


CURRENT

Medical Diagnosis & Treatment



2013

MAXINE A. PAPADAKIS

STEPHEN J. MCPHEE

ASSOCIATE EDITOR MICHAEL W. RABOW

**Mc
Graw
Hill**

LANGE[®]

a LANGE medical book

2013

CURRENT

Medical Diagnosis & Treatment

FIFTY-SECOND EDITION

Edited by

Maxine A. Papadakis, MD

Professor of Medicine
Associate Dean of Students
School of Medicine
University of California, San Francisco

Stephen J. McPhee, MD

Professor of Medicine, Emeritus
Division of General Internal Medicine
Department of Medicine
University of California, San Francisco

Associate Editor

Michael W. Rabow, MD

Professor of Medicine
Division of General Internal Medicine
Department of Medicine
University of California, San Francisco

With Associate Authors



Medical

New York Chicago San Francisco Lisbon London Madrid Mexico City
Milan New Delhi San Juan Seoul Singapore Sydney Toronto

Copyright © 2013 by The McGraw-Hill Companies, Inc. All rights reserved. Except as permitted under the United States Copyright Act of 1976, no part of this publication may be reproduced or distributed in any form or by any means, or stored in a database or retrieval system, without the prior written permission of the publisher.

ISBN: 978-0-07-178183-1

MHID: 0-07-178183-8

The material in this eBook also appears in the print version of this title: ISBN: 978-0-07-178182-4, MHID: 0-07-178182-X.

All trademarks are trademarks of their respective owners. Rather than put a trademark symbol after every occurrence of a trademarked name, we use names in an editorial fashion only, and to the benefit of the trademark owner, with no intention of infringement of the trademark. Where such designations appear in this book, they have been printed with initial caps.

McGraw-Hill eBooks are available at special quantity discounts to use as premiums and sales promotions, or for use in corporate training programs. To contact a representative please e-mail us at bulksales@mcgraw-hill.com.

Notice

Medicine is an ever-changing science. As new research and clinical experience broaden our knowledge, changes in treatment and drug therapy are required. The authors and the publisher of this work have checked with sources believed to be reliable in their efforts to provide information that is complete and generally in accord with the standards accepted at the time of publication. However, in view of the possibility of human error or changes in medical sciences, neither the authors nor the publisher nor any other party who has been involved in the preparation or publication of this work warrants that the information contained herein is in every respect accurate or complete, and they disclaim all responsibility for any errors or omissions or for the results obtained from use of the information contained in this work. Readers are encouraged to confirm the information contained herein with other sources. For example and in particular, readers are advised to check the product information sheet included in the package of each medication they plan to administer to be certain that the information contained in this work is accurate and that changes have not been made in the recommended dose or in the contraindications for administration. This recommendation is of particular importance in connection with new or infrequently used medications.

TERMS OF USE

This is a copyrighted work and The McGraw-Hill Companies, Inc. ("McGraw-Hill") and its licensors reserve all rights in and to the work. Use of this work is subject to these terms. Except as permitted under the Copyright Act of 1976 and the right to store and retrieve one copy of the work, you may not decompile, disassemble, reverse engineer, reproduce, modify, create derivative works based upon, transmit, distribute, disseminate, sell, publish or sublicense the work or any part of it without McGraw-Hill's prior consent. You may use the work for your own noncommercial and personal use; any other use of the work is strictly prohibited. Your right to use the work may be terminated if you fail to comply with these terms.

THE WORK IS PROVIDED "AS IS." MCGRAW-HILL AND ITS LICENSORS MAKE NO GUARANTEES OR WARRANTIES AS TO THE ACCURACY, ADEQUACY OR COMPLETENESS OF OR RESULTS TO BE OBTAINED FROM USING THE WORK, INCLUDING ANY INFORMATION THAT CAN BE ACCESSED THROUGH THE WORK VIA HYPERLINK OR OTHERWISE, AND EXPRESSLY DISCLAIM ANY WARRANTY, EXPRESS OR IMPLIED, INCLUDING BUT NOT LIMITED TO IMPLIED WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. McGraw-Hill and its licensors do not warrant or guarantee that the functions contained in the work will meet your requirements or that its operation will be uninterrupted or error free. Neither McGraw-Hill nor its licensors shall be liable to you or anyone else for any inaccuracy, error or omission, regardless of cause, in the work or for any damages resulting therefrom. McGraw-Hill has no responsibility for the content of any information accessed through the work. Under no circumstances shall McGraw-Hill and/or its licensors be liable for any indirect, incidental, special, punitive, consequential or similar damages that result from the use of or inability to use the work, even if any of them has been advised of the possibility of such damages. This limitation of liability shall apply to any claim or cause whatsoever whether such claim or cause arises in contract, tort or otherwise.

Contents

Authors	xi	Depression	63
Preface	xvii	Delirium	64
1. Disease Prevention & Health Promotion	1	Immobility	65
<i>Michael Pignone, MD, MPH, & René Salazar, MD</i>		Falls & Gait Disorders	65
Prevention of Infectious Diseases	3	Urinary Incontinence	67
Prevention of Cardiovascular Disease	5	Undernutrition & Frailty	69
Prevention of Osteoporosis	11	Pressure Ulcers	70
Prevention of Physical Inactivity	12	Pharmacotherapy & Polypharmacy	71
Prevention of Overweight & Obesity	13	Vision Impairment	72
Cancer Prevention	15	Hearing Impairment	72
Prevention of Injuries & Violence	17	Elder Mistreatment & Self Neglect	72
Prevention of Substance Abuse: Alcohol & Illicit Drugs	18		
2. Common Symptoms	21	5. Palliative Care & Pain Management	74
<i>Ralph Gonzales, MD, MSPH, & Paul L. Nadler, MD</i>		<i>Michael W. Rabow, MD, & Steven Z. Pantilat, MD</i>	
Cough	21	Definition & Scope of Palliative Care	74
Dyspnea	24	Pain Management	74
Hemoptysis	26	Principles of Pain Management	74
Chest Pain	28	Pain at the End of Life	75
Palpitations	30	Pharmacologic Pain Management Strategies	76
Lower Extremity Edema	33	Nonpharmacologic Treatments	85
Fever & Hyperthermia	35	Palliation of Other Common Symptoms	85
Involuntary Weight Loss	37	Dyspnea	85
Fatigue & Chronic Fatigue Syndrome	38	Nausea & Vomiting	86
Acute Headache	40	Constipation	86
Dysuria	43	Fatigue	86
		Delirium & Agitation	86
		End-of-Life Care	87
		Tasks after Death	92
3. Preoperative Evaluation & Perioperative Management	46	6. Dermatologic Disorders	94
<i>Hugo Q. Cheng, MD</i>		<i>Timothy G. Berger, MD</i>	
Evaluation of the Asymptomatic Patient	46	Principles of Dermatologic Therapy	94
Cardiac Risk Assessment & Reduction	46	Common Dermatoses	100
Pulmonary Evaluation in Non-Lung Resection Surgery	50	Pigmented Lesions	100
Evaluation of the Patient with Liver Disease	51	Scaling Disorders	103
Preoperative Hematologic Evaluation	52	Vesicular Dermatoses	118
Neurologic Evaluation	53	Weeping or Crusted Lesions	123
Management of Endocrine Diseases	54	Pustular Disorders	125
Kidney Disease	55	Erythemas	132
Antibiotic Prophylaxis of Surgical Site Infections	55	Blistering Diseases	138
		Papules	139
		Violaceous to Purple Papules & Nodules	143
		Pruritus (Itching)	145
		Inflammatory Nodules	150
		Epidermal Inclusion Cyst	152
		Photodermatitis	152
		Ulcers	153
		Miscellaneous Dermatologic Disorders	155
4. Geriatric Disorders	57	Pigmentary Disorders	155
<i>C. Bree Johnston, MD, MPH, G. Michael Harper, MD, & C. Seth Landefeld, MD</i>		Baldness (Alopecia)	156
General Principles of Geriatric Care	57	Nail Disorders	157
Assessment of the Older Adult	57	Dermatitis Medicamentosa (Drug Eruption)	158
Management of Common Geriatric Problems	59		
Dementia	59		

7. Disorders of the Eyes & Lids 162*Paul Riordan-Eva, FRCOphth*

Refractive Errors	162
Disorders of the Lids & Lacrimal Apparatus	163
Conjunctivitis	164
Pinguecula & Pterygium	167
Corneal Ulcer	167
Acute Angle-Closure Glaucoma	174
Chronic Glaucoma	175
Uveitis	177
Cataract	179
Retinal Detachment	179
Vitreous Hemorrhage	180
Age-Related Macular Degeneration	180
Central & Branch Retinal Vein Occlusions	181
Central & Branch Retinal Artery Occlusions	183
Transient Monocular Blindness	184
Retinal Disorders Associated with Systemic Diseases	185
Ischemic Optic Neuropathy	187
Optic Neuritis	188
Optic Disk Swelling	189
Ocular Motor Palsies	190
Dysthyroid Eye Disease	191
Orbital Cellulitis	191
Ocular Trauma	192
Ultraviolet Keratitis (Actinic Keratitis)	194
Chemical Conjunctivitis & Keratitis	194
Treatment of Ocular Disorders	194
Precautions in Management of Ocular Disorders	194
Adverse Ocular Effects of Systemic Drugs	195

8. Ear, Nose & Throat Disorders 198*Lawrence R. Lustig, MD, & Joshua S. Schindler, MD*

Diseases of the Ear	198
Diseases of the Nose & Paranasal Sinuses	213
Diseases of the Oral Cavity & Pharynx	224
Diseases of the Salivary Gland	232
Diseases of the Larynx	233
Tracheostomy & Cricothyrotomy	238
Foreign Bodies in the Upper Aerodigestive Tract	238
Diseases Presenting as Neck Masses	239

9. Pulmonary Disorders 242*Mark S. Chesnutt, MD, Thomas J. Prendergast, MD, & Emmanuel T. Tavan, MD*

Disorders of the Airways	242
Pulmonary Infections	270
Pulmonary Neoplasms	289
Interstitial Lung Disease (Diffuse Parenchymal Lung Disease)	292
Disorders of the Pulmonary Circulation	297
Environmental & Occupational Lung Disorders	307
Pleural Diseases	313
Disorders of Control of Ventilation	317
Acute Respiratory Failure	319
Acute Respiratory Distress Syndrome	322

10. Heart Disease 324*Thomas M. Bashore, MD, Christopher B. Granger, MD, Patrick Hranitzky, MD, & Manesh R. Patel, MD*

Congenital Heart Disease	324
Valvular Heart Disease	333
Coronary Heart Disease (Atherosclerotic CAD, Ischemic Heart Disease)	350
Disorders of Rate & Rhythm	376
Bradycardias & Conduction Disturbances	394
Congestive Heart Failure	398
Myocarditis & the Cardiomyopathies	409
Rheumatic Fever	417
Diseases of the Pericardium	419
Pulmonary Hypertension & Pulmonary Heart Disease	423
Neoplastic Diseases of the Heart	426
Cardiac Involvement in Miscellaneous Systemic Diseases	427
Traumatic Heart Disease	428
Risk of Surgery in the Cardiac Patient	429
Heart Disease & Pregnancy	429
Cardiovascular Screening of Athletes	431

11. Systemic Hypertension 433*Michael Sutters, MD, MRCP (UK)*

How Is Blood Pressure Measured and Hypertension Diagnosed?	433
Prehypertension	434
Approach to Hypertension	435
Drug Therapy: Current Antihypertensive Agents	444
Resistant Hypertension	459
Hypertensive Urgencies & Emergencies	460

12. Blood Vessel & Lymphatic Disorders 464*Joseph H. Rapp, MD, Christopher D. Owens, MD, MSc, & Meshell D. Johnson, MD*

Atherosclerotic Peripheral Vascular Disease	464
Nonatherosclerotic Vascular Disease	471
Arterial Aneurysms	472
Venous Diseases	478
Diseases of the Lymphatic Channels	483
Shock	485

13. Blood Disorders 490*Lloyd E. Damon, MD, Charalambos Andreadis, MD, & Charles A. Linker, MD*

Anemias	490
Neutropenia	509
Leukemias & Other Myeloproliferative Neoplasms	511
Lymphomas	524
Stem Cell Transplantation	532
Blood Transfusions	534

14. Disorders of Hemostasis, Thrombosis, & Antithrombotic Therapy 538*Patrick F. Fogarty, MD, & Tracy Minichiello, MD*

Platelet Disorders	538
Disorders of Coagulation	549
Antithrombotic Therapy	554

15. Gastrointestinal Disorders 564*Kenneth R. McQuaid, MD*

Symptoms & Signs of Gastrointestinal Disease	564
Diseases of the Peritoneum	587
Diseases of the Esophagus	591
Diseases of the Stomach & Duodenum	607
Diseases of the Small Intestine	621
Diseases of the Colon & Rectum	632
Anorectal Diseases	657

16. Liver, Biliary Tract, & Pancreas Disorders 662*Lawrence S. Friedman, MD*

Jaundice & Evaluation of Abnormal Liver	
Biochemical Tests	662
Diseases of the Liver	665
Diseases of the Biliary Tract	702
Diseases of the Pancreas	711

17. Breast Disorders 718*Armando E. Giuliano, MD, & Sara A. Hurvitz, MD*

Benign Breast Disorders	718
Fibrocystic Condition	718
Fibroadenoma of the Breast	719
Nipple Discharge	720
Fat Necrosis	720
Breast Abscess	721
Disorders of the Augmented Breast	721
Carcinoma of the Female Breast	722
Carcinoma of the Male Breast	745

18. Gynecologic Disorders 747*H. Trent MacKay, MD, MPH, & Jason Woo, MD, MPH, FACOG*

Abnormal Premenopausal Bleeding	747
Postmenopausal Vaginal Bleeding	749
Premenstrual Syndrome	
(Premenstrual Tension)	749
Dysmenorrhea	750
Vaginitis	751
Cervical Polyps	753
Bartholin Duct Cysts & Abscesses	753
Cervical Intraepithelial Neoplasia (CIN)	
(Dysplasia of the Cervix)	754
Carcinoma of the Cervix	756
Leiomyoma of the Uterus (Fibroid Tumor)	757
Carcinoma of the Endometrium	759
Carcinoma of the Vulva	759

Endometriosis	760
Pelvic Organ Prolapse	762
Pelvic Inflammatory Disease	
(Salpingitis, Endometritis)	762
Ovarian Cancer & Ovarian Tumors	764
Polycystic Ovary Syndrome	765
Female Sexual Dysfunction	766
Infertility	768
Contraception	770
Rape	777
Menopausal Syndrome	779

19. Obstetrics & Obstetric Disorders 781*Vanessa L. Rogers, MD, & Kevin C. Worley, MD*

Diagnosis of Pregnancy	781
Essentials of Prenatal Care	782
Nutrition in Pregnancy	785
Prevention of Rhesus Alloimmunization	785
Lactation	786
Travel & Immunizations during Pregnancy	786
Obstetric Complications of the	
First & Second Trimesters	787
Vomiting of Pregnancy (Morning Sickness) & Hyperemesis Gravidarum (Pernicious Vomiting of Pregnancy)	787
Spontaneous Abortion	788
Recurrent (Habitual) Abortion	789
Ectopic Pregnancy	790
Gestational Trophoblastic Disease (Hydatidiform Mole & Choriocarcinoma)	791
Obstetric Complications of the Second & Third Trimesters	792
Preeclampsia-Eclampsia	792
Acute Fatty Liver of Pregnancy	795
Preterm Labor	796
Third-Trimester Bleeding	797
Obstetric Complications of the Peripartum Period	797
Puerperal Mastitis	797
Chorioamnionitis & Metritis	798
Medical Conditions Complicating Pregnancy	798
Anemia	798
Antiphospholipid Syndrome	799
Thyroid Disease	800
Diabetes Mellitus	800
Chronic Hypertensive Disease	802
Heart Disease	802
Asthma	803
Seizure Disorders	803
Infectious Conditions Complicating Pregnancy	803
Urinary Tract Infection	803
Group B Streptococcal Infection	804
Varicella	804
Tuberculosis	805
HIV/AIDS during Pregnancy	805
Maternal Hepatitis B & C Carrier State	806
Herpes Genitalis	806

25. Psychiatric Disorders 1038*Stuart J. Eisendrath, MD, & Jonathan E. Lichtmacher, MD*

Common Psychiatric Disorders	1038
Substance Use Disorders (Drug Dependency, Drug Abuse)	1079
Delirium & Other Cognitive Disorders (Formerly: Organic Brain Syndrome)	1087
Psychiatric Problems Associated with Hospitalization & Illness	1089

26. Endocrine Disorders 1093*Paul A. Fitzgerald, MD*

Diseases of the Hypothalamus & Pituitary Gland	1093
Diseases of the Thyroid Gland	1105
Diseases of the Parathyroids	1135
Metabolic Bone Disease	1144
Diseases of the Adrenal Cortex	1154
Pheochromocytoma & Paraganglioma	1166
Pancreatic & Duodenal Neuroendocrine Tumors	1171
Diseases of the Testes & Male Breast	1173
Amenorrhea & Menopause	1179
Multiple Endocrine Neoplasia	1188
Clinical Use of Corticosteroids	1190

27. Diabetes Mellitus & Hypoglycemia 1192*Umesh Masharani, MB, BS, MRCP (UK)*

Diabetes Mellitus	1192
Diabetic Coma	1231
The Hypoglycemic States	1238

28. Lipid Disorders 1245*Robert B. Baron, MD, MS*

Lipoproteins & Atherogenesis	1245
Lipid Fractions & the Risk of Coronary Heart Disease	1246
Therapeutic Effects of Lowering Cholesterol	1246
Secondary Conditions that Affect Lipid Metabolism	1247
Clinical Presentations	1247
Screening for High Blood Cholesterol	1248
Treatment of High Low-Density Lipoprotein Cholesterol	1252
High Blood Triglycerides	1255

29. Nutritional Disorders 1257*Robert B. Baron, MD, MS*

Protein-Energy Malnutrition	1257
Obesity	1258
Eating Disorders	1262
Disorders of Vitamin Metabolism	1264
Diet Therapy	1268
Nutritional Support	1270

30. Common Problems in Infectious Diseases & Antimicrobial Therapy 1276*Peter V. Chin-Hong, MD, & B. Joseph Guglielmo, PharmD*

Common Problems in Infectious Diseases	1276
Fever of Unknown Origin	1276
Infections in the Immunocompromised Patient	1278
Health Care-Associated Infections	1282
Infections of the Central Nervous System	1285
Animal & Human Bite Wounds	1288
Sexually Transmitted Diseases	1290
Infections in Drug Users	1292
Acute Infectious Diarrhea	1293
Infectious Diseases in the Returning Traveler	1296
Traveler's Diarrhea	1297
Antimicrobial Therapy	1298
Selected Principles of Antimicrobial Therapy	1298
Hypersensitivity Tests & Desensitization	1305
Immunization Against Infectious Diseases	1307
Recommended Immunization of Infants, Children, & Adolescents	1307
Recommended Immunization for Adults	1307
Recommended Immunization for Travelers	1314
Vaccine Safety	1316

31. HIV Infection & AIDS 1319*Andrew R. Zolopa, MD, & Mitchell H. Katz, MD*

Epidemiology	1319
Etiology	1322
Pathogenesis	1322
Pathophysiology	1322
Clinical Findings	1322
Differential Diagnosis	1324
Complications	1324
Prevention	1333
Treatment	1336
Course & Prognosis	1349
When to Refer	1349
When to Admit	1349

32. Viral & Rickettsial Infections 1350*Wayne X. Shandera, MD, & Ingrid L. Roig, MD*

Viral Diseases	1350
Human Herpesviruses	1350
Major Vaccine-Preventable Viral Infections	1367
Other Neurotropic Viruses	1376
Other Systemic Viral Diseases	1384
Common Viral Respiratory Infections	1393
Adenovirus Infections	1401
Other Exanthematous Viral Infections	1402
Viruses & Gastroenteritis	1404
Enteroviruses that Produce Several Syndromes	1405
Rickettsial Diseases	1408
Typhus Group	1408

Spotted Fevers	1412	Coccidioidomycosis	1532
Other Rickettsial & Rickettsial-Like Diseases	1414	Pneumocystosis (<i>Pneumocystis jiroveci</i> Pneumonia)	1533
Kawasaki Disease	1417	Cryptococcosis	1535
33. Bacterial & Chlamydial Infections	1419	Aspergillosis	1537
<i>Brian S. Schwartz, MD</i>		Mucormycosis	1538
Infections Caused by Gram-Positive Bacteria	1419	Blastomycosis	1538
Infective Endocarditis	1435	Paracoccidioidomycosis (South American Blastomycosis)	1539
Infections Caused by Gram-Negative Bacteria	1440	Sporotrichosis	1539
Actinomycosis	1456	<i>Penicillium marneffe</i> Infections	1540
Nocardiosis	1457	Chromoblastomycosis (Chromomycosis)	1540
Infections Caused by Mycobacteria	1458	Mycetoma (Maduromycosis & Actinomycetoma)	1540
Infections Caused by Chlamydiae	1461	Other Opportunistic Mold Infections	1540
		Antifungal Therapy	1541
34. Spirochetal Infections	1464	37. Disorders Related to Environmental Factors	1543
<i>Susan S. Philip, MD, MPH</i>		<i>Jacqueline A. Nemer, MD, FACEP</i>	
Syphilis	1464	Cold & Heat	1543
Non-Sexually Transmitted Treponematoses	1474	Thermal Burns	1549
Selected Spirochetal Diseases	1475	Electrical Injury	1552
Relapsing Fever	1475	Radiation Exposure	1553
Rat-Bite Fever	1476	Near Drowning	1555
Leptospirosis	1477	Environmental Disorders Related to Altitude	1557
Lyme Disease (Lyme Borreliosis)	1478	38. Poisoning	1562
35. Protozoal & Helminthic Infections	1484	<i>Kent R. Olson, MD</i>	
<i>Philip J. Rosenthal, MD</i>		Initial Evaluation: Poisoning or Overdose	1562
Protozoal Infections	1484	The Symptomatic Patient	1562
African Trypanosomiasis (Sleeping Sickness)	1484	Antidotes & Other Treatment	1566
American Trypanosomiasis (Chagas Disease)	1486	Diagnosis of Poisoning	1568
Leishmaniasis	1487	Selected Poisonings	1570
Malaria	1490	39. Cancer	1593
Babesiosis	1499	<i>Patricia A. Cornett, MD, & Tiffany O. Dea, PharmD</i>	
Toxoplasmosis	1500	Etiology	1593
Amebiasis	1503	Modifiable Risk Factors	1593
Infections with Pathogenic Free-Living Amebas	1505	Staging	1594
Coccidiosis (Cryptosporidiosis, Isosporiasis, Cyclosporiasis, Sarcocystosis) & Microsporidiosis	1506	The Paraneoplastic Syndromes	1594
Giardiasis	1509	Types of Cancer	1595
Other Intestinal Flagellate Infections	1510	Lung Cancer	1595
Trichomoniasis	1510	Hepatobiliary Cancers	1603
Helminthic Infections	1511	Alimentary Tract Cancers	1612
Trematode (Fluke) Infections	1511	Cancers of the Genitourinary Tract	1630
Liver, Lung, & Intestinal Flukes	1512	Cancer Complications & Emergencies	1644
Cestode Infections	1514	Primary Cancer Treatment	1648
Intestinal Nematode (Roundworm) Infections	1517	Systemic Cancer Therapy	1648
Invasive Nematode (Roundworm) Infections	1520	Toxicity & Dose Modification of Chemotherapeutic Agents	1649
Filariasis	1524	Prognosis	1663
36. Mycotic Infections	1529	40. Clinical Genetic Disorders	1664
<i>Samuel A. Shelburne, MD, PhD, & Richard J. Hamill, MD</i>		<i>Reed E. Pyeritz, MD, PhD</i>	
Candidiasis	1529	Acute Intermittent Porphyria	1664
Histoplasmosis	1531	Alkaptonuria	1665

Down Syndrome	1666	Ankle Injuries	1703
Fragile X Mental Retardation	1667	Inversion Ankle Sprains	1703
Gaucher Disease	1667	Eversion (“High”) Ankle Sprains	1704
Disorders of Homocysteine Metabolism	1668		
Klinefelter Syndrome	1669	42. Women’s Health Issues	1706
Marfan Syndrome	1670	<i>Megan McNamara, MD, MSc, & Judith Walsh, MD, MPH</i>	
Hereditary Hemorrhagic Telangiectasia	1671	Preventive Health Care	1706
		Cardiovascular Disease Prevention	1706
41. Sports Medicine & Outpatient Orthopedics	1673	Cancer Prevention	1708
<i>Anthony Luke, MD, MPH, & C. Benjamin Ma, MD</i>		Osteoporosis Prevention	1710
General Approach to Musculoskeletal Injuries	1673	Prevention of Sexually Transmitted Infections	1711
Shoulder	1674	Depression Screening	1711
Subacromial Impingement Syndrome	1674	Specific Issues & Conditions	1711
Rotator Cuff Tears	1675	Intimate Partner Violence	1711
Shoulder Dislocation & Instability	1681	Eating Disorders	1712
Adhesive Capsulitis (“Frozen Shoulder”)	1682	Sexuality & Sexual Health	1714
Spine Problems	1683	Chronic Pelvic Pain	1714
Low Back Pain	1683	Mastalgia	1716
Spinal Stenosis	1685	The Palpable Breast Mass	1717
Lumbar Disk Herniation	1685	Nipple Discharge	1719
Neck Pain	1686	Female Pattern Hair Loss	1719
Upper Extremity	1687	Treatment of Varicose Veins	1720
Lateral & Medial Epicondylitis	1687	Age-Related Facial Changes	1720
Carpal Tunnel Syndrome	1688		
Hip	1689	Appendix: Therapeutic Drug Monitoring, Pharmacogenetic Testing, & Laboratory Reference Intervals	1722
Hip Fractures	1689	<i>C. Diana Nicoll, MD, PhD, MPA, & Chuanyi Mark Lu, MD, PhD</i>	
Osteoarthritis	1691	Index	1737
Knee	1692		
Knee Pain	1692		
Anterior Cruciate Ligament Injury	1693		
Collateral Ligament Injury	1698		
Posterior Cruciate Ligament Injury	1699		
Meniscus Injuries	1700		
Patellofemoral Pain	1700		
Osteoarthritis	1701		

ONLINE-ONLY CHAPTERS

www.AccessMedicine.com/CMDT

Anti-infective Chemotherapeutic & Antibiotic Agents

B. Joseph Guglielmo, PharmD

Penicillins	Alternative Drugs in Tuberculosis Treatment
Cephalosporins	Rifamycins
Other β -Lactam Drugs	Sulfonamides & Antifolate Drugs
Erythromycin Group (Macrolides)	Sulfones Used in the Treatment of Leprosy
Ketolides	Specialized Drugs Used Against Bacteria
Tetracycline Group	Streptogramins
Glycylcyclines	Oxazolidinones
Chloramphenicol	Daptomycin
Aminoglycosides	Telavancin
Polymyxins	Quinolones
Antituberculous Drugs	Pentamidine & Atovaquone
	Urinary Antiseptics
	Antifungal Drugs
	Antiviral Chemotherapy

Basic Genetics

Reed E. Pyeritz, MD, PhD

- Introduction to Medical Genetics
 - Genes & Chromosomes
 - Mutation
 - Genes in Individuals
 - Genes in Families
 - Disorders of Multifactorial Causation
 - Chromosomal Aberrations
- The Techniques of Medical Genetics
 - Family History & Pedigree Analysis
 - Cytogenetics & Cytogenomics
 - Biochemical Genetics
 - DNA Analysis
 - Prenatal Diagnosis
 - Neoplasia: Cytogenomic & DNA Analysis

Diagnostic Testing & Medical Decision Making

C. Diana Nicoll, MD, PhD, MPA, Michael Pignone, MD, MPH, & Chuanyi Mark Lu, MD, PhD

- Benefits, Costs, & Risks
- Performance of Diagnostic Tests
- Test Characteristics
- Use of Tests in Diagnosis & Management
- Odds-Likelihood Ratios

Information Technology in Patient Care

Russ Cucina, MD, MS

- Patient Confidentiality & Information Technology
- Clinical Uses of E-mail
- Electronic Health Records
- Computerized Provider Order Entry
- Clinical Decision Support Systems
- Social Media & Websites in Clinical Practice
- Mobile Computing for Clinicians
- Telemedicine

Complementary & Alternative Medicine

Kevin Barrows, MD

- Botanical Medicines
- Dietary Supplements
- Acupuncture
- Mind-Body Medicine

Authors

Michael J. Aminoff, MD, DSc, FRCP

Distinguished Professor and Executive Vice Chair,
Department of Neurology, University of California, San
Francisco; Attending Physician, University of California
Medical Center, San Francisco
aminoffm@neurology.ucsf.edu
Nervous System Disorders

Charalambos Babis Andreadis, MD, MSCE

Assistant Professor of Medicine, Division of Hematology/
Oncology, University of California, San Francisco
candreadis@medicine.ucsf.edu
Blood Disorders

David M. Barbour, PharmD, BCPS

Pharmacist, Denver, Colorado
dbarbour99@gmail.com
Drug References

Robert B. Baron, MD, MS

Professor of Medicine; Associate Dean for Graduate and
Continuing Medical Education; Vice Chief, Division of
General Internal Medicine, University of California,
San Francisco
baron@medicine.ucsf.edu
Lipid Disorders; Nutritional Disorders

Kevin Barrows, MD

Associate Clinical Professor of Family and Community
Medicine, Medical Director, Osher Center for Integrative
Medicine; Department of Family and Community
Medicine, University of California, San Francisco
barrowsk@ocim.ucsf.edu
CMDT Online—Complementary & Alternative Medicine

Thomas M. Bashore, MD

Professor of Medicine; Clinical Chief, Division of
Cardiology, Duke University Medical Center, Durham,
North Carolina
thomas.bashore@duke.edu
Heart Disease

Timothy G. Berger, MD

Professor of Clinical Dermatology, Department of
Dermatology, University of California, San Francisco
bergert@derm.ucsf.edu
Dermatologic Disorders

Kara Bischoff, MD

Resident, Department of Medicine, University of
California, San Francisco
References

Brook Calton, MD, MHS

Resident Physician, Department of Medicine, University
of California, San Francisco
References

Hugo Q. Cheng, MD

Clinical Professor of Medicine, University of California,
San Francisco
quinny@medicine.ucsf.edu
Preoperative Evaluation & Perioperative Management

Mark S. Chesnutt, MD

Clinical Professor, Pulmonary & Critical Care Medicine,
Dotter Interventional Institute, Oregon Health &
Science University, Portland, Oregon; Director, Critical
Care, Portland Veterans Affairs Medical Center
chesnutm@ohsu.edu
Pulmonary Disorders

Peter V. Chin-Hong, MD

Associate Professor, Division of Infectious Diseases,
Department of Medicine, University of California,
San Francisco
peter.chin-hong@ucsf.edu
*Common Problems in Infectious Diseases & Antimicrobial
Therapy*

Kerry C. Cho, MD

Assistant Clinical Professor of Medicine, Division of
Nephrology, University of California, San Francisco
kerry.cho@ucsf.edu
Electrolyte & Acid-Base Disorders

Patricia A. Cornett, MD

Professor of Medicine, University of California, San
Francisco; Chief, Hematology/Oncology, San Francisco
Veterans Affairs Medical Center, San Francisco,
California
patricia.cornett@va.gov
Cancer

Russ Cucina, MD, MS

Associate Professor of Hospital Medicine; Medical
Director, Information Technology, UCSF Medical
Center; University of California, San Francisco
rcucina@medicine.ucsf.edu
CMDT Online—Information Technology in Patient Care

Lloyd E. Damon, MD

Professor of Clinical Medicine, Department of Medicine, Division of Hematology/Oncology; Director of Adult Hematologic Malignancies and Blood and Marrow Transplantation, University of California, San Francisco
damonl@medicine.ucsf.edu
Blood Disorders

Tiffany O. Dea, PharmD, BCOP

Oncology Pharmacist, Veterans Affairs Medical Center, San Francisco, California; Adjunct Professor, Thomas J. Long School of Pharmacy and Health Sciences, Stockton, California
tiffany.dea@va.gov
Cancer

Tonja Dirkx, MD

Assistant Professor of Medicine, Division of Nephrology, Department of Medicine, Oregon Health and Sciences University, Portland, Oregon; Renal Clinic Director, Portland Veterans Affairs Medical Center
dirkxt@ohsu.edu
Kidney Disease

Stuart J. Eisendrath, MD

Professor of Psychiatry; Director of The UCSF Depression Center, Langley Porter Psychiatric Hospital and Clinics, University of California, San Francisco
stuart.eisendrath@ucsf.edu
Psychiatric Disorders

Paul A. Fitzgerald, MD

Clinical Professor of Medicine, Department of Medicine, Division of Endocrinology, University of California, San Francisco
paul.fitzgerald@ucsf.edu
Endocrine Disorders

Patrick F. Fogarty, MD

Assistant Professor of Medicine, Department of Medicine; Director, Penn Comprehensive Hemophilia and Thrombosis Program, Hospital of the University of Pennsylvania, Philadelphia
patrick.fogarty@uphs.upenn.edu
Disorders of Hemostasis, Thrombosis, & Antithrombotic Therapy

Lawrence S. Friedman, MD

Professor of Medicine, Harvard Medical School; Professor of Medicine, Tufts University School of Medicine, Boston, Massachusetts; Chair, Department of Medicine, Newton-Wellesley Hospital, Newton, Massachusetts; Assistant Chief of Medicine, Massachusetts General Hospital, Boston, Massachusetts
lfriedman@partners.org
Liver, Biliary Tract, & Pancreas Disorders; Hepatobiliary Cancers (in Chapter 39)

Armando E. Giuliano, MD, FACS, FRCSEd

Executive Vice Chair of Surgery, Associate Director of Surgical Oncology, Cedars-Sinai Medical Center, Los Angeles, California
armando.giuliano@cshs.org
Breast Disorders

Ralph Gonzales, MD, MSPH

Professor of Medicine; Professor of Epidemiology & Biostatistics, Division of General Internal Medicine, Department of Medicine, University of California, San Francisco
ralphg@medicine.ucsf.edu
Common Symptoms

Christopher B. Granger, MD

Professor of Medicine; Director, Cardiac Care Unit, Duke University Medical Center, Duke Clinical Research Institute, Durham, North Carolina
christopher.granger@dm.duke.edu
Heart Disease

B. Joseph Guglielmo, PharmD

Professor and Chair, Department of Clinical Pharmacy, School of Pharmacy, University of California, San Francisco
guglielmoj@pharmacy.ucsf.edu
Common Problems in Infectious Diseases & Antimicrobial Therapy; CMDT Online—Anti-infective Chemotherapeutic & Antibiotic Agents

Richard J. Hamill, MD

Professor, Division of Infectious Diseases, Departments of Medicine and Molecular Virology & Microbiology, Baylor College of Medicine, Houston, Texas
rhamill@bcm.edu
Mycotic Infections

G. Michael Harper, MD

Associate Professor, Department of Medicine, University of California San Francisco School of Medicine; Associate Chief of Staff for Geriatrics, Palliative and Extended Care, San Francisco Veterans Affairs Medical Center, San Francisco, California
michael.harper3@med.va.gov
Geriatric Disorders

David B. Hellmann, MD, MACP

Aliki Perroti Professor of Medicine; Vice Dean for Johns Hopkins Bayview; Chairman, Department of Medicine, Johns Hopkins Bayview Medical Center, Johns Hopkins University School of Medicine, Baltimore, Maryland
hellmann@jhmi.edu
Musculoskeletal & Immunologic Disorders

Patrick Hranitzky, MD

Assistant Professor of Medicine; Director, Clinical Cardiac Electrophysiology; Director, Clinical Cardiac Electrophysiology Fellowship Program, Duke University Medical Center, Durham, North Carolina
patrick.hranitzky@duke.edu
Heart Disease

Sara A. Hurvitz, MD

Assistant Professor; Director, Breast Oncology Program, Division of Hematology/Oncology, Department of Internal Medicine, University of California, Los Angeles
shurvitz@mednet.ucla.edu
Breast Disorders

John B. Imboden, Jr., MD

Alice Betts Endowed Chair for Arthritis Research; Professor of Medicine, University of California, San Francisco; Chief, Division of Rheumatology, San Francisco General Hospital
John.Imboden@ucsf.edu
Musculoskeletal & Immunologic Disorders

Meshell D. Johnson, MD

Assistant Professor, Division of Pulmonary and Critical Care Medicine, Department of Medicine, University of California, San Francisco
meshell.johnson@ucsf.edu
Blood Vessel & Lymphatic Disorders

C. Bree Johnston, MD, MPH

Director of Palliative and Supportive Care, PeaceHealth St. Joseph Medical Center, Bellingham, Washington; Clinical Professor of Medicine, Division of Geriatrics, UC San Francisco
bjohnston@peacehealth.org
Geriatric Disorders

Mitchell H. Katz, MD

Clinical Professor of Medicine, Epidemiology & Biostatistics, University of California, San Francisco; Director of Health Services, Los Angeles County
mkatz@dhs.lacounty.gov
HIV Infection & AIDS

Robin K. Kelley, MD

Assistant Professor of Medicine, Division of Hematology/Oncology, University of California, San Francisco
katie.kelley@ucsf.edu
Alimentary Tract Cancers (in Chapter 39)

Geoffrey A. Kerchner, MD, PhD

Assistant Professor of Neurology and Neurological Sciences, Stanford Center for Memory Disorders, Stanford University School of Medicine, Stanford, California
kerchner@stanford.edu
Nervous System Disorders

C. Seth Landefeld, MD

Professor; Chief, Division of Geriatrics; Associate Chair for Strategic Planning and Implementation, Department of Medicine, University of California, San Francisco; Staff Physician, San Francisco Veterans Affairs Medical Center
sethl@medicine.ucsf.edu
Geriatric Disorders

Brett Ley, MD

Chief Resident, Department of Medicine, University of California, San Francisco
References

Jonathan E. Lichtmacher, MD

Health Sciences Clinical Professor of Psychiatry; Director, Adult Psychiatry Clinic, Langley Porter Hospitals and Clinics, University of California, San Francisco
jonathanl@lppi.ucsf.edu
Psychiatric Disorders

Charles A. Linker, MD

Professor of Medicine Emeritus, University of California, San Francisco
linkerc@medicine.ucsf.edu
Blood Disorders

Chuanyi Mark Lu, MD, PhD

Associate Professor, Department of Laboratory Medicine, University of California, San Francisco; Chief, Hematology and Hematopathology, Laboratory Medicine Service, Veterans Affairs Medical Center, San Francisco, California
mark.lu@va.gov
Appendix: Therapeutic Drug Monitoring, Pharmacogenetic Testing, & Laboratory Reference Intervals; CMDT Online—Diagnostic Testing & Medical Decision Making

Anthony Luke, MD, MPH

Professor of Clinical Orthopaedics, Department of Orthopaedics; Director, UCSF Primary Care Sports Medicine; Director, Human Performance Center at the Orthopaedic Institute, University of California, San Francisco
LukeA@orthosurg.ucsf.edu
Sports Medicine & Outpatient Orthopedics

Lawrence R. Lustig, MD

Francis A. Sooy, MD Professor of Otolaryngology—Head & Neck Surgery; Division Chief of Otolaryngology & Neurotology, Department of Otolaryngology—Head & Neck Surgery, University of California, San Francisco
llustig@ohns.ucsf.edu
Ear, Nose, & Throat Disorders

Colleen S. Lynch, MD

Clinical Instructor, Division of Hospital Medicine, University of California, San Francisco
References

C. Benjamin Ma, MD

Associate Professor, Department of Orthopaedic Surgery;
Chief, Sports Medicine and Shoulder Service,
University of California, San Francisco
MaBen@orthosurg.ucsf.edu
Sports Medicine & Outpatient Orthopedics

H. Trent MacKay, MD, MPH

Professor of Obstetrics and Gynecology, Uniformed
Services University of the Health Sciences, Bethesda,
Maryland; Staff Physician, Department of Obstetrics
and Gynecology, Walter Reed National Military
Medical Center, Bethesda, Maryland
mackayt@mail.nih.gov
Gynecologic Disorders

Umesh Masharani, MB, BS, MRCP(UK)

Professor of Medicine, Division of Endocrinology and
Metabolism, Department of Medicine, University of
California, San Francisco
umesh.masharani@ucsf.edu
Diabetes Mellitus & Hypoglycemia

Megan McNamara, MD, MSc

Assistant Professor of Medicine, Department of Medicine,
Case Western Reserve University, Cleveland, Ohio;
Director of the Center for the Advancement of Medical
Learning, Case Western Reserve School of Medicine,
Cleveland, Ohio
Megan.Mcnamara@va.gov
Women's Health Issues

Kenneth R. McQuaid, MD

Professor of Clinical Medicine, University of California,
San Francisco; Chief, Gastroenterology Section, San
Francisco Veterans Affairs Medical Center
kenneth.mcquaid@med.va.gov
Gastrointestinal Disorders; Alimentary Tract Cancers
(in Chapter 39)

Neil Mehta, MD

Fellow, Division of Gastroenterology, Department of
Medicine, University of California, San Francisco
Illustrations

Maxwell V. Meng, MD, FACS

Associate Professor, Department of Urology, University of
California, San Francisco
mmeng@urology.ucsf.edu
Urologic Disorders; Cancers of the Genitourinary Tract
(in Chapter 39)

Tracy Minichiello, MD

Associate Professor of Medicine, University of California,
San Francisco; Chief, Anticoagulation and Thrombosis
Services, San Francisco Veterans Affairs Medical Center
minichie@medicine.ucsf.edu
*Disorders of Hemostasis, Thrombosis, & Antithrombotic
Therapy*

Paul L. Nadler, MD

Clinical Professor of Medicine; Director, Screening and
Acute Care Clinic, Division of General Internal
Medicine, Department of Medicine, University of
California, San Francisco
nadler@medicine.ucsf.edu
Common Symptoms

Michelle Nazareth, MD

Fellow, Division of Gastroenterology, Department of
Medicine, University of California, San Francisco
Illustrations

Jacqueline A. Nemer, MD, FACEP

Associate Professor of Emergency Medicine, Department
of Emergency Medicine, University of California,
San Francisco
jacqueline.nemer@ucsf.edu
Disorders Related to Environmental Factors

C. Diana Nicoll, MD, PhD, MPA

Clinical Professor and Vice Chair, Department of
Laboratory Medicine; Associate Dean, University of
California, San Francisco; Chief of Staff and Chief,
Laboratory Medicine Service, San Francisco Veterans
Affairs Medical Center
diana.nicoll@va.gov
*Appendix: Therapeutic Drug Monitoring,
Pharmacogenetic Testing, & Laboratory Reference
Intervals; CMDT Online—Diagnostic Testing &
Medical Decision Making*

Grace J. No, MD

Clinical Fellow, Division of Nephrology, Department of
Medicine, University of California, San Francisco
References

Kent R. Olson, MD

Clinical Professor of Medicine, Pediatrics, and Pharmacy,
University of California, San Francisco; Medical
Director, San Francisco Division, California Poison
Control System
kent.olson@ucsf.edu
Poisoning

Robert Osterhoff, MD

Fellow, Division of Gastroenterology, Department of
Medicine, University of California, San Francisco
Illustrations

Christopher D. Owens, MD, MSc

Assistant Professor of Surgery, Division of Vascular and
Endovascular Surgery, Department of Surgery,
University of California, San Francisco
christopher.owens@ucsfmedctr.org
Blood Vessel & Lymphatic Disorders

Steven Z. Pantilat, MD

Professor of Clinical Medicine, Department of Medicine; Alan M. Kates and John M. Burnard Endowed Chair in Palliative Care; Director, Palliative Care Program, University of California, San Francisco
stevep@medicine.ucsf.edu
Palliative Care & Pain Management

Manesh R. Patel, MD

Assistant Professor of Medicine, Division of Cardiology, Department of Medicine, Duke University Medical Center, Durham, North Carolina
patel017@notes.duke.edu
Heart Disease

Susan S. Philip, MD, MPH

Assistant Clinical Professor, Division of Infectious Diseases, Department of Medicine, University of California, San Francisco; Director, STD Prevention and Control Section, San Francisco Department of Public Health, San Francisco, California
susan.philip@sfdph.org
Spirochetal Infections

Michael Pignone, MD, MPH

Professor of Medicine, Division of General Internal Medicine, Department of Medicine, University of North Carolina, Chapel Hill
pignone@med.unc.edu
Disease Prevention & Health Promotion; CMDT Online—Diagnostic Testing & Medical Decision Making

Thomas J. Prendergast, MD

Associate Professor of Medicine, Oregon Health and Science University; Pulmonary Critical Care Section Chief, Portland Veterans Affairs Medical Center, Portland, Oregon
thomas.prendergast@va.gov
Pulmonary Disorders

Reed E. Pyeritz, MD, PhD

Professor of Medicine and Genetics; Vice-Chair for Academic Affairs, Department of Medicine, Raymond and Ruth Perelman School of Medicine of the University of Pennsylvania, Philadelphia
reed.pyeritz@uphs.upenn.edu
Clinical Genetic Disorders; CMDT Online—Basic Genetics

Gene R. Quinn, MD, MS

Resident Physician, Department of Medicine, University of California, San Francisco
References

Michael W. Rabow, MD, FAAHPM

Professor of Clinical Medicine, Division of General Internal Medicine, Department of Medicine; Director, Symptom Management Service, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco
mrabow@medicine.ucsf.edu
Palliative Care & Pain Management

Joseph H. Rapp, MD

Professor of Surgery in Residence, University of California, San Francisco; Chief, Vascular Surgery Service, Veterans Affairs Medical Center, San Francisco, California
rappj@surgery.ucsf.edu
Blood Vessel & Lymphatic Disorders

Nicole Richman, MD

Fellow, Division of Rheumatology, Department of Medicine, University of California, San Francisco
Illustrations

Paul Riordan-Eva, FRCOphth

Consultant Ophthalmologist, King's College Hospital, London, United Kingdom
paul.riordan-eva@nhs.net
Disorders of the Eyes & Lids

Vanessa L. Rogers, MD

Associate Professor, Obstetrics and Gynecology, University of Texas Southwestern Medical Center, Dallas, Texas
vanessa.rogers@utsouthwestern.edu
Obstetrics & Obstetric Disorders

Ingrid L. Roig, MD

Fellow, Section of Infectious Diseases, Department of Medicine, Baylor College of Medicine, Houston, Texas
rroig@bcm.edu
Viral & Rickettsial Infections

Philip J. Rosenthal, MD

Professor, Division of Infectious Diseases, Department of Medicine, University of California, San Francisco; San Francisco General Hospital
prosenthal@medsfgh.ucsf.edu
Protozoal & Helminthic Infections

René Salazar, MD

Associate Professor of Clinical Medicine, Division of General Internal Medicine, Department of Medicine, University of California, San Francisco
salazarr@medicine.ucsf.edu
Disease Prevention & Health Promotion

Varun Saxena, MD

Chief Medical Resident, San Francisco VA Medical Center, Department of Medicine, University of California, San Francisco
References

Joshua S. Schindler, MD

Assistant Professor, Department of Otolaryngology, Oregon Health & Science University, Portland, Oregon; Medical Director, OHSU-Northwest Clinic for Voice and Swallowing
schindlj@ohsu.edu
Ear, Nose, & Throat Disorders

Brian S. Schwartz, MD

Assistant Clinical Professor, Division of Infectious Diseases, Department of Medicine, University of California, San Francisco

brian.schwartz@ucsf.edu

Bacterial & Chlamydial Infections

Wayne X. Shandera, MD

Assistant Professor, Department of Internal Medicine, Baylor College of Medicine, Houston, Texas

shandera@bcm.tmc.edu

Viral & Rickettsial Infections

Samuel A. Shelburne, MD, PhD

Assistant Professor, Department of Infectious Diseases, MD Anderson Cancer Center, Houston, Texas

sshelburne@mdanderson.org

Mycotic Infections

Aparajita Singh, MD, MPH

Fellow, Division of Gastroenterology, Department of Medicine, University of California, San Francisco

References

Krishan Soni, MD, MBA

Chief Resident for Quality Improvement and Patient Safety, Department of Medicine, University of California, San Francisco

References

Marshall L. Stoller, MD

Professor and Vice Chairman, Department of Urology, University of California, San Francisco

mstoller@urology.ucsf.edu

Urologic Disorders

Michael Sutters, MD, MRCP(UK)

Attending Nephrologist, Virginia Mason Medical Center, Seattle, Washington; Affiliate Assistant Professor of Medicine, Division of Nephrology, University of Washington School of Medicine, Seattle, Washington

michael.sutters@vmmc.org

Systemic Hypertension

Emmanuel T. Tavan, MD

Fellow, Division of Pulmonary and Critical Care Medicine, Oregon Health and Science University, Portland, Oregon

tavane@ohsu.edu

Pulmonary Disorders

Jorge Tello, MD

Resident Physician, Department of Medicine, University of California, San Francisco

References

Philip Tiso

Principal Editor, Division of General Internal Medicine, University of California, San Francisco

References

Judith Walsh, MD, MPH

Professor of Clinical Medicine, Division of General Internal Medicine, Women's Health Center of Excellence, University of California, San Francisco

Judith.Walsh@ucsf.edu

Women's Health Issues

Thomas J. Walsh, MD, MS

Assistant Professor, Department of Urology, University of Washington School of Medicine, Seattle, Washington

walshst@u.washington.edu

Urologic Disorders

Sunny Wang, MD

Assistant Clinical Professor of Medicine, Division of Hematology and Oncology, University of California, San Francisco; San Francisco Veterans Affairs Medical Center

sunny.wang@ucsf.edu

Lung Cancer (in Chapter 39)

Suzanne Watnick, MD

Associate Professor of Medicine, Division of Nephrology and Hypertension, Oregon Health & Science University, Portland; Portland Veterans Affairs Medical Center, Portland, Oregon

watnicks@ohsu.edu

Kidney Disease

CAPT Jason Woo, MD, MPH, FACOG

Medical Monitor, Contraceptive and Reproductive Health Branch, Eunice Kennedy Shriver National Institute for Child Health and Human Development, National Institutes for Health, Rockville, MD

jasonwoo@pol.net

Gynecologic Disorders

Darcy A. Wooten, MD, MS

Resident Physician, University of California, San Francisco

References

Kevin C. Worley, MD

Assistant Professor of Obstetrics and Gynecology, Department of Obstetrics and Gynecology, Division of Maternal-Fetal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas

Kevin.Worley@UTSouthwestern.edu

Obstetrics & Obstetric Disorders

Rebecca C. Wylie, MD, MS

Clinical Educator, Division of Hospital Medicine, University of California, San Francisco

References

Andrew R. Zolopa, MD

Professor of Medicine, Division of Infectious Diseases and Geographic Medicine, Stanford University, Stanford, California

azolopa@stanford.edu

HIV Infection & AIDS

Preface

Current Medical Diagnosis & Treatment 2013 (CMDT 2013) is the 52nd edition of this single-source reference for practitioners in both hospital and ambulatory settings. The book emphasizes the practical features of clinical diagnosis and patient management in all fields of internal medicine and in specialties of interest to primary care practitioners and to subspecialists who provide general care.

INTENDED AUDIENCE FOR *CMDT*

House officers, medical students, and all other health professions students will find the descriptions of diagnostic and therapeutic modalities, with citations to the current literature, of everyday usefulness in patient care.

Internists, family physicians, hospitalists, nurse practitioners, physicians' assistants, and all primary care providers will appreciate *CMDT* as a ready reference and refresher text. Physicians in other specialties, pharmacists, and dentists will find the book a useful basic medical reference text. Nurses, nurse-practitioners, and physicians' assistants will welcome the format and scope of the book as a means of referencing medical diagnosis and treatment.

Patients and their family members who seek information about the nature of specific diseases and their diagnosis and treatment may also find this book to be a valuable resource.

NEW IN THIS EDITION OF *CMDT*

- Addition of a new chapter on Women's Health Issues
- Expanded use of photos in chapters
- Updated CDC recommendations for adult and adolescent immunizations, including Tdap to prevent pertussis
- New algorithm for diagnosis and assessment of hypertension, and new sections on treatment of hypertension in the elderly and on treatment of hypertensive emergency
- Recommendations for anticoagulation and antiplatelet therapy for acute coronary syndromes
- New risk assessment model for deep venous thrombosis and new therapy for its prevention following hip or knee replacement
- Update on use of the thrombopoietin receptor agonists, eltrombopag and romiplostim
- Thoroughly updated breast cancer treatment options
- Updated guidelines for percutaneous coronary intervention, for coronary artery angiography and stent placement and for diagnosis of myocardial infarction by high-sensitivity troponin assay
- New antiarrhythmic and anticoagulant treatments of atrial fibrillation and use of CHADS₂ and CHADS-VASC scores to determine appropriateness of such anticoagulation
- Update on new percutaneous technique for PDA closure and newer interventional approaches to aortic, mitral, and pulmonary valve replacement
- Inclusion of new questionnaire methods to detect alcohol dependence, obstructive sleep apnea, cognitive dysfunction, and confusion
- New lung cancer screening recommendations
- Review of benefits of screening mammography, prostate specific antigen testing, and transvaginal ultrasound and serum CA-125 testing
- Update on cervical screening recommendations from the US Preventive Services Task Force
- Updated section on treating menopause
- Updated CDC guidelines for the treatment of sexually transmitted infections
- Information on new medications to lower serum uric acid
- Stepwise approach to assessing surgical risk in cardiac patients undergoing noncardiac surgery and update on postoperative myocardial infarction
- New classification of pulmonary hypertension and revised treatment options algorithm
- New drug treatment (ivacaftor) for cystic fibrosis
- FDA approval for belimumab to treat patients with active antibody-positive systemic lupus erythematosus
- FDA approval for a single rapid treponemal test for syphilis and data on sensitivity by stage of several other new tests for syphilis
- New therapeutic approach for patients with hypertrophic cardiomyopathy

- Information on mistreatment and self-neglect and on advance financial planning for elders
- Review of utility of antiretroviral medication therapy pre- and post-HIV exposure
- Strategies aimed at preventing preterm birth in high-risk women
- Information regarding a new recombinant hepatitis E vaccine and new ACIP recommendation of HPV vaccination of young males
- Extensive revision of the section on rhabdomyolysis
- Updated recommendations for inferior vena cava filter placement, tracking, and removal
- Updated rules for discontinuing hepatitis C treatment
- Updates on measuring liver stiffness for estimating degree of liver fibrosis without the need for liver biopsy
- Update on best techniques for detection of small hepatic carcinomas in patients eligible for resection
- New section on peripheral artery aneurysms
- Revised recommendations for tuberculosis screening and guidelines for a new assay to detect *Mycobacterium tuberculosis*
- Information about atypical hemolytic uremic syndrome and its treatment with eculizumab
- Update on management of factor inhibitors in hemophilia
- Information on when a laboratory work-up for thrombophilia is indicated
- Substantial revision of the following chapters: Viral & Rickettsial Infections, Disorders Related to Environmental Factors, and Blood Disorders

OUTSTANDING FEATURES OF CMDT

- Medical advances up to time of annual publication
- Detailed presentation of all primary care topics, including gynecology, obstetrics, dermatology, ophthalmology, otolaryngology, psychiatry, neurology, toxicology, urology, geriatrics, orthopedics, preventive medicine, and palliative care
- Concise format, facilitating efficient use in any practice setting
- More than 1000 diseases and disorders
- Annual update on HIV infection and AIDS
- Specific disease prevention information
- Easy access to medication dosages, with trade names indexed and costs updated in each edition
- Recent references, with unique identifiers (PubMed, PMID numbers) for rapid downloading of article abstracts and, in some instances, full-text reference articles
- ICD-9 codes listed on the inside covers

CMDT Online (www.AccessMedicine.com) provides full electronic access to *CMDT 2013* plus expanded basic science information and five additional chapters. The five online-only chapters (Anti-infective Chemotherapeutic & Antibiotic Agents, Basic Genetics, Diagnostic Testing & Medical Decision Making, Information Technology in Patient Care, and Complementary & Alternative Medicine) are available at www.AccessMedicine.com/CMDT. CMDT Online is updated throughout the year and includes an expanded, dedicated Media Gallery as well as links to related Web sites. Subscribers also receive access to *Diagnosaurus* with 1000+ differential diagnoses, *Pocket Guide to Diagnostic Tests*, *Quick Answers*, and *CURRENT Practice Guidelines in Primary Care*.

ACKNOWLEDGMENTS

We wish to thank our associate authors for participating once again in the annual updating of this important book. We are especially grateful to Shruti Patel, MD, who is leaving *CMDT* this year. We have all benefited from her clinical wisdom and commitment.

Many students and physicians also have contributed useful suggestions to this and previous editions, and we are grateful. We continue to welcome comments and recommendations for future editions in writing or via electronic mail. The editors' and authors' institutional and e-mail addresses are given in the Authors section.

Maxine A. Papadakis, MD
papadakM@medsch.ucsf.edu
Stephen J. McPhee, MD
smcphee@medicine.ucsf.edu
Michael W. Rabow, MD
mrabow@medicine.ucsf.edu
San Francisco, California

From inability to let alone; from too much zeal for the new and contempt for what is old; from putting knowledge before wisdom, and science before art and cleverness before common sense; from treating patients as cases; and from making the cure of the disease more grievous than the endurance of the same, Good Lord, deliver us.

—Sir Robert Hutchison

This page intentionally left blank

Disease Prevention & Health Promotion

Michael Pignone, MD, MPH,
& René Salazar, MD

1

GENERAL APPROACH TO THE PATIENT

The medical interview serves several functions. It is used to collect information to assist in diagnosis (the “history” of the present illness), to assess and communicate prognosis, to establish a therapeutic relationship, and to reach agreement with the patient about further diagnostic procedures and therapeutic options. It also serves as an opportunity to influence patient behavior, such as in motivational discussions about smoking cessation or medication adherence. Interviewing techniques that avoid domination by the clinician increase patient involvement in care and patient satisfaction. Effective clinician-patient communication and increased patient involvement can improve health outcomes.

▶ Patient Adherence

For many illnesses, treatment depends on difficult fundamental behavioral changes, including alterations in diet, taking up exercise, giving up smoking, cutting down drinking, and adhering to medication regimens that are often complex. Adherence is a problem in every practice; up to 50% of patients fail to achieve full adherence, and one-third never take their medicines. Many patients with medical problems, even those with access to care, do not seek appropriate care or may drop out of care prematurely. Adherence rates for short-term, self-administered therapies are higher than for long-term therapies and are inversely correlated with the number of interventions, their complexity and cost, and the patient’s perception of overmedication.

As an example, in HIV-infected patients, adherence to antiretroviral therapy is a crucial determinant of treatment success. Studies have unequivocally demonstrated a close relationship between patient adherence and plasma HIV RNA levels, CD4 cell counts, and mortality. Adherence levels of > 95% are needed to maintain virologic suppression. However, studies show that over 60% of patients are < 90% adherent and that adherence tends to decrease over time.

Patient reasons for nonadherence include simple forgetfulness, being away from home, being busy, and changes in daily routine. Other reasons include psychiatric disorders (depression or substance abuse), uncertainty about the

effectiveness of treatment, lack of knowledge about the consequences of poor adherence, regimen complexity, and treatment side effects.

Patients seem better able to take prescribed medications than to adhere to recommendations to change their diet, exercise habits, or alcohol intake or to perform various self-care activities (such as monitoring blood glucose levels at home). A 2008 review on the effectiveness of interventions to improve medication adherence found that for short-term regimens, adherence to medications can be improved by giving clear instructions. Writing out advice to patients, including changes in medication, may be helpful. Because low functional health literacy is common (almost half of English-speaking US patients are unable to read and understand standard health education materials), other forms of communication—such as illustrated simple text, videotapes, or oral instructions—may be more effective. For non-English-speaking patients, clinicians and health care delivery systems can work to provide culturally and linguistically appropriate health services.

To help improve adherence to long-term regimens, clinicians can work with patients to reach agreement on the goals for therapy, provide information about the regimen, ensure understanding by using the “teach-back” method, counsel about the importance of adherence and how to organize medication-taking, reinforce self-monitoring, provide more convenient care, prescribe a simple dosage regimen for all medications (preferably one or two doses daily), suggest ways to help in remembering to take doses (time of day, mealtime, alarms) and to keep appointments, and provide ways to simplify dosing (medication boxes). Single-unit doses supplied in foil wrappers can increase adherence but should be avoided for patients who have difficulty opening them. Medication boxes with compartments (eg, Medisets) that are filled weekly are useful. Microelectronic devices can provide feedback to show patients whether they have taken doses as scheduled or to notify patients within a day if doses are skipped. Reminders, including cell phone text messages, are another effective means of encouraging adherence. The clinician can also enlist social support from family and friends, recruit an adherence monitor, provide a more convenient care environment, and provide rewards and recognition

for the patient's efforts to follow the regimen. Collaborative programs that utilize pharmacists to help ensure adherence have also been shown to be effective.

Adherence is also improved when a trusting doctor-patient relationship has been established and when patients actively participate in their care. Clinicians can improve patient adherence by inquiring specifically about the behaviors in question. When asked, many patients admit to incomplete adherence with medication regimens, with advice about giving up cigarettes, or with engaging only in "safer sex" practices. Although difficult, sufficient time must be made available for communication of health messages.

Medication adherence can be assessed generally with a single question: "In the past month, how often did you take your medications as the doctor prescribed?" Other ways of assessing medication adherence include pill counts and refill records; monitoring serum, urine, or saliva levels of drugs or metabolites; watching for appointment nonattendance and treatment nonresponse; and assessing predictable drug effects such as weight changes with diuretics or bradycardia from β -blockers. In some conditions, even partial adherence, as with drug treatment of hypertension and diabetes mellitus, improves outcomes compared with nonadherence; in other cases, such as HIV antiretroviral therapy or treatment of tuberculosis, partial adherence may be worse than complete nonadherence.

▶ Guiding Principles of Care

Ethical decisions are often called for in medical practice, at both the "micro" level of the individual patient-clinician relationship and at the "macro" level of the allocation of resources. Ethical principles that guide the successful approach to diagnosis and treatment are honesty, beneficence, justice, avoidance of conflict of interest, and the pledge to do no harm. Increasingly, Western medicine involves patients in important decisions about medical care, including how far to proceed with treatment of patients who have terminal illnesses (see Chapter 5).

The clinician's role does not end with diagnosis and treatment. The importance of the empathic clinician in helping patients and their families bear the burden of serious illness and death cannot be overemphasized. "To cure sometimes, to relieve often, and to comfort always" is a French saying as apt today as it was five centuries ago—as is Francis Peabody's admonition: "The secret of the care of the patient is in caring for the patient." Training to improve mindfulness and enhance patient-centered communication increases patient satisfaction and may also improve clinician satisfaction.

Krasner MS et al. Association of an educational program in mindful communication with burnout, empathy and attitudes among primary care physicians. *JAMA*. 2009 Sep 23; 302(12): 1284–93. [PMID: 19773563]

Lester RT et al. Effects of a mobile phone short message service on antiretroviral treatment adherence in Kenya (WelTel Kenya1): a randomised trial. *Lancet*. 2010 Nov 27;376(9755): 1838–45. [PMID: 21071074]

Weber CA et al. Pharmacist-physician co-management of hypertension and reduction in 24-hour ambulatory blood pressures. *Arch Intern Med*. 2010 Oct 11;170(18):1634–9. [PMID: 20937921]

Table 1-1. Leading causes of death in the United States, 2008.

Category	Estimate
All causes	2,472,699
1. Diseases of the heart	617,527
2. Malignant neoplasms	566,137
3. Chronic lower respiratory diseases	141,075
4. Cerebrovascular diseases	133,750
5. Accidents (unintentional injuries)	121,207
6. Alzheimer disease	82,476
7. Diabetes mellitus	70,601
8. Influenza and pneumonia	56,335
9. Nephritis, nephrotic syndrome, and nephrosis	48,283
10. Septicemia	35,961

Source: National Center for Health Statistics 2010.

HEALTH MAINTENANCE & DISEASE PREVENTION

Preventive medicine can be categorized as primary, secondary, or tertiary. Primary prevention aims to remove or reduce disease risk factors (eg, immunization, giving up or not starting smoking). Secondary prevention techniques promote early detection of disease or precursor states (eg, routine cervical Papanicolaou screening to detect carcinoma or dysplasia of the cervix). Tertiary prevention measures are aimed at limiting the impact of established disease (eg, partial mastectomy and radiation therapy to remove and control localized breast cancer). Tables 1-1 and 1-2 give leading causes of death in the United States and estimates of deaths from preventable causes.

Many effective preventive services are underutilized, and few adults receive all of the most strongly recommended services. The three highest-ranking services in terms of potential health benefits and cost-effectiveness include discussing aspirin use with high-risk adults, tobacco-use screening and brief interventions, and immunizing children. Other high-ranking services with data with substantial room for improvement in utilization are screening adults aged 50 and older for colorectal cancer, immunizing adults aged 65 and older against pneumococcal disease, and screening young women for *Chlamydia*.

Several methods, including the use of provider or patient reminder systems, reorganization of care environments, and possibly provision of financial incentives, can increase utilization of preventive services, but such methods have not been widely adopted.

Danaei G et al. The preventable causes of death in the United States: comparative risk assessment of dietary, lifestyle, and metabolic risk factors. *PLoS Med*. 2009 Apr 28;6(4):e1000058. [PMID: 19399161]

Table 1-2. Deaths from all causes attributable to common preventable risk factors. (Numbers given in the thousands.)

Risk Factor	Male (95% CI)	Female (95% CI)	Both Sexes (95% CI)
Tobacco smoking	248 (226-269)	219 (196-244)	467 (436-500)
High blood pressure	164 (153-175)	231 (213-249)	395 (372-414)
Overweight-obesity (high BMI)	114 (95-128)	102 (80-119)	216 (188-237)
Physical inactivity	88 (72-105)	103 (80-128)	191 (164-222)
High blood glucose	102 (80-122)	89 (69-108)	190 (163-217)
High LDL cholesterol	60 (42-70)	53 (44-59)	113 (94-124)
High dietary salt (sodium)	49 (46-51)	54 (50-57)	102 (97-107)
Low dietary omega-3 fatty acids (seafood)	45 (37-52)	39 (31-47)	84 (72-96)
High dietary trans fatty acids	46 (33-58)	35 (23-46)	82 (63-97)
Alcohol use	45 (32-49)	20 (17-22)	64 (51-69)
Low intake of fruits and vegetables	33 (23-45)	24 (15-36)	58 (44-74)
Low dietary polyunsaturated fatty acids (in replacement of saturated fatty acids)	9 (6-12)	6 (3-9)	15 (11-20)

BMI, body mass index; CI, confidence interval; LDL, low-density lipoprotein.

Note: Numbers of deaths cannot be summed across categories.

Used, with permission, from Danaei G et al. The preventable causes of death in the United States: comparative risk assessment of dietary, lifestyle, and metabolic risk factors. *PLoS Med.* 2009 Apr 28;6(4):e1000058.

Gavagan TF et al. Effect of financial incentives on improvement in medical quality indicators for primary care. *J Am Board Fam Med.* 2010 Sep-Oct;23(5):622-31. [PMID: 20823357]
 Maciosek MV et al. Greater use of preventive services in U.S. health care could save lives at little or no cost. *Health Aff (Millwood).* 2010 Sep;29(9):1656-60. [PMID: 20820022]

PREVENTION OF INFECTIOUS DISEASES

Much of the decline in the incidence and fatality rates of infectious diseases is attributable to public health measures—especially immunization, improved sanitation, and better nutrition.

Immunization remains the best means of preventing many infectious diseases. Recommended immunization schedules for children and adolescents can be found online at <http://www.cdc.gov/vaccines/recs/schedules/child-schedule.htm> and the schedule for adults is outlined in Table 30-7. Substantial vaccine-preventable morbidity and mortality continue to occur among adults from vaccine-preventable diseases, such as hepatitis A, hepatitis B, influenza, and pneumococcal infections. For example, in adults in the United States, there are an estimated 50,000–70,000 deaths annually from influenza, hepatitis B, and invasive pneumococcal disease. Strategies to enhance vaccinations include increasing community demand for vaccinations; enhancing access to vaccination services; and provider- or system-based interventions, such as reminder systems.

Evidence suggests annual **influenza vaccination** is safe and effective with potential benefit in all age groups, and the Advisory Committee on Immunization Practices (ACIP) recommends routine influenza vaccination for all persons aged 6 months and older, including all adults.

When vaccine supply is limited, certain groups should be given priority, such as adults 50 years and older, individuals with chronic illness or immunosuppression, and pregnant women. An alternative high-dose inactivated vaccine for adults 65 years and older is available. This inactivated trivalent vaccine contains 60 mcg of hemagglutinin antigen per influenza vaccine virus strain (Fluzone High-Dose [Sanofi Pasteur]). Adults 65 years and older can receive either the standard dose or high-dose vaccine, whereas those younger than 65 years should receive a standard-dose preparation.

Increasing reports of **pertussis** among US adolescents, adults, and their infant contacts have stimulated vaccine development for older age groups. A safe and effective tetanus-diphtheria 5-component acellular pertussis vaccine (Tdap) is available for use in adolescents and in adults younger than 65 years. Compared with DTaP, which is used in children under the age of 7, Tdap has a reduced dose of the diphtheria and pertussis vaccines. The ACIP recommends routine use of a single dose of Tdap for adults aged 19–64 years to replace the next booster dose of tetanus and diphtheria toxoids vaccine (Td). Due to increasing reports of pertussis in the United States, clinicians may choose to give Tdap to persons aged 65 years and older despite limited published data on the safety and efficacy of the vaccine in this age group.

Both **hepatitis A vaccine** and immune globulin provide protection against hepatitis A; however, administration of immune globulin may provide a modest benefit over vaccination in some settings. A recombinant protein **hepatitis E vaccine** has been developed that has proven safe and efficacious in preventing hepatitis E among high-risk populations.

Human papillomavirus (HPV) virus-like particle (VLP) vaccines have demonstrated effectiveness in preventing persistent HPV infections, and thus may impact the rate of cervical intraepithelial neoplasia (CIN) II–III. The American Academy of Pediatrics (AAP) recommends routine HPV vaccination for girls aged 11–12 years. The AAP also recommends that all unvaccinated girls and women ages 13–26 years receive the HPV vaccine. It is estimated that routine use of HPV vaccination of females at 11 to 12 years of age and catch-up vaccination of females at age 13–16 (with vaccination of girls age 9 and 10 at the discretion of the physician) could prevent 95% to 100% of CIN and adenocarcinoma in situ, 99% of genital warts and approximately 70% of cervical cancer cases worldwide; thus, the role of HPV testing will need redefinition. In October 2011, the ACIP approved recommendations for routine vaccination of males 11 or 12 years of age with three doses of HPV4 (quadrivalent vaccine). Vaccination of males with HPV may lead to indirect protection of women by reducing transmission of HPV. Despite the effectiveness of the vaccine, rates of immunization are low. Interventions addressing personal beliefs and system barriers to vaccinations may help address the slow adoption of this vaccine.

Persons traveling to countries where infections are endemic should take precautions described in Chapter 30. Immunization registries—confidential, population-based, computerized information systems that collect vaccination data about all residents of a geographic area—can be used to increase and sustain high vaccination coverage.

Skin testing for **tuberculosis** (see Table 9–16) and treating selected patients reduce the risk of reactivation tuberculosis. Two blood tests, which are not confounded by prior BCG (bacille Calmette–Guérin) vaccination, have been developed to detect tuberculosis infection by measuring in vitro T-cell interferon-gamma release in response to two antigens (the enzyme-linked immunospot [ELISpot], [T-SPOT.TB] and the other, a quantitative ELISA [QuantIFERON-TBGold] test). These T-cell–based assays have an excellent specificity that is higher than tuberculin skin testing in BCG-vaccinated populations. The rate of tuberculosis in the United States has been declining since 1992. In 2009, the US tuberculosis rate was 3.8 cases per 100,000 population, a decrease of 11.4% from the 2008 rate (4.2 per 100,000). This represents the greatest single-year decrease ever recorded and was the lowest recorded rate since national tuberculosis surveillance began in 1953.

The Advisory Council for the Elimination of Tuberculosis has called for a renewed commitment to eliminating tuberculosis in the United States, and the Institute of Medicine has published a detailed plan for achieving that goal. Patients with HIV infection are at an especially high risk for tuberculosis, and tuberculosis preventive therapy in the era of HIV will require further work to overcome implementation barriers and to identify optimal duration of preventive therapy and treatment approach for individuals receiving highly active antiretroviral therapy (HAART).

Treatment of tuberculosis poses a risk of hepatotoxicity and thus requires close monitoring of liver transaminases.

Alanine aminotransferase (ALT) monitoring during the treatment of latent tuberculosis infection is recommended for certain individuals (preexisting liver disease, pregnancy, chronic alcohol consumption). ALT should be monitored in HIV-infected patients during treatment of tuberculosis disease and should be considered in patients over the age of 35. Symptomatic patients with an ALT elevation three times the upper limit of normal (ULN) or asymptomatic patients with an elevation five times the ULN should be treated with a modified or alternative regimen.

In 2010, the Centers for Disease Control and Prevention (CDC) updated guidelines for the prevention and treatment of sexually transmitted diseases. Highlights of these guidelines include updated treatments for bacterial vaginosis and genital warts as well as antibiotic-resistant *Neisseria gonorrhoeae*, the prevalence of which has risen.

HIV infection is a major infectious disease problem in the world, and it affects 850,000–950,000 persons in the United States. Since sexual contact is a common mode of transmission, primary prevention relies on eliminating unsafe sexual behavior by promoting abstinence, later onset of first sexual activity, decreased number of partners, and use of latex condoms. Appropriately used, condoms can reduce the rate of HIV transmission by nearly 70%. In one study, couples with one infected partner who used condoms inconsistently had a considerable risk of infection: the rate of seroconversion was estimated to be 13% after 24 months. No seroconversions were noted with consistent condom use. Unfortunately, as many as one-third of HIV-positive persons continue unprotected sexual practices after learning that they are HIV-infected. Preexposure prophylaxis with antiretroviral drugs in men who have sex with men could have a major impact on preventing HIV infection, and studies evaluating the impact in other groups are underway. Postexposure prophylaxis is widely used after occupational and nonoccupational contact, and it has been estimated to reduce the risk of transmission by approximately 80%.

With regard to secondary prevention, many HIV-infected persons in the United States receive the diagnosis at advanced stages of immunosuppression, and almost all will progress to AIDS if untreated. On the other hand, HAART substantially reduces the risk of clinical progression or death in patients with advanced immunosuppression. Screening tests for HIV are extremely (> 99%) accurate. While the benefits of HIV screening appear to outweigh its harms, current screening is generally based on individual patient risk factors. Such screening can identify persons at risk for AIDS but misses a substantial proportion of those infected. Nonetheless, the yield from screening higher prevalence populations is substantially greater than that from screening the general population, and more widespread screening of the population remains controversial.

In immunocompromised patients, live vaccines are contraindicated but many killed or component vaccines are safe and recommended. *Asymptomatic* HIV-infected patients have not shown adverse consequences when given live MMR and influenza vaccinations as well as tetanus, hepatitis B,

H influenzae type b and pneumococcal vaccinations—all should be given. However, if poliomyelitis immunization is required, the inactivated poliomyelitis vaccine is indicated. In *symptomatic* HIV-infected patients, live virus vaccines such as MMR should generally be avoided, but annual influenza vaccination is safe.

Whenever possible, immunizations should be completed before procedures that require or induce immunosuppression (organ transplantation or chemotherapy), or that reduce immunogenic responses (splenectomy). However, if this is not possible, the patient may mount only a partial immune response, yet even this partial response can be beneficial. Patients who undergo allogeneic bone marrow transplantation lose preexisting immunities and should be revaccinated. In many situations, family members should also be vaccinated to protect the immunocompromised patient, although oral live polio vaccine should be avoided because of the risk of infecting the patient.

Herpes zoster, caused by reactivation from previous varicella zoster virus (VZV) infection, affects many older adults and people with immune system dysfunction. Whites are at higher risk than other ethnic groups and the incidence in adults age 65 and older may be higher than previously described. It can cause postherpetic neuralgia, a potentially debilitating chronic pain syndrome. A varicella vaccine is available for the prevention of herpes zoster. Several clinical trials have shown that this vaccine (Zostavax) is safe, elevates VZV-specific cell-mediated immunity, and significantly reduces the incidence of herpes zoster and postherpetic neuralgia in persons older than 60 years. In one randomized, double-blind, placebo-controlled trial among more than 38,000 older adults, the vaccine reduced the incidence of postherpetic neuralgia by 66% and the incidence of herpes zoster by 51%. The ACIP recommends routine zoster vaccination, administered as a one-time subcutaneous dose (0.65 mL), of all persons aged 60 years or older. Persons who report a previous episode of zoster can be vaccinated; however, the vaccine is contraindicated in immunocompromised (primary or acquired) individuals. The durability of vaccine response and whether any booster vaccination is needed are still uncertain. The cost effectiveness of the vaccine varies substantially, and the patient's age should be considered in vaccine recommendations. One study reported a cost-effectiveness exceeding \$100,000 per quality-adjusted life year saved. Despite its availability, uptake of the vaccine remains low at 2–7% nationally. Financial barriers (cost, limited knowledge of reimbursement) have had a significant impact on its underutilization.

Methicillin-resistant *Staphylococcus aureus* (MRSA), previously recognized as a nosocomial pathogen, has emerged as a common cause of staphylococcal infection in the outpatient setting; it accounts for more than 50% of outpatient staphylococcal infections. Community-acquired (CA)-MRSA strains affect healthy individuals, and the burden of disease can range from a furuncle to more severe life-threatening infections. Treatment of CA-MRSA is different from nosocomial MRSA because CA-MRSA strains typically retain susceptibility to antibiotics that are ineffective in treating nosocomial strains.

American Academy of Pediatrics. 2011 Immunization Schedules: Persons Aged 7–18 Years. <http://www.aap.org/immunization/IZSchedule.html>

Cataldo MA et al. Methicillin-resistant *Staphylococcus aureus*: a community health threat. *Postgrad Med*. 2010 Nov;122(6):16–23. [PMID: 21084777]

Centers for Disease Control and Prevention (CDC). ACIP recommends all 11–12 year-old males get vaccinated against HPV. http://www.cdc.gov/media/releases/2011/a1025_ACIP_HPV_Vote.html

Centers for Disease Control and Prevention (CDC). Decrease in reported tuberculosis cases—United States, 2009. *MMWR Morb Mortal Wkly Rep*. 2010 Mar 19;59(10):289–94. [PMID: 20300055]

Centers for Disease Control and Prevention (CDC). Pertussis (whooping cough) outbreaks, 2010. <http://www.cdc.gov/pertussis/outbreaks.html>

Centers for Disease Control and Prevention (CDC). Recommended adult immunization schedule—United States, 2011. *MMWR Morb Mortal Wkly Rep*. 2011 Feb 4;60(4):1–4. [PMID: 21381442]

Fiore AE et al; Centers for Disease Control and Prevention (CDC). Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. *MMWR Recomm Rep*. 2010 Aug 6;59(RR-8):1–62. [PMID: 20689501]

Gidengil CA et al. Tetanus-diphtheria-acellular pertussis vaccination of adults in the USA. *Expert Rev Vaccines*. 2008 Jul;7(5):621–34. [PMID: 18564017]

Hurley LP et al. Barriers to the use of herpes zoster vaccine. *Ann Intern Med*. 2010 May 4;152(9):555–60. [PMID: 20439573]

Kelesidis T et al. Preexposure prophylaxis for HIV prevention. *Curr HIV/AIDS Rep*. 2011 Jun;8(2):94–103. [PMID: 21465112]

Mazurek GH et al. Updated guidelines for using interferon gamma release assays to detect *Mycobacterium tuberculosis* infection—United States, 2010. *MMWR Recomm Rep*. 2010 Jun 25;59(RR-5):1–25. [PMID: 20577159]

Rey D. Post-exposure prophylaxis for HIV infection. *Expert Rev Anti Infect Ther*. 2011 Apr;9(4):431–42. [PMID: 21504400]

Sanford M et al. Zoster vaccine (Zostavax): a review of its use in preventing herpes zoster and postherpetic neuralgia in older adults. *Drugs Aging*. 2010 Feb 1;27(2):159–76. [PMID: 20104941]

Victor JC et al. Hepatitis A vaccine versus immune globulin for postexposure prophylaxis. *N Engl J Med*. 2007 Oct 25;357(17):1685–94. [PMID: 17947390]

Workowski KA et al; Centers for Disease Control and Prevention (CDC). Sexually transmitted diseases treatment guidelines, 2010. *MMWR Recomm Rep*. 2010 Dec 17;59(RR-12):1–110. Erratum in *MMWR Recomm Rep*. 2011 Jan 14;60(1);18. [PMID: 21160459]

Zhu FC et al. Efficacy and safety of a recombinant hepatitis E vaccine in healthy adults: a large-scale, randomized, double-blind placebo-controlled, phase 3 trial. *Lancet*. 2010 Sep 11;376(9744):895–902. [PMID: 20728932]

PREVENTION OF CARDIOVASCULAR DISEASE

Cardiovascular diseases, including coronary heart disease (CHD) and stroke, represent two of the most important causes of morbidity and mortality in developed countries. Several risk factors increase the risk for coronary disease and stroke. These risk factors can be divided into those that are modifiable (eg, lipid disorders, hypertension, cigarette smoking) and those that are not (eg, gender, age, family history of early coronary disease). Impressive

declines in age-specific mortality rates from heart disease and stroke have been achieved in all age groups in North America during the past two decades, in large part through improvement of modifiable risk factors: reductions in cigarette smoking, improvements in lipid levels, and more aggressive detection and treatment of hypertension. This section considers the role of screening for cardiovascular risk and the use of effective therapies to reduce such risk. Key recommendations for cardiovascular prevention are shown in Table 1–3.

Kahn R et al. The impact of prevention on reducing the burden of cardiovascular disease. *Circulation*. 2008 Jul 29;118(5):576–85. [PMID: 18606915]

▶ Abdominal Aortic Aneurysm

One-time screening for abdominal aortic aneurysm (AAA) by ultrasonography in men aged 65–75 years is associated with a significant reduction in AAA-related mortality (odds ratio, 0.56 [95% CI, 0.44 to 0.72]). With long-term (7–15 years) follow-up, the reduction in AAA-related mortality is sustained, and screening appears to produce a reduction in all-cause mortality (OR = 0.94, 95% CI 0.92, 0.97). Women do not appear to benefit from screening, and most of the benefit in men appears to accrue among current or former smokers. Recent analyses suggest that screening men aged 65 years and older is highly cost-effective.

Lindholt JS et al. Long-term benefit and cost-effectiveness analysis of screening for abdominal aortic aneurysms from a randomized controlled trial. *Br J Surg*. 2010 Jun;97(6):826–34. [PMID: 20473995]

Lindholt JS et al. Screening for abdominal aortic aneurysm reduces overall mortality in men. A meta-analysis of the mid- and long-term effects of screening for abdominal aortic aneurysms. *Eur J Vasc Endovasc Surg*. 2008 Aug;36(2):167–71. [PMID: 18485756]

Thompson SG et al. Screening men for abdominal aortic aneurysm: 10 year mortality and cost effectiveness results from the randomised Multicentre Aneurysm Screening Study. *BMJ*. 2009 Jun 24;338:b2307. [PMID: 19553269]

▶ Cigarette Smoking

Cigarette smoking remains the most important cause of preventable morbidity and early mortality. In 2000, there were an estimated 4.8 million premature deaths in the world attributable to smoking, 2.4 million in developing countries and 2 million in industrialized countries. More than three-quarters (3.8 million) of these deaths were in men. The leading causes of death from smoking were cardiovascular diseases (1.7 million deaths), chronic obstructive pulmonary disease (COPD) (1 million deaths), and lung cancer (0.9 million deaths). Cigarettes are responsible for one in every four deaths in the United States. Fortunately, US smoking rates are declining. Currently, 20% of US adults and 21.6% of adolescents in 12th grade are smokers.

Nicotine is highly addictive, raises brain levels of dopamine, and produces withdrawal symptoms on discontinuation.

Smokers die 5–8 years earlier than never-smokers. They have twice the risk of fatal heart disease, 10 times the risk of lung cancer, and several times the risk of cancers of the mouth, throat, esophagus, pancreas, kidney, bladder, and cervix; a twofold to threefold higher incidence of stroke and peptic ulcers (which heal less well than in non-smokers); a twofold to fourfold greater risk of fractures of the hip, wrist, and vertebrae; four times the risk of invasive pneumococcal disease; and a twofold increase in cataracts.

In the United States, over 90% of cases of COPD occur among current or former smokers. Both active smoking and passive smoking are associated with deterioration of the elastic properties of the aorta (increasing the risk of aortic aneurysm) and with progression of carotid artery atherosclerosis. Smoking has also been associated with increased risks of leukemia, of colon and prostate cancers, of breast cancer among postmenopausal women who are slow acetylators of *N*-acetyltransferase-2 enzymes, osteoporosis, and Alzheimer disease. In cancers of the head and neck, lung, esophagus, and bladder, smoking is linked to mutations of the *P53* gene, the most common genetic change in human cancer. Patients with head and neck cancer who continue to smoke during radiation therapy have lower rates of response than those who do not smoke. Olfaction and taste are impaired in smokers, and facial wrinkles are increased. Heavy smokers have a 2.5 greater risk of age-related macular degeneration.

The children of smokers have lower birth weights, are more likely to be mentally retarded, have more frequent respiratory infections and less efficient pulmonary function, have a higher incidence of chronic ear infections than children of nonsmokers, and are more likely to become smokers themselves.

In addition, exposure to environmental tobacco smoke has been shown to increase the risk of cervical cancer, lung cancer, invasive pneumococcal disease, and heart disease; to promote endothelial damage and platelet aggregation; and to increase urinary excretion of tobacco-specific lung carcinogens. The incidence of breast cancer may be increased as well. Of approximately 450,000 smoking-related deaths in the United States annually, as many as 53,000 are attributable to environmental tobacco smoke. Annual costs of smoking-related health care is approximately \$96 billion per year in the United States, with another \$97 billion in productivity losses.

Smoking cessation reduces the risks of death and of myocardial infarction in people with coronary artery disease; reduces the rate of death and acute myocardial infarction in patients who have undergone percutaneous coronary revascularization; lessens the risk of stroke; slows the rate of progression of carotid atherosclerosis; and is associated with improvement of COPD symptoms. On average, women smokers who quit smoking by age 35 add about 3 years to their life expectancy, and men add more than 2 years to theirs. Smoking cessation can increase life expectancy even for those who stop after the age of 65.

Although tobacco use constitutes the most serious common medical problem, it is undertreated. Almost 40% of smokers attempt to quit each year, but only 4%

Table 1-3. Expert recommendations for cardiovascular prevention methods: US Preventive Services Task Force (USPSTF).¹

Prevention Method	Recommendation
Screening for abdominal aortic aneurysm	<p>Recommends one-time screening for abdominal aortic aneurysm (AAA) by ultrasonography in men aged 65 to 75 who have ever smoked. (B)</p> <p>No recommendation for or against screening for AAA in men aged 65 to 75 who have never smoked. (C)</p> <p>Recommends against routine screening for AAA in women. (D)</p>
Aspirin use	<p>Recommends the use of aspirin for men age 45 to 79 years when the potential benefit due to a reduction in myocardial infarctions outweighs the potential harm due to an increase in gastrointestinal hemorrhage. (A)</p> <p>Recommends the use of aspirin for women age 55 to 79 years when the potential benefit of a reduction in ischemic strokes outweighs the potential harm of an increase in gastrointestinal hemorrhage. (A)</p> <p>Current evidence is insufficient to assess the balance of benefits and harms of aspirin for cardiovascular disease prevention in men and women 80 years or older. (I)</p> <p>Recommends against the use of aspirin for stroke prevention in women younger than 55 years and for myocardial infarction prevention in men younger than 45. (D)</p>
Blood pressure screening	Recommends screening for high blood pressure in adults aged 18 and older. (A)
Serum lipid screening	<p>Strongly recommends screening men aged 35 and older for lipid disorders. (A)</p> <p>Recommends screening men aged 20 to 35 for lipid disorders if they are at increased risk for coronary heart disease. (B)</p> <p>Strongly recommends screening women aged 45 and older for lipid disorders if they are at increased risk for coronary heart disease. (A)</p> <p>Recommends screening women aged 20 to 45 for lipid disorders if they are at increased risk for coronary heart disease. (B)</p> <p>No recommendation for or against routine screening for lipid disorders in men aged 20 to 35, or in women aged 20 and older who are not at increased risk for coronary heart disease. (C)</p>
Counseling about healthy diet	<p>Evidence is insufficient to recommend for or against routine behavioral counseling to promote a healthy diet in unselected patients in primary care settings. (I)</p> <p>Recommends intensive behavioral dietary counseling for adult patients with hyperlipidemia and other known risk factors for cardiovascular and diet-related chronic disease. Intensive counseling can be delivered by primary care clinicians or by referral to other specialists, such as nutritionists or dietitians. (B)</p>
Screening for diabetes mellitus	<p>Recommends screening for type 2 diabetes mellitus in asymptomatic adults with sustained blood pressure (either treated or untreated) > 135/80 mm Hg. (B)</p> <p>Current evidence is insufficient to assess the balance of benefits and harms of screening for type 2 diabetes in asymptomatic adults with blood pressure of 135/80 mm Hg or lower. (I)</p>
Counseling to promote physical activity	Evidence is insufficient to recommend for or against behavioral counseling in primary care settings to promote physical activity. (I)
Screening for smoking and counseling to promote cessation	Recommends that clinicians ask all adults about tobacco use and provide tobacco cessation interventions for those who use tobacco products. (A)

Recommendation A: The USPSTF strongly recommends that clinicians routinely provide the service to eligible patients. (The USPSTF found good evidence that the service improves important health outcomes and concludes that benefits substantially outweigh harms.)

Recommendation B: The USPSTF recommends that clinicians routinely provide the service to eligible patients. (The USPSTF found at least fair evidence that the service improves important health outcomes and concludes that benefits substantially outweigh harms.)

Recommendation C: The USPSTF makes no recommendation for or against routine provision of the service.

Recommendation D: The USPSTF recommends against routinely providing the service to asymptomatic patients. (The USPSTF found at least fair evidence that the service is ineffective or that harms outweigh benefits.)

Recommendation I: The USPSTF concludes that the evidence is insufficient to recommend for or against routinely providing the service. <http://www.uspreventiveservicestaskforce.org/3rduspstf/ratings.htm>

are successful. Persons whose clinicians advise them to quit are 1.6 times as likely to attempt quitting. Over 70% of smokers see a physician each year, but only 20% of them receive any medical quitting advice or assistance.

Factors associated with successful cessation include having a rule against smoking in the home, being older, and having greater education. Several effective interventions are available to promote smoking cessation, including counseling, pharmacotherapy, and combinations of the two. The five steps for helping smokers quit are summarized in Table 1–4.

Common elements of supportive smoking cessation treatments are reviewed in Table 1–5. A system should be implemented to identify smokers, and advice to quit should be tailored to the patient's level of readiness to change. Pharmacotherapy to reduce cigarette consumption is ineffective in smokers who are unwilling or not ready to quit. Conversely, all patients trying to quit should be offered pharmacotherapy except those with medical contraindications, women who are pregnant or breast-feeding, and adolescents. Weight gain occurs in most patients (80%) following smoking cessation. For many, it averages 2 kg, but for others (10–15%) major weight gain—over 13 kg—may occur. Planning for the possibility of weight gain, and means of mitigating it, may help with maintenance of cessation.

Several pharmacologic therapies have been shown to be effective in promoting cessation. Nicotine replacement therapy doubles the chance of successful quitting. The nicotine patch, gum, and lozenges are available over-the-counter, and nicotine nasal spray and inhalers by prescription. The sustained-release antidepressant drug bupropion (150–300 mg/d orally) is an effective smoking cessation agent and is associated with minimal weight gain, although seizures are a contraindication. It acts by boosting brain levels of dopamine and norepinephrine, mimicking the effect of nicotine. More recently, varenicline, a partial nicotinic acetylcholine-receptor agonist, has been shown to improve cessation rates; however, its adverse effects, particularly its effects on mood, are not completely understood and warrant careful consideration. No single pharmacotherapy is clearly more effective than others, so patient preferences and data on adverse effects should be taken into account in selecting a treatment.

Clinicians should not show disapproval of patients who failed to stop smoking or who are not ready to make a quit attempt. Thoughtful advice that emphasizes the benefits of cessation and recognizes common barriers to success can increase motivation to quit and quit rates. An intercurrent illness such as acute bronchitis or acute myocardial infarction may motivate even the most addicted smoker to quit.

Individualized or group counseling is very cost-effective, even more so than treating hypertension. Smoking cessation counseling by telephone (“quitlines”) has proved effective, and a recent trial showed a text messaging-based intervention to be effective. An additional strategy is to recommend that any smoking take place out of doors to limit the effects of passive smoke on housemates and coworkers. This can lead to smoking reduction and quitting.

The clinician's role in smoking cessation is summarized in Table 1–4. Public policies, including higher cigarette taxes and more restrictive public smoking laws, have also been shown to encourage cessation, as have financial incentives directed to patients.

Centers for Disease Control and Prevention (CDC). Smoking-attributable mortality, years of potential life lost, and productivity losses—United States, 2000–2004. *MMWR Morb Mortal Wkly Rep.* 2008 Nov 14;57(45):1226–8. [PMID: 19008791]

Eisenberg MJ et al. Pharmacotherapies for smoking cessation: a meta-analysis of randomized controlled trials. *CMAJ.* 2008 Jul 15;179(2):135–44. [PMID: 18625984]

Free C et al. Smoking cessation support delivered via mobile phone text messaging (txt2stop): a single-blind, randomised trial. *Lancet.* 2011 Jul 2;378(9785):49–55. [PMID: 21722952]

Lee CW et al. Factors associated with successful smoking cessation in the United States, 2000. *Am J Public Health.* 2007 Aug; 97(8):1503–9. [PMID: 17600268]

Moore D et al. Effectiveness and safety of nicotine replacement therapy assisted reduction to stop smoking: systematic review and meta-analysis. *BMJ.* 2009 Apr 2;338:b1024. [PMID: 19342408]

Mottillo S et al. Behavioural interventions for smoking cessation: a meta-analysis of randomized controlled trials. *Eur Heart J.* 2009 Mar;30(6):718–30. [PMID: 19109354]

Myung SK et al. Effects of Web- and computer-based smoking cessation programs: meta-analysis of randomized controlled trials. *Arch Intern Med.* 2009 May 25;169(10):929–37. [PMID: 19468084]

Stead LF et al. Physician advice for smoking cessation. *Cochrane Database Syst Rev.* 2008 Apr 16;(2):CD000165. [PMID: 18253970]

Volpp KG et al. A randomized, controlled trial of financial incentives for smoking cessation. *N Engl J Med.* 2009 Feb 12; 360(7):699–709. [PMID: 19213683]

► Lipid Disorders

Higher low-density lipoprotein (LDL) cholesterol concentrations and lower high-density lipoprotein (HDL) levels are associated with an increased risk of CHD. Cholesterol lowering therapy reduces the relative risk of CHD events, with the degree of reduction proportional to the reduction in LDL cholesterol achieved. The absolute benefits of screening for—and treating—abnormal lipid levels depend on the presence and number of other cardiovascular risk factors, including hypertension, diabetes, smoking, age, and gender. If other risk factors are present, cardiovascular risk is higher and the benefits of therapy are greater. Patients with known cardiovascular disease are at higher risk and have larger benefits from reduction in LDL cholesterol.

Evidence for the effectiveness of statin-type drugs is better than for the other classes of lipid-lowering agents or dietary changes specifically for improving lipid levels. Multiple large randomized, placebo-controlled trials have demonstrated important reductions in total mortality, major coronary events, and strokes with lowering levels of LDL cholesterol by statin therapy for patients with known cardiovascular disease. Statins also reduce cardiovascular events for patients with diabetes mellitus. For patients with

Table 1-4. Actions and strategies for the primary care clinician to help patients quit smoking.

Action	Strategies for Implementation
Step 1. Ask—Systematically Identify All Tobacco Users at Every Visit	
Implement an officewide system that ensures that for every patient at every clinic visit, tobacco-use status is queried and documented ¹	Expand the vital signs to include tobacco use. Data should be collected by the health care team. The action should be implemented using preprinted progress note paper that includes the expanded vital signs, a vital signs stamp or, for computerized records, an item assessing tobacco-use status. Alternatives to the vital signs stamp are to place tobacco-use status stickers on all patients' charts or to indicate smoking status using computerized reminder systems.
Step 2. Advise—Strongly Urge All Smokers to Quit	
In a clear, strong, and personalized manner, urge every smoker to quit	Advice should be Clear: "I think it is important for you to quit smoking now, and I will help you. Cutting down while you are ill is not enough." Strong: "As your clinician, I need you to know that quitting smoking is the most important thing you can do to protect your current and future health." Personalized: Tie smoking to current health or illness and/or the social and economic costs of tobacco use, motivational level/readiness to quit, and the impact of smoking on children and others in the household. Encourage clinic staff to reinforce the cessation message and support the patient's quit attempt.
Step 3. Attempt—Identify Smokers Willing to Make a Quit Attempt	
Ask every smoker if he or she is willing to make a quit attempt at this time	If the patient is willing to make a quit attempt at this time, provide assistance (see step 4). If the patient prefers a more intensive treatment or the clinician believes more intensive treatment is appropriate, refer the patient to interventions administered by a smoking cessation specialist and follow up with him or her regarding quitting (see step 5). If the patient clearly states he or she is not willing to make a quit attempt at this time, provide a motivational intervention.
Step 4. Assist—Aid the Patient in Quitting	
A. Help the patient with a quit plan	Set a quit date. Ideally, the quit date should be within 2 weeks, taking patient preference into account. Help the patient prepare for quitting. The patient must: Inform family, friends, and coworkers of quitting and request understanding and support. Prepare the environment by removing cigarettes from it. Prior to quitting, the patient should avoid smoking in places where he or she spends a lot of time (eg, home, car). Review previous quit attempts. What helped? What led to relapse? Anticipate challenges to the planned quit attempt, particularly during the critical first few weeks.
B. Encourage nicotine replacement therapy except in special circumstances	Encourage the use of the nicotine patch or nicotine gum therapy for smoking cessation
C. Give key advice on successful quitting	Abstinence: Total abstinence is essential. Not even a single puff after the quit date. Alcohol: Drinking alcohol is highly associated with relapse. Those who stop smoking should review their alcohol use and consider limiting or abstaining from alcohol use during the quit process. Other smokers in the household: The presence of other smokers in the household, particularly a spouse, is associated with lower success rates. Patients should consider quitting with their significant others and/or developing specific plans to maintain abstinence in a household where others still smoke.
D. Provide supplementary materials	Source: Federal agencies, including the National Cancer Institute and the Agency for Health Care Policy and Research; nonprofit agencies (American Cancer Society, American Lung Association, American Heart Association); or local or state health departments. Selection concerns: The material must be culturally, racially, educationally, and age appropriate for the patient. Location: Readily available in every clinic office.

(continued)

Table 1-4. Actions and strategies for the primary care clinician to help patients quit smoking. (continued)

Action	Strategies for Implementation
Step 5. Arrange—Schedule Follow-Up Contact	
Schedule follow-up contact, either in person or via telephone	<p>Timing: Follow-up contact should occur soon after the quit date, preferably during the first week. A second follow-up contact is recommended within the first month. Schedule further follow-up contacts as indicated.</p> <p>Actions during follow-up: Congratulate success. If smoking occurred, review the circumstances and elicit recommitment to total abstinence. Remind the patient that a lapse can be used as a learning experience and is not a sign of failure. Identify the problems already encountered and anticipate challenges in the immediate future. Assess nicotine replacement therapy use and problems. Consider referral to a more intense or specialized program.</p>

Repeated assessment is not necessary in the case of the adult who has never smoked or not smoked for many years and for whom the information is clearly documented in the medical record.

Adapted and reproduced, with permission, from: The Agency for Health Care Policy and Research. Smoking Cessation Clinical Practice Guideline. JAMA. 1996 Apr 24;275(16):1270-80. Copyright © 1996 American Medical Association. All rights reserved.

no previous history of cardiovascular events or diabetes, a meta-analysis showed important reductions of cardiovascular events. The JUPITER trial suggested that statins reduce coronary events relatively similarly for both men and women.

Table 1-5. Common elements of supportive smoking treatments.

Component	Examples
Encouragement of the patient in the quit attempt	Note that effective cessation treatments are now available. Note that half the people who have ever smoked have now quit. Communicate belief in the patient's ability to quit.
Communication of caring and concern	Ask how the patient feels about quitting. Directly express concern and a willingness to help. Be open to the patient's expression of fears of quitting, difficulties experienced, and ambivalent feelings.
Encouragement of the patient to talk about the quitting process	Ask about: Reasons that the patient wants to quit. Difficulties encountered while quitting. Success the patient has achieved. Concerns or worries about quitting.
Provision of basic information about smoking and successful quitting	Inform the patient about: The nature and time course of withdrawal. The addictive nature of smoking. The fact that any smoking (even a single puff) increases the likelihood of full relapse.

Adapted, with permission, from: The Agency for Health Care Policy and Research. Smoking Cessation Clinical Practice Guideline. JAMA. 1996 Apr 24;275(16):1270-80. Copyright © 1996 American Medical Association. All rights reserved.

Guidelines for therapy are discussed in Chapter 28.

Brugts JJ et al. The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials. *BMJ*. 2009 Jun 30;338:b2376. [PMID: 19567909]

Cholesterol Treatment Trialists' (CTT) Collaborators; Kearney PM et al. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. *Lancet*. 2008 Jan 12;371(9607):117-25. [PMID: 18191683]

Ridker PM et al; JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. *N Engl J Med*. 2008 Nov 20;359(21):2195-207. [PMID: 18997196]

▶ Hypertension

Over 43 million adults in the United States have hypertension, but 31% are unaware of their elevated blood pressure; 17% are aware but untreated; 29% are being treated but have not controlled their blood pressure (still greater than 140/90 mm Hg); and only 23% are well controlled. In every adult age group, higher values of systolic and diastolic blood pressure carry greater risks of stroke and congestive heart failure. Systolic blood pressure is a better predictor of morbid events than diastolic blood pressure. Home monitoring is better correlated with target organ damage than clinic-based values. Clinicians can apply specific blood pressure criteria, such as those of the Joint National Committee, along with consideration of the patient's cardiovascular risk and personal values, to decide at what levels treatment should be considered in individual cases. Table 11-1 presents a classification of hypertension based on blood pressures.

Primary prevention of hypertension can be accomplished by strategies aimed at both the general population and special high-risk populations. The latter include persons with high-normal blood pressure or a family history of hypertension, blacks, and individuals with various behavioral risk factors such as physical inactivity; excessive consumption of salt, alcohol, or calories; and deficient

intake of potassium. Effective interventions for primary prevention of hypertension include reduced sodium and alcohol consumption, weight loss, and regular exercise. Potassium supplementation lowers blood pressure modestly, and a diet high in fresh fruits and vegetables and low in fat, red meats, and sugar-containing beverages also reduces blood pressure. Interventions of unproven efficacy include pill supplementation of potassium, calcium, magnesium, fish oil, or fiber; macronutrient alteration; and stress management.

Improved identification and treatment of hypertension is a major cause of the recent decline in stroke deaths as well as the reduction in incidence of heart failure-related hospitalizations. Because hypertension is usually asymptomatic, screening is strongly recommended to identify patients for treatment. Despite strong recommendations in favor of screening and treatment, hypertension control remains suboptimal. An intervention that included patient education and provider education was more effective than provider education alone in achieving control of hypertension, suggesting the benefits of patient participation; another trial found that home monitoring combined with telephone-based nurse support was more effective than home monitoring alone for blood pressure control. Pharmacologic management of hypertension is discussed in Chapter 11.

Bosworth HB et al. Two self-management interventions to improve hypertension control: a randomized trial. *Ann Intern Med.* 2009 Nov 17;151(10):687–95. [PMID: 19920269]
Wolff T et al. Evidence for the reaffirmation of the U.S. Preventive Services Task Force recommendation on screening for high blood pressure. *Ann Intern Med.* 2007 Dec 4; 147(11):787–91. [PMID: 18056663]

► Chemoprevention

As discussed in Chapters 10 and 24, regular use of low-dose aspirin (81–325 mg) can reduce the incidence of myocardial infarction in men. Low-dose aspirin reduces stroke but not myocardial infarction in middle-aged women. Based on its ability to prevent cardiovascular events, aspirin use appears cost-effective for men and women who are at increased cardiovascular risk, which can be defined as 10-year risk over 10%. Results from a meta-analysis suggest that aspirin may also reduce the risk of death from several common types of cancer.

Nonsteroidal anti-inflammatory drugs may reduce the incidence of colorectal adenomas and polyps but may also increase heart disease and gastrointestinal bleeding, and thus are not recommended for colon cancer prevention in average risk patients.

Antioxidant vitamin (vitamin E, vitamin C, and beta-carotene) supplementation produced no significant reductions in the 5-year incidence of—or mortality from—vascular disease, cancer, or other major outcomes in high-risk individuals with coronary artery disease, other occlusive arterial disease, or diabetes mellitus. More recently, a large prospective cohort study found modestly increased risk of mortality with several common dietary supplements.

Antithrombotic Trialists' (ATT) Collaboration; Baigent C et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. *Lancet.* 2009 May 30;373(9678): 1849–60. [PMID: 19482214]
Greving JP et al. Cost-effectiveness of aspirin treatment in the primary prevention of cardiovascular disease events in subgroups based on age, gender, and varying cardiovascular risk. *Circulation.* 2008 Jun 3;117(22):2875–83. [PMID: 18506010]
Mursu J et al. Dietary supplements and mortality rate in older women: the Iowa Women's Health Study. *Arch Intern Med.* 2011 Oct 10;171(18):1625–33. [PMID: 21987192]
Rothwell P et al. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. *Lancet.* 2011 Jan 1;377(9759):31–41. [PMID: 21144578]
Wolff T et al. Aspirin for the primary prevention of cardiovascular events: an update of the evidence for the U.S. Preventive Services Task Force. *Ann Intern Med.* 2009 Mar 17;150(6): 405–10. [PMID: 19293073]

PREVENTION OF OSTEOPOROSIS

Osteoporosis, characterized by low bone mineral density, is common and associated with an increased risk of fracture. The lifetime risk of an osteoporotic fracture is approximately 50% for women and 30% for men. Osteoporotic fractures can cause significant pain and disability. As such, research has focused on means of preventing osteoporosis and related fractures. Primary prevention strategies include calcium supplementation, vitamin D supplementation, and exercise programs. A 2007 systematic review and meta-analysis found that calcium supplementation of 1200 mg per day or more (with or without vitamin D) could decrease fracture risk for adults (mainly women were studied) over age 50. Vitamin D supplements alone do not appear to reduce fracture risk.

Screening for osteoporosis on the basis of low bone mineral density is also recommended for women over age 60, based on indirect evidence that screening can identify women with low bone mineral density and that treatment of women with low bone density with bisphosphonates is effective in reducing fractures. However, real-world adherence to pharmacologic therapy for osteoporosis is low: one-third to one-half of patients do not take their medication as directed. The effectiveness of screening for osteoporosis in younger women and in men has not been established. Concern has been raised that bisphosphonates may increase the risk of certain types of fractures and osteonecrosis of the jaw, making consideration of the benefits and risks of therapy important when considering screening.

Avenell A et al. Vitamin D and vitamin D analogues for preventing fractures associated with involutional and post-menopausal osteoporosis. *Cochrane Database Syst Rev.* 2009 Apr 15;(2): CD000227. [PMID: 19370554]
Giusti A et al. Atypical fractures of the femur and bisphosphonate therapy: a systematic review of case/case series studies. *Bone.* 2010 Aug;47(2):169–80. [PMID: 20493982]
Hilgsmann M et al. Cost-effectiveness of osteoporosis screening followed by treatment: the impact of medication adherence. *Value Health.* 2010 Jun–Jul;13(4):394–401. [PMID: 20102558]

Kanis JA et al; European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). European guidance for the diagnosis and management of osteoporosis in postmenopausal women. *Osteoporos Int*. 2008 Apr;19(4):399–428. [PMID: 18266020]

Tang BM. Use of calcium or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50 years and older: a meta-analysis. *Lancet*. 2007 Aug 25;370(9588):657–66. [PMID: 17720017]

Wang L et al. Systematic review: Vitamin D and calcium supplementation in prevention of cardiovascular events. *Ann Intern Med*. 2010 Mar 2;152(5):315–23. [PMID: 20194238]

PREVENTION OF PHYSICAL INACTIVITY

Lack of sufficient physical activity is the second most important contributor to preventable deaths, trailing only tobacco use. A sedentary lifestyle has been linked to 28% of deaths from leading chronic diseases. The US Department of Health and Human Services and the CDC recommends that adults and older adults engage in 150 minutes of moderate-intensity (such as brisk walking) or 75 minutes of vigorous-intensity aerobic activity (such as jogging or running) or an equivalent mix of moderate- and vigorous-intensity aerobic activity each week. In addition to the activity recommendations, the CDC recommends activities to strengthen all major muscle groups (abdomen, arms, back, chest, hips, legs, and shoulders) at least twice a week.

Patients who engage in regular moderate to vigorous exercise have a lower risk of myocardial infarction, stroke, hypertension, hyperlipidemia, type 2 diabetes mellitus, diverticular disease, and osteoporosis. Evidence supports the recommended guidelines of 30 minutes of moderate physical activity on most days of the week in both the primary and secondary prevention of CHD.

In older nonsmoking men, walking 2 miles or more per day is associated with an almost 50% lower age-related mortality. Diet and increased physical activity have been shown to prevent the onset of diabetes, which has reached epidemic proportions in the United States. In sedentary individuals with dyslipidemia, high amounts of high-intensity exercise produce significant beneficial effects on serum lipoprotein profiles. Physical activity is associated with a lower risk of colon cancer (although not rectal cancer) in men and women and of breast and reproductive organ cancer in women. Finally, weight-bearing exercise (especially resistance and high-impact activities) increases bone mineral content and retards development of osteoporosis in women and contributes to a reduced risk of falls in older persons. Resistance training has been shown to enhance muscular strength, functional capacity, and quality of life in men and women with and without CHD and is endorsed by the American Heart Association.

Exercise may also confer benefits on those with chronic illness. Men and women with chronic symptomatic osteoarthritis of one or both knees benefited from a supervised walking program, with improved self-reported functional status and decreased pain and use of pain medication. Exercise produces sustained lowering of both systolic and diastolic blood pressure in patients with mild hypertension. Physical activity reduces depression and anxiety;

improves adaptation to stress; improves sleep quality; and enhances mood, self-esteem, and overall performance.

In longitudinal cohort studies, individuals who report higher levels of leisure time physical activity are less likely to gain weight. Conversely, individuals who are overweight are less likely to stay active. However, at least 60 minutes of daily moderate-intensity physical activity may be necessary to maximize weight loss and prevent significant weight regain. Moreover, adequate levels of physical activity appear to be important for the prevention of weight gain and the development of obesity. Physical activity also appears to have an independent effect on health-related outcomes such as development of type 2 diabetes mellitus in patients with impaired glucose tolerance when compared with body weight, suggesting that adequate levels of activity may counteract the negative influence of body weight on health outcomes.

Only about 20% of adults in the United States are active at the moderate level—and only 8% currently exercise at the more vigorous level—recommended for health benefits. Instead, 60% report irregular or no leisure time physical activity.

Increased activity increases the risk of musculoskeletal injuries, which can be minimized by proper warm-up and stretching and by gradual rather than sudden increase in activity. In insulin-requiring diabetic patients who undertake vigorous exercise, the need for insulin is reduced; hypoglycemia may be a consequence. Physical exertion can rarely trigger the onset of acute myocardial infarction, particularly in persons who are habitually sedentary. Other potential complications of exercise include angina pectoris, arrhythmias, sudden death, and asthma.

The value of routine electrocardiography stress testing prior to initiation of an exercise program in middle-aged or older adults remains controversial. Patients with ischemic heart disease or other cardiovascular disease require medically supervised, graded exercise programs. Medically supervised exercise prolongs life in patients with congestive heart failure. Exercise should not be prescribed for patients with decompensated congestive heart failure, complex ventricular arrhythmias, unstable angina pectoris, hemodynamically significant aortic stenosis, or significant aortic aneurysm. Five- to 10-minute warm-up and cool-down periods, stretching exercises, and gradual increases in exercise intensity help prevent musculoskeletal and cardiovascular complications.

Physical activity can be incorporated into any person's daily routine. For example, the clinician can advise a patient to take the stairs instead of the elevator, to walk or bike instead of driving, to do housework or yard work, to get off the bus one or two stops earlier and walk the rest of the way, to park at the far end of the parking lot, or to walk during the lunch hour. The basic message should be the more the better and anything is better than nothing.

To be more effective in counseling about exercise, clinicians can also incorporate motivational interviewing techniques, adopt a whole practice approach (eg, use practice nurses to assist), and establish linkages with community agencies. Clinicians can incorporate the “5 As” approach:

1. Ask (identify those who can benefit).
2. Assess (current activity level).

3. Advise (individualize plan).
4. Assist (provide a written exercise prescription and support material).
5. Arrange (appropriate referral and follow-up).

Such interventions have a moderate effect on self-reported physical activity and cardiorespiratory fitness, even if they do not always help patients achieve a predetermined level of physical activity. In their counseling, clinicians should advise patients about both the benefits and risks of exercise, prescribe an exercise program appropriate for each patient, and provide advice to help prevent injuries or cardiovascular complications.

Behavioral change interventions have been proven effective in increasing physical activity in sedentary older women, although evidence is lacking to support the use of pedometers to increase physical activity in this population. Although primary care providers regularly ask patients about physical activity and advise them with verbal counseling, few providers provide written prescriptions or perform fitness assessments. Tailored interventions may potentially help increase physical activity in individuals. Exercise counseling with a prescription, eg, for walking at either a hard intensity or a moderate intensity-high frequency, can produce significant long-term improvements in cardiorespiratory fitness. To be effective, exercise prescriptions must include recommendations on type, frequency, intensity, time, and progression of exercise and must follow disease-specific guidelines. In addition, published research suggests that getting patients to change physical activity levels requires motivational strategies beyond simple exercise instruction including patient education about goal-setting, self-monitoring, and problem-solving. For example, helping patients identify emotionally rewarding and physically appropriate activities, meet contingencies, and find social support will increase rates of exercise continuation.

Some physical activity is always preferable to a sedentary lifestyle. For home-bound elderly who have limited mobility and strength, such physical activity could focus on “functional fitness,” such as mobility, transfers, and performing activities of daily living. Exercise-based rehabilitation can protect against falls and fall-related injuries and improve functional performance.

Kruger J et al. The prescribed amount of physical activity in randomized clinical trials in older adults. *Gerontologist*. 2009 Jun;49(Suppl 1):S100–7. [PMID: 19525210]

McMurdo ME et al. Do pedometers increase physical activity in sedentary older women? A randomized controlled trial. *J Am Geriatr Soc*. 2010 Nov;58(11):2099–106. [PMID: 21054290]

Petrella RJ et al. Physical activity counseling and prescription among Canadian primary care physicians. *Arch Intern Med*. 2007 Sep 10;167(16):1774–81. [PMID: 17846397]

Thomas GN et al. A systematic review of lifestyle modification and glucose intolerance in the prevention of type 2 diabetes. *Curr Diabetes Rev*. 2010 Nov;6(6):378–87. [PMID: 20879973]

U.S. Department of Health and Human Services. 2008 Physical activity guidelines for Americans. <http://health.gov/PAGuidelines/>

PREVENTION OF OVERWEIGHT & OBESITY

Obesity is now a true epidemic and public health crisis that both clinicians and patients must face. Normal body weight is defined as a body mass index (BMI), calculated as the weight in kilograms divided by the height in meters squared, of < 25 kg/m²; overweight is defined as a BMI = 25.0–29.9 kg/m², and obesity as a BMI > 30 kg/m². Over the last several years, the prevalence of obesity in the US population has increased dramatically. Among US adults, rates of obesity have risen from 15.9% in 1995 to 27.2% in 2009. There is significant variation in rates of obesity by race. Between 2006 and 2008, blacks (35.7%) had 51% greater prevalence of obesity and Hispanics (28.7%) had 21% greater prevalence when compared with non-Hispanic whites (23.7%). This trend has been linked both to declines in physical activity and to increased caloric intake in diets rich in fats and carbohydrates.

Adequate levels of physical activity appear to be important for the prevention of weight gain and the development of obesity. Despite this, only 49% of Americans are physically active at a moderate level and 20% at a more vigorous level. In addition, only 3% of Americans meet four of the five recommendations for the intake of grains, fruits, vegetables, dairy products, and meat of the Food Guide Pyramid. Only one of four Americans eats the recommended five or more fruits and vegetables per day.

Risk assessment of the overweight and obese patient begins with determination of BMI, waist circumference for those with a BMI of 35 or less, presence of comorbid conditions, and a fasting blood glucose and lipid panel. Obesity is clearly associated with type 2 diabetes mellitus, hypertension, hyperlipidemia, cancer, osteoarthritis, cardiovascular disease, obstructive sleep apnea, and asthma. One of the most important sequelae of the rapid surge in prevalence of obesity has been a dramatic increase in the prevalence of diabetes. Diabetes mellitus affects approximately 8% of the US population, and in 2010, 27% of US residents aged 65 years and older were diabetic. In addition, almost one-quarter of the US population currently has the metabolic syndrome, putting them at high risk for the development of CHD. Metabolic syndrome is defined as the presence of any three of the following: waist measurement of 40 inches or more for men and 35 inches or more for women, triglyceride levels of 150 mg/dL or above, HDL cholesterol level < 40 mg/dL for men and < 50 mg/dL for women, blood pressure of 130/85 mm Hg or above, fasting blood glucose levels of 100 mg/dL or above.

The relationship between overweight and obesity and diabetes, hypertension, and coronary artery disease is thought to be due to insulin resistance and compensatory hyperinsulinemia. Persons with a BMI ≥ 40 have death rates from cancers that are 52% higher for men and 62% higher for women than the rates in men and women of normal weight. Significant trends of increasing risk of death with higher BMIs are observed for cancers of the stomach and prostate in men and for cancers of the breast, uterus, cervix, and ovary in women, and for cancers of the esophagus, colon and rectum, liver, gallbladder, pancreas, and kidney, non-Hodgkin lymphoma, and multiple myeloma in both men and women.

In the Framingham Heart Study, overweight and obesity were associated with large decreases in life expectancy. For example, 40-year-old female nonsmokers lost 3.3 years and 40-year-old male nonsmokers lost 3.1 years of life expectancy because of overweight, and 7.1 years and 5.8 years of life expectancy, respectively, because of obesity. Obese female smokers lost 7.2 years and obese male smokers lost 6.7 years of life expectancy compared with normal-weight smokers, and 13.3 years and 13.7 years, respectively, compared with normal-weight nonsmokers. Clinicians must work to identify and provide the best prevention and treatment strategies for patients who are overweight and obese. Patients with abdominal obesity (high waist to hip size ratio) are at particularly increased risk. Control of visceral obesity in addition to other cardiovascular risk factors (hypertension, insulin resistance, and dyslipidemia) is essential to reducing cardiovascular risk.

Prevention of overweight and obesity involves both increasing physical activity and dietary modification to reduce caloric intake. Clinicians can help guide patients to develop personalized eating plans to reduce energy intake, particularly by recognizing the contributions of fat, concentrated carbohydrates, and large portion sizes (see Chapter 29). Patients typically underestimate caloric content, especially when consuming food away from home. Providing patients with caloric and nutritional information may help address the current obesity epidemic. To prevent the long-term chronic disease sequelae of overweight or obesity, clinicians must work with patients to modify other risk factors, eg, by smoking cessation (see above) and strict blood pressure and glycemic control (see Chapters 11 and 27).

Lifestyle modification, including diet, physical activity, and behavior therapy has been shown to induce clinically significant weight loss. Other treatment options for obesity include pharmacotherapy and surgery. In overweight and obese persons, at least 60 minutes of moderate-high intensity physical activity may be necessary to maximize weight loss and prevent significant weight regain. Counseling interventions or pharmacotherapy can produce modest (3–5 kg) sustained weight loss over 6–12 months. Counseling appears to be most effective when intensive and combined with behavioral therapy. Pharmacotherapy appears safe in the short term; long-term safety is still not established. Lorcaserin, a selective 5-hydroxytryptamine (5-HT) (2C) agonist, has been shown to reduce body weight through a reduction of energy intake without influencing energy expenditure; however, it is not yet approved by the US Food and Drug Administration (FDA).

In dietary therapy, a 2008 study comparing various diets revealed that Mediterranean (moderate fat, restricted calorie) and low-carbohydrate (non-restricted calorie) diets are effective alternatives to low-fat diets. In a randomized trial comparing low carbohydrate and low fat diets combined with behavioral treatment, there was no difference in weight loss at 2 years (7%). Commercial weight loss programs are effective in promoting weight loss and weight loss management. A randomized controlled trial of over 400 overweight or obese women demonstrated the effectiveness of a free

prepared meal and incentivized structured weight loss program compared with usual care.

Weight loss strategies using dietary, physical activity, or behavioral interventions can produce significant improvements in weight among persons with prediabetes and a significant decrease in diabetes incidence. Lifestyle interventions including diet combined with physical activity are effective in achieving weight loss and reducing cardiometabolic risk factors among patients with severe obesity.

Bariatric surgical procedures, eg, vertical banded gastroplasty and Roux-en-Y gastric bypass, are reserved for patients with morbid obesity whose BMI exceeds 40, or for less severely obese patients (with BMIs between 35 and 40) with high-risk comorbid conditions such as life-threatening cardiopulmonary problems (eg, severe sleep apnea, Pickwickian syndrome, and obesity-related cardiomyopathy) or severe diabetes mellitus. In selected patients, surgery can produce substantial weight loss (10 to 159 kg) over 1 to 5 years, with rare but sometimes severe complications. Nutritional deficiencies are one complication of bariatric surgical procedures and close monitoring of a patient's metabolic and nutritional status is essential.

Clinicians seem to share a general perception that almost no one succeeds in long-term maintenance of weight loss. However, research demonstrates that approximately 20% of overweight individuals are successful at long-term weight loss (defined as losing $\geq 10\%$ of initial body weight and maintaining the loss for ≥ 1 year). National Weight Control Registry members who lost an average of 33 kg and maintained the loss for more than 5 years have provided useful information about how to maintain weight loss. Members report engaging in high levels of physical activity (approximately 60 min/d), eating a low-calorie, low-fat diet, eating breakfast regularly, self-monitoring weight, and maintaining a consistent eating pattern from weekdays to weekends. The development and implementation of innovative public health strategies is essential in the fight against obesity.

Alberti KG et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. *Circulation*. 2009 Oct 20;120(16):1640–5. [PMID: 19805654]

Centers for Disease Control and Prevention (CDC). Behavioral Risk Factor Surveillance System Survey Data. Prevalence and trends data: Overweight and Obesity (BMI), 2009. <http://apps.nccd.cdc.gov/brfss/list.asp?cat=OB&yr=2009&qkey=4409&state=All>

Centers for Disease Control and Prevention (CDC). Differences in prevalence of obesity among black, white and Hispanic adults—United States, 2006–2008. *MMWR Morb Mortal Wkly Rep*. 2009 Jul 17;58(27):740–4. [PMID: 19609247]

Centers for Disease Control and Prevention. National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States, 2011. <http://www.cdc.gov/diabetes/pubs/factsheet11.htm>

Flegal KM et al. Prevalence and trends in obesity among US adults, 1999–2008. *JAMA*. 2010 Jan 20;303(3):235–41. [PMID: 20071471]

Foster GD et al. Weight and metabolic outcomes after 2 years on a low-carbohydrate versus low-fat diet: a randomized trial. *Ann Intern Med.* 2010 Aug 3;153(3):147–57. [PMID: 20679559]

Goodpaster BH. Effects of diet and physical activity interventions on weight loss and cardiometabolic risk factors in severely obese adults: a randomized trial. *JAMA.* 2010 Oct 27;304(16):1795–802. [PMID: 20935337]

Kulick D et al. The bariatric surgery patient: a growing role for registered dietitians. *J Am Diet Assoc.* 2010 Apr;110(4):593–9. [PMID: 20338285]

Martin CK et al. Lorcaserin, a 5-HT_{2C} receptor agonist, reduces body weight by decreasing energy intake without influencing energy expenditure. *J Clin Endocrinol Metab.* 2011 Mar;96(3):837–45. [PMID: 21190985]

Rock CL et al. Effect of a free prepared meal and incentivized weight loss program on weight loss maintenance in obese and overweight women: a randomized controlled trial. *JAMA.* 2010 Oct 27;304(16):1803–10. [PMID: 20935388]

Shai I et al; Dietary Intervention Randomized Controlled Trial (DIRECT) Group. Weight loss with a low-carbohydrate, Mediterranean, or low-fat diet. *N Engl J Med.* 2008 Jul 17;359(3):229–41. [PMID: 18635428]

CANCER PREVENTION

► Primary Prevention

Cancer mortality rates continue to decrease in the United States; part of this decrease results from reductions in tobacco use, since cigarette smoking is the most important preventable cause of cancer. Primary prevention of skin cancer consists of restricting exposure to ultraviolet light

by wearing appropriate clothing and use of sunscreens. In the past 2 decades, there has been a threefold increase in the incidence of squamous cell carcinoma and a fourfold increase in melanoma in the United States. Persons who engage in regular physical exercise and avoid obesity have lower rates of breast and colon cancer. Prevention of occupationally induced cancers involves minimizing exposure to carcinogenic substances such as asbestos, ionizing radiation, and benzene compounds. Chemoprevention has been widely studied for primary cancer prevention (see above Chemoprevention section and Chapter 39). Use of tamoxifen, raloxifene, and aromatase inhibitors for breast cancer prevention is discussed in Chapters 17 and 39. Hepatitis B vaccination can prevent hepatocellular carcinoma (HCC), and screening and vaccination programs may be cost-effective and useful in preventing HCC in high-risk groups such as Asians and Pacific Islanders. The use of HPV vaccine to prevent cervical cancer is discussed above in the Prevention of Infectious Disease section.

Jemal A et al. Cancer statistics, 2010. *CA Cancer J Clin.* 2010 Sep–Oct;60(5):277–300. [PMID: 20610543]

Robotin MC. Hepatitis B prevention and control: Lessons from the East and the West. *World J Hepatol.* 2011 Feb 27;3(2):31–7. [PMID: 21423912]

► Screening & Early Detection

Screening prevents death from cancers of the breast, colon, and cervix. Current cancer screening recommendations from the USPSTF are shown in Table 1–6.

Table 1–6. Cancer screening recommendations for average-risk adults: US Preventive Services Task Force (USPSTF).¹

Test	USPSTF Recommendations
Breast self-examination	Recommends against teaching breast self-examination (D).
Clinical breast examination	Insufficient evidence to recommend for or against.
Mammography	Recommends biennial screening mammography for women aged 50 to 74 years (B). Decision to start biennial screening before the age of 50 should be an individual one and take patient context into account, including the patient's values regarding specific benefits and harms (C).
Papanicolaou test	Strongly recommends screening for cervical cancer in sexually active women who have a cervix (A). Recommends against routinely screening women older than age 65 if they have had adequate recent screening with normal Pap tests and are not otherwise at high risk for cervical cancer (D).
Colorectal cancer (CRC) screening	Recommends CRC screening using fecal occult blood testing, ² sigmoidoscopy, or colonoscopy, in adults, beginning at age 50 years and continuing until age 75 years (A). Recommends against routine screening in adults age 76–85 years (C). Recommends against screening in adults older than age 85 years (D).
Prostate cancer screening	Insufficient evidence to recommend for or against. Recommends against screening in men >75 years.

¹United States Preventive Services Task Force recommendations available at <http://www.ahrq.gov/clinic/pocketgd1011/gcp10s2.htm>.
²Home test with three samples.

Recommendation A: The USPSTF strongly recommends that clinicians routinely provide the service to eligible patients. (The USPSTF found good evidence that the service improves important health outcomes and concludes that benefits substantially outweigh harms.)

Recommendation B: The USPSTF recommends that clinicians routinely provide the service to eligible patients. (The USPSTF found at least fair evidence that the service improves important health outcomes and concludes that benefits substantially outweigh harms.)

Recommendation C: The USPSTF recommends against routinely providing the service. There may be considerations that support providing the service in an individual patient. There is at least moderate certainty that the net benefit is small.

Recommendation D: The USPSTF recommends against routinely providing the service to asymptomatic patients. (The USPSTF found at least fair evidence that the service is ineffective or that harms outweigh benefits.)

Evidence suggests that the benefit of screening mammography on breast cancer mortality may not outweigh the risks associated with screening. A 2011 Cochrane review estimated that screening with mammography led to a reduction in breast cancer mortality of 15% but resulted in 30% overdiagnosis and overtreatment. Currently, the appropriate form and frequency of screening for breast cancer remains controversial and screening guidelines vary. In 2009, the USPSTF updated its recommendation statement on breast cancer screening in the general population. A change, which generated discussion from many groups, was the recommendation against routine screening mammography in women aged 40–49 years. Clinicians should discuss the risks and benefits with each patient and consider individual patient preferences when deciding when to begin screening.

Digital mammography is more sensitive in women with dense breasts and younger women; however, studies exploring outcomes are lacking. The use of MRI is not currently recommended for general screening, although the American Cancer Society does recommend screening MRI for women at high risk (≥ 20 –25%), including those with a strong family history of breast or ovarian cancer. A 2008 systematic review reported that screening with both MRI and mammography might be superior to mammography alone in ruling out cancerous lesions in women with an inherited predisposition to breast cancer.

All current recommendations call for cervical and colorectal cancer screening. Screening for testicular cancers among asymptomatic adolescent or adult males is not recommended by the USPSTF. Prostate cancer screening, however, is controversial, as no completed studies have answered the question whether early detection and treatment after screen detection produce sufficient benefits to outweigh harms of treatment. A 2009 published study of 76,000 US men comparing annual screening (prostate-specific antigen [PSA] and digital rectal examination) to usual care did not reveal a difference in mortality. A 2011 Cochrane systematic review revealed that prostate cancer screening with PSA testing did not significantly decrease either all cause or prostate cancer–specific mortality in men aged 50–74 years. Furthermore, it appeared that any benefits from screening would take more than 10 years to accrue, and screening men with less than 10–15 years life expectancy was not advised.

Annual or biennial fecal occult blood testing reduces mortality from colorectal cancer by 16–33%. Immunochemical fecal occult blood tests (FIT) are superior to guaiac-based fecal occult blood tests (FOBT) in detecting advanced adenomatous polyps and colorectal cancer, and patients are more likely to favor FIT over FOBTs. The risk of death from colon cancer among patients undergoing at least one sigmoidoscopic examination is reduced by 60–80% compared with that among those not having sigmoidoscopy. Colonoscopy has also been advocated as a screening examination. It is more accurate than flexible sigmoidoscopy for detecting cancer and polyps, but its value in reducing colon cancer mortality has not been studied directly. CT colonography (virtual colonoscopy) is a noninvasive option in screening for colorectal cancer. It has

been shown to have a high safety profile and performance similar to colonoscopy.

Screening for cervical cancer with a Papanicolaou smear is indicated in sexually active adolescents and in adult women every 1–3 years. Screening for vaginal cancer with a Papanicolaou smear is not indicated in women who have undergone hysterectomies for benign disease with removal of the cervix—except in diethylstilbestrol (DES)-exposed women (see Chapter 18). Women over age 70 who have had normal results on three or more previous Papanicolaou smears may elect to stop screening.

In a randomized, controlled trial, transvaginal ultrasound combined with serum cancer antigen 125 (CA-125) as screening tools to detect ovarian cancer did not reduce mortality. Furthermore, complications were associated with diagnostic evaluations to follow up false-positive screening test results. Thus, screening for ovarian cancer with transvaginal ultrasound and CA-125 is not recommended.

Evidence suggests that chest CT is significantly more sensitive than chest radiography in identifying small asymptomatic lung cancers. The National Lung Screening Trial (NLST), a randomized clinical trial of over 53,000 individuals at high risk for lung cancer, revealed a 20% relative reduction and 6.7% absolute reduction in lung cancer mortality in those who were screened with annual low-dose CTs for 3 years compared with those who had chest radiographs. There were a greater number of false-positive results in the low-dose CT group compared with those in the radiography group (23.3% vs 6.5%).

- Andriole GL et al; PLCO Project Team. Mortality results from a randomized prostate-cancer screening trial. *N Engl J Med.* 2009 Mar 26;360(13):1310–9. [PMID: 19297565]
- Buyss SS et al; PLCO Project Team. Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. *JAMA.* 2011 Jun 8;305(22):2295–303. [PMID: 21642681]
- Deutekom M et al. Comparison of guaiac and immunological fecal occult blood tests in colorectal cancer screening: the patient perspective. *Scand J Gastroenterol.* 2010 Nov;45(11):1345–9. [PMID: 20560814]
- Gotzsche PC et al. Screening for breast cancer with mammography. *Cochrane Database Syst Rev.* 2011 Jan 19;(1):CD001877. [PMID: 21249649]
- Ilic D et al. Screening for prostate cancer: an updated Cochrane systematic review. *BJU Int.* 2011 Mar;107(6):882–91. [PMID: 2392207]
- Johnson CD. CT colonography: coming of age. *AJR Am J Roentgenol.* 2009 Nov;193(5):1239–42. [PMID: 19843736]
- Johnson CD et al. Accuracy of CT colonography for detection of large adenomas and cancers. *N Engl J Med.* 2008 Sep 18;359(12):1207–17. [PMID: 18799557]
- Levi Z et al. A higher detection rate for colorectal cancer and advanced adenomatous polyp for screening with immunochemical fecal occult blood test than guaiac fecal occult blood test, despite lower compliance rate. A prospective, controlled, feasibility study. *Int J Cancer.* 2011 May 15;128(10):2415–24. [PMID: 20658527]
- Lopes Pegna A et al. Lung cancer screening update. *Curr Opin Pulm Med.* 2009 Jul;15(4):327–33. [PMID: 19395971]
- National Lung Screening Trial Research Team; Aberle DR et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. *N Engl J Med.* 2011. Aug 4;365(5):395–409. [PMID: 21714641]

Nelson HD et al; U.S. Preventive Services Task Force. Screening for breast cancer: an update for the U.S. Preventive Services Task Force. *Ann Intern Med.* 2009 Nov 17;151(10):727–37, W237–42. [PMID: 19920273]

Saslow D et al. American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. *CA Cancer J Clin.* 2007 Mar–Apr;57(2):75–89. [PMID: 17392385]

U.S. Preventive Services Task Force. Screening for breast cancer: U.S. Preventive Services Task Force recommendation statement. *Ann Intern Med.* 2009 Nov 17;151(10):716–26, W-236. [PMID: 19920272]

U.S. Preventive Services Task Force. Screening for testicular cancer: U.S. Preventive Services Task Force reaffirmation recommendation statement. *Ann Intern Med.* 2011 Apr 5;154(7):483–6. [PMID: 21464350]

Warner E et al. Systematic review: using magnetic resonance imaging to screen women at high risk for breast cancer. *Ann Intern Med.* 2008 May 6;148(9):671–9. [PMID: 18458280]

PREVENTION OF INJURIES & VIOLENCE

Injuries remain the most important cause of loss of potential years of life before age 65. Homicide and motor vehicle accidents are a major cause of injury-related deaths among young adults, and accidental falls are the most common cause of injury-related death in the elderly. Other causes of injury-related deaths include suicide and accidental exposure to smoke, fire, and flames.

Motor vehicle accident deaths per miles driven continue to decline in the United States, and the rate of seatbelt use has increased from 69% in 1998 to 88% in 2009. Each year in the United States, more than 500,000 people are nonfatally injured while riding bicycles. The rate of helmet use by bicyclists and motorcyclists is significantly increased in states with helmet laws. Young men appear most likely to resist wearing helmets. Clinicians should try to educate their patients about seat belts, safety helmets, the risks of using cellular telephones while driving, drinking and driving—or using other intoxicants or long-acting benzodiazepines and then driving—and the risks of having guns in the home.

Long-term alcohol abuse adversely affects outcome from trauma and increases the risk of readmission for new trauma. Alcohol and illicit drug use are associated with an increased risk of violent death.

Males aged 16–35 are at especially high risk for serious injury and death from accidents and violence, with blacks and Latinos at greatest risk. For 16- and 17-year-old drivers, the risk of fatal crashes increases with the number of passengers. Deaths from firearms have reached epidemic levels in the United States and will soon surpass the number of deaths from motor vehicle accidents. Having a gun in the home increases the likelihood of homicide nearly threefold and of suicide fivefold. In 2007, an estimated 34,500 suicides occurred in the United States. Educating clinicians to recognize and treat depression as well as restricting access to lethal methods have been found to reduce suicide rates.

Finally, clinicians have a critical role in detection, prevention, and management of intimate partner violence. Inclusion of a single question in the medical history—“At any time, has a partner ever hit you, kicked you, or otherwise

physically hurt you?”—can increase identification of this common problem. Another screen consists of three questions: (1) “Have you ever been hit, kicked, punched, or otherwise hurt by someone within the past year? If so, by whom?” (2) “Do you feel safe in your current relationship?” (3) “Is there a partner from a previous relationship who is making you feel unsafe now?” Assessment for abuse and offering of referrals to community resources creates potential to interrupt and prevent recurrence of domestic violence and associated trauma. Screening patients in emergency departments for intimate partner violence appears to have no adverse effects related to screening and may lead to increased patient contact with community resources. Clinicians should take an active role in following up with patients whenever possible, since intimate partner violence screening with passive referrals to services may not be adequate. A randomized control trial to assess the impact of intimate partner violence screening on violence reduction and health outcomes in women revealed no difference in violence occurrence between screened and nonscreened women. Evaluation of services for patients *after* identification of intimate partner violence should be a priority.

Physical and psychological abuse, exploitation, and neglect of older adults are serious underrecognized problems. Clues to elder mistreatment include the patient’s appearance, recurrent urgent-care visits, missed appointments, suspicious physical findings, and implausible explanations for injuries.

Injuries at home are common, and the majority of injuries to children less than 5 years of age and adults aged 75 and older occur at home. The impact of physical adaptations to the home environment has not been shown to reduce injuries at home. Larger randomized controlled trials to measure injury outcomes are needed to assess more adequately the impact modifications to the home environment.

Amstadter AB et al. Prevalence and correlates of poor self-rated health in the United States: the national elder mistreatment study. *Am J Geriatr Psychiatry.* 2010 Jul;18(7):615–23. [PMID: 20220579]

Centers for Disease Control and Prevention (CDC). Alcohol-Related Disease Impact (ARDI). <http://www.cdc.gov/alcohol/ardi.htm>

Centers for Disease Control and Prevention (CDC). Web-based Injury Statistics Query and Reporting System (WISQARS). <http://www.cdc.gov/injury/wisqars/index.html>

Gillespie LD et al. Interventions for preventing falls in older people living in the community. *Cochrane Database Syst Rev.* 2009 Apr 15;(2):CD007146. [PMID: 19370674]

Houry D et al. Does screening in the emergency department hurt or help victims of intimate partner violence? *Ann Emerg Med.* 2008 Apr;51(4):433–42. [PMID: 18313800]

MacMillan HL et al; McMaster Violence Against Women Research Group. Screening for intimate partner violence in health care settings: a randomized trial. *JAMA.* 2009 Aug 5;302(5):493–501. [PMID: 19654384]

National Highway Traffic Safety Administration (NHTSA). Fatality Analysis Reporting System: national statistics summary, 2010. <http://www-fars.nhtsa.dot.gov/Main/index.aspx>

National Institute of Mental Health (NIMH). Suicide in the U.S.: statistics and prevention. <http://www.mentalhealth.gov/health/publications/suicide-in-the-us-statistics-and-prevention/index.shtml>

National Safety Council. Seat belts: your single most effective safety step. http://www.nsc.org/safety_road/DriverSafety/Pages/SeatBelts.aspx

Rahmani P et al. Prevention of osteoporosis-related fractures among postmenopausal women and older men. *CMAJ*. 2009 Nov 24;181(11):815–20. [PMID: 19841053]

Turner S et al. Modification of the home environment for the reduction of injuries. *Cochrane Database Syst Rev*. 2011 Feb 16; (2):CD003600. [PMID: 21328262]

PREVENTION OF SUBSTANCE ABUSE: ALCOHOL & ILLICIT DRUGS

Substance abuse is a major public health problem in the United States. In the United States, approximately 52% of adults 18 years and older are current regular drinkers (at least 12 drinks in the past year). Alcohol dependence often coexists with other substance disorders as well as with mood, anxiety, and personality disorders. Underdiagnosis and treatment of alcohol abuse is substantial, both because of patient denial and lack of detection of clinical clues. Treatment rates for alcohol dependence have slightly declined over the last several years. Only a quarter of alcohol-dependent patients have ever been treated.

As with cigarette use, clinician identification and counseling about alcoholism may improve the chances of recovery. About 10% of all adults seen in medical practices are problem drinkers. An estimated 15–30% of hospitalized patients have problems with alcohol abuse or dependence, but the connection between patients' presenting complaints and their alcohol abuse is often missed. The CAGE test (Table 1–7) is both sensitive and specific for chronic alcoholism. However, it is less sensitive in detecting heavy or binge drinking in elderly patients and has been criticized for being less applicable to minority groups or to women.

The Alcohol Use Disorder Identification Test (AUDIT) consists of questions on the quantity and frequency of alcohol consumption, on alcohol dependence symptoms, and on alcohol-related problems (Table 1–7). The AUDIT questionnaire is a cost-effective and efficient diagnostic tool for routine screening of alcohol use disorders in primary care settings. Choice of therapy remains controversial. However, use of screening procedures and brief intervention methods (Table 1–8; see Chapter 25) can produce a 10–30% reduction in long-term alcohol use and alcohol-related problems. Brief advice and counseling without regular follow-up and reinforcement cannot sustain significant long-term reductions in unhealthy drinking behaviors.

Time restraints may prevent clinicians from screening patients and single-question screening tests for unhealthy alcohol use may help increase the frequency of screening in primary care settings. The National Institute on Alcohol Abuse and Alcoholism recommends the following single-question screening test: "How many times in the past year have you had X or more drinks in a day?" (X is 5 for men and 4 for women, and a response of >1 is considered positive.) The single-item screening test has been validated in primary care settings.

Several pharmacologic agents are effective in reducing alcohol consumption. In acute alcohol detoxification, standard treatment regimens use long-acting benzodiazepines, the preferred medications for alcohol detoxification, because they can be given on a fixed schedule or through "front-loading" or "symptom-triggered" regimens. Adjuvant sympatholytic medications can be used to treat hyperadrenergic symptoms that persist despite adequate sedation. Three drugs are FDA approved for treatment of alcohol dependence—disulfiram, naltrexone, and acamprosate. Disulfiram, an aversive agent, has significant adverse effects and consequently, compliance difficulties have resulted in no clear evidence that it increases abstinence rates, decreases relapse rates, or reduces cravings. Persons who receive short-term treatment with naltrexone have a lower chance of alcoholism relapse. Compared with placebo, naltrexone can lower the risk of treatment withdrawal in alcohol-dependent patients, and long-acting intramuscular formulation of naltrexone has been found to be well-tolerated and to reduce drinking significantly among treatment-seeking alcoholics over a 6-month period. In a randomized, controlled trial, patients receiving medical management with naltrexone, a combined behavioral intervention, or both, fared better on drinking outcomes, whereas acamprosate showed no evidence of efficacy with or without combined behavioral intervention. A depot formulation of naltrexone is available with good evidence for clinical efficacy. Topiramate is a promising treatment for alcohol dependence. A 6-month randomized trial of topiramate versus naltrexone revealed a greater reduction of alcohol intake and cravings in participants receiving topiramate. Topiramate's side effect profile is favorable, and the benefits appear to increase over time. Clinicians should be aware that although topiramate appears to be an effective treatment for alcohol dependence, the manufacturer has not pursued FDA approval for this indication.

Use of illegal drugs—including cocaine, methamphetamine, and so-called "designer drugs"—either sporadically or episodically remains an important problem. Lifetime prevalence of drug abuse is approximately 8% and is generally greater among men, young and unmarried individuals, Native Americans, and those of lower socioeconomic status. As with alcohol, drug abuse disorders often coexist with personality, anxiety, and other substance abuse disorders. Abuse of anabolic-androgenic steroids has been associated with use of other illicit drugs, alcohol, and cigarettes and with violence and criminal behavior.

As with alcohol abuse, the lifetime treatment rate for drug abuse is low (8%). The recognition of drug abuse presents special problems and requires that the clinician actively consider the diagnosis. Clinical aspects of substance abuse are discussed in Chapter 25.

Currently, evidence does not support the use of carbamazepine, disulfiram, mazindol, phenytoin, nimodipine, lithium, antidepressants, or dopamine agonists in the treatment of cocaine dependence.

Buprenorphine has potential as a medication to ameliorate the symptoms and signs of withdrawal from opioids and has been shown to be effective in reducing concomitant

Table 1-7. Screening for alcohol abuse.

A. CAGE screening test¹				
Have you ever felt the need to	Cut down on drinking?			
Have you ever felt	Annoyed by criticism of your drinking?			
Have you ever felt	Guilty about your drinking?			
Have you ever taken a morning	Eye opener?			
INTERPRETATION: Two “yes” answers are considered a positive screen. One “yes” answer should arouse a suspicion of alcohol abuse.				
B. The Alcohol Use Disorder Identification Test (AUDIT).² (Scores for response categories are given in parentheses. Scores range from 0 to 40, with a cutoff score of ≥ 5 indicating hazardous drinking, harmful drinking, or alcohol dependence.)				
1. How often do you have a drink containing alcohol?				
(0) Never	(1) Monthly or less	(2) Two to four times a month	(3) Two or three times a week	(4) Four or more times a week
2. How many drinks containing alcohol do you have on a typical day when you are drinking?				
(0) 1 or 2	(1) 3 or 4	(2) 5 or 6	(3) 7 to 9	(4) 10 or more
3. How often do you have six or more drinks on one occasion?				
(0) Never	(1) Less than monthly	(2) Monthly	(3) Weekly	(4) Daily or almost daily
4. How often during the past year have you found that you were not able to stop drinking once you had started?				
(0) Never	(1) Less than monthly	(2) Monthly	(3) Weekly	(4) Daily or almost daily
5. How often during the past year have you failed to do what was normally expected of you because of drinking?				
(0) Never	(1) Less than monthly	(2) Monthly	(3) Weekly	(4) Daily or almost daily
6. How often during the past year have you needed a first drink in the morning to get yourself going after a heavy drinking session?				
(0) Never	(1) Less than monthly	(2) Monthly	(3) Weekly	(4) Daily or almost daily
7. How often during the past year have you had a feeling of guilt or remorse after drinking?				
(0) Never	(1) Less than monthly	(2) Monthly	(3) Weekly	(4) Daily or almost daily
8. How often during the past year have you been unable to remember what happened the night before because you had been drinking?				
(0) Never	(1) Less than monthly	(2) Monthly	(3) Weekly	(4) Daily or almost daily
9. Have you or has someone else been injured as a result of your drinking?				
(0) No	(2) Yes, but not in the past year		(4) Yes, during the past year	
10. Has a relative or friend or a doctor or other health worker been concerned about your drinking or suggested you cut down?				
(0) No	(2) Yes, but not in the past year		(4) Yes, during the past year	

¹Source: Mayfield D et al. The CAGE questionnaire: validation of a new alcoholism screening instrument. *Am J Psychiatry*. 1974;131:1121.

²Adapted, with permission, from BMJ Publishing Group Ltd. and Piccinelli M et al. Efficacy of the alcohol use disorders identification test as a screening tool for hazardous alcohol intake and related disorders in primary care: a validity study. *BMJ*. 1997 Feb 8;314(7078):420-4.

Table 1-8. Basic counseling steps for patients who abuse alcohol.

Establish a therapeutic relationship Make the medical office or clinic off-limits for substance abuse Present information about negative health consequences Emphasize personal responsibility and self-efficacy Convey a clear message and set goals Involve family and other supports Establish a working relationship with community treatment resources Provide follow-up
--

Reproduced from the United States Department of Health Human Services, U.S. Public Health Service, Office of Disease Prevention Health Promotion. *Clinician's Handbook of Preventive Services: Put Prevention Into Practice*. U.S. Government Printing Office, 1994.

cocaine and opiate abuse. The risk of overdose is lower with buprenorphine than methadone and is preferred for patients at high risk for methadone toxicity. Evidence does not support the use of naltrexone in maintenance treatment of opioid addiction. Rapid opioid detoxification with opioid antagonist induction using general anesthesia has emerged as an approach to treat opioid dependence. However, a randomized comparison of buprenorphine-assisted rapid opioid detoxification with naltrexone induction and clonidine-assisted opioid

detoxification with delayed naltrexone induction found no significant differences in rates of completion of inpatient detoxification, treatment retention, or proportions of opioid-positive urine specimens, and the anesthesia procedure was associated with more potentially life-threatening adverse events. Finally, cognitive behavior therapy, contingency management, couples and family therapy, and other types of behavioral treatment have been shown to be effective interventions for drug addiction.

- Drummond C et al. Effectiveness and cost-effectiveness of a stepped care intervention for alcohol use disorders in primary care: pilot study. *Br J Psychiatry*. 2009 Nov;195(5):448–56. [PMID: 19880936]
- Flórez G et al. Topiramate for the treatment of alcohol dependence: comparison with naltrexone. *Eur Addict Res*. 2011; 17(1):29–36. [PMID: 20975274]
- Kahan M et al. Buprenorphine: new treatment of opioid addiction in primary care. *Can Fam Physician*. 2011 Mar; 57(3):281–9. [PMID: 21402963]
- Kenna GA et al. Review of topiramate: an antiepileptic for the treatment of alcohol dependence. *Curr Drug Abuse Rev*. 2009 May;2(2):135–42. [PMID: 19630744]
- Pleis JR et al. Summary health statistics for U.S. adults: National Health Interview Survey, 2009. *Vital Health Stat* 10. 2010 Dec; (249):1–207. [PMID: 21905346]
- Smith PC et al. Primary care validation of a single-question alcohol screening test. *J Gen Intern Med*. 2009 July;24(7): 783–8. [PMID: 19247718]
- Soyka M et al. Emerging drugs to treat alcoholism. *Expert Opin Emerg Drugs*. 2010 Dec;15(4):695–711. [PMID: 20560783]

Common Symptoms

Ralph Gonzales, MD, MSPH,
& Paul L. Nadler, MD

2

COUGH



ESSENTIAL INQUIRIES

- ▶ Age.
- ▶ Duration of cough.
- ▶ Dyspnea (at rest or with exertion).
- ▶ Tobacco use history.
- ▶ Vital signs (heart rate, respiratory rate, body temperature).
- ▶ Chest examination.
- ▶ Chest radiography when unexplained cough lasts more than 3–6 weeks.

▶ General Considerations

Cough adversely affects personal and work-related interactions, disrupts sleep, and often causes discomfort of the throat and chest wall. Most people seeking medical attention for acute cough desire symptom relief; few are worried about serious illness. Cough results from stimulation of mechanical or chemical afferent nerve receptors in the bronchial tree. Effective cough depends on an intact afferent–efferent reflex arc, adequate expiratory and chest wall muscle strength, and normal mucociliary production and clearance.

▶ Clinical Findings

A. Symptoms

Distinguishing **acute** (< 3 weeks), **persistent** (3–8 weeks), and **chronic** (> 8 weeks) cough illness syndromes is a useful first step in evaluation. Postinfectious cough lasting 3–8 weeks has also been referred to as **subacute** cough to distinguish this common, distinct clinical entity from acute and chronic cough.

1. Acute cough—In healthy adults, most acute cough syndromes are due to viral respiratory tract infections. Additional features of infection such as fever, nasal

congestion, and sore throat help confirm the diagnosis. Dyspnea (at rest or with exertion) may reflect a more serious condition, and further evaluation should include assessment of oxygenation (pulse oximetry or arterial blood gas measurement), airflow (peak flow or spirometry), and pulmonary parenchymal disease (chest radiography). The timing and character of the cough have not been found to be very useful in establishing the cause of acute cough syndromes, although cough-variant asthma should be considered in adults with prominent nocturnal cough, and persistent cough with phlegm increases the patient's likelihood of chronic obstructive pulmonary disease (COPD). The presence of post-tussive emesis or inspiratory whoop modestly increases the likelihood of pertussis, and the absence of paroxysmal cough decreases the likelihood of pertussis in adolescents and adults with cough lasting more than 1 week. Uncommon causes of acute cough should be suspected in those with heart disease (congestive heart failure [CHF]) or hay fever (allergic rhinitis) and those with environmental risk factors (such as farm workers).

2. Persistent and chronic cough—Cough due to acute respiratory tract infection resolves within 3 weeks in the vast majority of patients (over 90%). Pertussis infection should be considered in adolescents and adults who present with persistent or severe cough lasting more than 3 weeks. In selected geographic areas, the prevalence of pertussis approaches 20% when cough has persisted beyond 3 weeks, although the exact prevalence of pertussis is difficult to ascertain due to the limited sensitivity of diagnostic tests.

When angiotensin-converting enzyme (ACE) inhibitor therapy, acute respiratory tract infection, and chest radiograph abnormalities are absent, the majority of cases of persistent and chronic cough are due to or exacerbated by postnasal drip, asthma, or gastroesophageal reflux disease (GERD). A history of nasal or sinus congestion, wheezing, or heartburn should direct subsequent evaluation and treatment, though these conditions frequently cause persistent cough in the absence of typical symptoms. Dyspnea at rest or with exertion is not commonly reported among patients with persistent cough. The report of dyspnea requires assessment for other evidence of chronic lung disease, CHF, or anemia.

Bronchogenic carcinoma is suspected when cough is accompanied by unexplained weight loss and fevers with

night sweats, particularly in persons with significant tobacco or occupational exposures. Persistent and chronic cough accompanied by excessive mucus secretions increases the likelihood of COPD, particularly among smokers, or bronchiectasis in a patient with a history of recurrent or complicated pneumonia; chest radiographs are helpful in diagnosis.


B. Physical Examination

Examination can direct subsequent diagnostic testing for acute and persistent cough. Pneumonia is suspected when acute cough is accompanied by vital sign abnormalities (tachycardia, tachypnea, fever). Findings suggestive of airspace consolidation (rales, decreased breath sounds, fremitus, egophony) are significant predictors of community-acquired pneumonia but are present in the minority of cases. Purulent sputum is associated with bacterial infections in patients with structural lung disease (eg, COPD, cystic fibrosis), but it is a poor predictor of pneumonia in the otherwise healthy adult. Wheezing and rhonchi are frequent findings in adults with acute bronchitis and do not represent adult-onset asthma in most cases.

Physical examination of patients with persistent cough should look for evidence of chronic sinusitis, contributing to postnasal drip syndrome or asthma. Chest and cardiac signs may help distinguish COPD from CHF. In patients with cough and dyspnea, a normal match test (ability to blow out a match from 25 cm away) and maximum laryngeal height > 4 cm (measured from the sternal notch to the cricoid cartilage at end expiration) substantially decrease the likelihood of COPD. Similarly, normal jugular venous pressure and no hepatojugular reflux decrease the likelihood of biventricular CHF.

C. Diagnostic Studies

1. Acute cough—Chest radiography should be considered for any adult with acute cough who shows abnormal vital signs or in whom the chest examination is suggestive of pneumonia. The relationship between specific clinical findings and the probability of pneumonia is shown in Figure 2–1. In patients with dyspnea, pulse oximetry and peak flow help exclude hypoxemia or obstructive airway disease.



▲ **Figure 2-1.** Revised pneumonia probabilities based on history and physical examination findings. (Reproduced, with permission, from Metlay JP et al. Testing strategies in the initial management of patients with community-acquired pneumonia. *Ann Intern Med.* 2003 Jan 21;138:109-118.)

However, a normal pulse oximetry value (eg, > 93%) does not rule out a significant alveolar–arterial (A–a) gradient when patients have effective respiratory compensation. During documented influenza outbreaks, the positive predictive value of the clinical diagnosis of influenza approaches 70% and usually obviates the usefulness of rapid diagnostic tests.

2. Persistent and chronic cough—Chest radiography is indicated when ACE inhibitor therapy–related and postinfectious cough are excluded by history or further diagnostic testing. If pertussis infection is suspected, testing should be performed using polymerase chain reaction on a nasopharyngeal swab or nasal wash specimen—keeping in mind that the ability to detect pertussis decreases as the duration of cough increases. When the chest film is normal, postnasal drip, asthma, and GERD are the most likely causes. The presence of typical symptoms of these conditions directs further evaluation or empiric therapy, though typical symptoms are often absent. Definitive procedures for determining the presence of each are available (Table 2–1). However, empiric treatment with a maximum-strength regimen for postnasal drip, asthma, or GERD for 2–4 weeks is one recommended approach since documenting the presence of postnasal drip, asthma, and GERD does not mean they are the cause of the cough illness. Alternative approaches to identifying patients who have corticosteroid-responsive cough include examining induced sputum for increased eosinophil counts (> 3%); measuring increased exhaled nitric oxide levels; or providing an empiric trial of prednisone, 30 mg daily for 2 weeks. Spirometry may help identify large airway obstruction in patients who have persistent cough and wheezing and who are not responding to asthma treatment. When empiric treatment trials are not helpful, additional evaluation with pH manometry, endoscopy, barium swallow, sinus CT or high-resolution chest CT may identify the cause.

► Differential Diagnosis

A. Acute Cough

Acute cough may be a symptom of acute respiratory tract infection, asthma, allergic rhinitis, and CHF, as well as a myriad of other less common causes.

Table 2-1. Empiric treatments or tests for persistent cough.

Suspected Condition	Step 1 (Empiric Therapy)	Step 2 (Diagnostic Testing)
Postnasal drip	Therapy for allergy or chronic sinusitis	ENT referral; sinus CT scan
Asthma	β_2 -Agonist	Spirometry; consider methacholine challenge if normal
GERD	Proton pump inhibitors	Esophageal pH monitoring

ENT, ear, nose, and throat; GERD, gastroesophageal reflux disease.

B. Persistent and Chronic Cough

Causes of persistent cough include environmental exposures (cigarette smoke, air pollution), pertussis infection, postnasal drip syndrome (or upper airway cough syndrome), asthma (including cough-variant asthma), GERD, COPD, bronchiectasis, eosinophilic bronchitis, tuberculosis or other chronic infection, interstitial lung disease, and bronchogenic carcinoma. COPD is a common cause of persistent cough among patients > 50 years of age. Persistent cough may also be psychogenic.

▶ Treatment

A. Acute Cough

Treatment of acute cough should target the underlying etiology of the illness, the cough reflex itself, and any additional factors that exacerbate the cough. When influenza is diagnosed, treatment with amantadine, rimantadine, oseltamivir, or zanamivir is equally effective (1 less day of illness) when initiated within 30–48 hours of illness onset, although treatment is recommended regardless of illness duration when patients present with severe illness requiring hospitalization. Furthermore, in the setting of H1N1 influenza, neuraminidase inhibitors are the preferred treatment due to resistance to amantadine/rimantidine. In the setting of *Chlamydia* or *Mycoplasma*-documented infection or outbreaks, first-line antibiotics include erythromycin, 250 mg orally four times daily for 7 days, or doxycycline, 100 mg orally twice daily for 7 days. In patients diagnosed with acute bronchitis, inhaled β_2 -agonist therapy reduces severity and duration of cough in some patients. Evidence supports a modest benefit of dextromethorphan, but not codeine, on cough severity in adults with cough due to acute respiratory tract infections. Treatment of postnasal drip (with antihistamines, decongestants, or nasal corticosteroids) or GERD (with H_2 -blockers or proton-pump inhibitors), when accompanying acute cough illness, can also be helpful. There is good evidence that vitamin C and echinacea are not effective in reducing the severity of acute cough after it develops; however, evidence does support vitamin C (at least 1 g daily) for prevention of colds among persons with major physical stressors (eg, post-marathon) or malnutrition. Treatment with zinc lozenges, when initiated within 24 hours of symptom onset, reduces the duration and severity of cold symptoms.

B. Persistent and Chronic Cough

Evaluation and management of persistent cough often requires multiple visits and therapeutic trials, which frequently lead to frustration, anger, and anxiety. When pertussis infection is suspected, treatment with a macrolide antibiotic (azithromycin 500 mg on day 1, then 250 mg once daily for days 2–5; clarithromycin 500 mg twice daily for 7 days; erythromycin 250 mg four times daily for 14 days) is appropriate to reduce shedding and transmission of the organism. When pertussis infection has lasted

more than 7–10 days, antibiotic treatment does not affect the duration of cough, which can last up to 6 months. Early identification and treatment of patients who work or live with persons at high-risk for complications from pertussis is encouraged (pregnant women, infants [particularly younger than 1 year], and immunosuppressed individuals). There is no evidence to guide how long treatment for persistent cough due to postnasal drip, asthma, or GERD should be continued.

▶ When to Refer

- Failure to control persistent or chronic cough following empiric treatment trials. The small percentage of patients with idiopathic persistent cough should be managed in consultation with an otolaryngologist or a pulmonologist; treatment options include nebulized lidocaine therapy and morphine sulfate, 5–10 mg orally twice daily.
- Patients with recurrent symptoms should be referred to an otolaryngologist or a pulmonologist.

▶ When to Admit

- Patient at high risk for tuberculosis for whom compliance with respiratory precautions is uncertain.
- Need for urgent bronchoscopy, such as suspected foreign body.
- Smoke or toxic fume inhalational injury.
- Intractable cough despite treatment, when cough impairs gas exchange or in patients at high risk for barotraumas (eg, recent pneumothorax).

- Barry MA. A 29-year-old woman with flu-like symptoms: review of influenza diagnosis and treatment. *JAMA*. 2010 Aug 11;304(6):671–8. [PMID: 20699459]
- Broekhuizen BD et al. Undetected chronic obstructive pulmonary disease and asthma in people over 50 years with persistent cough. *Br J Gen Pract*. 2010 Jul;60(576):489–94. [PMID: 20594438]
- Chung KF et al. Prevalence, pathogenesis and causes of chronic cough. *Lancet*. 2008 Apr 19;371(9621):1364–74. [PMID: 18424325]
- Cornia PB et al. Does this coughing adolescent or adult patient have pertussis? *JAMA*. 2010 Aug 25;304(8):890–6. [PMID: 20736473]
- Metlay JP et al. Testing strategies in the initial management of patients with community-acquired pneumonia. *Ann Intern Med*. 2003 Jan 21;138(2):109–18. [PMID: 12529093]
- Morice AH et al. Opiate therapy in chronic cough. *Am J Respir Crit Care Med*. 2007 Feb 15;175(4):312–5. [PMID: 17122382]
- Singh M et al. Zinc for the common cold. *Cochrane Database Syst Rev*. 2011 Feb 16;(2):CD001364. [PMID: 21328251]
- Smith SM et al. Over-the-counter medications for acute cough in children and adults in ambulatory settings. *Cochrane Database Syst Rev*. 2008 Jan 23;(1):CD001831. [PMID: 18253996]
- Wenzel RP et al. Acute bronchitis. *N Engl J Med*. 2006 Nov 16;355(20):2125–30. [PMID: 17108344]
- Yu L et al. Clinical benefit of sequential three-step empirical therapy in the management of chronic cough. *Respirology*. 2008 May;13(3):353–8. [PMID: 18399856]

DYSPNEA



ESSENTIAL INQUIRIES

- ▶ Fever.
- ▶ Cough.
- ▶ Chest pain.
- ▶ Vital sign measurements; pulse oximetry.
- ▶ Cardiac and chest examination.
- ▶ Chest radiography.
- ▶ Arterial blood gas measurement.

▶ General Considerations

Dyspnea is a subjective experience or perception of uncomfortable breathing. However, the relationship between level of dyspnea and the severity of underlying disease varies widely across individuals. Dyspnea can result from conditions that increase the mechanical effort of breathing (eg, COPD, restrictive lung disease, respiratory muscle weakness), from conditions that produce compensatory tachypnea (eg, hypoxemia or acidosis), or from psychogenic origins. The following factors play a role in how and when dyspnea presents in patients: rate of onset, previous dyspnea, medications, comorbidities, psychological profile, and the severity of underlying disorder. In patients with established COPD, the patient-reported severity of dyspnea is superior to forced expiratory volume in 1 second (FEV₁) in predicting quality of life and 5-year mortality.

▶ Clinical Findings

A. Symptoms

The duration, severity, and periodicity of dyspnea influence the tempo of the clinical evaluation. Rapid onset, severe dyspnea in the absence of other clinical features should raise concern for pneumothorax, pulmonary embolism, or increased left ventricular end-diastolic pressure (LVEDP). Spontaneous pneumothorax is usually accompanied by chest pain and occurs most often in thin, young males, or in those with underlying lung disease. Pulmonary embolism should always be suspected when a patient with new dyspnea reports a recent history (previous 4 weeks) of prolonged immobilization, estrogen therapy, or other risk factors for deep venous thrombosis (DVT) (eg, previous history of thromboembolism, cancer, obesity, lower extremity trauma) and when the cause of dyspnea is not apparent. Silent myocardial infarction, which occurs more frequently in diabetic persons and women, can result in acute heart failure and dyspnea.

Accompanying symptoms provide important clues to various etiologies of dyspnea. When cough and fever are present, pulmonary disease (particularly infections) is the primary concern, although myocarditis, pericarditis, and septic emboli can also present in this manner. Chest pain

should be further characterized as acute or chronic, pleuritic or exertional. Although acute pleuritic chest pain is the rule in acute pericarditis and pneumothorax, most patients with pleuritic chest pain in the outpatient clinic have pleurisy due to acute viral respiratory tract infection. Periodic chest pain that precedes the onset of dyspnea is suspicious for myocardial ischemia as well as pulmonary embolism. When associated with wheezing, most cases of dyspnea are due to acute bronchitis; however, when acute bronchitis seems unlikely, the clinician should also consider new-onset asthma, foreign body, and vocal cord dysfunction.

When a patient reports prominent dyspnea with mild or no accompanying features, consider noncardiopulmonary causes of impaired oxygen delivery (anemia, methemoglobinemia, cyanide ingestion, carbon monoxide), metabolic acidosis due to a variety of conditions, panic disorder, and chronic pulmonary embolism.

B. Physical Examination

A focused physical examination should include evaluation of the head and neck, chest, heart, and lower extremities. Visual inspection of the patient's respiratory pattern can suggest obstructive airway disease (pursed-lip breathing, use of extra respiratory muscles, barrel-shaped chest), pneumothorax (asymmetric excursion), or metabolic acidosis (Kussmaul respirations). Patients with impending upper airway obstruction (eg, epiglottitis, foreign body), or severe asthma exacerbation, sometimes assume a tripod position. Focal wheezing raises the suspicion for a foreign body or other bronchial obstruction. Maximum laryngeal height (the distance between the top of the thyroid cartilage and the suprasternal notch at end expiration) is a measure of hyperinflation. Obstructive airway disease is virtually nonexistent when a nonsmoking patient younger than 45 years has a maximum laryngeal height ≤ 4 cm (Table 2–2). Absent breath sounds suggests a pneumothorax. An accentuated pulmonic component of the second heart sound (loud P2) is a sign of pulmonary hypertension and pulmonary embolism.

Table 2–2. Clinical findings suggesting obstructive airway disease.

	Adjusted Likelihood Ratios	
	Factor Present	Factor Absent
> 40 pack-years smoking	11.6	0.9
Age ≥ 45 years	1.4	0.5
Maximum laryngeal height ≤ 4 cm	3.6	0.7
All three factors	58.5	0.3

Reproduced, with permission, from Straus SE et al. The accuracy of patient history, wheezing, and laryngeal measurements in diagnosing obstructive airway disease. CARE-COAD1 Group. Clinical Assessment of the Reliability of the Examination—Chronic Obstructive Airways Disease. JAMA. 2000 Apr 12;283(14):1853–7.

Table 2-3. Clinical findings suggesting increased left ventricular end-diastolic pressure.

Tachycardia
Systolic hypotension
Jugular venous distention (> 5–7 cm H ₂ O) ¹
Hepatojugular reflux (> 1 cm) ²
Crackles, especially bibasilar
Third heart sound ³
Lower extremity edema
Radiographic pulmonary vascular redistribution or cardiomegaly ¹

¹These findings are particularly helpful.

²Proper abdominal compression for evaluating hepatojugular reflux requires > 30 seconds of sustained right upper quadrant abdominal compression.

³Cardiac auscultation of the patient at 45-degree angle in left lateral decubitus position doubles the detection rate of third heart sounds.

Source: Badgett RG et al. Can the clinical examination diagnose left-sided heart failure in adults? JAMA. 1997 Jun 4;277(21):1712–9.

A systematic review has identified several clinical predictors of increased LVEDP useful in the evaluation of dyspneic patients with no prior history of CHF (Table 2–3). When none is present, there is a very low probability (< 10%) of increased LVEDP, and when two or more are present, there is a very high probability (> 90%) of increased LVEDP.

C. Diagnostic Studies

Causes of dyspnea that can be managed without chest radiography are few: ingestions causing lactic acidosis, methemoglobinemia, and carbon monoxide poisoning. The diagnosis of pneumonia should be confirmed by chest radiography in most patients. When COPD exacerbation is severe enough to require hospitalization, results of chest radiography can influence management decisions in up to 20% of patients. Chest radiography is fairly sensitive and specific for new-onset CHF (represented by redistribution of pulmonary venous circulation) and can help guide treatment decisions in patients with dyspnea secondary to cardiac disease. End-expiratory chest radiography enhances detection of a small pneumothorax.

A normal chest radiograph has substantial diagnostic value. When there is no physical examination evidence of COPD or CHF and the chest radiograph is normal, the major remaining causes of dyspnea include pulmonary embolism, *Pneumocystis jiroveci* infection (initial radiograph may be normal in up to 25%), upper airway obstruction, foreign body, anemia, and metabolic acidosis. If a patient has tachycardia and hypoxemia but a normal chest radiograph and electrocardiogram (ECG), then further tests to exclude pulmonary emboli are warranted (see Chapter 9), provided blood tests exclude significant anemia or metabolic acidosis. High-resolution chest CT is particularly useful in the evaluation of pulmonary embolism and has the added benefit of providing information about interstitial and alveolar lung disease.

Serum or whole blood brain natriuretic peptide (BNP or NT-proBNP) testing can be useful in distinguishing

cardiac from noncardiac causes of dyspnea in the emergency department, since elevated BNP levels are both sensitive and specific for increased LVEDP in symptomatic persons. Cut points for ruling out acute heart failure increase with age, with one study recommending < 300 g/L to rule out heart failure, and three cut points for ruling-in heart failure (> 450 ng/L for age < 50 years; > 900 ng/L for age 50–75 years; and > 1800 ng/L for age > 75 years).

Persistent uncertainty following clinical examination and routine diagnostic testing warrants arterial blood gas measurement. With two notable exceptions (carbon monoxide poisoning and cyanide toxicity), arterial blood gas measurement distinguishes increased mechanical effort causes of dyspnea (respiratory acidosis with or without hypoxemia) from compensatory tachypnea (respiratory alkalosis with or without hypoxemia or metabolic acidosis) from psychogenic dyspnea (respiratory alkalosis). Carbon monoxide and cyanide impair oxygen delivery with minimal alterations in PO₂; percent carboxyhemoglobin identifies carbon monoxide toxicity. Cyanide poisoning should be considered in a patient with profound lactic acidosis following exposure to burning vinyl (such as a theater fire or industrial accident). Suspected carbon monoxide poisoning or methemoglobinemia can also be confirmed with venous carboxyhemoglobin or methemoglobin levels.

Because arterial blood gas testing is impractical in most outpatient settings, **pulse oximetry** has assumed a central role in the office evaluation of dyspnea. Oxygen saturation values above 96% almost always correspond with a PO₂ > 70 mm Hg, and values < 94% almost always represent clinically significant hypoxemia. Important exceptions to this rule include carbon monoxide toxicity, which leads to a normal oxygen saturation (due to the similar wavelengths of oxyhemoglobin and carboxyhemoglobin), and methemoglobinemia, which results in an oxygen saturation of about 85% that fails to increase with supplemental oxygen. A delirious or obtunded patient with obstructive lung disease warrants immediate measurement of arterial blood gases to exclude hypercapnia and the need for intubation, regardless of the oxygen saturation. When pulse oximetry yields equivocal results, assessment of desaturation with ambulation (eg, a brisk walk around the clinic) can be a useful finding (eg, when *Pneumocystis jiroveci* pneumonia is suspected) for confirming impaired gas exchange.

Episodic dyspnea can be challenging if an evaluation cannot be performed during symptoms. Life-threatening causes include recurrent pulmonary embolism, myocardial ischemia, and reactive airway disease. When associated with audible wheezing, vocal cord dysfunction should be considered, particularly in a young woman who does not respond to asthma therapy. Spirometry is very helpful in further classifying patients with obstructive airway disease but is rarely needed in the initial or emergent evaluation of patients with acute dyspnea.

► Differential Diagnosis

Acute dyspnea, particularly as the chief complaint, demands urgent evaluation. Urgent and emergent conditions causing acute dyspnea include pneumonia, COPD, asthma, pneumothorax, pulmonary embolism, cardiac disease (eg, CHF,

acute myocardial infarction, valvular dysfunction, arrhythmia, cardiac shunt), metabolic acidosis, cyanide toxicity, methemoglobinemia, and carbon monoxide poisoning.

► Treatment

The treatment of urgent or emergent causes of dyspnea should aim to relieve the underlying cause. Pending diagnosis, patients with hypoxemia should be immediately provided supplemental oxygen unless significant hypercapnia is present or strongly suspected pending arterial blood gas measurement. Dyspnea frequently occurs in patients nearing the end of life; whereas opioid therapy can provide substantial relief independent of the severity of hypoxemia, oxygen therapy appears to be most beneficial to patients with significant hypoxemia (see Chapter 5). There appears to be limited benefit of supplemental oxygen when patients with life-limiting illness have $\text{PaO}_2 > 55$ mm Hg. In patients with severe COPD and hypoxemia, oxygen therapy improves mortality and exercise performance. Current clinical trials are attempting to determine benefits of supplemental oxygen in patients with COPD and moderate hypoxemia at rest or desaturation with exercise. Pulmonary rehabilitation programs are another therapeutic option for patients with moderate to severe COPD or interstitial pulmonary fibrosis.

► When to Refer

- Patients with advanced COPD should be referred to a pulmonologist, and patients with CHF or valvular heart disease should be referred to a cardiologist following acute stabilization.
- Cyanide toxicity should be managed in conjunction with a toxicologist.

► When to Admit

- Impaired gas exchange from any cause or high risk of pulmonary embolism pending definitive diagnosis.
- Suspected cyanide poisoning.

Cranston JM et al. Oxygen therapy for dyspnoea in adults. *Cochrane Database Syst Rev.* 2008 Jul 16;(3):CD004769. [PMID: 18646110]

Gallagher R. The use of opioids for dyspnea in advanced disease. *CMAJ.* 2011 Jul 12;183(10):1170. [PMID: 21746829]

Hildebrandt P et al. Amino-terminal pro-B-type natriuretic peptide testing to assist the diagnostic evaluation of heart failure in symptomatic primary care patients. *Am J Cardiol.* 2008 Feb 4;101(3A):25–8. [PMID: 18243854]

Karnani NG et al. Evaluation of chronic dyspnea. *Am Fam Physician.* 2005 Apr 15;71(8):1529–37. [PMID: 15864893]

Nonoyama ML et al. Effect of oxygen on health quality of life in patients with chronic obstructive pulmonary disease with transient exertional hypoxemia. *Am J Respir Crit Care Med.* 2007 Aug 15;176(4):343–9. [PMID: 17446339]

Stoller JK et al; Long-term Oxygen Treatment Trial Research Group. Oxygen therapy for patients with COPD: current evidence and the long-term oxygen treatment trial. *Chest.* 2010 Jul;138(1):179–87. [PMID: 20605816]

Voll-Aanerud M et al. Changes in respiratory symptoms and health-related quality of life. *Chest.* 2007 Jun;131(6):1890–7. [PMID: 17505046]

Weintraub NL et al. Acute heart failure syndromes: emergency department presentation, treatment, and disposition: current approaches and future aims: a scientific statement from the American Heart Association. *Circulation.* 2010 Nov 9;122(19):1975–96. [PMID: 20937981]

HEMOPTYSIS



ESSENTIAL INQUIRIES

- Smoking history.
- Fever, cough, and other symptoms of lower respiratory tract infection.
- Nasopharyngeal or gastrointestinal bleeding.
- Chest radiography and complete blood count.

► General Considerations

Hemoptysis is the expectoration of blood that originates below the vocal cords. It is commonly classified as trivial, mild, or massive—the latter defined as more than 200–600 mL (about 1–2 cups) in 24 hours. The dividing lines are arbitrary, since the amount of blood is rarely quantified with precision. Massive hemoptysis can be usefully defined as any amount that is hemodynamically significant or threatens ventilation, in which case the initial management goal is not diagnostic but therapeutic.

The lungs are supplied with a dual circulation. The pulmonary arteries arise from the right ventricle to supply the pulmonary parenchyma in a low-pressure circuit. The bronchial arteries arise from the aorta or intercostal arteries and carry blood under systemic pressure to the airways, blood vessels, hila, and visceral pleura. Although the bronchial circulation represents only 1–2% of total pulmonary blood flow, it can increase dramatically under conditions of chronic inflammation—eg, chronic bronchiectasis—and is frequently the source of hemoptysis.

The causes of hemoptysis can be classified anatomically. Blood may arise from the airways in COPD, bronchiectasis, and bronchogenic carcinoma; from the pulmonary vasculature in left ventricular failure, mitral stenosis, pulmonary embolism, idiopathic pulmonary arterial hypertension, and arteriovenous malformations; or from the pulmonary parenchyma in pneumonia, inhalation of crack cocaine, or granulomatosis with polyangiitis (formerly Wegener granulomatosis). Diffuse alveolar hemorrhage is due to small vessel bleeding usually caused by autoimmune or hematologic disorders and results in alveolar infiltrates on chest radiography. Most cases of hemoptysis presenting in the outpatient setting are due to infection (eg, acute or chronic bronchitis, pneumonia, tuberculosis). Hemoptysis due to lung cancer increases with age, accounting for up to 20% of cases among the elderly. Less commonly (< 10% of cases), pulmonary venous hypertension (eg, mitral stenosis, pulmonary embolism) causes hemoptysis. Most cases of

hemoptysis that have no visible cause on CT scan or bronchoscopy will resolve within 6 months without treatment, with the notable exception of patients at high risk for lung cancer (smokers older than 40 years). Iatrogenic hemorrhage may follow transbronchial lung biopsies, anticoagulation, or pulmonary artery rupture due to distal placement of a balloon-tipped catheter. No cause is identified in up to 15–30% of cases.

▶ Clinical Findings

A. Symptoms

Blood-tinged sputum in the setting of an upper respiratory tract infection in an otherwise healthy, young (age < 40 years) nonsmoker does not warrant an extensive diagnostic evaluation if the hemoptysis subsides with resolution of the infection. However, hemoptysis is frequently a sign of serious disease, especially in patients with a high prior probability of underlying pulmonary pathology. One should not distinguish between blood-streaked sputum and cough productive of blood alone with regard to the evaluation plan. The goal of the history is to identify patients at risk for one of the disorders listed above. Pertinent features include past or current tobacco use, duration of symptoms, and the presence of respiratory infection. Nonpulmonary sources of hemorrhage—from the nose or the gastrointestinal tract—should also be excluded.

B. Physical Examination

Elevated pulse, hypotension, and decreased oxygen saturation suggest large volume hemorrhage that warrants emergent evaluation and stabilization. The nares and oropharynx should be carefully inspected to identify a potential upper airway source of bleeding. Chest and cardiac examination may reveal evidence of CHF or mitral stenosis.

C. Diagnostic Studies

Diagnostic evaluation should include a chest radiograph and complete blood count. Kidney function tests, urinalysis, and coagulation studies are appropriate in specific circumstances. Hematuria that accompanies hemoptysis may be a clue to Goodpasture syndrome or vasculitis. Flexible bronchoscopy reveals endobronchial cancer in 3–6% of patients with hemoptysis who have a normal (non-lateralizing) chest radiograph. Nearly all of these patients are smokers over the age of 40, and most will have had symptoms for more than 1 week. Bronchoscopy is indicated in such patients. High-resolution chest CT scan complements bronchoscopy and should be strongly considered in patients with normal chest radiograph and low risk for malignancy. It can visualize unsuspected bronchiectasis and arteriovenous malformations and will show central endobronchial lesions in many cases. High-resolution chest CT scanning is the test of choice for suspected small peripheral malignancies. Helical CT pulmonary angiography has become the initial test of choice for evaluating patients with suspected pulmonary embolism, although caution should be taken to avoid large contrast loads in patients with even mild chronic kidney disease (serum

creatinine > 2.0 g/dL or rapidly rising creatinine in normal range). Helical CT scanning can be avoided in patients who are at “unlikely” risk for pulmonary embolism using the Wells clinical decision rule and who have a normal sensitive D-dimer test.

▶ Treatment

The management of mild hemoptysis consists of identifying and treating the specific cause. Massive hemoptysis is life-threatening. The airway should be protected with endotracheal intubation, ventilation ensured, and effective circulation maintained. If the location of the bleeding site is known, the patient should be placed in the decubitus position with the involved lung dependent. Uncontrollable hemorrhage warrants rigid bronchoscopy and surgical consultation. In stable patients, flexible bronchoscopy may localize the site of bleeding, and angiography can embolize the involved bronchial arteries. Embolization is effective initially in 85% of cases, although rebleeding may occur in up to 20% of patients over the following year. The anterior spinal artery arises from the bronchial artery in up to 5% of people, and paraplegia may result if it is inadvertently cannulated.

▶ When to Refer

- When bronchoscopic evaluation of lower respiratory tract is required, refer patients to a pulmonologist.
- Patients should be referred to an otolaryngologist for evaluation of upper respiratory tract bleeding source.
- Patients with severe coagulopathy complicating management should be referred to a hematologist.

▶ When to Admit

- To stabilize bleeding process in patients at risk for or experiencing massive hemoptysis.
- To correct disordered coagulation (clotting factors or platelets, or both).
- To stabilize gas exchange.

- Bidwell JL et al. Hemoptysis: diagnosis and management. *Am Fam Physician*. 2005 Oct 1;72(7):1253–60. [PMID: 16225028]
- Conway AJ et al. Is investigation of patients with haemoptysis and normal chest radiograph justified? *Thorax*. 2011 Apr;66(4):352. [PMID: 20805153]
- Fartoukh M et al. Aetiology, diagnosis and management of infective causes of severe haemoptysis in intensive care units. *Curr Opin Pulm Med*. 2008 May;14(3):195–202. [PMID: 18427242]
- Jedy J et al; Expert Panel on Thoracic Imaging. ACR Appropriateness Criteria hemoptysis. *J Thorac Imaging*. 2010 Aug;25(3):W67–9. [PMID: 20711032]
- Pasha SM et al. Safety of excluding acute pulmonary embolism based on an unlikely clinical probability by the Wells rule and normal D-dimer concentration: a meta-analysis. *Thromb Res*. 2010 Apr;125(4):e123–7. [PMID: 19942258]
- Shigemura N et al. Multidisciplinary management of life-threatening massive hemoptysis: a 10-year experience. *Ann Thorac Surg*. 2009 Mar;87(3):849–53. [PMID: 19231404]
- Zyłowska J et al. Recurrent hemoptysis: an emerging life-threatening complication in idiopathic pulmonary arterial hypertension. *Chest*. 2011 Mar;139(3):690–3. [PMID: 21362657]

CHEST PAIN



ESSENTIAL INQUIRIES

- ▶ Chest pain onset, character, location/size, duration, periodicity, and exacerbators.
- ▶ Shortness of breath.
- ▶ Vital signs.
- ▶ Chest and cardiac examination.
- ▶ Electrocardiography.
- ▶ Biomarkers of myocardial necrosis.

▶ General Considerations

Chest pain (or chest discomfort) is a common symptom that can occur as a result of cardiovascular, pulmonary, pleural, or musculoskeletal disease, esophageal or other gastrointestinal disorders, or anxiety states. The frequency and distribution of life-threatening causes of chest pain, such as acute coronary syndrome (ACS), pericarditis, aortic dissection, pulmonary embolism, pneumonia, and esophageal perforation, vary substantially between clinical settings. Systemic lupus erythematosus, rheumatoid arthritis, and HIV are conditions that confer a strong risk for coronary artery disease. Because pulmonary embolism can present with a wide variety of symptoms, consideration of the diagnosis and rigorous risk factor assessment for venous thromboembolism (VTE) is critical. Classic VTE risk factors include cancer, trauma, recent surgery, prolonged immobilization, pregnancy, oral contraceptives, and family history and prior history of VTE. Other conditions associated with increased risk of pulmonary embolism include CHF and COPD. Sickle cell anemia can cause acute chest syndrome. Patients with this syndrome often have chest pain, fever, and cough.

Although uncommon in the office setting, delays in diagnosing life-threatening causes of chest pain can result in serious morbidity and mortality.

▶ Clinical Findings

A. Symptoms

Myocardial ischemia is usually described as dull, aching sensation of “pressure,” “tightness,” “squeezing,” or “gas,” rather than as sharp or spasmodic. Ischemic symptoms usually subside within 5–20 minutes but may last longer. Progressive symptoms or symptoms at rest may represent unstable angina. Prolonged chest pain episodes might represent myocardial infarction, although up to one-third of patients with acute myocardial infarction do not report chest pain. When present, pain due to myocardial ischemia is commonly accompanied by a sense of anxiety or uneasiness. The location is usually retrosternal or left precordial. Because the heart lacks somatic innervation, precise localization of pain due to cardiac ischemia is difficult; the pain is commonly referred to the throat, lower jaw, shoulders, inner arms,

upper abdomen, or back. Ischemic pain may be precipitated or exacerbated by exertion, cold temperature, meals, stress, or combinations of these factors and is usually relieved by rest. However, many episodes do not conform to these patterns; and atypical presentations of ACS are more common in the elderly, women, and persons with diabetes. Other symptoms that are associated with ACS include shortness of breath; dizziness; a feeling of impending doom; and vagal symptoms, such as nausea and diaphoresis. In the elderly, fatigue is a common presenting complaint of ACS. Likelihood ratios for cardinal symptoms considered in the evaluation of acute myocardial infarction are summarized in Table 2–4.

Hypertrophy of either ventricle or aortic stenosis may also give rise to chest pain with less typical features. Pericarditis may produce pain that is greater when supine than upright and may increase with respiration, coughing, or swallowing. Pleuritic chest pain is usually not ischemic,

Table 2–4. Likelihood ratios (LRs) for clinical features associated with acute myocardial infarction.

Clinical Feature	LR+ (95% CI)
History	
Chest pain that radiates to the left arm	2.3 (1.7–3.1)
Chest pain that radiates to the right shoulder	2.9 (1.4–3.0)
Chest pain that radiates to both arms	7.1 (3.6–14.2)
Pleuritic chest pain	0.2 (0.2–0.3)
Sharp or stabbing chest pain	0.3 (0.2–0.5)
Positional chest pain	0.3 (0.2–0.4)
Chest pain reproduced by palpation	0.2–0.4 ¹
Nausea or vomiting	1.9 (1.7–2.3)
Diaphoresis	2.0 (1.9–2.2)
Physical examination	
Systolic blood pressure ≤ 80 mm Hg	3.1 (1.8–5.2)
Pulmonary crackles	2.1 (1.4–3.1)
Third heart sound	3.2 (1.6–6.5)
Electrocardiogram	
Any ST segment elevation (≥ 1 mm)	11.2 (7.1–17.8)
Any ST segment depression	3.2 (2.5–4.1)
Any Q wave	3.9 (2.7–7.7)
Any conduction defect	2.7 (1.4–5.4)
New ST segment elevation (≥ 1 mm)	5.7–53.9 ¹
New ST segment depression	3.0–5.2 ¹
New Q wave	5.3–24.8 ¹
New conduction defect	6.3 (2.5–15.7)

¹Heterogenous studies do not allow for calculation of a point estimate.

Adapted, with permission, from Panju AA et al. The rational clinical examination. Is this patient having a myocardial infarction? JAMA. 1998 Oct 14;280(14):1256–63.

and pain on palpation may indicate a musculoskeletal cause. Aortic dissection classically produces an abrupt onset of tearing pain of great intensity that often radiates to the back; however, this classic presentation occurs in a small proportion of cases. Anterior aortic dissection can also lead to myocardial or cerebrovascular ischemia.

Pulmonary embolism has a wide range of clinical presentations, with chest pain present in only 75% of cases. The chief objective in evaluating patients with suspected pulmonary embolism is to assess the patient's clinical risk for VTE based on medical history and associated signs and symptoms (see above and Chapter 9). Esophageal perforation of the thoracic region is another cause of chest pain, with most cases resulting from medical procedures of the esophagus.

B. Physical Examination

Findings on physical examination can occasionally yield important clues to the underlying cause of chest pain; however, a normal physical examination should never be used as the sole basis for ruling-out most diagnoses, particularly ACS and aortic dissection. Vital sign measurement, including pulse oximetry, is always the first step for assessing the urgency and tempo of the subsequent examination and diagnostic work-up.

Findings that increase the likelihood of ACS include diaphoresis, hypotension, S3 or S4 gallop, pulmonary crackles, or elevated jugular venous pressure (see Table 2–4). Although chest pain that is reproducible or worsened with palpation strongly suggests a musculoskeletal cause, up to 15% of patients with ACS will have reproducible chest wall tenderness. Pointing to the location of the pain with one finger has been shown to be highly correlated with nonischemic chest pain. Aortic dissection can result in differential blood pressures (> 20 mm Hg), pulse amplitude deficits, and new diastolic murmurs. Although hypertension is considered the rule in patients with aortic dissection, systolic blood pressure < 100 mm Hg is present in up to 25% of patients.

A cardiac friction rub represents pericarditis until proven otherwise. It can best be heard with the patient sitting forward at end-expiration. Tamponade should be excluded in all patients with a clinical diagnosis of pericarditis by assessing pulsus paradoxus (a decrease in systolic blood pressure during inspiration > 10 mm Hg) and inspection of jugular venous pulsations. Subcutaneous emphysema is common following cervical esophageal perforation but present in only about one-third of thoracic perforations (ie, those most commonly presenting with chest pain).

The absence of physical examination findings in patients with suspected pulmonary embolism usually serves to *increase* the likelihood of pulmonary embolism, although a normal physical examination is also compatible with the much more common conditions of panic/anxiety disorder and musculoskeletal disease.

C. Diagnostic Studies

Unless a competing diagnosis can be confirmed, an ECG is warranted in the initial evaluation of most patients with acute chest pain to help exclude ACS. ST segment elevation is the ECG finding that is the strongest predictor of acute

myocardial infarction (see Table 2–4); however, up to 20% of patients with ACS can have a normal ECG. A 2007 study concluded that patients with suspected ACS can be safely removed from cardiac monitoring in the emergency department if they are pain-free at initial physician assessment and have a normal or nonspecific ECG. This decision rule had 100% sensitivity for serious arrhythmia (95% confidence interval, 80–100%), but deserves further validation. Clinically stable patients with cardiovascular disease risk factors, normal ECG, normal cardiac biomarkers, and no alternative diagnoses (such as typical GERD or costochondritis) should be followed-up with a timely exercise stress test that includes perfusion imaging. The ECG can also provide evidence for alternative diagnoses, such as pericarditis and pulmonary embolism. Chest radiography is often useful in the evaluation of chest pain, and is always indicated when cough or shortness of breath accompanies chest pain. Findings of pneumomediastinum or new pleural effusion are consistent with esophageal perforation. Sixty-four-slice CT coronary angiography has been studied for diagnosing acute coronary syndromes and predicting outcomes in the emergency department. One study of 58 patients found a high positive predictive value for diagnosing acute coronary syndromes, and a negative predictive value of 97%. Another study found that it compared favorably with stress nuclear imaging in the detection and exclusion of ACS in low-risk chest pain patients. CT is the study of choice at most centers for the diagnosis of esophageal perforation as well as for aortic dissection (helical CT). Current generation highly-sensitive assays for cardiac troponin I have been studied in an effort to more rapidly prognosticate outcomes in patients presenting with suspected ACS. Patients presenting to the emergency department with chest pain of intermediate or high probability for ACS without electrocardiographic or biomarker evidence of a myocardial infarction can be safely discharged from an observation unit after stress cardiac magnetic imaging.

The role of CT coronary calcium assessment in the evaluation of chest pain in the emergency department is still being defined. A study suggests that the coronary artery calcium score appears to be an effective initial tool for risk stratification of low- to intermediate-risk patients with possible acute coronary syndromes, on the basis of its high negative predictive value and additive diagnostic value.

In the evaluation of pulmonary embolism, diagnostic test decisions and results must be interpreted in the context of the clinical likelihood of VTE. A negative D-dimer test is helpful for excluding pulmonary embolism in patients with low clinical probability of VTE (3 month incidence = 0.5%); however, the 3-month risk of VTE among patients with intermediate and high risk of VTE is sufficiently high in the setting of a negative D-dimer test (3.5% and 21.4%, respectively) to warrant further imaging given the life-threatening nature of this condition if left untreated. CT angiography (with helical or multidetector CT imaging) has replaced ventilation-perfusion scanning as the preferred diagnostic test for pulmonary embolism, having approximately 90–95% sensitivity and 95% specificity for detecting pulmonary embolism (compared with pulmonary angiography). However, according to guidelines

published by the American Academy of Family Physicians and the American College of Physicians (AAFP/ACP), the sensitivity of helical CT is probably not sufficiently high to exclude pulmonary embolism among patients with high clinical probability of VTE, in whom lower extremity ultrasound or pulmonary angiogram may be appropriate. When ventilation-perfusion scanning is performed, only results that are normal or high probability are useful for improving one's clinical assessment of pulmonary embolism.

Panic disorder is a common cause of chest pain, accounting for up to 25% of cases that present to emergency departments and a higher proportion of cases presenting in primary care office practices. Features that correlate with an increased likelihood of panic disorder include absence of coronary artery disease, atypical quality of chest pain, female sex, younger age, and a high level of self-reported anxiety.

► Treatment

Treatment of chest pain should be guided by the underlying etiology. The term “noncardiac chest pain” is used to describe patients who evade diagnosis after receiving extensive work-up. Although under-studied, one small trial of patients with noncardiac chest pain found that about half fulfilled criteria for anxiety or depression and almost half reported symptom improvement with high-dose proton-pump inhibitor therapy.

► When to Refer

- Refer patients with poorly controlled, noncardiac chest pain to a pain specialist.
- Refer patients with sickle cell anemia to a hematologist.

► When to Admit

- Failure to adequately exclude (to a sufficient degree) life-threatening causes of chest pain, particularly myocardial infarction, dissecting aortic aneurysm, pulmonary embolism, and esophageal rupture.
- Pain control for rib fracture that impairs gas exchange.

Body R et al. Rapid exclusion of acute myocardial infarction in patients with undetectable troponin using a high-sensitivity assay. *J Am Coll Cardiol*. 2011 Sep 20;58(13):1332–9. [PMID: 21920261]

Bonaca M et al. Prospective evaluation of the prognostic implications of improved assay performance with a sensitive assay for cardiac troponin I. *J Am Coll Cardiol*. 2010 May 11;55(19):2118–24. [PMID: 20447535]

Chow BJ et al. Usefulness of computed tomographic coronary angiography in patients with acute chest pain with and without high-risk features. *Am J Cardiol*. 2010 Aug 15;106(4):463–9. [PMID: 20691302]

Cullen MW et al. Outcomes in patients with chest pain evaluated in a chest pain unit: the chest pain evaluation in the emergency room study cohort. *Am Heart J*. 2011 May;161(5):871–7. [PMID: 21570516]

Fernandez-Friera L et al. Diagnostic value of coronary artery calcium scoring in low-intermediate risk patients evaluated in the emergency department for acute coronary syndrome. *Am J Cardiol*. 2011 Jan;107(1):17–23. [PMID: 21146680]

Geersing GJ et al. Excluding venous thromboembolism using point of care D-dimer tests in outpatients: a diagnostic meta-analysis. *BMJ*. 2009 Aug 14;339:b2990. [PMID: 19684102]

Gottlieb I et al. The absence of coronary calcification does not exclude obstructive coronary artery disease or the need for revascularization in patients referred for conventional coronary angiography. *J Am Coll Cardiol*. 2010 Feb 16;55(7):627–34. [PMID: 20170786]

Laudon DA et al. Computed tomographic coronary artery calcium assessment for evaluating chest pain in the emergency department: long-term outcome of a prospective blind study. *Mayo Clin Proc*. 2010 Apr;85(4):314–22. [PMID: 20360291]

Miller CD et al. Stress cardiac magnetic resonance imaging with observation unit care reduces cost for patients with emergent chest pain: a randomized trial. *Ann Emerg Med*. 2010 Sep;56(3):209–219.e2. [PMID: 20554078]

Mills NL et al. Implementation of a sensitive troponin I assay and risk of recurrent myocardial infarction and death in patients with suspected acute coronary syndrome. *JAMA*. 2011 Mar 23;305(12):1210–6. [PMID: 21427373]

Min JK et al. Determinants of coronary calcium conversion among patients with a normal coronary calcium scan: what is the “warranty period” for remaining normal? *J Am Coll Cardiol*. 2010 Mar 16;55(11):1110–7. [PMID: 20223365]

Ranasinghe AM et al. Acute aortic dissection. *BMJ*. 2011 Jul 29;343:d4487. doi: 10.1136/bmj.d4487. [PMID: 21803810]

Skinner JS et al; Chest Pain Guideline Development Group. NICE guidance. Chest pain of recent onset: assessment and diagnosis of recent onset chest pain or discomfort of suspected cardiac origin. *Heart*. 2010 Jun;96(12):974–8. [PMID: 20538674]

Wilson SR et al. Detection of myocardial injury in patients with unstable angina using a novel nanoparticle cardiac troponin I assay: observations from the PROTECT-TIMI 30 Trial. *Am Heart J*. 2009 Sep;158(3):386–91. [PMID: 19699861]

Woo KM et al. High-risk chief complaints I: chest pain—the big three. *Emerg Med Clin North Am*. 2009 Nov;27(4):685–712. [PMID: 19932401]

PALPITATIONS



ESSENTIAL INQUIRIES

- Forceful, rapid, or irregular beating of the heart.
- Rate, duration, and degree of regularity of heart beat.
- Age at first episode.
- Factors that precipitate or terminate episodes.
- Light-headedness or syncope.
- Neck pounding.
- Chest pain.

► General Considerations

Palpitations are defined as an unpleasant awareness of the forceful, rapid, or irregular beating of the heart. They are a common presenting complaint and are usually benign; however, they are occasionally the symptom of a life-threatening arrhythmia. To avoid missing a dangerous cause of the patient's symptom, clinicians sometimes pursue expensive

and invasive testing when a conservative diagnostic evaluation is sufficient. The converse is also true; in one study, 54% of patients with supraventricular tachycardia were initially wrongly diagnosed with panic, stress, or anxiety disorder. A disproportionate number of these misdiagnosed patients are women.

► Clinical Findings

A. Symptoms

Although described by patients in a myriad of ways, guiding the patient through a careful description of their palpitations may indicate a mechanism and narrow the differential diagnosis. Pertinent questions include the age at first episode; precipitants; and the rate, duration, and degree of regularity of the heart beat during the subjective palpitations. The examiner can ask the patient to “tap out” the rhythm with their fingers. The circumstances associated with onset and termination can also be helpful in determining the cause. Palpitations that start and stop abruptly suggest supraventricular or ventricular tachycardias. Patient-terminated palpitations using vagal maneuvers (such as the Valsalva maneuver) suggests supraventricular tachycardia.

Three common descriptions of palpitations are (1) “flip-flopping” (or “stop and start”), often caused by premature contraction of the atrium or ventricle, with the perceived “stop” from the pause following the contraction, and the “start” from the subsequent forceful contraction; (2) rapid “fluttering in the chest,” with regular “fluttering” suggesting supraventricular or ventricular arrhythmias (including sinus tachycardia) and irregular “fluttering” suggesting atrial fibrillation, atrial flutter, or tachycardia with variable block; and (3) “pounding in the neck” or neck pulsations, often due to “cannon” A waves in the jugular venous pulsations that occur when the right atrium contracts against a closed tricuspid valve.

Palpitations associated with chest pain suggests ischemic heart disease, or if the chest pain is relieved by leaning forward, pericardial disease is suspected. Palpitations associated with light-headedness, presyncope, or syncope suggests hypotension and may signify a life-threatening cardiac arrhythmia. Palpitations that occur regularly with exertion suggests a rate-dependent bypass tract or hypertrophic cardiomyopathy. If a benign etiology for these concerning symptoms cannot be ascertained at the index visit, then ambulatory monitoring or prolonged cardiac monitoring in the hospital might be warranted.

Noncardiac symptoms should also be elicited since the palpitations may be caused by a normal heart responding to a metabolic or inflammatory condition. Weight loss may suggest hyperthyroidism. Palpitations can be precipitated by vomiting or diarrhea that leads to electrolyte disorders and hypovolemia. Palpitations associated with hyperventilation, hand tingling, and nervousness are common when anxiety or panic disorder is the root cause.

B. Physical Examination

It is uncommon for the clinician to have the opportunity to examine a patient during an episode of palpitations.

However, careful cardiovascular examination can find abnormalities that can increase the likelihood of specific cardiac arrhythmias. The midsystolic click of mitral valve prolapse can suggest the diagnosis of a supraventricular arrhythmia as the cause for the palpitations. The harsh holosystolic murmur of hypertrophic cardiomyopathy, which occurs along the left sternal border and increases with the Valsalva maneuver, suggests atrial fibrillation or ventricular tachycardia. The presence of dilated cardiomyopathy, suggested on examination by a displaced and enlarged cardiac point-of-maximal impulse, increases the likelihood of ventricular tachycardia and atrial fibrillation. In patients with chronic atrial fibrillation, in-office exercise (eg, a brisk walk in the hallway) may reveal an intermittent accelerated ventricular response as the cause of the palpitations. The clinician should also look for signs of hyperthyroidism, such as tremulousness, brisk deep tendon reflexes, fine hand tremor, or signs of stimulant drug use (such as dilated pupils or skin or nasal septal lesions). The presence of visible neck pulsations (LR, 2.68; 95% CI, 1.25–5.78) in association with palpitations increases the likelihood of atrioventricular nodal reentry tachycardia.

C. Diagnostic Studies

The two cardiac studies that are commonly used in the initial evaluation of a patient with palpitations are the 12-lead ECG and ambulatory monitoring devices, such as the Holter monitor or the event recorder.

A 12-lead ECG should be performed on all patients reporting palpitations because it can provide evidence for a wide variety of causes. Although in most instances a specific arrhythmia will not be detected on the tracing, a careful evaluation of the ECG can help the clinician deduce a likely etiology in certain circumstances.

For instance, bradyarrhythmias and heart block can be associated with ventricular ectopy or escape beats that may be experienced as palpitations by the patient. Evidence of prior myocardial infarction by history or on ECG (eg, Q waves) increases the patient’s risk for nonsustained or sustained ventricular tachycardia. Ventricular preexcitation (Wolff-Parkinson-White syndrome) is suggested by a short PR interval (< 0.20 ms) and delta waves (upsloping PR segments). Left ventricular hypertrophy with deep septal Q waves in I, AVL, and V4 through V6 is seen in patients with hypertrophic obstructive cardiomyopathy. The presence of left atrial enlargement as suggested by a terminal P-wave force in V1 more negative than 0.04 msec and notched in lead II reflects a patient at increased risk for atrial fibrillation. A prolonged QT interval and abnormal T-wave morphology suggests the long-QT syndrome, which puts patients at increased risk for ventricular tachycardia.

For high-risk patients (Table 2–5), further diagnostic studies are warranted. A step-wise approach has been suggested—starting with ambulatory monitoring devices (Holter monitoring if the palpitations are expected to occur within the subsequent 72-hour period, event monitoring if less frequent), followed by invasive electrophysiologic testing if the ambulatory monitor records a worrisome arrhythmia or if serious arrhythmias are strongly suspected

Table 2–5. Palpitations: Patients at high risk for a cardiovascular cause.

Historical risk factors
Family history of significant arrhythmias
Personal or family history of syncope or resuscitated sudden death
History of myocardial infarction (and likely scarred myocardium)
Physical examination findings
Structural heart disease such as dilated or hypertrophic cardiomyopathies
Valvular disease (stenotic or regurgitant)
ECG findings
Long QT syndrome
Bradycardia
Second- or third-degree heart block
Sustained ventricular arrhythmias

despite normal findings on an appropriate ambulatory monitor.

In patients with a prior myocardial infarction, ambulatory cardiac monitoring or signal-averaged-ECG are appropriate next steps to assess ventricular tachycardia. ECG exercise testing is appropriate in patients who have palpitations with physical exertion and patients with suspected coronary artery disease. Echocardiography is useful when physical examination or ECG suggests structural abnormalities or decreased ventricular function.

► Differential Diagnosis

When assessing a patient with palpitations in an urgent care setting, the clinician must ascertain whether the symptoms represent (1) an arrhythmia that is minor and transient, (2) significant cardiovascular disease, (3) a cardiac manifestation of a systemic disease such as thyrotoxicosis, or (4) a benign somatic symptom that is amplified by underlying psychosocial characteristics of the patient.

Palpitations in patients with a known history of cardiac disease or palpitations that occur during sleep increase the likelihood of a cardiac arrhythmia. A history of panic disorder or palpitations that last < 5 minutes make a cardiac arrhythmia slightly less likely. Patients who seek medical attention in the emergency department instead of a medical clinic are more likely to have a cardiac etiology (47% versus 21%), while psychiatric causes are more common among patients with palpitations who seek medical attention in office practices (45% versus 27%). In a study of patients who went to a university medical clinic with the chief complaint of palpitations, etiologies were cardiac in 43%, psychiatric in 31%, and miscellaneous in 10% (including illicit drugs, medications, anemia, thyrotoxicosis, and mastocytosis).

Cardiac arrhythmias that can result in symptoms of palpitations include sinus bradycardia; sinus, supraventricular, and ventricular tachycardia; premature ventricular and atrial contractions; sick sinus syndrome; and advanced atrioventricular block.

Nonarrhythmic cardiac causes of palpitations include valvular heart diseases, such as aortic insufficiency or stenosis, atrial or ventricular septal defect, cardiomyopathy, congenital heart disease, and pericarditis.

Noncardiac causes of palpitations include fever, dehydration, hypoglycemia, anemia, thyrotoxicosis, and pheochromocytoma. Drugs such as cocaine, alcohol, caffeine, and pseudoephedrine can precipitate palpitations, as can prescription medications, including digoxin, phenothiazines, theophylline, and β -agonists as well as ephedra-containing herbal remedies or supplements, which are banned by the US Food and Drug Administration.

The most common psychiatric causes of palpitations are anxiety and panic disorder. The release of catecholamines during a panic attack or significant stress can trigger an arrhythmia. Asking a single question, “Have you experienced brief periods, for seconds or minutes, of an overwhelming panic or terror that was accompanied by racing heartbeats, shortness of breath, or dizziness?” can help identify patients with panic disorder.

► Treatment

After ambulatory monitoring, most patients with palpitations are found to have benign atrial or ventricular ectopy and nonsustained ventricular tachycardia. In patients with structurally normal hearts, these arrhythmias are not associated with adverse outcomes. Abstinence from caffeine and tobacco may help. Often, reassurance suffices. If not, or in very symptomatic patients, a trial of a β -blocker may be prescribed. For treatment of specific atrial or ventricular arrhythmias, see Chapter 10.

► When to Refer

- For electrophysiologic studies.
- For advice regarding treatment of atrial or ventricular arrhythmias.

► When to Admit

- Palpitations associated with syncope or near-syncope, particularly when the patient is aged 75 years or older and has an abnormal ECG, hematocrit < 30%, shortness of breath, respiratory rate > 24/min, or a history of CHF.
- Patients with risk factors for a serious arrhythmia.

Abbott AV. Diagnostic approach to palpitations. *Am Fam Physician.* 2005;71(4):743–50. [PMID: 15742913]

Hoefman E et al. Predictive value of history taking and physical examination in diagnosing arrhythmias in general practice. *Fam Pract.* 2007 Dec;24(6):636–41. [PMID: 17986627]

Indik JH. When palpitations worsen. *Am J Med.* 2010 Jun;123(6):517–9. [PMID: 20569756]

Jonsbu E et al. Patients with noncardiac chest pain and benign palpitations referred for cardiac outpatient investigation: a 6-month follow-up. *Gen Hosp Psychiatry.* 2010 Jul–Aug; 32(4):406–12. [PMID: 20633745]

Lawless CE et al. Palpitations in athletes. *Sports Med.* 2008;38(8): 687–702. [PMID: 18620468]

Nobles MB et al. Clinical inquiries. Should you evaluate for CAD in seniors with premature ventricular contractions? *J Fam Pract.* 2008 May;57(5):325–6. [PMID: 18460298]

Thavendiranathan P et al. Does this patient with palpitations have a cardiac arrhythmia? *JAMA.* 2009 Nov 18;302(19):2135–43. [PMID: 19920238]

Vallès E et al. Diagnostic and prognostic value of electrophysiologic study in patients with nondocumented palpitations. *Am J Cardiol.* 2011 May 1;107(9):1333–7. [PMID: 21371684]

LOWER EXTREMITY EDEMA



ESSENTIAL INQUIRIES

- ▶ History of venous thromboembolism.
- ▶ Symmetry.
- ▶ Pain.
- ▶ Dependence.
- ▶ Skin findings.

▶ General Considerations

Acute and chronic lower extremity edema present important diagnostic and treatment challenges. Lower extremities can swell in response to increased venous or lymphatic pressures, decreased intravascular oncotic pressure, increased capillary leak, and local injury or infection. **Chronic venous insufficiency** is by far the most common cause, affecting up to 2% of the population, and the incidence of venous insufficiency has not changed during the past 25 years. Venous insufficiency is a common complication of DVT; however, only a small number of patients with chronic venous insufficiency report a history of this disorder. Venous ulcer formation commonly affects patients with chronic venous insufficiency, and management of venous ulceration is labor-intensive and expensive. Other causes of lower extremity edema include cellulitis, musculoskeletal disorders (Baker cyst rupture, gastrocnemius tear or rupture), lymphedema, CHF, cirrhosis, and nephrotic syndrome as well as side effects from calcium channel blockers, minoxidil, or thiazolidinediones.

▶ Clinical Findings

A. Symptoms and Signs

Normal lower extremity venous pressure (in the erect position: 80 mm Hg in deep veins, 20–30 mm Hg in superficial veins) and cephalad venous blood flow require competent bicuspid venous valves, effective muscle contractions, and normal respirations. When one or more of these components fail, venous hypertension may result. Chronic exposure to elevated venous pressure by the postcapillary venules in the legs leads to leakage of fibrinogen and growth factors into the interstitial space, leukocyte aggregation and activation, and obliteration of the cutaneous lymphatic network. These changes account for the brawny, fibrotic skin changes observed in patients with chronic venous insufficiency, and the predisposition toward skin ulceration, particularly in the medial malleolar area.

Among common causes of lower extremity swelling, DVT is the most life-threatening. Clues suggesting DVT include a history of cancer, recent limb immobilization, or confinement to bed for at least 3 days following major surgery within the past month (Table 2–6). A search for alternative explanations is equally important in excluding DVT. Bilateral involvement and significant improvement

Table 2–6. Risk stratification of adults referred for ultrasound to rule out DVT.

Step 1: Calculate risk factor score		
Score 1 point for each		
	Untreated malignancy	
	Paralysis, paresis, or recent plaster immobilization	
	Recently bedridden for > 3 days due to major surgery within 4 weeks	
	Localized tenderness along distribution of deep venous system	
	Entire leg swelling	
	Swelling of one calf > 3 cm more than the other (measured 10 cm below tibial tuberosity)	
	Ipsilateral pitting edema	
	Collateral superficial (nonvaricose) veins	
	Previously documented DVT	
Alternative diagnosis as likely as or more likely than DVT: subtract 2 points		
Step 2: Obtain ultrasound		
Score	Ultrasound Positive	Ultrasound Negative
≤ 0	Confirm with venogram	DVT ruled out
1–2	Treat for DVT	Repeat ultrasound in 3–7 days
≥ 3	Treat for DVT	Confirm with venogram

DVT, deep venous thrombosis.

upon awakening favor systemic causes (eg, venous insufficiency, CHF, and cirrhosis). “Heavy legs” are the most frequent symptom among patients with chronic venous insufficiency, followed by itching. Pain, particularly if severe, is uncommon in uncomplicated venous insufficiency. Lower extremity swelling and inflammation in a limb recently affected by DVT could represent anticoagulation failure and thrombus recurrence but more often are caused by **postphlebotic syndrome** with valvular incompetence. Other causes of a painful, swollen calf include ruptured popliteal cyst, calf strain or trauma, and cellulitis.

Lower extremity swelling is a familiar complication of therapy with calcium channel blockers (particularly felodipine and amlodipine), thiazolidinediones, and minoxidil. Bilateral lower extremity edema can be a presenting symptom of nephrotic syndrome or volume overload caused by renal failure. Prolonged airline flights (>10 hours) are associated with increased risk of edema. In those with low to medium risk of thromboembolism (eg, women taking oral contraceptives), long flights are associated with a 2% incidence of asymptomatic popliteal DVT.

B. Physical Examination

Physical examination should include assessment of the heart, lungs, and abdomen for evidence of pulmonary hypertension (primary, or secondary to chronic lung disease), CHF, or cirrhosis. Some patients with cirrhosis have

pulmonary hypertension without lung disease. There is a spectrum of skin findings related to chronic venous insufficiency that depends on the severity and chronicity of the disease, ranging from hyperpigmentation and stasis dermatitis to abnormalities highly specific for chronic venous insufficiency: lipodermatosclerosis (thick brawny skin; in advanced cases, the lower leg resembles an inverted champagne bottle) and atrophie blanche (small depigmented macules within areas of heavy pigmentation). The size of both calves should be measured 10 cm below the tibial tuberosity and elicitation of pitting and tenderness performed. Swelling of the entire leg or swelling of one leg 3 cm more than the other suggests deep venous obstruction. In normal persons, the left calf is slightly larger than the right as a result of the left common iliac vein coursing under the aorta.

An ulcer located over the medial malleolus is a hallmark of chronic venous insufficiency but can be due to other causes. Shallow, large, modestly painful ulcers are characteristic of venous insufficiency, whereas small, deep, and more painful ulcers are more apt to be due to arterial insufficiency, vasculitis, or infection (including cutaneous diphtheria). Diabetic vascular ulcers, however, may be painless. When an ulcer is on the foot or above the mid calf, causes other than venous insufficiency should be considered.

C. Diagnostic Studies

Most causes of lower extremity swelling can be demonstrated with color duplex ultrasonography. Patients without an obvious cause of acute lower extremity swelling (eg, calf strain) should have an ultrasound performed, since DVT is difficult to exclude on clinical grounds. A predictive rule allows a clinician to exclude a lower extremity DVT in patients without an ultrasound if the patient has low pretest probability for DVT and has a negative sensitive D-dimer test (the “Wells rule”). Assessment of the ankle-brachial pressure index (ABPI) is important in the management of chronic venous insufficiency, since peripheral arterial disease may be exacerbated by compression therapy. This can be performed at the same time as ultrasound. Caution is required in interpreting the results of ABPI in older patients and diabetics due to decreased compressibility of their arteries. A dipstick urine test that is strongly positive for protein can suggest nephrotic syndrome, and a serum creatinine can help estimate kidney function.

► Treatment

Treatment of lower extremity edema should be guided by the underlying etiology. See relevant chapters for treatment of edema in patients with CHF (Chapter 10), nephrosis (Chapter 22), cirrhosis (Chapter 16), and lymphedema (Chapter 12). Edema resulting from calcium channel blocker therapy responds to concomitant therapy with ACE inhibitors or angiotensin receptor blockers.

In patients with chronic venous insufficiency without a comorbid volume overload state (eg, CHF), it is best to avoid diuretic therapy. These patients have relatively decreased

intravascular volume, and administration of diuretics may result in acute renal insufficiency and oliguria. The most effective treatment involves (1) leg elevation, above the level of the heart, for 30 minutes three to four times daily, and during sleep; (2) compression therapy; and (3) ambulatory exercise to increase venous return through calf muscle contractions. A wide variety of stockings and devices are effective in decreasing swelling and preventing ulcer formation. They should be put on with awakening, before hydrostatic forces result in edema. To control simple edema, 20-30 mm Hg is usually sufficient; whereas, > 30-40 mm Hg is usually required to control moderate to severe edema associated with ulcer formation. Escin, 50 mg orally twice daily (or as horse chestnut seed extract, 300 mg orally twice daily) has been shown in several randomized trials to be equivalent to compression stockings and can be quite useful in nonambulatory patients; however, this medication is not approved by the US Food and Drug Administration. Patients with decreased ABPI should be managed in concert with a vascular surgeon. Compression stockings (12–18 mm Hg at the ankle) are effective in preventing edema and asymptomatic thrombosis associated with long airline flights in low- to medium-risk persons. See Chapter 12 for treatment of venous stasis ulcers.

► When to Refer

- Chronic lower extremity ulcerations requiring specialist wound care.
- Nephrotic syndrome should be managed with nephrology consultation.
- When there is coexisting severe arterial insufficiency (claudication) complicating treatment with compression stockings.

► When to Admit

- Pending definitive diagnosis in patients at high risk for DVT with normal lower extremity ultrasound.
- Concern for impending compartment syndrome.
- Severe edema that impairs ability to ambulate or perform activities of daily living.

Amsler F et al. Compression therapy for occupational leg symptoms and chronic venous disorders—a meta-analysis of randomized controlled trials. *Eur J Vasc Endovasc Surg.* 2008 Mar; 35(3):366–72. [PMID: 18063393]

Deatrick KB et al. Chronic venous insufficiency: current management of varicose vein disease. *Am Surg.* 2010 Feb;76(2): 125–32. [PMID: 20336886]

Mockler J et al. Clinical inquiries. What is the differential diagnosis of chronic leg edema in primary care? *J Fam Pract.* 2008 Mar;57(3):188–9. [PMID: 18321457]

Raju S et al. Clinical practice. Chronic venous insufficiency and varicose veins. *N Engl J Med.* 2009 May 28;360(22):2319–27. [PMID: 19474429]

Wells PS et al. Does this patient have deep vein thrombosis? *JAMA.* 2006 Jan 11;295(2):199–207. [PMID: 16403932]

Wolinsky CD et al. Chronic venous disease. *Med Clin North Am.* 2009 Nov;93(6):1333–46. [PMID: 19932334]

Word R. Medical and surgical therapy for advanced chronic venous insufficiency. *Surg Clin North Am.* 2010 Dec;90(6): 1195–214. [PMID: 21074036]

FEVER & HYPERTHERMIA



ESSENTIAL INQUIRIES

- ▶ Age.
- ▶ Localizing symptoms.
- ▶ Weight loss.
- ▶ Joint pain.
- ▶ Injection substance use.
- ▶ Immunosuppression or neutropenia.
- ▶ History of cancer.
- ▶ Medications.
- ▶ Travel.

▶ General Considerations

The average normal oral body temperature taken in mid-morning is 36.7°C (range 36–37.4°C). This spectrum includes a mean and 2 standard deviations, thus encompassing 95% of a normal population, measured in mid-morning (normal diurnal temperature variation is 0.5–1°C). The normal rectal or vaginal temperature is 0.5°C higher than the oral temperature, and the axillary temperature is correspondingly lower. Rectal temperature is more reliable than oral temperature, particularly in patients who breathe through their mouth or in tachypneic states.

Fever is a regulated rise to a new “set point” of body temperature. When stimuli act on monocyte-macrophages, these cells elaborate pyrogenic cytokines, causing elevation of the set point through effects in the hypothalamus. These cytokines include interleukin-1 (IL-1), tumor necrosis factor (TNF), interferon-gamma, and interleukin-6 (IL-6). The elevation in temperature results from either increased heat production (eg, shivering) or decreased loss (eg, peripheral vasoconstriction). Body temperature in cytokine-induced fever seldom exceeds 41.1°C unless there is structural damage to hypothalamic regulatory centers.

1. Fever

Fever as a symptom provides important information about the presence of illness—particularly infections—and about changes in the clinical status of the patient. The fever pattern, however, is of marginal value for most specific diagnoses except for the relapsing fever of malaria, borreliosis, and occasional cases of lymphoma, especially Hodgkin disease. Furthermore, the degree of temperature elevation does not necessarily correspond to the severity of the illness. In general, the febrile response tends to be greater in children than in adults. In older persons, neonates, and in persons receiving certain medications (eg, NSAIDs or corticosteroids), a normal temperature or even hypothermia may be observed. Markedly elevated body temperature may result in profound metabolic disturbances. High temperature during the first trimester of pregnancy may cause

birth defects, such as anencephaly. Fever increases insulin requirements and alters the metabolism and disposition of drugs used for the treatment of the diverse diseases associated with fever.

2. Hyperthermia

Hyperthermia—not mediated by cytokines—occurs when body metabolic heat production or environmental heat load exceeds normal heat loss capacity or when there is impaired heat loss; heat stroke is an example. Body temperature may rise to levels (> 41.1°C) capable of producing irreversible protein denaturation and resultant brain damage; no diurnal variation is observed.

Neuroleptic malignant syndrome is a rare and potentially lethal idiosyncratic reaction to major tranquilizers, particularly haloperidol and fluphenazine; however, it has also been reported with the atypical neuroleptics (such as olanzapine or risperidone). **Serotonin syndrome** resembles neuroleptic malignant syndrome but occurs within hours of ingestion of agents that increase levels of serotonin in the central nervous system, including serotonin reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, meperidine, dextromethorphan, bromocriptine, tramadol, lithium, and psychostimulants (such as cocaine, methamphetamine, and MDMA). Clonus and hyperreflexia are more common in serotonin syndrome whereas “lead pipe” rigidity is more common in neuroleptic malignant syndrome. Neuroleptic malignant and serotonin syndromes share common clinical and pathophysiologic features to **malignant hyperthermia** of anesthesia (see Chapters 25 and 38).

3. Fever of Undetermined Origin

(See Fever of Unknown Origin, Chapter 30)

Most febrile illnesses are due to common infections, are short-lived, and are relatively easy to diagnose. In certain instances, however, the origin of the fever may remain obscure (“fever of undetermined origin,” FOU) even after protracted diagnostic examination. In upper respiratory tract infections, fever typically lasts no more than 3–5 days, beyond which additional evaluation should be considered. The term “FUO” has traditionally been reserved for unexplained cases of fever exceeding 38.3°C on several occasions for at least 3 weeks in patients without neutropenia or immunosuppression (see Chapter 30). Some authors have advocated for changing the definition of FOU in frail elderly nursing home patients to a persistent oral or tympanic membrane temperature of 37.2°C (99°F) or greater, or persistent rectal temperature of 37.5°C (99.5°F) or greater.

▶ Differential Diagnosis

See Table 2–7. The causes of FOU among elderly patients differ from those in younger patients, and a definitive diagnosis can be achieved in a larger proportion of elderly patients (up to 70%). Although the general diagnostic approach and distribution of infectious and noninfectious causes are roughly similar between age groups, tuberculosis

Table 2-7. Differential diagnosis of fever and hyperthermia.

Fever—common causes

Infections: bacterial, viral, rickettsial, fungal, parasitic
 Autoimmune diseases
 Central nervous system disease, including head trauma and mass lesions
 Malignant disease, especially renal cell carcinoma, primary or metastatic liver cancer, leukemia, and lymphoma

Fever—less common causes

Cardiovascular diseases, including myocardial infarction, thrombophlebitis, and pulmonary embolism
 Gastrointestinal diseases, including inflammatory bowel disease, alcoholic hepatitis, and granulomatous hepatitis
 Miscellaneous diseases, including drug fever, sarcoidosis, familial Mediterranean fever, tissue injury, hematoma, and factitious fever

Hyperthermia

Peripheral thermoregulatory disorders, including heat stroke, malignant hyperthermia of anesthesia, and malignant neuroleptic syndrome

and temporal arteritis are particularly more common causes of FUO in the elderly.

► Treatment

Most fever is well tolerated. When the temperature is $> 40^{\circ}\text{C}$, symptomatic treatment may be required. A temperature $> 41^{\circ}\text{C}$ is likely to be hyperthermia and thus not cytokine mediated, and *emergent management is indicated*. (See Heat Stroke, Chapter 37.)

A. General Measures for Removal of Heat

Regardless of the cause of the fever, alcohol sponges, cold sponges, ice bags, ice-water enemas, and ice baths will lower body temperature. They are more useful in hyperthermia, since patients with cytokine-related fever will attempt to override these therapies.

B. Pharmacologic Treatment of Fever

1. Antipyretic drugs—Antipyretic therapy is not needed except for patients with marginal hemodynamic status. Aspirin or acetaminophen, 325–650 mg every 4 hours, is effective in reducing fever. These drugs are best administered continuously rather than as needed, since “prn” dosing results in periodic chills and sweats due to fluctuations in temperature caused by varying levels of drug.

2. Antimicrobial therapy—In most febrile patients, empiric antibiotic therapy should be deferred pending further evaluation. However, empiric antibiotic therapy is sometimes warranted. Prompt broad-spectrum antimicrobials are indicated for febrile patients who are clinically unstable, even before infection can be documented. These include patients with hemodynamic instability, those with neutropenia (neutrophils $< 500/\text{mCL}$), others who are asplenic (surgically or secondary

to sickle cell disease) or immunosuppressed (including individuals taking systemic corticosteroids, azathioprine, cyclosporine, or other immunosuppressive medications) (Tables 30–4 and 30–5), and those who are HIV infected (see Chapter 31). For treatment of fever during neutropenia following chemotherapy, outpatient parenteral antimicrobial therapy with an agent such as ceftriaxone can be provided effectively and safely. If a fungal infection is suspected in patients with prolonged fever and neutropenia, fluconazole is an equally effective but less toxic alternative to amphotericin B.

C. Treatment of Hyperthermia

Discontinuation of the offending agent is mandatory. Treatment of neuroleptic malignant syndrome includes dantrolene in combination with bromocriptine or levodopa (see Chapter 25). Treatment of serotonin syndrome includes administration of a central serotonin receptor antagonist—cyproheptadine or chlorpromazine—alone or in combination with a benzodiazepine (see Chapter 25). In patients for whom it is difficult to distinguish which syndrome is present, treatment with a benzodiazepine may be the safest therapeutic option.

► When to Refer

Once the diagnosis of FUO is made, referral to infectious disease specialist or rheumatologist may be appropriate to guide specific additional tests.

► When to Admit

- Malignant hyperthermia.
- Heat stroke.
- For measures to control temperature when it is $> 41^{\circ}\text{C}$ or when associated with seizure or other mental status changes.

- Affronti M et al. Low-grade fever: how to distinguish organic from non-organic forms. *Int J Clin Pract.* 2010 Feb;64(3):316–21. [PMID: 20456171]
- Bleeker-Rovers CP et al. Fever of unknown origin. *Semin Nucl Med.* 2009 Mar;39(2):81–7. [PMID: 19187801]
- Bottieau E et al. Fever after a stay in the tropics: diagnostic predictors of the leading tropical conditions. *Medicine (Baltimore).* 2007 Jan;86(1):18–25. [PMID: 17220752]
- Denecke B et al. Hantavirus infection: a neglected diagnosis in thrombocytopenia and fever? *Mayo Clin Proc.* 2010 Nov;85(11):1016–20. [PMID: 21037045]
- Norman DC et al. Fever of unknown origin in older persons. *Infect Dis Clin North Am.* 2007 Dec;21(4):937–45. [PMID: 18061083]
- Pien BC et al. The clinical and prognostic importance of positive blood cultures in adults. *Am J Med.* 2010 Sep;123(9):819–28. [PMID: 20800151]
- Rusyniak DE et al. Toxin-induced hyperthermic syndromes. *Med Clin North Am.* 2005 Nov;89(6):1277–96. [PMID: 16227063]
- Siikamäki HM et al. Fever in travelers returning from malaria-endemic areas: don't look for malaria only. *J Travel Med.* 2011 Jul–Aug;18(4):239–44. [PMID: 2172234]

INVOLUNTARY WEIGHT LOSS



ESSENTIAL INQUIRIES

- ▶ Age.
- ▶ Caloric intake.
- ▶ Fever.
- ▶ Change in bowel habits.
- ▶ Secondary confirmation (eg, changes in clothing size).
- ▶ Substance use.
- ▶ Age-appropriate cancer screening history.

▶ General Considerations

Body weight is determined by a person's caloric intake, absorptive capacity, metabolic rate, and energy losses. The metabolic rate can be affected by a multitude of medical conditions through the release of various cytokines such as cachectin and interleukins. Body weight normally peaks by the fifth or sixth decade and then gradually declines at a rate of 1–2 kg per decade. In NHANES II, a national survey of community-dwelling elders (age 50–80 years), recent involuntary weight loss (> 5% usual body weight) was reported by 7% of respondents, and this was associated with a 24% higher mortality.

▶ Etiology

Involuntary weight loss is regarded as clinically significant when it exceeds 5% or more of usual body weight over a 6- to 12-month period and often indicates serious physical or psychological illness. Physical causes are usually evident during the initial evaluation. Cancer (about 30%), gastrointestinal disorders (about 15%), and dementia or depression (about 15%) are the most common causes. When an adequately nourished-appearing patient complains of weight loss, inquiry should be made about exact weight changes (with approximate dates) and about changes in clothing size. Family members can provide confirmation of weight loss, as can old documents such as driver's licenses. A mild, gradual weight loss occurs in some older individuals. It is due to changes in body composition, including loss of height and lean body mass and lower basal metabolic rate, leading to decreased energy requirements. However, rapid involuntary weight loss is predictive of morbidity and mortality in any population. In addition to various disease states, causes in older individuals include loss of teeth and consequent difficulty with chewing, alcoholism, and social isolation.

▶ Clinical Findings

Once the weight loss is established, the history, medication profile, physical examination, and conventional laboratory

and radiologic investigations (such as complete blood count, serologic tests including HIV, thyroid-stimulating hormone [TSH] level, urinalysis, fecal occult blood test, chest radiography, and upper gastrointestinal series) usually reveal the cause. When these tests are normal, the second phase of evaluation should focus on more definitive gastrointestinal investigation (eg, tests for malabsorption; endoscopy) and cancer screening (eg, Papanicolaou smear, mammography, prostate specific antigen [PSA]).

If the initial evaluation is unrevealing, follow-up is preferable to further diagnostic testing. Death at 2-year follow-up was not nearly as high in patients with unexplained involuntary weight loss (8%) as in those with weight loss due to malignant (79%) and established nonmalignant diseases (19%). Psychiatric consultation should be considered when there is evidence of depression, dementia, anorexia nervosa, or other emotional problems. Ultimately, in approximately 15–25% of cases, no cause for the weight loss can be found.

▶ Differential Diagnosis

Malignancy, gastrointestinal disorders (eg, malabsorption, pancreatic insufficiency), dementia, depression, anorexia nervosa, hyperthyroidism, alcoholism, and social isolation are all established causes. "Meals on Wheels" is a useful mnemonic for remembering the common treatable causes of involuntary weight loss in the elderly (see box below).

MEALS ON WHEELS: A Mnemonic for Common Treatable Causes of Unintentional Weight Loss in the Elderly.

- Medication effects
- Emotional problems, especially depression
- Anorexia tardive (nervosa), alcoholism
- Late-life paranoia
- Swallowing disorders
- Oral factors (eg, poorly fitting dentures, cavities)
- No money
- Wandering and other dementia-related behaviors
- Hyperthyroidism, hypothyroidism, hyperparathyroidism, hypoadrenalism
- Enteric problems (eg, malabsorption)
- Eating problems (eg, inability to feed self)
- Low-salt, low-cholesterol diets
- Social problems (eg, isolation, inability to obtain preferred foods), gallstones

Adapted, with permission, from Morley JE et al. Nutritional issues in nursing home care. *Ann Intern Med.* 1995 Dec 1; 123(11):850–9.

▶ Treatment

Weight stabilization occurs in most surviving patients with both established and unknown causes of weight loss through treatment of the underlying disorder and caloric supplementation. Nutrient intake goals are established in relation to the severity of weight loss, in general ranging from 30 to 40 kcal/kg/d. In order of preference, route of administration options include oral, temporary nasogastric tube, or percutaneous gastric or jejunal tube. Parenteral nutrition is reserved for patients with serious associated problems. A variety of pharmacologic agents have been proposed for the treatment of weight loss. These can be categorized into appetite stimulants (corticosteroids, progestational agents, dronabinol, and serotonin antagonists); anabolic agents (growth hormone and testosterone derivatives); and anticatabolic agents (omega-3 fatty acids, pentoxifylline, hydrazine sulfate, and thalidomide).

▶ When to Refer

- Weight loss caused by malabsorption.
- Persistent nutritional deficiencies despite adequate supplementation.
- Weight loss as a result of anorexia or bulimia.

▶ When to Admit

- Severe protein-energy malnutrition, including the syndromes of kwashiorkor and marasmus.
- Vitamin deficiency syndromes.
- Cachexia with anticipated progressive weight loss secondary to unmanageable psychiatric disease.
- To carefully manage electrolyte and fluid replacement in protein-energy malnutrition and avoid “re-feeding syndrome.”

Chapman IM. Nutritional disorders in the elderly. *Med Clin North Am.* 2006 Sep;90(5):887–907. [PMID: 16962848]

Chapman IM. Weight loss in older persons. *Med Clin North Am.* 2011 May;95(3):579–93. [PMID: 21549879]

Hopkinson JB et al. Management of weight loss and anorexia. *Ann Oncol.* 2008 Sep;19(Suppl 7):vii289–93. [PMID: 18790968]

Inelmen EM et al. An open-ended question: Alzheimer’s disease and involuntary weight loss: which comes first? *Aging Clin Exp Res.* 2010 Jun;22(3):192–7. [PMID: 19940557]

Metalidis C et al. Involuntary weight loss. Does a negative baseline evaluation provide adequate reassurance? *Eur J Intern Med.* 2008 Jul;19(5):345–9. [PMID: 18549937]

Morley JE. Weight loss in older persons: new therapeutic approaches. *Curr Pharm Des.* 2007;13(35):3637–47. [PMID: 18220800]

Schilp J et al. Early determinants for the development of undernutrition in an older general population: Longitudinal Aging Study Amsterdam. *Br J Nutr.* 2011 Sep;106(5):708–17. [PMID: 21450117]

Visvanathan R et al. Undernutrition and anorexia in the older person. *Gastroenterol Clin North Am.* 2009 Sep;38(3):393–409. [PMID: 19699404]

FATIGUE & CHRONIC FATIGUE SYNDROME



ESSENTIAL INQUIRIES

- ▶ Weight loss.
- ▶ Fever.
- ▶ Sleep-disordered breathing.
- ▶ Medications.
- ▶ Substance use.

▶ General Considerations

Fatigue, as an isolated symptom, accounts for 1–3% of visits to generalists. The symptom of fatigue is often poorly described and less well defined by patients than symptoms associated with specific dysfunction of organ systems. Fatigue or lassitude and the closely related complaints of weakness, tiredness, and lethargy are often attributed to overexertion, poor physical conditioning, sleep disturbance, obesity, undernutrition, and emotional problems. A history of the patient’s daily living and working habits may obviate the need for extensive and unproductive diagnostic studies.

Chronic fatigue syndrome may be due to retrovirus infection or an immune dysregulation mechanism, or both. Recent studies, however, have failed to show any differences in levels of xenotropic murine leukemia-virus-related virus in US patients with and without chronic fatigue syndrome. The diagnosis of chronic fatigue syndrome remains hotly debated because of the lack of a gold standard. Persons with chronic fatigue syndrome meeting specific criteria (such as those from the CDC) report a greater frequency of childhood trauma and psychopathology and demonstrate higher levels of emotional instability and self-reported stress than persons who do not have chronic fatigue. Neuropsychological, neuroendocrine, and brain imaging studies reveal neurobiologic abnormalities in most patients, but none with a consistent pattern. Sleep disorders have been reported in 40–80% of patients with chronic fatigue syndrome, but their treatment has provided only modest benefit, suggesting that it is an effect rather than a cause of the fatigue. Veterans of the Gulf War show a tenfold greater incidence of chronic fatigue syndrome compared with nondeployed military personnel.

▶ Clinical Findings

A. Fatigue

Clinically relevant fatigue is composed of three major components: generalized weakness (difficulty in initiating activities); easy fatigability (difficulty in completing activities); and mental fatigue (difficulty with concentration and memory). Important diseases that can cause fatigue include hyperthyroidism and hypothyroidism, CHF, infections (endocarditis, hepatitis), COPD, sleep apnea, anemia, autoimmune disorders, irritable bowel syndrome, and cancer. Alcoholism, side effects from such drugs as sedatives, and β -blockers may be the cause. Psychological conditions, such as insomnia, depression, anxiety, panic attacks, dysthymia,

and somatization disorder, may cause fatigue. Common outpatient infectious causes include mononucleosis and sinusitis. These conditions are usually associated with other characteristic signs, but patients may emphasize fatigue and not reveal their other symptoms unless directly asked. The lifetime prevalence of significant fatigue (present for at least 2 weeks) is about 25%. Fatigue of unknown cause or related to psychiatric illness exceeds that due to physical illness, injury, medications, drugs, or alcohol.

B. Chronic Fatigue Syndrome

A working case definition of chronic fatigue syndrome indicates that it is not a homogeneous abnormality, and there is no single pathogenic mechanism (Figure 2–2). No physical finding or laboratory test can be used to confirm the diagnosis of this disorder.


The evaluation of chronic fatigue syndrome includes a history and physical examination as well as complete blood count, erythrocyte sedimentation rate, serum chemistries—

blood urea nitrogen (BUN), electrolytes, glucose, creatinine, and calcium; liver and thyroid function tests—antinuclear antibody, urinalysis, and tuberculin skin test; and screening questionnaires for psychiatric disorders. Other tests to be performed as clinically indicated are serum cortisol, rheumatoid factor, immunoglobulin levels, Lyme serology in endemic areas, and tests for HIV antibody. More extensive testing is usually unhelpful, including antibody to Epstein-Barr virus. There may be an abnormally high rate of postural hypotension. MRI scans may show brain abnormalities on T₂-weighted images—chiefly small, punctate, subcortical white matter hyperintensities, predominantly in the frontal lobes; however, brain MRI is not recommended in the routine evaluation of chronic fatigue syndrome.

► Treatment

A. Fatigue

Management of fatigue involves identification and treatment of conditions that contribute to fatigue, such as cancer,



▲ **Figure 2–2.** Evaluation and classification of unexplained chronic fatigue. (CBC, complete blood count; ESR, erythrocyte sedimentation rate; ALT, alanine aminotransferase; Ca²⁺, calcium; PO₄³⁻, phosphate; BUN, blood urea nitrogen; TSH, thyroid-stimulating hormone; UA, urinalysis.) (Modified and reproduced, with permission, from Fukuda K et al. The chronic fatigue syndrome: a comprehensive approach to its definition and study. *Ann Intern Med.* 1994 Dec 15; 121(12):953–9.)

pain, depression, disordered sleep, weight loss, and anemia. Resistance training and aerobic exercise lessens fatigue and improves performance for a number of chronic conditions associated with a high prevalence of fatigue, including CHF, COPD, arthritis, and cancer. Continuous positive airway pressure is an effective treatment for obstructive sleep apnea. Psychostimulants such as methylphenidate have shown inconsistent results in randomized trials of treatment of cancer-related fatigue.

B. Chronic Fatigue Syndrome

A variety of agents and modalities have been tried for the treatment of chronic fatigue syndrome. Acyclovir, intravenous immunoglobulin, nystatin, and low-dose hydrocortisone/fludrocortisone do not improve symptoms except in patients with postural hypotension, some of whom report response to increases in dietary sodium as well as fludrocortisone, 0.1 mg orally daily. There is a greater prevalence of past and current psychiatric diagnoses in patients with this syndrome. Affective disorders are especially common. Patients with chronic fatigue syndrome have benefited from a comprehensive multidisciplinary intervention, including optimal medical management, treating any ongoing affective or anxiety disorder pharmacologically, and implementing a comprehensive cognitive-behavioral treatment program. **Cognitive-behavioral therapy**, a form of non-pharmacologic treatment emphasizing self-help and aiming to change perceptions and behaviors that may perpetuate symptoms and disability, is helpful. Although few patients are cured, the treatment effect is substantial. Response to cognitive-behavioral therapy is not predictable on the basis of severity or duration of chronic fatigue syndrome, although patients with low interest in psychotherapy rarely benefit. Graded exercise has also been shown to improve functional work capacity and physical function. At present, cognitive-behavioral therapy and graded exercise are the treatments of choice for patients with chronic fatigue syndrome. A 2011 randomized trial (PACE trial) has confirmed the independent benefits of cognitive behavioral therapy and graded exercise, and found no benefit of adaptive pacing therapy.

In addition, the clinician's sympathetic listening and explanatory responses can help overcome the patient's frustrations and debilitation by this still mysterious illness. All patients should be encouraged to engage in normal activities to the extent possible and should be reassured that full recovery is eventually possible in most cases.

► When to Refer

- Infections not responsive to standard treatment.
- Difficult to control hyperthyroidism or hypothyroidism.
- Severe psychological disease.
- Malignancy.

► When to Admit

- Failure to thrive.
- Fatigue severe enough to impair activities of daily living.

Ali MA, et al. Xenotropic murine leukemia virus-related virus is not associated with chronic fatigue syndrome in patients from different areas of the us in the 1990s. *Virology*. 2011 Sep 24;8:450. PubMed PMID: 21943244.

de Lange FP et al. Increase in prefrontal cortical volume following cognitive behavioural therapy in patients with chronic fatigue syndrome. *Brain*. 2008 Aug;131(Pt 8):2172–80. [PMID: 18587150]

Carruthers BM et al. Myalgic encephalomyelitis: International Consensus Criteria. *J Intern Med*. 2011 Oct;270(4):327–38. doi: 10.1111/j.1365-2796.2011.02428.x. Epub 2011 Aug 22. [PMID: 21777306]

Häuser W et al. Treatment of fibromyalgia syndrome with antidepressants: a meta-analysis. *JAMA*. 2009 Jan 14;301(2):198–209. [PMID: 19141768]

Knoop H et al. Efficacy of cognitive behavioral therapy for adolescents with chronic fatigue syndrome: long-term follow-up of a randomized, controlled trial. *Pediatrics*. 2008 Mar;121(3):e619–25. [PMID: 18310181]

Lo SC et al. Detection of MLV-related virus gene sequences in blood of patients with chronic fatigue syndrome and healthy blood donors. *Proc Natl Acad Sci U S A*. 2010 Sep 7;107(36):15874–9. [PMID: 20798047]

Nijrolder I et al. Prognosis of fatigue and functioning in primary care: a 1-year follow-up study. *Ann Fam Med*. 2008 Nov–Dec;6(6):519–27. [PMID: 19001304]

Prins JB et al. Chronic fatigue syndrome. *Lancet*. 2006 Jan 28;367(9507):346–55. [PMID: 16443043]

van der Meer JW et al. A controversial consensus—comment on article by Broderick et al. *J Intern Med*. 2012 Jan;271(1):29–31. doi: 10.1111/j.1365-2796.2011.02468.x. Epub 2011 Nov 11. [PMID: 21988219]

White PD et al. Comparison of adaptive pacing therapy, cognitive behaviour therapy, graded exercise therapy, and specialist medical care for chronic fatigue syndrome (PACE): a randomized trial. *Lancet*. 2011 Mar 5;377(9768):823–36. [PMID: 21334061]

ACUTE HEADACHE



ESSENTIAL INQUIRIES

- Age > 50 years.
- Rapid onset and severe intensity (ie, “thunderclap” headache).
- Fever.
- Trauma.
- Vision changes.
- HIV infection.
- Current or past history of hypertension.
- Neurologic findings (mental status changes, motor or sensory deficits).

► General Considerations

Headache is a common reason that adults seek medical care, accounting for approximately 13 million visits each year in the United States to physicians' offices, urgent care clinics, and emergency departments. A broad range of disorders can cause headache. This chapter will deal only with the approach to the acute nontraumatic headache in adolescents and adults. The challenge in the initial evaluation of

acute headache is to identify which patients are presenting with an uncommon but life-threatening condition. In the emergency department setting, approximately 1% of patients seeking medical attention for acute headache will have a life-threatening condition, whereas the prevalence of life-threatening conditions in the office practice setting is considerably lower.

Regardless of the underlying cause, headache is currently believed to occur as a result of the release of neuropeptides from trigeminal nerve endings that encapsulate the blood vessels of the pia mater and dura mater, resulting in neurogenic inflammation. Because this represents a final common pathway for many etiologies, diminution of headache in response to typical migraine therapies (such as serotonin receptor antagonists or ketorolac) does not rule out critical conditions such as subarachnoid hemorrhage or meningitis as the underlying cause.

► Clinical Findings

A. Symptoms

A careful history and physical examination should aim to identify causes of acute headache that require immediate treatment. These causes can be broadly classified as imminent or completed **vascular events** (intracranial hemorrhage, thrombosis, vasculitis, malignant hypertension, arterial dissection, or aneurysm), **infections** (abscess, encephalitis, meningitis), **intracranial masses** causing intracranial hypertension, **preeclampsia**, and **carbon monoxide poisoning**. Having the patient carefully describe the onset of headache can be helpful in diagnosing a serious cause. Report of a sudden-onset headache that reaches maximal and severe intensity within seconds or a few minutes is the classic description of a “thunderclap headache” and should precipitate workup for subarachnoid hemorrhage, since the estimated prevalence of subarachnoid hemorrhage in the setting of a thunderclap headache is 43%.

The general medical history can also guide the need for additional work-up. A new headache in a patient over the age of 50 or with a history of HIV disease under most circumstances (including a normal neurologic examination) warrants neuroimaging immediately (Table 2–8). When the patient has a medical history of hypertension—particularly uncontrolled hypertension—a complete search for criteria satisfying a diagnosis of “malignant hypertension” is appropriate to determine the correct urgency level of hypertension management (see Chapter 11). Headache and hypertension associated with pregnancy may be due to preeclampsia. Episodic headache associated with the triad of hypertension, heart palpitations, and sweats is suggestive of pheochromocytoma. In the absence of thunderclap headache, advanced age, and HIV disease, a careful physical examination and detailed neurologic examination will usually determine acuity of the work-up and need for further diagnostic testing.

Patient symptoms can also be useful for diagnosing migraine headache in the absence of the “classic” migraine pattern involving scintillating scotoma followed by unilateral headache, photophobia, and nausea and vomiting (Table 2–9). The presence of three or more of these features

Table 2–8. Clinical features associated with acute headache that warrant urgent or emergent neuroimaging.

Prior to lumbar puncture
Abnormal neurologic examination
Abnormal mental status
Abnormal funduscopic examination (papilledema; loss of venous pulsations)
Meningeal signs
Emergent (conduct prior to leaving office or emergency department)
Abnormal neurologic examination
Abnormal mental status
Thunderclap headache
Urgent (scheduled prior to leaving office or emergency department)
HIV-positive patient ¹
Age > 50 years (normal neurologic examination)

¹Use CT with or without contrast or MRI if HIV positive.

Source: American College of Emergency Physicians. Clinical Policy: critical issues in the evaluation and management of patients presenting to the emergency department with acute headache. *Ann Emerg Med.* 2002 Jan;39(1):108–22.

can establish the diagnosis of migraine (in the absence of other clinical features that warrant neuroimaging studies), and the presence of none or one of these features (provided it is not nausea) can help to rule out migraine.

B. Physical Examination

Critical components of the physical examination of the patient with acute headache include vital sign measurements, neurologic examination, and vision testing with funduscopic examination. The finding of fever with acute headache warrants additional maneuvers to elicit evidence of meningeal inflammation, such as Kernig and Brudzinski signs. Besides malignant hypertension, significant hypertension can also be a sign of intracranial hemorrhage, preeclampsia, and pheochromocytoma. Patients over 60 years of age should be examined for scalp or temporal artery tenderness.

Careful assessment of visual acuity, ocular gaze, visual fields, pupillary defects, the optic disk, and retinal vein pulsations is crucial. Diminished visual acuity is suggestive of glaucoma, temporal arteritis, or optic neuritis. Ophthalmoplegia or visual field defects may be signs of venous sinus thrombosis, tumor, or aneurysm. Afferent

Table 2–9. Summary likelihood ratios (LRs) for individual clinical features associated with migraine diagnosis.

Clinical Feature	LR+ (95% CI)	LR- (95% CI)
Nausea	19 (15–25)	0.19 (0.18–0.20)
Photophobia	5.8 (5.1–6.6)	0.24 (0.23–0.26)
Phonophobia	5.2 (4.5–5.9)	0.38 (0.36–0.40)
Exacerbation by physical activity	3.7 (3.4–4.0)	0.24 (0.23–0.26)

pupillary defects can be due to intracranial masses or optic neuritis. Ipsilateral ptosis and miosis suggest Horner syndrome and in conjunction with acute headache may signify carotid artery dissection. Finally, papilledema or absent retinal venous pulsations are signs of elevated intracranial pressure—findings that should be followed by neuroimaging prior to performing lumbar puncture (Table 2–8).

Mental status and complete neurologic evaluations are also critical and should include assessment of motor and sensory systems, reflexes, gait, cerebellar function, and pronator drift. Any abnormality on mental status or neurologic evaluation warrants emergent neuroimaging (Table 2–8).

C. Diagnostic Studies

Guidance on when to perform neuroimaging is summarized in Table 2–8. Under most circumstances, a noncontrast head CT is sufficient to exclude intracranial hypertension with impending herniation, intracranial hemorrhage, and many types of intracranial masses (notable exceptions include lymphoma and toxoplasmosis in HIV-positive patients, herpes simplex encephalitis, and brain abscess). When appropriate, a contrast study can often be ordered to follow a normal noncontrast study. A normal neuroimaging study does not sufficiently exclude subarachnoid hemorrhage and should be followed by lumbar puncture. In patients for whom there is a high level of suspicion for subarachnoid hemorrhage or aneurysm, a normal CT and lumbar puncture should be followed by angiography within the next few days (provided the patient is medically stable). Lumbar puncture is also indicated to exclude infectious causes of acute headache, particularly in patients with fever or meningeal signs. Cerebrospinal fluid tests should routinely include Gram stain, white blood cell count with differential, red blood cell count, glucose, total protein, and bacterial culture. In appropriate patients, also consider testing cerebrospinal fluid for VDRL (syphilis), cryptococcal antigen (HIV-positive patients), acid-fast bacillus stain and culture, and complement fixation and culture for coccidioidomycosis. Storage of an extra tube with 5 mL of cerebrospinal fluid is also prudent for conducting unanticipated tests in the immediate future. Consultation with infectious disease experts regarding local availability of polymerase chain reaction tests for specific infectious pathogens (eg, herpes simplex 2) should also be considered in patients with evidence of central nervous system infection but no identifiable pathogen.

In addition to neuroimaging and lumbar puncture, additional diagnostic tests for exclusion of life-threatening causes of acute headache include erythrocyte sedimentation rate (temporal arteritis; endocarditis), urinalysis (malignant hypertension; preeclampsia), and sinus CT or radiograph (bacterial sinusitis, independently or as a cause of venous sinus thrombosis).

► Treatment

Treatment should be directed at the cause of acute headache. In patients in whom migraine or migraine-like headache has been diagnosed, early treatment with NSAIDs or triptans can often abort or provide significant

relief of symptoms. The effectiveness of NSAIDs and triptans appears to be equivalent, although combination sumatriptan-naproxen appears to provide a greater sustained response (2–24 hours) compared with monotherapy with either agent alone. Nonoral medication administration is often necessary for patients with significant nausea and vomiting, in which case nasal and subcutaneous triptans and intramuscular ketorolac are therapeutic options. Other causes of acute headache, such as subarachnoid hemorrhage, intracranial mass, or meningitis, usually require emergent treatment in the hospital.

► When to Refer

- Frequent migraines not responsive to standard therapy.
- Migraines with atypical features.
- Chronic daily headaches due to medication overuse.

► When to Admit

- Need for repeated doses of parenteral pain medication.
- To facilitate an expedited work-up requiring a sequence of procedures and neuroimaging.
- Monitoring for progression of symptoms and neurologic consultation when the initial emergency department work-up is inconclusive.
- Pain severe enough to impair activities of daily living or limit participation in follow-up appointments or consultation.

- Bamford CC et al. Unusual headaches in the elderly. *Curr Pain Headache Rep.* 2011 Aug;15(4):295–301. [PMID: 21455737]
- Cady RK et al. Sumatriptan-naproxen sodium for menstrual migraine and dysmenorrhea: satisfaction, productivity, and functional disability outcomes. *Headache.* 2011 May;51(5):664–73. [PMID: 21521204]
- Detsky ME et al. Does this patient with headache have a migraine or need neuroimaging? *JAMA.* 2006 Sep 13;296(10):1274–83. [PMID: 16968852]
- Edlow JA et al. Clinical policy: critical issues in the evaluation and management of adult patients presenting to the emergency department with acute headache. *Ann Emerg Med.* 2008 Oct;52(4):407–36. [PMID: 18809105]
- Evans RW. Diagnostic testing for migraine and other primary headaches. *Neurol Clin.* 2009 May;27(2):393–415. [PMID: 19289222]
- Friedman BW et al. Headache in the emergency department. *Curr Pain Headache Rep.* 2011 Aug;15(4):302–7. [PMID: 21400252]
- Jamshidi S et al. Clinical predictors of significant findings on head computed tomographic angiography. *J Emerg Med.* 2011 Apr;40(4):469–75. [PMID: 19854018]
- Kuo CL et al. Thunderclap headache. *Headache.* 2010 Jul;50(7):1201–2. [PMID: 20572877]
- Loder E. Triptan therapy in migraine. *N Engl J Med.* 2010 Jul 1;363(1):63–70. [PMID: 20592298]
- Perry JJ et al. High risk clinical characteristics for subarachnoid haemorrhage in patients with acute headache: prospective cohort study. *BMJ.* 2010 Oct 28;341:c5204. [PMID: 21030443]
- van Gijn J et al. Subarachnoid hemorrhage. *Lancet.* 2007 Jan 27;369(9558):306–18. [PMID: 17258671]
- Wilson JF. In the clinic. Migraine. *Ann Intern Med.* 2007 Nov 6;147(9):ITC11-1–ITC11-16. [PMID: 17975180]

DYSURIA



ESSENTIAL INQUIRIES

- ▶ Fever.
- ▶ Nausea or vomiting.
- ▶ New back or flank pain.
- ▶ Vaginal discharge.
- ▶ Pregnancy risk.
- ▶ Structural abnormalities.
- ▶ Instrumentation of urethra or bladder.

▶ General Considerations

Dysuria (painful urination) is a common reason for adolescents and adults to seek urgent medical attention. An inflammatory process (eg, infection; autoimmune disorder) underlies most causes of dysuria. In women, cystitis will be diagnosed in up to 50–60% of cases and has an incidence of 0.5–0.7% per year in sexually active young women. The key objective in evaluating women with dysuria is to exclude serious upper urinary tract disease, such as acute pyelonephritis, and sexually transmitted diseases. In elderly men, dysuria may be a symptom of prostatitis. In contrast, in younger men, urethritis accounts for the vast majority of cases of dysuria.

▶ Clinical Findings

A. Symptoms

Well-designed cohort studies have shown that some women can be reliably diagnosed with uncomplicated cystitis without a physical examination or urinalysis, and randomized controlled trials show that telephone management of uncomplicated cystitis is safe and effective. An increased likelihood of cystitis is present when women report multiple irritative voiding symptoms (dysuria, urgency, frequency), fever, or back pain (likelihood ratios = 1.6–2.0). Inquiring about symptoms of vulvovaginitis is imperative. When women report dysuria and urinary frequency, and deny vaginal discharge and irritation, the likelihood ratio for culture-confirmed cystitis is 24.5. In contrast, when vaginal discharge or irritation is present, as well as dysuria or urinary frequency, the likelihood ratio is 0.7. Gross hematuria in women with voiding symptoms usually represents hemorrhagic cystitis but can also be a sign of bladder cancer (particularly in older patients) or upper tract disease. Failure of hematuria to resolve with antibiotic treatment should prompt further evaluation of the bladder and kidneys. Chlamydial infection should be strongly considered among women age 25 years or younger who are sexually active and seeking medical attention for a suspected urinary tract infection for the first time or have a new partner.

Because fever and back pain, as well as nausea and vomiting, are considered harbingers of (or clinical criteria for) acute pyelonephritis, women with these symptoms should

usually be examined by a clinician prior to treatment in order to exclude coexistent urosepsis, hydronephrosis, or nephrolithiasis. Other major risk factors for acute pyelonephritis (among women 18–49 years of age) relate to sexual behaviors (frequency of sexual intercourse three or more times per week, new sexual partner in previous year, recent spermicide use), as well as diabetes mellitus and recent urinary tract infection or incontinence. Finally, pregnancy, underlying structural factors (polycystic kidney disease, nephrolithiasis, neurogenic bladder), immunosuppression, diabetes, and a history of recent bladder or urethral instrumentation usually alter the treatment regimen (antibiotic choice or duration of treatment, or both) of uncomplicated cystitis. In men, lower urinary tract symptoms and depressive symptoms are strongly associated and reciprocally related. Erectile dysfunction increases the odds of both disorders.

B. Physical Examination

The presence of fever, tachycardia, or hypotension should alert the clinician to the possibility of urosepsis and the potential need for hospitalization. A focused examination in women, in uncomplicated circumstances, could be limited to ascertainment of costovertebral angle tenderness and to a lower abdominal and pelvic examination, if the history suggests vulvovaginitis or cervicitis.

C. Diagnostic Studies

1. Urinalysis—Urinalysis is probably overutilized in the evaluation of dysuria. The probability of culture-confirmed urinary tract infection among women with a history and physical examination compatible with uncomplicated cystitis is about 70–90%. Urinalysis is most helpful when the woman with dysuria does not have other typical features of cystitis. Dipstick detection (> trace) of leukocytes, nitrites, or blood supports a diagnosis of cystitis. When both leukocyte and nitrite tests are positive, the likelihood ratio is 4.2, and when both are negative, the likelihood ratio is 0.3. The negative predictive value of urinalysis is not sufficient to exclude culture-confirmed urinary tract infection in women with multiple and typical symptoms; and randomized trial evidence shows that antibiotic treatment is beneficial to women with typical symptoms and negative urinalysis dipstick tests.

2. Urine culture—Urine culture should be considered for all women with upper tract symptoms (prior to initiating antibiotic therapy), as well as those with dysuria and a negative urine dipstick test. In symptomatic women, a clean-catch urine culture is considered positive when 10^2 – 10^3 colony-forming units/mL of a uropathogenic organism is detected.

3. Renal imaging—When severe flank or back pain is present, the possibility of complicated kidney infection (perinephric abscess, nephrolithiasis) or of hydronephrosis should be considered. Depending on local availability, acceptable imaging options to assess for hydronephrosis include abdominal radiographs, renal ultrasound, or CT scanning. To exclude nephrolithiasis, noncontrast helical CT scanning is more accurate than intravenous urography and is rapidly becoming the diagnostic test of choice for

this purpose. In a meta-analysis, the positive and negative likelihood ratios of helical CT scanning for diagnosis of nephrolithiasis were 23.2 and 0.05, respectively.


► Differential Diagnosis

The differential diagnosis of dysuria in women includes acute cystitis, acute pyelonephritis, vaginitis (*Candida*, bacterial vaginosis, *Trichomonas*, herpes simplex), urethritis/cervicitis (*Chlamydia*, gonorrhea), and interstitial cystitis/painful bladder syndrome. Nucleic acid amplification tests from first-void urine or vaginal swab specimens are highly

sensitive for detecting chlamydial infection. Other infectious pathogens associated with dysuria and urethritis in men include *Mycoplasma genitalium* and Enterobacteriaceae.

► Treatment

Definitive treatment is directed to the underlying cause of the dysuria. An evidence-informed algorithm for managing suspected urinary tract infection in women is shown in Figure 2–3. This algorithm supports antibiotic treatment of most women with multiple and typical symptoms of urinary tract infection without performing urinalysis or urine culture.



¹In women who have risk factors for sexually transmitted diseases, consider testing for *Chlamydia*. The US Preventive Services Task Force recommends screening for *Chlamydia* for all women 25 years or younger and women of any age with more than one sexual partner, a history of sexually transmitted disease, or inconsistent use of condoms.

²A complicated UTI is one in an individual with a functional or anatomic abnormality of the urinary tract, including a history of polycystic renal disease, nephrolithiasis, neurogenic bladder, diabetes mellitus, immunosuppression, pregnancy, indwelling urinary catheter, or recent urinary tract instrumentation.

³The only physical examination finding that increases the likelihood of UTI is costovertebral angle tenderness, and clinicians may consider not performing this test in patients with typical symptoms of acute uncomplicated UTI (as in telephone management).

▲ **Figure 2-3.** Proposed algorithm for evaluating women with symptoms of acute urinary tract infection (UTI). (Modified and reproduced, with permission, from Bent S et al. Does this woman have an acute uncomplicated urinary tract infection? JAMA. 2002 May 22-29;287(20):2701-10.)

Symptomatic relief can be provided with phenazopyridine, a urinary analgesic that is available over-the-counter; it is used in combination with antibiotic therapy (when a urinary tract infection has been confirmed) but for no more than 2 days. Patients should be informed that phenazopyridine will cause orange/red discoloration of their urine and other bodily fluids (eg, some contact lens wearers have reported discoloration of their lenses). Rare cases of methemoglobinemia and hemolytic anemia have been reported, usually with overdoses or underlying renal dysfunction.

In cases of interstitial cystitis/painful bladder syndrome (see Chapter 23), patients will often respond to a multimodal approach that may include urethral/vesicular dilation, bio-feedback, cognitive behavioral therapy, antidepressants, dietary changes, vaginal emollients, and other supportive measures.

▶ When to Refer

- Anatomic abnormalities leading to repeated urinary infections.
- Infections associated with nephrolithiasis.
- Persistent interstitial cystitis/painful bladder syndrome.

▶ When to Admit

- Severe pain requiring parenteral medication or impairing ambulation or urination (such as severe primary herpes simplex genitalis).
- Dysuria associated with urinary retention or obstruction.

Abrams P et al. Evaluation and treatment of lower urinary tract symptoms in older men. *J Urol*. 2009 Apr;181(4):1779–87. [PMID: 19233402]

Hanno PM et al; Interstitial Cystitis Guidelines Panel of the American Urological Association Education and Research, Inc. AUA guideline for the diagnosis and treatment of interstitial cystitis/bladder pain syndrome. *J Urol*. 2011 Jun;185(6):2162–70. [PMID: 21497847]

Little P et al. Validating the prediction of lower urinary tract infection in primary care: sensitivity and specificity of urinary dipsticks and clinical scores in women. *Br J Gen Pract*. 2010 Jul;60(576):495–500. [PMID: 20594439]

Nicolle LE. Uncomplicated urinary tract infection in adults including uncomplicated pyelonephritis. *Urol Clin North Am*. 2008 Feb;35(1):1–12. [PMID: 18061019]

Sholes D et al. Risk factors associated with acute pyelonephritis in healthy women. *Ann Intern Med*. 2005 Jan 4;142(1):20–7. [PMID: 15630106]

3

Preoperative Evaluation & Perioperative Management

Hugo Q. Cheng, MD

EVALUATION OF THE ASYMPTOMATIC PATIENT

Patients without significant medical problems—especially those under age 50—are at very low risk for perioperative complications. Their preoperative evaluation should include a history and physical examination. Special emphasis is placed on the assessment of functional status, exercise tolerance, and cardiopulmonary symptoms and signs in an effort to reveal previously unrecognized disease (especially cardiopulmonary disorders) that may require further evaluation prior to surgery. In addition, a directed bleeding history (Table 3–1) should be taken to uncover coagulopathy that could contribute to excessive surgical blood loss. Routine preoperative testing of asymptomatic healthy patients under age 50 has not been found to help predict or prevent complications.

Patients who are older than 50 years and those with risk factors for coronary artery disease should have a 12-lead ECG because evidence of clinically silent coronary artery disease should prompt further cardiac evaluation before surgery. Minor ECG abnormalities such as bundle branch block, T wave changes, and premature ventricular contractions do not predict adverse postoperative outcomes. Of note, patients undergoing minor or minimally invasive procedures (such as cataract surgery) may not require any routine preoperative tests.

Chopra V et al. Perioperative practice: time to throttle back. *Ann Intern Med.* 2010 Jan 5;152(1):47–51. [PMID: 19949135]

Gupta A. Preoperative screening and risk assessment in the ambulatory surgery patient. *Curr Opin Anaesthesiol.* 2009 Dec;22(6):705–11. [PMID: 19633545]

Laine C et al. In the clinic. Preoperative evaluation. *Ann Intern Med.* 2009 Jul 7;151(1):ITC1–15. [PMID: 19581642]

CARDIAC RISK ASSESSMENT & REDUCTION

Cardiac complications of noncardiac surgery are a major cause of perioperative morbidity and mortality. The most important perioperative cardiac complications are myocardial infarction (MI) and cardiac death. Other complications include congestive heart failure (CHF), arrhythmias,

and unstable angina. The principal patient-specific risk factor is the presence of end-organ cardiovascular disease. This includes not only coronary artery disease and CHF, but also cerebrovascular disease and chronic kidney disease if due to atherosclerosis. Diabetes mellitus, especially if treated with insulin, is considered a cardiovascular disease equivalent and has also been shown to increase the risk of cardiac complications. Major abdominal, thoracic, and vascular surgical procedures (especially abdominal aortic aneurysm repair) carry a higher risk of postoperative cardiac complications, likely due to their associated major fluid shifts, hemorrhage, and hypoxemia. These risk factors were identified in a validated multifactorial risk prediction tool: the Revised Cardiac Risk Index (Table 3–2). The Revised Cardiac Risk Index has become a widely used tool for assessing and communicating cardiac risk and has been incorporated into perioperative management guidelines. Limited exercise capacity (eg, the inability to walk for two blocks at a normal pace or climb a flight of stairs without resting) and greater severity of cardiac symptoms also predict higher cardiac risk. Emergency operations are also associated with greater cardiac risk. However, emergency operations should not be delayed by extensive cardiac evaluation. Instead, patients facing emergency surgery should be medically optimized for surgery as quickly as possible and closely monitored for cardiac complications during the perioperative period.

▶ Role of Preoperative Noninvasive Ischemia Testing

Most patients can be accurately risk-stratified by history, physical examination, and electrocardiogram (ECG). Patients without clinical predictors for cardiac complications (Table 3–2), who are undergoing minor operations, or who have at least fair functional capacity are at low risk for cardiac complications. Noninvasive testing in these patients generally does not improve risk stratification or management. Patients with poor functional capacity, or a high Revised Cardiac Risk Index score are much more likely to suffer cardiac complications. Stress testing prior to vascular surgery in these patients can stratify them into low-risk and high-risk subgroups. The absence of ischemia

Table 3-1. Findings suggestive of a bleeding disorder.

Unprovoked bruising on the trunk of > 5 cm in diameter
Frequent unprovoked epistaxis or gingival bleeding
Menorrhagia with iron deficiency
Hemarthrosis with mild trauma
Prior excessive surgical blood loss or reoperation for bleeding
Family history of abnormal bleeding
Presence of severe kidney or liver disease

on dipyridamole scintigraphy or dobutamine stress echocardiography is reassuring. Similarly, the presence of only mild, limited ischemia in vascular surgery patients with multiple Revised Cardiac Risk Index predictors, but who are optimally managed with perioperative β -blockers, predicts a generally acceptable risk of perioperative cardiac death or MI. In contrast, extensive inducible ischemia in this population predicts a very high risk of cardiac complications, which may not be modifiable by either medical management or coronary revascularization. The predictive value of an abnormal stress test result for nonvascular surgery patients is less well established. An approach to perioperative cardiac risk assessment and management in patients with known or suspected stable coronary artery disease is shown in Figure 3-1.

► Perioperative Management of Patients with Coronary Artery Disease

Patients with acute coronary syndromes require immediate management of their cardiac disease prior to any preoperative

evaluation (see Chapter 10). Patients with stable coronary artery disease undergoing major surgery have a 1–5% risk of MI and about a 1% mortality rate. In a large cohort study, postoperative MI as evidenced by ECG changes and an elevated biomarker level typically occurred within 3 days of surgery, and was associated with a 30-day mortality rate of 11.6%. Postoperative MI is usually silent or may present atypically. Symptoms and signs that should prompt consideration of postoperative MI include unexplained hypotension, hypoxemia, or delirium. However, current evidence is insufficient to formulate specific recommendations for screening asymptomatic patients for perioperative ischemia through the use of ECG or cardiac enzyme monitoring.

A. Medications

Preoperative antianginal medications, including β -blockers, calcium channel blockers, and nitrates, should be continued preoperatively and during the postoperative period. Evidence for a cardioprotective effect of perioperative β -adrenergic blockade has been mixed. A randomized trial in vascular surgery patients with ischemia on dobutamine stress echocardiography found that bisoprolol reduced the 30-day risk of cardiac mortality or nonfatal MI from 34% to 3% in these high-risk patients. In contrast, subsequent trials found less benefit and potential harm in lower risk patients. In the largest of these studies, a high, fixed dose of β -blocker (metoprolol succinate 100 mg given by mouth a few hours before and after surgery) reduced the absolute risk of cardiac complications by only 1.1% in patients with at least one Revised Cardiac Risk Index predictor who underwent major surgery. This was offset, however, by a 0.8% absolute increase in total mortality. Hypotension and bradycardia were more common when patients received β -blockers; in addition, the risks of stroke and death from sepsis were higher in these patients. In contrast, a subsequent study demonstrated a 6% absolute risk reduction in cardiac mortality and nonfatal MI in patients who received a more conservative, titrated dose of β -blocker (bisoprolol 2.5 mg, started a median of 1 month prior to surgery, and increased by 1.25–2.5 mg daily after surgery to a maximum dose of 10 mg daily). Because of the uncertain benefit-to-risk ratio of perioperative β -blockade, it should be reserved for patients with a relatively high risk of cardiac complications. Suggested indications for prophylactic β -blockade are presented in Table 3-3. Comparative trials between different cardioselective β -blockers are lacking. Reasonable starting oral doses for normotensive patients are atenolol 25 mg daily, metoprolol 25 mg twice daily, or bisoprolol 2.5 mg daily. Ideally, β -blockers should be started well in advance of surgery, to allow time to gradually titrate up the dose without causing excessive bradycardia or hypotension. The dose should be adjusted to maintain a heart rate between 50 and 70 beats per minute while keeping systolic blood pressure above 100 mm Hg. β -Blockers should be continued for at least 3–7 days after surgery.


Observational studies show an association between the use of HMG-CoA reductase inhibitors (statins) during the perioperative period and lower rates of mortality and postoperative MI. A randomized trial in statin-naïve patients

Table 3-2. Revised cardiac risk index.

Independent Predictors of Postoperative Cardiac Complications	
1. Intrathoracic, intraperitoneal, or infrainguinal vascular surgery	
2. History of ischemic heart disease	
3. History of congestive heart failure	
4. Insulin treatment for diabetes mellitus	
5. Serum creatinine level > 2 mg/dL [$> 176.8 \mu\text{mol/L}$]	
6. History of cerebrovascular disease	
Scoring (Number of Predictors Present)	Risk of Major Cardiac Complications ¹
None	0.4%
One	0.9%
Two	7.0%
More than two	11%

¹Myocardial infarction, pulmonary edema, ventricular fibrillation, cardiac arrest, and complete heart block.

Data from Lee TH et al. Derivation and prospective validation of a simple index for prediction of cardiac risk of major noncardiac surgery. *Circulation*. 1999 Sept 7; 100(10):1043–9.



▲ **Figure 3-1.** Assessment and management of patients with known or suspected stable coronary artery disease (CAD) undergoing elective major noncardiac surgery. (OR, operating room.)

undergoing vascular surgery found that extended-release fluvastatin 80 mg orally daily reduced the 30-day risk of cardiac death or nonfatal MI from 10.1% to 4.8%. Statins should be considered in all patients undergoing vascular surgery and other patients deemed to be at high risk for

cardiac complications, regardless of lipid levels. Patients already taking statins should continue these agents during the perioperative period.

B. Coronary Revascularization

Retrospective studies suggest that patients who had previously undergone coronary artery bypass grafting (CABG) surgery or percutaneous coronary interventions (PCI) have a relatively low risk of cardiac complications when undergoing subsequent noncardiac surgery. However, one trial randomized over 500 patients with angiographically proven coronary artery disease to either coronary revascularization (with either CABG or PCI) or medical management alone before vascular surgery. Postoperative nonfatal MI, 30-day mortality, and long-term mortality did not differ, suggesting that prophylactic revascularization before noncardiac surgery does not prevent cardiac complications. Thus, current data argue that preoperative CABG or PCI should only be performed on patients who have indications for the procedure independent of the planned noncardiac operation. In patients who have undergone recent intracoronary stenting, observational studies suggest that perioperative cardiac

Table 3-3. Indications for prophylactic perioperative β -blockade.

Strong indications	Patient already taking β -blocker to treat ischemia, arrhythmia, or hypertension
Possible indications	Patients with coronary artery disease undergoing vascular or other major surgery Patient with multiple clinical predictors (heart failure, chronic kidney disease, diabetes mellitus, or cerebrovascular disease) undergoing vascular or other major surgery

The dose of β -blocker should be carefully titrated to keep heart rate < 70 bpm and systolic blood pressure > 100 mm Hg.

mortality rate may be very high if antiplatelet therapy is stopped prematurely due to concern for surgical site bleeding. The presumed mechanism of this increased mortality is acute stent thrombosis that results from premature discontinuation of antiplatelet therapy. Therefore, elective surgery should be deferred for at least 4–6 weeks after placement of a bare-metal stent and for a full year after placement of a drug-eluting stent if antiplatelet therapy must be stopped preoperatively.

► CHF & Left Ventricular Dysfunction

Decompensated CHF, manifested by an elevated jugular venous pressure, an audible third heart sound, or evidence of pulmonary edema on physical examination or chest radiography, significantly increases the risk of perioperative pulmonary edema (roughly 15%) and cardiac death (2–10%). Elective surgery should be postponed in patients with decompensated CHF until it can be evaluated and brought under control.

Patients with compensated left ventricular dysfunction are at increased risk for cardiac complications. In a cohort of over 1000 vascular surgery patients who had preoperative echocardiography, asymptomatic left ventricular dysfunction (either systolic or diastolic) was associated with a twofold increase in cardiac complications. A history of symptomatic CHF was much more predictive, being associated with a sevenfold increase in risk. Current guidelines recommend preoperative echocardiography in patients without known CHF with unexplained dyspnea and in patients with known CHF with clinical deterioration.

Patients should continue taking all medications for chronic heart failure up to the day of surgery. Patients receiving digoxin and diuretics should have serum electrolyte and digoxin levels measured prior to surgery because abnormalities in these levels may increase the risk of perioperative arrhythmias. Clinicians must be cautious not to give too much diuretic, since the volume-depleted patient will be much more susceptible to intraoperative hypotension. The surgeon and anesthesiologist should be made aware of the presence and severity of left ventricular dysfunction so that appropriate decisions can be made regarding perioperative fluid management and intraoperative monitoring.

► Valvular Heart Disease

Candidates for valve replacement surgery or valvuloplasty independent of the planned noncardiac surgery should have the valve correction procedure performed first. The severity of valvular lesions should be evaluated by echocardiography or cardiac catheterization before noncardiac surgery to allow for appropriate fluid management and consideration of invasive intraoperative monitoring. Patients with severe symptomatic aortic stenosis are at markedly increased risk for cardiac complications and should not undergo elective surgery. In a series of patients with aortic stenosis who underwent noncardiac surgery, death or nonfatal MI occurred in 31% in patients with severe aortic stenosis (aortic valve area $< 0.7 \text{ cm}^2$), in 11%

in those with moderate aortic stenosis (aortic valve area $0.7\text{--}1.0 \text{ cm}^2$), and in 2% in those without aortic stenosis. Other studies have found that patients with asymptomatic aortic stenosis appeared to be at lower risk than patients with symptomatic aortic stenosis. Patients with atrial fibrillation due to mitral stenosis require heart rate control to maintain diastolic filling time. Patients with aortic or mitral regurgitation likely benefit from afterload reduction and careful attention to volume status.

► Arrhythmias

The finding of a rhythm disturbance on preoperative evaluation should prompt consideration of further cardiac evaluation, particularly when the finding of structural heart disease would alter perioperative management. Patients with a rhythm disturbance without evidence of underlying heart disease are at low risk for perioperative cardiac complications. Patients with symptomatic arrhythmias should not undergo elective surgery until their cardiac condition has been addressed.

Management of patients with arrhythmias in the preoperative period should be guided by factors independent of the planned surgery. In patients with atrial fibrillation or other supraventricular arrhythmias, adequate rate control should be established prior to surgery. Symptomatic ventricular tachycardia must be controlled prior to surgery. There is no evidence that the use of antiarrhythmic medications to suppress an asymptomatic arrhythmia alters perioperative risk.

Patients who have indications for a permanent pacemaker should have it placed prior to noncardiac surgery. When surgery is urgent, these patients may be managed perioperatively with temporary transvenous pacing. Patients with bundle branch block who do not meet recognized criteria for a permanent pacemaker do not require pacing during surgery. The anesthesiologist must be notified that a patient has an implanted pacemaker or defibrillator so that steps may be taken to prevent device malfunction caused by electromagnetic interference from the intraoperative use of electrocautery.

► Hypertension

Mild to moderate hypertension (systolic blood pressure below 180 mm Hg and diastolic blood pressure below 110 mm Hg) is associated with intraoperative blood pressure lability and asymptomatic myocardial ischemia but does not appear to be an independent risk factor for more serious cardiac complications. No evidence supports delaying surgery in order to better control mild to moderate hypertension. Most medications for chronic hypertension should generally be continued up to and including the day of surgery. Consideration should be given to holding angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on the day of surgery, as these agents may increase the risk of intraoperative hypotension. Diuretic agents, if not needed to control heart failure, are also frequently held on the day of surgery to prevent hypovolemia and electrolyte disorders.

Severe hypertension, defined as a systolic pressure > 180 mm Hg or diastolic pressure > 110 mm Hg, appears to be an independent predictor of perioperative cardiac complications, including MI and CHF. It seems wise to delay surgery in patients with severe hypertension until blood pressure can be controlled, although it is not known whether the risk of cardiac complications is reduced with this approach.

Devereaux PJ et al. Characteristics and short-term prognosis of perioperative myocardial infarction in patients undergoing noncardiac surgery: a cohort study. *Ann Intern Med.* 2011 Apr;154(8):523–8. [PMID: 21502650]

Fleisher LA et al. 2009 ACCF/AHA focused update on perioperative beta blockade incorporated into the ACC/AHA 2007 guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery. *J Am Coll Cardiol.* 2009 Nov 24;54(22):e13–e118. [PMID: 19926002]

Ford MK et al. Systematic review: prediction of perioperative cardiac complications and mortality by the revised cardiac risk index. *Ann Intern Med.* 2010 Jan 5;152(1):26–35. [PMID: 20048269]

Task Force for Preoperative Cardiac Risk Assessment and Perioperative Cardiac Management in Non-cardiac Surgery; European Society of Cardiology (ESC) et al. Guidelines for pre-operative cardiac risk assessment and perioperative cardiac management in non-cardiac surgery. *Eur Heart J.* 2009 Nov;30(22):2769–812. [PMID: 19713421]

PULMONARY EVALUATION IN NON-LUNG RESECTION SURGERY

Pneumonia and respiratory failure requiring prolonged mechanical ventilation are the most important postoperative pulmonary complications and occur in 2–19% of surgical procedures. The occurrence of a postoperative pulmonary complication has been associated with a significant increase in hospital length of stay.

► Risk Factors for the Development of Postoperative Pulmonary Complications

The risk of developing a pulmonary complication is highest in patients undergoing cardiac, thoracic, and upper abdominal surgery, with reported complication rates ranging from 9% to 19%. The risk in patients undergoing lower abdominal or pelvic procedures ranges from 2% to 5%, and for extremity procedures the range is < 1–3%. The pulmonary complication rate for laparoscopic procedures appears to be much lower than that for open procedures. In one series of over 1500 patients who underwent laparoscopic cholecystectomy, the pulmonary complication rate was < 1%. Other procedure-related risk factors include prolonged anesthesia time, need for general anesthesia, and emergency operations.

Among the many patient-specific risk factors for postoperative pulmonary complications, the strongest predictor appears to be advanced age. Surgical patients in their seventh decade had a fourfold higher risk of pulmonary complications compared with patients under age 50. Patients with chronic obstructive pulmonary disease (COPD) or

Table 3–4. Clinical risk factors for postoperative pulmonary complications.

Upper abdominal or cardiothoracic surgery
Prolonged anesthesia time (> 4 hours)
Age > 60 years
Chronic obstructive pulmonary disease
Congestive heart failure
Tobacco use (> 20 pack-years)
Impaired cognition or sensorium
Functional dependency or prior stroke
Morbid obesity
Low serum albumin level
Obstructive sleep apnea

CHF have at least twice the risk compared with patients without these conditions. In a large prospective cohort of US military veterans, additional clinical risk factors for the development of postoperative pneumonia included dependent functional status, impaired sensorium, prior stroke, long-term corticosteroid use, heavy alcohol consumption, and current cigarette smoking.

Patients with asthma are at slightly increased risk for bronchospasm during tracheal intubation and extubation and during the postoperative period. However, if patients are at their optimal pulmonary function (as determined by symptoms, physical examination, or peak flow rate) at the time of surgery, they are not at increased risk for other pulmonary complications. Obesity causes restrictive pulmonary physiology, which may increase pulmonary risk in surgical patients. However, it is unclear if obesity is an independent risk predictor. Obstructive sleep apnea has been associated with a variety of postoperative complications, particularly in patients undergoing bariatric surgery. The STOP screening questionnaire asks whether a patient has snoring, tiredness during the day, observed apnea, and high blood pressure. The presence of two or more of these findings had a 78% positive predictive value for obstructive sleep apnea and was associated with a doubled risk for postoperative pulmonary complications. A summary of risk factors for pulmonary complications is presented in Table 3–4.

► Pulmonary Function Testing & Laboratory Studies

Few data support the use of preoperative testing to assess pulmonary risk. Pulmonary function testing (PFT) in unselected patients is not helpful in predicting postoperative pulmonary complications. The main role for preoperative PFT is to help identify and characterize pulmonary disease in patients with unexplained symptoms prior to major abdominal or cardiothoracic surgery. In patients with diagnosed lung disease, PFT often adds little information above clinical assessment. Furthermore, there is no clear degree of PFT abnormality that can be used as an absolute contraindication to non-lung resection surgery. Chest radiographs in unselected patients also rarely add

clinically useful information. In one study, only 0.1% of routine preoperative chest radiographs changed clinical management. They may be more useful in patients who are undergoing abdominal or thoracic surgery who are over age 50 or have known cardiopulmonary disease. Some experts have also advocated polysomnography to diagnose obstructive sleep apnea prior to bariatric surgery, but the benefits of this approach are unproven. Abnormally low or high blood urea nitrogen levels (indicating malnutrition and renal insufficiency, respectively) and hypoalbuminemia predict postoperative pulmonary complications and mortality, although the role of laboratory testing is uncertain. Arterial blood gas measurement is not routinely recommended except in patients with known lung disease and suspected hypoxemia or hypercapnia.

► Perioperative Management

The preoperative period may be an optimal time to initiate smoking cessation efforts. A systematic review found that smoking cessation programs started in a preoperative evaluation clinic increased the odds of abstinence at 3–6 months by nearly 60%. Retrospective studies have shown that smoking cessation reduced the incidence of pulmonary complications, but only if it was initiated at least 1–2 months before surgery. In several randomized trials, preoperative smoking cessation programs reduced surgical wound complications, but these studies did not have adequate statistical power to detect an impact on respiratory complications.

The incidence of postoperative pulmonary complications in patients with COPD or asthma may be reduced by preoperative optimization of pulmonary function. Patients who are wheezing should receive preoperative therapy with bronchodilators and, in certain cases, corticosteroids. Antibiotics may be beneficial for patients with COPD who cough with purulent sputum. Patients receiving oral theophylline should continue taking the drug perioperatively. A serum theophylline level should be measured to rule out toxicity. Most patients with COPD can be treated with cardioselective β -blockers if indicated to prevent perioperative cardiac complications without suffering respiratory compromise.

Postoperative risk reduction strategies have centered on promoting lung expansion through the use of incentive spirometry, continuous positive airway pressure (CPAP), intermittent positive-pressure breathing (IPPB), and deep breathing exercises. Although trial results have been mixed, all these techniques have been shown to reduce the incidence of postoperative atelectasis and, in a few studies, to reduce the incidence of postoperative pulmonary complications. In most comparative trials, these methods were equally effective. Given the higher cost of CPAP and IPPB, incentive spirometry and deep breathing exercises are the preferred methods for most patients. Incentive spirometry must be performed for 15 minutes every 2 hours. Deep breathing exercises must be performed hourly and consist of 3-second breath-holding, pursed lip breathing, and coughing. These measures should be started preoperatively and be continued for 1–2 days postoperatively.

Guimarães MM et al. Incentive spirometry for prevention of postoperative pulmonary complications in upper abdominal surgery. *Cochrane Database Syst Rev.* 2009 Jul 8;(3):CD006058. [PMID: 19588380]

Qaseem A et al; Clinical Efficacy Assessment Subcommittee of the American College of Physicians. Risk assessment for and strategies to reduce perioperative pulmonary complications for patients undergoing noncardiothoracic surgery: a guideline from the American College of Physicians. *Ann Intern Med.* 2006 Apr 18;144(8):575–80. [PMID: 16618955]

Seet E et al. Obstructive sleep apnea: preoperative assessment. *Anesthesiol Clin.* 2010 Jun;28(2):199–215. [PMID: 20488390]

Turan A et al. Smoking and perioperative outcomes. *Anesthesiology.* 2011 Apr;114(4):837–46. [PMID: 21372682]

EVALUATION OF THE PATIENT WITH LIVER DISEASE

Patients with serious liver disease are at increased risk for perioperative morbidity and demise. Appropriate preoperative evaluation requires consideration of the effects of anesthesia and surgery on postoperative liver function and of the complications associated with anesthesia and surgery in patients with preexisting liver disease.

► The Effects of Anesthesia & Surgery on Liver Function

Postoperative elevation of serum aminotransferase levels is a relatively common finding after major surgery. Most of these elevations are transient and not associated with hepatic dysfunction. General anesthetic agents may cause deterioration of hepatic function either via intraoperative reduction in hepatic blood flow leading to ischemic injury or, in the case of inhalational agents, direct hepatotoxicity. The latter effect, however, is rare with modern anesthetic agents such as desflurane and sevoflurane. Medications used for regional anesthesia produce similar reductions in hepatic blood flow and thus may be equally likely to lead to ischemic liver injury. Intraoperative hypotension, hemorrhage, and hypoxemia may also contribute to liver injury.

► Risk Factors for Surgical Complications

Observational studies have found that surgery in patients with serious liver disease is associated with a variety of complications, including hemorrhage, infection, renal failure, and encephalopathy, and with a substantial mortality rate. A key limitation in interpreting these data is our inability to determine the contribution of the liver disease to the observed complications independent of the surgical procedure.

Acute hepatitis appears to increase surgical risk. In three small series of patients with acute viral hepatitis who underwent abdominal surgery, the mortality rate was roughly 10%. Similarly, patients with undiagnosed alcoholic hepatitis had high mortality rates when undergoing abdominal surgery. Thus, elective surgery in patients with acute viral or alcoholic hepatitis should be delayed until the acute episode has resolved. There are few data regarding the risks of surgery in patients with chronic hepatitis. In the absence of cirrhosis or synthetic dysfunction, chronic viral

hepatitis is unlikely to increase risk significantly. A large cohort study of hepatitis C seropositive patients who underwent surgery found a mortality rate of less than 1%. Similarly, nonalcoholic fatty liver disease by itself probably does not pose a serious risk in surgical patients.

In patients with cirrhosis, postoperative complication rates correlate with the severity of liver dysfunction. Traditionally, severity of dysfunction has been assessed with the Child-Turcotte-Pugh score (see Chapter 16). Patients with Child-Turcotte-Pugh class C cirrhosis who underwent portosystemic shunt surgery, biliary surgery, or trauma surgery during the 1970s and 1980s had a 50–85% mortality rate. Patients with Child-Turcotte-Pugh class A or B cirrhosis who underwent abdominal surgery during the 1990s, however, had relatively low mortality rates (hepatectomy 0–8%, open cholecystectomy 0–1%, laparoscopic cholecystectomy 0–1%). A conservative approach would be to avoid elective surgery in patients with Child-Turcotte-Pugh class C cirrhosis and pursue it with great caution in class B patients. The Model for End-stage Liver Disease (MELD) score, based on bilirubin and creatinine levels, and the prothrombin time expressed as the International Normalized Ratio, also predicted surgical mortality and outperformed the Child-Turcotte-Pugh classification in some studies. A web-based risk assessment calculator incorporating age and MELD score can predict both perioperative and long-term mortality (mayoclinic.org/meld/mayomodel9.html).

In addition, when surgery is elective, it is prudent to attempt to reduce the severity of ascites, encephalopathy, and coagulopathy preoperatively. Ascites is a particular problem in abdominal operations, where it can lead to wound dehiscence or hernias. Great care should be taken when using analgesics and sedatives, as this can worsen hepatic encephalopathy. In general, short-acting agents and lower doses should be used. Patients with coagulopathy should receive vitamin K and may need plasma transfusion at the time of surgery.

O'Leary JG et al. Surgery in the patient with liver disease. *Clin Liver Dis.* 2009 May;13(2):211–31. [PMID: 19442915]

PREOPERATIVE HEMATOLOGIC EVALUATION

Three of the more common clinical situations faced by the medical consultant are the patient with preexisting anemia, the assessment of bleeding risk, and the perioperative management of oral anticoagulation.

The key issue in the anemic patient is to determine the need for preoperative diagnostic evaluation and the need for transfusion. When feasible, the diagnostic evaluation of the patient with previously unrecognized anemia should be done prior to surgery because certain types of anemia (particularly sickle cell disease and immune hemolytic anemia) may have implications for perioperative management. Preoperative anemia is common, with a prevalence of 43% in a large cohort of elderly veterans undergoing surgery. In this cohort, morbidity and mortality increased as the preoperative hemoglobin level decreased, even after adjusting for comorbidities. No data exist to identify a specific preoperative hemoglobin level that should prompt

transfusion prior to surgery. It is also not known whether such transfusions will improve postoperative outcomes. Determination of the need for preoperative transfusion in an individual patient must consider factors other than the absolute hemoglobin level, including the presence of cardiopulmonary disease, the type of surgery, and the likely severity of surgical blood loss. The few studies that have compared different postoperative transfusion thresholds failed to demonstrate improved outcomes with a more aggressive transfusion strategy. One trial randomized patients undergoing hip fracture repair to either transfusion to maintain a hemoglobin level > 10 g/dL or transfusion for symptomatic anemia. Patients receiving symptom-triggered transfusion received far few units of packed red blood cells without increased mortality or complication rates.

The most important component of the bleeding risk assessment is a directed bleeding history (see Table 3–1). Patients who are reliable historians and who reveal no suggestion of abnormal bleeding on directed bleeding history and physical examination are at very low risk for having an occult bleeding disorder. Laboratory tests of hemostatic parameters in these patients are generally not needed. When the directed bleeding history is unreliable or incomplete or when abnormal bleeding is suggested, a formal evaluation of hemostasis should be done prior to surgery and should include measurement of the prothrombin time, activated partial thromboplastin time, and platelet count (see Chapter 13).

Patients receiving long-term oral anticoagulation are at risk for thromboembolic complications when an operation requires interruption of this therapy. In a cohort study of 1293 interruptions of warfarin therapy for invasive procedures, the 30-day thromboembolic risk was 0.7%. There are insufficient data to determine the excess risk incurred by holding warfarin therapy or whether this risk may be mitigated through the practice of “bridging” anticoagulation, where unfractionated or low-molecular-weight heparin is administered parenterally while oral anticoagulants are held until just prior to surgery. The bleeding risk associated with bridging anticoagulation can be substantial. Patients in this cohort who received bridging anticoagulation had a 13% incidence of clinically significant bleeding, compared with 0.8% for patients who did not receive bridging anticoagulation. Although firm evidence-based guidelines for perioperative bridging are lacking, most experts recommend bridging therapy only in patients at high risk for thromboembolism. An approach to perioperative anticoagulation management is shown in Table 3–5, but the recommendations must be considered in the context of patient preference and hemorrhagic risk.

Douketis JD et al; American College of Chest Physicians. The perioperative management of antithrombotic therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). *Chest.* 2008 Jun;133(6 Suppl):299S–339S. [PMID: 18574269]

Mussalam KM et al. Preoperative anaemia and postoperative outcomes in non-cardiac surgery: a retrospective cohort study. *Lancet.* 2011 Oct;378(9800):1396–407. [PMID: 21982521]

Vinik R et al. Perioperative antithrombotic management: a review of the literature and practical approach for the hospitalist physician. *J Hosp Med.* 2009 Nov;4(9):551–9. [PMID: 20013858]

Table 3-5. Recommendations for perioperative anticoagulation management.

Thromboembolic Risk without Anticoagulation	Recommendation
<p>Low (< 8% annual risk: eg, atrial fibrillation with no more than two other stroke risk factors,¹ mechanical bileaflet aortic valve prosthesis with no more than one other stroke risk factors, or single venous thromboembolism > 3 months ago without hypercoagulable condition²)</p>	<ol style="list-style-type: none"> 1. Stop oral anticoagulation 4-5 days before surgery 2. Measure INR the day before surgery to confirm that it is < 1.6 3. Resume oral anticoagulation the night of surgery, if possible 4. No bridging with parenteral anticoagulants before or after surgery
<p>High (> 8% annual risk: eg, atrial fibrillation or mechanical heart valve with prior stroke, mechanical mitral valve prosthesis, caged-ball or tilting disk valve prosthesis, or venous thrombosis < 3 months ago or associated with hypercoagulable condition²)</p>	<ol style="list-style-type: none"> 1. Stop oral anticoagulation 4-5 days before surgery 2. Begin therapeutic dose UFH or LMWH 2 days after stopping oral anticoagulation, and discontinue it 12-24 hours before surgery 3. Measure INR the day before surgery to confirm that it is < 1.6 4. Resume oral anticoagulation the night of surgery, if possible 5. If procedure has a low risk of bleeding, consider therapeutic dose UFH or LMWH beginning 24-48 hours after surgery and continuing until the INR is therapeutic

¹Congestive heart failure, hypertension, diabetes mellitus, age > 75 years.

²Patients should receive venous thromboembolism prophylaxis after surgery (see Chapter 14).

INR, international normalized ratio; LMWH, low-molecular-weight heparin; UFH, unfractionated heparin.

NEUROLOGIC EVALUATION

Delirium occurs after major surgery in 5–50% of patients over the age of 50 years and is particularly common after hip fracture repair and aortic surgery, occurring in 30–60% of such patients. Postoperative delirium has been associated with higher rates of major postoperative cardiac and pulmonary complications, poor functional recovery, an increased length of hospital stay, an increased risk of subsequent dementia and functional decline, and increased mortality. Several preoperative and postoperative factors have been associated with the development of postoperative delirium, most notably age, preoperative functional or cognitive impairment, preoperative psychotropic drug use, and derangements of serum chemistry. Patients with multiple risk factors are at especially high risk. Delirium occurred in half of the patients with at least three of the risk factors listed in Table 3-6.

Two types of delirium reducing interventions have been evaluated: focused geriatric care and psychotropic medications. In a randomized, controlled trial of hip fracture surgery patients, those who received daily visits and targeted

recommendations from a geriatrician had a lower risk of postoperative delirium (32%) than the control patients (50%). The most frequent interventions to prevent delirium were maintenance of the hematocrit > 30%; minimizing the use of benzodiazepines and anticholinergic medications; maintenance of regular bowel function; and early discontinuation of urinary catheters. Other studies comparing postoperative care in specialized geriatrics units with standard wards have shown similar reductions in the incidence of delirium. Although the use of neuroleptics to prevent postoperative delirium is uncommon, limited data support their effectiveness. A randomized trial in cardiac surgery patients demonstrated that risperidone (1 mg sublingual after regaining consciousness) reduced the incidence of postoperative delirium compared with placebo (11.1% vs. 31.7%). Another trial found that prophylactic oral haloperidol in orthopedic surgery patients failed to prevent delirium but did reduce its severity and duration.

Postoperative cognitive dysfunction is defined as a reduction in memory, language comprehension, visuospatial comprehension, attention, or concentration. Postoperative cognitive dysfunction may occur in up to 25% patients after cardiopulmonary bypass and in 15% of patients after major noncardiac surgery. The symptoms are generally transient, lasting < 3 months. It is more common in older patients and occurs with equal frequency after general or regional anesthesia.

Stroke complicates < 1% of all surgical procedures but may occur in 1–6% of patients undergoing cardiac or carotid artery surgery. Most of the strokes in cardiac surgery patients are embolic in origin, and about half occur within the first postoperative day. Stroke after cardiac surgery is associated with significantly increased mortality, up to 22% in some studies. A prediction model for stroke after coronary artery bypass surgery includes the following risk factors: age > 60 years, female sex, urgent or emergency surgery, diabetes mellitus, chronic kidney disease, peripheral vascular disease, and systolic dysfunction.

Table 3-6. Risk factors for the development of postoperative delirium.

<p>Preoperative factors</p> <ul style="list-style-type: none"> Age > 70 years Alcohol abuse Cognitive impairment Poor physical function status Markedly abnormal serum sodium, potassium, or glucose level Aortic, thoracic, hip fracture surgery, or emergency surgery <p>Postoperative factors</p> <ul style="list-style-type: none"> Use of meperidine or benzodiazepines, anticholinergics, antihistamines Postoperative hematocrit < 30% Use of urinary catheters

Symptomatic carotid artery stenosis is associated with a high risk for stroke in patients undergoing cardiac surgery. In general, symptomatic carotid lesions should be treated prior to elective cardiac surgery. In contrast, most studies suggest that asymptomatic carotid bruits and asymptomatic carotid stenosis are associated with little or no increased risk of stroke in surgical patients. Prophylactic carotid endarterectomy in patients with asymptomatic carotid artery disease is unlikely to be beneficial in most patients, as the stroke risk of the carotid procedure likely outweighs any risk reduction it provides in a subsequent operation. On the other hand, patients with carotid disease with independent indications for carotid endarterectomy (see Chapter 12) should probably have the carotid surgery prior to the elective surgery.

Bateman BT et al. Perioperative acute ischemic stroke in noncardiac and nonvascular surgery: incidence, risk factors, and outcomes. *Anesthesiology*. 2009 Feb;110(2):231–8. [PMID: 19194149]
 Flinn DR et al. Prevention, diagnosis, and management of postoperative delirium in older adults. *J Am Coll Surg*. 2009 Aug;209(2):261–8. [PMID: 19632604]
 Robinson TN et al. Postoperative delirium in the elderly: risk factors and outcomes. *Ann Surg*. 2009 Jan;249(1):173–8. [PMID: 19106695]

MANAGEMENT OF ENDOCRINE DISEASES

▶ Diabetes Mellitus

Patients with diabetes mellitus are at increased risk for postoperative infections, particularly those involving the surgical site. Patients with a preoperative hemoglobin $A_{1c} < 7\%$ have roughly half the risk for developing a postoperative infection compared with those with a hemoglobin $A_{1c} > 7\%$. Furthermore, diabetic patients are at increased risk for postoperative cardiac complications. The most challenging issue in diabetic patients, however, is the maintenance of glucose control during the perioperative period. The increased secretion of cortisol, epinephrine, glucagon, and growth hormone during surgery is associated with insulin resistance and hyperglycemia in diabetic patients. The goal of management is the prevention of severe hyperglycemia or hypoglycemia in the perioperative period.

The ideal postoperative blood glucose level is not known. Tighter perioperative glycemic control leads to better clinical outcomes in cardiac surgery patients. In a study of 1200 patients in a critical care unit, most of whom had undergone cardiac surgery, those randomized to strict normalization of serum glucose (80–110 mg/dL) had significantly less morbidity and a shorter length of stay in the critical care unit than patients who were treated only for serum glucose > 215 mg/dL. These results do not apply to other surgical patients, however, as a subsequent trial demonstrated increased mortality with tight control in critically ill surgical patients. The specific pharmacologic management of diabetes during the perioperative period depends on the type of diabetes (insulin-dependent or not), the level of glycemic control, and the type and length of surgery. In general, all patients with type 1 diabetes and some with type 2 diabetes will need an intravenous insulin infusion perioperatively. In a randomized trial, basal-bolus

Table 3–7. Perioperative management of diabetic patients who do not need insulin.

Patient	Recommended Management
Diabetes well controlled on diet alone	Measure glucose every 4 hours while fasting or NPO and give subcutaneous regular insulin as needed to maintain blood glucose < 130 mg/dL [> 7.08 mmol/L] Avoid glucose-containing solutions during surgery
Diabetes well controlled on an oral sulfonylurea, metformin, or a thiazolidinedione	The last dose of medication should be taken on the evening before surgery Measure glucose every 4 hours while fasting or NPO and give subcutaneous regular insulin as needed to maintain blood glucose < 130 mg/dL [> 7.08 mmol/L] Measure blood glucose level every 4 hours (or more frequently as indicated) during surgery Resume oral hypoglycemic therapy when the patient returns to baseline diet

NPO, nothing by mouth.

insulin dosing improved glycemic control and reduced postoperative complications in patients with type 2 diabetes mellitus, when compared with sliding scale insulin. Mild hyperglycemia was more common with basal-bolus dosing. Perioperative management of all diabetic patients requires frequent blood glucose monitoring to prevent hypoglycemia and to ensure prompt treatment of hyperglycemia. Recommendations for glycemic control in patients who generally do not need intraoperative insulin are shown in Table 3–7. Perioperative use of corticosteroids, common in neurosurgical and organ transplant procedures, increases glucose intolerance. Patients receiving corticosteroids often require additional regular insulin with meals, while their fasting glucose levels may remain relatively unchanged.

▶ Corticosteroid Replacement

Perioperative complications (predominantly hypotension) resulting from primary or secondary adrenocortical insufficiency are rare. The common practice of administering high-dose corticosteroids during the perioperative period in patients at risk for adrenocortical insufficiency has not been rigorously studied. While definitive recommendations regarding perioperative corticosteroid therapy cannot be made, a conservative approach would be to consider any patient to be at risk for having adrenocortical insufficiency who has received either the equivalent of 20 mg of prednisone daily for 3 weeks or the equivalent of 7.5 mg of prednisone daily for 1 month within the past year. A commonly used regimen is 50–100 mg of hydrocortisone given intravenously every 8 hours beginning before induction of anesthesia and continuing for 24–48 hours. Tapering the dose is not necessary. Patients being maintained on long-term corticosteroids should also continue their usual dose throughout the perioperative period.

► Thyroid Disease

Severe symptomatic hypothyroidism has been associated with several perioperative complications, including intraoperative hypotension, CHF, cardiac arrest, and death. Elective surgery should be delayed in patients with severe hypothyroidism until adequate thyroid hormone replacement can be achieved. Similarly, patients with symptomatic hyperthyroidism are at risk for perioperative thyroid storm and should not undergo elective surgery until their thyrotoxicosis is controlled. An endocrinologist should be consulted if emergency surgery is needed in such patients. Conversely, patients with asymptomatic or mild hypothyroidism generally tolerate surgery well, with only a slight increase in the incidence of intraoperative hypotension; surgery need not be delayed for the month or more required to ensure adequate thyroid hormone replacement.

- Hanazaki K et al. Relationship between perioperative glycemic control and postoperative infections. *World J Gastroenterol*. 2009 Sep 7;15(33):4122–5. [PMID: 19725144]
- Kansagara D et al. Intensive insulin therapy in hospitalized patients: a systematic review. *Ann Intern Med*. 2011 Feb 15; 154(4):268–82. [PMID: 21320942]
- Kohl BA et al. Surgery in the patient with endocrine dysfunction. *Med Clin North Am*. 2009 Sep;93(5):1031–47. [PMID: 19665618]
- Lipshutz AK et al. Perioperative glycemic control: an evidence-based review. *Anesthesiology*. 2009 Feb;110(2):408–21. [PMID: 19194167]
- Yong SL et al. Supplemental perioperative steroids for surgical patients with adrenal insufficiency. *Cochrane Database Syst Rev*. 2009 Oct 7;(4):CD005367. [PMID: 19821345]

KIDNEY DISEASE

Approximately 1% of patients suffer a significant reduction in kidney function after major surgery. The risk is much higher, however, in patients undergoing cardiac operations, where 10–30% of patients develop acute kidney injury. The development of acute kidney injury is an independent predictor of mortality, even if renal dysfunction resolves. The mortality associated with the development of perioperative acute kidney injury that requires dialysis exceeds 50%. Risk factors associated with postoperative deterioration in kidney function are shown in Table 3–8. Several

Table 3–8. Risk factors for the development of postoperative acute renal failure.

Preoperative chronic renal insufficiency
Aortic and major peripheral vascular surgery
Cardiac surgery
Severe heart failure
Preoperative jaundice
Age > 70 years
Diabetes mellitus
COPD requiring daily bronchodilator therapy

COPD, chronic obstructive pulmonary disease.

medications, including “renal dose” dopamine, mannitol, *N*-acetylcysteine, and furosemide, have been evaluated in an attempt to preserve kidney function during the perioperative period. None of these have proved effective in clinical trials and generally should not be used for this indication. Maintenance of adequate intravascular volume is likely to be the most effective method to reduce the risk of perioperative deterioration in kidney function. Exposure to renal toxic agents such as nonsteroidal anti-inflammatory drugs and intravenous contrast should be minimized or avoided. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers reduce renal perfusion and may increase the risk of perioperative acute kidney injury. Although firm evidence is lacking, it may be useful to temporarily discontinue these medications in patients at risk for perioperative acute kidney injury.

Although the mortality rate for elective major surgery is low (1–4%) in patients with dialysis-dependent chronic kidney disease, the risk for perioperative complications, including postoperative hyperkalemia, pneumonia, fluid overload, and bleeding, is substantially increased. Postoperative hyperkalemia requiring emergent hemodialysis has been reported to occur in 20–30% of patients. Patients should undergo dialysis preoperatively within 24 hours before surgery, and their serum electrolyte levels should be measured just prior to surgery and monitored closely during the postoperative period.

- Borthwick E et al. Perioperative acute kidney injury: risk factors, recognition, management, and outcomes. *BMJ*. 2010 Jul 5;341:c3365. [PMID: 20603317]
- Josephs SA et al. Perioperative risk assessment, prevention, and treatment of acute kidney injury. *Int Anesthesiol Clin*. 2009 Fall;47(4):89–105. [PMID: 19820480]
- Shimada M et al. Practice implications of recent clinical trials for the prevention of acute kidney injury in cardiovascular surgery. *Hosp Pract (Minneapolis)*. 2010 Apr;38(2):67–73. [PMID: 20469615]

ANTIBIOTIC PROPHYLAXIS OF SURGICAL SITE INFECTIONS

There are an estimated 0.5–1 million surgical site infections annually in the United States. Surgical site infection is estimated to occur in roughly 4% of general or vascular operations. For most major procedures, the use of prophylactic antibiotics has been demonstrated to reduce the incidence of surgical site infections significantly. For example, antibiotic prophylaxis in colorectal surgery reduces the incidence of surgical site infection from 25–50% to below 20%. In addition, in a case-control study of Medicare beneficiaries, the use of preoperative antibiotics within 2 hours of surgery was associated with a twofold reduction in 60-day mortality.

Other strategies to prevent surgical site infections have proven to be controversial. Evidence suggests that nasal carriage with *Staphylococcus aureus* is associated with a twofold to ninefold increased risk of surgical site and catheter-related infections in surgical patients. Treatment of nasal carriers of *S aureus* with 2% mupirocin ointment (twice daily intranasally for 3 days) prior to cardiac surgery

decreases the risk of surgical site infections. However, in a 2008 cohort study, universal screening for methicillin-resistant *S aureus* in surgical patients failed to reduce infection rates from this pathogen. An early finding that high concentration oxygen delivered in the immediate postoperative period reduced surgical site infections was not verified in subsequent trials. Thus, high-flow supplemental oxygen specifically to prevent these infections is not recommended. Preoperative bathing with antiseptic agents and preoperative hair removal are common practices but have not demonstrated a reduction in surgical site infections in randomized trials. The use of razors for hair removal actually seems to increase the risk of surgical site infections and is therefore specifically not recommended. If preoperative hair removal is indicated, the use of clippers is preferred.

Guidelines for antibiotic prophylaxis against infective endocarditis in patients undergoing invasive procedures are presented in Chapter 33. The American Association of Orthopaedic Surgeons recommends consideration of prophylactic antibiotics in patients with prosthetic joints on a case-by-case basis. More definitive or evidence-based guidelines for antibiotic prophylaxis against prosthetic joint infection are lacking.

Casey AL et al. Progress in the prevention of surgical site infection. *Curr Opin Infect Dis*. 2009 Aug;22(4):370–5. [PMID: 19448534]

Patel NP et al. Antimicrobial agents for surgical infections. *Surg Clin North Am*. 2009 Apr;89(2):327–47. [PMID: 19281887]

Geriatric Disorders

C. Bree Johnston, MD, MPH,
G. Michael Harper, MD,
& C. Seth Landefeld, MD

4

GENERAL PRINCIPLES OF GERIATRIC CARE

The following principles help in caring for older adults:

1. Many disorders are multifactorial in origin and are best managed by multifactorial interventions.
2. Diseases often present atypically.
3. Not all abnormalities require evaluation and treatment.
4. Complex medication regimens, adherence problems, and polypharmacy are common challenges.

ASSESSMENT OF THE OLDER ADULT

Comprehensive assessment addresses three topics in addition to conventional assessment of symptoms and diseases: prognosis, values and preferences, and ability to function independently. Each topic merits at least brief consideration in each clinical decision. Comprehensive assessment is warranted before major clinical decisions (eg, whether major surgery should be performed, or whether a patient should be admitted to the hospital).

► Assessment of Prognosis

When an older person's life expectancy is > 10 years (ie, 50% of similar persons live longer than 10 years), it is reasonable to consider effective tests and treatments much as they are considered in younger persons. When life expectancy is < 10 years (and especially when it is much less), choices of tests and treatments should be made on the basis of their ability to improve that particular patient's prognosis and quality of life in the shorter term of that patient's life expectancy. The relative benefits and harms of tests and treatments often change as prognosis worsens.

When an older patient's clinical situation is dominated by a single disease process (eg, lung cancer metastatic to brain), prognosis can be estimated well with a disease-specific instrument. Even in this situation, however, prognosis generally worsens with age (especially age > 90 years) and with the presence of serious age-related conditions, such as dementia, malnutrition, or impaired ability to walk.

When an older patient's clinical situation is not dominated by a single disease process, prognosis can be estimated

initially by considering the patient's age, sex, and general health (Figure 4-1). For example, < 25% of men age 95 years will live 5 years, whereas nearly 75% of women age 70 years will live 10 years.

The prognosis of older persons living at home can be estimated by considering age, sex, comorbid conditions, and function (Table 4-1). The prognosis of older persons discharged from the hospital is worse than that of those living at home and can be estimated by considering gender, comorbid conditions, and function at discharge (Table 4-2).

► Assessment of Values & Preferences


Although patients vary in their values and preferences, most frail older patients prioritize maintaining their independence over prolonging survival or relieving pain or other symptoms. Values and preferences are determined by speaking directly with a patient or, when the patient cannot express preferences reliably, with the patient's surrogate. Values and preferences can be assessed most readily in the context of a specific medical decision. For example, the clinician might ask a patient considering a hip replacement, "How would you like your hip pain and function to be different? Tell me about the risk and discomfort you are willing to go through to achieve that improvement."

In assessing values and preferences, it is important to keep in mind the following:

1. Patients are experts about their preferences for outcomes and experiences; however, they often do not have adequate information to express informed preferences for specific tests or treatments.
2. Patients' preferences often change over time. For example, some patients find living with a disability more acceptable than they thought before experiencing it.

► Assessment of Function

People often lose function in multiple domains as they age, with the results that they may not be able to do some activities as quickly or capably and may need assistance with other activities. Assessment of function improves prognostic estimates (see above). Assessment of function is essential to



▲ **Figure 4-1.** Median life expectancy of older women and men. (Adapted, with permission, from Walter LC et al. Screening for colorectal, breast, and cervical cancer in the elderly: a review of the evidence. *Am J Med.* 2005 Oct; 118(10):1078-86.) Copyright © Elsevier.

determining an individual's needs in the context of their values and preferences, and the possible effects of prescribed treatment.

About one-fourth of patients over 65 have impairments in their IADLs (instrumental activities of daily living: transportation, shopping, cooking, using the telephone, managing money, taking medications, housecleaning, laundry) or ADLs (basic activities of daily living: bathing, dressing, eating, transferring from bed to chair, continence, toileting). Half of those persons older than 85 years have these latter impairments.

In general, persons who need help only with IADLs can usually live independently with minimal supports, such as financial services (eg, a representative payee) or a chore worker. If institutional care is needed, residential care, board-and-care, or assisted living is usually sufficient. While many persons who need help with ADLs may require a nursing home level of care, most live at home with caregivers and other community services (eg, day care).

Table 4-1. Prognostic factors, "risk points," and 4-year mortality rates for older persons living at home.

Prognostic Factor	Risk Points
Age	
60-64 years	1
64-69 years	2
70-74 years	3
74-79 years	4
80-84 years	5
85 years and older	7
Male sex	2
Comorbid conditions reported by patients	
Diabetes mellitus	1
Cancer	2
Lung disease	2
Heart failure	2
Body mass index < 25	1
Current smoker	2
Function	
Bathing difficulty	2
Difficulty handling finances	2
Difficulty walking several blocks	2
Sum of Risk Points	4-year Mortality Rate
1-2	2%
3-6	7%
7-10	19%
> 10	53%

Reprinted, with permission, from Lee SJ et al. Development and validation of a prognostic index for 4-year mortality in older adults. *JAMA.* 2006 Feb 15;295(7):801-8. Copyright © 2006 American Medical Association. All rights reserved.

► Caregiver Issues

Most elders with functional impairment live in the community with the help of an "informal" caregiver, most commonly a spouse or daughter. The health and well-being of the patient and caregiver are closely linked. High levels of functional dependency place an enormous burden on a caregiver, and may result in caregiver "burnout," depression, morbidity, and even increased mortality.

An older patient's need for nursing home placement is predicted better by the caregiver's ability and stress than the severity of the patient's illness. Therefore, part of caring for a frail elder involves paying attention to the well-being of the caregiver. The older patient who is also a caregiver is at risk for depression and should be screened for it. For the

Table 4-2. Prognostic factors, “risk points,” and 1-year mortality rates for patients discharged from the hospital after an acute medical illness.

Prognostic Factor	Risk Points
Male sex	1
Comorbid conditions reported by patients	
Cancer, metastatic	8
Cancer, not metastatic	3
Serum creatinine > 3 mg/dL	2
Albumin < 3 mg/dL	2
Albumin 3.0–3.4 mg/dL	1
Function	
Dependent in 1–4 ADL ¹	2
Dependent in 5 ADL	5
Sum of Risk Points	
0–1	4%
2–3	19%
4–6	34%
> 6	64%

¹ADL refers to five activities of daily living: bathing, dressing, transferring, using the toilet, and eating.

Reprinted, with permission, from Walter LC et al. Development and validation of a prognostic index for 1-year mortality in older adults after hospitalization. *JAMA*. 2001 Jun 20;285(23):2987–94. Copyright © 2006 American Medical Association. All rights reserved.

stressed caregiver, a social worker may help identify programs such as caregiver support groups, respite programs, adult day care, or hired home health aides.

▶ Functional Screening Instrument

Functional screening should include assessment of ADL and IADL and questions to detect weight loss, falls, incontinence, depressed mood, self neglect, fear for personal safety, and common serious impairments (eg, hearing, vision, cognition, and mobility). Standard functional screening measures may not be useful in capturing subtle impairments in highly functional independent elders. One technique for these patients is to identify and regularly ask about a target activity, such as bowling or gardening. If the patient begins to have trouble with or discontinues such an “advanced activity of daily living,” it may indicate early impairment, such as dementia, incontinence, or worsening hearing loss, which additional gentle questioning or assessment may uncover.

Busy providers may find it more manageable to perform the elements of functional geriatric assessment over three or four visits or to train office personnel to perform some elements of the assessment.

Chang HJ et al. *JAMA* patient page. Preventive care for older adults. *JAMA*. 2009 Dec 23;302(24):2722. [PMID: 20040564]
 Fried TR et al. Health outcome prioritization to elicit preferences of older persons with multiple health conditions. *Patient Educ Couns*. 2011 May;83(2):278–82. [PMID: 20570078]
 Kane RL. Finding the right level of care: “We didn’t realize that there was any other option for him”. *JAMA*. 2011 Jan 19; 305(3):284–93. [PMID: 21245184]
 Reuben DB. Medical care for the final years of life: “When you’re 83, it’s not going to be 20 years”. *JAMA*. 2009 Dec 23;302(24): 2686–94. [PMID: 20040557]
 Sudore RL et al. Redefining the “planning” in advance care planning: preparing for end-of-life decision making. *Ann Intern Med*. 2010 Aug 17;153(4):256–261. [PMID: 20713793]

MANAGEMENT OF COMMON GERIATRIC PROBLEMS

1. Dementia



ESSENTIALS OF DIAGNOSIS

- ▶ Progressive decline of intellectual function.
- ▶ Loss of short-term memory and at least one other cognitive deficit.
- ▶ Deficit severe enough to cause impairment of function.
- ▶ Not delirious.

▶ General Considerations

Dementia is an acquired persistent and progressive impairment in intellectual function, with compromise of memory and at least one other cognitive domain, most commonly aphasia (typically, word finding difficulty), apraxia (inability to perform motor tasks, such as cutting a loaf of bread, despite intact motor function), agnosia (inability to recognize objects), and impaired executive function (poor abstraction, mental flexibility, planning, and judgment). The diagnosis of dementia requires a significant decline in function that is severe enough to interfere with work or social life.

Dementia has a prevalence that doubles every 5 years in the older population, reaching 30–50% at age 85. Women suffer disproportionately, both as patients and as caregivers. Alzheimer disease accounts for roughly two-thirds of dementia cases in the United States, with vascular dementia (either alone or combined with Alzheimer disease) and dementia with Lewy bodies accounting for much of the rest. Some of the risk factors for Alzheimer disease are older age, family history, lower education level, and female sex. Education, cognitive “exercises,” and social support may be protective. Risk factors for vascular dementia are those for stroke, ie, older age, hypertension, cigarette use, atrial fibrillation, diabetes mellitus, and hyperlipidemia.

Depression and delirium are also common in elders, may coexist with dementia, and may also present with

cognitive impairment. Depression is a common concomitant of early dementia. A patient with depression and cognitive impairment whose intellectual function improves with treatment of the mood disorder has an almost fivefold greater risk of suffering irreversible dementia later in life. Delirium, characterized by acute confusion, occurs much more commonly in patients with underlying dementia.

► Clinical Findings

A. Screening

1. Cognitive impairment—Although there is no consensus at present on whether older patients should be screened for dementia, the benefits of early detection include identification of potentially reversible causes, planning for the future (including discussing values and completing advance care directives), and providing support and counseling for the caregiver.

The combination of a clock drawing task with a three-item word recall (also known as the “mini-cog”) is a simple screening test that is fairly quick to administer. While different methods for administering and scoring the clock draw test have been described, the authors of this chapter favor the approach of pre-drawing a four inch circle on a sheet of paper and instructing the patient to “draw a clock” with the time set at 10 minutes after 11. Scores are classified as normal, almost normal, or abnormal. When a patient is able to draw a clock normally and can remember all 3 objects, dementia is unlikely. When a patient fails this simple screen, further cognitive evaluation with a standardized instrument is warranted. The Montreal Cognitive Assessment (MoCA ©) is a 30-point test that takes about 10 minutes to administer and examines several areas of cognitive function. A score below 26 is considered abnormal. Free downloadable versions in multiple languages are available at <http://www.mocatest.org>.

2. Decision-making capacity—Cognitively impaired elders commonly face serious medical decisions, and the clinicians involved in their care must ascertain whether the capacity exists to make the choice. While no single test of capacity exists, the following five elements should be considered in a thorough assessment: (1) ability to express a choice; (2) understanding relevant information about the risks and benefits of planned therapy and the alternatives, in the context of one’s values, including no treatment; (3) comprehension of the problem and its consequences; (4) ability to reason; and (5) consistency. A patient’s choice should follow from an understanding of the consequences.

Sensitivity must be used in applying these five components to people of various cultural backgrounds. Decision-making capacity varies over time: A delirious patient may regain his capacity after an infection is treated, and so reassessments are often appropriate. Furthermore, the capacity to make a decision is a function of the decision in question. A woman with mild dementia may lack the capacity to consent to coronary artery bypass grafting yet retain the capacity to designate a surrogate decision maker.

B. Symptoms and Signs

The clinician can gather important information about the type of dementia that may be present by asking about: (1) the rate of progression of the deficits as well as their nature (including any personality or behavioral change); (2) the presence of other neurologic symptoms, particularly motor problems; (3) risk factors for HIV; (4) family history of dementia; and (5) medications, with particular attention to recent changes.

Work-up is directed at identifying any potentially reversible causes of dementia. However, such cases are indeed rare. For a detailed description of the symptoms and signs of different forms of dementia, see Chapter 24.

C. Physical Examination

The neurologic examination emphasizes assessment of mental status but should also include evaluation for sensory deficits, possible previous strokes, parkinsonism, or peripheral neuropathy. The remainder of the physical examination should focus on identifying comorbid conditions that may aggravate the individual’s disability. For a detailed description of the neuropsychological assessment, see Chapter 24.

D. Laboratory Findings

Laboratory studies should include a complete blood count, electrolytes, calcium, creatinine, glucose, thyroid-stimulating hormone (TSH), and vitamin B₁₂ levels. While hypothyroidism or vitamin B₁₂ deficiency may contribute to the cognitive impairment, treating these conditions typically does not completely reverse the dementia. HIV testing, RPR (rapid plasma reagin) test, heavy metal screen, and liver biochemical tests may be informative in selected patients but should not be considered part of routine testing. For a detailed description of laboratory findings, see Chapter 24.

E. Imaging

Most patients should receive neuroimaging as part of the diagnostic work-up to rule out subdural hematoma, tumor, previous stroke, and hydrocephalus (usually normal pressure). Those who are younger and those who have focal neurologic symptoms or signs, seizures, gait abnormalities, and an acute or subacute onset are most likely to yield positive findings and most likely to benefit from MRI scanning. In older patients with a more classic picture of Alzheimer disease in whom neuroimaging is desired, a non-contrast CT scan is sufficient. For a detailed description of imaging, see Chapter 24.

► Differential Diagnosis

Older individuals experience occasional difficulty retrieving items from memory (usually manifested as word-finding complaints) and experience a slowing in their rate of information processing. **Mild cognitive impairment** is an increasingly recognized condition in which a patient complains of memory problems, demonstrates mild deficits

(most commonly in short-term memory) on formal testing, but does not meet criteria for dementia. Dementia will develop in more than half of people with mild cognitive impairment within 5 years. Acetylcholinesterase inhibitors have not consistently demonstrated a delay in the progression of mild cognitive impairment to Alzheimer disease. An elderly patient with intact cognition but with severe impairments in vision or hearing commonly becomes confused in an unfamiliar medical setting and consequently may be falsely labeled as demented. Cognitive testing is best performed after optimal correction of the sensory deficits.

Delirium can be distinguished from dementia by its acute onset, fluctuating course, and deficits in attention rather than memory. Because delirium and dementia often coexist, it may not be possible to determine how much impairment is attributable to each condition until the patient is fully recovered and back in their usual setting. Many medications have been associated with delirium and other types of cognitive impairment in older patients. Anticholinergic agents, hypnotics, neuroleptics, opioids, nonsteroidal anti-inflammatory drugs (NSAIDs), antihistamines (including H₁ and H₂-antagonists), and corticosteroids are just some of the medications that have been associated with cognitive impairment in elders.

► Treatment

Patients and families should be made aware of the Alzheimer's Association (<http://www.alz.org>) as well as the wealth of helpful community and online resources and publications available. Caregiver support, education, and counseling can prevent or delay nursing home placement. Education should include the manifestations and natural history of dementia as well as the availability of local support services such as respite care. Even under the best of circumstances, caregiver stress can be substantial. Collaborative care models and disease management programs appear to improve the quality of care for patients with dementia.

A. Cognitive Impairment

Because demented patients have greatly diminished cognitive reserve, they are at high risk for experiencing acute cognitive or functional decline in the setting of new medical illness. Consequently, fragile cognitive status may be best maintained by ensuring that comorbid diseases such as congestive heart failure and infections are detected and treated.

1. Acetylcholinesterase inhibitors—Many experts recommend considering a trial of acetylcholinesterase inhibitors (eg, donepezil, galantamine, rivastigmine) in most patients with mild to moderate Alzheimer disease. These medications produce a modest improvement in cognitive function that is not likely to be detected in routine clinical encounters. Acetylcholinesterase inhibitors may also have similarly modest cognitive benefits in patients with vascular dementia or dementia with Lewy bodies. However, acetylcholinesterase inhibitors have not convincingly been shown to delay institutionalization or functional decline.

Starting doses, respectively, of donepezil, galantamine, and rivastigmine, are 5 mg orally once daily (maximum 10 mg once daily), 4 mg orally twice daily (maximum 12 mg twice daily), and 1.5 mg orally twice daily (maximum 6 mg twice daily). The doses are increased gradually as tolerated. The most bothersome side effects include diarrhea, nausea, anorexia, weight loss, and syncope. In those patients who have had no apparent benefit, experience side effects, or for whom the financial outlay is a burden, the drug should be discontinued.

2. Memantine—In clinical trials, patients with more advanced disease have been shown to have statistical benefit from the use of memantine, an *N*-methyl-D-aspartate (NMDA) antagonist, with or without concomitant use of an acetylcholinesterase inhibitor. Long-term and meaningful functional outcomes have yet to be demonstrated.

B. Behavioral Problems

1. Nonpharmacologic approaches—Behavioral problems in demented patients are often best managed with a nonpharmacologic approach. Initially, it should be established that the problem is not unrecognized delirium, pain, urinary obstruction, or fecal impaction. It also helps to inquire whether the caregiver or institutional staff can tolerate the behavior, as it is often easier to find ways to accommodate to the behavior than to modify it. If not, the caregiver should keep a brief log in which the behavior is described along with antecedent events and consequences. Recurring precipitants of the behavior are often found to be present or it may be that the behavior is rewarded—for example, by increased attention. Caregivers are taught to use simple language when communicating with the patient, to break down activities into simple component tasks, and to use a “distract, not confront” approach when the patient seems disturbed by a troublesome issue. Additional steps to address behavioral problems include providing structure and routine, discontinuing all medications except those considered absolutely necessary, and correcting, if possible, sensory deficits.

2. Pharmacologic approaches—There is no clear consensus about pharmacologic approaches to treatment of behavioral problems in patients who have not benefited from nonpharmacologic therapies. The target symptoms—depression, anxiety, psychosis, mood lability, or pain—may suggest which class of medications might be most helpful in a given patient. Patients with depressive symptoms may show improvement with antidepressant therapy. Patients with dementia with Lewy bodies have shown clinically significant improvement in behavioral symptoms when treated with rivastigmine (3–6 mg orally twice daily).

For those with Alzheimer disease and agitation, no agents have demonstrated consistent efficacy. Despite the lack of strong evidence, antipsychotic medications have remained a mainstay for the treatment of behavioral disturbances, largely because of the lack of alternatives. The newer atypical antipsychotic agents (risperidone, olanzapine, quetiapine, aripiprazole, clozapine, ziprasidone) are reported to be better tolerated than older agents but should be avoided in patients with vascular risk factors due to an increased risk

of stroke; they can cause weight gain and are also associated with hyperglycemia in diabetic patients and are considerably more expensive. Both typical and atypical antipsychotics in several short-term trials and one long-term trial have been demonstrated to increase mortality compared with placebo when used to treat elderly demented patients with behavioral disturbances. When the choice is made to use these agents, patients and caregivers should be carefully warned of the risks. Starting and target dosages should be much lower than those used in schizophrenia (eg, haloperidol, 0.5–2 mg orally; risperidone, 0.25–2 mg orally). Federal regulations require that if antipsychotic agents are used in treatment of a nursing home patient, drug reduction efforts must be made at least every 6 months.

C. Driving

A common yet vexing problem that providers are regularly asked to assess is whether a patient with dementia is able to continue driving. The consequences of a decision to either stop or continue driving can be far-reaching for both the patient and the general public and therefore every case requires careful consideration. Although drivers with dementia are at an increased risk for motor vehicle accidents, many patients continue to drive safely well beyond the time of diagnosis, making the timing of when to recommend that a patient stop driving particularly challenging.

There is no clear-cut evidence to suggest a single best approach to determining an individual patient's risk, and there is no accepted "gold standard" test. The result is that clinicians must consider several factors upon which to base their judgment. For example, determining the severity of dementia can be useful. Patients with very mild or mild dementia according to the Clinical Dementia Rating Scale were able to pass formal road tests at rates of 88% and 69%, respectively. Experts agree that patients with moderately severe or more advanced dementia should be counseled to stop driving. Although not well studied, clinicians should also consider the effects of comorbid conditions and medications and the role each may play in contributing to the risk of driving by a patient with dementia. Assessment of the ability to carry out IADLs may also add to the determination of risk. Caregivers of patients with at least a 30% decline in their IADL score were more likely to rate them as unable to drive safely than other, less impaired patients. Finally, in some cases of mild dementia, referral may be needed to a driver rehabilitation specialist for evaluation. Although not standardized, this evaluation often consists of both off- and on-road testing. The cost for this assessment can be substantial, and it is typically not covered by health insurance. Experts recommend such an evaluation for patients with mild dementia, for those with dementia for whom new impairment in driving skills is observed, and for those with significant deficits in cognitive domains such as attention, executive function, and visuospatial skills. At present, there is no convincing evidence to support the use of interventions to improve driving skills and driver safety.

Clinicians must also be aware of the reporting requirements in their individual jurisdictions. Some states have

mandatory reporting laws for clinicians, but in other states, the decision to report an unsafe driver with dementia is voluntary. When a clinician has made the decision to report an unsafe driver to the Department of Motor Vehicles, he or she must consider the impact as a potential breach in confidentiality and must weigh and address, in advance when possible, the consequences from the loss of driving independence.

D. Advance Financial Planning

Difficulty in managing financial affairs often develops early in the course of dementia. The patient's caregiver may seek advice from the patient's primary care clinician. Although expertise is not expected, clinicians should have some proficiency to address financial concerns. Just as clinicians counsel patients and families about advance care planning, the same should be done to educate about the need for advance financial planning and to recommend that patients complete a durable power of attorney for finance matters (DPOAF) when the capacity to do so still exists. In most states the DPOAF can be executed with or without the aid of an attorney. Other options to assist in managing and monitoring finances include online banking, automatic bill payments, direct deposits and joint bank accounts. A potential risk of the joint account is that the joint account holder has no obligation to act in the best interest of the patient.

No gold standard test is available to identify when a patient with dementia no longer has financial capacity. However, the clinician should be on the lookout for signs that a patient is either at risk for or actually experiencing financial incapacity. Because financial impairment can occur when dementia is mild, making that diagnosis should alone be enough to warrant further investigation. Questioning patients and caregivers about late, missed or repeated bill payments, unusual or uncharacteristic purchases or gifts, overdrawn bank accounts and reports of missing funds can provide evidence of suspected financial impairment. Patients with dementia are also at increased risk for becoming victims of financial abuse and some answers to these same questions might also be signs of potential financial abuse. When financial abuse is suspected, clinicians should be aware of the reporting requirements in their local jurisdictions.

► Prognosis

Life expectancy after a diagnosis of Alzheimer disease is typically 3–15 years; it may be shorter than previously reported. Other neurodegenerative dementias, such as dementia with Lewy bodies, show more rapid decline. Hospice is often appropriate for patients with end-stage dementia.

► When to Refer

Referral for neuropsychological testing may be helpful in the following circumstances: to distinguish dementia from depression, to diagnose dementia in persons of very poor education or very high premorbid intellect, and to aid diagnosis when impairment is mild.

- Carr DB et al. The older adult driver with cognitive impairment: "It's a very frustrating life". *JAMA*. 2010 April 28;303(16):1632–41. [PMID: 20424254]
- Gill SS et al. Syncope and its consequences in patients with dementia receiving cholinesterase inhibitors: a population-based cohort study. *Arch Intern Med*. 2009 May 11;169(9):867–73. [PMID: 19433698]
- Nasreddine ZS et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. *J Am Geriatr Soc*. 2005 April; 53(4):695–99. [PMID: 15817019]
- Torpy JM et al. JAMA patient page. Dementia. *JAMA*. 2009 Aug 12;302(6):704. [PMID: 19671914]
- Torpy JM et al. JAMA patient page. Mild cognitive impairment. *JAMA*. 2009 Jul 22;302(4):452. [PMID: 19622827]
- Widera E et al. Finances in the older patient with cognitive impairment: "He didn't want me to take over". *JAMA*. 2011 Feb 16;305(7):698–706. [PMID: 21325186]

2. Depression

ESSENTIALS OF DIAGNOSIS

- ▶ Depressed elders may not admit to depressed mood.
- ▶ Depression screening in elders should include a question about anhedonia.

▶ General Considerations

Depressive symptoms—often related to loss, disease, and life changes—may be present in more than 25% of elders; however, the prevalence of major depression is similar in younger and older populations. Depression is particularly common in hospitalized and institutionalized elders. Older single men have the highest suicide rate of any demographic group. Geriatric patients with depression are more likely to have somatic complaints, less likely to report depressed mood, and more likely to experience delusions than younger patients. In addition, depression may be an early symptom of a neurodegenerative condition such as dementia. Depressed patients who have other comorbidities, such as congestive heart failure or diabetes, have worse outcomes than their non-depressed counterparts.

▶ Clinical Findings

A simple two-question screen—which consists of asking “During the past 2 weeks, have you felt down, depressed, or hopeless?” and “During the past 2 weeks, have you felt little interest or pleasure in doing things?”—is highly sensitive for detecting major depression in persons over age 65. Positive responses can be followed up with more comprehensive, structured interviews, such as the Geriatric Depression Scale (<http://www.stanford.edu/~yesavage/GDS.html>) or the PHQ-9 (<http://www.depression-primarycare.org>).

Elderly patients with depressive symptoms should be questioned about medication use, since many drugs

(eg, benzodiazepines, corticosteroids) may contribute to the clinical picture. Similarly, several medical problems can cause fatigue, lethargy, or hypoactive delirium, all of which may be mistaken for depression. Particularly when delirium is the differential diagnosis, laboratory testing should include a complete blood count; liver, thyroid, and kidney function tests; serum calcium; urinalysis; and electrocardiogram.

▶ Treatment

Choice of antidepressant agent in elders is usually based on side effect profile and cost. Citalopram and sertraline are often used as first-line agents because of their low side-effect profiles. In general, fluoxetine is avoided because of its long duration of action and tricyclic antidepressants are avoided because of their high anticholinergic side effects. Mirtazapine is often used for patients with weight loss, anorexia, or insomnia. Venlafaxine can be useful in patients who also have neuropathic pain. Regardless of the drug chosen, many experts recommend starting elders at a relatively low dose, titrating to full dose slowly, and continuing for a longer trial (at least 9 weeks) before trying a different medication. Problem-solving therapy and cognitive behavioral therapy can be effective alone or in combination with medication therapy. Depressed elders may do better with a collaborative care model that includes socialization and other support elements than with usual care, and such models may also improve comorbid conditions. Recurrence of major depression is common in elders; any elder with a history of depression should be closely monitored for recurrence and considered for longer-term maintenance medication therapy.

▶ When to Refer

Referral should be considered for patients who have not responded to an initial antidepressant drug trial and for patients with symptoms of mania, suicidality, or psychosis.

▶ When to Admit

Patients who are suicidal, homicidal, psychotic, or a danger to self or others should be considered for acute psychiatric hospitalization.

- Areán PA et al. Problem-solving therapy and supportive therapy in older adults with major depression and executive dysfunction. *Am J Psychiatry*. 2010 Nov;167(11):1391–8. [PMID: 20516155]
- Katon WJ et al. Collaborative care for patients with depression and chronic illnesses. *N Engl J Med*. 2010 Dec 30;363(27):2611–20. [PMID: 21190455]
- Kok RM et al. Continuing treatment of depression in the elderly: a systematic review and meta-analysis of double-blinded randomized controlled trials with antidepressants. *Am J Geriatr Psychiatry*. 2011 March;19(3):249–55. [PMID: 21425505]

3. Delirium

ESSENTIALS OF DIAGNOSIS

- ▶ Rapid onset and fluctuating course.
- ▶ Primary deficit in attention rather than memory.
- ▶ May be hypoactive or hyperactive.
- ▶ Dementia frequently coexists.

▶ General Considerations

Delirium is an acute, fluctuating disturbance of consciousness, associated with a change in cognition or the development of perceptual disturbances (see also Chapter 25). It is the pathophysiologic consequence of an underlying general medical condition such as infection, coronary ischemia, hypoxemia, or metabolic derangement. Delirium persists in up to 25% of patients and is associated with worse clinical outcomes (higher in-hospital and postdischarge mortality, longer lengths of stay, greater probability of placement in a nursing facility).

Although the acutely agitated elderly patient often comes to mind when considering delirium, many episodes are more subtle. Such quiet, or hypoactive, delirium may only be suspected if one notices new cognitive slowing or inattention.

Cognitive impairment is an important risk factor for delirium. Approximately 25% of delirious patients are demented, and 40% of demented hospitalized patients are delirious. Other risk factors are male sex, severe illness, hip fracture, fever or hypothermia, hypotension, malnutrition, polypharmacy and use of psychoactive medications, sensory impairment, use of restraints, use of intravenous lines or urinary catheters, metabolic disorders, depression, and alcoholism.

▶ Clinical Findings

A number of bedside instruments for the assessment of delirium are available. The confusion assessment method (CAM), which requires (1) acute onset and fluctuating course and (2) inattention and *either* (3) disorganized thinking *or* (4) altered level of consciousness, is easy to administer and performs well.

A key component of a delirium work-up is review of medications because a large number of drugs, the addition of a new drug, or the discontinuation of a medication known to cause withdrawal symptoms are all associated with the development of delirium. Medications that are particularly likely to increase the risk of delirium include opioids, benzodiazepines, dihydropyridines, and antihistamines.

Laboratory evaluation of most patients should include a complete blood count, electrolytes, blood urea nitrogen (BUN) and serum creatinine, glucose, calcium, albumin, liver function studies, urinalysis, and electrocardiography.

In selected cases, serum magnesium, serum drug levels, arterial blood gas measurements, blood cultures, chest radiography, urinary toxin screen, head CT scan, and lumbar puncture may be helpful.

▶ Prevention

Prevention is the best approach in the management of delirium. Measures include improving cognition (frequent reorientation, activities, socialization with family and friends, when possible), sleep (massage, noise reduction, minimizing interruptions at night), mobility, vision (visual aids and adaptive equipment), hearing (portable amplifiers, cerumen disimpaction), and hydration status (volume repletion). No medications have been consistently shown to prevent delirium or reduce its duration or severity.

▶ Treatment

Management of established episodes of delirium is largely supportive and includes reassurance and reorientation, treatment of underlying causes, eliminating unnecessary medications, and avoidance of indwelling catheters and restraints. Antipsychotic agents (such as haloperidol, 0.5–1 mg, or quetiapine, 25 mg, at bedtime or twice daily) are considered the medication of choice when drug treatment of delirium is necessary. Other medications (eg, trazodone, acetylcholinesterase inhibitors, and mood stabilizers) have also been used, but evidence in support of these approaches is weak. In ventilated patients in the intensive care unit setting, dexmedetomidine or propofol (or both) may also be useful alternatives or adjuncts to antipsychotic therapy in patients with delirium.

Most episodes of delirium clear in a matter of days after correction of the precipitant, but some patients suffer episodes of longer duration, and a few never return to their former baseline level of functioning. These individuals merit closer follow-up for the development of dementia if not already diagnosed.

▶ When to Refer

If an initial evaluation does not reveal the cause of delirium or if entities other than delirium are in the differential diagnosis, referral to a neuropsychologist, neurologist, or geropsychiatrist should be considered.

▶ When to Admit

Patients with delirium of unknown cause should be admitted for an expedited work-up if consistent with the patient's goals of care.

Clegg A et al. Which medications to avoid in people at risk of delirium: a systematic review. *Age Aging*. 2011 Jan;40(1):23–9. [PMID: 21068014]

Wong CL et al. Does this patient have delirium? Value of bedside instruments. *JAMA*. 2010 Aug 18;304 (7):779–86. [PMID: 20716741]

4. Immobility

Although common in older people, reduced mobility is never normal and is often treatable if its causes are identified. Bed rest is an important cause of hospital-induced functional decline. Among hospitalized medical patients over 70, about 10% experience a decline in function, much of which results from preventable reductions in mobility.

The hazards of bed rest in older adults are multiple, serious, quick to develop, and slow to reverse. Deconditioning of the cardiovascular system occurs within days and involves fluid shifts, decreased cardiac output, decreased peak oxygen uptake, and increased resting heart rate. More striking changes occur in skeletal muscle, with loss of contractile velocity and strength. Pressure sores, deep venous thrombosis, and pulmonary embolism are additional serious risks. Within days after being confined to bed, the risk of postural hypotension, falls, and skin breakdown rises rapidly in the older patient. Moreover, recovery from these changes usually takes weeks to months.

► Prevention & Treatment

When immobilization cannot be avoided, several measures can be used to minimize its consequences. Skin, particularly areas over pressure points, should be inspected at least daily. If the patient is unable to shift position, staff should do so every 2 hours. To minimize cardiovascular deconditioning, patients should be positioned as close to the upright position as possible, several times daily. To reduce the risks of contracture and weakness, range of motion and strengthening exercises should be started immediately and continued as long as the patient is in bed. Whenever possible, patients should assist with their own positioning, transferring, and self-care. As long as the patient remains immobilized, antithrombotic measures should be used if that is consistent with the patient's goals of care.

Avoiding restraints and discontinuing invasive devices (intravenous lines, urinary catheters) may increase an elderly patient's prospects for early mobility. Graduated ambulation should begin as soon as it is feasible. Advice from a physical therapist is often helpful both before and after discharge. Prior to discharge, physical therapists can recommend appropriate exercises and assistive devices; after discharge, they can recommend safety modifications and maintenance exercises.

Covinsky KE et al. Hospitalization-associated disability: "She was probably able to ambulate, but I'm not sure". *JAMA*. 2011 Oct 26;306(16):1782-93. [PMID: 22028354]

5. Falls & Gait Disorders

About one-third of people over age 65 fall each year, and the frequency of falls increases markedly with advancing age. About 10% of falls result in serious injuries such as fractures, soft tissue injuries, and traumatic brain injuries. Complications from falls are the leading cause of death from injury in persons over age 65. Hip fractures are common precursors to functional impairment, nursing home

placement, and death. Furthermore, fear of falling may lead some elders to restrict their activities.

Every older person should be asked about falls; many will not volunteer such information. Assessment of patients who fall should include postural blood pressure and pulse, thorough cardiac examination, evaluations of strength, range of motion, cognition, and proprioception, and examination of feet and footwear. A thorough gait assessment should be performed in all older people. Gait and balance can be readily assessed by the "Up and Go Test," in which the patient is asked to stand up from a sitting position without use of hands, walk 10 feet, turn around, walk back, and sit down. Patients who take < 10 seconds are usually normal, patients who take longer than 30 seconds tend to need assistance with many mobility tasks, and those in between tend to vary widely with respect to gait, balance, and function. The ability to recognize common patterns of gait disorders is an extremely useful clinical skill to develop. Examples of gait abnormalities and their causes are listed in Table 4-3.

► Causes of Falls

Balance and ambulation require a complex interplay of cognitive, neuromuscular, and cardiovascular function. With age, balance mechanisms can become compromised and postural sway increases. These changes predispose the older person to a fall when challenged by an additional insult to any of these systems.

A fall may be the clinical manifestation of an occult problem, such as pneumonia or myocardial infarction, but much more commonly falls are due to the interaction between an impaired patient and an environmental risk factor. Falls in older people are rarely due to a single cause, and effective intervention entails a comprehensive assessment of the patient's intrinsic deficits (usually diseases and medications), the activity engaged in at the time of the fall, and environmental obstacles.

Intrinsic deficits are those that impair sensory input, judgment, blood pressure regulation, reaction time, and balance and gait. Dizziness may be closely related to the deficits associated with falls and gait abnormalities. While it may be impossible to isolate a sole "cause" or a "cure" for falls, gait abnormalities, or dizziness, it is often possible to identify and ameliorate some of the underlying contributory conditions and improve the patient's overall function.

As for most geriatric conditions, medication use is one of the most common, significant, and reversible causes of falling. A meta-analysis found that sedative/hypnotics, antidepressants, and benzodiazepines were the classes of drugs most likely to be associated with falling. The use of multiple medications simultaneously has also been associated with an increased fall risk. Other often overlooked but treatable contributors include postural hypotension (including postprandial, which peaks 30-60 minutes after a meal), insomnia, use of multifocal lenses, and urinary urgency.

Since most falls occur in or around the home, a visit by a visiting nurse, physical therapist, or health care provider reaps substantial benefits in identifying environmental obstacles and is generally reimbursed by third-party payers, including Medicare.

Table 4-3. Evaluation of gait abnormalities.

Gait Abnormality	Possible Cause
Inability to stand without use of hands	Deconditioning Myopathy (hyperthyroidism, alcohol, statin-induced) Hip or knee pain
Unsteadiness upon standing	Orthostatic hypotension Balance problem (peripheral neuropathy, vision problem, vestibular, other central nervous system causes) Generalized weakness
Stagger with eyes closed	Often indicates that vision is compensating for another deficit
Short steps	Weakness Parkinson disease or related condition
Asymmetry	Cerebrovascular accident Focal pain or arthritis
Wide-based gait	Fear, balance problems
Flexed knees	Contractures, quadriceps weakness
Slow gait	Fear of falling, weakness, deconditioning, peripheral vascular disease, chronic obstructive pulmonary disease, congestive heart failure, angina pectoris

► Complications of Falls

The most common fractures resulting from falls are of the wrist, hip, and vertebrae. There is a high mortality rate (approximately 20% in 1 year) in elderly women with hip fractures, particularly if they were debilitated prior to the time of the fracture.

Fear of falling again is a common, serious, but treatable factor in the elderly person's loss of confidence and independence. Referral to a physical therapist for gait training with special devices is often all that is required.

Chronic subdural hematoma is an easily overlooked complication of falls that must be considered in any elderly patient presenting with new neurologic symptoms or signs. Headache or known history of trauma may both be absent.

Patients who are unable to get up from a fall are at risk for dehydration, electrolyte imbalance, pressure sores, rhabdomyolysis, and hypothermia.

► Prevention & Management

The risk of falling and consequent injury, disability, and potential institutionalization can be reduced by modifying those factors outlined in Table 4-4. Emphasis is placed on treating all contributory medical conditions (eg, cataracts), minimizing environmental hazards, and eliminating medications where the harms may outweigh the benefits—particularly those that induce orthostasis and parkinsonism (eg, α -blockers, nitrates, antipsychotics). Also important are strength, balance, and gait training as well as screening and treatment for osteoporosis, if present. Falls and fractures may be prevented by prescribing vitamin D at a dose of 800 international units daily or higher.

Assistive devices, such as canes and walkers, are useful for many older adults but are often used incorrectly. Canes should be used on the “good” side. The height of walkers and canes should generally be about the level of the wrist. Physical therapists are invaluable in assessing the need for

an assistive device, selecting the best device, and training a patient in its correct use.

Early surgery for patients with cataracts may reduce falls, but eyeglasses, particularly bifocal or graduated lenses, may actually increase the risk of falls, particularly in the early weeks of use. Patients should be counseled about the need to take extra care when new eyeglasses are being used (eg, to look down to use the lens above the bifocal when going up or down stairs).

Patients with repeated falls are often reassured by the availability of phones at floor level, a portable phone, or a lightweight radio call system. Their therapy should also include training in techniques for arising after a fall. The clinical utility of anatomically designed external hip protectors in reducing fractures is currently uncertain.

► When to Refer

Patients with a recent history of falls should be referred for physical therapy, eye examination, and home safety evaluation.

► When to Admit

If the patient has new falls that are unexplained, particularly in combination with a change in the physical examination, hospitalization should be considered.

Chang HJ et al. JAMA patient page. Falls and older adults. JAMA. 2010 Jan 20;303(3):288. [PMID: 20085959]

Michael YL et al. Primary care-relevant interventions to prevent falling in older adults: a systematic evidence review for the U.S. Preventive Services Task Force. Ann Intern Med. 2010 Dec 21;153(12):815–25. [PMID: 21173416]

Tinetti ME et al. The patient who falls: “It’s always a trade-off”. JAMA. 2010 Jan 20;303(3):258–66. [PMID: 20085954]

Woolcott JC et al. Meta-analysis of the impact of 9 medication classes on falls in elderly persons. Arch Intern Med. 2009 Nov 23;169(21):1952–60. [PMID: 19933955]

Table 4-4. Fall risk factors and targeted interventions and best evidence for fall prevention.

Risk Factor	Targeted Intervention
Postural hypotension (> 20 mm Hg drop in systolic blood pressure, or systolic blood pressure < 90 mm Hg)	Behavioral recommendations, such as hand clenching, elevation of head of bed; discontinuation or substitution of high-risk medications
Use of benzodiazepine or sedative-hypnotic agent	Education about sleep hygiene; discontinuation or substitution of medications
Use of multiple prescription medications	Review of medications
Environmental hazards	Appropriate changes; installation of safety equipment (eg, grab bars)
Gait impairment	Gait training, assistive devices, balance or strengthening exercises
Impairment in transfer or balance	Balance exercises, training in transfers, environmental alterations (eg, grab bars)
Impairment in leg or arm muscle strength or limb range of motion	Exercise with resistance bands or putty, with graduated increases in resistance
Best Evidence for Fall Prevention ¹	Number of Trials and Risk Ratios
Exercise or physical therapy	16 randomized controlled trials Risk ratio for falls 0.87 (confidence interval 0.81-0.94)
Vitamin D supplementation	9 randomized controlled trials Risk ratio for falls 0.83 (confidence interval 0.77-0.89)
Multifactorial Intervention	19 randomized controlled trials Risk ratio for falls 0.94 (confidence interval 0.87-1.02)

¹Adapted, with permission, from Michael YL et al. Primary care-relevant interventions to prevent falling in older adults: a systematic evidence review for the U.S. Preventive Services Task Force. *Ann Intern Med.* 2010 Dec 21;153(12):815-25. [PMID: 21173416]

6. Urinary Incontinence



ESSENTIALS OF DIAGNOSIS

- ▶ Involuntary loss of urine.
- ▶ *Stress* incontinence: leakage of urine upon coughing, sneezing, or standing.
- ▶ *Urge* incontinence: urgency and inability to delay urination.
- ▶ *Overflow* incontinence: may have variable presentation.

▶ General Considerations

Incontinence in older adults is common, and interventions can improve most patients. Many patients fail to tell their providers about it. A simple question about involuntary leakage of urine is a reasonable screen: “Do you have a problem with urine leaks or accidents?”

▶ Classification

Because continence requires adequate mobility, mentation, motivation, and manual dexterity, problems outside the bladder often result in incontinence. In general, the authors of this chapter find it useful to differentiate between “transient” or “potentially reversible” causes of incontinence and more “established” causes.

A. Transient Causes

Use of the mnemonic “DIAPPERS” may be helpful in remembering the categories of transient incontinence.

1. Delirium—A clouded sensorium impedes recognition of both the need to void and the location of the nearest toilet. Delirium is the most common cause of incontinence in hospitalized patients; once it clears, incontinence usually resolves.

2. Infection—Symptomatic urinary tract infection commonly causes or contributes to urgency and incontinence. Asymptomatic bacteriuria does not.

3. Atrophic urethritis or vaginitis—Atrophic urethritis can usually be diagnosed presumptively by the presence of vaginal mucosal telangiectasia, petechiae, erosions, erythema, or friability. Urethral inflammation, if symptomatic, may contribute to incontinence in some women. Some experts suggest a trial of topical estrogen in these cases.

4. Pharmaceuticals—Drugs are one of the most common causes of transient incontinence. Typical offending agents include potent diuretics, anticholinergics, psychotropics, opioid analgesics, α -blockers (in women), α -agonists (in men), and calcium channel blockers.

5. Psychological factors—Severe depression with psychomotor retardation may impede the ability or motivation to reach a toilet.

6. Excess urinary output—Excess urinary output may overwhelm the ability of an older person to reach a toilet in time. In addition to diuretics, common causes include excess

fluid intake; metabolic abnormalities (eg, hyperglycemia, hypercalcemia, diabetes insipidus); and disorders associated with peripheral edema, with its associated heavy nocturia when previously dependent legs assume a horizontal position in bed.

7. Restricted mobility—(See Immobility section, above.) If mobility cannot be improved, access to a urinal or commode (eg, at the bedside) may improve continence.

8. Stool impaction—This is a common cause of urinary incontinence in hospitalized or immobile patients. Although the mechanism is still unknown, a clinical clue to its presence is the onset of both urinary and fecal incontinence. Disimpaction usually restores urinary continence.

B. Established Causes

Causes of established incontinence should be addressed after the transient causes have been uncovered and managed appropriately. Risk factors for incontinence include older age, female sex, increased body mass index, and limited physical activity.

1. Detrusor overactivity (urge incontinence)—Detrusor overactivity refers to uninhibited bladder contractions that cause leakage. It is the most common cause of established geriatric incontinence, accounting for two-thirds of cases, and is usually idiopathic. Women will complain of urinary leakage after the onset of an intense urge to urinate that cannot be forestalled. In men, the symptoms are similar, but detrusor overactivity commonly coexists with urethral obstruction from benign prostatic hyperplasia. Because detrusor overactivity also may be due to bladder stones or tumor, the abrupt onset of otherwise unexplained urge incontinence—especially if accompanied by perineal or suprapubic discomfort or sterile hematuria—should be investigated by cystoscopy and cytologic examination of a urine specimen.

2. Urethral incompetence (stress incontinence)—Urethral incompetence is the second most common cause of established urinary incontinence in older women. Stress incontinence is most commonly seen in men after radical prostatectomy. Stress incontinence is characterized by instantaneous leakage of urine in response to a stress maneuver. It commonly coexists with detrusor overactivity. Typically, urinary loss occurs with laughing, coughing, or lifting heavy objects. Leakage is worse or occurs only during the day, unless another abnormality (eg, detrusor overactivity) is also present. To test for stress incontinence, have the patient relax her perineum and cough vigorously (a single cough) while standing with a full bladder. Instantaneous leakage indicates stress incontinence if urinary retention has been excluded by postvoiding residual determination using ultrasound. A delay of several seconds or persistent leakage suggests that the problem is instead caused by an uninhibited bladder contraction induced by coughing.

3. Urethral obstruction—Urethral obstruction (due to prostatic enlargement, urethral stricture, bladder neck contracture, or prostatic cancer) is a common cause of established incontinence in older men but is rare in older women.

It can present as dribbling incontinence after voiding, urge incontinence due to detrusor overactivity (which coexists in two-thirds of cases), or overflow incontinence due to urinary retention. Renal ultrasound is required to exclude hydronephrosis in men whose postvoiding residual urine exceeds 150 mL.

4. Detrusor underactivity (overflow incontinence)—Detrusor underactivity is the least common cause of incontinence. It may be idiopathic or due to sacral lower motor nerve dysfunction. When it causes incontinence, detrusor underactivity is associated with urinary frequency, nocturia, and frequent leakage of small amounts. The elevated postvoiding residual urine (generally over 450 mL) distinguishes it from detrusor overactivity and stress incontinence, but only urodynamic testing differentiates it from urethral obstruction in men. Such testing usually is not required in women, in whom obstruction is rarely present.

► Treatment

A. Transient Causes

Each identified transient cause should be treated regardless of whether an established cause coexists. For patients with urinary retention induced by an anticholinergic agent, discontinuation of the drug should first be considered. If this is not feasible, substituting a less anticholinergic agent may be useful.

B. Established Causes

1. Detrusor overactivity—The cornerstone of treatment is bladder training. Patients start by voiding on a schedule based on the shortest interval recorded on a bladder record. They then gradually lengthen the interval between voids by 30 minutes each week using relaxation techniques to postpone the urge to void. Lifestyle modifications, including weight loss and caffeine reduction, may also improve incontinence symptoms. For cognitively impaired patients and nursing home residents who are unable to manage on their own, timed and prompted voiding initiated by caregivers is effective.

Pelvic floor muscle (“Kegel”) exercises, with or without biofeedback, can reduce the frequency of incontinence episodes when performed correctly and sustained. If behavioral approaches prove insufficient, drug therapy with antimuscarinic agents may provide additional benefit. The two oral drugs for which there is the most experience are tolterodine and oxybutynin. Available regimens of these drugs follow: short-acting tolterodine, 1–2 mg twice a day; long-acting tolterodine, 2–4 mg daily; short-acting oxybutynin, 2.5–5 mg twice or three times a day; long-acting oxybutynin, 5–15 mg daily; and oxybutynin transdermal patch, 3.9 mg per day applied twice weekly. All of these agents can produce delirium, dry mouth, or urinary retention; long-acting preparations may be better tolerated. Agents such as fesoterodine (4–8 mg orally once daily), trospium chloride (20 mg orally once or twice daily), darifenacin (7.5–15 mg orally daily), and solifenacin (5–10 mg orally daily)

appear to have similar efficacy and have not been clearly demonstrated to be better tolerated than the older agents in long-acting form.

The combination of behavioral therapy and antimuscarinics appears to be more effective than either alone although one study in a group of younger women showed that adding behavioral therapy to individually titrated doses of extended-release oxybutynin was no better than drug treatment alone.

In men with both benign prostatic hyperplasia and detrusor overactivity and who have postvoid residual volumes of 150 mL or less, an antimuscarinic agent added to an α -blocker may provide additional relief of lower urinary tract symptoms.

2. Urethral incompetence (stress incontinence)—

Lifestyle modifications, including limiting caffeine intake and timed voiding, may be helpful for some women, particularly women with mixed stress/urge incontinence. Pelvic floor muscle exercises are effective for women with mild to moderate stress incontinence; the exercises can be combined, if necessary, with biofeedback, electrical stimulation, or vaginal cones. Instruct the patient to pull in the pelvic floor muscles and hold for 6–10 seconds and to perform three sets of 8–12 contractions daily. Benefits may not be seen for 6 weeks. Pessaries or vaginal cones may be helpful in some women but should be prescribed by providers who are experienced with using these modalities.

Although a last resort, surgery is the most effective treatment for stress incontinence, resulting in a cure rate as high as 96% even in older women. Drug therapy is limited. Clinical trials have shown that duloxetine, a serotonin and norepinephrine reuptake inhibitor, reduces stress incontinence episodes in women but efficacy in older women remains unknown. It is approved for use for this indication in some countries but not the United States. Side effects, including nausea, are common.

3. Urethral obstruction—Surgical decompression is the most effective treatment for obstruction, especially in the setting of urinary retention due to benign prostatic hyperplasia. A variety of less invasive techniques make decompression feasible even for frail men. For the nonoperative candidate with urinary retention, intermittent or indwelling catheterization is used. For a man with prostatic obstruction who does not require or desire immediate surgery, treatment with α -blocking agents (eg, terazosin, 1–10 mg daily; prazosin, 1–5 mg orally twice daily; tamsulosin, 0.4–0.8 mg daily) can improve symptoms and delay obstruction. Finasteride, 5 mg daily, can provide additional benefit to an α -blocking agent in men with an enlarged prostate.

4. Detrusor underactivity—For the patient with a poorly contractile bladder, augmented voiding techniques (eg, double voiding, suprapubic pressure) often prove effective. If further emptying is needed, intermittent or indwelling catheterization is the only option. Antibiotics should be used only for symptomatic upper urinary tract infection or as prophylaxis against recurrent symptomatic infections in a patient using intermittent catheterization; they should not be used as prophylaxis with an indwelling catheter.

► When to Refer

- Men with urinary obstruction who do not respond to medical therapy should be referred to a urologist.
- Women who do not respond to medical and behavioral therapy should be referred to a urogynecologist or urologist.

Burgio KL et al. Combined behavioral and individualized drug therapy versus individualized drug therapy alone for urge urinary incontinence in women. *J Urol*. 2010 Aug;184(2):598–603. [PMID: 20639023]

Goode PS et al. Incontinence in older women. *JAMA*. 2010 Jun 2;303(21):2172–81. [PMID: 20516418]

7. Undernutrition & Frailty

► General Considerations

Undernutrition affects substantial numbers of elderly. The degree of unintended weight loss that deserves evaluation is not agreed upon, although a reasonable threshold is loss of 5% of body weight in 1 month or 10% of body weight in 6 months.

“Frailty” is a term that may be clinically useful for describing a subgroup of patients—almost always elders—who have delicate health, are not robust, and have decreased functional reserve. Although clinicians generally agree on most of the clinical characteristics that define the frailty syndrome, there is not yet a consensus definition of frailty. Frailty may be accompanied by physiologic changes in inflammatory and neuroendocrine systems. The label of “failure to thrive” is typically applied when some triggering event—loss of social support, a bout of depression or pneumonia, the addition of a new medication—pulls a struggling elderly person below the threshold of successful independent living.

► Clinical Findings

Useful laboratory and radiologic studies for the patient with weight loss include complete blood count, serum chemistries (including glucose, TSH, creatinine, calcium), urinalysis, and chest radiograph. These studies are intended to uncover an occult metabolic or neoplastic cause but are not exhaustive. Exploring the patient’s social situation, cognition, mood, and dental health are at least as important as looking for a purely medical cause of weight loss.

There is not yet a standard assessment tool for frailty. However, the most widely recognized definition of frailty requires that the patient exhibit at least three of the five following clinical criteria: (1) slow gait speed; (2) low hand grip strength; (3) exhaustion; (4) weight loss; and (5) low energy expenditure. Few physicians screen for the syndrome, since an evidence-based treatment for frailty does not yet exist. Patients who meet criteria for the frailty syndrome are at increased risk for poor clinical outcomes.

► Treatment

Oral nutritional supplements of 200–1000 kcal/d can increase weight and improve outcomes in malnourished hospitalized elders. Megestrol acetate as an appetite stimulant has not been shown to increase body mass or lengthen life in the elderly population. For those who have lost the ability to feed themselves, assiduous hand feeding may allow maintenance of weight. Although artificial nutrition and hydration (“tube feeding”) may seem a more convenient alternative, it deprives the patient of the taste and texture of food as well as the social milieu typically associated with mealtime; before this option is chosen, the patient or his or her surrogate should be offered the opportunity to review the benefits and burdens of the treatment in light of overall goals of care. If the patient makes repeated attempts to pull out the tube during a trial of artificial nutrition, the treatment burden becomes substantial, and the utility of tube feeding should be reconsidered. Although commonly used, there is no evidence that tube feeding prolongs life in patients with end-stage dementia.

The ideal strategies for preventing the frailty syndrome are unknown. At present, treatment is largely supportive, multifactorial, and individualized based on patient goals, life expectancy, and comorbidities. Sometimes, transitioning a patient to a palliative approach or a hospice program is the most appropriate clinical intervention when efforts to prevent functional decline fail.

Abellan van Kan G et al. The assessment of frailty in older adults. *Clin Geriatr Med.* 2010 May;26(2):275–86. [PMID: 20497846]

Boockvar KS et al. Chapter 8: Palliative care for frail older adults: “There are things I can’t do anymore that I wish I could. . . .” In: McPhee SJ et al [editors]: *Care at the Close of Life: Evidence and Experience.* McGraw-Hill, 2010.

8. Pressure Ulcers



ESSENTIALS OF DIAGNOSIS

- Examine at-risk patients on admission to hospital and daily thereafter.
- Pressure ulcers should be described by one of six stages:
 - Blanchable hyperemia (stage I).
 - Extension through epidermis (stage II).
 - Full thickness skin loss (stage III).
 - Full thickness wounds with extension into muscle, bone, or supporting structures (stage IV).
 - If eschar or slough overlies the wound, the wound is unstageable.
 - Suspected deep tissue injury is an area of discolored or blistered skin.

► General Considerations

The majority of pressure ulcers develop during a hospital stay for an acute illness. Incident rates range from 3% to 30% and vary according to patient characteristics. The primary risk factor for pressure ulcers is immobility. Other contributing risk factors include reduced sensory perception, moisture (urinary and fecal incontinence), poor nutritional status, and friction and shear forces.

In 2007, the National Pressure Ulcer Advisory Panel added two stages to the original four pressure ulcer stages: suspected deep tissue injury and unstageable. Ulcers in which the base is covered by slough (yellow, tan, gray, green or brown) and/or eschar (tan, brown or black) are considered unstageable. Suspected deep tissue injury is an area of purple or maroon discolored intact skin or blood-filled blister. The area may be preceded by tissue that is painful, firm, mushy, boggy, warmer or cooler compared with adjacent tissue.

A number of risk assessment instruments including the Braden Scale and the Norton score can be used to assess the risk of developing pressure ulcers; both have reasonable performance characteristics. These instruments can be used to identify the highest risk patients who might benefit most from scarce resources such as mattresses that reduce or relieve pressure.

As of October 2008, Medicare will no longer reimburse for hospital-acquired pressure ulcers. Pressure ulcers present on admission will qualify for a higher reimbursement. The medical record must contain documentation of pressure ulcers present on admission, and coders are required to use physician documentation as the basis for coding and reporting; therefore, physicians should include a full skin assessment on every admission history and physical.

► Prevention

Using specialized support surfaces (including mattresses, beds, and cushions), patient repositioning, optimizing nutritional status, and moisturizing sacral skin are strategies that have been shown to reduce pressure ulcers. For moderate- to high-risk patients, mattresses or overlays that reduce tissue pressure below a standard mattress appear to be superior to standard mattresses. The literature comparing specific products is sparse and inconclusive.

► Evaluation

Evaluation of pressure ulcers should include patient’s risk factors and goals of care, wound stage, size, depth, presence or absence of exudate, type of exudate present, appearance of the wound bed, and whether there appears to be surrounding infection, sinus tracking, or cellulitis. In poorly healing or atypical pressure ulcers, biopsy should be performed to rule out malignancy or other less common lesions such as pyoderma gangrenosum.

► Treatment

Treatment is aimed toward removing necrotic debris and maintaining a moist wound bed that will promote healing and formation of granulation tissue. The type of dressing that is recommended depends on the location and depth of

Table 4-5. Treatment of pressure ulcers.

Ulcer Type	Dressing Type and Considerations
Stage I and suspected deep tissue injury	Polyurethane film Hydrocolloid wafer Semipermeable foam dressing
Stage II	Hydrocolloid wafers Semipermeable foam dressing Polyurethane film
Stage III/IV	For highly exudative wounds , use highly absorptive dressing or packing, such as calcium alginate Wounds with necrotic debris must be debrided Debridement can be autolytic, mechanical (wet to moist), or surgical Shallow, clean wounds can be dressed with hydrocolloid wafers, semipermeable foam, or polyurethane film Deep wounds can be packed with gauze; if the wound is deep and highly exudative, an absorptive packing should be used
Heel ulcer	Do not remove eschar on heel ulcers because it can help promote healing (eschar in other locations should be debrided)
Unstageable	Debride before deciding on further therapy

the wound, whether necrotic tissue or dead space is present, and the amount of exudate (Table 4-5). Pressure-reducing devices (eg, air-fluid beds and low air loss beds) are associated with improved healing rates. Although poor nutritional status is a risk factor for the development of pressure ulcers, the results of trials of nutritional supplementation in the treatment of pressure ulcers have been disappointing.

Providers can become easily overwhelmed by the array of products available for treatment of established pressure ulcers. Most institutions should designate a wound care expert or wound care team to select a streamlined wound care product line that has simple guidelines. In a patient with end-stage disease who is receiving palliative care, appropriate treatment might be directed toward comfort (including minimizing dressing changes and odors) rather than efforts directed at healing.

► Complications

Pressure ulcers are associated with increased mortality rates, although a causal link has not been proven. Complications include pain, cellulitis, osteomyelitis, systemic sepsis, and prolongation of lengths of stay in the inpatient or nursing home setting.

► When to Refer

Ulcers that are large or nonhealing should be referred to a plastic or general surgeon or dermatologist for biopsy, debridement, and possible skin grafting.

► When to Admit

Patients with pressure ulcers should be admitted if the primary residence is unable to provide adequate wound care or pressure reduction, if the wound is infected, or for complex or surgical wound care.

Langemo DK et al; National Pressure Ulcer Advisory Panel. Pressure ulcers in individuals receiving palliative care: a National Pressure Ulcer Advisory Panel white paper. *Adv Skin Wound Care*. 2010 Feb;23(2):59-72. [PMID: 20087072]
Lohi J et al. Local dressings for pressure ulcers: what is the best tool to apply in primary and secondary care? *Wound Care*. 2010 Mar;19(3):123-7. [PMID: 20559190]
National Pressure Ulcer Advisory Panel Website: <http://www.npuap.org/pr2.htm>
Reddy M et al. Treatment of pressure ulcers: a systematic review. *JAMA*. 2008 Dec 10;300(22):2647-62. [PMID: 19066385]

9. Pharmacotherapy & Polypharmacy

There are several reasons for the greater incidence of iatrogenic drug reactions in the elderly population, the most important of which is the high number of medications that elders take. Drug metabolism is often impaired in this group due to a decrease in glomerular filtration rate as well as reduced hepatic clearance. The latter is due to decreased activity of microsomal enzymes and reduced hepatic perfusion with aging. The volume of distribution of drugs is also affected. Since older adults have a decrease in total body water and a relative increase in body fat, water-soluble drugs become more concentrated and fat-soluble drugs have longer half-lives. Older individuals often have varying responses to a given serum drug level. Thus, they are more sensitive to some drugs (eg, opioids) and less sensitive to others (eg, β -blocking agents). Most emergency hospitalizations for recognized adverse drug events among older persons result from a only a few medications used alone or in combination; examples include warfarin, antiplatelet agents, insulins, oral hypoglycemic agents, and to a lesser extent, opioid analgesics and digoxin.

► Precautions in Administering Drugs

Nonpharmacologic interventions can often be a first-line alternative to drugs (eg, diet for mild hypertension or type 2 diabetes mellitus). Therapy is begun with less than the usual adult dosage and the dosage increased slowly, consistent with its pharmacokinetics in older patients. However, age-related changes in drug distribution and clearance are variable among individuals, and some require full doses. After determining acceptable measures of success and toxicity, the dose is increased until one or the other is reached.

Despite the importance of beginning new drugs in a slow, measured fashion, all too often an inadequate trial is attempted (in terms of duration or dose) before discontinuation. Antidepressants, in particular, are frequently stopped before therapeutic dosages are reached.

A number of simple interventions can help improve adherence to the prescribed medical regimen. When possible, the provider should keep the dosing schedule simple,

the number of pills low, the medication changes as infrequent as possible, and encourage the patient to use a single pharmacy. Pillboxes or “medi-sets” help some patients with adherence.

Having the patient or caregiver bring in all medications at each visit can help the provider perform medication reconciliation and reinforce reasons for drug use, dosage, frequency of administration, and possible adverse effects. Medication reconciliation is particularly important if the patient sees multiple providers.

Although serum drug levels may be useful for monitoring certain drugs with narrow therapeutic windows (eg, digoxin), toxicity can still occur even with “normal” therapeutic levels of many drugs. The risk of toxicity goes up with the number of medications prescribed. Certain combinations of medications (eg, warfarin and many types of antibiotics, digoxin and clarithromycin, angiotensin-converting enzyme inhibitors and NSAIDs) are particularly likely to cause drug-drug interactions, and should be watched carefully.

Trials of individual drug discontinuation should be considered (including sedative-hypnotics, antipsychotic medications, digoxin, proton pump inhibitors, NSAIDs) when the original indication is unclear, the goals of care have changed, or the patient might be experiencing side effects.

► When to Refer

Patients with poor or uncertain adherence may benefit from referral to a pharmacist or a home health nurse.

Budnitz DS et al. Emergency hospitalizations for adverse drug events in older Americans. *N Engl J Med.* 2011 Nov 24;365(21):2002–12. [PMID: 22111719]

Onder G et al. Development and validation of a score to assess risk of adverse drug reactions among in-hospital patients 65 years or older: the GerontoNet ADR risk score. *Arch Intern Med.* 2010 Jul 12;170(13):1142–8. [PMID: 20625022]

Steinman MA et al. Managing medications in clinically complex elders: “There’s got to be a happy medium”. *JAMA.* 2010 Oct 13;304(14):1592–601. [PMID: 20940385]

10. Vision Impairment

Although visual loss is not severe in many elders, visual impairment is an independent risk factor for falls; it also has a significant impact on quality of life. The prevalence of serious and correctable visual disorders in elders is sufficient to warrant a complete eye examination by an ophthalmologist or optometrist annually or biannually for most elders. Many patients with visual loss benefit from a referral to a low vision program, and primary care providers should not assume that an ophthalmologist or optometrist will automatically make this referral.

Rosenberg EA et al. The visually impaired patient. *Am Fam Physician.* 2008 May 15;77(10):1431–6. [PMID: 18533377]

11. Hearing Impairment

Over one-third of persons over age 65 and half of those over age 85 have some hearing loss. This deficit is correlated with

social isolation and depression. A reasonable screen is to ask patients if they have hearing impairment. Those who answer “yes” should be referred for audiometry. Those who answer “no” may still have hearing impairment and can be screened by a handheld audioscope or the whispered voice test. The whispered voice test is administered by standing 2 feet behind the subject, whispering three random numbers, and simultaneously rubbing the external auditory canal of the non-tested ear to mask the sound. If the patient is unable to identify all three numbers, the test should be repeated with different numbers, and if still abnormal, a referral should be made to audiometry. To determine the degree to which hearing impairment interferes with functioning, the provider may ask if the patient becomes frustrated when conversing with family members, is embarrassed when meeting new people, has difficulty watching TV, or has problems understanding conversations. Caregivers or family members often have important information on the impact of hearing loss on the patient’s social interactions.

Hearing amplification can improve hearing-related quality of life in patients with hearing loss. However, compliance with hearing amplification can be a challenge because of the stigma associated with hearing aid use as well as the cost of such devices, which are not paid for under most Medicare plans. Special telephones, amplifiers for the television, and many other devices are available to aid the person with hearing loss. Portable amplifiers are pager-sized units with earphones attached; they can be purchased inexpensively at many electronics stores and can be useful in health care settings for improving communication with hearing impaired patients. In general, facing the patient and speaking slowly in a low tone is a more effective communication strategy than yelling for patients with age-related hearing loss.

Chou R et al. Screening adults aged 50 years or older for hearing loss: a review of the evidence for the U.S. Preventive Service Task Force. *Ann Intern Med.* 2011 March 1;154(5):347–55. [PMID: 21357912]

12. Elder Mistreatment & Self Neglect

Elder mistreatment is defined as “actions that cause harm or create a serious risk of harm to an older adult by a caregiver or other person who stands in a trust relationship to the older adult, or failure by a caregiver to satisfy the elder’s basic needs or to protect the elder from harm.” Self neglect is the most common form of elder mistreatment and occurs among all demographic strata of the aging population. According to the best available estimates, the prevalence of potential neglect and psychological and financial abuse, are each about 5%, with other forms of abuse being less common.

Clues to the possibility of elder abuse include behavioral changes in the presence of the caregiver, delays between occurrence of injuries and sought treatment, inconsistencies between an observed injury and associated explanation, lack of appropriate clothing or hygiene, and not filling prescriptions. Many elders with cognitive impairment become targets of financial abuse. Both elder

Table 4-6. Phrases and actions that may be helpful in situations of suspected abuse or neglect.

Questions for the Elder

1. Has anyone hurt you?
2. Are you afraid of anybody?
3. Is anyone taking or using your money without your permission?

Questions for the Caregiver

1. Are your dad's needs more than you can handle?
2. Are you worried that you might hit your dad?
3. Have you hit your dad?

If abuse is suspected

Tell the patient that you are concerned, want to help, and will call Adult Protective Services to see if there is anything that they can do to help

Document any injuries

Document the patient's words

Document whether or not the patient has decision making capacity using a tool such as Aid to Capacity Evaluation

abuse and self neglect are associated with an increased risk of mortality.

It is helpful to observe and talk with every older person alone for at least part of a visit in order to ask questions directly about possible abuse and neglect (Table 4-6). When self neglect is suspected, it is critical to establish whether a patient has decision making capacity in order to determine what course of action needs to be taken. A patient who has full decision making capacity should be provided with help and support but can choose to live in conditions of self neglect, providing that the public is not endangered by the actions of the person. In contrast, a patient who lacks decision making capacity who lives in conditions of self neglect will require more aggressive

intervention, which may include guardianship, in-home help, or placement in a supervised setting. Mental state scores, such as the MOCA or the Mini-Mental State Exam (MMSE), may provide some insight into the patient's cognitive status but are not designed to assess decision making capacity. A standardized tool, such as the "Aid to Capacity Evaluation," is easy to administer, has good performance characteristics for determining decision making capacity, and is available free online at www.jointcentreforbioethics.ca/tools/ace_download.shtml.

► When to Refer

The laws in most states require health care providers to report suspected abuse or neglect to Adult Protective Services; agencies are available in all 50 states to assist in cases of suspected elder abuse. The Web site for the National Center for Elder Abuse is <http://www.ncea.aoa.gov>. When it is unclear whether a patient has decision making capacity after an initial assessment, or whether an untreated mental health disorder is contributing to the problem, a referral to a mental health professional is appropriate.

► When to Admit

Hospital admission is appropriate when a patient is unsafe in the community and an alternate plan cannot be put into place in a timely manner.

Mosqueda L et al. Elder abuse and self-neglect: "I don't care anything about going to the doctor, to be honest...". *JAMA*. 2011 Aug 3;306(5):532-40. [PMID: 21813431]
 Sessums LL et al. Does this patient have medical decision-making capacity? *JAMA*. 2011 July 27;306(4):420-7. [PMID: 21791691]

5

Palliative Care & Pain Management

Michael W. Rabow, MD
Steven Z. Pantilat, MD

DEFINITION & SCOPE OF PALLIATIVE CARE

The focus of palliative care is to improve symptoms and quality of life at any stage of illness, utilizing the expertise of an interdisciplinary team. At the end of life, palliative care often becomes the only focus of care, but palliative care alongside cure-focused treatment is beneficial throughout the course of serious chronic and terminal illnesses, regardless of prognosis, whether the goal is to cure disease or manage chronic illness.

The World Health Organization defines palliative care as “an approach that improves the quality of life of patients and their families facing the problem associated with life-threatening illness, through the prevention and relief of suffering by means of early identification and impeccable assessment and treatment of pain and other problems, physical, psychosocial and spiritual.” Palliative care commonly involves management of pain and other symptoms, including dyspnea, nausea and vomiting, constipation, and agitation; emotional distress, such as depression, anxiety, and interpersonal strain; and existential distress, such as spiritual crisis. While palliative care has been recognized formally as a medical subspecialty by the American Board of Medical Specialties and palliative care experts are increasingly available in hospital and outpatient settings, all clinicians should possess the basic skills to be able to manage pain; treat dyspnea; identify possible depression; communicate about important issues, such as prognosis and patient preferences for care; and help address spiritual distress. In 2011, the Joint Commission began offering advanced certification in palliative care to hospitals providing high quality palliative services.

Symptoms that cause significant suffering are a medical emergency that should be managed aggressively with frequent elicitation, continuous reassessment, and individualized treatment. While patients at the end of life may experience a host of distressing symptoms, pain, dyspnea, and delirium are among the most feared and burdensome. The palliation of these common symptoms is described later in this chapter. The principles of palliative care dictate that properly informed patients or their surrogates may decide to pursue aggressive symptom relief at the end of life even if, as a known but unintended consequence,

the treatments preclude further unwanted curative interventions or even hasten death. There is a growing awareness and data from a randomized trial that scrupulous symptom control for patients with end-stage illness may even prolong life.

Bakitas M et al. Effects of a palliative care intervention on clinical outcomes in patients with advanced cancer: the Project ENABLE II randomized controlled trial. *JAMA*. 2009 Aug 19;302(7):741–9. [PMID: 19690306]

El-Jawahri A et al. Does palliative care improve outcomes for patients with incurable illness? A review of the evidence. *J Support Oncol*. 2011 May–Jun;9(3):87–94. [PMID: 21702398]

Temel JS et al. Early palliative care for patients with metastatic non-small-cell lung cancer. *N Engl J Med*. 2010 Aug 19;363(8):733–42. [PMID: 20818875]

PAIN MANAGEMENT

PRINCIPLES OF PAIN MANAGEMENT

The experience of pain includes the patient’s emotional reaction to it and is influenced by many factors, including the patient’s prior experiences with pain, meaning given to the pain, emotional stresses, and family and cultural influences. Pain is a subjective phenomenon, and clinicians cannot reliably detect its existence or quantify its severity without asking the patient directly. A useful means of assessing pain and evaluating the effectiveness of analgesia is to ask the patient to rate the degree of pain along a numeric or visual pain scale (Table 5–1).

General guidelines for management of pain are recommended for the treatment of all patients with pain (Table 5–2). Clinicians should ask about the nature, severity, timing, location, quality, and aggravating and relieving factors of the pain. Distinguishing between neuropathic and nociceptive (somatic or visceral) pain is essential to proper tailoring of pain treatments. The goal of pain management is properly decided by the patient. Some patients may wish to be completely free of pain even at the cost of significant sedation, while others will wish to control pain to a level that still allows maximal functioning.

Table 5-1. Pain assessment scales.

A. Numeric Rating Scale					
B. Numeric Rating Scale Translated into Word and Behavior Scales					
Pain intensity	Word scale	Nonverbal behaviors			
0	No pain	Relaxed, calm expression			
1-2	Least pain	Stressed, tense expression			
3-4	Mild pain	Guarded movement, grimacing			
5-6	Moderate pain	Moaning, restless			
7-8	Severe pain	Crying out			
9-10	Excruciating pain	Increased intensity of above			
C. Wong Baker FACES Pain Rating Scale ¹					
0 No hurt	1 Hurts Little Bit	2 Hurts Little More	3 Hurts Even More	4 Hurts Whole Lot	5 Hurts Worst

¹Especially useful for patients who cannot read English and for pediatric patients. Reprinted, with permission, from Hockenberry M, Wilson D, Winkelstein ML. *Wong's Essentials of Pediatric Nursing*, ed. 8. Copyright © 2009, Mosby, St. Louis.

Chronic severe pain should be treated continuously. For ongoing pain, a long-acting analgesic can be given around the clock with a short-acting medication as needed for “breakthrough” pain. Whenever possible, the oral route of administration is preferred because it is easier to administer at home, is not painful, and imposes no risk from needle

exposure. Near the end of life, rectal, transdermal, subcutaneous, and intravenous administration are also frequently used; intrathecal administration is used when necessary (albeit rarely). Patient-controlled analgesia (PCA) of intravenous medications can achieve better analgesia faster with less medication use and its principles have been adapted for use with oral administration.

The underlying cause of pain should be diagnosed and treated, balancing the burden of diagnostic tests with the patient’s suffering. For example, radiation therapy for painful bone metastases or mechanical stents for obstructing lesions, may obviate the need for ongoing treatment with analgesics and their side effects. Regardless of decisions about seeking and treating the underlying cause of pain, every patient should be offered prompt relief.

Table 5-2. Recommended clinical approach to pain management.

<p>Ask about pain regularly. Assess pain systematically (quality, description, location, intensity or severity, aggravating and ameliorating factors, cognitive responses). Ask about goals for pain control, management preferences.</p> <p>Believe the patient and family in their reports of pain and what relieves it.</p> <p>Choose pain control options appropriate for the patient, family, and setting. Consider drug type, dosage, route, contraindications, side effects. Consider nonpharmacologic adjunctive measures.</p> <p>Deliver interventions in a timely, logical, coordinated manner.</p> <p>Empower patients and their families. Enable patients to control their course to the greatest extent possible.</p> <p>Follow up to reassess persistence of pain, changes in pain pattern, development of new pain.</p>
--

Data from Jacox AK et al. *Management of Cancer Pain: Quick Reference Guide No. 9*. AHCPR Publication No. 94-0593. Rockville, MD: Agency for Health Care Policy and Research, Public Health Service, U.S. Department of Health and Human Services. March 1994.

PAIN AT THE END OF LIFE

▶ Definition & Prevalence

Pain is a common problem for patients at the end of life. Up to 75% of patients dying of cancer or other diseases experience pain, and up to 50% of severely ill hospitalized patients spent half of their time during the last 3 days of life in moderate to severe pain. Pain is what many people say they fear most about dying and is routinely undertreated. Joint Commission reviews of healthcare organizations now include pain management standards.

► Barriers to Good Care

Deficiencies in pain management at the end of life have been documented in many settings. Some clinicians refer pain management to others when they believe that a patient's pain is not due to the disease for which they are treating the patient. Even oncologists often misperceive the origin of their patients' pain and inappropriately ignore complaints of pain.

Many clinicians have limited training and clinical experience with pain management and thus are understandably reluctant to attempt to manage severe pain. Lack of knowledge about the proper selection and dosing of analgesic medications carries with it attendant and typically exaggerated fears about the side effects of pain medications, including the possibility of respiratory depression from opioids. Most clinicians, however, can develop good pain management skills, and nearly all pain, even at the end of life, can be managed without hastening death through respiratory depression. In rare instances, palliative sedation may be necessary to control intractable suffering as an intervention of last resort.

A misunderstanding of the physiologic effects of opioids can lead to unfounded concerns on the part of clinicians, patients, or family members that patients will become addicted to opioids. While physiologic **tolerance** (requiring increasing dosage to achieve the same analgesic effect) and **dependence** (requiring continued dosing to prevent symptoms of medication withdrawal) are expected with regular opioid use, the use of opioids at the end of life for relief of pain and dyspnea is not generally associated with a risk of psychological **addiction** (misuse of a substance for purposes other than one for which it was prescribed and despite negative consequences in health, employment, or legal and social spheres). The risk for problematic use of pain medications is higher, however, in patients with a history of addiction. Yet even patients with such a history need pain relief, albeit with closer monitoring. Some patients who demonstrate behaviors associated with addiction (demand for specific medications and doses, anger and irritability, poor cooperation or disturbed interpersonal reactions) may have **pseudo-addiction**, defined as exhibiting behaviors associated with addiction but only because their pain is inadequately treated. Once pain is relieved, these behaviors cease. In all cases, clinicians must be prepared to use appropriate doses of opioids in order to relieve distressing symptoms for patients at the end of life.

Some clinicians fear legal repercussions from prescribing the high doses of opioids sometimes necessary to control pain at the end of life. Some states have special training, licensing and documentation requirements for opioid prescribing. However, governmental and professional medical groups, regulators, and the US Supreme Court have made it clear that appropriate treatment of pain is the right of the patient and a fundamental responsibility of the clinician. In fact, clinicians have been successfully sued for undertreatment of pain. Although clinicians may feel trapped between consequences of over- or under-prescribing opioids, there remains a wide range

of practice in which clinicians can appropriately treat pain. Referral to pain or palliative care experts is appropriate whenever pain cannot be controlled expeditiously by the primary clinician.

PHARMACOLOGIC PAIN MANAGEMENT STRATEGIES

In general, pain can be well controlled with analgesic medications—both opioid and nonopioid—at any stage of illness. Evidence-based summaries and guidelines are available from the Agency for Healthcare Research and Quality (<http://www.ncbi.nlm.nih.gov/books/bv.fcgi?rid=hstat1.chapter.86205>) and other organizations (http://www.nccn.org/professionals/physician_gls/PDF/pain.pdf). For mild to moderate pain, acetaminophen, aspirin, and nonsteroidal anti-inflammatory drugs (NSAIDs) may be sufficient. For moderate to severe pain, these agents combined with opioids may be helpful.

► Acetaminophen & NSAIDs

Appropriate doses of acetaminophen may be just as effective an analgesic and antipyretic as NSAIDs but without the risk of gastrointestinal bleeding or ulceration. Acetaminophen can be given at a dosage of 500–1000 mg orally every 6 hours, although it can be taken every 4 hours as long as the risk of hepatotoxicity is kept in mind. Hepatotoxicity is of particular concern because of how commonly acetaminophen is also an ingredient in various over-the-counter medications. Total acetaminophen doses should not exceed 3–4 g/d long-term or 2 g/d for older patients and for those with liver disease.

Aspirin (325–650 mg orally every 4 hours) is an effective analgesic, antipyretic, and anti-inflammatory medication. Gastrointestinal irritation and bleeding are side effects that are lessened with enteric-coated formulations of aspirin and concomitant use of proton-pump inhibitor medication. Bleeding, allergy, and an association with Reye syndrome in children and teenagers further limit its use.

Commonly used NSAIDs and their dosages are listed in Table 5–3. Like aspirin, the NSAIDs are antipyretic, analgesic, and anti-inflammatory. NSAIDs increase the risk of gastrointestinal bleeding by 1.5 times normal. The risks of bleeding and nephrotoxicity from NSAIDs are both increased in elders. Gastrointestinal bleeding and ulceration may be prevented with the concurrent use of proton pump inhibitors (eg, omeprazole, 20–40 mg orally daily) or with the class of NSAIDs that inhibit only cyclooxygenase (COX)-2. Celecoxib (100 mg/d to 200 mg orally twice daily) is the only COX-2 inhibitor available and should be used with caution in patients with cardiac disease. The NSAIDs, including COX-2 inhibitors, can lead to fluid retention and exacerbations of congestive heart failure and should be used with caution in patients with that condition. Topical formulations of NSAIDs (such as diclofenac 1.3% patch or 1% gel), placed over the painful body part, result in lower systemic levels of the medication and may be associated with fewer side effects than oral administration.

Table 5-3. Acetaminophen, COX-2 inhibitors, and useful nonsteroidal anti-inflammatory drugs.

Drug	Usual Dose for Adults ≥ 50 kg	Usual Dose for Adults < 50 kg ¹	Cost per Unit	Cost for 30 Days ²	Comments ³
Acetaminophen ⁴ (Tylenol, Datril, etc)	650 mg every 4 hours or 975 mg every 6 hours	10-15 mg/kg every 4 hours (oral); 15-20 mg/kg every 4 hours (rectal)	\$0.02/325 mg (oral) OTC; \$0.71/650 mg (rectal) OTC	\$7.20 (oral); \$127.80 (rectal)	Not an NSAID because it lacks peripheral anti-inflammatory effects. Equivalent to aspirin as analgesic and antipyretic agent. Limit dose to 3-4 g/d and to 2 g/d in older patients and those with liver disease. Be mindful of multiple sources of acetaminophen as in combination analgesics, cold remedies and sleep aids.
Aspirin ⁵	650 mg every 4 hours or 975 mg every 6 hours	10-15 mg/kg every 4 hours (oral); 15-20 mg/kg every 4 hours (rectal)	\$0.02/325 mg OTC; \$1.51/600 mg (rectal) OTC	\$7.20 (oral); \$271.80 (rectal)	Available also in enteric-coated form that is more slowly absorbed but better tolerated.
Celecoxib ⁴ (Celebrex)	200 mg once daily (osteoarthritis); 100-200 mg twice daily (RA)	100 mg once or twice daily	\$3.21/100 mg; \$5.26/200 mg	\$157.80 OA; \$315.60 RA	Cyclooxygenase-2 inhibitor. No antiplatelet effects. Lower doses for elderly who weigh < 50 kg. Lower incidence of endoscopic gastrointestinal ulceration. Not known if true lower incidence of gastrointestinal bleeding. Possible link to cardiovascular toxicity. Celecoxib is contraindicated in sulfonamide allergy.
Choline magnesium salicylate ⁶ (Trilasate, others)	1000-1500 mg three times daily	25 mg/kg three times daily	\$0.46/500 mg	\$124.20	Salicylates cause less gastrointestinal distress and kidney impairment than NSAIDs but are probably less effective in pain management than NSAIDs.
Diclofenac (Voltaren, Cataflam, others)	50-75 mg orally two or three times daily; 1% gel 2-4 g four times daily; 1.3% patch two times daily		\$1.56/50 mg; \$1.77/75 mg	\$140.40; \$159.30	May impose higher risk of hepatotoxicity. Enteric-coated product; slow onset. Topical formulations may result in fewer side effects than oral formulations.
Diclofenac sustained release (Voltaren-XR, others)	100-200 mg once daily		\$2.81/100 mg	\$168.60	
Diflunisal ⁷ (Dolobid, others)	500 mg every 12 hours		\$1.55/500 mg	\$93.00	Fluorinated acetylsalicylic acid derivative.
Etodolac (Lodine, others)	200-400 mg every 6-8 hours		\$1.47/400 mg	\$176.40	
Fenoprofen calcium (Nalfon, others)	300-600 mg every 6 hours		\$1.78/600 mg	\$213.60	Perhaps more side effects than others, including tubulointerstitial nephritis.
Flurbiprofen (Ansaid)	50-100 mg three or four times daily		\$0.79/50 mg; \$1.19/100 mg	\$94.80; \$142.80	Adverse gastrointestinal effects may be more common among elderly.
Ibuprofen (Motrin, Advil, Rufen, others)	400-800 mg every 6 hours	10 mg/kg every 6-8 hours	\$0.28/600 mg Rx; \$0.05/200 mg OTC	\$33.60; \$9.00	Relatively well tolerated and inexpensive.
Indomethacin (Indocin, Indometh, others)	25-50 mg two to four times daily		\$0.38/25 mg; \$0.64/50 mg	\$45.60; \$76.80	Higher incidence of dose-related toxic effects, especially gastrointestinal and bone marrow effects.
Ketoprofen (Orudis, Oruvail, others)	25-75 mg every 6-8 hours (max 300 mg/d)		\$0.96/50 mg Rx; \$1.07/75 mg Rx; \$0.09/12.5 mg OTC	\$172.80; \$128.40; \$16.20	Lower doses for elderly.

(continued)

Table 5-3. Acetaminophen, COX-2 inhibitors, and useful nonsteroidal anti-inflammatory drugs. (continued)

Drug	Usual Dose for Adults ≥ 50 kg	Usual Dose for Adults < 50 kg ¹	Cost per Unit	Cost for 30 Days ²	Comments ³
Ketorolac tromethamine (Toradol)	10 mg every 4–6 hours to a maximum of 40 mg/d orally		\$0.93/10 mg	Not recommended	Short-term use (< 5 days) only; otherwise, increased risk of gastrointestinal side effects.
Ketorolac tromethamine ⁸ (Toradol)	60 mg IM or 30 mg IV initially, then 30 mg every 6 hours IM or IV		\$1.50/30 mg	Not recommended	Intramuscular or intravenous NSAID as alternative to opioid. Lower doses for elderly. Short-term use (< 5 days) only.
Magnesium salicylate (various)	467–934 mg every 6 hours		\$0.23/467 mg OTC	\$9.60	
Meclofenamate sodium ⁹ (Meclomen)	50–100 mg every 6 hours		\$4.35/100 mg	\$522.00	Diarrhea more common.
Mefenamic acid (Ponstel)	250 mg every 6 hours		\$17.41/250 mg	\$2089.20	
Nabumetone (Relafen)	500–1000 mg once daily (max dose 2000 mg/d)		\$1.38/500 mg; \$1.63/750 mg	\$97.80	May be less ulcerogenic than ibuprofen, but overall side effects may not be less.
Naproxen (Naprosyn, Anaprox, Aleve [OTC], others)	250–500 mg every 6–8 hours	5 mg/kg every 8 hours	\$1.29/500 mg Rx; \$0.08/220 mg OTC	\$154.80; \$7.20 OTC	Generally well tolerated. Lower doses for elderly.
Oxaprozin (Daypro, others)	600–1200 mg once daily		\$1.50/600 mg	\$90.00	Similar to ibuprofen. May cause rash, pruritus, photosensitivity.
Piroxicam (Feldene, others)	20 mg daily		\$2.64/20 mg	\$79.20	Not recommended in the elderly due to high adverse drug reaction rate. Single daily dose convenient. Long half-life. May cause higher rate of gastrointestinal bleeding and dermatologic side effects.
Sodium salicylate	325–650 mg every 3–4 hours		\$0.08/650 mg OTC	\$19.20	
Sulindac (Clinoril, others)	150–200 mg twice daily		\$0.98/150 mg; \$1.21/200 mg	\$58.80; \$72.60	May cause higher rate of gastrointestinal bleeding. May have less nephrotoxic potential.
Tolmetin (Tolectin)	200–600 mg four times daily		\$0.75/200 mg; \$3.22/600 mg	\$90.00; \$386.40	Perhaps more side effects than others, including anaphylactic reactions.

¹Acetaminophen and NSAID dosages for adults weighing < 50 kg should be adjusted for weight.

²Average wholesale price (AWP, for AB-rated generic when available) for quantity listed. Source: *Red Book Online*, 2012, Thomson Reuters (Healthcare) Inc. AWP may not accurately represent the actual pharmacy cost because wide contractual variations exist among institutions.

³The adverse effects of headache, tinnitus, dizziness, confusion, rashes, anorexia, nausea, vomiting, gastrointestinal bleeding, diarrhea, nephrotoxicity, visual disturbances, etc, can occur with any of these drugs. Tolerance and efficacy are subject to great individual variations among patients. Note: All NSAIDs can increase serum lithium levels.

⁴Acetaminophen and celecoxib lack antiplatelet effects.

⁵May inhibit platelet aggregation for 1 week or more and may cause bleeding.

⁶May have minimal antiplatelet activity.

⁷Administration with antacids may decrease absorption.

⁸Has the same gastrointestinal toxicities as oral NSAIDs.

⁹Coombs-positive autoimmune hemolytic anemia has been associated with prolonged use.

COX-2, cyclooxygenase-2; OA, osteoarthritis; RA, rheumatoid arthritis; OTC, over-the-counter; Rx, prescription;

Data from Jacox AK et al. *Management of Cancer Pain: Quick Reference Guide for Clinicians No. 9*. AHCPR Publication No. 94-0593. Rockville, MD: Agency for Health Care Policy and Research, Public Health Service, U.S. Department of Health and Human Services. March 1994.

► Opioid Medications

For many patients, opioids are the mainstay of pain management. Opioids are appropriate for severe pain due to any cause, including neuropathic pain. Opioid medications are listed in Table 5–4. Full opioid agonists such as morphine, hydromorphone, oxycodone, methadone, fentanyl, hydrocodone, and codeine are used most commonly. Hydrocodone and codeine are typically combined with acetaminophen or an NSAID, although the US Food and Drug Administration will be restricting the amounts of acetaminophen in these combinations due to the risk for toxicity. **Short-acting formulations** of oral morphine sulfate (starting dosage 4–8 mg orally every 3–4 hours), hydro-morphine (1–2 mg orally every 3–4 hours), or oxycodone (5 mg orally every 3–4 hours) are useful for acute pain not controlled with other analgesics. These same oral medications, or oral transmucosal fentanyl (200 mcg orally dissolved in mouth) or buccal fentanyl (100 mcg dissolved in the mouth), can be used for “rescue” treatment for patients experiencing pain that breaks through long-acting medications. For chronic stable pain, **long-acting medications** are preferred, such as oral sustained-release morphine (one to three times a day), oxycodone (two or three times a day), or methadone (three or four times a day). Methadone is inexpensive, available in a liquid formulation, and may have added efficacy for neuropathic pain. However, equianalgesic dosing is complex because it varies with the patient’s opioid dose and caution must be used at higher methadone doses (generally > 100–150 mg/d) because of the risk of QT prolongation. Consultation with a palliative medicine or pain specialist may be appropriate.

Transdermal fentanyl is appropriate for patients already tolerant to other opioids at a dose equivalent to at least 60 mg/d of oral morphine (equivalent to transdermal fentanyl 25 mcg/h every 72 hours) and therefore should not be used in the postoperative setting or be the first opioid used. Medications that inhibit cytochrome P450 3A4, such as ritonavir, ketoconazole, itraconazole, troleandomycin, clarithromycin, nelfinavir, nefazodone, amiodarone, amprenavir, aprepitant, diltiazem, erythromycin, fluconazole, fosamprenavir, and verapamil, and grapefruit juice can cause increased levels and duration of transdermal fentanyl. Since the fentanyl patch can require 24–48 hours to achieve pharmacologic “steady state,” patients should be given short-acting opioids while awaiting the full analgesic effect of transdermal fentanyl, and changes in dose of the fentanyl patch should be made no more frequently than every 6 days. For complete information about prescribing guidelines for the fentanyl patch see <http://www.duragesic.com/prescribing-information.html>.

A useful technique for opioid management of chronic pain is equianalgesic dosing (Table 5–4). The dosages of any full opioid agonists used to control pain can be converted into an equivalent dose of any other opioid. In this way, 24-hour opioid requirements and dosing regimens established using shorter-acting opioid medications can be converted into equivalent dosages of long-acting medications or formulations. Cross-tolerance is often incomplete, however, so less than the full calculated equianalgesic dosage is generally administered initially when switching between

opioid formulations. Equianalgesic dosing for methadone is more complex and varies by dose and duration of use.

While some clinicians and patients inexperienced with the management of severe chronic pain may feel more comfortable with combined nonopioid-opioid agents, full agonist opioids are typically a better choice in patients with severe pain because the dose of opioid is not limited by the toxicities of the acetaminophen, aspirin, or NSAID component of combination preparations. There is no maximal allowable or effective dose for full opioid agonists. The dose should be increased to whatever is necessary to relieve pain, remembering that certain types of pain, such as neuropathic pain, may respond better to agents other than opioids, or to combinations of opioids with co-analgesics (see below).

While physiologic tolerance is possible with opioids, failure of a previously effective opioid dose to adequately relieve pain is usually due to worsening of the underlying condition causing pain, such as growth of a tumor or a new metastasis in a patient with cancer. In this case, for moderate unrelieved pain, the dose of opioid can be increased by 25–50%. For severe unrelieved pain, a dose increase of 50–100% may be appropriate. The frequency of dosing should be adjusted so that pain control is continuous. Long-term dosing may then be adjusted by adding the average daily amount of short-acting opioid necessary for breakthrough pain over the preceding 72–96 hours to the long-acting medication dose. In establishing or reestablishing adequate dosing, frequent reassessment of the patient’s pain and medication side effects is necessary.

As opioids are titrated upwards, increasing difficulty with the side effects can be expected. Constipation is common at any dose of opioid, and tolerance to this side effect does not develop over time. Opioid-induced constipation should be anticipated and prevented in all patients (see below).

Sedation can be expected with opioids, although tolerance to this effect typically develops within 24–72 hours at a stable dose. Sedation typically appears well before significant respiratory depression. If treatment for sedation is desired, dextroamphetamine (2.5–7.5 mg orally at 8 AM and noon) or methylphenidate (2.5–10 mg orally at 8 AM and noon) may be helpful. Caffeinated beverages can also ameliorate minor opioid sedation.

Although sedation is more common, patients may experience euphoria when first taking opioids or when the dose is increased. However, tolerance to sedation or euphoria typically develops after a few days at a stable dose. Opioid-induced neurotoxicity—characterized by myoclonus, followed by hyperalgesia, delirium with hallucinosis, and seizures—may develop in patients who take high doses of opioids for a prolonged period. These symptoms may resolve after lowering the dose or switching opioids, especially to ones like fentanyl or methadone that do not have active metabolites. While waiting for the level of the offending opioid to fall, low doses of lorazepam, baclofen, or gabapentin may be helpful for treating myoclonus; haloperidol may be useful for treating delirium. Avoiding or correcting dehydration may be helpful for prevention and treatment of opioid-induced neurotoxicity.

Table 5-4. Useful opioid agonist analgesics.

Drug	Approximate Equianalgesic Dose (compared to morphine 30 mg orally or 10 mg IV/SC) ¹		Usual Starting Dose				Potential Advantages	Potential Disadvantages
			Adults ≥ 50 kg Body Weight		Adults < 50 kg Body Weight			
	Oral	Parenteral	Oral	Parenteral	Oral	Parenteral		
Opioid agonists²								
Buprenorphine transdermal	Not available	Not available	Not available orally. Transdermal doses available: 5, 10, and 20 mcg/h Initiate 5 mcg/h patch for opioid-naïve patients (may currently be using non-opioid analgesics) \$60.00/10 mcg/h	Not available	Not available	Not available	7-day analgesia, may be initiated in opioid-naïve patients. Can titrate up dose after 72 hours.	QT prolongation
Fentanyl	Not available	100 mcg every hour	Not available	50–100 mcg IV/IM every hour or 0.5–1.5 mcg/kg/h IV infusion \$0.41/100 mcg	Not available	0.5–1 mcg/kg IV every 1–4 hours or 1–2 mcg/kg IV × 1, then 0.5–1 mcg/kg/h infusion	Possibly less neuroexcitatory effects, including in kidney failure.	
Fentanyl oral transmucosal (Actiq); buccal (Fentora)	Not available	Not available	200 mcg transmucosal; 100 mcg buccal; \$18.80/200 mcg transmucosal; \$36.13/200 mcg buccal	Not available	Not available	Not available	For pain breaking through long-acting opioid medication.	Transmucosal and buccal formulations are not bioequivalent; there is higher bioavailability of buccal formulation.

Fentanyl transdermal	Conversion to fentanyl patch is based on total daily dose of oral morphine ² : morphine 60–134 mg/d orally = fentanyl 25 mcg/h patch; morphine 135–224 mg/d orally = fentanyl 50 mcg/h patch; morphine 225–314 mg/day orally = fentanyl 75 mcg/h patch; and morphine 315–404 mg/d orally = fentanyl 100 mcg/h patch	Not available	Not available orally 12.5–25 mcg/h patch every 72 hours; \$14.42/25 mcg/h	Not available	12.5–25 mcg/h patch every 72 hours	Not available	Stable medication blood levels.	Not for use in opioid-naïve patients.
Hydromorphone ³ (Dilaudid)	7.5 mg every 3–4 hours	1.5 mg every 3–4 hours	1–2 mg every 3–4 hours; \$0.48/2 mg	1.5 mg every 3–4 hours; \$1.14/2 mg	0.06 mg/every 3–4 hours	0.015 mg/kg every 3–4 hours	Similar to morphine. Available in injectable high-potency preparation, rectal suppository.	Short duration.
Levorphanol (Levo-Dromoran)	4 mg every 6–8 hours	2 mg every 6–8 hours	4 mg every 6–8 hours; \$1.07/2 mg	Not available	0.04 mg/kg every 6–8 hours	Not available	Longer-acting than morphine sulfate.	
Meperidine ⁴ (Demerol)	300 mg every 2–3 hours; normal dose 50–150 mg every 3–4 hours	100 mg every 3 hours	Not recommended	100 mg every 3 hours; \$1.32/100 mg	Not recommended	0.75 mg/kg every 2–3 hours	Use only when single dose, short duration analgesia is needed as for outpatient procedures like colonoscopy. Not recommended for chronic pain or for repeated dosing.	Short duration. Normeperidine metabolite accumulates in kidney failure and other situations, and in high concentrations may cause irritability and seizures.
Methadone (Dolophine, others)	10–20 mg every 6–8 hours (when converting from < 100 mg long-term daily oral morphine ²)	5–10 mg every 6–8 hours	5–20 mg every 6–8 hours; \$0.15/10 mg	2.5–10 mg every 6–8 hours; \$8.60/10 mg	0.2 mg/kg every 6–8 hours	0.1 mg/kg every 6–8 hours	Somewhat longer-acting than morphine. Useful in cases of intolerance to morphine. May be particularly useful for neuropathic pain. Available in liquid formulation.	Analgesic duration shorter than plasma duration. May accumulate, requiring close monitoring during first weeks of treatment. Equianalgesic ratios vary with opioid dose.

(continued)

Table 5-4. Useful opioid agonist analgesics. (continued)

Drug	Approximate Equianalgesic Dose (compared to morphine 30 mg orally or 10 mg IV/SC) ¹		Usual Starting Dose				Potential Advantages	Potential Disadvantages
			Adults ≥ 50 kg Body Weight		Adults < 50 kg Body Weight			
	Oral	Parenteral	Oral	Parenteral	Oral	Parenteral		
Morphine ³ immediate release (Morphine sulfate tablets, Roxanol liquid)	30 mg every 3-4 hours (repeat around-the-clock dosing); 60 mg every 3-4 hours (single or intermittent dosing)	10 mg every 3-4 hours	4-8 mg every 3-4 hours; Used for breakthrough pain in patients already taking controlled-release preparations \$0.18/15 mg tab; 0.69/20 mg liquid	10 mg every 3-4 hours; \$1.57/10 mg	0.3 mg/kg every 3-4 hours	0.1 mg/kg every 3-4 hours	Standard of comparison; multiple dosage forms available.	No unique problems when compared with other opioids.
Morphine controlled-release ³ (MS Contin, Oramorph)	90-120 mg every 12 hours	Not available	15-60 mg every 12 hours; \$1.69/30 mg	Not available	Not available	Not available		
Morphine extended release (Kadian, Avinza)	180-240 mg every 24 hours	Not available	20-30 mg every 24 hours; \$6.32/30 mg	Not available	Not available	Not available	Once-daily dosing possible.	
Oxycodone (Roxicodone, OxyIR)	20-30 mg every 3-4 hours	Not available	5-10 mg every 3-4 hours; \$0.48/5 mg	Not available	0.2 mg/kg every 3-4 hours	Not available	Similar to morphine.	
Oxycodone controlled release (Oxycontin)	40 mg every 12 hours	Not available	20-40 mg every 12 hours; \$4.42/20 mg					
Oxymorphone ⁶ oral, immediate release (Opana)	10 mg every 3-4 hours	Not available	5-10 mg every 3-4 hours; \$2.95/5 mg	Not available				New formulation with less known about equianalgesic dosing.
Oxymorphone ⁶ extended release (Opana ER)	30-40 mg every 12 hours	Not available	15-30 mg every 12 hours; \$4.35/10 mg	Not available				New formulation with less known about equianalgesic dosing.

Combination Opioid-NSAID Preparations								
Codeine ^{7,8} (with aspirin or acetaminophen) ⁹	180-200 mg every 3-4 hours; commonly available dose in combination with acetaminophen, 15-60 mg every 4-6 hours	130 mg every 3-4 hours	60 mg every 4-6 hours; \$0.64/60 mg	60 mg every 2 hours (IM/SC); \$3.05/60 mg	0.5-1 mg/kg every 3-4 hours	Not recommended	Similar to morphine.	Closely monitor for efficacy as patients vary in their ability to convert the prodrug codeine to morphine.
Hydrocodone ⁶ (in Lorcet, Lortab, Vicodin, others) ⁹	30 mg every 3-4 hours	Not available	10 mg every 3-4 hours; \$0.45/5 mg	Not available	0.2 mg/kg every 3-4 hours	Not available		Combination with acetaminophen limits dosage titration.
Oxycodone ⁷ (in Percocet, Percodan, Tylox, others) ⁹	30 mg every 3-4 hours	Not available	10 mg every 3-4 hours; \$0.52/5 mg	Not available	0.2 mg/kg every 3-4 hours	Not available	Similar to morphine.	Combination with acetaminophen and aspirin limits dosage titration.

¹Published tables vary in the suggested doses that are equianalgesic to morphine. Clinical response is the criterion that must be applied for each patient; titration to clinical efficacy is necessary. Because there is not complete cross-tolerance among these drugs, it is usually necessary to use a lower than equianalgesic dose initially when changing drugs and to retitrate to response.

²Conversion is conservative; therefore, do not use these equianalgesic doses for converting back from fentanyl patch to other opioids because they may lead to inadvertent overdose. Patients may require breakthrough doses of short-acting opioids during conversion to transdermal fentanyl.

³**Caution:** For morphine, hydromorphone, and oxymorphone, rectal administration is an alternative route for patients unable to take oral medications. Equianalgesic doses may differ from oral and parenteral doses. A short-acting opioid should normally be used for initial therapy.

⁴Not recommended for chronic pain. Doses listed are for brief therapy of acute pain only. Switch to another opioid for long-term therapy.

⁵Methadone conversion varies depending on the equivalent total daily dose of morphine. Consult with a pain management or palliative care expert for conversion.

⁶**Caution:** Recommended doses do not apply for adult patients with kidney or hepatic insufficiency or other conditions affecting drug metabolism.

⁷**Caution:** Doses of aspirin and acetaminophen in combination products must also be adjusted to the patient's body weight.

⁸**Caution:** Doses of codeine above 60 mg often are not appropriate because of diminishing incremental analgesia with increasing doses but continually increasing nausea, constipation, and other side effects.

⁹**Caution:** Monitor total acetaminophen dose carefully, including any OTC use. Total acetaminophen dose maximum 3-4 g/d. If liver impairment or heavy alcohol use, maximum is 2 g/d. Available dosing formulations of these combination medications are being adjusted to reflect increased caution about acetaminophen toxicity. Acetaminophen doses in a single combination tablet or capsule will be limited to no more than 325 mg.

Note: Average wholesale price (AWP, generic when available) for quantity listed. Source: *Red Book Online*, 2012, Thomson Reuters (Healthcare) Inc. AWP may not accurately represent the actual pharmacy cost because wide contractual variations exist among institutions.

Data from Jacox AK et al. *Management of Cancer Pain: Quick Reference Guide for Clinicians No. 9*. AHCPR Publication No. 94-0593. Rockville, MD. Agency for Health Care Policy and Research, Public Health Service, U.S. Department of Health and Human Services. March 1994, and from Erstad BL. A rational approach to the management of acute pain states. *Hosp Formul* 1994;29 (8 Part 2):586.

Nausea due to opioids may occur with initiation of therapy and resolve after a few days. Severe or persistent nausea can be treated by switching opioids or by giving haloperidol, 0.5–4 mg orally, subcutaneously, or intravenously every 6 hours; prochlorperazine, 10 mg orally or intravenously or 25 mg rectally every 6 hours; or metoclopramide, 5–20 mg orally, subcutaneously, or intravenously before meals and bed; or ondansetron, 4–8 mg orally or intravenously every 6 hours. Notably, unrelieved constipation may be a more common cause of nausea in the setting of opioid use than opioid-induced nausea.

Although clinicians may worry about respiratory depression with opioids, this side effect is uncommon when a low dose is given initially and titrated upward slowly. Patients at particular risk for respiratory depression include those with chronic obstructive pulmonary disease, obstructive sleep apnea, and baseline CO₂ retention, those with liver or kidney or combined liver-kidney failure, and those with adrenal insufficiency or frank myxedema. Yet, even patients with severe pulmonary disease can tolerate low-dose opioids, but they should be monitored carefully. Clinicians should not allow concerns about respiratory depression to prevent them from treating pain adequately.

True allergy (with urticaria) to opioids is rare. More commonly, patients will describe intolerance due to side effects such as nausea, pruritus, or urinary retention in response to a particular opioid. If such symptoms develop, they can usually be relieved by lowering the dose or switching to another opioid.

► Medications for Neuropathic Pain

It is essential when taking a patient's history to listen for descriptions such as burning, shooting, pins and needles, or electricity, and for pain associated with numbness. Such a history suggests neuropathic pain, which is treated with some medications not typically used for other types of pain. While opioids are effective for neuropathic pain, a number of nonopioid medications have been found to be effective in randomized trials (Table 5–5). Successful management of neuropathic pain often requires the use of more than one effective medication.

The tricyclic antidepressants (TCAs) are good first-line therapy. Desipramine, 10–200 mg/d orally, and nortriptyline, 10–150 mg/d orally, are good first choices because they cause less orthostatic hypotension and have fewer anticholinergic effects than amitriptyline. Start with a low dosage (10–25 mg orally daily) and titrate upward every 4 or 5 days.

The calcium channel α 2- δ ligands gabapentin and pregabalin are also considered first-line therapy for neuropathic pain. Both medications can cause sedation, dizziness, ataxia, and gastrointestinal side effects but have no significant drug interactions. Both drugs require dose adjustments in patients with kidney dysfunction. Gabapentin should be started at low dosages of 100–300 mg orally three times a day and titrated upward by 300 mg/d every 4 or 5 days with a typical effective dose of 1800–3600 mg/d. Pregabalin should be started at 150 mg/d in two or three divided doses. If necessary, the dose of pregabalin can be titrated upward to 300–600 mg/d in two or three divided

Table 5–5. Pharmacologic management of neuropathic pain.

Drug ¹	Starting Dose	Typical Dose
Antidepressants²		
Nortriptyline	10 mg orally at bedtime	10–150 mg orally at bedtime
Desipramine	10 mg orally at bedtime	10–200 mg orally at bedtime
Calcium-channel α2-δ ligands		
Gabapentin ³	100–300 mg orally once to three times daily	300–1200 mg orally three times daily
Pregabalin ⁴	50 mg orally three times daily	100 mg orally three times daily
Selective serotonin norepinephrine reuptake inhibitors		
Duloxetine	60 mg orally daily or 20 mg orally twice daily in elders	60 mg orally daily
Venlafaxine ⁵	75 mg orally daily divided into two or three doses	150–225 mg orally daily divided into two or three doses
Opioids	(see Table 5-4)	(see Table 5-4)
Other medications		
Lidocaine transdermal	5% patch applied daily, for a maximum of 12 hours	1–3 patches applied daily for a maximum of 12 hours
Tramadol hydrochloride	50 mg orally four times daily	100 mg orally two to four times daily

¹Begin at the starting dose and titrate up every 4 or 5 days. Within each category, drugs listed in order of prescribing preference.

²Begin with a low dose. Pain relief may be achieved at doses below antidepressant doses, thereby minimizing adverse side effects.

³Common side effects include nausea, somnolence, and dizziness. Take medication on a full stomach. Do not combine with serotonin or norepinephrine uptake inhibitors, or with tricyclic antidepressants.

⁴Common side effects include dizziness, somnolence, peripheral edema, and weight gain. Must adjust dose for kidney impairment.

⁵Caution: Can cause hypertension and ECG changes. Obtain baseline ECG and monitor.

doses. Both drugs are relatively safe in accidental overdose and may be preferred over TCAs for a patient with a history of congestive heart failure or arrhythmia or if there is a risk of suicide. Prescribing gabapentin and morphine for neuropathic pain may provide better analgesia at lower doses than if each is used as a single agent.

The selective serotonin norepinephrine reuptake inhibitors (SSNRIs), duloxetine (60 mg/d or 20 mg twice daily in elders), and venlafaxine (150–225 mg/d) are also considered first-line treatments for neuropathic pain. Patients should be advised to take duloxetine on a full stomach because nausea is a common side effect. Duloxetine should not be combined with other serotonin or norepinephrine uptake inhibitors, but it can be combined with gabapentin or pregabalin. Because venlafaxine can cause hypertension and induce ECG changes, patients with cardiovascular risk factors should be carefully monitored when starting this drug.

Other medications effective for neuropathic pain include tramadol and the 5% lidocaine patch. Tramadol should be started at 50 mg orally daily and can be titrated up to 100 mg orally four times daily. The 5% lidocaine patch (1–4 patches at a time) is effective in postherpetic neuralgia and may be effective in other types of localized neuropathic pain. A new patch is applied to the painful region daily for up to 12 hours daily.

▶ Adjuvant Pain Medications & Treatments

If pain cannot be controlled without uncomfortable medication side effects, clinicians should consider using lower doses of multiple medications, as is done commonly for neuropathic pain, rather than larger doses of one or two medications. For metastatic bone pain, the anti-inflammatory effect of NSAIDs can be particularly helpful. Radiation therapy and bisphosphonates may also relieve bone pain. For some patients, a nerve block can provide substantial relief, such as a celiac plexus block for pain from pancreatic cancer. Intrathecal pumps may be useful for patients with severe pain responsive to opioids but who require such large doses that systemic side effects (eg, sedation and constipation) become limiting. There is some evidence for the use of cannabinoids as analgesics.

Corticosteroids such as dexamethasone or prednisone can be helpful for patients with headache due to increased intracranial pressure, pain from spinal cord compression, metastatic bone pain, and neuropathic pain due to invasion or infiltration of nerves by tumor. Because of the side effects of long-term corticosteroid administration, they are most appropriate in patients with end-stage disease. Low-dose intravenous or oral ketamine has been used successfully for neuropathic and other pain syndromes refractory to opioids. Haloperidol and benzodiazepines may be used prophylactically to minimize ketamine's psychotomimetic side effects.

NONPHARMACOLOGIC TREATMENTS

Nonpharmacologic therapies are valuable in treating pain. Hot or cold packs, massage, and physical therapy can be

helpful for musculoskeletal pain. Similarly, biofeedback, acupuncture, chiropractic, meditation, music therapy, cognitive behavioral therapy, guided imagery, cognitive distraction, and framing may be of help in treating pain. Because mood and psychological issues play an important role in the patient's perception of and response to pain, psychotherapy, support groups, prayer, and pastoral counseling can also help in the management of pain. Major depression, which may be instigated by chronic pain or may alter the response to pain, should be treated aggressively.

▶ When to Refer

- Pain not responding to opioids at typical doses.
- Neuropathic pain not responding to first-line treatments.
- Complex methadone management issues.
- Intolerable side effects from oral opioids.
- Severe pain from bone metastases.
- For a surgical or anesthesia-based procedure, intrathecal pump, or nerve block.

▶ When to Admit

- Patients should be hospitalized for severe exacerbation of pain that is not responsive to previous stable oral opioid around-the-clock plus breakthrough doses.
- Patients whose pain is so severe that they cannot be cared for at home should be hospitalized.
- Uncontrollable side effects from opioids, including nausea, vomiting, and altered mental status, should prompt hospitalization.

Bengochea I et al. Opioid use at the end of life and survival in a Hospital at Home unit. *J Palliat Med.* 2010 Sep;13(9):1079–83. [PMID: 20799903]

Brewer AR et al. Gastrointestinal tolerability of diclofenac epolamine topical patch 1.3%: a pooled analysis of 14 clinical studies. *Postgrad Med.* 2011 Jul;123(4):168–76. [PMID: 21681001]

Dworkin RH et al. Recommendations for the pharmacological management of neuropathic pain: an overview and literature update. *Mayo Clin Proc.* 2010 Mar;85(3 Suppl):S3–14. [PMID: 20194146]

Krantz MJ et al. QTc interval screening in methadone treatment. *Ann Intern Med.* 2009 Mar 17;150(6):387–95. [PMID: 19153406]

Martín-Sánchez E et al. Systematic review and meta-analysis of cannabis treatment for chronic pain. *Pain Med.* 2009 Nov; 10(8):1353–68. [PMID: 19732371]

PALLIATION OF OTHER COMMON SYMPTOMS

DYSPNEA

Dyspnea is the subjective experience of difficulty breathing and may be characterized by patients as tightness in the chest, shortness of breath, or a feeling of suffocation. Up to 50% of terminally ill patients may experience severe dyspnea.

Treatment of dyspnea is usually first directed at the cause (see Chapter 9). At the end of life, dyspnea is often treated nonspecifically with opioids. **Immediate-release morphine** given orally (2–4 mg every 4 hours) or intravenously (1–2 mg every 4 hours) treats dyspnea effectively. Doses are typically lower than would be necessary for the relief of moderate pain. **Sustained-release morphine** given at 10 mg daily appears to be safe and effective for most patients with dyspnea. Supplemental oxygen may be useful for the dyspneic patient *who is hypoxic*. However, a nasal cannula and face mask are sometimes not well tolerated, and fresh air from a window or fan may provide relief. Judicious use of noninvasive ventilation as well as nonpharmacologic relaxation techniques such as meditation and guided imagery may be beneficial for some patients. Benzodiazepines may be useful adjuncts for treatment of dyspnea.

NAUSEA & VOMITING

Nausea and vomiting are common and distressing symptoms. As with pain, the management of nausea may be maximized by regular dosing. An understanding of the four major inputs to the vomiting center may help direct treatment (see Chapter 15).

Vomiting associated with a particular opioid may be relieved by dose reduction or substitution with an equianalgesic dose of another opioid or a sustained-release formulation. In addition to the other dopamine receptor antagonist antiemetics listed in Table 15–2 that block the trigger zone, haloperidol (0.5–4 mg orally every 4–6 hours) is commonly used empirically.

Vomiting may be due to stimulation of peripheral afferent nerves from the gut. Offering patients small amounts of food only when they are hungry may prevent nausea and vomiting. Nasogastric suction may provide rapid, short-term relief for vomiting associated with constipation, gastroparesis, or gastric outlet obstruction, with the addition of laxatives; prokinetic agents (only in the setting of partial not complete obstruction), such as metoclopramide (5–20 mg orally or intravenously four times a day); scopolamine (1.5-mg patch every 3 days); and high-dose corticosteroids as more definitive treatment. Nausea often requires treatment with more than one agent; when it is refractory to other treatments or due to increased intracranial pressure, it may respond to high-dose corticosteroids (eg, dexamethasone, 20 mg orally or intravenously daily in divided doses).

Vomiting due to disturbance of the vestibular apparatus may be treated with anticholinergic and antihistaminic agents (including diphenhydramine, 25 mg orally or intravenously every 8 hours, or scopolamine, 1.5-mg patch every 3 days).

Benzodiazepines can be effective in preventing the anticipatory nausea associated with chemotherapy but are otherwise not indicated for nausea and vomiting. Finally, many patients find medical marijuana or dronabinol (2.5–20 mg orally every 4–6 hours) helpful in the management of nausea and vomiting.

CONSTIPATION

Given the frequent use of opioids, poor dietary intake, and physical inactivity, constipation is a common problem in the dying. Clinicians must inquire about any difficulty with hard or infrequent stools. Constipation is an easily preventable and treatable cause of discomfort, distress, and nausea and vomiting (see Chapter 15).

Constipation may be prevented or relieved if patients can increase their activity and their intake of fluids. Simple considerations such as privacy, undisturbed toilet time, and a bedside commode rather than a bedpan may be important for some patients.

For patients taking opioids, anticipating and preventing constipation is important. A prophylactic bowel regimen with a stimulant laxative (bisacodyl or senna) should be started when opioid treatment is begun. Table 15–4 lists other agents (including polyethylene glycol) that can be added as needed. Docusate, a stool softener, adds little to senna in hospitalized patients, has a lingering bad taste that may suppress appetite, and thus is no longer recommended. Methylnaltrexone, a subcutaneous medication, is a peripherally acting mu-receptor antagonist and is available for severe, unrelieved, opioid-induced constipation.

FATIGUE

Fatigue is a distressing symptom and is the most common complaint among patients with cancer. Specific abnormalities that can contribute to fatigue, including anemia, hypothyroidism, hypogonadism, cognitive and functional impairment, and malnutrition, should be corrected. Pain, depression, and fatigue often coexist in patients with cancer; pain and depression should be managed adequately in the setting of patients with fatigue. Fatigue from medication adverse effects and polypharmacy is common and should be addressed. For nonspecific fatigue, exercise and physical rehabilitation may be most effective. Low-doses of psychostimulants, such as methylphenidate 5mg orally in the morning and afternoon or modafinil 200 mg orally in the morning, can be effective. Corticosteroids may have a short-term benefit and selective androgen receptor modulators are being investigated in the treatment of fatigue.

DELIRIUM & AGITATION

Many terminally ill patients die in a state of delirium—a disturbance of consciousness and a change in cognition that develops over a short time and is manifested by misinterpretations, illusions, hallucinations, disturbances in the sleep-wake cycle, psychomotor disturbances (eg, lethargy, restlessness), and mood disturbance (eg, fear, anxiety). Delirium may be hyperactive, hypoactive, or mixed. Agitated delirium at the end of life has been called **terminal restlessness**.

Careful attention to patient safety and nonpharmacologic strategies to help the patient remain oriented (clocks, calendars, a familiar environment, reassurance and redirection from caregivers) may be sufficient to prevent or manage

minor delirium. Some delirious patients may be “pleasantly confused,” and a decision by the patient’s family and the clinician not to treat delirium may be justified.

More commonly, however, delirium at the end of life is distressing to patients and family and requires treatment. Delirium may interfere with the family’s ability to feel comforting to the patient and may prevent a patient from being able to recognize and report important symptoms. While there are many reversible causes of delirium (see Chapter 25), identifying and correcting the underlying cause at the end of life is often complex because a patient may have many possible causes. When the cause of delirium cannot be identified, treated, or corrected rapidly enough, delirium may be treated symptomatically with neuroleptics, such as haloperidol (1–10 mg orally, subcutaneously, intramuscularly, or intravenously twice or three times a day) or risperidone (1–3 mg orally twice a day). The benefits of neuroleptics in the treatment of agitation must be weighed carefully against potential harms, based on evidence showing an association between antipsychotic medications and increased mortality for older adults with dementia. The role of hydration as a treatment of delirium at the end of life is unclear. When delirium is refractory to treatment and remains intolerable, sedation may be required to provide relief and may be achieved rapidly with midazolam (0.5–5 mg/h subcutaneously or intravenously) or barbiturates.

Abernethy AP et al. Effect of palliative oxygen versus room air in relief of breathlessness in patients with refractory dyspnoea: a double-blind, randomised controlled trial. *Lancet*. 2010 Sep 4;376(9743):784–93. [PMID: 20816546]

Candy B et al. Laxatives or methylnaltrexone for the management of constipation in palliative care patients. *Cochrane Database Syst Rev*. 2011 Jan 19;(1):CD003448. [PMID: 21249653]

Currow DC et al. Once-daily opioids for chronic dyspnea: a dose increment and pharmacovigilance study. *J Pain Symptom Manage*. 2011 Sep;42(3):388–99. [PMID: 21458217]

Davidson PM et al. Update on the role of palliative oxygen. *Curr Opin Support Palliat Care*. 2011 Jun;5(2):87–91. [PMID: 21532348]

Elliott MW. Non-invasive ventilation: established and expanding roles. *Clin Med*. 2011 Apr;11(2):150–3. [PMID: 21526697]

Galanakis C et al. Assessing the role of hydration in delirium at the end of life. *Curr Opin Support Palliat Care*. 2011 Jun;5(2):169–73. [PMID: 21532351]

Iyer S et al. Opioid use patterns and health care resource utilization in patients prescribed opioid therapy with and without constipation. *Manag Care*. 2010 Mar;19(3):44–51. [PMID: 20361548]

Peuckmann V et al. Pharmacological treatments for fatigue associated with palliative care. *Cochrane Database Syst Rev*. 2010 Nov 10;(11):CD006788. [PMID: 21069692]

END-OF-LIFE CARE

In the United States, approximately 2.5 million people die each year. Caring for patients at the end of life is an important responsibility and a rewarding opportunity for clinicians. Clinicians focused on prolonging life must also recognize when life is ending in order to continue caring properly for their patients. From the medical perspective,

the end of life may be defined as that time when death—whether due to terminal illness or acute or chronic illness—is expected within weeks to months and can no longer be reasonably forestalled by medical intervention. End-of-life care refers to focusing care for those approaching death on the goals of relieving distressing symptoms and promoting quality of life rather than attempting to cure underlying disease. Unfortunately, most clinical practice guidelines devote scant attention to end-of-life care.

► Prognosis at the End of Life

Clinicians must help patients understand when they are approaching the end of life. This information influences patients’ treatment decisions and may change how they spend their remaining time but does not impact patient survival.

While certain diseases such as cancer are more amenable to prognostic estimates regarding the time course to death, the other common causes of mortality in the United States—including heart disease, stroke, chronic lung disease, and dementia—have more variable trajectories and difficult to predict prognoses. Even for patients with cancer, clinician estimates of prognosis are often inaccurate and generally overly optimistic. Nonetheless, clinical experience, epidemiologic data, guidelines from professional organizations (eg, the National Hospice and Palliative Care Organization), and computer modeling and prediction tools (eg, the Acute Physiology and Chronic Health Evaluation [APACHE] system, the Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatment [SUPPORT] model, or the Palliative Performance Scale) may be used to help patients identify the end period of their lives. Clinicians can also ask themselves “Would I be surprised if this patient died in the next year?” to determine whether a discussion of prognosis and focus on end-of-life care would be appropriate. If the answer is “no,” then the clinician should initiate a discussion. Recognizing that patients may have different levels of comfort with prognostic information, clinicians can introduce the topic by simply saying, “I have information about the likely time course of your illness. Would you like to talk about it?”

► Expectations About the End of Life

Patients’ experiences at the end of life are influenced by their expectations about how they will die and the meaning of death. Many people fear how they will die more than death itself. Patients report fears of dying in pain or of suffocation, of loss of control, indignity, isolation, and of being a burden to their families. All of these anxieties may be ameliorated with good supportive care provided by an attentive group of caretakers.

Death is often regarded by clinicians, patients, and families as a failure of medical science. This attitude can create or heighten a sense of guilt about the failure to prevent dying. Both the general public and clinicians often are complicit in denying death, treating dying persons merely as patients and death as an enemy to be battled furiously in

hospitals rather than as an inevitable outcome to be experienced as a part of life at home. As a result, approximately 75–80% of people in the United States die in hospitals or long-term care facilities.

Even when the clinician continues to pursue cure of potentially reversible disease, relieving suffering, providing support, and helping the patient prepare for death are foremost considerations. Patients at the end of life and their families identify a number of elements as important to quality end-of-life care: managing pain and other symptoms adequately, avoiding inappropriate prolongation of dying, preserving dignity, preparing for death, achieving a sense of control, relieving the burden on others, and strengthening relationships with loved ones.

► Communication & Care of the Patient

Caring for patients at the end of life requires the same skills clinicians use in other tasks of medical care: diagnosing treatable conditions, providing patient education, facilitating decision-making, and expressing understanding and caring. Communication skills are vitally important and can be improved through training. Higher-quality communication is associated with greater satisfaction and awareness of patient wishes. When needed, the use of a professional interpreter can facilitate clear communication and help broker cultural issues. In particular, clinicians must become proficient at delivering bad news and then dealing with its consequences (Table 5–6).

Three further obligations are central to the clinician's role at this time. First, he or she must work to identify, understand, and relieve suffering, which may include physical, psychological, social, or spiritual distress. Second, clinicians can serve as facilitators or catalysts for hope. While hope for a particular outcome may fade (such as cure of advanced cancer following exhaustive conventional and experimental treatments), it can be redefined by the patient's belief of what is *still* possible. Although expecting a "miraculous cure" may be simplistic and even harmful, hope for relief of pain, for reconciliation with loved ones, for discovery of meaning, and for spiritual transformation is realistic at the end of life. With such questions as "What is still possible now for you?" "When you look to the future, what do you hope for?" "What good might come of this?" clinicians can help patients uncover hope, explore meaningful and realistic goals, and develop strategies to realize them.

Table 5–6. Suggestions for the delivery of bad news.

- Prepare an appropriate place and time.
- Address basic information needs.
- Be direct; avoid jargon and euphemisms.
- Allow for silence and emotional ventilation.
- Assess and validate patient reactions.
- Respond to immediate discomforts and risks.
- Listen actively and express empathy.
- Achieve a common perception of the problem.
- Reassure about pain relief.
- Ensure basic follow-up and make specific plans for the future.

Finally, dying patients' feelings of isolation and fear demand that clinicians assert that they will care for the patient throughout the final stage of life. The promise of nonabandonment is perhaps the central principle of end-of-life care and is a clinician's pledge to an individual patient to serve as a caring partner, a resource for creative problem-solving and relief of suffering, a guide during uncertain times, and a witness to the patient's experiences—no matter what happens. Clinicians can say to a patient, "I will care for you whatever happens." Dying patients need their clinicians to offer their presence—not necessarily the ability to solve all problems but rather a commitment to recognize and receive the patients' difficulties and experiences with respect and empathy. At its best, the patient-clinician relationship can be a covenant of compassion and a recognition of common humanity.

► Caring for the Family

In caring for patients at the end of life, clinicians must appreciate the central role played by family, friends, and partners and often must deal with strong emotions of fear, anger, shame, sadness, and guilt experienced by those individuals. While significant others may support and comfort a patient at the end of life, the threatened loss of a loved one may also create or reveal dysfunctional or painful family dynamics. Furthermore, clinicians must be attuned to the potential impact of illness on the patient's family: substantial physical caregiving responsibilities and financial burdens as well as increased rates of anxiety, depression, chronic illness, and even mortality. Family caregivers, typically women, commonly provide the bulk of care for patients at the end of life, yet their work is often not acknowledged or compensated.

Clinicians can help families confront the imminent loss of a loved one (Table 5–7) and often must negotiate amid complex and changing family needs. Identifying a

Table 5–7. Clinician interventions helpful to families of dying patients.

- Excellent communication**, including clinician willingness to talk about death, timely and clear information, proactive guidance, listening, and empathic responses
- Advance care planning and clear decision-making**, including culturally sensitive communication, achieving consensus among family members and an understanding that surrogate decision-makers are trying to determine what the *patient* would have wanted, not what the surrogate would want
- Support for home care**, including orienting family members to the scope and details of family caregiving, providing clear direction about how to contact professional caregivers, and informing patients and families of the benefits of hospice care
- Empathy for family emotions and relationships**, including recognizing and validating common positive and negative feelings
- Attention to grief and bereavement**, including support for anticipatory grief and follow-up with the family after the patient's death

Data from Rabow MW et al. Supporting family caregivers at the end of life: "they don't know what they don't know." *JAMA*. 2004 Jan 28;291(4):483–91.

spokesperson for the family, conducting family meetings, allowing all to be heard, and providing time for consensus may help the clinician work effectively with the family.

► Clinician Self-Care

Many clinicians find caring for patients at the end of life to be one of the most rewarding aspects of practice. However, working with the dying requires tolerance of uncertainty, ambiguity, and existential challenges. Clinicians must recognize and respect their own limitations and attend to their own needs in order to avoid being overburdened, overly distressed, or emotionally depleted.

- Candy B et al. Interventions for supporting informal caregivers of patients in the terminal phase of a disease. *Cochrane Database Syst Rev*. 2011 Jun 15;(6):CD007617. [PMID: 21678368]
- Goelz T et al. Specific training program improves oncologists' palliative care communication skills in a randomized controlled trial. *J Clin Oncol*. 2011 Sep 1;29(25):3402–7. [PMID: 21825268]
- Hudson PL et al. A systematic review of psychosocial interventions for family carers of palliative care patients. *BMC Palliat Care*. 2010 Aug 5;9:17. [PMID: 20687960]
- Kearney MK et al. Self-care of physicians caring for patients at the end of life: “Being connected . . . a key to my survival”. *JAMA*. 2009 Mar 18;301(11):1155–64. [PMID: 19293416]
- Moss AH et al. Prognostic significance of the “surprise” question in cancer patients. *J Palliat Med*. 2010 Jul;13(7):837–40. [PMID: 20636154]
- Pantilat SZ. Communicating with seriously ill patients: better words to say. *JAMA*. 2009 Mar 25;301(12):1279–81. [PMID: 19318656]
- Sinclair S. Impact of death and dying on the personal lives and practices of palliative and hospice care professionals. *CMAJ*. 2011 Feb 8;183(2):180–7. [PMID: 21135081]
- Temel JS et al. Longitudinal perceptions of prognosis and goals of therapy in patients with metastatic non-small-cell lung cancer: results of a randomized study of early palliative care. *J Clin Oncol*. 2011 Jun 10;29(17):2319–26. [PMID: 21555700]
- Yun YH et al. Impact of awareness of terminal illness and use of palliative care or intensive care unit on the survival of terminally ill patients with cancer: prospective cohort study. *J Clin Oncol*. 2011 Jun 20;29(18):2474–80. [PMID: 21576638]
- Zhang B et al. Health care costs in the last week of life: associations with end-of-life conversations. *Arch Intern Med*. 2009 Mar 9;169(5):480–8. [PMID: 19273778]

► Decision-Making, Advance Care Planning, & Advance Directives

Well-informed, competent adults have a right to refuse medical intervention even if this is likely to result in death. Many are willing to sacrifice some quantity of life to protect a certain quality of life. In order to promote patient autonomy, clinicians are obligated to inform patients about the risks, benefits, alternatives, and expected outcomes of end-of-life medical interventions such as cardiopulmonary resuscitation (CPR), mechanical ventilation, hospitalization and ICU care, and nutrition and hydration. Advance directives are oral or written statements made by patients when they are competent that are intended to guide care should they become incompetent. Advance directives allow patients to project their autonomy into the future and are an important part of advance care planning—a process whereby clinicians help

patients match treatments and care to their goals and values. Advance directives take effect when the patient can no longer communicate his or her preferences directly. While oral statements about these matters are ethically binding, they are not legally binding in all states. State-specific advance directive forms are available from a number of sources, including <http://www.caringinfo.org>.

Clinicians should educate all patients—ideally, well before the end of life—about the opportunity to formulate an advance directive. Most patients with serious illness have already thought about end-of-life issues, want to discuss them with their clinician, want the clinician to bring up the subject, and feel better for having had the discussion. Patients who have such discussions with their clinicians are perceived by their family as having a better quality of life at the end of life and their loved ones are less likely to suffer from depression during bereavement.

One type of advance directive is the Durable Power of Attorney for Health Care (DPOA-HC) that, in addition to documenting patient preferences for care, allows the patient to designate a surrogate decision-maker. The DPOA-HC is particularly useful because it is often difficult to anticipate what decisions will need to be made. The responsibility of the surrogate is to provide “substituted judgment”—to decide as the *patient* would, not as the *surrogate* wants, although about one-third of surrogates suffer negative emotional effects as a result of the burden of their responsibility. Clinicians should encourage patients to talk with their surrogates about their preferences generally and about scenarios that are likely to arise, such as the need for mechanical ventilation in a patient with end-stage emphysema. In the absence of a designated surrogate, clinicians usually turn to family members or next of kin. Despite regulations requiring health care institutions to inform patients of their rights to formulate an advance directive, only about 10% of people in the United States (including clinicians themselves) have completed them. POLST (Physician Orders for Life-Sustaining Treatment) forms are physician orders that accompany patients wherever they are cared for—home, hospital, or nursing home—and complement advance directives.

► Do Not Attempt Resuscitation Orders

As part of advance care planning, clinicians can elicit patient preferences about CPR. Most patients and many clinicians overestimate the chances of success of CPR. Only about 15% of all patients who undergo CPR in the hospital survive to hospital discharge. Moreover, among certain populations—especially those with multisystem organ failure, metastatic cancer, and sepsis—the likelihood of survival to hospital discharge following CPR is virtually nil. Clinicians must also inform patients about the sequelae of surviving CPR including fractured ribs, lacerated internal organs, neurologic disability, and the need for other aggressive interventions (such as ICU care). Patients may ask their clinician to write an order that CPR not be attempted on them. Although this order initially was referred to as a DNR (do not resuscitate) order, many clinicians prefer the term “DNAR” (do not attempt resuscitation) to emphasize the low likelihood of success.

For some patients at the end of life, decisions about CPR may not be about whether they will live but about how they will die. Clinicians should correct the misconception that withholding CPR in appropriate circumstances is tantamount to “not doing everything” or “just letting someone die.” While respecting the patient’s right ultimately to make the decision—and keeping in mind their own biases and prejudices—clinicians should offer explicit recommendations about DNAR orders and protect dying patients and their families from feelings of guilt and from the sorrow associated with vain hopes. Clinicians should discuss what interventions will be continued and started to promote quality of life rather than focusing only on what is not to be done. For patients with internal cardiac defibrillators, clinicians must also address issues of turning off these devices as death approaches to prevent them from discharging during the dying process.

► Hospice & Other Palliative Care Institutions

In the United States, hospice is a service focused on addressing the physical and emotional needs of the dying. In the United States, 41% of people who die use hospice. About 80% of patients receiving hospice care remain at home where they can be cared for by their family and visiting hospice staff, although hospice care can also be provided in hospitals and institutional residences. Hospice embodies the palliative care philosophy that emphasizes individualized attention, human contact, and an interdisciplinary team approach. Hospice care can include arranging for respite for family caregivers and providing legal, financial, and other services. Primary care clinicians are strongly encouraged to continue caring for their patients during the time they are receiving hospice care.

Hospice care is highly rated by families and has been shown to increase patient satisfaction, to reduce costs (depending on when patients are referred to hospice care), and to decrease family caregiver mortality. Despite evidence that suggests that hospice care does not increase mortality and may even extend life, hospice care tends to be used very near the end of life. The average length of stay in hospices in the United States is 67 days, with 31% of patients dying within 7 days of beginning hospice care.

Most hospice organizations require clinicians to estimate the patient’s probability of survival to be < 6 months, since this is a criterion for eligibility to receive Medicare or other insurance coverage. Regrettably, the hospice benefit can be difficult to provide to people who are homeless or isolated or who have terminal prognoses that are difficult to quantify.

► Cultural Issues

The individual patient’s experience of dying occurs in the context of a complex interaction of personal, philosophic, and cultural influences. Various religious, ethnic, gender, class, and cultural traditions help determine patients’ styles of communication, comfort in discussing particular topics, expectations about dying and medical interventions, and attitudes about the appropriate disposition of dead bodies.

While each patient is an individual, being sensitive to a person’s cultural beliefs and respecting ethnic traditions are important responsibilities of the clinician caring for a patient at the end of life, especially when the cultures of origin of the clinician and patient differ. A clinician may ask a patient, “What do I need to know about you and your beliefs that will help me take care of you?”

Detering KM et al. The impact of advance care planning on end of life care in elderly patients: randomised controlled trial. *BMJ*. 2010 Mar 23;340:c1345. [PMID: 20332506]
 Ehlenbach WJ et al. Epidemiologic study of in-hospital cardiopulmonary resuscitation in the elderly. *N Engl J Med*. 2009 Jul 2;361(1):22–31. [PMID: 19571280]
 Saito AM et al. Hospice care and survival among elderly patients with lung cancer. *J Palliat Med*. 2011 Aug;14(8):929–39. [PMID: 21767153]
 Siegel MD. End-of-life decision making in the ICU. *Clin Chest Med*. 2009 Mar;30(1):181–94. [PMID: 19186289]
 Smith AK et al. Palliative care for Latino patients and their families: whenever we prayed, she wept. *JAMA*. 2009 Mar 11; 301(10):1047–57. [PMID: 19278947]
 Wendler D et al. Systematic review: the effect on surrogates of making treatment decisions for others. *Ann Intern Med*. 2011 Mar 1;154(5):336–46. [PMID: 21357911]

► Nutrition & Hydration

People approaching the end of life often lose their appetite and ultimately stop eating and drinking. The anorexia-cachexia syndrome frequently occurs in patients with advanced cancer, and cachexia is a common and poor prognostic sign in patients with heart failure. Ill people often have no hunger with total caloric deprivation, and the associated ketonemia produces a sense of well-being, analgesia, and mild euphoria. However, carbohydrate intake even in small amounts (such as that provided by 5% intravenous dextrose solution) blocks ketone production and may blunt the well-being effects of total caloric deprivation. Although it is unclear to what extent withholding hydration at the end of life creates an uncomfortable sensation of thirst, any such sensation is usually relieved by simply moistening the dry mouth. Ice chips, hard candy, swabs, popsicles, or minted mouthwash may be effective. Although this normal process of diminishing oral intake and accompanying weight loss is very common, it can be distressing to patients and families who may associate the offering of food with compassion and love and lack of eating with distressing images of starvation. In response, patients and families often ask about supplemental enteral or parenteral nutrition.

Unfortunately supplemental, artificial nutrition and hydration offers little benefit and rarely achieves patient and family goals. For example, although tube feedings are often considered in patients who aspirate, they do not prevent aspiration pneumonia and there is debate about whether artificial nutrition prolongs life in the terminally ill. Furthermore, force feeding may cause nausea and vomiting in ill patients, and eating can lead to diarrhea in the setting of malabsorption. Artificial nutrition and hydration may increase oral and airway secretions as well as increase the risk of choking, aspiration, and dyspnea; ascites, edema, and

effusions may be worsened. Nasogastric and gastrostomy tube feeding and parenteral nutrition impose risks of infection, epistaxis, pneumothorax, electrolyte imbalance, and aspiration—as well as the need to physically restrain the delirious patient to prevent dislodgment of catheters and tubes.

Individuals at the end of life have a right to refuse nutrition and hydration. Because they may have deep social and cultural significance for patients, families, and clinicians themselves, decisions about nutrition and hydration are not simply medical. Eliciting perceived goals of artificial nutrition and hydration and correcting misperceptions can help patients and families make clear decisions. Family and friends can be encouraged to express their love and caring in ways other than intrusive attempts at force feeding or hydration.

► Withdrawal of Curative Efforts

Requests from appropriately informed and competent patients or their surrogates for withdrawal of life-sustaining interventions must be respected. In addition, clinicians may determine unilaterally that particular interventions are medically inappropriate—eg, continuing kidney dialysis in a patient dying of multiorgan failure. In such cases, the clinician's intention to withdraw a specific intervention should be communicated to the patient and family. If differences of opinion persist about the appropriateness of what is being done, the assistance of an institutional ethics committee should be sought.

Limitation of life support prior to death is an increasingly common practice in intensive care units. The withdrawal of life-sustaining interventions such as mechanical ventilation must be approached carefully to avoid needless patient suffering and distress for those in attendance. Clinicians should educate the patient and family about the expected course of events and the difficulty of determining the precise timing of death after withdrawal of interventions. Sedative and analgesic agents should be administered to ensure patient comfort even at the risk of respiratory depression or hypotension. Scopolamine (10 mcg/h subcutaneously or intravenously, or a 1.5-mg patch every 3 days), glycopyrrolate (1 mg orally every 4 hours), or atropine (1% ophthalmic solution, 1 or 2 drops sublingually as often as every hour) can be used for controlling airway secretions and the resultant “death rattle.” A guideline for withdrawal of mechanical ventilation is provided in Table 5–8.

► Psychological, Social, & Spiritual Issues

Dying is not exclusively or even primarily a biomedical event. It is an intimate personal experience with profound psychological, interpersonal, and existential meanings. For many people at the end of life, the prospect of impending death stimulates a deep and urgent assessment of their identity, the quality of their relationships, and the meaning and purpose of their existence.

A. Psychological Challenges

In 1969, Elisabeth Kübler-Ross identified five psychological stages or patterns of emotions that patients at the end of

Table 5–8. Guidelines for withdrawal of mechanical ventilation.

1. Stop neuromuscular blocking agents.
2. Administer opioids or sedatives to eliminate distress. If not already sedated, begin with fentanyl 100 mcg (or morphine sulfate 10 mg) by intravenous bolus and infusion of fentanyl 100 mcg/h intravenously (or morphine sulfate 10 mg/h intravenously). Distress is indicated by RR > 24, nasal flaring, use of accessory muscles of respiration, HR increase > 20%, MAP increase > 20%, grimacing, clutching.
3. Discontinue vasoactive agents and other agents unrelated to patient comfort, such as antibiotics, intravenous fluids, and diagnostic procedures.
4. Decrease F_{iO_2} to room air and PEEP to 0 cm H_2O .
5. Observe patient for distress. If patient is distressed, increase opioids by repeating bolus dose and increasing hourly infusion rate by 50 mcg fentanyl (or 5 mg morphine sulfate),¹ then return to observation. If patient is not distressed, place on T piece and observe. If patient continues without distress, extubate patient and continue to observe for distress.

¹Ventilatory support may be increased until additional opioids have effect.

RR, respiratory rate; HR, heart rate; MAP, mean airway pressure; F_{iO_2} , fraction of inspired oxygen; PEEP, positive end-expiratory pressure. Adapted, with permission, from San Francisco General Hospital Guidelines for Withdrawal of Mechanical Ventilation/Life Support.

life may experience: denial and isolation, anger, bargaining, depression, and acceptance. Not every patient will experience all these emotions, and typically not in an orderly progression. In addition to these five stages are the perpetual challenges of anxiety and fear of the unknown. Simple information, listening, assurance, and support may help patients with these psychological challenges. In fact, patients and families rank emotional support as one of the most important aspects of good end-of-life care. Psychotherapy and group support may be beneficial as well.

Despite the significant emotional stress of facing death, clinical depression is not normal at the end of life and should be treated. Cognitive and affective signs of depression (such as hopelessness) may help distinguish depression from the low energy and other vegetative signs common with end-stage illness. Although traditional antidepressant treatments such as selective serotonin reuptake inhibitors are effective, more rapidly acting medications such as dextroamphetamine or methylphenidate (in doses used for sedation described earlier in this chapter) may be particularly useful when the end of life is near or while waiting for other antidepressant medication to take effect. Some research suggests a mortality benefit from treating depression in the setting of serious illness.

B. Social Challenges

At the end of life, patients should be encouraged to discharge personal, professional, and business obligations. This might include completing important work or personal projects, distributing possessions, writing a will, and making funeral and burial arrangements. The prospect of death often prompts patients to examine the quality of

Table 5-9. Five statements often necessary for the completion of important interpersonal relationships.

(1) "Forgive me."	(An expression of regret)
(2) "I forgive you."	(An expression of acceptance)
(3) "Thank you."	(An expression of gratitude)
(4) "I love you."	(An expression of affection)
(5) "Goodbye."	(Leave-taking)

Reprinted, with permission, from Byock I. *Dying Well: Peace and Possibilities at the End of Life*. New York: Riverhead Books, 1997.

their interpersonal relationships and to begin the process of saying goodbye (Table 5-9). Dying may intensify a patient's need to feel cared for by the clinician and the need for clinician empathy and compassion. Concern about estranged relationships or "unfinished business" with significant others and interest in reconciliation may become paramount at this time.

C. Spiritual Challenges

Spirituality is the attempt to understand or accept the underlying meaning of life, one's relationships to oneself and other people, one's place in the universe, and the possibility of a "higher power" in the universe. Spirituality is distinguished from particular religious practices or beliefs and is generally considered a universal human concern.

Perhaps because of an inappropriately exclusive attention to the biologic challenge of forestalling death or perhaps from feelings of discomfort or incompetence, clinicians frequently ignore their patients' spiritual concerns or reflexively refer these important issues to chaplains, psychiatrists or other caretakers (nurses, social workers, clergy). However, the existential challenges of dying are central to the well-being of people at the end of life and are the proper concern of clinicians. Clinicians can help dying patients by providing care to the whole person—by providing physical comfort and social support and by helping patients discover their own unique meaning in the world and an acceptance of death as a part of life. Dignity therapy has been shown to be effective in improving quality of life and spiritual well-being.

Unlike physical ailments such as infections and fractures, which usually require a clinician's intervention to be treated, the patient's spiritual concerns often require only a clinician's attention, listening, and witness. Clinicians might choose to inquire about the patient's spiritual concerns and ask whether the patient wishes to discuss them. For example, asking, "How are you within yourself?" communicates that the clinician is interested in the patient's whole experience and provides an opportunity for the patient to share perceptions about his or her inner life. Questions that might constitute an existential "review of systems" are presented in Table 5-10.

While dying may be a period of inevitable loss of physical functioning, the end of life also offers an opportunity for psychological, interpersonal, and spiritual development. Individuals may grow—even achieve a heightened sense of well-being or transcendence—in the process of dying. Through listening, support, and presence, clinicians may help foster

Table 5-10. An existential review of systems.

Intrapersonal

What does your illness/dying mean to you?
 What do you think caused your illness?
 How have you been healed in the past?
 What do you think is needed for you to be healed now?
 What is right with you now?
 What do you hope for?

Interpersonal

Who is important to you?
 To whom does your illness/dying matter?
 Do you have any unfinished business with significant others?

Transpersonal

What is your source of strength, help, or hope?
 Do you have spiritual concerns or a spiritual practice?
 If so, how does your spirituality relate to your illness/dying, and how can I help integrate your spirituality into your health care?
 What do you think happens after we die?
 What purpose might your illness/dying serve?
 What do you think is trying to happen here?

this learning and be a catalyst for this transformation. Rather than thinking of dying simply as the termination of life, clinicians and patients may be guided by a developmental model of dying that recognizes a series of lifelong developmental tasks and landmarks and allows for growth at the end of life.

- Candy B et al. Interventions for supporting informal caregivers of patients in the terminal phase of a disease. *Cochrane Database Syst Rev*. 2011 Jun 15;(6):CD007617. [PMID: 21678368]
- Chochinov HM et al. Effect of dignity therapy on distress and end-of-life experience in terminally ill patients: a randomised controlled trial. *Lancet Oncol*. 2011 Aug;12(8):753-62. [PMID: 21741309]
- Puchalski C et al. Improving the quality of spiritual care as a dimension of palliative care: the report of the Consensus Conference. *J Palliat Med*. 2009 Oct;12(10):885-904. [PMID: 19807235]
- Rayner L et al. Antidepressants for the treatment of depression in palliative care: systematic review and meta-analysis. *Palliat Med*. 2011 Jan;25(1):36-51. [PMID: 20935027]
- Satin JR et al. Depression as a predictor of disease progression and mortality in cancer patients: a meta-analysis. *Cancer*. 2009 Nov 15;115(22):5349-61. [PMID: 19753617]
- Winkelman WD et al. The relationship of spiritual concerns to the quality of life of advanced cancer patients: preliminary findings. *J Palliat Med*. 2011 Sep;14(9):1022-8. [PMID: 21767165]

TASKS AFTER DEATH

After the death of a patient, the clinician is called upon to perform a number of tasks, both required and recommended. The clinician must plainly and directly inform the family of the death, complete a death certificate, contact an organ procurement organization, and request an autopsy. Providing words of sympathy and reassurance, time for questions and initial grief, and a quiet private room for the family at this time is appropriate and much appreciated.

► The Pronouncement & Death Certificate

In the United States, state policies direct clinicians to confirm the death of a patient in a formal process called “pronouncement.” The clinician must verify the absence of spontaneous respirations and cardiac activity. A note describing these findings and the time of death is entered in the patient’s chart. In many states, when a patient whose death is expected dies outside of the hospital (at home or in prisons, for example) nurses may be authorized to report the death over the telephone to a physician who must then sign the death certificate within 24 hours. For traumatic deaths, some states allow emergency medical technicians to pronounce a patient dead at the scene based on clearly defined criteria and with physician telephonic or radio supervision.

While the pronouncement may often seem like an awkward and unnecessary formality, clinicians may use this time to reassure the patient’s loved ones at the bedside that the patient died peacefully and that all appropriate care had been given. Both clinicians and families may use the ritual of the pronouncement as an opportunity to begin to process emotionally the death of the patient.

Physicians are legally required to accurately report the underlying cause of death on the death certificate. This reporting is important both for patients’ families (for insurance purposes and the need for an accurate family medical history) and for the epidemiologic study of disease and public health. The physician should be specific about the major cause of death being the condition without which the patient would not have died (eg, “decompensated cirrhosis”) and its contributory cause (eg, “hepatitis B and hepatitis C infections and chronic alcoholic hepatitis”) as well as any associated conditions (eg, “acute kidney injury”)—and not simply put down “cardiac arrest” as the cause of death.

► Autopsy & Organ Donation

Discussing the options and obtaining consent for autopsy and organ donation with patients prior to death is usually the best practice. This approach advances the principle of patient autonomy and lessens the responsibilities of distressed family members during the period immediately following the death. However, after a patient dies, or in the case of brain death, designated organ transplant personnel are more successful than the treating clinicians at obtaining consent for organ donation from surviving family members. Federal regulations require that a designated representative of an organ procurement organization approach the family about organ donation if the organs are appropriate for transplantation. Most people in the United States support the donation of organs for transplants. Currently, however, organ transplantation is severely limited by the availability of donor organs. Many potential donors and the families of actual donors experience a sense of reward in contributing, even through death, to the lives of others.

Clinicians must be sensitive to ethnic and cultural differences in attitudes about autopsy and organ donation. Patients or their families should be reminded of their right to limit autopsy or organ donation in any way they choose,

although such restriction may limit the utility of autopsy. Pathologists can perform autopsies without interfering with funeral plans or the appearance of the deceased.

The results of an autopsy may help surviving family members and clinicians understand the exact cause of a patient’s death and foster a sense of closure. A clinician-family conference to review the results of the autopsy provides a good opportunity for clinicians to assess how well families are grieving and to answer questions. Despite the advantages of conducting postmortem examinations, autopsy rates are < 15%. Families report refusing autopsies out of fear of disfigurement of the body or delay of the funeral or say they were simply not asked. They allow autopsies in order to advance medical knowledge, to identify the exact cause of their loved one’s death, and to be reassured that appropriate care was given. Routinely addressing these issues when discussing autopsy may help increase the autopsy rate; the most important mistake is the failure to ask for permission to perform it.

► Follow-up & Grieving

Proper care of patients at the end of life includes following up with surviving family members after the patient has died, although clinicians often do not facilitate adequate bereavement services. Following up by telephone enables the clinician to assuage any guilt about decisions the family may have made, assess how families are grieving, reassure them about the nature of normal grieving, and identify complicated grief or depression. Clinicians can recommend support groups and counseling as needed. A card or telephone call from the clinician to the family days to weeks after the patient’s death (and perhaps on the anniversary of the death) allows the clinician to express concern for the family and the deceased.

After a patient dies, the clinician too may need to grieve. Although clinicians may be relatively unaffected by the deaths of some patients, other deaths may cause distressing feelings of sadness, loss, and guilt. These emotions should be recognized as the first step toward processing them or preventing them in the future. Each clinician may find personal or communal resources that help with the process of grieving. Shedding tears, the support of colleagues, time for reflection, and traditional or personal mourning rituals all may be effective. Attending the funeral of a patient who has died can be a satisfying personal experience that is almost universally appreciated by families and that may be the final element in caring well for people at the end of life.

Chau NG et al. Bereavement practices of physicians in oncology and palliative care. *Arch Intern Med.* 2009 May 25; 169(10): 963–71. [PMID: 19468090]

Simpkin AL et al. Modifiable factors influencing relatives’ decision to offer organ donation: systematic review. *BMJ.* 2009 Apr 21;338:b991. [PMID: 19383730]

Wittouck C et al. The prevention and treatment of complicated grief: A meta-analysis. *Clin Psychol Rev.* 2011 Feb;31(1):69–78. [PMID: 21130937]

6

Dermatologic Disorders

Timothy G. Berger, MD

Dermatologic diseases are diagnosed by the types of lesions they cause. To make a diagnosis: (1) identify the type of lesion(s) the patient exhibits by morphology establishing a differential diagnosis (Table 6–1); and (2) obtain the elements of the history, physical examination, and appropriate laboratory tests to confirm the diagnosis. Unique clinical situations, such as the ill ICU patient, lead to different diagnostic considerations.

PRINCIPLES OF DERMATOLOGIC THERAPY

► Frequently Used Treatment Measures

A. Bathing

Soap should be used only in the axillae and groin and on the feet by persons with dry or inflamed skin. Soaking in water for 10–15 minutes before applying topical corticosteroids enhances their efficacy (Soak and Smear). Bath oils can be used, but add little above the use of moisturizers, and may make the tub slippery, increasing the risk of falling.

B. Topical Therapy

Nondermatologists should become familiar with a representative agent in each category for each indication (eg, topical corticosteroid, topical retinoid, etc).

1. Corticosteroids—Topical corticosteroid creams, lotions, ointments, gels, foams, and sprays are presented in Table 6–2. Topical corticosteroids are divided into classes based on potency. There is little (except price) to recommend one agent over another within the same class. For a given agent, an ointment is more potent than a cream. The potency of a topical corticosteroid may be dramatically increased by applying an occlusive dressing over the corticosteroid. Optimally, at least 4 hours of occlusion should be prescribed to enhance penetration. Such dressings may include gloves, plastic wrap, or plastic occlusive suits for patients with generalized erythroderma or atopy. Caution should be used in applying topical corticosteroids to areas of thin skin (face, scrotum, vulva, skin folds). Topical corticosteroid use on the eyelids may result in glaucoma or

cataracts. One may estimate the amount of topical corticosteroid needed by using the “rule of nines” (as in burn evaluation; see Figure 37–2). In general, it takes an average of 20–30 g to cover the body surface of an adult once. Systemic absorption does occur, but adrenal suppression, diabetes mellitus, hypertension, osteoporosis, and other complications of systemic corticosteroids are very rare with topical corticosteroid therapy.

2. Emollients for dry skin (“moisturizers”)—Dry skin is not related to water intake but to abnormal function of the epidermis. Many types of emollients are available. Petrolatum, mineral oil, Aquaphor, Vanicream, and Eucerin cream are the heaviest and best. Emollients are most effective when applied to wet skin. If the skin is too greasy after application, pat dry with a damp towel. Vanicream is relatively allergen-free and can be used if allergic contact dermatitis to topical products is suspected.

The scaly appearance of dry skin may be improved by urea, lactic acid, or glycolic acid-containing products provided no inflammation (erythema or pruritus) is present.

3. Drying agents for weepy dermatoses—If the skin is weepy from infection or inflammation, drying agents may be beneficial. The best drying agent is water, applied as repeated compresses for 15–30 minutes, alone or with aluminum salts (Burow solution, Domeboro tablets) or colloidal oatmeal (Aveeno).

4. Topical antipruritics—Lotions that contain 0.5% each of camphor and menthol (Sarna) or pramoxine hydrochloride 1% (with or without 0.5% menthol, eg, Prax, PrameGel, Aveeno Anti-Itch lotion) are effective antipruritic agents. Hydrocortisone, 1% or 2.5%, may be incorporated for its anti-inflammatory effect (Pramosone cream, lotion, or ointment). Doxepin cream 5% may reduce pruritus but may cause drowsiness. Pramoxine and doxepin are most effective when applied with topical corticosteroids. Monoamine oxidase inhibitors should be discontinued at least 2 weeks before treatment with doxepin. Topical capsaicin can be effective in some forms of neuropathic itch. Ice in a plastic bag covered by a thin cloth applied to itchy spots can be effective.

Table 6-1. Morphologic categorization of skin lesions and diseases.

Pigmented	Freckle, lentigo, seborrheic keratosis, nevus, blue nevus, halo nevus, atypical nevus, melanoma
Scaly	Psoriasis, dermatitis (atopic, stasis, seborrheic, chronic allergic contact or irritant contact), xerosis (dry skin), lichen simplex chronicus, tinea, tinea versicolor, secondary syphilis, pityriasis rosea, discoid lupus erythematosus, exfoliative dermatitis, actinic keratoses, Bowen disease, Paget disease, intertrigo
Vesicular	Herpes simplex, varicella, herpes zoster, dyshidrosis (vesicular dermatitis of palms and soles), vesicular tinea, dermatophytid, dermatitis herpetiformis, miliaria crystallina, scabies, photosensitivity
Weepy or encrusted	Impetigo, acute contact allergic dermatitis, any vesicular dermatitis
Pustular	Acne vulgaris, acne rosacea, folliculitis, candidiasis, miliaria pustulosa, any vesicular dermatitis
Figurate ("shaped") erythema	Urticaria, erythema multiforme, erythema migrans, cellulitis, erysipelas, erysipeloid, arthropod bites
Bullous	Impetigo, blistering dactylitis, pemphigus, pemphigoid, porphyria cutanea tarda, drug eruptions, erythema multiforme, toxic epidermal necrolysis
Papular	Hyperkeratotic: warts, corns, seborrheic keratoses Purple-violet: lichen planus, drug eruptions, Kaposi sarcoma Flesh-colored, umbilicated: molluscum contagiosum Pearly: basal cell carcinoma, intradermal nevi Small, red, inflammatory: acne, miliaria rubra, candidiasis, scabies, folliculitis
Pruritus ¹	Xerosis, scabies, pediculosis, bites, systemic causes, anogenital pruritus
Nodular, cystic	Erythema nodosum, furuncle, cystic acne, follicular (epidermal) inclusion cyst
Photodermatitis (photodistributed rashes)	Drug, polymorphic light eruption, lupus erythematosus
Morbilliform	Drug, viral infection, secondary syphilis
Erosive	Any vesicular dermatitis, impetigo, aphthae, lichen planus, erythema multiforme
Ulcerated	Decubiti, herpes simplex, skin cancers, parasitic infections, syphilis (chancre), chancroid, vasculitis, stasis, arterial disease

¹Not a morphologic class but included because it is one of the most common dermatologic presentations.

Table 6-2. Useful topical dermatologic therapeutic agents.

Agent	Formulations, Strengths, and Prices ¹	Apply	Potency Class	Common Indications	Comments
Corticosteroids					
Hydrocortisone acetate	Cream 1%: \$3.00/30 g Ointment 1%: \$3.00/30 g Lotion 1%: \$7.20/120 mL	Twice daily	Low	Seborrheic dermatitis Pruritus ani Intertrigo	Not the same as hydrocortisone butyrate or valerate Not for poison oak OTC lotion (Aquihal HC) OTC solution (Scalpicin, T Scalp)
	Cream 2.5%: \$26.40/30 g	Twice daily	Low	As for 1% hydrocortisone	Perhaps better for pruritus ani Not clearly better than 1% More expensive Not OTC
Alclometasone dipropionate (Acloivate)	Cream 0.05%: \$20.25/15 g Ointment 0.05%: \$19.95/15 g	Twice daily	Low	As for hydrocortisone	More efficacious than hydrocortisone Perhaps causes less atrophy
Desonide	Cream 0.05%: \$15.45/15 g Ointment 0.05%: \$40.15/60 g Lotion 0.05%: \$99.60/60 mL	Twice daily	Low	As for hydrocortisone For lesions on face or body folds resistant to hydrocortisone	More efficacious than hydrocortisone Can cause rosacea or atrophy Not fluorinated

(continued)

Table 6-2. Useful topical dermatologic therapeutic agents. (continued)

Agent	Formulations, Strengths, and Prices ¹	Apply	Potency Class	Common Indications	Comments
Clocortolone (Cloderm)	Cream 0.1%: \$129.96/30 g	Three times daily	Medium	Contact dermatitis Atopic dermatitis	Does not cross-react with other corticosteroids chemically and can be used in patients allergic to other corticosteroids
Prednicarbate (Dermatop)	Emollient cream 0.1%: \$56.76/60 g Ointment 0.1%: \$30.00/15 g	Twice daily	Medium	As for triamcinolone	May cause less atrophy No generic formulations Preservative-free
Triamcinolone acetonide	Cream 0.1%: \$5.55/15 g Ointment 0.1%: \$5.55/15 g Lotion 0.1%: \$42.44/60 mL	Twice daily	Medium	Eczema on extensor areas Used for psoriasis with tar Seborrheic dermatitis and psoriasis on scalp	Caution in body folds, face Economical in 0.5-lb and 1-lb sizes for treatment of large body surfaces Economical as solution for scalp
	Cream 0.025%: \$4.45/15 g Ointment 0.025%: \$11.20/80 g	Twice daily	Medium	As for 0.1% strength	Possibly less efficacy and few advantages over 0.1% formulation
Fluocinolone acetonide	Cream 0.025%: \$33.75/15 g Ointment 0.025%: \$33.75/15 g	Twice daily	Medium	As for triamcinolone	
	Solution 0.01%: \$90.00/60 mL	Twice daily	Medium	As for triamcinolone solution	
Mometasone furoate (Elocon)	Cream 0.1%: \$26.90/15 g Ointment 0.1%: \$24.45/15 g Lotion 0.1%: \$57.00/60 mL	Once daily	Medium	As for triamcinolone	Often used inappropriately on the face or on children Not fluorinated
Diflorasone diacetate	Cream 0.05%: \$53.54/15 g Ointment 0.05%: \$51.86/30 g	Twice daily	High	Nummular dermatitis Allergic contact dermatitis Lichen simplex chronicus	
Amcinonide (Cyclocort)	Cream 0.1%: \$26.00/15 g Ointment 0.1%: \$194.40/60 g	Twice daily	High	As for betamethasone	
Fluocinonide (Lidex)	Cream 0.05%: \$19.95/15 g Gel 0.05%: \$24.60/15 g Ointment 0.05%: \$6.60/15 g Solution 0.05%: \$50.40/60 mL	Twice daily	High	As for betamethasone Gel useful for poison oak	Economical generics Lidex cream can cause stinging on eczema Lidex emollient cream preferred
Betamethasone dipropionate (Diprolene)	Cream 0.05%: \$35.70/15 g Ointment 0.05%: \$30.00/15 g Lotion 0.05%: \$112.80/60 mL	Twice daily	Ultra-high	For lesions resistant to high-potency corticosteroids Lichen planus Insect bites	Economical generics available
Clobetasol propionate (Temovate)	Cream 0.05%: \$24.75/15 g Ointment 0.05%: \$24.75/15 g Lotion 0.05%: \$294.00/60 mL	Twice daily	Ultra-high	As for betamethasone dipropionate	Somewhat more potent than diflorasone Limited to 2 continuous weeks of use Limited to 50 g or less per week Cream may cause stinging; use "emollient cream" formulation Generic available
Halobetasol propionate (Ultravate)	Cream 0.05%: \$31.50/15 g Ointment 0.05%: \$31.50/15 g	Twice daily	Ultra-high	As for clobetasol	Same restrictions as clobetasol Cream does not cause stinging Compatible with calcipotriene (Dovonex)
Flurandrenolide (Cordran)	Tape: \$88.10/80" × 3" roll Lotion 0.05%: \$358.80/60 mL	Every 12 hours	Ultra-high	Lichen simplex chronicus	Protects the skin and prevents scratching

(continued)

Table 6–2. Useful topical dermatologic therapeutic agents. (continued)

Agent	Formulations, Strengths, and Prices ¹	Apply	Potency Class	Common Indications	Comments
Nonsteroidal anti-inflammatory agents					
Tacrolimus ² (Protopic)	Ointment 0.1%: \$174.72/30 g Ointment 0.03%: \$174.72/30 g	Twice daily	N/A	Atopic dermatitis	Steroid substitute not causing atrophy or striae Burns in ≥ 40% of patients with eczema
Pimecrolimus ² (Elidel)	Cream 1%: \$165.60/30 g	Twice daily	N/A	Atopic dermatitis	Steroid substitute not causing atrophy or striae
Antibiotics (for acne)					
Clindamycin phosphate	Solution 1%: \$12.00/30 mL Gel 1%: \$32.10/30 mL Lotion 1%: \$45.00/60 mL Pledge 1%: \$45.90/60	Twice daily	N/A	Mild papular acne	Lotion is less drying for patients with sensitive skin
Erythromycin	Solution 2%: \$17.44/60 mL Gel 2%: \$25.20/30 g Pledge 2%: \$94.55/60	Twice daily	N/A	As for clindamycin	Many different manufacturers Economical
Erythromycin/Benzoyl peroxide (Benzamycin)	Gel: \$58.35/23.3 g Gel: \$111.64/46.6 g	Twice daily	N/A	As for clindamycin Can help treat comedonal acne	No generics More expensive More effective than other topical antibiotic Main jar requires refrigeration
Clindamycin/Benzoyl peroxide (BenzaClin)	Gel: \$163.00/25 g Gel: \$169.63/50 g	Twice daily		As for benzamycin	No generic More effective than either agent alone
Antibiotics (for impetigo)					
Mupirocin (Bactroban)	Ointment 2%: \$42.50/22 g Cream 2%: \$62.52/15 g	Three times daily	N/A	Impetigo, folliculitis	Because of cost, use limited to tiny areas of impetigo Used in the nose twice daily for 5 days to reduce staphylococcal carriage
Antifungals: Imidazoles					
Clotrimazole	Cream 1%: \$19.90/15 g OTC Solution 1%: \$7.40/10 mL	Twice daily	N/A	Dermatophyte and <i>Candida</i> infections	Available OTC Inexpensive generic cream available
Econazole (Spectazole)	Cream 1%: \$17.50/15 g	Once daily	N/A	As for clotrimazole	No generic Somewhat more effective than clotrimazole and miconazole
Ketoconazole	Cream 2%: \$16.46/15 g	Once daily	N/A	As for clotrimazole	No generic Somewhat more effective than clotrimazole and miconazole
Miconazole	Cream 2%: \$5.50/30 g OTC	Twice daily	N/A	As for clotrimazole	As for clotrimazole
Oxiconazole (Oxistat)	Cream 1%: \$121.69/30 g Lotion 1%: \$127.82/30 mL	Twice daily	N/A		
Sertaconazole (Ertaczo)	Cream 2%: \$132.08/30 g	Twice daily	N/A	Refractory tinea pedis	By prescription More expensive
Sulconazole (Exelderm)	Cream 1%: \$54.20/15 g Solution 1%: \$95.36/30 mL	Twice daily	N/A	As for clotrimazole	No generic Somewhat more effective than clotrimazole and miconazole

(continued)

Table 6–2. Useful topical dermatologic therapeutic agents. (continued)

Agent	Formulations, Strengths, and Prices ¹	Apply	Potency Class	Common Indications	Comments
Other antifungals					
Butenafine (Mentax)	Cream 1%: \$81.39/15 g	Once daily	N/A	Dermatophytes	Fast response; high cure rate; expensive Available OTC
Ciclopirox (Loprox) (Penlac)	Cream 0.77%: \$51.10/30 g Lotion 0.77%: \$96.15/60 mL Solution 8%: \$18.48/6.6 mL	Twice daily	N/A	As for clotrimazole	No generic Somewhat more effective than clotrimazole and miconazole
Naftifine (Naftin)	Cream 1%: \$331.37/30 g Gel 1%: \$331.37/60 mL	Once daily	N/A	Dermatophytes	No generic Somewhat more effective than clotrimazole and miconazole
Terbinafine (Lamisil)	Cream 1%: \$8.15/12 g OTC	Once daily	N/A	Dermatophytes	Fast clinical response OTC
Antipruritics					
Camphor/menthol (Sarna)	Lotion 0.5%/0.5%: \$7.80/222 mL	Two to three times daily	N/A	Mild eczema, xerosis, mild contact dermatitis	
Pramoxine hydrochloride (Prax)	Lotion 1%: \$19.07/120 mL OTC	Four times daily	N/A	Dry skin, varicella, mild eczema, pruritus ani	OTC formulations (Prax, Aveeno Anti-Itch Cream or Lotion; Itch-X Gel) By prescription mixed with 1% or 2% hydrocortisone
Doxepin (Zonalon)	Cream 5%: \$183.28/30 g	Four times daily	N/A	Topical antipruritic, best used in combination with appropriate topical corticosteroid to enhance efficacy	Can cause sedation
Emollients					
Aveeno	Cream, lotion, others	Once to three times daily	N/A	Xerosis, eczema	Choice is most often based on personal preference by patient
Aqua glycolic	Cream, lotion, shampoo, others	Once to three times daily	N/A	Xerosis, ichthyosis, keratosis pilaris Mild facial wrinkles Mild acne or seborrheic dermatitis	Contains 8% glycolic acid Available from other makers, eg, Alpha Hydrox, or generic 8% glycolic acid lotion May cause stinging on eczematous skin
Aquaphor	Ointment: \$5.91/100 g	Once to three times daily	N/A	Xerosis, eczema For protection of area in pruritus ani	Not as greasy as petrolatum
Carmol	Lotion 10%: \$18.89/180 mL Cream 20%: \$17.38/90 g	Twice daily	N/A	Xerosis	Contains urea as humectant Nongreasy hydrating agent (10%); debrides keratin (20%)
Complex 15	Lotion: \$6.48/240 mL Cream: \$4.82/75 g	Once to three times daily	N/A	Xerosis Lotion or cream recommended for split or dry nails	Active ingredient is a phospholipid
DML	Cream, lotion, facial moisturizer: \$5.95/240 mL	Once to three times daily	N/A	As for Complex 15	Face cream has sunscreen
Eucerin	Cream: \$7.37/240 g Lotion: \$5.10/240 mL	Once to three times daily	N/A	Xerosis, eczema	Many formulations made Eucerin Plus contains alpha-hydroxy acid and may cause stinging on eczematous skin Facial moisturizer has SPF 25 sunscreen

(continued)

Table 6-2. Useful topical dermatologic therapeutic agents. (continued)

Agent	Formulations, Strengths, and Prices ¹	Apply	Potency Class	Common Indications	Comments
Lac-Hydrin-Five	Lotion: \$11.37/226 g OTC	Twice daily	N/A	Xerosis, ichthyosis, keratosis pilaris	Prescription strength is 12%
Lubriderm	Lotion: \$7.33/473 mL	Once to three times daily	N/A	Xerosis, eczema	Unscented usually preferred
Neutrogena	Cream, lotion, facial moisturizer: \$7.39/240 mL	Once to three times daily	N/A	Xerosis, eczema	Face cream has titanium-based sunscreen
Ceratopic Cream	Cream: \$60.00/6 oz	Twice daily	N/A	Xerosis, eczema	Contains ceramide; anti-inflammatory and nongreasy moisturizer
U-Lactin	Lotion: \$14.16/240 mL OTC	Once daily	N/A	Hyperkeratotic heels	Moisturizes and removes keratin

¹Average wholesale price (AWP, for AB-rated generic when available) for quantity listed. AWP may not accurately represent the actual pharmacy cost because wide contractual variations exist among institutions. Source: *Red Book Online*, 2012, Thomson Reuters (Healthcare) Inc.

²Topical tacrolimus and pimecrolimus should only be used when other topical treatments are ineffective. Treatment should be limited to an area and duration to be as brief as possible. Treatment with these agents should be avoided in persons with known immunosuppression, HIV infection, bone marrow and organ transplantation, lymphoma, at high risk for lymphoma, and those with a prior history of lymphoma. N/A, not applicable; OTC, over-the-counter.

C. Systemic antipruritic drugs

1. Antihistamines—H₁-blockers are the agents of choice for pruritus when due to histamine, such as in urticaria. Otherwise, they appear to relieve pruritus only by their sedating effects. Except in the case of urticaria, nonsedating antihistamines are of limited value in inflammatory skin diseases. Hydroxyzine, 25–50 mg nightly, can be an effective initial treatment. When inadequate, the combination of antihistamines of different classes may lead to better control of non-urticarial pruritus (for example, cetirizine or loratadine 10 mg orally twice daily plus fexofenadine 180 mg orally once or twice daily plus hydroxyzine 25–50 mg orally nightly). Some antidepressants, such as doxepin, mirtazapine, sertraline, and paroxetine can be effective antipruritics. Neurally active agents such as gabapentin, pregabalin, and duloxetine are especially useful in neuropathic pruritus, such as seen in diabetic neuropathy.

2. Systemic corticosteroids

(See Chapter 26.)

Elmariah SB et al. Topical therapies for pruritus. *Semin Cutan Med Surg.* 2011 Jun;30(2):118–26. [PMID: 21767774]
 Ständer S et al. Treatment of chronic pruritus with the selective serotonin re-uptake inhibitors paroxetine and fluvoxamine: results of an open-labelled, two-arm proof-of-concept study. *Acta Derm Venereol.* 2009;89(1):45–51. [PMID: 19197541]
 Steinhoff M et al. Pruritus: management algorithms and experimental therapies. *Semin Cutan Med Surg.* 2011 Jun;30(2):127–37. [PMID: 21767775]

► Sunscreens

Protection from ultraviolet light should begin at birth and will reduce the incidence of actinic keratoses, melanoma, and some nonmelanoma skin cancers when initiated at

any age. The best protection is shade, but protective clothing, avoidance of direct sun exposure during the peak hours of the day, and daily use of chemical sunscreens are important.

Fair-complexioned persons should use a sunscreen with an SPF (sun protective factor) of at least 15 and preferably 30–40 every day. Sunscreens with high SPF values (> 30) usually afford some protection against UVA as well as UVB and are helpful in managing photosensitivity disorders. The actual SPF achieved is about one-quarter or less than that listed on the product, since patients apply only one-quarter as much sunscreen per unit area when compared with the amount used in tests to determine the SPF listed on the product. Aggressive sunscreen use should be accompanied by vitamin D supplementation in persons at risk for osteopenia (eg, organ transplant recipients).

Green AC et al. Reduced melanoma after regular sunscreen use: randomized trial follow-up. *J Clin Oncol.* 2010 Jan;29(3):257–63. [PMID: 21135266]

Robinson JK et al. Prevention of melanoma with regular sunscreen use. *JAMA.* 2011 Jul 20;306(3):302–3. [PMID: 21712528]

Schalka S et al. The influence of the amount of sunscreen applied and its sun protection factor (SPF): evaluation of two sunscreens including the same ingredients at different concentrations. *Photodermatol Photoimmunol Photomed.* 2009 Aug;25(4):175–80. [PMID: 19614894]

► Complications of Topical Dermatologic Therapy

Complications of topical therapy can be largely avoided. They fall into several categories:

A. Allergy

Of the topical antibiotics, neomycin and bacitracin have the greatest potential for sensitization. Diphenhydramine, benzocaine, vitamin E, aromatic essential oils, and bee pollen are potential sensitizers in topical medications. Preservatives and even the topical corticosteroids themselves can cause allergic contact dermatitis.

B. Irritation

Preparations of tretinoin, benzoyl peroxide, and other acne medications should be applied sparingly to the skin.

C. Overuse

Topical corticosteroids may induce acne-like lesions on the face (steroid rosacea) and atrophic striae in body folds.

COMMON DERMATOSES

PIGMENTED LESIONS

MELANOCYTIC NEVI (Normal Moles)


In general, a **benign mole** is a small (< 6 mm) lesion with a well-defined border and a single shade of pigment from beige or pink to dark brown. The physical examination must take precedence over the history.

Moles have a normal natural history. In the patient's first decade of life, moles often appear as flat, small, brown lesions. They are called **junctional nevi** because the nevus cells are at the junction of the epidermis and dermis. Over the next 2 decades, these moles grow in size and often become raised, reflecting the appearance of a dermal component, giving rise to **compound nevi** (Figure 6-1). Moles may darken and grow during pregnancy. As white patients enter their seventh and eighth decades, most moles have lost their junctional component and dark pigmentation. At every stage of life, normal moles should be well-demarcated, symmetric, and uniform in contour and color.

Marsden JR et al; British Association of Dermatologists (BAD) Clinical Standards Unit. Revised UK guidelines for the management of cutaneous melanoma 2010. *J Plast Reconstr Aesthet Surg*. 2010 Sep;63(9):1401-19. [PMID: 20728418]
 U.S. Preventive Services Task Force. Screening for skin cancer: U.S. Preventive Services Task Force recommendation statement. *Ann Intern Med*. 2009 Feb 3;150(3):188-93. [PMID: 19189908]

ATYPICAL NEVI

The term "atypical nevus" or "atypical mole" has supplanted "dysplastic nevus." The diagnosis of atypical moles is made clinically and not histologically, and moles should be removed only if they are suspected to be melanomas. Clinically, these moles are large (≥ 6 mm in diameter), with an ill-defined, irregular border and irregularly distributed pigmentation (Figure 6-2). It is estimated that 5-10% of the white population in the United States has one or more



▲ **Figure 6-1.** Benign, flat and macular compound nevus on the arm. (Courtesy of Richard P. Usatine, MD; used, with permission, from Usatine RP, Smith MA, Mayeaux EJ Jr, Chumley H, Tysinger J. *The Color Atlas of Family Medicine*. McGraw-Hill, 2009.)

atypical nevi, and recreational sun exposure is a primary risk for the development of atypical nevi in nonfamilial settings. Studies have defined an increased risk of melanoma in the following populations: patients with 50 or more nevi with one or more atypical moles and one mole



▲ **Figure 6-2.** Atypical (dysplastic) nevus on the chest. (Courtesy of Richard P. Usatine, MD; used, with permission, from Usatine RP, Smith MA, Mayeaux EJ Jr, Chumley H, Tysinger J. *The Color Atlas of Family Medicine*. McGraw-Hill, 2009.)

at least 8 mm or larger, and patients with a few to many definitely atypical moles. These patients deserve education and regular (usually every 6–12 months) follow-up. Kindreds with familial melanoma (numerous atypical nevi and a strong family history) deserve even closer attention, as the risk of developing single or even multiple melanomas in these individuals approaches 50% by age 50.

Clark LE. Dysplastic nevi. *Clin Lab Med.* 2011 Jun;31(2):255–65. [PMID: 21549239]
 Lasithiotakis KG et al. Factors associated with the prevalence of atypical nevus in a Mediterranean pigmented skin lesion clinic. *Melanoma Res.* 2011 Oct;21(5):469–73. [PMID: 21760555]

BLUE NEVI

Blue nevi are small, slightly elevated, blue-black lesions (Figure 6–3) that favor the dorsal hands. They are common in persons of Asian descent, and an individual patient may have several of them. If present without change for many years, they may be considered benign, since malignant blue nevi are rare. However, blue-black papules and nodules that



▲ **Figure 6–3.** Blue nevus on the left cheek, with some resemblance to a melanoma. (Courtesy of Richard P. Usatine, MD; used, with permission, from Usatine RP, Smith MA, Mayeaux EJ Jr, Chumley H, Tysinger J. *The Color Atlas of Family Medicine.* McGraw-Hill, 2009.)

are new or growing must be evaluated to rule out nodular melanoma.

Murali R et al. Blue nevi and related lesions: a review highlighting atypical and newly described variants, distinguishing features and diagnostic pitfalls. *Adv Anat Pathol.* 2009 Nov;16(6):365–82. [PMID: 19851128]

FRECKLES & LENTIGINES

Freckles (ephelides) and lentigines are flat brown spots. Freckles first appear in young children, darken with ultraviolet exposure, and fade with cessation of sun exposure. In adults lentigines gradually appear in sun-exposed areas, particularly the dorsa of the hands, upper back, and upper chest, starting in the fourth to fifth decade of life. They are macular, usually 3–5 mm in diameter. On the upper back, they may have a very irregular border (inkspot lentigines). They do not fade with cessation of sun exposure. They should be evaluated like all pigmented lesions: If the pigmentation is homogeneous and they are symmetric and flat, they are most likely benign. They can be treated with topical 0.1% tretinoin, 0.1% tazarotene, 2% 4-hydroxyanisole with 0.01% tretinoin (Solage), laser therapy, or cryotherapy.

Kim J et al. Quantitative comparison of MiTF, Melan-A, HMB-45 and Mel-5 in solar lentigines and melanoma in situ. *J Cutan Pathol.* 2011 Oct;38(10):775–9. [PMID: 21797920]

SEBORRHEIC KERATOSES

Seborrheic keratoses are benign plaques, beige to brown or even black, 3–20 mm in diameter, with a velvety or warty surface (Figure 6–4). They appear to be stuck or pasted onto the skin. They are extremely common—especially in



▲ **Figure 6–4.** Seborrheic keratosis with “stuck on appearance” but irregular borders and color variation suspicious for possible melanoma. (Courtesy of Richard P. Usatine, MD; used, with permission, from Usatine RP, Smith MA, Mayeaux EJ Jr, Chumley H, Tysinger J. *The Color Atlas of Family Medicine.* McGraw-Hill, 2009.)

the elderly—and may be mistaken for melanomas or other types of cutaneous neoplasms. Although they may be frozen with liquid nitrogen or curetted if they itch or are inflamed, no treatment is needed.

Fink AM et al. Seborrheic keratoses in patients with internal malignancies: a case-control study with prospective accrual of patients. *J Eur Acad Dermatol Venereol.* 2009 Nov;23(11):1316–9. [PMID: 19309432]

MALIGNANT MELANOMA

ESSENTIALS OF DIAGNOSIS

- ▶ May be flat or raised.
- ▶ Should be suspected in any pigmented skin lesion with recent change in appearance.
- ▶ Examination with good light may show varying colors, including red, white, black, and bluish.
- ▶ Borders typically irregular.

▶ General Considerations

Malignant melanoma is the leading cause of death due to skin disease. In 2010, there were 68,130 cases of melanoma in the United States, with 38,870 cases in men (representing 5% of all cancers in men) and 29,260 cases in women (representing 4% of all cancers in women). There were 8461 deaths from melanoma in 2009; of those, 5506 were in men. One in four cases of melanoma occurs before the age of 40. Increased detection of early melanomas has led to increased survival, but melanoma fatalities continue to increase, especially in elderly men.

Tumor thickness is the single most important prognostic factor. Ten-year survival rates—related to thickness in millimeters—are as follows: < 1 mm, 95%; 1–2 mm, 80%; 2–4 mm, 55%; and > 4 mm, 30%. With lymph node involvement, the 5-year survival rate is 30%; with distant metastases, it is < 10%.

▶ Clinical Findings

Primary malignant melanomas may be classified into various clinicohistologic types, including lentigo maligna melanoma (arising on chronically sun-exposed skin of older individuals); superficial spreading malignant melanoma (two-thirds of all melanomas arising on intermittently sun-exposed skin); nodular malignant melanoma; acral-lentiginous melanomas (arising on palms, soles, and nail beds); ocular melanoma; and malignant melanomas on mucous membranes. These different clinical types of melanoma appear to have different oncogenic mutations, which may be important in the treatment of patients with advanced disease. Clinical features of pigmented lesions suspicious for melanoma are an irregular notched border where the pigment appears to be leaking into the normal surrounding skin; a topography that may be irregular, ie,



▲ **Figure 6-5.** Malignant melanoma, with multiple colors and classic “ABCDE” features. (Used, with permission, from Berger TG, Dept Dermatology, UCSF.)

partly raised and partly flat (Figure 6–5). Color variegation is present, and colors such as pink, blue, gray, white, and black are indications for referral. A useful mnemonic is the ABCD rule: “ABCD = Asymmetry, Border irregularity, Color variegation, and Diameter > 6 mm.” “E” for Evolution can be added. The history of a changing mole (evolution) is the single most important historical reason for close evaluation and possible referral. Bleeding and ulceration are ominous signs. A mole that stands out from the patient’s other moles deserves special scrutiny—the “ugly duckling sign.” A patient with a large number of moles is statistically at increased risk for melanoma and deserves careful and periodic examination, particularly if the lesions are atypical. Referral of suspicious pigmented lesions is always appropriate.

While superficial spreading melanoma is largely a disease of whites, persons of other races are still at risk for this and other types of melanoma, particularly acral lentiginous melanoma. These occur as dark, sometimes irregularly shaped lesions on the palms and soles and as new, often broad and solitary, darkly pigmented longitudinal streaks in the nails. Acral lentiginous melanoma may be a difficult diagnosis because benign pigmented lesions of the hands, feet, and nails occur commonly in more darkly pigmented persons and clinicians may hesitate to biopsy the palms, soles, and nail beds. As a result, the diagnosis is often delayed until the tumor has become clinically obvious and histologically thick. Clinicians should give special attention to new or changing lesions in these areas.

▶ Treatment

Treatment of melanoma consists of excision. After histologic diagnosis, the area is usually reexcised with margins dictated by the thickness of the tumor. Thin low-risk and intermediate-risk tumors require only conservative margins of 1–3 cm. More specifically, surgical margins of 0.5–1 cm for melanoma in situ and 1 cm for lesions < 1 mm in thickness are recommended.

Sentinel lymph node biopsy (selective lymphadenectomy) using preoperative lymphoscintigraphy and intraoperative lymphatic mapping is effective for staging

melanoma patients with intermediate risk without clinical adenopathy and is recommended for all patients with lesions over 1 mm in thickness or with high-risk histologic features. Referral of intermediate-risk and high-risk patients to centers with expertise in melanoma is strongly recommended. Identifying the oncogenic mutations in patients with advanced melanoma may be important in their treatment. The long-term use of β -blockers may reduce the risk of progression of high-risk melanoma.

- Bichakjian CK et al; American Academy of Dermatology. Guidelines of care for the management of primary cutaneous melanoma. *J Am Acad Dermatol*. 2011 Nov;65(5):1032–47. [PMID: 21868127]
- De Giorgi V et al. Treatment with β -blockers and reduced disease progression in patients with thick melanoma. *Arch Intern Med*. 2011 Apr 25;171(8):779–81.
- Scolyer RA. Evolving concepts in melanoma classification and their relevance to multidisciplinary melanoma patient care. *Mol Oncol*. 2011 Apr;5(2):124–36. [PMID: 21482206]
- Swetter SM et al. Melanoma in middle-aged and older men: a multi-institutional survey study of factors related to tumor thickness. *Arch Dermatol*. 2009 Apr;145(4):397–404. [PMID: 19380661]
- Tuong W et al. Melanoma: epidemiology, diagnosis, treatment, and outcomes. *Dermatol Clin*. 2012 Jan;30(1):113–24. [PMID: 22117873]

SCALING DISORDERS

ATOPIC DERMATITIS



ESSENTIALS OF DIAGNOSIS

- ▶ Pruritic, exudative, or lichenified eruption on face, neck, upper trunk, wrists, and hands and in the antecubital and popliteal folds.
- ▶ Personal or family history of allergic manifestations (eg, asthma, allergic rhinitis, atopic dermatitis).
- ▶ Tendency to recur.
- ▶ Onset in childhood in most patients. Onset after age 30 is very uncommon.

▶ General Considerations

Atopic dermatitis looks different at different ages and in people of different races. Diagnostic criteria for atopic dermatitis must include pruritus, typical morphology and distribution (flexural lichenification, hand eczema, nipple eczema, and eyelid eczema in adults), onset in childhood, and chronicity. Also helpful are: (1) a personal or family history of atopic disease (asthma, allergic rhinitis, atopic dermatitis), (2) xerosis-ichthyosis, (3) facial pallor with infraorbital darkening, (4) elevated serum IgE, and (5) repeated skin infections.

▶ Clinical Findings

A. Symptoms and Signs

Itching may be severe and prolonged. Rough, red plaques usually without the thick scale and discrete demarcation of psoriasis affect the face, neck, and upper trunk. The flexural surfaces of elbows and knees are often involved. In chronic cases, the skin is dry, leathery, and lichenified. Pigmented persons may have poorly demarcated hypopigmented patches (pityriasis alba) on the cheeks and extremities. In black patients with severe disease, pigmentation may be lost in lichenified areas. During acute flares, widespread redness with weeping, either diffusely or in discrete plaques, is common.

B. Laboratory Findings

Food allergy is an uncommon cause of flares of atopic dermatitis in adults. Radioallergosorbent tests (RASTs) or skin tests may suggest dust mite allergy. Eosinophilia and increased serum IgE levels may be present.

▶ Differential Diagnosis

Atopic dermatitis must be distinguished from seborrheic dermatitis (less pruritic, frequent scalp and face involvement, greasy and scaly lesions, and quick response to therapy). Secondary staphylococcal infections may exacerbate atopic dermatitis, and should be considered during hyperacute, weepy flares of atopic dermatitis. Fissuring where the earlobe connects to the neck is a cardinal sign of secondary infection. Since virtually all patients with atopic dermatitis have skin disease before age 5, a new diagnosis of atopic dermatitis in an adult over age 30 should be made cautiously and only after consultation. Atopic-like dermatitis associated with marked elevation of IgE, recurrent staphylococcal abscesses, recurrent pneumonia with pneumatocele formation, and retained primary dentition may indicate hyper-IgE syndrome.

▶ Treatment

Patient education regarding gentle skin care and exactly how to use medications is critical in the successful management of atopic dermatitis.

A. General Measures

Atopic patients have hyperirritable skin. Anything that dries or irritates the skin will potentially trigger dermatitis. Atopic individuals are sensitive to low humidity and often get worse in the winter. Adults with atopic disorders should not bathe more than once daily. Soap should be confined to the armpits, groin, scalp and feet. Washcloths and brushes should not be used. After rinsing, the skin should be patted dry (not rubbed) and then immediately—within three minutes—covered with a thin film of an emollient such as Aquaphor, Eucerin, petrolatum, Vanicream, or a corticosteroid as needed. Vanicream can be used if contact dermatitis resulting from additives in medication is suspected. Atopic patients may be irritated by scratchy fabrics, including wools and acrylics. Cottons

are preferable, but synthetic blends also are tolerated. Other triggers of eczema in some patients include sweating, ointments, hot baths, and animal danders.

B. Local Treatment

Corticosteroids should be applied sparingly to the dermatitis once or twice daily and rubbed in well. Their potency should be appropriate to the severity of the dermatitis. In general, one should begin with triamcinolone 0.1% or a stronger corticosteroid then taper to hydrocortisone or another slightly stronger mild corticosteroid (alclometasone, desonide). It is vital that patients taper off corticosteroids and substitute emollients as the dermatitis clears to avoid the side effects of corticosteroids. Tapering is also important to avoid rebound flares of the dermatitis that may follow their abrupt cessation. Tacrolimus ointment (Protopic 0.03% or 0.1%) and pimecrolimus cream (Elidel 1%) can be effective in managing atopic dermatitis when applied twice daily. Burning on application occurs in about 50% of patients using Protopic and in 10–25% of Elidel users, but it may resolve with continued treatment. These medications do not cause skin atrophy or striae, and are safe for application on the face and even the eyelids.

The US Food and Drug Administration (FDA) has issued a black box warning for both topical tacrolimus and pimecrolimus due to concerns about the development of T-cell lymphoma. The agents should be used sparingly and only in locations where less expensive corticosteroids cannot be used. Tacrolimus and pimecrolimus should be avoided in patients at high risk for lymphoma (ie, those with HIV, iatrogenic immunosuppression, prior lymphoma).

The treatment of atopic dermatitis is dictated by the pattern and stage of the dermatitis—acute/weepy, subacute/scaly, or chronic/lichenified.

1. Acute weeping lesions—Use water or aluminum subacetate solution (Domeboro tablets, one in a pint of cool water) or colloidal oatmeal (Aveeno; dispense one box, and use as directed on box) as soothing or astringent soaks, baths, or wet dressings for 10–30 minutes two to four times daily. Lesions on extremities particularly may be bandaged for protection at night. Use high-potency corticosteroids after soaking but spare the face and body folds. Tacrolimus is usually not tolerated at this stage. Systemic corticosteroids may be required (see below).

2. Subacute or scaly lesions—At this stage, the lesions are dry but still red and pruritic. Mid- to high-potency corticosteroids in ointment form should be continued until scaling and elevated skin lesions are cleared and itching is decreased substantially. At that point, patients should begin a 2- to 4-week taper from twice-daily to daily to alternate-day dosing with topical corticosteroids to reliance on emollients, with occasional use of corticosteroids on specific itchy areas. Instead of tapering the frequency of usage of a more potent corticosteroid, it may be preferable to switch to a low-potency corticosteroid. Tacrolimus and pimecrolimus are more expensive alternatives and may be added if corticosteroids cannot be stopped. They avoid the complications of long-term topical corticosteroid use.

3. Chronic, dry, lichenified lesions—Thickened and usually well-demarcated, they are best treated with high-potency to ultra-high-potency corticosteroid ointments. Nightly occlusion for 2–6 weeks may enhance the initial response. Occasionally, adding tar preparations such as LCD (liquor carbonis detergens) 10% in Aquaphor or 2% crude coal tar may be beneficial.

4. Maintenance treatment—Once symptoms have improved, constant application of effective moisturizers is recommended to prevent flares. In patients with moderate disease, weekend only use of topical anti-inflammatories can prevent flares.

C. Systemic and Adjuvant Therapy

Systemic corticosteroids are indicated only for severe acute exacerbations. Oral prednisone dosages should be high enough to suppress the dermatitis quickly, usually starting with 40–60 mg daily for adults. The dosage is then tapered to nil over a period of 2–4 weeks. Owing to the chronic nature of atopic dermatitis and the side effects of chronic systemic corticosteroids, long-term use of these agents is not recommended for maintenance therapy. Classic antihistamines may relieve severe pruritus. Hydroxyzine, diphenhydramine, or doxepin may be useful—the dosage increased gradually to avoid drowsiness. Fissures, crusts, erosions, or pustules indicate staphylococcal infection clinically. Antistaphylococcal antibiotics given systemically—such as a first-generation cephalosporin or doxycycline if methicillin-resistant *Staphylococcus aureus* is suspected—may be helpful in management. Cultures to exclude methicillin-resistant *S aureus* are recommended. Phototherapy can be an important adjunct for severely affected patients, and the properly selected patient with recalcitrant disease may benefit greatly from therapy with UVB with or without coal tar or PUVA (psoralen plus ultraviolet A). Oral cyclosporine, mycophenolate mofetil, methotrexate, or azathioprine may be used for the most severe and recalcitrant cases.

► Complications of Treatment

The clinician should monitor for skin atrophy. **Eczema herpeticum**, a generalized herpes simplex infection manifested by monomorphic vesicles, crusts, or scalloped erosions superimposed on atopic dermatitis or other extensive eczematous processes, is treated successfully with oral acyclovir, 200 mg five times daily, or intravenous acyclovir in a dose of 10 mg/kg intravenously every 8 hours (500 mg/m² every 8 hours). Tacrolimus and pimecrolimus may increase the risk of eczema herpeticum. Smallpox vaccination is absolutely contraindicated in patients with atopic dermatitis or a history thereof because of the risk of eczema vaccinatum (widespread vaccinia infection, preferentially in areas of dermatitis).

► Prognosis

Atopic dermatitis runs a chronic or intermittent course. Affected adults may have only hand dermatitis. Poor

prognostic factors for persistence into adulthood in atopic dermatitis include onset early in childhood, early generalized disease, and asthma. Only 40–60% of these patients have lasting remissions.

Boguniewicz M et al. Recent insights into atopic dermatitis and implications for management of infectious complications. *J Allergy Clin Immunol.* 2010 Jan;125(1):4–13. [PMID: 20109729]

Hong J et al. Management of itch in atopic dermatitis. *Semin Cutan Med Surg.* 2011 Jun;30(2):71–86. [PMID: 21767767]

Schmitt J et al. Efficacy and tolerability of proactive treatment with topical corticosteroids and calcineurin inhibitors for atopic eczema: systematic review and meta-analysis of randomized controlled trials. *Br J Dermatol.* 2011 Feb;164(2):415–28. [PMID: 20819086]

LICHEN SIMPLEX CHRONICUS (Circumscribed Neurodermatitis)



ESSENTIALS OF DIAGNOSIS

- ▶ Chronic itching and scratching.
- ▶ Lichenified lesions with exaggerated skin lines overlying a thickened, well-circumscribed scaly plaque.
- ▶ Predisposition for nape of neck, wrists, external surfaces of forearms, lower legs, scrotum, and vulva.

▶ General Considerations

Lichen simplex chronicus represents a self-perpetuating scratch-itch cycle—a learned behavior that is hard to disrupt.

▶ Clinical Findings

Intermittent itching incites the patient to scratch the lesions. Itching may be so intense as to interfere with sleep. Dry, leathery, hypertrophic, lichenified plaques appear on the neck, ankles, or perineum (Figure 6–6). The patches are rectangular, thickened, and hyperpigmented. The skin lines are exaggerated.

▶ Differential Diagnosis

This disorder can be differentiated from plaque-like lesions such as psoriasis (redder lesions having whiter scales on the elbows, knees, and scalp and nail findings), lichen planus (violaceous, usually smaller polygonal papules), and nummular (coin-shaped) dermatitis. Lichen simplex chronicus may complicate chronic atopic dermatitis.

▶ Treatment

For lesions in extra-genital regions, superpotent topical corticosteroids are effective, with or without occlusion,



▲ **Figure 6-6.** Lichen simplex chronicus. (Used, with permission, from Berger TG, Dept Dermatology, UCSF.)

when used twice daily for several weeks. In some patients, flurandrenolide (Cordran) tape may be effective, since it prevents scratching and rubbing of the lesion. The injection of triamcinolone acetonide suspension (5–10 mg/mL) into the lesions may occasionally be curative. Continuous occlusion with a flexible hydrocolloid dressing for 7 days at a time for 1–2 months may also be helpful. For genital lesions, see the section Pruritus Ani.

▶ Prognosis

The disease tends to remit during treatment but may recur or develop at another site.

Engin B et al. The effect of transcutaneous electrical nerve stimulation in the treatment of lichen simplex: a prospective study. *Clin Exp Dermatol.* 2009 Apr;34(3):324–8. [PMID: 19175614]

Martin-Brufau R et al. Personality differences between patients with lichen simplex chronicus and normal population: a study of pruritus. *Eur J Dermatol.* 2010 May–Jun;20(3):359–63. [PMID: 20388609]

PSORIASIS



ESSENTIALS OF DIAGNOSIS

- ▶ Silvery scales on bright red, well-demarcated plaques, usually on the knees, elbows, and scalp.
- ▶ Nail findings including pitting and onycholysis (separation of the nail plate from the bed).
- ▶ Mild itching (usually).
- ▶ May be associated with psoriatic arthritis.
- ▶ Psoriasis patients are at increased risk for metabolic syndrome and lymphoma.
- ▶ Histopathology is not often useful and can be confusing.

▶ General Considerations

Psoriasis is a common benign, chronic inflammatory skin disease with both a genetic basis and known environmental triggers. Injury or irritation of normal skin tends to induce lesions of psoriasis at the site (Koebner phenomenon). Obesity worsens psoriasis, and significant weight loss in persons with high body mass index (BMI) may lead to substantial improvement of their psoriasis. Psoriasis has several variants—the most common is the plaque type. Eruptive (guttate) psoriasis consisting of myriad lesions 3–10 mm in diameter occurs occasionally after streptococcal pharyngitis. Rarely, grave, occasionally life-threatening forms (generalized pustular and erythrodermic psoriasis) may occur. Plaque type or extensive erythrodermic psoriasis with abrupt onset may accompany HIV infection.

▶ Clinical Findings

There are often no symptoms, but itching may occur and be severe. Favored sites include the scalp, elbows, knees, palms and soles, and nails (Figure 6–7). The lesions are red,



▲ **Figure 6–7.** Nail pitting due to psoriasis. (Courtesy of Richard P. Usatine, MD; used, with permission, from Usatine RP, Smith MA, Mayeaux EJ Jr, Chumley H, Tysinger J. *The Color Atlas of Family Medicine*. McGraw-Hill, 2009.)



▲ **Figure 6–8.** Plaque psoriasis in the sacral region and intergluteal fold. (Courtesy of Richard P. Usatine, MD; used, with permission, from Usatine RP, Smith MA, Mayeaux EJ Jr, Chumley H, Tysinger J. *The Color Atlas of Family Medicine*. McGraw-Hill, 2009.)

sharply defined plaques covered with silvery scales (Figure 6–8). The glans penis and vulva may be affected. Occasionally, only the flexures (axillae, inguinal areas) are involved. Fine stippling (“pitting”) in the nails is highly suggestive of psoriasis. Patients with psoriasis often have a pink or red intergluteal fold. Not all patients have findings in all locations, but the occurrence of a few may help make the diagnosis when other lesions are not typical. Some patients have mainly hand or foot dermatitis and only minimal findings elsewhere. There may be associated arthritis that is most commonly distal and oligoarticular, although the rheumatoid variety with a negative rheumatoid factor may occur. The psychosocial impact of psoriasis is a major factor in determining the treatment of the patient.

▶ Differential Diagnosis

The combination of red plaques with silvery scales on elbows and knees, with scaliness in the scalp or nail findings, is diagnostic (see Figure 6–7). Psoriasis lesions are well demarcated and affect extensor surfaces—in contrast to atopic dermatitis, with poorly demarcated plaques in flexural distribution. In body folds, scraping and culture for *Candida* and examination of scalp and nails will distinguish psoriasis from intertrigo and candidiasis. Dystrophic changes in nails may simulate onychomycosis, but again, the general examination combined with a potassium

hydroxide (KOH) preparation or fungal culture will be valuable in diagnosis. The cutaneous features of reactive arthritis (Reiter syndrome) mimic psoriasis.

► Treatment

There are many therapeutic options in psoriasis to be chosen according to the extent (body surface area [BSA] affected) and the presence of other findings (for example, arthritis). Certain drugs, such as β -blockers, antimalarials, statins, and lithium, may flare or worsen psoriasis. Even tiny doses of systemic corticosteroids given to patients with psoriasis may lead to severe rebound flares of their disease when they are tapered. Never use systemic corticosteroids to treat flares of psoriasis. In general, patients with moderate to severe psoriasis should be managed by or in conjunction with a dermatologist.

A. Limited Disease

For patients with numerous small plaques, phototherapy is the best therapy (see below). For patients with large plaques and < 10% of the BSA involved, the easiest regimen is to use a high-potency to ultra-high-potency topical corticosteroid cream or ointment. It is best to restrict the ultra-high-potency corticosteroids to 2–3 weeks of twice-daily use and then use them in a pulse fashion three or four times on weekends or switch to a midpotency corticosteroid. Topical corticosteroids rarely induce a lasting remission. They may cause psoriasis to become unstable. Additional measures are therefore commonly added to topical corticosteroid therapy. Calcipotriene ointment 0.005% or calcitriol ointment 0.003%, both vitamin D analogs, are used twice daily for plaque psoriasis. Initially, patients are treated with twice-daily corticosteroids plus a vitamin D analog twice daily. This rapidly clears the lesions. The vitamin D analog is then used alone once daily and with the corticosteroid once daily for several weeks. Eventually, the topical corticosteroids are stopped, and once- or twice-daily application of the vitamin D analog is continued long-term. Calcipotriene usually cannot be applied to the groin or on the face because of irritation. Treatment of extensive psoriasis with vitamin D analogs may result in hypercalcemia, so that the maximum dose for calcipotriene is 100 g/week and for calcitriol is 200 g/week. Calcipotriene is incompatible with many topical corticosteroids (but not halobetasol), so if used concurrently it must be applied at a different time. Tar preparations such as Fototar cream, LCD (liquor carbonis detergens) 10% in Nutraderm lotion, alone or mixed directly with triamcinolone 0.1%, are useful adjuncts when applied twice daily. Occlusion alone has been shown to clear isolated plaques in 30–40% of patients. Thin, occlusive hydrocolloid dressings are placed on the lesions and left undisturbed for as long as possible (a minimum of 5 days, up to 7 days) and then replaced. Responses may be seen within several weeks.

For the scalp, start with a tar shampoo, used daily if possible. For thick scales, use 6% salicylic acid gel (eg, Keralyt), P & S solution (phenol, mineral oil, and glycerin), or fluocinonide acetone 0.01% in oil (Derma-Smoother/FS)

under a shower cap at night, and shampoo in the morning. In order of increasing potency, triamcinolone 0.1%, or fluocinonide, betamethasone dipropionate, fluocinonide or amcinonide, and clobetasol are available in solution form for use on the scalp twice daily. For psoriasis in the body folds, treatment is difficult, since potent corticosteroids cannot be used and other agents are poorly tolerated. Tacrolimus ointment 0.1% or 0.03% or pimecrolimus cream 1% may be effective in penile, groin, and facial psoriasis.

B. Moderate Disease

Psoriasis affecting 10–30% of the patient's BSA is frequently treated with UV phototherapy, either in a medical office or via a home light unit. Systemic agents listed below may also be used.

C. Generalized Disease

If psoriasis involves > 30% of the body surface, it is difficult to treat with topical agents. The treatment of choice is outpatient narrowband UVB (NB-UVB) three times weekly. Clearing occurs in an average of 7 weeks, but maintenance may be required. Severe psoriasis unresponsive to outpatient ultraviolet light may be treated in a psoriasis day care center with the Goeckerman regimen, which involves use of crude coal tar for many hours and exposure to UVB light. Such treatment may offer the best chance for prolonged remissions.

PUVA may be effective even in patients who have not responded to standard NB-UVB treatment. Long-term use of PUVA is associated with an increased risk of skin cancer (especially squamous cell carcinoma and perhaps melanoma), particularly in persons with fair complexions. Thus, periodic examination of the skin is imperative. Atypical lentigines are a common complication. There can be rapid aging of the skin in fair individuals. Cataracts have not been reported with proper use of protective glasses. PUVA may be used in combination with other therapy, such as acitretin or methotrexate.

Methotrexate is very effective for severe psoriasis in doses up to 25 mg once weekly. It should be used according to published protocols. Long-term methotrexate use may be associated with cirrhosis. After receiving a 1.5–2 g cumulative dose, the patient should be referred to a hepatologist for consideration of a liver biopsy. Administration of folic acid, 1–2 mg daily, can eliminate nausea caused by methotrexate without compromising efficacy.

Acitretin, a synthetic retinoid, is most effective for pustular psoriasis in dosages of 0.5–0.75 mg/kg/d. Liver enzymes and serum lipids must be checked periodically. Because acitretin is a teratogen and persists for long periods in fat, women of childbearing age must wait at least 3 years after completing acitretin treatment before considering pregnancy. When used as single agents, retinoids will flatten psoriatic plaques, but will rarely result in complete clearing. Retinoids find their greatest use when combined with phototherapy—either UVB or PUVA, with which they are synergistic.

Cyclosporine dramatically improves psoriasis and may be used to control severe cases. Rapid relapse (rebound) is the rule after cessation of therapy, so another agent must be

added if cyclosporine is stopped. The tumor necrosis factor (TNF) inhibitors etanercept (Enbrel), 50 mg twice weekly; infliximab (Remicade); and adalimumab (Humira) are effective in pustular and chronic plaque psoriasis and are also effective for the associated arthritis. Infliximab provides the most rapid response and can be used for severe pustular or erythrodermic flares. Etanercept is used more frequently for long-term treatment at a dose of 50 mg twice weekly for 3 months, then 50 mg once weekly. All three TNF inhibitors can also induce or worsen psoriasis. Alefacept (Amevive) generally has moderate efficacy, but in a small percentage of patients, it is dramatically effective. IL-12/23 monoclonal antibodies (ustekinumab [Stelara]) are also effective and may be considered instead of using a TNF inhibitor. Given the large number of immunosuppressive and biologic agents available, consultation with a dermatologist is recommended when considering institution of treatment with a systemic agent for moderate to severe psoriasis.

► Prognosis

The course tends to be chronic and unpredictable, and the disease may be refractory to treatment. Patients (especially those older than 40 years) should be monitored for metabolic syndrome, which correlates with the severity of their skin disease.

Langan SM et al. Prevalence of metabolic syndrome in patients with psoriasis: a population-based study in the United Kingdom. *J Invest Dermatol.* 2011 (2012 Mar;132(3Pt1):556–62. [PMID: 22113483]

Laws PM et al. Ustekinumab for the treatment of psoriasis. *Expert Rev Clin Immunol.* 2011 Mar;7(2):155–64. [PMID: 21426253]

Levine D et al. Evaluation and management of psoriasis: an internist's guide. *Med Clin North Am.* 2009 Nov;93(6):1291–303. [PMID: 19932332]

Morar N et al. HIV-associated psoriasis: pathogenesis, clinical features, and management. *Lancet Infect Dis.* 2010 Jul;10(7):470–8. [PMID: 20610329]

Mortel MR et al. Prospective new biologic therapies for psoriasis and psoriatic arthritis. *J Drugs Dermatol.* 2010 Aug;9(8):947–58. [PMID: 20684145]

Ryan C et al. Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials. *JAMA.* 2011 Aug 24;306(8):864–71. [PMID: 21862748]

Shelling ML et al. Lack of appropriate screening for the metabolic syndrome in patients with psoriasis risks underrecognition and undertreatment of important comorbidities: comment on "Prevalence of the metabolic syndrome in psoriasis". *Arch Dermatol.* 2011 Apr;147(4):424–5. [PMID: 21482893]

PITYRIASIS ROSEA



ESSENTIALS OF DIAGNOSIS

- ▶ Oval, fawn-colored, scaly eruption following cleavage lines of trunk.
- ▶ Herald patch precedes eruption by 1–2 weeks.
- ▶ Occasional pruritus.

► General Considerations

This is a common mild, acute inflammatory disease that is 50% more common in females. Young adults are principally affected, mostly in the spring or fall. Concurrent household cases have been reported.

► Clinical Findings

Itching is common but is usually mild. The diagnosis is made by finding one or more classic lesions. The lesions consist of oval, fawn-colored plaques up to 2 cm in diameter. The centers of the lesions have a crinkled or “cigarette paper” appearance and a collarette scale, ie, a thin bit of scale that is bound at the periphery and free in the center. Only a few lesions in the eruption may have this characteristic appearance, however. Lesions follow cleavage lines on the trunk (so-called Christmas tree pattern, Figure 6–9), and the proximal portions of the extremities are often involved. A variant that affects the flexures (axillae and groin), so called inverse pityriasis rosea, and a papular variant, especially in black patients, also occur. An initial lesion (“herald patch”) that is often larger than the later lesions often precedes the general eruption by 1–2 weeks. The eruption usually lasts 6–8 weeks and heals without scarring.

► Differential Diagnosis

A serologic test for syphilis should be performed if at least a few perfectly typical lesions are not present and especially



▲ **Figure 6-9.** Pityriasis rosea with scaling lesions following skin lines and resembling a Christmas tree. (Courtesy of EJ Mayeaux, MD; used, with permission, from Usatine RP, Smith MA, Mayeaux EJ Jr, Chumley H, Tysinger J. *The Color Atlas of Family Medicine.* McGraw-Hill, 2009.)

if there are palmar and plantar or mucous membrane lesions or adenopathy, features that are suggestive of secondary syphilis. For the nonexpert, an RPR (rapid plasma reagin) test in all cases is not unreasonable. Tinea corporis may present with red, slightly scaly plaques, but rarely are there more than a few lesions of tinea corporis compared to the many lesions of pityriasis rosea. Seborrheic dermatitis on occasion presents on the body with poorly demarcated patches over the sternum, in the pubic area, and in the axillae. Tinea versicolor lacks the typical collarette rimmed lesions. Certain drugs (eg, angiotensin-converting enzyme [ACE] inhibitors and metronidazole) and influenza immunization may induce a skin eruption mimicking pityriasis rosea.

► Treatment

Pityriasis rosea often requires no treatment. In Asians, Hispanics, or blacks, in whom lesions may remain hyperpigmented for some time, more aggressive management may be indicated. Treatment is, otherwise, only indicated if the patient is symptomatic. No treatment has been demonstrated efficacious in pityriasis rosea in adequately controlled and reproduced trials. Most dermatologists recommend UVB treatments, or prednisone as used for contact dermatitis for severe or severely symptomatic cases. For mild to moderate cases, topical corticosteroids of medium strength (triamcinolone 0.1%) and oral antihistamines may also be used if pruritus is bothersome.

► Prognosis

Pityriasis rosea is usually an acute self-limiting illness that disappears in about 6 weeks.

Rebora AE et al. A novel influenza A (H1N1) virus as a possible cause of pityriasis rosea? A comment. *J Eur Acad Dermatol Venereol.* 2011 Aug;25(8):991–2. [PMID: 21585559]
 Wollenberg A et al. Skin diseases following a Christmas tree pattern. *Clin Dermatol.* 2011 Mar–Apr;29(2):189–94. [PMID: 21396559]

SEBORRHEIC DERMATITIS & DANDRUFF



ESSENTIALS OF DIAGNOSIS

- ▶ Dry scales and underlying erythema.
- ▶ Scalp, central face, presternal, interscapular areas, umbilicus, and body folds.

► General Considerations

Seborrheic dermatitis is an acute or chronic papulosquamous dermatitis that often coexists with psoriasis.

► Clinical Findings

Pruritus is an inconstant finding. The scalp, face, chest, back, umbilicus, eyelid margins, and body folds have dry scales or oily yellowish scurf (Figure 6–10). Patients with Parkinson



▲ **Figure 6–10.** Seborrheic dermatitis. (Used, with permission, from Berger TG, Dept Dermatology, UCSF.)

disease, HIV infection, and patients who become acutely ill and are hospitalized often have seborrheic dermatitis.

► Differential Diagnosis

There is a spectrum from seborrheic dermatitis to scalp psoriasis. Extensive seborrheic dermatitis may simulate intertrigo in flexural areas, but scalp, face, and sternal involvement suggests seborrheic dermatitis.

► Treatment

A. Seborrhea of the Scalp

Shampoos that contain zinc pyrithione or selenium are used daily if possible. These may be alternated with ketoconazole shampoo (1% or 2%) used twice weekly. A combination of shampoos is used in refractory cases. Tar shampoos are also effective for milder cases and for scalp psoriasis. Topical corticosteroid solutions or lotions are then added if necessary and are used twice daily. (See treatment for scalp psoriasis, above.)

B. Facial Seborrheic Dermatitis

The mainstay of therapy is a mild corticosteroid (hydrocortisone 1%, alclometasone, desonide) used intermittently and not near the eyes. If the disorder cannot be controlled with intermittent use of a mild topical corticosteroid alone, ketoconazole (Nizoral) 2% cream is added twice daily. Topical tacrolimus (Protopic) and pimecrolimus (Elidel) are steroid-sparing alternatives.

C. Seborrheic Dermatitis of Nonhairy Areas

Low-potency corticosteroid creams—ie, 1% or 2.5% hydrocortisone, desonide, or alclometasone dipropionate—are highly effective.

D. Seborrhea of Intertriginous Areas

Apply low-potency corticosteroid lotions or creams twice daily for 5–7 days and then once or twice weekly for maintenance as necessary. Ketoconazole or clotrimazole cream may be a useful adjunct. Tacrolimus or pimecrolimus topically may avoid corticosteroid atrophy in chronic cases.

E. Involvement of Eyelid Margins

“Marginal blepharitis” usually responds to gentle cleaning of the lid margins nightly as needed, with undiluted Johnson and Johnson Baby Shampoo using a cotton swab.

► Prognosis

The tendency is for lifelong recurrences. Individual outbreaks may last weeks, months, or years.

FUNGAL INFECTIONS OF THE SKIN

Mycotic infections are traditionally divided into two principal groups—superficial and deep. In this chapter, we will discuss only the superficial infections: tinea corporis and tinea cruris; dermatophytosis of the feet and dermatophytid of the hands; tinea unguium (onychomycosis); and tinea versicolor. See Chapter 36 for discussion of deep mycoses.

The diagnosis of fungal infections of the skin is usually based on the location and characteristics of the lesions and on the following laboratory examinations: (1) Direct demonstration of fungi in 10% KOH of scrapings from suspected lesions. “If it’s scaly, scrape it” is a time-honored maxim (Figure 6–11). (2) Cultures of organisms from skin scrapings. (3) Histologic sections of biopsies stained with

periodic acid-Schiff (Hotchkiss-McManus) technique may be diagnostic if scrapings and cultures are negative.

► Principles of Treatment

A diagnosis should always be confirmed by KOH preparation, culture, or biopsy. Many other diseases cause scaling, and use of an antifungal agent without a firm diagnosis makes subsequent diagnosis more difficult. In general, fungal infections are treated topically except for those involving the nails, those that are very extensive, or those that involve the hair follicles.

Griseofulvin is safe and effective for treating dermatophyte infections of the skin (except for the scalp and nails). Itraconazole, an azole antifungal, and terbinafine, an allylamine oral antifungal, have excellent activity against dermatophytes and can be used in shorter courses than griseofulvin.

Fluconazole has excellent activity against yeasts and may be the treatment of choice for many forms of mucocutaneous candidiasis. Itraconazole, fluconazole, and terbinafine can all cause elevation of liver function tests and—though rarely in the dosing regimens used for the treatment of dermatophytosis—clinical hepatitis. Ketoconazole is no longer recommended for the treatment of dermatophytosis (except for tinea versicolor) because of the higher rate of hepatitis when it is used for more than a month.

► General Measures & Prevention

Since moist skin favors the growth of fungi, dry the skin carefully after bathing or after perspiring heavily. Talc or other drying powders may be useful. The use of topical corticosteroids for other diseases may be complicated by intercurrent tinea or candidal infection, and topical antifungals are often used in intertriginous areas with corticosteroids to prevent this.


1. Tinea Corporis or Tinea Circinata (Body Ringworm)

ESSENTIALS OF DIAGNOSIS

- Ring-shaped lesions with an advancing scaly border and central clearing or scaly patches with a distinct border.
- On exposed skin surfaces or the trunk.
- Microscopic examination of scrapings or culture confirms the diagnosis.

► General Considerations

The lesions are often on exposed areas of the body such as the face and arms. A history of exposure to an infected cat may occasionally be obtained, usually indicating *Microsporum* infection. *Trichophyton rubrum* is the most common pathogen, usually representing extension onto the trunk or extremities of tinea cruris, pedis, or manuum.



▲ **Figure 6–11.** KOH preparation of fungus demonstrating pseudohyphae and budding yeast forms. (Reproduced, with permission, from Nicoll D et al. *Pocket Guide to Diagnostic Tests*, 6th ed. McGraw-Hill, 2012.)

► Clinical Findings

A. Symptoms and Signs

Itching may be present. In classic lesions, rings of erythema have an advancing scaly border and central clearing (Figure 6–12).

B. Laboratory Findings

The diagnosis may be confirmed by KOH preparation or culture.

► Differential Diagnosis

Positive fungal studies distinguish tinea corporis from other skin lesions with annular configuration, such as the

annular lesions of psoriasis, lupus erythematosus, syphilis, granuloma annulare, and pityriasis rosea. Psoriasis has typical lesions on elbows, knees, scalp, and nails. Secondary syphilis is often manifested by characteristic palmar, plantar, and mucous membrane lesions. Tinea corporis rarely has the large number of symmetric lesions seen in pityriasis rosea. Granuloma annulare lacks scales.

► Complications

Complications include extension of the disease down the hair follicles (in which case it becomes much more difficult to cure) and pyoderma.

► Prevention

Treat infected household pets (*Microsporum* infections).

► Treatment

A. Local Measures

Tinea corporis responds to most topical antifungals, including miconazole, clotrimazole, butenafine, and terbinafine, which are available over the counter (see Table 6–2). Terbinafine and butenafine require shorter courses and lead to the most rapid response. Treatment should be continued for 1–2 weeks after clinical clearing. Betamethasone dipropionate with clotrimazole (Lotrisone) is not recommended. Long-term improper use may result in side effects from the high-potency corticosteroid component, especially in body folds. Cases of tinea that are clinically resistant to this combination but respond to topical antifungals without the topical corticosteroid can occur.

B. Systemic Measures

Griseofulvin (ultramicrosize), 250–500 mg twice daily, is used. Typically, only 4–6 weeks of therapy are required. Itraconazole as a single week-long pulse of 200 mg daily is also effective in tinea corporis. Terbinafine, 250 mg daily for 1 month, is an alternative.

► Prognosis

Body ringworm usually responds promptly to conservative topical therapy or to an oral agent within 4 weeks.

2. Tinea Cruris (Jock Itch)



▲ **Figure 6–12.** Tinea pedis and corporis. (Used, with permission, from Berger TG, Dept Dermatology, UCSF.)

ESSENTIALS OF DIAGNOSIS

- ▶ Marked itching in intertriginous areas, usually sparing the scrotum.
- ▶ Peripherally spreading, sharply demarcated, centrally clearing erythematous lesions.
- ▶ May have associated tinea infection of feet or toenails.
- ▶ Laboratory examination with microscope or culture confirms diagnosis.

▶ General Considerations

Tinea cruris lesions are confined to the groin and gluteal cleft. Intractable pruritus ani may occasionally be caused by a tinea infection.

▶ Clinical Findings

A. Symptoms and Signs

Itching may be severe, or the rash may be asymptomatic. The lesions have sharp margins, cleared centers, and active, spreading scaly peripheries. Follicular pustules are sometimes encountered. The area may be hyperpigmented on resolution.

B. Laboratory Findings

Hyphae can be demonstrated microscopically in KOH preparations. The organism may be cultured.

▶ Differential Diagnosis

Tinea cruris must be distinguished from other lesions involving the intertriginous areas, such as candidiasis, seborrheic dermatitis, intertrigo, psoriasis of body folds (“inverse psoriasis”), and erythrasma. Candidiasis is generally bright red and marked by satellite papules and pustules outside of the main border of the lesion. *Candida* typically involves the scrotum. Seborrheic dermatitis also often involves the face, sternum, and axillae. Intertrigo tends to be more red, less scaly, and present in obese individuals in moist body folds with less extension onto the thigh. Inverse psoriasis is characterized by distinct plaques. Other areas of typical psoriatic involvement should be checked, and the KOH examination will be negative. Erythrasma is best diagnosed with Wood (ultraviolet) light—a brilliant coral-red fluorescence is seen.

▶ Treatment

A. General Measures

Drying powder (eg, miconazole nitrate [Zeamorb-AF]) can be dusted into the involved area in patients with excessive perspiration or occlusion of skin due to obesity.

B. Local Measures

Any of the topical antifungal preparations listed in Table 6–2 may be used. Terbinafine cream is curative in over 80% of cases after once-daily use for 7 days.

C. Systemic Measures

Griseofulvin ultramicrosize is reserved for severe cases. Give 250–500 mg orally twice daily for 1–2 weeks. One week of either itraconazole, 200 mg daily, or terbinafine, 250 mg daily, can be effective.

▶ Prognosis

Tinea cruris usually responds promptly to topical or systemic treatment but often recurs.

3. Tinea Manuum & Tinea Pedis (Dermatophytosis, Tinea of Palms & Soles, “Athlete’s Foot”)



ESSENTIALS OF DIAGNOSIS

- ▶ Most often presenting with asymptomatic scaling.
- ▶ May progress to fissuring or maceration in toe web spaces.
- ▶ Common cofactor in lower leg cellulitis.
- ▶ Itching, burning, and stinging of interdigital web; scaling palms, and soles; vesicles of soles in inflammatory cases.
- ▶ The fungus is shown in skin scrapings examined microscopically or by culture of scrapings.

▶ General Considerations

Tinea of the feet is an extremely common acute or chronic dermatosis. Most infections are caused by *Trichophyton* species.

▶ Clinical Findings

A. Symptoms and Signs

The presenting symptom may be itching, burning, or stinging. Pain may indicate secondary infection with complicating cellulitis. Interdigital tinea pedis is the most common predisposing cause of lower leg cellulitis in healthy individuals. Regular examination of the feet of diabetic patients for evidence of scaling and fissuring and treatment of any identified tinea pedis may prevent complications. Tinea pedis has several presentations that vary with the location. On the sole and heel, tinea may appear as chronic noninflammatory scaling, occasionally with thickening and fissuring. This may extend over the sides of the feet in a “moccasin” distribution. The KOH preparation is usually positive. Tinea pedis often appears as a scaling or fissuring of the toe webs, perhaps with sodden maceration (Figure 6–13). As the web spaces become more macerated, the KOH preparation and fungal culture are less often positive because bacterial species begin to dominate. Finally, there may also be grouped vesicles distributed anywhere on the soles, generalized exfoliation of the skin of the soles, or nail involvement in the form of discoloration and thickening and crumbling of the nail plate.

B. Laboratory Findings

KOH and culture does not always demonstrate pathogenic fungi from macerated areas.

▶ Differential Diagnosis

Differentiate from other skin conditions involving the same areas, such as interdigital erythrasma (use Wood light). Psoriasis may be a cause of chronic scaling on the palms or soles and may cause nail changes. Repeated fungal cultures should be negative, and the condition will not



▲ **Figure 6-13.** Tinea pedis in the interdigital space between fourth and fifth digits. (Courtesy of Richard P. Usatine, MD; used, with permission, from Usatine RP, Smith MA, Mayeaux EJ Jr, Chumley H, Tysinger J. *The Color Atlas of Family Medicine*. McGraw-Hill, 2009.)

respond to antifungal therapy. Contact dermatitis (from shoes) will often involve the dorsal surfaces and will respond to topical or systemic corticosteroids. Vesicular lesions should be differentiated from pompholyx (dyshidrosis) and scabies by proper scraping of the roofs of individual vesicles. Rarely, gram-negative organisms may cause toe web infections, manifested as an acute erosive flare of interdigital disease. This entity is treated with aluminum salts (see below) and imidazole antifungal agents or ciclopirox.

► Prevention

The essential factor in prevention is personal hygiene. Wear open-toed sandals if possible. Use of sandals in community showers and bathing places is often recommended, though the effectiveness of this practice has not been studied. Careful drying between the toes after showering is essential. A hair dryer used on low setting may be used. Socks should be changed frequently, and absorbent nonsynthetic socks are preferred. Apply dusting and drying powders as necessary. The use of powders containing antifungal agents (eg, Zeasorb-AF) or chronic use of antifungal creams may prevent recurrences of tinea pedis.

► Treatment

A. Local Measures

1. Macerated stage—Treat with aluminum subacetate solution soaks for 20 minutes twice daily. Broad-spectrum antifungal creams and solutions (containing imidazoles or ciclopirox instead of tolnaftate and haloprogin) will help combat diphtheroids and other gram-positive organisms present at this stage and alone may be adequate therapy. If topical imidazoles fail, 1 week of once-daily topical allylamine treatment (terbinafine or butenafine) will often result in clearing.

2. Dry and scaly stage—Use any of the antifungal agents listed in Table 6-2. The addition of urea 10–20% lotion or cream may increase the efficacy of topical treatments in thick (“moccasin”) tinea of the soles.

B. Systemic Measures

Griseofulvin may be used for severe cases or those recalcitrant to topical therapy. If the infection is cleared by systemic therapy, the patient should be encouraged to begin maintenance with topical therapy, since recurrence is common. Itraconazole, 200 mg daily for 2 weeks or 400 mg daily for 1 week, or terbinafine, 250 mg daily for 2–4 weeks, may be used in refractory cases.

► Prognosis

For many individuals, tinea pedis is a chronic affliction, temporarily cleared by therapy only to recur.

Matricciani L et al. Safety and efficacy of tinea pedis and onychomycosis treatment in people with diabetes: a systematic review. *J Foot Ankle Res*. 2011 Dec 4;4:26. [PMID: 22136082]
Parish LC et al. A randomized, double-blind, vehicle-controlled efficacy and safety study of naftifine 2% cream in the treatment of tinea pedis. *J Drugs Dermatol*. 2011 Nov 1;10(11):1282–8. [PMID: 22052309]

4. Tinea Versicolor (Pityriasis Versicolor)



ESSENTIALS OF DIAGNOSIS

- ▶ Velvety, tan, or pink macules or white macules that do not tan.
- ▶ Fine scales that are not visible but are seen by scraping the lesion.
- ▶ Central upper trunk the most frequent site.
- ▶ Yeast and short hyphae observed on microscopic examination of scales.

► General Considerations

Tinea versicolor is a mild, superficial *Malassezia* infection of the skin (usually of the upper trunk). This yeast is a colonizer of all humans, which accounts for the high recurrence rate after treatment. The eruption is often called to patients' attention by the fact that the involved areas will not tan, and the resulting hypopigmentation may be mistaken for vitiligo. A hyperpigmented form is not uncommon.

► Clinical Findings

A. Symptoms and Signs

Lesions are asymptomatic, but a few patients note itching. The lesions are velvety, tan, pink, or white macules that vary from 4–5 mm in diameter to large confluent areas. The lesions initially do not look scaly, but scales may be readily obtained by scraping the area. Lesions may appear on the trunk, upper arms, neck, and groin.

B. Laboratory Findings

Large, blunt hyphae and thick-walled budding spores (“spaghetti and meatballs”) are seen on KOH. Fungal culture is not useful.

▶ Differential Diagnosis

Vitiligo usually presents with larger periorificial lesions. Vitiligo (and not tinea versicolor) is characterized by total depigmentation, not just a lessening of pigmentation. Vitiligo does not scale. Pink and red-brown lesions on the chest are differentiated from seborrheic dermatitis of the same areas by the KOH preparation.

▶ Treatment & Prognosis

Topical treatments include selenium sulfide lotion, which may be applied from neck to waist daily and left on for 5–15 minutes for 7 days; this treatment is repeated weekly for a month and then monthly for maintenance. Ketoconazole shampoo, 1% or 2%, lathered on the chest and back and left on for 5 minutes may also be used weekly for treatment and to prevent recurrence. Clinicians must stress to the patient that the raised and scaly aspects of the rash are being treated; the alterations in pigmentation may take months to fade or fill in.

Ketoconazole, 200 mg daily orally for 1 week or 400 mg as a single oral dose, with exercise to the point of sweating after ingestion, results in short-term cure of 90% of cases. Patients should be instructed not to shower for 8–12 hours after taking ketoconazole, because it is delivered in sweat to the skin. The single dose may not work in more hot and humid areas, and more protracted therapy carries a small risk of drug-induced hepatitis. Two doses of oral fluconazole, 300 mg, 14 days apart has similar efficacy. Without maintenance therapy, recurrences will occur in over 80% of “cured” cases over the subsequent 2 years. Imidazole creams, solutions, and lotions are quite effective for localized areas but are too expensive for use over large areas such as the chest and back.

Bonifaz A et al. Tinea versicolor, tinea nigra, white piedra, and black piedra. *Clin Dermatol*. 2010 Mar 4;28(2):140–5. [PMID: 20347655]

DISCOID & SUBACUTE LUPUS ERYTHEMATOSUS (Chronic Cutaneous Lupus Erythematosus)



ESSENTIALS OF DIAGNOSIS

- ▶ Localized red plaques, usually on the face.
- ▶ Scaling, follicular plugging, atrophy, dyspigmentation, and telangiectasia of involved areas.
- ▶ Histology distinctive.
- ▶ Photosensitive.

▶ General Considerations

The two most common forms of chronic cutaneous lupus erythematosus (CCLE) are chronic scarring (discoid) lesions (DLE) and erythematous non-scarring red plaques (subacute cutaneous LE) (SCLE). Both occur most frequently in areas exposed to solar irradiation. Permanent hair loss and loss of pigmentation are common sequelae of discoid lesions. Systemic lupus erythematosus (SLE) is discussed in Chapter 20. Patients with SLE may have DLE or SCLE lesions.

▶ Clinical Findings

A. Symptoms and Signs

Symptoms are usually mild. The lesions consist of dusky red, well-localized, single or multiple plaques, 5–20 mm in diameter, usually on the head in DLE and the trunk in SCLE. In DLE, the scalp, face, and external ears may be involved. In discoid lesions, there is atrophy, telangiectasia, depigmentation, and follicular plugging. On the scalp, significant permanent hair loss may occur in lesions of DLE. In SCLE, the lesions are erythematous annular or psoriasisiform plaques up to several centimeters in diameter and favor the upper chest and back.

B. Laboratory Findings

In patients with DLE, the diagnosis of SLE should be considered if the following findings are present: positive anti-nuclear antibody (ANA), other positive serologic studies (eg, anti-double stranded DNA or anti-Smith antibody), presence of hypocomplementemia, or widespread lesions (not localized to the head). Patients with marked photosensitivity and a picture otherwise suggestive of lupus may have negative ANA tests but are positive for antibodies against Ro/SSA or La/SSB (SCLE).

▶ Differential Diagnosis

The diagnosis is based on the clinical appearance confirmed by skin biopsy in all cases. In DLE, the scales are dry and “thumbtack-like” and can thus be distinguished from those of seborrheic dermatitis and psoriasis. Older lesions that have left depigmented scarring (classically in the concha of the ear) or areas of hair loss will also differentiate lupus from these diseases. Ten percent of patients with SLE have discoid skin lesions, and 5% of patients with discoid lesions have SLE. Medications (most commonly, hydrochlorothiazide, calcium channel blockers, ACE inhibitors, TNF inhibitors, and terbinafine) may induce SCLE with a positive Ro/SSA.

▶ Treatment

A. General Measures

Protect from sunlight. Use high-SPF (> 50) sunblock with UVB and UVA coverage daily. **Caution:** Do not use any form of radiation therapy. Avoid using drugs that are potentially photosensitizing when possible.

B. Local Treatment

For limited lesions, the following should be tried before systemic therapy: high-potency corticosteroid creams

applied each night and covered with airtight, thin, pliable plastic film (eg, Saran Wrap); or Cordran tape; or ultra-high-potency corticosteroid cream or ointment applied twice daily without occlusion.

C. Local Infiltration

Triamcinolone acetonide suspension, 2.5–10 mg/mL, may be injected into the lesions of DLE once a month.

D. Systemic Treatment

1. Antimalarials—Caution: These drugs should be used only when the diagnosis is secure because they have been associated with flares of psoriasis, which may be in the differential diagnosis. They may also cause ocular changes, and ophthalmologic evaluation is required at the onset of therapy and at regular intervals during treatment.

A. Hydroxychloroquine sulfate—0.2–0.4 g orally daily for several months may be effective and is often used prior to chloroquine. A minimum 3-month trial is recommended.

B. Chloroquine sulfate—250 mg daily may be effective in some cases where hydroxychloroquine is not.

C. Quinacrine (Atabrine)—100 mg daily may be the safest of the antimalarials, since eye damage has not been reported. It colors the skin yellow and is therefore not acceptable to some patients. It may be added to the other antimalarials for incomplete responses.

2. Isotretinoin—Isotretinoin, 1 mg/kg/d, is effective in hypertrophic DLE lesions and lesions of CLE or SCLE. Recurrences are prompt and predictable on discontinuation of therapy.

3. Thalidomide—Thalidomide is effective in refractory cases in doses of up to 300 mg daily. Monitor for neuropathy.

Both isotretinoin and thalidomide are teratogens and should be used with appropriate contraception and monitoring in women of childbearing age.

► Prognosis

The disease is persistent but not life-endangering unless systemic lupus is present. Treatment with antimalarials is effective in perhaps 60% of cases. Although the only morbidity may be cosmetic, this can be of overwhelming significance in more darkly pigmented patients with widespread disease. Scarring alopecia can be prevented or lessened with close attention and aggressive therapy. Over years, DLE tends to become inactive. Drug-induced SCLC usually resolves over months when the inciting medication is stopped.

Jessop S et al. Drugs for discoid lupus erythematosus. Cochrane Database Syst Rev. 2009 Oct 7;(4):CD002954. [PMID: 19821298]

Kuhn A et al. Photoprotective effects of a broad-spectrum sunscreen in ultraviolet-induced cutaneous lupus erythematosus: a randomized, vehicle-controlled, double-blind study. J Am Acad Dermatol. 2011 Jan;64(1):37–48. [PMID: 21167404]

Marzano AV et al. Drug-induced lupus: an update on its dermatologic aspects. Lupus. 2009 Oct;18(11):935–40. [PMID: 19762393]

Vera-Recabarren MA et al. Comparative analysis of subacute cutaneous lupus erythematosus and chronic cutaneous lupus erythematosus: clinical and immunological study of 270 patients. Br J Dermatol. 2010 Jan;162(1):91–101. [PMID: 19785596]

Wahie S et al. Measuring disease activity and damage in discoid lupus erythematosus. Br J Dermatol. 2010 May;162(5):1030–7. [PMID: 20199547]

CUTANEOUS T CELL LYMPHOMA (Mycosis Fungoides)



ESSENTIALS OF DIAGNOSIS

- ▶ Localized or generalized erythematous scaling patches and plaques.
- ▶ Pruritus.
- ▶ Lymphadenopathy.
- ▶ Distinctive histology.

► General Considerations

Mycosis fungoides is a cutaneous T cell lymphoma that begins on the skin and may involve only the skin for years or decades. Certain medications (including selective serotonin reuptake inhibitors) and photoallergy may produce eruptions clinically and histologically identical to those of mycosis fungoides.

► Clinical Findings

A. Symptoms and Signs

Localized or generalized erythematous patches or plaques are present usually on the trunk. Plaques are almost always over 5 cm in diameter. Pruritus is a frequent complaint. The lesions often begin as nondescript or nondiagnostic patches, and it is not unusual for the patient to have skin lesions for more than a decade before the diagnosis can be confirmed. In more advanced cases, tumors appear. Lymphadenopathy may occur locally or widely. Lymph node enlargement may be due to benign expansion of the node (dermatopathic lymphadenopathy) or by specific involvement with mycosis fungoides.

B. Laboratory Findings

The skin biopsy remains the basis of diagnosis, though at times numerous biopsies are required before the diagnosis can be confirmed. In more advanced disease, circulating malignant T cells (Sézary cells) can be detected in the blood (T cell gene rearrangement test). Eosinophilia may be present.

► Differential Diagnosis

Mycosis fungoides may be confused with psoriasis, a drug eruption, an eczematous dermatitis, or tinea corporis. Histologic examination can distinguish these conditions.

► Treatment

The treatment of mycosis fungoides is complex. Early and aggressive treatment has not proved to cure or prevent progression of the disease. Skin-directed therapies including topical corticosteroids, topical mechlorethamine, bexarotene gel, and UV phototherapy, are used initially. If the disease progresses, PUVA plus retinoids, PUVA plus interferon, extracorporeal photophoresis, bexarotene, α -interferon with or without retinoids, interleukin 12, denileukin, and total skin electron beam treatment are used.

► Prognosis

Mycosis fungoides is usually slowly progressive (over decades). Prognosis is better in patients with patch or plaque stage disease and worse in patients with erythroderma, tumors, and lymphadenopathy. Survival is not reduced in patients with limited patch disease. Elderly patients with limited patch and plaque stage disease commonly die of other causes. Overly aggressive treatment may lead to complications and premature demise.

Agar NS et al. Survival outcomes and prognostic factors in mycosis fungoides/Sézary syndrome: validation of the revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer staging proposal. *J Clin Oncol*. 2010 Nov 1;28(31):4730–9. [PMID: 20855822]

Galper SL et al. Diagnosis and management of mycosis fungoides. *Oncology (Williston Park)*. 2010 May;24(6):491–501. [PMID: 20568590]

Lansigan F et al. Current and emerging treatment strategies for cutaneous T-cell lymphoma. *Drugs*. 2010 Feb 12;70(3):273–86. [PMID: 20166766]

Meyer N et al. Pruritus in cutaneous T-cell lymphomas: frequent, often severe and difficult to treat. *Acta Derm Venereol*. 2010;90(1):12–7. [PMID: 20107719]

Prince HM et al. How I treat mycosis fungoides and Sézary syndrome. *Blood*. 2009 Nov 12;114(20):4337–53. [PMID: 19696197]

EXFOLIATIVE DERMATITIS (Exfoliative Erythroderma)



ESSENTIAL OF DIAGNOSIS

- Scaling and erythema over most of the body.
- Itching, malaise, fever, chills, weight loss.

► General Considerations

Erythroderma describes generalized redness and scaling of the skin of > 30% BSA. A preexisting dermatosis is the cause of exfoliative dermatitis in two-thirds of cases, including psoriasis, atopic dermatitis, contact dermatitis, pityriasis rubra pilaris, and seborrheic dermatitis. Reactions to topical or systemic drugs account for perhaps 20–40% of cases and cancer (underlying lymphoma, solid tumors and,

most commonly, cutaneous T cell lymphoma) for 10–20%. Causation of the remainder is indeterminable. At the time of acute presentation, without a clear-cut prior history of skin disease or drug exposure, it may be impossible to make a specific diagnosis of the underlying condition, and diagnosis may require continued observation.

► Clinical Findings

A. Symptoms and Signs

Symptoms may include itching, weakness, malaise, fever, and weight loss. Chills are prominent. Redness and scaling is widespread. Loss of hair and nails can occur. Generalized lymphadenopathy may be due to lymphoma or leukemia or may be reactive. The mucosae are spared.

B. Laboratory Findings

A skin biopsy is required and may show changes of a specific inflammatory dermatitis or cutaneous T cell lymphoma. Peripheral leukocytes may show clonal rearrangements of the T cell receptor in Sézary syndrome.

► Differential Diagnosis

It may be impossible to identify the cause of exfoliative erythroderma early in the course of the disease, so careful follow-up is necessary.

► Complications

Debility (protein loss) and dehydration may develop in patients with generalized inflammatory exfoliative erythroderma; or sepsis may occur.

► Treatment

A. Topical Therapy

Home treatment is with cool to tepid baths and application of mid-potency corticosteroids under wet dressings or with the use of an occlusive plastic suit. If the exfoliative erythroderma becomes chronic and is not manageable in an outpatient setting, the patient should be hospitalized. Keep the room at a constant warm temperature and provide the same topical treatment as for an outpatient.

B. Specific Measures

Stop all medications, if possible. Systemic corticosteroids may provide spectacular improvement in severe or fulminant exfoliative dermatitis, but long-term therapy should be avoided (see Chapter 26). In addition, systemic corticosteroids must be used with caution because some patients with erythroderma have psoriasis and could develop pustular psoriasis. For cases of psoriatic erythroderma and pityriasis rubra pilaris, acitretin, methotrexate, cyclosporine, or a TNF inhibitor may be indicated. Erythroderma secondary to lymphoma or leukemia requires specific topical or systemic chemotherapy. Suitable antibiotic drugs with coverage for *Staphylococcus* should be given when there is evidence of bacterial infection.

► Prognosis

Most patients recover completely or improve greatly over time but may require long-term therapy. Deaths are rare in the absence of cutaneous T cell lymphoma. A minority of patients will suffer from undiminished erythroderma for indefinite periods.

Bhandarkar AP et al. Nevirapine induced exfoliative dermatitis in an HIV-infected patient. *Indian J Pharmacol.* 2011 Nov;43(6):738–9. [PMID: 22144790]

Mumoli N et al. Severe exfoliative dermatitis caused by esomeprazole. *J Am Geriatr Soc.* 2011 Dec;59(12):2377–8. [PMID: 22188084]

Yuan XY et al. Erythroderma: a clinical-etiological study of 82 cases. *Eur J Dermatol.* 2010 May-Jun;20(3):373–7. [PMID: 20400388]

MISCELLANEOUS SCALING DERMATOSES

Isolated scaly patches may represent actinic (solar) keratoses, nonpigmented seborrheic keratoses, or Bowen or Paget disease.

1. Actinic Keratoses

Actinic keratoses are small (0.2–0.6 cm) macules or papules—flesh-colored, pink, or slightly hyperpigmented—that feel like sandpaper and are tender when the finger is drawn over them. They occur on sun-exposed parts of the body in persons of fair complexion. Actinic keratoses are considered premalignant, but only 1:1000 lesions per year progress to become squamous cell carcinomas.

Application of liquid nitrogen is a rapid and effective method of eradication. The lesions crust and disappear in 10–14 days. An alternative treatment is the use of fluorouracil cream. This agent may be rubbed into the lesions morning and night until they become first red and sore and then crusted and eroded (usually 2–3 weeks). Carac (0.5% fluorouracil) may be used once daily for a longer period (4 weeks to several months). Keratoses may clear with less irritation. Imiquimod 5% cream applied two to three times weekly for 3–6 weeks is the more costly alternative to topical fluorouracil (5FU). Photodynamic therapy can be effective in refractory cases and reduces the duration of treatment. Any lesions that persist should be evaluated for possible biopsy.

Akarsu S et al. Comparison of topical 3% diclofenac sodium gel and 5% imiquimod cream for the treatment of actinic keratoses. *Clin Exp Dermatol.* 2011 Jul;36(5):479–84. [PMID: 21418281]

Berman B et al. Pharmacotherapy of actinic keratosis. *Expert Opin Pharmacother.* 2009 Dec;10(18):3015–31. [PMID: 19925043]

Neidecker MV et al. Pharmacoeconomic considerations in treating actinic keratosis. *Pharmacoeconomics.* 2009;27(6):451–64. [PMID: 19640009]

2. Bowen Disease & Paget Disease

Bowen disease (intraepidermal squamous cell carcinoma) occurs either on both sun-exposed and non-sun-exposed



▲ **Figure 6-14.** Paget disease of the breast surrounding the nipple. (Courtesy of the University of Texas Health Sciences Center, Division of Dermatology; used, with permission, from Usatine RP, Smith MA, Mayeaux EJ Jr, Chumley H, Tysinger J. *The Color Atlas of Family Medicine.* McGraw-Hill, 2009.)

skin. The lesion is usually a small (0.5–3 cm), well-demarcated, slightly raised, pink to red, scaly plaque and may resemble psoriasis or a large actinic keratosis. These lesions may progress to invasive squamous cell carcinoma. Excision or other definitive treatment is indicated.

Extramammary Paget disease, a manifestation of intraepidermal carcinoma or underlying genitourinary or gastrointestinal cancer, resembles chronic eczema and usually involves apocrine areas such as the genitalia. Mammary Paget disease of the nipple, a unilateral or rarely bilateral red scaling plaque that may ooze, is associated with an underlying intraductal mammary carcinoma (Figure 6-14). While these lesions appear as red patches and plaques in fair skinned persons, in Asians, Hispanics, and other persons of color, hyperpigmentation may be prominent.

Hida T et al. Pigmented mammary Paget's disease mimicking melanoma: report of three cases. *Eur J Dermatol.* 2011 Nov 7. [Epub ahead of print]. [PMID: 22064040]

Lazaridou E et al. Persistent erythematous lesion of the vulva: a diagnostic and treatment challenge. *J Drugs Dermatol.* 2012 Jan 1;11(1):110–2. [PMID: 22206086]

Zhang N et al. Extramammary Paget's disease of scrotum—report of 25 cases and literature review. *Urol Oncol.* 2010 Jan-Feb;28(1):28–33. [PMID: 18805708]

INTERTRIGO

Intertrigo is caused by the macerating effect of heat, moisture, and friction. It is especially likely to occur in obese persons and in humid climates. The symptoms are itching, stinging, and burning. The body folds develop fissures, erythema, and sodden epidermis, with superficial denudation. Candidiasis may complicate intertrigo. “Inverse psoriasis,” seborrheic dermatitis, tinea cruris, erythrasma, and candidiasis must be ruled out.

Maintain hygiene in the area, and keep it dry. Compresses may be useful acutely. Hydrocortisone 1% cream plus an imidazole or nystatin cream is effective. Recurrences are common.

VESICULAR DERMATOSES

HERPES SIMPLEX (Cold or Fever Sore; Genital Herpes)



ESSENTIALS OF DIAGNOSIS

- ▶ Recurrent small grouped vesicles on an erythematous base, especially in the orolabial and genital areas.
- ▶ May follow minor infections, trauma, stress, or sun exposure; regional lymph nodes may be swollen and tender.
- ▶ Viral cultures and direct fluorescent antibody tests are positive.

▶ General Considerations

Over 85% of adults have serologic evidence of herpes simplex type 1 (HSV-1) infections, most often acquired asymptotically in childhood. Occasionally, primary infections may be manifested as severe gingivostomatitis. Thereafter, the patient may have recurrent self-limited attacks, provoked by sun exposure, orofacial surgery, fever, or a viral infection.

About 25% of the United States population has serologic evidence of infection with herpes simplex type 2 (HSV-2). HSV-2 causes lesions whose morphology and natural history are similar to those caused by HSV-1 on the genitalia of both sexes. The infection is acquired by sexual contact. In monogamous heterosexual couples where one partner has HSV-2 infection, seroconversion of the noninfected partner occurs in 10% over a 1-year period. Up to 70% of such infections appeared to be transmitted during periods of asymptomatic shedding. Genital herpes may also be due to HSV-1.

▶ Clinical Findings

A. Symptoms and Signs

The principal symptoms are burning and stinging. Neuralgia may precede or accompany attacks. The lesions consist of small, grouped vesicles that can occur anywhere but which most often occur on the vermilion border of the lips (Figure 6-15), the penile shaft, the labia, the perianal skin, and the buttocks. Any erosion in the anogenital region can be due to HSV-2 (or HSV-1). Regional lymph nodes may be swollen and tender. The lesions usually crust and heal in 1 week. Herpes simplex is the most common cause of painful genital ulcerations in patients with HIV infection and other forms of immunosuppression.

B. Laboratory Findings

Lesions of herpes simplex must be distinguished from chancroid, syphilis, pyoderma, or trauma. Direct fluorescent antibody slide tests offer rapid, sensitive diagnosis. Viral culture may also be helpful. Herpes serology is not



▲ **Figure 6-15.** Herpes simplex type 1 vesicles at the vermilion border of the lip. (Courtesy of Richard P. Usatine, MD; used, with permission, from Usatine RP, Smith MA, Mayeaux EJ Jr, Chumley H, Tysinger J. *The Color Atlas of Family Medicine*. McGraw-Hill, 2009.)

used in the diagnosis of an acute genital ulcer. However, specific HSV-2 serology by Western blot assay or enzyme-linked immunosorbent assay (ELISA) can determine who is HSV-infected and potentially infectious. Such testing is very useful in couples in which only one partner reports a history of genital herpes.

▶ Complications

Complications include pyoderma, eczema herpeticum, herpetic whitlow, herpes gladiatorum (epidemic herpes in wrestlers transmitted by contact), proctitis, esophagitis, neonatal infection, keratitis, and encephalitis.

▶ Prevention

Sunscreens are useful adjuncts in preventing sun-induced recurrences. Prophylactic use of oral acyclovir may prevent recurrences. Acyclovir should be started at a dosage of 200 mg four times daily beginning 24 hours prior to ultraviolet light exposure, dental surgery, or orolabial cosmetic surgery. Comparable doses are 500 mg twice daily for valacyclovir and 250 mg twice daily for famciclovir.

▶ Treatment

A. Systemic Therapy

Three systemic agents are available for the treatment of herpes infections: acyclovir, its valine analog valacyclovir, and famciclovir. All three agents are very effective and, when used properly, virtually nontoxic. Only acyclovir is available for intravenous administration. In the immunocompetent, with the exception of severe orolabial herpes, only genital disease is treated. For first clinical episodes of herpes simplex, the dosage of acyclovir is 400 mg orally five times daily (or 800 mg three times daily); of valacyclovir, 1000 mg twice daily; and of famciclovir, 250 mg three times daily. The duration of treatment is from 7 to 10 days

depending on the severity of the outbreak. Most cases of recurrent herpes are mild and do not require therapy. In addition, pharmacotherapy of recurrent HSV is of limited benefit, with studies finding a reduction in the average outbreak by only 12–24 hours. To be effective, the treatment must be initiated by the patient at the first sign of recurrence. If treatment is desired, recurrent genital herpes outbreaks may be treated with 3 days of valacyclovir, 500 mg twice daily, 5 days of acyclovir, 200 mg five times a day, or 5 days of famciclovir, 125 mg twice daily. Valacyclovir, 2 g twice daily for 1 day, or famciclovir, 1 g once or twice in 1 day, are equally effective short-course alternatives, and can abort impending recurrences of both orolabial and genital herpes. The addition of a potent topical corticosteroid three times daily reduces the duration, size, and pain of orolabial herpes treated with an oral antiviral agent.

In patients with frequent or severe recurrences, suppressive therapy is most effective in controlling disease. Suppressant treatment will reduce outbreaks by 85% and reduces viral shedding by > 90%. This results in about a 50% reduced risk of transmission. The recommended suppressive doses, taken continuously, are acyclovir, 400 mg twice daily; valacyclovir, 500 mg once daily; or famciclovir, 125–250 mg twice daily. Long-term suppression appears very safe, and after 5–7 years a substantial proportion of patients can discontinue treatment. The use of condoms and patient education have proved effective in reducing genital herpes transmission in some studies and in others have not been beneficial. No single or combination intervention absolutely prevents transmission.

B. Local Measures

In general, topical therapy has only limited efficacy. It is strongly urged that 5% acyclovir ointment, if used at all, be limited to the restricted indications for which it has been approved, ie, initial herpes genitalis and mucocutaneous herpes simplex infections in immunocompromised patients. Penciclovir cream, to be applied at the first symptom every 2 hours while awake for 4 days for recurrent orolabial herpes, reduces the average attack duration from 5 days to 4.5 days.

► Prognosis

Aside from the complications described above, recurrent attacks last several days, and patients recover without sequelae.

Harmenberg J et al. Prevention of ulcerative lesions by episodic treatment of recurrent herpes labialis: A literature review. *Acta Derm Venereol.* 2010 Mar;90(2):122–30. [PMID: 20169294]

Martens MG et al. Once daily valacyclovir for reducing viral shedding in subjects newly diagnosed with genital herpes. *Infect Dis Obstet Gynecol.* 2009;2009:1053–76. [PMID: 19680456]

Paz-Bailey G et al. Improvement in healing and reduction in HIV shedding with episodic acyclovir therapy as part of syndromic management among men: a randomized, controlled trial. *J Infect Dis.* 2009 Oct 1;200(7):1039–49. [PMID: 19715417]

HERPES ZOSTER (Shingles)



ESSENTIALS OF DIAGNOSIS

- Pain along the course of a nerve followed by grouped vesicular lesions.
- Involvement is unilateral; some lesions (< 20) may occur outside the affected dermatome.
- Lesions are usually on face or trunk.
- Direct fluorescent antibody positive, especially in vesicular lesions.

► General Considerations

Herpes zoster is an acute vesicular eruption due to the varicella-zoster virus. It usually occurs in adults. With rare exceptions, patients suffer only one attack. Dermatomal herpes zoster does not imply the presence of a visceral malignancy. Generalized disease, however, raises the suspicion of an associated immunosuppressive disorder such as HIV infection. HIV-infected patients are 20 times more likely to develop zoster, often before other clinical findings of HIV disease are present. A history of HIV risk factors and HIV testing when appropriate should be considered, especially in patients with zoster who are younger than 55 years.

► Clinical Findings

Pain usually precedes the eruption by 48 hours or more and may persist and actually increase in intensity after the lesions have disappeared. The lesions consist of grouped, tense, deep-seated vesicles distributed unilaterally along a dermatome (Figure 6–16). The most common distributions are on the trunk or face. Up to 20 lesions may be found outside the affected dermatomes, even in immunocompetent persons. Regional lymph glands may be tender and swollen.

► Differential Diagnosis

Since poison oak and poison ivy dermatitis can occur unilaterally, they must be differentiated at times from herpes zoster. Allergic contact dermatitis is pruritic; zoster is painful. One must differentiate herpes zoster from lesions of herpes simplex, which occasionally occurs in a dermatomal distribution. Doses of antivirals appropriate for zoster should be used in the absence of a clear diagnosis. Facial zoster may simulate erysipelas initially, but zoster is unilateral and shows vesicles after 24–48 hours. The pain of preeruptive herpes zoster may lead the clinician to diagnose migraine, myocardial infarction, acute abdomen, herniated disc, etc, depending on the dermatome involved.

► Complications

Sacral zoster may be associated with bladder and bowel dysfunction. Persistent neuralgia, anesthesia or scarring of the affected area, facial or other nerve paralysis, and



▲ **Figure 6-16.** Herpes zoster. (Used, with permission, from Berger TG, Dept Dermatology, UCSF.)

encephalitis may occur. Postherpetic neuralgia is most common after involvement of the trigeminal region, and in patients over the age of 55. Early (within 72 hours after onset) and aggressive antiviral treatment of herpes zoster reduces the severity and duration of postherpetic neuralgia. Zoster ophthalmicus (V_1) can result in visual impairment.

► Prevention

An effective live herpes zoster vaccine (Zostavax) is available to prevent both herpes zoster and postherpetic neuralgia. It is approved for persons over the age of 50 and recommended in persons aged 60 and older, even in those who have had zoster.

► Treatment

A. General Measures

1. Immunocompetent host—Since early antiviral treatment of zoster reduces postherpetic neuralgia, those with a

risk of developing this complication should be treated, ie, those over age 50 and those with nontruncal eruption. In addition, younger patients with acute moderate to severe pain or rash may benefit from effective antiviral therapy. Treatment can be given with oral acyclovir, 800 mg five times daily; famciclovir, 500 mg three times daily; or valacyclovir, 1 g three times daily—all for 7 days (see Chapter 32). For reasons of increased bioavailability and ease of dosing schedule, the preferred agents are those given three times daily. Patients should maintain good hydration. The dose of antiviral should be adjusted for kidney function as recommended. Nerve blocks may be used in the management of initial severe pain. Ophthalmologic consultation is vital for involvement of the first branch of the trigeminal nerve, even if the patient has no ocular symptoms. Systemic corticosteroids are effective in reducing acute pain, improving quality of life, and returning patients to normal activities much more quickly. They do not increase the risk of dissemination in immunocompetent hosts. If not contraindicated, a tapering 3-week course of prednisone, starting at 60 mg/d, should be considered for its adjunctive benefit in immunocompetent patients. Oral corticosteroids do not reduce the prevalence, severity, or duration of postherpetic neuralgia beyond that achieved by effective antiviral therapy. Adequate analgesia should be given from the onset of zoster-associated pain, which might include opioids, tricyclic antidepressants, and gabapentin in patients with severe pain.

2. Immunocompromised host—Given the safety and efficacy of currently available antivirals, most immunocompromised patients with herpes zoster are candidates for antiviral therapy. The dosage schedule is as listed above, but treatment should be continued until the lesions have completely crusted and are healed or almost healed (up to 2 weeks). Because corticosteroids increase the risk of dissemination in immunosuppressed patients, they should not be used in these patients. Progression of disease may necessitate intravenous therapy with acyclovir, 10 mg/kg intravenously, three times daily. After 3–4 days, oral therapy may be substituted if there has been a good response to intravenous therapy. Adverse effects include decreased kidney function from crystallization, nausea and vomiting, and abdominal pain.

Foscarnet, administered in a dosage of 40 mg/kg two or three times daily intravenously, is indicated for treatment of acyclovir-resistant varicella-zoster virus infections.

B. Local Measures

Calamine or starch shake lotions may be of some help.

C. Postherpetic Neuralgia Therapy

The most effective treatment is prevention with vaccination of those at risk for developing zoster and early and aggressive antiviral therapy once zoster has occurred. Once established, postherpetic neuralgia may be treated with capsaicin ointment, 0.025–0.075%, or lidocaine (Lidoderm) topical patches. Chronic postherpetic neuralgia may be relieved by regional blocks (stellate ganglion, epidural,

local infiltration, or peripheral nerve), with or without corticosteroids added to the injections. Amitriptyline, 25–75 mg orally as a single nightly dose, is the first-line therapy beyond simple analgesics. Gabapentin, up to 3600 mg orally daily (starting at 300 mg orally three times daily), or duloxetine, up to 60–120 mg orally daily (starting at 30–60 mg orally daily) may be added for additional pain relief. Referral to a pain management clinic should be considered in moderate to severe cases and in those failing the above treatments.

► Prognosis

The eruption persists 2–3 weeks and usually does not recur. Motor involvement in 2–3% of patients may lead to temporary palsy.

- Dworkin RH et al. A randomized, placebo-controlled trial of oxycodone and of gabapentin for acute pain in herpes zoster. *Pain*. 2009 Apr;142(3):209–17. [PMID: 19195785]
- Ji G et al. The effectiveness of repetitive paravertebral injections with local anesthetics and steroids for the prevention of postherpetic neuralgia in patients with acute herpes zoster. *Anesth Analg*. 2009 Nov;109(5):1651–5. [PMID: 19713253]
- Oxman MN. Zoster vaccine: current status and future prospects. *Clin Infect Dis*. 2010 Jul 15;51(2):197–213. [PMID: 20550454]
- Shapiro M et al. Update on herpes zoster vaccination: a family practitioner's guide. *Can Fam Physician*. 2011 Oct;57(10):1127–31. [PMID: 21998225]
- Torpy JM et al. JAMA patient page. Shingles. *JAMA*. 2009 Jul 1;302(1):108. [PMID: 19567448]
- Whitley RJ et al. Management of herpes zoster and post-herpetic neuralgia now and in the future. *J Clin Virol*. 2010 May; 48(Suppl 1):S20–8. [PMID: 20510264]

POMPHOLYX; VESICULOBULLOUS HAND ECZEMA (Formerly Known as Dyshidrosis, Dyshidrotic Eczema)



ESSENTIALS OF DIAGNOSIS

- “Tapioca” vesicles of 1–2 mm on the palms, soles, and sides of fingers, associated with pruritus.
- Vesicles may coalesce to form multiloculated blisters.
- Scaling and fissuring may follow drying of the blisters.
- Appearance in the third decade, with lifelong recurrences.

► General Considerations

This is an extremely common form of hand dermatitis, preferably called pompholyx (Gr “bubble”) or vesiculobullous dermatitis of the palms and soles. Patients often have an atopic background and report flares with stress. Patients with widespread dermatitis due to any cause may develop pompholyx-like eruptions as a part of an autoeczematization response.



▲ **Figure 6–17.** Pompholyx (acute vesiculobullous hand eczema). (Used, with permission, from Berger TG, Dept Dermatology, UCSF.)

► Clinical Findings

Small clear vesicles stud the skin at the sides of the fingers and on the palms (Figure 6–17) or soles. They look like the grains in tapioca. They may be associated with intense itching. Later, the vesicles dry and the area becomes scaly and fissured.

► Differential Diagnosis

Unroofing the vesicles and examining the blister roof with a KOH preparation will reveal hyphae in cases of bullous tinea. Patients with inflammatory tinea pedis may have a vesicular dermatophytid of the palms. Always examine the feet of a patient with a hand eruption. Nonsteroidal anti-inflammatory drugs (NSAIDs) may produce an eruption very similar to that of dyshidrosis on the hands.

► Prevention

There is no known way to prevent attacks.

► Treatment

Topical and systemic corticosteroids help some patients dramatically. Since this is a chronic problem, systemic

corticosteroids are generally not appropriate therapy. A high-potency topical corticosteroid used early in the attack may help abort the flare and ameliorate pruritus. Topical corticosteroids are also important in treating the scaling and fissuring that are seen after the vesicular phase. It is essential that patients avoid anything that irritates the skin; they should wear cotton gloves inside vinyl gloves when doing dishes or other wet chores, use long-handled brushes instead of sponges, and use a hand cream after washing the hands. Patients respond to PUVA therapy and injection of botulinum toxin into the palms as for hyperhidrosis.

► Prognosis

For most patients, the disease is an inconvenience. For some, vesiculobullous hand eczema can be incapacitating.

Veien NK. Acute and recurrent vesicular hand dermatitis. *Dermatol Clin.* 2009 Jul;27(3):337–53. [PMID: 19580928]

PORPHYRIA CUTANEA TARDA



ESSENTIALS OF DIAGNOSIS

- Noninflammatory blisters on sun-exposed sites, especially the dorsal surfaces of the hands.
- Hypertrichosis, skin fragility.
- Associated liver disease.
- Elevated urine porphyrins.

► General Considerations

Porphyria cutanea tarda is the most common type of porphyria. Cases are sporadic or hereditary. The disease is associated with ingestion of certain medications (eg, estrogens), and liver disease from alcoholism or hepatitis C. In patients with liver disease, hemosiderosis is often present.

► Clinical Findings

A. Symptoms and Signs

Patients complain of painless blistering and fragility of the skin of the dorsal surfaces of the hands (Figure 6–18). Facial hypertrichosis and hyperpigmentation are common.

B. Laboratory Findings

Urinary uroporphyrins are elevated twofold to fivefold above coproporphyrins. Patients may also have abnormal liver function tests, evidence of hepatitis C infection, increased liver iron stores, and hemochromatosis gene mutations. Multiple triggering factors are often discovered.



▲ **Figure 6–18.** Porphyria cutanea tarda. (Courtesy of Lewis Rose, MD; used, with permission, from Usatine RP, Smith MA, Mayeaux EJ Jr, Chumley H, Tysinger J. *The Color Atlas of Family Medicine.* McGraw-Hill, 2009.)

► Differential Diagnosis

Skin lesions identical to those of porphyria cutanea tarda may be seen in patients who receive maintenance dialysis and in those who take certain medications (tetracyclines and NSAIDs, especially naproxen, and voriconazole). In this so-called pseudoporphyria, the biopsy results are identical to those associated with porphyria cutanea tarda, but urine porphyrins are normal.

► Prevention

Although the lesions are triggered by sun exposure, the wavelength of light triggering the lesions is beyond that absorbed by sunscreens, which for that reason are ineffective. Barrier sun protection with clothing is required.

► Treatment

Stopping all triggering medications and substantially reducing or stopping alcohol consumption may alone lead to improvement. Phlebotomy without oral iron supplementation at a rate of 1 unit every 2–4 weeks will gradually lead to improvement. Very low dose antimalarials (as low as 200 mg of hydroxychloroquine twice weekly), alone or in combination with phlebotomy, will increase the excretion of porphyrins, improving the skin disease. Treatment is continued until the patient is asymptomatic. Urine porphyrins may be monitored.

► Prognosis

Most patients improve with treatment. Sclerodermoid skin lesions may develop on the trunk, scalp, and face.

DERMATITIS HERPETIFORMIS

Dermatitis herpetiformis is an uncommon disease manifested by pruritic papules, vesicles, and papulovesicles mainly on the elbows, knees, buttocks, posterior neck, and scalp. It appears to have its highest prevalence in

Scandinavia and is associated with HLA antigens -B8, -DR3, and -DQ2. The diagnosis is made by light microscopy, which demonstrates neutrophils at the dermal papillary tips. Direct immunofluorescence studies show granular deposits of IgA in the dermal papillae. Circulating antibodies to tissue transglutaminase are present in 90% of cases. NSAIDs may cause flares. Patients have gluten-sensitive enteropathy, but for the great majority it is subclinical. However, ingestion of gluten is the cause of the disease, and strict long-term avoidance of dietary gluten has been shown to decrease the dose of dapsone (usually 100–200 mg daily) required to control the disease and may even eliminate the need for treatment. Patients with dermatitis herpetiformis are at increased risk for development of gastrointestinal lymphoma, and this risk is reduced by a gluten-free diet.

Caproni M et al. Guidelines for the diagnosis and treatment of dermatitis herpetiformis. *J Eur Acad Dermatol Venereol.* 2009 Jun;23(6):633–8. [PMID: 19470076]

Jalil S et al. Associations among behavior-related susceptibility factors in porphyria cutanea tarda. *Clin Gastroenterol Hepatol.* 2010 Mar;8(3):297–302. [PMID: 19948245]

Muñoz-Santos C et al. Familial and sporadic porphyria cutanea tarda: clinical and biochemical features and risk factors in 152 patients. *Medicine (Baltimore).* 2010 Mar;89(2):69–74. [PMID: 20517178]

WEEPING OR CRUSTED LESIONS

IMPETIGO



ESSENTIALS OF DIAGNOSIS

- ▶ Superficial blisters filled with purulent material that rupture easily.
- ▶ Crusted superficial erosions.
- ▶ Positive Gram stain and bacterial culture.

▶ General Considerations

Impetigo is a contagious and autoinoculable infection of the skin caused by staphylococci or streptococci.

▶ Clinical Findings

A. Symptoms and Signs

The lesions consist of macules, vesicles, bullae, pustules, and honey-colored gummy crusts that when removed leave denuded red areas (Figure 6–19). The face and other exposed parts are most often involved. **Ecthyma** is a deeper form of impetigo caused by staphylococci or streptococci, with ulceration and scarring. It occurs frequently on the extremities.

B. Laboratory Findings

Gram stain and culture confirm the diagnosis. In temperate climates, most cases are associated with *S aureus* infection.



▲ **Figure 6–19.** Bullous impetigo. (Used, with permission, from Berger TG, Dept Dermatology, UCSF.)

Streptococcus species are more common in tropical infections. Community-associated methicillin-resistant *S aureus* (CA-MRSA) can be isolated from lesions of impetigo and ecthyma.

▶ Differential Diagnosis

The main differential diagnoses are acute allergic contact dermatitis and herpes simplex. Contact dermatitis may be suggested by the history or by linear distribution of the lesions, and culture should be negative for staphylococci and streptococci. Herpes simplex infection usually presents with grouped vesicles or discrete erosions and may be associated with a history of recurrences. Viral cultures are positive.

▶ Treatment

Soaks and scrubbing can be beneficial, especially in unroofing lakes of pus under thick crusts. Topical agents such as bacitracin, mupirocin, or retapamulin can be attempted for infections limited to small areas. Mupirocin and retapamulin are more expensive than systemic treatments. In most cases, systemic antibiotics are indicated. Cephalexin, 250 mg four times daily, is usually effective. Doxycycline, 100 mg twice daily, is a reasonable alternative. CA-MRSA may cause impetigo, and initial coverage for MRSA could include doxycycline, clindamycin, or trimethoprim-sulfamethoxazole (TMP-SMZ). About 50% of CA-MRSA cases are quinolone resistant. Recurrent impetigo is associated with nasal carriage of *S aureus* and is treated with rifampin, 600 mg daily for 5 days. Intranasal mupirocin ointment twice daily for 5 days clears the carriage of 40% of MRSA strains. Bleach baths (½ to 1 cup per 20 liters of bathwater for 15 minutes 3–5 times weekly) for all family members, and the use of dilute household bleach to clean showers and other bath surfaces may help reduce the spread. Individuals should not share towels if there is a case of impetigo in the household.

Geria AN et al. Impetigo update: new challenges in the era of methicillin resistance. *Cutis.* 2010 Feb;85(2):65–70. [PMID: 20349679]

CONTACT DERMATITIS

ESSENTIALS OF DIAGNOSIS

- ▶ Erythema and edema, with pruritus, often followed by vesicles and bullae (in allergic contact dermatitis) in an area of contact with a suspected agent.
- ▶ Later, weeping, crusting, or secondary infection.
- ▶ A history of previous reaction to suspected contactant.
- ▶ Patch test with agent positive (in allergic contact dermatitis).

▶ General Considerations

Contact dermatitis (irritant or allergic) is an acute or chronic dermatitis that results from direct skin contact with chemicals or allergens. Eighty percent of cases are due to excessive exposure to or additive effects of primary or universal irritants (eg, soaps, detergents, organic solvents) and are called irritant contact dermatitis. This appears red and scaly but not vesicular. The most common causes of allergic contact dermatitis are poison ivy or poison oak; topically applied antimicrobials (especially bacitracin and neomycin), anesthetics (benzocaine); hair-care products; preservatives; jewelry (nickel); rubber; vitamin E; essential oils; propolis (from bees); and adhesive tape. Occupational exposure is an important cause of allergic contact dermatitis. Weeping and crusting are typically due to allergic and not irritant dermatitis.

▶ Clinical Findings

A. Symptoms and Signs

In allergic contact dermatitis, the acute phase is characterized by tiny vesicles and weepy and crusted lesions, whereas resolving or chronic contact dermatitis presents with scaling, erythema, and possibly thickened skin (Figure 6–20). Itching, burning, and stinging may be severe. The lesions, distributed on exposed parts or in bizarre asymmetric patterns, consist of erythematous macules, papules, and vesicles. The affected area is often hot and swollen, with exudation and crusting, simulating—and at times complicated by—infection. The pattern of the eruption may be diagnostic (eg, typical linear streaked vesicles on the extremities in poison oak or ivy dermatitis). The location will often suggest the cause: Scalp involvement suggests hair dyes or shampoos; face involvement, creams, cosmetics, soaps, shaving materials, nail polish; and neck involvement, jewelry, hair dyes.

B. Laboratory Findings

Gram stain and culture will rule out impetigo or secondary infection (impetiginization). If itching is generalized, then scabies should be considered. After the episode of allergic contact dermatitis has cleared, patch testing may be useful if the triggering allergen is not known.



▲ **Figure 6–20.** Contact dermatitis with linear pattern due to poison ivy. (Used, with permission, from Berger TG, Dept Dermatology, UCSF.)

▶ Differential Diagnosis

Asymmetric distribution, blotchy erythema around the face, linear lesions, and a history of exposure help distinguish acute contact dermatitis from other skin lesions. The most commonly mistaken diagnosis is impetigo. Chronic allergic contact dermatitis must be differentiated from scabies, atopic dermatitis, pompholyx, and other eczemas.

▶ Prevention

Prompt and thorough removal of the causative oil by washing with liquid dishwashing soap (eg, Dial Ultra) may be effective if done within 30 minutes after exposure to poison oak or ivy. Goop and Tecnu are also effective but much more costly without increased efficacy. The three most effective over-the-counter barrier creams which are applied prior to exposure and prevent/reduce the severity of the dermatitis are Stokogard, Hollister Moisture Barrier, and Hydropel.

The mainstay of prevention is identification of the agent causing the dermatitis and avoidance of exposure or

use of protective clothing and gloves. In industry-related cases, prevention may be accomplished by moving or retraining the worker.

► Treatment

A. Overview

While local measures are important, severe or widespread involvement is difficult to manage without systemic corticosteroids because even the highest-potency topical corticosteroids seem not to work well on vesicular and weepy lesions. Localized involvement (except on the face) can often be managed solely with topical agents. Irritant contact dermatitis is treated by protection from the irritant and use of topical corticosteroids as for atopic dermatitis (described above). The treatment of allergic contact dermatitis is detailed below.

B. Local Measures

1. Acute weeping dermatitis—Compresses are most often used. It is unwise to scrub lesions with soap and water. Calamine lotion may be used between wet dressings, especially for involvement of intertriginous areas or when oozing is not marked. Lesions on the extremities may be bandaged with wet dressings for 30–60 minutes several times a day. High potency topical corticosteroids in gel or cream form (eg, fluocinonide, clobetasol, or halobetasol) may help suppress acute contact dermatitis and relieve itching. This treatment should be followed by tapering of the number of applications per day or use of a mid-potency corticosteroid such as triamcinolone 0.1% cream to prevent rebound of the dermatitis. A soothing formulation is 2 oz of 0.1% triamcinolone acetonide cream in 7.5 oz Sarna lotion (0.5% camphor, 0.5% menthol, 0.5% phenol) mixed by the patient.

2. Subacute dermatitis (subsiding)—Mid-potency (triamcinolone 0.1%) to high-potency corticosteroids (clobetasol, amcinonide, fluocinonide, desoximetasone) are the mainstays of therapy.

3. Chronic dermatitis (dry and lichenified)—High-potency to superpotency corticosteroids are used in ointment form.

C. Systemic Therapy

For acute severe cases, prednisone may be given orally for 12–21 days. Prednisone, 60 mg for 4–7 days, 40 mg for 4–7 days, and 20 mg for 4–7 days without a further taper is one useful regimen. Another is to dispense seventy-eight 5-mg pills to be taken 12 the first day, 11 the second day, and so on. The key is to use enough corticosteroid (and as early as possible) to achieve a clinical effect and to taper slowly enough to avoid rebound. A Medrol Dosepak (methylprednisolone) with 5 days of medication is inappropriate on both counts. (See Chapter 26.)

► Prognosis

Allergic contact dermatitis is self-limited if reexposure is prevented but often takes 2–3 weeks for full resolution.

Usatine RP et al. Diagnosis and management of contact dermatitis. *Am Fam Physician*. 2010 Aug 1;82(3):249–55. [PMID: 20672788]

PUSTULAR DISORDERS

ACNE VULGARIS



ESSENTIALS OF DIAGNOSIS

- Occurs at puberty, though onset may be delayed into the third or fourth decade.
- Open and closed comedones are the hallmark of acne vulgaris.
- The most common of all skin conditions.
- Severity varies from purely comedonal to papular or pustular inflammatory acne to cysts or nodules.
- Face and upper trunk may be affected.
- Scarring may be a sequela of the disease or picking and manipulating by the patient.

► General Considerations

Acne vulgaris is polymorphic. Open and closed comedones, papules, pustules, and cysts are found. The disease is activated by androgens in those who are genetically predisposed.

Acne vulgaris is more common and more severe in males. It does not always clear spontaneously when maturity is reached. Twelve percent of women and 3% of men over age 25 have acne vulgaris. This rate does not decrease until after age 44. The skin lesions parallel sebaceous activity. Pathogenic events include plugging of the infundibulum of the follicles, retention of sebum, overgrowth of the acne bacillus (*Propionibacterium acnes*) with resultant release of and irritation by accumulated fatty acids, and foreign body reaction to extrafollicular sebum. The mechanism of antibiotics in controlling acne is not clearly understood, but they may work because of their antibacterial or anti-inflammatory properties.

When a resistant case of acne is encountered in a woman, hyperandrogenism may be suspected. This may or may not be accompanied by hirsutism, irregular menses, or other signs of virilism. Polycystic ovary syndrome (PCOS) is the most common identifiable cause.

► Clinical Findings

There may be mild soreness, pain, or itching. The lesions occur mainly over the face, neck, upper chest, back, and shoulders. Comedones are the hallmark of acne vulgaris. Closed comedones are tiny, flesh-colored, noninflamed bumps that give the skin a rough texture or appearance. Open comedones typically are a bit larger and have black



▲ **Figure 6-21.** Acne vulgaris, severe nodular cystic form with scarring. (Courtesy of Richard P. Usatine, MD; used, with permission, from Usatine RP, Smith MA, Mayeaux EJ Jr, Chumley H, Tysinger J. *The Color Atlas of Family Medicine*. McGraw-Hill, 2009.)

material in them. Inflammatory papules, pustules, ectopic pores, acne cysts, and scarring are also seen (Figure 6-21).

Acne may have different presentations at different ages. Preteens often present with comedones as their first lesions. Inflammatory lesions in young teenagers are often found in the middle of the face, extending outward as the patient becomes older. Women in their third and fourth decades (often with no prior history of acne) commonly present with papular lesions on the chin and around the mouth.

► Differential Diagnosis

In adults, acne rosacea presents with papules and pustules in the middle third of the face, but telangiectasia, flushing, and the absence of comedones distinguish this disease from acne vulgaris. A pustular eruption on the face in patients receiving antibiotics or with otitis externa should be investigated with culture to rule out an uncommon gram-negative folliculitis. Acne may develop in patients who use systemic corticosteroids or topical fluorinated corticosteroids on the face. Acne may be exacerbated or caused by irritating creams or oils. Pustules on the face can also be caused by tinea infections. Lesions on the back are more problematic. When they occur alone, staphylococcal folliculitis, miliaria (“heat rash”) or, uncommonly, *Malassezia* folliculitis should be suspected. Bacterial culture, trial of an antistaphylococcal antibiotic, and observing

the response to therapy will help in the differential diagnosis. In patients with HIV infection, folliculitis is common and may be either staphylococcal folliculitis or eosinophilic folliculitis.

► Complications

Cyst formation, pigmentary changes in pigmented patients, severe scarring, and psychological problems may result.

► Treatment

A. General Measures

1. Education of the patient—When scarring seems out of proportion to the severity of the lesions, clinicians must suspect that the patient is manipulating the lesions. It is essential that the patient be educated in a supportive way about this complication. Anxiety and depression are often the underlying cause of young women excoriating minor acne. It is wise to let the patient know that at least 4–6 weeks will be required to see improvement and that old lesions may take months to fade. Therefore, improvement will be judged according to the number of new lesions forming after 6–8 weeks of therapy. Additional time will be required to see improvement on the back and chest, as these areas are slowest to respond. If hair pomades are used, they should contain glycerin and not oil. Avoid topical exposure to oils, cocoa butter (theobroma oil), and greases.

2. Diet—A low glycemic diet that results in weight loss has been reported to improve acne in males aged 18–25. This improvement was associated with a reduction in insulin resistance. Hyperinsulinemia has also been associated with acne in eumenorrheic women. The metabolic syndrome with insulin resistance can also be a feature of PCOS in women. This finding suggests a possible common pathogenic mechanism for acne in both adult women and men.

B. Comedonal Acne

Treatment of acne is based on the type and severity of lesions. Comedones require treatment different from that of pustules and cystic lesions. In assessing severity, take the sequelae of the lesions into account. An individual who gets only a few new lesions per month that scar or leave postinflammatory hyperpigmentation must be treated much more aggressively than a comparable patient whose lesions clear without sequelae. Soaps play little role in acne treatment, and unless the patient’s skin is exceptionally oily, a mild soap should be used to avoid irritation that will limit the usefulness of other topicals, all of which are themselves somewhat irritating. The agents effective in comedonal acne are listed in the order in which they should be tried.

1. Topical retinoids—Tretinoin is very effective for comedonal acne or for treatment of the comedonal component of more severe acne, but its usefulness is limited by irritation. Start with 0.025% cream (not gel) and have the patient use it at first twice weekly at night, then build up to

as often as nightly. A few patients cannot use even this low-strength preparation more than three times weekly but even that may cause improvement. A lentil-sized amount is sufficient to cover the entire face. To avoid irritation, have the patient wait 20 minutes after washing to apply. Adapalene gel 0.1% and reformulated tretinoin (Renova, Retin A Micro, Avita) are other options for patients irritated by standard tretinoin preparations. Some patients—especially teenagers—do best on 0.01% gel. Although the absorption of tretinoin is minimal, its use during pregnancy is contraindicated. Some patients report photosensitivity with tretinoin. Patients should be warned that they may flare in the first 4 weeks of treatment. Tazarotene gel (0.05% or 0.1%) (Tazorac) is another topical retinoid approved for treatment of psoriasis and acne, and may be used in patients intolerant of the other retinoids.

2. Benzoyl peroxide—Benzoyl peroxide products are available in concentrations of 2.5%, 4%, 5%, 8%, and 10%, but it appears that 2.5% is as effective as 10% and less irritating. In general, water-based and not alcohol-based gels should be used to decrease irritation. Benzoyl peroxide in combination with adapalene is available as a single formulation.

3. Antibiotics—Use of topical antibiotics (see below) has been demonstrated to decrease pustular and comedonal lesions.

C. Papular or Cystic Inflammatory Acne

Antibiotics are the mainstay for treatment of inflammatory acne. They may be used topically or orally. The oral antibiotics of choice are tetracycline and doxycycline. Minocycline is often effective in acne unresponsive or resistant to treatment with these antibiotics but it is more expensive. Rarely, other antibiotics such as TMP-SMZ (one double-strength tablet twice daily), clindamycin (150 mg twice daily), or a cephalosporin (cefadroxil or cephalexin) may be used. Topical clindamycin phosphate and erythromycin are also used (see below). Topicals are probably the equivalent of about 500 mg/d of tetracycline given orally, which is half the usual starting dose. Topical antibiotics are used in three situations: for mild papular acne that can be controlled by topicals alone, for patients who refuse or cannot tolerate oral antibiotics, or to wean patients under good control from oral to topical preparations. To decrease resistance, benzoyl peroxide should be used in combination with the topical antibiotic.

1. Mild acne—The first choice of topical antibiotics in terms of efficacy and relative lack of induction of resistant *P. acnes* is the combination of erythromycin or clindamycin with benzoyl peroxide topical gel. Clindamycin (Cleocin T) lotion (least irritating), gel, or solution, or one of the many brands of topical erythromycin gel or solution, may be used twice daily and the benzoyl peroxide in the morning. (A combination of erythromycin or clindamycin with benzoyl peroxide is available as a prescription item.) The addition of tretinoin 0.025% cream or 0.01% gel at night may increase improvement, since it works via a different mechanism.

2. Moderate acne—Tetracycline, 500 mg twice daily, doxycycline, 100 mg twice daily, and minocycline, 50–100 mg twice daily, are all effective though minocycline is more expensive. When initiating minocycline therapy, start at 100 mg in the evening for 4–7 days, then 100 mg twice daily, to decrease the incidence of vertigo. Plan a return visit in 6 weeks and at 3–4 months after that. If the patient's skin is quite clear, instructions should be given for tapering the dose by 250 mg for tetracycline, by 100 mg for doxycycline, or by 50 mg for minocycline every 6–8 weeks—while treating with topicals—to arrive at the lowest systemic dose needed to maintain clearing. In general, immediately lowering the dose to zero without other therapy results in prompt recurrence. Tetracycline, minocycline, and doxycycline are contraindicated in pregnancy, but oral erythromycin may be used.

It is important to discuss the issue of contraceptive failure when prescribing antibiotics for women taking oral contraceptives. Women may need to consider using barrier methods as well, and should report breakthrough bleeding. Oral contraceptives or spironolactone (50–200 mg daily) may be added as an antiandrogen in women with antibiotic-resistant acne or in women in whom relapse occurs after isotretinoin therapy.

3. Severe acne

A. ISOTRETINOIN—A vitamin A analog, isotretinoin is used for the treatment of severe cystic acne that has not responded to conventional therapy. A dosage of 0.5–1 mg/kg/d for 20 weeks for a cumulative dose of at least 120 mg/kg is usually adequate for severe cystic acne. Patients should be offered isotretinoin therapy before they experience significant scarring if they are not promptly and adequately controlled by antibiotics. The drug is *absolutely contraindicated during pregnancy* because of its teratogenicity; two serum pregnancy tests should be obtained before starting the drug in a female and every month thereafter. Sufficient medication for only 1 month should be dispensed. Two forms of effective contraception must be used. Informed consent must be obtained before its use and patients must be enrolled in a monitoring program (iPledge). Side effects occur in most patients, usually related to dry skin and mucous membranes (dry lips, nosebleed, and dry eyes). If headache occurs, pseudotumor cerebri must be considered. Depression has been reported. Hypertriglyceridemia will develop in about 25% of patients, hypercholesterolemia in 15%, and a lowering of high-density lipoproteins in 5%. Minor elevations in liver function tests may develop in some patients. Fasting blood sugar may be elevated. Miscellaneous adverse reactions include decreased night vision, musculoskeletal symptoms, dry skin, thinning of hair, exuberant granulation tissue in lesions, and bony hyperostoses (seen only with very high doses or with long duration of therapy). Moderate to severe myalgias rarely necessitate decreasing the dosage or stopping the drug. Inflammatory bowel disease has first appeared after acne treatment with both tetracyclines and isotretinoin at a rate of 1:1000 cases treated or less. Causality of this association has not been established. Young adults with severe acne who are

potential candidates for isotretinoin should be asked about any bowel symptoms prior to starting isotretinoin. Laboratory tests to be performed in all patients before treatment and after 4 weeks on therapy include complete blood cell count (CBC), cholesterol, triglycerides, and liver function studies.

Elevations of liver enzymes and triglycerides return to normal upon conclusion of therapy. The drug may induce long-term remissions in 40–60%, or acne may recur that is more easily controlled with conventional therapy. Occasionally, acne does not respond or promptly recurs after therapy, but it may clear after a second course.

B. INTRALESIONAL INJECTION—In otherwise moderate acne, intralesional injection of dilute suspensions of triamcinolone acetonide (2.5 mg/mL, 0.05 mL per lesion) will often hasten the resolution of deeper papules and occasional cysts.

C. LASER DERMABRASION—Cosmetic improvement may be achieved by excision and punch-grafting of deep scars and by abrasion of inactive acne lesions, particularly flat, superficial scars. The technique is not without untoward effects, since hyperpigmentation, hypopigmentation, grooving, and scarring have been known to occur. Dark-skinned individuals do poorly. Corrective surgery within 12 months after isotretinoin therapy may not be advisable. Active acne of all types can be treated with certain laser and photodynamic therapies. This can be considered when standard treatments are contraindicated or fail.

► Prognosis

Acne vulgaris eventually remits spontaneously, but when this will occur cannot be predicted. The condition may persist throughout adulthood and may lead to severe scarring if left untreated. Patients treated with antibiotics continue to improve for the first 3–6 months of therapy. Relapse during treatment may suggest the emergence of resistant *P. acnes*. The disease is chronic and tends to flare intermittently in spite of treatment. Remissions following systemic treatment with isotretinoin may be lasting in up to 60% of cases. Relapses after isotretinoin usually occur within 3 years and require a second course in up to 20% of patients.

Bowe WP et al. Diet and acne. *J Am Acad Dermatol*. 2010 Jul;63(1):124–41. [PMID: 20338665]

Feldman SR et al. The efficacy of adapalene-benzoyl peroxide combination increases with number of acne lesions. *J Am Acad Dermatol*. 2011 Jun;64(6):1085–91. [PMID: 21439678]

Hamilton FL et al. Laser and other light therapies for the treatment of acne vulgaris: systematic review. *Br J Dermatol*. 2009 Jun;160(6):1273–85. [PMID: 19239470]

Kaymak Y et al. Comparison of depression, anxiety and life quality in acne vulgaris patients who were treated with either isotretinoin or topical agents. *Int J Dermatol*. 2009 Jan; 48(1):41–6. [PMID: 19126049]

Smith EV et al. What's new in acne? An analysis of systematic reviews published in 2009–2010. *Clin Exp Dermatol*. 2011 Mar;36(2):119–22. [PMID: 20738323]

ROSACEA



ESSENTIALS OF DIAGNOSIS

- ▶ A chronic facial disorder.
- ▶ A neurovascular component (erythema and telangiectasis and a tendency to flush easily).
- ▶ An acneiform component (papules and pustules) may also be present.
- ▶ A glandular component accompanied by hyperplasia of the soft tissue of the nose (rhinophyma).

► General Considerations

The pathogenesis of this disorder is not known. Topical corticosteroids applied to the lower face can induce rosacea-like conditions.

► Clinical Findings

Patients frequently report flushing or exacerbation of their rosacea due to heat or cold, hot drinks, spicy food, sunlight, exercise, alcohol, emotions, or menopausal flushing. The cheeks, nose, and chin—at times the entire face—may have a rosy hue. No comedones are seen. In its mildest form, erythema and dilated vessels are seen on the cheeks. Inflammatory papules may be superimposed on this background and may evolve to pustules (Figure 6–22). Associated seborrhea may be found. The patient often complains of burning or stinging with episodes of flushing. Patients may have associated ophthalmic disease, including blepharitis and keratitis, that often requires systemic antibiotic therapy.

► Differential Diagnosis

Rosacea is distinguished from acne by the presence of the neurovascular component and the absence of comedones. The rosy hue of rosacea and telangiectasis will pinpoint the diagnosis. Lupus is often misdiagnosed, but the presence of pustules excludes that diagnosis.

► Treatment

Educating patients to avoid the factors they know to produce exacerbations is important. Patients should wear a broad-spectrum sunscreen with UVA coverage; however, exquisite sensitivity to topical preparations may limit patient options. Zinc- or titanium-based sunscreens are better tolerated, and barrier protective silicones in the sun-block may enhance tolerance. Medical management is effective only for the inflammatory papules and pustules and the erythema that surrounds them. Rosacea is usually a lifelong condition, so maintenance therapy is required.

A. Local Therapy

Avoidance of triggers (especially alcohol) and sucking on an ice cube may be effective in reducing facial erythema and flushing. Metronidazole (available as creams, gels, or



▲ **Figure 6-22.** Rosacea. (Used, with permission, from Berger TG, Dept Dermatology, UCSF.)

lotions), 0.75% applied twice daily or 1% applied once daily, is the topical treatment of choice. If metronidazole is not tolerated, topical clindamycin (solution, gel, or lotion) 1% applied twice daily is effective. Response is noted in 4–8 weeks. Sulfur-sodium sulfacetamide-containing topicals are helpful in patients only partially responsive to topical antibiotics. Benzoyl peroxide, as in acne vulgaris, may be helpful in reducing the pustular component. Topical retinoids can be carefully added for maintenance.

B. Systemic Therapy

Tetracycline, 250 or 500 mg orally twice daily on an empty stomach, should be used when topical therapy is inadequate. Minocycline or doxycycline, 50–100 mg orally daily to twice daily, is also effective. Metronidazole or amoxicillin, 250–500 mg orally twice daily, or rifaximin, 550 mg orally twice daily, may be used in refractory cases. Side effects are few, although metronidazole may produce a disulfiram-like effect when the patient ingests alcohol and it may cause neuropathy with long-term use. Isotretinoin may succeed where other measures fail. A dosage of 0.5 mg/kg/d orally for 12–28 weeks is recommended. See precautions above. Telangiectasias are benefitted by laser therapy, and phymatous overgrowth of the nose can be treated by surgical reduction.

► Prognosis

Rosacea tends to be a persistent process. With the regimens described above, it can usually be controlled adequately.

Scharschmidt TC et al. Neurogenic rosacea: a distinct clinical subtype requiring a modified approach to treatment. *Arch Dermatol.* 2011 Jan;147(1):123–6. [PMID: 21242409]
van Zuuren EJ et al. Interventions for rosacea. *Cochrane Database Syst Rev.* 2011 Mar 16;(3):CD003262. [PMID: 21412882]

FOLLICULITIS (Including Sycosis)



- ▶ Itching and burning in hairy areas.
- ▶ Pustules in the hair follicles.

► General Considerations

Folliculitis has multiple causes. It is frequently caused by staphylococcal infection and may be more common in the diabetic patient. When the lesion is deep-seated, chronic, and recalcitrant on the head and neck, it is called sycosis.

Gram-negative folliculitis, which may develop during antibiotic treatment of acne, may present as a flare of acne pustules or nodules. *Klebsiella*, *Enterobacter*, *Escherichia coli*, and *Proteus* have been isolated from these lesions.

“Hot tub folliculitis,” caused by *Pseudomonas aeruginosa*, is characterized by pruritic or tender follicular, pustular lesions occurring within 1–4 days after bathing in a contaminated hot tub, whirlpool, or public swimming pool. Rarely, systemic infections may result. Neutropenic patients should avoid these exposures.

Nonbacterial folliculitis may also be caused by friction and oils. Occlusion, perspiration, and rubbing, such as that resulting from tight jeans and other heavy fabrics on the upper legs can worsen this type of folliculitis.

Steroid acne may be seen during topical or systemic corticosteroid therapy.

A form of sterile folliculitis called eosinophilic folliculitis consisting of urticarial papules with prominent eosinophilic infiltration is common in patients with AIDS. It may appear first with institution of highly active antiretroviral therapy (HAART) and be mistaken for a drug eruption.

Pseudofolliculitis is caused by ingrowing hairs in the beard area. It occurs in men and women with tightly curled beard hair. In this entity, the papules and pustules are located at the side of and not in follicles. It may be treated by growing a beard, by using chemical depilatories, or by shaving with a foil-guard razor. Laser hair removal is dramatically beneficial in patients with pseudofolliculitis, requires limited maintenance, and can be done on patients of any skin color. Pseudofolliculitis is a true medical indication for such a procedure and should not be considered cosmetic.

► Clinical Findings

The symptoms range from slight burning and tenderness to intense itching. The lesions consist of pustules of hair follicles (Figure 6–23).



▲ **Figure 6-23.** Bacterial folliculitis. (Used, with permission, from Berger TG, Dept Dermatology, UCSF.)

► Differential Diagnosis

It is important to differentiate bacterial from nonbacterial folliculitis. The history is important for pinpointing the causes of nonbacterial folliculitis, and a Gram stain and culture are indispensable. One must differentiate folliculitis from acne vulgaris or pustular miliaria (heat rash) and from infections of the skin such as impetigo or fungal infections. *Pseudomonas* folliculitis is often suggested by the history of hot tub use. Eosinophilic folliculitis in AIDS often requires biopsy for diagnosis.

► Complications

Abscess formation is the major complication of bacterial folliculitis.

► Prevention

Correct any predisposing local causes such as oils or friction. Be sure that the water in hot tubs and spas is treated properly. If staphylococcal folliculitis is persistent, treatment of nasal or perineal carriage with rifampin, 600 mg daily for 5 days, or with topical mupirocin ointment 2% twice daily for 5 days, may help. Prolonged oral clindamycin, 150–300 mg/d for 4–6 weeks, or oral TMP-SMZ given 1 week per month for 6 months can be effective in preventing recurrent staphylococcal folliculitis and furunculosis. Bleach baths (½ to 1 cup per 20 liters of bathwater for 15 minutes 3–5 times weekly) may reduce cutaneous

staphylococcal carriage and not contribute to antibiotic resistance. Control of blood glucose in diabetes may reduce the number of these infections.

► Treatment

A. Local Measures

Anhydrous ethyl alcohol containing 6.25% aluminum chloride (Xerac AC), applied to lesions and environs, may be helpful, especially for chronic frictional folliculitis of the buttocks. Topical antibiotics are generally ineffective if bacteria have invaded the hair follicle.

B. Specific Measures

Pseudomonas folliculitis will clear spontaneously in non-neutropenic patients if the lesions are superficial. It may be treated with ciprofloxacin, 500 mg twice daily for 5 days.

Systemic antibiotics are recommended for bacterial folliculitis due to other organisms. Extended periods of treatment (4–8 weeks or more) with antistaphylococcal antibiotics are required if infection has involved the scalp or densely hairy areas such as the axilla, beard, or groin.

Gram-negative folliculitis in acne patients may be treated with isotretinoin in compliance with all precautions discussed above (see Acne Vulgaris).

Eosinophilic folliculitis may be treated initially by the combination of potent topical corticosteroids and oral antihistamines. In more severe cases, treatment is with one of the following: topical permethrin (application for 12 hours every other night for 6 weeks); itraconazole, 200–400 mg daily; UVB or PUVA phototherapy; or isotretinoin, 0.5 mg/kg/d for up to 5 months. A remission may be induced by some of these therapies, but long-term treatment may be required.

► Prognosis

Bacterial folliculitis is occasionally stubborn and persistent, requiring prolonged or intermittent courses of antibiotics.

Hernandez C et al. Acute onset of facial pruritic papules in a patient with AIDS: AIDS-associated eosinophilic folliculitis. *Am Fam Physician.* 2009 Mar 15;79(6):511–2. [PMID: 19323365]

MILIARIA (Heat Rash)



ESSENTIALS OF DIAGNOSIS

- ▶ Burning, itching, superficial aggregated small vesicles, papules, or pustules on covered areas of the skin, usually the trunk.
- ▶ More common in hot, moist climates.
- ▶ Rare forms associated with fever and even heat prostration.

► General Considerations

Miliaria occurs most commonly on the trunk and intertriginous areas. A hot, moist environment is the most

frequent cause. Occlusive clothing required for certain occupations may increase the risk. Bedridden febrile patients are susceptible. Plugging of the ostia of sweat ducts occurs, with ultimate rupture of the sweat duct, producing an irritating, stinging reaction. Increase in numbers of resident aerobes, notably cocci, plays a role. Drugs that enhance sweat gland function (eg, clonidine, β -blockers, opiates) may contribute.

► Clinical Findings

The usual symptoms are burning and itching. The lesions consist of small, superficial, red, thin-walled, discrete vesicles (miliaria crystallina), papules (miliaria rubra), or vesicopustules or pustules (miliaria pustulosa). The reaction virtually always affects the back in a hospitalized patient.

► Differential Diagnosis

Miliaria is to be distinguished from drug eruption and folliculitis.

► Prevention

Use of an antibacterial preparation such as chlorhexidine prior to exposure to heat and humidity may help prevent the condition. Frequent turning or sitting of the hospitalized patient may reduce miliaria on the back.

► Treatment

The patient should keep cool and wear light clothing. Triamcinolone acetonide, 0.1% in Sarna lotion, or a mid-potency corticosteroid in a lotion or cream should be applied two to four times daily. Secondary infections (superficial pyoderma) are treated with appropriate antistaphylococcal antibiotics. Anticholinergic drugs given by mouth may be helpful in severe cases, eg, glycopyrrolate, 1 mg twice daily.

► Prognosis

Miliaria is usually a mild disorder, but severe forms (tropical anhidrosis and asthenia) result from interference with the heat-regulating mechanism.

Carter R 3rd et al. Patients presenting with miliaria while wearing flame resistant clothing in high ambient temperatures: a case series. *J Med Case Reports*. 2011 Sep 22;5(1):474. [PMID: 21939537]

MUCOCUTANEOUS CANDIDIASIS



ESSENTIALS OF DIAGNOSIS

- Severe pruritus of vulva, anus, or body folds.
- Superficial denuded, beefy-red areas with or without satellite vesicopustules.
- Whitish curd-like concretions on the oral and vaginal mucous membranes.
- Yeast and pseudohyphae on microscopic examination of scales or curd.



▲ **Figure 6-24.** Oral mucosal candidiasis. (Courtesy of Sol Silverman, Jr., DDS, Public Health Image Library, CDC.)

► General Considerations

Mucocutaneous candidiasis is a superficial fungal infection that may involve almost any cutaneous or mucous surface of the body. It is particularly likely to occur in diabetics, during pregnancy, and in obese persons. Systemic antibiotics, oral corticosteroids, and oral contraceptive agents may be contributory. Oral candidiasis may be the first sign of HIV infection (see Chapter 31).

► Clinical Findings

A. Symptoms and Signs

Itching may be intense. Burning is reported, particularly around the vulva and anus. The lesions consist of superficially denuded, beefy-red areas in the depths of the body folds such as in the groin and the intergluteal cleft, beneath the breasts, at the angles of the mouth, and in the umbilicus. The peripheries of these denuded lesions are superficially undermined, and there may be satellite vesicopustules. Whitish, curd-like concretions may be present on mucosal lesions (Figure 6-24). Paronychia may occur (Figure 6-25).



▲ **Figure 6-25.** Acute paronychia. (Courtesy of EJ Mayeaux, MD; used, with permission, from Usatine RP, Smith MA, Mayeaux EJ Jr, Chumley H, Tysinger J. *The Color Atlas of Family Medicine*. McGraw-Hill, 2009.)

B. Laboratory Findings

Clusters of budding yeast and pseudohyphae can be seen under high power (400×) when skin scales or curd-like lesions have been cleared in 10% KOH. Culture can confirm the diagnosis.

► Differential Diagnosis

Intertrigo, seborrheic dermatitis, tinea cruris, “inverse psoriasis,” and erythrasma involving the same areas may mimic mucocutaneous candidiasis.

► Complications

Systemic invasive candidiasis with candidemia may be seen with immunosuppression and in patients receiving broad-spectrum antibiotic and hypertonic glucose solutions, as in hyperalimentation. There may or may not be clinically evident mucocutaneous candidiasis.

► Treatment

A. General Measures

Affected parts should be kept dry and exposed to air as much as possible. If possible, discontinue systemic antibiotics. For treatment of systemic invasive candidiasis, see Chapter 36.

B. Local Measures

1. Nails and paronychia—Apply clotrimazole solution 1% twice daily. Thymol 4% in ethanol applied once daily is an alternative.

2. Skin—Apply nystatin ointment or clotrimazole cream 1%, either with hydrocortisone cream 1%, twice daily. Gentian violet 0.5% solution is economical and highly effective in treating cutaneous candidiasis (and also mucosal disease), but the purple discoloration represents a cosmetic issue in some patients.

3. Vulvar and anal mucous membranes—For vaginal candidiasis, single-dose fluconazole (150 mg) is effective. Intravaginal clotrimazole, miconazole, terconazole, or nystatin may also be used. Long-term suppressive therapy may be required for recurrent or “intractable” cases. Non-*albicans* candidal species may be identified by culture in some refractory cases and may respond to oral itraconazole, 200 mg twice daily for 2–4 weeks.

4. Balanitis—This is most frequent in uncircumcised men, and *Candida* usually plays a role. Topical nystatin ointment is the initial treatment if the lesions are mildly erythematous or superficially erosive. Soaking with dilute aluminum acetate for 15 minutes twice daily may quickly relieve burning or itching. Chronicity and relapses, especially after sexual contact, suggest reinfection from a sexual partner who should be treated. Severe purulent balanitis is usually due to bacteria. If it is so severe that phimosis occurs, oral antibiotics—some with activity against anaerobes—are required; if rapid improvement does not occur, urologic consultation is indicated.

5. Mastitis—Lancinating breast pain and nipple dermatitis in breastfeeding women may be a manifestation of *Candida* colonization/infection of the breast ducts. Treatment with oral fluconazole, 200 mg daily can be dramatically effective. Topical gentian violet 0.5% is also useful in these cases.

► Prognosis

Cases of cutaneous candidiasis range from the easily cured to the intractable and prolonged.

Amir LH et al. The role of micro-organisms (*Staphylococcus aureus* and *Candida albicans*) in the pathogenesis of breast pain and infection in lactating women: study protocol. BMC Pregnancy Childbirth. 2011 Jul 22;11:54. [PMID: 21777483]
Worthington HV et al. Interventions for treating oral candidiasis for patients with cancer receiving treatment. Cochrane Database Syst Rev. 2010 Jul 7;7:CD001972. [PMID: 20614427]

ERYTHEMAS

REACTIVE ERYTHEMAS

1. Urticaria & Angioedema

ESSENTIALS OF DIAGNOSIS

- ▶ Eruptions of evanescent wheals or hives.
- ▶ Itching is usually intense but may on rare occasions be absent.
- ▶ Special forms of urticaria have special features (dermatographism, cholinergic urticaria, solar urticaria, or cold urticaria).
- ▶ Most incidents are acute and self-limited over a period of 1–2 weeks.
- ▶ Chronic urticaria (episodes lasting > 6 weeks) may have an autoimmune basis.

► General Considerations

Urticaria can result from many different stimuli on an immunologic or nonimmunologic basis. The most common immunologic mechanism is mediated by IgE, as seen in the majority of patients with acute urticaria; another involves activation of the complement cascade. Some patients with chronic urticaria demonstrate autoantibodies directed against mast cell IgE receptors. ACE inhibitor and angiotensin receptor blocker therapy may be complicated by urticaria or angioedema. In general, extensive costly workups are not indicated in patients who have urticaria. A careful history and physical examination are more helpful.

► Clinical Findings

A. Symptoms and Signs

Lesions are itchy red swellings of a few millimeters to many centimeters (Figure 6–26). The morphology of the lesions



▲ **Figure 6-26.** Urticaria. (Used, with permission, from Berger TG, Dept Dermatology, UCSF.)

may vary over a period of minutes to hours, resulting in geographic or bizarre patterns. Individual lesions in true urticaria last <24 hours, and often only 2–4 hours. Angioedema is involvement of deeper subcutaneous tissue with swelling of the lips, eyelids, palms, soles, and genitalia. Angioedema is no more likely than urticaria to be associated with systemic complications such as laryngeal edema or hypotension. In cholinergic urticaria, triggered by a rise in core body temperature (hot showers, exercise), wheals are 2–3 mm in diameter with a large surrounding red flare. Cold urticaria is acquired or inherited and triggered by exposure to cold and wind (see Chapter 37).

B. Laboratory Findings

Laboratory studies are not likely to be helpful in the evaluation of acute or chronic urticaria. The most common causes of acute urticaria are foods, infections, and medications. The cause of chronic urticaria is often not found. In patients with individual lesions that persist past 24 hours, skin biopsy may confirm neutrophilic urticaria or urticarial vasculitis. A functional ELISA test can detect patients with an autoimmune basis for their chronic urticaria.

► Differential Diagnosis

Papular urticaria resulting from insect bites persists for days. A central punctum can usually be seen. Streaked urticarial lesions may be seen in the 24–48 hours before blisters appear in acute allergic plant dermatitis, eg, poison ivy, oak, or sumac. Urticarial response to heat, sun, water, and pressure are quite rare. Urticarial vasculitis may be

seen as part of serum sickness, associated with fever and arthralgia. In this setting, a low serum complement level may be associated with severe systemic disease.

In hereditary angioedema, there is generally a positive family history and gastrointestinal or respiratory symptoms. Urticaria is not part of the syndrome, and lesions are not pruritic.

► Treatment

A. General Measures

A detailed search by history for a cause of acute urticaria should be undertaken, and treatment may then be tailored to include the provocative condition. The chief causes are medications—eg, aspirin, NSAIDs, morphine, and codeine; arthropod bites—eg, insect bites and bee stings (though the latter may cause anaphylaxis as well as angioedema); physical factors such as heat, cold, sunlight, and pressure; and, presumably, neurogenic factors, as in cholinergic urticaria induced by exercise, excitement, hot showers, etc. Other causes may include penicillins and other medications; inhalants such as feathers and animal danders; ingestion of shellfish, tomatoes, or strawberries; vaccines; external contactants, including various chemicals and cosmetics; and infections such as viral hepatitis (causing urticarial vasculitis).

B. Systemic Treatment

The mainstay of treatment initially includes H₁-antihistamines (see above). Initial therapy is hydroxyzine, 10 mg twice daily to 25 mg three times daily, or as a single nightly dose of 50–75 mg to reduce sedation. Cyproheptadine, 4 mg four times daily, may be especially useful for cold urticaria. “Nonsedating” or less sedating antihistamines are added if the generic sedating antihistamines are not effective. Options include fexofenadine, 60 mg twice daily (or 180 mg once daily); or cetirizine or loratadine, 10 mg daily. Higher doses of these second-generation antihistamines may be required to suppress urticaria (up to four times the standard recommended dose) than are required for allergic rhinitis. These high doses are safe and can be used in refractory cases.

Doxepin (a tricyclic antidepressant), 10–75 mg at bedtime, can be very effective in chronic urticaria. It has anticholinergic side effects.

H₂-antihistamines in combination with H₁-blockers may be helpful in patients with symptomatic dermatographism and to a lesser degree in chronic urticaria. UVB phototherapy can suppress some cases of chronic urticaria. If neutrophils are a significant component of the inflammatory infiltrate in chronic urticaria, dapsone may be useful.

A few patients with chronic urticaria may respond to elimination of salicylates and tartrazine (coloring agent). Asymptomatic foci of infection—sinusitis, vaginal candidiasis, cholecystitis, and intestinal parasites—may rarely cause chronic urticaria. Systemic corticosteroids in a dose of about 40 mg daily will usually suppress acute and chronic urticaria. However, the use of corticosteroids is rarely indicated, since properly selected combinations of

antihistamines with less toxicity are usually effective. Once corticosteroids are withdrawn, the urticaria virtually always returns if it had been chronic. Instead of instituting systemic corticosteroids, consultation should be sought from a dermatologist or allergist with experience in managing severe urticaria. Cyclosporine (3–5 mg/kg/d) and other immunosuppressives may be effective in severe cases of autoimmune chronic urticaria.

C. Local Treatment

Local treatment is rarely rewarding.

► Prognosis

Acute urticaria usually lasts only a few days to weeks. Half of patients whose urticaria persists for > 6 weeks will have it for years. Patients in whom angioedema develops with an ACE inhibitor may be switched to an angiotensin receptor blocker with caution (estimated cross reaction about 10%).

Beavers CJ et al. The role of angiotensin receptor blockers in patients with angiotensin-converting enzyme inhibitor-induced angioedema. *Ann Pharmacother.* 2011 Apr;45(4):520–4. [PMID: 21427294]

Fonacier L et al. Clinical evaluation and treatment of chronic urticaria. *Postgrad Med.* 2010 Mar;122(2):148–56. [PMID: 20203466]

Weis M. Clinical review of hereditary angioedema: diagnosis and management. *Postgrad Med.* 2009 Nov;121(6):113–20. [PMID: 19940422]

2. Erythema Multiforme



ESSENTIALS OF DIAGNOSIS

- ▶ Sudden onset of symmetric erythematous skin lesions with history of recurrence.
- ▶ May be macular, papular, urticarial, bullous, or purpuric.
- ▶ “Target” lesions with clear centers and concentric erythematous rings or “iris” lesions may be noted in erythema multiforme minor. These are rare in drug-associated erythema multiforme major.
- ▶ Erythema multiforme minor on extensor surfaces, palms, soles, or mucous membranes. Erythema multiforme major favors the trunk.
- ▶ Herpes simplex is the most common cause of erythema multiforme minor.
- ▶ Drugs are the most common cause of erythema multiforme major in adults.

► General Considerations

Erythema multiforme is an acute inflammatory skin disease that is divided clinically into minor and major types based on the clinical findings. Approximately 90% of cases of erythema multiforme minor follow outbreaks of herpes simplex, and so is now preferably termed “herpes-associated

erythema multiforme.” The term “erythema multiforme major” has been replaced by three terms: Stevens-Johnson syndrome (SJS), with < 10% BSA skin loss; toxic epidermal necrolysis (TEN) when there is > 30% BSA skin loss; and SJS/TEN overlap for cases with between 10% and 30% BSA denudation. The abbreviation SJS/TEN is often used to refer to these three variants of what is considered one syndrome. All these clinical scenarios are characterized by toxicity and involvement of two or more mucosal surfaces (often oral and conjunctival). They are most often caused by drugs, especially sulfonamides, NSAIDs, allopurinol, and anticonvulsants. In certain races, polymorphisms of antigen presenting major histocompatibility (MHC) loci increase the risk for the development of SJS/TEN. *Mycoplasma pneumoniae* may trigger a skin eruption closely resembling SJS and may be the cause of SJS in up to 50% of children in some series. Erythema multiforme may also present as chronic or recurring ulceration localized to the oral mucosa, with skin lesions present in only half of the cases. The exposure to drugs associated with SJS/TEN may be systemic or topical (eg, eyedrops).

► Clinical Findings

A. Symptoms and Signs

A classic target lesion, found most commonly in herpes-associated erythema multiforme, consists of three concentric zones of color change, most often found acrally on the hands and feet. Not all lesions will have this appearance (Figure 6–27). Drug-associated bullous eruptions in the SJS/TEN spectrum present with raised purpuric target-like lesions, with only two zones of color change and a central blister, or nondescript reddish or purpuric macules. Pain on eating, swallowing, and urination can occur if the appropriate mucosae are involved.

B. Laboratory Findings

Blood tests are not useful for diagnosis. Skin biopsy is diagnostic. Direct immunofluorescence studies are negative.



▲ **Figure 6–27.** Erythema multiforme. (Used, with permission, from Berger TG, Dept Dermatology, UCSF.)

► Differential Diagnosis

Urticaria and drug eruptions are the chief entities that must be differentiated from erythema multiforme minor. Individual lesions of true urticaria should come and go within 24 hours and are usually responsive to antihistamines. In erythema multiforme major, the differential diagnosis includes autoimmune bullous diseases (including pemphigus and pemphigoid) and acute generalized exanthematous pustulosis. The presence of a blistering eruption requires biopsy and consultation for appropriate diagnosis and treatment.

► Complications

The tracheobronchial mucosa and conjunctiva may be involved in severe cases with resultant scarring. Ophthalmologic consultation is required if ocular involvement is present because vision loss is the major consequence of SJS/TEN.

► Treatment

A. General Measures

TEN is best treated in a burn unit, or hospital setting with similar support. Otherwise, patients need not be admitted unless mucosal involvement interferes with hydration and nutrition. Patients who begin to blister should be seen daily. Open lesions should be managed like second-degree burns. Immediate discontinuation of the inciting medication (before blistering occurs) is a significant predictor of outcome. Delay in establishing the diagnosis and inadvertently continuing the offending medication results in higher morbidity and mortality.

B. Specific Measures

The most important aspect of treatment is to stop the offending medication and to move patients with > 25–30% BSA involvement to an appropriate acute care environment. Nutritional and fluid support and high vigilance for infection are the most important aspects of care. Recent reviews of systemic treatments for SJS and TEN have been conflicting, but the largest series have failed to show statistically significant benefit with treatment. Some data support the use of high-dose corticosteroids. If corticosteroids are to be tried in more severe cases, they should be used early, before blistering occurs, and in moderate to high doses (prednisone, 100–250 mg) and stopped within days if there is no dramatic response. Intravenous immunoglobulin (IVIG) (1 g/kg/d for 4 days) has become standard of care at some centers for TEN cases and can be considered in cases with > 30% BSA involvement. It has not been proven to reduce mortality. Oral and topical corticosteroids are useful in the oral variant of erythema multiforme. Oral acyclovir prophylaxis of herpes simplex infections may be effective in preventing recurrent herpes-associated erythema multiforme minor.

C. Local Measures

Topical therapy is not very effective in this disease. For oral lesions, 1% diphenhydramine elixir mixed with Kaopectate or with 1% dyclonine may be used as a mouth rinse several times daily.

► Prognosis

Erythema multiforme minor usually lasts 2–6 weeks and may recur. SJS/TEN may be serious with a mortality of about 30% in cases with > 30% BSA involvement.

Harr T et al. Severe cutaneous adverse reactions: acute generalized exanthematous pustulosis, toxic epidermal necrolysis and Stevens-Johnson syndrome. *Med Clin North Am.* 2010 Jul;94(4):727–42. [PMID: 20609860]

Reese D et al. Cyclosporine for SJS/TEN: a case series and review of the literature. *Cutis.* 2011 Jan;87(1):24–9. [PMID: 21323097]

Teo L et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: efficacy of intravenous immunoglobulin and a review of treatment options. *Singapore Med J.* 2009 Jan;50(1):29–33. [PMID: 19224081]

3. Erythema Migrans (See also Chapter 34)

Erythema migrans is a unique cutaneous eruption that characterizes the localized or generalized early stage of Lyme disease (borreliosis). Three to 32 days (median: 7 days) after a tick bite, there is gradual expansion of redness around the papule representing the bite site (Figure 6–28). The advancing border is usually slightly raised, warm, red to bluish-red, and free of any scale. Centrally, the site of the



▲ **Figure 6–28.** Erythema migrans due to *Borrelia burgdorferi* (Lyme disease). (Courtesy of James Gathany, Public Health Image Library, CDC.)

bite may clear, leaving only a rim of peripheral erythema, or it may become indurated, vesicular, or necrotic. The annular erythema usually grows to a median diameter of 15 cm (range: 3–68 cm, but virtually always > 5 cm). It is accompanied by a burning sensation in half of patients; rarely, it is pruritic or painful. Multiple secondary annular lesions similar in appearance to the primary lesion but without indurated centers and generally of smaller size will develop in 20% of patients. In the southeastern United States, similar lesions are seen in patients who are not as ill and who tend to have classic central clearing of their lesions. These patients have negative Lyme serology tests. This condition has been called Southern tick-associated rash illness (STARI). This illness is transmitted by the lone-star tick; some cases are caused by *Borrelia lonestari*, for which the white tail deer is the animal reservoir. Systemic symptoms are uncommon in STARI and the skin lesions respond to the same antibiotic agents used for Lyme disease, suggesting that a spirochete (probably as yet unidentified *Borrelia* species) is causative in all these cases.

Without treatment, erythema migrans and the secondary lesions fade in a median of 28 days, though some may persist for months. Ten percent of untreated patients experience recurrences over the ensuing months. Treatment with systemic antibiotics (see Table 34–4) is necessary to prevent systemic involvement. However, only 60–70% of those with systemic involvement have experienced erythema migrans.

Bhate C et al. Lyme disease: Part I. Advances and perspectives. *J Am Acad Dermatol.* 2011 Apr;64(4):619–36. [PMID: 21414493]

Bhate C et al. Lyme disease: Part II. Management and prevention. *J Am Acad Dermatol.* 2011 Apr;64(4):639–53. [PMID: 21414494]

INFECTIOUS ERYTHEMAS

1. Erysipelas



ESSENTIALS OF DIAGNOSIS

- ▶ Edematous, spreading, circumscribed, hot, erythematous area, with or without vesicles or bullae.
- ▶ Central face frequently involved.
- ▶ Pain, chills, fever, and systemic toxicity may be striking.

▶ General Considerations

Erysipelas is a superficial form of cellulitis that occurs classically on the cheek, caused by β -hemolytic streptococci.

▶ Clinical Findings

A. Symptoms and Signs

The symptoms are pain, malaise, chills, and moderate fever. A bright red spot appears first, very often near a fissure at

the angle of the nose. This spreads to form a tense, sharply demarcated, glistening, smooth, hot plaque. The margin characteristically makes noticeable advances in days or even hours. The lesion is somewhat edematous and may pit slightly with the finger. Vesicles or bullae occasionally develop on the surface. The lesion does not usually become pustular or gangrenous and heals without scar formation. The disease may complicate any break in the skin that provides a portal of entry for the organism.

B. Laboratory Findings

Leukocytosis is almost invariably present; blood cultures may be positive.

▶ Differential Diagnosis

Erysipeloid is a benign bacillary infection producing cellulitis of the skin of the fingers or the backs of the hands in fishermen and meat handlers.

▶ Complications

Unless erysipelas is promptly treated, death may result from extension of the process and systemic toxicity, particularly in the elderly.

▶ Treatment

Place the patient at bed rest with the head of the bed elevated. Intravenous antibiotics effective against group A β -hemolytic streptococci and staphylococci are indicated for the first 48 hours in all but the mildest cases. A 7-day course is completed with penicillin VK, 250 mg, dicloxacillin, 250 mg, or a first-generation cephalosporin, 250 mg, orally four times a day. Alternatives in penicillin-allergic patients are clindamycin (250 mg twice daily orally for 7–14 days) or erythromycin (250 mg four times daily orally for 7–14 days), the latter only if the infection is known to be due to streptococci.

▶ Prognosis

With appropriate treatment, rapid improvement is expected. Recurrence is uncommon.

Pertel PE et al. The efficacy and safety of daptomycin vs. vancomycin for the treatment of cellulitis and erysipelas. *Int J Clin Pract.* 2009 Mar;63(3):368–75. [PMID: 19222623]

2. Cellulitis



ESSENTIALS OF DIAGNOSIS

- ▶ Edematous, expanding, erythematous, warm plaque with or without vesicles or bullae.
- ▶ Lower leg is frequently involved.
- ▶ Pain, chills, and fever are commonly present.
- ▶ Septicemia may develop.



▲ **Figure 6–29.** Erysipelas Cellulitis. (Used, with permission, from Berger TG, Dept Dermatology, UCSF.)

► General Considerations

Cellulitis, a diffuse spreading infection of the dermis and subcutaneous tissue, is usually on the lower leg (Figure 6–29) and most commonly due to gram-positive cocci, especially group A β -hemolytic streptococci and *S aureus*. Rarely, gram-negative rods or even fungi can produce a similar picture. In otherwise healthy persons, the most common portal of entry for lower leg cellulitis is toe web intertrigo with fissuring, usually a complication of interdigital tinea pedis. Venous insufficiency can also predispose to lower leg cellulitis. Injection drug use and open ulcerations may also be complicated by cellulitis. Cellulitis in the diabetic foot may be a major problem and is often associated with neuropathy and hyperkeratotic nodules from ill-fitting shoes and abnormal weight bearing.

► Clinical Findings

A. Symptoms and Signs

Cellulitis begins as a small patch, which from its onset is tender. Swelling, erythema, and pain are often present. The

lesion expands over hours, so that from onset to presentation is usually 6 to 36 hours. As the lesion grows, the patient becomes more ill with progressive chills, fever, and malaise. If septicemia develops, hypotension may develop, followed by shock.

B. Laboratory Findings

Leukocytosis or at least a neutrophilia (left shift) is present from early in the course. Blood cultures may be positive. If a central ulceration, pustule, or abscess is present, culture may be of value. Aspiration of the advancing edge has a low yield (20%) and is usually not performed. Instead, if an unusual organism is suspected and there is no loculated site to culture, a full thickness skin biopsy taken before antibiotics are given can be useful. Part is cultured and part processed for histologic evaluation with Gram stain. This technique is particularly useful in the immunocompromised patient. If a primary source for the infection is identified (wound, leg ulcer, toe web intertrigo), cultures from these sites isolate the causative pathogen in half of cases and can be used to guide antibiotic therapy.

► Differential Diagnosis

Two potentially life threatening entities that can mimic cellulitis (ie, present with a painful, red, swollen lower extremity) include deep venous thrombosis and necrotizing fasciitis. The diagnosis of necrotizing fasciitis should be suspected in a patient who has a very toxic appearance, bullae, crepitus or anesthesia of the involved skin, overlying skin necrosis, and laboratory evidence of rhabdomyolysis (elevated creatine kinase [CK]) or disseminated intravascular coagulation. While these findings may be present with severe cellulitis and bacteremia, it is essential to rule out necrotizing fasciitis because rapid surgical debridement is essential. Other skin lesions that may resemble cellulitis include sclerosing panniculitis, an acute, exquisitely tender red plaque on the medial lower legs above the malleolus in patients with venous stasis or varicosities, and acute severe contact dermatitis on a limb, which produces erythema, vesiculation, and edema as seen in cellulitis, but with itching instead of pain.

► Treatment

Intravenous or parenteral antibiotics may be required for the first 2–5 days, with adequate coverage for *Streptococcus* and *Staphylococcus*. Hospitalization is required in cases with severe local symptoms and signs, hypotension, elevated serum creatinine, low serum bicarbonate, elevated creatine kinase, elevated white blood cell count with marked left shift, or elevated C-reactive protein. If CA-MRSA is suspected, therapy is vancomycin, clindamycin, or TMP-SMZ plus a β -lactam. In mild cases or following the initial parenteral therapy, dicloxacillin or cephalexin, 250–500 mg four times daily for 5–10 days, is usually adequate. If MRSA is suspected, use of TMP-SMZ, clindamycin, or the combination of doxycycline plus rifampin should be considered. In patients in whom intravenous treatment is not instituted, the first dose of oral antibiotic can be doubled to achieve rapid high blood levels.

Chira S et al. *Staphylococcus aureus* is the most common identified cause of cellulitis: a systematic review. *Epidemiol Infect.* 2010 Mar;138(3):313–7. [PMID: 19646308]

Kilburn SA et al. Interventions for cellulitis and erysipelas. *Cochrane Database Syst Rev.* 2010 Jun 16;6:CD004299. [PMID: 20556757]

Morgan MS. Diagnosis and management of necrotising fasciitis: a multiparametric approach. *J Hosp Infect.* 2010 Aug;75(4):249–57. [PMID: 20542593]

BLISTERING DISEASES

PEMPHIGUS



ESSENTIALS OF DIAGNOSIS

- ▶ Relapsing crops of bullae.
- ▶ Often preceded by mucous membrane bullae, erosions, and ulcerations.
- ▶ Superficial detachment of the skin after pressure or trauma variably present (Nikolsky sign).
- ▶ Acantholysis on biopsy.
- ▶ Immunofluorescence studies are confirmatory.

▶ General Considerations

Pemphigus is an uncommon intraepidermal blistering disease occurring on skin and mucous membranes. It is caused by autoantibodies to adhesion molecules expressed in the skin and mucous membranes. The cause is unknown, and in the preantibiotic, presteroid era, the condition was usually fatal within 5 years. The bullae appear spontaneously and are tender and painful when they rupture. Drug-induced pemphigus from penicillamine, captopril, and others has been reported. There are several forms of pemphigus: **pemphigus vulgaris** and its variant, **pemphigus vegetans**; and the more superficially blistering **pemphigus foliaceus** and its variant, **pemphigus erythematosus**. All forms may occur at any age but most commonly in middle age. The vulgaris form begins in the mouth in over 50% of cases. The foliaceus form is especially apt to be associated with other autoimmune diseases, or it may be drug-induced. Paraneoplastic pemphigus, a unique form of the disorder, is associated with numerous types of benign and malignant neoplasms but most frequently non-Hodgkin lymphoma.

▶ Clinical Findings

A. Symptoms and Signs

Pemphigus is characterized by an insidious onset of flaccid bullae, crusts, and erosions in crops or waves (Figure 6–30). In pemphigus vulgaris, lesions often appear first on the oral mucous membranes. These rapidly become erosive. The scalp is another site of early involvement. Rubbing a cotton swab or finger laterally on the surface of uninvolved skin may cause easy separation of the epidermis (**Nikolsky sign**).



▲ **Figure 6–30.** Pemphigus. (Used, with permission, from Berger TG, Dept Dermatology, UCSF.)

B. Laboratory Findings

The diagnosis is made by light microscopy and by direct and indirect immunofluorescence (IIF) microscopy. Autoantibodies to intercellular adhesion molecules can be detected with ELISA assays and have replaced the use of IIF in some centers.

▶ Differential Diagnosis

Blistering diseases include erythema multiforme, drug eruptions, bullous impetigo, contact dermatitis, dermatitis herpetiformis, and bullous pemphigoid, but flaccid blisters are not typical of these diseases, and acantholysis is not seen on biopsy. All of these diseases have clinical characteristics and different immunofluorescence test results that distinguish them from pemphigus.

Paraneoplastic pemphigus is clinically, histologically, and immunologically distinct from other forms of the disease. Oral erosions and erythematous plaques resembling erythema multiforme are seen. Survival rates are low because of the underlying malignancy.

▶ Complications

Secondary infection commonly occurs; this is a major cause of morbidity and mortality. Disturbances of fluid, electrolyte, and nutritional intake can occur as a result of painful oral ulcers.

▶ Treatment

A. General Measures

When the disease is severe, hospitalize the patient at bed rest and provide antibiotics and intravenous feedings as indicated. Anesthetic troches used before eating ease painful oral lesions.

B. Systemic Measures

Pemphigus requires systemic therapy as early in its course as possible. However, the main morbidity in this disease is

due to the side effects of such therapy. Initial therapy is with systemic corticosteroids: prednisone, 60–80 mg daily. In all but the most mild cases, a steroid-sparing agent is added from the beginning, since the course of the disease is long and the steroid-sparing agents take several weeks to exert their activity. Azathioprine (100–200 mg daily) or mycophenolate mofetil (1–1.5 g twice daily) is used most frequently, the latter seeming to be the most reliable and recommended for most cases. Rituximab may be given in refractory cases to diminish the amount of autoantibody production. If this fails, monthly IVIG at 2 g/kg intravenously over 3 days with rituximab is dramatically beneficial and has replaced high-dose corticosteroids plus cyclophosphamide and pulse intravenous corticosteroids as rescue therapy. Increased risk of thromboembolism is associated with IVIG therapy in these doses.

C. Local Measures

In patients with limited disease, skin and mucous membrane lesions should be treated with topical corticosteroids. Complicating infection requires appropriate systemic and local antibiotic therapy.

► Prognosis

The course tends to be chronic in most patients, though about one-third appear to experience remission. Infection is the most frequent cause of death, usually from *S aureus* septicemia.

Amagai M et al; Pemphigus Study Group. A randomized double-blind trial of intravenous immunoglobulin for pemphigus. *J Am Acad Dermatol.* 2009 Apr;60(4):595–603. [PMID: 19293008]

Aoyama Y. What's new in i.v. immunoglobulin therapy and pemphigus: high-dose i.v. immunoglobulin therapy and its mode of action for treatment of pemphigus. *J Dermatol.* 2010 Mar;37(3):239–45. [PMID: 20507387]

Meyer N et al. Geoepidemiologic considerations of autoimmune pemphigus. *Autoimmun Rev.* 2010 Mar;9(5):A379–82. [PMID: 19895907]

BULLOUS PEMPHIGOID

Many other autoimmune skin disorders are characterized by formation of bullae, or blisters. These include bullous pemphigoid, cicatricial pemphigoid, dermatitis herpetiformis, and pemphigoid gestationis.

Bullous pemphigoid is a relatively benign pruritic disease characterized by tense blisters in flexural areas, usually remitting in 5 or 6 years, with a course characterized by exacerbations and remissions. Most affected persons are over the age of 60 (often in their 70s or 80s), and men are affected twice as frequently as women. The appearance of blisters may be preceded by urticarial or edematous lesions for months. Oral lesions are present in about one-third of affected persons. The disease may occur in various forms, including localized, vesicular, vegetating, erythematous, erythrodermic, and nodular.

The diagnosis is made by biopsy and direct immunofluorescence examination. Light microscopy shows a subepidermal blister. With direct immunofluorescence, IgG

and C3 are found at the dermal-epidermal junction. If the patient has mild disease, ultrapotent corticosteroids may be adequate. Prednisone at a dosage of 0.75 mg/kg daily is often used to achieve rapid control of more widespread disease. Although slower in onset of action, tetracycline or erythromycin, 500 mg three times daily, alone or combined with nicotinamide—*not nicotinic acid or niacin!*—(up to 1.5 g/d), if tolerated, may control the disease in patients who cannot use corticosteroids or may allow decreasing or eliminating corticosteroids after control is achieved. Dapsone is particularly effective in mucous membrane pemphigoid. If these drugs are not effective, methotrexate, 5–25 mg weekly, or azathioprine, 50 mg one to three times daily, may be used as steroid-sparing agents. Mycophenolate mofetil (1 g twice daily) may be used in refractory cases.

Joly P et al. A comparison of two regimens of topical corticosteroids in the treatment of patients with bullous pemphigoid: a multicenter randomized study. *J Invest Dermatol.* 2009 Jul;129(7):1681–7. [PMID: 19177141]

Kasperkiewicz M et al. Current treatment of autoimmune blistering diseases. *Curr Drug Discov Technol.* 2009 Dec;6(4):270–80. [PMID: 20025595]

Ujiiie H et al. What's new in bullous pemphigoid. *J Dermatol.* 2010 Mar;37(3):194–204. [PMID: 20507382]

PAPULES

WARTS

ESSENTIALS OF DIAGNOSIS

- Verrucous papules anywhere on the skin or mucous membranes, usually no larger than 1 cm in diameter.
- Prolonged incubation period (average 2–18 months). Spontaneous “cures” are frequent (50% at 2 years for common warts).
- “Recurrences” (new lesions) are frequent.

► General Considerations

Warts (common, plantar, and genital) are caused by human papillomaviruses (HPVs). Typing of HPV lesions is NOT a part of standard medical evaluation except in the case of genital dysplasia. Genital HPV types are divided into low-risk and high-risk depending on the likelihood of their association with cervical and anal cancer.

► Clinical Findings

There are usually no symptoms. Tenderness on pressure occurs with plantar warts; itching occurs with anogenital warts (Figure 6–31). Flat warts are most evident under oblique illumination. Periungual warts may be dry, fissured, and hyperkeratotic and may resemble hangnails or other nonspecific changes. Plantar warts resemble plantar corns or calluses.



▲ **Figure 6-31.** Condylomata acuminata, or genital warts, of the anal region due to human papillomavirus. (Public Health Image Library, CDC.)

► Differential Diagnosis

Some warty-looking lesions are actually hypertrophic actinic keratoses or squamous cell carcinomas. Some genital warty lesions may be due to secondary syphilis (condylomata lata). The lesions of molluscum contagiosum are pearly with a central dell. In AIDS, wart-like lesions may be caused by varicella zoster virus.

► Prevention

Administration of a vaccine against certain genital HPV types can prevent infection with these wart types and reduce cervical dysplasia. It is recommended for teenagers and young adults (see Chapters 1 and 18).

► Treatment

Treatment is aimed at inducing “wart-free” intervals for as long as possible without scarring, since no treatment can guarantee a remission or prevent recurrences. In immunocompromised patients, the goal is even more modest, ie, to control the size and number of lesions present.

A. Removal

For common warts of the hands, patients are usually offered liquid nitrogen or keratolytic agents. The former may work in fewer treatments but requires office visits and is painful.

1. Liquid nitrogen—Liquid nitrogen is applied to achieve a thaw time of 30–45 seconds. Two freeze-thaw cycles are given every 2–4 weeks for several visits. Scarring will occur if it is used incorrectly. Liquid nitrogen may cause permanent depigmentation in pigmented individuals. Cryotherapy is first-line physician applied surgical treatment for genital warts (condyloma acuminata).

2. Keratolytic agents and occlusion—Salicylic acid products may be used against common warts or plantar warts. They are applied then occluded. Plantar warts may be treated by applying a 40% salicylic acid plaster (Mediplast) after paring. The plaster may be left on for 5–6 days, then removed, the lesion pared down, and another plaster applied. Although it may take weeks or months to eradicate the wart, the method is safe and effective with almost no side effects. Chronic occlusion alone with water-impermeable tape (duct tape, adhesive tape) is less effective than cryotherapy.

3. Podophyllum resin—For genital warts, the purified active component of the podophyllum resin, podofilox, is applied by the patient twice daily 3 consecutive days a week for cycles of 4–6 weeks. It is less irritating and more effective than “physician-applied” podophyllum resin. After a single 4-week cycle, 45% of patients were wart-free; but of these, 60% relapsed at 6 weeks. Thus, multiple cycles of treatment are often necessary. Patients unable to obtain the take home podofilox may be treated in the clinician’s office by painting each wart carefully (protecting normal skin) every 2–3 weeks with 25% podophyllum resin (podophyllin) in compound tincture of benzoin. Pregnant patients should not be so treated. Podophyllin is ineffective for common warts and plantar warts.

4. Imiquimod—A 5% cream of this local interferon inducer has moderate activity in clearing external genital warts (EGWs). Treatment is once daily on 3 alternate days per week. Response may be slow, with patients who eventually cleared having responses at 8 weeks (44%) or 12 weeks (69%). There is a marked gender difference with respect to response, with 77% of women and 40% of men having complete clearing of their lesions. Once cleared, about 13% have recurrences in the short term.

In accidental exposure during pregnancy, there is less risk with imiquimod than with podophyllum resin (category B versus category X). Imiquimod is considerably more expensive than podophyllotoxin, but given the high rate of response in women and its safety, it appears to be the “patient-administered” treatment of choice for EGWs in women. In men, the more rapid response, lower cost, and similar efficacy make podophyllotoxin the initial treatment of choice, with imiquimod used for recurrences or refractory cases. Imiquimod has no demonstrated efficacy for—and should not be used to treat—plantar or common warts.

5. Operative removal—Plantar warts may be removed by blunt dissection. For genital warts, snip biopsy (scissors) removal followed by light electrocautery is more effective than cryotherapy, especially for patients with pedunculated or large lesions.

6. Laser therapy—The CO₂ laser can be effective for treating recurrent warts, periungual warts, plantar warts, and condylomata acuminata. It leaves open wounds that must fill in with granulation tissue over 4–6 weeks and is best reserved for warts resistant to all other modalities. Lasers with emissions of 585, 595, or 532 nm may also be used every 3–4 weeks to gradually ablate common or plantar

warts. This is no more effective than cryotherapy in controlled trials. For genital warts, it has not been shown that laser therapy is more effective than electrosurgical removal. Photodynamic therapy can be considered in refractory widespread flat and genital warts.

7. Other agents—Bleomycin diluted to 1 unit/mL may be injected into common and plantar warts. It has been shown to have a high cure rate. It should be used with caution on digital warts because of the potential complications of Raynaud phenomenon, nail loss, and terminal digital necrosis.

B. Immunotherapy

Squaric acid dibutylester may be effective. It is applied in a concentration of 0.2–2% directly to the warts from once weekly to five times weekly to induce a mild contact dermatitis. Between 60% and 80% of warts clear over 10–20 weeks. Injection of *Candida* antigen starting at 1:50 dilution and repeated every 3–4 weeks may be similarly effective in stimulating immunologic regression of common and plantar warts.

C. Physical Modalities

Soaking warts in hot (42.2°C) water for 10–30 minutes daily for 6 weeks has resulted in involution in some cases.

► Prognosis

There is a striking tendency to the development of new lesions. Warts may disappear spontaneously or may be unresponsive to treatment.

Batista CS et al. 5-FU for genital warts in non-immunocompromised individuals. *Cochrane Database Syst Rev.* 2010 Apr 14;4:CD006562. [PMID: 20393949]

Giuliano AR et al. Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males. *N Engl J Med.* 2011 Feb 3;364(5):401–11. [PMID: 21288094]

Komericki P et al. Efficacy and safety of imiquimod versus podophyllotoxin in the treatment of anogenital warts. *Sex Transm Dis.* 2011 Mar;38(3):216–8. [PMID: 20938374]

Oon SF et al. Perianal condylomas, anal squamous intraepithelial neoplasms and screening: a review of the literature. *J Med Screen.* 2010;17(1):44–9. [PMID: 20356945]

CALLOSITIES & CORNS OF FEET OR TOES

Callosities and corns are caused by pressure and friction due to faulty weight-bearing, orthopedic deformities, improperly fitting shoes, or neuropathies.

Tenderness on pressure and “after-pain” are the only symptoms. The hyperkeratotic well-localized overgrowths always occur at pressure points. Dermatoglyphics (finger-print lines) are preserved over the surface (not so in warts). When the surface is shaved with a 15 blade, a glassy core is found (which differentiates them from plantar warts, which have multiple capillary bleeding points or black dots when pared).

Treatment consists of correcting mechanical abnormalities that cause friction and pressure. Callosities may be removed by careful paring of the callus after a warm water soak or with keratolytic agents as found in various brands of corn pads.

Plantar hyperkeratosis of the heels can be treated successfully by using 20% urea (Ureacin 20) or 12% lactic acid (Amlactin) or combinations nightly and a pumice stone after soaking in water.

Callosities on diabetic feet, especially in the setting of hyposensate neuropathy, can be a major problem and the value of early podiatric management to prevent complications is very high.

Fujiwara Y et al. Beneficial effects of foot care nursing for people with diabetes mellitus: an uncontrolled before and after intervention study. *J Adv Nurs.* 2011 Sep;67(9):1952–62. [PMID: 21480962]

MOLLUSCUM CONTAGIOSUM

Molluscum contagiosum, caused by a poxvirus, presents as single or multiple dome-shaped, waxy papules 2–5 mm in diameter that are umbilicated (Figure 6–32). Lesions at first are firm, solid, and flesh-colored but upon reaching maturity become soft, whitish, or pearly gray and may suppurate. The principal sites of involvement are the face, lower abdomen, and genitals.

The lesions are autoinoculable and spread by wet skin-to-skin contact. In sexually active individuals, they may be confined to the penis, pubis, and inner thighs and are considered a sexually transmitted infection.

Molluscum contagiosum is common in patients with AIDS, usually with a helper T cell count < 100/mcL. Extensive lesions tend to develop over the face and neck as well as in the genital area.



▲ **Figure 6–32.** Molluscum contagiosum lesion on the back. (Courtesy of Richard P. Usatine, MD; used, with permission, from Usatine RP, Smith MA, Mayeaux EJ Jr, Chumley H, Tysinger J. *The Color Atlas of Family Medicine.* McGraw-Hill, 2009.)

The diagnosis is easily established in most instances because of the distinctive central umbilication of the dome-shaped lesion. The best treatment is by curettage or applications of liquid nitrogen as for warts—but more briefly. When lesions are frozen, the central umbilication often becomes more apparent. Light electrosurgery with a fine needle is also effective. It has been estimated that individual lesions persist for about 2 months. They are difficult to eradicate in patients with AIDS unless immunity improves. However, in AIDS, with highly effective anti-retroviral treatment, molluscum do not need to be treated because they usually spontaneously clear.

Villa L et al. Molluscum contagiosum: a 20-year study in a sexually transmitted infections unit. *Sex Transm Dis.* 2010 Jul;37(7):423–4. [PMID: 20414149]

BASAL CELL CARCINOMA



ESSENTIALS OF DIAGNOSIS

- ▶ Pearly papule, erythematous patch > 6 mm, or nonhealing ulcer, in sun exposed areas (face, trunk, lower legs).
- ▶ History of bleeding.
- ▶ Fair-skinned person with a history of sun exposure (often intense, intermittent).

▶ General Considerations

Basal cell carcinomas are the most common form of cancer. They occur on sun-exposed skin in otherwise normal fair-skinned individuals; ultraviolet light is the cause. The most common presentation is a papule or nodule that may have a central scab or erosion (Figure 6–33). Occasionally the nodules have stippled pigment (pigmented basal cell carcinoma). Intra-dermal nevi without pigment on the face of older white individuals may resemble basal cell carcinomas. Basal cell carcinomas grow slowly, attaining a size of 1–2 cm or more in diameter, usually only after years of growth. There is a waxy, “pearly” appearance, with telangiectatic vessels easily visible. It is the pearly or translucent quality of these lesions that is most diagnostic, a feature best appreciated if the skin is stretched. On the back and chest, basal cell carcinomas appear as reddish, somewhat shiny, scaly patches.

Clinicians should examine the whole skin routinely, looking for bumps, patches, and scabbed lesions. When examining the face, look at the eyelid margins and medial canthi, the nose and alar folds, the lips, and then around and behind the ears.

▶ Treatment

Lesions suspected to be basal cell carcinomas should be biopsied, by shave or punch biopsy. Therapy is then aimed at eradication with minimal cosmetic deformity, often by



▲ **Figure 6–33.** Nodular basal cell carcinoma of the nose. (Courtesy of Richard P. Usatine, MD; used, with permission, from Usatine RP, Smith MA, Mayeaux EJ Jr, Chumley H, Tysinger J. *The Color Atlas of Family Medicine.* McGraw-Hill, 2009.)

excision and suturing with recurrence rates of 5% or less. The technique of three cycles of curettage and electrodesiccation depends on the skill of the operator and is not recommended for head and neck lesions. After 4–6 weeks of healing, it leaves a broad, hypopigmented, at times hypertrophic scar. Radiotherapy is effective and sometimes appropriate for older individuals (over age 65), but recurrent tumors after radiation therapy are more difficult to treat and may be more aggressive. Radiation therapy is the most expensive method to treat basal cell carcinoma and should only be used if other treatment options are not appropriate. Mohs surgery—removal of the tumor followed by immediate frozen section histopathologic examination of margins with subsequent reexcision of tumor-positive areas and final closure of the defect—gives the highest cure rates (98%) and results in least tissue loss. It is appropriate therapy for tumors of the eyelids, nasolabial folds, canthi, external ear, and temple; for recurrent lesions; or where tissue sparing is needed for cosmesis. Since up to half of patients with a basal cell carcinoma will develop a second lesion, patients with basal cell carcinomas must be monitored to detect new or recurrent lesions.

Dessinioti C et al. Basal cell carcinoma: what's new under the sun. *Photochem Photobiol.* 2010 May–Jun;86(3):481–91. [PMID: 20550646]

Macbeth AE et al. What's new in skin cancer? An analysis of guidelines and systematic reviews published in 2008–2009. *Clin Exp Dermatol.* 2011 Jul;36(5):453–8. [PMID: 21671988]

Muller FM et al. Randomized comparison of Mohs micrographic surgery and surgical excision for small nodular basal cell carcinoma: tissue-sparing outcome. *Dermatol Surg.* 2009 Sep;35(9):1349–54. [PMID: 19500127]

SQUAMOUS CELL CARCINOMA



ESSENTIALS OF DIAGNOSIS

- ▶ Nonhealing ulcer or warty nodule.
- ▶ Skin damage due to long-term sun exposure.
- ▶ Common in fair-skinned organ transplant recipients.

Squamous cell carcinoma usually occurs subsequent to prolonged sun exposure on exposed parts in fair-skinned individuals who sunburn easily and tan poorly. It may arise from an actinic keratosis. The lesions appear as small red, conical, hard nodules that occasionally ulcerate (Figure 6–34). The frequency of metastasis is not precisely known, though metastatic spread is said to be less likely with squamous cell carcinoma arising out of actinic keratoses than with those that arise *de novo*. In actinically induced squamous cell cancers, rates of metastasis are estimated from retrospective studies to be 3–7%. Squamous cell carcinomas of the ear, lip, oral cavity, tongue, and genitalia have much higher rates of metastasis and require special management.

Examination of the skin and therapy are essentially the same as for basal cell carcinoma. The preferred treatment

of squamous cell carcinoma is excision. Electrodesiccation and curettage and x-ray radiation may be used for some lesions, and fresh tissue microscopically controlled excision (Mohs) is recommended for high-risk lesions (lips, temples, ears, nose) and for recurrent tumors. Follow-up for squamous cell carcinoma must be more frequent and thorough than for basal cell carcinoma, starting at every 3 months, with careful examination of lymph nodes. In addition, palpation of the lips is essential to detect hard or indurated areas that represent early squamous cell carcinoma. All such cases must be biopsied. Multiple squamous cell carcinomas are very common on the sun-exposed skin of organ transplant patients. The intensity of immunosuppression, not the use of any particular immunosuppressive agent, is the primary risk factor in determining the development of skin cancer after transplant. The tumors begin to appear after 5 years of immunosuppression. Voriconazole treatment appears to increase the risk of development of squamous cell carcinoma, especially in lung transplant patients. Regular dermatologic evaluation in at-risk organ transplant recipients is recommended. Biologic behavior of skin cancer in organ transplant recipients may be aggressive, and careful management is required. Other forms of immunosuppression such as chronic lymphocytic leukemia, HIV/AIDS, and chronic iatrogenic immunosuppression may also increase skin cancer risk and be associated with more aggressive skin cancer behavior.



▲ **Figure 6–34.** Squamous cell carcinoma. (Used, with permission, from Berger TG, Dept Dermatology, UCSF.)

Lansbury L et al. Interventions for non-metastatic squamous cell carcinoma of the skin. *Cochrane Database Syst Rev.* 2010 Apr 14;4:CD007869. [PMID: 20393962]

Love WE et al. Topical imiquimod or fluorouracil therapy for basal and squamous cell carcinoma: a systematic review. *Arch Dermatol.* 2009 Dec;145(12):1431–8. [PMID: 20026854]

Vadnerkar A et al. Voriconazole exposure and geographic location are independent risk factors for squamous cell carcinoma of the skin among lung transplant recipients. *J Heart Lung Transplant.* 2010 Nov;29(11):1240–4. [PMID: 20591690]

Zwald FO et al. Skin cancer in solid organ transplant recipients: advances in therapy and management: part I. Epidemiology of skin cancer in solid organ transplant recipients. *J Am Acad Dermatol.* 2011 Aug;65(2):253–61. [PMID: 21763561]

VIOLACEOUS TO PURPLE PAPULES & NODULES

LICHEN PLANUS



ESSENTIALS OF DIAGNOSIS

- ▶ Pruritic, violaceous, flat-topped papules with fine white streaks and symmetric distribution.
- ▶ Lacy or erosive lesions of the buccal and vaginal mucosa; nail dystrophy.
- ▶ Commonly seen along linear scratch marks (Koebner phenomenon) on anterior wrists, penis, legs.
- ▶ Histopathologic examination is diagnostic.

► General Considerations

Lichen planus is an inflammatory pruritic disease of the skin and mucous membranes characterized by distinctive papules with a predilection for the flexor surfaces and trunk. The three cardinal findings are typical skin lesions, mucosal lesions, and histopathologic features of band-like infiltration of lymphocytes in the upper dermis. The most common drugs causing lichen planus-like reactions include sulfonamides, tetracycline, quinidine, NSAIDs, and hydrochlorothiazide. Hepatitis C infection is found with greater frequency in lichen planus patients than in controls. Allergy to mercury and other metal containing amalgams can trigger oral lesions identical to lichen planus.

► Clinical Findings

Itching is mild to severe. The lesions are violaceous, flat-topped, angulated papules, up to 1 cm in diameter, discrete or in clusters, with very fine white streaks (Wickham striae) on the flexor surfaces of the wrists and on the penis, lips, tongue as well as buccal, vaginal, esophageal, and anorectal mucous membranes. The papules may become bullous or eroded. The disease may be generalized (Figure 6–35).



▲ **Figure 6–35.** Lichen planus. (Used, with permission, from Berger TG, Dept Dermatology, UCSF.)

Mucous membrane lesions have a lacy white network overlying them that may be confused with leukoplakia. The presence of oral and vaginal lichen planus in the same patient is common. Patients with both these mucous membranes involved are at much higher risk for esophageal lichen planus. The Koebner phenomenon (appearance of lesions in areas of trauma) may be seen.

A special form of lichen planus is the erosive or ulcerative variety, a major problem in the mouth or genitalia. Squamous cell carcinoma develops in 5% of patients with erosive oral or genital lichen planus and may occur in esophageal lichen planus.

► Differential Diagnosis

Lichen planus must be distinguished from similar lesions produced by medications (see above) and other papular lesions such as psoriasis, lichen simplex chronicus, graft-versus-host disease, and syphilis. Lichen planus on the mucous membranes must be differentiated from leukoplakia. Erosive oral lesions require biopsy and often direct immunofluorescence for diagnosis since lichen planus may simulate other erosive diseases.

► Treatment

A. Topical Therapy

Superpotent topical corticosteroids applied twice daily are most helpful for localized disease in nonflexural areas. Alternatively, high-potency corticosteroid cream or ointment may be used nightly under thin pliable plastic film.

Topical tacrolimus appears effective in oral and vaginal erosive lichen planus, but long-term therapy is required to prevent relapse. If tacrolimus is used, lesions must be observed carefully for development of cancer. Since absorption can occur through mucous membranes, serum tacrolimus levels should be checked at least once if widespread mucosal application (> 5–10 cm²) is used. If the erosive oral lichen planus lesions are adjacent to a metal containing amalgam, removal of the amalgam may result in clearing of the erosions.

B. Systemic Therapy

Corticosteroids (see Chapter 26) may be required in severe cases or in circumstances where the most rapid response to treatment is desired. Unfortunately, relapse almost always occurs as the corticosteroids are tapered, making systemic corticosteroid therapy an impractical option for the management of chronic lichen planus. NB-UVB, bath PUVA, oral PUVA, and the combination of an oral retinoid plus PUVA (re-PUVA) are all forms of phototherapy that can improve lichen planus. Hydroxychloroquine, 200 mg orally twice daily, can also be effective in mucosal lichen planus.

► Prognosis

Lichen planus is a benign disease, but it may persist for months or years and may be recurrent. Hypertrophic lichen planus and oral lesions tend to be especially persistent, and neoplastic degeneration has been described in chronically eroded lesions.

Farhi D et al. Pathophysiology, etiologic factors, and clinical management of oral lichen planus, part I: facts and controversies. *Clin Dermatol*. 2010 Jan–Feb;28(1):100–8. [PMID: 20082959]

Quispel R et al. High prevalence of esophageal involvement in lichen planus: a study using magnification chromoendoscopy. *Endoscopy*. 2009 Mar;41(3):187–93. [PMID: 19280529]

Throngprasom K et al. Interventions for treating oral lichen planus. *Cochrane Database Syst Rev*. 2011 Jul 6;(7):CD001168. [PMID: 21735381]

Wedgeworth EK et al. Management of symptomatic esophageal involvement with lichen planus. *J Clin Gastroenterol*. 2009 Nov–Dec;43(10):915–9. [PMID: 19525865]

KAPOSI SARCOMA

► General Considerations

Before 1980 in the United States, this rare malignant skin lesion was seen mostly in elderly men, had a chronic clinical course, and was rarely fatal. Kaposi sarcoma occurs endemically in an often aggressive form in young black men of equatorial Africa, but it is rare in American blacks. Kaposi sarcoma continues to occur largely in homosexual men with HIV infection as an AIDS-defining illness. Kaposi sarcoma may complicate immunosuppressive therapy, and stopping the immunosuppression may result in improvement. Human herpes virus 8 (HHV-8), or Kaposi sarcoma-associated herpes virus (KSHV), is universally present in all forms of Kaposi sarcoma.

Red or purple plaques or nodules on cutaneous or mucosal surfaces are characteristic. Marked edema may occur with few or no skin lesions. Kaposi sarcoma commonly involves the gastrointestinal tract and can be screened for by fecal occult blood testing. In asymptomatic patients, these lesions are not sought or treated. Pulmonary Kaposi sarcoma can present with shortness of breath, cough, hemoptysis, or chest pain; it may be asymptomatic, appearing only on chest radiograph. Bronchoscopy may be indicated. The incidence of AIDS-associated Kaposi sarcoma is diminishing; however, chronic Kaposi sarcoma can develop in patients with HIV infection, high CD4 counts, and low viral loads. In this setting, the Kaposi sarcoma usually resembles the endemic form, being indolent and localized. At times, however, it can be clinically aggressive.

► Treatment

For Kaposi sarcoma in the elderly, palliative local therapy with intralesional chemotherapy or radiation is usually all that is required. In the setting of iatrogenic immunosuppression, the treatment of Kaposi sarcoma is primarily reduction of doses of immunosuppressive medications. In AIDS-associated Kaposi sarcoma, the patient should first be given effective anti-HIV antiretrovirals because in most cases this treatment alone is associated with improvement. Other therapeutic options include cryotherapy or intralesional vinblastine (0.1–0.5 mg/mL) for cosmetically objectionable lesions; radiation therapy for accessible and space-occupying lesions; and laser surgery for certain intraoral and pharyngeal lesions. Systemic therapy is indicated in patients with

rapidly progressive skin disease (more than ten new lesions per month), with edema or pain, and with symptomatic visceral disease or pulmonary disease. Liposomal doxorubicin is highly effective in controlling these cases and has considerably less toxicity—and greater efficacy—than anthracycline monotherapy or combination chemotherapeutic regimens. α -Interferon may also be used. Paclitaxel and other taxanes can be effective even in patients who do not respond to anthracycline treatment.

Riva G et al. Immunological and inflammatory features of Kaposi's sarcoma and other Kaposi's sarcoma-associated herpesvirus/human herpesvirus 8-associated neoplasias. *AIDS Rev*. 2010 Jan–Mar;12(1):40–51. [PMID: 20216909]

PRURITUS (ITCHING)

Pruritus is a disagreeable sensation that provokes a desire to scratch. It is modulated by central factors, including anxiety, depression, and amphetamine and cocaine use. Many cases of pruritus are not mediated by histamine.

Dry skin is the first cause of itch that should be sought, since it is common and easily treated. Other causes include scabies, atopic dermatitis, insect bites, pediculosis, contact dermatitis, drug reactions, urticaria, psoriasis, lichen planus, lichen simplex chronicus, and fiberglass dermatitis.

Persistent pruritus not explained by cutaneous disease or association with a primary skin eruption should prompt a staged workup for systemic causes. Perhaps the most common cause of pruritus associated with systemic disease is uremia in conjunction with hemodialysis. This condition and to a lesser degree the pruritus of liver disease may be helped by phototherapy with ultraviolet B or PUVA. Naltrexone and nalmefene have been shown to relieve the pruritus of liver disease. Naltrexone is not effective in pruritus associated with advanced chronic kidney disease, but gabapentin may be effective. Endocrine disorders such as hypothyroidism or hyperthyroidism, psychiatric disturbances, lymphoma, leukemia, and other internal malignant disorders, iron deficiency anemia, and certain neurologic disorders may also cause pruritus. The treatment of chronic pruritus can be frustrating. Combinations of antihistamines, gabapentin, mirtazapine, and opioid antagonists can be attempted in refractory cases.

► Prognosis

Elimination of external factors and irritating agents may give complete relief. Pruritus accompanying a specific skin disease will subside when the skin disease is controlled. Pruritus accompanying serious internal disease may not respond to any type of therapy.

Bergasa NV. The itch of liver disease. *Semin Cutan Med Surg*. 2011 Jun;30(2):93–8. [PMID: 21767769]

Berger TG et al. Pruritus and renal failure. *Semin Cutan Med Surg*. 2011 Jun;30(2):99–100. [PMID: 21767770]

Chiang HC et al. Cancer and itch. *Semin Cutan Med Surg*. 2011 Jun;30(2):107–12. [PMID: 21767772]

Reich A et al. Opioid-induced pruritus: an update. *Clin Exp Dermatol.* 2010 Jan;35(1):2–6. [PMID: 19663845]
 Serling SL et al. Approach to pruritus in the adult HIV-positive patient. *Semin Cutan Med Surg.* 2011 Jun;30(2):101–6. [PMID: 21767771]

ANOGENITAL PRURITUS

ESSENTIALS OF DIAGNOSIS

- ▶ Itching, chiefly nocturnal, of the anogenital area.
- ▶ Examination is highly variable, ranging from no skin findings to excoriations and inflammation of any degree, including lichenification.

▶ General Considerations

Anogenital pruritus may be due to intertrigo, psoriasis, lichen simplex chronicus, or seborrheic or contact dermatitis (from soaps, colognes, douches, contraceptives, and perhaps scented toilet tissue), or it may be due to irritating secretions, as in diarrhea, leukorrhea, or trichomoniasis, or to local disease (candidiasis, dermatophytosis, erythrasma), and at times oxyuriasis (pinworms). Lichen sclerosus may at times be the cause. Erythrasma (Figure 6–36) is easily diagnosed by demonstration of coral-red fluorescence with Wood light; it is easily cured with erythromycin orally or topically.

In pruritus ani, hemorrhoids are often found, and leakage of mucus and bacteria from the distal rectum onto the perianal skin may be important in cases in which no other skin abnormality is found.

Many women experience pruritus vulvae. Pruritus vulvae does not usually involve the anal area, though anal itching may spread to the vulva. In men, pruritus of the scrotum is most commonly seen in the absence of pruritus ani. Up to one-third of causes of anogenital pruritus may be due to nerve impingements of the lumbosacral spine, so referral for evaluation of lumbosacral spine disease is appropriate if no skin disorder is identified, and topical therapy is ineffective.

Squamous cell carcinoma of the anus and extramammary Paget disease are rare causes of genital pruritus.

▶ Clinical Findings

A. Symptoms and Signs

The only symptom is itching. Physical findings are usually not present, but there may be erythema, fissuring, maceration, lichenification, excoriations, or changes suggestive of candidiasis or tinea.

B. Laboratory Findings

Urinalysis and blood glucose testing may lead to a diagnosis of diabetes mellitus. Microscopic examination or culture of tissue scrapings may reveal yeasts or fungi. Stool examination may show pinworms. Radiologic studies may demonstrate spinal cord disease.



▲ **Figure 6–36.** Erythrasma of the axilla. (Courtesy of Richard P. Usatine, MD; used, with permission, from Usatine RP, Smith MA, Mayeaux EJ Jr, Chumley H, Tysinger J. *The Color Atlas of Family Medicine.* McGraw-Hill, 2009.)

▶ Differential Diagnosis

The etiologic differential diagnosis consists of *Candida* infection, parasitosis, local irritation from contactants or irritants, nerve impingement and other primary skin disorders of the genital area such as psoriasis, seborrhea, intertrigo, or lichen sclerosus et atrophicus.

▶ Prevention

Instruct the patient in proper anogenital hygiene after treating systemic or local conditions. If appropriate, physical therapy and exercises to support the lower spine are recommended.

▶ Treatment

A. General Measures

Treating constipation, preferably with high-fiber management (psyllium), may help. Instruct the patient to use very soft or moistened tissue or cotton after bowel movements and to clean the perianal area thoroughly with cool water if possible. Women should use similar precautions after urinating.

B. Local Measures

Pramoxine cream or lotion or hydrocortisone-pramoxine (Pramosone), 1% or 2.5% cream, lotion, or ointment, is helpful in managing pruritus in the anogenital area. The ointment or cream should be applied after a bowel movement. Topical doxepin cream 5% is similarly effective, but it may be sedating. The use of strong corticosteroids on the scrotum may lead to persistent severe burning upon withdrawal of the drug. Underclothing should be changed daily, and in men, the seam of their “boxers” should not rub against or contact the scrotum. Balneol Perianal Cleansing Lotion or Tucks premoistened pads, ointment, or cream may be very useful for pruritus ani. About one-third of patients with scrotal or anal pruritus will respond to capsaicin

0.006%. Treatment for underlying spinal neurologic disease may be required.

► Prognosis

Although benign, anogenital pruritus is often persistent and recurrent.

Markell KW et al. Pruritus ani: etiology and management. *Surg Clin North Am.* 2010 Feb;90(1):125–35. [PMID: 20109637]

SCABIES



ESSENTIALS OF DIAGNOSIS

- ▶ Generalized very severe itching.
- ▶ Pruritic burrows, vesicles and pustules, especially on finger webs and in wrist creases.
- ▶ Mites, ova, and brown dots of feces visible microscopically.
- ▶ Red papules or nodules on the scrotum and on the penile glans and shaft are pathognomonic.

► General Considerations

Scabies is caused by infestation with *Sarcoptes scabiei*. The infestation usually spares the head and neck (though even these areas may be involved in infants, in the elderly, and in patients with AIDS). Scabies is usually acquired by sleeping with or in the bedding of an infested individual or by other close contact. The entire household may be affected. Hospital-associated scabies is increasingly common, primarily in long-term care facilities. Index patients are usually elderly and immunosuppressed. When these patients are hospitalized, hospital-based epidemics can occur. These epidemics are difficult to eradicate since many health care workers become infected and spread the infestation to other patients.

► Clinical Findings

A. Symptoms and Signs

Itching is almost always present and can be quite severe. The lesions consist of more or less generalized excoriations with small pruritic vesicles, pustules, and “burrows” in the web spaces and on the heels of the palms, wrists (Figure 6–37), elbows, around the axillae, and on the breasts of women. The feet are a good place to identify burrows, since they may have been scratched off in other locations. The burrow appears as a short irregular mark, 2–3 mm long and the width of a hair. Characteristic nodular lesions may occur on the scrotum or penis and along the posterior axillary line.

B. Laboratory Findings

The diagnosis should be confirmed by microscopic demonstration of the organism, ova, or feces in a mounted specimen, examined with tap water. Best results are obtained when multiple lesions are scraped, choosing the



▲ **Figure 6–37.** Scabies. (Used, with permission, from Berger TG, Dept Dermatology, UCSF.)

best unexcoriated lesions from interdigital webs, wrists, elbows, or feet. A No. 15 blade is used to scrape each lesion until it is flat. Pinpoint bleeding may result from the scraping. Patients with crusted/hyperkeratotic scabies must be evaluated for immunosuppression (especially HIV and HTLV-1 infections) if no iatrogenic cause of immunosuppression is present.

► Differential Diagnosis

Scabies must be distinguished from the various forms of pediculosis, from bedbug and flea bites, and from other causes of pruritus.

► Treatment & Prognosis

Treatment is aimed at killing scabies mites and controlling the dermatitis, which can persist for months after effective eradication of the mites. Bedding and clothing should be laundered or cleaned or set aside for 14 days in plastic bags. High heat (60°C) is required to kill the mites and ova. Unless treatment is aimed at all infected persons in a family or institutionalized group, reinfestations will probably occur.

Permethrin 5% cream is highly effective and safe in the management of scabies. Treatment consists of a single application for 8–12 hours, repeated in 1 week.

Pregnant patients should be treated only if they have documented scabies themselves. Permethrin 5% cream once for 12 hours—or 5% or 6% sulfur in petrolatum applied nightly for 3 nights from the collarbones down—may be used.

Patients will continue to itch for several weeks after treatment. Use of triamcinolone 0.1% cream will help resolve the dermatitis. Scabies in nursing home patients, institutionalized or mentally impaired (especially Down syndrome) patients, and AIDS patients may be much more difficult to treat.

Most failures in normal persons are related to incorrect use or incomplete treatment of the housing unit. In these cases, repeat treatment with permethrin once weekly for 2 weeks, with reeducation regarding the method and extent of application, is suggested. In immunocompetent individuals, ivermectin in a dose of 200 mcg/kg is effective in about 75% of cases with a single dose and 95% of cases with two doses 2 weeks apart. In immunosuppressed hosts

and those with crusted (hyperkeratotic) scabies, multiple doses of ivermectin (every 2 weeks for two or three doses) plus topical therapy with permethrin once weekly may be effective when topical treatment and oral therapy alone fail. Oral ivermectin can be very beneficial in mass treatment to eradicate infections in institutions or villages.

If secondary pyoderma is present, it is treated with systemic antibiotics. In areas where nephritogenic streptococcal strains are prevalent, infestation with scabies or exposure to scabies-infested dogs may be followed by acute post-streptococcal glomerulonephritis.

Persistent pruritic postscabetic papules may be treated with mid- to high-potency corticosteroids or with intralesional triamcinolone acetonide (2.5–5 mg/mL).

Bouvesse S et al. Scabies in healthcare settings. *Curr Opin Infect Dis.* 2010 Apr;23(2):111–8. [PMID: 20075729]
 Hay RJ. Scabies and pyoderma—diagnosis and treatment. *Dermatol Ther.* 2009 Nov–Dec;22(6):466–74. [PMID: 19889132]

PEDICULOSIS

ESSENTIALS OF DIAGNOSIS

- ▶ Pruritus with excoriation.
- ▶ Nits on hair shafts; lice on skin or clothes.
- ▶ Occasionally, sky-blue macules (maculae ceruleae) on the inner thighs or lower abdomen in pubic louse infestation.

▶ General Considerations

Pediculosis is a parasitic infestation of the skin of the scalp, trunk, or pubic areas. Body lice usually occur among people who live in overcrowded dwellings with inadequate hygiene facilities. Pubic lice may be sexually transmitted. Head lice may be transmitted by shared use of hats or combs. Adults contacting children with head lice frequently acquire the infestation.

There are three different varieties: (1) pediculosis pubis, caused by *Phthirus pubis* (pubic louse, “crabs”); (2) pediculosis corporis, caused by *Pediculus humanus* var *corporis* (body louse); and (3) pediculosis capitis, caused by *Pediculus humanus* var *capitis* (head louse).

Head and body lice are similar in appearance and are 3–4 mm long. The body louse can seldom be found on the body, because the insect comes onto the skin only to feed and must be looked for in the seams of the clothing. Trench fever, relapsing fever, and typhus are transmitted by the body louse in countries where those diseases are endemic.

▶ Clinical Findings

Itching may be very intense in body louse infestations, and scratching may result in deep excoriations, especially over the upper shoulders, posterior flanks, and neck. In some cases, only itching is present, with few excoriations seen. Pyoderma may be the presenting sign. Head lice can be found on the scalp or may be manifested as small nits

resembling pussy willow buds on the scalp hairs close to the skin. They are easiest to see above the ears and at the nape of the neck. Pubic louse infestations are occasionally generalized, particularly in hairy individuals; the lice may even be found on the eyelashes and in the scalp.

▶ Differential Diagnosis

Head louse infestation must be distinguished from seborrheic dermatitis, body louse infestation from scabies and bedbug bites, and pubic louse infestation from anogenital pruritus and eczema.

▶ Treatment

Body lice are treated by disposing of the infested clothing and addressing the patient’s social situation. For pubic lice, permethrin rinse 1% for 10 minutes and permethrin cream 5% applied for 8 hours are effective. Sexual contacts should be treated. Clothes and bedclothes should be washed and dried at high temperature if possible.

Permethrin 1% cream rinse (Nix) is a topical over-the-counter pediculicide and ovicide and is the treatment of choice for head lice. It is applied to the scalp and hair and left on for 8 hours before being rinsed off. Permethrin resistance of head lice is common. Malathion lotion 1% (Ovide) is very effective, but it is highly volatile and flammable, so application must be done in a well-ventilated room or out of doors. For involvement of eyelashes, petrolatum is applied thickly twice daily for 8 days, and remaining nits are then plucked off.

Scott GR et al; IUSTI/WHO. European guideline for the management of pediculosis pubis, 2010. *Int J STD AIDS.* 2011 Jun;22(6):304–5. [PMID: 21680662]

SKIN LESIONS DUE TO OTHER ARTHROPODS

ESSENTIALS OF DIAGNOSIS

- ▶ Localized rash with pruritus.
- ▶ Furuncle-like lesions containing live arthropods.
- ▶ Tender erythematous patches that migrate (“larva migrans”).
- ▶ Generalized urticaria or erythema multiforme in some patients.

▶ General Considerations

Some arthropods (eg, mosquitoes and biting flies) are readily detected as they bite. Many others are not because they are too small, because there is no immediate reaction, or because they bite during sleep. Reactions are allergic and may be delayed for hours to days. Patients are most apt to consult a clinician when the lesions are multiple and pruritus is intense.

Many persons will react severely only to their earliest contacts with an arthropod, thus presenting pruritic

lesions when traveling, moving into new quarters, etc. Body lice, fleas, bedbugs, and mosquitoes should be considered. Bedbug exposure typically occurs in hotels and in housing with inadequate hygiene but also may occur in stable domiciles. Spiders are often incorrectly believed to be the source of bites; they rarely attack humans, though the brown spider (*Loxosceles laeta*, *L. reclusa*) may cause severe necrotic reactions and death due to intravascular hemolysis, and the black widow spider (*Latrodectus mactans*) may cause severe systemic symptoms and death. (See also Chapter 38.) The majority of patient-diagnosed, physician-diagnosed, and even published cases of brown recluse spider bites (or loxoscelism) are incorrect, especially if made in areas where these spiders are not endemic. Many of these lesions are actually due to CA-MRSA.

In addition to arthropod bites, the most common lesions are venomous stings (wasps, hornets, bees, ants, scorpions) or bites (centipedes), furuncle-like lesions due to fly maggots or sand fleas in the skin, and a linear creeping eruption due to a migrating larva.

► Clinical Findings

The diagnosis may be difficult when the patient has not noticed the initial attack but suffers a delayed reaction. Individual bites are often in clusters and tend to occur either on exposed parts (eg, midges and gnats) or under clothing, especially around the waist or at flexures (eg, small mites or insects in bedding or clothing). The reaction is often delayed for 1–24 hours or more. Pruritus is almost always present and may be all but intolerable once the patient starts to scratch. Secondary infection may follow scratching. Urticarial wheals are common. Papules may become vesicular. The diagnosis is aided by searching for exposure to arthropods and by considering the patient's occupation and recent activities.

The principal arthropods are as follows:

1. **Fleas:** Fleas are bloodsucking ectoparasites that feed on dogs, cats, humans, and other species. Flea saliva produces papular urticaria in sensitized individuals. To break the life cycle of the flea, one must treat the home and pets, using quick-kill insecticides, residual insecticides, and a growth regulator.
2. **Bedbugs:** In crevices of beds or furniture; bites tend to occur in lines or clusters. Papular urticaria is a characteristic lesion of bedbug (*Cimex lectularius*) bites. Bedbugs are not restricted to any socioeconomic group and are a major health problem in some major metropolitan areas, especially in commercial and residential hotels.
3. **Ticks:** Usually picked up by brushing against low vegetation.
4. **Chiggers or red bugs:** These are larvae of trombiculid mites. A few species confined to particular regions and locally recognized habitats (eg, berry patches, woodland edges, lawns, brush turkey mounds in Australia, poultry farms) attack humans, often around the waist, on the ankles, or in flexures, raising intensely itching erythematous papules after a delay of many hours. The red chiggers may sometimes be seen in the center of papules that have not yet been scratched.
5. **Bird and rodent mites:** Larger than chiggers, bird mites infest birds and their nests. Bites are multiple anywhere on the body. Room air conditioning units may suck in bird mites and infest the inhabitants of the room. Rodent mites from mice or rats may cause similar effects. If the domicile has evidence of rodent activity, then rodent mite dermatitis should be suspected, as the mites are rarely found. Pet rodents or birds may be infested with mites, maintaining the infestation.
6. **Mites in stored products:** These are white and almost invisible and infest products such as copra, vanilla pods, sugar, straw, cottonseeds, and cereals. Persons who handle these products may be attacked, especially on the hands and forearms and sometimes on the feet.
7. **Caterpillars of moths with urticating hairs:** The hairs are blown from cocoons or carried by emergent moths, causing severe and often seasonally recurrent outbreaks after mass emergence. The gypsy moth is a cause in the eastern United States.
8. **Tungiasis:** Tungiasis is due to the burrowing flea known as *Tunga penetrans* and is found in Africa, the West Indies, and South and Central America. The female burrows under the skin, sucks blood, swells to 0.5 cm, and then ejects her eggs onto the ground. Ulceration, lymphangitis, gangrene, and septicemia may result, in some cases with lethal effect. Simple surgical removal is usually performed.

► Differential Diagnosis

Arthropods should be considered in the differential diagnosis of skin lesions showing any of the above symptoms.

► Prevention

Arthropod infestations are best prevented by avoidance of contaminated areas, personal cleanliness, and disinfection of clothing, bedclothes, and furniture as indicated. Chiggers and mites can be repelled by permethrin applied to the head and clothing. (It is not necessary to remove clothing.) Bedbugs are no longer repelled by permethrin. Aggressive cleaning, usually requiring removal of the affected occupant from the domicile, may be necessary to eradicate bedbug infestation in a residence.

► Treatment

Living arthropods should be removed carefully with tweezers after application of alcohol and preserved in alcohol for identification. In endemic Rocky Mountain spotted fever areas, ticks should not be removed with the bare fingers.

Corticosteroid lotions or creams are helpful. Topical antibiotics may be applied if secondary infection is suspected. Localized persistent lesions may be treated with intralesional corticosteroids.

Stings produced by many arthropods may be alleviated by applying papain powder (Adolph's Meat Tenderizer) mixed with water, or aluminum chloride hexahydrate (Xerac AC).

Extracts from venom sacs of bees, wasps, yellow jackets, and hornets are available for immunotherapy of patients at risk for anaphylaxis.

Doggett SL et al. Bed bugs—what the GP needs to know. *Aust Fam Physician*. 2009 Nov;38(11):880–4. [PMID: 19893834]
 Goddard J et al. Bed bugs (*Cimex lectularius*) and clinical consequences of their bites. *JAMA*. 2009 Apr 1;301(13):1358–66. [PMID: 19336711]

INFLAMMATORY NODULES

ERYTHEMA NODOSUM



ESSENTIALS OF DIAGNOSIS

- ▶ Painful red nodules without ulceration on anterior aspects of legs.
- ▶ Slow regression over several weeks to resemble contusions.
- ▶ Women are predominantly affected by a ratio of 10:1 over men.
- ▶ Some cases associated with infection, inflammatory bowel disease, or drug exposure.

▶ General Considerations

Erythema nodosum is a symptom complex characterized by tender, erythematous nodules that appear most commonly on the extensor surfaces of the lower legs. It usually lasts about 6 weeks and may recur. The disease may be associated with various infections—streptococcosis, primary coccidioidomycosis, other deep fungal infections, tuberculosis, *Yersinia pseudotuberculosis* and *Y enterocolitica* infection, diverticulitis, or syphilis. It may accompany sarcoidosis, Behçet disease, and inflammatory bowel disease. Erythema nodosum may be associated with pregnancy or with use of oral contraceptives.

▶ Clinical Findings

A. Symptoms and Signs

The subcutaneous swellings are exquisitely tender and may be preceded by fever, malaise, and arthralgia. They are most often located on the anterior surfaces of the legs below the knees but may occur on the arms, trunk, and face. The lesions, 1–10 cm in diameter, are at first pink to red; with regression, all the various hues seen in a contusion can be observed (Figure 6–38).

B. Laboratory Findings

Evaluation of patients presenting with acute erythema nodosum should include a careful history (including drug exposures) and physical examination for prior upper respiratory infection or diarrheal illness, symptoms of any deep fungal infection endemic to the area, a chest radiograph, a PPD, and two consecutive ASO/DNAse B titers at 2- to 4-week intervals. If no underlying cause is found, only a small percentage of patients will go on to develop a significant underlying illness (usually sarcoidosis) over the next year.



▲ **Figure 6–38.** Erythema nodosum. (Used, with permission, from Berger TG, Dept Dermatology, UCSF.)

▶ Differential Diagnosis

Erythema induratum from tuberculosis is seen on the posterior surfaces of the legs and may ulcerate. Lupus panniculitis presents as tender nodules on the buttocks and posterior arms that heal with depressed scars. In polyarteritis nodosa, the subcutaneous nodules are often associated with a fixed livedo. In the late stages, erythema nodosum must be distinguished from simple bruises and contusions.

▶ Treatment

First, the underlying cause should be identified and treated. Primary therapy is with NSAIDs in usual doses. Saturated solution of potassium iodide, 5–15 drops three times daily, results in prompt involution in many cases. Complete bed rest may be advisable if the lesions are painful. Systemic therapy directed against the lesions themselves may include corticosteroid therapy (see Chapter 26) unless contraindicated by associated infection.

► Prognosis

The lesions usually disappear after about 6 weeks, but they may recur.

Gheith O et al. Erythema nodosum in renal transplant recipients: multiple cases and review of literature. *Transpl Infect Dis.* 2010 Apr;12(2):164–8. [PMID: 20002354]

Larsen S et al. Extraintestinal manifestations of inflammatory bowel disease: epidemiology, diagnosis, and management. *Ann Med.* 2010 Mar;42(2):97–114. [PMID: 20166813]

FURUNCULOSIS (Boils) & CARBUNCLES



ESSENTIALS OF DIAGNOSIS

- Extremely painful inflammatory swelling based on a hair follicle that forms an abscess.
- Predisposing condition (diabetes mellitus, HIV disease, injection drug use) sometimes present.
- Coagulase-positive *S aureus* is the causative organism.

► General Considerations

A furuncle (boil) is a deep-seated infection (abscess) caused by *S aureus* and involving the entire hair follicle and adjacent subcutaneous tissue. The most common sites of occurrence are the hairy parts exposed to irritation and friction, pressure, or moisture. Because the lesions are autoinoculable, they are often multiple. Diabetes mellitus (especially if using insulin injections), injection drug use, allergy injections, and HIV disease all increase the risk of staphylococcal infections by increasing the rate of carriage. Certain other exposures including hospitalization, athletic teams, prisons, military service, and homelessness may also increase the risk of infection.

A carbuncle consists of several furuncles developing in adjoining hair follicles and coalescing to form a conglomerate, deeply situated mass with multiple drainage points.

► Clinical Findings

A. Symptoms and Signs

Pain and tenderness may be prominent. The abscess is either rounded or conical. It gradually enlarges, becomes fluctuant, and then softens and opens spontaneously after a few days to 1–2 weeks to discharge a core of necrotic tissue and pus. The inflammation occasionally subsides before necrosis occurs. Infection of the soft tissue around the nails (paronychia) may be due to staphylococci when it is acute or *Candida* when chronic.

B. Laboratory Findings

There may be slight leukocytosis, but a white blood cell count is rarely required. Pus should be cultured to rule out MRSA or other bacteria. Culture of the anterior nares may

identify chronic staphylococcal carriage in cases of recurrent cutaneous infection.

► Differential Diagnosis

The most common entity in the differential is an inflamed epidermal inclusion cyst that suddenly becomes red, tender, and expands greatly in size over one to a few days. The history of a prior cyst in the same location, the presence of a clearly visible cyst orifice, and the extrusion of malodorous cheesy rather than purulent material helps in the diagnosis. Tinea profunda (deep dermatophyte infection of the hair follicle) may simulate recurrent furunculosis. Furuncle is also to be distinguished from deep mycotic infections, such as sporotrichosis; from other bacterial infections, such as anthrax and tularemia (rare); from atypical mycobacterial infections; and from acne cysts. Hidradenitis suppurativa (acne inversa) presents with recurrent tender sterile abscesses in the axillae and groin, on the buttocks, or below the breasts. The presence of old scars or sinus tracts plus negative cultures suggests this diagnosis.

► Complications

Serious and sometimes fatal complications of staphylococcal infection such as septicemia can occur.

► Prevention

Identifying and eliminating the source of infection is critical to prevent recurrences after treatment. The source individual may have chronic dermatitis or be an asymptomatic carrier. Local measures such as meticulous hand-washing; no sharing of towels and clothing; aggressive scrubbing of showers, bathrooms and surfaces with bleach; bleach baths ($1/2$ to 1 cup per 20 liters of bathwater for 15 minutes 3–5 times weekly) and isolation of infected patients who reside in institutions to prevent spread are all effective measures.

► Treatment

A. Specific Measures

Incision and drainage is recommended for all loculated suppurations and is the mainstay of therapy. Systemic antibiotics are usually given, although they offer little beyond adequate incision and drainage. Sodium dicloxacillin or cephalexin, 1 g daily in divided doses by mouth for 10 days, is usually effective. Doxycycline 100 mg twice daily, trimethoprim-sulfamethoxazole DS one tablet twice daily, and clindamycin 150–300 mg twice daily are effective in treating MRSA. Recurrent furunculosis may be effectively treated with a combination of cephalexin, 250–500 mg four times daily for 2–4 weeks, and rifampin, 300 mg twice daily for 5 days during this period. Chronic clindamycin, 150–300 mg daily for 1–2 months, may also cure recurrent furunculosis. Family members and intimate contacts may need evaluation for staphylococcal carrier state and perhaps concomitant treatment. Applications of topical 2% mupirocin to the nares, axillae, and anogenital areas twice daily for 5 days may eliminate the staphylococcal carrier state, although resistance is increasing.

B. Local Measures

Immobilize the part and avoid overmanipulation of inflamed areas. Use moist heat to help larger lesions “localize.” Use surgical incision and drainage *after* the lesions are “mature.” To incise and drain an acute staphylococcal paronychia, insert a flat metal spatula or sharpened hardwood stick into the nail fold where it adjoins the nail. This will release pus from a mature lesion.

► Prognosis

Recurrent crops may harass the patient for months or years.

Hansra NK et al. Cutaneous community-acquired and hospital-acquired methicillin-resistant *Staphylococcus aureus*. *Dermatol Ther*. 2011 Mar–Apr;24(2):263–72. [PMID: 21410616]

EPIDERMAL INCLUSION CYST



ESSENTIALS OF DIAGNOSIS

- ▶ Firm dermal papule or nodule.
- ▶ Overlying black comedone or “punctum.”
- ▶ Expressible foul-smelling cheesy material.
- ▶ May become red and drain, mimicking an abscess.

► General Considerations

Epidermal inclusion cysts (EICs) are common, benign growths of the upper portion of the hair follicle. They are common in Gardner syndrome and may be the first stigmata of the condition.

Epidermal inclusion cysts favor the face and trunk and may complicate nodulocystic acne vulgaris. Individual lesions range in size from 0.3 cm to several centimeters. An overlying pore or punctum is characteristic. Lateral pressure may lead to extrusion of a foul-smelling, cheesy material.

► Differential Diagnosis

EICs are distinguished from lipomas by being more superficial (in the dermis not the subcutaneous fat) and by their overlying punctum. Many other benign and malignant tumors may superficially resemble EICs, but all lack the punctum.

► Complications

EICs may rupture, creating an acute inflammatory nodule very similar to an abscess. Cultures of the expressed material will be sterile.

► Treatment

Treatment is not required if asymptomatic. Inflamed lesions may be treated with incision and drainage or intralesional

triamcinolone acetamide 5–10 mg/mL. For large or symptomatic cysts, surgical excision is curative.

Lin SH et al. Facial epidermal inclusion cysts are associated with smoking in men: a hospital-based case-control study. *Dermatol Surg*. 2010 Jun;36(6):894–8. [PMID: 20482735]

PHOTODERMATITIS



ESSENTIALS OF DIAGNOSIS

- ▶ Painful or pruritic erythema, edema, or vesiculation on sun-exposed surfaces: the face, neck, hands, and “V” of the chest.
- ▶ Inner upper eyelids spared, as is the area under the chin.

► General Considerations

In most cases, photosensitivity is an acute or chronic skin reaction due to hypersensitivity to ultraviolet radiation. It is caused by certain drugs, by lupus erythematosus, and some inherited disorders including the porphyrias. Contact photosensitivity may occur with plants, perfumes, and sunscreens. Three percent of persons with atopic dermatitis, especially middle-aged women, are photosensitive.

Photodermatitis is manifested as phototoxicity—a tendency for the individual to sunburn more easily than expected—or, as photoallergy, a true immunologic reaction that often presents with dermatitis.

► Clinical Findings

A. Symptoms and Signs

The acute inflammatory skin reaction, if severe enough, is accompanied by pain, fever, gastrointestinal symptoms, malaise, and even prostration, but this is very rare. Signs include erythema, edema, and possibly vesiculation and oozing on exposed surfaces. Peeling of the epidermis and pigmentary changes often result. The key to diagnosis is localization of the rash to photoexposed areas, though these eruptions may become generalized with time to involve even photoprotected areas. The lower lip may be affected.

B. Laboratory Findings

Blood and urine tests are generally not helpful unless porphyria cutanea tarda is suggested by the presence of blistering, scarring, milia (white cysts 1–2 mm in diameter) and skin fragility of the dorsal hands, and facial hypertrichosis. Eosinophilia may be present in chronic photoallergic responses.

► Differential Diagnosis

The differential diagnosis is long. If a clear history of the use of a topical or systemic photosensitizer is not available and if the eruption is persistent, then a workup including biopsy

and light testing may be required. Photodermatitis must be differentiated from contact dermatitis that may develop from one of the many substances in suntan lotions and oils, as these may often have a similar distribution. Sensitivity to actinic rays may also be part of a more serious condition such as porphyria cutanea tarda or lupus erythematosus. These disorders are diagnosed by appropriate blood or urine tests. Phenothiazines, quinine or quinidine, griseofulvin, sulfonyleureas (especially hydrochlorothiazide), NSAIDs, and antibiotics (eg, some tetracyclines, quinolone, TMP-SMZ) may photosensitize the skin. Polymorphous light eruption (PMLE) is a very common idiopathic photodermatitis and often has its onset in the third to fourth decades except in Native Americans and Latinos, in whom it may present in childhood. PMLE is chronic in nature. Transitory periods of spontaneous remission do occur. The action spectrum of PMLE may also extend into the long ultraviolet wavelengths (UVA; 320–400 nm). Drug-induced photosensitivity is triggered by UVA.

► Complications

Some individuals continue to be chronic light reactors even when they apparently are no longer exposed to photosensitizing drugs.

► Prevention

While sunscreens are useful agents in general and should be used by persons with photosensitivity, patients may react to such low amounts of energy that sunscreens alone may not be sufficient. Sunscreens with an SPF of 30–60 and broad UVA coverage, containing dicamphor sulfonic acid (Mexoryl SX), avobenzone (Parasol 1789), titanium dioxide, and micronized zinc oxide, are especially useful in patients with photoallergic dermatitis. Photosensitivity due to porphyria is not prevented by sunscreens and requires barrier protection (clothing) to prevent outbreaks.

► Treatment

A. Specific Measures

Drugs should be suspected in cases of photosensitivity even if the particular medication (such as hydrochlorothiazide) has been used for months.

B. Local Measures

When the eruption is vesicular or weepy, treatment is similar to that of any acute dermatitis, using cooling and soothing wet dressing.

Sunscreens should be used as described above. Mid-potency to high-potency topical corticosteroids are of limited benefit in sunburn reactions but may help in PMLE and photoallergic reactions. Since the face is often involved, close monitoring for corticosteroid side effects is recommended.

C. Systemic Measures

Aspirin may have some value for fever and pain of acute sunburn. Systemic corticosteroids in doses as described for acute contact dermatitis may be required for severe

photosensitivity reactions. Otherwise, different photodermatoses are treated in specific ways.

Patients with severe photoallergy may require immunosuppressives, such as azathioprine, in the range of 50–300 mg/d, or cyclosporine, 3–5 mg/kg/d.

► Prognosis

The most common phototoxic sunburn reactions are usually benign and self-limited. PMLE and some cases of photoallergy can persist for years.

Chew AL et al. Contact and photocontact sensitization in chronic actinic dermatitis: a changing picture. *Contact Dermatitis*. 2010 Jan;62(1):42–6. [PMID: 20136878]
 Gambichler T et al. Immunologically mediated photodermatoses: diagnosis and treatment. *Am J Clin Dermatol*. 2009;10(3):169–80. [PMID: 19354331]
 Victor FC et al. A 20-year analysis of previous and emerging allergens that elicit photoallergic contact dermatitis. *J Am Acad Dermatol*. 2010 Apr;62(4):605–10. [PMID: 20163891]

ULCERS

LEG ULCERS SECONDARY TO VENOUS INSUFFICIENCY

ESSENTIALS OF DIAGNOSIS

- Past history of varicosities, thrombophlebitis, or postphlebotic syndrome.
- Irregular ulceration, often on the medial aspect of the lower legs above the malleolus.
- Edema of the legs, varicosities, hyperpigmentation, and red and scaly areas (stasis dermatitis) and scars from old ulcers support the diagnosis.

► General Considerations

Patients at risk may have a history of venous insufficiency, either with obvious varicosities or with a past history of thrombophlebitis, or with immobility of the calf muscle group (paraplegics, etc). Red, pruritic patches of stasis dermatitis often precede ulceration. Because venous insufficiency plays a role in between 75% and 90% of lower leg ulcerations, testing of venous competence is a required part of a leg ulcer evaluation even when no changes of venous insufficiency are present.

► Clinical Findings

A. Symptoms and Signs

Classically, chronic edema is followed by a dermatitis, which is often pruritic. These changes are followed by hyperpigmentation, skin breakdown, and eventually sclerosis of the skin of the lower leg (Figure 6–39). The ulcer base may be clean, but it often has a yellow fibrin eschar that may require surgical removal. Ulcers that appear on the feet, toes, or above the knees should be approached with other diagnoses in mind.



▲ **Figure 6–39.** Venous stasis ulcer near the medial malleolus. (Courtesy of Maureen Sheehan, MD; used, with permission, from Usatine RP, Smith MA, Mayeaux EJ Jr, Chumley H, Tysinger J. *The Color Atlas of Family Medicine*. McGraw-Hill, 2009.)

B. Laboratory Findings

Thorough evaluation of the patient's vascular system (including measurement of the ankle/brachial index [ABI]) is essential. If the ABI is < 0.7 , the patient should be referred to a vascular surgeon for surgical evaluation. Doppler and light rheography examinations as office procedures are usually sufficient (except in the diabetic) to elucidate the cause of most vascular cases of lower leg ulceration.

► Differential Diagnosis

The differential includes vasculitis, pyoderma gangrenosum, arterial ulcerations, infection, trauma, skin cancer, arachnid bites, and sickle cell anemia. When the diagnosis is in doubt, a punch biopsy from the border (not base) of the lesion may be helpful.

► Prevention

Compression stockings to reduce edema are the most important means of prevention. Compression should achieve a pressure of 30 mm Hg below the knee and 40 mm Hg at the ankle. The stockings should not be used in patients with arterial insufficiency with an ABI < 0.7 . Pneumatic sequential compression devices may be of great benefit when edema is refractory to standard compression dressings.

► Treatment

A. Local Measures

Clean the base of the ulcer with saline or cleansers such as Saf-Cleans. A curette or small scissors can be used to remove the yellow fibrin eschar; local anesthesia may be used if the areas are very tender.

The ulcer is treated with metronidazole gel to reduce bacterial growth and odor. Any red dermatitic skin is

treated with a medium- to high-potency corticosteroid ointment. The ulcer is then covered with an occlusive hydroactive dressing (DuoDerm, Hydrasorb or Cutinova) or a polyurethane foam (Allevyn) followed by an Unna zinc paste boot. This is changed weekly. The ulcer should begin to heal within weeks, and healing should be complete within 4–6 months. If the patient is diabetic, becaplermin (Regranex) may be applied to those ulcers that are not becoming smaller or developing a granulating base. Some ulcerations require grafting. Full- or split-thickness grafts often do not take, and pinch grafts (small shaves of skin laid onto the bed) may be effective. Cultured epidermal cell grafts may accelerate wound healing, but they are very expensive. They should be considered in refractory ulcers, especially those that have not healed after a year or more of conservative therapy. Manuka honey has been purported to accelerate wound healing, but comparative controlled trials of efficacy are lacking.

No topical intervention has evidence to suggest that it will improve healing of arterial leg ulcers.

B. Systemic Therapy

Pentoxifylline, 400 mg three times daily administered with compression dressings, is beneficial in accelerating healing of venous insufficiency leg ulcers. Zinc supplementation is occasionally beneficial in patients with low serum zinc levels. The diagnosis of cellulitis in the setting of a venous insufficiency ulcer can be very difficult. Surface cultures are of limited value. The diagnosis of cellulitis should be considered in the following settings: 1) expanding warmth and erythema surrounding the ulceration with or without 2) increasing pain of the ulceration. The patient may also report increased exudate from the ulceration, but this without the other cardinal findings of cellulitis does not confirm the diagnosis of cellulitis. If cellulitis accompanies the ulcer, systemic antibiotics are recommended: dicloxacillin, 250 mg orally four times a day, or levofloxacin, 500 mg once daily for 1–2 weeks is usually adequate. Routine use of antibiotics and treating bacteria isolated from a chronic ulcer without clinical evidence of infection is discouraged. If the ulcer fails to heal or there is a persistent draining tract in the ulcer, an underlying osteomyelitis should be sought.

► Prognosis

The combination of limited debridement, compression dressings or stockings, and newer moist dressings will heal the majority of venous stasis ulcers within months (average 18 months). These need to be applied at least 80% of the time to optimize ulcer healing. Topical growth factors, antibiotics, debriding agents, and xenografts and autografts can be considered in recalcitrant cases, but they are usually not required in most patients. The failure of venous insufficiency ulcerations to heal is most often related to not using the basic treatment methods consistently, rather than failure to use these specific modalities. Ongoing control of edema is essential to prevent recurrent ulceration. The use of compression stockings following ulcer healing is critical to prevent recurrence, with recurrence rates 2–20 times

higher if patients do not comply with compression stocking use. If the ABI is < 0.5 , the prognosis for healing is poor.

- Amsler F et al. In search of optimal compression therapy for venous leg ulcers: a meta-analysis of studies comparing divers bandages with specifically designed stockings. *J Vasc Surg.* 2009 Sep;50(3):668–74. [PMID: 19595551]
- Armstrong DG. Manuka honey improved wound healing in patients with sloughy venous leg ulcers. *Evid Based Med.* 2009 Oct;14(5):148. [PMID: 19794023]
- Milic DJ et al. Risk factors related to the failure of venous leg ulcers to heal with compression treatment. *J Vasc Surg.* 2009 May;49(5):1242–7. [PMID: 19233601]
- Moffatt C et al. Venous leg ulcers: patient concordance with compression therapy and its impact on healing and prevention of recurrence. *Int Wound J.* 2009 Oct;6(5):386–93. [PMID: 19912396]
- Olson JM et al. Guideline concordant venous ulcer care predicts healing in a tertiary care Veterans Affairs Medical Center. *Wound Repair Regen.* 2009 Sep–Oct;17(5):666–70. [PMID: 19769720]
- O'Meara S et al. Antibiotics and antiseptics for venous leg ulcers. *Cochrane Database Syst Rev.* 2010 Jan 20;(1):CD003557. [PMID: 20091548]
- O'Meara S et al. Compression for venous leg ulcers. *Cochrane Database Syst Rev.* 2009 Jan 21;(1):CD000265. [PMID: 19160178]

MISCELLANEOUS DERMATOLOGIC DISORDERS¹

PIGMENTARY DISORDERS

Although the color of skin may be altered by many diseases and agents, the vast majority of patients have either an increase or decrease in pigment secondary to some inflammatory disease such as acne or atopic dermatitis.

Other pigmentary disorders include those resulting from exposure to exogenous pigments such as carotenemia, argyria, and tattooing. Other endogenous pigmentary disorders are attributable to metabolic substances—including hemosiderin (iron)—in purpuric processes; or to homogentisic acid in ochronosis; and bile pigments.

► Classification

First, determine whether the disorder is hyperpigmentation or hypopigmentation, ie, an increase or decrease in normal skin colors. Each may be considered to be primary or to be secondary to other disorders.

A. Primary Pigmentary Disorders

1. Hyperpigmentation—The disorders in this category are nevoid, congenital or acquired, and include pigmented nevi, ephelides (juvenile freckles), and lentigines (senile freckles). Hyperpigmentation occurs also in arsenical melanosis or in association with Addison disease. **Melasma (chloasma)** occurs as patterned hyperpigmentation of the



▲ **Figure 6-40.** Vitiligo of the hands. (Courtesy of Richard P. Usatine, MD; used, with permission, from Usatine RP, Smith MA, Mayeaux EJ Jr, Chumley H, Tysinger J. *The Color Atlas of Family Medicine.* McGraw-Hill, 2009.)

face, usually as a direct effect of estrogens. It occurs not only during pregnancy but also in 30–50% of women taking oral contraceptives, and rarely in men. One report suggests that such men have low testosterone and elevated luteinizing hormone levels.

2. Hypopigmentation and depigmentation—The disorders in this category are vitiligo, albinism, and piebaldism. In vitiligo, pigment cells (melanocytes) are destroyed (Figure 6-40). Vitiligo, present in approximately 1% of the population, may be associated with other autoimmune disorders such as autoimmune thyroid disease, pernicious anemia, diabetes mellitus, and Addison disease.

B. Secondary Pigmentary Disorders

Any damage to the skin (irritation, allergy, infection, excoriation, burns, or dermatologic therapy such as chemical peels and freezing with liquid nitrogen) may result in hyperpigmentation or hypopigmentation. Several disorders of clinical importance are described below.

1. Hyperpigmentation—The most common type of secondary hyperpigmentation occurs after another dermatologic condition, such as acne, and is most commonly seen in moderately complexioned persons (Asians, Hispanics, and light-skinned African Americans). It is called post-inflammatory hyperpigmentation.

Pigmentation may be produced by certain drugs, eg, chloroquine, chlorpromazine, minocycline, and amiodarone. Fixed drug eruptions to phenolphthalein in laxatives, to TMP-SMZ, to NSAIDs, and to tetracyclines, for example, are further causes.

2. Hypopigmentation—Leukoderma may complicate atopic dermatitis, lichen planus, psoriasis, DLE, and lichen simplex chronicus. Practitioners must exercise special care in using liquid nitrogen on any patient with olive or darker complexions, since doing so may result in

¹Hirsutism is discussed in Chapter 26.

hypopigmentation or depigmentation, at times permanent. Intralesional or intra-articular injections of high concentrations of corticosteroids may also cause localized temporary hypopigmentation.

► Differential Diagnosis

The evaluation of pigmentary disorders is helped by Wood's light, which accentuates epidermal pigmentation and highlights hypopigmentation. Depigmentation, as seen in vitiligo, enhances with Wood's light examination, whereas postinflammatory hypopigmentation does not.

► Complications

Actinic keratoses and skin cancers are more likely to develop in persons with vitiligo. Severe emotional trauma may occur in extensive vitiligo and other types of hypopigmentation and hyperpigmentation, particularly in naturally dark-skinned persons.

► Treatment & Prognosis

A. Hyperpigmentation

Therapeutic bleaching preparations generally contain hydroquinone. Hydroquinone has occasionally caused unexpected hypopigmentation, hyperpigmentation, or even secondary ochronosis and pigmented milia, particularly with prolonged use.

The role of exposure to ultraviolet light cannot be overstressed as a factor promoting or contributing to most disorders of hyperpigmentation, and such exposure should be minimized. Melasma, ephelides, and postinflammatory hyperpigmentation may be treated with varying success with 3–4% hydroquinone cream, gel, or solution and a sunscreen containing UVA photoprotectants (Avobenzone, Mexoryl, zinc oxide, titanium dioxide). Tretinoin cream, 0.025–0.05%, may be added. Superficial melasma responds well, but if there is predominantly dermal deposition of pigment (does *not* enhance with Wood's light), the prognosis is poor. Response to therapy may take months and requires avoidance of sunlight. Hyperpigmentation often recurs after treatment if the skin is exposed to ultraviolet light. Solar lentigines respond to liquid nitrogen application. Tretinoin, 0.1% cream and tazarotene 0.1% used over 10 months, will fade solar lentigines (liver spots), hyperpigmented facial macules in Asians, and postinflammatory hyperpigmentation in blacks. New laser systems for the removal of epidermal and dermal pigments are available, and referral should be considered for patients whose responses to medical treatment are inadequate.

B. Hypopigmentation

In secondary hypopigmentation, repigmentation may occur spontaneously. Cosmetics such as Covermark and Dermablend are highly effective for concealing disfiguring patches. Therapy of vitiligo is long and tedious, and the patient must be strongly motivated. If < 20% of the skin is involved (most cases), topical tacrolimus 0.1% twice daily is the first-line therapy. A superpotent corticosteroid may also be used, but local skin atrophy from prolonged use

may ensue. With 20–25% involvement, narrowband UVB or oral PUVA is best. Severe phototoxic response (sunburn) may occur with PUVA. The face and upper chest respond best, and the fingertips and the genital areas do not respond as well to treatment. Years of treatment may be required. Newer techniques of using epidermal autografts and cultured epidermis combined with PUVA therapy give hope for surgical correction of vitiligo.

Ta'ieb A et al. Clinical practice. Vitiligo. *N Engl J Med*. 2009 Jan 8;360(2):160–9. [PMID: 19129529]

BALDNESS (Alopecia)

► Baldness Due to Scarring (Cicatricial Alopecia)

Cicatricial baldness may occur following chemical or physical trauma, lichen planopilaris, bacterial or fungal infections, severe herpes zoster, chronic DLE, scleroderma, and excessive ionizing radiation. The specific cause is often suggested by the history, the distribution of hair loss, and the appearance of the skin, as in lupus erythematosus. Biopsy is useful in the diagnosis of scarring alopecia, but specimens must be taken from the active border and not from the scarred central zone.

Scarring alopecias are irreversible and permanent. It is important to diagnose and treat the scarring process as early in its course as possible.

► Baldness Not Associated with Scarring

Nonscarring alopecia may occur in association with various systemic diseases such as SLE, secondary syphilis, hyperthyroidism or hypothyroidism, iron deficiency anemia, and pituitary insufficiency. The only treatment necessary is prompt and adequate control of the underlying disorder and usually leads to regrowth of the hair.

Androgenetic (pattern) baldness, the most common form of alopecia, is of genetic predetermination. The earliest changes occur at the anterior portions of the calvarium on either side of the “widow's peak” and on the crown (vertex). The extent of hair loss is variable and unpredictable. Minoxidil 5% is available over the counter and can be specifically recommended for persons with recent onset (< 5 years) and smaller areas of alopecia. Approximately 40% of patients treated twice daily for a year will have moderate to dense growth. Finasteride (Propecia), 1 mg orally daily, has similar efficacy and may be additive to minoxidil. As opposed to minoxidil, finasteride is used only in males.

Hair loss or thinning of the hair in women results from the same cause as common baldness in men (androgenetic alopecia) and may be treated with topical minoxidil. A workup consisting of determination of serum testosterone, DHEAS, iron, total iron binding capacity, thyroid function tests, and a complete blood count will identify most other causes of hair thinning in premenopausal women. Women who complain of thin hair but show little evidence of alopecia need follow-up, because > 50% of the scalp hair can be lost before the clinician can perceive it.

Telogen effluvium is transitory increase in the number of hairs in the telogen (resting) phase of the hair growth cycle. This may occur spontaneously, may appear at the termination of pregnancy, may be precipitated by “crash dieting,” high fever, stress from surgery or shock, malnutrition, or may be provoked by hormonal contraceptives. Whatever the cause, telogen effluvium usually has a latent period of 2–4 months. The prognosis is generally good. The condition is diagnosed by the presence of large numbers of hairs with white bulbs coming out upon gentle tugging of the hair. Counts of hairs lost by the patient on combing or shampooing often exceed 150 per day, compared to an average of 70–100. In one study, a major cause of telogen effluvium was found to be iron deficiency, and the hair counts bore a clear relationship to serum iron levels. If iron deficiency is suspected, a serum ferritin should be obtained, and the value followed with supplementation.

Alopecia areata is of unknown cause but is believed to be an immunologic process. Typically, there are patches that are perfectly smooth and without scarring. Tiny hairs 2–3 mm in length, called “exclamation hairs,” may be seen. Telogen hairs are easily dislodged from the periphery of active lesions. The beard, brows, and lashes may be involved. Involvement may extend to all of the scalp hair (alopecia totalis) or to all scalp and body hair (alopecia universalis). Severe forms may be treated by systemic corticosteroid therapy, although recurrences follow discontinuation of therapy. Alopecia areata is occasionally associated with Hashimoto thyroiditis, pernicious anemia, Addison disease, and vitiligo.

Intralesional corticosteroids are frequently effective for alopecia areata. Triamcinolone acetonide in a concentration of 2.5–10 mg/mL is injected in aliquots of 0.1 mL at approximately 1- to 2-cm intervals, not exceeding a total dose of 30 mg per month for adults. Alternatively, anthralin 0.5% ointment, used daily, may help some patients. Alopecia areata is usually self-limiting, with complete regrowth of hair in 80% of patients with focal disease. Some mild cases are resistant to treatment, as are the extensive totalis and universalis types. Both topical diphencyprone and squaric acid dibutylester, have been used to treat persistent alopecia areata. The principle is to sensitize the skin, then intermittently apply weaker concentrations to produce and maintain a slight dermatitis. Hair regrowth in 3–6 months in some patients has been reported to be remarkable. Long-term safety and efficacy have not been established. Support groups for patients with extensive alopecia areata are very beneficial.

In **trichotillomania** (the pulling out of one’s own hair), the patches of hair loss are irregular and short growing hairs are always present, since they cannot be pulled out until they are long enough. The patches are often unilateral, occurring on the same side as the patient’s dominant hand. The patient may be unaware of the habit.

Alkhalifah A et al. Alopecia areata update: part II. Treatment. *J Am Acad Dermatol.* 2010 Feb;62(2):191–202. [PMID: 20115946]

NAIL DISORDERS

1. Morphologic Abnormalities of the Nails

► Classification

Acquired nail disorders may be classified as local or those associated with systemic or generalized skin diseases.

A. Local Nail Disorders

Onycholysis (distal separation of the nail plate from the nail bed, usually of the fingers) is caused by excessive exposure to water, soaps, detergents, alkalies, and industrial cleaning agents. Candidal infection of the nail folds and subungual area, nail hardeners, and drug-induced photosensitivity may cause onycholysis, as may hyperthyroidism, hypothyroidism, and psoriasis.

1. Distortion of the nail occurs as a result of chronic inflammation of the nail matrix underlying the eponychial fold. Such changes may also be caused by warts, tumors, or cysts, impinging on the nail matrix.
2. Discoloration and crumbly thickened nails are noted in dermatophyte infection and psoriasis.
3. Allergic reactions (to resins in undercoats and polishes or to nail glues) are characterized by onycholysis or by grossly distorted, hypertrophic, and misshapen nails.

B. Nail Changes Associated with Systemic or Generalized Skin Diseases

Beau lines (transverse furrows) may follow any serious systemic illness.

1. Atrophy of the nails may be related to trauma or to vascular or neurologic disease.
2. Clubbed fingers may be due to the prolonged hypoxemia associated with cardiopulmonary disorders (Figure 6–41). (See Chapter 9.)
3. Spoon nails may be seen in anemic patients.
4. Stippling or pitting of the nails is seen in psoriasis, alopecia areata, and hand eczema.
5. Nail hyperpigmentation may be caused by many chemotherapeutic agents, but especially the taxanes.

► Differential Diagnosis

Onychomycosis may cause nail changes identical to those seen in psoriasis. Careful examination for more characteristic lesions elsewhere on the body is essential to the diagnosis of the nail disorders. Cancer should be suspected (eg, Bowen disease or squamous cell carcinoma) as the cause of any persistent solitary subungual or periungual lesion.

► Complications

Toenail changes may lead to an ingrown nail—in turn often complicated by bacterial infection and occasionally by exuberant granulation tissue. Poor manicuring and



▲ **Figure 6-41.** Clubbing of the fingers in congenital heart disease. (Courtesy of Richard P. Usatine, MD; used, with permission, from Usatine RP, Smith MA, Mayeaux EJ Jr, Chumley H, Tysinger J. *The Color Atlas of Family Medicine*. McGraw-Hill, 2009.)

poorly fitting shoes may contribute to this complication. Cellulitis may result.

► Treatment & Prognosis

Treatment consists usually of careful debridement and manicuring and, above all, reduction of exposure to irritants (soaps, detergents, alkali, bleaches, solvents, etc). Longitudinal grooving due to temporary lesions of the matrix, such as warts, synovial cysts, and other impingements, may be cured by removal of the offending lesion.

2. Tinea Unguium (Onychomycosis)

Tinea unguium is a trichophyton infection of one or more (but rarely all) fingernails or toenails. The species most commonly found is *T rubrum*. “Saprophytic” fungi may rarely (< 5%) cause onychomycosis.

The nails are lusterless, brittle, and hypertrophic, and the substance of the nail is friable. Laboratory diagnosis is mandatory since only 50% of dystrophic nails are due to dermatophytosis. Portions of the nail should be cleared with 10% KOH and examined under the microscope for hyphae. Fungi may also be cultured. Periodic acid-Schiff stain of a histologic section of the nail plate will also demonstrate the fungus readily. Each technique is positive in only 50% of cases so several different tests may need to be performed.

Onychomycosis is difficult to treat because of the long duration of therapy required and the frequency of recurrences. Fingernails respond more readily than toenails. For toenails, treatment is limited to patients with discomfort, inability to exercise, and immune compromise.

In general, systemic therapy is required to effectively treat nail onychomycosis. Topical therapy has limited value

and the adjunctive value of surgical procedures is unproven. Efficacy of laser treatments is lacking, especially with regard to long-term cures. Fingernails can virtually always be cured and toenails are cured 35–50% of the time and are clinically improved about 75% of the time. In all cases, before treatment, the diagnosis should be confirmed. The costs of the various treatment options should be known and the most cost-effective treatment chosen. Drug interactions must be avoided. Ketoconazole, due to its higher risk for hepatotoxicity, is not recommended to treat any form of onychomycosis. For fingernails, ultramicrocrized griseofulvin 250 mg orally three times daily for 6 months can be effective. Alternative treatments are (in order of preference) oral terbinafine 250 mg daily for 6 weeks, oral itraconazole 400 mg daily for 7 days each month for 2 months, and oral itraconazole 200 mg daily for 2 months. Off-label use of fluconazole, 400 mg once weekly for 6 months, can also be effective, but there is limited evidence for this option. Once clear, fingernails usually remain free of disease for some years.

Onychomycosis of the toenails does not respond to griseofulvin therapy or topical treatments. The best treatment, which is also FDA approved, is oral terbinafine 250 mg daily for 12 weeks. Liver function tests and a complete blood count with platelets are performed monthly during treatment. Pulse oral itraconazole 200 mg twice daily for 1 week per month for 3 months is inferior to standard terbinafine treatments, but it is an acceptable alternative for those unable to take terbinafine. The courses of terbinafine or itraconazole may need to be repeated 6 months after the first treatment cycle if fungal cultures of the nail are still positive.

Bergstrom KG. Onychomycosis: is there a role for lasers? *J Drugs Dermatol.* 2011 Sep 1;10(9):1074–75. [PMID: 22052283]
 de Berker D. Clinical practice. Fungal nail disease. *N Engl J Med.* 2009 May 14;360(20):2108–16. [PMID: 19439745]
 Robb-Nicholson C. By the way, doctor, I’ve tried a lot of things for a fungal infection in one of my toenails, but it just won’t go away. What do you know about a new treatment that uses laser? *Harv Womens Health Watch.* 2010 Apr;17(8):8. [PMID: 20506605]
 Welsh O et al. Onychomycosis. *Clin Dermatol.* 2010 Mar 4;28(2):151–9. [PMID: 20347657]

DERMATITIS MEDICAMENTOSA (Drug Eruption)



ESSENTIALS OF DIAGNOSIS

- ▶ Usually, abrupt onset of widespread, symmetric erythematous eruption.
- ▶ May mimic any inflammatory skin condition.
- ▶ Constitutional symptoms (malaise, arthralgia, headache, and fever) may be present.

► General Considerations

As is well recognized, only a minority of cutaneous drug reactions result from allergy. True allergic drug reactions

Table 6-3. Skin reactions due to systemic drugs.

Reaction	Appearance	Distribution and Comments	Common Offenders
Toxic erythema	Morbilliform, maculopapular, exanthematous reactions.	The most common skin reaction to drugs. Often more pronounced on the trunk than on the extremities. In previously exposed patients, the rash may start in 2-3 days. In the first course of treatment, the eruption often appears about the seventh to ninth days. Fever may be present.	Antibiotics (especially ampicillin and TMP-SMZ), sulfonamides and related compounds (including thiazide diuretics, furosemide, and sulfonyleurea hypoglycemic agents), and barbiturates.
SJS/TEN	Target-like lesions. Bullae may occur. Mucosal involvement.	Usually trunk and proximal extremities.	Sulfonamides, anticonvulsants, allopurinol and NSAIDs.
Erythema nodosum	Inflammatory cutaneous nodules.	Usually limited to the extensor aspects of the legs. May be accompanied by fever, arthralgias, and pain.	Oral contraceptives.
Allergic vasculitis	Inflammatory changes may present as urticaria that lasts over 24 hours, hemorrhagic papules ("palpable purpura"), vesicles, bullae, or necrotic ulcers.	Most severe on the legs.	Sulfonamides, phenytoin, propylthiouracil.
Exfoliative dermatitis and erythroderma	Red and scaly.	Entire skin surface.	Allopurinol, sulfonamides, isoniazid, anticonvulsants, or carbamazepine.
Photosensitivity: increased sensitivity to light, often of ultraviolet A wavelengths, but may be due to UVB or visible light as well	Sunburn, vesicles, papules in photodistributed pattern.	Exposed skin of the face, the neck, and the backs of the hands and, in women, the lower legs. Exaggerated response to ultraviolet light.	Sulfonamides and sulfonamide-related compounds (thiazide diuretics, furosemide, sulfonyleureas), tetracyclines, phenothiazines, sulindac, amiodarone, voriconazole, and NSAIDs.
Drug-related lupus erythematosus	May present with a photosensitive rash, annular lesions or psoriasis on upper trunk.	Less severe than systemic lupus erythematosus, sparing the kidneys and central nervous system. Recovery often follows drug withdrawal.	Diltiazem, etanercept, hydrochlorothiazide, infliximab, lisinopril, terbinafine.
Lichenoid and lichen planus-like eruptions	Pruritic, erythematous to violaceous polygonal papules that coalesce or expand to form plaques.	May be in photo- or nonphoto-distributed pattern.	Carbamazepine, furosemide, hydroxychloroquine, phenothiazines, β -blockers, quinidine, quinine, sulfonyleureas, tetracyclines, thiazides, and triprolidine.
Fixed drug eruptions	Single or multiple demarcated, round, erythematous plaques that often become hyperpigmented.	Recur at the same site when the drug is repeated. Hyperpigmentation, if present, remains after healing.	Numerous drugs, including antimicrobials, analgesics, barbiturates, cardiovascular drugs, heavy metals, antiparasitic agents, antihistamines, phenolphthalein, ibuprofen, and naproxen.
Urticaria	Red, itchy wheals that vary in size from < 1 cm to many centimeters. May be accompanied by angioedema.	Chronic urticaria is rarely caused by drugs.	Acute urticaria: penicillins, NSAIDs, sulfonamides, opioids, and salicylates. Angioedema is common in patients receiving ACE inhibitors and angiotensin receptor blockers.

(continued)

Table 6-3. Skin reactions due to systemic drugs. (continued)

Reaction	Appearance	Distribution and Comments	Common Offenders
Pigmentary changes	Flat hyperpigmented areas.	Forehead and cheeks (chloasma, melasma). The most common pigmentary disorder associated with drug ingestion. Improvement is slow despite stopping the drug.	Oral contraceptives are the usual cause.
	Blue-gray discoloration.	Light-exposed areas.	Chlorpromazine and related phenothiazines.
	Brown or blue-gray pigmentation.	Generalized.	Heavy metals (silver, gold, bismuth, and arsenic).
	Yellow color.	Generalized.	Quinacrine.
	Blue-black patches on the shins.		Minocycline, chloroquine.
	Blue-black pigmentation of the nails and palate and depigmentation of the hair.		Chloroquine.
	Slate-gray color.	Primarily in photoexposed areas.	Amiodarone.
	Brown discoloration of the nails.	Especially in more darkly pigmented patients.	Hydroxyurea.
Psoriasiform eruptions	Scaly red plaques.	May be located on trunk and extremities. Palms and soles may be hyperkeratotic. May cause psoriasiform eruption or worsen psoriasis.	Antimalarials, lithium, β -blockers, and tumor necrosis factor (TNF)-inhibitors.
Pityriasis rosea-like eruptions	Oval, red, slightly raised patches with central scale.	Mainly on the trunk.	Barbiturates, bismuth, captopril, clonidine, methopromazine, metoprolol, metronidazole, and tripeleminamine.

ACE, angiotensin-converting enzyme; NSAIDs, nonsteroidal anti-inflammatory drugs; SJS/TEN, Stevens-Johnson syndrome/toxic epidermal necrolysis.

involve prior exposure, an “incubation” period, reactions to doses far below the therapeutic range, manifestations different from the usual pharmacologic effects of the drug, involvement of only a small portion of the population at risk, restriction to a limited number of syndromes (anaphylactic and anaphylactoid, urticarial, vasculitic, etc), and reproducibility.

Rashes are among the most common adverse reactions to drugs and occur in 2–3% of hospitalized patients. Amoxicillin, TMP-SMZ, and ampicillin or penicillin are the most common causes of urticarial and maculopapular reactions. Toxic epidermal necrolysis and Stevens-Johnson syndrome are most commonly produced by sulfonamides and anticonvulsants. Phenolphthalein, pyrazolone derivatives, tetracyclines, NSAIDs, TMP-SMZ, and barbiturates are the major causes of fixed drug eruptions.

► Clinical Findings

A. Symptoms and Signs

Drug eruptions are generally classified as “simple” or “complex.” Simple drug eruptions involve an exanthem, usually appear in the second week of drug therapy, and have no associated constitutional or laboratory findings. Antibiotics, including the penicillins and quinolones are the most common causes. Complex drug eruptions (also called drug-induced hypersensitivity syndromes) occur during the third week of treatment on average and have constitutional and laboratory findings. These may include fevers, chills, hematologic abnormalities (especially eosinophilia), and abnormal liver or kidney function. A mnemonic for complex eruptions is “DRESS” (DRUG Eruption with Eosinophilia and Systemic Symptoms). The most common

causes are the long-acting sulfonamides, allopurinol, and anticonvulsants. The use of anticonvulsants to treat bipolar disorder and chronic pain has led to an apparent increase in these reactions. In patients of certain races, polymorphisms of antigen presenting major histocompatibility (MHC) loci increases risk for the development of severe drug eruptions. Coexistent reactivation of Epstein-Barr virus, HHV-6, or cytomegalovirus is often present and may be important in the pathogenesis of these complex drug eruptions. Table 6–3 summarizes the types of skin reactions, their appearance and distribution, and the common offenders in each case.

B. Laboratory Findings

Routinely ordered blood work is of no value in the diagnosis of simple drug eruptions. In complex drug eruptions, the CBC, liver biochemical tests, and renal function tests should be monitored. Skin biopsies may be helpful in making the diagnosis.

► Differential Diagnosis

Observation after discontinuation, which may be a slow process, helps establish the diagnosis. Rechallenge, though of theoretical value, may pose a danger to the patient and is best avoided.

► Complications

Some cutaneous drug reactions may be associated with visceral involvement. The organ systems involved depend on the individual medication or drug class. Most common is an infectious mononucleosis-like illness and hepatitis associated with administration of anticonvulsants. Myocarditis may be a serious complication of drug-induced hypersensitivity syndrome. Months after recovering from DRESS, patients may suffer hypothyroidism.

► Treatment

A. General Measures

Systemic manifestations are treated as they arise (eg, anemia, icterus, purpura). Antihistamines may be of value in urticarial and angioneurotic reactions. Epinephrine 1:1000, 0.5–1 mL intravenously or subcutaneously, should be used as an emergency measure. In drug-induced hypersensitivity syndromes (DRESS), systemic corticosteroids

may be required, starting at about 1 mg/kg/d and tapering very slowly.

B. Local Measures

SJS/TEN with extensive blistering eruptions resulting in erosions and superficial ulcerations, which demand hospitalization and nursing care as for burn patients, develops in some DRESS patients.

► Prognosis

Drug rash usually disappears upon withdrawal of the drug and proper treatment. DRESS may be associated with autoimmune phenomena, including abnormal thyroid function. This can occur months after the hypersensitivity syndrome has resolved.

- Bircher AJ et al. Delayed cutaneous manifestations of drug hypersensitivity. *Med Clin North Am.* 2010 Jul;94(4):711–25. [PMID: 20609859]
- Brown RJ et al. Minocycline-induced drug hypersensitivity syndrome followed by multiple autoimmune sequelae. *Arch Dermatol.* 2009 Jan;145(1):63–6. [PMID: 19153345]
- Chung WH et al. Genetic predisposition of life-threatening antiepileptic-induced skin reactions. *Expert Opin Drug Saf.* 2010 Jan;9(1):15–21. [PMID: 20001755]
- Cornejo-Garcia JA et al. Hypersensitivity reactions to non-steroidal anti-inflammatory drugs. *Curr Drug Metab.* 2009 Nov;10(9):971–80. [PMID: 20214589]
- Harr T et al. Severe cutaneous adverse reactions: acute generalized exanthematous pustulosis, toxic epidermal necrolysis and Stevens-Johnson syndrome. *Med Clin North Am.* 2010 Jul;94(4):727–42. [PMID: 20609860]
- Limsuwan T et al. Acute symptoms of drug hypersensitivity (urticaria, angioedema, anaphylaxis, anaphylactic shock). *Med Clin North Am.* 2010 Jul;94(4):691–710. [PMID: 20609858]
- Tassaneeyakul W et al. Strong association between HLA-B*5801 and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population. *Pharmacogenet Genomics.* 2009 Sep;19(9):704–9. [PMID: 19696695]
- Walsh SA et al. Drug reaction with eosinophilia and systemic symptoms (DRESS): a clinical update and review of current thinking. *Clin Exp Dermatol.* 2011 Jan;36(1):6–11. [PMID: 21143513]
- Ward KE et al. Severe adverse skin reactions to nonsteroidal antiinflammatory drugs: a review of the literature. *Am J Health Syst Pharm.* 2010 Feb 1;67(3):206–13. [PMID: 20101062]

7

Disorders of the Eyes & Lids

Paul Riordan-Eva, FRCOphth

REFRACTIVE ERRORS

Refractive errors are the most common cause of reduced clarity of vision (visual acuity) and may be a readily treatable component of poor vision in patients with other diagnoses. In the normal state (**emmetropia**), objects at infinity are seen clearly. Focusing on objects nearer than infinity requires an increase in the refractive power of the crystalline lens by the process of accommodation. In farsightedness (**hyperopia**), objects at infinity are not seen clearly unless accommodation is used, and near objects may not be seen because accommodative capacity is finite. Farsightedness is corrected with plus (convex) lenses. In nearsightedness (**myopia**), the unaccommodated eye focuses on objects closer than infinity. The markedly nearsighted eye is able to focus on very near objects without glasses. Objects beyond this distance cannot be seen without the aid of corrective (minus, concave) lenses. **Astigmatism**, in which the refractive errors in the horizontal and vertical axes differ, is corrected with cylindrical lenses. **Presbyopia** is the natural loss of accommodative capacity with age. Persons with emmetropia usually notice inability to focus on objects at a normal reading distance at about age 45. Farsighted individuals experience symptoms at an earlier age. Presbyopia is corrected with plus lenses for near work.

Use of a pinhole will overcome most refractive errors and thus allows their identification as a cause of reduced visual acuity.

1. Contact Lenses

Contact lenses are used mostly for correction of refractive errors, for which they provide better optical correction than glasses, as well as for management of diseases of the cornea, conjunctiva, or lids. The major types of lenses are rigid (gas-permeable) and soft. Rigid lenses, which need to be removed each day, are more durable and easier to care for than soft lenses but are more difficult to tolerate. Usually removed each day, soft lenses are available for extended wear. Disposable soft lenses to be renewed daily, or less frequently (up to monthly), are available.

Contact lens care includes cleaning and sterilization whenever the lenses are to be reused and removal of

protein deposits as required. Sterilization is usually by chemical methods. For individuals developing reactions to preservatives in contact lens solutions, preservative-free systems are available.

The major risk from contact lens wear is bacterial, amebic, or fungal corneal infection, potentially a blinding condition. Such infections occur more commonly with soft lenses, particularly extended wear, for which there is at least a fivefold increase in risk of corneal ulceration compared with daily wear, and with certain contact lens solutions. Contact lens wearers should be made aware of the risks they face and ways to minimize them, such as avoiding overnight wear and maintaining meticulous lens hygiene, including not using tap water or saliva for lens cleaning. Whenever there is ocular discomfort or redness, contact lenses should be removed. Ophthalmologic care should be sought if symptoms persist.

► When to Refer

Any contact lens wearer with an acute painful red eye must be referred emergently to an ophthalmologist.

Cavanagh HD et al. Castroviejo Lecture 2009: 40 years in search of the perfect contact lens. *Cornea*. 2010 Oct;29(10):1075–85. [PMID: 20622672]

Jeng BH et al. Epidemiology of ulcerative keratitis in Northern California. *Arch Ophthalmol*. 2010 Aug;128(8):1022–8. [PMID: 20697003]

2. Surgical Correction

Various surgical techniques are available for the correction of refractive errors, particularly nearsightedness. Laser corneal refractive surgery reshapes the mid-portion (stroma) of the cornea with an excimer laser. Laser assisted in situ keratomileusis (LASIK), including femtosecond laser assisted LASIK (IntraLASIK), and the surface ablation techniques epithelial LASIK (Epi-LASIK), laser epithelial keratomileusis (also known as laser-assisted subepithelial keratectomy) (LASEK), and photorefractive keratectomy (PRK) differ according to how access to the stroma is achieved. LASIK is most commonly performed because postoperative visual recovery is rapid and there is little

postoperative discomfort, but it is contraindicated if the cornea is relatively thin. Approximately 16 million procedures have been performed worldwide with > 90% patient satisfaction after primary surgery. However, outcomes for individual cases are not completely predictable. It has been reported that repeated treatment is required in up to 15% of patients and serious complications occur in up to 5%. Other refractive surgery techniques are extraction of the clear crystalline lens with insertion of a single vision, multifocal or accommodative intraocular lens; insertion of an intraocular lens without removal of the crystalline lens (phakic intraocular lens); intrastromal corneal ring segments (INTACS); and conductive keratoplasty (CK). Topical atropine and pirenzepine, a selective muscarinic antagonist, and rigid contact lens wear during sleep (orthokeratology) are also being investigated for nearsightedness.

Bastwrous A et al. Laser refractive eye surgery. *BMJ*. 2011 Apr 20;342:d2345. [PMID: 21508060]

Messmer JJ. LASIK: a primer for family physicians. *Am Fam Physician*. 2010 Jan;81(1):42–7. [PMID: 20052962]

Reynolds A et al. Excimer laser surface ablation—a review. *Clin Experiment Ophthalmol*. 2010 Mar;38(2):168–82. [PMID: 20398106]

Taneri S et al. Surface ablation techniques. *J Cataract Refract Surg*. 2011 Feb;37(2):392–408. [PMID: 21241926]

DISORDERS OF THE LIDS & LACRIMAL APPARATUS

1. Hordeolum

Hordeolum is a common staphylococcal abscess that is characterized by a localized red, swollen, acutely tender area on the upper or lower lid (Figure 7–1). Internal hordeolum is a meibomian gland abscess that usually



▲ **Figure 7-1.** External hordeolum (black arrow) and chalazion (white arrow), which developed from an internal hordeolum. (Courtesy of Richard P. Usatine, MD. Reproduced, with permission, from Usatine RP, Smith MA, Mayeaux EJ Jr, Chumley H, Tysinger J. *The Color Atlas of Family Medicine*. McGraw-Hill, 2009.)

points onto the conjunctival surface of the lid; external hordeolum or sty usually is smaller and on the margin.

Warm compresses are helpful. Incision may be indicated if resolution does not begin within 48 hours. An antibiotic ointment (bacitracin or erythromycin) applied to the eyelid every 3 hours may be beneficial during the acute stage. Internal hordeolum may lead to generalized cellulitis of the lid.

2. Chalazion

Chalazion is a common granulomatous inflammation of a meibomian gland that may follow an internal hordeolum (Figure 7–1). It is characterized by a hard, nontender swelling on the upper or lower lid with redness and swelling of the adjacent conjunctiva. If the chalazion is large enough to impress the cornea, vision will be distorted. Treatment is usually by incision and curettage but corticosteroid injection may also be effective.

Arbabi EM et al. Chalazion. *BMJ*. 2010 Aug 10;341:c4044. [PMID: 21155069]

3. Blepharitis

Blepharitis is a common chronic bilateral inflammatory condition of the lid margins. **Anterior blepharitis** involves the eyelid skin, eyelashes, and associated glands. It may be ulcerative, because of infection by staphylococci, or seborrheic in association with seborrhea of the scalp, brows, and ears. **Posterior blepharitis** results from inflammation of the meibomian glands. There may be bacterial infection, particularly with staphylococci, or primary glandular dysfunction, in which there is a strong association with acne rosacea.

► Clinical Findings

Symptoms are irritation, burning, and itching. In **anterior blepharitis**, the eyes are “red-rimmed,” and scales or granulations can be seen clinging to the lashes. In **posterior blepharitis**, the lid margins are hyperemic with telangiectasias; the meibomian glands and their orifices are inflamed, with dilation of the glands, plugging of the orifices, and abnormal secretions. The lid margin is frequently rolled inward to produce a mild entropion, and the tears may be frothy or abnormally greasy.

Blepharitis is a common cause of recurrent conjunctivitis. Both anterior and, more particularly, posterior blepharitis may be complicated by hordeola or chalazions; abnormal lid or lash positions, producing trichiasis; epithelial keratitis of the lower third of the cornea; marginal corneal infiltrates; and inferior corneal vascularization and thinning.

► Treatment

Anterior blepharitis is usually controlled by cleanliness of the lid margins, eyebrows, and scalp. Scales should be removed from the lids daily with a hot wash cloth or a damp cotton applicator and baby shampoo. In acute exacerbations, an antistaphylococcal antibiotic eye ointment such as bacitracin or erythromycin is applied daily to the

lid margins. Antibiotic sensitivity studies may be helpful in severe cases.

In **mild posterior blepharitis**, regular meibomian gland expression may be sufficient to control symptoms. Inflammation of the conjunctiva and cornea indicates a need for more active treatment, including long-term low-dose oral antibiotic therapy, usually with tetracycline (250 mg twice daily), doxycycline (100 mg daily), minocycline (50–100 mg daily) or erythromycin (250 mg three times daily), and possibly short-term topical corticosteroids, eg, prednisolone, 0.125% twice daily. Topical therapy with antibiotics such as ciprofloxacin 0.3% ophthalmic solution twice daily may be helpful but should be restricted to short courses.

Bernardes TF et al. Blepharitis. *Semin Ophthalmol.* 2010 May;25(3):79–83. [PMID: 20590417]

4. Entropion & Ectropion

Entropion (inward turning of usually the lower lid) occurs occasionally in older people as a result of degeneration of the lid fascia, or may follow extensive scarring of the conjunctiva and tarsus. Surgery is indicated if the lashes rub on the cornea. Botulinum toxin injections may also be used for temporary correction of the involutional lower eyelid entropion of older people.

Ectropion (outward turning of the lower lid) is common with advanced age. Surgery is indicated if there is excessive tearing, exposure keratitis, or a cosmetic problem.

Bedran EG et al. Ectropion. *Semin Ophthalmol.* 2010 May;25(3):59–65. [PMID: 20590414]

Pereira MG et al. Eyelid entropion. *Semin Ophthalmol.* 2010 May;25(3):52–8. [PMID: 20590413]

5. Tumors

Eyelid tumors are usually benign. Basal cell carcinoma is the most common malignant tumor. Squamous cell carcinoma, meibomian gland carcinoma, and malignant melanoma also occur. Surgery for any lesion involving the lid margin should be performed by an ophthalmologist or suitably trained plastic surgeon to avoid deformity of the lid. Otherwise, small lesions can often be excised by the nonophthalmologist. Histopathologic examination of eyelid tumors should be routine, since 2% of lesions thought to be benign clinically are found to be malignant. The Mohs technique of intraoperative examination of excised tissue is particularly valuable in ensuring complete excision so that the risk of recurrence is reduced.

Deprez M et al. Clinicopathological features of the eyelid skin tumors. A retrospective study of 5504 cases and review of literature. *Am J Dermatopathol.* 2009 May;31(3):256–62. [PMID: 19384066]

Murchison AP et al. Non-surgical treatments of primary, non-melanoma eyelid malignancies: a review. *Clin Experiment Ophthalmol.* 2011 Jan;39(1):65–83. [PMID: 21040309]

6. Dacryocystitis

Dacryocystitis is infection of the lacrimal sac usually due to congenital or acquired obstruction of the nasolacrimal system. It may be acute or chronic and occurs most often in infants and in persons over 40 years. It is usually unilateral. The usual infectious organisms are *Staphylococcus aureus* and β -hemolytic streptococci in acute dacryocystitis and *S epidermidis*, anaerobic streptococci, or *Candida albicans* in chronic dacryocystitis.

Acute dacryocystitis is characterized by pain, swelling, tenderness, and redness in the tear sac area; purulent material may be expressed. In chronic dacryocystitis, tearing and discharge are the principal signs, and mucus or pus may also be expressed.

Acute dacryocystitis responds well to systemic antibiotic therapy. Surgical relief of the underlying obstruction is usually done electively but may be performed urgently in acute cases. The chronic form may be kept latent with antibiotics, but relief of the obstruction is the only cure. In adults, the standard procedure for obstruction of the lacrimal drainage system is dacryocystorhinostomy, which involves surgical exploration of the lacrimal sac and formation of a fistula into the nasal cavity; if necessary, the procedure can be supplemented by nasolacrimal intubation. Laser-assisted endoscopic dacryocystorhinostomy and balloon dilation or probing of the nasolacrimal system are alternatives. Congenital nasolacrimal duct obstruction is common and often resolves spontaneously. It can be treated by probing of the nasolacrimal system and supplemented by nasolacrimal intubation or balloon catheter dilation, if necessary. Dacryocystorhinostomy is rarely required.

Anijeet D et al. Endonasal versus external dacryocystorhinostomy for nasolacrimal duct obstruction. *Cochrane Database Syst Rev.* 2011 Jan 19;(1):CD007097. [PMID: 21249688]

Dantas RR. Lacrimal drainage system obstruction. *Semin Ophthalmol.* 2010 May;25(3):98–103. [PMID: 20590420]

Frick KD et al. Cost-effectiveness of 2 approaches to managing nasolacrimal duct obstruction in infants: the importance of the spontaneous resolution rate. *Arch Ophthalmol.* 2011 May;129(5):603–9. [PMID: 21555614]

CONJUNCTIVITIS

Conjunctivitis is the most common eye disease. It may be acute or chronic. Most cases are due to viral or bacterial (including gonococcal and chlamydial) infection. Other causes include keratoconjunctivitis sicca, allergy, chemical irritants, and deliberate self-harm. The mode of transmission of infectious conjunctivitis is usually direct contact via fingers, towels, handkerchiefs, etc, to the fellow eye or to other persons. It may be through contaminated eye drops.

Conjunctivitis must be differentiated from acute uveitis, acute glaucoma, and corneal disorders (Table 7–1).

1. Viral Conjunctivitis

Adenovirus is the most common cause of viral conjunctivitis. There is usually bilateral disease with copious watery discharge, often with marked foreign body sensation, and a

Table 7-1. The inflamed eye: Differential diagnosis of common causes.

	Acute Conjunctivitis	Acute Anterior Uveitis (Iritis)	Acute Angle-Closure Glaucoma	Corneal Trauma or Infection
Incidence	Extremely common	Common	Uncommon	Common
Discharge	Moderate to copious	None	None	Watery or purulent
Vision	No effect on vision	Often blurred	Markedly blurred	Usually blurred
Pain	Mild	Moderate	Severe	Moderate to severe
Conjunctival injection	Diffuse; more toward fornices	Mainly circumcorneal	Mainly circumcorneal	Mainly circumcorneal
Cornea	Clear	Usually clear	Cloudy	Clarity change related to cause
Pupil size	Normal	Small	Moderately dilated	Normal or small
Pupillary light response	Normal	Poor	None	Normal
Intraocular pressure	Normal	Usually normal but may be low or elevated	Markedly elevated	Normal
Smear	Causative organisms	No organisms	No organisms	Organisms found only in corneal infection

follicular conjunctivitis. Infection spreads easily. Eye clinics and contaminated swimming pools are sometimes the source of infection. Epidemic keratoconjunctivitis, which may result in visual loss due to corneal subepithelial infiltrates, is usually caused by adenovirus types 8, 19, and 37. The disease lasts at least 2 weeks. Infection with adenovirus types 3, 4, 7, and 11 is typically associated with pharyngitis, fever, malaise, and preauricular adenopathy (pharyngoconjunctival fever). The disease usually lasts 10 days. Viral conjunctivitis may also be due to herpes simplex virus (HSV), when it is usually unilateral and may be associated with lid vesicles, and enterovirus 70 or coxsackievirus A24 that characteristically cause acute hemorrhagic conjunctivitis (see Chapter 32).

Except for HSV infection for which topical or systemic antivirals may be prescribed, there is no specific treatment. Cold compresses reduce discomfort and topical sulfonamides (or other antibiotics) can be prescribed to prevent secondary bacterial infection. The value of weak topical corticosteroids or topical cyclosporine for corneal infiltrates due to adenoviral infection is uncertain.

Kaufman HE. Adenovirus advances: new diagnostic and therapeutic options. *Curr Opin Ophthalmol*. 2011 Jul;22(4):290–3. [PMID: 21537185]

Skevaki CL et al. Treatment of viral conjunctivitis with antiviral drugs. *Drugs*. 2011 Feb 12;71(3):331–47. [PMID: 21319870]

2. Bacterial Conjunctivitis

The organisms isolated most commonly in bacterial conjunctivitis are staphylococci, streptococci (particularly *S pneumoniae*), *Haemophilus* species, *Pseudomonas*, and *Moraxella*. All may produce a copious purulent discharge. There is no blurring of vision and only mild discomfort. In

severe (hyperpurulent) cases, examination of stained conjunctival scrapings and cultures is recommended, particularly to identify gonococcal infection.

The disease is usually self-limited, lasting about 10–14 days if untreated. Topical sulfonamide (eg, sulfacetamide, 10% ophthalmic solution or ointment three times a day) will usually clear the infection in 2–3 days but the need for antibacterial therapy is disputed. The use of topical fluoroquinolones is rarely justified for treatment of a generally self-limiting, benign infection.

Hutnik C et al. Bacterial conjunctivitis. *Clin Ophthalmol*. 2010 Dec 6;4:1451–7. [PMID: 21188158]

Tarabishy AB et al. Bacterial conjunctivitis: a review for internists. *Cleve Clin J Med*. 2008 Jul;75(7):507–12. [PMID: 18646586]

A. Gonococcal Conjunctivitis

Gonococcal conjunctivitis, usually acquired through contact with infected genital secretions, typically causes copious purulent discharge. It is an ophthalmologic emergency because corneal involvement may rapidly lead to perforation. The diagnosis should be confirmed by stained smear and culture of the discharge. A single 1-g dose of intramuscular ceftriaxone is usually adequate. (Fluoroquinolone resistance is common.) Topical antibiotics such as erythromycin and bacitracin may be added. Other sexually transmitted diseases, including chlamydiosis, syphilis, and HIV infection, should be considered.

B. Chlamydial Keratoconjunctivitis

1. Trachoma—Trachoma is the most common infectious cause of blindness worldwide, with approximately 40 million people affected and 1.3 million with profound vision

loss. Recurrent episodes of infection in childhood manifest as bilateral follicular conjunctivitis, epithelial keratitis, and corneal vascularization (pannus). Cicatrization of the tarsal conjunctiva leads to entropion and trichiasis in adulthood, with secondary central corneal scarring.

Immunologic tests or polymerase chain reaction on conjunctival samples will confirm the diagnosis but treatment should be started on the basis of clinical findings. Single-dose therapy with oral azithromycin, 20 mg/kg, is the preferred drug treatment but improvements in hygiene and living conditions probably have contributed more to the marked reduction in the prevalence of trachoma during the past 25 years. Local treatment is not necessary. Surgical treatment includes correction of eyelid deformities and corneal transplantation.

Evans JR et al. Antibiotics for trachoma. *Cochrane Database Syst Rev*. 2011 Mar 16;(3):CD001860. [PMID: 21412875]
Hu VH et al. Epidemiology and control of trachoma: systematic review. *Trop Med Int Health*. 2010 Jun;15(6):673–91. [PMID: 20374566]

2. Inclusion conjunctivitis—The agent of inclusion conjunctivitis is a common cause of genital tract disease in adults. The eye is usually involved following contact with genital secretions. The disease starts with acute redness, discharge, and irritation. The eye findings consist of follicular conjunctivitis with mild keratitis. A nontender preauricular lymph node can often be palpated. Healing usually leaves no sequelae. Diagnosis can be rapidly confirmed by immunologic tests or polymerase chain reaction on conjunctival samples. Treatment is with a single-dose of azithromycin, 1 g orally. Before treatment, all cases should be assessed for genital tract infection so that management can be adjusted accordingly, and other venereal diseases sought.

3. Dry Eyes (Keratoconjunctivitis Sicca)

This is a common disorder, particularly in older women. Hypofunction of the lacrimal glands, causing loss of the aqueous component of tears, may be due to aging, hereditary disorders, systemic disease (eg, Sjögren syndrome), or systemic drugs. Excessive evaporation of tears may be due to environmental factors (eg, a hot, dry, or windy climate) or abnormalities of the lipid component of the tear film, as in blepharitis. Mucin deficiency may be due to vitamin A deficiency, or conjunctival scarring from trachoma, Stevens-Johnson syndrome and related conditions, mucous membrane pemphigoid, burns, or topical drugs or their preservatives.

► Clinical Findings

The patient complains of dryness, redness, or foreign body sensation. In severe cases, there is persistent marked discomfort, with photophobia, difficulty in moving the eyelids, and often excessive mucus secretion. In many cases, inspection reveals no abnormality, but on slit-lamp examination there are subtle abnormalities of tear film stability and reduced volume of the tear film meniscus along the lower lid. In more severe cases, damaged corneal and conjunctival cells stain with 1% rose bengal. In the most severe cases,

there is marked conjunctival injection, loss of the normal conjunctival and corneal luster, epithelial keratitis that may progress to frank ulceration, and mucous strands. Schirmer test, which measures the rate of production of the aqueous component of tears, may be helpful.

► Treatment

Aqueous deficiency can be treated with various types of artificial tears. The simplest preparations are physiologic (0.9%) or hypo-osmotic (0.45%) solutions of sodium chloride, which can be used as frequently as every half-hour, but in most cases are needed only three or four times a day. More prolonged duration of action can be achieved with drop preparations containing methylcellulose, polyvinyl alcohol, or polyacrylic acid (carbomers) or by using petrolatum ointment or a hydroxypropyl cellulose (Lacrisert) insert. Such mucomimetics are particularly indicated when there is mucin deficiency. If there is tenacious mucus, mucolytic agents (eg, acetylcysteine, 20% one drop six times daily) may be helpful. Autologous serum eye drops are used for severe dry eyes. Presumably due to its effects on ocular surface and lacrimal gland inflammation, cyclosporine (0.05% ophthalmic emulsion [Restasis] twice a day) has been shown to be beneficial in moderate and severe dry eyes with few adverse effects even in individuals treated for up to 4 years.

Lacrimal punctal occlusion by canalicular plugs or surgery is useful in severe cases. Blepharitis is treated as described above. Associated blepharospasm may benefit from botulinum toxin injections.

Artificial tear preparations are generally very safe and without side effects. Preservatives included in some preparations to maintain sterility are potentially toxic and allergenic and may cause keratitis and cicatrizing conjunctivitis in frequent users. The development of such reactions may be misinterpreted by both the patient and the clinician as a worsening of the dry eye state requiring more frequent use of the artificial tears and leading in turn to further deterioration, rather than being recognized as a need to change to a preservative-free preparation.

Akpek EK et al. Treatment of Sjögren's syndrome-associated dry eye: an evidence-based review. *Ophthalmology*. 2011 Jul; 118(7):1242–52. [PMID: 21459453]
Donnenfeld E et al. Topical ophthalmic cyclosporine: pharmacology and clinical uses. *Surv Ophthalmol*. 2009 May–Jun; 54(3):321–38. [PMID: 19422961]
Sullivan BD et al. An objective approach to dry eye disease severity. *Invest Ophthalmol Vis Sci*. 2010 Dec;51(12):6125–30. [PMID: 20631232]
Tavares Fde P et al. Dry eye disease. *Semin Ophthalmol*. 2010 May;25(3):84–93. [PMID: 20590418]

4. Allergic Eye Disease

Allergic eye disease is common and takes a number of different forms but all are expressions of atopy, which may also manifest as atopic asthma, atopic dermatitis, or allergic rhinitis.

► Clinical Findings

Symptoms include itching, tearing, redness, stringy discharge and, occasionally, photophobia and visual loss.

Allergic conjunctivitis is a benign disease, occurring usually in late childhood and early adulthood. It may be seasonal (hay fever), developing usually during the spring or summer, or perennial. Clinical signs are limited to conjunctival hyperemia and edema (chemosis), the latter at times being marked and sudden in onset. **Vernal keratoconjunctivitis** also tends to occur in late childhood and early adulthood. It is usually seasonal, with a predilection for the spring. Large “cobblestone” papillae are noted on the upper tarsal conjunctiva. There may be lymphoid follicles at the limbus. **Atopic keratoconjunctivitis** is a more chronic disorder of adulthood. Both the upper and the lower tarsal conjunctivas exhibit a fine papillary conjunctivitis with fibrosis, resulting in forniceal shortening and entropion with trichiasis. Staphylococcal blepharitis is a complicating factor. Corneal involvement, including refractory ulceration, is frequent during exacerbations of both vernal and atopic keratoconjunctivitis. The latter may be complicated by herpes simplex keratitis.

► Treatment

A. Mild and Moderately Severe Allergic Eye Disease

Treatments include topical histamine H_1 -receptor antagonist (Table 7-2), such as levocabastine hydrochloride 0.05% or emedastine difumarate 0.05%, or ketorolac tromethamine 0.5%, a nonsteroidal anti-inflammatory agent, four times daily. Ketotifen 0.025% two to four times daily and bepotastine 1.5% twice daily, have histamine H_1 -receptor antagonist, mast cell stabilizer, and eosinophil inhibitor activity. Olopatadine, 0.2% once daily or 0.1% twice daily; azelastine, 0.05% twice daily; and epinastine, 0.05% twice daily reduce symptoms by similar mechanisms. Topical mast cell stabilizers, such as cromolyn sodium 4% or lodoxamide tromethamine 0.1%, applied four times daily, or nedocromil sodium 2%, applied twice daily, produce longer-term prophylaxis but the therapeutic response may be delayed. Topical vasoconstrictors and antihistamines are of limited efficacy in allergic eye disease and may produce rebound hyperemia and follicular conjunctivitis. Systemic antihistamines (eg, loratadine 10 mg orally daily) may be useful in prolonged atopic keratoconjunctivitis. In allergic conjunctivitis, specific allergens may be avoidable. In vernal keratoconjunctivitis, a cooler climate often provides significant benefit.

B. Acute Exacerbations and Severe Allergic Eye Disease

Topical corticosteroids (Table 7-2) are essential to the control of acute exacerbations of both vernal and atopic keratoconjunctivitis. Corticosteroid-induced side effects, including cataracts, glaucoma, and exacerbation of herpes simplex keratitis, are major problems but may be attenuated by the ester corticosteroid, loteprednol 0.5%. Topical cyclosporine or tacrolimus is also effective. Systemic corticosteroid or other immunosuppressant therapy and even plasmapheresis may be required in severe atopic keratoconjunctivitis.

- Bielory B et al. Atopic dermatitis and keratoconjunctivitis. *Immunol Allergy Clin North Am.* 2010 Aug;30(3):323–36. [PMID: 20670816]
- Bilkhu PS et al. A review of non-pharmacological and pharmacological management of seasonal and perennial allergic conjunctivitis. *Cont Lens Anterior Eye.* 2011 Sep 16. [Epub ahead of print] [PMID: 21925924]
- Friedlaender MH. Ocular allergy. *Curr Opin Allergy Clin Immunol.* 2011 Oct;11(5):477–82. [PMID: 21822130]
- Guglielmetti S et al. Atopic keratoconjunctivitis and atopic dermatitis. *Curr Opin Allergy Clin Immunol.* 2010 Oct;10(5):478–85. [PMID: 20720488]
- Kumar S et al. Modern approach to managing vernal keratoconjunctivitis. *Curr Allergy Asthma Rep.* 2010 May;10(3):155–62. [PMID: 20425012]

PINGUECULA & PTERYGIUM

Pinguecula is a yellow elevated conjunctival nodule, more commonly on the nasal side, in the area of the palpebral fissure. It is common in persons over age 35 years. Pterygium is a fleshy, triangular encroachment of the conjunctiva onto the nasal side of the cornea and is usually associated with constant exposure to wind, sun, sand, and dust (Figure 7-2). Pinguecula and pterygium are often bilateral.

Pingueculae rarely grow but may become inflamed (pingueculitis). Pterygia become inflamed and may grow. No treatment is usually required for inflammation of pinguecula or pterygium, but artificial tears are often beneficial, and short courses of topical nonsteroidal anti-inflammatory agents or weak corticosteroids (prednisolone, 0.125% three times a day) may be necessary.

The indications for excision of pterygium are growth that threatens vision by encroaching on the visual axis, marked induced astigmatism, or severe ocular irritation. Recurrence is common and often more aggressive than the primary lesion.

- Bradley JC et al. The science of pterygia. *Br J Ophthalmol.* 2010 Jul;94(7):815–20. [PMID: 19515643]
- Viso E et al. Prevalence of pinguecula and pterygium in a general population in Spain. *Eye (Lond).* 2011 Mar;25(3):350–7. [PMID: 21183945]

CORNEAL ULCER

Corneal ulcers are most commonly due to infection by bacteria, viruses, fungi, or amebas. Noninfectious causes—all of which may be complicated by infection—include neurotrophic keratitis (resulting from loss of corneal sensation), exposure keratitis (due to inadequate eyelid closure), severe dry eyes, severe allergic eye disease, and various inflammatory disorders that may be purely ocular or part of a systemic vasculitis. Delayed or ineffective treatment of corneal infection may lead to devastating consequences with corneal scarring or intraocular infection. Prompt referral is essential.

Patients complain of pain, photophobia, tearing, and reduced vision. The eye is red, with predominantly circumferential injection, and there may be purulent or watery discharge. The corneal appearance varies according to the organisms involved.

Table 7-2. Topical ophthalmic agents.

Agent	Cost/Size ¹	Recommended Regimen	Indications
Antibacterial Agents²			
Bacitracin 500 units/g ointment (various) ³	\$57.46/3.5 g	Refer to package insert (instructions vary)	Ocular surface infection involving lid, conjunctiva, or cornea.
Cefazolin 10% (fortified) solution	Compounding pharmacy		
Chloramphenicol 1% ointment ⁴	Compounding pharmacy		
Chloramphenicol 0.5% solution ⁴	Compounding pharmacy		
Ciprofloxacin HCl 0.3% solution (Ciloxan)	\$47.30/5 mL		
Ciprofloxacin HCl 0.3% ointment	\$119.40/3.5 g		
Erythromycin 0.5% ointment (various) ⁵	\$19.00/3.5 g		
Fusidic acid 1% in gel (Fucithalmic)	Not available in United States		
Gatifloxacin 0.3% solution (Zymaxid)	\$107.23/2.5 mL		
Gentamicin sulfate 0.3% solution (various)	\$17.93/5 mL		
Gentamicin sulfate 0.3% ointment (various)	\$18.03/3.5 g		
Levofloxacin 0.5% solution (various), 1.5% solution (Iquix)	\$91.98/5 mL		
Moxifloxacin 0.5% solution (Vigamox)	\$102.12/3 mL		
Norfloxacin 0.3% solution	Compounding pharmacy		
Ofloxacin 0.3% solution (Ocuflox)	\$13.75/5 mL		
Polymyxin B/Trimethoprim sulfate 10,000 U/mL/1 mg/mL (Polytrim) ⁶	\$17.42/10 mL		
Sulfacetamide sodium 10% solution (various)	\$16.54/15 mL	1 or 2 drops every 1-3 hours	
Sulfacetamide sodium 10% ointment (various)	\$65.86/3.5 g	Apply small amount (0.5 inch) into lower conjunctival sac once to four times daily and at bedtime	
Tobramycin 0.3% solution (various)	\$18.60/5 mL		
Tobramycin 1.5% (fortified) solution	Compounding pharmacy		
Tobramycin 0.3% ointment (Tobrex)	\$97.92/3.5 g		
Antifungal Agents			
Amphotericin 0.1-0.5% solution	Compounding pharmacy		
Natamycin 5% suspension (Natacyn)	\$260.28/15 mL	1 drop every 1-2 hours	Fungal ocular infections.
Voriconazole 1% solution	Compounding pharmacy		
Antiviral Agents			
Acyclovir 3% ointment (Zovirax)	Not available in United States	5 times daily	Herpes simplex virus keratitis.
Ganciclovir 0.15% gel (Zirgan)	214.00/5 g	5 times daily	

(continued)

Table 7-2. Topical ophthalmic agents. (continued)

Agent	Cost/Size ¹	Recommended Regimen	Indications
Trifluridine 1% solution (Viroptic)	\$167.76/7.5 mL	1 drop onto cornea every 2 hours while awake for a maximum daily dose of 9 drops until resolution occurs; then an additional 7 days of 1 drop every 4 hours while awake (minimum five times daily)	
Anti-Inflammatory Agents			
Antihistamines⁷			
Azelastine HCl 0.05% ophthalmic solution (Optivar)	\$158.35/6 mL	1 drop two to four times daily (up to 6 weeks)	Allergic eye disease.
Bepotastine besilate 1.5% solution (Bepreve)	\$238.96/10 mL	1 drop twice daily	
Emedastine difumarate 0.05% solution (Emadine)	\$95.40/5 mL	1 drop four times daily	
Epinastine HCl 0.05% ophthalmic solution (Elestat)	\$130.24/5 mL	1 drop twice daily (up to 8 weeks)	
Levocabastine HCl 0.05% ophthalmic solution (Livostin)	Discontinued	1 drop four times daily (up to 2 weeks)	
Mast cell stabilizers			
Cromolyn sodium 4% solution (Crolom)	\$37.20/10 mL	1 drop four to six times daily	Allergic eye disease.
Ketotifen fumarate 0.025% solution (Zaditor)	\$11.70/5 mL	1 drop two to four times daily	
Lodoxamide tromethamine 0.1% solution (Alomide)	\$123.12/10 mL	1 or 2 drops four times daily (up to 3 months)	
Nedocromil sodium 2% solution (Alocril)	\$109.81/5 mL	1 drop twice daily	
Olopatadine hydrochloride 0.1% solution (Patanol)	\$140.64/5 mL	1 drop twice daily	
Nonsteroidal anti-inflammatory agents⁸			
Bromfenac 0.09% solution (Xibrom)	\$155.00/2.5 mL	1 drop to operated eye twice daily beginning 24 hours after cataract surgery and continuing through first 2 postoperative weeks	Treatment of postoperative inflammation following cataract extraction.
Diclofenac sodium 0.1% solution (Voltaren)	\$17.50/5 mL	1 drop to operated eye four times daily beginning 24 hours after cataract surgery and continuing through first 2 postoperative weeks.	Treatment of postoperative inflammation following cataract extraction and laser corneal surgery.
Flurbiprofen sodium 0.03% solution (various)	\$6.98/2.5 mL	1 drop every half hour beginning 2 hours before surgery; 1 drop to operated eye four times daily beginning 24 hours after cataract surgery	Inhibition of intraoperative miosis. Treatment of cystoid macular edema and inflammation after cataract surgery.
Ketorolac tromethamine 0.5% solution (Acular)	\$33.60/5 mL	1 drop four times daily	Treatment of allergic eye disease, postoperative inflammation following cataract extraction and laser corneal surgery.

(continued)

Table 7-2. Topical ophthalmic agents. (continued)

Agent	Cost/Size ¹	Recommended Regimen	Indications
Nepafenac 0.1% suspension (Nevanac)	\$153.72/3 mL	1 drop to operated eye three times daily beginning 24 hours after cataract surgery and continuing through first 2 postoperative weeks	Treatment of postoperative inflammation following cataract extraction.
Corticosteroids⁹			
Dexamethasone sodium phosphate 0.1% solution (various)	\$20.34/5 mL	1 or 2 drops as often as indicated by severity; use every hour during the day and every 2 hours during the night in severe inflammation; taper off as inflammation decreases	Treatment of steroid-responsive inflammatory conditions of anterior segment.
Dexamethasone sodium phosphate 0.05% ointment	Compounding pharmacy	Apply thin coating on lower conjunctival sac three or four times daily	
Fluorometholone 0.1% suspension (various) ¹⁰	\$16.01/10 mL	1 or 2 drops as often as indicated by severity; use every hour during the day and every 2 hours during the night in severe inflammation; taper off as inflammation decreases	
Fluorometholone 0.25% suspension (FML Forte) ¹⁰	\$51.72/10 mL		
Fluorometholone 0.1% ointment (FML S.O.P.)	\$46.79/3.5 g	Apply thin coating on lower conjunctival sac three or four times daily	
Loteprednol etabopate 0.5% (Lotemax)	\$252.02/10 mL	1 or 2 drops four times daily	
Prednisolone acetate 0.12% suspension (Pred Mild)	\$42.62/10 mL	1 or 2 drops as often as indicated by severity of inflammation; use every hour during the day and every 2 hours during the night in severe inflammation; taper off as inflammation decreases	
Prednisolone sodium phosphate 0.125% solution	Compounding pharmacy		
Prednisolone acetate 1% suspension (various)	\$16.32/10 mL		
Prednisolone sodium phosphate 1% solution (various)	\$57.55/10 mL		
Rimexolone 1% suspension (Vexol)	\$88.74/10 mL		
Immunomodulator			
Cyclosporine 0.05% emulsion (Restasis) 0.4 mL/container	\$154.42/30 containers	1 drop twice daily	Dry eyes and severe allergic eye disease.
Agents for Glaucoma and Ocular Hypertension			
Sympathomimetics			
Apraclonidine HCl 0.5% solution (Iopidine)	\$77.10/5 mL	1 drop three times daily	Reduction of intraocular pressure. Expensive. Reserve for treatment of resistant cases.
Apraclonidine HCl 1% solution (Iopidine)	\$19.95/unit dose	1 drop 1 hour before and immediately after anterior segment laser surgery	To control or prevent elevations of intraocular pressure after laser trabeculoplasty or iridotomy.

(continued)

Table 7-2. Topical ophthalmic agents. (continued)

Agent	Cost/Size ¹	Recommended Regimen	Indications
Brimonidine tartrate 0.2% solution (Alphagan)	\$18.13/5 mL	1 drop two or three times daily	Reduction of intraocular pressure.
β-Adrenergic blocking agents			
Betaxolol HCl 0.5% solution (Betoptic) and 0.25% suspension (Betoptic S) ¹²	0.5%: \$123.28/10 mL 0.25%: \$176.04/10 mL	1 drop twice daily	Reduction of intraocular pressure.
Carteolol HCl 1% and 2% solution (Various, Teoptic ¹³)	1%: \$37.07/10 mL 2%	1 drop twice daily	
Levobunolol HCl 0.25% and 0.5% solution (Betagan) ¹⁴	0.5%: \$32.25/10 mL	1 drop once or twice daily	
Metipranolol HCl 0.3% solution (OptiPranolol) ¹⁴	\$41.06/10 mL	1 drop twice daily	
Timolol 0.25% and 0.5% solution (Betimol) ¹⁴	0.5%: \$97.56/10 mL	1 drop once or twice daily	
Timolol maleate 0.25% and 0.5% solution (Timoptic) and 0.25% and 0.5% gel (Timoptic-XE, Timoptic GFS) ¹⁴	0.5% solution: \$32.35/10 mL 0.5% gel: \$43.68/5 mL	1 drop once or twice daily	
Miotics			
Pilocarpine HCl (various) ¹⁵ 1-4%, 6%, 8%, and 10%	2%: \$66.15/15 mL	1 drop three or four times daily	Reduction of intraocular pressure, treatment of acute or chronic angle-closure glaucoma, and pupillary constriction.
Pilocarpine HCl 4% gel (Pilopine HS)	\$95.64/4 g	Apply 0.5-inch ribbon in lower conjunctival sac at bedtime	
Carbonic anhydrase inhibitors			
Brimonidine 1% suspension (Azopt)	\$129.36/10 mL	1 drop three times daily	Reduction of intraocular pressure.
Dorzolamide HCl 2% solution (Trusopt)	\$83.75/10 mL	1 drop three times daily	
Prostaglandin analogs			
Bimatoprost 0.03% solution (Lumigan)	\$107.76/2.5 mL	1 drop once daily at night	Reduction of intraocular pressure.
Latanoprost 0.005% solution (Xalatan)	\$114.56/2.5 mL	1 drop once or twice daily at night	Reduction of intraocular pressure.
Tafloprost 0.0015% solution (Zioptan)	\$116.40/30 Units	1 drop once daily at night	
Travoprost 0.004% solution (Travatan)	\$107.04/2.5 mL	1 drop once daily at night	
Unoprostone isopropyl 0.15% solution (Rescula)	Not available in United States	1 drop twice daily	
Combined preparations			
Azarga (brinzolamide 1% and timolol 0.5%)	Not available in United States	1 drop twice daily	Reduction of intraocular pressure.
Combigan (brimonidine 0.2% and timolol 0.5%)	\$194.74/10 mL	1 drop twice daily	
Cosopt (dorzolamide 2% and timolol 0.5%)	\$153.67/10 mL	1 drop twice daily	
DuoTrav (travoprost 0.004% and timolol 0.5%)	Not available in United States	1 drop daily	

(continued)

Table 7-2. Topical ophthalmic agents. (continued)

Agent	Cost/Size ¹	Recommended Regimen	Indications
Ganfort (bimatoprost 0.03% and timolol 0.5%)	Not available in United States	1 drop daily in the morning	
Xalacom (latanoprost 0.005% and timolol 0.5%)	Not available in United States	1 drop daily in the morning	

¹Average wholesale price (AWP, for AB-rated generic when available) for quantity listed. Source: *Red Book Online, 2012*, Thomson Reuters (Healthcare) Inc. AWP may not accurately represent the actual pharmacy cost because wide contractual variations exist among institutions.

²Many combination products containing antibacterials or antifungals and corticosteroids are available.

³Little efficacy against gram-negative organisms (except *Neisseria*).

⁴Aplastic anemia has been reported with prolonged ophthalmic use.

⁵Also indicated for prophylaxis of neonatal conjunctivitis due to *Neisseria gonorrhoeae* or *Chlamydia trachomatis*.

⁶No gram-positive coverage.

⁷May produce rebound hyperemia and local reactions.

⁸Cross-sensitivity to aspirin and other nonsteroidal anti-inflammatory drugs.

⁹Long-term use increases intraocular pressure, causes cataracts and predisposes to bacterial, herpes simplex virus, and fungal keratitis.

¹⁰Less likely to elevate intraocular pressure.

¹¹Macular edema occurs in 30% of patients.

¹²Cardioselective (β_1) β -blocker.

¹³Teoptic is not available in the United States.

¹⁴Nonselective (β_1 and β_2) β -blocker. Monitor all patients for systemic side effects, particularly exacerbation of asthma.


¹⁵Decreased night vision, headaches possible.

► When to Refer

Any patient with an acute painful red eye and corneal abnormality should be referred emergently to an ophthalmologist.

1. Bacterial Keratitis

Bacterial keratitis usually pursues an aggressive course. Precipitating factors include contact lens wear—especially overnight wear—and corneal trauma, including refractive surgery. The pathogens most commonly isolated are *Pseudomonas aeruginosa*, *Pneumococcus*, *Moraxella* species,



▲ **Figure 7-2.** A medial pterygium extending to the cornea. (Courtesy of Paul D. Corneau. Reproduced, with permission from, Usatine RP, Smith MA, Mayeaux EJ Jr, Chumley H, Tysinger J. *The Color Atlas of Family Medicine*. McGraw-Hill, 2009.)

and staphylococci. The cornea is hazy, with a central ulcer and adjacent stromal abscess. Hypopyon is often present. The ulcer is scraped to recover material for Gram stain and culture prior to starting treatment with high-concentration topical antibiotic drops applied hourly day and night for at least the first 48 hours. Fluoroquinolones such as levofloxacin 0.5%, ofloxacin 0.3%, norfloxacin 0.3%, or ciprofloxacin 0.3% are commonly used as first-line agents as long as local prevalence of resistant organisms is low (Table 7-2). The fourth-generation fluoroquinolones (moxifloxacin 0.5% and gatifloxacin 0.3%) may be preferable because they are also active against mycobacteria. Gram-positive cocci can also be treated with a cephalosporin such as fortified cefazolin 10%; and gram-negative bacilli can be treated with an aminoglycoside such as fortified tobramycin 1.5%. If no organisms are seen on Gram stain, these two agents can be used together in areas where resistance to fluoroquinolones is common. Adjunctive topical corticosteroid therapy should only be prescribed by an ophthalmologist.

► When to Refer

Any patient with suspected bacterial keratitis must be referred emergently to an ophthalmologist.

Shah A et al. Geographic variations in microbial keratitis: an analysis of the peer-reviewed literature. *Br J Ophthalmol*. 2011 Jun;95(6):762-7. [PMID: 21478201]

Shah VM et al. Randomized clinical study for comparative evaluation of fourth-generation fluoroquinolones with the combination of fortified antibiotics in the treatment of bacterial corneal ulcers. *Cornea*. 2010 Jul;29(7):751-7. [PMID: 20489580]

2. Herpes Simplex Keratitis

Herpes simplex keratitis is an important cause of ocular morbidity. The ability of the virus to colonize the trigeminal ganglion leads to recurrences that may be precipitated by fever, excessive exposure to sunlight, or immunodeficiency.

The dendritic (branching) ulcer is the most characteristic manifestation. More extensive (“geographic”) ulcers also occur, particularly if topical corticosteroids have been used. These ulcers are most easily seen after instillation of fluorescein and examination with a blue light. Such epithelial disease in itself does not lead to corneal scarring. It responds well to simple debridement and patching. More rapid healing can be achieved by the addition of topical antivirals, such as trifluridine drops, ganciclovir gel, or acyclovir ointment (Table 7–2), or oral antivirals, such as acyclovir, 400 mg five times daily. Long-term oral acyclovir, 400 mg twice daily, or valacyclovir, 500 mg once daily, reduces the rate of recurrent epithelial disease, particularly in atopic individuals.

Stromal herpes simplex keratitis produces increasingly severe corneal opacity with each recurrence. Topical antivirals alone are insufficient to control stromal disease, so topical corticosteroids are used as well but they may enhance viral replication, exacerbating epithelial disease; steroid dependence is common. Oral acyclovir, 200–400 mg five times a day, is often helpful in the treatment of severe herpetic keratitis. The role of topical cyclosporine is being determined. Severe stromal scarring may require corneal grafting, but the overall outcome is relatively poor. **Caution:** For patients with known or possible herpetic disease, topical corticosteroids should be prescribed only with ophthalmologic supervision.

► When to Refer

Any patient with a history of herpes simplex keratitis and an acute red eye should be referred urgently to an ophthalmologist.

Croxtall JD. Ganciclovir ophthalmic gel 0.15%: in acute herpetic keratitis (dendritic ulcers). *Drugs*. 2011 Mar 26;71(5):603–10. [PMID: 21443283]

Wilhelmus KR. Antiviral treatment and other therapeutic interventions for herpes simplex virus epithelial keratitis. *Cochrane Database Syst Rev*. 2010 Dec 8;12:CD002898. [PMID: 21154352]

Young RC et al. Incidence, recurrence, and outcomes of herpes simplex virus eye disease in Olmsted County, Minnesota, 1976–2007: the effect of oral antiviral prophylaxis. *Arch Ophthalmol*. 2010 Sep;128(9):1178–83. [PMID: 20837803]

3. Herpes Zoster Ophthalmicus

Herpes zoster frequently involves the ophthalmic division of the trigeminal nerve. It presents with malaise, fever, headache, and periorbital burning and itching. These symptoms may precede the eruption by a day or more. The rash is initially vesicular, quickly becoming pustular and then crusting. Involvement of the tip of the nose or

the lid margins predicts involvement of the eye. Ocular signs include conjunctivitis, keratitis, episcleritis, and anterior uveitis, often with elevated intraocular pressure. Recurrent anterior segment inflammation, neurotrophic keratitis, and posterior subcapsular cataract are long-term complications. Optic neuropathy, cranial nerve palsies, acute retinal necrosis, and cerebral angiitis occur infrequently. HIV infection is an important risk factor for herpes zoster ophthalmicus and increases the likelihood of complications.

High-dose oral acyclovir (800 mg five times a day), valacyclovir (1g three times a day), or famciclovir (250–500 mg three times a day) started within 72 hours after the appearance of the rash reduces the incidence of ocular complications but not of postherpetic neuralgia. Anterior uveitis requires treatment with topical corticosteroids and cycloplegics. Neurotrophic keratitis is an important cause of long-term morbidity.

► When to Refer

Any patient with herpes zoster ophthalmicus and ocular symptoms or signs should be referred urgently to an ophthalmologist.

Adam RS et al. Triaging herpes zoster ophthalmicus patients in the emergency department: do all patients require referral? *Acad Emerg Med*. 2010 Nov;17(11):1183–8. [PMID: 21175516]

Chen N et al. Corticosteroids for preventing postherpetic neuralgia. *Cochrane Database Syst Rev*. 2010 Dec 8;12:CD005582. [PMID: 21154361]

Ghaznawi N et al. Herpes zoster ophthalmicus: comparison of disease in patients 60 years and older versus younger than 60 years. *Ophthalmology*. 2011 Nov;118(11):2242–50. [PMID: 21788078]

Gupta N et al. Herpes zoster ophthalmicus: disease spectrum in young adults. *Middle East Afr J Ophthalmol*. 2011 Apr;18(2):178–82. [PMID: 21731332]

Lam FC et al. Herpes zoster ophthalmicus. *BMJ*. 2009 Aug 13;339:457–8. [PMID: 19679612]

Puri LR et al. Ocular manifestations in herpes zoster ophthalmicus. *Nepal J Ophthalmol*. 2011 Jul;3(6):165–71. [PMID: 21876592]

Watkinson S et al. Managing the care of patients with herpes zoster ophthalmicus. *Nurs Stand*. 2011 Jun 1–7;25(39):35–40. [PMID: 21739797]

4. Fungal Keratitis

Fungal keratitis tends to occur after corneal injury involving plant material or in an agricultural setting, in eyes with chronic ocular surface disease, and increasingly in contact lens wearers. It is usually an indolent process, with the cornea characteristically having multiple stromal abscesses and relatively little epithelial loss. Intraocular infection is common. Corneal scrapings should be cultured on media suitable for fungi whenever the history or corneal appearance is suggestive of fungal disease. Diagnosis is often delayed and treatment is difficult. Natamycin 5%, amphotericin 0.1–0.5%, and voriconazole 1% are the most commonly used topical agents. Systemic imidazoles may be helpful. Corneal grafting is often required.

- Arora R et al. Voriconazole versus natamycin as primary treatment in fungal corneal ulcers. *Clin Experiment Ophthalmol*. 2011 Jul;39(5):434–40. [PMID: 21105974]
- Gower EW et al. Trends in fungal keratitis in the United States, 2001 to 2007. *Ophthalmology*. 2010 Dec;117(12):2263–7. [PMID: 20591493]
- Kalkanci A et al. Ocular fungal infections. *Curr Eye Res*. 2011 Mar;36(3):179–89. [PMID: 21158591]
- Keay LJ et al. Clinical and microbiological characteristics of fungal keratitis in the United States, 2001–2007: a multicenter study. *Ophthalmology*. 2011 May;118(5):920–6. [PMID: 21295857]
- Nath R et al. Mycotic corneal ulcers in upper Assam. *Indian J Ophthalmol*. 2011 Sep–Oct;59(5):367–71. [PMID: 21836342]
- Pradhan L et al. Natamycin in the treatment of keratomycosis: correlation of treatment outcome and in vitro susceptibility of fungal isolates. *Indian J Ophthalmol*. 2011 Nov;59(6):512–4. [PMID: 22011503]
- Sengupta S et al. Comparative study on the incidence and outcomes of pigmented versus non pigmented keratomycosis. *Indian J Ophthalmol*. 2011 Jul–Aug;59(4):291–6. [PMID: 21666314]
- Sharma S et al. Microsporidial keratitis: need for increased awareness. *Surv Ophthalmol*. 2011 Jan–Feb;56(1):1–22. [PMID: 21071051]
- Vaddavalli PK et al. Role of confocal microscopy in the diagnosis of fungal and Acanthamoeba keratitis. *Ophthalmology*. 2011 Jan;118(1):29–35. [PMID: 20801515]
- Yildiz EH et al. Update on fungal keratitis from 1999 to 2008. *Cornea*. 2010 Dec;29(12):1406–11. [PMID: 20847685]

5. Acanthamoeba Keratitis

Acanthamoeba infection is an important cause of keratitis in contact lens wearers. Although severe pain with perineural and ring infiltrates in the corneal stroma is characteristic, earlier forms with changes confined to the corneal epithelium are identifiable. Diagnosis is facilitated by confocal microscopy. Culture requires specialized media. Treatment is hampered by the organism's ability to encyst within the corneal stroma. Topical biguanides are probably the only effective primary treatment. Topical corticosteroids may be beneficial. Corneal grafting may be required after resolution of infection to restore vision. Systemic anti-inflammatory therapy is helpful if there is scleral involvement.

- Chew HF et al. Clinical outcomes and prognostic factors associated with Acanthamoeba keratitis. *Cornea*. 2011 Apr;30(4):435–41. [PMID: 21045665]
- Dart JK et al. Acanthamoeba keratitis: diagnosis and treatment update 2009. *Am J Ophthalmol*. 2009 Oct;148(4):487–99. [PMID: 19660733]
- Oldenburg CE et al. Practice patterns and opinions in the treatment of Acanthamoeba keratitis. *Cornea*. 2011 Dec;30(12):1363–8. [PMID: 21993459]
- Panjwani N. Pathogenesis of acanthamoeba keratitis. *Ocul Surf*. 2010 Apr;8(2):70–9. [PMID: 20427010]
- Patel DV et al. Acanthamoeba keratitis: a comprehensive photographic reference of common and uncommon signs. *Clin Experiment Ophthalmol*. 2009 Mar;37(2):232–8. [PMID: 19723132]
- Qian Y et al. Clinical experience with Acanthamoeba keratitis at the Cole Eye Institute, 1999–2008. *Cornea*. 2010 Sep;29(9):1016–21. [PMID: 20539213]

ACUTE ANGLE-CLOSURE GLAUCOMA



ESSENTIALS OF DIAGNOSIS

- ▶ Older age group, particularly farsighted individuals.
- ▶ Rapid onset of severe pain and profound visual loss with “halos around lights.”
- ▶ Red eye, cloudy cornea, dilated pupil.
- ▶ Hard eye to palpation.

▶ General Considerations

Primary acute angle-closure glaucoma occurs only with closure of a preexisting narrow anterior chamber angle, for which the predisposing factors are age, owing to enlargement of the crystalline lens; farsightedness; and inheritance, being particularly prevalent among Asians and Inuits. It may be precipitated by pupillary dilation and thus can occur from sitting in a darkened theater, during times of stress, following nonocular administration of anticholinergic or sympathomimetic agents (eg, nebulized bronchodilators, atropine for preoperative medication, antidepressants, bowel or bladder antispasmodics, nasal decongestants, or tocolytics) or, rarely, from pharmacologic mydriasis (see Precautions in Management of Ocular Disorders, below). Secondary acute angle-closure glaucoma may occur in anterior uveitis, dislocation of the lens, or topiramate therapy. Symptoms are the same as in primary acute angle-closure glaucoma, but differentiation is important because of differences in management. Chronic angle-closure glaucoma is particularly common in eastern Asia. It presents in the same way as open-angle glaucoma (see below).

▶ Clinical Findings

Patients with acute glaucoma usually seek treatment immediately because of extreme pain and blurred vision, though there are subacute cases. The blurred vision is associated with halos around lights. Nausea and abdominal pain may occur. The eye is red, the cornea cloudy, and the pupil moderately dilated and nonreactive to light. Intraocular pressure is usually over 50 mm Hg, producing a hard eye on palpation.

▶ Differential Diagnosis

Acute glaucoma must be differentiated from conjunctivitis, acute uveitis, and corneal disorders (Table 7–1).

▶ Treatment

A. Primary

Initial treatment in primary angle-closure glaucoma is reduction of intraocular pressure. A single 500-mg intravenous dose of acetazolamide, followed by 250 mg orally four times a day, is usually sufficient. Osmotic diuretics such as oral glycerin and intravenous urea or mannitol—the dosage of all three being 1–2 g/kg—may be necessary if there is no response to acetazolamide. Laser therapy to the

peripheral iris (iridoplasty) or anterior chamber paracentesis is also effective. Once the intraocular pressure has started to fall, topical 4% pilocarpine, 1 drop every 15 minutes for 1 hour and then four times a day, is used to reverse the underlying angle closure. The definitive treatment is laser peripheral iridotomy or surgical peripheral iridectomy. Cataract extraction is a possible alternative. If it is not possible to control the intraocular pressure medically, glaucoma drainage surgery as for uncontrolled open-angle glaucoma (see below) may be required.

All patients with primary acute angle-closure should undergo prophylactic laser peripheral iridotomy to the unaffected eye, unless that eye has already undergone cataract or glaucoma surgery. Whether prophylactic laser peripheral iridotomy should be undertaken in asymptomatic patients with narrow anterior chamber angles is uncertain and mainly influenced by the risk of the more common chronic angle-closure (see below).

B. Secondary

In secondary acute angle-closure glaucoma, systemic acetazolamide is also used, with or without osmotic agents. Further treatment is determined by the cause.

► Prognosis

Untreated acute angle-closure glaucoma results in severe and permanent visual loss within 2–5 days after onset of symptoms. Affected patients need to be observed for development of chronic glaucoma.

► When to Refer

Any patient with suspected acute angle-closure glaucoma must be referred emergently to an ophthalmologist.

Jiang Y et al. Design and methodology of a randomized controlled trial of laser iridotomy for the prevention of angle closure in southern China: the Zhongshan Angle Closure Prevention Trial. *Ophthalmic Epidemiol.* 2010 Oct;17(5):321–32. [PMID: 20868259]

Mancino R et al. Acute bilateral angle-closure glaucoma and choroidal effusion associated with acetazolamide administration after cataract surgery. *J Cataract Refract Surg.* 2011 Feb;37(2):415–7. [PMID: 21241929]

Nouri-Mahdavi K et al. Patterns of damage in chronic angle-closure glaucoma compared to primary open-angle glaucoma. *Am J Ophthalmol.* 2011 Jul;152(1):74–80. [PMID: 2147059]

Ramli N et al. Efficacy of medical therapy in the initial management of acute primary angle closure in Asians. *Eye (Lond).* 2010 Oct;24(10):1599–602. [PMID: 20577272]

Razeghinejad MR et al. Iatrogenic glaucoma secondary to medications. *Am J Med.* 2011 Jan;124(1):20–5. [PMID: 21092926]

Razeghinejad MR et al. Non-steroidal drug-induced glaucoma. *Eye (Lond).* 2011 Aug;25(8):971–80. [PMID: 21637303]

See JL et al. Management of angle closure glaucoma. *Indian J Ophthalmol.* 2011 Jan;59(Suppl):S82–7. [PMID: 21150039]

Sihota R. An Indian perspective on primary angle closure and glaucoma. *Indian J Ophthalmol.* 2011 Jan;59(Suppl):S76–81. [PMID: 21150038]

Subak-Sharpe I et al. Pharmacological and environmental factors in primary angle-closure glaucoma. *Br Med Bull.* 2010;93:125–43. [PMID: 19933218]

Tan GS et al. Is routine pupil dilation safe among Asian patients with diabetes? *Invest Ophthalmol Vis Sci.* 2009 Sep;50(9):4110–3. [PMID: 19443719]

White J. Diagnosis and management of acute angle-closure glaucoma. *Emerg Nurse.* 2011 Jun;19(3):27. [PMID: 21823566]

CHRONIC GLAUCOMA



ESSENTIALS OF DIAGNOSIS

- No symptoms in early stages.
- Insidious progressive bilateral loss of peripheral vision, resulting in tunnel vision but preserved visual acuities.
- Pathologic cupping of the optic disks.
- Intraocular pressure is usually elevated.

► General Considerations

Chronic glaucoma is characterized by gradually progressive excavation (“cupping”) and pallor of the optic disk with loss of vision progressing from slight constriction of the peripheral fields to complete blindness. In chronic open-angle glaucoma, primary or secondary, the intraocular pressure is elevated due to reduced drainage of aqueous fluid through the trabecular meshwork. In chronic angle-closure glaucoma, flow of aqueous fluid into the anterior chamber angle is obstructed. In normal-tension glaucoma, intraocular pressure is not elevated but the same pattern of optic nerve damage occurs, probably due to vascular insufficiency.

Primary open-angle glaucoma is bilateral. There is an increased prevalence in first-degree relatives of affected individuals and in diabetic patients. In blacks, it is more frequent, occurs at an earlier age, and results in more severe optic nerve damage. Secondary open-angle glaucoma may result from uveitis; ocular trauma; or corticosteroid therapy, whether it is topical, systemic, inhaled, or administered by nasal spray.

In the United States, it is estimated that 2% of people over 40 years of age have glaucoma, affecting more than 2 million individuals and being three times more prevalent in blacks. At least 25% of cases are undetected. Over 90% of cases are of the open-angle type. Worldwide, about 4.5 million people are bilaterally blind from chronic open-angle glaucoma and 4 million, of which approximately 50% live in China, are bilaterally blind from chronic angle-closure glaucoma.

► Clinical Findings

Because initially there are no symptoms, chronic glaucoma is often suspected at a routine eye test. Diagnosis requires consistent and reproducible abnormalities in at least two of three parameters—optic disk, visual field, and intraocular pressure. Optic disk cupping is identified as an absolute increase or an asymmetry between the two eyes of the ratio

of the diameter of the optic cup to the diameter of the whole optic disk (cup-disk ratio, Figure 7-3). (Cup-disk ratio greater than 0.5 or 0.2 or more asymmetry between eyes is suggestive.) Visual field abnormalities initially develop in the paracentral region, followed by constriction of the peripheral visual field. Central vision remains good until late in the disease. The normal range of intraocular pressure is 10–21 mm Hg.

In many individuals, elevated intraocular pressure is not associated with optic disk or visual field abnormalities (**ocular hypertension**). Treatment to reduce intraocular pressure is justified if there is a moderate to high risk of progression to glaucoma, determined by several factors, including age, optic disk appearance, level of intraocular

pressure, and corneal thickness. A significant proportion of eyes with primary open-angle glaucoma have normal intraocular pressure when it is first measured, and only repeated measurements identify the abnormally high pressure. In normal-tension glaucoma, intraocular pressure is always within the normal range.

There are many causes of optic disk abnormalities or visual field changes that mimic glaucoma, and visual field testing may prove unreliable in some patients, particularly in the older age group. The diagnosis of glaucoma is not always straightforward, hampering the effectiveness of screening programs.

▶ Prevention


All persons over age 50 years should have intraocular pressure measurement and optic disk examination every 3–5 years. In persons with diabetes and in individuals with a family history of glaucoma, annual examination is indicated. Regular ophthalmic screening should be considered in patients taking long-term oral or combined intranasal and inhaled corticosteroid therapy.

▶ Treatment

A. Medications

The prostaglandin analogs (latanoprost 0.005%, bimatoprost 0.03%, travoprost 0.004%, and tafluprost 0.0015% once daily at night, and unoprostone 0.15% twice daily) are commonly used as first-line therapy because of their efficacy, their lack of systemic side effects, as well as the convenience of once-daily dosing (except unoprostone) (Table 7-2). All may produce conjunctival hyperemia, permanent darkening of the iris and eyebrow color, and increased eyelash growth. Latanoprost has been associated with reactivation of uveitis and macular edema. Tafluprost is not available in the United States.

Topical β -adrenergic blocking agents such as timolol 0.25% or 0.5%, carteolol 1%, levobunolol 0.5%, and metipranolol 0.3% solutions twice daily or timolol 0.25% or 0.5% gel once daily may be used alone or in combination with a prostaglandin analog. They are contraindicated in patients with reactive airway disease or heart failure. Betaxolol, 0.25% or 0.5%, a β -receptor selective blocking agent, is theoretically safer in reactive airway disease but less effective at reducing intraocular pressure. Brimonidine 0.2%, a selective α_2 -agonist, and dorzolamide 2% or brinzolamide 1%, topical carbonic anhydrase inhibitors, also can be used in addition to a prostaglandin analog or a β -blocker (twice daily) or as initial therapy when prostaglandin analogs and β -blockers are contraindicated (brimonidine twice daily, dorzolamide and brinzolamide three times daily). All three are associated with allergic reactions. Combination drops Xalacom (latanoprost 0.005% and timolol 0.5%), Ganfort (bimatoprost 0.03% and timolol 0.5%), and DuoTrav (travoprost 0.004% and timolol 0.5%), each used once daily, and Cosopt (dorzolamide 2% and timolol 0.5%), Azarga (brinzolamide 1% and timolol 0.5%), and Combigan (brimonidine 0.2% and timolol 0.5%), each used twice daily improve compliance when multiple medications are required.



▲ **Figure 7-3.** A: Normal eye with a normal optic cup-to-disk ratio of 0.4. B: Glaucoma with an increased optic cup-to-disk ratio of 0.8. (Courtesy of Paul D. Corneau. Reproduced, with permission, from Usatine RP, Smith MA, Mayeaux EJ Jr, Chumley H, Tysinger J. *The Color Atlas of Family Medicine*. McGraw-Hill, 2009.)

Apraclonidine, 0.5–1%, another α_2 -agonist, can be used three times a day to postpone the need for surgery in patients receiving maximal medical therapy, but long-term use is limited by drug reactions. It is more commonly used to control acute rises in intraocular pressure such as after laser therapy. Pilocarpine 1–4%, epinephrine, 0.5–1%, and the prodrug dipivefrin, 0.1%, are rarely used because of adverse effects. Oral carbonic anhydrase inhibitors (eg, acetazolamide) may still be used on a long-term basis if topical therapy is inadequate and surgical or laser therapy is inappropriate.

Formulations of topical agents without preservative or not including benzalkonium chloride as the preservative are becoming available.

B. Laser Therapy and Surgery

Laser trabeculoplasty is used as an adjunct to topical therapy to defer surgery and is also advocated as primary treatment. Surgery is generally undertaken when intraocular pressure is inadequately controlled by medical and laser therapy, but it may also be used as primary treatment. Trabeculectomy remains the standard procedure. Adjunctive treatment with subconjunctival mitomycin or fluorouracil is used perioperatively or postoperatively in difficult cases. Viscocanalostomy and deep sclerectomy with collagen implant—two alternative procedures that avoid a full-thickness incision into the eye—may be as effective as trabeculectomy but are more difficult to perform.

In chronic angle-closure glaucoma, laser peripheral iridotomy or surgical peripheral iridectomy may be helpful. In patients with asymptomatic narrow anterior chamber angles, which includes about 10% of Chinese adults, prophylactic laser peripheral iridotomy can be performed to reduce the risk of acute and chronic angle-closure glaucoma. However, there are concerns about the efficacy of such treatment and the risk of cataract progression and corneal decompensation. In the United States, about 1% of people over age 35 years have narrow anterior chamber angles, but acute and chronic angle-closure are sufficiently uncommon that prophylactic therapy is not generally advised.

► Prognosis

Untreated chronic glaucoma that begins at age 40–45 years will probably cause complete blindness by age 60–65. Early diagnosis and treatment can preserve useful vision throughout life. In primary open-angle glaucoma—and if treatment is required in ocular hypertension—the aim is to reduce intraocular pressure to a level that will adequately reduce progression of visual field loss. In eyes with marked visual field or optic disk changes, intraocular pressure must be reduced to less than 16 mm Hg. In normal-tension glaucoma with progressive visual field loss, it is necessary to achieve even lower intraocular pressure such that surgery is often required.

► When to Refer

All patients with suspected chronic glaucoma should be referred to an ophthalmologist.

- Francis BA et al. Novel glaucoma procedures: a report by the American Academy of Ophthalmology. *Ophthalmology*. 2011 Jul;118(7):1466–80. [PMID: 21724045]
- Francis BA et al. Population and high risk group screening for glaucoma: The Los Angeles Latino Eye Study. *Invest Ophthalmol Vis Sci*. 2011 Aug 5;52(9):6257–64. [PMID: 21245400]
- Guedes G et al. Glaucoma and aging. *Curr Aging Sci*. 2011 Jul;4(2):110–7. [PMID: 21235491]
- Hommer A. A review of preserved and preservative-free prostaglandin analogues for the treatment of open-angle glaucoma and ocular hypertension. *Drugs Today (Barc)*. 2010 Jun;46(6):409–16. [PMID: 20571609]
- Hommer A. Role of fixed combinations in the management of open-angle glaucoma. *Expert Rev Pharmacoecon Outcomes Res*. 2011 Feb;11(1):91–9. [PMID: 21351861]
- Kwon YH et al. Primary open-angle glaucoma. *N Engl J Med*. 2009 Mar 12;360(11):1113–24. [PMID: 19279343]
- National Collaborating Centre for Acute Care (UK). Glaucoma: Diagnosis and Management of Chronic Open Angle Glaucoma and Ocular Hypertension. London: National Collaborating Centre for Acute Care (UK); 2009 Apr. [PMID: 21938863]
- Pan Y et al. Natural history of glaucoma. *Indian J Ophthalmol*. 2011 Jan;59(Suppl):S19–23. [PMID: 21150029]
- Quigley HA. Glaucoma. *Lancet*. 2011 Apr 16;377(9774):1367–77. [PMID: 21453963]
- See JL et al. Management of angle closure glaucoma. *Indian J Ophthalmol*. 2011 Jan;59(Suppl):S82–7. [PMID: 21150039]
- Sihota R. Classification of primary angle closure disease. *Curr Opin Ophthalmol*. 2011 Mar;22(2):87–95. [PMID: 21252672]
- Sihota R. Lasers in primary open angle glaucoma. *Indian J Ophthalmol*. 2011 Jan;59(Suppl):S114–7. [PMID: 21150022]

UVEITIS



ESSENTIALS OF DIAGNOSIS

- Usually immunologic but possibly infective or neoplastic.
- Acute nongranulomatous anterior uveitis: pain, redness, photophobia, and visual loss.
- Granulomatous anterior uveitis: blurred vision in a mildly inflamed eye.
- Posterior uveitis: gradual loss of vision in a quiet eye.

► General Considerations

Intraocular inflammation (uveitis) is classified into acute or chronic, and nongranulomatous or granulomatous according to the clinical signs, or by its distribution—anterior or posterior uveitis, predominantly affecting the anterior or posterior segments of the eye, or panuveitis, in which both segments are affected equally. The common types are acute nongranulomatous anterior uveitis, granulomatous anterior uveitis, and posterior uveitis.

In most cases, the pathogenesis of uveitis is primarily immunologic, but infection may be the cause, particularly in immunodeficiency states. The systemic disorders associated with acute nongranulomatous anterior uveitis are the HLA-B27-related conditions ankylosing spondylitis, reactive

arthritis, psoriasis, ulcerative colitis, and Crohn disease. Behçet syndrome produces both anterior uveitis, with recurrent hypopyon but little discomfort, and posterior uveitis, characteristically with branch retinal vein occlusions. Both herpes simplex and herpes zoster infections may cause non-granulomatous anterior uveitis as well as retinitis (acute retinal necrosis), which has a very poor prognosis.

Diseases producing granulomatous anterior uveitis also tend to be causes of posterior uveitis. These include sarcoidosis, toxoplasmosis, tuberculosis, syphilis, Vogt-Koyanagi-Harada syndrome (bilateral uveitis associated with alopecia, poliosis [depigmented eyelashes, eyebrows, or hair], vitiligo, and hearing loss), and sympathetic ophthalmia following penetrating ocular trauma. In toxoplasmosis, there may be evidence of previous episodes of retinochoroiditis. Syphilis characteristically produces a “salt and pepper” fundus but may present with a wide variety of clinical manifestations. The other principal pathogens responsible for ocular inflammation in HIV infection (see below) are cytomegalovirus (CMV), herpes simplex and herpes zoster viruses, mycobacteria, *Cryptococcus*, *Toxoplasma*, and *Candida*.

Autoimmune retinal vasculitis and pars planitis (intermediate uveitis) are idiopathic conditions that produce posterior uveitis.

► Clinical Findings

Anterior uveitis is characterized by inflammatory cells and flare within the aqueous. In severe cases, there may be hypopyon (layered collection of white cells) and fibrin within the anterior chamber. Cells may also be seen on the corneal endothelium as keratic precipitates (KPs). In granulomatous uveitis, these are large “mutton-fat” KPs, and iris nodules may be seen. In nongranulomatous uveitis, the KPs are smaller and iris nodules are not seen. The pupil is usually small, and with the development of posterior synechiae (adhesions between the iris and anterior lens capsule), it also becomes irregular.

Nongranulomatous anterior uveitis tends to present acutely with unilateral pain, redness, photophobia, and visual loss. Granulomatous anterior uveitis is more indolent, causing blurred vision in a mildly inflamed eye.

In **posterior uveitis**, there are cells in the vitreous. Inflammatory lesions may be present in the retina or choroid. Fresh lesions are yellow, with indistinct margins, and there may be retinal hemorrhages, whereas older lesions have more definite margins and are commonly pigmented. Retinal vessel sheathing may occur adjacent to such lesions or more diffusely. In severe cases, vitreous opacity precludes visualization of retinal details.

Posterior uveitis tends to present with gradual visual loss in a relatively quiet eye. Bilateral involvement is common. Visual loss may be due to vitreous haze and opacities, inflammatory lesions involving the macula, macular edema, retinal vein occlusion or, rarely, associated optic neuropathy.

► Differential Diagnosis

Retinal detachment, intraocular tumors, and central nervous system lymphoma may all masquerade as uveitis.

► Treatment

Anterior uveitis usually responds to topical corticosteroids. Occasionally, periocular corticosteroid injections or even systemic corticosteroids may be required. Dilation of the pupil is important to relieve discomfort and prevent posterior synechiae. **Posterior uveitis** more commonly requires systemic, periocular or intravitreal corticosteroid therapy and occasionally systemic immunosuppression with agents such as azathioprine, tacrolimus, cyclosporine, mycophenolate, or methotrexate. The value of biologic therapies is being evaluated. Pupillary dilation is not usually necessary.

If an infectious cause is identified, specific antimicrobial therapy may be indicated. In general, the prognosis for anterior uveitis, particularly the nongranulomatous type, is better than that for posterior uveitis.

► When to Refer

- Any patient with suspected acute uveitis should be referred urgently to an ophthalmologist or emergently if visual loss or pain is severe.
- Any patient with suspected chronic uveitis should be referred to an ophthalmologist, urgently if there is more than mild visual loss.

► When to Admit

Patients with severe uveitis, particularly those requiring intravenous therapy, may require hospital admission.

- Ali A et al. Use of methotrexate in patients with uveitis. *Clin Exp Rheumatol*. 2010 Sep–Oct;28(5 Suppl 61):S145–50. [PMID: 21044449]
- Amaratunge BC et al. Syphilitic uveitis: a review of clinical manifestations and treatment outcomes of syphilitic uveitis in human immunodeficiency virus-positive and negative patients. *Clin Experiment Ophthalmol*. 2010 Jan;38(1):68–74. [PMID: 20447104]
- Basu S et al. Pitfalls in the management of TB-associated uveitis. *Eye (Lond)*. 2010 Nov;24(11):1681–4. [PMID: 20706283]
- Baughman RP et al. Ocular sarcoidosis. *Semin Respir Crit Care Med*. 2010 Aug;31(4):452–62. [PMID: 20665395]
- Bordaberry MF. Vogt-Koyanagi-Harada disease: diagnosis and treatments update. *Curr Opin Ophthalmol*. 2010 Nov;21(6):430–5. [PMID: 20829689]
- Cowan CL Jr. Review for disease of the year: differential diagnosis of ocular sarcoidosis. *Ocul Immunol Inflamm*. 2010 Dec;18(6):442–51. [PMID: 21091057]
- Cunningham ET Jr et al. Practical approach to the use of corticosteroids in patients with uveitis. *Can J Ophthalmol*. 2010 Aug;45(4):352–8. [PMID: 20648092]
- Delair E et al. Clinical manifestations of ocular toxoplasmosis. *Ocul Immunol Inflamm*. 2011 Apr;19(2):91–102. [PMID: 21428746]
- Guly CM et al. Investigation and management of uveitis. *BMJ*. 2010 Oct 13;341:c4976. [PMID: 20943722]
- Khairallah M et al. Novel infectious agents causing uveitis. *Int Ophthalmol*. 2010 Oct;30(5):465–83. [PMID: 19711015]
- Lobo AM et al. Drug delivery options for the treatment of ocular inflammation. *Semin Ophthalmol*. 2010 Sep–Nov;25(5-6):283–8. [PMID: 21091013]
- Papadia M et al. Diagnosis of ocular sarcoidosis. *Ocul Immunol Inflamm*. 2010 Dec;18(6):432–41. [PMID: 21091056]

CATARACT



ESSENTIALS OF DIAGNOSIS

- ▶ Gradually progressive blurred vision.
- ▶ No pain or redness.
- ▶ Lens opacities (may be grossly visible).

▶ General Considerations

Cataract is opacity of the crystalline lens. It is the leading cause of blindness worldwide, but access to treatment and quality of outcome are still limited in many areas. Cataracts are usually bilateral. They may be congenital (owing to intrauterine infections such as rubella and CMV, or inborn errors of metabolism such as galactosemia); traumatic; or secondary to systemic disease (diabetes, myotonic dystrophy, atopic dermatitis), systemic or inhaled corticosteroid treatment, or uveitis; but senile cataract is by far the most common type. Most persons over age 60 have some degree of lens opacity. Cigarette smoking increases the risk of cataract formation.

▶ Clinical Findings

The predominant symptom is progressive blurring of vision. Glare, especially in bright light or when driving at night; change of focusing, particularly development of nearsightedness; and monocular double vision may also occur.

Even in its early stages, a cataract can be seen through a dilated pupil with an ophthalmoscope or slit lamp. As the cataract matures, the retina will become increasingly more difficult to visualize, until finally the fundus reflection is absent and the pupil is white.

▶ Treatment

In adults, functional visual impairment is the prime criterion for surgery. The cataract is usually removed by one of the techniques in which the posterior lens capsule remains (extracapsular), thus providing support for a prosthetic intraocular lens that dispenses with the need for heavy cataract glasses or contact lenses. Laser treatment may be required subsequently if the posterior capsule opacifies. Ultrasonic fragmentation (phacoemulsification) of the lens nucleus and foldable intraocular lenses allow cataract surgery to be performed through a small incision without the need for sutures, thus reducing the postoperative complication rate and accelerating visual rehabilitation. Multifocal and accommodative intraocular lenses reduce the need for both distance and near vision correction.

Management of congenital cataract is complicated by additional technical difficulties during surgery, changes in the optics of the eye with growth influencing choice of intraocular lens power, and treatment of associated amblyopia.

▶ Prognosis

In the developed world, cataract surgery in adults improves visual acuity in 95% of cases, whereas in less developed

areas the outcome is less good, in part due to uncorrected refractive error. In the other 5%, there is preexisting retinal damage or operative or postoperative complications. Treatment with α_1 -antagonists, particularly with tamsulosin for benign prostatic hyperplasia, or with risperidone for psychiatric disease increases the risk of intraoperative (floppy iris syndrome) and postoperative complications.

▶ When to Refer

Patients with cataracts should be referred to an ophthalmologist when their visual impairment adversely affects their everyday activities.

- Behndig A et al. One million cataract surgeries: Swedish National Cataract Register 1992–2009. *J Cataract Refract Surg*. 2011 Aug;37(8):1539–45. [PMID: 21782099]
- Chatziralli IP et al. Risk factors for intraoperative floppy iris syndrome: a meta-analysis. *Ophthalmology*. 2011 Apr; 118(4): 730–50. [PMID: 21168223]
- Davenport KM et al. Cataracts. *Pediatr Rev*. 2011 Feb;32(2):82–3. [PMID: 21285306]
- Fedorowicz Z et al. Day care versus in-patient surgery for age-related cataract. *Cochrane Database Syst Rev*. 2011 Jul 6;(7):CD004242. [PMID: 21735397]
- Hildreth CJ et al. JAMA patient page. Cataracts. *JAMA*. 2009 May 20;301(19):2060. [PMID: 19454646]
- Kubal AA. Multifocal versus accommodating intraocular lenses: a review of the current technology, outcomes, and complications. *Int Ophthalmol Clin*. 2011 Spring;51(2):131–41. [PMID: 21383586]
- Michael R et al. The ageing lens and cataract: a model of normal and pathological ageing. *Philos Trans R Soc Lond B Biol Sci*. 2011 Apr 27;366(1568):1278–92. [PMID: 21402586]
- Rao GN et al. The global burden of cataract. *Curr Opin Ophthalmol*. 2011 Jan;22(1):4–9. [PMID: 21107260]

RETINAL DETACHMENT



ESSENTIALS OF DIAGNOSIS

- ▶ Curtain spreading across field of vision or sudden onset of visual loss in one eye.
- ▶ No pain or redness.
- ▶ Detachment seen by ophthalmoscopy.

▶ General Considerations

Most cases of retinal detachment are due to development of a retinal tear (rhegmatogenous retinal detachment). This is usually spontaneous, is related to changes in the vitreous, and generally occurs in persons over 50 years of age. Nearsightedness and cataract extraction are the two most common predisposing causes. Retinal tear may also be caused by penetrating or blunt ocular trauma. Once there is a tear in the retina, fluid vitreous is able to pass through the tear behind the sensory retina. This, combined with vitreous traction and the pull of gravity, results in progressive detachment.

Tractional retinal detachment occurs when there is preretinal fibrosis, such as in association with proliferative retinopathy secondary to diabetic retinopathy or retinal vein

occlusion. Serous retinal detachment results from accumulation of subretinal fluid, such as in neovascular age-related macular degeneration or secondary to choroidal tumors.

► Clinical Findings

Rhegmatogenous retinal detachment usually starts in the superior temporal area and spreads rapidly, causing visual field loss that starts inferiorly and expands upwards. Central vision remains intact until the macula becomes detached. On ophthalmoscopic examination, the retina is seen hanging in the vitreous like a gray cloud. One or more retinal tears will usually be found on further examination.

In traction retinal detachment, there is irregular retinal elevation with fibrosis. With serous retinal detachment, the retina is dome-shaped and the subretinal fluid may shift position with changes in posture.

► Treatment

Treatment of rhegmatogenous retinal detachments is directed at closing the retinal tears. A permanent adhesion between the neurosensory retina, the retinal pigment epithelium, and the choroid is produced in the region of the tears by laser photocoagulation to the retina or cryotherapy to the sclera. Indentation of the sclera with a silicone sponge or buckle; subretinal fluid drainage via an incision in the sclera; or injection of an expansile gas into the vitreous cavity, possibly following intraocular surgery to remove the vitreous (pars plana vitrectomy) may be required to achieve apposition of the neurosensory retina to the retinal pigment epithelium while the adhesion is developing. Certain types of uncomplicated retinal detachment may be treated by pneumatic retinopexy, in which an expansile gas is injected into the vitreous cavity followed by positioning of the patient's head to facilitate reattachment of the retina. Once the retina is repositioned, the tear is sealed by laser photocoagulation or cryotherapy; these two methods are also used to seal retinal tears without associated detachment.

In complicated retinal detachments—particularly those in which fibroproliferative tissue has developed on the surface of the retina or within the vitreous cavity, ie, traction retinal detachments—retinal reattachment can be accomplished only by pars plana vitrectomy, direct manipulation of the retina, and internal tamponade of the retina with air, expansile gases, or even silicone oil. (The presence of an expansile gas within the eye is a contraindication to air travel, mountaineering at high altitude, and nitrous oxide anesthesia. Such gases persist in the globe for weeks after surgery.) Treatment of serous retinal detachments is determined by the underlying cause.

► Prognosis

About 80% of uncomplicated rhegmatogenous retinal detachments can be cured with one operation; an additional 15% will need repeated operations; and the remainder never reattach. The visual prognosis is worse if the macula is detached or if the detachment is of long duration. Without treatment, retinal detachment often becomes total within 6 months. Spontaneous detachments are ultimately bilateral in up to 25% of cases.

► When to Refer

All cases of retinal detachment must be referred urgently to an ophthalmologist, emergently if central vision is good because this indicates that the macula has not detached. During transportation, the patient's head is positioned so that the detached portion of the retina will fall back with the aid of gravity.

- Hatten B et al. Retinal detachment. *Emerg Med J*. 2011 Jan;28(1):83. [PMID: 20378746]
 Kang HK et al. Management of retinal detachment: a guide for non-ophthalmologists. *BMJ*. 2008 May 31;336(7655):1235–40. [PMID: 18511798]
 Mitry D et al. The fellow eye in retinal detachment: findings from the Scottish Retinal Detachment Study. *Br J Ophthalmol*. 2011 Mar 3. [Epub ahead of print] [PMID: 21378003]
 Mitry D et al. The predisposing pathology and clinical characteristics in the Scottish Retinal Detachment Study. *Ophthalmology*. 2011 Jul;118(7):1429–34. [PMID: 21561662]

VITREOUS HEMORRHAGE

Patients with vitreous hemorrhage complain of sudden visual loss, abrupt onset of floaters that may progressively increase in severity or, occasionally, “bleeding within the eye.” Visual acuity ranges from 20/20 (6/6) to light perception only. The eye is not inflamed, and the clue to diagnosis is the inability to see fundal details clearly despite the presence of a clear lens. Causes of vitreous hemorrhage include diabetic retinopathy, retinal tears (with or without detachment), retinal vein occlusions, neovascular age-related macular degeneration, blood dyscrasias, trauma, and subarachnoid hemorrhage. In all cases, examination by an ophthalmologist is essential. Retinal tears and detachments necessitate urgent treatment (see above).

► When to Refer

All patients with suspected vitreous hemorrhage must be referred urgently to an ophthalmologist.

- Newman DK. Surgical management of the late complications of proliferative diabetic retinopathy. *Eye (Lond)*. 2010 Mar; 24(3):441–9. [PMID: 20139916]
 Tan HS et al. Early vitrectomy for vitreous hemorrhage associated with retinal tears. *Am J Ophthalmol*. 2010 Oct;150(4): 529–33. [PMID: 20579632]

AGE-RELATED MACULAR DEGENERATION



ESSENTIALS OF DIAGNOSIS

- Older age group.
- Acute or chronic deterioration of central vision in one or both eyes.
- Distortion or abnormal size of images.
- No pain or redness.
- Macular abnormalities seen by ophthalmoscopy.

► General Considerations

In developed countries, age-related macular degeneration is the leading cause of permanent visual loss in the older population. The exact cause is unknown, but the prevalence increases with each decade over age 50 years (to almost 30% by age 75), and there is an association with genetically determined variations in the complement pathway. Other associated factors are race (usually white), sex (slight female predominance), family history, and cigarette smoking.

Age-related macular degeneration is classified into atrophic (“dry,” “geographic”) and neovascular (“wet,” “exudative”). Although both are progressive and usually bilateral, they differ in manifestations, prognosis, and management.

► Clinical Findings

The precursor to age-related macular degeneration is age-related maculopathy, characterized by retinal drusen. Hard drusen appear ophthalmoscopically as discrete yellow deposits. Soft drusen are larger, paler, and less distinct. Large, confluent soft drusen are particularly associated with neovascular age-related macular degeneration.

Atrophic degeneration is characterized by gradually progressive bilateral visual loss of moderate severity due to atrophy and degeneration of the outer retina and retinal pigment epithelium. In **neovascular degeneration**, choroidal new vessels grow between the retinal pigment epithelium and Bruch membrane, leading to accumulation of serous fluid, hemorrhage, and fibrosis. The onset of visual loss is more rapid and more severe in neovascular degeneration than in atrophic degeneration. The two eyes are frequently affected sequentially over a period of a few years. Neovascular disease accounts for about 90% of all cases of legal blindness due to age-related macular degeneration. Macular degeneration results in loss of central vision only. Peripheral fields and hence navigational vision are maintained, though these may become impaired by cataract formation for which surgery may be helpful.

► Treatment

In the Age-Related Eye Disease Study (AREDS), oral treatment with antioxidants (vitamin A [beta-carotene], vitamin C and vitamin E), and zinc and copper reduced the risk of disease progression in patients with moderate age-related maculopathy or severe disease in one eye, but there are concerns about long-term adverse effects and adherence to treatment is poor. Lack of disease progression has also been found to be associated with high dietary consumption of other carotenoids, lutein and zeaxanthin, and omega-3 long-chain polyunsaturated fatty acids, and with dietary supplementation with a combination of folic acid, vitamin B₆ and vitamin B₁₂ in women. Laser retinal photocoagulation results in regression of drusen but does not reduce the risk of disease progression.

Inhibitors of vascular endothelial growth factors (VEGF), including ranibizumab, pegaptanib, and bevacizumab, reverse the choroidal neovascularization, resulting in stabilization and less frequently improvement in vision in neovascular degeneration. They have to be administered by

intravitreal injection. Initial trials involved monthly injections for 2 years. Current studies are determining whether it is feasible to initially treat monthly for 3 months and then only when there is evidence of reactivation of disease. Treatment is well tolerated with minimal adverse effects, although there is a small risk of intraocular infection and inflammation, retinal detachment, or traumatic cataract.

There is no specific treatment for atrophic degeneration, but—as with the neovascular form—patients may benefit from low vision aids.

► When to Refer

Older patients developing sudden visual loss due to macular disease—particularly paracentral distortion or scotoma with preservation of central acuity—should be referred urgently to an ophthalmologist.

- Bird AC. Therapeutic targets in age-related macular disease. *J Clin Invest.* 2010 Sep 1;120(9):3033–41. [PMID: 20811159]
- Chakravarthy U et al. Clinical risk factors for age-related macular degeneration: a systematic review and meta-analysis. *BMC Ophthalmol.* 2010 Dec 13;10:31. [PMID: 21144031]
- Chiang A et al. Preferred therapies for neovascular age-related macular degeneration. *Curr Opin Ophthalmol.* 2011 May; 22(3):199–204. [PMID: 21427571]
- Deangelis MM et al. Genetics of age-related macular degeneration: current concepts, future directions. *Semin Ophthalmol.* 2011 May;26(3):77–93. [PMID: 21609220]
- Folk JC et al. Ranibizumab therapy for neovascular age-related macular degeneration. *N Engl J Med.* 2010 Oct 21;363(17): 1648–55. [PMID: 20961248]
- Meleth AD et al. Treatment for atrophic macular degeneration. *Curr Opin Ophthalmol.* 2011 May;22(3):190–3. [PMID: 21427574]
- Moshfeghi AA. Endophthalmitis following intravitreal anti-vascular endothelial growth factor injections for neovascular age-related macular degeneration. *Semin Ophthalmol.* 2011 May;26(3):139–48. [PMID: 21609227]
- Olson JH et al. Nutritional supplementation and age-related macular degeneration. *Semin Ophthalmol.* 2011 May;26(3): 131–6. [PMID: 21609225]
- Siemsen DW et al. Vision rehabilitation of persons with age related macular degeneration. *Semin Ophthalmol.* 2011 May;26(3):65–8. [PMID: 21609218]
- Thakkinian A et al. Systematic review and meta-analysis of the association between complement component 3 and age-related macular degeneration: a HuGE review and meta-analysis. *Am J Epidemiol.* 2011 Jun 15;173(12):1365–79. [PMID: 21576320]
- Yehoshua Z et al. Current clinical trials in dry AMD and the definition of appropriate clinical outcome measures. *Semin Ophthalmol.* 2011 May;26(3):167–80. [PMID: 21609230]
- Yuan A et al. Emerging therapies for the treatment of neovascular age related macular degeneration. *Semin Ophthalmol.* 2011 May;26(3):149–55. [PMID: 21609228]

CENTRAL & BRANCH RETINAL VEIN OCCLUSIONS



ESSENTIALS OF DIAGNOSIS

- Sudden monocular loss of vision.
- No pain or redness.
- Widespread or sectoral retinal hemorrhages.

► General Considerations

All patients with retinal vein occlusion should be screened for diabetes, systemic hypertension, hyperlipidemia, and glaucoma. In younger patients, antiphospholipid antibodies, inherited thrombophilia, and hyperhomocysteinemia should be considered. Rarely, hyperviscosity syndromes, including myeloproliferative disorders, are associated with retinal vein occlusions and particularly should be considered in bilateral disease.

► Clinical Findings

A. Symptoms and Signs

The visual impairment in central retinal vein occlusion is commonly first noticed upon waking. Ophthalmoscopic signs include widespread retinal hemorrhages, retinal venous dilation and tortuosity, retinal cotton-wool spots, and optic disk swelling.

Branch retinal vein occlusions may present in a variety of ways. Sudden loss of vision may occur at the time of occlusion if the fovea is involved or some time afterward from vitreous hemorrhage due to retinal new vessels. More gradual visual loss may occur with development of macular edema. In acute branch retinal vein occlusion, the retinal abnormalities (hemorrhages, venous dilation and tortuosity, and cotton-wool spots) are confined to the area drained by the obstructed vein. Check blood pressure in all patients.

B. Laboratory Findings

Obtain screening studies for diabetes and hyperlipidemia. In younger patients, consider obtaining antiphospholipid antibodies, lupus anticoagulant, tests for inherited thrombophilia, and plasma homocysteine levels. Very high paraproteins, found on serum protein electrophoresis (particularly IgM), can cause hyperviscosity.

► Complications

If central retinal vein occlusion is associated with widespread retinal ischemia, manifesting as poor visual acuity (20/200 (6/60) or worse), florid retinal abnormalities, and extensive areas of capillary closure on fluorescein angiography, there is a high risk of development of neovascular (rubeotic) glaucoma, typically within first 3 months.

Branch retinal vein occlusion may be complicated by peripheral retinal neovascularization or chronic macular edema.

► Treatment

Eyes at risk of neovascular glaucoma following ischemic central retinal vein occlusion can be treated by panretinal laser photocoagulation either prophylactically or as soon as there is evidence of neovascularization, the latter approach necessitating frequent monitoring. Regression of iris neovascularization has been achieved with intravitreal injections of bevacizumab, an inhibitor of VEGF. In branch retinal vein occlusion complicated by retinal neovascularization, the ischemic retina should be laser photocoagulated.

Retinal laser photocoagulation may be indicated in chronic macular edema due to branch but not central retinal vein occlusion. Intravitreal injection of a VEGF inhibitor, ranibizumab, bevacizumab, or pegaptanib, is beneficial in chronic macular edema due to either branch or nonischemic central retinal vein occlusion. Intravitreal triamcinolone improves vision in chronic macular edema due to nonischemic central retinal vein occlusion, whereas an intravitreal implant containing dexamethasone is beneficial in both central and branch retinal vein occlusion.

Improvement in vision has been reported after vitrectomy with direct injection of tissue plasminogen activator into the retinal venous system or incision of the sclera at the edge of the optic disk (radial optic neurotomy). Improvement has also been reported after isovolemic hemodilution in central retinal vein occlusion and after vitrectomy alone or combined with surgical incision of the retinal vascular adventitia (arteriovenous sheathotomy) and injection of tissue plasminogen activator in branch retinal vein occlusion. However, the overall value of each technique remains uncertain.

► Prognosis

In central retinal vein occlusion, severity of visual loss initially is a good guide to visual outcome. Initial visual acuity of 20/60 (6/18) or better indicates a good prognosis. Visual prognosis is poor for eyes with neovascular glaucoma.

Visual outcome in branch retinal vein occlusion is determined by the severity of macular damage from hemorrhage, ischemia, or edema.

► When to Refer

All patients with retinal vein occlusion should be referred urgently to an ophthalmologist.

- Aref AA et al. Management of macular edema secondary to branch retinal vein occlusion: an evidence-based update. *Adv Ther.* 2011 Jan;28(1):28–39. [PMID: 21153509]
- Aref AA et al. Management of macular edema secondary to central retinal vein occlusion: an evidence-based update. *Adv Ther.* 2011 Jan;28(1):40–50. [PMID: 21153510]
- Coscas G et al. Management of retinal vein occlusion—consensus document. *Ophthalmologica.* 2011;226(1):4–28. [PMID: 21577038]
- Ehlers JP et al. Retinal vein occlusion: beyond the acute event. *Surv Ophthalmol.* 2011 Jul–Aug;56(4):281–99. [PMID: 21601903]
- Jonas J et al. Retinal vein occlusions. *Dev Ophthalmol.* 2010; 47:111–35. [PMID: 20703046]
- Lattanzio R et al. Retinal vein occlusion: current treatment. *Ophthalmologica.* 2011;225(3):135–43. [PMID: 20938213]
- London NJ et al. Update and review of central retinal vein occlusion. *Curr Opin Ophthalmol.* 2011 May;22(3):159–65. [PMID: 21460724]
- McIntosh RL et al. Natural history of central retinal vein occlusion: an evidence-based systematic review. *Ophthalmology.* 2010 Jun;117(6):1113–23. [PMID: 20430446]
- Rogers SL et al. Natural history of branch retinal vein occlusion: an evidence-based systematic review. *Ophthalmology.* 2010 Jun;117(6):1094–1101. [PMID: 20430447]
- Tseng MY et al. Simultaneous bilateral central retinal vein occlusion as the initial presentation of acute myeloid leukemia. *Am J Med Sci.* 2010 Apr;339(4):387–9. [PMID: 20186040]
- Wong TY et al. Clinical practice. Retinal-vein occlusion. *N Engl J Med.* 2010 Nov 25;363(22):2135–44. [PMID: 21105795]

CENTRAL & BRANCH RETINAL ARTERY OCCLUSIONS



ESSENTIALS OF DIAGNOSIS

- ▶ Sudden monocular loss of vision.
- ▶ No pain or redness.
- ▶ Widespread or sectoral retinal pallid swelling.

▶ General Considerations

In patients 50 years of age or older with central retinal artery occlusion, giant cell arteritis must be considered (see Ischemic Optic Neuropathy and Chapter 20). Carotid and cardiac sources of emboli must be sought in central and in branch retinal artery occlusion in particular, even if no retinal emboli are identified on ophthalmoscopy, so that appropriate treatment can be given to reduce the risk of stroke (see Chapters 12 and 14). Migraine, oral contraceptives, systemic vasculitis, congenital or acquired thrombophilia, and hyperhomocysteinemia should be considered in young patients. Internal carotid artery dissection should be considered when there is neck pain or a recent history of neck trauma. Diabetes, hyperlipidemia, and systemic hypertension should be considered in all patients.

▶ Clinical Findings

A. Symptoms and Signs

Central retinal artery occlusion presents as sudden profound monocular visual loss. Visual acuity is usually reduced to counting fingers or worse, and visual field is restricted to an island of vision in the temporal field. Ophthalmoscopy reveals pallid swelling of the retina, most obvious in the posterior segment, with a cherry-red spot at the fovea. The retinal arteries are attenuated, and “box-car” segmentation of blood in the veins may be seen. Occasionally, emboli are seen in the central retinal artery or its branches. The retinal swelling subsides over a period of 4–6 weeks, leaving a pale optic disk and attenuated arterioles with otherwise a relatively normal retinal appearance but thinning of the inner retina is detectable by optical coherence tomography.

Branch retinal artery occlusion may also present with sudden loss of vision if the fovea is involved, but more commonly sudden loss of visual field is the presenting complaint. Fundal signs of retinal swelling and adjacent cotton-wool spots are limited to the area of retina supplied by the occluded artery.

Evaluate all patients for arrhythmia, particularly atrial fibrillation, as well as cardiac murmurs. In addition, measure the patient’s blood pressure and identify risk factors for cardiac source of emboli. Clinical features of giant cell arteritis, which generally occurs in patients 50 years or older, include jaw claudication (which is very specific), headache, scalp tenderness, general malaise, weight loss,

symptoms of polymyalgia rheumatica, and tenderness, thickening, or absence of pulse of the superficial temporal arteries. Table 20–14 lists the clinical manifestations of vasculitis.

B. Laboratory Findings

Screen for diabetes and hyperlipidemia in all patients. Erythrocyte sedimentation rate and C-reactive protein are usually markedly elevated in giant cell arteritis but one or both may be normal. Consider screening for other types of vasculitis (see Table 20–13). In younger patients, consider obtaining antiphospholipid antibodies, lupus anticoagulant, tests for inherited thrombophilia and a plasma homocysteine level.

C. Imaging

Obtain duplex ultrasonography of the carotid arteries, ECG, and echocardiography, with transesophageal studies (if necessary), to identify carotid and cardiac sources of emboli and, when indicated, obtain CT or MR angiography for internal carotid artery dissection.

▶ Treatment

If the patient is seen within a few hours after onset, emergency treatment—including laying the patient flat, ocular massage, high concentrations of inhaled oxygen, intravenous acetazolamide, and anterior chamber paracentesis—may influence the visual outcome. Studies of early thrombolysis, particularly by local intra-arterial injection but also intravenously, have shown good results in central retinal artery occlusion not due to giant cell arteritis but the former method has a high incidence of adverse effects.

In giant cell arteritis, there is risk—highest in the first few days—of involvement of the other eye. When the diagnosis is suspected, high-dose corticosteroids (oral prednisolone 1–1.5 mg/kg/d, if necessary preceded by intravenous hydrocortisone 250–500 mg stat, or methylprednisolone 0.5–1 g/d for 1–3 days followed by oral prednisolone, especially in patients with bilateral visual loss) must be instituted immediately, possibly together with low-dose aspirin (~81 mg/d orally). The patient must be monitored closely to ensure that treatment is adequate. A temporal artery biopsy should be performed promptly, and if necessary, assistance should be sought from a rheumatologist.

▶ When to Refer

- Patients with central retinal artery occlusion should be referred emergently to an ophthalmologist.
- Patients with branch retinal artery occlusion should be referred urgently.

▶ When to Admit

Patients with visual loss due to giant cell arteritis may require emergency admission for high-dose corticosteroid

therapy and close monitoring to ensure that treatment is adequate.

- Aldrich EM et al. Local intraarterial fibrinolysis administered in aliquots for the treatment of central retinal artery occlusion: the Johns Hopkins Hospital experience. *Stroke*. 2008 Jun; 39(6):1746–50. [PMID: 18420951]
- Dasgupta B et al. Concise guidance: diagnosis and management of giant cell arteritis. *Clin Med*. 2010 Aug;10(4):381–6. [PMID: 20849016]
- Davies CG et al. The role of temporal artery biopsies in giant cell arteritis. *Ann R Coll Surg Engl*. 2011 Jan;93(1):4–5. [PMID: 21418754]
- Harder N. Temporal arteritis: an approach to suspected vasculitides. *Prim Care*. 2010 Dec;37(4):757–66. [PMID: 21050956]
- Hayreh SS. Acute retinal arterial occlusive disorders. *Prog Retin Eye Res*. 2011 Sep;30(5):359–94. [PMID: 21620994]
- Hayreh SS. Vascular disorders in neuro-ophthalmology. *Curr Opin Neurol*. 2011 Feb;24(1):6–11. [PMID: 21102333]
- Kale N et al. Diagnosis and management of giant cell arteritis: a review. *Curr Opin Ophthalmol*. 2010 Nov;21(6):417–22. [PMID: 20811283]
- Scheurer RA et al. Treatment of vision loss in giant cell arteritis. *Curr Treat Options Neurol*. 2011 Oct 27. [Epub ahead of print] [PMID: 22037998]
- Schmidt J et al. Polymyalgia rheumatica and giant cell arteritis in older patients: diagnosis and pharmacological management. *Drugs Aging*. 2011 Aug 1;28(8):651–66. [PMID: 21812500]
- Schumacher M et al. Central retinal artery occlusion: local intra-arterial fibrinolysis versus conservative treatment, a multicenter randomized trial. *Ophthalmology*. 2010 Jul;117(7):1367–75.e1. [PMID: 20609991]
- Waqar S et al. Ophthalmic manifestations of giant cell arteritis. *Br J Hosp Med (Lond)*. 2011 Jan;72(1):26–30. [PMID: 21240114]
- Weizbilit N et al. Ophthalmic problem. Central retinal artery occlusion. *Can Fam Physician*. 2009 Feb;55(2):167–8. [PMID: 19221078]
- Wolf A et al. Comparison of superselective intraarterial fibrinolysis with conservative therapy. Use in patients with acute non-arteritic central retinal artery occlusion. *Ophthalmology*. 2010 Sep;107(9):799–805. [PMID: 20821332]
- Ypsilantis E et al. Importance of specimen length during temporal artery biopsy. *Br J Surg*. 2011 Nov;98(11):1556–60. [PMID: 21706476]

TRANSIENT MONOCULAR BLINDNESS



ESSENTIALS OF DIAGNOSIS

- ▶ Monocular loss of vision usually lasting a few minutes with complete recovery.

Transient monocular blindness may be caused by retinal emboli from ipsilateral carotid disease or the heart. The visual loss is characteristically described as a curtain passing vertically across the visual field with complete monocular visual loss lasting a few minutes and a similar curtain effect as the episode passes (amaurosis fugax; also called “fleeting blindness”). Emboli are rarely seen on ophthalmoscopy. Other causes of temporary ocular

ischemia are giant cell arteritis, antiphospholipid syndrome, and severe occlusive carotid disease; in the last case, the visual loss characteristically occurs on exposure to bright light. More transient episodes of visual loss, lasting only a few seconds to 1 minute and affecting one or both eyes, occur in patients with raised intracranial pressure. In young patients, there is a benign form of transient visual loss that has been ascribed to choroidal or retinal vascular spasm.

▶ Diagnostic Studies

Clinical assessment and investigations are the same as for retinal artery occlusion (see above).

▶ Treatment

To reduce the risk of stroke, all patients with transient monocular blindness due to retinal emboli from ipsilateral carotid disease should be treated with oral aspirin (~ 81 mg daily), or another antiplatelet drug, and their vascular risk factors should be controlled. Patients with 70–99% stenosis and possibly those with 50–69% stenosis should be considered for early carotid endarterectomy or possibly angioplasty with stenting, but surgery is less likely to be necessary than in patients with cerebral hemispheric events (see Chapter 12).

In younger patients with the benign variant of transient monocular blindness, calcium channel blockers, such as slow-release nifedipine, 60 mg/d, may be effective.

▶ When to Refer

In all cases of episodic visual loss, early ophthalmologic consultation is advisable.

- Kulkarni SR et al. The importance of early carotid endarterectomy in symptomatic patients. *Ann R Coll Surg Engl*. 2009 Apr;91(3):210–3. [PMID: 19220938]
- Rerkasem K et al. Carotid endarterectomy for symptomatic carotid stenosis. *Cochrane Database Syst Rev*. 2011 Apr 13;(4):CD001081. [PMID: 21491381]
- Ricotta JJ et al. Updated Society for Vascular Surgery guidelines for management of extracranial carotid disease. *J Vasc Surg*. 2011 Sep;54(3):e1–31. [PMID: 21889701]
- Ricotta JJ et al. Updated Society for Vascular Surgery guidelines for management of extracranial carotid disease: executive summary. *J Vasc Surg*. 2011 Sep;54(3):832–6. [PMID: 21889705]
- Ross CB et al. Late outcomes of carotid artery stenting: a critical review. *Am Surg*. 2011 Sep;77(9):1117–30. [PMID: 21944619]
- Safian RD. Treatment strategies for carotid stenosis in patients at increased risk for surgery. *Prog Cardiovasc Dis*. 2011 Jul–Aug;54(1):22–8. [PMID: 21722783]
- Shrikhande GV et al. Choosing the appropriate intervention for symptomatic and asymptomatic carotid disease in the era of multiple therapies: integration of risk profile and technical data. *Semin Vasc Surg*. 2011 Mar;24(1):53–9. [PMID: 21718933]
- Utz VM et al. Ocular manifestations of the antiphospholipid syndrome. *Br J Ophthalmol*. 2011 Apr;95(4):454–9. [PMID: 20693557]

RETINAL DISORDERS ASSOCIATED WITH SYSTEMIC DISEASES

1. Diabetic Retinopathy

ESSENTIALS OF DIAGNOSIS

- ▶ Present in about 40% of diagnosed diabetic patients.
- ▶ Present in up to 20% of type 2 diabetic patients at diagnosis.
- ▶ Background retinopathy: mild retinal abnormalities without visual loss.
- ▶ Maculopathy: macular edema, exudates, or ischemia.
- ▶ Proliferative retinopathy: new retinal vessels.

▶ General Considerations


In the United States, diabetic retinopathy is present in about 40% of diagnosed diabetic patients. It is the leading cause of new blindness among adults aged 20–65 years; the number of affected individuals aged 65 years or older is particularly increasing. Retinopathy increases in prevalence and severity with increasing duration and poorer control of diabetes. In type 1 diabetes, retinopathy is not detectable for at least 3 years after diagnosis. In type 2 diabetes, retinopathy is present in up to 20% of patients at diagnosis and may be the presenting feature. It is broadly classified as **nonproliferative**, comprising **background retinopathy** and **maculopathy**, or **proliferative**. Maculopathy and proliferative retinopathy may coexist, particularly in severe disease.

▶ Clinical Findings

Nonproliferative retinopathy manifests as dilation of veins, microaneurysms, retinal hemorrhages, retinal edema, and hard exudates. In **background retinopathy**, the abnormalities are mild and do not cause any impairment of visual acuity. Pre-proliferative retinopathy is characterized by marked vascular abnormalities and retinal hemorrhages.

Maculopathy manifests as edema, exudates, or ischemia involving the macula (Figure 7–4). Assessment requires stereoscopic examination of the retina, retinal imaging with optical coherence tomography, and sometimes fluorescein angiography. Visual acuity is a poor guide to the presence of treatable maculopathy—hence the need for regular ophthalmologic follow-up. Maculopathy is the most common cause of legal blindness in type 2 diabetes.

Proliferative retinopathy is characterized by neovascularization, arising from either the optic disk or the major vascular arcades. Vitreous hemorrhage is a common sequela. Proliferation into the vitreous of blood vessels, with their associated fibrous component, may lead to tractional retinal detachment. Without treatment, the visual prognosis with proliferative retinopathy is generally much worse than that with nonproliferative retinopathy.



▶ **Figure 7-4.** Diabetic exudative maculopathy. (Courtesy of Victor Chong. Reproduced, with permission, from Riordan-Eva P, Cunningham ET Jr. *Vaughan & Asbury's General Ophthalmology*, 18th edition, McGraw-Hill, 2011.)

▶ Screening

Adult and adolescent patients with diabetes should undergo at least yearly screening by fundal photography, preferably after pupil dilation (mydriasis), or by slit-lamp examination after pupil dilation. (Failure to identify diabetic retinopathy by direct ophthalmoscopy is common, particularly if the pupils are not dilated. Non-mydriatic fundal photography, possibly with centralized screening by telemedicine, may increase rates of participation.) More frequent monitoring is required in women during pregnancy and in those planning pregnancy. Patients with type 2 diabetes mellitus should be screened shortly after diagnosis.

▶ Treatment

Treatment includes optimizing blood glucose, blood pressure, renal function, and serum lipids, although such measures are probably more important in preventing the development of retinopathy than in influencing its subsequent course.

Macular edema and exudates, but not ischemia, may respond to laser photocoagulation, intravitreal corticosteroid or VEGF inhibitor, or vitrectomy.

Proliferative retinopathy is usually treated by panretinal laser photocoagulation, preferably before vitreous hemorrhage or tractional detachment has occurred. Regression of neovascularization can also be achieved by intravitreal injection of a VEGF inhibitor. Determining whether panretinal laser photocoagulation should be undertaken for pre-proliferative retinopathy may be helped by assessing the degree of retinal ischemia on fluorescein angiography.

Vitreotomy is necessary for removal of persistent vitreous hemorrhage, to improve vision and allow panretinal laser photocoagulation for the underlying retinal neovascularization, for treatment of tractional retinal detachment involving the macula, and for management of rapidly progressive proliferative disease.

Proliferative diabetic retinopathy, especially after successful laser treatment, is not a contraindication to treatment with thrombolytic agents, aspirin, or warfarin unless there has been recent vitreous or pre-retinal hemorrhage.

▶ When to Refer

- All diabetic patients with sudden loss of vision or retinal detachment should be referred emergently to an ophthalmologist.
- Proliferative retinopathy or maculopathy requires urgent referral to an ophthalmologist.
- Pre-proliferative retinopathy or unexplained reduction of visual acuity requires early referral to an ophthalmologist.

Abbate M et al. Prevention and treatment of diabetic retinopathy: evidence from clinical trials and perspectives. *Curr Diabetes Rev*. 2011 May;7(3):190–200. [PMID: 21438851]

Ali S et al. Diabetes in pregnancy: health risks and management. *Postgrad Med J*. 2011 Jun;87(1028):417–27. [PMID: 21368321]

Augustin AJ. Upcoming therapeutic advances in diabetic macular edema: an intravitreal dexamethasone drug delivery system. *Expert Opin Drug Deliv*. 2011 Feb;8(2):271–9. [PMID: 21222552]

Bhatnagar A et al. Diabetic retinopathy in pregnancy. *Curr Diabetes Rev*. 2009 Aug;5(3):151–6. [PMID: 19689249]

Bressler NM et al. Panretinal photocoagulation for proliferative diabetic retinopathy. *N Engl J Med*. 2011 Oct 20;365(16):1520–6. [PMID: 22010918]

Cheung N et al. Diabetic retinopathy. *Lancet*. 2010 Jul 10;376(9735):124–36. [PMID: 20580421]

Hazin R et al. Challenges to establishing nationwide diabetic retinopathy screening programs. *Curr Opin Ophthalmol*. 2011 May;22(3):174–9. [PMID: 21460726]

Mathiesen ER et al. Therapeutic management of type 1 diabetes before and during pregnancy. *Expert Opin Pharmacother*. 2011 Apr;12(5):779–86. [PMID: 21329488]

Montero JA et al. Intravitreal anti-VEGF drugs as adjuvant therapy in diabetic retinopathy surgery. *Curr Diabetes Rev*. 2011 May;7(3):176–84. [PMID: 21438852]

Ockrim Z et al. Managing diabetic retinopathy. *BMJ*. 2010 Oct 25;341:c5400. [PMID: 20974661]

Porta M et al. New approaches to the treatment of diabetic retinopathy. *Diabetes Obes Metab*. 2011 Sep;13(9):784–90. [PMID: 21535345]

Tillin T et al. The role of antihypertensive therapy in reducing vascular complications of type 2 diabetes. Findings from the Diabetic REtinopathy Candesartan Trials-Protect 2 study. *J Hypertens*. 2011 Jul;29(7):1457–62. [PMID: 21602709]

Virgili G et al. Optical coherence tomography (OCT) for detection of macular oedema in patients with diabetic retinopathy. *Cochrane Database Syst Rev*. 2011 Jul 6;(7):CD008081. [PMID: 21735421]

Waisbourd M et al. Treatment of diabetic retinopathy with anti-VEGF drugs. *Acta Ophthalmol*. 2011 May;89(3):203–7. [PMID: 21044274]

Williams ME. The goal of blood pressure control for prevention of early diabetic microvascular complications. *Curr Diab Rep*. 2011 Aug;11(4):323–9. [PMID: 21526351]

Witkin AJ et al. Update on nonsurgical therapy for diabetic macular edema. *Curr Opin Ophthalmol*. 2011 May;22(3):185–9. [PMID: 21427573]

Wright AD et al. Medical management of diabetic retinopathy: fenofibrate and ACCORD Eye studies. *Eye (Lond)*. 2011 Jul;25(7):843–9. [PMID: 21436845]

2. Hypertensive Retinopathy

Systemic hypertension affects both the retinal and choroidal circulations. The clinical manifestations vary according to the degree and rapidity of rise in blood pressure and the underlying state of the ocular circulation. The most florid disease occurs in young patients with abrupt elevations of blood pressure, such as may occur in pheochromocytoma, malignant hypertension, or preeclampsia-eclampsia.

Chronic hypertension accelerates the development of atherosclerosis. The retinal arterioles become more tortuous and narrow and develop abnormal light reflexes (“silver-wiring” and “copper-wiring”). There is increased venous compression at the retinal arteriovenous crossings (“arteriovenous nicking”), an important factor predisposing to branch retinal vein occlusions. Flame-shaped hemorrhages occur in the nerve fiber layer of the retina.

Acute elevations of blood pressure result in loss of autoregulation in the retinal circulation, leading to the breakdown of endothelial integrity and occlusion of precapillary arterioles and capillaries. These pathologic changes are manifested as cotton-wool spots, retinal hemorrhages, retinal edema, and retinal exudates, often in a stellate appearance at the macula (see Figure 11–2). In the choroid, vasoconstriction and ischemia result in serous retinal detachments and retinal pigment epithelial infarcts. These infarcts later develop into pigmented lesions that may be focal, linear, or wedge-shaped. The abnormalities in the choroidal circulation may also affect the optic nerve head, producing ischemic optic neuropathy with optic disk swelling. Malignant hypertensive retinopathy was the term previously used to describe the constellation of clinical signs resulting from the combination of abnormalities in the retinal, choroidal, and optic disk circulation. When there is such severe disease, there is likely to be permanent retinal, choroidal, or optic nerve damage. Precipitous reduction of blood pressure may exacerbate such damage.

Bhargava M et al. How does hypertension affect your eyes? *J Hum Hypertens*. 2011 Apr 21. [Epub ahead of print] [PMID: 21509040]

Henderson AD et al. Hypertension-related eye abnormalities and the risk of stroke. *Rev Neurol Dis*. 2011;8(1–2):1–9. [PMID: 21769065]

Meetz RE et al. The optometrist’s role in the management of hypertensive crises. *Optometry*. 2011 Feb;82(2):108–16. [PMID: 21168370]

3. Blood Dyscrasias

In conditions characterized by severe thrombocytopenia or anemia, various types of hemorrhages occur in both the retina and choroid and may lead to visual loss. If the

macula is uninvolved, normal vision is usually regained after resolution of the hemorrhages.

Sickle cell retinopathy is particularly common in hemoglobin SC disease but may also occur with other hemoglobin S variants. Manifestations include “salmon-patch” preretinal/intraretinal hemorrhages, “black sunbursts” resulting from intraretinal hemorrhage, and new vessels. Severe visual loss is rare. Retinal laser photocoagulation reduces the frequency of vitreous hemorrhage from new vessels. Surgery is occasionally needed for persistent vitreous hemorrhage or tractional retinal detachment.

Elagouz M et al. Sickle cell disease and the eye: old and new concepts. *Surv Ophthalmol.* 2010 Jul 8;55(4):359–77. [PMID: 20452638]

4. AIDS

Cotton-wool spots, retinal hemorrhages, and microaneurysms are the most common ophthalmic abnormalities in AIDS patients.


CMV retinitis occurs when CD4 counts are below 50/mcL (or $0.05 \times 10^6/L$). It is characterized by progressively enlarging yellowish-white patches of retinal opacification, which are accompanied by retinal hemorrhages; they usually begin adjacent to the major retinal vascular arcades (Figure 7–5). Patients are often asymptomatic until there is involvement of the fovea or optic nerve or until retinal detachment develops.

Choices for initial therapy are (1) valganciclovir 900 mg orally twice daily for 3 weeks; (2) ganciclovir 5 mg/kg intravenously twice a day, foscarnet 60 mg/kg intravenously three times a day, or cidofovir 5 mg/kg intravenously once weekly, for 2–3 weeks; or (3) local administration, using either intravitreal injection of ganciclovir or foscarnet, or the sustained-release ganciclovir intravitreal implant. Major

side effects are neutropenia and thrombocytopenia with systemic ganciclovir and nephrotoxicity with foscarnet and cidofovir. Doses of both ganciclovir and foscarnet are adjusted in patients with renal failure. Oral probenecid and intravenous hydration are used to minimize nephrotoxicity from cidofovir. All available agents are virostatic. Maintenance therapy can be conducted with lower-dose therapy (oral valganciclovir 900 mg once daily, intravenous ganciclovir 5 mg/kg/d, intravenous foscarnet 90 mg/kg/d, or intravenous cidofovir 5 mg/kg once every 2 weeks) or with intravitreal therapy. Local therapy tends to be more effective than systemic therapy and avoids systemic side effects, but there is a risk of intraocular complications, and the incidence of retinitis in the fellow eye and of extraocular CMV infection is higher. Unresponsive disease or reactivation during maintenance therapy can be managed by changing to a different agent or by use of combination therapy. Retinal detachment, either due to retinitis or as a complication of intravitreal therapy, requires vitrectomy and intravitreal silicone oil. Pharmacologic prophylaxis against CMV retinitis in patients with low CD4 counts or high CMV burdens has not been found to be worthwhile.

In all patients with CMV retinitis, highly active antiretroviral therapy (HAART) needs to be instituted or adjusted. This may lead to the immune reconstitution inflammatory syndrome (IRIS), of which the immune recovery uveitis may lead to visual loss, predominantly due to cystoid macular edema. If the CD4 count is maintained above 100/mcL ($0.1 \times 10^6/L$), it may be possible to discontinue maintenance anti-CMV therapy.

Other ophthalmic manifestations of opportunistic infections occurring in AIDS patients include herpes simplex retinitis, toxoplasmic and candidal chorioretinitis, herpes zoster ophthalmicus, and various entities due to syphilis or tuberculosis. Kaposi sarcoma of the conjunctiva (see Chapter 31) and orbital lymphoma may also be seen on rare occasions.



▲ **Figure 7-5.** Retinal changes in HIV infection: cytomegalovirus retinitis. (Courtesy of Elizabeth Graham. Reproduced, with permission, from Riordan-Eva P, Cunningham ET Jr. *Vaughan & Asbury's General Ophthalmology*, 18th edition, McGraw-Hill, 2011.)

Jabs DA. Cytomegalovirus retinitis and the acquired immunodeficiency syndrome—bench to bedside: LXVII Edward Jackson Memorial Lecture. *Am J Ophthalmol.* 2011 Feb;151(2):198–216.e1. [PMID: 21168815]

Jabs DA et al. Course of cytomegalovirus retinitis in the era of highly active antiretroviral therapy: five-year outcomes. *Ophthalmology.* 2010 Nov;117(11):2152–61.e1–2. [PMID: 20673591]

Stewart MW. Optimal management of cytomegalovirus retinitis in patients with AIDS. *Clin Ophthalmol.* 2010 Apr;26;4:285–99. [PMID: 20463796]

Thorne JE et al. Visual field loss in patients with cytomegalovirus retinitis. *Ophthalmology.* 2011 May;118(5):895–901. [PMID: 21146225]

ISCHEMIC OPTIC NEUROPATHY



ESSENTIALS OF DIAGNOSIS

- ▶ Sudden painless visual loss with signs of optic nerve dysfunction.
- ▶ Optic disc swelling in anterior ischemic optic neuropathy.

Anterior ischemic optic neuropathy—due to inadequate perfusion of the posterior ciliary arteries that supply the anterior portion of the optic nerve—produces sudden visual loss, usually with an altitudinal field defect, and optic disk swelling. In older patients, it is often caused by giant cell arteritis, which necessitates emergency high-dose systemic corticosteroid treatment to prevent visual loss in the other eye. (See Central & Branch Retinal Artery Occlusions, above and Polymyalgia Rheumatica & Giant Cell Arteritis, Chapter 20.) The predominant factor predisposing to nonarteritic anterior ischemic optic neuropathy is a congenitally crowded optic disk. Other causative factors include systemic hypertension, diabetes mellitus, hyperlipidemia, systemic vasculitis, inherited or acquired thrombophilia, and possibly ingestion of sildenafil, interferon-alpha therapy, and sleep apnea. Rarely, an optic neuropathy that can be difficult to differentiate from nonarteritic anterior optic neuropathy can develop in patients taking amiodarone.

Ischemic optic neuropathy, usually involving the retrobulbar optic nerve and thus not causing any optic disk swelling (**posterior ischemic optic neuropathy**), may occur after severe blood loss or nonocular surgery, particularly prolonged lumbar spine surgery in the prone position.

▶ When to Refer

Patients with ischemic optic neuropathy should be referred urgently to an ophthalmologist.

▶ When to Admit

Patients with ischemic optic neuropathy due to giant cell arteritis may require emergency admission for high-dose corticosteroid therapy and close monitoring to ensure that treatment is adequate.

- Atkins EJ. Nonarteritic anterior ischemic optic neuropathy. *Curr Treat Options Neurol*. 2011 Feb;13(1):92–100. [PMID: 21063919]
- Berg KT et al. Perioperative visual loss in ocular and nonocular surgery. *Clin Ophthalmol*. 2010 Jun 24;4:531–46. [PMID: 20596508]
- Dasgupta B et al. Concise guidance: diagnosis and management of giant cell arteritis. *Clin Med*. 2010 Aug;10(4):381–6. [PMID: 20849016]
- Dickemper RL et al. Vision loss as a complication of nonophthalmologic surgery: implications for care for the perianesthesia nurse. *J Perianesth Nurs*. 2010 Feb;25(1):29–35. [PMID: 20159532]
- Hayreh SS. Management of ischemic optic neuropathies. *Indian J Ophthalmol*. 2011 Mar–Apr;59(2):123–36. [PMID: 21350282]
- Hayreh SS. Treatment of non-arteritic anterior ischaemic optic neuropathy. *Br J Ophthalmol*. 2011 Nov;95(11):1617–8. [PMID: 21951569]
- Hayreh SS. Vascular disorders in neuro-ophthalmology. *Curr Opin Neurol*. 2011 Feb;24(1):6–11. [PMID: 21102333]
- Kaesler PF et al. Visual loss after orthopedic procedures. *J Arthroplasty*. 2011 Feb;26(2):338.e17–9. [PMID: 20149578]
- Kale N et al. Diagnosis and management of giant cell arteritis: a review. *Curr Opin Ophthalmol*. 2010 Nov;21(6):417–22. [PMID: 20811283]

- Lee LA et al. Postoperative ischemic optic neuropathy. *Spine (Phila Pa 1976)*. 2010 Apr 20;35(9 Suppl):S105–16. [PMID: 20407342]
- Lee MS et al. Incidence of nonarteritic anterior ischemic optic neuropathy: increased risk among diabetic patients. *Ophthalmology*. 2011 May;118(5):959–63. [PMID: 21439645]
- Miller NR. Current concepts in the diagnosis, pathogenesis, and management of nonarteritic anterior ischemic optic neuropathy. *J Neuroophthalmol*. 2011 Jun;31(2):e1–3. [PMID: 21593625]
- Moschos MM et al. Bilateral simultaneous anterior ischemic optic neuropathy associated with sildenafil. *Case Report Ophthalmol*. 2011 May;2(2):262–5. [PMID: 21941503]
- Scheurer RA et al. Treatment of vision loss in giant cell arteritis. *Curr Treat Options Neurol*. 2011 Oct 27. [Epub ahead of print] [PMID: 22037998]
- Schmidt J et al. Polymyalgia rheumatica and giant cell arteritis in older patients: diagnosis and pharmacological management. *Drugs Aging*. 2011 Aug 1;28(8):651–66. [PMID: 21812500]
- Waqar S et al. Ophthalmic manifestations of giant cell arteritis. *Br J Hosp Med (Lond)*. 2011 Jan;72(1):26–30. [PMID: 21240114]

OPTIC NEURITIS



ESSENTIALS OF DIAGNOSIS

- ▶ Subacute unilateral visual loss with signs of optic nerve dysfunction.
- ▶ Pain exacerbated by eye movements.
- ▶ Optic disc usually normal in acute stage but subsequently develops pallor.

▶ General Considerations

Inflammatory optic neuropathy (optic neuritis) is strongly associated with demyelinating disease, particularly multiple sclerosis but also acute disseminated encephalomyelitis. It also occurs in sarcoidosis; as a component of neuromyelitis optica (Devic syndrome); with viral infections (including measles, mumps, influenza and those caused by the varicella zoster virus); with various autoimmune disorders, particularly systemic lupus erythematosus; and by spread of inflammation from the meninges, orbital tissues, or paranasal sinuses.

▶ Clinical Findings

Optic neuritis in demyelinating disease is characterized by unilateral loss of vision, which usually develops over a few days. Vision ranges from 20/30 (6/9) to no perception of light. Commonly there is pain in the region of the eye, particularly on eye movements. Field loss is usually a central scotoma, but a wide range of monocular field defects is possible. There is marked loss of color vision and a relative afferent pupillary defect. In about two-thirds of cases, the optic nerve is normal during the acute stage (retrobulbar optic neuritis). In the remainder, the optic disk is swollen (papillitis) with occasional flame-shaped peripapillary hemorrhages. Visual acuity usually improves within 2–3 weeks and returns to 20/40 (6/12) or better in 95% of previously

unaffected eyes. Optic atrophy subsequently develops if there has been destruction of sufficient optic nerve fibers. Any patient with presumed demyelinating optic neuritis in which visual recovery does not occur or there are other atypical features, including continuing deterioration of vision or persisting pain after 2 weeks, should undergo further investigation, including CT or MRI of the head and orbits to exclude a lesion compressing the optic nerve.

► Treatment

In acute demyelinating optic neuritis, intravenous methylprednisolone (1 g daily for 3 days followed by a tapering course of oral prednisolone) has been shown to accelerate visual recovery, although in clinical practice, the oral taper is not often prescribed. Use in an individual patient is determined by the degree of visual loss, the state of the fellow eye, and the patient's visual requirements.

Optic neuritis due to sarcoidosis, neuromyelitis optica, herpes zoster, or systemic lupus erythematosus generally has a poorer prognosis, requires more prolonged corticosteroid therapy, and may necessitate long-term immunosuppression.

► Prognosis

Among patients with a first episode of clinically isolated optic neuritis, multiple sclerosis will develop in 50% within 15 years but the visual and neurologic prognosis is good. The major risk factors are female gender and multiple white matter lesions on brain MRI. In patients with multiple cerebral white matter lesions, long-term interferon therapy reduces the risk of subsequent development of multiple sclerosis by 25% at 5 years, although the effect on long-term disability remains uncertain and some patients do not respond. Other disease-modifying drugs are available.

► When to Refer

All patients with optic neuritis should be referred urgently for ophthalmologic or neurologic assessment.

Clark D et al. Optic neuritis. *Neurol Clin*. 2010 Aug;28(3):573–80. [PMID: 20637989]

Collongues N et al. Current and future treatment approaches for neuromyelitis optica. *Ther Adv Neurol Disord*. 2011 Mar; 4(2):111–21. [PMID: 21694808]

Costanzi C et al. Azathioprine: tolerability, efficacy, and predictors of benefit in neuromyelitis optica. *Neurology*. 2011 Aug 16;77(7):659–66. [PMID: 21813788]

Frigui M et al. Optic neuropathy as a presenting feature of systemic lupus erythematosus: two case reports and literature review. *Lupus*. 2011 Oct;20(11):1214–8. [PMID: 21669911]

Giovannoni G. Promising emerging therapies for multiple sclerosis. *Neurol Clin*. 2011 May;29(2):435–48. [PMID: 21439452]

Jenkins TM et al. Diagnosing and managing multiple sclerosis. *Practitioner*. 2009 Sep;253(1721):25–30, 2–3. [PMID: 19873856]

Kappos L et al. Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring. *Lancet Neurol*. 2011 Aug;10(8):745–58. [PMID: 21777829]

Matà S et al. Neuromyelitis optica: an update. *J Neurol Sci*. 2011 Apr 15;303(1–2):13–21. [PMID: 21300379]

Pau D et al. Optic neuritis. *Eye (Lond)*. 2011 Jul;25(7):833–42. [PMID: 21527960]

Rejda K et al. Multiple sclerosis: a practical overview for clinicians. *Br Med Bull*. 2010;95:79–104. [PMID: 20603280]

Shams PN et al. Optic neuritis: a review. *Int MS J*. 2009 Sep;16(3):82–9. [PMID: 19878630]

Thornton IL et al. Neuromyelitis optica: a review. *Semin Ophthalmol*. 2011 Jul–Sep;26(4–5):337–41. [PMID: 21958184]


Voss E et al. Clinical approach to optic neuritis: pitfalls, red flags and differential diagnosis. *Ther Adv Neurol Disord*. 2011 Mar;4(2):123–34. [PMID: 21694809]

OPTIC DISK SWELLING

Optic disk swelling may result from intraocular disease, orbital and optic nerve lesions, severe hypertensive retin-ochoroidopathy, or raised intracranial pressure, the last necessitating urgent imaging to exclude an intracranial mass or cerebral venous sinus occlusion. Intraocular causes include central retinal vein occlusion, posterior uveitis, and posterior scleritis. Optic nerve lesions causing disk swelling include optic neuritis; anterior ischemic optic neuropathy; optic disk drusen; optic nerve sheath meningioma; and nerve infiltration by sarcoidosis, leukemia, or lymphoma. Any orbital lesion causing nerve compression may produce disk swelling.

Papilledema (optic disk swelling due to raised intracranial pressure) is usually bilateral and most commonly produces enlargement of the blind spot without loss of acuity (Figure 7–6). Chronic papilledema, as in idiopathic intra-cranial hypertension and cerebral venous sinus occlusion, or severe acute papilledema may be associated with visual field loss and occasionally with profound loss of acuity. All patients with chronic papilledema must be monitored carefully—especially their visual fields—and cerebrospinal fluid shunt or optic nerve sheath fenestration should be considered in those with progressive visual failure not controlled by medical therapy (weight loss where appropriate and acetazolamide).

Optic disk drusen and congenitally crowded optic disks, which are associated with farsightedness, cause optic



▲ Figure 7-6. Severe acute papilledema.

disk elevation that may be mistaken for swelling (pseudopapilledema). Exposed optic disk drusen may be obvious clinically or can be demonstrated by their autofluorescence. Buried drusen are best detected by orbital ultrasound or CT scanning. Other family members may be similarly affected.

Abubaker K et al. Idiopathic intracranial hypertension: lumboperitoneal shunts versus ventriculoperitoneal shunts—case series and literature review. *Br J Neurosurg.* 2011 Feb;25(1):94–9. [PMID: 21323404]

Fraser C et al. The syndrome of pseudotumour cerebri and idiopathic intracranial hypertension. *Curr Opin Neurol.* 2011 Feb;24(1):12–7. [PMID: 21150597]

Jung JJ et al. Analysis of the causes of optic disc swelling. *Korean J Ophthalmol.* 2011 Feb;25(1):33–6. [PMID: 21350692]

Sadun AA et al. Abnormalities of the optic disc. *Handb Clin Neurol.* 2011;102:117–57. [PMID: 21601065]

Sinclair AJ et al. Is cerebrospinal fluid shunting in idiopathic intracranial hypertension worthwhile? A 10-year review. *Cephalalgia.* 2011 Oct 3. [Epub ahead of print] [PMID: 21968519]

Wall M. Idiopathic intracranial hypertension. *Neurol Clin.* 2010 Aug;28(3):593–617. [PMID: 20637991]

OCULAR MOTOR PALSIES

In complete **third nerve paralysis**, there is ptosis with a divergent and slightly depressed eye. Extraocular movements are restricted in all directions except laterally (preserved lateral rectus function). Intact fourth nerve (superior oblique) function is detected by the presence of inward rotation on attempted depression of the eye.

Pupillary involvement (dilated pupil that does not constrict to light) is an important sign differentiating “surgical,” including traumatic, from “medical” causes of isolated third nerve palsy. Compressive lesions of the third nerve—eg, aneurysm of the posterior communicating artery and uncus herniation due to a supratentorial mass lesion—characteristically have pupillary involvement. Patients with painful acute isolated third nerve palsy and pupillary involvement should be assumed to have a posterior communicating artery aneurysm until this has been excluded. Pituitary apoplexy is a rarer cause. Medical causes of isolated third nerve palsy include diabetes mellitus, hypertension, and giant cell arteritis.

Fourth nerve paralysis causes upward deviation of the eye with failure of depression on adduction. In acquired cases, there is vertical and torsional diplopia that are most apparent on looking down. Trauma is a major cause of acquired—particularly bilateral—fourth nerve palsy, but posterior fossa tumor and medical causes such as in third nerve palsies should also be considered. Similar clinical features are seen in congenital cases due to developmental anomaly of the nerve, muscle or tendon.

Sixth nerve paralysis causes convergent squint in the primary position with failure of abduction of the affected eye, producing horizontal diplopia that increases on gaze to the affected side and on looking into the distance. It is an important sign of raised intracranial pressure. Sixth nerve palsy may also be due to trauma, neoplasms,

brainstem lesions, or medical causes such as in third nerve palsy.

An intracranial or intraorbital mass lesion should be considered in any patient with an isolated ocular motor palsy. In patients with isolated ocular motor nerve palsies presumed to be due to medical causes, brain MRI is generally only necessary if recovery has not begun within 3 months, although some authors suggest that it should be undertaken in all cases.

Ocular motor nerve palsies occurring in association with other neurologic signs may be due to lesions in the brainstem, the cavernous sinus, or in the orbit. Lesions around the cavernous sinus involve the upper divisions of the trigeminal nerve, the ocular motor nerves, and occasionally the optic chiasm. Orbital apex lesions involve the optic nerve and the ocular motor nerves.

Myasthenia gravis and dysthyroid eye disease should also be considered in the differential diagnosis of disordered extraocular movements.

▶ When to Refer

- Any patient with recent onset isolated third nerve palsy, particularly if there is pupillary involvement or pain, must be referred emergently for neurologic assessment and possible CT, MR, or catheter angiography for intracranial aneurysm.
- All patients with recent onset double vision should be referred urgently to an ophthalmologist or neurologist, particularly if there is multiple cranial nerve dysfunction or other neurologic abnormalities.

▶ When to Admit

Patients with double vision due to giant cell arteritis may require emergency admission for high-dose corticosteroid therapy and close monitoring to ensure that treatment is adequate.

Brazis PW. Isolated palsies of cranial nerves III, IV, and VI. *Semin Neurol.* 2009 Feb;29(1):14–28. [PMID: 19214929]

Kim JH et al. Absence of the trochlear nerve in patients with superior oblique hypoplasia. *Ophthalmology.* 2010 Nov; 117(11):2208–13. [PMID: 20570358]

Kim JH et al. MR imaging of familial superior oblique hypoplasia. *Br J Ophthalmol.* 2010 Mar;94(3):346–50. [PMID: 19822909]

Lueck CJ. Infranuclear ocular motor disorders. *Handb Clin Neurol.* 2011;102:281–318. [PMID: 21601071]

Mittal V et al. Etiology and treatment of pediatric sixth nerve palsy. *J AAPOS.* 2011 Oct;15(5):507–8. [PMID: 21958902]

Mizuno T. Pituitary apoplexy with third cranial nerve palsy after off-pump coronary artery bypass grafting. *Interact Cardiovasc Thorac Surg.* 2011 Aug;13(2):240–2. [PMID: 21527463]

Mollan SP et al. Aetiology and outcomes of adult superior oblique palsies: a modern series. *Eye (Lond).* 2009 Mar; 23(3):640–4. [PMID: 18327160]

Murchison AP et al. Neuroimaging and acute ocular motor mononeuropathies: a prospective study. *Arch Ophthalmol.* 2011 Mar;129(3):301–5. [PMID: 21402985]

Panagiotopoulos V et al. Recovery of ophthalmoplegia after endovascular treatment of intracranial aneurysms. *AJNR Am J Neuroradiol.* 2011 Feb;32(2):276–82. [PMID: 21071536]

Tamhankar MA et al. Adult hypertropia: a guide to diagnostic evaluation based on review of 300 patients. *Eye (Lond)*. 2011 Jan;25(1):91–6. [PMID: 21057518]
 Zhang SH et al. Endovascular management and recovery from oculomotor nerve palsy associated with aneurysms of the posterior communicating artery. *World Neurosurg*. 2010 Aug–Sep;74(2–3):316–9. [PMID: 21492565]

DYSTHYROID EYE DISEASE

Dysthyroid eye disease is a syndrome of clinical and orbital imaging abnormalities caused by deposition of mucopolysaccharides and infiltration with chronic inflammatory cells of the orbital tissues, particularly the extraocular muscles. It usually occurs in association with autoimmune hyperthyroidism, when it is known as Graves disease. However clinical or laboratory evidence of thyroid dysfunction and thyroid autoantibodies may not be detectable at presentation or even on long-term follow-up. Radioiodine therapy and cigarette smoking increase its severity.

Clinical Findings

The primary clinical features are proptosis, lid retraction and lid lag, conjunctival chemosis and episcleral inflammation, and extraocular muscle dysfunction. Resulting symptoms are cosmetic abnormalities, surface irritation, which usually responds to artificial tears, and diplopia, which should be treated conservatively (eg, with prisms) in the active stages of the disease and only by surgery when the disease has been static for at least 6 months. The important complications are corneal exposure and optic nerve compression, both of which may lead to marked visual loss. The primary imaging features are enlargement of the extraocular muscles, usually affecting both orbits.

Treatment

Treatment options for optic nerve compression or severe corneal exposure are intravenous pulse methylprednisolone therapy (eg, 1 g daily for 3 days, repeated weekly for 3 weeks), oral prednisolone 80–100 mg/d, radiotherapy, or surgery (usually consisting of extensive removal of bone from the medial, inferior, and lateral walls of the orbit), either singly or in combination.

The optimal management of moderately severe dysthyroid eye disease without visual loss is controversial. Systemic corticosteroids and radiotherapy have not been shown to provide definite long-term benefit. Peribulbar corticosteroid injections have been advocated. Surgical decompression may be justified in patients with marked proptosis. Lateral tarsorrhaphy may be used for moderately severe corneal exposure. Other procedures are particularly useful for correcting lid retraction but should not be undertaken until the orbital disease is quiescent and orbital decompression or extraocular muscle surgery has been undertaken. Oral selenium seems to be beneficial in mild disease. Establishing and maintaining euthyroidism are important in all cases.

When to Refer

All patients with dysthyroid eye disease should be referred to an ophthalmologist, urgently if there is reduced vision.

- Bahn RS. Graves' ophthalmopathy. *N Engl J Med*. 2010 Feb 25; 362(8):726–38. [PMID: 20181974]
 Bartalena L. The dilemma of how to manage Graves' hyperthyroidism in patients with associated orbitopathy. *J Clin Endocrinol Metab*. 2011 Mar;96(3):592–9. [PMID: 21190983]
 Douglas RS et al. The pathophysiology of thyroid eye disease: implications for immunotherapy. *Curr Opin Ophthalmol*. 2011 Sep;22(5):385–90. [PMID: 21730841]
 Estcourt S et al. Quality of life in thyroid eye disease: impact of quality of care. *Eur J Endocrinol*. 2011 May;164(5):649–55. [PMID: 21367964]
 Hegedüs L et al. Targeted biological therapies for Graves' disease and thyroid-associated ophthalmopathy. Focus on B-cell depletion with Rituximab. *Clin Endocrinol (Oxf)*. 2011 Jan;74(1):1–8. [PMID: 20455896]
 Marcocci C et al. Selenium and the course of mild Graves' orbitopathy. *N Engl J Med*. 2011 May 19;364(20):1920–31. [PMID: 21591944]
 Rajendram R et al. Smoking and strabismus surgery in patients with thyroid eye disease. *Ophthalmology*. 2011 Dec;118(12): 2493–7. [PMID: 21872937]
 Soeters MR et al. Optimal management of Graves orbitopathy: a multidisciplinary approach. *Neth J Med*. 2011 Jul–Aug;69(7): 302–8. [PMID: 21934174]
 Zang S et al. Clinical review: Intravenous glucocorticoids for Graves' orbitopathy: efficacy and morbidity. *J Clin Endocrinol Metab*. 2011 Feb;96(2):320–32. [PMID: 21239515]

ORBITAL CELLULITIS

Orbital cellulitis is characterized by fever, proptosis, restriction of extraocular movements, and swelling with redness of the lids. Immediate treatment with intravenous antibiotics is necessary to prevent optic nerve damage and spread of infection to the cavernous sinuses, meninges, and brain. Infection of the paranasal sinuses is the usual underlying cause; examples of infecting organisms include *S pneumoniae*, other streptococci, *H influenzae* and, less commonly, *S aureus*. Penicillinase-resistant penicillin, such as nafcillin, is recommended, possibly together with metronidazole or clindamycin to treat anaerobic infections (Table 30–5). If trauma is the underlying cause, a cephalosporin, such as cefazolin or ceftriaxone, should be added to ensure coverage for *S aureus* and group A β -hemolytic streptococci. Vancomycin or clindamycin may be required if there is concern about methicillin-resistant *S aureus* (MRSA). For patients with penicillin hypersensitivity, vancomycin, levofloxacin, and metronidazole are recommended. The response to antibiotics is usually excellent, but abscess formation may necessitate surgical drainage. In immunocompromised patients, zygomycosis must be considered.

When to Refer

All patients with suspected orbital cellulitis must be referred emergently to an ophthalmologist.

Brook I. Role of methicillin-resistant *Staphylococcus aureus* in head and neck infections. *J Laryngol Otol.* 2009 Dec;123(12):1301–7. [PMID: 19664316]

Hauser A et al. Periorbital and orbital cellulitis. *Pediatr Rev.* 2010 Jun;31(6):242–9. [PMID: 20516236]

Mahalingam-Dhingra A et al. Orbital and periorbital infections: a national perspective. *Arch Otolaryngol Head Neck Surg.* 2011 Aug;137(8):769–73. [PMID: 21844410]

Mallis A et al. Rhinocerebral mucormycosis: an update. *Eur Rev Med Pharmacol Sci.* 2010 Nov;14(11):987–92. [PMID: 21284348]

Pandian DG et al. Nine years' review on preseptal and orbital cellulitis and emergence of community-acquired methicillin-resistant *Staphylococcus aureus* in a tertiary hospital in India. *Indian J Ophthalmol.* 2011 Nov;59(6):431–5. [PMID: 22011486]

OCULAR TRAUMA

1. Conjunctival & Corneal Foreign Bodies

If a patient complains of “something in my eye” and gives a consistent history, a foreign body is usually present on the cornea or under the upper lid even though it may not be visible. Visual acuity should be tested before treatment is instituted, as a basis for comparison in the event of complications.

After a local anesthetic (eg, proparacaine, 0.5%) is instilled, the eye is examined with a hand flashlight, using oblique illumination, and loupe. Corneal foreign bodies may be made more apparent by the instillation of sterile fluorescein. They are then removed with a sterile wet cotton-tipped applicator or hypodermic needle. Polymyxin-bacitracin ophthalmic ointment should be instilled. It is not necessary to patch the eye.

Steel foreign bodies usually leave a diffuse rust ring. This requires excision of the affected tissue and is best done under local anesthesia using a slit lamp. **Caution:** Anesthetic drops should not be given to the patient for self-administration.

If there is no infection, a layer of corneal epithelial cells will line the crater within 24 hours. The intact corneal epithelium forms an effective barrier to infection, but once it is disturbed the cornea becomes extremely susceptible to infection. Early infection is manifested by a white necrotic area around the crater and a small amount of gray exudate.

In the case of a foreign body under the upper lid, a local anesthetic is instilled and the lid is everted by grasping the lashes gently and exerting pressure on the mid portion of the outer surface of the upper lid with an applicator. If a foreign body is present, it can easily be removed by passing a wet sterile cotton-tipped applicator across the conjunctival surface.

► When to Refer

Urgent referral to an ophthalmologist should be arranged if a corneal foreign body cannot be removed or if there is suspicion of corneal infection.

Yagci A et al. Topical anesthetic abuse keratopathy: a commonly overlooked health care problem. *Cornea.* 2011 May;30(5):571–5. [PMID: 21490529]

2. Intraocular Foreign Body

Intraocular foreign body requires emergency treatment by an ophthalmologist. Patients giving a history of “something hitting the eye”—particularly while hammering on metal or using grinding equipment—must be assessed for this possibility, especially when no corneal foreign body is seen, a corneal or scleral wound is apparent, or there is marked visual loss or media opacity. Such patients must be treated as for corneal laceration (see below) and referred without delay. Intraocular foreign bodies significantly increase the risk of intraocular infection.

► When to Refer

Patients with suspected intraocular foreign body must be referred emergently to an ophthalmologist.

Bhagat N et al. Post-traumatic infectious endophthalmitis. *Surv Ophthalmol.* 2011 May–Jun;56(3):214–51. [PMID: 21397289]

Choovuthayakorn J et al. Predictive factors and outcomes of posterior segment intraocular foreign bodies. *Eye (Lond).* 2011 Sep 16. [Epub ahead of print] [PMID: 21921948]

Zhang Y et al. Intraocular foreign bodies in China: clinical characteristics, prognostic factors, and visual outcomes in 1,421 eyes. *Am J Ophthalmol.* 2011 Jul;152(1):66–73. [PMID: 21529762]

3. Corneal Abrasions

A patient with a corneal abrasion complains of severe pain and photophobia. There is often a history of trauma to the eye, commonly involving a fingernail, piece of paper, or contact lens. Visual acuity is recorded, and the cornea and conjunctiva are examined with a light and loupe to rule out a foreign body. If an abrasion is suspected but cannot be seen, sterile fluorescein is instilled into the conjunctival sac: the area of corneal abrasion will stain a deeper green than the surrounding cornea.

Treatment includes polymyxin-bacitracin ophthalmic ointment, mydriatic (cyclopentolate 1%), and analgesics either topical or oral nonsteroidal anti-inflammatory agents. Padding the eye is probably not helpful for small abrasions. Recurrent corneal erosion may follow corneal abrasions.

4. Contusions

Contusion injuries of the eye and surrounding structures may cause ecchymosis (“black eye”), subconjunctival hemorrhage, edema or rupture of the cornea, hemorrhage into the anterior chamber (hyphema), rupture of the root of the iris (iridodialysis), paralysis of the pupillary sphincter, paralysis of the muscles of accommodation, cataract, dislocation of the lens, vitreous hemorrhage, retinal hemorrhage and edema (most common in the macular area), detachment of the retina, rupture of the choroid, fracture of the orbital floor (“blowout fracture”), or optic nerve injury. Many of these injuries are immediately obvious; others may not become apparent for days or weeks. The possibility of globe injury must always be considered in patients with facial injury, particularly if there is an orbital fracture. Patients with moderate to severe contusions should be seen by an ophthalmologist.



▲ **Figure 7-7.** Severe ocular injury with total hyphema. (Courtesy of James Augsburger; Reproduced, with permission, from Riordan-Eva P, Cunningham ET Jr. *Vaughn & Asbury's General Ophthalmology*, 18th edition, McGraw-Hill, 2011.)

Any injury causing hyphema involves the danger of secondary hemorrhage, which may cause intractable glaucoma with permanent visual loss (Figure 7–7). The patient should be advised to rest until complete resolution has occurred. Daily ophthalmologic assessment is essential. Aspirin and any drugs inhibiting coagulation increase the risk of secondary hemorrhage and are to be avoided. Sick cell anemia or trait adversely affects outcome.

► When to Refer

Patients with moderate or severe ocular contusion should be referred to an ophthalmologist, emergently if there is hyphema.

de Silva DJ et al. Orbital blowout fractures and race. *Ophthalmology*. 2011 Aug;118(8):1677–80. [PMID: 21684604]
 Gharaibeh A et al. Medical interventions for traumatic hyphema. *Cochrane Database Syst Rev*. 2011 Jan 19;1:CD005431. [PMID: 21249670]
 Gosau M et al. Retrospective analysis of orbital floor fractures—complications, outcome, and review of literature. *Clin Oral Investig*. 2011 Jun;15(3):305–13. [PMID: 20165966]
 Nowinski D et al. Treatment of orbital fractures: evaluation of surgical techniques and materials for reconstruction. *J Craniofac Surg*. 2010 Jul;21(4):1033–7. [PMID: 20613564]
 Poeschl PW et al. Functional outcome after surgical treatment of orbital floor fractures. *Clin Oral Investig*. 2011 Aug 20. [Epub ahead of print] [PMID: 21858424]
 Scott R. The injured eye. *Philos Trans R Soc Lond B Biol Sci*. 2011 Jan 27;366(1562):251–60. [PMID: 21149360]
 Wei LA et al. Pediatric orbital floor fractures. *J AAPOS*. 2011 Apr;15(2):173–80. [PMID: 21596296]

5. Lacerations

A. Lids

If the lid margin is lacerated, the patient should be referred for specialized care, since permanent notching may result.

Lacerations of the lower eyelid near the inner canthus often sever the lower canaliculus, for which canalicular intubation is likely to be required. Lid lacerations not involving the margin may be sutured like any skin laceration.

Murchison AP et al. Management of eyelid injuries. *Facial Plast Surg*. 2010 Dec;26(6):464–81. [PMID: 21086233]
 Priel A et al. Medial canthal degloving injuries: the triad of telecanthus, ptosis, and lacrimal trauma. *Plast Reconstr Surg*. 2011 Oct;128(4):300e–5e. [PMID: 21921742]
 Tint NL et al. Eyelid avulsion repair with bi-canalicular silicone stenting without medial canthal tendon reconstruction. *Br J Ophthalmol*. 2011 Oct;95(10):1389–92. [PMID: 21775766]

B. Conjunctiva


In lacerations of the conjunctiva, sutures are not necessary. To prevent infection, sulfonamides or other antibiotics are instilled into the eye until the laceration is healed.

C. Cornea or Sclera

Patients with suspected corneal or scleral lacerations must be seen promptly by an ophthalmologist (Figure 7–8). Manipulation is kept to a minimum, since pressure may result in extrusion of the intraocular contents. The eye is bandaged lightly and covered with a metal shield that rests on the orbital bones above and below. The patient should be instructed not to squeeze the eye shut and to remain still. The eye is routinely imaged by radiography, and CT scanning if necessary, to identify and localize any metallic intraocular foreign body. MRI is contraindicated because of the risk of movement of the foreign body in the magnetic field. Endophthalmitis occurs in over 5% of open globe injuries.

► When to Refer

Patients with suspected globe laceration must be referred emergently to an ophthalmologist.



▲ **Figure 7-8.** Corneal laceration with extrusion of iris. (Courtesy of James Augsburger. Reproduced, with permission, from Riordan-Eva P, Cunningham ET Jr. *Vaughn & Asbury's General Ophthalmology*, 18th edition, McGraw-Hill, 2011.)

Agrawal R et al. Prognostic factors for vision outcome after surgical repair of open globe injuries. *Indian J Ophthalmol*. 2011 Nov;59(6):465–70. [PMID: 22011491]

Dunkin JM et al. Globe trauma. *Semin Ultrasound CT MR*. 2011 Feb;32(1):51–6. [PMID: 21277491]

Faghihi H et al. Posttraumatic endophthalmitis: Report No. 2. *Retina*. 2011 Jul 19. [Epub ahead of print] [PMID: 21775927]

Kanoff JM et al. Characteristics and outcomes of work-related open globe injuries. *Am J Ophthalmol*. 2010 Aug;150(2):265–269.e2. [PMID: 20522411]

Lesniak SP et al. Twelve-year review of pediatric traumatic open globe injuries in an urban U.S. population. *J Pediatr Ophthalmol Strabismus*. 2011 Jul 19:1–7. [PMID: 21766730]

Patel SN et al. Diagnostic value of clinical examination and radiographic imaging in identification of intraocular foreign bodies in open globe injury. *Eur J Ophthalmol*. 2011 May 17. [Epub ahead of print] [PMID: 21607931]

ULTRAVIOLET KERATITIS (Actinic Keratitis)

Ultraviolet burns of the cornea are usually caused by use of a sunlamp without eye protection, exposure to a welding arc, or exposure to the sun when skiing (“snow blindness”). There are no immediate symptoms, but about 6–12 hours later the patient complains of agonizing pain and severe photophobia. Slit-lamp examination after instillation of sterile fluorescein shows diffuse punctate staining of both corneas.

Treatment consists of binocular patching and instillation of 1–2 drops of 1% cyclopentolate (to relieve the discomfort of ciliary spasm). All patients recover within 24–48 hours without complications. Local anesthetics should not be prescribed because they delay corneal epithelial healing.

Yagci A et al. Topical anesthetic abuse keratopathy: a commonly overlooked health care problem. *Cornea*. 2011 May;30(5):571–5. [PMID: 21490529]

CHEMICAL CONJUNCTIVITIS & KERATITIS

Chemical burns are treated by copious irrigation of the eyes with tap water, saline solution, or buffering solution if available as soon as possible after exposure. Neutralization of an acid with an alkali or vice versa generates heat and may cause further damage. Alkali injuries are more serious and require prolonged irrigation, since alkalies are not precipitated by the proteins of the eye as are acids. It is important to remove any retained particulate matter such as is typically present in injuries involving cement and building plaster. This may require double eversion of the upper lid. The pupil should be dilated with 1% cyclopentolate, 1 drop twice a day, to relieve discomfort and prophylactic topical antibiotics should be started. In moderate to severe injuries, intensive topical corticosteroids and topical and systemic vitamin C are also necessary. Complications include mucus deficiency, scarring of the cornea and conjunctiva, symblepharon (adhesions between the tarsal and bulbar conjunctiva), tear duct obstruction, and secondary

infection. It can be difficult to assess severity of chemical burns without slit-lamp examination.

Chau JP et al. A systematic review of methods of eye irrigation for adults and children with ocular chemical burns. *Worldviews Evid Based Nurs*. 2011 Jun 7. [Epub ahead of print] [PMID: 21649853]

Erdurman FC et al. Ocular injuries from improvised explosive devices. *Eye (Lond)*. 2011 Nov;25(11):1491–8. [PMID: 21852806]

Gicquel JJ. Management of ocular surface chemical burns. *Br J Ophthalmol*. 2011 Feb;95(2):159–61. [PMID: 21071758]

Gupta N et al. Comparison of prognostic value of Roper Hall and Dua classification systems in acute ocular burns. *Br J Ophthalmol*. 2011 Feb;95(2):194–8. [PMID: 20805137]

Hong J et al. Clinical characteristics and visual outcome of severe ocular chemical injuries in Shanghai. *Ophthalmology*. 2010 Dec;117(12):2268–72. [PMID: 20591491]

Le Q et al. Vision-related quality of life in patients with ocular chemical burns. *Invest Ophthalmol Vis Sci*. 2011 Nov 21;52(12):8951–6. [PMID: 22003122]

Lin Y et al. Prognostic factors and visual outcome for fireworks-related burns during spring festival in South China. *J Burn Care Res*. 2011 Sep 28. [Epub ahead of print] [PMID: 21959209]

Rama P et al. Limbal stem-cell therapy and long-term corneal regeneration. *N Engl J Med*. 2010 Jul 8;363(2):147–55. [PMID: 20573916]

Ratnapalan S et al. Causes of eye burns in children. *Pediatr Emerg Care*. 2011 Feb;27(2):151–6. [PMID: 21293228]

Rodrigues Z. Irrigation of the eye after alkaline and acidic burns. *Emerg Nurse*. 2009 Dec;17(8):26–9. [PMID: 20043429]

Sharifipour F et al. Oxygen therapy for acute ocular chemical or thermal burns: a pilot study. *Am J Ophthalmol*. 2011 May;151(5):823–8. [PMID: 21310381]

Tandon R et al. Amniotic membrane transplantation as an adjunct to medical therapy in acute ocular burns. *Br J Ophthalmol*. 2011 Feb;95(2):199–204. [PMID: 20675729]

TREATMENT OF OCULAR DISORDERS

Table 7–2 lists commonly used ophthalmic drugs and their indications and costs.

PRECAUTIONS IN MANAGEMENT OF OCULAR DISORDERS

1. Use of Local Anesthetics

Unsupervised self-administration of local anesthetics is dangerous because the patient may further injure an anesthetized eye without knowing it. The drug may also interfere with the normal healing process.

Yagci A et al. Topical anesthetic abuse keratopathy: a commonly overlooked health care problem. *Cornea*. 2011 May;30(5):571–5. [PMID: 21490529]

2. Pupillary Dilation

Dilating the pupil can very occasionally precipitate acute glaucoma if the patient has a narrow anterior chamber angle and should be undertaken with caution if the anterior chamber is obviously shallow (readily determined by oblique illumination of the anterior segment of the eye). A

short-acting mydriatic such as tropicamide should be used and the patient warned to report immediately if ocular discomfort or redness develops. Angle closure is more likely to occur if pilocarpine is used to overcome pupillary dilation than if the pupil is allowed to constrict naturally.

3. Corticosteroid Therapy

Repeated use of local corticosteroids presents several hazards: herpes simplex (dendritic) keratitis, fungal infection, open-angle glaucoma, and cataract formation. Furthermore, perforation of the cornea may occur when corticosteroids are used for herpes simplex keratitis. Topical nonsteroidal anti-inflammatory agents are being used increasingly. The potential for causing or exacerbating systemic hypertension, diabetes mellitus, gastritis, osteoporosis, or glaucoma must always be borne in mind when systemic corticosteroids are prescribed, such as for uveitis or giant cell arteritis.

Razeghinejad MR et al. Steroid-induced iatrogenic glaucoma. *Ophthalmic Res.* 2011 Jul 13;47(2):66–80. [PMID: 21757964]

4. Contaminated Eye Medications

Ophthalmic solutions are prepared with the same degree of care as fluids intended for intravenous administration, but once bottles are opened there is always a risk of contamination, particularly with solutions of tetracaine, proparacaine, fluorescein, and any preservative-free preparations. The most dangerous is fluorescein, as this solution is frequently contaminated with *P aeruginosa*, which can rapidly destroy the eye. Sterile fluorescein filter paper strips are recommended for use in place of fluorescein solutions.

Whether in plastic or glass containers, eye solutions should not remain in use for long periods after the bottle is opened. Four weeks after opening is an absolute maximal time to use a solution containing preservatives before discarding. Preservative-free preparations should be kept refrigerated and discarded within 1 week after opening.

If the eye has been injured accidentally or by surgical trauma, it is of the greatest importance to use freshly opened bottles of sterile medications or single-use eye-dropper units.

5. Toxic & Hypersensitivity Reactions to Topical Therapy

In patients receiving long-term topical therapy, local toxic or hypersensitivity reactions to the active agent or preservatives may develop, especially if there is inadequate tear secretion. Preservatives in contact lens cleaning solutions may produce similar problems. Burning and soreness are exacerbated by drop instillation or contact lens insertion; occasionally, fibrosis and scarring of the conjunctiva and cornea may occur.

An antibiotic instilled into the eye can sensitize the patient to that drug and cause an allergic reaction upon subsequent systemic administration.

6. Systemic Effects of Ocular Drugs

The systemic absorption of certain topical drugs (through the conjunctival vessels and lacrimal drainage system) must be considered when there is a systemic medical contraindication to the use of the drug. Ophthalmic solutions of the nonselective β -blockers, eg, timolol, may worsen bradycardia, congestive heart failure, or asthma. Phenylephrine eye drops may precipitate hypertensive crises and angina. Also to be considered are adverse interactions between systemically administered and ocular drugs. Using only 1 or 2 drops at a time and a few minutes of nasolacrimal occlusion or eyelid closure ensure maximum efficacy and decrease systemic side effects of topical agents.

ADVERSE OCULAR EFFECTS OF SYSTEMIC DRUGS

Systemically administered drugs produce a wide variety of adverse effects on the visual system. Table 7–3 lists the major examples.

Blomquist PH. Ocular complications of systemic medications. *Am J Med Sci.* 2011 Jul;342(1):62–9. [PMID: 21139494]
 Fraunfelder FW. Ocular & systemic side effects of drugs. In: *Vaughan & Asbury's General Ophthalmology*, 18th ed. Riordan-Eva P et al (editors). McGraw-Hill, 2011.
 Razeghinejad MR et al. Iatrogenic glaucoma secondary to medications. *Am J Med.* 2011 Jan;124(1):20–5. [PMID: 21092926]
 Razeghinejad MR et al. Non-steroidal drug-induced glaucoma. *Eye (Lond).* 2011 Aug;25(8):971–80. [PMID: 21637303]

Table 7–3. Adverse ophthalmic effects of systemic drugs.

Drug	Possible Side Effects
Respiratory drugs	
Anticholinergic bronchodilators	Angle-closure glaucoma due to mydriasis, blurring of vision due to cycloplegia, dry eyes.
Oxygen	Retinopathy of prematurity.
Sympathomimetic bronchodilators and decongestants	Angle-closure glaucoma due to mydriasis.
Cardiovascular system drugs	
α_2 -Antagonists (terazosin, doxazosin)	Complications during (floppy-iris syndrome) and after cataract surgery.

(continued)

Table 7-3. Adverse ophthalmic effects of systemic drugs. (continued)

Drug	Possible Side Effects
Amiodarone	Corneal deposits (vortex keratopathy), optic neuropathy, thyroid ophthalmopathy.
Carbonic anhydrase inhibitors (acetazolamide)	Stevens-Johnson syndrome, near-sightedness, angle-closure glaucoma due to ciliary body swelling.
Digitalis	Disturbance of color vision, photopsia.
Phosphodiesterase type 5 inhibitors (eg, sildenafil)	Disturbance of color vision, ischemic optic neuropathy.
Statins	Extraocular muscle paralysis (myasthenic syndrome).
Thiazides	Xanthopsia (yellow vision), near-sightedness.
Gastrointestinal drugs	
Anticholinergic agents	Angle-closure glaucoma due to mydriasis, blurring of vision due to cycloplegia, dry eyes.
Urinary tract drugs	
α_2 -Antagonists (tamsulosin, alfuzosin, terazosin, doxazosin)	Complications during (floppy-iris syndrome) and after cataract surgery.
Central nervous system drugs	
Amphetamines	Widening of palpebral fissure, blurring of vision due to mydriasis, elevated intraocular pressure.
Anticholinergic agents including preoperative medications	Angle-closure glaucoma due to mydriasis, blurring of vision due to cycloplegia, dry eyes.
Diazepam	Nystagmus.
Haloperidol	Capsular cataract.
Lithium carbonate	Proptosis, oculozytic crisis, nystagmus.
Monoamine oxidase inhibitors	Nystagmus.
Morphine	Miosis.
Neostigmine	Nystagmus, miosis.
Paroxetine	Angle-closure glaucoma.
Phenothiazines	Pigmentary deposits in conjunctiva, cornea, lens, and retina, oculozytic crisis.
Phenytoin	Nystagmus.
Risperidone	Complications during (floppy-iris syndrome) and after cataract surgery.
Thioridazine	Corneal and lens deposits, retinopathy, oculozytic crisis.
Topiramate	Angle-closure glaucoma due to ciliary body swelling, near-sightedness.
Tricyclic agents	Angle-closure glaucoma due to mydriasis, blurring of vision due to cycloplegia.
Vigabatrin	Visual field constriction.
Obstetric drugs	
Sympathomimetic tocolytics	Angle-closure glaucoma due to mydriasis.
Hormonal agents	
Female sex hormones	Retinal artery occlusion, retinal vein occlusion, papilledema, cranial nerve palsies, ischemic optic neuropathy.
Tamoxifen	Crystalline retinal and corneal deposits, optic neuropathy.
Immunomodulators	
Alpha-interferon	Retinopathy, keratoconjunctivitis, dry eyes, optic neuropathy.
Corticosteroids	Cataract (posterior subcapsular); susceptibility to viral (herpes simplex), bacterial, and fungal infections; steroid-induced glaucoma.
Cyclosporine	Posterior reversible leukoencephalopathy.
Tacrolimus	Optic neuropathy, posterior reversible leukoencephalopathy.

(continued)

Table 7-3. Adverse ophthalmic effects of systemic drugs. (continued)

Drug	Possible Side Effects
Antibacterials	
Chloramphenicol	Optic neuropathy.
Ethambutol	Optic neuropathy.
Fluoroquinolones	Diplopia.
Isoniazid	Optic neuropathy.
Linezolid	Optic neuropathy.
Streptomycin	Optic neuropathy, Stevens-Johnson syndrome.
Sulfonamides	Stevens-Johnson syndrome, near-sightedness, angle-closure glaucoma due to ciliary body swelling.
Tetracycline, doxycycline, minocycline	Papilledema.
Antimalarial agents	
Chloroquine, hydroxychloroquine	Retinal degeneration principally involving the macula, keratopathy.
Quinine	Retinal toxicity, pupillary abnormalities.
Amebicides	
Iodochlorhydroxyquin	Optic neuropathy.
Chemotherapeutic agents	
Chlorambucil	Optic neuropathy.
Cisplatin	Optic neuropathy
Fluorouracil	Lacrimal obstruction.
Vincristine	Optic neuropathy.
Chelating agents	
Deferoxamine	Retinopathy, optic neuropathy, lens opacity.
Penicillamine	Ocular pemphigoid, optic neuropathy, extraocular muscle paralysis (myasthenic syndrome).
Oral hypoglycemic agents	
Chlorpropamide	Refractive error, Stevens-Johnson syndrome, optic neuropathy.
Vitamins	
Vitamin A	Papilledema.
Vitamin D	Band-shaped keratopathy.
Antirheumatic agents	
Gold salts	Deposits in the cornea, conjunctiva, and lens.
Indomethacin	Corneal deposits.
Penicillamine	Ocular pemphigoid, optic neuropathy, extraocular muscle paralysis (myasthenic syndrome).
Phenylbutazone	Retinal hemorrhages.
Salicylates	Subconjunctival and retinal hemorrhages, nystagmus.
Dermatologic agents	
Retinoids (isotretinoin, tretinoin, acitretin, and etretinate)	Papilledema, blepharoconjunctivitis, corneal opacities, decreased contact lens tolerance, decreased dark adaptation, teratogenic ocular abnormalities.
Bisphosphonates	
Alendronate	Scleritis, episcleritis, uveitis.
Pamidronate	Scleritis, episcleritis, uveitis.

8

Ear, Nose, & Throat Disorders

Lawrence R. Lustig, MD, &
Joshua S. Schindler, MD

DISEASES OF THE EAR

HEARING LOSS

ESSENTIALS OF DIAGNOSIS

- ▶ Three main types of hearing loss: conductive, sensory, and neural.
- ▶ Most commonly due to cerumen impaction, transient eustachian tube dysfunction associated with upper respiratory tract infection, or age-related hearing loss.

▶ Classification & Epidemiology

Table 8–1 categorizes hearing loss as normal, mild, moderate, severe, and profound and outlines the vocal equivalent as well as the decibel range.

A. Conductive Hearing Loss

Conductive hearing loss results from dysfunction of the external or middle ear. There are four mechanisms, each resulting in impairment of the passage of sound vibrations to the inner ear: (1) obstruction (eg, cerumen impaction), (2) mass loading (eg, middle ear effusion), (3) stiffness effect (eg, otosclerosis), and (4) discontinuity (eg, ossicular disruption). Conductive losses in adults are most commonly due to cerumen impaction or transient eustachian tube dysfunction associated with upper respiratory tract infection. Persistent conductive losses usually result from chronic ear infection, trauma, or otosclerosis. Conductive hearing loss is often correctable with medical or surgical therapy—or in some cases both.

B. Sensory Hearing Loss

Sensory and neural causes of hearing loss are difficult to differentiate due to testing methodology, thus often referred to as ‘sensorineural.’ Sensory hearing loss results

from deterioration of the cochlea, usually due to loss of hair cells from the organ of Corti. Sensorineural losses in adults are common. The most common form is a gradually progressive, predominantly high-frequency loss with advancing age (presbycusis). Additional common causes include excessive noise exposure, head trauma, and systemic diseases. An individual’s genetic make-up influences all of these causes of hearing loss. Sensory hearing loss is usually not correctable with medical or surgical therapy but often may be prevented or stabilized. An exception is a sudden sensory hearing loss, which may respond to corticosteroids if delivered within several weeks of onset.

Huang Q et al. Age-related hearing loss or presbycusis. *Eur Arch Otorhinolaryngol*. 2010 Aug;267(8):1179–91. [PMID: 20464410]

Rauch SD. Clinical practice. Idiopathic sudden sensorineural hearing loss. *N Engl J Med*. 2008 Aug 21;359(8):833–40. [PMID: 18716300]

Rauch SD et al. Oral vs intratympanic corticosteroid therapy for idiopathic sudden sensorineural hearing loss: a randomized trial. *JAMA*. 2011 May 25;305(20):2071–9. [PMID: 21610239]

Shearer AE et al. Deafness in the genomics era. *Hear Res*. 2011 Dec;282(1–2):1–9. [PMID: 22016077]

C. Neural Hearing Loss

Neural hearing loss occurs with lesions involving the eighth nerve, auditory nuclei, ascending tracts, or auditory cortex. It is the least common clinically recognized cause of hearing loss. Causes include acoustic neuroma, multiple sclerosis, and auditory neuropathy.

Manchaiah VK et al. The genetic basis of auditory neuropathy spectrum disorder (ANSD). *Int J Pediatr Otorhinolaryngol*. 2011 Feb;75(2):151–8. [PMID: 21176974]

▶ Evaluation of Hearing (Audiology)

In a quiet room, the hearing level may be estimated by having the patient repeat aloud words presented in a soft whisper, a normal spoken voice, or a shout. A 512-Hz tuning fork is useful in differentiating conductive from

Table 8-1. Hearing loss classification.

Classification	Vocal Equivalent	Decibel (dB) Range
Normal	Soft whisper	0-20 dB
Mild	Soft spoken voice	20-40 dB
Moderate	Normal spoken	40-60 dB
Severe	Loud spoken voice	60-80 dB
Profound	Shout	>80 dB

sensorineural losses. In the **Weber test**, the tuning fork is placed on the forehead or front teeth. In conductive losses, the sound appears louder in the poorer-hearing ear, whereas in sensorineural losses it radiates to the better side. In the **Rinne test**, the tuning fork is placed alternately on the mastoid bone and in front of the ear canal. In conductive losses > 25dB, bone conduction exceeds air conduction; in sensorineural losses, the opposite is true.

Formal audiometric studies are performed in a sound-proofed room. Pure-tone thresholds in decibels (dB) are obtained over the range of 250–8000 Hz for both air and bone conduction. Conductive losses create a gap between the air and bone thresholds, whereas in sensorineural losses both air and bone thresholds are equally diminished. Speech discrimination measures the clarity of hearing, reported as percentage correct (90–100% is normal). The site of the lesion responsible for sensorineural loss (cochlea versus central auditory system) may be determined with auditory brainstem-evoked responses; however, an MRI scan is preferred for its better sensitivity and specificity in the evaluation of central lesions.

Every patient who complains of a hearing loss should be referred for audiologic evaluation unless the cause is easily remediable (eg, cerumen impaction, otitis media). Because idiopathic sudden sensorineural hearing loss requires treatment (corticosteroids) within a limited several week time period, any new-onset hearing loss without obvious ear pathology needs an immediate audiometric referral. Routine audiologic screening is recommended for adults who have been exposed to potentially injurious levels of noise or in those who have reached the age of 65, after which screening evaluations may be done every few years.

Isaacson B. Hearing loss. *Med Clin North Am.* 2010 Sep;94(5):973–88. [PMID: 20736107]

Jeger J. New horizons in speech audiometry? *J Am Acad Audiol.* 2010 Jul–Aug;21(7):424–5. [PMID: 20807478]

▶ Hearing Rehabilitation

Patients with hearing loss not correctable by medical therapy may benefit from hearing amplification. Contemporary hearing aids are comparatively free of distortion and have been miniaturized to the point where they often may be contained entirely within the ear canal or lie inconspicuously behind the ear. To optimize the benefit, a hearing aid

must be carefully selected to conform to the nature of the hearing loss. Digitally programmable hearing aids are widely available and allow optimization of speech intelligibility and improved performance in difficult listening circumstances. Aside from hearing aids, many assistive devices are available to improve comprehension in individual and group settings, to help with hearing television and radio programs, and for telephone communication.

For patients with conductive loss or unilateral profound sensorineural loss, the bone-anchored hearing aid uses an oscillating post drilled into the mastoid, directly stimulating the ipsilateral cochlea (for conductive losses) or contralateral ear (profound unilateral sensorineural loss).

For patients with severe to profound sensory hearing loss, the cochlear implant—an electronic device that is surgically implanted into the cochlea to stimulate the auditory nerve—offers socially beneficial auditory rehabilitation to most adults with acquired deafness and children with congenital or genetic deafness. New trends in cochlear implantation include its use for patients with only partial deafness, preserving residual hearing and allowing both acoustic and electrical hearing in the same ear, as well as bilateral cochlear implantation.

Carlson ML et al. Cochlear implantation in the octogenarian and nonagenarian. *Otol Neurotol.* 2010 Oct;31(8):1343–9. [PMID: 20729782]

Hol MK et al. Bone-anchored hearing aids in patients with acquired and congenital unilateral inner ear deafness (Baha CROS): clinical evaluation of 56 cases. *Ann Otol Rhinol Laryngol.* 2010 Jul;119(7):447–54. [PMID: 20734965]

Woodson EA et al. The hybrid cochlear implant: a review. *Adv Otorhinolaryngol.* 2010;67:125–34. [PMID: 19955729]

DISEASES OF THE AURICLE

Disorders of the auricle are for the most part dermatologic. Skin cancers due to sun exposure are common and may be treated with standard techniques. Traumatic auricular hematoma must be recognized and drained to prevent significant cosmetic deformity (cauliflower ear) or canal blockage resulting from dissolution of supporting cartilage. Similarly, cellulitis of the auricle must be treated promptly to prevent development of perichondritis and its resultant deformity. Relapsing polychondritis is a rheumatologic disorder often associated with recurrent, frequently bilateral, painful episodes of auricular erythema and edema. Treatment with corticosteroids may help forestall cartilage dissolution. Respiratory compromise may occur as a result of progressive involvement of the cartilaginous tracheobronchial tree. Chondritis and perichondritis may be differentiated from auricular cellulitis by sparing of involvement of the lobule, which does not contain cartilage.

Kubota T et al. Treatment of auricular hematoma by OK-432. *Otolaryngol Head Neck Surg.* 2010 Jun;142(6):863–6. [PMID: 20493359]

van der Hulst AE et al. A red ear. *J Pediatr.* 2009 Apr;154(4):624. [PMID: 19324228]

DISEASES OF THE EAR CANAL

1. Cerumen Impaction

Cerumen is a protective secretion produced by the outer portion of the ear canal. In most persons, the ear canal is self-cleansing. Recommended hygiene consists of cleaning the external opening with a washcloth over the index finger without entering the canal itself. In most cases, cerumen impaction is self-induced through ill-advised attempts at cleaning the ear. It may be relieved with detergent ear drops (eg, 3% hydrogen peroxide; 6.5% carbamide peroxide), mechanical removal, suction, or irrigation. Irrigation is performed with water at body temperature to avoid a vestibular caloric response. The stream should be directed at the posterior ear canal wall adjacent to the cerumen plug. Irrigation should be performed only when the tympanic membrane is known to be intact.

Use of jet irrigators designed for cleaning teeth (eg, WaterPik) for wax removal should be avoided since they may result in tympanic membrane perforations. Following professional irrigation, the ear canal should be thoroughly dried (eg, by instilling isopropyl alcohol or using a hair blow-dryer on low-power setting) to reduce the likelihood of inducing external otitis. Specialty referral for cleaning under microscopic guidance is indicated when the impaction is frequently recurrent, has not responded to routine measures, or if the patient has a history of chronic otitis media or tympanic membrane perforation.

Roland PS et al. Clinical practice guideline: cerumen impaction. *Otolaryngol Head Neck Surg.* 2008 Sep;139(3 Suppl 2):S1–S21. [PMID: 18707628]

2. Foreign Bodies

Foreign bodies in the ear canal are more frequent in children than in adults. Firm materials may be removed with a loop or a hook, taking care not to displace the object medially toward the tympanic membrane; microscopic guidance is helpful. Aqueous irrigation should not be performed for organic foreign bodies (eg, beans, insects), because water may cause them to swell. Living insects are best immobilized before removal by filling the ear canal with lidocaine.

Burton M et al. Foreign body in the external auditory canal. *Ear Nose Throat J.* 2009 Jul;88(7):988. [PMID: 19623522]

3. External Otitis

ESSENTIALS OF DIAGNOSIS

- ▶ Painful erythema and edema of the ear canal skin.
- ▶ Often with purulent exudate
- ▶ May evolve into osteomyelitis of the skull base, often called malignant external otitis, particularly in the diabetic or immunocompromised patient.

▶ General Considerations

External otitis presents with otalgia, frequently accompanied by pruritus and purulent discharge. There is often a history of recent water exposure (ie, swimmer's ear) or mechanical trauma (eg, scratching, cotton applicators). External otitis is usually caused by gram-negative rods (eg, *Pseudomonas*, *Proteus*) or fungi (eg, *Aspergillus*), which grow in the presence of excessive moisture. Persistent external otitis in the diabetic or immunocompromised patient may evolve into osteomyelitis of the skull base, often called **malignant external otitis**. Usually caused by *Pseudomonas aeruginosa*, osteomyelitis begins in the floor of the ear canal and may extend into the middle fossa floor, the clivus, and even the contralateral skull base.

▶ Clinical Findings

Examination reveals erythema and edema of the ear canal skin, often with a purulent exudate. Manipulation of the auricle often elicits pain. Because the lateral surface of the tympanic membrane is ear canal skin, it is often erythematous. However, in contrast to acute otitis media, it moves normally with pneumatic otoscopy. When the canal skin is very edematous, it may be impossible to visualize the tympanic membrane. **Malignant external otitis** usually presents with persistent foul aural discharge, granulations in the ear canal, deep otalgia, and in advanced cases, progressive cranial nerve palsies involving nerves VI, VII, IX, X, XI, or XII. Diagnosis is confirmed by the demonstration of osseous erosion on CT and radionuclide scanning.

▶ Treatment

Fundamental to the treatment of external otitis is protection of the ear from additional moisture and avoidance of further mechanical injury by scratching. In cases of swimmer's ear, acidification with a drying agent (ie, a 50/50 mixture of isopropyl alcohol/white vinegar) after getting moisture into the ear is often helpful. When infected, acidic otic antibiotic drops that contain either an aminoglycoside or fluoroquinolone antibiotic, with or without corticosteroids, are usually effective (eg, neomycin sulfate, polymyxin B sulfate, and hydrocortisone). Purulent debris filling the ear canal should be gently removed to permit entry of the topical medication. Drops should be used abundantly (five or more drops three or four times a day) to penetrate the depths of the canal. When substantial edema of the canal wall prevents entry of drops into the ear canal, a wick is placed to facilitate entry of the medication. In recalcitrant cases—particularly when cellulitis of the periauricular tissue has developed—oral fluoroquinolones (eg, ciprofloxacin, 500 mg twice daily for 1 week) are the drugs of choice because of their effectiveness against *Pseudomonas* species. Any case of persistent otitis externa in an immunocompromised or diabetic individual must be referred for specialty evaluation.

Treatment of **malignant external otitis** is medical, requiring prolonged antipseudomonal antibiotic administration, often for several months. Although intravenous therapy is often required (eg, ciprofloxacin 200–400 mg

every 12 hours), selected patients may be treated with oral ciprofloxacin (500–1000 mg twice daily), which has proved effective against many of the causative *Pseudomonas* strains. To avoid relapse, antibiotic therapy should be continued, even in the asymptomatic patient, until gallium scanning indicates a marked reduction in the inflammatory process. Surgical debridement of infected bone is reserved for cases of deterioration despite medical therapy.

- Carfrae MJ et al. Malignant otitis externa. *Otolaryngol Clin North Am.* 2008 Jun;41(3):537–49. [PMID: 18435997]
- Kaushik V et al. Interventions for acute otitis externa. *Cochrane Database Syst Rev.* 2010 Jan 20;(1):CD004740. [PMID: 20091565]
- Patmore H et al. Skull base infection presenting with multiple lower cranial nerve palsies. *Am J Otolaryngol.* 2010 Sep–Oct; 31(5):376–80. [PMID: 20015773]
- Roland PS et al; Cipro HC Study Group. A single topical agent is clinically equivalent to the combination of topical and oral antibiotic treatment for otitis externa. *Am J Otolaryngol.* 2008 Jul–Aug;29(4):255–61. [PMID: 18598837]
- Wall GM et al. Ciprofloxacin 0.3%/dexamethasone 0.1% sterile otic suspension for the topical treatment of ear infections: a review of the literature. *Pediatr Infect Dis J.* 2009 Feb;28(2): 141–4. [PMID: 19116600]

4. Pruritus

Pruritus of the external auditory canal, particularly at the meatus, is a common problem. While it may be associated with external otitis or with dermatologic conditions such as seborrheic dermatitis and psoriasis, most cases are self-induced either from excoriation or by overly zealous ear cleaning. To permit regeneration of the protective cerumen blanket, patients should be instructed to avoid use of soap and water or cotton swabs in the ear canal and avoid any scratching. Patients with excessively dry canal skin may benefit from application of mineral oil, which helps counteract dryness and repel moisture. When an inflammatory component is present, topical application of a corticosteroid (eg, 0.1% triamcinolone) may be beneficial. Symptomatic reduction of pruritus may also be obtained by use of oral antihistamines (eg, diphenhydramine, 25 mg orally at bedtime).

- Acar B et al. New treatment strategy and assessment questionnaire for external auditory canal pruritus: topical pimecrolimus therapy and Modified Itch Severity Scale. *J Laryngol Otol.* 2010 Feb;124(2):147–51. [PMID: 19922703]
- Garvey C et al. A review of common dermatologic disorders of the external ear. *J Am Acad Audiol.* 2008 Mar;19(3):226–32. [PMID: 18672650]

5. Exostoses & Osteomas

Bony overgrowths of the ear canal are a frequent incidental finding and occasionally have clinical significance. Clinically, they present as skin-covered bony mounds in the medial ear canal obscuring the tympanic membrane to a variable degree. Solitary osteomas are of no significance as long as they do not cause obstruction or infection. Multiple exostoses, which are generally acquired from repeated exposure to cold water (eg, “surfer’s ear”) often progress and require surgical removal.

- King JF et al. Laterality of exostosis in surfers due to evaporative cooling effect. *Otol Neurotol.* 2010 Feb;31(2):345–51. [PMID: 19806064]

6. Neoplasia

The most common neoplasm of the ear canal is squamous cell carcinoma (SCC). When an apparent otitis externa does not resolve on therapy, a malignancy should be suspected and biopsy performed. This disease carries a very high 5-year mortality rate because the tumor tends to invade the lymphatics of the cranial base and must be treated with wide surgical resection and radiation therapy. Adenomatous tumors, originating from the ceruminous glands, generally follow a more indolent course.

- Chang CH et al. Treatments and outcomes of malignant tumors of external auditory canal. *Am J Otolaryngol.* 2009 Jan–Feb; 30(1):44–8. [PMID: 19027512]
- Prabhu R et al. Squamous cell carcinoma of the external auditory canal: long-term clinical outcomes using surgery and external-beam radiotherapy. *Am J Clin Oncol.* 2009 Aug; 32(4):401–4. [PMID: 19398900]

DISEASES OF THE EUSTACHIAN TUBE

1. Eustachian Tube Dysfunction



ESSENTIALS OF DIAGNOSIS

- ▶ Aural fullness.
- ▶ Fluctuating hearing.
- ▶ Discomfort with barometric pressure change.
- ▶ At risk for serous otitis media.

The tube that connects the middle ear to the nasopharynx—the eustachian tube—provides ventilation and drainage for the middle ear cleft. It is normally closed, opening only during swallowing or yawning. When eustachian tube function is compromised, air trapped within the middle ear becomes absorbed and negative pressure results. The most common causes of eustachian tube dysfunction are diseases associated with edema of the tubal lining, such as viral upper respiratory tract infections and allergy. The patient usually reports a sense of fullness in the ear and mild to moderate impairment of hearing. When the tube is only partially blocked, swallowing or yawning may elicit a popping or crackling sound. Examination may reveal retraction of the tympanic membrane and decreased mobility on pneumatic otoscopy. Following a viral illness, this disorder is usually transient, lasting days to weeks. Treatment with systemic and intranasal decongestants (eg, pseudoephedrine, 60 mg orally every 4 hours; oxymetazoline, 0.05% spray every 8–12 hours) combined with autoinflation by forced exhalation against closed nostrils may hasten relief. Autoinflation should not be recommended to patients with active intranasal infection, since this maneuver may precipitate middle ear infection. Allergic patients

may also benefit from desensitization or intranasal corticosteroids (eg, beclomethasone dipropionate, two sprays in each nostril twice daily for 2–6 weeks). Air travel, rapid altitudinal change, and underwater diving should be avoided during an active phase of the disease.

Conversely, an overly patent eustachian tube, termed “patulous eustachian tube,” is a relatively uncommon problem, though may be quite distressing. Typical complaints include fullness in the ear and autophony, an exaggerated ability to hear oneself breathe and speak. A patulous eustachian tube may develop during rapid weight loss, or it may be idiopathic. In contrast to a hypofunctioning eustachian tube, the aural pressure is often made worse by exertion and may diminish during an upper respiratory tract infection. Although physical examination is usually normal, respiratory excursions of the tympanic membrane may occasionally be detected during vigorous breathing. Treatment includes avoidance of decongestant products, insertion of a ventilating tube to reduce the outward stretch of the eardrum during phonation, and, rarely, surgical narrowing of the eustachian tube.

Bartlett C et al. Simple mass loading of the tympanic membrane to alleviate symptoms of patulous eustachian tube. *J Otolaryngol Head Neck Surg.* 2010 Jun;39(3):259–68. [PMID: 20470670]

Caffier PP et al. Impact of laser eustachian tuboplasty on middle ear ventilation, hearing, and tinnitus in chronic tube dysfunction. *Ear Hear.* 2011 Feb;32(1):132–9. [PMID: 20585250]

Daudia A et al. Long-term middle-ear ventilation with subannular tubes. *J Laryngol Otol.* 2010 Sep;124(9):945–9. [PMID: 20403228]

2. Serous Otitis Media



ESSENTIALS OF DIAGNOSIS

- ▶ Blocked eustachian tube remains for a prolonged period.
- ▶ Resultant negative pressure will result in transudation of fluid.

Prolonged eustachian tube dysfunction with resultant negative middle ear pressure may cause a transudation of fluid. This condition, known as serous otitis media, is especially common in children because their eustachian tubes are narrower and more horizontal in orientation than those in adults. Serous otitis media is less common in adults, in whom it usually occurs after an upper respiratory tract infection, with barotraumas, or with chronic allergic rhinitis. In any adult with persistent unilateral serous otitis media, nasopharyngeal carcinoma must be excluded. The tympanic membrane in serous otitis media is dull and hypomobile, occasionally accompanied by air bubbles in the middle ear and conductive hearing loss. The treatment of serous otitis media is similar to that for eustachian tube dysfunction. A short course of oral corticosteroids (eg, prednisone, 40 mg/d for 7 days) has been advocated by some clinicians, as have oral antibiotics (eg, amoxicillin,

250 mg three times daily for 7 days)—or even a combination of the two. The role of these regimens remains controversial, but they are probably of little lasting benefit.

When medication fails to bring relief after several months, a ventilating tube placed through the tympanic membrane may restore hearing and alleviate the sense of aural fullness. Endoscopically guided laser expansion of the nasopharyngeal orifice of the eustachian tube may improve function in recalcitrant cases.

Campbell RG et al. Management of otitis media with effusion in children with primary ciliary dyskinesia: a literature review. *Int J Pediatr Otorhinolaryngol.* 2009 Dec;73(12):1630–8. [PMID: 19796826]

Skoner AR et al. Allergic rhinitis, histamine, and otitis media. *Allergy Asthma Proc.* 2009 Sep–Oct;30(5):470–81. [PMID: 19843400]

3. Barotrauma

Persons with poor eustachian tube function (eg, congenital narrowness or acquired mucosal edema) may be unable to equalize the barometric stress exerted on the middle ear by air travel, rapid altitudinal change, or underwater diving. The problem is generally most acute during airplane descent, since the negative middle ear pressure tends to collapse and block the eustachian tube. Several measures are useful to enhance eustachian tube function and avoid otic barotrauma. The patient should be advised to swallow, yawn, and autoinflate frequently during descent, which may be painful if the eustachian tube collapses. Systemic decongestants (eg, pseudoephedrine, 60–120 mg) should be taken several hours before anticipated arrival time so that they will be maximally effective during descent. Topical decongestants such as 1% phenylephrine nasal spray should be administered 1 hour before arrival.

For acute negative middle ear pressure that persists on the ground, treatment includes decongestants and attempts at autoinflation. Myringotomy (creation of a small eardrum perforation) provides immediate relief and is appropriate in the setting of severe otalgia and hearing loss. Repeated episodes of barotrauma in persons who must fly frequently may be alleviated by insertion of ventilating tubes.

Underwater diving may represent an even a greater barometric stress to the ear than flying. The problem occurs most commonly during the descent phase, when pain develops within the first 15 feet if inflation of the middle ear via the eustachian tube has not occurred. Divers must descend slowly and equilibrate in stages to avoid the development of severely negative pressures in the tympanum that may result in hemorrhage (hemotympanum) or perilymphatic fistula. In the latter, the oval or round window ruptures, resulting in sensory hearing loss and acute vertigo. Emesis due to acute labyrinthine dysfunction can be very dangerous during an underwater dive. Sensory hearing loss or vertigo, which develops during the ascent phase of a saturation dive, may be the first (or only) symptom of decompression sickness. Immediate recompression will return intravascular gas bubbles to solution and restore the inner ear microcirculation. Patients should be

warned to avoid diving when they have upper respiratory infections or episodes of nasal allergy. Tympanic membrane perforation is an absolute contraindication to diving, as the patient will experience an unbalanced thermal stimulus to the semicircular canals and may experience vertigo, disorientation, and even emesis.

Duplessis C et al. Exploiting otoacoustic emission testing to identify clinical and subclinical inner ear barotrauma in divers: potential risk factor for sensorineural hearing loss. *J Otolaryngol Head Neck Surg.* 2009 Feb;38(1):67–76. [PMID: 19344615]

Goplen FK et al. Vestibular effects of diving—a 6-year prospective study. *Occup Med (Lond).* 2010 Jan;60(1):43–8. [PMID: 19854795]

DISEASES OF THE MIDDLE EAR

1. Acute Otitis Media



ESSENTIALS OF DIAGNOSIS

- ▶ Otolgia, often with an upper respiratory tract infection.
- ▶ Erythema and hypomobility of tympanic membrane.

▶ General Considerations

Acute otitis media is a bacterial infection of the mucosally lined air-containing spaces of the temporal bone. Purulent material forms not only within the middle ear cleft but also within the pneumatized mastoid air cells and petrous apex. Acute otitis media is usually precipitated by a viral upper respiratory tract infection that causes eustachian tube obstruction. This results in accumulation of fluid and mucus, which becomes secondarily infected by bacteria. The most common pathogens both in adults and in children are *Streptococcus pneumoniae*, *Haemophilus influenzae*, and *Streptococcus pyogenes*.

▶ Clinical Findings

Acute otitis media is most common in infants and children, although it may occur at any age. Presenting symptoms and signs include otalgia, aural pressure, decreased hearing, and often fever. The typical physical findings are erythema and decreased mobility of the tympanic membrane. Occasionally, bullae will be seen on the tympanic membrane.

Rarely, when middle ear empyema is severe, the tympanic membrane can bulge outward. In such cases, tympanic membrane rupture is imminent. Rupture is accompanied by a sudden decrease in pain, followed by the onset of otorrhea. With appropriate therapy, spontaneous healing of the tympanic membrane occurs in most cases. When perforation persists, chronic otitis media may evolve. Mastoid tenderness often accompanies acute otitis media and is due to the presence of pus within the mastoid air cells. This alone does not indicate suppurative (surgical) mastoiditis. Frank swelling over the mastoid bone or the

association of cranial neuropathies or central findings indicates severe disease requiring urgent care.

▶ Treatment

The treatment of acute otitis media is specific antibiotic therapy, often combined with nasal decongestants. The first-choice oral antibiotic treatment is amoxicillin (20–40 mg/kg/d) or erythromycin (50 mg/kg/d) plus sulfonamide (150 mg/kg/d) for 10 days. Alternatives useful in resistant cases are cefaclor (20–40 mg/kg/d) or amoxicillin-clavulanate (20–40 mg/kg/d) combinations.

Tympanocentesis for bacterial (aerobic and anaerobic) and fungal culture may be performed by any experienced physician. A 20-gauge spinal needle bent 90 degrees to the hub attached to a 3-mL syringe is inserted through the inferior portion of the tympanic membrane. Interposition of a pliable connecting tube between the needle and syringe permits an assistant to aspirate without inducing movement of the needle. Tympanocentesis is useful for otitis media in immunocompromised patients and when infection persists or recurs despite multiple courses of antibiotics.

Surgical drainage of the middle ear (myringotomy) is reserved for patients with severe otalgia or when complications of otitis (eg, mastoiditis, meningitis) have occurred.

Recurrent acute otitis media may be managed with long-term antibiotic prophylaxis. Single daily oral doses of sulfamethoxazole (500 mg) or amoxicillin (250 or 500 mg) are given over a period of 1–3 months. Failure of this regimen to control infection is an indication for insertion of ventilating tubes.

Coco A et al. Management of acute otitis media after publication of the 2004 AAP and AAFP clinical practice guideline. *Pediatrics.* 2010 Feb;125(2):214–20. [PMID: 20100746]

Gunasekera H et al. Management of children with otitis media: a summary of evidence from recent systematic reviews. *J Paediatr Child Health.* 2009 Oct;45(10):554–62. [PMID: 19751382]

2. Chronic Otitis Media



ESSENTIALS OF DIAGNOSIS

- ▶ Chronic otorrhea with or without otalgia.
- ▶ Tympanic membrane perforation with conductive hearing loss.
- ▶ Often amenable to surgical correction.

▶ General Considerations

Chronic infection of the middle ear and mastoid generally develops as a consequence of recurrent acute otitis media, although it may follow other diseases and trauma. Perforation of the tympanic membrane is usually present. This may be accompanied by mucosal changes such as polypoid degeneration and granulation tissue and osseous changes such as osteitis and sclerosis. The bacteriology of chronic otitis media differs from that of acute otitis media. Common organisms include *P aeruginosa*, *Proteus* species, *Staphylococcus aureus*, and mixed anaerobic infections.

► Clinical Findings

The clinical hallmark of chronic otitis media is purulent aural discharge. Drainage may be continuous or intermittent, with increased severity during upper respiratory tract infection or following water exposure. Pain is uncommon except during acute exacerbations. Conductive hearing loss results from destruction of the tympanic membrane or ossicular chain, or both.

► Treatment

The medical treatment of chronic otitis media includes regular removal of infected debris, use of earplugs to protect against water exposure, and topical antibiotic drops for exacerbations. The activity of ciprofloxacin against *Pseudomonas* may help dry a chronically discharging ear when given in a dosage of 500 mg orally twice a day for 1–6 weeks.

Definitive management is surgical in most cases. Tympanic membrane repair may be accomplished with temporalis muscle fascia. Successful reconstruction of the tympanic membrane may be achieved in about 90% of cases, often with elimination of infection and significant improvement in hearing. When the mastoid air cells are involved by irreversible infection, they should be exenterated at the same time through a mastoidectomy.

Hartzell LD et al. Timing of tympanoplasty in children with chronic otitis media with effusion. *Curr Opin Otolaryngol Head Neck Surg.* 2010 Dec;18(6):550–3. [PMID: 21045692]
 Morris PS et al. Acute and chronic otitis media. *Pediatr Clin North Am.* 2009 Dec;56(6):1383–99. [PMID: 19962027]

► Complications of Otitis Media

A. Cholesteatoma

Cholesteatoma is a special variety of chronic otitis media (Figure 8–1). The most common cause is prolonged eustachian tube dysfunction, with resultant chronic negative middle ear pressure that draws inward the upper flaccid portion of the tympanic membrane. This creates a squamous epithelium-lined sac, which—when its neck becomes obstructed—may fill with desquamated keratin and become chronically infected. Cholesteatomas typically erode bone, with early penetration of the mastoid and destruction of the ossicular chain. Over time they may erode into the inner ear, involve the facial nerve, and on rare occasions spread intracranially. Otoscopic examination may reveal an epitympanic retraction pocket or a marginal tympanic membrane perforation that exudes keratin debris, or granulation tissue. The treatment of cholesteatoma is surgical marsupialization of the sac or its complete removal. This may require the creation of a “mastoid bowl” in which the ear canal and mastoid are joined into a large common cavity that must be periodically cleaned.

Nankivell PC et al. Surgery for tympanic membrane retraction pockets. *Cochrane Database Syst Rev.* 2010 Jul 7;(7):CD007943. [PMID: 20614467]



▲ **Figure 8–1.** Cholesteatoma. (Courtesy of Vladimir Zlinksy, MD in Roy F. Sullivan, PhD: *Audiology Forum: Video Otoscopy*, www.RCSullivan.com; used with permission from Usatine RP, Smith MA, Mayeaux EJ Jr, Chumley H, Tysinger, J. *The Color Atlas of Family Medicine*. McGraw-Hill, 2009.)

Saunders JE. Does early surgical intervention of middle ear atelectasis improve long-term results and prevent cholesteatoma? *Arch Otolaryngol Head Neck Surg.* 2008 Oct;134(10):1040–4. [PMID: 18936347]

B. Mastoiditis

Acute suppurative mastoiditis usually evolves following several weeks of inadequately treated acute otitis media. It is characterized by postauricular pain and erythema accompanied by a spiking fever. CT scan reveals coalescence of the mastoid air cells due to destruction of their bony septa. Initial treatment consists of intravenous antibiotics directed against the most common offending organisms (eg, cefazolin 0.5–1.5 g every 6–8 hours), and myringotomy for culture and drainage. Failure of medical therapy indicates the need for surgical drainage (mastoidectomy).

Groth A et al. Acute mastoiditis in children in Sweden 1993–2007—no increase after new guidelines. *Int J Pediatr Otorhinolaryngol.* 2011 Dec;75(12):1496–501. [PMID: 21945244]
 Osborn AJ et al. Decisions regarding intracranial complications from acute mastoiditis in children. *Curr Opin Otolaryngol Head Neck Surg.* 2011 Sep 15. [Epub ahead of print] [PMID: 21926622]

C. Petrous Apicitis

The medial portion of the petrous bone between the inner ear and clivus may become a site of persistent infection when the drainage of its pneumatic cell tracts becomes blocked. This may cause foul discharge, deep ear and retro-orbital pain, and sixth nerve palsy (Gradenigo syndrome); meningitis may be a complication. Treatment is with prolonged antibiotic therapy (based on culture results) and surgical drainage via petrous apicectomy.

Wanna GB et al. Contemporary management of intracranial complications of otitis media. *Otol Neurotol*. 2010 Jan;31(1):111–7. [PMID: 19887978]

D. Facial Paralysis

Facial palsy may be associated with either acute or chronic otitis media. In the acute setting, it results from inflammation of the seventh nerve in its middle ear segment, perhaps mediated through bacterially secreted neurotoxins. Treatment consists of myringotomy for drainage and culture, followed by intravenous antibiotics (based on culture results). The use of corticosteroids is controversial. The prognosis is excellent, with complete recovery in most cases.

Facial palsy associated with chronic otitis media usually evolves slowly due to chronic pressure on the seventh nerve in the middle ear or mastoid by cholesteatoma. Treatment requires surgical correction of the underlying disease. The prognosis is less favorable than for facial palsy associated with acute otitis media.

Lorch M et al. Facial nerve palsy: etiology and approach to diagnosis and treatment. *Pediatr Emerg Care*. 2010 Oct;26(10):763–9. [PMID: 20930602]

Yonamine FK et al. Facial paralysis associated with acute otitis media. *Braz J Otorhinolaryngol*. 2009 Mar–Apr;75(2):228–30. [PMID: 19575108]

E. Sigmoid Sinus Thrombosis

Trapped infection within the mastoid air cells adjacent to the sigmoid sinus may cause septic thrombophlebitis. This is heralded by signs of systemic sepsis (spiking fevers, chills), at times accompanied by signs of increased intracranial pressure (headache, lethargy, nausea and vomiting, papilledema). Diagnosis can be made noninvasively by magnetic resonance venography. Primary treatment is with intravenous antibiotics (based on culture results). Surgical drainage with ligation of the internal jugular vein may be indicated when embolization is suspected.

Thorne MC et al. Suppurative complications of acute otitis media: changes in frequency over time. *Arch Otolaryngol Head Neck Surg*. 2009 Jul;135(7):638–41. [PMID: 19620582]

F. Central Nervous System Infection

Otogenic meningitis is by far the most common intracranial complication of ear infection. In the setting of acute suppurative otitis media, it arises from hematogenous spread of bacteria, most commonly *H influenzae* and *S pneumoniae*. In chronic otitis media, it results either from passage of infections along preformed pathways such as the petrosquamous suture line or from direct extension of disease through the dural plates of the petrous pyramid.

Epidural abscesses arise from direct extension of disease in the setting of chronic infection. They are usually asymptomatic but may present with deep local pain, headache, and low-grade fever. They are often discovered as an incidental finding at surgery. Brain abscess may arise in the

temporal lobe or cerebellum as a result of septic thrombophlebitis adjacent to an epidural abscess. The predominant causative organisms are *S aureus*, *S pyogenes*, and *S pneumoniae*. Rupture into the subarachnoid space results in meningitis and often death. (See Chapter 30.)

Wanna GB et al. Contemporary management of intracranial complications of otitis media. *Otol Neurotol*. 2010 Jan;31(1):111–7. [PMID: 19887978]

3. Otosclerosis

Otosclerosis is a progressive disease with a marked familial tendency that affects the bony otic capsule. Lesions involving the footplate of the stapes result in increased impedance to the passage of sound through the ossicular chain, producing conductive hearing loss. This may be treated either through the use of a hearing aid or surgical replacement of the stapes with a prosthesis (stapedectomy). When otosclerotic lesions impinge on the cochlea ('cochlear otosclerosis'), permanent sensory hearing loss occurs. Some evidence suggests that hearing loss associated with cochlear otosclerosis may be stabilized by treatment with oral sodium fluoride over prolonged periods of time (Floral—8.3 mg sodium fluoride and 364 mg calcium carbonate—two tablets orally each morning).

Cruise AS et al. Sodium fluoride in otosclerosis treatment: review. *J Laryngol Otol*. 2010 Jun;124(6):583–6. [PMID: 20163750]

Kisilevsky VE et al. Results of stapedotomy in otosclerosis with severe and profound hearing loss. *J Otolaryngol Head Neck Surg*. 2010 Jun;39(3):244–52. [PMID: 20470668]


Markou K et al. An overview of the etiology of otosclerosis. *Eur Arch Otorhinolaryngol*. 2009 Jan;266(1):25–35. [PMID: 18704474]

4. Trauma to the Middle Ear

Tympanic membrane perforation may result from impact injury or explosive acoustic trauma (Figure 8–2). Spontaneous healing occurs in most cases. Persistent perforation may result from secondary infection brought on by exposure to water. Patients should be advised to wear earplugs while swimming or bathing during the healing period. Hemorrhage behind an intact tympanic membrane (hemotympanum) may follow blunt trauma or extreme barotrauma. Spontaneous resolution over several weeks is the usual course. When a conductive hearing loss > 30 dB persists for more than 3 months following trauma, disruption of the ossicular chain should be suspected. Middle ear exploration with reconstruction of the ossicular chain, combined with repair of the tympanic membrane when required, will usually restore hearing.

Darley DS et al. Otologic considerations of blast injury. *Disaster Med Public Health Prep*. 2010 Jun;4(2):145–52. [PMID: 20526137]

Mick P et al. Penetrating and blast ear trauma: 7-year review of two pediatric practices. *J Otolaryngol Head Neck Surg*. 2008 Dec;37(6):774–6. [PMID: 19128702]



▲ **Figure 8-2.** Traumatic perforation of the left tympanic membrane. (Courtesy of William Clark, MD; used with permission, from Usatine RP, Smith MA, Mayeaux EJ Jr, Chumley H, Tysinger, J. *The Color Atlas of Family Medicine*. McGraw-Hill, 2009.)

5. Middle Ear Neoplasia

Primary middle ear tumors are rare. Glomus tumors arise either in the middle ear (glomus tympanicum) or in the jugular bulb with upward erosion into the hypotympanum (glomus jugulare). They present clinically with pulsatile tinnitus and hearing loss. A vascular mass may be visible behind an intact tympanic membrane. Large glomus jugulare tumors are often associated with multiple cranial neuropathies, especially involving nerves VII, IX, X, XI, and XII. Treatment usually requires surgery, radiotherapy, or both. Pulsatile tinnitus thus warrants magnetic resonance angiography and venography to rule out a vascular mass.

Alaani A et al. The crucial role of imaging in determining the approach to glomus tympanicum tumours. *Eur Arch Otorhinolaryngol*. 2009 Jun;26(6):827–31. [PMID: 18841375]

Bierry G et al. Middle ear adenomatous tumor: a not so rare glomus tympanicum-mimicking lesion. *J Neuroradiol*. 2010 May;37(2):116–21. [PMID: 19573921]

EARACHE

Earache can be caused by a variety of otologic problems, but external otitis and acute otitis media are most the common. Differentiation of the two should be apparent by pneumatic otoscopy (see above relevant sections on otitis externa and otitis media). Pain out of proportion to the physical findings may be due to herpes zoster oticus, especially when vesicles appear in the ear canal or concha. Persistent pain and discharge from the ear suggest osteomyelitis of the skull base or cancer, and patients with these complaints should be referred for specialty evaluation.

Nonotologic causes of otalgia are numerous. The sensory innervation of the ear is derived from the trigeminal, facial, glossopharyngeal, vagal, and upper cervical nerves.

Because of this rich innervation, referred otalgia is quite frequent. Temporomandibular joint dysfunction is a common cause of referred ear pain. Pain is exacerbated by chewing or psychogenic grinding of the teeth (bruxism) and may be associated with dental malocclusion. Management includes soft diet, local heat to the masticatory muscles, massage, nonsteroidal anti-inflammatory medications, and dental referral. Repeated episodes of severe lancinating otalgia may occur in glossopharyngeal neuralgia. Treatment with carbamazepine (100–300 mg orally every 8 hours) often confers substantial symptomatic relief. Severe glossopharyngeal neuralgia, which is refractory to medical management, may respond to microvascular decompression of the ninth cranial nerve. Infections and neoplasia that involve the oropharynx, hypopharynx, and larynx frequently cause otalgia. Persistent earache demands specialty referral to exclude cancer of the upper aerodigestive tract.

Neilan RE et al. Otalgia. *Med Clin North Am*. 2010 Sep;94(5):961–71. [PMID: 20736106]

DISEASES OF THE INNER EAR

1. Sensory Hearing Loss

Diseases of the cochlea result in sensory hearing loss, a condition that is usually irreversible. Most cochlear diseases result in bilateral symmetric hearing loss. The presence of unilateral or asymmetric sensorineural hearing loss suggests a lesion proximal to the cochlea. Lesions affecting the eighth cranial nerve and central auditory system are discussed in the section on neural hearing loss. The primary goals in the management of sensory hearing loss are prevention of further losses and functional improvement with amplification and auditory rehabilitation.

A. Presbycusis

Presbycusis, or age-related hearing loss, is the most frequent cause of sensory hearing loss and is progressive, predominantly high-frequency, and symmetrical. It is difficult to separate the various etiologic factors (eg, noise trauma, drug exposure) that may contribute to presbycusis, but genetic predisposition and prior noise exposure appear to play an important role. Most patients notice a loss of speech discrimination that is especially pronounced in noisy environments. About 25% of people between the ages of 65 and 75 years and almost 50% of those over 75 experience hearing difficulties.

Ko J. Presbycusis and its management. *Br J Nurs*. 2010 Feb 11–24;19(3):160–5. [PMID: 20220659]

Schneider JM et al. Role of general practitioners in managing age-related hearing loss. *Med J Aust*. 2010 Jan 4;192(1):20–3. [PMID: 20047543]

Sprinzel GM et al. Current trends in treating hearing loss in elderly people: a review of the technology and treatment options—a mini-review. *Gerontology*. 2010;56(3):351–8. [PMID: 20090297]

B. Noise Trauma

Noise trauma is the second most common cause of sensory hearing loss. Sounds exceeding 85 dB are potentially injurious to the cochlea, especially with prolonged exposures. The loss typically begins in the high frequencies (especially 4000 Hz) and progresses to involve the speech frequencies with continuing exposure. Among the more common sources of injurious noise are industrial machinery, weapons, and excessively loud music. Personal music devices (eg, MP3 and CD players) used at excessive loudness levels may also be potentially injurious. Monitoring noise levels in the workplace by regulatory agencies has led to preventive programs that have reduced the frequency of occupational losses. Individuals of all ages, especially those with existing hearing losses, should wear earplugs when exposed to moderately loud noises and specially designed earmuffs when exposed to explosive noises.

El Dib RP et al. Interventions to promote the wearing of hearing protection. *Cochrane Database Syst Rev.* 2009 Oct 7;(4):CD005234. [PMID: 19821342]

Henderson E et al. Prevalence of noise-induced hearing-threshold shifts and hearing loss among US youths. *Pediatrics.* 2011 Jan;127(1):e39–46. [PMID: 21187306]

C. Physical Trauma

Head trauma has effects on the inner ear similar to those of severe acoustic trauma. Some degree of sensory hearing loss may occur following simple concussion and is frequent after skull fracture. Deployment of air bags during an automobile accident has also been associated with hearing loss.

Mick P et al. Penetrating and blast ear trauma: 7-year review of two pediatric practices. *J Otolaryngol Head Neck Surg.* 2008 Dec;37(6):774–6. [PMID: 19128702]

D. Ototoxicity

Ototoxic substances may affect both the auditory and vestibular systems. The most commonly used ototoxic medications are aminoglycosides; loop diuretics; and several antineoplastic agents, notably cisplatin. These medications may cause irreversible hearing loss even when administered in therapeutic doses. When using these medications, it is important to identify high-risk patients such as those with preexisting hearing losses or kidney disease. Patients simultaneously receiving multiple ototoxic agents are at particular risk owing to ototoxic synergy. Useful measures to reduce the risk of ototoxic injury include serial audiometry and monitoring of serum peak and trough levels and substitution of equivalent nontoxic drugs whenever possible. Efforts are underway to develop strategies, known as ototoxic chemoprotection, using drugs that shield the inner ear from damage during ototoxic exposure.

It is possible for topical agents that enter the middle ear to be absorbed into the inner ear via the round window. When the tympanic membrane is perforated, use of potentially

ototoxic ear drops (eg, neomycin, gentamicin) is best avoided.

Helt-Cameron J et al. Cisplatin ototoxicity in children: implications for primary care providers. *Pediatr Nurs.* 2009 Mar–Apr; 35(2):121–7. [PMID: 19472677]

Konrad-Martin D et al. Evaluation of audiometric threshold shift criteria for ototoxicity monitoring. *J Am Acad Audiol.* 2010 May;21(5):301–14. [PMID: 20569665]

E. Sudden Sensory Hearing Loss

Idiopathic sudden loss of hearing in one ear may occur at any age, but typically, it occurs in persons over age 20 years. The cause is unknown; however, one hypothesis is that it results from a viral infection or a sudden vascular occlusion of the internal auditory artery. Prognosis is mixed, with many patients suffering permanent deafness in the involved ear while others have complete recovery. Prompt treatment with corticosteroids has been shown to improve the odds of recovery. A common regimen is oral prednisone, 1 mg/kg/d, followed by a tapering dose over a 10-day period. Intratympanic administration of corticosteroids alone or in association with oral corticosteroids is increasingly being used for this problem and has been associated with an equal or more favorable prognosis in some reports. Because treatment appears to be most effective as close to the onset of the loss as possible, and appears not to be effective after 6 weeks, a prompt audiogram should be obtained in all patients who present with sudden hearing loss without obvious middle ear pathology.

Chau JK et al. Systematic review of the evidence for the etiology of adult sudden sensorineural hearing loss. *Laryngoscope.* 2010 May;120(5):1011–21. [PMID: 20422698]

Hu A et al. Intratympanic steroids for inner ear disorders: a review. *Audiol Neurootol.* 2009;14(6):373–82. [PMID: 19923807]

Labus J et al. Meta-analysis for the effect of medical therapy vs. placebo on recovery of idiopathic sudden hearing loss. *Laryngoscope.* 2010 Sep;120(9):1863–71. [PMID: 20803741]

Rauch SD et al. Oral vs intratympanic corticosteroid therapy for idiopathic sudden sensorineural hearing loss: a randomized trial. *JAMA.* 2011 May 25;305(20):2071–9. [PMID: 21610239]

F. Hereditary Hearing Loss

Sensory hearing loss with onset during adult life often runs in families. The mode of inheritance may be either autosomal dominant or recessive. The age at onset, the rate of progression of hearing loss, and the audiometric pattern (high-frequency, low-frequency, or flat) can often be predicted by studying family members. Great strides have been made in identifying the molecular genetic errors associated with hereditary hearing loss. The connexin-26 mutation, the most common cause of genetic deafness, may be tested clinically. Hearing loss is also frequently found in hereditary mitochondrial disorders. Progress is being made toward the development of methods to restore lost hair cells in genetic and other forms of deafness via gene therapy or stem cell–mediated techniques.

Dror AA et al. Hearing loss: mechanisms revealed by genetics and cell biology. *Annu Rev Genet.* 2009;43:411–37. [PMID: 19694516]
 Ito T et al. Hereditary hearing loss and deafness genes in Japan. *J Med Dent Sci.* 2010 Mar;57(1):1–10. [PMID: 20437760]
 Shearer AE et al. Deafness in the genomics era. *Hear Res.* 2011 Dec;282(1–2):1–9. [PMID: 22016077]

G. Autoimmune Hearing Loss

Sensory hearing loss may be associated with a wide array of systemic autoimmune disorders such as systemic lupus erythematosus, granulomatosis with polyangiitis (formerly Wegener granulomatosis), and Cogan syndrome (hearing loss, keratitis, aortitis). The loss is most often bilateral and progressive. The hearing level often fluctuates, with periods of deterioration alternating with partial or even complete remission. The tendency is for the gradual evolution of permanent hearing loss, which usually stabilizes with some remaining auditory function but occasionally proceeds to complete deafness. Vestibular dysfunction, particularly dysequilibrium and postural instability, may accompany the auditory symptoms. A syndrome resembling Ménière disease may also occur with intermittent attacks of severe vertigo.

In many cases, the autoimmune pattern of audiovestibular dysfunction presents in the absence of recognized systemic autoimmune disease. Use of laboratory tests to screen for autoimmune disease (eg, antinuclear antibody, rheumatoid factor, erythrocyte sedimentation rate) may be informative. Specific tests of immune reactivity against inner ear antigens (anticochlear antibodies, lymphocyte transformation tests) are currently of interest for research purposes only, demonstrating limited clinical value to date. Responsiveness to oral corticosteroid treatment is helpful in making the diagnosis and constitutes first-line therapy. If stabilization of hearing becomes dependent on long-term corticosteroid use, steroid-sparing immunosuppressive regimens may become necessary.

Alexander TH et al. Safety of high-dose corticosteroids for the treatment of autoimmune inner ear disease. *Otol Neurotol.* 2009 Jun;30(4):443–8. [PMID: 19395984]
 Buniel MC et al. Immunosuppressive therapy for autoimmune inner ear disease. *Immunotherapy.* 2009 May;1(3):425–34. [PMID: 19885385]

2. Tinnitus

Tinnitus is the perception of abnormal ear or head noises. Persistent tinnitus often, though not always, indicates the presence of sensory hearing loss. Intermittent periods of mild, high-pitched tinnitus lasting seconds to minutes are common in normal-hearing persons. When severe and persistent, tinnitus may interfere with sleep and the ability to concentrate, resulting in considerable psychological distress.

The most important treatment of tinnitus is avoidance of exposure to excessive noise, ototoxic agents, and other factors that may cause cochlear damage. Masking the tinnitus with music or through amplification of normal

sounds with a hearing aid may also bring some relief. Among the numerous drugs that have been tried, oral antidepressants (eg, nortriptyline at an initial dosage of 50 mg orally at bedtime) have proved to be the most effective. Habituation techniques, such as tinnitus retraining therapy, and masking techniques may prove beneficial in those with refractory symptoms. Transcranial magnetic stimulation of the central auditory system has been shown to improve symptoms in some patients. Progress is also being made toward implantable brain stimulators to treat tinnitus.

Pulsatile tinnitus—often described by the patient as listening to one’s own heartbeat—should be distinguished from tonal tinnitus. Although often ascribed to conductive hearing loss, this symptom may be far more serious and may indicate a vascular abnormality such as glomus tumor, venous sinus stenosis, carotid vaso-occlusive disease, arteriovenous malformation, or aneurysm. Magnetic resonance angiography and venography should be considered to establish the diagnosis.

In contrast, a staccato “clicking” tinnitus may result from middle ear muscle spasm, sometimes associated with palatal myoclonus. The patient typically perceives a rapid series of popping noises, lasting seconds to a few minutes, accompanied by a fluttering feeling in the ear.

Adjajian P et al. The mechanisms of tinnitus: perspectives from human functional neuroimaging. *Hear Res.* 2009 Jul;253(1–2):15–31. [PMID: 19364527]
 Hoare DJ et al. Systematic review and meta-analyses of randomized controlled trials examining tinnitus management. *Laryngoscope.* 2011 Jul;121(7):1555–64. [PMID: 21671234]
 Hoekstra CE et al. Anticonvulsants for tinnitus. *Cochrane Database Syst Rev.* 2011 Jul 6;(7):CD007960. [PMID: 21735419]
 Meng Z et al. Repetitive transcranial magnetic stimulation for tinnitus. *Cochrane Database Syst Rev.* 2011 Oct 5;(10):CD007946. [PMID: 21975776]

3. Hyperacusis

Excessive sensitivity to sound may occur in normal-hearing individuals either in association with ear disease, following noise trauma, in patients susceptible to migraines, or for psychological reasons. Patients with cochlear dysfunction commonly experience “recruitment,” an abnormal sensitivity to loud sounds despite a reduced sensitivity to softer ones. Fitting hearing aids and other amplification devices to patients with recruitment requires use of compression circuitry to avoid uncomfortable overamplification. For normal-hearing individuals with hyperacusis, use of an earplug in noisy environments may be beneficial, though attempts should be made at habituation.

Gu JW et al. Tinnitus, diminished sound-level tolerance, and elevated auditory activity in humans with clinically normal hearing sensitivity. *J Neurophysiol.* 2010 Dec;104(6):3361–70. [PMID: 20881196]
 Meeus OM et al. Correlation between hyperacusis measurements in daily ENT practice. *Int J Audiol.* 2010 Jan;49(1):7–13. [PMID: 20053152]

4. Vertigo



ESSENTIALS OF DIAGNOSIS

- ▶ Either a sensation of motion when there is no motion or an exaggerated sense of motion in response to movement.
- ▶ Duration of vertigo episodes and association with hearing loss is the key to diagnosis.
- ▶ Must differentiate peripheral from central etiologies of vestibular dysfunction.
- ▶ **Peripheral:** Onset is sudden; often associated with tinnitus and hearing loss; horizontal nystagmus may be present.
- ▶ **Central:** Onset is gradual; no associated auditory symptoms.
- ▶ Evaluation includes audiogram and electronystagmography (ENG) or videonystagmography (VNG) and MRI.

▶ General Considerations

Vertigo can be caused by either a peripheral and central etiology, or both (Table 8–2).

▶ Clinical Findings

A. Symptoms and Signs

Vertigo is the cardinal symptom of vestibular disease. It is either a sensation of motion when there is no motion or an exaggerated sense of motion in response to a given bodily movement. While vertigo is typically experienced as a distinct “spinning” sensation, it may also present as a sense of tumbling or of falling forward or backward. It should be distinguished from imbalance, light-headedness, and syncope, all of which are nonvestibular in origin (Table 8–3).

1. Peripheral vestibular disease—Peripheral vestibulopathy usually causes vertigo of sudden onset, may be so severe that the patient is unable to walk or stand, and is frequently accompanied by nausea and vomiting. Tinnitus and hearing loss may be associated and provide strong support for a peripheral (ie, otologic) origin.

A thorough history will often narrow down, if not confirm the diagnosis. Critical elements of the history include the duration of the discrete vertiginous episodes (seconds, minutes to hours, or days), and associated symptoms. Triggers should also be sought, including diet (eg, high salt in the case of Ménière disease), stress, fatigue, and bright lights (eg, migraine-associated dizziness).

The physical examination of the patient with vertigo includes evaluation of the ears, eye motion in response to head turning and observation for nystagmus, cranial nerve examination, and Romberg testing. In acute peripheral lesions, nystagmus is usually horizontal with a rotatory component; the fast phase usually beats away from the diseased side. Visual fixation tends to inhibit nystagmus

Table 8–2. Causes of vertigo.

Peripheral causes
Vestibular neuritis/labyrinthitis
Ménière disease
Benign positional vertigo
Ethanol intoxication
Inner ear barotrauma
Semicircular canal dehiscence
Central causes
Seizure
Multiple sclerosis
Wernicke encephalopathy
Chiari malformation
Cerebellar ataxia syndromes
Mixed central and peripheral causes
Migraine
Stroke and vascular insufficiency
Posterior inferior cerebellar artery stroke
Anterior inferior cerebellar artery stroke
Vertebral artery insufficiency
Vasculitides
Cogan syndrome
Susac syndrome
Granulomatosis with polyangiitis (formerly Wegener granulomatosis)
Behçet disease
Cerebellpontine angle tumors
Vestibular schwannoma
Meningioma
Infections
Lyme disease
Syphilis
Vascular compression
Hyperviscosity syndromes
Waldenström macroglobulinemia
Endocrinopathies
Hypothyroidism
Pendred syndrome

except in very acute peripheral lesions or with central nervous system disease. Dix-Hallpike testing (quickly lowering the patient to the supine position with the head extending over the edge and placed 30 degrees lower than the body, turned either to the left or right) will elicit a delayed onset (~10 sec) fatiguable nystagmus in cases of benign positional vertigo. Nonfatigable nystagmus in this position indicates a central etiology for the dizziness.

Since visual fixation often suppresses observed nystagmus, many of these maneuvers are performed with Frenzel goggles, which prevent visual fixation, and often bring out subtle forms of nystagmus. The Fukuda test, in which the patient consistently rotates when walking in place with eyes closed, can also demonstrate vestibular asymmetry.

2. Central disease—In contrast to peripheral forms of vertigo, dizziness arising from central etiologies (Table 8–2) tends to develop gradually and then become progressively more severe and debilitating. Nystagmus is not always present but can occur in any direction and may be dissociated in the two eyes. The associated nystagmus is often nonfatigable, vertical rather than horizontal in orientation, without latency, and unsuppressed by visual fixation. ENG is useful in documenting these characteristics. The evaluation of central audiovestibular dysfunction requires imaging of the brain with MRI.

Episodic vertigo can occur in patients with diplopia from external ophthalmoplegia and is maximal when the patient looks in the direction where the separation of images is greatest. Cerebral lesions involving the temporal cortex may also produce vertigo, which is sometimes the initial symptom of a seizure. Finally, vertigo may be a feature of a number of systemic disorders and can occur as a side effect of certain anticonvulsant, antibiotic, hypnotic, analgesic, and tranquilizing drugs or of alcohol.

B. Laboratory Findings

Laboratory investigations such as audiologic evaluation, caloric stimulation, ENG, VNG, vestibular-evoked myogenic potentials (VEMPs), and MRI are indicated in patients with persistent vertigo or when central nervous system disease is suspected. These studies will help distinguish between central and peripheral lesions and to identify causes requiring specific therapy. ENG consists of objective recording of the nystagmus induced by head and body movements, gaze, and caloric stimulation. It is helpful in quantifying the degree of vestibular hypofunction. Computer-driven rotary chairs and posturography platforms offer additional diagnostic modalities from specialized centers.

Ahmed MF et al. Caloric test versus rotational sinusoidal harmonic acceleration and step-velocity tests in patients with and without suspected peripheral vestibulopathy. *Otol Neurotol.* 2009 Sep;30(6):800–5. [PMID: 19623096]
 Brantberg K. Vestibular evoked myogenic potentials (VEMPs): usefulness in clinical neurotology. *Semin Neurol.* 2009 Nov;29 (5):541–7. [PMID: 19834866]
 Post RE. Dizziness: a diagnostic approach. *Am Fam Physician.* 2010 Aug 15;82(4):361–8. [PMID: 20704166]

► Vertigo Syndromes Due to Peripheral Lesions

A. Endolymphatic Hydrops (Ménière Syndrome)

The cause of Ménière syndrome is unknown. Distention of the endolymphatic compartment of the inner ear is a pathologic finding and thought to be part of the pathogenesis of the disorder. Although a precise cause of hydrops cannot be established in most cases, two known causes are syphilis and head trauma. The classic syndrome consists of episodic vertigo, with discrete vertigo spells lasting 20 minutes to several hours in association with fluctuating low-frequency sensorineural hearing loss, tinnitus (usually low-tone and “blowing” in quality), and a sensation of unilateral aural pressure (Table 8–3). These symptoms in the absence of hearing fluctuations suggests migraine-associated dizziness. Symptoms wax and wane as the endolymphatic pressure rises and falls. Caloric testing commonly reveals loss or impairment of thermally induced nystagmus on the involved side. Primary treatment involves a low salt diet and diuretics (eg, acetazolamide). In refractory cases, patients may undergo intratympanic corticosteroid injections, endolymphatic sac decompression or vestibular ablation either through transtympanic gentamicin, vestibular nerve section, or surgical labyrinthectomy.

Herraiz C et al. Transtympanic steroids for Ménière’s disease. *Otol Neurotol.* 2010 Jan;31(1):162–7. [PMID: 19924013]
 Pullens B et al. Surgery for Ménière’s disease. *Cochrane Database Syst Rev.* 2010 Jan 20;(1):CD005395. [PMID: 20091573]

B. Labyrinthitis

Patients with labyrinthitis suffer from acute onset of continuous, usually severe vertigo lasting several days to a

Table 8–3. Common vestibular disorders: differential diagnosis based on classic presentations.

Duration of Typical Vestiginous Episodes	Auditory Symptoms Present	Auditory Symptoms Absent
Seconds	Perilymphatic fistula	Positioning vertigo (cupulolithiasis), vertebrobasilar insufficiency, migraine-associated vertigo
Hours	Endolymphatic hydrops (Ménière syndrome, syphilis)	Migraine-associated vertigo
Days	Labyrinthitis, labyrinthine concussion, autoimmune inner ear disease	Vestibular neuronitis, migraine-associated vertigo
Months	Acoustic neuroma, ototoxicity	Multiple sclerosis, cerebellar degeneration

week, accompanied by hearing loss and tinnitus. During a recovery period that lasts for several weeks, the vertigo gradually improves. Hearing may return to normal or remain permanently impaired in the involved ear. The cause of labyrinthitis is unknown. Treatment consists of antibiotics if the patient is febrile or has symptoms of a bacterial infection, and supportive care. Vestibular suppressants are useful during the acute phase of the attack (eg, diazepam or meclizine) but should be discontinued as soon as feasible to avoid long-term dysequilibrium from inadequate compensation.

Newman-Toker DE et al. Disconnect between charted vestibular diagnoses and emergency department management decisions: a cross-sectional analysis from a nationally representative sample. *Acad Emerg Med.* 2009 Oct;16(10):970–7. [PMID: 19799573]

Post RE. Dizziness: a diagnostic approach. *Am Fam Physician.* 2010 Aug 15;82(4):361–8. [PMID: 20704166]

C. Benign Paroxysmal Positioning Vertigo

Patients suffering from recurrent spells of vertigo, lasting under several minutes per spell, associated with changes in head position (often provoked by rolling over in bed), usually have benign paroxysmal positioning vertigo. The term “positioning vertigo” is more accurate than “positional vertigo” because it is provoked by changes in head position rather than by the maintenance of a particular posture.

The typical symptoms of positioning vertigo occur in clusters that persist for several days. There is a brief (10–15 sec) latency period following a head movement before symptoms develop, and the acute vertigo subsides within 10–60 seconds, though the patient may remain imbalanced for several hours. Constant repetition of the positional change leads to habituation. Since some central nervous system disorders can mimic BPPV (eg, vertebrobasilar insufficiency), recurrent cases warrant MRI scanning of the head. In central lesions, there is no latent period, fatigability, or habituation of the symptoms and signs. Treatment of BPPV involves physical therapy protocols (eg, the Epley maneuver or Brandt-Daroff exercises), based on the theory that peripheral positioning vertigo results from free-floating otoconia within a semicircular canal.

Bhattacharyya N et al. American Academy of Otolaryngology-Head and Neck Surgery Foundation. Clinical practice guideline: benign paroxysmal positional vertigo. *Otolaryngol Head Neck Surg.* 2008 Nov;139(5 Suppl 4):S47–81. [PMID: 18973840]

Marom T et al. Revisiting benign paroxysmal positional vertigo pathophysiology. *Am J Otolaryngol.* 2009 Jul–Aug;30(4):250–5. [PMID: 19563936]

D. Vestibular Neuronitis

In vestibular neuronitis, a paroxysmal, usually single attack of vertigo occurs without accompanying impairment of auditory function and will persist for several days to a week before gradually clearing. During the acute phase, examination reveals nystagmus and absent responses to caloric stimulation on one or both sides. The cause of the disorder

is unclear though presumed to be viral. Treatment consists of supportive care, including diazepam or meclizine during the acute phases of the vertigo only, followed by vestibular therapy if the patient does not completely compensate.

Post RE. Dizziness: a diagnostic approach. *Am Fam Physician.* 2010 Aug 15;82(4):361–8. [PMID: 20704166]

E. Traumatic Vertigo

The most common cause of vertigo following head injury is labyrinthine concussion. Symptoms generally diminish within several days but may linger for a month or more. Basilar skull fractures that traverse the inner ear usually result in severe vertigo lasting several days to a week and deafness in the involved ear. Chronic posttraumatic vertigo may result from cupulolithiasis. This occurs when traumatically detached statoconia (otoconia) settle on the ampulla of the posterior semicircular canal and cause an excessive degree of cupular deflection in response to head motion. Clinically, this presents as episodic positioning vertigo. Treatment consists of supportive care and vestibular suppressant medication (diazepam or meclizine) during the acute phase of the attack, and vestibular therapy.

Scherer MR et al. Traumatic brain injury and vestibular pathology as a comorbidity after blast exposure. *Phys Ther.* 2009 Sep;89(9):980–92. [PMID: 19628578]

F. Perilymphatic Fistula

Leakage of perilymphatic fluid from the inner ear into the tympanic cavity via the round or oval window is often discussed as a cause of vertigo and sensory hearing loss but is actually very rare. Most cases result from either physical injury (eg, blunt head trauma, hand slap to ear); extreme barotrauma during airlift, scuba diving, etc; or vigorous Valsalva maneuvers (eg, during weight lifting). Treatment may require middle ear exploration and window sealing with a tissue graft; however, this is seldom indicated without a clear-cut history of a precipitating traumatic event.

Al Felasi M et al. Perilymphatic fistula of the round window. *Eur Ann Otorhinolaryngol Head Neck Dis.* 2011 Jun;128(3):139–41. [PMID: 21288793]

G. Cervical Vertigo

Position receptors located in the facets of the cervical spine are important physiologically in the coordination of head and eye movements. Cervical proprioceptive dysfunction is a common cause of vertigo triggered by neck movements. This disturbance often commences after neck injury, particularly hyperextension. An association also exists with degenerative cervical spine disease. Although symptoms vary, vertigo may be triggered by assuming a particular head position as opposed to moving to a new head position (the latter typical of labyrinthine dysfunction). Diagnosis may often be confused with migraine-associated vertigo, which is also associated with head movement. Management

consists of neck movement exercises to the extent permitted by orthopedic considerations.

Schikora N et al. Influence of cervical spine stabilization via Stiff Neck on the postural system in healthy patients: compensation or decompensation of the postural system? *Eur Arch Otorhinolaryngol.* 2010 Oct;267(10):1623–8. [PMID: 20443016]

H. Migrainous Vertigo

Episodic vertigo is frequently associated with a migraine type of headache. Head trauma may also be a precipitating feature. The vertigo may be temporally related to the headache and last up to several hours, although the vertigo may also occur in the absence of any headache. It may appear identical to Ménière disease but without associated hearing loss or tinnitus. Accompanying symptoms may include head pressure, visual and motion sensitivity, auditory sensitivity, and photosensitivity. Symptoms typically worsen with lack of sleep and anxiety or stress. There is often a history of motion intolerance (easily carsick as a child) and there may be a familial tendency. Food triggers may also be common, including caffeine, chocolate, and alcohol among others. Treatment includes dietary and lifestyle changes (improved sleep pattern, avoidance of stress) and antimigraine prophylactic medication.

Felisati G et al. Migraine and vertigo: two diseases with the same pathogenesis? *Neurol Sci.* 2010 Jun;31(Suppl 1):S107–9. [PMID: 20464597]

Fotuhi M et al. Vestibular migraine: a critical review of treatment trials. *J Neurol.* 2009 May;256(5):711–6. [PMID: 19252785]

Jeong SH et al. Vestibular dysfunction in migraine: effects of associated vertigo and motion sickness. *J Neurol.* 2010 Jun; 257(6):905–12. [PMID: 20041331]

I. Superior Semicircular Canal Dehiscence

Deficiency in the bony covering of the superior semicircular canal may be associated with vertigo triggered by loud noise exposure, straining, and an apparent conductive hearing loss. Diagnosis is with coronal high-resolution CT scan and VEMPs. Surgically sealing the dehiscent canal can improve symptoms.

Chi FL et al. Variety of audiologic manifestations in patients with superior semicircular canal dehiscence. *Otol Neurotol.* 2010 Jan;31(1):2–10. [PMID: 20050265]

Phillips DJ et al. Diagnosis and outcomes of middle cranial fossa repair for patients with superior semicircular canal dehiscence syndrome. *J Clin Neurosci.* 2010 Mar;17(3):339–41. [PMID: 20074960]

► Vertigo Syndromes Due to Central Lesions

Central nervous system causes of vertigo include brainstem vascular disease, arteriovenous malformations, tumor of the brainstem and cerebellum, multiple sclerosis, and vertebrobasilar migraine (Table 8–2). Vertigo of central origin often becomes unremitting and disabling. The associated

nystagmus is often nonfatigable, vertical rather than horizontal in orientation, without latency, and unsuppressed by visual fixation. ENG is useful in documenting these characteristics. There are commonly other signs of brainstem dysfunction (eg, cranial nerve palsies; motor, sensory, or cerebellar deficits in the limbs) or of increased intracranial pressure. Auditory function is generally spared. The underlying cause should be treated.

Karatas M. Central vertigo and dizziness: epidemiology, differential diagnosis, and common causes. *Neurologist.* 2008 Nov;14(6):355–64. [PMID: 19008741]

Kutz JW Jr. The dizzy patient. *Med Clin North Am.* 2010 Sep;94(5):989–1002. [PMID: 20736108]

Lempert T et al. Management of common central vestibular disorders. *Curr Opin Otolaryngol Head Neck Surg.* 2010 Oct;18(5):436–40. [PMID: 20639762]

DISEASES OF THE CENTRAL AUDITORY & VESTIBULAR SYSTEMS (Table 8–3)

Lesions of the eighth cranial nerve and central audiovestibular pathways produce neural hearing loss and vertigo. One characteristic of neural hearing loss is deterioration of speech discrimination out of proportion to the decrease in pure tone thresholds. Another is auditory adaptation, wherein a steady tone appears to the listener to decay and eventually disappear. Auditory evoked responses are useful in distinguishing cochlear from neural losses and may give insight into the site of lesion within the central pathways.

The evaluation of central audiovestibular disorders usually requires imaging of the internal auditory canal, cerebellopontine angle, and brain with enhanced MRI.

1. Vestibular Schwannoma (Acoustic Neuroma)

Eighth cranial nerve schwannomas are among the most common intracranial tumors. Most are unilateral, but about 5% are associated with the hereditary syndrome, neurofibromatosis type 2, in which bilateral eighth nerve tumors may be accompanied by meningiomas and other intracranial and spinal tumors. These benign lesions arise within the internal auditory canal and gradually grow to involve the cerebellopontine angle, eventually compressing the pons and resulting in hydrocephalus. Their typical auditory symptoms are unilateral hearing loss with a deterioration of speech discrimination exceeding that predicted by the degree of pure tone loss. Nonclassic presentations, such as sudden unilateral hearing loss, are fairly common. Any individual with a unilateral or asymmetric sensorineural hearing loss should be evaluated for an intracranial mass lesion. Vestibular dysfunction more often takes the form of continuous dysequilibrium than episodic vertigo. Other lesions of the cerebellopontine angle such as meningioma and epidermoids may have similar audiovestibular manifestations. Diagnosis is made by enhanced MRI. Treatment consists of observation, microsurgical excision, or stereotactic radiotherapy, depending on such factors as patient age, underlying health, and size of the tumor at presentation. Bevacizumab (vascular endothelial growth

factor blocker) has recently shown promise for treatment of tumors in patients with neurofibromatosis type 2.

Gal TJ et al. Current epidemiology and management trends in acoustic neuroma. *Otolaryngol Head Neck Surg.* 2010 May;142(5):677–81. [PMID: 20416455]

Plotkin SR et al. Hearing improvement after bevacizumab in patients with neurofibromatosis type 2. *N Engl J Med.* 2009 Jul 23;361(4):358–67. [PMID: 19587327]

Tan M et al. Trends in the management of vestibular schwannomas at Johns Hopkins 1997–2007. *Laryngoscope.* 2010 Jan;120(1):144–9. [PMID: 19877188]

Whitehouse K et al. Vestibular schwannomas—when should conservative management be reconsidered? *Br J Neurosurg.* 2010 Apr;24(2):185–90. [PMID: 19886818]

2. Vascular Compromise

Vertebrobasilar insufficiency is a common cause of vertigo in the elderly. It is often triggered by changes in posture or extension of the neck. Reduced flow in the vertebrobasilar system may be demonstrated noninvasively through magnetic resonance angiography. Empiric treatment is with vasodilators and aspirin.

Vascular loops that impinge upon the brainstem root entry zone of cranial nerves have been shown to cause dysfunction. Widely recognized examples are hemifacial spasm and tic douloureux. It has been suggested that hearing loss, tinnitus, and disabling positioning vertigo may result from a vascular loop abutting the eighth cranial nerve, although this is controversial.

Karatas M. Vascular vertigo: epidemiology and clinical syndromes. *Neurologist.* 2011 Jan;17(1):1–10. [PMID: 21192184]

Otto V et al. Treatment of vertebrobasilar insufficiency-associated vertigo with a fixed combination of cinnarizine and dimenhydrinate. *Int Tinnitus J.* 2008;14(1):57–67. [PMID: 18616088]

3. Multiple Sclerosis

Patients with multiple sclerosis may suffer from episodic vertigo and chronic imbalance. Hearing loss in this disease is most commonly unilateral and of rapid onset. Spontaneous recovery may occur.

Bovo R et al. Vertigo and autoimmunity. *Eur Arch Otorhinolaryngol.* 2010 Jan;267(1):13–9. [PMID: 19834724]

Peyvandi A et al. Neuro-otologic manifestations of multiple sclerosis. *Arch Iran Med.* 2010 May;13(3):188–92. [PMID: 20433222]

OTOLOGIC MANIFESTATIONS OF AIDS

The otologic manifestations of AIDS are protean. The pinna and external auditory canal may be affected by Kaposi sarcoma as well as persistent and potentially invasive fungal infections, particularly due to *Aspergillus fumigatus*. The most common middle ear manifestation of AIDS is serous otitis media due to eustachian tube dysfunction arising from adenoidal hypertrophy (HIV lymphadenopathy), recurrent mucosal viral infections, or an obstructing nasopharyngeal tumor (eg, lymphoma). For middle ear effusions, ventilating tubes are seldom helpful and may

trigger profuse watery otorrhea. Acute otitis media is usually caused by the typical bacterial organisms that occur in nonimmunocompromised patients, although *Pneumocystis jiroveci* otitis has been reported. Sensorineural hearing loss is common and in some cases appears to result from viral central nervous system infection. In cases of progressive hearing loss, it is important to evaluate for cryptococcal meningitis and syphilis. Acute facial paralysis due to herpes zoster infection (Ramsay Hunt syndrome) is quite common and follows a clinical course similar to that in nonimmunocompromised patients. Treatment is primarily with high-dose acyclovir (see Chapters 6 and 32). Corticosteroids may also be effective.

DISEASES OF THE NOSE & PARANASAL SINUSES

INFECTIONS OF THE NOSE & PARANASAL SINUSES

1. Acute Viral Rhinosinusitis (Common Cold)



ESSENTIALS OF DIAGNOSIS

- ▶ Clear rhinorrhea, hyposmia, and nasal congestion.
- ▶ Associated symptoms, including malaise, headache, and cough.
- ▶ Erythematous, engorged nasal mucosa on examination without intranasal purulence.
- ▶ Symptoms last < 4 weeks and typically < 10 days.
- ▶ Symptoms are self-limited.

▶ Clinical Findings

The nonspecific symptoms of the ubiquitous common cold are present in the early phases of many diseases that affect the upper aerodigestive tract. Because there are numerous serologic types of rhinoviruses, adenoviruses, and other viruses, patients remain susceptible throughout life. These infections, while generally quite benign and self-limited, have been implicated in the development or exacerbation of more serious conditions, such as acute bacterial sinusitis, acute otitis media, asthma and cystic fibrosis exacerbation, and bronchitis. Nasal congestion, decreased sense of smell, watery rhinorrhea, and sneezing accompanied by general malaise, throat discomfort and, occasionally, headache are typical in viral infections. Nasal examination usually shows erythematous, edematous mucosa and a watery discharge. The presence of purulent nasal discharge suggests bacterial rhinosinusitis.

▶ Treatment

Despite ongoing research into viral chemotherapy, at this time, there are no effective antiviral therapies for either the prevention or treatment of viral rhinitis. There is a common misperception among patients that antibiotics are

helpful. Zinc for the treatment of viral rhinitis has been controversial. A 2011 meta-analysis of randomized controlled trials demonstrated no benefit in five studies that used < 75 mg of zinc acetate daily, but significant reduction in duration of cold symptoms was noted in all three studies that used zinc acetate in daily doses of over 75 mg. The effect with zinc salts other than acetate was also significant at doses > 75 mg/d, but not as high as the zinc acetate lozenge studies (20% vs 42%). Buffered hypertonic saline (3–5%) nasal irrigation has been shown to improve symptoms and reduce the need for nonsteroidal anti-inflammatory drugs. Other supportive measures, such as oral decongestants (pseudoephedrine, 30–60 mg every 4–6 hours or 120 mg twice daily), may provide some relief of rhinorrhea and nasal obstruction. Nasal sprays, such as oxymetazoline or phenylephrine, are rapidly effective but should not be used for more than a few days to prevent rebound congestion. Withdrawal of the drug after prolonged use leads to **rhinitis medicamentosa**, an almost addictive need for continuous usage. Treatment of rhinitis medicamentosa requires mandatory cessation of the sprays, and this is often extremely frustrating for patients. Topical intranasal corticosteroids (eg, flunisolide, 2 sprays in each nostril twice daily), intranasal anticholinergic (ipratropium 0.06% nasal spray, 2–3 sprays every 8 hours as needed) or a short tapering course of oral prednisone may help during the process of withdrawal.

► Complications

Other than eustachian tube dysfunction or transient middle ear effusion, complications of viral rhinitis are unusual. Secondary acute bacterial rhinosinusitis may occur and is suggested by persistence of symptoms beyond 10 days, accompanied both by purulent green or yellow nasal secretions and unilateral facial or tooth pain. (See Acute Bacterial Rhinosinusitis below.)

While the symptoms of influenza A/H1N1 (swine flu) are much the same as other respiratory viruses, certain persons (including children younger than 5 years, adults older than 65 years, pregnant women, patients with underlying respiratory or immune disorders, and adolescents younger than 19 years receiving aspirin therapy) are at particular risk for the development of hypoxia and acute respiratory distress syndrome (ARDS). Mortality in those in whom ARDS developed was > 17%. Diagnosis of influenza A/H1N1 is confirmed by nasopharyngeal, oropharyngeal, or endobronchial swab or aspirate and identification of the virus by reverse transcriptase-polymerase chain reaction (RT-PCR). Treatment with oseltamivir or zanamivir has been effective, but up to date diagnosis, treatment, and containment guidelines should be sought from the Centers for Disease Control and Prevention at www.cdc.gov/h1n1flu/ if the diagnosis is suspected.

Hemilä H. Zinc lozenges may shorten the duration of colds: a systematic review. *Open Respir Med J.* 2011;5:51–8. [PMID: 21769305]
Sullivan SJ et al. 2009 H1N1 Influenza. *Mayo Clin Proc.* 2010 Jan;85(1):64–76. [PMID: 20007905]

2. Acute Bacterial Rhinosinusitis (Sinusitis)

ESSENTIALS OF DIAGNOSIS

- ▶ Purulent yellow-green nasal discharge or expectoration.
- ▶ Facial pain or pressure over the affected sinus or sinuses.
- ▶ Nasal obstruction.
- ▶ Acute onset of symptoms (between 1 and 4 weeks duration).
- ▶ Associated symptoms, including cough, malaise, fever, and headache.

► General Considerations

Acute sinus infections are uncommon compared with viral rhinitis, but they still affect nearly 20 million Americans annually, accounting for over 2 billion dollars in health care expenditures for sinusitis annually. Such infections are often associated with inflammation of the mucosal of the nasal cavity near the drainage pores of the sinuses. To acknowledge this inflammation as a major component of the disease and to differentiate it from such processes as allergic or acute viral rhinitis, otolaryngologists prefer the term “bacterial rhinosinusitis.”

Acute bacterial rhinosinusitis usually is a result of impaired mucociliary clearance and obstruction of the osteomeatal complex, or sinus “pore.” Edematous mucosa causes obstruction of the complex, resulting in the accumulation of mucous secretion in the sinus cavity that becomes secondarily infected by bacteria. The largest of these osteomeatal complexes is deep to the middle turbinate in the middle meatus. This complex is actually a confluence of complexes draining the maxillary, ethmoid, and frontal sinuses. The sphenoid drains from a separate complex between the septum and superior turbinate.

The typical pathogens of bacterial sinusitis are the same as those that cause acute otitis media: *S pneumoniae*, other streptococci, *H influenzae* and, less commonly, *S aureus* and *Moraxella catarrhalis*. Pathogens vary regionally in both prevalence and drug resistance. It should be kept in mind that about 25% of healthy asymptomatic individuals may, if sinus aspirates are cultured, harbor such bacteria as well. Understanding of the anatomy, pathogenesis and microbiology of acute bacterial rhinosinusitis can help the clinician afford the most expeditious and cost-effective diagnosis and treatment while avoiding serious complications.

► Clinical Findings

A. Symptoms and Signs

There are no agreed upon criteria for the diagnosis of acute bacterial rhinosinusitis in adults. All study groups note a number of major symptoms, including purulent nasal drainage, nasal obstruction or congestion, facial pain/pressure, altered smell, cough, and fever. Minor symptoms

include headache, otalgia, halitosis, dental pain, and fatigue. Many of the more specific signs and symptoms may be related to the affected sinuses. It is important to note that studies have demonstrated no correlation between patient reports of “sinus headache” and presence of sinusitis on CT scan. Bacterial rhinosinusitis can be distinguished from viral rhinitis by persistence of symptoms more than 10 days after onset or worsening of symptoms within 10 days after initial improvement. Acute infections are defined as those lasting less than 4 weeks, with subacute infections lasting between 4 weeks and 12 weeks.

Acute maxillary sinusitis is the most common form of acute bacterial rhinosinusitis because the maxillary is the largest sinus with a single drainage pathway that is easily obstructed. Unilateral facial fullness, pressure and tenderness over the cheek are common symptoms, but may not be present in many cases. Pain may refer to the upper incisor and canine teeth via branches of the trigeminal nerve, which traverse the floor of the sinus. Purulent nasal drainage should be noted with nasal airway obstruction or facial pain (pressure). Maxillary sinusitis may result from dental infection, and teeth that are tender should be carefully examined for signs of abscess. Removal of the diseased tooth or drainage of the periapical abscess typically resolves the sinus infection.

Acute ethmoiditis in adults is often accompanied by maxillary sinusitis and symptoms are similar to those described above. Localized ethmoid sinusitis may present with pain and pressure over the high lateral wall of the nose between the eyes that may radiate to the orbit.

Sphenoid sinusitis is usually seen in the setting of pansinusitis, or infection of all the paranasal sinuses on at least one side. The patient may complain of a headache “in the middle of the head” and often points to the vertex.

Acute frontal sinusitis may cause pain and tenderness of the forehead. This is most easily elicited by palpation of the orbital roof just below the medial end of the eyebrow.

Hospital-associated sinusitis is a form of acute bacterial rhinosinusitis that may present without any symptoms in the head and neck. It is a common source of fever in critically ill patients and is often associated with prolonged presence of a nasogastric or, rarely, nasotracheal tube causing inflammation of the nasal mucosa and osteomeatal complex obstruction. Pansinusitis on the side of the tube is common on imaging studies.

B. Imaging

It is usually possible to make the diagnosis of acute bacterial rhinosinusitis on clinical grounds alone. Although more sensitive than clinical examination, routine radiographs are not cost-effective and are not recommended by the Agency for Health Care Policy and Research or American Association of Otolaryngology Guidelines in the routine diagnosis of acute bacterial rhinosinusitis. They may, however, be helpful when clinically based criteria are difficult to evaluate, when the patient does not respond to appropriate therapy, or when symptoms of more serious infection are noted.

When necessary, noncontrast, screening coronal CT scans are more cost-effective and provide more information than conventional sinus films. CT provides a rapid and

effective means to assess all of the paranasal sinuses, identify areas of greater concern (such as bony dehiscence, periosteal elevation or maxillary tooth root exposure within the sinus), and speed appropriate therapy.

CT scans are reasonably sensitive but are not specific. Swollen soft tissue and fluid may be difficult to distinguish when opacification of the sinus is present from other conditions, such as chronic rhinosinusitis, nasal polyposis, or mucus retention cysts. Sinus abnormalities can be seen in most patients with an upper respiratory infection, while bacterial rhinosinusitis develops in only 2%.

If malignancy, intracranial extension or opportunistic infection is suspected, MRI with gadolinium should be ordered instead of, or in addition to, CT. MRI will distinguish tumor from fluid, inflammation, and inspissated mucus far better than CT, as well as better delineating tumor extent with respect to adjacent structures such as the orbit, skull base, and palate. Bone destruction can be demonstrated as well by MRI as by CT.

► Treatment

All patients with acute bacterial rhinosinusitis should have careful evaluation of pain. Nonsteroidal anti-inflammatory drugs are generally recommended. Sinus symptoms may be improved with oral or nasal decongestants (or both)—eg, oral pseudoephedrine, 30–120 mg per dose, up to 240 mg/d; nasal oxymetazoline, 0.05%, or xylometazoline, 0.05–0.1%, one or two sprays in each nostril every 6–8 hours for up to 3 days. All clinical practice guidelines recommend using intranasal corticosteroids (eg, fluticasone, 100 mcg each nostril twice daily) in the first 5 days of symptoms that could be acute bacterial rhinosinusitis or acute viral rhinitis. However, this use has not been approved in the United States by the Food and Drug Administration.

Eighty percent of patients with acute bacterial rhinosinusitis improve symptomatically within 2 weeks without antibiotic therapy. However, antibiotics may be considered when symptoms last more than 10–14 days or when symptoms (including fever, facial pain, and swelling of the face) are severe. Administration of antibiotics does, however, reduce the incidence of clinical failure by 50% and, coupled with clinical criteria-based diagnosis, represents the most cost-effective treatment strategy. Double-blinded studies exist to support numerous antibiotic choices. A summary of national guidelines for the treatment of acute sinusitis can be found in Table 8–4. Selection of antibiotics is usually empiric and based on a number of factors including regional patterns of antibiotic resistance, antibiotic allergy, cost, and patient tolerance. Unless the patient is allergic to penicillin, amoxicillin should be used as the first-line agent. Treatment is usually for 7–10 days, although longer courses are sometimes required to prevent relapses. Macrolide therapy has been recommended as first-line therapy in patients with penicillin allergy, and tetracycline have also been used.

Multidrug resistant *S pneumoniae* prevalence is growing in many urban areas of the United States as are β -lactamase β -lactam inhibitor producing strains of *H influenzae* and *M catarrhalis*. In such regions, guidelines call for empiric use of amoxicillin-clavulanate or second- or third-generation cephalosporins. Fluoroquinolones are reserved for treatment

Table 8-4. Oral antibiotic regimens for acute sinusitis.

Drug	Dose	Duration	Notes
First-line therapy			
Amoxicillin	1000 mg three times daily	7-10 days	
Trimethoprim-sulfamethoxazole	160 mg-800 mg twice daily	7-10 days	Suitable in penicillin allergy
Doxycycline	200 mg once daily × 1 day, 100 mg twice daily thereafter	7-10 days	Suitable in penicillin allergy
Amoxicillin-clavulanate ¹	1000/62.5 mg ER 2 tablets twice daily	10 days	If no improvement after 3 days on first-line therapy
First-line therapy after recent antibiotic use²			
Levofloxacin	500 mg once daily	10 days	
Amoxicillin-clavulanate	875/125 mg twice daily	10 days	
Second-line therapy			
Amoxicillin-clavulanate	1000/62.5 mg ER 2 tablets twice daily	10 days	If no improvement after 3 days on first-line therapy
Moxifloxacin	400 mg once daily	10 days	If no improvement after 3 days on first-line therapy

¹In communities where there is multidrug resistant *S pneumoniae* and β -lactamase β -lactam inhibitor producing strains of *H influenzae* and *M catarrhalis*.

²Within last 4-6 weeks.

Adapted, with permission, from Marple BF et al. Acute bacterial rhinosinusitis: a review of U.S. treatment guidelines. *Otolaryngol Head Neck Surg.* 2006 Sep;135(3):341-8. Copyright © 2006 Sage Publications. Reprinted by permission of Sage Publications.

failures or for patients with a recent history of antibiotic therapy for another infection. Recurrent sinusitis or sinusitis that does not appear to respond clinically warrants CT imaging and evaluation by a specialist.

Hospital-associated infections in critically ill patients are treated differently from community-acquired infections. Broad-spectrum antibiotic coverage for bacteria including *P aeruginosa*, *S aureus* (including methicillin-resistant strains) and anaerobes must be considered. Removal of the nasogastric tube and improved nasal hygiene (nasal saline sprays, humidification of supplemental nasal oxygen, and nasal decongestants) are critical interventions and often curative in mild cases without aggressive antibiotic use. Endoscopic or transantral cultures may help direct medical therapy in complicated cases.

► Complications

Local complications of acute bacterial rhinosinusitis include orbital cellulitis and abscess, osteomyelitis, intracranial extension and cavernous sinus thrombosis.

Any change in the ocular examination in a patient with acute bacterial rhinosinusitis necessitates immediate CT imaging. Orbital complications typically occur by extension of ethmoid sinusitis through the lamina papyracea, a thin layer of bone that comprises the medial orbital wall. Extension in this area may cause orbital cellulitis leading to proptosis, gaze restriction, and orbital pain. Select cases are responsive to intravenous antibiotics with or without corticosteroids and should be managed in close conjunction with an ophthalmologist or otolaryngologist, or both. Extension through the lamina papyracea can also lead to subperiosteal abscess formation (orbital abscess). Such abscesses cause marked proptosis, ophthalmoplegia and

pain with medial gaze. While some of these abscesses will respond to antibiotics, such findings should prompt an immediate referral to a specialist for consideration of decompression and evacuation. Failure to intervene quickly may lead to permanent visual impairment and a “frozen globe.”

Osteomyelitis requires prolonged antibiotics as well as removal of necrotic bone. The frontal sinus is most commonly affected, with bone involvement suggested by a tender puffy swelling of the forehead (Pott puffy tumor). Following treatment, secondary cosmetic reconstructive procedures may be necessary.

Intracranial complications of sinusitis can occur either through hematogenous spread, as in cavernous sinus thrombosis and meningitis, or by direct extension, as in epidural and intraparenchymal brain abscesses. Fortunately, they are rare today. Cavernous sinus thrombosis is heralded by ophthalmoplegia, chemosis, and visual loss. The diagnosis is most commonly confirmed by MRI and, when identified early, it typically responds to intravenous antibiotics. Frontal epidural and intracranial abscesses are often clinically silent, but may present with altered mental status, persistent fever, or severe headache.

► When to Refer

Failure of acute bacterial rhinosinusitis to resolve after an adequate course of oral antibiotics may necessitate referral to an otolaryngologist for evaluation. Endoscopic cultures may direct further treatment choices. Nasal endoscopy and CT scan are indicated when symptoms persist longer than 4-12 weeks. Any patients with suspected extension of disease outside the sinuses should be evaluated urgently by an otolaryngologist and imaging.

▶ When to Admit

- Facial swelling and erythema indicative of facial cellulitis.
- Proptosis.
- Vision change or gaze abnormality indicative of orbital cellulitis.
- Abscess or cavernous sinus involvement.
- Mental status changes suggestive of intracranial extension.
- Immunocompromised status.
- Failure to respond to appropriate first-line treatment for acute bacterial rhinosinusitis or symptoms persisting longer than 4 weeks.

Ahovuo-Saloranta A et al. Antibiotics for acute maxillary sinusitis. *Cochrane Database Syst Rev.* 2008 Apr 16;(2):CD000243. [PMID: 18425861]

Chan Y et al. An update on the classifications, diagnosis, and treatment of rhinosinusitis. *Curr Opin Otolaryngol Head Neck Surg.* 2009 Jun;17(3):204–8. [PMID: 19346944]

Desrosiers M. Diagnosis and management of acute rhinosinusitis. *Postgrad Med.* 2009 May;121(3):83–9. [PMID: 19491544]

Meltzer EO et al. Rhinosinusitis diagnosis and management for the clinician: a synopsis of recent consensus guidelines. *Mayo Clin Proc.* 2011 May 86(5):427–43. [PMID: 21490181]

Pant H et al. The role of allergy in rhinosinusitis. *Curr Opin Otolaryngol Head Neck Surg.* 2009 Jun;17(3):232–8. [PMID: 19469053]

Ryan MW. Evaluation and management of the patient with “sinus”. *Med Clin North Am.* 2010 Sep;94(5):881–90. [PMID: 20736100]

3. Nasal Vestibulitis & *S aureus* Nasal Colonization

Inflammation of the nasal vestibule may result from folliculitis of the hairs that line this orifice and is usually the result of nasal manipulation or hair trimming. Systemic antibiotics effective against *S aureus* (such as dicloxacillin, 250 mg orally four times daily for 7–10 days) are indicated. Topical mupirocin or bacitracin (applied two or three times daily) may be a helpful addition and may prevent future occurrences. If recurrent, the addition of rifampin (10 mg/kg orally twice daily for the last 4 days of treatment) may eliminate the *S aureus* carrier state. If a furuncle exists, it should be incised and drained, preferably intranasally. Adequate treatment of these infections is important to prevent retrograde spread of infection through valveless veins into the cavernous sinus and intracranial structures.

S aureus is the leading nosocomial pathogen in the world, and nasal carriage is a well-defined risk factor in the development and spread of nosocomial infections. While the vast majority of patients have no vestibulitis symptoms, screening methods (including nasal swabs and PCR-based assays) have demonstrated rates of *S aureus* nasal colonization at around 30% and methicillin-resistant *S aureus* colonization in patients in the intensive care unit to be as high as 11%. Elimination of the carrier state is challenging, but

studies of mupirocin (2% topical nasal application twice daily) have demonstrated efficacy in reducing surgical and catheter/hardware infections. Consensus screening and treatment recommendations are not yet available.

van Rijen M et al. Mupirocin ointment for preventing *Staphylococcus aureus* infections in nasal carriers. *Cochrane Database Syst Rev.* 2008 Oct 8;(4):CD006216. [PMID: 18843708]

4. Invasive Fungal Sinusitis

Invasive fungal sinusitis is rare and includes both rhinocerebral mucormycosis (*Mucor*, *Absidia*, and *Rhizopus sp.*) and other invasive fungal infections, such as *Aspergillus*. The fungus spreads rapidly through vascular channels and may be lethal if not detected early. Patients with mucormycosis almost invariably have a contributing factor that results in some degree of immunocompromise, such as diabetes mellitus, long-term corticosteroid therapy, or end-stage renal disease. Mucormycosis is more common, however, in patients who are profoundly immunocompromised for the treatment of hematologic malignancies. Occasional cases have been reported in patients with AIDS though *Aspergillus sp.* is more common in this setting. The initial symptoms may be similar to those of acute bacterial rhinosinusitis, although facial pain is often more severe. Nasal drainage is typically clear or straw-colored, rather than purulent, and visual symptoms may be noted at presentation in the absence of significant nasal findings. On examination, the classic finding of mucormycosis is a black eschar on the middle turbinate. This finding is not universal and may be inapparent if the infection is deep or high within the nasal bones. Often the mucosa appears normal or simply pale and dry. Early diagnosis requires suspicion of the disease and nasal biopsy with silver stains, revealing broad nonseptate hyphae within tissues and necrosis with vascular occlusion. Because CT or MRI may initially show only soft tissue changes, biopsy and ultimate debridement should be based on the clinical setting rather than radiographic demonstration of bony destruction or intracranial changes.

Invasive fungal sinusitis represents a medical and surgical emergency. Once recognized, prompt wide surgical debridement and amphotericin B by intravenous infusion are indicated for patients with reversible immune deficiency. Lipid-based amphotericin B (Ambisome) may be used in patients who have kidney disease or in those in whom it develops secondary to nephrotoxic doses of non-lipid amphotericin. Other antifungals, including voriconazole and caspofungin, may be appropriate therapy depending on the speciation of the organism. There is evidence that suggests that iron chelator therapy may also be a useful adjunct. While necessary for any possibility of cure, surgical management often results in tremendous disfigurement and functional deficits. Even with early diagnosis and immediate appropriate intervention, the prognosis is guarded and often results in the loss of at least one eye. In persons with diabetes, the mortality rate is about

20%. If kidney disease is present or develops, mortality is over 50%; in the setting of AIDS or hematologic malignancy with neutropenia, mortality approaches 100%.

Epstein VA et al. Invasive fungal sinusitis and complications of rhinosinusitis. *Otolaryngol Clin North Am.* 2008 Jun; 41(3): 497–524. [PMID: 18435995]

Kasapoglu F et al. Acute invasive fungal rhinosinusitis: evaluation of 26 patients treated with endonasal or open surgical procedures. *Otolaryngol Head Neck Surg.* 2010 Nov;143(5): 614–20. [PMID: 20974328]

ALLERGIC RHINITIS



ESSENTIALS OF DIAGNOSIS

- ▶ Clear rhinorrhea, sneezing, tearing, eye irritation, and pruritus.
- ▶ Associated symptoms, including cough, bronchospasm, eczematous dermatitis.
- ▶ Environmental allergen exposure with presence of allergen specific IgE.

▶ General Considerations

Allergic rhinitis is very common in the United States. Population studies have reported the prevalence as between 14% and 40% among Americans, with most consensus panels agreeing on 20%. Allergic rhinitis adversely affects school and work performance, costing about \$6 billion annually in the United States. These costs may be underestimated as epidemiology studies consistently show an association with asthma. Seasonal allergic rhinitis is most commonly caused by pollens and spores. Flowering shrub and tree pollens are most common in the spring, flowering plants and grasses in the summer, and ragweed and molds in the fall. Dust, household mites, air pollution, and pet dander may produce year-round symptoms, termed “perennial rhinitis.”

Allergic rhinitis is caused by exposure to an airborne allergen in a predisposed individual. Activation of both humoral (B-cell) and cytotoxic (T-cell) immune responses with subsequent allergen-specific IgE responses causes release of inflammatory mediators. The response is increased as antigen is passed to regional lymph nodes for greater T-cell activation. Interleukin and cytokine release causes specific activation of mast cells, eosinophils, plasma cells, basophils and other T-cells. Many of these circulating cells then migrate into the nasal and ocular epithelium where they contribute directly to symptoms through proinflammatory mediators, including histamine, prostaglandins, and kinins.

▶ Clinical Findings

The symptoms of “hay fever” are similar to those of viral rhinitis but are usually persistent and may show seasonal

variation. Nasal symptoms are often accompanied by eye irritation, pruritus, conjunctival erythema, and excessive tearing. Many patients will note a strong family history of atopy or allergy.

The clinician should be careful to distinguish allergic rhinitis from nonallergic or vasomotor rhinitis. **Vasomotor rhinitis** is caused by increased sensitivity of the vidian nerve and is a common cause of clear rhinorrhea in the elderly. Often patients will report that they have troubling rhinorrhea in response to numerous nasal stimuli, including warm or cold air, odors or scents, light, or particulate matter.

On physical examination, the mucosa of the turbinates is usually pale or violaceous because of venous engorgement. This is in contrast to the erythema of viral rhinitis. Nasal polyps, which are yellowish boggy masses of hypertrophic mucosa, are associated with long-standing allergic rhinitis.

▶ Treatment

A. Intranasal Corticosteroids

Intranasal corticosteroid sprays have revolutionized the treatment of allergic rhinitis. Evidence-based literature reviews show that these are more effective—and frequently less expensive—than nonsedating antihistamines. Patients should be reminded that there may be a delay in onset of relief of 2 or more weeks. Corticosteroid sprays may also shrink hypertrophic nasal mucosa and nasal polyps, thereby providing an improved nasal airway and osteomeatal complex drainage. Because of this effect, intranasal corticosteroids are critical in treating allergy in patients prone to recurrent acute bacterial rhinosinusitis or chronic rhinosinusitis. There are many available preparations, including beclomethasone (42 mcg/spray twice daily per nostril), flunisolide (25 mcg/spray twice daily per nostril), mometasone furoate (200 mcg once daily per nostril), budesonide (100 mcg twice daily per nostril) and fluticasone propionate (200 mcg once daily per nostril). All intranasal corticosteroids are considered equally effective. Probably the most critical factor is compliance with regular use and proper introduction into the nasal cavity. In order to deliver medication to the region of the middle meatus, proper application involves holding the bottle straight up with the head tilted forward and pointing the bottle toward the ipsilateral ear when spraying. Side effects are limited and the most annoying is epistaxis. Some experts believe that this is related to incorrect delivery of the drug to the nasal septum.

B. Antihistamines

Treatment of allergic and perennial rhinitis has improved in recent years. Antihistamines offer temporary, but immediate, control of many of the most troubling symptoms of allergic rhinitis. Over-the-counter antihistamines include nonsedating loratadine (10 mg orally once daily) and minimally sedating cetirizine (10 mg orally once daily). Brompheniramine or chlorpheniramine (4 mg orally

every 6–8 hours, or 8–12 mg orally every 8–12 hours as a sustained-release tablet) and clemastine (1.34–2.68 mg orally twice daily) may be less expensive, although usually associated with some drowsiness. Prescription oral H₁-receptor antagonists include fexofenadine (60 mg twice daily or 120 mg once daily) and desloratadine (5 mg once daily). Fexofenadine appears to be nonsedating; desloratadine is minimally sedating. Also shown to be effective in randomized trials are ebastine (10–20 mg orally once daily) and misolastine (10 mg orally once daily). The H₁-receptor antagonist antihistamine nasal spray azelastine (1–2 sprays per nostril daily) has also been shown to be effective in a randomized trial. Topical nasal sprays are particularly useful in patients who experience side effects, mostly xerostomia and sedation, of oral antihistamines. Many patients who find initial benefit from an antihistamine complain that allergy symptoms eventually return after several months of use. In such patients, typically with perennial allergy problems, antihistamine tolerance seems to develop and alternating effective antihistamines periodically can control symptoms over the long term.

C. Adjunctive Treatment Measures

In addition to intranasal corticosteroid sprays and antihistamines, including H₁-receptor antagonists, the literature supports the use of antileukotriene medications such as montelukast (10 mg/d orally) alone or with cetirizine (10 mg/d orally) or loratadine (10 mg/d orally). There are proinflammatory effects of cysteinyl leukotrienes in upper airway disease, including allergic rhinitis, and hyperplastic polyposis, and sinusitis. Improved nasal rhinorrhea, sneezing, and congestion are seen with the use of leukotriene receptor antagonists, often in conjunction with antihistamines. Cromolyn sodium and sodium nedocromil are also useful adjunct agents for allergic rhinitis. They work by stabilizing mast cells and preventing proinflammatory mediator release. They are not absorbed by the gastrointestinal tract but do function topically and have very few side effects. The most useful form of cromolyn is probably the ophthalmologic preparation; the nasal preparation is not nearly as effective as inhaled corticosteroids. Intranasal cromolyn is cleared rapidly and must be administered four times daily for continued relief of symptoms.

Intranasal anticholinergic agents, such as ipratropium bromide 0.03% or 0.06% sprays (42–84 mcg per nostril three times daily), may be helpful adjuncts when rhinorrhea is a major symptom. Ipratropium nasal sprays are not as effective as intranasal corticosteroids for treating allergic rhinitis but are useful for treating **vasomotor rhinitis**.

Avoiding or reducing exposure to airborne allergens is the most effective means of alleviating symptoms of allergic rhinitis. Depending on the allergen, this can be extremely difficult. Maintaining an allergen-free environment by covering pillows and mattresses with plastic covers, substituting synthetic materials (foam mattress, acrylics) for animal products (wool, horsehair), and removing dust-collecting household fixtures (carpets, drapes, bedspreads,

wicker) is worth the attempt to help more troubled patients. Air purifiers and dust filters may also aid in maintaining an allergen-free environment. Nasal saline irrigations are a useful adjunct in the treatment of allergic rhinitis to mechanically flush the allergens from the nasal cavity. Though debated, there is no clear benefit to hypertonic saline over commercially available normal saline preparations (eg, Ayr or Ocean Spray). When symptoms are extremely bothersome, a search for offending allergens may prove helpful. This can either be done by serum radioallergen sorbent test (RAST) testing or skin testing by an allergist.

In some cases, allergic rhinitis symptoms are inadequately relieved by medication and avoidance measures. Often, such patients have a strong family history of atopy and may also have lower respiratory manifestations such as allergic asthma. Referral to an allergist may be appropriate for consideration of immunotherapy. This treatment course is quite involved, with proper identification of offending allergens, progressively increasing doses of allergen(s) and eventual maintenance dose administration over a period of 3–5 years. Immunotherapy has been proven to reduce circulating IgE levels in patients with allergic rhinitis and reduce the need for allergy medications. While oral allergen exposure is actively being investigated, currently the primary mode of allergen exposure is by subcutaneous injection. Treatments are given at a suitable medical facility with monitoring following treatment because of the risk of anaphylaxis during dose escalation. Local reactions are common and usually self-limited.

Bernstein DI et al. Current standards and future directions in immunotherapy: perspectives on challenges and opportunities for the allergist. *Ann Allergy Asthma Immunol*. 2011 Nov;107(5):422–5. [PMID: 22018613]

Bousquet J et al. Implementation of guidelines for allergic rhinitis in specialist practice. A randomized pragmatic controlled trial. *Int Arch Allergy Immunol*. 2009;150(1):75–82. [PMID: 19339805]

Church MK et al. Treating allergic rhinitis: continuous versus on-demand regime? Executive summary of the Supportive Initiatives for the Global Management of Allergy (SIGMA): report from the Belgian Working Group. *B-ENT*. 2009;5(Suppl 12):1–25. [PMID: 19475789]

Sheikh A et al. House dust mite avoidance measures for perennial allergic rhinitis. *Cochrane Database Syst Rev*. 2007 Jan 24;(1):CD001563. [PMID: 17253461]

OLFACTORY DYSFUNCTION



ESSENTIALS OF DIAGNOSIS

- ▶ Subjective diminished smell or taste sensation.
- ▶ Lack of objective nasal obstruction.
- ▶ Objective decrease in olfaction demonstrated by testing.

► General Considerations

Odorant molecules traverse the nasal vault to reach the cribriform area and become soluble in the mucus overlying the exposed dendrites of receptor cells. Anatomic blockage of the nasal cavity with subsequent airflow disruption is the most common cause of olfactory dysfunction (hyposmia or anosmia). Polyps, septal deformities, and nasal tumors may be the cause. Transient olfactory dysfunction often accompanies the common cold, nasal allergies, and perennial rhinitis through changes in the nasal and olfactory epithelium. About 20% of olfactory dysfunction is idiopathic, although it often follows a viral illness. Central nervous system neoplasms, especially those that involve the olfactory groove or temporal lobe, may affect olfaction and must be considered in patients with no other explanation for their hyposmia or other neurologic signs. Head trauma accounts for < 5% of cases of hyposmia but is more commonly associated with anosmia. Absent, diminished, or distorted smell or taste has been reported in a wide variety of endocrine, nutritional, and nervous disorders. In particular, olfactory dysfunction in Parkinson disease and Alzheimer disease has been the subject of research. A great many medications have also been implicated in altering olfaction.

► Clinical Findings

Evaluation of olfactory dysfunction should include a thorough history of systemic illnesses and medication use as well as a physical examination focusing on the nose and nervous system. Nasal obstruction (from polyps, trauma, foreign bodies or nasal masses) can cause functional hyposmia and should be excluded before concluding that the disruption of olfaction is primary. Most clinical offices are not set up to test olfaction, but such tests may at times be worthwhile if only to assess whether a patient possesses any sense of smell at all. The University of Pennsylvania Smell Identification Test (UPSIT) is available commercially and is a simple, self-administered “scratch-and-sniff” test that is useful in differentiating hyposmia, anosmia, and malingering. Odor threshold can be tested at regional specialty centers using increasing concentrations of various odorants.

► Treatment

There is no specific treatment for primary disruption of olfaction. While some disturbances spontaneously resolve, little evidence supports the use of large doses of vitamin A and zinc to patients with transient olfactory dysfunction. The degree of hyposmia is the greatest predictor of recovery, with less severe hyposmia recovering at a much higher rate. In permanent hyposmia, counseling should be offered about seasoning foods with spices (eg, pepper) that stimulate the trigeminal as well as olfactory chemoreceptors, abuse of table salt as a seasoning, and safety issues such as the use of smoke alarms and electric rather than gas home appliances.

Doty RL. The olfactory system and its disorders. *Semin Neurol*. 2009 Feb;29(1):74–81. [PMID: 19214935]
 Hummel T et al. Prognostic factors of olfactory dysfunction. *Arch Otolaryngol Head Neck Surg*. 2010 Apr;136(4):347–51. [PMID: 20403850]
 Lafreniere D et al. Anosmia: loss of smell in the elderly. *Otolaryngol Clin North Am*. 2009 Feb;42(1):123–31. [PMID: 19134495]

EPISTAXIS



ESSENTIALS OF DIAGNOSIS

- Bleeding from the unilateral anterior nasal cavity most commonly.
- Most cases may be successfully treated by direct pressure on the bleeding site for 15 minutes. When this is inadequate, topical sympathomimetics and various nasal tamponade methods are usually effective.
- Posterior, bilateral, or large volume epistaxis should be triaged immediately to a specialist in a critical care setting.

► General Considerations

Epistaxis is an extremely common problem in the primary care setting. Predisposing factors include nasal trauma (nose picking, foreign bodies, forceful nose blowing), rhinitis, drying of the nasal mucosa from low humidity or supplemental nasal oxygen, deviation of the nasal septum, hypertension, atherosclerotic disease, hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu syndrome), inhaled nasal cocaine or other drug use, and alcohol use. Anticoagulation or antiplatelet medications may be associated with a higher incidence of epistaxis, more frequent recurrence of epistaxis, and greater difficulty controlling bleeding, but they do not cause epistaxis. Bleeding is most common in the anterior septum where a confluence of veins creates a superficial venous plexus (Kiesselbach plexus).

► Clinical Findings

It is important in all patients with epistaxis to consider underlying causes of the bleeding. Laboratory assessment of bleeding parameters may be indicated, especially in recurrent cases. Once the acute episode has passed, careful examination of the nose and paranasal sinuses to rule out neoplasia and hereditary hemorrhagic telangiectasia is wise.

Patients presenting with epistaxis often have higher blood pressures than control patients, but in many cases, blood pressure returns to normal following treatment of acute bleeding. Repeat evaluation for clinically significant hypertension and treatment should be performed following control of epistaxis and removal of any packing.

► Treatment

Most cases of anterior epistaxis may be successfully treated by direct pressure on the site by compression of the nares continuously for 15 min. Venous pressure is reduced in the sitting position, and slight leaning forward lessens the swallowing of blood. Short-acting topical nasal decongestants (eg, phenylephrine, 0.125–1% solution, one or two sprays), which act as vasoconstrictors, may also be helpful. When the bleeding does not readily subside, the nose should be examined, using good illumination and suction, in an attempt to locate the bleeding site. Topical 4% cocaine applied either as a spray or on a cotton strip serves both as an anesthetic and a vasoconstrictor. If cocaine is unavailable, a topical decongestant (eg, oxymetazoline) and a topical anesthetic (eg, tetracaine or lidocaine) provide similar results. When visible, the bleeding site may be cauterized with silver nitrate, diathermy, or electrocautery. A supplemental patch of Surgicel or Gelfoam may be helpful with a moisture barrier, such as petroleum-based ointment, to prevent drying and crusting.

Occasionally, a site of bleeding may be inaccessible to direct control, or attempts at direct control may be unsuccessful. In such cases there are a number of alternatives. When the site of bleeding is anterior, a hemostatic sealant, pneumatic nasal tamponade, or anterior packing may suffice. There are a number of ways to do this, such as with several feet of lubricated iodoform packing systematically placed in the floor of the nose and then the vault of the nose, or with various manufactured products designed for nasal tamponade.

About 5% of nasal bleeding originates in the **posterior nasal cavity**. Such bleeds are more commonly associated with atherosclerotic disease and hypertension. If an anteriorly placed pneumatic nasal tamponade is unsuccessful, it may be necessary to consult an otolaryngologist for a pack to occlude the choana before placing a pack anteriorly. In emergency settings, double balloon packs (Epistat) may facilitate rapid control of bleeding with little or no mucosal trauma. Because such packing is uncomfortable, bleeding may persist, and vasovagal syncope is quite possible, hospitalization for monitoring and stabilization is indicated. Opioid analgesics are needed to reduce the considerable discomfort and elevated blood pressure caused by a posterior pack.

Surgical management of epistaxis, through ligation of the nasal arterial supply (internal maxillary artery and ethmoid arteries) is an alternative to posterior nasal packing. Endovascular embolization of the internal maxillary artery or facial artery is also quite effective and can allow very specific control of hemorrhage. Such alternatives are necessary when packing fails to control life-threatening hemorrhage. On very rare occasions, ligation of the external carotid artery may be necessary.

After control of epistaxis, the patient is advised to avoid straining and vigorous exercise for several days. Nasal saline should be applied to the packing frequently to keep the packing moist. Avoidance of hot or spicy foods and tobacco is also advisable, since these may cause nasal vasodilation. Avoiding nasal trauma, including nose picking, is

an obvious necessity. Lubrication with petroleum jelly or bacitracin ointment and increased home humidity may also be useful ancillary measures. Finally, antistaphylococcal antibiotics (eg, cephalexin, 500 mg orally four times daily, or clindamycin, 150 mg orally four times daily) are indicated to reduce the risk of toxic shock syndrome developing while the packing remains in place (at least 5 days).

► When to Refer

- Patients with recurrent epistaxis, large volume epistaxis, and episodic epistaxis with associated nasal obstruction should be referred to an otolaryngologist for endoscopic evaluation and possible imaging.
- Those with ongoing bleeding beyond 15 minutes should be taken to a local emergency department if the clinician is not prepared to manage acute epistaxis.

Manes RP. Evaluating and managing the patient with nosebleeds. *Med Clin North Am.* 2010 Sep;94(5):903–12. [PMID: 20736102]

Reaven D et al. Management of posterior epistaxis. *Acad Emerg Med.* 2008 Jun;15(6):585. [PMID: 18616451]

Schlosser RJ. Clinical practice. Epistaxis. *N Engl J Med.* 2009 Feb 19;360(8):784–9. [PMID: 19228621]

NASAL TRAUMA

The nasal pyramid is the most frequently fractured bone in the body. Fracture is suggested by crepitation or palpably mobile bony segments. Epistaxis and pain are common, as are soft tissue hematomas (“black eye”). It is important to make certain that there is no palpable step-off of the infraorbital rim, which would indicate the presence of a zygomatic complex fracture. Radiologic confirmation may at times be helpful but is not necessary in uncomplicated nasal fractures. It is also important to assess for possible concomitant additional facial, pulmonary, or intracranial injuries when the circumstances of injury are suggestive, as in the case of automobile and motorcycle accidents.

Treatment is aimed at maintaining long-term nasal airway patency and cosmesis. Closed reduction, using topical 4% cocaine and locally injected 1% lidocaine, should be attempted within 1 week of injury. In the presence of marked nasal swelling, it is best to wait several days for the edema to subside before undertaking reduction. Persistent functional or cosmetic defects may be repaired by delayed reconstructive nasal surgery.

Intranasal examination should be performed in all cases to rule out septal hematoma, which appears as a widening of the anterior septum, visible just posterior to the columella. The septal cartilage receives its only nutrition from its closely adherent mucoperichondrium. An untreated subperichondrial hematoma will result in loss of the nasal cartilage with resultant saddle nose deformity. Septal hematomas may become infected, with *S aureus* most commonly, and should be drained with an incision in the inferior mucoperichondrium on both sides.

Packing for 2–5 days is often helpful to help prevent re-formation of the hematoma. Antibiotics with

antistaphylococcal efficacy (eg, cephalexin, 500 mg four times daily, or clindamycin, 150 mg four times daily) should be given for 3–5 days or the duration of the packing to reduce the risk of toxic shock syndrome and the drained fluid sent for culture.

Green KM. Reduction of nasal fractures under local anaesthetic. *Rhinology*. 2001 Mar;39(1):43–6. [PMID: 11340695]
Ziccardi VB et al. Management of nasal fractures. *Oral Maxillofac Surg Clin North Am*. 2009 May;21(2):203–8. [PMID: 19348986]

TUMORS & GRANULOMATOUS DISEASE

1. Benign Nasal Tumors

A. Nasal Polyps

Nasal polyps are pale, edematous, mucosally covered masses commonly seen in patients with allergic rhinitis, but compelling evidence argues against a purely allergic pathogenesis. They may result in chronic nasal obstruction and a diminished sense of smell. In patients with nasal polyps and a history of asthma, aspirin should be avoided as it may precipitate a severe episode of bronchospasm, known as **triad asthma** (Samter triad). Such patients may have an immunologic salicylate sensitivity. The presence of polyps in children should suggest the possibility of cystic fibrosis.

Initial treatment with topical nasal corticosteroids (see Allergic Rhinitis section for specific drugs) for 1–3 months is usually successful for small polyps and may reduce the need for operation. A short course of oral corticosteroids (eg, prednisone, 6-day course using 21 5-mg tablets: 30 mg on day 1 and tapering by 5 mg each day) may also be of benefit. When polyps are massive or medical management is unsuccessful, polyps may be removed surgically. In healthy persons, this is a minor outpatient procedure. In recurrent cases or when surgery itself is associated with increased risk (such as in patients with asthma), a more complete procedure, such as ethmoidectomy, may be advisable. In recurrent polyposis, it may be necessary to remove polyps from the ethmoid, sphenoid, and maxillary sinuses to provide longer-lasting relief. Intranasal corticosteroid should be continued following polyp removal to prevent recurrence, and the clinician should consider allergen testing to determine the offending allergen and avoidance measures.

Becker SS. Surgical management of polyps in the treatment of nasal airway obstruction. *Otolaryngol Clin North Am*. 2009 Apr;42(2):377–85. [PMID: 19328899]
Martinez-Devesa P et al. Oral steroids for nasal polyps. *Cochrane Database Syst Rev*. 2011 Jul 6;(7):CD005232. [PMID: 21735400]
Rasp G. Is there a role for leukotriene antagonists in the prevention of recurrent nasal polyps? *Curr Opin Allergy Clin Immunol*. 2010 Jun;10(3):200–5. [PMID: 20431368]
Williams AN et al. The clinical effectiveness of aspirin desensitization in chronic rhinosinusitis. *Curr Allergy Asthma Rep*. 2008 May;8(3):245–52. [PMID: 18589844]

B. Inverted Papilloma

Inverted papillomas are benign tumors caused by human papillomavirus (HPV) that usually arise on the lateral nasal wall. They present with unilateral nasal obstruction and occasionally hemorrhage. They are often easily seen on anterior rhinoscopy as cauliflower-like growths in or around the middle meatus. Because SCC is seen in about 10% of inverted or schneiderian papillomas, complete excision is strongly recommended. This usually requires a medial maxillectomy, but in selected cases an endoscopic approach may be possible. Because recurrence rates for inverted papilloma are reported to be as high as 20%, subsequent clinical and radiologic follow-up is imperative. All excised tissue (not just a portion) should be carefully reviewed by the pathologist to be sure no carcinoma is present.

Anari S et al. Sinonasal inverted papilloma: narrative review. *J Laryngol Otol*. 2010 Jul;124(7):705–15. [PMID: 20388243]
Reh DD et al. The role of endoscopic sinus surgery in the management of sinonasal inverted papilloma. *Curr Opin Otolaryngol Head Neck Surg*. 2009 Feb;17(1):6–10. [PMID: 19225300]

C. Juvenile Angiofibroma

These highly vascular tumors arise in the nasopharynx, typically in adolescent males. Initially, they cause nasal obstruction and hemorrhage. Any adolescent male with recurrent epistaxis should be evaluated for an angiofibroma. *The clinician should take great care when considering a biopsy because these masses can bleed profusely.* Although benign, these tumors expand locally from the sphenopalatine foramen to the pterygopalatine fossa at the pterygoid canal and extend to the pterygoid base, the greater wing of the sphenoid, the nasal cavity, and the paranasal sinuses. They may involve the skull base, usually extracranially, and extend into the superior clivus. Treatment consists of preoperative embolization followed by surgical excision via an approach appropriate for the tumor extent. Small angiofibromas that do not involve the infratemporal fossa may be resected endoscopically. Extensive ones may require skull base approaches. Recurrences are not uncommon and should be resected if possible. Unresectable recurrences that do not appear to grow significantly may be followed radiologically with serial MR scans in expectation of possible eventual involution stabilization or involution of tumor. Low-dose (30 Gy) irradiation may be helpful in nonresectable, continually growing tumors.

Carrillo JF et al. Juvenile nasopharyngeal angiofibroma: clinical factors associated with recurrence, and proposal of a staging system. *J Surg Oncol*. 2008 Aug 1;98(2):75–80. [PMID: 18623038]
Glad H et al. Juvenile nasopharyngeal angiofibromas in Denmark 1981–2003: diagnosis, incidence, and treatment. *Acta Otolaryngol*. 2007 Mar;127(3):292–9. [PMID: 17364367]

2. Malignant Nasopharyngeal & Paranasal Sinus Tumors

Though rare, malignant tumors of the nose, nasopharynx, and paranasal sinuses are quite problematic because they tend to remain asymptomatic until late in their course. SCC is the most common cancer found in the sinuses and nasopharynx. It is especially common in the nasopharynx, where it obstructs the eustachian tube and results in serous otitis media. Nasopharyngeal carcinoma (poorly differentiated SCC, nonkeratinizing SCC, or lymphoepithelioma) is usually associated with elevated IgA antibody to the viral capsid antigen of the Epstein-Barr virus (EBV). It is particularly common in patients of southern Chinese descent. Adenocarcinomas, mucosal melanomas, sarcomas, and non-Hodgkin lymphomas are less commonly encountered neoplasms of this area.

Early symptoms are nonspecific, mimicking those of rhinitis or sinusitis. Unilateral nasal obstruction, otitis media, and discharge are common, with pain and recurrent hemorrhage often clues to the diagnosis of cancer. Any adult with persistent unilateral nasal symptoms or new otitis media should be thoroughly evaluated with nasal endoscopy and nasopharyngoscopy. A high index of suspicion remains a key to early diagnosis of these tumors. Patients often present with advanced symptoms such as proptosis, expansion of a cheek, or ill-fitting maxillary dentures. Malar hypesthesia, due to involvement of the infraorbital nerve, is common in maxillary sinus tumors. Biopsy is necessary for definitive diagnosis, and MRI is the best imaging study to delineate the extent of disease and plan appropriate surgery and radiation.

Treatment depends on the tumor type and the extent of disease. Nasopharyngeal carcinoma at this time is best treated by concomitant radiation and cisplatin followed by adjuvant chemotherapy with cisplatin and fluorouracil—this protocol significantly decreases local, nodal, and distant failures and increased progression-free and overall survival. Locally recurrent nasopharyngeal carcinoma may in selected cases be treated with repeat irradiation protocols or surgery with moderate success and a high degree of concern about local wound healing. Other SCCs are best treated—when resectable—with a combination of surgery and irradiation. Numerous protocols investigating the role of chemotherapy are under evaluation. Cranial base surgery appears to be an effective modality in improving the overall prognosis in paranasal sinus malignancies eroding the ethmoid roof. More centers are capable of performing such resections endoscopically using image navigation. Although the prognosis is poor for advanced tumors, the results of treating resectable tumors of paranasal sinus origin have improved with the wider use of skull base resections and intensity-modulated radiation therapy. Cure rates are often 45–60%.

Bourhis J et al; Meta-Analysis of Chemotherapy in Head, Neck Cancer Collaborative Group; Meta-Analysis of Radiotherapy in Carcinoma of Head, Neck Collaborative Group; Meta-Analysis of Chemotherapy in Nasopharynx Carcinoma Collaborative Group. Individual patients' data meta-analyses in head and neck cancer. *Curr Opin Oncol*. 2007 May;19(3):188–94. [PMID: 17414635]

Khademi B et al. Malignant neoplasms of the sinonasal tract: report of 71 patients and literature review and analysis. *Oral Maxillofac Surg*. 2009 Dec;13(4):191–9. [PMID: 19795137]

Myers LL et al. Differential diagnosis and treatment options in paranasal sinus cancers. *Surg Oncol Clin N Am*. 2004 Jan;13(1):167–86. [PMID: 15062368]

3. Sinonasal Inflammatory Disease (Granulomatosis with Polyangiitis & Sarcoidosis)

The nose and paranasal sinuses are involved in over 90% of cases of granulomatosis with polyangiitis (formerly Wegener granulomatosis). It is often not realized that involvement at these sites is more common than involvement of lungs or kidneys. Examination shows bloodstained crusts and friable mucosa. Biopsy, when positive, shows necrotizing granulomas and vasculitis. Other recognized sites of granulomatosis with polyangiitis (formerly Wegener granulomatosis) in the head and neck include the subglottis and the middle ear.

Sarcoidosis also commonly involves the paranasal sinuses and is clinically similar to other chronic sinonasal inflammatory processes. Sinonasal symptoms, including rhinorrhea, nasal obstruction, and hyposmia or anosmia may precede diagnosis of sarcoidosis in other organ systems. Clinically, the turbinates appear engorged with small white granulomas. Biopsy shows classic noncaseating granulomas. Notably, patients with sinonasal involvement generally have more trouble managing sarcoidosis in other organ systems.

Polymorphic reticulosis (midline malignant reticulosis, idiopathic midline destructive disease, lethal midline granuloma)—as the multitude of apt descriptive terms suggest—is not well understood but appears to be a nasal T-cell or NK cell lymphoma. In contrast to granulomatosis with polyangiitis (formerly Wegener granulomatosis), involvement is limited to the mid face, and there may be extensive bone destruction. Many destructive lesions of the mucosa and nasal structures labeled as polymorphic reticulosis are in fact non-Hodgkin lymphoma of either NK cell or T cell origin. Immunophenotyping, especially for CD56 expression, is essential in the histologic evaluation. Even when apparently localized, these lymphomas have a poor prognosis, with progression and death within a year the rule.

For treatment of granulomatosis with polyangiitis (formerly Wegener granulomatosis), see Chapter 20.

Cannady SB et al. Sinonasal Wegener granulomatosis: a single-institution experience with 120 cases. *Laryngoscope*. 2009 Apr;119(4):757–61. [PMID: 19263410]

Fuchs HA et al. Granulomatous disorders of the nose and paranasal sinuses. *Curr Opin Otolaryngol Head Neck Surg*. 2009 Feb;17(1):23–7. [PMID: 19225301]

Gulati S et al. Sinonasal involvement in sarcoidosis: a report of seven cases and review of literature. *Eur Arch Otorhinolaryngol*. 2011 Sep 27. [Epub ahead of print] [PMID: 21947433]

Mendenhall WM et al. Lethal midline granuloma-nasal natural killer/T-cell lymphoma. *Am J Clin Oncol*. 2006 Apr;29(2):202–6. [PMID: 16601443]

DISEASES OF THE ORAL CAVITY & PHARYNX

LEUKOPLAKIA, ERYTHROPLAKIA, ORAL LICHEN PLANUS, & ORAL CANCER

ESSENTIALS OF DIAGNOSIS

- ▶ **Leukoplakia**—A white lesion that cannot be removed by rubbing the mucosal surface.
- ▶ **Erythroplakia**—Similar to leukoplakia except that it has a definite erythematous component.
- ▶ **Oral Lichen Planus**—Most commonly presents as lacy leukoplakia but may be erosive; definitive diagnosis requires biopsy.
- ▶ **Oral Cancer**—Early lesions appear as leukoplakia or erythroplakia; more advanced lesions will be larger, with invasion into tongue such that a mass lesion is palpable. Ulceration may be present.

Leukoplakic regions range from small to several centimeters in diameter (Figure 8–3). Histologically, they are often hyperkeratoses occurring in response to chronic irritation (eg, from dentures, tobacco, lichen planus); about 2–6%, however, represent either dysplasia or early invasive SCC. Distinguishing between **erythroplakia** and **leukoplakia** is important because about 90% of cases of erythroplakia are either dysplasia or carcinoma. **SCC** accounts for 90% of oral cancer. Alcohol and tobacco use are the major epidemiologic risk factors.

The differential diagnosis may include oral candidiasis, necrotizing sialometaplasia, pseudoepitheliomatous hyperplasia, median rhomboid glossitis, and vesiculoerosive



▲ **Figure 8–3.** Leukoplakia with moderate dysplasia on the lateral border of the tongue. (Courtesy of Ellen Eisenberg, DMD; used, with permission, from Usatine RP, Smith MA, Mayeaux EJ Jr, Chumley H, Tysinger, J. *The Color Atlas of Family Medicine*. McGraw-Hill, 2009.)

inflammatory disease such as erosive lichen planus. This should not be confused with the brown-black gingival melanin pigmentation—diffuse or speckled—common in nonwhites, blue-black embedded fragments of dental amalgam, or other systemic disorders associated with general pigmentation (neurofibromatosis, familial polyposis, Addison disease). Intraoral melanoma is extremely rare and carries a dismal prognosis.

Any area of **erythroplakia**, enlarging area of **leukoplakia**, or a lesion that has submucosal depth on palpation should have an incisional biopsy or an exfoliative cytologic examination. Ulcerative lesions are particularly suspicious and worrisome. Specialty referral should be sought early both for diagnosis and treatment. A systematic intraoral examination—including the lateral tongue, floor of the mouth, gingiva, buccal area, palate, and tonsillar fossae—and palpation of the neck for enlarged lymph nodes should be part of any general physical examination, especially in patients over the age of 45 who smoke tobacco or drink immoderately. Indirect or fiberoptic examination of the nasopharynx, oropharynx, hypopharynx, and larynx by an otolaryngologist, head and neck surgeon, or radiation oncologist should also be considered for such patients when there is unexplained or persistent throat or ear pain, oral or nasal bleeding, or oral erythroplakia. Fine-needle aspiration (FNA) biopsy may expedite the diagnosis if an enlarged lymph node is found. To date, there are no approved therapies for reversing or stabilizing leukoplakia or erythroplakia.

Oral lichen planus is a relatively common (0.5–2% of the population) chronic inflammatory autoimmune disease that may be difficult to diagnose clinically because of its numerous distinct phenotypic subtypes. For example, the reticular pattern may mimic candidiasis or hyperkeratosis, while the erosive pattern may mimic SCC. Management begins with distinguishing it from other oral lesions. Exfoliative cytology or a small incisional or excisional biopsy is indicated, especially if SCC is suspected. Therapy is aimed at managing pain and discomfort. Corticosteroids have been used widely both locally and systemically. Cyclosporines and retinoids have also been used. Many think there is a low rate (1%) of SCC arising within lichen planus (in addition to the possibility of clinical misdiagnosis).

Hairy leukoplakia occurs on the lateral border of the tongue and is a common early finding in HIV infection (see Chapter 31). It often develops quickly and appears as slightly raised leukoplakic areas with a corrugated or “hairy” surface (Figure 8–4). Clinical response following administration of zidovudine or acyclovir has been reported, and treatment is under active investigation.

Early detection of **SCC** is the key to successful management (Figure 8–5). Lesions < 4 mm in depth have a low propensity to metastasize. Most patients in whom the tumor is detected before it is 2 cm in diameter are cured by local resection. Radiation is an alternative but not generally used as first-line therapy for small lesions. Large tumors are usually treated with a combination of resection, neck dissection, and external beam radiation. Reconstruction, if required, is done at the time of resection and can involve



▲ **Figure 8-4.** Oral hairy leukoplakia on the side of the tongue in AIDS. (Courtesy of Richard P. Usatine, MD; used, with permission, from Usatine RP, Smith MA, Mayeaux EJ Jr, Chumley H, Tysinger, J. *The Color Atlas of Family Medicine*. McGraw-Hill, 2009.)

the use of myocutaneous flaps or vascularized free flaps with or without bone.

A number of clinical trials have suggested a role for beta-carotene, cyclooxygenase (COX)-2 inhibitors, vitamin E, and retinoids in producing regression of leukoplakia and reducing the incidence of recurrent SCCs. Retinoids suppress head and neck and lung carcinogenesis in animal models and inhibit carcinogenesis in individuals with pre-malignant lesions. They also seem to reduce the incidence of second primary cancers in head and neck and lung cancer patients previously treated for a primary.



▲ **Figure 8-5.** Squamous cell carcinoma of the palate. (Courtesy of Frank Miller, MD; used, with permission, from Usatine RP, Smith MA, Mayeaux EJ Jr, Chumley H, Tysinger, J. *The Color Atlas of Family Medicine*. McGraw-Hill, 2009.)

Amagasa T et al. Oral premalignant lesions: from a clinical perspective. *Int J Clin Oncol*. 2011 Feb;16(1):5–14. [PMID: 21225307]

Carbone M et al. Topical clobetasol in the treatment of atrophic-erosive oral lichen planus: a randomized controlled trial to compare two preparations with different concentrations. *J Oral Pathol Med*. 2009 Feb;38(2):227–33. [PMID: 19141065]

Curado MP et al. Recent changes in the epidemiology of head and neck cancer. *Curr Opin Oncol*. 2009 May;21(3):194–200. [PMID: 19363341]

Liu W et al. Malignant transformation of oral leukoplakia: a retrospective cohort study of 218 Chinese patients. *BMC Cancer*. 2010 Dec 16;10:685. [PMID: 21159209]

Thongprasom K et al. Steroids in the treatment of lichen planus: a review. *J Oral Sci*. 2008 Dec;50(4):377–85. [PMID: 19106464]

ORAL CANDIDIASIS



ESSENTIALS OF DIAGNOSIS

- ▶ Fluctuating throat or mouth discomfort.
- ▶ Systemic or local immunosuppression, such as recent corticosteroid, chemotherapy, or antibiotic use.
- ▶ Erythema of the oral cavity or oropharynx with fluffy, white patches.
- ▶ Rapid resolution of symptoms with appropriate treatment.

▶ Clinical Findings

A. Symptoms and Signs

Oral candidiasis (thrush) is usually painful and looks like creamy-white curd-like patches overlying erythematous mucosa (see Figure 6–24). Because these white areas are easily rubbed off (eg, by a tongue depressor)—unlike leukoplakia or lichen planus—only the underlying irregular erythema may be seen. Oral candidiasis is commonly encountered among the following adult patients: (1) those who wear dentures, (2) those who are debilitated and have poor oral hygiene, (3) those with diabetes, (4) those with anemia, (5) those undergoing chemotherapy or local irradiation, and (6) those receiving corticosteroids (oral or systemic) or broad-spectrum antibiotics. Angular cheilitis is another manifestation of candidiasis, although it is also seen in nutritional deficiencies (Figure 8–6).

B. Diagnostic Studies

The diagnosis is made clinically. A wet preparation using potassium hydroxide will reveal spores and may show non-septate mycelia. Biopsy will show intraepithelial pseudomycelia of *Candida albicans*.

Candidiasis is often the first manifestation of HIV infection, and HIV testing should be considered in patients with no known predisposing cause for *Candida* overgrowth (see also Chapter 31). The US Department of Health Services Clinical Practice Guideline for Evaluation and Management of Early HIV Infection recommends



▲ **Figure 8-6.** Severe angular cheilitis in HIV-positive man with oral thrush. (Courtesy of Richard P. Usatine, MD; used, with permission, from Usatine RP, Smith MA, Mayeaux EJ Jr, Chumley H, Tysinger, J. *The Color Atlas of Family Medicine*. McGraw-Hill, 2009.)

examination of the oral mucosa with each clinician visit as well as at a dental examination every 6 months.

► Treatment

Effective antifungal therapy may be achieved with any of the following: fluconazole (100 mg orally daily for 7 days), ketoconazole (200–400 mg with breakfast [requires acidic gastric environment for absorption] for 7–14 days), clotrimazole troches (10 mg dissolved orally five times daily), or nystatin vaginal troches (100,000 units dissolved orally five times daily) or mouth rinses (500,000 units [5 mL of 100,000 units/mL] held in the mouth before swallowing three times daily). In patients with HIV infection, however, longer courses of therapy with fluconazole may be needed, and oral itraconazole (200 mg/d) may be indicated in fluconazole-refractory cases. Many of the *Candida* species in these patients are resistant to first-line azoles and may require newer drugs, such as voriconazole. In addition, 0.12% chlorhexidine or half-strength hydrogen peroxide mouth rinses may provide local relief. Nystatin powder (100,000 units/g) applied to dentures three or four times daily for several weeks may help denture wearers.

Egusa H et al. Oral candidosis in HIV-infected patients. *Curr HIV Res*. 2008 Nov;6(6):485–99. [PMID: 18991614]

Giannini PJ et al. Diagnosis and management of oral candidiasis. *Otolaryngol Clin North Am*. 2011 Feb;44(1):231–40. [PMID: 21093632]

Pienaar ED et al. Interventions for the prevention and management of oropharyngeal candidiasis associated with HIV infection in adults and children. *Cochrane Database Syst Rev*. 2010 Nov 10;11:CD003940. [PMID: 21069679]

GLOSSITIS, GLOSSODYNIA, DYSGEUSIA, & BURNING MOUTH SYNDROME

Inflammation of the tongue with loss of filiform papillae leads to a red, smooth-surfaced tongue (glossitis). Rarely painful, it may be secondary to nutritional deficiencies (eg,

niacin, riboflavin, iron, or vitamin E), drug reactions, dehydration, irritants, foods and liquids, and possibly autoimmune reactions or psoriasis. If the primary cause cannot be identified and corrected, empiric nutritional replacement therapy may be of value.

Glossodynia is burning and pain of the tongue, which may occur with or without glossitis. In the absence of any clinical findings, it has been termed “burning mouth syndrome.” Glossodynia with glossitis has been associated with diabetes mellitus, drugs (eg, diuretics), tobacco, xerostomia, and candidiasis as well as the listed causes of glossitis. Periodontal disease is not apt to be a factor. The burning mouth syndrome typically has no identifiable associated risk factors and seems to be most common in postmenopausal women. Treating possible underlying causes, changing long-term medications to alternative ones, and smoking cessation may resolve symptoms of glossitis. Both glossodynia and the burning mouth syndrome are benign, and reassurance that there is no infection or tumor is likely to be appreciated. Effective treatments for the burning mouth syndrome include alpha-lipoic acid and clonazepam. Clonazepam is most effective as a rapid dissolving tablet placed on the tongue in doses from 0.25 mg to 0.5 mg every 8–12 hours. Behavioral therapy has also been shown to be effective. Unilateral symptoms, symptoms that cannot be related to a specific medication, and symptoms and signs involving regions supplied by other cranial nerves all may suggest neuropathology, and imaging of the brain, brainstem, and skull base with MRI should be considered.

Minor JS et al. Burning mouth syndrome and secondary oral burning. *Otolaryngol Clin North Am*. 2011 Feb;44(1):205–19. [PMID: 21093630]

Patton LL et al. Management of burning mouth syndrome: systematic review and management recommendations. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod*. 2007 Mar;103 (Suppl):S39:e1–13. [PMID: 17379153]

INTRAORAL ULCERATIVE LESIONS

1. Necrotizing Ulcerative Gingivitis (Trench Mouth, Vincent Angina)

Necrotizing ulcerative gingivitis, often caused by an infection of both spirochetes and fusiform bacilli, is common in young adults under stress (classically at examination time). Underlying systemic diseases may also predispose to this disorder. Clinically, there is painful acute gingival inflammation and necrosis, often with bleeding, halitosis, fever, and cervical lymphadenopathy. Warm half-strength peroxide rinses and oral penicillin (250 mg three times daily for 10 days) may help. Dental gingival curettage may prove necessary.

Feller L et al. Necrotizing periodontal diseases in HIV-seropositive subjects: pathogenic mechanisms. *J Int Acad Periodontol*. 2008 Jan;10(1):10–5. [PMID: 18333595]

2. Aphthous Ulcer (Canker Sore, Ulcerative Stomatitis)

Aphthous ulcers are very common and easy to recognize. Their cause remains uncertain, although an association with human herpesvirus 6 has been suggested. Found on freely moving, nonkeratinized mucosa (eg, buccal and labial mucosa and not attached gingiva or palate), they may be single or multiple, are usually recurrent, and appear as painful small round ulcerations with yellow-gray fibrinoid centers surrounded by red halos (Figure 8–7). Minor aphthous ulcers are < 1 cm and generally heal in 10–14 days. Major aphthous ulcers are > 1 cm and can be disabling due to the degree of associated oral pain.

Treatment is nonspecific. Topical corticosteroids (triamcinolone acetonide, 0.1%, or fluocinonide ointment, 0.05%) in an adhesive base (Orabase Plain) do appear to provide symptomatic relief. Other topical therapies shown to be effective in controlled studies include diclofenac 3% in hyaluronan 2.5%, doxymycine-cyanoacrylate, mouthwashes containing the enzymes amyloglucosidase and glucose oxidase, and amlexanox 5% oral paste. A 1-week tapering course of prednisone (40–60 mg/d) has also been used successfully. Cimetidine maintenance therapy may be useful in patients with recurrent aphthous ulcers. Thalidomide has been used selectively in recurrent aphthous ulcerations in HIV-positive patients.

Large or persistent areas of ulcerative stomatitis may be secondary to erythema multiforme or drug allergies, acute herpes simplex, pemphigus, pemphigoid, epidermolysis bullosa acquisita, bullous lichen planus, Behçet disease, or inflammatory bowel disease. SCC may occasionally present



▲ **Figure 8–7.** Aphthous stomatitis. (Courtesy of Ellen Eisenberg, MD and Dr. Joanna Douglas; used, with permission, from Usatine RP, Smith MA, Mayeaux EJ Jr, Chumley H, Tysinger, J. *The Color Atlas of Family Medicine*. McGraw-Hill, 2009.)

in this fashion. When the diagnosis is not clear, incisional biopsy is indicated.

Chattopadhyay A et al. Recurrent aphthous stomatitis. *Otolaryngol Clin North Am.* 2011 Feb;44(1):79–88. [PMID: 21093624]
Scully C et al. Oral mucosal disease: recurrent aphthous stomatitis. *Br J Oral Maxillofac Surg.* 2008 Apr;46(3):198–206. [PMID: 17850936]

3. Herpetic Stomatitis

Herpetic gingivostomatitis is common, mild, and short-lived and requires no intervention in most adults. In immunocompromised persons, however, reactivation of herpes simplex virus infection is frequent and may be severe. Clinically, there is initial burning, followed by typical small vesicles that rupture and form scabs. Lesions are most commonly found on the attached gingiva and mucocutaneous junction of the lip, but lesions can also form on the tongue, buccal mucosa, and soft palate. Acyclovir (200–800 mg orally five times daily for 7–14 days) may shorten the course and reduce postherpetic pain. Differential diagnosis includes aphthous stomatitis (see above), erythema multiforme, syphilitic chancre, and carcinoma. Coxsackievirus-caused lesions (grayish white tonsillar plaques and palatal ulcers of herpangina or buccal and lip ulcers in hand-foot-and-mouth disease) are seen more commonly in children under age 6.

Arduino PG et al. Herpes simplex virus type 1 infection: overview on relevant clinico-pathological features. *J Oral Pathol Med.* 2008 Feb;37(2):107–21. [PMID: 18197856]
Nasser M et al. Acyclovir for treating primary herpetic gingivostomatitis. *Cochrane Database Syst Rev.* 2008 Oct 8;(4):CD006700. [PMID: 18843726]
Sciubba JJ. Oral mucosal diseases in the office setting—part I: Aphthous stomatitis and herpes simplex infections. *Gen Dent.* 2007 Jul–Aug;55(4):347–56. [PMID: 17682646]

PHARYNGITIS & TONSILLITIS



ESSENTIALS OF DIAGNOSIS

- ▶ Sore throat.
- ▶ Fever.
- ▶ Anterior cervical adenopathy.
- ▶ Tonsillar exudate.
- ▶ Focus is to treat group A β -hemolytic streptococcus infection to prevent rheumatic sequelae.

▶ General Considerations

Pharyngitis and tonsillitis account for over 10% of all office visits to primary care clinicians and 50% of outpatient antibiotic use. The most appropriate management continues to be debated because some of the issues are deceptively complex, but consensus has increased in recent years.

The main concern is determining who is likely to have a group A β -hemolytic streptococcal infection (GABHS), as this can lead to subsequent complications such as rheumatic fever and glomerulonephritis. A second public health policy concern is reducing the extraordinary cost (both in dollars and in the development of antibiotic-resistant *S pneumoniae*) in the United States associated with unnecessary antibiotic use. Questions now being asked: Is there still a role for culturing a sore throat, or have the rapid antigen tests supplanted this procedure under most circumstances? Are clinical criteria alone a sufficient basis for decisions about which patients should be given antibiotics? Should any patient receive any antibiotic other than penicillin (or erythromycin if penicillin-allergic)? For how long should treatment be continued? Numerous well-done studies in the past few years as well as increasing experience with rapid laboratory tests for detection of streptococci (eliminating the delay caused by culturing) appear to make a consensus approach more possible.

► Clinical Findings

A. Symptoms and Signs

The clinical features most suggestive of GABHS pharyngitis include fever over 38°C, tender anterior cervical adenopathy, lack of a cough, and a pharyngotonsillar exudate (Figures 8–8 and 8–9). These four features (the Centor criteria), when present, strongly suggest GABHS, and some would treat regardless of laboratory results. When three of the four are present, laboratory sensitivity of rapid antigen testing for GABHS exceeds 90%. When only one criterion is present, GABHS is unlikely. Sore throat may be severe, with odynophagia, tender adenopathy, and a scarlatiniform rash. An elevated white count and left shift are also possible. Hoarseness, cough, and coryza are not suggestive of this disease.



▲ **Figure 8-8.** Streptococcal pharyngitis showing tonsillar exudate and erythema. (Courtesy of Michael Nguyen, MD; used, with permission, from Usatine RP, Smith MA, Mayeaux EJ Jr, Chumley H, Tysinger, J. *The Color Atlas of Family Medicine*. McGraw-Hill, 2009.)



▲ **Figure 8-9.** Pharyngeal inflammation and petechiae of the soft palate caused by group A streptococcus. (Courtesy of Dr. Heinz F. Eichenwald, Public Health Image Library, CDC.)

Marked lymphadenopathy and a shaggy white-purple tonsillar exudate, often extending into the nasopharynx, suggest mononucleosis, especially if present in a young adult. With about 90% sensitivity, lymphocyte to white blood cell ratios of > 35% suggest EBV infection and not tonsillitis. Hepatosplenomegaly and a positive heterophil agglutination test or elevated anti-EBV titer are corroborative. However, about one-third of patients with infectious mononucleosis have secondary streptococcal tonsillitis, requiring treatment. Ampicillin should routinely be avoided if mononucleosis is suspected because it induces a rash that might be misinterpreted by the patient as a penicillin allergy. Diphtheria (extremely rare but described in the alcoholic population) presents with low-grade fever and an ill patient with a gray tonsillar pseudomembrane.

The most common pathogens other than GABHS in the differential diagnosis of “sore throat” are viruses, *Neisseria gonorrhoeae*, *Mycoplasma*, and *Chlamydia trachomatis*. Rhinorrhea and lack of exudate would suggest a virus, but in practice it is not possible to confidently distinguish viral upper respiratory infection from GABHS on clinical grounds alone. Infections with *Corynebacterium diphtheriae*, anaerobic streptococci, and *Corynebacterium haemolyticum* (which responds better to erythromycin than penicillin) may also mimic pharyngitis due to GABHS.

B. Laboratory Findings

A single-swab throat culture is 90–95% sensitive and the rapid antigen detection testing (RADT) is 90–99% sensitive for GABHS. Results from the RADT are available much sooner than from the throat culture.

► Treatment

Given the availability of many well-documented studies in recent years, one would think that a consensus might develop as to the most appropriate way to treat a sore throat. The Infectious Diseases Society of America recommends laboratory confirmation of the clinical diagnosis by means of either throat culture or RADT of the throat swab.

The American College of Physicians–American Society of Internal Medicine (ACP-ASIM), in collaboration with the Centers for Disease Control and Prevention, advocates use of a clinical algorithm alone—in lieu of microbiologic testing—for confirmation of the diagnosis in adults for whom the suspicion of streptococcal infection is high. Others examine the assumptions of the ACP-ASIM guideline for using a clinical algorithm alone and question whether those recommendations will achieve the stated objective of dramatically decreasing excess antibiotic use. A reasonable strategy to follow is that patients with zero or one Centor criteria are at very low risk for GABHS and therefore, do not need throat cultures or RADT of the throat swap and should not receive antibiotics. Patients with two or three Centor criteria need throat cultures or RADT of the throat swap, since positive results would warrant antibiotic treatment. Patients who have four Centor criteria are likely to have GABHS and can receive empiric therapy without throat culture or RADT.

Convincing clinical trials as well as clinician reminders and patient-based interventions may be needed before clinicians are likely to abandon long-held teachings (even though different clinicians appear to have been taught different strategies) regarding diagnosis and management of group A streptococcal pharyngitis. A Cochrane review concluded that multifaceted interventions where educational interventions occur on many levels were the only interventions whose effects were of sufficient magnitude to potentially reduce the incidence of antibiotic-resistant bacteria.

Thirty years ago, a single intramuscular injection of benzathine penicillin or procaine penicillin, 1.2 million units once, was the standard antibiotic treatment. This remains effective, but the injection is painful. It is now used for patients if compliance with an oral regimen is an issue. Currently, oral treatment is effective and preferred. Antibiotic choice aims to reduce the already low (10–20%) incidence of treatment failures (positive culture after treatment despite symptomatic resolution) and recurrences. Penicillin V potassium (250 mg orally three times daily or 500 mg twice daily for 10 days) or cefuroxime axetil (250 mg orally twice daily for 5–10 days) are both effective. The efficacy of a 5-day regimen of penicillin V potassium appears to be similar to that of a 10-day course, with a 94% clinical response rate and an 84% streptococcal eradication rate. Erythromycin (also active against *Mycoplasma* and *Chlamydia*) is a reasonable alternative to penicillin in allergic patients. Cephalosporins are somewhat more effective than penicillin in producing bacteriologic cures; 5-day administration has been successful for cefpodoxime and cefuroxime. The macrolide antibiotics have also been reported to be successful in shorter-duration regimens. Azithromycin (500 mg once daily), because of its long half-life, need be taken for only 3 days.

Adequate antibiotic treatment usually avoids the streptococcal complications of scarlet fever, glomerulonephritis, rheumatic myocarditis, and local abscess formation.

Antibiotics for treatment failures are also somewhat controversial. Surprisingly, penicillin-tolerant strains are not isolated more frequently in those who fail treatment than in those treated successfully with penicillin. The reasons for failure appear to be complex, and a second course of

treatment with the same drug is not unreasonable. Alternatives to penicillin include cefuroxime and other cephalosporins, dicloxacillin (which is β -lactamase-resistant), and amoxicillin with clavulanate. When there is a history of penicillin allergy, alternatives should be used, such as erythromycin. Erythromycin resistance—with failure rates of about 25%—is an increasing problem in many areas. In cases of severe penicillin allergy, cephalosporins should be avoided as the cross-reaction is common (8% or more).

Ancillary treatment of pharyngitis includes analgesics and anti-inflammatory agents, such as aspirin or acetaminophen. Some patients find that salt water gargling is soothing. In severe cases, anesthetic gargles and lozenges (eg, benzocaine) may provide additional symptomatic relief. Occasionally, odynophagia is so intense that hospitalization for intravenous hydration and antibiotics is necessary. (See Chapter 33.)

Patients who have had rheumatic fever should be treated with a continuous course of antimicrobial prophylaxis (erythromycin, 250 mg twice daily orally, or penicillin G, 500 mg once daily orally) for at least 5 years.

Linder JA. Evaluation and management of adult pharyngitis. *Compr Ther.* 2008 Fall–Winter;34(3–4):196–203. [PMID: 19137763]

van Driel ML et al. Different antibiotic treatments for group A streptococcal pharyngitis. *Cochrane Database Syst Rev.* 2010 Oct 6;(10):CD004406. [PMID: 20927734]

PERITONSILLAR ABSCESS & CELLULITIS

When infection penetrates the tonsillar capsule and involves the surrounding tissues, peritonsillar cellulitis results. Peritonsillar abscess (**quinsy**) and cellulitis present with severe sore throat, odynophagia, trismus, medial deviation of the soft palate and peritonsillar fold, and an abnormal muffled (“hot potato”) voice. Following therapy, peritonsillar cellulitis usually either resolves over several days or evolves into peritonsillar abscess, also known as quinsy. The existence of an abscess may be confirmed by aspirating pus from the peritonsillar fold just superior and medial to the upper pole of the tonsil. A 19-gauge or 21-gauge needle should be passed medial to the molar and no deeper than 1 cm, because the internal carotid artery may lie more medially than its usual location and pass posterior and deep to the tonsillar fossa. Most commonly, patients with peritonsillar abscess present to the emergency department and receive a dose of parenteral amoxicillin (1 g), amoxicillin-sulbactam (3 g), or clindamycin (600–900 mg). Less severe cases and patients who are able to tolerate oral intake may be treated for 7–10 days with oral antibiotics, including amoxicillin, 500 mg three times a day; amoxicillin-clavulanate, 875 mg twice a day; or clindamycin, 300 mg four times daily. Although antibiotic treatment is generally undisputed, there is controversy regarding the surgical management of peritonsillar abscess. Methods include needle aspiration, incision and drainage, and tonsillectomy. Some clinicians incise and drain the area and continue with parenteral antibiotics, whereas others aspirate only and monitor as an outpatient. To drain the abscess and avoid recurrence, it may be appropriate to consider immediate tonsillectomy

(quinsy tonsillectomy). About 10% of patients with peritonsillar abscess exhibit relative indications for tonsillectomy. All three approaches are effective and have support in the literature. Regardless of the method used, one must be sure the abscess is adequately treated, since complications such as extension to the retropharyngeal, deep neck, and posterior mediastinal spaces are possible. Bacteria may also be aspirated into the lungs, resulting in pneumonia. While there is controversy about whether a single abscess is sufficient indication for tonsillectomy, most would agree that patients with recurrent abscesses should have a tonsillectomy.

Johnson RF et al. The contemporary approach to diagnosis and management of peritonsillar abscess. *Curr Opin Otolaryngol Head Neck Surg.* 2005 Jun;13(3):157–60. [PMID: 15908813]
Kilty SJ et al. Clinical predictors of peritonsillar abscess in adults. *J Otolaryngol Head Neck Surg.* 2008 Apr;37(2):165–8. [PMID: 19128606]

TONSILLECTOMY

Despite the frequency with which tonsillectomy is performed, the indications for the procedure remain controversial. Most clinicians would agree that airway obstruction causing sleep apnea or cor pulmonale is an absolute indication for tonsillectomy. Similarly, persistent marked tonsillar asymmetry should prompt an excisional biopsy to rule out lymphoma. Relative indications include recurrent streptococcal tonsillitis, causing considerable loss of time from school or work, recurrent peritonsillar abscess, and chronic tonsillitis.

Tonsillectomy is not an entirely benign procedure. The pros and cons of tonsillectomy need to be discussed with each prospective patient. Postoperative bleeding occurs in 2–4% of cases and on rare occasions can lead to laryngospasm and airway obstruction. Pain may be considerable, especially in the adult. Protracted emesis or fever may also occasionally occur. Secondary bleeding 5–8 days postoperatively is far more common than bleeding in the first 24 hours. There is increasing economic pressure for these procedures to be done as outpatient surgery. At present, it seems clear that outpatient tonsillectomy is usually safe when followed by a 6-hour period of uneventful observation, but individual circumstances may mandate hospitalization.

Although reports in the 1970s suggested an association of tonsillectomy with Hodgkin disease, careful review of this literature reveals no conclusively causative association.

Alho OP et al. Tonsillectomy versus watchful waiting in recurrent streptococcal pharyngitis in adults: randomised controlled trial. *BMJ.* 2007 May 5;334(7600):939. [PMID: 17347187]

Blakley BW et al. The role of tonsillectomy in reducing recurrent pharyngitis: a systematic review. *Otolaryngol Head Neck Surg.* 2009 Mar;140(3):291–7. [PMID: 19248931]

Burton MJ et al. Tonsillectomy or adeno-tonsillectomy versus non-surgical treatment for chronic/recurrent acute tonsillitis. *Cochrane Database Syst Rev.* 2009 Jan 21;(1):CD001802. [PMID: 19160201]

Choby BA. Diagnosis and treatment of streptococcal pharyngitis. *Am Fam Physician.* 2009 Mar 1;79(5):383–90. [PMID: 19275067]

DEEP NECK INFECTIONS



ESSENTIALS OF DIAGNOSIS

- ▶ Marked acute neck pain and swelling.
- ▶ Abscesses are emergencies because rapid airway compromise may occur.
- ▶ May spread to the mediastinum or cause sepsis.

▶ General Considerations

Ludwig angina is the most commonly encountered neck space infection. It is a cellulitis of the sublingual and submaxillary spaces, often arising from infection of the mandibular dentition. **Deep neck abscesses** most commonly originate from odontogenic infections. Other causes include suppurative lymphadenitis, direct spread of pharyngeal infection, penetrating trauma, pharyngoesophageal foreign bodies, cervical osteomyelitis, and intravenous injection of the internal jugular vein, especially in drug abusers. Recurrent deep neck infection may suggest an underlying congenital lesion such as a branchial cleft cyst. Suppurative lymphadenopathy in middle-age persons who smoke and drink alcohol regularly should be considered a manifestation of malignancy (typically metastatic SCC) until proven otherwise.

▶ Clinical Findings

Patients with **Ludwig angina** have edema and erythema of the upper neck under the chin and often of the floor of the mouth. The tongue may be displaced upward and backward by the posterior spread of cellulitis and coalescence of pus is often present in the floor of mouth. This may lead to occlusion of the airway. Microbiologic isolates include streptococci, staphylococci, *Bacteroides*, and *Fusobacterium*.

Patients with **deep neck abscesses** usually present with marked neck pain and swelling. Fever is common but not always present. *Deep neck abscesses are emergencies because they may rapidly compromise the airway.* Untreated or inadequately treated, they may spread to the mediastinum or cause sepsis.

Contrast-enhanced CT usually augments the clinical examination in defining the extent of the infection. It often will distinguish inflammation and phlegmon (requiring antibiotics) from abscess (requiring drainage), and define for the surgeon the extent of an abscess. CT with MRI may also identify thrombophlebitis of the internal jugular vein secondary to oropharyngeal inflammation. This condition, known as **Lemierre syndrome**, is rare and usually associated with severe headache. The presence of pulmonary infiltrates consistent with septic emboli in the setting of a neck abscess should lead one to suspect Lemierre syndrome.

▶ Treatment

Usual doses of penicillin plus metronidazole, ampicillin-sulbactam, clindamycin, or selective cephalosporins are good initial choices for treatment of **Ludwig angina**.

Culture and sensitivity data are then used to refine the choice. Dental consultation is advisable to address the offending tooth or teeth. External drainage via bilateral submental incisions is required if the airway is threatened or when medical therapy has not reversed the process.

Treatment of **deep neck abscesses** includes securing the airway, intravenous antibiotics, and incision and drainage. When the infection involves the floor of mouth, base of tongue, supraglottic or paraglottic space, the airway may be secured either by intubation or tracheotomy. Tracheotomy is preferable in the patients with substantial pharyngeal edema, since attempts at intubation may precipitate acute airway obstruction. Bleeding in association with a deep neck abscess is very rare but suggests carotid artery or internal jugular vein involvement and requires prompt neck exploration both for drainage of pus and for vascular control.

Patients with **Lemierre syndrome** require prompt institution of antibiotics appropriate for *Fusobacterium necrophorum* as well as the more usual upper airway pathogens. The use of anticoagulation in treatment is debated and of no proven benefit.

Caccamese JF Jr et al. Deep neck infections: clinical considerations in aggressive disease. *Oral Maxillofac Surg Clin North Am.* 2008 Aug;20(3):367–80. [PMID: 18603197]
 Reynolds SC et al. Life-threatening infections of the peripharyngeal and deep fascial spaces of the head and neck. *Infect Dis Clin North Am.* 2007 Jun;21(2):557–76. [PMID: 17561083]
 Vieira F et al. Deep neck infection. *Otolaryngol Clin North Am.* 2008 Jun;41(3):459–83. [PMID: 18435993]

SNORING



ESSENTIALS OF DIAGNOSIS

- ▶ Noise produced on inspiration during sleep.
- ▶ Snoring is associated with obstructive sleep apnea (OSA) but has no disruption of sleep by clinical sleep evaluation.

▶ General Considerations

Ventilation disorders during sleep are extremely common. While OSA occurs in 5–10% of Americans, clinically relevant snoring may occur in as many as 59%. In general, sleep-disordered breathing problems are attributed to narrowing of the upper aerodigestive tract during sleep due to changes in position, muscle tone, and soft tissue hypertrophy or laxity. The most common sites of obstruction are the oropharynx and the base of the tongue. The spectrum of the problem ranges from simple snoring without cessation of airflow to OSA with long periods of apnea and life-threatening physiologic sequelae. OSA is discussed in Chapter 9. In contrast to OSA, snoring is almost exclusively a social problem, and despite its prevalence and association with OSA, there is comparatively little known about the management of this problem.

▶ Clinical Findings

A. Symptoms and Signs

All patients who complain of snoring should be evaluated for OSA as discussed in Chapter 9. Symptoms of OSA (including snoring, excessive daytime somnolence, daytime headaches, and weight gain) may be present in as many as 30% of patients without demonstrable apnea or hypopnea on formal testing. Clinical examination should include examination of the nasal cavity, nasopharynx, oropharynx, and larynx to help exclude other causes of dynamic airway obstruction. In many cases of isolated snoring, the palate and uvula appear enlarged and elongated with excessive mucosa hanging below the muscular portion of the soft palate.

B. Imaging and Diagnostic Testing

Sleep examination with polysomnography is strongly advised in the evaluation of a patient with complaints of snoring. Radiographic imaging of the head or neck is generally not necessary for management of primary snoring.

▶ Treatment

Expedient and inexpensive management solutions of snoring are sought, often with little or no benefit. Diet modification and a regimen of physical exercise can lead to improvement in snoring through weight loss and improvement in pharyngeal tone that accompanies overall physical conditioning. Position change during sleep can be effective, and time-honored treatments such as taping or sewing a tennis ball to the back of a shirt worn during sleep may satisfactorily eliminate symptoms by ensuring recumbency on one side.

Anatomic management of snoring can be challenging. As with OSA, snoring can come from a number of sites in the upper aerodigestive tract. While medical or surgical correction of nasal obstruction may help alleviate snoring problems, most interventions aim to improve airflow through the nasopharynx and oropharynx. Nonsurgical options include mandibular advancement appliances designed to pull the base of tongue forward and continuous positive airway pressure via face or nasal mask. Compliance with both of these treatment options is problematic because snorers without OSA do not notice the physiologic benefits of these devices noted by patients with sleep apnea.

Surgical correction of snoring is most commonly directed at the soft palate. Historical approaches involved resection of redundant mucosa and the uvula similar to uvulopalatopharyngoplasty which is used for OSA. Regardless of how limited the procedure or what technique was used, postoperative pain, expense of general anesthesia and high recurrence rates limit the utility of these procedures. Office-based approaches have become more widely used because of these limitations. Most of these procedures aim to stiffen the palate to prevent vibration rather than remove it. A series of procedures, including injection snoreplasty, radiofrequency thermal fibrosis, and implantable palatal device have been used with variable

success and patient tolerance. The techniques can be technically challenging. Persistent symptoms may occur following initial treatment necessitating costly (and sometimes painful) repeat procedures. The durability of these procedures in alleviating symptoms is also poorly understood and late failures can lead to patient and clinician frustration.

Bäck LJ et al. Radiofrequency ablation treatment of soft palate for patients with snoring: a systematic review of effectiveness and adverse effects. *Laryngoscope*. 2009 Jun;119(6):1241–50. [PMID: 19365852]

Friedman M et al. Palatal implants for the treatment of snoring and obstructive sleep apnea/hypopnea syndrome. *Otolaryngol Head Neck Surg*. 2008 Feb;138(2):209–16. [PMID: 18241718]

Saylam G et al. Do palatal implants really reduce snoring in long-term follow-up? *Laryngoscope*. 2009 May;119(5):1000–4. [PMID: 19199348]

Uluap SO. Snoring and obstructive sleep apnea. *Med Clin North Am*. 2010 Sep;94(5):1047–55. [PMID: 20736112]

DISEASES OF THE SALIVARY GLAND

ACUTE INFLAMMATORY SALIVARY GLAND DISORDERS

1. Sialadenitis

Acute bacterial sialadenitis in the adult most commonly affects either the parotid or submandibular gland. It typically presents with acute swelling of the gland, increased pain and swelling with meals, and tenderness and erythema of the duct opening. Pus often can be massaged from the duct. Sialadenitis often occurs in the setting of dehydration or in association with chronic illness. Underlying Sjögren syndrome may contribute. Ductal obstruction, often by an inspissated mucous plug, is followed by salivary stasis and secondary infection. The most common organism recovered from purulent draining saliva is *S aureus*. Treatment consists of intravenous antibiotics such as nafcillin (1 g intravenously every 4–6 hours) and measures to increase salivary flow, including hydration, warm compresses, sialagogues (eg, lemon drops), and massage of the gland. Treatment can usually then be switched to an oral agent based on clinical and microbiologic improvement to complete a 10-day treatment course. Less severe cases can often be treated with oral antibiotics with similar spectrum. Complete resolution of parotid swelling and pain can take 2–3 weeks. Failure of the process to improve and ultimately resolve on this regimen suggests abscess formation, ductal stricture, stone, or tumor causing obstruction. Ultrasound or CT scan may be helpful in establishing the diagnosis. In the setting of acute illness, a severe and potentially life-threatening form of sialadenitis, sometimes called **suppurative sialadenitis**, may develop. The causative organism is usually *S aureus*, but often no pus will drain from Stensen papilla. These patients often do not respond to rehydration and intravenous antibiotics

and thus may require operative incision and drainage to resolve the infection.

2. Sialolithiasis

Calculus formation is more common in Wharton duct (draining the submandibular glands) than in Stensen duct (draining the parotid glands). Clinically, a patient may note postprandial pain and local swelling, often with a history of recurrent acute sialadenitis. Stones in Wharton duct are usually large and radiopaque, whereas those in Stensen duct are usually radiolucent and smaller. Those very close to the orifice of Wharton duct may be palpated manually in the anterior floor of the mouth and removed intraorally by dilating or incising the distal duct. The duct proximal to the stone must be temporarily clamped (using, for instance, a single throw of a suture) to keep manipulation of the stone from pushing it back toward the submandibular gland. Those more than 1.5–2 cm from the duct are too close to the lingual nerve to be removed safely in this manner. Similarly, dilation of Stensen duct, located on the buccal surface opposite the second maxillary molar, may relieve distal stricture or allow a small stone to pass. Extracorporeal shock-wave lithotripsy and fluoroscopically guided basket retrieval have been used successfully, but are being replaced by sialoendoscopy for the management of chronic sialolithiasis. Repeated episodes of sialadenitis are usually associated with stricture and chronic infection. If the obstruction cannot be safely removed or dilated, excision of the gland may be necessary to relieve recurrent symptoms.

Harrison JD. Causes, natural history, and incidence of salivary stones and obstructions. *Otolaryngol Clin North Am*. 2009 Dec;42(6):927–47. [PMID: 19962002]

CHRONIC INFLAMMATORY & INFILTRATIVE DISORDERS OF THE SALIVARY GLANDS

Numerous infiltrative disorders may cause unilateral or bilateral parotid gland enlargement. Sjögren syndrome and sarcoidosis are examples of lymphoepithelial and granulomatous diseases that may affect the salivary glands. Metabolic disorders, including alcoholism, diabetes mellitus, and vitamin deficiencies, may also cause diffuse enlargement. Several drugs have been associated with parotid enlargement, including thioureas, iodine, and drugs with cholinergic effects (eg, phenothiazines), which stimulate salivary flow and cause more viscous saliva.

Salomonsson S et al. Minor salivary gland immunohistology in the diagnosis of primary Sjögren's syndrome. *J Oral Pathol Med*. 2009 Mar;38(2):282–8. [PMID: 18793250]

SALIVARY GLAND TUMORS

Approximately 80% of salivary gland tumors occur in the parotid gland. In adults, about 80% of these are

benign. In the submandibular triangle, it is sometimes difficult to distinguish a primary submandibular gland tumor from a metastatic submandibular space node. Only 50–60% of primary submandibular tumors are benign. Tumors of the minor salivary glands are most likely to be malignant, with adenoid cystic carcinoma predominating, and may be found throughout the oral cavity or oropharynx.

Most parotid tumors present as an asymptomatic mass in the superficial part of the gland. Their presence may have been noted by the patient for months or years. Facial nerve involvement correlates strongly with malignancy. Tumors may extend deep to the plane of the facial nerve or may originate in the parapharyngeal space. In such cases, medial deviation of the soft palate is visible on intraoral examination. MRI and CT scans have largely replaced sialography in defining the extent of tumor.

When the clinician encounters a patient with an otherwise asymptomatic salivary gland mass where tumor is the most likely diagnosis, the choice is whether to simply excise the mass via a parotidectomy with facial nerve dissection or submandibular gland excision or to first obtain an FNA biopsy. Although the accuracy of FNA biopsy for malignancy has been reported to be quite high, results vary among institutions. If a negative FNA biopsy would lead to a decision not to proceed to surgery, then it should be considered. Poor overall health of the patient and the possibility of inflammatory disease as the cause of the mass are situations where FNA biopsy might be helpful. In otherwise straightforward nonrecurrent cases, excision is indicated. In benign and small low-grade malignant tumors, no additional treatment is needed. Postoperative irradiation is indicated for larger and high-grade cancers.

Carrillo JF et al. Diagnostic accuracy of fine needle aspiration biopsy in preoperative diagnosis of patients with parotid gland masses. *J Surg Oncol*. 2009 Aug 1;100(2):133–8. [PMID: 19507187]

de Oliveira FA et al. Salivary gland tumor: a review of 599 cases in a Brazilian population. *Head Neck Pathol*. 2009 Dec;3(4):271–5. [PMID: 20596844]

Mendenhall WM et al. Salivary gland pleomorphic adenoma. *Am J Clin Oncol*. 2008 Feb;31(1):95–9. [PMID: 18376235]

Scianna JM et al. Contemporary management of tumors of the salivary glands. *Curr Oncol Rep*. 2007 Mar;9(2):134–8. [PMID: 17288880]

DISEASES OF THE LARYNX

DYSPHONIA, HOARSENESS, & STRIDOR

The primary symptoms of laryngeal disease are hoarseness and stridor. Hoarseness is caused by an abnormal vibration of the vocal folds. The voice is breathy when too much air passes incompletely apposed vocal folds, as in unilateral vocal fold paralysis or vocal fold mass. The voice is harsh when the vocal folds are stiff and vibrate irregularly, as is the case in laryngitis or malignancy. Heavy, edematous vocal folds produce a rough, low-pitched vocal quality. Stridor (a high-pitched, typically inspiratory,

sound) is the result of turbulent airflow from a narrowed upper airway. Airway narrowing at or above the vocal folds produces inspiratory stridor. Airway narrowing below the vocal fold level produces either expiratory or biphasic stridor. The timing and rapidity of onset of stridor are critically important in determining the seriousness of the airway problem. *All cases of stridor should be evaluated by a specialist and rapid-onset stridor should be evaluated emergently.*

Evaluation of an abnormal voice begins with obtaining a history of the circumstances preceding its onset and an examination of the airway.

Any patient with hoarseness that has persisted beyond 2 weeks should be evaluated by an otolaryngologist with laryngoscopy. Especially when the patient has a history of tobacco use, laryngeal cancer or lung cancer (leading to paralysis of a recurrent laryngeal nerve) must be strongly considered. In addition to structural causes of dysphonia, laryngoscopy can help identify functional problems with the voice including vocal fold paralysis, muscle tension dysphonia, and spasmodic dysphonia.

Johns MM 3rd et al. Shortfalls of the American Academy of Otolaryngology-Head and Neck Surgery's Clinical practice guideline: Hoarseness (Dysphonia). *Otolaryngol Head Neck Surg*. 2010 Aug;143(2):175–7. [PMID: 20647114]

Klein AM et al. Vocal emergencies. *Otolaryngol Clin North Am*. 2007 Oct;40(5):1063–80. [PMID: 17765695]

Richardson BE et al. Clinical evaluation of vocal fold paralysis. *Otolaryngol Clin North Am*. 2004 Feb;37(1):45–58. [PMID: 15062686]

Schwartz SR et al. Clinical practice guideline: hoarseness (dysphonia). *Otolaryngol Head Neck Surg*. 2009 Sep;141(3 Suppl 2):S1–S31. [PMID: 19729111]

COMMON LARYNGEAL DISORDERS

1. Acute Laryngitis

Acute laryngitis is probably the most common cause of hoarseness, which may persist for a week or so after other symptoms of an upper respiratory infection have cleared. The patient should be warned to avoid vigorous use of the voice (singing, shouting) until their voice returns to normal, since persistent use may lead to the formation of traumatic vocal fold hemorrhage, polyps, and cysts. Although thought to be usually viral in origin, both *M catarrhalis* and *H influenzae* may be isolated from the nasopharynx at higher than expected frequencies. Erythromycin, cefuroxime, or amoxicillin-clavulanate may reduce the severity of hoarseness and cough. Oral or intramuscular corticosteroids may be used in highly selected cases of professional vocalists to speed recovery and allow scheduled performances. Examination of the vocal folds and assessment of vocal technique are mandatory prior to corticosteroid initiation, since inflamed vocal folds are at greater risk for hemorrhage and the subsequent development of traumatic vocal fold pathology.

Dworkin JP. Laryngitis: types, causes, and treatments. *Otolaryngol Clin North Am*. 2008 Apr;41(2):419–36. [PMID: 18328379]

2. Laryngopharyngeal Reflux



ESSENTIALS OF DIAGNOSIS

- ▶ Commonly associated with hoarseness, throat irritation, and chronic cough.
- ▶ Symptoms typically occur when upright and half of patients do not experience heartburn.
- ▶ Laryngoscopy is critical to exclude other causes of hoarseness.
- ▶ Diagnosis is made based on response to proton pump inhibitor therapy, as no gold-standard for the condition exists.
- ▶ Treatment failure with proton pump inhibitors is common and may suggest other etiologies.

Gastroesophageal reflux into the larynx (laryngopharyngeal reflux) is considered a cause of chronic hoarseness when other causes of abnormal vocal fold vibration (such as tumor or nodules) have been excluded by laryngoscopy. Gastroesophageal reflux disease (GERD) has also been suggested as a contributing factor to other symptoms such as throat clearing, throat discomfort, chronic cough, a sensation of postnasal drip, esophageal spasm, and some cases of asthma. Since less than half of patients with laryngeal acid exposure have typical symptoms of heartburn and regurgitation, the lack of such symptoms should not be construed as eliminating this cause. Indeed, most patients with symptomatic laryngopharyngeal reflux, as it is now called, do not meet criteria for GERD by pH probe testing and these entities must be considered separately. The prevalence of this condition is hotly debated in the literature and laryngopharyngeal reflux may not be as common as once thought.

Evaluation should initially exclude other causes of dysphonia through laryngoscopy; consultation with an otolaryngologist is advisable. Many clinicians opt for an empiric trial of a proton pump inhibitor. Such an empiric trial should not precede visualization of the vocal folds to exclude other causes of hoarseness. When used, the American Academy of Otolaryngology Head and Neck Surgery recommends twice daily therapy with full strength proton pump inhibitor (eg, omeprazole 40 mg orally twice daily, or equivalent) for a minimum of 3 months. Patients may note improvement in symptoms after 3 months, but the changes in the larynx often take 6 months to resolve. If symptoms improve and cessation of therapy leads to symptoms again, then a proton pump inhibitor is resumed at the lowest dose effective for remission, usually daily but at times on a demand basis. Although H₂-receptor antagonists are an alternative to proton pump inhibitors, they are generally both less clinically effective and less cost-effective. Nonresponders should undergo pH testing and manometry. Twenty-four-hour pH monitoring of the pharynx should best document laryngopharyngeal reflux and is advocated by some as the initial management step but it is costly, more difficult, and less available than

lower esophageal monitoring alone. Double pH probe (proximal and distal esophageal probes) testing is the best option for evaluation, since lower esophageal pH monitoring alone does not correlate well with laryngopharyngeal reflux symptoms. Oropharyngeal pH probe testing is available, but its ability to predict response to reflux treatment in patients with laryngopharyngeal reflux is not known.

Ford CN. GERD-related chronic laryngitis: pro. *Arch Otolaryngol Head Neck Surg.* 2010 Sep;136(9):910–3. [PMID: 20855685]

Gupta R et al. Laryngopharyngeal reflux: current concepts and questions. *Curr Opin Otolaryngol Head Neck Surg.* 2009 Jun;17(3):143–8. [PMID: 19395970]

Hammer HF. Reflux-associated laryngitis and laryngopharyngeal reflux: a gastroenterologist's point of view. *Dig Dis.* 2009;27(1):14–7. [PMID: 19439955]

Koufman JA et al. Laryngopharyngeal reflux: Position statement of the Committee on Speech, Voice, and Swallowing Disorders of the American Academy of Otolaryngology-Head and Neck Surgery. *Otolaryngol Head Neck Surg.* 2002 Jul;127(1):32–5. [PMID: 12161727]

Vaezi MF. Gastroesophageal reflux-related chronic laryngitis: con. *Arch Otolaryngol Head Neck Surg.* 2010 Sep;136(9):908–9. [PMID: 20855684]

3. Recurrent Respiratory Papillomatosis

Papillomas are common lesions of the larynx and other sites where ciliated and squamous epithelia meet. Unlike oral papillomas, recurrent respiratory papillomatosis typically becomes symptomatic, with hoarseness that occasionally progresses over weeks to months. These papillomas are almost always due to HPV types 6 and 11. The disease is more common in children where it causes hoarseness and stridor. Repeated laser vaporizations or cold knife resections via operative laryngoscopy are the mainstay of treatment. Severe cases can cause airway compromise even in adults and require treatment as often as every 6 weeks to maintain airway patency. Extension can occur into the trachea and lungs. Tracheotomy should be avoided, if possible, since it introduces an additional squamociliary junction for which papillomas appear to have an affinity. Interferon treatment has been under investigation for many years but is only indicated in severe cases with pulmonary involvement. Rarely, cases of malignant transformation have been reported (often in smokers), but recurrent respiratory papillomatosis should generally be thought of as a benign condition. Cidofovir (a cytosine nucleotide analog in use to treat cytomegalovirus retinitis) is also being investigated as intralesional therapy for recurrent respiratory papillomatosis and has had reported success in both adults and children. Because cidofovir causes adenocarcinomas in laboratory animals, its potential for carcinogenesis is being monitored. While the quadrivalent recombinant human HPV vaccine (Gardasil) is not useful as a treatment option for patients with recurrent respiratory papillomatosis, this vaccine offers hope for the eventual eradication of this benign, but terribly morbid, disease.

Bonagura VR et al. Recurrent respiratory papillomatosis: a complex defect in immune responsiveness to human papillomavirus-6 and -11. *APMIS*. 2010 Jun;118(6-7):455-70. [PMID: 20553528]

Blumin JH et al. Dysplasia in adults with recurrent respiratory papillomatosis: incidence and risk factors. *Ann Otol Rhinol Laryngol*. 2009 Jul;118(7):481-5. [PMID: 19708485]

Carvalho CM et al. Prognostic factors of recurrent respiratory papillomatosis from a registry of 72 patients. *Acta Otolaryngol*. 2009 Apr;129(4):462-70. [PMID: 19235575]

Chadha NK. Antiviral agents for the treatment of recurrent respiratory papillomatosis: a systematic review of the English-language literature. *Otolaryngol Head Neck Surg*. 2007 Jun;136(6):863-9. [PMID: 17547971]

Gallagher TQ et al. Recurrent respiratory papillomatosis: update 2008. *Curr Opin Otolaryngol Head Neck Surg*. 2008 Dec;16(6):536-42. [PMID: 19005325]

4. Epiglottitis

Epiglottitis (or, more correctly, supraglottitis) in adults should be suspected when a patient presents with a rapidly developing sore throat or when odynophagia (pain on swallowing) is out of proportion to apparently minimal oropharyngeal findings on examination. It is more common in diabetic patients and may be viral or bacterial in origin. Rarely in the era of *H influenzae* type b vaccine is this bacterium isolated in adults. Unlike in children, indirect laryngoscopy is generally safe and may demonstrate a swollen, erythematous epiglottitis. Lateral plain radiographs may demonstrate an enlarged epiglottis (the epiglottis “thumb sign”). Initial treatment is hospitalization for intravenous antibiotics—eg, ceftriaxone, 1–2 g intravenously every 8–12 hours; or cefuroxime, 750–1500 mg intravenously every 8 hours; and dexamethasone, usually 4–10 mg as initial bolus, then 4 mg intravenously every 6 hours—and observation of the airway. Corticosteroids may be tapered as symptoms and signs resolve. Similarly, substitution of oral antibiotics may be appropriate to complete a 10-day course. Less than 10% of adults require intubation. Indications for intubation are dyspnea, rapid pace of sore throat (where progression to airway compromise may occur before the effects of corticosteroids and antibiotics), and endolaryngeal abscess noted on CT imaging. If the patient is not intubated, prudence suggests monitoring oxygen saturation with continuous pulse oximetry and initial admission to a monitored unit.

Glynn F et al. Diagnosis and management of supraglottitis (epiglottitis). *Curr Infect Dis Rep*. 2008 May;10(3):200-4. [PMID: 18510881]

Lotfzadeh A et al. Viral supraglottitis in an adult. *Ear Nose Throat J*. 2009 Feb;88(2):768-70. [PMID: 19224474]

Sobol SE et al. Epiglottitis and croup. *Otolaryngol Clin North Am*. 2008 Jun;41(3):551-66. [PMID: 18435998]

MASSES OF THE LARYNX

1. Traumatic Lesions of the Vocal Folds

Vocal fold nodules are smooth, paired lesions that form at the junction of the anterior one-third and posterior two-thirds of the vocal folds. They are a common cause of

hoarseness resulting from vocal abuse. In adults, they are referred to as “singer’s nodules” and in children, as “screamer’s nodules.” Treatment requires modification of voice habits, and referral to a speech therapist is indicated. While nearly all true nodules will resolve with behavior modification, recalcitrant nodules may require surgical excision. Often, additional pathology, such as a polyp or cyst, may be encountered.

Vocal fold polyps are unilateral masses that form within the superficial lamina propria of the vocal fold. They are related to vocal trauma and seem to follow resolution of vocal fold hemorrhage. Small, sessile polyps may resolve with conservative measures, such as voice rest and corticosteroids, but larger polyps are often irreversible and require operative removal to restore normal voice.

Vocal fold cysts are also considered traumatic lesions of the vocal folds and are either true cysts with an epithelial lining or pseudocysts. They typically form from mucus-secreting glands on the inferior aspect of the vocal folds. Cysts may fluctuate in size from week to week and cause a variable degree of hoarseness. They rarely, if ever, resolve completely and may leave behind a sulcus, or vocal fold scar, if they decompress or are marsupialized. Such scarring can be a frustrating cause of permanent dysphonia.

Polypoid corditis is different from vocal fold polyps and may form from loss of elastin fibers and loosening of the intracellular junctions within the lamina propria. This loss allows swelling of the gelatinous matrix of the superficial lamina propria (called **Reinke edema**). These changes in the vocal folds are strongly associated with smoking, but also with vocal abuse, chemical industrial irritants, and hypothyroidism. While this problem is common in both male and female smokers, women seem more troubled by the characteristic decline in modal pitch caused by the increased mass of the vocal folds. If the patient stops smoking or the lesions cause stridor and airway obstruction, surgical resection of the hyperplastic vocal fold mucosa may be indicated to improve the voice or airway, or both.

A common but often unrecognized cause of hoarseness and odynophonia are **contact ulcers** or their close relatives, **granulomas**. Both lesions form on the vocal processes of the arytenoid cartilages, and patients often can correctly inform the clinician which side is affected. The cause of these ulcers and granulomas is disputed, but they are clearly related to trauma and may be related to exposure of the underlying perichondrium. They are common following intubation and generally resolve quite quickly. Chronic ulceration or granuloma formation has been associated with gastroesophageal reflux but is also common in patients with muscle tension dysphonia. Treatment is often multimodal and an inhaled corticosteroid (eg, fluticasone 440 mcg twice daily) may be the most effective pharmacologic therapy. Adjunct treatment measures include proton pump inhibitor therapy (omeprazole 40 mg orally twice daily, or equivalent) and voice therapy with special attention to vocal hygiene. Rare cases can be quite stubborn and persistent without adequate therapy. Surgical removal is rarely, if ever, required for nonobstructive lesions.

Altman KW. Vocal fold masses. *Otolaryngol Clin North Am*. 2007 Oct;40(5):1091–108. [PMID: 17765697]
 Gökcän KM et al. Vascular lesions of the vocal fold. *Eur Arch Otorhinolaryngol*. 2009 Apr;266(4):527–33. [PMID: 18704472]

2. Laryngeal Leukoplakia

Leukoplakia of the vocal folds is commonly found in association with hoarseness in smokers. Direct laryngoscopy with biopsy is advised in almost all cases. Histologic examination usually demonstrates mild, moderate, or severe dysplasia. In some cases, invasive SCC is present in the initial biopsy specimen. Cessation of smoking may reverse or stabilize mild or moderate dysplasia. A certain percentage of patients—estimated to be < 5% of those with mild dysplasia and about 35–60% of those with severe dysplasia—will subsequently develop SCC. Treatment options include close follow-up with laryngovideostroboscopy, serial resection, and external beam radiation therapy. Despite their cost and the lack of any evidence for their use in the treatment of leukoplakia, proton pump inhibitors have become the mainstay of treatment for these lesions.

Isenberg JS et al. Institutional and comprehensive review of laryngeal leukoplakia. *Ann Otol Rhinol Laryngol*. 2008 Jan; 117(1):74–9. [PMID: 18254375]

3. Squamous Cell Carcinoma of the Larynx



ESSENTIALS OF DIAGNOSIS

- ▶ New and persistent (more than 2 weeks duration) hoarseness in a smoker.
- ▶ Persistent throat or ear pain, especially with swallowing.
- ▶ Neck mass.
- ▶ Hemoptysis.
- ▶ Stridor or other symptoms of a compromised airway.

▶ General Considerations

SCC of the larynx, the most common malignancy of the larynx, occurs almost exclusively in patients with a history of significant tobacco use. SCC is usually seen in men age 50–70 years; about 13,000 new cases are seen in United States each year. There may be an association between laryngeal cancer and HPV type 16 or 18 infection, but this association is much less strong than that between HPV 16 or 18 and oropharyngeal cancer. In both cancer types, the association with HPV seems to be strongest in nonsmokers. Laryngeal cancer is very treatable and early detection is the key to maximizing posttreatment voice, swallowing, and breathing function.

▶ Clinical Findings

A. Symptoms and Signs

A change in voice quality is most often the presenting complaint, although throat or ear pain, hemoptysis, dysphagia, weight loss, and airway compromise may occur. Because of their early impact on vocal quality, glottic cancers are among the smallest detectable human malignancies and treatment success is very high with early lesions. Neck metastases are not common in early glottic (true vocal fold) cancer in which the vocal folds are mobile, but a third of patients in whom there is impaired fold mobility will also have involved lymph nodes at neck dissection. Supraglottic carcinoma (false vocal folds, aryepiglottic folds, epiglottis), on the other hand, often metastasizes to both sides of the neck early in the disease. Complete head and neck examination, including laryngoscopy, by an experienced clinician is mandated for any person with the concerning symptoms listed under Essentials of Diagnosis.

B. Imaging and Laboratory Studies

Radiologic evaluation by CT or MRI is helpful in assessing tumor extent. Imaging evaluates neck nodes, tumor volume, and cartilage sclerosis or destruction. A chest CT scan is indicated if there are level VI enlarged nodes (around the trachea and the thyroid gland) or IV enlarged nodes (inferior to the cricoid cartilage along the internal jugular vein) or if a chest film is concerning for a second primary lesion or metastases. Laboratory evaluation includes complete blood count and liver function tests. Formal cardiopulmonary evaluation may be indicated, especially if partial laryngeal surgery is being considered. All partial laryngectomy candidates should have good to excellent lung function and exercise tolerance because chronic microaspiration may be expected following the procedure. A positron emission tomography (PET) scan or CT-PET scan may be indicated to assess for distant metastases when there appears to be advanced local or regional disease.

C. Biopsy

Diagnosis is made by biopsy at the time of laryngoscopy. At that time, true fold mobility and arytenoid fixation, as well as surface tumor extent, can be evaluated. Most otolaryngologists recommend esophagoscopy and bronchoscopy at the same time to exclude synchronous primary tumor. Although an FNA biopsy of an enlarged neck node may have already been done, it is generally acceptable to assume radiographically enlarged neck nodes (> 1–1.5 cm) or nodes with necrotic centers are neck metastases. Open biopsies of nodal metastases should be discouraged because they may lead to higher rates of tumor treatment failure.

D. Tumor Staging

The American Joint Committee on Cancer (AJCC) staging of laryngeal cancers uses the TNM system to describe tumor extent and can be used for prognosis. Early laryngeal cancers, T1 and T2 (stage I and II) lesions, involve

1–2 laryngeal subsites locally and have no nodal metastases or profound functional abnormalities. T3 and T4 lesions may involve multiple laryngeal subsites with limitation of laryngeal mobility. These locally advanced lesions are stage III or IV cancers and any size tumor with regional nodal metastases is at least a stage III tumor. Stage I and II lesions are generally treated with single modality therapy (surgery or radiation) while multimodality therapy, usually including chemotherapy with radiation therapy, is reserved for more advanced stage III and IV lesions.

► Treatment

Treatment of laryngeal carcinoma has four goals: cure, preservation of safe effective swallowing, preservation of useful voice, and avoidance of a permanent tracheostoma. For early glottic and supraglottic cancers, radiation therapy is the standard of care since cure rates are > 95% and 80%, respectively. That said, radiation therapy carries substantial morbidity and many early tumors (T1 and T2 lesions, without involved nodes) and selected advanced tumors (T3 and T4) may be treated with partial laryngectomy if at least one cricoarytenoid unit can be preserved. Five-year locoregional cure rates exceed 80–90% with surgery, and patient-reported satisfaction is excellent. In supraglottic tumors, even when clinically N0, elective limited neck dissection is indicated following surgical resection because of the high risk of neck node involvement.

For advanced stage III and IV tumors, multimodality therapy—typically including chemotherapy—is warranted. Twenty-five years ago, total laryngectomy was often recommended for such patients. However, the 1994 VA study (with induction cisplatin and 5-fluorouracil followed by irradiation alone in responders) demonstrated that two-thirds of patients could preserve their larynx. Since that study, cisplatin-based chemotherapy concomitant with radiation therapy has been shown to be superior to either irradiation alone or induction chemotherapy followed by radiation. The same benefits have been demonstrated with the epidermal growth factor receptor blocker cetuximab with lower overall systemic toxicity and better patient tolerance. However, chemoradiation of either form is associated with prolonged gastrostomy-dependent dysphagia. This high rate of chemoradiation-associated dysphagia has prompted a reevaluation of the role of extended, but less-than-total, laryngeal surgery for selected advanced laryngeal carcinoma in which at least one cricoarytenoid unit is intact. In addition, overall success in the treatment of larynx cancer has declined in parallel with the increase in organ preservation chemoradiation therapy. Some experts have proposed that this decline is the direct result of the shift in management of advanced laryngeal cancer away from surgery. Organ preservation surgery should be considered and discussed as an alternative to chemoradiation. Patient comorbidities and patient choice, after thorough discussion, play an important role in the choice between surgery and chemoradiation. The patient and treating clinicians must carefully consider *different* side effects and complications associated with different treatment modalities.

The presence of malignant adenopathy in the neck affects the prognosis greatly. Supraglottic tumors metastasize

early and bilaterally to the neck, and this must be included in the treatment plans even when the neck is apparently uninvolved. Glottic tumors in which the true vocal folds are mobile (T1 or T2) have less than a 5% rate of nodal involvement; when a fold is immobile, the rate of ipsilateral nodal involvement climbs to about 30%. An involved neck is treated by surgery or chemoradiation, or both. This decision will depend on the treatment chosen for the larynx and the extent of neck involvement.

Total laryngectomy is largely reserved for patients with advanced resectable tumors with extralaryngeal spread or cartilage involvement, for those with persistent tumor following chemoradiation, and for patients with recurrent or second primary tumor following previous radiation therapy. Voice rehabilitation via a primary (or at times secondary) tracheoesophageal puncture produces intelligible and serviceable speech in about 75–85% of patients. Indwelling prostheses that are changed every 3–6 months are a common alternative to patient-inserted prostheses, which need changing more frequently.

Long-term follow-up is critical in head and neck cancer patients. In addition to the 3–4% annual rate of second tumors and monitoring for recurrence, psychosocial aspects of treatment are common. Dysphagia, impaired communication, and altered appearance, may result in patient difficulties adapting to the workplace and to social interactions. In addition, smoking cessation and alcohol abatement are common challenges. Nevertheless, about 65% of patients with larynx cancer are cured, most have useful speech, and many resume their prior livelihoods with adaptations.

Agrawal A et al. Transoral carbon dioxide laser supraglottic laryngectomy and irradiation in stage I, II, and III squamous cell carcinoma of the supraglottic larynx: report of Southwest Oncology Group Phase 2 Trial S9709. *Arch Otolaryngol Head Neck Surg.* 2007 Oct;133(10):1044–50. [PMID: 17938330]

Bonner JA et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. *Lancet Oncol.* 2010 Jan;11(1):21–8. [PMID: 19897418]

Hashibe M et al. Alcohol drinking in never users of tobacco, cigarette smoking in never drinkers, and the risk of head and neck cancer: pooled analysis in the International Head and Neck Cancer Epidemiology Consortium. *J Natl Cancer Inst.* 2007 May 16;99(10):777–89. [PMID: 17505073]

Machtay M et al. Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: an RTOG analysis. *J Clin Oncol.* 2008 Jul 20;26(21):3582–9. [PMID: 18559875]

Wang CJ et al. Current concepts of organ preservation in head and neck cancer. *Eur Arch Otorhinolaryngol.* 2011 Apr; 268(4):481–7. [PMID: 21107854]

VOCAL FOLD PARALYSIS

Vocal fold paralysis can result from a lesion or damage to either the vagus or recurrent laryngeal nerve and usually results in breathy dysphonia and effortful voicing. Common causes of **unilateral recurrent laryngeal nerve** involvement include thyroid surgery (and occasionally thyroid cancer), other neck surgery (anterior discectomy and carotid endarterectomy), and mediastinal or apical involvement by lung

cancer. Skull base tumors often involve or abut upon lower cranial nerves and may affect the vagus nerve directly, or the vagus nerve may be damaged during surgical management of the lesion. While iatrogenic injury is the most common cause of unilateral vocal fold paralysis, the second most common cause is idiopathic. However, before deciding whether the paralysis is due to iatrogenic injury or is idiopathic, the clinician must exclude other causes, such as malignancy. In the absence of other cranial neuropathies, a CT scan with contrast from the skull base to the aorto-pulmonary window (the span of the recurrent laryngeal nerve) should be performed. If other cranial nerve deficits or high vagal weakness with palate paralysis is noted, a MRI scan of the brain and brainstem is warranted.

Unlike unilateral fold paralysis, **bilateral fold paralysis** usually causes inspiratory stridor with deep inspiration. If the onset of bilateral fold paralysis is insidious, it may be asymptomatic at rest and the patient may have a normal voice. However, the acute onset of bilateral vocal fold paralysis with inspiratory stridor at rest should be managed by a specialist immediately in a critical care environment. Causes of bilateral fold paralysis include thyroid surgery, esophageal cancer, and ventricular shunt malfunction. Unilateral or bilateral fold immobility may also be seen in cricoarytenoid arthritis secondary to advanced rheumatoid arthritis, intubation injuries, glottic and subglottic stenosis and, of course, laryngeal cancer. The goal of intervention is the creation of a safe airway with minimal reduction in voice quality and airway protection from aspiration. A number of fold lateralization procedures for bilateral paralysis have been advocated as a means of removing the tracheotomy tube.

Unilateral vocal fold paralysis is occasionally temporary and may take over a year to resolve spontaneously. Surgical management of persistent or irrecoverable symptomatic unilateral vocal fold paralysis has evolved over the last several decades. The primary goal is medialization of the paralyzed fold in order to create a stable platform for vocal fold vibration. Additional goals include improving pulmonary toilet by facilitating of cough and advancing diet. Success has been reported for years with injection laryngoplasty using Teflon, Gelfoam, fat and collagen. Teflon is the only permanent injectable material, but its use is discouraged because of granuloma formation within the vocal folds of some patients. Temporary injectable materials, such as collagen or fat, provide excellent temporary restoration of voice and can be placed under local or general anesthesia. Once the paralysis is determined to be permanent, formal medialization thyroplasty may be performed by creating a small window in the thyroid cartilage and placing an implant between the thyroarytenoid muscle and inner table of the thyroid cartilage. This procedure moves the vocal fold medially and creates a stable platform for bilateral, symmetric mucosal vibration.

Azadarmaki R et al. Unilateral true vocal fold synkinesis presenting with airway obstruction. *Ann Otol Rhinol Laryngol.* 2009 Aug;118(8):587–91. [PMID: 19746758]

Bajaj Y et al. Vocal fold paralysis: role of bilateral transverse cordotomy. *J Laryngol Otol.* 2009 Dec;123(12):1348–51. [PMID: 19740454]

TRACHEOSTOMY & CRICOTHYROTOMY

There are two primary indications for tracheotomy: airway obstruction at or above the level of the larynx and respiratory failure requiring prolonged mechanical ventilation. In an acute emergency, cricothyrotomy secures an airway more rapidly than tracheotomy, with fewer potential immediate complications such as pneumothorax and hemorrhage. Percutaneous dilatational tracheotomy as an elective bedside (or intensive care unit) procedure has undergone scrutiny in recent years as an alternative to tracheotomy. In experienced hands, the various methods of percutaneous tracheotomy have been documented to be safe in carefully selected patients. Simultaneous videobronchoscopy can reduce the incidence of major complications. The major cost reduction comes from avoiding the operating room. Bedside tracheotomy (in the intensive care unit) achieves similar cost reduction and is advocated by some experts as slightly less costly than the percutaneous procedures.

The most common indication for elective tracheotomy is the need for prolonged mechanical ventilation. There is no firm rule about how many days a patient must be intubated before conversion to tracheotomy should be advised. The incidence of serious complications such as subglottic stenosis increases with extended endotracheal intubation. As soon as it is apparent that the patient will require protracted ventilatory support, tracheotomy should replace the endotracheal tube. Less frequent indications for tracheostomy are life-threatening aspiration pneumonia, the need to improve pulmonary toilet to correct problems related to insufficient clearing of tracheobronchial secretions, and sleep apnea.

Posttracheotomy care requires humidified air to prevent secretions from crusting and occluding the inner cannula of the tracheotomy tube. The tracheotomy tube should be cleaned several times daily. The most frequent early complication of tracheotomy is dislodgment of the tracheotomy tube. Surgical creation of an inferiorly based tracheal flap sutured to the inferior neck skin may make reinsertion of a dislodged tube easier. It should be recalled that the act of swallowing requires elevation of the larynx, which is limited by tracheotomy. Therefore, frequent tracheal and bronchial suctioning is often required to clear the aspirated saliva as well as the increased tracheobronchial secretions. Care of the skin around the stoma is important to prevent maceration and secondary infection.

Down J et al. Early vs late tracheostomy in critical care. *Br J Hosp Med (Lond).* 2009 Sep 9;70(9):510–13. [PMID: 19749640]

Groves DS et al. Tracheostomy in the critically ill: indications, timing and techniques. *Curr Opin Crit Care.* 2007 Feb; 13(1):90–7. [PMID: 17198055]

Homewood J et al. Tracheostomy care. *Br J Hosp Med (Lond).* 2005 Nov;66(11):M72–3. [PMID: 16308953]

FOREIGN BODIES IN THE UPPER AERODIGESTIVE TRACT

FOREIGN BODIES OF THE TRACHEA & BRONCHI

Aspiration of foreign bodies occurs much less frequently in adults than in children. The elderly and denture wearers

appear to be at greatest risk. Wider familiarity with the Heimlich maneuver has reduced deaths. If the maneuver is unsuccessful, cricothyrotomy may be necessary. Plain chest radiographs may reveal a radiopaque foreign body. Detection of radiolucent foreign bodies may be aided by inspiration-expiration films that demonstrate air trapping distal to the obstructed segment. Atelectasis and pneumonia may occur later.

Tracheal and bronchial foreign bodies should be removed under general anesthesia with rigid bronchoscopy by a skilled endoscopist working with an experienced anesthesiologist.

Digoy GP. Diagnosis and management of upper aerodigestive tract foreign bodies. *Otolaryngol Clin North Am.* 2008 Jun;41(3):485–96. [PMID: 18435994]

ESOPHAGEAL FOREIGN BODIES

Foreign bodies in the esophagus create urgent but not life-threatening situations as long as the airway is not compromised. There is probably time to consult an experienced clinician for management. It is a useful diagnostic sign of complete obstruction if the patient is drooling or cannot handle secretions. Patients may often point to the exact level of the obstruction. Indirect laryngoscopy often shows pooling of saliva at the esophageal inlet. Plain films may detect radiopaque foreign bodies such as chicken bones. Coins tend to align in the coronal plane in the esophagus and sagittally in the trachea. If a foreign body is suspected, a barium swallow may help make the diagnosis.

The treatment of an esophageal foreign body depends very much on identification of its nature. In children, swallowed nonfood objects are common. In adults, however, food foreign bodies are more common, and there is the greater possibility of underlying esophageal pathology. Endoscopic removal and examination is usually best via flexible esophagoscopy or rigid laryngoscopy and esophagoscopy. If there is nothing sharp such as a bone, some clinicians advocate a hospitalized 24-hour observation period prior to esophagoscopy, noting that spontaneous passage of the foreign body will occur in 50% of adult patients. In the management of meat obstruction, the use of papain (meat tenderizer) should be discouraged because it can damage the esophageal mucosa and lead to stenosis or perforation.

Weissberg D et al. Foreign bodies in the esophagus. *Ann Thorac Surg.* 2007 Dec;84(6):1854–7. [PMID: 18036898]

DISEASES PRESENTING AS NECK MASSES

The differential diagnosis of neck masses is heavily dependent on the location in the neck, the age of the patient, and the presence of associated disease processes. Rapid growth and tenderness suggest an inflammatory process, while firm, painless, and slowly enlarging masses are often neoplastic. In young adults, most neck masses are benign (branchial cleft cyst, thyroglossal duct cyst, reactive lymphadenitis), although malignancy should always be

considered (lymphoma, metastatic thyroid carcinoma). Lymphadenopathy is common in HIV-positive persons, but a growing or dominant mass may well represent lymphoma. In adults over age 40, cancer is the most common cause of persistent neck mass. A metastasis from SCC arising within the mouth, pharynx, larynx, or upper esophagus should be suspected, especially if there is a history of tobacco or significant alcohol use. Especially among patients younger than 30 or older than 70, lymphoma should be considered. In any case, a comprehensive otolaryngologic examination is needed. Cytologic evaluation of the neck mass via FNA biopsy is likely to be the next step if an obvious primary tumor is not obvious on physical examination.

CONGENITAL LESIONS PRESENTING AS NECK MASSES IN ADULTS

1. Branchial Cleft Cysts

Branchial cleft cysts usually present as a soft cystic mass along the anterior border of the sternocleidomastoid muscle. These lesions are usually recognized in the second or third decades of life, often when they suddenly swell or become infected. To prevent recurrent infection and possible carcinoma, they should be completely excised, along with their fistulous tracts.

First branchial cleft cysts present high in the neck, sometimes just below the ear. A fistulous connection with the floor of the external auditory canal may be present. Second branchial cleft cysts, which are far more common, may communicate with the tonsillar fossa. Third branchial cleft cysts, which may communicate with the piriform sinus, are rare and present low in the neck.

Acierio SP et al. Congenital cervical cysts, sinuses and fistulae. *Otolaryngol Clin North Am.* 2007 Feb;40(1):161–76. [PMID: 17346566]

Papadogeorgakis N et al. Branchial cleft cysts in adults. Diagnostic procedures and treatment in a series of 18 cases. *Oral Maxillofac Surg.* 2009 Jun;13(2):79–85. [PMID: 19308468]

2. Thyroglossal Duct Cysts

Thyroglossal duct cysts occur along the embryologic course of the thyroid's descent from the tuberculum impar of the tongue base to its usual position in the low neck. Although they may occur at any age, they are most common before age 20. They present as a midline neck mass, often just below the hyoid bone, which moves with swallowing. Surgical excision is recommended to prevent recurrent infection. This requires removal of the entire fistulous tract along with the middle portion of the hyoid bone through which many of the fistulas pass. Preoperative evaluation should include a thyroid ultrasound to confirm anatomic position of the thyroid.

Lin ST et al. Thyroglossal duct cyst: a comparison between children and adults. *Am J Otolaryngol.* 2008 Mar–Apr;29(2):83–7. [PMID: 18314017]

INFECTIOUS & INFLAMMATORY NECK MASSES

1. Reactive Cervical Lymphadenopathy

Normal lymph nodes in the neck are usually < 1 cm in length. Infections involving the pharynx, salivary glands, and scalp often cause tender enlargement of neck nodes. Enlarged nodes are common in HIV-infected persons. Except for the occasional node that suppurates and requires incision and drainage, treatment is directed against the underlying infection. An enlarged node (> 1.5 cm) or node with a necrotic center that is not associated with an obvious infection should be further evaluated, especially if the patient has a history of smoking, alcohol use, or prior cancer. Other common indications for FNA biopsy of a node include its persistence or continued enlargement. Common causes of cervical adenopathy include tumor (SCC, lymphoma, occasional metastases from non-head and neck sites) and infection (eg, reactive nodes, mycobacteria [discussed below], and cat scratch disease). Rare causes of adenopathy include Kikuchi disease (histiocytic necrotizing lymphadenitis) and autoimmune adenopathy.

Leung AK et al. Cervical lymphadenitis: etiology, diagnosis, and management. *Curr Infect Dis Rep.* 2009 May;11(3):183–9. [PMID: 19366560]

2. Tuberculous & Nontuberculous Mycobacterial Lymphadenitis

Granulomatous neck masses are not uncommon. The differential diagnosis includes mycobacterial adenitis, sarcoidosis, and cat-scratch disease due to *Bartonella henselae*. Mycobacterial lymphadenitis is on the rise both in immunocompromised and immunocompetent individuals. The usual presentation of granulomatous disease in the neck is simply single or matted nodes. Although mycobacterial adenitis can extend to the skin and drain externally (as described for atypical mycobacteria and referred to as scrofula), this late presentation is no longer common.

FNA biopsy is usually the best initial diagnostic approach: cytology, smear for acid-fast bacilli, culture, and sensitivity test can all be done. Excisional biopsy of a node may be needed.

PCR from FNA (or from excised tissue) is the single most sensitive test and is particularly useful when conventional methods have not been diagnostic but clinical impression remains consistent for tuberculous infection.

Short-course therapy (6 months) consisting of an initial 4 months of streptomycin, isoniazid, rifampin, and pyrazinamide followed by 2 months of rifampin is the current recommended treatment for tuberculous lymphadenopathy (see Table 9–18). For atypical (nontuberculous) lymphadenopathy, treatment depends on sensitivity results of culture, but antibiotics likely to be useful include 6 months of isoniazid and rifampin and, for at least the first 2 months, ethambutol—all in standard dosages. Some would totally excise the involved nodes prior to chemotherapy, depending on location and other factors, but this can lead to chronic draining fistulas.

Polesky A et al. Peripheral tuberculous lymphadenitis: epidemiology, diagnosis, treatment, and outcome. *Medicine (Baltimore).* 2005 Nov;84(6):350–62. [PMID: 16267410]

3. Lyme Disease

Lyme disease, caused by the spirochete *Borrelia burgdorferi* and transmitted by ticks of the *Ixodes* genus, may have protean manifestation, but over 75% of patients have symptoms involving the head and neck. Facial paralysis, dysesthesias, dysgeusia, or other cranial neuropathies are most common. Headache, pain, and cervical lymphadenopathy may occur. See Chapter 34 for a more detailed discussion.

DePietropaolo DL et al. Diagnosis of Lyme disease. *Am Fam Physician.* 2005 Jul 15;72(2):297–304. [PMID: 16050454]
Hagemann G et al. Bilateral facial palsy in neuroborreliosis. *Arch Neurol.* 2009 Apr;66(4):534–5. [PMID: 19364942]

TUMOR METASTASES

In older adults, 80% of firm, persistent, and enlarging neck masses are metastatic in origin. The great majority of these arise from SCC of the upper aerodigestive tract. A complete head and neck examination may reveal the tumor of origin, but examination under anesthesia with direct laryngoscopy, esophagoscopy, and bronchoscopy is usually required to fully evaluate the tumor and exclude second primaries.

It is often helpful to obtain a cytologic diagnosis if initial head and neck examination fails to reveal the primary tumor. An open biopsy should be done only when neither physical examination by an experienced clinician specializing in head and neck cancer nor FNA biopsy performed by an experienced cytopathologist yields a diagnosis. In such a setting, one should strongly consider obtaining an MRI or PET scan prior to open biopsy, as these methods may yield valuable information about a possible presumed primary site or another site for FNA.

With the exception of papillary thyroid carcinoma, non-squamous cell metastases to the neck are infrequent. While tumors that are not primary in the head or neck seldom metastasize to the cervical lymph nodes, the supraclavicular lymph nodes are quite often involved by lung, gastroesophageal, and breast tumors. Infradiaphragmatic tumors, with the exception of renal cell carcinoma and testicular cancer, rarely metastasize to the neck.

Barzilai G et al. Pattern of regional metastases from cutaneous squamous cell carcinoma of the head and neck. *Otolaryngol Head Neck Surg.* 2005 Jun;132(6):852–6. [PMID: 15944554]

LYMPHOMA

About 10% of lymphomas present in the head and neck. Multiple rubbery nodes, especially in the young adult or in

patients who have AIDS, are suggestive of this disease. A thorough physical examination may demonstrate other sites of nodal or organ involvement. FNA biopsy may be diagnostic, but open biopsy is often required to determine architecture and an appropriate treatment course.

Howlett DC et al. Diagnostic adequacy and accuracy of fine needle aspiration cytology in neck lump assessment: results from a regional cancer network over a one year period. *J Laryngol Otol.* 2007 Jun;121(6):571-9. [PMID: 17134537]

9

Pulmonary Disorders

Mark S. Chesnutt, MD
 Thomas J. Prendergast, MD
 Emmanuel T. Tavan, MD

DISORDERS OF THE AIRWAYS

Airway disorders have diverse causes but share certain common pathophysiologic and clinical features. Airflow limitation is characteristic and frequently causes dyspnea and cough. Other symptoms are common and typically disease-specific. Disorders of the airways can be classified as those that involve the upper airways—loosely defined as those above and including the vocal folds—and those that involve the lower airways.

DISORDERS OF THE UPPER AIRWAYS

Acute upper airway obstruction can be immediately life-threatening and must be relieved promptly to avoid asphyxia. Causes of acute upper airway obstruction include trauma to the larynx or pharynx, foreign body aspiration, laryngospasm, laryngeal edema from thermal injury or angioedema, infections (acute epiglottitis, Ludwig angina, pharyngeal or retropharyngeal abscess), and acute allergic laryngitis.

Chronic obstruction of the upper airway may be caused by carcinoma of the pharynx or larynx, laryngeal or subglottic stenosis, laryngeal granulomas or webs, or bilateral vocal fold paralysis. Laryngeal or subglottic stenosis may become evident weeks or months following a period of translaryngeal endotracheal intubation. Inspiratory stridor, intercostal retractions on inspiration, a palpable inspiratory thrill over the larynx, and wheezing localized to the neck or trachea on auscultation are characteristic findings. Flow-volume loops may show flow limitations characteristic of obstruction. Soft tissue radiographs of the neck may show supraglottic or infraglottic narrowing. CT and MRI scans can reveal exact sites of obstruction. Flexible endoscopy may be diagnostic, but caution is necessary to avoid exacerbating upper airway edema and precipitating critical airway narrowing.

Vocal fold dysfunction syndrome is a condition characterized by paradoxical vocal fold adduction, resulting in both acute and chronic upper airway obstruction. It can cause dyspnea and wheezing that may present as asthma or exercise-induced asthma but may be distinguished from asthma by the lack of response to bronchodilator therapy,

normal spirometry immediately after an attack, spirometric evidence of upper airway obstruction, a negative bronchial provocation test, or direct visualization of adduction of the vocal folds on both inspiration and expiration. The condition appears to be psychogenic in nature. Bronchodilators are of no therapeutic benefit. Treatment consists of speech therapy, which uses breathing, voice, and neck relaxation exercises to abort the symptoms.

Gaissert HA et al. The compromised airway: tumors, strictures, and tracheomalacia. *Surg Clin North Am.* 2010 Oct;90(5):1065–89. [PMID: 20955884]
 Morris MJ et al. Diagnostic criteria for the classification of vocal cord dysfunction. *Chest.* 2010 Nov;138(5):1213–23. [PMID: 21051397]

DISORDERS OF THE LOWER AIRWAYS

Tracheal obstruction may be intrathoracic (below the suprasternal notch) or extrathoracic. Fixed tracheal obstruction may be caused by acquired or congenital tracheal stenosis, primary or secondary tracheal neoplasms, extrinsic compression (tumors of the lung, thymus, or thyroid; lymphadenopathy; congenital vascular rings; aneurysms, etc), foreign body aspiration, tracheal granulomas and papillomas, and tracheal trauma. Tracheomalacia, foreign body aspiration, and retained secretions may cause variable tracheal obstruction.

Acquired **tracheal stenosis** is usually secondary to previous tracheotomy or endotracheal intubation. Dyspnea, cough, and inability to clear pulmonary secretions occur weeks to months after tracheal decannulation or extubation. Physical findings may be absent until tracheal diameter is reduced 50% or more, when wheezing, a palpable tracheal thrill, and harsh breath sounds may be detected. The diagnosis is usually confirmed by plain films or CT of the trachea. Complications include recurring pulmonary infection and life-threatening respiratory failure. Management is directed toward ensuring adequate ventilation and oxygenation and avoiding manipulative procedures that may increase edema of the tracheal mucosa. Surgical reconstruction, endotracheal stent placement, or laser photoresection may be required.

Bronchial obstruction may be caused by retained pulmonary secretions, aspiration, foreign bodies, bronchomalacia, bronchogenic carcinoma, compression by extrinsic masses, and tumors metastatic to the airway. Clinical and radiographic findings vary depending on the location of the obstruction and the degree of airway narrowing. Symptoms include dyspnea, cough, wheezing, and, if infection is present, fever and chills. A history of recurrent pneumonia in the same lobe or segment or slow resolution (> 3 months) of pneumonia on successive radiographs suggests the possibility of bronchial obstruction and the need for bronchoscopy.

Roentgenographic findings include **atelectasis** (local parenchymal collapse), postobstructive infiltrates, and air trapping caused by unidirectional expiratory obstruction. CT scanning may demonstrate the nature and the exact location of obstruction of the central bronchi. MRI may be superior to CT for delineating the extent of underlying disease in the hilum, but it is usually reserved for cases in which CT findings are equivocal. Bronchoscopy is the definitive diagnostic study, particularly if tumor or foreign body aspiration is suspected. The finding of bronchial breath sounds on physical examination or an air bronchogram on chest radiograph in an area of atelectasis rules out complete airway obstruction. Bronchoscopy is unlikely to be of therapeutic benefit in this situation.

Boyd M et al. Tracheobronchial foreign body aspiration in adults. *South Med J*. 2009 Feb;102(2):171–4. [PMID: 19139679]
 Kwon KY et al. Middle lobe syndrome: a clinicopathological study of 21 patients. *Hum Pathol*. 1995 Mar;26(3):302–7. [PMID: 7890282]
 Shrab S et al. Management of central airway obstruction. *Clin Lung Cancer*. 2007 Mar;8(5):305–12. [PMID: 17562229]

ASTHMA

ESSENTIALS OF DIAGNOSIS

- ▶ Episodic or chronic symptoms of airflow obstruction.
- ▶ Reversibility of airflow obstruction, either spontaneously or following bronchodilator therapy.
- ▶ Symptoms frequently worse at night or in the early morning.
- ▶ Prolonged expiration and diffuse wheezes on physical examination.
- ▶ Limitation of airflow on pulmonary function testing or positive bronchoprovocation challenge.

▶ General Considerations

Asthma is a common disease, affecting approximately 7–10% of the population. It is slightly more common in male children (< 14 years old) and in female adults. A genetic predisposition to asthma is recognized. Prevalence, hospitalizations, and fatal asthma have all increased in the United States over the past 20 years. Each year, approximately 500,000 hospital

admissions and 4500 deaths in the United States are attributed to asthma. Hospitalization rates have been highest among blacks and children, and death rates for asthma are consistently highest among blacks aged 15–24 years.

▶ Definition & Pathogenesis

Asthma is a chronic inflammatory disorder of the airways. No single histopathologic feature is pathognomonic but common findings include inflammatory cell infiltration with eosinophils, neutrophils, and lymphocytes (especially T lymphocytes); goblet cell hyperplasia, sometimes with plugging of small airways with thick mucus; collagen deposition beneath the basement membrane; hypertrophy of bronchial smooth muscle; airway edema; mast cell activation; and denudation of airway epithelium. This airway inflammation underlies disease chronicity and contributes to airway hyper-responsiveness and airflow limitation.

The strongest identifiable predisposing factor for the development of asthma is atopy, but obesity is increasingly recognized as a risk factor. Exposure of sensitive patients to inhaled allergens increases airway inflammation, airway hyper-responsiveness, and symptoms. Symptoms may develop immediately (immediate asthmatic response) or 4–6 hours after allergen exposure (late asthmatic response). Common allergens include house dust mites (often found in pillows, mattresses, upholstered furniture, carpets, and drapes), cockroaches, cat dander, and seasonal pollens. Substantially reducing exposure reduces pathologic findings and clinical symptoms.

Nonspecific precipitants of asthma include exercise, upper respiratory tract infections, rhinitis, sinusitis, postnasal drip, aspiration, gastroesophageal reflux, changes in the weather, and stress. Exposure to environmental tobacco smoke increases asthma symptoms and the need for medications and reduces lung function. Increased air levels of respirable particles, ozone, SO₂, and NO₂ precipitate asthma symptoms and increase emergency department visits and hospitalizations. Selected individuals may experience asthma symptoms after exposure to aspirin, nonsteroidal anti-inflammatory drugs, or tartrazine dyes. Certain other medications may also precipitate asthma symptoms (see Table 9–27). **Occupational asthma** is triggered by various agents in the workplace and may occur weeks to years after initial exposure and sensitization. Women may experience catamenial asthma at predictable times during the menstrual cycle. **Exercise-induced bronchoconstriction** begins during exercise or within 3 minutes after its end, peaks within 10–15 minutes, and then resolves by 60 minutes. This phenomenon is thought to be a consequence of the airways' attempt to warm and humidify an increased volume of expired air during exercise. **“Cardiac asthma”** is wheezing precipitated by decompensated congestive heart failure.

▶ Clinical Findings

Symptoms and signs vary widely from patient to patient as well as individually over time. General clinical findings in stable asthma patients are listed in Figure 9–1 and Table 9–1; findings seen during asthma exacerbations are listed in Tables 9–2 and 9–3.

Components of Severity		Classification of Asthma Severity ≥ 12 years of age			
		Intermittent	Persistent		
			Mild	Moderate	Severe
Impairment Normal FEV ₁ /FVC: 8–19 yr 85% 20–39 yr 80% 40–59 yr 75% 60–80 yr 70%	Symptoms	≤ 2 days/week	> 2 days/week but not daily	Daily	Throughout the day
	Nighttime awakenings	≤ 2x/month	3–4x/month	> 1x/week but not nightly	Often 7x/week
	Short-acting β ₂ -agonist use for symptom control (not prevention of EIB)	≤ 2 days/week	> 2 days/week but not daily, and not more than 1x on any day	Daily	Several times per day
	Interference with normal activity	None	Minor limitation	Some limitation	Extremely limited
	Lung function	<ul style="list-style-type: none"> Normal FEV₁ between exacerbations FEV₁ > 80% predicted FEV₁/FVC normal 	<ul style="list-style-type: none"> FEV₁ > 80% predicted FEV₁/FVC normal 	<ul style="list-style-type: none"> FEV₁ > 60% but < 80% predicted FEV₁/FVC reduced 5% 	<ul style="list-style-type: none"> FEV₁ < 60% predicted FEV₁/FVC reduced > 5%
Risk	Exacerbations requiring oral systemic corticosteroids	0–1/year (see note)	≥ 2/year (see note) →		
		← Consider severity and interval since last exacerbation. Frequency and severity may fluctuate over time for patients in any severity category. → Relative annual risk of exacerbations may be related to FEV ₁ .			
Recommended Step for Initiating Treatment		Step 1	Step 2	Step 3	Step 4 or 5
(See Figure 9–2 for treatment steps.)		In 2–6 weeks, evaluate level of asthma control that is achieved and adjust therapy accordingly.			
		and consider short course of oral systemic corticosteroids			

EIB, exercise-induced bronchospasm; FEV₁, forced expiratory volume in 1 second; FVC, forced vital capacity; ICU, intensive care unit.

Notes:

- The stepwise approach is meant to assist, not replace, the clinical decision-making required to meet individual patient needs.
- Level of severity is determined by assessment of both impairment and risk. Assess impairment domain by patient's/caregiver's recall of previous 2–4 weeks and spirometry. Assign severity to the most severe category in which any feature occurs.
- At present, there are inadequate data to correspond frequencies of exacerbations with different levels of asthma severity. In general, more frequent and intense exacerbations (eg, requiring urgent, unscheduled care, hospitalization, or ICU admission) indicate greater underlying disease severity. For treatment purposes, patients who had ≥ 2 exacerbations requiring oral systemic corticosteroids in the past year may be considered the same as patients who have persistent asthma, even in the absence of impairment levels consistent with persistent asthma.

▲ **Figure 9–1.** Classifying asthma severity and initiating treatment. (Adapted from National Asthma Education and Prevention Program. Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma. National Institutes of Health Pub. No. 08-4051. Bethesda, MD, 2007. <http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm>.)

A. Symptoms and Signs

Asthma is characterized by episodic wheezing, difficulty in breathing, chest tightness, and cough. Excess sputum production is common. The frequency of asthma symptoms is

highly variable. Some patients have infrequent, brief attacks of asthma while others may suffer nearly continuous symptoms. Asthma symptoms may occur spontaneously or may be precipitated or exacerbated by many different triggers as discussed above. Asthma symptoms are frequently

Table 9-1. Assessing asthma control.

Components of Control		Classification of Asthma Control (≥ 12 years of age)		
		Well Controlled	Not Well Controlled	Very Poorly Controlled
Impairment	Symptoms	≤ 2 days/week	> 2 days/week	Throughout the day
	Nighttime awakenings	≤ 2×/month	1-3×/week	≥ 4×/week
	Interference with normal activity	None	Some limitation	Extremely limited
	Short-acting β ₂ -agonist use for symptom control (not prevention of EIB)	≤ 2 days/week	> 2 days/week	Several times/day
	FEV ₁ or peak flow	> 80% predicted/personal best	60-80% predicted/personal best	< 60% predicted/personal best
	Validated questionnaires			
	ATAQ ACQ ACT	0 ≤ 0.75 ¹ ≥ 20	1-2 ≥ 1.5 16-19	3-4 N/A ≤ 15
Risk	Exacerbations requiring oral system corticosteroids	0-1/year	≥ 2/year (see note)	
		Consider severity and interval since last exacerbation		
	Progressive loss of lung function	Evaluation requires long-term follow-up care		
	Treatment-related adverse effects	Medication side effects can vary in intensity from none to very troublesome and worrisome. The level of intensity does not correlate to specific levels of control but should be considered in the overall assessment of risk.		
Recommended Action for Treatment (see Figure 9-2 for steps)		<ul style="list-style-type: none"> Maintain current step Regular follow-ups every 1-6 months to maintain control. Consider step down if well controlled for at least 3 months. 	<ul style="list-style-type: none"> Step up 1 step and Reevaluate in 2-6 weeks. For side effects, consider alternative treatment options. 	<ul style="list-style-type: none"> Consider short course of oral systemic corticosteroids, Step up 1-2 steps, and Reevaluate in 2 weeks. For side effects, consider alternative treatment options.

¹ACQ values of 0.76-1.4 are indeterminate regarding well-controlled asthma.

EIB, exercise-induced bronchospasm; ICU, intensive care unit.

Notes:

- The stepwise approach is meant to assist, not replace, the clinical decision-making required to meet individual patient needs.
- The level of control is based on the most severe impairment or risk category. Assess impairment domain by patient's recall of previous 2-4 weeks and by spirometry or peak flow measures. Symptom assessment for longer periods should reflect a global assessment, such as inquiring whether the patient's asthma is better or worse since the last visit.
- At present, there are inadequate data to correspond frequencies of exacerbations with different levels of asthma control. In general, more frequent and intense exacerbations (eg, requiring urgent, unscheduled care, hospitalization, or ICU admission) indicate poorer disease control. For treatment purposes, patients who had ≥ 2 exacerbations requiring oral systemic corticosteroids in the past year may be considered the same as patients who have not-well-controlled asthma, even in the absence of impairment levels consistent with not-well-controlled asthma.
- Validated Questionnaires for the impairment domain (the questionnaire did not assess lung function or the risk domain).
ATAQ = Asthma Therapy Assessment Questionnaire©
ACQ = Asthma Control Questionnaire© (user package may be obtained at www.qoltech.co.uk or juniper@qoltech.co.uk)
ACT = Asthma Control Test™
Minimal Importance Difference: 1.0 for the ATAQ; 0.5 for the ACQ; not determined for the ACT.
- Before step up in therapy:
 - Review adherence to medication, inhaler.
 - If an alternative treatment option was used in a step, discontinue and use the preferred treatment for that step.

Adapted from National Asthma Education and Prevention Program. Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma. National Institutes of Health Pub. No. 08-4051. Bethesda, MD, 2007. <http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm>

Table 9-2. Classifying severity of asthma exacerbations.

Patients are instructed to use quick-relief medications if symptoms occur or if PEF drops below 80% predicted or personal best. If PEF is 50–79%, the patient should monitor response to quick relief medications carefully and consider contacting a clinician. If PEF is below 50%, immediate medical care is usually required. In the urgent or emergency care setting, the following parameters describe the severity and likely clinical course of an exacerbation

Severity	Symptoms and Signs	Initial PEF (or FEV ₁)	Clinical Course
Mild	Dyspnea only with activity	PEF \geq 70% predicted or personal best	<ul style="list-style-type: none"> • Usually cared for at home • Prompt relief with inhaled SABA • Possible short course of oral systemic corticosteroids
Moderate	Dyspnea interferes with or limits usual activity	PEF 40–69% predicted or personal best	<ul style="list-style-type: none"> • Usually requires office or ED visit • Relief from frequent inhaled SABA • Oral systemic corticosteroids; some symptoms last for 1–2 days after treatment is begun
Severe	Dyspnea at rest; interferes with conversation	PEF $<$ 40% predicted or personal best	<ul style="list-style-type: none"> • Usually requires ED visit and likely hospitalization • Partial relief from frequent inhaled SABA • Oral systemic corticosteroids; some symptoms last for $>$ 3 days after treatment is begun • Adjunctive therapies are helpful
<i>Subset:</i> Life-threatening	Too dyspneic to speak; perspiring	PEF $<$ 25% predicted or personal best	<ul style="list-style-type: none"> • Requires ED/hospitalization; possible ICU • Minimal or no relief from frequent inhaled SABA • Intravenous corticosteroids • Adjunctive therapies are helpful

ED, emergency department; FEV₁, forced expiratory volume in 1 second; ICU, intensive care unit; PEF, peak expiratory flow; SABA, short-acting β_2 -agonist.

Adapted from National Asthma Education and Prevention Program. Expert Panel Report 3: Guidelines for Diagnosis and Management of Asthma. National Institutes of Health Pub. No. 08-4051. Bethesda, MD, 2007. <http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm>

worse at night; circadian variations in bronchomotor tone and bronchial reactivity reach their nadir between 3 AM and 4 AM, increasing symptoms of bronchoconstriction.

Some physical examination findings increase the probability of asthma. Nasal mucosal swelling, increased nasal secretions, and nasal polyps are often seen in patients with allergic asthma. Eczema, atopic dermatitis, or other manifestations of allergic skin disorders may also be present. Wheezing during normal breathing or a prolonged forced expiratory phase correlates well with the presence of airflow obstruction. Wheezing during forced expiration does not. Chest examination may be normal between exacerbations in patients with mild asthma. During severe asthma exacerbations, airflow may be too limited to produce wheezing, and the only diagnostic clue on auscultation may be globally reduced breath sounds with prolonged expiration. Hunched shoulders and use of accessory muscles of respiration suggest an increased work of breathing.

B. Laboratory Findings

Arterial blood gas measurements may be normal during a mild asthma exacerbation, but respiratory alkalosis and an increase in the alveolar-arterial oxygen difference ($A-a-DO_2$) are common. During severe exacerbations, hypoxemia develops and the $PaCO_2$ returns to normal. The combination of an increased $PaCO_2$ and respiratory acidosis may indicate impending respiratory failure and the need for mechanical ventilation.

C. Pulmonary Function Testing

Clinicians are able to identify airflow obstruction on examination, but they have limited ability to assess severity or to predict whether it is reversible. The evaluation for asthma should therefore include spirometry (forced expiratory volume in 1 second [FEV₁], forced vital capacity [FVC], FEV₁/FVC) before and after the administration of a short-acting bronchodilator. These measurements help determine the presence and extent of airflow obstruction and whether it is immediately reversible. Airflow obstruction is indicated by a reduced FEV₁/FVC ratio. Significant reversibility of airflow obstruction is defined by an increase of \geq 12% and 200 mL in FEV₁ or \geq 15% and 200 mL in FVC after inhaling a short-acting bronchodilator. A positive bronchodilator response strongly confirms the diagnosis of asthma but a lack of responsiveness in the pulmonary function laboratory does not preclude success in a clinical trial of bronchodilator therapy. Severe airflow obstruction results in significant air trapping, with an increase in residual volume and consequent reduction in FVC, resulting in a pattern that may mimic a restrictive ventilatory defect.

Bronchial provocation testing with inhaled histamine or methacholine may be useful when asthma is suspected but spirometry is nondiagnostic. Bronchial provocation is not recommended if the FEV₁ is less than 65% of predicted. A positive methacholine test is defined as a \geq 20% fall in the FEV₁ at exposure to a concentration of 8 mg/mL or

Table 9-3. Evaluation of asthma exacerbation severity.

	Mild	Moderate	Severe	Subset: Respiratory Arrest Imminent
Symptoms				
Breathlessness	While walking Can lie down	While at rest Prefers sitting	While at rest Sits upright	
Talks in	Sentences	Phrases	Words	
Alertness	May be agitated	Usually agitated	Usually agitated	Drowsy or confused
Signs				
Respiratory rate	Increased	Increased	Often > 30/minute	
Use of accessory muscles; suprasternal retractions	Usually not	Commonly	Usually	Paradoxical thoracoabdominal movement
Wheeze	Moderate, often only end expiratory	Loud; throughout exhalation	Usually loud; throughout inhalation and exhalation	Absence of wheeze
Pulse/minute	< 100	100-120	> 120	Bradycardia
Pulsus paradoxus	Absent < 10 mm Hg	May be present 10-25 mm Hg	Often present > 25 mm Hg	Absence suggests respiratory muscle fatigue
Functional Assessment				
PEF Percent predicted or percent personal best	≥ 70%	Approx. 40-69% or response lasts < 2 hours	< 40%	< 25% Note: PEF testing may not be needed in very severe attacks
Pao ₂ (on air)	Normal (test not usually necessary)	≥ 60 mm Hg (test not usually necessary)	< 60 mm Hg: possible cyanosis	
and/or Pco ₂	< 42 mm Hg (test not usually necessary)	< 42 mm Hg (test not usually necessary)	≥ 42 mm Hg: possible respiratory failure	
Sao ₂ percent (on air) at sea level	> 95% (test not usually necessary)	90-95% (test not usually necessary)	< 90%	
	Hypercapnia (hypoventilation) develops more readily in young children than in adults and adolescents			

PEF, peak expiratory flow; Sao₂, oxygen saturation.

Adapted from National Asthma Education and Prevention Program. Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma. National Institutes of Health Pub. No. 08-4051. Bethesda, MD, 2007. <http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm>

less. A negative test has a negative predictive value for asthma of 95%. Exercise challenge testing may be useful in patients with symptoms of exercise-induced bronchospasm.

Peak expiratory flow (PEF) meters are handheld devices designed as personal monitoring tools. PEF monitoring can establish peak flow variability, quantify asthma severity, and provide both the patient and the clinician with objective measurements on which to base treatment decisions. There are conflicting data about whether measuring PEF improves asthma outcomes, but doing so is recommended to help confirm the diagnosis of asthma, to improve asthma control in patients with poor perception

of airflow obstruction, and to identify environmental and occupational causes of symptoms. Predicted values for PEF vary with age, height, and gender but are poorly standardized. Comparison with reference values is less helpful than comparison with the patient's own baseline. PEF shows diurnal variation. It is generally lowest on first awakening and highest several hours before the midpoint of the waking day. PEF should be measured in the morning before the administration of a bronchodilator and in the afternoon after taking a bronchodilator. A 20% change in PEF values from morning to afternoon or from day to day suggests inadequately controlled asthma. PEF values less than 200 L/min indicate severe airflow obstruction.

D. Additional Testing

Routine chest radiographs in patients with asthma are usually normal or show only hyperinflation. Other findings may include bronchial wall thickening and diminished peripheral lung vascular shadows. Chest imaging is indicated when pneumonia, another disorder mimicking asthma, or a complication of asthma such as pneumothorax is suspected.

Skin testing or in vitro testing to assess sensitivity to environmental allergens can identify atopy in patients with persistent asthma who may benefit from therapies directed at their allergic diathesis. Evaluations for paranasal sinus disease or gastroesophageal reflux should be considered in asthma patients with pertinent symptoms and in those with severe or refractory asthma symptoms.

Noninvasive assessment of underlying airway inflammation through measurement of eosinophilia in induced sputum, or fractional nitric oxide concentration in exhaled breath condensates (FeNO), offers the promise of improved diagnosis and treatment strategies. Adjusting corticosteroid dose to minimize sputum eosinophilia appears to reduce the frequency of exacerbations compared with conventional clinical management, but the data are conflicting regarding the impact of FeNO on asthma outcomes.

► Complications

Complications of asthma include exhaustion, dehydration, airway infection, and tussive syncope. Pneumothorax occurs but is rare. Acute hypercapnic and hypoxemic respiratory failure occurs in severe disease.

► Differential Diagnosis

It is prudent to consider conditions that mimic asthma in patients who have atypical symptoms or poor response to therapy. These disorders typically fall into one of four categories: upper airway disorders, lower airway disorders, systemic vasculitides, and psychiatric disorders. **Upper airway disorders** that mimic asthma include vocal fold paralysis, vocal fold dysfunction syndrome, foreign body aspiration, laryngotracheal masses, tracheal narrowing, tracheomalacia, and airway edema as in the setting of angioedema or inhalation injury. **Lower airway disorders** include nonasthmatic COPD (chronic bronchitis or emphysema), bronchiectasis, allergic bronchopulmonary mycosis, cystic fibrosis, eosinophilic pneumonia, and bronchiolitis obliterans. **Systemic vasculitides** with pulmonary involvement may have an asthmatic component, such as Churg-Strauss syndrome. **Psychiatric causes** include conversion disorders, which have been variably referred to as functional asthma, emotional laryngeal wheezing, vocal fold dysfunction, or episodic laryngeal dyskinesia. Münchausen syndrome or malingering may rarely explain a patient's complaints.

► NAEPP 3 Diagnosis & Management Guidelines

In 2007, the National Asthma Education and Prevention Program (NAEPP), in conjunction with the Global Initiative

for Asthma (GINA), a collaboration between the National Institutes of Health (NIH)/National Heart, Lung, and Blood Institute (NHLBI) and the World Health Organization (WHO), released its third Expert Panel Report providing guidelines for diagnosis and management of asthma (NAEPP 3). This report identifies four components of chronic asthma diagnosis and management: (1) assessing and monitoring asthma severity and asthma control, (2) patient education designed to foster a partnership for care, (3) control of environmental factors and comorbid conditions that affect asthma, and (4) pharmacologic agents for asthma.

1. Assessing and monitoring asthma severity and asthma control

Severity is the intrinsic intensity of the disease process. Control is the degree to which symptoms and limitations on activity are minimized by therapy. **Responsiveness** is the ease with which control is achieved with therapy. NAEPP 3 guidelines emphasize control over classifications of severity, since the latter is variable over time and in response to therapy. A measure of severity on initial presentation (see Figure 9–1) is helpful, however, in guiding the initiation of therapy. Control of asthma is assessed in terms of **impairment** (frequency and intensity of symptoms and functional limitations) and **risk** (the likelihood of acute exacerbations or chronic decline in lung function). A key insight is that these two domains of control may respond differently to treatment: some patients may have minimal impairment yet remain at risk for severe exacerbations, for example, in the setting of an upper respiratory tract infection. Table 9–1 is used to assess the adequacy of asthma control and is used in conjunction with Figure 9–2 to guide adjustments in therapy based on the level of control.

2. Patient education designed to foster a partnership for care


Active self-management reduces urgent care visits and hospitalizations and improves perceived control of asthma. Therefore, an outpatient preventive approach that includes self-management education is an integral part of effective asthma care.

All patients, but particularly those with poorly controlled symptoms or a history of severe exacerbations, should have a written asthma action plan that includes instructions for daily management and measures to take in response to specific changes in status. Patients should be taught to recognize symptoms—especially patterns indicating inadequate asthma control or predicting the need for additional therapy.

3. Control of environmental factors and comorbid conditions that affect asthma

Significant reduction in exposure to nonspecific airway irritants or to inhaled allergens in atopic patients may reduce symptoms as well as medication needs. Comorbid conditions that impair asthma management, such as rhinosinusitis, gastroesophageal reflux, obesity, and obstructive sleep apnea, should be identified and treated. This search for complicating conditions is particularly crucial in the initial evaluation of a new diagnosis, and in patients whose asthma is difficult to control or subject to frequent exacerbations.

4. Pharmacologic agents for asthma—Asthma medications can be divided into two categories: quick-relief



Key: Alphabetical order is used when more than one treatment option is listed within either preferred or alternative therapy. EIB, exercise-induced bronchospasm; ICS, inhaled corticosteroid; LABA, inhaled long-acting β_2 -agonist; LTRA, leukotriene receptor antagonist; SABA, inhaled short-acting β_2 -agonist

Notes:

- The stepwise approach is meant to assist, not replace, the clinical decision-making required to meet individual patient needs.
- If alternative treatment is used and response is inadequate, discontinue it and use the preferred treatment before stepping up.
- Zileuton is a less desirable alternative as adjunctive therapy due to limited studies and the need to monitor liver function. Theophylline requires monitoring of serum concentration levels.
- In step 6, before oral systemic corticosteroids are introduced, a trial of high-dose ICS + LABA + either LTRA, theophylline, or zileuton may be considered, although this approach has not been studied in clinical trials.
- Step 1, 2, and 3 preferred therapies are based on Evidence A; step 3 alternative therapy is based on Evidence A for LTRA, Evidence B for theophylline, and Evidence D for zileuton. Step 4 preferred therapy is based on Evidence B, and alternative therapy is based on Evidence B for LTRA and theophylline and Evidence D for zileuton. Step 5 preferred therapy is based on Evidence B. Step 6 preferred therapy is based on (EPR 2 1997) and Evidence B for omalizumab.
- Immunotherapy for steps 2–4 is based on Evidence B for house-dust mites, animal danders, and pollens; evidence is weak or lacking for molds and cockroaches. Evidence is strongest for immunotherapy with single allergens. The role of allergy in asthma is greater in children than in adults.
- Clinicians who administer immunotherapy or omalizumab should be prepared and equipped to identify and treat anaphylaxis that may occur.

▲ **Figure 9–2.** Stepwise approach to managing asthma. (Adapted from National Asthma Education and Prevention Program. Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma. National Institutes of Health Pub. No. 08-4051. Bethesda, MD, 2007. <http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm>.)

(**reliever**) medications that act principally by direct relaxation of bronchial smooth muscle, thereby promoting prompt reversal of acute airflow obstruction to relieve accompanying symptoms, and long-term control (**controller**) medications that act primarily to attenuate airway inflammation and are taken daily independent of symptoms to achieve and maintain control of persistent asthma.

Most asthma medications are administered orally or by inhalation. Inhalation of an appropriate agent results in a more rapid onset of pulmonary effects as well as fewer systemic effects compared with oral administration of the same dose. Metered-dose inhalers (MDIs) propelled by chlorofluorocarbons (CFCs) have been the most widely used delivery system, but non-CFC propellant systems such as hydrofluoroalkane (HFA), and dry powder inhalers (DPIs) are increasingly available. Proper inhaler technique and the use of an inhalation chamber with MDIs improve drug delivery to the lung and decrease oropharyngeal deposition. Nebulizer therapy is reserved for acutely ill patients and those who cannot use inhalers because of difficulties with coordination or cooperation.

► Treatment

The goals of asthma therapy are to minimize chronic symptoms that interfere with normal activity (including exercise), to prevent recurrent exacerbations, to reduce or eliminate the need for emergency department visits or hospitalizations, and to maintain normal or near-normal pulmonary function. These goals should be met while providing pharmacotherapy with the fewest adverse effects and while meeting patients' and families' expectations of satisfaction with asthma care. NAEP 3 recommendations emphasize daily anti-inflammatory therapy with inhaled corticosteroids as the cornerstone of treatment of persistent asthma.

A. Long-Term Control Medications

Anti-inflammatory agents, long-acting bronchodilators, and leukotriene modifiers comprise the important long-term control medications (Tables 9-4 and 9-5). Other classes of agents are mentioned briefly below.

1. Anti-inflammatory agents—Corticosteroids are the most potent and consistently effective anti-inflammatory agents currently available. They reduce both acute and chronic inflammation, resulting in fewer asthma symptoms, improvement in airflow, decreased airway hyperresponsiveness, and fewer asthma exacerbations. These agents may also potentiate the action of β -adrenergic agonists.

Inhaled corticosteroids are preferred, first-line agents for all patients with persistent asthma. Patients with persistent symptoms or asthma exacerbations who are not taking inhaled corticosteroids should be started on an inhaled corticosteroid. The most important determinants of agent selection and appropriate dosing are the patient's status and response to treatment. Dosages for inhaled corticosteroids vary depending on the specific agent and delivery device. For most patients, twice-daily dosing provides adequate control of asthma. Once-daily dosing may be

sufficient in selected patients. Maximum responses from inhaled corticosteroids may not be observed for months. The use of an inhalation chamber coupled with mouth washing after MDI use decreases local side effects (cough, dysphonia, oropharyngeal candidiasis) and systemic absorption. DPIs are not used with an inhalation chamber. Systemic effects (adrenal suppression, osteoporosis, skin thinning, easy bruising, and cataracts) may occur with high-dose inhaled corticosteroid therapy.

Systemic corticosteroids (oral or parenteral) are most effective in achieving prompt control of asthma during exacerbations or when initiating long-term asthma therapy in patients with severe symptoms. In patients with refractory, poorly controlled asthma, systemic corticosteroids may be required for the long-term suppression of symptoms. Repeated efforts should be made to reduce the dose to the minimum needed to control symptoms. Alternate-day treatment is preferred to daily treatment. Concurrent treatment with calcium supplements and vitamin D should be initiated to prevent corticosteroid-induced bone mineral loss in long-term administration. Bisphosphonates may offer additional protection to these patients. Rapid discontinuation of systemic corticosteroids after long-term use may precipitate adrenal insufficiency.

2. Long-acting bronchodilators

A. MEDIATOR INHIBITORS—Cromolyn sodium and nedocromil are long-term control medications that prevent asthma symptoms and improve airway function in patients with mild persistent asthma or exercise-induced symptoms. These agents modulate mast cell mediator release and eosinophil recruitment and inhibit both early and late asthmatic responses to allergen challenge and exercise-induced bronchospasm. They can be effective when taken before an exposure or exercise but do not relieve asthmatic symptoms once present. The clinical response to these agents is less predictable than the response to inhaled corticosteroids. Nedocromil may help reduce the dose requirements for inhaled corticosteroids. Both agents have excellent safety profiles.

B. β -ADRENERGIC AGONISTS—Long-acting β_2 -agonists provide bronchodilation for up to 12 hours after a single dose. Salmeterol and formoterol are the two long-acting β_2 -agonists available in the United States. They are administered via dry powder delivery devices. They are indicated for long-term prevention of asthma symptoms, nocturnal symptoms, and for prevention of exercise-induced bronchospasm. When added to low and medium daily doses of inhaled corticosteroids (Table 9-5), long-acting β_2 -agonists provide control equivalent to what is achieved by doubling the inhaled corticosteroid dose. Side effects are minimal at standard doses. Long-acting β_2 -agonists should not be used as monotherapy since they have no anti-inflammatory effect and since monotherapy with long-acting β_2 -agonists has been associated in two large studies with a small but statistically significant increased risk of severe or fatal asthma attacks. This increased risk may relate to genetic variation in the β -adrenergic receptor, but it has not been fully explained and remains an area of controversy. The efficacy of combined inhaled corticosteroid and long-acting

Table 9-4. Long-term control medications for asthma.

Medication	Dosage Form	Adult Dose	Comments
Inhaled Corticosteroids			(See Table 9-5)
Systemic Corticosteroids			(Applies to all three corticosteroids)
Methylprednisolone	2, 4, 6, 8, 16, 32 mg tablets	7.5-60 mg daily in a single dose in AM or every other day as needed for control	<ul style="list-style-type: none"> Administer single dose in AM either daily or on alternate days (alternate-day therapy may produce less adrenal suppression). Short courses or "bursts" are effective for establishing control when initiating therapy or during a period of gradual deterioration. There is no evidence that tapering the dose following improvement in symptom control and pulmonary function prevents relapse.
Prednisolone	5 mg tablets, 5 mg/5 mL, 15 mg/5 mL	Short-course "burst": to achieve control, 40-60 mg per day as single or 2 divided doses for 3-10 days	
Prednisone	1, 2.5, 5, 10, 20, 50 mg tablets; 5 mg/mL, 5 mg/mL		
Inhaled Long-Acting β_2-Agonists			Should not be used for symptom relief or exacerbations. Use with inhaled corticosteroids.
Salmeterol	DPI 50 mcg/blister	1 blister every 12 hours	<ul style="list-style-type: none"> Decreased duration of protection against EIB may occur with regular use.
Formoterol	DPI 12 mcg/single-use capsule	1 capsule every 12 hours	<ul style="list-style-type: none"> Decreased duration of protection against EIB may occur with regular use. Each capsule is for single use only; additional doses should not be administered for at least 12 hours. Capsules should be used only with the Aerolizer™ inhaler and should not be taken orally.
Combined Medication			
Fluticasone/Salmeterol	DPI 100 mcg/50 mcg, 250 mcg/50 mcg, or 500 mcg/50 mcg	1 inhalation twice daily; dose depends on severity of asthma	<ul style="list-style-type: none"> 100/50 DPI or 45/21 HFA for patient not controlled on low- to medium-dose inhaled corticosteroids 250/50 DPI or 115/21 HFA for patients not controlled on medium- to high-dose inhaled corticosteroids
	HFA 45 mcg/21 mcg 115 mcg/21 mcg 230 mcg/21 mcg		
Budesonide/ Formoterol	HFA MDI 80 mcg/4.5 mcg 160 mcg/4.5 mcg	2 inhalations twice daily; dose depends on severity of asthma	<ul style="list-style-type: none"> 80/4.5 for asthma not controlled on low- to medium-dose inhaled corticosteroids 160/4.5 for asthma not controlled on medium- to high-dose inhaled corticosteroids
Cromolyn and Nedocromil			
Cromolyn	MDI 0.8 mg/puff	2 puffs four times daily	<ul style="list-style-type: none"> 4-6 week trial may be needed to determine maximum benefit.
	Nebulizer 20 mg/ampule	1 ampule four times daily	<ul style="list-style-type: none"> Dose by MDI may be inadequate to affect hyperresponsiveness.
Nedocromil	MDI 1.75 mg/puff	2 puffs four times daily	<ul style="list-style-type: none"> One dose before exercise or allergen exposure provides effective prophylaxis for 1-2 hours. Not as effective for EIB as SABA. Once control is achieved, the frequency of dosing may be reduced.

(continued)

Table 9-4. Long-term control medications for asthma. (Continued)

Medication	Dosage Form	Adult Dose	Comments
Inhaled Long-Acting Anticholinergic			Should not be used for symptom relief or exacerbations. Use with inhaled corticosteroids.
Tiotropium	DPI 18 mcg/blister	1 blister daily	
Leukotriene Modifiers			
Leukotriene Receptor Antagonists			
Montelukast	4 mg or 5 mg chewable tablet 10 mg tablet	10 mg each night at bedtime	• Exhibits a flat dose-response curve. Doses > 10 mg will not produce a greater response in adults.
Zafirlukast	10 or 20 mg tablet	40 mg daily (20 mg tablet twice daily)	• Administration with meals decreases bioavailability; take at least 1 hour before or 2 hours after meals. • Monitor for symptoms and signs of hepatic dysfunction.
5-Lipoxygenase Inhibitor			
Zileuton	600 mg tablet	2400 mg daily (600 mg four times daily)	• Monitor hepatic enzymes (ALT).
Methylxanthines			
Theophylline	Liquids, sustained-release tablets, and capsules	Starting dose 10 mg/kg/d up to 300 mg maximum; usual maximum dose 800 mg/d	• Adjust dosage to achieve serum concentration of 5-15 mcg/mL at steady-state (at least 48 hours on same dosage). • Due to wide interpatient variability in theophylline metabolic clearance, routine serum theophylline level monitoring is important.
Immunomodulators			
Omalizumab	Subcutaneous injection, 150 mg/1.2 mL following reconstitution with 1.4 mL sterile water for injection	150-375 mg subcutaneously every 2-4 weeks, depending on body weight and pretreatment serum IgE level	• Do not administer more than 150 mg per injection site. • Monitor for anaphylaxis for 2 hours following at least the first 3 injections.

β_2 -agonist therapy has led to marketing of combination medications that deliver both agents simultaneously (see Table 9-4). Combination inhalers containing formoterol and budesonide have shown efficacy in both maintenance and rescue, given formoterol's short time to onset.

C. ANTICHOLINERGICS—The long-acting anticholinergic tiotropium has been studied as add-on therapy for patients who have either a bronchodilator response or a positive methacholine challenge that is not adequately controlled with low-dose inhaled corticosteroid. After 14 weeks of treatment, the addition of tiotropium resulted in improvements in PEF, FEV₁, and symptom control; the improvements were greater than those achieved by doubling the dose of the inhaled corticosteroid for the same period of time. The addition of tiotropium was not inferior to the addition of salmeterol. The short treatment period does not permit a determination of whether long-acting β_2 -agonists are comparable to tiotropium in reducing asthma exacerbations and whether it is an effective and safe alternative to long-acting β_2 -agonists for the long-term management of asthma.

D. PHOSPHODIESTERASE INHIBITORS—Theophylline provides mild bronchodilation in asthmatic patients. Theophylline also has anti-inflammatory and immunomodulatory properties, enhances mucociliary clearance, and strengthens diaphragmatic contractility. Sustained-release theophylline preparations are effective in controlling nocturnal symptoms and as added therapy in patients with moderate or severe persistent asthma whose symptoms are inadequately controlled by inhaled corticosteroids. When added to inhaled corticosteroids, theophylline may allow equivalent control at lower corticosteroid doses.

Theophylline serum concentrations need to be monitored closely owing to the drug's narrow toxic-therapeutic range, individual differences in metabolism, and the effects of many factors on drug absorption and metabolism. Potential adverse effects at therapeutic doses include insomnia, aggravation of dyspepsia and gastroesophageal reflux symptoms, and urination difficulties in elderly men with prostatism. Dose-related toxicities include nausea, vomiting, tachyarrhythmias, headache, seizures, hyperglycemia, and hypokalemia. Newer agents that selectively inhibit phosphodiesterase-4 are in clinical trials.

Table 9-5. Estimated comparative daily dosages for inhaled corticosteroids for asthma.

Drug	Low Daily Dose Adult	Medium Daily Dose Adult	High Daily Dose Adult
Beclomethasone HFA 40 or 80 mcg/puff	80-240 mcg	> 240-480 mcg	> 480 mcg
Budesonide DPI 90, 180, or 200 mcg/inhalation	180-600 mcg	> 600-1200 mcg	> 1200 mcg
Flunisolide 250 mcg/puff	500-1000 mcg	> 1000-2000 mcg	> 2000 mcg
Flunisolide HFA 80 mcg/puff	320 mcg	> 320-640 mcg	> 640 mcg
Fluticasone HFA/MDI: 44, 110, or 220 mcg/puff DPI: 50, 100, or 250 mcg/inhalation	88-264 mcg	> 264-440 mcg	> 440 mcg
	100-300 mcg	> 300-500 mcg	> 500 mcg
Mometasone DPI 200 mcg/puff	200 mcg	400 mcg	> 400 mcg
Triamcinolone acetonide 75 mcg/puff	300-750 mcg	> 750-1500 mcg	> 1500 mcg

DPI, dry power inhaler; HFA, hydrofluoroalkaline; MDI, metered-dose inhaler.

Notes:

- The most important determinant of appropriate dosing is the clinician's judgment of the patient's response to therapy.
- Potential drug interactions

A number of the inhaled corticosteroids, including fluticasone, budesonide, and mometasone, are metabolized in the gastrointestinal tract and liver by CYP 3A4 isoenzymes. Potent inhibitors of CYP 3A4, such as ritonavir and ketoconazole, have the potential for increasing systemic concentrations of these inhaled corticosteroids by increasing oral availability and decreasing systemic clearance. Some cases of clinically significant Cushing syndrome and secondary adrenal insufficiency have been reported.

Adapted from National Asthma Education and Prevention Program. Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma. National Institutes of Health Pub. No. 08-4051. Bethesda, MD, 2007. <http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm>

3. Leukotriene modifiers—Leukotrienes are potent biochemical mediators that contribute to airway obstruction and asthma symptoms by contracting airway smooth muscle, increasing vascular permeability and mucus secretion, and attracting and activating airway inflammatory cells. Zileuton is a 5-lipoxygenase inhibitor that decreases leukotriene production, and zafirlukast and montelukast are cysteinyl leukotriene receptor antagonists. In randomized controlled trials, these agents cause modest improvements in lung function and reductions in asthma symptoms and lessen the need for β_2 -agonist rescue therapy. These agents are alternatives to low-dose inhaled corticosteroids in patients with mild persistent asthma, although, as monotherapy, their effect is generally less than inhaled corticosteroids. In pragmatic, real-life community trials, leukotriene receptor antagonists were equivalent in efficacy to an inhaled corticosteroid as first-line long-term controller medication or to a long-acting β_2 -agonist as add-on therapy. Zileuton can cause reversible elevations in plasma aminotransferase levels, and Churg-Strauss syndrome has been diagnosed in a small number of patients who have taken montelukast or zafirlukast, although this is suspected to be an effect of corticosteroid withdrawal as opposed to a direct drug effect.

4. Desensitization—Immunotherapy for specific allergens may be considered in selected asthma patients who have exacerbations of asthma symptoms when exposed to allergens to which they are sensitive and who do not respond to

environmental control measures or other forms of conventional therapy. Studies show a reduction in asthma symptoms in patients treated with single-allergen immunotherapy. Because of the risk of immunotherapy-induced bronchoconstriction, it should be administered only in a setting where such complications can be immediately treated.

5. Omalizumab—Omalizumab is a recombinant antibody that binds IgE without activating mast cells. In clinical trials in patients with moderate to severe asthma and elevated IgE levels, omalizumab reduced the need for corticosteroids.

6. Vaccination—Patients with asthma should receive pneumococcal vaccination (Pneumovax) and annual influenza vaccinations, including influenza (seasonal and epidemic influenza A [H1N1]). Inactive vaccines (Pneumovax) are associated with few side effects but use of the live attenuated influenza vaccine intranasally may be associated with an increase in asthma exacerbations in young children.

7. Miscellaneous agents—Oral sustained-release β_2 -agonists are reserved for patients with bothersome nocturnal asthma symptoms or moderate to severe persistent asthma who do not respond to other therapies.

B. Quick-Relief Medications

Short-acting bronchodilators and systemic corticosteroids comprise the important medications in this group of agents (Table 9-6).

Table 9-6. Quick-relief medications for asthma.

Medication	Dosage Form	Adult Dose	Comments
Inhaled Short-Acting β_2-Agonists			
<i>MDI</i>			
Albuterol CFC	90 mcg/puff, 200 puffs/ canister	2 puffs 5 minutes before exercise	<ul style="list-style-type: none"> An increasing use or lack of expected effect indicates diminished control of asthma. Not recommended for long-term daily treatment. Regular use exceeding 2 days/week for symptom control (not prevention of EIB) indicates the need to step up therapy. Differences in potency exist, but all products are essentially comparable on a per puff basis. May double usual dose for mild exacerbations. Should prime the inhaler by releasing four actuations prior to use. Periodically clean HFA activator, as drug may block/plug orifice. Nonselective agents (ie, epinephrine, isoproterenol, metaproterenol) are not recommended due to their potential for excessive cardiac stimulation, especially in high doses.
Albuterol HFA	90 mcg/puff, 200 puffs/ canister	2 puffs every 4-6 hours as needed	
Pirbuterol CFC	200 mcg/puff, 400 puffs/ canister		
Levalbuterol HFA	45 mcg/puff, 200 puffs/ canister		
<i>Nebulizer solution</i>			
Albuterol	0.63 mg/3 mL 1.25 mg/3 mL 2.5 mg/3 mL 5 mg/mL (0.5%)	1.25-5 mg in 3 mL of saline every 4-8 hours as needed	<ul style="list-style-type: none"> May mix with budesonide inhalant suspension, cromolyn or ipratropium nebulizer solutions. May double dose for severe exacerbations.
Levalbuterol (R-albuterol)	0.31 mg/3 mL 0.63 mg/3 mL 1.25 mg/0.5 mL 1.25 mg/3 mL	0.63 mg-1.25 mg every 8 hours as needed	<ul style="list-style-type: none"> Compatible with budesonide inhalant suspension. The product is a sterile-filled, preservative-free, unit dose vial.
Anticholinergics			
<i>MDI</i>			
Ipratropium HFA	17 mcg/puff, 200 puffs/ canister	2-3 puffs every 6 hours	<ul style="list-style-type: none"> Evidence is lacking for anticholinergics producing added benefit to β_2-agonists in long-term control asthma therapy.
<i>Nebulizer solution</i>			
	0.25 mg/mL (0.025%)	0.25 mg every 6 hours	
<i>MDI</i>			
Ipratropium with albuterol	18 mcg/puff of ipratropium bromide and 90 mcg/puff of albuterol 200 puffs/canister	2-3 puffs every 6 hours	
<i>Nebulizer solution</i>			
	0.5 mg/3 mL ipratropium bromide and 2.5 mg/ 3 mL albuterol	3 mL every 4-6 hours	<ul style="list-style-type: none"> Contains EDTA to prevent discolorations of the solution. This additive does not induce bronchospasm.
Systemic Corticosteroids			
Methylprednisolone	2, 4, 6, 8, 16, 32 mg tablets	Short course "burst": 40-60 mg/d as single or 2 divided doses for 3-10 days	<ul style="list-style-type: none"> Short courses or "bursts" are effective for establishing control when initiating therapy or during a period of gradual deterioration. The burst should be continued until symptoms resolve and the PEF is at least 80% of personal best. This usually requires 3-10 days but may require longer. There is no evidence that tapering the dose following improvements prevents relapse.
Prednisolone	5 mg tablets, 5 mg/5 mL, 15 mg/5 mL		
Prednisone	1, 2.5, 5, 10, 20, 50 mg tablets; 5 mg/mL, 5 mg/5mL		

(continued)

Table 9-6. Quick-relief medications for asthma. (Continued)

Medication	Dosage Form	Adult Dose	Comments
	<i>Repository injection</i>		
(Methylprednisolone acetate)	40 mg/mL 80 mg/mL	240 mg intramuscularly once	May be used in place of a short burst of oral corticosteroids in patients who are vomiting or if adherence is a problem.

CFC, chlorofluorocarbon; EIB, exercise-induced bronchospasm; HFA, hydrofluoroalkane; MDI, metered-dose inhaler; PEF, peak expiratory flow.

Adapted from National Asthma Education and Prevention Program. Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma. National Institutes of Health Pub. No. 08-4051. Bethesda, MD, 2007. <http://www.nhlbi.gov/guidelines/asthma/asthgdln.htm>

1. β -Adrenergic agonists—Short-acting inhaled β_2 -agonists, including albuterol, levalbuterol, bitolterol, pirbuterol, and terbutaline, are the most effective bronchodilators during exacerbations. All patients with acute symptoms should take one of these agents. There is no convincing evidence to support the use of one agent over another. β_2 -Agonists relax airway smooth muscle and cause a prompt increase in airflow and reduction of symptoms. Administration before exercise effectively prevents exercise-induced bronchoconstriction. β_2 -Selective agents may produce less cardiac stimulation than those with mixed β_1 and β_2 activities, although clinical trials have not consistently demonstrated this finding.

Inhaled β -adrenergic therapy is as effective as oral or parenteral therapy in relaxing airway smooth muscle and improving acute asthma and offers the advantages of rapid onset of action (< 5 minutes) with fewer systemic side effects. Repetitive administration produces incremental bronchodilation. One or two inhalations of a short-acting inhaled β_2 -agonist from an MDI are usually sufficient for mild to moderate symptoms. Severe exacerbations frequently require higher doses: 6–12 puffs every 30–60 minutes of albuterol by MDI with an inhalation chamber or 2.5 mg by nebulizer provide equivalent bronchodilation. Administration by nebulization does not offer more effective delivery than MDIs but does provide higher doses. With most β_2 -agonists, the recommended dose by nebulizer for acute asthma (albuterol, 2.5 mg) is 25–30 times that delivered by a single activation of the MDI (albuterol, 0.09 mg). This difference suggests that standard dosing of inhalations from an MDI will often be insufficient in the setting of an acute exacerbation. Independent of dose, nebulizer therapy may be more effective in patients who are unable to coordinate inhalation of medication from an MDI because of age, agitation, or severity of the exacerbation.

Scheduled daily use of short-acting β_2 -agonists is not recommended. Increased use (more than one canister a month) or lack of expected effect indicates diminished asthma control and dictates the need for additional long-term control therapy.

2. Anticholinergics—Anticholinergic agents reverse vagally mediated bronchospasm but not allergen- or exercise-induced bronchospasm. They may decrease mucus gland hypersecretion seen in asthma. Ipratropium bromide, a

quaternary derivative of atropine free of atropine's side effects, is less effective than β_2 -agonists for relief of acute bronchospasm, but it is the inhaled drug of choice for patients with intolerance to β_2 -agonists and with bronchospasm due to β -blocker medications. Ipratropium bromide reduces the rate of hospital admissions when added to inhaled short-acting β_2 -agonists in patients with moderate to severe asthma exacerbations.

3. Phosphodiesterase inhibitors—Methylxanthines are not recommended for therapy of asthma exacerbations. Aminophylline has clearly been shown to be less effective than β_2 -agonists when used as single-drug therapy for acute asthma and adds little except toxicity to the acute bronchodilator effects achieved by nebulized metaproterenol alone. Patients with exacerbations who are currently taking a theophylline-containing preparation should have their serum theophylline concentration measured to exclude theophylline toxicity.

4. Corticosteroids—Systemic corticosteroids are effective primary treatment for patients with moderate to severe asthma exacerbations and for patients with exacerbations who do not respond promptly and completely to inhaled β_2 -agonist therapy. These medications speed the resolution of airflow obstruction and reduce the rate of relapse. Delays in administering corticosteroids may result in delayed benefits from these important agents. Therefore, oral corticosteroids should be available for early administration at home in many patients with moderate to severe asthma. The minimal effective dose of systemic corticosteroids for asthma patients has not been identified. Outpatient prednisone “burst” therapy is 0.5–1 mg/kg/d (typically 40–60 mg) as a single or in two divided doses for 3–10 days. Severe exacerbations requiring hospitalization typically require 1 mg/kg of prednisone or methylprednisolone every 6–12 hours for 48 hours or until the FEV₁ (or PEF rate) returns to 50% of predicted (or 50% of baseline). The dose is then decreased to 60–80 mg/d until the PEF reaches 70% of predicted or personal best. No clear advantage has been found for higher doses of corticosteroids in severe exacerbations. It may be prudent to administer corticosteroids to critically ill patients via the intravenous route in order to avoid concerns about altered gastrointestinal absorption.

5. Antimicrobials—Multiple studies suggest that infections with viruses (rhinovirus) and bacteria (*Mycoplasma pneumoniae*, *Chlamydomphila pneumoniae*) predispose to acute exacerbations of asthma and may underlie chronic, severe asthma. The use of empiric antibiotics is, however, not recommended in routine asthma exacerbations because there is no consistent evidence to support improved clinical outcomes. Antibiotics should be considered when there is a high likelihood of acute bacterial respiratory tract infection, such as for patients with fever or purulent sputum and evidence of pneumonia or bacterial sinusitis.

► Treatment of Asthma Exacerbations

NAEPP 3 asthma treatment algorithms begin with an assessment of the severity of a patient's baseline asthma. Adjustments to that algorithm follow a stepwise approach based on a careful assessment of asthma control. Most instances of uncontrolled asthma are mild and can be managed successfully by patients at home with the telephone assistance of a clinician (Figure 9–3).

More severe exacerbations require evaluation and management in an urgent care or emergency department setting (Figure 9–4).

A. Mild Exacerbations

Mild asthma exacerbations are characterized by only minor changes in airway function ($PEF > 80\%$) and minimal symptoms and signs of airway dysfunction (see Tables 9–2 and 9–3). The majority of such exacerbations can be managed at home with the telephone assistance of a clinician. Many patients respond quickly and fully to an inhaled short-acting β_2 -agonist alone. However, an inhaled short-acting β_2 -agonist may need to be continued at increased doses, eg, every 3–4 hours for 24–48 hours. In patients not taking an inhaled corticosteroid, initiation of this agent should be considered during the mild exacerbation. In patients already taking an inhaled corticosteroid, a 7-day course of oral corticosteroids (0.5–1.0 mg/kg/d) may be necessary. Doubling the dose of inhaled corticosteroid is not effective in the acute setting and is not recommended in the NAEPP 3 guidelines.

B. Moderate Exacerbations

The principal goals of treatment of moderate asthma exacerbations are correction of hypoxemia, reversal of airflow obstruction, and reduction of the likelihood of recurrence of obstruction. Early intervention may lessen the severity and shorten the duration of an exacerbation. Of paramount importance is correction of hypoxemia through the use of supplemental oxygen. Airflow obstruction is treated with continuous administration of an inhaled short-acting β_2 -agonist and the early administration of systemic corticosteroids. Serial measurements of lung function to quantify the severity of airflow obstruction and its response to treatment are useful. The improvement in FEV_1 after 30 minutes of treatment correlates significantly with a broad range of indices of the severity of asthma exacerbations. Serial measurement of airflow in the emergency

department is an important factor in disposition and may reduce the rate of hospital admissions for asthma exacerbations. The post-exacerbation care plan is an important aspect of management. Regardless of the severity, all patients should be provided with necessary medications and education in how to use them, instruction in self-assessment, a follow-up appointment, and instruction in an action plan for managing recurrence.

C. Severe Exacerbations

Owing to the life-threatening nature of severe exacerbations of asthma, treatment should be started immediately once the exacerbation is recognized. All patients with a severe exacerbation should immediately receive oxygen, high doses of an inhaled short-acting β_2 -agonist, and systemic corticosteroids. A brief history pertinent to the exacerbation can be completed while treatment is being initiated. More detailed assessments, including laboratory studies, usually add little in the early phase of evaluation and management and should be postponed until after therapy is instituted.

Oxygen therapy is very important because asphyxia is a common cause of fatal asthma.


Supplemental oxygen should be given to maintain an $SaO_2 > 90\%$ or a $PaO_2 > 60$ mm Hg. Oxygen-induced hypoventilation is extremely rare, and concern for hypercapnia should never delay correction of hypoxemia.

Frequent high-dose delivery of an **inhaled short-acting β_2 -agonist** is indicated and is usually well tolerated in the setting of severe airway obstruction. Some studies suggest that continuous therapy is more effective than intermittent administration of these agents, but there is no clear consensus as long as similar doses are administered. At least three MDI or nebulizer treatments should be given in the first hour of therapy. Thereafter, the frequency of administration varies according to the improvement in airflow and associated symptoms and the occurrence of side effects. Ipratropium bromide reduces the rate of hospital admissions when added to inhaled short-acting β_2 -agonists in patients with moderate to severe asthma exacerbations.

Systemic corticosteroids are administered as detailed above. Mucolytic agents (eg, acetylcysteine, potassium iodide) may worsen cough or airflow obstruction. Anxiolytic and hypnotic drugs are generally contraindicated in severe asthma exacerbations because of their respiratory depressant effects.

Intravenous magnesium sulfate (2 g intravenously over 20 minutes) produces a detectable improvement in airflow and may reduce hospitalization rates in acute severe asthma ($FEV_1 < 25\%$ of predicted on presentation, or failure to respond to initial treatment).

Repeat assessment of patients with severe exacerbations should be made after the initial dose of inhaled bronchodilator and after three doses of inhaled bronchodilators (60–90 minutes after initiating treatment). The response to initial treatment is a better predictor of the need for hospitalization than is the severity of an exacerbation on presentation. The decision to hospitalize a patient should be based on the duration and severity of symptoms, severity




▲ **Figure 9–3.** Management of asthma exacerbations: home treatment. (Adapted from National Asthma Education and Prevention Program. Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma. National Institutes of Health Pub. No. 08-4051. Bethesda, MD, 2007. <http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm>.)

of airflow obstruction, course and severity of prior exacerbations, medication use at the time of the exacerbation, access to medical care and medications, adequacy of social support and home conditions, and presence of psychiatric illness. In general, discharge to home is appropriate if the PEF or FEV₁ has returned to \geq 60% of predicted or personal

best and symptoms are minimal or absent. Patients with a rapid response to treatment should be observed for 30 minutes after the most recent dose of bronchodilator to ensure stability of response before discharge to home.

In the **intensive care setting**, a small subset of patients will not respond to treatment and will progress to impending



FEV₁, forced expiratory volume in 1 second; ICS, inhaled corticosteroid; MDI, metered-dose inhaler; PEF, peak expiratory flow; SABA, short-acting β_2 -agonist; SaO₂, oxygen saturation.

▲ **Figure 9-4.** Management of asthma exacerbations: emergency department and hospital-based treatment. (Adapted from National Asthma Education and Prevention Program. Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma. National Institutes of Health Pub. No. 08-4051. Bethesda, MD, 2007. <http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm>.)

respiratory failure due to a combination of worsening airflow obstruction and respiratory muscle fatigue (see Table 9–3). Such patients can deteriorate rapidly and thus should be monitored in a critical care setting. Intubation of an acutely ill asthma patient is technically difficult and is best done semi-electively, before the crisis of a respiratory arrest. At the time of intubation, close attention should be given to maintaining intravascular volume because hypotension commonly accompanies the administration of sedation and the initiation of positive-pressure ventilation in patients dehydrated due to poor recent oral intake and high insensible losses.

The main goals of mechanical ventilation are to ensure adequate oxygen and to avoid barotrauma. Controlled hypoventilation with permissive hypercapnia is often required to limit airway pressures. Frequent high-dose delivery of inhaled short-acting β_2 -agonists should be continued along with anti-inflammatory agents as discussed above. Many questions remain regarding the optimal delivery of inhaled β_2 -agonists to intubated, mechanically ventilated patients. Further studies are needed to determine the comparative efficacy of MDIs and nebulizers, optimal ventilator settings to use during drug delivery, ideal site along the ventilator circuit for introduction of the delivery system, and maximal acceptable drug doses. Unconventional therapies such as helium-oxygen mixtures and inhalational anesthetic agents are of unclear benefit but may be appropriate in selected patients.

▶ When to Refer

- Atypical presentation or uncertain diagnosis, particularly if additional diagnostic testing is required (bronchoprovocation challenge, skin testing for allergies, rhinoscopy, consideration of occupational exposure).
- Complicating comorbid problems, such as rhinosinusitis, tobacco use, multiple environmental allergies, suspected allergic bronchopulmonary aspergillosis.
- Suboptimal response to therapy.
- Patient is not meeting goals of asthma therapy after 3–6 months of treatment.
- Requires high-dose inhaled corticosteroids for control.
- More than two courses of oral prednisone therapy in the past 12 months.
- Any life-threatening asthma exacerbation or exacerbation requiring hospitalization in the past 12 months.
- Presence of social or psychological issues interfering with asthma management.

Gibson PG et al. Asthma in older adults. *Lancet*. 2010 Sep 4; 376(9743):803–13. [PMID: 20816547]

Global Initiative for Asthma. <http://www.ginasthma.com>

Krishnan JA et al. An umbrella review: corticosteroid therapy for adults with acute asthma. *Am J Med*. 2009 Nov;122(11):977–91. [PMID: 19854321]

Lazarus SC. Clinical practice. Emergency treatment of asthma. *N Engl J Med*. 2010 Aug 19;363(8):755–64. [PMID: 20818877]

Mannam P et al. Analytic review: management of life-threatening asthma in adults. *J Intensive Care Med*. 2010 Jan–Feb; 25(1): 3–15. [PMID: 20085924]

Murphy DM et al. Recent advances in the pathophysiology of asthma. *Chest*. 2010 Jun;137(6):1417–26. [PMID: 20525652]

National Asthma Education and Prevention Program: Expert panel report III: Guidelines for the diagnosis and management of asthma. Bethesda, MD: National Heart, Lung, and Blood Institute, 2007. (NIH publication no. 08-4051). <http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm>

Wechsler ME. Managing asthma in primary care: putting new guideline recommendations into context. *Mayo Clin Proc*. 2009 Aug;84(8):707–17. [PMID: 19648388]

CHRONIC OBSTRUCTIVE PULMONARY DISEASE



ESSENTIALS OF DIAGNOSIS

- ▶ History of cigarette smoking.
- ▶ Chronic cough, dyspnea, and sputum production.
- ▶ Rhonchi, decreased intensity of breath sounds, and prolonged expiration on physical examination.
- ▶ Airflow limitation on pulmonary function testing that is not fully reversible and most often progressive.

▶ General Considerations

The American Thoracic Society defines COPD as a disease state characterized by the presence of airflow obstruction due to chronic bronchitis or emphysema; the airflow obstruction is generally progressive, may be accompanied by airway hyperreactivity, and may be partially reversible. The NHLBI estimates that 14 million Americans have been diagnosed with COPD; an equal number are thought to be afflicted but remain undiagnosed. Grouped together, COPD and asthma now represent the fourth leading cause of death in the United States, with over 120,000 deaths reported annually. The death rate from COPD is increasing rapidly, especially among elderly men.

Most patients with COPD have features of both emphysema and chronic bronchitis. **Chronic bronchitis** is a clinical diagnosis defined by excessive secretion of bronchial mucus and is manifested by daily productive cough for 3 months or more in at least 2 consecutive years. **Emphysema** is a pathologic diagnosis that denotes abnormal permanent enlargement of air spaces distal to the terminal bronchiole, with destruction of their walls and without obvious fibrosis.

Cigarette smoking is clearly the most important cause of COPD in North America and Western Europe. Nearly all smokers suffer an accelerated decline in lung function that is dose- and duration-dependent. Fifteen percent develop progressively disabling symptoms in their 40s and 50s. It is estimated that 80% of patients seen for COPD have significant exposure to tobacco smoke. The remaining 20% frequently have a combination of exposures to environmental tobacco smoke, occupational dusts and chemicals, and indoor air pollution from biomass fuel used for cooking and heating in poorly ventilated buildings. Outdoor air pollution, airway infection, familial factors, and allergy

have also been implicated in chronic bronchitis, and hereditary factors (deficiency of α_1 -antitrypsin [α_1 -antitrypsin]) have been implicated in COPD. The pathogenesis of emphysema may involve excessive lysis of elastin and other structural proteins in the lung matrix by elastase and other proteases derived from lung neutrophils, macrophages, and mononuclear cells. Atopy and the tendency for bronchoconstriction to develop in response to nonspecific airway stimuli may be important risks for COPD.

► Clinical Findings

A. Symptoms and Signs

Patients with COPD characteristically present in the fifth or sixth decade of life complaining of excessive cough, sputum production, and shortness of breath. Symptoms have often been present for 10 years or more. Dyspnea is noted initially only on heavy exertion, but as the condition progresses it occurs with mild activity. In severe disease, dyspnea occurs at rest. As the disease progresses, two symptom patterns tend to emerge, historically referred to as “pink puffers” and “blue bloaters” (Table 9–7). Most COPD patients have pathologic evidence of both disorders, and

their clinical course may reflect other factors such as central control of ventilation and concomitant sleep-disordered breathing.

Pneumonia, pulmonary hypertension, cor pulmonale, and chronic respiratory failure characterize the late stage of COPD. A hallmark of COPD is the exacerbation of symptoms beyond normal day-to-day variation, often including increased dyspnea, an increased frequency or severity of cough, increased sputum volume or change in sputum character. These exacerbations are commonly precipitated by infection (more often viral than bacterial) or environmental factors. Exacerbations of COPD vary widely in severity but typically require a change in regular therapy.

B. Laboratory Findings

Spirometry provides objective information about pulmonary function and assesses the results of therapy. Pulmonary function tests early in the course of COPD reveal only evidence of abnormal closing volume and reduced midexpiratory flow rate. Reductions in FEV₁ and in the ratio of forced expiratory volume to vital capacity (FEV₁% or FEV₁/FVC ratio) (Table 9–7) occur later. In severe disease, the FVC is markedly reduced. Lung volume measurements

Table 9–7. Patterns of disease in advanced COPD.

	Type A: Pink Puffer (Emphysema Predominant)	Type B: Blue Bloater (Bronchitis Predominant)
History and physical examination	Major complaint is dyspnea, often severe, usually presenting after age 50. Cough is rare, with scant clear, mucoid sputum. Patients are thin, with recent weight loss common. They appear uncomfortable, with evident use of accessory muscles of respiration. Chest is very quiet without adventitious sounds. No peripheral edema.	Major complaint is chronic cough, productive of mucopurulent sputum, with frequent exacerbations due to chest infections. Often presents in late 30s and 40s. Dyspnea usually mild, though patients may note limitations to exercise. Patients frequently overweight and cyanotic but seem comfortable at rest. Peripheral edema is common. Chest is noisy, with rhonchi invariably present; wheezes are common.
Laboratory studies	Hemoglobin usually normal (12–15 g/dL). Pao ₂ normal to slightly reduced (65–75 mm Hg) but Sao ₂ normal at rest. Paco ₂ normal to slightly reduced (35–40 mm Hg). Chest radiograph shows hyperinflation with flattened diaphragms. Vascular markings are diminished, particularly at the apices.	Hemoglobin usually elevated (15–18 g/dL). Pao ₂ reduced (45–60 mm Hg) and Paco ₂ slightly to markedly elevated (50–60 mm Hg). Chest radiograph shows increased interstitial markings (“dirty lungs”), especially at bases. Diaphragms are not flattened.
Pulmonary function tests	Airflow obstruction ubiquitous. Total lung capacity increased, sometimes markedly so. D _{LCO} reduced. Static lung compliance increased.	Airflow obstruction ubiquitous. Total lung capacity generally normal but may be slightly increased. D _{LCO} normal. Static lung compliance normal.
Special evaluations		
\dot{V}/\dot{Q} matching	Increased ventilation to high \dot{V}/\dot{Q} areas, ie, high dead space ventilation.	Increased perfusion to low \dot{V}/\dot{Q} areas.
Hemodynamics	Cardiac output normal to slightly low. Pulmonary artery pressures mildly elevated and increase with exercise.	Cardiac output normal. Pulmonary artery pressures elevated, sometimes markedly so, and worsen with exercise.
Nocturnal ventilation	Mild to moderate degree of oxygen desaturation not usually associated with obstructive sleep apnea.	Severe oxygen desaturation, frequently associated with obstructive sleep apnea.
Exercise ventilation	Increased minute ventilation for level of oxygen consumption. Pao ₂ tends to fall, Paco ₂ rises slightly.	Decreased minute ventilation for level of oxygen consumption. Pao ₂ may rise; Paco ₂ may rise significantly.

D_{LCO}, single-breath diffusing capacity for carbon monoxide; \dot{V}/\dot{Q} , ventilation-perfusion.

reveal a marked increase in residual volume (RV), an increase in total lung capacity (TLC), and an elevation of the RV/TLC ratio, indicative of air trapping, particularly in emphysema.

Arterial blood gas measurements characteristically show no abnormalities early in COPD other than an increased $A-a-DO_2$. Indeed, they are unnecessary unless (1) hypoxemia or hypercapnia is suspected, (2) the FEV_1 is $< 40\%$ of predicted, or (3) there are clinical signs of right heart failure. Hypoxemia occurs in advanced disease, particularly when chronic bronchitis predominates. Compensated respiratory acidosis occurs in patients with chronic respiratory failure, particularly in chronic bronchitis, with worsening of acidemia during acute exacerbations.

Examination of the sputum may reveal *Streptococcus pneumoniae*, *H influenzae*, or *Moraxella catarrhalis*. Positive sputum cultures are poorly correlated with acute exacerbations, and research techniques demonstrate evidence of preceding viral infection in a majority of patients with exacerbations. The ECG may show sinus tachycardia and, in advanced disease, chronic pulmonary hypertension may produce electrocardiographic abnormalities typical of cor pulmonale. Supraventricular arrhythmias (multifocal atrial tachycardia, atrial flutter, and atrial fibrillation) and ventricular irritability also occur.

C. Imaging

Radiographs of patients with chronic bronchitis typically show only nonspecific peribronchial and perivascular markings. Plain radiographs are insensitive for the diagnosis of emphysema; they show hyperinflation with flattening of the diaphragm or peripheral arterial deficiency in about half of cases. CT of the chest, particularly using a high-resolution reconstruction algorithm, is more sensitive and specific than plain radiographs for the diagnosis of emphysema. Pulmonary hypertension may be suggested by enlargement of central pulmonary arteries in advanced disease. Doppler echocardiography provides a noninvasive estimate of pulmonary artery pressure if pulmonary hypertension is suspected.

► Differential Diagnosis

Clinical, imaging, and laboratory findings should enable the clinician to distinguish COPD from other obstructive pulmonary disorders such as bronchial asthma, bronchiectasis, cystic fibrosis, bronchopulmonary mycosis, and central airflow obstruction. Simple asthma is characterized by complete or near-complete reversibility of airflow obstruction. Bronchiectasis is distinguished from COPD by features such as recurrent pneumonia and hemoptysis, digital clubbing, and characteristic imaging abnormalities. Patients with severe α_1 -antitrypsin (α_1 -antitrypsin) deficiency are recognized by family history and the appearance of panacinar bibasilar emphysema early in life, usually in the third or fourth decade; hepatic cirrhosis and hepatocellular carcinoma may occur. Cystic fibrosis occurs in children and younger adults. Rarely, mechanical obstruction of the central airways simulates COPD. Flow-volume loops may help separate patients with central airway obstruction

from those with diffuse intrathoracic airway obstruction characteristic of COPD.

► Complications

Acute bronchitis, pneumonia, pulmonary thromboembolism, atrial dysrhythmias (such as atrial fibrillation, atrial flutter, and multifocal atrial tachycardia), and concomitant left ventricular failure may worsen otherwise stable COPD. Pulmonary hypertension, cor pulmonale, and chronic respiratory failure are common in advanced COPD. Spontaneous pneumothorax occurs in a small fraction of patients with emphysema. Hemoptysis may result from chronic bronchitis or may signal bronchogenic carcinoma.

► Prevention

COPD is largely preventable through elimination of long-term exposure to tobacco smoke. Smokers with early evidence of airflow limitation can significantly alter their disease by smoking cessation. Smoking cessation slows the decline in FEV_1 in middle-aged smokers with mild airways obstruction. Vaccination against seasonal influenza, epidemic influenza A (H1N1), and pneumococcal infection may also be of benefit.

► Treatment

The treatment of COPD is guided by the severity of symptoms or the presence of an exacerbation or stable symptoms. Standards for the management of patients with stable COPD and COPD exacerbations by the American Thoracic Society and the Global Initiative for Obstructive Lung Disease (GOLD), a joint expert committee of the NHLBI and the WHO, are incorporated in the recommendations below. See Chapter 37 for a discussion of air travel in patients with lung disease.

A. Ambulatory Patients

1. Smoking cessation—The single most important intervention in smokers with COPD is to encourage smoking cessation. Simply telling a patient to quit succeeds 5% of the time. Behavioral approaches, ranging from clinician advice to intensive group programs, may improve cessation rates. Pharmacologic therapy includes nicotine replacement (transdermal patch, gum, lozenge, inhaler, or nasal spray), bupropion, and varenicline (a partial agonist of nicotine acetylcholine receptors) (see Chapter 1). Combined pharmacotherapies (two forms of nicotine replacement, or nicotine replacement and bupropion), with or without behavioral approaches have also been recommended. The Lung Health Study reported 22% sustained abstinence at 5 years in their intervention group (behavior modification plus nicotine gum). Varenicline has proved effective but wider use has revealed significant CNS side effects, including some reports of an increase in suicide.

2. Oxygen therapy—Supplemental oxygen is the only drug therapy for which there is evidence showing improvement in the natural history of COPD in those patients with resting hypoxemia. Proved benefits of home oxygen therapy in hypoxemic patients include longer survival, reduced

hospitalization needs, and better quality of life. Survival in hypoxemic patients with COPD treated with supplemental oxygen therapy is directly proportionate to the number of hours per day oxygen is administered: in hypoxemic patients treated with continuous oxygen, the survival after 36 months is about 65%—significantly better than the survival rate of about 45% in those who are treated with only nocturnal oxygen. Oxygen by nasal prongs must be given at least 15 hours a day unless therapy is intended only for exercise or sleep. Several studies of supplemental oxygen therapy in COPD patients with low-normal resting oxygen levels (PaO₂ between 56 and 69 mm Hg) showed no survival benefit. Patients with normal or low-normal resting oxygen levels who desaturate with exertion improve their exercise tolerance and shorten recovery from dyspnea when supplemental oxygen therapy is used during activity, but there is no evidence of a mortality benefit. Requirements for Medicare coverage for a patient's home use of oxygen and oxygen equipment are listed in Table 9–8. Arterial blood gas analysis is preferred over oximetry to guide initial oxygen therapy. Hypoxemic patients with pulmonary hypertension, chronic cor pulmonale, erythrocytosis, impaired cognitive function, exercise intolerance, nocturnal restlessness, or morning headache are particularly likely to benefit from home oxygen therapy.

Home oxygen may be supplied by liquid oxygen systems, compressed gas cylinders, or oxygen concentrators. Most patients benefit from having both stationary and

portable systems. For most patients, a flow rate of 1–3 L/min achieves a PaO₂ greater than 55 mm Hg. The monthly cost of home oxygen therapy ranges from \$300.00 to \$500.00 or more, higher for liquid oxygen systems. Medicare covers approximately 80% of home oxygen expenses. **Transtracheal oxygen** is an alternative method of delivery and may be useful for patients who require higher flows of oxygen than can be delivered via the nose or who are experiencing troublesome side effects from nasal delivery such as nasal drying or epistaxis. Reservoir nasal cannulas or “pendants” and demand (pulse) oxygen delivery systems are also available to conserve oxygen.

3. Inhaled bronchodilators—Bronchodilators do not alter the inexorable decline in lung function that is a hallmark of COPD, but they offer many patients improvement in symptoms, exercise tolerance, and overall health status. Aggressiveness of bronchodilator therapy should be matched to the severity of the patient's disease. In patients who experience no symptomatic improvement, bronchodilators should be discontinued.

The most commonly prescribed short-acting bronchodilators are the anticholinergic ipratropium bromide and β_2 -agonists (eg, albuterol, metaproterenol), delivered by MDI or as an inhalation solution by nebulizer. Ipratropium bromide is generally preferred to the short-acting β_2 -agonists as a first-line agent because of its longer duration of action and absence of sympathomimetic side effects. Some studies have suggested that ipratropium achieves superior bronchodilation in COPD patients. Typical doses are two to four puffs (36–72 mcg) every 6 hours. Short-acting β_2 -agonists are less expensive and have a more rapid onset of action, commonly leading to greater patient satisfaction. At maximal doses, β_2 -agonists have bronchodilator action equivalent to that of ipratropium but may cause tachycardia, tremor, or hypokalemia. There does not appear to be any advantage of scheduled use of short-acting β_2 -agonists compared with as-needed administration. Use of both short-acting β_2 -agonists and anticholinergics at submaximal doses leads to improved bronchodilation compared with either agent alone but does not improve dyspnea.

Long-acting β_2 -agonists (eg, formoterol, salmeterol) and anticholinergics (tiotropium) appear to achieve bronchodilation that is equivalent or superior to what is experienced with ipratropium, in addition to similar improvements on health status. Although they are more expensive than short-acting agents, long-acting bronchodilators may have superior clinical efficacy in persons with advanced disease. A 2008 randomized controlled trial (RCT) of long-term administration of tiotropium added to standard therapy reported fewer exacerbations or hospitalizations, and improved dyspnea scores, in the tiotropium group. Tiotropium had no effect on long-term decline in lung function, however. Another RCT comparing the effects of tiotropium with those of salmeterol-fluticasone in COPD over 2 years reported no difference in the risk of exacerbation. The incidence of pneumonia was higher in the salmeterol-fluticasone group, yet dyspnea scores were lower and there was a mortality benefit compared with tiotropium. This last finding awaits confirmation in further studies.

Table 9–8. Home oxygen therapy: Requirements for Medicare coverage.¹

Group I (any of the following):

1. PaO₂ ≤ 55 mm Hg or Sao₂ ≤ 88% taken while awake, at rest, breathing room air.
2. During sleep (prescription for nocturnal oxygen use only):
 - a. PaO₂ ≤ 55 mm Hg or Sao₂ ≤ 88% for a patient whose awake, resting, room air PaO₂ is ≥ 56 mm Hg or Sao₂ ≥ 89%,
or
 - b. Decrease in PaO₂ > 10 mm Hg or decrease in Sao₂ > 5% associated with symptoms or signs reasonably attributed to hypoxemia (eg, impaired cognitive processes, nocturnal restlessness, insomnia).
3. During exercise (prescription for oxygen use only during exercise):
 - a. PaO₂ ≤ 55 mm Hg or Sao₂ ≤ 88% taken during exercise for a patient whose awake, resting, room air PaO₂ is ≥ 56 mm Hg or Sao₂ ≥ 89%,
and
 - b. There is evidence that the use of supplemental oxygen during exercise improves the hypoxemia that was demonstrated during exercise while breathing room air.

Group II²:

- PaO₂ = 56–59 mm Hg or Sao₂ = 89% if there is evidence of any of the following:
1. Dependent edema suggesting congestive heart failure.
 2. P pulmonale on ECG (P wave > 3 mm in standard leads II, III, or aVF).
 3. Hematocrit > 56%.

¹Centers for Medicare & Medicaid Services, 2003.

²Patients in this group must have a second oxygen test 3 months after the initial oxygen set-up.

The symptomatic benefits of long-acting bronchodilators are firmly established. Whether there is a mortality benefit associated with salmeterol-fluticasone therapy remains controversial, especially since serious concerns have been raised about the safety of both long-acting β_2 -agonists and anticholinergics. Two large RCTs in asthmatic patients reported an increase in exacerbations and mortality in patients treated with salmeterol. These findings have not been observed in COPD patients, however, and several studies report a trend toward lower mortality in patients treated with salmeterol alone, compared with placebo. Several small studies and a 2008 meta-analysis reported an increase in cardiovascular events among patients treated with long- and short-acting anticholinergics. In contrast, the 4-year tiotropium trial reported fewer cardiovascular events in the intervention group. Subsequent meta-analyses that include the 4-year tiotropium trial do not support an increase in cardiovascular events in these patients. This is an area of ongoing study but most practitioners believe that the documented benefits of anticholinergic therapy outweigh potential risks.

4. Corticosteroids—Multiple large clinical trials have reported a reduction in the frequency of COPD exacerbations and an increase in self-reported functional status in COPD patients treated with inhaled corticosteroids. These same trials demonstrate no effect of inhaled corticosteroids on mortality or the characteristic decline in lung function experienced by COPD patients. At this time, inhaled corticosteroids alone should not be considered first-line therapy in stable COPD patients, who benefit more from bronchodilators, smoking cessation, and pulmonary rehabilitation.

Combination therapy with an inhaled corticosteroid and a long-acting β_2 -agonist reduces the frequency of COPD exacerbations and improves self-reported functional status in COPD patients, compared with placebo or sole use of inhaled corticosteroids, long-acting β_2 -agonists, or anticholinergics. Addition of an inhaled corticosteroid/long-acting β_2 -agonist to tiotropium therapy in COPD patients does not reduce the frequency of COPD exacerbations but did improve hospitalization rates as well as self-reported functional status in one RCT.

Apart from acute exacerbations, COPD is not generally responsive to oral corticosteroid therapy. Only 10–20% of stable outpatients with COPD given oral corticosteroids will have a > 20% increase in FEV₁ compared with patients receiving placebo. There may be a subset of steroid-responsive COPD patients more likely to benefit from long-term oral or inhaled corticosteroids. Since there are no clinical predictors to identify such responders, empiric trials of oral corticosteroids are common. Current research provides little guidance to interpret clinically relevant benefit and clinically significant changes in spirometry, however. If empiric trials of oral corticosteroids are conducted, the baseline FEV₁ should be stable, ie, not measured during an exacerbation, and documented on maximal bronchodilator therapy. The postbronchodilator FEV₁ value is considered the appropriate baseline. After a 3–4 week trial of 0.25–0.5 mg/kg oral prednisone, the drug should be discontinued unless there is a 20% or greater increase in FEV₁.

Responders to oral agents are usually switched to inhaled corticosteroids, but there are few data to guide this practice. The use of oral or systemic corticosteroids has well-recognized adverse effects, and it is prudent to minimize cumulative oral corticosteroid exposure. Some patients may be truly “corticosteroid-dependent,” but clinical experience suggests that this is rare when all other available therapies are optimized.

5. Theophylline—Oral theophylline is a fourth-line agent for treating patients with COPD who do not achieve adequate symptom control with anticholinergics, β_2 -agonists, and inhaled corticosteroid therapy. Sustained-release theophylline improves hemoglobin saturation during sleep in COPD patients and is a first-line agent for those with sleep-related breathing disorders. Theophylline improves dyspnea ratings, exercise performance, and pulmonary function in many patients with stable COPD. Its benefits result from bronchodilation; anti-inflammatory properties; and extrapulmonary effects on diaphragm strength, myocardial contractility, and kidney function. Theophylline toxicity is a significant concern due to the drug’s narrow therapeutic window, and long-term administration requires careful monitoring of serum levels. Despite the potential adverse effects, theophylline continues to have a beneficial role in carefully selected patients.

6. Antibiotics—Antibiotics are commonly prescribed to outpatients with COPD for the following indications: (1) to treat an acute exacerbation, (2) to treat acute bronchitis, and (3) to prevent acute exacerbations of chronic bronchitis (prophylactic antibiotics). Antibiotics appear to improve outcomes slightly in the first two situations, but there is no convincing evidence to support the use of prophylactic antibiotics in patients with COPD. Patients with a COPD exacerbation associated with increased sputum purulence accompanied by dyspnea or an increase in the quantity of sputum are thought to benefit the most from antibiotic therapy. An optimal antibiotic regimen has not been identified. The choice of antibiotic depends on local bacterial resistance patterns and individual risk of *Pseudomonas aeruginosa* infection (history of *Pseudomonas* isolation, FEV₁ < 50% of predicted, recent hospitalization (2 or more days in the past 3 months), more than three courses of antibiotics within the past year, use of systemic corticosteroids). Oral antibiotic options include doxycycline (100 mg every 12 hours), trimethoprim-sulfamethoxazole (160/800 mg every 12 hours), a cephalosporin (eg, cefpodoxime 200 mg every 12 hours or cefprozil 500 mg every 12 hours), a macrolide (eg, azithromycin 500 mg followed by 250 mg daily for 5 days), a fluoroquinolone (eg, ciprofloxacin 500 mg every 12 hours), and amoxicillin-clavulanate (875/125 mg every 12 hours). Suggested duration of therapy is 3–7 days and depends on response to therapy; some studies suggest that 5 days is as effective as 7 days but with fewer adverse effects. There are few controlled trials of antibiotics in severe COPD exacerbations, but prompt administration of antibiotics is appropriate, particularly in persons with risk factors for poor outcomes (age > 65 years, FEV₁ < 50% predicted, three or more exacerbations in the past year, antibiotic

therapy within the past 3 months, comorbid conditions such as cardiac disease).

7. Pulmonary rehabilitation—Graded aerobic physical exercise programs (eg, walking 20 minutes three times weekly or bicycling) are helpful to prevent deterioration of physical condition and to improve patients' ability to carry out daily activities. Training of inspiratory muscles by inspiring against progressively larger resistive loads reduces dyspnea and improves exercise tolerance, health status, and respiratory muscle strength in some but not all patients. Pursed-lip breathing to slow the rate of breathing and abdominal breathing exercises to relieve fatigue of accessory muscles of respiration may reduce dyspnea in some patients. Many patients undergo these exercise and educational interventions in a structured rehabilitation program. In a number of studies, pulmonary rehabilitation has been shown to improve exercise capacity, decrease hospitalizations, and enhance quality of life. Referral to a comprehensive rehabilitation program is recommended in patients who have severe dyspnea, reduced quality of life, or frequent hospitalizations despite optimal medical therapy.

8. Other measures—In patients with chronic bronchitis, increased mobilization of secretions may be accomplished through the use of adequate systemic hydration, effective cough training methods, or use of a hand-held flutter device and postural drainage, sometimes with chest percussion or vibration. Postural drainage and chest percussion should be used only in selected patients with excessive amounts of retained secretions that cannot be cleared by coughing and other methods; these measures are of no benefit in pure emphysema. Expectorant-mucolytic therapy has generally been regarded as unhelpful in patients with chronic bronchitis. Cough suppressants and sedatives should be avoided as routine measures.

Human α_1 -antitrypsin is available for replacement therapy in emphysema due to congenital deficiency (PiZZ or null genotype) of α_1 -antiprotease (α_1 -antitrypsin). Patients over 18 years of age with airflow obstruction by spirometry and serum levels less than 11 $\mu\text{mol/L}$ (~ 50 mg/dL) are potential candidates for replacement therapy. α_1 -Antitrypsin is administered intravenously in a dose of 60 mg/kg body weight once weekly. There is no evidence that replacement therapy is beneficial to heterozygotes (eg, PiMZ) with low-normal serum levels, although such patients may be at slightly increased risk for emphysema, especially in the setting of tobacco smoke exposure. Severe dyspnea in spite of optimal medical management may warrant a clinical trial of an opioid (eg, morphine 5–10 mg orally every 3–4 hours, oxycodone 5–10 mg orally every 4–6 hours). Sedative-hypnotic drugs (eg, diazepam, 5 mg three times daily) marginally improve intractable dyspnea but cause significant drowsiness; they may benefit very anxious patients. Transnasal positive-pressure ventilation at home to rest the respiratory muscles is an approach to improve respiratory muscle function and reduce dyspnea in patients with severe COPD. A bilevel transnasal ventilation system has been reported to reduce dyspnea in ambulatory patients with severe COPD, but the long-term

benefits of this approach and compliance with it have not been defined.

B. Hospitalized Patients

Management of the hospitalized patient with an acute exacerbation of COPD includes supplemental oxygen (titrated to maintain Sao_2 between 90% and 94% or Pao_2 between 60 mm Hg and 70 mm Hg), inhaled ipratropium bromide (500 mcg by nebulizer, or 36 mcg by MDI with spacer, every 4 hours as needed) plus β_2 -agonists (eg, albuterol 2.5 mg diluted with saline to a total of 3 mL by nebulizer, or MDI, 90 mcg per puff, four to eight puffs via spacer, every 1–4 hours as needed), and broad-spectrum antibiotics.

For patients without risk factors for *Pseudomonas*, management options include a fluoroquinolone (eg, levofloxacin 750 mg orally or intravenously per day, or moxifloxacin 400 mg orally or intravenously every 24 hours) or a third-generation cephalosporin (eg, ceftriaxone 1 g intravenously per day, or cefotaxime 1 g intravenously every 8 hours).

For patients with risk factors for *Pseudomonas*, therapeutic options include piperacillin-tazobactam (4.5 g intravenously every 6 hours), ceftazidime (1 g intravenously every 8 hours), cefepime (1 g intravenously every 12 hours), levofloxacin (750 mg orally or intravenously per day for 3–7 days), or corticosteroids (prednisone 30–40 mg orally per day for 7–10 days is usually sufficient) and, in selected cases, chest physiotherapy.

Theophylline should not be initiated in the acute setting, but patients taking theophylline prior to acute hospitalization should have their theophylline serum levels measured and maintained in the therapeutic range. Oxygen therapy should not be withheld for fear of worsening respiratory acidemia; hypoxemia is more detrimental than hypercapnia. Cor pulmonale usually responds to measures that reduce pulmonary artery pressure, such as supplemental oxygen and correction of acidemia; bed rest, salt restriction, and diuretics may add some benefit. Cardiac dysrhythmias, particularly multifocal atrial tachycardia, usually respond to aggressive treatment of COPD itself. Atrial flutter may require DC cardioversion after initiation of the above therapy. If progressive respiratory failure ensues, tracheal intubation and mechanical ventilation are necessary. In clinical trials of COPD patients with hypercapnic acute respiratory failure, noninvasive positive-pressure ventilation (NPPV) delivered via face mask reduced the need for intubation and shortened lengths of stay in the intensive care unit (ICU). Other studies have suggested a lower risk of nosocomial infections and less use of antibiotics in COPD patients treated with NPPV. These benefits do not appear to extend to hypoxemic respiratory failure or to patients with acute lung injury or acute respiratory distress syndrome (ARDS).

C. Surgery for COPD

1. Lung transplantation—Experience with both single and bilateral sequential lung transplantation for severe COPD is extensive. Requirements for lung transplantation are severe lung disease, limited activities of daily living, exhaustion of medical therapy, ambulatory status, potential for pulmonary rehabilitation, limited life expectancy

without transplantation, adequate function of other organ systems, and a good social support system. Average total charges for lung transplantation through the end of the first postoperative year exceed \$250,000. The 2-year survival rate after lung transplantation for COPD is 75%. Complications include acute rejection, opportunistic infection, and obliterative bronchiolitis. Substantial improvements in pulmonary function and exercise performance have been noted after transplantation.

2. Lung volume reduction surgery—Lung volume reduction surgery (LVRS), or reduction pneumoplasty, is a surgical approach to relieve dyspnea and improve exercise tolerance in patients with advanced diffuse emphysema and lung hyperinflation. Bilateral resection of 20–30% of lung volume in selected patients results in modest improvements in pulmonary function, exercise performance, and dyspnea. The duration of any improvement as well as any mortality benefit remains uncertain. Prolonged air leaks occur in up to 50% of patients postoperatively. Mortality rates in centers with the largest experience with LVRS range from 4% to 10%.

The National Emphysema Treatment Trial compared LVRS with medical treatment in a randomized, multicenter clinical trial of 1218 patients with severe emphysema. Overall, surgery improved exercise capacity but not mortality when compared with medical therapy. The persistence of this benefit remains to be defined. Subgroup analysis suggested that patients with upper lobe predominant emphysema and low exercise capacity might have improved survival, while other groups suffered excess mortality when randomized to surgery.

3. Bullectomy—Bullectomy is an older surgical procedure for palliation of dyspnea in patients with severe bullous emphysema. Bullectomy is most commonly pursued when a single bulla occupies at least 30–50% of the hemithorax. In this procedure, the surgeon removes a large emphysematous bulla that demonstrates no ventilation or perfusion on lung scanning and compresses adjacent lung with preserved function. Bullectomy can be performed with a CO₂ laser via thoracoscopy.

► Prognosis

The outlook for patients with clinically significant COPD is poor. The degree of pulmonary dysfunction at the time the patient is first seen is an important predictor of survival: median survival of patients with FEV₁ ≤ 1 L is about 4 years. A multidimensional index (the BODE index), which includes body mass index (BMI), airway obstruction (FEV₁), dyspnea (Medical Research Council dyspnea score), and exercise capacity is a tool that predicts death and hospitalization better than FEV₁ alone. Comprehensive care programs, cessation of smoking, and supplemental oxygen may reduce the rate of decline of pulmonary function, but therapy with bronchodilators and other approaches probably has little, if any, impact on the natural course of COPD.

Dyspnea at the end of life can be extremely uncomfortable and distressing to the patient and family. As patients near the end of life, meticulous attention to palliative care is essential to effectively manage dyspnea (see Chapter 5).

► When to Refer

- COPD onset occurs before the age of 40.
- Frequent exacerbations (two or more a year) despite optimal treatment.
- Severe or rapidly progressive COPD.
- Symptoms disproportionate to the severity of airflow obstruction.
- Need for long-term oxygen therapy.
- Onset of comorbid illnesses (such as bronchiectasis, heart failure, or lung cancer).

► When to Admit

- Severe symptoms or acute worsening that fails to respond to outpatient management.
- Acute or worsening hypoxemia, hypercapnia, peripheral edema, or change in mental status.
- Inadequate home care, or inability to sleep or maintain nutrition/hydration due to symptoms.
- The presence of high-risk comorbid conditions.

Daniels JM et al. Antibiotics in addition to systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease. *Am J Respir Crit Care Med.* 2010 Jan 15; 181(2):150–7. [PMID: 19875685]

Littner MR. In the clinic. Chronic obstructive pulmonary disease. *Ann Intern Med.* 2011 Apr 5;154(7):ITC4-1–ITC4-15. [PMID: 21464346]

Rabe KF et al; Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. *Am J Respir Crit Care Med.* 2007 Sep 15;176(6):532–55. [PMID: 17507545]

Salvi SS et al. Chronic obstructive pulmonary disease in non-smokers. *Lancet.* 2009 Aug 29;374(9691):733–43. [PMID: 19716966]

Tashkin DP. Long-acting anticholinergic use in chronic obstructive pulmonary disease: efficacy and safety. *Curr Opin Pulm Med.* 2010 Mar;16(2):97–105. [PMID: 20019615]

Torpy JM et al. JAMA patient page. Chronic obstructive pulmonary disease. *JAMA.* 2008 Nov 26;300(20):2448. [PMID: 19033597]

Walters JA et al. Systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease. *Cochrane Database Syst Rev.* 2009 Jan 21;(1):CD001288. [PMID: 19160195]

ZuWallack R et al. Primary care of the patient with chronic obstructive pulmonary disease—part 3: pulmonary rehabilitation and comprehensive care for the patient with chronic obstructive pulmonary disease. *Am J Med.* 2008 Jul;121(7 Suppl):S25–32. [PMID: 18558104]

BRONCHIECTASIS



ESSENTIALS OF DIAGNOSIS

- Chronic productive cough with dyspnea and wheezing.
- Radiographic findings of dilated, thickened airways and scattered, irregular opacities.

► General Considerations

Bronchiectasis is a congenital or acquired disorder of the large bronchi characterized by permanent, abnormal dilation and destruction of bronchial walls. It may be caused by recurrent inflammation or infection of the airways and may be localized or diffuse. Cystic fibrosis causes about half of all cases of bronchiectasis. Other causes include lung infection (tuberculosis, fungal infections, lung abscess, pneumonia), abnormal lung defense mechanisms (humoral immunodeficiency, α_1 -antiprotease [α_1 -antitrypsin] deficiency with cigarette smoking, mucociliary clearance disorders, rheumatic diseases), and localized airway obstruction (foreign body, tumor, mucoid impaction). Immunodeficiency states that may lead to bronchiectasis include congenital or acquired panhypogammaglobulinemia; common variable immunodeficiency; selective IgA, IgM, and IgG subclass deficiencies; and acquired immunodeficiency from cytotoxic therapy, AIDS, lymphoma, multiple myeloma, leukemia, and chronic kidney and liver diseases. Most patients with bronchiectasis have panhypergammaglobulinemia, however, presumably reflecting an immune system response to chronic airway infection. Acquired primary bronchiectasis is now uncommon in the United States because of improved control of bronchopulmonary infections.

► Clinical Findings

A. Symptoms and Signs

Symptoms of bronchiectasis include chronic cough with production of copious amounts of purulent sputum, hemoptysis, and pleuritic chest pain. Dyspnea and wheezing occur in 75% of patients. Weight loss, anemia, and other systemic manifestations are common. Physical findings are nonspecific, but persistent crackles at the lung bases are common. Clubbing is infrequent in mild cases but is common in severe disease (see Figure 6–41). Copious, foul-smelling, purulent sputum is characteristic. Obstructive pulmonary dysfunction with hypoxemia is seen in moderate or severe disease.

B. Imaging

Radiographic abnormalities include dilated and thickened bronchi that may appear as “tram-tracks” or as ring-like markings on chest radiograph. Scattered irregular opacities, atelectasis, and focal consolidation may be present. High-resolution CT is the diagnostic study of choice.

C. Microbiology

Haemophilus influenzae is the most common organism recovered from non-cystic fibrosis patients with bronchiectasis. *P aeruginosa*, *S pneumoniae*, and *Staphylococcus aureus* are commonly identified. Nontuberculous mycobacteria are seen less commonly. Patients with *Pseudomonas* infection experience an accelerated course, with more frequent exacerbations and more rapid decline in lung function.

► Treatment

Treatment of acute exacerbations consists of antibiotics, daily chest physiotherapy with postural drainage and chest

percussion, and inhaled bronchodilators. Hand-held flutter valve devices may be as effective as chest physiotherapy in clearing secretions. Antibiotic therapy should be guided by sputum smears and cultures. If a specific bacterial pathogen cannot be isolated, then empiric oral antibiotic therapy for 10–14 days is appropriate. Common regimens include amoxicillin or amoxicillin-clavulanate (500 mg every 8 hours), ampicillin or tetracycline (250–500 mg four times daily), trimethoprim-sulfamethoxazole (160/800 mg every 12 hours), or ciprofloxacin (500–750 mg twice daily). It is important to screen patients for infection with nontuberculous mycobacteria because these organisms may underlie a lack of treatment response. Preventive or suppressive treatment is sometimes given to stable outpatients with bronchiectasis who have copious purulent sputum. Clinical trial data to guide this practice are scant. Common regimens include macrolides (azithromycin, 500 mg three times a week; erythromycin, 500 mg twice daily), high-dose (3 g/d) amoxicillin or alternating cycles of the antibiotics listed above given orally for 2–4 weeks. In patients with underlying cystic fibrosis, inhaled aerosolized aminoglycosides reduce colonization by *Pseudomonas* species, improve FEV₁ and reduce hospitalizations; in non-cystic fibrosis bronchiectasis, adding inhaled tobramycin to oral ciprofloxacin for acute exacerbations due to *Pseudomonas* decreases microbial sputum burden but without apparent clinical benefit. Complications of bronchiectasis include hemoptysis, cor pulmonale, amyloidosis, and secondary visceral abscesses at distant sites (eg, brain). Bronchoscopy is sometimes necessary to evaluate hemoptysis, remove retained secretions, and rule out obstructing airway lesions. Massive hemoptysis may require embolization of bronchial arteries or surgical resection. Surgical resection is otherwise reserved for the few patients with localized bronchiectasis and adequate pulmonary function in whom conservative management fails.

Cantin L et al. Bronchiectasis. *Am J Roentgenol*. 2009 Sep;193(3):W158–71. [PMID: 19696251]

Ilowite J et al. Pharmacological treatment options for bronchiectasis: focus on antimicrobial and anti-inflammatory agents. *Drugs*. 2009;69(4):407–19. [PMID: 19323585]

Pasteur MC et al. British Thoracic Society guideline for non-CF bronchiectasis. *Thorax*. 2010 Jul;65 (Suppl 1):i1–58. [PMID: 20627931]

ALLERGIC BRONCHOPULMONARY MYCOSIS

Allergic bronchopulmonary mycosis is a pulmonary hypersensitivity disorder caused by allergy to fungal antigens that colonize the tracheobronchial tree. It usually occurs in atopic asthmatic individuals who are 20–40 years of age, in response to antigens of *Aspergillus* species. For this reason, the disorder is commonly referred to as allergic bronchopulmonary aspergillosis (ABPA). Primary criteria for the diagnosis of ABPA include (1) a clinical history of asthma, (2) peripheral eosinophilia, (3) immediate skin reactivity to *Aspergillus* antigen, (4) precipitating antibodies to *Aspergillus* antigen, (5) elevated serum IgE levels, (6) pulmonary infiltrates (transient or fixed), and (7) central bronchiectasis. If the first six of these seven primary criteria

are present, the diagnosis is almost certain. Secondary diagnostic criteria include identification of *Aspergillus* in sputum, a history of brown-flecked sputum, and late skin reactivity to *Aspergillus* antigen. High-dose prednisone (0.5–1 mg/kg orally per day) for at least 2 months is the treatment of choice, and the response in early disease is usually excellent. Depending on the overall clinical situation, prednisone can then be cautiously tapered. Relapses are frequent, and protracted or repeated treatment with corticosteroids is not uncommon. Patients with corticosteroid-dependent disease may benefit from itraconazole (200 mg orally three times a day with food for 3 days followed by twice daily for at least 16 weeks) without added toxicity. Bronchodilators (Table 9–6) are also helpful. Complications include hemoptysis, severe bronchiectasis, and pulmonary fibrosis.

Agarwal R. Allergic bronchopulmonary aspergillosis. *Chest*. 2009 Mar;135(3):805–26. [PMID: 19265090]

Riscili BP et al. Noninvasive pulmonary *Aspergillus* infections. *Clin Chest Med*. 2009 Jun;30(2):315–35. [PMID: 19375638]

CYSTIC FIBROSIS



ESSENTIALS OF DIAGNOSIS

- ▶ Chronic or recurrent productive cough, dyspnea, and wheezing.
- ▶ Recurrent airway infections or chronic colonization of the airways with *H influenzae*, *P aeruginosa*, *S aureus*, or *Burkholderia cepacia*. Bronchiectasis and scarring on chest radiographs.
- ▶ Airflow obstruction on spirometry.
- ▶ Pancreatic insufficiency, recurrent pancreatitis, distal intestinal obstruction syndrome, chronic hepatic disease, nutritional deficiencies, or male urogenital abnormalities.
- ▶ Sweat chloride concentration > 60 mEq/L on two occasions or gene mutation known to cause cystic fibrosis.

▶ General Considerations

Cystic fibrosis is the most common cause of severe chronic lung disease in young adults and the most common fatal hereditary disorder of whites in the United States. It is an autosomal recessive disorder affecting about 1 in 3200 whites; 1 in 25 is a carrier. Cystic fibrosis is caused by abnormalities in a membrane chloride channel (the cystic fibrosis transmembrane conductance regulator [CFTR] protein) that results in altered chloride transport and water flux across the apical surface of epithelial cells. Almost all exocrine glands produce an abnormal mucus that obstructs glands and ducts and leads to tissue damage. In the respiratory tract, inadequate hydration of the tracheobronchial epithelium impairs mucociliary function. High concentration of DNA in airway secretions (due to chronic airway inflammation and autolysis of neutrophils) increases

sputum viscosity. Over 1000 mutations in the gene that encodes CFTR have been described, and at least 230 mutations are known to be associated with clinical abnormalities. The mutation referred to as $\Delta F508$ accounts for about 60% of cases of cystic fibrosis.

Over one-third of the nearly 30,000 cystic fibrosis patients in the United States are adults. Because of the wide range of alterations seen in the CFTR protein structure and function, cystic fibrosis in adults may present with a variety of pulmonary and nonpulmonary manifestations. Patients with cystic fibrosis have an increased risk of malignancies of the gastrointestinal tract, osteopenia, and arthropathies.

▶ Clinical Findings

A. Symptoms and Signs

Cystic fibrosis should be suspected in a young adult with a history of chronic lung disease (especially bronchiectasis), pancreatitis, or infertility. Cough, sputum production, decreased exercise tolerance, and recurrent hemoptysis are typical complaints. Patients also often complain of chronic rhinosinusitis symptoms, steatorrhea, diarrhea, and abdominal pain. Patients with cystic fibrosis are often malnourished with low body mass index. Digital clubbing, increased anteroposterior chest diameter, hyperresonance on percussion, and apical crackles are noted on physical examination. Sinus tenderness, purulent nasal secretions, and nasal polyps may also be seen. Nearly all men with cystic fibrosis have congenital bilateral absence of the vas deferens with azoospermia. Biliary cirrhosis and gallstones may occur.

B. Laboratory Findings

Arterial blood gas studies often reveal hypoxemia and, in advanced disease, a chronic, compensated respiratory acidosis. Pulmonary function studies show a mixed obstructive and restrictive pattern. There is a reduction in FVC, airflow rates, and TLC. Air trapping (high ratio of RV to TLC) and reduction in pulmonary diffusing capacity are common.

C. Imaging

Hyperinflation is seen early in the disease process. Peribronchial cuffing, mucus plugging, bronchiectasis (ring shadows and cysts), increased interstitial markings, small rounded peripheral opacities, and focal atelectasis are common findings. Pneumothorax can also be seen. Thin-section CT scanning often confirms the presence of bronchiectasis.

D. Diagnosis

The quantitative pilocarpine iontophoresis sweat test reveals elevated sodium and chloride levels (> 60 mEq/L) in the sweat of patients with cystic fibrosis. Two tests on different days performed in experienced laboratories are required for accurate diagnosis. A normal sweat chloride test does not exclude the diagnosis in which case genotyping or other alternative diagnostic studies (such as measurement of nasal membrane potential difference, semen analysis, or

assessment of pancreatic function) should be pursued, especially if there is a high clinical suspicion of cystic fibrosis. Standard genotyping is a limited diagnostic tool because it screens for only a fraction of the known cystic fibrosis mutations, although complete genetic testing is available.

► Treatment

Early recognition and comprehensive multidisciplinary therapy improve symptom control and the chances of survival. Referral to a regional cystic fibrosis center is strongly recommended. Conventional treatment programs focus on the following areas: clearance and reduction of lower airway secretions, reversal of bronchoconstriction, treatment of respiratory tract infections and airway bacterial burden, pancreatic enzyme replacement, and nutritional and psychosocial support (including genetic and occupational counseling). The Pulmonary Therapies Committee, established by the Cystic Fibrosis Foundation, has issued evidenced-based recommendations regarding long-term use of medications for maintenance of lung function and reduction of exacerbations in patients with cystic fibrosis.

Clearance of lower airway secretions can be promoted by postural drainage, chest percussion or vibration techniques, positive expiratory pressure (PEP) or flutter valve breathing devices, directed cough, and other breathing techniques; these approaches require detailed patient instruction by experienced personnel. Sputum viscosity is increased by the large quantities of extracellular DNA that result from chronic airway inflammation and autolysis of neutrophils. Inhaled recombinant human deoxyribonuclease (rhDNase, dornase alpha) cleaves extracellular DNA in sputum; when administered long-term at a daily nebulized dose of 2.5 mg, this therapy leads to improved FEV₁ and reduces the risk of cystic fibrosis-related respiratory exacerbations and the need for intravenous antibiotics. Inhalation of hypertonic saline twice daily has been associated with small improvements in pulmonary function and fewer pulmonary exacerbations. The beneficial effects of hypertonic saline may derive from improved airway mucous clearance.

Short-term antibiotics are used to treat active airway infections based on results of culture and susceptibility testing of sputum. *S aureus* (including methicillin-resistant strains) and a mucoid variant of *P aeruginosa* are commonly present. *H influenzae*, *Stenotrophomonas maltophilia*, and *B cepacia* (a highly drug-resistant organism) are occasionally isolated. **Long-term administration of antibiotics** is helpful in slowing disease progression and reducing exacerbations in patients with sputum cultures positive for *P aeruginosa*. These antibiotics include azithromycin 500 mg orally three times a week, which has immunomodulatory properties, and various inhaled antibiotics (eg, tobramycin, aztreonam, colistin, and levofloxacin) taken two to three times a day. The length of therapy depends on the persistent presence of *P aeruginosa* in the sputum. The incidence of atypical mycobacterial colonization is higher in cystic fibrosis patients and directed antibiotic treatment is recommended for frequent exacerbations, progressive decline in lung function, or failure to thrive. Yearly screening with sputum acid-fast bacilli cultures is advised, especially in patients taking long-term macrolide therapy.

Inhaled bronchodilators (eg, albuterol, two puffs every 4 hours as needed) should be considered in patients who demonstrate an increase of at least 12% in FEV₁ after an inhaled bronchodilator. Vaccination against pneumococcal infection and annual influenza vaccination are advised. Screening of family members and genetic counseling are suggested. An inhaled corticosteroid should be added to the treatment regimen for patients who have cystic fibrosis with persistent asthma or allergic bronchopulmonary aspergillosis.

Ivacaftor is a new oral drug, available for the 5% of cystic fibrosis patients with a G551D mutation. Ivacaftor is a potentiator of the CFTR channel that works by increasing the time the channel remains open after being activated; it has been found to improve lung function by 10% within 2 weeks of treatment, decrease pulmonary exacerbations by 55%, and decrease sweat chloride into the indeterminate range. CFTR corrector therapy for the most common mutation ($\Delta F508$) is currently under trial.

Lung transplantation is currently the only definitive treatment for advanced cystic fibrosis. Double-lung or heart-lung transplantation is required. A few transplant centers offer living lobar lung transplantation to selected patients. The 3-year survival rate following transplantation for cystic fibrosis is about 55%.

Vaccination against pneumococcal infection and annual influenza vaccination are advised. Screening of family members and genetic counseling are suggested.

► Prognosis

The longevity of patients with cystic fibrosis is increasing, and the median survival age is over 35 years. Death occurs from pulmonary complications (eg, pneumonia, pneumothorax, or hemoptysis) or as a result of terminal chronic respiratory failure and cor pulmonale.

- Barto TL et al. Treatment of pulmonary exacerbations in adult cystic fibrosis patients: a review. *Hosp Pract (Minneap)*. 2010 Feb;38(1):26–34. [PMID: 20469621]
- Cohen-Cymerberknoh M et al. Managing cystic fibrosis: strategies that increase life expectancy and improve quality of life. *Am J Respir Crit Care Med*. 2011 Jun 1;183(11):1463–71. [PMID: 21330455]
- Flume PA et al; Cystic Fibrosis Foundation Pulmonary Therapies Committee. Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations. *Am J Respir Crit Care Med*. 2009 Nov 1;180(9):802–8. [PMID: 19729669]
- Flume PA et al; Cystic Fibrosis Foundation Pulmonary Therapies Committee. Cystic fibrosis pulmonary guidelines: pulmonary complications: hemoptysis and pneumothorax. *Am J Respir Crit Care Med*. 2010 Aug 1;182(3):298–306. [PMID: 20675678]
- Newton TJ. Respiratory care of the hospitalized patient with cystic fibrosis. *Respir Care*. 2009 Jun;54(6):769–75. [PMID: 19467163]
- O'Sullivan BP et al. Cystic fibrosis. *Lancet*. 2009 May 30;373(9678):1891–904. [PMID: 19403164]
- Ramsey BW et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. *N Engl J Med*. 2011 Nov 3;365(18):1663–72. [PMID: 2204755]

BRONCHIOLITIS



ESSENTIALS OF DIAGNOSIS

- ▶ Insidious onset of cough and dyspnea.
- ▶ Irreversible airflow obstruction on pulmonary function testing.
- ▶ Minimal findings on chest radiograph.
- ▶ Relevant exposure or risk factor: toxic fumes, viral infections, organ transplantation, connective tissue disease.

▶ General Considerations

Bronchiolitis is a generic term applied to varied inflammatory processes that affect the bronchioles, which are small conducting airways < 2 mm in diameter. In infants and children, bronchiolitis is common and usually caused by respiratory syncytial virus or adenovirus infection. In adults, bronchiolitis is less common but is encountered in multiple clinical settings. Disorders associated with bronchiolitis include organ transplantation, connective tissue diseases, and hypersensitivity pneumonitis. Inhalational injuries as well as postinfectious and drug-induced causes are identified by association with a known exposure or illness prior to the onset of symptoms. Idiopathic cases are characterized by the insidious onset of dyspnea or cough and include cryptogenic organizing pneumonitis (COP).

The clinical approach to bronchiolitis divides patients into groups based on etiology, but different clinical syndromes may have identical histopathological findings. As a result, no single classification scheme has been widely accepted, and there is an overlapping array of terms to describe these disorders from the viewpoints of the clinician, the pathologist, and the radiologist.

Histopathologic Findings

Acute bronchiolitis has a neutrophilic and mononuclear infiltration in the absence of fibroblast proliferation or collagen deposition. **Constrictive bronchiolitis** (also referred to as obliterative bronchiolitis, or bronchiolitis obliterans) is characterized by patchy chronic inflammation, concentric submucosal and peribronchiolar fibrosis, and smooth muscle hypertrophy causing luminal obstruction (obliteration).

In contrast to the minimally cellular pattern of constrictive bronchiolitis, **proliferative bronchiolitis** occurs when there is an organizing intraluminal exudate, consisting of fibroblasts, lipid laden (“foamy”) macrophages, and other cells that obstruct the bronchiolar lumen. These findings are more common than the constrictive pattern. When the organizing intraluminal exudate extends through the bronchiole into the alveolar space, with prominent intraluminal buds of fibroblasts embedded in immature collagen, the proliferative pattern is referred to as **cryptogenic organizing pneumonitis (COP)** formally referred to as **bronchiolitis obliterans with organizing pneumonia**

(BOOP) (see Table 9–20). **Follicular bronchiolitis** is characterized by chronic peribronchiolar inflammation and hyperplastic lymphoid follicles with reactive germinal centers arising from bronchus-associated lymphoid tissue (BALT). **Respiratory bronchiolitis** is a disorder of small airways in cigarette smokers characterized by accumulation of pigmented alveolar macrophages within respiratory bronchioles, associated with mild interstitial fibrosis and chronic inflammation. In some patients, however, respiratory bronchiolitis causes diffuse parenchymal infiltrates, a syndrome referred to as respiratory bronchiolitis–associated interstitial lung disease (RB-ILD) and considered with desquamative interstitial pneumonia (DIP) to represent part of the spectrum of the smoking-related interstitial lung diseases.

Diffuse panbronchiolitis is an idiopathic disorder of respiratory bronchioles, characterized by a peribronchiolar mixed inflammatory cell infiltrate and accumulation of lipid laden (“foamy”) macrophages within the interstitium and alveolar spaces.

▶ Clinical Findings

Acute bronchiolitis is most commonly seen following viral infection in children.

Constrictive bronchiolitis is relatively infrequent although it is the most common finding following inhalation injury. It may also be seen in rheumatoid arthritis; drug reactions; and chronic rejection following heart-lung, lung, or bone marrow transplant. Patients with constrictive bronchiolitis have airflow obstruction on spirometry; minimal radiographic abnormalities; and a progressive, deteriorating clinical course.

Proliferative bronchiolitis is associated with diverse pulmonary disorders including infection, aspiration, ARDS, hypersensitivity pneumonitis, connective tissue diseases, and organ transplantation. Compared with constrictive bronchiolitis, proliferative bronchiolitis is more likely to have an abnormal chest radiograph.

Cryptogenic organizing pneumonitis affects men and women between the ages of 50 and 70 years, typically with a dry cough, dyspnea, and constitutional symptoms that may be present for weeks to months prior to seeking medical attention. A history of a preceding viral illness is present in half of cases. Pulmonary function testing typically reveals a restrictive ventilatory defect and impaired oxygenation. The chest radiograph frequently shows bilateral patchy, ground-glass or alveolar infiltrates, although other patterns have been described (see Table 9–20).

Follicular bronchiolitis is most commonly associated with connective tissue disease, especially rheumatoid arthritis, and with immunodeficiency states.

Respiratory bronchiolitis usually occurs without symptoms or physiologic evidence of lung impairment.

Diffuse panbronchiolitis is most frequently diagnosed in Japan. Men are affected about twice as often as women, two-thirds are nonsmokers, and most patients have a history of chronic pansinusitis. Patients complain of dyspnea, cough, and sputum production, and chest examination shows crackles and rhonchi. Pulmonary function tests reveal obstructive abnormalities, and the chest radiograph

shows a distinct pattern of diffuse, small, nodular shadows with hyperinflation.

▶ Treatment

Constrictive bronchiolitis is relatively unresponsive to corticosteroids and is frequently progressive. Corticosteroids are effective in two-thirds of patients with **proliferative bronchiolitis**, and improvement can be prompt. Therapy is initiated with prednisone at 1 mg/kg/d orally for 1–3 months. The dose is then tapered slowly to 20–40 mg/d, depending on the response, and weaned over the subsequent 3–6 months as tolerated. Relapses are common if corticosteroids are stopped prematurely or tapered too quickly. Most patients with COP recover following corticosteroid treatment.

Drakopanagiotakis F et al. Cryptogenic and secondary organizing pneumonia: clinical presentation, radiographic findings, treatment response, and prognosis. *Chest*. 2011 Apr;139(4):893–900. [PMID: 20724743]

Pipavath SN et al. Imaging of Small Airway Disease (SAD). *Radiol Clin North Am*. 2009 Mar;47(2):307–16. [PMID: 19249458]

Rice A et al. The pathologist's approach to small airways disease. *Histopathology*. 2009 Jan;54(1):117–33. [PMID: 19187181]

Williams KM et al. Bronchiolitis obliterans after allogeneic hematopoietic stem cell transplantation. *JAMA*. 2009 Jul 15;302(3):306–14. [PMID: 19602690]

PULMONARY INFECTIONS

PNEUMONIA

1. Community-Acquired Pneumonia

ESSENTIALS OF DIAGNOSIS

- ▶ Fever or hypothermia, tachypnea, cough with or without sputum, dyspnea, chest discomfort, sweats or rigors (or both).
- ▶ Bronchial breath sounds or inspiratory crackles on chest auscultation.
- ▶ Parenchymal opacity on chest radiograph.
- ▶ Occurs outside of the hospital or within 48 hours of hospital admission in a patient not residing in a long-term care facility.

▶ General Considerations

Community-acquired pneumonia (CAP) is a common disorder, with approximately 4–5 million cases diagnosed each year in the United States, 25% of which require hospitalization. It is the most deadly infectious disease in the United States and the eighth leading cause of death. Mortality in milder cases treated as outpatients is < 1%. Among patients hospitalized for CAP, in-hospital mortality is approximately

Table 9–9. ATS/IDSA criteria for severe community-acquired pneumonia.

Major criteria ¹
Septic shock with need for vasopressor support
Respiratory failure with need for mechanical ventilation
Minor criteria ¹
Respiratory rate ≥ 30 breaths/min
Hypoxemia, defined as a $P_{aO_2}/F_{iO_2} \leq 250$
Hypothermia, with core temperature $< 36.0^\circ\text{C}$
Hypotension requiring aggressive intravenous fluid resuscitation
Confusion/disorientation
Multilobar pulmonary opacities
Leukopenia, due to infection, with white blood cell count $< 4.0 \times 10^9/\text{L}$
Thrombocytopenia, with platelet count $< 100 \times 10^9/\text{L}$
Uremia, with blood urea nitrogen level ≥ 7.1 mmol/L
Metabolic acidosis or elevated lactate level

¹Patients meeting either major criterion or three or more minor criteria generally require care in the intensive care unit.

ATS/IDSA, American Thoracic Society/Infectious Diseases Society of America.

Adapted, with permission of Oxford University Press, from Mandell LA et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. *Clin Infect Dis*. 2007;44:S27–72. [PMID: 17278083]

10–12% and 1-year mortality (in those over age 65) is > 40%. Risk factors for the development of CAP include advanced age; alcoholism; tobacco use; comorbid medical conditions, especially asthma or COPD; and immunosuppression. Markers of more severe illness are given in Table 9–9.

The patient's history, physical examination, and imaging studies are essential to establishing a diagnosis of CAP. None of these efforts identifies a specific microbiologic cause, however. Sputum examination may be helpful in selected patients but 40% of patients cannot produce an evaluable sputum sample and Gram stain and culture lack sensitivity for the most common causes of pneumonia. Since patient outcomes improve when the initial antibiotic choice is appropriate for the infecting organism, the American Thoracic Society and Infectious Disease Society of America recommend empiric treatment based on epidemiologic data (see Table 9–11). Such treatment improves initial antibiotic coverage, reduces unnecessary hospitalization, and appears to improve 30-day survival.

Decisions regarding hospitalization and ICU care should be based on prognostic criteria (see below).

▶ Definition & Pathogenesis

CAP is diagnosed outside of the hospital in ambulatory patients who are not residents of nursing homes or other long-term care facilities. It may also be diagnosed in a previously ambulatory patient within 48 hours after admission to the hospital.

Pulmonary defense mechanisms (cough reflex, mucociliary clearance system, immune responses) normally prevent the development of lower respiratory tract infections following aspiration of oropharyngeal secretions

containing bacteria or inhalation of infected aerosols. CAP occurs when there is a defect in one or more of these normal defense mechanisms or when a large infectious inoculum or a virulent pathogen overwhelms the immune response.

Prospective studies fail to identify the cause of CAP in 40–60% of cases; two or more causes are identified in up to 5% of cases. Bacteria are more commonly identified than viruses. The most common bacterial pathogen identified in most studies of CAP is *S pneumoniae*, accounting for approximately two-thirds of bacterial isolates. Other common bacterial pathogens include *H influenzae*, *M pneumoniae*, *C pneumoniae*, *S aureus*, *Neisseria meningitidis*, *M catarrhalis*, *Klebsiella pneumoniae*, other gram-negative rods, and *Legionella* species. Common viral causes of CAP include influenza virus, respiratory syncytial virus, adenovirus, and parainfluenza virus. A detailed assessment of epidemiologic risk factors may aid in diagnosing pneumonias due to the following uncommon causes: *Chlamydia psittaci* (psittacosis), *Coxiella burnetii* (Q fever), *Francisella tularensis* (tularemia), endemic fungi (*Blastomyces*, *Coccidioides*, *Histoplasma*), and sin nombre virus (hantavirus pulmonary syndrome).

► Clinical Findings

A. Symptoms and Signs

Most patients with CAP experience an acute or subacute onset of fever, cough with or without sputum production, and dyspnea. Other common symptoms include sweats, chills, rigors, chest discomfort, pleurisy, hemoptysis, fatigue, myalgias, anorexia, headache, and abdominal pain.

Common physical findings include fever or hypothermia, tachypnea, tachycardia, and arterial oxygen desaturation. Many patients appear acutely ill. Chest examination often reveals inspiratory crackles and bronchial breath sounds. Dullness to percussion may be observed if lobar consolidation or a parapneumonic pleural effusion is present. The clinical evaluation is < 50% sensitive compared to chest imaging for the diagnosis of CAP (see Imaging section below). In most patients, therefore, a chest radiograph is essential to the evaluation of suspected CAP.

B. Diagnostic Testing

Diagnostic testing for a specific infectious cause of CAP is not generally indicated in ambulatory patients treated as outpatients because empiric antibiotic therapy is almost always effective in this population. In ambulatory outpatients whose presentation (travel history, exposure) suggests an etiology not covered by standard therapy (eg, *Coccidioides*) or public health concerns (eg, *Mycobacterium tuberculosis*, influenza), diagnostic testing is appropriate. Diagnostic testing is recommended in hospitalized CAP patients for multiple reasons: the likelihood of an infectious cause unresponsive to standard therapy is higher in more severe illness, the inpatient setting allows narrowing of antibiotic coverage as specific diagnostic information is available, and the yield of testing is improved in more acutely ill patients.

Diagnostic testing results are used to guide initial antibiotic therapy, permit adjustment of empirically chosen

therapy to a specific infectious cause or resistance pattern, and facilitate epidemiologic analysis. There are three widely available, rapid point-of-care diagnostic tests that may guide initial therapy: the sputum Gram stain, urinary antigen tests for *S pneumoniae* and *Legionella* species, and rapid antigen detection tests for influenza. Sputum Gram stain is neither sensitive nor specific for *S pneumoniae*, the most common cause of CAP. The usefulness of a sputum Gram stain lies in broadening initial coverage in patients to be hospitalized for CAP, most commonly to cover *S aureus* (including community-acquired methicillin-resistant strains, CA-MRSA) or gram-negative rods. Urinary antigen assays for *Legionella pneumophila* and *S pneumoniae* are at least as sensitive and specific as sputum Gram stain and culture. Results are available immediately and are not affected by early initiation of antibiotic therapy. Positive tests may allow narrowing of initial antibiotic coverage. Rapid influenza testing has intermediate sensitivity but high specificity. Positive tests may reduce unnecessary antibacterial use and direct isolation of hospitalized patients.

Additional microbiologic testing including pre-antibiotic sputum and blood cultures (at least two sets with needle sticks at separate sites) has been standard practice for patients with CAP who require hospitalization. The yield of blood and sputum cultures is low. However, false-positive results are common, and the impact of culture results on patient outcomes is small. As a result, targeted testing based on specific indications is recommended (Table 9–10). Culture results are not available prior to initiation of antibiotic therapy. Their role is to allow narrowing of initial empiric antibiotic coverage, adjustment of coverage based on specific antibiotic resistance patterns, to identify unsuspected pathogens not covered by initial therapy, and to provide information for epidemiologic analysis.

Apart from microbiologic testing, hospitalized patients should undergo complete blood count with differential and a chemistry panel (including serum glucose, electrolytes, urea nitrogen, creatinine, bilirubin, and liver enzymes). Hypoxemic patients should have arterial blood gases sampled. Test results help assess severity of illness and guide evaluation and management. HIV testing should be considered in all adult patients, and performed in those with risk factors.

C. Imaging

A pulmonary opacity on chest radiography or CT scan is required to establish a diagnosis of CAP. Radiographic findings range from patchy airspace opacities to lobar consolidation with air bronchograms to diffuse alveolar or interstitial opacities. Additional findings can include pleural effusions and cavitation. Chest imaging cannot identify a specific microbiologic cause of CAP, however. There is no pattern of radiographic abnormalities pathognomonic of any infectious cause.

Chest imaging may help assess severity and response to therapy over time. Progression of pulmonary opacities during antibiotic therapy or lack of radiographic improvement over time are poor prognostic signs and also raise concerns about secondary or alternative pulmonary

Table 9–10. Clinical indications for more extensive diagnostic testing of patients with CAP.

Indication	Blood Culture	Sputum Culture	Legionella Urinary Antigen	Pneumococcal Urinary Antigen	Other
ICU admission	X	X	X	X	X ¹
Failure of outpatient antibiotic therapy		X	X	X	
Cavitary opacities	X	X			X ²
Leukopenia	X			X	
Active alcohol abuse	X	X	X	X	
Chronic severe liver disease	X			X	
Chronic obstructive or structural lung disease		X			
Asplenia	X			X	
Recent travel (within 2 weeks)			X		X ³
Positive <i>Legionella</i> urinary antigen test		X	n/a		
Positive pneumococcal urinary antigen test	X	X		n/a	
Pleural effusion	X	X	X	X	X ⁴

¹If intubated, endotracheal aspirate, or bronchoscopic or non-bronchoscopic bronchoalveolar lavage.

²Fungal and mycobacterial cultures.

³For pathogens related to specific travel and exposure history, see reference below.

⁴Thoracentesis and pleural fluid cultures.

Adapted, with permission of Oxford University Press, from Mandell LA et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. *Clin Infect Dis.* 2007;44:527–72. [PMID: 17278083]

processes. Clearing of pulmonary opacities in patients with CAP can take 6 weeks or longer. Clearance is usually quickest in younger patients, nonsmokers, and those with only single lobe involvement.

D. Special Examinations

Patients with CAP who have significant pleural fluid collections may require diagnostic thoracentesis (glucose, lactate dehydrogenase [LD], and total protein levels; leukocyte count with differential; pH determination) with pleural fluid Gram stain and culture. Positive pleural cultures indicate the need for tube thoracostomy drainage.

Sputum induction and fiberoptic bronchoscopy to obtain samples of lower respiratory secretions are indicated in patients who cannot provide expectorated sputum samples or who may have *Pneumocystis jiroveci* or *M tuberculosis* pneumonia.

Procalcitonin is a calcitonin precursor released in response to bacterial toxins and inhibited by viral infections. This divergent response to bacterial and viral infections offers laboratory support for a clinical judgment of a viral process in patients with lower respiratory symptoms. Multiple clinical trials have shown that procalcitonin measurement allows clinicians to reduce both initial administration of antibiotics and the duration of antibiotic therapy in CAP without compromising patient outcomes.

Serologic assays, polymerase chain reaction tests, specialized culture tests, and other diagnostic tests for organisms such as viruses, *Legionella*, *M pneumoniae*, and *C pneumoniae* may be performed when these diagnoses are suspected.

► Differential Diagnosis

The differential diagnosis of symptoms and signs of lower respiratory tract infection is extensive and includes upper respiratory tract infections, reactive airway diseases, congestive heart failure, cryptogenic organizing pneumonitis, lung cancer, pulmonary vasculitis, pulmonary thromboembolic disease, and atelectasis.

► Treatment

Two general principles guide antibiotic therapy once the diagnosis of CAP is established: **prompt** initiation of a drug to which the etiologic pathogen is **susceptible**.

In patients who require specific diagnostic evaluation, sputum and culture specimens should be obtained prior to initiation of antibiotics. Since early administration of antibiotics to acutely ill patients is associated with improved outcomes, obtaining diagnostic specimens or test results should not delay the initial dose of antibiotics by more than 6 hours from presentation.

Optimal antibiotic therapy would be pathogen directed, but a definitive microbiologic diagnosis is rarely available on or within 6 hours of presentation. A syndromic approach to therapy, based on clinical presentation and chest imaging, does not reliably predict the microbiology of CAP. Therefore, initial antibiotic choices are typically empiric, based on acuity (treatment as an outpatient, inpatient, or ICU), patient risk factors for specific pathogens, and local antibiotic resistance patterns (Table 9–11).

Since *S pneumoniae* remains a common cause of CAP in all patient groups, local prevalence of drug-resistant

S pneumoniae significantly affects initial antibiotic choice. Prior treatment with one antibiotic in a pharmacologic class (eg, β -lactam, macrolide, fluoroquinolone) predisposes the emergence of drug-resistant *S pneumoniae*, with resistance developing against that class of antibiotics to which the pathogen was previously exposed. Definitions of resistance have shifted based on observations of continued clinical efficacy at achievable serum levels. In CAP, for parenteral penicillin G or oral amoxicillin, susceptible strains have a minimum inhibitory concentration (MIC) ≤ 2 mcg/mL; intermediate resistance is defined as an MIC between 2 mcg/mL and 4 mcg/mL because treatment failures are uncommon with MIC ≤ 4 mcg/mL. Macrolide resistance has increased; approximately one-third of *S pneumoniae* isolates now show in vitro resistance to macrolides. Treatment failures have been reported but remain rare compared to the number of patients treated; current in vivo efficacy appears to justify maintaining macrolides as first-line therapy except in areas where there is a high prevalence of resistant strains. *S pneumoniae* resistant to fluoroquinolones is rare in the United States (1% to levofloxacin, 2% to ciprofloxacin) but is increasing.

Community-acquired methicillin-resistant *S aureus* (CA-MRSA) is genetically and phenotypically different from

hospital-acquired MRSA strains. Most produce Panton-Valentine leukocidin, a cytotoxin associated with tissue necrosis. CA-MRSA is a rare cause of necrotizing pneumonia, empyema, respiratory failure, and shock; it appears to be associated with prior influenza infection. Linezolid may be preferred to vancomycin in treatment of CA-MRSA pulmonary infection because linezolid may also act to reduce Panton-Valentine leukocidin toxin production. For expanded discussions of specific antibiotics, see Chapter 30.

A. Treatment of Outpatients

See Table 9–11 for specific drug dosages. The most common etiologies of CAP in outpatients who do not require hospitalization are *S pneumoniae*; *M pneumoniae*; *C pneumoniae*; and respiratory viruses, including influenza. For previously healthy patients with no recent (90 days) use of antibiotics, the recommended treatment is a macrolide (clarithromycin or azithromycin) or doxycycline.

In patients at risk for drug resistance (antibiotic therapy within the past 90 days, age > 65 years, comorbid illness, immunosuppression, exposure to a child in daycare), the recommended treatment is a respiratory fluoroquinolone

Table 9–11. Recommended empiric antibiotics for community-acquired pneumonia.

Outpatient management

- For previously healthy patients who have not taken antibiotics within the past 3 months:
 - A macrolide (clarithromycin, 500 mg orally twice a day; or azithromycin, 500 mg orally as a first dose and then 250 mg orally daily for 4 days, or 500 mg orally daily for 3 days), *or*
 - Doxycycline, 100 mg orally twice a day.
- For patients with such comorbid medical conditions as chronic heart, lung, liver, or renal disease; diabetes mellitus; alcoholism; malignancy; asplenia; immunosuppressant conditions or use of immunosuppressive drugs; or use of antibiotics within the previous 3 months (in which case, an alternative from a different antibiotic class should be selected):
 - A respiratory fluoroquinolone (moxifloxacin, 400 mg orally daily; gemifloxacin, 320 mg orally daily; levofloxacin, 750 mg orally daily) *or*
 - A macrolide (as above) *plus* a β -lactam (amoxicillin, 1 g orally three times a day; amoxicillin-clavulanate, 2 g orally twice a day are preferred to cefpodoxime, 200 mg orally twice a day; cefuroxime, 500 mg orally twice a day).
- In regions with a high rate (> 25%) of infection with high level (MIC ≥ 16 mcg/mL) macrolide-resistant *Streptococcus pneumoniae*, consider use of alternative agents listed above in (2) for patients with comorbidities.

Inpatient management not requiring intensive care

- A respiratory fluoroquinolone
 - See above for oral therapy.
 - For intravenous therapy, moxifloxacin, 400 mg daily; levofloxacin, 750 mg daily; ciprofloxacin, 400 mg every 8–12 hours *or*
- A macrolide *plus* a β -lactam
 - See above for oral therapy.
 - For intravenous therapy, ampicillin, 1–2 g every 4–6 hours; cefotaxime, 1–2 g every 4–12 hours; ceftriaxone, 1–2 g every 12–24 hours.

Inpatient intravenous management requiring intensive care

- Azithromycin (500 mg orally as a first dose and then 250 mg orally daily for 4 days, or 500 mg orally daily for 3 days) or a respiratory fluoroquinolone *plus* an antipneumococcal β -lactam (cefotaxime, ceftriaxone, or ampicillin-sulbactam, 1.5–3 g every 6 hours).
- For patients allergic to β -lactam antibiotics, a respiratory fluoroquinolone *plus* aztreonam (1–2 g every 6–12 hours).
- For patients at risk for *Pseudomonas* infection
 - An antipneumococcal, antipseudomonal β -lactam (piperacillin-tazobactam, 3.375–4.5 g every 6 hours; ceftazidime, 1–2 g twice a day; imipenem, 0.5–1 g every 6–8 hours; meropenem, 1 g every 8 hours) *plus* ciprofloxacin (400 mg every 8–12 hours) or levofloxacin, *or*
 - The above β -lactam *plus* an aminoglycoside (gentamicin, tobramycin, amikacin, all weight-based dosing administered daily adjusted to appropriate trough levels) *plus* azithromycin or a respiratory fluoroquinolone.
- For patients at risk for methicillin-resistant *Staphylococcus aureus* infection, add vancomycin (interval dosing based on renal function to achieve serum trough concentration 15–20 mcg/mL) *or* linezolid (600 mg twice a day).

MIC, minimum inhibitory concentration.

Adapted, with permission of Oxford University Press, from Mandell LA et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007;44:S27–72. [PMID: 17278083]

(moxifloxacin, gemifloxacin, or levofloxacin) or a macrolide plus a β -lactam (high-dose amoxicillin and amoxicillin-clavulanate are preferred to cefpodoxime and cefuroxime).

In regions where there is a high incidence of macrolide-resistant *S pneumoniae*, patients with no comorbidities may have a β -lactam added to a macrolide or use a respiratory fluoroquinolone as initial therapy.

There are limited data to guide recommendations for duration of treatment. The decision should be influenced by the severity of illness, the etiologic pathogen, response to therapy, other medical problems, and complications. Most expert recommendations suggest a minimum of 5 days of therapy and to continue antibiotics until the patient is afebrile for 48–72 hours. There appears to be no advantage to routinely extending antibiotic therapy beyond 3 days following clinical improvement with defervescence.

B. Treatment of Hospitalized Patients

The most common etiologies of CAP in patients who require hospitalization but not intensive care are *S pneumoniae*, *M pneumoniae*, *C pneumoniae*, *H influenzae*, *Legionella* species, and respiratory viruses. Some patients have aspiration as an immediate precipitant to the CAP without a specific bacterial etiology. First-line therapy in hospitalized patients is a respiratory fluoroquinolone (eg, moxifloxacin, gemifloxacin, or levofloxacin) or the combination of a macrolide (clarithromycin or azithromycin) plus a β -lactam (cefotaxime, ceftriaxone, or ampicillin) (see Table 9–11).

Almost all patients who are admitted to a hospital for treatment of CAP receive intravenous antibiotics. However, no studies demonstrated superior outcomes in hospitalized patients who received intravenous antibiotics compared with those who received oral antibiotics, as long as patients were able to tolerate the oral therapy and the drug was well absorbed. Duration of antibiotic treatment is the same as for outpatients with CAP.

The most common etiologies of CAP in patients who require admission to intensive care are *S pneumoniae*, *Legionella* species, *H influenzae*, *Enterobacteriaceae* species, *S aureus* and *Pseudomonas* species. First-line therapy in ICU patients with CAP is azithromycin or a respiratory fluoroquinolone (moxifloxacin, gemifloxacin, or levofloxacin) plus an antipneumococcal β -lactam (cefotaxime, ceftriaxone, or ampicillin-sulbactam). In patients at risk for *Pseudomonas* infection, use an antipneumococcal, antipseudomonal β -lactam (piperacillin-tazobactam, cefepime, imipenem, meropenem) plus ciprofloxacin or levofloxacin; the above antipneumococcal β -lactam plus an aminoglycoside (gentamicin, tobramycin, amikacin) plus azithromycin or a respiratory fluoroquinolone (moxifloxacin, gemifloxacin, or levofloxacin).

► Prevention

Polyvalent pneumococcal vaccine (containing capsular polysaccharide antigens of 23 common strains of *S pneumoniae*) has the potential to prevent or lessen the severity of the majority of pneumococcal infections in immunocompetent patients. Indications for pneumococcal vaccination include age ≥ 65 years or any chronic illness that increases the risk of CAP (see Chapter 30). Immunocompromised

patients and those at highest risk for fatal pneumococcal infections should receive a single revaccination 6 years after the first vaccination. Immunocompetent persons 65 years of age or older should receive a second dose of vaccine if the patient first received the vaccine 6 or more years previously and was under 65 years old at the time of vaccination.

The seasonal influenza vaccine is effective in preventing severe disease due to influenza virus with a resulting positive impact on both primary influenza pneumonia and secondary bacterial pneumonias. The seasonal influenza vaccine is administered annually to persons at risk for complications of influenza infection (age ≥ 65 years, residents of long-term care facilities, patients with pulmonary or cardiovascular disorders, patients recently hospitalized with chronic metabolic disorders) as well as health care workers and others who are able to transmit influenza to high-risk patients.

Hospitalized patients who would benefit from pneumococcal and influenza vaccines should be vaccinated during hospitalization. The vaccines can be given simultaneously, and there are no contraindications to use immediately after an episode of pneumonia.

► When to Admit

Once a diagnosis of CAP is made, the first management decision is to determine the site of care: Is it safe to treat the patient at home or does he or she require hospital or intensive care admission? There are two widely used clinical prediction rules available to guide admission and triage decisions, the Pneumonia Severity Index (PSI) and the CURB-65.

A. Hospital Admission Decision

The PSI is a validated prediction model that uses 20 items from demographics, medical history, physical examination, laboratory and imaging to stratify patients into five risk groups. The PSI is weighted toward discrimination at low predicted mortality. In conjunction with clinical judgment, it facilitates safe decisions to treat CAP in the outpatient setting. An on-line PSI risk calculator is available at <http://pda.ahrq.gov/clinic/psi/psicalc.asp>. The CURB-65 assesses five simple, independent predictors of increased mortality (confusion, uremia, respiratory rate, blood pressure and age > 65) to calculate a 30-day predicted mortality. Compared with the PSI, the simpler CURB-65 is less discriminating at low mortality but excellent at identifying patients with high mortality who may benefit from ICU level care. A modified version (CRB-65) dispenses with serum blood urea nitrogen and eliminates the need for laboratory testing. Both have the advantage of simplicity: Patients with zero CRB-65 predictors have a low predicted mortality ($< 1\%$) and usually do not need hospitalization; hospitalization should be considered for those with one or two predictors, since they have an increased risk of death, and urgent hospitalization is required for those with three or four predictors.

B. Intensive Care Unit Admission Decision

Expert opinion has defined major and minor criteria to identify patients at high risk for death (see Table 9–9). Either major criterion or three or more minor criteria of illness severity generally require ICU level care (see Table 9–9).

In addition to pneumonia-specific issues, good clinical practice always makes an admission decision in light of the whole patient. Additional factors that suggest the need for inpatient hospitalization include the following:

- Exacerbations of underlying disease that would benefit from hospitalization.
- Other medical or psychosocial needs (such as cognitive dysfunction, psychiatric disease, homelessness, drug abuse, lack of outpatient resources, or poor overall functional status).
- Failure of outpatient therapy, including inability to maintain oral intake and medications.

Brown SM et al. Validation of the Infectious Disease Society of America/American Thoracic Society 2007 guidelines for severe community-acquired pneumonia. *Crit Care Med*. 2009 Dec;37(12):3010–6. [PMID: 19789456]

Limper AH et al. An official American Thoracic Society statement: treatment of fungal infections in adult pulmonary and critical care patients. *Am J Respir Crit Care Med*. 2011 Jan 1;183(1):96–128. [PMID: 21193785]

Mandell LA et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. *Clin Infect Dis*. 2007 Mar 1;44(Suppl 2):S27–72. [PMID: 17278083]

Restrepo MI et al. Severe community-acquired pneumonia. *Infect Dis Clin North Am*. 2009 Sep;23(3):503–20. [PMID: 19665080]

Waterer GW et al. Management of community-acquired pneumonia in adults. *Am J Respir Crit Care Med*. 2011 Jan 15;183(2):157–64. [PMID: 20693379]

Watkins RR et al. Diagnosis and management of community-acquired pneumonia in adults. *Am Fam Physician*. 2011 Jun 1;83(11):1299–306. [PMID: 21661712]

2. Nosocomial Pneumonia (Hospital-Acquired, Ventilator-Associated, and Health Care–Associated)



ESSENTIALS OF DIAGNOSIS

- ▶ **Hospital-acquired pneumonia (HAP)** occurs > 48 hours after admission to the hospital or other health care facility and excludes any infection present at the time of admission.
- ▶ **Health care–associated pneumonia (HCAP)** occurs in community members whose extensive contact with healthcare has changed their risk for virulent and drug resistant organisms.
- ▶ At least two of the following: fever, leukocytosis, purulent sputum.
- ▶ New or progressive parenchymal opacity on chest radiograph.
- ▶ Especially common in patients requiring intensive care or mechanical ventilation.

▶ General Considerations

Hospitalized patients carry different flora with different resistance patterns than healthy patients in the community,

and their health status may place them at higher risk for more severe infection. The diagnostic approach and antibiotic treatment of patients with hospital-acquired pneumonia (HAP) is, therefore, different from patients with CAP. Similarly, management of patients in whom pneumonia develops following endotracheal intubation and mechanical ventilation (ventilator-associated pneumonia or VAP) should address issues specific to this group of patients. Some community members have extensive contact with the healthcare system and carry flora that more closely resemble hospitalized patients than healthy community residents. When pneumonia develops in these persons, the infection is referred to as health care–associated pneumonia (HCAP). Initial management and antibiotic therapy should be targeted to the common flora and specific risk factors for severe disease.

Considered together, these nosocomial pneumonias (HAP/VAP/HCAP) represent an important cause of morbidity and mortality despite widespread use of preventive measures, advances in diagnostic testing, and potent new antimicrobial agents. HAP is the second most common cause of infection among hospital inpatients and is the leading cause of death due to infection with mortality rates ranging from 20% to 50%. While a minority of cases occurs in ICU patients, the highest-risk patients are those in ICUs or who are being mechanically ventilated; these patients also experience higher morbidity and mortality from HAP. As management of more chronic illnesses shifts to the outpatient setting, more cases of HCAP are caused by unusual organisms, and there is a high frequency of drug resistance. Definitive identification of the infectious cause of a lower respiratory infection is rarely available on presentation, thus, rather than pathogen-directed antibiotic treatment, the choice of empiric therapy is informed by epidemiologic and patient data.

▶ Definition & Pathogenesis

HAP develops more than 48 hours after admission to the hospital and VAP develops in a mechanically ventilated patient more than 48 hours after endotracheal intubation. HCAP is defined as pneumonia that occurs in a nonhospitalized patient with extensive healthcare contact, and the risk factors for HCAP are outlined in Table 9–12.

Three factors distinguish nosocomial pneumonia from CAP: (1) different infectious causes; (2) different antibiotic susceptibility patterns, specifically, a higher incidence of drug resistance; and (3) the patients' underlying health status that puts them at risk for more severe infections. Since access to the lower respiratory tract occurs primarily through microaspiration, nosocomial pneumonia starts with a change in upper respiratory tract flora. Colonization of the pharynx and possibly the stomach with bacteria is the most important step in the pathogenesis of nosocomial pneumonia. Pharyngeal colonization is promoted by exogenous factors (eg, instrumentation of the upper airway with nasogastric and endotracheal tubes; contamination by dirty hands, equipment, and contaminated aerosols; and treatment with broad-spectrum antibiotics that promote the emergence of drug-resistant organisms) and patient factors (eg, malnutrition, advanced age, altered

Table 9–12. Risk factors for health care–associated pneumonia.

- Antibiotic therapy in the preceding 90 days.
- Acute care hospitalization for at least 2 days in the preceding 90 days.
- Residence in a nursing home or extended care facility.
- Home infusion therapy, including chemotherapy, within the past 30 days.
- Long-term dialysis within the past 30 days.
- Home wound care.
- Family member with an infection involving a multiple drug-resistant pathogen.
- Immunosuppressive disease or immunosuppressive therapy.

Adapted with permission of the American Thoracic Society. Copyright © American Thoracic Society. American Thoracic Society, Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated and healthcare-associated pneumonia. *Am J Respir Crit Care Med.* 2005;171(4):388-416. [PMID: 15699079]

consciousness, swallowing disorders, and underlying pulmonary and systemic diseases). Within 48 hours of admission, 75% of seriously ill hospitalized patients have their upper airway colonized with organisms from the hospital environment.

Impaired cellular and mechanical defense mechanisms in the lungs of hospitalized patients raise the risk of infection after aspiration has occurred. Tracheal intubation increases the risk of lower respiratory infection by mechanical obstruction of the trachea, impairment of mucociliary clearance, trauma to the mucociliary escalator system, and interference with coughing. Tight adherence of bacteria such as *Pseudomonas* to the tracheal epithelium and the biofilm that lines the endotracheal tube makes clearance of these organisms from the lower airway difficult.

The role of the stomach in the pathogenesis of HCAP remains controversial. Observational studies have suggested that elevation of gastric pH due to antacids, H₂-receptor antagonists, proton pump inhibitors (PPIs), or

Table 9–13. Organisms prevalent in nosocomial pneumonias.¹

- *Streptococcus pneumoniae*, often drug resistant, in HCAP
- *Staphylococcus aureus*, methicillin-sensitive (MSSA)
- *S aureus*, methicillin-resistant (MRSA)
- Gram-negative rods, non-ESBL
- ESBL-producing gram-negative rods including *Klebsiella pneumoniae*, *Escherichia coli* and *Enterobacter* species
- *Pseudomonas aeruginosa*
- *Acinetobacter* species

ESBL, extended spectrum β-lactamase producing.

¹Nosocomial pneumonias include hospital-associated pneumonia (HAP), ventilator-associated pneumonia (VAP), and health care-associated pneumonia (HCAP).

enteral feeding is associated with gastric microbial overgrowth, tracheobronchial colonization, and HAP/VAP. Sucralfate, a cytoprotective agent that does not alter gastric pH, is associated with a trend toward a lower incidence of VAP. The Infectious Disease Society of America recommends that acid suppressive medications (H₂-receptor antagonists and PPIs) only be given to patients at high risk for stress gastritis.

The microbiology of the nosocomial pneumonias differs from CAP but is substantially the same among HAP, VAP, and HCAP (Table 9–13). The most common organisms responsible for HAP include *S aureus* (both methicillin-sensitive *S aureus* and MRSA), *P aeruginosa*, gram-negative rods including non-extended spectrum β-lactamase (ESBL) producing and ESBL-producing (*Enterobacter* species, *K pneumoniae*, and *Escherichia coli*). VAP patients may be infected with *Acinetobacter* species and *Stenotrophomonas maltophilia*. HCAP patients may have common organisms (*S pneumoniae*, *H influenzae*) that are more likely to be drug resistant, or flora that resembles HAP. Anaerobic organisms (bacteroides, anaerobic streptococci, fusobacterium) may also cause pneumonia in the hospitalized patient; when isolated, they are commonly part of a polymicrobial flora. Mycobacteria, fungi, chlamydiae, viruses, rickettsiae, and protozoal organisms are uncommon causes of nosocomial pneumonias.

► Clinical Findings

A. Symptoms and Signs

The symptoms and signs associated with nosocomial pneumonias are nonspecific; however, two or more clinical findings (fever, leukocytosis, purulent sputum) in the setting of a new or progressive pulmonary opacity on chest radiograph are approximately 70% sensitive and 75% specific for the diagnosis of VAP in one study. Other findings include those listed above for CAP.

The differential diagnosis of new lower respiratory tract symptoms and signs in hospitalized patients includes congestive heart failure, atelectasis, aspiration, ARDS, pulmonary thromboembolism, pulmonary hemorrhage, and drug reactions.

B. Laboratory Findings

Diagnostic evaluation for suspected nosocomial pneumonia includes blood cultures from two different sites. Blood cultures can identify the pathogen in up to 20% of all patients with nosocomial pneumonias; positivity is associated with increased risk of complications and other sites of infection. Blood counts and clinical chemistry tests do not establish a specific diagnosis of HCAP; however, they help define the severity of illness and identify complications. The assessment of oxygenation by an arterial blood gas or pulse oximetry determination helps define the severity of illness and determines the need assisted ventilation. Thoracentesis for pleural fluid analysis should be considered in patients with pleural effusions.

Examination of sputum is attended by the same disadvantages as in CAP. Gram stains and cultures of sputum are

neither sensitive nor specific in the diagnosis of nosocomial pneumonias. The identification of a bacterial organism by culture of sputum does not prove that the organism is a lower respiratory tract pathogen. However, it can be used to help identify bacterial antibiotic sensitivity patterns and as a guide to adjusting empiric therapy.

C. Imaging

Radiographic findings in HAP/VAP are nonspecific and often confounded by other processes that led initially to hospitalization or ICU admission. (See also CAP section above.)

D. Special Examinations

Endotracheal aspiration using a sterile suction catheter and fiberoptic bronchoscopy with bronchoalveolar lavage or a protected specimen brush can be used to obtain lower respiratory tract secretions for analysis, most commonly in patients with VAP. Endotracheal aspiration cultures have significant negative predictive value but limited positive predictive value in the diagnosis of specific infectious causes of HAP/VAP. An invasive diagnostic approach using quantitative culture of bronchoalveolar lavage samples or protected specimen brush samples in patients in whom VAP is suspected leads to

significantly less antibiotic use, earlier attenuation of organ dysfunction, and fewer deaths at 14 days. Measurement of procalcitonin levels holds promise as a noninvasive strategy to distinguish bacterial pneumonia from noninfectious causes of fever with pulmonary infiltrates in hospitalized patients.

► Treatment

Treatment of the nosocomial pneumonias, like treatment of CAP, is usually empiric (Table 9–14). Because of the high mortality rate, therapy should be started as soon as pneumonia is suspected. There is no consensus on the best regimens because this patient population is heterogeneous and local flora and resistance patterns must be taken into account.

After results of sputum, blood, and pleural fluid cultures are available, it may be possible to de-escalate initially broad therapy. Duration of antibiotic therapy should be individualized based on the pathogen, severity of illness, response to therapy, and comorbid conditions. Data from a large trial assessing treatment outcomes in VAP suggest that 8 days of antibiotics is as effective as 15 days, except in cases caused by *P aeruginosa*.

For expanded discussions of specific antibiotics, see Chapter 30.

Table 9–14. Recommended empirical antibiotics for nosocomial pneumonias.¹

<p>When there is low risk for multiple drug-resistant pathogens, use one of the following:</p> <ul style="list-style-type: none"> Ceftriaxone, 1–2 g intravenously every 12–24 hours Gemifloxacin, 320 mg orally daily Moxifloxacin, 400 mg orally or intravenously daily Levofloxacin, 750 mg orally or intravenously daily Ciprofloxacin, 400 mg intravenously every 8–12 hours Ampicillin-sulbactam, 1.5–3 g intravenously every 6 hours Piperacillin-tazobactam 3.375–4.5 g intravenously every 6 hours Ertapenem, 1 g intravenously daily
<p>When there is higher risk for multiple drug-resistant pathogens, use one agent from each of the following categories:</p> <ol style="list-style-type: none"> 1. Antipseudomonal coverage <ol style="list-style-type: none"> a. Cefipime, 1–2 g intravenously twice a day <i>or</i> ceftazidime, 1–2 g intravenously every 8 hours b. Imipenem, 0.5–1 g intravenously every 6–8 hours <i>or</i> meropenem, 1 g intravenously every 8 hours c. Piperacillin-tazobactam, 3.375–4.5 g intravenously every 6 hours d. For penicillin allergic patients, aztreonam, 1–2 g intravenously every 6–12 hours 2. A second antipseudomonal agent <ol style="list-style-type: none"> a. Levofloxacin, 750 mg intravenously daily <i>or</i> ciprofloxacin, 400 mg intravenously every 8–12 hours b. Intravenous gentamicin, tobramycin, amikacin, all weight-based dosing administered daily adjusted to appropriate trough levels 3. Coverage for MRSA if appropriate with either <ol style="list-style-type: none"> a. Intravenous vancomycin (interval dosing based on renal function to achieve serum trough concentration 15–20 mcg/mL) <i>or</i> b. Linezolid, 600 mg intravenously twice a day

¹Nosocomial pneumonias includes hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP), and health care-associated pneumonia (HCAP).

MRSA, methicillin-resistant *Staphylococcus aureus*.

Adapted with permission of the American Thoracic Society. Copyright©

American Thoracic Society. American Thoracic Society, Infectious

Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated and healthcare-associated pneumonia. *Am J Respir Crit Care Med.* 2005;171(4):388-416. [PMID:15699079]

- Amin A et al. Health care-associated pneumonia. *Hosp Pract (Minneapolis)*. 2010 Jun;38(3):63–74. [PMID: 20499775]
- Bouadma L et al; for the PRORATA trial group. Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial. *Lancet*. 2010 Feb 6;375(9713):463–74. [PMID: 20097417]
- Brito V et al. Healthcare-associated pneumonia is a heterogeneous disease, and all patients do not need the same broad-spectrum antibiotic therapy as complex nosocomial pneumonia. *Curr Opin Infect Dis*. 2009 Jun;22(3):316–25. [PMID: 19352176]
- Esperatti M et al. Nosocomial pneumonia in the intensive care unit acquired by mechanically ventilated versus nonventilated patients. *Am J Respir Crit Care Med*. 2010 Dec 15;182(12):1533–9. [PMID: 20693381]
- O'Grady NP et al. Guidelines for evaluation of new fever in critically ill adult patients: 2008 update from the American College of Critical Care Medicine and the Infectious Diseases Society of America. *Crit Care Med*. 2008 Apr;36(4):1330–49. [PMID: 18379262]
- Sinuff T et al; Canadian Critical Care Trials Group. Ventilator-associated pneumonia: improving outcomes through guideline implementation. *J Crit Care*. 2008 Mar;23(1):118–25. [PMID: 18359429]
- Venditti M et al; Study Group of the Italian Society of Internal Medicine. Outcomes of patients hospitalized with community-acquired, health care-associated, and hospital-acquired pneumonia. *Ann Intern Med*. 2009 Jan 6;150(1):19–26. [PMID: 19124816]

3. Anaerobic Pneumonia & Lung Abscess

ESSENTIALS OF DIAGNOSIS

- ▶ History of or predisposition to aspiration.
- ▶ Indolent symptoms, including fever, weight loss, malaise.
- ▶ Poor dentition.
- ▶ Foul-smelling purulent sputum (in many patients).
- ▶ Infiltrate in dependent lung zone, with single or multiple areas of cavitation or pleural effusion.

▶ General Considerations

Aspiration of small amounts of oropharyngeal secretions occurs during sleep in normal individuals but rarely causes disease. Sequelae of aspiration of larger amounts of material include nocturnal asthma, chemical pneumonitis, mechanical obstruction of airways by particulate matter, bronchiectasis, and pleuropulmonary infection. Individuals predisposed to disease induced by aspiration include those with depressed levels of consciousness due to drug or alcohol use, seizures, general anesthesia, or central nervous system disease; those with impaired deglutition due to esophageal disease or neurologic disorders; and those with tracheal or nasogastric tubes, which disrupt the mechanical defenses of the airways.

Periodontal disease and poor dental hygiene, which increase the number of anaerobic bacteria in aspirated

material, are associated with a greater likelihood of anaerobic pleuropulmonary infection. Aspiration of infected oropharyngeal contents initially leads to pneumonia in dependent lung zones, such as the posterior segments of the upper lobes and superior and basilar segments of the lower lobes. Body position at the time of aspiration determines which lung zones are dependent. The onset of symptoms is insidious. By the time the patient seeks medical attention, necrotizing pneumonia, lung abscess, or empyema may be apparent.

Most aspiration patients with necrotizing pneumonia, lung abscess, and empyema are found to be infected with multiple species of anaerobic bacteria. Most of the remainder are infected with both anaerobic and aerobic bacteria. *Prevotella melaninogenica*, *Peptostreptococcus*, *Fusobacterium nucleatum*, and *Bacteroides* species are commonly isolated anaerobic bacteria.

▶ Clinical Findings

A. Symptoms and Signs

Patients with anaerobic pleuropulmonary infection usually present with constitutional symptoms such as fever, weight loss, and malaise. Cough with expectoration of foul-smelling purulent sputum suggests anaerobic infection, though the absence of productive cough does not rule out such an infection. Dentition is often poor. Patients are rarely edentulous; if so, an obstructing bronchial lesion is usually present.

B. Laboratory Findings

Expectorated sputum is inappropriate for culture of anaerobic organisms because of contaminating mouth flora. Representative material for culture can be obtained only by transthoracic aspiration, thoracentesis, or bronchoscopy with a protected brush. Transthoracic aspiration is rarely indicated, because drainage occurs via the bronchus and anaerobic pleuropulmonary infections usually respond well to empiric therapy.

C. Imaging

The different types of anaerobic pleuropulmonary infection are distinguished on the basis of their radiographic appearance. **Lung abscess** appears as a thick-walled solitary cavity surrounded by consolidation. An air-fluid level is usually present. Other causes of cavitary lung disease (tuberculosis, mycosis, cancer, infarction, granulomatosis with polyangiitis [formerly Wegener granulomatosis]) should be excluded. **Necrotizing pneumonia** is distinguished by multiple areas of cavitation within an area of consolidation. **Empyema** is characterized by the presence of purulent pleural fluid and may accompany either of the other two radiographic findings. Ultrasonography is of value in locating fluid and may also reveal pleural loculations.

▶ Treatment

Drugs of choice are clindamycin (600 mg intravenously every 8 hours until improvement, then 300 mg orally every

6 hours) or amoxicillin-clavulanate (875 mg orally every 12 hours). Penicillin (amoxicillin, 500 mg every 8 hours, or penicillin G, 1–2 million units intravenously every 4–6 hours) plus metronidazole (500 mg orally or intravenously every 8–12 hours) is another option. Penicillin alone is inadequate treatment for anaerobic pleuropulmonary infections because an increasing number of anaerobic organisms produce β -lactamases, and up to 20% of patients do not respond to penicillins. Antibiotic therapy for anaerobic pneumonia should be continued until the chest radiograph improves, a process that may take a month or more; patients with lung abscesses should be treated until radiographic resolution of the abscess cavity is demonstrated. Anaerobic pleuropulmonary disease requires adequate drainage with tube thoracostomy for the treatment of empyema. Open pleural drainage is sometimes necessary because of the propensity of these infections to produce loculations in the pleural space.

Marik PE. Aspiration syndromes: aspiration pneumonia and pneumonitis. *Hosp Pract (Minneap)*. 2010 Feb;38(1):35–42. [PMID: 20469622]

Shigemitsu H et al. Aspiration pneumonias: under-diagnosed and under-treated. *Curr Opin Pulm Med*. 2007 May;13(3):192–8. [PMID: 17414126]

PULMONARY INFILTRATES IN THE IMMUNOCOMPROMISED HOST

Pulmonary infiltrates in immunocompromised patients (patients with HIV disease, absolute neutrophil counts < 1000/mcL, current or recent exposure to myelosuppressive or immunosuppressive drugs, or those currently taking > 5 mg/d prednisone) may arise from infectious or noninfectious causes. Infection may be due to bacterial, mycobacterial, fungal, protozoal, helminthic, or viral pathogens. Noninfectious processes such as pulmonary edema, alveolar hemorrhage, drug reactions, pulmonary thromboembolic disease, malignancy, and radiation pneumonitis may mimic infection.

Although almost any pathogen can cause pneumonia in a compromised host, two clinical tools help the clinician narrow the differential diagnosis. The first is knowledge of the underlying immunologic defect. Specific immunologic defects are associated with particular infections. Defects in humoral immunity predispose to bacterial infections; defects in cellular immunity lead to infections with viruses, fungi, mycobacteria, and protozoa. Neutropenia and impaired granulocyte function predispose to infections from *S aureus*, *Aspergillus*, gram-negative bacilli, and *Candida*. Second, the time course of infection also provides clues to the etiology of pneumonia in immunocompromised patients. A fulminant pneumonia is often caused by bacterial infection, whereas an insidious pneumonia is more apt to be caused by viral, fungal, protozoal, or mycobacterial infection. Pneumonia occurring within 2–4 weeks after organ transplantation is usually bacterial, whereas several months or more after transplantation *P jiroveci*, viruses (eg, cytomegalovirus), and fungi (eg, *Aspergillus*) are encountered more often.

Clinical Findings

Chest radiography is rarely helpful in narrowing the differential diagnosis. Examination of expectorated sputum for bacteria, fungi, mycobacteria, *Legionella*, and *P jiroveci* is important and may preclude the need for expensive, invasive diagnostic procedures. Sputum induction is often necessary for diagnosis. The sensitivity of induced sputum for detection of *P jiroveci* depends on institutional expertise, number of specimens analyzed, and detection methods.

Routine evaluation frequently fails to identify a causative organism. The clinician may begin empiric antimicrobial therapy before proceeding to invasive procedures such as bronchoscopy, transthoracic needle aspiration, or open lung biopsy. The approach to management must be based on the severity of the pulmonary infection, the underlying disease, the risks of empiric therapy, and local expertise and experience with diagnostic procedures. Bronchoalveolar lavage using the flexible bronchoscope is a safe and effective method for obtaining representative pulmonary secretions for microbiologic studies. It involves less risk of bleeding and other complications than bronchial brushing and transbronchial biopsy. Bronchoalveolar lavage is especially suitable for the diagnosis of *P jiroveci* pneumonia in patients with AIDS when induced sputum analysis is negative. Surgical lung biopsy, now often performed by video-assisted thoracoscopy, provides the definitive option for diagnosis of pulmonary infiltrates in the immunocompromised host. However, a specific diagnosis is obtained in only about two-thirds of cases, and the information obtained rarely affects the outcome.

Corti M et al. Respiratory infections in immunocompromised patients. *Curr Opin Pulm Med*. 2009 May;15(3):209–17. [PMID: 19276812]

Crothers K et al. HIV infection and risk for incident pulmonary diseases in the combination antiretroviral therapy era. *Am J Respir Crit Care Med*. 2011 Feb 1;183(3):388–95. [PMID: 20851926]

Remund KF et al. Infections relevant to lung transplantation. *Proc Am Thorac Soc*. 2009 Jan 15;6(1):94–100. [PMID: 19131534]

Safadi AR et al. Diagnostic approach of pulmonary disease in the HIV negative immunocompromised host. *Eur J Intern Med*. 2009 May;20(3):268–79. [PMID: 19393494]

PULMONARY TUBERCULOSIS



ESSENTIALS OF DIAGNOSIS

- ▶ Fatigue, weight loss, fever, night sweats, and productive cough.
- ▶ Risk factors for acquisition of infection: household exposure, incarceration, drug use, travel to an endemic area.
- ▶ Chest radiograph: pulmonary opacities, most often apical.
- ▶ Acid-fast bacilli on smear of sputum or sputum culture positive for *M tuberculosis*.

► General Considerations

Tuberculosis is one of the world's most widespread and deadly illnesses. *M tuberculosis*, the organism that causes tuberculosis infection and disease, infects one-third of the world's population. In 2009, there were 9.4 million new cases of tuberculosis worldwide with 1.7 million people dying of the disease. In the United States, an estimated 11 million people are infected with *M tuberculosis*. Tuberculosis occurs disproportionately among disadvantaged populations such as the malnourished, homeless, and those living in overcrowded and substandard housing. There is an increased occurrence of tuberculosis among HIV-positive individuals.

Infection with *M tuberculosis* begins when a susceptible person inhales airborne droplet nuclei containing viable organisms. Tubercle bacilli that reach the alveoli are ingested by alveolar macrophages. Infection follows if the inoculum escapes alveolar macrophage microbicidal activity. Once infection is established, lymphatic and hematogenous dissemination of tuberculosis typically occurs before the development of an effective immune response. This stage of infection, **primary tuberculosis**, is usually clinically and radiographically silent. In most persons with intact cell-mediated immunity, T cells and macrophages surround the organisms in granulomas that limit their multiplication and spread. The infection is contained but not eradicated, since viable organisms may lie dormant within granulomas for years to decades.

Individuals with **latent tuberculosis infection** do not have active disease and cannot transmit the organism to others. However, reactivation of disease may occur if the host's immune defenses are impaired. Active tuberculosis will develop in approximately 6% of individuals with latent tuberculosis infection who are not given preventive therapy; half of these cases occur in the 2 years following primary infection. Diverse conditions such as gastrectomy, silicosis, diabetes mellitus, and an impaired immune response (eg, HIV infection; therapy with corticosteroids, tumor necrosis factor inhibitors or other immunosuppressive drugs) are associated with an increased risk of reactivation.

In approximately 5% of cases, the immune response is inadequate to contain the primary infection and **progressive primary tuberculosis** develops, accompanied by both pulmonary and constitutional symptoms as described below. The clinical presentation does not definitively distinguish primary disease from reactivation of latent tuberculosis infection. Standard teaching has held that 90% of tuberculosis in adults represents activation of latent disease. However, DNA fingerprinting of the bacillus suggests that as many as one-third of new cases of tuberculosis in urban populations are primary infections resulting from person-to-person transmission.

The prevalence of drug-resistant strains is increasing worldwide; however, in the United States, the rate of drug-resistant isolates has fallen to < 1%. Risk factors for drug resistance include immigration from countries with a high prevalence of drug-resistant tuberculosis, close and prolonged contact with individuals with drug-resistant tuberculosis, unsuccessful previous therapy, and nonadherence

to treatment. Drug resistance may be single or multiple. **Drug-resistant tuberculosis** is resistant to one first-line antituberculous drug, either isoniazid or rifampin. **Multidrug-resistant tuberculosis** is resistant to isoniazid and rifampin, and possibly additional agents. **Extensively drug-resistant tuberculosis** is resistant to isoniazid, rifampin, fluoroquinolones, and either aminoglycosides or capreomycin or both. Outcomes of drug-resistant tuberculosis treatment are worse than when the isolate is drug-sensitive, but outcomes appear to vary with HIV status. One retrospective study conducted in the United States showed that 97% of HIV-negative patients were cured of multidrug-resistant tuberculosis, while all 11 HIV-positive patients died. In a review of extensively drug-resistant tuberculosis cases in the United States, mortality was 10% and 68% in HIV-negative and HIV-positive patients, respectively. In one South African study, 52 of 53 HIV-positive patients with extensively drug-resistant tuberculosis died (median survival was 16 days from time of diagnosis).

► Clinical Findings

A. Symptoms and Signs

The patient with pulmonary tuberculosis typically presents with slowly progressive constitutional symptoms of malaise, anorexia, weight loss, fever, and night sweats. Chronic cough is the most common pulmonary symptom. It may be dry at first but typically becomes productive of purulent sputum as the disease progresses. Blood-streaked sputum is common, but significant hemoptysis is rarely a presenting symptom; life-threatening hemoptysis may occur in advanced disease. Dyspnea is unusual unless there is extensive disease. Rarely, the patient is asymptomatic. On physical examination, the patient appears chronically ill and malnourished. On chest examination, there are no physical findings specific for tuberculosis infection. The examination may be normal or may reveal classic findings such as posttussive apical rales.

B. Laboratory Findings

Definitive diagnosis depends on recovery of *M tuberculosis* from cultures or identification of the organism by DNA or RNA amplification techniques. Three consecutive morning sputum specimens are advised. Fluorochrome staining with rhodamine-auramine of concentrated, digested sputum specimens is performed initially as a screening method, with confirmation by the Kinyoun or Ziehl-Neelsen stains. Demonstration of acid-fast bacilli on sputum smear does not establish a diagnosis of *M tuberculosis*, since nontuberculous mycobacteria may colonize the airways and are increasingly recognized to cause clinical illness in patients with underlying structural lung disease.

In patients thought to have tuberculosis who cannot produce satisfactory specimens or when the smear of the spontaneously expectorated sputum is negative for acid-fast bacilli, sputum induction with 3% hypertonic saline should be performed. Flexible bronchoscopy with bronchial washings has similar diagnostic yield to induced sputum;

transbronchial lung biopsies do not significantly increase the diagnostic yield but may lead to earlier diagnosis by identifying tissue granulomas. Post-bronchoscopy expectorated sputum specimens should be collected. Early morning aspiration of gastric contents after an overnight fast is suitable only for culture and not for stained smear because nontuberculous mycobacteria may be present in the stomach in the absence of tuberculous infection. Positive blood cultures for *M tuberculosis* are uncommon in patients with normal CD4 cell counts but the organism may be cultured from blood in up to 50% of HIV-seropositive patients with tuberculosis whose CD4 cell counts are < 100/mcL.

Traditional light-microscopic examination of stained sputum for acid-fast bacilli and culture of sputum specimens remain the mainstay of tuberculosis diagnosis. The slow rate of mycobacterial growth, the urgency to provide early, appropriate treatment to patients to improve their outcomes and limit community spread, and concerns about potential drug toxicities in patients treated empirically who do not have tuberculosis infection, have fostered interest in rapid diagnostic techniques (see Table 9–15). Molecular diagnostics offer multiple options and many

advantages at significant increased expense. Nucleic acid amplification testing not only detects *M tuberculosis* (NAAT-TB) but it also identifies resistance markers (NAAT-R). NAAT-TB can identify *M tuberculosis* within hours of sputum processing, allowing early isolation and treatment, but the negative predictive value is low in smear-negative patients. NAAT-R allows rapid identification of primary drug resistance and is indicated in the following patients: (1) those treated previously for tuberculosis, (2) those born (or who lived for > 1 year) in a country with moderate tuberculosis incidence or a high incidence of multiple drug-resistant isolates, (3) contacts of patients with multidrug-resistant tuberculosis, or (4) those who are HIV seropositive. Clinical suspicion remains the critical factor in interpreting all these studies. Standard drug susceptibility testing of culture isolates is considered routine for the first isolate of *M tuberculosis*, when a treatment regimen is failing, and when sputum cultures remain positive after 2 months of therapy.

Needle biopsy of the pleura reveals granulomatous inflammation in approximately 60% of patients with pleural effusions caused by *M tuberculosis*. Pleural fluid cultures

Table 9-15. Essential laboratory tests for the detection of *Mycobacterium tuberculosis*.¹

Test	Time to Result	Test Characteristics
Acid-fast bacilli light microscopy	1 day	Three morning specimens recommended. Combined sensitivity of 70% (54% for the first specimen, 11% for the second specimen, and 5% for the third specimen). First morning specimen increased yield by 12% compared to spot specimen.
Nucleic acid amplification test, detection (NAAT-TB)	1 day	Sensitivity/specificity high for smear-positive specimens, 85–97% for both, but sensitivity falls in smear-negative specimens to ~66%. Therefore, a positive NAAT in smear-negative patients with intermediate to high (> 30%) pretest probability of <i>M tuberculosis</i> infection is helpful while a negative NAAT is not. Should not be ordered in patients with low pretest probability of <i>M tuberculosis</i> infection.
Nucleic acid amplification test, resistance markers (NAAT-R)	1–2 days	Multiple assays for rifampin and isoniazid are available. Specificity uniformly high, > 98%. Sensitivity varies from about 84% to 96% increases with multiple specimens. See text for indications for testing.
Mycobacterial growth detection Liquid (broth based) medium Solid (agar or egg based) medium	Up to 6–8 weeks Avg 10–14 days Avg 3–4 weeks	Liquid culture methods are more sensitive (~90% and 76%, respectively) with shorter time to detection but higher contamination with bacterial growth than solid culture methods. Specificity exceeds 99% for all methods.
Identification of <i>M tuberculosis</i> complex by DNA probe or high performance liquid chromatography	1 day ¹	May be useful in areas of low <i>M tuberculosis</i> incidence where nontuberculous mycobacteria are commonly isolated.
First-line drug susceptibility testing (liquid medium)	1–2 weeks ¹	Gold standard. Should be performed routinely on the initial isolate.
Second-line and novel compound drug susceptibility testing Liquid (broth based) medium Solid (agar or egg based) medium	1–2 weeks ¹ 3–4 weeks ¹	

¹Following detection of mycobacterial growth.


Adapted, with permission, from Diagnostic Standards and Classification of Tuberculosis in Adults and Children. This official statement of the American Thoracic Society and the Centers for Disease Control and Prevention was adopted by the ATS Board of Directors, July 1999. This statement was endorsed by the Council of the Infectious Disease Society of America, September 1999. *Am J Respir Crit Care Med.* 2000 Apr;161(4 Pt 1):1376-95.

for *M tuberculosis* are positive in less than 23–58% of cases of pleural tuberculosis. Culture of three pleural biopsy specimens combined with microscopic examination of a pleural biopsy yields a diagnosis in up to 90% of patients with pleural tuberculosis. Tests for pleural fluid adenosine deaminase (approximately 90% sensitivity and specificity for pleural tuberculosis at levels > 70 units/L) and interferon-gamma (89% sensitivity, 97% specificity in a recent meta-analysis) can be extremely helpful diagnostic aids, particularly in making decisions to pursue invasive testing in complex cases.

C. Imaging

Contrary to traditional teaching, molecular analysis demonstrates that radiographic abnormalities in pulmonary tuberculosis do not distinguish primary disease from reactivation of latent tuberculosis. The only independent predictor of an atypical pattern on chest radiograph—that is, not associated with upper lobe or cavitory disease—is an impaired host immune response.

The chest imaging pattern traditionally associated with primary disease includes small unilateral infiltrates, hilar and paratracheal lymph node enlargement, and segmental atelectasis. Pleural effusion is present in 30–40% of patients, sometimes as the sole radiographic abnormality. Reactivation tuberculosis traditionally has been associated with fibrocavitary apical disease (Figure 9–5), discrete nodules, and pneumonic infiltrates, usually in the apical or posterior segments of the upper lobes or in the superior segments of the lower lobes. Radiographic evidence of disease in other locations may be present in up to 30% of patients. This is especially true in elderly patients, in whom lower lobe infiltrates with or without pleural effusion are frequently encountered. Lower lung tuberculosis may masquerade as pneumonia or lung cancer. A “miliary” pattern (diffuse small nodular densities) can be seen with



▲ **Figure 9–5.** Advanced bilateral pulmonary tuberculosis. (Public Health Image Library, CDC.)

hematologic or lymphatic dissemination of the organism. Immunocompromised patients—particularly those with late-stage HIV infection—often display lower lung zone, diffuse, or miliary infiltrates; pleural effusions; and involvement of hilar and, in particular, mediastinal lymph nodes.

Resolution of active tuberculosis leaves characteristic radiographic findings. Dense nodules in the pulmonary hila, with or without obvious calcification, upper lobe fibronodular scarring, and bronchiectasis with volume loss are common findings. Ghon (calcified primary focus) and Ranke (calcified primary focus and calcified hilar lymph node) complexes are seen in a minority of patients.

D. Special Examinations

Testing for latent tuberculosis infection is used to evaluate an asymptomatic person in whom *M tuberculosis* infection is suspected (eg, following contact exposure) or to establish the prevalence of tuberculosis infection in a population. Testing may be used in a person with symptoms of active tuberculosis, but a positive test does not distinguish between active and latent infection. Routine testing of individuals at low risk for tuberculosis is not recommended.

The traditional approach to latent tuberculosis infection is the **tuberculin skin test**. The Mantoux test is the preferred method: 0.1 mL of purified protein derivative (PPD) containing 5 tuberculin units is injected intradermally on the volar surface of the forearm using a 27-gauge needle on a tuberculin syringe. The transverse width in millimeters of induration at the skin test site is measured after 48–72 hours. To optimize test performance, criteria for determining a positive reaction vary depending on the likelihood of infection. Table 9–16 summarizes the criteria established by the Centers for Disease Control and Prevention for interpretation of the Mantoux tuberculin skin test. Sensitivity and specificity of the tuberculin skin test are high: 77% and 97%, respectively. Specificity falls to 59% in populations previously vaccinated with bacillus Calmette-Guérin (BCG, an extract of *Mycobacterium bovis*). False-negative tuberculin skin test reactions may result from improper testing technique; concurrent infections, including fulminant tuberculosis; malnutrition; advanced age; immunologic disorders; malignancy; corticosteroid therapy; chronic kidney disease; and HIV infection. Some individuals with latent tuberculosis infection may have a negative tuberculin skin test when tested many years after exposure. Anergy testing is not recommended for routine use to distinguish a true-negative result from anergy. Poor anergy test standardization and lack of outcome data limit the evaluation of its effectiveness. Interpretation of the tuberculin skin test in persons who have previously received BCG vaccination is the same as in those who have not had BCG.

Interferon gamma release assays are in vitro assays of CD4+ T-cell-mediated interferon gamma release in response to stimulation by specific *M tuberculosis* antigens. The antigens are absent from all BCG strains and most nontuberculous mycobacteria; therefore, in whole blood, the specificity of interferon gamma release assays is

Table 9–16. Classification of positive tuberculin skin test reactions.¹

Induration Size	Group
≥ 5 mm	<ol style="list-style-type: none"> 1. HIV-positive persons. 2. Recent contacts of individuals with active tuberculosis. 3. Persons with fibrotic changes on chest x-rays suggestive of prior tuberculosis. 4. Patients with organ transplants and other immunosuppressed patients (receiving the equivalent of > 15 mg/d of prednisone for 1 month or more).
≥ 10 mm	<ol style="list-style-type: none"> 1. Recent immigrants (< 5 years) from countries with a high prevalence of tuberculosis (eg, Asia, Africa, Latin America). 2. HIV-negative injection drug users. 3. Mycobacteriology laboratory personnel. 4. Residents of and employees² in the following high-risk congregate settings: correctional institutions; nursing homes and other long-term facilities for the elderly; hospitals and other health care facilities; residential facilities for AIDS patients; and homeless shelters. 5. Persons with the following medical conditions that increase the risk of tuberculosis: gastrectomy, ≥ 10% below ideal body weight, jejunioileal bypass, diabetes mellitus, silicosis, advanced chronic kidney disease, some hematologic disorders, (eg, leukemias, lymphomas), and other specific malignancies (eg, carcinoma of the head or neck and lung). 6. Children < 4 years of age or infants, children, and adolescents exposed to adults at high risk.
≥ 15 mm	<ol style="list-style-type: none"> 1. Persons with no risk factors for tuberculosis.

¹A tuberculin skin test reaction is considered positive if the transverse diameter of the *indurated* area reaches the size required for the specific group. All other reactions are considered negative.

²For persons who are otherwise at low risk and are tested at entry into employment, a reaction of > 15 mm induration is considered positive.

Data from Screening for tuberculosis and tuberculosis infection in high-risk populations: recommendations of the Advisory Council for the Elimination of Tuberculosis. *MMWR Morb Mortal Wkly Rep* 1995 Sep 8;44(RR-11):19–34. [PMID: 7565540]

superior to the tuberculin skin test in BCG-vaccinated individuals. Sensitivity is comparable to the tuberculin skin test: 60–90% depending on the specific assay and study population. Sensitivity is reduced by HIV infection, particularly in patients with low CD4 counts. Specificity is high, > 95%. Potential advantages of interferon gamma release assay testing include fewer false-positive results from prior BCG vaccination, better discrimination of positive responses due to nontuberculous mycobacteria, and the requirement for only one patient contact (ie, no need for the patient to return to have the tuberculin skin test read 48–72 hours later). Disadvantages include the need for specialized laboratory equipment and personnel, and the substantially increased cost compared to the tuberculin skin test.

In endemic areas, interferon gamma release assays are no more sensitive than the tuberculin skin test in active tuberculosis (20–40% false-negative rate) and cannot distinguish active from latent disease. Interferon gamma release assays should not be used to exclude active tuberculosis.

Guidelines established by the US Centers for Disease Control and Prevention allow interferon gamma release assays to be used interchangeably with the tuberculin skin testing in the diagnosis of latent tuberculosis infection. Interferon gamma release assays are preferred in patients with prior BCG vaccination; the tuberculin skin test is preferred in children under 5 years old. Routine use of both tests is not recommended. In individuals with a positive tuberculin skin test but a low prior probability of latent tuberculosis infection and low risk for progression to active disease, the interferon gamma release assay may be helpful

as a confirmatory test to exclude a false-positive tuberculin skin test.

▶ Treatment

A. General Measures

The goals of therapy are to eliminate all tubercle bacilli from an infected individual while avoiding the emergence of clinically significant drug resistance. The basic principles of antituberculous treatment are (1) to administer multiple drugs to which the organisms are susceptible; (2) to add at least two new antituberculous agents to a regimen when treatment failure is suspected; (3) to provide the safest, most effective therapy in the shortest period of time; and (4) to ensure adherence to therapy.

All suspected and confirmed cases of tuberculosis should be reported promptly to local and state public health authorities. Public health departments will perform case investigations on sources and patient contacts to determine if other individuals with untreated, infectious tuberculosis are present in the community. They can identify infected contacts eligible for treatment of latent tuberculosis infection, and ensure that a plan for monitoring adherence to therapy is established for each patient with tuberculosis. Patients with tuberculosis should be treated by clinicians who are skilled in the management of this infection. Clinical expertise is especially important in cases of drug-resistant tuberculosis.

Nonadherence to antituberculous treatment is a major cause of treatment failure, continued transmission of tuberculosis, and the development of drug resistance. Adherence to treatment can be improved by providing

detailed patient education about tuberculosis and its treatment in addition to a case manager who oversees all aspects of an individual patient's care. **Directly observed therapy (DOT)**, which requires that a health care worker physically observe the patient ingest antituberculous medications in the home, clinic, hospital, or elsewhere, also improves adherence to treatment. The importance of direct observation of therapy cannot be overemphasized. The CDC recommends DOT for all patients with drug-resistant tuberculosis and for those receiving intermittent (twice- or thrice-weekly) therapy.

Hospitalization for initial therapy of tuberculosis is not necessary for most patients. It should be considered if a patient is incapable of self-care or is likely to expose new, susceptible individuals to tuberculosis. Hospitalized patients with active disease require a private room with negative-pressure ventilation until tubercle bacilli are no longer found in their sputum ("smear-negative") on three consecutive smears taken on separate days.

Characteristics of antituberculous drugs are provided in Table 9–17. Additional treatment considerations can be

found in Chapter 33. More complete information can be obtained from the CDC's Division of Tuberculosis Elimination Web site at <http://www.cdc.gov/tb/>.

B. Treatment of Tuberculosis in HIV-Negative Persons

Most patients with previously untreated pulmonary tuberculosis can be effectively treated with either a 6-month or a 9-month regimen, though the 6-month regimen is preferred. The initial phase of a 6-month regimen consists of 2 months of daily isoniazid, rifampin, pyrazinamide, and ethambutol. Once the isolate is determined to be isoniazid-sensitive, ethambutol may be discontinued. If the *M tuberculosis* isolate is susceptible to isoniazid and rifampin, the second phase of therapy consists of isoniazid and rifampin for a minimum of 4 additional months, with treatment to extend at least 3 months beyond documentation of conversion of sputum cultures to negative for *M tuberculosis*. If DOT is used, medications may be given intermittently using one of three regimens: (1) Daily isoniazid, rifampin,

Table 9–17. Characteristics of antituberculous drugs.

Drug	Most Common Side Effects	Tests for Side Effects	Drug Interactions	Remarks
Isoniazid	Peripheral neuropathy, hepatitis, rash, mild CNS effects.	AST and ALT; neurologic examination.	Phenytoin (synergistic); disulfiram.	Bactericidal to both extracellular and intracellular organisms. Pyridoxine, 10 mg orally daily as prophylaxis for neuritis; 50–100 mg orally daily as treatment.
Rifampin	Hepatitis, fever, rash, flu-like illness, gastrointestinal upset, bleeding problems, kidney failure.	CBC, platelets, AST and ALT.	Rifampin inhibits the effect of oral contraceptives, quinidine, corticosteroids, warfarin, methadone, digoxin, oral hypoglycemics; aminosalicylic acid may interfere with absorption of rifampin. Significant interactions with protease inhibitors and nonnucleoside reverse transcriptase inhibitors.	Bactericidal to all populations of organisms. Colors urine and other body secretions orange. Discoloring of contact lenses.
Pyrazinamide	Hyperuricemia, hepatotoxicity, rash, gastrointestinal upset, joint aches.	Uric acid, AST, ALT.	Rare.	Bactericidal to intracellular organisms.
Ethambutol	Optic neuritis (reversible with discontinuance of drug; rare at 15 mg/kg); rash.	Red-green color discrimination and visual acuity.	Rare.	Bacteriostatic to both intracellular and extracellular organisms. Mainly used to inhibit development of resistant mutants. Use with caution in kidney disease or when ophthalmologic testing is not feasible.
Streptomycin	Eighth nerve damage, nephrotoxicity.	Vestibular function (audiograms); BUN and creatinine.	Neuromuscular blocking agents may be potentiated and cause prolonged paralysis.	Bactericidal to extracellular organisms. Use with caution in older patients or those with kidney disease.

ALT, alanine aminotransferase; AST, aspartate aminotransferase; BUN, blood urea nitrogen; CBC, complete blood count.

pyrazinamide, and ethambutol for 2 months, followed by isoniazid and rifampin two or three times each week for 4 months if susceptibility to isoniazid and rifampin is demonstrated. (2) Daily isoniazid, rifampin, pyrazinamide, and ethambutol for 2 weeks, then administration of the same agents twice a week for 6 weeks followed by administration of isoniazid and rifampin twice each week for 4 months if susceptibility to isoniazid and rifampin is demonstrated. (3) Isoniazid, rifampin, pyrazinamide, and ethambutol three times a week for 6 months.

Patients who cannot or should not (eg, pregnant women) take pyrazinamide should receive daily isoniazid and rifampin along with ethambutol for 4–8 weeks. If susceptibility to isoniazid and rifampin is demonstrated or drug resistance is unlikely, ethambutol can be discontinued and isoniazid and rifampin may be given twice a week for a total of 9 months of therapy. If drug resistance is a concern, patients should receive isoniazid, rifampin, and ethambutol for 9 months. Patients with smear- and culture-negative disease (eg, pulmonary tuberculosis diagnosed on clinical grounds) and patients for whom drug susceptibility testing is not available can be treated with 6 months of isoniazid and rifampin combined with pyrazinamide for the first 2 months. This regimen assumes low prevalence of drug resistance. Previous guidelines have used streptomycin interchangeably with ethambutol. Increasing worldwide streptomycin resistance has made this drug less useful as empiric therapy.

When a twice-weekly or thrice-weekly regimen is used instead of a daily regimen, the dosages of isoniazid, pyrazinamide, and ethambutol or streptomycin must be increased. Recommended dosages for the initial treatment of tuberculosis are listed in Table 9–18. Fixed-dose combinations of isoniazid and rifampin (Rifamate) and of isoniazid, rifampin, and pyrazinamide (Rifater) are available to simplify treatment. Single tablets improve compliance but are more expensive than the individual drugs purchased separately.

C. Treatment of Tuberculosis in HIV-Positive Persons

Management of tuberculosis is complex in patients with concomitant HIV disease. Experts in the management of both tuberculosis and HIV disease should be involved in the care of such patients. The CDC has published detailed recommendations for the treatment of tuberculosis in HIV-positive patients. These documents can be obtained by accessing the CDC Division of Tuberculosis Elimination Web site at <http://www.cdc.gov/tb/>.

The basic approach to HIV-positive patients with tuberculosis is similar to that detailed above for patients without HIV disease. Additional considerations in HIV-positive patients include: (1) longer duration of therapy and (2) drug interactions between rifamycin derivatives such as rifampin and rifabutin, used to treat tuberculosis, and some of the protease inhibitors and nonnucleoside reverse transcriptase inhibitors (NNRTIs), used to treat HIV (see above Web site). DOT should be used for all HIV-positive tuberculosis patients. Pyridoxine (vitamin B₆), 25–50 mg orally each day, should be administered to all

HIV-positive patients being treated with isoniazid to reduce central and peripheral nervous system side effects.

D. Treatment of Drug-Resistant Tuberculosis

Patients with drug-resistant *M tuberculosis* infection require careful supervision and management. Clinicians who are unfamiliar with the treatment of drug-resistant tuberculosis should seek expert advice. Tuberculosis resistant only to isoniazid can be successfully treated with a 6-month regimen of rifampin, pyrazinamide, and ethambutol or streptomycin or a 12-month regimen of rifampin and ethambutol. When isoniazid resistance is documented during a 9-month regimen without pyrazinamide, isoniazid should be discontinued. If ethambutol was part of the initial regimen, rifampin and ethambutol should be continued for a minimum of 12 months. If ethambutol was not part of the initial regimen, susceptibility tests should be repeated and two other drugs to which the organism is susceptible should be added. Treatment of *M tuberculosis* isolates resistant to agents other than isoniazid and treatment of drug resistance in HIV-infected patients require expert consultation.

Multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis call for an individualized daily DOT plan under the supervision of a clinician experienced in the management of these entities. Treatment regimens are based on the patient's overall status and the results of susceptibility studies. Most drug-resistant isolates are resistant to at least isoniazid and rifampin and require a minimum of three drugs to which the organism is susceptible. These regimens are continued until culture conversion is documented, and then a two-drug regimen is continued for at least another 12 months. Some experts recommend at least 18–24 months of a three-drug regimen.

E. Treatment of Extrapulmonary Tuberculosis

In most cases, regimens that are effective for treating pulmonary tuberculosis are also effective for treating extrapulmonary disease. However, many experts recommend 9 months of therapy when miliary, meningial, or bone and joint disease is present. Treatment of skeletal tuberculosis is enhanced by early surgical drainage and debridement of necrotic bone. Corticosteroid therapy has been shown to help prevent cardiac constriction from tuberculous pericarditis and to reduce neurologic complications from tuberculous meningitis (see Chapter 33).

F. Treatment of Pregnant or Lactating Women

Tuberculosis in pregnancy is usually treated with isoniazid, rifampin, and ethambutol for 2 months, followed by isoniazid and rifampin for an additional 7 months. Ethambutol can be stopped after the first month if isoniazid and rifampin susceptibility is confirmed. Since the risk of teratogenicity with pyrazinamide has not been clearly defined, pyrazinamide should be used only if resistance to other drugs is documented and susceptibility to pyrazinamide is likely. Streptomycin is contraindicated in pregnancy because it may cause congenital deafness. Pregnant women taking isoniazid should receive pyridoxine

(vitamin B₆), 10–25 mg orally once a day, to prevent peripheral neuropathy.

Small concentrations of antituberculous drugs are present in breast milk. First-line therapy is not known to be harmful to nursing newborns at these concentrations. Therefore, breastfeeding is not contraindicated while receiving first-line antituberculous therapy. Lactating women receiving other agents should consult a tuberculosis expert.

G. Treatment Monitoring

Adults should have measurements of serum bilirubin, hepatic enzymes, urea nitrogen, creatinine, and a complete blood count (including platelets) before starting chemotherapy for tuberculosis. Visual acuity and red-green color vision tests are recommended before initiation of ethambutol and serum uric acid before starting pyrazinamide. Audiometry should be performed if streptomycin therapy is initiated.

Routine monitoring of laboratory tests for evidence of drug toxicity during therapy is not recommended, unless baseline results are abnormal or liver disease is suspected. Monthly questioning for symptoms of drug toxicity is advised. Patients should be educated about common side effects of antituberculous medications and instructed to seek medical attention should these symptoms occur. Monthly follow-up of outpatients is recommended, including sputum smear and culture for *M tuberculosis* until cultures convert to negative. Patients with negative sputum cultures after 2 months of treatment should have at least one additional sputum smear and culture performed at the end of therapy. Patients with drug-resistant isolates should have sputum cultures performed monthly during the entire course of treatment. A chest radiograph at the end of therapy provides a useful baseline for any future films.

Patients whose cultures do not become negative or whose symptoms do not resolve despite 3 months of therapy should be evaluated for drug-resistant organisms and for nonadherence to the treatment regimen. DOT is required for the remainder of the treatment regimen, and the addition of at least two drugs not previously given should be considered pending repeat drug susceptibility testing. The clinician should seek expert assistance if drug resistance is newly found, if the patient remains symptomatic, or if smears or cultures remain positive.

Patients with only a clinical diagnosis of pulmonary tuberculosis (smears and cultures negative for *M tuberculosis*) whose symptoms and radiographic abnormalities are unchanged after 3 months of treatment usually either have another process or have had tuberculosis in the past.

H. Treatment of Latent Tuberculosis

Treatment of latent tuberculous infection is essential to controlling and eliminating tuberculosis in the United States. Treatment of latent tuberculous infection substantially reduces the risk that infection will progress to active disease. Targeted testing with the tuberculin skin test or interferon gamma release assays is used to identify persons who are at high risk for tuberculosis and who stand to benefit from treatment of latent infection. Table 9–16 gives

the tuberculin skin test criteria for treatment of latent tuberculous infection. In general, patients with a positive tuberculin skin test or interferon gamma release assay who are at increased risk for exposure or disease are treated. It is essential that each person who meets the criteria for treatment of latent tuberculous infection undergo a careful assessment to exclude active disease. A history of past treatment for tuberculosis and contraindications to treatment should be sought. All patients at risk for HIV infection should be tested for HIV. Patients suspected of having tuberculosis should receive one of the recommended multidrug regimens for active disease until the diagnosis is confirmed or excluded.

Some close contacts of persons with active tuberculosis should be evaluated for treatment of latent tuberculous infection despite a negative tuberculin skin test reaction (< 5 mm induration). These include immunosuppressed persons and those who may develop disease quickly after tuberculous infection. Close contacts who have a negative tuberculin skin test reaction on initial testing should be retested 10–12 weeks later.

Several treatment regimens for both HIV-negative and HIV-positive persons are available for the treatment of latent tuberculous infection: (1) **Isoniazid:** A 9-month oral regimen (minimum of 270 doses administered within 12 months) is considered optimal. Dosing options include a daily dose of 300 mg or twice-weekly doses of 15 mg/kg. Persons at risk for developing isoniazid-associated peripheral neuropathy (diabetes mellitus, uremia, malnutrition, alcoholism, HIV infection, pregnancy, seizure disorder) may be given supplemental pyridoxine (vitamin B₆), 10–50 mg/d. (2) **Rifampin and pyrazinamide:** A 2-month oral regimen (60 doses administered within 3 months) of daily rifampin (10 mg/kg up to a maximum dose of 600 mg) and pyrazinamide (15–20 mg/kg up to a maximum dose of 2 g) is recommended. This regimen has been associated with significant hepatotoxicity, so careful laboratory monitoring is required. (3) **Rifampin:** Patients who cannot tolerate isoniazid or pyrazinamide can be considered for a 4-month regimen (minimum of 120 doses administered within 6 months) of rifampin. HIV-positive patients receiving protease inhibitors or NNRTIs who are given rifampin require management by experts in both tuberculosis and HIV disease (see Treatment of Tuberculosis in HIV-Positive Persons, above).

Contacts of persons with isoniazid-resistant, rifampin-sensitive tuberculosis should receive a 2-month regimen of rifampin and pyrazinamide or a 4-month regimen of daily rifampin alone. Contacts of persons with drug-resistant tuberculosis should receive two drugs to which the infecting organism has demonstrated susceptibility. Contacts in whom the tuberculin skin test or interferon gamma release assay is negative and contacts who are HIV seronegative may be observed without treatment or treated for 6 months. HIV-positive contacts should be treated for 12 months. All contacts of persons with multidrug-resistant tuberculosis or extensively drug-resistant tuberculosis should have 2 years of follow-up regardless of treatment.

Persons with a positive tuberculin skin test (≥ 5 mm of induration) and fibrotic lesions suggestive of old tubercu-

losis on chest radiographs who have no evidence of active disease and no history of treatment for tuberculosis should receive 9 months of isoniazid, or 2 months of rifampin and pyrazinamide, or 4 months of rifampin (with or without isoniazid). Pregnant or breastfeeding women with latent tuberculosis should receive either daily or twice-weekly isoniazid with pyridoxine (vitamin B₆).

Baseline laboratory testing is indicated for patients at risk for liver disease, patients with HIV infection, women who are pregnant or within 3 months of delivery, and persons who use alcohol regularly. Patients receiving treatment for latent tuberculous infection should be evaluated once a month to assess for symptoms and signs of active tuberculosis and hepatitis and for adherence to their treatment regimen. Routine laboratory testing during treatment is indicated for those with abnormal baseline laboratory tests and for those at risk for developing liver disease.

Vaccine BCG is an antimycobacterial vaccine developed from an attenuated strain of *M bovis*. Millions of individuals worldwide have been vaccinated with BCG. However, it is not generally recommended in the United States because of the low prevalence of tuberculous infection, the vaccine's interference with the ability to determine latent tuberculous infection using tuberculin skin test reactivity, and its variable effectiveness against pulmonary tuberculosis. BCG vaccination in the United States should only be undertaken after consultation with local health officials and experts in the management of tuberculosis. Vaccination of health care workers should be considered on an individual basis in settings in which a high percentage of tuberculosis patients are infected with strains resistant to both isoniazid and rifampin, in which transmission of such drug-resistant *M tuberculosis* and subsequent infection are likely, and in which comprehensive tuberculous infection-control precautions have been implemented but have not been successful. The BCG vaccine is contraindicated in persons with impaired immune responses due to disease or medications.

► Prognosis

Almost all properly treated immunocompetent patients with tuberculosis can be cured. Relapse rates are less than 5% with current regimens. The main cause of treatment failure is nonadherence to therapy.

American Thoracic Society; Centers for Disease Control and Prevention. Diagnostic Standards and Classification of Tuberculosis in Adults and Children. *Am J Respir Crit Care Med*. 2000 Apr;161(4 Part 1):1376–95. [PMID: 10764337]

American Thoracic Society; Centers for Disease Control and Prevention; Infectious Diseases Society of America. Controlling tuberculosis in the United States. *Am J Respir Crit Care Med*. 2005 Nov 1;172(9):1169–227. [PMID: 16249321]

Blumberg HM et al; American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America. Treatment of tuberculosis. *Am J Respir Crit Care Med*. 2003 Feb 15;167(4):603–62. [PMID: 12588714]

Geng E et al. Clinical and radiographic correlates of primary and reactivation tuberculosis: a molecular epidemiology study. *JAMA*. 2005 Jun 8;293(22):2740–5. [PMID: 15941803]

Grant A et al. Managing drug resistant tuberculosis. *BMJ*. 2008 Aug 28;337:a1110. [PMID: 18755763]

Horsburgh CR Jr et al. Clinical practice. Latent tuberculosis infection in the United States. *N Engl J Med*. 2011 Apr 14;364(15):1441–8. [PMID: 21488766]

Jeong YJ et al. Pulmonary tuberculosis: up-to-date imaging and management. *Am J Roentgenol*. 2008 Sep;191(3):834–44. [PMID: 18716117]

Lobue P et al. Treatment of latent tuberculosis infection: An update. *Respirology*. 2010 May;15(4):603–22. [PMID: 20409026]

Pai M et al. Systematic Review: T-cell- based assays for the diagnosis of latent tuberculosis infection: an update. *Ann Intern Med*. 2008 Aug 5;149(3):177–84. [PMID: 18593687]

Sia IG et al. Current concepts in the management of tuberculosis. *Mayo Clin Proc*. 2011 Apr;86(4):348–61. [PMID: 21454737]

PULMONARY DISEASE CAUSED BY NONTUBERCULOUS MYCOBACTERIA

ESSENTIALS OF DIAGNOSIS

- Chronic cough, sputum production, and fatigue; less commonly: malaise, dyspnea, fever, hemoptysis, and weight loss.
- Parenchymal opacities on chest radiograph, often with thin-walled cavities, that spread contiguously and often involve overlying pleura.
- Isolation of nontuberculous mycobacteria in a sputum culture.

► General Considerations

Mycobacteria other than *M tuberculosis*—nontuberculous mycobacteria (NTM), sometimes referred to as “atypical” mycobacteria—are ubiquitous in water and soil and have been isolated from tap water. There appears to be a continuing increase in the number and prevalence of NTM species. Marked geographic variability exists, both in the NTM species responsible for disease and in the prevalence of disease. These organisms are not considered communicable from person to person, have distinct laboratory characteristics, and are often resistant to most antituberculous drugs. See Chapter 33 for further information.

► Definition & Pathogenesis

The diagnosis of lung disease caused by NTM is based on a combination of clinical, radiographic, and bacteriologic criteria and the exclusion of other diseases that can resemble the condition. Specific diagnostic criteria are discussed below. Complementary data are important for diagnosis because NTM organisms can reside in or colonize the airways without causing clinical disease.

Mycobacterium avium complex (MAC) is the most frequent cause of NTM pulmonary disease in humans in the United States. *Mycobacterium kansasii* is the next most frequent pulmonary pathogen. Other NTM causes of

pulmonary disease include *Mycobacterium abscessus*, *Mycobacterium xenopi*, and *Mycobacterium mageritense*; the list of more unusual etiologic NTM species is long. Most NTM cause a chronic pulmonary infection that resembles tuberculosis but tends to progress more slowly. Disseminated disease is rare in immunocompetent hosts; however, disseminated MAC disease is common in patients with AIDS.

► Clinical Findings

A. Symptoms and Signs

NTM infection among immunocompetent hosts frequently presents in one of three prototypical patterns: cavitary, upper lobe lesions in older male smokers that may mimic *M tuberculosis*; nodular bronchiectasis affecting the mid lung zones in middle-aged women with chronic cough; and hypersensitivity pneumonitis following environmental exposure. Most patients with NTM infection experience a chronic cough, sputum production, and fatigue. Less common symptoms include malaise, dyspnea, fever, hemoptysis, and weight loss. Symptoms from coexisting lung disease (COPD, bronchiectasis, previous mycobacterial disease, cystic fibrosis, and pneumoconiosis) may confound the evaluation. In patients with bronchiectasis, coinfection with NTM and *Aspergillus* is a negative prognostic factor. New or worsening infiltrates as well as adenopathy or pleural effusion (or both) are described in HIV-positive patients with NTM infection as part of the immune reconstitution inflammatory syndrome following institution of highly active antiretroviral therapy.

B. Laboratory Findings

The diagnosis of NTM infection rests on recovery of the pathogen from cultures. Sputum cultures positive for atypical mycobacteria do not prove infection because NTM may exist as saprophytes colonizing the airways or may be environmental contaminants. Bronchial washings are considered to be more sensitive than expectorated sputum samples; however, their specificity for clinical disease is not known.

Bacteriologic criteria have been proposed based on studies of patients with cavitary disease with MAC or *M kansasii*. Diagnostic criteria in immunocompetent persons include the following: positive culture results from at least two separate expectorated sputum samples; or positive culture from at least one bronchial wash; or a positive culture from pleural fluid or any other normally sterile site. The diagnosis can also be established by demonstrating NTM cultured from a lung biopsy, bronchial wash, or sputum plus histopathologic changes such as granulomatous inflammation in a lung biopsy. Rapid species identification of some NTM is possible using DNA probes or high-pressure liquid chromatography.

Diagnostic criteria are less stringent for patients with severe immune suppression. HIV-infected patients may show significant MAC growth on culture of bronchial washings without clinical infection; therefore, HIV patients being evaluated for MAC infection must be considered individually.

Drug susceptibility testing on cultures of NTM is recommended for the following NTM: (1) *Mycobacterium*

avium intracellulare to macrolides only (clarithromycin and azithromycin); (2) *M kansasii* to rifampin; and (3) rapid growers (such as *Mycobacterium fortuitum*, *Mycobacterium chelonae*, *M abscessus*) to amikacin, doxycycline, imipenem, fluoroquinolones, clarithromycin, cefoxitin, and sulfonamides.

C. Imaging

Chest radiographic findings include infiltrates that are progressive or persist for at least 2 months, cavitary lesions, and multiple nodular densities. The cavities are often thin-walled and have less surrounding parenchymal infiltrate than is commonly seen with MTB infections. Evidence of contiguous spread and pleural involvement is often present. High-resolution CT of the chest may show multiple small nodules with or without multifocal bronchiectasis. Progression of pulmonary infiltrates during therapy or lack of radiographic improvement over time are poor prognostic signs and also raise concerns about secondary or alternative pulmonary processes. Clearing of pulmonary infiltrates due to NTM is slow.

► Treatment

Establishing NTM infection does not mandate treatment in all cases, for two reasons. First, clinical disease may never develop in some patients, particularly asymptomatic patients with few organisms isolated from single specimens. Second, the spectrum of clinical disease severity is very wide; in patients with mild or slowly progressive symptoms, traditional chemotherapeutic regimens using a combination of agents may lead to drug-induced side effects worse than the disease itself.

Specific treatment regimens and responses to therapy vary with the species of NTM. HIV-seronegative patients with MAC pulmonary disease usually receive a combination of daily clarithromycin or azithromycin, rifampin or rifabutin, and ethambutol (Table 9–18). For patients with severe fibrocavitary disease, streptomycin or amikacin is added for the first 2 months. The optimal duration of treatment is unknown, but therapy should be continued for 12 months after sputum conversion. Medical treatment is initially successful in about two-thirds of cases, but relapses after treatment are common; long-term benefit is demonstrated in about half of all patients. Those who do not respond favorably generally have active but stable disease. Surgical resection is an alternative for the patient with progressive disease that responds poorly to chemotherapy; the success rate with surgical therapy is good. Disease caused by *M kansasii* responds well to drug therapy. A daily regimen of rifampin, isoniazid, and ethambutol for at least 18 months with a minimum of 12 months of negative cultures is usually successful. Rapidly growing mycobacteria (*M abscessus*, *M fortuitum*, *M chelonae*) are generally resistant to standard antituberculous therapy.

► When to Refer

Patients with rapidly growing mycobacteria infection should be referred for expert management.

Table 9–18. Recommended dosages for the initial treatment of tuberculosis.

Drugs	Daily	Cost ¹	Twice a Week ²	Cost ¹ /wk	Three Times a Week ²	Cost ¹ /wk
Isoniazid	5 mg/kg Max: 300 mg/dose	\$0.13/300 mg	15 mg/kg Max: 900 mg/dose	\$0.78	15 mg/kg Max: 900 mg/dose	\$1.17
Rifampin	10 mg/kg Max: 600 mg/dose	\$5.15/600 mg	10 mg/kg Max: 600 mg/dose	\$10.30	10 mg/kg Max: 600 mg/dose	\$15.45
Pyrazinamide	15–30 mg/kg Max: 2 g/dose	\$4.80/2 g	50–70 mg/kg Max: 4 g/dose	\$19.20	50–70 mg/kg Max: 3 g/dose	\$21.60
Ethambutol	5–25 mg/kg Max: 2.5 g/dose	\$11.33/2.5 g	50 mg/kg Max: 2.5 g/dose	\$22.66	25–30 mg/kg Max: 2.5 g/dose	\$33.99
Streptomycin	15 mg/kg Max: 1 g/dose	\$14.65/1 g	25–30 mg/kg Max: 1.5 g/dose	\$58.60	25–30 mg/kg Max: 1.5 g/dose	\$87.90

¹Average wholesale price (AWP, for AB-rated generic when available) for quantity listed. Source: *Red Book Online*, 2012, Thomson Reuters (Healthcare) Inc. AWP may not accurately represent the actual pharmacy cost because wide contractual variations exist among institutions.

²All intermittent dosing regimens should be used with directly observed therapy.

Griffith DE et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. *Am J Respir Crit Care Med*. 2007 Feb 15;175(4):367–416. [PMID: 17277290]

Iseman MD. Mycobacterial infections in the era of modern biologic agents. *Am J Med Sci*. 2011 Apr;341(4):278–80. [PMID: 21378550]

Winthrop KL et al. Pulmonary nontuberculous mycobacterial disease prevalence and clinical features: an emerging public health disease. *Am J Respir Crit Care Med*. 2010 Oct 1;182(7):977–82. [PMID: 20508209]

PULMONARY NEOPLASMS

See Chapter 39 for discussions of Lung Cancer, Secondary Lung Cancer, and Mesothelioma.

SCREENING FOR LUNG CANCER

Two large, randomized controlled trials reported findings in 2011 that clarify the utility of lung cancer screening. The Prostate, Lung, Colorectal and Ovarian Randomized Trial (PLCO) randomized 154,901 adults (52% current or former smokers) between the ages of 55 and 74 years to receive either no screening or annual posterior-anterior chest radiographs for 4 consecutive years. The investigators monitored the participants after screening for an average of 12 years. Results showed no mortality benefit from four annual chest radiographs either in the whole cohort or in a subset of heavy smokers who met the entry criteria for the other major trial, the National Lung Screening Trial (NLST). The NLST enrolled 53,454 current or former smokers (minimum 30-pack year exposure history) between the ages of 55 and 74 years who were randomly assigned to one of two screening modalities: three annual posterior-anterior chest radiographs or three annual low-dose chest CT scans. They were monitored for an additional 6.5 years after screening. Compared with chest

radiography, low-dose chest CT detected more early-stage lung cancers and fewer advanced-stage lung cancers, indicating that CT screening systematically shifted the time of diagnosis to earlier stages, thereby providing more persons the opportunity for effective treatment. Furthermore, compared with chest radiographs, the cohort that received three annual CT scans had a statistically significant mortality benefit, with reductions in both lung cancer deaths (20.0%) and all-cause mortality (6.7%). This is the first time that evidence from a randomized, controlled trial demonstrated that lung cancer screening reduces all-cause mortality.

Additional information from PLCO, the NLST, and multiple other ongoing randomized trials are expected over the next few years. Salient issues that temper enthusiasm for widespread screening at this time include the following: (1) **Generalizability to community practice:** NLST-participating institutions demonstrated a high level of expertise in imaging interpretation and diagnostic evaluation. Ninety-six percent of findings on CT were false positives but the vast majority of patients were monitored with serial imaging. Invasive diagnostic evaluations were uncommon and were associated with a low complication rate (1.4%). (2) **Duration of screening:** The rate of detection of new lung cancers did not fall with each subsequent annual screening over 3 years. Since each year lung cancers first become detectable during that screening interval, the optimal number of annual CT scans is unknown as is the optimal screening interval. (3) **Overdiagnosis:** After 6.5 years of post-screening observation, there were more lung cancers in the NLST CT cohort than the chest radiography cohort (1060 and 941, respectively). Since the groups were randomized and well matched, lung cancer incidence should have been identical. Therefore, 11% of the lung cancers detected by CT remained clinically silent and invisible on chest radiograph for 6.5 years. Many, perhaps most, of these lung cancers will never cause clinical disease and represent overdiagnosis. (4) **Cost effectiveness:**

The number needed to screen with three annual chest CT scans to prevent one death from lung cancer was 320.

Clear evidence exists showing the benefit of screening with low-dose chest CT in high-risk individuals, and there is no evidence of benefit in a mixed population screened with chest radiography. The role of lung cancer screening will be an area of intense research interest for the coming several years.

National Lung Screening Trial Research Team. Reduced lung-cancer mortality with low-dose computed tomographic screening. *N Engl J Med.* 2011;365:395–409. [PMID: 21714641]

Oken MM et al. Screening by Chest Radiograph and Lung Cancer Mortality. The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Randomized Trial. *JAMA.* 2011;306:1865–73. [PMID: 22031728]

SOLITARY PULMONARY NODULE

A solitary pulmonary nodule, sometimes referred to as a “coin lesion,” is a < 3 cm isolated, rounded opacity on chest imaging outlined by normal lung and not associated with infiltrate, atelectasis, or adenopathy. Most are asymptomatic and represent an unexpected finding on chest radiography or CT scanning. The finding is important because it carries a significant risk of malignancy. The frequency of malignancy in surgical series ranges from 10% to 68% depending on patient population. Most benign nodules are infectious granulomas. **Benign neoplasms** such as hamartomas account for less than 5% of solitary nodules.

The goals of evaluation are to identify and resect malignant tumors in patients who will benefit from resection while avoiding invasive procedures in benign disease. The task is to identify nodules with a sufficiently high probability of malignancy to warrant biopsy or resection or a sufficiently low probability of malignancy to justify observation.

Symptoms alone rarely establish the cause, but clinical and imaging data can be used to assess the probability of malignancy. Malignant nodules are rare in persons under age 30. Above age 30, the likelihood of malignancy increases with age. Smokers are at increased risk, and the likelihood of malignancy increases with the number of cigarettes smoked daily. Patients with a prior malignancy have a higher likelihood of having a malignant solitary nodule.

The first and most important step in the imaging evaluation is to review old imaging studies. Comparison with prior studies allows estimation of doubling time, which is an important marker for malignancy. Rapid progression (doubling time less than 30 days) suggests infection while long-term stability (doubling time greater than 465 days) suggests benignity. Certain radiographic features help in estimating the probability of malignancy. Size is correlated with malignancy. A study of solitary nodules identified by CT scan showed a 1% malignancy rate in those measuring 2–5 mm, 24% in 6–10 mm, 33% in 11–20 mm, and 80% in 21–45 mm. The appearance of a smooth, well-defined edge is characteristic of a benign process. Ill-defined margins or a lobular appearance suggest malignancy. A high-resolution CT finding of spiculated margins and a peripheral

halo are both highly associated with malignancy. Calcification and its pattern are also helpful clues. Benign lesions tend to have dense calcification in a central or laminated pattern. Malignant lesions are associated with sparser calcification that is typically stippled or eccentric. Cavitory lesions with thick (> 16 mm) walls are much more likely to be malignant. High-resolution CT offers better resolution of these characteristics than chest radiography and is more likely to detect lymphadenopathy or the presence of multiple lesions. Chest CT is indicated in any suspicious solitary pulmonary nodule.

Treatment

Based on clinical and radiologic data, the clinician should assign a specific probability of malignancy to the lesion. The decision whether to recommend a biopsy or surgical excision depends on the interpretation of this probability in light of the patient’s unique clinical situation. The probabilities in parentheses below represent guidelines only and should not be interpreted as prescriptive.

In the case of solitary pulmonary nodules, a continuous probability function may be grouped into three categories. In patients with a **low probability (< 5%) of malignancy** (eg, age under 30, lesions stable for more than 2 years, characteristic pattern of benign calcification), watchful waiting is appropriate. Management consists of serial imaging studies (CT scans or chest radiographs) at intervals that identify growth suggestive of malignancy. Three-dimensional reconstruction of high-resolution CT images provides a more sensitive test for growth.

Patients with a **high probability (> 60%) of malignancy** should proceed directly to resection following staging, provided the surgical risk is acceptable. Biopsies rarely yield a specific benign diagnosis and are not indicated.

Optimal management of patients with an **intermediate probability of malignancy (5–60%)** remains controversial. The traditional approach is to obtain a diagnostic biopsy either through transthoracic needle aspiration (TTNA) or bronchoscopy. Bronchoscopy yields a diagnosis in 10–80% of procedures depending on the size of the nodule and its location. In general, the bronchoscopic yield for nodules that are < 2 cm and peripheral is low, although complications are generally rare. Newer bronchoscopic modalities such as electromagnetic navigation and ultrathin bronchoscopy are being studied, although their impact upon diagnostic yield remains uncertain. TTNA has a higher diagnostic yield, reported to be between 50% and 97%. The yield is strongly operator-dependent, however, and is affected by the location and size of the lesion. Complications are higher than bronchoscopy, with pneumothorax occurring in up to 30% of patients, with up to one-third of these patients requiring placement of a chest tube.

Disappointing diagnostic yields and a high false-negative rate (up to 20–30% in TTNA) have prompted alternative approaches. **Positron emission tomography (PET)** detects increased glucose metabolism within malignant lesions with high sensitivity (85–97%) and specificity (70–85%). Many diagnostic algorithms have incorporated PET into the assessment of patients with inconclusive

high-resolution CT findings. A positive PET increases the likelihood of malignancy, and a negative PET correctly excludes cancer in most cases. False-negative PET scans can occur with tumors with low metabolic activity (well-differentiated adenocarcinomas, carcinoids, and bronchioalveolar tumors), and follow-up CT imaging is typically performed at discrete intervals to ensure absence of growth. PET has several drawbacks, however: resolution below 1 cm is poor, the test is expensive, and availability remains limited.

Sputum cytology is highly specific but lacks sensitivity. It is used in central lesions and in patients who are poor candidates for invasive diagnostic procedures. Researchers have attempted to improve the sensitivity of sputum cytology through the use of monoclonal antibodies to proteins that are up-regulated in pulmonary malignancies. Such tests offer promise but remain research tools at this time.

Some centers recommend **video-assisted thoracoscopic surgery (VATS)** resection of all solitary pulmonary nodules with intermediate probability of malignancy. In some cases, the surgeon will remove the nodule and evaluate it in the operating room with frozen section. If the nodule is malignant, he or she will proceed to lobectomy and lymph node sampling, either thoracoscopically or through conversion to standard thoracotomy. This approach is less common when PET scanning is available.

All patients should be provided with an estimate of the likelihood of malignancy, and their preferences should be used to help guide diagnostic and therapeutic decisions. A strategy that recommends observation may not be preferred by a patient who desires a definitive diagnosis. Similarly, a surgical approach may not be agreeable to all patients unless the presence of cancer is definitive. Patient preferences should be elicited, and patients should be well informed regarding the specific risks and benefits associated with the recommended approach as well as the alternative strategies.

Gould MK et al. Evaluation of patients with pulmonary nodules: when is it lung cancer? ACCP evidence-based clinical practice guidelines (2nd edition). *Chest*. 2007 Sep;132(3 Suppl):108S–130S. [PMID: 17873164]

Klein JS et al. Imaging evaluation of the solitary pulmonary nodule. *Clin Chest Med*. 2008 Mar;29(1):15–38. [PMID: 18267182]

Thiessen NR et al. The solitary pulmonary nodule: approach for a general surgeon. *Surg Clin North Am*. 2010 Oct;90(5):1003–18. [PMID: 20955880]

Truong MT et al. Multidetector CT of solitary pulmonary nodules. *Radiol Clin North Am*. 2010 Jan;48(1):141–55. [PMID: 19995633]

RIGHT MIDDLE LOBE SYNDROME

Right middle lobe syndrome is recurrent or persistent atelectasis of the right middle lobe. This collapse is related to the relatively long length and narrow diameter of the right middle lobe bronchus and the oval (“fish mouth”) opening to the lobe, in the setting of impaired collateral ventilation. Fiberoptic bronchoscopy or CT scan is often necessary to rule out obstructing tumor. Foreign body or other benign causes are common.

Kwon KY et al. Middle lobe syndrome: a clinicopathological study of 21 patients. *Hum Pathol*. 1995 Mar;26(3):302–7. [PMID: 7890282]

BRONCHIAL CARCINOID TUMORS

Carcinoid and bronchial gland tumors are sometimes termed “bronchial adenomas.” This term should be avoided because it implies that the lesions are benign when, in fact, carcinoid tumors and bronchial gland carcinomas are low-grade malignant neoplasms.

Carcinoid tumors are about six times more common than bronchial gland carcinomas, and most of them occur as pedunculated or sessile growths in central bronchi. Men and women are equally affected. Most patients are under 60 years of age. Common symptoms of bronchial carcinoid tumors are hemoptysis, cough, focal wheezing, and recurrent pneumonia. Peripherally located bronchial carcinoid tumors are rare and present as asymptomatic solitary pulmonary nodules. **Carcinoid syndrome** (flushing, diarrhea, wheezing, hypotension) is rare. Fiberoptic bronchoscopy may reveal a pink or purple tumor in a central airway. These lesions have a well-vascularized stroma, and biopsy may be complicated by significant bleeding. CT scanning is helpful to localize the lesion and to follow its growth over time. Octreotide scintigraphy is also available for localization of these tumors.

Bronchial carcinoid tumors grow slowly and rarely metastasize. Complications involve bleeding and airway obstruction rather than invasion by tumor and metastases. Surgical excision of clinically symptomatic lesions is often necessary, and the prognosis is generally favorable. Most bronchial carcinoid tumors are resistant to radiation and chemotherapy (see Chapter 39).

Gustafsson BI et al. Bronchopulmonary neuroendocrine tumors. *Cancer*. 2008 Jul 1;113(1):5–21. [PMID: 18473355]

Oberg K et al; ESMO Guidelines Working Group. Neuroendocrine bronchial and thymic tumors: ESMO clinical recommendation for diagnosis, treatment and follow-up. *Ann Oncol*. 2008 May;19(Suppl 2):ii102–3. [PMID: 18456740]

Thomas R et al. Clinico-pathologic study of pulmonary carcinoid tumours—a retrospective analysis and review of literature. *Respir Med*. 2008 Nov;102(11):1611–4. [PMID: 18614346]

MEDIASTINAL MASSES

Various developmental, neoplastic, infectious, traumatic, and cardiovascular disorders may cause masses that appear in the mediastinum on chest radiograph. A useful convention arbitrarily divides the mediastinum into three compartments—anterior, middle, and posterior—in order to classify mediastinal masses and assist in differential diagnosis. Specific mediastinal masses have a predilection for one or more of these compartments; most are located in the anterior or middle compartment. The differential diagnosis of an **anterior mediastinal mass** includes thymoma, teratoma, thyroid lesions, lymphoma, and mesenchymal tumors (lipoma, fibroma). The differential diagnosis of a **middle mediastinal mass** includes lymphadenopathy,

pulmonary artery enlargement, aneurysm of the aorta or innominate artery, developmental cyst (bronchogenic, enteric, pleuropericardial), dilated azygous or hemiazygous vein, and foramen of Morgagni hernia. The differential diagnosis of a **posterior mediastinal mass** includes hiatal hernia, neurogenic tumor, meningocele, esophageal tumor, foramen of Bochdalek hernia, thoracic spine disease, and extramedullary hematopoiesis. The neurogenic tumor group includes neurilemmoma, neurofibroma, neurosarcoma, ganglioneuroma, and pheochromocytoma.

Symptoms and signs of mediastinal masses are nonspecific and are usually caused by the effects of the mass on surrounding structures. Insidious onset of retrosternal chest pain, dysphagia, or dyspnea is often an important clue to the presence of a mediastinal mass. In about half of cases, symptoms are absent, and the mass is detected on routine chest radiograph. Physical findings vary depending on the nature and location of the mass.

CT scanning is helpful in management; additional radiographic studies of benefit include barium swallow if esophageal disease is suspected, Doppler sonography or venography of brachiocephalic veins and the superior vena cava, and angiography. MRI is useful; its advantages include better delineation of hilar structures and distinction between vessels and masses. MRI also allows imaging in multiple planes, whereas CT permits only axial imaging. Tissue diagnosis is necessary if a neoplastic disorder is suspected. Treatment and prognosis depend on the underlying cause of the mediastinal mass.

Date H. Diagnostic strategies for mediastinal tumors and cysts. *Thorac Surg Clin.* 2009 Feb;19(1):29–35. [PMID: 19288818]
 Kim JY et al. Tumors of the mediastinum and chest wall. *Surg Clin North Am.* 2010 Oct;90(5):1019–40. [PMID: 20955881]
 Tomaszek S et al. Thymomas: review of current clinical practice. *Ann Thorac Surg.* 2009 Jun;87(6):1973–80. [PMID: 19463649]

INTERSTITIAL LUNG DISEASE (DIFFUSE PARENCHYMAL LUNG DISEASE)

ESSENTIALS OF DIAGNOSIS

- ▶ Insidious onset of progressive dyspnea and non-productive chronic cough; extrapulmonary findings may accompany specific diagnoses.
- ▶ Tachypnea, small lung volumes, bibasilar dry rales; digital clubbing and right heart failure with advanced disease.
- ▶ Chest radiographs with low lung volumes and patchy distribution of ground glass, reticular, nodular, reticulonodular, or cystic opacities.
- ▶ Reduced lung volumes, pulmonary diffusing capacity and 6-minute walk distance; hypoxemia with exercise.

Interstitial lung disease, or diffuse parenchymal lung disease, comprises a heterogeneous group of disorders that share common presentations (dyspnea), physical findings (late inspiratory crackles), and chest radiographs (septal thickening and reticulonodular changes).

The term “interstitial” is misleading since the pathologic process usually begins with injury to the alveolar epithelial or capillary endothelial cells (alveolitis). Persistent alveolitis may lead to obliteration of alveolar capillaries and reorganization of the lung parenchyma, accompanied by irreversible fibrosis. The process does not affect the airways proximal to the respiratory bronchioles. At least 180 disease entities may present as interstitial lung disease. Table 9–19 outlines a selected list of differential diagnoses of

Table 9–19. Differential diagnosis of interstitial lung disease.

Drug-related
Antiarrhythmic agents (amiodarone)
Antibacterial agents (nitrofurantoin, sulfonamides)
Antineoplastic agents (bleomycin, cyclophosphamide, methotrexate, nitrosoureas)
Antirheumatic agents (gold salts, penicillamine)
Phenytoin
Environmental and occupational (inhalation exposures)
Dust, inorganic (asbestos, silica, hard metals, beryllium)
Dust, organic (thermophilic actinomycetes, avian antigens, <i>Aspergillus</i> species)
Gases, fumes, and vapors (chlorine, isocyanates, paraquat, sulfur dioxide)
Ionizing radiation
Talc (injection drug users)
Infections
Fungus, disseminated (<i>Coccidioides immitis</i> , <i>Blastomyces dermatitidis</i> , <i>Histoplasma capsulatum</i>)
Mycobacteria, disseminated
<i>Pneumocystis jirovecii</i>
Viruses
Primary pulmonary disorders
Cryptogenic organizing pneumonia (COP)
Idiopathic interstitial pneumonia: Acute interstitial pneumonia, desquamative interstitial pneumonia, nonspecific interstitial pneumonia, usual interstitial pneumonia, respiratory bronchiolitis-associated interstitial lung disease
Pulmonary alveolar proteinosis
Systemic disorders
Acute respiratory distress syndrome
Amyloidosis
Ankylosing spondylitis
Autoimmune disease: Dermatomyositis, polymyositis, rheumatoid arthritis, systemic sclerosis (scleroderma), systemic lupus erythematosus
Chronic eosinophilic pneumonia
Goodpasture syndrome
Idiopathic pulmonary hemosiderosis
Inflammatory bowel disease
Langerhans cell histiocytosis (eosinophilic granuloma)
Lymphangitic spread of cancer (lymphangitic carcinomatosis)
Lymphangioleiomyomatosis
Pulmonary edema
Pulmonary venous hypertension, chronic
Sarcoidosis
Granulomatosis polyangiitis [formerly Wegener granulomatosis]

interstitial lung disease. In most patients, no specific cause can be identified. In the remainder, drugs and a variety of organic and inorganic dusts are the principal causes. The history—particularly the occupational and medication history—may provide evidence of a specific cause.

The connective tissue diseases are a group of immunologically mediated inflammatory disorders including rheumatoid arthritis, systemic lupus erythematosus, scleroderma, polymyositis-dermatomyositis, Sjögren syndrome, and other overlap conditions. The presence of diffuse parenchymal lung disease in the setting of an established connective tissue disease is suggestive of the etiology. In some cases, lung disease precedes the more typical manifestations of the underlying connective tissue disease by months or years.

Known causes of interstitial lung disease are dealt with in their specific sections. The important idiopathic forms are discussed below.

IDIOPATHIC INTERSTITIAL PNEUMONIAS



ESSENTIALS OF DIAGNOSIS

- ▶ Important to identify specific fibrosing disorders.
- ▶ Idiopathic disease may require biopsy for diagnosis.
- ▶ Accurate diagnosis identifies patients most likely to benefit from therapy.

▶ General Considerations

The most common diagnosis among patients with interstitial lung disease is idiopathic interstitial pneumonia. Historically, this diagnosis was based on clinical and radiographic criteria with only a small number of patients undergoing surgical lung biopsy. When biopsies were obtained, the common element of fibrosis led to the grouping together of several histologic patterns under the category of idiopathic interstitial pneumonia. These distinct histopathologic features are now recognized as being associated with different natural histories and responses to therapy (see Table 9–20). Therefore, in the evaluation of patients with interstitial lung disease, clinicians should attempt to identify specific disorders.

Patients with idiopathic interstitial pneumonia may have any of the histologic patterns described in Table 9–20. The first step in evaluation is to identify patients whose disease is truly idiopathic. As indicated in Table 9–19, most identifiable causes of interstitial lung disease are infectious, drug-related, or environmental or occupational agents. Interstitial lung diseases associated with other medical conditions (pulmonary-renal syndromes, collagen-vascular disease) may be identified through a careful medical history. Apart from acute interstitial pneumonia, the clinical presentations of the idiopathic interstitial pneumonias are sufficiently similar to preclude a specific diagnosis. Chest radiographs and high-resolution CT scans are occasionally diagnostic. Ultimately, many patients with apparently idiopathic disease require surgical lung biopsy to make a

definitive diagnosis. The importance of accurate diagnosis is twofold. First, it allows the clinician to provide accurate information about the cause and natural history of the illness. Second, accurate diagnosis helps distinguish patients most likely to benefit from therapy.

▶ Clinical Findings

A. Symptoms, Signs, and Imaging

The diagnosis of usual interstitial pneumonia (UIP) can be made on clinical grounds alone in selected patients (Table 9–20). A diagnosis of UIP can be made with 90% confidence in patients over 65 years of age who have (1) idiopathic disease by history and who demonstrate inspiratory crackles on physical examination; (2) restrictive physiology on pulmonary function testing; (3) characteristic radiographic evidence of progressive fibrosis over several years; and (4) diffuse, patchy fibrosis with pleural-based honeycombing on high-resolution CT scan. Such patients do not need surgical lung biopsy.

B. Special Studies

Three diagnostic techniques are in common use: bronchoalveolar lavage, transbronchial biopsy, and surgical lung biopsy, either through an open procedure or using VATS.

Bronchoalveolar lavage may provide a specific diagnosis in cases of infection, particularly with *P jiroveci* or mycobacteria, or when cytologic examination reveals the presence of malignant cells. The findings may be suggestive and sometimes diagnostic of eosinophilic pneumonia, Langerhans cell histiocytosis, or alveolar proteinosis. Analysis of the cellular constituents of lavage fluid may suggest a specific disease, but these findings are not diagnostic.

Transbronchial biopsy through the flexible bronchoscope is easily performed in most patients. The risks of pneumothorax (5%) and hemorrhage (1–10%) are low. However, the tissue specimens recovered are small, sampling error is common, and crush artifact may complicate diagnosis. Transbronchial biopsy can make a definitive diagnosis of sarcoidosis, lymphangitic spread of carcinoma, pulmonary alveolar proteinosis, miliary tuberculosis, and Langerhans cell histiocytosis. Note that the diagnosis of UIP cannot be confirmed on transbronchial lung biopsy since the histologic diagnosis requires a pattern of changes rather than a single pathognomonic finding. Transbronchial biopsy may exclude UIP by confirming a specific alternative diagnosis. Transbronchial biopsy also cannot establish a specific diagnosis of idiopathic interstitial pneumonia. These patients generally require surgical lung biopsy.

Surgical lung biopsy is the standard for diagnosis of interstitial lung disease. Two or three biopsies taken from multiple sites in the same lung, including apparently normal tissue, may yield a specific diagnosis as well as prognostic information regarding the extent of fibrosis versus active inflammation. Patients under age 60 without a specific diagnosis generally should undergo surgical lung biopsy. In older and sicker patients, the risks and benefits must be weighed carefully for three reasons: (1) the morbidity

Table 9–20. Idiopathic interstitial pneumonias.

Name and Clinical Presentation	Histopathology	Radiographic Pattern	Response to Therapy and Prognosis
<p>Usual interstitial pneumonia (UIP) Age 55–60, slight male predominance. Insidious dry cough and dyspnea lasting months to years. Cribbling present at diagnosis in 25–50%. Diffuse fine late inspiratory crackles on lung auscultation. Restrictive ventilatory defect and reduced diffusing capacity on pulmonary function tests. ANA and RF positive in ~25% in the absence of documented collagen-vascular disease.</p>	<p>Patchy, temporally and geographically nonuniform distribution of fibrosis, honeycomb change, and normal lung. Type I pneumocytes are lost, and there is proliferation of alveolar type II cells. “Fibroblast foci” of actively proliferating fibroblasts and myofibroblasts. Inflammation is generally mild and consists of small lymphocytes. Intra-alveolar macrophage accumulation is present but is not a prominent feature.</p>	<p>Diminished lung volume. Increased linear or reticular bibasilar and subpleural opacities. Unilateral disease is rare. High-resolution CT scanning shows minimal ground-glass and variable honeycomb change. Areas of normal lung may be adjacent to areas of advanced fibrosis. Between 2% and 10% have normal chest radiographs and high-resolution CT scans on diagnosis.</p>	<p>No randomized study has demonstrated improved survival compared with untreated patients. Inexorably progressive. Response to corticosteroids and cytotoxic agents at best 15%, and these probably represent misclassification of histopathology. Median survival approximately 3 years, depending on stage at presentation. Current interest in antifibrotic agents.</p>
<p>Respiratory bronchiolitis-associated interstitial lung disease (RB-ILD)¹ Age 40–45. Presentation similar to that of UIP though in younger patients. Similar results on pulmonary function tests, but less severe abnormalities. Patients with respiratory bronchiolitis are invariably heavy smokers.</p>	<p>Increased numbers of macrophages evenly dispersed within the alveolar spaces. Rare fibroblast foci, little fibrosis, minimal honeycomb change. In RB-ILD the accumulation of macrophages is localized within the peribronchiolar air spaces; in DIP¹, it is diffuse. Alveolar architecture is preserved.</p>	<p>May be indistinguishable from UIP. More often presents with a nodular or reticulonodular pattern. Honeycombing rare. High-resolution CT more likely to reveal diffuse ground-glass opacities and upper lobe emphysema.</p>	<p>Spontaneous remission occurs in up to 20% of patients, so natural history unclear. Smoking cessation is essential. Prognosis clearly better than that of UIP: median survival greater than 10 years. Corticosteroids thought to be effective, but there are no randomized clinical trials to support this view.</p>
<p>Acute interstitial pneumonia (AIP) Clinically known as Hamman-Rich syndrome. Wide age range, many young patients. Acute onset of dyspnea followed by rapid development of respiratory failure. Half of patients report a viral syndrome preceding lung disease. Clinical course indistinguishable from that of idiopathic ARDS.</p>	<p>Pathologic changes reflect acute response to injury within days to weeks. Resembles organizing phase of diffuse alveolar damage. Fibrosis and minimal collagen deposition. May appear similar to UIP but more homogeneous and there is no honeycomb change—though this may appear if the process persists for more than a month in a patient on mechanical ventilation.</p>	<p>Diffuse bilateral airspace consolidation with areas of ground-glass attenuation on high-resolution CT scan.</p>	<p>Supportive care (mechanical ventilation) critical but effect of specific therapies unclear. High initial mortality: Fifty to 90 percent die within 2 months after diagnosis. Not progressive if patient survives. Lung function may return to normal or may be permanently impaired.</p>
<p>Nonspecific interstitial pneumonia (NSIP) Age 45–55. Slight female predominance. Similar to UIP but onset of cough and dyspnea over months, not years.</p>	<p>Nonspecific in that histopathology does not fit into better-established categories. Varying degrees of inflammation and fibrosis, patchy in distribution but uniform in time, suggesting response to single injury. Most have lymphocytic and plasma cell inflammation without fibrosis. Honeycombing present but scant. Some have advocated division into cellular and fibrotic subtypes.</p>	<p>May be indistinguishable from UIP. Most typical picture is bilateral areas of ground-glass attenuation and fibrosis on high-resolution CT. Honeycombing is rare.</p>	<p>Treatment thought to be effective, but no prospective clinical studies have been published. Prognosis overall good but depends on the extent of fibrosis at diagnosis. Median survival greater than 10 years.</p>
<p>Cryptogenic organizing pneumonia (COP, formerly bronchiolitis obliterans organizing pneumonia [BOOP]) Typically age 50–60 but wide variation. Abrupt onset, frequently weeks to a few months following a flu-like illness. Dyspnea and dry cough prominent, but constitutional symptoms are common: fatigue, fever, and weight loss. Pulmonary function tests usually show restriction, but up to 25% show concomitant obstruction.</p>	<p>Included in the idiopathic interstitial pneumonias on clinical grounds. Buds of loose connective tissue (Masson bodies) and inflammatory cells fill alveoli and distal bronchioles.</p>	<p>Lung volumes normal. Chest radiograph typically shows interstitial and parenchymal disease with discrete, peripheral alveolar and ground-glass infiltrates. Nodular opacities common. High-resolution CT shows subpleural consolidation and bronchial wall thickening and dilation.</p>	<p>Rapid response to corticosteroids in two-thirds of patients. Long-term prognosis generally good for those who respond. Relapses are common.</p>

¹Includes desquamative interstitial pneumonia (DIP).

ANA, antinuclear antibody; ARDS, acute respiratory distress syndrome; RF, rheumatoid factor; UIP, usual interstitial pneumonia.

of the procedure can be significant; (2) a definitive diagnosis may not be possible even with surgical lung biopsy; and (3) when a specific diagnosis is made, there may be no effective treatment. Empiric therapy or no treatment may be preferable to surgical lung biopsy in some patients.

► Treatment

Treatment of idiopathic interstitial pneumonia is controversial. No randomized study has demonstrated that any treatment improves survival or quality of life compared with no treatment. Clinical experience suggests that patients with RB-ILD, nonspecific interstitial pneumonia (NSIP), or COP (see Table 9–20) frequently respond to corticosteroids and should be given a trial of therapy—typically prednisone, 1–2 mg/kg/d for a minimum of 2 months. The same therapy is almost uniformly ineffective in patients with UIP. Since this therapy carries significant morbidity, experts do not recommend routine use of corticosteroids in patients with UIP. A number of antifibrotic (pirfenidone, interferon gamma 1b) and immunomodulator/immunosuppressant (cyclosporine A, azathioprine, etanercept) agents have been investigated and none of them are recommended for the treatment of UIP in monotherapy or combination therapy. While the use of imatinib mesylate, a tyrosine kinase inhibitor, did not show any benefits, other tyrosine kinase inhibitors are under clinical trial. The only definitive treatment for UIP is lung transplantation, with a 5-year survival rate estimated at 50%.

Raghu G et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. *Am J Respir Crit Care Med.* 2011 Mar 15;183(6):788–824. [PMID: 21471066]

SARCOIDOSIS



ESSENTIALS OF DIAGNOSIS

- ▶ Symptoms related to the lung, skin, eyes, peripheral nerves, liver, kidney, heart, and other tissues.
- ▶ Demonstration of noncaseating granulomas in a biopsy specimen.
- ▶ Exclusion of other granulomatous disorders.

► General Considerations

Sarcoidosis is a systemic disease of unknown etiology characterized in about 90% of patients by granulomatous inflammation of the lung. The incidence is highest in North American blacks and northern European whites; among blacks, women are more frequently affected than men. Onset of disease is usually in the third or fourth decade.

► Clinical Findings

A. Symptoms and Signs

Patients may have malaise, fever, and dyspnea of insidious onset. Symptoms from skin involvement (erythema, lupus pernio [Figure 9–6]), iritis, peripheral neuropathy, arthritis (see Chapter 20), or cardiomyopathy may also cause the patient to seek care. Some individuals are asymptomatic and come to medical attention after abnormal findings (typically bilateral hilar and right paratracheal lymphadenopathy) on chest radiographs. Physical findings are atypical of interstitial lung disease in that crackles are uncommon on chest examination. Other symptoms and findings may include parotid gland enlargement, hepatosplenomegaly, and lymphadenopathy.

B. Laboratory Findings

Laboratory tests may show leukopenia, an elevated erythrocyte sedimentation rate, and hypercalcemia (about 5% of patients) or hypercalciuria (20%). Angiotensin-converting enzyme (ACE) levels are elevated in 40–80% of patients with active disease. This finding is neither sensitive nor specific enough to have diagnostic significance. Physiologic testing may reveal evidence of airflow obstruction, but restrictive changes with decreased lung volumes and diffusing capacity are more common. Skin test anergy is present in 70%. ECG may show conduction disturbances and dysrhythmias.

C. Imaging

Radiographic findings are variable and include bilateral hilar adenopathy alone (radiographic stage I), hilar adenopathy



▲ **Figure 9–6.** Skin involvement in sarcoidosis (lupus pernio), here involving the nasal rim. (Courtesy of Richard P. Usatine, MD; used, with permission, from Usatine RP, Smith MA, Mayeaux EJ Jr, Chumley H, Tysinger J. *The Color Atlas of Family Medicine.* McGraw-Hill, 2009.)

and parenchymal involvement (radiographic stage II), or parenchymal involvement alone (radiographic stage III). Parenchymal involvement is usually manifested radiographically by diffuse reticular infiltrates, but focal infiltrates, acinar shadows, nodules and, rarely, cavitation may be seen. Pleural effusion is noted in fewer than 10% of patients.

D. Special Examinations

The diagnosis of sarcoidosis generally requires histologic demonstration of noncaseating granulomas in biopsies from a patient with other typical associated manifestations. Other granulomatous diseases (eg, berylliosis, tuberculosis, fungal infections) and lymphoma must be excluded. Biopsy of easily accessible sites (eg, palpable lymph nodes, skin lesions, or salivary glands) is likely to be positive. Transbronchial lung biopsy has a high yield (75–90%) as well, especially in patients with radiographic evidence of parenchymal involvement. Some clinicians believe that tissue biopsy is not necessary when stage I radiographic findings are detected in a clinical situation that strongly favors the diagnosis of sarcoidosis (eg, a young black woman with erythema nodosum). Biopsy is essential whenever clinical and radiographic findings suggest the possibility of an alternative diagnosis such as lymphoma. Bronchoalveolar lavage fluid in sarcoidosis is usually characterized by an increase in lymphocytes and a high CD4/CD8 cell ratio. Bronchoalveolar lavage does not establish a diagnosis but may be useful in following the activity of sarcoidosis in selected patients. All patients require a complete ophthalmologic evaluation.

► Treatment

Indications for treatment with oral corticosteroids (prednisone, 0.5–1.0 mg/kg/d) include disabling constitutional symptoms, hypercalcemia, iritis, uveitis, arthritis, central nervous system involvement, cardiac involvement, granulomatous hepatitis, cutaneous lesions other than erythema nodosum, and progressive pulmonary lesions. Long-term therapy is usually required over months to years. Serum ACE levels usually fall with clinical improvement. Immunosuppressive drugs and cyclosporine have been tried, primarily when corticosteroid therapy has been exhausted, but experience with these drugs is limited.

► Prognosis

The outlook is best for patients with hilar adenopathy alone; radiographic involvement of the lung parenchyma is associated with a worse prognosis. Erythema nodosum portends a good outcome. About 20% of patients with lung involvement suffer irreversible lung impairment, characterized by progressive fibrosis, bronchiectasis, and cavitation. Pneumothorax, hemoptysis, mycetoma formation in lung cavities, and respiratory failure often complicate this advanced stage. Myocardial sarcoidosis occurs in about 5% of patients, sometimes leading to restrictive cardiomyopathy, cardiac dysrhythmias, and conduction disturbances. Death from pulmonary insufficiency occurs in about 5% of patients.

Patients require long-term follow-up; at a minimum, yearly physical examination, pulmonary function tests, chemistry panel, ophthalmologic evaluation, chest radiograph, and ECG.

Baughman RP et al. A concise review of pulmonary sarcoidosis. *Am J Respir Crit Care Med.* 2011 Mar 1;183(5):573–81. [PMID: 21037016]
Iannuzzi MC et al. Sarcoidosis: clinical presentation, immunopathogenesis, and therapeutics. *JAMA.* 2011 Jan 26;305(4):391–9. [PMID: 21266686]
Morgenthau AS et al. Recent advances in sarcoidosis. *Chest.* 2011 Jan;139(1):174–82. [PMID: 21208877]

PULMONARY ALVEOLAR PROTEINOSIS

Pulmonary alveolar proteinosis is a rare disease in which phospholipids accumulate within alveolar spaces. The condition may be primary (idiopathic) or secondary (occurring in immune deficiency; hematologic malignancies; inhalation of mineral dusts; or following lung infections, including tuberculosis and viral infections). Progressive dyspnea is the usual presenting symptom, and chest radiograph shows bilateral alveolar infiltrates suggestive of pulmonary edema. The diagnosis is based on demonstration of characteristic findings on bronchoalveolar lavage (milky appearance and PAS-positive lipoproteinaceous material) in association with typical clinical and radiographic features. In some cases, transbronchial or surgical lung biopsy (revealing amorphous intra-alveolar phospholipid) is necessary.

The course of the disease varies. Some patients experience spontaneous remission; others develop progressive respiratory insufficiency. Pulmonary infection with nocardia or fungi may occur. Therapy for alveolar proteinosis consists of periodic whole lung lavage.

Das M et al. Pulmonary alveolar proteinosis: an overview for internists and hospital physicians. *Hosp Pract (Minneapolis).* 2010 Feb;38(1):43–9. [PMID: 20469623]
Suzuki T et al. Hereditary pulmonary alveolar proteinosis: pathogenesis, presentation, diagnosis, and therapy. *Am J Respir Crit Care Med.* 2010 Nov 15;182(10):1292–304. [PMID: 20622029]

EOSINOPHILIC PULMONARY SYNDROMES

Eosinophilic pulmonary syndromes are a diverse group of disorders typically characterized by eosinophilic pulmonary infiltrates, dyspnea, and cough. Many patients have constitutional symptoms, including fever. Common causes include exposure to medications (nitrofurantoin, phenytoin, ampicillin, acetaminophen, ranitidine) or infection with helminths (eg, *Ascaris*, hookworms, *Strongyloides*) or filariae (eg, *Wuchereria bancrofti*, *Brugia malayi*, tropical pulmonary eosinophilia). **Löffler syndrome** refers to acute eosinophilic pulmonary infiltrates in response to transpulmonary passage of helminth larvae. Pulmonary eosinophilia can also be a feature of other illnesses, including ABPA, Churg-Strauss syndrome, systemic hypereosinophilic syndromes, eosinophilic granuloma of the lung (properly referred to as pulmonary Langerhans cell histiocytosis), neoplasms, and numerous interstitial lung diseases. If an

extrinsic cause is identified, therapy consists of removal of the offending drug or treatment of the underlying parasitic infection.

One-third of cases are idiopathic, and there are two common syndromes. **Chronic eosinophilic pneumonia** is seen predominantly in women and is characterized by fever, night sweats, weight loss, and dyspnea. Asthma is present in half of cases. Chest radiographs often show peripheral infiltrates, the “photographic negative” of pulmonary edema. Bronchoalveolar lavage typically has a marked eosinophilia; peripheral blood eosinophilia is present in greater than 80%. Therapy with oral prednisone (1 mg/kg/d for 1–2 weeks followed by a gradual taper over many months) usually results in dramatic improvement; however, most patients require at least 10–15 mg of prednisone every other day for a year or more (sometimes indefinitely) to prevent relapses. **Acute eosinophilic pneumonia** is an acute, febrile illness characterized by cough and dyspnea, sometimes rapidly progressing to respiratory failure. The chest radiograph is abnormal but nonspecific. Bronchoalveolar lavage frequently shows eosinophilia but peripheral blood eosinophilia is rare at the onset of symptoms. The response to corticosteroids is usually dramatic.

Alam M et al. Chronic eosinophilic pneumonia: a review. *South Med J*. 2007 Jan;100(1):49–53. [PMID: 17269525]
Wechsler ME. Pulmonary eosinophilic syndromes. *Immunol Allergy Clin North Am*. 2007 Aug;27(3):477–92. [PMID: 17868860]

DISORDERS OF THE PULMONARY CIRCULATION

PULMONARY VENOUS THROMBOEMBOLISM

ESSENTIALS OF DIAGNOSIS

- ▶ Predisposition to venous thrombosis, usually of the lower extremities.
- ▶ One or more of the following: dyspnea, chest pain, hemoptysis, syncope.
- ▶ Tachypnea and a widened alveolar-arterial P_{O_2} difference.
- ▶ Elevated rapid D-dimer and characteristic defects on CT arteriogram of the chest, ventilation-perfusion lung scan, or pulmonary angiogram.

▶ General Considerations

Pulmonary venous thromboembolism, often referred to as pulmonary embolism (PE), is a common, serious, and potentially fatal complication of thrombus formation within the deep venous circulation. PE is the third leading cause of death among hospitalized patients. Despite this prevalence, most cases are not recognized antemortem, and less than 10% of

patients with fatal emboli have received specific treatment for the condition. Management demands a vigilant systematic approach to diagnosis and an understanding of risk factors so that appropriate preventive therapy can be given.

Many substances can embolize to the pulmonary circulation, including air (during neurosurgery, from central venous catheters), amniotic fluid (during active labor), fat (long bone fractures), foreign bodies (talc in injection drug users), parasite eggs (schistosomiasis), septic emboli (acute infectious endocarditis), and tumor cells (renal cell carcinoma). The most common embolus is thrombus, which may arise anywhere in the venous circulation or heart but most often originates in the deep veins of the lower extremities. Thrombi confined to the calf rarely embolize to the pulmonary circulation. However, about 20% of calf vein thrombi propagate proximally to the popliteal and iliofemoral veins, at which point they may break off and embolize to the pulmonary circulation. Pulmonary emboli will develop in 50–60% of patients with proximal deep venous thrombosis (DVT); half of these embolic events will be asymptomatic. Approximately 50–70% of patients who have symptomatic pulmonary emboli will have lower extremity DVT when evaluated.

PE and DVT are two manifestations of the same disease. The risk factors for PE are the risk factors for thrombus formation within the venous circulation: venous stasis, injury to the vessel wall, and hypercoagulability (Virchow triad). Venous stasis increases with immobility (bed rest—especially postoperative—obesity, stroke), hyperviscosity (polycythemia), and increased central venous pressures (low cardiac output states, pregnancy). Vessels may be damaged by prior episodes of thrombosis, orthopedic surgery, or trauma. Hypercoagulability can be caused by medications (oral contraceptives, hormonal replacement therapy) or disease (malignancy, surgery) or may be the result of inherited gene defects. The most common inherited cause in white populations is resistance to activated protein C, also known as factor V Leiden. The trait is present in approximately 3% of healthy American men and in 20–40% of patients with idiopathic venous thrombosis. Other major risks for hypercoagulability include the following: deficiencies or dysfunction of protein C, protein S, and antithrombin; prothrombin gene mutation; and the presence of antiphospholipid antibodies (lupus anticoagulant and anticardiolipin antibody).

PE has multiple physiologic effects. Physical obstruction of the vascular bed and vasoconstriction from neurohumoral reflexes both increase pulmonary vascular resistance. Massive thrombus may cause right ventricular failure. Vascular obstruction increases physiologic dead space (wasted ventilation) and leads to hypoxemia through right-to-left shunting, decreased cardiac output, and surfactant depletion causing atelectasis. Reflex bronchoconstriction promotes wheezing and increased work of breathing.

▶ Clinical Findings

A. Symptoms and Signs

The clinical diagnosis of PE is notoriously difficult for two reasons. First, the clinical findings depend on both the size of

the embolus and the patient's preexisting cardiopulmonary status. Second, common symptoms and signs of pulmonary emboli are not specific to this disorder (Table 9–21).

Indeed, no single symptom or sign or combination of clinical findings is specific to PE. Some findings are fairly sensitive: dyspnea and pain on inspiration occur in 75–85% and 65–75% of patients, respectively. Tachypnea is the only sign reliably found in more than half of patients. A common clinical strategy is to use combinations of clinical findings to identify patients' risk for PE. For example, 97% of patients in the original Prospective Investigation of Pulmonary Embolism Diagnosis (PIOPED I) study with angiographically proved pulmonary emboli had one or more of three findings: dyspnea, chest pain with breathing, or tachypnea. Wells and colleagues have published and validated a simple clinical decision rule that quantifies and dichotomizes this clinical risk assessment, allowing diversion of patients deemed unlikely to have PE to a simpler diagnostic algorithm (see Integrated Approach to Diagnosis of Pulmonary Embolism).

B. Laboratory Findings

The ECG is abnormal in 70% of patients with PE. However, the most common abnormalities are sinus tachycardia and nonspecific ST and T wave changes, each seen in approximately 40% of patients. Five percent or less of patients in the PIOPED I study had P pulmonale, right ventricular hypertrophy, right axis deviation, and right bundle branch block.

Arterial blood gases usually reveal acute respiratory alkalosis due to hyperventilation. The arterial PO₂ and the alveolar-arterial oxygen difference (A–a–DO₂) are usually abnormal in patients with PE compared with healthy, age-matched controls. However, arterial blood gases are not diagnostic: among patients who were evaluated in the PIOPED I study, neither the PO₂ nor the A–a–DO₂ differentiated between those with and those without pulmonary emboli. Profound hypoxia with a normal chest radiograph in the absence of preexisting lung disease is highly suspicious for PE.

Table 9–21. Frequency of specific symptoms and signs in patients at risk for pulmonary thromboembolism.

	UPET ¹ PE + (n = 327)	PIOPED ² PE + (n = 117)	PIOPED ² PE – (n = 248)
Symptoms			
Dyspnea	84%	73%	72%
Respirophasic chest pain	74%	66%	59%
Cough	53%	37%	36%
Leg pain	Nr	26%	24%
Hemoptysis	30%	13%	8%
Palpitations	Nr	10%	18%
Wheezing	Nr	9%	11%
Anginal pain	14%	4%	6%
Signs			
Respiratory rate ≥ 16 UPET, ≥ 20 PIOPED I	92%	70%	68%
Crackles (rales)	58%	51%	40% ³
Heart rate ≥ 100/min	44%	30%	24%
Fourth heart sound (S ₄)	Nr	24%	13% ³
Accentuated pulmonary component of second heart sound (S ₂ P)	53%	23%	13% ³
T ≥ 37.5°C UPET, ≥ 38.5°C PIOPED	43%	7%	12%
Homans sign	Nr	4%	2%
Pleural friction rub	Nr	3%	2%
Third heart sound (S ₃)	Nr	3%	4%
Cyanosis	19%	1%	2%

¹Data from the Urokinase-Streptokinase Pulmonary Embolism Trial, as reported in Bell WR, et al. The clinical features of submassive and massive pulmonary emboli. *Am J Med.* 1977 Mar;62(3):355–60. [PMID: 842555]

²Data from patients enrolled in the PIOPED I study, as reported in Stein PD et al. Clinical, laboratory, roentgenographic, and electrocardiographic findings in patients with acute pulmonary embolism and no preexisting cardiac or pulmonary disease. *Chest.* 1991 Sep; 100(3):598–603. [PMID: 1909617]

³P < .05 comparing patients in the PIOPED I study.

PE+, confirmed diagnosis of pulmonary embolism; PE–, diagnosis of pulmonary embolism ruled out; nr, not reported.

Plasma levels of **D-dimer**, a degradation product of cross-linked fibrin, are elevated in the presence of thrombus. Using a D-dimer threshold between 300 and 500 ng/mL, a rapid quantitative enzyme-linked immunosorbent assay (ELISA) has shown a sensitivity for venous thromboembolism of 95–97% and a specificity of 45%. Therefore, a D-dimer < 500 ng/mL using a rapid quantitative ELISA provides strong evidence against venous thromboembolism, with a likelihood ratio of 0.11–0.13. Appropriate diagnostic thresholds have not been established for patients in whom D-dimer is elevated.

Serum troponin I, troponin T, and plasma beta-natriuretic peptide (BNP) levels are typically higher in patients with PE compared with those without embolism; the presence and magnitude of the elevation are not useful in diagnosis, but correlate with adverse outcomes, including death, mechanical ventilation and prolonged hospitalization.

C. Imaging and Special Examinations

1. Chest radiography—The chest radiograph is necessary to exclude other common lung diseases and to permit interpretation of the ventilation-perfusion (\dot{V}/\dot{Q}) scan, but it does not establish the diagnosis by itself. The chest radiograph was normal in only 12% of patients with confirmed PE in the PIOPEd I study. The most frequent findings were atelectasis, parenchymal infiltrates, and pleural effusions. However, the prevalence of these findings was the same in hospitalized patients without PE. A prominent central pulmonary artery with local oligemia (Westermarck sign) or pleural-based areas of increased opacity that represent intraparenchymal hemorrhage (Hampton hump) are uncommon. Paradoxically, the chest radiograph may be most suggestive of PE when normal in the setting of hypoxemia.

2. CT—Helical CT pulmonary angiography is used as the initial diagnostic study in North America for suspected PE. Helical CT pulmonary angiography requires administration of intravenous radiocontrast dye but is otherwise noninvasive. A high quality study is very sensitive for the detection of thrombus in the proximal pulmonary arteries but less so in more distal arteries where it may miss as many as 75% of subsegmental defects, compared with pulmonary angiography. Comparing helical CT pulmonary angiography to the \dot{V}/\dot{Q} scan as the initial test for PE, detection of thrombi is roughly comparable, although more alternative pulmonary diagnoses are made with CT scanning.

Test characteristics of helical CT pulmonary angiography vary widely by study and facility. Factors influencing results include patient size and cooperation, the type and quality of the scanner, the imaging protocol, and the experience of the interpreting radiologist. The 2006 PIOPEd II study, using multidetector (four-row) helical CT and excluding the 6% of patients whose studies were “inconclusive,” reported sensitivity of 83% and specificity of 96%.

A 15–20% false-negative rate is high for a screening test, and raises the practical question whether it is safe to withhold anticoagulation in patients with a negative helical CT. Research data provide two complementary answers. The insight of PIOPEd I, that the clinical assessment of pretest

probability improves the performance of the \dot{V}/\dot{Q} scan, was confirmed with helical CT pulmonary angiography in PIOPEd II, where positive and negative predictive values were highest in patients with concordant clinical assessments but poor with conflicting assessments. The negative predictive value of a normal helical CT in patients with a high pretest probability was only 60%. Therefore, a normal helical CT alone does not exclude PE in high-risk patients, and either empiric therapy or further testing is indicated.

A large, prospective trial, the Christopher Study, incorporated objective, validated pretest clinical assessment into diagnostic algorithms using D-dimer measurement. In this study, patients with a high pretest probability and a negative helical CT pulmonary angiogram who were not receiving anticoagulation had a low (< 2%) 3-month incidence of subsequent PE. This low rate of complications supports the contention that many false-negative studies represent clinically insignificant, small distal thrombi and provides support for monitoring most patients with a high-quality negative helical CT pulmonary angiogram off therapy (see Integrated Approach to Diagnosis of Pulmonary Embolism below). The rate of false-positive helical CT pulmonary angiograms and overtreatment of PE has not been as well studied to date.

3. Ventilation-perfusion lung scanning—A perfusion scan is performed by injecting radiolabeled microaggregated albumin into the venous system, allowing the particles to embolize to the pulmonary capillary bed. To perform a ventilation scan, the patient breathes a radioactive gas or aerosol while the distribution of radioactivity in the lungs is recorded. A defect on perfusion scanning represents diminished blood flow to that region of the lung. This finding is not specific for PE. Defects in the perfusion scan are interpreted in conjunction with the ventilation scan to give a high, low, or intermediate (indeterminate) probability that PE is the cause of the abnormalities. Criteria for the combined interpretation of ventilation and perfusion scans (commonly referred to as a single test, the \dot{V}/\dot{Q} scan) are complex, confusing, and not completely standardized. A normal perfusion scan excludes the diagnosis of clinically significant PE (negative predictive value of 91% in the PIOPEd I study). A high-probability \dot{V}/\dot{Q} scan is most often defined as having two or more segmental perfusion defects in the presence of normal ventilation and is sufficient to make the diagnosis of PE in most instances (positive predictive value of 88% among PIOPEd I patients). \dot{V}/\dot{Q} scans are most helpful when they are either normal or indicate a high probability of PE. Such readings are reliable—interobserver agreement is best for normal and high-probability scans—and they carry predictive power. The likelihood ratios associated with normal and high-probability scans are 0.10 and 18, respectively, indicating significant and frequently conclusive changes from pretest to posttest probability.

However, 75% of PIOPEd I \dot{V}/\dot{Q} scans were nondiagnostic, ie, of low or intermediate probability. At angiography, these patients had an overall incidence of PE of 14% and 30%, respectively.

One of the most important findings of PIOPEd I was that the clinical assessment of pretest probability could be

used to aid the interpretation of the \dot{V}/\dot{Q} scan. For patients with low-probability \dot{V}/\dot{Q} scans and a low (20% or less) clinical pretest probability of PE, the diagnosis was confirmed in only 4%. Such patients may reasonably be observed off therapy without angiography. All other patients with nondiagnostic \dot{V}/\dot{Q} scans require further testing to determine the presence of venous thromboembolism.

4. Venous thrombosis studies—Seventy percent of patients with PE will have DVT on evaluation, and approximately half of patients with DVT will have PE on angiography. Since the history and physical examination are neither sensitive nor specific for PE and since the results of \dot{V}/\dot{Q} scanning are frequently equivocal, documentation of DVT in a patient with suspected PE establishes the need for treatment and may preclude further testing.

Commonly available diagnostic techniques include venous ultrasonography, impedance plethysmography, and contrast venography. In most centers, **venous ultrasonography** is the test of choice to detect proximal DVT. Inability to compress the common femoral or popliteal veins in symptomatic patients is diagnostic of first-episode DVT (positive predictive value of 97%); full compressibility of both sites excludes proximal DVT (negative predictive value of 98%). The test is less accurate in distal thrombi, recurrent thrombi, or in asymptomatic patients. Impedance plethysmography relies on changes in electrical impedance between patent and obstructed veins to determine the presence of thrombus. Accuracy is comparable though not quite as high as ultrasonography. Both ultrasonography and impedance plethysmography are useful in the serial examination of patients with high clinical suspicion of venous thromboembolism but negative leg studies. In patients with suspected first-episode DVT and a negative ultrasound or impedance plethysmography examination, multiple studies have confirmed the safety of withholding anticoagulation while conducting two sequential studies on days 1–3 and 7–10. Similarly, patients with nondiagnostic \dot{V}/\dot{Q} scans and an initial negative venous ultrasound or impedance plethysmography examination may be monitored off therapy with serial leg studies over 2 weeks. When serial examinations are negative for proximal DVT, the risk of subsequent venous thromboembolism over the following 6 months is less than 2%.

Contrast venography remains the reference standard for the diagnosis of DVT. An intraluminal filling defect is diagnostic of venous thrombosis. However, venography has significant shortcomings and has been replaced by venous ultrasound as the diagnostic procedure of choice. Venography may be useful in complex situations where there is discrepancy between clinical suspicion and noninvasive testing.

5. Pulmonary angiography—Pulmonary angiography remains the reference standard for the diagnosis of PE. An intraluminal filling defect in more than one projection establishes a definitive diagnosis. Secondary findings highly suggestive of PE include abrupt arterial cutoff, asymmetry of blood flow—especially segmental oligemia—or a prolonged arterial phase with slow filling. Pulmonary angiography was performed in 755 patients in

the PIOPED I study. A definitive diagnosis was established in 97%; in 3% the studies were nondiagnostic. Four patients (0.8%) with negative angiograms subsequently had pulmonary thromboemboli at autopsy. Serial angiography has demonstrated minimal resolution of thrombus prior to day 7 following presentation. Thus, negative angiography within 7 days of presentation excludes the diagnosis.

Pulmonary angiography is a safe but invasive procedure with well-defined morbidity and mortality data. Minor complications occur in approximately 5% of patients. Most are allergic contrast reactions, transient kidney injury, or related to percutaneous catheter insertion; cardiac perforation and arrhythmias are reported but rare. Among the PIOPED I patients who underwent angiography, there were five deaths (0.7%) directly related to the procedure.

The appropriate role of pulmonary angiography in the diagnosis of PE remains a subject of ongoing debate. There is wide agreement that angiography is indicated in any patient in whom the diagnosis is in doubt when there is a high clinical pretest probability of PE or when the diagnosis of PE must be established with certainty, as when anticoagulation is contraindicated or placement of an inferior vena cava filter is contemplated.

6. MRI—MRI has sensitivity and specificity equivalent to contrast venography in the diagnosis of DVT. It has improved sensitivity when compared with venous ultrasound in the diagnosis of DVT, without loss of specificity. The test is noninvasive and avoids the use of potentially nephrotoxic radiocontrast dye. However, artifacts introduced by respiratory and cardiac motion have limited the use of MRI in the diagnosis of PE. New techniques have improved sensitivity and specificity to levels comparable with helical CT, but MRI remains primarily a research tool for PE.

▶ Integrated Approach to Diagnosis of Pulmonary Embolism

An integrated approach to diagnosis of PE uses the clinical likelihood of venous thromboembolism derived from a clinical prediction rule (Table 9–22) along with the results of diagnostic tests to come to one of three decision points: to establish venous thromboembolism (PE or DVT) as the diagnosis, to exclude venous thromboembolism with sufficient confidence to follow the patient off anticoagulation, or to refer the patient for additional testing. An ideal diagnostic algorithm would proceed in a cost-effective, stepwise fashion to come to these decision points at minimal risk to the patient. Most North American centers use a rapid D-dimer and helical CT pulmonary angiography based diagnostic algorithm (Figure 9–7). The standard \dot{V}/\dot{Q} scan based algorithm (Table 9–23) remains useful in many patients, especially those who are not able to undergo CT pulmonary angiography (eg, those with advanced chronic kidney disease). In the rigorously conducted Christopher Study, the incidence of venous thromboembolism was only 1.3% and fatal PE occurred in just 0.5% of persons monitored for 3 months off anticoagulation therapy after objective, validated tools for clinical assessment,

Table 9-22. Clinical prediction rule for pulmonary embolism (PE).

Variable	Points
Clinical symptoms and signs of deep venous thrombosis (DVT) (leg swelling and pain with palpation of deep veins)	3.0
Alternative diagnosis less likely than PE	3.0
Heart rate > 100 beats/min	1.5
Immobilization for more than 3 days or surgery in previous 4 weeks	1.5
Previous PE or DVT	1.5
Hemoptysis	1.0
Cancer (with treatment within past 6 months or palliative care)	1.0
Three-tiered clinical probability assessment	Score
High	> 6.0
Moderate	2.0 to 6.0
Low	< 2.0
Dichotomous clinical probability assessment	Score
PE likely	> 4.0
PE unlikely	< or = 4.0

Data from Wells PS et al. Derivation of a simple clinical model to categorize patients probability of pulmonary embolism: increasing the models utility with the SimpliRED D-dimer. *Thromb Haemost.* 2000 Mar;83(3):416-20. [PMID: 10744147]

quantitative rapid D-dimer assays and a negative helical CT pulmonary angiography. The incidence of PE following a negative evaluation by these three means is comparable to that seen following negative pulmonary angiography.

► Prevention


Venous thromboembolism is often clinically silent until it presents with significant morbidity or mortality. It is a prevalent disease, clearly associated with identifiable risk factors. For example, the incidence of proximal DVT, PE, and fatal PE in untreated patients undergoing hip fracture surgery is reported to be 10–20%, 4–10%, and 0.2–5%, respectively. There is unambiguous evidence of the efficacy of prophylactic therapy in this and other clinical situations, yet it remains underused. Only about 50% of surgical deaths from PE had received any form of preventive therapy. A discussion of strategies for the prevention of venous thromboembolism can be found in Chapter 14.

► Treatment

A. Anticoagulation

Anticoagulation is not definitive therapy but a form of secondary prevention. Heparin binds to and accelerates the ability of antithrombin to inactivate thrombin, factor Xa, and factor IXa. It thus retards additional thrombus formation, allowing endogenous fibrinolytic mechanisms to lyse existing clot. The standard regimen of heparin followed by 6 months of oral warfarin results in an 80–90% reduction in the risk of both recurrent venous thrombosis and death from PE. LMWHs are as effective as unfractionated heparin in the treatment of venous thromboembolism (see Tables 14–15, 14–19, 14–20).

The optimal duration of anticoagulation therapy for venous thromboembolism is unknown. There appears to be a protective benefit to continued anticoagulation in first-episode venous thromboembolism (twice the rate of recurrence in 6 weeks compared with 6 months of therapy) and recurrent disease (eightfold risk of recurrence in 6 months compared with 4 years of therapy). These studies do not distinguish patients with reversible risk factors,



▲ **Figure 9-7.** D-dimer and helical CT-PA based diagnostic algorithm for PE. CT-PA, CT pulmonary angiogram; PE, pulmonary embolism; ELISA, enzyme-linked immunosorbent assay; VTE, venous thromboembolic disease; LE US, lower extremity venous ultrasound for deep venous thrombosis; PA, pulmonary angiogram. (Reproduced, with permission, from van Belle A et al. Effectiveness of managing suspected pulmonary embolism using an algorithm combining clinical probability, D-dimer testing, and computed tomography. *JAMA.* 2006 Jan 11;295(2):172-9.)

Table 9–23. Pulmonary ventilation-perfusion scan based diagnostic algorithm for PE.

Clinical concern for PE:			
1. Analyze by three-tiered clinical probability assessment (Table 9–22)			
2. Obtain V/Q scan			
3. Match results in the following table			
Clinical suspicion for PE by clinical probability assessment			
	HIGH	MODERATE	LOW
High probability	STOP. Diagnosis established. Treat for PE.	STOP. Diagnosis established. Treat for PE.	Diagnosis likely (56% in PIOPED I, but small number of patients). Treat for PE or evaluate further with LE US or CT-PA.
Indeterminate	Diagnosis highly likely (66% in PIOPED I). Treat for PE or evaluate further with LE US or CT-PA.	Uncertain diagnosis. Evaluate further with LE US or CT-PA.	Uncertain diagnosis. Evaluate further with LE US or CT-PA.
Low probability	Uncertain diagnosis. Evaluate further with LE US or CT-PA.	Uncertain diagnosis. Evaluate further with LE US or CT-PA.	STOP. Diagnosis excluded; monitor off anticoagulation. Consider alternative diagnoses.
Normal	STOP. Diagnosis excluded; monitor off anticoagulation. Consider alternative diagnoses.	STOP. Diagnosis excluded; monitor off anticoagulation. Consider alternative diagnoses.	STOP. Diagnosis excluded; monitor off anticoagulation. Consider alternative diagnoses.

Data from The PIOPED Investigators. Value of the ventilation/perfusion scan in acute pulmonary embolism: results of the Prospective Investigation of Pulmonary Embolism Diagnosis (PIOPED). *JAMA*. 1990 May 23–30;263(20):2753–9. [PMID: 2332918] CT-PA, helical CT pulmonary angiography; LE US, lower extremity venous ultrasound for DVT; PE, pulmonary embolism.

such as surgery or transient immobility, from patients who have a nonreversible hypercoagulable state such as factor V Leiden, inhibitor deficiency, antiphospholipid syndrome, or malignancy. A randomized controlled trial of low-dose warfarin (INR 1.5–2.0) versus no therapy following 6 months of standard therapy in patients with idiopathic DVT was stopped early. The protective benefits of continued anticoagulation include fewer DVTs in addition to a trend toward lower mortality despite more hemorrhage in the warfarin group. Risk reductions were consistent across groups with and without inherited thrombophilia.

For many patients, venous thrombosis is a recurrent disease, and continued therapy results in a lower rate of recurrence at the cost of an increased risk of hemorrhage. Therefore, the appropriate duration of therapy needs to take into consideration potentially reversible risk factors, the individual's age, the likelihood and potential consequences of hemorrhage, and patient preferences for continued therapy. It is reasonable to continue therapy for 6 months after a first episode when there is a reversible risk factor, 12 months after a first-episode of idiopathic thrombosis,

and 6–12 months to indefinitely in patients with nonreversible risk factors or recurrent disease. D-dimer testing has been suggested to have a role in identifying those who may benefit from continued anticoagulation after 3 months of therapy. This is an area of active research.

The major complication of anticoagulation is hemorrhage. Risk factors for hemorrhage include the intensity of the anticoagulant effect; the duration of therapy; concomitant administration of drugs such as aspirin that interfere with platelet function; and patient characteristics, particularly increased age, previous gastrointestinal hemorrhage, and coexistent chronic kidney disease.

The reported incidence of major hemorrhage following intravenous administration of unfractionated heparin is nil to 7%; that of fatal hemorrhage is nil to 2%. The incidence with LMWHs is not statistically different. There is no information comparing hemorrhage rates at different doses of heparin. The risk of death from another pulmonary embolism during subtherapeutic heparin administration in the first 24–48 hours after diagnosis is significant; it appears to outweigh the risk of short-term supratherapeutic heparin levels. The incidence of hemorrhage during

therapy with warfarin is reported to be between 3% and 4% per patient year. The frequency varies with the target INR and is consistently higher when the INR exceeds 4.0. There is no apparent additional antithrombotic benefit in venous thromboembolism with a target INR above 2.0–3.0 (see Chapter 14).

B. Thrombolytic Therapy

Streptokinase, urokinase, and recombinant tissue plasminogen activator (rt-PA; alteplase) increase plasmin levels and thereby directly lyse intravascular thrombi. In patients with established PE, thrombolytic therapy accelerates resolution of emboli within the first 24 hours compared with standard heparin therapy. This is a consistent finding using angiography, \dot{V}/\dot{Q} scanning, echocardiography, and direct measurement of pulmonary artery pressures. However, at 1 week and 1 month after diagnosis, these agents show no difference in outcome compared with heparin and warfarin. There is no evidence that thrombolytic therapy improves mortality. Subtle improvements in pulmonary function, including improved single-breath diffusing capacity and a lower incidence of exercise-induced pulmonary hypertension, have been observed. The reliability and clinical importance of these findings is unclear. The major disadvantages of thrombolytic therapy compared with heparin are its greater cost and a significant increase in major hemorrhagic complications. The incidence of intracranial hemorrhage in patients with PE treated with alteplase is 2.1% compared with 0.2% in patients treated with heparin.

Current evidence supports thrombolytic therapy for PE in patients at high risk for death in whom the more rapid resolution of thrombus may be lifesaving. Such patients are usually hemodynamically unstable despite heparin therapy. Absolute contraindications to thrombolytic therapy include active internal bleeding and stroke within the past 2 months. Major contraindications include uncontrolled hypertension and surgery or trauma within the past 6 weeks. The role of thrombolysis in patients who are hemodynamically stable but with echocardiographic evidence of right heart strain from acute pulmonary embolism is unclear and is subject to considerable practice variation.

C. Additional Measures

Interruption of the inferior vena cava may be indicated in patients with a major contraindication to anticoagulation who have or are at high risk for development of proximal DVT or PE. Placement of an inferior vena cava filter is also recommended for recurrent thromboembolism despite adequate anticoagulation, for chronic recurrent embolism with a compromised pulmonary vascular bed (eg, in pulmonary hypertension), and with the concurrent performance of surgical pulmonary embolectomy or pulmonary thromboendarterectomy. Percutaneous transjugular placement of a mechanical filter is the preferred mode of inferior vena cava interruption. These devices reduce the short-term incidence of PE in patients presenting with

proximal lower extremity DVT. However, they are associated with a twofold increased risk of recurrent DVT in the first 2 years following placement.

In rare critically ill patients for whom thrombolytic therapy is contraindicated or unsuccessful, mechanical or surgical extraction of thrombus may be indicated. Pulmonary embolectomy is an emergency procedure of last resort with a very high mortality rate. It is performed only in a few specialized centers. Several catheter devices to fragment and extract thrombus through a transvenous approach have been reported in small numbers of patients. Comparative outcomes with surgery, thrombolytic therapy, or heparin have not been studied.

▶ Prognosis

PE is estimated to cause more than 50,000 deaths annually. In the majority of deaths, PE is not recognized antemortem or death occurs before specific treatment can be initiated. These statistics highlight the importance of preventive therapy in high-risk patients (see Chapter 14). The outlook for patients with diagnosed and appropriately treated PE is generally good. Overall prognosis depends on the underlying disease rather than the PE itself. Death from recurrent thromboemboli is uncommon, occurring in less than 3% of cases. Perfusion defects resolve in most survivors. Chronic thromboembolic pulmonary hypertension develops in approximately 1% of patients. Selected patients may benefit from pulmonary endarterectomy.

American College of Emergency Physicians Clinical Policies Subcommittee on Critical Issues in the Evaluation and Management of Adult Patients Presenting to the Emergency Department With Suspected Pulmonary Embolism, Fesmire FM et al. Critical issues in the evaluation and management of adult patients presenting to the emergency department with suspected pulmonary embolism. *Ann Emerg Med.* 2011 Jun;57(6):628–652.e75. [PMID: 21621092]

Jaff MR et al; American Heart Association Council on Cardiopulmonary, Critical Care, Perioperative and Resuscitation; American Heart Association Council on Peripheral Vascular Disease; American Heart Association Council on Arteriosclerosis, Thrombosis and Vascular Biology. Management of massive and submassive pulmonary embolism, iliofemoral deep vein thrombosis, and chronic thromboembolic pulmonary hypertension: a scientific statement from the American Heart Association. *Circulation.* 2011 Apr 26;123(16):1788–830. [PMID: 21422387]

Kearon C et al. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). *Chest.* 2008 Jun;133(6 Suppl):454S–545S. [PMID: 18574272]

Konstantinides S. Clinical practice. Acute pulmonary embolism. *N Engl J Med.* 2008 Dec 25;359(26):2804–13. [PMID: 19109575]

Lucassen W et al. Clinical decision rules for excluding pulmonary embolism: a meta-analysis. *Ann Intern Med.* 2011 Oct 4;155(7):448–60. [PMID: 21969343]

Moore LK et al. Current approach to the diagnosis of acute nonmassive pulmonary embolism. *Chest.* 2011 Aug;140(2):509–18. [PMID: 21813530]

PULMONARY HYPERTENSION

ESSENTIALS OF DIAGNOSIS

- ▶ Dyspnea, fatigue, chest pain, and syncope on exertion.
- ▶ Narrow splitting of second heart sound with loud pulmonary component; findings of right ventricular hypertrophy and cardiac failure in advanced disease.
- ▶ Hypoxemia and increased wasted ventilation on pulmonary function tests.
- ▶ Electrocardiographic evidence of right ventricular strain or hypertrophy and right atrial enlargement.
- ▶ Enlarged central pulmonary arteries on chest radiograph.

General Considerations

The pulmonary circulation is unique because of its high blood flow, low pressure (normally 25/8 mm Hg, mean 12), and low resistance (normally 200–250 dynes/sec/cm⁻⁵). It can accommodate large increases in blood flow during exercise with only modest increases in pressure because of its ability to recruit and distend lung blood vessels. Contraction of smooth muscle in the walls of pulmonary arteriolar resistance vessels becomes an important factor in numerous pathologic states. Pulmonary hypertension is present when pulmonary artery pressure rises to a level inappropriate for a given cardiac output. Once present, pulmonary hypertension is self-perpetuating. It introduces secondary structural abnormalities in pulmonary vessels, including smooth muscle hypertrophy and intimal proliferation, and these may eventually stimulate atheromatous changes and in situ thrombosis, leading to further narrowing of the arterial bed.

Idiopathic (formerly primary) pulmonary hypertension (see Chapter 10) is pulmonary arterial hypertension that occurs in the absence of other disease of the lungs or heart. This condition is also called **plexogenic pulmonary arteriopathy**, in reference to the characteristic histopathologic plexiform lesion found in muscular pulmonary arteries. Untreated, it is characterized by progressive dyspnea, a rapid downhill course, and an invariably fatal outcome.

Idiopathic pulmonary hypertension must be distinguished from **secondary pulmonary hypertension** that occurs with many disorders including systemic sclerosis, hepatic cirrhosis and portal hypertension, HIV infection, chronic thromboembolic disease, and the use of anorectic drugs. Selected mechanisms responsible for **secondary pulmonary hypertension** and examples of corresponding clinical conditions are set forth in Table 9–24.

Pulmonary arteriolar vasoconstriction due to chronic hypoxemia may complicate any chronic lung disease and compound the effects of loss of pulmonary blood vessels (as seen with disorders such as emphysema and pulmonary fibrosis) and obstruction of the pulmonary vascular bed

Table 9–24. Mechanisms of pulmonary hypertension and examples of corresponding clinical conditions.

Reduction in cross-sectional area of pulmonary arterial bed
Vasoconstriction
Hypoxemia from any cause (chronic lung disease, sleep-disordered breathing, etc)
Acidosis
Loss of vessels
Lung resection
Emphysema
Vasculitis
Interstitial lung disease
Collagen-vascular disease
Plexogenic narrowing of vessels
Pulmonary embolism (thromboemboli, tumor emboli, etc)
In situ thrombosis
Schistosomiasis
Sickle cell disease
Narrowing of vessels
Secondary structural changes due to pulmonary hypertension
Increased pulmonary venous pressure
Constrictive pericarditis
Left ventricular failure or reduced compliance
Mitral stenosis
Left atrial myxoma
Pulmonary veno-occlusive disease
Mediastinal diseases compressing pulmonary veins
Increased pulmonary blood flow
Congenital left-to-right intracardiac shunts
Increased blood viscosity
Polycythemia
Miscellaneous
Pulmonary hypertension occurring in association with hepatic cirrhosis and portal hypertension
HIV infection

(as seen with disorders such as chronic pulmonary thromboembolic disease). Sustained increases in pulmonary venous pressure from left ventricular failure (systolic, diastolic, or both), mitral stenosis, and pulmonary veno-occlusive disease may cause “postcapillary” pulmonary hypertension. Increased pulmonary blood flow due to intracardiac shunts and increased blood viscosity due to polycythemia can also cause pulmonary hypertension.

Pulmonary veno-occlusive disease is a rare cause of postcapillary pulmonary hypertension occurring in children and young adults. The cause is unknown, but associations with various conditions—such as viral infections, hematopoietic stem cell or bone marrow transplantation, chemotherapy (typically multiple agents administered repeatedly over many cycles), and many different autoimmune disorders—have been described. The disease is characterized by progressive fibrotic occlusion of pulmonary veins and venules, along with secondary hypertensive changes in the pulmonary arterioles and muscular pulmonary arteries. Nodular areas of pulmonary congestion, edema, hemorrhage, and hemosiderosis are found. Chest radiography reveals prominent, symmetric interstitial markings, Kerley B lines, pulmonary artery dilation, and normally sized left atrium and left ventricle. Antemortem

diagnosis is often difficult but is occasionally established by open lung biopsy. There is no effective therapy, and most patients die within 2 years as a result of progressive pulmonary hypertension.

► Clinical Findings

A. Symptoms and Signs

Pulmonary hypertension may cause or contribute to dyspnea, present initially on exertion and later at rest. Dull, retrosternal chest pain resembling angina pectoris may be present. Fatigue and syncope on exertion also occur, presumably a result of reduced cardiac output related to elevated pulmonary artery pressures or bradycardia. Secondary pulmonary hypertension is difficult to recognize clinically in the early stages, when symptoms and signs are primarily those of the underlying disease.

The signs of pulmonary hypertension include narrow splitting of the second heart sound, accentuation of the pulmonary component of the second heart sound, and a systolic ejection click. In advanced cases, tricuspid and pulmonary valve insufficiency and signs of right ventricular failure and cor pulmonale are found.

B. Laboratory Findings

Polycythemia is found in many cases of pulmonary hypertension that are associated with chronic hypoxemia. Electrocardiographic changes are those of right axis deviation, right ventricular hypertrophy, right ventricular strain, or right atrial enlargement.

C. Imaging and Special Examinations

Radiographs and high-resolution CT scans of the chest can assist in the diagnosis of pulmonary hypertension and determination of the cause. In chronic disease, dilation of the right and left main and lobar pulmonary arteries and enlargement of the pulmonary outflow tract are seen; in advanced disease, right ventricular and right atrial enlargement are seen. Peripheral “pruning” of large pulmonary arteries is characteristic of pulmonary hypertension in severe emphysema.

Echocardiography is helpful in evaluating patients thought to have mitral stenosis, left atrial myxoma, and pulmonary valvular disease and may also reveal right ventricular enlargement and paradoxical motion of the interventricular septum. Doppler ultrasonography is a reliable noninvasive means of estimating pulmonary artery systolic pressure. However, precise hemodynamic measurements can only be obtained with right heart catheterization, which is helpful when postcapillary pulmonary hypertension, intracardiac shunting, or thromboembolic disease is considered as part of the differential diagnosis.

The following studies may be useful to exclude causes of secondary pulmonary hypertension: pulmonary function tests (advanced emphysema and severe restriction are associated with elevations in pulmonary artery pressures, a reduction in the single breath diffusing capacity from diminution of the pulmonary capillary bed may suggest chronic thromboembolic disease), liver function tests, HIV

test, collagen-vascular serologic studies, sleep study, and surgical lung biopsy. CT pulmonary angiography, \dot{V}/\dot{Q} lung scanning, and pulmonary angiography are very helpful in identifying patients with pulmonary hypertension caused by recurrent pulmonary thromboemboli, a condition that is often difficult to recognize clinically.

► Treatment

Treatment of idiopathic pulmonary hypertension is discussed in Chapter 10. Treatment of secondary pulmonary hypertension consists mainly of treating the underlying disorder. Early recognition of pulmonary hypertension is crucial to interrupt the self-perpetuating cycle responsible for rapid clinical progression. Most patients who present with symptoms and signs of pulmonary hypertension, however, already have advanced disease. If hypoxemia or acidosis is detected, corrective measures should be started immediately. Supplemental oxygen administered for at least 15 hours per day has been demonstrated to slow the progression of pulmonary hypertension in patients with hypoxemic COPD.

Permanent anticoagulation is indicated in idiopathic pulmonary hypertension but should be given only to those patients with secondary pulmonary hypertension at high risk for thromboembolism. Vasodilator therapy using various pharmacologic agents (eg, calcium antagonists, hydralazine, isoproterenol, diazoxide, nitroglycerin) has shown disappointing results in secondary pulmonary hypertension. Other agents in research trials include subcutaneous (treprostinil), inhaled (iloprost), and oral (beraprost) prostacyclin analogs, endothelin receptor antagonists (bosentan), and phosphodiesterase inhibitors (sildenafil). Some of these agents have shown improvement in functional status but, so far, there is no evidence for improved outcomes. Combination therapy is an area of active research. Patients most likely to benefit from long-term pulmonary vasodilator therapy are those who respond favorably to a vasodilator challenge at right heart catheterization. It is clear that long-term oral vasodilator therapy should be used only if hemodynamic benefit is documented. Complications of pulmonary vasodilator therapy include systemic hypotension, hypoxemia, and even death.

Continuous long-term intravenous infusion (using a portable pump) of prostacyclin (PGI₂; epoprostenol), a potent pulmonary vasodilator, has been shown to confer hemodynamic and symptomatic benefits in selected patients with idiopathic pulmonary hypertension. This is the first therapy to demonstrate improved survival of patients with idiopathic pulmonary hypertension. Limitations of continuous infusion prostacyclin are difficulties in titration, technical problems with portable delivery systems, and the high cost of the drug. Patients with marked polycythemia (hematocrit > 60%) should undergo repeated phlebotomy in an attempt to reduce blood viscosity. Cor pulmonale complicating pulmonary hypertension is treated by managing the underlying pulmonary disease and by using diuretics, salt restriction and, in appropriate patients, supplemental oxygen. The use of digitalis in cor pulmonale remains controversial. Pulmonary

thromboendarterectomy may benefit selected patients with pulmonary hypertension secondary to chronic thrombotic obstruction of major pulmonary arteries.

Single or double lung transplantation may be performed on patients with end-stage idiopathic (primary) pulmonary hypertension. The 2-year survival rate is 50%.

► Prognosis

The prognosis in secondary pulmonary hypertension depends on the course of the underlying disease. The prognosis is favorable when pulmonary hypertension is detected early and the conditions leading to it are readily reversed. Patients with pulmonary hypertension due to fixed obliteration of the pulmonary vascular bed generally respond poorly to therapy; development of cor pulmonale in these cases implies a poor prognosis.

Badesch DB et al. Diagnosis and assessment of pulmonary arterial hypertension. *J Am Coll Cardiol*. 2009 Jun 30;54(1 Suppl):S55–66. [PMID: 19555859]

Barst RJ et al. Updated evidence-based treatment algorithm in pulmonary arterial hypertension. *J Am Coll Cardiol*. 2009 Jun 30;54(1 Suppl):S78–84. [PMID: 19555861]

Zeller JL et al. JAMA patient page. Pulmonary hypertension. *JAMA*. 2008 Jan 23;299(3):372. [PMID: 18212322]

PULMONARY VASCULITIS

Granulomatosis with polyangiitis [formerly Wegener granulomatosis] is an idiopathic disease manifested by a combination of glomerulonephritis, necrotizing granulomatous vasculitis of the upper and lower respiratory tracts, and varying degrees of small vessel vasculitis. Chronic sinusitis, arthralgias, fever, skin rash, and weight loss are frequent presenting symptoms. Specific pulmonary complaints occur less often. The most common sign of lung disease is nodular pulmonary infiltrates, often with cavitation, seen on chest radiography. Tracheal stenosis and endobronchial disease are sometimes seen. The diagnosis is most often based on serologic testing and biopsy of lung, sinus tissue, or kidney with demonstration of necrotizing granulomatous vasculitis. See Chapter 20.

Allergic angiitis and granulomatosis (Churg-Strauss syndrome) is an idiopathic multisystem vasculitis of small and medium-sized arteries that occurs in patients with asthma. The skin and lungs are most often involved, but other organs, including the paranasal sinuses, the heart, gastrointestinal tract, liver, and peripheral nerves, may also be affected. Peripheral eosinophilia > 1500 cells/mcL or > 10% of peripheral WBCs is the rule. Abnormalities on chest radiographs range from transient opacities to multiple nodules. This illness may be part of a spectrum that includes polyarteritis nodosa. The diagnosis requires demonstration of histologic features including fibrinoid necrotizing epithelioid and eosinophilic granulomas.

► Treatment

Treatment of pulmonary vasculitis usually requires corticosteroids and cyclophosphamide. Oral prednisone (1 mg/kg

ideal body weight per day initially, tapering slowly to alternate-day therapy over 3–6 months) is the corticosteroid of choice; in granulomatosis with polyangiitis, some clinicians may use cyclophosphamide alone. For fulminant vasculitis, therapy may be initiated with intravenous methylprednisolone (up to 1 g intravenously per day) for several days. Cyclophosphamide (1–2 mg/kg ideal body weight orally per day initially, with dosage adjustments to avoid neutropenia) is given until complete remission is obtained and then is slowly tapered, and often replaced with methotrexate or azathioprine for maintenance therapy.

► Prognosis

Five-year survival rates in patients with these vasculitis syndromes have been improved by the combination therapy. Complete remissions can be achieved in over 90% of patients with granulomatosis with polyangiitis. The addition of trimethoprim-sulfamethoxazole (one double-strength tablet by mouth twice daily) to standard therapy may help prevent relapses.

Alberts WM. Pulmonary manifestations of the Churg-Strauss syndrome and related idiopathic small vessel vasculitis syndromes. *Curr Opin Pulm Med*. 2007 Sep;13(5):445–50. [PMID: 17940492]

Grau RG. Churg-Strauss syndrome: 2005–2008 update. *Curr Rheumatol Rep*. 2008 Dec;10(6):453–8. [PMID: 19007535]

Seo P. Wegener's granulomatosis: managing more than inflammation. *Curr Opin Rheumatol*. 2008 Jan;20(1):10–6. [PMID: 18281851]

ALVEOLAR HEMORRHAGE SYNDROMES

Diffuse alveolar hemorrhage may occur in a variety of immune and nonimmune disorders. Hemoptysis, alveolar infiltrates on chest radiograph, anemia, dyspnea, and occasionally fever are characteristic. Rapid clearing of diffuse lung infiltrates within 2 days is a clue to the diagnosis of diffuse alveolar hemorrhage. Pulmonary hemorrhage can be associated with an increased DL_{CO} .

Causes of **immune alveolar hemorrhage** have been classified as anti-basement membrane antibody disease (Goodpasture syndrome), vasculitis and collagen vascular disease (systemic lupus erythematosus, [granulomatosis with polyangiitis formerly, **Wegener granulomatosis**], systemic necrotizing vasculitis, and others), and pulmonary capillaritis associated with idiopathic rapidly progressive glomerulonephritis. **Nonimmune causes** of diffuse hemorrhage include coagulopathy, mitral stenosis, necrotizing pulmonary infection, drugs (penicillamine), toxins (trimellitic anhydride), and idiopathic pulmonary hemosiderosis.

Goodpasture syndrome is idiopathic recurrent alveolar hemorrhage and rapidly progressive glomerulonephritis. The disease is mediated by anti-glomerular basement membrane antibodies. Goodpasture syndrome occurs mainly in men who are in their 30s and 40s. Hemoptysis is the usual presenting symptom, but pulmonary hemorrhage may be occult. Dyspnea, cough, hypoxemia, and diffuse bilateral alveolar infiltrates are typical features. Iron

deficiency anemia and microscopic hematuria are usually present. The diagnosis is based on characteristic linear IgG deposits detected by immunofluorescence in glomeruli or alveoli and on the presence of anti-glomerular basement membrane antibody in serum. Combinations of immunosuppressive drugs (initially methylprednisolone, 30 mg/kg intravenously over 20 minutes every other day for three doses, followed by daily oral prednisone, 1 mg/kg/d; with cyclophosphamide, 2 mg/kg orally per day) and plasmapheresis have yielded excellent results.

Idiopathic pulmonary hemosiderosis is a disease of children or young adults characterized by recurrent pulmonary hemorrhage; in contrast to Goodpasture syndrome, renal involvement and anti-glomerular basement membrane antibodies are absent, but iron deficiency is typical. Treatment of acute episodes of hemorrhage with corticosteroids may be useful. Recurrent episodes of pulmonary hemorrhage may result in interstitial fibrosis and pulmonary failure.

Ioachimescu OC et al. Diffuse alveolar hemorrhage: diagnosing it and finding the cause. *Cleve Clin J Med.* 2008 Apr;75(4):258, 260, 264–5. [PMID: 18491433]

ENVIRONMENTAL & OCCUPATIONAL LUNG DISORDERS

SMOKE INHALATION

The inhalation of products of combustion may cause serious respiratory complications. As many as one-third of patients admitted to burn treatment units have pulmonary injury from smoke inhalation. Morbidity and mortality due to smoke inhalation may exceed those attributed to the burns themselves. The death rate of patients with both severe burns and smoke inhalation exceeds 50%.

All patients in whom significant smoke inhalation is suspected must be assessed for three consequences of smoke inhalation: impaired tissue oxygenation, thermal injury to the upper airway, and injury to the lower airways and lung parenchyma. Impaired tissue oxygenation may result from inhalation of a hypoxemia gas mixture, carbon monoxide or cyanide, or from alterations in \dot{V}/\dot{Q} matching, and is an immediate threat to life. Immediate treatment with 100% oxygen is essential. The management of patients with carbon monoxide and cyanide poisoning is discussed in Chapter 38. The clinician must recognize that patients with carbon monoxide poisoning display a normal partial pressure of oxygen in arterial blood (PaO_2) but have a low *measured* (ie, not oximetric) hemoglobin saturation (SaO_2). Treatment with 100% oxygen should be continued until the measured carboxyhemoglobin level falls to less than 10% and concomitant metabolic acidosis has resolved.

Thermal injury to the mucosal surfaces of the upper airway occurs from inhalation of super-heated gases. Complications including mucosal edema, upper airway obstruction, and impaired ability to clear oral secretions usually become evident by 18–24 hours and produce inspiratory stridor. Respiratory failure occurs in severe

cases. Early management (see also Chapter 37) includes the use of a high-humidity face mask with supplemental oxygen, gentle suctioning to evacuate oral secretions, elevation of the head 30 degrees to promote clearing of secretions, and topical epinephrine to reduce edema of the oropharyngeal mucous membrane. Helium-oxygen gas mixtures (Heliox) may reduce labored breathing due to critical upper airway narrowing. Close monitoring with arterial blood gases and later with oximetry is important. Examination of the upper airway with a fiberoptic laryngoscope or bronchoscope is superior to routine physical examination. Endotracheal intubation is often necessary to establish airway patency and is likely to be necessary in patients with deep facial burns or oropharyngeal or laryngeal edema. Tracheotomy should be avoided if possible because of an increased risk of pneumonia and death from sepsis.

Injury to the lower airways and lung parenchyma results from inhalation of toxic gases and products of combustion, including aldehydes and organic acids. The site of lung injury depends on the solubility of the gases inhaled, the duration of exposure, and the size of inhaled particles that transport noxious gases to distal lung units. Bronchorrhoea and bronchospasm are seen early after exposure along with dyspnea, tachypnea, and tachycardia. Labored breathing and cyanosis may follow. Physical examination at this stage reveals diffuse wheezing and rhonchi. Bronchiolar and alveolar edema (eg, ARDS) may develop within 1–2 days after exposure. Sloughing of the bronchiolar mucosa may occur within 2–3 days, leading to airway obstruction, atelectasis, and worsening hypoxemia. Bacterial colonization and pneumonia are common by 5–7 days after the exposure.

Treatment of smoke inhalation consists of supplemental oxygen, bronchodilators, suctioning of mucosal debris and mucopurulent secretions via an indwelling endotracheal tube, chest physical therapy to aid clearance of secretions, and adequate humidification of inspired gases. Positive end-expiratory pressure (PEEP) has been advocated to treat bronchiolar edema. Judicious fluid management and close monitoring for secondary bacterial infection with daily sputum Gram stains round out the management protocol.

The routine use of corticosteroids for lung injury from smoke inhalation has been shown to be ineffective and may even be harmful. Routine or prophylactic use of antibiotics is not recommended.

Patients who survive should be watched for the late development of bronchiolitis obliterans.

Mlcak RP et al. Respiratory management of inhalation injury. *Burns.* 2007 Feb;33(1):2–13. [PMID: 17223484]

PULMONARY ASPIRATION SYNDROMES

Aspiration of material into the tracheobronchial tree results from various disorders that impair normal deglutition, especially disturbances of consciousness and esophageal dysfunction.

1. Acute Aspiration of Gastric Contents (Mendelson Syndrome)

Acute aspiration of gastric contents may be catastrophic. The pulmonary response depends on the characteristics and amount of gastric contents aspirated. The more acidic the material, the greater the degree of chemical pneumonitis. Aspiration of pure gastric acid (pH < 2.5) causes extensive desquamation of the bronchial epithelium, bronchiolitis, hemorrhage, and pulmonary edema. Acute gastric aspiration is one of the most common causes of ARDS. The clinical picture is one of abrupt onset of respiratory distress, with cough, wheezing, fever, and tachypnea. Crackles may be audible at the bases of the lungs. Hypoxemia may be noted immediately after aspiration occurs. Radiographic abnormalities, consisting of patchy alveolar opacities in dependent lung zones, appear within a few hours. If particulate food matter has been aspirated along with gastric acid, radiographic features of bronchial obstruction may be observed. Fever and leukocytosis are common even in the absence of infection.

Treatment of acute aspiration of gastric contents consists of supplemental oxygen, measures to maintain the airway, and the usual measures for treatment of acute respiratory failure. There is no evidence to support the routine use of prophylactic antibiotics or corticosteroids after gastric aspiration. Secondary pulmonary infection, which occurs in about one-fourth of patients, typically appears 2–3 days after aspiration. Management of infection depends on the observed flora of the tracheobronchial tree. Hypotension secondary to alveolar capillary membrane injury and intravascular volume depletion is common and is managed with the judicious administration of intravenous fluids.

2. Chronic Aspiration of Gastric Contents

Chronic aspiration of gastric contents may result from primary disorders of the larynx or the esophagus, such as achalasia, esophageal stricture, systemic sclerosis (scleroderma), esophageal carcinoma, esophagitis, and gastroesophageal reflux. In the last condition, relaxation of the tone of the lower esophageal sphincter allows reflux of gastric contents into the esophagus and predisposes to chronic pulmonary aspiration, especially at night. Cigarette smoking, consumption of alcohol or caffeine, and use of theophylline are known to relax the lower esophageal sphincter. Pulmonary disorders linked to gastroesophageal reflux and chronic aspiration include asthma, chronic cough, bronchiectasis, and pulmonary fibrosis. Even in the absence of aspiration, acid in the esophagus may trigger bronchospasm or bronchial hyperreactivity through reflex mechanisms.

The diagnosis and management of gastroesophageal reflux and chronic aspiration is challenging. A discussion of strategies for the evaluation, prevention, and management of extraesophageal reflux manifestations can be found in Chapter 15.

3. “Café Coronary”

Acute obstruction of the upper airway by food is associated with difficulty swallowing, old age, dental problems that

impair chewing, and use of alcohol and sedative drugs. The Heimlich procedure is lifesaving in many cases.

4. Retention of an Aspirated Foreign Body

Retention of an aspirated foreign body in the tracheobronchial tree may produce both acute and chronic conditions, including atelectasis, postobstructive hyperinflation, both acute and recurrent pneumonia, bronchiectasis, and lung abscess. Occasionally, a misdiagnosis of asthma, COPD, or lung cancer is made in adult patients who have aspirated a foreign body. The plain chest radiograph usually suggests the site of the foreign body. In some cases, an expiratory film, demonstrating regional hyperinflation due to a check-valve effect, is helpful. Bronchoscopy is usually necessary to establish the diagnosis and attempt removal of the foreign body.

5. Aspiration of Inert Material

Aspiration of inert material may cause asphyxia if the amount aspirated is massive and if cough is impaired, in which case immediate tracheobronchial suctioning is necessary. Most patients suffer no serious sequelae from aspiration of inert material.

6. Aspiration of Toxic Material

Aspiration of toxic material into the lung usually results in clinically evident pneumonia. **Hydrocarbon pneumonitis** is caused by aspiration of ingested petroleum distillates, eg, gasoline, kerosene, furniture polish, and other household petroleum products. Lung injury results mainly from vomiting of ingested products and secondary aspiration. Therapy is supportive. The lung should be protected from repeated aspiration with a cuffed endotracheal tube if necessary. **Lipoid pneumonia** is a chronic syndrome related to the repeated aspiration of oily materials, eg, mineral oil, cod liver oil, and oily nose drops; it usually occurs in elderly patients with impaired swallowing. Patchy opacities in dependent lung zones and lipid-laden macrophages in expectorated sputum are characteristic findings.

Boyd M et al. Tracheobronchial foreign body aspiration in adults. *South Med J*. 2009 Feb;102(2):171–4. [PMID: 19139679]

Marik PE. Aspiration syndromes: aspiration pneumonia and pneumonitis. *Hosp Pract (Minneapolis)*. 2010 Feb;38(1):35–42. [PMID: 20469622]

Raghavendran K et al. Aspiration-induced lung injury. *Crit Care Med*. 2011 Apr;39(4):818–26. [PMID: 21263315]

OCCUPATIONAL PULMONARY DISEASES

Many acute and chronic pulmonary diseases are directly related to inhalation of noxious substances encountered in the workplace. Disorders that are linked to occupational exposures may be classified as follows: (1) pneumoconiosis, (2) hypersensitivity pneumonitis, (3) obstructive airway disorders, (4) pulmonary edema, (5) lung cancer, (6) pleural diseases, and (7) miscellaneous disorders.

1. Pneumoconioses

Pneumoconioses are chronic fibrotic lung diseases caused by the inhalation of inorganic dusts. Pneumoconioses due to inhalation of inert dusts may be asymptomatic disorders with diffuse nodular opacities on chest radiograph or may be severe, symptomatic, life-shortening disorders. Clinically important pneumoconioses include coal worker's pneumoconiosis, silicosis, and asbestosis (Table 9–25). Treatment for each is supportive.

A. Coal Worker's Pneumoconiosis

In coal worker's pneumoconiosis, ingestion of inhaled coal dust by alveolar macrophages leads to the formation of coal macules, usually 2–5 mm in diameter, that appear on chest radiograph as diffuse small opacities that are especially prominent in the upper lung. Simple coal worker's pneumoconiosis is usually asymptomatic; pulmonary function abnormalities are unimpressive. Cigarette smoking does not increase the prevalence of coal worker's pneumoconiosis but may have an additive detrimental effect on ventilatory function. In complicated coal worker's pneumoconiosis

(“**progressive massive fibrosis**”), conglomeration and contraction in the upper lung zones occur, with radiographic features resembling complicated silicosis. **Caplan syndrome** is a rare condition characterized by the presence of necrobiotic rheumatoid nodules (1–5 cm in diameter) in the periphery of the lung in coal workers with rheumatoid arthritis.

B. Silicosis

In silicosis, extensive or prolonged inhalation of free silica (silicon dioxide) particles in the respirable range (0.3–5 mcm) causes the formation of small rounded opacities (silicotic nodules) throughout the lung. Calcification of the periphery of hilar lymph nodes (“eggshell” calcification) is an unusual radiographic finding that strongly suggests silicosis. Simple silicosis is usually asymptomatic and has no effect on routine pulmonary function tests; in complicated silicosis, large conglomerate densities appear in the upper lung and are accompanied by dyspnea and obstructive and restrictive pulmonary dysfunction. The incidence of pulmonary tuberculosis is increased in patients with silicosis. All patients with silicosis should have a tuberculin skin test and a current chest radiograph. If old, healed pulmonary tuberculosis is suspected, multidrug treatment for tuberculosis (not single-agent preventive therapy) should be instituted.

C. Asbestosis

Asbestosis is a nodular interstitial fibrosis occurring in workers exposed to asbestos fibers (shipyard and construction workers, pipe fitters, insulators) over many years (typically 10–20 years). Patients with asbestosis usually first seek medical attention at least 15 years after exposure with the following symptoms and signs: progressive dyspnea, inspiratory crackles, and in some cases, clubbing and cyanosis. The radiographic features of asbestosis include linear streaking at the lung bases, opacities of various shapes and sizes, and honeycomb changes in advanced cases. The presence of pleural calcifications may be a clue to diagnosis. High-resolution CT scanning is the best imaging method for asbestosis because of its ability to detect parenchymal fibrosis and define the presence of coexisting pleural plaques. Cigarette smoking in asbestos workers increases the prevalence of radiographic pleural and parenchymal changes and markedly increases the incidence of lung carcinoma. It may also interfere with the clearance of short asbestos fibers from the lung. Pulmonary function studies show restrictive dysfunction and reduced diffusing capacity. The presence of a ferruginous body in tissue suggests significant asbestos exposure; however, other histologic features must be present for diagnosis. There is no specific treatment.

Table 9–25. Selected pneumoconioses.

Disease	Agent	Occupations
Metal dusts		
Siderosis	Metallic iron or iron oxide	Mining, welding, foundry work
Stannosis	Tin, tin oxide	Mining, tin-working, smelting
Baritosis	Barium salts	Glass and insecticide manufacturing
Coal dust		
Coal worker's pneumoconiosis	Coal dust	Coal mining
Inorganic dusts		
Silicosis	Free silica (silicon dioxide)	Rock mining, quarrying, stone cutting, tunneling, sandblasting, pottery, diatomaceous earth
Silicate dusts		
Asbestosis	Asbestos	Mining, insulation, construction, shipbuilding
Talcosis	Magnesium silicate	Mining, insulation, construction, shipbuilding
Kaolin pneumoconiosis	Sand, mica, aluminum silicate	Mining of china clay; pottery and cement work
Shaver disease	Aluminum powder	Manufacture of corundum

Cohen RA et al. Lung disease caused by exposure to coal mine and silica dust. *Semin Respir Crit Care Med.* 2008 Dec; 29(6): 651–61. [PMID: 19221963]
 O'Reilly KM et al. Asbestos-related lung disease. *Am Fam Physician.* 2007 Mar 1;75(5):683–8. [PMID: 17375514]

2. Hypersensitivity Pneumonitis

Hypersensitivity pneumonitis (also called extrinsic allergic alveolitis) is a nonatopic, nonasthmatic inflammatory pulmonary disease. It is manifested mainly as an occupational disease (Table 9–26), in which exposure to inhaled organic antigens leads to an acute illness. Prompt diagnosis is essential since symptoms are usually reversible if the offending antigen is removed from the patient's environment early in the course of illness. Continued exposure may lead to progressive disease. The histopathology of acute hypersensitivity pneumonitis is characterized by interstitial infiltrates of lymphocytes and plasma cells, with noncaseating granulomas in the interstitium and air spaces.

► Clinical Findings

A. Acute Illness

The symptoms are characterized by sudden onset of malaise, chills, fever, cough, dyspnea, and nausea 4–8 hours after exposure to the offending antigen. This may occur after the patient has left work or even at night and thus may mimic paroxysmal nocturnal dyspnea. Bibasilar crackles, tachypnea, tachycardia, and (occasionally) cyanosis are noted. Small nodular densities sparing the apices and bases of the lungs are noted on chest radiograph. Laboratory

studies reveal an increase in the white blood cell count with a shift to the left, hypoxemia, and the presence of precipitating antibodies to the offending agent in serum. Hypersensitivity pneumonitis antibody panels against common offending antigens are available; positive results, while supportive, do not establish a definitive diagnosis. Pulmonary function studies reveal restrictive dysfunction and reduced diffusing capacity.

B. Subacute Illness

A subacute hypersensitivity pneumonitis syndrome (15% of cases) is characterized by the insidious onset of chronic cough and slowly progressive dyspnea, anorexia, and weight loss. Chronic exposure leads to progressive respiratory insufficiency and the appearance of pulmonary fibrosis on chest imaging. Surgical lung biopsy may be necessary for the diagnosis of subacute and chronic hypersensitivity pneumonitis. Even with surgical lung biopsy, however, chronic hypersensitivity pneumonitis may be difficult to diagnose because histopathologic patterns overlap with several idiopathic interstitial pneumonias.

► Treatment

Treatment of acute hypersensitivity pneumonitis consists of identification of the offending agent and avoidance of further exposure. In severe acute or protracted cases, oral corticosteroids (prednisone, 0.5 mg/kg daily as a single morning dose for 2 weeks, tapered to nil over 4–6 weeks) may be given. Change in occupation is often unavoidable.

Table 9–26. Selected causes of hypersensitivity pneumonitis.

Disease	Antigen	Source
Farmer's lung	<i>Micropolyspora faeni</i> , <i>Thermoactinomyces vulgaris</i>	Moldy hay
"Humidifier" lung	Thermophilic actinomycetes	Contaminated humidifiers, heating systems, or air conditioners
Bird fancier's lung ("pigeon-breeder's disease")	Avian proteins	Bird serum and excreta
Bagassosis	<i>Thermoactinomyces sacchari</i> and <i>T vulgaris</i>	Moldy sugar cane fiber (bagasse)
Sequoiosis	Graphium, <i>Aureobasidium</i> , and other fungi	Moldy redwood sawdust
Maple bark stripper's disease	<i>Cryptostroma (Coniosporium) corticale</i>	Rotting maple tree logs or bark
Mushroom picker's disease	Same as farmer's lung	Moldy compost
Suberosis	<i>Penicillium frequentans</i>	Moldy cork dust
Detergent worker's lung	<i>Bacillus subtilis</i> enzyme	Enzyme additives

Girard M et al. Hypersensitivity pneumonitis. *Allergy*. 2009 Mar;64(3):322–34. [PMID: 19210361]
 Lacasse Y et al. Myths and controversies in hypersensitivity pneumonitis. *Semin Respir Crit Care Med*. 2008 Dec;29(6):631–42. [PMID: 19221961]

3. Obstructive Airway Disorders

Occupational pulmonary diseases manifested as obstructive airway disorders include occupational asthma, industrial bronchitis, and byssinosis.

A. Occupational Asthma

It has been estimated that from 2% to 5% of all cases of asthma are related to occupation. Offending agents in the workplace are numerous; they include grain dust, wood dust, tobacco, pollens, enzymes, gum arabic, synthetic dyes, isocyanates (particularly toluene diisocyanate), rosin (soldering flux), inorganic chemicals (salts of nickel, platinum, and chromium), trimellitic anhydride, phthalic anhydride, formaldehyde, and various pharmaceutical agents. Diagnosis of occupational asthma depends on a high index of suspicion, an appropriate history, spirometric studies before and after exposure to the offending substance, and peak flow rate measurements in the workplace. Bronchial provocation testing may be helpful in some cases. Treatment consists of avoidance of further exposure to the offending agent and bronchodilators, but symptoms may persist for years after workplace exposure has been terminated.

B. Industrial Bronchitis

Industrial bronchitis is chronic bronchitis found in coal miners and others exposed to cotton, flax, or hemp dust. Chronic disability from industrial bronchitis is infrequent.

C. Byssinosis

Byssinosis is an asthma-like disorder in textile workers caused by inhalation of cotton dust. The pathogenesis is obscure. Chest tightness, cough, and dyspnea are characteristically worse on Mondays or the first day back at work, with symptoms subsiding later in the week. Repeated exposure leads to chronic bronchitis.

4. Toxic Lung Injury

Toxic lung injury from inhalation of irritant gases is discussed in the section on smoke inhalation. **Silo-filler's disease** is acute toxic high-permeability pulmonary edema caused by inhalation of nitrogen dioxide encountered in recently filled silos. Bronchiolitis obliterans is a common late complication, which may be prevented by early treatment of the acute reaction with corticosteroids. Extensive exposure to silage gas may be fatal. Inhalation of the compound diacetyl, a constituent of butter-flavoring, has been linked to the development of bronchiolitis obliterans among microwave popcorn production workers.

5. Lung Cancer

Many industrial pulmonary carcinogens have been identified, including asbestos, radon gas, arsenic, iron, chromium, nickel, coal tar fumes, petroleum oil mists, isopropyl oil, mustard gas, and printing ink. Cigarette smoking acts as a cocarcinogen with asbestos and radon gas to cause bronchogenic carcinoma. Asbestos alone causes malignant mesothelioma. Almost all histologic types of lung cancer have been associated with these carcinogens. Chloromethyl methyl ether specifically causes small cell carcinoma of the lung.

6. Pleural Diseases

Occupational diseases of the pleura may result from exposure to asbestos (see above) or talc. Inhalation of talc causes pleural plaques that are similar to those caused by asbestos. Benign asbestos pleural effusion occurs in some asbestos workers and may cause chronic blunting of the costophrenic angle on chest radiograph.

7. Other Occupational Pulmonary Diseases

Occupational agents are also responsible for other pulmonary disorders. These include exposure to beryllium, which now occurs in machining and handling of beryllium products and alloys. Beryllium miners are not at risk for berylliosis and beryllium is no longer used in fluorescent lamp production, which was a source of exposure before 1950. **Berylliosis**, an acute or chronic pulmonary disorder, occurs from absorption of beryllium through the lungs or skin and widely disseminated throughout the body. Acute berylliosis is a toxic, ulcerative tracheobronchitis and

chemical pneumonitis following intense and severe exposure to beryllium. Chronic berylliosis, a systemic disease closely resembling sarcoidosis, is more common. Chronic pulmonary beryllium disease is thought to be an alveolitis mediated by the proliferation of beryllium-specific helper-inducer T cells in the lung.

Cowl CT. Occupational asthma: review of assessment, treatment, and compensation. *Chest*. 2011 Mar;139(3):674–81. [PMID: 21362654]

Henneberger PK et al; ATS Ad Hoc Committee on Work-Exacerbated Asthma. An official American Thoracic Society statement: work-exacerbated asthma. *Am J Respir Crit Care Med*. 2011 Aug 1;184(3):368–78. [PMID: 21804122]

DRUG-INDUCED LUNG DISEASE

Typical patterns of pulmonary response to drugs implicated in drug-induced respiratory disease are summarized in Table 9–27. Pulmonary injury due to drugs occurs as a result of allergic reactions, idiosyncratic reactions, overdose, or undesirable side effects. In most patients, the mechanism of pulmonary injury is unknown.

Precise diagnosis of drug-induced pulmonary disease is often difficult, because results of routine laboratory studies are not helpful and radiographic findings are not specific. A high index of suspicion and a thorough medical history of drug usage are critical to establishing the diagnosis of drug-induced lung disease. The clinical response to cessation of the suspected offending agent is also helpful. Acute episodes of drug-induced pulmonary disease usually disappear 24–48 hours after the drug has been discontinued, but chronic syndromes may take longer to resolve. Challenge tests to confirm the diagnosis are risky and rarely performed.

Treatment of drug-induced lung disease consists of discontinuing the offending agent immediately and managing the pulmonary symptoms appropriately.

Inhalation of crack cocaine may cause a spectrum of acute pulmonary syndromes, including pulmonary infiltration with eosinophilia, pneumothorax and pneumomediastinum, bronchiolitis obliterans, and acute respiratory failure associated with diffuse alveolar damage and alveolar hemorrhage. Corticosteroids have been used with variable success to treat alveolar hemorrhage.

Babu KS et al. Drug-induced airway diseases. *Clin Chest Med*. 2004 Mar;25(1):113–22. [PMID: 15062603]

Huggins JT et al. Drug-induced pleural disease. *Clin Chest Med*. 2004 Mar;25(1):141–53. [PMID: 15062606]

RADIATION LUNG INJURY

The lung is an exquisitely radiosensitive organ that can be damaged by external beam radiation therapy. The degree of pulmonary injury is determined by the volume of lung irradiated, the dose and rate of exposure, and potentiating factors (eg, concurrent chemotherapy, previous radiation therapy in the same area, and simultaneous withdrawal of corticosteroid therapy). Symptomatic radiation lung injury occurs in about 10% of patients treated for carcinoma of

Table 9–27. Pulmonary manifestations of selected drug toxicities.

Asthma	Pulmonary edema
β-Blockers	Noncardiogenic
Aspirin	Aspirin
Nonsteroidal anti-inflammatory drugs	Chlordiazepoxide
Histamine	Cocaine
Methacholine	Ethchlorvynol
Acetylcysteine	Heroin
Aerosolized pentamidine	Cardiogenic
Any nebulized medication	β-Blockers
Chronic cough	Pleural effusion
Angiotensin-converting enzyme inhibitors	Bromocriptine
Pulmonary infiltration	Nitrofurantoin
Without eosinophilia	Any drug inducing systemic lupus erythematosus
Amitriptyline	Methysergide
Azathioprine	Chemotherapeutic agents (eg, carmustine, cyclophosphamide, dasatinib, docetaxel, GM-CSF, methotrexate)
Amiodarone	Mediastinal widening
With eosinophilia	Phenytoin
Sulfonamides	Corticosteroids
L-Tryptophan	Methotrexate
Nitrofurantoin	Respiratory failure
Penicillin	Neuromuscular blockade
Methotrexate	Aminoglycosides
Crack cocaine	Succinylcholine
Drug-induced systemic lupus erythematosus	Gallamine
Hydralazine	Dimethyltubocurarine (metocurine)
Procainamide	Central nervous system depression
Isoniazid	Sedatives
Chlorpromazine	Hypnotics
Phenytoin	Opioids
Interstitial pneumonitis/fibrosis	Alcohol
Nitrofurantoin	Tricyclic antidepressants
Bleomycin	Oxygen
Busulfan	
Cyclophosphamide	
Methysergide	
Phenytoin	

GM-CSF, granulocyte-macrophage colony-stimulating factor.

the breast, 5–15% of patients treated for carcinoma of the lung, and 5–35% of patients treated for lymphoma. Two phases of the pulmonary response to radiation are apparent: an acute phase (radiation pneumonitis) and a chronic phase (radiation fibrosis).

1. Radiation Pneumonitis

Acute radiation pneumonitis usually occurs 2–3 months (range 1–6 months) after completion of radiotherapy and is characterized by insidious onset of dyspnea, intractable dry cough, chest fullness or pain, weakness, and fever. Late radiation pneumonitis may develop 6–12 months after completion of radiation. The pathogenesis of acute radiation pneumonitis is unknown, but there is speculation that hypersensitivity mechanisms are involved. The dominant histopathologic findings are a lymphocytic interstitial

pneumonitis progressing to an exudative alveolitis. Inspiratory crackles may be heard in the involved area. In severe disease, respiratory distress and cyanosis occur that are characteristic of ARDS. An increased white blood cell count and elevated sedimentation rate are common. Pulmonary function studies reveal reduced lung volumes, reduced lung compliance, hypoxemia, reduced diffusing capacity, and reduced maximum voluntary ventilation. Chest radiography, which correlates poorly with the presence of symptoms, usually demonstrates alveolar or nodular opacities limited to the irradiated area. Air bronchograms are often observed. Sharp borders of an opacity may help distinguish radiation pneumonitis from other conditions such as infectious pneumonia, lymphangitic spread of carcinoma, and recurrent tumor; however, the opacity may extend beyond the radiation field. No specific therapy is proved to be effective in radiation pneumonitis, but prednisone (1 mg/kg/d orally) is commonly given immediately for about 1 week. The dose is then reduced and maintained at 20–40 mg/d for several weeks, then slowly tapered. Radiation pneumonitis may improve in 2–3 weeks following onset of symptoms as the exudative phase resolves. Acute respiratory failure, if present, is treated supportively. Death from ARDS is unusual in radiation pneumonitis.

2. Pulmonary Radiation Fibrosis

Radiation fibrosis may occur with or without antecedent radiation pneumonitis. Cor pulmonale and chronic respiratory failure are rare. Radiographic findings include obliteration of normal lung markings, dense interstitial and pleural fibrosis, reduced lung volumes, tenting of the diaphragm, and sharp delineation of the irradiated area. No specific therapy is proven effective, and corticosteroids have no value. Pulmonary fibrosis may develop after an intervening period (6–12 months) of well being in patients who experience radiation pneumonitis. Pulmonary radiation fibrosis occurs in most patients who receive a full course of radiation therapy for cancer of the lung or breast. Most patients are asymptomatic, although slowly progressive dyspnea may occur.

3. Other Complications of Radiation Therapy

Other complications of radiation therapy directed to the thorax include pericardial effusion, constrictive pericarditis, tracheoesophageal fistula, esophageal candidiasis, radiation dermatitis, and rib fractures. Small pleural effusions, radiation pneumonitis outside the irradiated area, spontaneous pneumothorax, and complete obstruction of central airways are unusual occurrences.

Berkey FJ. Managing the adverse effects of radiation therapy. *Am Fam Physician*. 2010 Aug 15;82(4):381–8, 394. [PMID: 20704169]

Camus P et al. Interstitial lung disease induced by drugs and radiation. *Respiration*. 2004 Jul–Aug;71(4):301–26. [PMID: 15316202]

Ghafoori P et al. Radiation-induced lung injury. Assessment, management, and prevention. *Oncology (Williston Park)*. 2008 Jan;22(1):37–47. [PMID: 18251282]

PLEURAL DISEASES

PLEURITIS

Pain due to acute pleural inflammation is caused by irritation of the parietal pleura. Such pain is localized, sharp, and fleeting; it is made worse by coughing, sneezing, deep breathing, or movement. When the central portion of the diaphragmatic parietal pleura is irritated, pain may be referred to the ipsilateral shoulder. There are numerous causes of pleuritis. The setting in which pleuritic pain develops helps narrow the differential diagnosis. In young, otherwise healthy individuals, pleuritis is usually caused by viral respiratory infections or pneumonia. The presence of pleural effusion, pleural thickening, or air in the pleural space requires further diagnostic and therapeutic measures. Simple rib fracture may cause severe pleurisy.

Treatment of pleuritis consists of treating the underlying disease. Analgesics and anti-inflammatory drugs (eg, indomethacin, 25 mg orally two or three times daily) are often helpful for pain relief. Codeine (30–60 mg orally every 8 hours) may be used to control cough associated with pleuritic chest pain if retention of airway secretions is not a likely complication. Intercostal nerve blocks are sometimes helpful but the benefit is usually transient.

PLEURAL EFFUSION

ESSENTIALS OF DIAGNOSIS

- ▶ May be asymptomatic; chest pain frequently seen in the setting of pleuritis, trauma, or infection; dyspnea is common with large effusions.
- ▶ Dullness to percussion and decreased breath sounds over the effusion.
- ▶ Radiographic evidence of pleural effusion.
- ▶ Diagnostic findings on thoracentesis.

▶ General Considerations

There is constant movement of fluid from parietal pleural capillaries into the pleural space at a rate of 0.01 mL/kg body weight/h. Absorption of pleural fluid occurs through parietal pleural lymphatics. The resultant homeostasis leaves 5–15 mL of fluid in the normal pleural space. A pleural effusion is an abnormal accumulation of fluid in the pleural space. Pleural effusions may be classified by differential diagnosis (Table 9–28) or by underlying pathophysiology. Five pathophysiologic processes account for most pleural effusions: increased production of fluid in the setting of normal capillaries due to increased hydrostatic or decreased oncotic pressures (**transudates**); increased production of fluid due to abnormal capillary permeability (**exudates**); decreased lymphatic clearance of fluid from the pleural space (**exudates**); infection in the pleural space (**empyema**); and bleeding into the pleural space (**hemothorax**). **Parapneumonic** pleural effusions are exudates that accompany bacterial pneumonias.

Table 9–28. Causes of pleural fluid transudates and exudates.

Transudates	Exudates
Congestive heart failure (> 90% of cases)	Pneumonia (parapneumonic effusion)
Cirrhosis with ascites	Cancer
Nephrotic syndrome	Pulmonary embolism
Peritoneal dialysis	Bacterial infection
Myxedema	Tuberculosis
Atelectasis (acute)	Connective tissue disease
Constrictive pericarditis	Viral infection
Superior vena cava obstruction	Fungal infection
Pulmonary embolism	Rickettsial infection
	Parasitic infection
	Asbestos
	Meigs syndrome
	Pancreatic disease
	Uremia
	Chronic atelectasis
	Trapped lung
	Chylothorax
	Sarcoidosis
	Drug reaction
	Post-myocardial injury syndrome

Diagnostic thoracentesis should be performed whenever there is a new pleural effusion and no clinically apparent cause. Observation is appropriate in some situations (eg, symmetric bilateral pleural effusions in the setting of congestive heart failure), but an atypical presentation or failure of an effusion to resolve as expected warrants thoracentesis. Sampling allows visualization of the fluid in addition to chemical and microbiologic analyses to identify the pathophysiologic processes listed above.

▶ Clinical Findings

A. Symptoms and Signs

Patients with pleural effusions most often report dyspnea, cough, or respirophasic chest pain. Symptoms are more common in patients with existing cardiopulmonary disease. Small pleural effusions are less likely to be symptomatic than larger effusions. Physical findings are usually absent in small effusions. Larger effusions may present with dullness to percussion and diminished or absent breath sounds over the effusion. Compressive atelectasis may cause bronchial breath sounds and egophony just above the effusion. A massive effusion with increased intrapleural pressure may cause contralateral shift of the trachea and bulging of the intercostal spaces. A pleural friction rub indicates infarction or pleuritis.

B. Laboratory Findings

The gross appearance of pleural fluid helps identify several types of pleural effusion. Grossly purulent fluid signifies empyema. Milky white pleural fluid should be centrifuged. A clear supernatant above a pellet of white cells indicates empyema, whereas a persistently turbid supernatant

suggests a **chylous effusion**; analysis of this supernatant reveals chylomicrons and a high triglyceride level (> 100 mg/dL [1 mmol/L]), often from disruption of the thoracic duct. **Hemorrhagic pleural effusion** is a mixture of blood and pleural fluid. Ten thousand red cells per milliliter create blood-tinged pleural fluid; 100,000/mL create grossly bloody pleural fluid. **Hemothorax** is the presence of gross blood in the pleural space, usually following chest trauma or instrumentation. It is defined as a ratio of pleural fluid hematocrit to peripheral blood hematocrit > 0.5 .

Pleural fluid samples should be sent for measurement of protein, glucose, and LD in addition to total and differential white blood cell counts. Chemistry determinations are used to classify effusions as transudates or exudates. This classification is important because the differential diagnosis and subsequent evaluation for each entity is vastly different (Table 9–28). A **pleural exudate** is an effusion that has *one or more* of the following laboratory features: (1) ratio of pleural fluid protein to serum protein > 0.5 ; (2) ratio of pleural fluid LD to serum LD > 0.6 ; (3) pleural fluid LD greater than two-thirds the upper limit of

normal serum LD. **Pleural transudates** occur in the setting of normal capillary integrity and demonstrate none of the laboratory features of exudates. A transudate suggests the absence of local pleural disease; characteristic laboratory findings include a glucose equal to serum glucose, pH between 7.40 and 7.55, and fewer than 1.0×10^3 white blood cells/mcL ($1.0 \times 10^9/L$) with a predominance of mononuclear cells.

Congestive heart failure accounts for 90% of transudates. Bacterial pneumonia and cancer are the most common causes of exudative effusion. Other causes of exudates with characteristic laboratory findings are summarized in Table 9–29.

Pleural fluid pH is useful in the assessment of parapneumonic effusions. A pH below 7.30 suggests the need for drainage of the pleural space. An elevated amylase level in pleural fluid suggests pancreatitis, pancreatic pseudocyst, adenocarcinoma of the lung or pancreas, or esophageal rupture.

Suspected tuberculous pleural effusion should be evaluated by thoracentesis with culture along with pleural

Table 9–29. Characteristics of important exudative pleural effusions.

Etiology or Type of Effusion	Gross Appearance	White Blood Cell Count (cells/mcL)	Red Blood Cell Count (cells/mcL)	Glucose	Comments
Malignancy	Turbid to bloody; occasionally serous	1000 to $< 100,000$ M	100 to several hundred thousand	Equal to serum levels; < 60 mg/dL in 15% of cases	Eosinophilia uncommon; positive results on cytologic examination
Uncomplicated parapneumonic	Clear to turbid	5000–25,000 P	< 5000	Equal to serum levels	Tube thoracostomy unnecessary
Empyema	Turbid to purulent	25,000–100,000 P	< 5000	Less than serum levels; often very low	Drainage necessary; putrid odor suggests anaerobic infection
Tuberculosis	Serous to serosanguineous	5000–10,000 M	$< 10,000$	Equal to serum levels; occasionally < 60 mg/dL	Protein > 4.0 g/dL and may exceed 5 g/dL; eosinophils ($> 10\%$) or mesothelial cells ($> 5\%$) make diagnosis unlikely; see text for discussion of additional diagnostic tests
Rheumatoid	Turbid; greenish yellow	1000–20,000 M or P	< 1000	< 40 mg/dL	Secondary empyema common; high LD, low complement, high rheumatoid factor, cholesterol crystals are characteristic
Pulmonary infarction	Serous to grossly bloody	1000–50,000 M or P	100 to $> 100,000$	Equal to serum levels	Variable findings; no pathognomonic features
Esophageal rupture	Turbid to purulent; red-brown	< 5000 to $> 50,000$ P	1000–10,000	Usually low	High amylase level (salivary origin); pneumothorax in 25% of cases; effusion usually on left side; pH < 6.0 strongly suggests diagnosis
Pancreatitis	Turbid to serosanguineous	1000–50,000 P	1000–10,000	Equal to serum levels	Usually left-sided; high amylase level

LD, lactate dehydrogenase; M, mononuclear cell predominance; P, polymorphonuclear leukocyte predominance.

biopsy, since pleural fluid culture positivity for *M tuberculosis* is low (< 23–58% of cases). Closed pleural biopsy reveals granulomatous inflammation in approximately 60% of patients, and culture of three pleural biopsy specimens combined with histologic examination of a pleural biopsy for granulomas yields a diagnosis in up to 90% of patients. Tests for pleural fluid adenosine deaminase (approximately 90% sensitivity and specificity for pleural tuberculosis at levels >70 units/L) and interferon-gamma (89% sensitivity, 97% specificity in a meta-analysis) can be extremely helpful diagnostic aids, particularly in making decisions to pursue invasive testing in complex patients.

Between 40% and 80% of exudative pleural effusions are malignant, while over 90% of malignant pleural effusions are exudative. Almost any form of cancer may cause effusions, but the most common causes are lung cancer (one-third of cases) and breast cancer. In 5–10% of malignant pleural effusions, no primary tumor is identified. The term “**paramalignant**” pleural effusion refers to an effusion in a patient with cancer when repeated attempts to identify tumor cells in the pleura or pleural fluid are non-diagnostic but when there is a presumptive relation to the underlying malignancy. For example, superior vena cava syndrome with elevated systemic venous pressures causing a transudative effusion would be “paramalignant.”

Pleural fluid specimens should be sent for cytologic examination in all cases of exudative effusions in patients suspected of harboring an underlying malignancy. The diagnostic yield depends on the nature and extent of the underlying malignancy. Sensitivity is between 50% and 65%. A negative cytologic examination in a patient with a high prior probability of malignancy should be followed by one repeat thoracentesis. If that examination is negative, thoracoscopy is preferred to closed pleural biopsy. The sensitivity of thoracoscopy is 92–96%.

C. Imaging

The lung is less dense than water and floats on pleural fluid that accumulates in dependent regions. Subpulmonary fluid may appear as lateral displacement of the apex of the diaphragm with an abrupt slope to the costophrenic sulcus or a greater than 2 cm separation between the gastric air bubble and the lung. On a standard upright chest radiograph, approximately 75–100 mL of pleural fluid must accumulate in the posterior costophrenic sulcus to be visible on the lateral view, and 175–200 mL must be present in the lateral costophrenic sulcus to be visible on the frontal view. Chest CT scans may identify as little as 10 mL of fluid. At least 1 cm of fluid on the decubitus view is necessary to permit blind thoracentesis. Ultrasonography is useful to guide thoracentesis in the setting of smaller effusions.

Pleural fluid may become trapped (loculated) by pleural adhesions, thereby forming unusual collections along the lateral chest wall or within lung fissures. Round or oval fluid collections in fissures that resemble intraparenchymal masses are called pseudotumors. Massive pleural effusion causing opacification of an entire hemithorax is most commonly caused by cancer but may be seen in tuberculosis and other diseases.

► Treatment

A. Transudative Pleural Effusion

Transudative pleural effusions characteristically occur in the absence of pleural disease. Therefore, treatment is directed at the underlying condition. Therapeutic thoracentesis for severe dyspnea typically offers only transient benefit. Pleurodesis and tube thoracostomy are rarely indicated.

B. Malignant Pleural Effusion

Chemotherapy or radiation therapy or both offer temporary control in some malignant effusions but are generally ineffective in lung cancer in the pleural space except for small cell lung cancer. Asymptomatic malignant effusions usually do not require specific treatment. Symptomatic patients should have a therapeutic thoracentesis. If symptoms are relieved but the effusion returns, the options are serial thoracenteses, attempted pleurodesis, or placement of an indwelling drainage catheter that the patient can access at home. Choice among these options depends on the rate of reaccumulation in addition to the functional status, tolerance for discomfort, and life expectancy of the patient. Consultation with a thoracic specialist is advised. See Chapter 39.

C. Parapneumonic Pleural Effusion

Parapneumonic pleural effusions are divided into three categories: simple or uncomplicated, complicated, and empyema. **Uncomplicated parapneumonic effusions** are free-flowing sterile exudates of modest size that resolve quickly with antibiotic treatment of pneumonia. They do not need drainage. **Empyema** is gross infection of the pleural space indicated by positive Gram stain or culture. Empyema should always be drained by tube thoracostomy to facilitate clearance of infection and to reduce the probability of fibrous encasement of the lung, causing permanent pulmonary impairment.

Complicated parapneumonic effusions present the most difficult management decisions. They tend to be larger than simple parapneumonic effusions and to show more evidence of inflammatory stimuli such as low glucose level, low pH, or evidence of loculation. Inflammation probably reflects ongoing bacterial invasion of the pleural space despite rare positive bacterial cultures. The morbidity associated with complicated effusions is due to their tendency to form a fibropurulent pleural “peel,” trapping otherwise functional lung and leading to permanent impairment. Tube thoracostomy is indicated when pleural fluid glucose is < 60 mg/dL (3.3 mmol/L) or the pH is < 7.2. These thresholds have not been prospectively validated and should not be interpreted strictly. The clinician should consider drainage of a complicated effusion if the pleural fluid pH is between 7.2 and 7.3 or the LD is > 1000 units/L (20 mckat/L). Pleural fluid cell count and protein have little diagnostic value in this setting.

Tube thoracostomy drainage of empyema or parapneumonic effusions is frequently complicated by loculation that prevents adequate drainage. Intrapleural instillation of

fibrinolytic agents has not been shown in controlled trials to improve drainage. The combination of intrapleural tissue plasminogen activator and deoxyribonuclease (DNase), an enzyme that catalyses extracellular DNA and degrades biofilm formation within the pleural cavity, has been found to improve clinical outcome (increased drainage, decrease length of stay and surgical referral) compared with placebo or either agent alone.

D. Hemothorax

A small-volume hemothorax that is stable or improving on chest radiographs may be managed by close observation. In all other cases, hemothorax is treated by immediate insertion of a large-bore thoracostomy tube to: (1) drain existing blood and clot, (2) quantify the amount of bleeding, (3) reduce the risk of fibrothorax, and (4) permit apposition of the pleural surfaces in an attempt to reduce hemorrhage. Thoracotomy may be indicated to control hemorrhage, remove clot, and treat complications such as bronchopleural fistula formation.

Christie NA. Management of pleural space: effusions and empyema. *Surg Clin North Am.* 2010 Oct;90(5):919–34. [PMID: 20955875]

Froudarakis ME. Diagnostic work-up of pleural effusions. *Respiration.* 2008;75(1):4–13. [PMID: 18185024]

Heffner JE et al. Recent advances in the diagnosis and management of malignant pleural effusions. *Mayo Clin Proc.* 2008 Feb;83(2):235–50. [PMID: 18241636]

Rahman NM et al. Intrapleural use of tissue plasminogen activator and DNase in pleural infection. *N Engl J Med.* 2011 Aug 11;365(6):518–26. [PMID: 21830966]

Sahn SA. The value of pleural fluid analysis. *Am J Med Sci.* 2008 Jan;335(1):7–15. [PMID: 18195577]

SPONTANEOUS PNEUMOTHORAX



ESSENTIALS OF DIAGNOSIS

- ▶ Acute onset of unilateral chest pain and dyspnea.
- ▶ Minimal physical findings in mild cases; unilateral chest expansion, decreased tactile fremitus, hyperresonance, diminished breath sounds, mediastinal shift, cyanosis and hypotension in tension pneumothorax.
- ▶ Presence of pleural air on chest radiograph.

▶ General Considerations

Pneumothorax, or accumulation of air in the pleural space, is classified as spontaneous (primary or secondary) or traumatic. Primary spontaneous pneumothorax occurs in the absence of an underlying lung disease, whereas secondary spontaneous pneumothorax is a complication of pre-existing pulmonary disease. Traumatic pneumothorax results from penetrating or blunt trauma. Iatrogenic pneumothorax may follow procedures such as thoracentesis, pleural biopsy, subclavian or internal jugular vein catheter

placement, percutaneous lung biopsy, bronchoscopy with transbronchial biopsy, and positive-pressure mechanical ventilation. Tension pneumothorax usually occurs in the setting of penetrating trauma, lung infection, cardiopulmonary resuscitation, or positive-pressure mechanical ventilation. In tension pneumothorax, the pressure of air in the pleural space exceeds ambient pressure throughout the respiratory cycle. A check-valve mechanism allows air to enter the pleural space on inspiration and prevents egress of air on expiration.

Primary pneumothorax affects mainly tall, thin boys and men between the ages of 10 and 30 years. It is thought to occur from rupture of subpleural apical blebs in response to high negative intrapleural pressures. Family history and cigarette smoking may also be important factors.

Secondary pneumothorax occurs as a complication of COPD, asthma, cystic fibrosis, tuberculosis, *Pneumocystis* pneumonia, menstruation (catamenial pneumothorax), and a wide variety of interstitial lung diseases including sarcoidosis, lymphangioleiomyomatosis, Langerhans cell histiocytosis, and tuberous sclerosis. Aerosolized pentamidine and a prior history of *Pneumocystis* pneumonia are considered risk factors for the development of pneumothorax. One-half of patients with pneumothorax in the setting of recurrent (but not primary) *Pneumocystis* pneumonia will develop pneumothorax on the contralateral side. The mortality rate of pneumothorax in *Pneumocystis* pneumonia is high.

▶ Clinical Findings

A. Symptoms and Signs

Chest pain ranging from minimal to severe on the affected side and dyspnea occur in nearly all patients. Symptoms usually begin during rest and usually resolve within 24 hours even if the pneumothorax persists. Alternatively, pneumothorax may present with life-threatening respiratory failure if underlying COPD or asthma is present.

If pneumothorax is small (< 15% of a hemithorax), physical findings, other than mild tachycardia, are normal. If pneumothorax is large, diminished breath sounds, decreased tactile fremitus, and decreased movement of the chest are often noted. Tension pneumothorax should be suspected in the presence of marked tachycardia, hypotension, and mediastinal or tracheal shift.

B. Laboratory Findings

Arterial blood gas analysis is often unnecessary but reveals hypoxemia and acute respiratory alkalosis in most patients. Left-sided primary pneumothorax may produce QRS axis and precordial T wave changes on the ECG that may be misinterpreted as acute myocardial infarction.

C. Imaging

Demonstration of a visceral pleural line on chest radiograph is diagnostic and may only be seen on an expiratory film. A few patients have secondary pleural effusion that demonstrates a characteristic air-fluid level on chest radiography. In supine patients, pneumothorax on a conventional chest radiograph may appear as an abnormally radiolucent

costophrenic sulcus (the “deep sulcus” sign). In patients with tension pneumothorax, chest radiographs show a large amount of air in the affected hemithorax and contralateral shift of the mediastinum.

► Differential Diagnosis

If the patient is a young, tall, thin, cigarette-smoking man, the diagnosis of primary spontaneous pneumothorax is usually obvious and can be confirmed by chest radiograph. In secondary pneumothorax, it is sometimes difficult to distinguish loculated pneumothorax from an emphysematous bleb. Occasionally, pneumothorax may mimic myocardial infarction, pulmonary embolism, or pneumonia.

► Complications

Tension pneumothorax may be life-threatening. Pneumomediastinum and subcutaneous emphysema may occur as complications of spontaneous pneumothorax. If pneumomediastinum is detected, rupture of the esophagus or a bronchus should be considered.

► Treatment

Treatment depends on the severity of pneumothorax and the nature of the underlying disease. In a reliable patient with a small (< 15% of a hemithorax), stable spontaneous primary pneumothorax, observation alone may be appropriate. Many small pneumothoraces resolve spontaneously as air is absorbed from the pleural space; supplemental oxygen therapy may increase the rate of reabsorption. Simple aspiration drainage of pleural air with a small-bore catheter (eg, 16 gauge angiocatheter or larger drainage catheter) can be performed for spontaneous primary pneumothoraces that are large or progressive. Placement of a small-bore chest tube (7F to 14F) attached to a one-way Heimlich valve provides protection against development of tension pneumothorax and may permit observation from home. The patient should be treated symptomatically for cough and chest pain, and followed with serial chest radiographs every 24 hours.

Patients with secondary pneumothorax, large pneumothorax, tension pneumothorax, or severe symptoms or those who have a pneumothorax on mechanical ventilation should undergo chest tube placement (tube thoracostomy). The chest tube is placed under water-seal drainage, and suction is applied until the lung expands. The chest tube can be removed after the air leak subsides.

All patients who smoke should be advised to discontinue smoking and warned that the risk of recurrence is 50%. Future exposure to high altitudes, flying in unpresurized aircraft, and scuba diving should be avoided.

Indications for thoracoscopy or open thoracotomy include recurrences of spontaneous pneumothorax, any occurrence of bilateral pneumothorax, and failure of tube thoracostomy for the first episode (failure of lung to reexpand or persistent air leak). Surgery permits resection of blebs responsible for the pneumothorax and pleurodesis by mechanical abrasion and insufflation of talc.

Management of pneumothorax in patients with *Pneumocystis* pneumonia is challenging because of a tendency

toward recurrence, and there is no consensus on the best approach. Use of a small chest tube attached to a Heimlich valve has been proposed to allow the patient to leave the hospital. Some clinicians favor its insertion early in the course.

► Prognosis

An average of 30% of patients with spontaneous pneumothorax experience recurrence of the disorder after either observation or tube thoracostomy for the first episode. Recurrence after surgical therapy is less frequent. Following successful therapy, there are no long-term complications.

Chan SS. The role of simple aspiration in the management of primary spontaneous pneumothorax. *J Emerg Med.* 2008 Feb; 34(2):131–8. [PMID: 17961959]

Kelly AM. Treatment of primary spontaneous pneumothorax. *Curr Opin Pulm Med.* 2009 Jul;15(4):376–9. [PMID: 19373088]

Noppen M et al. Pneumothorax. *Respiration.* 2008;76(2):121–7. [PMID: 18708734]

DISORDERS OF CONTROL OF VENTILATION

The principal influences on ventilatory control are arterial PCO_2 , pH, PO_2 , and brainstem tissue pH. These variables are monitored by peripheral and central chemoreceptors. Under normal conditions, the ventilatory control system maintains arterial pH and PCO_2 within narrow limits; arterial PO_2 is more loosely controlled.

Abnormal control of ventilation can be seen with a variety of conditions ranging from rare disorders such as Ondine curse, neuromuscular disorders, myxedema, starvation, and carotid body resection to more common disorders such as asthma, COPD, obesity, congestive heart failure, and sleep-related breathing disorders. A few of these disorders will be discussed in this section.

Annane D et al. Nocturnal mechanical ventilation for chronic hypoventilation in patients with neuromuscular and chest wall disorders. *Cochrane Database Syst Rev.* 2007 Oct 17;(4): CD001941. [PMID: 17943762]

Ward SA. Ventilatory control in humans: constraints and limitations. *Exp Physiol.* 2007 Mar;92(2):357–66. [PMID: 17234715]

PRIMARY ALVEOLAR HYPOVENTILATION

Primary alveolar hypoventilation (“Ondine curse”) is a rare syndrome of unknown cause characterized by inadequate alveolar ventilation despite normal neurologic function and normal airways, lungs, chest wall, and ventilatory muscles. Hypoventilation is even more marked during sleep. Individuals with this disorder are usually nonobese males in their third or fourth decades who have lethargy, headache, and somnolence. Dyspnea is absent. Physical examination may reveal cyanosis and evidence of pulmonary hypertension and cor pulmonale. Hypoxemia and hypercapnia are present and improve with voluntary

hyperventilation. Erythrocytosis is common. Treatment with ventilatory stimulants is usually unrewarding. Augmentation of ventilation by mechanical methods (phrenic nerve stimulation, rocking bed, mechanical ventilators) has been helpful to some patients. Adequate oxygenation should be maintained with supplemental oxygen, but nocturnal oxygen therapy should be prescribed only if diagnostic nocturnal polysomnography has demonstrated its efficacy and safety. Primary alveolar hypoventilation resembles—but should be distinguished from—**central alveolar hypoventilation**, in which impaired ventilatory drive with chronic respiratory acidemia and hypoxemia follows an insult to the brainstem (eg, bulbar poliomyelitis, infarction, meningitis, encephalitis, trauma).

Weese-Mayer DE et al; ATS Congenital Central Hypoventilation Syndrome Subcommittee. An official ATS clinical policy statement: congenital central hypoventilation syndrome: genetic basis, diagnosis, and management. *Am J Respir Crit Care Med.* 2010 Mar 15;181(6):626–44. [PMID: 20208042]

OBSIDITY-HYOVENTILATION SYNDROME (Pickwickian Syndrome)

In obesity-hypoventilation syndrome, alveolar hypoventilation appears to result from a combination of blunted ventilatory drive and increased mechanical load imposed upon the chest by obesity. Voluntary hyperventilation returns the PCO₂ and the PO₂ toward normal values, a correction not seen in lung diseases causing chronic respiratory failure such as COPD. Most patients with obesity-hypoventilation syndrome also suffer from obstructive sleep apnea (see below), which must be treated aggressively if identified as a comorbid disorder. Therapy of obesity-hypoventilation syndrome consists mainly of weight loss, which improves hypercapnia and hypoxemia as well as the ventilatory responses to hypoxia and hypercapnia. NPPV is helpful in some patients. Respiratory stimulants may be helpful and include theophylline, acetazolamide, and medroxyprogesterone acetate, 10–20 mg every 8 hours orally. Improvement in hypoxemia, hypercapnia, erythrocytosis, and cor pulmonale are goals of therapy.

Berger KI et al. Obesity hypoventilation syndrome. *Semin Respir Crit Care Med.* 2009 Jun;30(3):253–61. [PMID: 19452386]
Mokhlesi B et al. Assessment and management of patients with obesity hypoventilation syndrome. *Proc Am Thorac Soc.* 2008 Feb 15;5(2):218–25. [PMID: 18250215]

HYPERVENTILATION SYNDROMES

Hyperventilation is an increase in alveolar ventilation that leads to hypocapnia. It may be caused by a variety of conditions, such as pregnancy, hypoxemia, obstructive and infiltrative lung diseases, sepsis, hepatic dysfunction, fever, and pain. The term “central neurogenic hyperventilation” denotes a monotonous, sustained pattern of rapid and deep breathing seen in comatose patients with brainstem injury of multiple causes. Functional hyperventilation may be acute or chronic. **Acute hyperventilation** presents with

hyperpnea, paresthesias, carpopedal spasm, tetany, and anxiety. **Chronic hyperventilation** may present with various nonspecific symptoms, including fatigue, dyspnea, anxiety, palpitations, and dizziness. The diagnosis of chronic hyperventilation syndrome is established if symptoms are reproduced during voluntary hyperventilation. Once organic causes of hyperventilation have been excluded, treatment of acute hyperventilation consists of rebreathing expired gas from a paper bag held over the face in order to decrease respiratory alkalemia and its associated symptoms. Anxiolytic drugs may also be useful.

Foster GT et al. Respiratory alkalosis. *Respir Care.* 2001 Apr;46(4):384–91. [PMID: 11262557]
Laffey JG et al. Hypocapnia. *N Engl J Med.* 2002 Jul 4;347(1):43–53. [PMID: 12097540]

SLEEP-RELATED BREATHING DISORDERS

Abnormal ventilation during sleep is manifested by apnea (breath cessation for at least 10 seconds) or hypopnea (decrement in airflow with drop in hemoglobin saturation of at least 4%). Episodes of apnea are **central** if ventilatory effort is absent for the duration of the apneic episode, **obstructive** if ventilatory effort persists throughout the apneic episode but no airflow occurs because of transient obstruction of the upper airway, and **mixed** if absent ventilatory effort precedes upper airway obstruction during the apneic episode. Pure central sleep apnea is uncommon; it may be an isolated finding or may occur in patients with primary alveolar hypoventilation or with lesions of the brainstem. Obstructive and mixed sleep apneas are more common and may be associated with life-threatening cardiac arrhythmias, severe hypoxemia during sleep, daytime somnolence, pulmonary hypertension, cor pulmonale, systemic hypertension, and secondary erythrocytosis.

OBSTRUCTIVE SLEEP APNEA



ESSENTIALS OF DIAGNOSIS

- ▶ Daytime somnolence or fatigue.
- ▶ A history of loud snoring with witnessed apneic events.
- ▶ Overnight polysomnography demonstrating apneic episodes with hypoxemia.

▶ General Considerations

Upper airway obstruction during sleep occurs when loss of normal pharyngeal muscle tone allows the pharynx to collapse passively during inspiration. Patients with anatomically narrowed upper airways (eg, micrognathia, macroglossia, obesity, tonsillar hypertrophy) are predisposed to the development of obstructive sleep apnea. Ingestion of alcohol or sedatives before sleeping or nasal obstruction of any type, including the common cold, may

precipitate or worsen the condition. Hypothyroidism and cigarette smoking are additional risk factors for obstructive sleep apnea. Before making the diagnosis of obstructive sleep apnea, a drug history should be obtained and a seizure disorder, narcolepsy, and depression should be excluded.

► Clinical Findings

A. Symptoms and Signs

Most patients with obstructive or mixed sleep apnea are obese, middle-aged men. Systemic hypertension is common. Patients may complain of excessive daytime somnolence, morning sluggishness and headaches, daytime fatigue, cognitive impairment, recent weight gain, and impotence. Bed partners usually report loud cyclical snoring, breath cessation, witnessed apneas, restlessness, and thrashing movements of the extremities during sleep. Personality changes, poor judgment, work-related problems, depression, and intellectual deterioration (memory impairment, inability to concentrate) may also be observed.

Physical examination may be normal or may reveal systemic and pulmonary hypertension with cor pulmonale. The patient may appear sleepy or even fall asleep during the evaluation. The oropharynx is frequently found to be narrowed by excessive soft tissue folds, large tonsils, pendulous uvula, or prominent tongue. Nasal obstruction by a deviated nasal septum, poor nasal airflow, and a nasal twang to the speech may be observed. A “bull neck” appearance is common.

B. Laboratory Findings

Erythrocytosis is common. Thyroid function tests should be obtained.

C. Other Studies

Observation of the sleeping patient may reveal loud snoring interrupted by episodes of increasingly strong ventilatory effort that fail to produce airflow. A loud snort often accompanies the first breath following an apneic episode. Definitive diagnostic evaluation for suspected sleep apnea includes otorhinolaryngologic examination and overnight **polysomnography** (the monitoring of multiple physiologic factors during sleep). Screening may be performed using home nocturnal pulse oximetry, which when normal has a high negative predictive value in ruling out significant sleep apnea. A complete **polysomnography** examination includes electroencephalography, electro-oculography, electromyography, ECG, pulse oximetry, and measurement of respiratory effort and airflow. **Polysomnography** reveals apneic episodes lasting as long as 60 seconds. Oxygen saturation falls, often to very low levels. Bradydysrhythmias, such as sinus bradycardia, sinus arrest, or atrioventricular block, may occur. Tachydysrhythmias, including paroxysmal supraventricular tachycardia, atrial fibrillation, and ventricular tachycardia, may be seen once airflow is reestablished.

► Treatment

Weight loss and strict avoidance of alcohol and hypnotic medications are the first steps in management. Weight loss

may be curative, but most patients are unable to lose the 10–20% of body weight required. **Nasal continuous positive airway pressure (nasal CPAP)** at night is curative in many patients. Polysomnography is frequently necessary to determine the level of CPAP (usually 5–15 cm H₂O) necessary to abolish obstructive apneas. Unfortunately, only about 75% of patients continue to use nasal CPAP after 1 year. Pharmacologic therapy for obstructive sleep apnea is disappointing. Supplemental oxygen may lessen the severity of nocturnal desaturation but may also lengthen apneas; it should not be routinely prescribed. Polysomnography is necessary to assess the effects of oxygen therapy. Mechanical devices inserted into the mouth at bedtime to hold the jaw forward and prevent pharyngeal occlusion have modest effectiveness in relieving apnea; however, patient compliance is not optimal.

Uvulopalatopharyngoplasty (UPPP), a procedure consisting of resection of pharyngeal soft tissue and amputation of approximately 15 mm of the free edge of the soft palate and uvula, is helpful in approximately 50% of selected patients. It is more effective in eliminating snoring than apneic episodes. UPPP may be performed on an outpatient basis with a laser. **Nasal septoplasty** is performed if gross anatomic nasal septal deformity is present. **Tracheostomy** relieves upper airway obstruction and its physiologic consequences and represents the definitive treatment for obstructive sleep apnea. However, it has numerous adverse effects, including granuloma formation, difficulty with speech, and stoma and airway infection. Furthermore, the long-term care of the tracheostomy, especially in obese patients, can be difficult. Tracheostomy and other maxillofacial surgery approaches are reserved for patients with life-threatening arrhythmias or severe disability who have not responded to conservative therapy.

Some patients with sleep apnea have nocturnal bradycardia. A pilot study in 15 patients with either central or obstructive sleep apnea showed some improvement in oxygen saturation with atrial pacing. This single study must be considered preliminary.

- Chowdhuri S et al. Central sleep apnoea. *Indian J Med Res.* 2010 Feb;131:150–64. [PMID: 20308740]
- Eastwood PR et al. Obstructive sleep apnoea: from pathogenesis to treatment: current controversies and future directions. *Respirology.* 2010 May;15(4):587–95. [PMID: 20136736]
- Eckert DJ et al. Central sleep apnea: Pathophysiology and treatment. *Chest.* 2007 Feb;131(2):595–607. [PMID: 17296668]
- Ulualp SO. Snoring and obstructive sleep apnea. *Med Clin North Am.* 2010 Sep;94(5):1047–55. [PMID: 20736112]
- Yaggi HK et al. Adult obstructive sleep apnea/hypopnea syndrome: definitions, risk factors, and pathogenesis. *Clin Chest Med.* 2010 Jun;31(2):179–86. [PMID: 20488280]

ACUTE RESPIRATORY FAILURE

Respiratory failure is defined as respiratory dysfunction resulting in abnormalities of oxygenation or ventilation (CO₂ elimination) severe enough to threaten the function of vital organs. Arterial blood gas criteria for respiratory failure are not absolute but may be arbitrarily established

Table 9–30. Selected causes of acute respiratory failure in adults.

<p>Airway disorders</p> <ul style="list-style-type: none"> Asthma Acute exacerbation of chronic bronchitis or emphysema Obstruction of pharynx, larynx, trachea, main stem bronchus, or lobar bronchus by edema, mucus, mass, or foreign body <p>Pulmonary edema</p> <ul style="list-style-type: none"> Increased hydrostatic pressure Left ventricular dysfunction (eg, myocardial ischemia, heart failure) Mitral regurgitation Left atrial outflow obstruction (eg, mitral stenosis) Volume overload states Increased pulmonary capillary permeability Acute respiratory distress syndrome Acute lung injury Unclear etiology Neurogenic Negative pressure (inspiratory airway obstruction) Reexpansion Tocolytic-associated <p>Parenchymal lung disorders</p> <ul style="list-style-type: none"> Pneumonia Interstitial lung diseases Diffuse alveolar hemorrhage syndromes Aspiration Lung contusion <p>Pulmonary vascular disorders</p> <ul style="list-style-type: none"> Thromboembolism Air embolism Amniotic fluid embolism <p>Chest wall, diaphragm, and pleural disorders</p> <ul style="list-style-type: none"> Rib fracture Flail chest Pneumothorax Pleural effusion Massive ascites Abdominal distention and abdominal compartment syndrome 	<p>Neuromuscular and related disorders</p> <ul style="list-style-type: none"> Primary neuromuscular diseases Guillain-Barré syndrome Myasthenia gravis Poliomyelitis Polymyositis Drug- or toxin-induced Botulism Organophosphates Neuromuscular blocking agents Aminoglycosides Spinal cord injury Phrenic nerve injury or dysfunction <p>Electrolyte disturbances:</p> <ul style="list-style-type: none"> hypokalemia, hypophosphatemia <p>Myxedema</p> <p>Central nervous system disorders</p> <ul style="list-style-type: none"> Drugs: sedative, hypnotic, opioid, anesthetics Brainstem respiratory center disorders: trauma, tumor, vascular disorders, hypothyroidism Intracranial hypertension Central nervous system infections <p>Increased CO₂ production</p> <ul style="list-style-type: none"> Fever Infection Hyperalimentation with excess caloric and carbohydrate intake Hyperthyroidism Seizures Rigors Drugs
--	--

as a PO₂ under 60 mm Hg (7.8 kPa) or a PCO₂ over 50 mm Hg (6.5 kPa). Acute respiratory failure may occur in a variety of pulmonary and nonpulmonary disorders (Table 9–30). Only a few selected general principles of management will be reviewed here.

► Clinical Findings

Symptoms and signs of acute respiratory failure are those of the underlying disease combined with those of hypoxemia

or hypercapnia. The chief symptom of hypoxemia is dyspnea, though profound hypoxemia may exist in the absence of complaints. Signs of hypoxemia include cyanosis, restlessness, confusion, anxiety, delirium, tachypnea, bradycardia or tachycardia, hypertension, cardiac dysrhythmias, and tremor. Dyspnea and headache are the cardinal symptoms of hypercapnia. Signs of hypercapnia include peripheral and conjunctival hyperemia, hypertension, tachycardia, tachypnea, impaired consciousness, papilledema, and asterixis. The symptoms and signs of acute respiratory failure are both insensitive and nonspecific; therefore, the clinician must maintain a high index of suspicion and obtain arterial blood gas analysis if respiratory failure is suspected.

► Treatment

Treatment of the patient with acute respiratory failure consists of: (1) specific therapy directed toward the underlying disease; (2) respiratory supportive care directed toward the maintenance of adequate gas exchange; and (3) general supportive care. Only the last two aspects are discussed below.

A. Respiratory Support

Respiratory support has both nonventilatory and ventilatory aspects.

1. Nonventilatory aspects—The main therapeutic goal in acute hypoxemic respiratory failure is to ensure adequate oxygenation of vital organs. Inspired oxygen concentration should be the lowest value that results in an arterial hemoglobin saturation of $\geq 90\%$ (PO₂ ≥ 60 mm Hg [7.8 kPa]). Higher arterial oxygen tensions are of no proven benefit. Restoration of normoxia may rarely cause hypoventilation in patients with chronic hypercapnia; however, *oxygen therapy should not be withheld for fear of causing progressive respiratory acidemia*. Hypoxemia in patients with obstructive airway disease is usually easily corrected by administering low-flow oxygen by nasal cannula (1–3 L/min) or Venturi mask (24–40%). Higher concentrations of oxygen are necessary to correct hypoxemia in patients with ARDS, pneumonia, and other parenchymal lung diseases.

2. Ventilatory aspects—Ventilatory support consists of maintaining patency of the airway and ensuring adequate alveolar ventilation. Mechanical ventilation may be provided via face mask (noninvasive) or through tracheal intubation.

A. NONINVASIVE POSITIVE-PRESSURE VENTILATION—NPPV delivered via a full face mask or nasal mask is first-line therapy in COPD patients with hypercapnic respiratory failure who can protect and maintain the patency of their airway, handle their own secretions, and tolerate the mask apparatus. Several studies have demonstrated the effectiveness of this therapy in reducing intubation rates and ICU stays in patients with ventilatory failure. Patients with acute lung injury or ARDS or those who suffer from severely impaired oxygenation do not benefit and should be intubated if they require mechanical ventilation. A bilevel positive pressure ventilation mode is preferred for most patients.

B. TRACHEAL INTUBATION—Indications for tracheal intubation include: (1) hypoxemia despite supplemental oxygen, (2) upper airway obstruction, (3) impaired airway protection, (4) inability to clear secretions, (5) respiratory acidosis, (6) progressive general fatigue, tachypnea, use of accessory respiratory muscles, or mental status deterioration, and (7) apnea. In general, orotracheal intubation is preferred to nasotracheal intubation in urgent or emergency situations because it is easier, faster, and less traumatic. The position of the tip of the endotracheal tube at the level of the aortic arch should be verified by chest radiograph immediately following intubation, and auscultation should be performed to verify that both lungs are being inflated. Only tracheal tubes with high-volume, low-pressure air-filled cuffs should be used. Cuff inflation pressure should be kept below 20 mm Hg if possible to minimize tracheal mucosal injury.

C. MECHANICAL VENTILATION—Indications for mechanical ventilation include: (1) apnea, (2) acute hypercapnia that is not quickly reversed by appropriate specific therapy, (3) severe hypoxemia, and (4) progressive patient fatigue despite appropriate treatment.

Several modes of positive-pressure ventilation are available. Controlled mechanical ventilation (CMV; also known as assist-control or A-C) and synchronized intermittent mandatory ventilation (SIMV) are ventilatory modes in which the ventilator delivers a minimum number of breaths of a specified tidal volume each minute. In both CMV and SIMV, the patient may trigger the ventilator to deliver additional breaths. In CMV, the ventilator responds to breaths initiated by the patient above the set rate by delivering additional full tidal volume breaths. In SIMV, additional breaths are not supported by the ventilator unless the pressure support mode is added. Numerous alternative modes of mechanical ventilation now exist, the most popular being pressure support ventilation (PSV), pressure control ventilation (PCV), and CPAP.

PEEP is useful in improving oxygenation in patients with diffuse parenchymal lung disease such as ARDS. It should be used cautiously in patients with localized parenchymal disease, hyperinflation, or very high airway pressure requirements during mechanical ventilation.

D. COMPLICATIONS OF MECHANICAL VENTILATION—Potential complications of mechanical ventilation are numerous. Migration of the tip of the endotracheal tube into a main bronchus can cause atelectasis of the contralateral lung and overdistention of the intubated lung. Barotrauma (alternatively referred to as “volutrauma”), manifested by subcutaneous emphysema, pneumomediastinum, subpleural air cysts, pneumothorax, or systemic gas embolism, may occur in patients whose lungs are overdistended by excessive tidal volumes, especially those with hyperinflation caused by airflow obstruction. Subtle parenchymal lung injury due to overdistention of alveoli is another potential hazard. Strategies to avoid barotrauma include deliberate hypoventilation through the use of low mechanical tidal volumes and respiratory rates, resulting in “permissive hypercapnia.”

Acute respiratory alkalosis caused by overventilation is common. Hypotension induced by elevated intrathoracic pressure that results in decreased return of systemic venous blood to the heart may occur in patients treated with PEEP, those with severe airflow obstruction, and those with intravascular volume depletion. Ventilator-associated pneumonia is another serious complication of mechanical ventilation.

B. General Supportive Care

Maintenance of adequate nutrition is vital; parenteral nutrition should be used only when conventional enteral feeding methods are not possible. Overfeeding, especially with carbohydrate-rich formulas, should be avoided, because it can increase CO₂ production and may potentially worsen or induce hypercapnia in patients with limited ventilatory reserve. However, failure to provide adequate nutrition is more common. Hypokalemia and hypophosphatemia may worsen hypoventilation due to respiratory muscle weakness. Sedative-hypnotics and opioid analgesics are frequently used. They should be titrated carefully to avoid oversedation, leading to prolongation of intubation. Temporary paralysis with a nondepolarizing neuromuscular blocking agent is occasionally used to facilitate mechanical ventilation and to lower oxygen consumption. Prolonged muscle weakness due to an acute myopathy is a potential complication of these agents. Myopathy is more common in patients with kidney injury and in those given concomitant corticosteroids.

Psychological and emotional support of the patient and family, skin care to avoid decubitus ulcers, and meticulous avoidance of health care–associated infection and complications of tracheal tubes are vital aspects of comprehensive care for patients with acute respiratory failure.

Attention must also be paid to preventing complications associated with serious illness. Stress gastritis and ulcers may be avoided by administering sucralfate (1 g orally twice a day), histamine H₂-receptor antagonists, or PPIs. There is some concern that the latter two agents, which raise the gastric pH, may permit increased growth of gram-negative bacteria in the stomach, predisposing to pharyngeal colonization and ultimately HCAP; many clinicians therefore prefer sucralfate. The risk of DVT and PE may be reduced by subcutaneous administration of heparin (5000 units every 12 hours), the use of LMWH (see Table 14–13), or placement of a sequential compression device on an extremity.

► Course & Prognosis

The course and prognosis of acute respiratory failure vary and depend on the underlying disease. The prognosis of acute respiratory failure caused by uncomplicated sedative or narcotic drug overdose is excellent. Acute respiratory failure in patients with COPD who do not require intubation and mechanical ventilation has a good immediate prognosis. On the other hand, ARDS associated with sepsis has an extremely poor prognosis, with mortality rates of about 90%. Overall, adults requiring mechanical ventilation for all causes of acute respiratory failure have survival

rates of 62% to weaning, 43% to hospital discharge, and 30% to 1 year after hospital discharge.

Keenan SP et al. Noninvasive ventilation for patients presenting with acute respiratory failure: the randomized controlled trials. *Respir Care*. 2009 Jan;54(1):116–26. [PMID: 19111111]
 Roca O et al. High-flow oxygen therapy in acute respiratory failure. *Respir Care*. 2010 Apr;55(4):408–13. [PMID: 20406507]
 Soo Hoo GW. Noninvasive ventilation in adults with acute respiratory distress: a primer for the clinician. *Hosp Pract (Minneapolis)*. 2010 Feb;38(1):16–25. [PMID: 20469620]

ACUTE RESPIRATORY DISTRESS SYNDROME

ESSENTIALS OF DIAGNOSIS

- ▶ Acute onset of respiratory failure.
- ▶ Bilateral radiographic pulmonary opacities.
- ▶ Absence of elevated left atrial pressure (if measured, pulmonary capillary wedge pressure ≤ 18 mm Hg).
- ▶ Ratio of partial pressure of oxygen in arterial blood (P_{aO_2}) to fractional concentration of inspired oxygen (F_{iO_2}) < 200 , regardless of the level of PEEP.

General Considerations

ARDS denotes acute hypoxemic respiratory failure following a systemic or pulmonary insult without evidence of heart failure. ARDS is the most severe form of acute lung injury and is characterized by bilateral, widespread radiographic pulmonary infiltrates, normal pulmonary capillary wedge pressure (≤ 18 mm Hg) and a P_{aO_2}/F_{iO_2} ratio < 200 . ARDS may follow a wide variety of clinical events (Table 9–31). Common risk factors for ARDS include sepsis, aspiration of gastric contents, shock, infection, lung contusion, nonthoracic trauma, toxic inhalation, near-drowning, and multiple blood transfusions. About one-third of ARDS patients initially have sepsis syndrome. Pro-inflammatory cytokines released from stimulated inflammatory cells appear to be pivotal in lung injury. Although the mechanism of lung injury varies with the cause, damage to capillary endothelial cells and alveolar epithelial cells is common to ARDS regardless of cause. Damage to these cells causes increased vascular permeability and decreased production and activity of surfactant; these abnormalities lead to interstitial and alveolar pulmonary edema, alveolar collapse, and hypoxemia.

Clinical Findings

ARDS is marked by the rapid onset of profound dyspnea that usually occurs 12–48 hours after the initiating event. Labored breathing, tachypnea, intercostal retractions, and crackles are noted on physical examination. Chest radiography shows diffuse or patchy bilateral infiltrates that

Table 9–31. Selected disorders associated with ARDS.

Systemic Insults	Pulmonary Insults
Trauma	Aspiration of gastric contents
Sepsis	Embolism of thrombus, fat, air, or amniotic fluid
Pancreatitis	Miliary tuberculosis
Shock	Diffuse pneumonia (eg, SARS)
Multiple transfusions	Acute eosinophilic pneumonia
Disseminated intravascular coagulation	Cryptogenic organizing pneumonitis
Burns	Upper airway obstruction
Drugs and drug overdose	Free-base cocaine smoking
Opioids	Near-drowning
Aspirin	Toxic gas inhalation
Phenothiazines	Nitrogen dioxide
Tricyclic antidepressants	Chlorine
Amiodarone	Sulfur dioxide
Chemotherapeutic agents	Ammonia
Nitrofurantoin	Smoke
Protamine	Oxygen toxicity
Thrombotic thrombocytopenic purpura	Lung contusion
Cardiopulmonary bypass	Radiation exposure
Head injury	High-altitude exposure
Paraquat	Lung reexpansion or reperfusion

ARDS, acute respiratory distress syndrome; SARS, severe acute respiratory syndrome.

rapidly become confluent; these characteristically spare the costophrenic angles. Air bronchograms occur in about 80% of cases. Upper lung zone venous engorgement is distinctly uncommon. Heart size is normal, and pleural effusions are small or nonexistent. Marked hypoxemia occurs that is refractory to treatment with supplemental oxygen. Many patients with ARDS demonstrate multiple organ failure, particularly involving the kidneys, liver, gut, central nervous system, and cardiovascular system.

Differential Diagnosis

Since ARDS is a physiologic and radiographic syndrome rather than a specific disease, the concept of differential diagnosis does not strictly apply. Normal-permeability (“cardiogenic” or hydrostatic) pulmonary edema must be excluded, however, because specific therapy is available for that disorder. Measurement of pulmonary capillary wedge pressure by means of a flow-directed pulmonary artery catheter may be required in selected patients with suspected cardiac dysfunction. Routine use of the Swan-Ganz catheter in ARDS is discouraged.

Prevention

No measures that effectively prevent ARDS have been identified; specifically, prophylactic use of PEEP in patients at risk for ARDS has not been shown to be effective. Intravenous methylprednisolone does not prevent ARDS when given early to patients with sepsis syndrome or septic shock.

► Treatment

Treatment of ARDS must include identification and specific treatment of the underlying precipitating and secondary conditions (eg, sepsis). Meticulous supportive care must then be provided to compensate for the severe dysfunction of the respiratory system associated with ARDS and to prevent complications (see above).

Treatment of the hypoxemia seen in ARDS usually requires tracheal intubation and positive-pressure mechanical ventilation. The lowest levels of PEEP (used to recruit atelectatic alveoli) and supplemental oxygen required to maintain the PaO₂ above 55 mm Hg (7.13 kPa) or the SaO₂ above 88% should be used. Efforts should be made to decrease FiO₂ to less than 60% as soon as possible in order to avoid oxygen toxicity. PEEP can be increased as needed as long as cardiac output and oxygen delivery do not decrease and airway pressures do not increase excessively. Prone positioning may transiently improve oxygenation in selected patients by helping recruit atelectatic alveoli; however, great care must be taken during the maneuver to avoid dislodging catheters and tubes.

A variety of mechanical ventilation strategies are available. A multicenter study of 800 patients demonstrated that a protocol using volume-control ventilation with low tidal volumes (6 mL/kg of ideal body weight) resulted in a 10% absolute mortality reduction over therapy with standard tidal volumes (defined as 12 mL/kg of ideal body weight); this trial reported the lowest mortality (31%) of any intervention to date for ARDS.

Approaches to hemodynamic monitoring and fluid management in patients with acute lung injury have been carefully studied. A prospective, randomized trial comparing hemodynamic management guided either by a pulmonary artery catheter or a central venous catheter using an explicit management protocol demonstrated that a pulmonary artery catheter should not be routinely used for the management of acute lung injury. A subsequent randomized, prospective clinical study of restrictive fluid intake and diuresis as needed to maintain central venous pressure < 4 mm Hg or pulmonary artery occlusion pressure < 8 mm Hg (conservative strategy group) versus a fluid management protocol to target a central venous pressure of 10–14 mm Hg or a pulmonary artery occlusion pressure 14–18 mm Hg (liberal strategy group), showed that patients in the conservative strategy group experienced faster improvement in lung function and spent significantly fewer days on mechanical ventilation

and in the ICU without an improvement in death by 60 days or worsening nonpulmonary organ failure at 28 days. Oxygen delivery can be increased in anemic patients by ensuring that hemoglobin concentrations are at least 7 g/dL (70 g/L); patients are not likely to benefit from higher levels. Increasing oxygen delivery to supranormal levels through the use of inotropes and high hemoglobin concentrations is not clinically useful and may be harmful. Strategies to decrease oxygen consumption include the appropriate use of sedatives, analgesics, and antipyretics.

A large number of innovative therapeutic interventions to improve outcomes in ARDS patients have been or are being investigated. Unfortunately, to date, none have consistently shown benefit in clinical trials. Systemic corticosteroids have been studied extensively with variable and inconsistent results. While a few small studies suggest some specific improved outcomes when given within the first 2 weeks after the onset of ARDS, the routine use of corticosteroids is not recommended.

► Course & Prognosis

The mortality rate associated with ARDS is 30–40%. If ARDS is accompanied by sepsis, the mortality rate may reach 90%. The major causes of death are the primary illness and secondary complications such as multiple organ system failure or sepsis. Median survival is about 2 weeks. Many patients who succumb to ARDS and its complications die after withdrawal of support (see Withdrawal of Support in Chapter 5). Most survivors of ARDS are left with some pulmonary symptoms (cough, dyspnea, sputum production), which tend to improve over time. Mild abnormalities of oxygenation, diffusing capacity, and lung mechanics persist in some individuals.

Deja M et al. Evidence-based therapy of severe acute respiratory distress syndrome: an algorithm-guided approach. *J Int Med Res.* 2008 Mar–Apr;36(2):211–21. [PMID: 18380929]

Petrucci N et al. Lung protective ventilation strategy for the acute respiratory distress syndrome. *Cochrane Database Syst Rev.* 2007 Jul 18;(3):CD003844. [PMID: 17636739]

Wheeler AP et al. Acute lung injury and the acute respiratory distress syndrome: a clinical review. *Lancet.* 2007 May 5;369(9572):1553–64. [PMID: 17482987]

Wiedemann HP. A perspective on the Fluids and Catheters Treatment Trial (FACTT). Fluid restriction is superior in acute lung injury and ARDS. *Cleve Clin J Med.* 2008 Jan;75(1):42–8. [PMID: 18236729]

10

Heart Disease

Thomas M. Bashore, MD
 Christopher B. Granger, MD
 Patrick Hranitzky, MD
 Manesh R. Patel, MD

FUNCTIONAL CLASSIFICATION OF HEART DISEASE

In the management of patients with heart disease, it is important to quantify and monitor the severity of symptoms. A commonly used classification system is that of the New York Heart Association (NYHA), shown below. However, in monitoring individual patients, it is better to document specific activities that produce symptoms, such as walking a distance; climbing stairs; or performing activities of daily living, such as using a vacuum sweeper or going grocery shopping.

Class I: No limitation of physical activity. Ordinary physical activity does not cause undue fatigue, dyspnea, or anginal pain.

Class II: Slight limitation of physical activity. Ordinary physical activity results in symptoms.

Class III: Marked limitation of physical activity. Comfortable at rest, but less than ordinary activity causes symptoms.

Class IV: Unable to engage in any physical activity without discomfort. Symptoms may be present even at rest.

Other classifications have been proposed, but these are universally accepted, and clinically can be applied to both heart failure and anginal symptoms. Some experts use the category of **Class V** to describe symptoms that are atypical and can occur either at rest or with exertion.

A task force from the American College of Cardiology/American Heart Association (ACC/AHA) proposed that patients with heart failure be classified into four stages:

Stage A: Those at **high risk** for congestive heart failure (CHF) but no structural heart disease (ie, hypertension, coronary artery disease [CAD]) and no symptoms.

Stage B: Those with structural heart disease associated with CHF and **no symptoms**.

Stage C: Those with structural heart disease who have **current or prior symptoms**.

Stage D: Those with **refractory CHF** requiring some device or special intervention.

Bonow RO et al. ACC/AHA clinical performance measures for adults with chronic heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures (Writing Committee to Develop Heart Failure Clinical Performance Measures) endorsed by the Heart Failure Society of America. *J Am Coll Cardiol.* 2005 Sep 20;46(6):1144–78. [PMID: 16168305]

CONGENITAL HEART DISEASE

Congenital lesions account for only about 2% of heart disease that presents in adulthood. As surgical and medical techniques have improved, more and more children are now reaching adulthood, and it is estimated that there are well over 1 million adults in the United States surviving with congenital heart disease. In fact, there are more adults with congenital heart disease than children. The ACC/AHA has published guidelines for the management of adults with congenital heart disease.

Brown ML et al. The adult with congenital heart disease: medical and surgical considerations for management. *Curr Opin Pediatr.* 2009 Oct;21(5):561–4. [PMID: 19606038]

Khairy P et al. Adult congenital heart disease: toward prospective risk assessment of a multisystemic condition. *Circulation.* 2008 May 6;117(18):2311–2. [PMID: 18458179]

Warnes CA et al. ACC/AHA 2008 Guidelines for the Management of Adults With Congenital Heart Disease. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *Circulation.* 2008 Dec 2;118(23):e714–833. [PMID: 18997169]

PULMONARY STENOSIS

ESSENTIALS OF DIAGNOSIS

- ▶ Asymptomatic unless patient has at least moderately severe lesions.
- ▶ Severe cases may present with right-sided heart failure.
- ▶ High-pitched systolic ejection murmur maximal in the second left interspace with radiation to the left shoulder.
- ▶ P₂ delayed and soft or absent. Ejection click often present and decreases with inspiration—the only right heart auscultatory event that decreases with inspiration, all others increase.
- ▶ Echocardiography/Doppler is diagnostic.
- ▶ Patients with peak pulmonic valve gradients > 60 mm Hg or mean of 40 mm Hg by echocardiography/Doppler should undergo intervention regardless of symptoms.
- ▶ A dysplastic pulmonary valve usually requires surgical treatment, while a domed pulmonary valve stenosis usually can be treated with balloon valvuloplasty.
- ▶ RV outflow tract obstruction due to conduit stenosis may be treated with a percutaneous pulmonary valve.

▶ General Considerations

Stenosis of the pulmonary valve or RV infundibulum increases the resistance to RV outflow, raises the RV pressure, and limits pulmonary blood flow. Pulmonic stenosis is often congenital, associated with other cardiac lesions. Pulmonary blood flow preferentially goes to the left lung in valvular pulmonic stenosis. Most patients with valvular pulmonic stenosis have a domed valve, though some patients have a dysplastic valve, especially those with Noonan syndrome. The phenotype of Noonan syndrome includes short stature, web neck, dental malocclusion, antimongoloid slanting of the eyes, mental retardation, and hypogonadism. Unlike those with a domed valve, patients with a dysplastic valve do not have a dilated main pulmonary artery (PA) or commissural fusion. In the absence of associated shunts, arterial saturation is normal. Infundibular stenosis may be so severe that the right ventricle (RV) is divided into a low-pressure and high-pressure chamber (double-chambered RV). Peripheral pulmonic stenosis can accompany valvular pulmonic stenosis and may be part of a variety of clinical syndromes, including the congenital rubella syndrome. Patients who have had the Ross procedure for aortic valve disease (transfer of the pulmonary valve to the aortic position with a homograft pulmonary valve placed in the pulmonary position) may experience postoperative (noncongenital) pulmonic stenosis due to an immune response in the homograft.

▶ Clinical Findings

A. Symptoms and Signs

The gradients obtained by echocardiography/Doppler, rather than cardiac catheterization data, are now used clinically. Mild pulmonic stenosis is present if the peak gradient by echocardiography/Doppler is < 30 mm Hg, moderate pulmonic stenosis is present if the peak gradient is between 30 mm Hg and 60 mm Hg, and severe pulmonic stenosis is present if the peak gradient is > 60 mm Hg or the mean gradient is > 40 mm Hg. Mild cases of pulmonic stenosis are asymptomatic; moderate to severe pulmonic stenosis may cause symptoms of dyspnea on exertion, syncope, chest pain, and eventually RV failure.

On examination, there is often a palpable parasternal lift due to right ventricular hypertrophy (RVH) and the pulmonary outflow tract may be palpable if it is enlarged. A loud, harsh systolic murmur and occasionally a prominent thrill are present in the left second and third interspaces parasternally. The murmur radiates toward the left shoulder due to the flow pattern and increases with inspiration. In mild to moderate pulmonic stenosis, a loud ejection click can be heard to precede the murmur; this sound decreases with inspiration as the increased RV filling from inspiration prematurely opens the valve during atrial systole. This is the only right-sided auscultatory event that decreases with inspiration. The reason for this is that the valve excursion in systole is less with inspiration than with expiration. This relates to premature opening of the pulmonary valve with the atrial kick into the RV. The click therefore diminishes in intensity when more volume is ejected into the RV with inspiration, raising the RV diastolic pressure. The second sound is obscured by the murmur in severe cases; the pulmonary component may be diminished, delayed, or absent. A right-sided S₄ and a prominent *a* wave in the venous pulse are present when there is RV diastolic dysfunction or a *c-v* wave if there is tricuspid regurgitation present. Right-sided S₄ gallops may be best heard in the right subclavicular area (where left-sided gallops would be distinctly uncommon). Pulmonic valve regurgitation is relatively uncommon in primary pulmonic stenosis and may be very difficult to hear, as the gradient between the reduced PA diastolic pressure and the elevated RV diastolic pressure may be quite small (low-pressure pulmonic regurgitation).

B. ECG and Chest Radiography

Right axis deviation or RVH is noted; peaked P waves provide evidence of right atrial (RA) overload. Heart size may be normal on radiographs, or there may be a prominent RV and RA or gross cardiac enlargement, depending on the severity. There is often poststenotic dilation of the main and left pulmonary arteries. The dilatation is primarily due to intrinsic abnormalities of the vessel wall, though the jet flow from the pulmonary stenosis is primarily toward the left PA, and the left PA is usually larger than the right. Pulmonary vascularity is usually normal. A careful look at the chest radiograph may reveal greater vascular perfusion of the left than the right base (Chen sign) due to the flow differential discussed earlier. Calcium may also be present in the main PA or pulmonic valve.

C. Diagnostic Studies

Echocardiography/Doppler is the diagnostic tool of choice, can provide evidence for a doming valve versus a dysplastic valve, can determine the gradient across the valve, and can provide information regarding subvalvular obstruction and the presence or absence of tricuspid or pulmonic valvular regurgitation. Catheterization is usually unnecessary for the diagnosis; it should be used only if the data are unclear or in preparation for either a percutaneous intervention or surgery. MRI and CT do not add additional information unless there is concern regarding associated cardiac lesions or peripheral pulmonary arterial lesions.

► Prognosis & Treatment

Patients with mild pulmonic stenosis have a normal life span with no intervention. Moderate stenosis may be asymptomatic in childhood and adolescence, but symptoms often appear as patients grow older. The degree of stenosis does worsen with time in many patients, so serial follow-up is important. Severe stenosis is rarely associated with sudden death but can cause right heart failure in patients as early as in their 20s and 30s. Pregnancy and exercise tends to be well tolerated except in severe stenosis.

Class I indications for intervention include all symptomatic patients and all those with a resting peak gradient over 60 mm Hg or mean > 40 mm Hg, regardless of symptoms. Percutaneous balloon valvuloplasty is highly successful in domed valve patients and is the treatment of choice. Surgical commissurotomy can also be done, or pulmonary valve replacement (with either a bioprosthetic valve or homograft) when pulmonic regurgitation is too severe or the valve is dysplastic. Pulmonary outflow tract obstruction due to RV to PA conduit obstruction or to homograft pulmonary valve stenosis can be relieved with a percutaneously implanted pulmonary valve. The applicability of this approach to primary pulmonic valve stenosis remains under investigation.

In accordance with the newest guideline recommendations, endocarditis prophylaxis is unnecessary unless there has been prior pulmonary valve endocarditis (a very rare entity).

► When to Refer

All symptomatic patients and all asymptomatic patients whose peak pulmonary valve gradient is > 60 mm Hg or mean gradient > 40 mm Hg should be referred to a cardiologist with an interest and expertise in adult congenital heart disease.

Bashore TM. Adult congenital heart disease: right ventricular outflow tract lesions. *Circulation*. 2007 Apr 10;115(14):1933–47. [PMID: 17420363]

McElhinney DB et al. Short- and medium-term outcomes after transcatheter pulmonary valve replacement in the expanded multicenter US Melody valve trial. *Circulation*. 2010 Aug 3;122(5):507–16. [PMID: 20644013]

Warnes CA et al. ACC/AHA 2008 Guidelines for the Management of Adults With Congenital Heart Disease. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *Circulation*. 2008 Dec 2;118(23):e714–833. [PMID: 18997169]

COARCTATION OF THE AORTA

ESSENTIALS OF DIAGNOSIS

- ▶ Usual presentation is systemic hypertension.
- ▶ A gradient of > 20 mm Hg by echocardiography/Doppler may be significant due to collaterals around the coarctation area reducing gradient despite severe obstruction.
- ▶ Associated bicuspid aortic valve (in 50% of patients).
- ▶ Some patients have a webbed neck (XO karyotype, Turner syndrome).
- ▶ Absent or weak femoral pulses. Delay of the palpable pulse between the femoral and brachial or radial artery.
- ▶ Systolic pressure is higher in upper extremities than in lower extremities; diastolic pressures are similar.
- ▶ ECG shows left ventricular hypertrophy; chest radiograph shows rib notching; echocardiography/Doppler is diagnostic.

► General Considerations

Coarctation of the aorta consists of localized narrowing of the aortic arch just distal to the origin of the left subclavian artery. Collateral circulation develops around the coarctation through the intercostal arteries and the branches of the subclavian arteries and can result in a lower transcoarctation gradient by enabling blood flow to bypass the obstruction. Coarctation is a cause of secondary hypertension and should be considered in young patients with elevated blood pressure (BP). The renin–angiotensin system is reset, however, and contributes to the hypertension occasionally seen even after coarctation repair. A bicuspid valve is seen in over 50% of the cases, and there is an increased incidence of cerebral berry aneurysms.

► Clinical Findings

A. Symptoms and Signs

If cardiac failure does not occur in infancy, there are usually no symptoms until the hypertension produces left ventricular (LV) failure or cerebral hemorrhage occurs. Strong arterial pulsations are seen in the neck and suprasternal notch. Hypertension is present in the arms, but the pressure is normal or low in the legs. This difference is exaggerated by exercise. Femoral pulsations are weak and are delayed in comparison with the brachial or radial pulse. Patients may have severe coarctation, but with large collateral blood vessels may have relatively small gradients because of high flow through the collaterals to the aorta distal to the coarctation. A continuous murmur heard superiorly and midline in the back or over the left anterior chest may be present when collaterals carry a lot of flow.

A significant peak gradient is > 20 mm Hg. Obtaining an angiogram is important because the gradient may not reflect the severity of the lesion. The coarctation itself may result in systolic ejection murmurs at the base, often heard posteriorly. There may be an associated aortic regurgitation or stenosis murmur due to the bicuspid aortic valve.

B. ECG and Chest Radiography

The ECG usually shows LV hypertrophy (LVH). Radiography shows scalloping of the ribs due to enlarged collateral intercostal arteries, dilation of the left subclavian artery and poststenotic aortic dilation, and LV enlargement. The coarctation region and the poststenotic dilation of the descending aorta may result in a “3” sign along aortic shadow on the PA chest radiograph (the notch in the “3” representing the area of coarctation).

C. Diagnostic Studies

Echocardiography/Doppler is usually diagnostic and may provide additional evidence for a bicuspid aortic valve. Both MRI and CT can also provide excellent images of the coarctation local anatomy. MRI and echocardiography/Doppler can also provide estimates of the gradient across the lesion. Cardiac catheterization provides definitive gradient information and is necessary if percutaneous stenting is to be considered.

► Prognosis & Treatment

Cardiac failure is common in infancy and in older untreated patients; it is uncommon in late childhood and young adulthood. Patients with a demonstrated gradient of > 20 mm Hg should be considered for intervention, especially if there is evidence of collateral blood vessels. Most untreated patients with the adult form of coarctation die before age 50 years from the complications of hypertension, rupture of the aorta, infective endarteritis, or cerebral hemorrhage. Aortic dissection also occurs with increased frequency. Coarctation of any significance may be poorly tolerated in pregnancy because of the inability to support the placental flow.

Resection of the coarctation site has a surgical mortality rate of 1–4% and includes risk of spinal cord injury. The percutaneous interventional procedure of choice is endovascular stenting when anatomically feasible. Recently, self-expanding and balloon-expandable covered stents have been shown to have a potential advantage over bare metal stents. Otherwise, surgical resection (usually with end-to-end anastomosis) should be performed. About 25% of surgically corrected patients continue to be hypertensive years after surgery because of permanent changes in the renin–angiotensin system, endothelial dysfunction, aortic stiffness, altered arch morphology, and increased ventricular stiffness.

► When to Refer

All patients with coarctation and a detectable gradient should be referred to a cardiologist with an interest in adult congenital heart disease.

Kenny D et al. Coarctation of the aorta: from fetal life to adulthood. *Cardiol J*. 2011;18(5):487–95. [PMID: 21947983]

Kenny D et al. Self-expanding and balloon expandable covered stents in the treatment of aortic coarctation with or without aneurysm formation. *Catheter Cardiovasc Interv*. 2008 Jul 1;72(1):65–71. [PMID: 18412235]

Tanous D et al. Coarctation of the aorta: evaluation and management. *Curr Opin Cardiol*. 2009 Nov;24(6):509–15. [PMID: 19667980]

Warnes CA et al. ACC/AHA 2008 Guidelines for the Management of Adults With Congenital Heart Disease. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *Circulation*. 2008 Dec 2;118(23):e714–833. [PMID: 18997169]

ATRIAL SEPTAL DEFECT & PATENT FORAMEN OVALE



ESSENTIALS OF DIAGNOSIS

- Often asymptomatic and discovered on routine physical examination.
- RV lift; S₂ widely split and fixed.
- All atrial septal defects should be closed either by a percutaneous device or by surgery if there is any evidence of an RV volume overload regardless of symptoms.
- Echocardiography/Doppler is diagnostic.
- A patent foramen ovale is present in 25% of the population but can lead to paradoxical emboli and cerebrovascular events. Suspicion should be highest in patients who have cryptogenic stroke before age 55 years.

► General Considerations

The most common form of atrial septal defect (ASD) (80% of cases) is persistence of the ostium secundum in the mid septum. A second less common abnormality is persistence of the ostium primum (low in the septum). In many patients with an ostium primum defect, there are mitral or tricuspid valve clefts as well as a ventricular septal defect (VSD) as part of the atrioventricular (AV) septal defect. A third form of ASD is the **sinus venosus defect**, a hole usually at of the upper or lower part of the atrial septum due to failure of the embryonic superior vena cava (SVC) or the inferior vena cava (IVC) to merge with the atria properly. The IVC sinus venosus defect is uncommon. The SVC sinus venosus defect is usually associated with an anomalous connection of the right upper pulmonary vein into the SVC. The **coronary sinus ASD** is rare and basically an unroofed coronary sinus. In all cases, normally oxygenated blood from the higher-pressure LA passes into the RA, increasing RV output and pulmonary blood flow. In children, the degree of shunting across these defects may be quite large (pulmonary to systemic blood flow ratios of 3:1 or so). As the RV diastolic pressure rises from the chronic

volume overload, the RA pressure may rise and the degree of left-to-right shunting may decrease. Eventually, if the RA pressure exceeds the LA, the shunt may reverse and be primarily right-to-left and systemic cyanosis appears. The major factor in the direction of shunt flow is thus the compliance of the respective atrial chambers.

The pulmonary pressures are modestly elevated in most patients with an ASD due to the high pulmonary blood flow, but severe pulmonary hypertension with cyanosis (Eisenmenger physiology) is actually unusual, occurring in only about 15% of the patients with an ASD alone. Eventual RV failure may occur though, and most shunts should be corrected unless they are quite small ($< 1.5:1$ left-to-right shunt). In adults, a large left-to-right shunt may have begun to reverse, so the absolute left-to-right shunt measurement (Q_p/Q_s , where Q_p = pulmonary flow and Q_s = systemic flow) at the time the patient is studied may underestimate the original shunt size. In addition, in most patients the LV and LA compliance normally declines more over time than the RV and RA, and the natural history of small atrial septal shunts is to increase the left-to-right shunt as the patient ages.

ASDs predispose to atrial fibrillation due to RA enlargement, and paradoxical right-to-left emboli do occur. Interestingly, paradoxical emboli may be more common in patients with a patent foramen ovale (PFO) than a true ASD. An **aneurysm of the atrial septum** is not a true aneurysm but rather simply redundancy of the atrial septum. When present with a PFO, the back and forth swinging of the redundant atrial septum (“jump rope septum”) tends to pull open the PFO. This helps explain why more right-to-left shunting occurs in patients with an atrial septal aneurysm and PFO than in those with a PFO alone and creates the anatomic substrate for the occurrence of paradoxical emboli.

► Clinical Findings

A. Symptoms and Signs

Patients with a small or moderate ASD or with a PFO are asymptomatic unless a complication occurs. There is only trivial shunting in a PFO. With larger ASD shunts, exertional dyspnea or cardiac failure may develop, most commonly in the fourth decade of life or later. Prominent RV and PA pulsations are then readily visible and palpable. A moderately loud systolic ejection murmur can be heard in the second and third interspaces parasternally as a result of increased flow through the pulmonary valve. S_2 is widely split and does not vary with breathing due to the fact that the left-to-right shunt decreases as the RA pressure increases with inspiration and the increased RV flow is held relatively constant in inspiration and expiration (“fixed” splitting of the second sound results). In very large left-to-right shunts, a tricuspid rumble may be heard due to the high flow across the tricuspid valve.

B. ECG and Chest Radiography

Right axis deviation or RVH may be present depending on the size of the RV volume overload. Incomplete or complete right bundle branch block is present in nearly all cases of ASD, and superior axis deviation is noted in the AV septal defect, where complete heart block is often seen as well.

With sinus venous defects, the P axis is leftward of $+15^\circ$ due to abnormal atrial activation with loss of the upper RA tissue from around the sinus node. In some patients with a secundum defect, there is notching in the inferior QRS leads (sometimes referred to as *crochetage* since the negative spike resembles a crochet needle). The chest radiograph shows large pulmonary arteries, increased pulmonary vascularity, an enlarged RA and RV, and a small aortic knob with all pre-tricuspid valve cardiac left-to-right shunts.

C. Diagnostic Studies

Echocardiography demonstrates evidence of RA and RV volume overload. The atrial defect is usually observed, although sinus venous defects may be elusive. Many patients with a PFO also have an atrial septal aneurysm (defined as > 10 mm excursion of the septum from the static position). Echocardiography with agitated saline bubble contrast can demonstrate a right-to-left shunt, and both pulsed and color flow Doppler flow studies can demonstrate shunting in either direction. A transesophageal echocardiogram (TEE) is helpful when transthoracic echocardiography quality is not optimal because it improves the sensitivity for detection of small shunts and provides a better assessment of PFO anatomy. Radionuclide flow studies quantify left-to-right shunting by observing the bolus of contrast within the lung fields and demonstrating early recirculation, but these studies are rarely used any longer. Both CT and MRI can elucidate the atrial septal anatomy and demonstrate associated lesions, such as anomalous pulmonary venous connections. Atrial septal anatomy can be complex and MRI can both define multiple fenestrations and reveal whether there is an adequate rim around the defect to allow for safe positioning of an atrial septal device. Cardiac catheterization can define the size and location of the shunt and determine the pulmonary pressure and pulmonary vascular resistance (PVR). Cardiac catheterization is required if percutaneous closure is to be contemplated.

► Prognosis & Treatment

Patients with small atrial shunts live a normal life span with no intervention. Large shunts usually cause disability by age 40 years. Because left-to-right shunts tend to increase with age-related changes in LV compliance, most clinicians believe that closure of all left-to-right shunts over $1.5:1$ should be accomplished. This situation always results in RV volume overload. Current guidelines suggest that all ASDs should be closed if there is any evidence of RV volume overload on the echocardiogram. Increased PVR and pulmonary hypertension secondary to pulmonary vascular disease rarely occur in childhood or young adult life in secundum defects but are more common in primum defects. After age 40 years, cardiac arrhythmias (especially atrial fibrillation) and heart failure occur with increased frequency due to the chronic right heart volume overload. Paradoxical systemic arterial embolization also becomes more of a concern as RV compliance is lost and the left-to-right shunt begins to reverse.

PFOs are usually not associated with significant shunting, and therefore the patients are asymptomatic and the heart size is normal. However, PFOs are responsible for most

paradoxical emboli and are one of the most frequent causes of cryptogenic strokes in patients under age 55 years.

Occasionally, a PFO may be responsible for cyanosis, especially if the RA pressure is elevated from pulmonary or RV hypertension or from severe tricuspid regurgitation. Rarely, an enlarged aorta can torque the atrial septum and enlarge the PFO. Right-to-left shunting can usually be demonstrated by saline contrast (“bubbles”) injected during echocardiography.

Surgery involves anything from simple stitching of the foramen closed to patching of the hole with Dacron or a pericardial patch. Anomalous pulmonary venous connections are baffled to the LA through the sinus venosus defect when such anomalous veins are present. For ostium secundum ASDs, percutaneous closure by use of a variety of devices is preferred over surgery. The percutaneous closure devices often resemble double mesh umbrellas that lock the septum between the Dacron umbrellas when opened, although many designs are available, including a “coil-like” device (Hexel) with Dacron attachment where a few Dacron covered coils are placed on each side of the septum.

Patients with a PFO who have symptoms related to stroke or transient ischemic attack (especially if the age is under 55) or who have hypoxemia (especially upon standing—so called platypnea orthodeoxia) should probably have the PFO closed if no other cause for symptoms is evident. Migraine headaches with aura may be more common in patients with a PFO, suggesting some unknown substance normally metabolized in the lung is entering the systemic circulation through the PFO. However, a randomized trial of use of a PFO closure device generally did not demonstrate benefit and a case-control study did not confirm the relationship between migraine plus aura and a PFO. For patients with cryptogenic stroke or transient ischemic attack, it remains uncertain whether closure of the PFO, either by open surgical or percutaneous techniques, has any advantage over anticoagulation with either warfarin or aspirin. There are no data yet suggesting that PFO closure is better than medical therapy for cryptogenic stroke, although ongoing randomized trials will help settle this issue. The first reported trial, CLOSURE 1, did not demonstrate a clear advantage to PFO closure with a percutaneous device compared to medical therapy with aspirin. Other trials are nearing completion, and the final recommendation for how to treat this situation should soon become clearer. When cyanosis might be improved by PFO closure, it is appropriate to consider it. PFO closure is also occasionally recommended for deep sea divers to help prevent the “bends” due to nitrous oxide shunting.

▶ When to Refer

- All patients with an ASD initially discovered at echocardiography/Doppler should be evaluated by a cardiologist with expertise in adult congenital disease to ensure no other structural disease is present and to investigate whether the RV is enlarged.
- If the RA and RV sizes remain normal, serial echocardiography should be performed.
- If the RA and RV volumes increase, then referral to a cardiologist who performs percutaneous closure is warranted.

- Patients < 55 years of age with an apparent paradoxical embolus and a PFO should be referred for possible closure of the defect, although studies have yet to prove the effectiveness of percutaneous closure.
- Patients with cyanosis and a PFO with evidence for a right-to-left shunt by agitated saline bubble contrast on echocardiography.

Garg P et al. Lack of association between migraine headache and patent foramen ovale: results of a case-control study. *Circulation*. 2010 Mar 30;121(12):1406–12. [PMID: 20231534]

Hoffmann A et al. Cerebrovascular accidents in adult patients with congenital heart disease. *Heart*. 2010 Aug;96(15):1223–6. [PMID: 20639238]

Kent DM et al. Is patent foramen ovale a modifiable risk factor for stroke recurrence? *Stroke*. 2010 Oct;41(10 Suppl):S26–30. [PMID: 20876498]

Warnes CA et al. ACC/AHA 2008 Guidelines for the Management of Adults With Congenital Heart Disease. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *Circulation*. 2008 Dec 2; 118(23):e714–833. [PMID: 18997169]

VENTRICULAR SEPTAL DEFECT



ESSENTIALS OF DIAGNOSIS

- ▶ A restrictive VSD is small and makes a louder murmur than an unrestricted one.
- ▶ Small defects may be asymptomatic.
- ▶ Larger defects may result in pulmonary hypertension (Eisenmenger physiology) if not repaired.
- ▶ Echocardiography/Doppler is diagnostic.

▶ General Considerations

De novo VSDs are uncommon in adults. Congenital VSDs occur in various parts of the ventricular septum. Four types are often described: in **type A**, the VSD lies underneath the semilunar valves; in **type B**, the VSD is membranous with three variations; in **type C**, the inlet VSD is present below the tricuspid valve and often part of the AV canal defect; and **type D** is the muscular VSD. Membranous and muscular septal defects may spontaneously close in childhood as the septum grows and hypertrophies. A left-to-right shunt is present unless there is associated RV hypertension. The smaller the defect, the greater the gradient from the LV to the RV and the louder the murmur. The presentation in adults is dependent on the size of the shunt and whether there is associated pulmonic or subpulmonic stenosis that has protected the lung from the systemic pressure and volume. Unprotected lungs with large shunts invariably lead to pulmonary vascular disease and severe pulmonary hypertension (Eisenmenger physiology).

► Clinical Findings

A. Symptoms and Signs

The clinical features depend on the size of the defect and the presence or absence of RV outflow obstruction or increased PVR. Small shunts are associated with loud, harsh holosystolic murmurs in the left third and fourth interspaces along the sternum. A systolic thrill is common. Larger shunts may create RV volume and pressure overload. If pulmonary hypertension occurs, high-pressure pulmonary regurgitation may result. Right heart failure may gradually become evident late in the course, and the shunt will begin to balance or reverse as RV and LV systolic pressures equalize with the advent of pulmonary hypertension. Cyanosis from right-to-left shunting may then occur.

B. ECG and Chest Radiography

The ECG may be normal or may show right, left, or biventricular hypertrophy, depending on the size of the defect and the PVR. With large shunts, the RV, the LV, the LA, and the pulmonary arteries are enlarged and pulmonary vascularity is increased on chest radiographs. If an increased PVR (pulmonary hypertension) evolves, an enlarged PA with pruning of the distal pulmonary vascular bed is seen. In rare cases of a VSD high in the ventricular septum, an aortic cusp may prolapse into the VSD and reduce the VSD shunt but result in acute aortic regurgitation.

C. Diagnostic Studies

Echocardiography can demonstrate the size of the overloaded chambers and can usually define the defect anatomy. Doppler can qualitatively assess the magnitude of shunting by noting the gradient from LV to RV and, if some tricuspid regurgitation is present, the RV systolic pressure can be estimated. The septal leaflet of the tricuspid valve may be part of the VSD anatomy and the complex appears as a ventricular septal “aneurysm.” Color flow Doppler helps delineate the shunt severity and the presence of valvular regurgitation. MRI and cardiac CT can often visualize the defect and describe any other anatomic abnormalities. MRI can provide quantitative shunt data as well. Radionuclide flow studies are rarely used to quantify the relative size of the left-to-right shunt. Cardiac catheterization is usually reserved for those with at least moderate shunting to determine the PVR and the degree of pulmonary hypertension. A PVR of > 7.0 absolute units or a PVR/systemic vascular resistance (SVR) ratio of > 0.67 (two-thirds systemic) usually implies inoperability. The vasoreactivity of the pulmonary circuit may be tested at catheterization using agents such as inhaled nitric oxide.

► Prognosis & Treatment

Patients with the typical murmur as the only abnormality have a normal life expectancy except for the threat of infective endocarditis. Endocarditis is more typical of smaller shunts due to the high velocity of the jet lesion damaging the tricuspid septal leaflet or RV free wall. Antibiotic prophylaxis is still recommended in this situation. With large

shunts, CHF may develop early in life, and survival beyond age 40 years is unusual without intervention.

The newest guidelines for the management of patients with VSD include the following:

1. **Medical management (class 2b recommendation):** Pulmonary vasodilatory therapy is appropriate for adults with a VSD and severe pulmonary hypertension. The response to inhaled nitric oxide is used to guide which agent would be the best option.
2. **Surgical management (class 1 recommendation):** Closure is indicated when the left-to-right shunt ratio is > 2.0 or there is clinical LV volume overload. In addition, closure is recommended if there has been a history of infective endocarditis.
3. **Surgical management (class 2b recommendation):** Closure is reasonable if the left-to-right shunt is > 1.5 and pulmonary pressure and PVR are less than two-thirds systemic pressure and SVR. Closure is also reasonable if the shunt ratio is > 1.5 and there is evidence for heart failure.

Small shunts (pulmonary-to-systemic flow ratio < 1.5) in asymptomatic patients do not require surgery or other intervention. The presence of RV infundibular stenosis or pulmonary valve stenosis may protect the pulmonary circuit such that some patients even with a large VSD may still be operable as adults.

Surgical repair of a VSD is generally a low-risk procedure unless there is significant Eisenmenger physiology. Currently, several new percutaneous closure devices are under investigation for nonsurgical closure of VSDs. Devices for muscular VSDs are approved and those for membranous VSDs are being implanted with promising results; however, conduction disturbance is a major complication. The devices are also approved for closure of a VSD related to acute myocardial infarction, although the results in this very high-risk patient population have not been encouraging. The drugs used to treat pulmonary hypertension secondary to VSD are similar to those used to treat idiopathic (“primary”) pulmonary hypertension (see below).

► When to Refer

All patients with a VSD should be referred to a cardiologist with expertise in adult congenital disease initially to decide if long-term follow-up is warranted.

Penny DJ et al. Ventricular septal defect. *Lancet*. 2011 Mar 26;377(9771):1103–12. [PMID: 21349577]

Warnes CA et al. ACC/AHA 2008 Guidelines for the Management of Adults With Congenital Heart Disease. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *Circulation*. 2008 Dec 2;118(23):e714–833. [PMID: 18997169]

Xing Q et al. Minimally invasive periventricular device closure of perimembranous ventricular septal defect without cardiopulmonary bypass: multicenter experience and mid-term follow-up. *J Thorac Cardiovasc Surg*. 2010 Jun;139(6):1409–15. [PMID: 20363483]

Yang R et al. Transcatheter closure of perimembranous ventricular septal defects in children: safety and efficacy of symmetric and asymmetric occluders. *Catheter Cardiovasc Interv*. 2011 Jan 1;77(1):84–90. [PMID: 20928839]

TETRALOGY OF FALLOT



ESSENTIALS OF DIAGNOSIS

- ▶ Five features are characteristic:
 - VSD.
 - RVH.
 - RV outflow obstruction from infundibular stenosis.
 - Overriding aorta in half (< 50% of the aorta over the septum).
 - A right-sided aortic arch is seen in 25%.
- ▶ Echocardiography/Doppler may underestimate significant pulmonic regurgitation. Be wary if the RV is enlarged.
- ▶ Arrhythmias are common and periodic Holter monitoring is recommended.
- ▶ If the QRS width is > 180 msec, the patient may be subject to serious arrhythmias and sudden death.

▶ General Considerations

Patients with tetralogy of Fallot have a VSD, RV infundibular stenosis, RVH, and a dilated aorta (in about 50% of patients it overrides the septum). If there is an associated ASD, the complex is referred to as pentalogy of Fallot. There may or may not be pulmonary valve stenosis as well, usually due to a bicuspid pulmonary valve. The aorta can be quite enlarged and aortic regurgitation may occur. If more than 50% of the aorta overrides into the RV outflow tract, the situation is considered as double outlet RV. Two vascular abnormalities are common: a right-sided aortic arch (in 25%) and anomalous left anterior descending coronary artery from the right cusp (7–9%). The latter is important in that surgical correction must avoid cutting this vessel when repairing the RV outflow obstruction and resulting in an anterior myocardial infarction.

Most adult patients have undergone prior surgery. If significant RV outflow obstruction is present in infancy, a Blalock-Taussig (or similar) shunt is often the initial surgical procedure to improve pulmonary blood flow. This procedure enables blood to reach the underperfused lung either by directly attaching one of the subclavian arteries to the PA (**classic Blalock shunt**) or by creating a conduit between the two (**modified Blalock shunt**). Other types of systemic to pulmonary shunts no longer in use include a window between the right PA and the aorta (**Waterston-Cooley shunt**) or a window between the left PA and the descending aorta (**Potts shunt**). In the adult, there may be a reduced upper extremity pulse on the side used for the classic Blalock procedure. **Total repair** of the tetralogy of Fallot generally includes a VSD patch and usually an enlarging RV outflow tract patch, as well as a take-down of the Blalock shunt. Often the RV outflow tract patch extends through the pulmonary valve into the PA (transannular patch), and the patient is left with varying degrees of pulmonic regurgitation. Over the years, the volume overload from severe pulmonary regurgitation becomes

the major hemodynamic problem seen in adults. Ventricular arrhythmias can also originate from the edge of the patch, and tend to increase with the size of the RV.

▶ Clinical Findings

Most adult patients in whom tetralogy of Fallot has been repaired are relatively asymptomatic unless right heart failure occurs or arrhythmias become an issue. Patients can be active and generally require no specific therapy except endocarditis prophylaxis.

A. Symptoms and Signs

Physical examination should include checking both arms for any loss of pulse from a prior shunt procedure in infancy. The jugular venous pulsations (JVP) may reveal an increased *a* wave from poor RV compliance or rarely a *c-v* wave due to tricuspid regurgitation. The right-sided arch has no consequence. The precordium may be active, often with a persistent pulmonary outflow murmur. P₂ may or may not be audible. A right-sided gallop may be heard. A residual VSD or aortic regurgitation murmur may be present. At times, the insertion site of a prior Blalock or other shunt may create a stenotic area in the PA and a continuous murmur occurs as a result.

B. ECG and Chest Radiography

The ECG reveals RVH and right axis deviation; in repaired tetralogy, there is often a right bundle branch block pattern. The chest radiograph shows a classic boot-shaped heart with prominence of the RV and a concavity in the RV outflow tract. This may be less impressive following repair. The aorta may be enlarged and right-sided. Importantly, the width of the QRS should be examined yearly. There are data that persons at greatest risk for sudden death are those with a QRS width of > 180 msec. The width of the QRS corresponds to the RV size, and in some patients, the QRS width actually decreases following relief of the pulmonary regurgitation with use of a prosthetic pulmonary valve.

C. Diagnostic Studies

Echocardiography/Doppler usually establishes the diagnosis by noting the unrestricted (large) VSD, the RV infundibular stenosis, and the enlarged aorta. In patients who have had tetralogy of Fallot repaired, echocardiography/Doppler also provides data regarding the amount of pulmonic regurgitation, RV and LV function, and the presence of aortic regurgitation.

Cardiac MRI and CT can quantitate both the pulmonary insufficiency and the RV volumes. In addition, cardiac MRI and CT can identify whether there is either a native pulmonary arterial branch stenosis or a stenosis at the distal site of a prior Blalock or other shunts such as an ASD. Cardiac catheterization is occasionally required to document the degree of pulmonic regurgitation because noninvasive studies depend on velocity gradients. Pulmonary angiography demonstrates the degree of pulmonic regurgitation, and RV angiography helps assess any postoperative outflow tract aneurysm.

► Prognosis & Treatment

A few patients with “just the right amount” of pulmonic stenosis enter adulthood without having had surgery. However, most adult patients have had surgical repair of tetralogy of Fallot, including VSD closure, resection of infundibular muscle, and insertion of an outflow tract patch. Many have a transannular patch resulting in pulmonic regurgitation. Patients should be monitored to ensure the RV volume does not increase. Low-pressure pulmonic regurgitation is difficult to diagnose except during cardiac catheterization due to the fact that the RV diastolic pressures tend to be high and the pulmonary arterial diastolic pressure is low. This means there is little gradient between the PA and the RV in diastole, so that there may be little murmur or evidence for turbulence on color flow Doppler. If the RV begins to enlarge, it must be assumed that this is due to pulmonic regurgitation until proven otherwise. Early surgical pulmonary valve replacement is increasingly being favored. A percutaneous approach may evolve for very selected patients.

If an anomalous coronary is present, then an extracardiac conduit around it from the RV to the PA may be necessary. By 20-year follow-up, reoperation is needed in about 10–15%, not only for severe pulmonic regurgitation but also for residual infundibular stenosis. Usually the pulmonary valve is replaced with a pulmonary homograft, though a porcine bioprosthetic valve is also suitable. Cryoablation of tissue giving rise to arrhythmias is sometimes performed at the time of reoperation. Branch pulmonary stenosis may be percutaneously opened by stenting. All patients require endocarditis prophylaxis. Most adults with stable hemodynamics can be quite active, and most women can carry a pregnancy adequately.

Arrhythmias are not uncommon with both atrial fibrillation and ventricular ectopy noted especially after the age of 45. Left heart disease appears to cause these arrhythmias more often than right heart disease. Biventricular dysfunction is not an uncommon consequence as the patient ages. The cause of associated LV dysfunction is often multifactorial and frequently unclear.

► When to Refer

All patients with tetralogy of Fallot should be referred to a cardiologist with expertise in adult congenital heart disease.

Apitz C et al. Tetralogy of Fallot. *Lancet*. 2009 Oct 24; 374(9699):1462–71. [PMID: 19683809]

Bashore TM. Adult congenital heart disease: right ventricular outflow tract lesions. *Circulation*. 2007 Apr 10;115(14):1933–47. [PMID: 17420363]

Kantor PF et al. Pathophysiology and management of heart failure in repaired congenital heart disease. *Heart Fail Clin*. 2010 Oct;6(4):497–506. [PMID: 20869649]

Khairy P et al; Alliance for Adult Research in Congenital Cardiology (AARCC). Arrhythmia burden in adults with surgically repaired tetralogy of Fallot: a multi-institutional study. *Circulation*. 2010 Aug 31;122(9):868–75. [PMID: 20713900]

Scherptong RW et al. Follow-up after pulmonary valve replacement in adults with tetralogy of Fallot: association between QRS duration and outcome. *J Am Coll Cardiol*. 2010 Oct 26;56:1486–92. [PMID: 20951325]

PATENT DUCTUS ARTERIOSUS



ESSENTIALS OF DIAGNOSIS

- ▶ Rare in adults.
- ▶ Adults with small or moderate size patent ductus arteriosus are usually asymptomatic, at least until middle age.
- ▶ Widened pulse pressure; loud S_2 .
- ▶ Continuous murmur over left pulmonary area; thrill common.
- ▶ Echocardiography/Doppler is helpful, but the lesion is best visualized by MRI, CT, or contrast angiography.

► General Considerations

The embryonic ductus arteriosus allows shunting of blood from the PA to the aorta in utero. The ductus arteriosus normally closes immediately after birth so that pulmonary blood flows only to the pulmonary arteries. Failure to close results in a persistent shunt connecting the left PA and aorta, usually near the origin of the left subclavian artery. Prior to birth, the ductus is kept patent by the effect of circulating prostaglandins; in the neonate, a patent ductus can often be closed by administration of a prostaglandin inhibitor such as indomethacin. The effect of the persistent left-to-right shunt on the pulmonary circuit is dependent on the size of the ductus. If large enough, pulmonary hypertension (Eisenmenger physiology) may occur. A small ductus may be well tolerated until adulthood.

► Clinical Findings

A. Symptoms and Signs

There are no symptoms unless LV failure or pulmonary hypertension develops. The heart is of normal size or slightly enlarged, with a hyperdynamic apical impulse. The pulse pressure is wide, and diastolic pressure is low. A continuous rough “machinery” murmur, accentuated in late systole at the time of S_2 , is heard best in the left first and second interspaces at the left sternal border. Thrills are common. If pulmonary hypertension is present (Eisenmenger physiology), the shunt may reverse and the lower body receives desaturated blood, while the upper body receives saturated blood. Thus, the hands appear normal while the toes are cyanotic and clubbed.

B. ECG and Chest Radiography

A normal tracing or LVH is found, depending on the magnitude of shunting. On chest radiographs, the heart is normal in size and contour, or there may be LV and LA enlargement. The PA, aorta, and LA are prominent because they all are in the shunt pathway.

C. Diagnostic Studies

Echocardiography/Doppler can determine LV, RV, and atrial dimensions. Color flow Doppler allows visualization of the high velocity shunt jet into the proximal left PA. Cardiac MRI and CT can demonstrate the abnormality and assess the size of the pulmonary arteries. Cardiac catheterization can establish the shunt size and direction, and define the size and anatomic features of the ductus. It can also help determine whether pulmonary hypertension has occurred. If percutaneous closure is feasible, catheterization with the use of occluder devices can be therapeutic.

► Prognosis & Treatment

Large shunts cause a high mortality rate from cardiac failure early in life. Smaller shunts are compatible with long survival, CHF being the most common complication. Infective endocarditis or endarteritis may rarely occur, and antibiotic prophylaxis for dental procedures continues to be recommended by some clinicians.

Surgical ligation of the patent ductus can be accomplished with excellent results. If the ductus has a “neck” and is of small enough size, percutaneous approaches using either coils or occluder devices are the preferred therapy. Newer duct occluder devices have a high success rate at a very low risk and are preferred. Patients with Eisenmenger physiology who have not undergone surgical ligation may benefit from vasodilator therapy. To monitor these latter patients, serial assessment of toe oxygen saturation as a marker of improvement in the right-to-left shunt is important because of the reversal in flow in the ductus.

Table 10–1 outlines the current recommendations for intervention in adult patients with a patent ductus arteriosus.

► When to Refer

All patients with patent ductus arteriosus should be referred to a cardiologist with expertise in adult congenital disease.

Laughon M et al. Patent ductus arteriosus management: what are the next steps? *J Pediatr.* 2010 Sep;157(3):355–7. [PMID: 20580017]

Warnes CA et al. ACC/AHA 2008 Guidelines for the Management of Adults With Congenital Heart Disease. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *Circulation.* 2008 Dec 2;118(23):e714–833. [PMID: 18997169]

VALVULAR HEART DISEASE

At one time, most cases of valvular disease in the United States were due to rheumatic heart disease. While this is still true in developing countries, other causes are much more common. In the elderly, “degenerative” calcific aortic valvular disease is believed to be due to a process similar to that which produces atherosclerosis, and studies have suggested that up to 25% of adults over age 65 have some

Table 10–1. Recommendations for interventions in patients with patent ductus arteriosus.¹

Class I

- A. Closure of a patent ductus arteriosus either percutaneously or surgically is indicated for the following:
 1. Presence of left atrial or left ventricular enlargement, pulmonary artery hypertension, or net left-to-right shunting (level of evidence: C)
 2. Prior endarteritis (level of evidence: C)
- B. Consultation with adult congenital heart disease interventional cardiologists is recommended before surgical closure is selected as the method of repair for patients with a calcified patent ductus arteriosus (level of evidence: C).
- C. Surgical repair by a surgeon experienced in coronary heart disease surgery is recommended when:
 1. The patent ductus arteriosus is too large for device closure (level of evidence: C).
 2. Distorted ductal anatomy precludes device closure (eg, aneurysm or endarteritis) (level of evidence: B).

Class IIa

- A. It is reasonable to close an asymptomatic small patent ductus arteriosus by catheter device (level of evidence: C).
- B. Patent ductus arteriosus closure is reasonable for patients with pulmonary artery hypertension with a net left-to-right shunt (level of evidence: C).

Class III

Patent ductus arteriosus closure is not indicated for patients with pulmonary artery hypertension and net right-to-left shunt (level of evidence: C).

¹Class I indicates treatment is useful and effective, class IIa indicates weight of evidence is in favor of usefulness/efficacy, class IIb indicates weight of evidence is less well established, and class III indicates intervention is not useful/effective and may be harmful. Type A recommendations are based on data derived from multiple randomized clinical trials or meta-analyses. Type B recommendations are based on data derived from a single randomized clinical trials or large nonrandomized studies. Type C recommendations are based on consensus of opinion of the experts or on data derived from small studies, retrospective studies, or registries.

ACC/AHA, American College of Cardiology/American Heart Association.

thickening of their aortic valve (aortic sclerosis) while 2–3% have frank aortic stenosis. Aortic sclerosis alone is a marker for future cardiovascular events and death. There is also increasing information that genetic markers associated with aortic stenosis play a role in the expression of this disease. Calcium deposition may also occur in the mitral annulus creating enough dysfunction of the valve that either stenosis or regurgitation (or both) results. Mitral valve prolapse is still frequently seen and rarely associated with the hyperadrenergic syndrome in younger patients. AV valvular regurgitation may be due to LV dysfunction (mitral regurgitation) or RV dysfunction (tricuspid regurgitation).

The typical findings of each native lesion are described in Table 10–2. Table 10–3 outlines bedside maneuvers to distinguish among the various murmurs.

Table 10–2. Differential diagnosis of valvular heart disease.

	Mitral Stenosis	Mitral Regurgitation	Aortic Stenosis	Aortic Regurgitation	Tricuspid Stenosis	Tricuspid Regurgitation
Inspection	Malar flush, precordial bulge, and diffuse pulsation in young patients.	Usually prominent and hyperdynamic apical impulse to left of MCL.	Sustained PMI, prominent atrial filling wave.	Hyperdynamic PMI to left of MCL and downward. Visible carotid pulsations. Pulsating nailbeds (Quincke), head bob (deMusset).	Giant <i>a</i> wave in jugular pulse with sinus rhythm. Peripheral edema or ascites, or both.	Large <i>v</i> wave in jugular pulse; time with carotid pulsation. Peripheral edema or ascites, or both.
Palpation	“Tapping” sensation over area of expected PMI. Right ventricular pulsation left third to fifth ICS parasternally when pulmonary hypertension is present. P_2 may be palpable.	Forceful, brisk PMI; systolic thrill over PMI. Pulse normal, small, or slightly collapsing.	Powerful, heaving PMI to left and slightly below MCL. Systolic thrill over aortic area, sternal notch, or carotid arteries in severe disease. Small and slowly rising carotid pulse. If bicuspid AS, check for delay at femoral artery to exclude coarctation.	Apical impulse forceful and displaced significantly to left and downward. Prominent carotid pulses. Rapidly rising and collapsing pulses (Corrigan pulse).	Pulsating, enlarged liver in ventricular systole.	Right ventricular pulsation. Systolic pulsation of liver.
Heart sounds, rhythm, and blood pressure	S_1 loud if valve mobile. Opening snap following S_2 . The worse the disease, the closer the S_2 -opening snap interval.	S_1 normal or buried in early part of murmur (exception in mitral prolapse where murmur may be late). Prominent third heart sound when severe MR. Atrial fibrillation common. Blood pressure normal. Midsystolic clicks may be present and may be multiple.	A_2 normal, soft, or absent. Prominent S_4 . Blood pressure normal, or systolic pressure normal with high diastolic pressure.	S_1 normal or reduced, A_2 loud. Wide pulse pressure with diastolic pressure < 60 mm Hg. When severe, gentle compression of femoral artery with diaphragm of stethoscope may reveal diastolic flow (Duroziez) and pressure in leg on palpation > 40 mm Hg than arm (Hill).	S_1 often loud.	Atrial fibrillation may be present.
Murmurs						
Location and transmission	Localized at or near apex. Diastolic rumble best heard in left lateral position; may be accentuated by having patient do sit-ups. Rarely, short diastolic murmur along lower left sternal border (Graham Steell) in severe pulmonary hypertension.	Loudest over PMI; posteriorly directed jets (ie, anterior mitral prolapse) transmitted to left axilla, left infrascapular area; anteriorly directed jets (ie, posterior mitral prolapse) heard over anterior precordium. Murmur unchanged after premature beat.	Right second ICS parasternally or at apex, heard in carotid arteries and occasionally in upper interscapular area. May sound like MR at apex (Gallavardin phenomenon), but murmur occurs after S_1 and stops before S_2 .	Diastolic: louder along left sternal border in third to fourth interspace. Heard over aortic area and apex. May be associated with low-pitched middiastolic murmur at apex (Austin Flint) due to functional mitral stenosis. If due to an enlarged aorta, murmur may radiate to right sternal border.	Third to fifth ICS along left sternal border out to apex. Murmur increases with inspiration.	Third to fifth ICS along left sternal border. Murmur hard to hear but increases with inspiration. Sit-ups can increase cardiac output and accentuate murmur.

Timing	Relation of opening snap to A ₂ important. The higher the LA pressure, the earlier the opening snap. Presystolic accentuation before S ₁ if in sinus rhythm. Graham Steell begins with P ₂ (early diastole) if associated pulmonary hypertension.	Pansystolic: begins with S ₁ and ends at or after A ₂ . May be late systolic in mitral valve prolapse.	Begins after S ₁ , ends before A ₂ . The more severe the stenosis, the later the murmur peaks.	Begins immediately after aortic second sound and ends before first sound (blurring both); helps distinguish from MR.	Rumble often follows audible opening snap.	At times, hard to hear. Begins with S ₁ and fills systole. Increases with inspiration.
Character	Low-pitched, rumbling; presystolic murmur merges with loud S ₁ .	Blowing, high-pitched; occasionally harsh or musical.	Harsh, rough.	Blowing, often faint.	As for mitral stenosis.	Blowing, coarse, or musical.
Optimum auscultatory conditions	After exercise, left lateral recumbency. Bell chest piece lightly applied.	After exercise; use diaphragm chest piece. In prolapse, findings may be more evident while standing.	Use stethoscope diaphragm. Patient resting, leaning forward, breath held in full expiration.	Use stethoscope diaphragm. Patient leaning forward, breath held in expiration.	Use stethoscope bell. Murmur usually louder and at peak during inspiration. Patient recumbent.	Use stethoscope diaphragm. Murmur usually becomes louder during inspiration.
Radiography	Straight left heart border from enlarged LA appendage. Elevation of left mainstem bronchus. Large right ventricle and pulmonary artery if pulmonary hypertension is present. Calcification in mitral valve in rheumatic mitral stenosis or in annulus in calcific mitral stenosis.	Enlarged left ventricle and LA.	Concentric left ventricular hypertrophy. Prominent ascending aorta. Calcified aortic valve common.	Moderate to severe left ventricular enlargement. Aortic root often dilated.	Enlarged right atrium with prominent SVC and azygous shadow.	Enlarged right atrium and right ventricle.
ECG	Broad P waves in standard leads; broad negative phase of diphasic P in V ₁ . If pulmonary hypertension is present, tall peaked P waves, right axis deviation, or right ventricular hypertrophy appears.	Left axis deviation or frank left ventricular hypertrophy. P waves broad, tall, or notched in standard leads. Broad negative phase of diphasic P in V ₁ .	Left ventricular hypertrophy.	Left ventricular hypertrophy.	Tall, peaked P waves. Possible right ventricular hypertrophy.	Right axis usual.

(continued)

Table 10–2. Differential diagnosis of valvular heart disease. (Continued)

	Mitral Stenosis	Mitral Regurgitation	Aortic Stenosis	Aortic Regurgitation	Tricuspid Stenosis	Tricuspid Regurgitation
Echocardiography						
Two-dimensional echocardiography	Thickened, immobile mitral valve with anterior and posterior leaflets moving together. “Hockey stick” shape to opened anterior leaflet in rheumatic mitral stenosis. Annular calcium with thin leaflets in calcific mitral stenosis. LA enlargement, normal to small left ventricle. Orifice can be traced to approximate mitral valve orifice area.	Thickened mitral valve in rheumatic disease; mitral valve prolapse; flail leaflet or vegetations may be seen. Dilated left ventricle in volume overload. Operate for left ventricular end-systolic dimension > 4.5 cm.	Dense persistent echoes from the aortic valve with poor leaflet excursion. Left ventricular hypertrophy late in the disease. Bicuspid valve in younger patients.	Abnormal aortic valve or dilated aortic root. Diastolic vibrations of the anterior leaflet of the mitral valve and septum. In acute aortic regurgitation, premature closure of the mitral valve before the QRS. When severe, dilated left ventricle with normal or decreased contractility. Operate when left ventricular end-systolic dimension > 5.0 cm.	In rheumatic disease, tricuspid valve thickening, decreased early diastolic filling slope of the tricuspid valve. In carcinoid, leaflets fixed, but no significant thickening.	Enlarged right ventricle with paradoxical septal motion. Tricuspid valve often pulled open by displaced chordae.
Continuous and color flow Doppler and TEE	Prolonged pressure half-time across mitral valve allows estimation of gradient. MVA estimated from pressure half-time. Indirect evidence of pulmonary hypertension by noting elevated right ventricular systolic pressure measured from the tricuspid regurgitation jet.	Regurgitant flow mapped into LA. Use of PISA helps assess MR severity. TEE important in prosthetic mitral valve regurgitation.	Increased transvalvular flow velocity; severe AS when peak jet > 4 m/sec (64 mm Hg). Valve area estimate using continuity equation is poorly reproducible.	Demonstrates regurgitation and qualitatively estimates severity based on percentage of left ventricular outflow filled with jet and distance jet penetrates into left ventricle. TEE important in aortic valve endocarditis to exclude abscess. Mitral inflow pattern describes diastolic dysfunction.	Prolonged pressure half-time across tricuspid valve can be used to estimate mean gradient. Severe tricuspid stenosis present when mean gradient > 5 mm Hg.	Regurgitant flow mapped into right atrium and venae cavae. Right ventricular systolic pressure estimated by tricuspid regurgitation jet velocity.

A₂, aortic second sound; AS, aortic stenosis; ICS, intercostal space; LA, left atrial; MCL, midclavicular line; MR, mitral regurgitation; MVA, measured valve area; P₂, pulmonary second sound; PISA, proximal isovelocity surface area; PMI, point of maximal impulse; S₁, first heart sound; S₂, second heart sound; S₄, fourth heart sound; SVC, superior vena cava; TEE, transesophageal echocardiography; V₁, chest ECG lead 1.

Table 10-3. Effect of various interventions on systolic murmurs.

Intervention	Hypertrophic Obstructive Cardiomyopathy	Aortic Stenosis	Mitral Regurgitation	Mitral Prolapse
Valsalva	↑	↓	↓ or ×	↑ or ↓
Standing	↑	↑ or ×	↓ or ×	↑
Handgrip or squatting	↓	↓ or ×	↑	↓
Supine position with legs elevated	↓	↑ or ×	×	↓
Exercise	↑	↑ or ×	↓	↑

↑, increased; ↓, decreased; ×, unchanged.

Modified, with permission, from Paraskos JA. Combined valvular disease. In: *Valvular Heart Disease*. Dalen JE, Alpert JS (editors). Little, Brown, LWW, 2000.

Bonow RO et al. 2008 focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. *J Am Coll Cardiol*. 2008 Sep 23;52(13):e1–142. [PMID: 18848134]

Maganti K et al. Valvular heart disease: diagnosis and management. *Mayo Clin Proc*. 2010 May;85(5):483–500. [PMID: 20435842]

Pibarot P. Valvular disease in 2010: evolution and revolution in risk stratification and therapy. *Nat Rev Cardiol*. 2011 Feb;8(2):75–7. [PMID: 21270847]

Rheumatic mitral stenosis results in thickening of the leaflets, fusion of the mitral commissures, retraction, thickening and fusion of the chordae, and calcium deposition in the valve. Mitral stenosis can also occur due to congenital disease with chordal fusion or papillary muscle malposition. The papillary muscles may be abnormally close together, sometimes so close they merge into a single papillary muscle (the parachute mitral valve). In these patients, the chordae or valvular tissue (or both) may also be fused. In other patients, mitral annular calcification may build up enough to produce a mitral gradient, most often in the elderly or patients with end-stage renal disease. Calcium in the mitral annulus virtually invades the mitral leaflet from the annulus inward. Mitral valve obstruction may also develop in patients who have had mitral valve repair with a mitral annular ring that is too small, or in patients who have had a surgical valve replacement (prosthetic valve-patient mismatch).

MITRAL STENOSIS



ESSENTIALS OF DIAGNOSIS

- ▶ Exertional dyspnea, orthopnea, and paroxysmal nocturnal dyspnea when the stenosis becomes severe.
- ▶ Symptoms often precipitated by onset of atrial fibrillation or pregnancy.
- ▶ Two syndromes occur; one with moderate mitral stenosis and pulmonary edema, and one with severe mitral stenosis, pulmonary hypertension, and low cardiac output.
- ▶ Echocardiography/Doppler is diagnostic.
- ▶ Intervention indicated for symptoms or evidence of pulmonary hypertension. Most symptomatic patients have a valve area < 1.5 cm².

▶ General Considerations

Patients with mitral stenosis are usually presumed to have underlying rheumatic heart disease, though a history of rheumatic fever is usually noted in only about one-third.

▶ Clinical Findings

A. Symptoms and Signs

A characteristic finding of rheumatic mitral stenosis is an opening snap following A₂ due to the stiff mitral valve. The interval between the opening snap and aortic closure sound is long when the LA pressure is low but shortens as the LA pressure rises and approaches the aortic diastolic pressure. As mitral stenosis worsens, there is a localized diastolic murmur low in pitch whose duration increases with the severity of the stenosis. The heart murmur is best heard at the apex with the patient in the left lateral position (Table 10–2).

Two clinical syndromes occur with mitral stenosis. In **mild to moderate mitral stenosis**, LA pressure and cardiac output may be essentially normal, and the patient is either asymptomatic or symptomatic only with extreme exertion. The measured valve area is usually between 1.5 cm² and 1.0 cm². In **severe mitral stenosis** (valve area < 1.0 cm²), severe pulmonary hypertension develops due to a “secondary stenosis” of the pulmonary vasculature. In this condition, pulmonary edema is uncommon, but symptoms of low cardiac output and right heart failure predominate.

Paroxysmal or chronic atrial fibrillation develops in 50–80% of patients. Any increase in the heart rate reduces diastolic filling time and increases the mitral gradient. A sudden increase in heart rate may precipitate pulmonary edema. Therefore, heart rate control is important to maintain, with slow heart rates allowing for more diastolic filling of the LV.

B. Diagnostic Studies

Echocardiography is the most valuable technique for assessing mitral stenosis. A scoring system is used to help define which patients are eligible for percutaneous valvuloplasty. One to four points are assigned to each of four observed parameters, with one being the least involvement and four the greatest: mitral leaflet thickening, mitral leaflet mobility, submitral scarring, and commissural calcium. Patients with a total valve score of 8 or less respond best to balloon valvuloplasty. LA size can also be determined by echocardiography: increased size denotes an increased likelihood of atrial fibrillation and thrombus formation. The effective mitral valve area can be determined by planimetry of the smallest mitral orifice or by using the continuous-wave Doppler gradient. Some determination of the pulmonary pressure can also be quantitated by measuring the peak RV pressure from the tricuspid velocity jet signal.

Because echocardiography and careful symptom evaluation provide most of the needed information, cardiac catheterization is used primarily to detect associated valve, coronary, or myocardial disease—usually after the decision to intervene has been made.

► Treatment & Prognosis

In most cases, there is a long asymptomatic phase, followed by subtle limitation of activity. Pregnancy and its associated increase in cardiac output, which results in an increased transmitral pressure gradient, often precipitate symptoms. Toward the end of pregnancy, the cardiac output is also maintained by an increase in heart rate, further increasing the mitral gradient by shortening diastolic time. Patients with moderate to severe mitral stenosis should have the condition corrected prior to becoming pregnant if possible. Pregnant patients who become symptomatic can undergo successful surgery, preferably in the third trimester, although balloon valvuloplasty is the treatment of choice if the echo score is low enough.

The onset of atrial fibrillation often precipitates symptoms, which usually initially improve with control of the ventricular rate or restoration of sinus rhythm. Conversion to and subsequent maintenance of sinus rhythm are most commonly successful when the duration of atrial fibrillation is brief (< 6–12 months) and the LA is not severely dilated (diameter < 4.5 cm). Once atrial fibrillation occurs, the patient should receive warfarin anticoagulation therapy even if sinus rhythm is restored, since atrial fibrillation often recurs even with antiarrhythmic therapy and 20–30% of these patients will have systemic embolization if untreated. Systemic embolization in the presence of only mild to moderate disease is not an indication for surgery but should be treated with warfarin anticoagulation.

Newer novel anticoagulants, such as dabigatran and rivaroxaban, are currently not approved for the prevention of stroke and non-central nervous system embolism in patients with rheumatic valvular atrial fibrillation.

Indications for intervention focus on symptoms such as an episode of pulmonary edema, a decline in exercise capacity, or any evidence for pulmonary hypertension (peak systolic pulmonary pressure > 50 mm Hg). Some experts believe that the presence of atrial fibrillation should be a consideration for an intervention. Other groups use the findings from exercise echocardiography to help with decision making, but the results from these studies are not standardized. In some patients, symptoms develop with calculated mitral valve areas between 1.5 cm² and 1.0 cm². Symptoms should drive the decision to intervene in these patients, not the estimated valve area.

Open mitral commissurotomy is now rarely performed and has given way to percutaneous balloon valvuloplasty. Ten-year follow-up data comparing surgery to balloon valvuloplasty suggest no real difference in outcome between the two modalities. Replacement of the valve is indicated when combined stenosis and regurgitation are present or when the mitral valve echo score is > 8–10. Percutaneous mitral valvuloplasty has a very low mortality rate (< 0.5%) and low morbidity rate (3–5%). Operative mortality rates are also low: 1–3% in most institutions. Repeat valvuloplasty can be done if the morphology of the valve is suitable. A Maze procedure may be done at the same time to reduce recurrent atrial arrhythmias.

Mechanical mitral prosthetic valves are more prone to thrombosis than aortic valves. Bioprosthetic valves degenerate after about 10–12 years and percutaneous balloon valvuloplasty procedures cannot be done on bioprosthetic valves should stenosis occur. Younger patients and those with end-stage renal disease do least well with bioprosthetic heart valves, although recent data have questioned the role of chronic kidney disease as a major risk factor. Endocarditis prophylaxis is always indicated for prosthetic valves. Percutaneous balloon valvuloplasty can safely be done during pregnancy if symptoms warrant.

► When to Refer

- Patients with mitral stenosis should be monitored with yearly examinations and echocardiograms.
- All patients should initially be seen by a cardiologist, who can then decide how often the patient needs cardiology follow-up.

Bonow RO et al. 2008 focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. *J Am Coll Cardiol.* 2008 Sep 23;52(13):e1–142. [PMID: 18848134]
 Chandrasekhar Y et al. Mitral stenosis. *Lancet.* 2009 Oct 10;374(9697):271–83. [PMID: 19747723]
 Cubeddu RJ et al. Percutaneous techniques for mitral valve disease. *Cardiol Clin.* 2010 Feb;28(1):139–53. [PMID: 19962055]

MITRAL REGURGITATION (Mitral Insufficiency)



ESSENTIALS OF DIAGNOSIS

- ▶ May be asymptomatic for many years (or for life) or may cause left-sided heart failure.
- ▶ Echocardiographic findings can help decide when to operate.
- ▶ For chronic primary mitral regurgitation, surgery is indicated for symptoms or when the LV ejection fraction is $< 60\%$ or the echocardiographic LV end-systolic diameter is > 4.0 cm.
- ▶ In patients with mitral prolapse and severe mitral regurgitation, earlier surgery is indicated if mitral repair can be performed.

▶ General Considerations

Mitral regurgitation places a volume load on the heart (increases preload) but reduces afterload. The result is an enlarged LV with an increased ejection fraction (EF). Over time, the stress of the volume overload reduces myocardial contractile function; when this occurs, there is a drop in EF and a rise in end-systolic volume.

▶ Clinical Findings

A. Symptoms and Signs

In acute mitral regurgitation, the LA size is not large, and LA pressure rises abruptly, leading to pulmonary edema if severe. When chronic, the LA enlarges progressively and the increased volume can be handled without a major rise in the LA pressure; the pressure in pulmonary veins and capillaries may rise only transiently during exertion. Exertional dyspnea and fatigue progress gradually over many years.

Mitral regurgitation leads to chronic LA and LV enlargement and may result in subsequent atrial fibrillation and LV dysfunction. Clinically, mitral regurgitation is characterized by a pansystolic murmur maximal at the apex, radiating to the axilla and occasionally to the base; a hyperdynamic LV impulse and a brisk carotid upstroke; and a prominent third heart sound due to the increased volume returning to the LV in early diastole (Tables 10–2 and 10–3). The mitral regurgitation murmur due to mitral valve prolapse tends to radiate anteriorly in the presence of posterior leaflet prolapse and posteriorly when the prolapse is primarily of the anterior leaflet.

B. Diagnostic Studies

Echocardiography is useful in demonstrating the underlying pathologic process (rheumatic, prolapse, flail leaflet, cardiomyopathy), and Doppler techniques provide qualitative and semiquantitative estimates of the severity of mitral regurgitation. Echocardiographic information concerning LV size and function, LA size, PA pressure, and RV

function can be invaluable in planning treatment as well as in recognizing associated lesions. TEE may help reveal the cause of regurgitation and is especially useful in patients who have had mitral valve replacement, in suspected endocarditis, and in identifying candidates for valvular repair. Echocardiographic dimensions and measures of systolic function are critical in deciding the timing of surgery. In the past, exercise radionuclide angiography for measurements of exercise EF or determination of myocardial stress–EF relationships was recommended, but this is now rarely done. There is a growing body of evidence of the usefulness of B-type natriuretic peptide (BNP) in the early identification of LV dysfunction in the presence of mitral regurgitation, and it is likely that future guidelines will use this test to help decide when to intervene.

Cardiac MRI is occasionally useful, if specific myocardial causes are being sought (such as amyloid or myocarditis) or if myocardial viability assessment is needed prior to deciding whether to add coronary artery bypass grafting to mitral repair in patients with chronic ischemic mitral regurgitation.

Cardiac catheterization provides a further assessment of regurgitation and its hemodynamic impact along with LV function, resting cardiac output, and PA pressure. Coronary angiography is often indicated to determine the presence of CAD prior to valve surgery in all men over age 35 years and women over age 35 with risk factors, according to the 2006 ACC/AHA valvular guidelines. In younger patients (< 50 years of age), cardiac multidetector CT may be adequate to screen patients with valvular heart disease for asymptomatic CAD.

▶ Treatment & Prognosis

A. Primary Mitral Regurgitation

LA enlargement is at times considerable in chronic mitral regurgitation; the degree of LV enlargement usually reflects the severity and chronicity of regurgitation. Calcification of the mitral valve is less common than in pure mitral stenosis. Hemodynamically, LV volume overload may ultimately lead to LV failure and reduced cardiac output. For many years, the LV end-diastolic pressure and the cardiac output will be normal at rest. Nonrheumatic mitral regurgitation may develop abruptly, such as with papillary muscle dysfunction following myocardial infarction, valve perforation in infective endocarditis, or ruptured chordae tendineae in mitral valve prolapse.

Acute mitral regurgitation due to endocarditis, myocardial infarction, and ruptured chordae tendineae often requires emergency surgery. Some patients can be stabilized with vasodilators or intra-aortic balloon counterpulsation, which reduce the amount of regurgitant flow by lowering systemic vascular resistance. Patients with chronic lesions may remain asymptomatic for many years. Surgery is necessary when symptoms develop. However, because progressive and irreversible deterioration of LV function may occur prior to the onset of symptoms, early operation is indicated even in asymptomatic patients with a reduced EF ($< 60\%$) or marked LV dilation (end-systolic dimension > 4.0 cm on echocardiography). In some institutions, the calculation of an effective regurgitant orifice area by

echocardiogram has proven useful in helping decide the severity of the mitral regurgitation. Regurgitant orifice areas $> 40 \text{ mm}^2$ are considered severe.

There is controversy regarding the role of afterload reduction in mitral regurgitation, since the lesion inherently results in a reduction in afterload, and there are no data that chronic afterload reduction is effective. A heightened sympathetic state has led some experts to suggest β -blockade instead. Cardiomyopathy and mitral regurgitation due to persistent tachycardia may also improve with treatment of the higher heart rate.

B. Myocardial Disease and Mitral Regurgitation

When mitral regurgitation is due to papillary dysfunction, it may subside as the infarction heals or LV dilation diminishes. The cause of the regurgitation in most situations is displacement of the papillary muscles and an enlarged mitral annulus rather than true papillary muscle ischemia. The fundamental problem is the lack of leaflet coaptation during systole. In acute infarction, rupture of the papillary muscle may occur with catastrophic results. Transient—but sometimes severe—mitral regurgitation may occur during episodes of myocardial ischemia and contribute to flash pulmonary edema. Patients with dilated cardiomyopathies of any origin may have **secondary mitral regurgitation** due to papillary muscle displacement or dilation of the mitral annulus. In patients with ischemic cardiomyopathy, ventricular reconstructive surgery to restore the mitral apparatus anatomy and reshape the ventricle (Dor procedure) has had limited success. If mitral valve replacement is performed, preservation of the chordae to the native valve helps prevent further ventricular dilation following surgery. Several groups have reported good results with mitral valve repair in patients with left ventricular ejection fraction (LV EF) $< 30\%$ and secondary mitral regurgitation. Recent guidelines consider it acceptable to attempt mitral valve repair in patients with an EF $< 30\%$ or an LV end-systolic dimension $> 5.5 \text{ cm}$, or both, as long as repair and preservation of the chordae are possible. There may also be a role for cardiac resynchronization therapy with biventricular pacemaker insertion in reducing mitral regurgitation due to cardiomyopathy.

Currently, there are several ongoing trials of percutaneous approaches to reducing mitral regurgitation. These approaches include the use of a mitral clip device to create a double orifice mitral valve, various coronary catheter devices to reduce the mitral annular area, and devices to reduce the septal-lateral ventricular size and consequent mitral orifice size. Some success has been noted with the mitral clip device. In addition, vascular plugging and occluder devices are being used in selected patients to occlude perivalvular leaks around prosthetic valves.

► When to Refer

All patients with more than mild mitral regurgitation should be referred to a cardiologist for an evaluation. Serial examinations and echocardiograms (usually yearly) should be obtained, and referral made if there is any increase in the LV end-systolic dimensions, a fall in the EF to $< 60\%$, or symptoms.

- Bonow RO et al. 2008 focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. *J Am Coll Cardiol.* 2008 Sep 23;52(13):e1–142. [PMID: 18848134]
- Carabello BA. The current therapy for mitral regurgitation. *J Am Coll Cardiol.* 2008 Jul 29;52(5):319–26. [PMID: 18652937]
- Di Salvo TG et al. Mitral valve surgery in advanced heart failure. *J Am Coll Cardiol.* 2010 Jan 26;55(4):271–82. [PMID: 20117430]
- Feldman T et al; EVEREST II Investigators. Percutaneous repair or surgery for mitral regurgitation. *N Engl J Med.* 2011 Apr 14;364(15):1395–406. [PMID: 21463154]
- Kapoor JR. Role of mitral valve surgery for secondary mitral regurgitation in heart failure. *J Am Coll Cardiol.* 2009 Jan 6;53(1):74. [PMID: 19118728]
- Pizarro R et al. Prospective validation of the prognostic usefulness of brain natriuretic peptide in asymptomatic patients with chronic severe mitral regurgitation. *J Am Coll Cardiol.* 2009 Sep 15;54(12):1099–106. [PMID: 19744620]

MITRAL VALVE PROLAPSE



ESSENTIALS OF DIAGNOSIS

- Single or multiple mid-systolic clicks often heard on auscultation.
- Murmur may be pansystolic or only late in systole.
- Often associated with skeletal changes (straight back, pectus excavatum, and scoliosis) or hyperflexibility of joints.
- Echocardiography is confirmatory with prolapse of mitral leaflets in systole into the LA.
- Chest pain and palpitations common symptoms in the young adult.

► General Considerations

The significance of **mitral valve prolapse** (“floppy” or **myxomatous mitral valve**) is in dispute because of the frequency with which it is diagnosed by echocardiography even in healthy young women (up to 10%). A controversial hyperadrenergic syndrome has also been described (especially in young females) that may be responsible for some of the noncardiac symptoms observed. Fortunately, this hyperadrenergic component attenuates with age. Some patients with mitral prolapse have findings of a systemic collagen abnormality (Marfan or Ehlers-Danlos syndrome). In these conditions, a dilated aortic root and aortic regurgitation may coexist.

Patients who have only a mid-systolic click usually have no sequelae, but significant mitral regurgitation may develop, occasionally due to rupture of chordae tendineae (flail leaflet) or progressive annular dilation. The need for

valve repair or replacement increases with age, so that approximately 2% per year of patients with clinically significant regurgitation over age 60 years will eventually require surgery.

► Clinical Findings

A. Symptoms and Signs

Mitral valve prolapse is usually asymptomatic but may be associated with nonspecific chest pain, dyspnea, fatigue, or palpitations. Most patients are female, many are thin, and some have skeletal deformities such as pectus excavatum or scoliosis. On auscultation, there are characteristic mid-systolic clicks that may be multiple and emanate from the chordae or redundant valve tissue. If leaflets fail to come together properly, the clicks will be followed by a late systolic murmur. As the mitral regurgitation worsens, the murmur is heard more and more throughout systole. The smaller the LV chamber, the greater the degree of prolapse, and thus auscultatory findings are often accentuated in the standing position or during the Valsalva maneuver.

B. Diagnostic Studies

The diagnosis is primarily clinical and confirmed echocardiographically. Mitral prolapse is often associated with aortic root disease, and any evidence for a dilated aorta by chest radiography should prompt either CT or MRI angiography. If palpitations are an issue, an ambulatory monitor is often helpful to distinguish atrial from ventricular tachyarrhythmias.

► Treatment

β-Blockers in low doses are used to treat the hyperadrenergic state when present and are usually satisfactory for treatment of arrhythmias. Selective serotonin reuptake inhibitors have also been used, especially if orthostatic hypotension or anxiety is associated with mitral valve prolapse; results have been mixed. Afterload reduction has not been shown to be effective when mitral regurgitation is present.

Mitral valve repair is strongly favored over valve replacement, and its efficacy has led many to recommend intervention earlier and earlier in the course of the disease process. Mitral repair may include shortening of chordae, chordae transfers, wedge resection of redundant valve tissue, or the insertion of a mitral annular ring to reduce the annular size, or some combination of these techniques. Stitching of the leaflets together to create a double orifice mitral valve is also used at times (Alfieri procedure) and can be performed percutaneously. Mitral repair or replacement can be achieved through a right minithoracotomy with or without the use of a robotic device. Endocarditis prophylaxis is no longer recommended for most patients with mitral valve prolapse regardless of the degree of mitral regurgitation. A variety of percutaneous techniques and devices have been tried with some success (notably in the mitral clip trials). The

use of a ventricular remodeling device that pulls the mitral annulus in an anteroposterior direction and can be placed without cardiopulmonary bypass (the Coapsys system) reported favorable results, but it is unclear if it will ever be marketed.

► When to Refer

- All patients with mitral valve prolapse and audible mitral regurgitation should be seen at least once and then periodically by a cardiologist. If only mitral clicks are audible, then serial echocardiography is not warranted.
- Periodic echocardiography is warranted to assess LV size (especially end-systolic dimensions) and EF when mitral regurgitation is present.

Feldman T et al; EVEREST II Investigators. Percutaneous repair or surgery for mitral regurgitation. *N Engl J Med.* 2011 Apr 14;364(15):1395–406. [PMID: 21463154]

Filho AS et al. Mitral valve prolapse and anxiety disorders. *Br J Psychiatry.* 2011 Sep;199(3):247–8. [PMID: 21881100]

Grossi EA et al. Outcomes of the RESTOR-MV Trial (Randomized Evaluation of a Surgical Treatment for Off-Pump Repair of the Mitral Valve). *J Am Coll Cardiol.* 2010 Dec 7;56(24):1984–93. [PMID: 21126639]

Verma S et al. Mitral valve repair for mitral valve prolapse. *N Engl J Med.* 2009 Dec 3;361(23):2261–9. [PMID: 19955526]

Whitlow PL et al; EVEREST II Investigators. Acute and 12-month results with catheter-based mitral valve leaflet repair: The EVEREST II (Endovascular Valve Edge-to-Edge Repair) High Risk Study. *J Am Coll Cardiol.* 2012 Jan 10;59(2):130–9. [PMID: 22222076]

AORTIC STENOSIS



ESSENTIALS OF DIAGNOSIS

- Congenital bicuspid aortic valve, usually asymptomatic until middle or old age.
- “Degenerative” or calcific aortic stenosis; same risk factors as atherosclerosis.
- Symptoms likely once the mean gradient is > 40 mm Hg.
- Echocardiography/Doppler is diagnostic.
- Surgery indicated for symptoms.
- Surgery considered for asymptomatic patients with severe aortic stenosis.
- Emerging role for BNP as marker of early LV myocardial failure.

► General Considerations

There are two common clinical scenarios in which aortic stenosis is prevalent. The first is due to a congenitally abnormal **unicuspid** or **bicuspid valve**, rather than tricuspid. Symptoms occur in young or adolescent individuals if

the stenosis is severe, but more often emerge at age 50–65 years when calcification and degeneration of the valve becomes manifest. A dilated ascending aorta, primarily due to an intrinsic defect in the aortic root media, may accompany the bicuspid valve in half of these patients. Coarctation of the aorta is also seen in a number of patients with congenital aortic stenosis. Offspring of patients with a bicuspid valve have a much higher incidence of the disease as well (up to 30% in some series).

A second group develops what has traditionally been called **degenerative** or **calcific** aortic stenosis, which is thought to be related to calcium deposition due to processes similar to what occurs in atherosclerotic vascular disease. Approximately 25% of patients over age 65 years and 35% of those over age 70 years have echocardiographic evidence of aortic sclerosis. About 10–20% of these will progress to hemodynamically significant aortic stenosis over a period of 10–15 years. Certain genetic markers are now being discovered that are associated with aortic stenosis (most notably Notch 1), so a genetic component appears a likely contributor, at least in some patients. Other associated genetic markers have also been described.

Aortic stenosis has become the most common surgical valve lesion in developed countries, and many patients are elderly. The risk factors include hypertension, hypercholesterolemia, and smoking. Hypertrophic obstructive cardiomyopathy may also coexist with valvular aortic stenosis.

► Clinical Findings

A. Symptoms and Signs

Slightly narrowed, thickened, or roughened valves (aortic sclerosis) or aortic dilation may produce the typical ejection murmur of aortic stenosis. In mild or moderate cases where the valve is still pliable, an ejection click may precede the murmur. The characteristic systolic ejection murmur is heard at the aortic area and is usually transmitted to the neck and apex. In some cases, only the high-pitched components of the murmur are heard at the apex, and the murmur may sound like mitral regurgitation (so-called Gallavardin phenomenon). In severe aortic stenosis, a palpable LV heave or thrill, a weak to absent aortic second sound, or reversed splitting of the second sound is present (see Table 10–2). When the valve area is $< 0.8\text{--}1.0\text{ cm}^2$ (normal, $3\text{--}4\text{ cm}^2$), ventricular systole becomes prolonged and the typical carotid pulse pattern of delayed upstroke and low amplitude is present. This may be an unreliable finding in older patients with extensive arteriosclerotic vascular disease and a stiff aorta. LVH increases progressively due to the pressure overload, eventually resulting in elevation in ventricular end-diastolic pressure. Cardiac output is maintained until the stenosis is severe (with a valve area $< 0.8\text{ cm}^2$). LV failure, angina pectoris, or syncope may be presenting symptoms and signs of significant aortic stenosis; importantly, all symptoms tend to occur with exertion. In a few patients, there appears to be a mismatch among the typical aortic stenosis assessments: the aortic valve gradient severity (low), the aortic valve area (severe), the degree of

the LVH (severe), and the EF (normal). These low flow aortic stenosis patients may have significant LV afterload due to increased aortic vascular impedance as well as the valvular stenosis resistance. Some experts have suggested these lower aortic gradient patients might benefit from aortic valve replacement (AVR) if the calculated total resistance (Z score) is elevated. The Z score is calculated by dividing the sum of the aortic gradient and systolic BP by the stroke volume index.

Symptoms of LV failure may be sudden in onset or may progress gradually. Angina pectoris frequently occurs in aortic stenosis due to underperfusion of the endocardium. Of patients with calcific aortic stenosis and angina, 50% have significant associated CAD. Syncope is typically exertional and a late finding. Syncope occurs with exertion as the LV pressures rises, stimulating the LV baroreceptors to cause peripheral vasodilation. This vasodilation results in the need for an increase in stroke volume, which increases the LV systolic pressure again, creating a cycle of vasodilation and stimulation of the baroreceptors that eventually results in a drop in BP, as the stenotic valve prevents further increase in stroke volume. Less commonly, syncope may be due to arrhythmias (usually ventricular tachycardia but sometimes AV block as calcific invasion of the conduction system from the aortic valve may occur).

B. Diagnostic Studies

The clinical assessment of the severity of aortic stenosis may be difficult, especially when there is reduced cardiac output or significant associated aortic regurgitation. The ECG reveals LVH or secondary repolarization changes in most patients but can be normal in up to 10%. The chest radiograph may show a normal or enlarged cardiac silhouette, calcification of the aortic valve, and dilation and calcification of the ascending aorta. The echocardiogram provides useful data about aortic valve calcification and opening and the severity of LV wall thickness and overall ventricular function, while Doppler can provide an excellent estimate of the aortic valve gradient. Valve area estimation by echocardiography is less reliable. Cardiac catheterization mostly provides an assessment of the hemodynamic consequence of the aortic stenosis, and the anatomy of the coronary arteries. In younger patients, and in patients with high aortic gradients the aortic valve need not be crossed at catheterization. If the valve is crossed, the valve gradient can be measured at catheterization and an estimated valve area calculated; a valve area below 1.0 cm^2 indicates significant stenosis. Aortic regurgitation can be semiquantified by aortic root angiography.

In patients with a low EF and both low output and a low valve gradient, it may be unclear if an increased afterload is responsible for the low EF or if there is an associated cardiomyopathy. To sort this out, the patient should be studied at baseline and then during an intervention that increases cardiac output (eg, dobutamine or nitroprusside infusion). If the valve area increases and there is poor contractile reserve ($< 20\%$ increase in the stroke volume), the flow-limiting problem is not the valve, but rather the cardiomyopathy, and surgery is not warranted. If the valve area remains unchanged at the higher outputs and there remains

contractile reserve, then the valve is considered flow limiting and surgery is indicated. Recent data have suggested the use of BNP may provide prognostic data in the setting of poor LV function and aortic stenosis. A BNP > 550 pg/mL has been associated with a poor outcome in these patients regardless of the results of dobutamine testing.

► Prognosis & Treatment

Following the onset of heart failure, angina, or syncope, the prognosis without surgery is poor (50% 3-year mortality rate). Medical treatment may stabilize patients in heart failure, but surgery is indicated for all symptomatic patients with evidence of significant aortic stenosis. Valve replacement is usually not indicated in asymptomatic individuals, though a class II indication is to operate once the peak valve gradient by Doppler exceeds 64 mm Hg or the mean exceeds 40 mm Hg. Stress testing and perhaps the use of BNP may help identify patients who deny symptoms but are actually compromised from a ventricular function standpoint.

The surgical mortality rate for valve replacement is low, even in the elderly, and ranges from 2% to 5%. This low risk is due to the dramatic hemodynamic improvement that occurs with relief of the increased afterload. Mortality rates are substantially higher when there is an associated ischemic cardiomyopathy. Severe coronary lesions are usually bypassed at the same time, although there are little data to suggest this practice affects outcome.

All patients should have normal lipid levels, usually with goal of an LDL of ≤ 100 mg/dL, since progression of aortic stenosis theoretically may be slowed by control of cholesterol levels. Most studies have been negative or equivocal in this regard, but longer-term studies in patients with early disease are still pending. Many experts argue that for lipid lowering therapy to have any effect on the stenotic process, it needs to be initiated at an early stage in the disease. If patients with aortic stenosis have concomitant CAD, the LDL goal should be ≤ 70 mg/dL. Control of systemic hypertension is also an important adjunct, and inadequate systemic BP control is common due to unreasonable concerns about providing too much afterload reduction in patients with aortic stenosis.

The interventional options in patients with aortic stenosis are variable and dependent on the patient's lifestyle and age. In the young and adolescent patient, percutaneous valvuloplasty still has a role. Balloon valvuloplasty is less effective and is associated with early restenosis in the elderly, and thus is rarely used except as a temporizing measure in calcific aortic stenosis. Data suggest aortic balloon valvuloplasty in the elderly has an advantage only in those with preserved LV function, and such patients are usually excellent candidates for surgical AVR. The Ross procedure is generally still considered a viable option in younger patients, and it is performed by moving the patient's own pulmonary valve to the aortic position and replacing the pulmonary valve with a homograft (or rarely a bioprosthetic valve). However, dilation of the pulmonary valve autograft and consequent aortic regurgitation, plus early stenosis of the pulmonary homograft in the pulmonary position, has reduced the enthusiasm for this approach

in most institutions. Middle-aged adults generally can tolerate the anticoagulation therapy necessary for the use of mechanical AVR, so most undergo AVR with a bileaflet mechanical valve. If the aortic root is severely dilated as well (>4.5 cm), then the valve may be housed in a Dacron sheath (Bentall procedure) and the root replaced. Alternatively, a human homograft root and valve replacement can be used. In the elderly, bioprosthetic (either porcine or bovine pericardial) valves with a life expectancy of about 10–15 years are routinely used instead of mechanical valves to avoid need for anticoagulation. Recent data favor the bovine pericardial valve over the porcine aortic valve. If the aortic annulus is small, a bioprosthetic valve with a short sheath can be sewn to the aortic wall (the stentless AVR) rather than sewing the prosthetic annulus to the aortic annulus. (Annulus is a relative term when speaking of the aortic valve, since there is no true annulus.) Another surgical option becoming popular is the Wheat procedure; it involves aortic root replacement above the coronary arteries and AVR. The coronary arteries thus remain attached to the native aorta between the new graft and prosthetic valve rather than being reimplemented onto an artificial sheath or homograft.

In patients with a bicuspid aortic valve, there is often an associated ascending aortic aneurysm. If the maximal dimension of the aortic root exceeds 5.0 cm, it is recommended to proceed with root replacement regardless of the severity of the aortic valve disease. The aortic valve may be replaced at the same time or may be left alone (valve sparing operation).

Anticoagulation is required with the use of mechanical valves, and the international normalized ratio (INR) should be maintained between 2.0 and 3.0 or between 2.5 and 3.5, depending on type and position of valve and patient risk factors. In general, mechanical aortic valves are less subject to thrombosis than mechanical mitral valves. Some newer bileaflet mechanical valves (On-X) that require either no or a reduced dose of warfarin therapy are being evaluated, although the final data regarding the safety of this particular design are not available. The Prospective Randomized On-X valve AntiCoagulation Trial (PROACT) was begun in 2006 and is ongoing. Preliminary results have been reported and are very promising. Transcatheter aortic valve implantation (TAVI) is being used in Europe. In the United States, the Food and Drug Administration (FDA) has granted limited approval for one device (Edwards SAPIEN), and trials of a second device (CoreValve) are being completed. The devices use either a stent with a trileaflet bovine pericardial valve constructed in it or a stent with a large valve from a cow's jugular vein mounted inside. Both a retrograde approach (from the aorta or from the subclavian artery) and an antegrade approach (from the ventricles by way of a transeptal catheter across the atrial septum) are being investigated. The Edwards SAPIEN valve is a balloon-expandable valvular stent, while the CoreValve is a self-expanding valvular stent. The PARTNER TAVI trial randomized 358 high-risk patients who were not considered to be candidates for surgical AVR to either the TAVI or the medical therapy group. Confirming historical data, the medically treated patients had 50% mortality at 1 year,

compared with a 30% mortality in patients who underwent TAVI, a highly significant improved survival. An alternative approach using a minithoracotomy and LV puncture allows the aortic valve to be replaced from the LV apical area without opening the aortic root (transapical AVR)—a real advantage in some patients with severe calcification of the ascending aorta. Current TAVI is reserved for very high-risk surgical patients. Further data regarding outcomes will define whether this approach is appropriate for lower-risk patients.

▶ When to Refer

- All patients with an aortic murmur and echocardiographic evidence for mild-to-moderate aortic stenosis (estimated peak valve gradient > 30 mm Hg by echocardiography/Doppler) should be referred to a cardiologist for evaluation and to determine the frequency of follow-up.
- Any patients with symptoms suggestive of aortic stenosis should be seen by a cardiologist for further testing.
- Indications for AVR include symptoms and a mean gradient by echocardiography/Doppler of > 40 mm Hg or peak instantaneous gradient of > 64 mm Hg. When symptoms do not match the aortic stenosis severity by echocardiography/Doppler (either symptoms in those with minor gradients or no symptoms in those with severe gradients), then the use of serum BNP or N-terminal pro-B type natriuretic peptide (pro-NT BNP) is useful. Serial BNP levels may also be used to monitor patients; a progressive rise suggests early LV dysfunction even in the patients who deny symptoms.
- For newer interventional approaches, including mechanical valves that require little or no warfarin and percutaneous AVR.

Chan KL et al; ASTRONOMER Investigators. Effect of lipid lowering with rosuvastatin on progression of aortic stenosis: results of the aortic stenosis progression observation: measuring effects of rosuvastatin (ASTRONOMER) trial. *Circulation*. 2010 Jan 19;121(2):306–14. [PMID: 20048204]

Coeytaux RR et al. Percutaneous heart valve replacement for aortic stenosis: state of the evidence. *Ann Intern Med*. 2010 Sep 7;153(5):314–24. [PMID: 20679543]

Gurvitch R et al. Transcatheter aortic valve implantation: durability of clinical and hemodynamic outcomes beyond 3 years in a large patient cohort. *Circulation*. 2010 Sep 28;122(13):1319–27. [PMID: 20837893]

Jander N et al. Outcome of patients with low-gradient “severe” aortic stenosis and preserved ejection fraction. *Circulation*. 2011 Mar 1;123(8):887–95. [PMID: 21321152]

Kiefer TL et al. Management of patients with bicuspid aortic valve disease. *Curr Treat Options Cardiovasc Med*. 2011 Dec; 13(6):489–505. [PMID: 22009692]

Leon MB et al; PARTNER Trial Investigators. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. *N Engl J Med*. 2010 Oct 21;363(17):1597–607. [PMID: 20961243]

Webb J et al. Percutaneous transarterial aortic valve implantation: what do we know? *Eur Heart J*. 2011 Jan;32(2):140–7. [PMID: 21131653]

AORTIC REGURGITATION

ESSENTIALS OF DIAGNOSIS

- ▶ Usually asymptomatic until middle age; presents with left-sided failure or chest pain.
- ▶ Wide pulse pressure.
- ▶ Diastolic murmur along left sternal border.
- ▶ Echocardiography/Doppler is diagnostic.
- ▶ Afterload reduction may be beneficial if there is evidence for systolic BP elevation.
- ▶ Surgery indicated for symptoms, EF < 55%, or LV end-systolic dimension > 5.0–5.5 cm.

▶ General Considerations

Rheumatic aortic regurgitation has become much less common than in the preantibiotic era, and nonrheumatic causes now predominate. These include congenitally bicuspid valves, infective endocarditis, and hypertension. Many patients have aortic regurgitation secondary to aortic root diseases such as that associated with Marfan syndrome or to aortic dissection. Rarely, inflammatory diseases, such as ankylosing spondylitis or reactive arthritis, may be causative.

▶ Clinical Findings

A. Symptoms and Signs

The clinical presentation is determined by the rapidity with which regurgitation develops. In chronic aortic regurgitation, the only sign for many years may be a soft aortic diastolic murmur. As the severity of the aortic regurgitation increases, diastolic BP falls, and the LV progressively enlarges. Most patients remain asymptomatic even at this point. LV failure is a late event and may be sudden in onset. Exertional dyspnea and fatigue are the most frequent symptoms, but paroxysmal nocturnal dyspnea and pulmonary edema may also occur. Angina pectoris or atypical chest pain may occasionally be present. Associated CAD and presyncope or syncope are less common than in aortic stenosis.

Hemodynamically, because of compensatory LV dilation, patients eject a large stroke volume, which is adequate to maintain forward cardiac output until late in the course of the disease. LV diastolic pressure may rise when heart failure occurs. Abnormal LV systolic function, as manifested by reduced EF (< 55%) and increasing end-systolic LV volume (>5.0 cm), is a sign that surgical intervention is warranted.

The major physical findings in **chronic aortic regurgitation** relate to the high stroke volume being ejected into the systemic vascular system with rapid runoff as the regurgitation takes place (see Table 10–2). This results in a wide arterial pulse pressure. The pulse has a rapid rise and fall (water-hammer pulse or Corrigan pulse), with an elevated systolic and low diastolic pressure. The large stroke volume is also responsible for characteristic findings such

as Quincke pulses (nailbed capillary pulsations), Duroziez sign (to and fro murmur over a partially compressed peripheral artery, commonly the femoral), and Musset sign (head bob with each pulse). In younger patients, the increased stroke volume may summate with the pressure wave reflected from the periphery and create an even higher systolic pressure in the extremity compared with the central aorta. Since the peripheral bed is much larger in the leg than the arm, the BP in the leg may be over 40 mm Hg higher than in the arm (Hill sign). The apical impulse is prominent, laterally displaced, usually hyperdynamic, and may be sustained. A systolic murmur is usually present and may be quite soft and localized; the aortic diastolic murmur is usually high-pitched and decrescendo. A mid or late diastolic low-pitched mitral murmur (Austin Flint murmur) may be heard in advanced aortic regurgitation, owing to relative obstruction of mitral inflow produced by partial closure of the mitral valve by the rapidly rising LV diastolic pressure due to the aortic regurgitation.

In **acute aortic regurgitation** (usually from aortic dissection or infective endocarditis), LV failure is manifested primarily as pulmonary edema and may develop rapidly; surgery is urgently required in such cases. Patients with acute aortic regurgitation do not have the dilated LV of chronic aortic regurgitation and the extra volume is handled poorly. For the same reason, the diastolic murmur is shorter and may be minimal in intensity, and the pulse pressure may not be widened, making clinical diagnosis difficult. The mitral valve may close prematurely even before LV systole has been initiated (pre-closure) due to the rapid rise in the LV diastolic pressure, and the first heart sound is thus diminished or inaudible. Pre-closure of the mitral valve can be readily detected on echocardiography.

B. Diagnostic Studies

The ECG usually shows moderate to severe LVH. Radiographs show cardiomegaly with LV prominence and sometimes a dilated aorta.

Echocardiography demonstrates the major diagnostic features, including whether the lesion involves the proximal aortic root and what valvular pathology is present. Serial assessments of LV size and function are critical in determining the timing for valve replacement. Color Doppler techniques can qualitatively estimate the severity of regurgitation, though some "mild" regurgitation due to aortic valve closure is not uncommon and should not be overinterpreted. Cardiac MRI and CT can estimate aortic root size, particularly when there is concern for an ascending aneurysm. MRI can provide a regurgitant fraction to help confirm severity. Scintigraphic studies are infrequently used but can quantify LV function and functional reserve during exercise. Exercise increases the heart rate and reduces the diastolic time, resulting in less aortic regurgitation per beat; this complicates interpretation of the exercise EF, and this test has therefore proved less helpful in deciding surgical timing than anticipated. Cardiac catheterization may be unnecessary in younger patients, particularly those with acute aortic regurgitation, but can

help define hemodynamics, aortic root abnormalities, and associated CAD preoperatively in older patients. Increasing data are emerging that serum BNP or pro-NT BNP may be an early sign of LV dysfunction, and it is possible that these data will be added to recommendations for surgical intervention in the future.

► Treatment & Prognosis

Aortic regurgitation that appears or worsens during or after an episode of infective endocarditis or aortic dissection may lead to acute severe LV failure or subacute progression over weeks or months. The former usually presents as pulmonary edema; surgical replacement of the valve is indicated even during active infection. These patients may be transiently improved or stabilized by vasodilators.

Chronic aortic regurgitation may be tolerated for many years, but the prognosis without surgery becomes poor when symptoms occur. Since aortic regurgitation places both a volume and afterload increase on the LV, medications that decrease afterload can reduce regurgitation severity. Current recommendations continue to advocate afterload reduction in aortic regurgitation when there is associated systolic hypertension (systolic BP > 140 mm Hg). Afterload reduction in normotensive patients remains controversial. While β -blocker therapy has been traditionally used in patients with Marfan disease to slow the rate of aortic dilation by reducing the dP/dt , angiotensin receptor blockers (ARBs) are becoming preferred additions to the medical therapy in these patients because of their ability to reduce aortic stiffness (likely by blocking TGF- β). The role of β -blockers continues to be explored in aortic regurgitation in an attempt to reduce adverse neuroendocrine activation.

Patients with aortic regurgitation should be monitored serially by echocardiography. Surgery is indicated once symptoms emerge or for any evidence of LV dysfunction. LV dysfunction in this situation can be defined by echocardiography if the EF is < 55% or if the LV end-systolic dimension is > 5.0 cm (class 2b indication), even in the asymptomatic patient. In addition, aortic root diameters of > 4.5 cm in Marfan or > 5.0 cm in non-Marfan patients are indications for surgery to avoid rapid expansion. Although the operative mortality rate is higher when LV function is severely impaired, valve replacement or repair is still likely indicated, since LV function often improves and the long-term prognosis is thereby enhanced even in this situation. The issues with AVR covered in the above section concerning aortic stenosis pertain here. Currently, however, there are no percutaneous approaches to aortic regurgitation. The choice of prosthetic valve for AVR depends on the patient's age and compatibility with warfarin anticoagulation.

The operative mortality rate is usually in the 3–5% range. Aortic regurgitation due to aortic root disease requires repair or replacement of the root. Though valve-sparing operations have improved recently, most patients with root replacement undergo valve replacement at the same time. Root replacement procedures

include the Ross procedure (moving the pulmonary valve to the aortic position and replacing the pulmonary valve with a homograft or, less commonly, bioprosthetic valve), the direct homograft for the aortic root and valve, and the Bentall procedure (the use of a Dacron sheath with a mechanical or bioprosthetic valve sewn in place). Root replacement in association with valve replacement may require reanastomosis of the coronary arteries, and thus the procedure is more complex than valve replacement alone. The Wheat procedure replaces the aortic root but spares the area where the coronaries attach to avoid the necessity for their reimplantation. Following surgery, LV size usually decreases and LV function generally improves even when the baseline EF is depressed.

▶ When to Refer

- Patients with audible aortic regurgitation should be seen, at least initially, by a cardiologist and a decision made as to how often the patient needs follow-up.
- Patients with a dilated aortic root should be monitored by a cardiologist, since imaging studies other than the chest radiograph or echocardiogram may be required to decide surgical timing.

Brooke BS et al. Angiotensin II blockade and aortic-root dilation in Marfan's syndrome. *N Engl J Med.* 2008 Jun 26;358(26):2787–95. [PMID: 18579813]

Carabello BA. What is new in the 2006 ACC/AHA guidelines on valvular heart disease? *Curr Cardiol Rep.* 2008 Mar;10(2):85–90. [PMID: 18417007]

Elder DH et al. The impact of renin-angiotensin-aldosterone system blockade on heart failure outcomes and mortality in patients identified to have aortic regurgitation: a large population study. *J Am Coll Cardiol.* 2011 Nov 8;58(20):2084–91. [PMID: 22051330]

Gabriel RS et al. B-type natriuretic peptide and left ventricular dysfunction on exercise echocardiography in patients with chronic aortic regurgitation. *Heart.* 2008 Jul;94(7):897–902. [PMID: 17974697]

Sampat U et al. Effect of beta-blocker therapy on survival in patients with severe aortic regurgitation: results from a cohort of 756 patients. *J Am Coll Cardiol.* 2009 Jul 28;54(5):452–7. [PMID: 19628121]

TRICUSPID STENOSIS

ESSENTIALS OF DIAGNOSIS

- ▶ Female predominance.
- ▶ History of rheumatic heart disease. Carcinoid disease or prosthetic valve degeneration are the most common etiologies in the United States.
- ▶ Echocardiography/Doppler is key to diagnosis.
- ▶ Mean valve gradient > 5 mm Hg by echocardiography indicates severe tricuspid stenosis.

▶ General Considerations

Tricuspid stenosis is usually rheumatic in origin, although in the United States, tricuspid stenosis is more commonly due to tricuspid valve repair or replacement or to the carcinoid syndrome than to rheumatic fever. Tricuspid regurgitation frequently accompanies the lesion. It should be suspected when “right heart failure” appears in the course of mitral valve disease or in the postoperative period after tricuspid valve repair or replacement. Congenital forms of tricuspid stenosis may also be rarely observed, as have case reports of multiple pacemaker leads creating RV inflow obstruction at the tricuspid valve.

▶ Clinical Findings

A. Symptoms and Signs

Tricuspid stenosis is characterized by right heart failure with hepatomegaly, ascites, and dependent edema. In sinus rhythm, giant **a** wave is seen in the JVP, which is elevated (see Table 10–2). The typical diastolic rumble along the lower left sternal border mimics mitral stenosis, though the rumble increases with inspiration. In sinus rhythm, a presystolic liver pulsation also may be found.

B. Diagnostic Studies

In the absence of atrial fibrillation, the ECG reveals RA enlargement. The chest radiograph may show marked cardiomegaly with a normal PA size. A dilated SVC and azygous vein may be evident.

The normal valve area of the tricuspid valve is 10 cm², so significant stenosis must be present to produce a gradient. Hemodynamically, a mean diastolic pressure gradient of > 5 mm Hg is considered significant, although even a 2 mm Hg gradient can be considered abnormal. This can be demonstrated by echocardiography or cardiac catheterization.

▶ Treatment & Prognosis

Tricuspid stenosis may be progressive, eventually causing severe right-sided heart failure. Initial therapy is directed at reducing the fluid congestion, with diuretics the mainstay. When there is considerable bowel edema, torsemide may have an advantage over other loop diuretics, such as furosemide, because it is better absorbed from the gut. Aldosterone inhibitors also help, particularly if there is liver engorgement or ascites. Neither surgical nor percutaneous valvuloplasty is particularly effective for relief of tricuspid stenosis, as residual tricuspid regurgitation is common. Tricuspid valve replacement is clearly the preferred surgical approach. Mechanical tricuspid valve replacement is rarely done because the low flow predisposes to thrombosis and because the mechanical valve cannot be crossed should the need arise for right heart catheterization or pacemaker implantation. Therefore, bioprosthetic valves are almost always used. Often tricuspid valve replacement is done in conjunction with mitral valve replacement for mitral stenosis.

Hong SN. Carcinoid heart disease. *J Am Coll Cardiol*. 2010 May 4;55(18):1996. [PMID: 20430272]
 Yeter E et al. Tricuspid balloon valvuloplasty to treat tricuspid stenosis. *J Heart Valve Dis*. 2010 Jan;19(1):159–60. [PMID: 20329507]

TRICUSPID REGURGITATION

ESSENTIALS OF DIAGNOSIS

- ▶ Frequently occurs in patients with pulmonary or cardiac disease with pressure or volume overload on the right ventricle.
- ▶ Tricuspid valve regurgitation from pacemaker lead placement is becoming more common.
- ▶ Systolic c-v wave in jugular venous pulsations.
- ▶ Holosystolic murmur along left sternal border, which increases with inspiration.
- ▶ Echocardiography useful in determining cause (low- or high-pressure tricuspid regurgitation).

▶ General Considerations

Tricuspid valvular regurgitation often occurs whenever there is RV dilation from any cause. As tricuspid regurgitation increases, the RV size increases further, and this in turn worsens the severity of the tricuspid regurgitation. The causes of tricuspid regurgitation thus relate to anatomic issues with either the valve itself or to the RV geometry. In most cases, the cause is the RV and not primary tricuspid valve disease. An enlarged, dilated RV may be present if there is pulmonary hypertension for any reason, in severe pulmonic regurgitation, or in cardiomyopathy. The RV may be injured from myocardial infarction or may be inherently dilated due to infiltrative diseases (RV dysplasia or sarcoidosis). RV dilation is often secondary to left heart failure. Inherent abnormalities of the tricuspid valve include Ebstein anomaly (displacement of the septal and posterior, but never the anterior, leaflets into the RV), tricuspid valve prolapse, carcinoid plaque formation, collagen disease inflammation, valvular tumors, or tricuspid endocarditis. In addition, pacemaker lead valvular injury is becoming an increasingly recognized iatrogenic cause.

▶ Clinical Findings

A. Symptoms and Signs

The symptoms and signs of tricuspid regurgitation are identical to those resulting from RV failure due to any cause. As a generality, the diagnosis can be made by careful inspection of the JVP (see Table 10–2). The JVP waveform should decline during ventricular systole (the x descent). The timing of this decline can be observed by palpating the opposite carotid artery. As tricuspid regurgitation worsens, more and more of this valley in the JVP is filled with the

regurgitant wave until all of the x descent is obliterated and a positive systolic waveform will be noted in the JVP. An associated tricuspid regurgitation murmur may or may not be audible and can be distinguished from mitral regurgitation by the left parasternal location and increase with inspiration. An S₃ may accompany the murmur and is related to the high flow returning from the RA. Cyanosis may be present if the increased RA pressure stretches the atrial septum and opens a PFO or there is a true ASD (eg, in about 50% of patients with Ebstein anomaly).

B. Diagnostic Studies

The ECG is usually nonspecific, though atrial fibrillation is not uncommon. The chest radiograph may reveal evidence of an enlarged RA or dilated azygous vein and pleural effusion. The echocardiogram helps assess severity of tricuspid regurgitation, RV systolic pressure, and RV size and function. A paradoxically moving interventricular septum may be present due to the volume overload on the RV. Catheterization confirms the presence of the regurgitant wave in the RA and elevated RA pressures. If the PA or RV systolic pressure is < 40 mm Hg, primary valvular tricuspid regurgitation should be suspected.

▶ Treatment & Prognosis

Mild tricuspid regurgitation is common and generally can be well managed with diuretics. When present, bowel edema may reduce the effectiveness of diuretics such as furosemide, and intravenous diuretics should initially be used. Torsemide is better absorbed in this situation when oral diuretics are added. Aldosterone antagonists have a role as well, particularly if ascites is present. At times, the efficacy of loop diuretics can be enhanced by adding a thiazide diuretic. Aquapheresis has also been proven helpful to reduce the edema in marked right heart failure.

Definitive treatment usually requires elimination of the cause of the tricuspid regurgitation. If the problem is left heart disease, then treatment of the left heart issues may lower pulmonary pressures, reduce RV size, and resolve the tricuspid regurgitation. Treatment for primary and secondary causes of pulmonary hypertension will generally reduce the tricuspid regurgitation. It is a class I recommendation that tricuspid annuloplasty be performed when tricuspid regurgitation is present and mitral valve replacement or repair is being performed for mitral regurgitation. Annuloplasty without insertion of a prosthetic ring (DeVega annuloplasty) may also be effective in reducing the tricuspid annular dilation. The valve leaflet itself can occasionally be repaired in tricuspid valve endocarditis. In years past, tricuspid regurgitation due to endocarditis in substance abuse patients was treated temporarily with removal of the valve, although it had to be replaced eventually (usually by 3–6 months); this practice is rarely done now. If there is an inherent defect in the tricuspid valve apparatus that cannot be repaired, then replacement of the tricuspid valve is warranted. Almost always, a bioprosthetic valve, and not a mechanical valve, is used. Anticoagulation is not required for bioprosthetic valves unless there is associated atrial fibrillation.

▶ When to Refer

- Anyone with moderate or severe tricuspid regurgitation should be seen at least once by a cardiologist to determine whether further studies are needed to elucidate cause and whether any other intervention is needed.
- Severe tricuspid regurgitation requires regular follow-up by a cardiologist.

Bonow RO et al. 2008 focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. *J Am Coll Cardiol.* 2008 Sep 23;52(13):e1–142. [PMID: 18848134]

Irwin RB et al. Tricuspid regurgitation: contemporary management of a neglected valvular lesion. *Postgrad Med J.* 2010 Nov;86(1021):648–55. [PMID: 20956397]

Roshanali F et al. Echocardiographic approach to the decision-making process for tricuspid valve repair. *J Thorac Cardiovasc Surg.* 2010 Jun;139(6):1483–7. [PMID: 19909984]

Shah PM et al. Tricuspid valve disease. *Curr Probl Cardiol.* 2008 Feb;33(2):47–84. [PMID: 18222317]

PULMONARY VALVE REGURGITATION

ESSENTIALS OF DIAGNOSIS

- ▶ Most cases are due to pulmonary hypertension.
- ▶ Echocardiogram is definitive in high-pressure, but may be less definitive in low-pressure, pulmonic regurgitation.
- ▶ Low-pressure pulmonic regurgitation is well tolerated.

▶ General Considerations

Pulmonary valve regurgitation can be divided into **high-pressure causes** (due to pulmonary hypertension) and **low-pressure causes** (usually due to a dilated pulmonary annulus, to a congenitally abnormal [bicuspid or dysplastic] pulmonary valve, or to plaque from carcinoid disease). It may also follow surgical repair, eg, frequently occurring after repair of tetralogy of Fallot with a transannular patch. Because the RV tolerates a volume load better than a pressure load, it tends to tolerate low pressure pulmonic regurgitation for long periods of time without dysfunction.

▶ Clinical Findings

On examination, a hyperdynamic RV can usually be palpated (RV lift). If the PA is enlarged, it may be palpated along the left sternal border. P₂ will be palpable in pulmonary hypertension and both systolic and diastolic thrills are occasionally noted. On auscultation, the second heart sound may be widely split due to prolonged RV systole. Systolic clicks may be noted as well as a right-sided gallop. If pulmonic stenosis is also present, the ejection click may decline with inspiration while any associated systolic

murmur will increase. In high-pressure pulmonic regurgitation, the pulmonary diastolic (Graham Steell) murmur is readily audible. It is often due to a dilated pulmonary annulus. The murmur increases with inspiration and diminishes with the Valsalva maneuver. In low-pressure pulmonic regurgitation, the PA diastolic pressure may be only a few mm Hg higher than the RV diastolic pressure, and there is little diastolic gradient to produce a murmur or characteristic echocardiography/Doppler findings. At times, only contrast angiography or MRI of the main PA will show the free flowing pulmonic regurgitation in low-pressure pulmonic regurgitation. This situation is common in following patients with repair of tetralogy of Fallot where, despite little murmur, there may be free flowing pulmonic regurgitation. This can be suspected by noting an enlarging right ventricle.

The ECG is generally of little value, although right bundle branch block is common, and there may be ECG criteria for RVH. The chest radiograph may show only the enlarged RV and PA. Echocardiography may demonstrate evidence of RV volume overload (paradoxical septal motion and an enlarged RV), and Doppler can determine peak systolic RV pressure and reveal any associated tricuspid regurgitation. The interventricular septum may appear flattened if there is pulmonary hypertension. The size of the main PA can be determined and color flow Doppler can demonstrate the pulmonic regurgitation, particularly in the high-pressure situation. Cardiac MRI and CT can be useful for assessing the size of the PA, for imaging the jet lesion, for excluding other causes of pulmonary hypertension (eg, thromboembolic disease, peripheral PA stenosis), and for evaluating RV function. MRI provides a regurgitant fraction to help quantitate the degree of pulmonic regurgitation. Cardiac catheterization is confirmatory.

▶ Treatment & Prognosis

Pulmonary valve regurgitation rarely needs specific therapy other than treatment of the primary cause. In low-pressure pulmonic regurgitation due to surgical patch repair of tetralogy of Fallot, pulmonary valve replacement may be indicated if RV enlargement or dysfunction is present. In tetralogy of Fallot, the QRS will widen as RV function declines and the ECG is helpful here (a QRS > 180 msec suggests a higher risk for sudden death) and increasing RV volumes should trigger an evaluation for potential pulmonary valve regurgitation. In carcinoid heart disease, pulmonary valve replacement with a porcine bioprosthesis may be undertaken, though the plaque from this disorder eventually covers the prosthetic pulmonary valve, and this tends to limit the lifespan of these valves. In high-pressure pulmonic regurgitation, treatment to control the cause of the pulmonary hypertension is key. Low-pressure pulmonic regurgitation is well tolerated over many years; exercise and pregnancy are not interdicted. High-pressure pulmonic regurgitation is poorly tolerated and is a serious condition that needs a thorough evaluation for cause and therapy. High pulmonary pressures require a thorough evaluation to distinguish a primary pulmonary cause versus one due to left-sided heart disease.

▶ When to Refer

- Patients with pulmonary valve regurgitation that results in RV enlargement should be referred to a cardiologist regardless of the estimated pulmonary pressures.

McElhinney DB et al. Short- and medium-term outcomes after transcatheter pulmonary valve replacement in the expanded multicenter US Melody valve trial. *Circulation*. 2010 Aug 3;122(5):507–16. [PMID: 20644013]

Warnes CA et al. ACC/AHA 2008 Guidelines for the Management of Adults With Congenital Heart Disease. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *Circulation*. 2008 Dec 2;118(23):e714–833. [PMID: 18997169]

CHOICE & MANAGEMENT OF SURGICAL VALVE REPLACEMENT OR REPAIR

Less invasive surgical procedures for valve replacement have increased in prevalence over the past few decades. There are now mini-incisional approaches to aortic, mitral, and tricuspid valve replacement and repair. Percutaneous valvuloplasty has replaced surgical commissurotomy for mitral stenosis in most cases. However, percutaneous aortic valvuloplasty is moderately effective only in children and adolescents and has a very limited role in adults. Neither surgical nor percutaneous tricuspid valvuloplasty for tricuspid stenosis is very effective. Percutaneous valve replacement is discussed above (see Aortic Stenosis).

Repair of the mitral valve is remarkably successful in appropriate patients and has lowered the threshold for intervention in mitral regurgitation to the point that some experts recommend that all mitral prolapse patients with mitral regurgitation undergo mitral valve repair even when other indications are not present. When tricuspid regurgitation is present and mitral valve repair or replacement is planned, tricuspid repair is a class I recommendation. Aortic valve sparing procedures are also improving and may obviate the need for AVR, especially in patients undergoing root replacement. Although early experience with aortic valve repair was mixed, recent studies reveal this as a more attractive option for some patients. Direct valvular repair and removal of vegetations are also viable options in some patients with endocarditis.

The choice of prosthetic valve depends on a variety of considerations, such as assessing the expected survival of the patient versus the durability of the valve and the safety of warfarin for the patient. Bioprosthetic valves usually have a life expectancy of 10–15 years, but less in young patients, those on dialysis, or those with hypercalcemia. High lipid levels may accelerate the degenerative process as much as in native heart valves. The lifespan of bovine pericardial valves is somewhat longer than porcine valves, and these are becoming the favorite bioprostheses. Bioprosthetic valves, homografts, and the Ross procedure (replacement of the aortic valve with the patient's own pulmonary valve, then replacement of the removed pulmonary valve usually with a homograft) do not require anticoagulation with warfarin, though current guidelines suggest warfarin be

used for 3 months after valve implantation to allow for endothelial growth over the sewing ring. This latter recommendation is controversial. Mechanical valves have a much longer lifespan, but all currently available ones require use of warfarin (and frequently aspirin as an adjunct, especially when used in the mitral position). The long-term risk of warfarin depends on patient compliance and whether there is coexisting disease that may predispose to bleeding. A newer mechanical valve, the On-X, may allow for either a reduced dose of warfarin or no warfarin at all (especially when used in the aortic position); trials are currently being completed but preliminary data are promising.

Mechanical mitral valve prostheses pose a greater risk for thrombosis than mechanical aortic valves. For that reason, the INR should be kept between 2.5 and 3.5 for mechanical mitral prosthetic valves but can be kept between 2.0 and 2.5 for mechanical aortic prosthetic valves. Enteric-coated aspirin (81 mg once daily) is given to patients with both types of mechanical valves but appears to be more important for mitral valve prostheses and for both types of valves when other risk factors are present, such as atrial fibrillation, a reduced EF, a hypercoagulable state, associated CAD, peripheral vascular disease, or a history of CVA.

Warfarin causes fetal skeletal abnormalities in about 2% of women who become pregnant while taking it, so every effort is made to defer valve replacement in women until after childbearing age. However, if a woman with a mechanical valve becomes pregnant while taking warfarin, the risk of stopping warfarin may be higher for the mother than the risk of continuing warfarin for the fetus. The risk of warfarin to the fetal skeleton is greatest during the first trimester, so if pregnancy is planned in a woman with a mechanical valve, unfractionated heparin is often used temporarily during the first trimester. After the first trimester, warfarin use is safe again until 2 weeks before planned delivery, when the patient should be switched back to unfractionated heparin. Low-molecular-weight heparin has not been shown to be effective and should not be substituted for unfractionated heparin in the pregnant patient with a mechanical heart valve.

When patients with mechanical valves must undergo noncardiac surgery, the risk of thrombosis from stopping warfarin versus the risk of excessive bleeding from continuing warfarin must be weighed. In general, for bileaflet aortic mechanical valves, warfarin can be stopped 5 days ahead of the surgical procedure and resumed the night of the procedure with no preprocedural “bridging”. After the procedure, unfractionated heparin or low-molecular-weight heparin can be used until the INR is 2.0. In patients with a bileaflet mitral valve, warfarin may be stopped 5 days ahead of time and bridging with either unfractionated heparin or low-molecular-weight heparin is recommended preoperatively once the INR falls below 2.0. The last dose of low-molecular-weight heparin should be half the therapeutic dose and be given 24 hours before any procedure. If unfractionated heparin is used, it should be stopped 4 hours before the procedure. As with AVR patients, warfarin is generally started within 24 hours after surgery, but heparin should not be started for 48–72 hours or until hemostasis is secured. Heparin therapy should be continued until the INR is > 2.0.

There is great interest in the use of direct antithrombin inhibitors, such as dabigatran, in place of warfarin. Ongoing trials are addressing whether these agents provide safe and effective anticoagulation in patients with mechanical prosthetic valves. Finally, there are an increasing number of isolated reports of the use of percutaneous methods to address both perivalvular regurgitation associated with prosthetic valve replacement by use of vascular plugs similar to those used to close a ductus arteriosus. The Melody percutaneous pulmonary valve has been approved for pulmonary valve replacement in patients with pulmonary valve regurgitation or stenosis in either a conduit or homograft. The use of percutaneously implanted valves in patients with dysfunctional aortic valves and even dysfunctional mitral and tricuspid valves has also been reported, although the long-term follow-up of these procedures is still lacking.

- Asoh K et al. Percutaneous pulmonary valve implantation within bioprosthetic valves. *Eur Heart J*. 2010;31:1404–9. [PMID: 20231157]
- El-Hamamsy I et al. Long-term outcomes after autograft versus homograft aortic root replacement in adults with aortic valve disease: a randomised controlled trial. *Lancet*. 2010 Aug 14;376(9740):524–31. [PMID: 20684981]
- Hagler DJ et al. Assessment of percutaneous catheter treatment of paravalvular prosthetic regurgitation. *JACC Cardiovasc Imaging*. 2010 Jan;3(1):88–91. [PMID: 20129537]
- Hasan BS et al. Short-term performance of the transcatheter Melody valve in high-pressure hemodynamic environments in the pulmonary and systemic circulations. *Circ Cardiovasc Interv*. 2011 Dec 1;4(6):615–20. [PMID: 22075926]
- Hirsh J et al; American College of Chest Physicians. Executive summary: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). *Chest*. 2008 Jun;133(6 Suppl):71S–109S. [PMID: 18574259]
- Rahimtoola SH. Choice of prosthetic heart valve in adults: an update. *J Am Coll Cardiol*. 2010 Jun a;55(22):2413–26. [PMID: 20510209]
- Stone PH. Current selection of optimal prosthetic aortic valve replacement in middle-aged patients: still dealer's choice. *J Am Coll Cardiol*. 2009 Nov 10;54(20):1869–71. [PMID: 19892238]

CORONARY HEART DISEASE (ATHEROSCLEROTIC CAD, ISCHEMIC HEART DISEASE)

Coronary heart disease, or atherosclerotic CAD, is the number one killer in the United States and worldwide. Every minute, an American dies of coronary heart disease. About 37% of people who experience an acute coronary event, either angina or myocardial infarction, will die of it in the same year. Death rates of coronary heart disease have declined every year since 1968, with about half of the decline from 1980 to 2000 due to treatments and half due to improved risk factors. Coronary heart disease is still responsible for approximately one of five deaths and over 600,000 deaths per year in the United States. Coronary heart disease afflicts nearly 16 million Americans and the prevalence rises steadily with age; thus, the aging of the US population promises to increase the overall burden of coronary heart disease.

Risk Factors for CAD

Most patients with coronary heart disease have some identifiable risk factor. These include a positive family history (the younger the onset in a first-degree relative, the greater the risk), male sex, blood lipid abnormalities, diabetes mellitus, hypertension, physical inactivity, abdominal obesity, and cigarette smoking, psychosocial factors, consumption of too few fruits and vegetables and too much alcohol. Smoking remains the number one preventable cause of death and illness in the United States. Although smoking rates have declined in the United States in recent decades, 18% of women and 21% of men still smoke. According to the World Health Organization, 1 year after quitting, the risk of coronary heart disease decreases by 50%. Various interventions have been shown to increase the likelihood of successful smoking cessation (see Chapter 1).

Hypercholesterolemia and other lipid abnormalities provide an important modifiable risk factor for coronary heart disease. Risk increases progressively with higher levels of low-density lipoprotein (LDL) cholesterol and declines with higher levels of high-density lipoprotein (HDL) cholesterol. Composite risk scores, such as the Framingham score (see Table 28–2), provide estimates of 10-year probability of development of coronary heart disease that can guide primary prevention strategies.

The metabolic syndrome is defined as a constellation of three or more of the following: abdominal obesity, triglycerides ≥ 150 mg/dL, HDL cholesterol < 40 mg/dL for men and < 50 mg/dL for women, fasting glucose ≥ 110 mg/dL, and hypertension. This syndrome is increasing in prevalence at an alarming rate. Related to the metabolic syndrome, the epidemic of obesity in the United States is likewise a major factor contributing to coronary heart disease risk. Data from National Health and Nutrition Examination Survey (NHANES) show that 34% of the US adult population was obese (body mass index [BMI] ≥ 30 kg/m²) in the 2007–2008 survey. Particularly alarming is the rapidly increasing incidence of obesity in adolescents in the United States, such that for children aged 12–19 years, prevalence of obesity increased from 5% (in 1976–1980) to 18%. Increasing physical activity is an important goal to help combat obesity and its consequences. Although the AHA continues to promote a diet based largely on low saturated fat, more information is needed on the health consequences of all diets, especially given the lack of protection from a low-fat diet in the largest randomized study ever done, the Women's Health Initiative trial. Low carbohydrate diets, even when high in saturated fat, may improve the cholesterol profile in overweight men and are as effective at achieving weight loss. Fish, rich in omega-3 fatty acids, may help protect against vascular disease, and it is recommended that it be eaten three times a week by patients at risk.

Markers of inflammation are strong risk factors for CAD. High-sensitivity CRP (hsCRP) is the best-characterized inflammatory marker, but others include interleukin-6, CD-40 ligand, myeloperoxidase, and placental growth factor. Although hsCRP levels > 10 mg/dL (>100 mg/L) are often

found in systemic inflammation, levels < 1 , $1-3$, and > 3 mg/dL (< 10 , $10-30$, and > 30 mg/L), respectively, identify patients at low, intermediate, and high risk for future cardiovascular events. The prognostic value of CRP levels is independent and additive to lipid levels. Use of CRP may be helpful in determining which patients at intermediate risk according to the Framingham 10-year risk of coronary heart disease calculation (score of $10-20\%$) are at high enough risk to warrant more intensive primary prevention, including use of statins to lower LDL cholesterol. CRP is included as a factor in the Reynolds Risk Score, as is family history; the Reynolds Risk Score aims to enhance the prognostic ability of the Framingham score (www.reynolds-riskscore.org). HsCRP ≥ 2 mg/L identifies older people without vascular disease and with normal cholesterol who benefit from statin therapy, specifically rosuvastatin. HsCRP levels are often elevated in patients who have other conditions associated with accelerated atherosclerosis, such as diabetes, the metabolic syndrome, and obesity. In patients presenting with acute coronary syndromes, the hsCRP elevation identifies a group that is at high risk for early recurrent events.

► Myocardial Hibernation & Stunning

Areas of myocardium that are persistently underperfused but still viable may develop sustained contractile dysfunction. This phenomenon, which is termed “myocardial hibernation,” appears to represent an adaptive response that maybe associated with depressed LV function. It is important to recognize this phenomenon, since this form of dysfunction is reversible following coronary revascularization. Hibernating myocardium can be identified by radionuclide testing, positron emission tomography (PET), contrast-enhanced MRI, or its retained response to inotropic stimulation with dobutamine. A related phenomenon, termed “myocardial stunning,” is the occurrence of persistent contractile dysfunction following prolonged or repetitive episodes of myocardial ischemia. Clinically, myocardial stunning is often seen after reperfusion of acute myocardial infarction and is defined with improvement following revascularization.

Centers for Disease Control and Prevention. Obesity and overweight. <http://www.cdc.gov/obesity>

Gardner CD et al. Comparison of the Atkins, Zone, Ornish, and LEARN diets for change in weight and related risk factors among overweight premenopausal women: the A to Z Weight Loss Study: a randomized trial. *JAMA*. 2007 Mar 7;297(9):69-77. [PMID: 17341711]

Hall SL et al. Secondary prevention of coronary artery disease. *Am Fam Physician*. 2010 Feb 1;81(3):289-96. [PMID: 20112887]

Yusuf S et al; INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. *Lancet*. 2004 Sep 11-17;364(9438):937-52. [PMID: 15364185]

CHRONIC STABLE ANGINA PECTORIS



ESSENTIALS OF DIAGNOSIS

- Precordial chest pain, usually precipitated by stress or exertion, relieved rapidly by rest or nitrates.
- ECG or scintigraphic evidence of ischemia during pain or stress testing.
- Angiographic demonstration of significant obstruction of major coronary vessels.

► General Considerations

Angina pectoris is usually due to atherosclerotic heart disease. Coronary vasospasm may occur at the site of a lesion or, less frequently, in apparently normal vessels. Other unusual causes of coronary artery obstruction such as congenital anomalies, emboli, arteritis, or dissection may cause ischemia or infarction. Angina may also occur in the absence of coronary artery obstruction as a result of severe myocardial hypertrophy, severe aortic stenosis or regurgitation, or in response to increased metabolic demands, as in hyperthyroidism, marked anemia, or paroxysmal tachycardias with rapid ventricular rates. Rarely, angina occurs with angiographically normal coronary arteries and without other identifiable causes. This presentation has been labeled **syndrome X** and is most likely due to inadequate flow reserve in the resistance vessels (microvasculature). Syndrome X remains difficult to diagnose. Although treatment is often not very successful in relieving symptoms, the prognosis of syndrome X is good.

► Clinical Findings

A. Symptoms

The diagnosis of angina pectoris depends principally upon the history, which should specifically include the following information: circumstances that precipitate and relieve angina, characteristics of the discomfort, location and radiation, duration of attacks, and effect of nitroglycerin.

1. Circumstances that precipitate and relieve angina—

Angina occurs most commonly during activity and is relieved by resting. Patients may prefer to remain upright rather than lie down, as increased preload in recumbency increases myocardial work. The amount of activity required to produce angina may be relatively consistent under comparable physical and emotional circumstances or may vary from day to day. The threshold for angina is usually less after meals, during excitement, or on exposure to cold. It is often lower in the morning or after strong emotion; the latter can provoke attacks in the absence of exertion. In addition, discomfort may occur during sexual activity, at rest, or at night as a result of coronary spasm.

2. Characteristics of the discomfort—Patients often do not refer to angina as “pain” but as a sensation of tightness, squeezing, burning, pressing, choking, aching, bursting,

“gas,” indigestion, or an ill-characterized discomfort. It is often characterized by clenching a fist over the mid chest. The distress of angina is rarely sharply localized and is not spasmodic.

3. Location and radiation—The distribution of the distress may vary widely in different patients but is usually the same for each patient unless unstable angina or myocardial infarction supervenes. In most cases, the discomfort is felt behind or slightly to the left of the mid sternum. When it begins farther to the left or, uncommonly, on the right, it characteristically moves centrally substernally. Although angina may radiate to any dermatome from C8 to T4, it radiates most often to the left shoulder and upper arm, frequently moving down the inner volar aspect of the arm to the elbow, forearm, wrist, or fourth and fifth fingers. It may also radiate to the right shoulder or arm, the lower jaw, the neck, or even the back.

4. Duration of attacks—Angina is generally of short duration and subsides completely without residual discomfort. If the attack is precipitated by exertion and the patient promptly stops to rest, it usually lasts < 3 minutes. Attacks following a heavy meal or brought on by anger often last 15–20 minutes. Attacks lasting more than 30 minutes are unusual and suggest the development of unstable angina, myocardial infarction, or an alternative diagnosis.

5. Effect of nitroglycerin—The diagnosis of angina pectoris is supported if sublingual nitroglycerin promptly and invariably shortens an attack and if prophylactic nitrates permit greater exertion or prevent angina entirely.

B. Signs

Examination during angina frequently reveals a significant elevation in systolic and diastolic BP, although hypotension may also occur, and may reflect more severe ischemia or inferior ischemia (especially with bradycardia) due to a Bezold–Jarisch reflex. Occasionally, a gallop rhythm and an apical systolic murmur due to transient mitral regurgitation from papillary muscle dysfunction are present during pain only. Supraventricular or ventricular arrhythmias may be present, either as the precipitating factor or as a result of ischemia.

It is important to detect signs of diseases that may contribute to or accompany atherosclerotic heart disease, eg, diabetes mellitus (retinopathy or neuropathy), xanthelasma, tendinous xanthomas, hypertension, thyrotoxicosis, myxedema, or peripheral artery disease. Aortic stenosis or regurgitation, hypertrophic cardiomyopathy, and mitral valve prolapse should be sought, since they may produce angina or other forms of chest pain.

C. Laboratory Findings

Other than standard laboratory tests to evaluate for acute coronary syndrome (troponin and CK-MB), factors contributing to ischemia (such as anemia), and to screen for risk factors that may increase the probability of true coronary heart disease (such as hyperlipidemia), blood tests are not helpful to diagnose chronic angina.

D. ECG

The resting ECG is often normal in patients with angina. In the remainder, abnormalities include old myocardial infarction, nonspecific ST–T changes, and changes of LVH. During anginal episodes, as well as during asymptomatic ischemia, the characteristic ECG change is horizontal or downsloping ST-segment depression that reverses after the ischemia disappears. T wave flattening or inversion may also occur. Less frequently, transient ST-segment elevation is observed; this finding suggests severe (transmural) ischemia from coronary occlusion, and it can occur with coronary spasm.

E. Pretest Probability

The history as detailed above, the physical examination findings, and laboratory and ECG findings are used to develop a pretest probability of CAD as the cause of the clinical symptoms. Other important factors to include in calculating the pretest probability of CAD are patient age, sex, and clinical symptoms. Patients with low to intermediate pretest probability for CAD should undergo noninvasive stress testing whereas patients with high pretest probability are generally referred for cardiac catheterization. Of note, a recent large review of diagnostic cardiac catheterization findings in patients without known CAD undergoing invasive angiography, found that 38% had significant obstruction in one or more coronary arteries. These findings have highlighted the importance of careful pretest probability assessment.

F. Exercise ECG

Exercise testing is the most commonly used noninvasive procedure for evaluating for inducible ischemia in the patient with angina. Exercise testing is often combined with imaging studies (nuclear, echocardiography, or MRI [see below]), but in low-risk patients without baseline ST segment abnormalities or in whom anatomic localization is not necessary, the exercise ECG remains the recommended initial procedure because of considerations of cost and convenience.

Exercise testing can be done on a motorized treadmill or with a bicycle ergometer. A variety of exercise protocols are utilized, the most common being the Bruce protocol, which increases the treadmill speed and elevation every 3 minutes until limited by symptoms. At least two ECG leads should be monitored continuously.

1. Precautions and risks—The risk of exercise testing is about one infarction or death per 1000 tests, but individuals who have pain at rest or minimal activity are at higher risk and should not be tested. Many of the traditional exclusions, such as recent myocardial infarction or CHF, are no longer used *if the patient is stable and ambulatory*, but symptomatic aortic stenosis remains a contraindication.

2. Indications—Exercise testing is used (1) to confirm the diagnosis of angina; (2) to determine the severity of limitation of activity due to angina; (3) to assess prognosis in patients with known coronary disease, including those

recovering from myocardial infarction, by detecting groups at high or low risk; (4) to evaluate responses to therapy; and (5) less successfully, to screen asymptomatic populations for silent coronary disease. The latter application is controversial. Because false-positive tests often exceed true positives, leading to much patient anxiety and self-imposed or mandated disability, exercise testing of asymptomatic individuals should be done only for those whose occupations place them or others at special risk (eg, airline pilots), and older individuals commencing strenuous activity.

3. Interpretation—The usual ECG criterion for a positive test is 1 mm (0.1 mV) horizontal or downsloping ST-segment depression (beyond baseline) measured 80 milliseconds after the J point. By this criterion, 60–80% of patients with anatomically significant coronary disease will have a positive test, but 10–30% of those without significant disease will also be positive. False positives are uncommon when a 2-mm depression is present. Additional information is inferred from the time of onset and duration of the ECG changes, their magnitude and configuration, BP and heart rate changes, the duration of exercise, and the presence of associated symptoms. In general, patients exhibiting more severe ST-segment depression (>2 mm) at low workloads (< 6 minutes on the Bruce protocol) or heart rates (< 70% of age-predicted maximum)—especially when the duration of exercise and rise in BP are limited or when hypotension occurs during the test—have more severe disease and a poorer prognosis. Depending on symptom status, age, and other factors, such patients should be referred for coronary arteriography and possible revascularization. On the other hand, less impressive positive tests in asymptomatic patients are often “false positives.” Therefore, exercise testing results that do not conform to the clinical picture should be confirmed by stress imaging.

G. Myocardial Stress Imaging

Myocardial stress imaging (scintigraphy, echocardiography, or MRI) is indicated (1) when the resting ECG makes an exercise ECG difficult to interpret (eg, left bundle branch block, baseline ST–T changes, low voltage); (2) for confirmation of the results of the exercise ECG when they are contrary to the clinical impression (eg, a positive test in an asymptomatic patient); (3) to localize the region of ischemia; (4) to distinguish ischemic from infarcted myocardium; (5) to assess the completeness of vascularization following bypass surgery or coronary angioplasty; or (6) as a prognostic indicator in patients with known coronary disease. Recently, criteria have been published that summarize these indications for stress testing.

1. Myocardial perfusion scintigraphy—This test provides images in which radionuclide uptake is proportionate to blood flow at the time of injection. Thallium-201, technetium-99m sestamibi, and tetrafosmin are most frequently used. If the radiotracer is injected during exercise or dipyridamole- or adenosine-induced coronary vasodilation, scintigraphic defects indicate a zone of hypoperfusion that may represent either ischemia or scar. If the

myocardium is viable, as relative blood flow equalizes over time or during a scintigram performed under resting conditions, these defects tend to “fill in” or reverse, indicating reversible ischemia. Defects observed when the radiotracer is injected at rest or still present 3–4 hours after an injection during exercise or pharmacologic vasodilation (intravenous adenosine or dipyridamole) usually indicate myocardial infarction (old or recent) but may be present with severe ischemia. Occasionally, other conditions, including infiltrative diseases (sarcoidosis, amyloidosis), left bundle branch block, and dilated cardiomyopathy, may produce resting or persistent perfusion defects.

Stress imaging is positive in about 75–90% of patients with anatomically significant coronary disease and in 20–30% of those without it. False-positive radionuclide tests may occur as a result of diaphragmatic attenuation or, in women, attenuation through breast tissue. Tomographic imaging (single-photon emission computed tomography, SPECT) can reduce the severity of artifacts. Gated imaging allows for analysis of ventricular size, EF, and regional wall motion.

2. Radionuclide angiography—This procedure images the LV and measures its EF and wall motion. In coronary disease, resting abnormalities usually represent infarction, and those that occur only with exercise usually indicate stress-induced ischemia. Exercise radionuclide angiography has approximately the same sensitivity as thallium-201 scintigraphy, but it is less specific in older individuals and those with other forms of heart disease. The indications are similar to those for thallium-201 scintigraphy.

3. Stress echocardiography—Echocardiograms performed during supine exercise or immediately following upright exercise may demonstrate exercise-induced segmental wall motion abnormalities as an indicator of ischemia. This technique requires considerable expertise; however, in experienced laboratories, the test accuracy is comparable to that obtained with scintigraphy—though a higher proportion of tests is technically inadequate. While exercise is the preferred stress because of other information derived, pharmacologic stress with high-dose dobutamine (20–40 mcg/kg/min) can be used as an alternative to exercise. Echocardiography contrast agents allow for perfusion imaging and may improve the diagnostic accuracy of this form of testing, although these are not commonly used.

H. Other Imaging

1. Positron emission tomography—PET scanning uses positron-emitting agents to demonstrate either perfusion or metabolism of myocardium. PET scanning can accurately distinguish transiently dysfunctional (“stunned”) myocardium from scar by showing persistent glycolytic metabolism with the tracer fluorodeoxyglucose (FDG) in regions with reduced blood flow. The newer SPECT camera can provide acceptable images without the more expensive PET technology.

2. CT and MRI scanning—CT scanning can image the heart and, with contrast medium and multislice technology,

the coronary arteries, with increasing resolution. Coronary artery images can be obtained by 64- and higher slice technology, and, if the images are normal, this technology has high sensitivity for excluding significant CAD.

Thus, multislice CT angiography may be useful in evaluating patients with low likelihood of significant CAD who would otherwise have undergone coronary angiography. CT angiography may also be useful for evaluating chest pain and suspected acute coronary syndrome. However, the role of CT angiography in routine practice is yet to be established, since it currently requires both radiation exposure and contrast load. It should also be noted that radionuclide SPECT imaging also has similar radiation exposure.

Electron beam CT (EBCT) can quantify coronary artery calcification, which is highly correlated with atherosclerotic plaque and has high sensitivity, but low specificity, for obstructive coronary disease. Thus, although this test can stratify patients into lower and higher risk groups, the appropriate management of individual patients with asymptomatic coronary artery calcification—beyond aggressive risk factors modification—is unclear. This test has not traditionally been used in symptomatic patients. According to the American Heart Association, persons who are at low risk (< 10% 10-year risk) or at high risk (>20% 10-year risk) do not benefit from coronary calcium assessment (class III, level of evidence: B) (see Tables 28–2 and 28–3). However, in clinically selected, intermediate-risk patients, it may be reasonable to determine the atherosclerosis burden using EBCT in order to refine clinical risk prediction and to select patients for more aggressive target values for lipid-lowering therapies (class IIb, level of evidence: B).

Cardiac MRI provides high-resolution images of the heart and great vessels without radiation exposure or use of iodinated contrast media. Gadolinium, the contrast agent used for cardiac MRI, has been associated with a rare but fatal complication in patients with severe renal dysfunction, called necrotizing systemic fibrosis. Cardiac MRI provides excellent assessment of pericardial disease, neoplastic disease of the heart, myocardial thickness, chamber size, and many congenital heart defects. It is an excellent noninvasive test for nonemergently evaluating dissection of the aorta. Rapid acquisition sequences are a useful alternative when the echocardiogram is suboptimal. Perfusion imaging can be done with gadolinium first pass perfusion using dobutamine or adenosine to produce pharmacologic stress. Advances have been made in imaging the proximal coronary arteries, but this application remains investigational. Perhaps the most clinically used indication of cardiac MRI is for identification of myocardial fibrosis, either from myocardial infarction or infiltration. This allows high resolution imaging of myocardial viability.

I. Ambulatory ECG Monitoring

Ambulatory ECG recorders can monitor for ischemic ST-segment depression. In patients with CAD, these episodes usually signify ischemia, even when asymptomatic (“silent”). In many patients, silent episodes are more

frequent than symptomatic ones. In most cases, they occur in patients with other evidence of ischemia, so the role of ambulatory monitoring is limited.

J. Coronary Angiography

Selective coronary arteriography is the definitive diagnostic procedure for CAD. It can be performed with low mortality (about 0.1%) and morbidity (1–5%), but the cost is high, and with currently available noninvasive techniques it is usually not indicated solely for diagnosis.

Coronary arteriography should be performed in the following circumstances if percutaneous transluminal coronary angioplasty or bypass surgery is a consideration:

1. Limited stable angina despite an adequate medical regimen.
2. Clinical presentation (unstable angina, postinfarction angina, etc) or noninvasive testing suggests high-risk disease (see Indications for Revascularization).
3. Concomitant aortic valve disease and angina pectoris, to determine whether the angina is due to accompanying coronary disease.
4. Asymptomatic older patients undergoing valve surgery so that concomitant bypass may be done if the anatomy is propitious.
5. Recurrence of symptoms after coronary revascularization to determine whether bypass grafts or native vessels are occluded.
6. Cardiac failure where a surgically correctable lesion, such as LV aneurysm, mitral regurgitation, or reversible ischemic dysfunction, is suspected.
7. Survivors of sudden death or symptomatic or life-threatening arrhythmias when CAD may be a correctable cause.
8. Chest pain of uncertain cause or cardiomyopathy of unknown cause.
9. Emergently performed cardiac catheterization with intention to perform primary PCI in patients with suspected acute myocardial infarction.

A narrowing > 50% of the luminal diameter is considered hemodynamically (and clinically) significant, although most lesions producing ischemia are associated with narrowing in excess of 70%. In those with strongly positive exercise ECGs or scintigraphic studies, three-vessel or left main disease may be present in 75–95% depending on the criteria used. **Intravascular ultrasound (IVUS)** can be positioned within the artery and image beneath the endothelial surface. This technique is useful when the angiogram is equivocal as well as for assessing the results of angioplasty or stenting. In addition, IVUS is the invasive diagnostic method of choice for ostial left main lesions and coronary dissections. Fractional flow reserve is an important invasive method for evaluation of equivocal coronary stenosis. In this method, a pressure wire is used to measure the relative change in pressure across a coronary lesion after the administration of adenosine (usual dosing is 140 mcg/kg/min). Recent studies have demonstrated that

revascularization based on abnormal fractional flow reserve improves clinical outcomes compared to revascularization of all angiographically stenotic lesions.

LV angiography is usually performed at the same time as coronary arteriography. Global and regional LV function are visualized, as well as mitral regurgitation if present. LV function is a major determinant of prognosis in coronary heart disease.

► Differential Diagnosis

When atypical features are present—such as prolonged duration (hours or days) or darting, knifelike pains at the apex or over the precordium—ischemia is less likely.

Anterior chest wall syndrome is characterized by sharply localized tenderness of intercostal muscles. Inflammation of the chondrocostal junctions, which may be warm, swollen, and red, may result in diffuse chest pain that is also reproduced by local pressure (Tietze syndrome). Intercostal neuritis (due to herpes zoster, diabetes mellitus, for example) also mimics angina.

Cervical or thoracic spine disease involving the dorsal roots produces sudden sharp, severe chest pain suggesting angina in location and “radiation” but related to specific movements of the neck or spine, recumbency, and straining or lifting. Pain due to cervical or thoracic disk disease involves the outer or dorsal aspect of the arm and the thumb and index fingers rather than the ring and little fingers.

Reflux esophagitis, peptic ulcer, chronic cholecystitis, esophageal spasm, and functional gastrointestinal disease may produce pain suggestive of angina pectoris. The picture may be especially confusing because ischemic pain may also be associated with upper gastrointestinal symptoms, and esophageal motility disorders may be improved by nitrates and calcium channel blockers. Assessment of esophageal motility may be helpful.

Degenerative and inflammatory lesions of the left shoulder and thoracic outlet syndromes may cause chest pain due to nerve irritation or muscular compression; the symptoms are usually precipitated by movement of the arm and shoulder and are associated with paresthesias.

Pneumonia, pulmonary embolism, and spontaneous pneumothorax may cause chest pain as well as dyspnea. Dissection of the thoracic aorta can cause severe chest pain that is commonly felt in the back; it is sudden in onset, reaches maximum intensity immediately, and may be associated with changes in pulses. Other cardiac disorders such as mitral valve prolapse, hypertrophic cardiomyopathy, myocarditis, pericarditis, aortic valve disease, or RVH may cause atypical chest pain or even myocardial ischemia.

► Treatment

Sublingual nitroglycerin is the drug of choice for acute management; it acts in about 1–2 minutes. Nitrates decrease arteriolar and venous tone, reduce preload and afterload, and lower the oxygen demand of the heart. As soon as the attack begins, one fresh tablet is placed under the tongue. This may be repeated at 3- to 5-minute intervals, but current

recommendations are that if pain is not relieved or improving after 5 minutes, that the patient call 9-1-1. The dosage (0.3, 0.4, or 0.6 mg) and the number of tablets to be used before seeking further medical attention must be individualized. Nitroglycerin buccal spray is also available as a metered (0.4 mg) delivery system. It has the advantage of being more convenient for patients who have difficulty handling the pills and of being more stable. Nitroglycerin can also be used prophylactically before activities likely to precipitate angina. Pain not responding to three tablets or lasting more than 20 minutes may represent evolving infarction, and the patient should be instructed to seek immediate medical attention.

► Prevention of Further Attacks

A. Aggravating Factors

Angina may be aggravated by hypertension, LV failure, arrhythmia (usually tachycardias), strenuous activity, cold temperatures, and emotional states. These factors should be identified and treated when possible.

B. Nitroglycerin

Nitroglycerin, 0.3–0.6 mg sublingually or 0.4–0.8 mg translingually by spray, should be taken 5 minutes before any activity likely to precipitate angina. Sublingual isosorbide dinitrate (2.5–10 mg) is only slightly longer-acting than sublingual nitroglycerin.

C. Long-Acting Nitrates

Longer-acting nitrate preparations include isosorbide dinitrate, 10–40 mg orally three times daily; isosorbide mononitrate, 10–40 mg orally twice daily or 60–120 mg once daily in a sustained-release preparation; oral sustained-release nitroglycerin preparations, 6.25–12.5 mg two to four times daily; nitroglycerin ointment, 6.25–25 mg applied two to four times daily; and transdermal nitroglycerin patches that deliver nitroglycerin at a predetermined rate (usually 5–20 mg/24 h). The main limitation to long-term nitrate therapy is tolerance, which can be limited by using a regimen that includes a minimum 8- to 10-hour period per day without nitrates. Isosorbide dinitrate can be given three times daily, with the last dose after dinner, or longer-acting isosorbide mononitrate once daily. Transdermal nitrate preparations should be removed overnight in most patients.

Nitrate therapy is often limited by headache. Other side effects include nausea, light-headedness, and hypotension.

D. β -Blockers

β -Blockers are the only antianginal agents that have been demonstrated to prolong life in patients with coronary disease (post-myocardial infarction). They are at least as effective at relieving angina as alternative agents in studies employing exercise testing, ambulatory monitoring, and symptom assessment. β -Blockers should be considered for first-line therapy in most patients with chronic angina.

β -Blockers with intrinsic sympathomimetic activity, such as pindolol, are less desirable because they may exacerbate angina in some individuals and have not been

effective in secondary prevention trials. The pharmacology and side effects of the β -blockers are discussed in Chapter 11 (see Table 11–7). The dosages of all these drugs when given for angina are similar. The major contraindications are severe bronchospastic disease, bradyarrhythmias, and decompensated heart failure.

E. Calcium Channel Blocking Agents

Unlike the β -blockers, calcium channel blockers have not been shown to reduce mortality postinfarction and in some cases have increased ischemia and mortality rates. This appears to be the case with some dihydropyridines and with diltiazem and verapamil in patients with clinical heart failure or moderate to severe LV dysfunction. Meta-analyses have suggested that short-acting nifedipine in moderate to high doses causes an increase in mortality. It is uncertain whether these findings are relevant to longer-acting dihydropyridines. Nevertheless, considering the uncertainties and the lack of demonstrated favorable effect on outcomes, calcium channel blockers should be considered third-line anti-ischemic drugs in the postinfarction patient. Similarly, with the exception of amlodipine, which in the still-unpublished PRAISE trial proved safe in patients with heart failure, these agents should be avoided in patients with CHF or low EFs.

The pharmacologic effects and side effects of the calcium channel blockers are discussed in Chapter 11 and summarized in Table 11–9. Diltiazem and verapamil are preferable because they produce less reflex tachycardia and because the former, at least, may cause fewer side effects. Nifedipine, nicardipine, and amlodipine are also approved agents for angina. Isradipine, felodipine, and nisoldipine are not approved for angina but probably are as effective as the other dihydropyridines.

F. Ranolazine

Ranolazine is the first new antianginal drug to be approved by the FDA in many years, and it is approved as first-line use for chronic angina. It decreases the late sodium current and thereby decreases intracellular calcium overload. Ranolazine has no effect on heart rate and BP, and it has been shown in clinical trials to prolong exercise duration and time to angina, both as monotherapy and when administered with conventional antianginal therapy. It is safe to use with erectile dysfunction drugs. The usual dose is 500 mg orally twice a day. Because it can cause QT prolongation, it is contraindicated in patients with existing QT prolongation; in patients taking QT prolonging drugs, such as class I or III antiarrhythmics (eg, quinidine, dofetilide, sotalol); and in those taking potent and moderate CYP450 3A inhibitors. Of interest, in spite of the QT prolongation, there is a significantly lower rate of ventricular arrhythmias with its use following acute coronary syndromes, shown in the MERLIN trial. It also decreases occurrence of atrial fibrillation and results in a small decrease in Hgb_{A1C}. It is contraindicated in patients with significant liver and kidney disease. Ranolazine is not to be used for treatment of acute anginal episodes.

G. Alternative and Combination Therapies

Patients who do not respond to one class of antianginal medication often respond to another. It may, therefore, be worthwhile to use an alternative agent before progressing to combinations. If the patient remains symptomatic, a β -blocker and a long-acting nitrate or a β -blocker and a calcium channel blocker (other than verapamil, where the risk of AV block or heart failure is higher) are the most appropriate combinations. A few patients will have a further response to a regimen including all three agents.

H. Platelet-Inhibiting Agents

Several studies have demonstrated the benefit of antiplatelet drugs for patients with stable and unstable vascular disease. Therefore, unless contraindicated, aspirin (81–325 mg daily) should be prescribed for all patients with angina. Clopidogrel, 75 mg daily, reduces vascular events in patients with stable vascular disease (as an alternative to aspirin) and in patients with acute coronary syndromes (in addition to aspirin). Thus, it is also a good alternative in aspirin-intolerant patients. Clopidogrel may rarely induce thrombotic thrombocytopenic purpura.

I. Risk Reduction

Patients with coronary disease should undergo aggressive risk factor modification. This approach, with a particular focus on statin treatment, treating hypertension, stopping smoking, and exercise and weight control (especially for patients with metabolic syndrome or at risk for diabetes), may markedly improve outcome. For patients with diabetes and cardiovascular disease, there is uncertainty about the optimal target blood sugar control. The ADVANCE trial suggested some benefit for tight blood sugar control with target Hgb A_{1C} \leq 6.5%. The ACCORD trial found that routine aggressive targeting for blood sugar control to Hgb A_{1C} to $<$ 6.0% in patients with diabetes and coronary disease was associated with increased mortality. Therefore, tight blood sugar control should be avoided particularly in patients with history of severe hypoglycemia, long-standing diabetes, and advanced vascular disease. Aggressive BP control (target systolic BP $<$ 120 mm Hg) in the ACCORD trial was not associated with reduction in coronary heart disease events, although stroke was reduced.

J. Revascularization

1. Indications—There is general agreement that otherwise healthy patients in the following groups should undergo revascularization: (1) Patients with unacceptable symptoms despite medical therapy to its tolerable limits. (2) Patients with left main coronary artery stenosis $>$ 50% with or without symptoms. (3) Patients with three-vessel disease with LV dysfunction (EF $<$ 50% or previous transmural infarction). (4) Patients with unstable angina who after symptom control by medical therapy continue to exhibit ischemia on exercise testing or monitoring. (5) Post-myocardial infarction patients with continuing angina or severe ischemia on noninvasive testing. The use of revascularization for patients with acute coronary

syndromes and acute ST elevation myocardial infarction is discussed below.

In addition, many cardiologists have believed that patients with less severe symptoms should be revascularized if they have two-vessel disease associated with underlying LV dysfunction, anatomically critical lesions (>90% proximal stenoses, especially of the proximal left anterior descending artery), or physiologic evidence of severe ischemia (early positive exercise tests, large exercise-induced thallium scintigraphic defects, or frequent episodes of ischemia on ambulatory monitoring). Two sources of data have tempered some of the enthusiasm for coronary intervention for stable angina. Drug-eluting stents, widely used because of their benefits in preventing restenosis, have been associated with higher rates of late stent thrombosis. Moreover, data from the COURAGE trial have shown that for patients with chronic angina and disease suitable for percutaneous coronary intervention (PCI), PCI offers no mortality benefit beyond excellent medical therapy, and relatively moderate long-term symptomatic improvement. The ACC/AHA have recently developed criteria for appropriateness of coronary revascularization that highlight these conclusions.

2. Type of procedure

A. CORONARY ARTERY BYPASS GRAFTING—Coronary artery bypass grafting (CABG) can be accomplished with a very low mortality rate (1–3%) in otherwise healthy patients with preserved cardiac function. However, the mortality rate of this procedure rises to 4–8% in older individuals and in patients who have had a prior CABG.

Grafts using one or both internal mammary arteries (usually to the left anterior descending artery or its branches) provide the best long-term results in terms of patency and flow. Segments of the saphenous vein (or, less optimally, other veins) or the radial artery interposed between the aorta and the coronary arteries distal to the obstructions are also used. One to five distal anastomoses are commonly performed.

Minimally invasive surgical techniques utilize different approaches to the heart than standard sternotomy and cardiopulmonary bypass. The surgical approach may involve a limited sternotomy, lateral thoracotomy (MIDCAB), or thoracoscopy (port-access). These techniques allow earlier postoperative mobilization and discharge. They are more technically demanding, usually not suitable for more than two grafts, and do not have established durability. Bypass surgery can be performed both on circulatory support (on pump) and without direct circulatory support (off-pump). Recent randomized trial data have not shown a benefit with off-pump bypass surgery.

The operative mortality rate is increased in patients with poor LV function (LV EF < 35%) or those requiring additional procedures (valve replacement or ventricular aneurysmectomy). Patients over 70 years of age, patients undergoing repeat procedures, or those with important noncardiac disease (especially chronic kidney disease and diabetes) or poor general health also have higher operative mortality and morbidity rates, and full recovery is slow. Thus, CABG should be reserved for more severely

symptomatic patients in this group. Early (1–6 months) graft patency rates average 85–90% (higher for internal mammary grafts), and subsequent graft closure rates are about 4% annually. Early graft failure is common in vessels with poor distal flow, while late closure is more frequent in patients who continue smoking and those with untreated hyperlipidemia. Antiplatelet therapy with aspirin improves graft patency rates. Smoking cessation and vigorous treatment of blood lipid abnormalities (particularly with statins) are necessary. While the most important principle is to use proven doses of statins shown to improve outcomes in large trials, many advocate a goal for LDL cholesterol of 70–100 mg/dL (8.2–26 mmol/L) and for HDL cholesterol of \geq 45 mg/dL (11.1 mmol/L). Repeat revascularization (see below) may be necessitated because of recurrent symptoms due to progressive native vessel disease and graft occlusions. Reoperation is technically demanding and less often fully successful than the initial operation.

B. PERCUTANEOUS CORONARY INTERVENTION INCLUDING STENTING—PCI, including balloon angioplasty and coronary stenting, can effectively open stenotic coronary arteries. Coronary stenting, with either bare metal stents or drug-eluting stents, has substantially reduced restenosis. Stenting can also be used selectively for left main coronary stenosis, particularly when CABG is contraindicated.

PCI is possible but often less successful in bypass graft stenoses. Experienced operators are able to successfully dilate > 90% of lesions attempted. The major early complication is intimal dissection with vessel occlusion, although this is rare with coronary stenting. The use of intravenous platelet glycoprotein IIb/IIIa inhibitors (abciximab, eptifibatid, tirofiban) has substantially reduced the rate of periprocedural myocardial infarction, and placement of intracoronary stents has markedly improved initial and long-term angiographic results, especially with complex and long lesions. After percutaneous coronary intervention, all patients should have CK-MB and troponin measured, and a new rise of greater than three times the upper limit of normal constitutes a significant periprocedural myocardial infarction. Acute thrombosis after stent placement can largely be prevented by aggressive antithrombotic therapy (long-term aspirin, 81–325 mg, plus clopidogrel, 300–600 mg loading dose followed by 75 mg daily, for between 30 days and 1 year, and with acute use of platelet glycoprotein IIb/IIIa inhibitors).

A major limitation with PCI has been **restenosis**, which occurs in the first 6 months in < 10% of vessels treated with drug-eluting stents, 15–30% of vessels treated with bare metal stents, and 30–40% of vessels without stenting. Factors associated with higher restenosis rates include diabetes, small luminal diameter, longer and more complex lesions, and lesions at coronary ostia or in the left anterior descending coronary artery. Drug-eluting stents that elute antiproliferative agents such as sirolimus, everolimus, zotarolimus, or paclitaxel have substantially reduced restenosis. In-stent restenosis is often treated with restenting with drug-eluting stents, and rarely with brachytherapy. The nearly 2 million PCIs performed worldwide per year far exceeds the number of CABG operations, but the rationale for many of the procedures performed in patients with stable

angina should be for angina symptom reduction. The COURAGE trial has confirmed earlier studies in showing that even for patients with moderate anginal symptoms and positive stress tests, PCI provides no benefit over medical therapy with respect to death or with respect to death or myocardial infarction. PCI was more effective at relieving angina, although most patients in the medical group had improvement in symptoms. Thus, in patients with mild or moderate stable symptoms, aggressive lipid-lowering and antianginal therapy may be a preferable initial strategy, reserving PCI for patients with significant and refractory symptoms or for those who are unable to take the prescribed medicines.

Several studies of PCI, including with drug-eluting stents, versus CABG in patients with multivessel disease have been reported. The most recent trial with drug-eluting stent use in PCI patients, SYNTAX, reported similar findings to prior studies. The consistent finding has been comparable mortality and infarction rates over follow-up periods of 1–3 years but a high rate (approximately 40%) of repeat procedures following PCI. Stroke rates are higher with CABG. As a result, the choice of revascularization procedure may depend on details of coronary anatomy and is often a matter of patient preference. However, it should be noted that < 20% of patients with multivessel disease meet the entry criteria for the clinical trials, so these results cannot be generalized to all multivessel disease patients. Outcomes with percutaneous revascularization in diabetics have generally been inferior to those with CABG. However, most of these trials preceded the widespread use of stenting.

K. Mechanical Extracorporeal Counterpulsation

Extracorporeal counterpulsation (ECP) entails repetitive inflation of a high-pressure chamber surrounding the lower half of the body during the diastolic phase of the cardiac cycle for daily 1-hour sessions over a period of 7 weeks. Randomized trials have shown that ECP reduces angina, improves exercise tolerance, and can reduce symptoms of heart failure.

L. Neuromodulation

Spinal cord stimulation can be used to relieve chronic refractory angina. Spinal cord stimulators are subcutaneously implantable via a minimally invasive procedure under local anesthesia.

► Prognosis

The prognosis of angina pectoris has improved with development of therapies aimed at secondary prevention. Mortality rates vary depending on the number of vessels diseased, the severity of obstruction, the status of LV function, and the presence of complex arrhythmias. Mortality rates are progressively higher in patients with one-, two-, and three-vessel disease and those with left main coronary artery obstruction (ranging from 1% per year to 25% per year). The outlook in individual patients is unpredictable, and nearly half of the deaths are sudden. Therefore, risk stratification is often attempted. Patients with accelerating symptoms have a poorer outlook. Among stable patients,

Table 10–4. Duke treadmill score: Calculation and interpretation.

Time in minutes on Bruce protocol	=	_____
–5 × amount of depression (in mm)	=	_____
–4 × angina index	=	_____
0 = no angina on test		
1 = angina, not limiting		
2 = limiting angina		
Total Score	Risk Group	Annual Mortality
≥ 5	Low	0.25%
–10 to +4	Intermediate	1.25%
≤ –11	High	5.25%

those whose exercise tolerance is severely limited by ischemia (< 6 minutes on the Bruce treadmill protocol) and those with extensive ischemia by exercise ECG or scintigraphy have more severe anatomic disease and a poorer prognosis. The Duke Treadmill Score, based on a standard Bruce protocol exercise treadmill test, provides an estimate of risk of death at 1 year. The score uses time on the treadmill, amount of ST-segment depression, and presence of angina (Table 10–4).

► Trial Results

Several randomized trials have shown that over follow-up periods of several years, the mortality and infarction rates with percutaneous revascularization and CABG are generally comparable. Exceptions are patients with left main or three-vessel disease with reduced ventricular function, and perhaps diabetic patients, who have had better outcomes with CABG. The increasing popularity of PCI and stenting primarily reflects the lower cost and shorter hospitalization, the perception that CABG is best done only once and can be reserved for later, and the preference of patients for less invasive treatment. These arguments make PCI the procedure of choice for revascularization of single-vessel disease. The situation is less clear with multivessel disease. It should also be noted that the excellent outcome of patients treated medically has made it difficult to show an advantage with either revascularization approach except in patients who remain symptom limited or have left main lesions or three-vessel disease and LV dysfunction. The issue of late stent thrombosis may shift the balance toward bare metal stents, especially for patients who cannot tolerate or take long-term clopidogrel.

► When to Refer

All patients with new or worsening symptoms believed to represent angina or a positive stress test for myocardial ischemia (or both) should be referred to a cardiologist.

► When to Admit

- Patients with elevated cardiac biomarkers, ischemic ECG findings, or hemodynamic instability.

- Patients with new or worsened symptoms possibly thought to be ischemic but who lack high-risk features can be observed with serial ECGs and biomarkers, and discharged if stress testing shows low-risk findings.

ACCORD Study Group; Cushman WC et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. *N Engl J Med*. 2010 Apr 29;362(17):1575–85. [PMID: 20228401]

Agarwal M et al. Nonacute coronary syndrome anginal chest pain. *Med Clin North Am*. 2010 Mar;94(2):201–16. [PMID: 20380951]

American Diabetes Association. Standards of medical care in diabetes—2010. *Diabetes Care*. 2010 Jan;33(Suppl 1):S11–61. [PMID: 20042772]

Boden WE et al; COURAGE Trial Research Group. Optimal medical therapy with or without PCI for stable coronary disease. *N Engl J Med*. 2007 Apr 12;356(15):1503–16. [PMID: 17387127]

Budoff MJ et al. Assessment of coronary artery disease by cardiac computed tomography: a scientific statement from the American Heart Association Committee on Cardiovascular Imaging and Intervention, Council on Cardiovascular Radiology and Intervention, and Committee on Cardiac Imaging, Council on Clinical Cardiology. *Circulation*. 2006 Oct 17;114(16):1761–91. [PMID: 17015792]

Cassar A et al. Chronic coronary artery disease: diagnosis and management. *Mayo Clin Proc*. 2009 Dec;84(12):1130–46. [PMID: 19955250]

Fraker TD Jr et al. 2007 chronic angina focused update of the ACC/AHA 2002 guidelines for the management of patients with chronic stable angina. *J Am Coll Cardiol*. 2007 Dec 4;50(23):2264–74. [PMID: 18061078]

Gibbons RJ et al. ACC/AHA 2002 guideline update for the management of patients with chronic stable angina—summary article: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Committee on the Management of Patients With Chronic Stable Angina). *J Am Coll Cardiol*. 2003 Jan 1;41(1):159–68. [PMID: 12570960]

Goldstein J et al. A randomized controlled trial of multi-slice coronary computed tomography for evaluation of acute chest pain. *J Am Coll Cardiol*. 2007 Feb 27;49(8):863–71. [PMID: 17320744]

Grines CL et al. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. *Circulation*. 2007 Feb 13;115(6):813–8. [PMID: 17224480]

Hendel RC et al. ACCF/ASNC/ACR/AHA/ASE/SCCT/SCMR/SNM 2009 Appropriate Use Criteria for Cardiac Radionuclide Imaging: A Report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, the American Society of Nuclear Cardiology, the American College of Radiology, the American Heart Association, the American Society of Echocardiography, the Society of Cardiovascular Computed Tomography, the Society for Cardiovascular Magnetic Resonance, and the Society of Nuclear Medicine. *J Am Coll Cardiol*. 2009 Jun 9;53(23):2201–29. [PMID: 19497454]

Levine GN et al. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. *Circulation*. 2011 Dec 6;124(23):e574–651. [PMID: 22064601]

Morrow DA et al. Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial. *JAMA*. 2007 Apr 25;297(16):1775–83. [PMID: 17456819]

Patel MR et al. ACCF/SCAI/STS/AATS/AHA/ASNC 2009 Appropriateness Criteria for Coronary Revascularization: a report by the American College of Cardiology Foundation Appropriateness Criteria Task Force, Society for Cardiovascular Angiography and Interventions, Society of Thoracic Surgeons, American Association for Thoracic Surgery, American Heart Association, and the American Society of Nuclear Cardiology Endorsed by the American Society of Echocardiography, the Heart Failure Society of America, and the Society of Cardiovascular Computed Tomography. *J Am Coll Cardiol*. 2009 Feb 10;53(6):530–53. [PMID: 19195618]

Patel MR et al. Low diagnostic yield of elective coronary angiography. *N Engl J Med*. 2010 Mar 11;362(10):886–95. [PMID: 20220183]

Raff GL et al. Coronary angiography by computed tomography: coronary imaging evolves. *J Am Coll Cardiol*. 2007 May 8;49(18):1830–3. [PMID: 17481441]

Riddle MC. Effects of intensive glucose lowering in the management of patients with type 2 diabetes mellitus in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. *Circulation*. 2010 Aug 24;122(8):844–6. [PMID: 20733112]

Skyler JS et al. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA Diabetes Trials: a position statement of the American Diabetes Association and a Scientific Statement of the American College of Cardiology Foundation and the American Heart Association. *J Am Coll Cardiol*. 2009 Jan 20;53(3):298–304. [PMID: 19147051]

Tonino PA et al; FAME Study Investigators. Fractional flow reserve versus angiography for guiding percutaneous coronary intervention. *N Engl J Med*. 2009 Jan 15;360(3):213–24. [PMID: 19144937]

Torpy JM et al. JAMA patient page. Cardiac stress testing. *JAMA*. 2008 Oct 15;300(15):1836. [PMID: 18854548]

Toutouzas K et al. Percutaneous coronary intervention in chronic stable angina. *Am J Med Sci*. 2010 Jun;339(6):568–72. [PMID: 20375692]

CORONARY VASOSPASM & ANGINA WITH NORMAL CORONARY ARTERIOGRAMS



ESSENTIALS OF DIAGNOSIS

- ▶ Precordial chest pain, often occurring at rest during stress or without known precipitant, relieved rapidly by nitrates.
- ▶ ECG evidence of ischemia during pain, sometime with ST-segment elevation, including by Holter monitor.
- ▶ Angiographic demonstration of no significant obstruction of major coronary vessels.
- ▶ Angiographic demonstration of coronary spasm that responds to intra-coronary nitroglycerin or calcium channel blockers.

▶ General Considerations

Although most symptoms of myocardial ischemia result from fixed stenosis of the coronary arteries or intraplaque

hemorrhage or thrombosis at the site of lesions, some ischemic events may be precipitated or exacerbated by coronary vasoconstriction.

Spasm of the large coronary arteries with resulting decreased coronary blood flow may occur spontaneously or may be induced by exposure to cold, emotional stress, or vasoconstricting medications, such as ergot derivative drugs. Spasm may occur both in normal and in stenosed coronary arteries. Even myocardial infarction may occur as a result of spasm in the absence of visible obstructive coronary heart disease, although most instances of such coronary spasm occur in the presence of coronary stenosis.

Cocaine can induce myocardial ischemia and infarction by causing coronary artery vasoconstriction or by increasing myocardial energy requirements. It also may contribute to accelerated atherosclerosis and thrombosis. The ischemia in **Prinzmetal (variant) angina** usually results from coronary vasoconstriction. It tends to involve the right coronary artery and there may be no fixed stenoses. Myocardial ischemia may also occur in patients with normal coronary arteries as a result of disease of the coronary microcirculation or abnormal vascular reactivity. This has been termed “syndrome X.”

► Clinical Findings

Ischemia may be silent or result in angina pectoris.

Prinzmetal (variant) angina is a clinical syndrome in which chest pain occurs without the usual precipitating factors and is associated with ST-segment elevation rather than depression. It often affects women under 50 years of age. It characteristically occurs in the early morning, awakening patients from sleep, and is apt to be associated with arrhythmias or conduction defects. It may be diagnosed by challenge with ergonovine (a vasoconstrictor), although the results of such provocation are not specific and it entails risk.

► Treatment

Patients with chest pain associated with ST-segment elevation should undergo coronary arteriography to determine whether fixed stenotic lesions are present. If they are, aggressive medical therapy or revascularization is indicated, since this may represent an unstable phase of the disease. If significant lesions are not seen and spasm is suspected, avoidance of precipitants such as cigarette smoking and cocaine is the top priority. Episodes of coronary spasm generally respond well to nitrates, and both nitrates and calcium channel blockers (including long-acting nifedipine, diltiazem, or amlodipine) are effective prophylactically. By allowing unopposed α_1 -mediated vasoconstriction, β -blockers have exacerbated coronary vasospasm, but they may have a role in management of patients in whom spasm is associated with fixed stenoses.

► When to Refer

All patients with persistent symptoms of chest pain that may represent spasm should be referred to a cardiologist.

Agarwal M et al. Nonacute coronary syndrome anginal chest pain. *Med Clin North Am.* 2010 Mar;94(2):201–16. [PMID: 20380951]

Al Suwaidi J et al. Pathophysiology, diagnosis, and current management strategies for chest pain in patients with normal findings on angiography. *Mayo Clin Proc.* 2001 Aug;76(8):813–22. [PMID: 11499821]

ACUTE CORONARY SYNDROMES WITHOUT ST SEGMENT ELEVATION

► General Considerations

Acute coronary syndromes comprise the spectrum of unstable cardiac ischemia from unstable angina to acute myocardial infarction. Acute coronary syndromes are classified based on the presenting ECG as either “ST segment elevation” (STEMI) or “non-ST segment elevation.” This allows for immediate classification and guides determination of whether patients should be considered for acute reperfusion therapy. The evolution of cardiac biomarkers then allows determination of whether myocardial infarction has occurred. The universal definition of myocardial infarction is a rise of cardiac biomarkers with at least one value above the 99th percentile of the upper reference limit together with evidence of myocardial ischemia with at least one of the following: symptoms of ischemia, ECG changes of new ischemia, new Q waves, or imaging evidence of new loss of viable myocardium or new wall motion abnormality.

Acute coronary syndromes represent a dynamic state in which patients frequently shift from one category to another, as new ST elevation can develop after presentation and cardiac biomarkers can become abnormal with recurrent ischemic episodes.

Chest pain is one of the most frequent reasons for emergency department visits. Algorithms have been developed to aid in determining the likelihood that a patient has an acute coronary syndrome, and for those patients who do have an acute coronary syndrome, the risk of ischemic events and death.

► Clinical Findings

A. Symptoms and Signs

Patients with acute coronary syndromes generally have symptoms and signs of myocardial ischemia either at rest or with minimal exertion. These symptoms and signs are similar to chronic angina symptoms described above, consisting of substernal chest pain or discomfort that may radiate to the jaw, left shoulder or arm. Dyspnea, nausea, diaphoresis or syncope may either accompany the chest discomfort or may be the only symptom of acute coronary syndrome. About one-third of patients with myocardial infarction have no chest pain per se—these patients tend to be older, female, have diabetes, and be at higher risk for subsequent mortality. Patients with acute coronary syndromes have signs of heart failure in about 10% of cases, and this is also associated with higher risk of death.

Many hospitals have developed **chest pain observation units** to provide a systematic approach toward serial risk stratification to improve the triage process. In many cases, those who have not experienced new chest pain and have insignificant ECG changes and no cardiac biomarker elevation undergo treadmill exercise tests or imaging procedures to exclude ischemia at the end of an 8- to 24-hour period and are discharged directly from the emergency department if these tests are negative.

B. Laboratory Findings

Depending on the time from symptom onset to presentation, initial laboratory findings may be normal. The markers of cardiac myocyte necrosis, myoglobin, CK, CK-MB, and troponin I and T may all be used to identify acute myocardial infarction. These markers have a well-described pattern of release over time in patients with myocardial infarction. In patients with STEMI, these initial markers are often within normal limits as the patient is being rushed to immediate reperfusion. In patients without ST-segment elevation, it is the presence of abnormal CK-MB or troponin values that are associated with myocyte necrosis and the diagnosis of myocardial infarction. Serum creatinine is an important determinant of risk, and estimated creatinine clearance is important to guide dosing of certain antithrombotics, including eptifibatid and enoxaparin.

C. ECG

Many patients with acute coronary syndromes will exhibit ECG changes during pain—either ST-segment elevation, ST-segment depression, or T wave flattening or inversion. Dynamic ST segment shift is the most specific for acute coronary syndrome. Patients may exhibit signs of LV dysfunction during pain and for a time thereafter.

► Treatment

A. General Measures

Treatment of acute coronary syndromes without ST elevation should be multifaceted. Patients who are at medium or high risk should be hospitalized, maintained at bed rest or at very limited activity for the first 24 hours, monitored, and given supplemental oxygen. Sedation with a benzodiazepine agent may help if anxiety is present.

B. Specific Measures

Table 10–5 provides a summary of the ACC/AHA Guideline recommendations for selected medical treatments.

C. Anticoagulation and Antiplatelet Therapy

Patients should receive a combination of antiplatelet and anticoagulant agents. **Aspirin**, 81–325 mg daily, and an **anticoagulant** (unfractionated heparin, enoxaparin, fondaparinux, or bivalirudin) should be commenced on presentation. The large CURRENT trial comparing 81 mg versus 325 mg of aspirin (in addition to **clopidogrel**) for the first month following diagnosis of ACS found little difference

in thrombotic events or in major bleeding. Thus, either dose is reasonable, at least for the first month. The longer-term optimal aspirin dose may be 81 mg/d (versus 160 mg/d or 325 mg/d) based on similar thrombotic event rates and lower rates of bleeding, and the 2011 ACC/AHA guidelines recommend the 81 mg/d as preferable to higher doses following coronary stenting. Several trials have shown that **low-molecular-weight heparin** (enoxaparin 1 mg/kg subcutaneously every 12 hours) is somewhat more effective than **unfractionated heparin** in preventing recurrent ischemic events in the setting of acute coronary syndromes. However, the SYNERGY trial showed that unfractionated heparin and enoxaparin had similar rates of death or (re)infarction in the setting of frequent early coronary intervention. **Fondaparinux**, a specific factor Xa inhibitor given in a dose of 2.5 mg subcutaneously once a day, was found in the OASIS-5 trial to be equally effective as enoxaparin among 20,000 patients at preventing early death, myocardial infarction, and refractory ischemia, and resulted in a 50% reduction in major bleeding. This reduction in major bleeding translated into a significant reduction in mortality (and in death and/or myocardial infarction) at 30 days. While catheter-related thrombosis was more common during coronary intervention procedures with fondaparinux, the FUTURA trial found that it can be controlled by adding unfractionated heparin (in a dose of 85 units/kg without glycoprotein IIb/IIIa inhibitors, and 60 units/kg with glycoprotein IIb/IIIa inhibitors) during the procedure. Guidelines recommend fondaparinux, describing it as especially favorable for patients who are initially treated medically and who are at high risk for bleeding, such as the elderly.

The ACUTY trial showed that the direct thrombin inhibitor **bivalirudin** appears to be a reasonable alternative to heparin (unfractionated heparin or enoxaparin) plus a glycoprotein IIb/IIIa antagonist for many patients with acute coronary syndromes who are undergoing early coronary intervention. Bivalirudin (without routine glycoprotein IIb/IIIa inhibitor) is associated with substantially less bleeding than heparin plus glycoprotein IIb/IIIa inhibitor. The ISAR REACT-4 trial showed that bivalirudin has similar efficacy compared to abciximab but better bleeding outcomes in NSTEMI patients.

The Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) trial demonstrated a 20% reduction in the composite end point of cardiovascular death, myocardial infarction, and stroke with the addition of **clopidogrel** (300 mg loading dose, 75 mg/d for 9–12 months) in patients with non-ST-segment elevation acute coronary syndromes.

ACC/AHA guidelines call for either a P2Y₁₂ inhibitor (clopidogrel, prasugrel [at the time of PCI], or ticagrelor) or a glycoprotein IIb/IIIa inhibitor “up-front” (prior to coronary angiography) as a class I recommendation. The European Society of Cardiology guidelines provide a stronger recommendation for a P2Y₁₂ inhibitor up-front, as a class IA recommendation for all patients.

The large CURRENT trial showed that “double-dose” **clopidogrel** (600 mg initial oral loading dose, followed by 150 mg orally daily) for 7 days reduced stent thrombosis

Table 10-5. Summary of the current ACC/AHA guideline recommendations for medical management of acute coronary syndromes (ACS) and acute myocardial infarction (AMI).¹

Medication	Acute Therapies ACS	Acute Therapies AMI	Discharge Therapies
Aspirin (ASA)	IA	IA	IA
Clopidogrel in ASA-allergic patients	IA	IC	IA
Clopidogrel, intended medical management	IA	—	IA
Clopidogrel, early catheterization/percutaneous coronary intervention (catheterization/percutaneous coronary intervention [cath/PCI])	IA (prior to or at time of PCI)	IB	IA
Prasugrel (as an alternative to clopidogrel), for unstable angina/non-STEMI patients undergoing PCI and for primary PCI	IB ²	IB ²	
Ticagrelor (as an alternative to clopidogrel)	IB	IB	IB
Clopidogrel and IIb/IIIa inhibitor, up front (prior to catheterization)	IIa, B		
Heparin (unfractionated or low-molecular-weight)	IA	IC ³	—
Fondaparinux	IB	IC	
Bivalirudin	IB	IB ⁴	
Bivalirudin for early invasive strategy (without IIb/IIIa inhibitor), if clopidogrel at least 300 mg was administered 6 hours before planned catheterization or PCI	IIa, B		
β-Blockers (oral)	IB	IA	IB
β-Blockers (intravenous) ⁵	IIaB ⁵	IIaB ⁵	
Angiotensin-converting enzyme (ACE) inhibitors	IB ⁵	IA/IIaB ⁶	IA/IIaB ⁷
GP IIb/IIIa inhibitors for intended early cath/PCI:			
Eptifibatide/tirofiban	IA	IIa, B	—
Abciximab	IA	IIaA	—
Adding GP IIb/IIIa inhibitors to clopidogrel for high-risk patients without intended early cath/PCI:			
Eptifibatide/tirofiban	IIbB	—	—
Abciximab	III A	—	—
Lipid-lowering agent ⁸	—	—	IA
Smoking cessation counseling	—	—	IB
Nonsteroidal anti-inflammatory agents (other than aspirin)	IIIC	IIIC	—

¹Class I indicates treatment is useful and effective, class IIa indicates weight of evidence is in favor of usefulness/efficacy, class IIb indicates weight of evidence is less well established, and class III indicates intervention is not useful/effective and may be harmful. Type A recommendations are based on data derived from multiple randomized clinical trials or meta-analyses; Type B recommendations are based on data derived from single randomized clinical trial or large nonrandomized studies; Type C recommendations are based on consensus of opinion of the experts or on data derived from small studies, retrospective studies, or registries. ACC/AHA = American College of Cardiology/American Heart Association.

²In STEMI patients with a prior history of stroke and transient ischemic attack for whom primary PCI is planned, prasugrel is not recommended as part of a dual-antiplatelet therapy regimen. (Class III, Level of Evidence: C).

³Unfractionated heparin, enoxaparin, or fondaparinux have established efficacy and should be used (IC) for a minimum of 48 hours and preferably for the duration of the hospitalization, up to 8 days. Enoxaparin or fondaparinux are preferred if therapy is given for more than 48 hours because of risk of heparin-induced thrombocytopenia (IA). Because of risk of catheter thrombosis, fondaparinux should not be used as the sole anticoagulant to support PCI.

⁴With primary PCI, with or without prior heparin bolus.

⁵For patients with hypertension and no heart failure, low output state, increased risk of shock, or other contraindications to β-blockers.

⁶For patients with persistent hypertension despite treatment, diabetes mellitus, congestive heart failure, or any left ventricular dysfunction.

⁷IA for patients with congestive heart failure or ejection fraction < 0.40, IIa for others, in absence of hypotension (systolic blood pressure < 100 mm Hg); angiotensin receptor blocker (valsartan or candesartan) for patients with ACE inhibitor intolerance.

⁸For patients with a low-density lipoprotein cholesterol level > 70 mg/dL.

STEMI, ST elevation myocardial infarction.

with a modest increase in major (but not fatal) bleeding and, therefore, it is an option for patients with ACS undergoing PCI.

Prasugrel is a P2Y₁₂ inhibitor that is both more potent and has a faster onset of action than clopidogrel. The TRITON trial compared prasugrel with clopidogrel in patients with STEMI or non-ST elevation MI in whom PCI was planned; prasugrel resulted in a 19% relative reduction in death from cardiovascular causes, myocardial infarction, or stroke, at the expense of a small increase in serious bleeding (including fatal bleeding). Stent thrombosis was reduced by half. Because patients with prior stroke or transient ischemic attack had higher risk of intracranial hemorrhage, prasugrel is contraindicated in such patients. Bleeding was also higher in patients with low body weight (< 60 kg) and older age (≥ 75 years), and caution should be used in these populations. For patients with STEMI treated with PCI, prasugrel appears to be especially effective without a substantial increase in bleeding.

Ticagrelor is a P2Y₁₂ inhibitor that has a faster onset of action than clopidogrel and a more consistent and potent effect. The PLATO trial showed that when ticagrelor was started at the time of presentation in ACS patients (UA/NSTEMI and STEMI), it reduced cardiovascular death, myocardial infarction, and stroke by 16% when compared with clopidogrel. In addition, there was a 22% relative risk reduction in mortality with ticagrelor. The overall rates of bleeding were similar between ticagrelor and clopidogrel, although non-CABG related bleeding was modestly higher. The finding of a lesser treatment effect in the United States may have been related to use of higher-dose aspirin, and thus when using ticagrelor, low-dose aspirin (81 mg/d) is recommended. The European College of Cardiology guidelines recommend (at a class I level) ticagrelor for all patients at moderate to high risk for ACS; prasugrel for patients who have not yet received another P2Y₁₂ inhibitor, who have planned PCI, and who are not at high risk for life-threatening bleeding; and clopidogrel only for patients who cannot receive either ticagrelor or prasugrel.

Small molecule inhibitors of the platelet glycoprotein IIb/IIIa receptor are useful adjuncts in high-risk patients (usually defined by fluctuating ST-segment depression or positive biomarkers) with acute coronary syndromes, particularly when they are undergoing PCI. **Tirofiban**, 0.4 mcg/kg/min for 30 minutes, followed by 0.1 mcg/kg/min, and **eptifibatide**, 180 mcg/kg bolus followed by a continuous infusion of 2 mcg/kg/min, have both been shown to be effective. Downward dose adjustments (1 mcg/kg/min) are required in patients with reduced kidney function. For example, if the estimated creatinine clearance is below 50 mL/min, the eptifibatide infusion should be cut in half to 1 mcg/kg/min. The ISAR-REACT 2 trial showed that for patients undergoing PCI with high-risk acute coronary syndrome, especially with elevated troponin, intravenous **abciximab** (added to clopidogrel 600 mg loading dose) reduces ischemic events by about 25%. The EARLY-ACS trial in over 10,000 patients with high-risk ACS found no benefit from eptifibatide started on admission compared with eptifibatide

treatment at the time of invasive coronary angiography, and higher rates of bleeding.

Fibrinolytic therapy should be avoided in patients without ST-segment elevation since they generally have a patent culprit artery, and since the risk of such therapy appears to outweigh the benefit.

D. Temporary Discontinuation of Antiplatelet Therapy for Procedures

Patients who have had recent coronary stents are at risk for thrombotic events, including **stent thrombosis**, if P2Y₁₂ inhibitors are discontinued for procedures (eg, dental procedures or colonoscopy). If possible, these procedures should be delayed until the end of the necessary treatment period with P2Y₁₂ inhibitors, which generally is at least 1 month with bare metal stents and 6 months with drug-eluting stents. Before that time, if a procedure is necessary, risk and benefit of continuing the antiplatelet therapy through the time of the procedure should be assessed. Aspirin should generally be continued.

E. Nitroglycerin

Nitrates are first-line therapy for patients with acute coronary syndromes presenting with chest pain. Nonparenteral therapy with sublingual or oral agents or nitroglycerin ointment is usually sufficient. If pain persists or recurs, intravenous nitroglycerin should be started. The usual initial dosage is 10 mcg/min. The dosage should be titrated upward by 10–20 mcg/min (to a maximum of 200 mcg/min) until angina disappears or mean arterial pressure drops by 10%. Careful—usually continuous—BP monitoring is required when intravenous nitroglycerin is used. Avoid hypotension (systolic BP < 100 mm Hg). Tolerance to continuous nitrate infusion is common.

F. β-Blockers

β-Blockers are an important part of the initial treatment of unstable angina unless otherwise contraindicated. The pharmacology of these agents is discussed in Chapter 11 and summarized in Table 11–7. Use of agents with intrinsic sympathomimetic activity should be avoided in this setting. Oral medication is adequate in most patients, but intravenous treatment with metoprolol, given as three 5-mg doses 5 minutes apart as tolerated and in the absence of heart failure, achieves a more rapid effect. Oral therapy should be titrated upward as BP permits.

G. Calcium Channel Blockers

Calcium channel blockers have not been shown to favorably affect outcome in unstable angina, and they should be used primarily as third-line therapy in patients with continuing symptoms on nitrates and β-blockers or those who are not candidates for these drugs. In the presence of nitrates and without accompanying β-blockers, diltiazem or verapamil is preferred, since nifedipine and the other dihydropyridines are more likely to cause reflex tachycardia or hypotension. The initial dosage should be low, but upward titration should proceed steadily (see Table 11–9).

H. Statins

The PROVE-IT trial provides evidence for starting a statin in the days immediately following an acute coronary syndrome. In this trial, more intensive therapy with atorvastatin 80 mg a day, regardless of total or LDL cholesterol level, improved outcome compared to pravastatin 40 mg a day, with the curves of death or major cardiovascular event separating as early as 3 months after starting therapy.

► Indications for Coronary Angiography

For patients with acute coronary syndrome, including non-ST-segment elevation myocardial infarction, risk stratification is important for determining intensity of care. Several therapies, including glycoprotein IIb/IIIa receptor antagonists, low-molecular-weight heparin, and early invasive catheterization, have been shown to have the greatest benefit in higher-risk patients with acute coronary syndrome. As outlined in the ACC/AHA guidelines, patients with any high-risk feature (Table 10–6) generally warrant an early invasive strategy with catheterization and revascularization. For patients without these high-risk features, either an invasive or noninvasive approach, using exercise (or pharmacologic stress for patients unable to exercise) stress testing to identify patients who have residual ischemia and/or high risk, can be used. Moreover, based on the ICTUS trial, a strategy based on selective coronary angiography and revascularization for instability or inducible ischemia, or both, even for patients with positive troponin, is acceptable (ACC/AHA class IIB recommendation).

Two risk-stratification tools are available that can be used at the bedside, the TIMI Risk Score and the GRACE Risk Score. The TIMI Risk Score includes nine variables: age ≥ 65 , three or more cardiac risk factors, prior coronary stenosis $\geq 50\%$, ST-segment deviation, two anginal events in prior 24 hours, acetylsalicylic acid in prior 7 days, and elevated cardiac markers. The GRACE risk score, which applies to patients with or without ST elevation, includes Killip class, BP, ST-segment deviation, cardiac arrest at presentation, serum creatinine, elevated creatine kinase (CK)-MB or troponin, and heart rate. The TIMI Risk Score is available for PDA download at http://www.outcomes-umassmed.org/grace/acs_risk_content.html.

► When to Refer

All patients with acute myocardial infarction should be referred to a cardiologist.

Patients who are taking a P2Y₁₂ inhibitor following coronary stenting should consult a cardiologist before discontinuing treatment for nonemergency procedures.

FUTURA/OASIS-8 Trial Group; Steg PG et al. Low-dose vs standard-dose unfractionated heparin for percutaneous coronary intervention in acute coronary syndromes treated with fondaparinux: the FUTURA/OASIS-8 randomized trial. *JAMA*. 2010 Sep 22;304(12):1339–49. [PMID: 20805623]
Greenhalgh J et al. Drug-eluting stents versus bare metal stents for angina or acute coronary syndromes. *Cochrane Database Syst Rev*. 2010 May 12;5:CD004587. [PMID: 20464732]

Table 10–6. Indications for catheterization and percutaneous coronary intervention.¹

Acute coronary syndromes (unstable angina and non-ST elevation MI)	
Class I	Early invasive strategy for any of the following high-risk indicators:
	Recurrent angina/ischemia at rest or with low-level activity
	Elevated troponin
	ST-segment depression
	Recurrent ischemia with evidence of CHF
	High-risk stress test result
	EF < 40%
	Hemodynamic instability
	Sustained ventricular tachycardia
	PCI within 6 months
	Prior CABG
	In the absence of these findings, either an early conservative or early invasive strategy
Class IIa	Early invasive strategy for patients with repeated presentations for ACS despite therapy
Class III	Extensive comorbidities in patients in whom benefits of revascularization are not likely to outweigh the risks
	Acute chest pain with low likelihood of ACS
Acute MI after fibrinolytic therapy (2009 ACC/AHA AMI Guideline Update)	
Class I	Recurrent ischemia (spontaneous or provoked)
	Recurrent MI
	Cardiogenic shock or hemodynamic instability
Class IIa	Reasonable to transfer high-risk patients treated with fibrinolytic therapy at a non-PCI center as soon as possible to a PCI facility for early diagnostic angiography and revascularization. (Level of evidence: B)
Class IIb	Consider transfer of non-high risk patients treated with fibrinolytic therapy at a non-PCI center to a PCI facility, especially if ischemic symptoms persist and failure to reperfuse is suspected.

¹Class I indicates treatment is useful and effective, IIa indicates weight of evidence is in favor of usefulness/efficacy, class IIb indicates weight of evidence is less well established, and class III indicates intervention is not useful/effective and may be harmful. Level of evidence A recommendations are derived from large-scale randomized trials, and B recommendations are derived from smaller randomized trials or carefully conducted observational analyses.

ACC/AHA, American College of Cardiology/American Heart Association; ACS, acute coronary syndrome; AMI, acute myocardial infarction; CABG, coronary artery bypass grafting; CHF, congestive heart failure; EF, ejection fraction; LV EF, left ventricular ejection fraction; MI, myocardial infarction; PCI, percutaneous coronary intervention.

- Hamm CW et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). *Eur Heart J*. 2011 Dec;32(23):2999–3054. [PMID: 21873419]
- Hirsch A et al; Invasive versus Conservative Treatment in Unstable coronary Syndromes (ICTUS) investigators. Long-term outcome after an early invasive versus selective invasive treatment strategy in patients with non-ST-elevation acute coronary syndrome and elevated cardiac troponin T (the ICTUS trial): a follow-up study. *Lancet*. 2007 Mar 10;369(9564):827–35. [PMID: 17350451]
- Hoening MR et al. Early invasive versus conservative strategies for unstable angina and non-ST elevation myocardial infarction in the stent era. *Cochrane Database Syst Rev*. 2010 Mar 17;(3):CD004815. [PMID: 20238333]
- Mehta SR et al; TIMACS Investigators. Early versus delayed invasive intervention in acute coronary syndromes. *N Engl J Med*. 2009 May 21;360(21):2165–75. [PMID: 19458363]
- Thygesen K et al; Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction. Universal definition of myocardial infarction. *Eur Heart J*. 2007 Oct;28(20):2525–38. [PMID: 17951287]
- Wallentin L et al; PLATO Investigators. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. *N Engl J Med*. 2009 Sep 10;361(11):1045–57. [PMID: 19717846]
- Wiviott SD et al; TITRON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. *N Engl J Med*. 2007 Nov 15;357(20):2001–15. [PMID: 17982182]
- Wright RS et al. 2011 ACCF/AHA Focused Update of the Guidelines for the Management of Patients With Unstable Angina/ Non-ST-Elevation Myocardial Infarction (Updating the 2007 Guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *Circulation*. 2011 May 10;123(18):2022–60. [PMID: 21444889]
- Yusuf S et al; Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. *N Engl J Med*. 2006 Apr 6;354(14):1464–76. [PMID: 16537663]

ACUTE MYOCARDIAL INFARCTION WITH ST SEGMENT ELEVATION



ESSENTIALS OF DIAGNOSIS

- ▶ Sudden but not instantaneous development of prolonged (> 30 minutes) anterior chest discomfort (sometimes felt as “gas” or pressure).
- ▶ Sometimes painless, masquerading as acute CHF, syncope, stroke, or shock.
- ▶ ECG: ST-segment elevation or left bundle branch block.
- ▶ Immediate reperfusion treatment is warranted.
- ▶ Primary PCI within 90 minutes of first medical contact is the goal and is superior to thrombolysis.
- ▶ Thrombolysis within 30 minutes of hospital presentation and 6–12 hours of onset of symptoms reduces mortality.

▶ General Considerations

STEMI results, in most cases, from an occlusive coronary thrombus at the site of a preexisting (though not necessarily severe) atherosclerotic plaque. More rarely, infarction may result from prolonged vasospasm, inadequate myocardial blood flow (eg, hypotension), or excessive metabolic demand. Very rarely, myocardial infarction may be caused by embolic occlusion, vasculitis, aortic root or coronary artery dissection, or aortitis. Cocaine is a cause of infarction, which should be considered in young individuals without risk factors. A condition that may mimic STEMI is stress cardiomyopathy (also referred to as Tako-Tsubo or apical ballooning syndrome) (see below).

ST elevation connotes an acute coronary occlusion and thus warrants immediate reperfusion therapy.

▶ Clinical Findings

A. Symptoms

1. Premonitory pain—There is usually a worsening in the pattern of angina preceding the onset of symptoms of myocardial infarction; classically the onset of angina occurs with minimal exertion or at rest.

2. Pain of infarction—Unlike anginal episodes, most infarctions occur at rest, and more commonly in the early morning. The pain is similar to angina in location and radiation but it may be more severe, and it builds up rapidly or in waves to maximum intensity over a few minutes or longer. Nitroglycerin has little effect; even opioids may not relieve the pain.

3. Associated symptoms—Patients may break out in a cold sweat, feel weak and apprehensive, and move about, seeking a position of comfort. They prefer not to lie quietly. Light-headedness, syncope, dyspnea, orthopnea, cough, wheezing, nausea and vomiting, or abdominal bloating may be present singly or in any combination.

4. Painless infarction—One-third of patients with acute myocardial infarction present without chest pain, and these patients tend to be undertreated and have poor outcomes. Older patients, women, and patients with diabetes mellitus are more likely to present without classic chest pain. As many as 25% of infarctions are detected on routine ECG without any recallable acute episode.

5. Sudden death and early arrhythmias—Of all deaths from myocardial infarction, about 50% occur before the patients arrive at the hospital, with death presumably caused by ventricular fibrillation.

B. Signs

1. General—Patients may appear anxious and sometimes are sweating profusely. The heart rate may range from marked bradycardia (most commonly in inferior infarction) to tachycardia, low cardiac output, or arrhythmia. The BP may be high, especially in former hypertensive patients, or low in patients with shock. Respiratory distress usually indicates heart failure. Fever, usually low grade, may appear after 12 hours and persist for several days.

2. Chest—The **Killip classification** is the standard way to classify heart failure in patients with acute myocardial infarction and has powerful prognostic value. Killip class I is absence of rales and S_3 , class II is rales that do not clear with coughing over one-third or less of the lung fields or presence of an S_3 , class III is rales that do not clear with coughing over more than one-third of the lung fields, and class IV is cardiogenic shock (rales, hypotension, and signs of hypoperfusion).

3. Heart—The cardiac examination may be unimpressive or very abnormal. Jugular venous distention reflects RA hypertension, and a Kussmaul sign (failure of decrease of jugular venous pressure with inspiration) is suggestive of RV infarction. Soft heart sounds may indicate LV dysfunction. Atrial gallops (S_4) are the rule, whereas ventricular gallops (S_3) are less common and indicate significant LV dysfunction. Mitral regurgitation murmurs are not uncommon and may indicate papillary muscle dysfunction or, rarely, rupture. Pericardial friction rubs are uncommon in the first 24 hours but may appear later.

4. Extremities—Edema is usually not present. Cyanosis and cold temperature indicate low output. The peripheral pulses should be noted, since later shock or emboli may alter the examination.

C. Laboratory Findings

Cardiac-specific markers of myocardial damage include quantitative determinations of CK-MB, troponin I, and troponin T. Normal cut-off levels for troponins depend on the assay used and reference ranges for the laboratory performing the test. Troponins are more sensitive and specific than CK-MB. Each of these tests may become positive as early as 4–6 hours after the onset of a myocardial infarction and should be abnormal by 8–12 hours. Circulating levels of troponins may remain elevated for 5–7 days or longer and therefore are generally not useful for evaluating suspected early reinfarction. Elevated CK-MB generally normalizes within 24 hours, thus being more helpful for evaluation of reinfarction. High-sensitivity troponin assays are becoming available that have a 10- to 100-fold lower limit of detection with high analytic precision, enabling myocardial infarction to be detected earlier. While many conditions including chronic heart failure are associated with elevated levels of the high-sensitivity troponin assays, these assays may be especially useful when negative to exclude myocardial infarction in patients complaining of chest pain.

D. ECG

The extent of the ECG abnormalities, especially the sum of the total amount of ST-segment deviation, is a good indicator of extent of acute infarction and risk of subsequent adverse events. The classic evolution of changes is from peaked (“hyperacute”) T waves, to ST-segment elevation, to Q wave development, to T wave inversion. This may occur over a few hours to several days. The evolution of new Q waves (>30 milliseconds in duration and 25% of the R wave amplitude) is diagnostic, but Q waves do not occur

in 30–50% of acute infarctions (non-Q wave infarctions). Left bundle branch block, especially when new (or not known to be old), in a patient with symptoms of an acute myocardial infarction, is considered to be a “STEMI equivalent”; reperfusion therapy is indicated for the affected patient. Concordant ST elevation (ie, ST elevation in leads with an overall positive QRS complex) with left bundle branch block is a specific finding indicating STEMI.

E. Chest Radiography

The chest radiograph may demonstrate signs of CHF, but these changes often lag behind the clinical findings. Signs of aortic dissection, including mediastinal widening, should be sought as a possible alternative diagnosis.

F. Echocardiography

Echocardiography provides convenient bedside assessment of LV global and regional function. This can help with the diagnosis and management of infarction; echocardiography has been used successfully to make judgments about admission and management of patients with suspected infarction, including in patients with ST-segment elevation or left bundle branch block of uncertain significance, since normal wall motion makes an infarction unlikely. Doppler echocardiography is generally the most convenient procedure for diagnosing postinfarction mitral regurgitation or VSD.

G. Other Noninvasive Studies

Diagnosis of myocardial infarction and extent of myocardial infarction can be assessed by various imaging studies in addition to echocardiography. **MRI** with gadolinium contrast enhancement is now the most sensitive test to detect and quantitate extent of infarction, with the ability to detect as little as 2 g of myocardial infarction. **Technetium-99m pyrophosphate scintigraphy**, when injected at least 18 hours postinfarction, complexes with calcium in necrotic myocardium to provide a “hot spot” image of the infarction. This test is insensitive to small infarctions, and false-positive studies occur, so its use is limited to patients in whom the diagnosis by ECG and enzymes is not possible—principally those who present several days after the event or have intraoperative infarctions. **Scintigraphy with thallium-201** or technetium-based perfusion tracers will demonstrate “cold spots” in regions of diminished perfusion, which usually represent infarction when the radiotracer is administered at rest, but abnormalities do not distinguish recent from old damage. All of these tests may be considered after the patient has had revascularization.

H. Hemodynamic Measurements

These can be helpful in managing the patient with suspected cardiogenic shock. Use of PA catheters, however, has generally not been associated with better outcomes and should be limited to patients with severe hemodynamic compromise (Table 10–7).

Table 10-7. Hemodynamic subsets in acute myocardial infarction.

Category	CI or SWI	PCWP	Treatment	Comment
Normal	> 2.2, < 30	< 15	None	Mortality rate < 5%.
Hyperdynamic	> 3.0, > 40	< 15	β-Blockers	Characterized by tachycardia; mortality rate < 5%.
Hypovolemic	< 2.5, < 30	< 10	Volume expansion	Hypotension, tachycardia, but preserved left ventricular function by echocardiography; mortality rate 4–8%.
Left ventricular failure	< 2.2, < 30	> 15	Diuretics	Mild dyspnea, rales, normal blood pressure; mortality rate 10–20%.
Severe failure	< 2.0, < 20	> 18	Diuretics, vasodilators	Pulmonary edema, mild hypotension; inotropic agents, IABC may be required; mortality rate 20–40%.
Shock	< 1.8, < 30	> 20	Inotropic agents, IABC	IABC early unless rapid reversal occurs; mortality rate > 60%.

CI, cardiac index (L/min/m²); SWI, stroke work index (g-m/m², calculated as [mean arterial pressure – PCWP] × stroke volume index × 0.0136); PCWP, pulmonary capillary wedge pressure (in mm Hg; pulmonary artery diastolic pressure may be used instead); IABC, intra-aortic balloon counterpulsation.

Ricciardi MJ et al. Visualization of discrete microinfarction after percutaneous coronary intervention associated with mild creatine kinase-MB elevation. *Circulation*. 2001 Jun 12;103(23):2780–3. [PMID: 11401931]

Thygesen K et al; Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction. Universal definition of myocardial infarction. *Circulation*. 2007 Nov 27;116(22):2634–53. [PMID: 17951284]

► Treatment

Table 10-5 provides a summary of the ACC/AHA Guideline recommendations for selected medical treatments.

A. Aspirin, Clopidogrel, Prasugrel, and Ticagrelor

All patients with definite or suspected myocardial infarction should receive aspirin at a dose of 162 mg or 325 mg at once regardless of whether thrombolytic therapy is being considered or the patient has been taking aspirin. Chewable aspirin provides more rapid blood levels. Patients with a definite aspirin allergy should be treated with a P2Y₁₂ inhibitor (clopidogrel, prasugrel, or ticagrelor). Clopidogrel at a loading dose of 600 mg (or 300 mg) will result in faster onset of action than the standard 75 mg maintenance dose.

Clopidogrel, in combination with aspirin, has also been shown to provide important benefits in patients with acute ST elevation myocardial infarction. In the CLARITY trial, a loading dose of 300 mg of clopidogrel given with thrombolytic therapy, followed by 75 mg a day, led to substantial improvement in coronary patency on catheterization 3.5 days following thrombolysis. Moreover, there was no increase in serious bleeding in this population of patients up to 75 years of age. The COMMIT/CCS-2 trial randomized over 45,000 patients in China with acute myocardial infarction to clopidogrel 75 mg a day or placebo, and found a small but statistically significant reduction in early death, myocardial reinfarction, and stroke, with no excess in

major bleeding. Thus, guidelines now call for clopidogrel to be added to aspirin to all patients with STEMI, regardless of whether or not reperfusion is given, and continued for at least 14 days, and generally for 1 year. For patients who have received thrombolytic therapy but will undergo angiography in the first day or two, the early benefits of clopidogrel need to be weighed against the necessary delay in bypass surgery for approximately 5 days for those patients found to require surgical revascularization.

Compared with standard dose clopidogrel, “double dose” clopidogrel (600 mg oral loading dose followed by 150 mg orally daily) for 1 week reduces stent thrombosis at the cost of a modest increase in bleeding. In the TRITON study, prasugrel was shown to be of greater benefit than clopidogrel in reducing thrombotic events in the subgroup of patients with STEMI, including a 50% reduction in stent thrombosis. Prasugrel is contraindicated in patients with history of stroke. In the PLATO trial, ticagrelor was shown to be of greater benefit than clopidogrel in reducing cardiovascular death, myocardial infarction, and stroke as well as in reducing stent thrombosis.

B. Reperfusion Therapy

The current recommendation is to treat patients with STEMI who seek medical attention within 12 hours of the onset of symptoms with reperfusion therapy, either primary PCI or thrombolytic therapy. Patients without ST-segment elevation (previously labeled “non-Q wave” infarctions) do not benefit, and may derive harm, from thrombolysis.

1. Primary percutaneous coronary intervention—Immediate coronary angiography and primary PCI (including stenting) of the infarct-related artery have been shown to be superior to thrombolysis when done by experienced operators in high-volume centers with rapid time from first medical contact to intervention (“door-to-balloon”). US and European guidelines call for first medical contact or “door-to-balloon” times of < 90 minutes.

Several trials have shown that if efficient transfer systems are in place, transfer of patients with acute myocardial infarction from hospitals without primary PCI capability to hospitals with primary PCI capability with first door-to-device times of < 120 minutes can improve outcome compared with thrombolytic therapy at the presenting hospital, although this requires sophisticated systems to ensure rapid identification, transfer, and PCI. Primary PCI is the approach of choice in patients with absolute and many relative contraindications to thrombolytic therapy. The results of this approach in specialized centers are excellent, exceeding those obtainable by thrombolytic therapy even in good candidates, but this experience may not be generalizable to centers and operators with less experience or expertise. Stenting—generally in conjunction with either bivalirudin preferred over the platelet glycoprotein IIb/IIIa antagonist abciximab (based on the HORIZONS trial)—is standard for patients with acute myocardial infarction. Although randomized trials have shown a benefit with regards to fewer repeat interventions for restenosis with use of drug-eluting stents in STEMI patients, bare metal stents are used more commonly since the patient's ability to obtain and comply with P2Y₁₂ inhibitor therapy is often not known at the time of PCI. In the subgroup of patients with cardiogenic shock, early catheterization and percutaneous or surgical revascularization are the preferred management and have been shown to reduce mortality. Because an acute interventional approach carries a lower risk of hemorrhagic complications including intracranial hemorrhage, it may also be the preferred strategy in many older patients (see Tables 10–5 and 10–6 for factors to consider in choosing thrombolytic therapy or primary PCI).

Glycoprotein IIb/IIIa inhibitors, and specifically abciximab, have been shown to reduce major thrombotic events, and possibly mortality, when added to heparin for patients undergoing primary PCI. The HORIZONS trial showed that compared with unfractionated heparin plus abciximab, bivalirudin (with provisional use of “bail-out” IIb/IIIa inhibitors) results in similar rates of thrombotic events and 40% less bleeding. This appeared to be accompanied by lower mortality at 30 days and 1 year, providing further support for the safety and efficacy of bivalirudin in this setting.

In part because patients in the United States who are transferred for primary PCI tend to have long delays from first hospital arrival to balloon inflation, there has been interest in developing “facilitated” PCI whereby a combination of medications (full or reduced dose fibrinolytic agents with or without glycoprotein IIb/IIIa inhibitors) is given followed by immediate PCI. However, recent trials (and overviews of completed trials) have shown either no benefit or harm with this approach. Thus, patients should be treated either with fibrinolytic agents (and immediate rescue PCI for reperfusion failure) or with primary PCI, if it can be done promptly as outlined in the ACC/AHA and European guidelines. Timely access to most appropriate reperfusion, including primary PCI, can be expanded with development of regional systems of care, including emergency medical systems and networks of hospitals. Patients treated with fibrinolytic therapy appear to have improved

outcomes if transferred for routine coronary angiography and PCI within 24 hours. The American Heart Association has a program called Mission: Lifeline to support systems development (see <http://www.heart.org/missionlifeline>).

2. Thrombolytic therapy

A. BENEFIT—Thrombolytic therapy reduces mortality and limits infarct size in patients with acute myocardial infarction associated with ST-segment elevation (defined as ≥ 0.1 mV in two inferior or lateral leads or two contiguous precordial leads), or with left bundle branch block (not known to be old). The greatest benefit occurs if treatment is initiated within the first 3 hours, when up to a 50% reduction in mortality rate can be achieved. The magnitude of benefit declines rapidly thereafter, but a 10% relative mortality reduction can be achieved up to 12 hours after the onset of chest pain. The survival benefit is greatest in patients with large—usually anterior—infarctions.

B. CONTRAINDICATIONS—Major bleeding complications occur in 0.5–5% of patients, the most serious of which is intracranial hemorrhage. The major risk factors for intracranial bleeding are older age (> 65 years), hypertension at presentation (especially over 180/110 mm Hg), low body weight (< 70 kg), and the use of clot-specific thrombolytic agents (alteplase, reteplase, tenecteplase). Although patients over age 75 years have a much higher mortality rate with acute myocardial infarction and therefore may derive greater benefit, the risk of severe bleeding is also higher, particularly among patients with risk factors for intracranial hemorrhage, such as severe hypertension or recent stroke. Patients presenting more than 12 hours after the onset of chest pain may also derive a small benefit, particularly if pain and ST-segment elevation persist, but rarely does this benefit outweigh the attendant risk.

Contraindications to thrombolytic therapy include previous hemorrhagic stroke, other strokes or cerebrovascular events within 1 year, known intracranial neoplasm, recent head trauma (including minor trauma), active internal bleeding (excluding menstruation), or suspected aortic dissection. Relative contraindications are BP > 180/110 mm Hg at presentation, other intracerebral pathology not listed above as a contraindication, known bleeding diathesis, trauma (including minor head trauma) within 2–4 weeks, major surgery within 3 weeks, prolonged (> 10 minutes) or traumatic cardiopulmonary resuscitation, recent (within 2–4 weeks) internal bleeding, noncompressible vascular punctures, active diabetic retinopathy, pregnancy, active peptic ulcer disease, a history of severe hypertension, current use of anticoagulants (INR > 2.0–3.0), and (for streptokinase) prior allergic reaction or exposure to streptokinase or anistreplase within 2 years.

C. THROMBOLYTIC AGENTS—The following thrombolytic agents are available for acute myocardial infarction and are characterized in Table 10–8.

Alteplase (recombinant tissue plasminogen activator; t-PA) is a naturally occurring plasminogen activator that is modestly fibrin specific, resulting in about a 50% reduction in circulating fibrinogen. In the first GUSTO trial, which compared a 90-minute dosing of t-PA (with unfractionated

Table 10-8. Thrombolytic therapy for acute myocardial infarction.

	Alteplase; Tissue Plasminogen Activator (t-PA)	Retepase	Tenecteplase (TNK-t-PA)	Streptokinase
Source	Recombinant DNA	Recombinant DNA	Recombinant DNA	Group C streptococcus
Half-life	5 minutes	15 minutes	20 minutes	20 minutes
Usual dose	100 mg	20 units	40 mg	1.5 million units
Administration	Initial bolus of 15 mg, followed by 50 mg infused over the next 30 minutes and 35 mg over the following 60 minutes	10 units as a bolus over 2 minutes, repeated after 30 minutes	Single weight-adjusted bolus, 0.5 mg/kg	750,000 units over 20 minutes followed by 750,000 units over 40 minutes
Anticoagulation after infusion	Aspirin, 325 mg daily; heparin, 5000 units as bolus, followed by 1000 units per hour infusion, subsequently adjusted to maintain PTT 1.5-2 times control	Aspirin, 325 mg; heparin as with t-PA	Aspirin, 325 mg daily	Aspirin, 325 mg daily; there is no evidence that adjunctive heparin improves outcome following streptokinase
Clot selectivity	High	High	High	Low
Fibrinogenolysis	+	+	+	+++
Bleeding	+	+	+	+
Hypotension	+	+	+	+++
Allergic reactions	0	0	+	++
Reocclusion	10-30%	—	5-20%	5-20%
Approximate cost ¹	\$4779.71	\$5211.86	\$3238.76	Not available in the United States

¹Average wholesale price (AWP, for AB-rated generic when available) for quantity listed.

Source: *Red Book 2010*, Thomson Reuters (Healthcare) Inc. AWP may not accurately represent the actual pharmacy cost because wide contractual variations exist among institutions.

PTT, partial thromboplastin time.

heparin) with streptokinase, the 30-day mortality rate with t-PA was one absolute percentage point lower (one additional life saved per 100 patients treated), though there was also a small *increase* in the rate of intracranial hemorrhage. An angiographic substudy confirmed a higher 90-minute patency rate and a higher rate of normal (TIMI grade 3) flow in patients.

Retepase is a recombinant deletion mutant of t-PA that is slightly less fibrin specific. In comparative trials, it appears to have efficacy similar to that of alteplase, but it has a longer duration of action and can be administered as two boluses 30 minutes apart.

Tenecteplase (TNK-t-PA) is a genetically engineered substitution mutant of native t-PA that has reduced plasma clearance, increased fibrin sensitivity, and increased resistance to plasminogen activator inhibitor-1. It can be given as a single weight-adjusted bolus. In a large comparative trial, this agent was equivalent to t-PA with regard to efficacy and resulted in significantly less noncerebral bleeding.

Streptokinase is commonly used elsewhere in the world, but not commonly used in the United States since it is somewhat less effective at opening occluded arteries and less effective at reducing mortality. It is non-fibrin-specific, causes depletion of circulating fibrinogen, and has a tendency to induce hypotension, particularly if infused rapidly.

This can be managed by slowing or interrupting the infusion and administering fluids. There is controversy as to whether adjunctive heparin is beneficial in patients given streptokinase, unlike its administration with the more clot-specific agents. Allergic reactions, including anaphylaxis, occur in 1-2% of patients, and this agent should generally not be administered to patients with prior exposure.

(1) Selection of a thrombolytic agent—In the United States, most patients are treated with alteplase, reteplase, or tenecteplase. The differences in efficacy between them are small compared with the potential benefit of treating a greater proportion of appropriate candidates in a more prompt manner. The principal objective should be to administer a thrombolytic agent within 30 minutes of presentation—or even during transport. The ability to administer tenecteplase as a single bolus is an attractive feature that may facilitate earlier treatment. The combination of a reduced-dose thrombolytic given with a platelet glycoprotein IIb/IIIa antagonist has been investigated in several trials, with no evidence of reduction in mortality but a modest increase in bleeding complications.

(2) Postthrombolytic management—After completion of the thrombolytic infusion, aspirin (81-325 mg/d) and heparin should be continued. The 2008 ACC/AHA guidelines recommend continued anticoagulation for the duration of

the hospital stay (or up to 8 days) with some anticoagulant, with advantages favoring either enoxaparin or fondaparinux.

(A) UNFRACTIONATED HEPARIN—Anticoagulation with intravenous heparin (initial dose of 60 units/kg bolus to a maximum of 4000 units, followed by an infusion of 12 units/kg/min to a maximum of 1000 units, then adjusted to maintain an activated partial thromboplastin time [aPTT] of 50–75 seconds beginning with an aPTT drawn 3 hours after thrombolytic) is continued for at least 48 hours after alteplase, reteplase, or tenecteplase, and with continuation of some anticoagulant until revascularization (if performed) or until hospital discharge (or day 8).

(B) LOW-MOLECULAR-WEIGHT HEPARIN—In the EXTRACT trial, enoxaparin significantly reduced death and myocardial infarction at day 30 (compared with unfractionated heparin), at the expense of a modest increase in bleeding. In patients younger than age 75, enoxaparin was given as a 30 mg intravenous bolus and 1 mg/kg every 12 hours; in patients age 75 years and older, it was given with no bolus and 0.75 mg/kg intravenously every 12 hours. This appeared to attenuate the risk of intracranial hemorrhage in the elderly that had been seen with full-dose enoxaparin. Another antithrombotic option is fondaparinux, given at a dose of 2.5 mg subcutaneously once a day. In the OASIS-6 trial, it resulted in significant reductions in death and reinfarction when compared with control (unfractionated heparin when indicated, otherwise placebo). Similar to the findings of the OASIS-5 trial, fondaparinux tended to result in less bleeding, despite its longer duration compared with heparin and despite its comparison to placebo in about half of the enrolled patients. There was no benefit of fondaparinux among patients undergoing primary PCI, and fondaparinux is not recommended as a sole anticoagulant during PCI due to risk of catheter thrombosis.

For all patients with acute myocardial infarction treated with intensive antithrombotic therapy, prophylactic treatment with proton pump inhibitors or antacids and an H₂-blocker is advisable, although certain proton pump inhibitors, such as omeprazole and esomeprazole, decrease the effect of clopidogrel.

3. Assessment of myocardial reperfusion, recurrent ischemic pain, reinfarction—Myocardial reperfusion can be recognized clinically by the early cessation of pain and the resolution of ST-segment elevation. Although at least 50% resolution of ST-segment elevation by 90 minutes may occur without coronary reperfusion, ST resolution is a strong predictor of better outcome. Even with anticoagulation, 10–20% of reperfused vessels will reocclude during hospitalization, although reocclusion and reinfarction appear to be reduced following intervention. Reinfarction, indicated by recurrence of pain and ST-segment elevation, can be treated by readministration of a thrombolytic agent or immediate angiography and PCI.

C. General Measures

Cardiac care unit monitoring should be instituted as soon as possible. Patients without complications can be transferred

to a telemetry unit after 24 hours. Activity should initially be limited to bed rest but can be advanced within 24 hours. Progressive ambulation should be started after 24–72 hours if tolerated. For patients without complications, discharge by day 4 appears to be appropriate. Low-flow oxygen therapy (2–4 L/min) should be given if oxygen saturation is reduced.

D. Analgesia

An initial attempt should be made to relieve pain with sublingual nitroglycerin. However, if no response occurs after two or three tablets, intravenous opioids provide the most rapid and effective analgesia and may also reduce pulmonary congestion. Morphine sulfate, 4–8 mg, or meperidine, 50–75 mg, should be given. Subsequent small doses can be given every 15 minutes until pain abates.

Nonsteroidal anti-inflammatory agents, other than aspirin, should be avoided during hospitalization for STEMI due to increased risk of mortality, myocardial rupture, hypertension, heart failure, and kidney injury with their use.

E. β -Adrenergic Blocking Agents

Although trials have shown modest short-term benefit from β -blockers given immediately after acute myocardial infarction, it has not been clear that intravenous β -blockers provide an advantage over simply beginning an oral β -blocker, which should be started during the first 24 hours if there are no contraindications. The Chinese COMMIT/CCS-2 trial involving 45,000 patients found no overall benefit to intravenous followed by oral metoprolol; the aggressive dosing (three 5 mg intravenous boluses followed by 200 mg/d orally) appeared to prevent reinfarction at the cost of increasing shock, with overall harm in patients presenting with heart failure. Thus, early β -blockade should be avoided in patients with any degree of heart failure, evidence of low output state, increased risk of cardiogenic shock, or other relative contraindications to β -blockade. The CAPRICORN trial showed the benefits of carvedilol (beginning at 6.25 mg twice a day, titrated to 25 mg twice a day) following the acute phase of large myocardial infarction with contemporary care.

F. Nitrates

Nitroglycerin is the agent of choice for continued or recurrent ischemic pain and is useful in lowering BP or relieving pulmonary congestion. However, routine nitrate administration is not recommended, since no improvement in outcome has been observed in the ISIS-4 or GISSI-3 trials, in which a total of over 70,000 patients were randomized to nitrate treatment or placebo. Nitrates should be avoided in patients who received phosphodiesterase inhibitors (sildenafil, vardenafil, and tadalafil) in the prior 24 hours.

G. Angiotensin-Converting Enzyme (ACE) Inhibitors

A series of trials (SAVE, AIRE, SMILE, TRACE, GISSI-III, and ISIS-4) have shown both short- and long-term

improvement in survival with ACE inhibitor therapy. The benefits are greatest in patients with EF \leq 40%, large infarctions, or clinical evidence of heart failure. Because substantial amounts of the survival benefit occur on the first day, ACE inhibitor treatment should be commenced early in patients without hypotension, especially patients with large or anterior myocardial infarction. Given the benefits of ACE-inhibitors for patients with vascular disease, it is reasonable to use ACE-inhibitors for all patients following STEMI who do not have contraindications.

H. Angiotensin Receptor Blockers

Although there has been inconsistency in the effects of different ARBs on mortality for patients post-myocardial infarction with heart failure and/or LV dysfunction, the VALIANT trial showed that valsartan 160 mg twice a day is equivalent to captopril in reducing mortality. Thus, valsartan should be used for all patients with ACE inhibitor intolerance, and is a reasonable, albeit more expensive, alternative to captopril. The combination of captopril and valsartan (at reduced dose) was no better than either agent alone and resulted in more side effects.

I. Aldosterone Antagonists

The RALES trial showed that spironolactone can reduce the mortality rate of patients with advanced heart failure, and the EPHESUS trial showed a 15% relative risk reduction in mortality with eplerenone for patients post-myocardial infarction with LV dysfunction and either heart failure or diabetes. Kidney dysfunction or hyperkalemia are contraindications, and patients must be monitored carefully for development of hyperkalemia.

J. Antiarrhythmic Prophylaxis

The incidence of ventricular fibrillation in hospitalized patients is approximately 5%, with 80% of episodes occurring in the first 12–24 hours. Prophylactic lidocaine infusions (1–2 mg/min) prevent most episodes, but this therapy has not reduced the mortality rate and it increases the risk of asystole, so this approach is no longer recommended except in patients with sustained ventricular tachycardia.

K. Calcium Channel Blockers

There are no studies to support the routine use of calcium channel blockers in most patients with acute myocardial infarction—and indeed, they have the potential to exacerbate ischemia and cause death from reflex tachycardia or myocardial depression. Long-acting calcium channel blockers should generally be reserved for management of hypertension or ischemia as second- or third-line drugs after β -blockers and nitrates.

L. Long-Term Antithrombotic Therapy

Discharge on aspirin, 81–325 mg/d, since it is highly effective, inexpensive, and well tolerated, is a key quality indicator

of myocardial infarction care. In the WARIS-II trial, long-term anticoagulation with warfarin post-myocardial infarction was associated with a reduction in the composite of death, reinfarction, and stroke. However, whether the results of this trial are transferable to the United States where anticoagulation services may be less organized and effective than in Norwegian hospitals is unknown. In the CURE trial, clopidogrel, 75 mg/d, (in addition to aspirin) for 3–12 months for non-ST elevation acute coronary syndromes resulted in a similar 20% relative risk reduction in cardiovascular death, myocardial infarction, and stroke, and continuing clopidogrel for 1 year for patients with STEMI is reasonable, regardless of whether they underwent reperfusion therapy. The TRITON trial showed that prasugrel was more beneficial than clopidogrel in reducing ischemic events in patients undergoing PCI, but it resulted in more bleeding. The PLATO trial showed that long-term therapy with ticagrelor and low-dose aspirin was superior to clopidogrel and aspirin.

Patients who have received a coronary stent and who require warfarin anticoagulation present a particular challenge, since “triple therapy” with aspirin, clopidogrel, and warfarin has a high risk of bleeding. Triple therapy should be (1) limited to patients with a clear indication for warfarin (such as CHADS2 score of 2 to 3 or more), (2) used for the shortest period of time (such as 1 month after placement of bare metal stent; drug-eluting stents that would require longer clopidogrel duration should be avoided), (3) used with low-dose aspirin and with strategies to reduce risk of bleeding (eg, proton pump inhibitors for patients with history of gastrointestinal bleeding).

M. Coronary Angiography

For patients who do not reperfuse based on lack of at least 50% resolution of ST elevation, rescue angioplasty should be performed and has been shown to reduce the composite of death, reinfarction, stroke, or severe heart failure. According to the evidence in the European Guidelines and the updated recommendations of the AHA/ACC for high-risk patients, patients treated with coronary angiography and PCI 3–24 hours after fibrinolytic therapy showed improved outcomes. Patients with recurrent ischemic pain prior to discharge should undergo catheterization and, if indicated, revascularization. Asymptomatic, clinically stable patients should undergo predischARGE stress testing to determine whether residual jeopardized myocardium is present. This can be accomplished by submaximal exercise or pharmacologic stress scintigraphy. Those with significantly positive tests or a low threshold for symptomatic ischemia should undergo angiography and revascularization where feasible. PCI of a totally occluded infarct-related artery > 24 hours after STEMI should generally not be performed in asymptomatic patients with one or two vessel disease without evidence of severe ischemia.

► When to Refer

All patients with acute myocardial infarction should be referred to a cardiologist.

- Antman EM et al; ExTRACT-TIMI 25 Investigators. Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction. *N Engl J Med*. 2006 Apr 6;354(14):1477–88. [PMID: 16537665]
- Body R et al. Rapid exclusion of acute myocardial infarction in patients with undetectable troponin using a high-sensitivity assay. *J Am Coll Cardiol*. 2011 Sep 20;58(13):1332–9. [PMID: 21920261]
- Chen SF et al. Use of drug-eluting versus bare-metal stents in ST-segment elevation myocardial infarction. *J Invasive Cardiol*. 2009 Nov;21(11):E206–12. [PMID: 19901420]
- Fox KA et al; FIR Collaboration. Long-term outcome of a routine versus selective invasive strategy in patients with non-ST-segment elevation acute coronary syndrome a meta-analysis of individual patient data. *J Am Coll Cardiol*. 2010 Jun 1;55(22):2435–45. [PMID: 20359842]
- Hansen ML et al. Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. *Arch Intern Med*. 2010 Sep 13;170(16):1433–41. [PMID: 20837828]
- Hochman JS et al; Occluded Artery Trial Investigators. Coronary intervention for persistent occlusion after myocardial infarction. *N Engl J Med*. 2006 Dec 7;355(23):2395–407. [PMID: 17105759]
- Keeley EC et al. Comparison of primary and facilitated percutaneous coronary interventions for ST-elevation myocardial infarction: quantitative review of randomised trials. *Lancet*. 2006 Feb 18;367(9510):579–88. [PMID: 16488801]
- Kushner FG et al. 2009 Focused Updates: ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction (updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (updating the 2005 Guideline and 2007 Focused Update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *Circulation*. 2009 Dec 1;120(22):2271–306. Erratum in: *Circulation*. 2010 Mar 30;121(12):e257. Dosage error in article text. [PMID: 19923169]
- Levine GN et al. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. *Circulation*. 2011 Dec 6;124(23):e574–651. [PMID: 22064601]
- Mehta S et al. Adjunct therapy in STEMI intervention. *Cardiol Clin*. 2010 Feb;28(1):107–25. [PMID: 19962053]
- Pfeffer MA et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. *N Engl J Med*. 2003 Nov 13;349(20):1893–906. [PMID: 14610160]
- Stone GW et al; HORIZONS-AMI Trial Investigators. Bivalirudin during primary PCI in acute myocardial infarction. *N Engl J Med*. 2008 May 22;358(21):2218–30. [PMID: 18499566]
- Torpy JM et al. JAMA patient page. Myocardial infarction. *JAMA*. 2008 Jan 30;299(4):476. [PMID: 18230786]
- Wijns W et al. Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). *Eur Heart J*. 2010 Oct;31(20):2501–55. [PMID: 20802248]
- Yusuf S et al; OASIS-6 Trial Group. Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. *JAMA*. 2006 Apr 5;295(13):1519–30. [PMID: 16537725]

► Complications

A variety of complications can occur after myocardial infarction even when treatment is initiated promptly.

A. Postinfarction Ischemia

In clinical trials of thrombolysis, recurrent ischemia occurred in about one-third of patients, was more common following non-ST elevation myocardial infarction than after STEMI, and had important short- and long-term prognostic implications. Vigorous medical therapy should be instituted, including nitrates and β -blockers as well as aspirin 81–325 mg/d, anticoagulant therapy (unfractionated heparin, enoxaparin, or fondaparinux) and clopidogrel. Most patients with postinfarction angina—and all who are refractory to medical therapy—should undergo early catheterization and revascularization by PCI or CABG.

B. Arrhythmias

Abnormalities of rhythm and conduction are common.

1. Sinus bradycardia—This is most common in inferior infarctions or may be precipitated by medications. Observation or withdrawal of the offending agent is usually sufficient. If accompanied by signs of low cardiac output, atropine, 0.5–1 mg intravenously, is usually effective. Temporary pacing is rarely required.

2. Supraventricular tachyarrhythmias—Sinus tachycardia is common and may reflect either increased adrenergic stimulation or hemodynamic compromise due to hypovolemia or pump failure. In the latter, β -blockade is contraindicated. Supraventricular premature beats are common and may be premonitory for atrial fibrillation. Electrolyte abnormalities and hypoxia should be corrected and causative agents (especially aminophylline) stopped. Atrial fibrillation should be rapidly controlled or converted to sinus rhythm. Intravenous β -blockers such as metoprolol (2.5–5 mg/h) or short-acting esmolol (50–200 mcg/kg/min) are the agents of choice if cardiac function is adequate. Intravenous diltiazem (5–15 mg/h) may be used if β -blockers are contraindicated or ineffective. Digoxin (0.5 mg as initial dose, then 0.25 mg every 90–120 minutes [up to 1–1.25 mg] for a loading dose, followed by 0.25 mg daily if kidney function is normal) is preferable if heart failure is present with atrial fibrillation, but the onset of action is delayed. Electrical cardioversion (commencing with 100 J) may be necessary if atrial fibrillation is complicated by hypotension, heart failure, or ischemia, but the arrhythmia often recurs. Amiodarone (150 mg intravenous bolus and then 15–30 mg/h intravenously, or rapid oral loading with 400 mg three times daily) may be helpful to restore or maintain sinus rhythm.

3. Ventricular arrhythmias—Ventricular arrhythmias are most common in the first few hours after infarction and are a marker of high risk. Ventricular premature beats may be premonitory for ventricular tachycardia or fibrillation but generally should not be treated in the absence of frequent or sustained ventricular tachycardia. Lidocaine is *not* recommended as a prophylactic measure. Toxicity (tremor, anxiety, confusion, seizures) is common, especially in older patients and those with hypotension, heart failure, or liver disease.

Sustained ventricular tachycardia should be treated with a 1 mg/kg bolus of lidocaine if the patient is stable or by electrical cardioversion (100–200 J) if not. If the arrhythmia cannot be suppressed with lidocaine, procainamide (100 mg boluses over 1–2 minutes every 5 minutes to a cumulative dose of 750–1000 mg) or intravenous amiodarone (150 mg over 10 minutes, which may be repeated as needed, followed by 360 mg over 6 hours and then 540 mg over 18 hours) should be initiated, followed by an infusion of 20–80 mg/kg/min. Ventricular fibrillation is treated electrically (300–400 J). Unresponsive ventricular fibrillation should be treated with additional amiodarone and repeat cardioversion while cardiopulmonary resuscitation (CPR) is administered.

Accelerated idioventricular rhythm is a regular, wide-complex rhythm at a rate of 70–100/min. It may occur with or without reperfusion and should not be treated with antiarrhythmics, which could cause asystole.

4. Conduction disturbances—All degrees of AV block may occur in the course of acute myocardial infarction. Block at the level of the AV node is more common than infranodal block and occurs in approximately 20% of inferior myocardial infarctions. First-degree block is the most common and requires no treatment. Second-degree block is usually of the Mobitz type I form (Wenckebach), is often transient, and requires treatment only if associated with a heart rate slow enough to cause symptoms. Complete AV block occurs in up to 5% of acute inferior infarctions, usually is preceded by Mobitz I second-degree block, and generally resolves spontaneously, though it may persist for hours to several weeks. The escape rhythm originates in the distal AV node or AV junction and hence has a narrow QRS complex and is reliable, albeit often slow (30–50 beats/min). Treatment is often necessary because of resulting hypotension and low cardiac output. Intravenous atropine (1 mg) usually restores AV conduction temporarily, but if the escape complex is wide or if repeated atropine treatments are needed, temporary ventricular pacing is indicated. The prognosis for these patients is only slightly worse than for patients in whom AV block did not develop.

In anterior infarctions, the site of block is distal, below the AV node, and usually a result of extensive damage of the His-Purkinje system and bundle branches. New first-degree block (prolongation of the PR interval) is unusual in anterior infarction; Mobitz type II AV block or complete heart block may be preceded by intraventricular conduction defects or may occur abruptly. The escape rhythm, if present, is an unreliable wide-complex idioventricular rhythm. Urgent ventricular pacing is mandatory, but even with successful pacing, morbidity and mortality are high because of the extensive myocardial damage. New conduction abnormalities such as right or left bundle branch block or fascicular blocks may presage progression, often sudden, to second- or third-degree AV block. Temporary ventricular pacing is recommended for new-onset alternating bilateral bundle branch block, bifascicular block, or bundle branch block with worsening first-degree AV block. Patients with anterior infarction who progress to second- or third-degree block even transiently should be considered for insertion of a prophylactic permanent ventricular pacemaker before discharge.

C. Myocardial Dysfunction

The severity of cardiac dysfunction is proportionate to the extent of myocardial necrosis but is exacerbated by preexisting dysfunction and ongoing ischemia. Persons with hypotension not responsive to fluid resuscitation or refractory heart failure or cardiogenic shock should be considered for urgent echocardiography to assess left and right ventricular function and for mechanical complications, right heart catheterization, and continuous measurements of arterial pressure. These measurements permit the accurate assessment of volume status and may facilitate decisions about volume resuscitation, selective use of pressors and inotropes, and mechanical support. Table 10–7 categorizes patients based on these hemodynamic findings.

1. Acute LV failure—Dyspnea, diffuse rales, and arterial hypoxemia usually indicate LV failure. General measures include supplemental oxygen to increase arterial saturation to above 95% and elevation of the trunk. Diuretics are usually the initial therapy unless RV infarction is present. Intravenous furosemide (10–40 mg) or bumetanide (0.5–1 mg) is preferred because of the reliably rapid onset and short duration of action of these drugs. Higher dosages can be given if an inadequate response occurs. Morphine sulfate (4 mg intravenously followed by increments of 2 mg) is valuable in acute pulmonary edema.

Diuretics are usually effective; however, because most patients with acute infarction are not volume overloaded, the hemodynamic response may be limited and may be associated with hypotension. Vasodilators will reduce PCWP and improve cardiac output by a combination of venodilation (increasing venous capacitance) and arteriolar dilation (reducing afterload and LV wall stress). In mild heart failure, sublingual isosorbide dinitrate (2.5–10 mg every 2 hours) or nitroglycerin ointment (6.25–25 mg every 4 hours) may be adequate to lower PCWP. In more severe failure, especially if cardiac output is reduced and BP is normal or high, sodium nitroprusside may be the preferred agent. It should be initiated only with arterial pressure monitoring; the initial dosage should be low (0.25 mcg/kg/min) to avoid excessive hypotension, but the dosage can be increased by increments of 0.5 mcg/kg/min every 5–10 minutes up to 5–10 mcg/kg/min until the desired hemodynamic response is obtained. Excessive hypotension (mean BP < 65–75 mm Hg) or tachycardia (>10/min increase) should be avoided.

Intravenous nitroglycerin (starting at 10 mcg/min) also may be effective but may lower PCWP with less hypotension. Oral or transdermal vasodilator therapy with nitrates or ACE inhibitors is often necessary after the initial 24–48 hours (see below).

Inotropic agents should be avoided if possible, because they often increase heart rate and myocardial oxygen requirements and worsen clinical outcomes. Dobutamine has the best hemodynamic profile, increasing cardiac output and modestly lowering PCWP, usually without excessive tachycardia, hypotension, or arrhythmias. The initial dosage is 2.5 mcg/kg/min, and it may be increased by similar increments up to 15–20 mcg/kg/min at intervals of

5–10 minutes. Dopamine is more useful in the presence of hypotension (see below), since it produces peripheral vasoconstriction, but it has a less beneficial effect on PCWP. Digoxin has not been helpful in acute infarction except to control the ventricular response in atrial fibrillation, but it may be beneficial if chronic heart failure persists.

2. Hypotension and shock—Patients with hypotension (systolic BP < 90 mm Hg, individualized depending on prior BP) and signs of diminished perfusion (low urinary output, confusion, cold extremities) that does not respond to fluid resuscitation should be presumed to have cardiogenic shock and should be considered for urgent catheterization and revascularization, intra-aortic balloon pump (IABP) support, and hemodynamic monitoring with a PA catheter. Up to 20% will have findings indicative of intravascular hypovolemia (due to diaphoresis, vomiting, decreased venous tone, medications—such as diuretics, nitrates, morphine, β -blockers, calcium channel blockers, and thrombolytic agents—and lack of oral intake). These should be treated with successive boluses of 100 mL of normal saline until PCWP reaches 15–18 mm Hg to determine whether cardiac output and BP respond. Pericardial tamponade due to hemorrhagic pericarditis (especially after thrombolytic therapy or cardiopulmonary resuscitation) or ventricular rupture should be considered and excluded by echocardiography if clinically indicated. RV infarction, characterized by a normal PCWP but elevated RA pressure, can produce hypotension. This is discussed below.

Most patients with cardiogenic shock will have moderate to severe LV systolic dysfunction, with a mean EF of 30% in the SHOCK trial. If hypotension is only modest (systolic pressure > 90 mm Hg) and the PCWP is elevated, diuretics and an initial trial of nitroprusside (see above for dosing) are indicated. If the BP falls, inotropic support will need to be added or substituted. Such patients should generally also be treated with IABP counterpulsation, which can both reduce myocardial energy requirements (systolic unloading) and improve diastolic coronary blood flow.

Dopamine is generally considered to be the most appropriate pressor for cardiogenic hypotension. It should be initiated at a rate of 2–4 mcg/kg/min and increased at 5-minute intervals to the appropriate hemodynamic end point. At low dosages (< 5 mcg/kg/min), it improves renal blood flow; at intermediate dosages (2.5–10 mcg/kg/min), it stimulates myocardial contractility; at higher dosages (> 8 mcg/kg/min), it is a potent α_1 -adrenergic agonist. In general, BP and cardiac index rise, but PCWP does not fall. Dopamine may be combined with nitroprusside or dobutamine (see above for dosing), or the latter may be used in its place if hypotension is not severe. Norepinephrine (0.1–0.5 mcg/kg/min) is generally reserved for failure of other vasopressors, since epinephrine produces less vasoconstriction and does not increase coronary perfusion pressure (aortic diastolic pressure), but it does tend to worsen the balance between myocardial oxygen delivery and utilization.

Patients with cardiogenic shock not due to hypovolemia have a poor prognosis, with 30-day mortality rates of

40–80%. If they do not respond rapidly, IABP should be instituted to both reduce myocardial energy requirements (systolic unloading) and improve diastolic coronary blood flow. Surgically implanted (or percutaneous) ventricular assist devices may be used in refractory cases. Emergent cardiac catheterization and coronary angiography followed by percutaneous or surgical revascularization offer the best chance of survival.

D. RV Infarction

RV infarction is present in one-third of patients with inferior wall infarction but is clinically significant in < 50% of these. It presents as hypotension with relatively preserved LV function and should be considered whenever patients with inferior infarction exhibit low BP, raised venous pressure, and clear lungs. Hypotension is often exacerbated by medications that decrease intravascular volume or produce venodilation, such as diuretics, nitrates, and narcotics. RA pressure and jugular venous pulsations are high, while PCWP is normal or low and the lungs are clear. The diagnosis is suggested by ST-segment elevation in right-sided anterior chest leads, particularly RV_4 . The diagnosis can be confirmed by echocardiography or hemodynamic measurements. Treatment consists of fluid loading to improve LV filling, and inotropic agents if necessary.

E. Mechanical Defects

Partial or complete rupture of a papillary muscle or of the interventricular septum occurs in < 1% of acute myocardial infarctions and carries a poor prognosis. These complications occur in both anterior and inferior infarctions, usually 3–7 days after the acute event. They are detected by the appearance of a new systolic murmur and clinical deterioration, often with pulmonary edema. The two lesions are distinguished by the location of the murmur (apical versus parasternal) and by Doppler echocardiography. Hemodynamic monitoring is essential for appropriate management and demonstrates an increase in oxygen saturation between the RA and PA in VSD and, often, a large v wave with mitral regurgitation. Treatment by nitroprusside and, preferably, IABC reduces the regurgitation or shunt, but surgical correction is mandatory. In patients remaining hemodynamically unstable or requiring continuous parenteral pharmacologic treatment or counterpulsation, early surgery is recommended, though mortality rates are high (15% to nearly 100%, depending on residual ventricular function and clinical status). Patients who are stabilized medically can have delayed surgery with lower risks (10–25%), although this may be due to the death of sicker patients, some of whom may have been saved by earlier surgery.

F. Myocardial Rupture

Complete rupture of the LV free wall occurs in < 1% of patients and usually results in immediate death. It occurs 2–7 days postinfarction, usually involves the anterior wall, and is more frequent in older women. Incomplete or gradual rupture may be sealed off by the pericardium, creating a **pseudoaneurysm**. This may be

recognized by echocardiography, radionuclide angiography, or LV angiography, often as an incidental finding. It demonstrates a narrow-neck connection to the LV. Early surgical repair is indicated, since delayed rupture is common.

G. LV Aneurysm

An LV aneurysm, a sharply delineated area of scar that bulges paradoxically during systole, develops in 10–20% of patients surviving an acute infarction. This usually follows anterior Q wave infarctions. Aneurysms are recognized by persistent ST-segment elevation (beyond 4–8 weeks), and a wide neck from the LV can be demonstrated by echocardiography, scintigraphy, or contrast angiography. They rarely rupture but may be associated with arterial emboli, ventricular arrhythmias, and CHF. Surgical resection may be performed for these indications if other measures fail. The best results (mortality rates of 10–20%) are obtained when the residual myocardium contracts well and when significant coronary lesions supplying adjacent regions are bypassed.

H. Pericarditis

The pericardium is involved in approximately 50% of infarctions, but pericarditis is often not clinically significant. Twenty percent of patients with Q wave infarctions will have an audible friction rub if examined repetitively. Pericardial pain occurs in approximately the same proportion after 2–7 days and is recognized by its variation with respiration and position (improved by sitting). Often, no treatment is required, but aspirin (650 mg every 4–6 hours) will usually relieve the pain. Indomethacin and corticosteroids can cause impaired infarct healing and predispose to myocardial rupture, and therefore should generally be avoided in the early post-myocardial infarction period. Likewise, anticoagulation should be used cautiously, since hemorrhagic pericarditis may result.

One week to 12 weeks after infarction, Dressler syndrome (post-myocardial infarction syndrome) occurs in < 5% of patients. This is an autoimmune phenomenon and presents as pericarditis with associated fever, leukocytosis and, occasionally, pericardial or pleural effusion. It may recur over months. Treatment is the same as for other forms of pericarditis. A short course of nonsteroidal agents or corticosteroids may help relieve symptoms.

I. Mural Thrombus

Mural thrombi are common in large anterior infarctions but not in infarctions at other locations. Arterial emboli occur in approximately 2% of patients with known infarction, usually within 6 weeks. Anticoagulation with heparin followed by short-term (3-month) warfarin therapy prevents most emboli and should be considered in all patients with large anterior infarctions. Mural thrombi can be detected by echocardiography or cardiac MRI, but these procedures should not be relied upon for determining the need for anticoagulation.

Hochman JS et al. Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK Investigators. Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock. *N Engl J Med.* 1999 Aug 26; 341(9):625–34. [PMID: 10460813]

Pfisterer M. Right ventricular involvement in myocardial infarction and cardiogenic shock. *Lancet.* 2003 Aug 2;362(9381): 392–4. [PMID: 12907014]

Rathore SS et al. Acute myocardial infarction complicated by heart block in the elderly: prevalence and outcomes. *Am Heart J.* 2001 Jan;141(1):47–54. [PMID: 11136486]

▶ Postinfarction Management

After the first 24 hours, the focus of patient management is to prevent recurrent ischemia, improve infarct healing and prevent remodeling, and prevent recurrent vascular events. Patients with hemodynamic compromise, who are at high risk for death, need careful monitoring and management of volume status.

A. Risk Stratification

Risk stratification is important for management of STEMI. GRACE and TIMI risk scores can be helpful tools. The TIMI Risk Score is available for PDA download at <http://www.timi.org>, and the GRACE risk score at <http://www.outcomes-umassmed.org/grace>. Patients with recurrent ischemia (spontaneous or provoked), hemodynamic instability, impaired LV function, heart failure, or serious ventricular arrhythmias should undergo cardiac catheterization (Table 10–6). ACE inhibitor (or ARB) therapy is indicated in patients with clinical heart failure or LV EF \leq 40%. Aldosterone blockade is indicated for patients with an LV EF \leq 40% and either heart failure or diabetes mellitus.

For patients not undergoing cardiac catheterization, submaximal exercise (or pharmacologic stress testing for patients unable to exercise) before discharge or a maximal test after 3–6 weeks (the latter being more sensitive for ischemia) helps patients and clinicians plan the return to normal activity. Imaging in conjunction with stress testing adds additional sensitivity for ischemia and provides localizing information. Both exercise and pharmacologic stress imaging have successfully predicted subsequent outcome. One of these tests should be used prior to discharge in patients who have received thrombolytic therapy as a means of selecting appropriate candidates for coronary angiography.

B. Secondary Prevention

Postinfarction management should begin with identification and modification of risk factors. Treatment of hyperlipidemia and smoking cessation both prevent recurrent infarction and death. Statin therapy should be started before the patient is discharged from the hospital to reduce recurrent atherothrombotic events. BP control and cardiac rehabilitation or exercise are also recommended.

β -Blockers improve survival rates, primarily by reducing the incidence of sudden death in high-risk subsets of patients, though their value may be less in patients without complications with small infarctions and normal exercise

tests. While a variety of β -blockers have been shown to be beneficial, for patients with LV dysfunction managed with contemporary treatment, carvedilol titrated to 25 mg twice a day has been shown to reduce mortality. β -Blockers with intrinsic sympathomimetic activity have not proved beneficial in postinfarction patients.

Antiplatelet agents are beneficial; aspirin (81–325 mg daily) is recommended, and adding clopidogrel (75 mg daily) has been shown to provide additional benefit short term after STEMI and for up to 1 year after non-ST elevation acute coronary syndromes. Prasugrel provides further reduction in thrombotic outcomes compared with clopidogrel, at the cost of more bleeding. Likewise, ticagrelor provides benefit over clopidogrel but should be used with low-dose aspirin (81 mg/d). Warfarin anticoagulation for 3 months reduces the incidence of arterial emboli after large anterior infarctions, and according to the results of at least one study it improves long-term prognosis, but these studies were before routine use of aspirin and clopidogrel. An advantage to combining low-dose aspirin and warfarin has not been demonstrated, except perhaps in patients with atrial fibrillation.

Calcium channel blockers have not been shown to improve prognoses overall and should not be prescribed purely for secondary prevention. Antiarrhythmic therapy other than with β -blockers has not been shown to be effective except in patients with symptomatic arrhythmias. Amiodarone has been studied in several trials of postinfarction patients with either LV dysfunction or frequent ventricular ectopy. Although survival was not improved, amiodarone was not harmful—unlike other agents in this setting. Therefore, it is the agent of choice for individuals with symptomatic postinfarction supraventricular arrhythmias. While implantable defibrillators improve survival for patients with postinfarction LV dysfunction and heart failure, the DINAMIT trial found no benefit to implantable defibrillators implanted in the 40 days following acute myocardial infarction.

Cardiac rehabilitation programs and exercise training can be of considerable psychological benefit and appear to improve prognosis.

C. ACE Inhibitors and ARBs in Patients with LV Dysfunction

Patients who sustain substantial myocardial damage often experience subsequent progressive LV dilation and dysfunction, leading to clinical heart failure and reduced long-term survival. In patients with EFs < 40%, long-term ACE inhibitor (or ARB) therapy prevents LV dilation and the onset of heart failure and prolongs survival. The HOPE trial, as well as an overview of trials of ACE-inhibitors for secondary prevention, also demonstrated a reduction of approximately 20% in mortality rates and the occurrence of nonfatal myocardial infarction and stroke with ramipril treatment of patients with vascular disease and without confirmed LV systolic dysfunction. Therefore, ACE inhibitor therapy should be strongly considered in this broader group of patients—and especially in diabetics and patients with even mild systolic hypertension, in whom the greatest benefit was observed.

D. Revascularization

Postinfarction patients not treated with primary PCI who appear likely to benefit from early revascularization if the anatomy is appropriate are (1) those who have undergone thrombolytic therapy and have high-risk features (including systolic BP of < 100 mm Hg, heart rate of > 100 bpm, Killip class II or III, ST segment depression of 2 mm or more in the anterior leads); (2) patients with LV dysfunction (EF < 30–40%); (3) patients with non-ST elevation MI and high-risk features; and (4) patients with markedly positive exercise tests and multi-vessel disease. The value of revascularization in the following groups is less clear: (1) patients without high-risk features treated with thrombolytic agents, with little evidence of reperfusion or residual ischemia; and (2) patients with preserved LV function who have mild ischemia and are not symptom limited. In general, patients without high-risk features who survive infarctions without complications, have preserved LV function (EF > 50%), and have no exercise-induced ischemia have an excellent prognosis and do not require invasive evaluation.

Ades PA. Cardiac rehabilitation and secondary prevention of coronary heart disease. *N Engl J Med*. 2001 Sep 20;345(12):892–902. [PMID: 11565523]

Dagenais GR et al. Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials. *Lancet*. 2006 Aug 12;368(9535):581–8. [PMID: 16905022]

Dargie HJ et al. Effect of carvedilol on outcome after myocardial infarction in patients with left ventricular dysfunction: the CAPRICORN randomized trial. *Lancet*. 2001 May 5;357(9266):1385–90. [PMID: 11356434]

Kushner FG et al. 2009 Focused Updates: ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction (updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (updating the 2005 Guideline and 2007 Focused Update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *Circulation*. 2009 Dec 1;120(22):2271–306. Erratum in: *Circulation*. 2010 Mar 30;121(12):e257. Dosage error in article text. [PMID: 19923169]

DISORDERS OF RATE & RHYTHM

Abnormalities of cardiac rhythm and conduction can be symptomatic (syncope, near syncope, dizziness, fatigue, or palpitations), or asymptomatic. In addition, they can be lethal (sudden cardiac death) or dangerous to the extent that they reduce cardiac output, so that perfusion of the brain and myocardium is impaired. Stable supraventricular tachycardia is generally well tolerated in patients without underlying heart disease but may lead to myocardial ischemia or CHF in patients with coronary disease, valvular abnormalities, and systolic or diastolic myocardial dysfunction. Ventricular tachycardia, if prolonged (lasting more than 10–30 seconds), often results in hemodynamic compromise and may deteriorate into ventricular fibrillation if left untreated.

Whether slow heart rates produce symptoms at rest or with exertion depends on whether cerebral and peripheral perfusion can be maintained, which is generally a function of

whether the patient is upright or supine and whether LV function is adequate to maintain stroke volume. If the heart rate abruptly slows, as with the onset of complete heart block or sinus arrest, syncope or convulsions (or both) may result.

Arrhythmias are detected either because they produce symptoms or because they are detected during the course of monitoring. Arrhythmias causing sudden death, syncope, or near syncope require further evaluation and treatment unless they are related to conditions that are reversible or immediately treatable (eg, electrolyte abnormalities or acute myocardial infarction). In contrast, there is controversy over when and how to evaluate and treat rhythm disturbances that are not symptomatic but are possible markers for more serious abnormalities (eg, nonsustained ventricular tachycardia [NSVT]). This uncertainty reflects two issues: (1) the difficulty of reliably stratifying patients into high-risk and low-risk groups; and (2) the lack of treatments that are both effective and safe. Thus, screening patients for these so-called “premonitory” abnormalities is often not productive.

A number of procedures are used to evaluate patients with symptoms who are believed to be at risk for life-threatening arrhythmias, including in-hospital and ambulatory ECG monitoring, event recorders (instruments that can be used for prolonged periods to record or transmit rhythm tracings when infrequent episodes occur), exercise testing, catheter-based electrophysiologic studies (to assess sinus node function, AV conduction, and inducibility of arrhythmias), and tests of autonomic nervous system function (tilt-table testing).

Treatment of arrhythmias varies and can include modalities such as antiarrhythmic drugs (see Table 10–9) and more invasive techniques such as catheter ablation.

► Antiarrhythmic Drugs (Table 10–9)

Antiarrhythmic drugs are frequently used to treat arrhythmias, but have variable efficacy and produce frequent side effects. They are often divided into classes based on their electropharmacologic actions and many of these drugs have multiple actions. The most frequently used classification scheme is the Vaughan-Williams classification, which consists of four classes.

Class I agents block membrane sodium channels. Three subclasses are further defined by the effect of the agents on the Purkinje fiber action potential. Class Ia drugs (ie, quinidine, procainamide, disopyramide) slow the rate of rise of the action potential (V_{max}) and prolong its duration, thus slowing conduction and increasing refractoriness (moderate depression of phase 0 upstroke of the action potential). Class Ib agents (ie, lidocaine, mexiletine, phenytoin) shorten action potential duration; they do not affect conduction or refractoriness (minimal depression of phase 0 upstroke of the action potential). Class Ic agents (ie, flecainide, propafenone) prolong V_{max} and slow repolarization, thus slowing conduction and prolonging refractoriness, but more so than class Ia drugs (maximal depression of phase 0 upstroke of the action potential).

Class II agents are the β -blockers, which decrease automaticity, prolong AV conduction, and prolong refractoriness.

Class III agents (ie, amiodarone, dronedarone, sotalol, dofetilide, ibutilide) block potassium channels and prolong repolarization, widening the QRS and prolonging the QT interval. They decrease automaticity and conduction and prolong refractoriness. Dronedarone has been shown to reduce cardiovascular hospitalizations when used in patients with paroxysmal atrial fibrillation in the absence of heart failure; however, the PALLAS trial found an *increase* in cardiovascular events when dronedarone was used in patients with permanent atrial fibrillation.

Class IV agents are the calcium channel blockers, which decrease automaticity and AV conduction.

There are some antiarrhythmic agents that do not fall into one of these categories. The most frequently used are digoxin and adenosine. Digoxin inhibits the Na^+ , K^+ -ATPase pump. Digoxin prolongs AV nodal conduction and the AV nodal refractory period, but it shortens the action potential and decreases the refractoriness of the ventricular myocardium and Purkinje fibers. Adenosine can block AV nodal conduction and shortens atrial refractoriness.

Although the *in vitro* electrophysiologic effects of most of these agents have been defined, their use remains largely empiric. All can exacerbate arrhythmias (proarrhythmic effect), and many depress LV function.

The risk of antiarrhythmic agents has been highlighted by many studies, most notably the Coronary Arrhythmia Suppression Trial (CAST), in which two class Ic agents (flecainide, encainide) and a class Ia agent (moricizine) increased mortality rates in patients with asymptomatic ventricular ectopy after myocardial infarction. A similar result has been reported in the Mortality in the Survival With Oral D-sotalol (SWORD) study with d-sotalol, a class III agent without the β -blocking activity of the currently marketed formulation d,l-sotalol. Therefore, these agents (and perhaps any antiarrhythmic drug) should not be used except for life-threatening ventricular arrhythmias and symptomatic supraventricular tachyarrhythmias and patients receiving these agents should be monitored regularly.

The use of antiarrhythmic agents for specific arrhythmias is discussed below.

Connolly SJ et al; PALLAS Investigators. Dronedarone in high-risk permanent atrial fibrillation. *N Engl J Med*. 2011 Dec 15;365(24):2268–76. [PMID: 22082198]

Ganjehei L et al. Pharmacologic management of arrhythmias. *Tex Heart Inst J*. 2011;38(4):344–9. [PMID: 21841856]

Kowey PR et al. Classification and pharmacology of antiarrhythmic drugs. *Am Heart J*. 2000 Jul;140(1):12–20. [PMID: 10874257]

Li EC et al. Drug-induced QT-interval prolongation: considerations for clinicians. *Pharmacotherapy*. 2010 Jul;30(7):684–701. [PMID: 20575633]

Shu J et al. Pharmacotherapy of cardiac arrhythmias—basic science for clinicians. *Pacing Clin Electrophysiol*. 2009 Nov; 32(11):1454–65. [PMID: 19744278]

Thireau J et al. New drugs vs. old concepts: a fresh look at antiarrhythmics. *Pharmacol Ther*. 2011 Nov;132(2):125–45. [PMID: 21420430]

Torp-Pedersen C et al. Antiarrhythmic drugs: safety first. *J Am Coll Cardiol*. 2010 April 13;55(15):1569–76. [PMID: 20378074]

Table 10-9. Antiarrhythmic drugs.

Agent	Intravenous Dosage	Oral Dosage	Therapeutic Plasma Level	Route of Elimination	Side Effects
Class Ia: Action: Sodium channel blockers: Depress phase 0 depolarization; slow conduction; prolong repolarization.					
Indications: Supraventricular tachycardia, ventricular tachycardia, prevention of ventricular fibrillation, symptomatic ventricular premature beats.					
Quinidine	6-10 mg/kg (intramuscularly or intravenously) over 20 min (rarely used parenterally)	200-400 mg every 4-6 h or every 8 h (long-acting)	2-5 mg/mL	Hepatic	GI, ↓LVEF, ↑Dig
Procainamide	100 mg/1-3 min to 500-1000 mg; maintain at 2-6 mg/min	50 mg/kg/d in divided doses every 3-4 h or every 6 h (long-acting)	4-10 mg/mL; NAPA (active metabolite), 10-20 mcg/mL	Renal	SLE, hypersensitivity, ↓LVEF
Disopyramide		100-200 mg every 6-8 h	2-8 mg/mL	Renal	Urinary retention, dry mouth, markedly ↓LVEF
Class Ib: Action: Shorten repolarization.					
Indications: Ventricular tachycardia, prevention of ventricular fibrillation, symptomatic ventricular beats.					
Lidocaine	1-2 mg/kg at 50 mg/min; maintain at 1-4 mg/min		1-5 mg/mL	Hepatic	CNS, GI
Mexiletine		100-300 mg every 6-12 h; maximum: 1200 mg/d	0.5-2 mg/mL	Hepatic	CNS, GI, leukopenia
Class Ic: Action: Depress phase 0 repolarization; slow conduction. Propafenone is a weak calcium channel blocker and α-blocker and prolongs action potential and refractoriness.					
Indications: Life-threatening ventricular tachycardia or fibrillation, refractory supraventricular tachycardia.					
Flecainide		100-200 mg twice daily	0.2-1 mg/mL	Hepatic	CNS, GI, ↓↓LVEF, incessant VT, sudden death
Propafenone		150-300 mg every 8-12 h	<i>Note:</i> Active metabolites	Hepatic	CNS, GI, ↓↓LVEF, ↑Dig
Class II: Action: β-blocker, slows AV conduction. <i>Note:</i> Other β-blockers may also have antiarrhythmic effects but are not yet approved for this indication in the United States.					
Indications: Supraventricular tachycardia; may prevent ventricular fibrillation.					
Esmolol	500 mcg/kg over 1-2 min; maintain at 25-200 mcg/kg/min	Other β -blockers may be used concomitantly	Not established	Hepatic	↓LVEF, bronchospasm
Propranolol	1-5 mg at 1 mg/min	40-320 mg in 1-4 doses daily (depending on preparation)	Not established	Hepatic	↓LVEF, bradycardia, AV block, bronchospasm
Metoprolol	2.5-5 mg	50-200 mg daily	Not established	Hepatic	↓LVEF, bradycardia, AV block
Class III: Action: Prolong action potential.					
Indications: <i>Amiodarone:</i> refractory ventricular tachycardia, supraventricular tachycardia, prevention of ventricular tachycardia, atrial fibrillation, ventricular fibrillation; <i>dofetilide:</i> atrial fibrillation and flutter; <i>sotalol:</i> ventricular tachycardia, atrial fibrillation; <i>ibutilide:</i> conversion of atrial fibrillation and flutter.					
Amiodarone	150-300 mg infused rapidly, followed by 1-mg/min infusion for 6 h (360 mg) and then 0.5 mg/min	800-1600 mg/d for 7-21 days; maintain at 100-400 mg/d (higher doses may be needed)	1-5 mg/mL	Hepatic	Pulmonary fibrosis, hypothyroidism, hyperthyroidism, photosensitivity, corneal and skin deposits, hepatitis, ↑Dig, neurotoxicity, GI

(continued)

Table 10-9. Antiarrhythmic drugs. (Continued)

Agent	Intravenous Dosage	Oral Dosage	Therapeutic Plasma Level	Route of Elimination	Side Effects
Dronedaron		400 mg twice daily		Hepatic (contraindicated in severe impairment)	QTc prolongation, CHF. Contraindicated in CHF (NYHA class IV and class II and III if recent decompensation)
Sotalol		80-160 mg every 12 h (higher doses may be used for life-threatening arrhythmias)		Renal (dosing interval should be extended if creatinine clearance is < 60 mL/min)	Early incidence of torsades de pointes, ↓LVEF, bradycardia, fatigue (and other side effects associated with β-blockers)
Dofetilide		500 mcg every 12 h		Renal (dose must be reduced with kidney dysfunction)	Torsades de pointes in 3%; interaction with cytochrome P-450 inhibitors
Ibutilide	1 mg over 10 min, followed by a second infusion of 0.5-1 mg over 10 min			Hepatic and renal	Torsades de pointes in up to 5% of patients within 3 h after administration; patients must be monitored with defibrillator nearby
Class IV: Action: Slow calcium channel blockers.					
Indications: Supraventricular tachycardia.					
Verapamil	10-20 mg over 2-20 min; maintain at 5 mg/kg/min	80-120 mg every 6-8 h; 240-360 mg once daily with sustained-release preparation	0.1-0.15 mg/mL	Hepatic	↓LVEF, constipation, ↑Dig, hypotension
Diltiazem	0.25 mg/kg over 2 min; second 0.35-mg/kg bolus after 15 min if response is inadequate; infusion rate, 5-15 mg/h	180-360 mg daily in 1-3 doses depending on preparation (oral forms not approved for arrhythmias)		Hepatic metabolism, renal excretion	Hypotension, ↓LVEF
Miscellaneous: Indications: Supraventricular tachycardia.					
Adenosine	6 mg rapidly followed by 12 mg after 1-2 min if needed; use half these doses if administered via central line			Adenosine receptor stimulation, metabolized in blood	Transient flushing, dyspnea, chest pain, AV block, sinus bradycardia; effect ↓ by theophylline, ↑ by dipyridamole
Digoxin	0.5 mg over 20 min followed by increment of 0.25 or 0.125 mg to 1-1.5 mg over 24 h	1-1.5 mg over 24-36 h in 3 or 4 doses; maintenance, 0.125-0.5 mg/d	0.7-2 mg/mL	Renal	AV block, arrhythmias, GI, visual changes

AV, atrioventricular; CHF, congestive heart failure; CNS, central nervous system; ↑Dig, elevation of serum digoxin level; GI, gastrointestinal (nausea, vomiting, diarrhea); ↓LVEF, reduced left ventricular function; NAPA, *N*-acetylprocainamide; NYHA, New York Heart Association; SLE, systemic lupus erythematosus; VT, ventricular tachycardia.

► Catheter Ablation for Cardiac Arrhythmias

Catheter ablation has become first-line therapy for the treatment of many arrhythmias. This growing trend reflects the increasing ability to localize the origin or conduction circuit of many arrhythmias and safely deliver lesions to eliminate the arrhythmia focus. Catheter ablation has become the primary modality of therapy for many symptomatic supraventricular arrhythmias, including AV nodal reentrant tachycardia, tachycardias involving accessory pathways, paroxysmal atrial tachycardia, and atrial flutter. Catheter ablation of atrial fibrillation is more complex and usually involves complete electrical isolation of the pulmonary veins (which are often the sites of initiation of atrial fibrillation) or placing linear lesions within the atria to prevent propagation throughout the atrial chamber. This technique is considered a reasonable second-line therapy for certain patients with symptomatic drug-refractory atrial fibrillation. Catheter ablation of ventricular arrhythmias has proved more difficult, but experienced centers have had reasonable success with all types of ventricular tachycardias including: bundle-branch reentry, tachycardia originating in the ventricular outflow tract or papillary muscles, tachycardias originating in the left side of the interventricular septum (also called fascicular ventricular tachycardia), and even ventricular tachycardias occurring in patients with ischemic or dilated cardiomyopathy.

Catheter ablation has also been successfully performed for the treatment of ventricular fibrillation when an inciting uniform premature ventricular contraction can be identified. In addition, patients with symptomatic premature ventricular contractions (PVCs) or PVCs occurring at a high enough burden to result in a cardiomyopathy (usually > 10,000/day) are often referred for catheter ablation as well.

There is also increasing data to suggest effectiveness of ablation of many of these arrhythmias from the epicardial surface of the heart via a percutaneous subxiphoid approach.

These procedures are generally reasonably safe, with an overall major complication rate ranging from 2% to 8%. There is a low incidence of perforation of the myocardial wall that results in pericardial tamponade. Sufficient damage to the AV node to require permanent cardiac pacing occurs in < 5% of patients. In addition, some procedures involve transeptal access through the interatrial septum or retrograde LV catheterization, with the attendant potential complications of aortic perforation, damage to the heart valves, damage to a coronary artery, or systemic emboli. A potentially fatal complication during the ablation of atrial fibrillation is the development of an atrio-esophageal fistula resulting from ablation lesions of the posterior wall of the LA just overlying the esophagus, but this is extremely rare.

Aliot EM et al. EHRA/HRS Expert Consensus on Catheter Ablation of Ventricular Arrhythmias: developed in a partnership with the European Heart Rhythm Association (EHRA), a Registered Branch of the European Society of Cardiology (ESC), and the Heart Rhythm Society (HRS); in collaboration with the American College of Cardiology (ACC) and the American Heart Association (AHA). *Heart Rhythm*. 2009 Jun;6(6):886–933. [PMID: 19467519]

Calkins H et al. HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for personnel, policy, procedures and follow-up. A report of the Heart Rhythm Society (HRS) Task Force on Catheter and Surgical Ablation of Atrial Fibrillation developed in partnership with the European Heart Rhythm Association (EHRA) and the European Cardiac Arrhythmia Society (ECAS); in collaboration with the American College of Cardiology (ACC), American Heart Association (AHA) and the Society of Thoracic Surgeons (STS). Endorsed and approved by the governing bodies of the American College of Cardiology, the American Heart Association, the European Cardiac Arrhythmia Society, the European Heart Rhythm Association, the Society of Thoracic Surgeons, and the Heart Rhythm Society. *Heart Rhythm*. 2007 Jun;4(6):818–61. [PMID: 17556213]

Doppalapudi H et al. Complications during catheter ablation of atrial fibrillation: identification and prevention. *Heart Rhythm*. 2009 Dec;6(12 Suppl):S18–25. [PMID: 19864189]

Hunter RJ et al. Long-term outcome after catheter ablation for atrial fibrillation: safety, efficacy and impact on prognosis. *Heart*. 2010 Aug;96(16):1259–63. [PMID: 20659943]

Parinet S et al. JAMA patient page. Atrial fibrillation. *JAMA*. 2007 Dec 19;298(23):2820. [PMID: 18165677]

Spector P et al. Meta-analysis of ablation of atrial flutter and supraventricular tachycardia. *Am J Cardiol*. 2009 Sep 1;104(5):671–7. [PMID: 19699343]

Tokuda M et al. Outcomes of cardiac perforation complicating catheter ablation of ventricular arrhythmias. *Circ Arrhythm Electrophysiol*. 2011 Oct;4(5):660–6. [PMID: 21753037]

Wazni O et al. Catheter ablation for atrial fibrillation. *N Engl J Med*. 2011 Dec 15;365(24):2296–304. [PMID: 22168644]

Wilber DJ et al; ThermoCool AF Trial Investigators. Comparison of antiarrhythmic drug therapy and radiofrequency catheter ablation in patients with paroxysmal atrial fibrillation: a randomized controlled trial. *JAMA*. 2010 Jan 27;303(4):333–40. [PMID: 20103757]

SINUS ARRHYTHMIA, BRADYCARDIA, & TACHYCARDIA

Sinus arrhythmia is a cyclic increase in normal heart rate with inspiration and decrease with expiration. It results from reflex changes in vagal influence on the normal pacemaker and disappears with breath holding or increase of heart rate. It has no clinical significance. It is common in both the young and the elderly.

Sinus bradycardia is a heart rate slower than 60 beats/min due to increased vagal influence on the normal pacemaker or organic disease of the sinus node. The rate usually increases during exercise or administration of atropine. In healthy individuals, and especially in patients who are in excellent physical condition, sinus bradycardia to rates of 50 beats/min or even lower is a normal finding. However, severe sinus bradycardia (< 45 beats/min) may be an indication of sinus node pathology (see below), especially in elderly patients and individuals with heart disease. It may cause weakness, confusion, or syncope if cerebral perfusion is impaired. Atrial, junctional and ventricular ectopic rhythms are more apt to occur with slow sinus rates. Pacing may be required if symptoms correlate with the bradycardia.

Sinus tachycardia is defined as a heart rate faster than 100 beats/min that is caused by rapid impulse formation from the sinoatrial node; it occurs with fever, exercise, emotion, pain, anemia, heart failure, shock, thyrotoxicosis,

or in response to many drugs. Alcohol and alcohol withdrawal are common causes of sinus tachycardia and other supraventricular arrhythmias. The onset and termination are usually gradual, in contrast to paroxysmal supraventricular tachycardia due to reentry. The rate infrequently exceeds 160 beats/min but may reach 180 beats/min in young persons. The rhythm is generally regular, but serial 1-minute counts of the heart rate indicate that it varies five or more beats per minute with changes in position, with breath holding, or with sedation. In rare instances, individuals have persistent or episodic “inappropriate” sinus tachycardia that may be very symptomatic or may lead to LV contractile dysfunction. Pharmacologic agents, such as β -blockers and in some cases flecainide, or catheter-based radiofrequency modification of the sinus node have shown to have varying success in treating this problem.

► When to Refer

Patients with symptoms related to bradycardia or tachycardia when reversible etiologies have been excluded.

► When to Admit

Patients with bradycardia and recent or recurrent syncope.

Dilaveris P et al. Heart rate lowering by inhibition of the pacemaker current: a new therapeutic perspective in cardiovascular disease. *Cardiovasc Hematol Agents Med Chem*. 2006 Oct;4(4):313–8. [PMID: 17073608]

Still AM et al. Prevalence, characteristics and natural course of inappropriate sinus tachycardia. *Europace*. 2005 Mar;7(2):104–12. [PMID: 15763524]

Yusuf S et al. Deciphering the sinus tachycardias. *Clin Cardiol*. 2005 Jun;28(6):267–76. [PMID: 16028460]

ATRIAL PREMATURE BEATS (Atrial Extrasystoles)



ESSENTIALS OF DIAGNOSIS

- ▶ Usually asymptomatic.
- ▶ Isolated interruption in regular rhythm.
- ▶ Can be harbingers of future development of atrial fibrillation.
- ▶ P-wave morphology on ECG usually differs from sinus P-wave morphology.

Atrial premature beats occur when an ectopic focus in the atria fires before the next sinus node impulse or a reentry circuit is established. The contour of the P wave usually differs from the patient’s normal complex, unless the ectopic focus is near the sinus node. Such premature beats occur frequently in normal hearts. Acceleration of the heart rate by any means usually abolishes most premature beats. Early atrial premature beats may cause aberrant QRS complexes (wide and bizarre) or may not be conducted to

the ventricles because the AV node or ventricles are still refractory.

Differentiation of Aberrantly Conducted Supraventricular Beats from Ventricular Beats

This distinction can be very difficult in patients with a wide QRS complex; it is important because of the differing prognostic and therapeutic implications of each type. Findings favoring a ventricular origin include (1) AV dissociation; (2) a QRS duration exceeding 0.14 second; (3) capture or fusion beats (infrequent); (4) left axis deviation with right bundle branch block morphology; (5) monophasic (R) or biphasic (qR, QR, or RS) complexes in V_1 ; and (6) a qR or QS complex in V_6 . Supraventricular origin is favored by (1) a triphasic QRS complex, especially with initial negativity in leads I and V_6 ; (2) ventricular rates exceeding 170 beats/min; (3) QRS duration longer than 0.12 second but not longer than 0.14 second; and (4) the presence of preexcitation syndrome.

The relationship of the P waves to the tachycardia complex is helpful. A 1:1 relationship usually means a supraventricular origin, except in the case of ventricular tachycardia with retrograde P waves.

PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA



ESSENTIALS OF DIAGNOSIS

- ▶ Frequently associated with palpitations.
- ▶ Abrupt onset/offset.
- ▶ Rapid, regular rhythm.
- ▶ Most commonly seen in young adults.
- ▶ Rarely causes syncope.
- ▶ Usually have a narrow QRS complex on ECG.
- ▶ Often responsive to vagal maneuvers, AV nodal blockers, or adenosine.

► General Considerations

This is a common paroxysmal tachycardia and often occurs in patients without structural heart disease. The most common mechanism for paroxysmal supraventricular tachycardia is reentry, which may be initiated or terminated by a fortuitously timed atrial or ventricular premature beat. The reentrant circuit most commonly involves dual pathways (a slow and a fast pathway) within the AV node. This is referred to as AV nodal reentrant tachycardia (AVNRT). Less commonly, reentry is due to an accessory pathway between the atria and ventricles, referred to as AV reentrant tachycardia (AVRT). Approximately one-third of patients with supraventricular tachycardia have accessory pathways to the ventricles. The pathophysiology and management of arrhythmias due to accessory pathways differ in important ways and are discussed separately below.

► Clinical Findings

A. Symptoms and Signs

Patients may be asymptomatic except for awareness of rapid heart action, but some experience mild chest pain or shortness of breath, especially when episodes are prolonged, even in the absence of associated cardiac abnormalities. Episodes begin and end abruptly and may last a few seconds to several hours or longer.

B. ECG

The heart rate may be 140–240 beats/min (usually 160–220 beats/min) and is regular (despite exercise or change in position). The P wave usually differs in contour from sinus beats and is often buried in the QRS complex.

► Treatment

In the absence of structural heart disease, serious effects are rare, and most episodes resolve spontaneously. Particular effort should be made to terminate the episode quickly if cardiac failure, syncope, or anginal pain develops or if there is underlying cardiac or (particularly) coronary disease. Because reentry is the most common mechanism for paroxysmal supraventricular tachycardia, effective therapy requires that conduction be interrupted at some point in the reentry circuit and the vast majority of these circuits involve the AV node.

A. Mechanical Measures

A variety of maneuvers have been used to interrupt episodes, and patients may learn to perform these themselves. These maneuvers result in an acute increase in vagal tone and include the Valsalva maneuver, stretching the arms and body, lowering the head between the knees, coughing, splashing cold water on the face, and breath holding. Carotid sinus massage is often performed by physicians but should be avoided if the patient has carotid bruits or a history of transient cerebral ischemic attacks. Firm but gentle pressure and massage are applied first over the right carotid sinus for 10–20 seconds and, if unsuccessful, then over the left carotid sinus. **Pressure should not be exerted on both sides at the same time!** Continuous ECG or auscultatory monitoring of the heart rate is essential so that pressure can be relieved as soon as the rhythm is broken or if excessive bradycardia occurs. Carotid sinus pressure will interrupt up to half of the attacks, especially if the patient has received a digitalis glycoside or other agent (such as adenosine or a calcium channel blocker) that delays AV conduction. These maneuvers stimulate a vagal outpouring, delay AV conduction, and block the reentry mechanism at the level of the AV node, terminating the arrhythmia.

B. Drug Therapy

If mechanical measures fail, two rapidly acting intravenous agents will terminate more than 90% of episodes. Intravenous **adenosine** has a very brief duration of action and minimal negative inotropic activity (Table 10–9).

Initially, a 6 mg bolus is administered. If no response is observed after 1–2 minutes, a 12 mg bolus should be given, followed by another 12 mg bolus if necessary. Because the half-life of adenosine is < 10 seconds, the drug must be given rapidly (in 1–2 seconds from a peripheral intravenous line); use half the dose if given through a central line. Adenosine causes block of electrical conduction through the AV node. Adenosine is very well tolerated, but nearly 20% of patients will experience transient flushing, and some patients experience severe chest discomfort. Caution must be taken when adenosine is given to elderly patients because the resulting pause can be prolonged. Adenosine must also be used with caution in patients with reactive airways disease because it can promote bronchospasm.

Calcium channel blockers also rapidly induce AV block and break many episodes of reentrant supraventricular tachycardia. These agents should be used with caution in patients with heart failure due to their negative inotropic effects. Intravenous **verapamil** may be given as a 2.5 mg bolus, followed by additional doses of 2.5–5 mg every 1–3 minutes up to a total of 20 mg if BP and rhythm are stable. If the rhythm recurs, further doses can be given. Oral verapamil, 80–120 mg every 4–6 hours, can be used as well in stable patients who are tolerating the rhythm without difficulty, but avoid it if there is any concern that the arrhythmia may be ventricular in origin. Intravenous **diltiazem** (0.25 mg/kg over 2 minutes, followed by a second bolus of 0.35 mg/kg if necessary and then an infusion of 5–15 mg/h) may cause less hypotension and myocardial depression.

Esmolol, a very short-acting β -blocker, may also be effective; the initial dose is 500 mcg/kg intravenously over 1 minute followed by an infusion of 25–200 mcg/min. **Metoprolol** is also effective and can be given in 5 mg boluses every 5 minutes and repeated up to two times. If the tachycardia is believed to be mediated by an accessory pathway, intravenous **procainamide** may terminate the tachycardia by prolonging refractoriness in the accessory pathway; however, because it facilitates AV conduction and an initial increase in rate may occur, it is usually not given until after a calcium channel blocker or a β -blocker has been administered. Although intravenous amiodarone is safe, it is usually not required and often ineffective for treatment of these arrhythmias.

C. Cardioversion

If the patient is hemodynamically unstable or if adenosine, β -blockers, and verapamil are contraindicated or ineffective, synchronized electrical cardioversion (beginning at 100 J) is almost universally successful. If digitalis toxicity is present or strongly suspected, as in the case of paroxysmal tachycardia with block, electrical cardioversion should be avoided.

► Prevention

A. Catheter Ablation

Because of concerns about the safety and the intolerability of antiarrhythmic medications, radiofrequency ablation is the preferred approach to patients with recurrent symptomatic reentrant supraventricular tachycardia, whether it is

due to dual pathways within the AV node or to accessory pathways.

B. Drugs

AV nodal blocking agents are the drugs of choice as first-line medical therapy (Table 10–9). β -Blockers or non-dihydropyridine calcium channel blockers, such as diltiazem and verapamil, are typically used first. Patients who do not respond to agents that increase refractoriness of the AV node may be treated with antiarrhythmics. The class Ic agents (flecainide, propafenone) can be used in patients without underlying structural heart disease. In patients with evidence of structural heart disease, class III agents, such as sotalol or amiodarone, are probably a better choice because of the lower incidence of ventricular proarrhythmia during long-term therapy.

Blomstrom-Lundqvist C et al; European Society of Cardiology Committee, NASPE-Heart Rhythm Society. ACC/AHA/ESC guidelines for the management of patients with supraventricular arrhythmias—executive summary. A report of the American College of Cardiology/American Heart Association task force on practice guidelines and the European Society of Cardiology committee for practice guidelines (writing committee to develop guidelines for the management of patients with supraventricular arrhythmias) developed in collaboration with NASPE-Heart Rhythm Society. *J Am Coll Cardiol*. 2003 Oct 15;42(8):1493–531. [PMID: 14563598]

Colucci RA et al. Common types of supraventricular tachycardia: diagnosis and management. *Am Fam Physician*. 2010 Oct 15;82(8):942–52. [PMID: 20949888]

Fox DJ et al. Supraventricular tachycardia: diagnosis and management. *Mayo Clin Proc*. 2008 Dec;83(12):1400–11. [PMID: 19046562]

Linton NW et al. Narrow complex (supraventricular) tachycardias. *Postgrad Med J*. 2009 Oct;85(1008):546–51. [PMID: 19789194]

Marill KA et al. Adenosine for wide-complex tachycardia: efficacy and safety. *Crit Care Med*. 2009 Sep;37(9):2512–8. [PMID: 19623049]

Rosso R et al. Focal atrial tachycardia. *Heart*. 2010 Feb;96(3):181–5. [PMID: 19443472]

Tabatabaei N et al. Supraventricular arrhythmia: identifying and ablating the substrate. *Circ Arrhythm Electrophysiol*. 2009 Jun;2(3):316–26. [PMID: 19808482]

SUPRAVENTRICULAR TACHYCARDIAS DUE TO ACCESSORY AV PATHWAYS (Preexcitation Syndromes)

ESSENTIALS OF DIAGNOSIS

- ▶ Frequently associated with palpitations.
- ▶ Can be associated with syncope.
- ▶ Rapid, regular rhythm.
- ▶ May have narrow or wide QRS complex on ECG.
- ▶ Often have preexcitation (delta wave) on baseline ECG.

▶ General Considerations

Accessory pathways or bypass tracts between the atrium and the ventricle bypass the compact AV node and can predispose to reentrant arrhythmias, such as AVRT and atrial fibrillation. These may be wholly or partly within the node (eg, Mahaim fibers), yielding a short PR interval and normal QRS morphology. More commonly, they make direct connections between the atrium and ventricle through Kent bundles (**Wolff-Parkinson-White syndrome**). This often produces a short PR interval with a delta wave (preexcitation) at the onset of the wide, slurred QRS complex owing to early ventricular depolarization of the region adjacent to the pathway. Although the morphology and polarity of the delta wave can suggest the location of the pathway, mapping by intracardiac recordings is required for precise anatomic localization.

Accessory pathways occur in 0.1–0.3% of the population and facilitate reentrant arrhythmias owing to the disparity in refractory periods of the AV node and accessory pathway. Whether the tachycardia is associated with a narrow or wide QRS complex is frequently determined by whether antegrade conduction is through the node (narrow) or the bypass tract (wide). Some bypass tracts only conduct in a retrograde direction. In these cases, the bypass tract is termed “concealed.” Orthodromic reentrant tachycardia is a reentrant rhythm that conducts antegrade down the AV node and retrograde up the accessory pathway, resulting in a narrow QRS complex unless an underlying bundle branch block or interventricular conduction delay is present. Antidromic reentrant tachycardia conducts antegrade down the accessory pathway and retrograde through the AV node, resulting in a wide QRS complex. Accessory pathways are often less refractory than specialized conduction tissue and thus tachycardias involving accessory pathways have the potential to be more rapid. Up to 30% of patients with Wolff-Parkinson-White syndrome will develop atrial fibrillation or flutter with antegrade conduction down the accessory pathway and a rapid ventricular response. If this conduction is very rapid, it can potentially degenerate to ventricular fibrillation.

▶ Treatment

Some patients have a delta wave found incidentally on ECG. In the absence of palpitations, light-headedness, or syncope, these patients do not require specific therapy. They should be advised to report the onset of any of these symptoms. Occasionally, these patients are referred for exercise treadmill testing to determine if preexcitation is lost at rapid rates. Patients found incidentally to have delta waves who have jobs that could potentially put others at risk (ie, pilot, bus driver, etc) may need to undergo electrophysiologic testing with possible catheter ablation to ensure that they are not at an increased risk for syncope or sudden death.

A. Catheter Ablation

As with AVNRT, radiofrequency ablation has become the procedure of choice in patients with accessory pathways and

recurrent symptoms. Patients with preexcitation syndromes who have episodes of atrial fibrillation or flutter should be tested by induction of atrial fibrillation in the electrophysiology laboratory, noting duration of the RR cycle length; if it is < 220 ms, a short refractory period is present. These individuals are at highest risk for sudden death, and prophylactic ablation is indicated. Success rates for ablation of accessory pathways with radiofrequency catheters exceed 90% in appropriate patients.

B. Pharmacologic Therapy

Narrow-complex reentrant rhythms involving a bypass tract can be managed as discussed for AVNRT. Atrial fibrillation and flutter with a concomitant antegrade conducting bypass tract must be managed differently, since agents such as digoxin, calcium channel blockers, and even β -blockers may decrease the refractoriness of the accessory pathway or increase that of the AV node, often leading to faster ventricular rates. Therefore, these agents should be avoided. The class Ia, class Ic, and class III antiarrhythmic agents will increase the refractoriness of the bypass tract and are the drugs of choice for wide-complex tachycardias involving accessory pathways. If hemodynamic compromise is present, electrical cardioversion is warranted.

Long-term therapy often involves a combination of agents that increase refractoriness in the bypass tract (class Ia or Ic agents) and in the AV node (verapamil and β -blockers), provided that atrial fibrillation or flutter with short RR cycle lengths is not present (see above). The class III agent, amiodarone, can be effective in refractory cases. Patients who are difficult to manage should undergo electrophysiological evaluation.

▶ When to Refer

- Patients with an incidental finding of preexcitation and a high-risk job.
- Patients with recurrent symptoms or episodes despite treatment with AV nodal blocking agents.
- Patients with preexcitation and a history of atrial fibrillation.

▶ When to Admit

- Patients with paroxysmal supraventricular tachycardia and syncope.
- Patients with a history of syncope and preexcitation identified on an ECG.

Brembilla-Perrot B. When and how to assess an asymptomatic ventricular pre-excitation syndrome? *Arch Cardiovasc Dis*. 2008 Jun;101(6):407–11. [PMID: 18809154]

Cantú F et al; EHRA Scientific Initiatives Committee. Sudden cardiac death stratification in asymptomatic ventricular preexcitation. *Europace*. 2009 Nov;11(11):1536–7. [PMID: 19880412]

Mark DG et al. Preexcitation syndromes: diagnostic consideration in the ED. *Am J Emerg Med*. 2009 Sep;27(7):878–88. [PMID: 19683122]

Santinelli V et al. The natural history of asymptomatic ventricular pre-excitation a long-term prospective follow-up study of 184 asymptomatic children. *J Am Coll Cardiol*. 2009 Jan 20;53(3):275–80. [PMID: 19147045]

Schwiler JH et al. Reentry in an accessory atrioventricular pathway as a trigger for atrial fibrillation initiation in manifest Wolff-Parkinson-White syndrome: a matter of reflection? *Heart Rhythm*. 2008 Sep;5(9):1238–47. [PMID: 18774096]

Tischenko A et al. When should we recommend catheter ablation for patients with the Wolff-Parkinson-White syndrome? *Curr Opin Cardiol*. 2008 Jan;23(1):32–7. [PMID: 18281825]

ATRIAL FIBRILLATION



ESSENTIALS OF DIAGNOSIS

- ▶ Irregularly irregular heart rhythm.
- ▶ Usually tachycardic.
- ▶ Often associated with palpitations (acute onset) or fatigue (chronic).
- ▶ ECG shows erratic atrial activity with irregular ventricular response.
- ▶ High incidence and prevalence in the elderly population.

▶ General Considerations

Atrial fibrillation is the most common chronic arrhythmia, with an incidence and prevalence that rise with age, so that it affects approximately 9% of individuals over age 80 years. It occurs in rheumatic and other forms of valvular heart disease, dilated cardiomyopathy, ASD, hypertension, and coronary heart disease as well as in patients with no apparent cardiac disease; it may be the initial presenting sign in thyrotoxicosis, and this condition should be excluded with the initial episode. The heart rate may range from quite slow to extremely rapid, but is uniformly irregular unless underlying complete heart block and a permanent ventricular pacemaker is in place. The surface ECG typically demonstrates erratic, disorganized atrial activity between discrete QRS complexes occurring in an irregular pattern. The atrial activity may be very fine and difficult to detect on the ECG, or quite coarse and often mistaken for atrial flutter. Atrial fibrillation often appears in a paroxysmal fashion before becoming the established rhythm. Pericarditis, chest trauma, thoracic or cardiac surgery, thyroid disorders, obstructive sleep apnea, or pulmonary disease (as well as medications such as theophylline and β -adrenergic agonists) may cause attacks in patients with normal hearts. Acute alcohol excess and alcohol withdrawal—and, in predisposed individuals, even consumption of small amounts of alcohol—may precipitate atrial fibrillation. This latter presentation, which is often termed “holiday heart,” is usually transient and self-limited. Short-term rate control usually suffices as treatment. Perhaps the most serious consequence of atrial fibrillation is the propensity for thrombus formation due to stasis in the atria (particularly the left atrial appendage) and

Table 10–10. CHADS₂ Risk Score for assessing risk of stroke and for selecting antithrombotic therapy for patients with atrial fibrillation.

	Condition	Points
C	Congestive heart failure	1
H	Hypertension (current or treated)	1
A	Age ≥ 75 years	1
D	Diabetes mellitus	1
S ₂	Stroke or transient ischemic attack	2
CHADS ₂ Score	Adjusted Stroke Rate, %/year (95% Confidence Interval)	Patients ¹ (n = 1733)
0	1.9 (1.2 to 3.0)	120
1	2.8 (2.0 to 3.8)	463
2	4.0 (3.1 to 5.1)	523
3	5.9 (4.6 to 7.3)	337
4	8.5 (6.3 to 11)	220
5	12.5 (8.2 to 17.5)	65

¹Validation performed in a population of Medicare beneficiaries age 65 to 95 years who were not prescribed warfarin at hospital discharge.

Reproduced, with permission, from Gage BF et al. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. *JAMA*. 2001;285(22):2864–70.

consequent embolization, most devastatingly to the cerebral circulation. Overall, the rate of stroke is approximately 5 events per 100 patient-years of follow-up. However, patients with significant obstructive valvular disease, chronic heart failure or LV dysfunction, diabetes mellitus, hypertension, or age over 75 years and those with a history of prior stroke or other embolic events are at substantially higher risk (up to nearly 20 events per 100 patient-years in patients with multiple risk factors) (Table 10–10).

► Clinical Findings

A. Symptoms and Signs

Atrial fibrillation itself is rarely life-threatening; however, it can have serious consequences if the ventricular rate is sufficiently rapid to precipitate hypotension, myocardial ischemia, or tachycardia-induced myocardial dysfunction. Moreover, particularly in patients with risk factors, atrial fibrillation is a major preventable cause of stroke. Although many patients—particularly older or inactive individuals—have relatively few symptoms if the rate is controlled, some patients are aware of the irregular rhythm and may find it very uncomfortable. Most patients will complain of fatigue whether they experience other symptoms or not. The heart rate may range from quite slow to extremely rapid, but is uniformly irregular unless underlying complete heart block and a permanent ventricular pacemaker is in place. Atrial fibrillation is the only common arrhythmia in which the ventricular rate is rapid and the rhythm very irregular.

Because of the varying stroke volumes resulting from varying periods of diastolic filling, not all ventricular beats produce a palpable peripheral pulse. The difference between the apical rate and the pulse rate is the “pulse deficit”; this deficit is greater when the ventricular rate is high.

B. ECG

The surface ECG typically demonstrates erratic, disorganized atrial activity between discrete QRS complexes occurring in an irregular pattern. The atrial activity may be very fine and difficult to detect on the ECG, or quite coarse and often mistaken for atrial flutter.

► Treatment

A. Newly Diagnosed Atrial Fibrillation

1. Initial management

A. HEMODYNAMICALLY STABLE PATIENT—If, as is often the case—particularly in older individuals—the patient has no symptoms, hemodynamic instability, or evidence of important precipitating conditions (such as silent myocardial infarction or ischemia, decompensated heart failure, pulmonary embolism, or hemodynamically significant valvular disease), hospitalization is usually not necessary. In most of these cases, atrial fibrillation is an unrecognized chronic or paroxysmal condition and should be managed accordingly (see below). For new onset atrial fibrillation, thyroid function tests and assessment for occult valvular or myocardial disease should be performed.

B. HEMODYNAMICALLY UNSTABLE PATIENT—If the patient is hemodynamically unstable—usually as a result of a rapid ventricular rate or associated cardiac or noncardiac conditions—hospitalization and immediate treatment of atrial fibrillation are required. Urgent cardioversion is usually indicated in patients with shock or severe hypotension, pulmonary edema, or ongoing myocardial infarction or ischemia. There is a potential risk of thromboembolism in patients undergoing cardioversion who have not received anticoagulation therapy if atrial fibrillation has been present for > 48 hours; however, in hemodynamically unstable patients the need for immediate rate control outweighs that risk. Electrical cardioversion is usually preferred in unstable patients. An initial shock with 100–200 J is administered in synchrony with the R wave. If sinus rhythm is not restored, an additional attempt with 360 J is indicated. If this fails, cardioversion may be successful after loading with intravenous **ibutilide** (1 mg over 10 minutes, repeated in 10 minutes if necessary).

In more stable patients or those at particularly high risk for embolism (ie, underlying mitral stenosis, a history of prior embolism, or severe heart failure), a strategy of rate control and anticoagulation is appropriate. This is also true when the conditions that precipitated atrial fibrillation are likely to persist (such as following cardiac or noncardiac surgery, with respiratory failure, or with pericarditis). Rate control and anticoagulation is also appropriate even when the conditions causing the atrial fibrillation might resolve spontaneously over a period of hours to days (such as alcohol-induced atrial fibrillation, electrolyte or fluid

imbalance-related atrial fibrillation, atrial fibrillation due to exposure to excessive theophylline or sympathomimetic agents, or that due to some of the other conditions cited above). The choice of agent is guided by the hemodynamic status of the patient, associated conditions, and the urgency of achieving rate control. Although both hypotension and heart failure may improve when the ventricular rate is slowed, calcium channel blockers and β -blockers may themselves precipitate hemodynamic deterioration. Digoxin is less risky, but even when used aggressively (0.5 mg intravenously over 30 minutes, followed by increments of 0.25 mg every 1–2 hours to a total dose of 1–1.5 mg over 24 hours in patients not previously receiving this agent), rate control is rather slow and may be inadequate, particularly in patients with sympathetic activation. In the setting of myocardial infarction or ischemia, β -blockers are the preferred agent. The most frequently used agents are either metoprolol (administered as a 5 mg intravenous bolus, repeated twice at intervals of 5 minutes and then given as needed by repeat boluses or orally at total daily doses of 50–400 mg) or, in very unstable patients, esmolol (0.5 mg/kg intravenously, repeated once if necessary, followed by a titrated infusion of 0.05–0.2 mg/kg/min). If β -blockers are contraindicated, calcium channel blockers are immediately effective. Diltiazem (20 mg bolus, repeated after 15 minutes if necessary, followed by a maintenance infusion of 5–15 mg/h) is the preferred calcium blocker if hypotension or LV dysfunction is present. Otherwise, verapamil (5–10 mg intravenously over 2–3 minutes, repeated after 30 minutes if necessary) may be used. Amiodarone, even when administered intravenously, has a relatively slow onset but is often a useful adjunct when rate control with the previously cited agents is incomplete or contraindicated or when cardioversion is planned in the near future. However, amiodarone should not be used in this setting if long-term therapy is planned with other antiarrhythmic agents.

If rate control proves unsuccessful or early cardioversion is considered necessary and the duration of atrial fibrillation exceeds 2–3 days or is unknown, a strategy of transesophageal echocardiography-guided cardioversion should be considered. By this approach, the presence of atrial thrombus is excluded and electrical cardioversion can be attempted while the patient remains under sedation. If thrombus is present, the cardioversion is delayed until after a 4-week period of therapeutic anticoagulation. In any case, because atrial contractile activity may not recover for several weeks after restoration of sinus rhythm in patients who have been in atrial fibrillation for more than several days, cardioversion is usually followed by anticoagulation for at least 1 month unless there is a contraindication.

2. Subsequent management—Up to two-thirds of patients experiencing a first episode of atrial fibrillation will spontaneously revert to sinus rhythm within 24 hours. If atrial fibrillation persists or has been present for more than a week, spontaneous conversion is unlikely. In most cases early cardioversion is not required, so management consists of rate control and anticoagulation whether or not the patient has been admitted to hospital. Rate control is usually relatively easy to achieve with β -blockers, rate-slowing calcium blockers and, occasionally, digoxin, used as single

agents or more often in combination. Following the RACE II trial that failed to show benefit from strict rate control (resting heart rate < 80 bpm and exercise heart rate < 120 bpm), published guidelines no longer recommend strict rate control (to < 110 bpm) for patients without symptoms or LV dysfunction. In older patients, who often have diminished AV nodal function and relatively limited activity, modest rate control can often be achieved with a single agent. Most younger or more active individuals require a combination of two agents. Choice of the initial medication is best based on the presence of accompanying conditions: Hypertensive patients should be given β -blockers or calcium blockers; coronary patients should usually receive a β -blocker; and patients with heart failure should be given a β -blocker with consideration of adding digoxin. Adequacy of rate control should be evaluated by recording the apical pulse rate both at rest and with an appropriate level of activity (such as after brisk walking around the corridor or climbing stairs).

A. ANTICOAGULATION—For patients with atrial fibrillation, even when it is paroxysmal or occurs rarely, oral anticoagulation should be established and maintained indefinitely for patients with no contraindication to anticoagulation and at least one risk factor for stroke (Table 10–10). In addition to the traditional five risk factors that comprise the CHADS₂ score (heart failure, hypertension, age \geq 75 years, diabetes mellitus, and (2 points for) history of stroke or TIA), the European guidelines recommend that three additional factors included in the CHADS-VASC score be considered: age 65–74 years, female gender, and presence of vascular disease. The CHADS-VASC score is especially relevant for patients who have a CHADS₂ score of 0 or 1. If the CHADS-VASC score is \geq 2, oral anticoagulation is recommended, and if CHADS-VASC score is 1, oral anticoagulation or aspirin should be used, taking into account risk, benefit, and patient preferences.

In addition to vitamin K antagonists such as warfarin, three additional oral anticoagulants have been shown to be at least as effective as warfarin for stroke prevention: dabigatran, rivaroxaban, and apixaban. Unfortunately, studies show that only about half of patients with atrial fibrillation and an indication for oral anticoagulation are receiving it, and even when treated with warfarin, they are out of the target INR range nearly half the time. Cardioversion, if planned, should be performed after at least 3–4 weeks of anticoagulation at a therapeutic level. Anticoagulation clinics with systematic management of warfarin dosing and adjustment have been shown to result in better maintenance of target anticoagulation. For patients unable to take warfarin, clopidogrel plus aspirin (versus aspirin alone) was shown to reduce stroke risk by 28% in the ACTIVE-A trial, although with an increased risk of bleeding.

Dabigatran, an oral direct thrombin inhibitor, was compared with warfarin (in the RELY trial) for prevention of stroke and systemic embolism for patients with atrial fibrillation and at least one additional risk factor for stroke. The lower dabigatran dose (110 mg orally twice daily) was noninferior to warfarin in stroke prevention and caused significantly less bleeding, and a second higher (150 mg orally twice daily) dose, which has been approved by the FDA, resulted in significantly fewer strokes with similar

bleeding rates. Both doses of dabigatran caused substantially less intracerebral hemorrhage than warfarin. Patients with kidney disease (estimated creatinine clearance < 30 mL/min) were excluded because dabigatran is 80% renally metabolized, (the FDA approved a lower dose, 75 mg twice a day, for patients with creatinine clearances 15–30 mL/min). There was a higher incidence of gastrointestinal bleeding with dabigatran. Dabigatran is a very attractive alternative to warfarin for many patients because it eliminates the need for INR monitoring. There is no readily available reversal agent for dabigatran. The thrombin time provides a more accurate indication of dabigatran effect than other tests, although the aPTT can sometimes be used to see if there is a dabigatran effect. Patients may be converted from warfarin to dabigatran by stopping the warfarin and beginning dabigatran once the INR is ≤ 2.0 .

Rivaroxaban is an oral factor Xa inhibitor approved by the FDA for stroke prevention in atrial fibrillation. In the ROCKET AF trial, rivaroxaban proved noninferior to warfarin for stroke prevention for patients with high-risk features of thromboembolism. Rivaroxaban is dosed at 20 mg once daily, with a reduced dose (15 mg/d) for patients with creatinine clearances < 50 mL/min. Similar to dabigatran, there was substantially less intracranial hemorrhage with rivaroxaban than warfarin.

Apixaban is another oral factor Xa inhibitor shown to be more effective than warfarin at stroke prevention while having a substantially lower risk of major bleeding (in the ARISOTLE trial). Dosed at 5 mg twice daily, and 2.5 mg twice daily for patients with two of three high-risk criteria (age ≥ 80 years, body weight ≤ 60 kg, and serum creatinine ≥ 1.5 mg/dL), apixaban was associated with less intracranial hemorrhage and was well tolerated. Apixaban was also shown to be superior to aspirin, and better tolerated than aspirin, in the AVERROES trial of patients deemed not suitable for warfarin. Approval for apixaban by the US FDA is pending (to be considered in 2012).

Exceptions to the need for anticoagulation is the patient with “lone atrial fibrillation” (eg, no evidence of associated heart disease, hypertension, atherosclerotic vascular disease, or diabetes mellitus) who is under age 65 years or the patient with a low-risk profile (see Table 10–10). Such patients should be treated with aspirin 81–325 mg daily or no antithrombotic therapy, with the choice of no antithrombotic therapy preferred for patients with a CHADS-VASC score of 0.

B. RATE CONTROL OR ELECTIVE CARIOVERSION—Two large randomized controlled trials (the 4060-patient Atrial Fibrillation Follow-up Investigation of Rhythm Management, or AFFIRM trial; and the Rate Control Versus Electrical Cardioversion for Persistent Atrial Fibrillation, or RACE trial) compared strategies of rate control and rhythm control. In both, a strategy of rate control and long-term anticoagulation was associated with no higher rates of death or stroke—both, if anything, favored rate control—and only a modestly increased risk of hemorrhagic events than a strategy of restoring sinus rhythm and maintaining it with antiarrhythmic drug therapy. Of note is that exercise tolerance and quality of life were not significantly better in the rhythm control group. Nonetheless, the decision as to whether to

attempt to restore sinus rhythm following the initial episode remains controversial. Elective cardioversion following an appropriate period of anticoagulation is generally recommended for the initial episode in patients in whom atrial fibrillation is thought to be of recent onset and when there is an identifiable precipitating factor. Similarly, cardioversion is appropriate in patients who remain symptomatic from the rhythm despite aggressive efforts to achieve rate control. However, it should be noted that even in patients for whom this is the initial episode of atrial fibrillation, the recurrence rate is sufficiently high that longer-term anticoagulation is generally appropriate until persistence of sinus rhythm can be confirmed for at least 6 months.

In cases in which elective cardioversion is required, it may be accomplished electrically (as described above) or pharmacologically. Intravenous ibutilide may be used as described above in a setting in which the patient can undergo continuous ECG monitoring for at least 3 hours following administration. In patients in whom a decision has been made to continue antiarrhythmic therapy to maintain sinus rhythm (see next paragraph), cardioversion can be attempted with an agent that is being considered for long-term use. For instance, after therapeutic anticoagulation has been established, amiodarone can be initiated on an outpatient basis (400 mg twice daily for 2 weeks, followed by 200 mg twice daily for at least 2–4 weeks and then a maintenance dose of 200 mg daily). Because amiodarone increases the prothrombin time in patients taking warfarin and increases digoxin levels, careful monitoring of anticoagulation and drug levels is required.

Other agents that may be used for both cardioversion and maintenance therapy include dofetilide, propafenone, flecainide, and sotalol. **Dofetilide** (125–500 mcg twice daily orally) must be initiated in hospital due to the potential risk of torsades de pointes and the downward dose adjustment is required for patients with renal impairment. **Propafenone** (150–300 mg orally every 8 hours) should be avoided in patients with structural heart disease. **Flecainide** (50–150 mg twice daily orally) should be used in conjunction with an AV nodal blocking drug if there is a history of atrial flutter and should be avoided in patients with structural heart disease. **Sotalol** (80–160 mg orally twice daily) must be initiated in the hospital in patients with structural heart disease due to a risk of torsades de pointes; it is not very effective for converting atrial fibrillation but can be used to maintain sinus rhythm following cardioversion.

Unfortunately, sinus rhythm will persist in only 25% of patients who have had a sustained (lasting more than several days) or recurrent episode of atrial fibrillation. However, if the patient is treated long-term with an antiarrhythmic agent, sinus rhythm will persist in approximately 50%. The most commonly used medications are amiodarone, dronedarone, sotalol, propafenone, flecainide, and dofetilide, but the latter four agents are associated with a clear risk of proarrhythmia; dronedarone has less efficacy than amiodarone, and amiodarone frequently causes other adverse effects. Therefore, it may be prudent to determine whether atrial fibrillation recurs during a period of 6 months without antiarrhythmic drugs during which anticoagulation is maintained. If it does recur, the decision

as to whether to restore sinus rhythm and initiate long-term antiarrhythmic therapy can be based on how well the patient tolerates atrial fibrillation. In such a patient, long-term anticoagulation is probably indicated in any case, because of the high rate of recurrence and the likely occurrence of asymptomatic paroxysmal episodes.

B. Paroxysmal and Refractory Atrial Fibrillation

1. Recurrent paroxysmal atrial fibrillation—It is now well established that patients with recurrent paroxysmal atrial fibrillation are at similar stroke risk as those who are in atrial fibrillation chronically. Although these episodes may be apparent to the patient, many are not recognized and may be totally asymptomatic. Thus, ambulatory ECG monitoring or event recorders are indicated in those in whom paroxysmal atrial fibrillation is suspected. Antiarrhythmic agents are usually not successful in preventing all paroxysmal atrial fibrillation episodes. However, dofetilide has been shown to be as effective as amiodarone in maintaining sinus rhythm in certain patients and does not have as many untoward long-term effects. Long-term anticoagulation should be considered for all patients except in those who are under 65 years of age and have no additional stroke risk factors (see above).

2. Refractory atrial fibrillation—Because of trial results indicating that important adverse clinical outcomes (death, stroke, hemorrhage, heart failure) are no more common with rate control than rhythm control, atrial fibrillation should generally be considered refractory if it causes persistent symptoms or limits activity. This is much more likely in younger individuals and those who are very active or engage in strenuous exercise. Even in such individuals, two-drug or three-drug combinations of a β -blocker, rate-slowing calcium blocker, and digoxin usually can prevent excessive ventricular rates, though in some cases they are associated with excessive bradycardia during sedentary periods.

If no drug works, radiofrequency AV node ablation and permanent pacing ensure rate control and may facilitate a more physiologic rate response to activity, but this is used only as a last resort. The current practice for drug-refractory, symptomatic atrial fibrillation is catheter ablation of foci in and around the pulmonary veins that initiate atrial fibrillation, following which sinus rhythm may be restored or maintained. This therapy is a reasonable second-line therapy for individuals with symptomatic atrial fibrillation that is refractory to pharmacologic therapy. Ablation is successful about 70% of the time but more than one procedure is often required. The procedure is routinely performed in the electrophysiology laboratory using a catheter-based approach and can also be performed via a subxiphoid approach thoracoscopically, via thoracotomy, or via median sternotomy in the operating room by experienced surgeons.

► When to Refer

- Symptomatic atrial fibrillation with or without rate control.
- Asymptomatic atrial fibrillation with poor rate control despite AV nodal blockers.

► When to Admit

- Atrial fibrillation with rapid ventricular response resulting in hemodynamic compromise.
- Atrial fibrillation resulting in acute heart failure.

- Camm AJ et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). *Eur Heart J*. 2010 Oct;31(19):2369–429. [PMID: 20802247]
- Connolly SJ et al. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. *N Engl J Med*. 2009 May 14;360(20):2066–78. [PMID: 19336502]
- Connolly SJ et al; AVERROES Steering Committee and Investigators. Apixaban in patients with atrial fibrillation. *N Engl J Med*. 2011 Mar 3;364(9):806–17. [PMID: 21309657]
- Connolly SJ et al; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. *N Engl J Med*. 2009 Sep 17;361(12):1139–51. Erratum in: *N Engl J Med*. 2010 Nov 4;363(19):1877. [PMID: 19717844]
- Dagues N et al. Mortality after catheter ablation for atrial fibrillation compared with antiarrhythmic drug therapy. A meta-analysis of randomized trials. *Am Heart J*. 2009 Jul;158(1):15–20. [PMID: 19540387]
- Dobrev D et al. New antiarrhythmic drugs for treatment of atrial fibrillation. *Lancet*. 2010 Apr 3;375(9721):1212–23. [PMID: 20334907]
- Fuster V et al. 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 Guidelines for the management of patients with atrial fibrillation. *J Am Coll Cardiol*. 2011 Mar 15;57(11):e101–98. [PMID: 21392637]
- Granger CB et al; ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. *N Engl J Med*. 2011 Sep 15;365(11):981–92. [PMID: 21870978]
- Joglar JA et al. Electrical cardioversion of atrial fibrillation. *Cardiol Clin*. 2004 Feb;22(1):101–11. [PMID: 14994851]
- Kozlowski D et al. Lone atrial fibrillation: what do we know? *Heart*. 2010 Apr;96(7):498–503. [PMID: 19713203]
- Lip GY et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on Atrial Fibrillation. *Chest*. 2010 Feb;137(2):263–72. [PMID: 19762550]
- McKeown PP et al; American College of Chest Physicians. Executive summary: American College of Chest Physicians guidelines for the prevention and management of postoperative atrial fibrillation after cardiac surgery. *Chest*. 2005 Aug;128(2 Suppl):1S–5S. [PMID: 16167657]
- Parment S et al. JAMA patient page. Atrial fibrillation. *JAMA*. 2007 Dec 19;298(23):2820. [PMID: 18165677]
- Patel MR et al; ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. *N Engl J Med*. 2011 Sep 8;365(10):883–91. [PMID: 21830957]
- Stevenson WG et al. Management of atrial fibrillation in patients with heart failure. *Heart Rhythm*. 2007 Mar;4(3 Suppl):S28–30. [PMID: 17336880]
- Van Gelder IC et al; RACE II Investigators. Lenient versus strict rate control in patients with atrial fibrillation. *N Engl J Med*. 2010 Apr 15;362(15):1363–73. [PMID: 20231232]
- Wilber DJ et al; ThermoCool AF Trial Investigators. Comparison of antiarrhythmic drug therapy and radiofrequency catheter ablation in patients with paroxysmal atrial fibrillation: a randomized controlled trial. *JAMA*. 2010 Jan 27;303(4):333–40. [PMID: 20103757]

ATRIAL FLUTTER



ESSENTIALS OF DIAGNOSIS

- ▶ Usually regular heart rhythm.
- ▶ Often tachycardic (100–150 beats/min).
- ▶ Often associated with palpitations (acute onset) or fatigue (chronic).
- ▶ ECG shows “sawtooth” pattern of atrial activity in leads II, III, and AVF.
- ▶ Often seen in conjunction with structural heart disease or chronic obstructive pulmonary disease.

Atrial flutter is less common than fibrillation. It occurs most often in patients with chronic obstructive pulmonary disease (COPD) but may be seen also in those with rheumatic or coronary heart disease, CHF, ASD, or surgically repaired congenital heart disease. The reentrant circuit generates atrial rates of 250–350 beats/min, usually with transmission of every second, third, or fourth impulse through the AV node to the ventricles. The ECG typically demonstrates a “sawtooth” pattern of atrial activity in the inferior leads (II, III, and AVF).

▶ Treatment

Ventricular rate control is accomplished using the same agents used in atrial fibrillation, but it is much more difficult with atrial flutter than with atrial fibrillation. Conversion of atrial flutter to sinus rhythm with class I antiarrhythmic agents is also difficult to achieve, and administration of these drugs has been associated with slowing of the atrial flutter rate to the point at which 1:1 AV conduction can occur at rates in excess of 200 beats/min, with subsequent hemodynamic collapse. The intravenous class III antiarrhythmic agent ibutilide has been significantly more successful in converting atrial flutter. About 50–70% of patients return to sinus rhythm within 60–90 minutes following the infusion of 1–2 mg of this agent. Electrical cardioversion is also very effective for atrial flutter, with approximately 90% of patients converting following synchronized shocks of as little as 25–50 J.

The persistence of atrial contractile function in this arrhythmia provides some protection against thrombus formation, though the risk of systemic embolization remains increased. Precardioversion anticoagulation is not necessary for atrial flutter of < 48 hours duration except in the setting of mitral valve disease. However, **anticoagulation** is necessary in chronic atrial flutter, given that the stroke risk is the same as with chronic atrial fibrillation, perhaps because transient periods of atrial fibrillation are common in these patients.

Chronic atrial flutter is often a difficult management problem, as rate control is difficult. If pharmacologic therapy is chosen, amiodarone and dofetilide are the antiarrhythmics of choice. Dofetilide is often given in conjunction with an AV nodal blocker (other than verapamil). Atrial flutter can follow a typical or atypical reentry circuit around

the atrium. The anatomy of the typical circuit has been well defined and allows for catheter ablation within the atrium to interrupt the circuit and eliminate atrial flutter. Catheter ablation is a highly successful treatment that has become the preferred approach for recurrent typical atrial flutter.

▶ When to Refer

- Symptomatic atrial flutter with or without rate control.
- Asymptomatic atrial flutter with poor rate control despite AV nodal blockers.

▶ When to Admit

- Atrial flutter with 1:1 conduction resulting in hemodynamic compromise.
- Atrial flutter resulting in acute heart failure.

Da Costa A et al. Results from the Loire-Ardèche-Drôme-Isère-Puy-de-Dôme (LADIP) trial on atrial flutter, a multicentric prospective randomized study comparing amiodarone and radiofrequency ablation after the first episode of symptomatic atrial flutter. *Circulation*. 2006 Oct 17;114(16):1676–81. [PMID: 17030680]

Ghali WA et al. Atrial flutter and the risk of thromboembolism: a systematic review and meta-analysis. *Am J Med*. 2005 Feb;118(2):101–7. [PMID: 15694889]

Rodgers M et al. Curative catheter ablation in atrial fibrillation and typical atrial flutter: systematic review and economic evaluation. *Health Technol Assess*. 2008 Nov;12(34):1–198. [PMID: 19036232]

Spector P et al. Meta-analysis of ablation of atrial flutter and supraventricular tachycardia. *Am J Cardiol*. 2009 Sep 1;104(5):671–7. [PMID: 19699343]

MULTIFOCAL ATRIAL TACHYCARDIA



ESSENTIALS OF DIAGNOSIS

- ▶ ECG reveals three or more distinct P-wave morphologies.
- ▶ Often associated with palpitations.
- ▶ Associated with severe COPD.
- ▶ Treatment of the underlying lung disease is the most effective therapy.

This is a rhythm characterized by varying P wave morphology (by definition, three or more foci) and markedly irregular PP intervals. The rate is usually between 100 and 140 beats/min, and AV block is unusual. Most patients have concomitant severe COPD. Treatment of the underlying condition is the most effective approach; verapamil, 240–480 mg daily in divided doses, is also of value in some patients, but this particular arrhythmia is very difficult to manage.

Spodick DH. Multifocal atrial arrhythmia. *Am J Geriatr Cardiol*. 2005 May–Jun;14(3):162. [PMID: 15886545]

AV JUNCTIONAL RHYTHM



ESSENTIALS OF DIAGNOSIS

- ▶ Regular heart rhythm.
- ▶ Can have wide or narrow QRS complex.
- ▶ Often seen in digitalis toxicity.

The atrial-nodal junction or the nodal-His bundle junction may assume pacemaker activity for the heart, usually at a rate of 35–60 beats/min. This may occur in patients with myocarditis, CAD, and digitalis toxicity as well as in individuals with normal hearts. The rate responds normally to exercise, and the diagnosis is often an incidental finding on ECG monitoring, but it can be suspected if the jugular venous pulse shows cannon *a* waves. Junctional rhythm is often an escape rhythm because of depressed sinus node function with sinoatrial block or delayed conduction in the AV node. **Nonparoxysmal junctional tachycardia** results from increased automaticity of the junctional tissues in digitalis toxicity or ischemia and is associated with a narrow QRS complex and a rate usually < 120–130 beats/min. It is usually considered benign when it occurs in acute myocardial infarction, but the ischemia that induces it may also cause ventricular tachycardia and ventricular fibrillation.

VENTRICULAR PREMATURE BEATS (Ventricular Extrasystoles)

Ventricular premature beats, also called PVCs, are typically isolated beats originating from ventricular tissue. Sudden death occurs more frequently (presumably as a result of ventricular fibrillation) when ventricular premature beats occur in the presence of organic heart disease but not in individuals with no known cardiac disease.

Clinical Findings

The patient may or may not sense the irregular beat, usually as a skipped beat. Exercise generally abolishes premature beats in normal hearts, and the rhythm becomes regular. Ventricular premature beats are characterized by wide QRS complexes that differ in morphology from the patient's normal beats. They are usually not preceded by a P wave, although retrograde ventriculoatrial conduction may occur. Unless the latter is present, there is a fully compensatory pause (ie, without change in the PP interval). Bigeminy and trigeminy are arrhythmias in which every second or third beat is premature; these patterns confirm a reentry mechanism for the ectopic beat. Ambulatory ECG monitoring or monitoring during graded exercise may reveal more frequent and complex ventricular premature beats than occur in a single routine ECG. An increased frequency of ventricular premature beats during exercise is associated with a higher risk of cardiovascular mortality, though there is no evidence that specific therapy has a role.

Treatment

If no associated cardiac disease is present and if the ectopic beats are asymptomatic, no therapy is indicated. If they are frequent, electrolyte abnormalities (especially hypokalemia or hyperkalemia and hypomagnesemia), hyperthyroidism, and occult heart disease should be excluded. Pharmacologic treatment is indicated only for patients who are symptomatic. Because of concerns about worsening arrhythmia and sudden death with most antiarrhythmic agents, β -blockers are the agents of first choice. If the underlying condition is mitral prolapse, hypertrophic cardiomyopathy, LVH, or coronary disease—or if the QT interval is prolonged— β -blocker therapy is appropriate. The class I and III agents (see Table 10–9) are all effective in reducing ventricular premature beats but often cause side effects and may exacerbate serious arrhythmias in 5–20% of patients. Therefore, every attempt should be made to avoid using class I or III antiarrhythmic agents in patients without symptoms. Catheter ablation is now a well-established therapy for symptomatic individuals who do not respond to antiarrhythmic drugs or for those patients whose burden of ectopic beats has resulted in a tachycardia-induced cardiomyopathy.

Das MK et al. Role of ablation therapy in ventricular arrhythmias. *Cardiol Clin*. 2008 Aug;26(3):459–79. [PMID: 18538191]

Morshedi-Meibodi A et al. Clinical correlates and prognostic significance of exercise-induced ventricular premature beats in the community: the Framingham Heart Study. *Circulation*. 2004 May 25;109(20):2417–22. [PMID: 15148273]

Ng GA. Treating patients with ventricular ectopic beats. *Heart*. 2006 Nov;92(11):1707–12. [PMID: 17041126]

O'Neill JO et al. Severe frequent ventricular ectopy after exercise as a predictor of death in patients with heart failure. *J Am Coll Cardiol*. 2004 Aug 18;44(4):820–6. [PMID: 15312865]

Wijnmaalen AP et al. Beneficial effects of catheter ablation on left ventricular and right ventricular function in patients with frequent premature ventricular contractions and preserved ejection fraction. *Heart*. 2010 Aug;96(16):1275–80. [PMID: 20659945]

VENTRICULAR TACHYCARDIA



ESSENTIALS OF DIAGNOSIS

- ▶ Fast, wide complex rhythm.
- ▶ Often associated with structural heart disease.
- ▶ Frequently associated with syncope.
- ▶ If associated with structural heart disease, the implantable cardioverter-defibrillator is the recommended therapy.

General Considerations

Ventricular tachycardia is defined as three or more consecutive ventricular premature beats. The usual rate is 160–240 beats/min and is moderately regular but less so

than atrial tachycardia. The usual mechanism is reentry, but abnormally triggered rhythms occur.

Ventricular tachycardia is a frequent complication of acute myocardial infarction and dilated cardiomyopathy but may occur in chronic coronary disease, hypertrophic cardiomyopathy, mitral valve prolapse, myocarditis, and in most other forms of myocardial disease. It can also be a consequence of atypical forms of cardiomyopathies, such as arrhythmogenic right ventricular cardiomyopathy. However, ventricular tachycardia can also occur in patients with structurally normal hearts. **Torsades de pointes**, a form of ventricular tachycardia in which QRS morphology twists around the baseline, may occur spontaneously in the setting of hypokalemia or hypomagnesemia or after any drug or condition that prolongs the QT interval. In nonacute settings, most patients with ventricular tachycardia have known or easily detectable cardiac disease, and the finding of ventricular tachycardia is an unfavorable prognostic sign.

► Clinical Findings

A. Symptoms and Signs

Patients may be asymptomatic or experience syncope or milder symptoms of impaired cerebral perfusion.

B. Laboratory Findings

Ventricular tachycardia can occur in the setting of hypokalemia and hypomagnesemia.

C. Differentiation of Aberrantly Conducted Supraventricular Beats from Ventricular Beats

Ventricular tachycardia is either nonsustained (three or more consecutive beats lasting < 30 seconds and terminating spontaneously) or sustained. The distinction from aberrant conduction of supraventricular tachycardia may be difficult in patients with a wide QRS complex; it is important because of the differing prognostic and therapeutic implications of each type. Findings favoring a ventricular origin include (1) AV dissociation; (2) a QRS duration exceeding 0.14 second; (3) capture or fusion beats (infrequent); (4) left axis deviation with right bundle branch block morphology; (5) monophasic (R) or biphasic (qR, QR, or RS) complexes in V_1 ; and (6) a qR or QS complex in V_6 . Supraventricular origin is favored by (1) a triphasic QRS complex, especially if there was initial negativity in leads I and V_6 ; (2) ventricular rates exceeding 170 beats/min; (3) QRS duration longer than 0.12 second but not longer than 0.14 second; and (4) the presence of preexcitation syndrome.

The relationship of the P waves to the tachycardia complex is helpful. A 1:1 relationship usually means a supraventricular origin, except in the case of ventricular tachycardia with retrograde P waves.

► Treatment

A. Acute Ventricular Tachycardia

The treatment of acute ventricular tachycardia is determined by the degree of hemodynamic compromise and the duration of the arrhythmia. The management of ventricular

tachycardia in acute myocardial infarction has been discussed. In other patients, if ventricular tachycardia causes hypotension, heart failure, or myocardial ischemia, synchronized DC cardioversion with 100–360 J should be performed immediately. If the patient is tolerating the rhythm, amiodarone 150 mg as a slow intravenous bolus over 10 minutes, followed by a slow infusion of 1 mg/min for 6 hours and then a maintenance infusion of 0.5 mg/min for an additional 18–42 hours can be used. Lidocaine, 1 mg/kg as an intravenous bolus injection, can also be used. If the ventricular tachycardia recurs, supplemental amiodarone infusions of 150 mg over 10 minutes can be given. If the patient is stable, intravenous procainamide, 20 mg/min intravenously (up to 1000 mg), followed by an infusion of 20–80 mcg/kg/min could also be tried. Empiric magnesium replacement (1–2 g intravenously) may help. Ventricular tachycardia can also be terminated by ventricular overdrive pacing, and this approach is useful when the rhythm is recurrent.

B. Chronic Recurrent Ventricular Tachycardia

1. Sustained ventricular tachycardia—Patients with symptomatic or sustained ventricular tachycardia in the absence of a reversible precipitating cause (acute myocardial infarction or ischemia, electrolyte imbalance, drug toxicity, etc) are at high risk for recurrence. In those with significant LV dysfunction, subsequent sudden death is common. Several trials, including the Antiarrhythmics Versus Implantable Defibrillator (AVID) and the Canadian Implantable Defibrillator trials, strongly suggest that these patients should be managed with implantable cardioverter-defibrillators (ICDs). In those with preserved LV function, the mortality rate is lower and the etiology is often different than in those with depressed ventricular function. Treatment with amiodarone, optimally in combination with a β -blocker, may be adequate. Sotalol may be an alternative, though there is less supporting evidence. However, many times if ventricular tachycardia occurs in a patient with preserved ventricular function, it is either an outflow tract tachycardia or a fascicular ventricular tachycardia, and these arrhythmias will often respond to AV nodal blockers and can be effectively treated with catheter ablation. The role of electrophysiologic studies in this group is less clear than was previously thought, but they may help identify patients who are candidates for radiofrequency ablation of a ventricular tachycardia focus. This is particularly the case for arrhythmias that originate in the ventricular outflow tract (often appearing as left bundle branch block with inferior axis on the surface ECG), the left posterior fascicle (right bundle branch block, superior axis morphology), or sustained bundle branch reentry. Catheter ablation can be used as a palliative therapy for those patients with recurrent tachycardia who receive ICD shocks despite antiarrhythmic therapy.

2. Nonsustained ventricular tachycardia (NSVT)

NSVT is defined as runs of three or more ventricular beats lasting < 30 seconds and terminating spontaneously. These may be symptomatic (usually experienced as light-headedness) or asymptomatic. In individuals without heart disease, NSVT is not clearly associated with a poor prognosis.

However, in patients with structural heart disease, particularly when they have reduced LV EF, there is an increased risk of subsequent symptomatic ventricular tachycardia or sudden death. β -Blockers reduce these risks in patients who have coronary disease with significant LV systolic dysfunction (EFs < 35–40%), but if sustained ventricular tachycardia has been induced during electrophysiologic testing, an implantable defibrillator may be indicated. In patients with chronic heart failure and reduced EFs—whether due to coronary disease or primary cardiomyopathy and regardless of the presence of asymptomatic ventricular arrhythmias— β -blockers reduce the incidence of sudden death by 40–50% and should be routine therapy (see section on Heart Failure).

Although there are no definitive data with amiodarone in this group, trends from a number of studies suggest that it may be beneficial. Other antiarrhythmic agents should generally be avoided because their proarrhythmic risk appears to outweigh any benefit, even in patients with inducible arrhythmias that are successfully suppressed in the electrophysiology laboratory.

► When to Admit

Any sustained ventricular tachycardia.

Das MK et al. Antiarrhythmic and nonantiarrhythmic drugs for sudden cardiac death prevention. *J Cardiovasc Pharmacol*. 2010 May;55(5):438–49. [PMID: 20509177]

Katritsis DG et al. Nonsustained ventricular tachycardia: where do we stand? *Eur Heart J*. 2004 Jul;25(13):1093–9. [PMID: 15231366]

Kuck KH et al; VTACH study group. Catheter ablation of stable ventricular tachycardia before defibrillator implantation in patients with coronary heart disease (VTACH): a multicentre randomised controlled trial. *Lancet*. 2010 Jan 2;375(9708):31–40. [PMID: 20109864]

Scirica BM et al. Relationship between nonsustained ventricular tachycardia after non-ST-elevation acute coronary syndrome and sudden cardiac death: observations from the metabolic efficiency with ranolazine for less ischemia in non-ST-elevation acute coronary syndrome-thrombolysis in myocardial infarction 36 (MERLIN-TIMI 36) randomized controlled trial. *Circulation*. 2010 Aug 3;122(5):455–62. [PMID: 20644019]

Shimizu W. Arrhythmias originating from the right ventricular outflow tract: how to distinguish “malignant” from “benign”? *Heart Rhythm*. 2009 Oct;6(10):1507–11. [PMID: 19695964]

Srivathsan K et al. Ventricular tachycardia and ventricular fibrillation. *Exp Rev Cardiovasc Ther*. 2009 Jul;7(7):801–9. [PMID: 19589116]

Stevenson WG. Ventricular scars and ventricular tachycardia. *Trans Am Clin Climatol Assoc*. 2009;120:403–12. [PMID: 19768192]

VENTRICULAR FIBRILLATION & DEATH

Sudden cardiac death is defined as unexpected nontraumatic death in clinically well or stable patients who die within 1 hour after onset of symptoms. The causative rhythm in most cases is ventricular fibrillation, which is usually preceded by ventricular tachycardia except in the setting of acute ischemia or infarction. Complete heart block and sinus node arrest may also cause sudden death.

A disproportionate number of sudden deaths occur in the early morning hours and this suggests that there is a strong interplay with the autonomic nervous system. Over 75% of victims of sudden cardiac death have severe CAD. Many have old myocardial infarctions. Sudden death may be the initial manifestation of coronary disease in up to 20% of patients and accounts for approximately 50% of deaths from coronary disease. Other conditions that predispose to sudden death include severe LVH, hypertrophic cardiomyopathy, congestive cardiomyopathy, aortic stenosis, pulmonary stenosis, primary pulmonary hypertension, cyanotic congenital heart disease, atrial myxoma, mitral valve prolapse, hypoxia, electrolyte abnormalities, prolonged QT interval syndrome, the Brugada syndrome, arrhythmogenic right ventricular cardiomyopathy, catecholaminergic polymorphic ventricular tachycardia, and conduction system disease.

► Treatment

Unless ventricular fibrillation occurs shortly after myocardial infarction, is associated with ischemia, or is seen with an unusual correctable process (such as an electrolyte abnormality, drug toxicity, or aortic stenosis), surviving patients require evaluation and intervention since recurrences are frequent. Coronary arteriography should be performed to exclude coronary disease as the underlying cause, since revascularization may prevent recurrence. When ventricular fibrillation occurs in the initial 24 hours after infarction, long-term management is no different from that of other patients with acute infarction. Conduction disturbances should be managed as described in the next section. The current consensus is that if myocardial infarction or ischemia, bradyarrhythmias and conduction disturbances or other identifiable and correctable precipitating causes of ventricular fibrillation are not found to be the cause of the sudden death episode, an implantable cardioverter-defibrillator is the treatment of choice. In addition, evidence from the MADIT II study and Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) suggest that patients with severe LV dysfunction—whether due to an ischemic cause such as a remote myocardial infarction or a nonischemic cause of advanced heart failure—have a reduced risk of death with the prophylactic implantation of an implantable cardioverter-defibrillator. However, the DINAMIT study demonstrated that implanting prophylactic ICDs in patients early after myocardial infarction is associated with a trend toward worse outcomes.

Bardy GH et al. An entirely subcutaneous implantable cardioverter-defibrillator. *N Engl J Med*. 2010 Jul 1;363(1):36–44. [PMID: 20463331]

Brodie WN et al; MADIT-II Research Group. Effects of beta-blockers on implantable cardioverter defibrillator therapy and survival in the patients with ischemic cardiomyopathy (from the Multicenter Automatic Defibrillator Implantation Trial-II). *Am J Cardiol*. 2005 Sep 1;96(5):691–5. [PMID: 16125497]

- Hohnloser SH et al; DINAMIT Investigators. Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction. *N Engl J Med*. 2004 Dec 9;351(24):2481–8. [PMID: 15590950]
- Kadish A et al; Defibrillators in Non-Ischemic Cardiomyopathy Treatment Evaluation (DEFINITE) Investigators. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. *N Engl J Med*. 2004 May 20;350(21):2151–8. [PMID: 15152060]
- Klein HU et al. Bridging a temporary high risk of sudden arrhythmic death. Experience with the wearable cardioverter defibrillator (WCD). *Pacing Clin Electrophysiol*. 2010 Mar;33(3):353–67. [PMID: 19889186]
- Knecht S et al. Long-term follow-up of idiopathic ventricular fibrillation ablation: a multicenter study. *J Am Coll Cardiol*. 2009 Aug 4;54(6):522–8. [PMID: 19643313]
- Olasveengen TM et al. Intravenous drug administration during out-of-hospital cardiac arrest: a randomized trial. *JAMA*. 2009 Nov 25;302(20):2222–9. [PMID: 19934423]
- Sasson C et al. Predictors of survival from out-of-hospital cardiac arrest: a systematic review and meta-analysis. *Circulation*. 2010 Jan 13;121(1):63–81. [PMID: 20123673]
- Svensson L et al. Compression-only CPR or standard CPR in out-of-hospital cardiac arrest. *N Engl J Med*. 2010 Jul 29;363(5):434–42. [PMID: 20818864]

ACCELERATED IDIOVENTRICULAR RHYTHM

Accelerated idioventricular rhythm is a regular wide complex rhythm with a rate of 60–120 beats/min, usually with a gradual onset. Because the rate is often similar to the sinus rate, fusion beats and alternating rhythms are common. Two mechanisms have been invoked: (1) an escape rhythm due to suppression of higher pacemakers resulting from sinoatrial and AV block or from depressed sinus node function; and (2) slow ventricular tachycardia due to increased automaticity or, less frequently, reentry. It occurs commonly in acute infarction and following reperfusion after thrombolytic drugs. The incidence of associated ventricular fibrillation is much less than that of ventricular tachycardia with a rapid rate, and treatment is not indicated unless there is hemodynamic compromise or more serious arrhythmias. This rhythm also is common in digitalis toxicity.

Accelerated idioventricular rhythm must be distinguished from the idioventricular or junctional rhythm with rates < 40–45 beats/min that occurs in the presence of complete AV block. AV dissociation—where ventricular rate exceeds sinus—but not AV block occurs in most cases of accelerated idioventricular rhythm.

LONG QT SYNDROME

Congenital long QT syndrome is an uncommon disease that is characterized by recurrent syncope, a long QT interval (usually 0.5–0.7 second), documented ventricular arrhythmias, and sudden death. It may occur in the presence (Jervell-Lange-Nielsen syndrome) or absence (Romano-Ward syndrome) of congenital deafness. Inheritance may

be autosomal recessive or autosomal dominant (Romano-Ward). Specific genetic mutations affecting membrane potassium and sodium channels have been identified and help delineate the mechanisms of susceptibility to arrhythmia.

Because this is a primary electrical disorder, usually with no evidence of structural heart disease or LV dysfunction, the long-term prognosis is excellent if arrhythmia is controlled. Long-term treatment with β -blockers or permanent pacing has been shown to be effective. ICD implantation is recommended for patients in whom recurrent syncope, sustained ventricular arrhythmias, or sudden cardiac death occurs despite drug therapy. The ICD should be considered as primary therapy in certain patients, such as those in whom aborted sudden cardiac death is the initial presentation of the long-QT syndrome, when there is a strong family history of sudden cardiac death, or when compliance or intolerance to drugs is a concern.

Acquired long QT interval secondary to use of antiarrhythmic agents, antidepressant drugs, or certain antibiotics; electrolyte abnormalities; myocardial ischemia; or significant bradycardia may result in ventricular tachycardia (particularly torsades de pointes, ie, twisting about the baseline into varying QRS morphology). Notably, many drugs that are in some settings effective for the treatment of ventricular arrhythmias prolong the QT interval. Prudence dictates that drug therapy that prolongs the QT interval beyond 500 ms or 15% longer than the baseline QT be discontinued.

The management of torsades de pointes differs from that of other forms of ventricular tachycardia. Class I, Ic, or III antiarrhythmics, which prolong the QT interval, should be avoided—or withdrawn immediately if being used. Intravenous β -blockers may be effective, especially in the congenital form; intravenous magnesium should be given acutely. An effective approach is temporary ventricular or atrial pacing, which can both break and prevent the rhythm.

- Goldenberg I et al. Sudden cardiac death without structural heart disease: update on the long QT and Brugada syndromes. *Curr Cardiol Rep*. 2005 Sep;7(5):349–56. [PMID: 16105490]
- Kaufman ES. Mechanisms and clinical management of inherited channelopathies: long QT syndrome, Brugada syndrome, catecholaminergic polymorphic ventricular tachycardia, and short QT syndrome. *Heart Rhythm*. 2009 Aug;6(8 Suppl):S51–5. [PMID: 19631908]
- Monnig G et al. Implantable cardioverter-defibrillator therapy in patients with congenital long-QT syndrome: a long-term follow-up. *Heart Rhythm*. 2005 May;2(5):497–504. [PMID: 15840474]
- Priori SG et al. Association of long QT syndrome loci and cardiac events among patients treated with beta-blockers. *JAMA*. 2004 Sep 15;292(11):1341–4. [PMID: 15367556]
- Roden DM. Clinical practice. Long-QT syndrome. *N Engl J Med*. 2008 Jan 10;358(2):169–76. [PMID: 18184962]
- Sherrid MV et al. Risks and challenges of implantable cardioverter-defibrillators in young adults. *Prog Cardiovasc Dis*. 2008 Nov–Dec;51(3):237–63. [PMID: 19026858]

BRADYCARDIAS & CONDUCTION DISTURBANCES

SICK SINUS SYNDROME

ESSENTIALS OF DIAGNOSIS

- ▶ Most patients are asymptomatic.
- ▶ More common in elderly population.
- ▶ May have recurrent supraventricular arrhythmia and bradyarrhythmia.
- ▶ Frequently seen in patients with concomitant atrial fibrillation.
- ▶ Often chronotropically incompetent.
- ▶ May be caused by drug therapy.

General Considerations

This imprecise diagnosis is applied to patients with sinus arrest, sinoatrial exit block (recognized by a pause equal to a multiple of the underlying PP interval or progressive shortening of the PP interval prior to a pause), or persistent sinus bradycardia. These rhythms are often caused or exacerbated by drug therapy (digitalis, calcium channel blockers, β -blockers, sympatholytic agents, antiarrhythmics), and agents that may be responsible should be withdrawn prior to making the diagnosis. Another presentation is of recurrent supraventricular tachycardias (paroxysmal reentry tachycardias, atrial flutter, and atrial fibrillation), associated with bradyarrhythmias (“tachy-brady syndrome”). The long pauses that often follow the termination of tachycardia cause the associated symptoms.

Sick sinus syndrome occurs most commonly in elderly patients and is frequently seen in patients with concomitant atrial fibrillation. The pathologic changes are usually nonspecific, characterized by patchy fibrosis of the sinus node and cardiac conduction system. Sick sinus syndrome may be caused by other conditions, including sarcoidosis, amyloidosis, Chagas disease, and various cardiomyopathies. Coronary disease is an uncommon cause.

Clinical Findings

Most patients with ECG evidence of sick sinus syndrome are asymptomatic, but rare individuals may experience syncope, dizziness, confusion, palpitations, heart failure, or angina. Because these symptoms are either nonspecific or are due to other causes, it is essential that they be demonstrated to coincide temporally with arrhythmias. This may require prolonged ambulatory monitoring or the use of an event recorder.

Treatment

Most symptomatic patients will require permanent pacing (see AV block, below). Dual-chamber pacing is preferred because ventricular pacing is associated with a higher incidence of subsequent atrial fibrillation, and subsequent AV

block occurs at a rate of 2% per year. In addition, resultant “pacemaker syndrome” can result from loss of AV synchrony. Treatment of associated tachyarrhythmias is often difficult without first instituting pacing, since digoxin and other antiarrhythmic agents may exacerbate the bradycardia. Unfortunately, symptomatic relief following pacing has not been consistent, largely because of inadequate documentation of the etiologic role of bradyarrhythmias in producing the symptom. Furthermore, many of these patients may have associated ventricular arrhythmias that may require treatment; however, carefully selected patients may become asymptomatic with permanent pacing alone.

Alboni P et al. Treatment of persistent sinus bradycardia with intermittent symptoms: are guidelines clear? *Europace*. 2009 May;11(5):562–4. [PMID: 19213798]
 Chen PS et al. The initiation of the heart beat. *Circ J*. 2010 Feb;74(2):221–5. [PMID: 20019407]
 Dobrzynski H et al. New insights into pacemaker activity: promoting understanding of sick sinus syndrome. *Circulation*. 2007 Apr 10;115(14):1921–32. [PMID: 17420362]
 Monfredi O et al. The anatomy and physiology of the sinoatrial node—a contemporary review. *Pacing Clin Electrophysiol*. 2010 Nov;33(11):1392–406. [PMID: 20946278]
 Sweeney MO et al; Search AV Extension and Managed Ventricular Pacing for Promoting Atrioventricular Conduction (SAVE PACE) Trial. Minimizing ventricular pacing to reduce atrial fibrillation in sinus node disease. *N Engl J Med*. 2007 Sep 6;357(10):1000–8. [PMID: 17804844]

AV BLOCK

AV block is categorized as first-degree (PR interval > 0.21 second with all atrial impulses conducted), second-degree (intermittent blocked beats), or third-degree (complete heart block, in which no supraventricular impulses are conducted to the ventricles).

Second-degree block is subclassified. In **Mobitz type I (Wenckebach)** AV block, the AV conduction time (PR interval) progressively lengthens, with the RR interval shortening, before the blocked beat; this phenomenon is almost always due to abnormal conduction within the AV node. In **Mobitz type II** AV block, there are intermittently nonconducted atrial beats not preceded by lengthening AV conduction. It is usually due to block within the His bundle system. The classification as Mobitz type I or Mobitz type II is only partially reliable because patients may appear to have both types on the surface ECG, and the site of origin of the 2:1 AV block cannot be predicted from the ECG. The width of the QRS complexes assists in determining whether the block is nodal or infranodal. When they are narrow, the block is usually nodal; when they are wide, the block is usually infranodal. Electrophysiologic studies may be necessary for accurate localization. Management of AV block in acute myocardial infarction has already been discussed. This section deals with patients in the nonischemic setting.

First-degree and **Mobitz type I block** may occur in normal individuals with heightened vagal tone. They may also occur as a drug effect (especially digitalis, calcium channel blockers, β -blockers, or other sympatholytic

agents), often superimposed on organic disease. These disturbances also occur transiently or chronically due to ischemia, infarction, inflammatory processes (including Lyme disease), fibrosis, calcification, or infiltration. The prognosis is usually good, since reliable alternative pacemakers arise from the AV junction below the level of block if higher degrees of block occur.

Mobitz type II block is almost always due to organic disease involving the infranodal conduction system. In the event of progression to complete heart block, alternative pacemakers are not reliable. Thus, prophylactic ventricular pacing is required.

Complete (third-degree) heart block is a more advanced form of block often due to a lesion distal to the His bundle and associated with bilateral bundle branch block. The QRS is wide and the ventricular rate is slower, usually < 50 beats/min. Transmission of atrial impulses through the AV node is completely blocked, and a ventricular pacemaker maintains a slow, regular ventricular rate, usually < 45 beats/min. Exercise does not increase the rate. The first heart sound varies in intensity; wide pulse pressure, a changing systolic BP level, and cannon venous pulsations in the neck are also present. Patients may be asymptomatic or may complain of weakness or dyspnea if the rate is < 35 beats/min; symptoms may occur at higher rates if the left ventricle cannot increase its stroke output. During periods of transition from partial to complete heart block, some patients have ventricular asystole that lasts several seconds to minutes. Syncope occurs abruptly.

Patients with episodic or chronic infranodal complete heart block require permanent pacing, and temporary pacing is indicated if implantation of a permanent pacemaker is delayed.

► Treatment

The indications for **permanent pacing** have been discussed: symptomatic bradyarrhythmias, asymptomatic Mobitz II AV block, or complete heart block. The versatility of pacemaker generator units has increased markedly, and dual-chamber multiple programmable units are being implanted with increasing frequency. A standardized nomenclature for pacemaker generators is used, usually consisting of four letters. The first letter refers to the chamber that is stimulated (A = atrium, V = ventricle, D = dual, for both). The second letter refers to the chamber in which sensing occurs (also A, V, or D). The third letter refers to the sensory mode (I = inhibition by a sensed impulse, T = triggering by a sensed impulse, D = dual modes of response). The fourth letter refers to the programmability or rate modulation capacity (usually P for programming for two functions, M for programming more than two, and R for rate modulation).

A pacemaker that senses and paces in both chambers is the most physiologic approach to pacing patients who remain in sinus rhythm. AV synchrony is particularly important in patients in whom atrial contraction produces a substantial increment in stroke volume and in those in whom sensing the atrial rate to provide rate-responsive ventricular pacing is useful. Dual-chamber pacing is most

useful for individuals with LV systolic or—perhaps more importantly—diastolic dysfunction and for physically active individuals. In patients with single-chamber pacemakers, the lack of an atrial kick may lead to the so-called pacemaker syndrome, in which the patient experiences signs of low cardiac output while upright.

Pulse generators are also available that can increase their rate in response to motion or respiratory rate when the atrial rate is not an indication of the optimal heart rate. These are most useful in active individuals. Follow-up after pacemaker implantation, usually by telephonic monitoring, is essential. All pulse generators and lead systems have an early failure rate that is now below 1% and an expected battery life varying from 4 years to 10 years.

Epstein AE et al. ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: executive summary. *Heart Rhythm*. 2008 Jun;5(6):934–55. [PMID: 18534377]

Lee S et al. Paroxysmal atrioventricular block. *Heart Rhythm*. 2009 Aug;6(8):1229–34. [PMID: 19632639]

Toff WD et al; United Kingdom Pacing and Cardiovascular Events Trial Investigators. Single-chamber versus dual-chamber pacing for high-grade atrioventricular block. *N Engl J Med*. 2005 Jul 14;353(2):145–55. [PMID: 16014884]

AV DISSOCIATION

When a ventricular pacemaker is firing at a rate faster than or close to the sinus rate (accelerated idioventricular rhythm, ventricular premature beats, or ventricular tachycardia), atrial impulses arriving at the AV node when it is refractory may not be conducted. This phenomenon is AV dissociation but does not necessarily indicate AV block. No treatment is required aside from management of the causative arrhythmia.

INTRAVENTRICULAR CONDUCTION DEFECTS

Intraventricular conduction defects, including bundle branch block, are common in individuals with otherwise normal hearts and in many disease processes, including ischemic heart disease, inflammatory disease, infiltrative disease, cardiomyopathy, and postcardiotomy. Below the AV node and bundle of His, the conduction system trifurcates into a right bundle and anterior and posterior fascicles of the left bundle. Conduction block in each of these fascicles can be recognized on the surface ECG. Although such conduction abnormalities are often seen in normal hearts, they are more commonly due to organic heart disease—either an isolated process of fibrosis and calcification or more generalized myocardial disease. Bifascicular block is present when two of these—right bundle, left anterior, and left posterior fascicle—are involved. Trifascicular block is defined as right bundle branch block with alternating left hemiblock, alternating right and left bundle branch block, or bifascicular block with documented prolonged infranodal conduction (long His-ventricular interval).

The prognosis of intraventricular block is generally that of the underlying myocardial process. Patients with no

apparent heart disease have an overall survival rate similar to that of matched controls. However, left bundle branch block—but not right—is associated with a higher risk of development of overt cardiac disease and cardiac mortality. Even in bifascicular block, the incidence of occult complete heart block or progression to it is low, and pacing is not usually warranted. In patients with symptoms (eg, syncope) consistent with heart block and intraventricular block, pacing should be reserved for those with documented concomitant complete heart block on monitoring or those with a very prolonged HV interval (>90 ms) with no other cause for symptoms. Even in the latter group, prophylactic pacing has not improved the prognosis significantly, probably because of the high incidence of ventricular arrhythmias in the same population.

- Elizari MV et al. Hemiblocks revisited. *Circulation*. 2007 Mar 6;115(9):1154–63. [PMID: 17339573]
- Brenyo A et al. Prognostic significance of QRS duration and morphology. *Cardiol J*. 2011;18(1):8–17. [PMID: 21305480]
- Francia P et al. Left bundle-branch block—pathophysiology, prognosis, and clinical management. *Clin Cardiol*. 2007 Oct;30(3):100–5. [PMID: 17385703]
- García D et al. Intraventricular conduction abnormality—an electrocardiographic algorithm for rapid detection and diagnosis. *Am J Emerg Med*. 2009 May;27(4):492–502. [PMID: 19555622]

SYNCOPE



ESSENTIALS OF DIAGNOSIS

- ▶ Transient loss of consciousness and postural tone from vasodepressor or cardiogenic causes.
- ▶ Prompt recovery without resuscitative measures.
- ▶ Common clinical problem.
- ▶ Accounts for 3% of all visits to the emergency department.

▶ General Considerations

Syncope is a symptom defined as a transient, self-limited loss of consciousness, usually leading to a fall. Thirty percent of the adult population will experience at least one episode of syncope. It accounts for approximately 3% of emergency department visits. Syncope may be neurocardiogenic in origin, mediated by excessive vagal stimulation, or an imbalance between sympathetic and parasympathetic autonomic activity. With assumption of upright posture, there is venous pooling in the lower limbs. However, instead of the normal response, which consists of an increase in heart rate and vasoconstriction, a sympathetically mediated increase in myocardial contractility activates mechanoreceptors that trigger reflex bradycardia and vasodilation. A specific cause of syncope is identified in about 50% of cases during the initial evaluation. The prognosis is relatively favorable except when accompanying cardiac disease is present. In many

patients with recurrent syncope or near syncope, arrhythmias are not the cause. This is particularly true when the patient has no evidence of associated heart disease by history, examination, standard ECG, or noninvasive testing.

Vasodepressor syncope may be due to excessive vagal tone or impaired reflex control of the peripheral circulation. The most frequent type of vasodepressor syncope is vasovagal hypotension or the “common faint,” which is often initiated by a stressful, painful, or claustrophobic experience, especially in young women. Enhanced vagal tone with resulting hypotension is the cause of syncope in carotid sinus hypersensitivity and postmicturition syncope; vagal-induced sinus bradycardia, sinus arrest, and AV block are common accompaniments and may themselves be the cause of syncope.

Orthostatic (postural) hypotension is another common cause of vasodepressor syncope, especially in the elderly; in diabetics or other patients with autonomic neuropathy; in patients with blood loss or hypovolemia; and in patients taking vasodilators, diuretics, and adrenergic-blocking drugs. In addition, a syndrome of chronic idiopathic orthostatic hypotension exists primarily in older men. In most of these conditions, the normal vasoconstrictive response to assuming upright posture, which compensates for the abrupt decrease in venous return, is impaired.

Cardiogenic syncope can occur on a mechanical or arrhythmic basis. There is usually no prodrome; thus, injury secondary to falling is common. Mechanical problems that can cause syncope include aortic stenosis (where syncope may occur from autonomic reflex abnormalities or ventricular tachycardia), pulmonary stenosis, hypertrophic obstructive cardiomyopathy, congenital lesions associated with pulmonary hypertension or right-to-left shunting, and LA myxoma obstructing the mitral valve. Episodes are commonly exertional or postexertional. More commonly, cardiac syncope is due to disorders of automaticity (sick sinus syndrome), conduction disorders (AV block), or tachyarrhythmias (especially ventricular tachycardia and supraventricular tachycardia with rapid ventricular rate).

▶ Clinical Findings

A. Symptoms and Signs

Syncope is characteristically abrupt in onset, often resulting in injury, transient (lasting for seconds to a few minutes), and followed by prompt recovery of full consciousness.

Vasodepressor premonitory symptoms, such as nausea, diaphoresis, tachycardia, and pallor, are usual in the “common faint.” Episodes can be aborted by lying down or removing the inciting stimulus. In **orthostatic (postural) hypotension**, a greater than normal decline (20 mm Hg) in BP immediately upon arising from the supine to the standing position is observed, with or without tachycardia depending on the status of autonomic (baroreceptor) function.

B. Diagnostic Tests

The evaluation for syncope depends on findings from the history and physical examination (especially orthostatic BP evaluation, examination of carotid and other arteries, and cardiac examination).

1. ECG—The resting ECG may reveal arrhythmias, evidence of accessory pathways, prolonged QT interval, and other signs of heart disease (such as infarction or hypertrophy). If the history is consistent with syncope, ambulatory ECG monitoring is essential. This may need to be repeated several times, since yields increase with longer periods of monitoring, at least up to 3 days. Event recorder and transtelephone ECG monitoring may be helpful in patients with intermittent presyncopal episodes. Caution is required before attributing a patient's symptom to rhythm or conduction abnormalities observed during monitoring without concomitant symptoms. In many cases, the symptoms are due to a different arrhythmia or to noncardiac causes. For instance, dizziness or syncope in older patients may be unrelated to concomitantly observed bradycardia, sinus node abnormalities, and ventricular ectopy.

2. Autonomic testing—Orthostatic hypotension from autonomic function can be diagnosed with more certainty by observing BP and heart rate responses to Valsalva maneuver and by tilt testing.

Carotid sinus massage in patients who do not have carotid bruits or a history of cerebral vascular disease can precipitate sinus node arrest or AV block in patients with carotid sinus hypersensitivity. **Head-up tilt-table testing** can identify patients whose syncope may be on a vasovagal basis. In older patients, vasoconstrictor abnormalities and autonomic insufficiency are perhaps the most common causes of syncope. Thus, tilt testing should be done before proceeding to invasive studies unless clinical and ambulatory ECG evaluation suggests a cardiac abnormality. Although different testing protocols are used, passive tilting to at least 70 degrees for 10–40 minutes—in conjunction with isoproterenol infusion or sublingual nitroglycerin, if necessary—is typical. Syncope due to bradycardia, hypotension, or both will occur in approximately one-third of patients with recurrent syncope. Some studies have suggested that, at least with some of the more extreme protocols, false-positive responses may occur.

3. Electrophysiologic studies—Electrophysiologic studies to assess sinus node function and AV conduction and to induce supraventricular or ventricular tachycardia are indicated in patients with recurrent episodes, nondiagnostic ambulatory ECGs, and negative autonomic testing if vasomotor syncope is a consideration. Electrophysiologic studies reveal an arrhythmic cause in 20–50% of patients, depending on the study criteria, and are most often diagnostic when the patient has had multiple episodes and has identifiable cardiac abnormalities.

4. Exercise testing—When the symptoms are associated with exertion or stress, exercise testing may be helpful.

► Treatment

Treatment consists largely of counseling patients to avoid predisposing situations. Paradoxically, β -blockers have been used in patients with altered autonomic function uncovered by head-up tilt testing but they have provided only minimal benefit. If symptomatic bradyarrhythmias or supraventricular tachyarrhythmias are detected, therapy can usually be

initiated without additional diagnostic studies. Permanent pacing has little benefit except in patients with documented severe pauses and bradycardiac responses.

Volume expanders, such as fludrocortisone, or vasoconstrictors, such as midodrine, have also been tried but with minimal benefit. Selective serotonin reuptake inhibitors have shown some benefit in select patients.

See Recommendations for Resumption of Driving, below.

► When to Admit

- Patients with syncope and concomitant structural heart disease or when a primary cardiac etiology is suspected.
- Patients with recent or recurrent syncope are often monitored in the hospital.
- Those with less ominous symptoms may be monitored as outpatients.

Barsheshet A et al. Cardiovascular syncope: diagnostic approach and risk assessment. *Minerva Med.* 2011 Jun;102(3):223–38. [PMID: 21593723]

Chen LY et al. Management of syncope in adults: an update. *Mayo Clin Proc.* 2008 Nov;83(11):1280–93. [PMID: 18990328]

Del Rosso A et al. Clinical predictors of cardiac syncope at initial evaluation in patients referred urgently to a general hospital: the EGSYS score. *Heart.* 2008 Dec;94(12):1620–6. [PMID: 18519550]

Grubb BP. Neurocardiogenic syncope. *N Engl J Med.* 2005 Mar 10;352(10):1004–10. [PMID: 15758011]

Kessler C et al. The emergency department approach to syncope: evidence-based guidelines and prediction rules. *Emerg Med Clin North Am.* 2010 Aug;28(3):487–500. [PMID: 20709240]

Moya A et al; International Study on Syncope of Uncertain Etiology 2 (ISSUE 2) Group. Reproducibility of electrocardiographic findings in patients with suspected reflex neurally-mediated syncope. *Am J Cardiol.* 2008 Dec 1;102(11):1518–23. [PMID: 19026307]

Ouyang H et al. Diagnosis and evaluation of syncope in the emergency department. *Emerg Med Clin North Am.* 2010 Aug;28(3):471–85. [PMID: 20709239]

Sheldon R. Tilt testing for syncope: a reappraisal. *Curr Opin Cardiol.* 2005 Jan;20(1):38–41. [PMID: 15596958]

RECOMMENDATIONS FOR RESUMPTION OF DRIVING

An important management problem in patients who have experienced syncope, symptomatic ventricular tachycardia, or aborted sudden death is to provide recommendations concerning automobile driving. According to a survey published in 1991, only eight states had specific laws dealing with this issue, whereas 42 had laws restricting driving in patients with seizure disorders. Patients with syncope or aborted sudden death thought to have been due to temporary factors (acute myocardial infarction, bradyarrhythmias subsequently treated with permanent pacing, drug effect, electrolyte imbalance) should be strongly advised after recovery not to drive for at least 1 month. Other patients with symptomatic ventricular tachycardia or aborted sudden death, whether treated pharmacologically, with antitachycardia devices, or with ablation therapy, should not drive for at least 6 months.

Longer restrictions are warranted in these patients if spontaneous arrhythmias persist. The physician should comply with local regulations and consult local authorities concerning individual cases.

Baessler C et al; DAVID Investigators. Time to resumption of driving after implantation of an automatic defibrillator (from the Dual chamber and VVI Implantable Defibrillator [DAVID] trial). *Am J Cardiol.* 2005 Mar 1;95(5):665–6. [PMID: 15721116]

CONGESTIVE HEART FAILURE

ESSENTIALS OF DIAGNOSIS

- ▶ **LV failure:** Exertional dyspnea, cough, fatigue, orthopnea, paroxysmal nocturnal dyspnea, cardiac enlargement, rales, gallop rhythm, and pulmonary venous congestion.
- ▶ **RV failure:** Elevated venous pressure, hepatomegaly, dependent edema; usually due to LV failure.
- ▶ Assessment of LV function is a crucial part of diagnosis and management.

▶ General Considerations

Heart failure is a common syndrome that is increasing in incidence and prevalence. Approximately 5 million patients in the United States have heart failure, and there are nearly 500,000 new cases each year. It is primarily a disease of aging, with over 75% of existing and new cases occurring in individuals over 65 years of age. The prevalence of heart failure rises from < 1% in individuals below 60 years to nearly 10% in those over 80 years of age.

Heart failure may be right sided or left sided (or both). Patients with **left heart failure** have symptoms of low cardiac output and elevated pulmonary venous pressure; dyspnea is the predominant feature. Signs of fluid retention predominate in **right heart failure**. Most patients exhibit symptoms or signs of both right- and left-sided failure, and LV dysfunction is the primary cause of RV failure. Although this section primarily concerns cardiac failure due to systolic LV dysfunction, approximately half of patients with heart failure have preserved systolic dysfunction, in large part due to **diastolic dysfunction**, experience many of the same symptoms and may be difficult to distinguish clinically.

Elevated diastolic pressures are transmitted to the pulmonary and systemic venous systems, resulting in dyspnea and edema. The most frequent cause of diastolic cardiac dysfunction is LVH, commonly resulting from hypertension, but conditions such as hypertrophic or restrictive cardiomyopathy, diabetes, and pericardial disease can produce the same clinical picture. In developed countries, CAD with resulting myocardial infarction and loss of functioning myocardium (ischemic cardiomyopathy) is the


most common cause of systolic heart failure. Systemic hypertension remains an important cause of CHF and, even more commonly in the United States, an exacerbating factor in patients with cardiac dysfunction due to other causes such as CAD. Several processes may present with dilated or congestive cardiomyopathy, which is characterized by LV or biventricular dilation and generalized systolic dysfunction. These are discussed elsewhere in this chapter, but the most common are alcoholic cardiomyopathy, viral myocarditis (including infections by HIV), and dilated cardiomyopathies with no obvious underlying cause (idiopathic cardiomyopathy). Rare causes of dilated cardiomyopathy include infiltrative diseases (hemochromatosis, sarcoidosis, amyloidosis, etc), other infectious agents, metabolic disorders, cardiotoxins, and drug toxicity. Valvular heart diseases—particularly degenerative aortic stenosis and chronic aortic or mitral regurgitation—are not infrequent causes of heart failure.

Heart failure is often preventable by early detection of patients at risk and by early intervention. The importance of these approaches is emphasized by guidelines that have incorporated a classification of heart failure that includes four stages. Stage A includes patients at risk for developing heart failure (such as patients with hypertension or CAD without current or previous symptoms or identifiable structural abnormalities of the myocardium). In the majority of these patients, development of heart failure can be prevented with interventions such as the aggressive treatment of hypertension, modification of coronary risk factors, and reduction of excessive alcohol intake (Figure 10–1). Stage B includes patients who have structural heart disease but no current or previously recognized symptoms of heart failure. Examples include patients with previous myocardial infarction, other causes of reduced systolic function, LVH, or asymptomatic valvular disease. Both ACE inhibitors and β -blockers prevent heart failure in the first two of these conditions, and more aggressive treatment of hypertension and early surgical intervention are effective in the latter two. Stages C and D include patients with clinical heart failure and the relatively small group of patients that has become refractory to the usual therapies, respectively. These are discussed below.

▶ Clinical Findings

A. Symptoms

The most common symptom of patients with **heart failure** is shortness of breath, chiefly exertional dyspnea at first and then progressing to orthopnea, paroxysmal nocturnal dyspnea, and rest dyspnea. A more subtle and often overlooked symptom of heart failure is a chronic nonproductive cough, which is often worse in the recumbent position. Nocturia due to excretion of fluid retained during the day and increased renal perfusion in the recumbent position is a common nonspecific symptom of heart failure. Patients also complain of fatigue and exercise intolerance. These symptoms correlate poorly with the degree of cardiac dysfunction. Patients with **right heart failure** have predominate signs of fluid retention, with the patient exhibiting edema, hepatic congestion and, on occasion, loss of appetite and nausea due to edema of the gut or impaired



▲ **Figure 10-1.** Stages in the evolution of heart failure and recommended therapy by stage. ACE, angiotensin-converting enzyme; ARBs, angiotensin receptor blockers. (Reproduced, with permission, from Hunt SA et al. ACC/AHA 2005 Guidelines Update for the evaluation and management of chronic heart failure in the adult: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines [Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure]. ACC/AHA 2005 Guidelines Update for the diagnosis and management of chronic heart failure in the adult. ©2005, American Heart Association.)

gastrointestinal perfusion and ascites. Surprisingly, some individuals with severe LV dysfunction will display few signs of left heart failure and appear to have isolated right heart failure. Indeed, they may be clinically indistinguishable from patients with cor pulmonale, who have right heart failure secondary to pulmonary disease.

Patients with acute heart failure from myocardial infarction, myocarditis, and acute valvular regurgitation due to endocarditis or other conditions usually present with pulmonary edema. Patients with episodic symptoms may be having LV dysfunction due to intermittent ischemia. Patients may also present with acute exacerbations of chronic, stable heart failure. Exacerbations are usually caused by alterations in therapy (or patient noncompliance), excessive salt and fluid intake, arrhythmias, excessive activity, pulmonary emboli, intercurrent infection, or progression of the underlying disease.

Patients with heart failure are often categorized by the NYHA classification as class I (asymptomatic), class II (symptomatic with moderate activity), class III (symptomatic with mild activity), or class IV (symptomatic at rest). However, this classification has limitations in that patient reports are highly subjective and in that symptoms vary from day to day.

B. Signs

Many patients with heart failure, including some with severe symptoms, appear comfortable at rest. Others will be dyspneic during conversation or minor activity, and those with long-standing severe heart failure may appear cachectic or cyanotic. The vital signs may be normal, but tachycardia, hypotension, and reduced pulse pressure may be present. Patients often show signs of increased sympathetic nervous system activity, including cold extremities and diaphoresis. Important peripheral signs of heart failure can be detected by examination of the neck, the lungs, the abdomen, and the extremities. RA pressure may be estimated through the height of the pulsations in the jugular venous system. In addition to the height of the venous pressure, abnormal pulsations such as regurgitant *v* waves should be sought. Examination of the carotid pulse may allow estimation of pulse pressure as well as detection of aortic stenosis. Thyroid examination may reveal occult hyperthyroidism or hypothyroidism, which are readily treatable causes of heart failure. Crackles at the lung bases reflect transudation of fluid into the alveoli. Pleural effusions may cause bibasilar dullness to percussion. Expiratory wheezing and rhonchi may be signs of heart failure.

Patients with severe right heart failure may have hepatic enlargement—tender or nontender—due to passive congestion. Systolic pulsations may be felt in tricuspid regurgitation. Sustained moderate pressure on the liver may increase jugular venous pressure (a positive hepatojugular reflux is an increase of > 1 cm). Ascites may also be present. Peripheral pitting edema is a common sign in patients with right heart failure and may extend into the thighs and abdominal wall.

Cardinal cardiac examination signs are a parasternal lift, indicating pulmonary hypertension; an enlarged and sustained LV impulse, indicating LV dilation and hypertrophy; a diminished first heart sound, suggesting impaired contractility; and an S_3 gallop originating in the LV and sometimes the RV. An S_4 is usually present in diastolic heart failure. Murmurs should be sought to exclude primary valvular disease; secondary mitral regurgitation and tricuspid regurgitation murmurs are common in patients with dilated ventricles. In chronic heart failure, many of the expected signs of heart failure may be absent despite markedly abnormal cardiac function and hemodynamic measurements.

C. Laboratory Findings

A blood count may reveal anemia and a high red-cell distribution width (RDW), both of which are associated with poor prognosis in chronic heart failure through poorly understood mechanisms. Renal function tests can determine whether cardiac failure is associated with prerenal azotemia. Chronic kidney disease is another poor prognostic factor in heart failure and may limit certain treatment options. Serum electrolytes may disclose hypokalemia, which increases the risk of arrhythmias; hyperkalemia, which may limit the use of inhibitors of the renin–angiotensin system; or hyponatremia, an indicator of marked activation of the renin–angiotensin system and a poor prognostic sign. Thyroid function should be assessed to detect occult thyrotoxicosis or myxedema and iron studies test should be checked to test for hemochromatosis. In unexplained cases, appropriate biopsies may lead to a diagnosis of amyloidosis. Myocardial biopsy may exclude specific causes of dilated cardiomyopathy but rarely reveals specific reversible diagnoses.

Serum BNP is a powerful prognostic marker that adds to clinical assessment in differentiating dyspnea due to heart failure from noncardiac causes. Two markers—BNP and N-terminal pro-BNP—provide similar diagnostic and prognostic information. BNP is expressed primarily in the ventricles and is elevated when ventricular filling pressures are high. It is quite sensitive in patients with symptomatic heart failure—whether due to systolic or to diastolic dysfunction—but less specific in older patients, women, and patients with COPD. Studies have shown that BNP can help in emergency department triage in diagnosis of acute decompensated heart failure and BNP may be helpful in guiding intensity of diuretic and other therapies for monitoring and management of chronic heart failure. Elevation of serum troponin, and especially of high-sensitivity troponin, is common in both chronic and acute heart failure, and is associated with higher risk of adverse outcomes.

D. ECG and Chest Radiography

ECG may indicate an underlying or secondary arrhythmia, myocardial infarction, or nonspecific changes that often include low voltage, intraventricular conduction defects, LVH, and nonspecific repolarization changes. Chest radiographs provide information about the size and shape of the cardiac silhouette. Cardiomegaly is an important finding and is a poor prognostic sign. Evidence of pulmonary venous hypertension includes relative dilation of the upper lobe veins, perivascular edema (haziness of vessel outlines), interstitial edema, and alveolar fluid. In acute heart failure, these findings correlate moderately well with pulmonary venous pressure. However, patients with chronic heart failure may show relatively normal pulmonary vasculature despite markedly elevated pressures. Pleural effusions are common and tend to be bilateral or right-sided.

E. Additional Studies

Many studies have indicated that the clinical diagnosis of systolic myocardial dysfunction is often inaccurate. The primary confounding conditions are diastolic dysfunction of the heart with decreased relaxation and filling of the LV (particularly in hypertension and in hypertrophic states) and pulmonary disease. Because patients with heart failure usually have significant resting ECG abnormalities, stress imaging procedures such as perfusion scintigraphy or dobutamine echocardiography are often indicated.

The most useful test is the echocardiogram. This will reveal the size and function of both ventricles and of the atria. It will also allow detection of pericardial effusion, valvular abnormalities, intracardiac shunts, and segmental wall motion abnormalities suggestive of old myocardial infarction as opposed to more generalized forms of dilated cardiomyopathy.

Radionuclide angiography measures LV EF and permits analysis of regional wall motion. This test is especially useful when echocardiography is technically suboptimal, such as in patients with severe pulmonary disease. When myocardial ischemia is suspected as a cause of LV dysfunction, stress testing should be performed.

F. Cardiac Catheterization

In most patients with heart failure, clinical examination and noninvasive tests can determine LV size and function and valve function well enough to confirm the diagnosis. Left heart catheterization may be helpful to define the presence and extent of CAD, although CT angiography may also be appropriate, especially when the likelihood of coronary disease is low. Evaluation for coronary disease is particularly important when LV dysfunction may be partially reversible by revascularization. The combination of angina or noninvasive evidence of significant myocardial ischemia with symptomatic heart failure is often an indication for coronary angiography if the patient is a potential candidate for revascularization. Right heart catheterization may be useful to select and monitor therapy in patients refractory to standard therapy.

- Drazner MH et al. Prognostic importance of elevated jugular venous pressure and a third heart sound in patients with heart failure. *N Engl J Med*. 2001 Aug 23;345(8):574–81. [PMID: 11529211]
- Jourdain P et al. Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: the STARS-BNP Multicenter Study. *J Am Coll Cardiol*. 2007 Apr 24;49(16):1733–9. [PMID: 17448376]
- Maisel AS et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. *N Engl J Med*. 2002 Jul 18;347(3):161–7. [PMID: 12124404]
- Torpy JM et al. JAMA patient page. Heart failure. *JAMA*. 2009 May 13;301(18):1950. [PMID: 19436025]

► Treatment

Although diuretics are often useful in patients with **right heart failure**, the other therapies discussed in this section (digitalis, vasodilators, inotropic agents) may be inappropriate.

A. Correction of Reversible Causes

The major reversible causes of chronic heart failure include valvular lesions, myocardial ischemia, uncontrolled hypertension, arrhythmias (especially persistent tachycardias), alcohol- or drug-induced myocardial depression, intracardiac shunts, and high-output states. Calcium channel blockers (specifically verapamil or diltiazem), antiarrhythmic drugs, thiazolidinediones, and nonsteroidal anti-inflammatory agents may be important contributors to worsening heart failure. Some metabolic and infiltrative cardiomyopathies may be partially reversible, or their progression may be slowed; these include hemochromatosis, sarcoidosis, and amyloidosis. Reversible causes of diastolic dysfunction include pericardial disease and LVH due to hypertension. Once possible reversible components are being addressed, the measures outlined below are appropriate.

B. Pharmacologic

See also the following section on Acute Heart Failure & Pulmonary Edema.

1. Diuretic therapy—Diuretics are the most effective means of providing symptomatic relief to patients with moderate to severe CHF. Few patients with symptoms or signs of fluid retention can be optimally managed without a diuretic. However, excessive diuresis can lead to electrolyte imbalance and neurohormonal activation. **A combination of a diuretic and an ACE inhibitor should be the initial treatment in most symptomatic patients.**

When fluid retention is mild, thiazide diuretics or a similar type of agent (hydrochlorothiazide, 25–100 mg; metolazone, 2.5–5 mg; chlorthalidone, 25–50 mg; etc) may be sufficient. Thiazide or related diuretics often provide better control of hypertension than short-acting loop agents. The thiazides are generally ineffective when the glomerular filtration rate falls below 30–40 mL/min, a not infrequent occurrence in patients with severe heart failure. Metolazone maintains its efficacy down to a glomerular filtration rate of approximately 20–30 mL/min. Adverse reactions include hypokalemia and intravascular volume

depletion with resulting prerenal azotemia, skin rashes, neutropenia and thrombocytopenia, hyperglycemia, hyperuricemia, and hepatic dysfunction.

Patients with more severe heart failure should be treated with one of the loop diuretics. These include furosemide (20–320 mg daily), bumetanide (1–8 mg daily), and torsemide (20–200 mg daily). These agents have a rapid onset and a relatively short duration of action. In patients with preserved kidney function, two or more doses are preferable to a single larger dose. In acute situations or when gastrointestinal absorption is in doubt, they should be given intravenously. They are active even in severe kidney disease, but larger doses (up to 500 mg of furosemide or equivalent) may be required. The major adverse reactions include intravascular volume depletion, prerenal azotemia, and hypotension. Hypokalemia, particularly with accompanying digitalis therapy, is a major problem. Less common side effects include skin rashes, gastrointestinal distress, and ototoxicity (the latter more common with ethacrynic acid and possibly less common with bumetanide).

The potassium-sparing agents spironolactone, triamterene, and amiloride are often useful in combination with the loop diuretics and thiazides. Triamterene and amiloride act on the distal tubule to reduce potassium secretion. Their diuretic potency is only mild and not adequate for most patients with heart failure, but they may minimize the hypokalemia induced by more potent agents. Side effects include hyperkalemia, gastrointestinal symptoms, and kidney dysfunction. Spironolactone and eplerenone are specific inhibitors of aldosterone, which is often increased in CHF and has important effects beyond potassium retention (see below). Their onsets of action are slower than the other potassium-sparing agents, and spironolactone's side effects include gynecomastia. Combinations of potassium supplements or ACE inhibitors and potassium-sparing drugs can produce hyperkalemia but have been used with success in patients with persistent hypokalemia.

Patients with refractory edema may respond to combinations of a loop diuretic and thiazide-like agents. Metolazone, because of its maintained activity with chronic kidney disease, is the most useful agent for such a combination. Extreme caution must be observed with this approach, since massive diuresis and electrolyte imbalances often occur; 2.5 mg of metolazone should be added to the previous dosage of loop diuretic. In many cases this is necessary only once or twice a week, but dosages up to 10 mg daily have been used in some patients.

2. Inhibitors of the renin-angiotensin-aldosterone system—Inhibition of renin-angiotensin-aldosterone system with ACE inhibitors should be considered part of the initial therapy of this syndrome based on their life-saving benefits.

A. ACE INHIBITORS—Many ACE inhibitors are available, and at least seven have been shown to be effective for the treatment of heart failure or the related indication of postinfarction LV dysfunction (see Table 11–8). ACE inhibitors reduce mortality by approximately 20% in

patients with symptomatic heart failure and have been shown also to prevent hospitalizations, increase exercise tolerance, and reduce symptoms in these patients. As a result, ACE inhibitors should be part of first-line treatment of patients with symptomatic LV systolic dysfunction (EF < 40%), usually in combination with a diuretic. They are also indicated for the management of patients with reduced EFs without symptoms because they prevent the progression to clinical heart failure.

Because ACE inhibitors may induce significant hypotension, particularly following the initial doses, they must be started with caution. Hypotension is most prominent in patients with already low BPs (systolic pressure < 100 mm Hg), hypovolemia, prerenal azotemia (especially if it is diuretic induced), and hyponatremia (an indicator of activation of the renin–angiotensin system). These patients should generally be started at low dosages (captopril 6.25 mg three times daily, enalapril 2.5 mg daily, or the equivalent), but other patients may be started at twice these dosages. Within several days (for those with the markers of higher risk) or at most 2 weeks, patients should be questioned about symptoms of hypotension, and both kidney function and K^+ levels should be monitored.

ACE inhibitors should be titrated to the dosages proved effective in clinical trials (captopril 50 mg three times daily, enalapril 10 mg twice daily, lisinopril 20 mg daily, or the equivalent) over a period of 1–3 months. Most patients will tolerate these doses. Asymptomatic hypotension is not a contraindication to up-titrating or continuing ACE inhibitors. Some patients exhibit increases in serum creatinine or K^+ , but they do not require discontinuation if the levels stabilize—even at values as high as 3 mg/dL and 5.5 mEq/L, respectively. Kidney dysfunction is more frequent in diabetics, older patients, and those with low systolic pressures, and these groups should be monitored more closely. The most common side effects of ACE inhibitors in heart failure patients are dizziness (often not related to the level of BP) and cough, though the latter is often due as much to heart failure or intercurrent pulmonary conditions as to the ACE inhibitor.

B. ANGIOTENSIN II RECEPTOR BLOCKERS—Another approach to inhibiting the renin–angiotensin–aldosterone system is the use of specific ARBs (see Table 11–8), which will block or decrease most of the effects of the system. In addition, because there are alternative pathways of angiotensin II production in many tissues, the receptor blockers may provide more complete system blockade.

However, these agents do not share the effects of ACE inhibitors on other potentially important pathways that produce increases in bradykinin, prostaglandins, and nitric oxide in the heart, blood vessels, and other tissues. The Valsartan in Heart Failure Trial (Val-HeFT) examined the efficacy of adding valsartan (titrated to a dose of 160 mg twice a day) to ACE inhibitor therapy. While the addition of valsartan did not reduce mortality, the composite of death or hospitalization for heart failure was significantly reduced. The CHARM trial randomized 7601 patients with chronic heart failure with or without LV systolic dysfunction and with or without background ACE inhibitor

therapy to candesartan (titrated to 32 mg a day) or placebo. Among patients with an LV EF of < 40%, there was an 18% reduction in cardiovascular death or heart failure hospitalization and a statistically significant 12% reduction in all-cause mortality. The benefits were similar among patients on ACE inhibitors, including among patients on full-dose ACE inhibitors. Thus, ARBs, specifically candesartan or valsartan, provide important benefits as an alternative to, and in addition to, ACE inhibitors in chronic heart failure with reduced LV EF. A large trial of patients with chronic heart failure and preserved LV EF found no benefit from the ARB irbesartan.

C. SPIRONOLACTONE AND EPLERENONE—Inhibiting aldosterone has become a mainstay of management of symptomatic heart failure with reduced LV EF. There is evidence that aldosterone mediates some of the major effects of renin–angiotensin–aldosterone system activation, such as myocardial remodeling and fibrosis, as well as sodium retention and potassium loss at the distal tubules. The RALES trial compared spironolactone 25 mg daily with placebo in patients with advanced heart failure (current or recent class IV) already receiving ACE inhibitors and diuretics and showed a 29% reduction in mortality as well as similar decreases in other clinical end points. Hyperkalemia was uncommon in this severe heart failure clinical trial population, which was maintained on high doses of diuretic, but hyperkalemia with spironolactone appears to be common in general practice. Potassium levels should be monitored closely during initiation of spironolactone (after 1 and 4 weeks of therapy), particularly for patients with even mild degrees of kidney injury, and in patients receiving ACE inhibitors. Based on the EMPHASIS-HF trial, the efficacy and safety of aldosterone antagonism—in the form of eplerenone, 25–50 mg orally daily—is established for patients with mild or moderate heart failure. This trial showed a significant reduction in cardiovascular death as well as in hospitalization for heart failure among patients with NYHA class II heart failure and LV EF < 30%. Most experts believe that spironolactone is likely to provide similar benefit. *Careful monitoring of serum potassium levels, in particular for patients with any degree of renal insufficiency, is important to avoid life-threatening hyperkalemia.*

3. β -Blockers— β -Blockers are part of the foundation of care of chronic heart failure based on their life-saving benefits. The mechanism of this benefit remains unclear, but it is likely that chronic elevations of catecholamines and sympathetic nervous system activity cause progressive myocardial damage, leading to worsening LV function and dilation. The primary evidence for this hypothesis is that over a period of 3–6 months, β -blockers produce consistent substantial rises in EF (averaging 10% absolute increase) and reductions in LV size and mass.

Clinical trial results have been reported in nearly 14,000 patients (ranging from asymptomatic post-myocardial infarction LV dysfunction to severe heart failure with LV EFs < 35–40%) receiving ACE inhibitors and diuretics randomized to β -blockers or placebo. Three drugs have strong evidence of reducing mortality:

carvedilol, metoprolol succinate (but not metoprolol tartrate), and bisoprolol.

Carvedilol, a nonselective β_1 - and β_2 -receptor blocker with additional weak α -blocking activity, was the first β -blocker approved for heart failure in the United States after showing a reduction in death and hospitalizations in four smaller studies with a total of nearly 1100 patients. Subsequently, trials with two β_1 -selective agents, bisoprolol (CIBIS II, with 2647 patients) and sustained-release metoprolol succinate (MERIT, with nearly 4000 patients), showed 35% reductions in mortality as well as fewer hospitalizations. A trial using carvedilol in 2200 patients with severe (NYHA class III/IV) heart failure was terminated ahead of schedule because of a 35% reduction in mortality. The SENIORS trial of 2135 patients found that nebivolol was effective in elderly patients (70 years and older) with chronic heart failure, although the evidence of degree of benefit was not as strong as with the three proven β -blockers carvedilol, metoprolol succinate, or bisoprolol. In these trials, there were reductions in sudden deaths and deaths from worsening heart failure, and benefits were seen in patients with underlying coronary disease and those with primary cardiomyopathies. In all these studies, the β -blockers were generally well tolerated, with similar numbers of withdrawals in the active and placebo groups. This has led to a strong recommendation that *stable* patients (defined as having no recent deterioration or evidence of volume overload) with mild, moderate, and even severe heart failure should be treated with a β -blocker unless there is a noncardiac contraindication. In the COPERNICUS trial, carvedilol was both well tolerated and highly effective in reducing both mortality and heart failure hospitalizations in a group of patients with severe (NYHA class III or IV) symptoms, but care was taken to ensure that they were free of fluid retention at the time of initiation. In this study, one death was prevented for every 13 patients treated for 1 year—as dramatic an effect as has been seen with a pharmacologic therapy in the history of cardiovascular medicine. One trial comparing carvedilol and (short-acting) metoprolol tartrate (COMET) found significant reductions in all-cause mortality and cardiovascular mortality with carvedilol. Thus, patients with chronic heart failure should be treated with extended-release metoprolol, bisoprolol, or carvedilol, but not short-acting metoprolol.

Because even apparently stable patients may deteriorate when β -blockers are initiated, initiation must be done gradually and with great care. Carvedilol is initiated at a dosage of 3.125 mg twice daily and may be increased to 6.25, 12.5, and 25 mg twice daily at intervals of approximately 2 weeks. The protocols for sustained-release metoprolol use were started at 12.5 or 25 mg daily and doubled at intervals of 2 weeks to a target dose of 200 mg daily (using the Toprol XL sustained-release preparation). Bisoprolol was administered at a dosage of 1.25, 2.5, 3.75, 5, 7.5, and 10 mg daily, with increments at 1- to 4-week intervals. More gradual up-titration is often more convenient and may be better tolerated.

Patients should be instructed to monitor their weights at home as an indicator of fluid retention and to report any

increase or change in symptoms immediately. Before each dose increase, the patient should be seen and examined to ensure that there has not been fluid retention or worsening of symptoms. If heart failure worsens, this can usually be managed by increasing diuretic doses and delaying further increases in β -blocker doses, though downward adjustments or discontinuation is sometimes required. Carvedilol, because of its β -blocking activity, may cause dizziness or hypotension. This can usually be managed by reducing the doses of other vasodilators and by slowing the pace of dose increases.

4. Digitalis glycosides—Although the digitalis glycosides were once the mainstay of treatment of CHF, their use in patients who are in sinus rhythm has declined because they lack the benefits of the neurohormonal antagonists on prognosis and because safety concerns persist. However, their efficacy in reducing the symptoms of heart failure has been established in at least four multicenter trials that have demonstrated that digoxin withdrawal is associated with worsening symptoms and signs of heart failure, more frequent hospitalizations for decompensation, and reduced exercise tolerance. This was also seen in the 6800-patient Digitalis Investigators Group (DIG) trial, though that study found no benefit (or harm) with regard to survival. A reduction in deaths due to progressive heart failure was balanced by an increase in deaths due to ischemic and arrhythmic events. Based on these results, digoxin should be used for patients who remain symptomatic when taking diuretics and ACE inhibitors as well as for patients with heart failure who are in atrial fibrillation and require rate control.

Digoxin, the only widely used digitalis preparation, has a half-life of 24–36 hours and is eliminated almost entirely by the kidneys. The oral maintenance dose may range from 0.125 mg three times weekly to 0.5 mg daily. It is lower in patients with kidney dysfunction, in older patients, and in those with smaller lean body mass. Although a loading dose of 0.75–1.25 mg (depending primarily on lean body size) over 24–48 hours may be given if an early effect is desired, in most patients with chronic heart failure it is sufficient to begin with the expected maintenance dose (usually 0.125–0.25 mg daily). Amiodarone, quinidine, propafenone, and verapamil are among the drugs that may increase digoxin levels up to 100%. It is prudent to measure a blood level after 7–14 days (and at least 6 hours after the last dose was administered). Most of the positive inotropic effect is apparent with serum digoxin levels between 0.7 ng/mL and 1.2 ng/mL, and levels above this range may be associated with a higher risk of arrhythmias and lower survival rates, though clinically evident toxicity is rare with levels below 1.8 ng/mL. Once an appropriate maintenance dose is established, subsequent levels are usually not indicated unless there is a change in kidney function or medications that affects digoxin levels or a significant deterioration in cardiac status that may be associated with reduced clearance. Digoxin may induce ventricular arrhythmias, especially when hypokalemia or myocardial ischemia is present.

Digoxin toxicity has become less frequent as there has been a better appreciation of its pharmacology, but the therapeutic-to-toxic ratio is quite narrow. Symptoms of

digitalis toxicity include anorexia, nausea, headache, blurring or yellowing of vision, and disorientation. Cardiac toxicity may take the form of AV conduction or sinus node depression; junctional, atrial, or ventricular premature beats or tachycardias; or ventricular fibrillation. Potassium administration (following serum potassium measurement, since severe toxicity may be associated with hyperkalemia) is usually indicated for the tachyarrhythmias even when levels are in the normal range, but may worsen conduction disturbances. Lidocaine or phenytoin may be useful for ventricular arrhythmias, as is overdrive pacing, but quinidine, amiodarone, and propafenone should be avoided because they will increase digoxin levels. Electrical cardioversion should be avoided if possible, as it may cause intractable ventricular fibrillation or cardiac standstill. Pacing is indicated for third-degree AV block (complete heart block) and symptomatic or severe block (heart rate < 40 beats/min) if they persist after treatment with atropine. Digoxin immune fab (ovine) is available for life-threatening toxicity or large overdoses, but it should be remembered that its half-life is shorter than that of digoxin and so repeat administration may be required.

5. Vasodilators—Because most patients with moderate to severe heart failure have both elevated preload and reduced cardiac output, the maximum benefit of vasodilator therapy can be achieved by an agent or combination of agents with both actions. Many patients with heart failure have mitral or tricuspid regurgitation; agents that reduce resistance to ventricular outflow tend to redirect regurgitant flow in a forward direction.

Although vasodilators that are also neurohumoral antagonists—specifically, the ACE inhibitors—improve prognosis, such a benefit is less clear with the direct-acting vasodilators. The combination of hydralazine and isosorbide dinitrate has improved survival, but to a lesser extent than ACE inhibitors. The A-HeFT trial studied hydralazine (75 mg) and isosorbide dinitrate (40 mg) three times a day in 1050 African Americans with NYHA class III or IV chronic heart failure, most of whom were treated with ACE inhibitors and β -blockers. The primary endpoint was a clinical composite. The trial was stopped early because of a significant 43% reduction in all-cause mortality with hydralazine and nitrates, although the relatively small sample size limits the confidence in the results. Whether the benefits of this approach are limited to African Americans, who may have a less active renin–angiotensin system is not known, but it is appropriate to use this combination in addition to other effective therapies in African Americans with severe heart failure.

See section on Acute Myocardial Infarction earlier in this chapter for a discussion on the intravenous vasodilating drugs and their dosages.

A. NITRATES—Intravenous vasodilators (sodium nitroprusside or nitroglycerin) are used primarily for acute or severely decompensated chronic heart failure, especially when accompanied by hypertension or myocardial ischemia. If neither of the latter is present, therapy is best initiated and adjusted based on hemodynamic measurements.

The starting dosage for nitroglycerin is generally about 10 mcg/min, which is titrated upward by 10–20 mcg/min (to a maximum of 200 mcg/min) until mean arterial pressure drops by 10%. Hypotension (BP < 100 mm Hg systolic) should be avoided. For sodium nitroprusside, the starting dosage is 0.3–0.5 mcg/kg/min with upward titration to a maximum dose of 10 mcg/kg/min.

Isosorbide dinitrate, 20–80 mg orally three times daily, has proved effective in several small studies. Nitroglycerin ointment, 12.5–50 mg (1–4 inches) every 6–8 hours, appears to be equally effective although somewhat inconvenient for long-term therapy. The nitrates are moderately effective in relieving shortness of breath, especially in patients with mild to moderate symptoms, but less successful—probably because they have little effect on cardiac output—in advanced heart failure. Nitrate therapy is generally well tolerated, but headaches and hypotension may limit the dose of all agents. The development of tolerance to long-term nitrate therapy occurs. This is minimized by intermittent therapy, especially if a daily 8- to 12-hour nitrate-free interval is used, but probably develops to some extent in most patients receiving these agents. Transdermal nitroglycerin patches have no sustained effect in patients with heart failure and should not be used for this indication.

B. NESIRITIDE—This agent, a recombinant form of human brain natriuretic peptide, is a potent vasodilator that reduces ventricular filling pressures and improves cardiac output. Its hemodynamic effects resemble those of intravenous nitroglycerin with a more predictable dose–response curve and a longer duration of action. In clinical studies, nesiritide (administered as 2 mcg/kg by intravenous bolus injection followed by an infusion of 0.01 mcg/kg/min, which may be up-titrated if needed) produced a rapid improvement in both dyspnea and hemodynamics. The primary adverse effect is hypotension, which may be symptomatic and sustained. The ASCEND trial randomized nearly 7000 patients with acute decompensated heart failure to receive either nesiritide or placebo; results showed a reduction in dyspnea, worsening in renal function, and no effect on death or heart failure rehospitalization. Because most patients with acute heart failure respond well to conventional therapy, the role of nesiritide may be primarily in patients who continue to be symptomatic after initial treatment with diuretics and nitrates.

C. HYDRALAZINE—Oral hydralazine is a potent arteriolar dilator and markedly increases cardiac output in patients with CHF. However, as a single agent, it has not been shown to improve symptoms or exercise tolerance during long-term treatment. The combination of nitrates and oral hydralazine produces greater hemodynamic effects.

Hydralazine therapy is frequently limited by side effects. Approximately 30% of patients are unable to tolerate the relatively high doses required to produce hemodynamic improvement in heart failure (200–400 mg daily in divided doses). The major side effect is gastrointestinal distress, but headaches, tachycardia, and hypotension are relatively common. ARBs have largely supplanted the use of the hydralazine–isosorbide dinitrate combination in ACE-intolerant patients.

6. Combination of medical therapies—Optimal management of chronic heart failure involves using combinations of proven life-saving therapies. In addition to ACE-inhibitors and β -blockers, patients who remain symptomatic should be considered for additional therapy, in the form of ARBs (best proven in class II–III heart failure), spironolactone (best proven in current or recent class IV heart failure), or hydralazine and isosorbide dinitrate (with evidence of benefit in African Americans).

7. Positive inotropic agents—The digitalis derivatives are the only available oral inotropic agents in the United States (see above). A number of other oral positive inotropic agents have been investigated for the long-term treatment of heart failure, but all have increased mortality without convincing evidence of improvement in symptoms. Intravenous agents, such as the β_1 -agonist dobutamine and the phosphodiesterase inhibitor milrinone, are sometimes used on a long-term or intermittent basis. The limited available data suggest that continuous therapy is also likely to increase mortality; intermittent inotropic therapy has never been evaluated in controlled trials, and its use is largely based on anecdotal experience. A randomized placebo-controlled trial of 950 patients evaluating intravenous milrinone in patients admitted for decompensated heart failure who had no definite indications for inotropic therapy showed no benefit in terms of survival, decreasing length of admission, or preventing readmission—and significantly increased rates of sustained hypotension and atrial fibrillation. Thus, the role of positive inotropic agents appears to be limited to patients with symptoms and signs of low cardiac output (primarily hypoperfusion and deteriorating kidney function) and those who do not respond to intravenous diuretics. In some cases, dobutamine or milrinone may help maintain patients who are awaiting cardiac transplantation.

8. Calcium channel blockers—First-generation calcium channel blockers may accelerate the progression of CHF. However, two trials with amlodipine in patients with severe heart failure showed that this agent was safe, though not superior to placebo. These agents should be avoided unless they need to be utilized to treat associated hypertension or angina, and for these indications amlodipine is the drug of choice.

9. Anticoagulation—Patients with LV failure and reduced EFs are at somewhat increased risk for developing intracardiac thrombi and systemic arterial emboli. However, this risk appears to be primarily in patients who are in atrial fibrillation or who have large recent anterior myocardial infarction, who should generally be anticoagulated with warfarin for 3 months following the MI. Other patients with heart failure have embolic rates of approximately two per 100 patient-years of follow-up, which approximates the rate of major bleeding, and routine anticoagulation does not appear warranted except in patients with prior embolic events or mobile LV thrombi.

10. Antiarrhythmic therapy—Patients with moderate to severe heart failure have a high incidence of both symptomatic and asymptomatic arrhythmias. Although < 10% of

patients have syncope or presyncope resulting from ventricular tachycardia, ambulatory monitoring reveals that up to 70% of patients have asymptomatic episodes of NSVT. These arrhythmias indicate a poor prognosis independent of the severity of LV dysfunction, but many of the deaths are probably not arrhythmia related. β -Blockers, because of their marked favorable effect on prognosis in general and on the incidence of sudden death specifically, should be initiated in these as well as all other patients with heart failure. Empiric antiarrhythmic therapy with amiodarone did not improve outcome in the SCD-HeFT trial, and most other agents are contraindicated because of their proarrhythmic effects in this population and their adverse effect on cardiac function.

11. Statin therapy—Even though vascular disease is present in many patients with chronic heart failure, the role of statins has not been well defined in the heart failure population. Two trials—the CORONA and the GISSI-HF trials—have failed to show benefits of statins in the chronic heart failure population.

C. Nonpharmacologic Treatment

1. Implantable cardioverter defibrillators—Randomized clinical trials have extended the indications for ICDs beyond patients with symptomatic or asymptomatic arrhythmias to the broad population of patients with chronic heart failure and LV systolic dysfunction after established medical therapy. In the second Multicenter Automatic Defibrillator Implantation Trial (MADIT II), 1232 patients with prior myocardial infarction and an EF < 30% were randomized to an ICD or a control group. Mortality was 31% lower in the ICD group, which translated into nine lives saved for each 100 patients who received a device and were monitored for 3 years. The Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) reinforced and extended these results, showing a 23% relative (7.2% absolute) reduction in mortality over 5 years with a simple single-lead ICD in a population of patients with symptomatic chronic heart failure and an EF of \leq 35%. Patients with class II symptoms appeared to have even larger benefits than patients with class III symptoms. These patients were well-managed with contemporary heart failure treatments, including β -blockers. Based on these results, the United States Centers for Medicare and Medicaid Services has provided reimbursement coverage to include patients with chronic heart failure and ischemic or nonischemic cardiomyopathy with an EF \leq 35%.

2. Biventricular pacing (resynchronization)—Many patients with heart failure due to systolic dysfunction have abnormal intraventricular conduction that results in dyssynchronous and hence inefficient contractions. Several studies have evaluated the efficacy of “multisite” pacing, using leads that stimulate the RV from the apex and the LV from the lateral wall via the coronary sinus. Patients with wide QRS complexes (generally \geq 120 milliseconds), reduced EFs, and moderate to severe symptoms have been evaluated. Results from trials with up to 2 years of follow-up have

shown an increase in EF, improvement in symptoms and exercise tolerance, and reduction in death and hospitalization. The COMPANION trial included 1520 patients with NYHA class III or IV heart failure, EF of $\leq 35\%$, and QRS duration ≥ 120 milliseconds. In addition to optimal medical therapy, resynchronization therapy with biventricular pacing with or without implantable defibrillator capability reduced death and hospitalization from any cause by about 20%. The CARE-HF trial randomized 813 similar patients, who also required mechanical evidence of dyssynchrony if QRS duration was 120–149 milliseconds, to resynchronization therapy. Over a mean follow-up of 29 months, death or hospitalization for cardiac cause was reduced by 37% and mortality was reduced by 36%. Thus, resynchronization therapy is indicated for patients with moderate to severe heart failure, EF $\leq 35\%$, and prolonged QRS duration. The MADIT-CRT trial showed reduced heart failure events (but not mortality) with cardiac resynchronization therapy among patients with mild heart failure symptoms, LV EF $\leq 30\%$, and QRS ≥ 130 msec. The RAFT trial, however, showed a survival benefit to patients with mild to moderate heart failure symptoms. Patients with New York Heart Association class II or III heart failure, LV EF $\leq 30\%$, and a QRS duration of 120 msec or more were randomized to an ICD alone or an ICD plus cardiac resynchronization therapy (CRT). The primary outcome (death from any cause or hospitalization for heart failure) was reduced by 25%, as was overall mortality.

3. Case management, diet, and exercise training—

Thirty to 50 percent of CHF patients who are hospitalized will be readmitted within 3–6 months. Strategies to prevent clinical deterioration, such as case management, home monitoring of weight and clinical status, and patient adjustment of diuretics, can prevent rehospitalizations and should be part of the treatment regimen of advanced heart failure. Involvement of a multidisciplinary team (rather than a single physician) and in-person (rather than telephonic) communication appear to be important features of successful programs.

Patients should routinely practice moderate salt restriction (2–2.5 g sodium or 5–6 g salt per day). More severe sodium restriction is usually difficult to achieve and unnecessary because of the availability of potent diuretic agents.

Exercise training improves activity tolerance in significant part by reversing the peripheral abnormalities associated with heart failure and deconditioning. In severe heart failure, restriction of activity may facilitate temporary recompensation. A large trial (HF ACTION, 2331 patients) showed no significant benefit (nor harm) from a structured exercise training program on death or hospitalization. Thus, in stable patients, a prudent increase in activity or a regular exercise regimen can be encouraged. Indeed, a gradual exercise program is associated with diminished symptoms and substantial increases in exercise capacity.

4. Coronary revascularization—Since underlying CAD is the cause of heart failure in the majority of patients, coronary revascularization has been thought to be able to both improve symptoms and prevent progression. However, the STITCH trial failed to show an overall survival benefit

from CABG among patients with multivessel coronary disease who were candidates for CABG but who had heart failure and a LV EF of $\leq 35\%$. Revascularization does appear warranted for some patients with heart failure, including those with more severe angina or left main coronary disease (excluded from the STITCH trial), or selected patients with less severe symptoms.

5. Cardiac transplantation—Because of the poor prognosis of patients with advanced heart failure, cardiac transplantation has become widely used. Many centers now have 1-year survival rates exceeding 80–90%, and 5-year survival rates above 70%. Infections, hypertension and kidney dysfunction caused by cyclosporine, rapidly progressive coronary atherosclerosis, and immunosuppressant-related cancers have been the major complications. The high cost and limited number of donor organs require careful patient selection early in the course.

6. Other surgical treatment options—Several surgical procedures for severe heart failure have received considerable publicity. Cardiomyoplasty is a procedure in which the latissimus dorsi muscle is wrapped around the heart and stimulated to contract synchronously with it. In ventricular reduction surgery, a large part of the anterolateral wall is resected to make the heart function more efficiently. Both approaches are too risky in end-stage patients and have not been shown to improve prognosis or symptoms in controlled studies, and for these reasons they have largely been dropped. Externally powered and implantable ventricular assist devices can be used in patients who require ventricular support either to allow the heart to recover or as a bridge to transplantation. The latest generation devices are small enough to allow patients unrestricted mobility and even discharge from the hospital. Continuous flow devices appear to be more effective than pulsatile flow devices. However, complications are frequent, including bleeding, thromboembolism, and infection, and the cost is very high, exceeding \$200,000 in the initial 1–3 months.

Although 1-year survival was improved in the REMATCH randomized trial, all 129 patients died by 26 months.

7. Palliative care—Despite the technologic advances of recent years, including cardiac resynchronization, implantable defibrillators, LV assist devices, and totally implantable artificial hearts, it should be remembered that many patients with chronic heart failure are elderly and have multiple comorbidities. Many of them will not experience meaningful improvements in survival with aggressive therapy, and the goal of management should be symptomatic improvement and palliation (see Chapter 5).

► Prognosis

Once manifest, heart failure carries a poor prognosis. Even with modern treatment, the 5-year mortality is approximately 50%. Mortality rates vary from $< 5\%$ per year in those with no or few symptoms to $> 30\%$ per year in those with severe and refractory symptoms. These figures emphasize the critical importance of early detection and intervention. Higher mortality is related to older age, lower LV EF, more severe symptoms, chronic kidney disease, and

diabetes. The prognosis of heart failure has improved in the past two decades, probably at least in part because of the more widespread use of ACE inhibitors and β -blockers, which markedly improve survival.

▶ When to Refer

Patients with new symptoms of heart failure not explained by an obvious cause should be referred to a cardiologist.

▶ When to Admit

- Patients with unexplained new or worsened symptoms, or positive cardiac biomarkers.
- Patients with hypoxia, fluid overload, or pulmonary edema not readily resolved in outpatient setting.

Bardy GH; Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. *N Engl J Med.* 2005 Jan 20;352(3):225–37. [PMID: 15659722]

Cleland JG et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. *N Engl J Med.* 2005 Apr 14;352(15):1539–49. [PMID: 15753115]

Davies EJ et al. Exercise based rehabilitation for heart failure. *Cochrane Database Syst Rev.* 2010 Apr 14;4:CD003331. [PMID: 20393935]

Deedwania PC et al. Atrial fibrillation in heart failure: a comprehensive review. *Am J Med.* 2010 Mar;123(3):198–204. [PMID: 20193823]

Dickstein K et al; ESC Committee for Practice Guidelines (CPG). ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. *Eur Heart J.* 2008 Oct;29(19):2388–442. Erratum in: *Eur Heart J.* 2010 Apr;12(4):416. Dosage error in article text. *Eur Heart J.* 2010 Mar;31(5):624. Dosage error in article text. [PMID: 18799522]

Ezekowitz JA et al. Standardizing care for acute decompensated heart failure in a large megatrial: the approach for the Acute Studies of Clinical Effectiveness of Nesiritide in Subjects with Decompensated Heart Failure (ASCEND-HF). *Am Heart J.* 2009 Feb;157(2):219–28. [PMID: 19185628]

Gissi-HF Investigators; Tavazzi L et al. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. *Lancet.* 2008 Oct 4;372(9645):1231–9. [PMID: 18757089]

Goldberg LR. Heart failure. *Ann Intern Med.* 2010 Jun 1;152(11):ITC61–15. [PMID: 20513825]

Howlett JG et al. The 2010 Canadian Cardiovascular Society guidelines for the diagnosis and management of heart failure update: Heart failure in ethnic minority populations, heart failure and pregnancy, disease management, and quality improvement/assurance programs. *Can J Cardiol.* 2010 Apr;26(4):185–202. [PMID: 20386768]

Hunt SA et al. 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. *Circulation.* 2009 Apr 14;119(14):e391–479. [PMID: 19324966]

Moss AJ et al. Cardiac-resynchronization therapy for the prevention of heart-failure events. *N Engl J Med.* 2009 Oct 1;361(14):1329–38. [PMID: 19723701]

Ramani GV et al. Chronic heart failure: contemporary diagnosis and management. *Mayo Clin Proc.* 2010 Feb;85(2):180–95. [PMID: 20118395]

Salukhe TV et al. Is there benefit in implanting defibrillators in patients with severe heart failure? *Heart.* 2010 Apr;96(8):599–603. [PMID: 20357388]

Slaughter MS et al; HeartMate II Investigators. Advanced heart failure treated with continuous-flow left ventricular assist device. *N Engl J Med.* 2009 Dec 3;361(23):2241–51. [PMID: 19920051]

Steinhart B et al. Improving the diagnosis of acute heart failure using a validated prediction model. *J Am Coll Cardiol.* 2009 Oct 13;54(16):1515–21. [PMID: 19815122]

Tang AS et al; Resynchronization-Defibrillation for Ambulatory Heart Failure Trial Investigators. Cardiac-resynchronization therapy for mild-to-moderate heart failure. *N Engl J Med.* 2010 Dec 16;363(25):2385–95. [PMID: 21073365]

Velazquez EJ et al; STICH Investigators. Coronary-artery bypass surgery in patients with left ventricular dysfunction. *N Engl J Med.* 2011 Apr 28;364(17):1607–16. [PMID: 21463150]

Zannad F et al; EMPHASIS-HF Study Group. Eplerenone in patients with systolic heart failure and mild symptoms. *N Engl J Med.* 2011 Jan 6;364(1):11–21. [PMID: 21073363]

ACUTE HEART FAILURE & PULMONARY EDEMA



ESSENTIALS OF DIAGNOSIS

- ▶ Acute onset or worsening of dyspnea at rest.
- ▶ Tachycardia, diaphoresis, cyanosis.
- ▶ Pulmonary rales, rhonchi; expiratory wheezing.
- ▶ Radiograph shows interstitial and alveolar edema with or without cardiomegaly.
- ▶ Arterial hypoxemia.

▶ General Considerations

Typical causes of acute cardiogenic pulmonary edema include acute myocardial infarction or severe ischemia, exacerbation of chronic heart failure, acute volume overload of the LV (valvular regurgitation), and mitral stenosis. By far the most common presentation in developed countries is one of acute or subacute deterioration of chronic heart failure, precipitated by discontinuation of medications, excessive salt intake, myocardial ischemia, tachyarrhythmias (especially rapid atrial fibrillation), or intercurrent infection. Often in the latter group, there is preceding volume overload with worsening edema and progressive shortness of breath for which earlier intervention can usually avoid the need for hospital admission.

▶ Clinical Findings

Acute pulmonary edema presents with a characteristic clinical picture of severe dyspnea, the production of pink, frothy sputum, and diaphoresis and cyanosis. Rales are present in all lung fields, as are generalized wheezing and rhonchi. Pulmonary edema may appear acutely or subacutely in the setting of chronic heart failure or may be the first manifestation of cardiac disease, usually acute myocardial infarction, which may be painful or silent. Less severe decompensations usually present with dyspnea at

rest and rales and other evidence of fluid retention but without severe hypoxia.

Noncardiac causes of pulmonary edema include intravenous opioids, increased intracerebral pressure, high altitude, sepsis, several medications, inhaled toxins, transfusion reactions, shock, and disseminated intravascular coagulation. These are distinguished from cardiogenic pulmonary edema by the clinical setting, the history, and the physical examination. Conversely, in most patients with cardiogenic pulmonary edema, an underlying cardiac abnormality can usually be detected clinically or by the ECG, chest radiograph, or echocardiogram.

The chest radiograph reveals signs of pulmonary vascular redistribution, blurriness of vascular outlines, increased interstitial markings, and, characteristically, the butterfly pattern of distribution of alveolar edema. The heart may be enlarged or normal in size depending on whether heart failure was previously present. Assessment of cardiac function by echocardiography is important, since a substantial proportion of patients has normal EFs with elevated atrial pressures due to diastolic dysfunction. In cardiogenic pulmonary edema, the PCWP is invariably elevated, usually over 25 mm Hg. In noncardiogenic pulmonary edema, the wedge pressure may be normal or even low.

▶ Treatment

In full-blown pulmonary edema, the patient should be placed in a sitting position with legs dangling over the side of the bed; this facilitates respiration and reduces venous return. Oxygen is delivered by mask to obtain an arterial $PO_2 > 60$ mm Hg. Noninvasive pressure support ventilation may improve oxygenation and prevent severe CO_2 retention while pharmacologic interventions take effect. However, if respiratory distress remains severe, endotracheal intubation and mechanical ventilation may be necessary.

Morphine is highly effective in pulmonary edema and may be helpful in less severe decompensations when the patient is uncomfortable. The initial dosage is 2–8 mg intravenously (subcutaneous administration is effective in milder cases) and may be repeated after 2–4 hours. Morphine increases venous capacitance, lowering LA pressure, and relieves anxiety, which can reduce the efficiency of ventilation. However, morphine may lead to CO_2 retention by reducing the ventilatory drive. It should be avoided in patients with opioid-induced pulmonary edema, who may improve with opioid-antagonists, and in those with neurogenic pulmonary edema.

Intravenous diuretic therapy (furosemide, 40 mg, or bumetanide, 1 mg—or higher doses if the patient has been receiving long-term diuretic therapy) is usually indicated even if the patient has not exhibited prior fluid retention. These agents produce venodilation prior to the onset of diuresis. The DOSE trial has shown that, for acute decompensated heart failure, bolus doses of furosemide are of similar efficacy as continuous intravenous infusion, and that higher dose furosemide (2.5 times the prior daily dose) resulted in more rapid fluid removal without a substantially higher risk of renal impairment.

Nitrate therapy accelerates clinical improvement by reducing both BP and LV filling pressures. Sublingual nitroglycerin or isosorbide dinitrate, topical nitroglycerin, or intravenous nitrates will ameliorate dyspnea rapidly prior to the onset of diuresis, and these agents are particularly valuable in patients with accompanying hypertension. Intravenous nesiritide (recombinant BNP), when given as a bolus followed by an infusion, improves dyspnea more rapidly than intravenous nitroglycerin, though this may reflect the cautious way in which nitroglycerin is uptitrated by many practitioners. This agent, as well as nitrates, may precipitate hypotension, especially since these agents are used in combination with multiple drugs that lower BP. In patients with low-output states—particularly when hypotension is present—positive inotropic agents are indicated. These approaches to treatment have been discussed previously.

Bronchospasm may occur in response to pulmonary edema and may itself exacerbate hypoxemia and dyspnea. Treatment with inhaled β -adrenergic agonists or intravenous aminophylline may be helpful, but both may also provoke tachycardia and supraventricular arrhythmias.

In most cases, pulmonary edema responds rapidly to therapy. When the patient has improved, the cause or precipitating factor should be ascertained. In patients without prior heart failure, evaluation should include echocardiography and in many cases cardiac catheterization and coronary angiography. Patients with acute decompensation of chronic heart failure should be treated to achieve a euvolemic state and have their medical regimen optimized. Generally, an oral diuretic and an ACE inhibitor should be initiated, with efficacy and tolerability confirmed prior to discharge. In selected patients, early but careful initiation of β -blockers in low doses should be considered.

- Di Marco F et al. Risk factors for treatment failure in patients with severe acute cardiogenic pulmonary oedema. *Anaesth Intensive Care*. 2008 May;36(3):351-9. [PMID: 18564795]
- Felker GM et al; NHLBI Heart Failure Clinical Research Network. Diuretic strategies in patients with acute decompensated heart failure. *N Engl J Med*. 2011 Mar 3;364(9):797-805. [PMID: 21366472]
- Gauthier N et al. New therapies in acute decompensated heart failure. *Curr Opin Cardiol*. 2008 Mar;23(2):134-40. [PMID: 18303526]
- Gray AJ et al; 3CPO Study Investigators. A multicentre randomised controlled trial of the use of continuous positive airway pressure and non-invasive positive pressure ventilation in the early treatment of patients presenting to the emergency department with severe acute cardiogenic pulmonary oedema: the 3CPO trial. *Health Technol Assess*. 2009 Jul;13(33):1-106. [PMID: 19615296]
- Johnson JM. Management of acute cardiogenic pulmonary edema: a literature review. *Adv Emerg Nurs J*. 2009 Jan-Mar;31(1):36-43. [PMID: 20118852]
- O'Connor CM et al. Causes of death and rehospitalization in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction: results from Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) program. *Am Heart J*. 2010 May;159(5):841-49.e1. [PMID: 20435194]

Rimoldi SF et al. Flash pulmonary edema. *Prog Cardiovasc Dis.* 2009 Nov–Dec;52(3):249–59. [PMID: 19917337]

Summers RL et al. Pathophysiology of acute decompensated heart failure. *Heart Fail Clin.* 2009 Jan;5(1):9–17. [PMID: 19026381]

Tribouilloy C et al. In-hospital mortality and prognostic factors in patients admitted for new-onset heart failure with preserved or reduced ejection fraction: a prospective observational study. *Arch Cardiovasc Dis.* 2008 Apr;101(4):226–34. [PMID: 18654097]

Weng CL et al. Meta-analysis: noninvasive ventilation in acute cardiogenic pulmonary edema. *Ann Intern Med.* 2010 May 4;152(9):590–600. [PMID: 20439577]

West RL et al. A review of dyspnea in acute heart failure syndromes. *Am Heart J.* 2010 Aug;160(2):209–14. [PMID: 20691823]

MYOCARDITIS & THE CARDIOMYOPATHIES

INFECTIOUS MYOCARDITIS

ESSENTIALS OF DIAGNOSIS

- ▶ Often follows an upper respiratory infection.
- ▶ May present with chest pain (pleuritic or nonspecific) or signs of heart failure.
- ▶ Echocardiogram documents cardiomegaly and contractile dysfunction.
- ▶ Myocardial biopsy, though not sensitive, may reveal a characteristic inflammatory pattern. MRI may now have a role in diagnosis.

▶ General Considerations

Cardiac dysfunction due to primary myocarditis is presumed generally to be caused by either an acute viral infection or a postviral immune response. Secondary myocarditis is the result of inflammation caused by nonviral pathogens, drugs, chemicals, physical agents, or inflammatory diseases such as systemic lupus erythematosus. The list of both infectious and noninfectious causes of myocarditis is extensive (Table 10–11).

Early phase myocarditis is initiated by infection of cardiac tissue. Both cellular and humoral inflammatory processes contribute to the progression to chronic injury, and there are subgroups that might benefit from immunosuppression.

Genetic predisposition is a likely factor in some cases. Autoimmune myocarditis (eg, giant cell myocarditis) may occur with no identifiable viral infection.

▶ Clinical Findings

A. Symptoms and Signs

Patients may present several days to a few weeks after the onset of an acute febrile illness or a respiratory infection or with heart failure without antecedent symptoms. The onset of heart failure may be gradual or may be abrupt and fulminant. Emboli may occur. Pleural-pericardial

Table 10-11. Causes of myocarditis.

1. INFECTIOUS CAUSES

RNA viruses: Picornaviruses (coxsackie A and B, echovirus, poliovirus, hepatitis virus), orthomyxovirus (influenza), paramyxoviruses (respiratory syncytial virus, mumps), togaviruses (rubella), flaviviruses (dengue fever, yellow fever)

DNA viruses: Adenovirus (A1, 2, 3 and 5), erythrovirus (Bi9V and 2), herpesviruses (human herpes virus 6 A and B, cytomegalovirus, Epstein-Barr virus, varicella-zoster), retrovirus (HIV).

Bacteria: Chlamydia (*Chlamydomphila pneumoniae*, *C psittaci*), *Haemophilus influenzae*, *Legionella*, *Pneumophila*, *Brucella*, *Clostridium*, *Francisella tularensis*, *Neisseria meningitis*, *Mycobacterium* (tuberculosis), *Salmonella*, *Staphylococcus*, streptococcus A, *Streptococcus pneumoniae*, tularemia, tetanus, syphilis, *Vibrio cholera*.

Spirocheta: *Borrelia recurrentis*, leptospira, *Treponema pallidum*

Rickettsia: *Coxiella burnetti*, *R. rickettsii*, *R. prowazekii*

Fungi: *Actinomyces*, *Aspergillus*, *Candida*, *Cryptococcus*,

Histoplasma, *Nocardia*

Protozoa: *Entamoeba histolytica*, *Plasmodium falciparum*, *Trypanosoma cruzi*, *T burcei*, *T gondii*, *Leishmania*.

Helminthic: *Ascaris*, *Echinococcus granulosus*, *Schistosoma*, *Trichinella spiralis*, *Wuchereria bancrofti*

2. NONINFECTIOUS CAUSES

Autoimmune diseases: Dermatomyositis, inflammatory bowel disease, rheumatoid arthritis, Sjögren syndrome, systemic lupus erythematosus, granulomatosis with polyangiitis (formerly Wegener granulomatosis), giant cell myocarditis

Drugs: Aminophyllin, amphetamine, anthracyclin, catecholamines, chloramphenicol, cocaine, cyclophosphamide, doxorubicin, 5-FU, mesylate, methsergide, phenytoin, trastuzumab, zidovudine

Hypersensitivity reactions due to drugs: Azitromycin, benzodiazepines, clozapine, cephalosporins, dapsone, dobutamine, lithium, diuretics, thiazide, methyl dopa, mexiletine, streptomycin, sulfonamides, nonsteroidal anti-inflammatory drugs, tetanus toxoid, tetracycline, tricyclic antidepressants

Hypersensitivity reactions due to venoms: Bee, wasp, black widow spider, scorpion, snakes

Systemic diseases: Churg-Strauss syndrome, collagen diseases, sarcoidosis, Kawasaki disease, scleroderma

Other: Heat stroke, hypothermia, transplant rejection, radiation injury

(Modified, with permission, from Schultheiss HP et al. The management of myocarditis. *Eur Heart J.* 2011;32:2616–25.)

chest pain is common. Examination reveals tachycardia, a gallop rhythm, and other evidence of heart failure or conduction defect. Many acute infections are subclinical, though they may present later as idiopathic cardiomyopathy or with ventricular arrhythmias. At times, the presentation may mimic an acute myocardial infarction with ST changes, positive cardiac markers, and regional wall motion abnormalities despite normal coronaries. Microaneurysms may also occur and may be associated with serious ventricular arrhythmias. Patients may present in a variety of ways with fulminant, subacute, or chronic myocarditis. In the European Study of Epidemiology and Treatment of Inflammatory Heart

Disease, 72% had dyspnea, 32% had chest pain, and 18% had arrhythmias.

B. ECG and Chest Radiography

ECG may show sinus tachycardia, other arrhythmias, non-specific repolarization changes, and intraventricular conduction abnormalities. The presence of Q waves or left bundle branch block portends a higher rate of death or cardiac transplantation. Ventricular ectopy may be the initial and only clinical finding. Chest radiograph is nonspecific, but cardiomegaly is frequent, though not universal. Evidence for pulmonary venous hypertension is common and frank pulmonary edema may be present.

C. Diagnostic Studies

There is no specific laboratory study that is consistently present, though the white blood cell count is usually elevated and the sedimentation rate and CRP may be increased. Troponin I levels are elevated in about one-third of patients, but CK-MB is elevated in only 10%. Echocardiography provides the most convenient way of evaluating cardiac function and can exclude many other processes. MRI with gadolinium enhancement reveals spotty areas of injury throughout the myocardium, but both T2 and T1-weighted images are needed to achieve optimal results; however, correlation with endomyocardial biopsy results has been poor.

D. Endomyocardial Biopsy

Confirmation of myocarditis still requires histologic evidence. An AHA/ACCF/ESC joint statement in 2007 made a class 1 recommendation for biopsy under the following situations: (1) in patients with heart failure, a normal-sized or dilated LV < 2 weeks after onset of symptoms, and hemodynamic compromise; or (2) in patients with a dilated LV 2 weeks to 3 months after onset of symptoms, new ventricular arrhythmias or AV nodal block (Mobitz II or complete heart block) or who do not respond to usual care after 1–2 weeks. In some cases, the identification of inflammation without viral genomes by PCR suggest that immunosuppression might be useful.

► Treatment & Prognosis

Patients with fulminant myocarditis may present with acute cardiogenic shock. Their ventricles are usually not dilated, but thickened (possibly due to myoedema). There is a high death rate, but if the patients recover, they are usually left with no residual cardiomyopathy. Patients who present with subacute disease have a dilated cardiomyopathy and generally make an incomplete recovery. Those who present with chronic disease tend to have only mild dilation of the LV and eventually present with a more restrictive cardiomyopathy. Treatment is directed toward the clinical scenario with ACE inhibitors and β -blockers if LV EF is < 40%. Nonsteroidal anti-inflammatory drugs should be used if myopericarditis-related chest pain occurs. Colchicine has been suggested if pericarditis predominates. Arrhythmias should be suppressed.

Specific antimicrobial therapy is indicated when an infecting agent is identified. Exercise should be limited

during the recovery phase. Some experts believe digoxin should be avoided and it likely has little value in this setting. Immunosuppressive therapy with corticosteroids and intravenous immunoglobulin (IVIG) has been used in the hopes of improving the outcome when the process is acute (< 6 months) and if the biopsy suggests ongoing inflammation. However, controlled trials have not suggested a benefit. Uncontrolled trials suggest that interferon might have a role. Studies are lacking as to when to discontinue the chosen therapy if the patient improves. Patients with fulminant myocarditis require aggressive short-term support including an IABP or an LV assist device. If severe pulmonary infiltrates accompany the fulminant myocarditis, extracorporeal membrane oxygenation (ECMO) support may be temporarily required. Ongoing studies are addressing whether patients with giant cell myocarditis may be responsive to immunosuppressive agents, as a special case. Overall, if improvement does not occur, many patients may be eventual candidates for cardiac transplantation or long-term use of the newer LV assist devices.

► When to Refer

Patients in whom myocarditis is suspected should be seen by a cardiologist at a tertiary care center where facilities are available for diagnosis and therapies available should a fulminant course ensue. The facility should have ventricular support devices and transplantation options available.

- Blauwet LA et al. Myocarditis. *Prog Cardiovasc Dis.* 2010 Jan-Feb;52(4):274–88. [PMID: 20109598]
- Childs H et al. Cardiovascular magnetic resonance imaging in myocarditis. *Prog Cardiovasc Dis.* 2011 Nov;54(3):266–75. [PMID: 22014493]
- Cooper LT et al. The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology. *J Am Coll Cardiol.* 2007 Nov 6;50(19):1914–31. [PMID: 17980265]
- Gupta S et al. Fulminant myocarditis. *Nat Clin Pract Cardiovasc Med.* 2008 Nov;5(11):693–706. [PMID: 18797433]
- Schultheiss HP et al. The management of myocarditis. *Eur Heart J.* 2011 Nov;32(21):2616–25. [PMID: 21705357]

DRUG-INDUCED & TOXIC MYOCARDITIS

A variety of medications, illicit drugs, and toxic substances can produce acute or chronic myocardial injury; the clinical presentation varies widely. The phenothiazines, lithium, chloroquine, disopyramide, antimony-containing compounds, and arsenicals can also cause ECG changes, arrhythmias, or heart failure. Hypersensitivity reactions to sulfonamides, penicillins, and aminosalicylic acid as well as other drugs can result in cardiac dysfunction. Radiation can cause an acute inflammatory reaction as well as a chronic fibrosis of heart muscle, usually in conjunction with pericarditis.

The incidence of cocaine cardiotoxicity has increased markedly. Cocaine can result in coronary artery spasm, myocardial infarction, arrhythmias, and myocarditis. Because many of these processes are believed to be mediated by cocaine's inhibitory effect on norepinephrine reuptake by sympathetic nerves, β -blockers have been used therapeutically.

In documented coronary spasm, calcium channel blockers and nitrates may be effective. Usual therapy for CHF or conduction system disease is warranted when symptoms occur.

The problem of cardiovascular side effects from cancer chemotherapy agents is a growing one. Anthracyclines remain the cornerstone of treatment of many malignancies. CHF can be expected in 5% of patients treated with a cumulative dose of 400–450 mg/m², and this rate is doubled if the patient is over age 65. The use of trastuzumab in combination with anthracyclines increases the risk of cardiac dysfunction to up to 28%; this has been an issue since combined use of these agents is particularly effective in *HER2*-positive breast cancer.

In patients receiving chemotherapy, it is important to look for subtle signs of cardiovascular compromise. Echocardiography, cardiac MRI, and serial multigated acquisition (MUGA) studies can provide concrete data regarding LV function. Serum troponin and BNP levels as markers of cardiac injury, and the neutrophil glucosamine-associated lipocalin as a marker of renal injury, are often elevated in patients with significant cardiotoxicity.

▶ When to Refer

Many patients with myocardial injury from toxic agents can be monitored safely if ventricular function remains relatively preserved (EF > 40%) and no CHF symptoms occur. Diastolic dysfunction may be subtle.

Once CHF becomes evident or significant conduction system disease becomes manifest, the patient should be evaluated and monitored by a cardiologist in case myocardial dysfunction worsens and further intervention becomes warranted.

Eschenhagen T et al. Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology. *Eur J Heart Fail*. 2011 Jan;13(1):1–10. [PMID: 21169385]

Khakoo AY et al. Therapy Insight: management of cardiovascular disease in patients with cancer and cardiac complications of cancer therapy. *Nat Clin Pract Oncol*. 2008 Nov;5(11):655–67. [PMID: 18797437]

DILATED CARDIOMYOPATHY



ESSENTIALS OF DIAGNOSIS

- ▶ Symptoms and signs of heart failure.
- ▶ Echocardiogram confirms LV dilation, thinning, and global dysfunction.
- ▶ Severity of RV dysfunction critical in long-term prognosis.

▶ General Considerations

The cardiomyopathies are a heterogeneous group of entities primarily affecting the myocardium and not associated with other major causes of cardiac disease, such as

ischemic heart disease, hypertension, pericardial disease, valvular disease, or congenital defects. More recently, two additional entities have been added to the list: a transient cardiomyopathy due to high catecholamine discharge (Tako-Tsubo cardiomyopathy, see below) and an embryologic defect resulting in massive trabeculation in the LV (ventricular noncompaction). Although some have specific causes, many cases are idiopathic. The classification of cardiomyopathies is based on features of presentation and pathophysiology (Table 10–12).

Dilated cardiomyopathies cause about 25% of all cases of CHF. They usually present with symptoms and signs of CHF (most commonly dyspnea). Occasionally, symptomatic ventricular arrhythmias are the presenting event. LV dilation and systolic dysfunction (EF < 50%) are essential for diagnosis. Dilated cardiomyopathy occurs more often in blacks than whites and in men more than women. A growing number of cardiomyopathies due to genetic abnormalities are being recognized, and it is estimated these may represent up to 30–48% of cases. Often no cause can be identified, but chronic alcohol abuse and unrecognized myocarditis are probably frequent causes. There is increasing recognition that chronic tachycardia may also precipitate a dilated cardiomyopathy that may improve over time if rate control can be achieved. Amyloidosis, sarcoidosis, hemochromatosis, and diabetes may rarely present as dilated cardiomyopathies, as well as the more classic restrictive picture. The RV may be primarily involved in arrhythmogenic RV dysplasia, an unusual cardiomyopathy with displacement of myocardial cells by adipose tissue, or in Uhl disease, in which there is extreme thinning of the RV walls. The function of the RV often determines how well patients do over the long term since RV dysfunction may or may not be present in patients with severe LV dysfunction.

Dilated cardiomyopathy can now be considered a disease that results from more varied perturbations, including, but not limited to, defects of the cytoskeleton. Positional cloning and candidate gene approaches have been successful in identifying greater than 40 disease loci, many of which have led to disease genes in hypertrophic cardiomyopathy, restrictive cardiomyopathy, dilated cardiomyopathy, and arrhythmogenic right ventricular dysplasia. This exciting area is only now being explored. Since most dilated cardiomyopathies are considered “idiopathic,” the potential for discovery of a genetic predisposition seems very promising.

Intraventricular thrombus is not uncommon in dilated cardiomyopathy. Histologically, the picture is one of extensive fibrosis unless a specific diagnosis, such as an infiltrative process, is established. Myocardial biopsy is rarely useful in establishing the diagnosis, though occasionally the underlying cause (eg, sarcoidosis, hemochromatosis) can be discerned. Biopsy is most useful in transplant rejection.

▶ Clinical Findings

A. Symptoms and Signs

In most patients, symptoms of heart failure develop gradually. The physical examination reveals rales, an elevated JVP, cardiomegaly, S₃ gallop rhythm, often the murmurs of

Table 10-12. Classification of the cardiomyopathies.

	Dilated	Hypertrophic	Restrictive
Frequent causes	Idiopathic, alcoholic, major catecholamine discharge, myocarditis, postpartum, doxorubicin, endocrinopathies, genetic diseases	Hereditary syndrome, possibly chronic hypertension in the elderly	Amyloidosis, post-radiation, post-open heart surgery, diabetes, endomyocardial fibrosis
Symptoms	Left or biventricular congestive heart failure	Dyspnea, chest pain, syncope	Dyspnea, fatigue, right-sided congestive heart failure > left heart failure
Physical examination	Cardiomegaly, S ₃ , elevated jugular venous pressure, rales	Sustained point of maximal impulse, S ₄ , variable systolic murmur, bisferiens carotid pulse	Elevated jugular venous pressure, Kussmaul sign
Electrocardiogram	ST-T changes, conduction abnormalities, ventricular ectopy	Left ventricular hypertrophy, exaggerated septal Q waves	ST-T changes, conduction abnormalities, low voltage
Chest radiograph	Enlarged heart, pulmonary congestion	Mild cardiomegaly	Mild to moderate cardiomegaly
Echocardiogram, nuclear studies, MRI	Left ventricular dilation and dysfunction	Left ventricular hypertrophy, asymmetric septal hypertrophy, small left ventricular size, normal or supranormal function, systolic anterior mitral motion, diastolic dysfunction	Small or normal left ventricular size, normal or mildly reduced left ventricular function. Gadolinium-hyperenhancement on MRI.
Cardiac catheterization	Left ventricular dilation and dysfunction, high diastolic pressures, low cardiac output. Coronary angiography important to exclude ischemic cause.	Small, hypercontractile left ventricle, dynamic outflow gradient, diastolic dysfunction	High diastolic pressure, "square root" sign, normal or mildly reduced left ventricular function

functional mitral or tricuspid regurgitation, peripheral edema, or ascites. In severe CHF, Cheyne-Stokes breathing, pulsus alternans, pallor, and cyanosis may be present.

B. ECG and Chest Radiography

The major findings are listed in Table 10-12. Sinus tachycardia is common. Other common abnormalities include left bundle branch block and ventricular or atrial arrhythmias. The chest radiograph reveals cardiomegaly, evidence for left and/or right heart failure, and pleural effusions (right > left).

C. Diagnostic Studies

An echocardiogram is indicated to exclude unsuspected valvular or other lesions and confirm the presence of dilated cardiomyopathy and the reduced systolic function (as opposed to pure diastolic heart failure). Mitral Doppler inflow patterns also help in the diagnosis of associated diastolic dysfunction. Color flow Doppler can reveal tricuspid or mitral regurgitation, and continuous Doppler can help define PA pressures. Exercise or pharmacologic stress myocardial perfusion imaging may suggest the possibility of underlying coronary disease. Radionuclide ventriculography provides a noninvasive measure of the EF and both RV and LV wall motion. Cardiac MRI is particularly helpful in inflammatory or infiltrative processes, such as sarcoidosis or hemochromatosis, and is the diagnostic study of choice for RV dysplasia where there is fatty infiltration. MRI can also help define an ischemic etiology by noting gadolinium hyperenhancement consistent with myocardial scar. Cardiac

catheterization is seldom of specific value unless myocardial ischemia or LV aneurysm is suspected. The serum ferritin is an adequate screening study for hemochromatosis. The erythrocyte sedimentation rate may be low due to liver congestion if right heart failure is present. The serum level of BNP or pro-BNP can be used to help quantitate the severity of CHF.

► Treatment

Standard therapy for heart failure should include ACE inhibitors, β -blockers, diuretics, and an aldosterone antagonist. Digoxin is a second-line drug but remains favored as an adjunct by some clinicians. Calcium channel blockers should generally be avoided unless absolutely necessary for rate control in atrial fibrillation. Sodium restriction is helpful, especially in acute CHF. When atrial fibrillation is present, heart rate control is important if sinus rhythm cannot be established or maintained. There are few data to suggest an advantage of sinus rhythm over atrial fibrillation on long-term outcomes. Many patients may be candidates for cardiac synchronization therapy with biventricular pacing and an implantable defibrillator. Few cases of cardiomyopathy are amenable to specific therapy for the underlying cause. Alcohol use should be discontinued, since there is often marked recovery of cardiac function following a period of abstinence in alcoholic cardiomyopathy. Endocrine causes (hyperthyroidism or hypothyroidism, acromegaly, and pheochromocytoma) should be treated. Immunosuppressive therapy is not indicated in chronic dilated cardiomyopathy. The management of CHF is

outlined in the section on heart failure. There are some patients who may benefit from implantable LV assist devices either as a bridge to transplantation or to temporize while cardiac function returns.

► Prognosis

The prognosis of dilated cardiomyopathy without clinical heart failure is variable, with some patients remaining stable, some deteriorating gradually, and others declining rapidly. Once heart failure is manifest, the natural history is similar to that of other causes of heart failure, with an annual mortality around 11–13%. Arterial and pulmonary emboli are more common in dilated cardiomyopathy than in ischemic cardiomyopathy. Suitable candidates may benefit from long-term anticoagulation, and all patients with atrial fibrillation should be so treated. Some clinicians use warfarin to prevent or treat an LV thrombus.

► When to Refer

- Referral to a cardiologist is warranted when there is any question about the etiology of reduced systolic function.
- Essentially all patients with a dilated cardiomyopathy need to have a coronary evaluation to exclude an underlying ischemic cause that might be treatable.
- Referral should also be considered when heart failure symptoms emerge, especially if there is a possibility the patient may eventually be a cardiac transplant candidate.

Anderson L et al. The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology. *Eur Heart J*. 2008 Dec;29(13):1696–97. [PMID: 18456711]

Hershberger RE et al. Update 2011: clinical and genetic issues in familial dilated cardiomyopathy. *J Am Coll Cardiol*. 2011 Apr 19;57(16):1641–7. [PMID: 21492761]

Jefferies JL et al. Dilated cardiomyopathy. *Lancet*. 2010 Feb 27;375(9716):752–62. [PMID: 20189027]

La Vecchia L et al. Right ventricular function predicts transplant-free survival in idiopathic dilated cardiomyopathy. *J Cardiovasc Med (Hagerstown)*. 2006 Sep;7(9):706–10. [PMID: 16932086]

TAKO-TSUBO CARDIOMYOPATHY



ESSENTIALS OF DIAGNOSIS

- Occurs after a major catecholamine discharge.
- Acute chest pain or shortness of breath.
- Predominately affects postmenopausal women.
- Presents as an acute anterior myocardial infarction, but coronaries normal at cardiac catheterization.
- Imaging reveals apical left ventricular ballooning due to anteroapical stunning of the myocardium.
- Most patients recover completely.

► General Considerations

LV apical ballooning (Tako-Tsubo syndrome) can follow a high catecholamine stress. The resulting shape of the LV suggests a rounded ampulla form similar to a Japanese octopus pot (tako-tsubo pot). Mid-ventricular ballooning has also been described. The acute myocardial injury is more common in postmenopausal women. It has been described following some stressful event, such as hypoglycemia, lightning strikes, earthquakes, postventricular tachycardia, during alcohol withdrawal, following surgery, during hyperthyroidism, after stroke, and following emotional stress (“broken-heart syndrome”). Virtually any event that triggers excess catecholamines may be implicated. Pericarditis and even tamponade has been described in isolated cases.

► Clinical Findings

A. Symptoms and Signs

The symptoms are similar to any acute coronary syndrome. Typical angina and dyspnea are usually present. Syncope is rare, although arrhythmias are not uncommon.

B. ECG and Chest Radiography

The ECG reveals ST segment elevation as well as deep anterior T wave inversion. The chest radiograph is either normal or reveals pulmonary congestion. The dramatic T wave inversions gradually resolve over time.

C. Diagnostic Studies

The echocardiogram reveals LV apical dyskinesia usually not consistent with any particular coronary distribution. The urgent cardiac catheterization reveals the LV apical ballooning in association with normal coronaries. Initial cardiac enzymes are positive but often taper quickly. In almost all cases, MRI hyperenhancement studies reveal no long-term scarring.

► Treatment

Immediate therapy is similar to any acute myocardial infarction. Initiation of long-term therapy depends on whether LV dysfunction persists. Most patients receive aspirin, β -blockers, and ACE-inhibitors until the LV fully recovers.

► Prognosis

Prognosis is good unless there is a serious complication (such as mitral regurgitation, ventricular rupture, ventricular tachycardia). Recovery is expected in most cases after a period of weeks to months. At times, the LV function recovers in days. Rarely, repeat episodes have been reported.

Eitel I et al. Clinical characteristics and cardiovascular magnetic resonance findings in stress (takotsubo) cardiomyopathy. *JAMA*. 2011 Jul 20;306(3):277–86. [PMID: 21771988]

Nef HM et al. Mechanisms of stress (Takotsubo) cardiomyopathy. *Nat Rev Cardiol*. 2010 Apr;7(4):187–93. [PMID: 20195267]

Sharkey SW et al. Natural history and expansive clinical profile of stress (tako-tsubo) cardiomyopathy. *J Am Coll Cardiol*. 2010 Jan;55(4):333–41. [PMID: 20117439]

HYPERTROPHIC CARDIOMYOPATHY



ESSENTIALS OF DIAGNOSIS

- ▶ May present with dyspnea, chest pain, syncope.
- ▶ Though LV outflow gradient is classic, symptoms are primarily related to diastolic dysfunction.
- ▶ Echocardiogram shows septal hypertrophy, which is usually asymmetric, and enhanced contractility. Systolic anterior motion of the anterior mitral valve is present when there is outflow tract obstruction.
- ▶ The highest risk group for sudden death includes those with a marked LVH, with a family history for sudden death, with ventricular ectopy, with unexplained syncope or with an abnormal BP response to exercise.

▶ General Considerations

Hypertrophic cardiomyopathy is noted when there is LV hypertrophy unrelated to any pressure or volume overload. The hypertrophy reduces LV systolic stress, increases the EF, and can result in an “empty ventricle” at end-systole. The interventricular septum may be disproportionately involved (asymmetric septal hypertrophy), but in some cases the hypertrophy is localized to the mid ventricle or to the apex. The LV outflow tract is narrowed during systole due to the hypertrophic septum and systolic anterior motion of the mitral valve. The obstruction is worsened by factors that increase myocardial contractility (sympathetic stimulation, digoxin, and postextrasystolic beat) or that decrease LV filling (Valsalva maneuver, peripheral vasodilators). The amount of obstruction is preload and afterload dependent and can vary from day to day. The consequence of the hypertrophy is elevated LV diastolic pressures rather than systolic dysfunction. Rarely, systolic dysfunction develops late in the disease. The LV is usually more involved than the RV and the atria are frequently significantly enlarged.

It has been increasingly appreciated that hypertrophic obstructive cardiomyopathy (HOCM) is inherited as an autosomal dominant trait with variable penetrance and is caused by mutations of one of a large number of genes, most of which code for myosin heavy chains or proteins regulating calcium handling. The prognosis is related to the specific gene mutation. Patients usually present in early adulthood. Elite athletes may demonstrate considerable hypertrophy that can be confused with HOCM, but generally diastolic dysfunction is not present in the athlete. The apical variety is particularly common in those of Asian descent. A mid-ventricular obstructive form is also known. A hypertrophic cardiomyopathy in the elderly (usually in association with hypertension) has also been defined as a distinct entity. Mitral annular calcification is often present. Mitral regurgitation is variable and often dynamic, depending on the degree of outflow tract obstruction.

▶ Clinical Findings

A. Symptoms and Signs

The most frequent symptoms are dyspnea and chest pain (Table 10–12). Syncope is also common and is typically postexertional, when diastolic filling diminishes and outflow obstruction increases due to residual circulating catecholamines. Arrhythmias are an important problem. Atrial fibrillation is a long-term consequence of chronically elevated LA pressures and is a poor prognostic sign. Ventricular arrhythmias are also common, and sudden death may occur, often in athletes after extraordinary exertion.

Features on physical examination include a bisferiens carotid pulse, triple apical impulse (due to the prominent atrial filling wave and early and late systolic impulses), and a loud S_4 . The JVP may reveal a prominent a wave due to reduced RV compliance. In cases with outflow obstruction, a loud systolic murmur is present along the left sternal border that increases with upright posture or Valsalva maneuver and decreases with squatting. These maneuvers help differentiate the murmur of HOCM from that of aortic stenosis, since in HOCM, reducing the LV volume increases obstruction and the murmur intensity; whereas in valvular aortic stenosis, reducing the stroke volume across the valve decreases the murmur. Mitral regurgitation is frequently present as well.

B. ECG and Chest Radiography

LVH is nearly universal in symptomatic patients, though entirely normal ECGs are present in up to 25%, usually in those with localized hypertrophy. Exaggerated septal Q waves inferolaterally may mimic myocardial infarction. The chest radiograph is often unimpressive. Unlike aortic stenosis, the ascending aorta is not dilated.

C. Diagnostic Studies

The echocardiogram is diagnostic, revealing asymmetric LVH, systolic anterior motion of the mitral valve, early closing followed by reopening of the aortic valve, a small and hypercontractile LV, and delayed relaxation and filling of the LV during diastole. The septum is usually 1.3–1.5 times the thickness of the posterior wall. Septal motion tends to be reduced. Doppler ultrasound reveals turbulent flow and a dynamic gradient in the LV outflow tract and, commonly, mitral regurgitation. Abnormalities in the diastolic filling pattern are present in 80% of patients. Echocardiography can usually differentiate the disease from ventricular noncompaction. Myocardial perfusion imaging may suggest septal ischemia in the presence of normal coronary arteries. Cardiac MRI confirms the hypertrophy and contrast enhancement frequently reveals evidence for scar at the junction of the RV attachment to the septum. Cardiac catheterization confirms the diagnosis and defines the presence of CAD. Frequently, coronary arterial bridging (squeezing in systole) occurs, especially of the septal arteries. Exercise studies are recommended to assess for ventricular arrhythmias and to document the BP response. Holter monitoring is recommended for determination of ventricular ectopy.

► Treatment

β -Blockers should be the initial drug in symptomatic individuals, especially when dynamic outflow obstruction is noted on the echocardiogram. The resulting slower heart rates assist with diastolic filling of the stiff LV. Dyspnea, angina, and arrhythmias respond in about 50% of patients. Calcium channel blockers, especially verapamil, have also been effective in symptomatic patients. Their effect is due primarily to improved diastolic function; however, their vasodilating actions can also increase outflow obstruction and cause hypotension. Disopyramide is also used because of its negative inotropic effects; it is usually used in addition to the medical regimen rather than as primary therapy or to help control atrial arrhythmias. Diuretics are frequently necessary due to the high diastolic pressure and PCWP. Patients do best in sinus rhythm, and atrial fibrillation should be aggressively treated with antiarrhythmics or radiofrequency ablation. Dual-chamber pacing may prevent the progression of hypertrophy and obstruction. There appears to be an advantage to the use of short-AV delay biventricular pacing. Nonsurgical septal ablation has been performed by injection of alcohol into septal branches of the left coronary artery with good results in small series of patients. Patients with malignant ventricular arrhythmias and unexplained syncope in the presence of a positive family history for sudden death with or without an abnormal BP response to exercise are probably best managed with an implantable defibrillator. Excision of part of the outflow myocardial septum (myotomy–myomectomy) by surgeons experienced with the procedure has been successful in patients with severe symptoms unresponsive to medical therapy. A few surgeons advocate mitral valve replacement, as this results in resolution of the gradient as well, and prevents associated mitral regurgitation. In some cases, myomectomy has been combined with an Alfieri stitch on the mitral valve with success. Rare cases with progression to dilation or with intractable symptoms can be considered for cardiac transplantation. Figure 10–2 provides an algorithm for the treatment of HOCM.

Pregnancy results in an increased risk in patients with symptoms or outflow tract gradients of > 50 mm Hg. Genetic counseling is indicated before planned conception. In pregnant patients with HOCM, continuation of β -blocker therapy is recommended.

► Prognosis

The natural history of HOCM is highly variable. Several specific mutations are associated with a higher incidence of early malignant arrhythmias and sudden death, and definition of the genetic abnormality provides the best estimate of prognosis. Some patients remain asymptomatic for many years or for life. Sudden death, especially during exercise, may be the initial event. The highest risk patients are those with (1) a personal history of serious ventricular arrhythmias or survival of a sudden death episode; (2) a family history of sudden death; (3) unexplained syncope; (4) documented NSVT, defined as three or more beats of ventricular tachycardia at ≥ 120 beats per minute on ambulatory Holter

monitoring; and (5) maximal LV wall thickness ≥ 30 mm. In addition, patients whose blood pressure does not increase during treadmill stress testing are also at some risk, as are those with double and compound genetic mutations and those with marked LV outflow tract obstruction. MRI data suggest that the extent of scarring on hyperenhancement may also be predictive of adverse events. HOCM is the pathologic feature most frequently associated with sudden death in athletes. Pregnancy is generally well tolerated. Endocarditis prophylaxis is no longer indicated. A final stage may be a transition into dilated cardiomyopathy in 5–10% of patients due to the long-term effects of LV remodeling; treatment at that stage is similar to that for dilated cardiomyopathy.

► When to Refer

Patients should be referred to a cardiologist when symptoms are difficult to control, syncope has occurred, or there are any of the high-risk features present as noted above.

Bruder O et al. Myocardial scar by cardiovascular magnetic resonance imaging predicts major events in hypertrophic cardiomyopathy. *J Am Coll Cardiol*. 2010 Sep 7;56(11):875–87. [PMID: 20667520]

Gersh BJ et al. 2011 ACCF/AHA guideline for the treatment of hypertrophic cardiomyopathy. *J Am Coll Cardiol*. 2011 Dec 13;58(25):e212–60. [PMID: 22075469]

Gimeno JR et al. Exercise-induced ventricular arrhythmias and risk of sudden cardiac death in patients with hypertrophic cardiomyopathy. *Eur Heart J*. 2009 Nov;30(21):2599–605. [PMID: 19689975]

Marian AJ. Hypertrophic cardiomyopathy: from genetics to treatment. *Eur J Clin Invest*. 2010 Apr;40(4):360–9. [PMID: 20503496]

RESTRICTIVE CARDIOMYOPATHY




ESSENTIALS OF DIAGNOSIS

- Right heart failure tends to dominate over left heart failure.
- Pulmonary hypertension present.
- Amyloidosis is the most common cause.
- Echocardiography is key to diagnosis. Rapid early filling is present with diastolic dysfunction. Normal or near normal EF with normal size LV.
- MRI and cardiac catheterization are helpful. Myocardial biopsy can confirm amyloid.

► General Considerations

Restrictive cardiomyopathy is characterized by impaired diastolic filling with reasonably preserved contractile function. The condition is relatively uncommon, with the most frequent cause being amyloidosis. In Africa, endomyocardial fibrosis, a specific entity in which there is severe fibrosis of the endocardium, often with eosinophilia (Löffler syndrome),



¹See section on AV Block in the text.

▲ **Figure 10-2.** Recommended therapeutic approach to the patient with hypertrophic obstructive cardiomyopathy (HOCM). ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blockers; CHF, congestive heart failure; LV EF, left ventricular ejection fraction. (Reproduced, with permission, from Gersh BJ et al. 2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the American Association for Thoracic Surgery, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. *J Am Coll Cardiol.* 2011 Dec 13;58(25):e212–60.)

is seen. Other causes of restrictive cardiomyopathy are infiltrative cardiomyopathies (eg, hemochromatosis, sarcoidosis) and connective tissue diseases (eg, scleroderma).

► Clinical Findings

A. Symptoms and Signs

Restrictive cardiomyopathy must be distinguished from constrictive pericarditis (Table 10–12). The key feature is that ventricular interaction is accentuated with respiration in constrictive pericarditis and that interaction is absent in restrictive cardiomyopathy. In addition, the pulmonary arterial pressure is invariably elevated in restrictive cardiomyopathy due to the high pulmonary capillary wedge pressure and is normal in uncomplicated constrictive pericarditis.

B. Diagnostic Studies

Conduction disturbances are frequently present. Low voltage on the ECG combined with ventricular hypertrophy on the echocardiogram is suggestive of disease. Cardiac MRI presents a distinctive pattern of diffuse hyperenhancement of the gadolinium image in amyloidosis and is a useful screening test. The echocardiogram reveals a small thickened LV with bright myocardium (speckled), rapid early diastolic filling revealed by the mitral inflow Doppler, and biatrial enlargement. Atrial septal thickening may be evident. Rectal, abdominal fat, or gingival biopsies can confirm systemic involvement, but myocardial involvement may still be present if these are negative, and requires endomyocardial biopsy for the confirmation of cardiac amyloid.

Demonstration of tissue infiltration on biopsy specimens using special stains followed by immunohistochemical studies and genetic testing is essential to define which specific protein is involved.

► Treatment

Unfortunately, little useful therapy is available for either the causative conditions or the restrictive cardiomyopathy itself. Diuretics can help, but excessive diuresis can produce worsening kidney dysfunction. As with most patients with severe right heart failure, loop diuretics, thiazides, and aldosterone antagonists are all useful. Recently, the use of ultrafiltration devices have allowed for improved diuresis. Digoxin may precipitate arrhythmias and generally should not be used. β -Blockers help slow heart rates and improve filling. Corticosteroids may be helpful in sarcoidosis but they are more effective for the conduction abnormalities than heart failure. In amyloidosis, the therapeutic strategy depends on the characterization of the type of amyloid protein and extent of disease and may include chemotherapy or bone marrow transplantation. In familial amyloidosis, liver transplantation may be an option. Cardiac transplantation has also been used in patients with primary cardiac amyloidosis.

► When to Refer

All patients with the diagnosis of a restrictive cardiomyopathy should be referred to a cardiologist to decide etiology and plan appropriate treatment. This is especially true if amyloidosis is suspected.

Denfield SW et al. Restrictive cardiomyopathy in childhood. *Heart Fail Clin.* 2010 Oct;6(4):445–52. [PMID: 20869645]
 Falk RH et al. Amyloid heart disease. *Prog Cardiovasc Dis.* 2010 Jan–Feb;52(4):347–61. [PMID: 20109604]
 Kapoor P et al. Cardiac amyloidosis: a practical approach to diagnosis and management. *Am J Med.* 2011 Nov;124(11):1006–15. [PMID: 22017778]
 Sen-Chowdhry S et al. Genetics of restrictive cardiomyopathy. *Heart Fail Clin.* 2010 Apr;6(2):179–86. [PMID: 20347786]

RHEUMATIC FEVER

ESSENTIALS OF DIAGNOSIS

- Uncommon in the United States (approximately 2 cases/100,000 population); more common (100 cases/100,000 population) in developing countries.
- Diagnosis based on Jones criteria and confirmation of streptococcal infection.

► General Considerations

Rheumatic fever is a systemic immune process that is a sequela of a β -hemolytic streptococcal infection of the

pharynx. Some experts believe molecular mimicry between streptococcal antigens and human proteins are at the core of the problem. The elucidation of chemokines and their receptors involved with the recruitment of T cells, as well as the function of T regulatory cells, likely contributes to the heart lesion responsible for rheumatic heart disease. Pyodermic infections are not associated with rheumatic fever. Signs of rheumatic fever usually commence 2–3 weeks after infection but may appear as early as 1 week or as late as 5 weeks. In recent years, the disease has become quite uncommon in the United States, except in immigrants; however, there have been reports of new outbreaks in several regions of the United States. The peak incidence is between ages 5 and 15 years; rheumatic fever is rare before age 4 years or after age 40 years. Rheumatic carditis and valvulitis may be self-limited or may lead to slowly progressive valvular deformity. The characteristic lesion is a perivascular granulomatous reaction with vasculitis. The mitral valve is attacked in 75–80% of cases, the aortic valve in 30% (but rarely as the sole valve), and the tricuspid and pulmonary valves in under 5% of cases. Overall, carditis is thought to occur in about 30–45% of cases of acute rheumatic fever.

Chronic rheumatic heart disease results from single or repeated attacks of rheumatic fever that produce rigidity and deformity of valve cusps, fusion of the commissures, or shortening and fusion of the chordae tendineae. Valvular stenosis or regurgitation results and the two often coexist. The mitral valve alone is affected in 50–60% of cases; combined lesions of the aortic and mitral valves occur in 20%; pure aortic lesions are less common. Tricuspid involvement occurs in about 10% of cases but only in association with mitral or aortic disease and is thought to be more common when recurrent infections have occurred. The pulmonary valve is rarely affected. A history of rheumatic fever is obtainable in only 60% of patients with rheumatic heart disease.

► Clinical Findings

The diagnostic criteria first described by Jones were updated in 1992. The presence of two major criteria—or one major and two minor criteria—establishes the diagnosis. Echocardiographic studies revealing valvular abnormalities have suggested that subclinical cardiac involvement may be missed using the strict Jones criteria. India, New Zealand, and Australia have all published revised guidelines.

A. Major Criteria

1. Carditis—Carditis is most likely to be evident in children and adolescents. Any of the following suggests the presence of carditis: (1) pericarditis; (2) cardiomegaly, detected by physical signs, radiography, or echocardiography; (3) CHF, right- or left-sided—the former perhaps more prominent in children, with painful liver engorgement due to tricuspid regurgitation; and (4) mitral or aortic regurgitation murmurs, indicative of dilation of a valve ring with or without associated valvulitis. The Carey–Coombs short mid-diastolic mitral murmur may be present.

In the absence of any of the above definitive signs, the diagnosis of carditis depends on the following less specific abnormalities: (1) ECG changes, including changing contour of P waves or inversion of T waves; (2) changing quality of heart sounds; and (3) sinus tachycardia, arrhythmia, or ectopic beats.

2. Erythema marginatum and subcutaneous nodules—Erythema marginatum begins as rapidly enlarging macules that assume the shape of rings or crescents with clear centers. They may be raised, confluent, and either transient or persistent.

Subcutaneous nodules are uncommon except in children. They are small (≤ 2 cm in diameter), firm, and nontender and are attached to fascia or tendon sheaths over bony prominences. They persist for days or weeks, are recurrent, and are indistinguishable from rheumatoid nodules.

3. Sydenham chorea—Sydenham chorea—involuntary choreoathetoid movements primarily of the face, tongue, and upper extremities—may be the sole manifestation; only 50% of cases have other overt signs of rheumatic fever. Girls are more frequently affected, and occurrence in adults is rare. This is the least common (3% of cases) but most diagnostic of the manifestations of rheumatic fever.

4. Polyarthritis—This is a migratory polyarthritis that involves the large joints sequentially. In adults, only a single joint may be affected. The arthritis lasts 1–5 weeks and subsides without residual deformity. Prompt response of arthritis to therapeutic doses of salicylates or nonsteroidal agents is characteristic.

B. Minor Criteria

These include fever, polyarthralgias, reversible prolongation of the PR interval, and an elevated erythrocyte sedimentation rate or CRP. Supporting evidence includes positive throat culture or rapid streptococcal antigen test and elevated or rising streptococcal antibody titer.

C. Laboratory Findings

There is nonspecific evidence of inflammatory disease, as shown by a rapid sedimentation rate. High or increasing titers of antistreptococcal antibodies (antistreptolysin O and anti-DNase B) are used to confirm recent infection; 10% of cases lack this serologic evidence.

► Treatment

A. General Measures

The patient should be kept at strict bed rest until the temperature returns to normal (without the use of antipyretic medications) and the sedimentation rate, plus the resting pulse rate, and the ECG have all returned to baseline.

B. Medical Measures

1. Salicylates—The salicylates markedly reduce fever and relieve joint pain and swelling. They have no effect on the natural course of the disease. Adults may require large

doses of aspirin, 0.6–0.9 g every 4 hours; children are treated with lower doses.

2. Penicillin—Penicillin (benzathine penicillin, 1.2 million units intramuscularly once, or procaine penicillin, 600,000 units intramuscularly daily for 10 days) is used to eradicate streptococcal infection if present. Erythromycin may be substituted (40 mg/kg/d).

3. Corticosteroids—There is no proof that cardiac damage is prevented or minimized by corticosteroids. A short course of corticosteroids (prednisone, 40–60 mg orally daily, with tapering over 2 weeks) usually causes rapid improvement of the joint symptoms and is indicated when response to salicylates has been inadequate.

► Prevention of Recurrent Rheumatic Fever

The initial episode of rheumatic fever can usually be prevented by early treatment of streptococcal pharyngitis. (See Chapter 33.) Prevention of recurrent episodes of rheumatic fever is critical. Recurrences of rheumatic fever are most common in patients who have had carditis during their initial episode and in children, 20% of whom will have a second episode within 5 years. The preferred method of prophylaxis is with benzathine penicillin G, 1.2 million units intramuscularly every 4 weeks. Oral penicillin (200,000–250,000 units twice daily) is less reliable.

If the patient is allergic to penicillin, sulfadiazine (or sulfisoxazole), 1 g daily, or erythromycin, 250 mg orally twice daily, may be substituted. The macrolide azithromycin is similarly effective against group A streptococcal infection. If the patient has not had an immediate hypersensitivity (anaphylactic-type) reaction to penicillin, then cephalosporin may also be used.

Recurrences are uncommon after 5 years following the first episode and in patients over 25 years of age. Prophylaxis is usually discontinued after these times except in groups with a high risk of streptococcal infection—parents or teachers of young children, nurses, military recruits, etc. Secondary prevention of rheumatic fever depends on whether carditis has occurred. If there is no evidence for carditis, preventive therapy can be stopped at age 21 years. If carditis has occurred but there is no residual valvular disease, it can be stopped at 10 years after the episode. If carditis has occurred with residual valvular involvement, it should be continued for 10 years after the last episode or until age 40 years if the patient is in a situation in which reexposure would be expected.

► Prognosis

Initial episodes of rheumatic fever may last months in children and weeks in adults. The immediate mortality rate is 1–2%. Persistent rheumatic carditis with cardiomegaly, heart failure, and pericarditis implies a poor prognosis; 30% of children thus affected die within 10 years after the initial attack. After 10 years, two-thirds of patients will have detectable valvular abnormalities (usually thickened valves with limited mobility), but significant symptomatic

valvular heart disease or persistent cardiomyopathy occurs in < 10% of patients with a single episode. In developing countries, acute rheumatic fever occurs earlier in life, recurs more frequently, and the evolution to chronic valvular disease is both accelerated and more severe.

Atatoa-Carr P et al. Rheumatic fever diagnosis, management, and secondary prevention: a New Zealand guideline. *N Z Med J*. 2008 Apr 4;121(1271):59–69. [PMID: 18392063]

Carapetis J et al. Prevention of rheumatic fever. *Pediatr Infect Dis J*. 2010 Jan;29(1):91–2. [PMID: 20035211]

Lee JL et al. Acute rheumatic fever and its consequences: a persistent threat to developing nations in the 21st century. *Autoimmun Rev*. 2009 Dec;9(2):117–23. [PMID: 19386288]

Saxena A et al; Working Group on Pediatric Acute Rheumatic Fever and Cardiology Chapter of Indian Academy of Pediatrics. Consensus guidelines on pediatric acute rheumatic fever and rheumatic heart disease. *Indian Pediatr*. 2008 Jul;45(7):565–73. [PMID: 18695275]

Singhi AK et al. Acute rheumatic fever: subcutaneous nodules and carditis. *Circulation*. 2010 Feb 23;121(7):946–7. [PMID: 20177010]

DISEASES OF THE PERICARDIUM

ACUTE INFLAMMATORY PERICARDITIS

ESSENTIALS OF DIAGNOSIS

- ▶ Anterior pleuritic chest pain that is worse supine than upright.
- ▶ Pericardial rub.
- ▶ Erythrocyte sedimentation rate usually elevated.
- ▶ ECG reveals diffuse ST segment elevation with associated PR depression.

▶ General Considerations

Acute (< 2 weeks) inflammation of the pericardium may be infectious in origin or may be due to systemic diseases (autoimmune syndromes, uremia), neoplasm, radiation, drug toxicity, hemopericardium, postcardiac surgery, or contiguous inflammatory processes in the myocardium or lung. In many of these conditions, the pathologic process involves both the pericardium and the myocardium.

Viral infections (especially infections with coxsackieviruses and echoviruses but also influenza, Epstein–Barr, varicella, hepatitis, mumps, and HIV viruses) are the most common cause of acute pericarditis and probably are responsible for many cases classified as idiopathic. Males—usually under age 50 years—are most commonly affected. The differential diagnosis is primarily with myocardial infarction. **Tuberculous pericarditis** has become rare in developed countries but remains common in other areas. It results from direct lymphatic or hematogenous spread; clinical pulmonary involvement may be absent or minor,

although associated pleural effusions are common. **Bacterial pericarditis** has become rare and usually results from direct extension from pulmonary infections. Pneumococci can cause a primary pericardial infection. *Borrelia burgdorferi*, the organism responsible for Lyme disease, can also cause myopericarditis. **Uremic pericarditis** is a common complication of chronic kidney disease. The pathogenesis is uncertain; it occurs both with untreated uremia and in otherwise stable dialysis patients. Spread of adjacent lung cancer as well as invasion by breast cancer, renal cell carcinoma, Hodgkin disease, and lymphomas are the most common **neoplastic processes** involving the pericardium and have become the most frequent causes of pericardial tamponade in many countries. Pericarditis may occur 2–5 days after infarction due to an inflammatory reaction to transmural myocardial necrosis [**postmyocardial infarction or postcardiotomy pericarditis (Dressler syndrome)**]. **Radiation** can initiate a fibrinous and fibrotic process in the pericardium, presenting as subacute pericarditis or constriction. Radiation pericarditis usually follows treatments of more than 4000 cGy delivered to ports including more than 30% of the heart.

Other causes of pericarditis include connective tissue diseases, such as lupus erythematosus and rheumatoid arthritis, drug-induced pericarditis (minoxidil, penicillins, clozapine), and myxedema.

▶ Clinical Findings

A. Symptoms and Signs

The presentation and course of inflammatory pericarditis depend on its cause, but most syndromes have associated chest pain, which is usually pleuritic and postural (relieved by sitting). The pain is substernal but may radiate to the neck, shoulders, back, or epigastrium. Dyspnea may also be present and the patient is often febrile. A pericardial friction rub is characteristic, with or without evidence of fluid accumulation or constriction (see below). The presentation of **tuberculous pericarditis** tends to be subacute, but nonspecific symptoms (fever, night sweats, fatigue) may be present for days to months. Pericardial involvement develops in 1–8% of patients with pulmonary tuberculosis. Symptoms and signs of **bacterial pericarditis** are similar to those of other types of inflammatory pericarditides, but patients appear toxic and are often critically ill. **Uremic pericarditis** can present with or without symptoms; fever is absent. Often **neoplastic pericarditis** is painless, and the presenting symptoms relate to hemodynamic compromise or the primary disease. **Postmyocardial infarction or postcardiotomy pericarditis (Dressler syndrome)** usually presents as a recurrence of pain with pleural-pericardial features. A rub is often audible, and repolarization changes on the ECG may be confused with ischemia. Large effusions are uncommon, and spontaneous resolution usually occurs in a few days. Dressler syndrome occurs days to weeks to several months after myocardial infarction or open heart surgery, may be recurrent, and probably represents an autoimmune syndrome. Patients present with typical pain, fever, malaise, and leukocytosis. Rarely, other symptoms of an autoimmune disorder, such as joint pain and fever, may occur. Tamponade is rare with Dressler

syndrome after myocardial infarction but not when it occurs postoperatively. The clinical onset of **radiation pericarditis** is usually within the first year but may be delayed for many years; often a full decade may pass before constriction becomes evident.

B. Laboratory Findings and Diagnostic Studies

The diagnosis of **viral pericarditis** is usually clinical, and leukocytosis is often present. Rising viral titers in paired sera may be obtained for confirmation but are rarely done. Cardiac enzymes may be slightly elevated, reflecting an epicardial myocarditis component. The echocardiogram is often normal or reveals only a trivial amount of fluid during the acute inflammatory process. The diagnosis of **tuberculous pericarditis** can be inferred if acid-fast bacilli are found elsewhere. The tuberculous pericardial effusions are usually small or moderate but may be large when chronic. The yield of organisms by pericardiocentesis is low; pericardial biopsy has a higher yield but may also be negative, and pericardiectomy may be required. If **bacterial pericarditis** is suspected on clinical grounds, diagnostic pericardiocentesis may be of value. In **uremic patients** not on dialysis, the incidence of pericarditis correlates roughly with the level of blood urea nitrogen (BUN) and creatinine. The pericardium is characteristically “shaggy” in uremic pericarditis, and the effusion is hemorrhagic and exudative. The diagnosis of **neoplastic pericarditis** can occasionally be made by cytologic examination of the effusion or by pericardial biopsy, but it may be difficult to establish clinically if the patient has received mediastinal radiation within the previous year. Neoplastic pericardial effusions develop over a long period of time and may become quite huge (>2 L). The sedimentation rate is high in **postmyocardial infarction or postcardiotomy pericarditis**. Large pericardial effusions and accompanying pleural effusions are frequent. Myxedema pericardial effusions due to hypothyroidism usually are characterized by the presence of cholesterol crystals.

C. Other Studies

The ECG usually shows generalized ST and T wave changes and may manifest a characteristic progression beginning with diffuse ST elevation, followed by a return to baseline and then to T wave inversion. Atrial injury is often present and manifested by PR depression especially in the limb leads. The chest radiograph is frequently normal, but may show cardiac enlargement if pericardial fluid is present, as well as signs of related pulmonary disease. Mass lesions and enlarged lymph nodes may suggest a neoplastic process. MRI and CT scan can visualize neighboring tumor in neoplastic pericarditis. A screening chest CT or MRI is often recommended to ensure there are no extracardiac diseases contiguous to the pericardium.

► Treatment

Nonsteroidal anti-inflammatory drugs and aspirin remain the agents of first choice in treating uncomplicated acute pericarditis, although colchicine can be used concomitantly in severe cases. Colchicine should be the initial

therapy in all refractory cases and in recurrent pericarditis. Aspirin should be used instead of nonsteroidal anti-inflammatory drugs in postmyocardial infarction pericarditis (Dressler syndrome). Systemic corticosteroids can be used in patients with severe symptoms, in refractory cases, or in patients with immune-mediated etiologies, but such therapy may entail a higher risk of recurrence. In general, symptoms subside in several days to weeks. The major early complication is tamponade, which occurs in < 5% of patients. There may be recurrences in the first few weeks or months. Rarely, when colchicine therapy alone fails, recurrent pericarditis may require more significant immunosuppression, such as cyclophosphamide or methotrexate. If colchicine plus more significant immunosuppression fails, surgical pericardial stripping may be required in recurrent cases even without constrictive pericarditis.

Standard antituberculous drug therapy is usually successful for **tuberculous pericarditis** (see Chapter 9), but constrictive pericarditis can occur. **Uremic pericarditis** usually resolves with the institution of—or with more aggressive—dialysis. Tamponade is fairly common, and partial pericardiectomy (pericardial window) may be necessary. Whereas anti-inflammatory agents may relieve the pain and fever associated with uremic pericarditis, indomethacin and systemic corticosteroids do not affect its natural history. The prognosis with **neoplastic effusion** is dismal, with only a small minority surviving 1 year. If it is compromising the clinical comfort of the patient, the effusion is initially drained percutaneously. A pericardial window, either by a subxiphoid approach or via video-assisted thoracic surgery, allows for partial pericardiectomy. Instillation of chemotherapeutic agents or tetracycline may be used to reduce the recurrence rate. Symptomatic therapy is the initial approach to **radiation pericarditis**, but recurrent effusions and constriction often require surgery.

► When to Refer

Patients who do not respond initially to conservative management, who have recurrences, or who appear to be developing constrictive pericarditis should be referred to a cardiologist for further assessment.

Khandaker MH et al. Pericardial disease: diagnosis and management. *Mayo Clin Proc.* 2010 Jun;85(6):572–93. [PMID: 20511488]

Lotrionte M et al. International collaborative systematic review of controlled clinical trials on the pharmacologic treatment of acute pericarditis and its recurrences. *Am Heart J.* 2010 Oct;160(4):662–70. [PMID: 20934560]

Sparano DM et al. Pericarditis and pericardial effusion: management update. *Curr Treat Options Cardiovasc Med.* 2011 Dec;13(6):543–55. [PMID: 21989746]

PERICARDIAL EFFUSION & TAMPONADE

Pericardial effusion can develop during any of the pericarditis processes. The speed of accumulation determines the physiologic importance of the effusion. Because the pericardium stretches, large effusions (>1000 mL) that develop slowly may produce no hemodynamic effects.

Conversely, smaller effusions that appear rapidly can cause tamponade due to the curvilinear relationship between the volume of fluid and the intrapericardial pressure. Tamponade is characterized by elevated intrapericardial pressure (>15 mm Hg), which restricts venous return and ventricular filling. As a result, the stroke volume and arterial pulse pressure fall, and the heart rate and venous pressure rise. Shock and death may result.

► Clinical Findings

A. Symptoms and Signs

Pericardial effusions may be associated with pain if they occur as part of an acute inflammatory process or may be painless, as is often the case with neoplastic or uremic effusion. Dyspnea and cough are common, especially with tamponade. Other symptoms may result from the primary disease.

A pericardial friction rub may be present even with large effusions. In cardiac tamponade, tachycardia, tachypnea, a narrow pulse pressure, and a relatively preserved systolic pressure are characteristic. Pulsus paradoxus is defined as a > 10 mm Hg decline in systolic pressure during inspiration. Since the RV and LV share the same pericardium, when there is significant pericardial effusion, as the RV enlarges with inspiratory filling, septal motion toward the LV reduces LV filling and results in a drop in the stroke volume and BP with inspiration. Central venous pressure is elevated and since the intrapericardial, and thus intracardiac, pressures are high even at the initiation of diastole, there is no evident *y* descent in the RA, RV, or LV hemodynamic tracings. This differs from constriction where most of the initial filling of the RV and LV occurs during early diastole, and it is only in mid to late diastole that the ventricles can no longer fill. Edema or ascites are rarely present in tamponade; these signs favor a more chronic process.

B. Laboratory Findings

Laboratory tests tend to reflect the underlying processes (see causes of pericarditis above). The echocardiogram is diagnostic.

C. Diagnostic Studies

Chest radiograph can suggest chronic effusion by an enlarged cardiac silhouette with a globular configuration but may appear normal in acute situations. The ECG often reveals nonspecific T wave changes and low QRS voltage. Electrical alternans is present uncommonly but is pathognomonic due to the heart swinging within the large effusion. Echocardiography is the primary method for demonstrating pericardial effusion and is quite sensitive. If tamponade is present, the high intrapericardial pressure may collapse lower pressure cardiac structures, such as the RA and RV. In tamponade, the normal inspiratory reduction in LV filling is accentuated due to RV/LV interaction and there is a > 25% reduction in maximal mitral inflow velocities. RV collapse is particularly evident in diastole as the enlarging diastolic LV crowds out the RV within the fixed space provided by the ventricles and pericardium. The apparent RV diastolic

“collapse” is due to the thinner RV being unable to fill appropriately during diastole at the same time that the thicker and more powerful LV enters diastole. Cardiac CT and MRI also demonstrate pericardial fluid, pericardial thickening, and any associated contiguous lesions. Diagnostic pericardiocentesis or biopsy is often indicated for microbiologic and cytologic studies; a pericardial biopsy may be performed relatively simply through a small subxiphoid incision or by use of a video-assisted thoracoscopic surgical procedure. Unfortunately, the quality of the pericardial fluid itself rarely leads to a diagnosis, and any type of fluid (serous, serosanguinous, bloody, etc) can be seen in most diseases. Pericardial fluid analysis is most useful in excluding a bacterial cause.

► Treatment

Small effusions can be followed clinically by careful observations of the JVP and by testing for a change in the paradoxical pulse. Serial echocardiograms are indicated if no intervention is immediately contemplated. When tamponade is present, urgent pericardiocentesis is required. Because the pressure-volume relationship in the pericardial fluid is curvilinear and upsloping, removal of a small amount of fluid often produces a dramatic fall in the intrapericardial pressure and immediate hemodynamic benefit; but complete drainage with a catheter is preferable. Continued or repeat drainage may be indicated, especially in malignant effusions. Pericardial windows via video-assisted thoracoscopy have been particularly effective in preventing recurrences. Effusions related to recurrent inflammatory pericarditis can be treated as noted above (see Acute Inflammatory Pericarditis).

Additional therapy is determined by the nature of the primary process. Recurrent effusion in neoplastic disease and uremia, in particular, may require partial pericardiectomy.

► When to Refer

- Any unexplained pericardial effusion should be referred to a cardiologist for a complete evaluation and treatment.
- Trivial pericardial effusions are common, especially in CHF, and need not be referred unless symptoms of pericarditis are evident.
- Hypotension or a paradoxical pulse suggesting the pericardial effusion is hemodynamically compromising the patient should prompt an immediate referral.
- Echocardiographic signs of tamponade should always trigger referral.

Imazio M et al. Medical therapy of pericardial diseases: part II: noninfectious pericarditis, pericardial effusions and constrictive pericarditis. *J Cardiovasc Med (Hagerstown)*. 2010 Nov;11(11):785–94. [PMID: 20925146]

Meurin P et al; French Society of Cardiology. Nonsteroidal anti-inflammatory drug treatment for postoperative pericardial effusion: a multicenter randomized, double-blind trial. *Ann Intern Med*. 2010 Feb 2;152(3):137–43. [PMID: 20124229]

O'Connor CJ et al. The intraoperative management of patients with pericardial tamponade. *Anesthesiol Clin*. 2010 Mar;28(1):87–96. [PMID: 20400042]

CONSTRUCTIVE PERICARDITIS



ESSENTIALS OF DIAGNOSIS

- ▶ Evidence of right heart failure with an elevated JVP, edema, hepatomegaly, and ascites.
- ▶ No fall or an elevation of the JVP with inspiration (Kussmaul sign).
- ▶ Echocardiographic evidence for septal bounce and reduced mitral inflow velocities with inspiration.
- ▶ Catheterization evidence for RV-LV interaction, a “square root” sign, equalization of diastolic pressures, normal PA pressure, and discordance of RV/LV systolic pressures with inspiration (RV systolic rises, LV systolic falls).
- ▶ Area of RV/LV pressure tracing ratio that decreases with inspiration.

▶ General Considerations

Inflammation can lead to a thickened, fibrotic, adherent pericardium that restricts diastolic filling and produces chronically elevated venous pressures. In the past, tuberculosis was the most common cause of constrictive pericarditis, but the process now more often occurs after radiation therapy, cardiac surgery, or viral pericarditis; histoplasmosis is another uncommon cause, occurring mainly in individuals who live in the Ohio River Valley.

At times, both pericardial tamponade and constrictive pericarditis may coexist, a condition referred to as effusive-constrictive pericarditis. The only definitive way to diagnose this condition is to reveal the underlying constrictive physiology once the pericardial fluid is drained.

▶ Clinical Findings

A. Symptoms and Signs

The principal symptoms are slowly progressive dyspnea, fatigue, and weakness. Chronic edema, hepatic congestion, and ascites are usually present. Ascites often seems out of proportion to the degree of peripheral edema. The examination reveals these signs and a characteristically elevated jugular venous pressure with a rapid γ descent. This can be detected at bedside by careful observation of the jugular pulse and noting an apparent increased pulse wave at the end of systole (due to an apparent accentuation of the ν wave by the rapid γ descent). Kussmaul sign—a failure of the JVP to fall with inspiration—is also a frequent finding. The apex may actually retract with systole and a pericardial “knock” may be heard in early diastole. Pulsus paradoxus is unusual. Atrial fibrillation is common.

B. Diagnostic Studies

At times constrictive pericarditis is extremely difficult to differentiate from restrictive cardiomyopathy. When

unclear, the use of both noninvasive testing and cardiac catheterization is required to sort out the difference.

1. Radiographic findings—The chest radiograph may show normal heart size or cardiomegaly. Pericardial calcification is best seen on the lateral view and is uncommon. It rarely involves the LV apex, and finding of calcification at the LV apex is more consistent with LV aneurysm.

2. Echocardiography—Echocardiography rarely demonstrates a thickened pericardium. A septal “bounce” reflecting the rapid early filling is common, though. RV/LV interaction may be demonstrated by a reduction in the mitral inflow Doppler pattern of > 25%, much as in tamponade.

3. Cardiac CT and MRI—These imaging tests are only occasionally helpful. Pericardial thickening of > 4 mm must be present to establish the diagnosis, and no pericardial thickening is demonstrable in 20–25% of patients with constrictive pericarditis. Some MRI techniques demonstrate the septal bounce and can provide evidence for ventricular interaction.

4. Cardiac catheterization—This procedure is often confirmatory or can be diagnostic in difficult cases. As a generality, the pulmonary pressure is low in constriction (as opposed to restrictive cardiomyopathy). In constrictive pericarditis, because of the need to demonstrate RV/LV interaction, cardiac catheterization should include simultaneous measurement of both the LV and RV pressure tracings with inspiration and expiration. Hemodynamically, patients with constriction have equalization of end-diastolic pressures throughout their cardiac chambers, there is rapid early filling then an abrupt increase in diastolic pressure (“square-root” sign), the RV end-diastolic pressure is more than one-third the systolic pressure, simultaneous measurements of RV and LV systolic pressure reveal a discordance with inspiration (the RV rises as the LV falls), and there is usually a Kussmaul sign (failure of the RA pressure to fall with inspiration). The area of the RV pressure tracing may also be less in expiration and greater during inspiration, reflecting the variability in filling of the RV with respiration. The ratio of the RV tracing area to the LV tracing area should fall with inspiration if constriction is present; this is due to the increased RV filling and higher RV systolic pressure with inspiration while the LV systolic pressure falls. In restrictive cardiomyopathy, the LV diastolic pressure is usually greater than the RV diastolic pressure by 5 mm Hg, there is pulmonary hypertension, and simultaneous measurements of the RV and LV systolic pressure reveal a concordant drop in the peak systolic ventricular pressures during inspiration with no change in the RV/LV tracing area ratio with inspiration.

▶ Treatment

Initial treatment consists of diuresis. As in other disorders of right heart failure, the diuresis should be aggressive, using loop diuretics (torsemide if bowel edema is suspected), thiazides, and aldosterone antagonists (especially if ascites is present). At times, aquaphoresis may be of value.

Surgical pericardiectomy should be done when diuretics are unable to control symptoms. Pericardiectomy removes only the pericardium between the phrenic nerve pathways, however, and most patients still require diuretics after the procedure, though symptoms are usually dramatically improved. Morbidity and mortality after pericardiectomy are high (up to 15%) and are greatest in those with the most disability prior to the procedure.

► When to Refer

If the diagnosis of constrictive pericarditis is unclear or the symptoms resist medical therapy, then referral to a cardiologist is warranted to both establish the diagnosis and recommend therapy.

Ariyarahaj V et al. The utility of cardiovascular magnetic resonance in constrictive pericardial disease. *Cardiol Rev*. 2009 Mar-Apr;17(2):77–82. [PMID: 19367149]

Bansal R et al. Pericardial constriction after cardiac transplantation. *J Heart Lung Transplant*. 2010 Mar;29(3):371–7. [PMID: 19804990]

Dal-Bianco JP et al. Role of echocardiography in the diagnosis of constrictive pericarditis. *J Am Soc Echocardiogr*. 2009 Jan;22(1):24–33. [PMID: 19130999]

Talreja DR et al. Constrictive pericarditis in the modern era: novel criteria for diagnosis in the cardiac catheterization laboratory. *J Am Coll Cardiol*. 2008 Jan 22;51(3):315–9. [PMID: 18206742]

PULMONARY HYPERTENSION & PULMONARY HEART DISEASE

PULMONARY HYPERTENSION



ESSENTIALS OF DIAGNOSIS

- Pulmonary hypertension is defined as a mean PA pressure ≥ 25 mm Hg with normal pulmonary capillary wedge pressure.
- Dyspnea, and often cyanosis, with no evidence of left heart disease.
- Enlarged pulmonary arteries on chest radiograph.
- Elevated JVP and RV heave.
- Echocardiography is often diagnostic.
- Multiple potential etiologies must be considered. Idiopathic pulmonary hypertension most frequently occurs in younger women.

► General Considerations

The normal pulmonary bed offers about one-tenth as much resistance to blood flow as the systemic arterial system. Experts now recommend that a diagnosis of idiopathic pulmonary hypertension should be firmly based on a mean PA pressure of ≥ 25 mm Hg in association with a pulmonary capillary wedge pressure of < 16 mm Hg at rest.

Table 10–13. Clinical classification of pulmonary hypertension.

Pulmonary arterial hypertension

Idiopathic pulmonary arterial hypertension

Heritable gene mutations

BMPR2 (bone morphogenic protein receptor type 2)

ALK1 (activin A receptor type II-like kinase-1), *endoglin* (with or without hereditary hemorrhagic telangiectasia)

Unknown

Drug and toxin-induced

Associated with

Connective tissue diseases

HIV infection

Portal hypertension

Congenital heart disease

Schistosomiasis

Chronic hemolytic anemia

Persistent pulmonary hypertension of the newborn

Pulmonary veno-occlusive disease and/or pulmonary capillary hemangiomatosis

Pulmonary hypertension due to left heart disease

Systolic dysfunction

Diastolic dysfunction

Pulmonary hypertension due to lung disease and/or hypoxia

Chronic obstructive pulmonary disease

Interstitial lung disease

Other pulmonary disease with mixed restrictive and obstructive pattern

Chronic thromboembolic pulmonary hypertension

Pulmonary hypertension with unclear multifactorial mechanisms

Hematologic disorders: myeloproliferative disorders, splenectomy

Systemic disorders: sarcoidosis, pulmonary Langerhans cell histiocytosis; lymphangioleiomyomatosis, neurofibromatosis, vasculitis

Metabolic disorders: glycogen storage disease, Gaucher disease, thyroid disorders

Others: tumoral obstruction, fibrosing mediastinitis, chronic renal failure on dialysis

(Modified, with permission, from Simonneau G et al. Updated clinical classification of pulmonary hypertension. *J Am Coll Cardiol*. 2009;54:543–54.)

The clinical classification of pulmonary hypertension was revised at the Fourth World Symposium on Pulmonary Hypertension. The new classification is outlined in Table 10–13.

Group 1 includes pulmonary arterial hypertension related to an underlying pulmonary vasculopathy. It includes the former “primary” pulmonary hypertension under the term “**idiopathic pulmonary hypertension**” and is defined as pulmonary hypertension and elevated pulmonary vascular resistance (PVR) in the absence of other disease of the lungs or heart. Its cause is unknown. Clear genetic patterns have been identified that result in a derangement in one or more biologic pathways, and these result in so-called “**heritable pulmonary hypertension**.” A mutation in the *BMPR2* gene (which encodes bone morphogenic receptor protein 2), a cell surface receptor for transforming growth factor- β (TGF- β), is the most common genetic abnormality known. Rarely, two other surface receptor genes have been identified including activin-like

kinase-type (*ALK-1*) and endoglin (*ENG*). About 20% of idiopathic pulmonary arterial hypertension patients will have *BMPR2* mutation. Pathologically, it is characterized by diffuse narrowing of the pulmonary arterioles. **Drug and toxic pulmonary hypertension** has been described associated with the use of anorexigenic agents that increase serotonin release and block its uptake. These include aminorex fumarate, fenfluramine, and dexfenfluramine. In some cases, there is epidemiologic linkage to ingestion of rapeseed oil or L-tryptophan and use of illicit drugs, such as amphetamines. **Pulmonary hypertension associated with connective tissue disease** includes cases associated with scleroderma—up to 8–12% of patients with scleroderma may be affected. Pulmonary hypertension has also been associated with **HIV infection, portal hypertension, congenital heart disease (Eisenmenger syndrome), schistosomiasis, and chronic hemolytic anemia** (eg, sickle cell anemia). In rare instances, obstruction of the pulmonary venous circulation may occur (**pulmonary veno-occlusive disease**).

Group 2 includes all cases related to **left heart disease**. **Group 3** includes cases due to **parenchymal lung disease, impaired control of breathing, or living at high altitude**. This group encompasses those with idiopathic pulmonary fibrosis and COPD. **Group 4** represents patients with **chronic thromboemboli**. **Group 5** includes multifactorial cases.

► Clinical Findings

A. Symptoms and Signs

The clinical picture is similar to that of pulmonary hypertension from other causes. Dyspnea, chest pain, fatigue, and lightheadedness are early symptoms; later symptoms include syncope, abdominal distention, ascites, and peripheral edema. Chronic lung disease, especially sleep apnea, can be overlooked as a cause for pulmonary hypertension. Patients with idiopathic pulmonary hypertension are characteristically young women who have evidence of right heart failure that is usually progressive, leading to death in 2–8 years without therapy. This is a decidedly different prognosis than patients with Eisenmenger physiology due to a left-to-right shunt; 40% of patients with Eisenmenger physiology are alive 25 years after the diagnosis has been made. Patients have manifestations of low cardiac output, with weakness and fatigue, as well as edema and ascites as right heart failure advances. Peripheral cyanosis is present, and syncope on effort may occur.


B. Diagnostic Studies

The laboratory evaluation of idiopathic pulmonary hypertension must exclude a secondary cause. A hypercoagulable state should be sought by measuring proteins C and S levels, the presence of a lupus anticoagulant, the level of factor V Leiden, and D-dimer. Chronic pulmonary emboli must be excluded (usually by ventilation-perfusion lung scan or contrast spiral CT); the ventilation-perfusion scan is the more sensitive test. The chest radiograph helps exclude a primary pulmonary etiology—evidence for patchy pulmonary edema may raise the suspicion of pulmonary veno-occlusive

disease. A sleep study may be warranted if sleep apnea is suspected. The ECG is generally consistent with RVH and RA enlargement. Echocardiography with Doppler helps exclude an intracardiac shunt and usually demonstrates an enlarged RV and RA—at times they may be huge and hypocontractile. Severe pulmonic or tricuspid regurgitation may be present. Septal flattening is consistent with pulmonary hypertension. Doppler interrogation of the tricuspid regurgitation jet helps provide an estimate of RV systolic pressure. Pulmonary function tests help exclude other disorders, though primary pulmonary hypertension may present with a reduced carbon monoxide diffusing capacity of the lung (DL_{CO}) and severe desaturation (particularly if a PFO has been stretched open and a right-to-left shunt is present). A declining DL_{CO} in a scleroderma patient may precede the development of pulmonary hypertension. Chest CT demonstrates enlarged pulmonary arteries and excludes other causes (such as emphysema or interstitial lung disease). Pulmonary angiography (or MR angiography or CT angiography) reveals loss of the smaller acinar pulmonary vessels and tapering of the larger ones. Catheterization allows measurement of pulmonary pressures and testing for vasoreactivity using a variety of agents, including 100% oxygen, adenosine, epoprostenol, and nitric oxide. Nitric oxide is preferred due to its ease of use and short half-life. A positive response is defined as one that decreases the pulmonary mean pressure by 10 mm Hg with the final mean pressure < 40 mm Hg.

► Treatment & Prognosis

A variety of therapeutic options is now available and approved for use (see Figure 10–3). General measures include the use of warfarin in all patients with idiopathic pulmonary hypertension who have no contraindication to its use, diuretics in patients with right-sided heart failure, oxygen (especially during sleep) with a goal of maintaining an oxygen saturation of > 90%, and occasionally, digoxin. Patients are advised against heavy physical exertion. A sodium restricted diet (< 2400 mg/d) is advised. The therapeutic algorithm is based on the response to an intravenous vasodilator trial and the clinical risk assessment. Patients with a positive response to the intravenous vasodilator should first be tried on oral calcium channel blockers or sildenafil, or both. Patients who do not have a positive response are then divided into those of lower risk (no RV failure, > 400 meters on a 6-minute walk test, peak VO_2 max > 10.4 mL/kg/min, minimal RV dysfunction, normal right heart hemodynamics and minimally elevated BNP) and those of highest risk (RV failure, rapidly progressive symptoms, < 300 meters on a 6-minute walk, peak VO_2 max < 10.4 mL/kg/min, abnormal echocardiographic findings (pericardial effusion, severe RV enlargement and dysfunction, RA pressure > 20 mm Hg, cardiac index < 2.0 L/min/m², or significantly elevated BNP). A negative response to vasodilators in a low-risk patient suggests the next line of therapy be endothelin receptor blockers or phosphodiesterase-5 inhibitors as initial oral treatment. If the patient does not respond, then the use of epoprostenol (intravenously) or treprostinil (intravenously), iloprost (inhaled),



▲ **Figure 10-3.** Pulmonary hypertension treatment algorithm. ERB, endothelin receptor blockers; PDE-5, phosphodiesterase-5. (Modified, with permission, from McLaughlin VV et al; American College of Cardiology Foundation Task Force on Expert Consensus Documents; American Heart Association; American College of Chest Physicians; American Thoracic Society, Inc; Pulmonary Hypertension Association. ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. *J Am Coll Cardiol.* 2009 Apr 28;53(17):1573–619.)

or treprostinil (subcutaneously) may be tried. For those high-risk patients who do not respond, then therapy consists of use of an intravenous prostacyclin (epoprostenol or treprostinil). Failure of all of these therapies suggests that lung transplantation should be considered. Palliation of patients who are not too cyanotic can be achieved by atrial septostomy to increase cardiac output.

Most patients die of RV failure; a severely dilated RV with poor contractile function (cor pulmonale) has been shown to predict early mortality. Pregnancy is potentially life-threatening and must be avoided or terminated early to save the mother's life if the pulmonary hypertension is severe. Survival in several recent registries has improved with idiopathic pulmonary hypertension, though it still remains a dread disease. One, 2- and 3-year survival rates of 85.7%, 69.5%, and 54.9% have been reported. Men fare worse than women, and etiology, functional class, exercise tolerance, and RV hemodynamics all adversely affect outcome.

► When to Refer

All patients with suspected pulmonary hypertension should be referred to either a cardiologist or pulmonologist who specializes in the evaluation and treatment of patients with unexplained pulmonary hypertension (RV systolic > 35 mm Hg as measured by an echocardiogram).

Benza RL et al. Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-term Pulmonary Arterial Hypertension Disease Management (REVEAL). *Circulation.* 2010 Jul 13;122(2):164–72. [PMID: 20585012]

Hoepfer MM et al. Diagnosis, assessment and treatment of non-pulmonary arterial pulmonary hypertension. *J Am Coll Cardiol.* 2009 Jun 30;54(1 Suppl):S85–96. [PMID: 19555862]
 McLaughlin VV et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. *J Am Coll Cardiol.* 2009 Apr 28;53(17):1573–619. [PMID: 19389575]
 Simonneau G et al. Updated clinical classification of pulmonary hypertension. *J Am Coll Cardiol.* 2009;54:S43–S54. [PMID: 19555858]

PULMONARY HEART DISEASE (Cor Pulmonale)

ESSENTIALS OF DIAGNOSIS

- ▶ Symptoms and signs of chronic bronchitis and pulmonary emphysema.
- ▶ Elevated jugular venous pressure, parasternal lift, edema, hepatomegaly, ascites.
- ▶ ECG shows tall, peaked P waves (P pulmonale), right axis deviation, and RVH.
- ▶ Chest radiograph: Enlarged RV and PA.
- ▶ Echocardiogram or radionuclide angiography excludes primary LV dysfunction.

▶ General Considerations

The term “cor pulmonale” denotes RV systolic and diastolic failure resulting from pulmonary disease and the attendant hypoxia or from pulmonary vascular disease (pulmonary hypertension). Its clinical features depend on both the primary underlying disease and its effects on the heart.

Cor pulmonale is most commonly caused by pulmonary hypertension from any cause (see above), COPD or idiopathic pulmonary fibrosis. Less frequent causes include pneumoconiosis and kyphoscoliosis.

▶ Clinical Findings

A. Symptoms and Signs

The predominant symptoms of compensated cor pulmonale are related to the pulmonary disorder and include chronic productive cough, exertional dyspnea, wheezing respirations, easy fatigability, and weakness. When the pulmonary disease causes RV failure, these symptoms may be intensified. Dependent edema and right upper quadrant pain may also appear. The signs of cor pulmonale include cyanosis, clubbing, distended neck veins, RV heave or gallop (or both), prominent lower sternal or epigastric pulsations, an enlarged and tender liver, dependent edema, and ascites. Severe lung disease can be a cause of low cardiac output by reducing LV filling and subsequently LV preload and stroke volume.

B. Laboratory Findings

Polycythemia is often present in cor pulmonale secondary to chronic hypoxemia. The arterial oxygen saturation is often below 85% and frequently falls with exertion; PCO_2 may or may not be elevated.

C. ECG and Chest Radiography

The ECG may show right axis deviation and peaked P waves. Deep S waves are present in lead V_6 . Right axis deviation and low voltage may be noted in patients with pulmonary emphysema. Frank RVH is uncommon except in pulmonary hypertension. The ECG often mimics myocardial infarction; Q waves may be present in leads II, III, and aVF because of the vertically placed heart, but they are rarely deep or wide, as in inferior myocardial infarction. Supraventricular arrhythmias are frequent and nonspecific.

The chest radiograph discloses the presence or absence of parenchymal disease and a prominent or enlarged RV and PA.

D. Diagnostic Studies

Pulmonary function tests usually confirm the underlying lung disease. The echocardiogram should show normal LV size and function but RV and RA dilation and RV dysfunction. Perfusion lung scans are rarely of value, but, if negative, they help exclude chronic pulmonary emboli. Multislice CT has replaced pulmonary angiography as the most specific method of diagnosis for the pulmonary emboli. The serum BNP level may be elevated from RV dysfunction.

▶ Differential Diagnosis

In its early stages, cor pulmonale can be diagnosed on the basis of the clinical examination and radiologic, echocardiographic, or ECG evidence. Catheterization of the right heart will establish a definitive diagnosis but is more often performed to exclude left-sided heart failure or pulmonary venous disease, which can be an unrecognized cause of right-sided failure in some patients. Differential diagnostic considerations relate primarily to the specific pulmonary disease that has produced RV failure (see above).

▶ Treatment

The details of the treatment of chronic pulmonary disease (chronic respiratory failure) are discussed in Chapter 9. Otherwise, therapy is directed at the pulmonary process responsible for right heart failure. Oxygen, salt and fluid restriction, and diuretics are mainstays, with combination diuretic therapy (loop diuretics, thiazides and spironolactone) often useful, as described above for other causes of right heart failure.

▶ Prognosis

Compensated cor pulmonale has the same prognosis as the underlying pulmonary disease. Once signs of heart failure appear, the average life expectancy is 2–5 years, but survival is significantly longer when uncomplicated emphysema is the cause.

▶ When to Refer

Patients with unexplained or difficult to manage right heart failure should be referred to a cardiologist or a pulmonologist in an effort to uncover correctable causes and to address therapeutic options.

Barr RG et al. Percent emphysema, airflow obstruction and impaired left ventricular filling. *N Engl J Med.* 2010 Jan 21; 362(3):217–27. [PMID: 20089972]

Han MK et al. Pulmonary diseases and the heart. *Circulation.* 2007 Dec 18;116(25):2992–3005. [PMID: 18086941]

Hoeper MM et al. Diagnosis, assessment and treatment of non-pulmonary arterial pulmonary hypertension. *J Am Coll Cardiol.* 2009 Jun 30;54(1 Suppl):S85–96. [PMID: 19555862]

NEOPLASTIC DISEASES OF THE HEART

Primary cardiac tumors are rare and constitute only a small fraction of all tumors that involve the heart or pericardium. The most common primary tumor is atrial myxoma; it comprises about 50% of all tumors in adult case series. It is generally attached to the atrial septum and is more likely to affect the LA than the RA. Familial myxomas occur as part of the **Carney complex**—that consists of myxomas, pigmented skin lesions, and endocrine neoplasia. Patients with myxoma can present with

the characteristics of a systemic illness, with obstruction of blood flow through the heart, or with signs of peripheral embolization. The characteristics include fever, malaise, weight loss, leukocytosis, elevated sedimentation rate, and emboli (peripheral or pulmonary, depending on the location of the tumor). This is often confused with infective endocarditis, lymphoma, other cancers, or autoimmune diseases. In other cases, the tumor may grow to considerable size and produce symptoms by obstructing mitral inflow. Episodic pulmonary edema (classically occurring when an upright posture is assumed) and signs of low output may result. Physical examination may reveal a diastolic sound related to motion of the tumor ("tumor plop") or a diastolic murmur similar to that of mitral stenosis. Right-sided myxomas may cause symptoms of right-sided failure.

The diagnosis is established by echocardiography or by pathologic study of embolic material. Cardiac MRI is useful as an adjunct only. Contrast angiography is frequently not necessary. Surgical excision is usually curative, though recurrences do occur and serial echocardiographic follow-up, on at least a yearly basis, is recommended.

The second most common primary cardiac tumors are valvular papillary fibroelastomas and atrial septal lipomas. These tend to be benign and usually require no therapy, although large ones may embolize or cause valvular dysfunction. Other primary cardiac tumors include rhabdomyomas (that often appear multiple in both the RV and LV), fibrous histiocytomas, hemangiomas, and a variety of unusual sarcomas. The diagnosis may be supported by an abnormal cardiac contour on radiograph. Echocardiography is usually helpful but may miss tumors infiltrating the ventricular wall. Cardiac MRI is emerging as the diagnostic procedure of choice.

Metastases from malignant tumors can also affect the heart. Most often this occurs in malignant melanoma, but other tumors involving the heart include bronchogenic carcinoma, carcinoma of the breast, the lymphomas, renal cell carcinoma, and, in patients with AIDS, Kaposi sarcoma. These are often clinically silent but may lead to pericardial tamponade, arrhythmias and conduction disturbances, heart failure, and peripheral emboli. The diagnosis is often made by echocardiography, but cardiac MRI and CT scanning can often better delineate the extent of involvement. ECG may reveal regional Q waves. The prognosis is dismal for secondary cardiac tumors; effective treatment is not available. On rare occasions, surgical resection or chemotherapy is warranted. Primary pericardial tumors, such as mesotheliomas related to asbestos exposure, may also occur.

Many primary tumors may be resectable. Atrial myxomas should be removed surgically due to the high incidence of embolization from these friable tumors. Papillary fibroelastomas are usually benign but may embolize and large ones should be considered for surgical excision. Large pericardial effusions from metastatic tumors may be drained for comfort, but the fluid recurs. Rhabdomyomas may be surgically cured if the tumor is accessible and can be removed while still leaving enough functioning myocardium intact.

▶ When to Refer

All patients with suspected cardiac tumors should be referred to a cardiologist or cardiac surgeon for evaluation and possible therapy.

Castillo JG et al. Characterization and management of cardiac tumors. *Semin Cardiothorac Vasc Anesth*. 2010 Mar;14(1):6–20. [PMID: 20472615]

Michael RJ. Cardiac tumor issue overview. *Methodist DeBakey Cardiovasc J*. 2010 Jul–Sep;6(3):2–3. [PMID: 20834204]

O'Donnell DH et al. Cardiac tumors: optimal cardiac MR sequences and spectrum of imaging appearances. *Am J Roentgen*. 2009 Aug;193(2):377–87. [PMID: 19620434]

▼ CARDIAC INVOLVEMENT IN MISCELLANEOUS SYSTEMIC DISEASES

The heart may be involved in a number of systemic syndromes. Many of these have been mentioned briefly in other sections of this chapter, particularly those that can result in pulmonary hypertension. The pericardium, myocardium, heart valves, and coronary arteries may be involved either singly or in various combinations. In most cases the cardiac manifestations are not the dominant feature, but in some it is the primary cause of symptoms and may be fatal.

The most common type of myocardial involvement is an infiltrative cardiomyopathy, such as systemic amyloidosis, sarcoidosis, hemochromatosis, Fabry or glycogen storage disease. These result in a restrictive cardiomyopathy. Cardiac calcinosis can occur in hyperparathyroidism (usually the secondary form) and in primary oxalosis. A number of muscular dystrophies can cause a cardiomyopathic picture (particularly Duchenne, less frequently myotonic dystrophy, and several rarer forms). Involvement of the heart in Duchenne dystrophy can result in a focal cardiomyopathy of the posterior wall; the classic ECG has prominent anterior precordial forces. In addition to LV dysfunction and heart failure, all of these conditions frequently cause conduction abnormalities, which may be the presenting or only feature. The myocardium may also be involved in inflammatory and autoimmune diseases. It is commonly affected in polymyositis and dermatomyositis, but usually this is subclinical. Systemic lupus erythematosus, scleroderma, and mixed connective tissue disease may cause myocarditis, but these more commonly involve the pericardium, coronary arteries, or valves. Several endocrinopathies, including acromegaly, thyrotoxicosis, myxedema, and pheochromocytoma, can produce dilated cardiomyopathies that resolve when the underlying disease is appropriately treated. Similarly, the heart may be involved transiently in Guillain-Barré syndrome.

Pericardial involvement is particularly common in many of the connective tissue diseases. Systemic lupus erythematosus may present with pericarditis, and pericardial involvement is not uncommon (but is less frequently symptomatic) in active rheumatoid arthritis, systemic sclerosis, and mixed connective tissue disease. Endocardial involvement takes

the form of patchy fibrous—predominantly on the right side—or inflammatory or sclerotic changes of the heart valves. At times, thrombosis and marantic (Libman-Sacks) endocarditis may occur. Patients with antiphospholipid syndrome may present with coronary occlusion or stroke at a young age. Carcinoid heart disease results from the layering of plaque-like material over the tricuspid valve, RV endocardium, and pulmonic valve and presents with right heart failure due to tricuspid and pulmonic regurgitation. Left heart structures may be involved with carcinoid if there is an associated PFO or ASD. The hypereosinophilic syndromes involve the endocardium, leading to restrictive cardiomyopathy. A variety of arthritic syndromes are associated with aortic valvulitis or aortitis with resulting aortic regurgitation. These include ankylosing spondylitis, rheumatoid arthritis, and reactive arthritis (formerly called Reiter syndrome). Disorders of collagen (Marfan syndrome is the most frequent, followed by Ehlers-Danlos syndrome, then the Loeys-Dietz syndrome) often affect the ascending aorta, with resulting aneurysmal dilation and aortic regurgitation and susceptibility to aortic dissection. Mitral valve prolapse is also a common finding in these disorders.

Almost any vasculitic syndrome can involve the coronary arteries, leading to myocardial infarction. This is most common with polyarteritis nodosa and systemic lupus erythematosus. Two vasculitic syndromes have a particular predilection for the coronary arteries—Kawasaki disease and Takayasu disease. Kawasaki disease can result in coronary aneurysms, occasionally of huge size. Takayasu disease affects the great vessels more often than the coronaries and smooth, tapering lesions are usually seen, particularly at the vessel ostia. In these, myocardial infarction may be the presenting symptom.

Therapy is usually aimed at the underlying disease process. Anti-inflammatory agents have traditionally been used, but there is new interest in the use of emerging biological agents for some disease states. Some enzyme replacement therapies (ie, α -galactosidase for Fabry disease) are available and may be effective. Replacement of hormone deficiency or blocking hormonal excess can be effective. Surgical intervention is indicated when there is an anatomic lesion that meets guidelines for repair.

► When to Refer

The patient should be referred to a cardiologist or relevant specialist (eg, rheumatologist) (or both) whenever there is more than minor involvement of the cardiac structures. Valvular and great vessel or coronary involvement should prompt a thorough cardiovascular evaluation.

Chung SA et al. Advances in the use of biological agents for the treatment of systemic vasculitis. *Current Opin Rheumatol*. 2009 Jan;21(1):3–9. [PMID: 19077713]

Finsterer J et al. Cardiac findings in congenital muscular dystrophies. *Pediatrics*. 2010 Sep;126(3):538–45. [PMID: 20679303]

Hidron A et al. Cardiac involvement with parasitic infections. *Clin Microbiol Rev*. 2010 Apr;23(2):324–49. [PMID: 20375355]

Meune C et al. Heart involvement in systemic sclerosis: evolving concept and diagnostic methodologies. *Arch Cardiovasc Dis*. 2010 Jan;103(1):46–52. [PMID: 20142120]

Mukerji S et al. Cardiovascular complications of the Guillain-Barré syndrome. *Am J Cardiol*. 2009 Nov 15;104(10):1452–5. [PMID: 19892067]

Patel MR et al. Detection of myocardial damage in patients with sarcoidosis. *Circulation*. 2009 Nov 17;120(20):1969–77. [PMID: 19884472]

Turiel M et al. The heart in rheumatoid arthritis. *Autoimmun Rev*. 2010 Apr;9(6):414–8. [PMID: 19913641]

TRAUMATIC HEART DISEASE

Penetrating wounds to the heart are usually lethal unless surgically repaired. Stab wounds to the RV occasionally lead to hemopericardium without progressing to tamponade.

Blunt trauma is a more frequent cause of cardiac injuries, particularly outside of the emergency department setting. This type of injury is quite frequent in motor vehicle accidents and may occur with any form of chest trauma, including CPR efforts. The most common injuries are myocardial contusions or hematomas. Other forms of nonischemic cardiac injury include metabolic injury due to burns, electrical current, or sepsis. These may be asymptomatic (particularly in the setting of more severe injuries) or may present with chest pain of a nonspecific nature or, not uncommonly, with a pericardial component. Elevations of cardiac enzymes are frequent but the levels do not correlate with prognosis. Echocardiography may reveal an akinetic segment or pericardial effusion. Pericardiocentesis is warranted if tamponade is evident. Heart failure is uncommon if there are no associated cardiac or pericardial injuries, and conservative management is usually sufficient.

Severe trauma may also cause myocardial or valvular rupture. Cardiac rupture may involve any chamber, but survival is most likely if injury is to one of the atria or the RV. Hemopericardium or pericardial tamponade is the usual clinical presentation, and surgery is almost always necessary. Mitral and aortic valve rupture may occur during severe blunt trauma—the former presumably if the impact occurs during systole and the latter if during diastole. Patients reach the hospital in shock or severe heart failure. Immediate surgical repair is essential. The same types of injuries may result in transection of the aorta, either at the level of the arch or distal to the takeoff of the left subclavian artery. Transthoracic echocardiography and TEE are the most helpful and immediately available diagnostic techniques.

Blunt trauma may also result in damage to the coronary arteries. Acute or subacute coronary thrombosis is the most common presentation. The clinical syndrome is one of acute myocardial infarction with attendant ECG, enzymatic, and contractile abnormalities. Emergent revascularization is sometimes feasible, either by the percutaneous route or by coronary artery bypass surgery. LV aneurysms are common outcomes of traumatic coronary occlusions, likely due to sudden occlusion with no collateral vascular support. Coronary artery dissection or rupture may also occur in the setting of blunt cardiac trauma.

As expected, patients with severe preexisting conditions fare the least well after cardiac trauma. Data from ReCONNECT, a trauma consortium, reveals that mortality is linked to volume of cases seen at various centers, preexisting

coronary disease or CHF, intubation, age, and a severity scoring index.

Embrey R. Cardiac trauma. *Thorac Surg Clin*. 2007 Feb;17(1):87–93. [PMID: 17650701]

Harrington DL et al; Research Consortium of New England Centers for Trauma (ReCONNECT). Factors associated with survival following blunt chest trauma in older patients: results from a large regional trauma cooperative. *Arch Surg*. 2010 May;145(5):432–7. [PMID: 20479340]

Navid F et al. Great vessel and cardiac trauma: diagnostic and management strategies. *Semin Thorac Cardiovasc Surg*. 2008 Spring;20(1):31–8. [PMID: 18420124]

Seamon MJ et al. Emergency department thoracotomy for penetrating injuries of the heart and great vessels: an appraisal of 283 consecutive cases from two urban trauma centers. *J Trauma*. 2009 Dec;67(6):1250–8. [PMID: 20009674]

RISK OF SURGERY IN THE CARDIAC PATIENT

There are guidelines to help the clinician and patient better define the risk of both cardiac and noncardiac surgery in heart patients. The easiest to use algorithms for cardiac surgery can be found on either of two websites: one includes the euroSCORE (www.euroSCORE.org/calc.html) and the other the STS (Society of Thoracic Surgeons) database that provides a longitudinal look at the risk of cardiac surgery (<http://www.sts.org/national-database>). The EuroScore method invariably results in a greater risk score than the STS.

To assess the risk of noncardiac surgery, the guidelines from the ACC/AHA Task Force provide clinically useful algorithms to help determine risk including the controversy surrounding β -blocker prophylaxis. The major cardiovascular societies have also outlined an approach to assessing risk for cardiac patients that need noncardiac surgery. It basically follows a stepwise approach that assesses the clinical status of the patient and combines that with the inherent risk of the surgical procedure (Figure 10–4).

Numerous studies have evaluated the excess risk of surgery in patients with various cardiac diseases. Recent (within 3 months) myocardial infarction, unstable angina, CHF, and significant aortic stenosis are associated with substantial increases in operative morbidity and mortality rates.

In patients judged to be at high risk or medium risk, there is now controversy regarding the use of β -blockers. Traditionally, it was recommended that they should be initiated preoperatively unless contraindicated. Recent data do not support their value in most situations.

Fleisher LA et al. ACC/AHA 2007 Guidelines on Perioperative Cardiovascular Evaluation and Care for Noncardiac Surgery: Executive Summary: A Report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery) Developed in Collaboration With the American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Rhythm Society, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, and Society for Vascular Surgery. *J Am Coll Cardiol*. 2007 Oct 23;50(17):1707–32. [PMID: 17950159]

Fleisher LA et al. 2009 ACCF/AHA focused update on perioperative beta blockade incorporated into the ACC/AHA 2007 guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery. *J Am Coll Cardiol*. 2009 Nov 24;54(22):e13–e18. [PMID: 19926002]

Gupta PK et al. Development and validation of a risk calculator for prediction of cardiac risk after surgery. *Circulation*. 2011 Jul 26;124(4):381–7. [PMID: 21730309]

Lee TH et al. Derivation and prospective validation of a simple index for prediction of cardiac risk of major noncardiac surgery. *Circulation*. 1999 Sep 7;100(10):1043–9. [PMID: 10477528]

HEART DISEASE & PREGNANCY

The management of cardiac disease in pregnancy is discussed in the references listed below, including the available scoring systems to assess risk. Only a few major points can be covered in this brief section. Fundamentally, the highest risk patients are those with pulmonary hypertension, severe valvular stenosis, cyanosis, and heart failure. Regurgitant valve disease patients tolerate pregnancy better than stenotic valve disease patients due to the afterloading effect of pregnancy.


A comprehensive review of the safety of drugs in pregnancy and during breast-feeding can be found at www.perinatology.com/exposures/druglist.htm.

CARDIOVASCULAR COMPLICATIONS OF PREGNANCY

Pregnancy-related hypertension (eclampsia and preeclampsia) is discussed in Chapter 19.

1. Cardiomyopathy of Pregnancy (Peripartum Cardiomyopathy)

In approximately one in 3000 to 4000 live births, dilated cardiomyopathy develops in the mother in the final month of pregnancy or within 6 months after delivery. The cause is unclear, but immune and viral causes have been postulated. More recently, it has been noted that the disease may be related to a cathepsin-D cleavage product of the hormone prolactin, suggesting blockage of prolactin may be a potential therapeutic strategy if proven in clinical trials using bromocriptine. The disease occurs more frequently in women over age 30 years, is generally related to the first or second pregnancy, and is associated with gestational hypertension and drugs used to stop uterine contractions. The course of the disease is variable; many cases improve or resolve completely over several months, but others progress to refractory heart failure. About 60% of patients make a complete recovery. Serum BNP levels are routinely elevated in pregnancy, but serial values may be useful in predicting who may be at increased risk for a worse outcome. Immunosuppressive therapy has been advocated, but few supportive data are available. Recently, β -blockers have been administered judiciously to these patients, with at least anecdotal success. Some experts advocate anticoagulation because of an increased risk of thrombotic events, and both



¹**Class I**, benefit >>> risk; procedure or treatment should be performed or administered. **Class IIa**, benefit >> risk; it is reasonable to perform procedure or administer treatment. **Class IIb**, benefit ≥ risk; procedure or treatment may be considered. **Level of evidence (LOE) B**, limited (2–3) population risk strata have been evaluated; **LOE C**, very limited (1–2) population risk strata have been evaluated.

²Includes unstable angina or recent myocardial infarction, decompensated congestive heart failure, significant arrhythmias, and severe aortic stenosis or symptomatic mitral stenosis.

³**High risk (> 5% mortality)**: vascular and peripheral vascular surgery. **Intermediate risk (1–5% mortality)**: intraperitoneal and intrathoracic surgery, carotid endarterectomy, head and neck surgery, orthopedic surgery and prostate surgery. **Low risk (< 1% mortality)**: endoscopic procedures, superficial procedures, cataract surgery, ambulatory surgery, breast surgery.

⁴Includes history of ischemic heart disease, history of congestive heart failure or stroke, diabetes mellitus, or renal insufficiency.

▲ **Figure 10-4.** Stepwise approach to assessing cardiac patient risk for noncardiac surgery. (Reproduced, with permission, from Fleisher LA et al. ACC/AHA 2007 Guidelines on Perioperative Cardiovascular Evaluation and Care for Noncardiac Surgery: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery) Developed in Collaboration With the American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Rhythm Society, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, and Society for Vascular Surgery. *J Am Coll Cardiol.* 2007 Oct 23;50(17):1707–32.)

warfarin and heparin have their proponents. In severe cases, transient use of extracorporeal oxygenation (ECMO) has been lifesaving. Recurrence in subsequent pregnancies is common, particularly if cardiac function has not completely recovered.

Biteker M et al. Role of bromocriptine in peripartum cardiomyopathy. *Am J Obstet Gynecol.* 2009 Aug;201(2):e13. [PMID: 19306960]

Leinwand LA. Molecular events underlying pregnancy-induced cardiomyopathy. *Cell.* 2007 Feb 9;128(3):437–8. [PMID: 17289564]

Moioli M et al. Peripartum cardiomyopathy. *Arch Gynecol Obstet.* 2010 Feb;281(2):183–8. [PMID: 19655159]

Sliwa K et al. Management of peripartum cardiomyopathy. *Curr Heart Fail Rep.* 2008 Dec;5(4):238–44. [PMID: 19032920]

Tanous D et al. B-type natriuretic peptide in pregnant women with heart disease. *J Am Coll Cardiol.* 2010 Oct 5;56(15):1247–53. [PMID: 20883932]

2. Coronary Artery & Other Vascular Abnormalities

There have been a number of reports of myocardial infarction during pregnancy. It is known that pregnancy predisposes to dissection of the aorta and other arteries, perhaps because of the accompanying connective tissue changes. The risk may be particularly high in patients with Marfan, Ehlers-Danlos, or Loeys-Dietz syndromes. However, coronary artery dissection is responsible for only a minority of the infarctions; most are caused by atherosclerotic CAD or coronary emboli. Most of the events occur near term or shortly following delivery, and paradoxical emboli through a PFO has been implicated in a few instances. Clinical management is essentially similar to that of other patients with acute infarction, unless there is a connective tissue disorder. If nonatherosclerotic dissection is present, coronary intervention is risky as further dissection can be aggravated. In most instances, conservative management is warranted. At times, extensive aortic dissection requires surgical intervention.

Goland S et al. Pregnancy in Marfan syndrome: maternal and fetal risks and recommendations for patient assessment and management. *Cardiol Rev.* 2009 Nov-Dec;17(6):253–62. [PMID: 19829173]

Kealey A. Coronary artery disease and myocardial infarction in pregnancy: a review of epidemiology, diagnosis, medical and surgical management. *Can J Cardiol.* 2010 Jun;26(6):185–9. [PMID: 20548979]

▶ 3. Prophylaxis for Infective Endocarditis During Pregnancy & Delivery

The ACC/AHA Task Force addressing adults with congenital heart disease has formulated new guidelines outlining recommendations for pregnant women during labor and delivery.

There are no class 1 indications nor class 3 contraindications. The patients who should be considered for coverage with antibiotics during delivery include those who fall into the class 2A category (level of evidence: B).

In select patients with the highest risk of adverse outcomes, it is reasonable to consider antibiotic prophylaxis against infective endocarditis before vaginal delivery at the time of membrane rupture. This includes patients with the following indications: (1) prosthetic cardiac valve or prosthetic material used for cardiac valve repair, and (2) unrepaired and palliated cyanotic congenital heart disease, including surgically constructed palliative shunts conduits.

Warnes CA et al. ACC/AHA 2008 Guidelines for the Management of Adults With Congenital Heart Disease. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *Circulation.* 2008 Dec 2;118(23):e714–833. [PMID: 18997169]

Wilson W et al. Prevention of infective endocarditis: guidelines from the American Heart Association: a guideline from the American Heart Association Rheumatic Fever, Endocarditis and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group. *J Am Dent Assoc.* 2007 Jun;138(6):739–45, 747–60. [PMID: 17545263]

▶ Management of Labor

Although vaginal delivery is usually well tolerated, unstable patients (including patients with severe hypertension and worsening heart failure) should have planned cesarean section. An increased risk of aortic rupture has been noted during delivery in patients with coarctation of the aorta and severe aortic root dilation with Marfan syndrome, and vaginal delivery should be avoided in these conditions. For most patients, even those with congenital heart disease, vaginal delivery is preferred.

CARDIOVASCULAR SCREENING OF ATHLETES

The sudden death of a competitive athlete inevitably becomes an occasion for local if not national publicity. On each occasion, the public and the medical community ask whether such events could be prevented by more careful or complete screening. Although each event is tragic, it must be appreciated that there are approximately 5 million competitive athletes at the high school level or above in any given year in the United States. The number of cardiac deaths occurring during athletic participation is unknown, but estimates at the high school level range from one in 300,000 to one in 100,000 participants. Death rates among more mature athletes increase as the prevalence of CAD rises. These numbers highlight the problem of how to screen individual participants. Even an inexpensive test such as an ECG would generate an enormous cost if required of all athletes, and it is likely that few at-risk individuals would be detected. Echocardiography, either as a routine test or as a follow-up examination for abnormal ECGs, would be prohibitively expensive except for the elite professional athlete. Thus, the most feasible approach is that of a careful medical history and cardiac examination performed by personnel aware of the conditions responsible for most sudden deaths in competitive athletes. In a series of 158 athletic deaths in the United States between 1985 and 1995, hypertrophic cardiomyopathy (36%) and coronary anomalies (19%) were by far the most frequent underlying conditions. LV hypertrophy was present in another 10%, ruptured aorta (presumably due to Marfan syndrome or cystic medial necrosis) in 6%, myocarditis or dilated cardiomyopathy in 6%, aortic stenosis in 4%, and arrhythmogenic RV dysplasia in 3%. In addition, commotio cordis, or sudden death due to direct myocardial injury, may occur. More common in children, it may occur even after a minor direct blow to the heart; it is thought to be due to the precipitation of a premature ventricular contraction just prior to the peak of the T wave on ECG.

It is likely that a careful family and medical history and cardiovascular examination will identify some individuals at risk. A family history of premature sudden death or cardiovascular disease or of any of these predisposing conditions should mandate further workup, including an ECG and echocardiogram. Symptoms of chest pain, syncope, or near-syncope also warrant further evaluation. A Marfan-like appearance, significant elevation of BP or abnormalities of heart rate or rhythm, and pathologic heart murmurs or heart sounds should also be investigated before clearance for

athletic participation is given. Such an evaluation is recommended before participation at the high school and college levels and every 2 years during athletic competition.

Stress-induced syncope or chest pressure may be the first clue to an anomalous origin of a coronary artery. Anatomically, this lesion occurs most often when the left anterior descending artery arises from the right coronary cusp and traverses between the aorta and pulmonary trunks. The “slit-like” orifice that results from the angulation at the vessel origin is thought to cause ischemia when the aorta and pulmonary arteries enlarge during rigorous exercise.

The toughest distinction may be in sorting out the healthy athlete with LVH from the athlete with hypertrophic cardiomyopathy. In general, the healthy athlete’s heart is *less* likely to have an unusual pattern of LVH, or to have LA enlargement, an abnormal ECG, an LV cavity < 45 mm in diameter at end-diastole, an abnormal diastolic filling pattern, or a family history of hypertrophic cardiomyopathy. In addition, the athlete is more likely to be male than the individual with hypertrophic cardiomyopathy. Increased risk is also evident in patients with the Wolff-Parkinson-White syndrome, a prolonged QTc interval, or the Brugada syndrome on their ECG.

Selective use of routine ECG and stress testing is recommended in men above age 40 years and women above age

50 years who continue to participate in vigorous exercise and at earlier ages when there is a positive family history for premature CAD, hypertrophic cardiomyopathy, or multiple risk factors. Because at least some of the risk features (long QT, LVH, Brugada syndrome, Wolff-Parkinson-White syndrome) may be evident on routine ECG screening, several cost-effectiveness studies have been done. Most suggest that pre-participation ECGs are of value. The issue remains controversial.

- Maron BJ et al; Working Groups of the American Heart Association Committee on Exercise, Cardiac Rehabilitation, and Prevention; Councils on Clinical Cardiology and Cardiovascular Disease in the Young. Recommendations for physical activity and recreational sports participation for young patients with genetic cardiovascular diseases. *Circulation*. 2004 Jun 8;109(22):2807–16. [PMID: 15184297]
- Rowland T. Prevention of sudden cardiac death in young athletes: controversies and conundrums. *Med Sport Sci*. 2011;56:171–86. [PMID: 21178373]
- Westrol MS et al. Causes of sudden cardiac arrest in young athletes. *Postgrad Med*. 2010 Jul;122(4):144–57. [PMID: 20675977]
- Wheeler MT et al. Cost-effectiveness of preparticipation screening for prevention of sudden cardiac death in young athletes. *Ann Intern Med*. 2010 Mar 2;152(5):276–86. [PMID: 20194233]

Systemic Hypertension

Michael Sutters, MD, MRCP (UK)



Sixty-six million Americans have elevated blood pressure (systolic blood pressure ≥ 140 mm Hg or diastolic blood pressure ≥ 90 mm Hg); of these, 72% are aware of their diagnosis, but only 61% are receiving treatment and only 35% are under control using a threshold criterion of 140/90 mm Hg. The prevalence of hypertension increases with age and is more common in blacks than in whites. The mortality rates for stroke and coronary heart disease, two of the major complications of hypertension, have declined by 50–60% over the past three decades but have recently leveled off. The number of patients with end-stage kidney disease and heart failure—two other conditions in which hypertension plays a major causative role—continues to rise.

Cardiovascular morbidity and mortality increase as both systolic and diastolic blood pressures rise, but in individuals over age 50 years, the systolic pressure and pulse pressure are better predictors of complications than diastolic pressure. Table 11–1 provides a summary of the classification and management of blood pressure in adults from the 7th Report of the U.S. Joint National Commission on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7).

HOW IS BLOOD PRESSURE MEASURED AND HYPERTENSION DIAGNOSED?

Blood pressure should be measured with a well-calibrated sphygmomanometer. The bladder width within the cuff should encircle at least 80% of the arm circumference. Readings should be taken after the patient has been resting comfortably, back supported in the sitting or supine position, for at least 5 minutes and at least 30 minutes after smoking or coffee ingestion. A video demonstrating the correct technique can be found at <http://www.abdn.ac.uk/medical/bhs/tutorial/tutorial.htm>.

Hypertension is diagnosed when systolic blood pressure is consistently elevated above 140 mm Hg, or diastolic blood pressure is above 90 mm Hg; a single elevated blood pressure reading is not sufficient to establish the diagnosis of hypertension. The major exceptions to this rule are hypertensive presentations with unequivocal evidence of

life-threatening end-organ damage, as seen in hypertensive emergency, or in hypertensive urgency where blood pressure is $> 220/125$ mm Hg but life-threatening end-organ damage is absent. In less severe cases, the diagnosis of hypertension depends on a series of measurements of blood pressure, since readings can vary and tend to regress toward the mean with time. Patients whose initial blood pressure is in the hypertensive range exhibit the greatest fall toward the normal range between the first and second encounters. However, the concern for diagnostic precision needs to be balanced by an appreciation of the importance of establishing the diagnosis of hypertension as quickly as possible, since a 3-month delay in treatment of hypertension in high-risk patients is associated with a twofold increase in cardiovascular morbidity and mortality. The guidelines of the 2011 Canadian Hypertension Education Program provide an algorithm designed to expedite the diagnosis of hypertension (Figure 11–1). To this end, these guidelines recommend short intervals between initial office visits and stress the importance of early identification of target organ damage or diabetes mellitus which, if present, obviates the need for protracted confirmation of blood pressure elevation prior to pharmacologic intervention. Guidelines developed in the UK by the National Institute for Health and Clinical Excellence (NICE) suggest that a 10-year cardiovascular risk of $> 20\%$ should also constitute a trigger for initiating treatment. Antihypertensive regimens should be designed to bring blood pressure down to target levels swiftly in uncomplicated cases, more cautiously in the elderly. The Canadian and UK guidelines exploit the less volatile ambulatory and home blood pressure measurements as complements to office-based evaluations. Hypertension is diagnosed at lower levels when based on measurements taken outside the office environment. The importance of ambulatory and diurnal blood pressure readings as powerful predictors of cardiovascular events demonstrates the need to consider blood pressure beyond the averaging out of occasional office readings. Blood pressure is normally lowest at night and the loss of this nocturnal dip is strongly associated with cardiovascular risk, particularly risk of thrombotic stroke. An accentuation of the normal morning increase in blood pressure

Table 11-1. Classification and management of blood pressure for adults aged 18 years or older.

BP Classification	Systolic BP, mm Hg ¹	And	Diastolic BP, mm Hg ¹	Lifestyle Modification	Management	
					Initial Drug Therapy	
					Without Compelling Indication	With Compelling Indications ²
Normal	< 120	And	< 80	Encourage		
Prehypertension	120-139	Or	80-89	Yes	No antihypertensive drug indicated	Drug(s) for the compelling indications ³
Stage ¹ hypertension	140-159	Or	90-99	Yes	Thiazide-type diuretics for most; may consider ACE inhibitor, ARB, β -blocker, CCB, or combination	Drug(s) for the compelling indications Other antihypertensive drugs (diuretics, ACE inhibitor, ARB, β -blocker, CCB) as needed
Stage 2 hypertension	\geq 160	or	\geq 100	Yes	Two-drug combination for most (usually thiazide-type diuretic and ACE inhibitor or ARB or β -blocker or CCB) ⁴	Drug(s) for the compelling indications Other antihypertensive drugs (diuretics, ACE inhibitor, ARB, β -blocker, CCB) as needed

¹Treatment determined by highest BP category.

²See Table 11-4.

³Treat patients with chronic kidney disease or diabetes mellitus to BP goal of < 130/80 mm Hg.

⁴Initial combined therapy should be used cautiously in those at risk for orthostatic hypotension.

ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; BP, blood pressure; CCB, calcium channel blocker.

Data from Chobanian AV et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. *JAMA*. 2003 May 21;289(19):2560-72.

is associated with increased likelihood of cerebral hemorrhage. Furthermore, visit-to-visit variability of systolic blood pressure predicts cardiovascular events independently of mean systolic blood pressure.

PREHYPERTENSION

Data from the Framingham cohort indicate that blood pressure bears a linear relationship with cardiovascular risk down to a systolic blood pressure of 115 mm Hg; based on these data, it is recommended that individuals with blood pressures in the gray area of 120–139/80–89 mm Hg be categorized as having prehypertension (Table 11-1). This demonstrates a trend away from defining hypertension as a simple numerical threshold and toward a more subtle appreciation of blood pressure as a component of overall cardiovascular risk. This trend gains support from increasing evidence for a relationship between blood pressure and disruption of cardiovascular function at levels below the hypertensive threshold. Because prehypertension often develops into hypertension (50% of people within 4 years), even low-risk prehypertensive patients should be monitored annually.

Chobanian AV. Shattuck Lecture. The hypertension paradox—more uncontrolled disease despite improved therapy. *N Engl J Med*. 2009 Aug 27;361(9):878–87. [PMID: 19710486]

Chobanian AV et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 Report. *JAMA*. 2003 May 21;289(19):2560–72. [PMID: 12748199]

Krause T et al. Management of hypertension: summary of NICE guidelines. *BMJ*. 2011 Aug 25;343:d4891. [PMID: 21868454]

Mallick S et al. Home blood pressure monitoring in clinical practice: a review. *Am J Med*. 2009 Sep;122(9):803–10. [PMID: 19699371]

Pimenta E et al. Prehypertension: epidemiology, consequences and treatment. *Nat Rev Nephrol*. 2010 Jan;6(1):21–30. [PMID: 19918256]


Rabi DM et al. The 2011 Canadian Hypertension Education Program recommendations for the management of hypertension: blood pressure measurement, diagnosis, assessment of risk, and therapy. *Can J Cardiol*. 2011 Jul–Aug;27(4):415–433. [PMID: 21801975]

Rothwell PM et al. Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension. *Lancet*. 2010 Mar 13;375(9718):895–905. [PMID: 20226988]

Waeber B et al. Nighttime blood pressure: a target for therapy? *Curr Hypertens Rep*. 2010 Dec;12(6):474–9. [PMID: 20862569]

Waeber B et al. Target organ damage: how to detect it and how to treat it? *J Hypertens*. 2009 Jun;27(Suppl 3):S13–8. [PMID: 19506446]

Weir MR et al. How early should blood pressure control be achieved for optimal cardiovascular outcomes? *J Hum Hypertens*. 2011 Apr;25(4):211–7. [PMID: 20596060]



▲ **Figure 11-1.** The Canadian Hypertension Education Program expedited assessment and diagnosis of patients with hypertension: Focus on validated technologies for blood pressure (BP) assessment. (Reprinted, with permission, from the Canadian Hypertension Education Program. The 2012 Canadian Hypertension Education Program recommendations for the management of hypertension: blood pressure management, diagnosis, assessment of risk, and therapy. <http://www.hypertension.ca>)

APPROACH TO HYPERTENSION

▶ **Etiology & Classification**

A. Primary Essential Hypertension

Essential hypertension is the term applied to the 95% of hypertensive patients in which elevated blood pressure results from complex interactions between multiple genetic and environmental factors. The proportion regarded as “essential” will diminish with improved detection of clearly defined secondary causes and with better understanding of pathophysiology. Essential hypertension occurs in 10–15% of white adults and 20–30% of black adults in the United States. The onset is usually between ages 25 and 55 years; it

is uncommon before age 20 years. The best understood endogenous and environmental determinants of blood pressure are discussed below.

1. Sympathetic nervous system hyperactivity—This is most apparent in younger persons with hypertension, who may exhibit tachycardia and an elevated cardiac output. However, correlations between plasma catecholamines and blood pressure are poor. Insensitivity of the baroreflexes may play a role in the genesis of adrenergic hyperactivity, and polymorphisms in the *phosducin* gene have been linked to increased blood pressure responses to stress.

2. Abnormal cardiovascular or renal development—The normal cardiovascular system develops so that

elasticity of the great arteries is matched to the resistance in the periphery to optimize large vessel pressure waves. In this way, myocardial oxygen consumption is minimized and coronary flow maximized. Elevated blood pressure later in life could arise from abnormal development of aortic elasticity or reduced development of the microvascular network. This has been postulated as the sequence of events in low birth weight infants, who have an increased risk of hypertension developing in adulthood. Another hypothesis proposes that the association between low birth weight and hypertension arises from reduced nephron number.

3. Renin-angiotensin system activity—Renin, a proteolytic enzyme, is secreted by cells surrounding glomerular afferent arterioles in response to a number of stimuli, including reduced renal perfusion pressure, diminished intravascular volume, circulating catecholamines, increased sympathetic nervous system activity, increased arteriolar stretch, and hypokalemia. Renin acts on angiotensinogen to cleave off the ten-amino-acid peptide angiotensin I. This peptide is then acted upon by angiotensin-converting enzyme (ACE) to create the eight-amino-acid peptide angiotensin II, a potent vasoconstrictor and stimulant of aldosterone secretion. Despite the role of renin in the regulation of blood pressure, it probably does not play a central role in the pathogenesis of most primary (essential) hypertension; only 10% of patients have high renin activity, whereas 60% have normal levels, and 30% have low levels. Black persons with hypertension and older patients tend to have lower plasma renin activity, which may be associated with expanded intravascular volume.

4. Defect in natriuresis—According to the classic Guyton hypothesis, increased salt intake triggers an increase in blood pressure that in turn promotes increased natriuresis, thereby bringing blood pressure back toward basal levels. Salt has long been implicated in the genesis of hypertension, and so-called salt-sensitive hypertension probably arises from a defect in this self-regulating pressure-natriuresis feedback loop.

5. Intracellular sodium and calcium—Intracellular Na^+ is elevated in primary (essential) hypertension. An increase in intracellular Na^+ may lead to increased intracellular Ca^{2+} concentration as a result of facilitated exchange and might explain the increase in vascular smooth muscle tone that is characteristic of established hypertension.

6. Exacerbating factors—A number of conditions have the potential to elevate blood pressure. **Obesity** is associated with an increase in intravascular volume, elevated cardiac output, activation of the renin-angiotensin system and, probably, increased sympathetic outflow. Weight reduction lowers blood pressure modestly. In patients with **sleep apnea**, treatment with continuous positive airway pressure (CPAP) has been associated with improvements in blood pressure. Increased salt intake probably increases blood pressure in some individuals so dietary salt restriction is recommended in patients with hypertension (see below).

Excessive use of **alcohol** also raises blood pressure, perhaps by increasing plasma catecholamines. Hypertension

can be difficult to control in patients who consume more than 40 g of ethanol (two drinks) daily or drink in “binges.” **Cigarette smoking** raises blood pressure, again by increasing plasma norepinephrine. Although the long-term effect of smoking on blood pressure is less clear, the synergistic effects of smoking and high blood pressure on cardiovascular risk are well documented. The relationship of **exercise** to hypertension is variable. Aerobic exercise lowers blood pressure in previously sedentary individuals, but increasingly strenuous exercise in already active subjects has less effect. The relationship between stress and hypertension is not established. **Polycythemia**, whether primary or due to diminished plasma volume, increases blood viscosity and may raise blood pressure. **Nonsteroidal anti-inflammatory drugs (NSAIDs)** produce increases in blood pressure averaging 5 mm Hg and are best avoided in patients with borderline or elevated blood pressures. Low **potassium intake** is associated with higher blood pressure in some patients; an intake of 90 mmol/d is recommended.

The complex of abnormalities termed the “metabolic syndrome” is associated with both the development of hypertension and an increased risk of adverse cardiovascular outcomes. The metabolic syndrome (sometimes also called syndrome X or the “deadly quartet”) consists of upper body obesity, hyperinsulinemia and insulin resistance, hypertriglyceridemia, and hypertension. Affected patients usually also have low high-density lipoprotein (HDL) cholesterol levels and elevated catecholamines and inflammatory markers such as C-reactive protein.

B. Secondary Hypertension

Approximately 5% of patients with hypertension have identifiable specific causes (Table 11-2). Secondary hypertension should be suspected in patients in whom hypertension develops at an early age, those who first exhibit hypertension when over age 50 years, or those previously well controlled who become refractory to treatment. Causes include genetic syndromes, kidney disease, renal vascular hypertension, primary hyperaldosteronism, Cushing syndrome, pheochromocytoma, coarctation of the aorta, and hypertension associated with pregnancy, estrogen use, hypercalcemia and medications.

Table 11-2. Identifiable causes of hypertension.

Sleep apnea
Drug-induced or drug-related
Chronic kidney disease
Primary aldosteronism
Renovascular disease
Long-term corticosteroid therapy and Cushing syndrome
Pheochromocytoma
Coarctation of the aorta
Thyroid or parathyroid disease

Data from Chobanian AV et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. *JAMA*. 2003 May 21;289(19):2560-72.

1. Genetic causes—Hypertension can be caused by mutations in single genes, inherited on a mendelian basis. Although rare, these conditions provide important insight into blood pressure regulation and possibly the genetic basis of essential hypertension. **Glucocorticoid remediable aldosteronism** is an autosomal dominant cause of early-onset hypertension with normal or high aldosterone and low renin levels. It is caused by the formation of a chimeric gene encoding both the enzyme responsible for the synthesis of aldosterone (transcriptionally regulated by angiotensin II) and an enzyme responsible for synthesis of cortisol (transcriptionally regulated by ACTH). As a consequence, aldosterone synthesis becomes driven by ACTH, which can be suppressed by exogenous cortisol. In the **syndrome of apparent mineralocorticoid excess**, early-onset hypertension with hypokalemic metabolic alkalosis is inherited on an autosomal recessive basis. Although plasma renin is low and plasma aldosterone level is very low in these patients, aldosterone antagonists are effective in controlling hypertension. This disease is caused by loss of the enzyme, 11 β -hydroxysteroid dehydrogenase, which normally metabolizes cortisol and thus protects the otherwise “promiscuous” mineralocorticoid receptor in the distal nephron from inappropriate glucocorticoid activation. Similarly, glycyrrhetic acid, found in licorice, causes increased blood pressure through inhibition of 11 β -hydroxysteroid dehydrogenase. The syndrome of **hypertension exacerbated in pregnancy** is inherited as an autosomal dominant trait. In these patients, a mutation in the mineralocorticoid receptor makes it abnormally responsive to progesterone and, paradoxically, to spironolactone. **Liddle syndrome** is an autosomal dominant condition characterized by early-onset hypertension, hypokalemic alkalosis, low renin and low aldosterone levels. This is caused by a mutation that results in constitutive activation of the epithelial sodium channel of the distal nephron, with resultant unregulated sodium reabsorption and volume expansion.

2. Renal disease—Renal parenchymal disease is the most common cause of secondary hypertension and is related to increased intravascular volume or increased activity of the renin–angiotensin–aldosterone system.

3. Renal vascular hypertension—Renal artery stenosis is present in 1–2% of hypertensive patients. Its cause in most younger individuals is fibromuscular dysplasia, particularly in women under 50 years of age. The remainder of renal vascular disease is due to atherosclerotic stenoses of the renal arteries. The mechanisms of hypertension relate to excessive renin release due to reduction in renal perfusion pressure and attenuation of pressure natriuresis with stenosis affecting a single kidney or with bilateral renal artery stenosis.

Renal vascular hypertension should be suspected in the following circumstances: (1) if the documented onset is before age 20 or after age 50 years, (2) hypertension is resistant to three or more drugs, (3) if there are epigastric or renal artery bruits, (4) if there is atherosclerotic disease of the aorta or peripheral arteries (15–25% of patients with symptomatic lower limb atherosclerotic vascular disease

have renal artery stenosis), (5) if there is an abrupt increase (> 25%) in the level of serum creatinine after administration of ACE inhibitors, or (6) if episodes of pulmonary edema are associated with abrupt surges in blood pressure. There is no ideal screening test for renal vascular hypertension. If suspicion is sufficiently high and endovascular intervention is a viable option, renal arteriography, the definitive diagnostic test, is the best approach. Renal arteriography is not recommended as a routine adjunct to coronary studies. Where suspicion is moderate to low, non-invasive angiography using magnetic resonance (MR) or CT are reasonable approaches. With improvements in technology, Doppler sonography may play an increasing role in detection of renal artery stenosis, providing physiologic indices of stenosis severity and ease of repeated examination to detect progression. However, results of all these modalities vary greatly between institutions. In 2006, a public health advisory was issued regarding the use of gadolinium (a contrast agent used in MRA), warning that it might precipitate nephrogenic systemic fibrosis in patients with advanced kidney disease. Gadolinium is contraindicated in patients with an estimated glomerular filtration rate (GFR) of < 30 mL/min. Clearly, no diagnostic study should be undertaken without a careful consideration of the risk-benefit ratio. In young patients with fibromuscular disease, angioplasty is very effective, but there is controversy regarding the best approach to the treatment of atheromatous renal artery stenosis. Correction of the stenosis in selected patients might reduce the number of medications required to control blood pressure and could protect kidney function, but the extent of preexisting parenchymal damage to the affected and contralateral kidney has a significant influence on both blood pressure and kidney function outcomes following revascularization. The real challenge is identifying those patients likely to benefit from intervention: in this regard, a hyperemic (papaverine-induced) systolic gradient > 21 mm Hg appears to predict a good response to renal artery angioplasty or stenting. A reasonable approach advocates medical therapy as long as hypertension can be well controlled and there is no progression of kidney disease. The addition of a statin should be considered. Endovascular intervention might be considered in patients with uncontrollable hypertension, progressive kidney disease, or episodic pulmonary edema attributable to the lesion. Angioplasty might also be warranted when progression of stenosis is either demonstrated or is predicted by a constellation of risk factors, including systolic blood pressure > 160 mm Hg, advanced age, diabetes mellitus or high-grade stenosis (> 60%) at the time of diagnosis. However, conclusive outcomes data to guide management are still awaited. Although ACE inhibitors have improved the success rate of medical therapy of hypertension due to renal artery stenosis, they have been associated with marked hypotension and (usually reversible) kidney dysfunction in individuals with bilateral disease. Thus, kidney function and blood pressure should be closely monitored during the first weeks of therapy in patients in whom this is a consideration.

4. Primary hyperaldosteronism—Over the past decade, studies have suggested that primary hyperaldosteronism

might account for some 10% of essential hypertension. However, this could be an overestimate due to sampling bias and problems with the specificity of a screening test based on the measurement of plasma aldosterone concentration (normal: 1–16 ng/dL) and plasma renin activity (normal: 1–2.5 ng/mL/h) and calculation of the plasma aldosterone/renin ratio (normal < 30). This is because “bottoming out” of renin assays leads to exponential increases in the plasma aldosterone/renin ratio even when aldosterone levels are normal. Hence, an elevated plasma aldosterone/renin ratio should probably not be taken as evidence of hyperaldosteronism unless the aldosterone level is actually elevated. The lesion responsible for hyperaldosteronism is an adrenal adenoma or bilateral adrenal hyperplasia and can be demonstrated by CT or MRI scanning. At least some aldosterone-secreting adenomas arise as a consequence of somatic mutations in a potassium channel gene in glomerulosa cells. Screening is appropriate in patients with resistant hypertension, (needing more than three drugs for control) and those with spontaneous or thiazide-induced hypokalemia, incidentaloma, or family history of primary hyperaldosteronism.

During the workup for hyperaldosteronism, medications that alter renin and aldosterone levels, including ACE inhibitors, angiotensin receptor blockers (ARBs), diuretics, β -blockers, and clonidine, should be discontinued for 2 weeks before sampling; spironolactone and eplerenone should be held for 4 weeks. Calcium channel and α -receptor blockers can be used to control blood pressure during this drug washout period. Based on this approach, patients with aldosterone/renin ratios of ≥ 30 with a plasma aldosterone level >16 ng/dL might require further evaluation for primary hyperaldosteronism.

5. Cushing syndrome—Hypertension occurs in about 80% of patients with spontaneous Cushing syndrome. Excess glucocorticoid may induce salt and water retention through mineralocorticoid effects, through increased angiotensinogen levels, or through permissive effects in the regulation of vascular tone.

Diagnosis and treatment of Cushing syndrome are discussed in Chapter 26.

6. Pheochromocytoma—Pheochromocytomas are uncommon; they are probably found in < 0.1% of all patients with hypertension and in approximately two individuals per million population. However, autopsy studies indicate that pheochromocytomas are very often undiagnosed in life. The blood pressure elevation caused by the catecholamine excess results mainly from α -receptor-mediated vasoconstriction of arterioles, with a contribution from β_1 -receptor-mediated increases in cardiac output and renin release. Chronic vasoconstriction of the arterial and venous beds leads to a reduction in plasma volume and predisposes to postural hypotension. Glucose intolerance develops in some patients. Hypertensive crisis in pheochromocytoma may be precipitated by a variety of drugs, including tricyclic antidepressants, antidopaminergic agents, metoclopramide, and naloxone. The diagnosis and treatment of pheochromocytoma are discussed in Chapter 26.

7. Coarctation of the aorta—This uncommon cause of hypertension is discussed in Chapter 10. Evidence of radial-femoral delay should be sought in all younger patients with hypertension.

8. Hypertension associated with pregnancy—Hypertension occurring de novo or worsening during pregnancy, including preeclampsia and eclampsia, is one of the most common causes of maternal and fetal morbidity and mortality (see Chapter 19).

9. Estrogen use—A small increase in blood pressure occurs in most women taking oral contraceptives. However, a more significant increase that brings the blood pressure to above 140/90 mm Hg is noted in about 5% of women, mostly in obese individuals older than age 35 who have been treated for more than 5 years. This is caused by volume expansion due to increased hepatic synthesis of angiotensinogen and consequent activation of the renin-angiotensin-aldosterone system. Postmenopausal estrogen does not generally cause hypertension, but rather maintains endothelium-mediated vasodilation.

10. Other causes of secondary hypertension—Hypertension has also been associated with hypercalcemia, acromegaly, hyperthyroidism, hypothyroidism, baroreceptor denervation, compression of the rostral ventrolateral medulla, and increased intracranial pressure. A number of medications may cause or exacerbate hypertension—most importantly cyclosporine, tacrolimus, angiogenesis inhibitors, decongestants, and NSAIDs; cocaine and alcohol should also be considered.

▶ When to Refer

Referral to a hypertension specialist should be considered in cases of severe, resistant or early/late onset hypertension or when secondary hypertension is suggested by screening.

- Bogaert YE et al. The role of obesity in the pathogenesis of hypertension. *Nat Clin Pract Nephrol*. 2009 Feb;5(2):101–11. [PMID: 19107106]
- Broeckel U. The identification of *phosducin* as a novel candidate gene for hypertension and its role in sympathetic activation. *Curr Opin Nephrol Hypertens*. 2011 Mar;20(2):118–24. [PMID: 21191291]
- Choi M. K+ channel mutations in adrenal aldosterone-producing adenomas and hereditary hypertension. *Science*. 2011 Feb 11;331(6018):768–72. [PMID: 21311022]
- Hood SJ et al. The spironolactone, amiloride, losartan, and thiazide (SALT) double-blind crossover trial in patients with low-renin hypertension and elevated aldosterone-renin ratio. *Circulation*. 2007 Jul 17;116(3):268–75. [PMID: 17606839]
- Karagiannis A et al. Pheochromocytoma: an update on genetics and management. *Endocr Relat Cancer*. 2007 Dec;14(4):935–56. [PMID: 18045948]
- Manger WM. The protean manifestations of pheochromocytoma. *Horm Metab Res*. 2009 Sep;41(9):658–63. [PMID: 19242899]
- Messerli FH et al. Essential hypertension. *Lancet*. 2007 Aug 18;370(9587):591–603. [PMID: 17707755]
- Nuyt AM et al. Developmental programming and hypertension. *Curr Opin Nephrol Hypertens*. 2009 Mar;18(2):144–52. [PMID: 19434052]

Ritz E. Salt and hypertension. *Nephrology* (Carlton). 2010 Jun; 15(Suppl 2):49–52. [PMID: 20586949]

Rossi GP. Diagnosis and treatment of primary aldosteronism. *Rev Endocr Metab Disord*. 2011 Mar;12(1):27–36. [PMID: 21369868]

Seddon M. Atherosclerotic renal artery stenosis: review of pathophysiology, clinical trial evidence, and management strategies. *Can J Cardiol*. 2011 Jul–Aug;27(4):468–80. [PMID: 21550203]

► Complications of Untreated Hypertension

Elevated blood pressure results in structural and functional changes in the vasculature and heart. Most of the adverse outcomes in hypertension are associated with thrombosis rather than bleeding, possibly because increased vascular shear stress converts the normally anticoagulant endothelium to a prothrombotic state. The excess morbidity and mortality related to hypertension approximately doubles for each 6 mm Hg increase in diastolic blood pressure. However, target-organ damage varies markedly between individuals with similar levels of office hypertension; ambulatory pressures are superior to office readings in the prediction of end-organ damage and variability in blood pressure from visit to visit predicts cardiovascular endpoints independently of mean office-based systolic blood pressure.

A. Hypertensive Cardiovascular Disease

Cardiac complications are the major causes of morbidity and mortality in primary (essential) hypertension. For any level of blood pressure, left ventricular hypertrophy is associated with incremental cardiovascular risk in association with congestive heart failure (through systolic or diastolic dysfunction), ventricular arrhythmias, myocardial ischemia, and sudden death.

The occurrence of heart failure is reduced by 50% with antihypertensive therapy. Hypertensive left ventricular hypertrophy regresses with therapy and is most closely related to the degree of systolic blood pressure reduction. Diuretics have produced equal or greater reductions of left ventricular mass when compared with other drug classes. Conventional β -blockers are less effective in reducing left ventricular hypertrophy but play a specific role in patients with established coronary artery disease or impaired left ventricular function.

B. Hypertensive Cerebrovascular Disease and Dementia

Hypertension is the major predisposing cause of hemorrhagic and ischemic stroke. Cerebrovascular complications are more closely correlated with systolic than diastolic blood pressure. The incidence of these complications is markedly reduced by antihypertensive therapy. Preceding hypertension is associated with a higher incidence of subsequent dementia of both vascular and Alzheimer types. Ambulatory blood pressure may be a better predictor of cognitive decline than office readings in older people.

Effective blood pressure control may reduce the risk of development of cognitive dysfunction later in life, but once cerebral small vessel disease is established, low blood pressure might exacerbate this problem.

C. Hypertensive Kidney Disease

Chronic hypertension leads to nephrosclerosis, a common cause of kidney disease that is particularly prevalent in blacks, in whom susceptibility is linked to *APOL1* mutations. These mutations became prevalent in people of African descent because they also conferred resistance to trypanosomal infection. Aggressive blood pressure control, to 130/80 mm Hg or lower, slows the progression of all forms of chronic kidney disease, especially when proteinuria is present.

D. Aortic Dissection

Hypertension is a contributing factor in many patients with dissection of the aorta. Its diagnosis and treatment are discussed in Chapter 12.

E. Atherosclerotic Complications

Most Americans with hypertension die of complications of atherosclerosis, but antihypertensive therapy seems to have a lesser impact on atherosclerotic complications compared with the other effects of treatment outlined above. Prevention of cardiovascular outcomes related to atherosclerosis probably requires control of multiple risk factors, of which hypertension is only one.

Dharmashankar K et al. Vascular endothelial function and hypertension: insights and directions. *Curr Hypertens Rep*. 2010 Dec;12(6):448–55. [PMID: 20857237]

Duron E et al. Antihypertensive treatments, cognitive decline, and dementia. *J Alzheimers Dis*. 2010;20(3):903–14. [PMID: 20182022]

Feihl F et al. The macrocirculation and microcirculation of hypertension. *Curr Hypertens Rep*. 2009 Jun;11(3):182–9. [PMID: 19442327]

Genovese G et al. Association of trypanolytic *APOL1* variants with kidney disease in African Americans. *Science*. 2010 Aug 13;329(5993):841–5. [PMID: 20647424]

Lee HY et al. Aging and arterial stiffness. *Circ J*. 2010 Oct 25; 74(11):2257–62. [PMID: 20962429]

White WB et al. Average daily blood pressure, not office blood pressure, is associated with progression of cerebrovascular disease and cognitive decline in older people. *Circulation*. 2011 Nov 22;124(21):2312–9. [PMID: 22105196]

► Clinical Findings

The clinical and laboratory findings are mainly referable to involvement of the target organs: heart, brain, kidneys, eyes, and peripheral arteries.

A. Symptoms

Mild to moderate primary (essential) hypertension is largely asymptomatic for many years. The most frequent symptom, headache, is also very nonspecific. Accelerated

hypertension is associated with somnolence, confusion, visual disturbances, and nausea and vomiting (hypertensive encephalopathy).

Hypertension in patients with pheochromocytomas that secrete predominantly norepinephrine is usually sustained but may be episodic. The typical attack lasts from minutes to hours and is associated with headache, anxiety, palpitation, profuse perspiration, pallor, tremor, and nausea and vomiting. Blood pressure is markedly elevated, and angina or acute pulmonary edema may occur. In primary aldosteronism, patients may have muscular weakness, polyuria, and nocturia due to hypokalemia; malignant hypertension is rare. Chronic hypertension often leads to left ventricular hypertrophy and diastolic dysfunction, which can present with exertional and paroxysmal nocturnal dyspnea. Cerebral involvement causes stroke due to thrombosis or hemorrhage from microaneurysms of small penetrating intracranial arteries. Hypertensive encephalopathy is probably caused by acute capillary congestion and exudation with cerebral edema, which is reversible.

B. Signs

Like symptoms, physical findings depend on the cause of hypertension, its duration and severity, and the degree of effect on target organs.

1. Blood pressure—Blood pressure is taken in both arms and, if lower extremity pulses are diminished or delayed, in the legs to exclude coarctation of the aorta. An orthostatic drop is present in pheochromocytoma. Older patients may have falsely elevated readings by sphygmomanometry because of noncompressible vessels. This may be suspected in the presence of Osler sign—a palpable brachial or radial artery when the cuff is inflated above systolic pressure. Occasionally, it may be necessary to make direct measurements of intra-arterial pressure, especially in patients with apparent severe hypertension who do not tolerate therapy.

2. Retinas—Narrowing of arterial diameter to < 50% of venous diameter, copper or silver wire appearance, exudates, hemorrhages, or papilledema are associated with a worse prognosis. The typical changes of hypertensive retinopathy are shown in Figure 11-2.

3. Heart—A left ventricular heave indicates severe or long-standing hypertrophy. Aortic insufficiency may be auscultated in up to 5% of patients, and hemodynamically insignificant aortic insufficiency can be detected by Doppler echocardiography in 10–20%. A presystolic (S_4) gallop due to decreased compliance of the left ventricle is quite common in patients in sinus rhythm.

4. Pulses—Radial-femoral delay suggests coarctation of the aorta; loss of peripheral pulses occurs due to atherosclerosis, less commonly aortic dissection, and rarely Takayasu arteritis, all of which can involve the renal arteries.

C. Laboratory Findings

Recommended testing includes the following: hemoglobin; urinalysis and serum creatinine; fasting blood sugar level



▲ **Figure 11-2.** This image shows severe acute hypertensive retinopathy with papilledema, intraretinal hemorrhages, nerve fiber layer infarcts (cotton-wool spots) and arteriovenous nicking. Retinal arteries show irregular thinning. (Used, with permission, from Dr. Richard S. Munsen, Department of Ophthalmology, University of Washington School of Medicine.)

(hypertension is a risk factor for the development of diabetes, and hyperglycemia can be a presenting feature of pheochromocytoma); plasma lipids (necessary to calculate cardiovascular risk and as a modifiable risk factor); serum uric acid (hyperuricemia is a relative contraindication to diuretic therapy); and serum electrolytes.

D. Electrocardiography and Chest Radiographs

Electrocardiographic criteria are highly specific but not very sensitive for left ventricular hypertrophy. The “strain” pattern of ST–T wave changes is a sign of more advanced disease and is associated with a poor prognosis. A chest radiograph is not necessary in the workup for uncomplicated hypertension.

E. Echocardiography

The primary role of echocardiography should be to evaluate patients with clinical symptoms or signs of cardiac disease.

F. Diagnostic Studies

Additional diagnostic studies are indicated only if the clinical presentation or routine tests suggest secondary or complicated hypertension. These may include tests such as 24-hour urine free cortisol, plasma metanephrines and the plasma aldosterone/renin ratio for endocrine causes of hypertension, renal ultrasound to diagnose primary kidney disease (polycystic kidneys, obstructive uropathy), and testing for renal artery stenosis. Further evaluation may include abdominal imaging studies (ultrasound, CT scan, or MRI) or renal arteriography.

G. Summary

Since most hypertension is essential or primary, few studies are necessary beyond those listed above. If conventional therapy is unsuccessful or if symptoms suggest a secondary cause, further studies are indicated.

DellaCroce JT. Hypertension and the eye. *Curr Opin Ophthalmol*. 2008 Nov;19(6):493–8. [PMID: 18854694]

► Nonpharmacologic Therapy

Lifestyle modification may have an impact on morbidity and mortality. A diet rich in fruits, vegetables, and low-fat dairy foods and low in saturated and total fats (DASH diet) has been shown to lower blood pressure. Additional measures, listed in Table 11–3, can prevent or mitigate hypertension or its cardiovascular consequences.

Table 11–3. Lifestyle modifications to manage hypertension.¹

Modification	Recommendation	Approximate Systolic BP Reduction, Range
Weight reduction	Maintain normal body weight (BMI, 18.5–24.9)	5–20 mm Hg/10-kg weight loss
Adopt DASH eating plan	Consume a diet rich in fruits, vegetables, and low-fat dairy products with a reduced content of saturated fat and total fat	8–14 mm Hg
Dietary sodium reduction	Reduce dietary sodium intake to no more than 100 mEq/d (2.4 g sodium or 6 g sodium chloride)	2–8 mm Hg
Physical activity	Engage in regular aerobic physical activity such as brisk walking (at least 30 minutes per day, most days of the week)	4–9 mm Hg
Moderation of alcohol consumption	Limit consumption to no more than two drinks per day (1 oz or 30 mL ethanol [eg, 24 oz beer, 10 oz wine, or 3 oz 80-proof whiskey]) in most men and no more than one drink per day in women and lighter-weight persons	2–4 mm Hg

¹For overall cardiovascular risk reduction, stop smoking. The effects of implementing these modifications are dose and time dependent and could be higher for some individuals.

BMI, body mass index calculated as weight in kilograms divided by the square of height in meters; BP, blood pressure; DASH, Dietary Approaches to Stop Hypertension.

Data from Chobanian AV et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. *JAMA*. 2003 May 21;289(19):2560–72.

All patients with high-normal or elevated blood pressures, those who have a family history of cardiovascular complications of hypertension, and those who have multiple coronary risk factors should be counseled about nonpharmacologic approaches to lowering blood pressure. Approaches of proved but modest value include weight reduction, reduced alcohol consumption and, in some patients, reduced salt intake. Gradually increasing activity levels should be encouraged in previously sedentary patients, but strenuous exercise training programs in already active individuals may have less benefit. Calcium and potassium supplements have been advocated, but their ability to lower blood pressure is limited. Smoking cessation will reduce overall cardiovascular risk. Overall, the effects of lifestyle modification on blood pressure are modest. Although all patients should be urged to modify risk factors, medication is likely to be required for optimal blood pressure control in stage 1 hypertension.

Blumenthal JA et al. Effects of the DASH diet alone and in combination with exercise and weight loss on blood pressure and cardiovascular biomarkers in men and women with high blood pressure: the ENCORE study. *Arch Intern Med*. 2010 Jan 25;170(2):126–35. [PMID: 20101007]

Cook NR et al. Trials of Hypertension Prevention Collaborative Research Group. Joint effects of sodium and potassium intake on subsequent cardiovascular disease: the Trials of Hypertension Prevention follow-up study. *Arch Intern Med*. 2009 Jan 12;169(1):32–40. [PMID: 19139321]

Sacks FM et al. Dietary therapy in hypertension. *N Engl J Med*. 2010 Jun 3;362(22):2102–12. [PMID: 20519681]

► Who Should Be Treated with Medications?

Treatment should ideally be offered to all persons in whom blood pressure reduction, irrespective of initial blood pressure levels, will reduce overall cardiovascular risk.

The decision to initiate drug therapy is relatively straightforward once hypertension has been unequivocally diagnosed (Table 11–1 and Figure 11–1), but less clear in persons with prehypertension (blood pressure of 120–139/80–89 mm Hg). Some experts have suggested that early blood pressure elevation, and perhaps antecedent metabolic abnormalities, lead to vascular damage that propels further blood pressure elevation in an ever accelerating spiral of progression. If so, then interception early in the course might modify the natural history of the disease, leading to diminished requirements for multiple antihypertensive agents and, perhaps, a much more dramatic effect on cardiovascular risk than can be attained with initiation of treatment once hypertension is established. In beginning to address this question, the TROPHY study showed that treatment of prehypertension in a population at no particular risk for cardiovascular events only seemed to delay the onset of hypertension, since blood pressure in the treated group increased toward the placebo group when treatment was discontinued. The situation is a little clearer in nonhypertensive patients at elevated cardiovascular risk, in whom the HOPE and PROGRESS trials indicated improved outcomes with

antihypertensive medication (ACE inhibitor and ACE inhibitor plus diuretic, respectively). These observations have prompted some to think in terms of “optimizing” blood pressure to a suggested 120/80 mm Hg. However, the public health consequences of recommendations to treat prehypertension would be enormous. Forty-eight percent of all Americans have hypertension or prehypertension, and much higher proportions fit these categories in a typical family medicine population. The JNC 7 guidelines suggest that antihypertensive medications be offered to persons with prehypertension with compelling indications for treatment such as chronic kidney disease or diabetes mellitus (Table 11–4). According to the British Hypertension Society (BHS) recommendations (Figure 11–3), risk analysis should be used to target treatment to patients with borderline hypertension who are most likely to benefit, particularly individuals at high combined risk of coronary heart or stroke event (> 20–30% within 10 years). Risk is calculated according to Framingham study criteria

(calculated from several of the risk factors listed in Table 11–5). A low-risk patient with blood pressure between 120–139/80–89 mm Hg may be advised to make lifestyle modifications (Table 11–3) and be monitored without receiving an absolute diagnosis of prehypertension. Patients can calculate their own cardiovascular risk at <https://www.myhealthcheckup.com/index.en.html>. A risk calculation tool can be downloaded from http://www.bhsoc.org/Cardiovascular_Risk_Charts_and_Calculators.stm (in using this tool, convert serum cholesterol from mg/dL to mmol/L by dividing by 38.7). Free iPhone application coronary heart disease risk calculators are available. In general, a 20% total cardiovascular risk (which includes stroke) is equivalent to a 15% coronary heart disease risk.

► Goals of Treatment

Most experts believe that blood pressure targets for hypertensive patients at the greatest risk for cardiovascular


Table 11–4. Clinical trial and guideline basis for compelling indications for individual drug classes.¹

High-Risk Conditions with Compelling Indication ²	Recommended Drugs						Clinical Trial Basis
	Diuretic	β-Blockers	ACE Inhibitors	ARB	CCB	Aldosterone Antagonist	
Heart failure	•	•	•	•		•	ACC/AHA Heart Failure Guideline, MERIT-HF, COPERNICUS, CIBIS, SOLVD, AIRE, TRACE, ValHEFT, RALES
Post-myocardial infarction		•	•			•	ACC/AHA Post-MI Guideline, BHAT, SAVE, Capricorn, EPHEBUS
High coronary disease risk	•	•	•		•		ALLHAT, HOPE, ANBP2, LIFE, CONVINC
Diabetes mellitus	•	•	•	•	•		NKF-ADA Guideline, UKPDS, ALLHAT
Chronic kidney disease			•	•			NKF Guideline, Captopril Trial, RENAAL, IDNT, REIN, AASK
Recurrent stroke prevention	•		•				PROGRESS

¹Compelling indications for antihypertensive drugs are based on benefits from outcome studies or existing clinical guidelines; the compelling indication is managed in parallel with the blood pressure.

²Conditions for which clinical trials demonstrate benefit of specific classes of antihypertensive drugs.

AASK, African American Study of Kidney Disease and Hypertension; ACC/AHA, American College of Cardiology/American Heart Association; ACE, angiotensin converting enzyme; AIRE, Acute Infarction Ramipril Efficacy; ALLHAT, Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial; ANBP2, Second Australian National Blood Pressure Study; ARB, angiotensin receptor blocker; BHAT, β-Blocker Heart Attack Trial; CCB, calcium channel blocker; CIBIS, Cardiac Insufficiency Bisoprolol Study; CONVINC, Controlled Onset Verapamil Investigation of Cardiovascular End Points; COPERNICUS, Carvedilol Prospective Randomized Cumulative Survival Study; EPHEBUS, Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study; HOPE, Heart Outcomes Prevention Evaluation Study; IDNT, Irbesartan Diabetic Nephropathy Trial; LIFE, Losartan Intervention For Endpoint Reduction in Hypertension Study; MERIT-HF, Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure; NKF-ADA, National Kidney Foundation–American Diabetes Association; PROGRESS, Perindopril Protection Against Recurrent Stroke Study; RALES, Randomized Aldactone Evaluation Study; REIN, Ramipril Efficacy in Nephropathy Study; RENAAL, Reduction of Endpoints in Non-Insulin-Dependent Diabetes Mellitus with the Angiotensin II Antagonist Losartan Study; SAVE, Survival and Ventricular Enlargement Study; SOLVD, Studies of Left Ventricular Dysfunction; TRACE, Trandolapril Cardiac Evaluation Study; UKPDS, United Kingdom Prospective Diabetes Study; ValHEFT, Valsartan Heart Failure Trial. Data from Chobanian AV et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. *JAMA*. 2003 May 21;289(19):2560–72.



¹Assessed with CVD risk chart.

▲ Figure 11-3. British Hypertension Society algorithm for diagnosis and treatment of hypertension, incorporating total cardiovascular risk in deciding which “prehypertensive” patients to treat. (CVD, cardiovascular disease.) CVD risk chart available at http://www.bhsoc.org/Cardiovascular_Risk_Charts_and_Calculators.stm (Reproduced, with permission, from Guidelines for management of hypertension: report of the Fourth Working Party of the British Hypertension Society, 2004-BHS IV. *J Hum Hypertens.* 2004 Mar;18(3):139-85.)

events, particularly patients with diabetes and those with chronic kidney disease, should be lower (< 130/80 mm Hg) than for individuals at lower total cardiovascular risk (< 140/90 mm Hg). Observational studies suggest that there does not seem to be a blood pressure level below which decrements in risk taper off. However, this may not be true with respect to pharmacologically modulated blood pressure. In fact, over-enthusiastic treatment may have adverse consequences in certain settings. There is an association between lower blood pressure and cognitive decline in elderly patients subjected to intensification of antihypertensive treatment later in life. Excessive lowering of diastolic pressure, perhaps below 70 mm Hg, should be avoided in patients with coronary artery disease. In diabetic patients, treatment of systolic pressures to below 130–135 mm Hg significantly increases the risk of serious adverse effects with no additional gain in terms of cardiac, renal, or retinal disease. On the other hand, reducing systolic pressure below 130 mm Hg does seem to further lower the risk of stroke, so lower targets might be justified in patients at high risk for cerebrovascular events.

There is no clear consensus on blood pressure goals in the management of prehypertension, but pressure should still be treated until it is < 130/80 mm Hg in prehypertensive patients with diabetes or chronic kidney disease and perhaps also in others at high risk for a cardiovascular event.

Large-scale trials in hypertension have focused on discrete end points occurring over relatively short intervals, thereby placing the emphasis on the prevention of catastrophic events in advanced disease. More recently, in parallel with a new emphasis on viewing hypertension in the context of overall cardiovascular risk, attention is turning to the importance of the long view. Accordingly, treatment of persons with hypertension should focus on comprehensive risk reduction with more careful consideration of the possible long-term adverse consequences of the metabolic derangements linked to some antihypertensives (particularly conventional β -blockers and thiazide diuretics).

Statins should be more widely used. In this respect, there is evidence from the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) that statins can significantly

Table 11-5. Cardiovascular risk factors.**Major risk factors**

Hypertension¹
 Cigarette smoking
 Obesity (BMI ≥ 30)¹
 Physical inactivity
 Dyslipidemia¹
 Diabetes mellitus¹
 Microalbuminuria or estimated GFR < 60 mL/min
 Age (> 55 years for men, > 65 years for women)
 Family history of premature cardiovascular disease
 (men < 55 years or women < 65 years)

Target-organ damage**Heart**

Left ventricular hypertrophy
 Angina or prior myocardial infarction
 Prior coronary revascularization
 Heart failure

Brain

Stroke or transient ischemic attack

Chronic kidney disease**Peripheral arterial disease****Retinopathy**

¹Components of the metabolic syndrome.

BMI indicates body mass index calculated as weight in kilograms divided by the square of height in meters; GFR, glomerular filtration rate.

Data from Chobanian AV et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. *JAMA*. 2003 May 21; 289(19):2560-72.

improve outcomes in persons with hypertension (with modest background cardiovascular risk) whose total cholesterol is < 250 mg/dL (6.5 mmol/L). Notably, this effect appeared to be synergistic with calcium channel blocker/ACE inhibitor regimens but not β -blocker/diuretic regimens. The BHS guidelines recommend that statins be offered as secondary prevention to patients whose total cholesterol exceeds 135 mg/dL (3.5 mmol/L) if they have documented coronary artery disease or a history of ischemic stroke. In addition, statins should be considered as primary prevention in patients with long-standing type 2 diabetes or in those with type 2 diabetes who are older than age 50 years, and perhaps in all persons with type 2 diabetes. Ideally, total and low-density lipoprotein (LDL) cholesterol should be reduced by 30% and 40% respectively, or to approximately < 155 mg/dL (4 mmol/L) and < 77 mg/dL (2 mmol/L), whichever is the greatest reduction. However, total and LDL cholesterol levels of < 194 mg/dL (5 mmol/L) and < 116 mg/dL (3 mmol/L) respectively, or reductions of 25% and 30% are regarded as clinically acceptable objectives. Primary prevention with statins might also be reasonably extended to all patients with total cholesterol > 135 mg/dL (3.5 mmol/L) and a total cardiovascular risk $> 20\%$ (to similar target cholesterol levels), but trial evidence for this is not currently available. Low-dose aspirin (81 mg/day) is likely to be beneficial in patients older than age 50 with either target

organ damage or elevated total cardiovascular risk (> 20 – 30%). Care should be taken to ensure that blood pressure is controlled to the recommended levels before starting aspirin to minimize the risk of bleeding.

- Arguedas JA et al. Treatment blood pressure targets for hypertension. *Cochrane Database Syst Rev*. 2009 Jul 8;(3): CD004349. [PMID: 19588353]
- Bangalore S et al. Blood pressure targets in subjects with type 2 diabetes mellitus/impaired fasting glucose: observations from traditional and bayesian random-effects meta-analyses of randomized trials. *Circulation*. 2011 Jun 21;123(24):2776–8. [PMID: 21632497]
- Julius S et al; Trial of Preventing Hypertension (TROPHY) Study Investigators. Feasibility of treating prehypertension with an angiotensin-receptor blocker. *N Engl J Med*. 2006 Apr 20; 354(16):1685–97. [PMID: 16537662]
- Sever PS et al; ASCOT Investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. *Lancet*. 2003 Apr 5;361(9364):1149–58. [PMID: 12686036]
- Sever P et al; ASCOT Steering Committee Members. Potential synergy between lipid-lowering and blood-pressure-lowering in the Anglo-Scandinavian Cardiac Outcomes Trial. *Eur Heart J*. 2006 Dec;27(24):2982–8. [PMID: 17145722]
- Towfighi A et al. The (pre)hypertension limbo: is it time to lower the treatment bar? *Neurology*. 2011 Oct 4;77(14):1322–3. [PMID: 21956719]
- Turnbull F et al; Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. *Arch Intern Med*. 2005 Jun 27;165(12):1410–9. [PMID: 15983291]
- Williams B et al. Systolic pressure is all that matters. *Lancet*. 2008 Jun 28;371(9631):2219–21. [PMID: 18561995]

DRUG THERAPY: CURRENT ANTIHYPERTENSIVE AGENTS

There are now many classes of potentially antihypertensive drugs of which six (diuretics, β -blockers, renin inhibitors, ACE inhibitors, calcium channel blockers, and ARBs) are suitable for initial therapy based on efficacy and tolerability. A number of considerations enter into the selection of the initial regimen for a given patient. These include the weight of evidence for beneficial effects on clinical outcomes, the safety and tolerability of the drug, its cost, demographic differences in response, concomitant medical conditions, and lifestyle issues. The specific classes of antihypertensive medications are discussed below, and guidelines for the choice of initial medications are offered.

A. Diuretics

Thiazide diuretics (Table 11–6) are the antihypertensives that have been most extensively studied and most consistently effective in clinical trials. They lower blood pressure initially by decreasing plasma volume, but during long-term therapy, their major hemodynamic effect is reduction of peripheral vascular resistance. Most of the

Table 11-6. Antihypertensive drugs: Diuretics.

Drugs	Proprietary Names	Initial Oral Doses	Dosage Range	Cost per Unit	Cost of 30 Days Treatment ¹ (Average Dosage)	Adverse Effects	Comments
Thiazides and related diuretics							
Hydrochlorothiazide	Esidrix, Microzide	12.5 or 25 mg once daily	12.5–50 mg once daily	\$0.08/25 mg	\$2.40	↓ K ⁺ , ↓ Mg ²⁺ , ↑ Ca ²⁺ , ↓ Na ⁺ , ↑ uric acid, ↑ glucose, ↑ LDL cholesterol, ↑ triglycerides; rash, erectile dysfunction.	Low dosages effective in many patients without associated metabolic abnormalities; metolazone more effective with concurrent kidney disease; indapamide does not alter serum lipid levels.
Chlorthalidone	Thalitone	12.5 or 25 mg once daily	12.5–50 mg once daily	\$0.50/25 mg	\$15.00		
Metolazone	Zaroxolyn	1.25 or 2.5 mg once daily	1.25–5 mg once daily	\$1.48/5 mg	\$44.40		
Indapamide	Lozol	2.5 mg once daily	2.5–5 mg once daily	\$0.83/2.5 mg	\$24.90		
Loop diuretics							
Furosemide	Lasix	20 mg twice daily	40–320 mg in 2 or 3 doses	\$0.16/40 mg	\$9.60	Same as thiazides, but higher risk of excessive diuresis and electrolyte imbalance. Increases calcium excretion.	Furosemide: Short duration of action a disadvantage; should be reserved for patients with kidney disease or fluid retention. Poor antihypertensive.
Ethacrynic acid	Edecrin	50 mg once daily	50–100 mg once or twice daily	\$4.29/25 mg	\$514.80		
Bumetanide	Bumex	0.25 mg twice daily	0.5–10 mg in 2 or 3 doses	\$0.45/1 mg	\$27.00		
Torsemide	Demadex	2.5 mg once daily	5–10 mg once daily	\$0.70/10 mg	\$21.00		Torsemide: Effective blood pressure medication at low dosage.
Aldosterone receptor blockers							
Spironolactone	Aldactone	12.5 or 25 mg once daily	12.5–100 mg once daily	\$0.46/25 mg	\$13.80	Hyperkalemia, metabolic acidosis, gynecomastia.	Can be useful add-on therapy in patients with refractory hypertension.
Amiloride	Midamor	5 mg once daily	5–10 mg once daily	\$1.29/5 mg	\$38.70		
Eplerenone	Inspra	25 mg once daily	25–100 mg once daily	\$4.10/25 mg	\$123.07		
Combination products							
Hydrochlorothiazide and triamterene	Dyazide (25/50 mg); Maxzide (25/37.5 mg; 50/75 mg)	1 tab once daily	1 or 2 tabs once daily	\$0.39	\$11.70	Same as thiazides plus GI disturbances, hyperkalemia rather than hypokalemia, headache; triamterene can cause kidney stones and kidney dysfunction; spironolactone causes gynecomastia. Hyperkalemia can occur if this combination is used in patients with advanced kidney disease or those taking ACE inhibitors.	Use should be limited to patients with demonstrable need for a potassium-sparing agent.
Hydrochlorothiazide and amiloride	Moduretic (50/5 mg)	½ tab once daily	1 or 2 tabs once daily	\$0.33	\$9.90		
Hydrochlorothiazide and spironolactone	Aldactazide (25/25 mg; 50/50 mg)	1 tab [25/25 mg] once daily	1 or 2 tabs once daily	\$0.50	\$15.00		

¹Average wholesale price (AWP, for AB-rated generic when available) for quantity listed.

Source: Red Book Online, 2012, Thomson Reuters (Healthcare), Inc. AWP may not accurately represent the actual pharmacy cost because wide contractual variations exist among institutions.

ACE, angiotensin-converting enzyme; GI, gastrointestinal; LDL, low-density lipoprotein.

antihypertensive effect of these agents is achieved at lower dosages than used previously (typically, 12.5 mg of hydrochlorothiazide or equivalent), but their biochemical and metabolic effects are dose related. Chlorthalidone has the advantage of better 24-hour blood pressure control than hydrochlorothiazide. The loop diuretics (such as furosemide) may lead to electrolyte and volume depletion more readily than the thiazides and have short durations of action; therefore, loop diuretics should not be used in hypertension except in the presence of kidney dysfunction (serum creatinine > 2.5 mg/dL [208.3 μmol/L]). Relative to β-blockers and ACE inhibitors, diuretics are more potent in blacks, older individuals, the obese, and other subgroups with increased plasma volume or low plasma renin activity (or both). Interestingly, they are relatively more effective in smokers than in nonsmokers. Long-term thiazide administration also mitigates the loss of bone mineral content in older women at risk for osteoporosis.

Overall, diuretics administered alone control blood pressure in 50% of patients with mild to moderate hypertension and can be used effectively in combination with all other agents. They are also useful for lowering isolated or predominantly systolic hypertension. The adverse effects of diuretics relate primarily to the metabolic changes listed in Table 11–6. Erectile dysfunction, skin rashes, and photosensitivity are less frequent. Hypokalemia has been a concern but is uncommon at the recommended dosages. The risk can be minimized by limiting dietary salt or increasing dietary potassium; potassium replacement is not usually required to maintain serum K⁺ at >3.5 mmol/L. Higher serum K⁺ levels are prudent in patients at special risk from intracellular potassium depletion, such as those taking digoxin or with a history of ventricular arrhythmias in which case a potassium-sparing agent could be used. Compared with ACE inhibitors and ARBs, diuretic therapy is associated with a slightly higher incidence of mild new-onset diabetes. Diuretics also increase serum uric acid and may precipitate gout. Increases in blood glucose, triglycerides, and LDL cholesterol may occur but are relatively minor during long-term low-dose therapy.

B. β-Adrenergic Blocking Agents

These drugs are effective in hypertension because they decrease the heart rate and cardiac output. Even after continued use of β-blockers, cardiac output remains lower and systemic vascular resistance higher with agents that do not have intrinsic sympathomimetic or α-blocking activity. The β-blockers also decrease renin release and are more efficacious in populations with elevated plasma renin activity, such as younger white patients. They neutralize the reflex tachycardia caused by vasodilators and are especially useful in patients with associated conditions that benefit from the cardioprotective effects of these agents. These include individuals with angina pectoris, previous myocardial infarction, and stable congestive heart failure as well as those with migraine headaches and somatic manifestations of anxiety.

Although all β-blockers appear to be similar in antihypertensive potency, they differ in a number of pharmacologic properties (these differences are summarized in

Table 11–7), including specificity to the cardiac β₁-receptors (cardioselectivity) and whether they also block the β₂-receptors in the bronchi and vasculature; at higher dosages, however, all agents are nonselective. The β-blockers also differ in their pharmacokinetics, lipid solubility—which determines whether they cross the blood–brain barrier and affect the incidence of central nervous system side effects—and route of metabolism. Unlike the traditional β-blockers, carvedilol and nebivolol also diminish peripheral vascular resistance. The implications of this distinction are discussed below.

The side effects of all β-blockers include inducing or exacerbating bronchospasm in predisposed patients; sinus node dysfunction and atrioventricular (AV) conduction depression (resulting in bradycardia or AV block); nasal congestion; Raynaud phenomenon; and central nervous system symptoms with nightmares, excitement, depression, and confusion. Fatigue, lethargy, and erectile dysfunction may occur. The traditional β-blockers (but not the vasodilator β-blockers carvedilol and nebivolol) have an adverse effect on lipids and glucose metabolism. β-Blockers have traditionally been considered contraindicated in patients with congestive heart failure. Evolving experience suggests that they have a propitious effect on the natural history of patients with chronic stable heart failure and reduced ejection fraction (see Chapter 10). β-Blockers are used cautiously in patients with type 1 diabetes, since they can mask the symptoms of hypoglycemia and prolong these episodes by inhibiting gluconeogenesis. These drugs should also be used with caution in patients with advanced peripheral vascular disease associated with rest pain or nonhealing ulcers, but they are generally well tolerated in patients with mild claudication. In treatment of pheochromocytoma, β-blockers should not be administered until α-blockade has been established. Otherwise, blockade of vasodilatory β₂-adrenergic receptors will allow unopposed vasoconstrictor α-adrenergic receptor activation with worsening of hypertension. For the same reason, β-blockers should not be used to treat hypertension arising from cocaine use.

Because of the lack of efficacy in prevention of myocardial infarction and inferiority compared with other drugs in prevention of stroke and left ventricular hypertrophy, there is now increasing doubt whether traditional β-blockers should still be regarded as ideal first-line agents in the treatment of hypertension without specific compelling indications (such as active coronary artery disease). In addition to adverse metabolic changes associated with their use, some experts have suggested that the therapeutic shortcomings of traditional β-blockers are the consequence of the particular hemodynamic profile associated with these drugs. Pressure peaks in the aorta are augmented by reflection of pressure waves from the peripheral circulation. These reflected waves are delayed in patients taking ACE inhibitors and thiazide diuretics, resulting in decreased systolic and pulse pressures. By contrast, traditional β-blockers appear to potentiate reflection of pressure waves, possibly because peripheral resistance vessels are a reflection point and peripheral resistance is increased by these drugs. This might explain why the traditional

Table 11-7. Antihypertensive drugs: β -Adrenergic blocking agents.

Drug	Proprietary Name	Initial Oral Dosage	Dosage Range	Cost per Unit	Cost of 30 Days Treatment (Based on Average Dosage) ¹	Special Properties					Comments ⁵
						β_1 Selectivity ²	ISA ³	MSA ⁴	Lipid Solubility	Renal vs Hepatic Elimination	
Acebutolol	Sectral	400 mg once daily	200–1200 mg in 1 or 2 doses	\$1.01/400 mg	\$30.30	+	+	+	+	H > R	Positive ANA; rare LE syndrome; also indicated for arrhythmias. Doses > 800 mg have β_1 and β_2 effects.
Atenolol	Tenormin	25 mg once daily	25–100 mg once daily	\$0.85/50 mg	\$25.50	+	0	0	0	R	Also indicated for angina pectoris and post-MI. Doses > 100 mg have β_1 and β_2 effects.
Betaxolol	Kerlone	10 mg once daily	10–40 mg once daily	\$1.24/10 mg	\$37.20	+	0	0	+	H > R	
Bisoprolol and hydrochlorothiazide	Ziac	2.5 mg/6.25 mg once daily	2.5 mg/6.25 mg–10 mg/6.25 mg once daily	\$1.14/2.5/6.25 mg	\$34.20	+	0	0	0	R = H	Low-dose combination approved for initial therapy. Bisoprolol also effective for heart failure.
Carvedilol	Coreg	6.25 mg twice daily	12.5–50 mg in 2 doses	\$2.13/25 mg	\$127.80 (25 mg twice a day)	0	0	0	+++	H > R	α : β -Blocking activity 1:9; may cause orthostatic symptoms; effective for congestive heart failure. Nitric oxide potentiating vasodilatory activity.
Labetalol	Normodyne, Trandate	100 mg twice daily	200–2400 mg in 2 doses	\$0.71/200 mg	\$42.60	0	0/+	0	++	H	α : β -Blocking activity 1:3; more orthostatic hypotension, fever, hepatotoxicity.
Metoprolol	Lopressor	50 mg twice daily	50–200 mg twice daily	\$0.53/50 mg	\$31.80	+	0	+	+++	H	Also indicated for angina pectoris and post-MI. Approved for heart failure. Doses > 100 mg have β_1 and β_2 effects.
	Toprol XL (SR preparation)	25 mg once daily	25–400 mg once daily	\$1.44/100 mg	\$43.20						

(continued)

Table 11-7. Antihypertensive drugs: β -Adrenergic blocking agents. (continued)

Drug	Proprietary Name	Initial Oral Dosage	Dosage Range	Cost per Unit	Cost of 30 Days Treatment (Based on Average Dosage) ¹	Special Properties					Comments ⁵
						β_1 Selectivity ²	ISA ³	MSA ⁴	Lipid Solubility	Renal vs Hepatic Elimination	
Metoprolol and hydrochlorothiazide	Lopressor HCT	50 mg/25 mg once daily	50 mg/25 mg-200 mg/50 mg	\$1.13/50 mg/25 mg	\$33.90	+	0	+	+++	H	
Nadolol	Corgard	20 mg once daily	20-320 mg once daily	\$1.05/40 mg	\$31.50	0	0	0	0	R	
Nebivolol	Bystolic	5 mg once daily	40 mg once daily	\$2.27/5 mg	\$68.10	+	0	0	++	H	Nitric oxide potentiating vasodilatory activity.
Penbutolol	Levitol	20 mg once daily	20-80 mg once daily	\$3.73/20 mg	\$111.90	0	+	0	++	R > H	
Pindolol	Visken	5 mg twice daily	10-60 mg in 2 doses	\$0.89/5 mg	\$53.40	0	++	+	+	H > R	In adults, 35% renal clearance.
Propranolol	Inderal	20 mg twice daily	40-640 mg in 2 doses	\$0.51/40 mg	\$30.60	0	0	++	+++	H	Once-daily SR preparation also available. Also indicated for angina pectoris and post-MI.
Timolol	Blocadren	5 mg twice daily	10-60 mg in 2 doses	\$0.59/10 mg	\$35.40	0	0	0	++	H > R	Also indicated for post-MI. 80% hepatic clearance.

¹Average wholesale price (AWP, for AB-rated generic when available) for quantity listed.

Source: *Red Book Online 2012*, Thomson Reuters (Healthcare) Inc. AWP may not accurately represent the actual pharmacy cost because wide contractual variations exist among institutions.

²Agents with β_1 selectivity are less likely to precipitate bronchospasm and decreased peripheral blood flow *in low doses*, but selectivity is only relative.

³Agents with ISA cause less resting bradycardia and lipid changes.

⁴MSA generally occurs at concentrations greater than those necessary for β -adrenergic blockade. The clinical importance of MSA by β -blockers has not been defined.

⁵Adverse effects of all β -blockers: bronchospasm, fatigue, sleep disturbance and nightmares, bradycardia and atrioventricular block, worsening of congestive heart failure, cold extremities, gastrointestinal disturbances, erectile dysfunction, \uparrow triglycerides, \downarrow HDL cholesterol, rare blood dyscrasias.

ANA, antinuclear antibody; ISA, intrinsic sympathomimetic activity; LE, lupus erythematosus; MI, myocardial infarction; MSA, membrane-stabilizing activity; SR, sustained release; 0, no effect; +, some effect; ++, moderate effect; +++, most effect.

β -blockers are less effective at controlling systolic and pulse pressure.

Despite these concerns, the compelling indications for β -blockers remain, such as active coronary artery disease and impaired left ventricular function. Great care should be exercised if the decision is made, in the absence of compelling indications, to remove β -blockers from the treatment regimen since abrupt withdrawal can precipitate acute coronary events and severe increases in blood pressure.

C. Renin Inhibitors

Since renin cleavage of angiotensinogen is the rate-limiting step in the renin-angiotensin cascade, the most efficient inactivation of this system would be expected with renin inhibition. Conventional ACE inhibitors and ARBs probably offer incomplete blockade, even in combination. Aliskiren, a renin inhibitor, binds the proteolytic site of renin, thereby preventing cleavage of angiotensinogen. As a consequence, levels of angiotensins I and II are reduced and renin concentration is increased. Aliskiren is synergistic with diuretics, ACE inhibitors, and ARBs in lowering blood pressure. As yet there is no trial data establishing the impact of aliskiren on cardiovascular events or mortality, but it is an effective and well-tolerated antihypertensive agent.

D. Angiotensin-Converting Enzyme Inhibitors

ACE inhibitors are being increasingly used as the initial medication in mild to moderate hypertension (Table 11–8). Their primary mode of action is inhibition of the renin-angiotensin-aldosterone system, but they also inhibit bradykinin degradation, stimulate the synthesis of vasodilating prostaglandins and, sometimes, reduce sympathetic nervous system activity. These latter actions may explain why they exhibit some effect even in patients with low plasma renin activity. ACE inhibitors appear to be more effective in younger white patients. They are relatively less effective in blacks and older persons and in predominantly systolic hypertension. Although as single therapy they achieve adequate antihypertensive control in only about 40–50% of patients, the combination of an ACE inhibitor and a diuretic or calcium channel blocker is potent.

ACE inhibitors are the agents of choice in persons with type 1 diabetes with frank proteinuria or evidence of kidney dysfunction because they delay the progression to end-stage kidney disease. Many authorities have expanded this indication to include persons with type 2 diabetes and those who have type 1 diabetes with microalbuminuria, even when they do not meet the usual criteria for antihypertensive therapy. ACE inhibitors may also delay the progression of nondiabetic kidney disease. The Heart Outcomes Prevention Evaluation (HOPE) trial demonstrated that the ACE inhibitor ramipril reduced the number of cardiovascular deaths, nonfatal myocardial infarctions, and nonfatal strokes and also reduced the incidence of new-onset heart failure, kidney dysfunction, and new-onset diabetes in a population of patients at high risk for vascular events. Although this was not specifically a hypertensive population, the benefits were associated with a modest reduction in blood pressure, and the results inferentially support the use of ACE inhibitors in

similar hypertensive patients. ACE inhibitors are a drug of choice (usually in conjunction with a diuretic and a β -blocker) in patients with congestive heart failure and are indicated also in asymptomatic patients with reduced ejection fraction. An advantage of the ACE inhibitors is their relative freedom from troublesome side effects. Severe hypotension can occur in patients with bilateral renal artery stenosis; acute renal failure may ensue but is usually reversible with discontinuation of ACE inhibition. Hyperkalemia may develop in patients with intrinsic kidney disease and type IV renal tubular acidosis (commonly seen in diabetics) and in the elderly. A chronic dry cough is common, seen in 10% of patients or more, and may require stopping the drug. Skin rashes are observed with any ACE inhibitor. Angioedema is an uncommon but potentially dangerous side effect of all agents of this class because of their inhibition of kininase. Exposure of the fetus to ACE inhibitors during the second and third trimesters of pregnancy has been associated with a variety of defects due to hypotension and reduced renal blood flow.

E. Angiotensin II Receptor Blockers

ARBs can improve cardiovascular outcomes in patients with hypertension as well as in patients with related conditions such as heart failure and type 2 diabetes with nephropathy. ARBs have not been compared with ACE inhibitors in randomized controlled trials in patients with hypertension, but two trials comparing losartan with captopril in heart failure and post-myocardial infarction left ventricular dysfunction showed trends toward worse outcomes in the losartan group. Whether this suggestion of reduced efficacy is specific to losartan or may also be true for other ARBs is as yet unknown. However, the Losartan Intervention for Endpoints (LIFE) trial in nearly 9000 hypertensive patients with electrocardiographic evidence of left ventricular hypertrophy—comparing losartan with the β -blocker atenolol as initial therapy—demonstrated a significant reduction in stroke with losartan. Of note is that in diabetic patients, death and myocardial infarction were also reduced, and there was a lower occurrence of new-onset diabetes. In this trial, as in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT), blacks treated with renin-angiotensin-aldosterone system (RAAS) inhibitors exhibited less blood pressure reduction and less benefit with regard to clinical end points. ARBs may synergize with ACE inhibitors in protection of heart and kidney, and ARB/ACE inhibitor combinations may also improve control of hypertension.

Unlike ACE inhibitors, the ARBs do not cause cough and are less likely to be associated with skin rashes or angioedema. However, as seen with ACE inhibitors, hyperkalemia can be a problem, and patients with bilateral renal artery stenosis may exhibit hypotension and worsened kidney function.

F. Aldosterone Receptor Antagonists

Spironolactone and eplerenone are natriuretic in sodium-retaining states, such as heart failure and cirrhosis, but only

Table 11–8. Antihypertensive drugs: Renin and ACE inhibitors and angiotensin II receptor blockers.

Drug	Proprietary Name	Initial Oral Dosage	Dosage Range	Cost per Unit	Cost of 30 Days Treatment (Average Dosage) ¹	Adverse Effects	Comments
Renin inhibitors							
Aliskiren	Tekturna	150 mg once daily	150–300 mg once daily	\$3.28/150 mg	\$98.40	Angioedema, hypotension, hyperkalemia Contraindicated in pregnancy.	Probably metabolized by CYP3A4. Absorption is inhibited by high fat meal.
Aliskiren and HCTZ	Tekturna HCT	150 mg/12.5 mg once daily	150 mg/12.5 mg–300 mg/25 mg once daily	\$3.30/150 mg/12.5 mg	\$99.00		
ACE inhibitors							
Benazepril	Lotensin	10 mg once daily	5–40 mg in 1 or 2 doses	\$1.05/20 mg	\$31.50	Cough, hypotension, dizziness, kidney dysfunction, hyperkalemia, angioedema; taste alteration and rash (may be more frequent with captopril); rarely, proteinuria, blood dyscrasia. Contraindicated in pregnancy.	More fosinopril is excreted by the liver in patients with renal dysfunction (dose reduction may or may not be necessary). Captopril and lisinopril are active without metabolism. Captopril, enalapril, lisinopril, and quinapril are approved for congestive heart failure.
Benazepril and HCTZ	Lotensin HCT	5 mg/6.25 mg once daily	5 mg/6.25 mg–20 mg/25 mg	\$1.05/any dose	\$31.50		
Benazepril and amlodipine	Lotrel	10 mg/2.5 mg once daily	10 mg/2.5 mg–40 mg/10 mg	\$3.32/20 mg/10 mg	\$99.60		
Captopril	Capoten	25 mg twice daily	50–450 mg in 2 or 3 doses	\$0.75/25 mg	\$45.00		
Captopril and HCTZ	Capozide	25 mg/15 mg twice daily	25 mg/15 mg–50 mg/25 mg	\$0.72/25 mg/15 mg	\$43.20		
Enalapril	Vasotec	5 mg once daily	5–40 mg in 1 or 2 doses	\$1.52/20 mg	\$45.60		
Enalapril and HCTZ	Vaseretic	5 mg/12.5 mg once daily	5 mg/12.5 mg–10 mg/25 mg	\$1.19/10 mg/25 mg	\$35.70		
Fosinopril	Monopril	10 mg once daily	10–80 mg in 1 or 2 doses	\$1.19/20 mg	\$35.70		
Fosinopril and HCTZ	Monopril HCT	10 mg/12.5 mg once daily	10 mg/12.5 mg–20 mg/12.5 mg	\$1.26/any dose	\$37.80		
Lisinopril	Prinivil, Zestril	5–10 mg once daily	5–40 mg once daily	\$1.06/20 mg	\$31.80		
Lisinopril and HCTZ	Prinzide or Zestoretic	10 mg/12.5 mg once daily	10 mg/12.5 mg–20 mg/12.5 mg	\$1.20/20 mg/12.5 mg	\$36.00		
Moexipril	Univasc	7.5 mg once daily	7.5–30 mg in 1 or 2 doses	\$1.01/7.5 mg	\$30.30		
Moexipril and HCTZ	Uniretic	7.5 mg/12.5 mg once daily	7.5 mg/12.5 mg–15 mg/25 mg	\$1.34/7.5 mg/12.5 mg	\$40.20		
Perindopril	Aceon	4 mg once daily	4–16 mg in 1 or 2 doses	\$2.69/8 mg	\$80.70		
Quinapril	Accupril	10 mg once daily	10–80 mg in 1 or 2 doses	\$1.22/20 mg	\$36.60		

Quinapril and HCTZ	Accuretic	10 mg/12.5 mg once daily	10 mg/12.5 mg-20 mg/25 mg	\$1.22/20 mg/12.5	\$36.60		
Ramipril	Altace	2.5 mg once daily	2.5-20 mg in 1 or 2 doses	\$1.89/5 mg	\$56.70		
Trandolapril	Mavik	1 mg once daily	1-8 mg once daily	\$1.24/4 mg	\$37.20		
Trandolapril and verapamil	Tarka	2 mg/180 mg ER once daily	2 mg/180 mg ER-8 mg/480 mg ER	\$3.12/any dose	\$93.60		
Angiotensin II receptor blockers							
Candesartan cilexetil	Atacand	16 mg once daily	8-32 mg once daily	\$3.05/16 mg	\$91.50	Hyperkalemia, kidney dysfunction, rare angioedema. Combinations have additional side effects. Contraindicated in pregnancy.	Losartan has a very flat dose-response curve. Valsartan and irbesartan have wider dose-response ranges and longer durations of action. Addition of low-dose diuretic (separately or as combination pills) increases the response.
Candesartan cilexetil/HCTZ	Atacand HCT	16 mg/12.5 mg once daily	32 mg/12.5 mg once daily	\$4.13/16 mg/12.5 mg	\$123.90		
Eprosartan	Teveten	600 mg once daily	400-800 mg in 1-2 doses	\$4.19/600 mg	\$125.70		
Eprosartan/HCTZ	Teveten HCT	600 mg/12.5 mg once daily	600 mg/12.5 mg-600 mg/25 mg once daily	\$4.44/600 mg/12.5 mg	\$133.20		
Irbesartan	Avapro	150 mg once daily	150-300 mg once daily	\$3.41/150 mg	\$102.30		
Irbesartan and HCTZ	Avalide	150 mg/12.5 mg once daily	150-300 mg irbesartan once daily	\$4.13/150 mg	\$123.90		
Losartan	Cozaar	50 mg once daily	25-100 mg in 1 or 2 doses	\$2.42/50 mg	\$72.60		
Losartan and HCTZ	Hyzaar	50 mg/12.5 mg once daily	50 mg/12.5 mg-100 mg/25 mg tablets once daily	\$2.67/50 mg/12.5 mg/tablet	\$80.10		
Olmesartan	Benicar	20 mg once daily	20-40 mg once daily	\$3.46/20 mg	\$103.80		
Olmesartan and HCTZ	Benicar HCT	20 mg/12.5 mg once daily	20 mg/12.5 mg-40 mg/25 mg once daily	\$3.46/20 mg/12.5 mg	\$103.80		
Olmesartan and amlodipine	Azor	20 mg/5 mg once daily	20 mg/5 mg-40 mg/10 mg	\$4.31/20 mg/5 mg	\$129.30		
Olmesartan and amlodipine and HCTZ	Tribenzor	20 mg/5 mg/12.5 mg once daily	20 mg/5 mg/12.5 mg-40 mg/10 mg/25 mg once daily	\$4.31/20 mg/5 mg/12.5 mg	\$129.30		
Telmisartan	Micardis	40 mg once daily	20-80 mg once daily	\$4.51/40 mg	\$135.30		
Telmisartan and HCTZ	Micardis HCT	40 mg/12.5 mg once daily	40 mg/12.5 mg-80 mg/25 mg once daily	\$4.51/40 mg/12.5 mg	\$135.30		

(continued)

Table 11–8. Antihypertensive drugs: Renin and ACE inhibitors and angiotensin II receptor blockers. (continued)

Drug	Proprietary Name	Initial Oral Dosage	Dosage Range	Cost per Unit	Cost of 30 Days Treatment (Average Dosage) ¹	Adverse Effects	Comments
Telmisartan and amlodipine	Twynsta	40 mg/5 mg once daily	40 mg/5 mg–80 mg/10 mg once daily	\$4.85/any dose	\$145.50	Hyperkalemia, kidney dysfunction, rare angioedema. Combinations have additional side effects. Contraindicated in pregnancy.	Losartan has a very flat dose-response curve. Valsartan and irbesartan have wider dose-response ranges and longer durations of action. Addition of low-dose diuretic (separately or as combination pills) increases the response.
Valsartan	Diovan	80 mg once daily	80–320 mg once daily	\$3.99/160 mg	\$119.70		
Valsartan and HCTZ	Diovan HCT	80 mg/12.5 mg once daily	80–320 mg valsartan once daily	\$4.35/160 mg/12.5 mg	\$130.50		
Valsartan and amlodipine	Exforge	160 mg/5 mg once daily	160 mg/5 mg–320 mg/10 mg once daily	\$4.97/160 mg/10 mg	\$149.10		
Other combination products							
Aliskiren and valsartan	Valturna	150 mg/160 mg once daily	150 mg/160 mg–300 mg/320 mg once daily	\$4.13/300 mg/320 mg	\$123.90	Angioedema, hypotension, hyperkalemia Contraindicated in pregnancy.	
Amlodipine/HCTZ/valsartan	Exforge HCT	5 mg/12.5 mg/160 mg once daily	10 mg/25 mg/320 mg up to once daily	\$4.97/160 mg valsartan	\$149.10	Angioedema, hypotension, hyperkalemia Contraindicated in pregnancy.	

¹Average wholesale price (AWP, for AB-rated generic when available) for quantity listed.

Source: *Red Book Online*, 2012, Thomson Reuters (Healthcare) Inc. AWP may not accurately represent the actual pharmacy cost because wide contractual variations exist among institutions. ACE, angiotensin-converting enzyme; HCTZ, hydrochlorothiazide.

very weakly so in hypertension. These drugs have reemerged in the treatment of hypertension, particularly in resistant patients and are helpful additions to most other antihypertensive medications. Consistent with the increasingly appreciated importance of aldosterone in essential hypertension, the aldosterone receptor blockers are effective at lowering blood pressure in all hypertensive patients regardless of renin level, and are also effective in blacks. Aldosterone plays a central role in target organ damage, including the development of ventricular and vascular hypertrophy and renal fibrosis. Aldosterone receptor antagonists ameliorate these consequences of hypertension, to some extent independently of effects on blood pressure. Spironolactone can cause breast pain and gynecomastia in men through activity at the progesterone receptor, an effect not seen with the more specific eplerenone. Hyperkalemia is a problem with both drugs, chiefly in patients with chronic kidney disease.

G. Calcium Channel Blocking Agents

These agents act by causing peripheral vasodilation but with less reflex tachycardia and fluid retention than other vasodilators. They are effective as single-drug therapy in approximately 60% of patients in all demographic groups and all grades of hypertension (Table 11–9). For these reasons, they may be preferable to β -blockers and ACE inhibitors in blacks and older persons. Verapamil and diltiazem should be combined cautiously with β -blockers because of their potential for depressing AV conduction and sinus node automaticity as well as contractility.

Initial concerns about possible adverse cardiac effects of calcium channel blockers have been convincingly allayed by several subsequent large studies which have demonstrated that calcium channel blockers are equivalent to ACE inhibitors and thiazide diuretics in prevention of coronary heart disease, major cardiovascular events, cardiovascular death, and total mortality. A protective effect against stroke with calcium channel blockers is well established, and in two trials (ALLHAT and the Systolic Hypertension in Europe trial), these agents appeared to be more effective than diuretic-based therapy.

The most common side effects of calcium channel blockers are headache, peripheral edema, bradycardia, and constipation (especially with verapamil in the elderly). The dihydropyridine agents—nifedipine, nicardipine, isradipine, felodipine, nisoldipine, and amlodipine—are more likely to produce symptoms of vasodilation, such as headache, flushing, palpitations, and peripheral edema. Calcium channel blockers have negative inotropic effects and should be used cautiously in patients with cardiac dysfunction. Amlodipine is the only calcium channel blocker with established safety in patients with severe heart failure.

H. α -Adrenoceptor Antagonists

Prazosin, terazosin, and doxazosin (Table 11–10) block postsynaptic α -receptors, relax smooth muscle, and reduce blood pressure by lowering peripheral vascular resistance. These agents are effective as single-drug therapy in some individuals, but tachyphylaxis may appear during long-term

therapy and side effects are relatively common. These include marked hypotension after the first dose which, therefore, should be small and given at bedtime. Post-dosing palpitations, headache, and nervousness may continue to occur during long-term therapy; these symptoms may be less frequent or severe with doxazosin because of its more gradual onset of action. Cataractectomy in patients exposed to α -blockers can be complicated by the floppy iris syndrome, even after discontinuation of the drug, so the ophthalmologist should be alerted that the patient has been taking the drug prior to surgery.

Unlike the β -blockers and diuretics, the α -blockers have no adverse effect on serum lipid levels—in fact, they increase HDL cholesterol while reducing total cholesterol. Whether this is beneficial in the long term has not been established. In ALLHAT, persons receiving doxazosin as initial therapy had a significant increase in heart failure hospitalizations and a higher incidence of stroke relative to the persons receiving diuretics, prompting discontinuation of this arm of the study. To summarize, α -blockers should generally not be used as initial agents to treat hypertension—except perhaps in men with symptomatic prostatism.

I. Drugs with Central Sympatholytic Action

Methyldopa, clonidine, guanabenz, and guanfacine (Table 11–10) lower blood pressure by stimulating α -adrenergic receptors in the central nervous system, thus reducing efferent peripheral sympathetic outflow. These agents are effective as single therapy in some patients, but they are usually used as second- or third-line agents because of the high frequency of drug intolerance, including sedation, fatigue, dry mouth, postural hypotension, and erectile dysfunction. An important concern is rebound hypertension following withdrawal. Methyldopa also causes hepatitis and hemolytic anemia and is avoided except in individuals who have already tolerated long-term therapy. There is considerable experience with methyldopa in pregnant women, and it is still used for this population. Clonidine is available in patches, which may have particular value in patients in whom compliance is a troublesome issue.

J. Arteriolar Dilators

Hydralazine and minoxidil (Table 11–10) relax vascular smooth muscle and produce peripheral vasodilation. When given alone, they stimulate reflex tachycardia, increase myocardial contractility, and cause headache, palpitations, and fluid retention. They are usually given in combination with diuretics and β -blockers in resistant patients. Hydralazine produces frequent gastrointestinal disturbances and may induce a lupus-like syndrome. Minoxidil causes hirsutism and marked fluid retention; this agent is reserved for the most refractory of cases.

K. Peripheral Sympathetic Inhibitors

These agents are now used infrequently and usually in refractory hypertension. Reserpine remains a cost-effective antihypertensive agent (Table 11–10). Its reputation for

Table 11-9. Antihypertensive drugs: Calcium channel blocking agents.

Drug	Proprietary Name	Initial Oral Dosage	Dosage Range	Cost of 30 Days Treatment (Average Dosage) ¹	Special Properties			Adverse Effects	Comments
					Peripheral Vasodilation	Cardiac Automaticity and Conduction	Contractility		
Nondihydropyridine agents									
Diltiazem	Cardizem SR	90 mg twice daily	180-360 mg in 2 doses	\$94.80 (120 mg twice daily)	++	↓↓	↓↓	Edema, headache, bradycardia, GI disturbances, dizziness, AV block, congestive heart failure, urinary frequency.	Also approved for angina.
	Cardizem CD; Cartia XT	180 mg once daily	180-360 mg once daily	\$42.90 (240 mg once daily)					
	Dilacor XR	180 or 240 mg once daily	180-480 mg once daily	\$19.20 (240 mg once daily)					
	Tiazac SA	240 mg once daily	180-540 mg once daily	\$50.10 (240 mg once daily)					
	Taztia XT	180 mg once daily	120-540 mg once daily						
Verapamil	Calan SR	180 mg once daily	180-480 mg in 1 or 2 doses	\$48.90 (240 mg once daily)	++	↓↓↓	↓↓↓	Same as diltiazem but more likely to cause constipation and congestive heart failure.	Also approved for angina and arrhythmias.
	Covera HS	240 mg once daily							
	Verelan	200 mg ER once daily	100-400 mg ER once daily	\$164.40 (200 mg once daily)					
Verelan PM									
Dihydropyridines									
Amlodipine	Norvasc	2.5 mg once daily	2.5-10 mg once daily	\$71.10 (10 mg once daily)	+++	↓/0	↓/0	Edema, dizziness, palpitations, flushing, headache, hypotension, tachycardia, GI disturbances, urinary frequency, worsening of congestive heart failure (may be less common with felodipine, amlodipine).	Amlodipine, nifedipine, and nifedipine also approved for angina.
Amlodipine and atorvastatin	Caduet	2.5 mg/10 mg once daily	10 mg/80 mg once daily	\$206.70 (10 mg/40 mg daily)	+++	↓/0	↓/0		
Felodipine	Plendil	5 mg ER once daily	5-10 mg ER once daily	\$81.60 (10 mg ER daily)	+++	↓/0	↓/0		
Isradipine	DynaCirc	2.5 mg twice daily	2.5-5 mg twice daily	\$102.00 (5 mg twice daily)	+++	↓/0	↓		
	DynaCirc CR	5 mg ER once daily	5-20 mg ER once daily	\$140.38 (10 mg ER once daily)					

Nicardipine	Cardene	20 mg three times daily	20-40 mg three times daily	\$45.90 (20 mg three times daily)	+++	↓/0	↓		
	Cardene SR	30 mg twice daily	30-60 mg twice daily	\$119.65 (30 mg twice daily)					
Nifedipine	Adalat CC	30 mg once daily	30-120 mg once daily	\$86.10 (60 mg once daily)	+++	↓	↓↓		
	Procardia XL	30 mg once daily	30-120 mg once daily	\$70.80 (60 mg once daily)					
Nisoldipine	Sular	20 mg daily	20-60 mg daily	\$228.00 (40 mg once daily)	+++	↓/0	↓		

¹Average wholesale price (AWP, for AB-rated generic when available) for quantity listed.

Source: *Red Book Online*, 2012, Thomson Reuters (Healthcare) Inc. AWP may not accurately represent the actual pharmacy cost because wide contractual variations exist among institutions. AV, atrioventricular; GI, gastrointestinal.

Table 11-10. α -Adrenoceptor blocking agents, sympatholytics, and vasodilators.

Drug	Proprietary Names	Initial Dosage	Dosage Range	Cost per Unit	Cost of 30 Days Treatment (Average Dosage) ¹	Adverse Effects	Comments
α-Adrenoceptor blockers							
Prazosin	Minipress	1 mg at bedtime	2-20 mg in 2 or 3 doses	\$0.78/5 mg	\$46.80 (5 mg twice daily)	Syncope with first dose; postural hypotension, dizziness, palpitations, headache, weakness, drowsiness, sexual dysfunction, anticholinergic effects, urinary incontinence; first-dose effects may be less with doxazosin.	May \uparrow HDL and \downarrow LDL cholesterol. May provide short-term relief of obstructive prostatic symptoms. Less effective in preventing cardiovascular events than diuretics.
Terazosin	Hytrin	1 mg at bedtime	1-20 mg in 1 or 2 doses	\$1.60/1, 2, 5, 10 mg	\$48.00 (5 mg once daily)		
Doxazosin	Cardura	1 mg at bedtime	1-16 mg once daily	\$0.97/4 mg	\$29.10 (4 mg once daily)		
	Cardura XL	4 mg ER	4-8 mg ER once daily				
Central sympatholytics							
Clonidine	Catapres	0.1 mg twice daily	0.2-0.6 mg in 2 doses	\$0.22/0.1 mg	\$13.20 (0.1 mg twice daily)	Sedation, dry mouth, sexual dysfunction, headache, bradyarrhythmias; side effects may be less with guanfacine. Contact dermatitis with clonidine patch. Methyldopa also causes hepatitis, hemolytic anemia, fever.	"Rebound" hypertension may occur even after gradual withdrawal. Methyldopa should be avoided in favor of safer agents.
	Catapres TTS	0.1 mg/d patch weekly	0.1-0.3 mg/d patch weekly	\$55.70/0.2 mg	\$223.06 (0.2 mg weekly)		
Clonidine and chlorthalidone	Clorpres	0.1 mg/15 mg one to three times daily	0.1 mg/15 mg-0.3 mg/15 mg	\$2.00/0.1 mg/15 mg	\$120.00/0.1 mg/15 mg twice daily		
Guanabenz	Wytensin	4 mg twice daily	8-64 mg in 2 doses	\$2.09/8 mg	\$125.40 (8 mg twice daily)		
Guanfacine	Tenex	1 mg once daily	1-3 mg once daily	\$0.87/1 mg	\$26.10 (1 mg once daily)		
Methyldopa	Aldochlor	250 mg twice daily	500-2000 mg in 2 doses	\$0.63/500 mg	\$37.80 (500 mg twice daily)		
Peripheral neuronal antagonists							
Reserpine	Serpasil; Serpalan	0.05 mg once daily	0.05-0.25 mg once daily	\$0.99/0.1 mg	\$29.70 (0.1 mg once daily)	Depression (less likely at low dosages, ie, < 0.25 mg), night terrors, nasal stuffiness, drowsiness, peptic disease, gastrointestinal disturbances, bradycardia.	
Direct vasodilators							
Hydralazine	Apresoline	25 mg twice daily	50-300 mg in 2-4 doses	\$0.51/25 mg	\$30.60 (25 mg twice daily)	GI disturbances, tachycardia, headache, nasal congestion, rash, LE-like syndrome.	May worsen or precipitate angina.
Minoxidil	Loniten	5 mg once daily	10-40 mg once daily	\$1.69/10 mg	\$50.70 (10 mg once daily)	Tachycardia, fluid retention, headache, hirsutism, pericardial effusion, thrombocytopenia.	Should be used in combination with β -blocker and diuretic.

¹Average wholesale price (AWP, for AB-rated generic when available) for quantity listed.Source: *Red Book ONLINE, 2012*, Thomson Reuters (Healthcare) Inc. AWP may not accurately represent the actual pharmacy cost because wide contractual variations exist among institutions.

GI, gastrointestinal; LE, lupus erythematosus.


inducing mental depression and its other side effects—sedation, nasal stuffiness, sleep disturbances, and peptic ulcers—has made it unpopular, though these problems are uncommon at low dosages. Guanethidine and guanadrel inhibit catecholamine release from peripheral neurons but frequently cause orthostatic hypotension (especially in the morning or after exercise), diarrhea, and fluid retention.

► Developing an Antihypertensive Regimen

Historically, data from a number of large trials support the overall conclusion that antihypertensive therapy with diuretics and β -blockers has a major beneficial effect on a broad spectrum of cardiovascular outcomes, reducing the incidence of stroke by 30–50% and of congestive heart failure by 40–50%, and halting progression to accelerated hypertension syndromes. The decreases in fatal and nonfatal coronary heart disease and cardiovascular and total mortality have been less dramatic, ranging from 10% to 15%. Similar placebo-controlled data pertaining to the newer agents are generally lacking, except for stroke reduction with the calcium channel blocker nitrendipine in the Systolic Hypertension in Europe trial. However, there is substantial evidence that ACE inhibitors, and to a lesser extent ARBs, reduce adverse cardiovascular outcomes in other related populations (eg, patients with diabetic nephropathy, heart failure, or postmyocardial infarction and individuals at high risk for cardiovascular events). Most large clinical trials that have compared outcomes in relatively unselected patients have failed to show a difference between newer agents—such as ACE inhibitors, calcium channel blockers, and ARBs—and the older diuretic-based regimens with regard to survival, myocardial infarction, and stroke. Where differences have been observed, they have mostly been attributable to subtle asymmetries in blood pressure control rather than to any inherent advantages of one agent over another. Therefore, experts have recommended thiazide diuretics as the first-line treatment of older and perhaps all patients with hypertension because these agents are very effective and less expensive than the newer drugs. More recently, recommendations for initial treatment have become more flexible, identifying ACE inhibitors, ARB, and calcium channel blockers as valid choices. Exceptions are appropriate for individuals who have specific (or “compelling”) indications for another class of agent, as outlined in Table 11–4.

As discussed above, many experts would suggest that β -blockers no longer be considered ideal first-line drugs in the treatment of hypertension without compelling indications for their use. Although theoretical considerations suggest that vasodilator β -blockers (such as carvedilol and nebivolol) may be superior to the older drugs, this possibility remains to be tested.

For the purpose of devising an optimal treatment regimen, drugs can be divided into two complementary groups easily remembered as AB and CD. A and B refer to drugs that interrupt the renin-angiotensin system (ACE/ARB/renin inhibitor and β -blockers) and C and D refer to those that do not (calcium channel blockers and thiazide



▲ **Figure 11–4.** The British Hypertension Society’s recommendations for combining blood pressure lowering drugs. The “ABCD” rule. A, Angiotensin-converting enzyme inhibitor or angiotensin receptor blocker; B, β -blocker (the parentheses indicate that β -blockers should no longer be considered ideal first-line agents); C, calcium channel blockers; D, diuretic (thiazide). (Reprinted, with permission, from Williams B; British Hypertension Society. Guidelines for management of hypertension: report of the Fourth Working Party of the British Hypertension Society, 2004-BHS IV. *J Hum Hypertens.* 2004 Mar;18(3):139–85.)

diuretics). Combinations of drugs between these groups are likely to be more potent in lowering blood pressure than combinations within a group. Drugs A/B are more effective in young, white persons, in whom renin tends to be higher, and drugs C/D are more effective in old or black persons, in whom renin levels are generally lower. Figure 11–4 illustrates guidelines established by the BHS for developing a rational antihypertensive regimen. In the BHS guidelines, “B” is placed in parentheses to reflect the increasingly prevalent view that β -blockers should no longer be considered an ideal first-line agent. In trials that include patients with systolic hypertension, most patients require two or more medications and even then a substantial proportion fail to achieve the goal systolic blood pressure of < 140 mm Hg (< 130 mm Hg in high-risk persons). In diabetic patients, three or four drugs are usually required to reduce systolic blood pressure to < 140 mm Hg. In many patients, blood pressure cannot be adequately controlled with any combination. As a result, debating the appropriate first-line agent is less relevant than determining the most appropriate combinations of agents. This has led many experts and practitioners to reconsider the use of fixed-dose combination antihypertensive agents as first-line therapy in patients with substantially elevated systolic pressures (> 160/100 mm Hg) or difficult-to-control hypertension (which is often associated with diabetes or kidney dysfunction). Based both on antihypertensive efficacy and complementarity, combinations of an ACE

inhibitor or ARB plus a calcium channel blocker or diuretic are recommended. In light of side effect profiles, some experts have expressed the view that calcium channel blockers might be preferable to thiazides in the younger hypertensive patient. Furthermore, based on the results from the ACCOMPLISH trial, a combination of ACE inhibitor and calcium channel blocker may also prove optimal for patients at high risk for cardiovascular events. The initial use of low-dose combinations allows faster blood pressure reduction without substantially higher intolerance rates and is likely to be better accepted by patients. Combined renin-angiotensin system blockade with ACE inhibitor or ARB plus renin inhibitor may be more potent. A suggested approach to treatment, tailored to patient demographics, is outlined in Table 11–11.

As a prelude to treatment, the patient should be informed of common side effects and the need for diligent compliance. In patients with mild hypertension (< 160/100 mm Hg), treatment should start with a single agent at a low dose, and follow-up visits should usually be at 4- to 6-week intervals to allow for full medication effects to be established (especially with diuretics) before further titration or adjustment. If, after titration to usual doses, the patient has shown a discernible but incomplete response and a good tolerance of the initial drug, a second medication should be added. As a rule of thumb, a blood pressure reduction of 10 mm Hg can be expected for each antihypertensive agent added to the regimen. In those with more severe hypertension, or with comorbidities likely to render them resistant to treatment, initiation with combination therapy is advised and more frequent follow-up is indicated.

Patients who are compliant with their medications and who do not respond to conventional combination regimens should usually be evaluated for secondary hypertension before proceeding to more complex regimens.

► Special Considerations in the Treatment of Diabetic Hypertensive Patients

Hypertensive patients with diabetes are at particularly high risk for cardiovascular events. More aggressive treatment of hypertension in these patients prevents progressive nephropathy, and a meta-analysis supports the notion that lower treatment goals (< 130/80 mm Hg) are especially effective at reducing cardiovascular risk in diabetic patients compared with nondiabetic patients. Blood pressures should probably not be dropped below 120/70 mm Hg. Because of the beneficial effects of ACE inhibitors (and ARBs or perhaps renin inhibitors in intolerant patients) in diabetic nephropathy, they should be part of the initial treatment regimen. However, most diabetic patients require combinations of three to five agents to achieve target blood pressure, usually including a diuretic and a calcium channel blocker or β -blocker. In addition to rigorous blood pressure control, treatment of persons with diabetes should include aggressive treatment of other risk factors.

► Treatment of Hypertension in Chronic Kidney Disease

Hypertension is present in 40% of patients with a GFR of 60–90 mL/min, and 75% of patients with a GFR < 30 mL/min. ACE inhibitors and ARBs have been shown to delay progression of kidney disease in persons with type 1 and type 2 diabetes, respectively. It is also likely that inhibition of the renin-angiotensin system protects kidney function in nondiabetic kidney disease associated with significant proteinuria. There is evidence of a significantly additive anti-proteinuric effect from blocking multiple points in the renin-angiotensin cascade. Whether ACE inhibitors, ARB, or renin inhibitors offer efficacy beyond their antihypertensive activity is debated, and control of blood pressure with other agents is also very effective at protecting kidney function.

Table 11–11. Choice of antihypertensive agent based on demographic considerations.^{1,2}

	Black, All Ages	All Others, Age < 55 Years	All Others, Age > 55 Years
First-line	Diuretic or CCB	ACE or ARB ^{3,4} or diuretic ⁵ or CCB	Diuretic ⁶ or CCB
Second-line	ACE or ARB ^{3,4} or vasodilating β -blocker	β -Blocker ⁵	ACE or ARB or β -blocker
Alternatives	α -Agonist or α -antagonist ⁷	α -Agonist or α -antagonist	α -Agonist or α -antagonist ⁷
Resistant hypertension	Spironolactone	Spironolactone	Spironolactone

¹Compelling indications may alter the selection of an antihypertensive drug.

²Start with full dose of one agent, or lower doses of combination therapy.

³ACE and ARB can be synergistic in combination.

⁴Women of childbearing age should avoid ACE and ARB or discontinue as soon as pregnancy is diagnosed.

⁵The adverse metabolic effects of thiazide diuretics and β -blockers should be considered in younger patients but may be less important in the older patient.

⁶For patients with significant renal impairment, use loop diuretic instead of thiazide.

⁷ α -Antagonists may precipitate or exacerbate orthostatic hypotension in the elderly.

ACE, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; CCB, calcium channel blocker.

As discussed above, hypertension should be treated until blood pressure reaches < 130/80 mm Hg in patients with chronic kidney disease. There is a lack of definitive data to show that this level of blood pressure control slows the decline of GFR in persons with hypertensive chronic kidney disease without high-grade proteinuria. However, since all patients with chronic kidney disease are at high risk for cardiovascular damage, treatment of blood pressure to the < 130/80 mm Hg target is appropriate, and interruption of the renin-angiotensin system would seem a reasonable approach. Transition from thiazide to loop diuretic is often necessary to control volume expansion as kidney function worsens. Evidence has demonstrated that ACE inhibitors remain protective and safe in kidney disease associated with significant proteinuria and serum creatinine as high as 5 mg/dL (380 μmol/L). Note that such treatment would likely result in acute worsening of kidney function in patients with significant renal artery stenosis, so kidney function and electrolytes should be monitored carefully after introduction of ACE inhibitors. Persistence with ACE inhibitor/ARB therapy in the face of hyperkalemia is probably not warranted, since other antihypertensive medications are renoprotective as long as goal blood pressures are maintained.

► Hypertension Management in Blacks

Substantial evidence indicates that blacks are not only more likely to become hypertensive and more susceptible to the cardiovascular and renal complications of hypertension—they also respond differently to many antihypertensive medications. This may reflect genetic differences in the cause of hypertension or the subsequent responses to it, differences in occurrence of comorbid conditions such as diabetes or obesity, or environmental factors such as diet, activity, stress, or access to health care services. In any case, as in all persons with hypertension, a multifaceted program of education and lifestyle modification is warranted. Early introduction of combination therapy has been advocated. Because it appears that ACE inhibitors and ARBs—in the absence of concomitant diuretics—are less effective in blacks than in whites, initial therapy should generally be a diuretic or a diuretic combination with a calcium channel blocker.

► Treating Hypertension in the Elderly

Several studies in older persons have confirmed that antihypertensive therapy prevents fatal and nonfatal myocardial infarction and reduces overall cardiovascular mortality. These trials placed the focus on control of systolic blood pressure (the hypertension affecting the majority of those over 60 years of age is predominantly systolic)—in contrast to the historical emphasis on diastolic blood pressures. The treatment target is generally the same in older patients as it is in younger patients, except pressure should be reduced more gradually with a safe intermediate goal of 160 mm Hg. The same medications are used, but at 50% lower doses. As treatment is initiated, older patients should be carefully monitored for orthostasis, altered cognition, and electrolyte disturbances. In the very elderly, over age 80 years, a reasonable goal would be 150/80 mm Hg.

► Follow-Up of Patients Receiving Hypertension Therapy

Once blood pressure is controlled on a well-tolerated regimen, follow-up visits can be infrequent and laboratory testing limited to tests appropriate for the patient and the medications used. Yearly monitoring of blood lipids is recommended, and an electrocardiogram should be repeated at 2- to 4-year intervals depending on whether initial abnormalities are present, the presence of coronary risk factors, and age. Pharmacy care programs and home blood pressure monitoring have been shown to improve compliance with medications. Patients who have had excellent blood pressure control for several years, especially if they have lost weight and initiated favorable lifestyle modifications, should be considered for “step-down” of therapy.

ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). *JAMA*. 2002 Dec 18;288(23):2981–97. [PMID: 12479763]

Basile JN. One size does not fit all: the role of vasodilating beta-blockers in controlling hypertension as a means of reducing cardiovascular and stroke risk. *Am J Med*. 2010 Jul;123(7 Suppl 1):S9–15. [PMID: 20609697]

Chobanian AV. Does it matter how hypertension is controlled? *N Engl J Med*. 2008 Dec 4;359(23):2485–8. [PMID: 19052130]

Einhorn PT et al; ALLHAT Cooperative Research Group. ALLHAT: still providing correct answers after 7 years. *Curr Opin Cardiol*. 2010 Jul;25(4):355–65. [PMID: 20520537]

Epstein BJ et al. Recent changes in the landscape of combination RAS blockade. *Expert Rev Cardiovasc Ther*. 2009 Nov;7(11):1373–84. [PMID: 19900020]

Flack JM et al. Management of high blood pressure in blacks: an update of the International Society on Hypertension in Blacks consensus statement. *Hypertension*. 2010 Nov;56(5):780–800. [PMID: 20921433]

Jamerson K et al; ACCOMPLISH Trial Investigators. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. *N Engl J Med*. 2008 Dec 4;359(23):2417–28. [PMID: 19052124]

Lattanzio MR et al. Have we fallen off target with concerns surrounding dual RAAS blockade? *Kidney Int*. 2010 Sep;78(6):539–45. [PMID: 20668429]

Sander GE et al. What is the blood pressure goal for the elder patient 75 years of age or older? *Curr Cardiol Rep*. 2011 Dec;13(6):485–91. [PMID: 21971761]

RESISTANT HYPERTENSION

Resistant hypertension is defined in JNC 7 as the failure to reach blood pressure control in patients who are adherent to full doses of an appropriate three-drug regimen (including a diuretic). In this situation, the clinician should first exclude identifiable causes of hypertension (Table 11–2), and then carefully explore reasons why the patient might not be at goal blood pressure (Table 11–12). The clinician should pay particular attention to the type of diuretic being used in relation to the patient’s kidney function.

Table 11–12. Causes of resistant hypertension.

Improper blood pressure measurement
Volume overload and pseudotolerance
Excess sodium intake
Volume retention from kidney disease
Inadequate diuretic therapy
Drug-induced or other causes
Nonadherence
Inadequate doses
Inappropriate combinations
Nonsteroidal anti-inflammatory drugs; cyclooxygenase-2 inhibitors
Cocaine, amphetamines, other illicit drugs
Sympathomimetics (decongestants, anorectics)
Oral contraceptives
Adrenal steroids
Cyclosporine and tacrolimus
Erythropoietin
Licorice (including some chewing tobacco)
Selected over-the-counter dietary supplements and medicines (eg, ephedra, ma huang, bitter orange)
Associated conditions
Obesity
Excess alcohol intake
Identifiable causes of hypertension (see Table 11–2)

Data from Chobanian AV et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. *JAMA*. 2003 May 21;289(19):2560–72.

Aldosterone may play an important role in resistant hypertension and aldosterone receptor blockers can be very useful. If goal blood pressure cannot be achieved following completion of these steps, consultation with a hypertension specialist should be considered. Interruption of autonomic reflexes through radiofrequency ablation of renal sympathetic nerves or stimulation of carotid baroreceptors presents opportunities for blood pressure control in individuals resistant to pharmacotherapy. However, these approaches have yet to be formally evaluated in controlled outcomes trials, and there are concerns about long-term effectiveness and safety.

Acelajado MC et al. Resistant hypertension, secondary hypertension, and hypertensive crises: diagnostic evaluation and treatment. *Cardiol Clin*. 2010 Nov;28(4):639–54. [PMID: 20937447]

Martin EA et al. Promise, promise, and potential limitations of invasive devices to treat hypertension. *Curr Cardiol Rep*. 2011 Feb;13(1):86–92. [PMID: 21128124]

HYPERTENSIVE URGENCIES & EMERGENCIES

Hypertensive emergencies have become less frequent in recent years but still require prompt recognition and aggressive but careful management. A spectrum of urgent presentations exists, and the appropriate therapeutic approach varies accordingly.

Hypertensive urgencies are situations in which blood pressure must be reduced within a few hours. These

include patients with asymptomatic severe hypertension (systolic blood pressure > 220 mm Hg or diastolic pressure > 125 mm Hg that persists after a period of observation) and those with optic disk edema, progressive target organ complications, and severe perioperative hypertension. Elevated blood pressure levels alone—in the absence of symptoms or new or progressive target organ damage—rarely require emergency therapy. Parenteral drug therapy is not usually required, and partial reduction of blood pressure with relief of symptoms is the goal.

Hypertensive emergencies require substantial reduction of blood pressure within 1 hour to avoid the risk of serious morbidity or death. Although blood pressure is usually strikingly elevated (diastolic pressure > 130 mm Hg), the correlation between pressure and end-organ damage is often poor. It is the latter that determines the seriousness of the emergency and the approach to treatment. Emergencies include hypertensive encephalopathy (headache, irritability, confusion, and altered mental status due to cerebrovascular spasm), hypertensive nephropathy (hematuria, proteinuria, and progressive kidney dysfunction due to arteriolar necrosis and intimal hyperplasia of the interlobular arteries), intracranial hemorrhage, aortic dissection, preeclampsia-eclampsia, pulmonary edema, unstable angina, or myocardial infarction. **Malignant hypertension** is by historical definition characterized by encephalopathy or nephropathy with accompanying papilledema. Progressive kidney disease usually ensues if treatment is not provided. The therapeutic approach is identical to that used with other antihypertensive emergencies.

Parenteral therapy is indicated in most hypertensive emergencies, especially if encephalopathy is present. The initial goal in hypertensive emergencies is to reduce the pressure by no more than 25% (within minutes to 1 or 2 hours) and then toward a level of 160/100 mm Hg within 2–6 hours. Excessive reductions in pressure may precipitate coronary, cerebral, or renal ischemia. To avoid such declines, the use of agents that have a predictable, dose-dependent, transient, and progressive antihypertensive effect is preferable. In that regard, the use of sublingual or oral fast-acting nifedipine preparations is best avoided.

Acute ischemic stroke is often associated with marked elevation of blood pressure, which will usually fall spontaneously. In such cases, antihypertensives should only be used if the systolic blood pressure exceeds 180–200 mm Hg, and blood pressure should be reduced cautiously by 10–15%. If thrombolytics are to be given, blood pressure should be maintained at < 185/110 mm Hg during treatment and for 24 hours following treatment.

In hemorrhagic stroke, the aim is to minimize bleeding with a target mean arterial pressure of < 130 mm Hg. In acute subarachnoid hemorrhage, as long as the bleeding source remains uncorrected, a compromise must be struck between preventing further bleeding and maintaining cerebral perfusion in the face of cerebral vasospasm. In this situation, blood pressure goals depend on the patient's usual blood pressure. In normotensive patients, the target should be a systolic blood pressure of 110–120 mm Hg; in hypertensive patients, blood pressure should be treated to 20% below baseline pressure. In the

treatment of hypertensive emergencies complicated by (or precipitated by) central nervous system injury, labetalol or nicardipine are good choices, since they are nonsedating and do not appear to cause significant increases in cerebral blood flow or intracranial pressure in this setting. In hypertensive emergencies arising from catecholaminergic mechanisms, such as pheochromocytoma or cocaine use, β -blockers can worsen the hypertension because of unopposed peripheral vasoconstriction; nicardipine, clevidipine, or phentolamine are better choices. Labetalol is useful in these patients if the heart rate must be controlled. Table 11–13 summarizes treatment recommendations in hypertensive emergency.

► Pharmacologic Management

A. Parenteral Agents

A growing number of agents are available for management of acute hypertensive problems. (Table 11–14 lists drugs, dosages, and adverse effects.) Sodium nitroprusside is no longer the treatment of choice; in most situations,

appropriate control of blood pressure is best achieved using combinations of nicardipine or clevidipine plus labetalol or esmolol.

1. Nitroprusside sodium—This agent is given by controlled intravenous infusion gradually titrated to the desired effect. It lowers the blood pressure within seconds by direct arteriolar and venous dilation. Monitoring with an intra-arterial line avoids hypotension. Nitroprusside—in combination with a β -blocker—is useful in patients with aortic dissection. Because of toxicity and adverse effects on cerebral and myocardial perfusion and intracranial pressure, nitroprusside is no longer a first-line drug in the majority of cases.

2. Nitroglycerin, intravenous—This agent should be reserved for patients with accompanying acute coronary ischemic syndromes.

3. Labetalol—This combined β - and α -blocking agent is the most potent adrenergic blocker for rapid blood pressure reduction. Other β -blockers are far less potent. Excessive blood pressure drops are unusual. Experience

Table 11–13. Treatment of hypertensive emergency depending on primary site of end organ damage.

Type of Hypertensive Emergency	Recommended Drug Options and Combinations	Drugs to Avoid
Myocardial ischemia and infarction	Nicardipine Nitroglycerin plus labetalol Nitroglycerin plus esmolol ¹	Hydralazine, diazoxide, minoxidil, nitroprusside
Acute kidney injury	Fenoldopam Nicardipine Clevidipine	
Aortic dissection	Esmolol plus nicardipine Esmolol plus clevidipine Labetalol Esmolol plus nitroprusside	Hydralazine, diazoxide, minoxidil
Acute pulmonary edema, LV systolic dysfunction	Nicardipine plus nitroglycerin ² plus a loop diuretic Clevidipine plus nitroglycerin ² plus a loop diuretic	Hydralazine, diazoxide, β -blockers
Acute pulmonary edema, diastolic dysfunction	Esmolol plus low-dose nitroglycerin plus a loop diuretic Labetalol plus low-dose nitroglycerin plus a loop diuretic	
Ischemic stroke (systolic blood pressure >180–200 mm Hg)	Nicardipine Clevidipine Labetalol	Nitroprusside, methyl dopa, clonidine, nitroglycerin
Intracerebral hemorrhage (systolic blood pressure >140–160 mm Hg)	Nicardipine Clevidipine Labetalol	Nitroprusside, methyl dopa, clonidine, nitroglycerin
Hyperadrenergic states, including cocaine use	Nicardipine plus a benzodiazepine Clevidipine plus a benzodiazepine Phentolamine Labetalol	β -Blockers
Preeclampsia, eclampsia	Labetalol Nicardipine	Diuretics, ACE inhibitors

ACE, angiotensin-converting enzyme; LV, left ventricular.

¹Avoid if LV systolic dysfunction.

²Drug of choice if LV systolic dysfunction is associated with ischemia.

Table 11-14. Drugs for hypertensive emergencies and urgencies.

Agent	Action	Dosage	Onset	Duration	Adverse Effects	Comments
Parenteral agents (intravenous unless noted)						
Nitroprusside (Nitropress)	Vasodilator	0.25-10 mcg/kg/min	Seconds	3-5 minutes	GI, CNS; thiocyanate and cyanide toxicity, especially with renal and hepatic insufficiency; hypotension. Coronary steal, decreased cerebral blood flow, increased intracranial pressure.	No longer the first-line agent.
Nitroglycerin	Vasodilator	0.25-5 mcg/kg/min	2-5 minutes	3-5 minutes	Headache, nausea, hypotension, bradycardia.	Tolerance may develop. Useful primarily with myocardial ischemia.
Labetalol (Normodyne, Trandate)	β - and α -blocker	20-40 mg every 10 minutes to 300 mg; 2 mg/min infusion	5-10 minutes	3-6 hours	GI, hypotension, bronchospasm, bradycardia, heart block.	Avoid in acute LV systolic dysfunction, asthma. May be continued orally.
Esmolol (Brevibloc)	β -Blocker	Loading dose 500 mcg/kg over 1 minute; maintenance, 25-200 mcg/kg/min	1-2 minutes	10-30 minutes	Bradycardia, nausea.	Avoid in acute LV systolic dysfunction, asthma. Weak anti-hypertensive.
Fenoldopam (Corlopam)	Dopamine receptor agonist	0.1-1.6 mcg/kg/min	4-5 minutes	< 10 minutes	Reflex tachycardia, hypotension, intraocular pressure.	May protect kidney function.
Nicardipine (Cardene)	Calcium channel blocker	5 mg/h; may increase by 1-2.5 mg/h every 15 minutes to 15 mg/h	1-5 minutes	3-6 hours	Hypotension, tachycardia, headache.	May precipitate myocardial ischemia.
Clevidipine (Cleviprex)	Calcium channel blocker	1-2 mg/h initially, double rate every 90 seconds until near goal, then by smaller amounts every 5-10 minutes to a maximum of 32 mg/h	2-4 minutes	5-15 minutes	Headache, nausea, vomiting	Lipid emulsion: contraindicated in patients with allergy to soy or egg.
Enalaprilat (Vasotec)	ACE inhibitor	1.25 mg every 6 hours	15 minutes	6 hours or more	Excessive hypotension.	Additive with diuretics; may be continued orally.
Furosemide (Lasix)	Diuretic	10-80 mg	15 minutes	4 hours	Hypokalemia, hypotension.	Adjunct to vasodilator.
Hydralazine (Apresoline)	Vasodilator	5-20 mg intravenously or intramuscularly (less desirable); may repeat after 20 minutes	10-30 minutes	2-6 hours	Tachycardia, headache, GI.	Avoid in coronary artery disease, dissection. Rarely used except in pregnancy.
Oral agents						
Nifedipine (Adalat, Procardia)	Calcium channel blocker	10 mg initially; may be repeated after 30 minutes	15 minutes	2-6 hours	Excessive hypotension, tachycardia, headache, angina, myocardial infarction, stroke.	Response unpredictable.
Clonidine (Catapres)	Central sympatholytic	0.1-0.2 mg initially; then 0.1 mg every hour to 0.8 mg	30-60 minutes	6-8 hours	Sedation.	Rebound may occur.
Captopril (Capoten)	ACE inhibitor	12.5-25 mg	15-30 minutes	4-6 hours	Excessive hypotension.	

ACE, angiotensin-converting enzyme; CNS, central nervous system; GI, gastrointestinal; LV, left ventricular.

with this agent in hypertensive syndromes associated with pregnancy has been favorable.

4. Esmolol—This rapidly acting β -blocker is approved only for treatment of supraventricular tachycardia but is often used for lowering blood pressure. It is less potent than labetalol and should be reserved for patients in whom there is particular concern about serious adverse events related to β -blockers.

5. Fenoldopam—Fenoldopam is a peripheral dopamine-1 (DA_1) receptor agonist that causes a dose-dependent reduction in arterial pressure without evidence of tolerance, rebound, or withdrawal or deterioration of kidney function. In higher dosage ranges, tachycardia may occur. This drug is natriuretic, which may simplify volume management in acute kidney injury.

6. Nicardipine—Intravenous nicardipine is the most potent and the longest acting of the parenteral calcium channel blockers. As a primarily arterial vasodilator, it has the potential to precipitate reflex tachycardia, and for that reason it should not be used without a β -blocker in patients with coronary artery disease.

7. Clevidipine—Intravenous clevidipine is an L-type calcium channel blocker with a 1-minute half-life, which facilitates swift and tight control of severe hypertension. It acts on arterial resistance vessels and is devoid of venodilatory or cardiodepressant effects.

8. Enalaprilat—This is the active form of the oral ACE inhibitor enalapril. The onset of action is usually within 15 minutes, but the peak effect may be delayed for up to 6 hours. Thus, enalaprilat is used primarily as an adjunctive agent.

9. Diuretics—Intravenous loop diuretics can be very helpful when the patient has signs of heart failure or fluid retention, but the onset of their hypotensive response is slow, making them an adjunct rather than a primary agent for hypertensive emergencies. Low dosages should be used initially (furosemide, 20 mg, or bumetanide, 0.5 mg). They facilitate the response to vasodilators, which often stimulate fluid retention.

10. Hydralazine—Hydralazine can be given intravenously or intramuscularly, but its effect is less predictable than

that of other drugs in this group. It produces reflex tachycardia and should not be given without β -blockers in patients with possible coronary disease or aortic dissection. Hydralazine is now used primarily in pregnancy and in children, but even in these situations, newer agents are supplanting it.

B. Oral Agents

Patients with less severe acute hypertensive syndromes can often be treated with oral therapy. Suitable drugs will reduce the blood pressure over a period of hours.

1. Nifedipine—The effect of fast-acting nifedipine capsules is unpredictable and may be excessive, resulting in hypotension and reflex tachycardia. Because myocardial infarction and stroke have been reported in this setting, the use of sublingual nifedipine is not advised. Nifedipine retard, 20 mg orally, appears to be a safe and effective alternative.

2. Clonidine—Clonidine, 0.2 mg orally initially, followed by 0.1 mg every hour to a total of 0.8 mg, will usually lower blood pressure over a period of several hours. Sedation is frequent, and rebound hypertension may occur if the drug is stopped.

3. Captopril—Captopril, 12.5–25 mg orally, will also lower blood pressure in 15–30 minutes. The response is variable and may be excessive.

C. Subsequent Therapy

When the blood pressure has been brought under control, combinations of oral antihypertensive agents can be added as parenteral drugs are tapered off over a period of 2–3 days. Most subsequent regimens should include a diuretic.

Marik PE et al. Hypertensive emergencies: an update. *Curr Opin Crit Care*. 2011 Dec;17(6):569–80. [PMID: 21986463]
van den Born BJ et al. Dutch guideline for the management of hypertensive crisis—2010 revision. *Neth J Med*. 2011 May;69(5):248–55. [PMID: 21646675]

12

Blood Vessel & Lymphatic Disorders

Joseph H. Rapp, MD
Christopher D. Owens, MD, MSc
Meshell D. Johnson, MD

ATHEROSCLEROTIC PERIPHERAL VASCULAR DISEASE

OCCLUSIVE DISEASE: AORTA & ILIAC ARTERIES

ESSENTIALS OF DIAGNOSIS

- ▶ Claudication: cramping pain or tiredness in the calf, thigh, or hip while walking.
- ▶ Diminished femoral pulses.
- ▶ Tissue loss (ulceration, gangrene) or rest pain.

▶ General Considerations

Occlusive atherosclerotic lesions can develop in the vessels of the legs and, less commonly, the arms. These peripheral lesions are symptoms of a systemic atherosclerotic process. Pathologic changes of atherosclerosis may be diffuse, but flow-limiting stenoses occur segmentally. In the lower extremities, they classically occur in three anatomic segments: the aortoiliac segment, femoral-popliteal segment, and the infrapopliteal or tibial segment of the arterial tree. Lesions in the distal aorta and proximal common iliac arteries often occur in men aged 50–60 years. The patient with aortoiliac disease is usually a smoker and the aortoiliac disease may be the initial manifestation of systemic atherosclerosis. Disease progression may lead to complete occlusion of one or both common iliac arteries, which can precipitate occlusion of the entire abdominal aorta to the level of the renal arteries. Lesions affecting the external iliac arteries are less common as are lesions isolated to the aorta. This is particularly true of younger patients with isolated aortoiliac disease, ie, with no involvement of the more distal vessels of the lower extremities.

▶ Clinical Findings

A. Symptoms and Signs

Pain occurs because blood flow cannot keep up with the increased demand of exercise. This pain, termed “claudication,” is defined as pain on exertion. It is typically

described as severe and cramping, and it primarily occurs in the calf muscles. The pain may extend into the thigh and buttocks with continued exercise. It may be bilateral if there is bilateral disease. Although generally reproducible, there is day-to-day variation in severity, and thus it is termed “intermittent claudication.” Rarely, patients complain only of weakness in the legs when walking, or simply extreme limb fatigue. The symptoms are relieved with rest. With bilateral common iliac disease, erectile dysfunction is a common complaint. Femoral pulses are absent or very weak as are the distal pulses. A bruit may be heard over the aorta, iliac, or femoral arteries or over all three arteries.

B. Doppler Findings

The ratio of systolic blood pressure detected by Doppler examination at the ankle compared with the brachial artery is reduced to below 0.9 (normal ratio is 1.0–1.2); this difference is exaggerated by exercise. By convention, the higher pedal pressure is used for calculation. Segmental waveforms or pulse volume recordings obtained by strain gauge technology through blood pressure cuffs demonstrate blunting of the arterial inflow throughout the lower extremity.

C. Imaging

CT angiography (CTA) and magnetic resonance angiography (MRA) have largely replaced invasive angiography to determine the anatomic location of disease. Imaging is only required when symptoms require intervention, since a history and physical examination with segmental waveform analysis should appropriately identify the involved levels of the arterial tree.

▶ Treatment

A. Conservative Care

A program that includes smoking cessation; risk factor reduction; weight loss; and consistent, moderate exercise will substantially improve walking distance. In patients with peripheral artery disease, nicotine replacement therapy, bupropion, and varenicline have established benefits

in smoking cessation. A trial of phosphodiesterase inhibitors, such as cilostazol 100 mg orally twice a day, may be beneficial in approximately two-thirds of patients. Antiplatelet agents reduce overall cardiovascular morbidity but do not ameliorate symptoms. Several large trials have failed to show a benefit from warfarin therapy. In the initial stages of a rehabilitation program, simply slowing the cadence of walking will allow patients to walk further without pain.

B. Endovascular Techniques

When the atherosclerotic lesions are truly segmental, they can be effectively treated with angioplasty and stenting. This approach matches the results of surgery for single stenoses but both effectiveness and durability decreases with longer or multiple stenoses.

C. Surgical Intervention

A prosthetic aorto-femoral bypass graft that bypasses the diseased segments of the aortoiliac system is a highly effective and durable treatment for this disease. Patients may be treated with a graft from the axillary artery to the femoral arteries (axillo-femoral bypass graft) or, in the unusual case of iliac disease limited to one side, a graft from the contralateral femoral artery (fem-fem bypass). The axillo-femoral and femoral to femoral grafts have lower operative risk; however, they are less durable.

► Complications

The complications of the aorto-femoral bypass are those of any major abdominal reconstruction in a patient population that has a high prevalence of cardiovascular disease. Mortality should be low, in the range of 2–3%, but morbidity is higher with a 5–10% rate of myocardial infarction. The total complication rate may be >10%. Complications of endovascular repair include rupture of heavily calcified arteries, embolization, and vessel dissection. These are relatively uncommon and the total complication rate should be <3%.

► Prognosis

Without intervention patients with aortoiliac disease may have a further reduction in walking distance but symptoms rarely progress to rest pain or threatened limb loss. Life expectancy is limited by their attendant cardiac disease with a mortality rate of 25–40% at 5 years.

Symptomatic relief is generally excellent after intervention. After aorto-femoral bypass, a patency rate of 90% at 5 years is common. Patency rates and symptom relief for less extensive procedures are also good with 20–30% symptom return at 3 years.

► When to Refer

Patients with progressive reduction in walking distance and those with limitations in ambulation that interfere with their activities of daily living should be referred for consultation to a vascular surgeon.

ACCF/AHA focused update of the guideline for the management of patients with peripheral artery disease (updating the 2005 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. *Circulation*. 2011 Nov 1;124(18):2020–45. [PMID: 21959305]

Bachoo P et al. Endovascular stents for intermittent claudication. *Cochrane Database Syst Rev*. 2010 Jan 20;(1):CD003228. [PMID: 20091540]

Le Faucheur A et al. Variability and short-term determinants of walking capacity in patients with intermittent claudication. *J Vasc Surg*. 2010 Apr;51(4):886–92. [PMID: 20347684]

Linnemann B et al. Variability of non-response to aspirin in patients with peripheral arterial occlusive disease during long-term follow-up. *Ann Hematol*. 2009 Oct;88(10):979–88. [PMID: 19247655]

OCCLUSIVE DISEASE: SUPERFICIAL & COMMON FEMORAL & POPLITEAL ARTERIES



ESSENTIALS OF DIAGNOSIS

- Cramping pain or tiredness in the calf with exercise.
- Reduced popliteal or pedal pulses.
- Foot pain at rest, relieved by dependency.
- Foot gangrene or ulceration.

► General Considerations

The superficial femoral artery is the artery most commonly occluded by atherosclerosis. The disease frequently occurs where the superficial femoral artery passes through the abductor magnus tendon in the distal thigh (Hunter canal). The common femoral artery and the popliteal artery are less commonly diseased but lesions in these vessels are debilitating, resulting in short-distance claudication. As with atherosclerosis of the aortoiliac segment, these lesions are closely associated with a history of smoking.

► Clinical Findings

A. Symptoms and Signs

Symptoms of intermittent claudication caused by lesions of the common femoral artery, superficial femoral artery, and popliteal artery are confined to the calf. Occlusion or stenosis of the superficial femoral artery at the adductor canal when the patient has good collateral vessels from the profunda femoris will cause claudication at approximately 2–4 blocks. However, with concomitant disease of the profunda femoris or the popliteal artery, much shorter distances may trigger symptoms. With short-distance claudication, dependent rubor of the foot with blanching on elevation may be present. Chronic low blood flow states will also cause atrophic changes in the lower leg and foot with loss of hair, thinning of the skin and subcutaneous tissues, and disuse atrophy of the muscles. With segmental occlusive disease of the superficial femoral artery, the common femoral pulsation is normal, but the popliteal and pedal pulses are reduced.

B. Laboratory Findings

The ankle-brachial index (ABI) is reduced; levels below 0.5 suggest severe reduction in flow. ABI readings depend on arterial compression. Since the vessels may be calcified in diabetic patients and the elderly, ABIs can be misleading and must be accompanied by a waveform analysis. Pulse volume recordings with cuffs placed at the high thigh, mid thigh, calf, and ankle will delineate the levels of obstruction with reduced pressures and blunted waveforms. Angiography, CTA, or MRA all adequately show the anatomic location of the obstructive lesions. Generally, these studies are only done if revascularization is planned.

▶ Treatment

A. Conservative Care

As with aortoiliac disease, conservative management has an important role for some patients, particularly those individuals with superficial femoral artery occlusion and good profunda femoris collateral vessels. For these patients conservative management as noted above can result in excellent outcomes with no intervention required.

B. Surgical Intervention

1. Bypass surgery—Intervention is indicated if intermittent claudication is progressive, incapacitating or interferes significantly with essential daily activities. Intervention is mandatory if there is rest pain or threatened tissue loss of the foot. The most effective and durable treatment for lesions of the superficial femoral artery is a femoral-popliteal bypass with autogenous saphenous vein. Synthetic material, usually polytetrafluoroethylene (PTFE), can be used, but these grafts do not have the durability of vein bypass.

2. Endovascular surgery—Endovascular techniques may be effective for lesions of the superficial femoral artery. The BASIL trial found similar short-term results for surgery and angioplasty but worse long-term outcomes with angioplasty. Angioplasty may be combined with stenting either with a bare metal stent or a PTFE-covered stent to prevent elastic recoil of the vessel or if a dissection occurs following angioplasty. These techniques have lower morbidity than bypass surgery but also have a lower rate of success and durability.

Endovascular therapy is most effective when the lesions are <10 cm long and in patients who are undergoing aggressive risk factor modification.

3. Thromboendarterectomy—Removal of the atherosclerotic plaque is limited to the lesions of the common femoral and the profunda femoris artery where bypass grafts and endovascular techniques have a more limited role.

▶ Complications

Open surgical procedures of the lower extremity, particularly long bypasses with vein harvest, have a risk of wound infection that is higher than in other areas of the body. Wound infection or seroma can occur in as many as 15–20% of cases. Myocardial infarction rates after open surgery are 5–10%, with a 1–4% mortality rate. Complication

rates of endovascular therapy are 1–5%, making these therapies attractive despite their lower durability.

▶ Prognosis

The prognosis for motivated patients with isolated superficial femoral artery disease is excellent, and surgery is not recommended for mild or moderate claudication in these patients. However, when claudication significantly limits daily activity and undermines quality of life as well as overall cardiovascular health, intervention may be warranted. All interventions require close postprocedure follow-up with ultrasound surveillance so that any recurrent narrowing can be treated promptly to prevent complete occlusion. The reported patency rate of bypass grafts of the femoral artery, superficial femoral artery, and popliteal artery is 65–70% at 3 years whereas the patency of angioplasty is less than 50% at 3 years.

Because of the extensive atherosclerotic disease, including associated coronary lesions, 5-year mortality among patients with lower extremity disease can be as high as 50%, particularly with involvement of the infrapopliteal vessels (see below). However, with aggressive risk factor modification, substantial improvement in longevity has been reported.

▶ When to Refer

Patients with progressive symptoms, short distance claudication, rest pain, or any ulceration should be referred to a peripheral vascular specialist.

Bradbury AW et al; BASIL trial Participants. Bypass versus Angioplasty in Severe Ischaemia of the Leg (BASIL) trial: analysis of amputation free and overall survival by treatment received. *J Vasc Surg.* 2010 May;51(5 Suppl):18S–31S. [PMID: 20435259]

Conte MS. Bypass versus Angioplasty in Severe Ischaemia of the Leg (BASIL) and the (hoped for) dawn of evidence-based treatment for advanced limb ischemia. *J Vasc Surg.* 2010 May;51(5 Suppl):69S–75S. [PMID: 20435263]

Forbes JF et al; BASIL trial Participants. Bypass versus Angioplasty in Severe Ischaemia of the Leg (BASIL) trial: Health-related quality of life outcomes, resource utilization, and cost-effectiveness analysis. *J Vasc Surg.* 2010 May;51(5 Suppl):43S–51S. [PMID: 20435261]

Torpy JM et al. JAMA patient page. Peripheral arterial disease. *JAMA.* 2009 Jan 14;301(2):236. [PMID: 19141772]

White C. Intermittent claudication. *N Engl J Med.* 2007 Mar 22; 356(12):1241–50. [PMID: 17377162]

OCCLUSIVE DISEASE: LOWER LEG & FOOT ARTERIES



ESSENTIALS OF DIAGNOSIS

- ▶ Severe pain of the forefoot that is relieved by dependency.
- ▶ Pain or numbness of the foot with walking.
- ▶ Ulceration or gangrene of the foot or toes.
- ▶ Pallor when the foot is elevated.

► General Considerations

Occlusive processes of the lower leg and foot primarily involve the tibial vessels with rare involvement of the arteries of the foot. There often is extensive calcification of the artery wall. Diabetes mellitus is a risk factor for this distribution of atherosclerosis.

► Clinical Findings

A. Symptoms and Signs

Unless there are associated lesions in the aortoiliac or femoral/superficial femoral artery segments, claudication may not be evident. The gastrocnemius and soleus muscles may receive adequate blood supply from collateral vessels from the popliteal artery; therefore, when disease is isolated to the tibial vessels, there may be foot ischemia without attendant claudication, and rest pain or ulceration may be the first sign of severe vascular insufficiency. Classically, rest pain is confined to the dorsum of the foot at the area of the metatarsal heads and is relieved with dependency. The pain is severe, usually burning in character and will awaken the patient from sleep. Because of the high incidence of neuropathy in these patients, it is important to differentiate rest pain from neuropathic dysesthesia. If the pain is relieved by simply dangling the foot over the edge of the bed, which increases blood flow to the foot, then the rest pain is due to vascular insufficiency. On examination, depending on whether associated proximal disease is present, there may or may not be femoral and popliteal pulses, but the pedal pulses will be absent. Dependent rubor may be prominent with pallor on elevation. The skin of the foot is generally cool, atrophic, and hairless.

B. Laboratory Findings

The ABI may be quite low (in the range of 0.3 or lower), but ABIs may be falsely elevated because of the noncompressibility of the calcified tibial vessels. Waveform analysis is important in these patients; a monophasic flow pattern denotes critically low flow. Segmental pulse volume recordings will show a fall-off in blood pressure between the calf and ankle, although pulse volume recordings also may also be affected by tibial vessel calcification.

C. Imaging

MRA or angiography is often needed to delineate the anatomy of the tibial-popliteal segment. CTA is less helpful for detection of lesions in this location.

► Treatment

Good foot care may avoid ulceration, and most diabetic patients will do well with a conservative regimen. However, if ulcerations appear and there is no significant healing within 2–3 weeks, revascularization will be required. Poor blood flow or infrequent rest pain is not an absolute indication for revascularization. However, rest pain occurring nightly with monophasic waveforms requires revascularization to prevent threatened tissue loss.

A. Bypass and Endovascular Techniques

Bypass with vein to the distal tibial or pedal arteries has been shown to be an effective mechanism to treat rest pain and heal gangrene or ischemic ulcerations of the foot. Because the foot often has relative sparing of vascular disease, these bypasses have had adequate patency rates (70% at 3 years). Fortunately, in nearly all series, limb salvage rates are much higher than patency rates.

Endovascular techniques are beginning to be used in the tibial vessels with modest results, but bypass grafting remains the primary technique of revascularization.

B. Amputation

Patients with rest pain and tissue loss are at high risk for amputation, particularly if revascularization cannot be done. It may be necessary to debride necrotic or severely infected tissue. Amputations of the second through fifth toes may have little or no effect on the mechanics of walking. However, removal of the first toe or a transmetatarsal amputation, removing all toes and the heads of the metatarsals, are durable but increase the energy required of walking by 5–10%. Unfortunately, the next level that can be successfully used for a prosthesis is at the below-knee level. The energy expenditure of walking is then increased by 50%. With an above-knee amputation, the energy required to ambulate may be increased as much as 100%. While there are good prosthetic alternatives for these patients, activity levels are limited after amputation, and there are issues relating to self-image. These factors combine to demand revascularization whenever possible to preserve the limb.

► Complications

The complications of intervention are similar to those listed for superficial femoral artery disease with evidence that the overall cardiovascular risk increases with decreasing ABI. The patients with critical limb ischemia require aggressive risk factor modification. Wound infection rates after bypass are higher if there is an open wound in the foot.

► Prognosis

Patients with tibial atherosclerosis have extensive atherosclerotic burden and a high prevalence of diabetes. Their prognosis without intervention is poor and complicated by the risk of amputation.

► When to Refer

Patients with diabetes should be referred to a vascular specialist for evaluation if pedal pulses are reduced (even slightly) and if ulcers are present (even if small). Intervention may not be necessary but the severity of the disease will be quantified, which has implications for future symptom development.

Martens JM et al. Update on PADI trial: percutaneous transluminal angioplasty and drug-eluting stents for infrapopliteal lesions in critical limb ischemia. *J Vasc Surg.* 2009 Sep;50(3):687–9. [PMID: 19700099]

Raghunathan A et al. Postoperative outcomes for patients undergoing elective revascularization for critical limb ischemia and intermittent claudication: a subanalysis of the Coronary Artery Revascularization Prophylaxis (CARP) trial. *J Vasc Surg.* 2006 Jun;43(6):1175–82. [PMID: 16765234]
 Torpy JM et al. JAMA patient page. Peripheral arterial disease. *JAMA.* 2009 Jan 14;301(2):236. [PMID: 19141772]

ACUTE ARTERIAL OCCLUSION OF A LIMB



ESSENTIALS OF DIAGNOSIS

- ▶ Sudden pain in an extremity.
- ▶ Generally associated with some element of neurologic dysfunction with numbness, weakness, or complete paralysis.
- ▶ Absent extremity pulses.

▶ General Considerations

Acute occlusion may be due to an embolus or to thrombosis of a diseased atherosclerotic segment. Arterial to arterial emboli can occur, but emboli large enough to occlude proximal arteries in the lower extremities are almost always from the heart. Over 50% of the emboli from cardiac sources go to the lower extremities, 20% to the cerebrovascular circulation, and the remainder to the upper extremities and mesenteric and renal circulation. Atrial fibrillation is the most common cause of cardiac thrombus formation; other causes are valvular disease or ischemic heart disease where thrombus has formed on the ventricular surface of a transmural myocardial infarct.

Emboli from arterial sources such as arterial ulcerations or calcified excrescences are usually small and go to the distal arterial tree (toes).

The typical patient with **primary** thrombosis has had a history of claudication and now has an acute occlusion. If the stenosis has developed over time, collateral blood vessels will develop, and the resulting occlusion may only cause a minimal increase in symptoms.

▶ Clinical Findings

A. Symptoms and Signs

The sudden onset of extremity pain, with loss or reduction in pulses, is diagnostic of acute arterial occlusion. This often will be accompanied by neurologic dysfunction, such as numbness or paralysis in extreme cases. With popliteal occlusion, symptoms may only affect the foot. With proximal occlusions, the whole leg may be affected. Signs of severe arterial ischemia include pallor on elevation, coolness of the extremity, and mottling. Impaired neurologic function progressing to anesthesia accompanied with paralysis suggest a poor prognosis.

B. Laboratory Findings

There will be little or no flow found with Doppler examination of the distal vessels. Imaging, if done, may show an abrupt cutoff of contrast with embolic occlusion. Blood work may indicate systemic acidosis.

C. Imaging

Whenever possible, imaging should be done in the operating room because obtaining angiography, MRA, or CTA may delay revascularization and jeopardize the viability of the extremity. However, in cases with only modest symptoms and where light touch of the extremity is maintained, imaging may be helpful in planning the revascularization procedure.

▶ Treatment

Immediate revascularization is required in all cases of symptomatic acute arterial thrombosis. Evidence of neurologic injury, including loss of light touch sensation, indicates that collateral flow is inadequate to maintain limb viability and revascularization should be accomplished within 3 hours. Longer delays carry a significant risk of irreversible tissue damage. This risk approaches 100% at 6 hours.

A. Heparin

As soon as the diagnosis is made, unfractionated heparin should be administered (5000–10,000 units) intravenously. This helps prevent clot propagation and may also help relieve associated vessel spasm. There may be some reduction in symptoms with aggressive anticoagulation, but revascularization will still be required.

B. Endovascular Techniques

Catheter directed chemical thrombolysis into the clot with TPA may be done but often requires 24 hours or longer to fully lyse the thrombus. This approach can be taken only in patients with an intact neurologic exam. An echocardiogram should be done to identify additional clot in the atrium. Catheter-based local mechanical thrombolysis may be an excellent alternative.

C. Surgical Intervention

General anesthesia is usually indicated; local anesthesia may be used in extremely high-risk patients if the exploration is to be limited to the common femoral artery. In extreme cases, it may be necessary to perform embolectomy from the femoral, popliteal and even the pedal vessels to revascularize the limb. Devices to pulverize and aspirate clot and intraoperative thrombolysis with tissue plasminogen activator (TPA) are being used to improve outcomes.

▶ Complications

Complications of revascularization of an acutely ischemic limb can include severe acidosis and myocardial arrest.

In cases where several hours have elapsed but recovery of viable tissue may still be possible, significant levels of lactic acid, potassium, and other harmful agents may be released into the circulation during revascularization. Pretreatment of the patient with sodium bicarbonate prior to reestablishing arterial flow is required. Surgery in the presence of thrombolytic agents and heparin carries a high risk of postoperative wound hematoma.

► Prognosis

There is a 10–25% risk of amputation with acute arterial occlusion caused by an embolus, and a 25% or higher in-hospital mortality rate. Prognosis for acute thrombotic occlusion of an atherosclerotic segment is generally much better because the collateral flow can maintain extremity viability. The longer term survival reflects the overall condition of the patient. In high-risk patients, an acute arterial occlusion suggests a dismal prognosis.

OCCLUSIVE CEREBROVASCULAR DISEASE



ESSENTIALS OF DIAGNOSIS

- Sudden onset of weakness and numbness of an extremity, aphasia, dysarthria, or unilateral blindness (amaurosis fugax).
- Bruit heard loudest in the mid neck.

► General Considerations

Unlike the other vascular territories, symptoms of occlusive cerebrovascular disease are predominantly due to emboli. Transient ischemic attacks (TIAs) are the result of small emboli, and the risk of additional emboli causing permanent deficits is high. One-third of all strokes may be due to emboli. In the absence of atrial fibrillation, approximately 90% of these emboli originate from the proximal internal carotid artery, an area uniquely prone to the development of atherosclerosis. Lesions in the proximal great vessels of the aortic arch and the common carotid are far less common. Intracranial atherosclerotic lesions are uncommon in the West but are the most common location of cerebrovascular disease in China.

► Clinical Findings

A. Symptoms and Signs

Generally, the symptoms of a TIA last only a few minutes but may continue up to 24 hours. The most common lesions are in the cortex with both motor and sensory involvement. Emboli to the retinal artery cause unilateral blindness which, when transient, is termed “amaurosis fugax.” Posterior circulation symptoms referable to the brainstem, cerebellum, and visual regions of the brain are due to atherosclerosis of the vertebral basilar systems and are much less common.

Signs of cerebrovascular disease include bruits in the mid-cervical area. However, they are not specific for narrowing within the vessel. There is poor correlation between the degree of stenosis and the presence of the bruit. Furthermore, absence of a bruit does not exclude the possibility of carotid stenosis. Nonfocal symptoms, such as dizziness and unsteadiness, seldom are related to cerebrovascular atherosclerosis.

B. Imaging

Duplex ultrasonography is the imaging modality of choice with a high specificity and sensitivity for detecting and grading the degree of stenosis at the carotid bifurcation: 50% stenosis in a symptomatic patient and 80% in an asymptomatic patient require intervention. Mild to moderate disease (30–50% stenosis) indicates the need for ongoing surveillance and aggressive risk factor modification.

Excellent depiction of the full anatomy of the cerebrovascular circulation from arch to cranium can be obtained with either MRA or CTA. Each of these modalities may have false-positive or false-negative findings. Since the decision to intervene in cases of carotid stenosis depends on an accurate assessment of the degree of stenosis, it is recommended that at least two modalities be used to confirm the degree of stenosis. Cerebral angiography is reserved for cases that cannot be resolved by MRA or CTA.

► Treatment

A. Asymptomatic Patients

Patients with no neurologic symptoms but with carotid stenosis on imaging will benefit from carotid intervention if they are considered to be at low risk for intervention and their expected survival is > 5 years. Recommendation for intervention also presumes that the treating institution has a stroke rate in asymptomatic patients that is acceptable (< 3%). Large studies indicate a reduction in stroke rate from 11.5% to 5.0% over 5 years with surgical treatment of asymptomatic carotid stenoses of > 60%. However, the usual practice is to only treat those patients who have > 80% stenosis. Patients with carotid stenosis that suddenly worsens are thought to have an unstable plaque and are at particularly high risk for embolic stroke.

B. Symptomatic Patients

Large randomized trials have shown that patients with TIAs or strokes from which they have completely or nearly completely recovered will benefit from carotid intervention if the ipsilateral carotid artery has a stenosis of $\geq 70\%$, and they are likely to derive benefit if the artery has a stenosis of 50–69%. In these situations, carotid endarterectomy (CEA) has been shown to have a durable effect in preventing further events.

► Complications

The most common complication from carotid intervention is cutaneous sensory or cranial nerve injury. However, the most dreaded complication is stroke due to embolization of

plaque material during the procedure. The American Heart Association has recommended upper limits of acceptable combined morbidity and mortality for these interventions: 3% for asymptomatic, 5% for those with TIAs, and 7% for patients with previous stroke. Results that do not match these guidelines will jeopardize the therapeutic benefit of carotid intervention.

A. Carotid Endarterectomy

In addition to stroke risk, CEA carries an 8% risk of transient cranial nerve injury (usually the vagus or hypoglossal nerve) and 1–2% risk of permanent deficits. There is also the risk of postoperative neck hematoma, which can cause acute compromise of the airway. Coronary artery disease exists as a comorbidity in most of these patients. Myocardial infarction rates after CEA are approximately 5%.

B. Angioplasty and Stenting

Carotid angioplasty and stenting has been advocated as an alternative to CEA. Carotid angioplasty and stenting offers the advantage of avoidance of both cranial nerve injury and neck hematoma. However, emboli are more common during carotid angioplasty and stenting in spite of the use of embolic protection devices during the procedure. The International Carotid Stenting Study showed increased stroke rates with carotid angioplasty and stenting in symptomatic patients while the Carotid Revascularization Endarterectomy versus Stent Trial (CREST) showed similar overall morbidity with higher myocardial infarction rates with CEA and higher stroke rates with carotid angioplasty and stenting.

C. Recurrent Carotid Stenosis

Scarring of the arterial wall at the site of the intervention after both angioplasty and endarterectomy may create recurrent stenosis. These lesions tend to be less embologenic, and treatment need not be as aggressive as for primary disease. The cranial nerve risk for these patients may be higher with repeat endarterectomy than with angioplasty of the narrowed segment.

► Prognosis

Prognosis for patients with carotid stenosis who have had a TIA or small stroke is poor without treatment; 25% of these patients will have a stroke with most of the events occurring in the first year of follow-up. Patients with carotid stenosis without symptoms have an annual stroke rate of just over 2% even with risk factor modification and antiplatelet agents. Symptomatic patients most likely have unstable plaques with ulceration or recent plaque enlargement. Prospective ultrasound screening is recommended in asymptomatic patients because approximately 10% of asymptomatic patients have evidence of plaque progression in a given year. Concomitant coronary artery disease is common and is an important factor in these patients both for perioperative risk and long-term prognosis. Aggressive risk factor modification should be prescribed

for patients with cerebrovascular disease regardless of planned intervention.

► When to Refer

Asymptomatic or symptomatic patients with a carotid stenosis of > 80% and patients with carotid stenosis of > 50% stenosis with symptoms of a TIA or stroke should be referred to a vascular specialist.

Bonati LH et al; CAVATAS Investigators. Long-term risk of carotid restenosis in patients randomly assigned to endovascular treatment or endarterectomy in the Carotid and Vertebral Artery Transluminal Angioplasty Study (CAVATAS): long-term follow-up of a randomized trial. *Lancet Neurol*. 2009 Oct;8(10):908–17. [PMID: 19717347]

Brott TG et al; CREST Investigators. Stenting versus endarterectomy for treatment of carotid-artery stenosis. *N Engl J Med*. 2010 Jul 1;363(1):11–23. [PMID: 20505173]

Hussain MS et al. Symptomatic delayed reocclusion after initial successful revascularization in acute ischemic stroke. *J Stroke Cerebrovasc Dis*. 2010 Jan;19(1):36–9. [PMID: 20123225]

International Carotid Stenting Study investigators; Ederle J et al. Carotid artery stenting compared with endarterectomy in patients with symptomatic carotid stenosis (International Carotid Stenting Study): an interim analysis of a randomised controlled trial. *Lancet*. 2010 Mar 20;375(9719):985–97. [PMID: 20189239]

Zeebregts CJ. Carotid artery stenting: a 2009 update. *Curr Opin Cardiol*. 2009 Nov;24(6):528–31. [PMID: 19638930]

VISCERAL ARTERY INSUFFICIENCY (Intestinal Angina)



ESSENTIALS OF DIAGNOSIS

- Severe postprandial abdominal pain.
- Weight loss with a “fear of eating.”
- Acute mesenteric ischemia: severe abdominal pain yet minimal findings on physical examination.

► General Considerations

Acute visceral artery insufficiency results from either embolic occlusion or primary thrombosis of at least one major mesenteric vessel. Ischemia can also result from **non-occlusive mesenteric vascular insufficiency**, which is generally seen in patients with low flow states, such as congestive heart failure, or hypotension. A **chronic syndrome** occurs when there is adequate perfusion for the viscera at rest but ischemia occurs with severe abdominal pain when flow demands increase with feeding. Because of the rich collateral network in the mesentery, generally at least two of the three major visceral vessels (celiac, superior mesenteric, inferior mesenteric arteries) are affected before symptoms develop. **Ischemic colitis**, a variant of mesenteric ischemia, usually occurs in the distribution of the inferior mesenteric artery. The intestinal mucosa is the most sensitive to ischemia and will slough if underperfused. The clinical presentation is similar to inflammatory bowel disease. Ischemic colitis can occur after aortic surgery, particularly aortic aneurysm resection or aortofemoral bypass for occlusive

disease, when there is sudden reduction in blood flow to the inferior mesenteric artery.

► Clinical Findings

A. Symptoms and Signs

1. Acute intestinal ischemia—Patients with primary visceral arterial thrombosis often give an antecedent history consistent with chronic intestinal ischemia. The key finding with acute intestinal ischemia is severe, steady epigastric and periumbilical pain with minimal or no findings on physical examination of the abdomen because the visceral peritoneum is severely ischemic or infarcted and the parietal peritoneum is not involved. A high white cell count, lactic acidosis, hypotension, and abdominal distention may aid in the diagnosis.

2. Chronic intestinal ischemia—Patients are generally over 45 years of age and may have evidence of atherosclerosis in other vascular beds. Symptoms consist of epigastric or periumbilical postprandial pain lasting 1–3 hours. To avoid the pain, patients limit food intake and may develop a fear of eating. Weight loss is universal.

3. Ischemic colitis—Characteristic symptoms are left lower quadrant pain and tenderness, abdominal cramping, and mild diarrhea, which is often bloody.

B. Imaging and Colonoscopy

In patients with **acute** or **chronic intestinal ischemia**, a CTA or MRA can demonstrate narrowing of the proximal visceral vessels. In acute intestinal ischemia from a nonocclusive low flow state, angiography is needed to display the typical “pruned tree” appearance of the distal visceral vascular bed. Ultrasound scanning of the mesenteric vessels may show proximal obstructing lesions in laboratories that have experience with this technique.

In patients with **ischemic colitis**, colonoscopy may reveal segmental ischemic changes, most often in the rectal sigmoid and splenic flexure where collateral circulation may be poor.

► Treatment

A high suspicion of **acute intestinal ischemia** dictates immediate exploration to determine bowel viability. If the bowel remains viable, bypass can be done from the aorta to the celiac and the superior mesentery artery. In cases where bowel viability is questionable or bowel resection will be required, the bypass can be done with autologous vein, or with PTFE. There is a surprisingly low incidence of graft infection in these cases.

In **chronic intestinal ischemia**, angioplasty and stenting of the proximal vessel may be beneficial depending on the anatomy of the stenosis. Should an endovascular solution not be available, an aorto-visceral artery bypass is the preferred management. The long-term results are highly durable. Visceral artery endarterectomy is reserved for cases with multiple lesions where bypass would be difficult.

The mainstay of treatment of **ischemic colitis** is maintenance of blood pressure and perfusion until collateral

circulation becomes well established. The patient must be monitored closely for evidence of perforation, which will require resection.

► Prognosis

The combined morbidity and mortality rates are 10–15% from surgical intervention in these debilitated patients. However, without intervention both acute and chronic intestinal ischemia are uniformly fatal. Adequate collateral circulation usually develops in those who have ischemic colitis, and the prognosis for this entity is better than chronic intestinal ischemia.

► When to Refer

Any patient in whom there is a suspicion of intestinal ischemia should be referred for imaging and possible intervention.

Acosta S. Epidemiology of mesenteric vascular disease: clinical implications. *Semin Vasc Surg.* 2010 Mar;23(1):4–8. [PMID: 20298944]

Acosta S et al. Clinical implications for the management of acute thromboembolic occlusion of the superior mesenteric artery: autopsy findings in 213 patients. *Ann Surg.* 2005 Mar;241(3):516–22. [PMID: 15729076]

Cangemi JR et al. Intestinal ischemia in the elderly. *Gastroenterol Clin North Am.* 2009 Sep;38(3):527–40. [PMID: 19699412]

ACUTE MESENTERIC VEIN OCCLUSION

The hallmarks of acute mesenteric vein occlusion are postprandial pain and evidence of a hypercoagulable state. Acute mesenteric vein occlusion presents similarly to the arterial occlusive syndromes but is much less common. Patients at risk include those with a systemic hypercoagulable state, such as that observed with paroxysmal nocturnal hemoglobinuria or protein C, protein S, antithrombin deficiencies, or the *JAK2* mutation. These lesions are difficult to treat surgically, and thrombolysis is the mainstay of therapy. Aggressive long-term anticoagulation is required for these patients.

NONATHEROSCLEROTIC VASCULAR DISEASE

THROMBOANGIITIS OBLITERANS (Buerger Disease)



ESSENTIALS OF DIAGNOSIS

- Typically occurs in male cigarette smokers.
- Distal extremities involved with severe ischemia, progressing to tissue loss.
- Thrombosis of the superficial veins may occur.
- Amputation will be necessary unless the patient stops smoking.

► General Considerations

Buerger disease is a segmental, inflammatory, and thrombotic process of the distal most arteries and occasionally veins of the extremities. Pathologic examination reveals arteritis in the affected vessels. The cause is not known but it is rarely seen in nonsmokers. Arteries most commonly affected are the plantar and digital vessels of the foot and lower leg. In advanced stages, the fingers and hands may become involved. While Buerger disease was once common, its incidence has decreased dramatically.

► Clinical Findings

A. Symptoms and Signs

Buerger disease may be initially difficult to differentiate from routine peripheral vascular disease, but in most cases, the lesions are on the toes and the patient is younger than 40 years old. The observation of superficial thrombophlebitis may aid the diagnosis. Because the distal vessels are usually affected, intermittent claudication is not common with Buerger disease, but rest pain, particularly pain in the distal most extremity (ie, toes), is frequent. This pain often progresses to tissue loss and amputation, unless the patient stops smoking. The progression of the disease seems to be intermittent with acute and dramatic episodes followed by some periods of remission.

B. Imaging

MRA or invasive angiography can demonstrate the obliteration of the distal arterial tree typical of Buerger disease.

► Differential Diagnosis

In atherosclerotic peripheral vascular disease, the onset of tissue ischemia tends to be less dramatic than in Buerger disease, and symptoms of proximal arterial involvement, such as claudication, predominate.

Symptoms of Raynaud disease may be difficult to differentiate from Buerger disease. Repetitive atheroemboli may also mimic Buerger disease and may be difficult to differentiate. It may be necessary to image the proximal arterial tree to rule out sources of arterial microemboli.

► Treatment

Smoking cessation is the mainstay of therapy and will halt the disease in most cases. As the distal arterial tree is occluded, revascularization is not possible. Sympathectomy is rarely effective.

► Prognosis

If smoking cessation can be achieved, the outlook for Buerger disease may be better than in patients with premature peripheral vascular disease. If smoking cessation is not achieved, then the prognosis is generally poor, with amputation of both lower and upper extremities the eventual outcome.

Al Mheid I et al. Cell therapy in peripheral arterial disease. *Angiology*. 2008 Dec–2009 Jan;59(6):705–16. [PMID: 18818233]
 Malecki R et al. Thromboangiitis obliterans in the 21st century—a new face of disease. *Atherosclerosis*. 2009 Oct;206(2):328–34. [PMID: 19269635]

ARTERIAL ANEURYSMS

ABDOMINAL AORTIC ANEURYSMS

ESSENTIALS OF DIAGNOSIS

- Most aortic aneurysms are asymptomatic until rupture.
- Abdominal aortic aneurysms measuring 5 cm are palpable in 80% of patients.
- Back or abdominal pain with aneurysmal tenderness may precede rupture.
- Rupture is catastrophic; hypotension; excruciating abdominal pain that radiates to the back.

► General Considerations

Dilatation of the infrarenal aorta is a normal part of aging. The aorta of a healthy young man measures approximately 2 cm. An aneurysm is considered present when the aortic diameter exceeds 3 cm, but aneurysms rarely rupture until their diameter exceeds 5 cm. Abdominal aortic aneurysms are found in 2% of men over 55 years of age; the male to female ratio is 4:1. Ninety percent of abdominal atherosclerotic aneurysms originate below the renal arteries. The aneurysms usually involve the aortic bifurcation and often involve the common iliac arteries.

Inflammatory aneurysms are an unusual variant. These have an inflammatory peel (similar to the inflammation seen with retroperitoneal fibrosis) that surrounds the aneurysm and encases adjacent retroperitoneal structures, such as the duodenum and, occasionally, the ureters.

► Clinical Findings

A. Symptoms and Signs

1. Asymptomatic—Although 80% of 5-cm infrarenal aneurysms are palpable on routine physical examination, most aneurysms are discovered as incidental findings on ultrasound or CT imaging during the evaluation of unrelated abdominal symptoms.

2. Symptomatic—

A. PAIN—Aneurysmal expansion may be accompanied by pain that is mild to severe midabdominal discomfort often radiating to the lower back. The pain may be constant or intermittent and is exacerbated by even gentle pressure on the aneurysm sack. Pain may also accompany inflammatory aneurysms. Most aneurysms have a thick layer of thrombus lining the aneurysmal sac, but embolization to the lower extremities is rarely seen.

B. RUPTURE—The sudden escape of blood into the retroperitoneal space causes severe pain, a palpable abdominal mass, and hypotension. Free rupture into the peritoneal cavity is a lethal event.

B. Laboratory Findings

Even with a contained rupture, there may be little change in routine laboratory findings. In acute cases, the hematocrit may be normal, since there has been no opportunity for hemodilution.

Patients with aneurysms may also have such cardiopulmonary diseases as coronary artery disease, carotid disease, renal impairment, and emphysema, which are typically seen in elderly men who smoke. Preoperative testing may indicate the presence of these comorbid conditions, which increase the risk of intervention.

C. Imaging

Abdominal ultrasonography is the diagnostic study of choice for initial screening for the presence of an aneurysm. In approximately three-quarters of patients with aneurysms, curvilinear calcifications outlining portions of the aneurysm wall may be visible on plain films of the abdomen or back. CT scans provide a more reliable assessment of aneurysm diameter and should be done when the aneurysm nears the diameter threshold (5.5 cm) for treatment. Contrast-enhanced CT scans show the arteries above and below the aneurysm. The visualization of this vasculature is essential for planning repair.

Once an aneurysm is identified, routine follow-up with ultrasound will determine size and growth rate. The frequency of imaging depends on aneurysm size ranging from every 2 years for small (< 4 cm aneurysms) to every 6 months for aneurysms at or approaching 5 cm. When an aneurysm measures approximately 5 cm, a CTA with contrast should be done to more accurately assess the size of the aneurysm and define the anatomy.

► Screening

Data support the use of abdominal ultrasound to screen 65- to 74-year-old men, but not women, who have a history of smoking. Repeated screening does not appear to be needed if the aorta shows no enlargement.

► Treatment

A. Elective Repair

In general, elective repair is indicated for aortic aneurysms ≥ 5.5 cm in diameter or aneurysms that have undergone rapid expansion (> 0.5 cm in 6 months). Symptoms such as pain or tenderness may indicate impending rupture and require urgent repair regardless of the aneurysm's diameter.

B. Aneurysmal Rupture

A ruptured aneurysm is a lethal event. Approximately half the patients exsanguinate prior to reaching a hospital. In the remainder, bleeding may be temporarily contained in the retroperitoneum (contained rupture), allowing the

patient to undergo urgent surgery. However, only half of those patients will survive. Endovascular repair is available for urgent aneurysm repair in most major vascular centers, with the results offering some improvement over open repair for these critically ill patients.

C. Inflammatory Aneurysm

The presence of peri-aortic inflammation (inflammatory aneurysm) is not an indication for surgical treatment, unless there is associated compression of retroperitoneal structures, such as the ureter. Interestingly, the inflammation that encases an inflammatory aneurysm recedes after either endovascular or open surgical aneurysm repair.

D. Assessment of Operative Risk

Aneurysms appear to be a variant of systemic atherosclerosis. Patients with aneurysms have a high rate of coronary disease. A 2004 trial demonstrated minimal value in addressing stable coronary artery disease prior to aneurysm resection. However, in patients with significant symptoms of coronary disease, the coronary disease should be treated first. Aneurysm resection should follow shortly thereafter because there is a significant increased risk in aneurysm rupture after the coronary procedures. In patients with concomitant carotid stenosis, repairing symptomatic (but not asymptomatic) carotid disease prior to aneurysm resection is beneficial.

E. Open Surgical Resection versus Endovascular Repair

In open surgical aneurysm repair, a graft is sutured to the non-dilated vessels above and below the aneurysm. This involves an abdominal incision, extensive dissection, and interruption of aortic blood flow. The mortality rate is low (2–5%) in centers that have a high volume for this procedure and when it is performed in good risk patients. Older, sicker patients may not tolerate the cardiopulmonary stresses of the operation. With endovascular repair, a stent-graft is used to line the aorta and exclude the aneurysm. The anatomic requirements to securely achieve aneurysm exclusion vary according to the performance characteristics of the specific stent-graft device. In general, successful attachment requires a segment of non-dilated aorta (neck) between the renal arteries and the aneurysm that is at least 15 mm in length, and device insertion requires the lumen of the iliac arteries to be at least 7 mm in diameter. Most studies have found that endovascular aneurysm repair offers patients reduced operative morbidity and mortality as well as shorter recovery periods. However, long-term survival is equivalent between the two techniques. Patients who undergo endovascular repair require more repeat interventions and need to be monitored postoperatively, since there is a 10–15% incidence of continued aneurysm growth post endovascular repair.

F. Thrombus in an Aneurysm

The presence of thrombus within the aneurysm is not an indication for anticoagulation.

► Complications

Myocardial infarction, the most common complication, occurs in up to 10% of patients who undergo open aneurysm repair. The incidence of myocardial infarction is substantially lower with endovascular repair. For routine infrarenal aneurysms, renal injury is unusual; however, when it does occur, or if the baseline creatinine is elevated, it is a significant complicating factor in the postoperative period. Respiratory complications are similar to those seen in most major abdominal surgery. Gastrointestinal hemorrhage, even years after aortic surgeries, suggests the possibility of graft enteric fistula; the incidence of this complication is higher when the initial surgery is performed on an emergency basis.

► Prognosis

The mortality rate for an open elective surgical resection is 1–5%, and the mortality rate for endovascular therapy is 0.5–2%. Of those who survive surgery, approximately 60% are alive at 5 years; myocardial infarction is the leading cause of death. The decision to repair aneurysms in high-risk patients has been made easier with the reduced perioperative morbidity and mortality of the endovascular approach.

Mortality rates of untreated aneurysms vary with aneurysm diameter. The mortality rate among patients with large aneurysms has been defined as follows: 12% annual risk of rupture with an aneurysm ≥ 6 cm in diameter and a 25% annual risk of rupture in aneurysms of ≥ 7 cm diameter. In general, a patient with an aortic aneurysm ≥ 5.5 cm has a threefold greater chance of dying of a consequence of rupture of the aneurysm than of dying of the surgical resection.

At present, endovascular aneurysm repair may be less definitive than open surgical repair and requires close follow up with an imaging procedure. Device migration, component separation, limb thrombosis, or limb kinking are common reasons for repeat intervention. With complete exclusion of blood from the aneurysm sac, the pressure is lowered, which causes the aneurysm to shrink. An “endoleak” from the top or bottom of the graft (type 1) or through a graft defect (type 3) is associated with a persistent risk of rupture. Indirect leakage of blood through persistent lumbar and inferior mesenteric branches of the aneurysm (endoleak, type 2) produces an intermediate picture with somewhat reduced pressure in the sac, slow shrinkage, and low rupture risk. However, type 2 endoleak warrants close observation because aneurysm dilatation and rupture can occur.

► When to Refer

- Any patient with a 4 cm aortic aneurysm or larger should be referred for imaging and assessment by a vascular specialist.
- Urgent referrals should be made if the patient complains of pain and gentle palpation of the aneurysm confirms that it is the source, regardless of the aneurysm size.

► When to Admit

Patients with signs of aortic rupture require hospital admission.

- De Bruin JL et al. Long-term outcome of open or endovascular repair of abdominal aortic aneurysm. *N Engl J Med.* 2010;362:1881–9. [PMID: 20484396]
- Kim LG et al. Multicentre Aneurysm Screening Group. A sustained mortality benefit from screening for abdominal aortic aneurysm. *Ann Intern Med.* 2007 May 15;146(10):699–706. [PMID: 17502630]
- Lederle FA et al; Open Versus Endovascular Repair (OVER) Veterans Affairs Cooperative Study Group. Outcomes following endovascular vs open repair of abdominal aortic aneurysm: a randomized trial. *JAMA.* 2009 Oct 14;302(14):1535–42. [PMID: 19826022]
- Schanzer A et al. Predictors of abdominal aortic aneurysm sac enlargement post endovascular repair. *Circulation.* 2011 June 21;123(24):2848–55. [PMID: 21478500]
- Schermerhorn ML et al. Endovascular vs. open repair of abdominal aortic aneurysms in the Medicare population. *N Engl J Med.* 2008 Jan 31;358(5):464–74. [PMID: 18234751]
- Stanres BW et al. Management of ruptured abdominal aortic aneurysm in the endovascular era. *J Vasc Surg.* 2010 Jan;51(1):9–17. [PMID: 19883986]
- United Kingdom EVAR Trial Investigators; Greenhalgh RM et al. Endovascular versus open repair of abdominal aortic aneurysm. *N Engl J Med.* 2010 May 20;362(20):1863–71. [PMID: 20382983]

THORACIC AORTIC ANEURYSMS



ESSENTIALS OF DIAGNOSIS

- Widened mediastinum on chest radiograph.
- With rupture, sudden onset chest pain radiating to the back.

► General Considerations

Most thoracic aortic aneurysms are due to atherosclerosis; syphilis is now a rare cause. Disorders of connective tissue and Ehlers-Danlos and Marfan syndromes also are rare causes but have important therapeutic implications. Traumatic, false aneurysms, caused by partial tearing of the aortic wall with deceleration injuries, may occur just beyond the origin of the left subclavian artery. Less than 10% of aortic aneurysms occur in the thoracic aorta.

► Clinical Findings

A. Symptoms and Signs

Most thoracic aneurysms are asymptomatic. When symptoms occur, they depend largely on the size and the position of the aneurysm and its rate of growth. Substernal back or neck pain may occur. Pressure on the trachea, esophagus, or superior vena cava can result in the following symptoms and signs: dyspnea, stridor, or brassy cough; dysphagia; and edema in the neck and arms as well as distended neck veins. Stretching of the left recurrent laryngeal

nerve causes hoarseness. With aneurysms of the ascending aorta, aortic regurgitation may be present due to dilation of the aortic valve annulus. Rupture of a thoracic aneurysm is catastrophic because bleeding is rarely contained, allowing no time for emergent repair.

B. Imaging

The aneurysm may be diagnosed on chest radiograph by the calcified outline of the dilated aorta. CT scanning is the modality of choice to demonstrate the anatomy and size of the aneurysm and to exclude lesions that can mimic aneurysms, such as neoplasms or substernal goiter. MRI can also be useful. Cardiac catheterization and echocardiography may be required to describe the relationship of the coronary vessels to an aneurysm of the ascending aorta.

▶ Treatment

Indications for repair depend on the location of dilation, rate of growth, associated symptoms, and overall condition of the patient. Aneurysms measuring 6 cm or larger may be considered for repair. Aneurysms of the **descending thoracic aorta** are treated routinely by endovascular grafting. Repair of **arch aneurysms** should be undertaken only if there is a skilled surgical team with an acceptable record of outcomes for these complex procedures. The availability of thoracic aortic endograft technique for descending thoracic aneurysms or experimental branched endovascular reconstructions for arch aneurysms (custom made grafts with branches to the vessels involved in the aneurysm) does not change the indications for aneurysm repair. Aneurysms that involve the proximal aortic arch or ascending aorta represent particularly challenging problems. Open surgery is usually required; however, it carries substantial risk of morbidity (including stroke, diffuse neurologic injury, and intellectual impairment) because interruption of arch blood flow is required.

▶ Complications

With the exception of endovascular repair for discrete saccular aneurysms of the descending thoracic aorta, the morbidity and mortality of thoracic repair is considerably higher than that for infra-renal abdominal aortic aneurysm repair. Paraplegia remains a devastating complication. Most large series report approximately 4–10% rate of paraplegia following endovascular repair of thoracic aortic aneurysms. The spinal arterial supply is segmental through intercostal branches of the aorta with variable degrees of intersegmental connection. Therefore, the more extensive the aneurysm, the greater is the risk of paraplegia with resection. Prior infrarenal abdominal aortic surgery, subclavian or internal iliac artery stenosis, and hypotension all increase the paraplegia risk. Involvement of the aortic arch also increases the risk of stroke, even when the aneurysm does not directly affect the carotid artery.

▶ Prognosis

Generally, degenerative aneurysms of the thoracic aorta will enlarge and require repair to prevent death from rupture.

However, stable aneurysms can be followed with CT scanning. Saccular aneurysms, particularly those distal to the left subclavian artery and the descending thoracic aorta, have had good results with endovascular repair. Resection of large complex aneurysms of the aortic arch involves major technical issues and requires a skilled surgical team and should only be attempted in low-risk patients. Branched fenestrated technology for endovascular grafting is becoming widely available and holds promise for reduced morbidity and mortality.

▶ When to Refer

Patients who are deemed to have a reasonable surgical risk with a 5–6 cm aneurysm should be considered for repair, particularly if the aneurysm involves the descending thoracic aorta.

▶ When to Admit

Any patient with chest or back pain with a known or suspected thoracic aorta aneurysm must be admitted to the hospital and undergo imaging studies to rule out the aneurysm as a cause of the pain.

Jonker FH et al. Meta-analysis of open versus endovascular repair for ruptured descending thoracic aortic aneurysm. *J Vasc Surg.* 2010 Apr;51(4):1026–32. [PMID: 20347700]

Jonker FH et al. Outcomes of endovascular repair of ruptured descending thoracic aortic aneurysms. *Circulation.* 2010 Jun 29;121(25):2718–23. [PMID: 20547930]

Park KH et al. Variation in the shape and length of the branches of a thoracoabdominal aortic stent graft: implications for the role of standard off-the-shelf components. *J Vasc Surg.* 2010 Mar;51(3):572–6. [PMID: 20045625]

Svensson LG et al; Society of Thoracic Surgeons Endovascular Surgery Task Force. Expert consensus document on the treatment of descending thoracic aortic disease using endovascular stent-grafts. *Ann Thorac Surg.* 2008 Jan;85(1 Suppl):S1–41. [PMID: 18083364]

Torsello GB et al. Midterm results from the TRAVIATA registry: treatment of thoracic aortic disease with the Valiant stent graft. *J Endovasc Ther.* 2010 Apr;17(2):137–50. [PMID: 20426628]

PERIPHERAL ARTERY ANEURYSMS



ESSENTIALS OF DIAGNOSIS

- ▶ Widened, prominent pulses.
- ▶ Acute leg or foot pain and paresthesias with loss of distal pulses.

▶ General Considerations

Like aortic aneurysms, peripheral artery aneurysms are silent until critically symptomatic. However, unlike aortic aneurysms, the presenting manifestations are due to peripheral embolization and thrombosis. Popliteal artery aneurysms account for 70% of peripheral arterial aneurysms. Popliteal aneurysms may embolize repetitively over

time and occlude distal arteries. Due to the redundant parallel arterial supply to the foot, ischemia does not occur until a final embolus occludes flow. Approximately one-third of patients will require an amputation. To prevent limb loss, popliteal artery aneurysms should be repaired if > 2 cm in diameter or if lined with thrombus at any size.

Primary femoral artery aneurysms are much less common. However, pseudoaneurysms of the femoral artery following arterial punctures for arteriography and cardiac catheterization occur with an incidence ranging from 0.05% to 6% of arterial punctures. Thrombosis and embolization are the main risks of femoral true or false aneurysms and, like popliteal aneurysms, should be repaired when > 2 cm in diameter.

► Clinical Findings

A. Symptoms and Signs

The patient may be aware of a pulsatile mass when the aneurysm is in the groin, but popliteal aneurysms are often undetected by the patient and clinician. Rarely, peripheral aneurysms may produce symptoms by compressing the local vein or nerve. The first symptom may be due to ischemia of acute arterial occlusion. The symptoms range from sudden onset pain and paralysis to short distance claudication that slowly lessens as collateral circulation develops. Symptoms from recurrent embolization to the leg are often transient, if they occur at all. Sudden ischemia may appear in a toe or part of the foot, followed by slow resolution, and the true diagnosis may be elusive. The onset of recurrent episodes of pain in the foot, particularly if accompanied by cyanosis, suggests embolization and requires investigation of the heart and proximal arterial tree.

Because popliteal pulses are somewhat difficult to palpate even in normal individuals, a particularly prominent or easily felt pulse is suggestive of aneurysm and should be investigated by ultrasound. Since popliteal aneurysms are bilateral in 60% of cases, the diagnosis of thrombosis of a popliteal aneurysm is often aided by the palpation of a pulsatile aneurysm in the contralateral popliteal space. Approximately 50% of patients with popliteal aneurysms have an aneurysmal abdominal aorta.

B. Imaging Studies

Duplex color ultrasound is the most efficient investigation to confirm the diagnosis of peripheral aneurysm, measure its size and configuration, and demonstrate mural thrombus. MRA or CTA are required to define the aneurysm and local arterial anatomy for reconstruction. Arteriography is not recommended because mural thrombus reduces the apparent diameter of the lumen on angiography.

► Treatment

Surgery is indicated when an aneurysm is associated with any peripheral embolization, is > 2 cm, or a mural thrombus is present. Immediate or urgent surgery is indicated when acute embolization or thrombosis has caused acute ischemia. Intra-arterial thrombolysis may be done in the setting of acute ischemia, if examination (light touch)

suggests that immediate surgery is not imperative. Bypass is generally performed. Endovascular exclusion of the aneurysm can be done but is reserved for high-risk patients. Acute pseudoaneurysms of the femoral artery due to arterial punctures can be successfully treated using ultrasound-guided compression. Open surgery with prosthetic interposition grafting is preferred for primary aneurysms of the femoral artery.

► Prognosis

The long-term patency of bypass grafts for femoral and popliteal aneurysms is generally excellent but depends on the adequacy of the outflow tract. Late graft occlusion is less common than in similar surgeries for occlusive disease.

► When to Refer

In addition to patients with symptoms of ischemia, any patient with a peripheral arterial aneurysm measuring 2 cm or with ultrasound evidence of thrombus within the aneurysm should be referred to prevent progression to limb-threatening ischemia.

Cross JE et al. Nonoperative versus surgical management of small (less than 3 cm), asymptomatic popliteal artery aneurysms. *J Vasc Surg.* 2011 Apr;53(4):1145–8. [PMID: 21439460]

AORTIC DISSECTION



ESSENTIALS OF DIAGNOSIS

- Sudden searing chest pain with radiation to the back, abdomen, or neck in a hypertensive patient.
- Widened mediastinum on chest radiograph.
- Pulse discrepancy in the extremities.
- Acute aortic regurgitation may develop.

► General Considerations

Aortic dissection occurs when a spontaneous intimal tear develops and blood dissects into the media of the aorta. The tear probably results from the repetitive torque applied to the ascending and proximal descending aorta during the cardiac cycle; hypertension is an important component of this disease process. **Type A dissection** involves the arch proximal to the left subclavian artery, and **type B dissection** occurs in the proximal descending thoracic aorta typically just beyond the left subclavian artery. Dissections may occur in the absence of hypertension but abnormalities of smooth muscle, elastic tissue, or collagen are more common in these patients. Pregnancy, bicuspid aortic valve, and coarctation also are associated with increased risk of dissection.

Blood entering the intimal tear may extend the dissection into the abdominal aorta, the lower extremities, the carotid arteries or, less commonly, the subclavian arteries.

Both absolute pressure levels and the pulse pressure are important in propagation of dissection. The aortic dissection is a true emergency and requires immediate control of blood pressure to limit the extent of the dissection. With type A dissection, which has the worse prognosis, death may occur within hours, usually due to rupture of the dissection into the pericardial sac. Rupture into the pleural cavity is also possible. The intimal/medial flap of the aortic wall created by the dissection may occlude major aortic branches, resulting in ischemia of the brain, intestines, kidney, or lower extremities. Patients whose blood pressure is controlled and who survive the acute episode without complications may have long-term survival without surgical treatment.

► Clinical Findings

A. Symptoms and Signs

Severe persistent chest pain of sudden onset radiating down the back or possibly into the anterior chest is characteristic. Radiation of the pain into the neck may also occur. The patient is usually hypertensive. Syncope, hemiplegia, or paralysis of the lower extremities may occur. Intestinal ischemia or renal insufficiency may develop. Peripheral pulses may be diminished or unequal. A diastolic murmur may develop as a result of a dissection in the ascending aorta close to the aortic valve, causing valvular regurgitation, heart failure, and cardiac tamponade.

B. Electrocardiographic Findings

Left ventricular hypertrophy from long-standing hypertension is often present. Acute changes suggesting myocardial ischemia do not develop unless dissection involves the coronary artery ostium. Classically, inferior wall abnormalities predominate since dissection leads to compromise of the right rather than the left coronary artery. In some patients, the ECG may be completely normal.

C. Imaging

A multiplanar CT scan is the immediate diagnostic imaging modality of choice; clinicians should have a low threshold for obtaining a CT scan in any hypertensive patient with chest pain and equivocal findings on ECG.

The CT scan should include both the chest and abdomen to fully delineate the extent of the dissected aorta. MRI is an excellent imaging modality for chronic dissections, but in the acute situation, the longer imaging time and the difficulty of monitoring patients in the MRI scanner make the CT scan preferable. Chest radiographs may reveal an abnormal aortic contour or widened superior mediastinum. Although transesophageal echocardiography (TEE) is an excellent diagnostic imaging method, it is generally not readily available in the acute setting.

► Differential Diagnosis

Aortic dissection is most commonly misdiagnosed as myocardial infarction or other causes of chest pain such as pulmonary embolization. Dissections may occur with

minimal pain; branch vessel occlusion of the lower extremity can mimic arterial embolus.

► Treatment

A. Medical

Aggressive measures to lower blood pressure should occur when an aortic dissection is suspected, even before the diagnostic studies have been completed. Treatment requires a simultaneous reduction of the systolic blood pressure to 100–120 mm Hg and pulse pressure. β -Blockers have the most desirable effect of reducing the left ventricular ejection force that continues to weaken the arterial wall and should be first-line therapy. Labetalol, both an α - and β -blocker, lowers pulse pressure and achieve rapid blood pressure control. Give 20 mg over 2 minutes by intravenous injection. Additional doses of 40–80 mg intravenously can be given every 10 minutes (maximum dose 300 mg) until the desired blood pressure has been reached. Alternatively, 2 mg/min may be given by intravenous infusion, titrated to desired effect. In patients who have asthma, bradycardia, or other conditions that necessitate the patient's reaction to β -blockers be tested, esmolol is a reasonable choice because of its short half-life. Give a loading dose of esmolol, 0.5 mg/kg over 1 minute followed by an infusion of 0.0025–0.02 mg/kg/min. Titrate the infusion to a goal heart rate of 60–70 beats/min. If β -blockade alone does not control the hypertension, nitroprusside may be added as follows: 50 mg of nitroprusside in 1000 mL of 5% dextrose and water, infused at a rate of 0.5 mL/min; the infusion rate is increased by 0.5 mL every 5 minutes until adequate control of the pressure has been achieved. In patients with bronchial asthma, while there are no data supporting the use of the calcium-channel antagonists, diltiazem and verapamil are potential alternatives to treatment with β -blocking drugs. Morphine sulfate is the appropriate drug to use for pain relief. Long-term medical care of patients should include β -blockers in their antihypertensive regimen.

B. Surgical Intervention

Urgent surgical intervention is required for all **type A dissections**. If a skilled cardiovascular team is not available, the patient should be transferred to an appropriate facility. The procedure involves grafting and replacing the diseased portion of the arch and brachiocephalic vessels as necessary. Replacement of the aortic valve may be required with reattachment of the coronary arteries.

Urgent surgery is required for **type B dissections** if there is aortic branch compromise resulting in malperfusion of the renal, visceral, or extremity vessels. While endovascular therapy may have a role in the treatment of complications following type B dissection, there is no evidence to support the early endovascular intervention of uncomplicated type B dissections.

► Prognosis & Follow-up

The mortality rate for untreated type A dissections is approximately 1% per hour for 72 hours and over 90% at 3 months. Mortality is also extremely high for untreated complicated

type B dissections. The surgical and endovascular options for these patients also have significant morbidity and mortality. They are technically demanding and require an experienced team to achieve perioperative mortalities of < 10%. Patients with uncomplicated type B dissections whose blood pressure is controlled and who survive the acute episode without complications may have long-term survival without surgical treatment. Aneurysmal enlargement of the false lumen may develop in these patients despite adequate antihypertensive therapy. Yearly CT scans are required to monitor the size of the aneurysm. Indications for repair are determined by size (≥ 6 cm), similar to undissected thoracic aneurysms. Endovascular covering of the intimal tear in the acute setting may prevent this complication, but initial trials on the routine endovascular treatment of type B dissections have not shown an advantage for early intervention and therefore cannot be widely endorsed at this time.

▶ When to Admit

Any dissection involving the aortic arch (type A) should be immediately repaired. Acute type B dissections require repair only when there is evidence of rupture or major branch occlusion.

Feezor RJ et al. Early outcomes after endovascular management of acute, complicated type B aortic dissection. *J Vasc Surg.* 2009 Mar;49(3):561–6. [PMID: 19268759]

Kim KM et al. Aortic remodeling, volumetric analysis, and clinical outcomes of endoluminal exclusion of acute complicated type B thoracic aortic dissections. *J Vasc Surg.* 2011 Aug;54(2):316–24. [PMID: 21819922]

Litmanovich D et al. CT and MRI in diseases of the aorta. *AJR Am J Roentgenol.* 2009 Oct;193(4):928–40. [PMID: 19770313]

Nienaber CA et al. Randomized comparison of strategies for type B aortic dissection: the INvestigation of STEnt Grafts in Aortic Dissection (INSTEAD) trial. *Circulation.* 2009 Dec 22;120(25):2519–28. [PMID: 19996018]

VENOUS DISEASES

VARICOSE VEINS



ESSENTIALS OF DIAGNOSIS

- ▶ Dilated, tortuous superficial veins in the lower extremities.
- ▶ May be asymptomatic or associated with aching discomfort or pain.
- ▶ Often hereditary.
- ▶ Increased frequency after pregnancy.

▶ General Considerations

Varicose veins develop in the lower extremities. Periods of high venous pressure related to prolonged standing or heavy

lifting are contributing factors, but the highest incidence occurs in women after pregnancy. Varicosities develop in 15% of all adults.

The greater saphenous vein and its tributaries are most commonly involved, but the short saphenous vein (posterior lower leg) may also be affected. Distention of the vein prevents the valve leaflets from coapting, creating incompetence. Thus, dilation at any point along the vein leads to increased pressure and distention of the vein segment below that valve, which in turn causes progressive failure of the next lower valve and progressive venous reflux. Perforating veins that connect the deep and superficial systems may become incompetent, allowing blood to reflux into the superficial veins from the deep system through the incompetent perforators and increasing venous pressure and distention.

Secondary varicosities can develop as a result of obstructive changes and valve damage in the deep venous system following thrombophlebitis, or rarely as a result of proximal venous occlusion due to neoplasm or fibrosis. Congenital or acquired arteriovenous fistulas or venous malformations are also associated with varicosities and should be considered in young patients with varicosities.

▶ Clinical Findings

A. Symptoms and Signs

Symptom severity is not correlated with the number and size of the varicosities; extensive varicose veins may produce no subjective symptoms, whereas minimal varicosities may produce many symptoms. Dull, aching heaviness or a feeling of fatigue of the legs brought on by periods of standing is the most common complaint.

Clinicians must be careful to identify symptoms of occlusive peripheral vascular disease, such as intermittent claudication and coldness of the feet, since occlusive arterial disease is usually a contraindication to the operative treatment of varicosities distal to the knee. Itching from a venous stasis dermatitis may occur either above the ankle or directly overlying large varicosities.

Dilated, tortuous veins beneath the skin in the thigh and leg are generally visible upon standing, although in very obese patients palpation may be necessary to detect their presence and location. Some swelling is common but secondary tissue changes may be absent even in extensive varicosities. However, if the varicosities are of long duration, brownish pigmentation and thinning of the skin above the ankle may be present. The presence of a bruit or a thrill is useful in making the diagnosis of an associated arteriovenous fistula.

B. Imaging

The identification of the source of venous reflux that feeds the symptomatic veins is necessary for effective surgical treatment. Duplex ultrasonography by a technician experienced in the diagnosis and localization of venous reflux is the test of choice for planning therapy. In most cases, reflux will arise from the greater saphenous vein.

► Differential Diagnosis

Primary varicose veins should be differentiated from those secondary to chronic venous insufficiency of the deep system of veins with extensive swelling, fibrosis, pigmentation, and ulceration of the distal lower leg (the postphlebitic syndrome). Pain or discomfort secondary to arthritis, radiculopathy, or arterial insufficiency should be distinguished from symptoms associated with coexistent varicose veins. In adolescent patients with varicose veins, imaging of the deep venous system is important to exclude a congenital malformation or atresia of the deep veins. Surgical treatment of varicose veins in these patients is contraindicated because the varicosities may play a significant role in venous drainage of the limb.

► Complications

Thrombophlebitis within a varicose vein is uncommon. This presents as subacute to acute localized pain and palpable hardness at the site of the phlebitis. The process is self-limiting, has a low risk of embolization, and usually resolves within weeks. Rarely, the phlebitis extends to involve the greater saphenous vein. Predisposing conditions for thrombophlebitis include pregnancy, local trauma, or prolonged periods of sitting.

In older patients, superficial varicosities may bleed with even minor trauma. The amount of bleeding can be alarming as the pressure in the varicosity is high.

► Treatment

A. Nonsurgical Measures

Nonsurgical treatment is effective. Elastic graduated compression stockings (medium or heavy weight) give external support to the veins. These stockings may be useful in early varicosities to prevent progression of disease. When elastic stockings worn during standing are combined with elevation of the legs when possible, good control can be maintained and the development of complications can often be avoided. This approach may be used in elderly patients, in those who refuse or wish to defer surgery, and in those with mild asymptomatic varicosities.

B. Surgical Measures

Treatment with endovenous ablation (with either radiofrequency or laser) or, less commonly, with greater saphenous vein stripping is very effective for reflux arising from the greater saphenous vein. Less common sources of reflux include the lesser saphenous vein (for varicosities in the posterior calf), and nonsaphenous incompetent perforator veins arising directly from the deep venous system in the thigh. Correction of reflux is performed at the same time as excision of the symptomatic varicose veins. Phlebectomy without correction of reflux results in a high rate of recurrent varicosities, as the uncorrected reflux progressively dilates adjacent veins. Concurrent reflux detected by ultrasonography in the deep system is not a contraindication to treatment of superficial reflux because the majority of deep vein dilatation is secondary

to volume overload in this setting, which will resolve with correction of the superficial reflux.

C. Compression Sclerotherapy

Sclerotherapy to obliterate and produce permanent fibrosis of the involved veins is generally reserved for the treatment of small varicose veins < 4 mm in diameter. Use of foam sclerotherapy can allow treatment of larger veins, although systemic embolization of the foam sclerosant may be a concern. The injection of the sclerosing solution into the varicose vein is followed by a period of compression of the segment, resulting in obliteration of the vein. Complications such as phlebitis, tissue necrosis, or infection may occur, and vary in incidence with the skill of the clinician.

► Prognosis

Surgical correction of venous insufficiency (reflux) and excision of varicose veins provide excellent results. The 5-year success rate (as defined as lack of pain and recurrent varicosities) is 85–90%. Simple excision (phlebectomy) or injection sclerotherapy without correction of reflux is associated with higher rates of recurrence. Even after adequate treatment, secondary tissue changes, such as lipodermosclerosis, may persist.

► When to Refer

- Absolute indications for referral for saphenous ablation include phlebitis and bleeding.
- Pain and cosmetic concerns are responsible for the majority of referrals for ablation.

Figueiredo M et al. Results of surgical treatment compared with ultrasound-guided foam sclerotherapy in patients with varicose veins: a prospective randomised study. *Eur J Vasc Endovasc Surg.* 2009 Dec;38(6):758–63. [PMID: 19744867]

Rasmussen LH et al. Randomised clinical trial comparing endovenous laser ablation with stripping of the great saphenous vein: clinical outcome and recurrence after 2 years. *Eur J Vasc Endovasc Surg.* 2010 May;39(5):630–5. [PMID: 20064730]

Subramonia S et al. Randomized clinical trial of radiofrequency ablation or conventional high ligation and stripping for great saphenous varicose veins. *Br J Surg.* 2010 Mar;97(3):328–36. [PMID: 20035541]

SUPERFICIAL VENOUS THROMBOPHLEBITIS



ESSENTIALS OF DIAGNOSIS

- Induration, redness, and tenderness along a superficial vein, usually the saphenous vein.
- Induration, redness, and tenderness at the site of a recent intravenous line.
- Significant swelling of the extremity may not be seen.

► General Considerations

Short-term venous catheterization of superficial arm veins as well as the use of longer term peripherally inserted central catheter (PICC) lines are the most common cause of superficial thrombophlebitis. Intravenous catheter sites should be observed daily for signs of local inflammation and should be removed if a local reaction develops in the vein. Serious thrombotic or septic complications can occur if this policy is not followed.

Superficial thrombophlebitis may occur spontaneously, as in pregnant or postpartum women or in individuals with varicose veins or thromboangiitis obliterans; or it may be associated with trauma, as in the case of a blow to the leg or following intravenous therapy with irritating solutions. It also may be a manifestation of systemic hypercoagulability secondary to abdominal cancer such as carcinoma of the pancreas and may be the earliest sign of these conditions. Superficial thrombophlebitis may be associated with occult deep venous thrombosis (DVT) in about 20% of cases. Pulmonary emboli are exceedingly rare and occur from an associated DVT. (See Chapters 9 and 14 for discussion on Deep Venous Thrombosis.)

► Clinical Findings

In spontaneous superficial thrombophlebitis, the greater saphenous vein is most often involved. The patient usually experiences a dull pain in the region of the involved vein. Local findings consist of induration, redness, and tenderness along the course of a vein. The process may be localized, or it may involve most of the long saphenous vein and its tributaries. The inflammatory reaction generally subsides in 1–2 weeks; a firm cord may remain for a much longer period. Edema of the extremity is uncommon.

Localized redness and induration at the site of a recent intravenous line requires urgent attention. Proximal extension of the induration and pain with chills and high fever suggest septic phlebitis and requires urgent treatment.

► Differential Diagnosis

The linear rather than circular nature of the lesion and the distribution along the course of a superficial vein serve to differentiate superficial phlebitis from cellulitis, erythema nodosum, erythema induratum, panniculitis, and fibrositis. Lymphangitis and deep thrombophlebitis must also be considered.

► Treatment

For spontaneous thrombophlebitis if the process is well localized and not near the saphenofemoral junction, local heat, and nonsteroidal anti-inflammatory medications are usually effective in limiting the process. If the induration is extensive or is progressing toward the saphenofemoral junction (leg) or cephalo-axillary junction (arm), ligation and division of the vein at the junction of the deep and superficial veins is indicated.

Anticoagulation therapy is usually not required unless the disease is rapidly progressing or there is concern for extension into the deep system.

Septic superficial thrombophlebitis is an intravascular abscess and requires urgent treatment with heparin (see Table 14–15) to limit additional thrombus formation and antibiotics (eg, vancomycin, 15 mg/kg intravenously every 12 hours plus ceftriaxone, 1 g intravenously every 24 hours). Surgical excision of the involved vein may also be necessary to control the infection. *Staphylococcus aureus* is the most common pathogen. If cultures are positive, therapy should be continued for 7–10 days or for 4–6 weeks if complicating endocarditis cannot be excluded. Other organisms, including fungi, may also be responsible.

► Prognosis

With spontaneous thrombophlebitis, the course is generally benign and brief. The prognosis depends on the underlying pathologic process. In patients with phlebitis secondary to varicose veins, recurrent episodes are likely unless correction of the underlying venous reflux and excision of varicosities is done. In contrast, the mortality from septic thrombophlebitis is 20% or higher and requires aggressive treatment. However, if the involvement is localized, the mortality is low and prognosis is excellent with early treatment.

van Weert H et al. Spontaneous superficial venous thrombophlebitis: does it increase risk for thromboembolism? A historic follow-up study in primary care. *J Fam Pract.* 2006 Jan;55(1):52–7. [PMID: 16388768]

CHRONIC VENOUS INSUFFICIENCY



ESSENTIALS OF DIAGNOSIS

- History of prior DVT or leg injury.
- Edema, stasis (brawny) skin pigmentation, subcutaneous liposclerosis in the lower leg.
- Large ulcerations at or above the ankle are common (stasis ulcers).

► General Considerations

Chronic venous insufficiency can result from changes secondary to acute deep venous thrombophlebitis (see Chapter 14), although a definite history of phlebitis is not obtainable in about 25% of these patients. There may be a history of leg trauma. Obesity is often a complicating factor. Chronic venous insufficiency also may occur in association with superficial venous reflux and varicose veins or as a result of neoplastic obstruction of the pelvic veins or congenital or acquired arteriovenous fistula.

The basic pathology is caused by valve leaflets that do not coapt because they are either thickened and scarred (the post-thrombotic syndrome) or in a dilated vein and are therefore functionally inadequate. This results in an abnormally high hydrostatic force transmitted to the subcutaneous veins and tissues of the lower leg. The resulting

edema results in dramatic and deleterious secondary changes. The stigmata of chronic venous insufficiency include fibrosis of the subcutaneous tissue and skin, pigmentation of skin (hemosiderin taken up by the dermal macrophages) and, later, ulceration which is extremely slow to heal. Itching may precipitate the formation of ulceration or local wound cellulitis. Dilation of the superficial veins may occur, leading to varicosities. Whereas primary varicose veins with no abnormality of the deep venous system may be associated with some similar changes, the edema is more pronounced in the post-thrombotic extremities, and the secondary changes are more extensive and debilitating.

► Clinical Findings

A. Symptoms and Signs

Progressive pitting edema of the leg (particularly the lower leg) is the primary presenting symptom. Secondary changes in the skin and subcutaneous tissues develop over time. The usual symptoms are itching, a dull discomfort made worse by periods of standing, and pain if an ulceration is present. The skin at the ankle is usually taut from swelling, shiny, and a brownish pigmentation (hemosiderin) often develops. If the condition is long-standing, the subcutaneous tissues become thick and fibrous. Ulcerations may occur, usually just above the ankle, on the medial or anterior aspect of the leg. Healing results in a thin scar on a fibrotic base that often breaks down with minor trauma or further bouts of leg swelling. Varicosities may appear that are associated with incompetent perforating veins. Cellulitis, which is often difficult to distinguish from the hemosiderin pigmentation, may be diagnosed by blanching erythema.

B. Imaging

Patients with post-thrombotic syndrome or signs of chronic venous insufficiency should undergo duplex ultrasonography to determine whether superficial reflux is present and to evaluate the degree of deep reflux and obstruction.

► Differential Diagnosis

Patients with congestive heart failure, chronic kidney disease, or decompensated liver disease may have bilateral edema of the lower extremities. Swelling from lymphedema may be unilateral, but varicosities are absent. Edema from these causes pits easily and brawny discoloration is rare. Lipedema is a disorder of adipose tissue that occurs almost exclusively in women, is bilateral and symmetric, and is characterized by stopping at a distinct line just above the ankles.

Primary varicose veins may be difficult to differentiate from the secondary varicosities that often develop in this condition, as discussed above.

Other conditions associated with chronic ulcers of the leg include autoimmune diseases (eg, Felty syndrome), arterial insufficiency (often very painful with absent pulses), sickle cell anemia, erythema induratum (bilateral and usually on the posterior aspect of the lower part of the leg), and fungal infections (cultures specific: no chronic swelling or varicosities).

► Prevention

Irreversible tissue changes and associated complications in the lower legs can be minimized through early and aggressive anticoagulation of acute DVT to minimize the valve damage and by prescribing compression stockings if chronic edema develops after the DVT has resolved. Catheter-directed thrombolysis or mechanical thrombectomy of acute DVT may be of greater value than simple anticoagulants in preventing post-thrombotic syndrome and chronic venous insufficiency.

► Treatment

A. General Measures

Well-fitting, graduated compression stockings worn from the mid foot to just below the knee during the day and evening are the mainstays of treatment and is usually sufficient. When it is not, additional measures, such as avoidance of long periods of sitting or standing and intermittent elevations of the involved leg and sleeping with the legs kept above the level of the heart, may be necessary to control the swelling. Pneumatic compression of the leg, which can pump the fluid out of the leg, is used in cases refractory to the above measures.

B. Ulceration

As the primary pathology is edema, healing of the ulcer will not occur until the edema is controlled. A lesion can often be treated on an ambulatory basis by means of a semi-rigid gauze boot made with Unna paste (Gelocast, Medicopaste) or a multi-layer compression (such as Profore) and applied to the leg after much of the swelling has been reduced by a period of elevation. The boot must be changed every 2–3 days, depending on the amount of drainage from the ulcer. The ulcer, tendons, and bony prominences must be adequately padded. As an alternative and after the ulcer has healed, elastic stockings with graduated compression below the knee are used in an effort to prevent recurrent edema and ulceration. If compression stockings are used with ulcers, an absorbent dressing must be applied under the stocking as the wounds can leak large volumes of fluid. The pumping action of the calf muscles on the blood flow out of the lower extremity is enhanced by a circumferential nonelastic bandage on the ankle and lower leg. Home compression therapy with a pneumatic compression device is also effective at reducing edema, but many patients have severe pain with the “milking” action of the pump device. Some patients will require admission for complete bed rest and leg elevation to achieve ulcer healing.

C. Correction of Superficial Reflux

Incompetent (refluxing) perforator veins that feed the area of ulceration can be treated with percutaneous means (radiofrequency ablation or endovenous laser treatment) to help decrease the venous pressure in the area of ulceration and promote healing. Venous valvular reconstructive surgery is under investigation. Where there is substantial obstruction of the deep venous system, superficial varicosities supply the venous return and they should not be removed.

► Prognosis

Individuals with chronic venous insufficiency often have recurrent problems, particularly if they do not consistently wear support stockings that have at least 30 mm Hg compression.

► When to Refer

- Patients with significant saphenous reflux should be evaluated for ablation as this may reduce the recirculation of blood and return the deep system to competence.
- Patients with ulcers should be monitored by a wound care team so that these challenging wounds can receive aggressive care.

Bergan JJ et al. Chronic venous disease. *N Engl J Med*. 2006 Aug 3; 355(5):488–98. [PMID: 16885552]
 Eberhard RT et al. Chronic venous insufficiency. *Circulation*. 2005 May 10;111(18):2398–409. [PMID: 15883226]
 Grey JE et al. Venous and arterial leg ulcers. *BMJ*. 2006 Feb 11; 332(7537):347–50. [PMID: 16470058]
 Patel NP et al. Current management of venous ulceration. *Plast Reconstr Surg*. 2006 Jun;117(7 Suppl):254S–260S. [PMID: 16799394]

SUPERIOR VENA CAVAL OBSTRUCTION



ESSENTIALS OF DIAGNOSIS

- Swelling of the neck, face and upper extremities.
- Dilated veins over the upper chest and neck.

► General Considerations

Partial or complete obstruction of the superior vena cava is a relatively rare condition that is usually secondary to neoplastic or inflammatory processes in the superior mediastinum. The most frequent causes are (1) neoplasms, such as lymphomas, primary malignant mediastinal tumors, or carcinoma of the lung with direct extension (over 80%); (2) chronic fibrotic mediastinitis, either of unknown origin or secondary to tuberculosis, histoplasmosis, pyogenic infections, or drugs, especially methysergide; (3) DVT, often by extension of the process from the axillary or subclavian vein into the innominate vein and vena cava associated with catheterization of these veins for dialysis or hyperalimentation; (4) aneurysm of the aortic arch; and (5) constrictive pericarditis.

► Clinical Findings

A. Symptoms and Signs

The onset of symptoms is acute or subacute. Symptoms include swelling of the neck and face, and upper extremities. Symptoms are often perceived as congestion and present as headache, dizziness, visual disturbances, stupor, syncope, or cough. Symptoms are particularly exacerbated

when the patient is supine or bends over. There is progressive obstruction of the venous drainage of the head, neck, and upper extremities. The cutaneous veins of the upper chest and lower neck become dilated, and flushing of the face and neck develops. Brawny edema of the face, neck, and arms occurs later, and cyanosis of these areas then appears. Cerebral and laryngeal edema ultimately results in impaired function of the brain as well as respiratory insufficiency. Bending over or lying down accentuates the symptoms; sitting quietly is generally preferred. The manifestations are more severe if the obstruction develops rapidly and if the azygos junction or the vena cava between that vein and the heart is obstructed.

B. Laboratory Findings

The venous pressure is elevated (often > 20 cm of water) in the arm and is normal in the leg. Since lung cancer is a common cause, bronchoscopy is often performed; transbronchial biopsy, however, is relatively contraindicated because of venous hypertension and the risk of bleeding.

C. Imaging

Chest radiographs and a CT scan will define the location and often the nature of the obstructive process, and contrast venography or magnetic resonance venography (MRV) will map out the extent and degree of the venous obstruction and the collateral circulation. Brachial venography or radionuclide scanning following intravenous injection of technetium Tc-99m pertechnetate demonstrates a block to the flow of contrast material into the right heart and enlarged collateral veins. These techniques also allow estimation of blood flow around the occlusion as well as serial evaluation of the response to therapy.

► Treatment

Urgent treatment for neoplasm consists of (1) cautious use of intravenous diuretics and (2) mediastinal irradiation, starting within 24 hours, with a treatment plan designed to give a high daily dose but a short total course of therapy to rapidly shrink the local tumor even further. Intensive combined therapy will palliate the process in up to 90% of patients. In patients with a subacute presentation, radiation therapy alone usually suffices. Chemotherapy is added if lymphoma or small-cell carcinoma is diagnosed.

Conservative measures, such as elevation of the head of the bed and lifestyle modification to avoid bending over, are useful. Balloon angioplasty of the obstructed caval segment combined with stent placement provides prompt relief of symptoms and is the procedure of choice. Occasionally, anticoagulation is needed, while thrombolysis is rarely needed. Long-term outcome is complicated by risk of re-occlusion from either thrombosis or further growth of neoplasm. Surgical procedures to bypass the obstruction are complicated by bleeding relating to high venous pressure. In cases where the thrombosis is secondary to an indwelling catheter, thrombolysis may be attempted. Clinical judgment is required since a long-standing clot may be fibrotic and the risk of bleeding will outweigh the potential benefit.

► Prognosis

The prognosis depends on the nature and degree of obstruction and its speed of onset. Slowly developing forms secondary to fibrosis may be tolerated for years. A high degree of obstruction of rapid onset secondary to cancer is often fatal in a few days or weeks because of increased intracranial pressure and cerebral hemorrhage, but treatment of the tumor with radiation and chemotherapeutic drugs may result in significant palliation. Balloon angioplasty and stenting provides good relief but may require re-treatment for recurrent symptoms secondary to thrombosis or restenosis.

► When to Refer

Referral should occur with any patient with progressive head and neck swelling to rule out superior vena cava syndrome.

► When to Admit

Any patient with acute edema of the head and neck or any patient in whom signs and symptoms of airway compromise, such as hoarseness or stridor, develop should be admitted.

Watkinson AF et al. Endovascular stenting to treat obstruction of the superior vena cava. *BMJ*. 2008 Jun 21;336(7658):1434–7. [PMID: 18566082]

Wilson LD et al. Clinical practice. Superior vena cava syndrome with malignant causes. *N Engl J Med*. 2007 May 3;356(18):1862–9. [PMID: 17476012]

DISEASES OF THE LYMPHATIC CHANNELS

LYMPHANGITIS & LYMPHADENITIS



ESSENTIALS OF DIAGNOSIS

- Red streak from wound or area of cellulitis toward regional lymph nodes, which are usually enlarged and tender.
- Chills, fever, and malaise may be present.

► General Considerations

Lymphangitis and lymphadenitis are common manifestations of a bacterial infection that is usually caused by hemolytic streptococci or *S aureus* (or by both organisms) and usually arises from the site of an infected wound. The wound may be very small or superficial, or an established abscess may be present, feeding bacteria into the lymphatics. The involvement of the lymphatics is often manifested by a red streak in the skin extending in the direction of the regional lymph nodes, which are, in turn, generally tender and engorged. Systemic manifestations include fever, chills, and malaise. The infection may progress rapidly, often in a matter of hours, and may lead to septicemia and even death.

► Clinical Findings

A. Symptoms and Signs

Throbbing pain is usually present in the area of cellulitis at the site of bacterial invasion. Malaise, anorexia, sweating, chills, and fever of 38–40 °C develop rapidly. The red streak, when present may be definite or may be very faint and easily missed, especially in dark-skinned patients. It is usually tender or indurated in the area of cellulitis. The involved regional lymph nodes may be significantly enlarged and are usually quite tender. The pulse is often rapid.

B. Laboratory Findings

Leukocytosis with a left shift is usually present. Blood cultures may be positive, most often for staphylococcal or streptococcal species. Culture and sensitivity studies of the wound exudate or pus may be helpful in treatment of the more severe or refractory infections but are often difficult to interpret because of skin contaminants.

► Differential Diagnosis

Lymphangitis may be confused with superficial thrombophlebitis, but the erythema and induration of thrombophlebitis is localized in and around the thrombosed vein. Venous thrombosis is not associated with lymphadenitis, and a wound of entrance with secondary cellulitis is generally absent.

Cat-scratch fever should be considered when lymphadenitis is present; the nodes, though often very large, are relatively nontender. Exposure to cats is common, but the patient may have forgotten about the scratch.

It is extremely important to differentiate cellulitis from acute streptococcal hemolytic gangrene or necrotizing fasciitis. These are deeper infections that may be extensive and are potentially lethal. Patients appear more seriously ill; there may be redness due to leakage of red cells, creating a non-blanching erythema; and subcutaneous crepitus may be palpated or auscultated using the diaphragm with light pressure over the involved area. Immediate wide debridement of all involved deep tissues should be done if these signs are present.

► Treatment

A. General Measures

Prompt treatment should include heat (hot, moist compresses or heating pad), elevation when feasible, and immobilization of the infected area. Analgesics may be prescribed for pain.

B. Specific Measures

Empiric antibiotic therapy for hemolytic streptococci or *S aureus* (or by both organisms) should always be instituted when local infection becomes invasive, as manifested by cellulitis and lymphangitis. Because such infections are so frequently caused by streptococci, cephalosporins or extended-spectrum penicillins are commonly used

(eg, cephalexin, 0.5 g orally four times daily for 7–10 days; see Table 30–6). Given the increasing incidence of methicillin-resistant *S aureus* (MRSA) in the community, coverage of this pathogen with appropriate antibiotic therapy (eg, trimethoprim-sulfamethoxazole, two double strength tablets twice daily for 7–10 days) should be considered (see Tables 30–4 and 30–6).

C. Wound Care

Any wound that is the initiating site of lymphangitis should be treated aggressively. Any necrotic tissue must be debrided and loculated pus drained.

► Prognosis

With proper therapy including an antibiotic effective against the invading bacteria, control of the infection can usually be achieved in a few days. Delayed or inadequate therapy can lead to overwhelming infection with septicemia.

► When to Admit

Infections causing lymphangitis should be treated in the hospital with intravenous antibiotics. Debridement may be required.

LYMPHEDEMA



ESSENTIALS OF DIAGNOSIS

- ▶ Painless persistent edema of one or both lower extremities, primarily in young women.
- ▶ Pitting edema without ulceration, varicosities, or stasis pigmentation.
- ▶ There may be episodes of lymphangitis and cellulitis.

► General Considerations

When lymphedema is due to congenital developmental abnormalities consisting of hypoplastic or hyperplastic involvement of the proximal or distal lymphatics, it is referred to as the **primary form**. The obstruction may be in the pelvic or lumbar lymph channels and nodes when the disease is extensive and progressive. The **secondary form** of lymphedema involves inflammatory or mechanical lymphatic obstruction from trauma, regional lymph node resection or irradiation, or extensive involvement of regional nodes by malignant disease or filariasis. Secondary dilation of the lymphatics that occurs in both forms leads to incompetence of the valve system, disrupts the orderly flow along the lymph vessels, and results in progressive stasis of a protein-rich fluid. Episodes of acute and chronic inflammation may be superimposed, with further stasis and secondary fibrosis.

► Clinical Findings

Hypertrophy of the limb results, with markedly thickened and fibrotic skin and subcutaneous tissue in very advanced cases.

Lymphangiography and radioactive isotope studies may identify focal defects in lymph flow but are of little value in planning therapy. T₂-weighted MRI has been used to identify lymphatics and proximal obstructing masses.

► Treatment

Since there is no effective cure for lymphedema, the treatment strategies are designed to control the problem and allow normal activity and function. Most patients can be treated with some of the following measures: (1) The flow of lymph out of the extremity can be aided through intermittent elevation of the extremity, especially during the sleeping hours (foot of bed elevated 15–20 degrees, achieved by placing pillows beneath the mattress); the constant use of graduated elastic compression stockings; and massage toward the trunk—either by hand or by means of pneumatic pressure devices designed to milk edema out of an extremity. (2) Secondary cellulitis in the extremity should be avoided by means of good hygiene and treatment of any trichophytosis of the toes. Once an infection starts, it should be treated by periods of elevation and antibiotic therapy that covers *Staphylococcus* and *Streptococcus* organisms (see Table 30–6). Infections can be a serious and recurring problem and are often difficult to control. Prophylactic antibiotics have not been shown to be of benefit. (3) Intermittent courses of diuretic therapy, especially in those with premenstrual or seasonal exacerbations, are rarely helpful. (4) Amputation is used only for the rare complication of lymphangiosarcoma in the extremity.

► Prognosis

With aggressive treatment, including pneumatic compression devices, good relief of symptoms can be achieved. The long-term outlook is dictated by the associated conditions and avoidance of recurrent cellulitis.

Ashikaga T et al; National Surgical Adjuvant Breast, Bowel Project. Morbidity results from the NSABP B-32 trial comparing sentinel lymph node dissection versus axillary dissection. *J Surg Oncol*. 2010 Aug 1;102(2):111–8. [PMID: 20648579]

Haghighat S et al. Comparing two treatment methods for post mastectomy lymphedema: complex decongestive therapy alone and in combination with intermittent pneumatic compression. *Lymphology*. 2010 Mar;43(1):25–33. [PMID: 20552817]

Rockson SG. Diagnosis and management of lymphatic vascular disease. *J Am Coll Cardiol*. 2008 Sep 2;52(10):799–806. [PMID: 18755341]

Torres Lacomba M et al. Effectiveness of early physiotherapy to prevent lymphoedema after surgery for breast cancer: randomised, single blinded, clinical trial. *BMJ*. 2010 Jan 12;340:b5396. [PMID: 20068255]

SHOCK

ESSENTIALS OF DIAGNOSIS

- ▶ Hypotension, tachycardia, oliguria, altered mental status.
- ▶ Peripheral hypoperfusion and impaired oxygen delivery.

▶ General Considerations

Shock occurs when the rate of arterial blood flow is inadequate to meet tissue metabolic needs. This results in regional hypoxia and subsequent lactic acidosis from anaerobic metabolism in peripheral tissues as well as eventual end-organ damage and failure.

▶ Classification (Table 12-1)

A. Hypovolemic Shock

Hypovolemic shock results from decreased intravascular volume secondary to loss of blood or fluids and electrolytes. The etiology may be suggested by the clinical setting (eg, trauma) or by signs and symptoms of blood loss (eg, gastrointestinal bleeding) or dehydration (eg, vomiting or diarrhea). Compensatory vasoconstriction may transiently maintain the blood pressure but unreplaced losses of over 15% of the intravascular volume can result in hypotension and progressive tissue hypoxia.

B. Cardiogenic Shock

Cardiogenic shock results from cardiac failure with the resultant inability of the heart to maintain adequate tissue perfusion. The clinical definition of cardiogenic shock is evidence of tissue hypoxia due to decreased cardiac output (cardiac index < 2.2 L/min/m²) in the presence of adequate intravascular volume. This is most often caused by myocardial infarction but can also be due to cardiomyopathy, myocardial contusion, valvular incompetence or stenosis, or arrhythmias. See Chapter 10.

C. Obstructive Shock

Cardiac tamponade, tension pneumothorax, and massive pulmonary embolism can cause an acute decrease in cardiac output resulting in shock. These are medical emergencies requiring prompt diagnosis and treatment.

D. Distributive Shock

Distributive or vasodilatory shock has many causes including sepsis, anaphylaxis, systemic inflammatory response syndrome (SIRS) produced by severe pancreatitis or burns, traumatic spinal cord injury, or acute adrenal insufficiency. The reduction in systemic vascular resistance results in inadequate cardiac output and tissue hypoperfusion despite normal circulatory volume.

Table 12-1. Classification of shock by mechanism and common causes.

Hypovolemic shock

- Loss of blood (hemorrhagic shock)
 - External hemorrhage
 - Trauma
 - Gastrointestinal tract bleeding
 - Internal hemorrhage
 - Hematoma
 - Hemothorax or hemoperitoneum
- Loss of plasma
 - Burns
 - Exfoliative dermatitis
- Loss of fluid and electrolytes
 - External losses
 - Vomiting
 - Diarrhea
 - Excessive sweating
 - Hyperosmolar states (diabetic ketoacidosis, hyperosmolar nonketotic coma)
 - Internal losses (third spacing)
 - Pancreatitis
 - Ascites
 - Bowel obstruction

Cardiogenic shock

- Dysrhythmia (tachyarrhythmia, bradyarrhythmia)
- "Pump failure" (secondary to myocardial infarction or other cardiomyopathy)
- Acute valvular dysfunction (especially regurgitant lesions)
- Rupture of ventricular septum or free ventricular wall

Obstructive shock

- Tension pneumothorax
- Pericardial disease (tamponade, constriction)
- Disease of pulmonary vasculature (massive pulmonary emboli, pulmonary hypertension)
- Cardiac tumor (atrial myxoma)
- Left atrial mural thrombus
- Obstructive valvular disease (aortic or mitral stenosis)

Distributive shock

- Septic shock
- Anaphylactic shock
- Neurogenic shock
- Vasodilator drugs
- Acute adrenal insufficiency

Reproduced, with permission, from Stone CK, Humphries RL (editors). *Current Emergency Diagnosis & Treatment*, 5th ed. p. 193. McGraw-Hill, 2004.

1. Septic shock—Sepsis is the most common cause of distributive shock and carries a mortality rate of 20–50%. Sepsis is typically secondary to bacteremia caused by such gram-negative organisms as *Escherichia coli*, *Klebsiella*, *Proteus*, and *Pseudomonas* and less often due to gram-negative anaerobes (eg, *Bacteroides*), but the incidence of sepsis from gram-positive bacteria (eg, *S aureus*) and fungal organisms is increasing. Risk factors include extremes of age, diabetes, immunosuppression, and history of a recent invasive procedure.

2. Neurogenic shock—Neurogenic shock is caused by traumatic spinal cord injury or effects of an epidural or spinal anesthetic. This results in loss of sympathetic tone

with a reduction in systemic vascular resistance and hypotension without a compensatory tachycardia. Reflex vagal parasympathetic stimulation evoked by pain, gastric dilation, or fright may simulate neurogenic shock, producing hypotension, bradycardia, and syncope.

► Clinical Findings

A. Symptoms and Signs

Hypotension is traditionally defined as a systolic blood pressure of ≤ 90 mm Hg or a mean arterial pressure of <60 – 65 mm Hg but must be evaluated relative to the patient's normal blood pressure. A drop in systolic pressure of > 10 – 20 mm Hg or an increase in pulse of > 15 beats per minute with positional change suggests depleted intravascular volume. However, blood pressure is often not the best indicator of end-organ perfusion because compensatory mechanisms, such as increased heart rate, increased cardiac contractility, and vasoconstriction can occur to prevent hypotension. Patients with hypotension often have cool or mottled extremities and weak or thready peripheral pulses. Splanchnic vasoconstriction may lead to oliguria, bowel ischemia, and hepatic dysfunction, which can ultimately result in multi-organ failure. Mentation may be normal or patients may become restless, agitated, confused, lethargic, or comatose as a result of inadequate perfusion of the brain.

Hypovolemic shock is evident when signs of hypoperfusion, such as oliguria, altered mental status, and cool extremities, are present. Jugular venous pressure is low, and there is a narrow pulse pressure indicative of reduced stroke volume. Rapid replacement of fluids restores tissue perfusion. In **cardiogenic shock**, there are also signs of global hypoperfusion with oliguria, altered mental status, and cool extremities. Jugular venous pressure is elevated and there may be evidence of pulmonary edema with respiratory compromise in the setting of left-sided heart failure. A transthoracic echocardiogram (TTE) or a TEE is an effective diagnostic tool to differentiate hypovolemic from cardiogenic shock. In hypovolemic shock, the left ventricle will be small because of decreased filling, but contractility is often preserved. Cardiogenic shock results from cardiac failure with a resultant decrease in left ventricular contractility. In some cases, the left ventricle may appear dilated and full because of the inability of the left ventricle to eject a sufficient stroke volume.

In **obstructive shock**, the central venous pressure may be elevated but the TEE or TTE may show reduced left ventricular filling, a pericardial effusion in the case of tamponade, or thickened pericardium as in the case of pericarditis. Pericardiocentesis or pericardial window for pericardial tamponade, chest tube placement for tension pneumothorax, or catheter-directed thrombolytic therapy in the case of massive pulmonary embolism can be lifesaving in cases of obstructive shock.

In **distributive shock**, signs include hyperdynamic heart sounds, warm extremities initially, and a wide pulse pressure indicative of large stroke volume. The echocardiogram may show a hyperdynamic left ventricle. Fluid resuscitation may have little effect on blood pressure, urinary output, or mentation.

Septic shock is diagnosed when there is clinical evidence of infection in the setting of persistent hypotension and evidence of organ hypoperfusion, such as lactic acidosis, decreased urinary output, or altered mental status despite volume resuscitation. **Neurogenic shock** is diagnosed when there is evidence of central nervous system injury and persistent hypotension despite volume resuscitation.

B. Laboratory Findings

Blood specimens should be evaluated for complete blood count, electrolytes, glucose, arterial blood gas determinations, coagulation parameters, lactate levels, typing and cross-matching, and bacterial cultures. An electrocardiogram and chest radiograph should also be part of the initial assessment.

► Treatment

A. General Measures

Treatment depends on prompt diagnosis and an accurate appraisal of inciting conditions. Initial management consists of basic life support with an assessment of the patient's airway, breathing, and circulation. This may entail airway intubation and mechanical ventilation. Ventilatory failure should be anticipated in patients with a severe metabolic acidosis in association with shock. Mechanical ventilation along with sedation can decrease the oxygen demand of the respiratory muscles and allow improved oxygen delivery to other hypoperfused tissues. Intravenous access and fluid resuscitation should be instituted along with cardiac monitoring and assessment of hemodynamic parameters such as blood pressure and heart rate. Cardiac monitoring can detect myocardial ischemia or malignant arrhythmias, which can be treated by standard advanced cardiac life support (ACLS) protocols.

Unresponsive or minimally responsive patients should have their glucose checked immediately and if their glucose level is low, 1 ampule of **50% dextrose** intravenously should be given. An **arterial line** should be placed for continuous blood pressure measurement, and a **Foley catheter** should be inserted to monitor urinary output.

B. Central Venous Pressure

Early consideration is given to placement of a central venous catheter (CVC) for infusion of fluids and medications and for hemodynamic pressure measurements. A CVC can provide measurements of the central venous pressure (CVP) and the central venous oxygen saturation, both of which can be used to manage sepsis. Pulmonary artery catheters (PACs) allow measurement of the pulmonary artery pressure, left-sided filling pressure or the pulmonary capillary wedge pressure (PCWP), and cardiac output. These catheters had previously been used in critically ill patients to guide response to volume and vasopressor therapy, but data emerged suggesting that PACs increased mortality, prompting further studies. Meta-analyses of multiple studies, including randomized controlled trials, suggested that the use of PACs did not increase overall mortality or length of hospital stay, but was

associated with higher use of inotropes and intravenous vasodilators in critically ill patients from different patient populations (including those with sepsis, myocardial ischemia, and those who were postsurgical). Thus, the routine use of PACs cannot be recommended. However, in some complex situations, PACs may be useful in distinguishing between cardiogenic and septic shock. The attendant risks associated with PACs (such as infection, arrhythmias, vein thrombosis, and pulmonary artery rupture) can be as high as 4–9%; therefore, the value of the information they might provide must be carefully weighed in each patient. TTE is a noninvasive alternative to the PAC. TTE can provide information about the pulmonary artery pressure, PCWP, and cardiac output; in addition, TTE can provide valuable information about current cardiac function. There has been increasing evidence to suggest that respiratory variation in radial artery pulse pressure or aortic blood flow may be more sensitive than CVP as a measure of fluid responsiveness in volume resuscitation in patients who are mechanically ventilated and in normal sinus rhythm, but this evidence is still evolving.

A CVP < 5 mm Hg suggests hypovolemia, and a CVP over 18 mm Hg suggests volume overload, cardiac failure, tamponade, or pulmonary hypertension. A cardiac index < 2 L/min/m² indicates a need for inotropic support. A high cardiac index > 4 L/min/m² in a hypotensive patient is consistent with early septic shock. The systemic vascular resistance is low (< 800 dynes · s/cm⁻⁵) in sepsis and neurogenic shock and high (> 1500 dynes · s/cm⁻⁵) in hypovolemic and cardiogenic shock. Treatment is directed at maintaining a CVP of 8–12 mm Hg, a mean arterial pressure of 65–90 mm Hg, a cardiac index of 2–4 L/min/m², and a central venous oxygen saturation of >70%.

C. Volume Replacement

Volume replacement is critical in the initial management of shock. **Hemorrhagic shock** is treated with immediate efforts to achieve hemostasis and rapid infusions of blood substitutes, such as type-specific or type O negative packed red blood cells (PRBCs) or whole blood, which also provides extra volume and clotting factors. Each unit of PRBC or whole blood is expected to raise the hematocrit by 3%. **Hypovolemic shock** secondary to dehydration is managed with rapid boluses of isotonic crystalloid (0.9% saline or lactated Ringer solution) usually in 1-liter increments. **Cardiogenic shock** in the absence of fluid overload requires smaller fluid challenges, usually in increments of 250 mL. **Septic shock** usually requires large volumes of fluid for resuscitation (usually > 2 L) as the associated capillary leak releases fluid into the extravascular space. Caution must be used with large-volume resuscitation with unwarmed fluids because this can produce hypothermia, which can lead to hypothermia-induced coagulopathy. Warming of fluids before administration can avoid this complication.

Meta-analyses of studies of critically ill heterogeneous populations comparing crystalloid and colloid resuscitation (with albumin) indicate no benefit of colloid over crystalloid solutions. Clinical trials and meta-analyses have also found no difference in mortality between trauma

patients receiving hypertonic saline (7.5%) and those receiving isotonic crystalloid. More positive results were found with hypertonic saline plus dextran with an increase in survival over patients managed with isotonic saline, particularly in patients with traumatic brain injury.

D. Early Goal-Directed Therapy

Early goal-directed therapy following set protocols for the treatment of septic shock provides significant benefits (see www.survivingsepsis.org). In a 2001 randomized controlled trial, patients with severe sepsis or septic shock were assigned to receive either 6 hours of early goal-directed therapy or usual care prior to admission to the intensive care unit. Patients assigned to early goal-directed care received fluid resuscitation to achieve a CVP of 8–12 mm Hg; vasopressors to maintain a mean arterial blood pressure of at least 65 mm Hg; PRBCs to reach a hematocrit of 30% if the central venous oxygen saturation was < 70%; and if, after PRBC transfusion, the central venous oxygen saturation remained < 70%, dobutamine to raise the central venous oxygen saturation > 70%. When compared with controls, these patients had a significantly lower in-hospital mortality rate (46.5% for standard therapy, 30.5% for early goal-directed therapy; $P = .009$) and 60-day mortality rate (57% for standard therapy, 44% for early goal-directed therapy; $P = .03$). A meta-analysis of hemodynamic optimization trials has also suggested that early treatment before the development of organ failure results in improved survival. Lactate clearance of > 10% can be used as a potential substitute for central venous oxygen saturation (ScvO₂) criteria if ScvO₂ monitoring is not available.

Compensated shock can occur in the setting of normalized hemodynamic parameters with ongoing global tissue hypoxia. Traditional endpoints of resuscitation such as blood pressure, heart rate, urinary output, mental status, and skin perfusion can therefore be misleading. Additional endpoints such as lactate levels and base deficit can help guide further resuscitative therapy. Patients who respond well to initial efforts demonstrate a survival advantage over nonresponders.

E. Medications

1. Vasoactive therapy—Vasopressors and inotropic agents are administered only after adequate fluid resuscitation. Choice of vasoactive therapy depends on the presumed etiology of shock as well as cardiac output. If there is evidence of low cardiac output with high filling pressures, inotropic support is needed to improve contractility. If there is continued hypotension with evidence of high cardiac output after adequate volume resuscitation, then vasopressor support is needed to improve vasomotor tone.

Dobutamine, a predominantly β -adrenergic agonist, is the first-line drug for **cardiogenic shock**, increasing contractility and decreasing afterload. The initial dose is 0.5–1 mcg/kg/min as a continuous intravenous infusion, which can be titrated every few minutes as needed to hemodynamic effect; the usual dosage range is 2–20 mcg/kg/min intravenously. Tachyphylaxis can occur after 48 hours secondary to the down-regulation of β -adrenergic receptors.

Amrinone or milrinone are phosphodiesterase inhibitors that can be substituted for dobutamine. These drugs increase cyclic AMP levels and increase cardiac contractility, bypassing the β -adrenergic receptor. However, vasodilation is a side effect of both amrinone and milrinone.

For **vasodilatory shock** when increased vasoconstriction is required to maintain an adequate perfusion pressure, α -adrenergic agonists such as norepinephrine and phenylephrine are generally used. Although **norepinephrine** is both an α -adrenergic and β -adrenergic agonist, it preferentially increases mean arterial pressure over cardiac output. The initial dose is 1–2 mcg/min as an intravenous infusion, titrated to maintain the systolic blood pressure to at least 80 mm Hg. The usual maintenance dose is 2–4 mcg/min intravenously (maximum dose is 30 mcg/min). Patients with refractory shock may require dosages of 10–30 mcg/min intravenously. **Epinephrine**, also with both α -adrenergic and β -adrenergic effects, may be used in severe shock and during acute resuscitation. It is the vasopressor of choice for anaphylactic shock. For severe shock, give 1 mcg/min as a continuous intravenous infusion initially and titrate to hemodynamic response; the usual dosage range is 1–10 mcg/min intravenously.

Dopamine has variable effects according to dosage. At low doses (2–5 mcg/kg/min intravenously), stimulation of dopaminergic and β -adrenergic receptors produces increased glomerular filtration, heart rate, and contractility. At doses of 5–10 mcg/kg/min, β_1 -adrenergic effects predominate, resulting in an increase in heart rate and cardiac contractility. At higher doses (> 10 mcg/kg/min), α -adrenergic effects predominate, resulting in peripheral vasoconstriction. The maximum dose is typically 50 mcg/kg/min.

There is no evidence documenting a survival benefit from, or the superiority of, a particular vasopressor in **septic shock**. Norepinephrine and dopamine are the initial vasopressors of choice to maintain the mean arterial pressure > 65 mm Hg; however, a 2010 randomized controlled trial did demonstrate that arrhythmias were more common in patients with shock who were treated with dopamine than with norepinephrine. The clinician must consider using other agents such as phenylephrine if dysrhythmias or tachycardias prevent the use of agents with β -adrenergic activity. While studies do not favor the use of vasopressin as first-line therapy, it may be useful as a second-line agent in the treatment of septic shock.

Vasopressin (antidiuretic hormone or ADH) is often used as an adjunctive therapy to catecholamine vasopressors in the treatment of **distributive** or **vasodilatory shock**. Vasopressin causes peripheral vasoconstriction via V1 receptors located on smooth muscle cells and attenuation of nitric oxide (NO) synthesis and cGMP, the second messenger of NO. The rationale for using low-dose vasopressin in the management of septic shock includes the relative deficiency of vasopressin in late shock and the increased sensitivity of the systemic circulation to the vasopressor effects of vasopressin. Vasopressin also potentiates the effects of catecholamines on the vasculature and stimulates cortisol production. In the Vasopressin and Septic Shock Trial (VASST), low doses of vasopressin did

not reduce mortality compared with norepinephrine in patients with septic shock who were being treated with catecholamine vasopressors. Some studies have reported reduced catecholamine requirements with vasopressin administration. Intravenous infusion of vasopressin at a low dose (0.01–0.04 units/min) may be safe and beneficial in septic patients with hypotension that is refractory to fluid resuscitation and conventional catecholamine vasopressors. Higher doses of vasopressin decrease cardiac output and may put patients at greater risk for splanchnic and coronary artery ischemia. The role of vasopressin in catecholamine-refractory shock or as an initial vasopressor is still unclear and warrants further study.

2. Corticosteroids—Corticosteroids are the treatment of choice in patients with shock secondary to adrenal insufficiency. The observation that severe sepsis may be associated with relative adrenal insufficiency or glucocorticoid receptor resistance has led to several trials to evaluate the role of treatment with corticosteroids in septic shock. Early trials where high doses of corticosteroids were administered to patients in septic shock did not show improved survival; rather, some worse outcomes were observed from increased rates of secondary infections. Subsequent trials have studied the use of low-dose corticosteroids in patients who were in septic shock and had relative adrenal insufficiency, defined by a cortisol response of 9 mcg/dL or less after one injection of 250 mcg of corticotropin. Low-dose corticosteroid regimens included hydrocortisone 50 mg every 6 hours and 50 mcg of 9-alpha-fludrocortisone once a day, both for 7 days, or hydrocortisone 50 mg by intravenous bolus, followed by a continuous infusion of 0.18 mg/kg of body weight/h until cessation of vasopressor support. These trials demonstrated a shorter duration of use of vasopressors, significantly reduced 28-day mortality rates, and no increased adverse effects. There was no benefit from low-dose corticosteroid use in patients who did not have adrenal insufficiency. In 2008, the Corticosteroid Therapy of Septic Shock (CORTICUS) study demonstrated that low-dose hydrocortisone (50 mg intravenously every 6 hours for 5 days and then tapered over 6 days) did not improve survival in patients with septic shock, either overall or in patients who did not respond to corticotropin. This study was a randomized, double-blinded, placebo-controlled trial that is the largest to date of corticosteroids in septic patients. One limitation of the CORTICUS trial was that it was not adequately powered to detect a clinically important difference in mortality. Thus, there is still uncertainty over the role of corticosteroids and corticotropin stimulation testing in patients with septic shock.

3. Activated protein C (Drotrecogin alfa)—Activated protein C is an endogenous protein that has antithrombotic, profibrinolytic, and anti-inflammatory properties. A large randomized trial published in 2001 demonstrated an improved 28-day mortality rate (from 31% to 25%) in patients with severe sepsis and organ failure when treated with recombinant human activated protein C (rhAPC). A retrospective follow up of the persons enrolled in the trial demonstrated that the survival benefit observed in patients with severe sepsis persisted only to hospital discharge. Post

hoc analysis, however, suggested that the benefit of rhAPC on long-term survival was greater in patients with APACHE (Acute Physiology and Chronic Health Evaluation) II scores ≥ 25 . Subsequently, a randomized, placebo-controlled study from 2005 evaluating patients with severe sepsis and a low risk of death, as defined by an APACHE II score of < 25 or single organ failure, confirmed the finding of no mortality benefit at 28 days. Due to the number of conflicting studies, the PROWESS-SHOCK trial was designed to readdress the efficacy of activated protein C. This study took 1696 patients with septic shock and randomized them to receive drotrecogin alfa (activated) or placebo. The 28-day all-cause mortality was 26.4% in the patients receiving drotrecogin alfa (activated) and 24.2% in those receiving placebo, resulting in the withdrawal of the drug from the market by the manufacturer in 2011 since it failed to show a survival benefit in patients with severe sepsis and septic shock.

4. Antibiotics—Definitive therapy for septic shock includes an early initiation of empiric broad-spectrum antibiotics after appropriate cultures have been obtained. Imaging studies may prove useful to attempt localization of sources of infection. Surgical management may also be necessary if necrotic tissue or loculated infections are present (see Table 30–5).

5. Sodium bicarbonate—For patients with sepsis of any etiology and lactic acidosis, clinical studies have failed to show any hemodynamic benefit from bicarbonate therapy, either in increasing cardiac output or in decreasing the vasopressor requirement even in patients with severe acidemia.

F. Other Treatment Modalities

Cardiac failure may require use of transcutaneous or transvenous pacing or placement of an intra-arterial balloon pump. Emergent revascularization by percutaneous angioplasty or coronary artery bypass surgery appears to improve long-term outcome with increased survival compared with initial medical stabilization for patients with myocardial ischemia leading to cardiogenic shock. Urgent hemodialysis or continuous venovenous hemofiltration

may be indicated for maintenance of fluid and electrolyte balance during acute renal insufficiency resulting in shock from multiple modalities.

- Castellanos-Ortega A et al. Impact of the Surviving Sepsis Campaign protocols on hospital length of stay and mortality in septic shock patients: results of a three-year follow-up quasi-experimental study. *Crit Care Med.* 2010 Apr;38(4):1036–43. [PMID: 20154597]
- COITSS Study Investigators; Annane D et al. Corticosteroid treatment and intensive insulin therapy for septic shock in adults: a randomized controlled trial. *JAMA.* 2010 Jan 27;303(4):341–8. [PMID: 20103758]
- De Backer D et al; SOAP II Investigators. Comparison of dopamine and norepinephrine in the treatment of shock. *N Engl J Med.* 2010 Mar 4;362(9):779–89. [PMID: 20200382]
- Ferrer R et al; Edusepsis Study Group. Effectiveness of treatments for severe sepsis: a prospective, multicenter, observational study. *Am J Respir Crit Care Med.* 2009 Nov 1;180(9):861–6. [PMID: 19696442]
- Levy MM et al. The Surviving Sepsis Campaign: results of an international guideline-based performance improvement program targeting severe sepsis. *Crit Care Med.* 2010 Feb;38(2):367–74. [PMID: 20035219]
- Marik PE et al. Recommendations for the diagnosis and management of corticosteroid insufficiency in critically ill adult patients: consensus statements from an international task force by the American College of Critical Care Medicine. *Crit Care Med.* 2008 Jun;36(6):1937–49. [PMID: 18496365]
- Patel GP et al. Efficacy and safety of dopamine versus norepinephrine in the management of septic shock. *Shock.* 2010 Apr;33(4):375–80. [PMID: 19851126]
- Prondzinsky R et al. Intra-aortic balloon counterpulsation in patients with acute myocardial infarction complicated by cardiogenic shock: the prospective, randomized IABP SHOCK Trial for attenuation of multiorgan dysfunction syndrome. *Crit Care Med.* 2010 Jan;38(1):152–60. [PMID: 19770739]
- Rivers E et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. *N Engl J Med.* 2001 Nov;345(19):1368–77. [PMID: 11794169]
- Russell JA et al; VASST Investigators. Vasopressin versus norepinephrine infusion in patients with septic shock. *N Engl J Med.* 2008 Feb 28;358(9):877–87. [PMID: 18305265]
- Sprung CL et al. Hydrocortisone therapy for patients with septic shock. *N Engl J Med.* 2008 Jan;358(2):111–24. [PMID: 18184957]
- Toussaint S et al. Activated protein C for sepsis. *N Engl J Med.* 2009 Dec 31;361(27):2646–52. [PMID: 20042756]

13

Blood Disorders

Lloyd E. Damon, MD
 Charalambos Andreadis, MD
 Charles A. Linker, MD

ANEMIAS

▶ General Approach to Anemias

Anemia is present in adults if the hematocrit is < 41% (hemoglobin < 13.5 g/dL) in males or < 36% (hemoglobin < 12 g/dL) in females. Congenital anemia is suggested by the patient's personal and family history. The most common cause of anemia is iron deficiency. Poor diet may result in folic acid deficiency and contribute to iron deficiency, but bleeding is much more commonly the cause of iron deficiency in adults. Physical examination demonstrates pallor. Attention to physical signs of primary hematologic diseases (lymphadenopathy; hepatosplenomegaly; or bone tenderness, especially in the sternum or anterior tibia) is important. Mucosal changes such as a smooth tongue suggest megaloblastic anemia.

Anemias are classified according to their pathophysiologic basis, ie, whether related to diminished production (relative or absolute reticulocytopenia) or accelerated loss of red blood cells (reticulocytosis) (Table 13–1), and according to red blood cell size (Table 13–2). A reticulocytosis occurs in one of three pathophysiologic states: acute blood loss, recent replacement of a missing erythropoietic nutrient, or reduced red blood cell survival (ie, hemolysis). A severely microcytic anemia (mean corpuscular volume [MCV] < 70 fL) is due either to iron deficiency or thalassemia, while a severely macrocytic anemia (MCV > 125 fL) is almost always due to either megaloblastic anemia or to cold agglutinins in blood analyzed at room temperature. A bone marrow biopsy is generally needed to complete the evaluation of anemia when the laboratory evaluation fails to reveal an etiology, when there are additional cytopenias present, or when an underlying primary or secondary bone marrow process is suspected.

IRON DEFICIENCY ANEMIAS

ESSENTIALS OF DIAGNOSIS

- ▶ Iron deficiency if serum ferritin < 12 ng/mL or < 30 ng/mL if also anemic.
- ▶ Caused by bleeding unless proved otherwise.
- ▶ Responds to iron therapy.

▶ General Considerations

Iron deficiency is the most common cause of anemia worldwide. The causes are listed in Table 13–3. Aside from circulating red blood cells, the major location of iron in the body is the storage pool as ferritin or as hemosiderin in macrophages.

The average American diet contains 10–15 mg of iron per day. About 10% of this amount is absorbed in the stomach, duodenum, and upper jejunum under acidic conditions. Dietary iron present as heme is efficiently absorbed (10–20%) but nonheme iron less so (1–5%), largely because of interference by phosphates, tannins, and other food constituents. The major iron transporter from the diet across the intestinal lumen is ferroportin, which also facilitates the transport of iron in macrophages to apotransferrin for delivery to erythroid cells prepared to synthesize hemoglobin. Hepcidin, produced during inflammation, negatively regulates iron transport by promoting the degradation of ferroportin. Small amounts of iron—approximately 1 mg/d—are normally lost through exfoliation of skin and mucosal cells.

Menstrual blood loss plays a major role in iron metabolism. The average monthly menstrual blood loss is

Table 13-1. Classification of anemias by pathophysiology.

<p>Decreased red blood cell production (relative or absolute reticulocytopenia)</p> <p>Hemoglobin synthesis lesion: iron deficiency, thalassemia, anemia of chronic disease</p> <p>DNA synthesis lesion: megaloblastic anemia</p> <p>Hematopoietic stem cell lesion: aplastic anemia, leukemia</p> <p>Bone marrow infiltration: carcinoma, lymphoma</p> <p>Immune-mediated inhibition: aplastic anemia, pure red cell aplasia</p> <p>Increased red blood cell destruction or accelerated red blood cell loss (reticulocytosis)</p> <p>Acute blood loss</p> <p>Hemolysis (intrinsic)</p> <p>Membrane lesion: hereditary spherocytosis, elliptocytosis</p> <p>Hemoglobin lesion: sickle cell, unstable hemoglobin</p> <p>Glycolysis abnormality: pyruvate kinase deficiency</p> <p>Oxidation lesion: glucose-6-phosphate dehydrogenase deficiency</p> <p>Hemolysis (extrinsic)</p> <p>Immune: warm antibody, cold antibody</p> <p>Microangiopathic: thrombotic thrombocytopenic purpura, hemolytic-uremic syndrome, mechanical cardiac valve, paravalvular leak</p> <p>Infection: Clostridium perfringens, malaria</p> <p>Hypersplenism</p>

approximately 50 mL but may be five times greater in some individuals. To maintain adequate iron stores, women with heavy menstrual losses must absorb 3–4 mg of iron from the diet each day. This strains the upper limit of what may reasonably be absorbed, and women with menorrhagia of this degree will almost always become iron deficient without iron supplementation.

Table 13-2. Classification of anemias by mean red blood cell volume (MCV).

<p>Microcytic</p> <p>Iron deficiency</p> <p>Thalassemia</p> <p>Anemia of chronic disease</p> <p>Lead toxicity</p> <p>Macrocytic (Megaloblastic)</p> <p>Vitamin B₁₂ deficiency</p> <p>Folate deficiency</p> <p>DNA synthesis inhibitors</p> <p>Macrocytic (Nonmegaloblastic)</p> <p>Myelodysplasia</p> <p>Liver disease</p> <p>Reticulocytosis</p> <p>Hypothyroidism</p> <p>Bone marrow failure state (eg, aplastic anemia, marrow infiltrative disorder, etc.)</p> <p>Normocytic</p> <p>Kidney disease</p> <p>Mild form of most acquired etiologies of anemia</p>
--

Table 13-3. Causes of iron deficiency.

<p>Deficient diet</p> <p>Decreased absorption</p> <p>Celiac sprue</p> <p>Increased requirements</p> <p>Pregnancy</p> <p>Lactation</p> <p>Blood loss (chronic)</p> <p>Gastrointestinal</p> <p>Menstrual</p> <p>Blood donation</p> <p>Hemoglobinuria</p> <p>Iron sequestration</p> <p>Pulmonary hemosiderosis</p> <p>Idiopathic</p>

In general, iron metabolism is balanced between absorption of 1 mg/d and loss of 1 mg/d. Pregnancy upsets the iron balance, since requirements increase to 2–5 mg of iron per day during pregnancy and lactation. Normal dietary iron cannot supply these requirements, and medicinal iron is needed during pregnancy and lactation. Repeated pregnancy (especially with breast-feeding) may cause iron deficiency if increased requirements are not met with supplemental medicinal iron. Decreased iron absorption can cause iron deficiency, such as in people affected with celiac disease, and it commonly occurs after surgical resection of the stomach or bypass of the jejunum.

The most important cause of iron deficiency anemia in adults is chronic blood loss, especially gastrointestinal blood loss. Prolonged aspirin use, or the use of other anti-inflammatory drugs, may cause it even without a documented structural lesion. Iron deficiency demands a search for a source of gastrointestinal bleeding if other sites of blood loss (menorrhagia, other uterine bleeding, and repeated blood donations) are excluded. Chronic hemoglobinuria may lead to iron deficiency since iron is lost in the urine, but this is uncommon; traumatic hemolysis due to a prosthetic cardiac valve and other causes of intravascular hemolysis (eg, paroxysmal nocturnal hemoglobinuria) should also be considered. The cause of iron deficiency is not found in up to 5% of cases.

▶ Clinical Findings

A. Symptoms and Signs

The primary symptoms of iron deficiency anemia are those of the anemia itself (easy fatigability, tachycardia, palpitations and tachypnea on exertion). Severe deficiency causes skin and mucosal changes, including a smooth tongue, brittle nails, spooning of nails (koilonychia), and cheilosis. Dysphagia because of the formation of esophageal webs (Plummer–Vinson syndrome) may occur in severe iron deficiency. Many iron-deficient patients develop pica, craving for specific foods (ice chips, etc) often not rich in iron.

B. Laboratory Findings

Iron deficiency develops in stages. The first is depletion of iron stores without anemia followed by anemia with a normal red blood cell size (normal MCV) followed by anemia with reduced red blood cell size (low MCV). Ferritin is a measure of total body iron stores. A ferritin value < 12 ng/mL in men (in the absence of scurvy) is a highly reliable indicator of depletion of iron stores. Note that the lower limit of normal for ferritin generally is below 12 ng/mL in women due to the fact that the normal range is generated by including the blood of healthy menstruating women who are iron deficient but not anemic. However, because serum ferritin levels may rise in response to inflammation or other stimuli, a normal or elevated ferritin level does not exclude a diagnosis of iron deficiency. A ferritin level of < 30 ng/mL almost always indicates iron deficiency in anyone who is anemic. As iron deficiency progresses, serum iron values decline to < 30 mcg/dL and transferrin levels rise to compensate, leading to transferrin saturations of $< 15\%$. Low transferrin saturation is also seen in anemia of inflammation, so caution in the interpretation of this test is warranted. Bone marrow biopsy for evaluation of iron stores is rarely performed. As the MCV falls (ie, microcytosis), the blood smear shows hypochromic microcytic cells. With further progression, anisocytosis (variations in red blood cell size) and poikilocytosis (variation in shape of red cells) develop. Severe iron deficiency will produce a bizarre peripheral blood smear, with severely hypochromic cells, target cells, and pencil-shaped or cigar-shaped cells. The platelet count is commonly increased, but it usually remains $< 800,000/\text{mL}$.

► Differential Diagnosis

Other causes of microcytic anemia include anemia of chronic disease (specifically, anemia of inflammation), thalassemia, lead poisoning, and congenital X-linked sideroblastic anemia. Anemia of chronic disease is characterized by normal or increased iron stores in bone marrow macrophages and a normal or elevated ferritin level; the serum iron and transferrin saturation are low, often drastically so, and the total iron-binding capacity (TIBC) and transferrin are either normal or low. Thalassemia produces a greater degree of microcytosis for any given level of anemia than does iron deficiency and, unlike virtually every other cause of anemia, has a normal or elevated (rather than a low) red blood cell count. In thalassemia, red blood cell morphology on the peripheral smear resembles severe iron deficiency.

► Treatment

The diagnosis of iron deficiency anemia can be made either by the laboratory demonstration of an iron-deficient state or by evaluating the response to a therapeutic trial of iron replacement. Since the anemia itself is rarely life-threatening, the most important part of management is identification of the cause—especially a source of occult blood loss.

A. Oral Iron

Ferrous sulfate, 325 mg three times daily, which provides 180 mg of iron daily of which up to 10 mg is absorbed, is the preferred therapy. Nausea and constipation limit compliance with ferrous sulfate. Compliance is improved by introducing the medicine more slowly in a gradually escalating dose with food. Alternatively, in cases of poor tolerance, one pill of ferrous sulfate can be taken at bedtime on an empty stomach. It may be preferable to prescribe a lower dose of iron or to allow ingestion concurrent with food than to insist on a more rigorous schedule that will not be followed. An appropriate response is a return of the hematocrit level halfway toward normal within 3 weeks with full return to baseline after 2 months. Iron therapy should continue for 3–6 months after restoration of normal hematologic values to replenish iron stores. Failure of response to iron therapy is usually due to noncompliance, although occasional patients may absorb iron poorly, particularly if the stomach is achlorhydric. Such patients may benefit from concomitant administration of oral ascorbic acid. Other reasons for failure to respond include incorrect diagnosis (anemia of chronic disease, thalassemia), celiac disease, and ongoing gastrointestinal blood loss that exceeds the rate of new erythropoiesis.

B. Parenteral Iron

The indications are intolerance to oral iron, refractoriness to oral iron, gastrointestinal disease (usually inflammatory bowel disease) precluding the use of oral iron, and continued blood loss that cannot be corrected, including hemodialysis. Parenteral iron preparations coat the iron in protective carbohydrate shells. Historical parenteral iron preparations, such as iron dextran, were problematic due to long infusion times (hours), polyarthralgia, and hypersensitivity reactions, including anaphylaxis. Current preparations are safe and can be infused in less than 5 minutes. Iron oxide coated with polyglucose sorbitol carboxymethylether can be given in doses up to 510 mg by intravenous bolus over 20 seconds, with no test dose required.

The iron deficit is calculated by determining the decrement in red blood cell mass from normal, recognizing there is 1 mg of iron in each milliliter of red blood cells. Total body iron ranges between 2 g and 4 g; approximately 50 mg/kg in men and 35 mg/kg in women. Most (70–95%) of the iron is present in hemoglobin in circulating red blood cells. In men, red blood cell volume is approximately 30 mL/kg; in women, it is about 27 mL/kg. Thus, a 50-kg woman whose hemoglobin is 9 g/dL (75% of normal) has an iron deficit of $0.25 \times 27 \text{ mg} \times 50 \text{ kg} = 337.5 \text{ mg}$. The parenteral iron dose is the iron deficit plus (usually) 1 extra gram to replenish iron stores and anticipate further iron losses, so in this case 1.4 g.

► When to Refer

Referral to a hematologist should not generally be necessary because most cases of iron deficiency are straight forward and easily treated with oral iron replacement. Refer if the diagnosis is not straight forward or if patient is not responsive to oral iron therapy.

- Auerbach M et al. Clinical use of intravenous iron: administration, efficacy, and safety. *Hematology Am Soc Hematol Educ Program*. 2010;2010:338–47. [PMID: 21239816]
- Clark SF. Iron deficiency anemia: diagnosis and management. *Curr Opin Gastroenterol*. 2009 Mar;25(2):122–8. [PMID: 19262200]
- Gozzard D. When is high-dose intravenous iron replacement needed? Assessing new treatment options. *Drug Des Devel Ther*. 2011 Jan 20;5:51–60. [PMID: 21340038]
- Muñoz M et al. Disorders of iron metabolism. Part II: iron deficiency and iron overload. *J Clin Pathol*. 2011 Apr;64(4):287–96. [PMID: 21177268]
- Zhu A et al. Evaluation and treatment of iron deficiency anemia: a gastroenterological perspective. *Dig Dis Sci*. 2010 Mar;55(3):548–59. [PMID: 20108038]

ANEMIA OF CHRONIC DISEASE



ESSENTIALS OF DIAGNOSIS

- ▶ Mild or moderate normocytic or microcytic anemia.
- ▶ Normal or increased ferritin and normal or reduced transferrin.
- ▶ Underlying chronic disease.

▶ General Considerations

Many chronic systemic diseases are associated with mild or moderate anemia. The anemias of chronic disease are characterized according to etiology and pathophysiology. The anemia of inflammation is associated with chronic inflammatory states (such as inflammatory bowel disease, rheumatoid arthritis, chronic infections, and malignancy) and is mediated through hepcidin (a negative regulator of ferroportin), resulting in reduced iron intake in the gut and reduced iron transfer from macrophages to erythroid progenitor cells in the bone marrow. There is also reduced responsiveness to erythropoietin, the elaboration of hemolysins that shorten red blood cell survival, and the production of inflammatory cytokines that dampen red cell production. The serum iron is low in the anemia of inflammation. The anemia of organ failure can occur with kidney disease, hepatic failure, and in endocrine gland failure. Erythropoietin is reduced and the red blood cell mass decreases in response to a diminished signal for red blood cell production; the serum iron is normal. The anemia of the elderly is present in up to 20% of individuals over age 85 years and a thorough evaluation for an etiology of anemia is negative. The anemia of the elderly is a consequence of relative erythropoietin resistance to red blood cell production, a decrease in erythropoietin production relative to the nephron mass in older people, and the negative erythropoietic influence of low levels of chronic inflammatory cytokines in this age group; the serum iron is normal.

▶ Clinical Findings

A. Symptoms and Signs

The clinical features are those of the causative condition. The diagnosis should be suspected in patients with known

chronic diseases. In cases of significant anemia, coexistent iron deficiency or folic acid deficiency should be suspected. Decreased dietary intake of folic acid or iron is common in these ill patients, and many will also have ongoing gastrointestinal blood losses. Patients undergoing hemodialysis regularly lose both iron and folic acid during dialysis.

B. Laboratory Findings

The hematocrit rarely falls below 60% of baseline (except in kidney failure). The MCV is usually normal or slightly reduced. Red blood cell morphology is usually normal, and the reticulocyte count is neither strikingly reduced nor increased. In the anemia of inflammation, serum iron values are low, and transferrin saturation may be extremely low, leading to an erroneous diagnosis of iron deficiency. In contrast to iron deficiency, serum ferritin values should be normal or increased. A serum ferritin value of < 30 ng/mL indicates coexistent iron deficiency. In the anemias of organ failure and of the elderly, the iron studies are generally normal. The anemia of the elderly is a diagnosis of exclusion in a patient with anemia who is over age 65 years.

A particular challenge is the diagnosis of iron deficiency in the setting of the anemia of inflammation in which the serum ferritin can be as high as 200 ng/mL. The gold standard for diagnosis is a bone marrow biopsy with iron stain. Absent iron staining indicates iron deficiency, and iron localized in marrow macrophages indicates pure anemia of inflammation. Bone marrow biopsies are rarely done for this purpose. Two other tests may help make this distinction. A reticulocyte hemoglobin concentration of < 28 pg, or a soluble serum transferrin receptor (units: ng/L) to log-ferritin ratio of > 0.8 indicate iron deficiency in the setting of inflammation. The ultimate test is hemoglobin response to oral or parenteral iron in the setting of inflammation when iron deficiency is suspected.

▶ Treatment

In most cases, no treatment is necessary and the primary management is to address the condition causing the anemia of chronic disease. When the anemia is severe or is adversely affecting the quality of life, then treatment involves either red blood cell transfusions or, more commonly, the administration of parenteral recombinant erythropoietin (epoetin alfa or darbepoetin). The indications for recombinant erythropoietin are hemoglobin < 10 g/dL and anemia due to rheumatoid arthritis, inflammatory bowel disease, hepatitis C, the administration of zidovudine in HIV-infected patients, or myelosuppressive chemotherapy in patients with solid malignancy (treated with palliative intent only), or chronic kidney disease (estimated glomerular filtration rate of < 60 mL/min). The dosing and schedule of recombinant erythropoietin are individualized to maintain the hemoglobin between 10 g/dL and 12 g/dL. The use of recombinant erythropoietin is associated with an increased risk of venothromboembolism and arterial thrombotic episodes, and there is controversy about whether it is associated with reduced survival in patients with malignancy.

▶ When to Refer

Referral to a hematologist is not necessary.

- Cheng PP et al. Hpcidin expression in anemia of chronic disease and concomitant iron-deficiency anemia. *Clin Exp Med*. 2011 Mar;11(1):33–42. [PMID: 20499129]
- Ferrucci L et al. Proinflammatory state, hepcidin, and anemia in older persons. *Blood*. 2010 May 6;115(18):3810–6. [PMID: 20081092]
- Ganz T et al. Iron sequestration and anemia of inflammation. *Semin Hematol*. 2009 Oct;46(4):387–93. [PMID: 19786207]
- Roy CN. Anemia of inflammation. *Hematology Am Soc Hematol Educ Program*. 2010;2010:276–80. [PMID: 21239806]
- Vanasse GJ et al. Anemia in elderly patients: an emerging problem for the 21st century. *Hematology Am Soc Hematol Educ Program*. 2010;2010:271–5. [PMID: 21239805]
- Zhang AS et al. Molecular mechanisms of normal iron homeostasis. *Hematology Am Soc Hematol Educ Program*. 2009;207–14. [PMID: 20008200]

THE THALASSEMIAS

ESSENTIALS OF DIAGNOSIS

- ▶ Microcytosis disproportionate to the degree of anemia.
- ▶ Positive family history or lifelong personal history of microcytic anemia.
- ▶ Normal or elevated red blood cell count.
- ▶ Abnormal red blood cell morphology with microcytes, hypochromia, acanthocytes, and target cells.
- ▶ In β -thalassemia, elevated levels of hemoglobin A_2 or F.

▶ General Considerations

The thalassemias are hereditary disorders characterized by reduction in the synthesis of globin chains (α or β). Reduced globin chain synthesis causes reduced hemoglobin synthesis and eventually produces a hypochromic microcytic anemia because of defective hemoglobinization of red blood cells. Thalassemias can be considered among the hypoproliferative anemias, the hemolytic anemias, and the anemias related to abnormal hemoglobin, since all of these factors play a role in pathogenesis. The hallmark laboratory features are small and pale red blood cells (low MCV and mean corpuscular hemoglobin [MCH]), anemia, and a normal to elevated red blood cell count (ie, a large number of small red blood cells are being produced). Although patients often exhibit an elevated reticulocyte count, generally the degree of reticulocyte output is inadequate to meet the degree of red blood cell destruction (hemolysis) and the patients remain anemic.

Normal adult hemoglobin is primarily hemoglobin A, which represents approximately 98% of circulating hemoglobin. Hemoglobin A is formed from a tetramer of two α chains and two β chains—and can be designated $\alpha_2\beta_2$. Two

copies of the α -globin gene are located on chromosome 16, and there is no substitute for α -globin in the formation of hemoglobin. The β -globin gene resides on chromosome 11 adjacent to genes encoding the β -like globins δ and γ (the so-called β -globin gene cluster region). The tetramer of $\alpha_2\delta_2$ forms hemoglobin A_2 , which normally comprises 1–2% of adult hemoglobin. The tetramer $\alpha_2\gamma_2$ forms hemoglobin F, which is the major hemoglobin of fetal life but which comprises < 1% of normal adult hemoglobin.

The thalassemias are described as “**trait**” when there are laboratory features without significant clinical impact, “**intermedia**” when there is an occasional red blood cell transfusion requirement or other moderate clinical impact, and “**major**” when the disorder is life-threatening and the patient is transfusion-dependent. Most patients with thalassemia major die of the consequences of iron overload.

α -Thalassemia is due primarily to gene deletions causing reduced α -globin chain synthesis (Table 13–4). Each α -globin gene produces one-quarter of the total α -globin quantity, so there is a predictable proportionate decrease in α -globin output with each lost α -globin gene. Since all adult hemoglobins are α containing, α -thalassemia produces no change in the percentage distribution of hemoglobins A, A_2 , and F on hemoglobin electrophoresis. In severe forms of α -thalassemia, excess β chains may form a β_4 tetramer called hemoglobin H.

β -Thalassemias are usually caused by point mutations rather than deletions (Table 13–5). These mutations result in premature chain termination or in problems with transcription of RNA and ultimately result in reduced or absent β -globin chain synthesis. The molecular defects leading to β -thalassemia are numerous and heterogeneous but run true within families. Defects that result in absent globin chain expression are termed β^0 , whereas those causing reduced but not absent synthesis are termed β^+ . In β^+ thalassemia, the degree of reduction of β -globin synthesis is consistent within families but is quite variable between families. The reduced β -globin chain synthesis in β -thalassemia results in a relative increase in the percentages of hemoglobins A_2 and F compared to hemoglobin A on hemoglobin electrophoresis, as the β -like globins

Table 13–4. α -Thalassemia syndromes.

Number of α -Globin Genes Transcribed	Syndrome	Hematocrit	MCV
4	Normal	Normal	Normal
3	Silent carrier	Normal	Normal
2	Thalassemia minor (or Trait)	28–40%	60–75 fL
1	Hemoglobin H disease	22–32%	60–70 fL
0	Hydrops fetalis		

MCV, mean cell volume.

Table 13-5. β -Thalassemia syndromes.

	α -Globin Genes Transcribed	Hb A	Hb A ₂	Hb F	Transfusions
Normal	Homozygous β	97-99%	1-3%	< 1%	
Thalassemia minor	Heterozygous β^0	80-95%	4-8%	1-5%	None
	Heterozygous β^{+}	80-95%	4-8%	1-5%	None
Thalassemia intermedia	Homozygous β^{+} (mild)	0-30%	0-10%	6-100%	Occasional
Thalassemia major	Homozygous β^0	0%	4-10%	90-96%	Dependent
Thalassemia major	Homozygous β^{+}	0-10%	4-10%	90-96%	Dependent

Hb, hemoglobin.

(δ and γ) substitute for the missing β chains. In the presence of reduced β chains, the excess α chains are unstable and precipitate, leading to damage of red blood cell membranes. This leads to both intramedullary (bone marrow) and peripheral blood hemolysis. The bone marrow demonstrates erythroid hyperplasia under the drive of anemia and ineffective erythropoiesis (intramedullary destruction of the developing erythroid cells). In cases of severe thalassemia, the marked expansion of the erythroid element in the bone marrow may cause severe bony deformities, osteopenia, and pathologic fractures.

► Clinical Findings

A. Symptoms and Signs

The α -thalassemia syndromes are seen primarily in persons from southeast Asia and China, and, less commonly, in blacks and persons of Mediterranean origin (Table 13-4). Normally, adults have four copies of the α -globin chain. When three α -globin genes are present, the patient is hematologically normal (silent carrier). When two α -globin genes are present, the patient is said to have α -thalassemia trait, one form of thalassemia minor. In α -thalassemia-1 trait, the α gene deletion is heterozygous (α^{-}/α^{-}) and affects mainly those of Asian descent. In α -thalassemia-2 trait, the α gene deletion is homozygous ($\alpha\alpha/---$) and affects mainly blacks. These patients are clinically normal and have a normal life expectancy and performance status, with a mild microcytic anemia. When only one α -globin chain is present ($\alpha^{-}/---$), the patient has hemoglobin H disease. This is a chronic hemolytic anemia of variable severity (thalassemia minor or intermedia). Physical examination will reveal pallor and splenomegaly. Although affected individuals do not usually require transfusions, they may do so during transient periods of hemolytic exacerbation caused by infection or other stressors or during periods of erythropoietic shutdown caused by certain viruses ("aplastic crisis"). When all four α -globin genes are deleted, no normal hemoglobin is produced and the affected fetus is stillborn (hydrops fetalis). In hydrops fetalis, the only hemoglobin species made is called hemoglobin Bart's (γ_4).

β -Thalassemia primarily affects persons of Mediterranean origin (Italian, Greek) and to a lesser extent Asians and blacks (Table 13-5). Patients homozygous for

β -thalassemia (β^0/β^0 or β^{+}/β^{+}) have thalassemia major. Affected children are normal at birth but after 6 months, when hemoglobin synthesis switches from hemoglobin F to hemoglobin A, develop severe anemia requiring transfusion. Numerous clinical problems ensue, including stunted growth, bony deformities (abnormal facial structure, pathologic fractures), hepatosplenomegaly, jaundice due to gallstones or hepatitis-related cirrhosis (or both), and thrombophilia. The clinical course is modified significantly by transfusion therapy, but the transfusional iron overload (hemosiderosis) results in a clinical picture similar to hemochromatosis, with heart failure, cardiac arrhythmias, cirrhosis, endocrinopathies, and pseudoxanthoma elasticum (calcification and fragmentation of the elastic fibers of the skin, retina, and cardiovascular system) usually after more than 100 units of red blood cells. These problems develop because of the body's inability to excrete the iron from transfused red cells. Before the application of allogeneic stem cell transplantation and the development of more effective forms of iron chelation, death from iron overload usually occurred between the ages of 20 and 30 years.

Patients homozygous for a milder form of β -thalassemia (β^{+}/β^{+} , but allowing a higher rate of β -globin synthesis) have thalassemia intermedia. These patients have chronic hemolytic anemia but do not require transfusions except under periods of stress or during aplastic crises. They also may develop iron overload because of periodic transfusion. They survive into adult life but with hepatosplenomegaly and bony deformities. Patients heterozygous for β -thalassemia (β/β^0 or β/β^{+}) have thalassemia minor and a clinically insignificant microcytic anemia.

Prenatal diagnosis is available, and genetic counseling should be offered and the opportunity for prenatal diagnosis discussed.

B. Laboratory Findings

1. α -Thalassemia trait—These patients have mild anemia, with hematocrits between 28% and 40%. The MCV is strikingly low (60–75 fL) despite the modest anemia, and the red blood count is normal or increased. The peripheral blood smear shows microcytes, hypochromia, occasional target cells, and acanthocytes (cells with irregularly spaced spiked projections). The reticulocyte count and iron

parameters are normal. Hemoglobin electrophoresis will show no increase in the percentage of hemoglobins A₂ or F and no hemoglobin H. α -Thalassemia trait is thus usually diagnosed by exclusion. Genetic testing to demonstrate α -globin gene deletion is available only in a limited number of laboratories.

2. Hemoglobin H disease—These patients have a more marked anemia, with hematocrits between 22% and 32%. The MCV is remarkably low (60–70 fL) and the peripheral blood smear is markedly abnormal, with hypochromia, microcytosis, target cells, and poikilocytosis. The reticulocyte count is elevated and the red blood cell count is normal or elevated. Hemoglobin electrophoresis will show a fast migrating hemoglobin (hemoglobin H), which comprises 10–40% of the hemoglobin. A peripheral blood smear can be stained with supravital dyes to demonstrate the presence of hemoglobin H.

3. β -Thalassemia minor—These patients have a modest anemia with hematocrit between 28% and 40%. The MCV ranges from 55 fL to 75 fL, and the red blood cell count is normal or increased. The reticulocyte count is normal or slightly elevated. The peripheral blood smear is mildly abnormal, with hypochromia, microcytosis, and target cells. In contrast to α -thalassemia, basophilic stippling is present. Hemoglobin electrophoresis shows an elevation of hemoglobin A₂ to 4–8% and occasional elevations of hemoglobin F to 1–5%.

4. β -Thalassemia major—These patients have severe anemia, and without transfusion the hematocrit may fall to < 10%. The peripheral blood smear is bizarre, showing severe poikilocytosis, hypochromia, microcytosis, target cells, basophilic stippling, and nucleated red blood cells. Little or no hemoglobin A is present. Variable amounts of hemoglobin A₂ are seen, and the major hemoglobin present is hemoglobin F.

► Differential Diagnosis

Mild forms of thalassemia must be differentiated from iron deficiency. Compared to iron deficiency anemia, patients with thalassemia have a lower MCV, a normal or elevated red blood cell count, and a more abnormal peripheral blood smear at modest levels of anemia. Iron studies are normal or the transferrin saturation or ferritin (or both) are elevated. Severe forms of thalassemia may be confused with other hemoglobinopathies. The diagnosis of β -thalassemia is made by the above findings and hemoglobin electrophoresis showing elevated levels of hemoglobins A₂ and F (provided the patient is replete in iron), but the diagnosis of α -thalassemia is made by exclusion since there is no change in the percentage of the normal adult hemoglobin species. The only other microcytic anemia with a normal or elevated red blood cell count is iron deficiency in a patient with polycythemia vera.

► Treatment

Patients with mild thalassemia (α -thalassemia trait or β -thalassemia minor) require no treatment and should be identified so that they will not be subjected to repeated

evaluations and treatment for iron deficiency. Patients with hemoglobin H disease should take folic acid supplementation (1 mg/d orally) and avoid medicinal iron and oxidative drugs such as sulfonamides. Patients with severe thalassemia are maintained on a regular transfusion schedule and receive folic acid supplementation. Splenectomy is performed if hypersplenism causes a marked increase in the transfusion requirement. Patients with regular transfusion requirements should be treated with iron chelation (such as oral deferasirox 20–30 mg/kg/d) in order to prevent life-limiting organ damage from iron overload.

Allogeneic stem cell transplantation is the treatment of choice for β -thalassemia major and the only available cure. Children who have not yet experienced iron overload and chronic organ toxicity do well, with long-term survival in more than 80% of cases.

► When to Refer

All patients with severe thalassemia should be referred to a hematologist. Any patient with an unexplained microcytic anemia should be referred to help establish a diagnosis. Patients with thalassemia minor or intermedia should be referred for genetic counseling because offspring of thalassaemic couples are at risk for inheriting thalassemia major.

Angelucci E. Hematopoietic stem cell transplantation in thalassemia. *Hematology Am Soc Hematol Educ Program*. 2010; 2010:456–62. [PMID: 21239835]

Borgna-Pignatti C et al. Complications of thalassemia major and their treatment. *Expert Rev Hematol*. 2011 Jun;4(3):353–66. [PMID: 21668399]

Cohen AR et al. Effect of transfusional iron intake on response to chelation therapy in beta-thalassemia major. *Blood*. 2008 Jan 15;111(2):583–7. [PMID: 17951527]

Cunningham MJ. Update on thalassemia: clinical care and complications. *Hematol Oncol Clin North Am*. 2010 Feb;24(1): 215–27. [PMID: 20113904]

Origa R et al. Pathophysiology of beta thalassemia. *Pediatr Endocrinol Rev*. 2011 Mar;8(Suppl 2):263–70. [PMID: 21705976]

SIDEROBLASTIC ANEMIA



ESSENTIALS OF DIAGNOSIS

- Presence of ringed sideroblasts in the bone marrow.
- Elevated serum iron levels and transferrin saturation.

► General Considerations

The sideroblastic anemias are a heterogeneous group of disorders in which hemoglobin synthesis is decreased because of reduced ability to synthesize heme or an impaired ability to incorporate heme into protoporphyrin IX. Iron accumulates, particularly in the mitochondria. The disorder is usually acquired; it is most often a subtype of myelodysplasia. Other causes include chronic alcoholism, lead poisoning, drugs (isoniazid and chloramphenicol), and chronic

infection or inflammation. Inherited forms are usually X-linked, but rare recessive forms have been documented.

► Clinical Findings

Patients have no specific clinical features other than those related to anemia. The anemia is usually moderate, with hematocrits of 20–30%, but transfusions may occasionally be required. In the sideroblastic subtype of myelodysplastic syndrome, the MCV is usually normal or slightly increased, as it when due to alcohol. In all other types, the MCV is usually low (especially in the inherited forms) leading to confusion with iron deficiency. However, the serum iron level is elevated and the transferrin saturation is high. The peripheral blood smear characteristically shows a dimorphic population of red blood cells, one normal and one hypochromic. In cases of lead poisoning, coarse basophilic stippling of the red cells is seen and the serum lead levels will be elevated.

The diagnosis is made by examination of the bone marrow. Characteristically, there is marked erythroid hyperplasia, a sign of ineffective erythropoiesis (expansion of the erythroid compartment of the bone marrow that does not result in the adequate production of reticulocytes in the peripheral blood). The Prussian blue iron stain of the bone marrow shows a generalized increase in iron stores and the presence of ringed sideroblasts (erythroid cells with iron deposits in mitochondria encircling the nucleus). Occasionally, the anemia is severe enough to require red blood cell transfusions. These patients usually do not respond well to recombinant erythropoietin therapy, especially when transfusion requirements are significant. There are occasional responses to oral pyridoxine (50–200 mg/d). Removal of offending toxins and drugs is needed in the secondary acquired forms.

► When to Refer

Refer to a hematologist if transfusion support is needed.

Cuijpers ML et al. Recent advances in the understanding of iron overload in sideroblastic myelodysplastic syndrome. *Br J Haematol*. 2010 May;149(3):322–33. [PMID: 20067561]

Harigae H et al. Hereditary sideroblastic anemia: pathophysiology and gene mutations. *Int J Hematol*. 2010 Oct;92(3):425–31. [PMID: 20848343]

Mufti GJ et al. Diagnosis and classification of myelodysplastic syndrome: International Working Group on Morphology of myelodysplastic syndrome (IWGM-MDS) consensus proposals for the definition and enumeration of myeloblasts and ring sideroblasts. *Haematologica*. 2008 Nov;93(11):1712–7. [PMID: 18838480]

VITAMIN B₁₂ DEFICIENCY



ESSENTIALS OF DIAGNOSIS

- Macrocytic anemia.
- Megaloblastic blood smear (macro-ovalocytes and hypersegmented neutrophils).
- Low serum vitamin B₁₂ level.

► General Considerations

Vitamin B₁₂ belongs to the family of cobalamins and serves as a cofactor for two important reactions in humans. As methylcobalamin, it is a cofactor for methionine synthetase in the conversion of homocysteine to methionine, and as adenosylcobalamin for the conversion of methylmalonyl-coenzyme A (CoA) to succinyl-CoA. These enzymatic steps are critical for annealing Okazaki fragments during DNA synthesis, particularly in erythroid progenitor cells. Vitamin B₁₂ comes from the diet and is present in all foods of animal origin. The daily absorption of vitamin B₁₂ is 5 mcg.

The liver contains 2–5 mg of stored vitamin B₁₂. Since daily utilization is 3–5 mcg, the body usually has sufficient stores of vitamin B₁₂ so that it takes more than 3 years for vitamin B₁₂ deficiency to occur if all intake or absorption immediately ceases.

Since vitamin B₁₂ is present in foods of animal origin, dietary vitamin B₁₂ deficiency is extremely rare and is seen only in vegans—strict vegetarians who avoid all dairy products as well as meat and fish (Table 13–6). Pernicious anemia is an autoimmune illness whereby autoantibodies destroy gastric parietal cells and cause atrophic gastritis or bind to and neutralize intrinsic factor, or both. Abdominal surgery may lead to vitamin B₁₂ deficiency in several ways. Gastrectomy will eliminate the site of intrinsic factor production; blind loop syndrome will cause competition for vitamin B₁₂ by bacterial overgrowth in the lumen of the intestine; and surgical resection of the ileum will eliminate the site of vitamin B₁₂ absorption. Rare causes of vitamin B₁₂ deficiency include fish tapeworm (*Diphyllobothrium latum*) infection, in which the parasite uses luminal vitamin B₁₂; pancreatic insufficiency (with failure to inactivate competing cobalamin-binding proteins); and severe Crohn disease, causing sufficient destruction of the ileum to impair vitamin B₁₂ absorption.

► Clinical Findings

A. Symptoms and Signs

Vitamin B₁₂ deficiency causes a moderate to severe anemia of slow onset; patients may have few symptoms relative to the degree of anemia. In advanced cases, the anemia may be severe, with hematocrits as low as 10–15%, and may be

Table 13–6. Causes of vitamin B₁₂ deficiency.

Dietary deficiency (rare)
Decreased production of intrinsic factor
Pernicious anemia
Gastrectomy
<i>Helicobacter pylori</i> infection
Competition for vitamin B ₁₂ in gut
Blind loop syndrome
Fish tapeworm (rare)
Pancreatic insufficiency
Decreased ileal absorption of vitamin B ₁₂
Surgical resection
Crohn disease
Transcobalamin II deficiency (rare)

accompanied by leukopenia and thrombocytopenia. The deficiency also produces changes in mucosal cells, leading to glossitis, as well as other vague gastrointestinal disturbances such as anorexia and diarrhea. Vitamin B₁₂ deficiency also leads to a complex neurologic syndrome. Peripheral nerves are usually affected first, and patients complain initially of paresthesias. As the posterior columns of the spinal cord become impaired, patients complain of difficulty with balance or proprioception, or both. In more advanced cases, cerebral function may be altered as well, and on occasion dementia and other neuropsychiatric abnormalities may be present. It is critical to recognize that the non-hematologic manifestations of vitamin B₁₂ deficiency can be manifest despite a completely normal complete blood count.

Patients are usually pale and may be mildly icteric or sallow. Typically later in the disease course, neurologic examination may reveal decreased vibration and position sense or memory disturbance (or both).

B. Laboratory Findings

The diagnosis of vitamin B₁₂ deficiency is made by finding a low serum vitamin B₁₂ (cobalamin) level. Whereas the normal vitamin B₁₂ level is > 210 pg/mL, most patients with overt vitamin B₁₂ deficiency have serum levels < 170 pg/mL, with symptomatic patients usually having levels < 100 pg/mL. The diagnosis of vitamin B₁₂ deficiency in low or low-normal values (level of 170–210 pg/mL) is best confirmed by finding an elevated level of serum methylmalonic acid (>1000 nmol/L). However, elevated levels of serum methylmalonic acid can be due to kidney disease.

The anemia of vitamin B₁₂ deficiency is typically moderate to severe with the MCV quite elevated (110–140 fL). However, it is possible to have vitamin B₁₂ deficiency with a normal MCV. Occasionally, the normal MCV may be explained by coexistent thalassemia or iron deficiency, but in other cases the reason is obscure. Patients with neurologic symptoms and signs that suggest possible vitamin B₁₂ deficiency should be evaluated for that deficiency despite a normal MCV and the absence of anemia. The peripheral blood smear is megaloblastic, defined as red blood cells that appear as macro-ovalocytes, (although other shape changes are usually present) and neutrophils that are hypersegmented (mean neutrophil lobe counts greater than four or the finding of six [or greater]-lobed neutrophils). The reticulocyte count is reduced. Because vitamin B₁₂ deficiency can affect all hematopoietic cell lines, the white blood cell count and the platelet count are reduced in severe cases.

Other laboratory abnormalities include elevated serum lactate dehydrogenase (LD) and a modest increase in indirect bilirubin. These two findings are a reflection of intramedullary destruction of developing abnormal erythroid cells and are similar to those observed in peripheral hemolytic anemias.

Bone marrow morphology is characteristically abnormal. Marked erythroid hyperplasia is present as a response to defective red blood cell production (ineffective erythropoiesis). Megaloblastic changes in the erythroid series include abnormally large cell size and asynchronous maturation of the nucleus and cytoplasm—ie, cytoplasmic maturation continues while impaired DNA synthesis

causes retarded nuclear development. In the myeloid series, giant meta-myelocytes are characteristically seen.

► Differential Diagnosis

Vitamin B₁₂ deficiency should be differentiated from folic acid deficiency, the other common cause of megaloblastic anemia, in which red blood cell folic acid is low while vitamin B₁₂ levels are normal. The bone marrow findings of vitamin B₁₂ deficiency are sometimes mistaken for a myelodysplastic syndrome or even acute erythrocytic leukemia. The distinction between vitamin B₁₂ deficiency and myelodysplasia is based on the characteristic morphology and the low vitamin B₁₂ and elevated methylmalonic acid levels.

► Treatment

Patients with vitamin B₁₂ deficiency have historically been treated with parenteral therapy. Intramuscular or subcutaneous injections of 100 mcg of vitamin B₁₂ are adequate for each dose. Replacement is usually given daily for the first week, weekly for the first month, and then monthly for life. The vitamin deficiency will recur if patients discontinue their therapy. Oral or sublingual cobalamin (1 mg/d) may be used instead of parenteral therapy once initial correction of the deficiency has occurred. Oral or sublingual replacement is effective, even in pernicious anemia, since approximately 1% of the dose is absorbed in the intestine via passive diffusion in the absence of active transport. It must be continued indefinitely and serum vitamin B₁₂ levels must be monitored to ensure adequate replacement. For patients with neurologic symptoms caused by B₁₂ deficiency, long-term parenteral vitamin B₁₂ therapy is prudent. Because many patients are concurrently folic acid deficient from intestinal mucosal disruption, simultaneous folic acid replacement (1 mg daily) is recommended for the first several months of vitamin B₁₂ replacement.

Patients respond to therapy with an immediate improvement in their sense of well-being. Hypokalemia may complicate the first several days of therapy, particularly if the anemia is severe. A brisk reticulocytosis occurs in 5–7 days, and the hematologic picture normalizes in 2 months. Central nervous system symptoms and signs are reversible if they are of relatively short duration (< 6 months) but are likely permanent if of longer duration. Red blood cell transfusions are rarely needed despite the severity of anemia, but when given, diuretics are also recommended to avoid heart failure because this anemia developed slowly and the plasma volume is increased.

► When to Refer

Referral to a hematologist is not usually necessary.

Andrès E et al. Efficacy of oral cobalamin (vitamin B12) therapy. *Expert Opin Pharmacother*. 2010 Feb;11(2):249–56. [PMID: 20088746]

Elmadfa I et al. Vitamin B-12 and homocysteine status among vegetarians: a global perspective. *Am J Clin Nutr*. 2009 May;89(5):1693S–8S. [PMID: 19357223]

Lahner E et al. Pernicious anemia: new insights from a gastroenterological point of view. *World J Gastroenterol*. 2009 Nov 7;15(41):5121–8. [PMID: 19891010]

FOLIC ACID DEFICIENCY



ESSENTIALS OF DIAGNOSIS

- ▶ Macrocytic anemia.
- ▶ Megaloblastic blood smear (macro-ovalocytes and hypersegmented neutrophils).
- ▶ Normal serum vitamin B₁₂ level.
- ▶ Reduced folic acid levels in red blood cells or serum.

▶ General Considerations

Folic acid is the term commonly used for pteroylmonoglutamic acid. Folic acid is present in most fruits and vegetables (especially citrus fruits and green leafy vegetables) and daily requirements of 50–100 mcg are usually met in the diet. Total body stores of folic acid are approximately 5 mg, enough to supply requirements for 2–3 months.

By far the most common cause of folic acid deficiency is inadequate dietary intake (Table 13–7). Alcoholic or anorectic patients, persons who do not eat fresh fruits and vegetables, and those who overcook their food are candidates for folic acid deficiency. Reduced folic acid absorption is rarely seen, since absorption occurs from the entire gastrointestinal tract. However, drugs such as phenytoin, trimethoprim-sulfamethoxazole, or sulfasalazine may interfere with its absorption. Folic acid absorption is poor in some patients with vitamin B₁₂ deficiency due to mucosal disruption from that missing nutrient. Folic acid requirements are increased in pregnancy, hemolytic anemia, and exfoliative skin disease, and in these cases the increased requirements (five to ten times normal) may not be met by a normal diet. Patients with increased folic acid requirements should receive supplementation with 1 mg/d of folic acid.

▶ Clinical Findings

A. Symptoms and Signs

The features are similar to those of vitamin B₁₂ deficiency due to anemia and megaloblastic changes in mucosa.

Table 13–7. Causes of folic acid deficiency.

Dietary deficiency
Decreased absorption
Tropical sprue
Drugs: phenytoin, sulfasalazine, trimethoprim-sulfamethoxazole
Concurrent vitamin B ₁₂ deficiency
Increased requirement
Chronic hemolytic anemia
Pregnancy
Exfoliative skin disease
Excess loss: hemodialysis
Inhibition of reduction to active form
Methotrexate

However, there are none of the neurologic abnormalities associated with vitamin B₁₂ deficiency.

B. Laboratory Findings

Megaloblastic anemia is identical to anemia resulting from vitamin B₁₂ deficiency (see above). However, the serum vitamin B₁₂ level is normal and should always be measured when folic acid deficiency is suspected. A red blood cell folic acid level of < 150 ng/mL is diagnostic of folic acid deficiency. The red blood cell folic acid level is preferred over the serum folic acid level because the former reflects body stores over the life span of the red blood cell, while the latter reflects immediate labile serum levels rather than body stores.

▶ Differential Diagnosis

The megaloblastic anemia of folic acid deficiency should be differentiated from vitamin B₁₂ deficiency by the finding of a normal vitamin B₁₂ level and a reduced red blood cell folic acid or serum folic acid level. Alcoholic patients, who often have nutritional deficiency, may also have anemia of liver disease. This latter macrocytic anemia does not cause megaloblastic morphologic changes but rather produces target cells in the peripheral blood. Hypothyroidism is associated with mild macrocytosis but also with pernicious anemia.

▶ Treatment

Folic acid deficiency is treated with daily oral folic acid (1 mg). The response is similar to that seen in the treatment of vitamin B₁₂ deficiency, with rapid improvement and a sense of well-being, reticulocytosis in 5–7 days, and total correction of hematologic abnormalities within 2 months. Large doses of folic acid may produce hematologic responses in cases of vitamin B₁₂ deficiency but will allow neurologic damage to progress, hence the importance of knowing the vitamin B₁₂ status in suspected folic acid deficiency.

▶ When to Refer

Referral to a hematologist is not usually necessary.

Green R. Indicators for assessing folate and vitamin B-12 status and for monitoring the efficacy of intervention strategies. *Am J Clin Nutr.* 2011 Aug;94(2):666S–72S. [PMID: 21733877]
 Sanghvi TG et al. Maternal iron-folic acid supplementation programs: evidence of impact and implementation. *Food Nutr Bull.* 2010 Jun;31(2 Suppl):S100–7. [PMID: 20715594]
 Varela-Moreiras G et al. Cobalamin, folic acid, and homocysteine. *Nutr Rev.* 2009 May;67(Suppl 1):S69–72. [PMID: 19453682]

PURE RED CELL APLASIA

Acquired pure red cell aplasia is rare. It is an autoimmune disease mediated either by T lymphocytes or (rarely) by an IgG antibody against erythroid precursors. In adults, the disease is usually idiopathic. However, cases have been seen in association with systemic lupus erythematosus, chronic

lymphocytic leukemia (CLL), lymphomas, or thymoma. Some drugs (phenytoin, chloramphenicol) may cause red cell aplasia. Rarely, anti-erythropoietin antibodies cause pure red cell aplasia in patients who are treated with recombinant erythropoietin. Transient episodes of red cell aplasia are probably common in response to viral infections, especially parvovirus infections. However, these acute episodes will go unrecognized unless the patient has a chronic hemolytic disorder or a chronic immunocompromised state, in which case the hematocrit may fall precipitously.

The only signs are those of anemia unless the patient has an associated autoimmune or lymphoproliferative disorder. The anemia is often severe and normochromic, with low or absent reticulocytes. Red blood cell morphology is normal, and the myeloid and platelet lines are unaffected. The bone marrow is normocellular, and the karyotype is normal on standard banding cytogenetics. All non-erythroid elements are present and normal, but erythroid precursors are markedly reduced or absent. In some cases, chest imaging studies will reveal a thymoma.

The disorder must be distinguished from aplastic anemia (in which the marrow is hypocellular and all cell lines are affected) and from myelodysplasia. This latter disorder is recognized by the presence of morphologic abnormalities that should not be present in pure red cell aplasia.

Possible offending drugs should be stopped. With thymoma, resection results in amelioration of anemia in some instances. High-dose intravenous immune globulin has produced excellent responses in a small number of cases, especially in parvovirus-related cases. For most cases, the treatment of choice is immunosuppressive therapy with a combination of antithymocyte globulin and a calcineurin inhibitor (cyclosporine or tacrolimus)—similar to therapy of aplastic anemia. Anti-CD20 monoclonal antibody (rituximab) has also had some success and may be the treatment of choice in the setting of anti-erythropoietin antibodies.

► When to Refer

All patients should be referred to a hematologist.

Behler CM et al. Rituximab therapy for pure red cell aplasia due to anti-epoetin antibodies in a woman treated with epoetin-alfa: a case report. *J Med Case Reports*. 2009 Jul 6;3:7335–9. [PMID: 19830190]

D'Arena G et al. Rituximab to treat chronic lymphoproliferative disorder-associated pure red cell aplasia. *Eur J Haematol*. 2009 Mar;82(3):235–9. [PMID: 19067738]

Sawada K et al. Diagnosis and management of acquired pure red cell aplasia. *Hematol Oncol Clin North Am*. 2009 Apr;23(2):249–59. [PMID: 19327582]

HEMOLYTIC ANEMIAS

Hemolytic disorders are generally classified according to whether the defect is intrinsic to the red cell or due to some external factor (Table 13–8). Intrinsic defects have been described in all components of the red blood cell, including the membrane, enzyme systems, and hemoglobin; most of these disorders are hereditary. Hemolytic anemias due to

Table 13–8. Classification of hemolytic anemias.

Intrinsic

Membrane defects: hereditary spherocytosis, hereditary elliptocytosis, paroxysmal nocturnal hemoglobinuria

Glycolytic defects: pyruvate kinase deficiency, severe hypophosphatemia

Oxidation vulnerability: glucose-6-phosphate dehydrogenase deficiency, methemoglobinemia

Hemoglobinopathies: sickle cell syndromes, unstable hemoglobins, methemoglobinemia

Extrinsic

Immune: autoimmune, lymphoproliferative disease, drug toxicity

Microangiopathic: thrombotic thrombocytopenic purpura, hemolytic-uremic syndrome, disseminated intravascular coagulation, valve hemolysis, metastatic adenocarcinoma, vasculitis

Infection: *Plasmodium*, *Clostridium*, *Borrelia*

Hypersplenism

Burns

external factors are the immune and microangiopathic hemolytic anemias.

Certain laboratory features are common to all the hemolytic anemias. Haptoglobin, a normal plasma protein that binds and clears free hemoglobin released into plasma, may be depressed in hemolytic disorders. However, haptoglobin levels are influenced by many factors and, by themselves, are not a reliable indicator of hemolysis, in particular in the setting of end-stage liver disease (its site of synthesis). When intravascular hemolysis occurs, transient hemoglobinemia occurs. Hemoglobin is filtered through the glomerulus and is usually reabsorbed by tubular cells. Hemoglobinuria will be present only when the capacity for reabsorption of hemoglobin by these cells is exceeded. In its absence, evidence for prior intravascular hemolysis is the presence of hemosiderin in shed renal tubular cells (positive urine hemosiderin). With severe intravascular hemolysis, hemoglobinemia and methemalbuminemia may be present. Hemolysis increases the indirect bilirubin, and the total bilirubin may rise to 4 mg/dL. Bilirubin levels higher than this may indicate some degree of hepatic dysfunction. Serum LD levels are strikingly elevated in cases of microangiopathic hemolysis (thrombotic thrombocytopenic purpura, hemolytic-uremic syndrome) and may be elevated in other hemolytic anemias.

HEREDITARY SPHEROCYTOSIS



ESSENTIALS OF DIAGNOSIS

- ▶ Positive family history.
- ▶ Splenomegaly.
- ▶ Spherocytes and increased reticulocytes on peripheral blood smear.
- ▶ Hyperchromic red blood cells (elevated mean corpuscular hemoglobin concentration [MCHC]).

► General Considerations

Hereditary spherocytosis is a disorder of the red blood cell membrane, leading to chronic hemolytic anemia.

In hereditary spherocytosis, the membrane defect is an abnormality in spectrin, actin, or other red blood cell membrane proteins, such as band 3 or protein 4.2; these proteins provide most of the scaffolding for the red blood cell membranes. The result is a decrease in surface-to-volume ratio that results in a spherical shape of the cell. These spherical cells are less deformable and unable to pass through the small fenestrations in the splenic red pulp. Hemolysis takes place because of trapping of red blood cells within the spleen and their removal by splenic macrophages.

► Clinical Findings

A. Symptoms and Signs

Hereditary spherocytosis is an autosomal dominant disease of variable severity. It is often diagnosed during childhood, but milder cases may be discovered incidentally late in adult life. Anemia may or may not be present, since the bone marrow may be able to compensate for shortened red cell survival. Severe anemia (aplastic crisis) may occur in folic acid deficiency or when bone marrow compensation is temporarily impaired by infection. Chronic hemolysis causes jaundice and pigment (calcium bilirubinate) gallstones, leading to attacks of cholecystitis. Examination may reveal icterus and a palpable spleen.

B. Laboratory Findings

The anemia is of variable severity, and the hematocrit may be normal. Reticulocytosis is always present. The peripheral blood smear shows the presence of spherocytes, small cells that have lost their central pallor. Spherocytes usually make up only a small percentage of red blood cells on the peripheral smear. Hereditary spherocytosis is the only important disorder associated with microcytosis (sometimes normocytic) and an increased MCHC, often > 36 g/dL. As with other hemolytic disorders, there may be an increase in indirect bilirubin. The Coombs test is negative.

Because spherocytes are red cells that have lost some membrane surface, they are abnormally vulnerable to swelling induced by hypotonic media. Increased osmotic fragility merely reflects the presence of spherocytes and does not distinguish hereditary spherocytosis from other spherocytic hemolytic disorders such as autoimmune hemolytic anemia. In some laboratories, the osmotic fragility test has been supplanted by ektacytometry, which has the advantages of better reliability and the ability to distinguish spherocytes from other red blood cell abnormalities such as elliptocytes.

► Treatment

Patients should receive uninterrupted supplementation with daily folic acid, 1 mg. The treatment of choice is splenectomy, which will correct neither the membrane defect nor the spherocytosis but will eliminate the site of

hemolysis. The timing of splenectomy is controversial, but certainly after 5 years of life whenever possible. In mild cases discovered late in adult life, splenectomy may not be necessary.

► When to Refer

Patients in whom hereditary spherocytosis is suspected should have the diagnosis confirmed by a hematologist, and decisions regarding splenectomy should be made in consultation with a hematologist.

Kar R et al. Clinico-hematological profile of hereditary spherocytosis: experience from a tertiary care center in North India. *Hematology*. 2009 Jun;14(3):164–7. [PMID: 19490762]
 Iolascon A et al. Hereditary spherocytosis. *Transfus Clin Biol*. 2010 Sep;17(3):138–42. [PMID: 20655264]
 Schilling RF. Risks and benefits of splenectomy versus no splenectomy for hereditary spherocytosis—a personal view. *Br J Haematol*. 2009 Jun;145(6):728–32. [PMID: 19388926]

PAROXYSMAL NOCTURNAL HEMOGLOBINURIA



ESSENTIALS OF DIAGNOSIS

- Episodic hemoglobinuria.
- Thrombosis is common.
- Suspect in confusing cases of hemolytic anemia or pancytopenia.
- Flow cytometry demonstrates deficiencies of CD55 and CD59.

► General Considerations

Paroxysmal nocturnal hemoglobinuria (PNH) is a rare acquired clonal hematopoietic stem cell disorder that results in abnormal sensitivity of the red blood cell membrane to lysis by complement. The underlying cause is an acquired defect in the gene for phosphatidylinositol class A (PIG-A), which results in a deficiency of the glycosylphosphatidylinositol (GPI) anchor for cellular membrane proteins. In particular, the complement-regulating proteins CD55 and CD59 are deficient, which permits unregulated formation of the membrane attack complex on red cell membranes and intravascular hemolysis. Free hemoglobin is released into the blood that scavenges nitric oxide and promotes esophageal spasms, male erectile dysfunction, renal damage, and thrombosis. Patients with significant PNH live 10–15 years; thrombosis is the primary cause of death.

► Clinical Findings

A. Symptoms and Signs

Classically, patients report episodic hemoglobinuria resulting in reddish brown urine. Hemoglobinuria is most often

noticed in the first morning urine due to the drop in blood pH while sleeping that facilitates hemolysis. Besides anemia, these patients are prone to thrombosis, especially within mesenteric and hepatic veins, central nervous system veins (sagittal vein), and skin vessels (with formation of painful nodules). As this is a hematopoietic stem cell disorder, PNH may appear de novo or arise in the setting of aplastic anemia with possible progression to myelodysplasia or acute myeloid leukemia (AML).

B. Laboratory Findings

Anemia is of variable severity and frequency, so reticulocytosis may or may not be present at any given time. Abnormalities on the blood smear are nondiagnostic and may include macro-ovalocytes and polychromasia. Since the episodic hemolysis is mainly intravascular, the finding of urine hemosiderin is a useful test. Serum LD is characteristically elevated. Iron deficiency is commonly present and is related to chronic iron loss from hemoglobinuria.

The white blood cell count and platelet count may be decreased and are always decreased in the setting of aplastic anemia. The best screening test is flow cytometry of blood granulocytes to demonstrate deficiency of CD55 and CD59. The FLAER assay (fluorescein-labeled proacrolysin variant) is even more sensitive. Bone marrow morphology is variable and may show either generalized hypoplasia or erythroid hyperplasia.

▶ Treatment

Most patients with PNH have mild disease not requiring intervention. In severe cases and in those occurring in the setting of aplastic anemia or myelodysplasia, allogeneic hematopoietic stem cell transplantation has been used. In patients with severe hemolysis (usually requiring red cell transfusions), or thrombosis, treatment with eculizumab is warranted. Eculizumab is a humanized monoclonal antibody against complement protein C5 – binding C5 prevents its cleavage so the membrane attack complex cannot assemble. Eculizumab improves quality of life and reduces hemolysis, transfusion requirements, and thrombosis risk. Iron replacement is indicated for treatment of iron deficiency when present, which may improve the anemia while also causing a transient increase in hemolysis. For unclear reasons, corticosteroids are effective in decreasing hemolysis.

▶ When to Refer

Most patients with PNH should be under the care of a hematologist.

Brodsky RA. How I treat paroxysmal nocturnal hemoglobinuria. *Blood*. 2009 Jun 25;113(26):6522–7. [PMID: 19372253]
Hill A et al. Eculizumab prevents intravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria and unmasks low-level extravascular hemolysis occurring through C3 opsonization. *Haematologica*. 2010 Apr;95(4):567–73. [PMID: 20145265]

Luzzatto L et al. Management of paroxysmal nocturnal haemoglobinuria: a personal view. *Br J Haematol*. 2011 Jun;153(6):709–20. [PMID: 21517820]

Madkaikar M et al. Paroxysmal nocturnal haemoglobinuria: diagnostic tests, advantages, & limitations. *Eur J Haematol*. 2009 Dec 1;83(6):503–11. [PMID: 19686268]

GLUCOSE-6-PHOSPHATE DEHYDROGENASE DEFICIENCY



ESSENTIALS OF DIAGNOSIS

- ▶ X-linked recessive disorder seen commonly in American black men.
- ▶ Episodic hemolysis in response to oxidant drugs or infection.
- ▶ Minimally abnormal peripheral blood smear.
- ▶ Reduced levels of glucose-6-phosphate dehydrogenase between hemolytic episodes.

▶ General Considerations

Glucose-6-phosphate dehydrogenase (G6PD) deficiency is a hereditary enzyme defect that causes episodic hemolytic anemia because of the decreased ability of red blood cells to deal with oxidative stresses. G6PD deficiency leads to excess oxidized glutathione that forces hemoglobin to denature and form precipitants called Heinz bodies. Heinz bodies cause red blood cell membrane damage, which leads to premature removal of these red blood cells by reticuloendothelial cells within the spleen (extravascular hemolysis).

Numerous G6PD isoenzymes have been described. The usual isoenzyme found in whites is designated G6PD-B and that in American blacks is designated G6PD-A, both of which have normal function and stability. Ten to 15 percent of American blacks have the variant G6PD isoenzyme designated A–, in which there is both a reduction in normal enzyme activity and a reduction in stability. The A– isoenzyme activity declines rapidly as the red blood cell ages past 40 days, a fact that explains many of the clinical findings in this disorder. Many other G6PD deficiency isoenzyme variants have been described, including some Mediterranean and Ashkenazi Jewish variants with extremely low enzyme activity, chronic hemolysis, and exacerbations due to oxidizing substances including fava beans.

▶ Clinical Findings

G6PD deficiency is an X-linked disorder affecting 10–15% of American hemizygous black males and rare female homozygotes. Female carriers are rarely affected—only when an unusually high percentage of cells producing the normal enzyme are X-inactivated.

A. Symptoms and Signs

Patients are usually healthy, without chronic hemolytic anemia or splenomegaly. Hemolysis occurs episodically as

a result of oxidative stress on the red blood cells, generated either by infection or exposure to certain drugs. Seven drugs initiate hemolysis and should be avoided: dapsone, methylthionium chloride (methylene blue), phenazopyridine, primaquine, rasburicase, toluidine chloride (toluidine blue), and nitrofurantoin. Other drugs, such as sulfonamides, have been implicated but are less certain as they are often given during infections. Even with continuous use of the offending drug, the hemolytic episode is self-limited because older red blood cells (with low enzyme activity) are removed and replaced with a population of young red blood cells (reticulocytes) with adequate functional levels of G6PD. Severe G6PD deficiency (as in Mediterranean variants) may produce a chronic hemolytic anemia.

B. Laboratory Findings

Between hemolytic episodes, the blood is normal. During episodes of hemolysis, the hemoglobin rarely falls below 8 g/dL, and there is reticulocytosis and increased serum indirect bilirubin. The red blood cell smear often reveals a small number of “bite” cells—cells that appear to have had a bite taken out of their periphery, or “blister” cells. This indicates pitting of hemoglobin aggregates by the spleen. Heinz bodies may be demonstrated by staining a peripheral blood smear with cresyl violet; they are not visible on the usual Wright–Giemsa–stained blood smear. Specific enzyme assays for G6PD may reveal a low level but may be falsely normal if they are performed during or shortly after a hemolytic episode when the enzyme-deficient cohort of red blood cells has been removed and replenished with reticulocytes. In these cases, the enzyme assays should be repeated weeks after hemolysis has resolved. In severe cases of G6PD deficiency, enzyme levels are always low.

▶ Treatment

No treatment is necessary except to avoid known oxidant drugs.

Beutler E. Glucose-6-phosphate dehydrogenase deficiency: a historical perspective. *Blood*. 2008 Jan 1;111(1):16–24. [PMID: 18156501]

Youngster I et al. Medications and glucose-6-phosphate dehydrogenase deficiency. An evidence-based review. *Drug Saf*. 2010 Sep 1;33(9):713–26. [PMID: 20701405]

SICKLE CELL ANEMIA & RELATED SYNDROMES



ESSENTIALS OF DIAGNOSIS

- ▶ Recurrent pain episodes.
- ▶ Positive family history and lifelong history of hemolytic anemia.
- ▶ Irreversibly sickled cells on peripheral blood smear.
- ▶ Hemoglobin S is the major hemoglobin seen on electrophoresis.

▶ General Considerations

Sickle cell anemia is an autosomal recessive disorder in which an abnormal hemoglobin leads to chronic hemolytic anemia with numerous clinical consequences. A single DNA base change leads to an amino acid substitution of valine for glutamine in the sixth position on the β -globin chain. The abnormal β chain is designated β^s and the tetramer of $\alpha_2\beta_2^s$ is designated hemoglobin S. Hemoglobin S is unstable and polymerizes in the setting of various stressors, including hypoxemia and acidosis, leading to the formation of sickled red blood cells.

The rate of sickling is influenced by the concentration of hemoglobin S and by the presence of other hemoglobins within the cell. Hemoglobin F cannot participate in polymer formation, and its presence markedly retards sickling. Factors that increase sickling are red cell dehydration and factors that lead to formation of deoxyhemoglobin S, eg, acidosis and hypoxemia, either systemic or locally in tissues. Hemolytic crises may be related to splenic sequestration of sickled cells (primarily in childhood before the spleen has been infarcted as a result of repeated sickling) or with coexistent disorders such as G6PD deficiency.

The hemoglobin S gene is carried in 8% of American blacks, and 1 of 400 American black children will be born with sickle cell anemia. Prenatal diagnosis is available for couples at risk for producing a child with sickle cell anemia. Genetic counseling should be made available to such couples.

▶ Clinical Findings

A. Symptoms and Signs

The disorder has its onset during the first year of life, when hemoglobin F levels fall as a signal is sent to switch from production of γ -globin to β -globin.

Chronic hemolytic anemia produces jaundice, pigment (calcium bilirubinate) gallstones, splenomegaly (early in life), and poorly healing ulcers over the lower tibia. Life-threatening severe anemia can occur during hemolytic or aplastic crises, generally associated with viral or other infection or by folic acid deficiency.

Acute painful episodes due to acute vaso-occlusion from clusters of sickled red cells may occur spontaneously or be provoked by infection, dehydration, or hypoxia. Common sites of acute painful episodes include the bones (especially the back and long bones) and the chest. These episodes last hours to days and may produce low-grade fever. Acute vaso-occlusion may cause strokes due to sagittal sinus thrombosis and may also cause priapism. Vaso-occlusive episodes are not associated with increased hemolysis.

Repeated episodes of vascular occlusion especially affect the heart, lungs, and liver. Ischemic necrosis of bone occurs, rendering the bone susceptible to osteomyelitis due to salmonellae and (somewhat less commonly) staphylococci. Infarction of the papillae of the renal medulla causes renal tubular concentrating defects and gross hematuria, more often encountered in sickle cell trait than in sickle cell anemia. Retinopathy similar to that noted in diabetes mellitus is often present and may lead to visual impairment.

Pulmonary hypertension may develop and is associated with a poor prognosis.

These patients are prone to delayed puberty. An increased incidence of infection is related to hyposplenism as well as to defects in the alternative pathway of complement.

On examination, patients are often chronically ill and jaundiced. There is hepatomegaly, but the spleen is not palpable in adult life. The heart is enlarged, with a hyperdynamic precordium and systolic murmurs. Nonhealing ulcers of the lower leg and retinopathy may be present.

Sickle cell anemia becomes a chronic multisystem disease, with death from organ failure. With improved supportive care, average life expectancy is now between 40 and 50 years of age.

B. Laboratory Findings

Chronic hemolytic anemia is present. The hematocrit is usually 20–30%. The peripheral blood smear is characteristically abnormal, with irreversibly sickled cells comprising 5–50% of red cells. Other findings include reticulocytosis (10–25%), nucleated red blood cells, and hallmarks of hyposplenism such as Howell–Jolly bodies and target cells. The white blood cell count is characteristically elevated to 12,000–15,000/mcL, and reactive thrombocytosis may occur. Indirect bilirubin levels are high.

After a screening test for sickle cell hemoglobin, the diagnosis of sickle cell anemia is confirmed by hemoglobin electrophoresis (Table 13–9). Hemoglobin S will usually comprise 85–98% of hemoglobin. In homozygous S disease, no hemoglobin A will be present. Hemoglobin F levels are variably increased, and high hemoglobin F levels are associated with a more benign clinical course.

▶ Treatment

Allogeneic hematopoietic stem cell transplantation can cure more than 80% of children with sickle cell anemia who have suitable HLA-matched donors. Transplantation remains investigational in adults. Other therapies modulate disease severity: cytotoxic agents, such as hydroxyurea, increase hemoglobin F levels epigenetically. Hydroxyurea (500–750 mg orally daily) reduces the frequency of painful crises in patients whose quality of life is disrupted by frequent pain crises. Long-term follow-up of patients taking hydroxyurea demonstrate it improves overall survival with little evidence for secondary malignancy.

Supportive care is the mainstay of treatment for sickle cell anemia. Patients are maintained on folic acid supplementation (1 mg orally daily) and given transfusions for aplastic or hemolytic crises. Pneumococcal vaccination reduces the incidence of infections with this pathogen. When acute painful episodes occur, precipitating factors should be identified and infections treated if present. The patient should be kept well hydrated, given generous analgesics, and supplied oxygen if hypoxic.

Acute vaso-occlusive crises can be treated with exchange transfusion. Exchange transfusions are primarily indicated for the treatment of intractable pain crises, acute chest syndrome, priapism, and stroke. Long-term transfusion

therapy has been shown to be effective in reducing the risk of recurrent stroke in children.

▶ When to Refer

Patients with sickle cell anemia should have their care coordinated with a hematologist and should be referred to a Comprehensive Sickle Cell Center if one is available.

▶ When to Admit

Patients should be admitted for management of acute chest crises or for painful episodes that do not respond to outpatient care.

- Buchanan G et al. Severe sickle cell disease—pathophysiology and therapy. *Biol Blood Marrow Transplant.* 2010 Jan;16 (1 Suppl):S64–7. [PMID: 19819341]
- Charneski L et al. Effects of antiplatelet and anticoagulant medications on the vasoocclusive and thrombotic complications of sickle cell disease: a review of the literature. *Am J Health Syst Pharm.* 2010 Jun 1;67(11):895–900. [PMID: 20484211]
- Khoury R et al. Stem-cell transplantation in children and adults with sickle cell disease: an update. *Expert Rev Hematol.* 2011 Jun;4(3):343–51. [PMID: 21668398]
- McGann PT et al. Hydroxyurea for sickle cell anemia: what have we learned and what questions still remain? *Curr Opin Hematol.* 2011 May;18(3):158–65. [PMID: 21372708]
- Mousa SA et al. Diagnosis and management of sickle cell disorders. *Methods Mol Biol.* 2010;663:291–307. [PMID: 20617425]
- Mousa SA et al. Management of painful vaso-occlusive crisis of sickle-cell anemia: consensus opinion. *Clin Appl Thromb Hemost.* 2010 Aug;16(4):365–76. [PMID: 20530056]
- Rees DC et al. Sickle-cell disease. *Lancet.* 2010 Dec 11;376(9757):2018–31. [PMID: 21131035]
- Steinberg MH et al. The risks and benefits of long-term hydroxyurea in sickle cell anemia: a 17.5 year follow-up. *Am J Hematol.* 2010 Jun;85(6):403–8. [PMID: 20513116]

SICKLE CELL TRAIT

People with the heterozygous genotype (AS) have sickle cell trait. These persons are hematologically normal, with no anemia and normal red blood cells on peripheral blood smear. A screening test for sickle hemoglobin will be positive, and hemoglobin electrophoresis will reveal that approximately 40% of hemoglobin is hemoglobin S (Table 13–9). People with sickle cell trait may experience sudden cardiac death and rhabdomyolysis during vigorous exercise, especially at high altitudes. They may also be at increased risk for venothromboembolism. Chronic sickling of red blood cells in the acidotic renal medulla results in microscopic and gross hematuria, hyposthenuria (poor urine concentrating ability), and possibly chronic kidney disease.

No treatment is necessary. Genetic counseling is recommended.

- Key NS et al. Sickle-cell trait: novel clinical significance. *Hematology Am Soc Hematol Educ Program.* 2010;2010:418–22. [PMID: 21239829]
- Tsaras G et al. Complications associated with sickle cell trait: a brief narrative review. *Am J Med.* 2009 Jun;122(6):507–12. [PMID: 19393983]

SICKLE THALASSEMIA

Patients with homozygous sickle cell anemia and α -thalassemia have less vigorous hemolysis and run higher hemoglobins than SS patients due to reduced red blood cell sickling related to reduced hemoglobin concentration within the red blood cell. The MCV is low, and the red cells are hypochromic.

Patients who are double heterozygotes for β^S and β -thalassemia are clinically affected with sickle cell syndromes. Sickle β^0 -thalassemia is clinically very similar to homozygous SS disease. Vaso-occlusive crises may be somewhat less severe, and the spleen is usually not infarcted. The MCV is low, in contrast to the normal MCV of sickle cell anemia. Hemoglobin electrophoresis reveals no hemoglobin A but will show an increase in hemoglobins A₂ and F, which is not present in sickle cell anemia (Table 13–9).

Sickle β^+ -thalassemia is a milder disorder than homozygous SS disease, with fewer crises. The spleen is usually palpable. The hemolytic anemia is less severe, and the hematocrit is usually 30–38%, with reticulocytes of 5–10%. Hemoglobin electrophoresis shows the presence of some hemoglobin A and elevated hemoglobins A₂ and F (Table 13–9). The MCV is low.

Sankaran VG et al. Modifier genes in Mendelian disorders: the example of hemoglobin disorders. *Ann NY Acad Sci.* 2010 Dec;1214:47–56. [PMID: 21039591]

HEMOGLOBIN C DISORDERS

Hemoglobin C is formed by a single amino acid substitution at the same site of substitution as in sickle hemoglobin (codon 6) but with lysine instead of valine substituted for glutamine. Hemoglobin C is nonsickling but may participate in polymer formation in association with hemoglobin S. Homozygous hemoglobin C disease produces a mild hemolytic anemia with splenomegaly, mild jaundice, and pigment (calcium bilirubinate) gallstones. The peripheral blood smear shows generalized red cell targeting and occasional cells with angular crystals of hemoglobin C. Persons heterozygous for hemoglobin C are clinically normal.

Patients with hemoglobin SC disease are double heterozygotes for β^S and β^C . These patients, like those with sickle β^+ -thalassemia, have a milder hemolytic anemia and milder clinical course than those with homozygous SS disease. There are fewer vaso-occlusive events, and the spleen remains palpable in adult life. However, persons with hemoglobin SC disease have more retinopathy, more ischemic necrosis of bone, and more priapism than those with SS disease. The hematocrit is usually 30–38%, with 5–10% reticulocytes, and compared to SS, fewer irreversibly sickled cells on the blood smear. Target cells are more numerous than in SS disease. Hemoglobin electrophoresis will show approximately 50% hemoglobin C, 50% hemoglobin S, and no increase in hemoglobin F levels.

Nagel RL et al. The paradox of hemoglobin SC disease. *Blood Rev.* 2003 Sep;17(3):167–78. [PMID: 12818227]
Old JM. Screening and genetic diagnosis of haemoglobinopathies. *Scand J Clin Lab Invest.* 2007;67(1):71–86. [PMID: 17365985]

UNSTABLE HEMOGLOBINS

Unstable hemoglobins are prone to oxidative denaturation even in the presence of a normal G6PD system. The disorder is autosomal dominant and of variable severity. Most patients have a mild chronic hemolytic anemia with splenomegaly, mild jaundice, and pigment (calcium bilirubinate) gallstones. Less severely affected patients are not anemic except under conditions of oxidative stress.

The diagnosis is suspected by the finding of Heinz bodies combined with a normal G6PD level. Hemoglobin electrophoresis is usually normal, since these hemoglobins characteristically do not have a change in their migration pattern. These hemoglobins precipitate in isopropanol. Usually no treatment is necessary. Patients with chronic hemolytic anemia should receive folic acid supplementation (1 mg orally) and avoid known oxidative drugs. In rare cases, splenectomy may be required.

Kutlar F. Diagnostic approach to hemoglobinopathies. *Hemoglobin.* 2007;31(2):243–50. [PMID: 17486507]
Yates AM. The diagnostic dilemma of congenital unstable hemoglobinopathies. *Pediatr Blood Cancer.* 2010 Dec 15;55(7):1393–5. [PMID: 20730880]

Table 13–9. Hemoglobin distribution in sickle cell syndromes.

Genotype	Clinical Diagnosis	Hb A	Hb S	Hb A ₂	Hb F
AA	Normal	97–99%	0	1–2%	< 1%
AS	Sickle trait	60%	40%	1–2%	< 1%
SS	Sickle cell anemia	0	86–98%	1–3%	5–15%
S, β^0 -thalassemia	Sickle β -thalassemia	0	70–80%	3–5%	10–20%
S, β^+ -thalassemia	Sickle β -thalassemia	10–20%	60–75%	3–5%	10–20%
AS, α -thalassemia	Sickle trait	70–75%	25–30%	1–2%	< 1%

Hb, hemoglobin.

AUTOIMMUNE HEMOLYTIC ANEMIA



ESSENTIALS OF DIAGNOSIS

- ▶ Acquired hemolytic anemia caused by IgG autoantibody.
- ▶ Spherocytes and reticulocytosis on peripheral blood smear.
- ▶ Positive antiglobulin (Coombs) test.

▶ General Considerations

Autoimmune hemolytic anemia is an acquired disorder in which an IgG autoantibody is formed that binds to the red blood cell membrane and does so most avidly at body temperature (ie, a “warm” autoantibody). The antibody is most commonly directed against a basic component of the Rh system present on most human red blood cells. When IgG antibodies coat the red blood cell, the Fc portion of the antibody is recognized by macrophages present in the spleen and other portions of the reticuloendothelial system. The interaction between splenic macrophages and the antibody-coated red blood cell results in removal of red blood cell membrane and the formation of a spherocyte because of the decrease in surface-to-volume ratio of the surviving red blood cell. These spherocytic cells have decreased deformability and become trapped in the red pulp of the spleen because of their inability to squeeze through the 2- μ m fenestrations of splenic sinusoids. When large amounts of IgG are present on red blood cells, complement may be fixed. Direct lysis of cells is rare, but the presence of C3b on the surface of red blood cells allows Kupffer cells in the liver to participate in the hemolytic process because of the presence of C3b receptors on Kupffer cells. The destruction of red blood cells in the spleen and liver designates this as extravascular hemolysis.

Approximately 50% of all cases of autoimmune hemolytic anemia are idiopathic. The disorder may also be seen in association with systemic lupus erythematosus, CLL, or lymphomas. It must be distinguished from drug-induced hemolytic anemia. When penicillin (or other drugs, especially cefotetan, ceftriaxone, and piperacillin) coats the red blood cell membrane, the antibody is directed against the membrane–drug complex. Fludarabine, an antineoplastic, causes autoimmune hemolytic anemia through its immunosuppression effects resulting in defective self-vs-non-self immune surveillance.

▶ Clinical Findings

A. Symptoms and Signs

Autoimmune hemolytic anemia typically produces an anemia of rapid onset that may be life-threatening in severity. Patients complain of fatigue and dyspnea and may present with angina or congestive heart failure. On examination, jaundice and splenomegaly are usually present.

B. Laboratory Findings

The anemia is of variable severity but may be severe, with hematocrit of <10%. Reticulocytosis is present, and spherocytes are seen on the peripheral blood smear. In cases of severe hemolysis, the stressed bone marrow may also release nucleated red blood cells. As with other hemolytic disorders, indirect bilirubin is increased. Approximately 10% of patients with autoimmune hemolytic anemia have coincident immune thrombocytopenia (Evans syndrome).

The antiglobulin (Coombs) test forms the basis for diagnosis. The Coombs reagent is a rabbit IgM antibody raised against human IgG or human complement. The direct antiglobulin (Coombs) test is performed by mixing the patient’s red blood cells with the Coombs reagent and looking for agglutination, which indicates the presence of antibody on the red blood cell surface. The indirect antiglobulin (Coombs) test is performed by mixing the patient’s serum with a panel of type O red blood cells. After incubation of the test serum and panel red blood cells, the Coombs reagent is added. Agglutination in this system indicates the presence of free antibody in the patient’s serum.

The direct antiglobulin test is positive (for IgG, complement, or both) in autoimmune hemolytic anemia, and the indirect antiglobulin test may or may not be positive. In approximately 10% of cases, the direct antiglobulin test is negative. A positive indirect antiglobulin test indicates the presence of a large amount of autoantibody that has saturated binding sites in the red blood cell and consequently appears in the serum. Because the patient’s serum usually contains the autoantibody, it may be difficult to obtain a compatible cross-match with homologous red blood cells to be used for transfusion.

▶ Treatment

Initial treatment consists of prednisone, 1–2 mg/kg/d orally in divided doses. Most transfused red blood cells will survive similarly to the patient’s own red blood cells. Because of difficulty in performing the cross-match, “incompatible” blood may need to be given. Decisions regarding transfusions should be made in consultation with a hematologist and a blood bank specialist. If prednisone is ineffective or if the disease recurs on tapering the dose, splenectomy should be considered. Splenectomy may cure the disorder. Death from cardiovascular collapse can occur in the setting of rapid hemolysis. In patients with rapid hemolysis, therapeutic plasmapheresis should be performed early in management to physically unload autoantibodies. Patients with autoimmune hemolytic anemia refractory to prednisone and splenectomy may be treated with a variety of agents. Treatment with rituximab, a monoclonal antibody against the B cell antigen CD20, is effective in some cases. The suggested dose is 375 mg/m² intravenously weekly for 4 weeks. Danazol, 600–800 mg/d orally, is less often effective than in immune thrombocytopenia but is well suited for long-term use because of its low toxicity. Immunosuppressive agents, including cyclophosphamide, azathioprine, mycophenolate mofetil, alemtuzumab (an anti-CD52 antibody), or cyclosporine, may also be used. High-dose intravenous immune globulin

(1 g/kg daily for 2 days) may be effective in controlling hemolysis. The benefit is short-lived (1–3 weeks), and the drug is very expensive. The long-term prognosis for patients with this disorder is good, especially if there is no underlying autoimmune disorder or lymphoma.

► When to Refer

Patients with autoimmune hemolytic anemia should be referred to a hematologist for confirmation of the diagnosis and subsequent care.

► When to Admit

Patients should be hospitalized for symptomatic anemia or rapidly falling hematocrit levels.

Barros MM et al. Warm autoimmune hemolytic anemia: recent progress in understanding the immunobiology and the treatment. *Transfus Med Rev.* 2010 Jul;24(3):195–210. [PMID: 20656187]

Garratty G. Immune hemolytic anemia associated with drug therapy. *Blood Rev.* 2010 July–Sep;24(4–5):143–50. [PMID: 20650555]

Lambert JF et al. Geoepidemiology of autoimmune hemolytic anemia. *Autoimmun Rev.* 2010 Mar;9(5):A350–4. [PMID: 19932202]

Lechner K et al. How I treat autoimmune hemolytic anemias in adults. *Blood.* 2010 Sept 16;116(11):1821–8. [PMID: 20548093]

Stasi R. Rituximab in autoimmune hematologic diseases: not just a matter of B cells. *Semin Hematol.* 2010 Apr;47(2):170–9. [PMID: 20350664]

Tai P et al. A review of autoimmune diseases associated with cancer. *Front Biosci (Elite Ed).* 2010 Jan 1;2:122–6. [PMID: 20036861]

COLD AGGLUTININ DISEASE



ESSENTIALS OF DIAGNOSIS

- ▶ Increased reticulocytes on peripheral blood smear.
- ▶ Antiglobulin (Coombs) test positive only for complement.
- ▶ Positive cold agglutinin titer.

► General Considerations

Cold agglutinin disease is an acquired hemolytic anemia due to an IgM autoantibody (called a cold agglutinin) usually directed against the I antigen on red blood cells. These IgM autoantibodies characteristically will not react with cells at 37 °C but only at lower temperatures (ie, “cold” autoantibody). Since the blood temperature (even in the most peripheral parts of the body) rarely goes lower than 20 °C, only antibodies reactive at relatively higher temperatures will produce clinical effects. Hemolysis results indirectly from attachment of IgM, which in the cooler parts of the circulation (fingers, nose, ears) binds and fixes complement. When the red blood cell returns to a warmer temperature, the IgM antibody dissociates, leaving complement

on the cell. Lysis of red blood cells rarely occurs. Rather, C3b, present on the red blood cells, is recognized by Kupffer cells (which have receptors for C3b), and red blood cell sequestration ensues. In some cases, the complement membrane attack complex forms, lysing the red blood cells (intravascular hemolysis).

Most cases of chronic cold agglutinin disease are idiopathic. Others occur in association with Waldenström macroglobulinemia or CLL, in which a monoclonal IgM paraprotein is produced. Acute postinfectious cold agglutinin disease occurs following mycoplasmal pneumonia or viral infection (infectious mononucleosis, measles, or mumps with antibody directed against antigen i rather than I).

► Clinical Findings

A. Symptoms and Signs

In chronic cold agglutinin disease, symptoms related to red blood cell agglutination occur on exposure to cold, and patients may complain of mottled or numb fingers or toes and episodic low back pain and dark colored urine. Hemolytic anemia is rarely severe, but episodic hemoglobinuria may occur on exposure to cold. The hemolytic anemia in acute postinfectious syndromes is rarely severe.

B. Laboratory Findings

Mild anemia is present with reticulocytosis and rarely spherocytes. The blood smear made at room temperature shows agglutinated red blood cells. The direct antiglobulin (Coombs) test will be positive for complement only. Serum cold agglutinin titer will semi-quantitate the autoantibody.

► Treatment

Treatment is largely symptomatic, based on avoiding exposure to cold. Splenectomy and prednisone are usually ineffective (except when associated with a lymphoproliferative disorder) since hemolysis takes place in the liver and blood stream. Rituximab, a monoclonal antibody directed against the CD20 antigen on B-lymphocytes, is the treatment of choice. The dose is 375 mg/m² intravenously weekly for 4 weeks. Relapses may be effectively re-treated. High-dose intravenous immunoglobulin (2 g/kg) may be effective temporarily, but it is rarely used because of the high cost and short duration of benefit. Patients with severe disease may be treated with alkylating agents, such as cyclophosphamide, or with immunosuppressive agents, such as cyclosporine. As in warm IgG-mediated autoimmune hemolysis, it may be difficult to find compatible blood for transfusion. Red blood cells should be transfused through an in-line blood warmer.

Berentsen S. How I manage cold agglutinin disease. *Br J Haematol.* 2011 May;153(3):309–17. [PMID: 21385173]

Lechner K et al. How I treat autoimmune hemolytic anemias in adults. *Blood.* 2010 Sep 16;116(11):1831–8. [PMID: 20548093]

Petz LD. Cold antibody autoimmune hemolytic anemias. *Blood Rev.* 2008 Jan;22(1):1–15. [PMID: 17904258]

MICROANGIOPATHIC HEMOLYTIC ANEMIAS

The microangiopathic hemolytic anemias are a group of disorders in which red blood cell fragmentation takes place. The anemia is intravascular, producing hemoglobinemia, hemoglobinuria and, in severe cases, methemalbuminemia. The hallmark of the disorder is the finding of fragmented red blood cells (schistocytes, helmet cells) on the peripheral blood smear.

These fragmentation syndromes can be caused by a variety of disorders (Table 13–8). Thrombotic thrombocytopenic purpura is the most important of these and is discussed in Chapter 14. Clinical features are variable and depend on the underlying disorder. Coagulopathy and thrombocytopenia are variably present.

Chronic microangiopathic hemolytic anemia (such as is present with a malfunctioning cardiac valve prosthesis) may cause iron deficiency anemia because of continuous low-grade hemoglobinuria.

APLASTIC ANEMIA

ESSENTIALS OF DIAGNOSIS

- ▶ Pancytopenia.
- ▶ No abnormal hematopoietic cells seen.
- ▶ Hypocellular bone marrow.

▶ General Considerations

Aplastic anemia is a condition of bone marrow failure that arises from injury to or suppression of the hematopoietic stem cell. The bone marrow becomes hypoplastic, fails to produce mature blood cells, and pancytopenia develops.

There are a number of causes of aplastic anemia (Table 13–10). Direct hematopoietic stem cell injury may be caused by radiation, chemotherapy, toxins, or pharmacologic agents. Systemic lupus erythematosus may rarely cause suppression of the hematopoietic stem cell by an IgG autoantibody directed against the hematopoietic stem cell. However, the most common pathogenesis of aplastic anemia appears to be autoimmune suppression of hematopoiesis by a T cell-mediated cellular mechanism. In some cases of idiopathic aplastic anemia, defects in maintenance of the

Table 13–10. Causes of aplastic anemia.

Congenital—defects in telomere length maintenance or DNA repair (rare)
“Idiopathic” (probably autoimmune)
Systemic lupus erythematosus
Chemotherapy, radiotherapy
Toxins: benzene, toluene, insecticides
Drugs: chloramphenicol, phenylbutazone, gold salts, sulfonamides, phenytoin, carbamazepine, quinacrine, tolbutamide
Post-viral hepatitis (non-A through G)
Pregnancy
Paroxysmal nocturnal hemoglobinuria

hematopoietic stem cell telomere length have been identified and are likely linked to both the initiation of bone marrow failure and the propensity to later progress to myelodysplasia, PNH, or AML.

▶ Clinical Findings

A. Symptoms and Signs

Patients come to medical attention because of the consequences of bone marrow failure. Anemia leads to symptoms of weakness and fatigue, neutropenia causes vulnerability to bacterial or fungal infections, and thrombocytopenia results in mucosal and skin bleeding. Physical examination may reveal signs of pallor, purpura, and petechiae. Other abnormalities such as hepatosplenomegaly, lymphadenopathy, or bone tenderness should *not* be present, and their presence should lead to questioning the diagnosis.

B. Laboratory Findings

The hallmark of aplastic anemia is pancytopenia. However, early in the evolution of aplastic anemia, only one or two cell lines may be reduced.

Anemia may be severe and is always associated with reticulocytopenia. Red blood cell morphology is unremarkable, but there may be mild macrocytosis. Neutrophils and platelets are reduced in number, and no immature or abnormal forms are seen on the blood smear. The bone marrow aspirate and the bone marrow biopsy appear hypocellular, with only scant amounts of morphologically normal hematopoietic progenitors. The bone marrow karyotype should be normal (or germline if normal variant).

▶ Differential Diagnosis

Aplastic anemia must be differentiated from other causes of pancytopenia (Table 13–11). Hypocellular forms of myelodysplasia or acute leukemia may occasionally be

Table 13–11. Causes of pancytopenia.

Bone marrow disorders
Aplastic anemia
Myelodysplasia
Acute leukemia
Chronic idiopathic myelofibrosis
Infiltrative disease: lymphoma, myeloma, carcinoma, hairy cell leukemia, etc.
Nonmarrow disorders
Hypersplenism
Systemic lupus erythematosus
Infection: tuberculosis, HIV infection, leishmaniasis, brucellosis, CMV, erythrovirus (parvovirus B19)
Nutritional deficiency (megaloblastic anemia)
Medications
Cytotoxic chemotherapy
Ionizing radiation
Portal hypertension with hypersplenism

confused with aplastic anemia. These are differentiated by the presence of morphologic abnormalities or increased blasts, or by the presence of an abnormal karyotype in bone marrow cells. Hairy cell leukemia has been misdiagnosed as aplastic anemia and should be recognized by the presence of splenomegaly and by abnormal lymphoid cells in a hypocellular bone marrow biopsy. Pancytopenia with a normocellular bone marrow may be due to systemic lupus erythematosus, disseminated infection, or hypersplenism. Isolated thrombocytopenia may occur early as aplastic anemia develops and may be confused with immune thrombocytopenia.

► Treatment

Mild cases of aplastic anemia may be treated with supportive care, including erythropoietic (epoetin or darbepoetin) or myeloid (filgrastim or sargramostim) growth factors. Red blood cell transfusions and platelet transfusions are given as necessary, and antibiotics are used to treat infections.

Severe aplastic anemia is defined by a neutrophil count of < 500/mcL, platelets < 20,000/mcL, reticulocytes < 1%, and bone marrow cellularity < 20%. The treatment of choice for young adults (under age 40 years) who have HLA-matched siblings is allogeneic bone marrow transplantation. Children or young adults may also benefit from allogeneic bone marrow transplantation using an unrelated donor. Because of the increased risks associated with unrelated-donor allogeneic bone marrow transplantation, this treatment is usually reserved for patients who have not benefited from immunosuppressive therapy.

For adults over age 40 years or those without HLA-matched donors, the treatment of choice for severe aplastic anemia is immunosuppression with antithymocyte globulin (ATG) plus cyclosporine (or tacrolimus). ATG is given in the hospital in conjunction with transfusion and antibiotic support. A useful regimen is equine ATG 40 mg/kg/d intravenously for 4 days in combination with cyclosporine, 6 mg/kg orally twice daily. Equine ATG is superior to rabbit ATG, resulting in a higher response rate and better survival. ATG must be used in combination with corticosteroids (prednisone 1–2 mg/kg/d orally for 1 week, followed by a taper over 2 weeks) to avoid ATG infusion reactions and serum sickness. Responses usually occur in 1–3 months and are usually only partial, but the blood counts rise high enough to give patients a safe and transfusion-free life. Cyclosporine is maintained for several years post-ATG. The anti-CD52 monoclonal antibody alemtuzumab can produce responses in patients with relapsed or refractory disease. Androgens (such as fluoxymesterone 1–20 mg/kg/d orally in divided doses) have been widely used in the past, with a low response rate, and may be considered in mild cases. Androgens appear to partially correct telomere length maintenance defects.

► Course & Prognosis

Patients with severe aplastic anemia have a rapidly fatal illness if left untreated. Allogeneic bone marrow transplant from a HLA-matched sibling donor produces survival rates over 80% in recipients under 20 years old and

about 65–70% in those 20- to 50-years-old. Respective survival rates drop 10–15% when the donor is HLA-matched but unrelated. ATG immunosuppressive treatment leads to a response in approximately 70% of patients. Up to one-third of patients will relapse with aplastic anemia after ATG-based therapy. Clonal hematologic disorders, such as PNH, AML, or myelodysplasia, may develop in one-quarter of these patients who have not undergone bone marrow transplantation after many years of follow-up. Factors that predict response to ATG-cyclosporine therapy are patient's age, reticulocyte count, lymphocyte count, and age-adjusted telomere length of leukocytes at the time of diagnosis.

► When to Refer

All patients should be referred to a hematologist.

► When to Admit

Admission is necessary for treatment of neutropenic infection, the administration of ATG, or allogeneic bone marrow transplantation.

Bacigalupo A et al. Diagnosis and treatment of acquired aplastic anemia. *Hematol Oncol Clin North Am.* 2009 Apr;23(2):159–70. [PMID: 19327577]

Morinet F et al. Concise review: anemia caused by viruses. *Stem Cells.* 2011 Nov;29(11):1656–60. [PMID: 21898692]

Passweg JR et al. Aplastic anemia: first-line treatment by immunosuppression and sibling marrow transplantation. *Hematology Am Soc Hematol Educ Program.* 2010;2010:36–42. [PMID: 21239768]

Scheinberg P et al. Horse versus rabbit antithymocyte globulin in acquired aplastic anemia. *N Engl J Med.* 2011 Aug 4;365(5):430–8. [PMID: 21812672]

Young NS et al. Aplastic anemia: pathophysiology and treatment. *Biol Blood Marrow Transplant.* 2010 Jan;16(1 Suppl):S119–25. [PMID: 19782144]

NEUTROPENIA

ESSENTIALS OF DIAGNOSIS

- Neutrophils < 1800/mcL.
- Severe neutropenia if neutrophils < 500/mcL.

► General Considerations

Neutropenia is present when the neutrophil count is < 1800/mcL, although blacks, Asians, and other specific population groups may normally have neutrophil counts as low as 1200/mcL. The neutropenic patient is increasingly vulnerable to infection by gram-positive and gram-negative bacteria and by fungi. The risk of infection is related to the severity of neutropenia. The risk of serious infection rises sharply with neutrophil counts < 500/mcL, and neutrophil counts < 100/mcL (“profound neutropenia”) are associated with a high risk of infection within

Table 13-12. Causes of neutropenia.**Bone marrow disorders**

Aplastic anemia
 Pure white cell aplasia
 Congenital
 Cyclic neutropenia
 Drugs: sulfonamides, chlorpromazine, procainamide, penicillin, cephalosporins, cimetidine, methimazole, phenytoin, chlorpropamide, antiretroviral medications, rituximab
 Myelosuppressive cytotoxic chemotherapy
 Benign chronic
 Large granular lymphocytic leukemia
 Hairy cell leukemia
 Myelodysplasia

Non-marrow disorders

Hypersplenism
 Sepsis
 Immune
 Felty syndrome
 HIV infection

days. Patients with “chronic benign neutropenia” are free of infection for years despite very low stable neutrophil levels; they seem to respond appropriately to infections and inflammatory stimuli with a neutrophilia. In contrast, the neutrophil count of patients with cyclic neutropenia periodically oscillate (usually in 21-day cycles) between normal and low, with infections occurring during the nadirs. Both cyclic neutropenia and congenital neutropenia represent problems in mutations in the neutrophil elastase genes *ELA-2* or *ELANE*.

A variety of bone marrow disorders and nonmarrow conditions may cause neutropenia (Table 13-12). All the causes of aplastic anemia (Table 13-10) and pancytopenia (Table 13-11) may cause neutropenia. The new onset of an isolated neutropenia is often due to an idiosyncratic reaction to a drug, and agranulocytosis (complete absence of neutrophils in the peripheral blood) is almost always due to a drug reaction. In these cases, examination of the bone marrow shows an almost complete absence of granulocyte precursors, with other cell lines undisturbed. This marrow finding is also seen in pure white blood cell aplasia, an autoimmune attack on marrow granulocyte precursors. Neutropenia in the presence of a normal bone marrow may be due to immunologic peripheral destruction (autoimmune neutropenia), sepsis, or hypersplenism. The presence in the serum of antineutrophil antibodies supports the diagnosis of autoimmune neutropenia. **Felty syndrome** is an immune neutropenia associated with seropositive nodular rheumatoid arthritis and splenomegaly. Severe neutropenia may be associated with clonal disorders of T lymphocytes, often with the morphology of large granular lymphocytes, referred to as CD3-positive T-cell large granular lymphocytic leukemia. Isolated neutropenia is an uncommon presentation of hairy cell leukemia or a myelodysplastic syndrome. By its nature, myelosuppressive cytotoxic chemotherapy causes neutropenia in a predictable manner.

Clinical Findings

Neutropenia results in stomatitis and in infections due to gram-positive or gram-negative aerobic bacteria or to fungi such as *Candida* or *Aspergillus*. The most common infections are septicemia, cellulitis, and pneumonia and fever should always be initially assumed to be of infectious origin until proven otherwise.

Treatment

Treatment of neutropenia depends on its cause. Potential causative drugs should be discontinued. Myeloid growth factors (filgrastim or sargramostim) help facilitate neutrophil recovery after offending drugs are stopped. Chronic myeloid growth factor administration (daily or every other day) is effective at dampening the neutropenia seen in cyclic or congenital neutropenia. When Felty syndrome leads to repeated bacterial infections, splenectomy has been the treatment of choice, but it now appears that sustained use of myeloid growth factors is effective and provides a nonsurgical alternative. Patients with autoimmune neutropenia often respond to immunosuppression with corticosteroids, with splenectomy held in reserve for corticosteroid failure. Patients with true pure white blood cell aplasia need immunosuppression with ATG and cyclosporine, as in aplastic anemia. The neutropenia associated with large granular lymphocytes may respond to therapy with either cyclosporine or low-dose methotrexate.

Fevers during neutropenia should be considered as infectious until proven otherwise. Febrile neutropenia is a life-threatening circumstance. Enteric gram-negative bacteria are of primary concern and often empirically treated with fluoroquinolones or second-generation cephalosporins. For protracted neutropenia, fungal infections are problematic and empiric coverage with azoles (fluconazole for yeast and voriconazole, itraconazole, or posaconazole for molds) or echinocandins is recommended. The neutropenia following myelosuppressive chemotherapy is predictable and is largely ameliorated by the use of myeloid growth factors. For patients with acute leukemia undergoing intense chemotherapy or patients with solid cancer undergoing high-dose chemotherapy, the prophylactic use of antimicrobial agents and the myeloid growth factors is recommended.

When to Refer

Refer to a hematologist if neutrophils are persistently and unexplainably < 1000/mcL.

When to Admit

Neutropenia by itself is not an indication for hospitalization. However, most patients with severe neutropenia have a serious underlying disease that may require inpatient treatment. Most patients with febrile neutropenia require hospitalization to treat infection.

Akhtari M et al. Autoimmune neutropenia in adults. *Autoimmun Rev.* 2009 Sep;9(1):62–6. [PMID: 19293004]
 Dale DC et al. Cyclic and chronic neutropenia. *Cancer Treat Res.* 2011;157:97–108. [PMID: 21052952]

Table 13-13. Classification of myeloproliferative disorders.

Myeloproliferative neoplasms
Polycythemia vera
Primary myelofibrosis
Essential thrombocytosis
Chronic myeloid leukemia
Myelodysplastic syndromes
Acute myeloid leukemia

Freifeld AG et al. Clinical practice guidelines for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. *Clin Infect Dis*. 2011 Feb 15;52(4):427–31. [PMID: 21205990]

Mebis J et al. Antibiotic management of febrile neutropenia: current developments and future directions. *J Chemother*. 2010 Feb;22(1):5–12. [PMID: 20227985]

Rezaei N et al. Neutropenia and primary immunodeficiency diseases. *Int Rev Immunol*. 2009;28(5):335–66. [PMID: 19811314]

Tesfa D et al. Idiosyncratic drug-induced agranulocytosis: possible mechanisms and management. *Am J Hematol*. 2009 Jul;84(7):428–34. [PMID: 19459150]

LEUKEMIAS & OTHER MYELOPROLIFERATIVE NEOPLASMS

Myeloproliferative disorders are due to acquired clonal abnormalities of the hematopoietic stem cell. Since the stem cell gives rise to myeloid, erythroid, and platelet cells, qualitative and quantitative changes are seen in all these cell lines. Classically, the myeloproliferative disorders produce characteristic syndromes with well-defined clinical and laboratory features (Tables 13–13 and 13–14). However, these disorders are grouped together because the disease may evolve from one form into another and because hybrid disorders are commonly seen. All of the myeloproliferative disorders may progress to AML.

The Philadelphia chromosome seen in chronic myeloid leukemia (CML) was the first recurrent cytogenetic abnormality to be described in a human malignancy. Since that time, there has been tremendous progress in elucidating the genetic nature of these disorders, with identification of mutations in JAK2, MPL, TET2, IDH1/2, and others.

POLYCYTHEMIA VERA



ESSENTIALS OF DIAGNOSIS

- ▶ JAK2 mutation.
- ▶ Increased red blood cell mass.
- ▶ Splenomegaly.
- ▶ Normal arterial oxygen saturation.
- ▶ Usually elevated white blood count and platelet count.

▶ General Considerations

Polycythemia vera is an acquired myeloproliferative disorder that causes overproduction of all three hematopoietic cell lines, most prominently the red blood cells. Erythroid production is independent of erythropoietin, and the serum erythropoietin level is low. A mutation in exon 14 of JAK2 (V617F), a signaling molecule, has been demonstrated in 95% of cases. Additional JAK2 mutations have been identified (exon 12) and suggest that JAK2 is involved in the pathogenesis of this disease and is a potential therapeutic target.

True erythrocytosis, with an elevated red blood cell mass, should be distinguished from spurious erythrocytosis caused by a constricted plasma volume. Primary polycythemia (polycythemia vera) is a bone marrow disorder characterized by autonomous overproduction of erythroid cells.

▶ Clinical Findings

A. Symptoms and Signs

Common complaints related to expanded blood volume and increased blood viscosity are headache, dizziness, tinnitus, blurred vision, and fatigue. Generalized pruritus, especially following a warm shower or bath, is related to histamine release from the basophilia. Epistaxis is probably related to engorgement of mucosal blood vessels in combination with abnormal hemostasis due to qualitative abnormalities in platelet function. Sixty percent of patients are men, and the median age at presentation is 60 years. Polycythemia rarely occurs in persons under age 40 years.

Table 13-14. Laboratory features of myeloproliferative neoplasms.

	White Count	Hematocrit	Platelet Count	Red Cell Morphology
Polycythemia vera	N or ↑	↑	N or ↑	N
Essential thrombocytosis	N or ↑	N	↑↑	N
Primary myelofibrosis	N or ↓ or ↑	↓	↓ or N or ↑	Abn
Chronic myeloid leukemia	↑↑	N	N or ↑	N

Abn, abnormal; N, normal.

Physical examination reveals plethora and engorged retinal veins. The spleen is palpable in 75% of cases but is nearly always enlarged when imaged.

Thrombosis is the most common complication of polycythemia vera and the major cause of morbidity and death in this disorder. Thrombosis appears to be related both to increased blood viscosity and abnormal platelet function. Uncontrolled polycythemia leads to a very high incidence of thrombotic complications of surgery, and elective surgery should be deferred until the condition has been treated. Paradoxically, in addition to thrombosis, increased bleeding also occurs. There is a high incidence of peptic ulcer disease.

B. Laboratory Findings

The hallmark of polycythemia vera is a hematocrit (at sea level) that exceeds 54% in males or 51% in females and, at times, exceeds 60%. Red blood cell morphology is normal (Table 13–14). By definition, the red blood cell mass is elevated, but this is now rarely measured. The white blood count is usually elevated to 10,000–20,000/mcL and the platelet count is variably increased, sometimes to counts exceeding 1,000,000/mcL. Platelet morphology is usually normal. White blood cells are usually normal, but basophilia and eosinophilia are frequently present. Erythropoietin levels are suppressed and are usually low. The diagnosis should be confirmed with JAK2 mutation screening. The absence of a mutation should lead the clinician to question the diagnosis.

The bone marrow is hypercellular, with panhyperplasia of all hematopoietic elements, but bone marrow examination is not necessary to establish the diagnosis. Iron stores are usually absent from the bone marrow, having been transferred to the increased circulating red blood cell mass. Iron deficiency may also result from chronic gastrointestinal blood loss. Bleeding may lower the hematocrit to the normal range (or lower), creating diagnostic confusion, and may lead to a situation with significant microcytosis with a normal hematocrit.

Vitamin B₁₂ levels are strikingly elevated because of increased levels of transcobalamin III (secreted by white blood cells). Overproduction of uric acid may lead to hyperuricemia.

Although red blood cell morphology is usually normal at presentation, microcytosis, hypochromia, and poikilocytosis may result from iron deficiency following treatment by phlebotomy (see below). Progressive hypersplenism may also lead to elliptocytosis.

► Differential Diagnosis

Spurious polycythemia, in which an elevated hematocrit is due to contracted plasma volume rather than increased red cell mass, may be related to diuretic use or may occur without obvious cause.

A secondary cause of polycythemia should be suspected if splenomegaly is absent and the high hematocrit is not accompanied by increases in other cell lines. Secondary causes of polycythemia include hypoxia and smoking; carboxyhemoglobin levels may be elevated in

Table 13–15. Causes of polycythemia.

Spurious polycythemia
Secondary polycythemia
Hypoxia: cardiac disease, pulmonary disease, high altitude
Carboxyhemoglobin: smoking
Kidney lesions
Erythropoietin-secreting tumors (rare)
Abnormal hemoglobins (rare)
Polycythemia vera

smokers (Table 13–15). A renal CT scan or sonogram may be considered to look for an erythropoietin-secreting cyst or tumor. A positive family history should lead to investigation for congenital high-oxygen-affinity hemoglobin. An absence of a mutation in JAK2 suggests a different diagnosis. However, JAK2 mutations are also commonly found in the myeloproliferative disorders essential thrombocytosis and myelofibrosis.

Polycythemia vera should be differentiated from other myeloproliferative disorders (Table 13–14). Marked elevation of the white blood count (above 30,000/mcL) suggests CML. Abnormal red blood cell morphology and nucleated red blood cells in the peripheral blood are seen in myelofibrosis. Essential thrombocytosis is suggested when the platelet count is strikingly elevated.

► Treatment

The treatment of choice is phlebotomy. One unit of blood (approximately 500 mL) is removed weekly until the hematocrit is < 45%; the hematocrit is maintained at < 45% by repeated phlebotomy as necessary. Patients for whom phlebotomy is problematic (because of poor venous access or logistical reasons) may be managed primarily with hydroxyurea (see below). Because repeated phlebotomy intentionally produces iron deficiency, the requirement for phlebotomy should gradually decrease. It is important to avoid medicinal iron supplementation, as this can thwart the goals of a phlebotomy program. Maintaining the hematocrit at normal levels has been shown to decrease the incidence of thrombotic complications. A diet low in iron also is not necessary but will increase the intervals between phlebotomies.

Occasionally, myelosuppressive therapy is indicated. Indications include a high phlebotomy requirement, thrombocytosis, and intractable pruritus. There is evidence that reduction of the platelet count to < 600,000/mcL will reduce the risk of thrombotic complications. Alkylating agents have been shown to increase the risk of conversion of this disease to acute leukemia and should be avoided. Hydroxyurea is widely used when myelosuppressive therapy is indicated. The usual dose is 500–1500 mg/d orally, adjusted to keep platelets < 500,000/mcL without reducing the neutrophil count to < 2000/mcL. Anagrelide may be substituted or added when hydroxyurea is not well tolerated, but it is not the preferred initial agent. Low-dose aspirin (75–81 mg/d orally) has been shown to reduce the risk of thrombosis without excessive bleeding, and should

be part of therapy for all patients without contraindications to aspirin.

Studies of pegylated alfa-2 interferon have demonstrated considerable efficacy, with hematologic response rates > 80%, as well as reductions in the abnormal clones (as measured by JAK2 mutations). Side effects were generally acceptable and much less significant than with nonpegylated forms of interferon. Studies with selective JAK2 inhibitors are ongoing.

Allopurinol 300 mg orally daily may be indicated for hyperuricemia. Antihistamine therapy with diphenhydramine or other H₁-blockers may be helpful for control of pruritus, and some reports suggest the efficacy of selective serotonin reuptake inhibitors in refractory cases.

► Prognosis

Polycythemia is an indolent disease with median survival of 11–15 years. The major cause of morbidity and mortality is arterial thrombosis. Over time, polycythemia vera may convert to myelofibrosis or to CML. In approximately 5% of cases, the disorder progresses to AML, which is usually refractory to therapy.

► When to Refer

Patients with polycythemia vera should be referred to a hematologist.

► When to Admit

Inpatient care is rarely required.

Quintás-Cardama A et al. Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera. *J Clin Oncol*. 2009 Nov 10;27(32):5418–24. [PMID: 19826111]

Tibes R et al. Myeloproliferative neoplasms 5 years after discovery of JAK2V617F: what is the impact of JAK2 inhibitor therapy? *Leuk Lymphoma*. 2011 Jul;52(7):1178–87. [PMID: 21599574]

Vainchenker W et al. New mutations and pathogenesis of myeloproliferative neoplasms. *Blood*. 2011 Aug 18;118(7):1723–35. [PMID: 21653328]

ESSENTIAL THROMBOCYTOSIS



ESSENTIALS OF DIAGNOSIS

- Elevated platelet count in absence of other causes.
- Normal red blood cell mass.
- Absence of *bcr/abl* gene (Philadelphia chromosome).

► General Considerations

Essential thrombocythemia is an uncommon myeloproliferative disorder of unknown cause in which marked proliferation of the megakaryocytes in the bone marrow leads to elevation of

the platelet count. As with polycythemia vera, the finding of a high frequency of mutations of JAK2 in these patients promises to advance the understanding of this disorder.

► Clinical Findings

A. Symptoms and Signs

The median age at presentation is 50–60 years, and there is a slightly increased incidence in women. The disorder is often suspected when an elevated platelet count is found. Less frequently, the first sign is thrombosis, which is the most common clinical problem. The risk of thrombosis rises with age. Venous thromboses may occur in unusual sites such as the mesenteric, hepatic, or portal vein. Some patients experience erythromelalgia, painful burning of the hands accompanied by erythema; this symptom is reliably relieved by aspirin. Bleeding, typically mucosal, is less common and is related to a concomitant qualitative platelet defect. Splenomegaly is present in at least 25% of patients.

B. Laboratory Findings

An elevated platelet count is the hallmark of this disorder, and may be over 2,000,000/mcL (Table 13–14). The white blood cell count is often mildly elevated, usually not above 30,000/mcL, but with some immature myeloid forms. The hematocrit is normal. The peripheral blood smear reveals large platelets, but giant degranulated forms seen in myelofibrosis are not observed. Red blood cell morphology is normal.

The bone marrow shows increased numbers of megakaryocytes but no other morphologic abnormalities. The Philadelphia chromosome is absent but should be assayed by molecular testing of peripheral blood for the *bcr/abl* fusion gene in all suspected cases to differentiate the disorder from CML.

► Differential Diagnosis

Essential thrombocythemia must be distinguished from secondary causes of an elevated platelet count. In reactive thrombocythemia, the platelet count seldom exceeds 1,000,000/mcL. Inflammatory disorders such as rheumatoid arthritis and ulcerative colitis cause significant elevations of the platelet count, as may chronic infection. The thrombocythemia of iron deficiency is observed only when anemia is significant. The platelet count is temporarily elevated after splenectomy. JAK2 mutations are found in 50% of cases.

Regarding other myeloproliferative disorders, the lack of erythrocytosis distinguishes it from polycythemia vera. Unlike myelofibrosis, red blood cell morphology is normal, nucleated red blood cells are absent, and giant degranulated platelets are not seen. In CML, the Philadelphia chromosome (or *bcr/abl* by molecular testing) establishes the diagnosis.

► Treatment

The risk of thrombosis can be reduced by control of the platelet count, which should be kept at < 500,000/mcL. The treatment of choice is oral hydroxyurea in a dose of

0.5–2 g/d. Hydroxyurea has been shown to be more effective than anagrelide in preventing thrombotic events, with no increase in toxicity. In cases in which hydroxyurea is not well tolerated because of anemia, low doses of anagrelide, 1–2 mg/d orally, may be added. Higher doses of anagrelide are often complicated by headache, peripheral edema, and congestive heart failure. As with polycythemia vera, trials of pegylated interferon alfa-2 have demonstrated significant hematologic responses, but its role in management has not yet been established.

Vasomotor symptoms such as erythromelalgia and paresthesias respond rapidly to aspirin, and its long-term low-dose use (81 mg/d orally) may reduce the risk of thrombotic complications. In the unusual event of severe bleeding, the platelet count can be lowered rapidly with plateletpheresis.

► Course & Prognosis

Essential thrombocytosis is an indolent disorder and allows long-term survival. Average survival is longer than 15 years from diagnosis, and the survival of patients younger than 50 years does not appear different from matched controls. The major source of morbidity—thrombosis—can be reduced by appropriate platelet control. Late in the course of the disease, the bone marrow may become fibrotic, and massive splenomegaly may occur, sometimes with splenic infarction. There is a 10–15% risk of progression to myelofibrosis after 15 years, and a 1–5% risk of transformation to acute leukemia over 20 years.

► When to Refer

Patients with essential thrombocytosis should be referred to a hematologist.

Tefferi A et al. Annual Clinical Updates in Hematological Malignancies: a continuing medical education series: polycythemia vera and essential thrombocythemia: 2011 update on diagnosis, risk-stratification, and management. *Am J Hematol.* 2011 Mar;86(3):292–301. [PMID: 21351120]

Vannucchi AM. Insights into the pathogenesis and management of thrombosis in polycythemia vera and essential thrombocythemia. *Intern Emerg Med.* 2010 Jun;5(3):177–84. [PMID: 19789961]

PRIMARY MYELOFIBROSIS



ESSENTIALS OF DIAGNOSIS

- Striking splenomegaly.
- Teardrop poikilocytosis on peripheral smear.
- Leukoerythroblastic blood picture; giant abnormal platelets.
- Hypercellular bone marrow with reticulin or collagen fibrosis.

► General Considerations

Primary myelofibrosis (myelofibrosis with myeloid metaplasia, agnogenic myeloid metaplasia, idiopathic myelofibrosis)

is a myeloproliferative disorder characterized by fibrosis of the bone marrow, splenomegaly, and a leukoerythroblastic peripheral blood picture with teardrop poikilocytosis. Myelofibrosis can also occur as a secondary process following the other myeloproliferative disorders (eg, polycythemia vera, essential thrombocytosis). It is believed that fibrosis occurs in response to increased secretion of platelet-derived growth factor (PDGF) and possibly other cytokines. In response to bone marrow fibrosis, extramedullary hematopoiesis takes place in the liver, spleen, and lymph nodes. In these sites, mesenchymal cells responsible for fetal hematopoiesis can be reactivated. As with other myeloproliferative diseases, abnormalities of JAK2 and MPL may be involved in the pathogenesis.

► Clinical Findings

A. Symptoms and Signs

Primary myelofibrosis develops in adults over age 50 years and is usually insidious in onset. Patients most commonly present with fatigue due to anemia or abdominal fullness related to splenomegaly. Uncommon presentations include bleeding and bone pain. On examination, splenomegaly is almost invariably present and is commonly massive. The liver is enlarged in more than 50% of cases.

Later in the course of the disease, progressive bone marrow failure takes place as it becomes increasingly more fibrotic. Progressive thrombocytopenia leads to bleeding. The spleen continues to enlarge, which leads to early satiety. Painful episodes of splenic infarction may occur. The patient becomes cachectic and may experience severe bone pain, especially in the upper legs. Hematopoiesis in the liver leads to portal hypertension with ascites, esophageal varices, and occasionally transverse myelitis caused by myelopoiesis in the epidural space.

B. Laboratory Findings

Patients are almost invariably anemic at presentation. The white blood count is variable—either low, normal, or elevated—and may be increased to 50,000/mcL. The platelet count is variable. The peripheral blood smear is dramatic, with significant poikilocytosis and numerous teardrop forms in the red cell line. Nucleated red blood cells are present and the myeloid series is shifted, with immature forms including a small percentage of promyelocytes or myeloblasts. Platelet morphology may be bizarre, and giant degranulated platelet forms (megakaryocyte fragments) may be seen. The triad of teardrop poikilocytosis, leukoerythroblastic blood, and giant abnormal platelets is highly suggestive of myelofibrosis.

The bone marrow usually cannot be aspirated (dry tap), though early in the course of the disease it is hypercellular, with a marked increase in megakaryocytes. Fibrosis at this stage is detected by a silver stain demonstrating increased reticulin fibers. Later, biopsy reveals more severe fibrosis, with eventual replacement of hematopoietic precursors by collagen. There is no characteristic chromosomal abnormality. JAK2 is mutated in ~65% of cases, and MPL is mutated ~40% of cases.

► Differential Diagnosis

A leukoerythroblastic blood picture from other causes may be seen in response to severe infection, inflammation, or infiltrative bone marrow processes. However, teardrop poikilocytosis and giant abnormal platelet forms will not be present. Bone marrow fibrosis may be seen in metastatic carcinoma, Hodgkin lymphoma, and hairy cell leukemia. These disorders are diagnosed by characteristic morphology of involved tissues.

Of the other myeloproliferative disorders, CML is diagnosed when there is marked leukocytosis, normal red blood cell morphology, and the presence of the *bcr/abl* fusion gene. Polycythemia vera is characterized by an elevated hematocrit. Essential thrombocytosis shows predominant platelet count elevations.

► Treatment

Patients with mild forms of the disease may require no therapy or occasional transfusion support. Anemic patients are supported with transfusion. Erythropoietin may increase red blood cell production and decrease transfusion requirements. Splenectomy is not routinely performed but is indicated for splenic enlargement causing recurrent painful episodes, severe thrombocytopenia, or an unacceptable transfusion requirement. Radiation therapy has a role for painful sites of extramedullary hematopoiesis, pulmonary hypertension, or severe bone pain. The only potentially curative option for this disease is allogeneic stem cell transplantation in selected patients.

Several newer agents have shown activity in this disease. The immunomodulators lenalidomide and pomalidomide result in control of anemia in 25% and thrombocytopenia in ~58% of cases, without significant reduction in splenic size. There are several JAK2 inhibitors in development. Ruxolitinib, a JAK2 inhibitor, has been approved by the US Food and Drug Administration for myelofibrosis. Even though treatment with ruxolitinib can exacerbate cytopenias, it results in reduction of spleen size and improvement of constitutional symptoms.

► Course & Prognosis

The median survival from time of diagnosis is approximately 5 years. The dynamic international prognostic scoring system is associated with overall survival. Therapies with biologic agents and the application of reduced-intensity allogeneic stem cell transplantation appear to offer the possibility of improving the outcome for many patients. End-stage myelofibrosis is characterized by generalized asthenia liver failure, and bleeding from thrombocytopenia, with some cases terminating in AML.

► When to Refer

Patients in whom myelofibrosis is suspected should be referred to a hematologist.

► When to Admit

Admission is not usually necessary.

- Cervantes F et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. *Blood*. 2009 Mar 26;113(13):2895–901. [PMID: 18988864]
- Kröger N et al. Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. *Blood*. 2009 Dec 17;114(26):5264–70. [PMID: 19812383]
- Pardanani A et al. JAK inhibitor therapy for myelofibrosis: critical assessment of value and limitations. *Leukemia*. 2011 Feb; 25(2):218–25. [PMID: 21079613]
- Tefferi A. Primary myelofibrosis: 2012 update on diagnosis, risk stratification, and management. *Am J Hematol*. 2011 Dec;86(12):1017–26. [PMID: 22086865]

CHRONIC MYELOID LEUKEMIA



ESSENTIALS OF DIAGNOSIS

- Elevated white blood count.
- Markedly left-shifted myeloid series but with a low percentage of promyelocytes and blasts.
- Presence of *bcr/abl* gene (Philadelphia chromosome).

► General Considerations

CML is a myeloproliferative disorder characterized by overproduction of myeloid cells. These myeloid cells retain the capacity for differentiation, and normal bone marrow function is retained during the early phases.

CML is characterized by a specific chromosomal abnormality and specific molecular abnormality. The Philadelphia chromosome is a reciprocal translocation between the long arms of chromosomes 9 and 22. A large portion of 22q is translocated to 9q, and a smaller piece of 9q is moved to 22q. The portion of 9q that is translocated contains *abl*, a protooncogene that is the cellular homolog of the Ableson murine leukemia virus. The *abl* gene is received at a specific site on 22q, the break point cluster (*bcr*). The fusion gene *bcr/abl* produces a novel protein that differs from the normal transcript of the *abl* gene in that it possesses tyrosine kinase activity (a characteristic activity of transforming genes). Evidence that the *bcr/abl* fusion gene is pathogenic is provided by transgenic mouse models in which introduction of the gene almost invariably leads to leukemia, and the outstanding clinical response of the disease to inhibitors of *bcr/abl* provide further compelling evidence.

Early CML (“chronic phase”) does not behave like a malignant disease. Normal bone marrow function is retained, white blood cells differentiate and, despite some qualitative abnormalities, the neutrophils combat infection normally. However, untreated CML is inherently unstable, and without treatment the disease progresses to an accelerated and then acute blast phase, which is morphologically indistinguishable from acute leukemia. Remarkable advances in therapy have changed the natural

history of the disease, and the relentless progression to more advanced stages of disease is at least greatly delayed, if not eliminated.

► Clinical Findings

A. Symptoms and Signs

CML is a disorder of middle age (median age at presentation is 55 years). Patients usually complain of fatigue, night sweats, and low-grade fever related to the hypermetabolic state caused by overproduction of white blood cells. Patients may also complain of abdominal fullness related to splenomegaly. In some cases, an elevated white blood count is discovered incidentally. Rarely, the patient will present with a clinical syndrome related to leukostasis with blurred vision, respiratory distress, or priapism. The white blood count in these cases is usually $> 500,000/\text{mCL}$.

On examination, the spleen is enlarged (often markedly so), and sternal tenderness may be present as a sign of marrow overexpansion. In cases discovered during routine laboratory monitoring, these findings are often absent.

Acceleration of the disease is often associated with fever in the absence of infection, bone pain, and splenomegaly.

B. Laboratory Findings

CML is characterized by an elevated white blood count; the median white blood count at diagnosis is $150,000/\text{mCL}$, although in some cases the white blood cell count is only modestly increased (Table 13–14). The peripheral blood is characteristic. The myeloid series is left shifted, with mature forms dominating and with cells usually present in proportion to their degree of maturation. Blasts are usually $< 5\%$. Basophilia and eosinophilia of granulocytes may be present. At presentation, the patient is usually not anemic. Red blood cell morphology is normal, and nucleated red blood cells are rarely seen. The platelet count may be normal or elevated (sometimes to strikingly high levels).

The bone marrow is hypercellular, with left-shifted myelopoiesis. Myeloblasts comprise $< 5\%$ of marrow cells.

The hallmark of the disease is that the *bcr/abl* gene is detected by the polymerase chain reaction (PCR) test in the peripheral blood. A bone marrow examination is not necessary for diagnosis, although it is useful for prognosis and for detecting additional chromosomal abnormalities in addition to the Philadelphia chromosome.

With progression to the accelerated and blast phases, progressive anemia and thrombocytopenia occur, and the percentage of blasts in the blood and bone marrow increases. Blast phase CML is diagnosed when blasts comprise more than 20% of bone marrow cells.

► Differential Diagnosis

Early CML must be differentiated from the reactive leukocytosis associated with infection. In such cases, the white blood count is usually $< 50,000/\text{mCL}$, splenomegaly is absent, and the *bcr/abl* gene is not present.

CML must be distinguished from other myeloproliferative disease (Table 13–14). The hematocrit should not be

elevated, the red blood cell morphology is normal, and nucleated red blood cells are rare or absent. Definitive diagnosis is made by finding the *bcr/abl* gene.

► Treatment

Treatment is usually not emergent even with white blood counts over $200,000/\text{mCL}$, since the majority of circulating cells are mature myeloid cells that are smaller and more deformable than primitive leukemic blasts. In the rare instances in which symptoms result from extreme hyperleukocytosis (priapism, respiratory distress, visual blurring, altered mental status), emergent leukapheresis is performed in conjunction with myelosuppressive therapy.

In chronic-phase CML, the goal of therapy is normalization of the hematologic abnormalities and suppression of the malignant, *bcr/abl*-expressing clone. The treatment of choice consists of a tyrosine kinase inhibitor targeting the aberrantly active *abl* kinase. It is expected that a hematologic complete remission, with normalization of blood counts and splenomegaly will occur within 3 months of treatment initiation. Second, a cytogenetic response should be achieved, ideally within 6 months but certainly within 12 months. A “major cytogenetic response” is identified when $< 35\%$ of metaphases contain the Philadelphia chromosome, and a “complete cytogenetic response” indicates the absence of the abnormal chromosome by standard cytogenetic testing. Lastly, a molecular response is desired and is defined as a reduction of the *bcr/abl* transcript as measured by quantitative PCR. The current goal of therapy is to achieve a “major molecular response,” with at least a 3-log reduction in *bcr/abl* level within a year. This roughly corresponds to a *bcr/abl* ratio (compared to *abl*) of < 0.01 . Patients who achieve this level of molecular response have an excellent prognosis, with 100% of such patients remaining free of progression at 8 years.

Imatinib mesylate was the first such agent to be approved and it results in nearly universal (98%) hematologic control of chronic phase disease at a dose of 400 mg/d. The rate of a major molecular response with imatinib in chronic-phase disease is $\sim 30\%$ at 1 year. The second-generation tyrosine kinase inhibitors, dasatinib and nilotinib, have also been approved for use as front-line therapy and have been shown to significantly increase the rate of achievement of a major molecular response compared to imatinib (71% for nilotinib at 300–400 mg twice daily by 2 years, 46% for dasatinib at 100 mg/d by 1 year) and result in a lower rate of progression to advanced-stage disease. However, these agents can also salvage 90% of patients who do not respond to treatment with imatinib and may therefore be reserved for use in that setting.

Patients taking tyrosine kinase inhibitors should be monitored with a quantitative PCR assay. Those with a consistent increase in *bcr/abl* transcript or those with a suboptimal molecular response as defined above should undergo *abl* mutation testing and then switched to an alternative tyrosine kinase inhibitor. The T315I mutation in *abl* is specifically resistant to therapy with imatinib, dasatinib, and nilotinib but appears to be sensitive to the

third-generation agent ponatinib. Patients who cannot achieve a good molecular response to any of these agents or progress following therapy should be considered for treatment with allogeneic transplantation.

Patients with advanced-stage disease (accelerated phase or myeloid/lymphoid blast crisis) should be treated with a tyrosine kinase inhibitor alone or in combination with myelosuppressive chemotherapy. The doses of tyrosine kinase inhibitors in that setting are usually higher than those appropriate for chronic-phase disease. Since the duration of response to tyrosine kinase inhibitors in this setting is limited, these patients should ultimately be considered for allogeneic stem cell transplantation.

Thus, allogeneic stem cell transplantation should be considered for patients in whom disease is not well controlled, in whom disease progresses after initial control, or for those who have accelerated or blast phase disease.

► Course & Prognosis

Since the introduction of imatinib therapy in 2001, and with the development of molecular targeted agents, more than 80% of patients remain alive and without disease progression at 9 years. Patients with good molecular responses to tyrosine kinase inhibitor therapy have an excellent prognosis, with essentially 100% survival at 9 years, and it is likely that some fraction of these patients will be cured. Small studies suggest that some patients with complete molecular responses (undetectable *bcr/abl*) lasting more than 2 years can stop drug therapy without disease recurrence, but these findings need confirmation and longer follow-up.

► When to Refer

All patients with CML should be referred to a hematologist.

► When to Admit

Hospitalization is rarely necessary and should be reserved for symptoms of leukostasis at diagnosis or for transformation to acute leukemia.

Kantarjian HM et al. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. *Lancet Oncol.* 2011 Sep;12(9):841–51. [PMID: 21856226]

O'Brien S et al. NCCN Task Force report: tyrosine kinase inhibitor therapy selection in the management of patients with chronic myelogenous leukemia. *J Natl Compr Canc Netw.* 2011 Feb;9(Suppl 2):S1–25. [PMID: 21335443]

Radich JP. Chronic myeloid leukemia 2010: where are we now and where can we go? *Hematology Am Soc Hematol Educ Program.* 2010;2010:122–8. [PMID: 21239781]

Soverini S et al. BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet. *Blood.* 2011 Aug 4;118(5):1208–15. [PMID: 21562040]

MYELODYSPLASTIC SYNDROMES



ESSENTIALS OF DIAGNOSIS

- Cytopenias with a hypercellular bone marrow.
- Morphologic abnormalities in two or more hematopoietic cell lines.

► General Considerations

The myelodysplastic syndromes are a group of acquired clonal disorders of the hematopoietic stem cell. They are characterized by the constellation of cytopenias, a usually hypercellular marrow, and a number of morphologic and cytogenetic abnormalities. The disorders are usually idiopathic but may be caused by prior exposure to cytotoxic chemotherapy or radiation or both. Ultimately, the disorder may evolve into AML, and the term “preleukemia” has been used in the past to describe these disorders, although this progression is by no means inevitable.

Myelodysplasia encompasses several heterogeneous syndromes. Those without excess bone marrow blasts are termed “refractory anemia,” with or without ringed sideroblasts. One important subgroup of the refractory anemia patients are those with the 5q– syndrome, characterized by the cytogenetic finding of loss of part of the long arm of chromosome 5. Those with excess blasts are diagnosed as “refractory anemia with excess blasts” (RAEB 5–19% blasts). Patients with a proliferative syndrome including peripheral blood monocytosis > 1000/mcL are termed “chronic myelomonocytic leukemia” (CMML), a disorder that shares features of myelodysplastic and myeloproliferative disorders. An International Prognostic Scoring System (IPSS) classifies patients by risk status based on the percentage of bone marrow blasts, cytogenetics, and the severity of cytopenias. The IPSS is associated with the rate of progression to AML as well as overall survival, which can range from a median of 6 years for the low-risk group to 5 months for the high-risk patients.

► Clinical Findings

A. Symptoms and Signs

Patients are usually over age 60 years. Many patients are asymptomatic when the diagnosis is made because of the finding of abnormal blood counts. Fatigue, infection, or bleeding related to bone marrow failure are usually the presenting symptoms and signs. The course may be indolent, and the disease may present as a wasting illness with fever, weight loss, and general debility. On examination, splenomegaly may be present in combination with pallor, bleeding, and various signs of infection. Myelodysplastic syndromes can also be accompanied by a variety of paraneoplastic syndromes that can occur prior to or following this diagnosis.

B. Laboratory Findings

Anemia may be marked and may require transfusion support. The MCV is normal or increased, and macro-ovalocytes may be seen on the peripheral blood smear. The white blood cell count is usually normal or reduced, and neutropenia is common. The neutrophils may exhibit morphologic abnormalities, including deficient numbers of granules or deficient segmentation of the nucleus, especially a bilobed nucleus (Pelger–Huet abnormality). The myeloid series may be left shifted, and small numbers of promyelocytes or blasts may be seen. The platelet count is normal or reduced, and hypogranular platelets may be present.

The bone marrow is characteristically hypercellular, but may be hypocellular. Erythroid hyperplasia is common, and signs of abnormal erythropoiesis include megaloblastic features, nuclear budding, or multinucleated erythroid precursors. The Prussian blue stain may demonstrate ringed sideroblasts. The myeloid series is often left shifted, with variable increases in blasts. Deficient or abnormal granules may be seen. A characteristic abnormality is the presence of dwarf megakaryocytes with a unilobed nucleus. Although no single specific chromosomal abnormality is seen in myelodysplasia, there are frequently abnormalities involving the long arm of chromosome 5 as well as deletions of chromosomes 5 and 7. Some patients with an indolent form of the disease have an isolated partial deletion of chromosome 5 (5q– syndrome). The presence of other abnormalities such as monosomy 7 or complex abnormalities is associated with more aggressive disease.

► Differential Diagnosis

Myelodysplastic syndromes should be distinguished from megaloblastic anemia, aplastic anemia, myelofibrosis, HIV-associated cytopenias, and acute or chronic drug effect. In subtle cases, cytogenetic evaluation of the bone marrow may help distinguish this clonal disorder from other causes of cytopenias. As the number of blasts increases in the bone marrow, myelodysplasia is arbitrarily separated from AML by the presence of < 20% blasts.

► Treatment

Myelodysplasia is a very heterogeneous disease, and the appropriate treatment depends on a number of factors. For patients in whom the primary problem is anemia, erythropoietin (epoetin alfa), 30,000 units subcutaneously weekly, may raise the hematocrit and reduce the red cell transfusion requirement. Patients with low serum erythropoietin (< 100 mU/mL) levels are the most likely to respond to erythropoietin treatment, whereas those with levels > 500 mU/mL almost never respond. The overall response rate is 20%, but a 4-week trial of epoetin alfa is reasonable since it will be cost-effective for the subgroup of responders. Addition of intermittent granulocyte colony-stimulating factor (G-CSF) therapy may augment the erythroid response to epoetin. Unfortunately, the patients with the highest transfusion requirements are the least likely to respond. Lenalidomide is approved for the treatment of transfusion-dependent anemia due to myelodysplasia. It is the treatment of choice in

patients with the 5q– syndrome, with significant responses in 70% of patients, and with responses typically lasting longer than 2 years. In addition, nearly half of these patients enter a cytogenetic remission with clearing of the abnormal 5q– clone, leading to the hope that lenalidomide may change the natural history of the disease. The response rate in patients with transfusion-dependent myelodysplasia lacking 5q– is only 25% and responses usually last < 1 year, but it is still worth trying. The recommended initial dose is 10 mg/d orally. The most common side effects are neutropenia and thrombocytopenia, but venous thrombosis is also seen and warrants prophylaxis with aspirin, 325 mg/d orally. In addition, the cost of lenalidomide is high, and the agent is not usually effective either for cell lines other than red blood cells or for patients with increased blasts. Patients who remain dependent on red blood cell transfusion and who do not have immediately life-threatening disease should receive iron chelation in order to prevent serious iron overload; the dose of oral agent deferasirox is 20 mg/kg/d. Patients affected primarily with severe neutropenia may benefit from the use of myeloid growth factors such as G-CSF. Oral agents such as romiplostim and eltrombopag that stimulate platelet production by mimicking the effect of thrombopoietin on the thrombopoietin receptor have shown some effectiveness in raising the platelet count in myelodysplasia.

Azacitidine is the current treatment of choice for patients with high-risk myelodysplasia and can improve both symptoms and blood counts and prolong both overall survival and the time to conversion to acute leukemia. A related agent, decitabine, can produce similar responses. Occasional patients can benefit from immunosuppressive therapy including antithymocyte globulin (ATG). Predictors of response to ATG include age < 60 years, absence of 5q–, and presence of HLA DR15. Allogeneic stem cell transplantation is the only curative therapy for myelodysplasia, but its role is limited by the advanced age of many patients and the indolent course of disease in some subsets of patients. The optimal use and timing of allogeneic transplantation are controversial, but the use of reduced-intensity preparative regimens for transplantation has expanded the role of this therapy, using both family and matched unrelated donors.

► Course & Prognosis

Myelodysplasia is an ultimately fatal disease, and allogeneic transplantation is the only curative therapy, with cure rates of 30–60% depending primarily on the risk status of the disease. Patients most commonly die of infections or bleeding. Patients with 5q– syndrome have a favorable prognosis, with 5-year survival over 90%. Other patients with low-risk disease (with absence of both excess blasts and adverse cytogenetics) may also do well, with similar survival. Those with excess blasts or CMML have a higher (30–50%) risk of developing acute leukemia, and short survival (< 2 years) without allogeneic transplantation.

► When to Refer

All patients with myelodysplasia should be referred to a hematologist.

▶ When to Admit

Hospitalization is needed only for specific complications, such as severe infection.

Cazzola M et al. Prognostic classification and risk assessment in myelodysplastic syndromes. *Hematol Oncol Clin North Am.* 2010 Apr;24(2):459–68. [PMID: 20359637]

Cutler C. Patient selection for transplantation in the myelodysplastic syndromes. *Hematol Oncol Clin North Am.* 2010 Apr;24(2):469–76. [PMID: 20359638]

Greenberg PL. Current therapeutic approaches for patients with myelodysplastic syndromes. *Br J Haematol.* 2010 Jul;150(2):131–43. [PMID: 20507314]

Guiron R et al. 5-azacitidine prolongs overall survival in patients with myelodysplastic syndrome—a systematic review and meta-analysis. *Haematologica.* 2010 Feb;95(2):303–10. [PMID: 19773261]

ACUTE LEUKEMIA



ESSENTIALS OF DIAGNOSIS

- ▶ Short duration of symptoms, including fatigue, fever, and bleeding.
- ▶ Cytopenias or pancytopenia.
- ▶ More than 20% blasts in the bone marrow.
- ▶ Blasts in peripheral blood in 90% of patients.
- ▶ Classify as acute myeloid leukemia (AML) or acute lymphoblastic leukemia (ALL).

▶ General Considerations

Acute leukemia is a malignancy of the hematopoietic progenitor cell. These cells proliferate in an uncontrolled fashion and replace normal bone marrow elements. Most cases arise with no clear cause. However, radiation and some toxins (benzene) are leukemogenic. In addition, a number of chemotherapeutic agents (especially cyclophosphamide, melphalan, other alkylating agents, and etoposide) may cause leukemia. The leukemias seen after toxin or chemotherapy exposure often develop from a myelodysplastic prodrome and are often associated with abnormalities in chromosomes 5 and 7, and those related to etoposide may have abnormalities in chromosome 11q23.

Acute promyelocytic leukemia (APL) is characterized by chromosomal translocation t(15;17), which produces the fusion gene *PML-RAR α* which interacts with the retinoic acid receptor to produce a block in differentiation that can be overcome with pharmacologic doses of retinoic acid (see below).

Most of the clinical findings in acute leukemia are due to replacement of normal bone marrow elements by the malignant cell. Less common manifestations result from organ infiltration (skin, gastrointestinal tract, meninges). Acute leukemia is potentially curable with combination chemotherapy.

ALL comprises 80% of the acute leukemias of childhood. The peak incidence is between 3 and 7 years of age.

It is also seen in adults, causing approximately 20% of adult acute leukemias. AML is primarily an adult disease with a median age at presentation of 60 years and an increasing incidence with advanced age.

▶ Classification of the Leukemias

A. Acute Myeloid Leukemia (AML)

AML has been characterized in several ways. The World Health Organization (WHO) has sponsored a classification of the leukemias and other hematologic malignancies that incorporates cytogenetic, molecular, and immunophenotype information. The most important baseline prognostic factor is cytogenetics. Favorable cytogenetics such as t(8;21) and inv(16)(p13;q22) are seen in 15% of cases and are termed the “core-binding factor” leukemias because of common genetic lesions affecting DNA-binding elements. These patients have a higher chance of achieving both short- and long-term disease control. Unfavorable cytogenetics confer a very poor prognosis. These consist of isolated monosomy 5 or 7, the presence of two or more monosomies, or three or more separate cytogenetic abnormalities. The majority of cases of AML are of intermediate risk and have either normal cytogenetics or abnormalities that do not confer strong prognostic significance. Within this large subgroup referred to as cytogenetically normal AML (CN-AML) molecular markers of response have been identified. Internal tandem duplication in the gene *FLT3* occurs in ~30% of CN-AML and is associated with a very poor prognosis. On the other hand, a relatively favorable group of patients has been defined that includes mutations of nucleophosmin 1 (NPM1) and lacks the internal tandem duplication of the *FLT3* gene.

B. Acute Lymphoblastic Leukemia (ALL)

ALL is most usefully classified by immunologic phenotype as follows: common, early B lineage, and T cell. The hyperdiploidy (with more than 50 chromosomes) is associated with a better prognosis but is seldom seen in adults. Unfavorable cytogenetics are the Philadelphia chromosome t(9;22) and t(4;11), which has fusion genes involving the *MLL* gene at 11q23.

C. Acute Promyelocytic Leukemia (APL)

In considering the various types of AML, APL is discussed separately because of its unique biologic features and unique response to non-chemotherapy treatments. APL is characterized by the cytogenetic finding of t(15;17) and the fusion gene *PML-RAR α* .

▶ Clinical Findings

A. Symptoms and Signs

Most patients have been ill only for days or weeks. Bleeding (usually due to thrombocytopenia) occurs in the skin and mucosal surfaces, with gingival bleeding, epistaxis, or menorrhagia. Less commonly, widespread bleeding is seen in patients with disseminated intravascular coagulation (DIC) (in APL and monocytic leukemia). Infection is due

to neutropenia, with the risk of infection rising as the neutrophil count falls below 500/mcL; with neutrophil counts < 100/mcL, infection within days is the rule. The most common pathogens are gram-negative bacteria (*Escherichia coli*, *Klebsiella*, *Pseudomonas*) or fungi (*Candida*, *Aspergillus*). Common presentations include cellulitis, pneumonia, and perirectal infections; death within a few hours may occur if treatment with appropriate antibiotics is delayed.

Patients may also seek medical attention because of gum hypertrophy and bone and joint pain. The most dramatic presentation is hyperleukocytosis, in which a markedly elevated circulating blast count (> 100,000/mcL) leads to impaired circulation, presenting as headache, confusion, and dyspnea. Such patients require emergent leukapheresis and chemotherapy as mortality approaches 40%.

On examination, patients appear pale and have purpura and petechiae; signs of infection may not be present. Stomatitis and gum hypertrophy may be seen in patients with monocytic leukemia, as may rectal fissures. There is variable enlargement of the liver, spleen, and lymph nodes. Bone tenderness may be present, particularly in the sternum, tibia, and femur.

B. Laboratory Findings

The hallmark of acute leukemia is the combination of pancytopenia with circulating blasts. However, blasts may be absent from the peripheral smear in as many as 10% of cases (“aleukemic leukemia”). The bone marrow is usually hypercellular and dominated by blasts. More than 20% blasts are required to make a diagnosis of acute leukemia.

Hyperuricemia may be seen. If DIC is present, the fibrinogen level will be reduced, the prothrombin time prolonged, and fibrin degradation products or fibrin D-dimers present. Patients with ALL (especially T cell) may have a mediastinal mass visible on chest radiograph. Meningeal leukemia will have blasts present in the spinal fluid, seen in approximately 5% of cases at diagnosis; it is more common in monocytic types of AML.

The Auer rod, an eosinophilic needle-like inclusion in the cytoplasm, is pathognomonic of AML and, if seen, secures the diagnosis. Leukemia cells retain properties of the lineages from which they are derived. Thus, histochemistry will demonstrate peroxidase in myeloid cells and butyrate esterase in monocytic cells, whereas ALL cells will not contain either of these enzymes. The phenotype of leukemia cells is usually demonstrated by flow cytometry. AML cells usually express myeloid antigens such as CD 13 or CD 33. ALL cells of B lineage will express CD19, common to all B cells, and most cases will express CD10, formerly known as the “common ALL antigen.” ALL cells of T lineage will usually not express mature T-cell markers, such as CD 3, 4, or 8, but will express some combination of CD 2, 5, and 7 and do not express surface immunoglobulin. Almost all ALL cells express terminal deoxynucleotidyl transferase (TdT). The uncommon Burkitt type of ALL has a “lymphoma” phenotype, expressing CD19, CD20 and surface immunoglobulin but not TdT.

► Differential Diagnosis

AML must be distinguished from other myeloproliferative disorders, CML, and myelodysplastic syndromes. Acute leukemia may also resemble a left-shifted bone marrow recovering from a previous toxic insult. If the question is in doubt, a bone marrow study should be repeated in several days to see if maturation has taken place. ALL must be separated from other lymphoproliferative disease such as CLL, lymphomas, and hairy cell leukemia. It may also be confused with the atypical lymphocytosis of mononucleosis and pertussis.

► Treatment

Most patients up to age 60 with acute leukemia are treated with the objective of effecting a cure. The first step in treatment is to obtain complete remission, defined as normal peripheral blood with resolution of cytopenias, normal bone marrow with no excess blasts, and normal clinical status. The type of initial chemotherapy depends on the subtype of leukemia.

1. AML—Most patients with AML are treated with a combination of an anthracycline (daunorubicin or idarubicin) plus cytarabine, either alone or in combination with other agents. This therapy will produce complete remissions in 80–90% of patients under age 60 years and in 50–60% of older patients (see Table 39–4). APL is treated differently from other forms of AML. Induction therapy for APL should include an anthracycline plus all-trans-retinoic acid. With this approach 90–95% of patients will achieve complete remission. For patients with high-risk APL based on an initial white blood cell count > 10,000/mcL, arsenic trioxide could be added and improves outcomes.

Once a patient has entered remission, postremission therapy should be given with curative intent whenever possible. Options include standard chemotherapy and autologous and allogeneic stem cell transplantation. The optimal treatment strategy depends on the patient’s age and clinical status, and the risk factor profile of the leukemia. With the use of all-trans retinoic acid, arsenic trioxide, and chemotherapy, 90% of patients with APL remain in long-term remission. Only the uncommon group of high-risk patients (based on initial white blood cell count > 10,000/mcL) have not shared in this favorable outcome, but studies of the potentially synergistic combination of retinoic acid and arsenic trioxide may improve results. For intermediate-risk patients with AML, cure rates for postremission therapy are 35–40% for chemotherapy, 40–50% for autologous transplantation, and 50–60% for allogeneic transplantation. Some types of AML whose cytogenetics involved core-binding factors have a more favorable prognosis, with cure rates of 50–60% with chemotherapy and 70–80% with autologous transplantation. Patients who do not enter remission or who have high-risk cytogenetics (monosomy 5 or 7, the presence of two or more monosomies, or three or more separate cytogenetic abnormalities) do far more poorly and are rarely cured with chemotherapy. FLT3 inhibitors are in development and have preliminarily shown activity in patients with FLT3+ AML. Allogeneic

transplantation is the treatment of choice for these very high-risk cases, but cure rates are only 20–30%. Patients over age 60 have had a poor prognosis, even in first remission, when treated with standard chemotherapy approaches, and only 10% become long-term survivors. The use of reduced-intensity allogeneic transplant appears to be improving the outcome for such patients, with initial studies suggesting that up to 40% of selected patients may be cured.

Once leukemia has recurred after initial chemotherapy, the prognosis is much more guarded. For patients in second remission, transplantation (autologous or allogeneic) offers a 20–30% chance of cure. For those patients with APL who relapse, arsenic trioxide can produce second remissions in 90% of cases.

2. ALL—Adults with ALL are treated with combination chemotherapy, including daunorubicin, vincristine, prednisone, and asparaginase. This treatment produces complete remissions in 90% of patients. Those patients with Philadelphia chromosome-positive ALL (or *bcr-abl* plus ALL) should have a tyrosine kinase inhibitor, such as dasatinib, added to their initial chemotherapy. Older patients (over age 60) may be treated with a tyrosine kinase inhibitor plus prednisone, without chemotherapy, and 90% can enter initial remission.

Remission induction therapy for ALL is less myelosuppressive than treatment for AML and does not necessarily produce marrow aplasia. After achieving complete remission, patients receive central nervous system prophylaxis so that meningeal sequestration of leukemic cells does not develop. As with AML, patients may be treated with either additional cycles of chemotherapy or high-dose chemotherapy plus bone marrow transplantation. Treatment decisions are made based on patient age and risk factors of the disease. Young adults have uniformly better outcomes when treated under pediatric protocols. Low-risk patients with ALL may be treated with chemotherapy with a 70% chance of cure. Intermediate-risk patients have a 30–50% chance of cure with chemotherapy, and high-risk patients are rarely cured with chemotherapy alone. High-risk patients with adverse cytogenetics or poor responses to chemotherapy are best treated with allogeneic transplantation. Autologous transplantation is a possibility in high-risk patients who lack a suitable donor.

► Prognosis

Approximately 70–80% of adults with AML under age 60 years achieve complete remission. High-dose postremission chemotherapy leads to cure in 35–40% of these patients, and high-dose cytarabine has been shown to be superior to therapy with lower doses. Allogeneic bone marrow transplantation (for younger adults with HLA-matched siblings) is curative in 50–60% of cases. Older adults with AML achieve complete remission in up to 50% of instances. The cure rates for older patients with AML have been very low (approximately 10–15%) even if they achieve remission and are able to receive postremission chemotherapy. The use of reduced-intensity allogeneic transplantation is being explored in order to improve on these outcomes.

► When to Refer

All patients should be referred to a hematologist.

► When to Admit

Most patients with acute leukemia will be admitted for treatment.

- Bassan R et al. Modern therapy of acute lymphoblastic leukemia. *J Clin Oncol.* 2011 Feb 10;29(5):532–43. [PMID: 21220592]
 Burnett A et al. Therapeutic advances in acute myeloid leukemia. *J Clin Oncol.* 2011 Feb 10;29(5):487–94. [PMID: 21220605]
 Fernandez HF. New trends in the standard of care for initial therapy of acute myeloid leukemia. *Hematology Am Soc Hematol Educ Program.* 2010;2010:56–61. [PMID: 21239771]
 Gupta V et al. Allogeneic hematopoietic cell transplantation for adults with acute myeloid leukemia: myths, controversies, and unknowns. *Blood.* 2011 Feb 24;117(8):2307–18. [PMID: 21098397]
 Kantarjian H et al. Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia. *Blood.* 2010 Nov 25;116(22):4422–9. [PMID: 20668231]
 Sanz MA et al. Modern approaches to treating acute promyelocytic leukemia. *J Clin Oncol.* 2011 Feb 10;29(5):495–503. [PMID: 21220600]

CHRONIC LYMPHOCYTIC LEUKEMIA



ESSENTIALS OF DIAGNOSIS

- B-cell lymphocytosis > 5000/mcL.
- Coexpression of CD19, CD5 on lymphocytes.

► General Considerations

CLL is a clonal malignancy of B lymphocytes. The disease is usually indolent, with slowly progressive accumulation of long-lived small lymphocytes. These cells are immunoincompetent and respond poorly to antigenic stimulation.

CLL is manifested clinically by immunosuppression, bone marrow failure, and organ infiltration with lymphocytes. Immunodeficiency is also related to inadequate antibody production by the abnormal B cells. With advanced disease, CLL may cause damage by direct tissue infiltration.

Information about CLL is evolving rapidly, with new findings in biology and new treatment options, and outcomes are improving significantly.

► Clinical Findings

A. Symptoms and Signs

CLL is a disease of older patients, with 90% of cases occurring after age 50 years and a median age at presentation of 70 years. Many patients will be incidentally discovered to have lymphocytosis. Others present with fatigue or lymphadenopathy. On examination, 80% of patients will have

lymphadenopathy and 50% will have enlargement of the liver or spleen.

The long-standing Rai classification system remains prognostically useful: stage 0, lymphocytosis only; stage I, lymphocytosis plus lymphadenopathy; stage II, organomegaly; stage III, anemia; stage IV, thrombocytopenia. These stages can be collapsed in to low-risk (stages 0–I), intermediate risk (stage II) and high-risk (stages III–IV).

CLL usually pursues an indolent course, but some subtypes behave more aggressively; a variant, prolymphocytic leukemia, is more aggressive. The morphology of the latter is different, characterized by larger and more immature cells. In 5–10% of cases, CLL may be complicated by autoimmune hemolytic anemia or autoimmune thrombocytopenia. In approximately 5% of cases, while the systemic disease remains stable, an isolated lymph node transforms into an aggressive large cell lymphoma (**Richter syndrome**).

B. Laboratory Findings

The hallmark of CLL is isolated lymphocytosis. The white blood count is usually $> 20,000/\text{mCL}$ and may be markedly elevated to several hundred thousand. Usually 75–98% of the circulating cells are lymphocytes. Lymphocytes appear small and mature, with condensed nuclear chromatin, and are morphologically indistinguishable from normal small lymphocytes, but smaller numbers of larger and activated lymphocytes may be seen. The hematocrit and platelet count are usually normal at presentation. The bone marrow is variably infiltrated with small lymphocytes. The immunophenotype of CLL demonstrates coexpression of the B lymphocyte lineage marker CD19 with the T lymphocyte marker CD5; this finding is commonly observed only in CLL and mantle cell lymphoma. CLL is distinguished from mantle cell lymphoma by the expression of CD23, low expression of surface immunoglobulin and CD20, and the absence of a translocation or overexpression of cyclin D1. Patients whose CLL cells have mutated forms of the immunoglobulin gene (which can currently be tested only in research laboratories) have a more indolent form of disease; these cells typically express low levels of the surface antigen CD38 and do not express the zeta-associated protein (ZAP-70). Conversely, patients whose cells have unmutated IgV genes and high levels of ZAP-70 expression do less well and require treatment sooner. The assessment of genomic changes by fluorescence in-situ hybridization (FISH) provides important prognostic information. The finding of deletions of chromosome 17p (TP53) or 11q (ATM) confers a poor prognosis, whereas those whose only genomic change is deletion of 13q have a very favorable outcome.

Hypogammaglobulinemia is present in 50% of patients and becomes more common with advanced disease. In some, a small amount of IgM paraprotein is present in the serum.

► Differential Diagnosis

Few syndromes can be confused with CLL. Viral infections producing lymphocytosis should be obvious from the presence of fever and other clinical findings; however, fever

may occur in CLL from concomitant bacterial infection. Pertussis may cause a particularly high total lymphocyte count. Other lymphoproliferative diseases such as Waldenström macroglobulinemia, hairy cell leukemia, or lymphoma (especially mantle cell) in the leukemic phase are distinguished on the basis of the morphology and immunophenotype of circulating lymphocytes and bone marrow. Monoclonal B-cell lymphocytosis is a disorder characterized by $< 5000/\text{mCL}$ B-cells and is considered a precursor to B-CLL.

► Treatment

Most cases of early indolent CLL require no specific therapy, and the standard of care for early stage disease has been observation. Indications for treatment include progressive fatigue, symptomatic lymphadenopathy, or anemia or thrombocytopenia. These patients have either symptomatic and progressive Rai stage II disease or stage III/IV disease. The initial treatment of choice is the combination of the chemotherapeutic agent fludarabine plus the monoclonal antibody rituximab, with or without the addition of the chemotherapeutic drug cyclophosphamide (see Table 39–11). The addition of cyclophosphamide appears to have greater anti-leukemic effectiveness, especially in patients with deletions of 11q, but also increases the risk of treatment-related infection. The question of whether this increase in toxicity is warranted by improved anti-leukemic effectiveness is currently being studied. Chlorambucil, 0.6–1 mg/kg orally every 3 weeks for approximately 6 months, was the standard treatment prior to the development of fludarabine. This treatment is convenient, well tolerated, and remains a reasonable first choice for frail elderly patients for whom frequent trips to the clinician's office is a hardship. The combination of rituximab and the alkylating agent bendamustine is another reasonable choice of therapy for the elderly patient. This combination has shown activity in the relapsed setting (59% overall response rate) including patients who had previously not responded to treatment with fludarabine. The monoclonal antibody alemtuzumab is approved for treatment of refractory CLL and can be especially useful in clearing the blood and bone marrow of disease. However, it produces significant immunosuppression, and its role in primary therapy has been limited due to the risk of severe and fatal infections. Lenalidomide has been shown to have effectiveness in refractory cases of CLL, and its role in primary therapy is being studied. This agent must be used carefully, since it can induce a “flare” reaction with marked swelling of involved lymph nodes that appears to be caused by an infiltration of reactive T cells. The oral agent PCI-02765, an inhibitor of Bruton's tyrosine kinase, has shown activity in patients with CLL.

Associated autoimmune hemolytic anemia or immune thrombocytopenia may require treatment with rituximab, prednisone, or splenectomy. Fludarabine should be avoided in patients with autoimmune hemolytic anemia since it may exacerbate this condition, but the concurrent use of rituximab helps reduce this risk. Patients with recurrent bacterial infections and hypogammaglobulinemia benefit from prophylactic infusions of gamma globulin 0.4 g/kg/

month), but this treatment is very expensive and can be justified only when these infections are severe. Patients undergoing therapy with a nucleoside analogue (fludarabine, pentostatin) or alemtuzumab should receive anti-infective prophylaxis for *P jiroveci* pneumonia, herpes viruses, and invasive fungal infections until there is evidence of T-cell recovery. Patients taking alemtuzumab should also be monitored for cytomegalovirus (CMV) reactivation.

Allogeneic transplantation offers potentially curative treatment for patients with CLL, but it should be used only in patients whose disease cannot be controlled by standard therapies. Nonmyeloablative allogeneic transplant has produced encouraging results and may expand the role of transplant in CLL. Some subtypes of CLL with genomic abnormalities such as 17p deletions have a sufficiently poor prognosis with standard therapies that early intervention with allogeneic transplant is being studied to assess whether it can improve outcomes.

► Prognosis

Therapies have changed the prognosis of CLL. In the past, median survival was approximately 6 years, and only 25% of patients lived more than 10 years. Patients with stage 0 or stage I disease have a median survival of 10–15 years, and these patients may be reassured that they can live a normal life for many years. Patients with stage III or stage IV disease had a median survival of < 2 years in the past, but with fludarabine-based combination therapies, 2-year survival is now > 90% and the long-term outlook appears to be substantially changed. For patients with high-risk and resistant forms of CLL, there is evidence that allogeneic transplantation can overcome risk factors and lead to long-term disease control.

► When to Refer

All patients with CLL should be referred to a hematologist.

► When to Admit

Hospitalization is rarely needed.

Dreger P et al. Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL 3XX trial. *Blood*. 2010 Oct 7;116(14):2438–47. [PMID: 20595516]

Fischer K et al. Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. *J Clin Oncol*. 2011 Sep 10;29(26):3559–66. [PMID: 21844497]

Gribben JG et al. Update on therapy of chronic lymphocytic leukemia. *J Clin Oncol*. 2011 Feb 10;29(5):544–50. [PMID: 21220603]

Hallek M et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Center Institute-Working Group 1996 guidelines. *Blood*. 2008 Jun 15;111(12):5446–56. [PMID: 18216293]

Jagłowski SM et al. The clinical application of monoclonal antibodies in chronic lymphocytic leukemia. *Blood*. 2010 Nov 11;116(19):3705–14. [PMID: 20610811]

Morrison VA. Infectious complications in patients with chronic lymphocytic leukemia: pathogenesis, spectrum of infection, and approaches to prophylaxis. *Clin Lymphoma Myeloma*. 2009 Oct;9(5):365–70. [PMID: 19858055]

Rawstron AC et al. Monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia. *N Engl J Med*. 2008 Aug 7;359(6):575–83. [PMID: 18687638]

HAIRY CELL LEUKEMIA



ESSENTIALS OF DIAGNOSIS

- ▶ Pancytopenia.
- ▶ Splenomegaly, often massive.
- ▶ Hairy cells present on blood smear and especially in bone marrow biopsy.

► General Considerations

Hairy cell leukemia is a rare malignancy of hematopoietic stem cells differentiated as mature B-lymphocytes with hairy cytoplasmic projections.

► Clinical Findings

A. Symptoms and Signs

The disease characteristically presents in middle-aged men. The median age at presentation is 55 years, and there is a striking 5:1 male predominance. Most patients present with gradual onset of fatigue, others complain of symptoms related to markedly enlarged spleen, and some come to attention because of infection.

Splenomegaly is almost invariably present and may be massive. The liver is enlarged in 50% of cases; lymphadenopathy is uncommon.

Hairy cell leukemia is usually an indolent disorder whose course is dominated by pancytopenia and recurrent infections, including mycobacterial infections.

B. Laboratory Findings

The hallmark of hairy cell leukemia is pancytopenia. Anemia is nearly universal, and 75% of patients have thrombocytopenia and neutropenia. The “hairy cells” are usually present in small numbers on the peripheral blood smear and have a characteristic appearance with numerous cytoplasmic projections. The bone marrow is usually inspirable (dry tap), and the diagnosis is made by characteristic morphology on bone marrow biopsy. The hairy cells have a characteristic histochemical staining pattern with tartrate-resistant acid phosphatase (TRAP). On immunophenotyping, the cells coexpress the antigens CD11c, CD20, CD22, CD25, CD103, and CD123. Pathologic examination of the spleen shows marked infiltration of the red pulp with hairy cells. This is in contrast to the usual predilection of lymphomas to involve the white pulp of the spleen.

► Differential Diagnosis

Hairy cell leukemia should be distinguished from other lymphoproliferative diseases such as Waldenström macroglobulinemia and non-Hodgkin lymphomas. It also may be confused with other causes of pancytopenia, including hypersplenism due to any cause, aplastic anemia, and paroxysmal nocturnal hemoglobinuria.

► Treatment

The treatment of choice is intravenous cladribine (2-chlorodeoxyadenosine; CdA), 0.1 mg/kg daily for 7 days. This is a relatively nontoxic drug that produces benefit in 95% of cases and complete remission in more than 80%. Responses are long lasting, with few patients relapsing in the first few years. Treatment with intravenous pentostatin produces similar results, but that drug is more cumbersome to administer. The anti-CD20 monoclonal antibody rituximab is sometimes given for minimal residual disease after cladribine or pentostatin.

► Course & Prognosis

The development of new therapies has changed the prognosis of this disease. Formerly, median survival was 6 years, and only one-third of patients survived longer than 10 years. More than 95% of patients with hairy cell leukemia now live longer than 10 years.

Cawley JC et al. The biology of hairy-cell leukaemia. *Curr Opin Hematol.* 2010 Jul;17(4):341–9. [PMID: 20375887]
 Grever MR et al. Long-term follow-up studies in hairy cell leukemia. *Leuk Lymphoma.* 2009 Oct;50(Suppl 1):23–6. [PMID: 19814694]
 Ravandi F. Chemo-immunotherapy for hairy cell leukemia. *Leuk Lymphoma.* 2011 Jun;52(Suppl 2):72–4. [PMID: 21417822]

LYMPHOMAS

NON-HODGKIN LYMPHOMAS



ESSENTIALS OF DIAGNOSIS

- Often present with painless lymphadenopathy.
- Pathologic diagnosis of lymphoma is made by pathologic examination of tissue.

► General Considerations

The non-Hodgkin lymphomas are a heterogeneous group of cancers of lymphocytes usually presenting as enlarged lymph nodes. The disorders vary in clinical presentation and course from indolent to rapidly progressive.

Molecular biology has provided clues to the pathogenesis of these disorders, often a matter of balanced chromosomal translocations whereby an oncogene becomes juxtaposed next to either an immunoglobulin gene (B-cell

lymphoma) or the T-cell receptor gene or related gene (T-cell lymphoma). The net result is oncogene overexpression and the development of lymphoma. The best-studied example is Burkitt lymphoma, in which a characteristic cytogenetic abnormality of translocation between the long arms of chromosomes 8 and 14 has been identified. The protooncogene *c-myc* is translocated from its normal position on chromosome 8 to the immunoglobulin heavy chain locus on chromosome 14. Overexpression of *c-myc* is related to malignant transformation through excess B-cell proliferation. In the follicular lymphomas, the t(14;18) translocation is characteristic and *bcl-2* is overexpressed, resulting in protection against apoptosis, the usual mechanism of B-cell death.

Classification of the lymphomas is a dynamic area still undergoing evolution. The most recent grouping (Table 13–16) separates diseases based on both clinical and pathologic features. Eighty-five percent of non-Hodgkin lymphomas are B-cell, 15% are T-cell, and the remainder NK-cell in origin. Even though non-Hodgkin lymphomas represent a very diverse group of diseases, they are historically divided in two categories based on clinical behavior and pathology: the indolent (low-grade) and the aggressive (intermediate or higher-grade).

► Clinical Findings

A. Symptoms and Signs

Patients with non-Hodgkin lymphomas usually present with painless lymphadenopathy, which may be isolated or widespread. Involved lymph nodes may be present peripherally or centrally (in the retroperitoneum, mesentery, and pelvis). The indolent lymphomas are usually disseminated at the time of diagnosis, and bone marrow involvement is

Table 13–16. World Health Organization classification of non-Hodgkin lymphomas (most common).

Precursor B-cell lymphoblastic lymphoma
Mature B-cell lymphomas
Diffuse large B cell lymphoma
Mediastinal large B cell lymphoma
Follicular lymphoma
Small lymphocytic lymphoma
Lymphoplasmacytic lymphoma (Waldenström macroglobulinemia)
Mantle cell lymphoma
Burkitt lymphoma
Marginal zone lymphoma
MALT type
Nodal type
Splenic type
Precursor T-cell lymphoblastic lymphoma
Mature T (and NK cell) lymphomas
Anaplastic T cell lymphoma
Angioimmunoblastic
Peripheral T cell lymphoma, NOS
Cutaneous T-cell lymphoma (mycosis fungoides)
Extranodal T/NK-cell lymphoma
Adult T-cell leukemia/lymphoma

NOS, not otherwise specified.

frequent. Many patients with lymphoma have constitutional symptoms such as fever, drenching night sweats, and weight loss of >10% (referred to as “B” symptoms).

On examination, lymphadenopathy may be isolated or diffuse, and extranodal sites of disease (such as the skin, gastrointestinal tract, liver, and bone marrow) may be found. Patients with Burkitt lymphoma are noted to have abdominal pain or abdominal fullness because of the predilection of the disease for the abdomen.

Once a pathologic diagnosis is established, staging is done using a whole body PET/CT scan, a bone marrow biopsy and, in patients with high-grade lymphoma or intermediate-grade lymphoma with high-risk features, a lumbar puncture.

B. Laboratory Findings

The peripheral blood is usually normal even with extensive bone marrow involvement by lymphoma. Circulating lymphoma cells in the blood are not commonly seen.

Bone marrow involvement is manifested as paratrabeular monoclonal lymphoid aggregates. In some high-grade lymphomas, the meninges are involved and malignant cells are found with cerebrospinal fluid cytology. The chest radiograph may show a mediastinal mass in some lymphomas. The serum LD has been shown to be a useful prognostic marker and is now incorporated in risk stratification of treatment.

The diagnosis of lymphoma is made by tissue biopsy. Needle aspiration may yield evidence for non-Hodgkin lymphoma, but a lymph node biopsy (or biopsy of involved extranodal tissue) is required for accurate diagnosis and classification.

► Treatment

A. Indolent Lymphomas

The most common lymphomas in this group are follicular lymphoma, marginal zone lymphomas, and small lymphocytic lymphoma (CLL). The treatment of **indolent lymphomas** depends on the stage of disease and the clinical status of the patient. A small number of patients have limited disease with only one or two contiguous abnormal lymph node groups and may be treated with localized irradiation with curative intent. However, most patients with indolent lymphoma have disseminated disease at the time of diagnosis and are not considered curable. Historically, treatment of these patients has not affected overall survival; therefore, treatment is only offered when symptoms develop or for high tumor bulk. Following each treatment response, patients will experience a relapse at increasingly shorter intervals. Some patients will have temporary spontaneous remissions. There are an increasing number of reasonable treatment options for indolent lymphomas, but no consensus has emerged on the best strategy. Treatment with the anti-CD20 monoclonal antibody rituximab (375 mg/m² intravenously weekly for 4 weeks) is commonly used either alone or in combination with chemotherapy and may be the only agent to affect overall survival in these disorders. Common rituximab-chemotherapy regimens include

bendamustine; cyclophosphamide, vincristine, and prednisone (R-CVP); and cyclophosphamide, doxorubicin, vincristine, prednisone (R-CHOP) (see Table 39–10). Radioimmunoconjugates that fuse anti-B cell monoclonal antibodies with radioactive nuclides produce higher response rates compared to antibody alone, and two such agents (yttrium-90 ibritumomab tiuxetan and iodine-131 tositumomab) are in use. Some patients with clinically aggressive low-grade lymphomas may be appropriate candidates for allogeneic stem cell transplantation with curative intent. The role of autologous hematopoietic stem cell transplantation remains uncertain, but some patients with recurrent disease appear to have prolonged remissions without the expectation of cure.

Patients with mucosal associated lymphoid tumors of the stomach may be appropriately treated with combination antibiotics directed against *Helicobacter pylori* and with acid blockade but require frequent endoscopic monitoring. Alternatively, MALT confined to the stomach can also be cured with whole-stomach radiotherapy.

B. Aggressive Lymphomas

Patients with **diffuse large B-cell lymphoma** are treated with curative intent. Those with localized disease receive short-course immunochemotherapy (such as three to four courses of R-CHOP) plus localized radiation or six cycles of immunochemotherapy without radiation. Most patients who have more advanced disease are treated with six cycles of immunochemotherapy such as R-CHOP (see Table 39–10). Patients with diffuse large B-cell lymphoma who relapse after initial chemotherapy can still be cured by autologous hematopoietic stem cell transplantation if their disease remains responsive to chemotherapy.

Mantle cell lymphoma is not effectively treated with standard immunochemotherapy regimens. Intensive initial immunochemotherapy including autologous hematopoietic stem cell transplantation has been shown to improve outcomes. Reduced-intensity allogeneic stem cell transplantation offers curative potential for selected patients. For **primary central nervous system lymphoma**, repetitive cycles of high-dose intravenous methotrexate with rituximab early in the treatment course produce better results than whole brain radiotherapy and with less cognitive impairment.

Patients with **high-grade lymphomas** (Burkitt or lymphoblastic) require intense, cyclic chemotherapy in the hospital similar to that given for ALL, and they also require intrathecal chemotherapy as central nervous system prophylaxis.

Patients with **peripheral T-cell lymphomas** usually have advanced stage nodal and extranodal disease and typically have inferior response rates to therapy compared to patients with aggressive B-cell disease.

► Prognosis

The median survival of patients with indolent lymphomas is 10–15 years. These diseases ultimately become refractory to chemotherapy. This often occurs at the time of histologic progression of the disease to a more aggressive form of lymphoma.

The International Prognostic Index is widely used to categorize patients with intermediate-grade lymphoma into risk groups. Factors that confer adverse prognosis are age over 60 years, elevated serum LD, stage III or stage IV disease, and poor performance status. Patients with no risk factors or one risk factor have high complete response rates (80%) to standard immunochemotherapy, and most responses (80%) are durable. Patients with two risk factors have a 70% complete response rate, 70% of which are long-lasting. Patients with higher-risk disease have lower response rates and poor survival with standard treatment regimens, and alternative treatments are needed.

For patients who relapse after initial chemotherapy, the prognosis depends on whether the lymphoma is still responsive to chemotherapy. If the lymphoma remains responsive to chemotherapy, autologous hematopoietic stem cell transplantation offers a 50% chance of long-term lymphoma-free survival.

The treatment of older patients with lymphoma has been difficult because of poorer tolerance of aggressive chemotherapy. The use of myeloid growth factors and prophylactic antibiotics to reduce neutropenic complications may improve outcomes.

Molecular profiling techniques using gene array technology and immunophenotyping have defined subsets of lymphomas with different biologic features and prognoses are being studied in clinical trials to determine choice of therapy.

▶ When to Refer

All patients with lymphoma should be referred to a hematologist or an oncologist.

▶ When to Admit

Admission is necessary only for specific complications of lymphoma or its treatment and for the treatment of all high-grade lymphomas.

Betancourt-García RD et al. Diffuse large-cell lymphoma. Part I: clinical features, histology and prognosis. *P R Health Sci J*. 2009 Mar;28(1):5–11. [PMID: 19266733]

Foss FM et al. Peripheral T-cell lymphoma. *Blood*. 2011 Jun 23;117(25):6756–67. [PMID: 21493798]

García-Pallas MV et al. Diffuse large-cell lymphoma. Part II: management. *P R Health Sci J*. 2009 Mar;28(1):12–7. [PMID: 19266734]

Lenz G et al. Aggressive lymphomas. *N Engl J Med*. 2010 Apr 15;362(15):1417–29. [PMID: 20393178]

Pérez-Galán P et al. Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era. *Blood*. 2011 Jan 6;117(1):26–38. [PMID: 20940415]

Tan D et al. Follicular lymphoma: clinical features and treatment. *Hematol Oncol Clin North Am*. 2008 Oct;22(5):863–82. [PMID: 18954741]

Vidal L et al. Immunotherapy for patients with follicular lymphoma: the contribution of systematic reviews. *Acta Haematol*. 2011;125(1–2):23–31. [PMID: 21150184]

HODGKIN LYMPHOMA



ESSENTIALS OF DIAGNOSIS

- ▶ Painless lymphadenopathy.
- ▶ Constitutional symptoms may or may not be present.
- ▶ Pathologic diagnosis by lymph node biopsy.

▶ General Considerations

Hodgkin lymphoma is characterized by Reed–Sternberg cells in an appropriate reactive cellular background. The malignant cell is derived from B lymphocytes of germinal center origin.

▶ Clinical Findings

There is a bimodal age distribution, with one peak in the 20s and a second over age 50 years. Most patients seek medical attention because of a painless mass, commonly in the neck. Others may seek medical attention because of constitutional symptoms such as fever, weight loss, or drenching night sweats, or because of generalized pruritus. An unusual symptom of Hodgkin lymphoma is pain in an involved lymph node following alcohol ingestion.

An important feature of Hodgkin lymphoma is its tendency to arise within single lymph node areas and spread in an orderly fashion to contiguous areas of lymph nodes. Late in the course of the disease, vascular invasion leads to widespread hematogenous dissemination.

Hodgkin lymphoma is divided into two subtypes: classic Hodgkin (nodular sclerosis, mixed cellularity, lymphocyte rich, and lymphocyte depleted) and non-classic Hodgkin (nodular lymphocyte predominant). Hodgkin lymphoma should be distinguished pathologically from other malignant lymphomas and may occasionally be confused with reactive lymph nodes seen in infectious mononucleosis, cat-scratch disease, or drug reactions (eg, phenytoin).

Patients undergo a staging evaluation to determine the extent of disease, including serum chemistries, whole body PET/CT scan, and bone marrow biopsy. The staging nomenclature (Ann Arbor) is as follows: stage I, one lymph node region involved; stage II, involvement of two or more lymph node regions on one side of the diaphragm; stage III, lymph node regions involved on both sides of the diaphragm; and stage IV, disseminated disease with extranodal involvement. Disease staging is further categorized as “A” if patients lack constitutional symptoms or as “B” if patients have 10% weight loss over 6 months, fever, or drenching night sweats (or some combination thereof). If symptoms are present, careful evaluation for higher numerical stage is warranted, as clinical stage IB (for example) is highly likely to emerge as stage IIB or stage IIIB.

▶ Treatment

The treatment of Hodgkin lymphoma has evolved, with radiation therapy only used as initial treatment for stage

IA patients with a high cervical lymph node and a low erythrocyte sedimentation rate. Chemotherapy is the mainstay of treatment and ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) remains the standard first-line regimen. Even though others such as Stanford V or BEACOPP (baseline or escalated) may improve response rates, they are usually associated with increased toxicity and lack a definitive overall survival advantage. Most patients with stage I and II disease receive a combination of short course chemotherapy with or without involved-field radiotherapy (see Table 39–10). Patients with stage II disease and a large mediastinal or other bulky mass need a full course of ABVD with or without mediastinal radiotherapy. Patients with stage III or IV disease receive a full course of ABVD (no radiotherapy). Pulmonary toxicity can unfortunately occur following either chemotherapy (bleomycin) or radiation and should be treated aggressively in these patients, since it can lead to permanent fibrosis and death.

Classic Hodgkin lymphoma relapsing after initial radiotherapy-only treatment may still be curable with chemotherapy. The treatment of choice for patients who relapse after initial chemotherapy is high-dose chemotherapy with autologous hematopoietic stem cell transplantation. This offers a 35–50% chance of cure when disease is still chemotherapy responsive. The antibody-drug conjugate brentuximab vedotin has shown impressive activity in patients relapsing after autologous stem cell transplantation (ORR: 75%; CR: 34%) and has been approved by the US Food and Drug Administration for this indication.

► Prognosis

All patients should be treated with curative intent. Prognosis in Hodgkin lymphoma is influenced by seven features: stage, age, gender, hemoglobin, albumin, white blood count, and lymphocyte count. The cure rate is 75% if zero to two risk features are present and 55% when three or more risk features are present. The prognosis of patients with stage IA or IIA disease is excellent, with 10-year survival rates in excess of 90%. Patients with advanced disease (stage III or IV) have 10-year survival rates of 50–60%. Poorer results are seen in patients who are older, those who have bulky disease, and those with lymphocyte depletion or mixed cellularity on histologic examination. Non-classic Hodgkin lymphoma (nodular lymphocyte predominant) is highly curable with radiotherapy alone for early-stage disease; however, for high-stage disease, it is characterized by long survival with repetitive relapses after chemotherapy.

► When to Refer

- All patients should be sent to an oncologist or hematologist.
- Secondary referral to a radiation oncologist might be appropriate.

► When to Admit

Patients should be admitted for complications of the disease or its treatment.

Bartlett NL. The present: optimizing therapy—too much or too little? *Hematology Am Soc Hematol Educ Program*. 2010;2010:108–14. [PMID: 21239779]

Borchmann P et al. The past: what have we learned in the last decade? *Hematology Am Soc Hematol Educ Program*. 2010;2010:101–7. [PMID: 21239778]

Herbst C et al. Combined modality treatment improves tumor control and overall survival in patients with early stage Hodgkin's lymphoma: a systematic review. *Haematologica*. 2010 Mar;95(3):494–500. [PMID: 19951972]

Viviani S et al. ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned. *N Engl J Med*. 2011 Jul 21;365(3):203–12. [PMID: 21774708]

Younes A et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. *N Engl J Med*. 2010 Nov 4;363(19):1812–21. [PMID: 21047225]

MULTIPLE MYELOMA



ESSENTIALS OF DIAGNOSIS

- Bone pain, often in the spine, ribs, or proximal long bones.
- Monoclonal paraprotein by serum or urine protein electrophoresis or immunofixation.
- Clonal plasma cells in the bone marrow or in a tissue biopsy, or both.
- Organ damage due to plasma cells (eg, bones, kidneys, hypercalcemia, anemia).

► General Considerations

Multiple myeloma is a malignancy of hematopoietic stem cells terminally differentiated as plasma cells characterized by replacement of the bone marrow, bone destruction, and paraprotein formation. The diagnosis is established when monoclonal plasma cells (either kappa or lambda light chain restricted) in the bone marrow (any percentage) or as a tumor (plasmacytoma), or both, are associated with end organ damage (such as bone disease [lytic lesions, osteopenia], anemia [hemoglobin < 10 g/dL], hypercalcemia [calcium > 11.5 mg/dL], or renal failure [creatinine > 2 mg/dL]) with or without paraprotein elaboration.

Malignant plasma cells can form tumors (plasmacytomas) that may cause spinal cord compression or other soft-tissue problems. Bone disease is common and due to excessive osteoclast activation mediated by the interaction of the receptor activator of NF-κB (RANK) with its ligand (RANKL). In multiple myeloma, osteoprotegerin (a decoy receptor for RANKL) is underproduced, thus promoting the binding of RANK with RANKL with consequent excessive bone resorption.

The paraproteins (monoclonal immunoglobulins) secreted by the malignant plasma cells may cause problems in their own right. Very high paraprotein levels (either IgG or IgA) may cause hyperviscosity, although this is more often common with the IgM in Waldenström macroglobulinemia. The light chain component of the immunoglobulin

often leads to kidney failure (often aggravated by hypercalcemia or hyperuricemia, or both). Light chain components may be deposited in tissues as amyloid, resulting in kidney failure with albuminuria and a vast array of systemic symptoms.

Myeloma patients are prone to recurrent infections for a number of reasons, including neutropenia, the underproduction of normal immunoglobulins and the immunosuppressive effects of chemotherapy. Myeloma patients are especially prone to infections with encapsulated organisms such as *Streptococcus pneumoniae* and *Haemophilus influenzae*.

▶ Clinical Findings

A. Symptoms and Signs

Myeloma is a disease of older adults (median age at presentation, 65 years). The most common presenting complaints are those related to anemia, bone pain, kidney disease, and infection. Bone pain is most common in the back, hips, or ribs or may present as a pathologic fracture, especially of the femoral neck or vertebrae. Patients may also come to medical attention because of spinal cord compression or the hyperviscosity syndrome (mucosal bleeding, vertigo, nausea, visual disturbances, alterations in mental status). Many patients are diagnosed because of laboratory findings of hypercalcemia, proteinuria, elevated sedimentation rate, or abnormalities on serum protein electrophoresis obtained for symptoms or in routine screening studies. A few patients come to medical attention because of organ dysfunction due to amyloidosis.

Examination may reveal pallor, bone tenderness, and soft tissue masses. Patients may have neurologic signs related to neuropathy or spinal cord compression. Patients with primary amyloidosis may have an enlarged tongue, peripheral or autonomic neuropathy, congestive heart failure, or hepatomegaly. Splenomegaly is absent unless amyloidosis is present. Fever occurs mainly with infection. Acute oliguric or nonoliguric renal failure may be present due to hypercalcemia, hyperuricemia, light-chain cast injury, or primary amyloidosis.

B. Laboratory Findings

Anemia is nearly universal. Red blood cell morphology is normal, but rouleaux formation is common and may be marked. The absence of rouleaux formation, however, excludes neither multiple myeloma nor the presence of a serum paraprotein. The neutrophil and platelet counts are usually normal at presentation. Only rarely will plasma cells be visible on peripheral blood smear (plasma cell leukemia).

The hallmark of myeloma is the finding of a paraprotein on serum or urine protein electrophoresis (PEP). The majority of patients will have a monoclonal spike visible in the β - or γ -globulin region. The semi-quantification of the paraprotein on the PEP is referred to as the M-protein. Immunofixation electrophoresis (IFE) will reveal this to be a monoclonal immunoglobulin. Approximately 15% of patients will have no demonstrable paraprotein in the serum because their myeloma cells produce only light

chains and not intact immunoglobulin, and the light chains pass rapidly through the glomerulus into the urine. Urine PEP and IFE will demonstrate the light chain paraprotein in this setting. The free light chain assay will sometimes demonstrate excess monoclonal light chains in serum and urine, and in a small proportion of patients, will be the only means to identify and quantify the paraprotein being produced. Overall, the paraprotein is IgG (60%), IgA (20%), or light chain only (15%) in multiple myeloma, with the remainder being rare cases of IgD or biclonal gammopathy. In sporadic cases, no paraprotein is present ("nonsecretory myeloma"); these patients have particularly aggressive disease.

The bone marrow will be infiltrated by variable numbers of monoclonal plasma cells. The plasma cells are usually morphologically abnormal. The plasma cells will display marked skewing of the kappa to lambda light chain ratio, which will indicate their clonality. Many benign processes can result in bone marrow plasmacytosis, but the presence of atypical plasma cells, light chain restriction, and effacement of normal bone marrow elements helps distinguish myeloma.

C. Imaging

Bone radiographs are important in establishing the diagnosis of myeloma. Lytic lesions are most commonly seen in the axial skeleton: skull, spine, proximal long bones, and ribs. At other times, only generalized osteoporosis is seen. The radionuclide bone scan is not useful in detecting bone lesions in myeloma, since there is usually no osteoblastic component. Magnetic resonance imaging (MRI) and positron emission tomography (PET) scans will demonstrate significantly more disease than is shown in plain radiographs, and these imaging studies are common practice in the evaluation of patients with known or suspected multiple myeloma.

▶ Differential Diagnosis

When a patient is discovered to have a paraprotein, the distinction between multiple myeloma or another lymphoproliferative malignancy with a paraprotein (CLL, Waldenström macroglobulinemia, non-Hodgkin lymphoma, primary amyloid, cryoglobulinemia) and monoclonal gammopathy of undetermined significance (MGUS) must be made. MGUS is present in 1% of all adults and 3% of adults over age 70 years. Thus, among all patients with paraproteins, MGUS is far more common than multiple myeloma. MGUS is defined as bone marrow monoclonal plasma cells < 10% in the setting of a paraprotein (serum M-protein < 3 g/dL) and the absence of end-organ damage. In approximately one-quarter of cases, MGUS progresses to overt malignant disease in a median of one decade. The transformation of MGUS to multiple myeloma is approximately 1% per year. Smoldering multiple myeloma is defined as a serum M-protein > 3 g/dL or bone marrow monoclonal plasma cells \geq 10% in the absence of end-organ damage. Multiple myeloma, smoldering multiple myeloma, and MGUS must be distinguished from reactive (benign) polyclonal hypergammaglobulinemia.

► Treatment

Patients with MGUS and smoldering multiple myeloma are observed without treatment. Most patients with multiple myeloma require treatment at diagnosis because of bone pain or other symptoms and complications related to the disease. The initial treatment generally involves at a minimum an immunomodulatory drug such as thalidomide or lenalidomide in combination with high-dose dexamethasone. The major side effects of lenalidomide are neutropenia and thrombocytopenia, venothromboembolism, and peripheral neuropathy. Bortezomib, a proteasome inhibitor, is also highly active and has the advantages of producing rapid responses and of being effective in poor-prognosis multiple myeloma. The major side effect of bortezomib is neuropathy (both peripheral and autonomic), which is largely ameliorated when given subcutaneously rather than intravenously. The most common regimen for initial treatment is RVD (lenalidomide, bortezomib, and dexamethasone). The combination of bortezomib, dexamethasone with the chemotherapeutic agent liposomal doxorubicin is also effective.

After initial therapy, many patients under age 76 years are consolidated with autologous hematopoietic stem cell transplantation. Autologous hematopoietic stem cell transplant prolongs both duration of remission and overall survival, and has the advantage of providing long treatment-free intervals. Lenalidomide or thalidomide prolong remissions and survival when given as posttransplant maintenance therapy. Allogeneic stem cell transplantation is potentially curative in myeloma, but its role has been limited because of the unusually high treatment-related mortality rate (40–50%) in multiple myeloma patients.

Localized radiotherapy may be useful for palliation of bone pain or for eradicating tumor at the site of pathologic fracture. Vertebral collapse with its attendant pain and mechanical disturbance can be treated with vertebroplasty or kyphoplasty. Hypercalcemia and hyperuricemia should be treated aggressively and immobilization and dehydration avoided. The bisphosphonates (pamidronate 90 mg or zoledronic acid 4 mg intravenously monthly) reduce pathologic fractures in patients with bone disease and are an important adjunct in this subset of patients. The bisphosphonates are also used to treat malignant hypercalcemia. However, long-term bisphosphonates, especially zoledronate, have been associated with a risk of osteonecrosis of the jaw, and patients must be monitored for this complication.

► Prognosis

The outlook for patients with myeloma has been steadily improving for the past decade. The median survival of patients is more than 5 years. Patients with low-stage disease who lack high-risk genomic changes respond very well to treatment and derive significant benefit from autologous hematopoietic stem cell transplantation and have survivals approaching a decade. The **International Staging System** for myeloma relies on two factors: β_2 -microglobulin and albumin. Stage 1 patients have both β_2 -microglobulin < 3.5 mg/L and albumin \geq 3.5 g/dL (survival > 5 years).

Stage 3 is diagnosed when β_2 -microglobulin > 5.5 mg/L (survival < 2 years). Stage 2 is diagnosed with values in between. The other laboratory finding of important adverse prognostic significance on a bone marrow sample is genetic abnormalities established by FISH involving the immunoglobulin heavy chain locus at chromosome 14q32 (such as the finding of t(4;14) or t(14;16)). Abnormalities of chromosome 17p confer a particularly poor prognosis.

► When to Refer

All patients with multiple myeloma should be referred to a hematologist or an oncologist.

► When to Admit

Hospitalization is indicated for treatment of acute kidney failure, hypercalcemia, or suspicion of spinal cord compression, certain chemotherapy regimens, or for hematopoietic stem cell transplantation.

Collins CD. Multiple myeloma. *Cancer Imaging*. 2010 Feb 11; 10(1):20–31. [PMID: 20159661]

Fili S et al. Therapeutic implications of osteoprotegerin. *Cancer Cell Int*. 2009 Sep 12;9:26–22. [PMID: 19747396]

Harousseau JL. Optimising patient outcomes in myeloma. *Cancer Treat Rev*. 2010 May;36(Suppl 2):S33–5. [PMID: 20472187]

Jagannath S et al. The current status and future of multiple myeloma in the clinic. *Clin Lymphoma Myeloma*. 2010 Feb;10(1):E1–16. [PMID: 20031526]

Kumar S. Treatment of newly diagnosed multiple myeloma: advances in current therapy. *Med Oncol*. 2010 Jun;27(Suppl 1): S14–24. [PMID: 20035387]

Kyle RA et al. Management of monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM). *Oncology (Williston Park)*. 2011 Jun;25(7): 578–86. [PMID: 21888255]

Palumbo A et al. Multiple myeloma. *N Engl J Med*. 2011 Mar 17;364(11):1046–60. [PMID: 21410373]

WALDENSTRÖM MACROGLOBULINEMIA



ESSENTIALS OF DIAGNOSIS

- Monoclonal IgM paraprotein.
- Infiltration of bone marrow by plasmacytic lymphocytes.
- Absence of lytic bone disease.

► General Considerations

Waldenström macroglobulinemia is a syndrome of IgM hypergammaglobulinemia that occurs in the setting of a low-grade non-Hodgkin lymphoma characterized by B-cells that are morphologically a hybrid of lymphocytes and plasma cells. These cells characteristically secrete the IgM paraprotein, and many clinical manifestations of the disease are related to this macroglobulin.

► Clinical Findings

A. Symptoms and Signs

This disease characteristically develops insidiously in patients in their 60s or 70s. Patients usually present with fatigue related to anemia. Hyperviscosity of serum may be manifested in a number of ways. Mucosal and gastrointestinal bleeding is related to engorged blood vessels and platelet dysfunction. Other complaints include nausea, vertigo, and visual disturbances. Alterations in consciousness vary from mild lethargy to stupor and coma. The IgM paraprotein may also cause symptoms of cold agglutinin disease (hemolysis) or chronic demyelinating peripheral neuropathy.

On examination, there may be hepatosplenomegaly or lymphadenopathy. The retinal veins are engorged. Purpura may be present. There should be no bone tenderness.

B. Laboratory Findings

Anemia is nearly universal, and rouleaux formation is common although the red blood cells are agglutinated when the blood smear is prepared at room temperature. The anemia is related in part to expansion of the plasma volume by 50–100% due to the presence of the paraprotein. Other blood counts are usually normal. The abnormal plasmacytic lymphocytes may appear in small numbers on the peripheral blood smear. The bone marrow is characteristically infiltrated by the plasmacytic lymphocytes.

The hallmark of macroglobulinemia is the presence of a monoclonal IgM spike seen on serum PEP in the β -globulin region. The serum viscosity is usually increased above the normal of 1.4–1.8 times that of water. Symptoms of hyperviscosity usually develop when the serum viscosity is over four times that of water, and marked symptoms usually arise when the viscosity is over six times that of water. Because paraproteins vary in their physicochemical properties, there is no strict correlation between the concentration of paraprotein and serum viscosity.

The IgM paraprotein may cause a positive antiglobulin (Coombs) test for complement and have cold agglutinin or cryoglobulin properties. If macroglobulinemia is suspected but the serum PEP shows only hypogammaglobulinemia, the test should be repeated while taking special measures to maintain the blood at 37°C, since the paraprotein may precipitate out at room temperature. Bone radiographs are normal, and there is no evidence of kidney failure.

► Differential Diagnosis

Waldenström macroglobulinemia is differentiated from MGUS by the finding of bone marrow infiltration with monoclonal malignant cells. It is distinguished from CLL by bone marrow morphology, the absence of CD5 expression and the absence of lymphocytosis and from multiple myeloma by bone marrow morphology and the finding of the characteristic IgM paraprotein and the absence of bone disease.

► Treatment

Patients with marked hyperviscosity syndrome (stupor, coma, pulmonary edema) should be treated on an emergency

basis with plasmapheresis. On a chronic basis, some patients can be managed with periodic plasmapheresis alone. As with other indolent malignant lymphoid diseases, the anti-CD20 monoclonal antibody rituximab (375 mg/m² intravenously weekly for 4–8 weeks) has activity. However, a word of caution: the IgM often rises first after rituximab therapy before it falls. Combination therapy is recommended for advanced disease (see Table 39–10). The proteasome inhibitor bortezomib and the purine analog fludarabine are also active. Autologous hematopoietic stem cell transplantation is reserved for relapsed disease.

► Prognosis

Waldenström macroglobulinemia is an indolent disease with a median survival rate of 5 years, and 10% of patients are alive at 15 years.

► When to Refer

All patients should be referred to a hematologist or an oncologist.

► When to Admit

Patients should be admitted for treatment of hyperviscosity syndrome.

Gertz MA. Waldenström macroglobulinemia: 2011 update on diagnosis, risk stratification, and management. *Am J Hematol*. 2011 May;86(5):411–6. [PMID: 21523800]

Stone MJ. Waldenström's macroglobulinemia: hyperviscosity syndrome and cryoglobulinemia. *Clin Lymphoma Myeloma*. 2009 Mar;9(1):97–9. [PMID: 19362986]

Treon SP. How I treat Waldenström macroglobulinemia. *Blood*. 2009 Sep 17;114(12):2375–85. [PMID: 19617573]

PRIMARY AMYLOIDOSIS



ESSENTIALS OF DIAGNOSIS

- Congo red positive amyloid protein on tissue biopsy.
- Amyloid protein is kappa or lambda immunoglobulin light chain.
- Serum or urine (or both) light chain paraprotein.

► General Considerations

Amyloidosis is an uncommon condition whereby a protein abnormally deposits in tissue resulting in organ dysfunction. The propensity of a protein to be amyloidogenic is a consequence of disturbed translational or posttranslational protein folding. The input of amyloid protein into tissues far exceeds its output, so amyloid build up inexorably proceeds to organ dysfunction and ultimately organ failure and premature death.

Amyloidosis is classified according to the type of amyloid protein deposited. The four main categories are **primary**

(immunoglobulin light chain [AL]), **secondary** (serum protein A, produced in inflammatory conditions [AA]), **hereditary** (transthyretin [TTR]; senile amyloid [atrial natriuretic peptide]; others), and **renal failure type** (β_2 -microglobulin, not filtered out by dialysis membranes [A β_2 M]). Amyloidosis is further classified as **localized** (amyloid deposits only in a single tissue type or organ) or, most common, **systemic** (widespread amyloid deposition).

► Clinical Findings

A. Symptoms and Signs

Patients with **localized amyloidosis** have symptoms and signs related to the affected single organ, such as hoarseness (vocal cords) or proptosis and visual disturbance (orbits). Patients with **systemic amyloidosis** have symptoms and signs of unexplained medical syndromes, including heart failure (infiltrative/restrictive cardiomyopathy), nephrotic syndrome, malabsorption and weight loss, hepatic dysfunction, autonomic insufficiency, carpal tunnel syndrome (often bilateral), and sensorimotor peripheral neuropathy. Other symptoms and signs include an enlarged tongue; waxy, rough plaques on skin; contusions (including the periorbital areas); cough or dyspnea; and disturbed deglutition. These symptoms and signs arise insidiously, and the diagnosis of amyloidosis is generally made late in the disease process.

B. Laboratory Findings

The diagnosis of amyloid protein requires a tissue biopsy that demonstrates deposition of a pink substance in the tissue with the H&E stain. This protein stains red with Congo Red and becomes an apple-green color when the light is polarized. Amyloid is a triple-stranded fibril composed of the amyloid protein, amyloid protein P, and glycosaminoglycan. The amyloid fibrils form beta-pleated sheets as demonstrated by electron microscopy. In primary amyloidosis, the amyloid protein is either the kappa or lambda immunoglobulin light chain.

When systemic amyloidosis is suspected, a blind aspiration of the abdominal fat pad will reveal amyloid two-thirds of the time. If the fat pad aspiration is unrevealing, then the affected organ needs biopsy. In 90% of patients with primary amyloidosis, analysis of the serum and urine will reveal a kappa or lambda light chain paraprotein by PEP, IFE, or free light chain assay; in the remainder, mass spectroscopy demonstrates light chain in the tissue biopsy. Lambda amyloid is more common than kappa amyloid, a relative proportion opposite from normal B-cell stoichiometry. Most patients with primary amyloidosis have a small excess of kappa or lambda restricted plasma cells in the bone marrow that may show interstitial amyloid deposition or amyloid in the blood vessels of the marrow.

Patients with cardiac amyloidosis have an infiltrative cardiomyopathy with thick ventricular walls on echocardiogram that sometimes shows a unique speckling pattern. Paradoxically, QRS voltages are low on ECG. With renal amyloid, albuminuria is present, which can be in the nephrotic range. Late in renal involvement, kidney function decreases.

► Differential Diagnosis

Primary amyloidosis must be distinguished from MGUS and multiple myeloma or other malignant lymphoproliferative syndromes. Of note, 12% of patients with MGUS will convert to primary amyloidosis in a median of 9 years. One-fifth of patients who have primary amyloidosis will meet the diagnostic criteria for multiple myeloma; conversely, 5% of patients with multiple myeloma will have amyloid deposition of the paraprotein.

► Treatment

The treatment approach to primary amyloidosis closely resembles that of multiple myeloma. Prospective, randomized trials of multiple myeloma chemotherapy versus colchicine have demonstrated a survival benefit to chemotherapy. The concept is reduction of light chain production and a reduction of light chain deposition as a means to arrest progressive end-organ dysfunction. Active agents in primary amyloidosis include melphalan, dexamethasone, lenalidomide, and bortezomib (see Table 39–10). As in multiple myeloma, autologous hematopoietic stem cell transplantation after high-dose melphalan is used in patients with reasonable organ function and a good performance status. The treatment-related mortality, however, is higher in patients with primary amyloidosis than in myeloma (10% vs 1%). Some patients will demonstrate end-organ improvement after therapy. Agents are being developed that facilitate amyloid dissolution or correct protein folding abnormalities in the amyloid protein.

► Prognosis

Untreated primary amyloidosis is associated with progressive end-organ failure and premature death. There is no known cure for primary amyloidosis. Although virtually every tissue examined at autopsy will contain amyloid, patients with primary amyloidosis will have one or two primary organs failing that clinically drive the presentation and prognosis. The cardiac biomarkers B-type natriuretic peptides and troponins T and I are prognostic in this disease regardless of overt clinical cardiac involvement. Historically, patients with predominantly cardiac or autonomic nerve presentations had survivals of 3–9 months, and those with carpal tunnel syndrome or nephrosis, 1.5–3 years, and those with peripheral neuropathy, 5 years. These survivals are roughly doubled with multiple myeloma-like treatment. In those patients able to undergo autologous hematopoietic stem cell transplantation, the median survival now approaches 5 years.

► When to Refer

- All patients who have primary amyloidosis or in whom it is suspected should be referred to a hematologist or oncologist.
- All patients with hereditary amyloidosis should be referred to a hepatologist for consideration of liver transplantation.

▶ When to Admit

- Patients with systemic amyloidosis require hospitalization to treat exacerbations of end-organ failure, such as heart failure to liver failure.
- Patients with primary amyloidosis require hospitalization to undergo autologous hematopoietic stem cell transplantation.

Chee CE et al. Pitfalls in the diagnosis of primary amyloidosis. *Clin Lymphoma Myeloma Leuk.* 2010 Jun;10(33):177–80. [PMID: 20511161]

Cohen AD et al. Systemic light-chain amyloidosis: advances in diagnosis, prognosis, and therapy. *Hematology Am Soc Hematol Educ Program.* 2010;2010:287–94. [PMID: 21239808]

Gertz MA et al. Treatment of immunoglobulin light chain (primary or AL) amyloidosis. *Oncology (Williston Park).* 2011 Jun;25(7):620–6. [PMID: 21888261]

Mhaskar R et al. Role of high-dose chemotherapy and autologous hematopoietic cell transplantation in primary systemic amyloidosis: a systematic review. *Biol Blood Marrow Transplant.* 2009 Aug;15(8):893–902. [PMID: 19589478]

STEM CELL TRANSPLANTATION

Stem cell transplantation using hematopoietic stem cells is an extremely valuable treatment for a variety of hematologic malignancies and is also used in a few non-hematologic cancers and some nonmalignant conditions. In many cases, stem cell transplantation offers the only curative option for some types of cancer and can be a life-saving procedure.

The basis of treatment with stem cell transplantation is the ability of the hematopoietic stem cell to completely restore bone marrow function and formation of all blood components, as well as the ability to re-form the immune system. These hematopoietic stem cells were formerly collected from the bone marrow but are now more commonly collected from the peripheral blood after maneuvers, usually involving the administration of filgrastim (G-CSF) to mobilize them from the bone marrow into the blood.

In the field of cancer chemotherapy, the dose-limiting toxicity of almost all chemotherapy has been myelosuppression from damage to the bone marrow. It is typical during the administration of chemotherapy for blood counts to be transiently suppressed and to have to wait for recovery of the blood in order to safely give the next treatment. However, if too high a dose of chemotherapy is given, it is possible to damage the bone marrow beyond recovery, and for the blood counts to never return to within normal ranges. For cancers for which there is a dose-response relationship, that is, a relationship between the dose of chemotherapy administered and the number of cancer cells killed, the limits placed on the allowable dose of chemotherapy can make the difference between cure and failure to cure. In stem cell transplantation, the limit placed on the allowable dose of chemotherapy by the risks of permanent bone marrow damage is eliminated and much higher doses of chemotherapy can be given, since reinfusion of hematopoietic stem cells can completely restore the bone marrow.

AUTOLOGOUS STEM CELL TRANSPLANTATION

Autologous stem cell transplantation is a treatment in which hematopoietic stem cells are collected from the patient and then re-infused after chemotherapy. Therefore, autologous stem cell transplantation relies solely for its effectiveness on the ability to give much higher doses of chemotherapy than would otherwise be possible. In this procedure, the hematopoietic stem cells are usually collected from the patient's peripheral blood. First, the hematopoietic stem cells are mobilized from the bone marrow into the blood. This can be accomplished by a variety of techniques, most commonly the use of myeloid growth factors such as filgrastim either alone or in combination with chemotherapy. The CXCR4 antagonist plerixafor can help mobilize these cells into the blood. During the process of leukopheresis the patient's blood is centrifuged into layers of different densities; the hematopoietic stem cells are collected from the appropriate layer while the remainder of the blood elements are returned unchanged to the patient. After collection, these autologous hematopoietic stem cells are frozen and cryopreserved for later use. Treatment with autologous stem cell transplantation involves administration of high-dose chemotherapy (referred to as the "preparative regimen") followed, after clearance of the chemotherapy out of the patient's system, by intravenous re-infusion of the thawed autologous hematopoietic stem cells. The hematopoietic stem cells home to the bone marrow and grow into new bone marrow cells.

With the autologous stem cell transplantation treatment, there is a period of severe pancytopenia during the gap between myelosuppression caused by the chemotherapy and the recovery produced from the new bone marrow derived from the infused hematopoietic stem cells. This period of pancytopenia typically lasts 7–10 days and requires support with transfusions of red blood cells and platelets as well as antibiotics. Hospitalization to receive such treatment usually lasts 2–3 weeks. The morbidity of such a treatment varies according to the type of chemotherapy used, and the chance of fatal treatment-related complications is between 1% and 4%.

Autologous stem cell transplantation has the potential to cure cancers that would otherwise be fatal and is the treatment of choice for lymphomas such as diffuse large B-cell lymphomas that have recurred after initial chemotherapy but are still responsive to chemotherapy. It is similarly also the treatment of choice for relapsed Hodgkin lymphoma that still responds to chemotherapy, and for testicular germ cell cancers that have recurred. Autologous stem cell transplantation also plays an important role in the treatment of AML in both first and second remission and is potentially curative in these settings. Autologous stem cell transplantation is currently part of the standard of care for the treatment of mantle cell lymphoma and multiple myeloma, based not on curative potential, but the prolongation of remission and overall survival.

ALLOGENEIC STEM CELL TRANSPLANTATION

Allogeneic stem cell transplantation is a treatment in which the source of hematopoietic stem cells to restore

bone marrow and immune function are derived, not from the patient, but from a different donor. Initially allogeneic stem cell transplantation was thought to derive its effectiveness from the high-dose chemotherapy (or radiation plus chemotherapy) that forms the “preparative regimen” in a manner similar to autologous stem cell transplantation. However, it is now known that there is a second type of effector mechanism in allogeneic stem cell transplantation, the alloimmune graft-versus-malignancy (GVM) effect derived from the donor immune system. In some cases, this GVM effect can be more important than the chemotherapy in producing a cure of disease. This understanding has led to the development of less myelotoxic preparative regimens, referred to as reduced-intensity or non-myeloablative.

In order to perform an allogeneic stem cell transplantation, an appropriate donor of hematopoietic stem cells must be located. At the present time, it is important that the donor be matched with the patient (recipient) at the HLA loci (HLA A, B, C, DR) that specify major histocompatibility antigens. These donors may be full siblings or unrelated donors recruited from a large panel of anonymous volunteer donors through the National Marrow Donor Program (NMDP). Cells derived from umbilical cord blood units may also be used. The hematopoietic stem cells are collected from the donor either from the bone marrow, or, more commonly through leukopheresis of the blood after mobilizing hematopoietic stem cells from the bone marrow with filgrastim (G-CSF). They are infused intravenously into the recipient and may be given either fresh or after cryopreservation and thawing. The hematopoietic stem cells home to the bone marrow and start to grow.

In the allogeneic stem cell transplantation procedure, the patient is treated with the “preparative regimen” with two purposes: to treat the underlying cancer and to sufficiently suppress the patient’s immune system so that the hematopoietic stem cells from the donor will not be rejected. As with autologous stem cell transplantation, the hematopoietic stem cells are infused after the preparative chemotherapy has been given and has had a chance to clear from the body. There is a period of pancytopenia in the gap between the effect of the chemotherapy given to the patient and the time it takes the infused hematopoietic stem cells to grow into bone marrow, usually 10–14 days.

A major difference between autologous and allogeneic SCT is that in the allogeneic setting, the patient becomes a “chimera,” that is, a mixture of self and non-self. In allogeneic stem cell transplantation, the infused cells contain mature cells of the donor immune system, and the infused hematopoietic stem cells will grow into bone marrow and blood cells as well as cells of the new immune system. Unless the donor is an identical twin (called a “syngeneic transplant”), the donor’s immune system will recognize the patient’s tissues as foreign and initiate the “graft-versus-host” (GVH) reaction, the graft from the donor reacting against the patient (host). This GVH is the major cause of morbidity and mortality during an allogeneic SCT. Immunosuppression must be given during allogeneic stem cell transplantation to reduce the incidence and severity of GVH reaction. The most common regimen used for GVH prophylaxis is a combination of a calcineurin inhibitor

(cyclosporine or tacrolimus) plus methotrexate. In contrast to the experience with solid organ transplant in which life-long immunosuppression is required to prevent rejection of the transplanted organ, in most cases of allogeneic stem cell transplantation, the immunosuppression can be tapered and discontinued 6 or more months after transplantation.

However, there is an important and positive side to the alloimmune reaction of the donor against the host. If there are residual cancer cells present in the patient that have survived the high-dose chemoradiotherapy of the preparative regimen, these residual cancer cells can be recognized as foreign by the donor immune system and killed in the GVM effect. Even cells that are resistant to chemotherapy may not be resistant to killing through the immune system. Depending on the type of cancer cell, this can be a highly effective mechanism of long-term cancer control. Based on the understanding of how important GVM can be, the allogeneic stem cell transplantation procedure can be modified by reducing the intensity of the preparative regimen, relying for cure more on the GVM effect and less on the high-dose chemotherapy. In these “reduced-intensity” allogeneic stem cell transplantation procedures, the preparative regimen still has to suppress the patient’s immune system enough to avoid rejection of the donor hematopoietic stem cells, but these types of transplants can be far less toxic than full-dose transplants. Based on this greatly reduced short-term toxicity, the potential benefits of allogeneic stem cell transplantation have been extended to older adults (age 60–75) and to those with comorbid conditions that would have been a contraindication to standard full-dose stem cell transplantation.

Allogeneic stem cell transplantation is the treatment of choice for high-risk acute leukemias, and in many cases will be the only potentially curative treatment. Allogeneic stem cell transplantation is the only curative treatment for myelodysplasia and for CML, although its use in CML has been greatly curtailed based on the effectiveness of imatinib and related tyrosine kinase inhibitors. Allogeneic stem cell transplantation is also the only definitive treatment for most cases of severe aplastic anemia. The use of reduced-intensity allogeneic stem cell transplantation has led to its exploration in the management of difficult cases of CLL and follicular lymphoma, and it will likely play a major role in these diseases. Given the age of many patients with AML and myelodysplasia, this procedure will likely play an important role in these diseases as well.

- Deeg HJ et al. Who is fit for allogeneic transplantation? *Blood*. 2010 Dec 2;116(23):4762–70. [PMID: 20702782]
- Dreger P. Allotransplantation for chronic lymphocytic leukemia. *Hematology Am Soc Hematol Educ Program*. 2009:602–9. [PMID: 20008245]
- Horwitz ME. Reduced intensity versus myeloablative allogeneic stem cell transplantation for the treatment of acute myeloid leukemia, myelodysplastic syndrome and acute lymphoid leukemia. *Curr Opin Oncol*. 2011 Mar;23(2):197–202. [PMID: 21252669]
- Jenq RR et al. Allogeneic haematopoietic stem cell transplantation: individualized stem cell and immune therapy of cancer. *Nat Rev Cancer*. 2010 Mar;10(3):213–21. [PMID: 20168320]

Sorror ML. Comorbidities and hematopoietic cell transplantation outcomes. *Hematology Am Soc Hematol Educ Program*. 2010;2010:237–47. [PMID: 21239800]

BLOOD TRANSFUSIONS

RED BLOOD CELL TRANSFUSIONS

Red blood cell transfusions are given to raise the hematocrit levels in patients with anemia or to replace losses after acute bleeding episodes.

► Preparations of Red Cells for Transfusion

Several types of preparations containing red blood cells are available.

A. Fresh Whole Blood

The advantage of whole blood for transfusion is the simultaneous presence of red blood cells, plasma, and fresh platelets. Fresh whole blood is never absolutely necessary, since all the above components are available separately. The major indications for use of whole blood are cardiac surgery or massive hemorrhage when more than 10 units of blood is required in a 24-hour period.

B. Packed Red Blood Cells

Packed red cells are the component most commonly used to raise the hematocrit. Each unit has a volume of about 300 mL, of which approximately 200 mL consists of red blood cells. One unit of packed red cells will usually raise the hematocrit by approximately 4%. The expected rise in hematocrit can be calculated using an estimated red blood cell volume of 200 mL/unit and a total blood volume of about 70 mL/kg. For example, a 70-kg man will have a total blood volume of 4900 mL, and each unit of packed red blood cells will raise the hematocrit by 200% 4900, or 4%.

C. Leukocyte-Poor Blood

Patients with severe leukoagglutinin reactions to packed red blood cells may require depletion of white blood cells and platelets from transfused units. White blood cells can be removed either by centrifugation or by washing. Preparation of leukocyte-poor blood is expensive and leads to some loss of red cells. Most blood products now are leukoreduced in-line during acquisition and are thus prospectively leukocyte-poor.

D. Frozen Packed Red Blood Cells

Packed red blood cells can be frozen and stored for up to 3 years, but the technique is cumbersome and expensive, and frozen blood should be used sparingly. The major application is for the purpose of maintaining a supply of rare blood types. Patients with such types may donate units for autologous transfusion should the need arise. Frozen red cells are also occasionally needed for patients with severe leukoagglutinin reactions or anaphylactic reactions

to plasma proteins, since frozen blood has essentially all white blood cells and plasma components removed.

E. Autologous Packed Red Blood Cells

Patients scheduled for elective surgery may donate blood for autologous transfusion. These units may be stored for up to 35 days before freezing is necessary.

► Compatibility Testing

Before transfusion, the recipient's and the donor's blood are typed and cross-matched to avoid hemolytic transfusion reactions. Although many antigen systems are present on red blood cells, only the ABO and Rh systems are specifically tested prior to all transfusions. The A and B antigens are the most important, because everyone who lacks one or both red cell antigens has IgM isoantibodies (called isoagglutinins) against the missing antigen or antigens in his or her plasma. The isoagglutinins activate complement and can cause rapid intravascular lysis of the incompatible red blood cells. In emergencies, type O/Rh-negative blood can be given to any recipient, but only packed cells should be given to avoid transfusion of donor plasma containing anti-A or anti-B antibodies.

The other important antigen routinely tested for is the D antigen of the Rh system. Approximately 15% of the population lack this antigen. In patients lacking the antigen, anti-D antibodies are not naturally present, but the antigen is highly immunogenic. A recipient whose red cells lack D and who receives D-positive blood may develop anti-D antibodies that can cause severe lysis of subsequent transfusions of D-positive red cells.

Blood typing includes a crossmatch assay of recipient serum for unusual alloantibodies directed against donor red blood cells by mixing recipient serum with panels of red blood cells representing commonly occurring minor antigens. The screening is particularly important if the recipient has had previous transfusions or pregnancy.

► Hemolytic Transfusion Reactions

The most severe hemolytic transfusion reactions are acute (temporally related to the transfusion), involving incompatible mismatches in the ABO system and are isoagglutinin-mediated. Most of these cases are due to clerical errors and mislabeled specimens. With current compatibility testing and double check clerical systems, the risk of an acute hemolytic reaction is 1 in 76,000 transfused units of red blood cells. Death from acute hemolytic reaction occurs in 1 in 1.8 million transfused units. Hemolysis is rapid and intravascular, releasing free hemoglobin into the plasma. The severity of these reactions depends on the dose of red blood cells given. The most severe reactions are those seen in surgical patients under anesthesia.

Delayed hemolytic transfusion reactions are caused by minor red blood cell antigen discrepancies and are typically less severe. The hemolysis usually takes place at a slower rate and is mediated by IgG alloantibodies causing extravascular red blood cell destruction. These transfusion reactions may be delayed for 5–10 days after transfusion. In such cases, the recipient has received red blood cells

containing an immunogenic antigen, and in the time since transfusion, a new alloantibody has formed. The most common antigens involved in such reactions are Duffy, Kidd, Kell, and C and E loci of the Rh system. The current risk of a delayed hemolytic transfusion reaction is 1 in 6000 transfused units of red blood cells.

A. Symptoms and Signs

Major acute hemolytic transfusion reactions cause fever and chills, with backache and headache. In severe cases, there may be apprehension, dyspnea, hypotension, and cardiovascular collapse. Patients under general anesthesia will not manifest such signs, and the first indication may be generalized bleeding and oliguria. *The transfusion must be stopped immediately.* In severe cases, acute DIC, acute kidney failure from tubular necrosis, or both can occur. Death occurs in 4% of acute hemolytic reactions due to ABO incompatibility.

Delayed hemolytic transfusion reactions are usually without symptoms or signs.

B. Laboratory Findings

When an acute hemolytic transfusion episode is suspected, the identification of the recipient and of the transfusion product bag should be rechecked. The transfusion product bag with its pilot tube must be returned to the blood bank, and a fresh sample of the recipient's blood must accompany the bag for retyping and re-cross-matching of donor and recipient blood samples.

The hematocrit will fail to rise by the expected amount. Coagulation studies may reveal evidence of acute kidney injury or DIC. The plasma free hemoglobin in the recipient will be elevated resulting in hemoglobinuria.

In cases of delayed hemolytic reactions, the hematocrit will fall and the indirect bilirubin will rise. In these cases, the new offending alloantibody is easily detected in the patient's serum.

C. Treatment

If an acute hemolytic transfusion reaction is suspected, the transfusion should be stopped at once. The patient should be vigorously hydrated to prevent acute tubular necrosis. Forced diuresis with mannitol may help prevent kidney injury.

▶ Leukoagglutinin Reactions

Most transfusion reactions are not hemolytic but represent reactions to antigens present on transfused passenger leukocytes in patients who have been sensitized to leukocyte antigens through previous transfusions or pregnancy. Transfusion products relatively rich in leukocyte-rich plasma, especially platelets, are most likely to cause this. Moderate to severe leukoagglutinin reactions occur in 1% of red blood cell transfusions and 2% of platelet transfusions. Most commonly, patients will develop fever and chills within 12 hours after transfusion. In severe cases, cough and dyspnea may occur and the chest radiograph may show transient pulmonary infiltrates. Because no

hemolysis is involved, the hematocrit rises by the expected amount despite the reaction.

Leukoagglutinin reactions may respond to acetaminophen (500–650 mg) and diphenhydramine (25 mg); corticosteroids, such as hydrocortisone (1 mg/kg), are also of value. Overall, leukoagglutination reactions are diminishing through the routine use of in-line leukotrapping during blood donation (ie, leukoreduced blood). Patients experiencing severe leukoagglutination episodes despite receiving leukoreduced blood transfusions should receive leukopoor or washed blood products.

▶ Hypersensitivity Reactions

Urticaria or bronchospasm may develop during or soon after a transfusion. These reactions are almost always due to exposure to allogeneic plasma proteins rather than to leukocytes. The risk is low enough that the routine use of antihistamine premedications has been eliminated before packed red blood cell transfusions. A hypersensitivity reaction, including anaphylactic shock, may develop in patients who are IgA deficient because of antibodies to IgA within the plasma component of the transfused blood product. Patients with such reactions may require transfusion of washed or even frozen red blood cells to avoid future severe reactions.

▶ Contaminated Blood

Blood products can be contaminated with bacteria. Platelets are especially prone to bacterial contamination because they cannot be refrigerated. Bacterial contamination occurs in 1 of every 2000 to 5000 platelet donations. Receipt of a blood product contaminated with gram-positive bacteria will cause fever and bacteremia but rarely causes a sepsis syndrome. Receipt of a blood product contaminated with gram-negative bacteria often causes septic shock, acute DIC, and acute kidney injury due to the transfused endotoxin and is usually fatal. Strategies to reduce bacterial contamination include enhanced venipuncture site skin cleansing, diverting of the first few milliliters of donated blood, use of single donor blood products (as opposed to pooled donor products), and point of care rapid bacterial screening in order to discard questionable units. The current risk of a septic transfusion reaction from a culture-negative unit of single-donor platelets is 1 in 60,000. In any patient who may have received contaminated blood, the recipient and the donor blood bag should both be cultured, and antibiotics should be given immediately to the recipient.

▶ Infectious Diseases Transmitted Through Transfusion

Despite the use of only volunteer blood donors and the routine screening of blood, transfusion-associated viral diseases remain a problem. All blood products (red blood cells, platelets, plasma, cryoprecipitate) can transmit viral diseases. All blood donors are screened with questionnaires designed to detect (and therefore reject) donors at high risk for transmitting infectious diseases. All blood is screened for hepatitis B surface antigen, antibody to hepatitis B core

antigen, syphilis, p24 antigen and antibody to HIV, antibody to hepatitis C virus (HCV), antibody to human T cell lymphotropic/leukemia virus (HTLV), and nucleic acid testing for West Nile virus. Clinical trials are examining the value of screening blood donors for *Trypanosoma cruzi*, the infectious agent that causes Chagas disease.

With improved screening, the risk of posttransfusion hepatitis has steadily decreased after the receipt of screened 'negative' blood products. The risk of acquiring hepatitis B is now so low that it is difficult to measure. The risk of hepatitis C acquisition is 1 in 1.5 to 2 million transfused units. The risk of HIV acquisition is 1 in 2 million transfused units. Unscreened leukoreduced blood products appear to be equivalent to CMV screened-negative blood products in terms of the risk of CMV transmission to a CMV-seronegative recipient.

▶ Transfusion Graft-Versus-Host Disease

Allogeneic passenger lymphocytes within transfused blood products will engraft in some recipients and mount an alloimmune attack against tissues expressing discrepant HLA-antigens causing graft-versus-host disease (GVHD). The symptoms and signs of transfusion-associated GVHD include fever, rash, diarrhea, hepatitis, lymphadenopathy, and severe pancytopenia. The outcome is usually fatal. Transfusion-associated GVHD occurs most often in recipients with immune defects, malignant lymphoproliferative disorders, solid tumors being treated with chemotherapy or immunotherapy, treatment with immunosuppressive medications (especially purine analogs such as fludarabine), or older patients undergoing cardiac surgery. HIV infection alone does not seem to increase the risk. The use of leukoreduced blood products is inadequate to prevent transfusion-associated GVHD. This complication can be avoided by irradiating blood products (25 Gy or more) to prevent lymphocyte proliferation in recipients at high risk for transfusion-associated GVHD.

▶ Transfusion-Related Acute Lung Injury

Transfusion-related acute lung injury (TRALI) occurs in 1 in every 5000 transfused units of blood products. It has been associated with allogeneic antibodies in the donor plasma component that bind to recipient leukocyte antigens, including HLA antigens and other granulocyte- and monocyte-specific antigens. In 20% of cases, no antileukocyte antibodies are identified raising the concern that bioactive lipids or other substances that accumulate while the blood product is in storage can also mediate TRALI in susceptible recipients. TRALI is clinically defined as non-cardiogenic pulmonary edema after a blood product transfusion without other explanation, and transfused surgical and critically ill patients seem most susceptible. Ten to 20% of female blood donors and 1–5% of male blood donors have antileukocyte antibodies in their serum. The risk of TRALI is reduced through the use of male only plasma donors, when possible. There is no specific treatment for TRALI, only supportive care.

PLATELET TRANSFUSIONS

Platelet transfusions are indicated in cases of thrombocytopenia due to decreased platelet production. They are of some use in immune thrombocytopenia when active bleeding is evident, but the clearance of transfused platelets is rapid as they are exposed to the same pathophysiologic forces as the recipient's endogenous platelets. The risk of spontaneous bleeding rises when the platelet count falls to < 80,000/mcL, and the risk of life-threatening bleeding increases when the platelet count is < 5000/mcL. Because of this, prophylactic platelet transfusions are often given at these very low levels, usually when < 10,000/mcL. Platelet transfusions are also given prior to invasive procedures or surgery in thrombocytopenic patients, and the goal is often to raise the platelet count to 50,000/mcL or more.

Platelets for transfusion are most commonly derived from single donor apheresis collections (roughly the equivalent to the platelets recovered from six donations of whole blood). A single donor unit of platelets should raise the platelet count by 50,000 to 60,000 platelets per mcL in a transfusion-naïve recipient without hypersplenism or ongoing platelet consumptive disorder. Transfused platelets typically last for 2 or 3 days. Platelet transfusion responses may be suboptimal with poor platelet increments and short platelet survival times. This may be due to one of several causes, including fever, sepsis, splenomegaly, DIC, large body habitus, low platelet dose in the transfusion, or platelet alloimmunization (from prior transfusions, prior pregnancy or prior organ transplantation). Many, but not all, alloantibodies causing platelet destruction are directed at HLA antigens. Patients requiring long periods of platelet transfusion support should be monitored to document adequate responses to transfusions so that the most appropriate product can be used. Patients requiring ongoing platelet transfusions who become alloimmunized may benefit from HLA-matched platelets derived from either volunteer donors or family members. Techniques of cross-matching platelets have been developed and appear to identify suitable volunteer platelet donors (nonreactive with the patient's serum) without the need for HLA typing. Leukocyte reduction of platelets has been shown to delay the onset of alloimmunization in multiply transfused recipients.

GRANULOCYTE TRANSFUSIONS

Granulocyte transfusions are seldom indicated and have largely been replaced by the use of myeloid growth factors (G-CSF and GM-CSF) that speed neutrophil recovery after myelosuppressive chemotherapy. However, they may be beneficial in patients with profound neutropenia (<100/mcL) who have gram-negative sepsis, progressive soft tissue infection, or invasive fungal infection despite optimal antibiotic therapy. In these cases, it is clear that progressive infection is due to failure of host defenses, generally neutropenia combined with disruption of natural barriers (such as the oral or gastrointestinal mucosa or the skin). In such situations, daily granulocyte transfusions may be considered and continued until the neutrophil

count rises to above 500/mcL. Such granulocytes must be derived from ABO-matched donors. Although HLA matching is not necessary, it is preferred, since patients with alloantibodies to donor white blood cells will have severe reactions and little benefit. About two-thirds of appropriately selected recipients benefit from granulocyte transfusions.

The donor cells usually contain lymphocytes capable of producing GVHD in HLA-incompatible recipients whose immunocompetence is impaired. Irradiation of the granulocyte products will prevent lymphocyte proliferation and thus prevent GVHD without functional harm to the granulocytes or platelets contained within. Granulocyte-transfusions are not commonly used due to the labor involved, the cost, the need to give myeloid growth factor injections to a normal donor to facilitate the collection of the granulocytes from peripheral blood, and the unpredictability of benefit.

TRANSFUSION OF PLASMA COMPONENTS

Fresh-frozen plasma is available in units of approximately 200 mL. Fresh frozen plasma contains normal levels of all coagulation factors (about 1 unit/mL of each factor). Fresh frozen plasma is used to correct coagulation factor deficiencies and to treat thrombotic thrombocytopenia purpura or hemolytic-uremic syndrome.

Cryoprecipitate is made from fresh plasma by cooling the plasma to 4°C and collecting the precipitate. One unit of cryoprecipitate has a volume of approximately 20 mL and contains approximately 250 mg of fibrinogen and between 80 and 100 units of factor VIII and von Willebrand factor. Cryoprecipitate is used to supplement fibrinogen in cases of congenital hypofibrinogenemia or, more commonly,

acute DIC. One unit of cryoprecipitate will raise the fibrinogen level by about 8 mg/dL. Cryoprecipitate is sometimes used to temporarily correct the acquired platelet dysfunction associated with kidney disease.

- Allain JP et al. Transfusion-transmitted infectious diseases. *Biologicals*. 2009 Apr;37(2):71–7. [PMID: 19231236]
- Al-Tanbal H et al. The value and practicality of granulocyte transfusion: a single oncology centre experience. *Transfus Med*. 2010 Jun;20(3):160–8. [PMID: 20070613]
- Alter HJ et al. The hazards of blood transfusion in historical perspective. *Blood*. 2008 Oct 1;112(7):2617–26. [PMID: 18809775]
- Benson AB et al. Transfusion-related acute lung injury (TRALI): a clinical review with emphasis on the critically ill. *Br J Haematol*. 2009 Nov;147(4):431–43. [PMID: 19663827]
- Ohsaka A et al; Japan Society of Transfusion Medicine and Cell Therapy, Granulocyte Transfusion Task Force. Guidelines for safety management of granulocyte transfusion in Japan. *Int J Hematol*. 2010 Mar;91(2):201–8. [PMID: 20146029]
- Roback JD et al; American Association for the Study of Liver; American Academy of Pediatrics; United States Army; American Society of Anesthesiology; American Society of Hematology. Evidence-based practice guidelines for plasma transfusion. *Transfusion*. 2010 Jun;50(6):1227–39. [PMID: 20345562]
- Slichter SJ et al. Dose of prophylactic platelet transfusions and prevention of hemorrhage. *N Engl J Med*. 2010 Feb 18;362(7):600–13. [PMID: 20164484]
- Sokolovic M et al. Transfusion therapy and acute lung injury. *Expert Rev Respir Med*. 2010 Jun;4(3):387–93. [PMID: 20524921]
- Valent J et al. Thrombocytopenia and platelet transfusions in patients with cancer. *Cancer Treat Res*. 2011;157:251–65. [PMID: 21052961]
- Vamvakas EC. Risk-reduction strategies for platelet transfusion in the United States. *Scientific World Journal*. 2011 Mar 7;11:624–40. [PMID: 21403979]

14

Disorders of Hemostasis, Thrombosis, & Antithrombotic Therapy

Patrick F. Fogarty, MD
Tracy Minichiello, MD

In assessing patients for defects of hemostasis, the clinical context must be considered carefully (Table 14–1). Heritable defects are suggested by bleeding that begins in infancy or childhood, is recurrent, and occurs at multiple anatomic sites, although many other patterns of presentation are possible. Acquired disorders of hemostasis more typically are associated with bleeding that begins later in life and may be related to introduction of medications (eg, agents that affect platelet activity) or to onset of underlying medical conditions (such as renal failure or myelodysplasia), or may be idiopathic. Importantly, however, a sufficient hemostatic challenge (such as major trauma) may produce excessive bleeding even in individuals with completely normal hemostasis.

Fogarty PF et al. Disorders of Hemostasis I: Coagulation. In: Rodgers GP et al (editors). *The Bethesda Handbook of Clinical Hematology*. Philadelphia: Lippincott Williams and Wilkins, 2010.

PLATELET DISORDERS

THROMBOCYTOPENIA

The causes of thrombocytopenia are shown in Table 14–2. The age of the patient and presence of any comorbid conditions may help direct the diagnostic work-up.

The risk of spontaneous bleeding (including petechial hemorrhage and bruising) does not typically increase appreciably until the platelet count falls below 10,000–20,000/mcL, although patients with dysfunctional platelets may bleed with higher platelet counts. Suggested platelet counts to prevent spontaneous bleeding or to provide adequate hemostasis around the time of invasive procedures are found in Table 14–3.

DECREASED PLATELET PRODUCTION

1. Bone Marrow Failure



ESSENTIALS OF DIAGNOSIS

- ▶ Bone marrow failure states may be congenital or acquired.
- ▶ Most congenital marrow failure disorders present in childhood.

▶ General Considerations

Congenital conditions that cause thrombocytopenia include amegakaryocytic thrombocytopenia, the thrombocytopenia-absent radius (TAR) syndrome, and Wiskott-Aldrich syndrome; these disorders usually feature isolated thrombocytopenia, whereas patients with Fanconi anemia and dyskeratosis congenita typically have depressions in other blood cell counts as well.

Acquired causes of bone marrow failure leading to thrombocytopenia include acquired aplastic anemia, myelodysplastic syndrome (MDS), and acquired amegakaryocytic thrombocytopenia. Unlike aplastic anemia, MDS is more common among older patients.

▶ Clinical Findings

Acquired aplastic anemia typically presents with reductions in multiple blood cell lines; a bone marrow biopsy subsequently reveals hypocellularity. **Myelodysplasia** may also present as cytopenias with variable marrow cellularity, at times mimicking aplastic anemia; however, the presence of macrocytosis, ringed sideroblasts on iron staining of the bone marrow aspirate, dysplasia of hematopoietic

Table 14-1. Evaluation of the bleeding patient.

Necessary Component of Evaluation	Diagnostic Correlate
Location	
Mucocutaneous (bruises, petechiae, gingival, nosebleeds)	Likely qualitative/quantitative platelet defects
Joints, soft tissue	Likely disorders of coagulation factors
Onset	
Infancy/childhood	Suggests heritable condition
Adulthood	Suggests milder heritable condition or acquired defect of hemostasis (eg, ITP, medication-related)
Clinical context	
Postsurgical	Anatomic/surgical defect must be ruled out
Pregnancy	vWD, HELLP syndrome, ITP, acquired factor VIII inhibitor
Sepsis	May indicate DIC
Patient taking anticoagulants	Rule out excessive anticoagulation
Personal history¹	
Absent	Suggests acquired rather than congenital defect, or anatomic/surgical defect (if applicable)
Present	Suggests established acquired defect or congenital disorder
Family history	
Absent	Suggests acquired defect or no defect of hemostasis
Present	May signify hemophilia A or B, vWD, other heritable bleeding disorders

¹Includes evaluation of prior spontaneous bleeding, as well as excessive bleeding with circumcision, menses, dental extractions, trauma, minor procedures (eg, endoscopy, biopsies) and major procedures (surgery).

DIC, disseminated intravascular coagulation; HELLP, hemolysis, elevated liver enzymes, low platelets; ITP, immune thrombocytopenia; vWD, von Willebrand disease.

elements, or cytogenetic abnormalities (especially monosomy 5 or 7, and trisomy 8) are more suggestive of MDS. Thrombocytopenia in patients with MDS is usually mild to moderate, rather than severe.

► Differential Diagnosis

Adult patients with acquired amegakaryocytic thrombocytopenia have isolated thrombocytopenia and reduced or absent megakaryocytes in the bone marrow, which (along with failure to respond to immunomodulatory regimens typically administered in immune thrombocytopenia [ITP]) distinguishes them from patients with ITP.

Table 14-2. Causes of thrombocytopenia.

Decreased production of platelets
Congenital bone marrow failure (eg, Fanconi anemia, Wiskott-Aldrich syndrome)
Acquired bone marrow failure (eg, aplastic anemia, myelodysplasia)
Exposure to chemotherapy, irradiation
Marrow infiltration (neoplastic, infectious)
Nutritional (deficiency of vitamin B ₁₂ , folate, iron; alcohol)
Increased destruction of platelets
Immune thrombocytopenia (including hepatitis C virus- and HIV-related, ¹ and drug-induced)
Heparin-induced thrombocytopenia
Thrombotic microangiopathy
Disseminated intravascular coagulation
Posttransfusion purpura
Neonatal alloimmune thrombocytopenia
Mechanical (aortic valvular dysfunction; extracorporeal bypass)
von Willebrand disease, type 2B
Hemophagocytosis
Increased sequestration of platelets
Hypersplenism (eg, related to cirrhosis, myeloproliferative disorders, lymphoma)
Other conditions causing thrombocytopenia
Gestational thrombocytopenia
Bernard-Soulier syndrome, gray platelet syndrome, May-Hegglin anomaly
Pseudothrombocytopenia

¹HIV-related thrombocytopenia as well as disorders such as some cases of immune thrombocytopenia and cyclic thrombocytopenia may feature both decreased production and increased clearance of platelets.

► Treatment

A. Congenital Conditions

Treatment is varied but may include blood product support, blood cell growth factors, androgens, and (some cases) allogeneic hematopoietic progenitor cell transplantation.

B. Acquired Conditions

Patients with severe aplastic anemia are treated with allogeneic hematopoietic progenitor cell transplantation, which

Table 14-3. Desired platelet count ranges.

Clinical Scenario	Platelet count (/mcl)
Prevention of spontaneous mucocutaneous bleeding	> 10,000–20,000
Insertion of central venous catheters	> 20,000–50,000 ¹
Administration of therapeutic anticoagulation	> 30,000–50,000
Minor surgery and selected invasive procedures ²	> 50,000–80,000
Major surgery	> 80,000–100,000

¹A platelet target within the higher range of the reference is required for tunneled catheters.

²Such as endoscopy with biopsy.

is the preferred therapy for patients younger than age 40 who have an HLA-matched sibling donor (see Chapter 13), or with immunosuppression, which is the preferred therapy for older patients and those who lack an HLA-matched sibling donor.

Treatment of thrombocytopenia due to MDS, if clinically significant bleeding is present or if the risk of bleeding is high, is limited to chronic transfusion of platelets in most instances (Table 14–3). Newer immunomodulatory agents such as lenalidomide do not produce increases in the platelet count in most patients. Use of the thrombopoietin receptor agonists, eltrombopag and romiplostim, is not recommended in patients with MDS due to the potential for accelerated development of leukemia.

Akhtari M. When to treat myelodysplastic syndromes. *Oncology (Williston Park)*. 2011 May;25(6):480–6. [PMID: 21717901]
 Guinan EC. Diagnosis and management of aplastic anemia. *Hematology Am Soc Hematol Educ Program*. 2011;2011:76–81. [PMID: 22160015]

2. Bone Marrow Infiltration

Replacement of the normal bone marrow elements by leukemic cells, myeloma, lymphoma, or other tumors or by infections (such as mycobacterial disease or ehrlichiosis) may cause thrombocytopenia; however, abnormalities in other blood cell lines are also usually present. These entities are easily diagnosed after examining the bone marrow biopsy and aspirate or determining the infecting organism from an aspirate specimen. Treatment of thrombocytopenia is directed at eradication of the underlying infiltrative disorder, but platelet transfusion may be required if clinically significant bleeding is present.

3. Chemotherapy & Irradiation

Chemotherapeutic agents and irradiation may lead to thrombocytopenia by direct toxicity to megakaryocytes, hematopoietic progenitor cells, or both. The severity and duration of chemotherapy-induced depressions in the platelet count are determined by the specific regimen used, although the platelet count typically resolves more slowly following a chemotherapeutic insult than does neutropenia or anemia, especially if multiple cycles of treatment have been given. Until recovery occurs, patients may be supported with transfused platelets if bleeding is present or the risk of bleeding is high (Table 14–3). Clinical trials to determine the role of the platelet growth factors eltrombopag and romiplostim in the treatment of chemotherapy-induced thrombocytopenia are ongoing.

4. Nutritional Deficiencies

Thrombocytopenia, typically in concert with anemia, may be observed when a deficiency of folate (that may accompany alcoholism) or vitamin B₁₂ is present (concomitant neurologic findings are common). In addition, thrombocytopenia rarely can occur in very severe iron deficiency. Replacing the deficient vitamin or mineral results in improvement in the platelet count.

5. Cyclic Thrombocytopenia

Cyclic thrombocytopenia is a very rare disorder that produces cyclic oscillations of the platelet count, usually with a periodicity of 3–6 weeks. The exact pathophysiologic mechanisms responsible for the condition may vary from patient to patient. Severe thrombocytopenia and bleeding typically occur at the platelet nadir. Oral contraceptive medications, androgens, azathioprine, and thrombopoietic growth factors have been used successfully in the management of cyclic thrombocytopenia.

Masoodi I et al. Hemorrhagic manifestation of megaloblastic anemia: report of two cases and literature review. *Blood Coagul Fibrinolysis*. 2011 Apr;22(3):234–5. [PMID: 21297452]

INCREASED PLATELET DESTRUCTION

1. Immune Thrombocytopenia



ESSENTIALS OF DIAGNOSIS

- ▶ Isolated thrombocytopenia.
- ▶ Assess for any new causative medications and HIV and hepatitis C infections.
- ▶ ITP is a diagnosis of exclusion.

▶ General Considerations

ITP is an autoimmune condition in which pathogenic antibodies bind platelets, resulting in accelerated platelet clearance. Contrary to the historical view of the disorder, it is now recognized that many patients with ITP also lack appropriate compensatory platelet production. The disorder is primary and idiopathic in most adult patients, although it can be associated with connective tissue disease (such as lupus), lymphoproliferative disease (such as lymphoma), medications (see below), and infections (such as hepatitis C virus and HIV infections). Targets of antiplatelet antibodies include glycoproteins IIb/IIIa and Ib/IX on the platelet membrane, although antibodies are demonstrable in only two-thirds of patients. In addition to production of antiplatelet antibodies, HIV and hepatitis C virus may lead to thrombocytopenia through additional mechanisms (for instance, by direct suppression of platelet production [HIV] and cirrhosis-related splenomegaly [hepatitis C virus]).

▶ Clinical Findings

A. Symptoms and Signs

Mucocutaneous bleeding manifestations may be present, depending on the platelet count. Spontaneous bruising, nosebleeds, gingival bleeding, or other types of hemorrhage generally do not occur until the platelet count has fallen below 20,000–30,000/mcL. Individuals with secondary ITP (such as due to collagen vascular disease, HIV or HCV

infection, or lymphoproliferative malignancy) may have additional disease-specific findings.

B. Laboratory Findings


Typically, patients have isolated thrombocytopenia. If bleeding has occurred, anemia may also be present. Hepatitis virus B and C and HIV infections should be excluded by serologic testing. Bone marrow should be examined in patients with unexplained cytopenias, in patients older than 60 years, or in those who did not respond to primary ITP-specific therapy. Megakaryocyte abnormalities and hypocellularity or hypercellularity are not characteristic of ITP. If there are clinical findings suggestive of a lymphoproliferative malignancy, a CT scan should be performed. In the absence of such findings, otherwise asymptomatic patients with unexplained isolated thrombocytopenia of recent onset may be considered to have ITP.

► Treatment

Only individuals with platelet counts < 20,000–30,000/mcL or those with significant bleeding should be treated; the

remainder may be monitored serially for progression. The mainstay of initial treatment of new-onset primary ITP is a short course of corticosteroids with or without intravenous immunoglobulin (IVIG) or anti-D (WinRho) (Figure 14–1). Responses are generally seen within 3–5 days of initiating treatment. Platelet transfusions may be given concomitantly if active bleeding is present.

Although over two-thirds of patients with ITP respond to initial treatment, most relapse following reduction of the corticosteroid dose. Patients with a persistent platelet count < 30,000/mcL or clinically significant bleeding are appropriate candidates for second-line treatments (Figure 14–1). These treatments are chosen empirically, bearing in mind potential toxicities and the patient's preference. Anti-D (WinRho) or IVIG temporarily increases platelet counts (duration, 3 weeks or longer), although serial anti-D treatment (platelet counts < 30,000/mcL) may allow adult patients to delay or avoid splenectomy. The monoclonal anti-B cell antibody rituximab leads to initial responses in about 50% of adults with corticosteroid-refractory chronic ITP, decreasing to 20% at 5 years. The **thrombopoietin receptor agonists**, **romiplostim** (administered subcutaneously weekly) and



¹ Use in nonsplenectomized, Rh blood type-positive, nonanemic patients only.

² Both lymphoma-type chemotherapy and single-agent vincristine have been used successfully in refractory cases of ITP.

▲ **Figure 14–1.** Management of immune thrombocytopenia (ITP).

eltrombopag (taken orally daily), are approved for use in adult patients with chronic ITP who have not responded durably to corticosteroids, IVIG, or splenectomy and must be taken indefinitely to maintain the platelet response. Splenectomy has a durable response rate of over 60% and may be considered for cases of severe thrombocytopenia that fail to respond durably to initial treatment or are refractory to second-line agents; patients should receive pneumococcal, *Haemophilus influenzae* type b, and meningococcal vaccination at least 2 weeks before the procedure. If available, laparoscopic splenectomy is preferred. Additional treatments for ITP are found in Figure 14–1.

The goal of management of pregnancy-associated ITP is a platelet count of 10,000–30,000/mcL in the first trimester, > 30,000/mcL during the second or third trimester, and > 50,000/mcL prior to cesarean section or vaginal delivery. Moderate-dose oral prednisone or intermittent infusions of IVIG are standard. Splenectomy is reserved for failure to respond to these therapies and may be performed in the first or second trimester. The safety of platelet growth factors in pregnancy has not been formally evaluated.

For thrombocytopenia associated with HIV or hepatitis C virus, treatment of either infection leads to an amelioration in the platelet count in most cases, whereas refractory thrombocytopenia may be treated with infusion of IVIG or anti-D (HIV and hepatitis C virus), splenectomy (HIV), or interferon-alpha or eltrombopag (hepatitis C virus, including eradication). Treatment with corticosteroids is not recommended in hepatitis C virus infection.

▶ When to Refer

Chronic thrombocytopenia will develop in most adult patients with newly diagnosed ITP; therefore, all patients with ITP should be referred to a subspecialist for evaluation at the time of diagnosis.

▶ When to Admit

Patients with major hemorrhage or very severe thrombocytopenia associated with bleeding should be admitted and monitored in-hospital until the platelet count has risen to > 20,000–30,000/mcL and hemodynamic stability has been achieved.

Afdhal N et al. Thrombocytopenia associated with chronic liver disease. *J Hepatol*. 2008 Jun;48(6):1000–7. [PMID: 18433919]
 Bussel JB et al. Eltrombopag. *Cancer Treat Res*. 2011;157:289–303. [PMID: 21052963]
 Kuter DJ et al. Romiplostim or standard of care in patients with immune thrombocytopenia. *N Engl J Med*. 2010 Nov 11;363(20):1889–99. [PMID: 21067381]
 Provan D et al. International consensus report on the investigation and management of primary immune thrombocytopenia. *Blood*. 2010 Jan 14;115(2):168–86. [PMID: 19846889]
 Semple JW et al. Recent progress in understanding the pathogenesis of immune thrombocytopenia. *Curr Opin Hematol*. 2010 Nov;17(6):590–5. [PMID: 20739879]

2. Thrombotic Microangiopathy



ESSENTIALS OF DIAGNOSIS

- ▶ Microangiopathic hemolytic anemia and thrombocytopenia, in the absence of another plausible explanation, are sufficient for the diagnosis of TMA.
- ▶ Fever, neurologic abnormalities, and renal insufficiency may occur concurrently but are not required for diagnosis.
- ▶ Renal insufficiency occurs in hemolytic-uremic syndrome.

▶ General Considerations

The thrombotic microangiopathies (TMAs) include thrombotic thrombocytopenic purpura (TTP) and the hemolytic-uremic syndrome (HUS). These disorders are characterized by thrombocytopenia, due to the incorporation of platelets into thrombi in the microvasculature, and microangiopathic hemolytic anemia, which results from shearing of erythrocytes in the microcirculation.

In idiopathic TTP, autoantibodies against the ADAMTS-13 (a disintegrin and metalloproteinase with thrombospondin type 1 repeat, member 13) molecule, also known as the von Willebrand factor cleaving protease (vWFPC), leads to accumulation of ultra-large von Willebrand factor (vWF) multimers that bridge platelets and facilitate excessive platelet aggregation, leading to TTP. In some cases of pregnancy-associated TMA, an antibody to vWFPC is present. In contrast, the activity of the vWFPC in congenital TTP is decreased due to a mutation in the gene encoding the molecule. Atypical HUS, an additional thrombotic microangiopathy, is a chronic disorder that typically leads to renal failure. Mutations in complement genes (such as factor H, a complement regulator) account for the uncontrolled activation of complement that characterizes the condition. Damage to endothelial cells—such as the damage that occurs in endemic HUS due to presence of toxins from *Escherichia coli* (especially type O157:H7 or O145) or in the setting of cancer, hematopoietic stem cell transplantation, or HIV infection—may also lead to TMA. Certain drugs (eg, cyclosporine, quinine, ticlopidine, clopidogrel, mitomycin C, and bleomycin) have been associated with the development of TMA, possibly by promoting injury to endothelial cells, although inhibitory antibodies to ADAMTS-13 also have been demonstrated in some cases.

▶ Clinical Findings

A. Symptoms and Signs

Microangiopathic hemolytic anemia and thrombocytopenia are presenting signs in all patients with TTP and most patients with HUS; in a subset of patients with HUS, the platelet count remains in the normal range. Only approximately 25% of patients with TMA manifest all components of the so-called pentad of findings (microangiopathic hemolytic anemia, thrombocytopenia,

Table 14-4. Clinical features of thrombotic microangiopathy.

Parameter	Thrombotic Thrombocytopenic Purpura	Hemolytic-Uremic Syndrome
Microangiopathic hemolytic anemia	All patients	All patients
Thrombocytopenia	All patients	Most patients (may be mild/absent in a subset of patients)
Fever	75% of patients	Usually absent
Renal insufficiency	Mild/absent in some patients	All patients
Neurologic defects	Most patients	Present in less than half
Epidemiologic	Most cases in adults	Most cases in children
Historical	Idiopathic (minority of cases: antecedent viral illness or familial)	Antecedent hemorrhagic enteritis in most patients
Laboratory findings	Decreased activity of ADAMTS-13	Positive stool culture for <i>Escherichia coli</i> O157:H7; ADAMTS-13 activity usually normal

ADAMTS-13, a disintegrin and metalloproteinase with a thrombospondin type 1 repeat, member 13 (von Willebrand factor cleaving protease).

fever, renal insufficiency, and neurologic system abnormalities) (Table 14-4). Most patients (especially children) with HUS have a recent or current diarrheal illness. Neurologic manifestations, including headache, somnolence, delirium, seizures, paresis, and coma, may result from deposition of microthrombi in the cerebral vasculature. Atypical HUS typically presents in childhood.

B. Laboratory Findings

Laboratory features of TMA include those associated with microangiopathic hemolytic anemia (anemia, elevated lactate dehydrogenase [LD], elevated indirect bilirubin, decreased haptoglobin, reticulocytosis, negative direct antiglobulin test, and schistocytes on the blood smear); thrombocytopenia; elevated creatinine; positive stool culture for *E coli* O157:H7 or stool assays for Shiga-toxin producing *E coli* to detect non-O157:H7 such as *E coli* O145 (HUS only); reductions in vWF activity (idiopathic TTP); and mutations of genes encoding complement proteins (atypical HUS; specialized laboratory assessment). Notably, routine coagulation studies are within the normal range in most patients with TMA.

▶ Treatment

Immediate administration of plasma exchange is essential in most cases due to the mortality rate of > 95% without treatment. With the exception of children or adults with endemic diarrhea-associated HUS, who generally recover with supportive care only, plasma exchange must be initiated as soon as the diagnosis of TMA is suspected. Plasma exchange usually is administered once daily until the platelet count and LD have returned to normal for at least 2 days, after which the frequency of treatments may be tapered slowly while the platelet count and LD are monitored for relapse. In cases of insufficient response to once-daily plasma exchange, twice-daily treatments should be given. Fresh frozen plasma (FFP) may be administered if immediate access to plasma exchange is not available or in cases of familial TMA. *Platelet transfusions are contraindicated* in the

treatment of TMAs due to reports of worsening thrombotic microangiopathy, possibly due to propagation of platelet-rich microthrombi. In cases of documented life-threatening bleeding, however, platelet transfusions may be given slowly and after plasma exchange is underway. Red blood cell transfusions may be administered in cases of clinically significant anemia. Hemodialysis should be considered for patients with significant renal impairment.

In cases of relapse following initial treatment, plasma exchange should be reinstated. If ineffective, or in cases of primary refractoriness, second-line treatments may be considered including rituximab, corticosteroids, IVIG, vincristine, cyclophosphamide, and splenectomy.

Cases of atypical HUS may respond to plasma infusion initially, and serial infusions of the anti-complement C5 antibody eculizumab have produced sustained remissions in some patients. If irreversible renal impairment has occurred, hemodialysis or renal transplantation may be necessary.

▶ When to Refer

Consultation by a hematologist or transfusion medicine specialist familiar with plasma exchange is required at the time of presentation. Patients with refractory or relapsing TMA require ongoing care by a subspecialist.

▶ When to Admit

All patients with newly suspected or diagnosed TMA should be hospitalized initially.

Alvarez-Larrán A et al. Newly diagnosed versus relapsed idiopathic thrombotic thrombocytopenic purpura: a comparison of presenting clinical characteristics and response to treatment. *Ann Hematol.* 2009 Oct;88(10):973-8. [PMID: 19205654]

Caramazza D et al. Relapsing or refractory idiopathic thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: the role of rituximab. *Transfusion.* 2010 Dec;50(12):2753-60. [PMID: 20576013]

Nürnberg et al. Eculizumab for atypical hemolytic-uremic syndrome. *N Engl J Med.* 2009 Jan 29;360(5):542–4. [PMID: 19179328]

Stella CL et al. The diagnostic dilemma of thrombotic thrombocytopenic purpura/hemolytic uremic syndrome in the obstetric triage and emergency department: lessons from 4 tertiary hospitals. *Am J Obstet Gynecol.* 2009 Apr;200(4):381.e1–6. [PMID: 19110215]

Tschumi S et al. Eculizumab in atypical hemolytic uremic syndrome: long-term clinical course and histological findings. *Pediatr Nephrol.* 2011 Nov;26(11):2085–8. [PMID: 21877169]

3. Heparin-Induced Thrombocytopenia

ESSENTIALS OF DIAGNOSIS

- ▶ Thrombocytopenia within 5–10 days of exposure to heparin.
- ▶ Decline in baseline platelet count of 50% or greater.
- ▶ Thrombosis occurs in 50% of cases; bleeding is uncommon.

▶ General Considerations

Heparin-induced thrombocytopenia (HIT) is an acquired disorder that affects approximately 3% of patients who are exposed to unfractionated heparin and 0.6% of patients who are exposed to low-molecular-weight heparin (LMWH). The condition results from formation of IgG antibodies to heparin-platelet factor 4 (PF4) complexes; the antibodies then bind platelets, which activates them. Platelet activation leads to both thrombocytopenia and a pro-thrombotic state.

▶ Clinical Findings

A. Symptoms and Signs

Patients are usually asymptomatic, and due to the pro-thrombotic nature of HIT, bleeding usually does not occur. Thrombosis (at any venous or arterial site), however, may be detected in up to 50% of patients, up to 30 days post-diagnosis.

B. Laboratory Findings

A presumptive diagnosis of HIT is made when new-onset thrombocytopenia is detected in a patient (frequently a hospitalized patient) within 5–10 days of exposure to heparin; other presentations (eg, rapid-onset HIT) are less common. A decline of $\geq 50\%$ or more from the baseline platelet count is typical. Clinical prediction systems such as the 4T score may assist in assessment of pretest probability. Confirmation of the diagnosis can be obtained through a positive PF4-heparin antibody enzyme-linked immunosorbent assay (ELISA) or functional assay (such as serotonin release assay), or both. The magnitude of a positive ELISA result correlates with the clinical probability of HIT.

▶ Treatment

Treatment should be initiated as soon as the diagnosis of HIT is suspected, before results of laboratory testing is available.

Management of HIT (Table 14–5) involves the immediate discontinuation of all forms of heparin.

If thrombosis has not already been detected, duplex Doppler ultrasound of the lower extremities should be performed to rule out subclinical deep venous thrombosis. Despite thrombocytopenia, platelet transfusions are rarely necessary. Due to the substantial frequency of thrombosis among HIT patients, an alternative anticoagulant, typically a direct thrombin inhibitor (DTI) such as argatroban or lepirudin should be administered immediately. The DTI should be continued until the platelet count has recovered to at least 100,000/mcL, at which point treatment with a vitamin K antagonist (warfarin) may be initiated. The DTI should be continued until therapeutic anticoagulation with the vitamin K antagonist has been achieved (international normalized ratio [INR] of 2.0–3.0) due to the warfarin effect; the infusion

Table 14–5. Management of suspected or proven HIT.

I. Discontinue all forms of heparin. Send PF4-heparin ELISA (if indicated).		
II. Begin treatment with direct thrombin inhibitor.		
Agent	Indication	Dosing
Argatroban	Prophylaxis or treatment of HIT	Continuous intravenous infusion of 0.5–1.2 mcg/kg/min, titrate to aPTT = 1.5 to 3 × the baseline value. ¹ Max infusion rate ≤ 10 mcg/kg/min.
Lepirudin	Treatment of HIT	Bolus of 0.4 mg/kg ² slowly intravenously followed by continuous intravenous infusion of 0.15 mg/kg/h. Titrate to aPTT = 1.5 – 2.5 × baseline value.
Bivalirudin	Percutaneous coronary intervention ³	Bolus of 0.75 mg/kg intravenously followed by initial continuous intravenous infusion of 1.75 mg/kg/h. Manufacturer indicates monitoring should be by ACT.
III. Perform Doppler ultrasound of lower extremities to rule out subclinical thrombosis (if indicated).		
IV. Follow platelet counts daily until recovery occurs.		
V. When platelet count has recovered, transition anticoagulation to warfarin; treat for 30 days (HIT) or 3–6 months (HITT).		
VI. Document heparin allergy in medical record (confirmed cases).		

¹Hepatic insufficiency: initial infusion rate = 0.5 mcg/kg/min.

²Renal insufficiency: initial bolus = 0.2 mg/kg.

³Not approved for HIT/HITT.

ACT, activated clotting time; aPTT, activated partial thromboplastin time; ELISA, enzyme-linked immunosorbent assay; HIT, heparin-induced thrombocytopenia; HITT, heparin-induced thrombocytopenia and thrombosis; PF4, platelet factor 4.

of argatroban must be temporarily discontinued for 2 hours before the INR is obtained so that it reflects the anticoagulant effect of warfarin alone. Warfarin is contraindicated as initial treatment of HIT because of its potential to transiently worsen hypercoagulability. In all patients with HIT, warfarin subsequently should be continued for at least 30 days, due to a persistent risk of thrombosis even after the platelet count has recovered, whereas in patients in whom thrombosis has been documented, anticoagulation with warfarin should continue for 3–6 months.

Subsequent exposure to heparin should be avoided in all patients with a prior history of HIT, if possible. If its use is regarded as necessary for a procedure, it should not be given until PF4-heparin antibodies are no longer detectable by ELISA (usually as of 100 days following an episode of HIT), and exposure should be limited to the shortest time period possible.

▶ When to Refer

Due to the tremendous thrombotic potential of the disorder and the complexity of use of the DTI, all patients with HIT should be evaluated by a hematologist.

▶ When to Admit

Most patients with HIT are hospitalized at the time of detection of thrombocytopenia. Any outpatient in whom HIT is suspected should be admitted because the DTIs must be administered by continuous intravenous infusion.

Cuker A. Heparin-induced thrombocytopenia: present and future. *J Thromb Thrombolysis*. 2011 Apr;31(3):353–66. [PMID: 21327506]

Otis SA et al. Heparin-induced thrombocytopenia: current status and diagnostic challenges. *Am J Hematol*. 2010 Sep;85(9):700–6. [PMID: 20665476]

Shantsila E et al. Heparin-induced thrombocytopenia. A contemporary clinical approach to diagnosis and management. *Chest*. 2009 Jun;135(6):1651–64. [PMID: 19497901]

Warkentin TE. Agents for the treatment of heparin-induced thrombocytopenia. *Hematol Oncol Clin North Am*. 2010 Aug;24(4):755–75. [PMID: 20659659]

4. Disseminated Intravascular Coagulation



ESSENTIALS OF DIAGNOSIS

- ▶ A frequent cause of thrombocytopenia in hospitalized patients.
- ▶ Prolonged activated partial thromboplastin time and prothrombin time.
- ▶ Thrombocytopenia and decreased fibrinogen levels.

▶ General Considerations

Disseminated intravascular coagulation (DIC) results from uncontrolled local or systemic activation of coagulation, which leads to depletion of coagulation factors and

fibrinogen and to thrombocytopenia as platelets are activated and consumed.

The numerous disorders that are associated with DIC include sepsis (in which coagulation is activated by presence of lipopolysaccharide) as well as cancer, trauma, burns, or pregnancy-associated morbidity (in which tissue factor is released). Aortic aneurysm and cavernous hemangiomas may promote DIC by leading to vascular stasis, and snake bites may result in DIC due to the introduction of exogenous toxins.

▶ Clinical Findings

A. Symptoms and Signs

Bleeding in DIC usually occurs at multiple sites, such as intravenous catheters or incisions, and may be widespread (purpura fulminans). Malignancy-related DIC may manifest principally as thrombosis (Trousseau syndrome).

B. Laboratory Findings

Frequently, there are acute and progressive prolongations in coagulation studies or thrombocytopenia is found in a patient who is being treated for a separate disorder. In early DIC, the platelet count and fibrinogen levels may remain within the normal range, albeit reduced from baseline levels. There is progressive thrombocytopenia (rarely severe), prolongation of the activated partial thromboplastin time (aPTT) and prothrombin time (PT), and low levels of fibrinogen. D-dimer levels typically are elevated due to the activation of coagulation and diffuse cross-linking of fibrin. Schistocytes on the blood smear, due to shearing of red cells through the microvasculature, are present in 10–20% of patients. Laboratory abnormalities in the HELLP syndrome (hemolysis, elevated liver enzymes, low platelets), a severe form of DIC with a particularly high mortality rate that occurs in peripartum women, include elevated liver transaminases and (many cases) renal dysfunction due to gross hemoglobinuria and pigment nephropathy. Malignancy-related DIC may feature normal platelet counts and coagulation studies.

▶ Treatment

The underlying causative disorder must be treated (eg, antimicrobials, chemotherapy, surgery, or delivery of conceptus [see below]). If clinically significant bleeding is present, hemostasis must be achieved (Table 14–6).

Blood products should be administered only if clinically significant hemorrhage has occurred or is thought likely to occur without intervention (Table 14–6). The goal of platelet therapy for most cases is $> 20,000/\text{mL}$ or $> 50,000/\text{mL}$ for serious bleeding, such as intracranial bleeding. FFP should be given only to patients with a prolonged aPTT and PT and significant bleeding; 4 units typically are administered at a time, and the posttransfusion platelet count should be documented. Cryoprecipitate may be given for bleeding and fibrinogen levels $< 80\text{--}100\text{ mg/dL}$. The PT, aPTT, fibrinogen, and platelet count should be monitored at least every 6 hours in acutely ill patients with DIC.

Table 14-6. Management of DIC.

I. Assess for underlying cause of DIC and treat.	
II. Establish baseline platelet count, PT, aPTT, D-dimer, fibrinogen.	
III. Transfuse blood products only if ongoing bleeding or high risk of bleeding:	Platelets: goal > 20,000/mcL (most patients) or > 50,000/mcL (severe bleeding, eg, intracranial hemorrhage)
	Cryoprecipitate: goal fibrinogen level > 80-100 mg/dL
	Fresh frozen plasma: goal PT and aPTT < 1.5 × normal
	Packed red blood cells: goal hemoglobin > 8 g/dL or improvement in symptomatic anemia
IV. Follow platelets, aPTT/PT, fibrinogen every 4-6 hours or as clinically indicated.	
V. If persistent bleeding, consider use of heparin ¹ (initial infusion, 5-10 units/kg/h); do not administer bolus.	
VI. Follow laboratory parameters every 4-6 hours until DIC resolved and underlying condition successfully treated	

¹Contraindicated if platelets cannot be maintained at > 50,000/mcL, in cases of gastrointestinal or central nervous system bleeding, in conditions that may require surgical management, or placental abruption.

aPTT, activated partial thromboplastin time; DIC, disseminated intravascular coagulation; PT, prothrombin time.

In some cases of refractory bleeding despite replacement of blood products, administration of low doses of heparin can be considered; it may help interfere with thrombin generation, which then could lead to a lessened consumption of coagulation proteins and platelets. An infusion of 6–10 units/kg/h (no bolus) may be used. Heparin, however, is contraindicated if the platelet count cannot be maintained at \geq 50,000/mcL and in cases of central nervous system/gastrointestinal bleeding, placental abruption, and any other condition that is likely to require imminent surgery. Fibrinolysis inhibitors may be considered in some patients with refractory DIC.

The treatment of **HELLP syndrome** must include evacuation of the uterus (eg, delivery of a term or near-term infant or removal of retained placental or fetal fragments). Patients with **Trousseau syndrome** require treatment of the underlying malignancy or administration of unfractionated heparin or subcutaneous therapeutic-dose LMWH as treatment of thrombosis, since warfarin typically is ineffective at secondary prevention of thromboembolism in the disorder. Immediate initiation of chemotherapy (usually within 24 hours of diagnosis) is required for patients with **acute promyelocytic leukemia (APL)-associated DIC**, along with administration of blood products as clinically indicated.

▶ When to Refer

Patients with diffuse bleeding that is unresponsive to administration of blood products should be evaluated by a hematologist.

▶ When to Admit

Most patients with DIC are hospitalized when DIC is detected.

- Franchini M et al. Disseminated intravascular coagulation in hematologic malignancies. *Semin Thromb Hemost.* 2010 Jun;36(4):388–403. [PMID: 20614391]
- Levi M et al. Disseminated intravascular coagulation in infectious disease. *Semin Thromb Hemost.* 2010 Jun;36(4):367–77. [PMID: 20614389]
- Levi M et al. Guidelines for the diagnosis and management of disseminated intravascular coagulation. British Committee for Standards in Haematology. *Br J Haematol.* 2009 Apr;145(1):24–33. [PMID: 19222477]
- Lippi G et al. Disseminated intravascular coagulation in trauma injuries. *Semin Thromb Hemost.* 2010 Jun;36(4):378–87. [PMID: 20614390]
- Martí-Carvajal AJ et al. Treatment for disseminated intravascular coagulation in patients with acute and chronic leukemia. *Cochrane Database Syst Rev.* 2011 Jun 15;(6):CD008562. [PMID: 21678379]

OTHER CONDITIONS CAUSING THROMBOCYTOPENIA

1. Drug-Induced Thrombocytopenia

The mechanisms underlying drug-induced thrombocytopenia are thought in most cases to be immune, although exceptions exist (such as chemotherapy). Table 14-7 lists medications associated with thrombocytopenia. The typical presentation of **drug-induced thrombocytopenia** is severe thrombocytopenia and mucocutaneous bleeding 7–14 days after exposure to a new drug, although a range of presentations is possible. Discontinuation of the offending agent leads to resolution of thrombocytopenia within 7–10 days in most cases, but patients with severe thrombocytopenia should be given platelet transfusions with (immune cases only) or without IVIG.

2. Posttransfusion Purpura

Posttransfusion purpura (PTP) is a rare disorder that features sudden-onset thrombocytopenia in an individual who recently has received transfusion of red cells, platelets, or plasma within 1 week prior to detection of thrombocytopenia. Antibodies against the human platelet antigen PI^{A1} are detected in most individuals with PTP. Patients with PTP almost universally are either multiparous women or persons who have received transfusions previously. Severe thrombocytopenia and bleeding is typical. Initial treatment consists of administration of IVIG (1 g/kg/d for 2 days) which should be administered as soon as the diagnosis is suspected. Platelets are not indicated unless severe bleeding is present, but if they are to be administered, HLA-matched platelets are preferred. A second course or IVIG, plasma exchange, corticosteroids, or splenectomy may be used in case of refractoriness. PI^{A1} -negative or washed blood products are preferred for subsequent transfusions.

Table 14-7. Medications causing drug-associated thrombocytopenia.

Class	Examples
Chemotherapy	Most agents
Antiplatelet agents	Anagrelide Abciximab Eptifibatid Tirofiban Ticlopidine
Antimicrobial agents	Penicillins Isoniazid Rifampin Sulfa drugs Vancomycin Adefovir Indinavir Ritonavir Fluconazole Linezolid
Cardiovascular agents	Digoxin Amiodarone Captopril Hydrochlorothiazide Procainamide Atorvastatin Simvastatin
Gastrointestinal agents	Cimetidine Ranitidine Famotidine
Neuropsychiatric agents	Haloperidol Carbamazepine Methyldopa Phenytoin
Analgesic agents	Acetaminophen Ibuprofen Sulindac Diclofenac Naproxen
Anticoagulant agents	Heparin Low-molecular-weight heparin
Immunomodulator agents	Interferon-alpha Gold Rituximab
Immunosuppressant agents	Mycophenolate mofetil Tacrolimus
Other agents	Iodinated contrast dye Immunizations

3. von Willebrand Disease Type 2B

von Willebrand disease (vWD) type 2B leads to chronic, characteristically mild to moderate thrombocytopenia via an abnormal vWF molecule that binds platelets with increased affinity, resulting in aggregation and clearance.

4. Platelet Sequestration

At any given time, one-third of the platelet mass is sequestered in the spleen. Splenomegaly, due to a variety of

Table 14-8. Selected causes of splenomegaly.

Lymphoproliferative/myeloproliferative disease
Lymphoma
Chronic lymphocytic leukemia
Chronic myeloid leukemia
Polycythemia vera
Essential thrombocythemia
Vascular congestion
Congestive heart failure
Cirrhosis
Hematologic defects
Hereditary spherocytosis
Paroxysmal nocturnal hemoglobinuria
Thalassemia
Autoimmunity
Collagen vascular disease
Felty syndrome, Systemic Lupus Erythematosus
Autoimmune lymphoproliferative disorder
Infection
Infectious hepatitis
Cytomegalovirus, Epstein Barr Virus
Malaria
Babesiosis
Inborn errors of metabolism
Gaucher disease
Niemann-Pick disease

conditions (Table 14-8), may lead to thrombocytopenia of variable severity. Whenever possible, treatment of the underlying disorder should be pursued, but splenectomy, splenic embolization, or splenic irradiation may be considered in selected cases.

5. Pregnancy

Gestational thrombocytopenia results from progressive expansion of the blood volume that typically occurs during pregnancy, leading to hemodilution. Cytopenias result, although production of blood cells is normal or increased. Platelet counts <100,000/mcL, however, are observed in <10% of pregnant women in the third trimester; decreases to <70,000/mcL should prompt consideration of pregnancy-related ITP (see above) as well as preeclampsia or a pregnancy-related thrombotic microangiopathy.

6. Infection or Sepsis

Both immune- and platelet production-mediated defects are possible, and there may be significant overlap with concomitant DIC (see above). In either case, the platelet count typically improves with effective antimicrobial treatment or after the infection has resolved. In some critically ill patients, a defect in immunomodulation may lead to bone marrow macrophages (histiocytes) engulfing cellular components of the marrow in a process also called hemophagocytosis. The phenomenon typically resolves with resolution of the infection, but with certain infections (Epstein Barr virus) immunosuppression may be required. Hemophagocytosis also may arise in the setting of malignancy, in which case the disorder is usually unresponsive to treatment with immunosuppression.

7. Pseudothrombocytopenia

Pseudothrombocytopenia results from EDTA anticoagulant-induced platelet clumping; the phenomenon typically disappears when blood is collected in a tube containing citrate anticoagulant.

Bockenstedt PL. Thrombocytopenia in pregnancy. *Hematol Oncol Clin North Am.* 2011 Apr;25(2):293–310. [PMID: 21444031]
 Perdomo J et al. Quinine-induced thrombocytopenia: drug-dependent GPIIb/IX antibodies inhibit megakaryocyte and proplatelet production in vitro. *Blood.* 2011 Jun 2;117(22):5975–86. [PMID: 21487107]

QUALITATIVE PLATELET DISORDERS

CONGENITAL DISORDERS OF PLATELET FUNCTION



ESSENTIALS OF DIAGNOSIS

- ▶ Usually diagnosed in childhood.
- ▶ Family history usually is positive.
- ▶ May be diagnosed in adulthood when there is excessive bleeding.

▶ General Considerations

Heritable qualitative platelet disorders are far less common than acquired disorders of platelet function (see below) and lead to variably severe bleeding, often beginning in childhood. Occasionally, however, disorders of platelet function may go undetected until later in life when excessive bleeding occurs following a sufficient hemostatic insult. Thus, the true incidence of hereditary qualitative platelet disorders is unknown.

Bernard-Soulier syndrome (BSS) is a rare, autosomal recessive bleeding disorder that is due to reduced or abnormal platelet membrane expression of glycoprotein Ib/IX (vWF receptor).

Glanzmann thrombasthenia results from a qualitative or quantitative abnormality in glycoprotein IIb/IIIa receptors on the platelet membrane, which are required to bind fibrinogen and vWF, both of which bridge platelets during aggregation. Inheritance is autosomal recessive.

Under normal circumstances, activated platelets release the contents of platelet granules to reinforce the aggregatory response. **Storage pool disease** is caused by defects in release of alpha or dense (delta) platelet granules, or both (alpha-delta storage pool disease).

▶ Clinical Findings

A. Symptoms and Signs

In patients with **Glanzmann thrombasthenia**, the onset of bleeding is usually in infancy or childhood. The degree of deficiency in IIb/IIIa may not correlate well with bleeding symptoms. Patients with **storage pool disease** are affected by variable bleeding, ranging from mild and trauma-related to spontaneous.

B. Laboratory Findings

In **Bernard-Soulier syndrome**, there are abnormally large platelets (approaching the size of red cells), moderate thrombocytopenia, and a prolonged bleeding time. Platelet aggregation studies show a marked defect in response to ristocetin, whereas aggregation in response to other agonists is normal; the addition of normal platelets corrects the abnormal aggregation. The diagnosis can be confirmed by platelet flow cytometry.

In **Glanzmann thrombasthenia**, platelet aggregation studies show marked impairment of aggregation in response to stimulation with typical agonists.

Storage pool disease describes defects in the number or content of platelet alpha or dense granules or both. The **gray platelet syndrome** comprises abnormalities of platelet alpha granules, thrombocytopenia, and marrow fibrosis. The blood smear shows agranular platelets, and the diagnosis is confirmed with electron microscopy.

Albinism-associated storage pool disease involves defective dense granules in disorders of oculocutaneous albinism, such as the Hermansky-Pudlak and Chediak-Higashi syndromes. Electron microscopy confirms the diagnosis.

Non-albinism-associated storage pool disease results from quantitative or qualitative defects in dense granules and is seen in Ehlers-Danlos and Wiskott-Aldrich syndromes, among others.

The **Quebec platelet disorder** comprises mild thrombocytopenia, an abnormal platelet factor V molecule, and a prolonged bleeding time. Patients typically experience moderate bleeding. Interestingly, platelet transfusion does not ameliorate the bleeding.

Patients have a prolonged bleeding time. Platelet aggregation studies characteristically show platelet dissociation following an initial aggregatory response, and electron microscopy confirms the diagnosis.

▶ Treatment

The mainstay of treatment (including periprocedural prophylaxis) is transfusion of normal platelets, although desmopressin acetate (DDAVP), antifibrinolytic agents, and recombinant human activated factor VII also have been used successfully.

Hers I et al. Understanding the therapeutic action of recombinant factor VIIa in platelet disorders. *Platelets.* 2008 Dec;19(8):571–81. [PMID: 19012175]

Kannan M et al. Glanzmann's thrombasthenia: an overview. *Clin Appl Thromb Hemost.* 2009 Mar–Apr;15(2):152–65. [PMID: 18930954]

Nurden P et al. Congenital disorders associated with platelet dysfunctions. *Thromb Haemost.* 2008 Feb;99(2):253–63. [PMID: 18278172]

ACQUIRED DISORDERS OF PLATELET FUNCTION

Platelet dysfunction is more commonly acquired than inherited; the widespread use of platelet-active medications accounts for most of the cases of qualitative defects (Table 14–9). In these cases, platelet inhibition typically declines within 5–10 days following discontinuation of the drug, and transfusion of platelets may be required if clinically significant bleeding is present.

Table 14-9. Causes of acquired platelet dysfunction.

Cause	Mechanism(s)	Treatment of Bleeding
Drug-induced		
Salicylates (eg, aspirin)	Irreversible inhibition of platelet cyclooxygenase	Discontinuation of drug; platelet transfusion
NSAIDs (eg, ibuprofen)	Reversible inhibition of cyclooxygenase	
Glycoprotein IIb/IIIa inhibitors (eg, abciximab, tirofiban, eptifibatid)	↓ Binding of fibrinogen to PM IIb/IIIa receptor	
Thienopyridines (eg, clopidogrel, ticlopidine)	↓ ADP binding to PM receptor	
Dipyridamole	↓ Intracellular cAMP metabolism	
SSRIs (eg, paroxetine, fluoxetine)	↓ Serotonin in dense-granules	
Omega-3 fatty acids (eg, DHA, EPA)	Disruption of PM phospholipid	
Antibiotics, (eg, high-dose penicillin, nafcillin, ticarcillin, cephalothin, moxalactam)	Not fully elucidated; PM binding may interfere with receptor-ligand interactions	
Alcohol	↓ TXA ₂ release	DDAVP, high-dose estrogens; platelet transfusion, dialysis
Uremia	↑ Nitric oxide; ↓ release of granules	
Myeloproliferative disorder/myelodysplastic syndrome	Abnormal PM receptors, signal transduction, and/or granule release	Platelet transfusion; myelosuppressive treatment (myeloproliferative disorder)
Cardiac bypass	Platelet activation in bypass circuit	Platelet transfusion

ADP, adenosine diphosphate; cAMP, cyclic adenosine monophosphate; DDAVP, desmopressin acetate; DHA, docosahexaenoic acid; EPA, eicosahexaenoic acid; NSAIDs, nonsteroidal anti-inflammatory drugs; PM, platelet membrane; SSRIs, selective serotonin reuptake inhibitors; TXA₂, thromboxane A₂.

Laboratory manifestations of aspirin toxicity include a prolonged epinephrine cartridge closure time in the platelet function analyzer (PFA)-100 system, or a decreased aggregation to low-dose collagen and thrombin (and preserved aggregation in response to high-dose collagen and thrombin) on platelet aggregation studies.

DISORDERS OF COAGULATION

CONGENITAL DISORDERS OF COAGULATION

1. Hemophilia A & B

ESSENTIALS OF DIAGNOSIS

- ▶ Hemophilia A: congenital deficiency of coagulation factor VIII.
- ▶ Hemophilia B: congenital deficiency of coagulation factor IX.
- ▶ Recurrent hemarthroses and arthropathy.
- ▶ Risk of development of inhibitory antibodies to factor VII or factor IX.
- ▶ In many older patients, infection with HIV or hepatitis C virus from receipt of contaminated blood products.

▶ General Considerations

The frequency of hemophilia A is 1 per 5000 live male births, whereas hemophilia B occurs in approximately 1 in 25,000 live male births. Inheritance is X-linked recessive, leading to affected males and carrier females. There is no race predilection. Testing is indicated for asymptomatic male infants with a hemophilic pedigree, for male infants with a family history of hemophilia who experience excessive bleeding, or for an otherwise asymptomatic adolescent or adult who experiences unexpected excessive bleeding with trauma or invasion.

Inhibitors to factor VIII will develop in approximately 25% of patients with hemophilia A, and inhibitors to factor IX will develop in < 5% of patients with hemophilia B.

▶ Clinical Findings

A. Symptoms and Signs

Severe hemophilia presents in infant males or in early childhood with spontaneous bleeding into joints, soft tissues, or other locations. Spontaneous bleeding is rare in patients with mild hemophilia, but bleeding may occur with a significant hemostatic challenge (eg, surgery, trauma). Intermediate clinical symptoms are seen in patients with moderate hemophilia. Female carriers of hemophilia are usually asymptomatic.

Significant hemophilic arthropathy is usually avoided in patients who have received long-term prophylaxis with factor concentrate starting in childhood, whereas joint

disease is common in adults who have experienced recurrent hemarthroses.

Inhibitor development to factor VIII or factor IX is characterized by bleeding episodes that are resistant to treatment with clotting factor VIII or IX concentrate, and by new or atypical bleeding.

B. Laboratory Findings

Hemophilia is diagnosed by demonstration of an isolated reproducibly low factor VIII or factor IX activity level, in the absence of other conditions. If the aPTT is prolonged, it typically corrects upon mixing with normal plasma. A variety of mutations, including inversions, large and small deletions, insertions, missense mutations, and nonsense mutations may be causative. Depending on the level of residual factor VIII or factor IX activity and the sensitivity of the thromboplastin used in the aPTT coagulation reaction, the aPTT may or may not be prolonged (although it typically is markedly prolonged in severe hemophilia). Hemophilia is classified according to the level of factor activity in the plasma. Severe hemophilia is characterized by < 1% factor activity, mild hemophilia features > 5% factor activity, and moderate hemophilia features 1–5% factor activity. Female carriers may become symptomatic if significant lyonization has occurred favoring the defective factor

VIII or factor IX gene, leading to factor VIII or factor IX activity level markedly < 50%.

In the presence of an inhibitor to factor VIII or factor IX, there is accelerated clearance of and suboptimal or absent rise in measured activity of infused factor, and the aPTT does not correct on mixing. The Bethesda assay measures the potency of the inhibitor.

► Treatment

Plasma-derived or recombinant factor concentrates are the mainstay of treatment. By the age of 4 years, most children with severe hemophilia have begun twice- or thrice-weekly infusions of factor to prevent the recurrent joint bleeding that otherwise would characterize the disorder and lead to severe musculoskeletal morbidity. Adults are frequently treated with factor concentrate as needed for bleeding episodes or prior to high-risk activities (Table 14–10). Patients with mild hemophilia A may respond to as-needed intravenous or intranasal treatment with DDAVP. Antifibrinolytic agents may be useful in cases of mucosal bleeding and are commonly used adjunctively, such as following dental procedures. Clinical trials of longer-acting FVIII and FIX molecules are underway. Delivery of normal factor VIII or factor IX genes via viral vectors continues to be explored in gene therapy trials.

It may be possible to overcome low-titer inhibitors (< 5 Bethesda units [BU]) by giving larger doses of factor,

Table 14–10. Treatment of selected inherited bleeding disorders.

Disorder	Subtype	Treatment for Minor Bleeding	Treatment for Major Bleeding	Comment
Hemophilia A	Mild	DDAVP ¹	DDAVP ¹ or factor VIII concentrate	Treat for 3–10 days for major bleeding or following surgery, keeping factor activity level 50–80% initially. Adjunctive aminocaproic acid may be useful for mucosal bleeding or procedures
	Moderate or severe	Factor VIII concentrate	Factor VIII concentrate	
Hemophilia B	Mild, moderate, or severe	Factor IX concentrate	Factor IX concentrate	
	von Willebrand disease	DDAVP	DDAVP, vWF concentrate	
Factor XI deficiency	Type 1	DDAVP	vWF concentrate	
	Type 2	DDAVP, ¹ vWF concentrate	vWF concentrate	
	Type 3	vWF concentrate	vWF concentrate	
Factor XI deficiency	—	FFP or aminocaproic acid	FFP	Adjunctive aminocaproic acid should be used for mucosal bleeding or procedures

¹Mild hemophilia A and type 2A or 2B vWD patients: therapeutic trial must have previously confirmed an adequate response (ie, elevation of factor VIII or vWF activity level into the normal range) and (for type 2B) no exacerbation of thrombocytopenia. DDAVP is not typically effective for type 2M vWD. A vWF-containing factor VIII concentrate is preferred for treatment of type 2N vWD.

Notes:

DDAVP dose is 0.3 mcg/kg intravenously in 50 mL saline over 20 minutes, or nasal spray 300 mcg for weight > 50 kg or 150 mcg for < 50 kg, every 12–24 hours, maximum of three doses in a 48-hour period. If more than two doses are used in a 12–24 hour period, free water restriction and/or monitoring for hyponatremia is essential.

EACA dose is 50 mg/kg orally four times daily for 3–5 d; maximum 24 g/d, useful for mucosal bleeding/dental procedures.

Factor VIII concentrate dose is 50 units/kg intravenously initially followed by 25 units/kg every 8 hours followed by lesser doses at longer intervals once hemostasis has been established.

Factor IX concentrate dose is 100 units/kg (120 units/kg if using Benefix) intravenously initially followed by 50 units/kg (60 units/kg if using Benefix) every 8 hours followed by lesser doses at longer intervals once hemostasis has been established.

vWF-containing factor VIII concentrate dose is 60–80 RCoF units/kg intravenously every 12 hours initially followed by lesser doses at longer intervals once hemostasis has been established.

FFP is typically administered in 4-unit boluses and may not need to be re-bolused after the initial administration due to the long half-life of factor XI.

DDAVP, desmopressin acetate; FFP, fresh frozen plasma; vWF, von Willebrand factor.

whereas treatment of bleeding in the presence of a high-titer inhibitor (> 5 BU) requires infusion of an activated prothrombin complex concentrate or recombinant activated factor VII. Inhibitor tolerance induction, achieved by giving large doses (50–300 units/kg intravenously of factor VIII daily) for 6–18 months, succeeds in eradicating the inhibitor in 70% of patients with hemophilia A and in 30% of patients with hemophilia B. Patients with hemophilia B who receive inhibitor tolerance induction, however, are at risk for development of nephrotic syndrome and anaphylactic reactions, making eradication of their inhibitors less feasible. Additional immunomodulation may allow for eradication in selected inhibitor tolerance induction–refractory patients.

Highly active antiretroviral treatment is almost universally administered to individuals with HIV infection.

► When to Refer

All patients with hemophilia should be seen regularly in a comprehensive hemophilia treatment center staffed by a hematologist.

► When to Admit

Most bleeding events can be treated as an outpatient.

- Some invasive procedures due to the need for serial infusions of clotting factor concentrate.
- Patients with hemophilia (with or without inhibitors) who experience bleeding that is unresponsive to outpatient treatment.

Berntorp E. Importance of rapid bleeding control in haemophilia complicated by inhibitors. *Haemophilia*. 2011 Jan; 17(1):11–6. [PMID: 20565546]

Callaghan MU. What is the evidence for the use of immunomodulatory agents to eradicate inhibitory antibodies in patients with severe hemophilia A who have previously failed to respond to immune tolerance induction? *Hematology Am Soc Hematol Educ Program*. 2011;2011:405–6. [PMID: 22160065]

Chambost H. Assessing risk factors: prevention of inhibitors in haemophilia. *Haemophilia*. 2010 Mar;16(Suppl 2):10–5. [PMID: 20132333]

Fogarty PF. Biological rationale for new drugs in the bleeding disorders pipeline. *Hematology Am Soc Hematol Educ Program*. 2011;2011:397–404. [PMID: 22160064]

Gringeri A et al; ESPRIT Study Group. A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study). *J Thromb Haemost*. 2011 Apr;9(4):700–10. [PMID: 21255253]

2. von Willebrand Disease

ESSENTIALS OF DIAGNOSIS

- The most common inherited bleeding disorder.
- von Willebrand factor aggregates platelets and prolongs the half-life of factor VIII.

► General Considerations

vWF is an unusually large multimeric glycoprotein that binds to its receptor, platelet glycoprotein Ib, bridging platelets together and tethering them to the subendothelial matrix at the site of vascular injury. vWF also has a binding site for factor VIII, prolonging its half-life in the circulation.

Between 75% and 80% of patients with vWD have type 1. It is a quantitative abnormality of the vWF molecule that usually does not feature an identifiable causal mutation in the vWF gene.

Type 2 vWD is seen in 15–20% of patients with vWD. In type 2A or 2B vWD, a qualitative defect in the vWF molecule is causative. Type 2N and 2M vWD are due to defects in vWF that decrease binding to factor VIII or to platelets, respectively. Importantly, type 2N vWD clinically resembles hemophilia A, with the exception of a family history that shows affected females. Factor VIII activity levels are markedly decreased, and vWF activity and antigen (Ag) are normal. Type 2M vWD features a normal multimer pattern. Type 3 vWD is rare, and mutational homozygosity or double heterozygosity leads to undetectable levels of vWF and severe bleeding in infancy or childhood.

► Clinical Findings

A. Symptoms and Signs

Patients with type 1 vWD usually have mild or moderate platelet-type bleeding (especially involving the integument and mucous membranes). Patients with type 2 vWD usually have moderate to severe bleeding that presents in childhood or adolescence.

B. Laboratory Findings

In type 1 vWD, the vWF activity (by ristocetin co-factor assay) and Ag are mildly depressed, whereas the vWF multimer pattern is normal (Table 14–11). Laboratory testing of type 2A or 2B vWD typically shows a ratio of vWF Ag:vWF activity of approximately 2:1 and a multimer pattern that lacks the highest molecular weight multimers. Thrombocytopenia is common in type 2B vWD due to a gain-of-function mutation of the vWF molecule, which leads to increased binding to its receptor on platelets, resulting in clearance; a ristocetin-induced platelet aggregation (RIPA) study shows an increase in platelet aggregation in response to low concentrations of ristocetin. Except in the more severe forms of vWD that feature a significantly decreased factor VIII activity, the aPTT and PT in vWD are usually normal.

► Treatment

The treatment of vWD is summarized in Table 14–10. DDAVP is useful in the treatment of mild bleeding in most cases of type 1 and some cases of type 2 vWD. DDAVP causes release of vWF and factor VIII from storage sites, leading to increases in vWF and factor VIII twofold to sevenfold that of baseline levels. Cryoprecipitate should not be given due to lack of viral inactivation. Antifibrinolytic agents (eg, aminocaproic acid) may be used adjunctively

Table 14-11. Laboratory diagnosis of von Willebrand disease.

Type	vWF Activity	vWF Antigen	FVIII	RIPA	Multimer Analysis
1	↓	↓	NI or ↓	↓	Normal pattern; uniform ↓ intensity of bands
2	A	↓↓	↓	↓	Large and intermediate multimers decreased or absent
	B	↓↓	↓	↑	Large multimers decreased or absent
	M	↓	↓	↓	Normal pattern; uniform ↓ intensity of bands
	N	NI	NI	↓↓	NI
3	↓↓↓	↓↓↓	↓↓↓	↓↓↓	Multimers absent

NI, normal; RIPA, ristocetin-induced platelet aggregation; vWF, von Willebrand factor.

for mucosal bleeding or procedures. Pregnant patients with vWD usually do not require treatment because of the natural physiologic increase in vWF levels (up to threefold that of baseline) that are observed by the time of delivery; however, if excessive bleeding is encountered, vWF-containing factor VIII concentrates may be given.

Castaman G et al. von Willebrand's disease diagnosis and laboratory issues. *Haemophilia*. 2010 Jul;16(Suppl 5):67–73. [PMID: 20590859]

Lipe BC et al. Von Willebrand disease in pregnancy. *Hematol Oncol Clin North Am*. 2011 Apr;25(2):335–58. [PMID: 21444034]

Mannucci PM et al; Italian Association of Hemophilia Centers. Evidence-based recommendations on the treatment of von Willebrand disease in Italy. *Blood Transfus*. 2009 Apr;7(2):117–26. [PMID: 19503633]

3. Factor XI Deficiency

Factor XI deficiency (sometimes referred to as **hemophilia C**) is inherited in an autosomal recessive manner, leading to heterozygous or homozygous defects. It is most prevalent among individuals of Ashkenazi Jewish descent. Levels of factor XI, while variably reduced, do not correlate well with bleeding symptoms. Mild bleeding is most common, and surgery or trauma may expose or worsen the bleeding tendency. FFP is the mainstay of treatment in locales where the plasma-derived factor XI concentrate is not available. Administration of adjunctive aminocaproic acid is regarded as mandatory for procedures or bleeding episodes involving the mucosa (Table 14-10).

Gomez K et al. Factor XI deficiency. *Haemophilia*. 2008 Nov;14(6):1183–9. [PMID: 18312365]

Martin-Salces M et al. Review: Factor XI deficiency: review and management in pregnant women. *Clin Appl Thromb Hemost*. 2010 Apr;16(2):209–13. [PMID: 19049995]

4. Less Common Heritable Disorders of Coagulation

Congenital deficiencies of clotting factors II, V, VII, and X are rare and typically are inherited in an autosomal recessive pattern. A prolongation in the PT (and aPTT for factor

X and factor II deficiency) that corrects upon mixing with normal plasma is typical. The treatment of factor II deficiency is with a prothrombin complex concentrate; factor V deficiency is treated with infusions of FFP or platelets (which contain factor V in alpha granules); factor VII deficiency is treated with recombinant human activated factor VII at 15–30 mcg/kg every 4–6 hours; and infusions of FFP may be used to treat factor X deficiency.

Deficiency of factor XIII, a transglutaminase that cross-links fibrin, characteristically leads to delayed bleeding that occurs hours to days after a hemostatic challenge (such as surgery or trauma). The condition is usually lifelong, and spontaneous intracranial hemorrhages as well as recurrent pregnancy loss appear to occur with increased frequency in these patients compared with other congenital deficiencies. Cryoprecipitate or infusion of a plasma-derived factor XIII concentrate (available through a research study; appropriate for patients with A-subunit deficiency only) is the treatment of choice for bleeding or surgical prophylaxis.

α_2 -Antiplasmin deficiency is a rare disorder that leads to accelerated fibrinolysis via insufficient inhibition of plasmin. Heterozygosity for the condition usually produces a mild bleeding tendency, while bleeding symptoms in homozygotes may be severe. The diagnosis is made by a documented antiplasmin level below the reference range; the aPTT and PT are normal. In some cases, treatment of bleeding or surgical prophylaxis is with aminocaproic acid. A **congenital deficiency of plasminogen activator I (PAI-1)** is extremely rare and can lead to mild to moderate bleeding; testing for the disorder can be difficult due to the extremely low extension of the normal reference range for PAI-1.

Congenital afibrinogenemia is exceedingly rare and produces mild to severe bleeding; the frequency of first-trimester miscarriage is increased among women with the disorder. The PT is more typically prolonged than the aPTT, and a functional fibrinogen assay shows reduced activity. Treatment is with a fibrinogen concentrate (RiaSTAP) (preferred and now FDA approved), cryoprecipitate, or FFP and is aimed at increasing the plasma fibrinogen concentration to at least > 80 mg/dL.

Congenital deficiencies of factor XII, prekallikrein, high molecular-weight kininogen may lead to a prolonged aPTT that corrects with extended incubation but do not lead to bleeding.

Bereczky Z et al. Factor XIII and venous thromboembolism. *Semin Thromb Hemost.* 2011 Apr;37(3):305–14. [PMID: 21455864]
 Peyvandi F et al. Rare bleeding disorders. *Semin Thromb Hemost.* 2009 Jun;35(4):345–7. [PMID: 19598062]

ACQUIRED DISORDERS OF COAGULATION

1. Acquired Antibodies to Factor VIII

Spontaneous antibodies to factor VIII occasionally occur in adults without a prior history of hemophilia; the elderly and patients with lymphoproliferative malignancy or connective tissue disease, who are postpartum, or postsurgical are at highest risk. The clinical presentation typically includes extensive soft-tissue ecchymoses, hematomas, and mucosal bleeding, as opposed to hemarthrosis in congenital hemophilia A. The aPTT is typically prolonged and does not correct upon mixing; factor VIII activity is found to be low and a Bethesda assay reveals the titer of the inhibitor. Inhibitors of low titer (< 5 BU) may often be overcome by infusion of high doses of factor VIII concentrates, whereas high-titer inhibitors (>5 BU) must be treated with serial infusions of activated prothrombin complex concentrates or recombinant human activated factor VII. Along with establishment of hemostasis by one of these measures, immunosuppressive treatment with corticosteroids and oral cyclophosphamide should be instituted; treatment with IVIG, rituximab, or plasmapheresis can be considered in refractory cases.

Bitting RL et al. The prognosis and treatment of acquired hemophilia: a systematic review and meta-analysis. *Blood Coagul Fibrinolysis.* 2009 Oct;20(7):517–23. [PMID: 19644360]
 Huth-Kühne A et al. International recommendations on the diagnosis and treatment of patients with acquired hemophilia A. *Haematologica.* 2009 Apr;94(4):566–75. [PMID: 19336751]

2. Acquired Antibodies to Factor II

Patients with antiphospholipid antibodies occasionally manifest specificity to coagulation factor II (prothrombin), leading typically to a severe hypoprothrombinemia and bleeding. Mixing studies may or may not reveal presence of an inhibitor, as the antibody typically binds a non-enzymatically active portion of the molecule that leads to accelerated clearance, but characteristically the PT is prolonged and levels of factor II are low. FFP should be administered for treatment of bleeding. Treatment is immunosuppressive.

3. Acquired Antibodies to Factor V

Products containing bovine factor V (such as topical thrombin or fibrin glue, frequently used in surgical procedures) can lead to formation of an anti-factor V antibody that has specificity for human factor V. Clinicopathologic manifestations range from a prolonged PT in an otherwise asymptomatic individual to severe bleeding. Mixing studies suggest the presence of an inhibitor, and the factor V activity level is low. In cases of serious or life-threatening

bleeding, IVIG or platelet transfusions, or both, should be administered, and immunosuppression (as for acquired inhibitors to factor VIII) may be offered.

4. Vitamin K Deficiency

Vitamin K deficiency may occur as a result of deficient dietary intake of vitamin K (from green leafy vegetables, soybeans, and other sources), malabsorption, or decreased production by intestinal bacteria (due to treatment with chemotherapy or antibiotics). Vitamin K normally participates in activity of the vitamin K epoxide reductase that assists in posttranslational gamma-carboxylation of the coagulation factors II, VII, IX, and X that is necessary for their activity. Thus, vitamin K deficiency typically features a prolonged PT (in which the activity of the vitamin K–dependent factors is more reflected than in the aPTT) that corrects upon mixing; levels of individual clotting factors II, VII, IX, and X typically are low. Importantly, a concomitantly low factor V activity level is not indicative of isolated vitamin K deficiency, and may indicate an underlying defect in liver synthetic function (see below).

For treatment, vitamin K₁ (phytonadione) may be administered via intravenous or oral routes; the subcutaneous route is not recommended due to erratic absorption. Oral absorption is typically excellent and at least partial improvement in the PT should be observed within 1 day of administration. Intravenous administration (1 mg/d) results in even faster normalization of a prolonged PT than oral administration (5–10 mg/d); due to descriptions of anaphylaxis, parenteral doses should be administered at lower doses and slowly (eg, over 30 minutes) with concomitant monitoring.

5. Coagulopathy of Liver Disease

Impaired hepatic function due to cirrhosis or other causes leads to decreased synthesis of clotting factors, including factors II, VII, V, IX, and fibrinogen, whereas factor VIII levels may be elevated in spite of depressed levels of other coagulation factors. The PT (and with advanced disease, the aPTT) is typically prolonged and corrects on mixing with normal plasma. A normal factor V level, in spite of decreases in the activity of factors II, VII, IX, and X, however, suggests vitamin K deficiency rather than liver disease (see above). Qualitative and quantitative deficiencies of fibrinogen also are prevalent among patients with advanced liver disease, typically leading to a prolonged PT, thrombin time, and reptilase time.

The coagulopathy of liver disease usually does not require hemostatic treatment until bleeding complications occur. Infusion of FFP may be considered if active bleeding is present and the aPTT and PT are markedly prolonged; however, the effect is transient and concern for volume overload may limit infusions. Patients with bleeding and a fibrinogen level consistently below 80 mg/dL should receive cryoprecipitate. Liver transplantation, if feasible, results in production of coagulation factors at normal levels. The appropriateness of use of recombinant human activated factor VII in patients with bleeding varices is controversial, although some patient subgroups may experience benefit.

De Gasperi A et al. Acute liver failure: managing coagulopathy and the bleeding diathesis. *Transplant Proc.* 2009 May;41(4):1256–9. [PMID: 19460532]

Franchini M et al. Acquired factor V inhibitors: a systematic review. *J Thromb Thrombolysis.* 2011 May;31(4):449–57. [PMID: 21052780]

Pluta A et al. Coagulopathy in liver diseases. *Adv Med Sci.* 2010 Jun;55(1):16–21. [PMID: 20513645]

6. Warfarin Ingestion

See **Antithrombotic Therapy** section, below.

7. Disseminated Intravascular Coagulation

The consumptive coagulopathy of DIC results in decreases in the activity of clotting factors, leading to bleeding in most patients (see above). The aPTT and PT are characteristically prolonged, and platelets and fibrinogen levels are reduced from baseline.

8. Heparin/Fondaparinux Use

The thrombin time is dramatically prolonged in the presence of heparin. Patients who are receiving heparin and who have bleeding should be managed by discontinuation of the heparin and (some cases) administration of protamine sulfate; 1 mg of protamine neutralizes approximately 100 units of heparin sulfate, and the maximum dose is 50 mg intravenously. LMWHs typically do not prolong clotting times and are incompletely reversible with protamine. There is no reversal agent for fondaparinux, although some experts have suggested using recombinant human activated factor VIIa for cases of life-threatening bleeding.

Schulman S et al. Anticoagulants and their reversal. *Transfus Med Rev.* 2007 Jan;21(1):37–48. [PMID: 17174219]

9. Lupus Anticoagulants

Lupus anticoagulants do not cause bleeding; however, because they prolong clotting times by binding proteins associated with phospholipid, which is a necessary component of coagulation reactions, clinicians may be concerned about a risk of bleeding. Lupus anticoagulants were so named because of their increased prevalence among patients with connective tissue disease, although they may occur with increased frequency in individuals with underlying infection, inflammation, or malignancy, and they also can occur in asymptomatic individuals in the general population. A prolongation in the aPTT is observed that does not correct completely on mixing. Specialized testing such as the hexagonal phase phospholipid neutralization assay, the dilute Russell viper venom time, and platelet neutralization assays can confirm the presence of a lupus anticoagulant.

Pengo V et al; Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. Update of the guidelines for lupus anticoagulant detection. *J Thromb Haemost.* 2009 Oct;7(10):1737–40. [PMID: 19624461]

OTHER CAUSES OF BLEEDING

Occasionally, abnormalities of the vasculature and integument may lead to bleeding despite normal hemostasis; congenital or acquired disorders may be causative. These abnormalities include Ehlers-Danlos syndrome, osteogenesis imperfecta, Osler-Weber-Rendu disease, and Marfan syndrome (heritable defects) and integumentary thinning due to prolonged corticosteroid administration or normal aging, amyloidosis, vasculitis, and scurvy (acquired defects). The bleeding time often is prolonged. If possible, treatment of the underlying condition should be pursued, but if this is not possible or feasible (ie, congenital syndromes), globally hemostatic agents such as DDAVP can be considered for treatment of bleeding.

Sharathkumar AA et al. Hereditary haemorrhagic telangiectasia. *Haemophilia.* 2008 Nov;14(6):1269–80. [PMID: 19141168]

ANTITHROMBOTIC THERAPY

The currently available anticoagulants include unfractionated heparin, LMWHs, fondaparinux, dabigatran, rivaroxaban, and vitamin K antagonists. (For a discussion of the injectable DTIs, see section on **Heparin-Induced Thrombocytopenia**, above.)

Unfractionated heparin is a repeating polymer of sulfated glycosaminoglycans that is most commonly derived from porcine intestinal tissue, which is rich in heparin-bearing mast cells. The pharmacokinetics of unfractionated heparin are poorly predictable, and the degree of anticoagulation must be monitored (by aPTT or anti-Xa level) in patients who are receiving the drug in therapeutic doses. Only a fraction of an infused dose of heparin is metabolized by the kidneys, however, making it safe to use in most patients with significant renal impairment. Unfractionated heparin can be effectively neutralized with the positively charged protamine sulfate (1 mg of protamine neutralizes approximately 100 units of heparin sulfate; maximum dose, 50 mg intravenously). Use of unfractionated heparin leads to HIT in approximately 3% of patients, so most individuals require serial platelet count determinations during the initial 10–14 days of exposure and (some patients) periodically thereafter.

The LMWHs are produced from chemical depolymerization of unfractionated heparin, resulting in products of lower molecular weight (mean molecular weight, 4500–6500d, depending on the LMWH). Due to less protein and cellular binding, the pharmacokinetics of the LMWHs are much more predictable than those of unfractionated heparin, allowing for fixed weight-based dosing. All LMWHs are principally renally cleared and must be avoided or used with extreme caution in individuals with creatinine clearance < 30 mL/min. A longer half-life permits once- or twice-daily subcutaneous dosing, allowing for greater convenience and outpatient therapy in selected cases. Most patients do not require monitoring, although

monitoring using the anti-Xa activity level is appropriate for morbidly obese (BMI > 35) and selected pregnant patients. About 30% of the molecules in a dose of LMWH are long enough (ie, sufficiently negatively charged) to bind protamine sulfate, allowing for some neutralization of anticoagulant effect. LMWHs are associated with a lower frequency of HIT (approximately 0.6%) than unfractionated heparin.

Fondaparinux is a synthetic molecule consisting of the highly active pentasaccharide sequence. Fondaparinux, like the LMWHs, is almost exclusively metabolized by the kidneys, and should be avoided or used with caution in patients with severe renal impairment. Predictable pharmacokinetics allow for weight-based dosing. A particularly long half-life (17–21 hours) allows for once-daily dosing, but the absence of necessary charge characteristics leads to a lack of binding to protamine sulfate; therefore, no effective neutralizing agent exists.

Dabigatran etexilate is an oral DTI that is approved for use in the United States for prevention of stroke and systemic embolism in nonvalvular atrial fibrillation. It is a prodrug that is converted to dabigatran with peak effect within 2 hours. Steady state is reached within 3 days. As renal excretion accounts for about 80% of clearance, dose adjustment is required for decreased renal function. It utilizes the p-glycoprotein transport system and so concomitant use of strong inducers, eg, rifampin, should be avoided. Concomitant use of strong P-gp inhibitors (eg, ketoconazole and dronedarone) should be used with caution, and dose reduction should be considered particularly if renal function is compromised. The half-life of the dabigatran etexilate is 12–17 hours. No laboratory monitoring is required. Neither the INR nor the aPTT may be used to reliably monitor drug effect. No antidote is available to reverse its effect although the drug may be removed by dialysis.

Rivaroxaban is an oral anti-Xa inhibitor that is approved in the United States for post-hip or post-knee replacement prevention of venous thrombosis and for prevention of nonvalvular atrial fibrillation–associated stroke. Its half-life ranges from 5 hours to 13 hours (longer in the elderly). As it has no antidote, rivaroxaban-associated bleeding may be treated by withholding the drug while the anticoagulant effect dissipates and by administration of activated charcoal (if a dose was taken recently).

Vitamin K antagonists such as **warfarin** inhibit the activity of the vitamin K–dependent carboxylase that is important for the posttranslational modification of coagulation factors II, VII, IX, and X. Although warfarin may be taken orally, leading to a significant advantage over the heparins and heparin derivatives, which must be given parenterally or subcutaneously, inter-individual differences in response to the agent related to nutritional status, comorbid diseases, concomitant medications, and genetic polymorphisms lead to a poorly predictable anticoagulant response. Individuals taking warfarin must undergo periodic monitoring to verify the intensity of the anticoagulant effect. The intensity of anticoagulant effect is reported as the INR, which corrects for differences in

potency of commercially available thromboplastin used to perform the PT.¹

Eerenberg ES et al. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. *Circulation*. 2011 Oct 4;124(14):1573–9. [PMID: 21900088]

Ma TK et al. Dabigatran etexilate versus warfarin as the oral anticoagulant of choice? A review of the clinical data. *Pharmacol Ther*. 2011 Feb;129(2):185–94. [PMID: 20920530]

Sattari M et al. Novel oral anticoagulants in development: dabigatran, rivaroxaban, and apixaban. *Am J Ther*. 2011 Jul;18(4):332–8. [PMID: 20535013]

▶ Prevention of Venous Thromboembolic Disease

The frequency of venous thromboembolic disease (VTE) among hospitalized patients ranges widely; up to 20% of low-risk medical patients and 80% of critical care patients and high-risk surgical patients have been reported to experience this complication, which includes deep venous thrombosis (DVT) and pulmonary embolism (PE).

Avoidance of fatal PE, which occurs in up to 5% of high-risk inpatients as a consequence of hospitalization or surgery is a major goal of pharmacologic prophylaxis. Table 14–12 provides a risk stratification for DVT/VTE among hospital inpatients. Standard prophylactic regimens are listed in Table 14–13. Prophylactic strategies should be guided by individual risk stratification, with all moderate- and high-risk patients receiving pharmacologic prophylaxis, unless contraindicated. Contraindications to VTE prophylaxis for hospital inpatients at high risk for VTE are listed in Table 14–14.

Certain high-risk patients should be considered for extended-duration prophylaxis, including those undergoing total hip replacement, hip fracture repair, cancer surgery, and high-risk medical patients (such as those who are immobile or older than 75 years of age). Despite the well-established efficacy and safety of these strategies, thromboprophylaxis continues to be underutilized, particularly in medical patients. Implementation of risk stratification schemas, electronic order sets, availability of new easily administered oral anticoagulants, and physician alerts may increase utilization. A new four-element risk assessment model (cancer, prior VTE, peripherally inserted central catheter [PICC line], or bed rest) may make risk stratification in medical patients easier, increasing use of DVT prophylaxis strategies. If bleeding is present, if the risk of bleeding is high, or if the risk of VTE is high for the inpatient (Table 14–12) and therefore combined prophylactic strategies are needed, some measure of thromboprophylaxis may be provided through use of mechanical devices, including intermittent pneumatic compression devices, venous foot pumps, or graduated compression stockings. The efficacy and safety of graduated compression stockings

¹ Importantly, because the INR is not standardized for abnormalities of factor V and fibrinogen, the INR should be used only in reference to anticoagulation in patients who are receiving warfarin.

Table 14-12. Risk stratification for DVT/VTE among hospital inpatients.

High Risk

Recent major orthopedic surgery/arthroplasty/or fracture
Abdominal/pelvic cancer undergoing surgery
Recent spinal cord injury or major trauma within 90 days
More than 3 of the intermediate risk factors (see below)

Intermediate Risk

Not ambulating independently outside of room at least twice daily
Active infectious or inflammatory process
Active malignancy
Major surgery (non-orthopedic)
History of VTE
Stroke
Central venous access or PICC line
Inflammatory bowel disease
Prior immobilization (> 72 hours) preoperatively
Obesity (BMI > 30)
Patient age > 50 years
Hormone replacement or oral contraceptive therapy
Hypercoagulable state
Nephrotic syndrome
Burns
Cellulitis
Varicose veins
Paresis
CHF (systolic dysfunction)
COPD exacerbation

Low Risk

Minor procedure and age < 40 years with no additional risk factors
Ambulatory with expected length of stay of < 24 hours or minor surgery

BMI, body mass index; CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease; DVT, deep venous thrombosis; PICC, peripherally inserted central catheter; VTE, venous thromboembolic disease (includes DVT and PE).

Adapted from Guidelines used at the VA Medical Center, San Francisco, CA.

in nonsurgical patients have recently been challenged. The CLOTS1 trial found no reduction in VTE in stroke patients randomized to receive them; however, a statistically significant increase in rates of skin breakdown, blisters and necrosis was found.

Bump GM et al. How complete is the evidence for thromboembolism prophylaxis in general medicine patients? A meta-analysis of randomized controlled trials. *J Hosp Med.* 2009 May;4(5):289–97. [PMID: 19504490]

CLOTS Trials Collaboration; Dennis M et al. Effectiveness of thigh-length graduated compression stockings to reduce deep vein thrombosis after stroke (CLOTS trial 1): a multicentre, randomised, controlled trial. *Lancet* 2009 Jun 6;373(9679):1958–65. [PMID: 19477503]

Geerts WH et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). *Chest.* 2008 Jun;133(6 Suppl):381S–453S. [PMID: 18574271]

Hull RD et al; EXCLAIM (Extended Prophylaxis for Venous ThromboEmbolic in Acutely Ill Medical Patients With Prolonged Immobilization) study. Extended-duration venous thromboembolism prophylaxis in acutely ill medical patients

with recently reduced mobility: a randomized trial. *Ann Intern Med.* 2010 Jul 6;153(1):8–18. [PMID: 20621900]

Piazza G et al. Physician alerts to prevent symptomatic venous thromboembolism in hospitalized patients. *Circulation.* 2009 Apr 28;119(16):2196–201. [PMID: 19364975]

Rasmussen MS et al. Prolonged thromboprophylaxis with low molecular weight heparin for abdominal or pelvic surgery. *Cochrane Database Syst Rev.* 2009 Jan 21;(1):CD004318. [PMID: 19160234]

Woller SC et al. Derivation and validation of a simple model to identify venous thromboembolism risk in medical patients. *Am J Med.* 2011 Oct;124(10):947–54. [PMID: 21962315]

► Treatment of Venous Thromboembolic Disease

A. Anticoagulant Therapy

Treatment for VTE should be offered to patients with objectively confirmed DVT or PE, or to those in whom the clinical suspicion is high for the disorder yet have not yet undergone diagnostic testing (see Chapter 9). The management of VTE primarily involves administration of anticoagulants, which initially are given parenterally followed by long-term oral therapy; the goal is to prevent recurrence, extension and embolization of thrombosis and to reduce the risk of post-thrombotic syndrome. Suggested anticoagulation regimens are found in Table 14–15.

B. Selecting Appropriate Anticoagulant Therapy

Most patients with DVT alone may be treated as outpatients, provided that their risk of bleeding is low, they are candidates for injectable anticoagulants, and they have good follow-up. Table 14–16 outlines the selection criteria for outpatient treatment of DVT. Patients who are hospitalized for DVT should receive initial anticoagulation with heparin or LMWH as outlined in Table 14–15.

Among patients with PE, risk stratification should be done at time of diagnosis to direct treatment and triage. Patients with persistent hemodynamic instability (or patients with massive PE) are classified as high risk and have an early PE-related mortality of > 15%. These patients should be admitted to an intensive care unit and receive thrombolysis in addition to anticoagulation. Intermediate-risk patients have a mortality rate of up to 15% and should be admitted to a higher level of inpatient care, with consideration of thrombolysis on a case-by-case basis. Those classified as low risk have a mortality rate < 3% and are candidates for expedited discharge or outpatient therapy. Although both intermediate- and low-risk patients are hemodynamically stable, additional assessment is necessary to differentiate the two. Echocardiography can be used to identify patients with right ventricular dysfunction, which connotes intermediate risk. However, real-time echocardiography involves added cost and is not always immediately available. An LV/RV ratio < 1.0 on chest CT angiogram has been shown to have good negative predictive value for adverse outcome but suffers from inter-observer variability. Serum biomarkers such as B-type natriuretic peptide and troponin have been studied and are

Table 14-13. Pharmacologic prophylaxis of VTE in selected clinical scenarios.¹

Anticoagulant	Dose	Frequency	Clinical Scenario	Comment
Enoxaparin	40 mg	Once daily	Most medical inpatients and critical care patients	—
			Surgical patients (moderate risk for VTE)	Consider continuing for 4 weeks total duration for cancer surgery and high-risk medical patients
	30 mg	Twice daily	Abdominal/pelvic cancer surgery	Higher doses may be required
			Bariatric surgery	Give for at least 10 days. For THR, TKA, or HFS, consider continuing up to 1 month after surgery in high-risk patients
		Twice daily	Orthopedic surgery ²	Not applicable to patients with isolated lower extremity trauma
		Major trauma	—	
Acute spinal cord injury	—			
Dalteparin	2500 units	Once daily	Most medical inpatients	—
	5000 units	Once daily	Abdominal surgery (moderate risk for VTE)	Give for 5-10 days
			Orthopedic surgery ²	First dose = 2500 units. Give for at least 10 days. For THR, TKA, or HFS, consider continuing up to 1 month after surgery in high-risk patients
	Abdominal surgery (higher-risk for VTE)	Give for 5-10 days		
Medical inpatients	—			
Fondaparinux	2.5 mg	Once daily	Orthopedic surgery ²	Give for at least 10 days. For THR, TKA or HFS, consider continuing up to 1 month after surgery in high-risk patients
Rivaroxaban	10 mg	Once daily	Orthopedic surgery—total hip and total knee replacement	Give for 12 days following total knee replacement; give for 35 days following total hip replacement
Unfractionated heparin	5000 units	Three times daily	Higher VTE risk with low bleeding risk	Includes gynecologic surgery for malignancy and urologic surgery, medical patients with multiple risk factors for VTE
	5000 units	Twice daily	Hospitalized patients at intermediate risk for VTE	Includes gynecologic surgery (moderate risk)
			Patients with epidural catheters	LMWHs usually avoided due to risk of spinal hematoma
Patients with severe renal insufficiency ³	LMWHs contraindicated			
Warfarin	(variable)	Once daily	Orthopedic surgery ²	Titrate to goal INR = 2.5. Give for at least 10 days. For high-risk patients undergoing THR, TKA, or HFS, consider continuing up to 1 month after surgery

¹All regimens administered subcutaneously, except for warfarin.

²Includes TKA, THR, and HFS.

³Defined as creatinine clearance < 30 mL/min.

HFS, hip fracture surgery; LMWH, low-molecular-weight heparin; THR, total hip replacement; TKA, total knee arthroplasty; VTE, venous thromboembolic disease.

most useful for their negative predictive value, and mainly in combination with other predictors. The PESI (pulmonary embolism severity index) clinical risk score, which does not require additional testing, has been validated and accurately identifies patients at low risk for 30-day PE-related mortality (Table 14-17). A simplified version of this risk score has been proposed and is undergoing further validation.

1. Heparin—Selection of a parenteral anticoagulant should be determined by patient characteristics (kidney function, immediate bleeding risk, weight) and clinical scenario (eg, whether thrombolysis is being considered). LMWHs are as efficacious as unfractionated heparin in the immediate treatment of DVT and PE and are preferred as initial treatment because of predictable pharmacokinetics, which allow for subcutaneous, once- or twice-daily dosing

Table 14-14. Contraindications to VTE prophylaxis for medical or surgical hospital inpatients at high risk for VTE.

Absolute contraindications

Acute hemorrhage from wounds or drains or lesions
 Intracranial hemorrhage within prior 24 hours
 Heparin-induced thrombocytopenia (HIT) considering using fondaparinux
 Severe trauma to head or spinal cord or extremities
 Epidural anesthesia/spinal block within 12 hours of initiation of anticoagulation (concurrent use of an epidural catheter and LMWH thromboprophylaxis should require approval by service who performed the epidural or spinal procedure, eg, anesthesia/pain service)
 Currently receiving warfarin or heparin or LMWH or direct thrombin inhibitor for other indications

Relative contraindications

Coagulopathy (INR > 1.5)
 Intracranial lesion or neoplasm
 Severe thrombocytopenia (platelet count < 50,000/mcL)
 Intracranial hemorrhage within past 6 months
 Gastrointestinal or genitourinary hemorrhage within past 6 months

INR, international normalized ratio; LMWH, low-molecular-weight heparin; VTE, venous thromboembolic disease.

Adapted from Guidelines used at the VA Medical Center, San Francisco, CA.

with no requirement for monitoring in most patients. Monitoring of the therapeutic effect of LMWH may be indicated in pregnancy, compromised kidney function, and extremes of weight. Accumulation of LMWH and increased rates of bleeding have been observed among patients with severe chronic kidney disease (creatinine clearance < 30 mL/min), leading to a recommendation to use intravenous unfractionated heparin preferentially in these patients. If concomitant thrombolysis is being considered, unfractionated heparin is indicated. In addition, patients with VTE and a perceived higher risk of bleeding (ie, post-surgery) may be better candidates for treatment with unfractionated heparin than LMWH given its shorter half-life and reversibility.

Weight-based, fixed-dose daily subcutaneous fondaparinux (a synthetic factor Xa inhibitor) may also be used for the initial treatment of DVT and PE, with no increase in bleeding over that observed with LMWH. Its lack of reversibility, long half-life, and primarily renal clearance limits its use in patients with an increased risk of bleeding or renal failure.

2. Warfarin—Patients with DVT with or without PE require a minimum of 3 months of anticoagulation in order to reduce the risk of recurrence of thrombosis. An oral vitamin K antagonist, such as warfarin, is usually initiated along with the parenteral anticoagulant, although patients with cancer-related thrombosis may benefit from ongoing treatment with LMWH alone. Most patients require 5 mg of warfarin daily for initial treatment, but lower doses (2.5 mg daily) should be considered for patients of Asian descent, the elderly, and those with hyperthyroidism, congestive heart failure, liver disease, recent

major surgery, malnutrition, certain polymorphisms for the CYP2C9 or the VKORC1 genes or who are receiving concurrent medications that increase sensitivity to warfarin (Table 14-18). Conversely, individuals of African descent, those with larger body mass index or hypothyroidism, and those who are receiving medications that increase warfarin metabolism may require higher initial doses (7.5 mg daily). Daily INR results should guide dosing adjustments (Table 14-19). Web-based warfarin dosing calculators that consider these clinical and genetic factors are available to help clinicians choose the appropriate starting dose (eg, see www.warfarindosing.org). Because an average of 5 days is required to achieve a steady-state reduction in the activity of vitamin K-dependent coagulation factors, the parenteral anticoagulant should be continued for at least 5 days and until the INR is > 2.0 on 2 consecutive days. Meticulous follow-up should be arranged for all patients taking warfarin (Table 14-19) because of the bleeding risk that is associated with initiation of therapy. INR monitoring should occur at least twice weekly during initiation. Once stabilized, the INR should be checked at an interval no longer than every 4 weeks and warfarin dosing adjusted in accordance with the guidelines outlined in Table 14-20. Nontherapeutic INRs should be managed according to evidence-based guidelines (Table 14-21).

3. New investigational oral anticoagulants—The vitamin K antagonists have been the only oral anticoagulants available for nearly 7 decades. Now, a number of novel oral anticoagulant agents that promise more predictable dose effect and ease of administration than warfarin are becoming available. Dabigatran, an oral DTI, has been shown to be noninferior to warfarin for treatment of VTE. Although not yet approved by the FDA for this indication, it is currently available for prevention of embolization in nonvalvular atrial fibrillation. Rivaroxaban, an oral direct factor Xa inhibitor, is approved in the United States for DVT prevention and stroke prevention in patients with atrial fibrillation; it has been shown to be as effective as standard therapy for the prevention of recurrent DVT. These new agents have predictable dose effects, minimal drug interactions, rapid onset of action, and no need for laboratory monitoring. Once additional therapies are available for treatment of VTE, agent selection will depend on renal function, concomitant medications, cost, and adherence issues.

4. Duration of anticoagulation therapy—The clinical scenario in which the thrombosis occurred is the strongest predictor of recurrence and, in most cases, guides duration of anticoagulation (Table 14-22). In the first year after discontinuation of anticoagulation therapy, the frequency of recurrence of VTE among individuals whose thrombosis occurred in the setting of a transient, major, reversible risk factor (such as surgery) is approximately 3%, compared with at least 8% for individuals whose thrombosis was unprovoked, and > 20% in patients with cancer. Patients with provoked VTE are generally treated with a minimum of 3 months of anticoagulation, whereas unprovoked VTE should prompt consideration of indefinite anticoagulation. Individual risk stratification may

Table 14-15. Initial anticoagulation for VTE.¹

Anticoagulant	Dose/ Frequency	Clinical Scenario					Comment
		DVT, Lower Extremity	DVT, Upper Extremity	PE	VTE, with Concomitant Severe Renal Impairment ²	VTE, Cancer- Related	
Unfractionated heparin	80 units/kg intravenous bolus then continuous intravenous infusion of 18 units/kg/h	×	×	×	×		Bolus may be omitted if risk of bleeding is perceived to be elevated. Maximum bolus, 10,000 units. Requires aPTT monitoring. Most patients: begin warfarin at time of initiation of heparin aPTT monitoring required with dose adjustment Fixed-dose; no aPTT monitoring required
	17,500 units subcutaneously every 12 hours (initial dose)						
	330 units/kg subcutaneously × 1 then 250 units/kg subcutaneously every 12 hours	×					
Enoxaparin ³	1 mg/kg subcutaneously every 12 hours	×	×	×			Most patients: begin warfarin at time of initiation of LMWH
	1.5 mg/kg subcutaneously once daily		×				
Tinzaparin ³	175 units/kg subcutaneously once daily	×	×	×		×	Cancer: administer LMWH for ≥ 3-6 months
Dalteparin ³	200 units/kg subcutaneously once daily for first month	×	×	×		×	Cancer: administer LMWH for ≥ 3-6 months; reduce dose to 150 units/kg after first month of treatment
Fondaparinux	5-10 mg subcutaneously once daily (see Comment)	×	×	×			Use 7.5 mg for body weight 50-100 kg; 10 mg for body weight > 100 kg

Note: An "×" denotes appropriate use of the anticoagulant.

¹Obtain baseline hemoglobin, platelet count, aPTT, PT/INR, creatinine, urinalysis, and hemocult prior to initiation of anticoagulation. *Anticoagulation is contraindicated in the setting of active bleeding.*

²Defined as creatinine clearance < 30 mL/min.

³Body weight < 50 kg: reduce dose and monitor anti-Xa levels.

DVT, deep venous thrombosis; PE, pulmonary embolism; VTE, venous thromboembolic disease (includes DVT and PE).

help identify patients most likely to suffer recurrent disease and thus most likely to benefit from ongoing anticoagulation therapy. Normal D-dimer levels 1 month after cessation of anticoagulation are associated with lower recurrence risk, although some would argue not low enough to consider staying off therapy. The predictive value of presence of residual vein thrombosis after completion of 3 months of anticoagulation is unclear, with some studies showing much lower recurrence rates in patients without residual thrombosis while other studies show equal recurrence rates regardless of findings on follow-up ultrasound. A risk scoring system using BMI, age, D-dimer and post-phlebotic symptoms has been developed to identify women at lower risk for recurrence after unprovoked VTE. The Vienna Prediction Model, a simple

scoring system based on age, sex, D-dimer, and location of thrombosis, can help estimate an individual's recurrence risk to guide duration of therapy decisions. The following facts are important to consider when determining duration of therapy: (1) men have a greater than twofold higher risk of recurrent VTE compared to women; and (2) recurrent PE is more likely to develop in patients with clinically apparent PE than in those with DVT alone. Work up for laboratory thrombophilia is no longer recommended routinely for determining duration of therapy because clinical presentation is a much stronger predictor of recurrence risk. This work up may be pursued in patients younger than 50 years, with a strong family history, with a clot in unusual locations, or with recurrent thromboses. In addition, a work up for thrombophilia

Table 14-16. Patient selection for outpatient treatment of DVT.**Patients considered appropriate for outpatient treatment**

No clinical signs or symptoms of PE and pain controlled
 Motivated and capable of self-administration of injections
 Confirmed prescription insurance that covers injectable medication or patient can pay out-of-pocket for injectable agents
 Capable and willing to comply with frequent follow-up
 Initially, patients may need to be seen daily to weekly

Potential contraindications for outpatient treatment

DVT involving inferior vena cava, iliac, common femoral, or upper extremity vein (these patients might benefit from vascular intervention)
 Comorbid conditions
 Active peptic ulcer disease, GI bleeding in past 14 days, liver synthetic dysfunction
 Brain metastases, current or recent CNS or spinal cord injury/surgery in the last 10 days, CVA \leq 4-6 weeks
 Familial bleeding diathesis
 Active bleeding from source other than GI
 Thrombocytopenia
 Creatinine clearance $<$ 30 mL/min
 Patient weighs $<$ 55 kg (male) or $<$ 45 kg (female)
 Recent surgery, spinal or epidural anesthesia in the past 3 days
 History of heparin-induced thrombocytopenia
 Inability to inject medication at home, reliably follow medication schedule, recognize changes in health status, understand or follow directions

Table 14-17. Pulmonary Embolism Severity Index (PESI)

Risk factor	Points	
Age	No. of years of age	
Male sex	10	
Cancer	30	
Heart failure	10	
Chronic lung disease	10	
Heart rate $>$ 110 bpm	20	
Systolic blood pressure $<$ 100 mm Hg	20	
Respiratory rate $>$ 30 breaths per minute	20	
Temperature $<$ 36°C	20	
Change in mental status	60	
Oxygen saturation $<$ 90%	20	
Severity class	Points	30-day mortality
I	0-65	$<$ 1.6%
II	66-85	$<$ 3.5%
III	86-105	$<$ 7.1%
IV	106-125	4-11.4%
V	$>$ 125	10-24.5%

Adapted, with permission, from Aujesky D et al. Derivation and validation of a prognostic model for pulmonary embolism. *Am J Respir Crit Care Med.* 2005 Oct 15;172(8):1041-6. Reprinted with permission of the American Thoracic Society. © American Thoracic Society

Table 14-18. Commonly used agents and their potential effect on the INR.

Tendency to Increase INR	Tendency to Decrease INR
Phenytoin	Phenytoin
Erythromycin	Rifampin/rifabutin
Metronidazole	Carbamazepine
Ketoconazole	Vitamin K
Trimethoprim-sulfamethoxazole	Phenobarbital
Amiodarone	Sucralfate
Cimetidine	Ginseng
Alcohol	Alcohol
Fluconazole	
Itraconazole	
Statins	

INR, international normalized ratio.

should be considered in women of childbearing age in whom results may influence fertility and pregnancy outcomes and management. The benefit of anticoagulation must be weighed against the bleeding risks posed, and the benefit-risk ratio should be assessed at the initiation of therapy, at 3 months, and then at least annually in any patient receiving prolonged anticoagulant therapy. Bleeding risk scores have been developed to help clinicians in this process.

Table 14-19. Warfarin adjustment guidelines for patients newly starting therapy.

	INR	Action
Day 1		5 mg (2.5 or 7.5 mg in select populations ¹)
Day 2	$<$ 1.5	Continue dose
	\geq 1.5	Decrease or hold dose ²
Day 3	\leq 1.2	Increase dose ²
	$>$ 1.2 and $<$ 1.7	Continue dose
	\geq 1.7	Decrease dose ²
Day 4 until therapeutic	Daily increase is $<$ 0.2 units	Increase dose ²
	Daily increase 0.2-0.3 units	Continue dose
	Daily increase 0.4-0.6 units	Decrease dose ²
	Daily increase \geq 0.7 units	Hold dose

¹See text

²In general, dosage adjustments should not exceed 2.5 mg or 50%.

Table 14-20. Warfarin dosing adjustment guidelines for patients receiving long-term therapy.

Patient INR	Weekly Dosing Change		
	Goal = 1.5-2.0 INR	Goal = 2.0-3.0 INR	Goal = 2.5-3.5 INR
< 1.5	↑5-10%	↑5-20%	↑15-20%
1.5-2.0	Therapeutic	↑5-10%	↑5-20%
2.0-2.5	↓ 5-10%	Therapeutic	↑5-10%
2.5-3.0	↓ 5-15%	Therapeutic	Therapeutic
3.0-3.5	(May hold) ↓ 10-20%	↓ 5-10% Or may stay same if just at or above 3.0	Therapeutic
3.5-4.0	HOLD dose ↓ 20-50%	(May hold) ↓ 5-10%	↓ 5-10% Or may stay same if just at or above 3.5
4.0-5.0	HOLD 2-3 days ↓ 20-50%	HOLD 1-2 days ↓ 10-20%	(May hold) ↓ 5-15%

Adapted from Guidelines used at the VA Medical Center, Reno NV.

Aujesky D et al. Outpatient versus inpatient treatment for patients with acute pulmonary embolism: an international, open-label, randomised, non-inferiority trial. *Lancet*. 2011 Jul 2;378(9785):41-8. [PMID: 21703676]

Douketis J et al. Risk of recurrence after venous thromboembolism in men and women: patient level meta-analysis. *BMJ*. 2011 Feb 24;342:d813. [PMID: 21349898]

Eichinger S et al. Risk assessment of recurrence in patients with unprovoked deep vein thrombosis or pulmonary embolism: the Vienna Prediction Model. *Circulation*. 2010 Apr 13;121(14):1630-6. [PMID: 20351233]

EINSTEIN Investigators; Bauersachs R et al. Oral rivaroxaban for symptomatic venous thromboembolism. *N Engl J Med*. 2010;Dec 23;363(26):2499-510. [PMID: 21128814]

Gage BF. Pharmacogenetics-based coumarin therapy. *Hematology Am Soc Hematol Educ Program*. 2006:467-73. [PMID: 17124101]

Jiménez D et al. Simplification of the Pulmonary Embolism Severity Index for prognostication in patients with acute symptomatic pulmonary embolism. *Arch Intern Med*. 2010;170(15):1383-9. [PMID: 20696966]

Table 14-21. American College of Chest Physicians Evidence-based Clinical Practice Guidelines for the Management of Nontherapeutic INR.

Clinical Situation	INR	Recommendations
No significant bleed	Above therapeutic range but < 5.0	<ul style="list-style-type: none"> Lower dose or omit dose Monitor more frequently and resume at lower dose when INR falls within therapeutic range (if INR only slightly above range, may not be necessary to decrease dose)
	≥ 5.0 but < 9.0	<ul style="list-style-type: none"> Hold next 1-2 doses Monitor more frequently and resume therapy at lower dose when INR falls within therapeutic range <i>Patients at high risk for bleeding</i>¹: Hold warfarin PLUS give vitamin K₁ 1-2.5 mg orally, check INR in 24-48 h to ensure response to therapy
	≥ 9.0	<ul style="list-style-type: none"> Hold warfarin Vitamin K₁ 2.5-5 mg orally Monitor frequently and resume therapy at lower dose when INR within therapeutic range
Serious/life-threatening bleed		<ul style="list-style-type: none"> Hold warfarin and give 10 mg vitamin K by slow intravenous infusion supplemented by FFP, PCC, or recombinant factor VIIa

¹Patients at higher risk for bleeding include the elderly; conditions that increase the risk of bleeding include renal failure, hypertension, falls, liver disease, and history of gastrointestinal or genitourinary bleeding.

FFP, fresh frozen plasma; INR, international normalized ratio; PCC, prothrombin complex concentrate.

Adapted, with permission, from Ansell J et al. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). *Chest*. 2008 Jun;133(6 Suppl):160S-198S.

Table 14-22. Duration of treatment of VTE.

Scenario	Suggested Duration of Therapy	Comments
Major transient risk factor (eg, immobilization, major surgery, major trauma, major hospitalization)	At least 3 months	VTE prophylaxis upon future exposure to transient risk factors
Minor transient risk factor (eg, exposure to exogenous estrogens/progestins, pregnancy, airline travel lasting more than 6 hours)	At least 3 months	VTE prophylaxis upon future exposure to transient risk factors
Cancer-related VTE	≥ 3–6 months or as long as cancer active, whichever is longer	LMWH recommended for initial treatment (see Table 14-15)
Unprovoked thrombosis	At least 3 months, consider indefinite if bleeding risk allows	May individually risk-stratify for recurrence with follow-up ultrasound, D-dimer, clinical risk score, and clinical presentation
Underlying significant thrombophilia (eg, antiphospholipid antibody syndrome, antithrombin deficiency, protein C deficiency, protein S deficiency, ≥ two concomitant thrombophilic conditions)	Indefinite	To avoid false positives, consider delaying investigation for laboratory thrombophilia until 3 months after event

LMWH, low-molecular-weight heparin; VTE, venous thromboembolic disease.

Kearon C et al. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guideline (8th Edition). *Chest*. 2008 Jun;133(6 Suppl):454S–545S. [PMID: 18574272]

Prandoni P et al. The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients. *Haematologica*. 2007 Feb;92(2):199–205. [PMID: 17296569]

Rodger MA et al. Identifying unprovoked thromboembolism patients at low risk for recurrence who can discontinue anticoagulant therapy. *CMAJ*. 2008 Aug 26;179(5):417–26. [PMID: 18725614]

Ruiz-Gimenez N et al. Predictive variables for major bleeding events in patients presenting with documented acute venous thromboembolism. Findings from the RIETE Registry. *Thromb Haemost*. 2008 Jul;100(1):26–31. [PMID: 18612534]

Schulman S et al; RE-COVER Study Group. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. *N Engl J Med*. 2009 Dec 10;361(24):2342–52. [PMID: 19966341]

Siragusa S et al. Residual vein thrombosis to establish duration of anticoagulation after a first episode of deep vein thrombosis: the Duration of Anticoagulation based on Compressive UltraSonography (DACUS) study. *Blood*. 2008 Aug 1;112(3):511–5. [PMID: 18497320]

Torbicki A et al. Guidelines on the diagnosis and management of acute pulmonary embolism: the Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). *Eur Heart J*. 2008 Sep;29(18):2276–315. [PMID: 18757870]

Verhovsek M et al. Systematic review: D-dimer to predict recurrent disease after stopping anticoagulant therapy for unprovoked venous thromboembolism. *Ann Intern Med*. 2008 Oct 7;149(7):481–90. [PMID: 18838728]

Weitz J et al. New antithrombotic drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guideline (8th Edition). *Chest*. 2008 Jun;133(6 Suppl):234S–256S. [PMID: 18574267]

Wittkowsky AK. New oral anticoagulants: a practical guide for clinicians. *J Thromb Thrombolysis*. 2010 Feb;29(2):182–91. [PMID: 19888552]

C. Thrombolytic Therapy

Anticoagulation alone is appropriate treatment for most patients with PE; however, those with high-risk, massive PE, defined as PE with persistent hemodynamic instability, have an in-hospital mortality rate that approaches 30% and require immediate thrombolysis in combination with anticoagulation (Table 14-23). A 50% reduced dosing

Table 14-23. Thrombolytic therapies for acute massive pulmonary embolism.

Thrombolytic Agent	Dose	Frequency	Comment
Alteplase	100 mg	Continuous intravenous infusion over 2 hours	Follow with continuous intravenous infusion of unfractionated heparin
	100 mg	Intravenous bolus × 1	Appropriate for acute management of cardiac arrest and suspected pulmonary embolism
Urokinase	4400 international units/kg	Intravenous bolus × 1 followed by 4400 international units/kg continuous intravenous infusion for 12 hours	Unfractionated heparin should be administered concurrently

regimen for tissue plasminogen activator (TPA) has recently been proposed, offering similar efficacy with lower risk of complications. Thrombolytic therapy also has been used in selected patients with intermediate-risk, submassive PE, defined as PE without hemodynamic instability but with evidence of right ventricular compromise. This approach remains controversial, however, given the paucity of data showing a clinically significant benefit of thrombolysis.

Limited data suggest that patients with large proximal iliofemoral DVT may also benefit from catheter-directed thrombolysis in addition to treatment with anticoagulation. However, standardized guidelines are lacking, and use of the intervention may be limited by institutional availability and provider experience. Importantly, thrombolytics should be considered only in patients who have a low risk of bleeding, as rates of bleeding are increased in patients who receive these products compared with rates of hemorrhage in those who are treated with anticoagulation alone.

Dong BR et al. Thrombolytic therapy for pulmonary embolism. *Cochrane Database Syst Rev.* 2009 Jul 8;(3):CD004437. [PMID: 19588357]

Enden T et al; CaVenT study group. Catheter-directed thrombolysis vs. anticoagulant therapy alone in deep vein thrombosis: results of an open randomized, controlled trial reporting on short-term patency. *J Thromb Haemost.* 2009 Aug;7(8):1268–75. [PMID: 19422443]

Kearon C et al. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guideline (8th Edition). *Chest.* 2008 Jun;133(6 Suppl):454S–545S. [PMID: 18574272]

Todd JL et al. Thrombolytic therapy for acute pulmonary embolism: a critical appraisal. *Chest.* 2009 May;135(5):1321–9. [PMID: 19420199]

Vedantham S. Interventional approaches to acute venous thromboembolism. *Semin Respir Crit Care Med.* 2008 Feb;29(1):56–65. [PMID: 18302087]

Wang C et al; China Venous Thromboembolism (VTE) Study Group. Efficacy and safety of low dose recombinant tissue-type plasminogen activator for the treatment of acute pulmonary thromboembolism: a randomized, multicenter, controlled trial. *Chest.* 2010 Feb;137(2):254–62. [PMID: 19741062]

In this study, patients with documented DVT received full intensity, time-limited anticoagulation with or without placement of an IVC filter. Patients with IVC filters had a lower rate of nonfatal PE at 12 days but an increased rate of DVT at 2 years. Most experts agree with placement of an IVC filter in patients with acute proximal DVT who concurrently have an absolute contraindication to anticoagulation. While IVC filters were once commonly used to prevent VTE recurrence in the setting of anticoagulation failure, many experts now recommend switching to an alternative agent or increasing the intensity of the current anticoagulant regimen instead. The remainder of the indications (submassive/ intermediate-risk PE, free-floating iliofemoral DVT, perioperative risk reduction) are controversial. If the contraindication to anticoagulation is temporary (active bleeding with subsequent resolution), placement of a retrievable IVC filter should be considered so that the device can be removed once anticoagulation has been started and has been shown to be tolerated. Rates of IVC filter retrieval are very low, often due to a failure to arrange for its removal. Thus, if a device is placed, timely removal should be arranged at the time of device placement.

Complications of IVC filters include local thrombosis, tilting, migration, fracture, and inability to retrieve the device. When considering placement of an IVC filter, it is best to consider both short- and long-term complications, since devices intended for removal may become permanent. To improve patient safety, institutions should develop systems that guide appropriate patient selection for IVC filter placement, tracking, and removal.

Barral FG. Vena cava filters: why, when, what and how? *J Cardiovasc Surg (Torino).* 2008 Feb;49(1):35–49. [PMID: 18212686]

Minichiello TA. Efforts to optimize patient benefit from inferior vena cava filters. *Arch Intern Med.* 2011 Nov 28;171(21):1948–64. [PMID: 22123807]

PREPIC Study Group. Eight-year follow-up of patients with permanent vena cava filters in the prevention of pulmonary embolism: the PREPIC (Prévention du Risque d'Embolie Pulmonaire par Interruption Cave) randomized study. *Circulation.* 2005 Jul 19;112(3):416–22. [PMID: 16009794]

D. Nonpharmacologic Therapy

1. Graduated compression stockings—In order to reduce the likelihood of the post-thrombotic syndrome, which is characterized by swelling, pain, and skin ulceration, all patients with DVT should wear a graduated compression stocking with 30–40 mm Hg pressure at the ankle on the affected lower extremity for 1–2 years. Stockings should be provided immediately to have the most impact on post-thrombotic syndrome; however, they are contraindicated in patients with peripheral vascular disease.

Kolbach DN et al. Non-pharmacologic measures for prevention of post-thrombotic syndrome. *Cochrane Database Syst Rev.* 2004;(1):CD004174. [PMID: 14974060]

2. Inferior vena caval (IVC) filters—There is a paucity of data to support the use of IVC filters for the prevention of PE in any clinical scenario. There is only one available randomized, controlled trial of IVC filters for prevention of PE.

▶ When to Refer

- Presence of large iliofemoral VTE, IVC thrombosis, portal vein thrombosis, or Budd-Chiari syndrome for consideration of catheter-directed thrombolysis.
- Massive PE for urgent embolectomy.
- History of HIT or prolonged PTT plus renal failure for alternative anticoagulation regimens.
- Consideration of IVC filter placement.

▶ When to Admit

- Documented or suspected PE (some patients with low-risk PE may not require admission).
- DVT with poorly controlled pain, high bleeding risk, contraindications to LMWH or fondaparinux.
- Large iliofemoral DVT for consideration of thrombolysis.
- Acute DVT and absolute contraindication to anticoagulation for IVC filter placement.

15

Gastrointestinal Disorders

Kenneth R. McQuaid, MD

SYMPTOMS & SIGNS OF GASTROINTESTINAL DISEASE

DYSPEPSIA



ESSENTIALS OF DIAGNOSIS

- ▶ Epigastric pain or burning, early satiety, or postprandial fullness.
- ▶ Endoscopy is warranted in patients with alarm features or in those older than 55 years.
- ▶ All other patients should first undergo testing for *Helicobacter pylori* or a trial of empiric proton pump inhibitor.

▶ General Considerations

Dyspepsia refers to acute, chronic, or recurrent pain or discomfort centered in the upper abdomen. An international committee of clinical investigators (Rome III Committee) has defined dyspepsia as epigastric pain or burning, early satiety, or postprandial fullness. Heartburn (retrosternal burning) should be distinguished from dyspepsia. When heartburn is the dominant complaint, gastroesophageal reflux is nearly always present. Dyspepsia occurs in 15% of the adult population and accounts for 3% of general medical office visits.

▶ Etiology

A. Food or Drug Intolerance

Acute, self-limited “indigestion” may be caused by overeating, eating too quickly, eating high-fat foods, eating during stressful situations, or drinking too much alcohol or coffee. Many medications cause dyspepsia, including aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), antibiotics (metronidazole, macrolides), diabetes drugs (metformin, α -glucosidase inhibitors, amylin analogs, GLP-1 receptor antagonists), antihypertensive medications (angiotensin-converting enzyme [ACE] inhibitors, angiotensin-receptor

blockers), cholesterol-lowering agents (niacin, fibrates), neuropsychiatric medications (cholinesterase inhibitors [donepezil, rivastigmine]), SSRIs (fluoxetine, sertraline), serotonin-norepinephrine-reuptake inhibitors (venlafaxine, duloxetine), Parkinson drugs (dopamine agonists, monoamine oxidase [MAO]-B inhibitors), corticosteroids, estrogens, digoxin, iron, and opioids.

B. Functional Dyspepsia

This is the most common cause of *chronic* dyspepsia. Up to three-fourths of patients have no obvious organic cause for their symptoms after evaluation. Symptoms may arise from a complex interaction of increased visceral afferent sensitivity, gastric delayed emptying or impaired accommodation to food, or psychosocial stressors. Although benign, these symptoms may be chronic and difficult to treat.

C. Luminal Gastrointestinal Tract Dysfunction

Peptic ulcer disease is present in 5–15% of patients with dyspepsia. Gastroesophageal reflux disease (GERD) is present in up to 20% of patients with dyspepsia, even without significant heartburn. Gastric or esophageal cancer is identified in 0.25–1% but is extremely rare in persons under age 55 years with uncomplicated dyspepsia. Other causes include gastroparesis (especially in diabetes mellitus), lactose intolerance or malabsorptive conditions, and parasitic infection (*Giardia*, *Strongyloides*, *Anisakis*).

D. *Helicobacter pylori* Infection

Although chronic gastric infection with *H pylori* is an important cause of peptic ulcer disease, it is an uncommon cause of dyspepsia in the absence of peptic ulcer disease. The prevalence of *H pylori*-associated chronic gastritis in patients with dyspepsia without peptic ulcer disease is 20–50%, the same as in the general population.

E. Pancreatic Disease

Pancreatic carcinoma and chronic pancreatitis may present with dyspepsia.

F. Biliary Tract Disease

The abrupt onset of epigastric or right upper quadrant pain due to cholelithiasis or choledocholithiasis should be readily distinguished from dyspepsia.

G. Other Conditions

Diabetes mellitus, thyroid disease, chronic kidney disease, myocardial ischemia, intra-abdominal malignancy, gastric volvulus or paraesophageal hernia, and pregnancy are sometimes accompanied by dyspepsia.

► Clinical Findings

A. Symptoms and Signs

Given the nonspecific nature of dyspeptic symptoms, the history has limited diagnostic utility. It should clarify the chronicity, location, and quality of the discomfort, and its relationship to meals. The discomfort may be characterized by one or more upper abdominal symptoms including epigastric pain or burning, early satiety, postprandial fullness, bloating, nausea, or vomiting. Concomitant weight loss, persistent vomiting, constant or severe pain, dysphagia, hematemesis, or melena warrants endoscopy or abdominal imaging. Potentially offending medications and excessive alcohol use should be identified and discontinued if possible. The patient's reason for seeking care should be determined. Recent changes in employment, marital discord, physical and sexual abuse, anxiety, depression, and fear of serious disease may all contribute to the development and reporting of symptoms. Patients with functional dyspepsia often are younger, report a variety of abdominal and extragastrointestinal complaints, show signs of anxiety or depression, or have a history of use of psychotropic medications.

The symptom profile alone does not differentiate between functional dyspepsia and organic gastrointestinal disorders. Based on the clinical history alone, primary care clinicians misdiagnose nearly half of patients with peptic ulcers or gastroesophageal reflux and have < 25% accuracy in diagnosing functional dyspepsia.

The physical examination is rarely helpful. Signs of serious organic disease such as weight loss, organomegaly, abdominal mass, or fecal occult blood are further evaluated. In patients older than age of 55 years, initial laboratory work should include a blood count, electrolytes, liver enzymes, calcium, and thyroid function tests.

B. Laboratory Findings

In patients younger than 55 years with uncomplicated dyspepsia (in whom gastric cancer is rare), initial noninvasive strategies should be pursued (see below). In most clinical settings, a noninvasive test for *H pylori* (urea breath test, fecal antigen test, or IgG serology) should be performed first. Although serologic tests are inexpensive, performance characteristics are poor in low-prevalence populations, whereas breath and fecal antigen tests have 95% accuracy. If *H pylori* breath test or fecal antigen test results are negative in a patient not taking NSAIDs, peptic ulcer disease is virtually excluded.

C. Upper Endoscopy

Upper endoscopy is indicated to look for gastric cancer or other serious organic disease in all patients over age 55 years with new-onset dyspepsia and in all patients with "alarm" features, such as weight loss, dysphagia, recurrent vomiting, evidence of bleeding, or anemia. Upper endoscopy is the study of choice to diagnose gastroduodenal ulcers, erosive esophagitis, and upper gastrointestinal malignancy. It is also helpful for patients who are concerned about serious underlying disease. For patients born in regions in which there is a higher incidence of gastric cancer, an age threshold of 45 years may be appropriate.

Endoscopic evaluation is also warranted when symptoms fail to respond to initial empiric management strategies within 4–8 weeks or when frequent symptom relapse occurs after discontinuation of antisecretory therapy.

D. Other Tests

Abdominal imaging (ultrasonography or CT scanning) is performed only when pancreatic or biliary tract disease is suspected. Gastric emptying studies are valuable only in patients with recurrent vomiting. Ambulatory esophageal pH testing may be of value when atypical gastroesophageal reflux is suspected.

► Treatment

Initial empiric treatment is warranted for patients who are < 55 years and who have no alarm features (defined above). All other patients as well as patients whose symptoms fail to respond or relapse after empiric treatment should undergo upper endoscopy with subsequent treatment directed at the specific disorder (eg, peptic ulcer, gastroesophageal reflux, cancer). Most patients will have no significant findings on endoscopy and will be given a diagnosis of functional dyspepsia.

A. Empiric Therapy

Young patients with uncomplicated dyspepsia may be treated empirically with either a proton pump inhibitor or evaluated with a noninvasive test for *H pylori*, followed if positive by treatment. The prevalence of *H pylori* in the population influences recommendations for the timing of these empiric therapies. In clinical settings in which the prevalence of *H pylori* infection in the population is low (< 10%), it may be more cost-effective to initially treat patients with a 4-week trial of a proton pump inhibitor. Patients who have symptom relapse after discontinuation of the proton pump inhibitor should be tested for *H pylori* and treated if results are positive. In clinical settings in which *H pylori* prevalence is >10%, it may be more cost-effective to initially test patients for *H pylori* infection. *H pylori*-negative patients most likely have functional dyspepsia or atypical GERD and can be treated with an antisecretory agent (proton pump inhibitor) for 4 weeks. For patients who have symptom relapse after discontinuation of the proton pump inhibitor, intermittent or long-term proton pump inhibitor therapy may be considered. For patients in whom test results are positive for *H pylori*, antibiotic therapy proves definitive for patients with underlying peptic ulcers and

may improve symptoms in a small subset (< 10%) of infected patients with functional dyspepsia. Patients with persistent dyspepsia after *H pylori* eradication can be given a trial of proton pump inhibitor therapy.

B. Treatment of Functional Dyspepsia

1. General measures—Most patients have mild, intermittent symptoms that respond to reassurance and lifestyle changes. Alcohol and caffeine should be reduced or discontinued. Patients with postprandial symptoms should be instructed to consume small, low-fat meals. A food diary, in which patients record their food intake, symptoms, and daily events, may reveal dietary or psychosocial precipitants of pain.

2. Pharmacologic agents—Drugs have demonstrated limited efficacy in the treatment of functional dyspepsia. One-third of patients derive relief from placebo. Antisecretory therapy for 4–8 weeks with oral proton pump inhibitors (omeprazole, esomeprazole, or rabeprazole 20 mg, dexlansoprazole or lansoprazole 30 mg, or pantoprazole 40 mg) may benefit 10–15% of patients, particularly those with dyspepsia characterized as epigastric pain (“ulcer-like dyspepsia”) or dyspepsia and heartburn (“reflux-like dyspepsia”). Low doses of antidepressants (eg, desipramine or nortriptyline, 10–50 mg orally at bedtime) are believed to benefit some patients, possibly by moderating visceral afferent sensitivity. However, side effects are common and response is patient-specific. Doses should be increased slowly. The prokinetic agent metoclopramide (5–10 mg three times daily) may improve symptoms, but improvement does not correlate with the presence or absence of gastric emptying delay. In 2009, the FDA issued a black box warning that metoclopramide use for more than 3 months is associated with a high incidence of tardive dyskinesia and should be avoided. The elderly, particularly elderly women, are most at risk. In 2006, a randomized, placebo-controlled study demonstrated efficacy of the novel prokinetic agent itopride in the treatment of functional dyspepsia. This agent enhances the release of gastric acetylcholine through dual inhibition of D₂ receptors and acetylcholinesterase. It is available in Canada but not yet in the United States.

3. Anti-*H pylori* treatment—Meta-analyses have suggested that a small number of patients with functional dyspepsia (< 10%) derive benefit from *H pylori* eradication therapy. Therefore, patients with functional dyspepsia should be tested and treated for *H pylori* as recommended above.

4. Alternative therapies—Psychotherapy and hypnotherapy may be of benefit in selected motivated patients with functional dyspepsia. Herbal therapies (peppermint, caraway) may offer benefit with little risk of adverse effects.

Ford AC et al. What is the prevalence of clinically significant endoscopic findings in subjects with dyspepsia? Systematic review and meta-analysis. *Clin Gastroenterol Hepatol.* 2010 Oct;8(10):830–7. [PMID: 20541625]

Kindt S et al. Longitudinal and cross-sectional factors associated with long-term clinical course in functional dyspepsia: a 5-year follow-up study. *Am J Gastroenterol.* 2011 Feb; 106(2): 340–8. [PMID: 20978482]

Pilichiewicz AN et al. Relationship between symptoms and dietary patterns in patients with functional dyspepsia. *Clin Gastroenterol Hepatol.* 2009 Mar;7(3):317–22. [PMID: 18929687]

Vakil N et al. Cost of detecting malignant lesions by endoscopy in 2741 primary care dyspeptic patients without alarm symptoms. *Clin Gastroenterol Hepatol.* 2009 Jul;7(7):756–61. [PMID: 19364542]

NAUSEA & VOMITING

Nausea is a vague, intensely disagreeable sensation of sickness or “queasiness” and is distinguished from anorexia. Vomiting often follows, as does retching (spasmodic respiratory and abdominal movements). Vomiting should be distinguished from regurgitation, the effortless reflux of liquid or food stomach contents; and from rumination, the chewing and swallowing of food that is regurgitated voluntarily after meals.

The brainstem vomiting center is composed of a group of neuronal areas (area postrema, nucleus tractus solitarius, and central pattern generator) within the medulla that coordinate emesis. It may be stimulated by four different sources of afferent input: (1) Afferent vagal fibers from the gastrointestinal viscera are rich in serotonin 5-HT₃ receptors; these may be stimulated by biliary or gastrointestinal distention, mucosal or peritoneal irritation, or infections. (2) Fibers of the vestibular system, which have high concentrations of histamine H₁ and muscarinic cholinergic receptors. (3) Higher central nervous system centers (amygdala); here, certain sights, smells, or emotional experiences may induce vomiting. For example, patients receiving chemotherapy may start vomiting in anticipation of its administration. (4) The chemoreceptor trigger zone, located outside the blood-brain barrier in the area postrema of the medulla, which is rich in opioid, serotonin 5-HT₃, neurokinin 1 (NK₁) and dopamine D₂ receptors. This region may be stimulated by drugs and chemotherapeutic agents, toxins, hypoxia, uremia, acidosis, and radiation therapy. Although the causes of vomiting are many, a simplified list is provided in Table 15–1.

► Clinical Findings

A. Symptoms and Signs

Acute symptoms without abdominal pain are typically caused by food poisoning, infectious gastroenteritis, drugs, or systemic illness. Inquiry should be made into recent changes in medications, diet, other intestinal symptoms, or similar illnesses in family members. The acute onset of severe pain and vomiting suggests peritoneal irritation, acute gastric or intestinal obstruction, or pancreaticobiliary disease. Persistent vomiting suggests pregnancy, gastric outlet obstruction, gastroparesis, intestinal dysmotility, psychogenic disorders, and central nervous system

Table 15-1. Causes of nausea and vomiting.

Visceral afferent stimulation	<p>Infections</p> <p>Mechanical obstruction Gastric outlet obstruction: peptic ulcer disease, malignancy, gastric volvulus Small intestinal obstruction: adhesions, hernias, volvulus, Crohn disease, carcinomatosis</p> <p>Dysmotility Gastroparesis: diabetic, postviral, postvagotomy Small intestine: scleroderma, amyloidosis, chronic intestinal pseudo-obstruction, familial myoneuropathies</p> <p>Peritoneal irritation Peritonitis: perforated viscus, appendicitis, spontaneous bacterial peritonitis Viral gastroenteritis: Norwalk agent, rotavirus "Food poisoning": toxins from <i>Bacillus cereus</i>, <i>Staphylococcus aureus</i>, <i>Clostridium perfringens</i> Hepatitis A or B Acute systemic infections</p> <p>Hepatobiliary or pancreatic disorders Acute pancreatitis Cholecystitis or choledocholithiasis</p> <p>Topical gastrointestinal irritants Alcohol, NSAIDs, oral antibiotics</p> <p>Postoperative</p> <p>Other Cardiac disease: acute myocardial infarction, congestive heart failure Urologic disease: stones, pyelonephritis</p>
Vestibular disorders	<p>Vestibular disorders Labyrinthitis, Meniere syndrome, motion sickness</p>
CNS disorders	<p>Increased intracranial pressure CNS tumors, subdural or subarachnoid hemorrhage</p> <p>Migraine</p> <p>Infections Meningitis, encephalitis</p> <p>Psychogenic Anticipatory vomiting, bulimia, psychiatric disorders</p>
Irritation of chemoreceptor trigger zone	<p>Antitumor chemotherapy</p> <p>Drugs and medications Opioids Anticonvulsants Antiparkinsonism drugs β-blockers, antiarrhythmics, digoxin Nicotine Oral contraceptives Cholinesterase inhibitors Diabetes medications (metformin, acarbose, pramlintide, exenatide)</p> <p>Radiation therapy</p> <p>Systemic disorders Diabetic ketoacidosis Uremia Adrenocortical crisis Parathyroid disease Hypothyroidism Pregnancy Paraneoplastic syndrome</p>

CNS, central nervous system; NSAIDs, nonsteroidal anti-inflammatory drugs.

or systemic disorders. Vomiting that occurs in the morning before breakfast is common with pregnancy, uremia, alcohol intake, and increased intracranial pressure. Vomiting immediately after meals strongly suggests bulimia or psychogenic causes. Vomiting of undigested food one to several hours after meals is characteristic of

gastroparesis or a gastric outlet obstruction; physical examination may reveal a succussion splash. Patients with acute or chronic symptoms should be asked about neurologic symptoms that suggest a central nervous system cause such as headache, stiff neck, vertigo, and focal paresthesias or weakness.

B. Special Examinations

With vomiting that is severe or protracted, serum electrolytes should be obtained to look for hypokalemia, azotemia, or metabolic alkalosis resulting from loss of gastric contents. Flat and upright abdominal radiographs or abdominal CT are obtained in patients with severe pain or suspicion of mechanical obstruction to look for free intraperitoneal air or dilated loops of small bowel. The cause of gastric outlet obstruction is best demonstrated by upper endoscopy, and the cause of small intestinal obstruction is best demonstrated with abdominal CT imaging. Gastroparesis is confirmed by nuclear scintigraphic studies or ¹³C-octanoic acid breath tests, which show delayed gastric emptying and either upper endoscopy or barium upper gastrointestinal series showing no evidence of mechanical gastric outlet obstruction. Abnormal liver function tests or elevated amylase or lipase suggest pancreaticobiliary disease, which may be investigated with an abdominal sonogram or CT scan. Central nervous system causes are best evaluated with either head CT or MRI.

► Complications

Complications include dehydration, hypokalemia, metabolic alkalosis, aspiration, rupture of the esophagus (Boerhaave syndrome), and bleeding secondary to a mucosal tear at the gastroesophageal junction (Mallory-Weiss syndrome).

► Treatment

A. General Measures

Most causes of acute vomiting are mild, self-limited, and require no specific treatment. Patients should ingest clear liquids (broths, tea, soups, carbonated beverages) and small quantities of dry foods (soda crackers). For more severe acute vomiting, hospitalization may be required. Patients unable to eat and losing gastric fluids may become dehydrated, resulting in hypokalemia with metabolic alkalosis. Intravenous 0.45% saline solution with 20 mEq/L of potassium chloride is given in most cases to maintain hydration. A nasogastric suction tube for gastric or mechanical small bowel obstruction improves patient comfort and permits monitoring of fluid loss.

B. Antiemetic Medications

Medications may be given either to prevent or to control vomiting. Combinations of drugs from different classes may provide better control of symptoms with less toxicity in some patients. Table 15–2 outlines common antiemetic dosing regimens.

1. Serotonin 5-HT₃-receptor antagonists—Ondansetron, granisetron, dolasetron, and palonosetron are effective in preventing chemotherapy- and radiation-induced emesis when initiated prior to treatment. Although 5-HT₃-receptor antagonists are effective as single agents for the prevention of chemotherapy-induced nausea and vomiting, their efficacy is enhanced by combination therapy with a corticosteroid (dexamethasone) and NK₁-receptor

Table 15–2. Common antiemetic dosing regimens.

	Dosage	Route
Serotonin 5-HT₃ antagonists		
Ondansetron	Doses vary: 4–8 mg twice daily for postoperative nausea and vomiting	Intravenously, orally
	8 mg twice daily for moderately emetogenic chemotherapy	Intravenously, orally
	24 mg for highly emetogenic chemotherapy	Intravenously, orally
Granisetron	1 mg once daily	Intravenously
	1–2 mg once daily	Orally
Dolasetron	12.5 mg postoperatively	Intravenously
	100 mg once daily	Oral
Palonosetron	0.25 mg once as a single dose 30 min before start of chemotherapy	Intravenously
	0.5 mg once as single dose	Orally
Corticosteroids		
Dexamethasone	4 mg once pre-induction for prevention of postoperative nausea and vomiting	Intravenously, orally
	8 mg once daily for chemotherapy	Intravenously, orally
Methylprednisolone	40–100 mg once daily	Intravenously Intramuscularly Orally
Dopamine receptor antagonists		
Metoclopramide	10–20 mg or 0.5 mg/kg every 6–8 hours	Intravenously
	10–20 mg every 6–8 hours	Orally
Prochlorperazine	5–10 mg every 4–6 hours	Intravenously Intramuscularly Orally
	25 mg suppository every 6 hours	
Promethazine	12.5–25 mg every 6–8 hours	Intravenously, Orally
	25 mg every 6–8 hours	Per rectum
Trimethobenzamide	200 mg every 6–8 hours	Orally
	250–300 mg every 6–8 hours	Intravenously, orally

(continued)

Table 15-2. Common antiemetic dosing regimens. (continued)

	Dosage	Route
Sedatives		
Diazepam	2-5 mg every 4-6 hours	Intravenously, orally
Lorazepam	1-2 mg every 4-6 hours	Intravenously, orally
Neurokinin receptor antagonists¹		
Aprepitant	125 mg once before chemotherapy; then 80 mg on day 1 and 2 after chemotherapy	Orally
Fosaprepitant	115 mg once 30 minutes before chemotherapy	Intravenously

¹Neurokinin receptor antagonists are used solely for highly emetogenic chemotherapy regimens in combination with 5-HT₃ antagonists or dexamethasone or both.

antagonist (see below). Serotonin antagonists increasingly are used for the prevention of postoperative nausea and vomiting because of increased restrictions on the use of other antiemetic agents (such as droperidol).

2. Corticosteroids—Corticosteroids (eg, dexamethasone) have antiemetic properties, but the basis for these effects is unknown. These agents enhance the efficacy of serotonin receptor antagonists for preventing acute and delayed nausea and vomiting in patients receiving moderately to highly emetogenic chemotherapy regimens.

3. Neurokinin receptor antagonists—Aprepitant and fosaprepitant are highly selective antagonists for NK₁-receptors in the area postrema. They are used in combination with corticosteroids and serotonin antagonists for the prevention of acute and delayed nausea and vomiting with highly emetogenic chemotherapy regimens. Combined therapy with a neurokinin1 receptor antagonist prevents acute emesis in 80–90% and delayed emesis in > 70% of patients treated with highly emetogenic regimens.

4. Dopamine antagonists—The phenothiazines, butyrophenones, and substituted benzamides have antiemetic properties that are due to dopaminergic blockade as well as to their sedative effects. High doses of these agents are associated with antidopaminergic side effects, including extrapyramidal reactions and depression. These agents are used in a variety of situations. Cases of QT prolongation leading to ventricular tachycardia (torsades de pointes) have been reported in several patients receiving droperidol, hence it is no longer recommended as an antiemetic agent.

5. Antihistamines and anticholinergics—These drugs (eg, meclizine, dimenhydrinate, transdermal scopolamine) may be valuable in the prevention of vomiting arising from stimulation of the labyrinth, ie, motion sickness, vertigo, and migraines. They may induce drowsiness. A combination of oral vitamin B₆ and doxylamine is recommended

by the American College of Obstetricians and Gynecologists as first-line therapy for nausea and vomiting during pregnancy.

6. Sedatives—Benzodiazepines are used in psychogenic and anticipatory vomiting.

7. Cannabinoids—Marijuana has been used widely as an appetite stimulant and antiemetic. Some states allow the use of medical marijuana with a clinician's certification. Pure Δ⁹-tetrahydrocannabinol (THC) is the major active ingredient in marijuana and is available by prescription as dronabinol. In doses of 5–15 mg/m², oral dronabinol is effective in treating nausea associated with chemotherapy, but it is associated with central nervous system side effects in most patients.

Feyer P et al. Update and new trends in antiemetic therapy: the continuing need for novel therapies. *Ann Oncol.* 2011 Jan; 22(1):30–8. [PMID: 20947707]

Niebyl JR. Clinical Practice. Nausea and vomiting in pregnancy. *N Engl J Med.* 2010 Oct 15;363(16):1544–50. [PMID: 20942670]

Roila F et al. Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. *Ann Oncol.* 2010 May;21(Suppl 5):v232–43. [PMID: 20555089]

HICCUPS (SINGULTUS)

Though usually a benign and self-limited annoyance, hiccups may be persistent and a sign of serious underlying illness. In patients on mechanical ventilation, hiccups can trigger a full respiratory cycle and result in respiratory alkalosis.

Causes of benign, self-limited hiccups include gastric distention (carbonated beverages, air swallowing, overeating), sudden temperature changes (hot then cold liquids, hot then cold shower), alcohol ingestion, and states of heightened emotion (excitement, stress, laughing). There are over 100 causes of recurrent or persistent hiccups, grouped into the following categories:

Central nervous system: Neoplasms, infections, cerebrovascular accident, trauma.

Metabolic: Uremia, hypocapnia (hyperventilation).

Irritation of the vagus or phrenic nerve: (1) Head, neck: Foreign body in ear, goiter, neoplasms. (2) Thorax: Pneumonia, empyema, neoplasms, myocardial infarction, pericarditis, aneurysm, esophageal obstruction, reflux esophagitis. (3) Abdomen: Subphrenic abscess, hepatomegaly, hepatitis, cholecystitis, gastric distention, gastric neoplasm, pancreatitis, or pancreatic malignancy.

Surgical: General anesthesia, postoperative.

Psychogenic and idiopathic.

► Clinical Findings

Evaluation of the patient with persistent hiccups should include a detailed neurologic examination, serum creatinine, liver chemistry tests, and a chest radiograph. When the cause remains unclear, CT of the head, chest, and abdomen, echocardiography, bronchoscopy, and upper endoscopy may help. On occasion, hiccups may be unilateral; chest fluoroscopy will make the diagnosis.

► Treatment

A number of simple remedies may be helpful in patients with acute benign hiccups. (1) Irritation of the nasopharynx by tongue traction, lifting the uvula with a spoon, catheter stimulation of the nasopharynx, or eating 1 teaspoon (tsp) (7 g) of dry granulated sugar. (2) Interruption of the respiratory cycle by breath holding, Valsalva maneuver, sneezing, gasping (fright stimulus), or rebreathing into a bag. (3) Stimulation of the vagus by carotid massage. (4) Irritation of the diaphragm by holding knees to chest or by continuous positive airway pressure during mechanical ventilation. (5) Relief of gastric distention by belching or insertion of a nasogastric tube.

A number of drugs have been promoted as being useful in the treatment of hiccups. Chlorpromazine, 25–50 mg orally or intramuscularly, is most commonly used. Other agents reported to be effective include anticonvulsants (phenytoin, carbamazepine), benzodiazepines (lorazepam, diazepam), metoclopramide, baclofen, gabapentin, and occasionally general anesthesia.

Pechlivanis I et al. A healthy man with intractable hiccups. *J Clin Neurosci*. 2010 Jun;17(6):781–3. [PMID: 20359895]

CONSTIPATION

Constipation occurs in 10–15% of adults and is a common reason for seeking medical attention. It is more common in women. The elderly are predisposed due to comorbid medical conditions, medications, poor eating habits, decreased mobility and, in some cases, inability to sit on a toilet (bed-bound patients). The first step in evaluating the patient is to determine what is meant by “constipation.” Patients may define constipation as infrequent stools (fewer than three in a week), hard stools, excessive straining, or a sense of incomplete evacuation. Table 15–3 summarizes the many causes of constipation, which are discussed below.

► Etiology

A. Primary Constipation

Most patients have constipation that cannot be attributed to any structural abnormalities or systemic disease. Some of these patients have normal colonic transit time; however, a subset have slow colonic transit or anorectal dysfunction. Normal colonic transit time is approximately 35 hours; more than 72 hours is significantly abnormal. Slow colonic transit is commonly idiopathic but may be part of a generalized gastrointestinal dysmotility syndrome. Patients may complain of infrequent bowel movements and abdominal bloating. Slow transit is more common in women, some of whom have a history of psychosocial problems (depression, anxiety, eating disorder, childhood trauma) or sexual abuse. Normal defecation requires coordination between relaxation of the anal sphincter and pelvic floor musculature while abdominal pressure is increased. Patients with dyssynergic defecation (also known as anismus or pelvic floor dyssynergia)—women more often than men—have impaired relaxation or paradoxical contraction of the anal sphincter and/or pelvic floor muscles during attempted defecation

Table 15–3. Causes of constipation in adults.

Most common
Inadequate fiber or fluid intake
Poor bowel habits
Systemic disease
Endocrine: hypothyroidism, hyperparathyroidism, diabetes mellitus
Metabolic: hypokalemia, hypercalcemia, uremia, porphyria
Neurologic: Parkinson disease, multiple sclerosis, sacral nerve damage (prior pelvic surgery, tumor), paraplegia, autonomic neuropathy
Medications
Opioids
Diuretics
Calcium channel blockers
Anticholinergics
Psychotropics
Calcium and iron supplements
NSAIDs
Clonidine
Cholestyramine
Structural abnormalities
Anorectal: rectal prolapse, rectocele, rectal intussusception, anorectal stricture, anal fissure, solitary rectal ulcer syndrome
Perineal descent
Colonic mass with obstruction: adenocarcinoma
Colonic stricture: radiation, ischemia, diverticulosis
Hirschsprung disease
Idiopathic megarectum
Slow colonic transit
Idiopathic: isolated to colon
Psychogenic
Eating disorders
Chronic intestinal pseudo-obstruction
Pelvic floor dyssynergia
Irritable bowel syndrome

NSAIDs, nonsteroidal anti-inflammatory drugs.

that impedes the bowel movement. This problem may be acquired during childhood or adulthood. Patients may complain of excessive straining, sense of incomplete evacuation, or need for digital manipulation. Patients with primary complaints of abdominal pain or bloating with alterations in bowel habits (constipation, or alternating constipation and diarrhea) may have irritable bowel syndrome (see below).

B. Secondary Constipation

Constipation may be caused by systemic disorders, medications, or obstructing colonic lesions. Systemic disorders can cause constipation because of neurologic gut dysfunction, myopathies, endocrine disorders, or electrolyte abnormalities (eg, hypercalcemia or hypokalemia); medication side effects are often responsible (eg, anticholinergics or opioids). Colonic lesions that obstruct fecal passage, such as neoplasms and strictures, are an uncommon cause but important in new-onset constipation. Such lesions should be excluded in patients older than 50 years, in patients with “alarm” symptoms or signs (hematochezia, weight loss, anemia, or positive fecal occult blood tests [FOBT] or fecal immunochemical tests [FIT]), and in patients with a family history of colon cancer or inflammatory bowel disease. Defecatory difficulties also can be due to a variety of anorectal problems that impede or obstruct flow (perineal

descent, rectal prolapse, rectocele), some of which may require surgery, and Hirschsprung disease (usually suggested by lifelong constipation).

► Clinical Findings

A. Symptoms and Signs

All patients should undergo a history and physical examination to distinguish primary from secondary causes of constipation. Physical examination should include digital rectal examination with assessment for anatomic abnormalities, such as anal stricture, rectocele, rectal prolapse, or perineal descent during straining. Further diagnostic tests should be performed in patients with any of the following: age 50 years or older, severe constipation, signs of an organic disorders, alarm symptoms (hematochezia, weight loss, positive FOBT or FIT), or a family history of colon cancer or inflammatory bowel disease. These tests should include laboratory studies (complete blood count; serum electrolytes, calcium, glucose, and thyroid-stimulating hormone); and a colonoscopy or flexible sigmoidoscopy.

B. Special Examinations

Patients with refractory constipation not responding to routine medical management warrant further diagnostic studies, including colonic transit and pelvic floor function studies, in order to distinguish slow colonic transit from anorectal dysfunction. Colon transit time is most commonly measured by performing an abdominal radiograph 120 hours after ingestion of 24 radiopaque markers. Retention of > 20% of the markers indicates prolonged transit. Dyssynergic defecation is assessed with balloon expulsion testing, anal manometry, and defecography.

► Treatment

A. Chronic Constipation

1. Dietary and lifestyle measures—Adverse psychosocial issues should be identified and addressed. Patients should be instructed on normal defecatory function and optimal toileting habits, including regular timing, proper positioning, and abdominal pressure. Proper dietary fiber intake should be emphasized. A trial of fiber supplements is recommended (Table 15-4). Increased dietary fiber may cause distention or flatulence, which often diminishes over several days. Response to fiber therapy is not immediate, and increases in dosage should be made gradually over 7-10 days. Fiber is most likely to benefit patients with normal colonic transit, but it may not benefit patients with colonic inertia, anorectal dysfunction, opioid-induced constipation, or irritable bowel syndrome; it may even exacerbate symptoms in these patients. Regular exercise is associated with a decreased risk of constipation. When possible, discontinue medications that may be causing or contributing to constipation.

2. Laxatives—Laxatives may be given on an intermittent or chronic basis for constipation that does not respond to dietary and lifestyle changes (Table 15-4). There is no evidence that long-term use of these agents is harmful.

A. OSMOTIC LAXATIVES—Nonabsorbable osmotic agents increase secretion of water into the intestinal lumen, thereby softening stools and promoting defecation. Magnesium hydroxide, nondigestible carbohydrates (sorbitol, lactulose), and polyethylene glycol are all efficacious and safe for treating acute and chronic cases. The dosages are adjusted to achieve soft to semi-liquid movements. Magnesium-containing saline laxatives should not be given to patients with chronic renal insufficiency. Nondigestible carbohydrates may induce bloating, cramps, and flatulence. Polyethylene glycol 3350 (Miralax) is a component of solutions traditionally used for colonic lavage prior to colonoscopy and does not cause flatulence. When used in conventional doses, the onset of action of these osmotic agents is generally within 24 hours. For more rapid treatment of acute constipation or as a purgative prior to surgical, endoscopic, or radiographic procedures, polyethylene glycol solutions (GoLYTELY, CoLYTE, NuLYTE, MoviPrep) may be used. Polyethylene glycol solutions (2-4 L administered over 2-4 hours) are balanced osmotic and electrolyte solutions that do not cause any significant fluid or electrolyte shifts and may be used safely in almost all patients. Alternatively, potent, hyperosmolar saline purgatives may be administered. These hyperosmolar agents draw significant fluid into the intestine and must be given with substantial oral fluids (2-4 L) to minimize fluid shifts that can result in dehydration or acute kidney injury. They should be avoided in patients with chronic kidney disease or congestive heart failure. Magnesium citrate may cause hypermagnesemia. Oral sodium phosphate preparations (Visicol, OsmoPrep, and Fleets Phospho-soda) can cause hypocalcemia, hyperphosphatemia, hypokalemia and, rarely, acute kidney injury due to acute phosphate nephropathy. The FDA has issued a warning that sodium phosphate should be avoided in people over age 55, people with known kidney disease, or people taking medications that affect kidney function (diuretics, NSAIDs, ACE inhibitors, angiotensin-receptor blockers). Patients taking sodium phosphate should be advised to ingest sufficient oral fluids (2-4 L).

B. STIMULANT LAXATIVES—These agents stimulate fluid secretion and colonic contraction, resulting in a bowel movement within 6-12 hours after oral ingestion or 15-60 minutes after rectal administration. Oral agents are usually administered once daily at bedtime. Common preparations include bisacodyl, senna, and cascara (Table 15-4).

Lubiprostone is an oral cyclic fatty acid that activates intestinal chloride channels, increasing fluid secretion and secondarily increasing peristalsis. In large, multicenter controlled trials, patients treated with lubiprostone 24 mcg orally twice daily increased the number of bowel movements to approximately four to five per week, compared with two to three per week in patients treated with placebo. Lubiprostone is associated with nausea in up to one-third of patients and should not be given to women who may be pregnant (category C). Because lubiprostone is expensive, it should be reserved for patients who have suboptimal response or side effects with less expensive agents.

C. OPIOID-RECEPTOR ANTAGONISTS—Long-term use of opioids can cause constipation by inhibiting peristalsis and

Table 15-4. Pharmacologic management of constipation.

Agent	Dosage	Onset of Action	Comments
Fiber laxatives			
Bran powder	1-4 tsp orally twice daily	Days	Inexpensive; may cause gas, flatulence
Psyllium	1 tsp once or twice daily	Days	(Metamucil; Perdiem)
Methylcellulose	1 tsp once or twice daily	Days	(Citrucel) Less gas, flatulence
Calcium polycarbophil	1 or 2 tablets once or twice daily	12-24 hours	(FiberCon) Does not cause gas; pill form
Guargum	1 tbsp once or twice daily	Days	(Benefiber) Non-gritty, tasteless, less gas
Stool surfactants			
Docusate sodium	100 mg once or twice daily	12-72 hours	(Colace) Marginal benefit
Mineral oil	15-45 mL once or twice daily	6-8 hours	May cause lipoid pneumonia if aspirated
Osmotic laxatives			
Magnesium hydroxide	15-30 mL orally once or twice daily	6-24 hours	(Milk of magnesia; Epsom salts)
Lactulose or 70% sorbitol	15-60 mL orally once daily to three times daily	6-48 hours	Cramps, bloating, flatulence
Polyethylene glycol (PEG 3350)	17 g in 8 oz liquid once or twice daily	6-24 hours	(Miralax) Less bloating than lactulose, sorbitol
Stimulant laxatives			
Bisacodyl	5-20 mg orally as needed	6-8 hours	May cause cramps; avoid daily use if possible
Bisacodyl	10 mg per rectum as needed	1 hour	
Cascara	4-8 mL or 2 tablets as needed	8-12 hours	(Nature's Remedy) May cause cramps; avoid daily use if possible
Senna	8.6-17.2 mg orally as needed	8-12 hours	(ExLax; Senekot) May cause cramps; avoid daily use if possible
Lubiprostone	24 mcg orally twice daily	12-48 hours	Expensive; may cause nausea. Contraindicated in pregnancy
Enemas			
Tap water	500 mL per rectum	5-15 minutes	
Sodium phosphate enema	120 mL per rectum	5-15 minutes	Commonly used for acute constipation or to induce movement prior to medical procedures
Mineral oil enema	100-250 mL per rectum		To soften and lubricate fecal impaction
Agents used for acute purgative or to clean bowel prior to medical procedures			
Polyethylene glycol (PEG 3350)	4 L orally administered over 2-4 hours	< 4 hours	(GoLYTELY; CoLYTE; NuLYTE, MoviPrep) Used to cleanse bowel before colonoscopy
Sodium phosphate	As directed with total of 2-4 L of clear liquids	1-6 hours	(OsmoPrep, Visicol, Fleets) Used before colonoscopy
Magnesium citrate	10 oz orally	3-6 hours	Lemon-flavored

increasing intestinal fluid absorption. Methylnaltrexone is a mu-opioid receptor antagonist that blocks peripheral opioid receptors (including the gastrointestinal tract) without affecting central analgesia. It is approved for the treatment of opioid-induced constipation in patients receiving palliative care for advanced illness who have not responded to conventional laxative regimens. In controlled trials, methylnaltrexone subcutaneously (8 mg [38-62 kg], 12 mg [62-114 kg], or 0.15 mg/kg [less 38 kg] every other day) achieves laxation in 50% of patients compared with 15% of patients who received placebo.

B. Fecal Impaction

Severe impaction of stool in the rectal vault may result in obstruction to further fecal flow, leading to partial or complete large bowel obstruction. Predisposing factors include medications (eg, opioids), severe psychiatric disease, prolonged bed rest, neurogenic disorders of the colon, and spinal cord disorders. Clinical presentation includes decreased appetite, nausea, and vomiting, and abdominal pain and distention. There may be paradoxical "diarrhea" as liquid stool leaks around the impacted feces. Firm feces are palpable on digital examination of the rectal vault. Initial treatment is

directed at relieving the impaction with enemas (saline, mineral oil, or diatrizoate) or digital disruption of the impacted fecal material. Long-term care is directed at maintaining soft stools and regular bowel movements (as above).

► When to Refer

- Patients with refractory constipation for anorectal testing.
- Patients with dyssynergic defecation may benefit from biofeedback therapy.
- Patients with alarm symptoms or who are over age 50 should be referred for colonoscopy.
- Rarely, surgery (subtotal colectomy) is required for patients with severe colonic inertia.

Bouras EP et al. Chronic constipation in the elderly. *Gastroenterol Clin North Am.* 2009 Sep;38(3):463–80. [PMID: 19699408]

Camilleri M. Opioid-induced constipation: challenges and therapeutic opportunities. *Am J Gastroenterol.* 2011 May;106(5):835–42. [PMID: 21343919]

Kamm MA et al. Oral bisacodyl is effective and well-tolerated in patients with chronic constipation. *Clin Gastroenterol Hepatol.* 2011 Jul;9(7):577–83. [PMID: 21440672]

McCallum IK et al. Chronic constipation in adults. *BMJ.* 2009 Mar 20;338:b831. [PMID: 19304766]

Suares NC et al. Prevalence of, and risk factors for, chronic idiopathic constipation in the community: systematic review and meta-analysis. *Am J Gastroenterol.* 2011 Sep;106(9):1582–91. [PMID: 21606976]

Wald A. A 27-year-old woman with constipation: diagnosis and treatment. *Clin Gastroenterol Hepatol.* 2010 Oct;8(10):838–42. [PMID: 20399904]

GASTROINTESTINAL GAS

► Belching

Belching (eructation) is the involuntary or voluntary release of gas from the stomach or esophagus. It occurs most frequently after meals, when gastric distention results in transient lower esophageal sphincter (LES) relaxation. Belching is a normal reflex and does not itself denote gastrointestinal dysfunction. Virtually all stomach gas comes from swallowed air. With each swallow, 2–5 mL of air is ingested, and excessive amounts may result in distention, flatulence, and abdominal pain. This may occur with rapid eating, gum chewing, smoking, and the ingestion of carbonated beverages. Chronic excessive belching is almost always caused by aerophagia, common in anxious individuals and institutionalized patients. Evaluation should be restricted to patients with other complaints such as dysphagia, heartburn, early satiety, or vomiting.

Once patients understand the relationship between aerophagia and belching, most can deal with the problem by behavioral modification. Physical defects that hamper normal swallowing (ill-fitting dentures, nasal obstruction) should be corrected. Antacids and simethicone are of no value.

► Flatus

The rate and volume of expulsion of flatus is highly variable. Healthy adults pass flatus up to 20 times daily and excrete up to 1500 mL. Flatus is derived from two sources: swallowed air (primarily nitrogen) and bacterial fermentation

of undigested carbohydrate (which produces H₂, CO₂, and methane). A number of carbohydrates are incompletely absorbed in the small intestine and pass into the colon. These include lactose (dairy products); fructose (fruits, corn syrups, and some sweeteners); sorbitol (stone-fruits and some sweeteners); and the alpha galactosyl oligosaccharides raffinose, stachyose, and verbascose (legumes, cruciferous vegetables, pasta, and whole grains). Abnormal gas production may be caused by increased ingestion of these carbohydrates or by disorders of malabsorption. Foul odor may be caused by garlic, onion, eggplant, mushrooms, and certain herbs and spices.

Determining abnormal from normal amounts of flatus is difficult. Patients with a long-standing history of flatulence and no other symptoms or signs of malabsorption disorders can be treated conservatively. Gum chewing and carbonated beverages should be avoided to reduce air swallowing. Lactose intolerance may be assessed by a 2-week trial of a lactose-free diet or by a hydrogen breath test. Other common gas-producing foods should be reviewed and the patient given an elimination trial. These include legumes (beans, peas, lentils, soy), cruciferous vegetables (brussels sprouts, cabbage, cauliflower, broccoli) leeks, onions, beer, and coffee. Fructose is present in many fruits and as fructose corn syrup in candy, fruit juices, and soda. For patients with persistent complaints, complex starches, and fiber may be eliminated, but such restrictive diets are unacceptable to most patients. Of refined flours, only rice flour is gas-free.

The nonprescription agent Beano (α -D-galactosidase enzyme) reduces gas caused by foods containing raffinose, stachyose, and verbascose. Activated charcoal may afford relief. Simethicone is of no proved benefit.

Complaints of chronic abdominal distention or bloating are common. Some of these patients may produce excess gas. However, many patients have impaired small bowel gas propulsion or enhanced visceral sensitivity to gas distention. Many of these patients have an underlying functional gastrointestinal disorder such as irritable bowel syndrome or functional dyspepsia. Reduction of dietary fat, which delays intestinal gas clearance, may be helpful. Rifaximin, 400 mg twice daily, a nonabsorbable oral antibiotic with high activity against enteric bacteria, has been shown to reduce abdominal bloating and flatulence in approximately 40% of treated patients compared with 20% of controls. Symptom improvement may be attributable to suppression of gas-producing colonic bacteria; however, relapse occurs within days after stopping the antibiotic. Further trials are needed to clarify the role of nonabsorbable antibiotics in symptom management. Many patients report reduced flatus production with use of probiotics, although there has been limited controlled study of these agents for this purpose. Patients interested in complementary medical therapies may be offered a trial of 4–8 ounces daily of Kefir, a commercially available fermented milk drink containing multiple probiotics.

Gasbarrini A et al; 1st Rome H2-Breath Testing Consensus Conference Working Group. Methodology and indications of H2-breath testing in gastrointestinal diseases: the Rome Consensus Conference. *Aliment Pharmacol Ther.* 2009 Mar 30;29(suppl 1):1–49. [PMID: 19344474]

Grabitske HA et al. Gastrointestinal effects of low-digestible carbohydrates. *Crit Rev Food Sci Nutr*. 2009 Apr;49(4):327–60. [PMID: 19234944]

Kalman DS et al. A prospective, randomized, double-blind, placebo-controlled parallel-group dual site trial to evaluate the effects of a *Bacillus coagulans*-based product on functional intestinal gas symptoms. *BMC Gastroenterol*. 2009 Nov 18;9:85. [PMID: 19922649]

DIARRHEA

Diarrhea can range in severity from an acute self-limited episode to a severe, life-threatening illness. To properly evaluate the complaint, the clinician must determine the patient's normal bowel pattern and the nature of the current symptoms.

Approximately 10 L of fluid enter the duodenum daily, of which all but 1.5 L are absorbed by the small intestine. The colon absorbs most of the remaining fluid, with < 200 mL lost in the stool. Although diarrhea sometimes is defined as a stool weight of more than 200–300 g/24 h, quantification of stool weight is necessary only in some patients with chronic diarrhea. In most cases, the physician's working definition of diarrhea is increased stool frequency (more than three bowel movements per day) or liquidity of feces.

The causes of diarrhea are myriad. In clinical practice, it is helpful to distinguish acute from chronic diarrhea, as the evaluation and treatment are entirely different (Tables 15–5 and 15–6).

Table 15–5. Causes of acute infectious diarrhea.

Noninflammatory Diarrhea	Inflammatory Diarrhea
Viral Noroviruses Rotavirus	Viral Cytomegalovirus
Protozoal <i>Giardia lamblia</i> <i>Cryptosporidium</i> <i>Cyclospora</i>	Protozoal <i>Entamoeba histolytica</i>
Bacterial 1. Preformed enterotoxin production <i>Staphylococcus aureus</i> <i>Bacillus cereus</i> <i>Clostridium perfringens</i> 2. Enterotoxin production Enterotoxigenic <i>E coli</i> (ETEC) <i>Vibrio cholerae</i>	Bacterial 1. Cytotoxin production Enterohemorrhagic <i>E coli</i> O157:H5 (EHEC) <i>Vibrio parahaemolyticus</i> <i>Clostridium difficile</i> 2. Mucosal invasion <i>Shigella</i> <i>Campylobacter jejuni</i> <i>Salmonella</i> Enteroinvasive <i>E coli</i> (EIEC) <i>Aeromonas</i> <i>Plesiomonas</i> <i>Yersinia enterocolitica</i> <i>Chlamydia</i> <i>Neisseria gonorrhoeae</i> <i>Listeria monocytogenes</i>

Table 15–6. Causes of chronic diarrhea.

<p>Osmotic diarrhea CLUES: Stool volume decreases with fasting; increased stool osmotic gap</p> <ol style="list-style-type: none"> 1. Medications: antacids, lactulose, sorbitol 2. Disaccharidase deficiency: lactose intolerance 3. Factitious diarrhea: magnesium (antacids, laxatives) <p>Secretory diarrhea CLUES: Large volume (> 1 L/d); little change with fasting; normal stool osmotic gap</p> <ol style="list-style-type: none"> 1. Hormonally mediated: VIPoma, carcinoid, medullary carcinoma of thyroid (calcitonin), Zollinger-Ellison syndrome (gastrin) 2. Factitious diarrhea (laxative abuse); phenolphthalein, cascara, senna 3. Villous adenoma 4. Bile salt malabsorption (idiopathic, ileal resection; Crohn ileitis; postcholecystectomy) 5. Medications <p>Inflammatory conditions CLUES: Fever, hematochezia, abdominal pain</p> <ol style="list-style-type: none"> 1. Ulcerative colitis 2. Crohn disease 3. Microscopic colitis 4. Malignancy: lymphoma, adenocarcinoma (with obstruction and pseudodiarrhea) 5. Radiation enteritis <p>Medications Common offenders: SSRIs, cholinesterase inhibitors, NSAIDs, proton pump inhibitors, angiotensin II receptor blockers, metformin, allopurinol</p>	<p>Malabsorption syndromes CLUES: Weight loss, abnormal laboratory values; fecal fat > 10 g/24h</p> <ol style="list-style-type: none"> 1. Small bowel mucosal disorders: celiac sprue, tropical sprue, Whipple disease, eosinophilic gastroenteritis, small bowel resection (short bowel syndrome), Crohn disease 2. Lymphatic obstruction: lymphoma, carcinoid, infectious (tuberculosis, MAI), Kaposi sarcoma, sarcoidosis, retroperitoneal fibrosis 3. Pancreatic disease: chronic pancreatitis, pancreatic carcinoma 4. Bacterial overgrowth: motility disorders (diabetes, vagotomy), scleroderma, fistulas, small intestinal diverticula <p>Motility disorders CLUES: Systemic disease or prior abdominal surgery</p> <ol style="list-style-type: none"> 1. Postsurgical: vagotomy, partial gastrectomy, blind loop with bacterial overgrowth 2. Systemic disorders: scleroderma, diabetes mellitus, hyperthyroidism 3. Irritable bowel syndrome <p>Chronic infections</p> <ol style="list-style-type: none"> 1. Parasites: <i>Giardia lamblia</i>, <i>Entamoeba histolytica</i>, <i>Strongyloidiasis stercoralis</i>, <i>Capillaria philippinensis</i> 2. AIDS-related: Viral: Cytomegalovirus, HIV infection (?) Bacterial: <i>Clostridium difficile</i>, <i>Mycobacterium avium</i> complex Protozoal: Microsporidia (<i>Enterocytozoon bieneusi</i>), <i>Cryptosporidium</i>, <i>Isospora belli</i> <p>Factitious See Osmotic and Secretory diarrhea above</p>
--	--

MAI, *Mycobacterium avium-intracellulare*; NSAIDs, nonsteroidal anti-inflammatory drugs; SSRIs, selective serotonin reuptake inhibitors.

1. Acute Diarrhea



ESSENTIALS OF DIAGNOSIS

- ▶ Diarrhea of < 2 weeks duration is most commonly caused by invasive or noninvasive pathogens and their enterotoxins.

Acute noninflammatory diarrhea

- ▶ Watery, nonbloody.
- ▶ Usually mild, self-limited.
- ▶ Caused by a virus or noninvasive bacteria.
- ▶ Diagnostic evaluation is limited to patients with diarrhea that is severe or persists beyond 7 days.

Acute inflammatory diarrhea

- ▶ Blood or pus, fever.
- ▶ Usually caused by an invasive or toxin-producing bacterium.
- ▶ Diagnostic evaluation requires routine stool bacterial cultures (including *E coli* O157:H7) in all and testing as clinically indicated for *Clostridium difficile* toxin, and ova and parasites.

▶ Etiology & Clinical Findings

Diarrhea acute in onset and persisting for < 2 weeks is most commonly caused by infectious agents, bacterial toxins (either preformed or produced in the gut), or medications. Community outbreaks (including nursing homes, schools, cruise ships) suggest a viral etiology or a common food source. Similar recent illnesses in family members suggest an infectious origin. Ingestion of improperly stored or prepared food implicates food poisoning. Day care attendance or exposure to unpurified water (camping, swimming) may result in infection with *Giardia* or *Cryptosporidium*. Large *Cyclospora* outbreaks have been traced to contaminated produce. Recent travel abroad suggests “traveler’s diarrhea” (see Chapter 30). Antibiotic administration within the preceding several weeks increases the likelihood of *C difficile* colitis. Finally, risk factors for HIV infection or sexually transmitted diseases should be determined. (AIDS-associated diarrhea is discussed in Chapter 31; infectious proctitis is discussed in this chapter under Anorectal Disorders.) Persons engaging in anal intercourse or oral-anal sexual activities are at risk for a variety of infections that cause proctitis, including gonorrhea, syphilis, lymphogranuloma venereum, and herpes simplex.

The nature of the diarrhea helps distinguish among different infectious causes (Table 15–5).

A. Noninflammatory Diarrhea

Watery, nonbloody diarrhea associated with periumbilical cramps, bloating, nausea, or vomiting suggests a small bowel source caused by either a toxin-producing bacterium (enterotoxigenic *E coli* [ETEC], *Staphylococcus aureus*, *Bacillus cereus*, *Clostridium perfringens*) or other agents

(viruses, *Giardia*) that disrupt normal absorption and secretory process in the small intestine. Prominent vomiting suggests viral enteritis or *S aureus* food poisoning. Although typically mild, the diarrhea (which originates in the small intestine) can be voluminous and result in dehydration with hypokalemia and metabolic acidosis (eg, cholera). Because tissue invasion does not occur, fecal leukocytes are not present.

B. Inflammatory Diarrhea

The presence of fever and bloody diarrhea (dysentery) indicates colonic tissue damage caused by invasion (shigellosis, salmonellosis, *Campylobacter* or *Yersinia* infection, amebiasis) or a toxin (*C difficile*, Shiga-toxin–producing *E coli* [STEC; also known as enterohemorrhagic *E coli*]). Because these organisms involve predominantly the colon, the diarrhea is small in volume (< 1 L/d) and associated with left lower quadrant cramps, urgency, and tenesmus. Fecal leukocytes or lactoferrin usually are present in infections with invasive organisms. *E coli* O157:H7 is a Shiga toxin-producing noninvasive organism most commonly acquired from contaminated meat that has resulted in several outbreaks of an acute, often severe hemorrhagic colitis. In 2011, an outbreak of severe gastroenteritis in Germany caused by an unusual Shiga-toxin–producing strain, *E coli* O104:H4, was traced to contaminated sprouts. A major complication of STEC is hemolytic-uremic syndrome, which develops in 6–22% of cases. In immunocompromised and HIV-infected patients, cytomegalovirus (CMV) can cause intestinal ulceration with watery or bloody diarrhea.


Infectious dysentery must be distinguished from acute ulcerative colitis, which may also present acutely with fever, abdominal pain, and bloody diarrhea. Diarrhea that persists for more than 14 days is not attributable to bacterial pathogens (except for *C difficile*) and should be evaluated as chronic diarrhea.

▶ Evaluation

In over 90% of patients with acute noninflammatory diarrhea, the illness is mild and self-limited, responding within 5 days to simple rehydration therapy or antidiarrheal agents; diagnostic investigation is unnecessary.

The isolation rate of bacterial pathogens from stool cultures in patients with acute noninflammatory diarrhea is under 3%. Thus, the goal of initial evaluation is to distinguish patients with mild disease from those with more serious illness. If diarrhea worsens or persists for more than 7 days, stool should be sent for fecal leukocyte or lactoferrin determination, ovum and parasite evaluation, and bacterial culture.

Prompt medical evaluation is indicated in the following situations (Figure 15–1): (1) Signs of inflammatory diarrhea manifested by any of the following: fever (> 38.5 °C), bloody diarrhea, or abdominal pain. (2) The passage of six or more unformed stools in 24 hours. (3) Profuse watery diarrhea and dehydration. (4) Frail older patients. (5) Immunocompromised patients (AIDS, posttransplantation). (6) Hospital-acquired diarrhea (onset following at least 3 days of hospitalization).



▲ **Figure 15-1.** Evaluation of acute diarrhea.

Physical examination pays note to the patient's level of hydration, mental status, and the presence of abdominal tenderness or peritonitis. Peritoneal findings may be present in infection with *C difficile* or STEC. Hospitalization is required in patients with severe dehydration, marked abdominal pain, or altered mental status. Stool specimens should be sent for examination for routine bacterial cultures.

The rate of positive bacterial cultures in such patients is 60–75%. For bloody stools, the laboratory should be directed to perform serotyping for Shiga-toxin-producing *E coli*. Special culture media are required for *Yersinia*, *Vibrio*, and *Aeromonas*. In patients who are hospitalized or who have a history of antibiotic exposure, a stool sample should be tested for *C difficile* toxin.

In patients with diarrhea that persists for more than 10 days, who have a history of travel to areas where amebiasis is endemic, or who engage in oral-anal sexual practices, three stool examinations for ova and parasites should also be performed. The stool antigen detection tests for both *Giardia* and *Entamoeba histolytica* are more sensitive than stool microscopy for detection of these organisms. A serum antigen detection test for *E histolytica* is also available. *Cyclospora* and *Cryptosporidium* are detected by fecal acid-fast staining.

► Treatment

A. Diet

Most mild diarrhea will not lead to dehydration provided the patient takes adequate oral fluids containing carbohydrates and electrolytes. Patients find it more comfortable to rest the bowel by avoiding high-fiber foods, fats, milk products, caffeine, and alcohol. Frequent feedings of tea, “flat” carbonated beverages, and soft, easily digested foods (eg, soups, crackers, bananas, applesauce, rice, toast) are encouraged.

B. Rehydration

In more severe diarrhea, dehydration can occur quickly, especially in children, the frail, and the elderly. Oral rehydration with fluids containing glucose, Na^+ , K^+ , Cl^- , and bicarbonate or citrate is preferred when feasible. A convenient mixture is $\frac{1}{2}$ tsp salt (3.5 g), 1 tsp baking soda (2.5 g NaHCO_3), 8 tsp sugar (40 g), and 8 oz orange juice (1.5 g KCl), diluted to 1 L with water. Alternatively, oral electrolyte solutions (eg, Pedialyte, Gatorade) are readily available. Fluids should be given at rates of 50–200 mL/kg/24 h depending on the hydration status. Intravenous fluids (lactated Ringer injection) are preferred in patients with severe dehydration.

C. Antidiarrheal Agents

Antidiarrheal agents may be used safely in patients with mild to moderate diarrheal illnesses to improve patient comfort. Opioid agents help decrease the stool number and liquidity and control fecal urgency. However, they should not be used in patients with bloody diarrhea, high fever, or systemic toxicity and should be discontinued in patients whose diarrhea is worsening despite therapy. With these provisos, such drugs provide excellent symptomatic relief. Loperamide is preferred, in a dosage of 4 mg orally initially, followed by 2 mg after each loose stool (maximum: 16 mg/24 h).

Bismuth subsalicylate (Pepto-Bismol), two tablets or 30 mL orally four times daily, reduces symptoms in patients with traveler's diarrhea by virtue of its anti-inflammatory and antibacterial properties. It also reduces vomiting associated with viral enteritis. Anticholinergic agents (eg, diphenoxylate with atropine) are contraindicated in acute diarrhea because of the rare precipitation of toxic megacolon.

D. Antibiotic Therapy

1. Empiric treatment—Empiric antibiotic treatment of all patients with acute diarrhea is not indicated. Even patients with inflammatory diarrhea caused by invasive pathogens usually have symptoms that will resolve within several days without antimicrobials. Empiric treatment may be considered in patients with non-hospital-acquired diarrhea with moderate to severe fever, tenesmus, or bloody stools or the presence of fecal lactoferrin while the stool bacterial culture is incubating, provided that infection with STEC is not suspected. It should also be considered in patients who are immunocompromised or who have significant dehydration. The oral drugs of choice for empiric treatment are the fluoroquinolones (eg, ciprofloxacin 500 mg, ofloxacin 400 mg, or norfloxacin 400 mg, twice daily, or levofloxacin 500 mg once daily) for 5–7 days. Alternatives include trimethoprim-sulfamethoxazole, 160/800 mg twice daily; or doxycycline, 100 mg twice daily. Macrolides and penicillins are no longer recommended because of widespread microbial resistance to these agents. Rifaximin, a nonabsorbed oral antibiotic, 200 mg three times daily for 3 days, is approved for empiric treatment of noninflammatory traveler's diarrhea (see Chapter 30).

2. Specific antimicrobial treatment—Antibiotics are not recommended in patients with nontyphoid *Salmonella*, *Campylobacter*, Shiga-toxin-producing *E coli*, *Aeromonas*, or *Yersinia*, except in severe disease, because they do not hasten recovery or reduce the period of fecal bacterial excretion. The infectious diarrheas for which treatment is recommended are shigellosis, cholera, extraintestinal salmonellosis, traveler's diarrhea, *C difficile* infection, giardiasis, and amebiasis. Therapy for traveler's diarrhea, infectious (sexually transmitted) proctitis, and AIDS-related diarrhea is presented in other chapters of this book.

▶ When to Admit

- Severe dehydration for intravenous fluids, especially if vomiting or unable to maintain sufficient oral fluid intake.

- Bloody diarrhea that is severe or worsening in order to distinguish infectious versus noninfectious cause.
- Severe abdominal pain, worrisome for toxic colitis, inflammatory bowel disease, intestinal ischemia, or surgical abdomen.
- Signs of severe infection or sepsis (temperature > 39.5°C, leukocytosis, rash).
- Severe or worsening diarrhea in patients who are > 70 years old or immunocompromised.
- Signs of hemolytic-uremic syndrome (acute kidney injury, thrombocytopenia, hemolytic anemia).

Buchholz U et al. German outbreak of *Escherichia coli* O104:H4 associated with sprouts. *N Engl J Med*. 2011 Nov 10;365(19):1763–70. [PMID: 22029753]

DuPont HL. Clinical practice. Bacterial diarrhea. *N Engl J Med*. 2009 Oct 15;361(1):1560–9. [PMID: 19828533]

Holtz LR et al. Acute bloody diarrhea: a medical emergency for patients of all ages. *Gastroenterology*. 2009 May;136(6):1887–98. [PMID: 19457417]

Pawlowski SW et al. Diagnosis and treatment of acute or persistent diarrhea. *Gastroenterology*. 2009 May;136(6):1874–86. [PMID: 19457416]

2. Chronic Diarrhea



ESSENTIALS OF DIAGNOSIS

- ▶ Diarrhea present for > 4 weeks.
- ▶ Before embarking on extensive work-up, common causes should be excluded, including medications, chronic infections, and irritable bowel syndrome.

▶ Etiology

The causes of chronic diarrhea may be grouped into the following major pathophysiologic categories: medications, osmotic diarrheas, secretory conditions, inflammatory conditions, malabsorptive conditions, motility disorders, chronic infections, and systemic disorders (Table 15–6).

A. Medications

Numerous medications can cause diarrhea. Common offenders include cholinesterase inhibitors, SSRIs, angiotensin II-receptor blockers, proton pump inhibitors, NSAIDs, metformin, allopurinol, and orlistat. All medications should be carefully reviewed, and discontinuation of potential culprits should be considered.

B. Osmotic Diarrheas

As stool leaves the colon, fecal osmolality is equal to the serum osmolality, ie, approximately 290 mosm/kg. Under normal circumstances, the major osmoles are Na⁺, K⁺, Cl⁻, and HCO₃⁻. The stool osmolality may be estimated by multiplying the stool (Na⁺ + K⁺) × 2. The **osmotic gap** is the difference between the *measured* osmolality of the stool (or serum) and the *estimated* stool osmolality and is normally

< 50 mosm/kg. An increased osmotic gap (> 125 mosm/kg) implies that the diarrhea is caused by ingestion or malabsorption of an osmotically active substance. The most common causes are carbohydrate malabsorption (lactose, fructose, sorbitol), laxative abuse, and malabsorption syndromes (see below). Osmotic diarrheas resolve during fasting. Those caused by malabsorbed carbohydrates are characterized by abdominal distention, bloating, and flatulence due to increased colonic gas production.

Carbohydrate malabsorption is common and should be considered in all patients with chronic diarrhea. Patients should be asked about their intake of dairy products (lactose), fruits and artificial sweeteners (fructose and sorbitol), and alcohol. The diagnosis of carbohydrate malabsorption may be established by an elimination trial for 2–3 weeks or by hydrogen breath tests.

Ingestion of magnesium- or phosphate-containing compounds (laxatives, antacids) should be considered in enigmatic chronic diarrhea. The fat substitute olestra also causes diarrhea and cramps in occasional patients.

C. Secretory Conditions

Increased intestinal secretion or decreased absorption results in a high-volume watery diarrhea with a normal osmotic gap. There is little change in stool output during the fasting state, and dehydration and electrolyte imbalance may develop. Causes include endocrine tumors (stimulating intestinal or pancreatic secretion) and bile salt malabsorption (stimulating colonic secretion).

D. Inflammatory Conditions

Diarrhea is present in most patients with inflammatory bowel disease (ulcerative colitis, Crohn disease). A variety of other symptoms may be present, including abdominal pain, fever, weight loss, and hematochezia. Microscopic colitis is a common cause of chronic watery diarrhea in the elderly (See Inflammatory Bowel Disease, below.)

E. Malabsorptive Conditions

The major causes of malabsorption are small mucosal intestinal diseases, intestinal resections, lymphatic obstruction, small intestinal bacterial overgrowth, and pancreatic insufficiency. Its characteristics are weight loss, osmotic diarrhea, steatorrhea, and nutritional deficiencies. Significant diarrhea in the absence of weight loss is not likely to be due to malabsorption. The physical and laboratory abnormalities related to deficiencies of vitamins or minerals are discussed in Chapter 29.

F. Motility Disorders (Including Irritable Bowel Syndrome)

Irritable bowel syndrome is the most common cause of chronic diarrhea in young adults (see Irritable Bowel Syndrome). It should be considered in patients with lower abdominal pain and altered bowel habits who have no other evidence of serious organic disease (weight loss, nocturnal diarrhea, anemia, or gastrointestinal bleeding). Abnormal intestinal motility secondary to systemic

disorders or surgery may result in diarrhea due to rapid transit or to stasis of intestinal contents with bacterial overgrowth, resulting in malabsorption.

G. Chronic Infections

Chronic parasitic infections may cause diarrhea through a number of mechanisms. Pathogens most commonly associated with diarrhea include the protozoans *Giardia*, *E histolytica*, and *Cyclospora* as well as the intestinal nematodes. Strongyloidiasis and capillariasis should be excluded in patients from endemic regions, especially in the presence of eosinophilia. Bacterial infections with *Aeromonas* and *Plesiomonas* may uncommonly be a cause of chronic diarrhea.

Immunocompromised patients are susceptible to infectious organisms that can cause acute or chronic diarrhea (see Chapter 31), including Microsporidia, *Cryptosporidium*, CMV, *Isospora belli*, *Cyclospora*, and *Mycobacterium avium* complex.

H. Systemic Conditions

Chronic systemic conditions, such as thyroid disease, diabetes, and collagen vascular disorders, may cause diarrhea through alterations in motility or intestinal absorption.


► Clinical Findings

The history and physical examination commonly suggest the underlying pathophysiology that guides the subsequent diagnostic work-up (Figure 15–2). The clinician should establish whether the diarrhea is continuous or intermittent and whether it occurs at night or during fasting. The stool appearance may suggest a malabsorption disorder (greasy or malodorous), inflammatory disorder (containing blood or pus), or a secretory process (watery). The presence of abdominal pain suggests irritable bowel syndrome or inflammatory bowel disease. Medications, diet, and recent psychosocial stressors should be reviewed. Physical examination should assess for signs of malnutrition, dehydration, and inflammatory bowel disease.

Because chronic diarrhea is caused by so many conditions, the subsequent diagnostic approach is guided by the relative suspicion for the underlying cause, and no specific algorithm can be followed in all patients. Prior to embarking on an extensive evaluation, the most common causes of chronic diarrhea should be considered, including medications, irritable bowel syndrome, and lactose intolerance. The presence of nocturnal diarrhea, weight loss, anemia, or positive results on FOBT are inconsistent with these disorders and warrant further evaluation. AIDS-associated diarrhea is discussed in Chapter 31.

A. Initial Diagnostic Tests

1. Routine laboratory tests—Complete blood count, serum electrolytes, liver function tests, calcium, phosphorus, albumin, thyroid-stimulating hormone, vitamin A and D levels, INR, erythrocyte sedimentation rate, and C-reactive protein should be obtained in most patients. Serologic testing for celiac sprue with IgA tissue transglutaminase (tTG)



▲ **Figure 15-2.** Decision diagram for diagnosis of causes of chronic diarrhea.

or anti-endomysial antibody tests may be recommended in the evaluation of most patients with chronic diarrhea and all patients with signs of malabsorption. Anemia occurs in malabsorption syndromes (folate, iron deficiency, or vitamin B₁₂) as well as inflammatory conditions. Hypoalbuminemia is present in malabsorption, protein-losing enteropathies, and inflammatory diseases. Hyponatremia and nonanion gap metabolic acidosis occur in secretory diarrheas. Increased erythrocyte sedimentation rate or C-reactive protein suggests inflammatory bowel disease.

2. Routine stool studies—Stool sample should be analyzed for ova and parasites, electrolytes (to calculate osmotic gap), qualitative staining for fat (Sudan stain), occult blood, and leukocytes or lactoferrin. The presence of *Giardia* and *E histolytica* may be detected in wet mounts. However, fecal antigen detection tests for *Giardia* and *E histolytica* are a more sensitive and specific method of detection. *Cryptosporidium* and *Cyclospora* are found with modified acid-fast staining. As discussed previously, an increased osmotic gap suggests an osmotic diarrhea or disorder of malabsorption. A positive fecal fat stain suggests a disorder

of malabsorption. The presence of fecal leukocytes or lactoferrin may suggest inflammatory bowel disease.

3. Endoscopic examination and mucosal biopsy—Most patients with chronic persistent diarrhea undergo colonoscopy with mucosal biopsy to exclude inflammatory bowel disease (including Crohn disease and ulcerative colitis), microscopic colitis, and colonic neoplasia. Upper endoscopy with small bowel biopsy is performed when a small intestinal malabsorptive disorder is suspected (celiac sprue, Whipple disease) from abnormal laboratory studies or a positive fecal fat stain. It may also be done in patients with advanced AIDS to document *Cryptosporidium*, Microsporidia, and *M avium-intracellulare* infection.

B. Further Studies

If the cause of diarrhea is still not apparent, further studies may be warranted.

1. 24-hour stool collection quantification of total weight and fat—A stool weight of < 200-300 g/24 h excludes diarrhea and suggests a functional disorder such as irritable bowel syndrome. A weight > 1000–1500 g suggests

a significant secretory process, including neuroendocrine tumors. A fecal fat determination in excess of 10 g/24 h confirms a malabsorptive disorder. Fecal elastase < 100 mcg/g may be caused by pancreatic insufficiency. (See Celiac Disease and specific tests for malabsorption, below.)

2. Other imaging studies—Calcification on a plain abdominal radiograph confirms a diagnosis of chronic pancreatitis, although abdominal CT and endoscopic ultrasonography are more sensitive for the diagnosis of chronic pancreatitis as well as pancreatic cancer. Small intestinal imaging with barium, CT, or MRI is helpful in the diagnosis of Crohn disease, small bowel lymphoma, carcinoid, and jejunal diverticula. Neuroendocrine tumors may be localized using somatostatin receptor scintigraphy. Retention of < 11% at 7 days of intravenous ⁷⁵Se-homotaurocholate on scintigraphy suggests bile salt malabsorption.

3. Laboratory tests—

A. SEROLOGIC TESTS FOR NEUROENDOCRINE TUMORS—

Secretory diarrheas due to neuroendocrine tumors are rare but should be considered in patients with chronic, high-volume watery diarrhea (> 1 L/d) with a normal osmotic gap that persists during fasting. Measurements of the secretagogues of various neuroendocrine tumors may be assayed, including serum chromogranin A, vasoactive intestinal peptide (VIP) (VIPoma), calcitonin (medullary thyroid carcinoma), gastrin (Zollinger-Ellison syndrome), and urinary 5-hydroxyindoleacetic acid (5-HIAA) (carcinoid).

B. BREATH TEST—The diagnosis of small bowel bacterial overgrowth is confirmed with noninvasive breath tests (d-¹⁴C]xylose, glucose, or lactulose) or by obtaining an aspirate of small intestinal contents for quantitative aerobic and anaerobic bacterial culture.

► Treatment

A number of antidiarrheal agents may be used in certain patients with chronic diarrheal conditions and are listed below. Opioids are safe in most patients with chronic, stable symptoms.

Loperamide: 4 mg orally initially, then 2 mg after each loose stool (maximum: 16 mg/d).

Diphenoxylate with atropine: One tablet orally three or four times daily as needed.

Codeine and deodorized tincture of opium: Because of potential habituation, these drugs are avoided except in cases of chronic, intractable diarrhea. Codeine may be given in a dosage of 15–60 mg orally every 4 hours; tincture of opium, 0.3–1.2 mL orally every 6 hours as needed.

Clonidine: α_2 -Adrenergic agonists inhibit intestinal electrolyte secretion. Clonidine, 0.1–0.6 mg orally twice daily, or a clonidine patch, 0.1–0.2 mg/d, may help in some patients with secretory diarrheas, diabetic diarrhea, or cryptosporidiosis.

Octreotide: This somatostatin analog stimulates intestinal fluid and electrolyte absorption and inhibits intestinal fluid secretion and the release of gastrointestinal peptides. It is given for secretory diarrheas due to neuroendocrine tumors (VIPomas, carcinoid) and in some cases of AIDS-related diarrhea. Effective doses range from 50 to 250 mcg subcutaneously three times daily.

Cholestyramine: This bile salt-binding resin may be useful in patients with bile salt-induced diarrhea, which may be idiopathic or secondary to intestinal resection or ileal disease. A dosage of 4 g orally once to three times daily is recommended.

Fan X et al. Small intestinal bacterial overgrowth, bile acid malabsorption and gluten intolerance as possible causes of chronic watery diarrhoea. *Aliment Pharmacol Ther.* 2009 May 15; 29(10):1069–77. [PMID: 19222407]

Gasbarrini A et al; 1st Rome H2-Breath Testing Consensus Conference Working Group. Methodology and indications of H2-breath testing in gastrointestinal diseases: the Rome Consensus Conference. *Aliment Pharmacol Ther.* 2009 Mar 30;29(suppl 1):1–49. [PMID: 19344474]

Schiller LR. Diarrhea and malabsorption in the elderly. *Gastroenterol Clin North Am.* 2009 Sep;38(3):481–502. [PMID: 19699409]

GASTROINTESTINAL BLEEDING

1. Acute Upper Gastrointestinal Bleeding



ESSENTIALS OF DIAGNOSIS

- Hematemesis (bright red blood or “coffee grounds”).
- Melena in most cases; hematochezia in massive upper gastrointestinal bleeds.
- Volume status to determine severity of blood loss; hematocrit is a poor early indicator of blood loss.
- Endoscopy diagnostic and may be therapeutic.

► General Considerations

There are over 250,000 hospitalizations a year in the United States for acute upper gastrointestinal bleeding, with a mortality rate of 4–10%. Approximately half of patients are over 60 years of age, and in this age group the mortality rate is even higher. Patients seldom die of exsanguination but rather from complications of an underlying disease.

The most common presentation of upper gastrointestinal bleeding is hematemesis or melena. Hematemesis may be either bright red blood or brown “coffee grounds” material. Melena develops after as little as 50–100 mL of blood loss in the upper gastrointestinal tract, whereas hematochezia requires a loss of more than 1000 mL. Although hematochezia generally suggests a lower bleeding source (eg, colonic), severe upper gastrointestinal bleeding may present with hematochezia in 10% of cases.

Upper gastrointestinal bleeding is self-limited in 80% of patients; urgent medical therapy and endoscopic evaluation are obligatory in the rest. Patients with bleeding more than 48 hours prior to presentation have a low risk of recurrent bleeding.

► Etiology

Acute upper gastrointestinal bleeding may originate from a number of sources. These are listed in order of their frequency and discussed in detail below.

A. Peptic Ulcer Disease

Peptic ulcers account for half of major upper gastrointestinal bleeding with an overall mortality rate of 6%. However, in North America the incidence of bleeding from ulcers is declining, perhaps due to eradication of *H pylori* and prophylaxis with proton pump inhibitors in high-risk patients.

B. Portal Hypertension

Portal hypertension accounts for 10–20% of upper gastrointestinal bleeding. Bleeding usually arises from esophageal varices and less commonly gastric or duodenal varices or portal hypertensive gastropathy. Approximately 25% of patients with cirrhosis have medium to large esophageal varices, of whom 30% experience acute variceal bleeding within a 2-year period. Due to improved care, the hospital mortality rate has declined over the past 20 years from 40% to 15%. Nevertheless, a mortality rate of 60–80% is expected at 1–4 years due to recurrent bleeding or other complications of chronic liver disease.

C. Mallory-Weiss Tears

Lacerations of the gastroesophageal junction cause 5–10% of cases of upper gastrointestinal bleeding. Many patients report a history of heavy alcohol use or retching. Less than 10% have continued or recurrent bleeding.

D. Vascular Anomalies

Vascular anomalies are found throughout the gastrointestinal tract and may be the source of chronic or acute gastrointestinal bleeding. They account for 7% of cases of acute upper tract bleeding. The most common are **angioectasias** (angiodysplasias) which are 1–10 mm distorted, aberrant submucosal vessels caused by chronic, intermittent obstruction of submucosal veins. They have a bright red stellate appearance and occur throughout the gastrointestinal tract but most commonly in the right colon. **Telangiectasias** are small, cherry red lesions caused by dilation of venules that may be part of systemic conditions (hereditary hemorrhagic telangiectasia, CREST syndrome) or occur sporadically. The Dieulafoy lesion is an aberrant, large-caliber submucosal artery, most commonly in the proximal stomach that causes recurrent, intermittent bleeding.

E. Gastric Neoplasms

Gastric neoplasms result in 1% of upper gastrointestinal hemorrhages.

F. Erosive Gastritis

Because this process is superficial, it is a relatively unusual cause of severe gastrointestinal bleeding (< 5% of cases) and more commonly results in chronic blood loss. Gastric mucosal erosions are due to NSAIDs, alcohol, or severe medical or surgical illness (stress-related mucosal disease).

G. Erosive Esophagitis

Severe erosive esophagitis due to chronic gastroesophageal reflux may rarely cause significant upper gastrointestinal bleeding, especially in patients who are bed bound long-term.

H. Others

An aortoenteric fistula complicates 2% of abdominal aortic grafts or, rarely, can occur as the initial presentation of a previously untreated aneurysm. Usually located between the graft or aneurysm and the third portion of the duodenum, these fistulas characteristically present with a herald nonexsanguinating initial hemorrhage, with melena and hematemesis, or with chronic intermittent bleeding. The diagnosis may be suspected by upper endoscopy or abdominal CT. Surgery is mandatory to prevent exsanguinating hemorrhage. Unusual causes of upper gastrointestinal bleeding include hemobilia (from hepatic tumor, angioma, penetrating trauma), pancreatic malignancy, and pseudoaneurysm (hemorrhage from pancreatic aneurysm).

▶ Initial Evaluation & Treatment

A. Stabilization

The initial step is assessment of the hemodynamic status. A systolic blood pressure < 100 mm Hg identifies a high-risk patient with severe acute bleeding. A heart rate over 100 beats/min with a systolic blood pressure over 100 mm Hg signifies moderate acute blood loss. A normal systolic blood pressure and heart rate suggest relatively minor hemorrhage. Postural hypotension and tachycardia are useful when present but may be due to causes other than blood loss. Because the hematocrit may take 24–72 hours to equilibrate with the extravascular fluid, it is not a reliable indicator of the severity of acute bleeding.

In patients with significant bleeding, two 18-gauge or larger intravenous lines should be started prior to further diagnostic tests. Blood is sent for complete blood count, prothrombin time with international normalized ratio (INR), serum creatinine, liver enzymes, and blood typing and screening (in anticipation of need for possible transfusion). In patients without hemodynamic compromise or overt active bleeding, aggressive fluid repletion can be delayed until the extent of the bleeding is further clarified. Patients with evidence of hemodynamic compromise are given 0.9% saline or lactated Ringer injection and cross-matched for 2–4 units of packed red blood cells. It is rarely necessary to administer type-specific or O-negative blood. Central venous pressure monitoring is desirable in some cases, but line placement should not interfere with rapid volume resuscitation.

Placement of a nasogastric tube is not routinely needed but may be helpful in the initial assessment and triage of selected patients with suspected active upper tract bleeding. The aspiration of red blood or “coffee grounds” confirms an upper gastrointestinal source of bleeding, though 10% of patients with confirmed upper tract sources of bleeding have nonbloody aspirates—especially when bleeding originates in the duodenum. An aspirate of bright red blood indicates active bleeding and is associated with the highest risk of further bleeding and complications, while a clear aspirate identifies patients at lower initial risk. Erythromycin (250 mg) administered intravenously 30 minutes prior to upper endoscopy promotes gastric emptying and may improve the quality of endoscopic evaluation when substantial amounts of blood or clot in the

stomach is suspected. Efforts to stop or slow bleeding by gastric lavage with large volumes of fluid are of no benefit and expose the patient to an increased risk of aspiration.

B. Blood Replacement

The amount of fluid and blood products required is based on assessment of vital signs, evidence of active bleeding from nasogastric aspirate, and laboratory tests. Sufficient packed red blood cells should be given to maintain a hemoglobin of 6–10 g/dL, based on the patient's hemodynamic status, comorbidities (especially cardiovascular disease), and presence of continued bleeding. In the absence of continued bleeding, the hemoglobin should rise approximately 1 g/dL for each unit of transfused packed red cells. Transfusion of blood should not be withheld from patients with brisk active bleeding regardless of the hemoglobin value. It is desirable to transfuse blood in anticipation of the nadir hematocrit. In actively bleeding patients, platelets are transfused if the platelet count is under 50,000/mcL and considered if there is impaired platelet function due to aspirin or clopidogrel use (regardless of the platelet count). Uremic patients (who also have dysfunctional platelets) with active bleeding are given three doses of desmopressin (DDAVP), 0.3 mcg/kg intravenously, at 12-hour intervals. Fresh frozen plasma is administered for actively bleeding patients with a coagulopathy and an INR > 1.8; however, endoscopy may be performed safely if the INR is < 2.5. In the face of massive bleeding, 1 unit of fresh frozen plasma should be given for each 5 units of packed red blood cells transfused.

C. Initial Triage

A preliminary assessment of risk based on several clinical factors aids in the resuscitation as well as the rational triage of the patient. Clinical predictors of increased risk of rebleeding and death include age > 60 years, comorbid illnesses, systolic blood pressure < 100 mm Hg, pulse > 100 beats/min, and bright red blood in the nasogastric aspirate or on rectal examination.

1. High risk—Patients with active bleeding manifested by hematemesis or bright red blood on nasogastric aspirate, shock, persistent hemodynamic derangement despite fluid resuscitation, serious comorbid medical illness, or evidence of advanced liver disease require admission to an intensive care unit (ICU). After adequate resuscitation, endoscopy should be performed within 2–24 hours in most patients but may be delayed in selected patients with serious comorbidities (eg, acute coronary syndrome) who do not have signs of continued bleeding.

2. Low to moderate risk—All other patients are admitted to a step-down unit or medical ward after appropriate stabilization for further evaluation and treatment. Patients without evidence of active bleeding undergo nonemergent endoscopy usually within 24 hours.

► Subsequent Evaluation & Treatment

Specific treatment of the various causes of upper gastrointestinal bleeding is discussed elsewhere in this chapter. The following general comments apply to most patients with bleeding.

The clinician's impression of the bleeding source is correct in only 40% of cases. Signs of chronic liver disease implicate bleeding due to portal hypertension, but a different lesion is identified in 25% of patients with cirrhosis. A history of dyspepsia, NSAID use, or peptic ulcer disease suggests peptic ulcer. Acute bleeding preceded by heavy alcohol ingestion or retching suggests a Mallory-Weiss tear, though most of these patients have neither.

A. Upper Endoscopy

Virtually all patients with upper tract bleeding should undergo upper endoscopy within 24 hours of arriving in the emergency department. The benefits of endoscopy in this setting are threefold.

1. To identify the source of bleeding—The appropriate acute and long-term medical therapy is determined by the cause of bleeding. Patients with portal hypertension will be treated differently from those with ulcer disease. If surgery or radiologic interventional therapy is required for uncontrolled bleeding, the source of bleeding as determined at endoscopy will determine the approach.

2. To determine the risk of rebleeding and guide triage—Patients with a nonbleeding Mallory-Weiss tear, esophagitis, gastritis, and ulcers that have a clean, white base have a very low risk (< 5%) of rebleeding. Patients with one of these findings who are < age 60 years, without hemodynamic instability or transfusion requirement, without serious coexisting illness, and who have stable social support may be discharged from the emergency department or medical ward after endoscopy with outpatient follow-up. All others with one of these low-risk lesions should be observed on a medical ward for 24–48 hours. Patients with ulcers that are actively bleeding or have a visible vessel or adherent clot, or who have variceal bleeding usually require at least a 3-day hospitalization with closer initial observation in an ICU or step down unit.

3. To render endoscopic therapy—Hemostasis can be achieved in actively bleeding lesions with endoscopic modalities such as cautery, injection, or endoclips. About 90% of bleeding or nonbleeding varices can be effectively treated immediately with injection of a sclerosant or application of rubber bands to the varices. Similarly, 90% of bleeding ulcers, angiomas, or Mallory-Weiss tears can be controlled with either injection of epinephrine, direct cauterization of the vessel by a heater probe or multipolar electrocautery probe, or application of an endoclip. Certain nonbleeding lesions such as ulcers with visible blood vessels, and angioectasias are also treated with these therapies. Specific endoscopic therapy of varices, peptic ulcers, and Mallory-Weiss tears is dealt with elsewhere in this chapter.

B. Acute Pharmacologic Therapies

1. Acid inhibitory therapy—Intravenous proton pump inhibitors (esomeprazole or pantoprazole, 80 mg bolus, followed by 8 mg/h continuous infusion for 72 hours) reduce the risk of rebleeding in patients with peptic ulcers with high-risk features (active bleeding, visible vessel, or adherent clot) after endoscopic treatment. **Oral proton**

pump inhibitors (omeprazole, esomeprazole, or pantoprazole 40 mg; lansoprazole or dexlansoprazole 30–60 mg) once or twice daily are sufficient for lesions at low-risk for rebleeding (eg, esophagitis, gastritis, clean-based ulcers, and Mallory-Weiss tears).

Administration of continuous intravenous proton pump inhibitor *before* endoscopy results in a decreased number of ulcers with lesions that require endoscopic therapy. It therefore is standard clinical practice at many institutions to administer either an intravenous or a high-dose oral proton pump inhibitor prior to endoscopy in patients with significant upper gastrointestinal bleeding. Based on the findings during endoscopy, the intravenous proton pump inhibitor may be continued or discontinued.

2. Octreotide—Continuous intravenous infusion of octreotide (100 mcg bolus, followed by 50–100 mcg/h) reduces splanchnic blood flow and portal blood pressures and is effective in the initial control of bleeding related to portal hypertension. It is administered promptly to all patients with active upper gastrointestinal bleeding and evidence of liver disease or portal hypertension until the source of bleeding can be determined by endoscopy. In countries where it is available, terlipressin may be preferred to octreotide for the treatment of bleeding related to portal hypertension because of its sustained reduction of portal and variceal pressures and its proven reduction in mortality.

C. Other Treatment

1. Intra-arterial embolization—Angiographic treatment is used in patients with persistent bleeding from ulcers, angiomas, or Mallory-Weiss tears who have failed endoscopic therapy and are poor operative risks.

2. Transvenous intrahepatic portosystemic shunts (TIPS)—Placement of a wire stent from the hepatic vein through the liver to the portal vein provides effective decompression of the portal venous system and control of acute variceal bleeding. It is indicated in patients in whom endoscopic modalities have failed to control acute variceal bleeding.

Barkun A et al. International consensus recommendations on the management of patients with nonvariceal upper gastrointestinal bleeding. *Ann Intern Med.* 2010 Jan 19;152(2):101–13. [PMID: 20083829]

Greenspoon J et al; International Consensus Upper Gastrointestinal Bleeding Conference Group. Management of patients with nonvariceal upper gastrointestinal bleeding. *Clin Gastroenterol Hepatol.* 2011 Aug 4. [Epub ahead of print] [PMID: 21820395]

Laine L et al. Endoscopic therapy for bleeding ulcers: an evidence-based approach based on meta-analyses of randomized controlled trials. *Clin Gastroenterol Hepatol.* 2009 Jan;7(1):33–47. [PMID: 18986845]

Sung JJ et al. Causes of mortality in patients with peptic ulcer bleeding: a prospective cohort study of 10,428 cases. *Am J Gastroenterol.* 2010 Jan;105(1):84–9. [PMID: 19755976]

Wang CH et al. High-dose and non-high-dose proton pump inhibitors after endoscopic treatment in patients with bleeding peptic ulcer: a systematic review and meta-analysis of randomized controlled trials. *Arch Intern Med.* 2010 May;170(9):751–8. [PMID: 20458081]

2. Acute Lower Gastrointestinal Bleeding



ESSENTIALS OF DIAGNOSIS

- ▶ Hematochezia usually present.
- ▶ Ten percent of cases of hematochezia due to upper gastrointestinal source.
- ▶ Evaluation with colonoscopy in stable patients.
- ▶ Massive active bleeding calls for evaluation with sigmoidoscopy, upper endoscopy, angiography, or nuclear bleeding scan.

▶ General Considerations

Lower gastrointestinal bleeding is defined as that arising below the ligament of Treitz, ie, the small intestine or colon; however, up to 95% of cases arise from the colon. The severity of lower gastrointestinal bleeding ranges from mild anorectal bleeding to massive, large-volume hematochezia. Bright red blood that drips into the bowl after a bowel movement or is mixed with solid brown stool signifies mild bleeding, usually from an anorectosigmoid source, and can be evaluated in the outpatient setting. Serious lower gastrointestinal bleeding is more common in older men. In patients hospitalized with gastrointestinal bleeding, lower tract bleeding is one-third as common as upper gastrointestinal hemorrhage and tends to have a more benign course. Patients hospitalized with lower gastrointestinal tract bleeding are less likely to present with shock or orthostasis (< 20%) or to require transfusions (< 40%). Spontaneous cessation of bleeding occurs in over 85% of cases, and hospital mortality is < 4%.

▶ Etiology

The cause of these lesions depends on both the age of the patient and the severity of the bleeding. In patients under 50 years of age, the most common causes are infectious colitis, anorectal disease, and inflammatory bowel disease. In older patients, significant hematochezia is most often seen with diverticulosis, angiectasias, malignancy, or ischemia. In 20% of acute bleeding episodes, no source of bleeding can be identified.

A. Diverticulosis

Hemorrhage occurs in 3–5% of all patients with diverticulosis and is the most common cause of major lower tract bleeding, accounting for 50% of cases. There is 1.35- to 3.49-fold increased risk of diverticular hemorrhage among patients who use aspirin or nonsteroidal anti-inflammatory agents. Although diverticula are more prevalent on the left side of the colon, bleeding more commonly originates on the right side. Diverticular bleeding usually presents as acute, painless, large-volume maroon or bright red hematochezia in patients over age 50 years. More than 95% of cases require < 4 units of blood transfusion. Bleeding subsides spontaneously in 80% but may recur in up to 25% of patients.

B. Angioectasias

Angioectasias (angiodysplasias) occur throughout the upper and lower intestinal tracts and cause painless bleeding ranging from melena or hematochezia to occult blood loss. They are responsible for 4% of cases of lower gastrointestinal bleeding, where they are most often seen in the cecum and ascending colon. They are flat, red lesions (2–10 mm) with ectatic peripheral vessels radiating from a central vessel, and are most common in patients over 70 years and in those with chronic renal failure. Bleeding in younger patients more commonly arises from the small intestine.

Most gastrointestinal angioectasias are degenerative lesions that are believed to arise from chronic colonic mucosal contraction obstructing venous mucosal drainage. Telangiectasias may be congenital; part of an inherited syndrome, such as hereditary hemorrhagic telangiectasia; or related to autoimmune disorders, typically scleroderma. Ectasias can be identified in up to 6% of persons over age 60 years, so the mere presence of ectasias does not prove that the lesion is the source of bleeding, since active bleeding is seldom seen.

C. Neoplasms

Benign polyps and carcinoma are associated with chronic occult blood loss or intermittent anorectal hematochezia. Furthermore, they may cause up to 7% of acute lower gastrointestinal hemorrhage. After endoscopic removal of colonic polyps, important bleeding may occur up to 2 weeks later in 0.3% of patients. In general, prompt colonoscopy is recommended to treat postpolypectomy hemorrhage and minimize the need for transfusions.

D. Inflammatory Bowel Disease

Patients with inflammatory bowel disease (especially ulcerative colitis) often have diarrhea with variable amounts of hematochezia. Bleeding varies from occult blood loss to recurrent hematochezia usually mixed with stool. Symptoms of abdominal pain, tenesmus, and urgency are often present.

E. Anorectal Disease

Anorectal disease (hemorrhoids, fissures) usually results in small amounts of bright red blood noted on the toilet paper, streaking of the stool, or dripping into the toilet bowl; clinically significant blood loss can sometimes occur. Hemorrhoids are the source in 10% of patients admitted with lower bleeding. Rectal ulcers may account for up to 8% of lower bleeding, usually in elderly or debilitated patients with constipation.

F. Ischemic Colitis

This condition is seen commonly in older patients, most of whom have atherosclerotic disease. Most cases occur spontaneously due to transient episodes of nonocclusive ischemia. Ischemic colitis may also occur in 5% of patients after surgery for ileo-aortic or abdominal aortic aneurysm. In young patients, colonic ischemia may develop due to vasculitis, coagulation disorders, estrogen therapy, and

long distance running. Ischemic colitis results in hematochezia or bloody diarrhea associated with mild cramps. In most patients, the bleeding is mild and self-limited.

G. Others

Radiation-induced proctitis causes anorectal bleeding that may develop months to years after pelvic radiation. Endoscopy reveals multiple rectal telangiectasias. Acute infectious colitis (see Acute Diarrhea, above) commonly causes bloody diarrhea. Rare causes of lower tract bleeding include vasculitic ischemia, solitary rectal ulcer, NSAID-induced ulcers in the small bowel or right colon, small bowel diverticula, and colonic varices.

► Clinical Findings

A. Symptoms and Signs

The color of the stool helps distinguish upper from lower gastrointestinal bleeding, especially when observed by the clinician. Brown stools mixed or streaked with blood predict a source in the rectosigmoid or anus. Large volumes of bright red blood suggest a colonic source; maroon stools imply a lesion in the right colon or small intestine; and black stools (melena) predict a source proximal to the ligament of Treitz. Although 10% of patients admitted with self-reported hematochezia have an upper gastrointestinal source of bleeding (eg, peptic ulcer), this almost always occurs in the setting of massive hemorrhage with hemodynamic instability. Painless large-volume bleeding usually suggests diverticular bleeding. Bloody diarrhea associated with cramping abdominal pain, urgency, or tenesmus is characteristic of inflammatory bowel disease, infectious colitis, or ischemic colitis.

B. Diagnostic Tests

Important considerations in management include exclusion of an upper tract source, anoscopy and sigmoidoscopy, colonoscopy, nuclear bleeding scans and angiography, and small intestine push enteroscopy or capsule imaging.

1. Exclusion of an upper tract source—A nasogastric tube with aspiration should be considered, especially in patients with hemodynamic compromise. Aspiration of red blood or dark brown (“coffee grounds”) guaiac-positive material strongly implicates an upper gastrointestinal source of bleeding. Upper endoscopy should be performed in most patients presenting with hematochezia and hemodynamic instability to exclude an upper gastrointestinal source before proceeding with evaluation of the lower gastrointestinal tract.

2. Anoscopy and sigmoidoscopy—In otherwise healthy patients without anemia under age 45 years with small-volume bleeding, anoscopy and sigmoidoscopy are performed to look for evidence of anorectal disease, inflammatory bowel disease, or infectious colitis. If a lesion is found, no further evaluation is needed immediately unless the bleeding persists or is recurrent. In patients over age 45 years with small-volume hematochezia, the entire colon must be evaluated with colonoscopy to exclude tumor.

3. Colonoscopy—In patients with acute, large-volume bleeding requiring hospitalization, colonoscopy is the preferred initial study in most cases. The bowel first is purged rapidly by administration of a high-volume colonic lavage solution, given until the effluent is clear of blood and clots (4–10 L of GoLYTELY, CoLYTE, NuLYTE given orally or 1 L every 30 minutes over 2–5 hours by nasogastric tube). For patients with stable vital signs and whose lower gastrointestinal bleeding appears to have stopped, colonoscopy can be performed electively within 24 hours of admission. For patients with signs of hemodynamically significant bleeding (unstable vital signs) or who have signs of continued active bleeding during bowel preparation, urgent colonoscopy should be performed within 1–2 hours of completing the bowel purgative, when the bowel discharge is without clots. The probable site of bleeding can be identified in 70–85% of patients, and a high-risk lesion can be identified and treated in up to 20%.

4. Nuclear bleeding scans and angiography—Technetium-labeled red blood cell scanning can detect significant active bleeding and, in some cases, can localize the source to the small intestine, right colon, or left colon. Thus, some physicians obtain a nuclear bleeding scan to guide initial decision-making. If no bleeding is detected on scintigraphy, an “elective” colonoscopy is performed within 24 hours after conventional bowel preparation. If bleeding is detected on scintigraphy, urgent angiography is performed instead of colonoscopy. Nuclear studies are more apt to be positive in patients who are passing bright red or maroon stools at the time of the scan. Because most bleeding is slow or intermittent, less than half of nuclear studies are diagnostic and the accuracy of localization is poor. Thus, the main utility of scintigraphy is to determine whether bleeding is ongoing in order to determine whether angiography should be pursued. Less than half of patients with a positive nuclear study have positive angiography. Accordingly, angiograms are performed only in patients with positive technetium scans believed to have significant, ongoing bleeding.

In patients with massive lower gastrointestinal bleeding manifested by continued hemodynamic instability and hematochezia, urgent angiography should be performed without attempt at colonoscopy or scintigraphy.

5. Small intestine push enteroscopy or capsule imaging—Up to 5% of acute episodes of lower gastrointestinal bleeding arise from the small intestine, eluding diagnostic evaluation with upper endoscopy and colonoscopy. Because of the difficulty of examining the small intestine and its relative rarity as a source of acute bleeding, evaluation of the small bowel is not usually pursued in patients during the initial episode of acute lower gastrointestinal bleeding. However, the small intestine is investigated in patients with unexplained recurrent hemorrhage of obscure origin. (See *Obscure Gastrointestinal Bleeding* below.)

► Treatment

Initial stabilization, blood replacement, and triage are managed in the same manner as described above for Acute Upper Gastrointestinal Bleeding.

A. Therapeutic Colonoscopy

High-risk lesions (eg, angioectasias or diverticulum, rectal ulcer with active bleeding, or a visible vessel) may be treated endoscopically with epinephrine injection, cautery (bipolar or heater probe), or application of metallic endoclips or bands. In diverticular hemorrhage with high-risk lesions identified at colonoscopy, rebleeding occurs in half of untreated patients compared with virtually no rebleeding in patients treated endoscopically. Radiation proctitis is effectively treated with applications of cautery therapy to the rectal telangiectasias, preferably with an argon plasma coagulator.

B. Intra-arterial Embolization

When a bleeding lesion is identified, angiography with selective embolization achieves immediate hemostasis in more than 95% of patients. Major complications occur in 5% (mainly ischemic colitis) and rebleeding occurs in up to 25%.

C. Surgical Treatment

Emergency surgery is required in < 5% of patients with acute lower gastrointestinal bleeding due to the efficacy of colonoscopic and angiographic therapies. It is indicated in patients with ongoing bleeding that requires more than 6 units of blood within 24 hours or more than 10 total units in whom attempts at endoscopic or angiographic therapy failed. Most such hemorrhages are caused by a bleeding diverticulum or angioectasia. Preoperative localization of the bleeding site by nuclear scan or angiography allows limited resection of the bleeding segment of small intestine or colon. When accurate localization is not possible or when emergency surgery is required for massive hemorrhage, total abdominal colectomy with ileorectal anastomosis is required—with significantly higher morbidity and mortality than limited resections.

Surgery may also be indicated in patients with two or more hospitalizations for diverticular hemorrhage depending on the severity of bleeding and the patient's other comorbid conditions.

Kaltenbach T et al. Colonoscopy with clipping is useful in the diagnosis and treatment of diverticular bleeding. *Clin Gastroenterol Hepatol.* 2012 Feb; 10(2):131–7. [PMID: 22056302]

Strate LL et al. The role of colonoscopy and radiologic procedures in the management of acute lower intestinal bleeding. *Clin Gastroenterol Hepatol.* 2010 Apr;8(4):333–43. [PMID: 20036757]

Strate LL et al. Use of aspirin or nonsteroidal anti-inflammatory drugs increases risk for diverticulitis and diverticular bleeding. *Gastroenterology.* 2011 May;140(5):1427–33. [PMID: 21320500]

3. Obscure Gastrointestinal Bleeding

Obscure gastrointestinal bleeding refers to bleeding of unknown origin that persists or recurs after initial endoscopic evaluation with upper endoscopy and colonoscopy. *Obscure-overt bleeding* is manifested by persistent or recurrent visible evidence of

gastrointestinal bleeding (hematemesis, hematochezia, or melena). Up to 5% of patients admitted to hospitals with clinically overt gastrointestinal bleeding do not have a cause identified on upper endoscopy or colonoscopy (and therefore have obscure-overt bleeding). *Obscure-occult bleeding* (discussed below) refers to bleeding that is not apparent to the patient. It is manifested by recurrent positive FOBTs or FITs or recurrent iron deficiency anemia, or both in the absence of visible blood loss (as described below).

Obscure bleeding (either occult or overt) most commonly arises from lesions in the small intestine. In up to one-third of cases, however, a source of bleeding has been overlooked in the upper or lower tract on prior endoscopic studies. Hematemesis or melena suggest an overlooked source proximal to the ligament of Treitz (ie, within the esophagus, stomach, or duodenum): erosions in a hiatal hernia (“Cameron erosions”), peptic ulcer, angioectasia, Dieulafoy vascular malformation, portal hypertensive gastropathy, gastroduodenal varices, duodenal neoplasms, aortoenteric fistula, or hepatic and pancreatic lesions. In the colon, the most commonly overlooked lesions are angioectasias and neoplasms. The etiology of obscure bleeding that arises from the small intestine depends on the age of the patient. The most common causes of small intestinal bleeding in patients younger than 40 years are neoplasms (stromal tumors, lymphomas, adenocarcinomas, carcinoids), Crohn disease, celiac disease, and Meckel diverticulum. These disorders also occur in patients over age 40; however, angioectasias and NSAID-induced ulcers are far more common.

Evaluation of Obscure Bleeding

The evaluation of obscure bleeding depends on the age and overall health status of the patient, associated symptoms, and severity of the bleeding. In an older patient with significant comorbid illnesses, no gastrointestinal symptoms, and occult or obscure bleeding in whom the suspected source of bleeding is angioectasias, it may be reasonable to limit diagnostic evaluations, provided the anemia can be managed with long-term iron therapy or occasional transfusions. On the other hand, aggressive diagnostic evaluation is warranted in younger patients with obscure bleeding (in whom small bowel tumors are the most common cause) and symptomatic older patients with overt or obscure bleeding. Upper endoscopy and colonoscopy should be repeated to ascertain that a lesion in these regions has not been overlooked. If these studies are unrevealing, capsule endoscopy should be performed to evaluate the small intestine. Capsule endoscopy is superior to radiographic studies (standard small bowel follow through, enteroclysis, or CT enterography) and standard push enteroscopy for the detection of small bowel abnormalities, demonstrating possible sources of occult bleeding in 60% of patients, most commonly vascular abnormalities (30%), ulcers (25%), and neoplasms (< 1–5%). Further management depends on the capsule endoscopic findings. Laparotomy is warranted if a small bowel tumor is identified by capsule endoscopy or radiographic studies. Most other lesions identified by capsule imaging can be further evaluated with one of several new enteroscopes that use

overtubes with balloons to advance the scope through most of the small intestine in a forward and retrograde direction. Neoplasms can be biopsied or resected, and angioectasias may be cauterized. For massive or hemodynamically significant acute bleeding, angiography may be superior to enteroscopy for localization and embolization of a bleeding vascular abnormality. Abdominal CT may be considered to exclude a hepatic or pancreatic source of bleeding. A nuclear scan for Meckel diverticulum should be obtained in patients under age 30. With the advent of capsule imaging and advanced endoscopic technologies for evaluating and treating bleeding lesions in the small intestine, intraoperative enteroscopy of the small bowel is seldom required.

4. Occult Gastrointestinal Bleeding

Occult gastrointestinal bleeding refers to bleeding that is not apparent to the patient. Chronic gastrointestinal blood loss of < 100 mL/d may cause no appreciable change in stool appearance. Thus, occult bleeding in an adult is identified by a positive FOBT, FIT, or iron deficiency anemia in the absence of visible blood loss. FOBT or FIT may be performed in patients with gastrointestinal symptoms or as a screening test for colorectal neoplasia (see Chapter 39). From 2% to 6% of patients in screening programs have a positive FOBT or FIT.

In the United States, 2% of men and 5% of women have iron deficiency anemia (serum ferritin < 30–45 mcg/L). In premenopausal women, iron deficiency anemia is most commonly attributable to menstrual and pregnancy-associated iron loss; however, a gastrointestinal source of chronic blood loss is present in 10%. Occult blood loss may arise from anywhere in the gastrointestinal tract. Among men and postmenopausal women, a potential gastrointestinal cause of blood loss can be identified in the colon in 15–30% and in the upper gastrointestinal tract in 35–55%; a malignancy is present in 10%. Iron deficiency on rare occasions is caused by malabsorption (especially celiac disease) or malnutrition. The most common causes of occult bleeding with iron deficiency are (1) neoplasms; (2) vascular abnormalities (angioectasias); (3) acid-peptic lesions (esophagitis, peptic ulcer disease, erosions in hiatal hernia); (4) infections (nematodes, especially hookworm; tuberculosis); (5) medications (especially NSAIDs or aspirin); and (6) other causes such as inflammatory bowel disease.

► Evaluation of Occult Bleeding

Asymptomatic adults with positive FOBTs or FITs that are performed for routine colorectal cancer screening should undergo colonoscopy (see Chapter 39). All symptomatic adults with positive FOBTs or FITs or iron deficiency anemia should undergo evaluation of the lower and upper gastrointestinal tract with colonoscopy and upper endoscopy, unless the anemia can be definitively ascribed to a nongastrointestinal source (eg, menstruation, blood donation, or recent surgery). Patients with iron deficiency anemia should be evaluated for possible celiac disease with either IgA anti-tissue transglutaminase or duodenal biopsy. After evaluation of the upper and lower gastrointestinal tract with upper

endoscopy and colonoscopy, the origin of occult bleeding remains unexplained in 30–50% of patients.

In younger patients (age < 60) with unexplained occult bleeding or iron deficiency, it is recommended to pursue further evaluation of the small intestine for a source of obscure-occult bleeding (as described above) in order to exclude a small intestinal neoplasm or inflammatory bowel disease. Patients over age 60 with occult bleeding who have a normal initial endoscopic evaluation and no other worrisome symptoms or signs (eg, abdominal pain, weight loss) most commonly have blood loss from angioectasias, which may be clinically unimportant. Therefore, it is reasonable to give an empiric trial of iron supplementation and observe the patient for evidence of clinically significant bleeding. For anemia that responds poorly to iron supplementation or recurrent or persistent chronic occult gastrointestinal blood loss, further evaluation is pursued for a source of obscure-occult bleeding (as described above). When possible, antiplatelet agents (aspirin, NSAIDs, clopidogrel) should be discontinued.

ASGE Standards of Practice Committee; Fisher L et al. The role of endoscopy in the management of obscure GI bleeding. *Gastrointest Endosc.* 2010 Sep;72(3):471–9. [PMID: 20801285]
 Liao Z et al. Indications and detection, completion, and retention rates of small-bowel capsule endoscopy: a systematic review. *Gastrointest Endosc.* 2010 Feb;71(2):280–6. [PMID: 20152309]
 Liu K et al. Review article: the diagnosis and investigation of obscure gastrointestinal bleeding. *Aliment Pharmacol Ther.* 2011 Aug;34(4):416–23. [PMID: 21692820]
 Xin L et al. Indications, detectability, positive findings, total enteroscopy, and complications of diagnostic double-balloon endoscopy: a systematic review of data over the first decade of use. *Gastrointest Endosc.* 2011 Sep;74(3):563–70. [PMID: 21620401]

DISEASES OF THE PERITONEUM

ASSESSMENT OF THE PATIENT WITH ASCITES

► Etiology of Ascites

The term “ascites” denotes the pathologic accumulation of fluid in the peritoneal cavity. Healthy men have little or no intraperitoneal fluid, but women normally may have up to 20 mL depending on the phase of the menstrual cycle. The causes of ascites may be classified into two broad pathophysiologic categories: that which is associated with a normal peritoneum and that which occurs due to a diseased peritoneum (Table 15–7). The most common cause of ascites is portal hypertension secondary to chronic liver disease, which accounts for over 80% of patients with ascites. The management of portal hypertensive ascites is discussed in Chapter 16. The most common causes of nonportal hypertensive ascites include infections (tuberculous peritonitis), intra-abdominal malignancy, inflammatory disorders of the peritoneum, and ductal disruptions (chylous, pancreatic, biliary).

Table 15–7. Causes of ascites.

Normal Peritoneum	
Portal hypertension (SAAG \geq 1.1 g/dL)	
1. Hepatic congestion¹	
Congestive heart failure	
Constrictive pericarditis	
Tricuspid insufficiency	
Budd-Chiari syndrome	
Veno-occlusive disease	
2. Liver disease²	
Cirrhosis	
Alcoholic hepatitis	
Fulminant hepatic failure	
Massive hepatic metastases	
Hepatic fibrosis	
Acute fatty liver of pregnancy	
3. Portal vein occlusion	
Hypoalbuminemia (SAAG < 1.1 g/dL)	
Nephrotic syndrome	
Protein-losing enteropathy	
Severe malnutrition with anasarca	
Miscellaneous conditions (SAAG < 1.1 g/dL)	
Chylous ascites	
Pancreatic ascites	
Bile ascites	
Nephrogenic ascites	
Urine ascites	
Myxedema (SAAG \geq 1.1 g/dL)	
Ovarian disease	
Diseased Peritoneum (SAAG < 1.1 g/dL)²	
Infections	
Bacterial peritonitis	
Tuberculous peritonitis	
Fungal peritonitis	
HIV-associated peritonitis	
Malignant conditions	
Peritoneal carcinomatosis	
Primary mesothelioma	
Pseudomyxoma peritonei	
Massive hepatic metastases	
Hepatocellular carcinoma	
Other conditions	
Familial Mediterranean fever	
Vasculitis	
Granulomatous peritonitis	
Eosinophilic peritonitis	

¹Hepatic congestion usually associated with SAAG \geq 1.1 g/dL and ascitic fluid total protein > 2.5 g/dL.

²There may be cases of “mixed ascites” in which portal hypertensive ascites is complicated by a secondary process such as infection. In these cases, the SAAG is \geq 1.1 g/dL.

SAAG, serum-ascites albumin gradient.

► Clinical Findings

A. Symptoms and Signs

The history usually is one of increasing abdominal girth, with the presence of abdominal pain depending on the cause. Because most ascites is secondary to chronic liver disease with portal hypertension, patients should be asked about risk factors for liver disease, especially alcohol

consumption, transfusions, tattoos, injection drug use, a history of viral hepatitis or jaundice, and birth in an area endemic for hepatitis. A history of cancer or marked weight loss arouses suspicion of malignant ascites. Fevers may suggest infected peritoneal fluid, including bacterial peritonitis (spontaneous or secondary). Patients with chronic liver disease and ascites are at greatest risk for developing spontaneous bacterial peritonitis. In immigrants, immunocompromised hosts, or severely malnourished alcoholics, tuberculous peritonitis should be considered.

Physical examination should emphasize signs of portal hypertension and chronic liver disease. Elevated jugular venous pressure may suggest right-sided congestive heart failure or constrictive pericarditis. A large tender liver is characteristic of acute alcoholic hepatitis or Budd-Chiari syndrome. The presence of large abdominal wall veins with cephalad flow also suggests portal hypertension; inferiorly directed flow implies hepatic vein obstruction. Signs of chronic liver disease include palmar erythema, cutaneous spider angiomas, gynecomastia, and muscle wasting. Asterixis secondary to hepatic encephalopathy may be present. Anasarca results from cardiac failure or nephrotic syndrome with hypoalbuminemia. Finally, firm lymph nodes in the left supraclavicular region or umbilicus may suggest intra-abdominal malignancy.

The physical examination is relatively insensitive for detecting ascitic fluid. In general, patients must have at least 1500 mL of fluid to be detected reliably by this method. Even the experienced clinician may find it difficult to distinguish between obesity and small-volume ascites. Abdominal ultrasound establishes the presence of fluid.

B. Laboratory Testing

1. Abdominal paracentesis—Abdominal paracentesis is performed as part of the diagnostic evaluation in all patients with new onset of ascites to help determine the cause. It also is recommended for patients admitted to the hospital with cirrhosis and ascites (in whom the prevalence of bacterial peritonitis is 10–20%) and when patients with known ascites deteriorate clinically (development of fever, abdominal pain, rapid worsening of renal function, or worsened hepatic encephalopathy) to exclude bacterial peritonitis.

A. INSPECTION—Cloudy fluid suggests infection. Milky fluid is seen with chylous ascites due to high triglyceride levels. Bloody fluid is most commonly attributable to a traumatic paracentesis, but up to 20% of cases of malignant ascites are bloody.

B. ROUTINE STUDIES

(1) Cell count—A white blood cell count with differential is the most important test. Normal ascitic fluid contains < 500 leukocytes/mL and < 250 polymorphonuclear neutrophils (PMNs)/mL. Any inflammatory condition can cause an elevated ascitic white blood cell count. A PMN count of > 250/mL (neutrocytic ascites) with a percentage of > 75% of all white cells is highly suggestive of bacterial peritonitis, either spontaneous primary peritonitis or secondary peritonitis (ie, caused by an intra-abdominal

source of infection, such as a perforated viscus or appendicitis). An elevated white count with a predominance of lymphocytes arouses suspicion of tuberculosis or peritoneal carcinomatosis.

(2) Albumin and total protein—The serum-ascites albumin gradient (SAAG) is the best single test for the classification of ascites into portal hypertensive and nonportal hypertensive causes (Table 15–7). Calculated by subtracting the ascitic fluid albumin from the serum albumin, the gradient correlates directly with the portal pressure. An SAAG \geq 1.1 g/dL suggests underlying portal hypertension, while gradients < 1.1 g/dL implicate nonportal hypertensive causes.

The accuracy of the SAAG exceeds 95% in classifying ascites. It should be recognized, however, that approximately 4% of patients have “mixed ascites,” ie, underlying cirrhosis with portal hypertension complicated by a second cause for ascites formation (such as malignancy or tuberculosis). Thus, a high SAAG is indicative of portal hypertension but does not exclude concomitant malignancy.

The ascitic fluid total protein provides some additional clues to the cause. An elevated SAAG and a high protein level (> 2.5 g/dL) are seen in most cases of hepatic congestion secondary to cardiac disease or Budd-Chiari syndrome. However, an increased ascitic fluid protein is also found in up to 20% of cases of uncomplicated cirrhosis. Two-thirds of patients with malignant ascites have a total protein level > 2.5 g/dL.

(3) Culture and Gram stain—The best technique consists of the inoculation of aerobic and anaerobic blood culture bottles with 5–10 mL of ascitic fluid at the patient’s bedside, which increases the sensitivity for detecting bacterial peritonitis to over 85% in patients with neutrocytic ascites (> 250 PMNs/mL), compared with approximately 50% sensitivity by conventional agar plate or broth cultures.

C. OPTIONAL STUDIES—Other laboratory tests are of utility in some specific clinical situations. Glucose and lactate dehydrogenase (LD) may be helpful in distinguishing spontaneous from secondary bacterial peritonitis (see below). An elevated amylase may suggest pancreatic ascites or a perforation of the gastrointestinal tract with leakage of pancreatic secretions into the ascitic fluid. Perforation of the biliary tree is suspected with an ascitic bilirubin concentration that is greater than the serum bilirubin. An elevated ascitic creatinine suggests leakage of urine from the bladder or ureters. Ascitic fluid cytologic examination is ordered if peritoneal carcinomatosis is suspected. Adenosine deaminase may be useful for the diagnosis of tuberculous peritonitis.

C. Imaging

Abdominal ultrasound is useful in confirming the presence of ascites and in the guidance of paracentesis. Both ultrasound and CT imaging are useful in distinguishing between causes of portal and nonportal hypertensive ascites. Doppler ultrasound and CT can detect thrombosis of the hepatic veins (Budd-Chiari syndrome) or portal veins. In patients with nonportal hypertensive ascites, these studies are useful in detecting lymphadenopathy and masses of the

mesentery and of solid organs such as the liver, ovaries, and pancreas. Furthermore, they permit directed percutaneous needle biopsies of these lesions. Ultrasound and CT are poor procedures for the detection of peritoneal carcinoma; the role of positron emission tomography (PET) imaging is unclear.

D. Laparoscopy

Laparoscopy is an important test in the evaluation of some patients with nonportal hypertensive ascites (low SAAG) or mixed ascites. It permits direct visualization and biopsy of the peritoneum, liver, and some intra-abdominal lymph nodes. Cases of suspected peritoneal tuberculosis or suspected malignancy with nondiagnostic CT imaging and ascitic fluid cytology are best evaluated by this method.

Hou W et al. Ascites: diagnosis and management. *Med Clin North Am.* 2009 Jul;9394:801–17. [PMID: 19577115]

SPONTANEOUS BACTERIAL PERITONITIS



ESSENTIALS OF DIAGNOSIS

- ▶ A history of chronic liver disease and ascites.
- ▶ Fever and abdominal pain.
- ▶ Peritoneal signs uncommonly encountered on examination.
- ▶ Ascitic fluid neutrophil count > 250 white blood cells/mcL.

▶ General Considerations

“Spontaneous” bacterial infection of ascitic fluid occurs in the absence of an apparent intra-abdominal source of infection. It is seen with few exceptions in patients with ascites caused by chronic liver disease. Translocation of enteric bacteria across the gut wall or mesenteric lymphatics leads to seeding of the ascitic fluid, as may bacteremia from other sites. Approximately 20–30% of cirrhotic patients with ascites develop spontaneous peritonitis; however, the incidence is > 40% in patients with ascitic fluid total protein < 1 g/dL, probably due to decreased ascitic fluid opsonic activity.

Virtually all cases of spontaneous bacterial peritonitis are caused by a monomicrobial infection. The most common pathogens are enteric gram-negative bacteria (*E coli*, *Klebsiella pneumoniae*) or gram-positive bacteria (*Streptococcus pneumoniae*, viridans streptococci, *Enterococcus* species). Anaerobic bacteria are not associated with spontaneous bacterial peritonitis.

▶ Clinical Findings

A. Symptoms and Signs

Eighty to ninety percent of patients with spontaneous bacterial peritonitis are symptomatic; in many cases the

presentation is subtle. Spontaneous bacterial peritonitis may be present in 10–20% of patients hospitalized with chronic liver disease, sometimes in the absence of any suggestive symptoms or signs.

The most common symptoms are fever and abdominal pain, present in two-thirds of patients. Spontaneous bacterial peritonitis may also present with a change in mental status due to exacerbation or precipitation of hepatic encephalopathy, or sudden worsening of renal function. Physical examination typically demonstrates signs of chronic liver disease with ascites. Abdominal tenderness is present in < 50% of patients, and its presence suggests other processes.

B. Laboratory Findings

The most important diagnostic test is abdominal paracentesis. Ascitic fluid should be sent for cell count with differential, and blood culture bottles should be inoculated at the bedside; Gram stain and reagent strips are insensitive.

In the proper clinical setting, an ascitic fluid PMN count of > 250 cells/mcL (neutrocytic ascites) is presumptive evidence of bacterial peritonitis. The percentage of PMNs is > 50–70% of the ascitic fluid white blood cells and commonly approximates 100%. Patients with neutrocytic ascites are presumed to be infected and should be started—regardless of symptoms—on antibiotics. Although 10–30% of patients with neutrocytic ascites have negative ascitic bacterial cultures (“culture-negative neutrocytic ascites”), it is presumed that these patients have bacterial peritonitis and should be treated empirically. Occasionally, a positive blood culture identifies the organism when ascitic fluid is sterile.

▶ Differential Diagnosis

Spontaneous bacterial peritonitis must be distinguished from secondary bacterial peritonitis, in which ascitic fluid has become secondarily infected by an intra-abdominal infection. Even in the presence of perforation, clinical symptoms and signs of peritonitis may be lacking owing to the separation of the visceral and parietal peritoneum by the ascitic fluid. Causes of secondary bacterial peritonitis include appendicitis, diverticulitis, perforated peptic ulcer, and perforated gallbladder. Secondary bacterial infection accounts for 3% of cases of infected ascitic fluid.

Ascitic fluid total protein, LD, and glucose are useful in distinguishing spontaneous bacterial peritonitis from secondary infection. Up to two-thirds of patients with secondary bacterial peritonitis have at least two of the following: decreased glucose level (< 50 mg/dL), an elevated LD level (greater than serum), and total protein > 1 g/dL. Ascitic neutrophil counts > 10,000/mcL also are suspicious; however, most patients with secondary peritonitis have neutrophil counts within the range of spontaneous peritonitis. The presence of multiple organisms on ascitic fluid Gram stain or culture is diagnostic of secondary peritonitis.

If secondary bacterial peritonitis is suspected, abdominal CT imaging of the upper and lower gastrointestinal tracts should be obtained to look for evidence of an intra-abdominal source of infection. If these studies are negative

and secondary peritonitis still is suspected, repeat paracentesis should be performed after 48 hours of antibiotic therapy to confirm that the PMN count is decreasing. Secondary bacterial peritonitis should be suspected in patients in whom the PMN count is not below the pretreatment value at 48 hours.

Neutrocytic ascites may also be seen in some patients with peritoneal carcinomatosis, pancreatic ascites, or tuberculous ascites. In these circumstances, however, PMNs account for < 50% of the ascitic white blood cells.

► Prevention

Up to 70% of patients who survive an episode of spontaneous bacterial peritonitis will have another episode within 1 year. Oral once-daily prophylactic therapy—with norfloxacin, 400 mg, ciprofloxacin, 250–500 mg, or trimethoprim-sulfamethoxazole, one double-strength tablet—has been shown to reduce the rate of recurrent infections to < 20% and is recommended. Prophylaxis should be considered also in patients who have not had prior bacterial peritonitis but are at increased risk of infection due to low-protein ascites (total ascitic protein < 1 g/dL). Although improvement in survival in cirrhotic patients with ascites treated with prophylactic antibiotics has not been shown, decision analytic modeling suggests that in patients with prior bacterial peritonitis or low ascitic fluid protein, the use of prophylactic antibiotics is a cost-effective strategy.

► Treatment

Empiric therapy for spontaneous bacterial peritonitis should be initiated with a third-generation cephalosporin (such as cefotaxime, 2 g intravenously every 8–12 hours, or ceftriaxone, 1–2 g intravenously every 24 hours) or a combination β -lactam/ β -lactamase agent (such as ampicillin/sulbactam, 2 g/1 g intravenously every 6 hours). Because of a high risk of nephrotoxicity in patients with chronic liver disease, aminoglycosides should not be used. A repeat paracentesis is recommended after 48 hours of treatment in patients without clinical improvement. If the ascitic neutrophil count has not decreased by 25%, antibiotic coverage should be adjusted (guided by culture and sensitivity results, if available) and secondary causes of peritonitis excluded. Although the optimal duration of therapy is unknown, a course of 5–10 days is sufficient in most patients, or until the ascites fluid PMN count decreases to < 250 cells/mL.

Kidney injury develops in up to 40% of patients and is a major cause of death. Intravenous albumin increases effective arterial circulating volume and renal perfusion, decreasing the incidence of kidney injury and mortality. Intravenous albumin, 1.5 g/kg on day 1 and 1 g/kg on day 3, should be administered to patients at high risk for hepatorenal failure (ie, patients with baseline creatinine > 1 mg/dL, blood urea nitrogen (BUN) > 30 mg/dL, or bilirubin > 4 mg/dL). Patients with suspected secondary bacterial peritonitis should be given broad-spectrum coverage for enteric aerobic and anaerobic flora with a third-generation cephalosporin and metronidazole pending identification and definitive (usually surgical) treatment of the cause.

► Prognosis

The mortality rate of spontaneous bacterial peritonitis exceeds 30%. However, if the disease is recognized and treated early, the rate is < 10%. As the majority of patients have underlying severe liver disease, many may die of liver failure, hepatorenal syndrome, or bleeding complications from portal hypertension. The most effective treatment for spontaneous bacterial peritonitis is liver transplant.

Chavez-Tapia NC et al. Antibiotic prophylaxis for cirrhotic patients with upper gastrointestinal bleeding. *Cochrane Database Syst Rev.* 2010 Sep 8;(9):CD002907. [PMID: 20824832]

European Association for the Study of the Liver. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. *J Hepatol.* 2010 Sep;53(3):397–417. [PMID: 20633946]

Garcia-Tsao G et al. Management and treatment of patients with cirrhosis and portal hypertension: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program. *Am J Gastroenterol.* 2009 Jul;104(7):1802–29. [PMID: 19455106]

Tandon P et al. Renal dysfunction is the most important independent predictor of mortality in cirrhotic patients with spontaneous bacterial peritonitis. *Clin Gastroenterol Hepatol.* 2011 Mar;9(3):260–5. [PMID: 21145427]

MALIGNANT ASCITES

Two-thirds of cases of malignant ascites are caused by peritoneal carcinomatosis. The most common tumors causing carcinomatosis are primary adenocarcinomas of the ovary, uterus, pancreas, stomach, colon, lung, or breast. The remaining one-third is due to lymphatic obstruction or portal hypertension due to hepatocellular carcinoma or diffuse hepatic metastases. Patients present with nonspecific abdominal discomfort and weight loss associated with increased abdominal girth. Nausea or vomiting may be caused by partial or complete intestinal obstruction. Abdominal CT may be useful to demonstrate the primary malignancy or hepatic metastases but seldom confirms the diagnosis of peritoneal carcinomatosis. In patients with carcinomatosis, paracentesis demonstrates a low serum ascites-albumin gradient (< 1.1 mg/dL), an increased total protein (> 2.5 g/dL), and an elevated white cell count (often both neutrophils and mononuclear cells) but with a lymphocyte predominance. Cytology is positive in over 95%, but laparoscopy may be required in patients with negative cytology to confirm the diagnosis and to exclude tuberculous peritonitis, with which it may be confused. Malignant ascites attributable to portal hypertension usually is associated with an increased serum ascites-albumin gradient (> 1.1 g/dL), a variable total protein, and negative ascitic cytology. Ascites caused by peritoneal carcinomatosis does not respond to diuretics.

Patients may be treated with periodic large-volume paracentesis for symptomatic relief. Intraperitoneal chemotherapy is sometimes used to shrink the tumor, but the overall prognosis is extremely poor, with only 10% survival

at 6 months. Ovarian cancers represent an exception to this rule. With newer treatments consisting of surgical debulking and intraperitoneal chemotherapy, long-term survival from ovarian cancer is possible.

Keen A et al. Management of drainage for malignant ascites in gynaecological cancer. *Cochrane Database Syst Rev.* 2010 Jan 20;(1):CD007794. [PMID: 20091648]

FAMILIAL MEDITERRANEAN FEVER

This is a rare autosomal recessive disorder of unknown pathogenesis that almost exclusively affects people of Mediterranean ancestry, especially Sephardic Jews, Armenians, Turks, and Arabs. Patients lack a protease in serosal fluids that normally inactivates interleukin-8 and the chemotactic complement factor 5A. Symptoms present in most patients before the age of 20 years. It is characterized by episodic bouts of acute peritonitis that may be associated with serositis involving the joints and pleura. Peritoneal attacks are marked by the sudden onset of fever, severe abdominal pain, and abdominal tenderness with guarding or rebound tenderness. If left untreated, attacks resolve within 24–48 hours. Because symptoms resemble those of surgical peritonitis, patients may undergo unnecessary exploratory laparotomy. Colchicine, 0.6 mg orally two or three times daily, has been shown to decrease the frequency and severity of attacks. Secondary amyloidosis (AA protein) with renal or hepatic involvement may occur in 25% of cases and is the main cause of death. Colchicine prevents or arrests further progression of amyloidosis development. In the absence of amyloidosis, the prognosis is excellent. The diagnosis of familial Mediterranean fever still is based on clinical criteria. Although the gene responsible for familial Mediterranean fever (MEFV) has been identified, commercial genetic tests fail to identify one of the known gene mutations in up to one-third of patients. Genetic testing is most useful to confirm the diagnosis in patients with atypical symptoms.

Shohat M et al. Familial Mediterranean Fever—a review. *Genet Med.* 2011 Jun;13(6):487–98. [PMID: 21358337]

MESOTHELIOMA

Primary abdominal malignant mesothelioma is a rare tumor. Over 70% of cases have a history of asbestos exposure. Presenting symptoms and signs include abdominal pain or bowel obstruction, increased abdominal girth, and small to moderate ascites. The chest radiograph reveals pulmonary asbestosis in over 50%. The ascitic fluid is hemorrhagic, with a low serum-ascites albumin gradient. Cytology is often negative. Abdominal CT or PET-CT may reveal sheet-like masses involving the mesentery and omentum. Diagnosis is made at laparotomy or laparoscopy. The prognosis is extremely poor, but long-term survivors have been described with a combination of surgical debulking of tumor followed by heated intraoperative intraperitoneal chemotherapy and early postoperative intraperitoneal chemotherapy. Postoperative radiotherapy

or combination chemotherapy may be helpful. Multicystic and well-differentiated papillary mesotheliomas are associated with a long survival with surgical treatment alone. (See Chapter 39 for Mesothelioma.)

De Pangher M et al. Malignant peritoneal mesothelioma: a multicenter study on 81 cases. *Ann Oncol.* 2010 Feb;21(2):348–53. [PMID: 19635740]

MISCELLANEOUS PERITONEAL DISEASES

Chylous ascites is the accumulation of lipid-rich lymph in the peritoneal cavity. The ascitic fluid is characterized by a milky appearance with a triglyceride level > 1000 mg/dL. The usual cause in adults is lymphatic obstruction or leakage caused by malignancy, especially lymphoma. Nonmalignant causes include postoperative trauma, cirrhosis, tuberculosis, pancreatitis, and filariasis.

Pancreatic ascites is the intraperitoneal accumulation of massive amounts of pancreatic secretions due either to disruption of the pancreatic duct or to a pancreatic pseudocyst. It is most commonly seen in patients with chronic pancreatitis and complicates up to 3% of cases of acute pancreatitis. Because the pancreatic enzymes are not activated, pain often is absent. The ascitic fluid is characterized by a high protein level (> 2.5 g/dL) but a low SAAG. Ascitic fluid amylase levels are in excess of 1000 units/L. In nonsurgical cases, initial treatment consists of bowel rest, total parenteral nutrition (TPN), and octreotide to decrease pancreatic secretion. Persistent leakage requires treatment with either endoscopic placement of stents into the pancreatic duct or surgical drainage.

Bile ascites is caused most commonly by complications of biliary tract surgery, percutaneous liver biopsy, or abdominal trauma. Unless the bile is infected, bile ascites usually does not cause abdominal pain, fever, or leukocytosis. Paracentesis reveals yellow fluid with a ratio of ascites bilirubin to serum bilirubin > 1.0. Treatment depends on the location and rate of bile leakage. Postcholecystectomy cystic duct leaks may be treated with endoscopic sphincterotomy or biliary stent placement to facilitate bile flow across the sphincter of Oddi. Other leaks may be treated with percutaneous drainage by interventional radiologists or with surgical closure.

Baiocchi G et al. Chylous ascites in gynecologic malignancies: cases report and literature review. *Arch Gynecol Obstet.* 2010 Apr;281(4):677–81. [PMID: 19685063]

Voermans RP et al. Endoscopic treatment of pancreatic fluid collections in 2008 and beyond. *Gastrointest Endosc.* 2009 Feb;69(2 Suppl):S186–91. [PMID: 19179154]

DISEASES OF THE ESOPHAGUS

(See Chapter 39 for Esophageal Cancer.)

► Symptoms

Heartburn, dysphagia, and odynophagia almost always indicate a primary esophageal disorder.

A. Heartburn

Heartburn (pyrosis) is the feeling of substernal burning, often radiating to the neck. Caused by the reflux of acidic (or, rarely, alkaline) material into the esophagus, it is highly specific for GERD.

B. Dysphagia

Difficulties in swallowing may arise from problems in transferring the food bolus from the oropharynx to the upper esophagus (oropharyngeal dysphagia) or from impaired transport of the bolus through the body of the esophagus (esophageal dysphagia). The history usually leads to the correct diagnosis.

1. Oropharyngeal dysphagia—The oropharyngeal phase of swallowing is a complex process requiring elevation of the tongue, closure of the nasopharynx, relaxation of the upper esophageal sphincter, closure of the airway, and pharyngeal peristalsis. A variety of mechanical and neuromuscular conditions can disrupt this process (Table 15–8). Problems with the oral phase of swallowing cause drooling or spillage of food from the mouth, inability to chew or initiate swallowing, or dry mouth. Pharyngeal dysphagia is characterized by an immediate sense of the bolus catching in the neck, the need to swallow repeatedly to clear food from the pharynx, or coughing or choking during meals. There may be associated dysphonia, dysarthria, or other neurologic symptoms.

2. Esophageal dysphagia—Esophageal dysphagia may be caused by **mechanical lesions** obstructing the esophagus or by **motility disorders** (Table 15–9). Patients with

Table 15–8. Causes of oropharyngeal dysphagia.

Neurologic disorders
Brainstem cerebrovascular accident, mass lesion
Amyotrophic lateral sclerosis, multiple sclerosis, pseudobulbar palsy, post-polio syndrome, Guillain-Barré syndrome
Parkinson disease, Huntington disease, dementia
Tardive dyskinesia
Muscular and rheumatologic disorders
Myopathies, polymyositis
Oculopharyngeal dystrophy
Sjögren syndrome
Metabolic disorders
Thyrotoxicosis, amyloidosis, Cushing disease, Wilson disease
Medication side effects: anticholinergics, phenothiazines
Infectious disease
Polio, diphtheria, botulism, Lyme disease, syphilis, mucositis (<i>Candida</i> , herpes)
Structural disorders
Zenker diverticulum
Cervical osteophytes, cricopharyngeal bar, proximal esophageal webs
Oropharyngeal tumors
Postsurgical or radiation changes
Pill-induced injury
Motility disorders
Upper esophageal sphincter dysfunction

Table 15–9. Causes of esophageal dysphagia.

Cause	Clues
Mechanical obstruction	Solid foods worse than liquids
Schatzki ring	Intermittent dysphagia; not progressive
Peptic stricture	Chronic heartburn; progressive dysphagia
Esophageal cancer	Progressive dysphagia; age over 50 years
Eosinophilic esophagitis	Young adults; small-caliber lumen, proximal stricture, corrugated rings, or white papules
Motility disorder	Solid and liquid foods
Achalasia	Progressive dysphagia
Diffuse esophageal spasm	Intermittent; not progressive; may have chest pain
Scleroderma	Chronic heartburn; Raynaud phenomenon

mechanical obstruction experience dysphagia, primarily for solids. This is recurrent, predictable, and, if the lesion progresses, will worsen as the lumen narrows. Patients with **motility disorders** have dysphagia for both solids and liquids. It is episodic, unpredictable, and can be progressive.

C. Odynophagia

Odynophagia is sharp substernal pain on swallowing that may limit oral intake. It usually reflects severe erosive disease. It is most commonly associated with infectious esophagitis due to *Candida*, herpesviruses, or CMV, especially in immunocompromised patients. It may also be caused by corrosive injury due to caustic ingestions and by pill-induced ulcers.

► Diagnostic Studies

A. Upper Endoscopy

Endoscopy is the study of choice for evaluating persistent heartburn, dysphagia, odynophagia, and structural abnormalities detected on barium esophagography. In addition to direct visualization, it allows biopsy of mucosal abnormalities and of normal mucosa (to evaluate for eosinophilic esophagitis) as well as dilation of strictures.

B. Videoesophagography

Oropharyngeal dysphagia is best evaluated with rapid-sequence videoesophagography.

C. Barium Esophagography

Patients with esophageal dysphagia often are evaluated first with a radiographic barium study to differentiate between mechanical lesions and motility disorders, providing important information about the latter in particular. In

patients with esophageal dysphagia and a suspected motility disorder, barium esophagoscopy should be obtained first. In patients in whom there is a high suspicion of a mechanical lesion, many clinicians will proceed first to endoscopic evaluation because it better identifies mucosa lesions (eg, erosions) and permits mucosal biopsy and dilation. However, barium study is more sensitive for detecting subtle esophageal narrowing due to rings, achalasia, and proximal esophageal lesions.

D. Esophageal Manometry

Esophageal motility may be assessed using manometric techniques. They are indicated: (1) to determine the location of the LES to allow precise placement of a conventional electrode pH probe; (2) to establish the etiology of dysphagia in patients in whom a mechanical obstruction cannot be found, especially if a diagnosis of achalasia is suspected by endoscopy or barium study; (3) for the preoperative assessment of patients being considered for anti-reflux surgery to exclude an alternative diagnosis (eg, achalasia) or possibly to assess peristaltic function in the esophageal body. High-resolution manometry may be superior to conventional manometry for distinguishing motility disorders.

E. Esophageal pH Recording and Impedance Testing

The pH within the esophageal lumen may be monitored continuously for 24–48 hours. There are two kinds of systems in use: catheter-based and wireless. Traditional systems use a long transnasal catheter that is connected directly to the recording device. Wireless systems are increasingly used; in these systems, a capsule is attached directly to the esophageal mucosa under endoscopic visualization and data are transmitted by radiotelemetry to the recording device. The recording provides information about the amount of esophageal acid reflux and the temporal correlations between symptoms and reflux.

Esophageal pH monitoring devices provide information about the amount of esophageal acid reflux but not nonacid reflux. Techniques using combined pH and multichannel intraluminal impedance allow assessment of acid and nonacid liquid reflux. They may be useful in evaluation of patients with atypical reflux symptoms or persistent symptoms despite therapy with proton pump inhibitors to diagnose hypersensitivity, functional symptoms, and symptoms caused by nonacid reflux.

Hirano I et al. A 78-year-old man with difficulty swallowing. *Clin Gastroenterol Hepatol*. 2011 Jun;9(6):470–4. [PMID: 21320642]

Lacy BE et al. The clinical utility of esophageal manometry. *J Clin Gastroenterol*. 2009 Oct;43(9):809–15. [PMID: 19295447]

Pandolfino JE et al. Esophageal-reflux monitoring. *Gastrointest Endosc*. 2009 Apr;69(4):917–30. [PMID: 19249037]

Vela MF. Non-acid reflux: detection by multichannel intraluminal impedance and pH, clinical significance and management. *Am J Gastroenterol*. 2009 Feb;104(2):277–80. [PMID: 19190606]

GASTROESOPHAGEAL REFLUX DISEASE



ESSENTIALS OF DIAGNOSIS

- ▶ Heartburn; may be exacerbated by meals, bending, or recumbency.
- ▶ Typical uncomplicated cases do not require diagnostic studies.
- ▶ Endoscopy demonstrates abnormalities in one-third of patients.

▶ General Considerations

GERD is a condition that develops when the reflux of stomach contents causes troublesome symptoms or complications. GERD affects 20% of adults, who report at least weekly episodes of heartburn, and up to 10% complain of daily symptoms. Although most patients have mild disease, esophageal mucosal damage (reflux esophagitis) develops in up to one-third and more serious complications develop in a few others. Several factors may contribute to GERD.

A. Impaired Lower Esophageal Sphincter Function

The antireflux barrier at the gastroesophageal junction depends on LES pressure, the intra-abdominal location of the sphincter, and the extrinsic compression of the sphincter by the crural diaphragm. In most patients with GERD, baseline LES pressures are normal (10–30 mm Hg). Most reflux episodes occur during transient relaxations of the LES that are triggered by gastric distention by a vagovagal reflex. A subset of patients with GERD have an incompetent (< 10 mm Hg) LES that results in increased acid reflux, especially when supine or when intra-abdominal pressures are increased by lifting or bending. A hypotensive sphincter is present in up to 50% of patients with severe erosive GERD.

B. Hiatal Hernia

Hiatal hernias are common and usually cause no symptoms. In patients with gastroesophageal reflux, however, they are associated with higher amounts of acid reflux and delayed esophageal acid clearance leading to more severe esophagitis, especially Barrett esophagus. Increased reflux episodes occur during normal swallowing-induced relaxation, transient LES relaxations, and straining due to reflux of acid from the hiatal hernia sac into the esophagus. Hiatal hernias are found in one-fourth of patients with nonerosive GERD, three-fourths of patients with severe erosive esophagitis, and over 90% of patients with Barrett esophagus.

C. Irritant Effects of Refluxate

Esophageal mucosal damage is related to the potency of the refluxate and the amount of time it is in contact with the mucosa. Acidic gastric fluid (pH < 4.0) is extremely caustic

to the esophageal mucosa and is the major injurious agent in the majority of cases. In some patients, reflux of bile or alkaline pancreatic secretions may be contributory.

D. Abnormal Esophageal Clearance

Acid refluxate normally is cleared and neutralized by esophageal peristalsis and salivary bicarbonate. During sleep, swallowing-induced peristalsis is infrequent, prolonging acid exposure to the esophagus. One-half of patients with severe GERD also have diminished peristaltic clearance. Certain medical conditions such as scleroderma are associated with diminished peristalsis. Sjögren syndrome, anticholinergic medications, and oral radiation therapy may exacerbate GERD due to impaired salivation.

E. Delayed Gastric Emptying

Impaired gastric emptying due to gastroparesis or partial gastric outlet obstruction potentiates GERD.

► Clinical Findings

A. Symptoms and Signs

The typical symptom is heartburn. This most often occurs 30–60 minutes after meals and upon reclining. Patients often report relief from taking antacids or baking soda. When this symptom is dominant, the diagnosis is established with a high degree of reliability. Many patients, however, have less specific dyspeptic symptoms with or without heartburn. Overall, a clinical diagnosis of gastroesophageal reflux has a sensitivity of 80% but a specificity of only 70%. Severity is not correlated with the degree of tissue damage. In fact, some patients with severe esophagitis are only mildly symptomatic. Patients may complain of regurgitation—the spontaneous reflux of sour or bitter gastric contents into the mouth. Dysphagia occurs in one-third of patients and may be due to erosive esophagitis, abnormal esophageal peristalsis, or the development of an esophageal stricture.

“Atypical” or “extraesophageal” manifestations of gastroesophageal disease may occur, including asthma, chronic cough, chronic laryngitis, sore throat, and noncardiac chest pain. Gastroesophageal reflux may be either a causative or an exacerbating factor in up to 50% of these patients, especially those with refractory symptoms. In the absence of heartburn or regurgitation, atypical symptoms are unlikely to be related to gastroesophageal reflux.

Physical examination and laboratory data are normal in uncomplicated disease.

B. Special Examinations

Initial diagnostic studies are not warranted for patients with typical GERD symptoms suggesting uncomplicated reflux disease. Patients with typical symptoms of heartburn and regurgitation should be treated empirically with a once- or twice-daily proton pump inhibitor for 4–8 weeks. Further investigation is required in patients with “alarm features” (troublesome dysphagia, odynophagia, weight loss, iron deficiency anemia) and in patients with troublesome symptoms that persist despite empiric proton pump

inhibitor therapy in order to identify complications of reflux disease and to diagnose other conditions with similar symptoms.

1. Upper endoscopy—Upper endoscopy with biopsy is excellent for documenting the type and extent of tissue damage in gastroesophageal reflux; for detecting other gastroesophageal lesions that may mimic GERD; and for detecting GERD complications, including esophageal stricture, Barrett metaplasia, and esophageal adenocarcinoma. In the absence of prior antisecretory therapy, up to one-third of patients with GERD have visible mucosal damage (known as reflux esophagitis), characterized by single or multiple erosions or ulcers in the distal esophagus at the squamocolumnar junction. In patients treated with a proton pump inhibitor prior to endoscopy, preexisting reflux esophagitis may be partially or completely healed. The Los Angeles (LA) classification grades reflux esophagitis on a scale of A (one or more isolated mucosal breaks \leq 5 mm that do not extend between the tops of two mucosal folds) to D (one or more mucosal breaks that involve at least 75% of the esophageal circumference).

2. Barium esophagography—This study plays a limited role. In patients with severe dysphagia, it is sometimes obtained prior to endoscopy to identify a stricture.

3. Esophageal pH or combined esophageal pH-impedance testing—Esophageal pH monitoring is unnecessary in most patients but may be indicated to document abnormal esophageal acid exposure in patients who have atypical or extraesophageal symptoms or who are being considered for antireflux surgery. Combined impedance-pH monitoring is indicated in patients with persistent symptoms despite proton pump inhibitor therapy to determine whether symptoms are caused by acid or nonacid reflux (40%) or are unrelated to reflux and indicative of a functional disorder.

► Differential Diagnosis

Symptoms of GERD may be similar to those of other diseases such as esophageal motility disorders, peptic ulcer, angina pectoris, or functional disorders. Reflux erosive esophagitis may be confused with pill-induced damage, eosinophilic esophagitis, or infections (CMV, herpes, *Candida*).

► Complications

A. Barrett Esophagus

This is a condition in which the squamous epithelium of the esophagus is replaced by metaplastic columnar epithelium containing goblet and columnar cells (specialized intestinal metaplasia). Present in up to 10% of patients with chronic reflux, it arises from chronic reflux-induced injury to the esophageal squamous epithelium. Barrett esophagus is suspected at endoscopy from the presence of orange, gastric type epithelium that extends upward from the stomach into the distal tubular esophagus in a tongue-like or circumferential fashion. Biopsies obtained at endoscopy confirm the diagnosis. Three types of columnar

epithelium may be identified: gastric cardiac, gastric fundic, and specialized intestinal metaplasia. Only the latter is believed to carry an increased risk of neoplasia.

Barrett esophagus does not provoke specific symptoms but gastroesophageal reflux does. Most patients have a long history of reflux symptoms, such as heartburn and regurgitation. Barrett esophagus should be treated with long-term proton pump inhibitors once or twice daily to control reflux symptoms. Although these medications do not appear to cause regression of Barrett esophagus, they may reduce the risk of cancer. Paradoxically, one-third of patients report minimal or no symptoms of GERD, suggesting decreased acid sensitivity of Barrett epithelium. Indeed, over 90% of individuals with Barrett esophagus in the general population do not seek medical attention.

The most serious complication of Barrett esophagus is esophageal adenocarcinoma. It is believed that most adenocarcinomas of the esophagus and many such tumors of the gastric cardia arise from dysplastic epithelium in Barrett esophagus. The incidence of adenocarcinoma in patients with Barrett esophagus has been estimated at 0.5%/year; however, two 2011 cohort studies of all patients with Barrett esophagus in Northern Ireland and Denmark found an incidence of only 0.12–0.13%/year, approximately 1 per 800 patient-years. Although this still is an 11-fold increase risk compared with patients without Barrett esophagus, adenocarcinoma of the esophagus remains a relatively uncommon malignancy in the United States (7000 cases/year). Given the large number of adults with chronic GERD relative to the small number in whom adenocarcinoma develops, 2011 clinical guidelines recommend against endoscopic screening for Barrett esophagus in adults with GERD except in those with multiple risk factors for adenocarcinoma (chronic GERD, hiatal hernia, obesity, white race, male gender, and age 50 years of older).

In patients known to have Barrett esophagus, surveillance endoscopy every 3–5 years is recommended to look for low- or high-grade dysplasia or adenocarcinoma. Patients with low-grade dysplasia have 1.8% risk/year of esophageal cancer or high-grade dysplasia. Patients with low-grade dysplasia require repeat endoscopic surveillance in 6 months to exclude coexisting high-grade dysplasia or cancer and, if low-grade dysplasia persists, endoscopic surveillance should be repeated yearly.

Approximately 13% of patient with high-grade dysplasia may harbor an unrecognized invasive esophageal cancer. Therefore, patients with high-grade dysplasia should undergo repeat staging endoscopy with mucosal biopsy, resection of visible mucosal nodules, and ultrasonography in order to exclude invasive cancer (for which esophagectomy is recommended). The subsequent management of patients with intramucosal cancer or high-grade dysplasia has rapidly evolved. Until recently, esophagectomy was recommended for patients deemed to have a low operative risk; however, this procedure is associated with high morbidity and mortality rates (40% and 1–5%, respectively). Therefore, it is now recommended that endoscopic therapy be performed for most patients with high-grade dysplasia or intramucosal adenocarcinoma. Endoscopic therapies

can remove or ablate dysplastic Barrett epithelium, using mucosal snare resection and radiofrequency wave ablation electrocautery. Snare resection is performed of visible neoplastic mucosal nodules to exclude submucosal invasion (which may favor surgical resection). Of the patients who have cancer confined to the mucosa, < 2% have recurrence of cancer or high-grade dysplasia after snare resection. Radiofrequency wave ablation electrocautery is used to ablate Barrett epithelium with flat (non-nodular) dysplasia and to ablate Barrett epithelium that remains after snare resection of dysplastic mucosal nodules. The efficacy of endoscopic ablation therapies in patients with Barrett dysplasia is supported by several studies. When high-dose proton pump inhibitors are administered to normalize intraesophageal pH, radiofrequency wave ablation electrocautery eradication of Barrett columnar epithelium is followed by complete healing with normal squamous epithelium in > 90% of patients. In a 2011 randomized, sham-controlled trial in 127 patients with Barrett dysplasia with 3-year follow up, eradication of high-grade dysplasia occurred in 98% after radiofrequency ablation (HALO) and progression to cancer was only 0.55%/year.

Endoscopic ablation techniques have a risk of complications (bleeding, perforation, strictures). Therefore, endoscopic eradication therapy currently is not recommended for patients with nondysplastic Barrett esophagus for whom the risk of developing esophageal cancer is low and treatment does not appear to be cost-effective.

B. Peptic Stricture

Stricture formation occurs in about 5% of patients with esophagitis. It is manifested by the gradual development of solid food dysphagia progressive over months to years. Often there is a reduction in heartburn because the stricture acts as a barrier to reflux. Most strictures are located at the gastroesophageal junction. Endoscopy with biopsy is mandatory in all cases to differentiate peptic stricture from stricture by esophageal carcinoma. Active erosive esophagitis is often present. Up to 90% of symptomatic patients are effectively treated with dilation with graduated polyvinyl catheters passed over a wire placed at the time of endoscopy or fluoroscopically, or balloons passed fluoroscopically or through an endoscope. Dilation is continued over one to several sessions. A luminal diameter of 13–17 mm is usually sufficient to relieve dysphagia. Long-term therapy with a proton pump inhibitor is required to decrease the likelihood of stricture recurrence. Some patients require intermittent dilation to maintain luminal patency, but operative management for strictures that do not respond to dilation is seldom required. Refractory strictures may benefit from endoscopic injection of triamcinolone into the stricture.

► Treatment

A. Medical Treatment

The goal of treatment is to provide symptomatic relief, to heal esophagitis (if present), and to prevent complications. In the majority of patients with uncomplicated disease, empiric treatment is initiated based on a compatible history

without the need for further confirmatory studies. Patients not responding and those with suspected complications undergo further evaluation with upper endoscopy or esophageal manometry and pH recording (see above).

1. Mild, intermittent symptoms—Patients with mild or intermittent symptoms that do not impact adversely on quality of life may benefit from lifestyle modifications with medical interventions taken as needed. Patients may find that eating smaller meals and elimination of acidic foods (citrus, tomatoes, coffee, spicy foods) and foods that precipitate reflux (fatty foods, chocolate, peppermint, alcohol, cigarettes) may reduce symptoms. Weight loss should be recommended for overweight patients. Patients with nocturnal symptoms should be advised to avoid lying down within 3 hours after meals (the period of greatest reflux) and to elevate the head of the bed on 6-inch blocks or a foam wedge to reduce reflux and enhance esophageal clearance.

Antacids are the mainstay for rapid relief of occasional heartburn; however, their duration of action is < 2 hours. Many are available over the counter. Those containing magnesium should not be used in renal failure, and patients with this condition should be cautioned appropriately.

All oral H₂-receptor antagonists are available in over-the-counter formulations: cimetidine 200 mg, ranitidine and nizatidine 75 mg, famotidine 10 mg—all of which are half of the typical prescription strength. When taken for active heartburn, these agents have a delay in onset of at least 30 minutes; antacids provide more immediate relief. However, once these agents take effect, they provide heartburn relief for up to 8 hours. When taken before meals known to provoke heartburn, these agents reduce the symptom. A combination agent containing famotidine 10 mg and antacid (calcium carbonate and magnesium hydroxide) is available.

2. Troublesome symptoms

A. INITIAL THERAPY—Patients with troublesome reflux symptoms and patients with known complications of GERD should be treated with a once-daily oral proton pump inhibitor (omeprazole or rabeprazole, 20 mg; omeprazole, 40 mg with sodium bicarbonate; lansoprazole, 30 mg; dexlansoprazole, 60 mg; esomeprazole or pantoprazole, 40 mg) taken 30 minutes before breakfast for 4–8 weeks. Because there appears to be little difference between these agents in efficacy or side effect profiles, the choice of agent is determined by cost. Omeprazole, 20 mg, is available both as an over-the-counter formulation and as a generic formulation available by prescription. Once-daily proton pump inhibitors achieve adequate control of heartburn in 80–90% of patients, complete heartburn resolution in over 50%, and healing of erosive esophagitis (when present) in over 80%. Because of their superior efficacy and ease of use, proton pump inhibitors are preferred to H₂-receptor antagonists for the treatment of acute and chronic GERD. Approximately 10–20% of patients do not achieve symptom relief with a once-daily dose within 2–4 weeks and require a twice-daily proton pump inhibitor (taken 30 minutes before breakfast and dinner). Patients

with inadequate symptom relief with empiric twice-daily proton pump inhibitor therapy should undergo evaluation with upper endoscopy. Many providers prefer to prescribe initial twice-daily proton pump inhibitor therapy for patients who have documented severe erosive esophagitis (LA Grade C or D), Barrett esophagus, or peptic stricture.

B. LONG-TERM THERAPY—In those who achieve good symptomatic relief with a course of empiric once-daily proton pump inhibitor, therapy may be discontinued after 8–12 weeks. Most patients (over 80%) will experience relapse of GERD symptoms, usually within 3 months. Patients whose symptoms relapse may be treated with either continuous proton pump inhibitor therapy, intermittent 2–4 week courses, or “on demand” therapy (ie, drug taken until symptoms abate) depending on symptom frequency and patient preference. Patients who required twice-daily proton pump inhibitor therapy for initial symptom control and patients with complications of GERD, including severe erosive esophagitis, Barrett esophagus, or peptic stricture, should be maintained on long-term therapy with a once- or twice-daily proton pump inhibitor titrated to the lowest effective dose to achieve satisfactory symptom control.

Side effects of proton pump inhibitors are uncommon. Headache, diarrhea, and abdominal pain may occur with any of the agents but generally resolve when another formulation is tried. Potential risks of long-term use of proton pump inhibitors include an increased risk of infectious gastroenteritis (including *C difficile*), iron and vitamin B₁₂ deficiency, pneumonia, hip fractures (possibly due to impaired calcium absorption), and fundic gland polyps (which appear to be of no clinical significance).

3. Extraesophageal reflux manifestations—Establishing a causal relationship between gastroesophageal reflux and extraesophageal symptoms (eg, asthma, hoarseness, cough) is difficult. Gastroesophageal reflux seldom is the sole cause of extraesophageal disorders but may be a contributory factor. Although ambulatory esophageal pH testing can document the presence of increased acid esophageal reflux, it does not prove a causative connection. A 2009 randomized controlled study in patients with poorly controlled asthma without GERD symptoms found no improvement in patients treated with a high-dose proton pump inhibitor (esomeprazole, 40 mg twice daily) versus placebo. Current guidelines recommend that a trial of a twice-daily proton pump inhibitor be administered for 3 months in patients with suspected extraesophageal GERD syndromes who also have typical GERD symptoms. Improvement of extraesophageal symptoms suggests but does not prove that acid reflux is the causative factor. Esophageal pH testing may be performed in patients whose symptoms persist after 3 months of twice-daily proton pump inhibitor therapy. The pH study is performed on therapy if the suspicion for GERD is high (to determine whether therapy has adequately suppressed acid esophageal reflux) and off therapy if the suspicion for GERD is low (to determine whether the patient has reflux disease). Combined esophageal pH monitoring with impedance

monitoring is preferred over pH testing alone because of its ability to detect both acid and nonacid reflux events.

4. Unresponsive disease—Approximately 5% do not respond to twice-daily proton pump inhibitors or a change to a different proton pump inhibitor. These patients should undergo endoscopy for detection of severe, inadequately treated reflux esophagitis and for other gastroesophageal lesions (including eosinophilic esophagitis) that may mimic GERD. The presence of active erosive esophagitis usually is indicative of inadequate acid suppression and can almost always be treated successfully with higher proton pump inhibitor doses (eg, omeprazole 40 mg twice daily). Truly refractory esophagitis may be caused by gastrinoma with gastric acid hypersecretion (Zollinger-Ellison syndrome), pill-induced esophagitis, resistance to proton pump inhibitors, and medical noncompliance. Patients without endoscopically visible esophagitis should undergo ambulatory impedance-pH monitoring while taking a twice-daily proton pump inhibitor to determine whether the symptoms are correlated with acid or nonacid reflux episodes. Approximately 60% of patients with unresponsive symptoms do not have increased reflux and may be presumed to have a functional disorder. Treatment with a low-dose tricyclic antidepressant (eg, imipramine or nortriptyline 25 mg at bedtime) may be beneficial.

B. Surgical Treatment

Surgical fundoplication affords good to excellent relief of symptoms and healing of esophagitis in over 85% of properly selected patients and can be performed laparoscopically with low complication rates in most instances. Although patient satisfaction is high, typical reflux symptoms recur in 10–30% of patients. Furthermore, new symptoms of dysphagia, bloating, increased flatulence, dyspepsia, or diarrhea develop in over 30% of patients. In 2011, results from a randomized trial comparing laparoscopic fundoplication with chronic medical therapy (esomeprazole 40 mg/d) for chronic GERD were reported. After 5 years, adequate GERD symptom control (symptom remission) were similar, occurring in 85–92% of patients; however, patients who had undergone fundoplication had increased dysphagia, bloating, and flatulence. Surgical treatment is not recommended for patients who are well controlled with medical therapies but should be considered for: (1) otherwise healthy, carefully selected patients with extraesophageal manifestations of reflux, as these symptoms often require high doses of proton pump inhibitors and may be more effectively controlled with antireflux surgery; (2) those with severe reflux disease who are unwilling to accept lifelong medical therapy due to its expense, inconvenience, or theoretical risks; and (3) patients with large hiatal hernias and persistent regurgitation despite proton pump inhibitor therapy.

► When to Refer

- Patients with typical GERD whose symptoms do not resolve with empiric management with a twice-daily proton pump inhibitor.

- Patients with suspected extraesophageal GERD symptoms that do not resolve with 3 months of twice-daily proton pump inhibitor therapy.
- Patients with significant dysphagia or other alarm symptoms for upper endoscopy.
- Patients with Barrett esophagus for endoscopic surveillance.
- Patients who have Barrett esophagus with dysplasia or early mucosal cancer.
- Surgical fundoplication is considered.

American Gastroenterological Association medical position statement on the management of Barrett's esophagus. *Gastroenterology*. 2011 Mar;140(3):1084–91. [PMID: 21376940]

Bhat S et al. Risk of malignant progression in Barrett's esophagus patients: results of a large population-based study. *J Natl Cancer Inst*. 2011 Jul 6;103(13):1049–57. [PMID: 21680910]

Dellon ES et al. Persistent reflux symptoms in the proton pump inhibitor era: the changing face of gastroesophageal reflux disease. *Gastroenterology*. 2010 Jul;139(1):7–13.e3. [PMID: 20493864]

Galmiche JP et al; LOTUS Trial Collaborators. Laparoscopic anti-reflux surgery vs esomeprazole treatment for chronic GERD. *JAMA*. 2011 May 18;305(19):1969–77. [PMID: 21586712]

Hvid-Jensen F et al. Incidence of adenocarcinoma among patients with Barrett's esophagus. *N Engl J Med*. 2011 Oct 13;365(15):1375–83. [PMID: 21995385]

Johnstone J et al. Meta-analysis: proton pump inhibitor use and the risk of community-acquired pneumonia. *Aliment Pharmacol Ther*. 2010 Jun;31(11):1165–77. [PMID: 20222914]

Lacy BE et al. The diagnosis of gastroesophageal reflux disease. *Am J Med*. 2010 Jul;123(7):583–92. [PMID: 20493461]

Lundell L et al. Comparison of outcomes twelve years after anti-reflux surgery or omeprazole maintenance therapy for reflux esophagitis. *Clin Gastroenterol Hepatol*. 2009 Jul;7(12):1292–8. [PMID: 19490952]

Pritchett JM et al. Efficacy of esophageal impedance/pH monitoring in patients with refractory gastroesophageal reflux disease, on and off therapy. *Clin Gastroenterol Hepatol*. 2009 Jul;7(7):743–8. [PMID: 19281866]

Savarino E et al. Characteristics of reflux episodes and symptom association in patients with erosive esophagitis and nonerosive reflux disease: study using combined impedance-pH off therapy. *Am J Gastroenterol*. 2010 May;105(5):1053–61. [PMID: 19997095]

Shaheen NJ et al. Durability of radiofrequency ablation in Barrett's esophagus with dysplasia. *Gastroenterology*. 2011 Aug;141(2):460–8. [PMID: 21679712]

Siersema PD et al. Dilation of refractory benign esophageal strictures. *Gastrointest Endosc*. 2009 Nov;70(5):1000–12. [PMID: 19879408]

Sikkema M et al. Risk of esophageal adenocarcinoma and mortality in patients with Barrett's esophagus: a systematic review and meta-analysis. *Clin Gastroenterol Hepatol*. 2010 Mar;8(3):235–44. [PMID: 19850156]

Wani S et al. Endoscopic eradication of Barrett's esophagus. *Gastrointest Endosc*. 2010 Jan;71(1):147–66. [PMID: 19879565]

Wani S et al. Patients with nondysplastic Barrett's esophagus have low risks for developing dysplasia or esophageal adenocarcinoma. *Clin Gastroenterol Hepatol*. 2011 Mar;9(3):220–7. [PMID: 21115133]

Wani S et al. Risk factors for progression of low-grade dysplasia in patients with Barrett's esophagus. *Gastroenterology*. 2011 Oct;141(4):1179–86. [PMID: 21723218]

INFECTIOUS ESOPHAGITIS



ESSENTIALS OF DIAGNOSIS

- ▶ Immunosuppressed patient.
- ▶ Odynophagia, dysphagia, and chest pain.
- ▶ Endoscopy with biopsy establishes diagnosis.

▶ General Considerations

Infectious esophagitis occurs most commonly in immunosuppressed patients. Patients with AIDS, solid organ transplants, leukemia, lymphoma, and those receiving immunosuppressive drugs are at particular risk for opportunistic infections. *Candida albicans*, herpes simplex, and CMV are the most common pathogens. *Candida* infection may occur also in patients who have uncontrolled diabetes and those being treated with systemic corticosteroids, radiation therapy, or systemic antibiotic therapy. Herpes simplex can affect normal hosts, in which case the infection is generally self-limited.

▶ Clinical Findings

A. Symptoms and Signs

The most common symptoms are odynophagia and dysphagia. Substernal chest pain occurs in some patients. Patients with candidal esophagitis are sometimes asymptomatic. Oral thrush is present in only 75% of patients with candidal esophagitis and 25–50% of patients with viral esophagitis and is therefore an unreliable indicator of the cause of esophageal infection. Patients with esophageal CMV infection may have infection at other sites such as the colon and retina. Oral ulcers (herpes labialis) are often associated with herpes simplex esophagitis.

B. Special Examinations

Treatment may be empiric. For diagnostic certainty, endoscopy with biopsy and brushings (for microbiologic and histopathologic analysis) is preferred because of its high diagnostic accuracy. The endoscopic signs of candidal esophagitis are diffuse, linear, yellow-white plaques adherent to the mucosa. CMV esophagitis is characterized by one to several large, shallow, superficial ulcerations. Herpes esophagitis results in multiple small, deep ulcerations.

▶ Treatment

A. Candidal Esophagitis

Systemic therapy is required for esophageal candidiasis. An empiric trial of antifungal therapy is often administered without performing diagnostic endoscopy. Initial therapy is generally with fluconazole, 400 mg on day 1, then 200–400 mg/d orally for 14–21 days. Patients not responding to empiric therapy within 3–5 days should undergo endoscopy with brushings, biopsy, and culture to distinguish resistant fungal infection from other infections (eg, CMV,

herpes). Esophageal candidiasis not responding to fluconazole therapy may be treated with itraconazole suspension (not capsules), 200 mg/d orally, or voriconazole, 200 mg orally twice daily. Refractory infection may be treated intravenously with caspofungin, 50 mg daily or amphotericin B, 0.3–0.7 mg/kg/d.

B. Cytomegalovirus Esophagitis

In patients with HIV infection, immune restoration with highly active antiretroviral therapy (HAART) is the most effective means of controlling CMV disease. Initial therapy is with ganciclovir, 5 mg/kg intravenously every 12 hours for 3–6 weeks. Neutropenia is a frequent dose-limiting side effect. Once resolution of symptoms occurs, it may be possible to complete the course of therapy with oral valganciclovir, 900 mg once daily. Patients who either do not respond to or cannot tolerate ganciclovir are treated acutely with foscarnet, 90 mg/kg intravenously every 12 hours for 3–6 weeks. The principal toxicity is renal failure, hypocalcemia, and hypomagnesemia.

C. Herpetic Esophagitis

Immunocompetent patients may be treated symptomatically and generally do not require specific antiviral therapy. Immunosuppressed patients may be treated with oral acyclovir, 400 mg orally five times daily, or 250 mg/m² intravenously every 8–12 hours, usually for 14–21 days. Oral famciclovir, 500 mg orally three times daily, or valacyclovir, 1 g twice daily, are also effective but more expensive than generic acyclovir. Nonresponders require therapy with foscarnet, 40 mg/kg intravenously every 8 hours for 21 days.

▶ Prognosis

Most patients with infectious esophagitis can be effectively treated with complete symptom resolution. Depending on the patient's underlying immunodeficiency, relapse of symptoms off therapy can raise difficulties. Long-term suppressive therapy is sometimes required.

Pappas PG et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. *Clin Infect Dis*. 2009 Mar 1;48(5):503–35. [PMID: 19191635]

PILL-INDUCED ESOPHAGITIS

A number of different medications may injure the esophagus, presumably through direct, prolonged mucosal contact. The most commonly implicated are the NSAIDs, potassium chloride pills, quinidine, zalcitabine, zidovudine, alendronate and risedronate, emepronium bromide, iron, vitamin C, and antibiotics (doxycycline, tetracycline, clindamycin, trimethoprim-sulfamethoxazole). Because injury is most likely to occur if pills are swallowed without water or while supine, hospitalized or bed-bound patients are at greater risk. Symptoms include severe retrosternal chest pain, odynophagia, and dysphagia, often beginning several hours after taking a pill. These may occur suddenly and

persist for days. Some patients (especially the elderly) have relatively little pain, presenting with dysphagia. Endoscopy may reveal one to several discrete ulcers that may be shallow or deep. Chronic injury may result in severe esophagitis with stricture, hemorrhage, or perforation. Healing occurs rapidly when the offending agent is eliminated. To prevent pill-induced damage, patients should take pills with 4 oz of water and remain upright for 30 minutes after ingestion. Known offending agents should not be given to patients with esophageal dysmotility, dysphagia, or strictures.

Pace F et al. What is new in esophageal injury (infection, drug-induced, caustic, stricture, perforation)? *Curr Opin Gastroenterol.* 2009 Jul;25(4):372–9. [PMID: 19530274]

Ueda K et al. A case of esophageal ulcer caused by alendronate sodium tablets. *Gastrointest Endosc.* 2011 May;73(5):1037–8. [PMID: 21521571]

CAUSTIC ESOPHAGEAL INJURY

Caustic esophageal injury occurs from accidental (usually children) or deliberate (suicidal) ingestion of liquid or crystalline alkali (drain cleaners, etc) or acid. Ingestion is followed almost immediately by severe burning and varying degrees of chest pain, gagging, dysphagia, and drooling. Aspiration results in stridor and wheezing. Initial examination should be directed to circulatory status as well as assessment of airway patency and the oropharyngeal mucosa, including laryngoscopy. Patients without major symptoms (dyspnea, dysphagia, drooling, hematemesis) or oropharyngeal lesions have a very low likelihood of having severe gastroesophageal injury. Subsequently, chest and abdominal radiographs are obtained looking for pneumonitis or free perforation. Initial treatment is supportive, with intravenous fluids and analgesics. Nasogastric lavage and oral antidotes may be dangerous and should generally not be administered. Most patients may be managed medically. Endoscopy is usually performed within the first 12–24 hours to assess the extent of injury, especially in patients with significant symptoms or oropharyngeal lesions. Many patients are discovered to have no mucosal injury to the esophagus or stomach, allowing prompt discharge and psychiatric referral. Patients with evidence of mild damage (edema, erythema, exudates or superficial ulcers) recover quickly, have low risk of developing stricture, and may be advanced from liquids to a regular diet over 24–48 hours. Patients with signs of severe injury—deep or circumferential ulcers or necrosis (black discoloration) have a high risk (up to 65%) of acute complications, including perforation with mediastinitis or peritonitis, bleeding, stricture, or esophageal-tracheal fistulas. These patients must be kept fasting and monitored closely for signs of deterioration that warrant emergency surgery with possible esophagectomy and colonic or jejunal interposition. A nasogastric feeding tube is placed after 24 hours. Oral feedings of liquids may be initiated after 2–3 days if the patient is able to tolerate secretions. Neither corticosteroids nor antibiotics are recommended. Esophageal strictures develop in up to 70% of patients with serious esophageal injury weeks to months after the initial injury,

requiring recurrent dilations. Endoscopic injection of intralesional corticosteroids (triamcinolone 40 mg) increases the interval between dilations. The risk of esophageal squamous carcinoma is 2–3%, warranting endoscopic surveillance 15–20 years after the caustic ingestion.

Atiq M et al. Corrosive injury to the GI tract in adults: a practical approach. *Expert Rev Gastroenterol Hepatol.* 2009 Dec;3(6):701–9. [PMID: 19929589]

Elshabrawi M et al. Caustic ingestion in children. *Expert Rev Gastroenterol Hepatol.* 2011 Oct;5(5):637–45. [PMID: 21910581]

BENIGN ESOPHAGEAL LESIONS

1. Mallory-Weiss Syndrome (Mucosal Laceration of Gastroesophageal Junction)



ESSENTIALS OF DIAGNOSIS

- ▶ Hematemesis; usually self-limited.
- ▶ Prior history of vomiting, retching in 50%.
- ▶ Endoscopy establishes diagnosis.

▶ General Considerations

Mallory-Weiss syndrome is characterized by a nonpenetrating mucosal tear at the gastroesophageal junction that is hypothesized to arise from events that suddenly raise transabdominal pressure, such as lifting, retching, or vomiting. Alcoholism is a strong predisposing factor. Mallory-Weiss tears are responsible for approximately 5% of cases of upper gastrointestinal bleeding.

▶ Clinical Findings

A. Symptoms and Signs

Patients usually present with hematemesis with or without melena. A history of retching, vomiting, or straining is obtained in about 50% of cases.

B. Special Examinations

As with other causes of upper gastrointestinal hemorrhage, upper endoscopy should be performed after the patient has been appropriately resuscitated. The diagnosis is established by identification of a 0.5- to 4-cm linear mucosal tear usually located either at the gastroesophageal junction or, more commonly, just below the junction in the gastric mucosa.

▶ Differential Diagnosis

At endoscopy, other potential causes of upper gastrointestinal hemorrhage are found in over 35% of patients with Mallory-Weiss tears, including peptic ulcer disease, erosive gastritis, arteriovenous malformations, and esophageal varices. Patients with underlying portal hypertension are at higher risk of continued or recurrent bleeding.

► Treatment

Patients are initially treated as needed with fluid resuscitation and blood transfusions. Most patients stop bleeding spontaneously and require no therapy. Endoscopic hemostatic therapy is employed in patients who have continuing active bleeding. Injection with epinephrine (1:10,000), cautery with a bipolar or heater probe coagulation device, or mechanical compression of the artery by application of an endoclip or band is effective in 90–95% of cases. Angiographic arterial embolization or operative intervention is required in patients who fail endoscopic therapy.

Fujisawa N et al. Risk factors for mortality in patients with Mallory-Weiss syndrome. *Hepatogastroenterology*. 2011 Mar–Apr; 58(106):417–20. [PMID: 21661406]

2. Eosinophilic Esophagitis

► General Considerations

Eosinophilic esophagitis is an entity that previously was recognized in children but is increasingly identified in young or middle-aged adults, predominantly men (75%). A history of allergies or atopic conditions (asthma, eczema, hayfever) is present in over half of patients.

► Clinical Findings

Most adults have a long history of dysphagia for solid-foods or an episode of food impaction. Heartburn may be present. Children may have abdominal pain, vomiting, chest pain, or failure to thrive. On laboratory tests, a few have eosinophilia or elevated IgE levels. Barium swallow studies may demonstrate a small-caliber esophagus; focal or long, tapered strictures; or multiple concentric rings. However, endoscopy with esophageal biopsy and histologic evaluation is required to establish the diagnosis. Endoscopic appearances include white exudates or papules, red furrows, corrugated concentric rings, and strictures; however, the esophagus is grossly normal in one-third of patients. Multiple biopsies (at least 5) from the proximal and distal esophagus should be obtained to demonstrate multiple (> 15/high-powered field) eosinophils in the mucosa. Most children have other coexisting atopic disorders. Skin testing for food allergies may be helpful to identify causative factors, especially in children.

► Treatment

GERD may cause increased eosinophils in the distal esophageal mucosa and must be excluded. All patients should be given an empiric trial of a proton pump inhibitor (eg, omeprazole, lansoprazole, pantoprazole, esomeprazole, rabeprazole) orally twice daily for 2 months or undergo esophageal pH testing. Up to 75% of symptomatic patients with increased esophageal eosinophils improve with proton pump inhibitor treatment. Patients with persistent symptoms may undergo repeated upper endoscopy with esophageal biopsy to confirm persistent increased eosinophils.

The optimal treatment of eosinophilic esophagitis is uncertain. Referral to an allergist for evaluation of coexisting

atopic disorders and for skin prick and patch testing for food and environmental allergens is recommended. In children, food elimination or elemental diets lead to clinical and histologic improvement in 75%; however, the effectiveness of dietary therapy in adults is not established. The most common allergenic foods are dairy, eggs, wheat, soy, peanuts, and shellfish. Corticosteroids (eg, use of fluticasone 250 mcg/puff inhaler without a spacer, swallowing two puffs after inspiration, twice daily after meals or budesonide suspension 1 mg twice daily) led to symptom resolution in 70% of adults. Symptomatic relapse is common after discontinuation of therapy. Graduated dilation of strictures should be conducted cautiously because there is an increased risk of perforation and postprocedural chest pain.

Allen KJ et al. Eosinophilic esophagitis: trials and tribulations. *J Clin Gastroenterol*. 2011 Aug;45(7):574–82. [PMID: 21415771]

Liacouras CA et al. Eosinophilic esophagitis: updated consensus recommendations for children and adults. *J Allergy Clin Immunol*. 2011 Jul;128(1):3–20. [PMID: 21477849]

Molina-Infante J et al. Esophageal eosinophilic infiltration responds to proton pump inhibitors in most adults. *Clin Gastroenterol Hepatol*. 2011 Feb;9(2):110–17. [PMID: 20920599]

Schoepfer AM et al. Esophageal dilation in eosinophilic esophagitis: effectiveness, safety, and impact on underlying inflammation. *Am J Gastroenterol*. 2010 May;105(5):1062–70. [PMID: 19935783]

3. Esophageal Webs & Rings

Esophageal webs are thin, diaphragm-like membranes of squamous mucosa that typically occur in the mid or upper esophagus and may be multiple. They may be congenital but also occur with eosinophilic esophagitis, graft-versus-host disease, pemphigoid, epidermolysis bullosa, pemphigus vulgaris, and, rarely, in association with iron deficiency anemia (Plummer-Vinson syndrome). Esophageal “Schatzki” rings are smooth, circumferential, thin (< 4 mm in thickness) mucosal structures located in the distal esophagus at the squamocolumnar junction. Their pathogenesis is controversial. They are associated in nearly all cases with a hiatal hernia, and reflux symptoms are common, suggesting that acid gastroesophageal reflux may be contributory in many cases. Most webs and rings are over 20 mm in diameter and are asymptomatic. Solid food dysphagia most often occurs with rings < 13 mm in diameter. Characteristically, dysphagia is intermittent and not progressive. Large poorly chewed food boluses such as beefsteak are most likely to cause symptoms. Obstructing boluses may pass by drinking extra liquids or after regurgitation. In some cases, an impacted bolus must be extracted endoscopically. Esophageal webs and rings are best visualized using a barium esophagogram with full esophageal distention. Endoscopy is less sensitive than barium esophagography.

The majority of symptomatic patients with a single ring or web can be effectively treated with the passage of bougie dilators to disrupt the lesion or endoscopic electrocautery incision of the ring. A single dilation may suffice, but

repeat dilations are required in many patients. Patients who have heartburn or who require repeated dilation should receive long-term acid suppressive therapy with a proton pump inhibitor.

Müller M et al. Is the Schatzki ring a unique esophageal entity? *World J Gastroenterol.* 2011 Jun 21;17(23):2838–43. [PMID: 21734791]

4. Esophageal Diverticula

Diverticula may occur in the proximal, mid, or distal esophagus. These may arise secondary to motility disorders (diffuse esophageal spasm, achalasia) or may develop above esophageal strictures. Diverticula are seldom symptomatic. For patients with severe symptoms or pulmonary complications, surgical myotomy with or without diverticulectomy is the optimal treatment.

► Zenker Diverticulum

Zenker diverticulum is a protrusion of pharyngeal mucosa that develops at the pharyngoesophageal junction between the inferior pharyngeal constrictor and the cricopharyngeus. The cause is believed to be loss of elasticity of the upper esophageal sphincter, resulting in restricted opening during swallowing. Symptoms of dysphagia and regurgitation tend to develop insidiously over years in older patients. Initial symptoms include vague oropharyngeal dysphagia with coughing or throat discomfort. As the diverticulum enlarges and retains food, patients may note halitosis, spontaneous regurgitation of undigested food, nocturnal choking, gurgling in the throat, or a protrusion in the neck. Complications include aspiration pneumonia, bronchiectasis, and lung abscess. The diagnosis is best established by a barium esophagogram.

Symptomatic patients require upper esophageal myotomy and, in most cases, surgical diverticulectomy. An intraluminal approach has been developed in which the septum between the esophagus and diverticulum is incised using a rigid or flexible endoscope. Significant improvement occurs in over 90% of patients treated surgically. Small asymptomatic diverticula may be observed.

Case DJ et al. Flexible endoscopic management of Zenker diverticulum: the Mayo Clinic experience. *Mayo Clin Proc.* 2010 Aug;85(8):719–22. [PMID: 20675509]

5. Benign Esophageal Neoplasms

Benign tumors of the esophagus are quite rare. They are submucosal, the most common being leiomyoma and fibrovascular polyps. Most are asymptomatic and picked up incidentally on endoscopy or barium esophagography. Larger lesions can cause dysphagia, pain, and rarely ulceration with bleeding. The risk of malignant transformation is low. Therefore, the major clinical importance of these lesions is to distinguish them from malignant neoplasms. At endoscopy, a smooth, sessile nodule is observed with

normal overlying mucosa. Because the lesion is submucosal, endoscopic biopsies are generally nonrevealing. Endoscopic ultrasonography is extremely helpful to confirm the submucosal origin of the tumor and to help distinguish benign leiomyomas from malignant leiomyosarcomas. Surgical (or in selected cases endoscopic) resection is indicated for lesions that are symptomatic, ulcerated, or increasing in size.

Chauhan S et al. Endoscopic removal of two giant fibrovascular polyps of the esophagus using the “two channel, two devices technique”. *Gastrointest Endosc.* 2011 May;73(5):1036–7. [PMID: 21288513]

Jiang G et al. Thoracoscopic enucleation of esophageal leiomyoma: a retrospective study on 40 cases. *Dis Esophagus.* 2009; 22(3):279–83. [PMID: 19021682]

6. Esophageal Varices



ESSENTIALS OF DIAGNOSIS

- Develop secondary to portal hypertension.
- Found in 50% of patients with cirrhosis.
- One-third of patients with varices develop upper gastrointestinal bleeding.
- Diagnosis established by upper endoscopy.

► General Considerations

Esophageal varices are dilated submucosal veins that develop in patients with underlying portal hypertension and may result in serious upper gastrointestinal bleeding. The causes of portal hypertension are discussed in Chapter 16. Under normal circumstances, there is a 2–6 mm Hg pressure gradient between the portal vein and the inferior vena cava. When the gradient exceeds 10–12 mm Hg, significant portal hypertension exists. Esophageal varices are the most common cause of important gastrointestinal bleeding due to portal hypertension, though gastric varices and, rarely, intestinal varices may also bleed. Bleeding from esophageal varices most commonly occurs in the distal 5 cm of the esophagus.

The most common cause of portal hypertension is cirrhosis. Approximately 50% of patients with cirrhosis have esophageal varices. Bleeding from varices occurs in 30% of patients with esophageal varices. In the absence of any treatment, variceal bleeding spontaneously stops in about 50% of patients. Patients surviving this bleeding episode have a 60% chance of recurrent variceal bleeding, usually within the first 6 weeks. With current therapies, the in-hospital mortality rate associated with bleeding esophageal varices is 15%.

A number of factors have been identified that may portend an increased risk of bleeding from esophageal varices. The most important are: (1) the size of the varices; (2) the presence at endoscopy of red wale markings (longitudinal dilated venules on the varix surface); (3) the severity of

liver disease (as assessed by Child scoring); and (4) active alcohol abuse—patients with cirrhosis who continue to drink have an extremely high risk of bleeding.

► Clinical Findings

A. Symptoms and Signs

Patients with bleeding esophageal varices present with symptoms and signs of acute gastrointestinal hemorrhage. (See Acute Upper Gastrointestinal Bleeding, above.) In some cases, there may be preceding retching or dyspepsia attributable to alcoholic gastritis or withdrawal. Varices per se do not cause symptoms of dyspepsia, dysphagia, or retching. Variceal bleeding usually is severe, resulting in hypovolemia manifested by postural vital signs or shock. Twenty percent of patients with chronic liver disease in whom bleeding develops have a nonvariceal source of bleeding.

B. Laboratory Findings

These are identical to those listed above in the section on acute upper gastrointestinal tract bleeding.

► Initial Management

A. Acute Resuscitation

The initial management of patients with acute upper gastrointestinal bleeding is also discussed in the section on acute upper gastrointestinal bleeding (see above). Variceal hemorrhage is life-threatening; rapid assessment and resuscitation with fluids or blood products are essential. Overtransfusion should be avoided as it leads to increased central and portal venous pressures, increasing the risk of rebleeding. Many patients with bleeding esophageal varices have coagulopathy due to underlying cirrhosis; fresh frozen plasma (20 mL/kg loading dose, then 10 mg/kg every 6 hours) or platelets should be administered to patients with INRs > 1.8–2.0 or with platelet counts < 50,000/mcL in the presence of active bleeding. Recombinant factor VIIa has not demonstrated efficacy in controlled studies and is not recommended. Patients with advanced liver disease are at high risk for poor outcome regardless of the bleeding source and should be transferred to an ICU.

B. Pharmacologic Therapy

1. Antibiotic prophylaxis—Cirrhotic patients admitted with upper gastrointestinal bleeding have a > 50% chance of developing a severe bacterial infection during hospitalization—such as bacterial peritonitis, pneumonia, or urinary tract infection. Most infections are caused by gram-negative organisms of gut origin. Prophylactic administration of oral or intravenous fluoroquinolones (eg, norfloxacin, 400 mg orally twice daily) or intravenous third-generation cephalosporins (eg, ceftriaxone, 1 g/d) for 5–7 days reduces the risk of serious infection to 10–20% as well as hospital mortality. Because of a rising incidence of infections caused by gram-positive organisms as well as fluoroquinolone-resistant organisms, intravenous third-generation cephalosporins may be preferred.

2. Vasoactive drugs—Somatostatin and octreotide infusions reduce portal pressures in ways that are poorly understood. Somatostatin (250 mcg/h)—not available in the United States—or octreotide (50 mcg intravenous bolus followed by 50 mcg/h) reduces splanchnic and hepatic blood flow and portal pressures in cirrhotic patients. Both agents appear to provide acute control of variceal bleeding in up to 80% of patients although neither has been shown to reduce mortality. Data about the absolute efficacy of both are conflicting, but they may be comparable in efficacy to endoscopic therapy. Combined treatment with octreotide or somatostatin infusion and endoscopic therapy (band ligation or sclerotherapy) is superior to either modality alone in controlling acute bleeding and early rebleeding, and it may improve survival. In patients with advanced liver disease and upper gastrointestinal hemorrhage, it is reasonable to initiate therapy with octreotide or somatostatin on admission and continue for 3–5 days if varices are confirmed by endoscopy. If bleeding is determined by endoscopy not to be secondary to portal hypertension, the infusion can be discontinued.

Terlipressin, 1–2 mg intravenous every 4 hours, (not available in the United States) is a synthetic vasopressin analog that causes a significant and sustained reduction in portal and variceal pressures while preserving renal perfusion. Where available, terlipressin may be preferred to somatostatin or octreotide. Terlipressin is contraindicated in patients with significant coronary, cerebral, or peripheral vascular disease.

3. Vitamin K—In cirrhotic patients with an abnormal prothrombin time, vitamin K (10 mg) should be administered subcutaneously.

4. Lactulose—Encephalopathy may complicate an episode of gastrointestinal bleeding in patients with severe liver disease. In patients with encephalopathy, lactulose should be administered in a dosage of 30 mL orally every 1–2 hours until evacuation occurs then reduced to 15–45 mL/h every 8–12 hours as needed to promote two or three bowel movements daily. (See Chapter 16.)

C. Emergent Endoscopy

Emergent endoscopy is performed after the patient's hemodynamic status has been appropriately stabilized (usually within 2–12 hours). In patients with active bleeding, endotracheal intubation is commonly performed to protect against aspiration during endoscopy. An endoscopic examination is performed to exclude other or associated causes of upper gastrointestinal bleeding such as Mallory-Weiss tears, peptic ulcer disease, and portal hypertensive gastropathy. In many patients, variceal bleeding has stopped spontaneously by the time of endoscopy, and the diagnosis of variceal bleeding is made presumptively. Acute endoscopic treatment of the varices is performed with either banding or sclerotherapy. These techniques arrest active bleeding in 80–90% of patients and reduce the chance of in-hospital recurrent bleeding to about 20%.

If banding is chosen, repeat sessions are scheduled at intervals of 2–4 weeks until the varices are obliterated or

reduced to a small size. Banding achieves lower rates of rebleeding, complications, and death than sclerotherapy and should be considered the endoscopic treatment of choice.

Sclerotherapy is still preferred by some endoscopists in the actively bleeding patient (in whom visualization for banding may be difficult). Sclerotherapy is performed by injecting the variceal trunks with a sclerosing agent (eg, ethanolamine, tetradecyl sulfate). Complications occur in 20–30% of patients and include chest pain, fever, bacteremia, esophageal ulceration, stricture, and perforation. After initial treatment, band ligation therapy should be performed.

D. Balloon Tube Tamponade

Mechanical tamponade with specially designed nasogastric tubes containing large gastric and esophageal balloons (Minnesota or Sengstaken-Blakemore tubes) provides initial control of active variceal hemorrhage in 60–90% of patients; rebleeding occurs in 50%. The gastric balloon is inflated first, followed by the esophageal balloon if bleeding continues. After balloon inflation, tension is applied to the tube to directly tamponade the varices. Complications of prolonged balloon inflation include esophageal and oral ulcerations, perforation, aspiration, and airway obstruction (due to a misplaced balloon). Endotracheal intubation is recommended before placement. Given its high rate of complications, mechanical tamponade is used as a temporizing measure only in patients with bleeding that cannot be controlled with pharmacologic or endoscopic techniques until more definitive decompressive therapy (eg, TIPS; see below) can be provided.

E. Portal Decompressive Procedures

In the 10–20% of patients with variceal bleeding that cannot be controlled with pharmacologic or endoscopic therapy, emergency portal decompression may be considered.

1. Transvenous intrahepatic portosystemic shunts (TIPS)—Over a wire that is passed through a catheter inserted in the jugular vein, an expandable wire mesh stent (8–12 mm in diameter) is passed through the liver parenchyma, creating a portosystemic shunt from the portal vein to the hepatic vein. TIPS can control acute hemorrhage in over 90% of patients actively bleeding from gastric or esophageal varices. However, when TIPS is performed in the actively bleeding patient, the mortality approaches 40%, especially in patients requiring ventilatory support or blood pressure support and patients with renal insufficiency, bilirubin > 3 mg/dL, or encephalopathy. Therefore, TIPS should be considered in the 10–20% of patients with acute variceal bleeding that cannot be controlled with pharmacologic and endoscopic therapy, but it may not be warranted in patients with a particularly poor prognosis.

2. Emergency portosystemic shunt surgery—Emergency portosystemic shunt surgery is associated with a 40–60% mortality rate. At centers where TIPS is available, that procedure has become the preferred means of providing emergency portal decompression.

► Prevention of Rebleeding

Once the initial bleeding episode has been controlled, therapy is warranted to reduce the high risk (60%) of rebleeding.

A. Combination β -Blockers and Variceal Band Ligation

Nonselective β -adrenergic blockers (propranolol, nadolol) reduce the risk of rebleeding from esophageal varices to about 40%. Likewise, long-term treatment with band ligation reduces the incidence of rebleeding to about 30%. In most patients, two to six treatment sessions (performed at 2- to 4-week intervals) are needed to eradicate the varices.

Meta-analyses of randomized controlled trials suggest that a *combination* of band ligation plus β -blockers is superior to either variceal band ligation alone (RR 0.68) or β -blockers alone (RR 0.71). Therefore, combination therapy is recommended for patients without contraindications to β -blockers. Recommended starting doses of β -blockers are propranolol, 20 mg orally twice daily, long-acting propranolol, 60 mg orally once daily, or nadolol, 20–40 mg orally once daily, with gradual increases in the dosage every 1–2 weeks until the heart rate falls by 25% or reaches 55–60 beats/min, provided the systolic blood pressure remains above 90 mm Hg and the patient has no side effects. The average dosage of long-acting propranolol is 120 mg once daily and for nadolol, 80 mg once daily. One-third of patients with cirrhosis are intolerant of β -blockers, experiencing fatigue or hypotension. Drug administration at bedtime may reduce the frequency and severity of side effects.

B. Transvenous Intrahepatic Portosystemic Shunt

TIPS has resulted in a significant reduction in recurrent bleeding compared with endoscopic sclerotherapy or band ligation—either alone or in combination with β -blocker therapy. At 1 year, rebleeding rates in patients treated with TIPS versus various endoscopic therapies average 20% and 40%, respectively. However, TIPS was also associated with a higher incidence of encephalopathy (35% vs 15%) and did not result in a decrease in mortality. Another limitation of TIPS is that stenosis and thrombosis of the stents occur in the majority of patients over time with a consequent risk of rebleeding. Therefore, periodic monitoring with Doppler ultrasonography or hepatic venography is required. Stent patency usually can be maintained by balloon angioplasty or additional stent placement. Given these problems, TIPS should be reserved for patients who have recurrent (two or more) episodes of variceal bleeding that have failed endoscopic or pharmacologic therapies. TIPS is also useful in patients with recurrent bleeding from gastric varices or portal hypertensive gastropathy (for which endoscopic therapies cannot be used). TIPS is likewise considered in patients who are noncompliant with other therapies or who live in remote locations (without access to emergency care).

C. Surgical Portosystemic Shunts

Shunt surgery has a significantly lower rate of rebleeding compared with endoscopic therapy but also a higher incidence

of encephalopathy. With the advent and widespread adoption of TIPS, surgical shunts are seldom performed.

D. Liver Transplantation

Candidacy for orthotopic liver transplantation should be assessed in all patients with chronic liver disease and bleeding due to portal hypertension. Transplant candidates should be treated with band ligation or TIPS to control bleeding pretransplant.

► Prevention of First Episodes of Variceal Bleeding

Among patients with varices that have not previously bled, bleeding occurs in 12% of patients each year, with a lifetime risk of 30%. Because of the high mortality rate associated with variceal hemorrhage, prevention of the initial bleeding episode is desirable. Therefore, patients with cirrhosis should undergo diagnostic endoscopy or capsule endoscopy to determine whether varices are present. Varices are present in 40% of patients with Child-Turcotte-Pugh class A cirrhosis and in 85% with Child-Turcotte-Pugh class C cirrhosis. In patients without varices on screening endoscopy, a repeat endoscopy is recommended in 3 years, since varices develop in 8% of patients per year. Patients with varices have a higher risk of bleeding if they have large varices (> 5 mm), varices with red wale markings, or Child-Turcotte-Pugh class B or C cirrhosis. The risk of bleeding in patients with small varices (< 5 mm) is 5% per year and with large varices is 15–20% per year. Patients with small varices without red wale marks and compensated (Child-Turcotte-Pugh class A) cirrhosis have a low-risk of bleeding; hence, prophylaxis is unnecessary, but endoscopy should be repeated in 1–2 years to reassess size.

Nonselective β -adrenergic blockers are recommended to reduce the risk of first variceal hemorrhage in patients with medium/large varices and patients with small varices who either have variceal red wale marks or advanced cirrhosis (Child-Turcotte-Pugh class B or C). (See Combination β -Blockers and Variceal Band Ligation, above.) Band ligation is not recommended for small varices due to technical difficulties in band application. Prophylactic band ligation may be preferred for higher risk patients with medium/large varices (Child-Turcotte-Pugh class B or C or varices with red wale markings) as well as patients with contraindications to or intolerance of β -blockers. In a 2009 controlled trial, patients treated with carvedilol 12.5 mg once daily had lower rates of first variceal hemorrhage than patients treated with endoscopic band ligation. Further studies are warranted before carvedilol can be recommended for primary prophylaxis.

► When to Refer

- All patients with upper gastrointestinal bleeding and suspected varices should be evaluated by a physician skilled in therapeutic endoscopy.
- Patients being considered for TIPS procedures or liver transplantation.
- Patients with cirrhosis for endoscopic evaluation for varices.

► When to Admit

All patients with acute upper gastrointestinal bleeding and suspected cirrhosis should be admitted to an ICU.

Garcia-Tsao G et al. Management and treatment of patients with cirrhosis and portal hypertension: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program. *Am J Gastroenterol.* 2009 Jul;104(7):1802–29. [PMID: 19455106]

Garcia-Tsao G et al. Management of varices and variceal hemorrhage in cirrhosis. *N Engl J Med.* 2010 Mar 4;362(9):823–32. [PMID: 20200386]

Ravipati M et al. Pharmacotherapy plus endoscopic intervention is more effective than pharmacotherapy or endoscopy alone in the secondary prevention of esophageal variceal bleeding: a meta-analysis of randomized, controlled trials. *Gastrointest Endosc.* 2009 Oct;70(4):658–64. [PMID: 19643407]

Tripathi D et al. Randomized controlled trial of carvedilol versus variceal band ligation for the prevention of first variceal bleed. *Hepatology.* 2009 Sep;50(3):825–33. [PMID: 19610055]

ESOPHAGEAL MOTILITY DISORDERS

1. Achalasia



ESSENTIALS OF DIAGNOSIS

- Gradual, progressive dysphagia for solids and liquids.
- Regurgitation of undigested food.
- Barium esophagogram with “bird’s beak” distal esophagus.
- Esophageal manometry confirms diagnosis.

► General Considerations

Achalasia is an idiopathic motility disorder characterized by loss of peristalsis in the distal two-thirds (smooth muscle) of the esophagus and impaired relaxation of the LES. There appears to be denervation of the esophagus resulting primarily from loss of nitric oxide-producing inhibitory neurons in the myenteric plexus. The cause of the neuronal degeneration is unknown.

► Clinical Findings

A. Symptoms and Signs

There is a steady increase in the incidence of achalasia with age; however, it can be seen in individuals as young as 25 years. Patients complain of the gradual onset of dysphagia for solid foods and, in the majority, of liquids also. Symptoms at presentation may have persisted for months to years. Substernal discomfort or fullness may be noted after eating. Many patients eat more slowly and adopt specific maneuvers such as lifting the neck or throwing the shoulders back to enhance esophageal emptying.

Regurgitation of undigested food is common and may occur during meals or up to several hours later. Nocturnal regurgitation can provoke coughing or aspiration. Up to 50% of patients report substernal chest pain that is unrelated to meals or exercise and may last up to hours. Weight loss is common. Physical examination is unhelpful.

B. Imaging

Chest radiographs may show an air-fluid level in the enlarged, fluid-filled esophagus. Barium esophagography discloses characteristic findings, including esophageal dilation, loss of esophageal peristalsis, poor esophageal emptying, and a smooth, symmetric “bird’s beak” tapering of the distal esophagus. Without treatment, the esophagus may become markedly dilated (“sigmoid esophagus”).

C. Special Examinations

After esophagography, endoscopy is always performed to evaluate the distal esophagus and gastroesophageal junction to exclude a distal stricture or a submucosal infiltrating carcinoma. The diagnosis is confirmed by esophageal manometry. The typical manometric features are as follows: (1) Complete absence of peristalsis; swallowing results in simultaneous waves that are usually of low amplitude. (2) Incomplete lower esophageal sphincter relaxation with swallowing. Whereas the normal sphincter relaxes by over 90%, relaxation with most swallows in patients with achalasia is < 50%. In many patients, the baseline lower esophageal sphincter pressure is quite elevated. (3) Intraesophageal pressures are greater than gastric pressures due to a fluid- and food-filled esophagus.

► Differential Diagnosis

Chagas disease is associated with esophageal dysfunction that is indistinguishable from idiopathic achalasia and should be considered in patients from endemic regions (Central and South America); it is becoming more common in the southern United States. Primary or metastatic tumors can invade the gastroesophageal junction, resulting in a picture resembling that of achalasia, called “pseudo-achalasia.” Endoscopic ultrasonography and chest CT may be required to examine the distal esophagus in suspicious cases. Tumors such as small cell lung cancer can cause a paraneoplastic syndrome resembling achalasia due to secretion of antineuronal nuclear antibodies (ANNA-1 or Anti-Hu) that affect the myenteric plexus. Achalasia must be distinguished from other motility disorders such as diffuse esophageal spasm and scleroderma esophagus with a peptic stricture.

► Treatment

A. Botulinum Toxin Injection

Endoscopically guided injection of botulinum toxin directly into the LES results in a marked reduction in LES pressure with initial improvement in symptoms in 65–85% of patients. However, symptom relapse occurs in over 50% of patients within 6–9 months and in all patients within 2 years. Three-fourths of initial responders who relapse have

improvement with repeated injections. Because it is inferior to pneumatic dilation therapy and surgery in producing sustained symptomatic relief, this therapy is most appropriate for patients with comorbidities who are poor candidates for more invasive procedures. Botulinum injection may cause submucosal scarring that may make subsequent surgical myotomy more difficult.

B. Pneumatic Dilation

Approximately 70% of patients derive good to excellent relief of dysphagia after one to three sessions of pneumatic dilation of the LES. Approximately 30% of patients respond poorly to dilation and require surgical myotomy. Dilation is less effective in patients who are younger than age 50 or have spastic esophageal contractions (“vigorous achalasia”). Symptoms recur in up to 60% within 10 years but usually respond to repeated dilation. Perforations occur in < 4% of dilations and may require operative repair. The success of laparoscopic myotomy is not compromised by prior pneumatic dilation.

C. Surgical Myotomy

A modified Heller cardiomyotomy of the LES and cardia results in good to excellent symptomatic improvement in over 85% of patients. Because gastroesophageal reflux develops in up to 20% of patients after myotomy, most surgeons also perform an antireflux procedure (fundoplication), and all patients are prescribed a once-daily proton pump inhibitor. Myotomy is performed with a laparoscopic approach and is preferred to the open surgical approach. The low morbidity of laparoscopic surgery has led some experts to recommend it for initial treatment, especially for young patients. In 2011, results from a large randomized, multicenter trial comparing laparoscopic myotomy to pneumatic dilation were reported. After 2 years of follow-up, adequate symptom control was achieved in 86% of the dilation group and 90% of the surgery group. Thus, in experienced hands, the initial efficacies of pneumatic dilation and laparoscopic myotomy are nearly equivalent.

Boeckxstaens GE et al; European Achalasia Trial Investigators. Pneumatic dilation versus laparoscopic Heller’s myotomy for idiopathic achalasia. *N Engl J Med.* 2011 May 12;364(19):1807–12. [PMID: 21561346]
Huselmans M et al. Long-term outcome of pneumatic dilation in the treatment of achalasia. *Clin Gastroenterol Hepatol.* 2010 Jan;8(1):30–5. [PMID: 19782766]

2. Other Primary Esophageal Motility Disorders

► Clinical Findings

A. Symptoms and Signs

Abnormalities in esophageal motility may cause dysphagia or chest pain. Dysphagia for liquids as well as solids tends to be intermittent and nonprogressive. Periods of normal swallowing may alternate with periods of dysphagia, which

usually is mild though bothersome—rarely severe enough to result in significant alterations in lifestyle or weight loss. Dysphagia may be provoked by stress, large boluses of food, or hot or cold liquids. Some patients may experience anterior chest pain that may be confused with angina pectoris but usually is nonexertional. The pain generally is unrelated to eating. (See Chest Pain of Undetermined Origin, below.)

B. Diagnostic Tests

The evaluation of suspected esophageal motility disorders includes barium esophagography, upper endoscopy, and, in some cases, esophageal manometry. Barium esophagography is useful to exclude mechanical obstruction and to evaluate esophageal motility. The presence of simultaneous contractions (spasm), disordered peristalsis, or failed peristalsis supports a diagnosis of esophageal dysmotility. Upper endoscopy also is performed to exclude a mechanical obstruction (as a cause of dysphagia) and to look for evidence of erosive reflux esophagitis (a common cause of chest pain) or eosinophilic esophagitis (confirmed by esophageal biopsy). Manometry is not routinely used for mild to moderate symptoms because the findings seldom influence further medical management, but it may be useful in patients with persistent, disabling dysphagia to exclude achalasia and to look for other disorders of esophageal motility. These include spastic disorders (diffuse esophageal spasm, nutcracker esophagus, and hypertensive LES) and findings of ineffective esophageal peristalsis (failed or low-amplitude esophageal contractions). The further evaluation of noncardiac chest pain is discussed in a subsequent section.

► Treatment

For patients with mild symptoms of dysphagia, therapy is directed at symptom reduction and reassurance. Patients should be instructed to eat more slowly and take smaller bites of food. In some cases, a warm liquid at the start of a meal may facilitate swallowing. Because unrecognized gastroesophageal reflux may cause dysphagia, a trial of a proton pump inhibitor (esomeprazole 40 mg, lansoprazole 30 mg) orally twice daily should be administered for 4–8 weeks. Treatment of patients with severe dysphagia is empiric. Suspected spastic disorders may be treated with nitrates (isosorbide, 10–20 mg four times daily) or nitroglycerin (0.4 mg sublingually as needed) and calcium channel blockers (nifedipine 10 mg or diltiazem 60–90 mg, 30–45 minutes before meals) may be tried; their efficacy is unproved. Phosphodiesterase type 5 inhibitors (eg, sildenafil) promote smooth muscle relaxation and improve esophageal motility in small numbers of patients with spastic disorders but require further clinical study before they can be recommended. Injection of botulinum toxin into the lower esophagus may improve chest pain and dysphagia in some patients for a limited time. For unclear reasons, esophageal dilation provides symptomatic relief in some cases. Debilitated patients with severe dysphagia and proven esophageal spasm may be treated with a long surgical myotomy.

Almansa C et al. Esophageal spasm: demographic, clinical, radiographic, and manometric features in 108 patients. *Dis Esophagus*. 2012 Apr; 25(3):214–21 [PMID: 21951821]
 Pandolfino JE et al. Distal esophageal spasm in high-resolution pressure topography: defining clinical phenotypes. *Gastroenterology*. 2011 Aug;141(2):469–75. [PMID: 21679709]

CHEST PAIN OF UNDETERMINED ORIGIN

One-third of patients with chest pain undergo negative cardiac evaluation. Patients with recurrent noncardiac chest pain thus pose a difficult clinical problem. Because coronary artery disease is common and can present atypically, it must be excluded prior to evaluation for other causes.

Causes of noncardiac chest pain may include the following.

A. Chest Wall and Thoracic Spine Disease

These are easily diagnosed by history and physical examination.

B. Gastroesophageal Reflux

Up to 50% of patients have increased amounts of gastroesophageal acid reflux or a correlation between acid reflux episodes and chest pain demonstrated on esophageal pH testing. An empiric 4-week trial of acid-suppressive therapy with a high-dose proton pump inhibitor is recommended (eg, omeprazole or rabeprazole, 40 mg orally twice daily; lansoprazole, 30–60 mg orally twice daily; or esomeprazole or pantoprazole, 40 mg orally twice daily), especially in patients with reflux symptoms. In patients with persistent symptoms, ambulatory esophageal pH or impedance and pH study may be useful to exclude definitively a relationship between acid and nonacid reflux episodes and chest pain events.

C. Esophageal Dysmotility

Esophageal motility abnormalities such as diffuse esophageal spasm or nutcracker esophagus are uncommon causes of noncardiac chest pain. In patients with chest pain and dysphagia, a barium swallow radiograph should be obtained to look for evidence of achalasia or diffuse esophageal spasm. Esophageal manometry is not routinely performed because of low specificity and the unlikelihood of finding a clinically significant disorder, but it may be recommended in patients with frequent symptoms.

D. Heightened Visceral Sensitivity

Some patients with noncardiac chest pain report pain in response to a variety of minor noxious stimuli such as physiologically normal amounts of acid reflux, inflation of balloons within the esophageal lumen, injection of intravenous edrophonium (a cholinergic stimulus), or intracardiac catheter manipulation. Low doses of oral antidepressants such as trazodone 50 mg or imipramine 10–50 mg reduce chest pain symptoms and are thought to

reduce visceral afferent awareness. In a 2010 controlled crossover trial, over 50% of patients treated with venlafaxine, 75 mg once daily at bedtime, achieved symptomatic improvement compared with only 4% treated with placebo.

E. Psychological Disorders

A significant number of patients have underlying depression, anxiety, and panic disorder. Patients reporting dyspnea, sweating, tachycardia, suffocation, or fear of dying should be evaluated for panic disorder.

Arora AS et al. How do I handle the patient with noncardiac chest pain? *Clin Gastroenterol Hepatol.* 2011 Apr;9(4):295–304. [PMID: 21056690]

Kushnir VM et al. Abnormal GERD parameters on ambulatory pH monitoring predict therapeutic success in noncardiac chest pain. *Am J Gastroenterol.* 2010 May;105(5):1032–8. [PMID: 19920808]

Lee H et al. Effects of venlafaxine for symptomatic relief in young adult patients with functional chest pain: a randomized, double-blind, placebo-controlled, crossover trial. *Am J Gastroenterol.* 2010 Jul;105(7):1504–12. [PMID: 20332772]

DISEASES OF THE STOMACH & DUODENUM

(See Chapter 39 for Gastric Cancers.)

GASTRITIS & GASTROPATHY

The term “gastropathy” should be used to denote conditions in which there is epithelial or endothelial damage without inflammation, and “gastritis” should be used to denote conditions in which there is histologic evidence of inflammation. In clinical practice, the term “gastritis” is commonly applied to three categories: (1) erosive and hemorrhagic “gastritis” (gastropathy); (2) nonerosive, non-specific (histologic) gastritis; and (3) specific types of gastritis, characterized by distinctive histologic and endoscopic features diagnostic of specific disorders.

1. Erosive & Hemorrhagic “Gastritis” (Gastropathy)

ESSENTIALS OF DIAGNOSIS

- ▶ Most commonly seen in alcoholic or critically ill patients, or patients taking NSAIDs.
- ▶ Often asymptomatic; may cause epigastric pain, nausea, and vomiting.
- ▶ May cause hematemesis; usually not significant bleeding.

▶ General Considerations

The most common causes of erosive gastropathy are medications (especially NSAIDs), alcohol, stress due to severe

medical or surgical illness, and portal hypertension (“portal gastropathy”). Major risk factors for stress gastritis include mechanical ventilation, coagulopathy, trauma, burns, shock, sepsis, central nervous system injury, liver failure, kidney disease, and multiorgan failure. The use of enteral nutrition reduces the risk of stress-related bleeding. Uncommon causes of erosive gastropathy include caustic ingestion and radiation. Erosive and hemorrhagic gastropathy typically are diagnosed at endoscopy, often being performed because of dyspepsia or upper gastrointestinal bleeding. Endoscopic findings include subepithelial hemorrhages, petechiae, and erosions. These lesions are superficial, vary in size and number, and may be focal or diffuse. There usually is no significant inflammation on histologic examination.

▶ Clinical Findings

A. Symptoms and Signs

Erosive gastropathy is usually asymptomatic. Symptoms, when they occur, include anorexia, epigastric pain, nausea, and vomiting. There is poor correlation between symptoms and the number or severity of endoscopic abnormalities. The most common clinical manifestation of erosive gastritis is upper gastrointestinal bleeding, which presents as hematemesis, “coffee grounds” emesis, or bloody aspirate in a patient receiving nasogastric suction, or as melena. Because erosive gastritis is superficial, hemodynamically significant bleeding is rare.

B. Laboratory Findings

The laboratory findings are nonspecific. The hematocrit is low if significant bleeding has occurred; iron deficiency may be found.

C. Special Examinations

Upper endoscopy is the most sensitive method of diagnosis. Although bleeding from gastritis is usually insignificant, it cannot be distinguished on clinical grounds from more serious lesions such as peptic ulcers or esophageal varices. Hence, endoscopy is generally performed within 24 hours in patients with upper gastrointestinal bleeding to identify the source. An upper gastrointestinal series is sometimes obtained in lieu of endoscopy in patients with hemodynamically insignificant upper gastrointestinal bleeds to exclude serious lesions but is insensitive for the detection of gastritis.

▶ Differential Diagnosis

Epigastric pain may be due to peptic ulcer, gastroesophageal reflux, gastric cancer, biliary tract disease, food poisoning, viral gastroenteritis, and functional dyspepsia. With severe pain, one should consider a perforated or penetrating ulcer, pancreatic disease, esophageal rupture, ruptured aortic aneurysm, gastric volvulus, and myocardial colic. Causes of upper gastrointestinal bleeding include peptic ulcer disease, esophageal varices, Mallory-Weiss tear, and angiodysplasias.

► Specific Causes & Treatment

A. Stress Gastritis

1. Prophylaxis—Stress-related mucosal erosions and subepithelial hemorrhages develop within 72 hours in the majority of critically ill patients. Clinically overt bleeding occurs in 6%, but clinically important bleeding in < 1.5%. Bleeding is associated with a higher mortality rate but is seldom the cause of death.

In critically ill patients, pharmacologic prophylaxis with intravenous H₂-receptor antagonists, oral sucralfate, and an oral, rapid-release suspension of omeprazole plus sodium bicarbonate (Zegerid) has been shown to reduce the incidence of clinically overt and significant bleeding by 50%. At this time, the optimal, cost-effective regimen for the reduction of stress-related mucosal bleeding is uncertain. Prophylaxis should be routinely administered upon admission to critically ill patients with risk factors for significant bleeding. Two of the most important risk factors are coagulopathy (platelets < 50,000/mcL or INR > 1.5) and respiratory failure with the need for mechanical ventilation for over 48 hours. When these two risk factors are absent, the risk of significant bleeding is only 0.1%. Other risk factors include sepsis, vasopressor therapy, corticosteroid therapy, burns, traumatic brain injury, and prior history of peptic ulcer disease and gastrointestinal bleeding. Early enteral tube feeding may decrease the risk of significant bleeding.

Continuous intravenous infusions of H₂-receptor antagonists provide adequate control of intragastric pH in most patients in the following doses over 24 hours: cimetidine (900–1200 mg), ranitidine (150 mg), or famotidine (20 mg). Although intravenous proton pump inhibitors also are widely used for prophylaxis, their efficacy and optimal dosing have not been established in controlled trials. For patients with nasogastric tubes, immediate-release omeprazole (40 mg at 1 and 6 hours on day 1; then 40 mg once daily beginning on day 2) may be preferred to intravenous H₂-receptor antagonists because of lower cost, ease of administration, and comparable efficacy.

Sucralfate suspension (1 g orally every 4–6 hours) is effective for the prevention of stress-related bleeding. However, there is a higher incidence of clinically important upper gastrointestinal bleeding with sucralfate (4%) versus H₂-receptor antagonists (2%) with no difference in nosocomial pneumonia in more recent studies. In most ICUs, intravenous H₂-receptor antagonists or proton pump inhibitors are preferred because of their ease of administration.

2. Treatment—Once bleeding occurs, patients should receive continuous infusions of a proton pump inhibitor (esomeprazole or pantoprazole, 80 mg intravenous bolus, followed by 8 mg/h continuous infusion) as well as sucralfate suspension, 1 g orally every 4 to 6 hours. Endoscopy should be performed in patients with clinically significant bleeding to look for treatable causes, especially stress-related peptic ulcers with active bleeding or visible vessels. When bleeding arises from diffuse gastritis, endoscopic hemostasis techniques are not helpful.

B. NSAID Gastritis

Of patients receiving NSAIDs in clinical trials, 25–50% have gastritis and 10–20% have ulcers at endoscopy; however, symptoms of significant dyspepsia develop in about 5%. NSAIDs that are more selective for the cyclooxygenase (COX)-2 enzyme (“coxibs”), such as celecoxib, etodolac, and meloxicam, decrease the incidence of endoscopically visible ulcers by approximately 75% and significant ulcer complications by up to 50% compared with nonselective NSAIDs (nsNSAIDs) (see below). However, a twofold increase in the incidence in cardiovascular complications (myocardial infarction, cerebrovascular infarction, and death) in patients taking coxibs compared with placebo has led to the withdrawal of two highly selective coxibs (rofecoxib and valdecoxib) from the market by the manufacturers. Celecoxib and all currently available nsNSAIDs (with notable exception of aspirin and possibly naproxen) are associated with increased risk of cardiovascular complications and therefore should be used with caution in patients with cardiovascular risk factors.

In population surveys, the rate of dyspepsia is increased 1.5- to 2-fold with nsNSAID and coxib use. However, dyspeptic symptoms correlate poorly with significant mucosal abnormalities or the development of adverse clinical events (ulcer bleeding or perforation). Given the frequency of dyspeptic symptoms in patients taking NSAIDs, it is neither feasible nor desirable to investigate all such cases. Patients with alarm symptoms or signs, such as severe pain, weight loss, vomiting, gastrointestinal bleeding, or anemia, should undergo diagnostic upper endoscopy. For other patients, symptoms may improve with discontinuation of the agent, reduction to the lowest effective dose, or administration with meals. Proton pump inhibitors have demonstrated efficacy in controlled trials for the treatment of NSAID-related dyspepsia and superiority to H₂-receptor antagonists for healing of NSAID-related ulcers even in the setting of continued NSAID use. Therefore, an empiric 2–4 week trial of an oral proton pump inhibitor (omeprazole, rabeprazole, or esomeprazole 20–40 mg/d; lansoprazole or dexlansoprazole, 30 mg/d; pantoprazole, 40 mg/d) is recommended for patients with NSAID-related dyspepsia, especially those in whom continued NSAID treatment is required. If symptoms do not improve, diagnostic upper endoscopy should be conducted.

C. Alcoholic Gastritis

Excessive alcohol consumption may lead to dyspepsia, nausea, emesis, and minor hematemesis—a condition sometimes labeled “alcoholic gastritis.” However, it is not proven that alcohol alone actually causes significant erosive gastritis. Therapy with H₂-receptor antagonists, proton pump inhibitors, or sucralfate for 2–4 weeks often is empirically prescribed.

D. Portal Hypertensive Gastropathy

Portal hypertension commonly results in gastric mucosal and submucosal congestion of capillaries and venules, which is correlated with the severity of the portal hypertension and

underlying liver disease. Usually asymptomatic, it may cause chronic gastrointestinal bleeding in 10% of patients and, less commonly, clinically significant bleeding with hematemesis. Treatment with propranolol or nadolol reduces the incidence of recurrent acute bleeding by lowering portal pressures. Patients who fail propranolol therapy may be successfully treated with portal decompressive procedures (see section above on treatment of esophageal varices).

Lanza FL et al; Practice Parameters Committee of the American College of Gastroenterology. Guidelines for prevention of NSAID-related ulcer complications. *Am J Gastroenterol*. 2009 Mar;104(3):728–38. [PMID: 19240698]

Lin PC et al. The efficacy and safety of proton pump inhibitors vs histamine-2 receptor antagonists for stress ulcer bleeding prophylaxis among critical care patients: a meta-analysis. *Crit Care Med*. 2010 Apr;38(4):1197–205. [PMID: 20173630]

Ripoll C et al. The management of portal hypertensive gastropathy and gastric antral vascular ectasia. *Dig Liver Dis*. 2011 May;43(5):345–51. [PMID: 21095166]

2. Nonerosive, Nonspecific Gastritis

The diagnosis of nonerosive gastritis is based on histologic assessment of mucosal biopsies. Endoscopic findings are normal in many cases and do not reliably predict the presence of histologic inflammation. The main types of nonerosive gastritis are those due to *H pylori* infection, those associated with pernicious anemia, and eosinophilic gastritis. (See Specific Types of Gastritis below.)

► *Helicobacter pylori* Gastritis

H pylori is a spiral gram-negative rod that resides beneath the gastric mucous layer adjacent to gastric epithelial cells. Although not invasive, it causes gastric mucosal inflammation with PMNs and lymphocytes. The mechanisms of injury and inflammation may in part be related to the products of two genes, *vacA* and *cagA*.

In developed countries the prevalence of *H pylori* is rapidly declining. In the United States, the prevalence rises from < 10% in non-immigrants under age 30 years to over 50% in those over age 60 years. The prevalence is higher in non-whites and immigrants from developing countries and is correlated inversely with socioeconomic status. Transmission is from person to person, mainly during infancy and childhood; however, the mode of transmission is unknown.

Acute infection with *H pylori* may cause a transient clinical illness characterized by nausea and abdominal pain that may last for several days and is associated with acute histologic gastritis with PMNs. After these symptoms resolve, the majority progress to chronic infection with chronic, diffuse mucosal inflammation (gastritis) characterized by PMNs and lymphocytes. Although chronic *H pylori* infection with gastritis is present in 30–50% of the population, most persons are asymptomatic and suffer no sequelae. Three gastritis phenotypes occur which determine clinical outcomes. Most infected people have a mild, diffuse gastritis that does not disrupt acid secretion and seldom causes clinically important outcomes. About 15% of infected people have inflammation that predominates in

the gastric antrum but spares the gastric body (where acid is secreted). People with this phenotype tend to have increased gastrin; increased acid production; and increased risk of developing peptic ulcers, especially duodenal ulcers. An even smaller subset of infected adults have inflammation that predominates in the gastric body. Over time, this may lead to destruction of acid-secreting glands with resultant mucosal atrophy, decreased acid secretion, and intestinal metaplasia. This phenotype is associated with an increased risk of gastric ulcers and gastric cancer. Chronic *H pylori* gastritis leads to the development of duodenal or gastric ulcers up to 10%, gastric cancer in 0.1–3%, and low-grade B cell gastric lymphoma (mucosa-associated lymphoid tissue lymphoma; MALToma) in < 0.01%.

Eradication of *H pylori* may be achieved with antibiotics in over 85% of patients and leads to resolution of the chronic gastritis (see section on Peptic Ulcer Disease). Testing for *H pylori* is indicated for patients with either active or a past history of documented peptic ulcer disease or gastric MALToma and for patients with a family history of gastric carcinoma. Testing and empiric treatment is cost-effective in young patients (< 55 years of age) with uncomplicated dyspepsia prior to further medical evaluation. The role of testing and treating *H pylori* in patients with functional dyspepsia remains controversial but is generally recommended (see Dyspepsia, above). *H pylori* eradication decreases the risk of gastric cancer in patients with peptic ulcer disease. Some groups recommend population-based screening of all asymptomatic persons in regions in which there is a high prevalence of *H pylori* and gastric cancer (such as Japan, Korea, and China) to reduce the incidence of gastric cancer. Population-based screening of asymptomatic individuals is not recommended in western countries, in which the incidence of gastric cancer is low, but should be considered in immigrants from high-prevalence regions.

1. Noninvasive Testing for *H pylori*—Although serologic tests are easily obtained and widely available, most clinical guidelines no longer endorse their use for testing for *H pylori* infection because they are less accurate than other noninvasive tests that measure active infection. Laboratory-based quantitative serologic ELISA tests have an overall accuracy of only 80%. In comparison, the fecal antigen immunoassay and [¹³C] urea breath test have excellent sensitivity and specificity (> 95%) at a cost of < \$60. Although more expensive and cumbersome to perform, these tests of active infection are more cost-effective in most clinical settings because they reduce unnecessary treatment for patients without active infection.

Recent proton pump inhibitors or antibiotics significantly reduce the sensitivity of urea breath tests and fecal antigen assays (but not serologic tests). Prior to testing, proton pump inhibitors should be discontinued 7–14 days and antibiotics for at least 28 days.

2. Endoscopic Testing for *H pylori*—Endoscopy is not indicated to diagnose *H pylori* infection in most circumstances. However, when it is performed for another reason, gastric biopsy specimens can be obtained for detection of *H pylori* and tested for active infection by urease production.

This simple, inexpensive (\$10) test has excellent sensitivity (90%) and specificity (95%). In patients with active upper gastrointestinal bleeding or patients recently taking proton pump inhibitors or antibiotics, histologic assessment for *H pylori* is preferred. Histologic assessment of biopsies from the gastric antrum and body is more definitive but more expensive (\$150–\$250) than a rapid urease test. Histologic assessment is also indicated in patients with suspected MALTomas and, possibly, in patients with suspected infection whose rapid urease test is negative. However, serologic testing is the most cost-effective means of confirming *H pylori* infection in patients with a negative rapid urease test.

Cover TL et al. *Helicobacter pylori* in health and disease. *Gastroenterology*. 2009 May;136(6):1863–73. [PMID: 19457415]

McCull KE. Clinical practice. *Helicobacter pylori* infection. *N Engl J Med*. 2010 Apr 29;362(17):1597–1604. [PMID: 20427808]

Wu CY et al. Early *Helicobacter pylori* eradication decreases risk of gastric cancer in patients with peptic ulcer disease. *Gastroenterology*. 2009 Nov;137(5):1641–8. [PMID: 19664631]

► Pernicious Anemia Gastritis

Pernicious anemia gastritis is an autoimmune disorder involving the fundic glands with resultant achlorhydria, decreased intrinsic factor secretion, and vitamin B₁₂ malabsorption. Of patients with B₁₂ deficiency, less than half have pernicious anemia. Most patients have malabsorption secondary to aging or chronic *H pylori* infection that results in atrophic gastritis, hypochlorhydria, and impaired release of B₁₂ from food. Fundic histology in pernicious anemia is characterized by severe gland atrophy and intestinal metaplasia caused by autoimmune destruction of the gastric fundic mucosa. Anti-intrinsic factor antibodies are present in 70% of patients. Achlorhydria leads to pronounced hypergastrinemia (> 1000 pg/mL) due to loss of acid inhibition of gastrin G cells. Hypergastrinemia may induce hyperplasia of gastric enterochromaffin-like cells that may lead to the development of small, multicentric carcinoid tumors in 5% of patients. Metastatic spread is uncommon in lesions smaller than 2 cm. The risk of gastric adenocarcinoma is increased threefold, with a prevalence of 1–3%. Endoscopy with biopsy is indicated in patients with pernicious anemia at the time of diagnosis. Patients with dysplasia or small carcinoids require periodic endoscopic surveillance. Pernicious anemia is discussed in detail in Chapter 13.

Lahner E et al. Pernicious anemia: new insights from a gastroenterological point of view. *World J Gastroenterol*. 2009 Nov; 15(41):5121–8. [PMID: 19891010]

3. Specific Types of Gastritis

A number of disorders are associated with specific mucosal histologic features.

Infections

Acute bacterial infection of the gastric submucosa and muscularis with a variety of aerobic or anaerobic organisms produces a rare, rapidly progressive, life-threatening condition known as phlegmonous or necrotizing gastritis, which requires broad-spectrum antibiotic therapy and, in many cases, emergency gastric resection. Viral infection with CMV is commonly seen in patients with AIDS and after bone marrow or solid organ transplantation. Endoscopic findings include thickened gastric folds and ulcerations. Fungal infection with mucormycosis and *Candida* may occur in immunocompromised and diabetic patients. Larvae of *Anisakis marina* ingested in raw fish or sushi may become embedded in the gastric mucosa, producing severe abdominal pain. Pain persists for several days until the larvae die. Endoscopic removal of the larvae provides rapid symptomatic relief.

Okano K et al. Acute abdomen with epigastric pain and vomiting in an adult healthy patient. *Gastroenterology*. 2010 Nov;139(5): 1465. [PMID: 20875783]

Eosinophilic Gastritis

This is a rare disorder in which eosinophils infiltrate the antrum and sometimes the proximal intestine. Infiltration may involve the mucosa, muscularis, or serosa. Peripheral eosinophilia is prominent. Symptoms include anemia from mucosal blood loss, abdominal pain, early satiety, and postprandial vomiting. Treatment with corticosteroids is beneficial in the majority of patients.

Chang JY et al. A shift in the clinical spectrum of eosinophilic gastroenteritis toward the mucosal disease type. *Clin Gastroenterol Hepatol*. 2010 Aug;8(8):669–75. [PMID: 20451664]

Ménétrier Disease (Hypertrophic Gastropathy)

This is an idiopathic entity characterized by giant thickened gastric folds involving predominantly the body of the stomach. Patients complain of nausea, epigastric pain, weight loss, and diarrhea. Because of chronic protein loss, patients may develop severe hypoproteinemia and anasarca. The cause is unknown. There are case reports of resolution of symptoms and improvement in histologic appearance after *H pylori* eradication. Dramatic improvement has been reported in a small number of patients with cetuximab, an antibody that binds epidermal growth factor receptor (EGFR). Gastric resection is required in severe cases.

Rich A et al. Distinguishing Ménétrier's disease from its mimics. *Gut*. 2010 Dec;59(12):1617–24. [PMID: 20926644]

PEPTIC ULCER DISEASE



ESSENTIALS OF DIAGNOSIS

- ▶ History of dyspepsia present in 80–90% of patients with variable relationship to meals.
- ▶ Ulcer symptoms characterized by rhythmicity and periodicity.
- ▶ Ten to 20 percent of patients present with ulcer complications without antecedent symptoms.
- ▶ Most NSAID-induced ulcers are asymptomatic.
- ▶ Upper endoscopy with gastric biopsy for *H pylori* is the diagnostic procedure of choice in most patients.
- ▶ Gastric ulcer biopsy or documentation of complete healing necessary to exclude gastric malignancy.

▶ General Considerations

Peptic ulcer is a break in the gastric or duodenal mucosa that arises when the normal mucosal defensive factors are impaired or are overwhelmed by aggressive luminal factors such as acid and pepsin. By definition, ulcers extend through the muscularis mucosae and are usually over 5 mm in diameter. In the United States, there are about 500,000 new cases per year of peptic ulcer and 4 million ulcer recurrences; the lifetime prevalence of ulcers in the adult population is approximately 10%. Ulcers occur five times more commonly in the duodenum, where over 95% are in the bulb or pyloric channel. In the stomach, benign ulcers are located most commonly in the antrum (60%) and at the junction of the antrum and body on the lesser curvature (25%).

Ulcers occur slightly more commonly in men than in women (1.3:1). Although ulcers can occur in any age group, duodenal ulcers most commonly occur in patients between the ages of 30 and 55 years, whereas gastric ulcers are more common in patients between the ages of 55 and 70 years. Ulcers are more common in smokers and in patients taking NSAIDs on a long-term basis (see below). Alcohol, dietary factors, and stress do not appear to cause ulcer disease. The incidence of duodenal ulcer disease has been declining dramatically for the past 30 years, but the incidence of gastric ulcers appears to be increasing as a result of the widespread use of NSAIDs and low-dose aspirin.

▶ Etiology

There are two major causes of peptic ulcer disease: NSAIDs and chronic *H pylori* infection. Evidence of *H pylori* infection or NSAID ingestion should be sought in all patients with peptic ulcer. Less than 5–10% of ulcers are caused by other conditions, including acid hypersecretory states (such as Zollinger-Ellison syndrome or systemic mastocytosis), CMV (especially in transplant recipients), Crohn disease, lymphoma, medications (eg, alendronate), chronic medical illness (cirrhosis or chronic kidney disease), or are

idiopathic. NSAID and *H pylori*-associated ulcers will be presented in this section; Zollinger-Ellison syndrome will be discussed subsequently.

A. *H pylori*-Associated Ulcers

H pylori infection appears to be a necessary cofactor for the majority of duodenal and gastric ulcers not associated with NSAIDs. Ulcer disease will develop in an estimated 10% of infected patients. The prevalence of *H pylori* infection in duodenal ulcer patients is 75–90%. Most *H pylori*-infected duodenal ulcer patients have infection predominantly in the gastric antrum, which is associated with increased gastric acid secretion. It is hypothesized that increased acid exposure can give rise to small islands of gastric metaplasia in the duodenal bulb. Colonization of these islands by *H pylori* may lead to duodenitis or duodenal ulcer. The association with gastric ulcers is lower, but *H pylori* is found in most patients in whom NSAIDs cannot be implicated. *H pylori*-associated gastric ulcers tend to form at the junction of the gastric body and antrum—the site of transition from oxyntic to pyloric epithelium. Most *H pylori*-infected gastric ulcer patients have infection that predominates in the gastric body and is associated with decreased acid secretion. It is hypothesized that chronic inflammation overwhelms the gastric mucosal defense mechanisms.

The natural history of *H pylori*-associated peptic ulcer disease is well defined. In the absence of specific antibiotic treatment to eradicate the organism, 85% of patients will have an endoscopically visible recurrence within 1 year. Half of these will be symptomatic. After successful eradication of *H pylori* with antibiotics, ulcer recurrence rates are reduced dramatically to 5–20% at 1 year. Most of these ulcer recurrences are due to NSAID use or, rarely, reinfection with *H pylori*.

B. NSAID-Induced Ulcers

There is a 10–20% prevalence of gastric ulcers and a 2–5% prevalence of duodenal ulcers in long-term NSAID users. Approximately 2–5%/year of long-term NSAID users will have an ulcer that causes clinically significant dyspepsia or a serious complication. The incidence of serious gastrointestinal complications (hospitalization, bleeding, perforation) is 0.2–1.9%/year. The risk of NSAID complications is greater within the first 3 months of therapy and in patients who are older than 60 years; who have a prior history of ulcer disease; or who take NSAIDs in combination with aspirin, corticosteroids, or anticoagulants.

Traditional nsNSAIDs inhibit prostaglandins through reversible inhibition of both COX-1 and COX-2 enzymes. Aspirin causes irreversible inhibition of COX-1 and COX-2 as well as of platelet aggregation. Coxibs (or selective NSAIDs) preferentially inhibit COX-2—the principal enzyme involved in prostaglandin production at sites of inflammation—while providing relative sparing of COX-1, the principal enzyme involved with mucosal cytoprotection in the stomach and duodenum. Celecoxib is the only coxib currently available in the United States, although other older NSAIDs (etodolac, meloxicam) may have similar COX-2/COX-1 selectivity.

Coxibs decrease the incidence of endoscopically visible ulcers by approximately 75% compared with nsNSAIDs. Of greater clinical importance, the risk of significant clinical events (obstruction, perforation, bleeding) is reduced by up to 50% in patients taking coxibs versus nsNSAIDs. However, a twofold increase in the incidence in cardiovascular complications (myocardial infarction, cerebrovascular infarction, and death) has been detected in patients taking coxibs compared with placebo, prompting the voluntary withdrawal of two coxibs (rofecoxib and valdecoxib) from the market by the manufacturers. It is hypothesized that selective inhibition of COX-2 leads to decreased vascular prostacyclin, reduced arterial vasodilation, hypertension, enhanced atherogenesis, and enhanced platelet adhesion. In two large, prospective, randomized controlled trials testing the efficacy of coxibs on polyp prevention, celecoxib was associated with a 1.3- to 3.4-fold increased risk of cardiovascular complications versus placebo; the risk was greatest in patients taking higher doses of celecoxib. A review by an FDA panel suggested that all NSAIDs (other than aspirin and, possibly, naproxen) may be associated with an increased risk of cardiovascular complications, but concluded that celecoxib, which has less COX-2 selectivity than rofecoxib and valdecoxib, does not have higher risk than other nsNSAIDs when used in currently recommended doses (200 mg/day).

Use of even low-dose aspirin (81–325 mg/d) leads to a twofold increased risk of gastrointestinal bleeding complications. In randomized controlled trials, the absolute annual increase of gastrointestinal bleeding attributable to low-dose aspirin is only 0.12% higher than with placebo therapy. However, in population studies, gastrointestinal bleeding occurs in 1.2% of patients each year. Patients with a prior history of peptic ulcers or gastrointestinal bleeding have a markedly increased risk of complications on low-dose aspirin. It should be noted that low-dose aspirin in combination with NSAIDs or coxibs increases the risk of ulcer complications by up to tenfold compared with NSAIDs or low-dose aspirin alone.

H pylori infection increases the risk of ulcer disease and complications over threefold in patients taking NSAIDs or low-dose aspirin. It is hypothesized that NSAID initiation may potentiate or aggravate ulcer disease in susceptible infected individuals.

► Clinical Findings

A. Symptoms and Signs

Epigastric pain (dyspepsia), the hallmark of peptic ulcer disease, is present in 80–90% of patients. However, this complaint is not sensitive or specific enough to serve as a reliable diagnostic criterion for peptic ulcer disease. The clinical history cannot accurately distinguish duodenal from gastric ulcers. Less than 25% of patients with dyspepsia have ulcer disease at endoscopy. Twenty percent of patients with ulcer complications such as bleeding have no antecedent symptoms (“silent ulcers”). Nearly 60% of patients with NSAID-related ulcer complications do not have prior symptoms.

Pain is typically well localized to the epigastrium and not severe. It is described as gnawing, dull, aching, or

“hunger-like.” Approximately 50% of patients report relief of pain with food or antacids (especially duodenal ulcers) and a recurrence of pain 2–4 hours later. However, many patients deny any relationship to meals or report worsening of pain. Two-thirds of duodenal ulcers and one-third of gastric ulcers cause nocturnal pain that awakens the patient. A change from a patient’s typical rhythmic discomfort to constant or radiating pain may reflect ulcer penetration or perforation. Most patients have symptomatic periods lasting up to several weeks with intervals of months to years in which they are pain free (periodicity).

Nausea and anorexia may occur with gastric ulcers. Significant vomiting and weight loss are unusual with uncomplicated ulcer disease and suggest gastric outlet obstruction or gastric malignancy.

The physical examination is often normal in uncomplicated peptic ulcer disease. Mild, localized epigastric tenderness to deep palpation may be present. FOBT or FIT is positive in one-third of patients.

B. Laboratory Findings

Laboratory tests are normal in uncomplicated peptic ulcer disease but are ordered to exclude ulcer complications or confounding disease entities. Anemia may occur with acute blood loss from a bleeding ulcer or less commonly from chronic blood loss. Leukocytosis suggests ulcer penetration or perforation. An elevated serum amylase in a patient with severe epigastric pain suggests ulcer penetration into the pancreas. A fasting serum gastrin level to screen for Zollinger-Ellison syndrome is obtained in some patients (see below).

C. Endoscopy

Upper endoscopy is the procedure of choice for the diagnosis of duodenal and gastric ulcers. Duodenal ulcers are virtually never malignant and do not require biopsy. Three to 5 percent of benign-appearing gastric ulcers prove to be malignant. Hence, biopsies of the ulcer margin are almost always performed. Provided that the gastric ulcer appears benign to the endoscopist and adequate biopsy specimens reveal no evidence of cancer, dysplasia, or atypia, the patient may be monitored without further endoscopy. If these conditions are not fulfilled, follow-up endoscopy should be performed 12 weeks after the start of therapy to document complete healing; nonhealing ulcers are suspicious for malignancy.

D. Imaging

Because barium upper gastrointestinal series is less sensitive for detection of ulcers and less accurate for distinguishing benign from malignant ulcers, it has been supplanted by upper endoscopy in most settings. Abdominal CT imaging is obtained in patients with suspected complications of peptic ulcer disease (perforation, penetration, or obstruction).

E. Testing for *H pylori*

In patients in whom an ulcer is diagnosed by endoscopy, gastric mucosal biopsies should be obtained both for a rapid

urease test and for histologic examination. The specimens for histology are discarded if the urease test is positive.

In patients with a history of peptic ulcer or when an ulcer is diagnosed by upper gastrointestinal series, noninvasive assessment for *H pylori* with fecal antigen assay or urea breath testing should be done, which both have a sensitivity and specificity of 95%. Proton pump inhibitors may cause false-negative urea breath tests and fecal antigen tests and should be withheld for at least 7–14 days before testing. Because of its lower sensitivity (85%) and specificity (79%), serologic testing should not be performed unless fecal antigen testing or urea breath testing is unavailable.

► Differential Diagnosis

Peptic ulcer disease must be distinguished from other causes of epigastric distress (dyspepsia). Over 50% of patients with dyspepsia have no obvious organic explanation for their symptoms and are classified as having functional dyspepsia (see sections above on Dyspepsia and Functional Dyspepsia). Atypical gastroesophageal reflux may be manifested by epigastric symptoms. Biliary tract disease is characterized by discrete, intermittent episodes of pain that should not be confused with other causes of dyspepsia. Severe epigastric pain is atypical for peptic ulcer disease unless complicated by a perforation or penetration. Other causes include acute pancreatitis, acute cholecystitis or choledocholithiasis, esophageal rupture, gastric volvulus, and ruptured aortic aneurysm.

► Pharmacologic Agents

The pharmacology of several agents that enhance the healing of peptic ulcers is briefly discussed here. They may be divided into three categories: (1) acid-antisecretory agents, (2) mucosal protective agents, and (3) agents that promote healing through eradication of *H pylori*. Recommendations for their use are provided in subsequent sections.

A. Acid-Antisecretory Agents

1. Proton pump inhibitors—Proton pump inhibitors covalently bind the acid-secreting enzyme $H^+-K^+-ATPase$, or “proton pump,” permanently inactivating it. Restoration of acid secretion requires synthesis of new pumps, which have a half-life of 18 hours. Thus, although these agents have a serum half-life of < 60 minutes, their duration of action exceeds 24 hours.

There are six oral proton pump inhibitors currently available: omeprazole, rabeprazole, esomeprazole, lansoprazole, dexlansoprazole, and pantoprazole. The available oral agents inhibit over 90% of 24-hour acid secretion, compared with under 65% for H_2 -receptor antagonists in standard dosages. Despite minor differences in their pharmacology, they are equally efficacious in the treatment of peptic ulcer disease. Treatment with oral proton pump inhibitors results in over 90% healing of duodenal ulcers after 4 weeks and 90% of gastric ulcers after 8 weeks when given once daily (30 minutes before breakfast) at the following recommended doses: omeprazole, 20–40 mg; esomeprazole, 40 mg; rabeprazole, 20 mg; lansoprazole, 30 mg; dexlansoprazole, 30–60 mg; pantoprazole, 40 mg. Compared

with H_2 -receptor antagonists, proton pump inhibitors provide faster pain relief and more rapid ulcer healing.

The proton pump inhibitors are remarkably safe for short-term therapy. Long-term use may lead to mild decreases in vitamin B_{12} , iron, and calcium absorption. Observational studies suggest an increased risk of enteric infections, including *C difficile* and bacterial gastroenteritis, a modest (1.4-fold) increased risk of hip fracture, and pneumonia. Serum gastrin levels rise significantly in 3% of patients receiving long-term therapy but return to normal limits within 2 weeks after discontinuation.

2. H_2 -receptor antagonists—Although H_2 -receptor antagonists are effective in the treatment of peptic ulcer disease, proton pump inhibitors are now the preferred agents because of their ease of use and superior efficacy. Four H_2 -receptor antagonists are available: cimetidine, ranitidine, famotidine, and nizatidine. All four agents effectively inhibit nocturnal acid output, but they are less effective at inhibiting meal-stimulated acid secretion. For uncomplicated peptic ulcers, H_2 -receptor antagonists may be administered once daily at bedtime as follows: ranitidine and nizatidine 300 mg, famotidine 40 mg, and cimetidine 800 mg. Duodenal and gastric ulcer healing rates of 85–90% are obtained within 6 weeks and 8 weeks, respectively. All four agents are well tolerated, and serious adverse effects are rare. Cimetidine is rarely used because it inhibits hepatic cytochrome P450 metabolism (raising the serum concentration of theophylline, warfarin, lidocaine, and phenytoin) and may cause gynecomastia or impotence.

B. Agents Enhancing Mucosal Defenses

Bismuth, misoprostol, and antacids all have been shown to promote ulcer healing through the enhancement of mucosal defensive mechanisms. Given the greater efficacy and safety of antisecretory agents and better compliance of patients, these other agents are no longer used as first-line therapy for active ulcers in most clinical settings.

C. *H pylori* Eradication Therapy

Eradication of *H pylori* has proved difficult. Combination regimens that use two or three antibiotics with a proton pump inhibitor or bismuth are required to achieve adequate rates of eradication and to reduce the number of failures due to antibiotic resistance. In the United States, up to 50% of strains are resistant to metronidazole and 13% are resistant to clarithromycin. Recommended regimens are listed in Table 15–10. At present, there is no clear consensus on the optimal regimen. In the United States, the preferred regimen has been a 14-day course of ‘triple therapy,’ with an oral proton pump inhibitor—once daily—plus amoxicillin 1 g twice daily and clarithromycin 500 mg twice daily. However, this regimen only achieves rates of eradication > 75% after 10–14 days of treatment. Because of this suboptimal efficacy, some experts recommend ‘quadruple therapy,’ with a proton pump inhibitor, bismuth, tetracycline, and metronidazole or tinidazole for 14 days (Table 15–10). In a 2011 randomized, controlled trial, the per protocol eradication rates were 93% with quadruple therapy and 70% with triple therapy. Quadruple therapy is

Table 15-10. Treatment options for peptic ulcer disease.**Active *Helicobacter pylori*-associated ulcer**

1. Treat with anti-*H pylori* regimen for 10-14 days. Treatment options:

Standard Triple Therapy

- Proton pump inhibitor orally twice daily¹
Clarithromycin 500 mg orally twice daily²
Amoxicillin 1 g orally twice daily (OR metronidazole 500 mg orally twice daily, if penicillin allergic³)

Standard Quadruple Therapy

- Proton pump inhibitor orally twice daily^{1,4}
Bismuth subsalicylate two tablets orally four times daily
Tetracycline 500 mg orally four times daily
Metronidazole 250 mg orally four times daily or 500 mg three times daily
(OR bismuth subcitrate potassium 140 mg/metronidazole 125 mg/tetracycline 125 mg [Pylera] three capsules orally four times daily)⁵

Sequential Quadruple Therapy

- Proton pump inhibitor orally twice daily^{1,6}
Days 1-5: amoxicillin 1 g orally twice daily
Days 6-10: clarithromycin 500 mg and metronidazole 500 mg, both orally twice daily

2. After completion of course of *H pylori* eradication therapy, continue treatment with proton pump inhibitor¹ once daily for 4-6 weeks if ulcer is large (> 1 cm) or complicated.
3. Confirm successful eradication of *H pylori* with urea breath test, fecal antigen test, or endoscopy with biopsy at least 4 weeks after completion of antibiotic treatment and 1-2 weeks after proton pump inhibitor treatment.

Active ulcer not attributable to *H pylori*

1. Consider other causes: NSAIDs, Zollinger-Ellison syndrome, gastric malignancy. Treatment options:

- Proton pump inhibitors¹:
Uncomplicated duodenal ulcer: treat for 4 weeks
Uncomplicated gastric ulcer: treat for 8 weeks
- H₂-receptor antagonists:
Uncomplicated duodenal ulcer: cimetidine 800 mg, ranitidine or nizatidine 300 mg, famotidine 40 mg, orally once daily at bedtime for 6 weeks
Uncomplicated gastric ulcer: cimetidine 400 mg, ranitidine or nizatidine 150 mg, famotidine 20 mg, orally twice daily for 8 weeks
Complicated ulcers: proton pump inhibitors are the preferred drugs

Prevention of ulcer relapse

1. NSAID-induced ulcer: prophylactic therapy for high-risk patients (prior ulcer disease or ulcer complications, use of corticosteroids or anti-coagulants, age > 60 years, serious comorbid illnesses).

Treatment options:

- Proton pump inhibitor once daily¹
COX-2 selective NSAID (celecoxib) (contraindicated in patients with increased risk of cardiovascular disease)
Misoprostol 200 mcg orally 4 times daily

2. Long-term "maintenance" therapy indicated in patients with recurrent ulcers who either are *H pylori*-negative or who have failed attempts at eradication therapy: once-daily oral proton pump inhibitor¹ or oral H₂-receptor antagonist at bedtime (cimetidine 400-800 mg, nizatidine or ranitidine 150-300 mg, famotidine 20-40 mg)

¹Oral proton pump inhibitors: omeprazole 20-40 mg, rabeprazole 20 mg, lansoprazole 30 mg, dexlansoprazole 30-60 mg, pantoprazole 40 mg, esomeprazole 40 mg. Proton pump inhibitors are administered 30 minutes before meals. Esomeprazole 40 mg and dexlansoprazole 60 mg may be given orally once daily.

²If patient has previously been treated with macrolide antibiotic, choose another regimen.

³Avoid in areas of known high metronidazole resistance or in patients who have failed a course of treatment that included metronidazole.

⁴Preferred regimen in patients who have previously received a macrolide antibiotic or are penicillin allergic. Effective against metronidazole-resistant organisms.

⁵Pylera is an FDA-approved formulation containing: bismuth subcitrate 140 mg/tetracycline 125 mg/metronidazole 125 mg per capsule.

⁶Regimen requires validation in US studies. Appears effective against clarithromycin-resistant organisms.

COX-2, cyclooxygenase-2; NSAIDs, nonsteroidal anti-inflammatory drugs.

recommended for patients who are allergic to penicillin, who have previously been treated with a macrolide antibiotic, or whose infection persists after an initial course of antibiotic therapy. Finally, several international studies report eradication rates of > 90% using a novel

10-day sequential regimen consisting of four drugs: a proton pump inhibitor and amoxicillin for 5 days, followed by a proton pump inhibitor, clarithromycin, and tinidazole for 5 days. Importantly, sequential therapy appears to be effective in patients with clarithromycin resistance. It is

debated whether there is any advantage to giving the four drugs sequentially (which increases the regimen complexity) compared with giving them simultaneously. A 2010 trial demonstrated similar eradication rates with sequential or concomitant therapy. A 2011 meta-analysis of 15 studies of non-bismuth based concomitant quadruple therapy reported a 90% *H pylori* eradication rate. Although promising, many experts believe corroboration by studies in North America is needed before this non-bismuth 'quadruple' therapy (sequential or concomitant) can be accepted as first-line therapy in the United States.

► Medical Treatment

Patients should be encouraged to eat balanced meals at regular intervals. There is no justification for bland or restrictive diets. Moderate alcohol intake is not harmful. Smoking retards the rate of ulcer healing and increases the frequency of recurrences and should be discouraged.

A. Treatment of *H pylori*-Associated Ulcers

1. Treatment of active ulcer—The goals of treatment of active *H pylori*-associated ulcers are to relieve dyspeptic symptoms, to promote ulcer healing, and to eradicate *H pylori* infection. Uncomplicated *H pylori*-associated ulcers should be treated for 10–14 days with one of the proton pump inhibitor-based *H pylori* eradication regimens listed in Table 15–10. At that point, no further antisecretory therapy is needed, provided the ulcer was small (< 1 cm) and dyspeptic symptoms have resolved. For patients with large or complicated ulcers, an antisecretory agent should be continued for an additional 2–4 weeks (duodenal ulcer) or 4–6 weeks (gastric ulcer) after completion of the antibiotic regimen to ensure complete ulcer healing. A once-daily oral proton pump inhibitor (as listed in Table 15–10) is recommended. Confirmation of *H pylori* eradication is recommended for all patients > 4 weeks after completion of antibiotic therapy and > 2 weeks after discontinuation of the proton pump inhibitor either with noninvasive tests (urea breath test, fecal antigen test) or endoscopy with biopsy for histology.

2. Therapy to prevent recurrence—Successful eradication reduces ulcer recurrences to < 20% after 1–2 years. The most common cause of recurrence after antibiotic therapy is failure to achieve successful eradication. Once cure has been achieved, reinfection rates are < 0.5% per year. Although *H pylori* eradication has reduced the need for long-term maintenance antisecretory therapy to prevent ulcer recurrences, there remains a subset of patients who require long-term therapy with either a proton pump inhibitor once daily or an H_2 -receptor antagonist at bedtime. This subset includes patients with *H pylori*-positive ulcers who have not responded to repeated attempts at eradication therapy, patients with a history of *H pylori*-positive ulcers who have recurrent ulcers despite successful eradication, and patients with idiopathic ulcers (ie, *H pylori*-negative and not taking NSAIDs). In all patients with recurrent ulcers, NSAID usage (unintentional or surreptitious) and hypersecretory states (including gastrinoma) should be excluded.

B. Treatment of NSAID-Associated Ulcers

1. Treatment of active ulcers—In patients with NSAID-induced ulcers, the offending agent should be discontinued whenever possible. Both gastric and duodenal ulcers respond rapidly to therapy with H_2 -receptor antagonists or proton pump inhibitors (Table 15–10) once NSAIDs are eliminated. In some patients with severe inflammatory diseases, it may not be feasible to discontinue NSAIDs. These patients should be treated with concomitant proton pump inhibitors once daily, which results in ulcer healing rates of approximately 80% at 8 weeks in patients continuing to take NSAIDs. All patients with NSAID-associated ulcers should undergo testing for *H pylori* infection. Antibiotic eradication therapy should be given if *H pylori* tests are positive.

2. Prevention of NSAID-induced ulcers—Clinicians should carefully weigh the benefits of NSAID therapy with the risks of cardiovascular and gastrointestinal complications. For all patients, NSAIDs should be prescribed at the lowest effective dose and for the shortest period possible. Both coxibs and nsNSAIDs with the possible exception of naproxen increase the risk of cardiovascular complications. Ulcer complications occur in up to 2% of all nsNSAID-treated patients per year but in up to 10–20% per year of patients with multiple risk factors. These include age over 60 years, history of ulcer disease or complications, concurrent use of antiplatelet therapy (low-dose aspirin or clopidogrel, or both), concurrent therapy with anticoagulants or corticosteroids, and serious underlying medical illness. After considering the patient's risk of cardiovascular and gastrointestinal complications due to NSAID use, the clinician can decide what type of NSAID (nsNSAID vs coxib) is appropriate and what strategies should be used to reduce the risk of such complications. To minimize cardiovascular and gastrointestinal risks, all NSAIDs should be used at the lowest effective dose and for the shortest time necessary.

A. TEST FOR AND TREAT *H PYLORI* INFECTION—All patients with a known history of peptic ulcer disease who are treated with NSAIDs or antiplatelet agents (aspirin, clopidogrel) should be tested for *H pylori* infection and treated, if positive. Although *H pylori* eradication may decrease the risk of NSAID-related complications, cotherapy with a proton pump inhibitor or misoprostol therapy is still required in high-risk patients.

B. PROTON PUMP INHIBITOR—Treatment with an oral proton pump inhibitor given once daily (rabeprazole 20 mg, omeprazole 20–40 mg, lansoprazole 30 mg, dexlansoprazole 30–60 mg, or pantoprazole or esomeprazole 40 mg) is effective in the prevention of NSAID-induced gastric and duodenal ulcers and is approved by the FDA for this indication. Among high-risk patients taking nsNSAIDs or coxibs, the incidence of endoscopically visible gastric and duodenal ulcers after 6 months of therapy in patients treated with esomeprazole 20–40 mg/d was 5%, compared with 17% who were given placebo. Nonetheless, proton pump inhibitors are not fully protective in high-risk patients in preventing NSAID-related complications. In prospective, controlled trials of patients with a prior

history of NSAID-related ulcer complications, the incidence of recurrent bleeding was almost 5% after 6 months in patients taking nsNSAIDs and a proton pump inhibitor. In prospective, controlled trials of patients with a prior history of ulcer complications related to low-dose aspirin, the incidence of recurrent ulcer bleeding in patients taking low-dose aspirin alone is approximately 15% per year compared with 0–2% per year in patients taking low-dose aspirin and proton pump inhibitor and 9–14% per year in patients taking clopidogrel. Thus, proton pump inhibitors are highly effective in preventing complications related to low-dose aspirin, even in high-risk patients. Enteric coating of aspirin may reduce direct topical damage to the stomach but does not reduce complications.

C. MISOPROSTOL—Misoprostol reduces the incidence of NSAID-induced gastric and duodenal ulcers by 50–75% and ulcer complications by 40% when given at a dosage of 100–200 mcg four times daily. However, misoprostol is less commonly used as a prophylactic agent against NSAID-induced complications than either concurrent therapy with a proton pump inhibitor or COX-2 selective agent because of its high side-effect profile and the need for dosing four times daily.

D. RECOMMENDATIONS TO REDUCE RISK OF ULCER COMPLICATIONS FROM nsNSAIDs AND COXIBS—For patients with a low-risk of cardiovascular disease who have no risk factors for gastrointestinal complications, an nsNSAID alone may be given. For patients with 1–2 gastrointestinal risk factors, a coxib alone or an nsNSAID should be given with a proton pump inhibitor once daily to reduce the risk of gastrointestinal complications. NSAIDs should be avoided if possible in patients with multiple risk factors; if required, however, combination therapy with a coxib or a partially COX-2 selective nsNSAIDs (etodolac, meloxicam) and a proton pump inhibitor once daily is recommended.

For patients with an increased risk of cardiovascular complications, it is preferable to avoid NSAIDs, if possible. If an NSAID is required, naproxen is preferred because it appears to have reduced risk of cardiovascular complications compared with other nsNSAIDs. Coxibs should not be prescribed in patients with increased cardiovascular risk. Almost all patients with increased cardiovascular risk also will be taking antiplatelet therapy with low-dose aspirin or clopidogrel, or both. Because combination therapy with an nsNSAID and antiplatelet therapy increases the risks of gastrointestinal complications, these patients should all receive cotherapy with a proton pump inhibitor once daily or misoprostol.

E. RECOMMENDATIONS TO REDUCE RISK OF ULCER COMPLICATIONS WITH USE OF ANTIPLATELET AGENTS—The risk of significant gastrointestinal complications in persons taking low-dose aspirin (81–325 mg/d) or clopidogrel, or both, for cardiovascular prophylaxis is 0.5%/year. Aspirin, 81 mg/d, is recommended in most patients because it has a lower risk of gastrointestinal complications but equivalent cardiovascular protection compared with higher aspirin doses. Complications are increased with combinations of aspirin and clopidogrel or aspirin and anticoagulants. Patients with dyspepsia or prior ulcer disease should be

tested for *H pylori* infection and treated, if positive. Patients younger than age 60 who have no other risk factors for gastrointestinal complications may be treated with low-dose aspirin alone without a proton pump inhibitor or misoprostol. Virtually all other patients who require low-dose aspirin or aspirin and anticoagulant therapy should receive a proton pump inhibitor once daily.

At the present time, the optimal management of patients who require dual antiplatelet therapy with clopidogrel and aspirin is uncertain. Clopidogrel is a prodrug that is activated by the cytochrome P450 CYP2C19 enzyme. All proton pump inhibitors inhibit CYP2C19 to varying degrees, with omeprazole having the highest and pantoprazole the least level of inhibition. In vitro and in vivo platelet aggregation studies demonstrate that proton pump inhibitors (especially omeprazole) may attenuate the antiplatelet effects of clopidogrel, although the clinical importance of this interaction is uncertain. Some large retrospective cohort studies reported a higher incidence (hazard ratio or odds ratio < 2) of myocardial infarction in patients taking clopidogrel and a proton pump inhibitor (especially omeprazole) than in patients taking clopidogrel alone, although the majority of observational studies have shown no association. By contrast, subgroup analysis from three prospective, randomized controlled trials (CREDO, TRITON, PRINCIPLE) have not found an increase in clinically important cardiac events in patients taking a combination of clopidogrel with proton pump inhibitors, including omeprazole. Furthermore, in 2010 a prospective, randomized controlled trial (COGENT) comparing a combination of clopidogrel with omeprazole versus placebo found no difference in adverse events. Notwithstanding, the FDA issued a warning in 2009 that patients should avoid using clopidogrel with omeprazole, stating further that the safety of other proton pump inhibitors also was uncertain. Faced with this warning, the optimal strategy to reduce the risk of gastrointestinal bleeding in patients taking clopidogrel (with or without aspirin) is uncertain. A 2010 expert consensus panel concluded that once daily treatment with an oral proton pump inhibitor (pantoprazole 40 mg; rabeprazole 20 mg; lansoprazole or dexlansoprazole 30 mg) may still be recommended for patients who have an increased risk of gastrointestinal bleeding (prior history of peptic ulcer disease or gastrointestinal bleeding; concomitant NSAIDs). In keeping with the FDA warning and product labeling, omeprazole and esomeprazole should not be used. For patients with a lower risk of gastrointestinal bleeding, the risks and benefits of proton pump inhibitors must be weighed. Pending further recommendations, an acceptable alternative is to treat with an oral H₂-receptor antagonist (famotidine 20 mg, ranitidine 150 mg, nizatidine 150 mg) twice daily. Cimetidine is a CYP2C19 inhibitor and should not be used. In 2011, the FDA approved ticagrelor, a new antiplatelet agent, for use with low-dose aspirin in the treatment of acute coronary syndrome. Like clopidogrel, ticagrelor blocks the platelet ADP p₂y₁₂ receptor; however, it does not require hepatic activation, it does not interact with the CYP2C19 enzyme, and its efficacy is not diminished by proton pump inhibitors. At this time, the clinical role of ticagrelor versus clopidogrel is unclear.

C. Refractory Ulcers

Ulcers that are truly refractory to medical therapy are now uncommon. Less than 5% of ulcers are unhealed after 8 weeks of once daily therapy with proton pump inhibitors, and almost all benign ulcers heal with twice daily therapy. Thus, noncompliance is the most common cause of ulcer nonhealing. NSAID and aspirin use, sometimes surreptitious, are commonly implicated in refractory ulcers and must be stopped. *H pylori* infection should be sought and the infection treated, if present, in all refractory ulcer patients. Single or multiple linear gastric ulcers may occur in large hiatal hernias where the stomach slides back and forth through the diaphragmatic hiatus (“Cameron lesions”), which may be a cause of iron deficiency anemia. Other causes of nonhealing ulcers include acid hypersecretion (Zollinger-Ellison syndrome), unrecognized malignancy (adenocarcinoma or lymphoma), medications causing gastrointestinal ulceration (eg, iron or bisphosphonates), Crohn disease, and unusual infections (*H heilmanii*, CMV, mucormycosis). Fasting serum gastrin levels should be obtained to exclude gastrinoma with acid hypersecretion (Zollinger-Ellison syndrome). Repeat ulcer biopsies are mandatory after 2–3 months of therapy in all nonhealed ulcers to look for malignancy or infection. Patients with persistent nonhealing ulcers are referred for surgical therapy after exclusion of NSAID use and persistent *H pylori* infection.

Abraham NS et al. ACCF/ACG/AHA 2010 expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ASSG/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. *Am J Gastroenterol*. 2010 Dec;105(12):2533–49. [PMID: 21131924]

Bhatt DL et al; COGENT Investigators. Clopidogrel with or without omeprazole in coronary artery disease. *N Engl J Med*. 2010 Nov 11;363(20):1909–17. [PMID: 20925534]

Gisbert JP et al. Review article: non-bismuth quadruple (concomitant) therapy for eradication of *Helicobacter pylori*. *Aliment Pharmacol Ther*. 2011 Sep;34(6):604–17. [PMID: 21745241]

Lanas A et al. Low doses of acetylsalicylic acid increase risk of gastrointestinal bleeding in a meta-analysis. *Clin Gastroenterol Hepatol*. 2011 Sep;9(9):762–8. [PMID: 21699808]

Lanza FL et al. Guidelines for the prevention of NSAID-ulcer complications. *Am J Gastroenterol*. 2009 Mar;104(3):728–38. [PMID: 19240698]

Lin KJ et al. Acid suppressants reduce risk of gastrointestinal bleeding in patients on antithrombotic or anti-inflammatory therapy. *Gastroenterology*. 2011 Jul;141(1):71–9. [PMID: 21458456]

Luther J et al. Empiric quadruple vs. triple therapy for primary treatment of *Helicobacter pylori* infection: systematic review and meta-analysis of efficacy and tolerability. *Am J Gastroenterol*. 2010 Jan;105(1):65–73. [PMID: 19755966]

Malfertheiner P et al. Peptic ulcer disease. *Lancet*. 2009 Oct 24;374(9699):1449–61. [PMID: 19683340]

Malfertheiner P et al; Pylera Study Group. *Helicobacter pylori* eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial. *Lancet*. 2011 Mar 12;377(9769):905–13. [PMID: 21345487]

McCull KE. Clinical Practice. *Helicobacter pylori* infection. *N Engl J Med*. 2010 Apr 29;362(17):1597–604. [PMID: 20427808]

Ticagrelor (Brilinta)—better than clopidogrel (Plavix)? *Med Lett Drugs Ther*. 2011 Sep 5;53(1372):69–70. [PMID: 21897348]

Wu DC et al. Sequential and concomitant therapy with four drugs is equally effective for eradicating *H pylori* infection. *Clin Gastroenterol Hepatol*. 2010 Jan;8(1):36–41. [PMID: 19804842]

Yang YX et al. Safety of proton pump inhibitor exposure. *Gastroenterology*. 2010 Oct;139(4):1115–27. [PMID: 20727892]

COMPLICATIONS OF PEPTIC ULCER DISEASE

1. Gastrointestinal Hemorrhage



ESSENTIALS OF DIAGNOSIS

- ▶ “Coffee grounds” emesis, hematemesis, melena, or hematochezia.
- ▶ Emergent upper endoscopy is diagnostic and therapeutic.

▶ General Considerations

Approximately 50% of all episodes of upper gastrointestinal bleeding are due to peptic ulcer. Clinically significant bleeding occurs in 10% of ulcer patients. About 80% of patients stop bleeding spontaneously and generally have an uneventful recovery; the remaining 20% have more severe bleeding. The overall mortality rate for ulcer bleeding is 7%, but it is higher in the elderly, in patients with comorbid medical problems, and in patients with hospital-associated bleeding. Mortality is also higher in patients who present with persistent hypotension or shock, bright red blood in the vomitus or nasogastric lavage fluid, or severe coagulopathy.

▶ Clinical Findings

A. Symptoms and Signs

Up to 20% of patients have no antecedent symptoms of pain; this is particularly true of patients receiving NSAIDs. Common presenting signs include melena and hematemesis. Massive upper gastrointestinal bleeding or rapid gastrointestinal transit may result in hematochezia rather than melena; this may be misinterpreted as signifying a lower tract bleeding source. Nasogastric lavage that demonstrates “coffee grounds” or bright red blood confirms an upper tract source. Recovered nasogastric lavage fluid that is negative for blood does not exclude active bleeding from a duodenal ulcer.

B. Laboratory Findings

The hematocrit may fall as a result of bleeding or expansion of the intravascular volume with intravenous fluids. The BUN may rise as a result of absorption of blood nitrogen from the small intestine and prerenal azotemia.

► Treatment

The assessment and initial management of upper gastrointestinal tract bleeding are discussed above. Specific issues pertaining to peptic ulcer bleeding are described below.

A. Medical Therapy

1. Antisecretory agents—Intravenous proton pump inhibitors should be administered for 3 days in patients with ulcers whose endoscopic appearance suggests a high risk of rebleeding after endoscopic therapy. Intravenous proton pump inhibitors have been associated with a reduction in rebleeding, transfusions, the need for further endoscopic therapy, and surgery in the subset of patients with high-risk ulcers, ie, an ulcer with active bleeding, visible vessel, or adherent clot (see below). After initial successful endoscopic treatment of ulcer hemorrhage, intravenous esomeprazole, pantoprazole, or omeprazole (80 mg bolus injection, followed by 8 mg/h continuous infusion for 72 hours) reduces the rebleeding rate from approximately 20% to < 10%; however, intravenous omeprazole is not available in the United States.

High-dose oral proton pump inhibitors (omeprazole 40 mg twice daily) also appear to be effective in reducing rebleeding but have not been compared with the intravenous regimen. Intravenous H₂-receptor antagonists have not been demonstrated to be of any benefit in the treatment of acute ulcer bleeding.

2. Long-term prevention of rebleeding—Recurrent ulcer bleeding develops within 3 years in one-third of patients if no specific therapy is given. In patients with bleeding ulcers who are *H pylori*-positive, successful eradication effectively prevents recurrent ulcer bleeding in almost all cases. It is therefore recommended that all patients with bleeding ulcers be tested for *H pylori* infection and treated if positive. Four to 8 weeks after completion of antibiotic therapy, a urea breath or fecal antigen test for *H pylori* should be administered or endoscopy performed with biopsy for histologic confirmation of successful eradication. In patients in whom *H pylori* persists or the small subset of patients whose ulcers are not associated with NSAIDs or *H pylori*, long-term acid suppression with a once-daily proton pump inhibitor should be prescribed to reduce the likelihood of recurrence of bleeding.

B. Endoscopy

Endoscopy is the preferred diagnostic procedure in almost all cases of upper gastrointestinal bleeding because of its high diagnostic accuracy, its ability to predict the likelihood of recurrent bleeding, and its availability for therapeutic intervention in high-risk lesions. Endoscopy should be performed within 24 hours in most cases. In cases of severe active bleeding, endoscopy is performed as soon as patients have been appropriately resuscitated and are hemodynamically stable.

On the basis of clinical and endoscopic criteria, it is possible to predict which patients are at a higher risk of rebleeding and therefore to make more rational use of hospital resources. Nonbleeding ulcers under 2 cm in size with a base that is clean have a < 5% chance of rebleeding.

Most young (under age 60 years), otherwise healthy patients with clean-based ulcers may be safely discharged from the emergency department or hospital after endoscopy. Ulcers that have a flat red or black spot have a < 10% chance of significant rebleeding. Patients who are hemodynamically stable with these findings should be admitted to a hospital ward for 24–72 hours and may begin immediate oral feedings and antiulcer (or anti-*H pylori*) medication.

By contrast, the risk of rebleeding or continued bleeding in ulcers with a firmly adherent clot is 12–33%, with a nonbleeding visible vessel is 50%, and with active bleeding it is 80–90%. Endoscopic therapy with thermocoagulation (bipolar or heater probes) or application of endoscopic clips (akin to a staple) is the standard of care for such lesions because it reduces the risk of rebleeding, the number of transfusions, and the need for subsequent surgery. For actively bleeding ulcers, a combination of epinephrine injection followed by thermocoagulation or clip application commonly is used. These techniques achieve successful hemostasis of actively bleeding lesions in 90% of patients. Significant rebleeding occurs in 10–20% of cases, of which over 70% can be managed successfully with repeat endoscopic treatment. After endoscopic treatment, patients should remain hospitalized for at least 72 hours, when the risk of rebleeding falls to below 3%.

C. Surgical Treatment

Patients with recurrent bleeding or bleeding that cannot be controlled by endoscopic techniques should be evaluated by a surgeon. However, < 5% of patients treated with hemostatic therapy require surgery for continued or recurrent bleeding. Overall surgical mortality for emergency ulcer bleeding is < 6%. The prognosis is poorer for patients over age 60 years, those with serious underlying medical illnesses or chronic renal failure, and those who require more than 10 units of blood transfusion. Percutaneous arterial embolization is an alternative to surgery for patients in whom endoscopic therapy has failed.

2. Ulcer Perforation

Perforations develop in < 5% of ulcer patients, usually from ulcers on the anterior wall of the stomach or duodenum. Perforation results in a chemical peritonitis that causes sudden, severe generalized abdominal pain that prompts most patients to seek immediate attention. Elderly or debilitated patients and those receiving long-term corticosteroid therapy may experience minimal initial symptoms, presenting late with bacterial peritonitis, sepsis, and shock. On physical examination, patients appear ill, with a rigid, quiet abdomen and rebound tenderness. Hypotension develops later after bacterial peritonitis has developed. If hypotension is present early with the onset of pain, other abdominal emergencies should be considered such as a ruptured aortic aneurysm, mesenteric infarction, or acute pancreatitis. Leukocytosis is almost always present. A mildly elevated serum amylase (less than twice normal) is sometimes seen. Abdominal CT usually establishes the diagnosis without need for further studies. The absence of free air may lead to a misdiagnosis of pancreatitis, cholecystitis, or appendicitis.

Laparoscopic perforation closure can be performed in many centers, significantly reducing operative morbidity compared with open laparotomy.

3. Gastric Outlet Obstruction

Gastric outlet obstruction occurs in < 2% of patients with ulcer disease and is due to edema or cicatricial narrowing of the pylorus or duodenal bulb. With the advent of potent antisecretory therapy with proton pump inhibitors and the eradication of *H pylori*, obstruction now is less commonly caused by peptic ulcers than by gastric neoplasms or extrinsic duodenal obstruction by intra-abdominal neoplasms. The most common symptoms are early satiety, vomiting, and weight loss. Later, vomiting may develop that typically occurs one to several hours after eating and consists of partially digested food contents. Patients may develop dehydration, metabolic alkalosis, and hypokalemia. On physical examination, a succussion splash may be heard in the epigastrium. In most cases, nasogastric aspiration will result in evacuation of a large amount (> 200 mL) of foul-smelling fluid, which establishes the diagnosis. Patients are treated initially with intravenous isotonic saline and KCl to correct fluid and electrolyte disorders, an intravenous proton pump inhibitor, and nasogastric decompression of the stomach. Upper endoscopy is performed after 24–72 hours to define the nature of the obstruction and to exclude gastric neoplasm.

Crooks C et al. Reductions in 28-day mortality following hospital admission for upper gastrointestinal hemorrhage. *Gastroenterology*. 2011 Jul;141(1):62–70. [PMID: 21447331]

Garc'a-Iglesias P et al. Meta-analysis: predictors of rebleeding after endoscopic treatment for bleeding peptic ulcer. *Aliment Pharmacol Ther*. 2011 Oct; 34(8):888–900. [PMID: 21899582]

Greenspoon J et al; International Consensus Upper Gastrointestinal Bleeding Conference Group. Management of patients with nonvariceal upper gastrointestinal bleeding. *Clin Gastroenterol Hepatol*. 2012 Mar; 10(3):234–9. [PMID: 21820395]

Laine L et al. Endoscopic therapy for bleeding ulcers: an evidence-based approach based on meta-analyses of randomized controlled trials. *Clin Gastroenterol Hepatol*. 2009 Jan;7(1): 33–47. [PMID: 18986845]

Wong TC et al. A comparison of angiographic embolization with surgery after failed endoscopic hemostasis to bleeding peptic ulcers. *Gastrointest Endosc*. 2011 May;73(5):900–8. [PMID: 21288512]

ZOLLINGER-ELLISON SYNDROME (Gastrinoma)



ESSENTIALS OF DIAGNOSIS

- ▶ Peptic ulcer disease; may be severe and atypical.
- ▶ Gastric acid hypersecretion.
- ▶ Diarrhea common, relieved by nasogastric suction.
- ▶ Most cases are sporadic; 25% with multiple endocrine neoplasia type 1 (MEN 1).

▶ General Considerations

Zollinger-Ellison syndrome is caused by gastrin-secreting gut neuroendocrine tumors (gastrinomas), which result in hypergastrinemia and acid hypersecretion. Less than 1% of peptic ulcer disease is caused by gastrinomas. Primary gastrinomas may arise in the pancreas (25%), duodenal wall (45%), or lymph nodes (5–15%), and in other locations or of unknown primary in 20%. Approximately 80% arise within the “gastrinoma triangle” bounded by the porta hepatis, the neck of the pancreas, and the third portion of the duodenum. Most gastrinomas are solitary or multifocal nodules that are potentially resectable. Over two-thirds of gastrinomas are malignant, and one-third have already metastasized to the liver at initial presentation. Approximately 25% of patients have small multicentric gastrinomas associated with MEN 1 that are more difficult to resect.

▶ Clinical Findings

A. Symptoms and Signs

Over 90% of patients with Zollinger-Ellison syndrome develop peptic ulcers. In most cases, the symptoms are indistinguishable from other causes of peptic ulcer disease and therefore may go undetected for years. Ulcers usually are solitary and located in the duodenal bulb, but they may be multiple or occur more distally in the duodenum. Isolated gastric ulcers do not occur. Gastroesophageal reflux symptoms occur often. Diarrhea occurs in one-third of patients, in some cases in the absence of peptic symptoms. Gastric acid hypersecretion can cause direct intestinal mucosal injury and pancreatic enzyme inactivation, resulting in diarrhea, steatorrhea, and weight loss; nasogastric aspiration of stomach acid stops the diarrhea. Screening for Zollinger-Ellison syndrome with fasting gastrin levels should be obtained in patients with ulcers that are refractory to standard therapies, giant ulcers (> 2 cm), ulcers located distal to the duodenal bulb, multiple duodenal ulcers, frequent ulcer recurrences, ulcers associated with diarrhea, ulcers occurring after ulcer surgery, and patients with ulcer complications. Ulcer patients with hypercalcemia or family histories of ulcers (suggesting MEN 1) should also be screened. Finally, patients with peptic ulcers who are *H pylori* negative and who are not taking NSAIDs should be screened.

B. Laboratory Findings

The most sensitive and specific method for identifying Zollinger-Ellison syndrome is demonstration of an increased fasting serum gastrin concentration (> 150 pg/mL [> 150 ng/L]). Levels should be obtained with patients not taking H_2 -receptor antagonists for 24 hours or proton pump inhibitors for 6 days. The median gastrin level is 500–700 pg/mL (500–700 ng/L), and 60% of patients have levels < 1000 pg/mL (< 1000 ng/L). Hypochlorhydria with increased gastric pH is a much more common cause of hypergastrinemia than is gastrinoma. Therefore, a measurement of gastric pH (and, where available, gastric secretory studies) is performed in patients with fasting hypergastrinemia. Most patients have a basal acid output

of over 15 mEq/h. A gastric pH of > 3.0 implies hypochlorhydria and excludes gastrinoma. In a patient with a serum gastrin level of > 1000 pg/mL (> 1000 ng/L) and acid hypersecretion, the diagnosis of Zollinger-Ellison syndrome is established. With lower gastrin levels (150–1000 pg/mL [150–1000 ng/L]) and acid secretion, a secretin stimulation test is performed to distinguish Zollinger-Ellison syndrome from other causes of hypergastrinemia. Intravenous secretin (2 units/kg) produces a rise in serum gastrin of over 200 pg/mL (200 ng/L) within 2–30 minutes in 85% of patients with gastrinoma. An elevated serum calcium suggests hyperparathyroidism and MEN 1 syndrome. In all patients with Zollinger-Ellison syndrome, a serum parathyroid hormone (PTH), prolactin, luteinizing hormone-follicle-stimulating hormone (LH-FSH), and growth hormone (GH) level should be obtained to exclude MEN 1.

C. Imaging

Imaging studies are obtained in an attempt to determine whether there is metastatic disease and, if not, to identify the site of the primary tumor. Gastrinomas express somatostatin receptors that bind radiolabeled octreotide. Somatostatin receptor scintigraphy (SRS) with single photon emission computed tomography (SPECT) allows total body imaging for detection of primary gastrinomas in the pancreas and lymph nodes, primary gastrinomas in unusual locations, and metastatic gastrinomas (liver and bone). SRS has a sensitivity ($> 80\%$) for tumor detection that exceeds all other imaging studies combined. If SRS is positive for tumor localization, further imaging studies are not necessary. In patients with negative SRS, endoscopic ultrasonography (EUS) may be useful to detect small gastrinomas in the duodenal wall, pancreas, or peripancreatic lymph nodes. CT and MRI scans are commonly obtained to look for large hepatic metastases and primary lesions, but they have low sensitivity for small lesions. With a combination of SRS and EUS, more than 90% of primary gastrinomas can be localized preoperatively.

► Differential Diagnosis

Gastrinomas are one of several gut neuroendocrine tumors that have similar histopathologic features and arise either from the gut or pancreas. These include carcinoid, insulinoma, VIPoma, glucagonoma, and somatostatinoma. These tumors usually are differentiated by the gut peptides that they secrete; however, poorly differentiated neuroendocrine tumors may not secrete any hormones. Patients may present with symptoms caused by tumor metastases (jaundice, hepatomegaly) rather than functional symptoms. Once a diagnosis of a neuroendocrine tumor is established from the liver biopsy, the specific type of tumor can subsequently be determined. Both carcinoid and gastrinoma tumors may be detected incidentally during endoscopy after biopsy of a submucosal nodule and must be distinguished by subsequent studies.

Hypergastrinemia due to gastrinoma must be distinguished from other causes of hypergastrinemia. Atrophic gastritis with decreased acid secretion is detected by gastric secretory analysis. Other conditions associated with

hypergastrinemia (eg, gastric outlet obstruction, vagotomy, chronic renal failure) are associated with a negative secretin stimulation test.

► Treatment

A. Metastatic Disease

The most important predictor of survival is the presence of hepatic metastases. In patients with multiple hepatic metastases, initial therapy should be directed at controlling hypersecretion. Oral proton pump inhibitors (omeprazole, esomeprazole, rabeprazole, pantoprazole, or lansoprazole) are given at a dose of 40–120 mg/d, titrated to achieve a basal acid output of < 10 mEq/h. At this level, there is complete symptomatic relief and ulcer healing. In patients with isolated hepatic metastases, surgical resection or cryoablation may decrease the need for antisecretory medications and may prolong survival. Owing to the slow growth of these tumors, 30% of patients with hepatic metastases have a survival of 10 years.

B. Localized Disease

Cure can be achieved only if the gastrinoma can be resected before hepatic metastatic spread has occurred. Lymph node metastases do not adversely affect prognosis. Laparotomy should be considered in all patients in whom preoperative studies fail to demonstrate hepatic or other distant metastases. A combination of preoperative studies, duodenotomy with careful duodenal inspection, and intraoperative palpation and sonography allows successful localization and resection in the majority of cases. The 15-year survival of patients who do not have liver metastases at initial presentation is over 95%. The role of surgery in patients with MEN 1 is controversial. Surgical cure in patients with MEN 1 rarely occurs, and long-term survival is common in the absence of surgery. Some experts recommend surgery only in patients with MEN 1 whose tumors are larger than 2 cm, in whom the risk of hepatic metastases is increased.

Ellison EC et al. The Zollinger-Ellison syndrome: a comprehensive review of historical, scientific, and clinical considerations. *Curr Probl Surg*. 2009 Jan;46(1):13–106. [PMID: 19059523]
Pritchard DM. Zollinger-Ellison syndrome: still a diagnostic challenge in the 21st century? *Gastroenterology*. 2011 May; 140(5):1380–83. [PMID: 21443889]

BENIGN TUMORS OF THE STOMACH

Gastric epithelial polyps are usually detected incidentally at endoscopy. The majority are fundic gland polyps or hyperplastic polyps, which are small, single or multiple, have no malignant potential, and do not require removal or endoscopic surveillance. There is an increased prevalence of fundic gland polyps in patients taking proton pump inhibitors. Adenomatous polyps account for 10–20% of gastric polyps. They are usually solitary lesions. In rare instances they ulcerate, causing chronic blood loss. Because of their premalignant potential, endoscopic removal is indicated. Annual endoscopic surveillance is recommended to screen for further polyp development. Submucosal gastric polypoid

lesions include benign gastric stromal tumors (commonly misclassified as leiomyomas) and pancreatic rests. (See Chapter 39 for Gastric Adenocarcinoma, Lymphoma, Carcinoid Tumors, and Mesenchymal Tumors.)

Zelter A et al. Fundic gland polyps and association with proton pump inhibitor intake: a prospective study in 1,780 endoscopies. *Dig Dis Sci.* 2011 Jun;56(6):1743–8. [PMID: 21127978]

DISEASES OF THE SMALL INTESTINE

MALABSORPTION

The term “malabsorption” denotes disorders in which there is a disruption of digestion and nutrient absorption. The clinical and laboratory manifestations of malabsorption are summarized in Table 15–11.

1. Celiac Disease



ESSENTIALS OF DIAGNOSIS

- ▶ *Typical symptoms:* weight loss, chronic diarrhea, abdominal distention, growth retardation.
- ▶ *Atypical symptoms:* dermatitis herpetiformis, iron deficiency anemia, osteoporosis.
- ▶ Abnormal serologic test results.
- ▶ Abnormal small bowel biopsy.
- ▶ Clinical improvement on gluten-free diet.

▶ General Considerations

Celiac disease (also called sprue, celiac sprue, and gluten enteropathy) is a permanent dietary disorder caused by an immunologic response to gluten, a storage protein found in certain grains, that results in diffuse damage to the proximal small intestinal mucosa with malabsorption of nutrients. Although symptoms may manifest between 6 months and 24 months of age after the introduction of weaning foods, the majority of cases present in childhood or adulthood. Population screening with serologic tests suggests that the disease is present in 1:100 whites of Northern European ancestry, in whom a clinical diagnosis of celiac disease is made in only 10%, suggesting that most cases are undiagnosed or asymptomatic. Celiac disease only develops in people with the HLA-DQ2 (95%) or -DQ8 (5%) class II molecules, which are present in 40% of the population. Although the precise pathogenesis is unclear, celiac disease arises in a small subset of genetically susceptible (-DQ2 or -DQ8) individuals when dietary gluten stimulates an inappropriate immunologic response.

▶ Clinical Findings

The most important step in diagnosing celiac disease is to consider the diagnosis. Symptoms are present for more than 10 years in most adults before the correct diagnosis is established. Because of its protean manifestations, celiac disease is grossly underdiagnosed in the adult population.

A. Symptoms and Signs

The gastrointestinal symptoms and signs of celiac disease depend on the length of small intestine involved and the

Table 15–11. Clinical manifestations and laboratory findings in malabsorption of various nutrients.

Manifestations	Laboratory Findings	Malabsorbed Nutrients
Steatorrhea (bulky, light-colored stools)	Increased fecal fat; decreased serum cholesterol; decreased serum carotene, vitamin A, vitamin D	Triglycerides, fatty acids, phospholipids, cholesterol. Fat soluble vitamins: A, D, E, K
Diarrhea (increased fecal water)	Increased stool volume and weight; increased fecal fat; increased stool osmolality gap	Fats, carbohydrates
Weight loss; muscle wasting	Increased fecal fat; decreased carbohydrate (D-xylose) absorption	Fat, protein, carbohydrates
Microcytic anemia	Low serum iron	Iron
Macrocytic anemia	Decreased serum vitamin B ₁₂ or red blood cell folate	Vitamin B ₁₂ or folic acid
Paresthesia; tetany; positive Trousseau and Chvostek signs	Decreased serum calcium or magnesium	Calcium, vitamin D, magnesium
Bone pain; pathologic fractures; skeletal deformities	Osteopenia on radiograph; osteoporosis (adults); osteomalacia (children)	Calcium, vitamin D
Bleeding tendency (ecchymoses, epistaxis)	Prolonged prothrombin time or INR	Vitamin K
Edema	Decreased serum total protein and albumin; increased fecal loss of α_1 -antitrypsin	Protein
Milk intolerance (cramps, bloating, diarrhea)	Abnormal lactose tolerance test	Lactose

INR, international normalized ratio.

patient's age when the disease presents. "Classic" symptoms of malabsorption, including diarrhea, steatorrhea, weight loss, abdominal distention, weakness, muscle wasting, or growth retardation, more commonly present in infants (< 2 years). Older children and adults are less likely to manifest signs of serious malabsorption. They may report chronic diarrhea, dyspepsia, or flatulence due to colonic bacterial digestion of malabsorbed nutrients, but the severity of weight loss is variable. Many adults have minimal or no gastrointestinal symptoms but present with extraintestinal "atypical" manifestations, including fatigue, depression, iron-deficiency anemia, osteoporosis, short stature, delayed puberty, amenorrhea, or reduced fertility. Approximately 40% of patients with positive serologic tests consistent with sprue have no symptoms of disease; the natural history of these patients with "silent" sprue is unclear.

Physical examination may be normal in mild cases or may reveal signs of malabsorption such as loss of muscle mass or subcutaneous fat, pallor due to anemia, easy bruising due to vitamin K deficiency, hyperkeratosis due to vitamin A deficiency, bone pain due to osteomalacia, or neurologic signs (peripheral neuropathy, ataxia) due to vitamin B₁₂ or vitamin E deficiency (Table 15–11). Abdominal examination may reveal distention with hyperactive bowel sounds.

Dermatitis herpetiformis is regarded as a cutaneous variant of celiac disease. It is a characteristic skin rash consisting of pruritic papulovesicles over the extensor surfaces of the extremities and over the trunk, scalp, and neck. Dermatitis herpetiformis occurs in < 10% of patients with celiac disease; however, almost all patients who present with dermatitis herpetiformis have evidence of celiac disease on intestinal mucosal biopsy, though it may not be clinically evident.

B. Laboratory Findings

1. Routine laboratory tests—Depending on the severity of illness and the extent of intestinal involvement, nonspecific laboratory abnormalities may be present that may raise the suspicion of malabsorption and celiac disease (Table 15–11). Limited proximal involvement may result only in microcytic anemia due to iron deficiency. Up to 5% of adults with iron deficiency not due to gastrointestinal blood loss have undiagnosed celiac disease. More extensive involvement results in a megaloblastic anemia due to folate or vitamin B₁₂ deficiency. Low serum calcium or elevated alkaline phosphatase may reflect impaired calcium or vitamin D absorption with osteomalacia or osteoporosis. Dual-energy x-ray densitometry scanning is recommended for all patients with sprue to screen for osteoporosis. Elevations of prothrombin time, or decreased vitamin A or D levels reflect impaired fat-soluble vitamin absorption. A low serum albumin may reflect small intestine protein loss or poor nutrition. Severe diarrhea may result in a nonanion gap acidosis and hypokalemia. Mild elevations of aminotransferases are found in up to 40%.

2. Serologic tests—Serologic tests should be performed in all patients in whom there is a suspicion of celiac disease.

The two tests with the highest diagnostic accuracy are the IgA endomysial antibody and IgA tTG antibody tests, both of which have a $\geq 90\%$ sensitivity and $\geq 95\%$ specificity for the diagnosis of celiac disease. A negative test reliably excludes the diagnosis of celiac disease. Antigliadin antibodies are not recommended because of their lower sensitivity and specificity. A new test that measures antibodies to deamidated gliadin is reported to have excellent sensitivity and specificity, including in early-state celiac disease, but is not yet used widely in clinical practice. Because up to 3% of patients with celiac disease have IgA deficiency, an IgA level should be obtained in patients with a negative IgA endomysial antibody or tTG antibody when celiac disease is strongly suspected. For the subset of patients with IgA deficiency, IgG tTG or endomysial antibodies can be obtained. Levels of all antibodies become undetectable after 6–12 months of dietary gluten withdrawal and may be used to monitor dietary compliance, especially in patients whose symptoms fail to resolve after institution of a gluten-free diet.

C. Mucosal Biopsy

Endoscopic mucosal biopsy of the distal duodenum or proximal jejunum is the standard method for confirmation of the diagnosis in patients with a positive serologic test for celiac disease. Rarely, mucosal biopsy may be pursued in patients with negative serologies when symptoms and laboratory studies are suggestive of celiac disease. At endoscopy, atrophy or scalloping of the duodenal folds may be observed. Histology reveals abnormalities ranging from intraepithelial lymphocytosis alone to extensive infiltration of the lamina propria with lymphocytes and plasma cells with hypertrophy of the intestinal crypts and, in its most severe form, to blunting or complete loss of intestinal villi. An adequate normal biopsy excludes the diagnosis. Partial or complete reversion of these abnormalities on repeat biopsy after a patient is placed on a gluten-free diet establishes the diagnosis. However, if a patient with a compatible biopsy demonstrates prompt clinical improvement on a gluten-free diet and a decrease in antigliadin antibodies, a repeat biopsy is unnecessary.

► Differential Diagnosis

Many patients with chronic diarrhea or flatulence are erroneously diagnosed as having irritable bowel syndrome. Celiac sprue must be distinguished from other causes of malabsorption, as outlined above. Severe panmalabsorption of multiple nutrients is almost always caused by mucosal disease. The histologic appearance of celiac sprue may resemble other mucosal diseases such as tropical sprue, bacterial overgrowth, cow's milk intolerance, viral gastroenteritis, eosinophilic gastroenteritis, and mucosal damage caused by acid hypersecretion associated with gastrinoma. Documentation of clinical response to gluten withdrawal therefore is essential to the diagnosis.

► Treatment

Removal of all gluten from the diet is essential to therapy— all wheat, rye, and barley must be eliminated. Although oats

appear to be safe, commercial products may be contaminated with wheat or barley during processing. Because of the pervasive use of gluten products in manufactured foods and additives, in medications, and by restaurants, it is imperative that patients and their families confer with a knowledgeable dietitian to comply satisfactorily with this lifelong diet. Several excellent dietary guides and patient support groups are available. Most patients with celiac disease also have lactose intolerance either temporarily or permanently and should avoid dairy products until the intestinal symptoms have improved on the gluten-free diet. Dietary supplements (folate, iron, calcium, and vitamins A, B₁₂, D, and E) should be provided in the initial stages of therapy but usually are not required long-term with a gluten-free diet. Patients with confirmed osteoporosis may require long-term calcium, vitamin D, and bisphosphonate therapy.

Improvement in symptoms should be evident within a few weeks on the gluten-free diet. The most common reason for treatment failure is incomplete removal of gluten. Acute severe diarrhea with dehydration, electrolyte imbalance, and malnutrition may require TPN and intravenous or oral corticosteroids (prednisone 40 mg or budesonide 9 mg) for 2 or more weeks as a gluten-free diet is initiated.

► Prognosis & Complications

If appropriately diagnosed and treated, patients with celiac disease have an excellent prognosis. Celiac disease may be associated with other autoimmune disorders, including Addison disease, Graves disease, type 1 diabetes mellitus, myasthenia gravis, scleroderma, Sjögren syndrome, atrophic gastritis, and pancreatic insufficiency. In some patients, celiac disease may evolve and become refractory to the gluten-free diet. The most common cause is intentional or unintentional dietary noncompliance, which may be suggested by positive serologic tests. Celiac disease that is truly refractory to gluten withdrawal occurs in < 5% and generally carries a poor prognosis. There are two types of refractory disease, which are distinguished by their intraepithelial lymphocyte phenotype. Type I has a normal (polyclonal) lymphocyte population, whereas type II has an aberrant population characterized by loss of surface expression of CD3 and CD8 and monoclonal rearrangement of the surface T-cell receptor by polymerase chain reaction (PCR). Type I disease usually responds to corticosteroids (prednisone or budesonide) with or without azathioprine; however, long-term therapy is usually required. Type II disease is less responsive to corticosteroid therapy and has a high risk of progression to intestinal T-cell lymphoma (50% at 5 years), which carries a poor prognosis with either chemotherapy or autologous bone marrow transplantation. This diagnosis should be considered in patients previously responsive to the gluten-free diet in whom new weight loss, abdominal pain, and malabsorption develop.

Celiac Disease Foundation, 13251 Ventura Blvd, Suite #1, Studio City, CA 91604-1838. <http://www.celiac.org>

Jamma S et al. Celiac crisis is a rare but serious complication of celiac disease in adults. *Clin Gastroenterol Hepatol*. 2010 Jul;8(7):587–90. [PMID: 20417725]

Katz KD et al. Screening for celiac disease in a North American population: sequential serology and gastrointestinal symptoms. *Am J Gastroenterol*. 2011 Jul;106(7):1333–9. [PMID: 21364545]

Roshan B et al. The incidence and clinical spectrum of refractory celiac disease in a North American referral center. *Am J Gastroenterol*. 2011 May;106(5):923–8. [PMID: 21468013]

Rubio-Tapia A et al. Celiac disease and persistent symptoms. *Clin Gastroenterol Hepatol*. 2011 Jan;9(1):13–7. [PMID: 20692372]

2. Whipple Disease



ESSENTIALS OF DIAGNOSIS

- ▶ Multisystemic disease.
- ▶ Fever, lymphadenopathy, arthralgias.
- ▶ Weight loss, malabsorption, chronic diarrhea.
- ▶ Duodenal biopsy with periodic acid-Schiff (PAS)-positive macrophages with characteristic bacillus.

► General Considerations

Whipple disease is a rare multisystemic illness caused by infection with the bacillus *Tropheryma whippelii*. It may occur at any age but most commonly affects white men in the fourth to sixth decades. The source of infection is unknown, but no cases of human-to-human spread have been documented.

► Clinical Findings

A. Symptoms and Signs

The clinical manifestations are protean; however, the most common are arthralgias, diarrhea, abdominal pain, and weight loss. Arthralgias or a migratory, nondeforming arthritis occurs in 80% and is typically the first symptom experienced. Gastrointestinal symptoms occur in approximately 75% of cases. They include abdominal pain, diarrhea, and some degree of malabsorption with distention, flatulence, and steatorrhea. Weight loss is the most common presenting symptom—seen in almost all patients. Loss of protein due to intestinal or lymphatic involvement may result in protein-losing enteropathy with hypoalbuminemia and edema. In the absence of gastrointestinal symptoms, the diagnosis often is delayed for several years. Intermittent low-grade fever occurs in over 50% of cases. There may be generalized lymphadenopathy that resembles sarcoidosis. Myocardial or valvular involvement may lead to congestive failure or valvular regurgitation. Central nervous system involvement is manifested by a variety of findings such as dementia, lethargy, coma, seizures, myoclonus, or hypothalamic signs. Cranial nerve findings include ophthalmoplegia or nystagmus.

Physical examination may reveal hypotension (a late finding), low-grade fever, and evidence of malabsorption (see Table 15–11). Lymphadenopathy is present in 50%. Heart murmurs due to valvular involvement may be evident.

Peripheral joints may be enlarged or warm, and peripheral edema may be present. Neurologic findings are cited above. Hyperpigmentation on sun-exposed areas is evident in up to 40%.

B. Laboratory Findings

If significant malabsorption is present, patients may have laboratory abnormalities as outlined in Table 15–11. There may be steatorrhea.

C. Histologic Evaluation

In most cases, the diagnosis of Whipple disease is established by endoscopic biopsy of the duodenum with histologic evaluation, which demonstrates infiltration of the lamina propria with PAS-positive macrophages that contain gram-positive bacilli (which are not acid-fast) and dilation of the lacteals. The Whipple bacillus has a characteristic trimellar wall appearance on electron microscopy. In some patients who present with nongastrointestinal symptoms, the duodenal biopsy may be normal, and biopsy of other involved organs or lymph nodes may be necessary. Because the PAS stain is less sensitive and specific for extraintestinal Whipple disease, PCR is used to confirm the diagnosis by demonstrating the presence of 16S ribosomal RNA of *T whippelii* in blood, vitreous fluid, synovial fluid, or cardiac valves. Because asymptomatic central nervous system infection occurs in 40% of patients, examination of the cerebrospinal fluid by PCR for *T whippelii* should be performed routinely. The sensitivity of PCR is 97% and the specificity 100%.

Differential Diagnosis

Whipple disease should be considered in patients who present with signs of malabsorption, fever of unknown origin, lymphadenopathy, seronegative arthritis, culture-negative endocarditis, or multisystemic disease. Small bowel biopsy readily distinguishes Whipple disease from other mucosal malabsorptive disorders, such as celiac sprue. Patients with AIDS and infection of the small intestine with *Mycobacterium avium* complex (MAC) may have a similar clinical and histologic picture; although both conditions are characterized by PAS-positive macrophages, they may be distinguished by the acid-fast stain, which is positive for MAC and negative for the Whipple bacillus. Other conditions that may be confused with Whipple disease include sarcoidosis, Reiter syndrome, familial Mediterranean fever, systemic vasculitides, Behçet disease, intestinal lymphoma, and subacute infective endocarditis.

Treatment

Antibiotic therapy results in a dramatic clinical improvement within several weeks, even in some patients with neurologic involvement. The optimal regimen is unknown. Complete clinical response usually is evident within 1–3 months; however, relapse may occur in up to one-third of patients after discontinuation of treatment. Therefore, prolonged treatment for at least 1 year is required. Drugs that cross the blood-brain barrier are preferred. A randomized

controlled trial in 40 patients with 3–10 years follow-up demonstrated 100% remission with either ceftriaxone 1 g intravenously twice daily or meropenem 1 g intravenously three times daily for 2 weeks, followed by trimethoprim-sulfamethoxazole 160/800 mg twice daily for 12 months. After treatment, repeat duodenal biopsies for histologic analysis and cerebrospinal fluid PCR should be obtained every 6 months for at least 1 year. The absence of PAS-positive material predicts a low likelihood of clinical relapse.

Prognosis

If untreated, the disease is fatal. Because some neurologic signs may be permanent, the goal of treatment is to prevent this progression. Patients must be followed closely after treatment for signs of symptom recurrence.

Feurle G et al. Efficacy of ceftriaxone or meropenem as initial therapies for Whipple's disease. *Gastroenterology*. 2010 Feb; 138(2):478–86. [PMID: 19879276]
Marth T. New insights into Whipple's disease—a rare intestinal inflammatory disorder. *Dig Dis*. 2009;27(4):494–501. [PMID: 19897965]

3. Bacterial Overgrowth



ESSENTIALS OF DIAGNOSIS

- ▶ Symptoms of distention, flatulence, diarrhea, and weight loss.
- ▶ Increased qualitative or quantitative fecal fat.
- ▶ Advanced cases associated with deficiencies of iron or vitamins A, D, and B₁₂.
- ▶ Diagnosis suggested by breath tests using glucose, lactulose, or 14C-xylose as substrates.
- ▶ Diagnosis confirmed by jejunal aspiration with quantitative bacterial cultures.

General Considerations

The small intestine normally contains a small number of bacteria. Bacterial overgrowth in the small intestine of whatever cause may result in malabsorption via a number of mechanisms. Bacterial deconjugation of bile salts may lead to inadequate micelle formation, resulting in decreased fat absorption with steatorrhea and malabsorption of fat-soluble vitamins (A, D). Microbial uptake of specific nutrients reduces absorption of vitamin B₁₂ and carbohydrates. Bacterial proliferation also causes direct damage to intestinal epithelial cells and the brush border, further impairing absorption of proteins, carbohydrates, and minerals. Passage of the malabsorbed bile acids and carbohydrates into the colon leads to an osmotic and secretory diarrhea and increased flatulence.

Causes of bacterial overgrowth include: (1) gastric achlorhydria (including proton pump inhibitor therapy); (2) anatomic abnormalities of the small intestine with

stagnation (afferent limb of Billroth II gastrojejunostomy, resection of ileocecal valve, small intestine diverticula, obstruction, blind loop); (3) small intestine motility disorders (vagotomy, scleroderma, diabetic enteropathy, chronic intestinal pseudo-obstruction); (4) gastrocolic or coloenteric fistula (Crohn disease, malignancy, surgical resection); and (5) miscellaneous disorders. Bacterial overgrowth is an important cause of malabsorption in the elderly, perhaps because of decreased gastric acidity or impaired intestinal motility. It may also be present in a subset of patients with irritable bowel syndrome.

► Clinical Findings

Many patients with bacterial overgrowth are asymptomatic. Symptoms are nonspecific and include distention, flatulence, weight loss, diarrhea, and sometimes steatorrhea. Severe cases may result in clinically significant vitamin and mineral deficiencies, including fat-soluble vitamins A or D, vitamin B₁₂, and iron (Table 15–11). Qualitative or quantitative fecal fat assessment typically is abnormal. Bacterial overgrowth should be considered in any patient with diarrhea, flatulence, weight loss, or macrocytic anemia, especially if the patient has a predisposing cause (such as prior gastrointestinal surgery). A stool collection should be obtained to corroborate the presence of steatorrhea. Vitamins A, D, B₁₂, and serum iron should be measured. A specific diagnosis can be established firmly only by an aspirate and culture of proximal jejunal secretion that demonstrates over 10⁵ organisms/mL. However, this is an invasive and laborious test that requires careful collection and culturing techniques and therefore is not available in many clinical settings. Noninvasive breath tests are easier to perform and have a sensitivity of 60–90% and specificity of 85% compared with jejunal cultures. Breath hydrogen and methane tests with glucose or lactulose as substrates are commonly done because of their ease of use. A small bowel barium radiography or CT enterography study should be obtained to look for mechanical factors predisposing to intestinal stasis.

Owing to the lack of an optimal test for bacterial overgrowth, many clinicians use an empiric antibiotic trial as a diagnostic and therapeutic maneuver in patients with predisposing conditions for bacterial overgrowth in whom unexplained diarrhea or steatorrhea develops.

► Treatment

Where possible, the anatomic defect that has potentiated bacterial overgrowth should be corrected. Otherwise, treatment as follows for 1–2 weeks with oral broad-spectrum antibiotics effective against enteric aerobes and anaerobes usually leads to dramatic improvement: twice daily ciprofloxacin 500 mg, norfloxacin 400 mg, or amoxicillin clavulanate 875 mg, or a combination of metronidazole 250 mg three times daily plus either trimethoprim-sulfamethoxazole (one double-strength tablet) twice daily or cephalexin 250 mg four times daily. Rifaximin 400 mg three times daily is a nonabsorbable antibiotic that also appears to be effective but has fewer side effects than the other systemically absorbed antibiotics.

In patients in whom symptoms recur off antibiotics, cyclic therapy (eg, 1 week out of 4) may be sufficient. Continuous antibiotics should be avoided, if possible, to avoid development of bacterial antibiotic resistance.

In patients with severe intestinal dysmotility, treatment with small doses of octreotide may prove to be of benefit.

Gasbarrini A et al. Methodology and indications of H₂-breath testing in gastrointestinal diseases: the Rome Consensus Conference. *Aliment Pharmacol Ther*. 2009 Mar 30;(29 Suppl 1):1–49. [PMID: 19344474]

Lombardo L et al. Increased incidence of small intestinal bacterial overgrowth during proton pump inhibitor therapy. *Clin Gastroenterol Hepatol*. 2010 Jun;8(6):504–8. [PMID: 20060064]

Quigley EM et al. Small intestinal bacterial overgrowth. *Infect Dis Clin North Am*. 2010 Dec; 24(4):943–59. [PMID: 20937459]

4. Short Bowel Syndrome

Short bowel syndrome is the malabsorptive condition that arises secondary to removal of significant segments of the small intestine. The most common causes in adults are Crohn disease, mesenteric infarction, radiation enteritis, volvulus, tumor resection, and trauma. The type and degree of malabsorption depend on the length and site of the resection and the degree of adaptation of the remaining bowel.

► Terminal Ileal Resection

Resection of the terminal ileum results in malabsorption of bile salts and vitamin B₁₂, which are normally absorbed in this region. Patients with low serum vitamin B₁₂ levels, an abnormal Schilling test, or resection of over 50 cm of ileum require monthly intramuscular vitamin B₁₂ injections. In patients with < 100 cm of ileal resection, bile salt malabsorption stimulates fluid secretion from the colon, resulting in watery diarrhea. This may be treated with bile salt binding resins (cholestyramine, 2–4 g orally three times daily with meals). Resection of over 100 cm of ileum leads to a reduction in the bile salt pool that results in steatorrhea and malabsorption of fat-soluble vitamins. Treatment is with a low-fat diet and vitamins supplemented with medium-chain triglycerides, which do not require micellar solubilization. Unabsorbed fatty acids bind with calcium, reducing its absorption and enhancing the absorption of oxalate. Oxalate kidney stones may develop. Calcium supplements should be administered to bind oxalate and increase serum calcium. Cholesterol gallstones due to decreased bile salts are common also. In patients with resection of the ileocolonic valve, bacterial overgrowth may occur in the small intestine, further complicating malabsorption (as outlined above).

► Extensive Small Bowel Resection

Resection of up to 40–50% of the total length of small intestine usually is well tolerated. A more massive resection may result in “short-bowel syndrome,” characterized by weight loss and diarrhea due to nutrient, water, and electrolyte malabsorption. After resection, the remaining small

intestine has a remarkable ability to adapt, gradually increasing its absorptive capacity up to fourfold over 1 year. The colon also plays an important role in absorption of fluids, electrolytes, and digestion of complex carbohydrates (through bacterial fermentation to short-chain fatty acids) after small bowel resection. If the colon is preserved, 100 cm of proximal jejunum may be sufficient to maintain adequate oral nutrition with a low-fat, high complex-carbohydrate diet, though fluid and electrolyte losses may still be significant. In patients in whom the colon has been removed, at least 200 cm of proximal jejunum is typically required to maintain oral nutrition. Duodenal resection may result in folate, iron, or calcium malabsorption. Levels of other minerals such as zinc, selenium, and magnesium should be monitored. Parenteral vitamin supplementation may be necessary. Antidiarrheal agents (loperamide, 2–4 mg orally three times daily) slow transit and reduce diarrheal volume. Octreotide reduces intestinal transit time and fluid and electrolyte secretion. Gastric hypersecretion initially complicates intestinal resection and should be treated with proton pump inhibitors.

Patients with < 100–200 cm of proximal jejunum remaining almost always require parenteral nutrition. Of patients who do, the estimated annual mortality rate is 2–5% per year. Death is most commonly due to TPN-induced liver disease, sepsis, or loss of venous access. Teduglutide is an investigational glucagon-like peptide-2 analogue that stimulates small bowel growth and absorption. In clinical trials, it has resulted in a reduced need for parenteral nutrition. Small intestine transplantation is now being performed with reported 5-year graft survival rates of 40%. Currently, it is performed chiefly in patients who develop serious problems due to parenteral nutrition.

Jeppesen PB et al. Randomised placebo-controlled trial of teduglutide in reducing parenteral nutrition and/or intravenous fluid requirements in patients with short bowel syndrome. *Gut*. 2011 Jul;60(7):902–14. [PMID: 21317170]

Sudan D. Long-term outcomes and quality of life after intestine transplantation. *Curr Opin Organ Transplant*. 2010 Jun;15(3):357–60. [PMID: 20445450]

5. Lactase Deficiency



ESSENTIALS OF DIAGNOSIS

- ▶ Diarrhea, bloating, flatulence, and abdominal pain after ingestion of milk-containing products.
- ▶ Diagnosis supported by symptomatic improvement on lactose-free diet.
- ▶ Diagnosis confirmed by hydrogen breath test.

▶ General Considerations

Lactase is a brush border enzyme that hydrolyzes the disaccharide lactose into glucose and galactose. The concentration of lactase enzyme levels is high at birth but declines steadily in most people of non-European ancestry during

childhood and adolescence and into adulthood. Thus, approximately 50 million people in the United States have partial to complete lactose intolerance. As many as 90% of Asian Americans, 70% of African Americans, 95% of Native Americans, 50% of Mexican Americans, and 60% of Jewish Americans are lactose intolerant compared with < 25% of white adults. Lactase deficiency may also arise secondary to other gastrointestinal disorders that affect the proximal small intestinal mucosa. These include Crohn disease, sprue, viral gastroenteritis, giardiasis, short bowel syndrome, and malnutrition. Malabsorbed lactose is fermented by intestinal bacteria, producing gas and organic acids. The nonmetabolized lactose and organic acids result in an increased stool osmotic load with an obligatory fluid loss.

▶ Clinical Findings

A. Symptoms and Signs

Patients have great variability in clinical symptoms, depending both on the severity of lactase deficiency and the amount of lactose ingested. Because of the nonspecific nature of these symptoms, there is a tendency for both lactose-intolerant and lactose-tolerant individuals to mistakenly attribute a variety of abdominal symptoms to lactose intolerance. Most patients with lactose intolerance can drink one or two 8 oz glasses of milk daily without symptoms if taken with food at wide intervals, though rare patients have almost complete intolerance. With mild to moderate amounts of lactose malabsorption, patients may experience bloating, abdominal cramps, and flatulence. With higher lactose ingestions, an osmotic diarrhea will result. Isolated lactase deficiency does not result in other signs of malabsorption or weight loss. If these findings are present, other gastrointestinal disorders should be pursued. Diarrheal specimens reveal an increased osmotic gap and a pH of < 6.0.

B. Laboratory Findings

The most widely available test for the diagnosis of lactase deficiency is the hydrogen breath test. After ingestion of 50 g of lactose, a rise in breath hydrogen of > 20 ppm within 90 minutes is a positive test, indicative of bacterial carbohydrate metabolism. In clinical practice, many clinicians prescribe an empiric trial of a lactose-free diet for 2 weeks. Resolution of symptoms (bloating, flatulence, diarrhea) is suggestive of lactase deficiency (though a placebo response cannot be excluded) and may be confirmed, if necessary, with a breath hydrogen study.

▶ Differential Diagnosis

The symptoms of late-onset lactose intolerance are nonspecific and may mimic a number of gastrointestinal disorders, such as inflammatory bowel disease, mucosal malabsorptive disorders, irritable bowel syndrome, and pancreatic insufficiency. Furthermore, lactase deficiency frequently develops secondary to other gastrointestinal disorders (as listed above). Concomitant lactase deficiency should always be considered in these gastrointestinal disorders.

► Treatment

The goal of treatment in patients with isolated lactase deficiency is achieving patient comfort. Patients usually find their “threshold” of intake at which symptoms will occur. Foods that are high in lactose include milk (12 g/cup), ice cream (9 g/cup), and cottage cheese (8 g/cup). Aged cheeses have a lower lactose content (0.5 g/oz). Unpasteurized yogurt contains bacteria that produce lactase and is generally well tolerated.

By spreading dairy product intake throughout the day in quantities of < 12 g of lactose (one cup of milk), most patients can take dairy products without symptoms and do not require lactase supplements. Most food markets provide milk that has been pretreated with lactase, rendering it 70–100% lactose free. Lactase enzyme replacement is commercially available as nonprescription formulations (Lactaid, Lactrase, Dairy Ease). Caplets or drops of lactase may be taken with milk products, improving lactose absorption and eliminating symptoms. The number of caplets ingested depends on the degree of lactose intolerance. Patients who choose to restrict or eliminate milk products may have increased risk of osteoporosis. Calcium supplementation (calcium carbonate 500 mg orally two to three times daily) is recommended for susceptible patients.

Casellas F et al. Subjective perception of lactose intolerance does not always indicate lactose malabsorption. *Clin Gastroenterol Hepatol.* 2010 Jul;8(7):581–6. [PMID: 20385250]

Suchy FJ et al. National Institutes of Health Consensus Development Conference: lactose intolerance and health. *Ann Intern Med.* 2010 Jun 15;152(12):792–6. [PMID: 20404261]

INTESTINAL MOTILITY DISORDERS

1. Acute Paralytic Ileus



ESSENTIALS OF DIAGNOSIS

- Precipitating factors: surgery, peritonitis, electrolyte abnormalities, medications, severe medical illness.
- Nausea, vomiting, obstipation, distention.
- Minimal abdominal tenderness; decreased bowel sounds.
- Plain abdominal radiography with gas and fluid distention in small and large bowel.

► General Considerations

Ileus is a condition in which there is neurogenic failure or loss of peristalsis in the intestine in the absence of any mechanical obstruction. It is commonly seen in hospitalized patients as a result of: (1) intra-abdominal processes such as recent gastrointestinal or abdominal surgery or peritoneal irritation (peritonitis, pancreatitis, ruptured viscus, hemorrhage); (2)

severe medical illness such as pneumonia, respiratory failure requiring intubation, sepsis or severe infections, uremia, diabetic ketoacidosis, and electrolyte abnormalities (hypokalemia, hypercalcemia, hypomagnesemia, hypophosphatemia); and (3) medications that affect intestinal motility (opioids, anticholinergics, phenothiazines). Following surgery, small intestinal motility usually normalizes first (often within hours), followed by the stomach (24–48 hours), and the colon (48–72 hours). Postoperative ileus is reduced by the use of patient-controlled or epidural analgesia and avoidance of intravenous opioids as well as early ambulation, gum chewing, and initiation of a clear liquid diet.

► Clinical Findings

A. Symptoms and Signs

Patients who are conscious report mild diffuse, continuous abdominal discomfort with nausea and vomiting. Generalized abdominal distention is present with minimal abdominal tenderness but no signs of peritoneal irritation (unless due to the primary disease). Bowel sounds are diminished to absent.

B. Laboratory Findings

The laboratory abnormalities are attributable to the underlying condition. Serum electrolytes, including potassium, magnesium, phosphorus, and calcium, should be obtained to exclude abnormalities as contributing factors.

C. Imaging

Plain film radiography of the abdomen demonstrates distended gas-filled loops of small and large intestine. Air-fluid levels may be seen. Under some circumstances, it may be difficult to distinguish ileus from partial small bowel obstruction. A CT scan may be useful in such instances to exclude mechanical obstruction, especially in postoperative patients.

► Differential Diagnosis

Ileus must be distinguished from mechanical obstruction of the small bowel or proximal colon. Pain from small bowel mechanical obstruction is usually intermittent, cramping, and associated initially with profuse vomiting. Acute gastroenteritis, acute appendicitis, and acute pancreatitis may all present with ileus.

► Treatment

The primary medical or surgical illness that has precipitated adynamic ileus should be treated. Most cases of ileus respond to restriction of oral intake with gradual liberalization of diet as bowel function returns. Severe or prolonged ileus requires nasogastric suction and parenteral administration of fluids and electrolytes. Alvimopan is a peripherally acting mu-opioid receptor antagonist with limited absorption or systemic activity that reverses opioid-induced inhibition of intestinal motility. In five randomized controlled trials, it reduced the time to first flatus, bowel movement, solid meal, and hospital discharge

compared with placebo in postoperative patients. Although its utility in clinical practice is unproven, alvimopan may be considered in patients undergoing partial large or small bowel resection when postoperative opioid therapy is anticipated.

Gaines SL et al. Real world efficacy of alvimopan on elective bowel resection patients: an analysis of statistical versus clinical significance. *Am J Surg.* 2012 Mar; 203(3):308–11. [PMID: 22178482]

Stewart D et al. Management of postoperative ileus. *Dis Mon.* 2010 Apr;56(4):204–10. [PMID: 20350653]

2. Acute Colonic Pseudo-obstruction (Ogilvie Syndrome)



ESSENTIALS OF DIAGNOSIS

- ▶ Severe abdominal distention.
- ▶ Arises in postoperative state or with severe medical illness.
- ▶ May be precipitated by electrolyte imbalances, medications.
- ▶ Absent to mild abdominal pain; minimal tenderness.
- ▶ Massive dilation of cecum or right colon.

▶ General Considerations

Spontaneous massive dilation of the cecum and proximal colon may occur in a number of different settings in hospitalized patients. Progressive cecal dilation may lead to spontaneous perforation with dire consequences. The risk of perforation correlates poorly with absolute cecal size and duration of colonic distention. Early detection and management are important to reduce morbidity and mortality. Colonic pseudo-obstruction is most commonly detected in postsurgical patients (mean 3–5 days), after trauma, and in medical patients with respiratory failure, metabolic imbalance, malignancy, myocardial infarction, congestive heart failure, pancreatitis, or a recent neurologic event (stroke, subarachnoid hemorrhage, trauma). Liberal use of opioids or anticholinergic agents may precipitate colonic pseudo-obstruction in susceptible patients. It may also occur as a manifestation of colonic ischemia. The etiology of colonic pseudo-obstruction is unknown, but either an increase in gut sympathetic activity or a decrease in sacral parasympathetic activity of the distal colon, or both, is hypothesized to impair colonic motility.

▶ Clinical Findings

A. Symptoms and Signs

Many patients are on ventilatory support or are unable to report symptoms due to altered mental status. Abdominal distention is frequently noted by the clinician as the first sign, often leading to a plain film radiograph that demonstrates

colonic dilation. Some patients are asymptomatic, although most report constant but mild abdominal pain. Nausea and vomiting may be present. Bowel movements may be absent, but up to 40% of patients continue to pass flatus or stool. Abdominal tenderness with some degree of guarding or rebound tenderness may be detected; however, signs of peritonitis are absent unless perforation has occurred. Bowel sounds may be normal or decreased.

B. Laboratory Findings

Laboratory findings reflect the underlying medical or surgical problems. Serum sodium, potassium, magnesium, phosphorus, and calcium should be obtained. Significant fever or leukocytosis raises concern for colonic ischemia or perforation.

C. Imaging

Radiographs demonstrate colonic dilation, usually confined to the cecum and proximal colon. The upper limits of normal for cecal size is 9 cm. A cecal diameter > 10–12 cm is associated with an increased risk of colonic perforation. Varying amounts of small intestinal dilation and air-fluid levels due to adynamic ileus may be seen. Because the dilated appearance of the colon may raise concern that there is a distal colonic mechanical obstruction due to malignancy, volvulus, or fecal impaction, a CT scan or water-soluble (diatrizoate meglumine) enema may sometimes be performed.

▶ Differential Diagnosis

Colonic pseudo-obstruction should be distinguished from distal colonic mechanical obstruction (as above) and toxic megacolon, which is acute dilation of the colon due to inflammation (inflammatory bowel disease) or infection (*C difficile*-associated colitis, CMV). Patients with toxic megacolon manifest fever; dehydration; significant abdominal pain; leukocytosis; and diarrhea, which is often bloody.

▶ Treatment

Conservative treatment is the appropriate first step for patients with no or minimal abdominal tenderness, no fever, no leukocytosis, and a cecal diameter < 12 cm. The underlying illness is treated appropriately. A nasogastric tube and a rectal tube should be placed. Patients should be ambulated or periodically rolled from side to side and to the knee-chest position in an effort to promote expulsion of colonic gas. All drugs that reduce intestinal motility, such as opioids, anticholinergics, and calcium channel blockers, are discontinued if possible. Enemas may be administered judiciously if large amounts of stool are evident on radiography. Oral laxatives are not helpful and may cause perforation, pain, or electrolyte abnormalities.

Conservative treatment is successful in over 80% of cases within 1–2 days. Patients must be watched for signs of worsening distention or abdominal tenderness. Cecal size should be assessed by abdominal radiographs every 12 hours. Intervention should be considered in patients with

any of the following: (1) no improvement or clinical deterioration after 24–48 hours of conservative therapy; (2) cecal dilation > 10 cm for a prolonged period (> 3–4 days); (3) patients with cecal dilation > 12 cm. Neostigmine injection should be given unless contraindicated. A single dose (2 mg intravenously) results in rapid (within 30 minutes) colonic decompression in 75–90% of patients. Cardiac monitoring during neostigmine infusion is indicated for possible bradycardia that may require atropine administration. Colonoscopic decompression is indicated in patients who fail to respond to neostigmine. Colonic decompression with aspiration of air or placement of a decompression tube is successful in 70% of patients. However, the procedure is technically difficult in an unprepared bowel and has been associated with perforations in the distended colon. Dilation recurs in up to 50% of patients. In patients in whom colonoscopy is unsuccessful, a tube cecostomy can be created through a small laparotomy or with percutaneous radiologically guided placement.

► Prognosis

In most cases, the prognosis is related to the underlying illness. The risk of perforation or ischemia is increased with cecal diameter > 12 cm and when distention has been present for more than 6 days. With aggressive therapy, the development of perforation is unusual.

Harrison ME et al; ASGE Standards of Practice Committee. The role of endoscopy in the management of patients with known and suspected colonic obstruction and pseudo-obstruction. *Gastrointest Endosc.* 2010 Apr;71(4):669–79. [PMID: 20363408]

3. Chronic Intestinal Pseudo-obstruction & Gastroparesis

Gastroparesis and chronic intestinal pseudo-obstruction are chronic conditions characterized by intermittent, waxing and waning symptoms and signs of gastric or intestinal obstruction in the absence of any mechanical lesions to account for the findings. They are caused by a heterogeneous group of endocrine disorders (diabetes mellitus, hypothyroidism, cortisol deficiency), postsurgical conditions (vagotomy, partial gastric resection, fundoplication, gastric bypass, Whipple procedure), neurologic conditions (Parkinson disease, muscular and myotonic dystrophy, autonomic dysfunction, multiple sclerosis, postpolio syndrome, porphyria), rheumatologic syndromes (progressive systemic sclerosis), infections (postviral, Chagas disease), amyloidosis, paraneoplastic syndromes, medications, and eating disorders (anorexia); a cause may not always be identified.

► Clinical Findings

A. Symptoms and Signs

Gastric involvement leads to chronic or intermittent symptoms of gastroparesis with postprandial fullness (early satiety), nausea, and vomiting (1–3 hours after meals). Patients with predominantly small bowel involvement may

have abdominal distention, vomiting, diarrhea, and varying degrees of malnutrition. Abdominal pain is not common and should prompt investigation for structural causes of obstruction. Bacterial overgrowth in the stagnant intestine may result in malabsorption. Colonic involvement may result in constipation or alternating diarrhea and constipation.

B. Imaging

Plain film radiography may demonstrate dilation of the esophagus, stomach, small intestine, or colon resembling ileus or mechanical obstruction. Mechanical obstruction of the stomach, small intestine, or colon is much more common than gastroparesis or intestinal pseudo-obstruction and must be excluded with endoscopy or CT or barium enterography, especially in patients with prior surgery, recent onset of symptoms, or abdominal pain. In cases of unclear origin, studies based on the clinical picture are obtained to exclude underlying systemic disease. Gastric scintigraphy with a low-fat solid meal is the optimal means for assessing gastric emptying. Gastric retention of 60% after 2 hours or more than 10% after 4 hours is abnormal. Small bowel manometry is useful for distinguishing visceral from myopathic disorders and for excluding cases of mechanical obstruction that are otherwise difficult to diagnose by endoscopy or radiographic studies.

► Treatment

There is no specific therapy for gastroparesis or pseudo-obstruction. Acute exacerbations are treated with nasogastric suction and intravenous fluids. Long-term treatment is directed at maintaining nutrition. Patients should eat small, frequent meals that are low in fiber, milk, gas-forming foods, and fat. Some patients may require liquid enteral supplements. Agents that reduce gastrointestinal motility (opioids, anticholinergics, calcium channel blockers) should be avoided. In diabetic patients, glucose levels should be maintained below 200 mg/dL, as hyperglycemia may slow gastric emptying even in the absence of diabetic neuropathy, and amylin analogs (exenatide or pramlintide) should be discontinued. Metoclopramide (5–20 mg orally or 5–10 mg intravenously or subcutaneously four times daily) and erythromycin (50–125 mg orally three times daily) before meals are each of benefit in treatment of gastroparesis but not small bowel dysmotility. The use of metoclopramide for more than 3 months is associated with an increased risk of tardive dyskinesia and should be avoided. The elderly are at greatest risk. Domperidone (20–30 mg four times daily) is another antidopaminergic agent that enhances gastric emptying and has efficacy as an antiemetic agent. Unlike metoclopramide, it does not cross the blood-brain barrier and therefore is devoid of neuropsychiatric side effects. Although unavailable in the United States, it is available in most other countries, where its use is preferred. Gastric electrical stimulation with internally implanted neurostimulators has shown reduction in nausea and vomiting in small studies and one controlled trial in some patients with severe gastroparesis; however, the mechanism of action is uncertain as improvement is not

correlated with changes in gastric emptying. Bacterial overgrowth should be treated with intermittent antibiotics (see above). Patients with predominant small bowel distention may require a venting gastrostomy to relieve distress. Some patients may require placement of a jejunostomy for long-term enteral nutrition. Patients unable to maintain adequate enteral nutrition require TPN or small bowel transplantation. Difficult cases should be referred to centers with expertise in this area.

Camilleri M et al. Epidemiology, mechanisms, and management of diabetic gastroparesis. *Clin Gastroenterol Hepatol.* 2011 Jan;9(1):5–12. [PMID: 20951838]

Reddymasu SC et al. Severe gastroparesis: medical therapy or gastric electrical stimulation. *Clin Gastroenterol Hepatol.* 2010 Feb;8(2):117–24. [PMID: 19765675]

APPENDICITIS



ESSENTIALS OF DIAGNOSIS

- ▶ *Early:* periumbilical pain; *later:* right lower quadrant pain and tenderness.
- ▶ Anorexia, nausea and vomiting, obstipation.
- ▶ Tenderness or localized rigidity at McBurney point.
- ▶ Low-grade fever and leukocytosis.

▶ General Considerations

Appendicitis is the most common abdominal surgical emergency, affecting approximately 10% of the population. It occurs most commonly between the ages of 10 and 30 years. It is initiated by obstruction of the appendix by a fecalith, inflammation, foreign body, or neoplasm. Obstruction leads to increased intraluminal pressure, venous congestion, infection, and thrombosis of intramural vessels. If untreated, gangrene and perforation develop within 36 hours.

▶ Clinical Findings

A. Symptoms and Signs

Appendicitis usually begins with vague, often colicky periumbilical or epigastric pain. Within 12 hours the pain shifts to the right lower quadrant, manifested as a steady ache that is worsened by walking or coughing. Almost all patients have nausea with one or two episodes of vomiting. Protracted vomiting or vomiting that begins before the onset of pain suggests another diagnosis. A sense of constipation is typical, and some patients administer cathartics in an effort to relieve their symptoms—though some report diarrhea. Low-grade fever (< 38°C) is typical; high fever or rigors suggest another diagnosis or appendiceal perforation.

On physical examination, localized tenderness with guarding in the right lower quadrant can be elicited with gentle palpation with one finger. When asked to cough,

patients may be able to precisely localize the painful area, a sign of peritoneal irritation. Light percussion may also elicit pain. Although rebound tenderness is also present, it is unnecessary to elicit this finding if the above signs are present. The psoas sign (pain on passive extension of the right hip) and the obturator sign (pain with passive flexion and internal rotation of the right hip) are indicative of adjacent inflammation and strongly suggestive of appendicitis.

B. Atypical Presentations of Appendicitis

Owing to the variable location of the appendix, there are a number of “atypical” presentations. Because the retrocecal appendix does not touch the anterior abdominal wall, the pain remains less intense and poorly localized; abdominal tenderness is minimal and may be elicited in the right flank. The psoas sign may be positive. With pelvic appendicitis, there is pain in the lower abdomen, often on the left, with an urge to urinate or defecate. Abdominal tenderness is absent, but tenderness is evident on pelvic or rectal examination; the obturator sign may be present. In the elderly, the diagnosis of appendicitis is often delayed because patients present with minimal, vague symptoms and mild abdominal tenderness. Appendicitis in pregnancy may present with pain in the right lower quadrant, periumbilical area, or right subcostal area owing to displacement of the appendix by the uterus.

C. Laboratory Findings

Moderate leukocytosis (10,000–20,000/mcL) with neutrophilia is common. Microscopic hematuria and pyuria are present in 25% of patients.

D. Imaging

Both abdominal ultrasound and CT scanning are useful in diagnosing appendicitis as well as excluding other diseases presenting with similar symptoms, including adnexal disease in younger women. However, CT scanning appears to be more accurate (sensitivity 94%, specificity 95%, positive likelihood ratio 13.3, negative likelihood ratio 0.09). Abdominal CT scanning is also useful in cases of suspected appendiceal perforation to diagnose a periappendiceal abscess. In patients in whom there is a clinically high suspicion of appendicitis, some surgeons feel that preoperative diagnostic imaging is unnecessary. However, studies suggest that even in this group, imaging studies suggest an alternative diagnosis in up to 15%.

▶ Differential Diagnosis

Given its frequency and myriad presentations, appendicitis should be considered in the differential diagnosis of all patients with abdominal pain. It is difficult to reliably diagnose the disease in some cases. A several-hour period of close observation with reassessment usually clarifies the diagnosis. Absence of the classic migration of pain (from the epigastrium to the right lower abdomen), right lower quadrant pain, fever, or guarding makes appendicitis less likely. Ten to twenty percent of patients with suspected appendicitis have either a negative examination at laparotomy or

an alternative surgical diagnosis. The widespread use of ultrasonography and CT has reduced the number of incorrect diagnoses to < 2%. Still, in some cases diagnostic laparotomy or laparoscopy is required. The most common causes of diagnostic confusion are gastroenteritis and gynecologic disorders. Viral gastroenteritis presents with nausea, vomiting, low-grade fever, and diarrhea and can be difficult to distinguish from appendicitis. The onset of vomiting before pain makes appendicitis less likely. As a rule, the pain of gastroenteritis is more generalized and the tenderness less well localized. Acute salpingitis or tubo-ovarian abscess should be considered in young, sexually active women with fever and bilateral abdominal or pelvic tenderness. A twisted ovarian cyst may also cause sudden severe pain. The sudden onset of lower abdominal pain in the middle of the menstrual cycle suggests mittelschmerz. Sudden severe abdominal pain with diffuse pelvic tenderness and shock suggests a ruptured ectopic pregnancy. A positive pregnancy test and pelvic ultrasonography are diagnostic. Retrocecal or retroileal appendicitis (often associated with pyuria or hematuria) may be confused with ureteral colic or pyelonephritis. Other conditions that may resemble appendicitis are diverticulitis, Meckel diverticulitis, carcinoid of the appendix, perforated colonic cancer, Crohn ileitis, perforated peptic ulcer, cholecystitis, and mesenteric adenitis. It is virtually impossible to distinguish appendicitis from Meckel diverticulitis, but both require surgical treatment.

► Complications

Perforation occurs in 20% of patients and should be suspected in patients with pain persisting for over 36 hours, high fever, diffuse abdominal tenderness or peritoneal findings, a palpable abdominal mass, or marked leukocytosis. Localized perforation results in a contained abscess, usually in the pelvis. A free perforation leads to suppurative peritonitis with toxicity. Septic thrombophlebitis (pylphlebitis) of the portal venous system is rare and suggested by high fever, chills, bacteremia, and jaundice.

► Treatment

The treatment of uncomplicated appendicitis is surgical appendectomy. When possible, a laparoscopic approach is preferred to open laparotomy. Prior to surgery, patients should be given broad-spectrum antibiotics with gram-negative and anaerobic coverage to reduce the incidence of postoperative infections. Recommended preoperative intravenous regimens include cefoxitin or cefotetan 1-2 g every 8 hours; ampicillin-sulbactam 3 g every 6 hours; or ertapenem 1 g as a single dose. Emergency appendectomy is also required in patients with perforated appendicitis with generalized peritonitis.

The optimal treatment of stable patients with perforated appendicitis and a contained abscess is controversial. Surgery in this setting can be difficult. Many recommend percutaneous CT-guided drainage of the abscess with intravenous fluids and antibiotics to allow the inflammation to subside. An interval appendectomy may be performed after 6 weeks to prevent recurrent appendicitis.

► Prognosis

The mortality rate from uncomplicated appendicitis is extremely low. Even with perforated appendicitis, the mortality rate in most groups is only 0.2%, though it approaches 15% in the elderly.

Kouhia ST et al. Long-term follow-up of a randomized clinical trial of open versus laparoscopic appendectomy. *Br J Surg*. 2010 Sep;97(9):1395-400. [PMID: 20632312]
Raja AS et al. Negative appendectomy rate in the era of CT: an 18-year perspective. *Radiology*. 2010 Aug;256(2):460-5. [PMID: 20529988]

INTESTINAL TUBERCULOSIS

Intestinal tuberculosis is common in underdeveloped countries. Previously rare in the United States, its incidence has been rising in immigrant groups and patients with AIDS. It is caused by both *Mycobacterium tuberculosis* and *M bovis*. Active pulmonary disease is present in < 50% of patients. The most frequent site of involvement is the ileocecal region; however, any region of the gastrointestinal tract may be involved. Intestinal tuberculosis may cause mucosal ulcerations or scarring and fibrosis with narrowing of the lumen. Patients may be without symptoms or complain of chronic abdominal pain, obstructive symptoms, weight loss, and diarrhea. An abdominal mass may be palpable. Complications include intestinal obstruction, hemorrhage, and fistula formation. The purified protein derivative (PPD) skin test may be negative, especially in patients with weight loss or AIDS. Barium radiography may demonstrate mucosal ulcerations, thickening, or stricture formation. Abdominal CT may show thickening of the cecum and ileocecal valve and massive lymphadenopathy. Colonoscopy may demonstrate an ulcerated mass, multiple ulcers with steep edges and adjacent small sessile polyps, small ulcers or erosions, or small diverticula, most commonly in the ileocecal region. The differential diagnosis includes Crohn disease, carcinoma, and intestinal amebiasis. The diagnosis is established by either endoscopic or surgical biopsy revealing acid-fast bacilli, caseating granuloma, or positive cultures from the organism. Detection of tubercle bacilli in biopsy specimens by PCR is now the most sensitive means of diagnosis.

Treatment with standard antituberculous regimens is effective.

Makharia GK et al. Clinical, endoscopic, and histologic differentiations between Crohn's disease and intestinal tuberculosis. *Am J Gastroenterol*. 2010 Mar;105(3):642-51. [PMID: 20087333]

PROTEIN-LOSING ENTEROPATHY

Protein-losing enteropathy comprises a number of conditions that result in excessive loss of serum proteins into the gastrointestinal tract. The essential diagnostic features are hypoalbuminemia and an elevated fecal α_1 -antitrypsin level.

The normal intact gut epithelium prevents the loss of serum proteins. Proteins may be lost through one of three

mechanisms: (1) mucosal disease with ulceration, resulting in the loss of proteins across the disrupted mucosal surface, such as in chronic gastric ulcer, gastric carcinoma, or inflammatory bowel disease; (2) lymphatic obstruction, resulting in the loss of protein-rich chylous fluid from mucosal lacteals, such as in primary intestinal lymphangiectasia, constrictive pericarditis or congestive heart failure, Whipple disease or tuberculosis, Kaposi sarcoma or lymphoma, retroperitoneal fibrosis, or sarcoidosis; and (3) idiopathic change in permeability of mucosal capillaries and conductance of interstitium, resulting in “weeping” of protein-rich fluid from the mucosal surface, such as in Ménétrier disease, Zollinger-Ellison syndrome, viral or eosinophilic gastroenteritis, celiac disease, giardiasis or hookworm, common variable immunodeficiency, systemic lupus erythematosus, amyloidosis, or allergic protein-losing enteropathy.

Hypoalbuminemia is the sine qua non of protein-losing enteropathy. However, a number of other serum proteins such as α_1 -antitrypsin also are lost from the gut epithelium. In protein-losing enteropathy caused by lymphatic obstruction, loss of lymphatic fluid commonly results in lymphocytopenia ($< 1000/\text{mL}$), hypoglobulinemia, and hypocholesterolemia.

In most cases, protein-losing enteropathy is recognized as a sequela of a known gastrointestinal disorder. In patients in whom the cause is unclear, evaluation is indicated and is guided by the clinical suspicion. Protein-losing enteropathy must be distinguished from other causes of hypoalbuminemia, which include liver disease and nephrotic syndrome; and from congestive heart failure. Protein-losing enteropathy is confirmed by determining the gut α_1 -antitrypsin clearance (24-hour volume of feces \times stool concentration of α_1 -antitrypsin \div serum α_1 -antitrypsin concentration). A clearance of more than 27 mL/24 h is abnormal.

Laboratory evaluation of protein-losing enteropathy includes serum protein electrophoresis, lymphocyte count, and serum cholesterol to look for evidence of lymphatic obstruction. Serum ANA and C3 levels are useful to screen for autoimmune disorders. Stool samples should be examined for ova and parasites. Evidence of malabsorption is evaluated by means of a stool qualitative fecal fat determination. Intestinal imaging is performed with small bowel enteroscopy biopsy, CT enterography, or wireless capsule endoscopy of the small intestine. Colonic diseases are excluded with colonoscopy. A CT scan of the abdomen is performed to look for evidence of neoplasms or lymphatic obstruction. Rarely, lymphangiography is helpful. In some situations, laparotomy with full-thickness intestinal biopsy is required to establish a diagnosis.

Treatment is directed at the underlying cause. Patients with lymphatic obstruction benefit from low-fat diets supplemented with medium-chain triglycerides. Case reports suggest that octreotide may lead to symptomatic and nutritional improvement in some patients.

Umar SB et al. Protein-losing enteropathy: case illustrations and clinical review. *Am J Gastroenterol.* 2010 Jan;105(1):43–9. [PMID: 19789526]

DISEASES OF THE COLON & RECTUM

(See Chapter 39 for Colorectal Cancer.)

IRRITABLE BOWEL SYNDROME

ESSENTIALS OF DIAGNOSIS

- ▶ Chronic functional disorder characterized by abdominal pain or discomfort with alterations in bowel habits.
- ▶ Symptoms usually begin in late teens to early twenties.
- ▶ Limited evaluation to exclude organic causes of symptoms.

▶ General Considerations

The functional gastrointestinal disorders are characterized by a variable combination of chronic or recurrent gastrointestinal symptoms *not explicable by the presence of structural or biochemical abnormalities*. Several clinical entities are included under this broad rubric, including chest pain of unclear origin (noncardiac chest pain), functional dyspepsia, and biliary dyskinesia (sphincter of Oddi dysfunction). There is a large overlap among these entities. For example, over 50% of patients with noncardiac chest pain and over one-third with functional dyspepsia also have symptoms compatible with irritable bowel syndrome. In none of these disorders is there a definitive diagnostic study. Rather, the diagnosis is a subjective one based on the presence of a compatible profile and the exclusion of similar disorders.

Irritable bowel syndrome can be defined, therefore, as an idiopathic clinical entity characterized by chronic (more than 6 months) abdominal pain or discomfort that occurs in association with altered bowel habits. These symptoms may be continuous or intermittent. Consensus definition of irritable bowel syndrome is abdominal discomfort or pain that has two of the following three features: (1) relieved with defecation, (2) onset associated with a change in frequency of stool, or (3) onset associated with a change in form (appearance) of stool. Other symptoms supporting the diagnosis include abnormal stool frequency; abnormal stool form (lumpy or hard; loose or watery); abnormal stool passage (straining, urgency, or feeling of incomplete evacuation); passage of mucus; and bloating or a feeling of abdominal distention.

Patients may have other somatic or psychological complaints such as dyspepsia, heartburn, chest pain, headaches, fatigue, myalgias, urologic dysfunction, gynecologic symptoms, anxiety, or depression.

The disorder is a common problem presenting to both gastroenterologists and primary care physicians. Up to 10% of the adult population have symptoms compatible with the diagnosis, but most never seek medical attention. Approximately two-thirds of patients with irritable bowel syndrome are women.

► Pathogenesis

A number of pathophysiologic mechanisms have been identified and may have varying importance in different individuals.

A. Abnormal Motility

A variety of abnormal myoelectrical and motor abnormalities have been identified in the colon and small intestine. In some cases, these are temporally correlated with episodes of abdominal pain or emotional stress. Whether they represent a primary motility disorder or are secondary to psychosocial stress is debated. Differences between patients with constipation-predominant and diarrhea-predominant syndromes are reported.

B. Visceral Hypersensitivity

Patients often have a lower visceral pain threshold, reporting abdominal pain at lower volumes of colonic gas insufflation or colonic balloon inflation than controls. Many patients complain of bloating and distention, which may be due to a number of different factors including increased visceral sensitivity, increased gas production (due to small bowel bacterial overgrowth or carbohydrate malabsorption), impaired gas transit through the intestine, or impaired rectal expulsion. Many patients report rectal urgency despite small rectal volumes of stool.

C. Enteric Infection

Symptoms compatible with irritable bowel syndrome develop within 1 year in up to 10% of patients after an episode of bacterial gastroenteritis compared with < 2% of controls. Women and patients with increased life stressors at the onset of gastroenteritis appear to be at increased risk for developing “postinfectious” irritable bowel syndrome. Increased inflammatory cells have been found in the mucosa, submucosa, and muscularis of some patients with irritable bowel syndrome, but their importance is unclear. Chronic inflammation is postulated by some investigators to contribute to alterations in motility or visceral hypersensitivity.

Some investigators suggest that alterations in the numbers and distribution of bacterial species (estimated 30,000 different species) may affect bowel transit time, gas production, and sensitivity. An increase in breath hydrogen or methane excretion after lactulose ingestion in 65% of patients with irritable bowel syndrome has been reported, believed by some investigators to indicate small intestinal bacterial overgrowth. However, many investigators dispute these findings because overgrowth was confirmed in only 4% of patients using jejunal aspiration and bacterial culture. Small bowel bacterial overgrowth may be more likely in patients with bloating, postprandial discomfort, and loose stools. It is hypothesized that bacterial overgrowth may lead to alterations in immune alterations that affect motility or visceral sensitivity or to degradation of carbohydrates in the small intestine that may cause increased postprandial gas, bloating, and distention.

D. Psychosocial Abnormalities

More than 50% of patients with irritable bowel who seek medical attention have underlying depression, anxiety, or somatization. By contrast, those who do not seek medical attention are similar psychologically to normal individuals. Psychological abnormalities may influence how the patient perceives or reacts to illness and minor visceral sensations. Chronic stress may alter intestinal motility or modulate pathways that affect central and spinal processing of visceral afferent sensation.

► Clinical Findings

A. Symptoms and Signs

Irritable bowel is a chronic condition. Symptoms usually begin in the late teens to twenties. Symptoms should be present for at least 3 months before the diagnosis can be considered. The diagnosis is established in the presence of compatible symptoms and the judicious use of tests to exclude organic disease.

Abdominal pain usually is intermittent, crampy, and in the lower abdominal region. As previously stated, the onset of pain typically is associated with a change in stool frequency or form and commonly is relieved by defecation. It does not usually occur at night or interfere with sleep. Patients with irritable bowel syndrome may be classified into one of three categories based on the predominant bowel habit: irritable bowel syndrome with diarrhea; irritable bowel syndrome with constipation; or irritable bowel syndrome with mixed constipation and diarrhea. It is important to clarify what the patient means by these complaints. Patients with irritable bowel and constipation report infrequent bowel movements (less than three per week), hard or lumpy stools, or straining. Patients with irritable bowel syndrome with diarrhea refer to loose or watery stools, frequent stools (more than three per day), urgency, or fecal incontinence. Many patients report that they have a firm stool in the morning followed by progressively looser movements. Complaints of visible distention and bloating are common, though these are not always clinically evident.

The patient should be asked about “alarm symptoms” that suggest a diagnosis other than irritable bowel syndrome and warrant further investigation. The acute onset of symptoms raises the likelihood of organic disease, especially in patients aged > 40–50 years. Nocturnal diarrhea, severe constipation or diarrhea, hematochezia, weight loss, and fever are incompatible with a diagnosis of irritable bowel syndrome and warrant investigation for underlying disease. Patients who have a family history of cancer, inflammatory bowel disease, or celiac disease should undergo additional evaluation.

A physical examination should be performed to look for evidence of organic disease and to allay the patient’s anxieties. The physical examination usually is normal. Abdominal tenderness, especially in the lower abdomen, is common but not pronounced. A new onset of symptoms in a patient over age 40 years warrants further examination.

B. Laboratory Findings and Special Examinations

In patients whose symptoms fulfill the diagnostic criteria for irritable bowel syndrome and who have no other alarm symptoms, evidence-based consensus guidelines do not support further diagnostic testing, as the likelihood of serious organic diseases does not appear to be increased. Although the vague nature of symptoms and patient anxiety may prompt clinicians to consider a variety of diagnostic studies, overtesting should be avoided. The use of routine blood tests (complete blood count, chemistry panel, serum albumin, thyroid function tests, erythrocyte sedimentation rate) is unnecessary in most patients. Stool specimen examinations for ova and parasites should be obtained only in patients with increased likelihood of infection (eg, day care workers, campers, foreign travelers). Routine sigmoidoscopy or colonoscopy also are not recommended in young patients with symptoms of irritable bowel syndrome without alarm symptoms but should be considered in patients who do not improve with conservative management. In all patients age 50 years or older who have not had a previous evaluation, colonoscopy should be obtained to exclude malignancy. When colonoscopy is performed, random mucosal biopsies should be obtained to look for evidence of microscopic colitis (which may have similar symptoms). In patients with irritable bowel syndrome with diarrhea, serologic tests for celiac disease should be performed. Routine testing for bacterial overgrowth with hydrogen breath tests are not recommended.

► Differential Diagnosis

A number of disorders may present with similar symptoms. Examples include colonic neoplasia, inflammatory bowel disease (ulcerative colitis, Crohn disease, microscopic colitis), hyperthyroidism or hypothyroidism, parasites, malabsorption (especially celiac disease, bacterial overgrowth, lactase deficiency), causes of chronic secretory diarrhea (carcinoid), and endometriosis. Psychiatric disorders such as depression, panic disorder, and anxiety must be considered as well. Women with refractory symptoms have an increased incidence of prior sexual and physical abuse. These diagnoses should be excluded in patients with presumed irritable bowel syndrome who do not improve within 2–4 weeks of empiric treatment or in whom subsequent alarm symptoms develop.

► Treatment

A. General Measures

As with other functional disorders, the most important interventions the clinician can offer are reassurance, education, and support. This includes identifying and responding to the patient's concerns, careful explanation of the pathophysiology and natural history of the disorder, setting realistic treatment goals, and involving the patient in the treatment process. Because irritable bowel symptoms are chronic, the patient's reasons for seeking consultation at this time should be determined. These may include major life events or recent psychosocial stressors, dietary or

medication changes, concerns about serious underlying disease, or reduced quality of life and impairment of daily activities. In discussing with the patient the importance of the mind-gut interaction, it may be helpful to explain that alterations in visceral motility and sensitivity may be exacerbated by environmental, social, or psychological factors such as foods, medications, hormones, and stress. Symptoms such as pain, bloating, and altered bowel habits may lead to anxiety and distress, which in turn may further exacerbate bowel disturbances due to disordered communication between the gut and the central nervous system. Fears that the symptoms will progress, require surgery, or degenerate into serious illness should be allayed. The patient should understand that irritable bowel syndrome is a chronic disorder characterized by periods of exacerbation and quiescence. The emphasis should be shifted from finding the cause of the symptoms to finding a way to cope with them. Moderate exercise is beneficial. Clinicians must resist the temptation to chase chronic complaints with new or repeated diagnostic studies.

B. Dietary Therapy

Patients commonly report dietary intolerances, although a role for dietary triggers in irritable bowel syndrome has never been convincingly demonstrated. Proposed mechanisms for dietary intolerance include food allergy, hypersensitivity, effects of gut hormones, changes in bacterial flora, increased bacterial gas production (arising in the small or large intestine), and direct chemical irritation. Fatty foods and caffeine are poorly tolerated by many patients with irritable bowel syndrome. In patients with diarrhea, bloating, and flatulence, lactose intolerance should be excluded with a hydrogen breath test or a trial of a lactose-free diet. A host of poorly absorbed, fermentable, short-chain carbohydrates may exacerbate bloating, flatulence, and diarrhea in some patients. These include fructose (corn syrups, apples, pears, watermelon, raisins), fructans (onions, leeks, asparagus, artichokes), wheat-based products (breads, pasta, cereals, cakes), sorbitol (stone fruits), and raffinose (legumes, lentils, brussel sprouts, cabbage).

A high-fiber diet and fiber supplements appears to be of little value in patients with irritable bowel syndrome. Many patients report little change in bowel frequency but increased gas and distention.

C. Pharmacologic Measures

More than two-thirds of patients with irritable bowel syndrome have mild symptoms that respond readily to education, reassurance, and dietary interventions. Drug therapy should be reserved for patients with moderate to severe symptoms that do not respond to conservative measures. These agents should be viewed as being adjunctive rather than curative. Given the wide spectrum of symptoms, no single agent is expected to provide relief in all or even most patients. Nevertheless, therapy targeted at the specific dominant symptom (pain, constipation, or diarrhea) may be beneficial.

1. Antispasmodic agents—Anticholinergic agents are used by some practitioners for treatment of acute episodes

of pain or bloating despite a lack of well-designed trials demonstrating efficacy. Available agents include hyoscyamine, 0.125 mg orally (or sublingually as needed) or sustained-release, 0.037 mg or 0.75 mg orally twice daily; dicyclomine, 10–20 mg orally; or methscopolamine 2.5–5 mg orally before meals and at bedtime. Anticholinergic side effects are common, including urinary retention, constipation, tachycardia, and dry mouth. Hence, these agents should be used with caution in the elderly and in patients with constipation. Peppermint oil formulations (which relax smooth muscle) may be helpful.

2. Antidiarrheal agents—Loperamide (2 mg orally three or four times daily) is effective for the treatment of patients with diarrhea, reducing stool frequency, liquidity, and urgency. It may best be used “prophylactically” in situations in which diarrhea is anticipated (such as stressful situations) or would be inconvenient (social engagements).

3. Anticonstipation agents—Treatment with osmotic laxatives (milk of magnesia or polyethylene glycol) may increase stool frequency, improve stool consistency, and reduce straining. Lactulose or sorbitol produces increased flatus and distention, which are poorly tolerated in patients with irritable bowel syndrome. Lubiprostone is a selective chloride C-2 activator that stimulates increased intestinal chloride secretion, which leads to increased stool frequency. Lubiprostone is approved for the treatment of chronic constipation (24 mcg orally twice daily) as well as for the treatment of women with irritable bowel with constipation (8 mcg twice daily). In clinical trials of patients with irritable bowel syndrome and constipation, lubiprostone led to global symptom improvement in 18% of patients compared with 10% of patients who received placebo. Patients with intractable constipation should undergo further assessment for slow colonic transit and pelvic floor dysfunction (see Constipation, above).

4. Psychotropic agents—Patients with predominant symptoms of pain or bloating may benefit from low doses of tricyclic antidepressants, which are believed to have effects on motility, visceral sensitivity, and central pain perception that are independent of their psychotropic effects. Because of their anticholinergic effects, these agents may be more useful in patients with diarrhea-predominant than constipation-predominant symptoms. Oral nortriptyline, desipramine, or imipramine, may be started at a low dosage of 10 mg at bedtime and increased gradually to 50–150 mg as tolerated. Response rates do not correlate with dosage, and many patients respond to doses of ≤ 50 mg daily. Side effects are common, and lack of efficacy with one agent does not preclude benefit from another. Improvement should be evident within 4 weeks. The oral serotonin reuptake inhibitors (sertraline, 25–100 mg daily; citalopram 10–20 mg; paroxetine 20–50 mg daily; or fluoxetine, 10–40 mg daily) may lead to improvement in overall sense of well-being but have little impact on abdominal pain or bowel symptoms. Anxiolytics should not be used chronically in irritable bowel syndrome because of their habituation potential. Patients with major depression or anxiety disorders should be identified and treated with therapeutic doses of appropriate agents.

5. Serotonin receptor agonists and antagonists—Serotonin is an important mediator of gastrointestinal motility and sensation. Alosetron and tegaserod modulate serotonin pathways. However, in 2007, tegaserod was withdrawn by the FDA from the US market after an analysis of safety data from over 18,000 patients in 29 clinical trials showed an excessive number of serious cardiovascular side effects.

Alosetron is a 5-HT₃ antagonist that is FDA-approved for the treatment of women with severe irritable bowel syndrome with predominant diarrhea. It appears to alter visceral sensation through blockade of peripheral 5-HT₃-receptors on enteric afferent neurons and inhibits enteric cholinergic motor neurons, resulting in inhibition of colonic motility. Alosetron (0.5–1 mg orally twice daily) reduces symptoms of pain, cramps, urgency, and diarrhea in 50–60% of women compared with 30–40% treated with placebo. Efficacy in men has not been demonstrated. In contrast to the excellent safety profile of other 5-HT₃ antagonists (eg, ondansetron), alosetron may cause constipation (sometimes severe) in 30% of patients or ischemic colitis in 4:1000 patients. Given the seriousness of these side effects, alosetron is restricted to women with severe irritable bowel syndrome with diarrhea who have not responded to conventional therapies and who have been educated about the relative risks and benefits of the agent. It should not be used in patients with constipation.

6. Nonabsorbable antibiotics—Two 2011 multicenter, randomized controlled studies reported global symptom improvement in 41% of patients with irritable bowel syndrome without constipation treated with the nonabsorbable antibiotic rifaximin, 550 mg orally three times daily for 2 weeks, compared with a 32% improvement in placebo-treated patients. Relief of bloating occurred in 40% of treated patients compared with 30% of controls. Improvement persisted over a 10-week follow-up period. Symptom improvement may be attributable to suppression of bacteria in either the small intestine or colon, resulting in decreased bacterial carbohydrate fermentation, diarrhea, and bloating. At this time, the role of rifaximin or other antibiotics in the treatment of irritable bowel remains controversial, due to uncertainties about duration of symptom improvement and concerns about bacterial resistance. At present, rifaximin is not approved for the treatment of irritable bowel syndrome but may be considered in patients with refractory symptoms, especially bloating.

7. Probiotics—Meta-analyses of small controlled clinical trials report improved symptoms in some patients treated with one probiotic, *Bifidobacterium infantis*, but not with another probiotic, *Lactobacillus salivarius*, or placebo. It is hypothesized that alterations in gut flora may reduce symptoms through suppression of inflammation or reduction of bacterial gas production, resulting in reduced distention, flatus, and visceral sensitivity. Such therapy is attractive because it is safe, well tolerated, and inexpensive. Although promising, further study is needed to define the efficacy and optimal formulations of probiotic therapy. The probiotics VSL#3 (1 packet twice daily) or

Bifidobacterium infantis (1 tablet twice daily) have shown modest benefit in small studies.

D. Psychological Therapies

Cognitive-behavioral therapies, relaxation techniques, and hypnotherapy appear to be beneficial in some patients. Patients with underlying psychological abnormalities may benefit from evaluation by a psychiatrist or psychologist. Patients with severe disability should be referred to a pain treatment center.

► Prognosis

The majority of patients with irritable bowel syndrome learn to cope with their symptoms and lead productive lives.

American College of Gastroenterology IBS Task Force. An evidence-based position statement on the management of irritable bowel syndrome. *Am J Gastroenterol.* 2009 Jan; 104(Suppl 1):S8–35. [PMID: 19521341]

Johannesson E et al. Physical activity improves symptoms in irritable bowel syndrome: a randomized controlled trial. *Am J Gastroenterol.* 2011 May;106(5):915–22. [PMID: 21206488]

Khan S et al. Diagnosis and management of IBS. *Nat Rev Gastroenterol Hepatol.* 2010 Oct;7(10):565–81. [PMID: 20890316]

Moayyedi P et al. The efficacy of probiotics in the treatment of irritable bowel syndrome: a systematic review. *Gut.* 2010 Mar;59(3):325–32. [PMID: 19091823]

Pimentel M et al; TARGET Study Group. Rifaximin therapy for patients with irritable bowel syndrome without constipation. *N Engl J Med.* 2011 Jan 6;364(1):22–32. [PMID: 21208106]

Spiegel BM. Questioning the bacterial overgrowth hypothesis of irritable bowel syndrome: an epidemiologic and evolutionary perspective. *Clin Gastroenterol Hepatol.* 2011 Jun;9(6):461–9. [PMID: 21397724]

ANTIBIOTIC-ASSOCIATED COLITIS



ESSENTIALS OF DIAGNOSIS

- ▶ Most cases of antibiotic-associated diarrhea are not attributable to *C difficile* and are usually mild and self-limited.
- ▶ Symptoms of antibiotic-associated colitis vary from mild to fulminant; almost all colitis is attributable to *C difficile*.
- ▶ Diagnosis in mild to moderate cases established by stool toxin assay.
- ▶ Flexible sigmoidoscopy provides most rapid diagnosis in severe cases.

► General Considerations

Antibiotic-associated diarrhea is a common clinical occurrence. Characteristically, the diarrhea occurs during the period of antibiotic exposure, is dose related, and resolves spontaneously after discontinuation of the antibiotic. In most cases, this diarrhea is mild, self-limited, and

does not require any specific laboratory evaluation or treatment. Stool examination usually reveals no fecal leukocytes, and stool cultures reveal no pathogens. Although *C difficile* is identified in the stool of 15–25% of cases of antibiotic-associated diarrhea, it is also identified in 5–10% of patients treated with antibiotics who do not have diarrhea. Most cases of antibiotic-associated diarrhea are due to changes in colonic bacterial fermentation of carbohydrates and are not due to *C difficile*.

Antibiotic-associated colitis is a significant clinical problem almost always caused by *C difficile* infection. Hospitalized patients are most susceptible. *C difficile*-colitis is the major cause of diarrhea in patients hospitalized for more than 3 days, affecting 22 patients of every 1000. This anaerobic bacterium colonizes the colon of 3% of healthy adults. It is acquired by fecal-oral transmission. Found throughout hospitals in patient rooms and bathrooms, it is readily transmitted from patient to patient by hospital personnel. Fastidious hand washing and use of disposable gloves are helpful in minimizing transmission. *C difficile* is acquired in approximately 20% of hospitalized patients, most of whom have received antibiotics that disrupt the normal bowel flora and thus allow the bacterium to flourish. Although almost all antibiotics have been implicated, colitis most commonly develops after use of ampicillin, clindamycin, third-generation cephalosporins, and fluoroquinolones. *C difficile*-colitis will develop in approximately one-third of infected patients. Prophylactic administration of probiotics (containing *Lactobacillus casei*, *Lactobacillus bulgaricus*, and *Streptococcus thermophilus*) to hospitalized patients who are receiving antibiotics may reduce the incidence of *C difficile*-associated diarrhea. Symptoms usually begin during or shortly after antibiotic therapy but may be delayed for up to 8 weeks. All patients with acute diarrhea should be asked about recent antibiotic exposure. Patients who are elderly; debilitated; immunocompromised; receiving multiple antibiotics or prolonged (> 10 days) antibiotic therapy; receiving enteral tube feedings, proton pump inhibitors, or chemotherapy; or who have inflammatory bowel disease have a higher risk of acquiring *C difficile* and developing *C difficile*-associated diarrhea.

The incidence and severity of *C difficile*-colitis in hospitalized patients appear to be increasing, which is attributable to the emergence of a more virulent strain of *C difficile* (NAP1) that contains an 18-base pair deletion of the *tcdC* inhibitory gene, resulting in higher toxin A and B production. This hypervirulent strain has been associated with several hospital outbreaks of severe disease with up to 7% mortality.

► Clinical Findings

A. Symptoms and Signs

Most patients report mild to moderate greenish, foul-smelling watery diarrhea 5–15 times per day with lower abdominal cramps. Physical examination is normal or reveals mild left lower quadrant tenderness. The stools may have mucus but seldom gross blood. In most patients, colitis is most severe in the distal colon and rectum. Over half of hospitalized patients diagnosed with *C difficile*-colitis

have a white blood count $> 15,000/\text{mCL}$, and *C difficile* should be considered in all hospitalized patients with unexplained leukocytosis.

Severe or fulminant disease occurs in 10-15% of patients. It is characterized by fever; hemodynamic instability; and abdominal distention, pain, and tenderness. Most patients have profuse diarrhea (up to 30 stools/day); however, diarrhea may be absent or appear to be improving in patients with fulminant disease or ileus. Laboratory data suggestive of severe disease include a white blood count $> 30,000/\text{mCL}$, albumin $< 2.5 \text{ g/dL}$ (due to protein-losing enteropathy), elevated serum lactate, or rising creatinine.

B. Special Examinations

1. Stool studies—Pathogenic strains of *C difficile* produce two toxins: toxin A is an enterotoxin and toxin B is a cytotoxin. A cytotoxicity assay (toxin B) performed in cell cultures has a specificity of 90% and a sensitivity of 95%. Although this is the definitive test, it is expensive and results are not available for 24–48 hours. To optimize cost-effective use of the cytotoxicity assay, some laboratories first perform an enzyme immunoassay (EIA) for glutamate dehydrogenase (a common *C difficile* antigen), which has a high sensitivity and specificity. A negative glutamate dehydrogenase assay effectively excludes infection, while a positive assay requires confirmation with the cytotoxicity assay to determine whether the strain that is present is toxin producing. Rapid EIAs (2–4 hours) for toxins A and B have a 75–90% sensitivity with a single stool specimen, which increases to 90–95% with two specimens. Until recently, EIA has been the preferred diagnostic test in most clinical settings because it is inexpensive, easy to use, and results are available within 24 hours. A rapid (same day) PCR assay that amplifies the toxin B gene has a 97% sensitivity compared with the gold-standard cell culture cytotoxicity assay. As a result, the PCR assay now is increasingly preferred by many laboratories.

2. Flexible sigmoidoscopy—Flexible sigmoidoscopy is not needed in patients who have typical symptoms and a positive stool toxin assay. It may be useful in patients with severe symptoms when a rapid diagnosis is desired. It also may clarify the diagnosis in patients with positive *C difficile* toxin assays who have atypical symptoms or who have persistent diarrhea despite appropriate therapy. In patients with mild to moderate symptoms, there may be no abnormalities or only patchy or diffuse, nonspecific colitis indistinguishable from other causes. In patients with severe illness, true **pseudomembranous colitis** is seen. This has a characteristic appearance, with yellow adherent plaques 2–10 mm in diameter scattered over the colonic mucosa interspersed with hyperemic mucosa. Biopsies reveal epithelial ulceration with a classic “volcano” exudate of fibrin and neutrophils. In 10% of cases, pseudomembranous colitis is confined to the proximal colon and may be missed at sigmoidoscopy.

3. Imaging studies—Abdominal radiographs or non-contrast abdominal CT scans are obtained in patients with severe or fulminant symptoms to look for evidence of colonic dilation and wall thickening. Abdominal CT also is

useful in the evaluation of hospitalized patients with abdominal pain or ileus without significant diarrhea, in whom the presence of colonic wall thickening suggests unsuspected *C difficile* colitis. CT scanning is also useful in the detection of possible perforation.

► Differential Diagnosis

In the hospitalized patient in whom acute diarrhea develops after admission, the differential diagnosis includes simple antibiotic-associated diarrhea (not related to *C difficile*), enteral feedings, medications, and ischemic colitis. Other infectious causes are unusual in hospitalized patients in whom diarrhea develops more than 72 hours after admission, and it is not cost-effective to obtain stool cultures unless tests for *C difficile* are negative. Rarely, other organisms (staphylococci, *Clostridium perfringens*) have been associated with pseudomembranous colitis. *Klebsiella oxytoca* may cause a distinct form of antibiotic-associated hemorrhagic colitis that is segmental (usually in the right or transverse colon); spares the rectum; and is more common in younger, healthier outpatients.

► Complications

Severe colitis may progress quickly to fulminant disease, resulting in hemodynamic instability, respiratory failure, metabolic acidosis, megacolon ($> 7 \text{ cm}$ diameter), perforation, and death. Chronic untreated colitis may result in weight loss and protein-losing enteropathy.

► Treatment

A. Immediate Treatment

If possible, antibiotic therapy should be discontinued and therapy with metronidazole, vancomycin, or fidaxomicin (a poorly absorbable macrolide antibiotic) should be initiated. For patients with mild disease, metronidazole (500 mg orally three times daily), vancomycin (125 mg orally four times daily), or fidaxomicin, (200 mg orally two times daily) are equally effective for initial treatment. Vancomycin and fidaxomicin are significantly more expensive than metronidazole. Therefore, metronidazole remains the preferred first-line therapy in patients with mild disease, except in patients who are intolerant of metronidazole, pregnant women, children, and patients who do not respond to metronidazole. The duration of initial therapy is usually 10–14 days. However, in patients requiring long-term systemic antibiotics, it may be appropriate to continue therapy until the antibiotics can be discontinued. Symptomatic improvement occurs in most patients within 72 hours.

For patients with severe disease, characterized by a white blood cell count $> 15,000/\text{mCL}$ or a rise in serum creatinine to > 1.5 times baseline, vancomycin, 125 mg orally four times daily, is the preferred agent because it achieves significantly higher response rates (97%) than metronidazole (76%). In patients with severe, complicated disease, characterized by ileus, megacolon, or shock, intravenous metronidazole, 500 mg every 6 hours, should be given—supplemented by vancomycin (500 mg four times

daily administered by nasogastric tube) and, in some cases, vancomycin enemas (500 mg in 100 mL every 6 hours). Intravenous vancomycin does not penetrate the bowel and should not be used. The efficacy of fidaxomicin for severe or fulminant disease requires further investigation. Early surgical consultation is recommended for all patients with severe or fulminant disease. Total abdominal colectomy or loop ileostomy with colonic lavage may be required in patients with toxic megacolon, perforation, sepsis, or hemorrhage.

B. Treatment of Relapse

Up to 25% of patients have a relapse of diarrhea from *C difficile* within 1 or 2 weeks after stopping initial therapy. This may be due to reinfection or failure to eradicate the organism. In a 2011 multicenter, randomized controlled trial, patients treated with fidaxomicin had significantly lower recurrence rates (7.8%) of non-NAP1 *C difficile* strains than patients treated with vancomycin (23.6%). The recurrence rates were not different among patients with the NAP1 strain. Fidaxomicin may be appropriate for patients with *C difficile* infection or as initial therapy in patients believed to be at higher risk for recurrent disease. A 2010 randomized controlled trial of a single infusion of neutralizing monoclonal antibodies against toxins A and B reduced recurrence rates from 25% in the placebo arm to 7% in the active treatment group. This therapy is not yet clinically available. Controlled trials show that oral administration of a live yeast, *Saccharomyces boulardii*, 500 mg twice daily, reduces the incidence of relapse by 50%. The optimal treatment regimen for recurrent relapses is unknown. Most relapses respond promptly to a second course of the same regimen used for the initial episode. Some patients have recurrent relapses that can be difficult to treat. For patients with multiple relapses, many authorities recommend a 7-week tapering regimen of vancomycin (125 mg orally four times daily for 14 days; twice daily for 7 days; once daily for 7 days; every other day for 7 days; and every third day for 2–8 weeks). Probiotic therapy is recommended as adjunctive therapy in patients with relapsing disease. In cases series, instillation of fecal bacteria from a healthy donor (“fecal transplant”) by nasogastric tube or enema results in disease remission in 90% of patients.

Cohen SH et al. Clinical Practice Guidelines for *Clostridium difficile* infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Disease Society of America (IDSA). *Infect Control Hosp Epidemiol.* 2010 May;31(5):431–55. [PMID: 20307191]

Landy J et al. Review article: faecal transplantation therapy for gastrointestinal disease. *Aliment Pharmacol Ther.* 2011 Aug;34(4):409–15. [PMID: 21682755]

Loo VG et al. Host and pathogen factors for *Clostridium difficile* infection and colonization. *N Engl J Med.* 2011 Nov 3;365(18):1693–703. [PMID: 22047560]

Louie TJ et al. Fidaxomicin versus vancomycin for *Clostridium difficile* infection. *N Engl J Med.* 2011 Feb 3;364(5):422–31. [PMID: 21288078]

Lowry I et al. Treatment with monoclonal antibodies against *Clostridium difficile* toxins. *N Engl J Med.* 2010 Jan 21;362(3):197–205. [PMID: 20089970]

INFLAMMATORY BOWEL DISEASE

The term “inflammatory bowel disease” includes ulcerative colitis and Crohn disease. Ulcerative colitis is a chronic, recurrent disease characterized by diffuse mucosal inflammation involving only the colon. Ulcerative colitis invariably involves the rectum and may extend proximally in a continuous fashion to involve part or all of the colon. Crohn disease is a chronic, recurrent disease characterized by patchy transmural inflammation involving any segment of the gastrointestinal tract from the mouth to the anus.

Crohn disease and ulcerative colitis may be associated in 50% of patients with a number of extraintestinal manifestations, including oral ulcers, oligoarticular or polyarticular nondeforming peripheral arthritis, spondylitis or sacroiliitis, episcleritis or uveitis, erythema nodosum, pyoderma gangrenosum, hepatitis and sclerosing cholangitis, and thromboembolic events.

► Pharmacologic Therapy

Although ulcerative colitis and Crohn disease appear to be distinct entities, the same pharmacologic agents are used to treat both. Despite extensive research, there are still no specific therapies for these diseases. The mainstays of therapy are 5-aminosalicylic acid derivatives, corticosteroids, immunomodulating agents (such as mercaptopurine or azathioprine and methotrexate), and biologic agents.

A. 5-Aminosalicylic Acid (5-ASA)

5-ASA is a topically active agent that has a variety of anti-inflammatory effects. It is used in the active treatment of ulcerative colitis and Crohn disease and during disease inactivity to maintain remission. It is readily absorbed from the small intestine but demonstrates minimal colonic absorption. A number of oral and topical compounds have been designed to target delivery of 5-ASA to the colon or small intestine while minimizing absorption. Commonly used formulations of 5-ASA are sulfasalazine, mesalamine, and azo compounds. Side effects of these compounds are uncommon but include nausea, rash, diarrhea, pancreatitis, and acute interstitial nephritis.

1. Oral mesalamine agents—These 5-ASA agents are coated in various pH-sensitive resins (Asacol, Apriso, and Lialda) or packaged in timed-release capsules (Pentasa). Pentasa releases 5-ASA slowly throughout the small intestine and colon. Asacol, Apriso, and Lialda tablets dissolve at pH 6.0–7.0, releasing 5-ASA in the terminal small bowel and proximal colon. Lialda has a multi-matrix system that gradually releases 5-ASA throughout the colon.

2. Azo compounds—Sulfasalazine, balsalazide and olsalazine contain 5-ASA linked by an azo bond that requires cleavage by colonic bacterial azoreductases to release 5-ASA. Absorption of these drugs from the small intestine is negligible. After release within the colon, the 5-ASA works topically and is largely unabsorbed. Olsalazine contains two 5-ASA molecules connected by the azo bond. Balsalazide contains 5-ASA linked to an inert carrier (4-aminobenzoyl-β-alanine).

Sulfasalazine contains 5-ASA linked to a sulfapyridine moiety. It is unclear whether the sulfapyridine group has any anti-inflammatory effects. One gram of sulfasalazine contains 400 mg of 5-ASA. The sulfapyridine group, however, is absorbed and may cause side effects in 15–30% of patients—much higher than with other 5-ASA compounds. Dose-related side effects include nausea, headaches, leukopenia, oligospermia, and impaired folate metabolism. Allergic and idiosyncratic side effects are fever, rash, hemolytic anemia, neutropenia, worsened colitis, hepatitis, pancreatitis, and pneumonitis. Because of its side effects, sulfasalazine is less frequently used than other 5-ASA agents. It should always be administered in conjunction with folate. Eighty percent of patients intolerant of sulfasalazine can tolerate mesalamine.

3. Topical mesalamine—5-ASA is provided in the form of suppositories (Canasa; 1000 mg) and enemas (Rowasa; 4 g/60 mL). These formulations can deliver much higher concentrations of 5-ASA to the distal colon than oral compounds. Side effects are uncommon.

B. Corticosteroids

A variety of intravenous, oral, and topical corticosteroid formulations have been used in inflammatory bowel disease. They have utility in the short-term treatment of moderate to severe disease. However, long-term use is associated with serious, potentially irreversible side effects and is to be avoided. The agents, route of administration, duration of use, and tapering regimens used are based more on personal bias and experience than on data from rigorous clinical trials. The most commonly used intravenous formulations have been hydrocortisone or methylprednisolone, which are given by continuous infusion or every 6 hours. Oral formulations are prednisone or methylprednisolone. Adverse events commonly occur during short-term systemic corticosteroid therapy, including mood changes, insomnia, dyspepsia, weight gain, edema, elevated serum glucose levels, acne, and moon facies. Side effects of long-term use include osteoporosis, osteonecrosis of the femoral head, myopathy, cataracts, and susceptibility to infections. Calcium and vitamin D supplementation should be administered to all patients receiving long-term corticosteroid therapy. Bone densitometry should be considered in patients with inflammatory bowel disease with other risk factors for osteoporosis and in all patients requiring corticosteroids for 3 months or more. Topical preparations are provided as hydrocortisone suppositories (100 mg), foam (90 mg), and enemas (100 mg). Budesonide is an oral glucocorticoid with high topical anti-inflammatory activity but low systemic activity due to high first-pass hepatic metabolism. A controlled-release formulation is available (Entocort) that targets delivery to the terminal ileum and proximal colon. It produces less suppression of the hypothalamic-pituitary-adrenal axis and fewer steroid-related side effects than hydrocortisone or prednisone.

C. Immunomodulating Drugs: Mercaptopurine, Azathioprine, or Methotrexate

Mercaptopurine and azathioprine are thiopurine drugs that are used in many patients with Crohn disease and

ulcerative colitis who are corticosteroid-dependent in an attempt to reduce or withdraw the corticosteroids and to maintain patients in remission. Azathioprine is converted in vivo to mercaptopurine. It is believed that the active metabolite of mercaptopurine is 6-thioguanine. Monitoring of 6-thioguanine levels is performed in some clinical settings but is of unproven value in the management of most patients. Side effects of mercaptopurine and azathioprine, including allergic reactions (fever, rash, or arthralgias) and nonallergic reactions (nausea, vomiting, pancreatitis, hepatotoxicity, bone marrow suppression, infections, and a higher risk of lymphoma), occur in 15% of patients.

Three competing enzymes are involved in the metabolism of mercaptopurine to its active (6-thioguanine) and inactive metabolites. About 1 person in 300 has a homozygous mutation of one of the enzymes that metabolizes thiopurine methyltransferase (TPMT), placing them at risk for profound immunosuppression; 1 person in 9 is heterozygous for TPMT, resulting in intermediate enzyme activity. Measurement of TPMT functional activity is recommended prior to initiation of therapy. Treatment should be withheld in patients with absent TPMT activity. The most effective dose of mercaptopurine is 1–1.5 mg/kg. For azathioprine, it is 2–3 mg/kg daily. For patients with normal TPMT activity, both drugs may be initiated at the weight-calculated dose. A complete blood count should be obtained weekly for 4 weeks, biweekly for 4 weeks, and then every 1–3 months for the duration of therapy. Liver function tests should be measured periodically. Some clinicians prefer gradual dose-escalation, especially for patients with intermediate TPMT activity or in whom TPMT measurement is not available; both drugs may be started at 25 mg/d and increased by 25 mg every 1–2 weeks while monitoring for myelosuppression until the target dose is reached. If the white blood count falls below 3000–4000/mcL or the platelet count falls below 100,000/mcL, the medication should be held for at least 1 week before reducing the daily dose by 25–50 mg.

Methotrexate is used in the treatment of patients with inflammatory bowel disease, especially patients with Crohn disease who are intolerant of mercaptopurine. Methotrexate is an analog of dihydrofolic acid. Although at high doses it interferes with cell proliferation through inhibition of nucleic acid metabolism, at low doses it has anti-inflammatory properties, including inhibition of expression of tumor necrosis factor (TNF) in monocytes and macrophages. Methotrexate may be given intramuscularly, subcutaneously, or orally. Side effects of methotrexate include nausea, vomiting, stomatitis, infections, bone marrow suppression, hepatic fibrosis, and life-threatening pneumonitis. A complete blood count and liver function tests should be monitored every 1–3 months. Folate supplementation (1 mg/d) should be administered.

D. Biologic Therapies

Although the etiology of inflammatory bowel disorders is uncertain, it appears that an abnormal response of the mucosal innate immune system to luminal bacteria may trigger inflammation, which is perpetuated by dysregulation of cellular immunity. A number of biologic therapies

are available or in clinical testing that more narrowly target various components of the immune system. Biologic agents are highly effective for patients with corticosteroid-dependent or refractory disease and potentially may improve the natural history of disease. The potential benefits of these agents, however, must be carefully weighed with their high cost and risk of serious and potentially life-threatening side effects.

1. Anti-TNF therapies—TNF is one of the key proinflammatory cytokines in the T_H1 response. TNF exists in two biologically active forms: a soluble form (sTNF), which is enzymatically cleaved from its cell surface, and membrane-bound precursor (tmTNF). When either form binds to the TNF-receptors on effector cells, they initiate a variety of signaling pathways that lead to inflammatory gene activation. Three monoclonal antibodies to TNF currently are available for the treatment of inflammatory bowel disease: infliximab, adalimumab, and certolizumab. All three agents bind and neutralize soluble as well as membrane-bound TNF on macrophages and activated T lymphocytes, thereby preventing TNF stimulation of effector cells. When bound to membrane-associated TNF, infliximab and adalimumab may also cause apoptosis and cell lysis of TNF-producing cells.

Infliximab is a chimeric (75% human/25% mouse) IgG₁ antibody that is administered by intravenous infusion. A three-dose regimen of 5 mg/kg administered at 0, 2, and 6 weeks is recommended for acute induction, followed by infusions every 8 weeks for maintenance therapy. Acute infusion reactions occur in 5–10% of infusions but occur less commonly in patients receiving regularly scheduled infusions or concomitant immunomodulators (ie, azathioprine or methotrexate). Most reactions are mild or moderate (nausea; headache; dizziness; urticaria; diaphoresis; or mild cardiopulmonary symptoms that include chest tightness, dyspnea, or palpitations) and can be treated by slowing the infusion rate and administering acetaminophen and diphenhydramine. Severe reactions (hypotension, severe shortness of breath, rigors, severe chest discomfort) occur in < 1% and may require oxygen, diphenhydramine, hydrocortisone, and epinephrine. Delayed serum sickness-like reactions occur in 1%. With repeated, intermittent intravenous injections, antibodies to infliximab develop in up to 40% of patients, which are associated with a shortened duration or loss of response and increased risk of acute or delayed infusion reactions. Giving infliximab in a regularly scheduled maintenance therapy (eg, every 8 weeks), concomitant use of infliximab with other immunomodulating agents (azathioprine, mercaptopurine, or methotrexate), or preinfusion treatment with corticosteroids (intravenous hydrocortisone 200 mg) significantly reduces the development of antibodies to approximately 10%.

Adalimumab is a fully human IgG₁ antibody that is administered by subcutaneous injection. A dose of 160 mg at week 0 and 80 mg at week 2 is recommended for acute induction, followed by maintenance therapy with 40 mg subcutaneously every other week. Certolizumab is a fusion compound in which the Fab1 portion of a chimeric (95% human/5% mouse) TNF-antibody is bound to polyethylene glycol in order to prolong the drug half-life. A dose of 400 mg at weeks 0, 2, and 4 is recommended for acute

induction, followed by maintenance therapy every 4 weeks with 400 mg. Both adalimumab and certolizumab are administered subcutaneously. Injection site reactions (burning, pain, redness, itching) are relatively common but are usually minor and self-limited. Because of their subcutaneous route of injection, acute and delayed hypersensitivity reactions are rare. Antibodies to adalimumab develop in 5% of patients and to certolizumab in 10%, which may lead to shortened duration or loss of response to the drug.

Serious infections with anti-TNF therapies may occur in 2–5% of patients, including sepsis, pneumonia, abscess, and cellulitis; however, controlled studies suggest the increased risk may be attributable to increased severity of disease and concomitant use of corticosteroids. Patients treated with anti-TNF therapies are at increased risk for the development of bacterial infections, tuberculosis, mycoses (candidiasis, histoplasmosis, coccidioidomycosis, nocardiosis), reactivation of hepatitis B, and other opportunistic infections. Prior to use of these agents, patients should be screened for latent tuberculosis with PPD testing and a chest radiograph. Antinuclear and anti-DNA antibodies occur in a large percentage of patients; however, the development of drug-induced lupus is rare. All agents may cause severe hepatic reactions leading to acute hepatic failure; liver enzymes should be monitored routinely during therapy. Studies suggest that anti-TNF therapies increase the risk of malignancies, especially non-Hodgkin lymphoma (6 per 10,000 patient-years) and nonmelanoma skin cancer. Rare cases of optic neuritis and demyelinating diseases, including multiple sclerosis have been reported. Anti-TNF therapies may worsen congestive heart failure in patients with cardiac disease.

2. Anti-Integrins—Natalizumab is a humanized monoclonal antibody targeted against α_4 -integrins, decreasing the trafficking of circulating leukocytes through the vasculature and reducing chronic inflammation. Natalizumab is efficacious for the induction and maintenance of response and remission in patients with Crohn disease. There is an increased incidence of progressive multifocal leukoencephalopathy caused by reactivation of the JC virus, approximately 1:1000 in patients receiving therapy for >1 year. A test for JC virus antibody became available in 2011, and patients with a negative antibody are presumed to be at low risk of PML. The use of natalizumab should be restricted to patients with Crohn disease who have not responded to other therapies and who have a negative antibody test for JC virus.

Atif W et al. Safety profile of IBD therapeutics: infectious risks. *Med Clin North Am.* 2010 Jan;94(1):115–33. [PMID: 19944801]

Cottone M et al. Advanced age is an independent risk factor for severe infections and mortality in patients given anti-tumor necrosis factor therapy for inflammatory bowel disease. *Clin Gastroenterol Hepatol.* 2011 Jan;9(1):30–5. [PMID: 20951835]

Ford AC et al. Glucocorticosteroid therapy in inflammatory bowel disease: systematic review and meta-analysis. *Am J Gastroenterol.* 2011 Apr;106(4):590–9. [PMID: 21407179]

Khan KJ et al. Efficacy of immunosuppressive therapy for inflammatory bowel disease: a systematic review and meta-analysis. *Am J Gastroenterol.* 2011 Apr;106(4):630–42. [PMID: 21407186]

Mowat C et al; IBD Section of the British Society of Gastroenterology. Guidelines for the management of inflammatory bowel disease in adults. *Gut*. 2011 May;60(5):571–607. [PMID: 21464096]

Siegel CA et al. Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulators therapy for the treatment of Crohn's disease: a meta-analysis. *Clin Gastroenterol Hepatol*. 2009 Aug;7(8):874–81. [PMID: 19558997]

Van Assche G et al. The London position statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organisation: safety. *Am J Gastroenterol*. 2011 Sep;106(9):1594–602. [PMID: 21844919]

► Social Support for Patients

Inflammatory bowel disease is a lifelong illness that can have profound emotional and social impacts on the individual. Patients should be encouraged to become involved in the Crohn's and Colitis Foundation of America (CCFA). National headquarters may be contacted at 444 Park Avenue South, 11th Floor, New York, NY 10016-7374; phone 212-685-3440. Internet address: <http://www.cffa.org>.

1. Crohn Disease

ESSENTIALS OF DIAGNOSIS

- ▶ Insidious onset.
- ▶ Intermittent bouts of low-grade fever, diarrhea, and right lower quadrant pain.
- ▶ Right lower quadrant mass and tenderness.
- ▶ Perianal disease with abscess, fistulas.
- ▶ Radiographic or endoscopic evidence of ulceration, stricturing, or fistulas of the small intestine or colon.

► General Considerations

One-third of cases of Crohn disease involve the small bowel only, most commonly the terminal ileum (ileitis). Half of all cases involve the small bowel and colon, most often the terminal ileum and adjacent proximal ascending colon (ileocolitis). In 20% of cases, the colon alone is affected. One-third of patients have associated perianal disease (fistulas, fissures, abscesses). Less than 5% patients have symptomatic involvement of the upper intestinal tract. Unlike ulcerative colitis, Crohn disease is a transmural process that can result in mucosal inflammation and ulceration, stricturing, fistula development, and abscess formation. Cigarette smoking is strongly associated with the development of Crohn disease, resistance to medical therapy, and early disease relapse.

► Clinical Findings

A. Symptoms and Signs

Because of the variable location of involvement and severity of inflammation, Crohn disease may present with a

variety of symptoms and signs. In eliciting the history, the clinician should take particular note of fevers, the patient's general sense of well-being, weight loss, the presence of abdominal pain, the number of liquid bowel movements per day, and prior surgical resections. Physical examination should focus on the patient's temperature, weight, and nutritional status, the presence of abdominal tenderness or an abdominal mass, rectal examination, and extraintestinal manifestations (described below). Most commonly, there is one or a combination of the following clinical constellations.

1. Chronic inflammatory disease—This is the most common presentation and is often seen in patients with ileitis or ileocolitis. Patients report malaise, weight loss, and loss of energy. In patients with ileitis or ileocolitis, there may be diarrhea, which is usually nonbloody and often intermittent. In patients with colitis involving the rectum or left colon, there may be bloody diarrhea and fecal urgency, which may mimic the symptoms of ulcerative colitis. Cramping or steady right lower quadrant or periumbilical pain is common. Physical examination reveals focal tenderness, usually in the right lower quadrant. A palpable, tender mass that represents thickened or matted loops of inflamed intestine may be present in the lower abdomen.

2. Intestinal obstruction—Narrowing of the small bowel may occur as a result of inflammation, spasm, or fibrotic stenosis. Patients report postprandial bloating, cramping pains, and loud borborygmi. This may occur in patients with active inflammatory symptoms (as above) or later in the disease from chronic fibrosis without other systemic symptoms or signs of inflammation.

3. Penetrating disease and fistulae—Sinus tracts that penetrate through the bowel, where they may be contained or form fistulas to adjacent structures, develop in a subset of patients. Penetration through the bowel can result in an intra-abdominal or retroperitoneal phlegmon or abscess manifested by fevers, chills, a tender abdominal mass, and leukocytosis. Fistulas between the small intestine and colon commonly are asymptomatic but can result in diarrhea, weight loss, bacterial overgrowth, and malnutrition. Fistulas to the bladder produce recurrent infections. Fistulas to the vagina result in malodorous drainage and problems with personal hygiene. Fistulas to the skin usually occur at the site of surgical scars.

4. Perianal disease—One-third of patients with either large or small bowel involvement develop perianal disease manifested by large painful skin tags, anal fissures, perianal abscesses, and fistulas.

5. Extraintestinal manifestations—Extraintestinal manifestations may be seen with both Crohn disease and ulcerative colitis. These include arthralgias, arthritis, iritis or uveitis, pyoderma gangrenosum, or erythema nodosum. Oral aphthous lesions are common. There is an increased prevalence of gallstones due to malabsorption of bile salts from the terminal ileum. Nephrolithiasis with urate or calcium oxalate stones may occur.

B. Laboratory Findings

There is a poor correlation between laboratory studies and the patient's clinical picture. Laboratory values may reflect inflammatory activity or nutritional complications of disease. A complete blood count and serum albumin should be obtained in all patients. Anemia may reflect chronic inflammation, mucosal blood loss, iron deficiency, or vitamin B₁₂ malabsorption secondary to terminal ileal inflammation or resection. Leukocytosis may reflect inflammation or abscess formation or may be secondary to corticosteroid therapy. Hypoalbuminemia may be due to intestinal protein loss (protein-losing enteropathy), malabsorption, bacterial overgrowth, or chronic inflammation. The sedimentation rate or C-reactive protein level is elevated in many patients during active inflammation. Fecal lactoferrin or calprotectin levels also are increased in patients with intestinal inflammation. Stool specimens are sent for examination for routine pathogens, ova and parasites, leukocytes, fat, and *C difficile* toxin.

C. Special Diagnostic Studies

In most patients, the initial diagnosis of Crohn disease is based on a compatible clinical picture with supporting endoscopic, pathologic, and radiographic findings. Colonoscopy usually is performed first to evaluate the colon and terminal ileum and to obtain mucosal biopsies. Typical endoscopic findings include aphthoid, linear or stellate ulcers, strictures, and segmental involvement with areas of normal-appearing mucosa adjacent to inflamed mucosa. In 10% of cases, it may be difficult to distinguish ulcerative colitis from Crohn disease. Granulomas on biopsy are present in < 25% of patients but are highly suggestive of Crohn disease. CT or MR enterography or a barium upper gastrointestinal series with small bowel follow-through often is obtained in patients with suspected small bowel involvement. Suggestive findings include ulcerations, strictures, and fistulas; in addition, CT or MR enterography may identify bowel wall thickening and vascularity, mucosal enhancement, and fat stranding. Capsule imaging may help establish a diagnosis when clinical suspicion for small bowel involvement is high but radiographs are normal or nondiagnostic. When the diagnosis remains uncertain, a panel of seven tests that measure autoantibodies to P-ANCA as well as antibodies to the yeast *Saccharomyces cerevisiae*, to the outer membrane porin C of *E coli*, and to the bacterial flagellin Cbir1 (Prometheus IBD Serology 7) is marketed as being 92% accurate for diagnosing inflammatory bowel disease and for distinguishing between Crohn disease and ulcerative colitis but is not used clinically by most inflammatory bowel disease experts.

► Complications

A. Abscess

The presence of a tender abdominal mass with fever and leukocytosis suggests an abscess. Emergent CT of the abdomen is necessary to confirm the diagnosis. Patients should be given broad-spectrum antibiotics. Percutaneous drainage or surgery is usually required.

B. Obstruction

Small bowel obstruction may develop secondary to active inflammation or chronic fibrotic stricturing and is often acutely precipitated by dietary indiscretion. Patients should be given intravenous fluids with nasogastric suction. Systemic corticosteroids are indicated in patients with symptoms or signs of active inflammation but are unhelpful in patients with inactive, fixed disease. Patients unimproved on medical management require surgical resection of the stenotic area or stricturoplasty.

C. Abdominal and Rectovaginal Fistulas

Many fistulas are asymptomatic and require no specific therapy. Most symptomatic fistulas eventually require surgical therapy; however, medical therapy is effective in a subset of patients and is usually tried first in outpatients who otherwise are stable. Large abscesses associated with fistulas require percutaneous or surgical drainage. After percutaneous drainage, long-term antibiotics are administered in order to reduce recurrent infections until the fistula is closed or surgically resected. Fistulas may close temporarily in response to TPN or oral elemental diets but recur when oral feedings are resumed. Immunomodulating agents heal fistulas in one-third of patients within 3–6 months. Anti-TNF agents may promote closure in up to 60% within 10 weeks; however, relapse occurs in over one-half of patients within 1 year despite continued therapy. Surgical therapy is required for symptomatic fistulas that do not respond to medical therapy. Fistulas that arise above (proximal to) areas of intestinal stricturing commonly require surgical treatment.

D. Perianal Disease

Patients with fissures, fistulas, and skin tags commonly have perianal discomfort. Successful treatment of active intestinal disease also may improve perianal disease. Specific treatment of perianal disease can be difficult and is best approached jointly with a surgeon with an expertise in colorectal disorders. Pelvic MRI and endoscopic ultrasonography are the best noninvasive studies for evaluating perianal fistulas. Patients should be instructed on proper perianal skin care, including gentle wiping with a premoistened pad (baby wipes) followed by drying with a cool hair dryer, daily cleansing with sitz baths or a water wash, and use of perianal cotton balls or pads to absorb drainage. Oral antibiotics (metronidazole, 250 mg three times daily, or ciprofloxacin, 500 mg twice daily) may promote symptom improvement or healing in patients with fissures or uncomplicated fistulas; however, recurrent symptoms are common. Refractory fissures may benefit from mesalamine suppositories or topical 0.1% tacrolimus ointment. Immunomodulators or anti-TNF agents or both promote short-term symptomatic improvement from anal fistulas in two-thirds of patients and complete closure in up to one-half of patients; however, less than one-third maintain symptomatic remission during long-term maintenance treatment.

Anorectal abscesses should be suspected in patients with severe, constant perianal pain, or perianal pain in

association with fever. Superficial abscesses are evident on perianal examination, but deep perirectal abscesses may be detected by digital examination or pelvic CT scan. Depending on the abscess location, surgical drainage may be achieved by incision, or catheter or seton placement. Surgery should be considered for patients with severe, refractory symptoms but is best approached after medical therapy of the Crohn disease has been optimized.

E. Carcinoma

Patients with colonic Crohn disease are at increased risk for developing colon carcinoma; hence, annual screening colonoscopy to detect dysplasia or cancer is recommended for patients with a history of 8 or more years of Crohn colitis. Patients with Crohn disease have an increased risk of lymphoma and of small bowel adenocarcinoma; however, both are rare.

F. Hemorrhage

Unlike ulcerative colitis, severe hemorrhage is unusual in Crohn disease.

G. Malabsorption

Malabsorption may arise after extensive surgical resections of the small intestine and from bacterial overgrowth in patients with enterocolonic fistulas, strictures, and stasis resulting in bacterial overgrowth.

► Differential Diagnosis

Chronic cramping abdominal pain and diarrhea are typical of both irritable bowel syndrome and Crohn disease, but radiographic examinations are normal in the former. Celiac disease may cause diarrhea with malabsorption. Acute fever and right lower quadrant pain may resemble appendicitis or *Yersinia enterocolitica* enteritis. Intestinal lymphoma causes fever, pain, weight loss, and abnormal small bowel radiographs that may mimic Crohn disease. Patients with undiagnosed AIDS may present with fever and diarrhea. Segmental colitis may be caused by tuberculosis, *E histolytica*, *Chlamydia*, or ischemic colitis. *C difficile* or CMV infection may develop in patients with inflammatory bowel disease, mimicking disease recurrence. Diverticulitis with abscess formation may be difficult to distinguish acutely from Crohn disease. NSAIDs may exacerbate inflammatory bowel disease and may also cause NSAID-induced colitis characterized by small bowel or colonic ulcers, erosion, or strictures that tend to be most severe in the terminal ileum and right colon.

► Treatment of Active Disease

Crohn disease is a chronic lifelong illness characterized by exacerbations and periods of remission. As no specific therapy exists, current treatment is directed toward symptomatic improvement and controlling the disease process. The treatment must address the specific problems of the individual patient. All patients with Crohn disease should be counseled to discontinue cigarettes.

A. Nutrition

1. Diet—Patients should eat a well-balanced diet with as few restrictions as possible. Eating smaller but more frequent meals may be helpful. Patients with diarrhea should be encouraged to drink fluids to avoid dehydration. Many patients report that certain foods worsen symptoms, especially fried or greasy foods. Because lactose intolerance is common, a trial off dairy products is warranted if flatulence or diarrhea is a prominent complaint. Patients with obstructive symptoms should be placed on a low-roughage diet, ie, no raw fruits or vegetables, popcorn, nuts, etc. Resection of more than 100 cm of terminal ileum results in fat malabsorption for which a low-fat diet is recommended. Parenteral vitamin B₁₂ (100 mcg intramuscularly per month) commonly is needed for patients with previous ileal resection or extensive terminal ileal disease.

2. Enteral therapy—Supplemental enteral therapy via nasogastric tube may be required for children and adolescents with poor intake and growth retardation.

3. Total parenteral nutrition—TPN is used short term in patients with active disease and progressive weight loss or those awaiting surgery who have malnutrition but cannot tolerate enteral feedings because of high-grade obstruction, high-output fistulas, severe diarrhea, or abdominal pain. It is required long term in a small subset of patients with extensive intestinal resections resulting in short bowel syndrome with malnutrition.

B. Symptomatic Medications

There are several potential mechanisms by which diarrhea may occur in Crohn disease in addition to active Crohn disease. A rational empiric treatment approach often yields therapeutic improvement that may obviate the need for corticosteroids or immunosuppressive agents. Involvement of the terminal ileum with Crohn disease or prior ileal resection may lead to reduced absorption of bile acids that may induce secretory diarrhea from the colon. This diarrhea commonly responds to cholestyramine 2–4 g, colestipol 5 g, or colesvelam 625 mg one to two times daily before meals to bind the malabsorbed bile salts. Patients with extensive ileal disease (requiring more than 100 cm of ileal resection) have such severe bile salt malabsorption that steatorrhea may arise. Such patients may benefit from a low-fat diet; bile salt-binding agents will exacerbate the diarrhea and should not be given. Patients with Crohn disease are at risk for the development of small intestinal bacterial overgrowth due to enteral fistulas, ileal resection, and impaired motility and may benefit from a course of broad-spectrum antibiotics (see Bacterial Overgrowth, above). Other causes of diarrhea include lactase deficiency and short bowel syndrome (described in other sections). Use of oral antidiarrheal agents may provide benefit in some patients. Loperamide (2–4 mg), diphenoxylate with atropine (one tablet), or tincture of opium (5–15 drops) may be given as needed up to four times daily. Because of the risk of toxic megacolon, these drugs should not be used in patients with active severe colitis.

C. Specific Drug Therapy

1. 5-Aminosalicylic acid agents—Mesalamine (Asacol 2.4–4.8 g/d orally; Pentasa 4 g/d orally) has long been used as initial therapy for the treatment of mild to moderately active colonic and ileocolonic Crohn disease. However, meta-analyses of published and unpublished trial data suggest that mesalamine is of little or no value in either the treatment of active Crohn disease or the maintenance of remission. Notwithstanding these data, many clinicians continue to use mesalamine as first-line therapy for patients with mild disease because of its safety relative to other agents.

2. Antibiotics—Antibiotics also are widely used by clinicians for the treatment of active luminal Crohn disease, although meta-analyses of controlled trials suggest that they have little or no efficacy. It is hypothesized that antibiotics may reduce inflammation through alteration of gut flora, reduction of bacterial overgrowth, or treatment of microperforations. Oral metronidazole (10 mg/kg/d) or ciprofloxacin (500 mg twice daily), or rifaximin (400 mg three times daily) are commonly administered for 6–12 weeks.

3. Corticosteroids—Approximately one-half of patients with Crohn disease require corticosteroids at some time in their illness. Corticosteroids dramatically suppress the acute clinical symptoms or signs in most patients with both small and large bowel disease; however, they do not alter the underlying disease. An ileal-release budesonide preparation (Entocort), 9 mg once daily for 8–16 weeks, induces remission in 50–70% of patients with mild to moderate Crohn disease involving the terminal ileum or ascending colon. After initial treatment, budesonide is tapered over 2–4 weeks in 3 mg increments. In some patients, low-dose budesonide (6 mg/d) may be used for up to 1 year to maintain remission. Budesonide is superior to mesalamine but somewhat less effective than prednisone. However, because budesonide has markedly reduced acute and chronic steroid-related adverse effects, including smaller reductions of bone mineral density, it is preferred to other systemic corticosteroids for the treatment of mild to moderate Crohn disease involving the terminal ileum or ascending colon.

Prednisone or methylprednisolone, 40–60 mg/d, is generally administered to patients with Crohn disease that is severe, that involves the distal colon or proximal small intestine, or that has failed treatment with budesonide. Remission or significant improvement occurs in > 80% of patients after 8–16 weeks of therapy. After improvement at 2 weeks, tapering proceeds at 5 mg/wk until a dosage of 20 mg/d is being given. Thereafter, slow tapering by 2.5 mg/wk is recommended. Approximately 20% of patients cannot be completely withdrawn from corticosteroids without experiencing a symptomatic flare-up. Furthermore, more than 50% of patients who achieve initial remission on corticosteroids will experience a relapse within 1 year. Use of long-term low corticosteroid doses (2.5–10 mg/d) should be avoided, because of associated complications (see above). Patients requiring long-term corticosteroid treatment should be given immunomodulatory drugs (as described below) in an effort to wean them from corticosteroids.

Patients with persisting symptoms despite oral corticosteroids or those with high fever, persistent vomiting, evidence of intestinal obstruction, severe weight loss, severe abdominal tenderness, or suspicion of an abscess should be hospitalized. In patients with a tender, palpable inflammatory abdominal mass, CT scan of the abdomen should be obtained prior to administering corticosteroids to rule out an abscess. If no abscess is identified, parenteral corticosteroids should be administered (as described for ulcerative colitis below).

4. Immunomodulating drugs: Azathioprine, mercaptopurine, or methotrexate—Immunomodulating agents are used in approximately two-thirds of patients with Crohn disease who have not responded to corticosteroids or who require repeated courses of long-term corticosteroids to control symptoms. These agents permit elimination or reduction of corticosteroids in over 75% and fistula closure in 30% of patients. In the United States, mercaptopurine or azathioprine are more commonly used than methotrexate. The mean time to symptomatic response is 2–4 months, so these agents are not useful for acute exacerbations. Meta-analyses of controlled trials suggest that patients with Crohn disease treated with immunomodulating agents are three times as likely to achieve remission and 2.25 times as likely to maintain remission as those treated with corticosteroids. Once patients achieve remission, immunomodulating drugs reduce the 3-year relapse rate from over 60% to < 25% (see Immunomodulating Drugs, above). Methotrexate (25 mg intramuscularly or subcutaneously weekly for 12 weeks, followed by 12.5–15 mg once weekly) is used in patients who are unresponsive to or intolerant of mercaptopurine or azathioprine. Because oral absorption may be erratic, parenteral administration is preferred. Other immunosuppressive agents have been investigated in the treatment of Crohn disease, including cyclosporine and thalidomide; however, efficacy has been modest and toxicity greater than with the thiopurines.

5. Anti-TNF therapies—Infliximab, adalimumab, and certolizumab are used for the treatment of patients with moderate to severe Crohn disease (including fistulizing disease) with an inadequate response to mesalamine, antibiotics, corticosteroids or immunomodulators. These agents are also used to treat severe disease in hospitalized patients and extraintestinal manifestations of Crohn disease (except optic neuritis).

A. ACUTE INDUCTION THERAPY—The doses for acute induction therapy are described above. Up to two-thirds of patients have significant clinical improvement during acute induction therapy.

B. MAINTENANCE THERAPY—After initial clinical response, symptom relapse occurs in > 80% of patients within 1 year in the absence of further maintenance therapy. Therefore, scheduled maintenance therapy is usually recommended (infliximab, 5 mg/kg infusion every 8 weeks; adalimumab, 40 mg subcutaneous injection every 2 weeks; certolizumab, 400 mg subcutaneous injection every 4 weeks). With long-term maintenance therapy, approximately two-thirds have continued clinical response and up to one-half

have complete symptom remission. A gradual or complete loss of efficacy occurs over time in some patients, necessitating increased dosing (infliximab 10 mg/kg; adalimumab 80 mg), decreased dosing intervals (infliximab every 6 weeks; adalimumab every week), changing to the alternative agent, or discontinuation of anti-TNF therapy. In some cases, loss of efficacy is due to the development of antibodies to the anti-TNF agent. Scheduled maintenance therapy is associated with a lower likelihood of developing antibodies to the anti-TNF agent and an increased likelihood of sustained response. Concomitant therapy with anti-TNF agents and immunomodulating agents (azathioprine, mercaptopurine, or methotrexate) reduces the risk of development of antibodies to the anti-TNF agent but may increase the risk of complications from anti-TNF agents, including the development of hepatosplenic T-cell lymphoma. Thus, it remains controversial whether anti-TNF agents should be used alone or in combination with immunomodulating agents for maintenance therapy, especially for the sole purpose of reducing the incidence of anti-TNF antibody formation.

C. OTHER CONSIDERATIONS—There have been two major controversies about the use of anti-TNF agents: (1) whether anti-TNF agents should be reserved as second-line therapy in patients with moderate to severe Crohn disease who have not responded to prior therapy with corticosteroids and immunomodulators (“step-up” therapy) or whether it should be used early in the course of illness with the goal of inducing early remission and altering the natural history of the disease; (2) whether anti-TNF therapy should be used alone or in combination with an immunomodulator to enhance remission and reduce the development of antibodies to the anti-TNF agent. In phase III pivotal trials assessing the efficacy of anti-TNF agents, remission rates were significantly higher among patients with a shorter duration of disease (< 5 years). A 2008 study of patients with moderate to severe Crohn disease of < 4 years duration, compared step-down therapy (infliximab for induction followed by azathioprine for maintenance) with step-up therapy (corticosteroids, followed by azathioprine, followed by infliximab). After 1-year, 61% of patients who received step-down therapy were in clinical remission compared with 42% who received step-up therapy. Moreover, mucosal healing occurred in 73% of patients treated with step-down therapy versus only 30% with step-up therapy. Further data in support of use of early combination therapy come from a large 2010 trial (SONIC) that compared three treatment arms: combination therapy with infliximab and azathioprine versus infliximab alone or azathioprine alone in patients with moderate to severe Crohn disease who had not previously been treated with immunomodulators or anti-TNF agents. After 6 months, clinical remission (57%) and mucosal healing (44%) was significantly higher with combination therapy than with either agent alone. Therefore, for patients with moderate to severe Crohn disease, data support the use of anti-TNF agents early in the course of disease and suggest that step-up therapy is obsolete. For most patients, anti-TNF therapy should be used in combination with an immunomodulator—at least during the first year of treatment. Combination therapy with anti-TNF and azathioprine

may not be appropriate in young men (< 26 years) in whom there is a higher risk of hepatosplenic T-cell lymphoma and in the elderly in whom there is a higher risk of lymphoma and infectious complications.

► Indications for Surgery

Over 50% of patients will require at least one surgical procedure. The main indications for surgery are intractability to medical therapy, intra-abdominal abscess, massive bleeding, symptomatic refractory internal or perianal fistulas, and intestinal obstruction. Patients with chronic obstructive symptoms due to a short segment of ileal stenosis are best treated with resection or stricturoplasty (rather than long-term medical therapy), which promotes rapid return of well-being and elimination of corticosteroids. After surgery, endoscopic evidence of recurrence occurs in 60% within 1 year. Endoscopic recurrence precedes clinical recurrence by months to years; clinical recurrence occurs in 20% of patients within 1 year and 80% within 10–15 years. Therapy with metronidazole, 250 mg three times daily for 3 months, or long-term therapy with immunomodulators (mercaptopurine or azathioprine) have only been modestly effective in preventing clinical and endoscopic recurrence after ileocolic resection; however, small uncontrolled studies suggest that anti-TNF therapies may prevent endoscopic recurrence in up to 90% of patients. Clinicians may choose to perform endoscopy in high-risk patients 6–12 months after surgery in order to identify patients with early endoscopic recurrence who may benefit from anti-TNF therapy.

► Prognosis

With proper medical and surgical treatment, the majority of patients are able to cope with this chronic disease and its complications and lead productive lives. Few patients die as a direct consequence of the disease.

► When to Refer

- For expertise in endoscopic procedures or capsule endoscopy.
- Any patient requiring hospitalization for follow-up.
- Patients with moderate to severe disease for whom therapy with immunomodulators or biologic agents is being considered.
- When surgery may be necessary.

► When to Admit

- An intestinal obstruction is suspected.
- An intra-abdominal or perirectal abscess is suspected.
- A serious infectious complication is suspected, especially in patients who are immunocompromised due to concomitant use of corticosteroids, immunomodulators, or anti-TNF agents.
- Patients with severe symptoms of diarrhea, dehydration, weight loss, or abdominal pain.
- Patients with severe or persisting symptoms despite treatment with corticosteroids.

- Cho SM et al. Postoperative management of Crohn disease. *Med Clin North Am.* 2010 Jan;94(1):179–88. [PMID: 19944804]
- Colombel JF et al; SONIC Study Group. Infliximab, azathioprine, or combination therapy for Crohn's disease. *N Engl J Med.* 2010 Apr 15;362(15):1383–95. [PMID: 20393175]
- Devlin SM et al. Evolving inflammatory bowel disease treatment paradigms: top-down versus step-up. *Med Clin North Am.* 2010 Jan;94(1):1–18. [PMID: 19944795]
- D'Haens GR et al. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response? *Am J Gastroenterol.* 2011 Feb;106(2):199–212. [PMID: 21045814]
- Ford AC et al. Efficacy of 5-aminosalicylates in Crohn's disease: systematic review and meta-analysis. *Am J Gastroenterol.* 2011 Apr;106(4):617–29. [PMID: 21407190]
- Ford AC et al. Efficacy of biologic therapies in inflammatory bowel disease: systematic review and meta-analysis. *Am J Gastroenterol.* 2011;106(4):644–59. [PMID: 21407183]
- Lichtenstein GR et al; Practice Parameters Committee of the American College of Gastroenterology. Management of Crohn's disease in adults. *Am J Gastroenterol.* 2009 Feb;104(2):465–83. [PMID: 19174807]
- Melmed GY et al. The appropriateness of concomitant immunomodulators with anti-tumor necrosis factor agents for Crohn's disease: one size does not fit all. *Clin Gastroenterol Hepatol.* 2010 Aug;8(8):655–9. [PMID: 20451665]
- Tromm A et al; International Budenofalk Study Group. Budesonide 9 mg is at least as effective as mesalazine 4.5 g in patients with mildly to moderately active Crohn's disease. *Gastroenterology.* 2011 Feb;140(2):425–34. [PMID: 21070781]

2. Ulcerative Colitis



ESSENTIALS OF DIAGNOSIS

- ▶ Bloody diarrhea.
- ▶ Lower abdominal cramps and fecal urgency.
- ▶ Anemia, low serum albumin.
- ▶ Negative stool cultures.
- ▶ Sigmoidoscopy is the key to diagnosis.

▶ General Considerations

Ulcerative colitis is an idiopathic inflammatory condition that involves the mucosal surface of the colon, resulting in diffuse friability and erosions with bleeding. Approximately one-third of patients have disease confined to the rectosigmoid region (proctosigmoiditis); one-third have disease that extends to the splenic flexure (left-sided colitis); and one-third have disease that extends more proximally (extensive colitis). There is some correlation between disease extent and symptom severity. In the majority of patients, the extent of colonic involvement does not progress over time. In most patients, the disease is characterized by periods of symptomatic flare-ups and remissions. Ulcerative colitis is more common in nonsmokers and former smokers. Disease severity may be lower in active smokers and may worsen in patients who stop smoking.

Appendectomy before the age of 20 years for acute appendicitis is associated with a reduced risk of developing ulcerative colitis.

▶ Clinical Findings

A. Symptoms and Signs

The clinical profile in ulcerative colitis is highly variable. Bloody diarrhea is the hallmark. On the basis of several clinical and laboratory parameters, it is clinically useful to classify patients as having mild, moderate, or severe disease (Table 15–12). Patients should be asked about stool frequency, the presence and amount of rectal bleeding, cramps, abdominal pain, fecal urgency, and tenesmus. Physical examination should focus on the patient's volume status as determined by orthostatic blood pressure and pulse measurements and by nutritional status. On abdominal examination, the clinician should look for tenderness and evidence of peritoneal inflammation. Red blood may be present on digital rectal examination.

1. Mild to moderate disease—Patients with mild disease have a gradual onset of infrequent diarrhea (less than four movements per day) with intermittent rectal bleeding and mucus. Stools may be formed or loose in consistency. Because of rectal inflammation, there is fecal urgency and tenesmus. Left lower quadrant cramps relieved by defecation are common, but there is no significant abdominal tenderness. Patients with moderate disease have more severe diarrhea with frequent bleeding. Abdominal pain and tenderness may be present but are not severe. There may be mild fever, anemia, and hypoalbuminemia.

2. Severe disease—Patients with severe disease have more than six bloody bowel movements per day, resulting in severe anemia, hypovolemia, and impaired nutrition with hypoalbuminemia. Abdominal pain and tenderness are present. “Fulminant colitis” is a subset of severe disease characterized by rapidly worsening symptoms with signs of toxicity.

Table 15–12. Ulcerative colitis: Assessment of disease activity.

	Mild	Moderate	Severe
Stool frequency (per day)	< 4	4–6	> 6 (mostly bloody)
Pulse (beats/min)	< 90	90–100	> 100
Hematocrit (%)	Normal	30–40	< 30
Weight loss (%)	None	1–10	> 10
Temperature (°F)	Normal	99–100	> 100
ESR (mm/h)	< 20	20–30	> 30
Albumin (g/dL)	Normal	3–3.5	< 3

ESR, erythrocyte sedimentation rate.

B. Laboratory Findings

The degree of abnormality of the hematocrit, sedimentation rate, and serum albumin reflects disease severity.

C. Endoscopy

In acute colitis, the diagnosis is readily established by sigmoidoscopy. The mucosal appearance is characterized by edema, friability, mucopus, and erosions. Colonoscopy should not be performed in patients with fulminant disease because of the risk of perforation. After patients have demonstrated improvement on therapy, colonoscopy is performed to determine the extent of disease.

D. Imaging

Plain abdominal radiographs are obtained in patients with severe colitis to look for significant colonic dilation. Barium enemas are of little utility in the evaluation of acute ulcerative colitis and may precipitate toxic megacolon in patients with severe disease.

► Differential Diagnosis

The initial presentation of ulcerative colitis is indistinguishable from other causes of colitis, clinically as well as endoscopically. Thus, the diagnosis of idiopathic ulcerative colitis is reached after excluding other known causes of colitis. Infectious colitis should be excluded by sending stool specimens for routine bacterial cultures (to exclude *Salmonella*, *Shigella*, and *Campylobacter*, as well as specific assays for *E coli* O157), ova and parasites (to exclude amebiasis), and stool toxin assay for *C difficile*. Mucosal biopsy can distinguish amebic colitis from ulcerative colitis. CMV colitis occurs in immunocompromised patients and is diagnosed on mucosal biopsy. Gonorrhea, chlamydial infection, herpes, and syphilis are considerations in sexually active patients with proctitis. In elderly patients with cardiovascular disease, ischemic colitis may involve the rectosigmoid. A history of radiation to the pelvic region can result in proctitis months to years later. Crohn disease involving the colon but not the small intestine may be confused with ulcerative colitis. In 10% of patients, a distinction between Crohn disease and ulcerative colitis may not be possible. Serologic testing (Prometheus IBD Serology 7 panel) in patients with indeterminate colitis is of limited clinical value (see discussion in the section on Crohn disease).

► Treatment

There are two main treatment objectives: (1) to terminate the acute, symptomatic attack and (2) to prevent recurrence of attacks. The treatment of acute ulcerative colitis depends on the extent of colonic involvement and the severity of illness.

Patients with mild to moderate disease should eat a regular diet but limit their intake of caffeine and gas-producing vegetables. Antidiarrheal agents should not be given in the acute phase of illness but are safe and helpful in patients with mild chronic symptoms. Oral loperamide (2 mg) or diphenoxylate with atropine (one tablet) may be

given up to four times daily. Such remedies are particularly useful at nighttime and when taken prophylactically for occasions when patients may not have reliable access to toilet facilities.

A. Mild to Moderate Distal Colitis

Patients with disease confined to the rectum or rectosigmoid region generally have mild to moderate but distressing symptoms. Patients may be treated with topical mesalamine, topical corticosteroids, or oral aminosalicylates (5-ASA) according to patient preference and cost considerations. Topical mesalamine is the drug of choice and is superior to topical corticosteroids and 5-ASA. Mesalamine is administered as a suppository, 1000 mg once daily at bedtime for proctitis, and as an enema, 4 g at bedtime for proctosigmoiditis, for 4–12 weeks, with 75% of patients improving. Patients who either decline or are unable to manage topical therapy may be treated with oral 5-ASA, as discussed below. Topical corticosteroids are a less expensive alternative to mesalamine but are also less effective. Hydrocortisone suppository or foam is prescribed for proctitis and hydrocortisone enema (80–100 mg) for proctosigmoiditis. Systemic effects from short-term use are very slight. For patients with distal disease who do not improve with topical or oral mesalamine therapy, the following options may be considered: (1) a combination of a topical agent with an oral 5-ASA agent is more effective than either drug alone; (2) combination topical therapy with a 5-ASA suppository or enema at bedtime and a corticosteroid enema or foam in the morning; or (3) a combination of oral 5-ASA agent, topical 5-ASA agent, and a topical corticosteroid. Patients with distal colitis who are refractory to all of these therapies or who have severe disease may require treatment with oral prednisone 40–60 mg/d or infliximab, as described below.

Patients whose acute symptoms resolve rapidly with immediate therapy may have prolonged periods of remission that are treated successfully with intermittent courses of therapy. Patients with early or frequent relapse should be treated with maintenance therapy with mesalamine suppositories (1000 mg) or enemas (4 g) nightly or every other night. For patients who have difficulty complying with topical therapies, oral 5-ASA agents are an acceptable, though possibly less effective, alternative (see below). Topical corticosteroids are ineffective for maintaining remission of distal colitis.

B. Mild to Moderate Colitis

1. 5-ASA Agents—Disease extending above the sigmoid colon is best treated with oral 5-ASA agents (mesalamine, balsalazide, or sulfasalazine), which result in symptomatic improvement in 50–75% of patients. Most patients improve within 3–6 weeks, though some require 2–3 months. Oral mesalamine (Asacol 0.8–1.6 g three times daily; Lialda 2.4–4.8 g once daily; Pentasa 0.5–1 g four times daily) and balsalazide, 2.25 g three times daily, are approved for active disease. These agents achieve clinical improvement in 50–70% of patients and remission in 20–30%. Total doses of mesalamine above 2–2.4 g/d result in marginal increases

in remission in patients with moderate disease. Oral sulfasalazine is comparable in efficacy to mesalamine and because of its low cost is still commonly used as a first-line agent by many providers, though it is associated with greater side effects. To minimize side effects, sulfasalazine is begun at a dosage of 500 mg twice daily and increased gradually over 1–2 weeks to 2 g twice daily. Total doses of 5–6 g/d may have greater efficacy but are poorly tolerated. Folic acid, 1 mg/d orally, should be administered to all patients taking sulfasalazine.

2. Corticosteroids—Patients with mild to moderate disease who do not improve after 4–8 weeks of 5-ASA therapy should have the addition of corticosteroid therapy. The addition of topical therapy with 5-ASA enemas (4 g once daily) or hydrocortisone foam or enemas (80–100 mg once or twice daily) may be tried first. Patients who do not improve after 2 more weeks require systemic corticosteroid therapy. Prednisone and methylprednisolone are most commonly used. Depending on the severity of illness, the initial oral dose of prednisone is 40–60 mg daily. Rapid improvement is observed in most cases within 2 weeks. Thereafter, tapering of prednisone should proceed by 5–10 mg/wk. After tapering to 20 mg/d, slower tapering (2.5 mg/week) is sometimes required. Complete tapering without symptomatic flare-ups is possible in the majority of patients.

3. Immunomodulating agents—A subset of patients either does not respond to aminosalicylates or corticosteroids or has symptomatic flares during attempts at corticosteroid tapering. Although surgical resection is traditionally recommended for patients with refractory disease, many patients may wish to avoid surgery and others have moderately severe disease for which surgery might not otherwise be warranted. Immunomodulating agents are used for the treatment of ulcerative colitis; however, the risks of these drugs from chronic immunosuppression must be weighed against the certainty of cure with surgical resection. Limited trials suggest mercaptopurine or azathioprine is of benefit in 60% of patients, allowing tapering of corticosteroids and maintenance of remission. There is less evidence that methotrexate is effective.

Infliximab is approved in the United States for the treatment of patients with moderate to severe ulcerative colitis who have had an inadequate response to conventional therapies (oral corticosteroids, mercaptopurine or azathioprine, and mesalamine). Following a three-dose induction regimen of 5 mg/kg administered at 0, 2, and 6 weeks, clinical response occurs in 65% and clinical remission in 35% (see Crohn Disease, above). Another anti-TNF agent, adalimumab, has demonstrated efficacy in phase III clinical trials but is not yet approved for treatment of ulcerative colitis.

4. Probiotics—VSL#3 (two packets twice daily), a probiotic compound containing eight different nonpathogenic strains of lactobacilli, bifidobacteria, and streptococci, has demonstrated significant benefit versus placebo in the treatment of mild to moderate ulcerative colitis in two, randomized, controlled multicenter trials. Although its efficacy relative to other agents is unclear, it may be considered as an adjunctive therapy for mild to moderate disease.

C. Severe Colitis

About 15% of patients with ulcerative colitis have a more severe course. Because they may progress to fulminant colitis or toxic megacolon, hospitalization is generally required.

1. General measures—Discontinue all oral intake for 24–48 hours or until the patient demonstrates clinical improvement. TPN is indicated only in patients with poor nutritional status or if feedings cannot be reinstated within 7–10 days. All opioid or anticholinergic agents should be discontinued. Restore circulating volume with fluids, correct electrolyte abnormalities, and consider transfusion for significant anemia (hematocrit < 25–28%). Abdominal examinations should be repeated to look for evidence of worsening distention or pain. A plain abdominal radiograph should be ordered on admission to look for evidence of colonic dilation. Send stools for bacterial culture, *C difficile* toxin assay, and examination for ova and parasites. CMV superinfection should be considered in patients receiving long-term immunosuppressive therapy who are unresponsive to corticosteroid therapy. Surgical consultation should be sought for all patients with severe disease.

2. Corticosteroid therapy—Methylprednisolone, 48–64 mg, or hydrocortisone, 300 mg, is administered intravenously in four divided doses or by continuous infusion over 24 hours. Higher or “pulse” doses are of no benefit. Hydrocortisone enemas (100 mg) may also be administered twice daily for treatment of urgency or tenesmus. Approximately 50–75% of patients achieve remission with systemic corticosteroids within 7–10 days. Once symptomatic improvement has occurred, oral fluids are reinstated. If fluids are well tolerated, intravenous corticosteroids are discontinued and the patient is started on oral prednisone (as described for moderate disease). Patients without significant improvement within 5 days of intravenous corticosteroid therapy should be referred for surgery or considered for anti-TNF therapies or cyclosporine.

3. Anti-TNF therapies—A single infusion of infliximab, 5 mg/kg, has been shown in controlled and uncontrolled studies to be effective in treating severe colitis in patients who did not improve within 4–7 days of intravenous corticosteroid therapy. In a controlled study of patients hospitalized for ulcerative colitis, colectomy was required within 3 months in 69% who received placebo therapy, compared with 47% who received infliximab. Thus, infliximab therapy should be considered in patients with severe ulcerative colitis who have not improved with intravenous corticosteroid therapy. (See Crohn Disease, above.)

4. Cyclosporine—Intravenous cyclosporine (2–4 mg/kg/d as a continuous infusion) benefits 60–75% of patients with severe colitis who have not improved after 7–10 days of corticosteroids, but it is associated with significant toxicity (nephrotoxicity, seizures, infection, hypertension). Up to two-thirds of responders may be maintained in remission with a combination of oral cyclosporine for 3 months and long-term therapy with mercaptopurine or azathioprine. A 2011 randomized study of patients with severe colitis

refractory to intravenous corticosteroids found similar response rates (85%) with cyclosporine and infliximab therapy.

5. Surgical therapy—Patients with severe disease who do not improve after corticosteroid, infliximab, or cyclosporine therapy are unlikely to respond to further medical therapy, and surgery is recommended.

D. Fulminant Colitis and Toxic Megacolon

A subset of patients with severe disease has a more fulminant course with rapid progression of symptoms over 1–2 weeks and signs of severe toxicity. These patients appear quite ill, with fever, prominent hypovolemia, hemorrhage requiring transfusion, and abdominal distention with tenderness. They are at a higher risk of perforation or development of toxic megacolon and must be followed closely. Broad-spectrum antibiotics should be administered to cover anaerobes and gram-negative bacteria.

Toxic megacolon develops in < 2% of cases of ulcerative colitis. It is characterized by colonic dilation of more than 6 cm on plain films with signs of toxicity. In addition to the therapies outlined above, nasogastric suction should be initiated. Patients should be instructed to roll from side to side and onto the abdomen in an effort to decompress the distended colon. Serial abdominal plain films should be obtained to look for worsening dilation or ischemia. Patients with fulminant disease or toxic megacolon who worsen or fail to improve within 48–72 hours should undergo surgery to prevent perforation. If the operation is performed before perforation, the mortality rate should be low.

► Maintenance of Remission

Without long-term therapy, 75% of patients who initially go into remission on medical therapy will experience a symptomatic relapse within 1 year. Long-term oral maintenance therapy with sulfasalazine, 1–1.5 g twice daily, or mesalamine have been shown to reduce relapse rates to < 35%. Acceptable mesalamine regimens are Asacol 0.8–1.2 g twice daily or 1.6–2.4 g once daily, Pentasa 1 g twice daily or 2 g once daily, Lialda 2.4 g once daily, and Apriso 1.5 g once daily. Mercaptopurine and azathioprine are useful in patients with frequent disease relapses (more than two per year) or corticosteroid-dependent disease to maintain remission. The role of long-term infliximab therapy in the maintenance of remission is evolving. In two, large, controlled studies of patients with active moderate to severe colitis, initial induction therapy was followed by infliximab maintenance infusions (5 mg/kg) administered every 8 weeks for 30–54 weeks. At the end of the study (30 or 54 weeks), 35% were in clinical remission, (21% in corticosteroid-free remission), a modest but impressive response in patients with more refractory disease. In considering long-term infliximab therapy, patients and clinicians need to weigh the long-term risks of immunosuppression against colectomy.

► Risk of Colon Cancer

In patients with ulcerative colitis with disease proximal to the rectum and in patients with Crohn colitis, there is a

markedly increased risk of developing colon carcinoma. A large meta-analysis of observational studies reported a cumulative incidence of 2% at 10 years, 8% at 20 years, and 18% after 30 years of disease. Retrospective studies suggest that the risk of colon cancer may be reduced in patients treated with long-term 5-ASA therapy. Ingestion of folic acid, 1 mg/d, also is associated with a decreased risk of cancer development. Colonoscopies are recommended every 1–2 years in patients with colitis, beginning 8–10 years after diagnosis. At colonoscopy, all adenoma-like polyps should be resected, when possible, and biopsies obtained of non-endoscopically resectable mass lesions. In addition, multiple (at least 32) random mucosal biopsies are taken throughout the colon at 10-cm intervals to look for evidence of dysplasia in flat mucosa. Because of the relatively high incidence of concomitant carcinoma in patients with dysplasia (either low or high grade) in flat mucosa or non-endoscopically resectable mass lesions, colectomy is recommended. Several prospective studies demonstrate that dye spraying with methylene blue or indigo carmine (“chromoendoscopy”) enhances the detection of subtle mucosal lesions, thereby significantly increasing the detection of dysplasia compared with standard colonoscopy. Although surveillance colonoscopy appears to be effective in reducing the incidence of colon cancer, patients must understand that approximately one-third of detected cancers are advanced, despite compliance with routine colonoscopy surveillance.

► Surgery in Ulcerative Colitis

Surgery is required in 25% of patients. Severe hemorrhage, perforation, and documented carcinoma are absolute indications for surgery. Surgery is indicated also in patients with fulminant colitis or toxic megacolon that does not improve within 48–72 hours, in patients with flat dysplasia or non-endoscopically resectable dysplastic lesions on surveillance colonoscopy, and in patients with refractory disease requiring long-term corticosteroids to control symptoms.

Although total proctocolectomy (with placement of an ileostomy) provides complete cure of the disease, most patients seek to avoid it out of concern for the impact it may have on their bowel function, their self-image, and their social interactions. After complete colectomy, patients may have a standard ileostomy with an external appliance, a continent ileostomy, or an internal ileal pouch that is anastomosed to the anal canal (ileal pouch-anal anastomosis). The latter maintains intestinal continuity, thereby obviating an ostomy. Under optimal circumstances, patients have five to seven loose bowel movements per day without incontinence. Endoscopic or histologic inflammation in the ileal pouch (“pouchitis”) develops in over 40% of patients, resulting in increased stool frequency, fecal urgency, cramping, and bleeding, but usually resolves with a 2-week course of oral metronidazole (250–500 mg three times daily) or ciprofloxacin (500 mg twice daily). Patients with frequently relapsing pouchitis may need continuous antibiotics. Probiotics containing nonpathogenic strains of lactobacilli, bifidobacteria, and streptococci (VSL#3) are effective in the maintenance of remission in patients with

recurrent pouchitis. Bismuth subsalicylate (Pepto Bismol, 262 mg, two tablets four times daily) has demonstrated benefit in some series. Some clinicians report that topical corticosteroids or oral budesonide 9 mg/d are of benefit. Refractory cases of pouchitis can be disabling and may require conversion to a standard ileostomy.

► Prognosis

Ulcerative colitis is a lifelong disease characterized by exacerbations and remissions. For most patients, the disease is readily controlled by medical therapy without need for surgery. The majority never require hospitalization. A subset of patients with more severe disease will require surgery, which results in complete cure of the disease. Properly managed, most patients with ulcerative colitis lead close to normal productive lives.

► When to Refer

- Colonoscopy: for evaluation of activity and extent of active disease and for surveillance for neoplasia in patients with quiescent disease for more than 8–10 years.
- When hospitalization is required.
- When surgical colectomy is indicated.

► When to Admit

- Patients with severe disease manifested by frequent bloody stools, anemia, weight loss, and fever.
- Patients with fulminant disease manifested by rapid progression of symptoms, worsening abdominal pain, distention, high fever, tachycardia.
- Patients with moderate to severe symptoms that do not respond to oral corticosteroids and require a trial of bowel rest and intravenous corticosteroids.

Danese S et al. Ulcerative colitis. *N Engl J Med*. 2011 Nov 3;365(18):1713–25. [PMID: 22047562]

Farraye FA et al. AGA medical position statement on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease. *Gastroenterology*. 2010 Feb;138(2):738–45. [PMID: 20141808]

Farraye FA et al. AGA technical review on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease. *Gastroenterology*. 2010 Feb;138(2):746–74. [PMID: 20141809]

Ford AC et al. Efficacy of 5-aminosalicylates in Crohn's disease: systematic review and meta-analysis. *Am J Gastroenterol*. 2011 Apr;106(4):617–29. [PMID: 21407190]

Kornbluth A et al. Ulcerative colitis practice guidelines in adults: American College Of Gastroenterology, Practice Parameters Committee. *Am J Gastroenterol*. 2010 Mar;105(3):501–23. [PMID: 20068560]

Reinisch W et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. *Gut*. 2011 Jun;60(6):780–6. [PMID: 21209123]

Sandborn WJ et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. *Gastroenterology*. 2011 Feb;142(2):257–65. [PMID: 22062358]

3. Microscopic Colitis

Microscopic colitis is an idiopathic condition that is found in up to 15% of patients who have chronic or intermittent watery diarrhea with normal-appearing mucosa at endoscopy. There are two major subtypes—lymphocytic colitis and collagenous colitis. In both, histologic evaluation of mucosal biopsies reveals chronic inflammation (lymphocytes, plasma cells) in the lamina propria and increased intraepithelial lymphocytes. Collagenous colitis is further characterized by the presence of a thickened band (> 10 μm) of subepithelial collagen. Both forms occur more commonly in women, especially in the fifth to sixth decades. Symptoms tend to be chronic or recurrent but may remit in most patients after several years. A more severe illness characterized by abdominal pain, fatigue, dehydration, and weight loss may develop in a subset of patients. The cause of microscopic colitis usually is unknown. Several medications have been implicated as etiologic agents, including NSAIDs, sertraline, paroxetine, lansoprazole, lisinopril, and simvastatin. Diarrhea usually abates within 30 days of stopping the offending medication. Celiac sprue may be present in up to 20% of patients and should be excluded with serologic testing (antitissue transglutaminase or antiendomysial antibody). Treatment is largely empiric since there are few well-designed, controlled treatment trials. Antidiarrheal therapy with loperamide is the first-line treatment, providing symptom improvement in up to 70%. For patients who do not respond to loperamide, the next option is budesonide (which is efficacious but expensive) versus other agents (which have limited data supporting efficacy but are less expensive). In uncontrolled studies, treatment with 5-ASAs (sulfasalazine, mesalamine) or bile-salt binding agents (cholestyramine, colestipol) is reported to be effective in many patients. A small unpublished controlled trial demonstrated efficacy for bismuth subsalicylate (two tablets three times daily) for 2 months; however, clinical experience has yielded only modest benefit. Delayed release budesonide (Entocort) 9 mg/d for 6–8 weeks has been shown in three prospective controlled studies to induce clinical remission in > 80% of patients; however, relapse occurs in most patients after stopping therapy. In two prospective studies, remission was maintained in 75% of patients treated with budesonide 6 mg/d compared with 25% of persons given placebo. In clinical practice, budesonide is tapered to the lowest effective dose for maintaining symptoms. Less than 3% of patients have refractory or severe symptoms, which may be treated with immunosuppressive agents (azathioprine or methotrexate).

Chande N et al. Interventions for treating microscopic colitis: a Cochrane inflammatory bowel disease and functional bowel disorders review group systematic review of randomized trials. *Am J Gastroenterol*. 2009 Jan;104(1):235–41. [PMID: 19098875]

Pardi DS et al. Microscopic colitis. *Gastroenterology*. 2011 Apr;140(4):1155–65. [PMID: 21303675]

DIVERTICULAR DISEASE OF THE COLON

Colonic diverticulosis increases with age, ranging from 5% in those under age 40, to 30% at age 60, to more than 50% over age 80 years in Western societies. Most are asymptomatic, discovered incidentally at endoscopy or on barium enema. Complications in one-third include lower gastrointestinal bleeding and diverticulitis.

Colonic diverticula may vary in size from a few millimeters to several centimeters and in number from one to several dozen. Almost all patients with diverticulosis have involvement in the sigmoid and descending colon; however, only 15% have proximal colonic disease.

In most patients, diverticulosis is believed to arise after many years of a diet deficient in fiber. The undistended, contracted segments of colon have higher intraluminal pressures. Over time, the contracted colonic musculature, working against greater pressures to move small, hard stools, develops hypertrophy, thickening, rigidity, and fibrosis. Diverticula may develop more commonly in the sigmoid because intraluminal pressures are highest in this region. The extent to which abnormal motility and hereditary factors contribute to diverticular disease is unknown. Patients with diffuse diverticulosis may have an inherent weakness in the colonic wall. Patients with abnormal connective tissue are also disposed to development of diverticulosis, including Ehlers-Danlos syndrome, Marfan syndrome, and scleroderma.

1. Uncomplicated Diverticulosis

More than two-thirds of patients with diverticulosis have uncomplicated disease and no specific symptoms. In some, diverticulosis may be an incidental finding detected during colonoscopic examination or barium enema examination. Some patients have nonspecific complaints of chronic constipation, abdominal pain, or fluctuating bowel habits. It is unclear whether these symptoms are due to alterations in the colonic musculature or underlying irritable bowel syndrome. Physical examination is usually normal but may reveal mild left lower quadrant tenderness with a thickened, palpable sigmoid and descending colon. Screening laboratory studies should be normal in uncomplicated diverticulosis.

There is no reason to perform imaging studies for the purpose of diagnosing uncomplicated disease. Diverticula are best seen on barium enema. Involved segments of colon may also be narrowed and deformed. Colonoscopy is a less sensitive means of detecting diverticula.

Asymptomatic patients in whom diverticulosis is discovered and patients with a history of complicated disease (see below) should be treated with a high-fiber diet or fiber supplements (bran powder, 1–2 tsp twice daily; psyllium or methylcellulose) (see section on constipation). Retrospective studies suggest that such treatment may decrease the likelihood of subsequent complications.

Maconi G et al. Treatment of diverticular disease of the colon and prevention of acute diverticulitis: a systematic review. *Dis Colon Rectum*. 2011 Oct;54(10):1326–38. [PMID: 21904150]
Tursi A et al. Review article: the current and evolving treatment of colonic diverticular disease. *Aliment Pharmacol Ther*. 2009 Sep 15;30(6):532–46. [PMID: 19549266]

2. Diverticulitis



ESSENTIALS OF DIAGNOSIS

- ▶ Acute abdominal pain and fever.
- ▶ Left lower abdominal tenderness and mass.
- ▶ Leukocytosis.

▶ Clinical Findings

A. Symptoms and Signs

Perforation of a colonic diverticulum results in an intra-abdominal infection that may vary from microperforation (most common) with localized paracolic inflammation to macroperforation with either abscess or generalized peritonitis. Thus, there is a range from mild to severe disease. Most patients with localized inflammation or infection report mild to moderate aching abdominal pain, usually in the left lower quadrant. Constipation or loose stools may be present. Nausea and vomiting are frequent. In many cases, symptoms are so mild that the patient may not seek medical attention until several days after onset. Physical findings include a low-grade fever, left lower quadrant tenderness, and a palpable mass. Stool occult blood is common, but hematochezia is rare. Leukocytosis is mild to moderate. Patients with free perforation present with a more dramatic picture of generalized abdominal pain and peritoneal signs.

B. Imaging

In patients with mild symptoms and a presumptive diagnosis of diverticulitis, empiric medical therapy is started without further imaging in the acute phase. Patients who respond to acute medical management should undergo complete colonic evaluation with colonoscopy or radiologic imaging (CT colonography or barium enema) after resolution of clinical symptoms to corroborate the diagnosis or exclude other disorders such as colonic neoplasms. In patients who do not improve rapidly after 2–4 days of empiric therapy and in those with severe disease, CT scan of the abdomen is obtained to look for evidence of diverticulitis and determine its severity, and to exclude other disorders that may cause lower abdominal pain. The presence of colonic diverticula and wall thickening, pericolic fat infiltration, abscess formation, or extraluminal air or contrast suggest diverticulitis. Endoscopy and colonography are contraindicated during the initial stages of an acute attack because of the risk of free perforation.

▶ Differential Diagnosis

Diverticulitis must be distinguished from other causes of lower abdominal pain, including perforated colonic carcinoma, Crohn disease, appendicitis, ischemic colitis, *C difficile*-associated colitis, and gynecologic disorders (ectopic pregnancy, ovarian cyst or torsion) by abdominal CT scan, pelvic ultrasonography, or radiographic studies of the distal colon that use water-soluble contrast enemas.

► Complications

Fistula formation may involve the bladder, ureter, vagina, uterus, bowel, and abdominal wall. Diverticulitis may result in stricturing of the colon with partial or complete obstruction.

► Treatment

A. Medical Management

Most patients can be managed with conservative measures. Patients with mild symptoms and no peritoneal signs may be managed initially as outpatients on a clear liquid diet and broad-spectrum oral antibiotics with anaerobic activity. Reasonable regimens include amoxicillin and clavulanate potassium (875 mg/125 mg) twice daily; or metronidazole, 500 mg three times daily; plus either ciprofloxacin, 500 mg twice daily, or trimethoprim-sulfamethoxazole, 160/800 mg twice daily orally, for 7–10 days or until the patient is afebrile for 3–5 days. Symptomatic improvement usually occurs within 3 days, at which time the diet may be advanced. Once the acute episode has resolved, a high fiber diet is often recommended. Patients with increasing pain, fever, or inability to tolerate oral fluids require hospitalization. Patients with severe diverticulitis (high fevers, leukocytosis, or peritoneal signs) and patients who are elderly or immunosuppressed or who have serious comorbid disease require hospitalization acutely. Patients should be given nothing by mouth and should receive intravenous fluids. If ileus is present, a nasogastric tube should be placed. Intravenous antibiotics should be given to cover anaerobic and gram-negative bacteria. Single-agent therapy with either a second-generation cephalosporin (eg, cefoxitin), piperacillin-tazobactam, or ticarcillin clavulanate appears to be as effective as combination therapy (eg, metronidazole or clindamycin plus an aminoglycoside or third-generation cephalosporin [eg, ceftazidime, cefotaxime]). Symptomatic improvement should be evident within 2–3 days. Intravenous antibiotics should be continued for 5–7 days, before changing to oral antibiotics.

B. Surgical Management

Surgical consultation and repeat abdominal CT imaging should be obtained on all patients with severe disease or those who do not improve after 72 hours of medical management. Patients with a localized abdominal abscess \geq 4 cm in size are usually treated urgently with a percutaneous catheter drain placed by an interventional radiologist. This permits control of the infection and resolution of the immediate infectious inflammatory process. In this manner, a subsequent elective one-stage surgical operation can be performed (if deemed necessary) in which the diseased segment of colon is removed and primary colonic anastomosis performed. Patients with chronic disease resulting in fistulas or colonic obstruction will also require elective surgical resection.

Indications for emergent surgical management include generalized peritonitis, large undrainable abscesses, and clinical deterioration despite medical management and percutaneous drainage. Surgery may be performed in one- or two-stage operations depending on the patient's

nutritional status, severity of illness, and extent of intra-abdominal peritonitis and abscess formation. In a two-stage operation, the diseased colon is resected and the proximal colon brought out to form a temporary colostomy. The distal colonic stump is either closed (forming a Hartmann pouch) or exteriorized as a mucous fistula. Weeks later, after inflammation and infection have completely subsided, the colon can be reconnected electively.

► Prognosis

Diverticulitis recurs in 10–30% of patients treated with medical management. Recurrent attacks warrant elective surgical resection, which carries a lower morbidity and mortality risk than emergency surgery.

► When to Refer

- Failure to improve within 72 hours of medical management.
- Presence of significant peridiverticular abscesses (\geq 4 cm) requiring possible percutaneous or surgical drainage.
- Generalized peritonitis or sepsis.
- Recurrent attacks.
- Chronic complications including colonic strictures or fistulas.

► When to Admit

- Severe pain or inability to tolerate oral intake.
- Signs of sepsis or peritonitis.
- CT scan showing signs of complicated disease (abscess, perforation).
- Failure to improve with outpatient management.
- Immunocompromised or frail, elderly patient.

Touzios JG et al. Diverticulosis and acute diverticulitis. *Gastroenterol Clin North Am.* 2009 Sep;38(3):513–25. [PMID: 19699411]

3. Diverticular Bleeding

Half of all cases of acute lower gastrointestinal bleeding are attributable to diverticulosis. For a full discussion, see the section on Acute Lower Gastrointestinal Bleeding, above.

POLYPS OF THE COLON

Polyps are discrete mass lesions that protrude into the intestinal lumen. Although most commonly sporadic, they may be inherited as part of a familial polyposis syndrome. Polyps may be divided into four major pathologic groups: **mucosal adenomatous polyps** (tubular, tubulovillous, and villous), **mucosal serrated polyps** (hyperplastic, sessile serrated polyp, and traditional serrated adenoma), **mucosal nonneoplastic polyps** (juvenile polyps, hamartomas, inflammatory polyps), and **submucosal lesions** (lipomas, lymphoid aggregates, carcinoids, pneumatosis cystoides intestinalis). Of polyps removed at colonoscopy,

over 70% are adenomatous; most of the remainder are serrated polyps. Adenomatous polyps and serrated polyps have significant clinical implications and will be considered further below.

NONFAMILIAL ADENOMATOUS & SERRATED POLYPS

Adenomas and serrated polyps may be flat, sessile, or pedunculated (containing a stalk). They are present in 30% of adults over 50 years of age. Their significance is that over 95% of cases of adenocarcinoma of the colon are believed to arise from these lesions. It is proposed that there is a polyp→carcinoma sequence whereby nonfamilial colorectal cancer develops through a continuous process from normal mucosa to adenoma or serrated polyps to carcinoma. The majority of cancers arise in adenomas after inactivation of the *APC* gene leads to chromosomal instability and inactivation or loss of other tumor suppressor genes. By contrast, cancers arising in the serrated pathway appear to have either *Kras* (traditional serrated adenomas) mutations or *BRAF* oncogene activation (sessile serrated adenomas) with methylation of CpG-rich promoter regions that leads to inactivation of tumor suppressor genes or mismatch repair genes (*MLH1*) with microsatellite instability.

Most adenomas are small (< 1 cm) and have a low risk of becoming malignant; < 5% of these enlarge with time. Adenomas are classified as “advanced” if they are ≥ 1 cm, or contain villous features or high-grade dysplasia. Advanced adenomas are believed to have a higher risk of harboring or progressing to malignancy. It has been estimated from longitudinal studies that it takes an average of 5 years for a medium-sized polyp to develop from normal-appearing mucosa and 10 years for a gross cancer to arise. In a 2009 meta-analysis of 18 studies in average-risk populations, the pooled prevalence of advanced adenomas is 6% and colorectal cancer 0.3%. The role of aspirin and NSAIDs for the chemoprevention of adenomatous polyps is discussed in Chapter 39, in the section on Colorectal Cancer.

Most sessile serrated polyps and traditional serrated adenomas are believed to arise from hyperplastic polyps. It is believed that sessile serrated polyps and traditional serrated adenomas harbor an increased risk of colorectal cancer similar or greater to that of adenomas. Many pathologists cannot reliably distinguish between hyperplastic polyps and sessile serrated polyps. Small hyperplastic polyps (< 5 mm) located in the rectosigmoid region are of no consequence, except that they cannot reliably be distinguished from adenomatous lesions other than by biopsy. Hyperplastic polyps located in the proximal colon (ie, proximal to the splenic flexure) may be associated with an increased prevalence of advanced neoplasia, particularly those larger than 1 cm.

► Clinical Findings

A. Symptoms and Signs

Most patients with adenomatous and serrated polyps are completely asymptomatic. Chronic occult blood loss may lead to iron deficiency anemia. Large polyps may ulcerate, resulting in intermittent hematochezia.

B. Fecal Occult Blood or Multitarget DNA Tests

FOBT, FIT, and fecal DNA tests are available as part of colorectal cancer screening programs (see Chapter 39). FIT is a fecal blood immunochemical test for hemoglobin that is more sensitive than guaiac-based tests for the detection of colorectal cancer and advanced adenomas. In prospective studies, the FIT test detected 15–35% of advanced noncancerous adenomas.

C. Radiologic Tests

Polyps are identified by means of barium enema examinations or CT colonography. Both studies require bowel cleansing with laxatives before the study and insertion of a rectal catheter for air insufflation during the study. CT colonography (“virtual colonoscopy”) uses data from helical CT imaging with computer-enabled luminal image reconstruction to generate two-dimensional and three-dimensional images of the colon. Using optimal imaging software with multidetector helical CT scanners, several studies report a sensitivity of ≥ 90% for the detection of polyps > 10 mm in size. However, the accuracy for detection of polyps 5–9 mm in size is significantly lower (sensitivity 50%). A small proportion of these small polyps harbor advanced histology (3–7%) or carcinoma (< 1%). Abdominal CT imaging results in a radiation exposure that may lead to a small risk of cancer. CT colonography is endorsed by US Multisociety Task Force as an acceptable option for screening for colorectal adenomatous polyps and cancer in average risk asymptomatic adults. Barium enema examinations as currently performed detect < 50% of colorectal polyps ≥ 1 cm in size. Where CT colonography is available, barium enema is no longer recommended due to its poor diagnostic accuracy.

D. Endoscopic Tests

Colonoscopy allows evaluation of the entire colon and is the best means of detecting and removing adenomatous and serrated polyps. It should be performed in all patients who have positive FOBT, FIT, fecal, or DNA tests or iron deficiency anemia (see Occult Gastrointestinal Bleeding and Obscure Gastrointestinal Bleeding, above), as the prevalence of colonic neoplasms is increased in these patients. Colonoscopy should also be performed in patients with polyps detected on radiologic imaging studies (barium enema or CT colonography) or adenomas detected on flexible sigmoidoscopy to remove these polyps and to fully evaluate the entire colon. Capsule endoscopy of the colon has a 73% sensitivity and 79% specificity for detection of adenomas with advanced histology or cancer compared with colonoscopy and cannot be recommended at this time to screen for colorectal neoplasia.

► Treatment

A. Colonoscopic Polypectomy

Most adenomatous and serrated polyps are amenable to colonoscopic removal with biopsy forceps or snare cautery. Large sessile polyps (> 2–3 cm) may be removed by snare cautery using a variety of techniques (eg, piecemeal or saline-lift assisted mucosal resection) or may require

surgical resection. Patients with large sessile polyps removed in piecemeal fashion should undergo repeated colonoscopy in 2–6 months to verify complete polyp removal. Complications after colonoscopic polypectomy include perforation in 0.2% and clinically significant bleeding in 0.3–1% of patients.

A malignant polyp is an adenoma that appears grossly benign at endoscopy but on histologic assessment is found to contain cancer that has penetrated through the muscularis mucosae into the submucosa. Malignant polyps may be considered to be adequately treated by polypectomy alone if: (1) the polyp is completely excised and submitted for pathologic examination, (2) it is well differentiated, (3) the margin is not involved, and (4) there is no vascular invasion. The risk of residual cancer or nodal metastasis with favorable histologic features is < 1%. The excision site of these “favorable” malignant polyps should be checked in 3 months for residual tissue. In patients with malignant polyps that have unfavorable histologic features, cancer resection is advisable if the patient is a good operative candidate.

B. Postpolypectomy Surveillance

Adenomas and serrated polyps can be found in 30–40% of patients when another colonoscopy is performed within 3–5 years after the initial examination. Periodic colonoscopic surveillance is therefore recommended to detect these “metachronous” lesions, which either may be new or may have been overlooked during the initial examination. Most of these polyps are small, without high-risk features and of little immediate clinical significance. The probability of detecting advanced neoplasms at surveillance colonoscopy depends on the number, size, and histologic features of the polyps removed on initial (index) colonoscopy. Patients with 1–2 small (< 1 cm) tubular adenomas (without villous features or high-grade dysplasia) should have their next colonoscopy in 5–10 years. Patients with 3–10 adenomas, an adenoma > 1 cm, or an adenoma with villous features or high-grade dysplasia should have their next colonoscopy at 3 years. Patients with more than 10 adenomas should have a repeat colonoscopy at 1–2 years and may be considered for evaluation for a familial polyposis syndrome (see below). Surveillance colonoscopy at 5 years is appropriate for patients with 1–2 small (< 1 cm) serrated polyps without cytologic dysplasia. Surveillance colonoscopy at 3 years should be considered for serrated polyps > 1 cm and those with cytologic atypia. No surveillance is recommended for patients with small, typical hyperplastic polyps located in the distal colon and rectum.

Ahnen DJ. The American College of Gastroenterology Emily Couric Lecture—the adenoma-carcinoma sequence revisited: has the era of genetic tailoring finally arrived? *Am J Gastroenterol.* 2011 Feb;106(2):190–8. [PMID: 21266962]

Allison JE. FIT: a valuable but underutilized screening test for colorectal cancer—it’s time for a change. *Am J Gastroenterol.* 2010 Sep;105(9):2026–8. [PMID: 20818351]

Heitman SJ et al. Prevalence of adenomas and colorectal cancer in average risk individuals: a systematic review and meta-analysis. *Clin Gastroenterol Hepatol.* 2009 Dec;7(12):1272–8. [PMID: 19523536]

Huang CS et al. The clinical significance of serrated polyps. *Am J Gastroenterol.* 2011 Feb;106(2):229–40. [PMID: 21045813]

Levin B et al. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. *Gastroenterology.* 2008 May;134(5):1570–95. [PMID: 18384785]

Regge D et al. Diagnostic accuracy of computed tomographic colonography for the detection of advanced neoplasia in individuals at increased risk of colorectal cancer. *JAMA.* 2009 Jun 17;301(23):2453–61. [PMID: 19531785]

Van Gossum A et al. Capsule endoscopy versus colonoscopy for the detection of polyps and cancer. *N Engl J Med.* 2009 Jul 16;361(3):264–70. [PMID: 19605831]

HEREDITARY COLORECTAL CANCER & POLYPOSIS SYNDROMES

Up to 4% of all colorectal cancers are caused by germline genetic mutations that impose on carriers a high lifetime risk of developing colorectal cancer (see Chapter 39). Because the diagnosis of these disorders has important implications for treatment of affected members and for screening of family members, it is important to consider these disorders in patients with a family history of colorectal cancer that has affected more than one family member, those with a personal or family history of colorectal cancer developing at an early age (≥ 50 years), those with a personal or family history of multiple polyps (> 20), and those with a personal or family history of multiple extracolonic malignancies.

1. Familial Adenomatous Polyposis

ESSENTIALS OF DIAGNOSIS

- ▶ Inherited condition characterized by early development of hundreds to thousands of colonic adenomatous polyps and adenocarcinoma.
- ▶ Variety of extracolonic manifestations, including duodenal adenomas, desmoid tumors, and osteomas.
- ▶ Attenuated variant with < 100 colonic adenomas.
- ▶ Genetic testing confirms mutation of *APC* gene (90%) or *MYH* gene (8%).
- ▶ Prophylactic colectomy recommended to prevent otherwise inevitable colon cancer.

▶ General Considerations

Familial adenomatous polyposis (FAP) is a syndrome affecting 1:10,000 people and accounts for approximately 0.5% of colorectal cancer. The classic form of FAP is characterized by the development of hundreds to thousands of colonic adenomatous polyps and a variety of extracolonic manifestations. An attenuated variant of FAP also has been recognized in which an average of only 25 polyps (range of 0–500) develop. FAP is most commonly caused

by autosomally dominant inherited mutations in the adenomatous polyposis coli (*APC*) gene on chromosome 5q21. FAP arises de novo in 15% of patients in the absence of genetic mutations in the parents. Mutations in the *MYH* gene, a gene involved with base excision repair, are present in patients with the classic and attenuated forms of FAP who do not have mutations of the *APC* gene. FAP due to *MYH* mutation is inherited in an autosomal recessive fashion, hence a family history of colorectal cancer may not be evident. Of patients with classic FAP, approximately 90% have a mutation in the *APC* gene and 8% in the *MYH* gene. In contrast, among patients with 10–100 adenomatous polyps and suspected attenuated FAP, *APC* mutations are identified in 15% but *MYH* mutations in 25%.

► Clinical Findings

A. Symptoms and Signs

Colorectal polyps develop by a mean age of 15 years and cancer at 40 years. Unless prophylactic colectomy is performed, colorectal cancer is inevitable by age 50 years. In attenuated FAP, the mean age for development of cancer is about 56 years.

Adenomatous polyps of the duodenum and periampullary area develop in over 90% of patients, resulting in a 5–8% lifetime risk of adenocarcinoma. Adenomas occur less frequently in the gastric antrum and small bowel and in those locations have a lower risk of malignant transformation. Gastric fundus gland polyps occur in over 50% but have an extremely low (0.6%) malignant potential.

A variety of other benign extraintestinal manifestations, including soft tissue tumors of the skin, desmoid tumors, osteomas, and congenital hypertrophy of the retinal pigment, develop in some patients with FAP. These extraintestinal manifestations vary among families, depending in part on the type or site of mutation in the *APC* gene. Desmoid tumors are locally invasive fibromas, most commonly intra-abdominal, that may cause bowel obstruction, ischemia, or hemorrhage. They occur in 15% of patients and are the second leading cause of death in FAP. Malignancies of the central nervous system (Turcot syndrome) and tumors of the thyroid and liver (hepatoblastomas) may also develop in patients with FAP.

B. Genetic Testing

Genetic counseling and testing should be offered to patients with a diagnosis of FAP established by endoscopy and to first-degree family members of patients with the disease; testing should be done also to confirm a diagnosis of attenuated disease in patients with 20 or more adenomas. Genetic testing is best performed by sequencing the *APC* gene to identify disease-associated mutations, which are identified in approximately 90% of cases of typical FAP. Mutational assessment of *MYH* should be considered in patients with negative test results and in patients with suspected attenuated FAP. First-degree relatives of patients with FAP should undergo genetic screening after age 10 years. If the assay cannot be done or is not informative, family members at risk should undergo yearly sigmoidoscopy beginning at 12 years of age.

► Treatment

Once the diagnosis has been established, complete proctocolectomy with ileoanal anastomosis or colectomy with ileorectal anastomosis is recommended, usually before age 20 years. Ileorectal anastomosis affords superior bowel function but has a 5% risk of development of rectal cancer, and for that reason frequent sigmoidoscopy with fulguration of polyps is required. Upper endoscopic evaluation of the stomach, duodenum, and periampullary area should be performed every 1–3 years to look for adenomas or carcinoma. Large (> 2 cm) periampullary adenomas require surgical resection. Sulindac and COX-2 selective agents (celecoxib) have been shown to decrease the number and size of polyps in the rectal stump but not the duodenum.

Latchford AR et al. Features of duodenal cancer in patients with familial adenomatous polyposis. *Clin Gastroenterol Hepatol*. 2009 Jun;7(6):659–63. [PMID: 19281862]

Stoffel EM et al. Genetic testing for hereditary colorectal cancer: challenges in identifying, counseling, and managing high-risk patients. *Gastroenterology*. 2010 Nov;139(5):1436–41. [PMID: 20858494]

Terdiman JP. MYH-associated disease: attenuated adenomatous polyposis of the colon is only part of the story. *Gastroenterology*. 2009 Dec;137(6):1883–6. [PMID: 19879216]

2. Hamartomatous Polyposis Syndromes

Hamartomatous polyposis syndromes are rare and account for < 0.1% of colorectal cancers.

Peutz-Jeghers syndrome is an autosomal dominant condition characterized by hamartomatous polyps throughout the gastrointestinal tract (most notably in the small intestine) as well as mucocutaneous pigmented macules on the lips, buccal mucosa, and skin. The hamartomas may become large, leading to bleeding, intussusception, or obstruction. Although hamartomas are not malignant, gastrointestinal malignancies (stomach, small bowel, and colon) develop in 40–60%, breast cancer in 30–50%, as well as a host of other malignancies of nonintestinal organs (gonads, pancreas). The defect has been localized to the serine threonine kinase 11 gene, and genetic testing is available.

Familial juvenile polyposis is also autosomal dominant and is characterized by several (more than ten) juvenile hamartomatous polyps located most commonly in the colon. There is an increased risk (up to 50%) of adenocarcinoma due to synchronous adenomatous polyps or mixed hamartomatous-adenomatous polyps. Genetic defects have been identified to loci on 18q and 10q (*MADH4* and *BMPRIA*). Genetic testing is available.

PTEN multiple hamartoma syndrome (Cowden disease) is characterized by hamartomatous polyps and lipomas throughout the gastrointestinal tract, trichilemmomas, and cerebellar lesions. An increased rate of malignancy is demonstrated in the thyroid, breast, and urogenital tract.

van Lier MG et al. High cancer risk in Peutz-Jeghers syndrome: a systematic review and surveillance recommendations. *Am J Gastroenterol*. 2010 Jun;105(6):1258–64. [PMID: 20051941]

3. Lynch Syndrome



ESSENTIALS OF DIAGNOSIS

- ▶ Autosomally dominant inherited condition
 - Caused by mutations in a gene that detect and repair DNA base-pair mismatches, resulting in DNA microsatellite instability and inactivation of tumor suppressor genes.
 - Increased lifetime risk of colorectal cancer (50–80%), endometrial cancer (30–60%), and other cancers that may develop at young age.
- ▶ Evaluation warranted in patients with personal history of early-onset colorectal cancer or family history of colorectal, endometrial, or other HNPCC-related cancers at young age or in multiple members.
- ▶ Diagnosis suspected by tumor tissue immunohistochemical staining for mismatch repair proteins or testing for microsatellite instability.
- ▶ Diagnosis confirmed by genetic testing.

▶ General Considerations

Lynch syndrome (also known as hereditary nonpolyposis colon cancer [HNPCC]) is an autosomal dominant condition in which there is a markedly increased risk of developing colorectal cancer as well as a host of other cancers, including endometrial, ovarian, renal or vesical, hepatobiliary, gastric, and small intestinal cancers. It is estimated to account for up to 3% of all colorectal cancers. Affected individuals have a 50–80% lifetime risk of developing colorectal carcinoma and a 30–60% lifetime risk of endometrial cancer. Unlike individuals with familial adenomatous polyposis, patients with HNPCC develop only a few adenomas, which may be flat and more often contain villous features or high-grade dysplasia. In contrast to the traditional polyp → cancer progression (which may take over 10 years), these polyps are believed to undergo rapid transformation over 1–2 years from normal tissue → adenoma → cancer. HNPCC and endometrial cancer tend to develop at an earlier age than sporadic, nonhereditary cancers (mean age 45–50 years). Compared with patients with sporadic tumors of similar pathologic stage, those with HNPCC tumors have improved survival. Synchronous or metachronous cancers occur within 10 years in up to 45% of patients.

HNPCC is caused by a defect in one of several genes that are important in the detection and repair of DNA base-pair mismatches: *MLH1*, *MSH2*, *MSH6*, *PMS2*, and *TACSTD1*. Germline mutations in *MLH1* and *MSH2* account for more than 90% of the known mutations in families with HNPCC. Mutations in any of these mismatch repair genes result in a characteristic phenotypic DNA abnormality known as microsatellite instability. In over 90% of cancers in patients with HNPCC, microsatellite instability is readily demonstrated by expansion or

contraction of DNA microsatellites (short, repeated DNA sequences). Microsatellite instability also occurs in 15% of sporadic colorectal cancers arising from serrated polyps, usually due to aberrant methylation of the *MLH1* promoter (resulting in decreased gene expression) and *BRAF* mutations.

▶ Clinical Findings

A thorough family cancer history is essential to identify families that may be affected with HNPCC so that appropriate genetic and colonoscopic screening can be offered. Owing to the limitations of genetic testing for HNPCC and the medical, psychological, and social implications that such testing may have, families with suspected HNPCC should be evaluated first by a genetic counselor and should give informed consent in writing before genetic testing is performed. Patients whose families meet any of the revised “Bethesda criteria” have an increased likelihood of harboring a germline mutation in one of the mismatch repair genes and should be considered for genetic testing. The “Bethesda criteria” are (1) colorectal cancer under age 50; (2) synchronous or metachronous colorectal or HNPCC-associated tumor regardless of age (endometrial, stomach, ovary, pancreas, ureter and renal pelvis, biliary tract, brain); (3) colorectal cancer with one or more first-degree relatives with colorectal or HNPCC-related cancer, with one of the cancers occurring before age 50; (4) colorectal cancer with two or more second-degree relatives with colorectal or HNPCC cancer, regardless of age; (5) tumors with infiltrating lymphocytes, mucinous/signet ring differentiation, or medullary growth pattern in patients younger than 60 years. Tumor tissues of affected individuals or family members meeting the revised Bethesda criteria should undergo immunohistochemical staining for *MLH1*, *MSH2*, *MSH6*, and *PMS2* (using commercially available assays) or testing for microsatellite instability (PCR amplification of a panel of DNA markers) or both. Individuals whose tumors have normal immunohistochemical staining or do not have microsatellite instability are unlikely to have germline mutations in mismatch repair genes, do not require further genetic testing, and do not require intensive cancer surveillance. Tumors with microsatellite instability or absent *MLH1* staining may undergo subsequent testing for *BRAF* mutation to detect sporadic (ie, noninherited) cancers arising from the serrated polyp pathway. Germline testing for gene mutations is positive in > 90% of individuals whose tumors show absent histochemical staining of one of the mismatch repair genes or high level of microsatellite instability without a *BRAF* mutation. Germline testing is also warranted in families with a strong history consistent with HNPCC when tumors from affected members are unavailable for assessment. If a mutation is detected in a patient with cancer in one of the known mismatch genes, genetic testing of other first-degree family members is indicated.

The Bethesda criteria identify approximately 70% of mutation-positive HNPCC families but overlook 30%. For this reason, expert guidelines issued in 2009–10 have recommended that all colorectal cancers should undergo testing for Lynch syndrome with either immunohistochemistry

or microsatellite instability and *BRAF* testing. Patients whose tumors test positive using one of these tests should be given genetic counseling before undergoing germline testing for gene mutations.

► Screening & Treatment

If genetic testing documents an HNPCC gene mutation, affected relatives should be screened with colonoscopy every year beginning at age 25 (or at age 5 years younger than the age at diagnosis of the youngest affected family member). If cancer is found, subtotal colectomy with ileorectal anastomosis (followed by annual surveillance of the rectal stump) should be performed. Women should undergo screening for endometrial and ovarian cancer beginning at age 25–35 years with pelvic examination, CA-125 assay, endometrial aspiration, and transvaginal ultrasound. Prophylactic hysterectomy and oophorectomy may be considered, especially in women of postchildbearing age. Similarly, consideration should be given for increased cancer surveillance in family members in proven or suspected HNPCC families who do not wish to undergo germline testing. (See Chapter 39 for Colorectal Cancer.)

Boland CR et al. Report from the Jerusalem workshop on Lynch syndrome—hereditary nonpolyposis colorectal cancer. *Gastroenterology*. 2010 Jun;138(7):2197.e1–7. [PMID: 20416305]

Edelstein DL et al. Rapid development of colorectal neoplasia in patients with Lynch syndrome. *Clin Gastroenterol Hepatol*. 2011 Apr;9(4):340–3. [PMID: 21070872]

Limburg PJ et al. Prevalence of alterations in DNA mismatch repair genes in patients with young-onset colorectal cancer. *Clin Gastroenterol Hepatol*. 2011 Jun;9(6):497–502. [PMID: 21056691]

ANORECTAL DISEASES

(See Chapter 39 for Carcinoma of the Anus.)

HEMORRHOIDS

ESSENTIALS OF DIAGNOSIS

- ▶ Bright red blood per rectum.
- ▶ Protrusion, discomfort.
- ▶ Characteristic findings on external anal inspection and anoscopic examination.

► General Considerations

Internal hemorrhoids are subepithelial vascular cushions consisting of connective tissue, smooth muscle fibers, and arteriovenous communications between terminal branches of the superior rectal artery and rectal veins. They are a normal anatomic entity, occurring in all adults, that contribute to normal anal pressures and ensure a water-tight closure of the anal canal. They commonly occur in three primary locations—right anterior, right posterior, and left

lateral. External hemorrhoids arise from the inferior hemorrhoidal veins located below the dentate line and are covered with squamous epithelium of the anal canal or perianal region.

Hemorrhoids may become symptomatic as a result of activities that increase venous pressure, resulting in distention and engorgement. Straining at stool, constipation, prolonged sitting, pregnancy, obesity, and low-fiber diets all may contribute. With time, redundancy and enlargement of the venous cushions may develop and result in bleeding or protrusion.

► Clinical Findings

A. Symptoms and Signs

Patients often attribute a variety of perianal complaints to “hemorrhoids.” However, the principal problems attributable to internal hemorrhoids are bleeding, prolapse, and mucoid discharge. Bleeding is manifested by bright red blood that may range from streaks of blood visible on toilet paper or stool to bright red blood that drips into the toilet bowl after a bowel movement. Uncommonly, bleeding is severe and prolonged enough to result in anemia. Initially, internal hemorrhoids are confined to the anal canal (stage I). Over time, the internal hemorrhoids may gradually enlarge and protrude from the anal opening. At first, this mucosal prolapse occurs during straining and reduces spontaneously (stage II). With progression over time, the prolapsed hemorrhoids may require manual reduction after bowel movements (stage III) or may remain chronically protruding (stage IV). Chronically prolapsed hemorrhoids may result in a sense of fullness or discomfort and mucoid perianal discharge, resulting in irritation and soiling of underclothes. Pain is unusual with internal hemorrhoids, occurring only when there is extensive inflammation and thrombosis of irreducible tissue or with thrombosis of an external hemorrhoid (see below).

B. Examination

External hemorrhoids are readily visible on perianal inspection. Nonprolapsed internal hemorrhoids are not visible but may protrude through the anus with gentle straining while the clinician spreads the buttocks. Prolapsed hemorrhoids are visible as protuberant purple nodules covered by mucosa. The perianal region should also be examined for other signs of disease such as fistulas, fissures, skin tags, condyloma, anal cancer, or dermatitis. On digital examination, uncomplicated internal hemorrhoids are neither palpable nor painful. Anoscopic evaluation, best performed in the prone jackknife position, provides optimal visualization of internal hemorrhoids.

► Differential Diagnosis

Small volume rectal bleeding may be caused by anal fissure or fistula, neoplasms of the distal colon or rectum, ulcerative colitis or Crohn colitis, infectious proctitis, or rectal ulcers. Rectal prolapse, in which a full thickness of rectum protrudes concentrically from the anus, is readily distinguished from mucosal hemorrhoidal prolapse.

Proctosigmoidoscopy or colonoscopy should be performed in all patients with hematochezia to exclude disease in the rectum or sigmoid colon that could be misinterpreted in the presence of hemorrhoidal bleeding.

► Treatment

A. Conservative Measures

Most patients with early (stage I and stage II) disease can be managed with conservative treatment. To decrease straining with defecation, patients should be given instructions for a high-fiber diet and told to increase fluid intake with meals. Dietary fiber may be supplemented with bran powder (1–2 tbsp twice daily added to food or in 8 oz of liquid) or with commercial bulk laxatives (eg, Benefiber, Metamucil, Citrucel). Suppositories and rectal ointments have no demonstrated utility in the management of mild disease. Mucoïd discharge may be treated effectively by the local application of a cotton ball tucked next to the anal opening after bowel movements.

B. Medical Treatment

Patients with stage I, stage II, and stage III hemorrhoids and recurrent bleeding despite conservative measures may be treated without anesthesia with injection sclerotherapy, rubber band ligation, or application of electrocoagulation (bipolar cautery or infrared photocoagulation). The choice of therapy is dictated by operator preference, but rubber band ligation is preferred due to its ease of use and high rate of efficacy. Major complications occur in <2%, including pelvic sepsis, pelvic abscess, urinary retention, and bleeding. Recurrence is common unless patients alter their dietary habits. Edematous, prolapsed (stage IV) internal hemorrhoids, may be treated acutely with topical creams, foams, or suppositories containing various combinations of emollients, topical anesthetics, (eg, pramoxine, dibucaine), vasoconstrictors (eg, phenylephrine), astringents (witch hazel) and corticosteroids. Common preparations include Preparation H (several formulations), Anusol HC, Proctofoam, Nupercainal, Tucks, and Doloproct (not available in the United States).

C. Surgical Treatment

Surgical excision (hemorrhoidectomy) is reserved for < 5–10% of patients with chronic severe bleeding due to stage III or stage IV hemorrhoids or patients with acute thrombosed stage IV hemorrhoids with necrosis. Complications of surgical hemorrhoidectomy include postoperative pain (which may persist for 2–4 weeks) and impaired continence.

Thrombosed External Hemorrhoid

Thrombosis of the external hemorrhoidal plexus results in a perianal hematoma. It most commonly occurs in otherwise healthy young adults and may be precipitated by coughing, heavy lifting, or straining at stool. The condition is characterized by the relatively acute onset of an exquisitely painful, tense and bluish perianal nodule covered with skin that may be up to several centimeters in size. Pain is most severe

within the first few hours but gradually eases over 2–3 days as edema subsides. Symptoms may be relieved with warm sitz baths, analgesics, and ointments. If the patient is evaluated in the first 24–48 hours, removal of the clot may hasten symptomatic relief. With the patient in the lateral position, the skin around and over the lump is injected subcutaneously with 1% lidocaine using a tuberculin syringe with a 30-gauge needle. An ellipse of skin is then excised and the clot evacuated. A dry gauze dressing is applied for 12–24 hours, and daily sitz baths are then begun.

► When to Refer

- Stage I, II, or III: When conservative measures fail and expertise in medical procedures is needed (injection, banding, thermocoagulation).
- Stage IV: When surgical excision is required.

Abramowitz L. Diagnosis and management of haemorrhoidal disease from a global perspective. *Aliment Pharmacol Ther.* 2010 May;31(Suppl 1):1–58. [PMID: 20500735]
 Jutabha R et al. Randomized prospective study of endoscopic rubber band ligation compared with bipolar coagulation for chronically bleeding internal hemorrhoids. *Am J Gastroenterol.* 2009 Aug; 104(8):2057–64. [PMID: 19513028]

ANORECTAL INFECTIONS

A number of organisms can cause inflammation of the anal and rectal mucosa. Proctitis is characterized by anorectal discomfort, tenesmus, constipation, and mucus or bloody discharge. Most cases of proctitis are sexually transmitted, especially by anal-receptive intercourse. Infectious proctitis must be distinguished from noninfectious causes of anorectal symptoms, including anal fissures or fistulae, perirectal abscesses, anorectal carcinomas, and inflammatory bowel disease (ulcerative colitis or Crohn disease).

► Etiology & Management

Several organisms may cause infectious proctitis.

A. *Neisseria gonorrhoeae*

Gonorrhea may cause itching, burning, tenesmus, and a mucopurulent discharge, although many anorectal infections are asymptomatic. Rectal swab specimens should be taken during anoscopy for culture; Gram staining is unreliable. Cultures should also be taken from the pharynx and urethra in men and from the cervix in women. Complications of untreated infections include strictures, fissures, fistulas, and perirectal abscesses. (For treatment, see Chapter 33.)

B. *Treponema pallidum*

Anal syphilis may be asymptomatic or may lead to perianal pain and discharge. With primary syphilis, the chancre may be at the anal margin or within the anal canal and may mimic a fissure, fistula, or ulcer. Proctitis or inguinal lymphadenopathy may be present. With secondary syphilis, condylomata lata (pale-brown, flat verrucous lesions)

may be seen, with secretion of foul-smelling mucus. Although the diagnosis may be established with dark-field microscopy or fluorescent antibody testing of scrapings from the chancre or condylomas, this requires proper equipment and trained personnel. The VDRL or RPR test is positive in 75% of primary cases and in 99% of secondary cases. (For treatment, see Chapter 34.)

C. *Chlamydia trachomatis*

Chlamydial infection may cause proctitis similar to gonorrheal proctitis; however, some infections are asymptomatic. It also may cause lymphogranuloma venereum, characterized by proctocolitis with fever and bloody diarrhea, painful perianal ulcerations, anorectal strictures and fistulas, and inguinal adenopathy (buboes). Previously rare in developed countries, an increasing number of cases have been identified among men who have sex with men. The diagnosis is established by serology, culture, or PCR-based testing of rectal discharge or rectal biopsy. Recommended treatment is doxycycline 100 mg orally twice daily for 21 days.

D. Herpes Simplex Type 2

Herpes simplex virus is a common cause of anorectal infection. Symptoms occur 4–21 days after exposure and include severe pain, itching, constipation, tenesmus, urinary retention, and radicular pain from involvement of lumbar or sacral nerve roots. Small vesicles or ulcers may be seen in the perianal area or anal canal. Sigmoidoscopy is not usually necessary but may reveal vesicular or ulcerative lesions in the distal rectum. Diagnosis is established by viral culture, PCR, or antigen detection assays of vesicular fluid. Symptoms resolve within 2 weeks, but viral shedding may continue for several weeks. Patients may remain asymptomatic with or without viral shedding or may have recurrent mild relapses. Treatment of acute infection for 7–10 days with acyclovir, 400 mg or famciclovir 250 mg orally three times daily or valacyclovir 1 g twice daily, has been shown to reduce the duration of symptoms and viral shedding. Patients with AIDS and recurrent relapses may benefit from long-term suppressive therapy (see Chapter 31).

E. *Condylomata Acuminata*

Condylomata acuminata (warts) are a significant cause of anorectal symptoms. Caused by the human papillomavirus (HPV), they may occur in the perianal area, the anal canal, or the genitals. Perianal or anal warts are seen in up to 25% of men who have sex with men. HIV-positive individuals with condylomas have a higher relapse rate after therapy and a higher rate of progression to high-grade dysplasia or anal cancer. The warts are located on the perianal skin and extend within the anal canal up to 2 cm above the dentate line (see Figure 6–31). Patients may have no symptoms or may report itching, bleeding, and pain. The warts may be small and flat or verrucous, or may form a confluent mass that may obscure the anal opening. Warts must be distinguished from condyloma lata (secondary syphilis) or anal cancer. Biopsies should be obtained from

large or suspicious lesions. Treatment can be difficult. Sexual partners should also be examined and treated. The treatment of anogenital warts is discussed in Chapter 30. HPV vaccines have demonstrated efficacy in preventing anogenital warts and routine vaccination is now recommended for all girls and women ages 9–26 years. In 2009, the FDA also approved HPV vaccination in boys and men ages 9–26 years (see Chapters 1 and 30). Vaccination also should be considered in men who have sex with men. HIV-positive individuals with condylomas who have detectable serum HIV RNA levels should have anosopic surveillance every 3–6 months.

Kim JJ. Targeted human papillomavirus vaccination of men who have sex with men in the USA: a cost-effectiveness modeling analysis. *Lancet Infect Dis*. 2010 Dec;10(12):845–52. [PMID: 21051295]

Van Kemseke C. Sexually transmitted diseases and the anorectum. *Acta Gastroenterol Belg*. 2009 Oct–Dec;72(4):413–9. [PMID: 20163035]

Workowski KA et al; Centers for Disease Control and Prevention (CDC). Sexually transmitted diseases treatment guidelines, 2010. *MMWR Recomm Rep*. 2010 Dec 17;59(RR-12):1–110. [PMID: 21160459]

FECAL INCONTINENCE

There are five general requirements for bowel continence: (1) solid or semisolid stool (even healthy young adults have difficulty maintaining continence with liquid rectal contents); (2) a distensible rectal reservoir (as sigmoid contents empty into the rectum, the vault must expand to accommodate); (3) a sensation of rectal fullness (if the patient cannot sense this, overflow may occur before the patient can take appropriate action); (4) intact pelvic nerves and muscles; and (5) the ability to reach a toilet in a timely fashion.

▶ Minor Incontinence

Many patients complain of inability to control flatus or slight soilage of undergarments that tends to occur after bowel movements or with straining or coughing. This may be due to local anal problems such as prolapsed hemorrhoids that make it difficult to form a tight anal seal or isolated weakness of the internal anal sphincter, especially if stools are somewhat loose. Patients should be treated with fiber supplements to provide greater stool bulk. Coffee and other caffeinated beverages should be eliminated. The perianal skin should be cleansed with moist, lanolin-coated tissue (baby wipes) to reduce excoriation and infection. After wiping, loose application of a cotton ball near the anal opening may absorb small amounts of fecal leakage. Prolapsing hemorrhoids may be treated with band ligation or surgical hemorrhoidectomy. Control of flatus and seepage may be improved by Kegel perineal exercises. Conditions such as ulcerative proctitis that cause tenesmus and urgency, chronic diarrheal conditions, and irritable bowel syndrome may result in difficulty in maintaining complete continence, especially if a toilet is not readily available. Loperamide may be helpful to reduce

urge incontinence in patients with loose stools and may be taken in anticipation of situations in which a toilet may not be readily available. The elderly may require more time or assistance to reach a toilet, which may lead to incontinence. Scheduled toileting and the availability of a bedside commode are helpful. Elderly patients with chronic constipation may develop stool impaction leading to “overflow” incontinence.

► Major Incontinence

Complete uncontrolled loss of stool reflects a significant problem with central perception or neuromuscular function. Incontinence that occurs without awareness suggests a loss of central awareness (eg, dementia, cerebrovascular accident, multiple sclerosis) or peripheral nerve injury (eg, spinal cord injury, cauda equina syndrome, pudendal nerve damage due to obstetric trauma or pelvic floor prolapse, aging, or diabetes mellitus). Incontinence that occurs despite awareness and active efforts to retain stool suggests sphincteric damage, which may be caused by traumatic childbirth (especially forceps delivery), episiotomy, prolapse, prior anal surgery, and physical trauma.

Physical examination should include careful inspection of the perianal area for hemorrhoids, rectal prolapse, fissures, fistulas, and either gaping or a keyhole defect of the anal sphincter (indicating severe sphincteric injury or neurologic disorder). The perianal skin should be stimulated to confirm an intact anocutaneous reflex. Digital examination during relaxation gives valuable information about resting tone (due mainly to the internal sphincter) and contraction of the external sphincter and pelvic floor during squeezing. It also excludes fecal impaction. Anoscopy is required to evaluate for hemorrhoids, fissures, and fistulas. Proctosigmoidoscopy is useful to exclude rectal carcinoma or proctitis. Anal ultrasonography or pelvic MRI is the most reliable test for definition of anatomic defects in the external and internal anal sphincters. Anal manometry may also be useful to define the severity of weakness, to assess sensation, and to predict response to biofeedback training. In special circumstances, surface electromyography is useful to document sphincteric denervation and proctography to document perineal descent or rectal intussusception.

Patients who are incontinent only of loose or liquid stools are treated with bulking agents and antidiarrheal drugs (eg, loperamide, 2 mg before meals and prophylactically before social engagements, shopping trips, etc). Patients with incontinence of solid stool benefit from scheduled toilet use after glycerin suppositories or tap water enemas. Biofeedback training with anal sphincteric strengthening (Kegel) exercises (alternating 5-second squeeze and 10-second rest for 10 minutes twice daily) may be helpful in motivated patients to lower the threshold for awareness of rectal filling—or to improve anal sphincter squeeze function—or both. Operative management is seldom needed but should be considered in patients with major incontinence due to prior injury to the anal sphincter who have not responded to medical therapy.

► When to Refer

- Conservative measures fail.
- Anorectal tests are deemed necessary (manometry, ultrasonography, electromyography).
- A surgically correctable lesion is suspected.

Leung FW et al. Approach to fecal incontinence and constipation in older hospitalized patients. *Hosp Pract (Minneapolis)*. 2011 Feb;39(1):97–104. [PMID: 21441765]

Rao SS. Advances in diagnostic assessment of fecal incontinence and dyssynergic defecation. *Clin Gastroenterol Hepatol*. 2010 Nov;8(11):910–9. [PMID: 20601142]

Whitehead WE et al. Fecal incontinence in US adults: epidemiology and risk factors. *Gastroenterology*. 2009 Aug;137(2):512–7. [PMID: 19410574]

OTHER ANAL CONDITIONS

► Anal Fissures

Anal fissures are linear or rocket-shaped ulcers that are usually < 5 mm in length. Most fissures are believed to arise from trauma to the anal canal during defecation, perhaps caused by straining, constipation, or high internal sphincter tone. They occur most commonly in the posterior midline, but 10% occur anteriorly. Fissures that occur off the midline should raise suspicion for Crohn disease, HIV/AIDS, tuberculosis, syphilis, or anal carcinoma. Patients complain of severe, tearing pain during defecation followed by throbbing discomfort that may lead to constipation due to fear of recurrent pain. There may be mild associated hematochezia, with blood on the stool or toilet paper. Anal fissures are confirmed by visual inspection of the anal verge while gently separating the buttocks. Acute fissures look like cracks in the epithelium. Chronic fissures result in fibrosis and the development of a skin tag at the outermost edge (sentinel pile). Digital and anoscopic examinations may cause severe pain and may not be possible. Medical management is directed at promoting effortless, painless bowel movements. Fiber supplements and sitz baths should be prescribed. Topical anesthetics (EMLA cream) may provide temporary relief. Healing occurs within 2 months in up to 45% of patients with conservative management. Chronic fissures may be treated with topical 0.2–0.4% nitroglycerin or diltiazem 2% ointment (1 cm of ointment) applied twice daily just inside the anus with the tip of a finger for 4–8 weeks or injection of botulinum toxin (20 units) into the internal anal sphincter. All of these treatments result in healing in 50–80% of patients with chronic anal fissure, but headaches occur in up to 40% of patients treated with nitroglycerin. Fissures recur in up to 40% of patients after treatment. Chronic or recurrent fissures benefit from lateral internal sphincterotomy; however, minor incontinence may complicate this procedure.

Festen S et al. Blinded randomized clinical trial of botulinum toxin versus isosorbide dinitrate ointment for treatment of anal fissure. *Br J Surg*. 2009 Dec;96(12):1393–9. [PMID: 19918859]
Nelson RL. Operative procedures for fissure in ano. *Cochrane Database Syst Rev*. 2010 Jan 20;(1):CD002199. [PMID: 20091532]

▶ Perianal Abscess & Fistula

The anal glands located at the base of the anal crypts at the dentate line may become infected, leading to abscess formation. Other causes of abscess include anal fissure and Crohn disease. Abscesses may extend upward or downward through the intersphincteric plane. Symptoms of perianal abscess are throbbing, continuous perianal pain. Erythema, fluctuance, and swelling may be found in the perianal region on external examination or in the ischiorectal fossa on digital rectal examination. Perianal abscesses are treated with local incision and drainage, while ischiorectal abscesses require drainage in the operating room. After drainage of an abscess, most patients are found to have a fistula in ano.

Fistula in ano most often arises in an anal crypt and is usually preceded by an anal abscess. In patients with fistulas that connect to the rectum, other disorders such as Crohn disease, lymphogranuloma venereum, rectal tuberculosis, and cancer should be considered. Fistulas are associated with purulent discharge that may lead to itching, tenderness, and pain. The treatment of Crohn-related fistula is discussed elsewhere in this chapter. Treatment of simple idiopathic fistula in ano is by surgical incision or excision under anesthesia. Care must be taken to preserve the anal sphincters. Surgical fistulotomy for treatment of complex (high, transsphincteric) anal fissures carries a high risk of incontinence. Techniques for healing the fistula while preserving the sphincter include an endoanal advancement flap over the internal opening and insertion of a bioprosthetic plug into the fistula opening.

Adamina M et al. To plug or not to plug: a cost-effectiveness analysis for complex anal fistula. *Surgery*. 2010 Jan;147(1):72–8. [PMID: 19733880]

▶ Perianal Pruritus

Perianal pruritus is characterized by perianal itching and discomfort. It may be caused by poor anal hygiene associated with fistulas, fissures, prolapsed hemorrhoids, skin tags, and minor incontinence. Conversely, overzealous cleansing with soaps may contribute to local irritation or contact dermatitis. Contact dermatitis, atopic dermatitis, bacterial infections (*Staphylococcus* or *Streptococcus*), parasites (pinworms, scabies), candidal infection (especially in diabetics), sexually transmitted disease (condylomata acuminata, herpes, syphilis, molluscum contagiosum), and other skin conditions (psoriasis, Paget, lichen sclerosis) must be excluded. In patients with idiopathic perianal pruritus, examination may reveal erythema, excoriations, or lichenified, eczematous skin. Education is vital to successful therapy. Spicy foods, coffee, chocolate, and tomatoes may cause irritation and should be eliminated. After bowel movements, the perianal area should be cleansed with nonscented wipes premoistened with lanolin followed by gentle drying. A piece of cotton ball should be tucked next to the anal opening to absorb perspiration or fecal seepage. Anal ointments and lotions may exacerbate the condition and should be avoided. A short course of high-potency topical corticosteroid may be tried, although efficacy has not been demonstrated. Diluted capsaicin cream (0.006%) led to symptomatic relief in 75% of patients in a double-blind crossover study. (See Chapter 39 for Carcinoma of the Anus.)

Markell KW et al. Pruritus ani: etiology and management. *Surg Clin North Am*. 2010 Feb;90(1):125–35. [PMID: 20109637]

16

Liver, Biliary Tract, & Pancreas Disorders

Lawrence S. Friedman, MD

JAUNDICE & EVALUATION OF ABNORMAL LIVER BIOCHEMICAL TESTS

ESSENTIALS OF DIAGNOSIS

- ▶ Jaundice results from accumulation of bilirubin in the body tissues; cause may be hepatic or nonhepatic.
- ▶ Hyperbilirubinemia may be due to abnormalities in the formation, transport, metabolism, and excretion of bilirubin.
- ▶ Mild elevations of the aminotransferase levels are common in clinical practice and caused most commonly by nonalcoholic fatty liver disease.
- ▶ Evaluation of obstructive jaundice begins with ultrasonography and is usually followed by cholangiography.

▶ General Considerations

Jaundice (icterus) results from the accumulation of bilirubin—a product of heme metabolism—in the body tissues. Hyperbilirubinemia may be due to abnormalities in the formation, transport, metabolism, and excretion of bilirubin. Total serum bilirubin is normally 0.2–1.2 mg/dL (3.42–20.52 μmol/L) (mean levels are higher in men than women and higher in whites and Hispanics than blacks and correlate inversely with the risk of stroke, respiratory disease, cardiovascular disease, and mortality, presumably because of an antioxidant effect). Jaundice may not be recognizable until serum bilirubin levels are about 3 mg/dL (51.3 μmol/L).

Jaundice is caused by predominantly unconjugated or conjugated bilirubin in the serum (Table 16–1). Unconjugated hyperbilirubinemia may result from overproduction of bilirubin because of hemolysis; impaired hepatic uptake of bilirubin due to certain drugs; or impaired conjugation of bilirubin by glucuronide, as in Gilbert syndrome, due to mild decreases in uridine diphosphate (UDP) glucuronyl

transferase, or Crigler–Najjar syndrome, caused by moderate decreases or absence of UDP glucuronyl transferase. Hemolysis alone rarely elevates the serum bilirubin level to more than 7 mg/dL (119.7 μmol/L). Predominantly conjugated hyperbilirubinemia may result from impaired excretion of bilirubin from the liver due to hepatocellular disease, drugs, sepsis, hereditary hepatocanalicular transport defects (such as Dubin–Johnson syndrome, progressive familial intrahepatic cholestasis syndromes, and some cases of intrahepatic cholestasis of pregnancy), or from extrahepatic biliary obstruction. Features of some hyperbilirubinemic syndromes are summarized in Table 16–2. The term “cholestasis” denotes retention of bile in the liver, and the term “cholestatic jaundice” is often used when conjugated hyperbilirubinemia results from impaired bile flow.

▶ Clinical Findings

A. Unconjugated Hyperbilirubinemia

Stool and urine color are normal, and there is mild jaundice and indirect (unconjugated) hyperbilirubinemia with no bilirubin in the urine. Splenomegaly occurs in hemolytic disorders except in sickle cell anemia.

B. Conjugated Hyperbilirubinemia

1. Hereditary cholestatic syndromes or intrahepatic cholestasis—The patient may be asymptomatic; cholestasis is often accompanied by pruritus, light-colored stools, and jaundice.

2. Hepatocellular disease—Malaise, anorexia, low-grade fever, and right upper quadrant discomfort are frequent. Dark urine, jaundice, and, in women, amenorrhea occur. An enlarged tender liver, vascular spiders, palmar erythema, ascites, gynecomastia, sparse body hair, fetor hepaticus, and asterixis may be present, depending on the cause, severity, and chronicity of liver dysfunction.

C. Biliary Obstruction

There may be right upper quadrant pain, weight loss (suggesting carcinoma), jaundice, dark urine, and light-colored stools.

Table 16-1. Classification of jaundice.

Type of Hyperbilirubinemia	Location and Cause
Unconjugated hyperbilirubinemia (predominant indirect-reacting bilirubin)	Increased bilirubin production (eg, hemolytic anemias, hemolytic reactions, hematoma, pulmonary infarction) Impaired bilirubin uptake and storage (eg, posthepatitis hyperbilirubinemia, Gilbert syndrome, Crigler-Najjar syndrome, drug reactions)
Conjugated hyperbilirubinemia (predominant direct-reacting bilirubin)	HEREDITARY CHOLESTATIC SYNDROMES
	Faulty excretion of bilirubin conjugates (eg, Dubin-Johnson syndrome, Rotor syndrome) or mutation in genes coding for bile salt transport proteins (eg, progressive familial intrahepatic cholestasis syndromes, benign recurrent intrahepatic cholestasis, and some cases of intrahepatic cholestasis of pregnancy)
	HEPATOCELLULAR DYSFUNCTION
	Biliary epithelial and hepatocyte damage (eg, hepatitis, hepatic cirrhosis) Intrahepatic cholestasis (eg, certain drugs, biliary cirrhosis, sepsis, postoperative jaundice) Hepatocellular damage or intrahepatic cholestasis resulting from miscellaneous causes (eg, spirochetal infections, infectious mononucleosis, cholangitis, sarcoidosis, lymphomas, industrial toxins)
	BILIARY OBSTRUCTION
	Cholelithiasis, biliary atresia, carcinoma of biliary duct, sclerosing cholangitis, choledochal cyst, external pressure on common duct, pancreatitis, pancreatic neoplasms

Symptoms and signs may be intermittent if caused by a stone, carcinoma of the ampulla, or cholangiocarcinoma. Pain may be absent early in pancreatic cancer. Occult blood in the stools suggests cancer of the ampulla. Hepatomegaly

and a palpable gallbladder (Courvoisier sign) are characteristic, but neither specific nor sensitive, of a pancreatic head tumor. Fever and chills are more common in benign obstruction with associated cholangitis.

Table 16-2. Hyperbilirubinemic disorders.

	Nature of Defect	Type of Hyperbilirubinemia	Clinical and Pathologic Characteristics
Gilbert syndrome	Reduced activity of glucuronyl transferase	Unconjugated (indirect) bilirubin	Benign, asymptomatic hereditary jaundice. Hyperbilirubinemia increased by 24- to 36-hour fast. No treatment required. Prognosis excellent.
Dubin-Johnson syndrome ¹	Faulty excretory function of hepatocytes	Conjugated (direct) bilirubin	Benign, asymptomatic hereditary jaundice. Gallbladder does not visualize on oral cholecystography. Liver darkly pigmented on gross examination. Biopsy shows centrilobular brown pigment. Prognosis excellent.
Rotor syndrome			Similar to Dubin-Johnson syndrome, but liver is not pigmented and the gallbladder is visualized on oral cholecystography. Prognosis excellent.
Recurrent intrahepatic cholestasis ²	Cholestasis, often on a familial basis	Unconjugated plus conjugated (total) bilirubin	Episodic attacks of jaundice, itching, and malaise. Onset in early life and may persist for a lifetime. Alkaline phosphatase increased. Cholestasis found on liver biopsy. (Biopsy may be normal during remission.) Prognosis is generally excellent for "benign" recurrent intrahepatic cholestasis but may not be for familial forms.
Intrahepatic cholestasis of pregnancy ³	Cholestasis		Benign cholestatic jaundice, usually occurring in the third trimester of pregnancy. Itching, gastrointestinal symptoms, and abnormal liver excretory function tests. Cholestasis noted on liver biopsy. Prognosis excellent, but recurrence with subsequent pregnancies or use of oral contraceptives is characteristic.

¹The Dubin-Johnson syndrome is caused by a point mutation in the gene coding for an organic anion transporter in bile canaliculi on chromosome 10q23-24.

²Mutations in genes that control hepatocellular transport systems that are involved in the formation of bile and inherited as autosomal recessive traits are on chromosomes 18q21-22, 2q24, and 7q21 in families with progressive familial intrahepatic cholestasis. Gene mutations on chromosome 18q21-22 alter a P-type ATPase expressed in the small intestine and liver and others on chromosome 2q24 alter the bile acid export pump and also cause benign recurrent intrahepatic cholestasis.

³Mutations in the *MDR3* gene on chromosome 7q 21 that are responsible for progressive familial intrahepatic cholestasis type 3 account for some cases of intrahepatic cholestasis of pregnancy.

Table 16-3. Liver biochemical tests: Normal values and changes in hepatocellular and obstructive jaundice.

Tests	Normal Values	Hepatocellular Jaundice	Uncomplicated Obstructive Jaundice
Bilirubin ¹			
Direct	0.1–0.3 mg/dL (1.71–5.13 μmol/L)	Increased	Increased
Indirect	0.2–0.7 mg/dL (3.42–11.97 μmol/L)	Increased	Increased
Urine bilirubin	None	Increased	Increased
Serum albumin	3.5–5.5 g/dL (35–55 g/L)	Decreased	Generally unchanged
Alkaline phosphatase	30–115 units/L (0.6–2.3 mkat/L)	Mildly increased (+)	Markedly increased (++++)
Prothrombin time	INR of 1.0–1.4. After vitamin K, 10% decrease in 24 hours	Prolonged if damage is severe; does not respond to parenteral vitamin K	Prolonged if obstruction is marked; generally responds to parenteral vitamin K
ALT, AST	ALT, ≤ 30 units/L (0.6 mkat/L) (men), ≤ 19 units/L (0.38 mkat/L) (women); AST, 5–40 units/L (0.1–0.8 mkat/L)	Increased in hepatocellular damage, as in viral hepatitis	Minimally increased

¹Measured by the van den Bergh reaction, which overestimates direct bilirubin in normal persons. ALT, alanine aminotransferase; AST, aspartate aminotransferase; INR, international normalized ratio.

► Diagnostic Studies (Tables 16-3, 16-4)

A. Laboratory Findings

Serum alanine and aspartate aminotransferase (ALT and AST) levels vary with age and correlate with body mass

Table 16-4. Causes of serum aminotransferase elevations.¹

Mild Elevations (< 5× normal)	Severe Elevations (> 15× normal)
Hepatic: ALT-predominant	Acute viral hepatitis (A–E, herpes)
Chronic hepatitis B, C, and D	Medications/toxins
Acute viral hepatitis (A–E, EBV, CMV)	Ischemic hepatitis
Steatosis/steatohepatitis	Autoimmune hepatitis
Hemochromatosis	Wilson disease
Medications/toxins	Acute bile duct obstruction
Autoimmune hepatitis	Acute Budd-Chiari syndrome
α ₁ -Antitrypsin (α ₁ -antiprotease) deficiency	Hepatic artery ligation
Wilson disease	
Celiac disease	
Hepatic: AST-predominant	
Alcohol-related liver injury (AST:ALT > 2:1)	
Cirrhosis	
Nonhepatic	
Strenuous exercise	
Hemolysis	
Myopathy	
Thyroid disease	
Macro-AST	

¹Almost any liver disease can cause moderate aminotransferase elevations (5–15× normal).

ALT, alanine aminotransferase; AST, aspartate aminotransferase; CMV, cytomegalovirus; EBV, Epstein-Barr virus.

Adapted with permission from Green RM et al. AGA technical review on the evaluation of liver chemistry tests. *Gastroenterology*. 2002 Oct;123(4):1367–84.

index and mortality from liver disease and inversely with caffeine consumption and possibly serum vitamin D levels. There is controversy about whether an elevated ALT level is associated with mortality from coronary artery disease, cancer, diabetes mellitus, and all causes. Normal reference values for ALT and AST are lower than generally reported when persons with risk factors for fatty liver are excluded. Truncal fat and early-onset paternal obesity are risk factors for increased ALT levels. Levels are mildly elevated in > 25% of persons with untreated celiac disease and in type 1 diabetic patients with so-called glycogenic hepatopathy and often rise transiently in healthy persons who begin taking 4 g of acetaminophen per day or experience rapid weight gain on a fast-food diet. Levels may rise strikingly in patients with acute biliary obstruction from cholelithiasis. Nonalcoholic fatty liver disease is by far the most common cause of mildly to moderately elevated aminotransferase levels. Elevated ALT and AST levels, often > 1000 units/L, are the hallmark of hepatocellular necrosis or inflammation. Elevated alkaline phosphatase levels are seen in cholestasis or infiltrative liver disease (such as tumor, granulomas, or amyloidosis). Isolated alkaline phosphatase elevations of hepatic rather than bone, intestinal, or placental origin are confirmed by concomitant elevation of γ-glutamyl transpeptidase or 5'-nucleotidase levels. Serum γ-glutamyl transpeptidase levels appear to correlate with the risk of mortality and disability in the general population. The differential diagnosis of any liver test elevation includes toxicity caused by drugs, herbal remedies, and toxins.

B. Imaging

Demonstration of dilated bile ducts by ultrasonography or CT indicates biliary obstruction (90–95% sensitivity). Ultrasonography, CT, and MRI may also demonstrate hepatomegaly, intrahepatic tumors, and portal hypertension. Use of color Doppler ultrasonography or contrast agents that produce microbubbles increases the sensitivity of

transcutaneous ultrasonography for detecting small neoplasms. MRI is the most accurate technique for identifying isolated liver lesions such as hemangiomas, focal nodular hyperplasia, or focal fatty infiltration and for detecting hepatic iron overload. The most sensitive techniques for detection of individual small hepatic lesions in patients eligible for resection of metastases are multiphase helical or multislice CT; CT arterial portography, in which imaging follows intravenous contrast infusion via a catheter placed in the superior mesenteric artery; MRI with use of gadolinium or ferumoxides as contrast agents; and intraoperative ultrasonography. Dynamic gadolinium-enhanced MRI and MRI following administration of superparamagnetic iron oxide show promise in visualizing hepatic fibrosis. Because of its much lower cost, ultrasonography is preferable to CT (~six times more expensive) or MRI (~seven times more expensive) as a screening test. Positron emission tomography (PET) can be used to detect small pancreatic tumors and metastases. Ultrasonography can detect gallstones with a sensitivity of 95%.

Magnetic resonance cholangiopancreatography (MRCP) is a sensitive, noninvasive method of detecting bile duct stones, strictures, and dilatation; however, it is less reliable than endoscopic retrograde cholangiopancreatography (ERCP) for distinguishing malignant from benign strictures. ERCP requires a skilled endoscopist and may be used to demonstrate pancreatic or ampullary causes of jaundice, carry out papillotomy and stone extraction, insert a stent through an obstructing lesion, or facilitate direct cholangiopancreatography. Complications of ERCP include pancreatitis ($\leq 5\%$) and, less commonly, cholangitis, bleeding, or duodenal perforation after papillotomy. Risk factors for post-ERCP pancreatitis include female sex, prior post-ERCP pancreatitis, suspected sphincter of Oddi dysfunction, and a difficult or failed cannulation. Percutaneous transhepatic cholangiography (PTC) is an alternative approach to evaluating the anatomy of the biliary tree. Severe complications of PTC occur in 3% and include fever, bacteremia, bile peritonitis, and intraperitoneal hemorrhage. Endoscopic ultrasonography is the most sensitive test for detecting small lesions of the ampulla or pancreatic head and for detecting portal vein invasion by pancreatic cancer. It is also accurate in detecting or excluding bile duct stones.

C. Liver Biopsy

Percutaneous liver biopsy is the definitive study for determining the cause and histologic severity of hepatocellular dysfunction or infiltrative liver disease. In patients with suspected metastatic disease or a hepatic mass, it is performed under ultrasound or CT guidance. A transjugular route can be used in patients with coagulopathy or ascites. The risk of bleeding after a percutaneous liver biopsy is approximately 0.5% and is increased in persons with a platelet count $\leq 60,000/\text{mCL}$. Panels of blood tests (eg, FibroSure) and transient or magnetic resonance elastography (using ultrasonographic and magnetic resonance techniques, respectively, to measure liver stiffness) are emerging approaches for estimating the degree of liver fibrosis without the need for liver biopsy.

► When to Refer

Patients with jaundice should be referred for diagnostic procedures.

► When to Admit

Patients with liver failure should be hospitalized.

- Breitling LP et al. Gamma-glutamyltransferase, general and cause-specific mortality in 19,000 construction workers followed over 20 years. *J Hepatol*. 2011 Sep;55(3):594–601. [PMID: 21256904]
- Horsfall LJ et al. Serum bilirubin and risk of respiratory disease and death. *JAMA*. 2011 Feb 16;305(7):691–7. [PMID: 21325185]
- Liangpunsakul S et al. Serum vitamin D concentrations and unexplained elevation in ALT among US adults. *Dig Dis Sci*. 2011 Jul;56(7):2124–9. [PMID: 21503677]
- Nguyen D et al. Noninvasive assessment of liver fibrosis. *Hepatology*. 2011 Jun;53(6):2107–10. [PMID: 21547935]
- Rogal SS et al. Clinical problem-solving. A sweet source of abdominal pain. *N Engl J Med*. 2011 May 5;364(18):1762–7. [PMID: 21542747]

DISEASES OF THE LIVER

See Chapter 39 for Hepatocellular Carcinoma.

ACUTE HEPATITIS A



ESSENTIALS OF DIAGNOSIS

- Prodrome of anorexia, nausea, vomiting, malaise, aversion to smoking.
- Fever, enlarged and tender liver, jaundice.
- Normal to low white cell count; markedly elevated aminotransferases.

► General Considerations

Hepatitis A virus (HAV) is a 27-nm RNA hepatovirus (in the picornavirus family) that causes epidemics or sporadic cases of hepatitis. The virus is transmitted by the fecal–oral route, and its spread is favored by crowding and poor sanitation. Since introduction of the HAV vaccine in the United States in 1995, the incidence rate of HAV infection has declined from 14 to 1.3 per 100,000 population, with a corresponding decline in the mortality rate of 32%, and international travel has emerged as the leading risk factor, accounting for over 40% of cases, with another 18% of cases attributable to exposure to an international traveler. Common source outbreaks may still result from contaminated water or food, including inadequately cooked shellfish. Outbreaks among people who inject drugs and cases among international adoptees and their contacts also have been reported.

The incubation period averages 30 days. HAV is excreted in feces for up to 2 weeks before clinical illness but rarely after the first week of illness. The mortality rate for hepatitis A is low, and fulminant hepatitis A is uncommon except for rare instances in which it occurs in a patient with chronic hepatitis C. There is no chronic carrier state. In the United States, about 30% of the population have serologic evidence of previous HAV infection.


► Clinical Findings

A. Symptoms and Signs

Figure 16–1 shows the typical course of acute hepatitis A. Clinical illness is more severe in adults than in children, in whom it is usually asymptomatic. The onset may be abrupt or insidious, with malaise, myalgia, arthralgia, easy fatigability, upper respiratory symptoms, and anorexia. A distaste for smoking, paralleling anorexia, may occur early. Nausea and vomiting are frequent, and diarrhea or constipation may occur. Fever is generally present but is low-grade except in occasional cases in which systemic toxicity may occur. Defervescence and a fall in pulse rate often coincide with the onset of jaundice.

Abdominal pain is usually mild and constant in the right upper quadrant or epigastrium, often aggravated by jarring or exertion, and rarely may be severe enough to simulate cholecystitis.

Jaundice occurs after 5–10 days but may appear at the same time as the initial symptoms. In many patients, jaundice never develops. With the onset of jaundice, prodromal symptoms often worsen, followed by progressive clinical improvement. Stools may be acholic during this phase.



▲ **Figure 16–1.** The typical course of acute type A hepatitis. (HAV, hepatitis A virus; anti-HAV, antibody to hepatitis A virus; ALT, alanine aminotransferase.)

(Reprinted, with permission, from Koff RS. Acute viral hepatitis. In: Friedman LS, Keeffe EB [editors]. *Handbook of Liver Disease*, 3rd ed. Philadelphia: Saunders Elsevier, 2012.)

The acute illness usually subsides over 2–3 weeks with complete clinical and laboratory recovery by 9 weeks. In some cases, clinical, biochemical, and serologic recovery may be followed by one or two relapses, but recovery is the rule. A protracted course has been reported to be associated with HLA *DRB1*1301*. Acute cholecystitis occasionally complicates the course of acute hepatitis A.

Hepatomegaly—rarely marked—is present in over half of cases. Liver tenderness is usually present. Splenomegaly is reported in 15% of patients, and soft, enlarged lymph nodes—especially in the cervical or epitrochlear areas—may occur.

B. Laboratory Findings

The white blood cell count is normal to low, especially in the preicteric phase. Large atypical lymphocytes may occasionally be seen. Mild proteinuria is common, and bilirubinuria often precedes the appearance of jaundice. Strikingly elevated AST or ALT occurs early, followed by elevations of bilirubin and alkaline phosphatase; in a minority of patients, the latter persist after aminotransferase levels have normalized. Cholestasis is occasionally marked. Antibody to hepatitis A (anti-HAV) appears early in the course of the illness (Figure 16–1). Both IgM and IgG anti-HAV are detectable in serum soon after the onset. Peak titers of IgM anti-HAV occur during the first week of clinical disease and disappear within 3–6 months. Detection of IgM anti-HAV is an excellent test for diagnosing acute hepatitis A but is not recommended for the evaluation of asymptomatic persons with persistently elevated serum aminotransferase levels because false-positive results occur. False-negative results have been described in a patient receiving rituximab for rheumatoid arthritis. Titers of IgG anti-HAV rise after 1 month of the disease and may persist for years. IgG anti-HAV (in the absence of IgM anti-HAV) indicates previous exposure to HAV, noninfectivity, and immunity.

► Differential Diagnosis

The differential diagnosis includes other viruses that cause hepatitis, particularly hepatitis B and C, and diseases such as infectious mononucleosis, cytomegalovirus infection, and herpes simplex virus infection; spirochetal diseases such as leptospirosis and secondary syphilis; brucellosis; rickettsial diseases such as Q fever; drug-induced liver disease; and ischemic hepatitis (shock liver). Occasionally, autoimmune hepatitis (see below) may have an acute onset mimicking acute viral hepatitis. Rarely, metastatic cancer of the liver, lymphoma, or leukemia may present as a hepatitis-like picture.

The prodromal phase of viral hepatitis must be distinguished from other infectious disease such as influenza, upper respiratory infections, and the prodromal stages of the exanthematous diseases. Cholestasis may mimic obstructive jaundice.

► Prevention

Strict isolation of patients is not necessary, but hand washing after bowel movements is required. Unvaccinated persons who are exposed to HAV are advised to receive postexposure

prophylaxis with a single dose of HAV vaccine or immune globulin (0.02 mL/kg) as soon as possible. The vaccine is preferred in healthy persons ages 1 year to 40 years, whereas immune globulin is preferred in those who are younger than 1 year or older than 40 years or who are immunocompromised or who have chronic liver disease.

Two effective inactivated hepatitis A vaccines are available in the United States and recommended for persons living in or traveling to endemic areas (including military personnel), patients with chronic liver disease upon diagnosis (after prescreening for immunity), persons with clotting-factor disorders who are treated with concentrates, men who have sex with men, animal handlers, illicit drug users, sewage workers, food handlers, close personal contacts of international adoptees, and children and caregivers in day-care centers and institutions. For healthy travelers, a single dose of vaccine at any time before departure can provide adequate protection. Routine vaccination is advised for all children in states with an incidence of hepatitis A at least twice the national average and has been approved by the Advisory Committee on Immunization Practices of the Centers for Disease Control and Prevention (CDC) for use in all children between ages 1 and 2 in the United States. HAV vaccine is also effective in the prevention of secondary spread to household contacts of primary cases. The recommended dose for adults is 1 mL (1440 ELISA units) of Havrix (GlaxoSmithKline) or 1 mL (50 units) of Vaqta (Merck) intramuscularly, followed by a booster dose at 6–18 months. A combined hepatitis A and B vaccine (Twinrix, GlaxoSmithKline) is available. HIV infection impairs the response to the HAV vaccine, especially in persons with a CD4 count <200/mL.

▶ Treatment

Bed rest is recommended only if symptoms are marked. If nausea and vomiting are pronounced or if oral intake is substantially decreased, intravenous 10% glucose is indicated.

Dietary management consists of palatable meals as tolerated, without overfeeding; breakfast is usually tolerated best. Strenuous physical exertion, alcohol, and hepatotoxic agents should be avoided. Small doses of oxazepam are safe because metabolism is not hepatic; morphine sulfate should be avoided.

Corticosteroids have no benefit in patients with viral hepatitis, including those with fulminant disease.

▶ Prognosis

In most patients, clinical recovery is generally complete within 3 months. Laboratory evidence of liver dysfunction may persist for a longer period, but most patients recover completely. Hepatitis A does not cause chronic liver disease, although it may persist for up to 1 year, and clinical and biochemical relapses may occur before full recovery. The mortality rate is <0.6%.

▶ When to Admit

- Encephalopathy is present.
- INR > 1.6.
- The patient is unable to maintain hydration.

American Academy of Pediatrics Committee on Infectious Diseases. Recommendations for administering hepatitis A vaccine to contacts of international adoptees. *Pediatrics*. 2011 Oct;128(4):803–4. [PMID: 21949136]

Centers for Disease Control and Prevention (CDC). Hepatitis A vaccination coverage among U.S. children aged 12–23 months—immunization information system sentinel sites, 2006–2009. *MMWR Morb Mortal Wkly Rep*. 2010 Jul 2;59(25):776–9. [PMID: 20592688]

Klevens RM et al. The evolving epidemiology of hepatitis A in the United States: incidence and molecular epidemiology from population-based surveillance, 2005–2007. *Arch Intern Med*. 2010 Nov 8;170(20):1811–8. [PMID: 21059974]

ACUTE HEPATITIS B



ESSENTIALS OF DIAGNOSIS

- ▶ Prodrome of anorexia, nausea, vomiting, malaise, aversion to smoking.
- ▶ Fever, enlarged and tender liver, jaundice.
- ▶ Normal to low white blood cell count; markedly elevated aminotransferases early in the course.
- ▶ Liver biopsy shows hepatocellular necrosis and mononuclear infiltrate but is rarely indicated.

▶ General Considerations

Hepatitis B virus (HBV) is a 42-nm hepadnavirus with a partially double-stranded DNA genome, inner core protein (hepatitis B core antigen, HBcAg), and outer surface coat (hepatitis B surface antigen, HBsAg). There are eight different genotypes (A–H), which may influence the course of infection and responsiveness to antiviral therapy. HBV is usually transmitted by inoculation of infected blood or blood products or by sexual contact and is present in saliva, semen, and vaginal secretions. HBsAg-positive mothers may transmit HBV at delivery; the risk of chronic infection in the infant is as high as 90%.

Since 1990, the incidence of HBV infection in the United States has decreased from 8.5 to 1.5 cases per 100,000 population. The prevalence is 0.27% in persons aged 6 or over. Because of universal vaccination since 1992, exposure to HBV is now very low among persons aged 18 or younger. HBV is prevalent in men who have sex with men and in people who inject drugs (about 7% of HIV-infected persons are coinfecting with HBV), but the greatest number of cases result from heterosexual transmission. Other groups at risk include patients and staff at hemodialysis centers, physicians, dentists, nurses, and personnel working in clinical and pathology laboratories and blood banks. Half of all patients with acute hepatitis B in the United States have previously been incarcerated or treated for a sexually transmitted disease. The risk of HBV infection from a blood transfusion is < 1 in 60,000 units transfused in the United States.

The incubation period of hepatitis B is 6 weeks to 6 months (average 12–14 weeks). The onset of hepatitis B is

more insidious and the aminotransferase levels are higher on average than in HAV infection. Fulminant hepatitis occurs in <1%, with a mortality rate of up to 60%. Following acute hepatitis B, HBV infection persists in 1–2% of immunocompetent adults but in a higher percentage of children and immunocompromised adults. There are up to 2 million persons with chronic hepatitis B in the United States. Persons with chronic hepatitis B, particularly when HBV infection is acquired early in life and viral replication persists, are at substantial risk for cirrhosis and hepatocellular carcinoma (up to 25–40%). Men are at greater risk than women. Infection caused by HBV may be associated with serum sickness, glomerulonephritis, and polyarteritis nodosa.

► Clinical Findings

A. Symptoms and Signs


The clinical picture of viral hepatitis is extremely variable, ranging from asymptomatic infection without jaundice to a fulminating disease and death in a few days. Figure 16–2 shows the typical course of HBV infection. The onset may be abrupt or insidious, and the clinical features are similar to those for acute hepatitis A (see earlier). Serum sickness may be seen early in acute hepatitis B. Fever is generally present and is low-grade. Defervescence and a fall in pulse rate often coincide with the onset of jaundice.

The acute illness usually subsides over 2–3 weeks with complete clinical and laboratory recovery by 16 weeks. In 5–10% of cases, the course may be more protracted, but < 1% will have a fulminant course. Hepatitis B may become chronic (see below).

B. Laboratory Findings

The laboratory features are similar to those for acute hepatitis A (see earlier), although serum aminotransferase levels are higher on average in acute hepatitis B, and marked cholestasis is not a feature. Marked prolongation of the prothrombin time in severe hepatitis correlates with increased mortality.

There are three distinct antigen–antibody systems that relate to HBV infection and circulating markers that are



▲ **Figure 16–2.** The typical course of acute type B hepatitis. (anti-HBs, antibody to HBsAg; HBeAg, hepatitis Be antigen; anti-HBe, antibody to HBeAg; anti-HBc, antibody to hepatitis B core antigen; ALT, alanine aminotransferase.)

(Reprinted, with permission, from Koff RS. Acute viral hepatitis. In: Friedman LS, Keeffe EB [editors]. *Handbook of Liver Disease*, 3rd ed. Philadelphia: Saunders Elsevier, 2012.)

useful in diagnosis. Interpretation of common serologic patterns is shown in Table 16–5.

1. HBsAg—The appearance of HBsAg in serum is the first evidence of infection, appearing before biochemical evidence of liver disease, and persists throughout the clinical illness. Persistence of HBsAg more than 6 months after the acute illness signifies chronic hepatitis B.

2. Anti-HBs—Specific antibody to HBsAg (anti-HBs) appears in most individuals after clearance of HBsAg and after successful vaccination against hepatitis B. Disappearance

Table 16–5. Common serologic patterns in hepatitis B virus infection and their interpretation.

HBsAg	Anti-HBs	Anti-HBc	HBeAg	Anti-HBe	Interpretation
+	–	IgM	+	–	Acute hepatitis B
+	–	IgG ¹	+	–	Chronic hepatitis B with active viral replication
+	–	IgG	–	+	Chronic hepatitis B with low viral replication
+	+	IgG	+ or –	+ or –	Chronic hepatitis B with heterotypic anti-HBs (about 10% of cases)
–	–	IgM	+ or –	–	Acute hepatitis B
–	+	IgG	–	+ or –	Recovery from hepatitis B (immunity)
–	+	–	–	–	Vaccination (immunity)
–	–	IgG	–	–	False-positive; less commonly, infection in remote past

¹Low levels of IgM anti-HBc may also be detected.

of HBsAg and the appearance of anti-HBs signal recovery from HBV infection, noninfectivity, and immunity.

3. Anti-HBc—IgM anti-HBc appears shortly after HBsAg is detected. (HBcAg alone does not appear in serum.) In the setting of acute hepatitis, IgM anti-HBc indicates a diagnosis of acute hepatitis B, and it fills the serologic gap in rare patients who have cleared HBsAg but do not yet have detectable anti-HBs. IgM anti-HBc can persist for 3–6 months or longer. IgM anti-HBc may also reappear during flares of previously inactive chronic hepatitis B (see later). IgG anti-HBc also appears during acute hepatitis B but persists indefinitely, whether the patient recovers (with the appearance of anti-HBs in serum) or chronic hepatitis B develops (with persistence of HBsAg). In asymptomatic blood donors, an isolated anti-HBc with no other positive HBV serologic results may represent a falsely positive result or latent infection in which HBV DNA is detectable in serum only by polymerase chain reaction testing.

4. HBeAg—HBeAg is a secretory form of HBcAg that appears in serum during the incubation period shortly after the detection of HBsAg. HBeAg indicates viral replication and infectivity. Persistence of HBeAg beyond 3 months indicates an increased likelihood of chronic hepatitis B. Its disappearance is often followed by the appearance of anti-HBe, generally signifying diminished viral replication and decreased infectivity.

5. HBV DNA—The presence of HBV DNA in serum generally parallels the presence of HBeAg, although HBV DNA is a more sensitive and precise marker of viral replication and infectivity. Very low levels of HBV DNA, detectable only by polymerase chain reaction testing, may persist in serum and liver long after a patient has recovered from acute hepatitis B, but the HBV DNA in serum is bound to IgG and is rarely infectious. In some patients with chronic hepatitis B, HBV DNA is present at high levels without HBeAg in serum because of development of a mutation in the core promoter or precore region of the gene that codes HBcAg; these mutations prevent synthesis of HBeAg in infected hepatocytes. When additional mutations in the core gene are present, the pre-core mutant enhances the severity of HBV infection and increases the risk of cirrhosis (see later).

► Differential Diagnosis

The differential diagnosis includes hepatitis A and the same disorders listed for the differential diagnosis of acute hepatitis A (see earlier). In addition, coinfection with HDV must be considered (see later).

► Prevention

Strict isolation of patients is not necessary. Thorough hand washing by medical staff who may contact contaminated utensils, bedding, or clothing is essential. Medical staff should handle disposable needles carefully and not recap them. Screening of donated blood for HBsAg, anti-HBc, and anti-HCV has reduced the risk of transfusion-associated hepatitis markedly. All pregnant women should undergo testing for HBsAg. HBV-infected persons should practice safe sex.

Hepatitis B immune globulin (HBIG) may be protective—or may attenuate the severity of illness—if given within 7 days after exposure (adult dose is 0.06 mL/kg body weight) followed by initiation of the HBV vaccine series (see below). This approach is currently recommended for persons exposed to HBsAg-contaminated material via mucous membranes or through breaks in the skin and for individuals who have had sexual contact with a person with HBV infection (irrespective of the presence or absence of HBeAg in the source). HBIG is also indicated for newborn infants of HBsAg-positive mothers followed by initiation of the vaccine series (see below).

The CDC recommends HBV vaccination of all infants and children in the United States and all adults who are at risk for hepatitis B (including persons under age 60 with diabetes mellitus) or who request vaccination. Over 90% of recipients of the vaccine mount protective antibody to hepatitis B; immunocompromised persons, including patients receiving dialysis (especially those with diabetes mellitus), respond poorly (see Table 30–7). Reduced response to the vaccine may have a genetic basis in some cases and has also been associated with age over 40 years and celiac disease. The standard regimen for adults is 10–20 mcg (depending on the formulation) repeated again at 1 and 6 months, but alternative schedules have been approved, including accelerated schedules of 0, 1, 2, and 12 months and of 0, 7, and 21 days plus 12 months. For greatest reliability of absorption, the deltoid muscle is the preferred site of inoculation. Vaccine formulations free of the mercury-containing preservative thimerosal are given to infants < 6 months of age. When documentation of seroconversion is considered desirable, postimmunization anti-HBs titers may be checked. Protection appears to be excellent even if the titer wanes—at least for 20 years—and booster reimmunization is not routinely recommended but is advised for immunocompromised persons in whom anti-HBs titers fall below 10 milli-international units/mL. For vaccine nonresponders, three additional vaccine doses may elicit seroprotective anti-HBs levels in 30–50% of persons. Doubling of the standard dose may also be effective. Universal vaccination of neonates in countries endemic for HBV has reduced the incidence of hepatocellular carcinoma.

► Treatment

Treatment of acute hepatitis B is the same as that for acute hepatitis A (see earlier). Encephalopathy or severe coagulopathy indicates impending acute liver failure, and hospitalization at a liver transplant center is mandatory (see below). Antiviral therapy is generally unnecessary in patients with acute hepatitis B but is usually prescribed in cases of fulminant hepatitis B as well as in spontaneous reactivation of chronic hepatitis B presenting as acute-on-chronic liver failure.

► Prognosis

In most patients, clinical recovery is complete in 3–6 months. Laboratory evidence of liver dysfunction may persist for a longer period, but most patients recover completely. The mortality rate for acute hepatitis B is 0.1–1% but is higher with superimposed hepatitis D (see later).

Chronic hepatitis, characterized by elevated aminotransferase levels for > 6 months, develops in 1–2% of immunocompetent adults with acute hepatitis B but in as many as 90% of infected neonates and infants and a substantial proportion of immunocompromised adults. Ultimately, cirrhosis develops in up to 40% of those with chronic hepatitis B; the risk of cirrhosis is even higher in HBV-infected patients coinfecting with hepatitis C or HIV. Patients with cirrhosis are at risk for hepatocellular carcinoma at a rate of 3–5% per year. Even in the absence of cirrhosis, patients with chronic hepatitis B—particularly those with active viral replication—are at increased risk.

▶ When to Refer

Refer patients with acute hepatitis who require liver biopsy for diagnosis.

▶ When to Admit

- Encephalopathy is present.
- INR >1.6.
- The patient is unable to maintain hydration.

Fabrizi F et al. Meta-analysis: the impact of diabetes mellitus on the immunological response to hepatitis B virus vaccine in dialysis patients. *Aliment Pharmacol Ther.* 2011 Apr;33(7):815–21. [PMID: 21281319]

Ioannou GN. Hepatitis B virus in the United States: infection, exposure, and immunity rates in a nationally representative survey. *Ann Intern Med.* 2011 Mar 1;154(5):319–28. [PMID: 21357909]

Mitchell AE et al. Institute of Medicine recommendations for the prevention and control of hepatitis B and C. *Hepatology.* 2010 Mar;51(3):729–33. [PMID: 20186842]

ACUTE HEPATITIS C & OTHER CAUSES OF ACUTE VIRAL HEPATITIS

Hepatitis can be caused by many drugs and toxic agents as well as by numerous viruses, the clinical manifestations of which may be quite similar. Common viruses causing acute hepatitis include HAV and HBV, both of which are discussed above. This section addresses other viruses that can cause hepatitis: hepatitis C virus (HCV), hepatitis D virus (HDV) (delta agent), and hepatitis E virus (HEV) (an enterically transmitted hepatitis seen in epidemic form in Asia, the Middle East, and North Africa). Hepatitis G virus (HGV) rarely, if ever, causes frank hepatitis. A DNA virus designated the TT virus (TTV) has been identified in up to 7.5% of blood donors and found to be transmitted readily by blood transfusions, but an association between this virus and liver disease has not been established. A related virus known as SEN-V has been found in 2% of US blood donors, is transmitted by transfusion, and may account for some cases of transfusion-associated non-ABCDE hepatitis. In immunocompromised and rare immunocompetent persons, cytomegalovirus, Epstein–Barr virus, and herpes simplex virus should be considered in the differential diagnosis of hepatitis. Severe acute respiratory syndrome (SARS) and influenza may be associated with

marked serum aminotransferase elevations. Unidentified pathogens account for a small percentage of cases of acute viral hepatitis.


1. Hepatitis C

HCV is a single-stranded RNA virus (hepacivirus) with properties similar to those of flaviviruses. Six major genotypes of HCV have been identified. In the past, HCV was responsible for over 90% of cases of posttransfusion hepatitis, yet only 4% of cases of hepatitis C were attributable to blood transfusions. Over 50% of cases are transmitted by injection drug use, and both reinfection and superinfection of HCV are common in people who actively inject drugs. Body piercing, tattoos, and hemodialysis are risk factors. The risk of sexual and maternal–neonatal transmission is low and may be greatest in a subset of patients with high circulating levels of HCV RNA. Having multiple sexual partners may increase the risk of HCV infection, and HIV coinfection, unprotected receptive anal intercourse with ejaculation, and sex while high on methamphetamine increases the risk of HCV transmission in men who have sex with men. Transmission via breastfeeding has not been documented. An outbreak of hepatitis C in patients with immune deficiencies has occurred in some recipients of intravenous immune globulin. Hospital- and outpatient facility-acquired transmission has occurred via multidose vials of saline used to flush Portacaths; through reuse of disposable syringes; through contamination of shared saline, radiopharmaceutical, and sclerosant vials; via inadequately disinfected endoscopy equipment; and between hospitalized patients on a liver unit. In the developing world, unsafe medical practices lead to a substantial number of cases of HCV infection. Covert transmission during bloody fistcuffs has even been reported, and incarceration in prison is a risk factor. In many patients, the source of infection is unknown. Coinfection with HCV is found in at least 30% of persons infected with HIV; HIV infection leads to an increased risk of acute liver failure and more rapid progression of chronic hepatitis C to cirrhosis; in addition, HCV increases the hepatotoxicity of highly active antiretroviral therapy. There are more than 2.7 million HCV carriers in the United States and another 1.3 million previously exposed persons who have cleared the virus. The incidence of new cases of acute, symptomatic hepatitis C declined from 1992 to 2005, but an increase was observed in persons aged 15 to 24 from 2002 to 2006, as a result of injection drug use.

▶ Clinical Findings

A. Symptoms and Signs

Figure 16–3 shows the typical course of HCV infection. The incubation period for hepatitis C averages 6–7 weeks, and clinical illness is often mild, usually asymptomatic, and characterized by waxing and waning aminotransferase elevations and a high rate (>80%) of chronic hepatitis. Spontaneous clearance of HCV following acute infection is more common (64%) in persons with the CC genotype of the *IL28B* gene (which encodes interferon lambda-3 on



▲ **Figure 16-3.** The typical course of acute and chronic hepatitis C. (ALT, alanine aminotransferase; Anti-HCV, antibody to hepatitis C virus by enzyme immunoassay; HCV RNA [PCR], hepatitis C viral RNA by polymerase chain reaction.)

chromosome 19) than in those with the CT or TT genotype (24% and 6%, respectively). In persons with the CC genotype, jaundice is more likely to develop during the course of acute hepatitis C. Patients with the CC genotype and chronic hepatitis C are more likely to respond to therapy with pegylated interferon (see Chronic Viral Hepatitis, below). Polymorphisms of the genes encoding the killer cell immunoglobulin-like receptors (KIR) and their HLA class I ligands (HLA-C1) are also associated with spontaneous resolution of viremia following HCV exposure as well as resistance to HCV infection. In pregnant patients with chronic hepatitis C, serum aminotransferase levels frequently normalize despite persistence of viremia, only to increase again after delivery.

B. Laboratory Findings

Diagnosis of hepatitis C is based on an enzyme immunoassay (EIA) that detects antibodies to HCV. Anti-HCV is not protective, and in patients with acute or chronic hepatitis, its presence in serum generally signifies that HCV is the cause. Limitations of the EIA include moderate sensitivity (false-negatives) for the diagnosis of acute hepatitis C early in the course and low specificity (false-positives) in some persons with elevated γ -globulin levels. In these situations, a diagnosis of hepatitis C may be confirmed by using an assay for HCV RNA. Occasional persons are found to have anti-HCV in serum, confirmed by a recombinant immunoblot assay (RIBA), without HCV RNA in serum, suggesting recovery from HCV infection in the past.

► Complications

HCV is a pathogenetic factor in mixed cryoglobulinemia and membranoproliferative glomerulonephritis and may be related to lichen planus, autoimmune thyroiditis, lymphocytic sialadenitis, idiopathic pulmonary fibrosis, sporadic

porphyria cutanea tarda, and monoclonal gammopathies. HCV infection confers a 20–30% increased risk of non-Hodgkin lymphoma. Hepatitis C may induce insulin resistance (which in turn increases the risk of hepatic fibrosis), and the risk of type 2 diabetes mellitus is increased in persons with chronic hepatitis C. Hepatic steatosis is a particular feature of infection with HCV genotype 3 and may also occur in patients infected with other HCV genotypes who have risk factors for fatty liver (see below). On the other hand, chronic HCV infection is associated with a decrease in serum cholesterol and low-density lipoprotein levels.

► Prevention

Testing donated blood for HCV has helped reduce the risk of transfusion-associated hepatitis C from 10% in 1990 to about 1 case per 2 million units in 2011. Screening of persons born between 1945 and 1965 (“baby boomers”) for HCV infection has been recommended. HCV-infected persons should practice safer sex, but there is little evidence that HCV is spread easily by sexual contact, and no specific precautions are recommended for persons in a monogamous relationship. Vaccination against HAV (after prescreening for prior immunity) and HBV is recommended for patients with chronic hepatitis C, and vaccination against HAV is recommended for patients with chronic hepatitis B or C.

► Treatment

Treatment of patients with acute hepatitis C with peginterferon (see later) for 6–24 weeks appreciably decreases the risk of chronic hepatitis. In general, patients infected with HCV genotype 1 require a 24-week course of treatment, but a 12-week course is adequate if HCV RNA is undetectable in serum by 4 weeks. Those infected with genotypes 2, 3, or 4 generally require 8–12 weeks of therapy. Because 20% of patients with acute hepatitis C, particularly those who are symptomatic, clear the virus without such treatment, reserving treatment for patients in whom serum HCV RNA levels fail to clear after 3 months may be advisable. Ribavirin may be added if HCV RNA fails to clear after 3 months of peginterferon, but some authorities recommend using ribavirin with peginterferon from the start of therapy.

► Prognosis

In most patients, clinical recovery is complete in 3–6 months. Laboratory evidence of liver dysfunction may persist for a longer period. The overall mortality rate is < 1%, but the rate is reportedly higher in older people. Fulminant hepatitis C is rare in the United States.

Chronic hepatitis, which progresses very slowly in many cases, develops in as many as 85% of all persons with acute hepatitis C. Ultimately, cirrhosis develops in up to 30% of those with chronic hepatitis C; the risk of cirrhosis is higher in patients coinfecting with both HCV and HBV or HIV. Patients with cirrhosis are at risk for hepatocellular carcinoma at a rate of 3–5% per year.

2. Hepatitis D (Delta Agent)

HDV is a defective RNA virus that causes hepatitis only in association with hepatitis B infection and specifically only in the presence of HBsAg; it is cleared when the latter is cleared. Eight major genotypes (I–VIII) have been identified.

HDV may coinfect with HBV or may superinfect a person with chronic hepatitis B, usually by percutaneous exposure. When acute hepatitis D is coincident with acute HBV infection, the infection is generally similar in severity to acute hepatitis B alone. In chronic hepatitis B, superinfection by HDV appears to carry a worse short-term prognosis, often resulting in fulminant hepatitis or severe chronic hepatitis that progresses rapidly to cirrhosis.

In the 1970s and early 1980s, HDV was endemic in some areas, such as the Mediterranean countries (and later in Central and Eastern Europe), where up to 80% of HBV carriers were superinfected with HDV. In the United States, HDV occurred primarily among people who inject drugs. However, new cases of hepatitis D are now infrequent in the United States primarily because of the control of HBV infection, and cases seen today are usually from cohorts infected years ago who survived the initial impact of hepatitis D and now have cirrhosis. These patients are at risk for decompensation and have a threefold increased risk of hepatocellular carcinoma. New cases are primarily seen in immigrants from endemic areas, including Africa, central Asia, Eastern Europe, and the Amazon region of Brazil. More than 15 million people are infected worldwide. The diagnosis of hepatitis D is made by detection of antibody to hepatitis D antigen (anti-HDV) or, where available, hepatitis D antigen (HDAG) or HDV RNA in serum.

3. Hepatitis E

HEV is a 29- to 32-nm RNA hepevirus (in the Hepeviridae family) that is a major cause of acute hepatitis throughout Central and Southeast Asia, the Middle East, and North Africa, where it is responsible for waterborne hepatitis outbreaks. It is uncommon in the United States but should be considered in patients with acute hepatitis after a trip to an endemic area and in rare cases of suspected drug-induced liver injury. In industrialized countries, it may be spread by swine, and having a pet in the home and consuming organ meats are risk factors. Illness generally is self-limited (no carrier state), but instances of chronic hepatitis with rapid progression to cirrhosis attributed to HEV have been reported in transplant recipients (particularly when tacrolimus rather than cyclosporine is used as the main immunosuppressant), and preliminary observations suggest that treatment with oral ribavirin may induce sustained clearance of HEV RNA from the serum of such patients. In endemic regions, the mortality rate is high (10–20%) in pregnant women and correlates with high levels of HEV RNA in serum and gene mutations that lead to reduced expression of progesterone receptors, and the risk of hepatic decompensation is increased in patients with underlying chronic liver disease. Improved public hygiene reduces the risk of HEV infection in endemic areas. A recombinant vaccine against HEV has shown promise in clinical trials.

4. Hepatitis G

HGV is a flavivirus that is percutaneously transmitted and associated with chronic viremia lasting at least 10 years. HGV has been detected in 1.5% of blood donors, 50% of people who inject drugs, 30% of hemodialysis patients, 20% of hemophiliacs, and 15% of patients with chronic hepatitis B or C, but it does not appear to cause important liver disease or affect the response of patients with chronic hepatitis B or C to antiviral therapy. HGV coinfection may improve survival in patients with HIV infection and reduce the degree of liver fibrosis in patients with HCV-HIV coinfection.

- Bose PD et al. High viral load and deregulation of the progesterone receptor signaling pathway: association with hepatitis E-related poor pregnancy outcome. *J Hepatol.* 2011 Jun;54(6):1107–13. [PMID: 21145845]
- Hughes SA et al. Hepatitis delta virus. *Lancet.* 2011 Jul 2; 378(9785):73–85. [PMID: 21511329]
- Kamar N et al. Factors associated with chronic hepatitis in patients with hepatitis E virus infection who have received solid organ transplants. *Gastroenterology.* 2011 May;140(5):1481–9. [PMID: 21354150]
- Knapp S et al. A polymorphism in IL28B distinguishes exposed, uninfected individuals from spontaneous resolvers of HCV infection. *Gastroenterology.* 2011 Jul;141(1):320–5. [PMID: 21600205]
- Loomba R et al. The natural history of acute hepatitis C: clinical presentation, laboratory findings and treatment outcomes. *Aliment Pharmacol Ther.* 2011 Mar;33(5):559–65. [PMID: 21198704]
- Williams IT et al. Incidence and transmission patterns of acute hepatitis C in the United States, 1982–2006. *Arch Intern Med.* 2011 Feb 14;171(3):242–8. [PMID: 21325115]

ACUTE LIVER FAILURE



ESSENTIALS OF DIAGNOSIS

- ▶ May be fulminant or subfulminant; both forms carry a poor prognosis.
- ▶ Acetaminophen and idiosyncratic drug reactions are the most common causes.

▶ General Considerations

Acute liver failure may be fulminant or subfulminant. Fulminant hepatic failure is characterized by the development of hepatic encephalopathy within 8 weeks after the onset of acute liver disease. Coagulopathy (international normalized ratio [INR] ≥ 1.5) is invariably present. Subfulminant hepatic failure occurs when these findings appear between 8 weeks and 6 months after the onset of acute liver disease and carries an equally poor prognosis.

An estimated 1600 cases of acute liver failure occur each year in the United States. Acetaminophen toxicity is the most common cause, accounting for at least 45% of cases. Suicide attempts account for 44% of cases of acetaminophen-induced hepatic failure, and unintentional overdoses

(“therapeutic misadventures”), which are often a result of a decrease in the threshold toxic dose because of chronic alcohol use or fasting, account for at least 48%. Other causes include idiosyncratic drug reactions (now the second most common cause, with antituberculosis drugs, antiepileptics, and antibiotics implicated most commonly), viral hepatitis, poisonous mushrooms (*Amanita phalloides*), shock, hyperthermia or hypothermia, Budd–Chiari syndrome, malignancy (most commonly lymphomas), Wilson disease, Reye syndrome, fatty liver of pregnancy and other disorders of fatty acid oxidation, autoimmune hepatitis, parvovirus B19 infection and, rarely, grand mal seizures. The risk of acute liver failure is increased in patients with diabetes mellitus, and outcome is worsened by obesity. Herbal and dietary supplements are thought to be contributory to acute liver failure in a substantial portion of cases, regardless of cause.

Viral hepatitis now accounts for only 12% of all cases of acute liver failure. The decline of viral hepatitis as the principal cause of acute liver failure is due to universal vaccination of infants and children against hepatitis B and the availability of the hepatitis A vaccine. In endemic areas, hepatitis E is an important cause of acute liver failure. Hepatitis C is a rare cause of acute liver failure in the United States, but acute hepatitis A or B superimposed on chronic hepatitis C may cause fulminant hepatitis.

► Clinical Findings

Gastrointestinal symptoms, systemic inflammatory response, renal dysfunction, and hemorrhagic phenomena are common. Adrenal insufficiency and subclinical myocardial injury manifesting as an elevated serum troponin I level often complicate acute liver failure. Jaundice may be absent or minimal early, but laboratory tests show severe hepatocellular damage. In acetaminophen toxicity, serum aminotransferase elevations are often towering (> 5000 units/L), and diagnosis is aided by the detection of acetaminophen-protein adducts in serum. In acute liver failure due to microvesicular steatosis (eg, fatty liver of pregnancy), serum aminotransferase elevations may be modest (< 300 units/L). Over 10% of patients have an elevated serum amylase level at least three times the upper limit of normal, often as a result of renal dysfunction. The blood ammonia level is typically elevated and correlates (along with the Model for End-Stage Liver Disease [MELD] score) with the development of encephalopathy and intracranial hypertension. The severity of extrahepatic organ dysfunction (as assessed by the Sequential Organ Failure Assessment, or SOFA) also correlates with the likelihood of intracranial hypertension.

► Treatment

The treatment of acute liver failure is directed toward correcting metabolic abnormalities. These include coagulation defects, electrolyte and acid-base disturbances, advanced chronic kidney disease, hypoglycemia, and encephalopathy. Cerebral edema and sepsis are the leading causes of death. Prophylactic antibiotic therapy decreases the risk of infection, observed in up to 90%, but has no effect on survival and is not routinely recommended. For suspected sepsis,

broad coverage is indicated. Despite a high rate of adrenal insufficiency, corticosteroids are of uncertain value. Stress gastropathy prophylaxis with an H₂-receptor blocker or proton pump inhibitor is recommended. Administration of acetylcysteine (140 mg/kg orally followed by 70 mg/kg orally every 4 hours for an additional 17 doses or 150 mg/kg in 5% dextrose intravenously over 15 minutes followed by 50 mg/kg over 4 hours and then 100 mg/kg over 16 hours) is indicated for acetaminophen toxicity up to 72 hours after ingestion and improves cerebral blood flow and oxygenation as well as transplant-free survival in patients with stage 1 or 2 encephalopathy due to fulminant hepatic failure of any cause. (Acetylcysteine treatment can prolong the prothrombin time, leading to the erroneous assumption that liver failure is worsening; it can also cause nausea, vomiting, and an anaphylactoid reaction [especially in persons with a history of asthma]. It may be detrimental in children with nonacetaminophen acute liver failure.) Penicillin G (300,000 to 1 million units/kg/day) or silibinin (silymarin or milk thistle), which is not licensed in the United States, is administered to patients with mushroom poisoning. Nucleoside analogs are recommended for patients with fulminant hepatitis B (see Chronic Viral Hepatitis), and intravenous acyclovir has shown benefit in those with herpes simplex virus hepatitis. Plasmapheresis combined with D-penicillamine has been used in fulminant Wilson disease. Subclinical seizure activity is common in patients with acute liver failure, but the value of prophylactic phenytoin is uncertain.

Early transfer to a liver transplantation center is essential. The head of the patient's bed should be elevated to 30 degrees, and patients with stage 3 or 4 encephalopathy should be intubated. Extradural sensors may be placed to monitor intracranial pressure for impending cerebral edema with the goal of maintaining the intracranial pressure below 20 mm Hg and the cerebral perfusion pressure above 70 mm Hg. Recombinant activated factor VII may be administered to reduce the risk of bleeding associated with intracranial pressure monitoring. Lactulose is administered for encephalopathy (see Cirrhosis). Mannitol, 0.5 g/kg, or 100–200 mL of a 20% solution by intravenous infusion over 10 minutes, may decrease cerebral edema but should be used with caution in patients with advanced chronic kidney disease. Intravenously administered hypertonic saline to induce hyponatremia (serum sodium concentration of 145–155 mEq/L [145–155 mmol/L]) also may reduce intracranial hypertension. Hypothermia to a temperature of 32–34 °C may reduce intracranial pressure when other measures have failed and may improve survival long enough to permit liver transplantation. The value of hyperventilation and intravenous prostaglandin E₁ is uncertain. A short-acting barbiturate, propofol, or administration of intravenous boluses of indomethacin, 25 mg, is considered for refractory intracranial hypertension. Nonbiologic liver support (eg, molecular adsorbent recirculating system [MARS], an albumin dialysis system), hepatic-assist devices using living hepatocytes, extracorporeal systems, hepatocyte transplantation, and liver xenografts have shown promise experimentally but have not been shown conclusively to reduce mortality in patients with acute liver failure. They may serve as a “bridge” to liver transplantation.

► Prognosis

The mortality rate of fulminant hepatic failure with severe encephalopathy is as high as 80%, except for acetaminophen hepatotoxicity, in which the transplant-free survival is 65% and no more than 8% of patients undergo liver transplantation. For patients with fulminant hepatic failure of other causes, the outlook is especially poor in patients younger than 10 and older than 40 years of age and in those with an idiosyncratic drug reaction but appears to be improved when acetylcysteine is administered to patients with stage 1 or 2 encephalopathy. Spontaneous recovery is less likely for hepatitis B than for hepatitis A. Polymorphisms of the genes that encode keratins 8 and 18 appear to affect outcomes. Other adverse prognostic factors are a serum bilirubin level > 18 mg/dL (307.8 μ mol/L), INR > 6.5 , onset of encephalopathy more than 7 days after the onset of jaundice, and a low factor V level ($< 20\%$ of normal). For acetaminophen-induced fulminant hepatic failure, indicators of a poor outcome are acidosis (pH < 7.3), INR > 6.5 , and azotemia (serum creatinine ≥ 3.4 mg/dL [283.22 μ mol/L]), whereas a rising serum α -fetoprotein level predicts a favorable outcome. An elevated blood lactate level (> 3.5 mmol/L), elevated blood ammonia level (> 124 μ mol/L), and possibly hyperphosphatemia (> 1.2 mmol/L) also predict poor survival. A prognostic (“BiLE”) score based on the serum bilirubin, serum lactate, and etiology has been proposed. Emergency liver transplantation is considered for patients with stage 2 to stage 3 encephalopathy (see Cirrhosis) and is associated with a 70% survival rate at 5 years. For mushroom poisoning, liver transplantation should be considered when the interval between ingestion and the onset of diarrhea is < 8 hours or the INR is ≥ 6.0 , even in the absence of encephalopathy.

► When to Admit

All patients with acute liver failure should be hospitalized.

Bernal W et al. Acute liver failure. *Lancet*. 2010 Jul 17;376(9736):190–201. [PMID: 20638564]

Stutchfield BM et al. Systematic review and meta-analysis of survival following extracorporeal liver support. *Br J Surg*. 2011 May;98(5):623–31. [PMID: 21462172]

Sundaram V et al. Acute liver failure: current practice and recent advances. *Gastroenterol Clin North Am*. 2011 Sep;40(3):523–39. [PMID: 21893272]

CHRONIC VIRAL HEPATITIS



ESSENTIALS OF DIAGNOSIS

- Defined by chronic infection (HBV, HCV, HDV) for > 3 –6 months.
- Diagnosis is usually made by antibody tests and viral nucleic acid in serum.

► General Considerations

Chronic hepatitis is defined as chronic necroinflammation of the liver of more than 3–6 months' duration, demonstrated by persistently elevated serum aminotransferase levels or characteristic histologic findings. In many cases, the diagnosis of chronic hepatitis may be made on initial presentation. The causes of chronic hepatitis include HBV, HCV, and HDV as well as autoimmune hepatitis; alcoholic and nonalcoholic steatohepatitis; certain medications, such as isoniazid and nitrofurantoin; Wilson disease; α_1 -antitrypsin deficiency; and, rarely, celiac disease. Chronic hepatitis is categorized on the basis of etiology; the grade of portal, periportal, and lobular inflammation (minimal, mild, moderate, or severe); and the stage of fibrosis (none, mild, moderate, severe, cirrhosis). In the absence of advanced cirrhosis, patients are often asymptomatic or have mild nonspecific symptoms.

1. Chronic Hepatitis B & Chronic Hepatitis D

► Clinical Findings & Diagnosis

Chronic hepatitis B afflicts nearly 400 million people worldwide (endemic areas include Asia and sub-Saharan Africa) and 1.25 million (predominantly males) in the United States. It may be noted as a continuum of acute hepatitis B or diagnosed because of repeated detection of HBsAg in serum, often with elevated aminotransferase levels.

Four phases of HBV infection are recognized: immune tolerant phase, immune clearance phase, inactive HBsAg carrier state, and reactivated chronic hepatitis B phase. In the **immune tolerant phase**, HBeAg and HBV DNA are present in serum, which is indicative of active viral replication, and serum aminotransferase levels are normal, with little necroinflammation in the liver. This phase is common in infants and young children whose immature immune system fails to mount an immune response to HBV. Persons in the immune tolerant phase and those who acquire HBV infection later in life may enter an **immune clearance phase**, in which aminotransferase levels are elevated and necroinflammation is present in the liver, with a risk of progression to cirrhosis (at a rate of 2–5.5% per year) and of hepatocellular carcinoma (at a rate of $> 2\%$ per year in those with cirrhosis); low-level IgM anti-HBc is present in serum in about 70%.

Patients enter the **inactive HBsAg carrier state** when biochemical improvement follows immune clearance. This improvement coincides with disappearance of HBeAg and reduced HBV DNA levels ($< 10^5$ copies/mL, or $< 20,000$ international units/mL) in serum, appearance of anti-HBe, and integration of the HBV genome into the host genome in infected hepatocytes. Patients in this phase are at a low risk for cirrhosis (if it has not already developed) and hepatocellular carcinoma.

The **reactivated chronic hepatitis B phase** may result from infection by a pre-core mutant of HBV or spontaneous mutation of the pre-core or core promoter region of the HBV genome during the course of chronic hepatitis caused by wild-type HBV. So-called HBeAg-negative

chronic hepatitis B accounts for <10% of cases of chronic hepatitis B in the United States, up to 50% in southeast Asia, and up to 90% in Mediterranean countries, reflecting in part differences in the frequencies of HBV genotypes. In reactivated chronic hepatitis B, there is a rise in serum HBV DNA levels and possible progression to cirrhosis (at a rate of 8–10% per year), particularly when additional mutations in the core gene of HBV are present. Risk factors for reactivation include male sex and HBV genotype C. In patients with either HBeAg-positive or HBeAg-negative chronic hepatitis B, the risk of cirrhosis and of hepatocellular carcinoma correlates with the serum HBV DNA level. Other risk factors include advanced age, alcohol use, cigarette smoking, and coinfection with HCV or HDV. HIV coinfection is also associated with an increased frequency of cirrhosis when the CD4 count is low.

Acute **hepatitis D** infection superimposed on chronic HBV infection may result in severe chronic hepatitis, which may progress rapidly to cirrhosis and may be fatal. Patients with long-standing chronic hepatitis D and B often have inactive cirrhosis and are at risk for decompensation and hepatocellular carcinoma. The diagnosis is confirmed by detection of anti-HDV or HDAG (or HDV RNA) in serum.

▶ Treatment

Patients with active viral replication (HBeAg and HBV DNA $\geq 10^5$ copies/mL, or $\geq 20,000$ international units/mL) in serum and elevated aminotransferase levels) may be treated with a nucleoside or nucleotide analog or with pegylated interferon. Nucleoside and nucleotide analogs are preferred because they are better tolerated and can be taken orally. For patients who are HBeAg-negative, the threshold for treatment is a serum HBV DNA level $\geq 10^4$ copies/mL, or ≥ 2000 international units/mL. If the threshold HBV DNA level for treatment is met but the serum ALT level is normal, treatment may still be considered in patients over age 35–40 if liver biopsy demonstrates a fibrosis stage of 2 (moderate) or higher. Therapy is aimed at reducing and maintaining the serum HBV DNA level to the lowest possible levels, thereby leading to normalization of the ALT level and histologic improvement. An additional goal in HBeAg-positive patients is seroconversion to anti-HBe, and some responders eventually clear HBsAg. Although nucleoside and nucleotide analogs generally have been discontinued 6–12 months after HBeAg-to-anti-HBe seroconversion, some patients serorevert to HBeAg after discontinuation, have a recurrence of hepatitis activity, and require long-term therapy, which also is required when seroconversion does not occur. All HBeAg-negative patients with chronic hepatitis B also require long-term therapy (see below).

The available nucleoside and nucleotide analogs—entecavir, tenofovir, lamivudine, adefovir, and telbivudine—differ in efficacy and rates of resistance; however, in HBeAg-positive patients, they all achieve an HBeAg-to-anti-HBe seroconversion rate of about 20% at 1 year, with higher rates after more prolonged therapy. The preferred first-line oral agents are entecavir and tenofovir. Entecavir, a nucleoside analog, is rarely associated with resistance

unless a patient is already resistant to lamivudine. The daily dose is 0.5 mg orally for patients not resistant to lamivudine and 1 mg for patients who previously became resistant to lamivudine. Entecavir is more effective than lamivudine and adefovir, with histologic improvement observed in 70% of treated patients and suppression of HBV DNA in serum in up to 80%. Entecavir has been reported to cause lactic acidosis when used in patients with decompensated cirrhosis. Tenofovir, a nucleotide analog, has substantial activity against HBV and is used as a first-line agent or when resistance to a nucleoside analog has developed. Like entecavir, tenofovir has a low rate of resistance when used as initial therapy. Long-term use may lead to an elevated serum creatinine level and reduced serum phosphate level (Fanconi-like syndrome) that is reversible with discontinuation of the drug.

The first available nucleoside analog was lamivudine, 100 mg orally daily, which reliably suppresses HBV DNA in serum, improves liver histology in 60% of patients, and leads to normal ALT levels in over 40% after 1 year of therapy. By the end of 1 year, however, 15–30% of responders experience a relapse (and occasionally frank decompensation) as a result of a mutation in the polymerase gene (the YMDD motif) of HBV DNA that confers resistance to lamivudine. The rate of resistance reaches 70% by 5 years of therapy, and the drug is no longer considered first-line therapy. In patients with advanced fibrosis or cirrhosis, treatment with lamivudine has been shown to reduce the risk of hepatic decompensation and hepatocellular carcinoma. Adefovir dipivoxil, a nucleotide analog, has activity against wild-type and lamivudine-resistant HBV but is the least potent of the oral antiviral agents for HBV. The standard dose is 10 mg orally once a day for at least 1 year. Adding the drug may be effective in patients who have become resistant to lamivudine. As with lamivudine, only a small number of patients achieve sustained suppression of HBV replication with adefovir, and long-term suppressive therapy is often required. Resistance to adefovir is less frequent than with lamivudine but is seen in up to 29% of patients treated for 5 years. Patients with underlying kidney dysfunction are at risk for nephrotoxicity from adefovir. Telbivudine, given in a daily dose of 600 mg orally, is more potent than either lamivudine or adefovir. Resistance to this drug may develop, however, particularly in patients who are resistant to lamivudine, and elevated creatine kinase levels are common in patients treated with telbivudine. Other antiviral agents are under study, and strategies using multiple drugs are being investigated.

Nucleoside and nucleotide analogs are well tolerated even in patients with decompensated cirrhosis (for whom the treatment threshold may be an HBV DNA level $<10^4$ copies/mL) and may be effective in patients with rapidly progressive hepatitis B (“fibrosing cholestatic hepatitis”) following organ transplantation. Although therapy with these agents leads to biochemical, virologic, and histologic improvement in patients with HBeAg-negative chronic hepatitis B and baseline HBV DNA levels $\geq 10^4$ copies/mL (≥ 2000 international units/mL), relapse is frequent when therapy is stopped, and long-term treatment is often required. Resistance is most likely to develop to lamivudine

and may develop to adefovir and telbivudine, but these drugs are no longer used frequently as first-line agents in the United States. The development of resistance occasionally results in hepatic decompensation. Sequential addition of a second antiviral agent is usually effective after resistance to the first agent has developed. Combined use of peginterferon and a nucleoside or nucleotide analog has not been shown convincingly to have a substantial advantage over the use of either type of drug alone.

Nucleoside analogs are also recommended for inactive HBV carriers prior to the initiation of immunosuppressive therapy (including anti-tumor necrosis factor antibody therapy) or cancer chemotherapy to prevent reactivation. In patients infected with both HBV and HIV, antiretroviral therapy, including two drugs active against both viruses (eg, tenofovir plus lamivudine or emtricitabine), has been recommended when treatment of HIV infection is indicated. Telbivudine and tenofovir are classified as pregnancy category B drugs, and lamivudine, a category C drug, has been shown to be safe in pregnant women with HIV infection.

Peginterferon alfa-2a is still an alternative to the oral agents in selected cases. A dose of 180 mcg subcutaneously once weekly for 48 weeks leads to sustained normalization of aminotransferase levels, disappearance of HBeAg and HBV DNA from serum, appearance of anti-HBe, and improved survival in up to 40% of treated patients. A response is most likely in patients with a low baseline HBV DNA level and high aminotransferase levels and is more likely in those infected with HBV genotype A than with other genotypes (especially genotype D). Moreover, most complete responders eventually clear HBsAg and develop anti-HBs in serum, and are thus cured. Relapses are uncommon in complete responders who seroconvert from HBeAg to anti-HBe. Peginterferon may be considered in order to avoid long-term therapy with an oral agent, as in young women who may want to become pregnant in the future. Patients with HBeAg-negative chronic hepatitis B have a response rate of 60% after 48 weeks of therapy with peginterferon, but the response may not be durable once peginterferon is stopped. Preliminary studies suggest that a rapid decline in serum HBsAg titers predicts a sustained response and ultimate clearance of HBsAg. The response to peginterferon is poor in patients with HIV coinfection.

Peginterferon alfa-2b (1.5 mcg/kg/wk for 48 weeks) may lead to normalization of serum aminotransferase levels, histologic improvement, and elimination of HDV RNA from serum in 20–50% of patients with **chronic hepatitis D**, but patients may relapse and tolerance is poor. Nucleoside and nucleotide analogs are not effective in treating chronic hepatitis D.

► Prognosis

The course of chronic hepatitis B is variable. The sequelae of chronic hepatitis secondary to hepatitis B include cirrhosis, liver failure, and hepatocellular carcinoma. The 5-year mortality rate is 0–2% in those without cirrhosis, 14–20% in those with compensated cirrhosis, and 70–86% following decompensation. The risk of cirrhosis and hepatocellular carcinoma correlates with serum HBV DNA

levels, and a focus of therapy is to suppress HBV DNA levels below 300 copies/mL (60 international units/mL). There is some evidence that HBV genotype C is associated with a higher risk of cirrhosis and hepatocellular carcinoma than other genotypes. Antiviral treatment improves the prognosis in responders, prevents (or leads to regression of) cirrhosis, and decreases the frequency of liver-related complications.

2. Chronic Hepatitis C

► Clinical Findings & Diagnosis

Chronic hepatitis C develops in up to 85% of patients with acute hepatitis C. It is clinically indistinguishable from chronic hepatitis due to other causes and may be the most common. Worldwide, 170 million people are infected with HCV, with 1.8% of the US population infected. Peak prevalence in the United States (about 4%) is in persons born between 1945 and 1964. In approximately 40% of cases, serum aminotransferase levels are persistently normal. The diagnosis is confirmed by detection of anti-HCV by EIA. In rare cases of suspected chronic hepatitis C but a negative EIA, HCV RNA is detected by polymerase chain reaction testing. Progression to cirrhosis occurs in 20% of affected patients after 20 years, with an increased risk in men, those who drink more than 50 g of alcohol daily, and those who acquire HCV infection after age 40 years. The rate of fibrosis progression accelerates after age 50. African Americans have a higher rate of chronic hepatitis C but lower rates of fibrosis progression and response to therapy than whites (see below). Immunosuppressed persons—including patients with hypogammaglobulinemia, HIV infection with a low CD4 count, or those receiving immunosuppressants—appear to progress more rapidly to cirrhosis than immunocompetent persons with chronic hepatitis C. Tobacco and cannabis smoking and hepatic steatosis also appear to promote progression of fibrosis, but coffee consumption appears to slow progression. Persons with chronic hepatitis C and persistently normal serum aminotransferase levels usually have mild chronic hepatitis with slow or absent progression to cirrhosis; however, cirrhosis is present in 10% of these patients.

► Treatment

Treatment of chronic hepatitis C is generally considered in patients under age 70 with more than mild fibrosis on liver biopsy. (A liver biopsy may be avoided if a FibroSure test result suggests absence of fibrosis or presence of cirrhosis.) Because of high response rates to treatment in patients infected with HCV genotype 2 or 3, treatment may be initiated in these patients without a liver biopsy.

Two formulations of pegylated interferon are approved for HCV infection: peginterferon alfa-2b, with a 12-kDa polyethylene glycol (PEG), 1.5 mcg/kg, and peginterferon alfa-2a, with a 40-kDa PEG, 180 mcg, both given subcutaneously once per week; in comparative studies, peginterferon alfa-2a has been slightly more effective. Addition of the nucleoside analog ribavirin, 800–1400 mg orally daily in two divided doses, results in higher sustained response rates than

peginterferon alone in previously untreated patients with chronic hepatitis C and in patients who have had a relapse after an initial response to interferon alfa (no longer available in the United States) and ribavirin. Still higher rates of response are achieved in persons infected with HCV genotype 1 when a direct acting antiviral agent—telaprevir or boceprevir, two protease inhibitors that were approved in 2011 by the US Food and Drug Administration (FDA)—is added to peginterferon and ribavirin.

Sustained response rates are as high as 75% for HCV genotype 1 with a three-drug regimen and up to 80% for HCV genotypes 2 or 3 with a two-drug regimen. Low levels of HCV RNA may persist in the liver, lymphocytes, and macrophages of successfully treated (“cured”) patients, but the significance of this finding is uncertain. Response rates to peginterferon and ribavirin are lower in patients with advanced fibrosis, high levels of viremia, alcohol consumption, HIV coinfection, obesity, insulin resistance, severe steatosis, vitamin D deficiency, and early menopause in women; they are also lower in blacks and Latinos than in whites, in part because of a higher rate of genotype 1 among infected black patients and in part because of intrinsic resistance to therapy. Response to peginterferon is associated most strongly with the CC genotype of the *IL28B* gene, with sustained response rates to peginterferon and ribavirin as high as 80%, compared with 40% for the TC genotype and 30% for the TT genotype. Coffee consumption of more than three cups per day has also been reported to improve virologic response to peginterferon and ribavirin. For prior nonresponders to standard interferon and ribavirin, sustained response rates to re-treatment with peginterferon alfa and ribavirin are only 10–15% but 35% with a three-drug regimen that includes telaprevir or boceprevir.

When used with peginterferon alfa-2b, the dose of ribavirin in patients infected with genotype 1 is based on the patient’s weight and may range from 800 mg to 1400 mg daily in two divided doses. When used with peginterferon alfa-2a, the daily ribavirin dose is 1000 mg or 1200 mg depending on whether the patient’s weight is less than or greater than 75 kg. In the past, patients infected with genotype 1 were generally treated for 48 weeks with peginterferon and ribavirin. If the serum HCV RNA level decreased to < 50 international units/mL by 4 weeks (rapid virologic response), treatment for at least 24 weeks resulted in a sustained virologic response rate of 90%. For those who did not achieve a rapid virologic response but had a serum HCV RNA level < 50 international units/mL by 12 weeks (complete early virologic response), treatment was continued for the full 48 weeks. If serum HCV RNA levels declined by at least 2 logs by 12 weeks (partial early virologic response) and became undetectable by 24 weeks (slow response), treatment might be extended to 72 weeks. If none of the aforementioned targets were reached, particularly a minimum of a partial early virologic response, treatment was discontinued. With the addition of a protease inhibitor, the treatment duration can now be shortened to 24 weeks in previously untreated patients and those who relapsed after previous treatment with peginterferon and ribavirin if they achieve an extended rapid virologic

response (negative HCV RNA in serum at 4 and 12 weeks). Telaprevir is given in a dose of 750 mg orally three times daily for the first 12 weeks. If boceprevir is used, it is started in a dose of 800 mg orally three times daily 4 weeks after the start of peginterferon and ribavirin and given for a variable duration depending on the rapidity of clearance of HCV RNA from serum (response-guided therapy). Detailed stopping rules for treatment have been developed; for example, therapy is stopped and considered unsuccessful if HCV RNA is still detectable in serum after 24 weeks of therapy. In patients who did not respond to peginterferon and ribavirin therapy previously, a total treatment duration of 48 weeks is prescribed with either three-drug regimen, with expected sustained virologic response rates of up to 40%. The role of *IL28B* testing to assess responsiveness to interferon when a three-drug regimen is used is under study. For patients infected with HCV genotype 1 and without any hepatic fibrosis, expectant management and a repeat assessment of hepatic fibrosis (often by liver biopsy) in 3–5 years are often recommended.

Patients infected with genotype 2 or 3 (without cirrhosis and with low levels of viremia) are treated for 24 weeks with peginterferon and ribavirin and require a ribavirin total daily dose of only 800 mg. For patients infected with these genotypes who clear the virus within 4 weeks (rapid virologic response), a total treatment duration of only 16 weeks may be sufficient, if the baseline HCV RNA level is < 400,000 international units/mL; however, such a short course is not routinely recommended. For patients with cirrhosis or a high viral level (> 400,000 international units/mL), 48 weeks of treatment and ribavirin dosing based on the patient’s weight (as for HCV genotype 1) may be preferred. The added benefit of telaprevir or boceprevir in patients infected with HCV genotype 2 or 3 is under study.

Peginterferon-based therapy may be beneficial in the treatment of cryoglobulinemia associated with chronic hepatitis C; an acute flare of cryoglobulinemia may first require treatment with rituximab, cyclophosphamide plus methylprednisolone, or plasma exchange. “Chronic HCV carriers” with normal serum aminotransferase levels respond just as well to treatment as do patients with elevated aminotransferase levels. Patients with both HCV and HIV infections may benefit from treatment of HCV. Moreover, in HCV/HIV-coinfecting persons, long-term liver-related mortality increases as mortality from HIV infection is reduced by highly active antiretroviral therapy.

Treatment with peginterferon-based therapy is costly (up to \$86,000 for 48 weeks of therapy with three drugs). Side effects, including flulike symptoms; psychiatric symptoms (irritability, depression); thyroid dysfunction; bone marrow suppression; and, in men, sexual impairment, are common. Discontinuation rates are as high as 15–30%, and higher in persons over age 60 years than in younger patients. Sustained response rates decline if < 60% of the cumulative dose is taken. A blood count is obtained at weeks 1, 2, and 4 after therapy is started and monthly thereafter. Peginterferon alfa is contraindicated in pregnant or breast-feeding patients and those with decompensated cirrhosis, profound cytopenias, severe psychiatric disorders, autoimmune diseases, or

an inability to self-administer treatment. HCV treatment can be successful in carefully selected people who continue to inject illicit drugs if they are managed by a multidisciplinary team. In patients with severe chronic kidney disease, the doses of peginterferon and ribavirin must be reduced. Patients taking ribavirin must be monitored for hemolysis. Variants in the *ITPA* gene that result in deficiency of inosine triphosphatase have been shown to protect against ribavirin-induced hemolytic anemia and decrease the need for reductions in dose. Men and women taking the drug must practice strict contraception until 6 months after conclusion of therapy because of teratogenic effects in animals. Ribavirin should be used with caution in persons over age 65 years and in others in whom hemolysis could pose a risk of angina or stroke. Rash, itching, headache, cough, and shortness of breath also occur with the drug. Lactic acidosis is a concern in patients also taking highly active antiretroviral therapy for HIV infection. Telaprevir can cause a troubling skin rash that requires discontinuation of the drug in up to 12% of patients, pruritus, gastrointestinal distress, anal pain, and anemia. The major side effects of boceprevir are anemia, nausea, vomiting, and dysgeusia. Both protease inhibitors have a low genetic barrier to resistance. A reduction in the dose of ribavirin followed (if necessary) by erythropoietin (epoetin alfa) and granulocyte colony-stimulating factor (filgrastim) may be used to treat therapy-induced anemia and leukopenia, respectively. Eltrombopag, an orally administered thrombopoietin-receptor agonist, may be considered in patients with a platelet count < 90,000/mcL before therapy. Peginterferon alfa is generally contraindicated in heart, lung, and kidney transplant recipients because of an increased risk of organ rejection. Selected liver transplant recipients with recurrent hepatitis C may be treated with peginterferon and ribavirin, but response rates are low; the benefit of adding a protease inhibitor is uncertain.

In patients with advanced fibrosis who are nonresponders to peginterferon-based therapy, long-term maintenance treatment with peginterferon as a strategy to prevent histologic progression and reduce the risk of cirrhosis and hepatocellular carcinoma has been shown to be ineffective. Antiviral agents under study include other protease inhibitors; polymerase inhibitors; virus entry, assembly, and secretion inhibitors; RNA interference sequences; cyclophilin inhibitors; interferon lambda-3; and therapeutic vaccines. In the future, it is anticipated that the use of combinations of oral direct antiviral agents will obviate the need for peginterferon.

► Prognosis

Chronic hepatitis C is an indolent, often subclinical disease that may lead to cirrhosis and hepatocellular carcinoma after decades. The overall mortality rate in patients with transfusion-associated hepatitis C may be no different from that of an age-matched control population. Nevertheless, mortality or transplantation rates clearly rise to 5% per year once cirrhosis develops, and mortality from cirrhosis and hepatocellular carcinoma due to hepatitis C is rising. There is some evidence that HCV

genotype 1b is associated with a higher risk of hepatocellular carcinoma than other genotypes. Peginterferon-based therapy has a beneficial effect on mortality and quality of life, is cost-effective, appears to retard and even reverse fibrosis, and reduces the risk of decompensated cirrhosis and hepatocellular carcinoma in responders. Even patients who achieve a sustained virologic response remain at an increased risk for mortality compared with the general population. The risk of mortality from drug addiction is higher than that for liver disease in patients with chronic hepatitis C.

► When to Refer

- For liver biopsy.
- For antiviral therapy.

► When to Admit

- For complications of decompensated cirrhosis.

Bacon BR et al; HCV RESPOND-2 Investigators. Boceprevir for previously treated chronic HCV genotype 1 infection. *N Engl J Med.* 2011 Mar 31;364(13):1207–17. [PMID: 21449784]

Ghany MG et al. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. *Hepatology.* 2011 Oct;54(4):1433–44. [PMID: 21898493]

Jacobson IM et al; ADVANCE Study Team. Telaprevir for previously untreated chronic hepatitis C virus infection. *N Engl J Med.* 2011 Jun 23;364(25):2405–16. [PMID: 21696307]

Lee M et al. Hepatitis B: modern end points of treatment and the specter of viral resistance. *Gastroenterol Clin North Am.* 2011 Sep;40(3):495–505. [PMID: 21893270]

Poordad F et al; SPRINT-2 Investigators. Boceprevir for untreated chronic HCV genotype 1 infection. *N Engl J Med.* 2011 Mar 31;364(13):1195–206. [PMID: 21449783]

Sherman KE et al; ILLUMINATE Study Team. Response-guided telaprevir combination treatment for hepatitis C virus infection. *N Engl J Med.* 2011 Sep 15;365(11):1014–24. [PMID: 21916639]

The Liverpool HIV & Hepatitis Pharmacology Group. Hepatitis drug interaction charts. <http://www.hep-druginteractions.org>

Zeuzem S et al; REALIZE Study Team. Telaprevir for retreatment of HCV infection. *N Engl J Med.* 2011 Jun 23;364(25):2417–28. [PMID: 21696308]

AUTOIMMUNE HEPATITIS



ESSENTIALS OF DIAGNOSIS

- Usually young to middle-aged women.
- Chronic hepatitis with high serum globulins and characteristic liver histology.
- Positive antinuclear antibody (ANA) and/or smooth muscle antibody in most common type.
- Responds to corticosteroids.

► General Considerations

Although autoimmune hepatitis is usually seen in young women, it can occur in either sex at any age. The incidence and prevalence are estimated to be 8.5 and 107 per million population, respectively. Affected younger persons are often positive for HLA-B8 and HLA-DR3; older patients are often positive for HLA-DR4. The principal susceptibility allele among white Americans and northern Europeans is HLA *DRB1*0301*; HLA *DRB1*0401* is a secondary but independent risk factor.

► Clinical Findings

A. Symptoms and Signs

The onset is usually insidious, but up to 40% of cases present with an acute (occasionally fulminant) attack of hepatitis and some cases follow a viral illness (such as hepatitis A, Epstein-Barr infection, or measles) or exposure to a drug or toxin (such as nitrofurantoin, minocycline, or infliximab). Exacerbations may occur postpartum. Thirty-four percent of patients are asymptomatic. Typically, examination reveals a healthy-appearing young woman with multiple spider nevi, cutaneous striae, acne, hirsutism, and hepatomegaly. Amenorrhea may be a presenting feature. Extrahepatic features include arthritis, Sjögren syndrome, thyroiditis, nephritis, ulcerative colitis, and Coombs-positive hemolytic anemia. Patients with autoimmune hepatitis are at increased risk for cirrhosis which, in turn, increases the risk of hepatocellular carcinoma (at a rate of about 1% per year).

B. Laboratory Findings

Serum aminotransferase levels may be > 1000 units/L, and the total bilirubin is usually increased. In type I (classic) autoimmune hepatitis, ANA or smooth muscle antibodies (either or both) are usually detected in serum. Serum γ -globulin levels are typically elevated (up to 5–6 g/dL [0.05–0.06 g/L]). In patients with the latter, the EIA for antibody to HCV may be falsely positive. Other antibodies, including atypical perinuclear antineutrophil cytoplasmic antibodies (pANCA) and antibodies to histones, may be found. Antibodies to soluble liver antigen (anti-SLA) characterize a variant of type I that is marked by severe disease, a high relapse rate after treatment, and absence of the usual antibodies (ANA and smooth muscle antibodies). Anti-SLA is directed against a transfer RNA complex responsible for incorporating selenocysteine into peptide chains—Sep (O-phosphoserine) tRNA:Sec (selenocysteine) tRNA synthase, or SEPSECS. Type II, seen more often in girls under age 14 in Europe, is characterized by circulating antibodies to liver-kidney microsome type 1 (anti-LKM1)—directed against cytochrome P450 2D6—without anti-smooth muscle antibodies or ANA. In some cases, anti-liver cytosol type 1, directed against formiminotransferase cyclodeaminase, is detected. This type of autoimmune hepatitis can be seen in patients with autoimmune polyglandular syndrome

type 1. Concurrent primary biliary cirrhosis or primary sclerosing cholangitis has been recognized in 11% and 5% of patients with autoimmune hepatitis, respectively. Liver biopsy is indicated to help establish the diagnosis (interface hepatitis is the hallmark), evaluate disease severity, and determine the need for treatment.

Simplified diagnostic criteria based on the detection of autoantibodies (1 or 2 points depending on titers), elevated IgG levels (1 or 2 points depending on levels), and characteristic histologic features (1 or 2 points depending on how typical the features are) and exclusion of viral hepatitis (2 points) can be useful for diagnosis; a score of 6 indicates probable and a score of 7 indicates definite autoimmune hepatitis with a high degree of specificity but moderate sensitivity.

► Treatment

Prednisone with or without azathioprine improves symptoms; decreases the serum bilirubin, aminotransferase, and γ -globulin levels; and reduces hepatic inflammation. Symptomatic patients with aminotransferase levels elevated tenfold (or fivefold if the serum globulins are elevated at least twofold) are optimal candidates for therapy, and asymptomatic patients with modest enzyme elevations may be considered for therapy depending on the clinical circumstances and histologic severity; however, asymptomatic patients usually remain asymptomatic, have either mild hepatitis or inactive cirrhosis on liver biopsy specimens, and have a good long-term prognosis without therapy.

Prednisone is given initially in a dose of 30 mg orally daily with azathioprine, 50 mg orally daily, which is generally well tolerated and permits the use of lower corticosteroid doses than a regimen beginning with prednisone 60 mg orally daily alone. Preliminary experience suggests that budesonide, 6–9 mg orally daily, may be at least as effective as prednisone in noncirrhotic autoimmune hepatitis and associated with fewer side effects. Whether patients should undergo testing for the genotype or level of thiopurine methyltransferase prior to treatment with azathioprine to predict toxicity is debated. Blood counts are monitored weekly for the first 2 months of therapy and monthly thereafter because of the small risk of bone marrow suppression. The dose of prednisone is lowered from 30 mg/d after 1 week to 20 mg/d and again after 2 or 3 weeks to 15 mg/d. Ultimately, a maintenance dose of 10 mg/d is achieved. While symptomatic improvement is often prompt, biochemical improvement is more gradual, with normalization of serum aminotransferase levels after several months in many cases. Histologic resolution of inflammation may require more than 12 months, and repeat liver biopsy is recommended after 18 months of treatment. Failure of aminotransferase levels to normalize invariably predicts lack of histologic resolution.

The response rate to therapy with prednisone and azathioprine is 80%. Older patients and those with HLA genotype *DRB1*04* are more likely to respond than younger patients and those with HLA *DRB1*03* or hyperbilirubinemia. Fibrosis may reverse with therapy and

rarely progresses after apparent biochemical and histologic remission. Once remission is achieved, therapy may be withdrawn, but the subsequent relapse rate is 50–80%. Relapses may again be treated in the same manner as the initial episode, with the same remission rate. After successful treatment of a relapse, the patient may continue taking azathioprine (up to 2 mg/kg) or the lowest dose of prednisone needed to maintain aminotransferase levels as close to normal as possible; another attempt at withdrawing therapy may be considered in patients remaining in remission long term (eg, ≥ 4 years). Prednisone can be used to treat rare flares during pregnancy, and maintenance azathioprine does not have to be discontinued.

Nonresponders to corticosteroids and azathioprine (failure of serum aminotransferase levels to decrease by 50% after 6 months) may be considered for a trial of cyclosporine, tacrolimus, everolimus, methotrexate, or rituximab. Mycophenolate mofetil, 1 g twice daily, is an effective alternative to azathioprine in patients who cannot tolerate it but is less effective in nonresponders to azathioprine. Bone density should be monitored—particularly in patients receiving maintenance corticosteroid therapy—and measures undertaken to prevent or treat osteoporosis (see Chapter 26). Liver transplantation may be required for treatment failures and patients with a fulminant presentation, but the outcome may be worse than that for primary biliary cirrhosis because of an increased rate of infectious complications, and the disease has been recognized to recur in up to 40% of transplanted livers (and rarely to develop *de novo*) as immunosuppression is reduced; sirolimus can be effective in such cases. Overall long-term mortality of patients with autoimmune hepatitis appears to be greater than that of the general population despite response to immunosuppressive therapy.

▶ When to Refer

- For liver biopsy.
- For immunosuppressive therapy.

▶ When to Admit

- Hepatic encephalopathy.
- INR >1.6 .

Baven-Prong AM et al. The role of mycophenolate mofetil in the management of autoimmune hepatitis and overlap syndromes. *Aliment Pharmacol Ther*. 2011 Aug;34(3):335–43. [PMID: 21668459]

Hoeroldt B et al. Long-term outcomes of patients with autoimmune hepatitis managed at a nontransplant center. *Gastroenterology*. 2011 Jun;140(7):1980–9. [PMID: 21396370]

Lohse AW et al. Autoimmune hepatitis. *J Hepatol*. 2011 Jul;55(1):171–82. [PMID: 21167232]

Manns MP et al. Diagnosis and management of autoimmune hepatitis. *Hepatology*. 2010 Jun;51(6):2193–213. [PMID: 20513004]

Mayo MJ. Management of autoimmune hepatitis. *Curr Opin Gastroenterol*. 2011 May;27(3):224–30. [PMID: 21451411]

ALCOHOLIC LIVER DISEASE

ESSENTIALS OF DIAGNOSIS

- ▶ Chronic alcohol intake usually exceeds 80 g/d in men and 30–40 g/d in women with alcoholic hepatitis or cirrhosis.
- ▶ Fatty liver is often asymptomatic.
- ▶ Fever, right upper quadrant pain, tender hepatomegaly, and jaundice characterize alcoholic hepatitis, but the patient may be asymptomatic.
- ▶ AST is usually elevated but usually not above 300 units/L (6 mkat/L); AST is greater than ALT, usually by a factor of 2 or more.
- ▶ Alcoholic hepatitis is often reversible but it is the most common precursor of cirrhosis in the United States.

▶ General Considerations

Excessive alcohol intake can lead to fatty liver, hepatitis, and cirrhosis. Alcoholic hepatitis is characterized by acute or chronic inflammation and parenchymal necrosis of the liver induced by alcohol. Alcoholic hepatitis is often a reversible disease, the most common precursor of cirrhosis in the United States, and associated with four to five times the number of hospitalizations and deaths as hepatitis C, which is the second most common cause of cirrhosis.

The frequency of alcoholic cirrhosis is estimated to be 10–15% among persons who consume over 50 g of alcohol (4 oz of 100-proof whiskey, 15 oz of wine, or four 12-oz cans of beer) daily for over 10 years (although the risk of cirrhosis may be lower for wine than for a comparable intake of beer or spirits). The risk of cirrhosis is lower (5%) in the absence of other cofactors such as chronic viral hepatitis and obesity. Genetic factors, including polymorphisms of the genes encoding tumor necrosis factor, cytochrome P450 2E1, and glutathione S-transferase may also account for differences in susceptibility. Women appear to be more susceptible than men, in part because of lower gastric mucosal alcohol dehydrogenase levels. Over 80% of patients with alcoholic hepatitis have been drinking 5 years or more before symptoms that can be attributed to liver disease develop; the longer the duration of drinking (10–15 or more years) and the larger the alcoholic consumption, the greater the probability of developing alcoholic hepatitis and cirrhosis. In individuals who drink alcohol excessively, the rate of ethanol metabolism can be sufficiently high to permit the consumption of large quantities without raising the blood alcohol level over 80 mg/dL.

Deficiencies in vitamins and calories probably contribute to the development of alcoholic hepatitis and its progression to cirrhosis. Many adverse effects of alcohol on the liver are thought to be mediated by tumor necrosis factor and by the oxidative metabolite acetaldehyde, which contributes to lipid

peroxidation and induction of an immune response following covalent binding to proteins in the liver.

► Clinical Findings

A. Symptoms and Signs

The clinical presentation of alcoholic liver disease can vary from asymptomatic hepatomegaly to a rapidly fatal acute illness or end-stage cirrhosis. A recent period of heavy drinking, complaints of anorexia and nausea, and the demonstration of hepatomegaly and jaundice strongly suggest the diagnosis. Abdominal pain and tenderness, splenomegaly, ascites, fever, and encephalopathy may be present. Infection is common in patients with severe alcoholic hepatitis.

B. Laboratory Findings

In patients with steatosis, mild liver enzyme elevations may be the only laboratory abnormality. Anemia (usually macrocytic) may be present. Leukocytosis with a shift to the left is common in patients with severe alcoholic hepatitis. Leukopenia is occasionally seen and resolves after cessation of drinking. About 10% of patients have thrombocytopenia related to a direct toxic effect of alcohol on megakaryocyte production or to hypersplenism.

AST is usually elevated but infrequently above 300 units/L (6 mckat/L). AST is greater than ALT, usually by a factor of 2 or more. Serum alkaline phosphatase is generally elevated, but seldom more than three times the normal value. Serum bilirubin is increased in 60–90% of patients with alcoholic hepatitis.

Serum bilirubin levels >10 mg/dL (171 μmol/L) and marked prolongation of the prothrombin time (≥6 seconds above control) indicate severe alcoholic hepatitis with a mortality rate as high as 50%. The serum albumin is depressed, and the γ -globulin level is elevated in 50–75% of individuals, even in the absence of cirrhosis. Increased transferrin saturation, hepatic iron stores, and sideroblastic anemia are found in many alcoholic patients. Folic acid deficiency may coexist.

C. Imaging

Imaging studies can detect moderate to severe hepatic steatosis reliably but not inflammation or fibrosis. Ultrasonography helps exclude biliary obstruction and identifies subclinical ascites. CT with intravenous contrast or MRI may be indicated in selected cases to evaluate patients for collateral vessels, space-occupying lesions of the liver, or concomitant disease of the pancreas.

D. Liver Biopsy

Liver biopsy, if done, demonstrates macrovesicular fat and, in patients with alcoholic hepatitis, polymorphonuclear infiltration with hepatic necrosis, Mallory (or Mallory-Denk) bodies (alcoholic hyaline), and perivenular and perisinusoidal fibrosis. Micronodular cirrhosis may be present as well. The findings are identical to those of non-alcoholic steatohepatitis.

► Differential Diagnosis

Alcoholic hepatitis may be closely mimicked by cholecystitis and cholelithiasis and by drug toxicity. Other causes of hepatitis or chronic liver disease may be excluded by serologic or biochemical testing, imaging studies, or liver biopsy. A formula based on the AST/ALT ratio, body mass index, mean corpuscular volume, and gender has been reported to reliably distinguish alcoholic liver disease from nonalcoholic fatty liver disease (NAFLD).

► Treatment

A. General Measures

Abstinence from alcohol is essential. Naltrexone or acamprosate may be considered in combination with counseling to reduce the likelihood of recidivism. Fatty liver is quickly reversible with abstinence. Every effort should be made to provide sufficient amounts of carbohydrates and calories in anorectic patients to reduce endogenous protein catabolism, promote gluconeogenesis, and prevent hypoglycemia. Nutritional support (40 kcal/kg with 1.5–2 g/kg as protein) improves liver disease, but not necessarily survival, in patients with malnutrition. Use of liquid formulas rich in branched-chain amino acids does not improve survival beyond that achieved with less expensive caloric supplementation. The administration of micronutrients, particularly folic acid, thiamine, and zinc, is indicated, especially when deficiencies are noted; glucose administration increases the thiamine requirement and can precipitate Wernicke–Korsakoff syndrome if thiamine is not coadministered.

B. Pharmacologic Measures

Methylprednisolone, 32 mg/d orally, or the equivalent, for 1 month, may reduce short-term mortality in patients with alcoholic hepatitis and either encephalopathy or a Maddrey discriminant function index (defined by the patient's prothrombin time minus the control prothrombin time times 4.6 plus the total bilirubin in mg/dL) of ≥ 32 . No benefit has been demonstrated in patients with concomitant gastrointestinal bleeding, but infection should not preclude treatment with corticosteroids if otherwise indicated.

Pentoxifylline—an inhibitor of tumor necrosis factor—400 mg orally three times daily for 4 weeks, may reduce 1-month mortality rates in patients with severe alcoholic hepatitis, primarily by decreasing the risk of hepatorenal syndrome. It is often used when corticosteroids are contraindicated. The combination of corticosteroids and N-acetylcysteine has been reported to improve 1-month but not 6-month survival and reduce the risk of hepatorenal syndrome and infections. Other experimental therapies include propylthiouracil, oxandrolone, S-adenosyl-L-methionine, infliximab, antioxidants, and extracorporeal liver support. Colchicine does not reduce mortality in patients with alcoholic cirrhosis, and etanercept may increase mortality after 6 months.

► Prognosis

A. Short-Term

The overall mortality rate is 34% (20% within 1 month) without corticosteroid therapy. Individuals in whom the prothrombin time prohibits liver biopsy have a 42% mortality rate at 1 year. Other unfavorable prognostic factors are older age, a serum bilirubin >10 mg/dL (171 μ mol/L), hepatic encephalopathy, coagulopathy, azotemia, leukocytosis, sepsis and other infections, lack of response to corticosteroid therapy, and possibly a paucity of steatosis on a liver biopsy specimen and reversal of portal blood flow by Doppler ultrasonography. Failure of the serum bilirubin level to decline after 7 days of treatment with corticosteroids predicts nonresponse and poor long-term survival, as does the Lille model (which includes age, serum creatinine, serum albumin, prothrombin time (or INR), serum bilirubin on admission, and serum bilirubin on day 7). The MELD score used for cirrhosis (see later) and the Glasgow alcoholic hepatitis score (based on age, white blood cell count, blood urea nitrogen, prothrombin time ratio, and bilirubin level) also correlate with mortality from alcoholic hepatitis and have higher specificities than the discriminant function and Lille score. A scoring system based on age, serum bilirubin, INR, and serum creatinine (ABIC) has been proposed, and one study has shown that the development of acute kidney injury is the most accurate predictor of 90-day mortality.

B. Long-Term

Overall mortality from alcoholic liver disease has declined slightly in the United States since 1980. Nevertheless, the 3-year mortality rate of persons who recover from acute alcoholic hepatitis is ten times greater than that of control individuals of comparable age; the 5-year mortality rate is as high as 85%. Histologically severe disease is associated with continued excessive mortality rates after 3 years, whereas the death rate is not increased after the same period in those whose liver biopsies show only mild alcoholic hepatitis. Complications of portal hypertension (ascites, variceal bleeding, hepatorenal syndrome), coagulopathy, and severe jaundice following recovery from acute alcoholic hepatitis also suggest a poor long-term prognosis. Alcoholic cirrhosis is a risk factor for hepatocellular carcinoma, and the risk is highest in carriers of the C282Y mutation for hemochromatosis or those with increased hepatic iron.

The most important prognostic consideration is continued excessive drinking. A 6-month period of abstinence is generally required before liver transplantation is considered, although this requirement has been questioned and early liver transplantation has been performed in selected patients with alcoholic hepatitis, with good outcomes. Optimal candidates have adequate social support, do not smoke, have no psychosis or personality disorder, are adherent to therapy, and have regular appointments with a psychiatrist or psychologist who specializes in addiction treatment. Patients with alcoholic liver disease are at higher risk for posttransplant malignancy than those with other types of liver disease because of alcohol and tobacco use.

► When to Refer

Refer patients with alcoholic hepatitis who require liver biopsy for diagnosis.

► When to Admit

- Hepatic encephalopathy.
- INR >1.6 .
- Total bilirubin ≥ 10 mg/dL.
- Inability to maintain hydration.

Altamirano J et al. Acute kidney injury is an early predictor of mortality for patients with alcoholic hepatitis. *Clin Gastroenterol Hepatol.* 2012 Jan;10(1):65–71. [PMID: 21946124]

Gao B et al. Alcoholic liver disease: pathogenesis and new therapeutic targets. *Gastroenterology.* 2011 Nov;141(5):1572–85. [PMID: 21920463]

Mathurin P et al. Early liver transplantation for severe alcoholic hepatitis. *N Engl J Med.* 2011 Nov 10;365(19):1790–800. [PMID: 22070476]

Nguyen-Khac E et al; AAH-NAC Study Group. Glucocorticoids plus N-acetylcysteine in severe alcoholic hepatitis. *N Engl J Med.* 2011 Nov 10;365(19):1781–9. [PMID: 22070475]

Singal AK et al. Alcoholic hepatitis: prognostic models and treatment. *Gastroenterol Clin North Am.* 2011 Sep;40(3):611–39. [PMID: 21893277]

DRUG- & TOXIN-INDUCED LIVER DISEASE

ESSENTIALS OF DIAGNOSIS

- Drug-induced liver disease can mimic viral hepatitis, biliary tract obstruction, or other types of liver disease.
- Clinicians must inquire about the use of many widely used therapeutic agents, including over-the-counter “natural” and herbal products, in any patient with liver disease.

► General Considerations

Many therapeutic agents may cause hepatic injury. The medications most commonly implicated are nonsteroidal anti-inflammatory drugs and antibiotics because of their widespread use. In any patient with liver disease, the clinician must inquire carefully about the use of potentially hepatotoxic drugs or exposure to hepatotoxins, including over-the-counter “natural” and herbal products. In some cases, coadministration of a second agent may increase the toxicity of the first (eg, isoniazid and rifampin, acetaminophen and alcohol). A relationship between increased serum ALT levels in premarketing clinical trials and postmarketing reports of hepatotoxicity has been identified. Except for drugs used to treat tuberculosis and HIV infection, the risk of hepatotoxicity is not increased in patients with preexisting cirrhosis. Drug toxicity may be categorized on the basis of pathogenesis or histologic appearance. Drug-induced

liver disease can mimic viral hepatitis, biliary tract obstruction, or other types of liver disease.

► Categorization by Pathogenesis

A. Direct Hepatotoxicity

Liver toxicity caused by this group of drugs is characterized by: (1) dose-related severity, (2) a latent period following exposure, and (3) susceptibility in all individuals. Examples include acetaminophen (toxicity is enhanced by fasting and chronic alcohol use because of depletion of glutathione and induction of cytochrome P450 2E1 and possibly reduced by statins, fibrates, and nonsteroidal anti-inflammatory drugs), alcohol, carbon tetrachloride, chloroform, heavy metals, mercaptopurine, niacin, plant alkaloids, phosphorus, pyrazinamide, tetracyclines, tipranavir, valproic acid, and vitamin A. Statins, like all cholesterol-lowering agents, may cause serum aminotransferase elevations but rarely cause true hepatitis and are no longer considered contraindicated in patients with liver disease.

B. Idiosyncratic Reactions

Except for acetaminophen, most severe hepatotoxicity is idiosyncratic. Reactions of this type are: (1) sporadic, (2) not related to dose, and (3) occasionally associated with features suggesting an allergic reaction, such as fever and eosinophilia, which may be associated with a favorable outcome. In many instances, toxicity results directly from a metabolite that is produced only in certain individuals on a genetic basis. Toxicity may be observed only on post-marketing surveillance and not during preclinical trials. Examples include abacavir, amiodarone, aspirin, carbamazepine, chloramphenicol, diclofenac, disulfiram, duloxetine, ezetimibe, fluoroquinolones, flutamide, halothane, isoniazid, ketoconazole, lamotrigine, methyl dopa, natalizumab, nevirapine, oxacillin, phenytoin, pyrazinamide, quinidine, streptomycin, thiazolidinediones, and perhaps tacrine.

► Categorization by Histopathology

A. Cholestasis

1. Noninflammatory—Drug-induced cholestasis results from inhibition or genetic deficiency of various hepatobiliary transporter systems. The following drugs cause cholestasis: anabolic steroids containing an alkyl or ethinyl group at carbon 17, azathioprine, cetirizine, diclofenac, indinavir (increased risk of indirect hyperbilirubinemia in patients with Gilbert syndrome), cyclosporine, estrogens, infliximab, mercaptopurine, methyltestosterone, tamoxifen, and ticlopidine.

2. Inflammatory—The following drugs cause inflammation of portal areas with bile duct injury (cholangitis), often with allergic features such as eosinophilia: amoxicillin-clavulanic acid (among the most common causes of drug-induced liver injury), azathioprine, azithromycin, captopril, celecoxib, cephalosporins, chlorothiazide, chlorpromazine, chlorpropamide, erythromycin, mercaptopurine, penicillamine, prochlorperazine, semisynthetic penicillins (eg,

cloxacillin), and sulfadiazine. Cholestatic and mixed cholestatic hepatocellular toxicity is more likely than pure hepatocellular toxicity to lead to chronic liver disease.

B. Acute or Chronic Hepatitis

Medications that may result in acute or chronic hepatitis that is histologically—and in some cases clinically—similar to autoimmune hepatitis include minocycline and nitrofurantoin most commonly as well as aspirin, isoniazid (increased risk in HBV and HCV carriers), methyl dopa, nonsteroidal anti-inflammatory drugs, propylthiouracil, and terbinafine. Histologic features that favor a drug cause include portal tract neutrophils and hepatocellular cholestasis. Hepatitis also can occur in patients taking cocaine, diclofenac, methylenedioxymethamphetamine (MDMA; Ecstasy), efavirenz, imatinib mesylate, nafazodone (has a black box warning for a potential to cause liver failure), nevirapine (like other protease inhibitors, increased risk in HBV and HCV carriers), pioglitazone, ritonavir (greater rate than other protease inhibitors), rosiglitazone, saquinavir, sulfonamides, telithromycin, and zafirlukast as well as a variety of alternative remedies (eg, chaparral, germander, green tea extracts, Herbalife products, hydroxycut, jin bu huan, kava, skullcap, and possibly black cohosh). In patients with jaundice due to drug-induced hepatitis, the mortality rate without liver transplantation is at least 10%.

C. Other Reactions

1. Fatty liver

A. MACROVESICULAR—This type of liver injury may be produced by alcohol, amiodarone, corticosteroids, methotrexate, irinotecan, tamoxifen, vinyl chloride (in exposed workers), zalcitabine, and possibly oxaliplatin.

B. MICROVESICULAR—Often resulting from mitochondrial injury, this condition is associated with didanosine, stavudine, tetracyclines, valproic acid, and zidovudine.

2. Granulomas—Allopurinol, quinidine, quinine, phenylbutazone, phenytoin, and pyrazinamide can lead to granulomas.

3. Fibrosis and cirrhosis—Methotrexate and vitamin A are associated with fibrosis and cirrhosis.

4. Sinusoidal obstruction syndrome (veno-occlusive disease)—This disorder may result from treatment with antineoplastic agents (eg, pre-bone marrow transplant, oxaliplatin), and pyrrolizidine alkaloids (eg, Comfrey).

5. Peliosis hepatis (blood-filled cavities)—Peliosis hepatis may be caused by anabolic steroids and oral contraceptive steroids as well as azathioprine and mercaptopurine, which may also cause nodular regenerative hyperplasia.

6. Neoplasms—Neoplasms may result from therapy with oral contraceptive steroids, including estrogens (hepatic adenoma but not focal nodular hyperplasia), and vinyl chloride (angiosarcoma).

▶ When to Refer

Refer patients with drug- and toxin-induced hepatitis who require liver biopsy for diagnosis.

▶ When to Admit

Patients with liver failure should be hospitalized.

- Begrache K et al. Drug-induced toxicity on mitochondria and lipid metabolism: mechanistic diversity and deleterious consequences for the liver. *J Hepatol.* 2011 Apr;54(4):773–94. [PMID: 21145849]
- Björnsson E. Review article: drug-induced liver injury in clinical practice. *Aliment Pharmacol Ther.* 2010 Jul;32(1):3–13. [PMID: 20374223]
- Czaja AJ. Drug-induced autoimmune-like hepatitis. *Dig Dis Sci.* 2011 Apr;56(4):958–76. [PMID: 21327704]
- Orman ES et al. Clinical and histopathologic features of fluoroquinolone-induced liver injury. *Clin Gastroenterol Hepatol.* 2011 Jun;9(6):517–523. [PMID: 21356330]
- Padda MS et al. Drug-induced cholestasis. *Hepatology.* 2011 Apr;53(4):1377–87. [PMID: 21480339]
- Suzuki A et al. The use of liver biopsy evaluation in discrimination of idiopathic autoimmune hepatitis versus drug-induced liver injury. *Hepatology.* 2011 Sep 2;54(3):931–9. [PMID: 21674554]

NONALCOHOLIC FATTY LIVER DISEASE



ESSENTIALS OF DIAGNOSIS

- ▶ Often asymptomatic.
- ▶ Elevated aminotransferase levels and/or hepatomegaly.
- ▶ Macrovesicular and/or microvesicular steatosis with or without inflammation and fibrosis on liver biopsy.

▶ General Considerations

Nonalcoholic fatty liver disease (NAFLD) is estimated to affect 20–45% of the US population. Causes of NAFLD are obesity (present in $\geq 40\%$), diabetes mellitus (in $\geq 20\%$), hypertriglyceridemia (in $\geq 20\%$), corticosteroids, amiodarone, diltiazem, tamoxifen, irinotecan, oxaliplatin, highly active antiretroviral therapy, toxins (vinyl chloride, carbon tetrachloride, yellow phosphorus), endocrinopathies such as Cushing syndrome and hypopituitarism, polycystic ovary syndrome, hypobetalipoproteinemia and other metabolic disorders, obstructive sleep apnea (with chronic intermittent hypoxia), excessive dietary fructose consumption, starvation and refeeding syndrome, and total parenteral nutrition. Genetic factors, including polymorphisms of the gene that encodes apolipoprotein C3, are likely to play a role, and polymorphisms of the patatin-like phospholipase domain containing 3 (*PNPLA3*) gene modify the natural history of NAFLD and may account in part for an

increased risk in Hispanics. The risk of NAFLD is increased in persons with psoriasis and appears to correlate with the activity of psoriasis. Soft drink consumption has been reported to be associated with NAFLD. Steatosis is nearly universal in obese alcoholic patients and is a hallmark of insulin resistance (metabolic syndrome), which is characterized by obesity, diabetes, hypertriglyceridemia, and hypertension. The risk of fatty liver in persons with metabolic syndrome is 4 to 11 times higher than that of persons without insulin resistance. Physical activity protects against the development of NAFLD. In addition to macrovesicular steatosis, histologic features may include focal infiltration by polymorphonuclear neutrophils and Mallory hyalin, a picture indistinguishable from that of alcoholic hepatitis and referred to as nonalcoholic steatohepatitis (NASH), which affects 3–5% of the US population. In patients with NAFLD, older age, obesity, and diabetes mellitus are risk factors for advanced hepatic fibrosis and cirrhosis. Cirrhosis caused by NASH appears to be uncommon in African Americans.

Microvesicular steatosis is seen with Reye syndrome, didanosine toxicity, valproic acid toxicity, high-dose tetracycline, or acute fatty liver of pregnancy and may result in fulminant hepatic failure. Women in whom fatty liver of pregnancy develops often have a defect in fatty acid oxidation due to reduced long-chain 3-hydroxyacyl-CoA dehydrogenase activity.

▶ Clinical Findings

A. Symptoms and Signs

Most patients with NAFLD are asymptomatic or have mild right upper quadrant discomfort. Hepatomegaly is present in up to 75% of patients, but stigmata of chronic liver disease are uncommon. Rare instances of subacute liver failure caused by previously unrecognized NASH have been described.

B. Laboratory Findings

Laboratory studies may show mildly elevated aminotransferase and alkaline phosphatase levels; however, laboratory values may be normal in up to 80% of persons with hepatic steatosis. In contrast to alcoholic liver disease, the ratio of ALT to AST is almost always >1 in NAFLD, but it decreases to <1 as advanced fibrosis and cirrhosis develop. Antinuclear or smooth muscle antibodies and an elevated serum ferritin level may each be detected in one-fourth of patients with NASH. Elevated serum ferritin levels may signify so-called dysmetabolic iron overload syndrome and mildly increased body iron stores, which may play a causal role in insulin resistance and oxidative stress in hepatocytes and correlate with advanced fibrosis; the frequency of mutations in the *HFE* gene for hemochromatosis is not increased in patients with NAFLD.

C. Imaging

Macrovascular steatosis may be demonstrated on ultrasonography, CT, or MRI. However, imaging does not distinguish

steatosis from steatohepatitis. Where available, magnetic resonance spectroscopy allows hepatic fat content to be quantitated, and transient elastography to assess liver stiffness can be used to estimate hepatic fibrosis.

D. Liver Biopsy

Percutaneous liver biopsy is diagnostic and is the standard approach to assessing the degree of inflammation and fibrosis. The risks of the procedure must be balanced against the impact of the added information on management decisions and assessment of prognosis. The histologic spectrum includes fatty liver, isolated portal fibrosis, steatohepatitis, and cirrhosis. A risk score for predicting advanced fibrosis, known as BARD, is based on body mass index >28 , AST/ALT ratio ≥ 0.8 , and diabetes mellitus; it has a 96% negative predictive value (ie, a low score reliably excludes advanced fibrosis). Another risk score for advanced fibrosis based on age, hyperglycemia, body mass index, platelet count, albumin, and AST/ALT ratio has a positive predictive value of over 80%. A clinical scoring system to predict the likelihood of NASH in morbidly obese persons includes six predictive factors: hypertension, type 2 diabetes mellitus, sleep apnea, AST >27 units/L (0.54 mkat/L), ALT >27 units/L (0.54 mkat/L), and non-black race.

► Treatment

Treatment consists of removing or modifying the offending factors. Weight loss, dietary fat restriction, and exercise (through reduction of abdominal obesity) often lead to improvement in liver biochemical tests and steatosis in obese patients with NAFLD. Various drugs are under study. Thiazolidinediones reverse insulin resistance and, in most relevant studies, have improved both serum aminotransferase levels and histologic features of steatohepatitis but lead to weight gain. Vitamin E (to reduce oxidative stress) also appears to be of benefit. Metformin, which reduces insulin resistance, improves abnormal liver chemistries but may not reliably improve liver histology. Pentoxifylline, which inhibits tumor necrosis factor, improves liver biochemical test levels but is associated with a high rate of side effects, particularly nausea. Betaine (a methyl donor) does not appear to be of benefit. Ursodeoxycholic acid, 12–15 mg/kg/d, has not consistently resulted in biochemical and histologic improvement in patients with NASH but may be effective when given in combination with vitamin E. Hepatic steatosis due to total parenteral nutrition may be ameliorated—and perhaps prevented—with supplemental choline. Other approaches under study include orlistat, an inhibitor of gastrointestinal lipases; recombinant human leptin; glucagon-like protein-1-receptor agonists, which promote insulin secretion; L-carnitine, which regulates the turnover of fatty acids in phospholipid membranes; omega-3 fatty acids, which alter hepatic gene expression to favor fatty acid oxidation over lipogenesis; probucol, a lipid-lowering agent; pentoxifylline; losartan, an angiotensin antagonist; and iron depletion therapy. Statins are not contraindicated in persons with NAFLD. Gastric bypass may be considered

in patients with a body mass index >35 and leads to improvement in hepatic steatosis. Liver transplantation is indicated in appropriate candidates with advanced cirrhosis caused by NASH, now the third most common indication for liver transplantation in the United States.

► Prognosis

Fatty liver often has a benign course and is readily reversible with discontinuation of alcohol (or no more than one glass of wine per day) or treatment of other underlying conditions; if untreated, cirrhosis develops in 1–3% of patients. In patients with NAFLD, the likelihood of NASH is increased by the following factors: obesity, older age, non-African American ethnicity, female sex, diabetes mellitus, hypertension, higher AST level, higher AST/ALT ratio, and low platelet count. NASH may be associated with hepatic fibrosis in 40% of cases; cirrhosis develops in 9–25%; and decompensated cirrhosis occurs in 30–50% of cirrhotic patients over 10 years. The course may be more aggressive in diabetic persons than in nondiabetic persons. Mortality is increased in patients with NAFLD and is more likely to be the result of malignancy and ischemic heart disease than liver disease. Risk factors for mortality are older age, male gender, white race, higher body mass index, hypertension, diabetes mellitus, and cirrhosis. Steatosis is a cofactor for the progression of fibrosis in patients with other causes of chronic liver disease, such as hepatitis C. Hepatocellular carcinoma is a complication of cirrhosis caused by NASH as it is for other causes of cirrhosis. NASH accounts for a substantial percentage of cases labeled as cryptogenic cirrhosis and can recur following liver transplantation. Central obesity is an independent risk factor for death from cirrhosis of any cause.

► When to Refer

Refer patients with non-alcoholic fatty liver disease who require liver biopsy for diagnosis.

Calori G et al. Fatty liver index and mortality: the Cremona study in the 15th year of follow-up. *Hepatology*. 2011 Jul;54(1):145–52. [PMID: 21488080]

Dowman JK et al. Systematic review: the diagnosis and staging of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. *Aliment Pharmacol Ther*. 2011 Mar;33(5):525–40. [PMID: 21198708]

Hernaes R et al. Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: a meta-analysis. *Hepatology*. 2011 Sep 2;54(3):1082–90. [PMID: 21618575]

Kowdley KV et al; NASH Clinical Research Network. Serum ferritin is an independent predictor of histologic severity and advanced fibrosis in patients with nonalcoholic fatty liver disease. *Hepatology*. 2012 Jan;55(1):77–85. [PMID: 21953442]

Williams CD et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. *Gastroenterology*. 2011 Jan;140(1):124–31. [PMID: 20858492]

CIRRHOSIS

ESSENTIALS OF DIAGNOSIS

- ▶ End result of injury that leads to both fibrosis and regenerative nodules.
- ▶ May be reversible if cause is removed.
- ▶ The clinical features result from hepatic cell dysfunction, portosystemic shunting, and portal hypertension.

▶ General Considerations

Cirrhosis, the twelfth leading cause of death in the United States, is the end result of hepatocellular injury that leads to both fibrosis and regenerative nodules throughout the liver. Causes include chronic viral hepatitis, alcohol, drug toxicity, autoimmune and metabolic liver diseases, and miscellaneous disorders. Many patients have more than one risk factor (eg, chronic hepatitis and alcohol use). Mexican Americans and African Americans have a higher frequency of cirrhosis than whites because of a higher rate of risk factors. In persons at increased risk for liver injury (eg, heavy alcohol use, obesity, iron overload), higher coffee and tea consumption has been reported to reduce the risk of cirrhosis. Hospitalization rates for cirrhosis and portal hypertension are rising in the United States. The risk of hospitalization or death due to cirrhosis has been reported to correlate with protein and cholesterol consumption and with hyperuricemia and inversely with carbohydrate consumption.

The most common histologic classification divides cirrhosis into micronodular, macronodular, and mixed forms. These are descriptive terms rather than separate diseases, and each form may be seen in the same patient at different stages of the disease. In micronodular cirrhosis—typical of alcoholic liver disease (Laennec cirrhosis)—the regenerative nodules are no larger than the original lobules, ie, approximately 1 mm in diameter or less. Macronodular cirrhosis is characterized by larger nodules, which can measure several centimeters in diameter and may contain central veins. This form corresponds more or less to postnecrotic (posthepatic) cirrhosis but does not necessarily follow episodes of massive necrosis and stromal collapse. Clinically, cirrhosis is considered to progress through three stages: compensated, compensated with varices, and decompensated (ascites, variceal bleeding, encephalopathy, or jaundice) that correlate with the thickness of fibrous septa.

▶ Clinical Findings

A. Symptoms and Signs

The clinical features of cirrhosis result from hepatocyte dysfunction, portosystemic shunting, and portal hypertension. Patients may have no symptoms for long periods. The onset of symptoms may be insidious or, less often, abrupt.

Weakness, fatigue, disturbed sleep, muscle cramps, and weight loss are common. In advanced cirrhosis, anorexia is usually present and may be extreme, with associated nausea and occasional vomiting. Abdominal pain may be present and is related either to hepatic enlargement and stretching of Glisson capsule or to the presence of ascites. Menstrual abnormalities (usually amenorrhea), erectile dysfunction, loss of libido, sterility, and gynecomastia in men may occur. Hematemesis is the presenting symptom in 15–25%.

Skin manifestations consist of spider angioma (invariably on the upper half of the body), palmar erythema (mottled redness of the thenar and hypothenar eminences), and Dupuytren contractures. Evidence of vitamin deficiencies (glossitis and cheilosis) is common. Weight loss, wasting, and the appearance of chronic illness are present. Jaundice—usually not an initial sign—is mild at first, increasing in severity during the later stages of the disease. In 70% of cases, the liver is enlarged, palpable, and firm if not hard and has a sharp or nodular edge; the left lobe may predominate. Splenomegaly is present in 35–50% of cases and is associated with an increased risk of complications of portal hypertension. The superficial veins of the abdomen and thorax are dilated, reflecting the intrahepatic obstruction to portal blood flow, as do rectal varices. The abdominal wall veins fill from below when compressed. Ascites, pleural effusions, peripheral edema, and ecchymoses are late findings. Encephalopathy characterized by day–night reversal, asterixis, tremor, dysarthria, delirium, drowsiness, and ultimately coma also occurs late except when precipitated by an acute hepatocellular insult or an episode of gastrointestinal bleeding. Fever may be a presenting symptom in up to 35% of patients and usually reflects associated alcoholic hepatitis, spontaneous bacterial peritonitis, or intercurrent infection.

B. Laboratory Findings

Laboratory abnormalities are either absent or minimal in early or compensated cirrhosis. Anemia, a frequent finding, is often macrocytic; causes include suppression of erythropoiesis by alcohol as well as folate deficiency, hemolysis, hypersplenism, and occult or overt blood loss from the gastrointestinal tract. The white blood cell count may be low, reflecting hypersplenism, or high, suggesting infection; thrombocytopenia, the most common cytopenia in cirrhotic patients, is secondary to alcoholic marrow suppression, sepsis, folate deficiency, or splenic sequestration. Prolongation of the prothrombin time may result from reduced levels of clotting factors (except factor VIII). However, bleeding risk correlates poorly with the prothrombin time because of concomitant abnormalities of fibrinolysis, and among hospitalized patients under age 45, cirrhosis is associated with an increased risk of venous thromboembolism.

Blood chemistries reflect hepatocellular injury and dysfunction, manifested by modest elevations of AST and alkaline phosphatase and progressive elevation of the bilirubin. Serum albumin decreases as the disease progresses;

γ -globulin is increased and may be as high as in autoimmune hepatitis. The risk of diabetes mellitus is increased in patients with cirrhosis, particularly when associated with HCV infection, alcoholism, hemochromatosis, or NAFLD. Vitamin D deficiency has been reported in as many as 91% of patients with cirrhosis. Patients with alcoholic cirrhosis may have elevated serum cardiac troponin I and brain natriuretic peptide levels. Blunted cardiac inotropic and chronotropic responses to exercise, stress, and drugs, as well as systolic and diastolic ventricular dysfunction (“cirrhotic cardiomyopathy”) and prolongation of the QT interval in the setting of a hyperkinetic circulation, are common in cirrhosis of all causes, but overt heart failure is rare in the absence of alcoholism. Relative adrenal insufficiency appears to be common in patients with advanced cirrhosis, even in the absence of sepsis.

Liver biopsy may show inactive cirrhosis (fibrosis with regenerative nodules) with no specific features to suggest the underlying cause. Alternatively, there may be additional features of alcoholic liver disease, chronic hepatitis, NASH, or other specific causes of cirrhosis. Combinations of routine blood tests (eg, AST, platelet count), including the FibroSure test, and serum markers of hepatic fibrosis (eg, hyaluronic acid, amino-terminal propeptide of type III collagen, tissue inhibitor of matrix metalloproteinase 1) are potential alternatives to liver biopsy for the diagnosis or exclusion of cirrhosis. In persons with chronic hepatitis C, for example, a low FibroSure score reliably excludes advanced fibrosis, a high score reliably predicts advanced fibrosis, and intermediate scores are inconclusive.

C. Imaging

Ultrasonography is helpful for assessing liver size and detecting ascites or hepatic nodules, including small hepatocellular carcinomas. Together with a Doppler study, it may establish patency of the splenic, portal, and hepatic veins. Hepatic nodules are characterized further by contrast-enhanced CT or MRI. Nodules suspicious for malignancy may be biopsied under ultrasound or CT guidance.

D. Other Examinations

Esophagogastroduodenoscopy confirms the presence of varices and detects specific causes of bleeding in the esophagus, stomach, and proximal duodenum. Liver biopsy may be performed by laparoscopy or, in patients with coagulopathy and ascites, by a transjugular approach. In selected cases, wedged hepatic vein pressure measurement may establish the presence and cause of portal hypertension. Transient elastography, which uses ultrasound to determine liver stiffness, and magnetic resonance elastography are available in a limited number of centers as noninvasive tests for cirrhosis and portal hypertension.

► Differential Diagnosis

The most common causes of cirrhosis are alcohol, chronic hepatitis C infection, NAFLD, and hepatitis B infection, and the prevalence of NAFLD has been increasing steadily because of the rapidly increasing prevalence of obesity in the United States. Hemochromatosis is the most commonly

identified genetic disorder that causes cirrhosis. Other metabolic diseases that may lead to cirrhosis include Wilson disease and α_1 -antitrypsin (α_1 -antiprotease) deficiency. Primary biliary cirrhosis occurs more frequently in women than men. Secondary biliary cirrhosis may result from chronic biliary obstruction due to a stone, stricture, or neoplasm. Heart failure and constrictive pericarditis may lead to hepatic fibrosis (“cardiac cirrhosis”) complicated by ascites and may be mistaken for other causes of cirrhosis. Hereditary hemorrhagic telangiectasia can lead to portal hypertension because of portosystemic shunting and nodular transformation of the liver as well as high-output heart failure. Many cases of cirrhosis are “cryptogenic,” in which unrecognized NAFLD may play a role. Mutations in the gene encoding cytokeratin 8 have been associated with some cases of cryptogenic cirrhosis, and mutations that decrease the activity of telomerase and lead to shortening of telomeres accelerate progression of fibrosis in patients with chronic liver disease.

► Complications

Upper gastrointestinal tract bleeding may occur from varices, portal hypertensive gastropathy, or gastroduodenal ulcer (see Chapter 15). Varices may also result from portal vein thrombosis, which may complicate cirrhosis. Liver failure may be precipitated by alcoholism, surgery, and infection. Hepatic Kupffer cell (reticuloendothelial) dysfunction and decreased opsonic activity lead to an increased risk of systemic infection, which increase mortality fourfold. Osteoporosis occurs in 12–55% of patients with cirrhosis. The risk of hepatocellular carcinoma is increased greatly in persons with cirrhosis (see Chapter 39).

► Treatment

A. General Measures

The most important principle of treatment is abstinence from alcohol. The diet should be palatable, with adequate calories (25–35 kcal/kg body weight per day in those with compensated cirrhosis and 35–40 kcal/kg/d in those with malnutrition) and protein (1–1.2 g/kg/d in those with compensated cirrhosis and 1.5 g/kg/d in those with malnutrition) and, if there is fluid retention, sodium restriction. In the presence of hepatic encephalopathy, protein intake should be reduced to no less than 60–80 g/d. The benefit of using specialized supplements containing branched-chain amino acids to prevent or treat hepatic encephalopathy or delay progressive liver failure is uncertain. Vitamin supplementation is desirable. Patients with cirrhosis should receive the HAV, HBV, and pneumococcal vaccines and a yearly influenza vaccine. Liver transplantation in appropriate candidates is curative, and pharmacologic treatments to halt progression of or even reverse cirrhosis are being developed.

B. Treatment of Complications

1. Ascites and edema—Diagnostic paracentesis is indicated for patients who have new ascites or who have been hospitalized for a complication of cirrhosis. Serious

complications, including bleeding, infection, or bowel perforation, occur in 1.6% of procedures and are associated with therapeutic paracentesis and possibly Child-Turcotte-Pugh class C, a platelet count $< 50,000/\text{mL}$ ($50 \times 10^9/\text{L}$), and alcoholic cirrhosis. In patients with coagulopathy, however, pre-paracentesis prophylactic transfusions do not appear to be necessary. In addition to a cell count and culture, the ascitic albumin level should be determined; a serum-ascites albumin gradient (serum albumin minus ascitic albumin) ≥ 1.1 suggests portal hypertension. An elevated ascitic adenosine deaminase level is suggestive of tuberculous peritonitis, but the sensitivity of the test is reduced in patients with portal hypertension. Occasionally, cirrhotic ascites is chylous (rich in triglycerides); other causes of chylous ascites are malignancy, tuberculosis, and recent abdominal surgery or trauma.

Ascites in patients with cirrhosis results from portal hypertension (increased hydrostatic pressure); hypoalbuminemia (decreased oncotic pressure); peripheral vasodilation, perhaps mediated by endotoxin-induced release of nitric oxide from splanchnic and systemic vasculature, with resulting increases in renin and angiotensin levels and sodium retention by the kidneys; impaired liver inactivation of aldosterone; and increased aldosterone secretion secondary to increased renin production. In individuals with ascites, the urinary sodium concentration is often $< 10 \text{ mEq/L}$ (10 mmol/L). Free water excretion is also impaired in cirrhosis, and hyponatremia may develop.

In all patients with cirrhotic ascites, dietary sodium intake may initially be restricted to 2000 mg/d ; the intake of sodium may be liberalized slightly after diuresis ensues. Nonsteroidal anti-inflammatory drugs are contraindicated, and angiotensin-converting enzyme inhibitors and angiotensin II antagonists should be avoided. In some patients, ascites diminishes promptly with bed rest and dietary sodium restriction alone. Fluid intake ($800\text{--}1000 \text{ mL/d}$) is often restricted in patients with hyponatremia. Treatment of severe hyponatremia (serum sodium $< 125 \text{ mEq/L}$ [125 mmol/L]) with vasopressin receptor antagonists (vaptans, including oral tolvaptan, beginning in a dose of 15 mg daily, and intravenous conivaptan, 20 mg daily) can be considered.

A. DIURETICS—Spironolactone, generally in combination with furosemide, should be used in patients who do not respond to salt restriction. An initial trial of furosemide 80 mg intravenously demonstrating a rise in urine sodium to 750 mmol in 8 hours may predict response to diuretic therapy. The dose of spironolactone is initially 100 mg orally daily and may be increased by 100 mg every 3–5 days (up to a maximal conventional daily dose of 400 mg/d , although higher doses have been used) until diuresis is achieved, typically preceded by a rise in the urinary sodium concentration. A “spot” urine sodium concentration that exceeds the potassium concentration correlates with a 24-hour sodium excretion $> 78 \text{ mmol/d}$, which predicts diuresis in patients adherent to a salt-restricted diet. Monitoring for hyperkalemia is important. In patients who cannot tolerate spironolactone because of side effects, such as painful gynecomastia, amiloride (another potassium-sparing diuretic) may be used in a dose of $5\text{--}10 \text{ mg}$

orally daily. Diuresis is augmented by the addition of a loop diuretic such as furosemide. This potent diuretic, however, will maintain its effect even with a falling glomerular filtration rate, with resulting prerenal azotemia. The dose of oral furosemide ranges from 40 mg/d to 160 mg/d , and the drug should be administered while blood pressure, urinary output, mental status, and serum electrolytes (especially potassium) are monitored.

The goal of weight loss in the ascitic patient without associated peripheral edema should be no more than $1\text{--}1.5 \text{ lb/d}$ ($0.5\text{--}0.7 \text{ kg/d}$).

B. LARGE-VOLUME PARACENTESIS—In patients with massive ascites and respiratory compromise, ascites refractory to diuretics (“diuretic resistant”), or intolerable diuretic side effects (“diuretic intractable”), large-volume paracentesis ($> 5 \text{ L}$) is effective. Intravenous albumin concomitantly at a dosage of $6\text{--}8 \text{ g/L}$ of ascites fluid removed protects the intravascular volume and may prevent postparacentesis circulatory dysfunction, although the usefulness of this practice is debated. Moreover, use of albumin adds considerable expense. Large-volume paracentesis can be repeated daily until ascites is largely resolved and may decrease the need for hospitalization. If possible, diuretics should be continued in the hope of preventing recurrent ascites.

C. TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT (TIPS)—TIPS is an effective treatment of variceal bleeding refractory to standard therapy (eg, endoscopic band ligation or sclerotherapy) and has shown benefit in the treatment of severe refractory ascites. The technique involves insertion of an expandable metal stent between a branch of the hepatic vein and the portal vein over a catheter inserted via the internal jugular vein. Increased renal sodium excretion and control of ascites refractory to diuretics can be achieved in about 75% of selected cases. The success rate is lower in patients with underlying chronic kidney disease. TIPS appears to be the treatment of choice for refractory hepatic hydrothorax (translocation of ascites across the diaphragm to the pleural space); video-assisted thoracoscopy with pleurodesis using talc may be effective when TIPS is contraindicated. Complications of TIPS include hepatic encephalopathy in 20–30% of cases, infection, shunt stenosis in up to 60% of cases, and shunt occlusion in up to 30% of cases when bare stents are used; however, polytetrafluoroethylene-covered stents are associated with long-term patency rates of 80–90%. Long-term patency often requires periodic shunt revisions. In most cases, patency can be maintained by balloon dilation, local thrombolysis, or placement of an additional stent. TIPS is particularly useful in patients who require short-term control of variceal bleeding or ascites until liver transplantation can be performed. In patients with refractory ascites, TIPS results in lower rates of ascites recurrence and hepatorenal syndrome but a higher rate of hepatic encephalopathy than occurs with repeated large-volume paracentesis; a benefit in survival has been demonstrated in one study and a meta-analysis. Chronic kidney disease, diastolic cardiac dysfunction, refractory encephalopathy, and hyperbilirubinemia ($> 5 \text{ mg/dL}$ [85.5 mcmol/L]) are associated with mortality after TIPS.

D. PERITONEOVENOUS SHUNTS—Peritoneovenous shunts are sometimes placed in patients with malignant ascites but are no longer used for refractory cirrhotic ascites because of a considerable complication rate: disseminated intravascular coagulation in 65% of patients (25% symptomatic; 5% severe), bacterial infections in 4–8%, heart failure in 2–4%, and variceal bleeding from sudden expansion of intravascular volume. TIPS is now preferred for refractory ascites.

2. Spontaneous bacterial peritonitis—Spontaneous bacterial peritonitis is heralded by abdominal pain, increasing ascites, fever, and progressive encephalopathy in a patient with cirrhotic ascites; symptoms are typically mild. (Analogously, spontaneous bacterial empyema may complicate hepatic hydrothorax and is managed similarly.) Risk factors in cirrhotic patients with ascites include gastroesophageal variceal bleeding and possibly use of a proton pump inhibitor. Paracentesis reveals an ascitic fluid with, most commonly, a total white cell count of up to 500 cells/mL with a high percentage of polymorphonuclear cells (PMNs) ($\geq 250/\text{mL}$) and a protein concentration of 1 g/dL (10 g/L) or less, corresponding to decreased ascitic opsonic activity. Rapid diagnosis of bacterial peritonitis can be made with a high degree of specificity with rapid reagent strips (“dipsticks”) that detect leukocyte esterase in ascitic fluid, but the sensitivity is too low for routine use. Cultures of ascites give the highest yield—80–90% positive—using blood culture bottles inoculated at the bedside. Common isolates are *Escherichia coli* and pneumococci. (Gram-positive cocci are the most common isolates in patients who have undergone an invasive procedure such as central venous line placement.) Anaerobes are uncommon. Pending culture results, if there are 250 or more PMNs/mL or symptoms or signs of infection, intravenous antibiotic therapy should be initiated with cefotaxime, 2 g every 8–12 hours for at least 5 days. Ceftriaxone and amoxicillin-clavulanic acid are alternative choices. Oral ofloxacin, 400 mg twice daily for 7 days, or, in a patient not already taking a fluoroquinolone for prophylaxis against bacterial peritonitis, a 2-day course of intravenous ciprofloxacin, 200 mg twice daily, followed by oral ciprofloxacin, 500 mg twice daily for 5 days, may be effective alternative regimens in selected patients. A carbapenem has been recommended for patients with hospital-acquired spontaneous bacterial peritonitis. Supplemental administration of intravenous albumin appears to reduce mortality, particularly in patients with a serum creatinine > 1 mg/dL (83.3 $\mu\text{mol/L}$), blood urea nitrogen > 30 mg/dL (10.8 mmol/L), or total bilirubin > 4 mg/dL (68.4 $\mu\text{mol/L}$). Response to therapy can be documented, if necessary, by a decrease in the PMN count of at least 50% on repeat paracentesis 48 hours after initiation of therapy. The overall mortality rate is high—up to 30% during hospitalization and up to 70% by 1 year. Patients with cirrhosis and septic shock have a high frequency of relative adrenal insufficiency, which if present requires administration of hydrocortisone. In survivors of bacterial peritonitis, the risk of recurrent peritonitis may be decreased by long-term norfloxacin, 400 mg orally daily; ciprofloxacin (eg, 500 mg orally once or twice a day); (although with recurrence

the causative organism is often resistant to fluoroquinolones) or trimethoprim-sulfamethoxazole (eg, one double-strength tablet five times a week) is a possible alternative agents. In high-risk cirrhotic patients (eg, those with ascitic protein < 1.5 g/dL and serum bilirubin > 3 mg/dL (51.3 $\mu\text{mol/L}$), serum creatinine > 1.2 mg/dL (99.96 $\mu\text{mol/L}$), blood urea nitrogen ≥ 25 mg/dL (9 mmol/L), or sodium ≤ 130 mEq/L [130 mmol/L]), the risk of peritonitis, hepatorenal syndrome, and mortality for at least 1 year may be reduced by prophylactic norfloxacin, 400 mg orally once a day. Oral norfloxacin (400 mg orally twice a day) or intravenous ceftriaxone (1 g per day), which may be preferable, for 7 days reduces the risk of bacterial peritonitis in patients hospitalized for acute variceal bleeding.

3. Hepatorenal syndrome—Hepatorenal syndrome occurs in up to 10% of patients with advanced cirrhosis and ascites and is characterized by azotemia (serum creatinine > 1.5 mg/dL [124.95 $\mu\text{mol/L}$]) in the absence of parenchymal kidney disease or shock and by failure of kidney function to improve following 2 days of diuretic withdrawal and volume expansion with albumin, 1 g/kg up to a maximum of 100 g/d. Oliguria, hyponatremia, and a low urinary sodium concentration are typical features. Hepatorenal syndrome is diagnosed only when other causes of acute kidney injury (including prerenal azotemia and acute tubular necrosis) have been excluded. Type I hepatorenal syndrome is characterized by doubling of the serum creatinine to a level > 2.5 mg/dL (208.25 $\mu\text{mol/L}$) or by halving of the creatinine clearance to < 20 mL/min (0.34 mL/s/1.73 m^2 BSA) in < 2 weeks. Type II hepatorenal syndrome is more slowly progressive and chronic. The pathogenesis involves intense renal vasoconstriction, possibly because of impaired synthesis of renal vasodilators such as prostaglandin E_2 and decreased total renal blood flow; histologically, the kidneys are normal. An acute decrease in cardiac output is often the precipitating event. In addition to discontinuation of diuretics, clinical improvement and an increase in short-term survival may follow intravenous infusion of albumin in combination with one of the following vasoconstrictor regimens for 7–14 days: oral midodrine, an α -adrenergic drug, plus the somatostatin analog octreotide, subcutaneously or intravenously; intravenous terlipressin (a long-acting vasopressin analog that is not available in the United States but that may be the preferred agent); or intravenous norepinephrine. Prolongation of survival has been associated with use of MARS, a modified dialysis method that selectively removes albumin-bound substances. Improvement and sometimes normalization of kidney function may also follow placement of a TIPS; survival after 1 year is reported to be predicted by the combination of a serum bilirubin level < 3 mg/dL (50 $\mu\text{mol/L}$) and a platelet count $> 75,000/\text{mL}$. Continuous venovenous hemofiltration and hemodialysis are of uncertain value in hepatorenal syndrome. Liver transplantation is the treatment of choice, but many patients die before a donor liver can be obtained. Mortality correlates with the MELD score and presence of a systemic inflammatory response. The 3-month probability of survival in patients with hepatorenal syndrome (15%) is lower than that for renal failure associated with infections (31%),

hypovolemia (46%), and parenchymal kidney disease (73%) in patients with cirrhosis.

4. Hepatic encephalopathy—Hepatic encephalopathy is a state of disordered central nervous system function resulting from failure of the liver to detoxify noxious agents of gut origin because of hepatocellular dysfunction and portosystemic shunting. A mutation in the promoter region of the kidney-type glutaminase gene has been reported to increase the risk of overt encephalopathy from about 19% to 40% in patients with cirrhosis. The clinical spectrum ranges from day-night reversal and mild intellectual impairment to coma. Patients with covert (formerly minimal) hepatic encephalopathy have no recognizable clinical symptoms but demonstrate mild cognitive and psychomotor deficits and attention deficit on standardized psychometric tests and an increased rate of traffic accidents. The stages of overt encephalopathy are: (1) mild confusion, (2) drowsiness, (3) stupor, and (4) coma. A revised staging system known as SONIC (spectrum of neurocognitive impairment in cirrhosis) encompasses absent, covert, and stages 2 to 4 encephalopathy. Ammonia is the most readily identified and measurable toxin but is not solely responsible for the disturbed mental status. Central to the pathogenesis is low-grade cerebral edema and astrocyte swelling accompanied by reduced cerebral oxygen consumption and increased production of reactive oxygen and nitrogen oxide species that trigger RNA and protein modifications and neutrophil dysfunction and thereby affect brain function. Factors that contribute to cerebral edema are ammonia, hyponatremia, benzodiazepines, and cytokines. Bleeding into the intestinal tract may significantly increase the amount of protein in the bowel and precipitate encephalopathy. Other precipitants include constipation, alkalosis, and potassium deficiency induced by diuretics, opioids, hypnotics, and sedatives; medications containing ammonium or amino compounds; paracentesis with consequent hypovolemia; hepatic or systemic infection; and portosystemic shunts (including TIPS). The diagnosis is based primarily on detection of characteristic symptoms and signs, including asterixis. The role of neuroimaging studies (eg, cerebral PET, magnetic resonance spectroscopy) in the diagnosis of hepatic encephalopathy is evolving.

Dietary protein is withheld during acute episodes if the patient cannot eat. When the patient resumes oral intake, protein intake should be 60–80 g/d as tolerated; vegetable protein is better tolerated than meat protein. Gastrointestinal bleeding should be controlled and blood purged from the gastrointestinal tract. This can be accomplished with 120 mL of magnesium citrate by mouth or nasogastric tube every 3–4 hours until the stool is free of gross blood, or by administration of lactulose. The value of treating patients with covert (formerly minimal) hepatic encephalopathy is uncertain; probiotic agents may have some benefit.

Lactulose, a nonabsorbable synthetic disaccharide syrup, is digested by bacteria in the colon to short-chain fatty acids, resulting in acidification of colon contents. This acidification favors the formation of ammonium ion in the $\text{NH}_4^+ \leftrightarrow \text{NH}_3 + \text{H}^+$ equation; NH_4^+ is not absorbable, whereas NH_3 is absorbable and thought to be neurotoxic.

Lactulose also leads to a change in bowel flora so that fewer ammonia-forming organisms are present. When given orally, the initial dose of lactulose for acute hepatic encephalopathy is 30 mL three or four times daily. The dose should then be titrated so that two or three soft stools per day are produced. When rectal use is indicated because of the patient's inability to take medicines orally, the dose is 300 mL of lactulose in 700 mL of saline or sorbitol as a retention enema for 30–60 minutes; it may be repeated every 4–6 hours. Continued use of lactulose after an episode of acute encephalopathy reduces the frequency of recurrences. Lactilol is a less sweet disaccharide alternative available as a powder in some countries.

The ammonia-producing intestinal flora may also be controlled with an oral antibiotic. The nonabsorbable agent rifaximin, 550 mg orally twice daily, is preferred and has been shown as well to maintain remission from and reduce the risk of rehospitalization for hepatic encephalopathy over a 6-month period in patients also taking lactulose. Metronidazole, 250 mg orally three times daily, has also shown benefit. In the past, neomycin sulfate, 0.5–1 g orally every 6 or 12 hours for 7 days, was used, but side effects (including diarrhea, malabsorption, superinfection, ototoxicity, and nephrotoxicity) were frequent, especially after prolonged use. Patients who do not respond to lactulose alone may improve with a course of an antibiotic added to treatment with lactulose.

Opioids and sedatives metabolized or excreted by the liver should be avoided. If agitation is marked, oxazepam, 10–30 mg, which is not metabolized by the liver, may be given cautiously by mouth or by nasogastric tube. Zinc deficiency should be corrected, if present, with oral zinc sulfate, 600 mg/d in divided doses. Sodium benzoate, 5 g orally twice daily, ornithine aspartate, 9 g orally three times daily, and L-acyl-carnitine (an essential factor in the mitochondrial transport of long-chain fatty acids), 4 g orally daily, may lower blood ammonia levels, but there is less experience with these drugs than with lactulose. The benzodiazepine competitive antagonist flumazenil is effective in about 30% of patients with severe hepatic encephalopathy, but the drug is short-acting and intravenous administration is required. Use of special dietary supplements enriched with branched-chain amino acids is usually unnecessary except in occasional patients who are intolerant of standard protein supplements. Treatment with acarbose (an α -glucosidase inhibitor) is under study; other therapies being evaluated include prebiotic and probiotic agents to modulate gut flora, anti-inflammatory agents to reduce neuroinflammation, and extracorporeal albumin dialysis (MARS).

5. Coagulopathy—Hypoprothrombinemia caused by malnutrition and vitamin K deficiency may be treated with vitamin K (eg, phytonadione, 5 mg orally or intravenously daily); however, this treatment is ineffective when synthesis of coagulation factors is impaired because of hepatic disease. In such cases, correcting the prolonged prothrombin time requires large volumes of fresh frozen plasma (see Chapter 13). Because the effect is transient, plasma infusions are not indicated except for active bleeding or before an invasive procedure, and even then, the value of such

treatment has been questioned because of concomitant alterations in anti-hemostatic factors and because bleeding risk does not correlate with the INR. Use of recombinant activated factor VIIa may be an alternative, but it is expensive and poses a 1–2% risk of thrombotic complications. Eltrombopag has shown promise in patients with cirrhosis and severe thrombocytopenia.

6. Hemorrhage from esophageal varices—See Chapter 15.

7. Hepatopulmonary syndrome and portopulmonary hypertension—Shortness of breath in patients with cirrhosis may result from pulmonary restriction and atelectasis caused by massive ascites. The hepatopulmonary syndrome—the triad of chronic liver disease, an increased alveolar-arterial gradient while the patient is breathing room air, and intrapulmonary vascular dilatations or arteriovenous communications that result in a right-to-left intrapulmonary shunt—occurs in 5–32% of patients with cirrhosis. The syndrome is presumed to result from enhanced pulmonary production of nitric oxide and polymorphisms in genes involved in the regulation of angiogenesis but does not correlate with the degrees of hepatic dysfunction and portal hypertension. Patients often have greater dyspnea (platypnea) and arterial deoxygenation (orthodeoxia) in the upright than in the recumbent position. The diagnosis should be suspected in a cirrhotic patient with a pulse oximetry level $\leq 96\%$.

Contrast-enhanced echocardiography is a sensitive screening test for detecting pulmonary vascular dilatations, whereas macroaggregated albumin lung perfusion scanning is more specific and may be used to confirm the diagnosis. High-resolution CT may be useful for detecting dilated pulmonary vessels that may be amenable to embolization in patients with severe hypoxemia ($PO_2 < 60$ mm Hg [7.8 kPa]) who respond poorly to supplemental oxygen.

Medical therapy has been disappointing; experimentally, intravenous methylene blue, oral garlic powder, and oral norfloxacin may improve oxygenation by inhibiting nitric oxide-induced vasodilatation, and pentoxifylline may prevent hepatopulmonary syndrome by inhibiting production of tumor necrosis factor. Long-term oxygen therapy is recommended for severely hypoxemic patients. The syndrome may reverse with liver transplantation, although postoperative mortality is increased in patients with a preoperative arterial $PO_2 < 50$ mm Hg (6.5 kPa) or with substantial intrapulmonary shunting. TIPS may provide palliation in patients with hepatopulmonary syndrome awaiting transplantation.

Portopulmonary hypertension occurs in 0.7% of patients with cirrhosis and is thought to result from an excess of circulating vasoconstrictors, particularly endothelin-1. Female sex and autoimmune hepatitis have been reported to be risk factors, and large spontaneous portosystemic shunts are present in many affected patients and are associated with a lack of response to treatment. In cases confirmed by right-sided heart catheterization, treatment with the prostaglandin epoprostenol, the endothelin-receptor antagonists bosentan or ambrisentan, or the phosphodiesterase-5 inhibitors sildenafil or tadalafil may reduce

pulmonary hypertension and thereby facilitate liver transplantation; β -blockers worsen exercise capacity and are contraindicated, and calcium channel blockers should be used with caution because they may worsen portal hypertension. Liver transplantation is contraindicated in patients with moderate to severe pulmonary hypertension (mean pulmonary pressure > 35 mm Hg).

C. Liver Transplantation

Liver transplantation is indicated in selected cases of irreversible, progressive chronic liver disease, acute liver failure, and certain metabolic diseases in which the metabolic defect is in the liver. Absolute contraindications include malignancy (except relatively small hepatocellular carcinomas in a cirrhotic liver), advanced cardiopulmonary disease (except hepatopulmonary syndrome), and sepsis. Relative contraindications include age over 70 years, morbid obesity, portal and mesenteric vein thrombosis, active alcohol or drug abuse, severe malnutrition, and lack of patient understanding. With the emergence of effective antiretroviral therapy for HIV disease, a major cause of mortality in these patients has shifted to liver disease caused by HCV and HBV infection; experience to date suggests that the outcome of liver transplantation is comparable to that for non-HIV-infected liver transplant recipients. Patients with alcoholism should be abstinent for 6 months. Liver transplantation should be considered in patients with worsening functional status, rising bilirubin, decreasing albumin, worsening coagulopathy, refractory ascites, recurrent variceal bleeding, or worsening encephalopathy; prioritization is based on the MELD score. Combined liver-kidney transplantation is indicated in patients with associated kidney failure presumed to be irreversible. The major impediment to more widespread use of liver transplantation is a shortage of donor organs. Adult living donor liver transplantation is an option for some patients, and extended-criteria donors are being used. Five-year survival rates as high as 80% are now reported. Hepatocellular carcinoma, hepatitis B and C, and some cases of Budd-Chiari syndrome and autoimmune liver disease may recur in the transplanted liver. The incidence of recurrence of hepatitis B can be reduced by preoperative and postoperative treatment with a nucleoside or nucleotide analog and perioperative administration of HBIG. Immunosuppression is achieved with combinations of cyclosporine, tacrolimus or sirolimus, corticosteroids, azathioprine, and mycophenolate mofetil and may be complicated by infections, advanced chronic kidney disease, neurologic disorders, and drug toxicity as well as graft rejection, vascular occlusion, or bile leaks. Patients taking these drugs are at risk for obesity, diabetes mellitus, and hyperlipidemia.

► Prognosis

Factors determining survival include the patient's ability to stop the intake of alcohol as well as the Child-Turcotte-Pugh score (Table 16–6). The MELD score, which incorporates the serum bilirubin and creatinine levels and the INR, is also a measure of mortality risk in patients with end-stage liver

Table 16-6. Child-Turcotte-Pugh and Model for End-Stage Liver Disease (MELD) scoring systems for staging cirrhosis.

Child-Turcotte-Pugh scoring system			
Parameter	Numerical Score		
	1	2	3
Ascites	None	Slight	Moderate to severe
Encephalopathy	None	Slight to moderate	Moderate to severe
Bilirubin (mg/dL) (mcmol/L)	< 2.0 (34.2)	2-3 (34.2-51.3)	> 3.0 (51.3)
Albumin (g/dL)(g/L)	> 3.5 (35)	2.8-3.5 (28-35)	< 2.8 (28)
Prothrombin time (seconds increased)	1-3	4-6	> 6.0
Total Numerical Score and Corresponding Child Class			
		Score	Class
		5-6	A
		7-9	B
		10-15	C
MELD scoring system			
MELD = 11.2 log _e (INR) + 3.78 log _e (bilirubin [mg/dL]) + 9.57 log _e (creatinine [mg/dL]) + 6.43. (Range 6-40).			

INR, international normalized ratio.

disease and is particularly useful for predicting short- and intermediate-term survival and complications of cirrhosis (eg, bacterial peritonitis) as well as determining allocation priorities for donor livers. The consistency of the MELD score among different hospitals may be improved when the INR is calibrated based on prothrombin time control samples that include patients with liver disease rather than those taking oral anticoagulants. A MELD score of > 14 is required for liver transplant listing. In patients with a relatively low MELD score (< 21) and a low priority for liver transplantation, a low serum sodium concentration (< 130 mEq/L [130 mmol/L]), an elevated hepatic venous pressure gradient, persistent ascites, and a low health-related quality of life appear to be additional independent predictors of mortality, and modifications of the MELD score, including one that incorporates the serum sodium (MELDNa), are under consideration. Only 50% of patients with severe hepatic dysfunction (serum albumin < 3 g/dL [30 g/L]), bilirubin > 3 mg/dL [51.3 mcmol/L]), ascites, encephalopathy, cachexia, and upper gastrointestinal bleeding) survive 6 months. The risk of death in this subgroup of patients with advanced cirrhosis is associated with chronic kidney disease, cognitive dysfunction, ventilatory insufficiency, age ≥ 65 years, and prothrombin time ≥ 16 seconds. Obesity and diabetes

mellitus appear to be risk factors for clinical deterioration and cirrhosis-related mortality, and the use of β-blockers is associated with poor survival in patients with refractory ascites. Patients with cirrhosis are at risk for the development of hepatocellular carcinoma, with rates of 3–5% per year for alcoholic and viral hepatitis-related cirrhosis. Liver transplantation has markedly improved the outlook for patients with cirrhosis who are candidates and are referred for evaluation early. Patients with compensated cirrhosis are given additional priority for liver transplantation if they are found to have a lesion > 2 cm in diameter consistent with hepatocellular carcinoma. In-hospital mortality from variceal bleeding in patients with cirrhosis has declined from over 40% in 1980 to 15% in 2000. Medical treatments to reverse hepatic fibrosis are under investigation.

▶ When to Refer

- For liver biopsy.
- Before the MELD score is ≥ 14.
- For upper endoscopy to screen for gastroesophageal varices.

▶ When to Admit

- Gastrointestinal bleeding.
- Stage 3–4 hepatic encephalopathy.
- Worsening kidney function.
- Severe hyponatremia.
- Profound hypoxia.

Martin-Llahí M et al. Prognostic importance of the cause of renal failure in patients with cirrhosis. *Gastroenterology*. 2011 Feb;140(2):488–496.e4. [PMID: 20682324]
 Mukhtar NA et al. Portopulmonary hypertension. *J Clin Gastroenterol*. 2011 Sep;45(8):703–10. [PMID: 21325952]
 Tripodi A et al. The coagulopathy of chronic liver disease. *N Engl J Med*. 2011 Jul 14;365(2):147–56. [PMID: 21751907]
 Wiest R et al. Spontaneous bacterial peritonitis: recent guidelines and beyond. *Gut*. 2012 Feb;61(2):297–310. [PMID: 22147550]
 Younossi ZM et al. Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008. *Clin Gastroenterol Hepatol*. 2011 Jun;9(6):524–30. [PMID: 21440669]

PRIMARY BILIARY CIRRHOSIS

ESSENTIALS OF DIAGNOSIS

- ▶ Occurs in middle-aged women.
- ▶ Often asymptomatic.
- ▶ Elevation of alkaline phosphatase, positive anti-mitochondrial antibodies, elevated IgM, increased cholesterol.
- ▶ Characteristic liver biopsy.
- ▶ In later stages, can present with fatigue, jaundice, features of cirrhosis, xanthelasma, xanthoma, steatorrhea.

► General Considerations

Primary biliary cirrhosis is a chronic disease of the liver characterized by autoimmune destruction of small intrahepatic bile ducts and cholestasis. It is insidious in onset, occurs usually in women aged 40–60 years, and is often detected by the chance finding of elevated alkaline phosphatase levels. Estimated incidence and prevalence rates in the United States are 4.5 and 65.4 per 100,000, respectively, in women, and 0.7 and 12.1 per 100,000, respectively, in men. The frequency of the disease among first-degree relatives of affected persons is 1.3–6%, and the concordance rate in identical twins is high. Primary biliary cirrhosis is associated with HLA *DRB1*08* and *DQB1*, as well as the *IL12A* and *IL12RB2* genes, which encode interleukin-12 α and interleukin 12 receptor β 2, respectively, and *IRF5-TNPO3*, which encodes interferon regulatory factor 5-transportin 3. The disease may be associated with Sjögren syndrome, autoimmune thyroid disease, Raynaud syndrome, scleroderma, hypothyroidism, and celiac disease. Infection with *Novosphingobium aromaticivorans* or *Chlamydomphila pneumoniae* may be triggering or causative in primary biliary cirrhosis; other triggers, including viruses (such as human betaretrovirus), lactobacillus vaccination to prevent recurrent vaginitis, and xenobiotics, are also suspected. X-chromosome monosomy may be a predisposing factor. A history of urinary tract infections (caused by *E coli* or *Lactobacillus delbrueckii*) and smoking, and possibly use of hormone replacement therapy and hair dye, are risk factors, and clustering of cases in time and space argues for a causative role of environmental agents.

► Clinical Findings

A. Symptoms and Signs

Many patients are asymptomatic for years. The onset of clinical illness is insidious and is heralded by fatigue (excessive daytime somnolence) and pruritus. With progression, physical examination reveals hepatosplenomegaly. Xanthomatous lesions may occur in the skin and tendons and around the eyelids. Jaundice, steatorrhea, and signs of portal hypertension are late findings. Autonomic dysfunction, including orthostatic hypotension, and cognitive dysfunction appear to be common. The risk of low bone density, osteoporosis, and fractures is increased in patients with primary biliary cirrhosis (who tend to be older women) possibly due in part to polymorphisms of the vitamin D receptor.

B. Laboratory Findings

Blood counts are normal early in the disease. Liver biochemical tests reflect cholestasis with elevation of alkaline phosphatase, cholesterol (especially high-density lipoproteins), and, in later stages, bilirubin. Antimitochondrial antibodies (directed against the dihydrolipoamide acetyltransferase component of pyruvate dehydrogenase or other 2-oxo-acid enzymes in mitochondria) are present in 95% of patients, and serum IgM levels are elevated. ANA directed against the nuclear pore complex (eg, against

gp210 in the nuclear envelope) may be detected in specialized laboratories.

► Diagnosis

The diagnosis of primary biliary cirrhosis is based on the detection of cholestatic liver chemistries (often initially an isolated elevation of the alkaline phosphatase) and antimitochondrial antibodies in serum. Liver biopsy is not essential for diagnosis but permits histologic staging: I, portal inflammation with granulomas; II, bile duct proliferation, periportal inflammation; III, interlobular fibrous septa; and IV, cirrhosis. Estimation of histologic stage by an “enhanced liver fibrosis assay” that incorporates serum levels of hyaluronic acid, tissue inhibitor of metalloproteinase-1, and procollagen III aminopeptide has shown promise.

► Differential Diagnosis

The disease must be differentiated from chronic biliary tract obstruction (stone or stricture), carcinoma of the bile ducts, primary sclerosing cholangitis, sarcoidosis, cholestatic drug toxicity (eg, chlorpromazine), and in some cases chronic hepatitis. Patients with a clinical and histologic picture of primary biliary cirrhosis but no antimitochondrial antibodies are said to have antimitochondrial antibody-negative primary biliary cirrhosis (“autoimmune cholangitis”), which has been associated with lower serum IgM levels and a greater frequency of smooth muscle antibodies and ANA. Many such patients are found to have antimitochondrial antibodies by immunoblot against recombinant proteins (rather than standard immunofluorescence). Some patients have overlapping features of primary biliary cirrhosis and autoimmune hepatitis.

► Treatment

Cholestyramine (4 g) in water or juice three times daily may be beneficial for pruritus; colestipol and colesevalam may be better tolerated but have thus far not been shown to reduce pruritus. Rifampin, 150–300 mg orally twice daily, is inconsistently beneficial. Opioid antagonists (eg, naloxone, 0.2 mcg/kg/min by intravenous infusion, or naltrexone, starting at 12.5 mg/d by mouth) show promise in the treatment of pruritus but may cause opioid withdrawal symptoms. The 5-hydroxytryptamine (5-HT₃) serotonin receptor antagonist ondansetron, 4 mg orally three times a day as needed, and the selective serotonin uptake inhibitor sertraline, 75–100 mg/d orally, may also provide some benefit. For refractory pruritus, plasmapheresis or extracorporeal albumin dialysis may be needed. Modafinil, 100–200 mg/d orally, may improve daytime somnolence but is poorly tolerated. Deficiencies of vitamins A, D, and K may occur if steatorrhea is present and are aggravated when cholestyramine or colestipol is administered. See Chapter 26 for discussion of prevention and treatment of osteoporosis and Chapter 20 for discussion of the treatment of Sjögren syndrome.

Because of its lack of toxicity, ursodeoxycholic acid (13–15 mg/kg/d in one or two doses) is the preferred

medical treatment (and only treatment approved by the US FDA) for primary biliary cirrhosis and has been shown to slow the progression of disease (particularly in early-stage disease), stabilize histology, improve long-term survival, reduce the risk of developing esophageal varices, and delay (and possibly prevent) the need for liver transplantation, although the benefit of the drug has been questioned. Complete normalization of liver biochemical tests occurs in 20% of treated patients within 2 years and 40% within 5 years, and survival is similar to that of healthy controls when the drug is given to patients with stage 1 or 2 primary biliary cirrhosis. Ursodeoxycholic acid therapy has also been reported to reduce the risk of recurrent colorectal adenomas in patients with primary biliary cirrhosis. Side effects include weight gain and rarely loose stools. Colchicine (0.6 mg orally twice daily) and methotrexate (15 mg/wk orally) have had some reported benefit in improving symptoms and serum levels of alkaline phosphatase and bilirubin. Methotrexate may also improve liver histology in some patients, but overall response rates have been disappointing. Penicillamine, prednisone, and azathioprine have proved to be of no benefit. Budesonide may improve liver histology but worsens bone density. Mycophenolate mofetil, rituximab, fenofibrate, and obeticholic acid (a farnesoid-X receptor agonist) are under study. For patients with advanced disease, liver transplantation is the treatment of choice.

► Prognosis

Without liver transplantation, survival averages 7–10 years once symptoms develop but has improved for younger women since the introduction of ursodeoxycholic acid. Progression to liver failure and portal hypertension is associated with the presence of anti-gp210 and anticentromere antibodies, respectively, and may be accelerated by smoking. Patients with early-stage disease in whom the alkaline phosphatase and AST are less than 1.5 times normal and bilirubin is ≤ 1 mg/dL (17.1 μ mol/L) after 1 year of therapy with ursodeoxycholic acid are at low long-term risk for cirrhosis and have a life expectancy similar to that of the healthy population. In advanced disease, an adverse prognosis is indicated by a high Mayo risk score that includes older age, high serum bilirubin, edema, low serum albumin, and prolonged prothrombin time as well as by variceal hemorrhage. Fatigue is associated with an increased risk of cardiac mortality. Among asymptomatic patients, at least one-third will become symptomatic within 15 years. The risk of hepatobiliary malignancies appears to be increased in patients with primary biliary cirrhosis; risk factors include older age, male sex, prior blood transfusions, advanced histologic stage, and signs of cirrhosis or portal hypertension. Liver transplantation for advanced primary biliary cirrhosis is associated with a 1-year survival rate of 85–90%. The disease recurs in the graft in 20% of patients by 3 years, but this does not seem to affect survival.

► When to Refer

- For liver biopsy.
- For liver transplant evaluation.

► When to Admit

- Gastrointestinal bleeding.
- Stage 3–4 hepatic encephalopathy.
- Worsening kidney function.
- Severe hyponatremia.
- Profound hypoxia.

Corpechot C et al. Early primary biliary cirrhosis: biochemical response to treatment and prediction of long-term outcome. *J Hepatol.* 2011 Dec;55(6):1361–7. [PMID: 21703194]
 Corpechot C et al. Smoking as an independent risk factor of liver fibrosis in primary biliary cirrhosis. *J Hepatol.* 2012 Jan;56(1):218–24. [PMID: 21703179]
 Leung J et al. Colchicine or methotrexate, with ursodiol, are effective after 20 years in a subset of patients with primary biliary cirrhosis. *Clin Gastroenterol Hepatol.* 2011 Sep;9(9):776–80. [PMID: 21699802]
 Poupon R. Treatment of primary biliary cirrhosis with ursodeoxycholic acid, budesonide and fibrates. *Dig Dis.* 2011;29(1):85–8. [PMID: 21691111]
 Selmi C et al. Primary biliary cirrhosis. *Lancet.* 2011 May 7;377(9777):1600–9. [PMID: 21529926]

HEMOCHROMATOSIS



ESSENTIALS OF DIAGNOSIS

- Usually suspected because of elevated iron saturation or serum ferritin or a family history.
- Most patients are asymptomatic; the disease is rarely recognized clinically before the fifth decade.
- Hepatic abnormalities and cirrhosis, heart failure, hypogonadism, and arthritis.
- *HFE* gene mutation (usually *C282Y/C282Y*) is found in most cases.

► General Considerations

Hemochromatosis is an autosomal recessive disease caused in many cases by a mutation in the *HFE* gene on chromosome 6. The *HFE* protein is thought to play an important role in the process by which duodenal crypt cells sense body iron stores, leading in turn to increased iron absorption from the duodenum. A decrease in the synthesis or expression of hepcidin, the principal iron regulatory hormone, is thought to be a key pathogenic factor in all forms of hemochromatosis. About 85% of persons with well-established hemochromatosis are homozygous for the *C282Y* mutation. The frequency of the gene mutation averages 7% in Northern European and North American white populations, resulting in a 0.5% frequency of homozygotes (of whom 38–50% will develop biochemical evidence of iron overload but only 28% of men and 1% of women will develop clinical symptoms). By contrast, the gene mutation and hemochromatosis are uncommon in blacks and Asian-American populations. A second genetic mutation (*H63D*) may contribute to the development of iron overload in a

small percentage (1.5%) of persons who are compound heterozygotes for *C282Y* and *H63D*; iron overload-related disease develops in few patients (particularly those who have a comorbidity such as diabetes mellitus and fatty liver). *H63D* homozygotes do not develop hemochromatosis but may be at increased risk for amyotrophic lateral sclerosis. Rare instances of hemochromatosis result from mutations in the genes that encode transferrin receptor 2 (*TFR2*) and ferroportin (*FPN1*). A juvenile-onset variant that is characterized by severe iron overload, cardiac dysfunction, hypogonadotropic hypogonadism, and a high mortality rate is usually linked to a mutation of a gene on chromosome 1q designated *HJV* that produces a protein called hemojuvelin or, rarely, to a mutation in the *HAMP* gene on chromosome 19 that encodes hepcidin but not to the *C282Y* mutation.

Hemochromatosis is characterized by increased accumulation of iron as hemosiderin in the liver, pancreas, heart, adrenals, testes, pituitary, and kidneys. Cirrhosis is more likely to develop in affected persons who drink alcohol excessively or have obesity-related hepatic steatosis than in those who do not. Eventually, hepatic and pancreatic insufficiency, heart failure, and hypogonadism may develop; overall mortality is increased slightly. Heterozygotes do not develop cirrhosis in the absence of associated disorders such as viral hepatitis or NAFLD.

► Clinical Findings

A. Symptoms and Signs

The onset of clinical disease is usually after age 50 years—earlier in men than in women; however, because of widespread liver biochemical testing and iron screening, the diagnosis is usually made long before symptoms develop. Early symptoms are nonspecific (eg, fatigue, arthralgia). Later clinical manifestations include arthropathy (and the need for joint replacement surgery), hepatomegaly and evidence of hepatic dysfunction (late finding), skin pigmentation (combination of slate-gray due to iron and brown due to melanin, sometimes resulting in a bronze color), cardiac enlargement with or without heart failure or conduction defects, diabetes mellitus with its complications, and erectile dysfunction in men. Interestingly, population studies have shown an increased prevalence of liver disease but not of diabetes mellitus, arthritis, or heart disease in *C282Y* homozygotes. In patients in whom cirrhosis develops, bleeding from esophageal varices may occur, and there is a 15–20% frequency of hepatocellular carcinoma. Affected patients are at increased risk of infection with *Vibrio vulnificus*, *Listeria monocytogenes*, *Yersinia enterocolitica*, and other siderophilic organisms. The risk of porphyria cutanea tarda is increased in persons with the *C282Y* or *H63D* mutation, and *C282Y* homozygotes have twice the risk of colorectal and breast cancer than persons without the *C282Y* variant.

B. Laboratory Findings

Laboratory findings include mildly abnormal liver tests (AST, alkaline phosphatase), an elevated plasma iron with > 45% transferrin saturation and an elevated serum ferritin (although a normal iron saturation or a normal ferritin does not exclude the diagnosis). Affected men are more

likely than affected women to have an elevated ferritin level. Testing for *HFE* mutations is indicated in any patient with evidence of iron overload.

C. Imaging

MRI and CT may show changes consistent with iron overload of the liver, and MRI can quantitate hepatic iron stores. There is also an emerging role for MRI for assessment of the degree of hepatic fibrosis.

D. Liver Biopsy

In patients who are homozygous for *C282Y*, liver biopsy is often indicated to determine whether cirrhosis is present. Biopsy can be deferred, however, in patients in whom the serum ferritin level is <1000 mcg/L, serum AST level is normal, and hepatomegaly is absent; the likelihood of cirrhosis is low in these persons. The combination of a serum ferritin level \geq 1000 mcg/L and a serum hyaluronic acid level \geq 46.5 mcg/L has been reported to identify all patients with cirrhosis, with a high specificity. Liver biopsy is also indicated when iron overload is suspected even though the patient is not homozygous for *C282Y* or a *C282Y/H63D* compound heterozygote. In patients with hemochromatosis, the liver biopsy characteristically shows extensive iron deposition in hepatocytes and in bile ducts, and the hepatic iron index—hepatic iron content per gram of liver converted to micromoles and divided by the patient's age—is generally > 1.9. Only 5% of patients with hereditary hemochromatosis identified by screening in a primary care setting have cirrhosis.

► Screening

Iron studies and *HFE* testing are recommended for all first-degree family members of a proband; children of an affected person (*C282Y* homozygote) need to be screened only if the patient's spouse carries the *C282Y* or *H63D* mutation. Average-risk population screening for hemochromatosis is not recommended because the clinical penetrance of *C282Y* homozygosity and morbidity and mortality from hemochromatosis are low. Patients with otherwise unexplained chronic liver disease, chondrocalcinosis, erectile dysfunction, and type 1 diabetes mellitus (especially late-onset) should be screened for iron overload.

► Treatment

Affected patients should avoid foods rich in iron (such as red meat), alcohol, vitamin C, raw shellfish, and supplemental iron. Weekly phlebotomies of 1 or 2 units (250–500 mL) of blood (each containing about 250 mg of iron) is indicated in all symptomatic patients, those with a serum ferritin level of at least 1000 mcg/L, and those with an increased fasting iron saturation and should be continued for up to 2–3 years to achieve depletion of iron stores. The hematocrit and serum iron values should be monitored. When iron store depletion is achieved (iron saturation < 50% and serum ferritin level 50–100 mcg/L), phlebotomies (every 2–4 months) to maintain serum ferritin levels between 50 mcg/L and 100 mcg/L are continued, although compliance has been reported to decrease with time; administration of a proton pump

inhibitor, which reduces intestinal iron absorption, appears to decrease the maintenance phlebotomy blood volume requirement. Complications of hemochromatosis—arthropathy, diabetes mellitus, heart disease, portal hypertension, and hypopituitarism—also require treatment.

The chelating agent deferoxamine is indicated for patients with hemochromatosis and anemia or in those with secondary iron overload due to thalassemia who cannot tolerate phlebotomies. The drug is administered intravenously or subcutaneously in a dose of 20–40 mg/kg/d infused over 24 hours and can mobilize 30 mg of iron per day; however, treatment is painful and time-consuming. An oral chelator, deferasirox, 20 mg/kg once daily, has been approved for treatment of iron overload due to blood transfusions, and a dose of 10 mg/kg daily may be appropriate in persons with hemochromatosis who cannot tolerate phlebotomy; however, this agent has many side effects and drug-drug interactions.

The course of hemochromatosis is favorably altered by phlebotomy therapy. Hepatic fibrosis may regress, and in precirrhotic patients, cirrhosis may be prevented. Cardiac conduction defects and insulin requirements improve with treatment. In patients with cirrhosis, varices may reverse, and the risk of variceal bleeding declines, although the risk of hepatocellular carcinoma persists. In the past, liver transplantation for advanced cirrhosis associated with severe iron overload, including hemochromatosis, was reported to lead to survival rates that were lower than those for other types of liver disease because of cardiac complications and an increased risk of infections, but since 1997, posttransplant survival rates have been excellent.

► When to Refer

- For liver biopsy.
- For initiation of therapy.

Bacon BR et al. Diagnosis and management of hemochromatosis: 2011 practice guideline by the American Association for the Study of Liver Diseases. *Hepatology*. 2011 Jul; 54(1):328–43. [PMID: 21452290]

Gan EK et al. Natural history and management of HFE-hemochromatosis. *Semin Liver Dis*. 2011 Aug;31(3):293–301. [PMID: 21901659]

van Bokhoven MA et al. Diagnosis and management of hereditary haemochromatosis. *BMJ*. 2011 Jan 19;342:c7251. [PMID: 21248018]

WILSON DISEASE



ESSENTIALS OF DIAGNOSIS

- Rare autosomal recessive disorder that usually occurs in persons under age 40.
- Excessive deposition of copper in the liver and brain.
- Serum ceruloplasmin, the plasma copper-carrying protein, is low.
- Urinary excretion of copper and hepatic copper concentration are high.

► General Considerations


Wilson disease (hepatolenticular degeneration) is a rare autosomal recessive disorder that usually occurs in persons under age 40. The worldwide prevalence is about 30 per million population. The condition is characterized by excessive deposition of copper in the liver and brain. The genetic defect, localized to chromosome 13, has been shown to affect a copper-transporting adenosine triphosphatase (*ATP7B*) in the liver and leads to copper accumulation in the liver and oxidative damage of hepatic mitochondria. Most patients are compound heterozygotes (ie, carry two different mutations). Over 500 mutations in the Wilson disease gene have been identified. The *H1069Q* mutation accounts for 37–63% of disease alleles in populations of Northern European descent.

The major physiologic aberration in Wilson disease is excessive absorption of copper from the small intestine and decreased excretion of copper by the liver, resulting in increased tissue deposition, especially in the liver, brain, cornea, and kidney.

► Clinical Findings

Wilson disease tends to present as liver disease in adolescents and neuropsychiatric disease in young adults, but there is great variability, and onset of symptoms after age 40 is more common than previously thought. The diagnosis should always be considered in any child or young adult with hepatitis, splenomegaly with hypersplenism, Coombs-negative hemolytic anemia, portal hypertension, and neurologic or psychiatric abnormalities. Wilson disease should also be considered in persons under 40 years of age with chronic or fulminant hepatitis.

Hepatic involvement may range from elevated liver biochemical tests (although the alkaline phosphatase may be low) to cirrhosis and portal hypertension. In a patient with acute liver failure, the diagnosis of Wilson disease is suggested by an alkaline phosphatase (in units/L)-to-total bilirubin (in mg/dL) ratio < 4 and an AST-to-ALT ratio > 2.2. The neurologic manifestations of Wilson disease are related to basal ganglia dysfunction and include an akinetic-rigid syndrome similar to parkinsonism, pseudosclerosis with tremor, ataxia, and a dystonic syndrome. Dysarthria, dysphagia, incoordination, and spasticity are common. Migraines, insomnia, and seizures have been reported. Psychiatric features include behavioral and personality changes and emotional lability and may precede characteristic neurologic features. The pathognomonic sign of the condition is the brownish or gray-green Kayser-Fleischer ring, which represents fine pigmented granular deposits in Descemet membrane in the cornea (Figure 16–4). The ring is usually most marked at the superior and inferior poles of the cornea. It is sometimes seen with the naked eye and is readily detected by slit-lamp examination. It may be absent in patients with hepatic manifestations only but is usually present in those with neuropsychiatric disease. Renal calculi, aminoaciduria, renal tubular acidosis, hypoparathyroidism, infertility, and hemolytic anemia may occur in patients with Wilson disease.



▲ **Figure 16-4.** Brownish Kayser-Fleischer ring at the rim of the cornea in a patient with Wilson disease. (Courtesy of Marc Solioz, University of Berne; used, with permission, from Usatine RP, Smith MA, Mayeaux EJ Jr, Chumley H, Tysinger J. *The Color Atlas of Family Medicine*. McGraw-Hill, 2009.)

▶ Diagnosis

The diagnosis can be challenging and is generally based on demonstration of increased urinary copper excretion (> 40 mcg/24 h and usually > 100 mcg/24 h) or low serum ceruloplasmin levels (< 20 mg/dL [200 mg/L]; < 5 mg/dL [50 mg/L] is diagnostic), and elevated hepatic copper concentration (> 250 mcg/g of dry liver). However, increased urinary copper and a low serum ceruloplasmin level (by a standard immunologic assay) are neither completely sensitive nor specific for Wilson disease, but an enzymatic assay for ceruloplasmin appears to be more accurate. In equivocal cases (when the serum ceruloplasmin level is normal), the diagnosis may require demonstration of a rise in urinary copper after a penicillamine challenge, although the test has been validated only in children. Liver biopsy may show acute or chronic hepatitis or cirrhosis. MRI of the brain may show evidence of increased basal ganglia, brainstem, and cerebellar copper even early in the course of the disease. If available, molecular analysis of *ATP7B* mutations can be diagnostic.

▶ Treatment

Early treatment to remove excess copper is essential before it can produce hepatic or neurologic damage. Early in the treatment phase, restriction of dietary copper (shellfish, organ foods, nuts, mushrooms, and chocolate) may be of value. Oral penicillamine (0.75–2 g/d in divided doses taken 1 h before or 2 h after food) is the drug of choice and enhances urinary excretion of chelated copper. Oral pyridoxine, 50 mg per week, is added, since penicillamine is an antimetabolite of this vitamin. If penicillamine treatment cannot be tolerated because of gastrointestinal intolerance, hypersensitivity, autoimmune reactions, nephrotoxicity, or bone marrow toxicity, consider the use of another chelating agent—trientine, 250–500 mg three times a day. Oral zinc acetate or zinc gluconate, 50 mg three times a day, interferes with intestinal absorption of copper, promotes fecal copper excretion, and has been used as first-line therapy in pre-symptomatic or pregnant patients and those with neurologic

disease and as maintenance therapy after decoppering with a chelating agent, but adverse gastrointestinal effects often lead to discontinuation and its long-term efficacy and safety (including a risk of hepatotoxicity) have been questioned. Ammonium tetrathiomolybdate, which complexes copper in the intestinal tract, has shown promise as initial therapy for neurologic Wilson disease.

Treatment should continue indefinitely. The doses of penicillamine and trientine should be reduced during pregnancy. Supplemental vitamin E, an antioxidant, has been recommended but not rigorously studied. Once the serum nonceruloplasmin copper level is within the normal range (50–150 mcg/L), the dose of chelating agent can be reduced to the minimum necessary for maintaining that level. The prognosis is good in patients who are effectively treated before liver or brain damage has occurred. Liver transplantation is indicated for fulminant hepatitis (often after plasma exchange or dialysis with MARS as a stabilizing measure), end-stage cirrhosis, and, in selected cases, intractable neurologic disease, although survival is lower when liver transplantation is undertaken for neurologic disease than for liver disease. Family members, especially siblings, require screening with serum ceruloplasmin, liver biochemical tests, and slit-lamp examination or, if the causative mutation is known, with mutation analysis.

▶ When to Refer

All patients with Wilson disease should be referred for diagnosis and treatment.

▶ When to Admit

- Acute liver failure.
- Gastrointestinal bleeding.
- Stage 3–4 hepatic encephalopathy.
- Worsening kidney function.
- Severe hyponatremia.
- Profound hypoxia.

Rosencrantz R et al. Wilson disease: pathogenesis and clinical considerations in diagnosis and treatment. *Semin Liver Dis*. 2011 Aug;31(3):245–59. [PMID: 21901655]

Weiss KH et al. Zinc monotherapy is not as effective as chelating agents in treatment of Wilson disease. *Gastroenterology*. 2011 Apr;140(4):1189–98. [PMID: 21185835]

HEPATIC VEIN OBSTRUCTION (Budd-Chiari Syndrome)



ESSENTIALS OF DIAGNOSIS

- ▶ Right upper quadrant pain and tenderness.
- ▶ Ascites.
- ▶ Imaging studies show occlusion/absence of flow in the hepatic vein(s) or inferior vena cava.
- ▶ Clinical picture is similar in sinusoidal obstruction syndrome but major hepatic veins are patent.

► General Considerations

Factors that predispose patients to hepatic vein obstruction, or Budd-Chiari syndrome, including hereditary and acquired hypercoagulable states, can be identified in 75% of affected patients; multiple disorders are found in up to 45%. Up to 50% of cases are associated with polycythemia vera or other myeloproliferative disease (which has a risk of Budd-Chiari syndrome of 1%). These cases (37% of patients with Budd-Chiari syndrome) are often associated with a specific mutation (*V617F*) in the gene that codes for JAK2 tyrosine kinase and may be subclinical. In some cases, other predispositions to thrombosis (eg, activated protein C resistance [factor V Leiden mutation] [25% of cases], protein C or S or antithrombin deficiency, hyperprothrombinemia [factor II G20210A mutation], the methylenetetrahydrofolate reductase *TT677* mutation, antiphospholipid antibodies) can be identified. Hepatic vein obstruction may be associated with caval webs, right-sided heart failure or constrictive pericarditis, neoplasms that cause hepatic vein occlusion, paroxysmal nocturnal hemoglobinuria, Behçet syndrome, blunt abdominal trauma, use of oral contraceptives, and pregnancy. Some cytotoxic agents and pyrrolizidine alkaloids (Comfrey or “bush teas”) may cause sinusoidal obstruction syndrome (previously known as veno-occlusive disease because the terminal venules are often occluded), which mimics Budd-Chiari syndrome clinically. Sinusoidal obstruction syndrome is common in patients who have undergone bone marrow transplantation, particularly those with pretransplant serum aminotransferase elevations or fever during cytoreductive therapy with cyclophosphamide, azathioprine, carmustine, busulfan, or etoposide or those receiving high-dose cytoreductive therapy or high-dose total body irradiation. In India, China, and South Africa, Budd-Chiari syndrome is associated with a poor standard of living and often the result of occlusion of the hepatic portion of the inferior vena cava, presumably due to prior thrombosis. The clinical presentation is mild but the course is frequently complicated by hepatocellular carcinoma.

► Clinical Findings

A. Symptoms and Signs

The presentation may be fulminant, acute, subacute, or chronic. An insidious (subacute) onset is most common. Clinical manifestations generally include tender, painful hepatic enlargement, jaundice, splenomegaly, and ascites. With chronic disease, bleeding varices and hepatic coma may be evident; hepatopulmonary syndrome may occur.

B. Imaging

Hepatic imaging studies may show a prominent caudate lobe, since its venous drainage may not be occluded. The screening test of choice is contrast-enhanced, color, or pulsed-Doppler ultrasonography, which has a sensitivity of 85% for detecting evidence of hepatic venous or inferior vena caval thrombosis. MRI with spin-echo and gradient-echo sequences and intravenous gadolinium injection allows

visualization of the obstructed veins and collateral vessels. Direct venography can delineate caval webs and occluded hepatic veins (“spider-web” pattern) most precisely.

C. Liver Biopsy

Percutaneous or transjugular liver biopsy, which may be considered when the results of noninvasive imaging are inconclusive, frequently shows characteristic centrilobular congestion and fibrosis and often multiple large regenerative nodules. Liver biopsy is often contraindicated in sinusoidal obstruction syndrome because of thrombocytopenia, and the diagnosis is based on clinical findings.

► Treatment

Ascites should be treated with fluid and salt restriction and diuretics. Treatable causes of Budd-Chiari syndrome should be sought. Prompt recognition and treatment of an underlying hematologic disorder may avoid the need for surgery; however, the optimal anticoagulation regimen is uncertain, and anticoagulation is associated with a high risk of bleeding, particularly in patients with portal hypertension and those undergoing invasive procedures. Low-molecular weight heparins are preferred over unfractionated heparin because of a high rate of heparin-induced thrombocytopenia with the latter. Infusion of a thrombolytic agent into recently occluded veins has been attempted with success. In patients with sinusoidal obstruction syndrome, defibrinogen, an adenosine receptor agonist that increases endogenous tissue plasminogen activator levels, has shown promise. TIPS placement may be attempted in patients with Budd-Chiari syndrome and persistent hepatic congestion or failed thrombolytic therapy. Late TIPS dysfunction is less frequent with the use of polytetrafluoroethylene-covered stents than uncovered stents. TIPS is now preferred over surgical decompression (side-to-side portacaval, mesocaval, or mesoatrial shunt) which, in contrast to TIPS, has not been proven to improve long-term survival. Older age, a higher serum bilirubin level, and a greater INR predict a poor outcome with TIPS. Balloon angioplasty, in some cases with placement of an intravascular metallic stent, is preferred in patients with an inferior vena caval web and is being performed increasingly in patients with a short segment of thrombosis in the hepatic vein. Liver transplantation is considered in patients with fulminant hepatic failure, cirrhosis with hepatocellular dysfunction, and failure of a portosystemic shunt, and outcomes have improved with the advent of patient selection based on the MELD score. Patients often require lifelong anticoagulation and treatment of the underlying myeloproliferative disease; antiplatelet therapy with aspirin and hydroxyurea has been suggested as an alternative to warfarin in patients with a myeloproliferative disorder. The overall 5-year survival rate is 50–90% with treatment (but <10% without intervention). Adverse prognostic factors in patients with Budd-Chiari syndrome are older age, high Child-Turcotte-Pugh score, ascites, encephalopathy, elevated total bilirubin, prolonged prothrombin time, elevated serum creatinine, concomitant portal vein thrombosis, and histologic features of acute liver disease superimposed on

chronic liver injury; 3-month mortality may be predicted by the Rotterdam score, which is based on encephalopathy, ascites, prothrombin time, and bilirubin. A serum ALT level at least fivefold above the upper limit of normal on presentation indicates hepatic ischemia and also predicts a poor outcome, particularly when the ALT level decreases slowly.

► When to Admit

All patients with hepatic vein obstruction should be hospitalized.

Qi X et al. Meta-analysis: the significance of screening for *JAK2V617F* mutation in Budd-Chiari syndrome and portal venous system thrombosis. *Aliment Pharmacol Ther.* 2011 May;33(10):1087–103. [PMID: 21395632]

Rautou PE et al. Bleeding in patients with Budd-Chiari syndrome. *J Hepatol.* 2011 Jan;54(1):56–63. [PMID: 20889223]

THE LIVER IN HEART FAILURE

Ischemic hepatitis, also called **ischemic hepatopathy**, **hypoxic hepatitis**, or **shock liver**, may affect up to 10% of patients in an intensive care unit and results from an acute fall in cardiac output due to acute myocardial infarction, arrhythmia, or septic shock, usually in a patient with passive congestion of the liver. Clinical hypotension may be absent (or unwitnessed). In some cases, the precipitating event is arterial hypoxemia due to respiratory failure, sleep apnea, severe anemia, heat stroke, carbon monoxide poisoning, cocaine use, or bacterial endocarditis. More than one precipitant is common. The hallmark is a rapid and striking elevation of serum aminotransferase levels (often >5000 units/L); an early rapid rise in the serum lactate dehydrogenase level is also typical, but elevations of serum alkaline phosphatase and bilirubin are usually mild. The prothrombin time may be prolonged, and encephalopathy or hepatopulmonary syndrome may develop. The mortality rate due to the underlying disease is high (particularly in patients receiving vasopressor therapy or with septic shock, renal failure, or coagulopathy), but in patients who recover, the aminotransferase levels return to normal quickly, usually within 1 week—in contrast to viral hepatitis.

In patients with **passive congestion of the liver** due to right-sided heart failure, the serum bilirubin level may be elevated, occasionally as high as 40 mg/dL (684 μmol/L), due in part to hypoxia of perivenular hepatocytes, and the level is a predictor of mortality and morbidity. Serum alkaline phosphatase levels are normal or slightly elevated, and aminotransferase levels are only mildly elevated in the absence of superimposed ischemia. Hepatojugular reflux is present, and with tricuspid regurgitation the liver may be pulsatile. Ascites may be out of proportion to peripheral edema, with a high serum ascites-albumin gradient (≥ 1.1) and a protein content of more than 2.5 g/dL (25 g/L). A markedly elevated serum N-terminal-proBNP level has been reported to distinguish ascites due to heart failure from ascites due to cirrhosis. In severe cases, signs of encephalopathy may develop.

Fuhrmann V et al. Impact of hypoxic hepatitis on mortality in the intensive care unit. *Intensive Care Med.* 2011 Aug;37(8):1302–10. [PMID: 21647720]

Raurich JM et al. Hypoxic hepatitis in critically ill patients: incidence, etiology and risk factors for mortality. *J Anesth.* 2011 Feb;25(1):50–6. [PMID: 21153035]

NONCIRRHOTIC PORTAL HYPERTENSION



ESSENTIALS OF DIAGNOSIS

- Splenomegaly or upper gastrointestinal bleeding from esophageal or gastric varices in patients without liver disease.

► General Considerations

Causes of noncirrhotic portal hypertension include extrahepatic portal vein obstruction (portal vein thrombosis often with cavernous transformation [portal cavernoma]), splenic vein obstruction (presenting as gastric varices without esophageal varices), schistosomiasis, nodular regenerative hyperplasia, and arterial-portal vein fistula. Idiopathic noncirrhotic portal hypertension is common in India but rare in Western countries and has been attributed to chronic infections, exposure to medications or toxins, prothrombotic disorders, immunologic disorders, and genetic disorders that result in obliterative vascular lesions in the liver. **Portal vein thrombosis** may occur in 10–25% of patients with cirrhosis and may be associated with hepatocellular carcinoma. Other risk factors are oral contraceptive use, pregnancy, chronic inflammatory diseases, injury to the portal venous system (including surgery), and other malignancies. **Splenic vein thrombosis** may complicate pancreatitis or pancreatic cancer. **Pylephlebitis** (septic thrombophlebitis of the portal vein) may complicate intra-abdominal inflammatory disorders such as appendicitis or diverticulitis, particularly when anaerobic organisms (especially *Bacteroides* species) are involved. **Nodular regenerative hyperplasia** results from altered hepatic perfusion and can be associated with collagen vascular diseases; myeloproliferative disorders; and drugs, including azathioprine, 5-fluorouracil, and oxaliplatin. In patients infected with HIV, exposure to didanosine has been reported to account for some cases of noncirrhotic portal hypertension due to nodular regenerative hyperplasia. The term obliterative portal venopathy is used to describe primary occlusion of intrahepatic portal veins in the absence of cirrhosis, inflammation, or hepatic neoplasia.

► Clinical Findings

A. Symptoms and Signs

Acute portal vein thrombosis usually causes abdominal pain. Aside from splenomegaly, the physical findings are not remarkable, although hepatic decompensation can follow severe gastrointestinal bleeding or a concurrent hepatic

disorder, and intestinal infarction may occur when portal vein thrombosis is associated with mesenteric venous thrombosis. Ascites may occur in 25% of persons with noncirrhotic portal hypertension. Minimal hepatic encephalopathy is reported to be common in patients with noncirrhotic portal vein thrombosis.

B. Laboratory Findings

Liver biochemical test levels are usually normal, but there may be findings of hypersplenism. An underlying hypercoagulable state is found in many patients with portal vein thrombosis; this includes myeloproliferative disorders (often associated with a specific mutation [V617F] in the gene coding for JAK2 tyrosine kinase, which is found in 24% of cases of portal vein thrombosis), mutation G20210A of prothrombin, factor V Leiden mutation, protein C and S deficiency, antiphospholipid syndrome, mutation TT677 of methylenetetrahydrofolate reductase, elevated factor VIII levels, hyperhomocysteinemia, and a mutation in the gene that codes for thrombin-activatable fibrinolysis inhibitor. It is possible, however, that in many cases evidence of hypercoagulability is a secondary phenomenon due to portosystemic shunting and reduced hepatic blood flow.

C. Imaging

Color Doppler ultrasonography and contrast-enhanced CT are usually the initial diagnostic tests for portal vein thrombosis. Magnetic resonance angiography (MRA) of the portal system is generally confirmatory. Endoscopic ultrasonography may be helpful in some cases. In patients with jaundice, magnetic resonance cholangiography may demonstrate compression of the bile duct by a large portal cavernoma (portal biliopathy), a finding that may be more common in patients with an underlying hypercoagulable state than in those without one. In patients with pylephlebitis, CT may demonstrate an intra-abdominal source of infection, thrombosis or gas in the portal venous system, and a hepatic abscess.

D. Other Studies

Endoscopy shows esophageal or gastric varices. Needle biopsy of the liver may be indicated to diagnose schistosomiasis, nodular regenerative hyperplasia, and noncirrhotic portal fibrosis and may demonstrate sinusoidal dilatation.

► Treatment

If splenic vein thrombosis is the cause of variceal bleeding, splenectomy is curative. For other causes of noncirrhotic portal hypertension, band ligation (or sclerotherapy) followed by β -blockers to reduce portal pressure is initiated for variceal bleeding, and portosystemic shunting (including TIPS) is reserved for failures of endoscopic therapy; rarely progressive liver dysfunction requires liver transplantation. Anticoagulation or thrombolytic therapy may be indicated for isolated acute portal vein thrombosis (and leads to recanalization in one-third of cases) and possibly acute splenic vein thrombosis and continued long-term if a hypercoagulable disorder is identified or if an acute portal

vein thrombosis extends into the mesenteric veins. The use of enoxaparin to prevent portal vein thrombosis in patients with cirrhosis is under study.

► When to Refer

All patients with noncirrhotic portal hypertension should be referred.

- Ames JT et al. Septic thrombophlebitis of the portal venous system: clinical and imaging findings in thirty-three patients. *Dig Dis Sci.* 2011 Jul;56(7):2179–84. [PMID: 21221797]
- Cazals-Hatem D et al. Obliterative portal venopathy: portal hypertension is not always present at diagnosis. *J Hepatol.* 2011 Mar;54(3):455–61. [PMID: 21087805]
- Luca A et al. Short- and long-term effects of the transjugular intrahepatic portosystemic shunt on portal vein thrombosis in patients with cirrhosis. *Gut.* 2011 Jun;60(6):846–52. [PMID: 21357252]
- Raffa S et al. Hypercoagulability in patients with chronic noncirrhotic portal vein thrombosis. *Clin Gastroenterol Hepatol.* 2012 Jan;10(1):72–8. [PMID: 21946303]
- Schouten JN et al. Idiopathic noncirrhotic portal hypertension. *Hepatology.* 2011 Sep 2;54(3):1071–81. [PMID: 21574171]

PYOGENIC HEPATIC ABSCESS



ESSENTIALS OF DIAGNOSIS

- Fever, right upper quadrant pain, jaundice.
- Often in setting of biliary disease, but up to 40% are “cryptogenic” in origin.
- Detected by imaging studies.

► General Considerations

The incidence of liver abscess is 3.6 per 100,000 population in the United States and has increased since the 1990s. The liver can be invaded by bacteria via (1) the bile duct (ascending cholangitis); (2) the portal vein (pylephlebitis); (3) the hepatic artery, secondary to bacteremia; (4) direct extension from an infectious process; and (5) traumatic implantation of bacteria through the abdominal wall. Risk factors for liver abscess include older age and male gender. Predisposing conditions include malignancy, diabetes mellitus, inflammatory bowel disease, cirrhosis, and liver transplantation.

Ascending cholangitis resulting from biliary obstruction due to a stone, stricture, or neoplasm is the most common identifiable cause of hepatic abscess in the United States. In 10% of cases, liver abscess is secondary to appendicitis or diverticulitis. At least 40% of abscesses have no demonstrable cause and are classified as cryptogenic. A dental source is identified in some cases. The most frequently encountered organisms are *E coli*, *Klebsiella pneumoniae*, *Proteus vulgaris*, *Enterobacter aerogenes*, and multiple microaerophilic and anaerobic species (eg, *Streptococcus milleri*). Liver abscess caused by virulent strains of *K pneumoniae* may be associated with thrombophlebitis of the portal or hepatic veins

and hematogenously spread septic ocular or central nervous system complications. *Staphylococcus aureus* is usually the causative organism in patients with chronic granulomatous disease. Uncommon causative organisms include *Salmonella*, *Haemophilus*, and *Yersinia*. Hepatic candidiasis, tuberculosis, and actinomycosis are seen in immunocompromised patients and those with hematologic malignancies. Rarely, hepatocellular carcinoma can present as a pyogenic abscess because of tumor necrosis, biliary obstruction, and superimposed bacterial infection (see Chapter 39). The possibility of an amebic liver abscess must always be considered (see Chapter 35).

► Clinical Findings

A. Symptoms and Signs

The presentation is often insidious. Fever is almost always present and may antedate other symptoms or signs. Pain may be a prominent complaint and is localized to the right upper quadrant or epigastric area. Jaundice, tenderness in the right upper abdomen, and either steady or spiking fever are the chief physical findings.

B. Laboratory Findings

Laboratory examination reveals leukocytosis with a shift to the left. Liver biochemical tests are nonspecifically abnormal. Blood cultures are positive in 50–100% of cases.

C. Imaging

Chest radiographs usually reveal elevation of the diaphragm if the abscess is on the right side. Ultrasonography, CT, or MRI may reveal the presence of intrahepatic lesions. On MRI, characteristic findings include high signal intensity on T2-weighted images and rim enhancement. The characteristic CT appearance of hepatic candidiasis, usually seen in the setting of systemic candidiasis, is that of multiple “bull’s-eyes,” but imaging studies may be negative in neutropenic patients.

► Treatment

Treatment should consist of antimicrobial agents (generally a third-generation cephalosporin such as cefoperazone 1–2 g intravenously every 12 hours and metronidazole 500 mg intravenously every 6 hours) that are effective against coliform organisms and anaerobes. Antibiotics are administered for 2–3 weeks, and sometimes up to 6 weeks. If the abscess is at least 5 cm in diameter or the response to antibiotic therapy is not rapid, intermittent needle aspiration, percutaneous or endoscopic ultrasound-guided catheter drainage or, if necessary, surgical (eg, laparoscopic) drainage should be done. Other suggested indications for abscess drainage are patient age of at least 55 years, symptom duration of at least 7 days, and involvement of both lobes of the liver. The underlying source (eg, biliary disease, dental infection) should be identified and treated. The mortality rate is still substantial ($\geq 5\%$ in most studies) and is highest in patients with underlying biliary malignancy or severe multiorgan dysfunction. Other risk factors for mortality

include older age, cirrhosis, chronic kidney disease, and cancer. Hepatic candidiasis often responds to intravenous amphotericin B (total dose of 2–9 g). Fungal abscesses are associated with mortality rates of up to 50% and are treated with intravenous amphotericin B and drainage.

► When to Admit

Nearly all patients with pyogenic hepatic abscess should be hospitalized.

- Alsafir HS et al. CT appearance of pyogenic liver abscesses caused by *Klebsiella pneumoniae*. *Radiology*. 2011 Jul;260(1):129–38. [PMID: 21460028]
- Mezhir JJ et al. Current management of pyogenic liver abscess: surgery is now second-line treatment. *J Am Coll Surg*. 2010 Jun;210(6):975–83. [PMID: 20510807]
- Pang TC et al. Pyogenic liver abscess: an audit of 10 years’ experience. *World J Gastroenterol*. 2011 Mar 28;17(12):1622–30. [PMID: 21472130]
- Reid-Lombardo KM et al. Hepatic cysts and liver abscess. *Surg Clin North Am*. 2010 Aug;90(4):679–97. [PMID: 20637941]

BENIGN LIVER NEOPLASMS

Benign neoplasms of the liver must be distinguished from hepatocellular carcinoma and metastases (see Chapter 39). The most common benign neoplasm of the liver is the **cavernous hemangioma**, often an incidental finding on ultrasonography or CT. This lesion may enlarge in women who take hormonal therapy and must be differentiated from other space-occupying intrahepatic lesions, usually by contrast-enhanced MRI, CT, or ultrasonography. Rarely, fine-needle biopsy is necessary to differentiate these lesions and does not appear to carry an increased risk of bleeding. Surgical resection of cavernous hemangiomas is rarely necessary but may be required for abdominal pain or rapid enlargement, to exclude malignancy, or to treat Kasabach-Merritt syndrome (consumptive coagulopathy complicating a hemangioma).

In addition to rare instances of sinusoidal dilatation and peliosis hepatis, two distinct benign lesions with characteristic clinical, radiologic, and histopathologic features have been described in women taking oral contraceptives—focal nodular hyperplasia and hepatocellular adenoma. **Focal nodular hyperplasia** occurs at all ages and in both sexes and is probably not caused by the oral contraceptives. It is often asymptomatic and appears as a hypervascular mass, often with a central hypodense “stellate” scar on CT or MRI. Microscopically, focal nodular hyperplasia consists of hyperplastic units of hepatocytes with a central stellate scar containing proliferating bile ducts. It is not a true neoplasm but a nonspecific reaction to altered blood flow. Focal nodular hyperplasia is associated with an elevated angiopoietin 1/angiopoietin 2 mRNA ratio and may also occur in patients with cirrhosis, with exposure to certain drugs such as azathioprine, and in antiphospholipid syndrome. The prevalence of hepatic hemangiomas is increased in patients with focal nodular hyperplasia.

Hepatocellular adenoma occurs most commonly in women in the third and fourth decades of life and is usually

caused by oral contraceptives; acute abdominal pain may occur if the tumor undergoes necrosis or hemorrhage. The tumor may be associated with mutations in: (1) the gene coding for hepatocyte nuclear factor 1 α (*HNF1 α*) (characterized by steatosis and a low risk of malignant transformation, particularly in men, in whom concomitant metabolic syndrome appears to increase the risk of malignant transformation); (2) the gene coding for β -catenin (characterized by a high rate of malignant transformation); or (3) neither gene (designated inflammatory adenoma [previously termed “telangiectatic focal nodular hyperplasia”], which is associated with a high body mass index and serum biomarkers of inflammation such as C-reactive protein). Rare instances of multiple hepatocellular adenomas in association with maturity-onset diabetes of the young occur in families with a germline mutation in *HNF1 α* . Hepatocellular adenomas also occur in patients with glycogen storage disease and familial adenomatous polyposis. The tumor is hypovascular. Grossly, the cut surface appears structureless. As seen microscopically, the hepatocellular adenoma consists of sheets of hepatocytes without portal tracts or central veins.

Cystic neoplasms of the liver, such as cystadenoma and cystadenocarcinoma, must be distinguished from simple and echinococcal cysts, von Meyenburg complexes (hamartomas), and polycystic liver disease.

► Clinical Findings

The only physical finding in focal nodular hyperplasia or hepatocellular adenoma is a palpable abdominal mass in a minority of cases. Liver function is usually normal. Arterial phase helical CT and MRI with contrast can distinguish an adenoma from focal nodular hyperplasia in 80–90% of cases and may suggest a specific subtype of adenoma (eg, homogeneous fat pattern in *HNF1 α* -mutated adenomas and marked and persistent arterial enhancement in inflammatory adenomas).

► Treatment

Treatment of focal nodular hyperplasia is resection only in the symptomatic patient; rarely is liver transplantation necessary. The prognosis is excellent. Hepatocellular adenoma may undergo bleeding, necrosis, and rupture, often after hormone therapy or in men, and resection is advised if the tumor causes symptoms or is > 5 cm in diameter, even in asymptomatic persons. In selected cases, laparoscopic resection or percutaneous radiofrequency ablation may be feasible. Regression of benign hepatic tumors may follow cessation of oral contraceptives.

► When to Refer

- Diagnostic uncertainty.
- For surgery.

► When to Admit

- Severe pain.
- Rupture.

Fowler KJ et al. Magnetic resonance imaging of focal liver lesions: approach to imaging diagnosis. *Hepatology*. 2011 Dec;54(6):2227–37. [PMID: 21932400]

Shaked O et al. Biologic and clinical features of benign solid and cystic lesions of the liver. *Clin Gastroenterol Hepatol*. 2011 Jul;9(7):547–62. [PMID: 21397723]

van Aalten SM et al. Validation of a liver adenoma classification system in a tertiary referral centre: implications for clinical practice. *J Hepatol*. 2011 Jul;55(1):120–5. [PMID: 21145863]

DISEASES OF THE BILIARY TRACT

See Chapter 39 for Carcinoma of the Biliary Tract.

CHOLELITHIASIS (Gallstones)

ESSENTIALS OF DIAGNOSIS

- Often asymptomatic.
- Classic biliary pain (“episodic gallbladder pain”) characterized by infrequent episodes of steady severe pain in epigastrium or right upper quadrant with radiation to right scapula.
- Detected on ultrasonography.

► General Considerations

Gallstones are more common in women than in men and increase in incidence in both sexes and all races with aging. In the United States, the prevalence of gallstones is 5.5% in men and 8.6% in women, with the highest rates in persons over age 60 and higher rates in Mexican-Americans than in non-Hispanic whites and African Americans, and gallstone disease is associated with increased overall, cardiovascular, and cancer mortality. Although cholesterol gallstones are less common in black people, cholelithiasis attributable to hemolysis occurs in over a third of individuals with sickle cell disease. Native Americans of both the Northern and Southern Hemispheres have a high rate of cholesterol cholelithiasis, probably because of a predisposition resulting from “thrifty” (*LITH*) genes that promote efficient calorie utilization and fat storage. As many as 75% of Pima and other American Indian women over the age of 25 years have cholelithiasis. Other genetic mutations that predispose persons to gallstones have been identified. Obesity is a risk factor for gallstones, especially in women. Rapid weight loss, as occurs after bariatric surgery, also increases the risk of symptomatic gallstone formation. Diabetes mellitus, glucose intolerance, and insulin resistance are risk factors for gallstones, and a high intake of carbohydrate and high dietary glycemic load increase the risk of cholecystectomy in women. Hypertriglyceridemia may promote gallstone formation by impairing gallbladder motility. The prevalence of gallbladder disease is increased in men (but not women) with cirrhosis and hepatitis C virus infection. Moreover, cholecystectomy has been reported to be associated with an increased risk of cirrhosis, possibly because gallstones and liver disease have some risk factors in common.

A low-carbohydrate diet, physical activity, and cardiorespiratory fitness may help prevent gallstones. Consumption of caffeinated coffee appears to protect against gallstones in women, and a high intake of magnesium and of polyunsaturated and monounsaturated fats reduces the risk of gallstones in men. A diet high in fiber, a diet rich in fruits and vegetables, and statin use reduce the risk of cholecystectomy, particularly in women. The incidence of gallstones is high in individuals with Crohn disease; approximately one-third of those with inflammatory involvement of the terminal ileum have gallstones due to disruption of bile salt resorption that results in decreased solubility of the bile. Drugs such as clofibrate, octreotide, and ceftriaxone can cause gallstones. In contrast, aspirin and other nonsteroidal anti-inflammatory drugs may protect against gallstones. Prolonged fasting (over 5–10 days) can lead to formation of biliary “sludge” (microlithiasis), which usually resolves with refeeding but can lead to gallstones or biliary symptoms. Pregnancy, particularly in obese women and those with insulin resistance, is associated with an increased risk of gallstones and of symptomatic gallbladder disease. Hormone replacement therapy appears to increase the risk of gallbladder disease and need for cholecystectomy; the risk is lower with transdermal than oral therapy.

Gallstones are classified according to their predominant chemical composition as cholesterol or calcium bilirubinate stones. The latter comprise <20% of the stones found in Europe or the United States but 30–40% of stones found in Japan.

► Clinical Findings

Table 16–7 lists the clinical and laboratory features of several diseases of the biliary tract as well as their treatment. Cholelithiasis is frequently asymptomatic and is discovered in the course of routine radiographic study, operation, or autopsy. Symptoms (biliary [or “episodic gallbladder”] pain) develop in 10–25% of patients (1–4% annually), and acute cholecystitis develops in 20% of these symptomatic persons over time. Occasionally, small intestinal obstruction due to “gallstone ileus” (or Bouveret syndrome when the obstructing stone is in pylorus or duodenum) presents as the initial manifestation of cholelithiasis.

► Treatment

There is generally no need for prophylactic cholecystectomy in an asymptomatic person unless the gallbladder is calcified, gallstones are over 3 cm in diameter, or the patient is a Native American or a candidate for bariatric surgery or cardiac transplantation. Laparoscopic cholecystectomy is the treatment of choice for symptomatic gallbladder disease. Pain relief after cholecystectomy is most likely in patients with episodic pain (generally once a month or less), pain lasting 30 minutes to 24 hours, pain in the evening or at night, and the onset of symptoms 1 year or less before presentation. Patients may go home within 1 day of the procedure and return to work within days (instead of weeks for those undergoing open cholecystectomy). The procedure is often performed on an outpatient basis and is suitable for most

Table 16–7. Diseases of the biliary tract.

	Clinical Features	Laboratory Features	Diagnosis	Treatment
Gallstones	Asymptomatic	Normal	Ultrasonography	None
Gallstones	Biliary pain	Normal	Ultrasonography	Laparoscopic cholecystectomy
Cholesterosis of gallbladder	Usually asymptomatic	Normal	Oral cholecystography	None
Adenomyomatosis	May cause biliary pain	Normal	Oral cholecystography	Laparoscopic cholecystectomy if symptomatic
Porcelain gallbladder	Usually asymptomatic, high risk of gallbladder cancer	Normal	Radiograph or CT	Laparoscopic cholecystectomy
Acute cholecystitis	Epigastric or right upper quadrant pain, nausea, vomiting, fever, Murphy sign	Leukocytosis	Ultrasonography, HIDA scan	Antibiotics, laparoscopic cholecystectomy
Chronic cholecystitis	Biliary pain, constant epigastric or right upper quadrant pain, nausea	Normal	Ultrasonography (stones), oral cholecystography (nonfunctioning gallbladder)	Laparoscopic cholecystectomy
Choledocholithiasis	Asymptomatic or biliary pain, jaundice, fever; gallstone pancreatitis	Cholestatic liver function tests; leukocytosis and positive blood cultures in cholangitis; elevated amylase and lipase in pancreatitis	Ultrasonography (dilated ducts), endoscopic Ultrasonography, MRCP, ERCP	Endoscopic sphincterotomy and stone extraction; antibiotics for cholangitis

ERCP, endoscopic retrograde cholangiopancreatography; HIDA, hepatic iminodiacetic acid; MRCP, magnetic resonance cholangiopancreatography.

patients, including those with acute cholecystitis. Conversion to a conventional open cholecystectomy may be necessary in 2–8% of cases (higher for acute cholecystitis than for uncomplicated cholelithiasis). Bile duct injuries occur in 0.1% of cases done by experienced surgeons. Cholecystectomy may increase the risk of esophageal, proximal small intestinal, and colonic adenocarcinomas because of increased duodenogastric reflux and changes in intestinal exposure to bile. In pregnant patients a conservative approach to biliary pain is advised, but for patients with repeated attacks of biliary pain or acute cholecystitis, cholecystectomy can be performed—even by the laparoscopic route—preferably in the second trimester. Enterolithotomy alone is considered adequate treatment in most patients with gallstone ileus. Cholecystectomy via natural orifice transluminal endoscopic surgery (NOTES) has been performed and is under study.

Cheno- and ursodeoxycholic acids are bile salts that when given orally for up to 2 years dissolve some cholesterol stones and may be considered in occasional, selected patients who refuse cholecystectomy. The dose is 7 mg/kg/d of cheno or 8–13 mg/kg of ursodeoxycholic acid in divided doses daily. They are most effective in patients with a functioning gallbladder, as determined by gallbladder visualization on oral cholecystography, and multiple small “floating” gallstones (representing not more than 15% of patients with gallstones). In half of patients, gallstones recur within 5 years after treatment is stopped. Ursodeoxycholic acid, 500–600 mg daily, reduces the risk of gallstone formation with rapid weight loss. Cholesterol-lowering agents (statins, ezetimibe) and drugs that act on specific nuclear receptors involved in cholesterol and bile metabolism are under study for the treatment of cholelithiasis.

Lithotripsy in combination with bile salt therapy for single radiolucent stones < 20 mm in diameter was an option in the past but is no longer generally used in the United States.

► When to Refer

Patients should be referred when they require surgery.

Ruhl CE et al. Gallstone disease is associated with increased mortality in the United States. *Gastroenterology*. 2011 Feb;140(2):508–16. [PMID: 21075109]

Soper NJ. Cholecystectomy: from Langenbuch to natural orifice transluminal endoscopic surgery. *World J Surg*. 2011 Jul;35(7):1422–7. [PMID: 21437744]

Thistle JL et al. Factors that predict relief from upper abdominal pain after cholecystectomy. *Clin Gastroenterol Hepatol*. 2011 Oct;9(10):891–6. [PMID: 21699805]

ACUTE CHOLECYSTITIS



ESSENTIALS OF DIAGNOSIS

- Steady, severe pain and tenderness in the right hypochondrium or epigastrium.
- Nausea and vomiting.
- Fever and leukocytosis.

► General Considerations

Cholecystitis is associated with gallstones in over 90% of cases. It occurs when a stone becomes impacted in the cystic duct and inflammation develops behind the obstruction. Acalculous cholecystitis should be considered when unexplained fever or right upper quadrant pain occurs within 2–4 weeks of major surgery or in a critically ill patient who has had no oral intake for a prolonged period; multiorgan failure is often present. Acute cholecystitis may be caused by infectious agents (eg, cytomegalovirus, cryptosporidiosis, or microsporidiosis) in patients with AIDS or by vasculitis (eg, polyarteritis nodosa).

► Clinical Findings

A. Symptoms and Signs

The acute attack is often precipitated by a large or fatty meal and is characterized by the sudden appearance of steady pain localized to the epigastrium or right hypochondrium, which may gradually subside over a period of 12–18 hours. Vomiting occurs in about 75% of patients and in half of instances affords variable relief. Fever is typical. Right upper quadrant abdominal tenderness (often with a Murphy sign, or inhibition of inspiration by pain on palpation of the right upper quadrant) is almost always present and is usually associated with muscle guarding and rebound tenderness (Table 16–7). A palpable gallbladder is present in about 15% of cases. Jaundice is present in about 25% of cases and, when persistent or severe, suggests the possibility of choledocholithiasis.

B. Laboratory Findings

The white blood cell count is usually high (12,000–15,000/mcL). Total serum bilirubin values of 1–4 mg/dL (17.1–68.4 μmol/L) may be seen even in the absence of bile duct obstruction. Serum aminotransferase and alkaline phosphatase levels are often elevated—the former as high as 300 units/mL, or even higher when associated with ascending cholangitis. Serum amylase may also be moderately elevated.

C. Imaging

Plain films of the abdomen may show radiopaque gallstones in 15% of cases. ^{99m}Tc hepatobiliary imaging (using iminodiacetic acid compounds), also known as the hepatic iminodiacetic acid (HIDA) scan, is useful in demonstrating an obstructed cystic duct, which is the cause of acute cholecystitis in most patients. This test is reliable if the bilirubin is under 5 mg/dL (85.5 μmol/L) (98% sensitivity and 81% specificity for acute cholecystitis). False-positive results can occur with prolonged fasting, liver disease, and chronic cholecystitis, and the specificity can be improved by intravenous administration of morphine, which induces spasm of the sphincter of Oddi. Right upper quadrant abdominal ultrasonography, which is often performed first, may show gallstones but is not as sensitive for acute cholecystitis (67% sensitivity, 82% specificity); findings suggestive of acute cholecystitis are gallbladder wall

thickening, pericholecystic fluid, and a sonographic Murphy sign. CT may show complications of acute cholecystitis, such as perforation or gangrene.

► Differential Diagnosis

The disorders most likely to be confused with acute cholecystitis are perforated peptic ulcer, acute pancreatitis, appendicitis in a high-lying appendix, perforated colonic carcinoma or diverticulum of the hepatic flexure, liver abscess, hepatitis, pneumonia with pleurisy on the right side, and even myocardial ischemia. Definite localization of pain and tenderness in the right upper quadrant, with radiation around to the infrascapular area, strongly favors the diagnosis of acute cholecystitis. True cholecystitis without stones suggests acalculous cholecystitis.

► Complications

A. Gangrene of the Gallbladder

Continuation or progression of right upper quadrant abdominal pain, tenderness, muscle guarding, fever, and leukocytosis after 24–48 hours suggests severe inflammation and possible gangrene of the gallbladder, resulting from ischemia due to splanchnic vasoconstriction and intravascular coagulation. Necrosis may occasionally develop without definite signs in the obese, diabetic, elderly, or immunosuppressed patient. Gangrene may lead to gallbladder perforation, usually with formation of a pericholecystic abscess, and rarely to generalized peritonitis. Other serious acute complications include emphysematous cholecystitis (secondary infection with a gas-forming organism) and empyema.

B. Chronic Cholecystitis and Other Complications

Chronic cholecystitis results from repeated episodes of acute cholecystitis or chronic irritation of the gallbladder wall by stones and is characterized pathologically by varying degrees of chronic inflammation of the gallbladder. Calculi are usually present. In about 4–5% of cases, the villi of the gallbladder undergo polypoid enlargement due to deposition of cholesterol that may be visible to the naked eye (“strawberry gallbladder,” cholesterosis). In other instances, hyperplasia of all or part of the gallbladder wall may be so marked as to give the appearance of a myoma (adenomyomatosis). Hydrops of the gallbladder results when acute cholecystitis subsides but cystic duct obstruction persists, producing distention of the gallbladder with a clear mucoid fluid. Occasionally, a stone in the neck of the gallbladder may compress the common hepatic duct and cause jaundice (Mirizzi syndrome). Xanthogranulomatous cholecystitis is a rare variant of chronic cholecystitis characterized by grayish-yellow nodules or streaks, representing lipid-laden macrophages, in the wall of the gallbladder.

Cholelithiasis with chronic cholecystitis may be associated with acute exacerbations of gallbladder inflammation, bile duct stone, fistulization to the bowel, pancreatitis and, rarely, carcinoma of the gallbladder. Calcified (porcelain) gallbladder is associated with gallbladder carcinoma and is generally

an indication for cholecystectomy; the risk of gallbladder cancer may be higher when calcification is mucosal rather than intramural.

► Treatment

Acute cholecystitis will usually subside on a conservative regimen (withholding of oral feedings, intravenous alimentation, analgesics, and intravenous antibiotics—generally a second- or third-generation cephalosporin such as cefoperazone, 1–2 g intravenously every 12 hours, with the addition of metronidazole, 500 mg intravenously every 6 hours; in severe cases, a fluoroquinolone such as ciprofloxacin, 250 mg intravenously every 12 hours, plus metronidazole may be given). Morphine or meperidine may be administered for pain. Because of the high risk of recurrent attacks (up to 10% by 1 month and over 30% by 1 year), cholecystectomy—generally laparoscopically—should generally be performed within 2–4 days after admission to the hospital for acute cholecystitis. If nonsurgical treatment has been elected, the patient (especially if diabetic or elderly) should be watched carefully for recurrent symptoms, evidence of gangrene of the gallbladder, or cholangitis. In high-risk patients, ultrasound-guided aspiration of the gallbladder, if feasible, percutaneous cholecystostomy, or endoscopic insertion of a stent or nasobiliary drain into the gallbladder may postpone or even avoid the need for surgery. Immediate cholecystectomy is mandatory when there is evidence of gangrene or perforation.

Surgical treatment of chronic cholecystitis is the same as for acute cholecystitis. If indicated, cholangiography can be performed during laparoscopic cholecystectomy. Choledocholithiasis can also be excluded by either preoperative or postoperative ERCP or MRCP.

► Prognosis

The overall mortality rate of cholecystectomy is <0.2%, but hepatobiliary tract surgery is a more formidable procedure in the elderly, in whom mortality rates are higher. A technically successful surgical procedure in an appropriately selected patient is generally followed by complete resolution of symptoms.

► When to Admit

All patients with acute cholecystitis should be hospitalized.

Charalal RA et al. Complicated cholecystitis: the complementary roles of sonography and computed tomography. *Ultrasound Q*. 2011 Sep;27(3):161–70. [PMID: 21873853]
 Huffman JL et al. Acute acalculous cholecystitis: a review. *Clin Gastroenterol Hepatol*. 2010 Jan;8(1):15–22. [PMID: 19747982]
 McGillicuddy EA et al. Acute cholecystitis in the elderly: use of computed tomography and correlation with ultrasonography. *Am J Surg*. 2011 Nov;202(5):524–7. [PMID: 21906722]

PRE- & POSTCHOLECYSTECTOMY SYNDROMES

1. Precholecystectomy

In a small group of patients (mostly women) with biliary pain, conventional radiographic studies of the upper

gastrointestinal tract and gallbladder—including cholangiography—are unremarkable. In some such cases, emptying of the gallbladder may be markedly reduced on gallbladder scintigraphy following injection of cholecystokin; cholecystectomy may be curative. Histologic examination of the resected gallbladder may show chronic cholecystitis or microlithiasis. An additional diagnostic consideration is sphincter of Oddi dysfunction (see below).

2. Postcholecystectomy

Following cholecystectomy, some patients complain of continuing symptoms, ie, right upper quadrant pain, flatulence, and fatty food intolerance. The persistence of symptoms in this group of patients suggests the possibility of an incorrect diagnosis prior to cholecystectomy, eg, esophagitis, pancreatitis, radiculopathy, or functional bowel disease. Choledocholithiasis or bile duct stricture should be ruled out. Pain may also be associated with dilatation of the cystic duct remnant, neuroma formation in the ductal wall, foreign body granuloma, or traction on the bile duct by a long cystic duct.

The clinical presentation of right upper quadrant pain, chills, fever, or jaundice suggests biliary tract disease. Endoscopic ultrasonography or retrograde cholangiography may be necessary to demonstrate a stone or stricture. Biliary pain associated with elevated liver biochemical tests or a dilated bile duct in the absence of an obstructing lesion suggests sphincter of Oddi dysfunction. Biliary manometry may be useful for documenting elevated baseline sphincter of Oddi pressures typical of sphincter dysfunction when biliary pain is associated with elevated liver biochemical tests (twofold) or a dilated bile duct (> 12 mm) (type II sphincter of Oddi dysfunction) but is not necessary when both are present (type I sphincter of Oddi dysfunction) and is associated with a high risk of pancreatitis. In the absence of either elevated liver biochemical tests or a dilated bile duct (type III sphincter of Oddi dysfunction), a nonbiliary source of symptoms should be suspected. (Analogous criteria have been developed for pancreatic sphincter dysfunction.) Biliary scintigraphy after intravenous administration of morphine and MRCP following intravenous administration of secretin are under study as screening tests for sphincter dysfunction. Endoscopic sphincterotomy is most likely to relieve symptoms in patients with types I or II sphincter of Oddi dysfunction or an elevated sphincter of Oddi pressure, although many patients continue to have some pain. In some cases, treatment with a calcium channel blocker, long-acting nitrate, or phosphodiesterase inhibitor (eg, vardenafil) or possibly injection of the sphincter with botulinum toxin may be beneficial. In refractory cases, surgical sphincteroplasty or removal of the cystic duct remnant may be considered.

► When to Refer

Patients with sphincter of Oddi dysfunction should be referred for diagnostic procedures.

Baillie J. Sphincter of Oddi dysfunction. *Curr Gastroenterol Rep.* 2010 Apr;12(2):130–4. [PMID: 20424985]
DiBiase JK et al. Cholecystokin-cholescintigraphy in adults: consensus recommendations of an interdisciplinary panel. *Clin Gastroenterol Hepatol.* 2011 May;9(5):376–84. [PMID: 21334459]

CHOLEDOCHOLITHIASIS & CHOLANGITIS

ESSENTIALS OF DIAGNOSIS

- ▶ Often a history of biliary pain, which may be accompanied by jaundice.
- ▶ Occasional patients present with painless jaundice.
- ▶ Nausea and vomiting.
- ▶ Cholangitis should be suspected with fever followed by hypothermia and gram-negative shock, jaundice, and leukocytosis.
- ▶ Stones in bile duct most reliably detected by ERCP or endoscopic ultrasonography.

► General Considerations

About 15% of patients with gallstones have choledocholithiasis (bile duct stones). The percentage rises with age, and the frequency in elderly people with gallstones may be as high as 50%. Bile duct stones usually originate in the gallbladder but may also form spontaneously in the bile duct after cholecystectomy. The risk is increased twofold in persons with a juxtapiillary duodenal diverticulum. Symptoms result if there is obstruction.

► Clinical Findings

A. Symptoms and Signs

A history of biliary pain or jaundice may be obtained. Biliary pain results from rapid increases in bile duct pressure due to obstructed bile flow. The features that suggest the presence of a bile duct stone are: (1) frequently recurring attacks of right upper abdominal pain that is severe and persists for hours; (2) chills and fever associated with severe pain; and (3) a history of jaundice associated with episodes of abdominal pain (Table 16–7). The combination of pain, fever (and chills), and jaundice represents **Charcot triad** and denotes the classic picture of acute cholangitis. The addition of altered mental status and hypotension (**Reynolds pentad**) signifies acute suppurative cholangitis and is an endoscopic emergency. According to the Tokyo guidelines (2006), the diagnosis of acute cholangitis is established by the presence of (1) the Charcot triad; or (2) two elements of the Charcot triad plus laboratory evidence of an inflammatory response (eg, elevated white blood cell count, C-reactive protein), elevated liver biochemical test levels, and imaging evidence of biliary dilatation or a cause of obstruction.

Hepatomegaly may be present in calculous biliary obstruction, and tenderness is usually present in the right

upper quadrant and epigastrium. Bile duct obstruction lasting >30 days results in liver damage leading to cirrhosis. Hepatic failure with portal hypertension occurs in untreated cases.

B. Laboratory Findings

Acute obstruction of the bile duct typically produces a transient albeit striking increase in serum aminotransferase levels (often > 1000 units/L [20 mkat/L]). Bilirubinuria and elevation of the serum bilirubin are present if the bile duct remains obstructed; levels commonly fluctuate. Serum alkaline phosphatase levels rise more slowly. Not uncommonly, serum amylase elevations are present because of secondary pancreatitis. When extrahepatic obstruction persists for more than a few weeks, differentiation of obstruction from chronic cholestatic liver disease becomes more difficult. Leukocytosis is present in patients with acute cholangitis. Prolongation of the prothrombin time can result from the obstructed flow of bile to the intestine. In contrast to hepatocellular dysfunction, hypoprothrombinemia due to obstructive jaundice will respond to 10 mg of intravenous vitamin K or water-soluble oral vitamin K (phytonadione, 5 mg) within 24–36 hours.

C. Imaging

Ultrasonography and CT may demonstrate dilated bile ducts, and radionuclide imaging may show impaired bile flow. Endoscopic ultrasonography, helical CT, and magnetic resonance cholangiography are accurate in demonstrating bile duct stones and may be used in patients thought to be at intermediate risk for choledocholithiasis (age > 55 years, cholecystitis, bile duct diameter > 6 mm on ultrasonography, serum bilirubin 1.8–4 mg/dL [30.78–68.4 μmol/L], elevated serum liver enzymes, pancreatitis). ERCP (occasionally with intraductal ultrasonography) or percutaneous transhepatic cholangiography provides the most direct and accurate means of determining the cause, location, and extent of obstruction. If the likelihood that obstruction is caused by a stone is high (bile duct diameter > 6 mm, bile duct stone seen on ultrasonography, serum bilirubin > 4 mg/dL [68.4 μmol/L]) or acute cholangitis is present, ERCP is the procedure of choice because it permits sphincterotomy with stone extraction or stent placement. Meticulous technique is required to avoid causing acute cholangitis.

► Differential Diagnosis

The most common cause of obstructive jaundice is a bile duct stone. Next in frequency are neoplasms of the pancreas, ampulla of Vater, or bile duct. Extrinsic compression of the bile duct may result from metastatic carcinoma (usually from the gastrointestinal tract or breast) involving porta hepatis lymph nodes or, rarely, from a large duodenal diverticulum. Gallbladder cancer extending into the bile duct often presents as obstructive jaundice. Chronic cholestatic liver diseases (primarily biliary cirrhosis, sclerosing cholangitis, drug-induced) must be considered. Hepatocellular

jaundice can usually be differentiated by the history, clinical findings, and liver biochemical tests, but liver biopsy is necessary on occasion. Recurrent pyogenic cholangitis should be considered in persons from Asia (and occasionally elsewhere) with intrahepatic biliary stones (particularly in the left ductal system) and recurrent cholangitis.

► Treatment

In general, bile duct stones should be removed, even in an asymptomatic patient. A bile duct stone in a patient with cholelithiasis or cholecystitis is usually treated by endoscopic sphincterotomy and stone extraction followed by laparoscopic cholecystectomy within 72 hours in patients with cholecystitis and within 2 weeks in those without cholecystitis. An alternative approach, which may be associated with a shorter duration of hospitalization, is laparoscopic cholecystectomy and bile duct exploration. For the elderly (> 70 years) or poor-risk patient with cholelithiasis and choledocholithiasis, cholecystectomy may be deferred after endoscopic sphincterotomy because the risk of subsequent cholecystitis is low. ERCP with sphincterotomy should be performed before cholecystectomy in patients with gallstones and cholangitis, jaundice (serum total bilirubin > 4 mg/dL [68.4 μmol/L]), a dilated bile duct (> 6 mm), or stones in the bile duct seen on ultrasonography or CT. (Stones may ultimately recur in up to 12% of patients, particularly in the elderly, when the bile duct diameter is ≥ 15 mm, or when brown pigment stones are found at the time of the initial sphincterotomy.) Endoscopic balloon dilation of the sphincter of Oddi may be associated with a higher rate of pancreatitis than endoscopic sphincterotomy and is generally reserved for patients with coagulopathy, in whom the risk of bleeding is lower with balloon dilation than with sphincterotomy. Endoscopic ultrasound-guided biliary drainage and PTC with drainage are second-line approaches if ERCP fails or is not possible. In patients with biliary pancreatitis that resolves rapidly, the stone usually passes into the intestine, and ERCP prior to cholecystectomy is not necessary if an intraoperative cholangiogram is planned.

Choledocholithiasis discovered at laparoscopic cholecystectomy may be managed via laparoscopic or, if necessary, open bile duct exploration or by postoperative endoscopic sphincterotomy. Operative findings of choledocholithiasis are palpable stones in the bile duct, dilatation or thickening of the wall of the bile duct, or stones in the gallbladder small enough to pass through the cystic duct. Laparoscopic intraoperative cholangiography (or intraoperative ultrasonography) should be done at the time of cholecystectomy in patients with liver enzyme elevations but a bile duct diameter of < 5 mm; if a ductal stone is found, the duct should be explored. In the post-cholecystectomy patient with choledocholithiasis, endoscopic sphincterotomy with stone extraction is preferable to transabdominal surgery. Lithotripsy (endoscopic or external), direct choledoscopy (cholangioscopy), or biliary stenting may be a therapeutic consideration for large stones. For the patient with a T tube and bile duct stone, the stone may be extracted via the T tube.

Postoperative antibiotics are not administered routinely after biliary tract surgery. Cultures of the bile are always taken at operation. If biliary tract infection was present preoperatively or is apparent at operation, ampicillin (500 mg every 6 hours intravenously) with gentamicin (1.5 mg/kg intravenously every 8 hours) and metronidazole (500 mg intravenously every 6 hours) or ciprofloxacin (250 mg intravenously every 12 hours) or a third-generation cephalosporin (eg, cefoperazone, 1–2 g intravenous every 12 hours) is administered postoperatively until the results of sensitivity tests on culture specimens are available. A T-tube cholangiogram should be done before the tube is removed, usually about 3 weeks after surgery. A small amount of bile frequently leaks from the tube site for a few days.

Urgent ERCP with sphincterotomy and stone extraction is generally indicated for choledocholithiasis complicated by acute cholangitis and is preferred to surgery. Before ERCP, liver function should be evaluated thoroughly. The prothrombin time should be restored to normal by intravenous administration of vitamin K (see above). For mild-to-moderately severe community-acquired acute cholangitis, ciprofloxacin, 500 mg intravenously every 12 hours, penetrates well into bile and is effective treatment for cholangitis, with the possible addition of metronidazole, 500 mg every 6–8 hours. Alternative regimens include intravenous ampicillin and sulbactam, 3 g every 6 hours; cefoxitin, 1–2 g every 6 hours; or ampicillin, 2 g every 6 hours, plus gentamicin, 1.7 mg/kg every 8 hours. Regimens for severe or hospital-acquired acute cholangitis include intravenous piperacillin and tazobactam, 3.375 g every 6 hours; ticarcillin and clavulanate, 3.1 g every 6 hours; ceftriaxone, 1–2 g daily, plus metronidazole, 500 mg every 6–8 hours; or, in patients at high risk for harboring antibiotic-resistant pathogens, meropenem, 1 g every 8 hours. Aminoglycosides should not be given for more than a few days because the risk of aminoglycoside nephrotoxicity is increased in patients with cholestasis. Emergent decompression of the bile duct, generally by ERCP, is required for patients who are septic or fail to improve on antibiotics within 12–24 hours. Medical therapy alone is most likely to fail in patients with tachycardia, serum albumin < 3 g/dL (30 g/L), marked hyperbilirubinemia, high serum ALT level, high white blood cell count, and prothrombin time > 14 seconds on admission. If sphincterotomy cannot be performed, decompression by a biliary stent or nasobiliary catheter can be done. Once decompression is achieved, antibiotics are generally continued for at least another 3 days. Elective cholecystectomy can be undertaken after resolution of cholangitis, unless the patient remains unfit for surgery. Mortality from acute cholangitis has been reported to correlate with a high total bilirubin level, prolonged partial thromboplastin time, and presence of a liver abscess.

► When to Refer

All symptomatic patients with choledocholithiasis should be referred.

► When to Admit

All patients with acute cholangitis should be hospitalized.

- ASGE Standards of Practice Committee, Maple JT et al. The role of endoscopy in the management of choledocholithiasis. *Gastrointest Endosc.* 2011 Oct;74(4):731–44. [PMID: 21951472]
- Frossard JL et al. Detection and management of bile duct stones. *Gastrointest Endosc.* 2010 Oct;72(4):808–16. [PMID: 20883860]
- Mosler P. Diagnosis and management of acute cholangitis. *Curr Gastroenterol Rep.* 2011 Apr;13(2):166–72. [PMID: 21207254]
- Reinders JS et al. Early laparoscopic cholecystectomy improves outcomes after endoscopic sphincterotomy for choledocholithiasis. *Gastroenterology.* 2010 Jun;138(7):2315–20. [PMID: 20206179]
- Rogers SJ et al. Prospective randomized trial of LC+LCBDE vs ERCP/S+LC for common bile duct stone disease. *Arch Surg.* 2010 Jan;145(1):28–33. [PMID: 20083751]

BILIARY STRICTURE

Benign biliary strictures are the result of surgical (including liver transplantation) anastomosis or injury in about 95% of cases. The remainder of cases are caused by blunt external injury to the abdomen, pancreatitis, erosion of the duct by a gallstone, or prior endoscopic sphincterotomy.

Signs of injury to the duct may or may not be recognized in the immediate postoperative period. If complete occlusion has occurred, jaundice will develop rapidly; more often, however, a tear has been made accidentally in the duct, and the earliest manifestation of injury may be excessive or prolonged loss of bile from the surgical drains. Bile leakage resulting in a bile collection (biloma) may predispose to localized infection, which in turn accentuates scar formation and the ultimate development of a fibrous stricture.

Cholangitis is the most common complication of stricture. Typically, the patient experiences episodes of pain, fever, chills, and jaundice within a few weeks to months after cholecystectomy. Physical findings may include jaundice during an acute attack of cholangitis and right upper quadrant abdominal tenderness. Serum alkaline phosphatase is usually elevated. Hyperbilirubinemia is variable, fluctuating during exacerbations and usually remaining in the range of 5–10 mg/dL (85.5–171 μmol/L). Blood cultures may be positive during an acute episode of cholangitis. Secondary biliary cirrhosis will inevitably develop if a stricture is not treated.

MRCP can be valuable in demonstrating the stricture, whereas ERCP permits biopsy and cytologic specimens to exclude malignancy (in conjunction with endoscopic ultrasound-guided fine-needle aspiration, an even more sensitive test for distal bile duct malignancy), sphincterotomy to allow closure of a bile leak, and dilation and stent placement, thereby avoiding surgical repair in some cases; when ERCP is unsuccessful, dilation of a stricture may be accomplished by PTC. Placement of multiple plastic stents appears to be more effective than placement of a single stent. Metal stents, which often cannot be removed endoscopically, are generally avoided in benign strictures unless life expectancy is < 2 years. The use of covered metal stents, which are more easily removed endoscopically than uncovered metal stents, as well as bioabsorbable stents, is emerging as an alternative to use of plastic stents. Strictures related to chronic pancreatitis are more difficult to treat endoscopically than

postsurgical strictures, and preliminary reports suggest that they may be best managed with a temporary covered metal stent. Following liver transplantation, endoscopic management is more successful for anastomotic than for nonanastomotic strictures, although results for nonanastomotic strictures may be improved with the use of multiple plastic stents. Results are disappointing for biliary strictures after live liver donor liver transplantation, particularly in patients with a late-onset (after 24 weeks) stricture or with intrahepatic biliary dilatation; in addition, the risk of post-ERCP pancreatitis appears to be increased. When malignancy cannot be excluded with certainty, additional endoscopic diagnostic approaches may be considered—if available—including endoscopic ultrasonography, intraductal ultrasonography, and direct cholangioscopy (cholangioscopy). Differentiation from cholangiocarcinoma may ultimately require surgical exploration. Operative treatment of a stricture frequently necessitates performance of an end-to-end ductal repair, choledochojejunostomy, or hepaticojejunostomy to reestablish bile flow into the intestine.

▶ When to Refer

All patients with biliary stricture should be referred.

▶ When to Admit

Patients with acute cholangitis should be hospitalized.

Costamagna G et al. Endotherapy of postoperative biliary strictures with multiple stents: results after more than 10 years of follow-up. *Gastrointest Endosc*. 2010 Sep;72(3):551–7. [PMID: 20630514]

Coté GA et al. Biliary stricture and negative cytology: what next? *Clin Gastroenterol Hepatol*. 2011 Sep;9(9):739–43. [PMID: 21554986]

PRIMARY SCLEROSING CHOLANGITIS



ESSENTIALS OF DIAGNOSIS

- ▶ Most common in men aged 20–50 years.
- ▶ Often associated with ulcerative colitis.
- ▶ Progressive jaundice, itching, and other features of cholestasis.
- ▶ Diagnosis based on characteristic cholangiographic findings.
- ▶ At least 10% risk of cholangiocarcinoma.

▶ General Considerations

Primary sclerosing cholangitis is an uncommon disease characterized by diffuse inflammation of the biliary tract leading to fibrosis and strictures of the biliary system. The disease is most common in men aged 20–50 years, with an incidence of nearly 1 per 100,000 (possibly increasing) and

a prevalence of 21 per 100,000 men and 6 per 100,000 women in the United States. The disease is closely associated with ulcerative colitis (and in some cases with Crohn colitis), which is present in approximately two-thirds of patients with primary sclerosing cholangitis; however, clinically significant sclerosing cholangitis develops in only 1–4% of patients with ulcerative colitis. As in ulcerative colitis, smoking is associated with a decreased risk of primary sclerosing cholangitis. Primary sclerosing cholangitis is associated with the histocompatible antigens HLA-B8 and -DR3 or -DR4, and first-degree relatives of patients with primary sclerosing cholangitis have a fourfold increased risk of primary sclerosing cholangitis and a threefold increased risk of ulcerative colitis. The diagnosis of primary sclerosing cholangitis may be difficult to make after biliary surgery.

▶ Clinical Findings

A. Symptoms and Signs

Primary sclerosing cholangitis presents as progressive obstructive jaundice, frequently associated with fatigue, pruritus, anorexia, and indigestion. Patients may be diagnosed in the presymptomatic phase because of an elevated alkaline phosphatase level. Complications of chronic cholestasis, such as osteoporosis and malabsorption of fat-soluble vitamins, may occur late in the course. Risk factors for osteoporosis include older age, lower body mass index, and longer duration of inflammatory bowel disease. Esophageal varices on initial endoscopy are most likely in patients with a higher Mayo risk score based on age, bilirubin, albumin, and AST and a higher AST/ALT ratio, and new varices are likely to develop in those with a lower platelet count and higher bilirubin at 2 years. In patients with primary sclerosing cholangitis, ulcerative colitis is frequently characterized by rectal sparing and backwash ileitis.

B. Diagnostic Findings

The diagnosis of primary sclerosing cholangitis is increasingly made by MRCP, the sensitivity of which approaches that of ERCP. Characteristic cholangiographic findings are segmental fibrosis of bile ducts with saccular dilatations between strictures. Biliary obstruction by a stone or tumor should be excluded. The disease may be confined to small intrahepatic bile ducts, in which case MRCP and ERCP are normal and the diagnosis is suggested by liver biopsy findings. These patients have a longer survival than patients with involvement of the large ducts and do not appear to be at increased risk for cholangiocarcinoma unless large-duct sclerosing cholangitis develops. Liver biopsy may show characteristic periductal fibrosis (“onion-skinning”) and allows staging, which is based on the degree of fibrosis. Perinuclear ANCA (directed against myeloid-specific tubulin-beta isotype 5) as well as antinuclear, anticardiolipin, antithyroperoxidase, and anti-*Saccharomyces cerevisiae* antibodies and rheumatoid factor are frequently detected in serum. Occasional patients have clinical and histologic features of both sclerosing cholangitis and autoimmune hepatitis. An association with autoimmune pancreatitis is also seen, and

this entity (IgG₄-associated cholangitis, or sclerosing pancreaticholangitis) is often responsive to corticosteroids, although it may be difficult to distinguish from primary sclerosing cholangitis and even cholangiocarcinoma. Primary sclerosing cholangitis must be distinguished from idiopathic adulthood ductopenia (a rare disorder that affects young to middle-aged adults who manifest cholestasis resulting from loss of interlobular and septal bile ducts yet who have a normal cholangiogram and that is caused in some cases by a mutation in the canalicular phospholipid transporter gene *ABCB4*) and from other cholangiopathies (including primary biliary cirrhosis; cystic fibrosis; eosinophilic cholangitis; AIDS cholangiopathy; allograft rejection; graft-versus-host disease; ischemic damage [often with biliary “casts,” a rapid progression to cirrhosis, and a poor outcome] caused by hepatic artery thrombosis, shock, respiratory failure, or drugs; intra-arterial chemotherapy; and sarcoidosis).

► Complications

Cholangiocarcinoma may complicate the course of primary sclerosing cholangitis in up to 20% of cases (1.2% per year) and may be difficult to diagnose by cytologic examination or biopsy because of false-negative results. A serum CA 19-9 level >100 units/mL is suggestive but not diagnostic of cholangiocarcinoma. Annual right-upper-quadrant ultrasonography or MRI with MRCP and serum CA 19-9 testing (a level of 20 is the threshold for further investigation) are recommended for surveillance, with ERCP and biliary cytology if the results are suggestive of malignancy. PET and cholecystoscopy may play roles in the early detection of cholangiocarcinoma. Patients with ulcerative colitis and primary sclerosing cholangitis are at high risk for colorectal neoplasia. The risks of gallstones, cholecystitis, gallbladder polyps, and gallbladder carcinoma appear to be increased in patients with primary sclerosing cholangitis.

► Treatment

Episodes of acute bacterial cholangitis may be treated with ciprofloxacin (750 mg twice daily orally or intravenously). Ursodeoxycholic acid in standard doses (10–15 mg/kg/d orally) may improve liver biochemical test results but does not appear to alter the natural history and is no longer recommended for primary sclerosing cholangitis. High-dose ursodeoxycholic acid (25–30 mg/kg/d) also has been shown not to reduce cholangiographic progression and liver fibrosis, nor to improve survival or prevent cholangiocarcinoma, and has been shown to increase the risk of death and need for liver transplantation in patients with a normal serum bilirubin level and an early histologic stage. Other drugs such as cyclosporine, tacrolimus, minocycline, and docosahexaenoic acid are under study. Careful endoscopic evaluation of the biliary tree may permit balloon dilation of localized strictures, and repeated dilation of a dominant stricture may improve survival, although such patients have reduced survival compared with patients who do not have a dominant stricture. Short-term placement of a stent in a major stricture also may relieve symptoms and improve biochemical abnormalities, with sustained improvement after the stent is removed. However, long-term stenting may

increase the rate of complications such as cholangitis. In patients without cirrhosis, surgical resection of a dominant bile duct stricture may lead to longer survival than endoscopic therapy by decreasing the subsequent risk of cholangiocarcinoma. When feasible, extensive surgical resection of cholangiocarcinoma complicating primary sclerosing cholangitis may result in 5-year survival rates of > 50%. In patients with ulcerative colitis, primary sclerosing cholangitis is an independent risk factor for the development of colorectal dysplasia and cancer (especially in the right colon), and strict adherence to a colonoscopic surveillance program (yearly for those with ulcerative colitis and every 5 years for those without ulcerative colitis) is recommended. Treatment with ursodeoxycholic acid has been reported to reduce the risk of colorectal dysplasia and carcinoma in patients with ulcerative colitis and primary sclerosing cholangitis. For patients with cirrhosis and clinical decompensation, liver transplantation is the procedure of choice; primary sclerosing cholangitis recurs in the graft in 30% of cases, with a possible reduction in the risk of recurrence when colectomy has been performed for ulcerative colitis before transplantation.

► Prognosis

Survival of patients with primary sclerosing cholangitis averages 12–17 years. Adverse prognostic markers are older age, hepatosplenomegaly, higher serum bilirubin and AST levels, lower albumin levels, a history of variceal bleeding, a dominant bile duct stricture, and extrahepatic duct changes. Variceal bleeding is also a risk factor for cholangiocarcinoma. Interestingly, patients with milder ulcerative colitis tend to have more severe primary cholangitis and a higher rate of liver transplantation. Actuarial survival rates with liver transplantation are as high as 85% at 3 years, but rates are much lower once cholangiocarcinoma has developed. Following transplantation, patients have an increased risk of nonanastomotic biliary strictures and—in those with ulcerative colitis—colon cancer. The retransplantation rate is higher than that for primary biliary cirrhosis. Those patients who are unable to undergo liver transplantation will ultimately require high-quality palliative care (see Chapter 5).

Culver EL et al. Systematic review: management options for primary sclerosing cholangitis and its variant forms—IgG4-associated cholangitis and overlap with autoimmune hepatitis. *Aliment Pharmacol Ther.* 2011 Jun;33(12):1273–91. [PMID: 21501198]

Marelli L et al. Does the severity of primary sclerosing cholangitis influence the clinical course of associated ulcerative colitis? *Gut.* 2011 Sep;60(9):1224–8. [PMID: 21402617]

Molodecky NA et al. Incidence of primary sclerosing cholangitis: a systematic review and meta-analysis. *Hepatology.* 2011 May; 53(5):1590–9. [PMID: 21351115]

Torres J et al. Review article: colorectal neoplasia in patients with primary sclerosing cholangitis and inflammatory bowel disease. *Aliment Pharmacol Ther.* 2011 Sep;34(5):497–508. [PMID: 21692821]

Triantos CK et al. Meta-analysis: ursodeoxycholic acid for primary sclerosing cholangitis. *Aliment Pharmacol Ther.* 2011 Oct;34(8): 901–10. [PMID: 21883323]

DISEASES OF THE PANCREAS

See Chapter 39 for Carcinoma of the Pancreas and Periampullary Area.

ACUTE PANCREATITIS



ESSENTIALS OF DIAGNOSIS

- ▶ Abrupt onset of deep epigastric pain, often with radiation to the back.
- ▶ History of previous episodes, often related to alcohol intake.
- ▶ Nausea, vomiting, sweating, weakness.
- ▶ Abdominal tenderness and distention and fever.
- ▶ Leukocytosis, elevated serum amylase, elevated serum lipase.

General Considerations

Most cases of acute pancreatitis are related to biliary tract disease (a passed gallstone, usually <5 mm in diameter) or heavy alcohol intake. The exact pathogenesis is not known but may include edema or obstruction of the ampulla of Vater, reflux of bile into pancreatic ducts, and direct injury of pancreatic acinar cells by prematurely activated pancreatic enzymes. Among the numerous other causes or associations are hypercalcemia, hyperlipidemias (chylomicronemia, hypertriglyceridemia, or both), abdominal trauma (including surgery), drugs (including azathioprine, mercaptopurine, asparaginase, pentamidine, didanosine, valproic acid, tetracyclines, dapson, isoniazid, metronidazole, estrogen and tamoxifen [by raising serum triglycerides], sulfonamides, mesalamine, sulindac, thiazides, simvastatin, enalapril, methyl dopa, procainamide, sitagliptin, exenatide, and possibly corticosteroids, and others), vasculitis, infections (eg, mumps, cytomegalovirus, *M avium* complex), peritoneal dialysis, cardiopulmonary bypass, ERCP, and genetic mutations that also predispose to chronic pancreatitis (see later). In patients with pancreas divisum, a congenital anomaly in which the dorsal and ventral pancreatic ducts fail to fuse, acute pancreatitis may result from stenosis of the minor papilla with obstruction to flow from the accessory pancreatic duct, although concomitant mutations in the cystic fibrosis transmembrane conductance regulator (*CFTR*) gene have also been reported to account for acute pancreatitis in some patients with pancreas divisum. Acute pancreatitis may also result from anomalous union of the pancreaticobiliary duct. Rarely, acute pancreatitis may be the presenting manifestation of a pancreatic or ampullary neoplasm. Celiac disease appears to be associated with an increased risk of acute and chronic pancreatitis. Apparently “idiopathic” acute pancreatitis is often caused by occult biliary microlithiasis and may be caused by sphincter of Oddi dysfunction involving the pancreatic duct. Between 15% and 25% of cases are truly idiopathic. Smoking increases the risk of alcoholic and idiopathic pancreatitis, and older age and obesity increase the risk of a

severe course. The incidence of pancreatitis has increased since 1990.

Clinical Findings

A. Symptoms and Signs

Epigastric abdominal pain, generally abrupt in onset, is steady, boring, and severe and often made worse by walking and lying supine and better by sitting and leaning forward. The pain usually radiates into the back but may radiate to the right or left. Nausea and vomiting are usually present. Weakness, sweating, and anxiety are noted in severe attacks. There may be a history of alcohol intake or a heavy meal immediately preceding the attack or a history of milder similar episodes or biliary pain in the past.

The abdomen is tender mainly in the upper part, most often without guarding, rigidity, or rebound. The abdomen may be distended, and bowel sounds may be absent with associated ileus. Fever of 38.4–39 °C, tachycardia, hypotension (even shock), pallor, and cool clammy skin are often present. Mild jaundice may be seen. Occasionally, an upper abdominal mass due to the inflamed pancreas or a pseudocyst may be palpated. Acute kidney injury (usually prerenal) may occur early in the course of acute pancreatitis.

B. Laboratory Findings

Serum amylase and lipase are elevated—usually more than three times the upper limit of normal—within 24 hours in 90% of cases; their return to normal is variable depending on the severity of disease. Lipase remains elevated longer than amylase and is slightly more accurate for the diagnosis of acute pancreatitis. Leukocytosis (10,000–30,000/mcL), proteinuria, granular casts, glycosuria (10–20% of cases), hyperglycemia, and elevated serum bilirubin may be present. Blood urea nitrogen and serum alkaline phosphatase may be elevated and coagulation tests abnormal. An elevated serum creatinine level (>1.8 mg/dL [149.94 μmol/L]) at 48 hours is associated with the development of pancreatic necrosis. In patients with clear evidence of acute pancreatitis, a serum ALT level of more than 150 units/L (3 mkat/L) suggests biliary pancreatitis. A decrease in serum calcium may reflect saponification and correlates with severity of the disease. Levels lower than 7 mg/dL (1.75 mmol/L) (when serum albumin is normal) are associated with tetany and an unfavorable prognosis. Patients with acute pancreatitis caused by hypertriglyceridemia generally have fasting triglyceride levels above 1000 mg/dL (10 mmol/L). An early rise in the hematocrit value above 44% suggests hemoconcentration and predicts pancreatic necrosis. An elevated C-reactive protein concentration (> 150 mg/L [1500 mg/L]) at 48 hours suggests severe disease.

Other diagnostic tests that offer the possibility of simplicity, rapidity, ease of use, and low cost—including urinary trypsinogen-2, trypsinogen activation peptide, and carboxypeptidase B—are not widely available. In patients in whom ascites or a left pleural effusion develops, fluid amylase content is high. Electrocardiography may show ST–T wave changes.

Table 16-8. Ranson criteria for assessing the severity of acute pancreatitis.**Three or more of the following predict a severe course complicated by pancreatic necrosis with a sensitivity of 60–80%**

- Age over 55 years
- White blood cell count $> 16 \times 10^3/\text{mcl}$ ($16 \times 10^9/\text{L}$)
- Blood glucose $> 200 \text{ mg/dL}$ (11 mmol/L)
- Serum lactic dehydrogenase $> 350 \text{ units/L}$ (7 mkat/L)
- Aspartate aminotransferase $> 250 \text{ units/L}$ (5 mkat/L)

Development of the following in the first 48 hours indicates a worsening prognosis

- Hematocrit drop of more than 10 percentage points
- Blood urea nitrogen rise $> 5 \text{ mg/dL}$ (1.8 mmol/L)
- Arterial PO_2 of $< 60 \text{ mm Hg}$ (7.8 kPa)
- Serum calcium of $< 8 \text{ mg/dL}$ (0.2 mmol/L)
- Base deficit over 4 mEq/L
- Estimated fluid sequestration of $> 6 \text{ L}$

Mortality rates correlate with the number of criteria present¹

Number of Criteria	Mortality Rate
0–2	1%
3–4	16%
5–6	40%
7–8	100%

¹An APACHE II score ≥ 8 also correlates with mortality.

C. Assessment of Severity

In addition to the individual laboratory parameters noted above, the severity of acute alcoholic pancreatitis can be assessed using several scoring systems, including the **Ranson criteria** (Table 16–8). The **Sequential Organ Failure Assessment (SOFA)** score can be used to assess injury to other organs, and the **Acute Physiology and Chronic Health Evaluation (APACHE II)** score is another tool for assessing severity. A simple 5-point clinical scoring system based on blood urea nitrogen $> 25 \text{ mg/dL}$ (9 mmol/L), impaired mental status, systemic inflammatory response

syndrome, age > 60 years, and pleural effusion (the **Bedside Index for Severity in Acute Pancreatitis**, or **BISAP**) during the first 24 hours (before the onset of organ failure) identifies patients at increased risk for mortality. More simply, an elevated blood urea nitrogen level on admission and a rise in blood urea nitrogen within the first 24 hours of hospitalization are independently associated with increased mortality; the greater the rise in blood urea nitrogen after admission, the greater the mortality rate. An early rise in serum levels of neutrophil gelatinase-associated lipocalin has also been proposed as a marker of severe acute pancreatitis. The absence of rebound abdominal tenderness or guarding, a normal hematocrit value, and a normal serum creatinine level (the “**harmless acute pancreatitis score**,” or **HAPS**) predicts a nonsevere course with 98% accuracy.

D. Imaging

Plain radiographs of the abdomen may show gallstones, a “sentinel loop” (a segment of air-filled small intestine most commonly in the left upper quadrant), the “colon cutoff sign”—a gas-filled segment of transverse colon abruptly ending at the area of pancreatic inflammation—or focal linear atelectasis of the lower lobe of the lungs with or without pleural effusion. Ultrasonography is often not helpful in diagnosing acute pancreatitis because of intervening bowel gas but may identify gallstones in the gallbladder. Unenhanced CT is useful for demonstrating an enlarged pancreas when the diagnosis of pancreatitis is uncertain, detecting pseudocysts, differentiating pancreatitis from other possible intra-abdominal catastrophes, and providing an initial assessment of prognosis (Table 16–9). Rapid-bolus intravenous contrast-enhanced CT following aggressive volume resuscitation is of particular value after the first 3 days of severe acute pancreatitis for identifying areas of necrotizing pancreatitis and assessing the degree of necrosis, although the use of intravenous contrast may increase the risk of complications of pancreatitis and of acute kidney injury and should be avoided when the serum creatinine level is $> 1.5 \text{ mg/dL}$ (124.95 mcmmol/L). MRI

Table 16-9. Severity index for acute pancreatitis.

CT Grade	Points	Pancreatic Necrosis	Additional Points	Severity Index ¹	Mortality Rate ²
A Normal pancreas	0	0%	0	0	0%
B Pancreatic enlargement	1	0%	0	1	0%
C Pancreatic inflammation and/or peripancreatic fat	2	$< 30\%$	2	4	$< 3\%$
D Single acute peripancreatic fluid collection	3	30–50%	4	7	6%
E Two or more acute peripancreatic fluid collections or retroperitoneal air	4	$> 50\%$	6	10	$> 17\%$

¹Severity index = CT Grade Points + Additional Points.

²Based on the severity index.

Adapted with permission from Balthazar EJ. Acute pancreatitis: assessment of severity with clinical and CT evaluation. *Radiology*. 2002 Jun;223(3):603–13.

appears to be a suitable alternative to CT. Perfusion CT on day 3 demonstrating areas of ischemia in the pancreas has been reported to predict the development of pancreatic necrosis. The presence of a fluid collection in the pancreas correlates with an increased mortality rate. CT-guided needle aspiration of areas of necrotizing pancreatitis after the third day may disclose infection, usually by enteric organisms, which invariably leads to death unless debridement is ultimately performed. The presence of gas bubbles on CT implies infection by gas-forming organisms. Endoscopic ultrasonography is useful in identifying occult biliary disease (eg, small stones, sludge), which, including microlithiasis, is present in a majority of patients with apparently idiopathic acute pancreatitis, and is indicated in persons over age 40 to exclude malignancy. ERCP is generally not indicated after a first attack of acute pancreatitis unless there is associated cholangitis or jaundice or a bile duct stone is known to be present, but endoscopic ultrasonography or MRCP should be considered, especially after repeated attacks of idiopathic acute pancreatitis. In selected cases, aspiration of bile for crystal analysis may confirm the suspicion of microlithiasis, and manometry of the pancreatic duct sphincter may detect sphincter of Oddi dysfunction as a cause of recurrent pancreatitis.

► Differential Diagnosis

Acute pancreatitis must be differentiated from an acutely perforated duodenal ulcer, acute cholecystitis, acute intestinal obstruction, leaking aortic aneurysm, renal colic, and acute mesenteric ischemia. Serum amylase may also be elevated in high intestinal obstruction, in gastroenteritis, in mumps not involving the pancreas (salivary amylase), in ectopic pregnancy, after administration of opioids, and after abdominal surgery. Serum lipase may also be elevated in many of these conditions.

► Complications

Intravascular volume depletion secondary to leakage of fluids in the pancreatic bed and ileus with fluid-filled loops of bowel may result in prerenal azotemia and even acute tubular necrosis without overt shock. This usually occurs within 24 hours of the onset of acute pancreatitis and lasts 8–9 days. Some patients require renal replacement therapy.

Sterile or infected necrotizing pancreatitis may complicate the course of 5–10% of cases and accounts for most of the deaths. The risk of infection does not correlate with the extent of necrosis. Pancreatic necrosis is often associated with fever, leukocytosis, and, in some cases, shock and is associated with organ failure (eg, gastrointestinal bleeding, respiratory failure, or acute kidney injury) in 50% of cases. Because infected pancreatic necrosis is almost always an indication for debridement, fine-needle aspiration of necrotic tissue under CT guidance should be performed (if necessary, repeatedly) for Gram stain and culture.

A serious complication of acute pancreatitis is acute respiratory distress syndrome (ARDS); cardiac dysfunction may be superimposed. It usually occurs 3–7 days after the onset of pancreatitis in patients who have required large volumes of fluid and colloid to maintain blood pressure

and urinary output. Most patients with ARDS require intubation, mechanical ventilation, and supplemental oxygen.

Pancreatic abscess (also referred to as infected or suppurative pseudocyst) is a suppurative process characterized by rising fever, leukocytosis, and localized tenderness and an epigastric mass usually 6 or more weeks into the course of acute pancreatitis. This may be associated with a left-sided pleural effusion or an enlarging spleen secondary to splenic vein thrombosis. In contrast to infected necrosis, the mortality rate is low following drainage.

Pseudocysts, encapsulated fluid collections with high amylase content, commonly appear in pancreatitis when CT is used to monitor the evolution of an acute attack. Pseudocysts that are smaller than 6 cm in diameter often resolve spontaneously. They most commonly are within or adjacent to the pancreas but can present almost anywhere (eg, mediastinal, retrorectal) by extension along anatomic planes. Multiple pseudocysts are seen in 14% of cases. Pseudocysts may become secondarily infected, necessitating drainage as for an abscess. Pancreatic ascites may present after recovery from acute pancreatitis as a gradual increase in abdominal girth and persistent elevation of the serum amylase level in the absence of frank abdominal pain. Marked elevations in ascitic protein (>3 g/dL) and amylase (>1000 units/L [20 mkat/L]) concentrations are typical. The condition results from disruption of the pancreatic duct or drainage of a pseudocyst into the peritoneal cavity.

Rare complications of acute pancreatitis include hemorrhage caused by erosion of a blood vessel to form a pseudoaneurysm and colonic necrosis. Chronic pancreatitis develops in about 10% of cases. Permanent diabetes mellitus and exocrine pancreatic insufficiency occur uncommonly after a single acute episode.

► Treatment

A. Treatment of Acute Disease

1. Mild disease—In most patients, acute pancreatitis is a mild disease (“nonsevere acute pancreatitis”) that subsides spontaneously within several days. The pancreas is “rested” by a regimen of withholding food and liquids by mouth, bed rest, and, in patients with moderately severe pain or ileus and abdominal distention or vomiting, nasogastric suction. Early fluid resuscitation (one-third of the total 72-hour fluid volume administered within 24 hours of presentation) may reduce the frequency of systemic inflammatory response syndrome and organ failure in this group of patients, and lactated Ringer solution may be preferable to normal saline; however, overly aggressive fluid resuscitation may lead to morbidity as well. Pain is controlled with meperidine, up to 100–150 mg intramuscularly every 3–4 hours as necessary. In those with severe liver or kidney dysfunction, the dose may need to be reduced. Morphine has been thought to cause sphincter of Oddi spasm but is now considered an acceptable alternative, and given the potential side effects of meperidine, may even be preferable. Oral intake of fluid and foods can be resumed when the patient is largely free of pain and has bowel sounds (even if the serum amylase is still elevated). Clear liquids are given first (this step may be skipped in patients with

mild acute pancreatitis), followed by gradual advancement to a low-fat diet, guided by the patient's tolerance and by the absence of pain. Pain may recur on refeeding in 20% of patients. Following recovery from acute biliary pancreatitis, laparoscopic cholecystectomy is generally performed, preferably during the same hospital admission, although in selected cases endoscopic sphincterotomy alone may be done. In patients with recurrent pancreatitis associated with pancreas divisum, insertion of a stent in the minor papilla (or minor papilla sphincterotomy) may reduce the frequency of subsequent attacks, although complications of such therapy are frequent. Hypertriglyceridemia with acute pancreatitis has been treated with insulin, heparin, or apheresis, but the benefit of these approaches has not been proven.

2. Severe disease—In more severe pancreatitis—particularly necrotizing pancreatitis—there may be considerable leakage of fluids, necessitating large amounts of intravenous fluids (eg, 500–1000 mL/h for several hours, then 250–300 mL/h) to maintain intravascular volume. Monitoring in an intensive care unit is required, and the importance of aggressive intravenous hydration cannot be overemphasized. Calcium gluconate must be given intravenously if there is evidence of hypocalcemia with tetany. Infusions of fresh frozen plasma or serum albumin may be necessary in patients with coagulopathy or hypoalbuminemia. With colloid solutions, there may be an increased risk of developing ARDS. If shock persists after adequate volume replacement (including packed red cells), pressors may be required. For the patient requiring a large volume of parenteral fluids, central venous pressure and blood gases should be monitored at regular intervals. Parenteral nutrition (including lipids) should be considered in patients who have severe pancreatitis and ileus and will be without oral nutrition for at least 7–10 days. Enteral nutrition via a nasojejunal or possibly nasogastric feeding tube is preferable but may not be tolerated in some patients with an ileus. The routine use of antibiotics to prevent conversion of sterile pancreatic necrosis to infected necrosis is still controversial and is not indicated in those with < 30% pancreatic necrosis. Imipenem (500 mg every 8 hours intravenously) and possibly cefuroxime (1.5 g intravenously three times daily, then 250 mg orally twice daily) administered for no more than 14 days to patients with sterile pancreatic necrosis has been reported in some studies to reduce the risk of pancreatic infection and mortality; meropenem and the combination of ciprofloxacin and metronidazole do not appear to reduce the frequency of infected necrosis, multiorgan failure, or mortality. When infected necrosis is confirmed, imipenem or meropenem should be continued. In occasional cases, a fungal infection is found, and appropriate antifungal therapy should be prescribed. The role of intravenous somatostatin in severe acute pancreatitis is uncertain, and octreotide is thought to have no benefit. To date, probiotic agents have not been shown to reduce infectious complications of severe pancreatitis and may increase mortality. Allopurinol, non-steroidal anti-inflammatory drugs (administered rectally), and ulinastatin, a protease inhibitor, have been reported to reduce the frequency and severity of post-ERCP pancreatitis.

There is conflicting evidence about whether the risk of pancreatitis after ERCP can be reduced by the administration of somatostatin, octreotide, gabexate mesilate and other protease inhibitors, or nitroglycerin. Placement of a stent across the pancreatic duct or orifice has been shown to reduce the risk of post-ERCP pancreatitis and is a common practice.

B. Treatment of Complications and Follow-Up

A surgeon should be consulted in all cases of severe acute pancreatitis. If the diagnosis is in doubt and investigation indicates a strong possibility of a serious surgically correctable lesion (eg, perforated peptic ulcer), exploratory laparotomy is indicated. When acute pancreatitis is found unexpectedly, it is usually wise to close without intervention. If the pancreatitis appears mild and cholelithiasis or microlithiasis is present, cholecystectomy or cholecystostomy may be justified. When severe pancreatitis results from choledocholithiasis and jaundice (serum total bilirubin >5 mg/dL [85.5 μmol/L]) or cholangitis is present, ERCP with endoscopic sphincterotomy and stone extraction is indicated. MRCP may be useful in selecting patients for therapeutic ERCP. Endoscopic sphincterotomy does not appear to improve the outcome of severe pancreatitis in the absence of cholangitis or jaundice.

Necrosectomy may improve survival in patients with necrotizing pancreatitis and clinical deterioration with multiorgan failure or lack of resolution by 4 weeks and is nearly always indicated for infected necrosis. The goal is to debride necrotic pancreas and surrounding tissue and establish adequate drainage. Outcomes are best if necrosectomy is delayed until the necrosis has organized, usually about 4 weeks after disease onset. A “step-up” approach in which nonsurgical drainage of walled-off pancreatic necrosis under radiologic guidance with subsequent open surgical necrosectomy has been shown to reduce mortality and resource utilization in selected patients with necrotizing pancreatitis and confirmed or suspected secondary infection. Endoscopic (transgastric or transduodenal) drainage combined with percutaneous drainage and, in some cases, laparoscopic guidance are additional options, depending on local expertise. Treatment is labor intensive, and multiple procedures are often required. Peritoneal lavage has not been shown to improve survival in severe acute pancreatitis, in part because the risk of late septic complications is not reduced.

The development of a pancreatic abscess is an indication for prompt percutaneous or surgical drainage. Chronic pseudocysts require endoscopic, percutaneous catheter, or surgical drainage when infected or associated with persisting pain, pancreatitis, or bile duct obstruction. For pancreatic infections, imipenem, 500 mg every 8 hours intravenously, is a good choice of antibiotic because it achieves bactericidal levels in pancreatic tissue for most causative organisms. Pancreatic duct leaks and fistulas may require endoscopic or surgical therapy.

► Prognosis

Mortality rates for acute pancreatitis have declined from at least 10% to around 5% since the 1980s, but the mortality

rate for severe acute pancreatitis (more than three Ranson criteria; Table 16–8) remains at least 20%, with rates of 10% and 25% in those with sterile and infected necrosis, respectively. Severe acute pancreatitis is predicted by features of the systemic inflammatory response on admission. Half of the deaths occur within the first 2 weeks, usually from multiorgan failure. Multiorgan failure is associated with a mortality rate of at least 30%, and if it persists beyond the first 48 hours, the mortality rate is over 50%. Later deaths occur because of complications of infected necrosis. The risk of death doubles when both organ failure and infected necrosis are present. Moreover, hospital-acquired infections increase the mortality of acute pancreatitis, independent of severity. Readmission to the hospital for acute pancreatitis within 30 days may be predicted by a scoring system based on five factors during the index admission: eating less than a solid diet at discharge; nausea, vomiting, or diarrhea at discharge; pancreatic necrosis; use of antibiotics at discharge; and pain at discharge. Recurrences are common in alcoholic pancreatitis but can be reduced by repeated, regularly scheduled interventions to eliminate alcohol consumption after discharge from the hospital. The risk of chronic pancreatitis following an episode of acute alcoholic pancreatitis is 13% in 10 years and 16% in 20 years.

▶ When to Admit

Nearly all patients with acute pancreatitis should be hospitalized.

Sadr-Azodi O et al. Cigarette smoking, smoking cessation and acute pancreatitis: a prospective population-based study. *Gut*. 2012 Feb;61(2):262–7. [PMID: 21836026]

Warndorf MG et al. Early fluid resuscitation reduces morbidity among patients with acute pancreatitis. *Clin Gastroenterol Hepatol*. 2011 Aug;9(8):705–9. [PMID: 21554987]

Whitlock TL et al. A scoring system to predict readmission of patients with acute pancreatitis to the hospital within thirty days of discharge. *Clin Gastroenterol Hepatol*. 2011 Feb;9(2):175–80. [PMID: 20832502]

Wu BU et al. Blood urea nitrogen in the early assessment of acute pancreatitis: an international validation study. *Arch Intern Med*. 2011 Apr 11;171(7):669–76. [PMID: 21482842]

Wu BU et al. Lactated Ringer's solution reduces systemic inflammation compared with saline in patients with acute pancreatitis. *Clin Gastroenterol Hepatol*. 2011 Aug;9(8):710–17. [PMID: 21645639]

CHRONIC PANCREATITIS



ESSENTIALS OF DIAGNOSIS

- ▶ Chronic or intermittent epigastric pain, steatorrhea, weight loss, abnormal pancreatic imaging.
- ▶ A mnemonic for the predisposing factors of chronic pancreatitis is TIGAR-O: toxic-metabolic, idiopathic, genetic, autoimmune, recurrent and severe acute pancreatitis, or obstructive.

▶ General Considerations

Chronic pancreatitis occurs most often in patients with alcoholism (45–80% of all cases). The risk of chronic pancreatitis increases with the duration and amount of alcohol consumed, but pancreatitis develops in only 5–10% of heavy drinkers. Tobacco smoking is a risk factor for idiopathic chronic pancreatitis and has been reported to accelerate progression of alcoholic chronic pancreatitis. About 2% of patients with hyperparathyroidism develop pancreatitis. In tropical Africa and Asia, tropical pancreatitis, related in part to malnutrition, is the most common cause of chronic pancreatitis. A stricture, stone, or tumor obstructing the pancreas can lead to obstructive chronic pancreatitis. Autoimmune pancreatitis is associated with hypergammaglobulinemia (IgG₄ in particular) and often with autoantibodies and other autoimmune diseases and is responsive to corticosteroids. Type 1 autoimmune pancreatitis is a multisystem disease characterized by lymphoplasmacytic sclerosing pancreatitis on biopsy, associated bile duct strictures, retroperitoneal fibrosis, renal and salivary gland lesions, and a high rate of relapse after treatment. Type 2 affects the pancreas alone and is characterized by idiopathic duct centric pancreatitis on biopsy, lack of systemic IgG₄ involvement, an association with inflammatory bowel disease, and a lower rate of relapse after treatment. Between 10% and 30% of cases of chronic pancreatitis are idiopathic, with either early onset (median age 23) or late onset (median age 62). Genetic factors may predispose to chronic pancreatitis in some of these cases and include mutations of the cystic fibrosis transmembrane conductance regulator (*CFTR*) gene, the pancreatic secretory trypsin inhibitory gene (*PTSI*, serine protease inhibitor, *SPINK1*), and possibly the gene for uridine 5'-diphosphate glucuronosyltransferase. Mutation of the cationic trypsinogen gene on chromosome 7 (*serine protease 1*, *PRSS1*) is associated with hereditary pancreatitis, transmitted as an autosomal dominant trait with variable penetrance. A useful mnemonic for the predisposing factors to chronic pancreatitis is TIGAR-O: toxic-metabolic, idiopathic, genetic, autoimmune, recurrent and severe acute pancreatitis, or obstructive.

The pathogenesis of chronic pancreatitis may be explained by the SAPE (sentinel acute pancreatitis event) hypothesis by which the first (sentinel) acute pancreatitis event initiates an inflammatory process that results in injury and later fibrosis (“necrosis-fibrosis”). In many cases, chronic pancreatitis is a self-perpetuating disease characterized by chronic pain or recurrent episodes of acute pancreatitis and ultimately by pancreatic exocrine or endocrine insufficiency (sooner in alcoholic pancreatitis than in other types). After many years, chronic pain may resolve spontaneously or as a result of surgery tailored to the cause of pain. Over 80% of adults develop diabetes mellitus within 25 years after the clinical onset of chronic pancreatitis.

▶ Clinical Findings

A. Symptoms and Signs

Persistent or recurrent episodes of epigastric and left upper quadrant pain with referral to the upper left lumbar region

are typical. The pain results in part from impaired inhibitory pain modulation by the central nervous system. Anorexia, nausea, vomiting, constipation, flatulence, and weight loss are common. During attacks tenderness over the pancreas, mild muscle guarding, and ileus may be noted. Attacks may last only a few hours or as long as 2 weeks; pain may eventually be almost continuous. Steatorrhea (as indicated by bulky, foul, fatty stools) may occur late in the course.

B. Laboratory Findings

Serum amylase and lipase may be elevated during acute attacks; however, normal values do not exclude the diagnosis. Serum alkaline phosphatase and bilirubin may be elevated owing to compression of the bile duct. Glycosuria may be present. Excess fecal fat may be demonstrated on chemical analysis of the stool. Pancreatic insufficiency generally is confirmed by response to therapy with pancreatic enzyme supplements; the secretin stimulation test can be used if available, as can detection of decreased fecal chymotrypsin or elastase levels, although the latter tests lack sensitivity and specificity. Vitamin B₁₂ malabsorption is detectable in about 40% of patients, but clinical deficiency of vitamin B₁₂ and fat-soluble vitamins is rare. Accurate diagnostic tests are available for the major trypsinogen gene mutations, but because of uncertainty about the mechanisms linking heterozygous *CFTR* and *PSTI* mutations with pancreatitis, genetic testing for mutations in these two genes is not currently recommended. Elevated IgG₄ levels, ANA, and antibodies to lactoferrin and carbonic anhydrase II are often found in patients with autoimmune pancreatitis (especially type 1); antibodies to peptide AIP₁₋₇ and to ubiquitin-protein ligase E3 component n-recogin 2 have been reported in a high percentage of patients with autoimmune pancreatitis but also in some patients with pancreatic cancer. Pancreatic biopsy, if necessary, shows a lymphoplasmacytic inflammatory infiltrate with characteristic IgG₄ immunostaining, which is also found in biopsy specimens of the major papilla, bile duct, and salivary glands, in type 1 autoimmune pancreatitis.

C. Imaging

Plain films show calcifications due to pancreaticolithiasis in 30% of affected patients. CT may show calcifications not seen on plain films as well as ductal dilatation and heterogeneity or atrophy of the gland. Occasionally, the findings raise suspicion of pancreatic cancer (“tumefactive chronic pancreatitis”). ERCP is the most sensitive imaging study for chronic pancreatitis and may show dilated ducts, intraductal stones, strictures, or pseudocyst, but the results may be normal in patients with so-called minimal change pancreatitis. MRCP (including secretin-enhanced MRCP) and endoscopic ultrasonography (with pancreatic tissue sampling) are less invasive alternatives to ERCP. Endoscopic ultrasonographic (“Rosemont”) criteria for the diagnosis of chronic pancreatitis include hyperechoic foci with shadowing indicative of calculi in the main pancreatic duct and lobularity with honeycombing of the pancreatic parenchyma. Characteristic imaging features of autoimmune

pancreatitis include diffuse enlargement of the pancreas, a peripheral rim of hypoattenuation, and irregular narrowing of the main pancreatic duct. In the United States, the diagnosis of autoimmune pancreatitis is based on the HISORt criteria: histology, imaging, serology, other organ involvement, and response to corticosteroid therapy.

► Complications

Opioid addiction is common. Other frequent complications include often brittle diabetes mellitus, pancreatic pseudocyst or abscess, cholestatic liver enzymes with or without jaundice, bile duct stricture, steatorrhea, malnutrition, and peptic ulcer. Pancreatic cancer develops in 4% of patients after 20 years; the risk may relate to tobacco and alcohol use. In patients with hereditary pancreatitis, the risk of pancreatic cancer rises after age 50 years and reaches 19% by age 70 years (see Chapter 39).

► Treatment

Correctable coexistent biliary tract disease should be treated surgically.

A. Medical Measures

A low-fat diet should be prescribed. Alcohol is forbidden because it frequently precipitates attacks. Opioids should be avoided if possible. Preferred agents for pain are acetaminophen, nonsteroidal anti-inflammatory drugs, and tramadol, along with pain-modifying agents such as tricyclic antidepressants, selective serotonin uptake inhibitors, and gabapentin or pregabalin. Steatorrhea is treated with pancreatic supplements that are selected on the basis of their high lipase activity. A total dose of 40,000 units of lipase in capsules is given with meals. Higher doses may be required in some cases. The tablets should be taken at the start of, during, and at the end of a meal. Concurrent administration of a H₂-receptor antagonist (eg, ranitidine, 150 mg orally twice daily), a proton pump inhibitor (eg, omeprazole, 20–60 mg orally daily), or sodium bicarbonate, 650 mg orally before and after meals, decreases the inactivation of lipase by acid and may thereby further decrease steatorrhea. In selected cases of alcoholic pancreatitis and in cystic fibrosis, enteric-coated microencapsulated preparations may offer an advantage. However, in patients with cystic fibrosis, high-dose pancreatic enzyme therapy has been associated with strictures of the ascending colon. Pain secondary to idiopathic chronic pancreatitis may be alleviated in some cases by the use of pancreatic enzymes (not enteric-coated) or octreotide, 200 mcg subcutaneously three times daily. Micronutrient therapy to correct electrophilic stress on key macromolecules in the pancreas by toxic metabolites has shown promise in early studies. Associated diabetes mellitus should be treated (see Chapter 27). Autoimmune pancreatitis is treated with prednisone 40 mg/d orally for 1–2 months, followed by a taper of 5 mg every 2–4 weeks. Nonresponse or relapse occurs in 45% of cases (particularly in those with concomitant IgG₄-associated cholangitis); azathioprine appears to reduce the risk of relapse. Other immunosuppressive therapies are under study.

B. Surgical and Endoscopic Treatment

Endoscopic therapy or surgery may be indicated in chronic pancreatitis to treat underlying biliary tract disease, ensure free flow of bile into the duodenum, drain persistent pseudocysts, treat other complications, eliminate obstruction of the pancreatic duct, attempt to relieve pain, or exclude pancreatic cancer. Liver fibrosis may regress after biliary drainage. Distal bile duct obstruction may be relieved by endoscopic placement of multiple bile duct stents. When obstruction of the duodenal end of the pancreatic duct can be demonstrated by ERCP, dilation of or placement of a stent in the duct and pancreatic duct stone lithotripsy or resection of the tail of the pancreas with implantation of the distal end of the duct by pancreaticojejunostomy may be performed. Many patients treated endoscopically eventually require surgery. When the pancreatic duct is diffusely dilated, anastomosis between the duct after it is split longitudinally and a defunctionalized limb of jejunum (modified Puestow procedure), in some cases combined with resection of the head of the pancreas (Beger or Frey procedure), is associated with relief of pain in 80% of cases. In advanced cases, subtotal or total pancreatectomy may be considered as a last resort but has variable efficacy and causes pancreatic insufficiency and diabetes mellitus. Perioperative administration of somatostatin or octreotide may reduce the risk of postoperative pancreatic fistulas. Endoscopic or surgical (including laparoscopic) drainage is indicated for symptomatic pseudocysts and, in many cases, those over 6 cm in diameter. Endoscopic ultrasonography may facilitate selection of an optimal site for endoscopic drainage. Pancreatic ascites or pancreaticopleural fistulas due to a disrupted pancreatic duct can be managed by endoscopic placement of a stent across the disrupted duct. Pancreatic sphincterotomy or fragmentation of stones in the pancreatic duct by lithotripsy and endoscopic removal of stones from the duct may relieve pain in selected patients. For patients with chronic pain and nondilated ducts, a percutaneous celiac plexus nerve block may be considered under either CT or endoscopic ultrasound guidance, with pain relief (albeit often short-lived) in approximately 50% of patients. A single session of radiotherapy to the pancreas has been reported to relieve otherwise refractory pain.

► Prognosis

Chronic pancreatitis often leads to disability. The prognosis is best in patients with recurrent acute pancreatitis caused by a remediable condition, such as cholelithiasis, choledocholithiasis, stenosis of the sphincter of Oddi, or hyperparathyroidism, and in those with autoimmune pancreatitis. Medical management of hyperlipidemia, if present, may also prevent recurrent attacks of pancreatitis. In alcoholic pancreatitis, pain relief is most likely when a dilated pancreatic duct can be decompressed. In patients with disease not amenable to decompressive surgery, addiction to opioids is a frequent outcome of treatment. The quality of life is poorer in patients with constant pain than in those with intermittent pain.

► When to Refer

All patients with chronic pancreatitis should be referred for diagnostic and therapeutic procedures.

► When to Admit

- Severe pain.
- New jaundice.
- New fever.

Braganza JM et al. Chronic pancreatitis. *Lancet*. 2011 Apr 2; 377(9772):1184–97. [PMID: 21397320]
Coté GA et al; North American Pancreatitis Study Group. Alcohol and smoking as risk factors in an epidemiology study of patients with chronic pancreatitis. *Clin Gastroenterol Hepatol*. 2011 Mar;9(3):266–73. [PMID: 21029787]
Dominguez-Muñoz JE. Chronic pancreatitis and persistent steatorrhea: what is the correct dose of enzymes? *Clin Gastroenterol Hepatol*. 2011 Jul;9(7):541–6. [PMID: 21377551]
Gubergrits N et al. A 6-month, open-label clinical trial of pancrelipase delayed-release capsules (Creon) in patients with exocrine pancreatic insufficiency due to chronic pancreatitis or pancreatic surgery. *Aliment Pharmacol Ther*. 2011 May;33(10):1152–61. [PMID: 21418260]
Maire F et al. Outcome of patients with type 1 or 2 autoimmune pancreatitis. *Am J Gastroenterol*. 2011 Jan;106(1):151–6. [PMID: 20736934]

17

Breast Disorders

Armando E. Giuliano, MD

Sara A. Hurvitz, MD

BENIGN BREAST DISORDERS

FIBROCYSTIC CONDITION

ESSENTIALS OF DIAGNOSIS

- ▶ Painful, often multiple, usually bilateral masses in the breast.
- ▶ Rapid fluctuation in the size of the masses is common.
- ▶ Frequently, pain occurs or worsens and size increases during premenstrual phase of cycle.
- ▶ Most common age is 30–50. Rare in postmenopausal women not receiving hormonal replacement.

▶ General Considerations

Fibrocystic condition is the most frequent lesion of the breast. Although commonly referred to as “fibrocystic disease,” it does not, in fact, represent a pathologic or anatomic disorder. It is common in women 30–50 years of age but rare in postmenopausal women who are not taking hormonal replacement. Estrogen is considered a causative factor. There may be an increased risk in women who drink alcohol, especially women between 18 and 22 years of age. Fibrocystic condition encompasses a wide variety of benign histologic changes in the breast epithelium, some of which are found so commonly in normal breasts that they are probably variants of normal but have nonetheless been termed a “condition” or “disease.”

The microscopic findings of fibrocystic condition include cysts (gross and microscopic), papillomatosis, adenosis, fibrosis, and ductal epithelial hyperplasia. Although fibrocystic condition has generally been considered to increase the risk of subsequent breast cancer, only the variants with a component of epithelial proliferation (especially with atypia) or increased breast density on mammogram represent true risk factors.

▶ Clinical Findings

A. Symptoms and Signs

Fibrocystic condition may produce an asymptomatic mass in the breast that is discovered by accident, but pain or tenderness often calls attention to it. Discomfort often occurs or worsens during the premenstrual phase of the cycle, at which time the cysts tend to enlarge. Fluctuations in size and rapid appearance or disappearance of a breast mass are common with this condition as are multiple or bilateral masses and serous nipple discharge. Patients will give a history of a transient lump in the breast or cyclic breast pain.

B. Diagnostic Tests

Mammography and ultrasonography should be used to evaluate a mass in a patient with fibrocystic condition. Ultrasonography alone may be used in women under 30 years of age. Because a mass due to fibrocystic condition is difficult to distinguish from carcinoma on the basis of clinical findings, suspicious lesions should be biopsied. Fine-needle aspiration (FNA) cytology may be used, but if a suspicious mass that is nonmalignant on cytologic examination does not resolve over several months, it should be excised or biopsied by core needle. Surgery should be conservative, since the primary objective is to exclude cancer. Occasionally, FNA cytology will suffice. Simple mastectomy or extensive removal of breast tissue is rarely, if ever, indicated for fibrocystic condition.

▶ Differential Diagnosis

Pain, fluctuation in size, and multiplicity of lesions are the features most helpful in differentiating fibrocystic condition from carcinoma. If a dominant mass is present, the diagnosis of cancer should be assumed until disproven by biopsy. Mammography may be helpful, but the breast tissue in these young women is usually too radiodense to permit a worthwhile study. Sonography is useful in differentiating a cystic mass from a solid mass, especially in women with dense breasts. Final diagnosis, however, depends on analysis of the excisional biopsy specimen or needle biopsy.

► Treatment

When the diagnosis of fibrocystic condition has been established by previous biopsy or is likely because the history is classic, aspiration of a discrete mass suggestive of a cyst is indicated to alleviate pain and, more importantly, to confirm the cystic nature of the mass. The patient is reexamined at intervals thereafter. If no fluid is obtained by aspiration, if fluid is bloody, if a mass persists after aspiration, or if at any time during follow-up a persistent or recurrent mass is noted, biopsy should be performed.

Breast pain associated with generalized fibrocystic condition is best treated by avoiding trauma and by wearing a good supportive brassiere during the night and day. Hormone therapy is not advisable, because it does not cure the condition and has undesirable side effects. Danazol (100–200 mg orally twice daily), a synthetic androgen, is the only treatment approved by the US Food and Drug Administration (FDA) for patients with severe pain. This treatment suppresses pituitary gonadotropins, but androgenic effects (acne, edema, hirsutism) usually make this treatment intolerable; in practice, it is rarely used. Similarly, tamoxifen reduces some symptoms of fibrocystic condition, but because of its side effects, it is not useful for young women unless it is given to reduce the risk of cancer. Postmenopausal women receiving hormone replacement therapy may stop or change doses of hormones to reduce pain. Oil of evening primrose (OEP), a natural form of gamolenic acid, has been shown to decrease pain in 44–58% of users. The dosage of gamolenic acid is six capsules of 500 mg orally twice daily. Studies have also demonstrated a low-fat diet or decreasing dietary fat intake may reduce the painful symptoms associated with fibrocystic condition. Further research is being done to determine the effects of topical treatments such as topical nonsteroidal anti-inflammatory drugs as well as topical hormonal drugs such as topical tamoxifen.

The role of caffeine consumption in the development and treatment of fibrocystic condition is controversial. Some studies suggest that eliminating caffeine from the diet is associated with improvement while other studies refute the benefit entirely. Many patients are aware of these studies and report relief of symptoms after giving up coffee, tea, and chocolate. Similarly, many women find vitamin E (400 international units daily) helpful; however, these observations remain anecdotal.

► Prognosis

Exacerbations of pain, tenderness, and cyst formation may occur at any time until menopause, when symptoms usually subside, except in patients receiving hormonal replacement. The patient should be advised to examine her own breasts regularly just after menstruation and to inform her practitioner if a mass appears. The risk of breast cancer developing in women with fibrocystic condition with a proliferative or atypical component in the epithelium is higher than that of the general population. These women should be monitored carefully with physical examinations and imaging studies.

Huff JG. The sonographic findings and differing clinical implications of simple, complicated, and complex breast cysts. *J Natl Compr Canc Netw*. 2009 Nov;7(10):1101–4. [PMID: 19930976]
 Kabat GC et al. A multi-center prospective cohort study of benign breast disease and risk of subsequent breast cancer. *Cancer Causes Control*. 2010 Jun;21(6):821–8. [PMID: 20084540]
 Pruthi S et al. Vitamin E and evening primrose oil for management of cyclical mastalgia: a randomized pilot study. *Altern Med Rev*. 2010 Apr;15(1):59–67. [PMID: 20359269]
 Rodden AM. Common breast concerns. *Prim Care*. 2009 Mar;36(1):103–13. [PMID: 19231604]

FIBROADENOMA OF THE BREAST

This common benign neoplasm occurs most frequently in young women, usually within 20 years after puberty. It is somewhat more frequent and tends to occur at an earlier age in black women. Multiple tumors are found in 10–15% of patients.

The typical **fibroadenoma** is a round or ovoid, rubbery, discrete, relatively movable, nontender mass 1–5 cm in diameter. It is usually discovered accidentally. Clinical diagnosis in young patients is generally not difficult. In women over 30 years, fibrocystic condition of the breast and carcinoma of the breast must be considered. Cysts can be identified by aspiration or ultrasonography. Fibroadenoma does not normally occur after menopause but may occasionally develop after administration of hormones.

No treatment is usually necessary if the diagnosis can be made by needle biopsy or cytologic examination. Excision with pathologic examination of the specimen is performed if the diagnosis is uncertain. In a 2005 study, cryoablation, or freezing of the fibroadenoma, appears to be a safe procedure if the lesion is consistent with fibroadenoma on histology prior to ablation. Cryoablation is not appropriate for all fibroadenomas because some are too large to freeze or the diagnosis may not be certain. There is no obvious advantage to cryoablation of a histologically proven fibroadenoma except that some patients may feel relief that a mass is gone. Reassurance seems preferable. It is usually not possible to distinguish a large fibroadenoma from a phyllodes tumor on the basis of needle biopsy results or imaging alone.

Phyllodes tumor is a fibroadenoma-like tumor with cellular stroma that grows rapidly. It may reach a large size and, if inadequately excised, will recur locally. The lesion can be benign or malignant. If benign, phyllodes tumor is treated by local excision with a margin of surrounding breast tissue. The treatment of malignant phyllodes tumor is more controversial, but complete removal of the tumor with a rim of normal tissue avoids recurrence. Because these tumors may be large, simple mastectomy is sometimes necessary. Lymph node dissection is not performed, since the sarcomatous portion of the tumor metastasizes to the lungs and not the lymph nodes.

El Hag IA et al. Cytological clues in the distinction between phyllodes tumor and fibroadenoma. *Cancer Cytopathol*. 2010 Feb 25;118(1):33–40. [PMID: 20094997]
 Jayasinghe Y et al. Fibroadenomas in adolescence. *Curr Opin Obstet Gynecol*. 2009 Oct;21(5):402–6. [PMID: 19606032]

Tse GM et al. Phyllodes tumor of the breast: an update. *Breast Cancer*. 2010;17(1):29–34. [PMID: 19434472]

NIPPLE DISCHARGE

In order of decreasing frequency, the following are the most common causes of nipple discharge in the nonlactating breast: duct ectasia, intraductal papilloma, and carcinoma. The important characteristics of the discharge and some other factors to be evaluated by history and physical examination are listed in Table 17–1.

Spontaneous, unilateral, serous or serosanguineous discharge from a single duct is usually caused by an intraductal papilloma or, rarely, by an intraductal cancer. A mass may not be palpable. The involved duct may be identified by pressure at different sites around the nipple at the margin of the areola. Bloody discharge is suggestive of cancer but is more often caused by a benign papilloma in the duct. Cytologic examination may identify malignant cells, but negative findings do not rule out cancer, which is more likely in women over age 50 years. In any case, the involved bloody duct—and a mass if present—should be excised. A ductogram (a mammogram of a duct after radiopaque dye has been injected) is of limited value since excision of the suspicious ductal system is indicated

Table 17–1. Characteristics of nipple discharge in the nonpregnant, nonlactating woman.

Finding	Significance
Serous	Most likely benign FCC, ie, duct ectasia
Bloody	More likely neoplastic—papilloma, carcinoma
Associated mass	More likely neoplastic
Unilateral	Either neoplastic or non-neoplastic
Bilateral	Most likely non-neoplastic
Single duct	More likely neoplastic
Multiple ducts	More likely FCC
Milky	Endocrine disorders, medications
Spontaneous	Either neoplastic or non-neoplastic
Produced by pressure at single site	Either neoplastic or non-neoplastic
Persistent	Either neoplastic or non-neoplastic
Intermittent	Either neoplastic or non-neoplastic
Related to menses	More likely FCC
Premenopausal	More likely FCC
Taking hormones	More likely FCC

FCC, fibrocystic condition.

regardless of findings. Ductoscopy, evaluation of the ductal system with a small scope inserted through the nipple, has been attempted but is not effective management.

In premenopausal women, spontaneous multiple duct discharge, unilateral or bilateral, most noticeable just before menstruation, is often due to fibrocystic condition. Discharge may be green or brownish. Papillomatosis and ductal ectasia are usually detected only by biopsy. If a mass is present, it should be removed.

A milky discharge from multiple ducts in the nonlactating breast may occur from hyperprolactinemia. Serum prolactin levels should be obtained to search for a pituitary tumor. Thyroid-stimulating hormone (TSH) helps exclude causative hypothyroidism. Numerous antipsychotic drugs and other drugs may also cause a milky discharge that ceases on discontinuance of the medication.

Oral contraceptive agents or estrogen replacement therapy may cause clear, serous, or milky discharge from a single duct, but multiple duct discharge is more common. In the premenopausal woman, the discharge is more evident just before menstruation and disappears on stopping the medication. If it does not stop, is from a single duct, and is copious, exploration should be performed since this may be a sign of cancer.

A purulent discharge may originate in a subareolar abscess and require removal of the abscess and the related lactiferous sinus.

When localization is not possible, no mass is palpable, and the discharge is nonbloody, the patient should be reexamined every 3 or 4 months for a year, and a mammogram and an ultrasound should be performed. Although most discharge is from a benign process, patients may find it annoying or disconcerting. Cytologic examination of the nipple discharge for exfoliated cancer cells is rarely helpful in determining a diagnosis. To eliminate the discharge, proximal duct excision can be performed both for treatment and diagnosis.

Chen L et al. Bloody nipple discharge is a predictor of breast cancer risk: a meta-analysis. *Breast Cancer Res Treat*. 2012 Feb;132(1):9–14 [PMID: 21947751]

Kamali S et al. Ductoscopy in the evaluation and management of nipple discharge. *Ann Surg Oncol*. 2010 Mar;17(3):778–83. [PMID: 20012502]

Montroni I et al. Nipple discharge: is its significance as a risk factor for breast cancer fully understood? Observational study including 915 consecutive patients who underwent selective duct excision. *Breast Cancer Res Treat*. 2010 Oct;123(3):895–900. [PMID: 20354781]

Morrogh M et al. Lessons learned from 416 cases of nipple discharge of the breast. *Am J Surg*. 2010 Jul;200(1):73–80. [PMID: 20079481]

Zervoudis S et al. Nipple discharge screening. *Womens Health (Lond Engl)*. 2010 Jan;6(1):135–51. [PMID: 20050819]

FAT NECROSIS

Fat necrosis is a rare lesion of the breast but is of clinical importance because it produces a mass (often accompanied by skin or nipple retraction) that is usually indistinguishable from carcinoma even with imaging studies.

Trauma is presumed to be the cause, though only about 50% of patients give a history of injury. Ecchymosis is occasionally present. If untreated, the mass effect gradually disappears. The safest course is to obtain a biopsy. Needle biopsy is often adequate, but frequently the entire mass must be excised, primarily to exclude carcinoma. Fat necrosis is common after segmental resection, radiation therapy, or flap reconstruction after mastectomy.

BREAST ABSCESS

During nursing, an area of redness, tenderness, and induration may develop in the breast. The organism most commonly found in these abscesses is *Staphylococcus aureus* (see Puerperal Mastitis, Chapter 19).

Infection in the nonlactating breast is rare. A subareolar abscess may develop in young or middle-aged women who are not lactating (Figure 17-1). These infections tend to recur after incision and drainage unless the area is explored during a quiescent interval, with excision of the involved lactiferous duct or ducts at the base of the nipple. In the nonlactating breast, inflammatory carcinoma must always be considered. Thus, incision and biopsy of any indurated tissue with a small piece of erythematous skin is indicated when suspected abscess or cellulitis in the nonlactating breast does not resolve promptly with antibiotics. Often needle or catheter drainage is adequate to treat an abscess, but surgical incision and drainage may be necessary.

Bharat A et al. Predictors of primary breast abscesses and recurrence. *World J Surg.* 2009 Dec;33(12):2582-6. [PMID: 19669231]

Rizzo M et al. Management of breast abscesses in nonlactating women. *Am Surg.* 2010 Mar;76(3):292-5. [PMID: 20349659]



▲ **Figure 17-1.** Breast abscess and cellulitis. (Courtesy of Richard P. Usatine, MD; used, with permission, from Usatine RP, Smith MA, Mayeaux EJ Jr, Chumley H, Tysinger J. *The Color Atlas of Family Medicine.* McGraw-Hill, 2009.)

DISORDERS OF THE AUGMENTED BREAST

At least 4 million American women have had breast implants. Breast augmentation is performed by placing implants under the pectoralis muscle or, less desirably, in the subcutaneous tissue of the breast. Most implants are made of an outer silicone shell filled with a silicone gel, saline, or some combination of the two. Capsule contraction or scarring around the implant develops in about 15–25% of patients, leading to a firmness and distortion of the breast that can be painful. Some require removal of the implant and surrounding capsule. In 2006, the FDA reapproved silicone implants for augmentation cosmetic surgery.

Implant rupture may occur in as many as 5–10% of women, and bleeding of gel through the capsule is noted even more commonly. Although silicone gel may be an immunologic stimulant, there is no increase in autoimmune disorders in patients with such implants. The FDA has advised symptomatic women with ruptured silicone implants to discuss possible surgical removal with their clinicians. However, women who are asymptomatic and have no evidence of rupture of a silicone gel prosthesis should probably not undergo removal of the implant. Women with symptoms of autoimmune illnesses often undergo removal, but no benefit has been shown.

Studies have failed to show any association between implants and an increased incidence of breast cancer. However, breast cancer may develop in a patient with an augmentation prosthesis, as it does in women without them. Detection in patients with implants is more difficult because mammography is less able to detect early lesions. Mammography is better if the implant is subpectoral rather than subcutaneous. The prosthesis should be placed retropectorally after mastectomy to facilitate detection of a local recurrence of cancer, which is usually cutaneous or subcutaneous and is easily detected by palpation.

If a cancer develops in a patient with implants, it should be treated in the same manner as in women without implants. Such women should be offered the option of mastectomy or breast-conserving therapy, which may require removal or replacement of the implant. Radiotherapy of the augmented breast often results in marked capsular contracture. Adjuvant treatments should be given for the same indications as for women who have no implants.

Araco A et al. Capsular contractures: a systematic review. *Plast Reconstr Surg.* 2009 Dec;124(6):1808-19. [PMID: 19952637]

Spear SL et al. History of breast implants and the food and drug administration. *Clin Plast Surg.* 2009 Jan;36(1):15-21. [PMID: 19055957]

Yang N et al. The augmented breast: a pictorial review of the abnormal and unusual. *AJR Am J Roentgenol.* 2011 Apr;196(4):W451-60. [PMID: 21427311]

Zakhireh J et al. Application of screening principles to the reconstructed breast. *J Clin Oncol.* 2010 Jan 1;28(1):173-80. [PMID: 19884555]

CARCINOMA OF THE FEMALE BREAST

ESSENTIALS OF DIAGNOSIS

- ▶ Most women with breast cancer do not have identifiable risk factors.
- ▶ Risk factors include delayed childbearing, positive family history of breast cancer or genetic mutations (*BRCA1*, *BRCA2*), and personal history of breast cancer or some types of proliferative conditions.
- ▶ **Early findings:** Single, nontender, firm to hard mass with ill-defined margins; mammographic abnormalities and no palpable mass.
- ▶ **Later findings:** Skin or nipple retraction; axillary lymphadenopathy; breast enlargement, erythema, edema, pain; fixation of mass to skin or chest wall.

▶ Incidence & Risk Factors

Breast cancer will develop in one of eight American women. Next to skin cancer, breast cancer is the most common cancer in women; it is second only to lung cancer as a cause of death. In 2011, there were approximately 230,480 new cases and 39,520 deaths from breast cancer in women in the United States. An additional 57,650 cases of breast carcinoma in situ were detected, principally by screening mammography. Worldwide, breast cancer is diagnosed in approximately 1.38 million women, and about 458,000 die of breast cancer each year, with the highest rates of diagnosis in Western and Northern Europe, Australia, New Zealand, and North America and lowest rates in Sub-Saharan Africa and Asia. These regional differences in incidence are likely due to the variable availability of screening mammography as well as differences in reproductive and hormonal factors. In western countries, incidence rates decreased with a reduced use of postmenopausal hormone therapy and mortality declined with increased use of screening and improved treatments. In contrast, incidence and mortality from breast cancer in many African and Asian countries has increased as reproductive factors have changed (such as delayed childbearing) and as the incidence of obesity has risen.

The most significant risk factor for the development of breast cancer is age. A woman's risk of breast cancer rises rapidly until her early 60s, peaks in her 70s, and then declines. A significant family history of breast or ovarian cancer may also indicate a high risk of developing breast cancer. Germline mutations in the *BRCA* family of tumor suppressor genes accounts for approximately 5–10% of breast cancer diagnoses and tend to cluster in certain ethnic groups, including women of Ashkenazi Jewish descent. Women with a mutation in the *BRCA1* gene, located on chromosome 17, have an estimated 85% chance of developing breast cancer in their lifetime. Other genes associated with an increased risk of breast and other cancers include *BRCA2* (associated with a gene on chromosome 13);

ataxia-telangiectasia mutation; and mutation of the tumor suppressor gene *p53*. If a woman has a compelling family history (such as breast cancer diagnosed in two first-degree relatives, especially if diagnosed younger than age 50; ovarian cancer; male breast cancer; or a first-degree relative with bilateral breast cancer), genetic testing may be appropriate. In general, it is best for a woman who has a strong family history to meet with a genetics counselor to undergo a risk assessment and decide whether genetic testing is indicated.

Even when genetic testing fails to reveal a predisposing genetic mutation, women with a strong family history of breast cancer are at higher risk for development of breast cancer. Compared with a woman with no affected family members, a woman who has one first-degree relative (mother, daughter, or sister) with breast cancer has double the risk of developing breast cancer and a woman with two first-degree relatives with breast cancer has triple the risk of developing breast cancer. The risk is further increased for a woman whose affected family member was premenopausal at the time of diagnosis or had bilateral breast cancer. Lifestyle and reproductive factors also contribute to risk of breast cancer. Nulliparous women and women whose first full-term pregnancy occurred after the age of 30 have an elevated risk. Late menarche and artificial menopause are associated with a lower incidence, whereas early menarche (under age 12) and late natural menopause (after age 55) are associated with an increase in risk. Combined oral contraceptive pills may increase the risk of breast cancer. Several studies show that concomitant administration of progesterone and estrogen to postmenopausal women may markedly increase the incidence of breast cancer, compared with the use of estrogen alone or with no hormone replacement treatment. The Women's Health Initiative prospective randomized study of hormone replacement therapy stopped treatment with estrogen and progesterone early because of an increased risk of breast cancer compared with untreated women or women treated with estrogen alone. Alcohol consumption, high dietary intake of fat, and lack of exercise may also increase the risk of breast cancer. Fibrocystic breast condition, when accompanied by proliferative changes, papillomatosis, or atypical epithelial hyperplasia, and increased breast density on mammogram are also associated with an increased incidence. A woman who had cancer in one breast is at increased risk for cancer developing in the other breast. In these women, a contralateral cancer develops at the rate of 1% or 2% per year. Women with cancer of the uterine corpus have a risk of breast cancer significantly higher than that of the general population, and women with breast cancer have a comparably increased risk of endometrial cancer. Socioeconomic factors have also been associated with breast cancer risk. Breast cancer tends to be diagnosed more frequently in women of higher socioeconomic status and is more frequent in white women than in black women.

Women at greater than average risk for developing breast cancer (Table 17–2) should be identified by their practitioners and monitored carefully. Risk assessment models have been developed and several have been validated (most extensively the Gail 2 model) to evaluate a

Table 17-2. Factors associated with increased risk of breast cancer.

Race	White
Age	Older
Family history	Breast cancer in mother, sister, or daughter (especially bilateral or premenopausal)
Genetics	<i>BRCA1</i> or <i>BRCA2</i> mutation
Previous medical history	Endometrial cancer Proliferative forms of fibrocystic disease Cancer in other breast
Menstrual history	Early menarche (under age 12) Late menopause (after age 50)
Reproductive history	Nulliparous or late first pregnancy

woman's risk of developing cancer. Those with an exceptional family history should be counseled about the option of genetic testing. Some of these high-risk women may consider prophylactic mastectomy, oophorectomy, or tamoxifen, an FDA-approved preventive agent. The Prevention and Observation of Surgical Endpoints (PROSE) consortium monitored women with deleterious *BRCA1/2* mutations from 1974 to 2008 and reported that 15% of women with a known *BRCA* mutation underwent bilateral prophylactic mastectomy, and none of them developed breast cancer during the 3 years of follow-up. In contrast, subsequent breast cancer developed in 98 (7%) of the 1372 women who did not have surgery. Moreover, women who underwent prophylactic salpingo-oophorectomy had a lower risk of ovarian cancer, all-cause mortality, as well as breast cancer- and ovarian cancer-specific mortality.

Women with genetic mutations in whom breast cancer develops may be treated in the same way as women who do not have mutations (ie, lumpectomy), though there is an increased risk of ipsilateral and contralateral recurrence after lumpectomy for these women. One study showed that of patients with a diagnosis of breast cancer who were found to be carriers of a *BRCA* mutation, approximately 50% chose to undergo bilateral mastectomy.

► Prevention

The National Surgical Adjuvant Breast Project (NSABP) conducted the first Breast Cancer Prevention Trial (BCPT) P-1, which evaluated tamoxifen, a selective estrogen receptor modulator (SERM), as a preventive agent in women with no personal history of breast cancer but at high risk for developing the disease. Women who received tamoxifen for 5 years had about a 50% reduction in noninvasive and invasive cancers compared with women taking placebo. However, women over age 50 who received the drug had an increased incidence of endometrial cancer and deep venous thrombosis.

The SERM raloxifene, effective in preventing osteoporosis, is also effective in preventing breast cancer. The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial compared raloxifene with tamoxifen for the prevention

of breast cancer in a high-risk population. With a median follow-up of 81 months, raloxifene was associated with a higher risk of invasive breast cancer RR raloxifene:tamoxifen 1.24 (95% confidence interval [CI], 1.05–1.47; $P = 0.01$) but had an equivalent risk for noninvasive disease 1.22 (95% CI, 0.95–1.59; $P = 0.12$) compared with tamoxifen. Uterine cancer, cataracts, and thromboembolic events were significantly lower in the raloxifene-treated patients than in tamoxifen-treated patients. While SERMs have been shown to be effective at reducing the risk of breast cancer, the uptake of this intervention by women has been relatively low, possibly due to the perceived risks and side effects of therapy. A cost-effectiveness study based on a meta-analysis of four randomized prevention trials showed that tamoxifen saves costs and improves life expectancy when higher risk (Gail 5-year risk at least 1.66%) women under the age of 55 years were treated.

Similar to SERMs, aromatase inhibitors (AI) have shown great success in preventing breast cancer with a lower risk of uterine cancer and thromboembolic events, although bone loss is a significant side effect of this treatment. In an international phase III clinical trial, 4560 postmenopausal women at high risk for breast cancer were randomly assigned to receive exemestane or placebo for 5 years. "High risk" was defined as at least one of the following: at least 60 years of age, Gail 5-year risk score > 1.66%; prior atypical ductal or lobular hyperplasia or lobular carcinoma in situ (LCIS); or ductal carcinoma in situ (DCIS) with mastectomy. With a median follow up of 35 months, there was a 65% relative risk reduction in the annual risk of invasive breast cancer (0.19% vs 0.55%; hazard ratio, 0.35; 95% CI, 0.18, 0.70; $P = 0.002$) for patients who received exemestane. While exemestane use was associated with a higher rate of adverse events (88% vs. 85%; $P = 0.003$), there were no significant differences between the groups in terms of skeletal fractures or cardiovascular events, though longer follow up is needed to accurately assess these outcomes. Based on these data, exemestane is a reasonable risk-reducing option for postmenopausal women at higher risk for breast cancer.

American College of Obstetricians and Gynecologists; ACOG Committee on Practice Bulletins—Gynecology; ACOG Committee on Genetics; Society of Gynecologic Oncologists. ACOG Practice Bulletin No. 103: Hereditary breast and ovarian cancer syndrome. *Obstet Gynecol.* 2009 Apr;113(4):957–66. [PMID: 19305347]

Amir E et al. Assessing women at high risk of breast cancer: a review of risk assessment models. *Natl Cancer Inst.* 2010 May 19;102(10):680–91. [PMID: 20427433]

Arun B et al. Breast cancer prevention trials: large and small trials. *Semin Oncol.* 2010 Aug;37(4):367–83. [PMID: 20816507]

Campeau PM et al. Hereditary breast cancer: new genetic developments, new therapeutic avenues. *Hum Genet.* 2008 Aug;124(1): 31–42. [PMID: 18575892]

Cummings SR et al. Prevention of breast cancer in postmenopausal women: approaches to estimating and reducing risk. *J Natl Cancer Inst.* 2009 Mar 18;101(6):384–98. [PMID: 19276457]

DeSantis C et al. Breast Cancer Statistics, 2011. *CA Cancer J Clin.* 2011 Nov–Dec;61(6):409–18. [PMID: 21969133]

Domchek SM et al. Association of risk-reducing surgery in *BRCA1* or *BRCA2* mutation carriers with cancer risk and mortality. *JAMA.* 2010 Sep 1;304(9):967–75. [PMID: 20810374]

- Goss PE et al; CTG MAP.3 Study Investigators. Exemestane for breast-cancer prevention in postmenopausal women. *N Engl J Med*. 2011 Jun 23;364(25):2381–91. [PMID: 21639806]
- Graeser MK et al. Contralateral breast cancer risk in *BRCA1* and *BRCA2* mutation carriers. *J Clin Oncol*. 2009 Dec 10;27(35):5887–92. [PMID: 19858402]
- Jemal A et al. Global cancer statistics. *CA Cancer J Clin*. 2011 Mar–Apr;61(2):69–90. [PMID: 21296855]
- Li CI et al. Alcohol consumption and risk of postmenopausal breast cancer by subtype: the Women's Health Initiative observational study. *J Natl Cancer Inst*. 2010 Sep 22;102(18):1422–31. [PMID: 20733117]
- Meads C et al. A systematic review of breast cancer incidence risk prediction models with meta-analysis of their performance. *Breast Cancer Res Treat*. 2012 Apr;132(2):365–77. [PMID: 22037780]
- Nelson HD et al. Systematic review: comparative effectiveness of medications to reduce risk for primary breast cancer. *Ann Intern Med*. 2009 Nov 17;151(10):703–15, W-226–35. [PMID: 19920271]
- Noah-Vanhoucke J et al. Cost-effectiveness of chemoprevention of breast cancer using tamoxifen in a postmenopausal U.S. population. *Cancer*. 2011 Aug 1;117(15):3322–31. [PMID: 21404271]
- Ropka ME et al. Patient decisions about breast cancer chemoprevention: a systematic review and meta-analysis. *J Clin Oncol*. 2010 Jun 20;28(18):3090–5. [PMID: 20458026]
- Schwartz MD et al. Impact of *BRCA1/BRCA2* counseling and testing on newly diagnosed breast cancer patients. *J Clin Oncol*. 2004 May 15;22(10):1823–9. [PMID: 15067026]
- Visvanathan K et al. American Society of Clinical Oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction. *J Clin Oncol*. 2009 Jul 1;27(19):3235–58. [PMID: 19470930]
- Vogel VG et al; National Surgical Adjuvant Breast and Bowel Project. Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: preventing breast cancer. *Cancer Prev Res (Phila)*. 2010 Jun;3(6):696–706. [PMID: 20404000]

► Early Detection of Breast Cancer

A. Screening Programs

A number of large screening programs, consisting of physical and mammographic examination of asymptomatic women, have been conducted over the years. On average, these programs identify 10 cancers per 1000 women over the age of 50 and 2 cancers per 1000 women under the age of 50. Screening detects cancer before it has spread to the lymph nodes in about 80% of the women evaluated. This increases the chance of survival to about 85% at 5 years.

Both physical examination and mammography are necessary for maximum yield in screening programs, since about 35–50% of early breast cancers can be discovered only by mammography and another 40% can be detected only by palpation. About one-third of the abnormalities detected on screening mammograms will be found to be malignant when biopsy is performed. The probability of cancer on a screening mammogram is directly related to the Breast Imaging Reporting and Data System (BIRADS) assessment, and work-up should be performed based on this classification. Women 20–40 years of age should have a breast examination as part of routine medical care every 2–3 years. Women over age 40 years should have annual

breast examinations. The sensitivity of mammography varies from approximately 60% to 90%. This sensitivity depends on several factors, including patient age (breast density) and tumor size, location, and mammographic appearance. In young women with dense breasts, mammography is less sensitive than in older women with fatty breasts, in whom mammography can detect at least 90% of malignancies. Smaller tumors, particularly those without calcifications, are more difficult to detect, especially in dense breasts. The lack of sensitivity and the low incidence of breast cancer in young women have led to questions concerning the value of mammography for screening in women 40–50 years of age. The specificity of mammography in women under 50 years varies from about 30% to 40% for nonpalpable mammographic abnormalities to 85% to 90% for clinically evident malignancies. In 2009, the US Preventive Services Task Force recommended against routine screening mammography in this age range, and also recommended mammography be performed every 2 years for women between the ages of 50 and 74. The change in recommendation for screening women age 40–50 were particularly controversial in light of several meta-analyses that included women in this age group and showed a 15–20% reduction in the relative risk of death from breast cancer with screening mammography. For this reason, the American Cancer Society continues to recommend yearly mammography for women beginning at the age of 40.

The beneficial effect of screening in women aged 50–69 years is undisputed and has been confirmed by all clinical trials. The efficacy of screening in older women—those older than 70 years—is inconclusive and is difficult to determine because few studies have examined this population.

B. Self-Examination

Breast self-examination (BSE) has not been shown to improve survival. Because of the lack of strong evidence demonstrating value, the American Cancer Society no longer recommends monthly BSE beginning at age 20 years. The recommendation is that patients be made aware of the potential benefits, limitations, and harms (increased biopsies or false-positive results) associated with BSE. Women who choose to perform BSE should be advised regarding the proper technique. Premenopausal women should perform the examination 7–8 days after the start of the menstrual period. First, breasts should be inspected before a mirror with the hands at the sides, overhead, and pressed firmly on the hips to contract the pectoralis muscles causing masses, asymmetry of breasts, and slight dimpling of the skin to become apparent. Next, in a supine position, each breast should be carefully palpated with the fingers of the opposite hand. Some women discover small breast lumps more readily when their skin is moist while bathing or showering. While BSE is not a recommended practice, patients should recognize and report any breast changes to their practitioners as it remains an important facet of proactive care.

C. Imaging

Mammography is the most reliable means of detecting breast cancer before a mass can be palpated. Slowly growing

cancers can be identified by mammography at least 2 years before reaching a size detectable by palpation. Film screen mammography delivers < 0.4 cGy to the mid breast per view. Although full-field digital mammography provides an easier method to maintain and review mammograms, it has not been proven that it provides better images or increases detection rates more than film mammography. In subset analysis of a large study, digital mammography seemed slightly superior in women with dense breasts. Computer-assisted detection has not shown any increase in detection of cancers.

Calcifications are the most easily recognized mammographic abnormality. The most common findings associated with carcinoma of the breast are clustered pleomorphic microcalcifications. Such calcifications are usually at least five to eight in number, aggregated in one part of the breast and differing from each other in size and shape, often including branched or V- or Y-shaped configurations. There may be an associated mammographic mass density or, at times, only a mass density with no calcifications. Such a density usually has irregular or ill-defined borders and may lead to architectural distortion within the breast but may be subtle and difficult to detect.

Indications for mammography are as follows: (1) to screen at regular intervals asymptomatic women at high risk for developing breast cancer (see above); (2) to evaluate each breast when a diagnosis of potentially curable breast cancer has been made, and at yearly intervals thereafter; (3) to evaluate a questionable or ill-defined breast mass or other suspicious change in the breast; (4) to search for an occult breast cancer in a woman with metastatic disease in axillary nodes or elsewhere from an unknown primary; (5) to screen women prior to cosmetic operations or prior to biopsy of a mass, to examine for an unsuspected cancer; (6) to monitor those women with breast cancer who have been treated with breast-conserving surgery and radiation; and (7) to monitor the contralateral breast in those women with breast cancer treated with mastectomy.

Patients with a dominant or suspicious mass must undergo biopsy despite mammographic findings. The mammogram should be obtained prior to biopsy so that other suspicious areas can be noted and the contralateral breast can be evaluated. Mammography is never a substitute for biopsy because it may not reveal clinical cancer, especially in a very dense breast, as may be seen in young women with fibrocystic changes, and may not reveal medullary cancers.

Communication and documentation among the patient, the referring practitioner, and the interpreting physician are critical for high-quality screening and diagnostic mammography. The patient should be told about *how* she will receive timely results of her mammogram; that mammography does not “rule out” cancer; and that she may receive a correlative examination such as ultrasound at the mammography facility if referred for a suspicious lesion. She should also be aware of the technique and need for breast compression and that this may be uncomfortable. The mammography facility should be informed in writing by the clinician of abnormal physical examination findings. The Agency for Health Care Policy and Research

(AHCPR) Clinical Practice Guidelines strongly recommend that all mammography reports be communicated in writing to the patient and referring practitioner. MRI and ultrasound may be useful screening modalities in women who are at high risk for breast cancer but not for the general population. The sensitivity of MRI is much higher than mammography; however, the specificity is significantly lower and this results in multiple unnecessary biopsies. The increased sensitivity despite decreased specificity may be considered a reasonable trade-off for those at increased risk for developing breast cancer but not for normal-risk population. In 2009, the National Comprehensive Cancer Network (NCCN) guidelines recommended MRI in addition to screening mammography for high-risk women, including those with *BRCA1/2* mutations, those who have a lifetime risk of breast cancer of > 20%, and those with a personal history of LCIS. Women who received radiation therapy to the chest in their teens or twenties are also known to be at high risk for developing breast cancer and screening MRI may be considered in addition to mammography. MRI is useful in women with breast implants to determine the character of a lesion present in the breast and to search for implant rupture and at times is helpful in patients with prior lumpectomy and radiation.

- Allen SS et al. The mammography controversy: when should you screen? *J Fam Pract.* 2011 Sep;60(9):524–31. [PMID: 21901178]
- Hendrick RE et al. United States Preventive Services Task Force screening mammography recommendations: science ignored. *AJR Am J Roentgenol.* 2011 Feb;196(2):W112–6. [PMID: 21257850]
- Jackson SL et al. Variability of interpretive accuracy among diagnostic mammography facilities. *J Natl Cancer Inst.* 2009 Jun 3;101(11):814–27. [PMID: 19470953]
- James JJ et al. Mammographic features of breast cancers at single reading with computer-aided detection and at double reading in a large multicenter prospective trial of computer-aided detection: CADET II. *Radiology.* 2010 Aug;256(2):379–86. [PMID: 20656831]
- Kalager M et al. Effect of screening mammography on breast-cancer mortality in Norway. *N Engl J Med.* 2010 Sep 23; 363(13):1203–10. [PMID: 20860502]
- Lehman CD et al. The role of MRI in breast cancer screening. *J Natl Compr Canc Netw.* 2009 Nov;7(10):1109–15. [PMID: 19930977]
- Meissner HI et al. Breast cancer screening beliefs, recommendations and practices: primary care physicians in the United States. *Cancer.* 2011 Jul 15;117(14):3101–11. [PMID: 21246531]
- Nelson HD et al. Screening for breast cancer: an update for the U.S. Preventive Services Task Force. *Ann Intern Med.* 2009 Nov 17;151(10):727–37. [PMID: 19920273]
- Vinnicombe S et al. Full-field digital versus screen-film mammography: comparison within the UK breast screening program and systematic review of published data. *Radiology.* 2009 May;251(2):347–58. [PMID: 19401569]
- Warner E. Clinical practice. Breast-cancer screening. *N Engl J Med.* 2011 Sep 15;365(11):1025–32. [PMID: 21916640]
- Whitman GJ et al. Workup and staging of locally advanced breast cancer. *Semin Radiat Oncol.* 2009 Oct;19(4):211–21. [PMID: 19732685]
- Wilke LG et al. Breast self-examination: defining a cohort still in need. *Am J Surg.* 2009 Oct;198(4):575–9. [PMID: 19800471]


► Clinical Findings Associated with Early Detection of Breast Cancer

A. Symptoms and Signs

The presenting complaint in about 70% of patients with breast cancer is a lump (usually painless) in the breast. About 90% of these breast masses are discovered by the patient. Less frequent symptoms are breast pain; nipple discharge; erosion, retraction, enlargement, or itching of the nipple; and redness, generalized hardness, enlargement, or shrinking of the breast. Rarely, an axillary mass or swelling of the arm may be the first symptom. Back or bone pain, jaundice, or weight loss may be the result of systemic metastases, but these symptoms are rarely seen on initial presentation. However, among patients who undergo screening mammography, cancer is detected in about 30–40% of cases before it is palpable.

The relative frequency of carcinoma in various anatomic sites in the breast is shown in Figure 17-2.

Inspection of the breast is the first step in physical examination and should be carried out with the patient sitting, arms at her sides and then overhead. Abnormal variations in breast size and contour, minimal nipple retraction, and slight edema, redness, or retraction of the skin can be identified (Figure 17-3). Asymmetry of the breasts and retraction or dimpling of the skin can often be accentuated by having the patient raise her arms overhead or press her hands on her hips to contract the pectoralis muscles. Axillary and supraclavicular areas should be thoroughly palpated for enlarged nodes with the patient sitting (Figure 17-4). Palpation of the breast for masses or other changes should be performed with the patient both seated and supine with the arm abducted (Figure 17-5). Palpation with a rotary motion of the examiner's fingers as well as a horizontal stripping motion has been recommended.




▲ **Figure 17-2.** Frequency of breast carcinoma at various anatomic sites.




▲ **Figure 17-3.** Peau d'orange sign (resemblance to the skin of an orange due to lymphedema) in advanced breast cancer. (Courtesy of Richard P. Usatine, MD; used, with permission, from Usatine RP, Smith MA, Mayeaux EJ Jr, Chumley H, Tysinger J. *The Color Atlas of Family Medicine*. McGraw-Hill, 2009.)

Breast cancer usually consists of a nontender, firm or hard mass with poorly delineated margins (caused by local infiltration). Very small (1–2 mm) erosions of the nipple epithelium may be the only manifestation of Paget disease of the breast. Watery, serous, or bloody discharge from the nipple is an occasional early sign but is more often associated with benign disease.

A small lesion, < 1 cm in diameter, may be difficult or impossible for the examiner to feel but may be discovered by the patient. She should always be asked to demonstrate



▲ **Figure 17-4.** Palpation of axillary region for enlarged lymph nodes.



▲ **Figure 17-5.** Palpation of breasts. Palpation is performed with the patient supine and arm abducted.

the location of the mass; if the practitioner fails to confirm the patient's suspicions and imaging studies are normal, the examination should be repeated in 2–3 months, preferably 1–2 weeks after the onset of menses. During the premenstrual phase of the cycle, increased innocuous nodularity may suggest neoplasm or may obscure an underlying lesion. If there is any question regarding the nature of an abnormality under these circumstances, the patient should be asked to return after her menses. Ultrasound is often valuable and mammography essential when an area is felt by the patient to be abnormal but the physician feels no mass. MRI may be considered, but the lack of specificity should be discussed by the practitioner and the patient. MRI should not be used to rule out cancer because MRI has a false-negative rate of about 3–5%. Although lower than mammography, this false-negative rate cannot permit safe elimination of the possibility of cancer. False negatives are more likely seen in infiltrating lobular carcinomas and DCIS.

Metastases tend to involve regional lymph nodes, which may be palpable. One or two movable, nontender, not particularly firm axillary lymph nodes 5 mm or less in diameter are frequently present and are generally of no significance. Firm or hard nodes larger than 1 cm are typical of metastases. Axillary nodes that are matted or fixed to skin or deep structures indicate advanced disease (at least stage III). On the other hand, if the examiner thinks that the axillary nodes are involved, that impression will be borne out by histologic section in about 85% of cases. The incidence of positive axillary nodes increases with the size of the primary tumor. Noninvasive cancers (in situ) do not metastasize. Metastases are present in about 30% of patients with clinically negative nodes.

In most cases, no nodes are palpable in the supraclavicular fossa. Firm or hard nodes of any size in this location or just beneath the clavicle are suggestive of metastatic cancer and should be biopsied. Ipsilateral supraclavicular or infraclavicular nodes containing cancer indicate that the tumor is in an advanced stage (stage III or IV). Edema of the ipsilateral arm, commonly caused by metastatic infiltration of regional lymphatics, is also a sign of advanced cancer.

B. Laboratory Findings

Liver or bone metastases may be associated with elevation of serum alkaline phosphatase. Hypercalcemia is an occasional important finding in advanced cancer of the breast. Carcinoembryonic antigen (CEA) and CA 15-3 or CA 27-29 may be used as markers for recurrent breast cancer but are not helpful in diagnosing early lesions. Many scientists are further investigating breast cancer markers through proteomics and hormone assays. These studies are ongoing and may prove to be helpful in early detection or evaluation of prognosis.

C. Imaging for Metastases

For patients with suspicious symptoms or signs (bone pain, abdominal symptoms, elevated liver enzymes) or locally advanced disease (clinically abnormal lymph nodes or large primary tumors), staging scans are indicated prior to surgery or systemic therapy. Chest imaging with CT or radiographs may be done to evaluate for pulmonary metastases. Abdominal imaging with CT or ultrasound may be obtained to evaluate for liver metastases. Bone scans using ^{99m}Tc -labeled phosphates or phosphonates are more sensitive than skeletal radiographs in detecting metastatic breast cancer. Bone scanning has not proved to be of clinical value as a routine preoperative test in the absence of symptoms, physical findings, or abnormal alkaline phosphatase or calcium levels. The frequency of abnormal findings on bone scan parallels the status of the axillary lymph nodes on pathologic examination. Positron emission tomography (PET) scanning alone or combined with CT (PET-CT) is effective for detecting soft tissue or visceral metastases in patients with symptoms or signs of metastatic disease.


D. Diagnostic Tests

1. Biopsy—The diagnosis of breast cancer depends ultimately on examination of tissue or cells removed by biopsy. Treatment should never be undertaken without an unequivocal histologic or cytologic diagnosis of cancer. The safest course is biopsy examination of all suspicious lesions found on physical examination or mammography, or both. About 60% of lesions clinically thought to be cancer prove on biopsy to be benign, while about 30% of clinically benign lesions are found to be malignant. These findings demonstrate the fallibility of clinical judgment and the necessity for biopsy.

All breast masses require a histologic diagnosis with one probable exception, a nonsuspicious, presumably fibrocystic mass, in a premenopausal woman. Rather, these masses can be observed through one or two menstrual cycles. However, if the mass is not cystic and does not completely resolve during this time, it must be biopsied. Figures 17–6 and 17–7 present algorithms for management of breast masses in premenopausal and postmenopausal patients.

The simplest biopsy method is needle biopsy, either by aspiration of tumor cells (FNA cytology) or by obtaining a small core of tissue with a hollow needle (core biopsy).

FNA cytology is a useful technique whereby cells are aspirated with a small needle and examined cytologically.




▲ **Figure 17-6.** Evaluation of breast masses in premenopausal women. (Adapted, with permission, from Chang S, Haigh PI, Giuliano AE. Breast disease. In: Berek JS, Hacker NF [editors], *Practical Gynecologic Oncology*, 4th edition, LWW, 2004.)

This technique can be performed easily with virtually no morbidity and is much less expensive than excisional or open biopsy. The main disadvantages are that it requires a pathologist skilled in the cytologic diagnosis of breast cancer and it is subject to sampling problems, particularly because deep lesions may be missed. Furthermore, noninvasive cancers usually cannot be distinguished from invasive cancers and immunohistochemical tests to determine expression of hormone receptors and the amplification of the *HER-2/neu* oncogene cannot be reliably performed on FNA biopsies. The incidence of false-positive diagnoses is extremely low, perhaps 1–2%. The false-negative rate is as high as 10%. Most experienced clinicians would not leave a suspicious dominant mass in the breast even when FNA

cytology is negative unless the clinical diagnosis, breast imaging studies, and cytologic studies were all in agreement, such as a fibrocystic lesion or fibroadenoma.

Large-needle (core needle) biopsy removes a core of tissue with a large cutting needle and is the diagnostic procedure of choice for both palpable and image-detected abnormalities. Hand-held biopsy devices make large-core needle biopsy of a palpable mass easy and cost effective in the office with local anesthesia. As in the case of any needle biopsy, the main problem is sampling error due to improper positioning of the needle, giving rise to a false-negative test result. This is extremely unusual with image-guided biopsies. Core biopsy has the advantage that tumor markers, such as estrogen receptor (ER), progesterone receptor (PR)



¹Biopsy may be excisional or by needle cytology, but if cytology appears benign and the mass persists, it should be excised.

▲ **Figure 17-7.** Evaluation of breast masses in postmenopausal women. (Adapted, with permission, from Chang S, Haigh PI, Giuliano AE. Breast disease. In: Berek JS, Hacker NF [editors], *Practical Gynecologic Oncology*, 4th edition, LWW, 2004.)

and *HER-2/neu* overexpression can be performed on cores of tissue.

Open biopsy under local anesthesia as a separate procedure prior to deciding upon definitive treatment is becoming less common with the increasing use of core needle biopsy. Needle biopsy, when positive, offers a more rapid approach with less expense and morbidity, but when non-diagnostic it must be followed by open biopsy. It generally consists of an excisional biopsy, which is done through an incision with the intent to remove the entire abnormality, not simply a sample. Additional evaluation for metastatic disease and therapeutic options can be discussed with the patient after the histologic or cytologic diagnosis of cancer has been established. As an alternative in highly suspicious circumstances, the diagnosis may be made on frozen section of tissue obtained by open biopsy under general anesthesia. If the frozen section is positive, the surgeon can proceed immediately with the definitive operation. This one-step method is rarely used today except when a cytologic study has suggested cancer but is not diagnostic and there is a high clinical suspicion of malignancy in a patient well prepared for the diagnosis of cancer and its treatment options.

In general, the two-step approach—outpatient biopsy followed by definitive operation at a later date—is preferred in the diagnosis and treatment of breast cancer, because patients can be given time to adjust to the diagnosis of cancer, can consider alternative forms of therapy, and can seek a second opinion if they wish. There is no adverse effect from the short delay of the two-step procedure.

2. Ultrasonography—Ultrasonography is performed primarily to differentiate cystic from solid lesions but may show signs suggestive of carcinoma. Ultrasonography may show an irregular mass within a cyst in the rare case of intracystic carcinoma. If a tumor is palpable and feels like a cyst, an 18-gauge needle can be used to aspirate the fluid and make the diagnosis of cyst. If a cyst is aspirated and the fluid is nonbloody, it does not have to be examined cytologically. If the mass does not recur, no further diagnostic test is necessary. Nonpalpable mammographic densities that appear benign should be investigated with ultrasound to determine whether the lesion is cystic or solid. These may even be needle biopsied with ultrasound guidance.

3. Mammography—When a suspicious abnormality is identified by mammography alone and cannot be palpated by the clinician, the lesion should be biopsied under mammographic guidance. In the **computerized stereotactic guided core needle** technique, a biopsy needle is inserted into the lesion with mammographic guidance, and a core of tissue for histologic examination can then be examined. Vacuum assistance increases the amount of tissue obtained and improves diagnosis.

Mammographic localization biopsy is performed by obtaining a mammogram in two perpendicular views and placing a needle or hook-wire near the abnormality so that the surgeon can use the metal needle or wire as a guide during operation to locate the lesion. After mammography confirms the position of the needle in relation to the lesion, an incision is made and the subcutaneous tissue is dissected until the needle is identified. Often, the abnormality cannot even be palpated through the incision—as is the case with microcalcifications—and thus it is essential to obtain a mammogram of the specimen to document that the lesion was excised. At that time, a second marker needle can further localize the lesion for the pathologist. Stereotactic core needle biopsies have proved equivalent to mammographic localization biopsies. Core biopsy is preferable to mammographic localization for accessible lesions since an operation can be avoided. A metal clip should be placed after any image-guided core biopsy to facilitate finding the site of the lesion if subsequent treatment is necessary.

4. Other imaging modalities—Other modalities of breast imaging have been investigated for diagnostic purposes. Automated breast ultrasonography is useful in distinguishing cystic from solid lesions but should be used only as a supplement to physical examination and mammography. Ductography may be useful to define the site of a lesion causing a bloody discharge, but since biopsy is almost always indicated, ductography may be omitted and the blood-filled nipple system excised. Ductoscopy has shown some promise in identifying intraductal lesions, especially in the case of pathologic nipple discharge, but in practice, this technique is rarely used. MRI is highly sensitive but not specific and should not be used for screening except in highly selective cases. For example, MRI is useful in differentiating scar from recurrence postlumpectomy and may be valuable to screen high-risk women (eg, women with *BRCA* mutations). It may also be of value to examine for multicentricity when there is a known primary

cancer; to examine the contralateral breast in women with cancer; to examine the extent of cancer, especially lobular carcinomas; or to determine the response to neoadjuvant chemotherapy. PET scanning does not appear useful in evaluating the breast itself but is valuable to examine for distant metastases.

5. Cytology—Cytologic examination of nipple discharge or cyst fluid may be helpful on rare occasions. As a rule, mammography (or ductography) and breast biopsy are required when nipple discharge or cyst fluid is bloody or cytologically questionable. Ductal lavage, a technique that washes individual duct systems with saline and loosens epithelial cells for cytologic evaluation, is being evaluated as a risk assessment tool but appears to be of little value.

► Differential Diagnosis

The lesions to be considered most often in the differential diagnosis of breast cancer are the following, in descending order of frequency: fibrocystic condition of the breast, fibroadenoma, intraductal papilloma, lipoma, and fat necrosis.

► Staging

The American Joint Committee on Cancer and the International Union Against Cancer have agreed on a TNM (tumor, regional lymph nodes, distant metastases) staging system for breast cancer. Using the TNM staging system enhances communication between researchers and clinicians. Table 17-3 outlines the TNM classification.

► Pathologic Types

Numerous pathologic subtypes of breast cancer can be identified histologically (Table 17-4).

Except for the in situ cancers, the histologic subtypes have only a slight bearing on prognosis when outcomes are compared after accurate staging. The noninvasive cancers by definition are confined by the basement membrane of the ducts and lack the ability to spread. Histologic parameters for invasive cancers, including lymphovascular invasion and tumor grade, have been shown to be of prognostic value. Immunohistochemical analysis for expression of hormone receptors and for overexpression of *HER-2* in the primary tumor offers prognostic and therapeutic information.

► Special Clinical Forms of Breast Cancer

A. Paget Carcinoma

Paget carcinoma is not common (about 1% of all breast cancers). It affects the nipple and may or may not be associated with a breast mass. Over 85% of cases are associated with an underlying invasive or noninvasive cancer, usually a well differentiated infiltrating ductal carcinoma or a

DCIS. The ducts of the nipple epithelium are infiltrated, but gross nipple changes are often minimal, and a tumor mass may not be palpable.

Because the nipple changes appear innocuous, the diagnosis is frequently missed. The first symptom is often itching or burning of the nipple, with superficial erosion or ulceration. These are often diagnosed and treated as dermatitis or bacterial infection, leading to delay or failure in detection. The diagnosis is established by biopsy of the area of erosion. When the lesion consists of nipple changes only, the incidence of axillary metastases is < 5%, and the prognosis is excellent. When a breast mass is also present, the incidence of axillary metastases rises, with an associated marked decrease in prospects for cure by surgical or other treatment.

B. Inflammatory Carcinoma

This is the most malignant form of breast cancer and constitutes < 3% of all cases. The clinical findings consist of a rapidly growing, sometimes painful mass that enlarges the breast. The overlying skin becomes erythematous, edematous, and warm. Often there is no distinct mass, since the tumor infiltrates the involved breast diffusely. The inflammatory changes, often mistaken for an infection, are caused by carcinomatous invasion of the subdermal lymphatics, with resulting edema and hyperemia. If the practitioner suspects infection but the lesion does not respond rapidly (1–2 weeks) to antibiotics, biopsy should be performed. The diagnosis should be made when the redness involves more than one-third of the skin over the breast and biopsy shows infiltrating carcinoma with invasion of the subdermal lymphatics. Metastases tend to occur early and widely, and for this reason inflammatory carcinoma is rarely curable. Radiation, hormone therapy, and chemotherapy are the measures most likely to be of value rather than operation. Mastectomy is indicated when chemotherapy and radiation have resulted in clinical remission with no evidence of distant metastases. In these cases, residual disease in the breast may be eradicated.

► Breast Cancer Occurring during Pregnancy or Lactation

Breast cancer complicates approximately one in 3000 pregnancies. The diagnosis is frequently delayed, because physiologic changes in the breast may obscure the lesion and screening mammography is not done in young or pregnant women. When the cancer is confined to the breast, the 5-year survival rate is about 70%. In 60–70% of patients, axillary metastases are already present, conferring a 5-year survival rate of 30–40%. A retrospective analysis of women who were younger than 36 years when breast cancer was diagnosed showed that while women with pregnancy-associated breast cancer were more frequently diagnosed with later stage breast cancer, they had similar rates of local regional recurrence, distant metastases and overall survival as women with

Table 17-3. TNM staging for breast cancer.

Primary Tumor (T)			
<p>Definitions for classifying the primary tumor (T) are the same for clinical and for pathologic classification. If the measurement is made by physical examination, the examiner will use the major headings (T1, T2, or T3). If other measurements, such as mammographic or pathologic measurements, are used, the subsets of T1 can be used. Tumors should be measured to the nearest 0.1 cm increment.</p>		N2a	Metastasis in ipsilateral axillary lymph nodes fixed to one another (matted) or to other structures
		N2b	Metastasis only in clinically apparent ¹ ipsilateral internal mammary nodes and in the <i>absence</i> of clinically evident axillary lymph node metastasis
		N3	Metastasis in ipsilateral infraclavicular lymph node(s) with or without axillary lymph node involvement, or in clinically apparent ¹ ipsilateral internal mammary lymph node(s) and in the <i>presence</i> of clinically evident axillary lymph node metastasis; or metastasis in ipsilateral supraclavicular lymph node(s) with or without axillary or internal mammary lymph node involvement
		N3a	Metastasis in ipsilateral infraclavicular lymph node(s)
TX	Primary tumor cannot be assessed	N3b	Metastasis in ipsilateral internal mammary lymph node(s) and axillary lymph node(s)
T0	No evidence of primary tumor	N3c	Metastasis in ipsilateral supraclavicular lymph node(s)
Tis	Carcinoma in situ	<i>Regional Lymph Nodes (pN)²</i>	
Tis (DCIS)	Ductal carcinoma in situ	pNX	Regional lymph nodes cannot be assessed (eg, previously removed, or not removed for pathologic study)
Tis (LCIS)	Lobular carcinoma in situ	pN0	No regional lymph node metastasis histologically, no-additional examination for isolated tumor cells
Tis (Paget)	Paget disease of the nipple with no tumor	<i>Note:</i> Isolated tumor cells (ITC) are defined as single tumor cells or small cell clusters not > 0.2 mm, usually detected only by immunohistochemical (IHC) or molecular methods but which may be verified on hematoxylin and eosin stains. ITCs do not usually show evidence of malignant activity, eg, proliferation or stromal reaction.	
<i>Note:</i> Paget disease associated with a tumor is classified according to the size of the tumor.		pN0(i-)	No regional lymph node metastasis histologically, negative IHC
T1	Tumor 2 cm or less in greatest dimension	pN0(i+)	No regional lymph node metastasis histologically, positive IHC, no IHC cluster > 0.2 mm
T1mic	Microinvasion 0.1 cm or less in greatest dimension	pN0(mol-)	No regional lymph node metastasis histologically, negative molecular findings (RT-PCR) ³
T1a	Tumor more than 0.1 cm but not more than 0.5 cm in greatest dimension	pN0(mol+)	No regional lymph node metastasis histologically, positive molecular findings (RT-PCR) ³
T1b	Tumor more than 0.5 cm but not more than 1 cm in greatest dimension	pN1	Metastasis in one to three axillary lymph nodes, and/or in internal mammary nodes with microscopic disease detected by sentinel lymph node dissection but not clinically apparent ⁴
T1c	Tumor more than 1 cm but not more than 2 cm in greatest dimension	pN1mi	Micrometastasis (> 0.2 mm, none > 2.0 mm)
T2	Tumor more than 2 cm but not more than 5 cm in greatest dimension	pN1a	Metastasis in one to three axillary lymph nodes
T3	Tumor more than 5 cm in greatest dimension	pN1b	Metastasis in internal mammary nodes with microscopic disease detected by sentinel lymph node dissection but not clinically apparent ⁴
T4	Tumor of any size with direct extension to (a) chest wall or (b) skin, only as described below	pN1c	Metastasis in one to three axillary lymph nodes and in internal mammary lymph nodes with microscopic disease detected by sentinel lymph node dissection but not clinically apparent. ⁴ (If associated with greater than three positive axillary lymph nodes, the internal mammary nodes are classified as pN3b to reflect increased tumor burden)
T4a	Extension to chest wall, not including pectoralis muscle		
T4b	Edema (including peau d'orange [see Figure 17-3]) or ulceration of the skin of the breast, or satellite skin nodules confined to the same breast		
T4c	Both T4a and T4b		
T4d	Inflammatory carcinoma		
Regional Lymph Nodes (N)			
<i>Clinical</i>			
NX	Regional lymph nodes cannot be assessed (eg, previously removed)		
N0	No regional lymph node metastasis		
N1	Metastasis in movable ipsilateral axillary lymph node(s)		
N2	Metastases in ipsilateral axillary lymph nodes fixed or matted, or in clinically apparent ¹ ipsilateral internal mammary nodes in the <i>absence</i> of clinically evident axillary lymph node metastasis		

(continued)

Table 17-3. TNM staging for breast cancer. (continued)

pN2	Metastasis in four to nine axillary lymph nodes, or in clinically apparent ¹ internal mammary lymph nodes in the <i>absence</i> of axillary lymph node metastasis	Distant Metastasis (M)			
		MX	Distant metastasis cannot be assessed		
		M0	No distant metastasis		
pN2a	Metastasis in four to nine axillary lymph nodes (at least one tumor deposit > 2.0 mm)	M1	Distant metastasis		
		Stage Grouping			
pN2b	Metastasis in clinically apparent ¹ internal mammary lymph nodes in the <i>absence</i> of axillary lymph node metastasis	Stage 0	Tis	N0	M0
		Stage 1	T1 ⁵	N0	M0
pN3	Metastasis in 10 or more axillary lymph nodes, or in infraclavicular lymph nodes, or in clinically apparent ¹ ipsilateral internal mammary lymph nodes in the <i>presence</i> of one or more positive axillary lymph nodes; or in more than three axillary lymph nodes with clinically negative microscopic metastasis in internal mammary lymph nodes; or in ipsilateral supraclavicular lymph nodes	Stage IIA	T0	N1	M0
			T1 ⁵	N1	M0
			T2	N0	M0
		Stage IIB	T2	N1	M0
			T3	N0	M0
		Stage IIIA	T0	N2	M0
			T1 ⁵	N2	M0
			T2	N2	M0
			T3	N1	M0
			T3	N2	M0
pN3a	Metastasis in 10 or more axillary lymph nodes (at least one tumor deposit > 2.0 mm), or metastasis to the infraclavicular lymph nodes	Stage IIIB	T4	N0	M0
			T4	N1	M0
			T4	N2	M0
pN3b	Metastasis in clinically apparent ¹ ipsilateral internal mammary lymph nodes in the <i>presence</i> of one or more positive axillary lymph nodes; or in more than three axillary lymph nodes and in internal mammary lymph nodes with microscopic disease detected by sentinel lymph node dissection but not clinically apparent ⁴	Stage IIIC	Any T	N3	M0
		Stage IV	Any T	Any N	M1
pN3c	Metastasis in ipsilateral supraclavicular lymph nodes	Note: Stage designation may be changed if postsurgical imaging studies reveal the presence of distant metastases, provided that the studies are carried out within 4 months of diagnosis in the absence of disease progression and provided that the patient has not received neoadjuvant therapy.			

¹Clinically apparent is defined as detected by imaging studies (excluding lymphoscintigraphy) or by clinical examination or grossly visible pathologically.

²Classification is based on axillary lymph node dissection with or without sentinel lymph node dissection. Classification based solely on sentinel lymph node dissection without subsequent axillary lymph node dissection is designated (sn) for "sentinel node," eg, pN0(i+)(sn).

³RT-PCR, reverse transcriptase/polymerase chain reaction.

⁴Not clinically apparent is defined as not detected by imaging studies (excluding lymphoscintigraphy) or by clinical examination.

⁵T1 includes T1mic.

Reproduced, with permission, of the American Joint Committee on Cancer (AJCC), Chicago, Illinois, *AJCC Cancer Staging Manual*, 7th edition, Springer-Science and Business Media LLC, New York, 2010, www.springer.com.

nonpregnancy-associated breast cancer. It is thus important for primary care and reproductive specialists to aggressively workup any breast abnormality discovered in a pregnant woman. Pregnancy (or lactation) is not a contraindication to operation or treatment, and therapy should be based on the stage of the disease as in the nonpregnant (or nonlactating) woman. Overall survival rates have improved, since cancers are now diagnosed in pregnant women earlier than in the past and treatment has improved. Breast-conserving surgery may be

performed—and chemotherapy given—even during the pregnancy.

► Bilateral Breast Cancer

Bilateral breast cancer occurs in < 5% of cases, but there is as high as a 20–25% incidence of later occurrence of cancer in the second breast. Bilaterality occurs more often in familial breast cancer, in women under age 50 years, and when the tumor in the primary breast is lobular. The incidence of

Table 17-4. Histologic types of breast cancer.

Type	Frequency of Occurrence
Infiltrating ductal (not otherwise specified)	80-90%
Medullary	5-8%
Colloid (mucinous)	2-4%
Tubular	1-2%
Papillary	1-2%
Invasive lobular	6-8%
Noninvasive	4-6%
Intraductal	2-3%
Lobular in situ	2-3%
Rare cancers	< 1%
Juvenile (secretory)	
Adenoid cystic	
Epidermoid	
Sudoriferous	

second breast cancers increases directly with the length of time the patient is alive after her first cancer—about 1–2% per year.

In patients with breast cancer, mammography should be performed before primary treatment and at regular intervals thereafter, to search for occult cancer in the opposite breast or conserved ipsilateral breast. MRI may be useful in this high-risk group.

► Noninvasive Cancer

Noninvasive cancer can occur within the ducts (DCIS) or lobules (LCIS). LCIS, although thought to be a premalignant lesion or a risk factor for breast cancer, in fact may behave like DCIS. In a 2004 analysis of multiple NSABP studies, invasive lobular breast cancer not only developed in patients with LCIS but it developed in the same breast and indexed location as the original LCIS. Although more research needs to be done in this area, the invasive potential of LCIS is being reconsidered. Higher grade and pleomorphic LCIS may behave more like DCIS, and may be associated with invasive carcinoma. For this reason, some pathologists are now recommending that nuclear grade 2 or greater LCIS be surgically removed with clear margins. DCIS tends to be unilateral and most often progresses to invasive cancer if untreated. In approximately 40–60% of women who have DCIS treated with biopsy alone, invasive cancer develops within the same breast.

The treatment of intraductal lesions is controversial. DCIS can be treated by wide excision with or without radiation therapy or with total mastectomy. Conservative

management is advised in patients with small lesions amenable to lumpectomy. Although research is defining the malignant potential of LCIS, it can be managed with observation. Patients unwilling to accept the increased risk of breast cancer may be offered surgical excision of the area in question or bilateral total mastectomy. Currently, the accepted standard of care offers the alternative of chemoprevention, which is effective in preventing invasive breast cancer in both LCIS and DCIS that has been completely excised. Axillary metastases from in situ cancers should not occur unless there is an occult invasive cancer. Sentinel node biopsy may be indicated in large DCIS treated with mastectomy.

Beadle BM et al. The impact of pregnancy on breast cancer outcomes in women ≤ 35 years. *Cancer*. 2009 Mar 15;115(6):1174–84. [PMID: 19204903]

Bruening W et al. Systematic review: comparative effectiveness of core-needle and open surgical biopsy to diagnose breast lesions. *Ann Intern Med*. 2010 Feb 16;152(4):238–46. [PMID: 20008742]

Gao F et al. Clinical importance of histologic grading of lobular carcinoma in situ in breast core needle biopsy specimens: current issues and controversies. *Am J Clin Pathol*. 2010 May;133(5):767–71. [PMID: 20395524]

Ho BC et al. Lobular neoplasia of the breast: 68 years on. *Pathology*. 2009 Jan;41(1):28–35. [PMID: 19089737]

Morrow M. Magnetic resonance imaging for screening, diagnosis, and eligibility for breast-conserving surgery: promises and pitfalls. *Surg Oncol Clin N Am*. 2010 Jul;19(3):475–92. [PMID: 20620922]

Rakha EA et al. The prognostic significance of lymphovascular invasion in invasive breast carcinoma. *Cancer*. 2011 Dec 16. [Epub ahead of print] [PMID: 22180017]

Robertson FM et al. Inflammatory breast cancer: the disease, the biology, the treatment. *CA Cancer J Clin*. 2010 Nov–Dec;60(6):351–75. [PMID: 20959401]

Sinclair S et al. Primary systemic chemotherapy for inflammatory breast cancer. *Cancer*. 2010 Jun 1;116(11 Suppl):2821–8. [PMID: 20503414]

Tohno E et al. Ultrasound screening of breast cancer. *Breast Cancer*. 2009;16(1):18–22. [PMID: 19009372]

Van Goethem M et al. Role of MRI of the breast in the evaluation of the symptomatic patient. *Curr Opin Obstet Gynecol*. 2009 Feb;21(1):74–9. [PMID: 19130631]

Veronesi U et al. Sentinel lymph node biopsy in breast cancer: ten-year results of a randomized controlled study. *Ann Surg*. 2010 Apr;251(4):595–600. [PMID: 20195151]

Virnig BA et al. Diagnosis and management of ductal carcinoma in situ (DCIS). *Evid Rep Technol Assess (Full Rep)*. 2009 Sep;(185):1–549. [PMID: 20629475]

Woodward WA et al. Inflammatory breast cancer. *Semin Radiat Oncol*. 2009 Oct;19(4):256–65. [PMID: 19732690]

► Biomarkers & Gene Expression Profiling

Determining the ER, PR and *HER-2/neu* status of the tumor at the time of diagnosis of early breast cancer and, if possible, at the time of recurrence is critical, both to gauge a patient's prognosis and to determine the best treatment regimen. In addition to ER status and PR status, the rate at which tumor divides (assessed by an immunohistochemical

stain for Ki-67) and the grade and differentiation of the cells are also important prognostic factors. These markers may be obtained on core biopsy or surgical specimens. Patients whose tumors are hormone receptor-positive tend to have a more favorable disease course than those whose tumors are receptor-negative. Moreover, treatment with an anti-hormonal agent is an essential component of therapy for hormone-receptor positive breast cancer at any stage. While up to 60% of patients with metastatic breast cancer will respond to hormonal manipulation if their tumors are ER-positive, <5% of patients with metastatic, ER-negative tumors will respond.

Another key element in determining treatment and prognosis is the amount of the *HER-2/neu* oncogene present in the cancer. *HER-2/neu* overexpression is measured by an immunohistochemical assay that is scored using a numerical system: 0 and 1+ are considered negative for overexpression, 2+ is borderline/indeterminate, and 3+ is overexpression. In the case of 2+ expression, fluorescence in situ hybridization (FISH) is recommended to more accurately assess *HER-2/neu* amplification. According to the College of American Pathologists, a FISH score of < 1.8 is negative for amplification, 1.8–2.2 is indeterminant, and > 2.2 is amplified. The presence of *HER-2/neu* amplification and overexpression is of prognostic significance and predicts the response to trastuzumab.

Individually these biomarkers are predictive and thus provide insight to guide appropriate therapy. Moreover, when combined they provide useful information regarding risk of recurrence and prognosis. In general, tumors that lack expression of *HER-2/neu*, ER and PR (“triple negative”) have a higher risk of recurrence and metastases and are associated with a worse survival compared with other types. Neither endocrine therapy nor *HER-2*-targeted agents are useful for this type of breast cancer, leaving chemotherapy as the only treatment option. In contrast, patients with early stage, hormone receptor-positive breast cancer may not benefit from the addition of chemotherapy to hormonal treatments. Several molecular tests have been developed to assess risk of recurrence and to predict which patients are most likely to benefit from chemotherapy. Oncotype DX (Genomic Health) evaluates the expression of 21 genes relating to ER, PR, *HER-2/neu*, and proliferation in a tumor specimen and categorizes a patient’s risk of recurrence (recurrence score) as high, intermediate, or low risk. In addition to providing prognostic information, the test also has predictive value since studies have shown that patients in the high-risk category are most likely to respond to chemotherapy. This test is primarily indicated for ER-positive, node-negative tumors but at least one study has shown that it may also have value in node-positive tumors. Centralized testing for ER, PR, *HER-2* and Ki67 by standard immunohistochemical techniques is able to provide as much prognostic information as Oncotype DX. Mammaprint (Agendia) is another assay that is available for evaluating prognosis. This 70-gene signature is FDA-approved and may be performed on fresh frozen tumor tissue taken at the time of a patient’s surgery. This test classifies patients into good and poor prognostic groups to predict clinical outcome and may be used on patients with

hormone receptor positive or negative breast cancer. Several other assays are in development to better stratify patients based on risk assessment.

- Albain KS et al; for The Breast Cancer Intergroup of North America. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. *Lancet Oncol.* 2010 Jan;11(1):55–65. [PMID: 20005174]
- Badve S et al. Oestrogen-receptor-positive breast cancer: toward bridging histopathological and molecular classifications. *J Clin Pathol.* 2009 Jan;62(1):6–12. [PMID: 18794199]
- Capala J et al. Molecular imaging of HER2-positive breast cancer: a step toward an individualized ‘image and treat’ strategy. *Curr Opin Oncol.* 2010 Nov;22(6):559–66. [PMID: 20842031]
- Cuzick J et al. Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer. *J Clin Oncol.* 2011 Nov 10;29(32):4273–8. [PMID: 21990413]
- Dobbe E et al. Gene-expression assays: new tools to individualize treatment of early-stage breast cancer. *Am J Health Syst Pharm.* 2008 Jan 1;65(1):23–8. [PMID: 18159035]
- Foulkes WD et al. Triple-negative breast cancer. *N Engl J Med.* 2010 Nov 11;363(20):1938–48. [PMID: 21067385]
- Galanina N et al. Molecular predictors of response to therapy for breast cancer. *Cancer J.* 2011 Mar–Apr;17(2):96–103. [PMID: 21427553]
- Macrinici V et al. Clinical updates on EGFR/HER targeted agents in early-stage breast cancer. *Clin Breast Cancer.* 2010;10(Suppl 1):E38–46. [PMID: 20587406]
- Retèl VP et al. Constructive Technology Assessment (CTA) as a tool in coverage with evidence development: the case of the 70-gene prognosis signature for breast cancer diagnostics. *Int J Technol Assess Health Care.* 2009 Jan;25(1):73–83. [PMID: 19126254]
- Sparano JA et al. Clinical application of gene expression profiling in breast cancer. *Surg Oncol Clin N Am.* 2010 Jul;19(3):581–606. [PMID: 20620929]
- Wolff AC et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. *Arch Pathol Lab Med.* 2007;131(1):18–43. [PMID: 19548375]

► Treatment: Curative

Clearly, not all breast cancer is systemic at the time of diagnosis. For this reason, a pessimistic attitude concerning the management of breast cancer is unwarranted. Most patients with early breast cancer can be cured. Treatment with a curative intent is advised for clinical stage I, II, and III disease (see Tables 17–3, 39–4). Patients with locally advanced (T3, T4) and even inflammatory tumors may be cured with multimodality therapy, but in most, palliation is all that can be expected. Treatment with palliative intent is appropriate for all patients with stage IV disease and for patients with unresectable local cancers (see Palliative section).

A. Choice and Timing of Primary Therapy

The extent of disease and its biologic aggressiveness are the principal determinants of the outcome of primary therapy. Clinical and pathologic staging help in assessing extent of

disease (see Table 17–3), but each is to some extent imprecise. Other factors such as tumor grade, hormone receptor assays, and *HER-2/neu* oncogene amplification are of prognostic value and are key to determining systemic therapy, but are not important in determining the type of local therapy.


Controversy has surrounded the choice of primary therapy of stage I, II, and III breast carcinoma. Currently, the standard of care for stage I, stage II, and most stage III cancer is surgical resection followed by adjuvant radiation or systemic therapy, or both, when indicated. Neoadjuvant therapy is becoming more popular since large tumors may be shrunk by chemotherapy prior to surgery, making some patients who require mastectomy candidates for lumpectomy. It is important for patients to understand all of the surgical options, including reconstructive options, prior to having surgery. Patients with large primary tumors, inflammatory cancer, or palpably enlarged lymph nodes should have staging scans performed to rule out distant metastatic disease prior to definitive surgery. In general, adjuvant systemic therapy is started when the breast has adequately healed, usually within 4–8 weeks after surgery. While no prospective studies have defined the appropriate timing of adjuvant chemotherapy, one retrospective population-based study has suggested that chemotherapy should be initiated within 12 weeks of surgery to avoid a compromise in relapse-free and overall survival.

B. Surgical Resection

1. Breast-conserving therapy—Multiple, large, randomized studies including the Milan and NSABP trials show that disease-free and overall survival rates are similar for patients treated with partial mastectomy plus axillary dissection followed by radiation therapy and for those treated by modified radical mastectomy (total mastectomy plus axillary dissection).

Twenty years of follow-up of the NSABP trial has shown that lumpectomy with axillary dissection followed by postoperative radiation therapy is as effective as modified radical mastectomy for the management of patients with stage I and stage II breast cancer.

Tumor size is a major consideration in determining the feasibility of breast conservation. The lumpectomy trial of the NSABP randomized patients with tumors as large as 4 cm. To achieve an acceptable cosmetic result, the patient must have a breast of sufficient size to enable excision of a 4-cm tumor without considerable deformity. Therefore, large tumor size is only a relative contraindication. Subareolar tumors, also difficult to excise without deformity, are not contraindications to breast conservation. Clinically detectable multifocality is a relative contraindication to breast-conserving surgery, as is fixation to the chest wall or skin or involvement of the nipple or overlying skin. The patient—not the surgeon—should be the judge of what is cosmetically acceptable. Given the relatively high risk of poor outcome after radiation, concomitant scleroderma is a contraindication to breast-conserving surgery. A history of prior therapeutic radiation to the ipsilateral breast or chest wall (or both) is also a contraindication for breast conservation.



▲ **Figure 17-8.** Sentinel node. (Used with permission from Giuliano AE.)

Axillary dissection is primarily used to properly stage cancer and plan radiation and systemic therapy. Intraoperative lymphatic mapping and sentinel node biopsy identify lymph nodes most likely to harbor metastases if present (Figure 17–8). Sentinel node biopsy is a reasonable alternative to axillary dissection in selected patients with invasive cancer. If sentinel node biopsy reveals no evidence of axillary metastases, it is highly likely that the remaining lymph nodes are free of disease and axillary dissection may be omitted. An important study from the American College of Surgeons Oncology group randomized women with sentinel node metastases to undergo completion of axillary dissection or to receive no further axillary treatment after lumpectomy; no difference in survival was found, showing that axillary dissection for selected node-positive women is not necessary. These results challenge standard treatment regimens.

Breast-conserving surgery with radiation is the preferred form of treatment for patients with **early-stage breast cancer**. Despite the numerous randomized trials showing no survival benefit of mastectomy over breast-conserving partial mastectomy and irradiation, breast-conserving surgery still appears underutilized.

2. Mastectomy—Modified radical mastectomy was the standard therapy for most patients with early-stage breast cancer. This operation removes the entire breast, overlying skin, nipple, and areolar complex as well as the underlying pectoralis fascia with the axillary lymph nodes in continuity. The major advantage of modified radical mastectomy is that radiation therapy may not be necessary, although radiation may be used when lymph nodes are involved with cancer or when the primary tumor is large (≥ 5 cm). The disadvantage of mastectomy is the cosmetic and psychological impact associated with breast loss. Radical mastectomy, which removes the underlying pectoralis muscle, should be performed rarely, if at all. Axillary node dissection is not indicated for noninfiltrating cancers because nodal metastases are rarely present. Skin-sparing and nipple-sparing mastectomy is currently gaining favor but is not appropriate for all patients. Breast-conserving surgery

and radiation should be offered whenever possible, since most patients would prefer to save the breast. Breast reconstruction, immediate or delayed, should be discussed with patients who choose or require mastectomy. Patients should have an interview with a reconstructive plastic surgeon to discuss options prior to making a decision regarding reconstruction. Time is well spent preoperatively in educating the patient and family about these matters.

C. Radiotherapy

Radiotherapy after partial mastectomy consists of 5–7 weeks of five daily fractions to a total dose of 5000–6000 cGy. Most radiation oncologists use a boost dose to the cancer location. Early results of studies examining the utility and recurrence rates after intraoperative radiation or dose dense radiation in which the time course of radiation is shortened show promising results similar to standard techniques. Accelerated partial breast irradiation, in which only the portion of the breast from which the tumor was resected is irradiated for 1–2 weeks, appears effective in achieving local control. The American Society of Breast Surgeons Registry Trial reported that in 1440 patients treated with brachytherapy, the 3-year actuarial rate of ipsilateral breast cancer recurrence was 2.15% and no unexpected adverse events were seen. Long-term follow-up will be necessary as will results from ongoing randomized clinical trials comparing brachytherapy to standard external beam radiation.

Current studies suggest that radiotherapy after mastectomy may improve recurrence rates and survival in patients with tumors ≥ 5 cm or positive lymph nodes. Researchers are also examining the utility of axillary irradiation as an alternative to axillary dissection in the clinically node-negative patient with sentinel node micrometastases. A Canadian trial (MA20) of postoperative nodal irradiation after lumpectomy and axillary dissection shows improved survival with nodal irradiation.

D. Adjuvant Systemic Therapy

The goal of systemic therapy, including hormone modulating drugs (endocrine therapy), cytotoxic chemotherapy, and the *HER-2/neu*-targeted agent trastuzumab, is to kill cancer cells that have escaped the breast and axillary lymph nodes as micrometastases before they become macrometastases (ie, stage IV cancer). Systemic therapy improves survival and is advocated for most patients with curable breast cancer. In practice, most medical oncologists are currently using adjuvant chemotherapy for patients with either node-positive or higher-risk (eg, hormone receptor-negative or *HER-2/neu*-positive) node-negative breast cancer and using endocrine therapy for all hormone receptor-positive invasive breast cancer unless contraindicated. Prognostic factors other than nodal status that are used to determine the patient's risks of recurrence are tumor size, ER and PR status, nuclear grade, histologic type, proliferative rate, oncogene expression (Table 17–5), and patient's age and menopausal status. In general, systemic chemotherapy decreases the chance of recurrence by about 30% and hormonal modulation decreases the risk of

Table 17–5. Prognostic factors in node-negative breast cancer.

Prognostic Factors	Increased Recurrence	Decreased Recurrence
Size	T3, T2	T1, T0
Hormone receptors	Negative	Positive
DNA flow cytometry	Aneuploid	Diploid
Histologic grade	High	Low
Tumor labeling index	< 3%	> 3%
S phase fraction	> 5%	< 5%
Lymphatic or vascular invasion	Present	Absent
Cathepsin D	High	Low
<i>HER-2/neu</i> oncogene	High	Low
Epidermal growth factor receptor	High	Low

recurrence by 40–50% (for hormone receptor-positive cancer). Systemic chemotherapy is usually given sequentially, rather than concurrently with radiation. In terms of sequencing, typically chemotherapy is given before radiation and endocrine therapy is started concurrent with or after radiation therapy.

The long-term advantage of systemic therapy has been well established. All patients with invasive hormone receptor-positive tumors should consider the use of hormone-modulating therapy. Most patients with *HER-2/neu*-positive tumors should receive trastuzumab-containing chemotherapy regimens. In general, adjuvant systemic chemotherapy should not be given to women who have small node-negative breast cancers with favorable histologic findings and tumor markers. The ability to predict more accurately which patients with *HER-2/neu*-negative, hormone receptor-positive, lymph node-negative tumors should receive chemotherapy is improving with the advent of prognostic tools, such as Oncotype DX and MammaPrint. These tests are undergoing prospective evaluation in two clinical trials (TAILORx and MINDACT).

1. Chemotherapy—The Early Breast Cancer Trialists' Collaborative Group (EBCTCG) meta-analysis involving over 28,000 women enrolled in 60 trials of adjuvant polychemotherapy versus no chemotherapy demonstrated a significant beneficial impact of chemotherapy on clinical outcome in early breast cancer. This study showed that adjuvant chemotherapy reduces the risk of recurrence and breast cancer-specific mortality in all women but also showed that women under the age of 50 derive the greatest benefit. On the basis of the superiority of anthracycline-containing regimens in metastatic breast cancer, both doxorubicin and epirubicin have been studied extensively in the adjuvant setting. Studies comparing Adriamycin (doxorubicin) and cyclophosphamide (AC) or epirubicin and cyclophosphamide (EC) to cyclophosphamide-methotrexate-5-fluorouracil (CMF) have shown that treatments with anthracycline-containing regimens are at least as

effective, and perhaps more effective, than treatment with CMF. The EBCTCG analysis including over 14,000 patients enrolled in trials comparing anthracycline-based regimens to CMF, showed a small but statistically significant improved disease-free and overall survival with the use of anthracycline-based regimens. It should be noted, however, that most of these studies included a mixed population of *HER-2/neu*-positive and *HER-2/neu*-negative breast cancer patients and were performed before the development of trastuzumab. Retrospective analyses of a number of these studies suggest that anthracyclines may be primarily effective in tumors with *HER-2/neu* overexpression or alteration in the expression of topoisomerase IIa (the target of anthracyclines and close to the *HER-2/neu* gene). Given this, for *HER-2/neu*-negative, node-negative breast cancer, four cycles of AC or six cycles of CMF are probably equally effective.

When taxanes (T = paclitaxel and docetaxel) emerged in the 1990s, multiple trials were conducted to evaluate their use in combination with anthracycline-based regimens. The majority of these trials showed an improvement in disease-free survival and at least one showed an improvement in overall survival with the taxane-based regimen. A meta-analysis of taxane versus non-taxane anthracycline-based regimen trials showed an improvement in disease-free and overall survival for the taxane-based regimens.

The US Oncology trial 9735 compared four cycles of AC with four cycles of Taxotere (docetaxel) and cyclophosphamide (TC). With a median of 7 years follow-up, this study showed a statistically significantly improved disease-free survival and overall survival in the patients who received TC. Until this, no trial had compared a non-anthracycline, taxane-based regimen to an anthracycline-based regimen.

An important ongoing study (US Oncology 06090) is prospectively evaluating whether anthracyclines add any incremental benefit to a taxane-based regimen by comparing six cycles of TAC to six cycles of TC in *HER-2/neu* negative breast cancer patients. A third arm was added to evaluate the benefit of adding bevacizumab, a monoclonal antibody directed against vascular endothelial growth factor (VEGF), to TC. While awaiting the results of this trial, oncologists are faced with choosing from among the above treatment regimens for *HER-2/neu*-negative breast cancer. Given the benefits described above, taxanes are now used for most patients receiving chemotherapy for early breast cancer.

The overall duration of adjuvant chemotherapy still remains uncertain. However, based on the meta-analysis performed in the Oxford Overview (EBCTCG), the current recommendation is for 3–6 months of the commonly used regimens. Although it is clear that dose intensity to a specific threshold is essential, there is little, if any, evidence to support the long-term survival benefit of high-dose chemotherapy with stem cell support.

Chemotherapy side effects are now generally well controlled. Nausea and vomiting are abated with drugs that directly affect the central nervous system, such as ondansetron and granisetron. Infertility and premature ovarian failure are common side effects of chemotherapy, especially in women over the age of 40, and should be

discussed with patients prior to starting treatment. The risk of life-threatening neutropenia associated with chemotherapy can be reduced by use of growth factors such as pegfilgrastim and filgrastim (G-CSF), which stimulate proliferation and differentiation of hematopoietic cells. Long-term toxicities from chemotherapy, including cardiomyopathy (anthracyclines) and leukemia/myelodysplasia (anthracyclines and alkylating agents), remain a small but significant risk.

2. Targeted therapy

A. *HER-2/NEU* OVEREXPRESSION—Twenty percent of breast cancers have overexpression or amplification of the *HER-2/neu* oncogene. The poor prognosis associated with *HER-2/neu* overexpression has been drastically improved with the development of *HER-2/neu*-targeted therapy. Trastuzumab (Herceptin [H]), a monoclonal antibody that binds to *HER-2/neu* receptors, has proved effective in combination with chemotherapy in patients with *HER-2/neu* overexpressing metastatic and early breast cancer. In the adjuvant setting, the first and most commonly studied chemotherapy backbone used with trastuzumab is AC-T. More recently, the BCIRG006 study showed similar efficacy for AC-TH and a nonanthracycline-containing regimen, TCH (docetaxel, carboplatin, trastuzumab). Both were significantly better than AC-T in terms of disease-free and overall survival and the TCH had a lower risk of cardiac toxicity. Both AC-TH and TCH are FDA-approved for nonmetastatic, *HER-2/neu*-positive breast cancer. In these regimens, trastuzumab is given with chemotherapy and then continues beyond the course of chemotherapy to complete a full year. One study has been reported that evaluated use of a shorter course of trastuzumab (FinHer trial) in addition to chemotherapy. Although this study showed benefits of adding a 9-week course of trastuzumab to chemotherapy, the current standard remains 1 full year of trastuzumab for adjuvant therapy. Another study, Herceptin Adjuvant (HERA), is a three-arm study that is comparing chemotherapy alone with sequential delivery of trastuzumab after chemotherapy for 1 or 2 years. This study demonstrated a benefit to the addition of trastuzumab for 1 year but data regarding 2 years versus 1 year have not been reported. The PHARE study is comparing 1 year to 6 months of trastuzumab given after chemotherapy. At least one study (N9831) suggests that concurrent, rather than sequential, delivery of trastuzumab with chemotherapy may be more beneficial. Another question being addressed in trials is whether to treat small (<1 cm), node-negative tumors with trastuzumab plus chemotherapy. Retrospective studies have shown that even small (stage T1a,b) *HER-2/neu*-positive tumors have a worse prognosis compared with same-sized *HER-2/neu*-negative tumors. The NSABP B43 study is also ongoing to evaluate whether the addition of trastuzumab to radiation therapy is warranted for DCIS.

Cardiomyopathy develops in a small but significant percent (1–4%) of patients who receive trastuzumab-based regimens. For this reason, anthracyclines and trastuzumab are usually not given concurrently and cardiac function is monitored periodically throughout therapy.

B. ENDOCRINE THERAPY—Adjuvant hormone modulation therapy is highly effective in decreasing recurrence and mortality by 25% in women with hormone receptor-positive tumors regardless of menopausal status. The traditional regimen has been 5 years of the estrogen-receptor antagonist/agonist tamoxifen, and this remains the standard for premenopausal women. Ovarian ablation in premenopausal patients with ER-positive tumors may produce a benefit similar to that of adjuvant systemic chemotherapy. Whether the use of ovarian ablation plus tamoxifen (or an AI) is more effective than either measure alone is still unclear. In the Stockholm subset of the Zoladex in Premenopausal Patients (ZIPP) study, 927 premenopausal women were randomly assigned to goserelin, tamoxifen, the combination of both, or to no endocrine therapy for 2 years. With a median follow-up of 12.3 years, this substudy showed that goserelin and tamoxifen each significantly reduce the risk of recurrence of hormone receptor-positive breast cancer compared to control (goserelin 32%, [$P = 0.005$] and tamoxifen 27% [$P = 0.018$]), yet the combination of goserelin and tamoxifen was not superior to either treatment alone. This issue is still not settled and is being addressed in ongoing clinical trials (Suppression of Ovarian Function Trial [SOFT] and Tamoxifen and Exemestane Trial [TEXT]) that have not yet reported. AIs, including anastrozole, letrozole, and exemestane, reduce estrogen production and are also effective in the adjuvant setting for postmenopausal women. Approximately seven large randomized trials enrolling more than 24,000 patients have compared the use of AIs with tamoxifen or placebo as adjuvant therapy. All of these studies have shown small but statistically significant improvements in disease-free survival (absolute benefits of 2–6%) with the use of AIs. In addition, AIs have been shown to reduce the risk of contralateral breast cancers and to have fewer associated serious side effects (such as endometrial cancers and thromboembolic events) than tamoxifen. However, they are associated with accelerated bone loss and an increased risk of fractures as well as a musculoskeletal syndrome characterized by arthralgias or myalgias (or both) in up to 50% of patients. The American Society of Clinical Oncology and the NCCN have recommended that postmenopausal women with hormone receptor-positive breast cancer be offered an AI either initially or after tamoxifen therapy.

3. Bisphosphonates—Two randomized studies (ZO-FAST and ABCSG-12) have evaluated the use of an adjuvant intravenous bisphosphonate (zoledronic acid) in addition to standard local and systemic therapy. The results showed a 32–40% relative reduction in the risk of cancer recurrence for hormone receptor-positive nonmetastatic breast cancer. In fact, at the San Antonio Breast Cancer Symposium in 2011, with a median follow-up of 76 months, the ABCSG-12 study reported improved overall survival for patients treated with zoledronic acid. Conflicting results have been reported from the AZURE study. In this randomized study that enrolled premenopausal and postmenopausal patients, there was no disease-free or overall survival benefits associated with the addition of zoledronic acid to endocrine therapy for the overall study population. However, a prespecified subset analysis

in patients who were postmenopausal for at least 5 years did demonstrate a significant disease-free and overall survival benefit with the addition of the bisphosphonate. Side effects associated with intravenous bisphosphonate therapy include bone pain, fever, osteonecrosis of the jaw (rare), and renal failure. Currently, the adjuvant use of bisphosphonates and other bone stabilizing drugs, such as inhibitors of receptor activator of nuclear factor kappa B ligand (RANK-B), remains investigational.

4. Adjuvant therapy in older women—Data relating to the optimal use of adjuvant systemic treatment for women over the age of 65 are limited. Results from the EBCTCG overview indicates that while adjuvant chemotherapy yields a smaller benefit for older women compared with younger women, it still improves clinical outcomes. Moreover, individual studies do show that older women with higher risk disease derive benefits from chemotherapy. One study compared the use of oral chemotherapy (capecitabine) to standard chemotherapy in older women and concluded that standard chemotherapy is preferred. Another study (USO TC vs AC) showed that women over the age of 65 derive similar benefits from the taxane-based regimen as women who are younger. The benefits of endocrine therapy for hormone receptor-positive disease appear to be independent of age. In general, decisions relating to the use of systemic therapy should take into account a patient's comorbidities and physiological age, more so than chronologic age.

E. Neoadjuvant Therapy

The use of chemotherapy or endocrine therapy prior to resection of the primary tumor (neoadjuvant) is gaining popularity. This enables the assessment of in vivo chemosensitivity. Patients with hormone receptor-negative or *HER-2* positive breast cancer (or both) are more likely to have a pathologic complete response to neoadjuvant chemotherapy than those with hormone receptor-positive breast cancer. A complete pathologic response at the time of surgery is associated with improvement in survival. Neoadjuvant chemotherapy also increases the chance of breast conservation by shrinking the primary tumor in women who would otherwise need mastectomy for local control. Survival after neoadjuvant chemotherapy is similar to that seen with postoperative adjuvant chemotherapy. Neoadjuvant AI therapy has been evaluated in a phase II study involving 115 postmenopausal patients with hormone receptor-positive breast cancer. The overall response rate was 62% in this study, and 38% of patients initially ineligible for breast conservation were able to have lumpectomy. There is considerable concern as to the timing of sentinel lymph node biopsy (SLNB), since the chemotherapy may affect any cancer present in the lymph nodes. Several studies have shown that sentinel node biopsy can be done after neoadjuvant therapy. Many physicians recommend performing SLNB before administering the chemotherapy in order to avoid a false-negative result and to aid in planning subsequent radiation therapy. Others prefer to perform SLNB after neoadjuvant therapy to avoid a second operation and assess post-chemotherapy nodal status. If a complete dissection is

necessary, this can be performed at the time of the definitive breast surgery.

Important questions remaining to be answered are the timing and duration of adjuvant and neoadjuvant chemotherapy, which chemotherapeutic agents should be applied for which subgroups of patients, the use of combinations of hormonal therapy and chemotherapy as well as possibly targeted therapy, and the value of prognostic factors other than hormone receptors in predicting response to therapy.

► Treatment: Palliative

Palliative treatments are those to manage symptoms, improve quality of life, and even prolong survival, without the expectation of achieving cure. Only 10% of patients have de novo metastatic breast cancer at the time of diagnosis. However, in most patients who have a breast cancer recurrence after initial local and adjuvant therapy, the recurrence presents as metastatic rather than local (in breast) disease. Breast cancer most commonly metastasizes to the liver, lungs and bone, causing symptoms such as fatigue, change in appetite, abdominal pain, respiratory symptoms or bone pain.

A. Radiotherapy and Bisphosphonates

Palliative radiotherapy may be advised for primary treatment of locally advanced cancers with distant metastases to control ulceration, pain, and other manifestations in the breast and regional nodes. Irradiation of the breast and chest wall and the axillary, internal mammary, and supraclavicular nodes should be undertaken in an attempt to cure locally advanced and inoperable lesions when there is no evidence of distant metastases. A small number of patients in this group are cured in spite of extensive breast and regional node involvement.

Palliative irradiation is of value also in the treatment of certain bone or soft-tissue metastases to control pain or avoid fracture. Radiotherapy is especially useful in the treatment of isolated bony metastases, chest wall recurrences, brain metastases, and acute spinal cord compression.

In addition to radiotherapy, bisphosphonate therapy has shown excellent results in delaying and reducing skeletal events in women with bony metastases. Zoledronic acid is an FDA-approved intravenous bisphosphonate given monthly for bone metastases from breast cancer. Denosumab, a fully human monoclonal antibody that targets RANK-ligand, was approved by the FDA in 2010 for the treatment of advanced breast cancer causing bone metastases, based on data showing that it reduced the time to first skeletal-related event (eg, pathologic fracture) compared to zoledronic acid.

Caution should be exercised when combining radiation therapy with chemotherapy because toxicity of either or both may be augmented by their concurrent administration. In general, only one type of therapy should be given at a time unless it is necessary to irradiate a destructive lesion of weight-bearing bone while the patient is receiving another regimen. The regimen should be changed only if the disease is clearly progressing. This is especially difficult to determine for patients with destructive bone metastases,

since changes in the status of these lesions are difficult to determine radiographically.

B. Targeted Therapy

1. Endocrine therapy for metastatic disease—Targeted therapy refers to agents that are directed specifically against a protein or molecule expressed uniquely on tumor cells or in the tumor microenvironment. The first targeted therapy was the use of antiestrogen therapy in hormone receptor-positive breast cancer. The administration of hormones (eg, estrogens, androgens, progestins; see Table 17–6); ablation of the ovaries, adrenals, or pituitary; administration of drugs that block hormone receptors (such as tamoxifen) or drugs that block the synthesis of hormones (such as AIs) have all been shown to be effective in hormone receptor-positive metastatic breast cancer. Palliative treatment of metastatic cancer should be based on the ER status of the primary tumor or the metastases. Because only 5–10% of women with ER-negative tumors respond, they should not receive endocrine therapy except in unusual circumstances, eg, in an older patient who cannot tolerate chemotherapy. The rate of response is nearly equal in premenopausal and postmenopausal women with ER-positive tumors. A favorable response to hormonal manipulation occurs in about one-third of patients with metastatic breast cancer. Of those whose tumors contain ER, the response is about 60% and perhaps as high as 80% for patients whose tumors contain PR as well. Women with ER-positive tumors who do not respond to first-line endocrine therapy or experience progression should be given a different form of hormonal manipulation. The initial endocrine treatment used is referred to as primary hormonal manipulation; subsequent endocrine treatment is called secondary or tertiary hormonal manipulation.

Because the quality of life during endocrine manipulation is usually superior to that during cytotoxic chemotherapy, it is best to try endocrine manipulation whenever possible. However, when receptor status is unknown, disease is progressing rapidly or involves visceral organs, chemotherapy should be used as first-line treatment.

A. THE PREMENOPAUSAL PATIENT

(1) Primary hormonal therapy—The potent SERM tamoxifen is by far the most common and preferred method of hormonal manipulation in the premenopausal patient, in large part because it can be given with less morbidity and fewer side effects than cytotoxic chemotherapy and does not require oophorectomy. Tamoxifen is given orally in a dose of 20 mg daily. The average remission associated with tamoxifen lasts about 12 months.

There is no significant difference in survival or response between tamoxifen therapy and bilateral oophorectomy. Bilateral oophorectomy is less desirable than tamoxifen in premenopausal women because tamoxifen is so well tolerated. However, oophorectomy can be achieved rapidly and safely either by surgery, by irradiation of the ovaries if the patient is a poor surgical candidate, or by chemical ovarian ablation using a gonadotropin-releasing hormone (GnRH) analog. Oophorectomy presumably works by eliminating estrogens, progestins, and androgens, which stimulate

Table 17-6. Agents commonly used for hormonal management of metastatic breast cancer.

Drug	Action	Dose, Route, Frequency	Major Side Effects
Tamoxifen citrate (Nolvadex)	SERM	20 mg orally daily	Hot flushes, uterine bleeding, thrombophlebitis, rash
Fulvestrant (Faslodex)	Steroidal estrogen receptor antagonist	250 mg intramuscularly monthly	Gastrointestinal upset, headache, back pain, hot flushes, pharyngitis
Toremifene citrate (Fareston)	SERM	40 mg orally daily	Hot flushes, sweating, nausea, vaginal discharge, dry eyes, dizziness
Diethylstilbestrol (DES)	Estrogen	5 mg orally three times daily	Fluid retention, uterine bleeding, thrombophlebitis, nausea
Goserelin (Zoladex)	Synthetic luteinizing hormone releasing analogue	3.6 mg subcutaneously monthly	Arthralgias, blood pressure changes, hot flushes, headaches, vaginal dryness
Megestrol acetate (Megace)	Progestin	40 mg orally four times daily	Fluid retention
Letrozole (Femara)	AI	2.5 mg orally daily	Hot flushes, arthralgia/arthritis, myalgia
Anastrozole (Arimidex)	AI	1 mg orally daily	Hot flushes, skin rashes, nausea and vomiting
Exemestane (Aromasin)	AI	25 mg orally daily	Hot flushes, increased arthralgia/arthritis, myalgia, and alopecia

AI, aromatase inhibitor; SERM, selective estrogen receptor modulator.

growth of the tumor. AIs should not be used in a patient with functioning ovaries since they do not block ovarian production of estrogen.

(2) *Secondary or tertiary hormonal therapy*—Patients who do not respond to tamoxifen or ovarian ablation may be treated with chemotherapy or may try a second endocrine regimen, such as GnRH analog plus AI. Whether to opt for chemotherapy or another endocrine measure depends largely on the sites of metastatic disease (visceral being more serious than bone-only, thus sometimes warranting the use of chemotherapy), the disease burden, the rate of growth of disease, and patient preference. Patients who take chemotherapy and then later have progressive disease may subsequently respond to another form of endocrine treatment (Table 17-6). The optimal choice for secondary endocrine manipulation has not been clearly defined for the premenopausal patient.

Patients who improve after oophorectomy but subsequently relapse should receive tamoxifen or an AI; if one fails, the other may be tried. Megestrol acetate, a progesterone agent, may also be considered. Adrenalectomy or hypophysectomy, procedures rarely done today, induced regression in 30–50% of patients who previously responded to oophorectomy. Pharmacologic hormonal manipulation has replaced these invasive procedures.

B. THE POSTMENOPAUSAL PATIENT

(1) *Primary hormonal therapy*—For postmenopausal women with metastatic breast cancer amenable to endocrine manipulation, tamoxifen or an AI is the initial therapy of choice. The side effect profile of AIs differs from tamoxifen and may be more effective. The main side effects of tamoxifen are nausea, skin rash, and hot flushes. Rarely, tamoxifen induces hypercalcemia in patients with bony metastases. Tamoxifen also increases the risk of

venous thromboembolic events and uterine hyperplasia and cancer. The main side effects of AIs include hot flushes, vaginal dryness, and joint stiffness; however, osteoporosis and bone fractures are significantly higher than with tamoxifen.

(2) *Secondary or tertiary hormonal therapy*—AIs are also used for the treatment of advanced breast cancer in postmenopausal women after tamoxifen treatment. In the event that the patient responds to AI but then has progression of disease, a pure antiestrogen receptor antagonist, fulvestrant, has shown efficacy with about 20–30% of women benefiting from use. Postmenopausal patients who do not respond to SERM or AI should be given cytotoxic drugs. Postmenopausal women who respond initially to a SERM or AI but later manifest progressive disease may be crossed over to another hormonal therapy. If they do not respond, they should receive cytotoxic drugs. Androgens (such as testosterone) have many toxicities and should be used infrequently. As in premenopausal patients, neither hypophysectomy nor adrenalectomy should be performed. High-dose estrogen therapy has also paradoxically been shown to induce responses in advanced breast cancer. A study that evaluated the use of low-dose (6 mg) versus high-dose (30 mg) estradiol daily orally for postmenopausal women with metastatic AI-resistant breast cancer showed that the two doses yielded similar clinical benefit rates (29% and 28%, respectively) and, as expected, the higher dose was associated with more adverse events than the low dose. Interestingly, seven patients who progressed after an initial response to estradiol were re-treated with an AI and, of these, two patients had a partial response and one had stable disease, indicating resensitization to the AI.

(3) *Newer agents in development*—Although endocrine therapy can lead to disease control for months to years in

some postmenopausal patients, resistance to hormonal manipulation will occur in virtually all patients with resulting progression of disease. Thus, molecularly targeted agents are still needed to circumvent signaling pathways that lead to drug resistance. One pathway that appears to be upregulated in endocrine resistance is the mammalian target of rapamycin (MTOR) pathway. Everolimus is an orally bioavailable inhibitor of MTOR that has been approved by the FDA for the treatment of renal cell carcinoma. A phase III, placebo-controlled trial (BOLERO-2) evaluated exemestane with or without everolimus in 724 patients with AI-resistant, hormone receptor–positive metastatic breast cancer, and at interim analysis found that patients treated with everolimus had a significantly improved progression free survival (10.6 months versus 4.1 months; HR, 0.36; 95% CI, 0.27–0.47; $P < 0.001$) and tolerated therapy relatively well.

2. HER-2/*neu* targeted agents—For patients with *HER-2/neu* overexpressing or amplified tumors, trastuzumab plus chemotherapy has been shown to increase survival. **Lapatinib** is a newer oral targeted drug that works by inhibiting the intracellular tyrosine kinases of the epidermal growth factor and *HER-2/neu* receptors. This drug is FDA-approved for the treatment of trastuzumab-resistant *HER-2/neu*-positive metastatic breast cancer in combination with capecitabine, thus, a completely oral regimen. The combination of trastuzumab plus lapatinib has been shown to be more effective than lapatinib alone for trastuzumab-resistant metastatic breast cancer. Moreover, several trials have shown a significant clinical benefit for continuing *HER-2/neu*-targeted agents beyond progression. Multiple drugs targeting the *HER-2/neu* pathway are in development. A few of these therapeutics in development of being investigated for this use include T-DM1, pertuzumab, neratinib, everolimus, afatinib, and a *HER-2/neu*-targeted vaccine. T-DM1 (emtansine) is a novel antibody drug conjugate in which trastuzumab is stably linked to a derivative of maytansine, enabling targeted delivery of the cytotoxic chemotherapy to *HER-2*-overexpressing cells. A phase II randomized study comparing T-DM1 to docetaxel plus trastuzumab in the first-line treatment of *HER-2* positive advanced breast cancer showed superior progression free survival and improved toxicity with T-DM1. The results of a phase III randomized trial comparing T-DM1 to lapatinib plus capecitabine (EMILIA) for *HER-2* positive metastatic breast cancer are awaited. Another promising agent is pertuzumab, a monoclonal antibody that targets the extracellular domain of *HER-2* at a different epitope than targeted by trastuzumab and inhibits receptor dimerization. A phase III placebo-controlled randomized study (CLEOPATRA) showed that patients treated with the combination of pertuzumab, trastuzumab, and docetaxel had a significantly longer progression free survival (18.5 months vs. 12.4 months; HR, 0.62; 95% CI, 0.51–0.75; $P < 0.001$) and trended toward improved overall survival compared with those treated with docetaxel and trastuzumab.

3. Targeting angiogenesis—Bevacizumab is a monoclonal antibody directed against VEGF. This growth factor stimulates endothelial proliferation and neoangiogenesis

in cancer. A phase III randomized trial (E2100) in women with metastatic breast cancer showed increased response rate and progression-free survival rate with the combination of bevacizumab and paclitaxel as first-line treatment compared with paclitaxel alone; however, there was no significant overall survival benefit. This led to the accelerated FDA approval of bevacizumab in early 2008. Since that time, two additional prospective randomized clinical trials (AVADO and RIBBON-1) have reported that the addition of bevacizumab to standard chemotherapy improves disease-free survival and objective response rates compared with single-agent chemotherapy alone. A benefit in overall survival has not been demonstrated. The RIBBON-2 study is the first randomized study to show a benefit (in terms of response rate and progression-free survival) with the use of bevacizumab plus chemotherapy as *second*-line therapy for metastatic breast cancer. Side effects from bevacizumab include hypertension, bleeding, and thromboembolic events.

While initial results were promising, the lack of both survival benefit and data to identify those tumor types most likely to benefit from bevacizumab resulted in the FDA revoking its approval of bevacizumab for metastatic breast cancer in 2011.

4. Targeting “triple-negative” breast cancer—Until very recently, breast cancers lacking expression of the hormone receptors, ER and PR, and *HER-2/neu* have only been amenable to therapy with cytotoxic chemotherapy. This type of “triple-negative” breast cancer, while heterogeneous, generally behaves aggressively and is associated with a poor prognosis. Newer classes of targeted agents are being evaluated specifically for triple-negative breast cancer. Some triple-negative breast cancers may be characterized by an inability to repair double-strand DNA breaks (due to mutation or epigenetic silencing of the *BRCA* gene). **Poly-ADP ribose-polymerase (PARP) inhibitors** are a new class of agents that prevent the repair of single strand DNA breaks and are showing promise in *BRCA*-mutated and triple-negative breast cancer. One relatively small randomized phase II clinical trial evaluating gemcitabine plus carboplatin with or without an agent that inhibits PARP (BSI-201) for triple-negative metastatic breast cancer showed improved clinical outcomes, including improved overall survival for PARP inhibitor–treated patients. However, the phase III randomized study of this agent failed to meet its endpoints, possibly relating to its relative weak inhibition of PARP. Research in this area is rapidly expanding with multiple clinical trials of other PARP inhibitors and other molecularly targeted agents ongoing.

C. Palliative Chemotherapy

Cytotoxic drugs should be considered for the treatment of metastatic breast cancer (1) if visceral metastases are present (especially brain, liver, or lymphangitic pulmonary), (2) if hormonal treatment is unsuccessful or the disease has progressed after an initial response to hormonal manipulation, or (3) if the tumor is ER-negative. Prior adjuvant chemotherapy does not seem to alter response rates in

patients who relapse. A number of chemotherapy drugs (including vinorelbine, paclitaxel, docetaxel, gemcitabine, ixabepilone, carboplatin, cisplatin, capecitabine, albumin-bound paclitaxel, eribulin, and liposomal doxorubicin) may be used as single agents with first-line objective response rates ranging from 30% to 50%. A phase III, open-label trial (EMBRACE) compared eribulin, a novel microtubule-targeted agent, to treatment of physician's choice (TPC) in 762 patients with treatment-refractory advanced breast cancer. This uniquely designed study demonstrated that overall survival was significantly better in eribulin-treated patients (13.1 months versus 10.6 months; HR, 0.81; 95% CI, 0.66–0.99; $P = 0.041$), leading to its FDA approval in the United States in 2010 for patients who have received at least two prior treatments for advanced disease.

Combination chemotherapy yields statistically significantly higher response rates and progression-free survival rates, but has not been conclusively shown to improve overall survival rates compared with sequential single-agent therapy. Combinations that have been tested in phase III studies and have proven efficacy compared with single-agent therapy include capecitabine/docetaxel, gemcitabine/paclitaxel, and capecitabine/ixabepilone (see Tables 39–11 and 39–12). Various other combinations of drugs have been tested in phase II studies, and a number of clinical trials are ongoing to identify effective combinations. For patients whose tumors have progressed after several lines of therapy and who are considering additional therapy, clinical trial participation with experimental drugs in phase I, II, or III testing should be encouraged.

In the past, high-dose chemotherapy and autologous bone marrow or stem cell transplantation aroused widespread interest for the treatment of metastatic breast cancer. However, multiple clinical trials failed to show any improvement in survival with high-dose chemotherapy with stem cell transplant over conventional chemotherapy and the procedure is now rarely, if ever, performed for stage IV breast cancer.

American College of Radiology. Practice guideline for the breast conservation therapy in the management of invasive breast carcinoma. *J Am Coll Surg*. 2007 Aug;205(2):362–376. [PMID: 17660085]

Baselga J et al; CLEOPATRA Study Group. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. *N Engl J Med*. 2012 Jan 12;366(2):109–19. [PMID: 22149875]

Baselga J et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. *N Engl J Med*. 2012 Feb 9;366(6):520–9. [PMID: 22149876]

BIG 1-98 Collaborative Group; Mouridsen H et al. Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. *N Engl J Med*. 2009 Aug 20;361(8):766–76. [PMID: 19692688]

Brufsky AM et al. RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. *J Clin Oncol*. 2011 Nov 10;29(32):4286–93. [PMID: 21990397]

Coleman RE et al; AZURE Investigators. Breast-cancer adjuvant therapy with zoledronic acid. *N Engl J Med*. 2011 Oct 13;365(15):1396–405. [PMID: 21995387]

Cortes J et al. Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. *Lancet*. 2011 Mar 12;377(9769):914–23. [PMID: 21376385]

Eidtmann H et al. Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST study. *Ann Oncol*. 2010 Nov;21(11):2188–94. [PMID: 20444845]

Ellis MJ et al. Lower-dose vs high-dose oral estradiol therapy of hormone receptor-positive, aromatase inhibitor-resistant advanced breast cancer: a phase 2 randomized study. *JAMA*. 2009 Aug 19;302(7):774–80. [PMID: 19690310]

Giuliano AE et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. *JAMA*. 2011 Feb 9;305(6):569–75. [PMID: 21304082]

Gnant M et al. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62 month follow up from the ABCSG-12 randomised trial. *Lancet Oncol*. 2011 Jul;12(7):631–41. [PMID: 21641868]

Gnant M et al. Long-Term Follow-Up in ABCSG-12: Significantly Improved Overall Survival with Adjuvant Zoledronic Acid in Premenopausal Patients with Endocrine-Receptor-Positive Early Breast Cancer. San Antonio Breast Cancer Symposium. December 2011. Abstract S1-2.

Gonzalez-Angulo AM et al. High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller. *J Clin Oncol*. 2009 Dec 1;27(34):5700–6. [PMID: 19884543]

Hurvitz SA et al. What's positive about triple negative breast cancer? *Future Oncol*. 2009 Sep;5(7):1015–25. [PMID: 19729270]

Iwata H. Neo(adjuvant) trastuzumab treatment: current perspectives. *Breast Cancer*. 2009;16(4):288–94. [PMID: 19609648]

Joensuu H et al. Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial. *J Clin Oncol*. 2009 Dec 1;27(34):5685–92. [PMID: 19884557]

Jones SE et al. Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7-year follow-up of US Oncology Research Trial 9735. *J Clin Oncol*. 2009 Mar 10;27(8):1177–83. [PMID: 19204201]

Khan SA et al. Optimal surgical treatment of breast cancer: implications for local control and survival. *J Surg Oncol*. 2010 Jun 15;101(8):677–86. [PMID: 20512943]

Martin M et al; GEICAM 9805 Investigators. Adjuvant docetaxel for high-risk, node-negative breast cancer. *N Engl J Med*. 2010 Dec 2;363(23):2200–10. [PMID: 21121833]

Maughan KL et al. Treatment of breast cancer. *Am Fam Physician*. 2010 Jun 1;81(11):1339–46. [PMID: 20521754]

Muss HB et al. Adjuvant chemotherapy in older women with early-stage breast cancer. *N Engl J Med*. 2009 May 14;360(20):2055–65. [PMID: 19439741]

National Comprehensive Cancer Network. NCCN Guidelines: Breast Cancer. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp

Nelson JC et al. Four-year clinical update from the American Society of Breast Surgeons MammoSite brachytherapy trial. *Am J Surg*. 2009 Jul;198(1):83–91. [PMID: 19268900]

Olson JA Jr et al. Improved surgical outcomes for breast cancer patients receiving neoadjuvant aromatase inhibitor therapy: results from a multicenter phase II trial. *J Am Coll Surg*. 2009 May;208(5):906–14. [PMID: 19476859]

Pal SK et al. Adjuvant systemic therapy for older adults with early-stage breast cancer. *Womens Health (Lond Engl)*. 2009 May;5(3):251–62. [PMID: 19392611]

Perez EA et al. Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer. *Clin Oncol*. 2011 Dec 1;29(34):4491–7. [PMID: 22042958]

Saurel CA et al. Changes to adjuvant systemic therapy in breast cancer: a decade in review. *Clin Breast Cancer*. 2010 Jun;10(3):196–208. [PMID: 20497918]

Serletti JM et al. Breast reconstruction after breast cancer. *Plast Reconstr Surg*. 2011 Jun;127(6):124e–35e. [PMID: 21617423]

Slamon D et al; Breast Cancer International Research Group. Adjuvant trastuzumab in HER2-positive breast cancer. *N Engl J Med*. 2011 Oct 6;365(14):1273–83. [PMID: 21991949]

Stopeck AT et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. *J Clin Oncol*. 2010 Dec 10;28(35):5132–9. [PMID: 21060033]

Sverrisdottir A et al. Interaction between goserelin and tamoxifen in a prospective randomised clinical trial of adjuvant endocrine therapy in premenopausal breast cancer. *Breast Cancer Res Treat*. 2011 Aug;128(3):755–63. [PMID: 21625929]

Swain SM et al. Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer. *N Engl J Med*. 2010 Jun 3;362(22):2053–65. [PMID: 20519679]

Veronesi U et al. Sentinel lymph node biopsy in breast cancer: ten-year results of a randomized controlled study. *Ann Surg*. 2010 Apr;251(4):595–600. [PMID: 20195151]

Von Minckwitz G et al. Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a German Breast Group 26/Breast International Group 03-05 Study. *J Clin Oncol*. 2009 Apr 20;27(12):1999–2006. [PMID: 19289619]

probably around 25–40% at 10 years. Increasingly, the use of biologic markers, such as ER, PR, grade, and *HER-2/neu*, is helping to identify high-risk tumor types as well as direct treatment used (see Biomarkers & Gene Expression Profiling). Gene analysis studies, such as Oncotype Dx, can predict disease-free survival for some subsets of patients.

The mortality rate of breast cancer patients exceeds that of age-matched normal controls for nearly 20 years. Thereafter, the mortality rates are equal, though deaths that occur among breast cancer patients are often directly the result of tumor. Five-year statistics do not accurately reflect the final outcome of therapy.

In general, breast cancer appears to be somewhat more malignant in younger than in older women, and this may be related to the fact that fewer younger women have ER-positive tumors. Adjuvant systemic chemotherapy, in general, improves survival by about 30% and adjuvant hormonal therapy by about 25%.

For those patients whose disease progresses despite treatment, studies suggest supportive group therapy may improve survival. As they approach the end of life, such patients will require meticulous palliative care (see Chapter 5).

Kim C et al. Gene-expression-based prognostic assays for breast cancer. *Nat Rev Clin Oncol*. 2010 Jun;7(6):340–7. [PMID: 20440284]

Wishart GC et al. PREDICT: a new UK prognostic model that predicts survival following surgery for invasive breast cancer. *Breast Cancer Res*. 2010;12(1):R1. [PMID: 20053270]

► Prognosis

Stage of breast cancer is the most reliable indicator of prognosis (Table 17–7). Axillary lymph node status is the best-analyzed prognostic factor and correlates with survival at all tumor sizes. When cancer is localized to the breast with no evidence of regional spread after pathologic examination, the clinical cure rate with most accepted methods of therapy is 75% to >90%. In fact, patients with small mammographically detected biologically favorable tumors and no evidence of axillary spread have a 5-year survival rate >95%. When the axillary lymph nodes are involved with tumor, the survival rate drops to 50–70% at 5 years and

Table 17–7. Approximate survival (%) of patients with breast cancer by TNM stage.

TNM Stage	Five Years	Ten Years
0	95	90
I	85	70
IIA	70	50
IIB	60	40
IIIA	55	30
IIIB	30	20
IV	5–10	2
All	65	30

► Follow-up Care

After primary therapy, patients with breast cancer should be monitored long-term in order to detect recurrences and to observe the opposite breast for a second primary carcinoma. Local and distant recurrences occur most frequently within the first 2–5 years. During the first 2 years, most patients should be examined every 6 months (with mammogram every 6 months on the affected breast), then annually thereafter. Since these women are at an increased risk for local or contralateral breast tumor, MRI is being used by many breast surgeons to monitor patients with prior malignancies. Most insurance companies will reimburse for this. Special attention is paid to the contralateral breast because a new primary breast malignancy will develop in 20–25% of patients. In some cases, metastases are dormant for long periods and may appear 10–15 years or longer after removal of the primary tumor. Although studies have failed to show an adverse effect of hormonal replacement in disease-free patients, it is rarely used after breast cancer treatment, particularly if the tumor was hormone receptor positive. Even pregnancy has not been associated with shortened survival of patients rendered disease free—yet many oncologists are reluctant to advise a young patient with breast cancer that it is safe to become pregnant, and most will not support prescribing hormone replacement for the postmenopausal breast cancer patient. The use of estrogen replacement for conditions such as osteoporosis and hot flashes may be considered for a woman with a history of breast cancer after discussion of the benefits and risks; however, it is not routinely recommended, especially

given the availability of nonhormonal agents for these conditions (such as bisphosphonates and denosumab for osteoporosis).

A. Local Recurrence

The incidence of local recurrence correlates with tumor size, the presence and number of involved axillary nodes, the histologic type of tumor, the presence of skin edema or skin and fascia fixation with the primary tumor, and the type of definitive surgery and local irradiation. Local recurrence on the chest wall after total mastectomy and axillary dissection develops in as many as 8% of patients. When the axillary nodes are not involved, the local recurrence rate is < 5%, but the rate is as high as 25% when they are heavily involved. A similar difference in local recurrence rate was noted between small and large tumors. Factors such as multifocal cancer, in situ tumors, positive resection margins, chemotherapy, and radiotherapy have an effect on local recurrence in patients treated with breast-conserving surgery. Adjuvant systemic therapy greatly decreases the rate of local recurrence.

Chest wall recurrences usually appear within the first several years but may occur as late as 15 or more years after mastectomy. All suspicious nodules and skin lesions should be biopsied. Local excision or localized radiotherapy may be feasible if an isolated nodule is present. If lesions are multiple or accompanied by evidence of regional involvement in the internal mammary or supraclavicular nodes, the disease is best managed by radiation treatment of the entire chest wall including the parasternal, supraclavicular, and axillary areas and usually by systemic therapy.

Local recurrence after mastectomy usually signals the presence of widespread disease and is an indication for studies to search for evidence of metastases. Distant metastases will develop within a few years in most patients with locally recurrent tumor after mastectomy. When there is no evidence of metastases beyond the chest wall and regional nodes, irradiation for cure after complete local excision should be attempted. After partial mastectomy, local recurrence does not have as serious a prognostic significance as after mastectomy. However, those patients in whom a recurrence develops have a worse prognosis than those who do not. It is speculated that the ability of a cancer to recur locally after radiotherapy is a sign of aggressiveness and resistance to therapy. Completion of the mastectomy should be done for local recurrence after partial mastectomy; some of these patients will survive for prolonged periods, especially if the breast recurrence is DCIS or occurs more than 5 years after initial treatment. Systemic chemotherapy or hormonal treatment should be used for women in whom disseminated disease develops or those in whom local recurrence occurs.

B. Breast Cancer Survivorship Issues

Given that most women with non-metastatic breast cancer will be cured, a significant number of women face survivorship issues stemming from either the diagnosis or the treatment of the breast cancer. These challenges include psychological struggles, upper extremity lymphedema,

cognitive decline (also called “chemo brain”), weight management problems, cardiovascular issues, bone loss, postmenopausal side effects, and fatigue. One randomized study reported that survivors who received psychological intervention from the time of diagnosis had a lower risk of recurrence and breast cancer-related mortality. A randomized study in older, overweight cancer survivors showed that diet and exercise reduced the rate of self-reported functional decline compared with no intervention. Cognitive dysfunction is a commonly reported symptom experienced by women who have undergone systemic treatment for early breast cancer. Studies are ongoing to understand the pathophysiology leading to this syndrome. An interesting study reported that 200 mg of modafinil daily improved speed and quality of memory as well as attention for breast cancer survivors dealing with cognitive dysfunction. This promising study requires validation in a larger clinical trial.

1. Edema of the arm—Significant edema of the arm occurs in about 10–30% of patients after axillary dissection with or without mastectomy. It occurs more commonly if radiotherapy has been given or if there was postoperative infection. Partial mastectomy with radiation to the axillary lymph nodes is followed by chronic edema of the arm in 10–20% of patients. Sentinel lymph node dissection has proved to be a more accurate form of axillary staging without the side effects of edema or infection. Judicious use of radiotherapy, with treatment fields carefully planned to spare the axilla as much as possible, can greatly diminish the incidence of edema, which will occur in only 5% of patients if no radiotherapy is given to the axilla after a partial mastectomy and lymph node dissection.

Late or secondary edema of the arm may develop years after treatment, as a result of axillary recurrence or infection in the hand or arm, with obliteration of lymphatic channels. When edema develops, a careful examination of the axilla for recurrence or infection is performed. Infection in the arm or hand on the dissected side should be treated with antibiotics, rest, and elevation. If there is no sign of recurrence or infection, the swollen extremity should be treated with rest and elevation. A mild diuretic may be helpful. If there is no improvement, a compressor pump or manual compression decreases the swelling, and the patient is then fitted with an elastic glove or sleeve. Most patients are not bothered enough by mild edema to wear an uncomfortable glove or sleeve and will treat themselves with elevation or manual compression alone. Benzopyrones have been reported to decrease lymphedema but are not approved for this use in the United States. Rarely, edema may be severe enough to interfere with use of the limb. Traditionally, patients were advised to avoid weight lifting with the ipsilateral arm to prevent a worsening in lymphedema. However, a prospective randomized study has shown that twice weekly progressive weight lifting improves lymphedema symptoms and exacerbations and improves extremity strength.

2. Breast reconstruction—Breast reconstruction is usually feasible after total or modified radical mastectomy. Reconstruction should be discussed with patients prior to mastectomy, because it offers an important psychological

focal point for recovery. Reconstruction is not an obstacle to the diagnosis of recurrent cancer. The most common breast reconstruction has been implantation of a silicone gel or saline prosthesis in the subpectoral plane between the pectoralis minor and pectoralis major muscles. Alternatively, autologous tissue can be used for reconstruction.

Autologous tissue flaps are aesthetically superior to implant reconstruction in most patients. They also have the advantage of not feeling like a foreign body to the patient. The most popular autologous technique currently is the transrectus abdominis muscle flap (TRAM flap), which is done by rotating the rectus abdominis muscle with attached fat and skin cephalad to make a breast mound. The free TRAM flap is done by completely removing a small portion of the rectus with overlying fat and skin and using microvascular surgical techniques to reconstruct the vascular supply on the chest wall. A latissimus dorsi flap can be swung from the back but offers less fullness than the TRAM flap and is therefore less acceptable cosmetically. An implant often is used to increase the fullness with a latissimus dorsi flap. Reconstruction may be performed immediately (at the time of initial mastectomy) or may be delayed until later, usually when the patient has completed adjuvant therapy. When considering reconstructive options, concomitant illnesses should be considered, since the ability of an autologous flap to survive depends on medical comorbidities. In addition, the need for radiotherapy may affect the choice of reconstruction as radiation may increase fibrosis around an implant or decrease the volume of a flap.

3. Risks of pregnancy—Data are insufficient to determine whether interruption of pregnancy improves the prognosis of patients who are identified to have potentially curable breast cancer and who receive definitive treatment during pregnancy. Theoretically, the high levels of estrogen produced by the placenta as the pregnancy progresses could be detrimental to the patient with occult metastases of hormone-sensitive breast cancer. However, retrospective studies have *not* shown a worse prognosis for women with gestational breast cancer. The decision whether or not to terminate the pregnancy must be made on an individual basis, taking into account the clinical stage of the cancer, the overall prognosis for the patient, the gestational age of the fetus, the potential for premature ovarian failure in the future with systemic therapy, and the patient's wishes. Women with early-stage gestational breast cancer who choose to continue their pregnancy should undergo surgery to remove the tumor and systemic therapy if indicated. Retrospective reviews of patients treated with anthracycline-containing regimens for gestational cancers (including leukemia and lymphomas) have established the relative safety of these regimens during pregnancy for both the patient and the fetus. Taxane-based and trastuzumab-based regimens have not been evaluated extensively, however. Radiation therapy should be delayed until the pregnant patient has delivered.

Equally important is the advice regarding future pregnancy (or abortion in case of pregnancy) to be given to women of child-bearing age who have had definitive treatment for breast cancer. To date, no adverse effect of

pregnancy on survival of women who have had breast cancer has been demonstrated. When counseling patients, oncologists must take into consideration the patients' overall prognosis, age, comorbidities, and life goals.

In patients with inoperable or metastatic cancer (stage IV disease), induced abortion is usually advisable because of the possible adverse effects of hormonal treatment, radiotherapy, or chemotherapy upon the fetus in addition to the expectant mother's poor prognosis.

Chalalasi P et al. Caring for the breast cancer survivor: a guide for primary care physicians. *Am J Med.* 2010 Jun;123(6):489–95. [PMID: 20569749]

Del Mastro L et al. Effect of the gonadotropin-releasing hormone analogue triptorelin on the occurrence of chemotherapy-induced early menopause in premenopausal women with breast cancer: a randomized trial. *JAMA.* 2011 Jul 20;306(3):269–76. [PMID: 21771987]

Hermelink K. Acute and late onset cognitive dysfunction associated with chemotherapy in women with breast cancer. *Cancer.* 2011 Mar 1;117(5):1103. [PMID: 20960507]

Kim C et al. Gene-expression-based prognostic assays for breast cancer. *Nat Rev Clin Oncol.* 2010 Jun;7(6):340–7. [PMID: 20440284]

Kohli S et al. The effect of modafinil on cognitive function in breast cancer survivors. *Cancer.* 2009 Jun 15;115(12):2605–16. [PMID: 19309747]

Lee ES et al. Health-related quality of life in survivors with breast cancer 1 year after diagnosis compared with the general population: a prospective cohort study. *Ann Surg.* 2011 Jan;253(1):101–8. [PMID: 21294288]

Morey MC et al. Effects of home-based diet and exercise on functional outcomes among older, overweight long-term cancer survivors: RENEW: a randomized controlled trial. *JAMA.* 2009 May 13;301(18):1883–91. [PMID: 19436015]

Rawson AE et al. Current concepts in breast reconstruction. *WV Med J.* 2009 Oct;105 Spec No:16–22. [PMID: 19999261]

Rourke LL et al. Breast cancer and lymphedema: a current overview for the healthcare provider. *Womens Health (Lond Engl).* 2010 May;6(3):399–406. [PMID: 20426606]

Sammarco A. Quality of life of breast cancer survivors: a comparative study of age cohorts. *Cancer Nurs.* 2009 Sep–Oct;32(5):347–56. [PMID: 19661800]

Schmitz KH et al. Weight lifting for women at risk for breast cancer-related lymphedema: a randomized trial. *JAMA.* 2010 Dec 22;304(24):2699–705. [PMID: 21148134]

CARCINOMA OF THE MALE BREAST

ESSENTIALS OF DIAGNOSIS

- ▶ A painless lump beneath the areola in a man usually over 50 years of age.
- ▶ Nipple discharge, retraction, or ulceration may be present.
- ▶ Generally poorer prognosis than in women.

▶ General Considerations

Breast cancer in men is a rare disease; the incidence is only about 1% of that in women. The average age at occurrence

is about 70 years and there may be an increased incidence of breast cancer in men with prostate cancer. As in women, hormonal influences are probably related to the development of male breast cancer. There is a high incidence of both breast cancer and gynecomastia in Bantu men, theoretically owing to failure of estrogen inactivation by a liver damaged by associated liver disease. It is important to note that first-degree relatives of men with breast cancer are considered to be at high risk. This risk should be taken into account when discussing options with the patient and family. In addition, *BRCA2* mutations are common in men with breast cancer. Men with breast cancer, especially with a history of prostate cancer, should receive genetic counseling. The prognosis, even in stage I cases, is worse in men than in women. Blood-borne metastases are commonly present when the male patient appears for initial treatment. These metastases may be latent and may not become manifest for many years.

► Clinical Findings

A painless lump, occasionally associated with nipple discharge, retraction, erosion, or ulceration, is the primary complaint. Examination usually shows a hard, ill-defined, nontender mass beneath the nipple or areola. Gynecomastia not uncommonly precedes or accompanies breast cancer in men. Nipple discharge is an uncommon presentation for breast cancer in men but is an ominous finding associated with carcinoma in nearly 75% of cases.

Breast cancer staging is the same in men as in women. Gynecomastia and metastatic cancer from another site (eg, prostate) must be considered in the differential diagnosis. Benign tumors are rare, and biopsy should be performed on all males with a defined breast mass.

► Treatment

Treatment consists of modified radical mastectomy in operable patients, who should be chosen by the same criteria as women with the disease. Breast conserving therapy is rarely performed. Irradiation is the first step in treating localized metastases in the skin, lymph nodes, or skeleton that are causing symptoms. Examination of the cancer for hormone receptor proteins and *HER-2/neu* overexpression is of value in determining adjuvant therapy. Men commonly have ER-positive tumors and rarely have overexpression of *HER-2/neu*. Adjuvant systemic therapy and radiation is used for the same indications as in breast cancer in women.

Because breast cancer in men is frequently a disseminated disease, endocrine therapy is of considerable importance in its management. Tamoxifen is the main drug for management of advanced breast cancer in men. Tamoxifen (20 mg orally daily) should be the initial treatment. There is little experience with AIs though they should be effective. Castration in advanced breast cancer is a successful measure and more beneficial than the same procedure in women but is rarely used. Objective evidence of regression

may be seen in 60–70% of men with hormonal therapy for metastatic disease—approximately twice the proportion in women. The average duration of tumor growth remission is about 30 months, and life is prolonged. Bone is the most frequent site of metastases from breast cancer in men (as in women), and hormonal therapy relieves bone pain in most patients so treated. The longer the interval between mastectomy and recurrence, the longer the remission following treatment is likely. As in women, there is correlation between ERs of the tumor and the likelihood of remission following hormonal therapy.

AIs should replace adrenalectomy in men as they have in women. Corticosteroid therapy alone has been considered to be efficacious but probably has no value when compared with major endocrine ablation. Either tamoxifen or AIs may be primary or secondary hormonal manipulation.

Estrogen therapy—5 mg of diethylstilbestrol three times daily orally—may be effective hormonal manipulation after others have been successful and failed, just as in women. Androgen therapy may exacerbate bone pain. Chemotherapy should be administered for the same indications and using the same dosage schedules as for women with metastatic disease or for adjuvant treatment.

► Prognosis

Men with breast cancer seem to have a worse prognosis than women with breast cancer because breast cancer is diagnosed in men at a later stage. However, a large population based, international study reported that after adjustment for prognostic features (age, stage, treatment), men had a significantly improved relative survival from breast cancer compared to women. For node-positive disease, 5-year survival is approximately 69%, and for node-negative disease, it is 88%. A practice-patterns database study reported that based on NCCN guidelines, only 59% of patients received the recommended chemotherapy, 82% received the recommended hormonal therapy, and 71% received the recommended post-mastectomy radiation, indicating a relatively low adherence to NCCN guidelines for men.

For those patients whose disease progresses despite treatment, meticulous efforts at palliative care are essential (see Chapter 5).

Kiluk JV et al. Male breast cancer: management and follow-up recommendations. *Breast J*. 2011 Sep–Oct;17(5):503–9. [PMID: 21883641]

Miao H et al. Incidence and outcome of male breast cancer: an international population-based study. *J Clin Oncol*. 2011 Nov 20;29(33):4381–6. [PMID: 21969512]

Ravi A et al. Breast cancer in men: prognostic factors, treatment patterns, and outcome. *Am J Mens Health*. 2012 Jan;6(1):51–8. [PMID: 21831929]

Wauters CA et al. Is cytology useful in the diagnostic workup of male breast lesions? A retrospective study over a 16-year period and review of the recent literature. *Acta Cytol*. 2010 May–Jun;54(3):259–64. [PMID: 20518408]

Zurrida S et al. Male breast cancer. *Future Oncol*. 2010 Jun; 6(6):985–91. [PMID: 20528235]

Gynecologic Disorders

H. Trent MacKay, MD, MPH
Jason Woo, MD, MPH, FACOG

18

ABNORMAL PREMENOPAUSAL BLEEDING

ESSENTIALS OF DIAGNOSIS

- ▶ Blood loss of over 80 mL per cycle.
- ▶ Excessive bleeding, often with the passage of clots, may occur at regular menstrual intervals (menorrhagia) or irregular intervals (dysfunctional uterine bleeding).
- ▶ Etiology most commonly dysfunctional uterine bleeding on a hormonal basis.

▶ General Considerations

Normal menstrual bleeding lasts an average of 4 days (range, 2–7 days), with a mean blood loss of 40 mL. Blood loss of over 80 mL per cycle is abnormal and frequently produces anemia. When there are < 21 days between the onset of bleeding episodes, the cycles are likely to be anovular. Ovulation bleeding, a single episode of spotting between regular menses, is quite common. Heavier or irregular intermenstrual bleeding warrants investigation.

Dysfunctional uterine bleeding is associated with anovulation, with overgrowth of the endometrium due to estrogen stimulation without progesterone to stabilize growth. Anovulation is most common in teenagers, in women aged late 30s to late 40s, and in extremely obese women or those with polycystic ovary syndrome.

▶ Clinical Findings

A. Symptoms and Signs

The diagnosis usually depends on the following: (1) A careful description of the duration and amount of flow, related pain, and relationship to the last menstrual period (LMP), with the presence of blood clots or the degree of inconvenience caused by the bleeding serving as useful indicators; (2) A history of pertinent illnesses, such as recent systemic infections or hospitalizations, or weight change; (3) A history of medications taken in the past month; (4) A history

of coagulation disorders in the patient or family members; (5) A pelvic examination to look for vulvar, vaginal or cervical lesions, pregnancy, uterine myomas, adnexal masses, adenomyosis, or infection.

B. Laboratory Studies

Cervical samples should be obtained for cytology and culture. A hemoglobin and hematocrit and a pregnancy test should be done, and studies of thyroid function and coagulation disorders should be considered. Up to 18% of women with severe menorrhagia may have a coagulopathy. If anovulatory bleeding is a concern, additional tests include basal body temperature records, serum progesterone measured 1 week before the expected onset of menses, or an endometrial biopsy specimen for secretory activity shortly before the onset of menstruation.

C. Imaging

Ultrasound may be useful to evaluate endometrial thickness or to diagnose intrauterine or ectopic pregnancy or adnexal masses. Endovaginal ultrasound with saline infusion sonohysterography may be used to diagnose endometrial polyps or subserous myomas. MRI can definitively diagnose submucous myomas and adenomyosis.

D. Cervical Biopsy and Endometrial Curettage

Biopsy, curettage, or aspiration of the endometrium and curettage of the endocervix may be necessary to diagnose the cause of bleeding. These and other invasive gynecologic diagnostic procedures are described in Table 18–1. Polyps, endometrial hyperplasia, and submucous myomas are commonly identified in this way. If cancer of the cervix is suspected, colposcopically directed biopsies and endocervical curettage are indicated as first steps.

E. Hysteroscopy

Hysteroscopy can visualize endometrial polyps, submucous myomas, and exophytic endometrial cancers, followed by removal of the polyp or myoma and endometrial sampling.

Table 18-1. Common gynecologic diagnostic procedures.

Colposcopy

Visualization of cervical, vaginal, or vulvar epithelium under 5–50× magnification with and without dilute acetic acid to identify abnormal areas requiring biopsy. An office procedure.

Dilation & curettage (D&C)

Dilation of the cervix and curettage of the entire endometrial cavity, using a metal curette or suction cannula and often using forceps for the removal of endometrial polyps. Can usually be done in the office under local anesthesia.

Endometrial biopsy

Removal of one or more areas of the endometrium by means of a curette or small aspiration device without cervical dilation. Diagnostic accuracy similar to D&C. An office procedure performed under local anesthesia.

Endocervical curettage

Removal of endocervical epithelium with a small curette for diagnosis of cervical dysplasia and cancer. An office procedure performed under local anesthesia.

Hysteroscopy

Visual examination of the uterine cavity with a small fiberoptic endoscope passed through the cervix. Biopsies and excision of myomas can be performed. Can be done in the office under local anesthesia or in the operating room under general anesthesia.

Saline infusion sonohysterography

Introduction of saline solution into endometrial cavity with a catheter to visualize submucous myomas or endometrial polyps by transvaginal ultrasound. May be performed in the office with oral analgesia.

Hysterosalpingography

Injection of radiopaque dye through the cervix to visualize the uterine cavity and oviducts. Mainly used in investigation of infertility.

Laparoscopy

Visualization of the abdominal and pelvic cavity through a small fiberoptic endoscope passed through a subumbilical incision. Permits diagnosis, tubal sterilization, and treatment of many conditions previously requiring laparotomy. General anesthesia is usually used.

▶ Treatment

Premenopausal patients with abnormal uterine bleeding include those with submucosal myomas, infection, early abortion, thrombophilias, or pelvic neoplasms. The history, physical examination, laboratory findings, imaging, and endometrial sampling should identify such patients, who require definitive therapy. A large group of patients remain, most of whom have dysfunctional uterine bleeding on the basis of anovulation.

Dysfunctional uterine bleeding can usually be treated hormonally. Women over the age of 35 should routinely have endometrial sampling to rule out endometrial hyperplasia or carcinoma prior to initiation of hormonal therapy. Progestins, which limit and stabilize endometrial growth, are generally effective. For patients with irregular or light bleeding, medroxyprogesterone acetate, 10 mg/d orally, or norethindrone acetate, 5 mg/d orally, should be

given for 10 days, following which withdrawal bleeding (so-called medical curettage) will occur. If successful, the treatment can be repeated for several cycles, starting medication on day 15 of subsequent cycles, or it can be reinstated if amenorrhea or dysfunctional bleeding recurs. In women who are experiencing heavier bleeding, any of the combination oral contraceptives (with 30–35 mcg of estrogen estradiol) can be given four times daily for 1 or 2 days followed by two pills daily through day 5 and then one pill daily through day 20; after withdrawal bleeding occurs, pills are taken in the usual dosage for three cycles. In cases of intractable heavy bleeding, a gonadotropin-releasing hormone (GnRH) agonist such as depot leuprolide, 3.75 mg intramuscularly monthly, or nafarelin, 0.2–0.4 mg intranasally twice daily, can be used for up to 6 months to create a temporary cessation of menstruation by ovarian suppression. An alternative, danazol 200 mg orally four times daily, may also be used to create an atrophic endometrium, although its use is limited by its androgenic side effects.

In cases of heavy bleeding requiring hospitalization, intravenous conjugated estrogens, 25 mg every 4 hours for three or four doses, can be used, followed by oral conjugated estrogens, 2.5 mg daily, or ethinyl estradiol, 20 mcg orally daily, for 3 weeks, with the addition of medroxyprogesterone acetate, 10 mg orally daily for the last 10 days of treatment, or a combination oral contraceptive daily for 3 weeks. This will thicken the endometrium and control the bleeding. Nonsteroidal anti-inflammatory drugs (NSAIDs), such as naproxen or mefenamic acid, in the usual anti-inflammatory doses will often reduce blood loss in menorrhagia—even that associated with a copper intrauterine device (IUD).

If the abnormal bleeding is not controlled by hormonal treatment, hysteroscopy, saline infusion sonohysterography, or a dilation and curettage (D&C) is necessary to check for polyps, submucous myomas, or endometrial cancer. In the absence of specific pathology, bleeding unresponsive to medical therapy may be treated with endometrial ablation, levonorgestrel-releasing IUD, or hysterectomy. While hysterectomy was used commonly in the past for bleeding unresponsive to medical therapy, the low risk of complications and the good short-term results of both endometrial ablation and levonorgestrel-releasing IUD make them attractive alternatives to hysterectomy. Endometrial ablation may be performed through the hysteroscope with laser photocoagulation or electrocautery. Nonhysteroscopic techniques include balloon thermal ablation, cryoablation, free-fluid thermal ablation, impedance bipolar radiofrequency ablation, and microwave ablation. The latter methods are well-adapted to outpatient therapy under local anesthesia.

The levonorgestrel-releasing IUD markedly reduces menstrual blood loss and may be a good alternative to other therapies. However, while short-term results with endometrial ablation and levonorgestrel-releasing IUD are satisfactory, at 5 years after either the endometrial ablation procedure or placement of the levonorgestrel IUD, up to 40% of women will have had either repeat ablation procedures or a hysterectomy.

▶ When to Refer

- If bleeding is not controlled with first-line therapy.
- If expertise is needed for a surgical procedure.

▶ When to Admit

If bleeding is uncontrollable with first-line therapy and the patient is not hemodynamically stable.

Maness DL et al. How best to manage dysfunctional uterine bleeding. *J Fam Pract.* 2010 Aug;59(8):449–58. [PMID: 20714455]

Thomas MC. Treatment options for dysfunctional uterine bleeding. *Nurse Pract.* 2011 Aug;36(8):14–20. [PMID: 21730879]

POSTMENOPAUSAL VAGINAL BLEEDING

ESSENTIALS OF DIAGNOSIS

- ▶ Vaginal bleeding that occurs 6 months or more following cessation of menstrual function.
- ▶ Bleeding is usually painless.
- ▶ Bleeding may be a single episode of spotting or profuse bleeding for days or months.

▶ General Considerations

Vaginal bleeding that occurs 6 months or more following cessation of menstrual function should be investigated. The most common causes are atrophic endometrium, endometrial proliferation or hyperplasia, endometrial or cervical cancer, and administration of estrogens with or without added progestin. Other causes include atrophic vaginitis, trauma, endometrial polyps, friction ulcers of the cervix associated with prolapse of the uterus, and blood dyscrasias. Uterine bleeding is usually painless, but pain may be present if the cervix is stenotic, if bleeding is severe and rapid, or if infection or torsion or extrusion of a tumor is present. The patient may report a single episode of spotting or profuse bleeding for days or months.

▶ Diagnosis

The vulva and vagina should be inspected for areas of bleeding, ulcers, or neoplasms. A cytologic smear of the cervix and vaginal pool should be taken. If available, transvaginal sonography should be used to measure endometrial thickness. A measurement of 4 mm or less indicates a low likelihood of hyperplasia or endometrial cancer. If the thickness is > 4 mm or there is a heterogeneous appearance to the endometrium, it should be determined if the thickening is global or focal. Sonohysterography may assist in making this distinction. If the thickening is global, endometrial biopsy or D&C is appropriate. If focal, guided sampling with hysteroscopy should be done.

▶ Treatment

Simple endometrial hyperplasia calls for cyclic or continuous progestin therapy (medroxyprogesterone acetate, 10 mg/d orally, or norethindrone acetate, 5 mg/d orally) for 21 or 30 days of each month for 3 months. The use of a levonorgestrel intrauterine system is also a treatment option. Repeat sampling should be performed. If endometrial hyperplasia with atypia or if carcinoma of the endometrium is found, hysterectomy is necessary.

▶ When to Refer

- Expertise in performing ultrasonography is required.
- Complex endometrial hyperplasia with atypia is present.
- Hysteroscopy is indicated.

Goldstein SR. The role of transvaginal ultrasound or endometrial biopsy in the evaluation of the menopausal endometrium. *Am J Obstet Gynecol.* 2009 Jul;201(1):5–11. [PMID: 19576369]

Haoula ZJ et al. Levonorgestrel intra-uterine system as a treatment option for complex endometrial hyperplasia. *Eur J Obstet Gynecol Reprod Biol.* 2011 Nov;159(1):176–9. [PMID: 21741152]

PREMENSTRUAL SYNDROME (Premenstrual Tension)

The premenstrual syndrome (PMS) is a recurrent, variable cluster of troublesome physical and emotional symptoms that develop during the 7–14 days before the onset of menses and subside when menstruation occurs. PMS intermittently affects about 40% of all premenopausal women, primarily those 25–40 years of age. In about 5–8% of affected women, the syndrome may be severe. Although not every woman experiences all the symptoms or signs at one time, many describe bloating, breast pain, ankle swelling, a sense of increased weight, skin disorders, irritability, aggressiveness, depression, inability to concentrate, libido change, lethargy, and food cravings. When emotional or mood symptoms predominate, along with physical symptoms, and there is a clear functional impairment, the term “premenstrual dysphoric disorder” (PMDD) may be applied. The pathogenesis of PMS/PMDD is still uncertain, and current treatment methods are mainly empiric. The clinician should provide support for both the patient’s emotional and physical distress. This includes the following:

1. Careful evaluation of the patient, with understanding, explanation, and reassurance.
2. Advise the patient to keep a daily diary of all symptoms for 2–3 months, to evaluate the timing and characteristics of her symptoms. If her symptoms occur throughout the month rather than in the 2 weeks before menses, she may have depression or other emotional problems instead of or in addition to PMS.
3. For mild to moderate symptoms, a program of aerobic exercise; reduction of caffeine, salt, and alcohol intake; the use of alternative therapies, such as an increase in dietary calcium (to 1200 mg per day), vitamin D (to 800

international units per day), and complex carbohydrates in the diet may be helpful, though these interventions remain unproven.

4. When physical symptoms predominate, spironolactone, 100 mg orally daily during the luteal phase, is effective for reduction of bloating and breast tenderness. Oral contraceptives or injectable progestin depot medroxyprogesterone acetate (DMPA) will decrease breast pain and cramping. A combined oral contraceptive containing the progestin drospirenone with a 4-day pill-free interval has been approved by the US Food and Drug Administration (FDA) for the treatment of PMDD. NSAIDs, such as mefenamic acid, 500 mg orally three times a day, will reduce a number of symptoms but not breast pain.
5. When mood disorders predominate, several serotonin reuptake inhibitors (such as fluoxetine, 20 mg orally, either daily or only on symptom days) have been shown to be effective in relieving tension, irritability, and dysphoria with few side effects.
6. When the above regimens are not effective, ovarian function can be suppressed with continuous high-dose progestin (20–30 mg/d of oral medroxyprogesterone acetate or 150 mg of DMPA orally every 3 months or GnRH agonist with add-back therapy, such as conjugated equine estrogen, 0.625 mg orally daily with medroxyprogesterone acetate, 2.5–5 mg orally daily).

Brown J et al. Selective serotonin reuptake inhibitors for premenstrual syndrome. *Cochrane Database Syst Rev.* 2009 Apr 15;(2):CD001396. [PMID: 19370564]

Lopez LM et al. Oral contraceptives containing drospirenone for premenstrual syndrome. *Cochrane Database Syst Rev.* 2009 Apr 15;(2):CD006586. [PMID: 19370644]

Vigod SN et al. Understanding and treating premenstrual dysphoric disorder: an update for the women's health practitioner. *Obstet Gynecol Clin North Am.* 2009 Dec;36(4):907–24. [PMID: 19944308]

DYSMENORRHEA

1. Primary Dysmenorrhea

Primary dysmenorrhea is menstrual pain associated with menstrual cycles in the absence of pathologic findings. The pain usually begins within 1–2 years after the menarche and may become more severe with time. The frequency of cases increases up to age 20 and then decreases with age and markedly with parity. Fifty to 75 percent of women are affected at some time and 5–6% have incapacitating pain.

► Clinical Findings

Primary dysmenorrhea is low, midline, wave-like, cramping pelvic pain often radiating to the back or inner thighs. Cramps may last for 1 or more days and may be associated with nausea, diarrhea, headache, and flushing. The pain is produced by uterine vasoconstriction, anoxia, and sustained contractions mediated by prostaglandins. The pelvic examination is normal between menses; examination during menses may produce discomfort, but there are no pathologic findings.

► Treatment

NSAIDs (ibuprofen, ketoprofen, mefenamic acid, naproxen) and the cyclooxygenase (COX)-2 inhibitor celecoxib are generally helpful. The medication should be started 1–2 days before expected menses. Symptoms can be suppressed with use of oral contraceptives, depot-medroxyprogesterone acetate, or the levonorgestrel-releasing IUD. Continuous use of oral contraceptives can be used to suppress menstruation completely and prevent dysmenorrhea. For women who do not wish to use hormonal contraception, other therapies that have shown at least some benefit include local heat; thiamine, 100 mg/d orally; vitamin E, 200 units/d orally from 2 days prior to and for the first 3 days of menses; and high-frequency transcutaneous electrical nerve stimulation.

2. Secondary Dysmenorrhea

Secondary dysmenorrhea is menstrual pain for which an organic cause exists, often associated with endometriosis or uterine fibroids. It usually begins well after menarche, sometimes even as late as the third or fourth decade of life.

► Clinical Findings

The history and physical examination may suggest endometriosis or fibroids. Other causes may be pelvic inflammatory disease (PID), submucous myoma(s), adenomyosis, IUD use, cervical stenosis with obstruction, or blind uterine horn (rare).

► Diagnosis

Cervical cultures should be obtained to rule out pelvic infections. Pelvic imaging is useful for detecting the presence of uterine fibroids or other anomalies. Submucous myomas can be detected most reliably by MRI but also by hysteroscopy, by hysteroscopy, or by passing a sound or curette over the uterine cavity during D&C. Adenomyosis, the presence of islands of endometrial tissue in the myometrium, may be diagnosed with ultrasound or, preferably, with MRI. Cervical stenosis may result from induced abortion, creating crampy pain at the time of expected menses with obstruction of blood flow; this is easily cured by passing a sound into the uterine cavity after administering a paracervical block. Laparoscopy may be used to diagnose endometriosis or other pelvic abnormalities not visualized by imaging.

► Treatment

A. Specific Measures

Periodic use of analgesics, including the NSAIDs given for primary dysmenorrhea, may be beneficial, and oral contraceptives may give relief, particularly in endometriosis. Danazol and GnRH agonists are effective in the treatment of endometriosis (see below), although their long-term use may be limited by cost or side effects. Adenomyosis may respond to the levonorgestrel-releasing intrauterine system, uterine artery embolization, or hormonal approaches used to treat endometriosis, but hysterectomy remains the

definitive treatment of choice for women who have completed childbearing.

B. Surgical Measures

If disability is marked or prolonged, laparoscopy or exploratory laparotomy is usually warranted. Definitive surgery depends on the degree of disability and the findings at operation.

▶ When to Refer

- Standard therapy fails to relieve pain.
- Suspicion of pelvic pathology, such as endometriosis, leiomyomas, or adenomyosis.

Sheng J et al. The LNG-IUS study on adenomyosis: a 3-year follow-up study of the efficacy and side effects of the use of the levonorgestrel intrauterine system of the treatment of dysmenorrhea associated with adenomyosis. *Contraception*. 2009 Mar;79(3):189–93. [PMID: 19185671]

Wong CL et al. Oral contraceptive pill as treatment for primary dysmenorrhoea. *Cochrane Database Syst Rev*. 2009 Apr 15;(2):CD002120. [PMID: 19370576]

VAGINITIS



ESSENTIALS OF DIAGNOSIS

- ▶ Vaginal irritation.
- ▶ Pruritus.
- ▶ Pain.
- ▶ Unusual discharge.

▶ General Considerations

Inflammation and infection of the vagina are common gynecologic problems, resulting from a variety of pathogens, allergic reactions to vaginal contraceptives or other products, vaginal atrophy, or the friction of coitus. The normal vaginal pH is 4.5 or less, and *Lactobacillus* is the predominant organism. At the time of the midcycle estrogen surge, clear, elastic, mucoid secretions from the cervical os are often profuse. In the luteal phase and during pregnancy, vaginal secretions are thicker, white, and sometimes adherent to the vaginal walls. These normal secretions can be confused with vaginitis by concerned women.

▶ Clinical Findings

When the patient complains of vaginal irritation, pain, or unusual discharge, a history should be taken, noting the onset of the LMP; recent sexual activity; use of contraceptives, tampons, or douches; recent changes in medications or use of antibiotics; and the presence of vaginal burning, pain, pruritus, or unusually profuse or malodorous discharge.

The physical examination should include careful inspection of the vulva and speculum examination of the vagina and cervix. The cervix is sampled for gonococcus and *Chlamydia* if appropriate. A specimen of vaginal discharge is examined under the microscope in a drop of 0.9% saline solution to look for trichomonads or clue cells and in a drop of 10% potassium hydroxide to search for *Candida*. The vaginal pH should be tested; it is frequently > 4.5 in infections due to trichomonads and bacterial vaginosis. A bimanual examination to look for evidence of pelvic infection should follow. Point-of-care testing is available for all three organisms that cause vaginitis. It can be used if microscopy is not available or for confirmatory testing of microscopy.

A. Vulvovaginal Candidiasis


Pregnancy, diabetes, and use of broad-spectrum antibiotics or corticosteroids predispose patients to *Candida* infections. Heat, moisture, and occlusive clothing also contribute to the risk. Pruritus, vulvovaginal erythema, and a white curd-like discharge that is not malodorous are found (Figure 18–1). Microscopic examination with 10% potassium hydroxide reveals hyphae and spores. Cultures with Nickerson medium may be used if *Candida* is suspected but not demonstrated.

B. *Trichomonas vaginalis* Vaginitis

This protozoal flagellate infects the vagina, Skene ducts, and lower urinary tract in women and the lower genitourinary tract in men. It is sexually transmitted. Pruritus and a malodorous frothy, yellow-green discharge occur, along with diffuse vaginal erythema and red macular lesions on the cervix in severe cases (Figure 18–2). Motile organisms with flagella are seen by microscopic examination of a wet mount with saline solution.

C. Bacterial Vaginosis

This condition is considered to be a polymicrobial disease that is not sexually transmitted. An overgrowth of



▲ **Figure 18–1.** Cervical candidiasis. (Public Health Image Library, CDC.)



▲ **Figure 18-2.** Strawberry cervix in *Trichomonas vaginalis* infection, with inflammation and punctate hemorrhages. (Courtesy of Richard P. Usatine, MD; used, with permission, from Usatine RP, Smith MA, Mayeaux EJ Jr, Chumley H, Tysinger J. *The Color Atlas of Family Medicine*. McGraw-Hill, 2009.)

Gardnerella and other anaerobes is often associated with increased malodorous discharge without obvious vulvitis or vaginitis. The discharge is grayish and sometimes frothy, with a pH of 5.0–5.5. An amine-like (“fishy”) odor is present if a drop of discharge is alkalinized with 10% potassium hydroxide. On wet mount in saline, epithelial cells are covered with bacteria to such an extent that cell borders are obscured (clue cells, Figure 18–3). Vaginal cultures are generally not useful in diagnosis.


D. Condylomata Acuminata (Genital Warts)

Warty growths on the vulva, perianal area, vaginal walls, or cervix are caused by various types of the human papillomavirus (HPV). They are sexually transmitted. Pregnancy and immunosuppression favor growth. Vulvar lesions may be obviously wart-like or may be diagnosed only after application of 4% acetic acid (vinegar) and colposcopy, when they appear whitish, with prominent papillae. Fissures may be present at the fourchette. Vaginal lesions may show diffuse hypertrophy or a cobblestone appearance.

► Treatment

A. Vulvovaginal Candidiasis

A variety of regimens are available to treat vulvovaginal candidiasis. Women with uncomplicated vulvovaginal



▲ **Figure 18-3.** Clue cells seen in bacterial vaginosis due to *Gardnerella vaginalis*. (Courtesy of Richard P. Usatine, MD; used, with permission, from Usatine RP, Smith MA, Mayeaux EJ Jr, Chumley H, Tysinger J. *The Color Atlas of Family Medicine*. McGraw-Hill, 2009.)

candidiasis will usually respond to a 1- to 3-day regimen of a topical azole. Women with complicated infection (including four or more episodes in 1 year, severe signs and symptoms, non-albicans species, uncontrolled diabetes, HIV infection, corticosteroid treatment, or pregnancy) should receive 7–14 days of a topical regimen or two doses of oral fluconazole 3 days apart. (Pregnant women should use only topical azoles.) In recurrent non-albicans infections, 600 mg of boric acid in a gelatin capsule intravaginally once daily for 2 weeks is approximately 70% effective. If recurrence occurs, referral to an infectious disease specialist is indicated.

1. Single-dose regimens—Effective single-dose regimens include miconazole (1200-mg vaginal suppository), tioconazole (6.5% cream, 5 g vaginally), sustained-release butoconazole (2% cream, 5 g vaginally), or fluconazole (150 mg oral tablet).

2. Three-day regimens—Effective 3-day regimens include butoconazole (2% cream, 5 g vaginally once daily), clotrimazole (2% cream, 5 g vaginally once daily), terconazole (0.8% cream, 5 g, or 80-mg vaginal suppository once daily), or miconazole (200 mg vaginal suppository once daily).

3. Seven-day regimens—The following regimens are given once daily: clotrimazole (1% cream), miconazole (2% cream, 5 g, or 100 mg vaginal suppository), or terconazole (0.4% cream, 5 g).

4. Fourteen-day regimen—An effective 14-day regimen is nystatin (100,000-unit vaginal tablet once daily).

5. Recurrent vulvovaginal candidiasis (maintenance therapy)—Clotrimazole (500 mg vaginal suppository once weekly or 200 mg cream twice weekly) or fluconazole

(100, 150, or 200 mg orally once weekly) are effective regimens for maintenance therapy for up to 6 months.

B. *Trichomonas vaginalis* Vaginitis

Treatment of both partners simultaneously is recommended; metronidazole or tinidazole, 2 g orally as a single dose or 500 mg orally twice a day for 7 days, is usually used.

In the case of treatment failure with metronidazole in the absence of reexposure, the patient should be re-treated with metronidazole, 500 mg orally twice a day for 7 days, or tinidazole, 2 g orally as a single dose. If treatment failure occurs again, give metronidazole or tinidazole, 2 g orally once daily for 5 days. If this is not effective in eradicating the organisms, metronidazole and tinidazole susceptibility testing can be arranged with the CDC at 404-718-4141 or at <http://www.cdc.gov/std>. Women infected with *T vaginalis* are at increased risk for concurrent infection with other sexually transmitted diseases.

C. Bacterial Vaginosis

The recommended regimens are metronidazole (500 mg orally, twice daily for 7 days), clindamycin vaginal cream (2%, 5 g, once daily for 7 days), or metronidazole gel (0.75%, 5 g, twice daily for 5 days). Alternative regimens include clindamycin (300 mg orally twice daily for 7 days), clindamycin ovules (100 g intravaginally at bedtime for 3 days), tinidazole (2 g orally once daily for 3 days), or tinidazole (1 g orally once daily for 7 days).

D. Condylomata Acuminata

Recommended treatments for vulvar warts include podophyllum resin 10–25% in tincture of benzoin (do not use during pregnancy or on bleeding lesions) or 80–90% trichloroacetic or bichloroacetic acid, carefully applied to avoid the surrounding skin. Surgical removal may be accomplished with tangential scissor excision, tangential shave excision, curettage, or electrotherapy. The pain of bichloroacetic or trichloroacetic acid application can be lessened by a sodium bicarbonate paste applied immediately after treatment. Podophyllum resin must be washed off after 2–4 hours. Freezing with liquid nitrogen or a cryoprobe and electrocautery are also effective. Patient-applied regimens, useful when the entire lesion is accessible to the patient, include podofilox 0.5% solution or gel, imiquimod 5% cream, or sinecatechins 15% ointment. Vaginal warts may be treated with cryotherapy with liquid nitrogen or trichloroacetic acid. Extensive warts may require treatment with CO₂ laser under local or general anesthesia. Interferon is not recommended for routine use because it is very expensive, associated with systemic side effects, and no more effective than other therapies. Routine examination of sex partners is not necessary for the management of genital warts since the risk of reinfection is probably minimal and curative therapy to prevent transmission is not available. However, partners may wish to be examined for detection and treatment of genital warts and other sexually transmitted diseases. While condom use does not appear to prevent HPV transmission, it may result in accelerated regression of associated lesions, including untreated

cervical intraepithelial neoplasia (CIN) and in accelerated clearance of genital HPV infection in women.

Allsworth JE et al. Trichomoniasis and other sexually transmitted infections: results from the 2001–2004 National Health and Nutrition Examination Surveys. *Sex Transm Dis.* 2009 Dec;36(12):738–44. [PMID: 19734826]
Workowski KA et al; Centers for Disease Control and Prevention (CDC). Sexually transmitted diseases treatment guidelines, 2010. *MMWR Recomm Rep.* 2010 Dec 17;59(RR-12):1–110. [PMID: 21160459]

CERVICAL POLYPS

Cervical polyps commonly occur after menarche and are occasionally noted in postmenopausal women. The cause is not known, but inflammation may play an etiologic role. The principal symptoms are discharge and abnormal vaginal bleeding. However, abnormal bleeding should not be ascribed to a cervical polyp without sampling the endocervix and endometrium. The polyps are visible in the cervical os on speculum examination.

Cervical polyps must be differentiated from polypoid neoplastic disease of the endometrium, small submucosal pedunculated myomas, large nabothian cysts, and endometrial polyps. Cervical polyps rarely contain dysplasia (0.5%) or malignant (0.5%) foci.

► Treatment

Asymptomatic polyps in women under age 45 may be left untreated. Cervical polyps can generally be removed in the office by avulsion with a uterine packing forceps or ring forceps. If the cervix is soft, patulous, or definitely dilated and the polyp is large, surgical D&C is required (especially if the pedicle is not readily visible). Hysteroscopy may aid removal and lead to identification of concomitant endometrial disease. If there is suspicion of endometrial disease, cervical polypectomy should be accompanied by endometrial sampling.

► When to Refer

- Polyp with a wide base is present.
- Inability to differentiate endocervical from endometrial polyp.

Younis MT et al. Women with asymptomatic cervical polyps may not need to see a gynaecologist or have them removed: an observational retrospective study of 1126 cases. *Eur J Obstet Gynecol Reprod Biol.* 2010 Jun;150(2):190–4. [PMID: 20206432]

BARTHOLIN DUCT CYSTS & ABSCESES

Trauma or infection may involve the Bartholin duct, causing obstruction of the gland. Drainage of secretions is prevented, leading to pain, swelling, and abscess formation (Figure 18–4). The infection usually resolves and pain disappears, but stenosis of the duct outlet with distention



▲ **Figure 18-4.** Right-sided Bartholin cyst (abscess). (Courtesy of Susan Lindsley, Public Health Image Library, CDC.)

often persists. Reinfection causes recurrent tenderness and further enlargement of the duct.

The principal symptoms are periodic painful swelling on either side of the introitus and dyspareunia. A fluctuant swelling 1–4 cm in diameter in the inferior portion of either labium minus is a sign of occlusion of Bartholin duct. Tenderness is evidence of active infection.

Pus or secretions from the gland should be cultured for *Chlamydia* and other pathogens and treated accordingly (see Chapter 33); frequent warm soaks may be helpful. If an abscess develops, aspiration or incision and drainage are the simplest forms of therapy, but the problem may recur. Marsupialization (in the absence of an abscess), incision and drainage with the insertion of an indwelling Word catheter, or laser treatment will establish a new duct opening. Antibiotics are unnecessary unless cellulitis is present. An asymptomatic cyst does not require therapy.

▶ When to Refer

Surgical therapy (marsupialization) is indicated.

CERVICAL INTRAEPITHELIAL NEOPLASIA (CIN) (Dysplasia of the Cervix)



ESSENTIALS OF DIAGNOSIS

- ▶ The presumptive diagnosis is made by an abnormal Papanicolaou smear of an asymptomatic woman with no grossly visible cervical changes.
- ▶ Diagnose by colposcopically directed biopsy.

▶ General Considerations

The squamocolumnar junction of the cervix is an area of active squamous cell proliferation. In childhood, this junction is located on the exposed vaginal portion of the cervix. At puberty, because of hormonal influence and possibly because of changes in the vaginal pH, the squamous margin

Table 18-2. Classification systems for Papanicolaou smears.

Numerical	Dysplasia	CIN	Bethesda System
1	Benign	Benign	Normal
2	Benign with inflammation	Benign with inflammation	Normal, ASC-US
3	Mild dysplasia	CIN I	Low-grade SIL
3	Moderate dysplasia	CIN II	High-grade SIL
3	Severe dysplasia	CIN III	
4	Carcinoma in situ		
5	Invasive cancer	Invasive cancer	Invasive cancer

ASC-US, atypical squamous cells of undetermined significance; CIN, cervical intraepithelial neoplasia; SIL, squamous intraepithelial lesion.

begins to encroach on the single-layered, mucus-secreting epithelium, creating an area of metaplasia (transformation zone). Factors associated with coitus (see Prevention, below) may lead to cellular abnormalities, which over a period of time can result in the development of squamous cell dysplasia or cancer. There are varying degrees of dysplasia (Table 18-2), defined by the degree of cellular atypia; all types must be observed and treated if they persist or become more severe.

▶ Clinical Findings

There are no specific symptoms or signs of CIN. The presumptive diagnosis is made by cytologic screening of an asymptomatic population with no grossly visible cervical changes. All visibly abnormal cervical lesions should be biopsied (Figure 18-5).



▲ **Figure 18-5.** Erosion of the cervix due to cervical intraepithelial neoplasia (CIN), a precursor lesion to cervical cancer. (Public Health Image Library, CDC.)

► Diagnosis

A. Cytologic Examination (Papanicolaou Smear)

Screening should begin at age 21. The recommendation to start screening at age 21 years regardless of the age of onset of sexual intercourse is based in part on the very low incidence of cancer in younger women. In contrast to the high rate of infection with HPV in sexually active adolescents, invasive cervical cancer is very rare in women younger than age 21 years. The recommendation is also based on the potential for adverse effects associated with follow-up of young women with abnormal cytology screening results. In a 2012 update, the US Preventive Services Task Force (USPSTF) recommends screening for cervical cancer in women age 21 to 65 years with cytology (Papanicolaou smear) every 3 years or, for women age 30 to 65 years who want to lengthen the screening interval, screening with a combination of cytology and HPV testing every 5 years. Screening may be done with either liquid-based or conventional cytology. Women with risk factors that place them at higher risk for CIN may require more frequent screening. These risk factors include HIV infection, immunosuppression, exposure to diethylstilbestrol in utero, and previous treatment for CIN 2, CIN 3, or cervical cancer. The USPSTF recommends against screening for cervical cancer with HPV testing, alone or in combination with cytology, in women younger than age 30 years. The USPSTF recommends against screening for cervical cancer in women older than age 65 years who have had adequate prior screening and are not otherwise at high risk for cervical cancer.

Cytologic reports from the laboratory may describe findings in one of several ways (see Table 18–2). The Bethesda System uses the terminology “atypical squamous cells of unknown significance” (ASC-US) and “squamous intraepithelial lesions,” either low-grade (LSIL) or high-grade (HSIL). Cytopathologists consider a Papanicolaou smear to be a medical consultation and will recommend further diagnostic procedures, treatment for infection, and comments on factors preventing adequate evaluation of the specimen.

Both liquid-based and conventional methods of cervical cytology screening are acceptable for screening. Exfoliated cells are collected from the transformation zone of the cervix and may be transferred to a vial of liquid preservative that is processed in the laboratory to produce a slide for interpretation—the liquid-based technique—or may be transferred directly to the slide and fixed using the conventional technique. Performance of conventional cervical cytology requires avoidance of contaminating blood, discharge, and lubricant.

Testing for HPV DNA currently is used in cervical cancer screening as a triage test to stratify risk to women aged 21 years and older with a cytologic diagnosis of ASC-US and postmenopausal women with a cytologic diagnosis of LSIL. It may be used as an adjunct to cytology for primary screening in women older than 30 years. It also may be used as a follow-up test after CIN 1 or negative findings on colposcopy in women whose prior cytologic diagnosis is ASC-US, atypical squamous cells, cannot rule out a high-grade lesion

(ASC-H), LSIL, or atypical glandular cells, and in follow-up after treatment for CIN 2 and CIN 3. HPV testing should not be used in females younger than 21 years and if inadvertently performed, a positive result should not influence management.

B. Colposcopy

Women with ASC-US and a negative HPV screening may be followed-up in 1 year. If the HPV screen is positive, colposcopy should be performed. If HPV screening is unavailable, repeat cytology may be done at 4- to 6-month intervals until two consecutive normal results, or the patient may be referred directly for colposcopy. All patients with SIL or atypical glandular cells should undergo colposcopy. Viewing the cervix with 10–20× magnification allows for assessment of the size and margins of an abnormal transformation zone and determination of extension into the endocervical canal. The application of 3–5% acetic acid (vinegar) dissolves mucus, and the acid’s desiccating action sharpens the contrast between normal and actively proliferating squamous epithelium. Abnormal changes include white patches and vascular atypia, which indicate areas of greatest cellular activity. In addition, the use of Lugol solution (strong iodine solution [Schiller test]) to paint the cervix results in normal squamous epithelium absorbing the stain, while nonstaining squamous epithelium should be biopsied. (The single-layered, mucus-secreting endocervical tissue will not stain either but can readily be distinguished by its darker pink, shinier appearance.)

C. Biopsy

Colposcopically directed punch biopsy and endocervical curettage are office procedures. If colposcopy is not available, the normal-appearing cervix shedding atypical cells can be evaluated by endocervical curettage and multiple punch biopsies of nonstaining squamous epithelium or biopsies from each quadrant of the cervix. Data from both cervical biopsy and endocervical curettage are important in deciding on treatment.

► Prevention

Cervical infection with the HPV is associated with a high percentage of all cervical dysplasias and cancers. There are over 70 recognized HPV subtypes, of which types 6 and 11 tend to cause genital warts and mild dysplasia, while types 16, 18, 31, and others cause higher-grade cellular changes. The FDA has approved two vaccines to prevent cervical cancer and vaginal and vulvar pre-cancers caused by HPV types 16 and 18, and to protect against low-grade and precancerous lesions caused by HPV types 16 and 18. The bivalent vaccine (known as Cervarix) provides protection against HPV types 16 and 18. The quadrivalent HPV 6/11/16/18 L1 virus-like-particle vaccine (known as Gardasil) also provides protection against genital warts caused by HPV types 6 and 11. Gardasil is recommended for all girls and women aged 9 to 26. Both vaccines provide partial protection against several other HPV types that cause approximately 30% of cervical cancers. Because

complete coverage of all carcinogenic HPV types is not provided by either vaccine, all women need to have regular cytologic screening as outlined above.

In addition to vaccination, measures to prevent cervical cancer include regular cytologic screening to detect abnormalities, limiting the number of sexual partners, using a diaphragm or condom for coitus, and stopping smoking or exposure to second-hand smoke.

► Treatment

Treatment varies depending on the degree and extent of CIN. Biopsies should always precede treatment.

A. Cauterization or Cryosurgery

The use of either hot cauterization or freezing (cryosurgery) is effective for noninvasive small lesions visible on the cervix without endocervical extension.

B. CO₂ Laser

This well-controlled method minimizes tissue destruction. It is colposcopically directed and requires special training. It may be used with large visible lesions. In current practice, it involves the vaporization of the transformation zone on the cervix and the distal 5–7 mm of endocervical canal.

C. Loop Excision

When the CIN is clearly visible in its entirety, a wire loop can be used for excisional biopsy. Cutting and hemostasis are achieved with a low-voltage electrosurgical machine. This office procedure with local anesthesia is quick and uncomplicated.

D. Conization of the Cervix

Conization is surgical removal of the entire transformation zone and endocervical canal. It should be reserved for cases of severe dysplasia (CIN III) or cancer in situ, particularly those with endocervical extension. The procedure can be performed with the scalpel, the CO₂ laser, the needle electrode, or by large-loop excision.

E. Follow-Up

Because recurrence is possible—especially in the first 2 years after treatment—and because the false-negative rate of a single cervical cytologic test is 20%, close follow-up after colposcopy and biopsy is imperative. For CIN II or III, cytologic examination or cytology and colposcopy should be repeated at 4- to 6-month intervals for up to 2 years. For CIN I, cytology should be performed at 6 and 12 months or HPV DNA testing can be done at 12 months. If testing is normal, routine cytologic screening can be resumed.

► When to Refer

- Patients with CIN II/III should be referred to an experienced colposcopist.
- Patients requiring conization biopsy should be referred to a gynecologist.

ACOG Committee on Gynecological Practice. ACOG committee opinion No. 431: Routine pelvic examination and cervical cytology screening. *Obstet Gynecol.* 2009 May;113(5):1190–3. [PMID: 19384150]

American College of Obstetricians-Gynecologists. ACOG Practice Bulletin No. 99: Management of abnormal cervical cytology and histology. *Obstet Gynecol.* 2008 Dec;112(6):1419–44. [PMID: 19037054]

American College of Obstetricians-Gynecologists. ACOG Practice Bulletin No. 109: Cervical cytology screening. *Obstet Gynecol.* 2009 Dec;114(6):1409–20. [PMID: 20134296]

Bornstein J. The HPV vaccines—which to prefer? *Obstet Gynecol Surv.* 2009 May;64(5):345–50. [PMID: 19386141]

Siebers AG et al. Comparison of liquid-based cytology with conventional cytology for detection of cervical cancer precursors. 2009 Oct;302(16):1757–64. [PMID: 19861667]

Whitlock EP et al. Liquid-based cytology and human papillomavirus testing to screen for cervical cancer: a systematic review for the U.S. Preventive Services Task Force. *Ann Intern Med.* 2011 Nov 15;155(10):687–97. [PMID: 22006930]

CARCINOMA OF THE CERVIX

ESSENTIALS OF DIAGNOSIS

- Increased risk in women with HIV and high-risk HPV types.
- Watery vaginal discharge, intermittent spotting, or postcoital bleeding may be early signs.
- Cervical lesion may be visible on inspection as a tumor or ulceration.
- Vaginal cytology usually positive; must be confirmed by biopsy.

► General Considerations

Cervical cancer can be considered a sexually transmitted disease. Both squamous cell and adenocarcinoma of the cervix are etiologically related to infection with HPV, primarily types 16 and 18. Women infected with HIV are at an increased risk of high-risk HPV infection and CIN. Smoking and possibly dietary factors such as decreased circulating vitamin A appear to be cofactors. While squamous cell carcinoma (SCC) accounts for 85% of cervical cancers, the incidence of SCC is decreasing while the incidence of adenocarcinoma of the cervix is increasing.

SCC appears first in the intraepithelial layers (the preinvasive stage, or carcinoma in situ). Preinvasive cancer (CIN III) is a common diagnosis in women 25–40 years of age. Two to 10 years are required for carcinoma to penetrate the basement membrane and invade the tissues. After invasion, death usually occurs within 3–5 years in untreated or unresponsive patients.

► Clinical Findings

A. Symptoms and Signs

The most common signs are metrorrhagia, postcoital spotting, and cervical ulceration. Bloody or purulent, odorous,

nonpruritic discharge may appear after invasion. Bladder and rectal dysfunction or fistulas and pain are late symptoms.

B. Cervical Biopsy and Endocervical Curettage, or Conization

These procedures are necessary steps after a positive Papanicolaou smear to determine the extent and depth of invasion of the cancer. Even if the smear is positive, treatment is never justified until definitive diagnosis has been established through biopsy.

C. "Staging" or Estimate of Gross Spread of Cancer of the Cervix

Staging of invasive cervical cancer is achieved by clinical evaluation, usually conducted under anesthesia. Further examinations, such as ultrasonography, CT, MRI, lymphangiography, laparoscopy, and fine-needle aspiration, are valuable for treatment planning.

► Complications

Metastases to regional lymph nodes occur with increasing frequency from stage I to stage IV. Paracervical extension occurs in all directions from the cervix. The ureters are often obstructed lateral to the cervix, causing hydronephrosis and consequently impaired kidney function. Almost two-thirds of patients with untreated carcinoma of the cervix die of uremia when ureteral obstruction is bilateral. Pain in the back, in the distribution of the lumbosacral plexus, is often indicative of neurologic involvement. Gross edema of the legs may be indicative of vascular and lymphatic stasis due to tumor.

Vaginal fistulas to the rectum and urinary tract are severe late complications. Hemorrhage is the cause of death in 10–20% of patients with extensive invasive carcinoma.

► Prevention

The FDA has approved a quadrivalent HPV 6/11/16/18 L1 virus-like-particle vaccine, known as Gardasil and a bivalent HPV 16/18 vaccine, known as Cervarix, to prevent cervical cancer caused by HPV types 16 and 18, and to protect against low-grade and precancerous lesions caused by these types (see Cervical Intraepithelial Neoplasia, above).

► Treatment

A. Emergency Measures

Vaginal hemorrhage originates from gross ulceration and cavitation in stage II–IV cervical carcinoma. Ligation and suturing of the cervix are usually not feasible, but ligation of the uterine or hypogastric arteries may be lifesaving when other measures fail. Styptics such as Monsel solution or acetone are effective, although delayed sloughing may result in further bleeding. Wet vaginal packing is helpful. Emergency irradiation usually controls bleeding.

B. Specific Measures

1. Carcinoma in situ (stage 0)—In women who have completed childbearing, total hysterectomy is the treatment of choice. In women who wish to retain the uterus, acceptable alternatives include cervical conization or ablation of the lesion with cryotherapy or laser. Close follow-up with Papanicolaou smears every 3 months for 1 year and every 6 months for another year is necessary after cryotherapy or laser.

2. Invasive carcinoma—Microinvasive carcinoma (stage IA1) is treated with simple, extrafascial hysterectomy. Stages IA2, IB1, and IIA cancers may be treated with either radical hysterectomy with concomitant radiation and chemotherapy or with radiation plus chemotherapy alone. Women with stage IB1 may be candidates for fertility-sparing surgery that includes radical trachelectomy and lymph node dissection with preservation of the uterus and ovaries. Stages IB2, IIB, III and IV cancers are treated with radiation therapy plus concurrent cisplatin-based chemotherapy.

► Prognosis

The overall 5-year relative survival rate for carcinoma of the cervix is 68% in white women and 55% in black women in the United States. Survival rates are inversely proportionate to the stage of cancer: stage 0, 99–100%; stage IA, > 95%; stage IB–IIA, 80–90%; stage IIB, 65%; stage III, 40%; and stage IV, < 20%.

► When to Refer

All patients with invasive cervical carcinoma (stage IA or higher) should be referred to a gynecologic oncologist.

Barbera L et al. Management of early and locally advanced cervical cancer. *Semin Oncol.* 2009 Apr;36(2):155–69. [PMID: 19332250]

Kim JH et al. Fertility-sparing laparoscopic radical trachelectomy for young women with early stage cervical cancer. *BJOG.* 2010 Feb;117(3):340–7. [PMID: 20015309]

LEIOMYOMA OF THE UTERUS (Fibroid Tumor)

ESSENTIALS OF DIAGNOSIS

- Irregular enlargement of the uterus (may be asymptomatic).
- Heavy or irregular vaginal bleeding, dysmenorrhea.
- Acute and recurrent pelvic pain if the tumor becomes twisted on its pedicle or infarcted.
- Symptoms due to pressure on neighboring organs (large tumors).

► General Considerations

Uterine leiomyoma is the most common benign neoplasm of the female genital tract. It is a discrete, round, firm, often multiple uterine tumor composed of smooth muscle and connective tissue. The most convenient classification is by anatomic location: (1) intramural, (2) submucous, (3) subserous, (4) intraligamentous, (5) parasitic (ie, deriving its blood supply from an organ to which it becomes attached), and (6) cervical. A submucous myoma may become pedunculated and descend through the cervix into the vagina.

► Clinical Findings

A. Symptoms and Signs

In nonpregnant women, myomas are frequently asymptomatic. The two most common symptoms of uterine leiomyomas for which women seek treatment are abnormal uterine bleeding and pelvic pressure. Occasionally, degeneration occurs, causing intense pain. Infertility may be due to a myoma that significantly distorts the uterine cavity.

B. Laboratory Findings

Iron deficiency anemia may result from blood loss; in rare cases, polycythemia is present, presumably as a result of the production of erythropoietin by the myomas.

C. Imaging

Ultrasonography will confirm the presence of uterine myomas and can be used sequentially to monitor growth. When multiple subserous or pedunculated myomas are being followed, ultrasonography is important to exclude ovarian masses. MRI can delineate intramural and submucous myomas accurately. Hystero-graphy or hysteroscopy can also confirm cervical or submucous myomas.

► Differential Diagnosis

Irregular myomatous enlargement of the uterus must be differentiated from the similar but symmetric enlargement that may occur with pregnancy or adenomyosis (the presence of endometrial glands and stroma in the myometrium). Subserous myomas must be distinguished from ovarian tumors. Leiomyosarcoma is an unusual tumor occurring in 0.5% of women operated on for symptomatic myoma. It is very rare under the age of 40 and increases in incidence thereafter.

► Treatment

A. Emergency Measures

Emergency surgery may be required for acute torsion of a pedunculated myoma. If the patient is markedly anemic as a result of long, heavy menstrual periods, preoperative treatment with depot medroxyprogesterone acetate, 150 mg intramuscularly every 28 days, or use of a GnRH agonist, such as depot leuprolide, 3.75 mg intramuscularly monthly, or nafarelin, 0.2–0.4 mg intranasally twice daily, will slow or stop bleeding, and medical treatment of

anemia can be given prior to surgery. The only emergency indication for myomectomy during pregnancy is torsion; abortion is not an inevitable result.

B. Specific Measures

Women who have small asymptomatic myomas should be examined annually. If necessary, elective myomectomy can be done to preserve the uterus. Myomas do not require surgery on an urgent basis unless they cause significant pressure on the ureters, bladder, or bowel or severe bleeding leading to anemia or unless they are undergoing rapid growth. Cervical myomas larger than 3–4 cm in diameter or pedunculated myomas that protrude through the cervix must be removed. Submucous myomas can be removed using a hysteroscope and laser or resection instruments.

Because the risk of surgical complications increases with the increasing size of the myoma, preoperative reduction of myoma size is desirable. GnRH analogs such as depot leuprolide, 3.75 mg intramuscularly monthly, or nafarelin, 0.2–0.4 mg intranasally twice a day, are used preoperatively for 3- to 4-month periods to induce reversible hypogonadism, which temporarily reduces the size of myomas, suppresses their further growth, and reduces surrounding vascularity. Low-dose (5–10 mg/d) mifepristone and other selective progesterone-receptor modulators have shown some promise for long-term medical treatment of myomas.

C. Surgical Measures

Surgical measures available for the treatment of myoma are laparoscopic or abdominal myomectomy and total or subtotal abdominal, vaginal, or laparoscopy-assisted vaginal hysterectomy. Myomectomy is the treatment of choice for women who wish to preserve fertility. Uterine artery embolization is a minimally invasive treatment for some uterine fibroids. In uterine artery embolization—also referred to as uterine fibroid embolization—a clinician uses a slender, flexible tube (catheter) to inject small particles into the uterine arteries, which supply blood to the uterus. The goal is to block tiny vessels that lead to the fibroids, starve the fibroids and cause them to necrose. Myolysis with MRI-guided high frequency focused ultrasound is another alternative, but long-term outcome data, particularly on pregnancy outcomes, are lacking.

► Prognosis

Surgical therapy is curative. Future pregnancies are not endangered by myomectomy, although cesarean delivery may be necessary after wide dissection with entry into the uterine cavity.

► When to Refer

Refer to a gynecologist for treatment of symptomatic leiomyomata.

► When to Admit

For acute abdomen associated with an infarcted leiomyoma.

American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 96: Alternatives to hysterectomy in the management of leiomyomas. *Obstet Gynecol.* 2008 Aug;112(2 Pt 1): 387–400. [PMID: 18669742]

Bagaria M et al. Low-dose mifepristone in treatment of uterine leiomyoma: a randomised double-blind placebo-controlled clinical trial. *Aust N Z J Obstet Gynaecol.* 2009 Feb;49(1):77–83. [PMID: 19281585]

Bradley LD. Uterine fibroid embolization: a viable alternative to hysterectomy. *Am J Obstet Gynecol.* 2009 Aug;201(2):127–35. [PMID: 19646564]

CARCINOMA OF THE ENDOMETRIUM



ESSENTIALS OF DIAGNOSIS

- ▶ Abnormal bleeding is the presenting sign in 80% of cases.
- ▶ Papanicolaou smear is frequently negative.
- ▶ After a negative pregnancy test, endometrial tissue is required to confirm the diagnosis.

▶ General Considerations

Adenocarcinoma of the endometrium is the second most common cancer of the female genital tract. It occurs most often in women 50–70 years of age. Obesity, nulliparity, diabetes, and polycystic ovaries with prolonged anovulation, unopposed estrogen therapy, and the extended use of tamoxifen for the treatment of breast cancer are also risk factors. Women with a family history of colon cancer (hereditary nonpolyposis colorectal cancer, Lynch syndrome) are at significantly increased risk, with a lifetime incidence as high as 30%.

Abnormal bleeding is the presenting sign in 80% of cases. Endometrial carcinoma may cause obstruction of the cervix with collection of pus (pyometra) or blood (hematometra) causing lower abdominal pain. However, pain generally occurs late in the disease, with metastases or infection.

Papanicolaou smears of the cervix occasionally show atypical endometrial cells but are an insensitive diagnostic tool. Endocervical and endometrial sampling is the only reliable means of diagnosis. Simultaneous hysteroscopy can be a valuable addition in order to localize polyps or other lesions within the uterine cavity. Vaginal ultrasonography may be used to determine the thickness of the endometrium as an indication of hypertrophy and possible neoplastic change.

Pathologic assessment is important in differentiating hyperplasias, which often can be treated with cyclic oral progestins.

▶ Prevention

Prompt endometrial sampling for patients who report abnormal menstrual bleeding or postmenopausal uterine bleeding will reveal many incipient as well as clinical cases of endometrial cancer. Younger women with chronic anovulation are at risk for endometrial hyperplasia and subsequent endometrial cancer. They can

reduce the risk of hyperplasia almost completely with the use of oral contraceptives or cyclic progestin therapy.

▶ Staging

Examination under anesthesia, endometrial and endocervical sampling, chest radiography, intravenous urography, cystoscopy, sigmoidoscopy, transvaginal sonography, and MRI will help determine the extent of the disease and its appropriate treatment. The staging is based on the surgical and pathologic evaluation.

▶ Treatment

Treatment consists of total hysterectomy and bilateral salpingo-oophorectomy. Peritoneal material for cytologic examination is routinely taken and lymph node sampling may be done. If invasion deep into the myometrium has occurred or if sampled lymph nodes are positive for tumor, postoperative irradiation is indicated. The role of adjuvant chemotherapy alone or with irradiation is currently under investigation, although one study has shown a modest increase in survival with chemotherapy alone versus whole abdominal radiation alone in women with stage III–IV disease. Palliation of advanced or metastatic endometrial adenocarcinoma may be accomplished with large doses of progestins, eg, medroxyprogesterone, 400 mg intramuscularly weekly, or megestrol acetate, 80–160 mg daily orally.

▶ Prognosis

With early diagnosis and treatment, the overall 5-year survival is 80–85%. With stage I disease, the depth of myometrial invasion is the strongest predictor of survival, with a 98% 5-year survival with <66% depth of invasion and 78% survival with ≥66% invasion.

▶ When to Refer

All patients with endometrial carcinoma should be referred to a gynecologic oncologist.

Goldstein SR. The role of transvaginal ultrasound or endometrial biopsy in the evaluation of the menopausal endometrium. *Am J Obstet Gynecol.* 2009 Jul;201(1):5–11. [PMID: 19576369]

Shah MM et al. Management of endometrial cancer in young women. *Clin Obstet Gynecol.* 2011 Jun;54(2):219–25. [PMID: 21508691]

CARCINOMA OF THE VULVA



ESSENTIALS OF DIAGNOSIS

- ▶ History of genital warts.
- ▶ History of prolonged vulvar irritation, with pruritus, local discomfort, or slight bloody discharge.
- ▶ Early lesions may suggest or include non-neoplastic epithelial disorders.
- ▶ Late lesions appear as a mass, an exophytic growth, or a firm, ulcerated area in the vulva.
- ▶ Biopsy is necessary for diagnosis.

► General Considerations

The majority of cancers of the vulva are squamous lesions that classically have occurred in women over 50 years of age. Several subtypes (particularly 16, 18, and 31) of HPV have been identified in some but not all vulvar cancers. About 70–90% of vulvar intraepithelial neoplasia (VIN) and 40–60% of vulvar cancers are HPV associated. As with squamous cell lesions of the cervix, a grading system of VIN from mild dysplasia to carcinoma in situ has been established.

► Differential Diagnosis

Benign vulvar disorders that must be excluded in the diagnosis of carcinoma of the vulva include chronic granulomatous lesions (eg, lymphogranuloma venereum, syphilis), condylomas, hidradenoma, or neurofibroma. Lichen sclerosus and other associated leukoplakic changes in the skin should be biopsied. The likelihood that a superimposed vulvar cancer will develop in a woman with a nonneoplastic epithelial disorder (vulvar dystrophy) is 1–5%.

► Diagnosis

Biopsy is essential for the diagnosis of VIN and vulvar cancer and should be performed with any localized atypical vulvar lesion, including white patches. Multiple skin-punch specimens can be taken in the office under local anesthesia, with care to include tissue from the edges of each lesion sampled. Preoperative colposcopy of vulva, vagina, and cervix can help in planning further treatment.

► Staging

Vulvar cancer generally spreads by direct extension into the vagina, urethra, perineum, and anus, with discontinuous spread into the inguinal and femoral lymph nodes. CT or MRI of the small pelvis or abdomen is generally not required except in advanced cases for planning therapeutic options.

► Treatment

A. General Measures

Early diagnosis and treatment of irritative or other predisposing causes, such as lichen sclerosis and VIN, should be pursued. A 7:3 combination of betamethasone and cromolone is particularly effective for itching. After an initial response, fluorinated steroids should be replaced with hydrocortisone because of their skin atrophying effect. For lichen sclerosus, recommended treatment is clobetasol propionate cream 0.05% twice daily for 2–3 weeks, then once daily until symptoms resolve. Application one to three times a week can be used for long-term maintenance therapy.

B. Surgical Measures

High-grade VIN may be treated with a variety of approaches including topical chemotherapy, laser ablation, wide local excision, skinning vulvectomy, and simple vulvectomy. Small, invasive basal cell carcinoma of the vulva should be

excised with a wide margin. If the VIN is extensive or multicentric, laser therapy or superficial surgical removal of vulvar skin may be required. In this way, the clitoris and uninvolved portions of the vulva may be spared.

Invasive carcinoma confined to the vulva without evidence of spread to adjacent organs or to the regional lymph nodes is treated with wide local excision and inguinal lymphadenectomy or wide local excision alone if invasion is < 1 mm. Patients with more advanced disease may receive preoperative radiation, chemotherapy, or both.

► Prognosis

Basal cell carcinomas very seldom metastasize, and carcinoma in situ by definition has not metastasized. With adequate excision, the prognosis for both lesions is excellent. Patients with invasive vulvar squamous cell carcinoma 2 cm in diameter or less, without inguinal lymph node metastases, have an 85–90% 5-year survival rate. If the lesion is > 2 cm and lymph node involvement is present, the likelihood of 5-year survival is approximately 40%.

► When to Refer

All patients with invasive vulvar carcinoma should be referred to a gynecologic oncologist.

Dittmer C et al. Diagnosis and treatment options of vulvar cancer: a review. *Arch Gynecol Obstet*, 2012 Jan; 285(1): 183–93. [PMID: 21909752]

Moore DH. Chemotherapy and radiation therapy in the treatment of squamous cell carcinoma of the vulva: are two therapies better than one? *Gynecol Oncol*. 2009 Jun;113(3):379–83. [PMID: 19232700]

ENDOMETRIOSIS



ESSENTIALS OF DIAGNOSIS

- Pelvic pain related to menstrual cycle.
- Dysmenorrhea.
- Dyspareunia.
- Increased frequency among infertile women.

► General Considerations

Endometriosis is an aberrant growth of endometrium outside the uterus, particularly in the dependent parts of the pelvis and in the ovaries, whose principal manifestations are chronic pain and infertility. While retrograde menstruation is the most widely accepted cause, its pathogenesis and natural course are not fully understood. The overall prevalence in the United States is 6–10% and is fourfold to fivefold greater among infertile women.

► Clinical Findings

The clinical manifestations of endometriosis are variable and unpredictable in both presentation and course. Dysmenorrhea,

chronic pelvic pain, and dyspareunia, are among the well-recognized manifestations. A significant number of women with endometriosis, however, remain asymptomatic. Pelvic examination may disclose tender nodules in the cul-de-sac or rectovaginal septum, uterine retroversion with decreased uterine mobility, cervical motion tenderness, or an adnexal mass or tenderness. Most women with endometriosis, though, have a normal pelvic examination.

Endometriosis must be distinguished from pelvic inflammatory disease, ovarian neoplasms, and uterine myomas. Bowel invasion by endometrial tissue may produce blood in the stool that must be distinguished from bowel neoplasm. Paradoxically, the severity of pain associated with endometriosis may be inversely related to the anatomic extent of the disease.

Imaging is of limited value and is only useful in the presence of a pelvic or adnexal mass. Transvaginal ultrasonography is the imaging modality of choice to detect the presence of deeply penetrating endometriosis of the rectum or rectovaginal septum, while MRI should be reserved for equivocal cases of rectovaginal or bladder endometriosis. Ultimately, a definitive diagnosis of endometriosis is made only by histology of lesions removed at surgery.

► Treatment

A. Medical Treatment

Medical treatment, using a variety of hormonal therapies, is effective in the amelioration of pain associated with endometriosis. However, there is no evidence that any of these agents increase the likelihood of pregnancy. Their preoperative use is of questionable value in reducing the difficulty of surgery. Most of these regimens are designed to inhibit ovulation over 4–9 months and lower hormone levels, thus preventing cyclic stimulation of endometriotic implants and inducing atrophy. The optimum duration of therapy is not clear, and the relative merits in terms of side effects and long-term risks and benefits show insignificant differences when compared with each other and, in mild cases, with placebo. Commonly used medical regimens include the following:

1. Although there is no conclusive evidence that NSAIDs improve pain associated with endometriosis, these agents are reasonable options in appropriately selected patients.
2. Low-dose oral contraceptives can also be given cyclically; prolonged suppression of ovulation often inhibits further stimulation of residual endometriosis, especially if taken after one of the therapies mentioned here. Any of the combination oral contraceptives, the contraceptive patch, or vaginal ring may be used continuously for 6–12 months. Breakthrough bleeding can be treated with conjugated estrogens, 1.25 mg orally daily for 1 week, or estradiol, 2 mg daily orally for 1 week.
3. Progestins, specifically oral norethindrone acetate and subcutaneous DMPA, have been approved by the FDA for treatment of endometriosis-associated pain.
4. GnRH agonists are highly effective in reducing the pain syndromes associated with endometriosis. However,

they are not superior to other methods such as combined oral contraceptives as first-line therapy. The GnRH analogs (such as nafarelin nasal spray, 0.2–0.4 mg twice daily, or long-acting injectable leuprolide acetate, 3.75 mg intramuscularly monthly, used for 6 months) suppress ovulation. Side effects of vasomotor symptoms and bone demineralization may be relieved by “add-back” therapy, such as conjugated equine estrogen, 0.625 mg, and norethindrone, 5 mg orally daily.

5. Danazol is an androgenic drug that has been used for the treatment of endometriosis-associated pain. It should be used for 4–6 months in the lowest dose necessary to suppress menstruation, usually 200–400 mg orally twice daily. However, danazol has a high incidence of androgenic side effects that are more severe than other drugs available, including decreased breast size, weight gain, acne, and hirsutism.
6. Intrauterine progestin use with the levonorgestrel intrauterine system also has been shown to be effective in reducing endometriosis-associated pelvic pain.
7. The use of aromatase inhibitors (such as anastrozole or letrozole) have been evaluated in women with chronic pain resistant to other forms of medical management or surgical management. Although promising, there are insufficient data to recommend their routine use.

B. Surgical Measures

Surgical treatment of endometriosis—particularly extensive disease—is effective both in reducing pain and in promoting fertility. Laparoscopic ablation of endometrial implants along with uterine nerve ablation significantly reduces pain. Ablation of implants and, if necessary, removal of ovarian endometriomas enhance fertility, although subsequent pregnancy rates are inversely related to the severity of disease. Women with disabling pain who no longer desire childbearing can be treated definitively with total abdominal hysterectomy and bilateral salpingo-oophorectomy (TAH-BSO). Hormone replacement may be used in premenopausal women to relieve vasomotor symptoms. However, there may be recurrence of disease and associated pain.

► Prognosis

There is little systematic research regarding either the progression of the disease or the prediction of clinical outcomes. The prognosis for reproductive function in early or moderately advanced endometriosis appears to be good with conservative therapy. Hysterectomy, with bilateral salpingo-oophorectomy, often is regarded as definitive therapy for the treatment of endometriosis associated with intractable pelvic pain, adnexal masses, or multiple previous conservative surgical procedures. However, symptoms may recur in women even after hysterectomy and oophorectomy.

► When to Refer

Refer to a gynecologist for laparoscopic diagnosis or treatment.

▶ When to Admit

Rarely necessary except for acute abdomen associated with ruptured or bleeding endometrioma.

American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 114: Management of endometriosis. *Obstet Gynecol.* 2010 July;116(1): 223–36. [PMID: 20567196]
 Giudice LC. Clinical practice. Endometriosis. *N Engl J Med.* 2010 Jun 24;362(25):2389–98. [PMID: 20573927]
 Kadri H et al. Hormone therapy for endometriosis and surgical menopause. *Cochrane Database Syst Rev.* 2009 Jan 21;(1): CD005997. [PMID: 19160262]

PELVIC ORGAN PROLAPSE

▶ General Considerations

Cystocele, rectocele, and enterocele are vaginal hernias commonly seen in multiparous women. Cystocele is a hernia of the bladder wall into the vagina, causing a soft anterior fullness. Cystocele may be accompanied by urethrocele, which is not a hernia but a sagging of the urethra following its detachment from the pubic symphysis during childbirth. Rectocele is a herniation of the terminal rectum into the posterior vagina, causing a collapsible pouch-like fullness. Enterocele is a vaginal vault hernia containing small intestine, usually in the posterior vagina and resulting from a deepening of the pouch of Douglas. Two or all three types of hernia may occur in combination. Risk factors may include vaginal birth, genetic predisposition, advancing age, prior pelvic surgery, connective tissue disorders, and increased intra-abdominal pressure associated with obesity or straining associated with chronic constipation or coughing.

▶ Classification

A simple classification system, the Baden-Walker System, standardizes the degree of descent of the anterior vaginal wall, cervix or vaginal apex, and the posterior vaginal wall. The degree of prolapse can be evaluated by having the woman perform the Valsalva maneuver while in the lithotomy position. In stage I prolapse, the presenting anatomy descends halfway to the hymen; in stage II prolapse, to the hymen; in stage III prolapse, halfway past the hymen; and in stage IV prolapse, there is the maximum possible descent. Evaluation of the ability to empty the bladder should be evaluated by measuring postvoid residual. If stress incontinence is not present on Valsalva, the prolapse should be reduced to evaluate the possibility of potential post-repair incontinence.

▶ Clinical Findings

Symptoms of pelvic organ prolapse may include sensation of a bulge or protrusion in the vagina, urinary or fecal incontinence, a sense of incomplete bladder emptying, and dyspareunia. The cause of pelvic organ prolapse, including prolapse of the uterus, vaginal apex, and anterior or posterior vaginal walls, is likely multifactorial.

▶ Treatment

The type of therapy depends on the extent of prolapse and the patient's age and her desire for menstruation, pregnancy, and coitus.

A. General Measures

Supportive measures include a high-fiber diet and laxatives to improve constipation. Weight reduction in obese patients and limitation of straining and lifting are helpful. Pelvic muscle training (Kegel exercises) is a simple, noninvasive intervention that may improve pelvic function that has clearly demonstrated benefit for women with urinary or fecal symptoms, especially incontinence. Pessaries may reduce cystocele, rectocele, or enterocele and are helpful in women who do not wish to undergo surgery or who are chronically ill.

B. Surgical Measures

The only cure for symptomatic cystocele, rectocele, enterocele, or associated stress urinary incontinence is corrective surgery. The most common surgical procedure is vaginal or abdominal hysterectomy with vaginal vault suspension by either uterosacral or sacrospinous fixation vaginally or abdominal sacral colpopexy. Since stress incontinence is common after vault suspension procedures, an anti-incontinence procedure should be considered. If the patient desires pregnancy, a partial resection of the cervix with plication of the cardinal ligaments can be attempted. For elderly women who do not desire coitus, colpocleisis, the partial obliteration of the vagina, is surgically simple and effective. Uterine suspension with sacrospinous cervicocolpopexy may be an effective approach in older women who wish to avoid hysterectomy but preserve coital function.

▶ When to Refer

- Refer to urogynecologist or gynecologist for stress urinary incontinence or stage III prolapse.
- Refer if nonsurgical therapy is ineffective.

ACOG Committee on Practice Bulletins—Gynecology. ACOG Practice Bulletin No. 85: Pelvic organ prolapse. *Obstet Gynecol.* 2007 Sep;110(3):717–29. [PMID: 17766624]
 Lapitan MC et al. Open retropubic colposuspension for urinary incontinence in women. *Cochrane Database Syst Rev.* 2009 Apr 15;(2):CD002912. [PMID: 19370577]
 Schaffer JI (editor). *Female Pelvic Medicine and Reconstructive Surgery.* *Obstet Gynecol Clin North Am* [entire issue]. 2009 Sep 1;36(3):401–722. [PMID: 19932406–19932423]

PELVIC INFLAMMATORY DISEASE (Salpingitis, Endometritis)



ESSENTIALS OF DIAGNOSIS

- ▶ Uterine, adnexal, or cervical motion tenderness.
- ▶ Abnormal discharge from the vagina or cervix.
- ▶ Absence of a competing diagnosis.

► General Considerations

Pelvic inflammatory disease (PID) is a polymicrobial infection of the upper genital tract associated with the sexually transmitted organisms *N gonorrhoeae* and *Chlamydia trachomatis* as well as endogenous organisms, including anaerobes, *Haemophilus influenzae*, enteric gram-negative rods, and streptococci. It is most common in young, nulliparous, sexually active women with multiple partners. Other risk markers include nonwhite race, douching, and smoking. The use of oral contraceptives or barrier methods of contraception may provide significant protection.

Tuberculous salpingitis is rare in the United States but more common in developing countries; it is characterized by pelvic pain and irregular pelvic masses not responsive to antibiotic therapy. It is not sexually transmitted.

► Clinical Findings

A. Symptoms and Signs

Patients with PID may have lower abdominal pain, chills and fever, menstrual disturbances, purulent cervical discharge, and cervical and adnexal tenderness. Right upper quadrant pain (Fitz-Hugh and Curtis syndrome) may indicate an associated perihepatitis. However, diagnosis of PID is complicated by the fact that many women may have subtle or mild symptoms that are not readily recognized as PID, such as postcoital bleeding, urinary frequency, or low back pain.

B. Minimum Diagnostic Criteria

Women with uterine, adnexal, or cervical motion tenderness should be considered to have PID and be treated with antibiotics unless there is a competing diagnosis such as ectopic pregnancy or appendicitis.

C. Additional Criteria

The following criteria may be used to enhance the specificity of the diagnosis: (1) oral temperature $> 38.3^{\circ}\text{C}$, (2) abnormal cervical or vaginal discharge with white cells on saline microscopy (> 1 leukocyte per epithelial cell), (3) elevated erythrocyte sedimentation rate, (4) elevated C-reactive protein, and (5) laboratory documentation of cervical infection with *N gonorrhoeae* or *C trachomatis*. Endocervical culture should be performed routinely, but treatment should not be delayed while awaiting results.

D. Definitive Criteria

In selected cases where the diagnosis based on clinical or laboratory evidence is uncertain, the following criteria may be used: (1) histopathologic evidence of endometritis on endometrial biopsy, (2) transvaginal sonography or MRI showing thickened fluid-filled tubes with or without free pelvic fluid or tubo-ovarian complex, and (3) laparoscopic abnormalities consistent with PID.

► Differential Diagnosis

Appendicitis, ectopic pregnancy, septic abortion, hemorrhagic or ruptured ovarian cysts or tumors, twisted ovarian

cyst, degeneration of a myoma, and acute enteritis must be considered. PID is more likely to occur when there is a history of PID, recent sexual contact, recent onset of menses, recent insertion of an IUD, or if the partner has a sexually transmitted disease. Acute PID is highly unlikely when recent intercourse has not taken place. A sensitive serum pregnancy test should be obtained to rule out ectopic pregnancy. Culdocentesis will differentiate hemoperitoneum (ruptured ectopic pregnancy or hemorrhagic cyst) from pelvic sepsis (salpingitis, ruptured pelvic abscess, or ruptured appendix). Pelvic and vaginal ultrasonography is helpful in the differential diagnosis of ectopic pregnancy of over 6 weeks. Laparoscopy is often used to diagnose PID, and it is imperative if the diagnosis is not certain or if the patient has not responded to antibiotic therapy after 48 hours. The appendix should be visualized at laparoscopy to rule out appendicitis. Cultures obtained at the time of laparoscopy are often specific and helpful.

► Treatment

A. Antibiotics

Early treatment with appropriate antibiotics effective against *N gonorrhoeae*, *C trachomatis*, and the endogenous organisms listed above is essential to prevent long-term sequelae. The sexual partner should be examined and treated appropriately. Most women with mild to moderate disease can be treated successfully as an outpatient. The recommended outpatient regimen is a single dose of cefoxitin, 2 g intramuscularly, with probenecid, 1 g orally, or ceftriaxone 250 mg intramuscularly plus doxycycline, 100 mg orally twice daily, for 14 days, with or without metronidazole 500 mg orally twice daily for 14 days. Adding metronidazole will treat bacterial vaginosis that is frequently associated with PID. For patients with severe disease or those who meet the other criteria for hospitalization, there are two recommended regimens. One regimen includes cefotetan, 2 g intravenously every 12 hours, or cefoxitin, 2 g intravenously every 6 hours, plus doxycycline 100 mg orally or intravenously every 12 hours. The other recommended regimen is clindamycin, 900 mg intravenously every 8 hours, plus gentamicin, a loading dose of 2 mg/kg intravenously or intramuscularly followed by a maintenance dose of 1.5 mg/kg every 8 hours (or as a single daily dose, 3–5 mg/kg). These regimens should be continued for a minimum of 24 hours after the patient shows significant clinical improvement. Then, an oral regimen should be continued for 14 days. Tetracycline, 100 mg orally twice daily, is recommended if no tubo-ovarian abscess is present. If a tubo-ovarian abscess is present, clindamycin, 450 mg orally four times a day, should be given for 14 days.

B. Surgical Measures

Tubo-ovarian abscesses may require surgical excision or transcuteaneous or transvaginal aspiration. Unless rupture is suspected, institute high-dose antibiotic therapy in the hospital, and monitor therapy with ultrasound. In 70% of cases, antibiotics are effective; in 30%, there is inadequate response in 48–72 hours, and surgical intervention is

required. Unilateral adnexectomy is acceptable for unilateral abscess. Hysterectomy and bilateral salpingo-oophorectomy may be necessary for overwhelming infection or in cases of chronic disease with intractable pelvic pain.

► Prognosis

In spite of treatment, long-term sequelae, including repeated episodes of infection, chronic pelvic pain, dyspareunia, ectopic pregnancy, or infertility, develop in one-fourth of women with acute disease. The risk of infertility increases with repeated episodes of salpingitis: it is estimated at 10% after the first episode, 25% after a second episode, and 50% after a third episode.

► When to Admit

The following patients with acute PID should be admitted for intravenous antibiotic therapy:

- The patient has a tubo-ovarian abscess (direct inpatient observation for at least 24 hours before switching to outpatient parenteral therapy).
- The patient is pregnant.
- The patient is unable to follow or tolerate an outpatient regimen.
- The patient has not responded clinically to outpatient therapy.
- The patient has severe illness, nausea and vomiting, or high fever.
- Another surgical emergency, such as appendicitis, cannot be ruled out.

Soper DE. Pelvic inflammatory disease. *Obstet Gynecol.* 2010 Aug;116(2 Pt 1):419–28. [PMID: 20664404]

Workowski KA et al; Centers for Disease Control and Prevention (CDC). Sexually transmitted diseases treatment guidelines, 2010. *MMWR Recomm Rep.* 2010 Dec 17;59(RR-12):1–110. [PMID: 21160459]

OVARIAN CANCER & OVARIAN TUMORS

ESSENTIALS OF DIAGNOSIS

- Vague gastrointestinal discomfort.
- Pelvic pressure and pain.
- Many cases of early-stage cancer are asymptomatic.
- Pelvic examination and ultrasound are mainstays of diagnosis.

► General Considerations

Ovarian tumors are common. Most are benign, but malignant ovarian tumors are the leading cause of death from reproductive tract cancer. The wide range of types and patterns of ovarian tumors is due to the complexity of ovarian embryology and differences in tissues of origin.

In women with no family history of ovarian cancer, the lifetime risk is 1.6%, whereas a woman with one affected first-degree relative has a 5% lifetime risk. Ultrasound or tumor marker screening for women with one or no affected first-degree relatives have not been shown to reduce mortality from ovarian cancer, and the risks associated with unnecessary prophylactic surgical procedures outweigh the benefits in low-risk women. With two or more affected first-degree relatives, the risk is 7%. Approximately 3% of women with two or more affected first-degree relatives will have a hereditary ovarian cancer syndrome with a lifetime risk of 40%. Women with a *BRCA1* gene mutation have a 45% lifetime risk of ovarian cancer and those with a *BRCA2* mutation a 25% risk. Consideration should be given to screening these women every 6 months with transvaginal sonography and serum CA 125 testing, starting at age 35 or 5–10 years earlier than the earliest age that ovarian cancer was first diagnosed in a family member. Because this screening regimen has not been shown to reduce mortality, oophorectomy is recommended by age 35 or whenever childbearing is completed because of the high risk of disease.

► Clinical Findings

A. Symptoms and Signs

Unfortunately, most women with both benign and malignant ovarian neoplasms are either asymptomatic or experience only mild nonspecific gastrointestinal symptoms or pelvic pressure. Women with early disease are typically detected on routine pelvic examination. Women with advanced malignant disease may experience abdominal pain and bloating, and a palpable abdominal mass with ascites is often present.

B. Laboratory Findings

CA 125 is elevated in 80% of women with epithelial ovarian cancer overall but in only 50% of women with early disease. Serum CA 125 may be elevated in premenopausal women with benign disease (such as endometriosis), minimizing its usefulness in ovarian cancer screening. In premenopausal women, other markers (such as human chorionic gonadotropin [hCG], lactate dehydrogenase, or alpha fetoprotein) may be indicators of the type of tumor present.

C. Imaging Studies

Transvaginal sonography is useful for screening high-risk women but has inadequate sensitivity for screening low-risk women. Ultrasound is helpful in differentiating ovarian masses that are benign and likely to resolve spontaneously from those with malignant potential. Color Doppler imaging may further enhance the specificity of ultrasound diagnosis.

► Differential Diagnosis

Once an ovarian mass has been detected, it must be categorized as functional, benign neoplastic, or potentially malignant. Predictive factors include age, size of the mass, ultrasound configuration, CA 125 levels, the presence of

symptoms, and whether the mass is unilateral or bilateral. In a premenopausal woman, an asymptomatic, mobile, unilateral, simple cystic mass < 7.5 cm may be observed for 4–6 weeks. Most will resolve spontaneously. If the mass is larger or unchanged on repeat pelvic examination and transvaginal sonography, surgical evaluation is required.

Most ovarian masses in postmenopausal women require surgical evaluation. However, a postmenopausal woman with an asymptomatic unilateral simple cyst < 5 cm in diameter and a normal CA 125 level may be followed closely with transvaginal sonography. All others require surgical evaluation.

Laparoscopy may be used when an ovarian mass is small enough to be removed with a laparoscopic approach. If malignancy is suspected, because of findings on transvaginal ultrasound with morphologic scoring, color Doppler assessment of vascular quality, and serum CA 125 level, then laparotomy is preferable.

▶ Treatment

If a malignant ovarian mass is suspected, surgical evaluation should be performed by a gynecologic oncologist. For benign neoplasms, tumor removal or unilateral oophorectomy is usually performed. For ovarian cancer in an early stage, the standard therapy is complete surgical staging followed by abdominal hysterectomy and bilateral salpingo-oophorectomy with omentectomy and selective lymphadenectomy. With more advanced disease, aggressive removal of all visible tumor improves survival. Except for women with low-grade ovarian cancer in an early stage, postoperative chemotherapy is indicated (see Table 39–11). Several chemotherapy regimens are effective, such as the combination of cisplatin or carboplatin with paclitaxel, with clinical response rates of up to 60–70% (see Table 39–12).

▶ Prognosis

Unfortunately, approximately 75% of women with ovarian cancer are diagnosed with advanced disease after regional or distant metastases have become established. The overall 5-year survival is approximately 17% with distant metastases, 36% with local spread, and 89% with early disease.

▶ When to Refer

If a malignant mass is suspected, surgical evaluation should be performed by a gynecologic oncologist.

American College of Obstetricians and Gynecologists Practice Bulletin. ACOG Practice Bulletin No. 89: Elective and risk-reducing salpingo-oophorectomy. *Obstet Gynecol.* 2008 Jan;111(1): 231–41. [PMID: 18165419]

American College of Obstetricians and Gynecologists Practice Bulletin. ACOG Practice Bulletin No. 103: Hereditary breast and ovarian cancer syndrome. *Obstet Gynecol.* 2009 Apr;113(4): 957–66. [PMID: 19305347]

Schorge JO et al. SGO White paper on ovarian cancer: etiology, screening and surveillance. *Gynecol Oncol.* 2010 Oct;119(11): 7–17. [PMID: 20692025]

Winter-Roach BA et al. Adjuvant (post-surgery) chemotherapy for early stage epithelial ovarian cancer. *Cochrane Database Syst Rev.* 2009 Jul 8;(3):CD004706. [PMID: 19588360]

POLYCYSTIC OVARY SYNDROME



ESSENTIALS OF DIAGNOSIS

- ▶ Clinical or biochemical evidence of hyperandrogenism.
- ▶ Oligoovulation or anovulation.
- ▶ Polycystic ovaries on ultrasonography.

▶ General Considerations

Polycystic ovary syndrome (PCOS) is a common endocrine disorder of unknown etiology affecting 5–10% of women of reproductive age. It is characterized by chronic anovulation, polycystic ovaries, and hyperandrogenism. It is associated with hirsutism, obesity, as well as an increased risk of diabetes mellitus, cardiovascular disease, and metabolic syndrome. Unrecognized or untreated PCOS is an important risk factor for cardiovascular disease.

Women with Cushing syndrome, congenital adrenal hyperplasia, and androgen-secreting adrenal tumors also tend to have high circulating androgen levels and anovulation with polycystic ovaries; these disorders must be ruled out in women with presumed PCOS.

▶ Clinical Findings

PCOS is manifested by hirsutism (50% of cases), obesity (80%), and virilization (20%). Fifty percent of patients have amenorrhea, 30% have abnormal uterine bleeding, and 20% have normal menstruation. In addition, they show insulin resistance and hyperinsulinemia, and these women are at increased risk for early-onset type 2 diabetes. The patients are often infertile, although they may ovulate occasionally. Patients who do become pregnant are at increased risk for perinatal complications. In addition, they have an increased long-term risk of cancer of the endometrium because of unopposed estrogen secretion.

▶ Differential Diagnosis

Anovulation in the reproductive years may also be due to: (1) premature ovarian failure (high FSH and LH levels); (2) rapid weight loss, extreme physical exertion (normal FSH and LH levels for age), or obesity; (3) discontinuation of hormonal contraceptives (anovulation for 6 months or more occasionally occurs); (4) pituitary adenoma with elevated prolactin (galactorrhea may or may not be present); and (5) hyperthyroidism or hypothyroidism. To rule out other etiologies in women with suspected PCOS, serum FSH, LH, prolactin, and TSH should be checked. Because of the high risk of insulin resistance and dyslipidemia, all women with suspected PCOS should have a hemoglobin A1C and fasting glucose along with a lipid and lipoprotein profile. Women with clinical evidence of androgen excess should have total testosterone and sex hormone-binding globulin or free (bioavailable) testosterone, and 17-hydroxyprogesterone measured. Women with stigmata of Cushing syndrome should have a 24-hour urinary free cortisol or a low-dose dexamethasone suppression test.

► Treatment

In obese patients with PCOS, weight reduction and exercise are often effective in reversing the metabolic effects and in inducing ovulation. For those women who do not respond to weight loss and exercise, metformin therapy may be helpful and may be offered along with contraceptive counseling to prevent unplanned pregnancy in case of a return of ovulatory cycles. For women who are seeking pregnancy and remain anovulatory, clomiphene or other drugs can be used for ovulatory stimulation (see section on Infertility below). The addition of dexamethasone, 0.5 mg orally at bedtime, to a clomiphene regimen may increase the likelihood of ovulation by suppression of ACTH and any circulating adrenal androgens. For women who are unresponsive to clomiphene, adding the oral hypoglycemic agent, metformin, 500 mg three times daily, may enhance the likelihood of ovulation. These agents reduce the hyperinsulinemia and hyperandrogenemia in PCOS. If induction of ovulation fails with the above regimens, treatment with low-dose gonadotropins or laparoscopic “ovarian drilling” may be considered. Women with PCOS are at greater risk than normal women for twin gestation with ovulation induction.

If the patient does not desire pregnancy, medroxyprogesterone acetate, 10 mg/d orally for the first 10 days of each month, should be given to ensure regular shedding of the endometrium and avoid hyperplasia. If contraception is desired, a low-dose combination oral contraceptive can be used; this is also useful in controlling hirsutism, for which treatment must be continued for 6–12 months before results are seen.

Dexamethasone, 0.5 mg orally each night, is helpful in women with excess adrenal androgen secretion. Spironolactone, an aldosterone antagonist, is also useful for hirsutism in doses of 25 mg three or four times daily. Flutamide, 125–250 mg orally daily, and finasteride, 5 mg orally daily, are also effective for treating hirsutism. Because these three agents are potentially teratogenic, they should be used only in conjunction with secure contraception. Topical eflornithine cream applied to affected facial areas twice daily for 6 months may be helpful in the majority of women. Hirsutism may also be managed with depilatory creams, electrolysis, and laser therapy. The combination of laser therapy and topical eflornithine may be particularly effective.

Weight loss, exercise, and treatment of unresolved metabolic derangements are important in preventing cardiovascular disease. Women with PCOS should be managed aggressively and should have regular monitoring of lipid profiles and glucose.

► When to Refer

- If expertise in diagnosis is needed.
- If patient is infertile.

American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 108: Polycystic ovary syndrome. *Obstet Gynecol.* 2009 Oct;114(4):936–49. [PMID: 19888063]
Macklon NS. Polycystic ovary syndrome. *BMJ.* 2011 Oct 13;343:d6407. [PMID: 21998338]

Wild RA et al. Assessment of cardiovascular risk in women with the polycystic ovary syndrome: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society. *J Clin Endocrinol Metab.* 2010 May;95(5):2038–49. [PMID: 20375205]

FEMALE SEXUAL DYSFUNCTION

► General Considerations

Female sexual dysfunction is a common problem. Depending on the questions asked, surveys have shown that from 35% to 98% of women report sexual concerns. Questions related to sexual functioning should be asked as part of the routine medical history. Three helpful questions are: “Are you currently involved in a sexual relationship?”, “With men, women, or both?”, and “Are there any sexual concerns or pain with sex?” If the woman is not involved in a sexual relationship, she should be asked about any concerns that are contributing to a lack of sexual behavior. If a history of sexual dysfunction is elicited, a complete history of factors that may affect sexual function should be taken. These factors include her reproductive history (including pregnancies and mode of delivery) as well as history of infertility, sexually transmitted diseases, rape or sexual abuse, gynecologic or urologic disorders, endocrine abnormalities (such as diabetes mellitus or thyroid disease), neurologic problems, cardiovascular disease, psychiatric disease, and current prescription and over-the-counter medication use. A detailed history of the specific sexual dysfunction should be elicited, and a gynecologic examination should focus on findings that may contribute to her sexual complaints.

► Etiology

A. Disorders of Sexual Desire

Sexual desire in women is a complex and poorly understood phenomenon. Emotion is a key factor in sexual desire. Anger toward a partner, fear or anxiety related to previous sexual encounters, or history of sexual abuse may contribute. Physical factors, such as chronic illness, fatigue, depression, and specific medical disorders (such as diabetes mellitus, thyroid disease, or adrenal insufficiency) may contribute to a lack of desire. Attitudes toward aging and menopause may play a role. In addition, sexual desire may be influenced by other sexual dysfunctions, such as arousal disorders, dyspareunia, or anorgasmia.

B. Sexual Arousal Disorders

Sexual arousal disorders may be both subjective and objective. Sexual stimulation normally leads to genital vasocongestion and lubrication. Some women may have a physiologic response to sexual stimuli but may not subjectively feel aroused because of factors such as distractions; negative expectations; anxiety; fatigue; depression; or medications, such as selective serotonin reuptake inhibitors (SSRIs) or oral contraceptives. Other women may lack both a subjective and physiologic response to sexual stimuli related to vaginal atrophy.

C. Orgasmic Disorders

In spite of subjective and physiologic arousal, women may experience a marked delay in orgasm, diminished sensation of an orgasm, or anorgasmia. The etiology is complex and typically multifactorial, but the disorder is usually amenable to treatment.

D. Sexual Pain Disorders

Dyspareunia and vaginismus are two subcategories of sexual pain disorders. **Dyspareunia** is defined as recurrent or persistent genital pain associated with sexual intercourse that is not caused exclusively by lack of lubrication or by vaginismus and causes marked distress or interpersonal difficulty. **Vaginismus** is defined as recurrent or persistent involuntary spasm of the musculature of the outer third of the vagina that interferes with sexual intercourse, causing marked distress or interpersonal difficulty. Other medical causes of sexual pain may include vulvovaginitis; vulvar disease, including lichen planus, lichen sclerosus, and lichen simplex chronicus; pelvic disease, such as endometriosis or chronic PID; vulvodynia; or vaginal atrophy. Vulvodynia is the most frequent cause of dyspareunia in premenopausal women. It is characterized by a sensation of burning along with other symptoms, including pain, itching, stinging, irritation, and rawness. The discomfort may be constant or intermittent, focal or diffuse, and experienced as either deep or superficial. There are generally no physical findings except minimal erythema that may be associated in a subset of patients with vulvodynia, those with vulvar vestibulitis. Vulvar vestibulitis is normally asymptomatic, but pain is associated with touching or pressure on the vestibule, such as with vaginal entry or insertion of a tampon. Pain occurring with deep thrusting during coitus is usually due to acute or chronic infection of the cervix, uterus, or adnexa; endometriosis; adnexal tumors; or adhesions resulting from prior pelvic disease or operation. Vaginismus is voluntary or involuntary contraction of the muscles around the introitus. It results from fear, pain, sexual trauma, or a negative attitude toward sex, often learned in childhood.

► Treatment

A. Disorders of Sexual Desire

In the absence of specific medical disorders, arousal or orgasmic disorders or dyspareunia, the focus of therapy is psychological. Cognitive behavioral therapy, sexual therapy, and marital therapy may all play a role. Success with pharmacologic therapy, particularly the use of dopamine agonists or testosterone with estrogen has been reported, but data from large long-term clinical trials are lacking.

B. Sexual Arousal Disorders

As with disorders of sexual desire, arousal disorders may respond to psychological therapy. Specific pharmacologic therapy is lacking. The use of the phosphodiesterase inhibitors used in men does not appear to benefit the majority of women with sexual arousal disorders. However, there is some evidence to suggest a role for sildenafil in women with sexual dysfunction due to multiple sclerosis, type 1 diabetes

mellitus, spinal cord injury, and antidepressant medications, if other, better established, approaches fail.

C. Orgasmic Disorders

For many women, brief sexual counseling along with the use of educational books (such as *For Yourself*, by Lonnie Barbach) may be adequate therapy. Also, the FDA has approved a vacuum device, the EROS-CTD, that increases clitoral enlargement and improves the likelihood of orgasm.

D. Sexual Pain Disorders

Specific medical disorders, such as endometriosis, vulvovaginitis, or vaginal atrophy, should be treated as outlined in other sections of this chapter. Lichen planus and lichen simplex chronicus are addressed in Chapter 6. Lichen sclerosus, a thinning and whitening of the vulvar epithelium is treated with clobetasol propionate 0.05% ointment, applied twice daily for 2–3 months.

Vaginismus may be treated initially with sexual counseling and education on anatomy and sexual functioning. The patient can be instructed in self-dilation, using a lubricated finger or test tubes of graduated sizes. Before coitus (with adequate lubrication) is attempted, the patient—and then her partner—should be able to easily and painlessly introduce two fingers into the vagina. Penetration should never be forced, and the woman should always be the one to control the depth of insertion during dilation or intercourse. Injection of botulinum toxin has been used successfully in refractory cases.

Since the cause of vulvodynia is unknown, management is difficult. Few treatment approaches have been subjected to methodologically rigorous trials. A variety of topical agents have been tried, although only topical anesthetics (eg, estrogen cream and a compounded mixture of topical amitriptyline 2% and baclofen 2% in a water washable base) have been useful in relieving vulvodynia. Useful oral medications include tricyclic antidepressants, such as amitriptyline in gradually increasing doses from 10 mg/d to 75–100 mg/d; various SSRIs; and anticonvulsants, such as gabapentin, starting at 300 mg three times daily and increasing to 1200 mg three times daily. Biofeedback and physical therapy, with a physical therapist experienced with the treatment of vulvar pain, have been shown to be helpful. Surgery—usually consisting of vestibulectomy—has been useful for women with introital dyspareunia.

► When to Refer

- When symptoms or concerns persist despite first-line therapy.
- For expertise in surgical procedures.

American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 119: Female sexual dysfunction. *Obstet Gynecol.* 2011 Apr;117(4):96–1007. [PMID: 21422879]

Brown DA et al. Assessing the clinical efficacy of sildenafil for the treatment of female sexual dysfunction. *Ann Pharmacother.* 2009 Jul;43(7):1275–85. [PMID: 19509350]

Steege JF et al. Evaluation and treatment of dyspareunia. *Obstet Gynecol.* 2009 May;113(5):1124–36. [PMID: 19384129]

INFERTILITY

A couple is said to be infertile if pregnancy does not result after 1 year of normal sexual activity without contraceptives. About 25% of couples experience infertility at some point in their reproductive lives; the incidence of infertility increases with age, with a decline in fertility beginning in the early 30s and accelerating in the late 30s. The male partner contributes to about 40% of cases of infertility, and a combination of factors is common.

A. Initial Testing

During the initial interview, the clinician can present an overview of infertility and discuss a plan of study. Separate private consultations are then conducted, allowing appraisal of psychosexual adjustment without embarrassment or criticism. Pertinent details (eg, sexually transmitted disease or prior pregnancies) must be obtained. The ill effects of cigarettes, alcohol, and other recreational drugs on male fertility should be discussed. Prescription medications that impair male potency and factors that may lead to scrotal hyperthermia, such as tight underwear or frequent use of saunas or hot tubs, should be discussed. The gynecologic history should include the menstrual pattern, the use and types of contraceptives, douching, libido, sex techniques, frequency and success of coitus, and correlation of intercourse with time of ovulation. Family history includes repeated spontaneous abortions and maternal DES use.

General physical and genital examinations are performed on the female partner. Basic laboratory studies include complete blood count, urinalysis, cervical culture for *Chlamydia*, rubella antibody determination, and thyroid function tests. If the woman has regular menses, the likelihood of ovulatory cycles is very high. A luteal phase serum progesterone above 3 ng/mL establishes ovulation. Couples should be advised that coitus resulting in conception occurs during the 6-day window around the day of ovulation. Self-performed urine tests for the midcycle LH surge at ovulation can enhance basal temperature charting.

A semen analysis to rule out a male factor for infertility should be completed. Men must abstain from sexual activity for at least 3 days before the semen is obtained. A clean, dry, wide-mouthed bottle for collection is preferred. Semen should be examined within 1–2 hours after collection. Semen is considered normal with the following minimum values: volume, 2.0 mL; concentration, 20 million sperm per milliliter; motility, $\geq 50\%$ forward progression, $\geq 25\%$ rapid progression; and normal forms, 30%. If the sperm count is abnormal, further evaluation includes physical examination of the male partner and a search for exposure to environmental and workplace toxins, alcohol or drug abuse.

B. Further Testing

1. Gross deficiencies of sperm (number, motility, or appearance) require repeat analysis. Zona-free hamster egg penetration tests are available to evaluate the ability of human sperm to fertilize an egg. Intracytoplasmic sperm injection (ICSI) is the treatment option available for sperm deficiencies except for azoospermia (absence of sperm).

2. A screening pelvic ultrasound and hysterosalpingography to identify uterine cavity or tubal anomalies should be performed. Hysterosalpingography using an oil dye is performed within 3 days following the menstrual period if structural abnormalities are suspected. This radiographic study will demonstrate uterine abnormalities (septa, polyps, submucous myomas) and tubal obstruction. This test has been associated with an increased pregnancy rate if an oil-based rather than water-soluble contrast medium is used. Women who have had prior pelvic inflammation should receive doxycycline, 100 mg orally twice daily, beginning immediately before and for 7 days after the radiographic study. Obvious obstruction of the uterine tubes requires assessment for microsurgery, although in vitro fertilization (IVF) is recommended as the primary treatment option for this condition.
3. Absent or infrequent ovulation requires additional laboratory evaluation. Elevated FSH and LH levels indicate ovarian failure causing premature menopause. Elevated LH levels in the presence of normal FSH levels confirm the presence of polycystic ovaries. Elevation of blood prolactin (PRL) levels suggests a pituitary adenoma. In women over age 35, evaluation of ovarian reserve should be assessed. A markedly elevated FSH (>15 – 20 international units/L) on day 3 of the menstrual cycle suggests inadequate ovarian reserve. In addition, a Clomiphene Citrate Challenge Test, with measurement of FSH on day 10 after administration of clomiphene from day 5–9, should be completed to determine if diminished ovarian reserve indicates a need for donor eggs.
4. Ultrasound monitoring of folliculogenesis may reveal the occurrence of unruptured luteinized follicles.
5. If all the above testing is normal, the patient is diagnosed with unexplained infertility. In approximately 25% of women whose basic evaluation is normal, laparoscopy will identify abnormal findings that may explain the couple's infertility (eg, peritubal adhesions, endometriotic implants).

▶ Treatment

A. Medical Measures

Fertility may be restored by treatment of endocrine abnormalities, particularly hypothyroidism or hyperthyroidism. Antibiotic treatment of cervicitis may be of value. Women who engage in vigorous athletic training often have low sex hormone levels; fertility improves with reduced exercise and some weight gain.

B. Surgical Measures

Excision of ovarian tumors or ovarian foci of endometriosis can improve fertility. Microsurgical relief of tubal obstruction due to salpingitis or tubal ligation will reestablish fertility in a significant number of cases, although with severe disease or proximal obstruction, IVF is preferable. Peritubal adhesions or endometriotic implants often can be treated via laparoscopy.

In a male with a varicocele, sperm characteristics are often improved following surgical treatment.

C. Induction of Ovulation

1. Clomiphene citrate—Clomiphene citrate stimulates gonadotropin release, especially LH. Consequently, plasma estrone (E_1) and estradiol (E_2) also rise, reflecting ovarian follicle maturation. If E_2 rises sufficiently, an LH surge occurs to trigger ovulation.

After a normal menstrual period or induction of withdrawal bleeding with progestin, one should give 50 mg of clomiphene orally daily for 5 days. If ovulation does not occur, the dosage is increased to 100 mg daily for 5 days. If ovulation still does not occur, the course is repeated with 150 mg daily and then 200 mg daily for 5 days, with the addition of chorionic gonadotropin, 10,000 units intramuscularly, 7 days after clomiphene.

The rate of ovulation following this treatment is 90% in the absence of other infertility factors. The pregnancy rate is high. Twinning occurs in 5% of these patients, and three or more fetuses are found in rare instances (<0.5% of cases).

In the presence of increased androgen production ($DHEA-S > 200$ mcg/dL), the addition of dexamethasone, 0.5 mg orally, or prednisone, 5 mg orally, at bedtime, improves the response to clomiphene. Dexamethasone should be discontinued after pregnancy is confirmed.

2. Letrozole—The aromatase inhibitor, letrozole, appears to be at least as effective as clomiphene for ovulation induction in women with PCOS. There is a reduced risk of multiple pregnancy, a lack of antiestrogenic effects, and a reduced need for ultrasound monitoring. The dose is 5–7.5 mg daily, starting on day 3 of the menstrual cycle.

3. Bromocriptine—Bromocriptine is used only if PRL levels are elevated and there is no withdrawal bleeding following progesterone administration (otherwise, clomiphene is used). The initial dosage is 2.5 mg orally once daily, increased to two or three times daily in increments of 1.25 mg. The drug is discontinued once pregnancy has occurred.

4. Human menopausal gonadotropins (hMG) or recombinant FSH—hMG or recombinant FSH is indicated in cases of hypogonadotropism and most other types of anovulation resistant to clomiphene treatment. Because of the complexities, laboratory tests, and expense associated with this treatment, these patients should be referred to an infertility specialist.

D. Treatment of Endometriosis

See above.

E. Artificial Insemination in Azoospermia

If azoospermia is present, artificial insemination by a donor usually results in pregnancy, assuming female function is normal. The use of frozen sperm is currently preferable to fresh sperm because the frozen specimen can be held pending cultures and blood test results for sexually transmitted diseases, including HIV infection.

F. Assisted Reproductive Technologies (ART)

Couples who have not responded to traditional infertility treatments, including those with tubal disease, severe endometriosis, oligospermia, and immunologic or unexplained infertility, may benefit from IVF, gamete intrafallopian transfer (GIFT), and zygote intrafallopian transfer (ZIFT). These techniques are complex and require a highly organized team of specialists. All of the procedures involve ovarian stimulation to produce multiple oocytes, oocyte retrieval by transvaginal sonography-guided needle aspiration, and handling of the oocytes outside the body. With IVF, the eggs are fertilized in vitro and the embryos transferred to the uterine fundus. ICSI allows fertilization with a single sperm. While originally intended for couples with male factor infertility, it is now used in more than half of all IVF procedures in the United States.

GIFT involves the placement of sperm and eggs in the uterine tube by laparoscopy or minilaparotomy. With ZIFT, fertilization occurs in vitro, and the early development of the embryo occurs in the uterine tube after transfer by laparoscopy or minilaparotomy. The latter two procedures are used infrequently.

The chance of a multiple gestation pregnancy (ie, twins, triplets) is increased in all assisted reproductive procedures, increasing the risk of preterm delivery and other pregnancy complications. To minimize this risk, most infertility specialists recommend only transferring one to four embryos depending on the woman's age and reproductive history. In the event of a multiple gestation pregnancy, a couple may consider selective reduction to avoid the medical issues generally related to multiple births. This issue should be discussed with the couple before embryo transfer.

► Prognosis

The prognosis for conception and normal pregnancy is good if minor (even multiple) disorders can be identified and treated; it is poor if the causes of infertility are severe, untreatable, or of prolonged duration (over 3 years).

It is important to remember that in the absence of identifiable causes of infertility, 60% of couples will achieve a pregnancy within 3 years. Couples with unexplained infertility who do not achieve pregnancy within 3 years may be offered ovulation induction or assisted reproductive technology. Women over the age of 35 should be offered a more aggressive approach, with consideration of ART within 3–6 months of not achieving pregnancy with more conservative approaches. Also, offering appropriately timed information about adoption is considered part of a complete infertility regimen.

► When to Refer

Refer to reproductive endocrinologist if ART are indicated.

Casper RF. Letrozole versus clomiphene citrate: which is better for ovulation induction? *Fertil Steril*. 2009 Sep;92(3):858–9. [PMID: 17588568]

Pauli SA et al. Current status of the approach to assisted reproduction. *Pediatr Clin North Am*. 2009 Jun;56(3):467–88. [PMID: 19501687]

Sunderam S et al; Centers for Disease Control and Prevention (CDC). Assisted reproductive technology surveillance—United States, 2006. *MMWR Surveill Summ.* 2009 Jun 12;58(5):1–25. [PMID: 19521336]

CONTRACEPTION

Voluntary control of childbearing benefits women, men, and their children. Contraception should be available to all women and men of reproductive age. Education about and access to contraception are especially important for sexually active teenagers and for women following childbirth or abortion.

1. Oral Contraceptives

A. Combined Oral Contraceptives

1. Efficacy and methods of use—Combined oral contraceptives have a perfect use failure rate of 0.3% and a typical use failure rate of 8%. Their primary mode of action is suppression of ovulation. The pills can be initially started on the first day of the menstrual cycle, the first Sunday after the onset of the cycle or on any day of the cycle. If started on any day other than the first day of the cycle, a backup method should be used. There are also pills packaged to be taken continuously for 84 days, followed by 7 days of placebos as well as a pill packaged for 365 days, to be taken continuously without a break. If an active pill is missed at any time, and no intercourse occurred in the past 5 days, two pills should be taken immediately and a backup method should be used for 7 days. If intercourse occurred in the previous 5 days, emergency contraception (see below) should be used immediately, and the pills restarted the following day. A backup method should be used for 5 days.

2. Benefits of oral contraceptives—Noncontraceptive benefits of oral contraceptives include lighter menses, reducing the likelihood of anemia. Dysmenorrhea is relieved for most women. Functional ovarian cysts are less likely with oral contraceptive use. The risk of ovarian and endometrial cancer is decreased. The risks of salpingitis and ectopic pregnancy may be diminished. Acne is usually improved. The frequency of developing myomas is lower in long-term users (> 4 years). There is a beneficial effect on bone mass.

3. Selection of an oral contraceptive—Any of the combination oral contraceptives containing 35 mcg or less of ethinyl estradiol or 3 mg of estradiol valerate are suitable for most women. There is some variation in potency of the various progestins in the pills, but there are essentially no clinically significant differences for most women among the progestins in the low-dose pills. Women who have acne or hirsutism may benefit from use of one of the pills containing the third-generation progestins, desogestrel, drospirenone, or norgestimate, as they are the least androgenic. A combination regimen with 84 active and 7 inert pills that results in only four menses per year is available. There is also a combination regimen that is taken

continuously with no regular menses. At the end of one year's use, 58% of the women had amenorrhea, and nearly 80% reported no bleeding requiring sanitary protection. Studies have not shown any significant risk from long-term amenorrhea in patients taking continuous oral contraceptives. The low-dose oral contraceptives commonly used in the United States are listed in Table 18–3.

4. Drug interactions—Several drugs interact with oral contraceptives to decrease their efficacy by causing induction of microsomal enzymes in the liver, or by other mechanisms. Some commonly prescribed drugs in this category are phenytoin, phenobarbital (and other barbiturates), primidone, topiramate, carbamazepine, and rifampin and St. John's Wort. Women taking these drugs should use another means of contraception for maximum safety.

Antiretroviral medications, specifically ritonavir-boosted protease inhibitors, may significantly decrease the efficacy of combined oral contraceptives, and the concomitant use of oral contraceptives may increase the toxicity of these antiretroviral agents. Non-nucleoside reverse transcriptase inhibitors have smaller effects on oral contraceptive efficacy, while nucleoside reverse transcriptase inhibitors appear to have no effect.

5. Contraindications and adverse effects—Oral contraceptives have been associated with many adverse effects; they are contraindicated in some situations and should be used with caution in others (Table 18–4).

A. MYOCARDIAL INFARCTION—The risk of heart attack is higher with use of oral contraceptives, particularly with pills containing 50 mcg of estrogen or more. Cigarette smoking, obesity, hypertension, diabetes, or hypercholesterolemia increases the risk. Young nonsmoking women have minimal increased risk. Smokers over age 35 and women with other cardiovascular risk factors should use other methods of birth control.

B. THROMBOEMBOLIC DISEASE—An increased rate of venous thromboembolism is found in oral contraceptive users, especially if the dose of estrogen is 50 mcg or more. While the overall risk is very low (5–6 per 100,000 woman-years), several studies have reported a twofold increased risk in women using oral contraceptives containing the progestins gestodene (not available in the United States), drospirenone, or desogestrel compared with women using oral contraceptives with levonorgestrel and norethindrone. Women in whom thrombophlebitis develops should stop using this method, as should those at increased risk for thrombophlebitis because of surgery, fracture, serious injury, hypercoagulable condition, or immobilization. Women with a known thrombophilia should not use oral contraceptives.

C. CEREBROVASCULAR DISEASE—Overall, a small increased risk of hemorrhagic stroke and subarachnoid hemorrhage and a somewhat greater increased risk of thrombotic stroke have been found; smoking, hypertension, and age over 35 years are associated with increased risk. Women should stop using contraceptives if such warning symptoms as severe headache, blurred or lost vision, or other transient neurologic disorders develop.

Table 18-3. Commonly used low-dose oral contraceptives.

Name	Progestin	Estrogen (Ethinyl Estradiol)	Cost per Month ¹
COMBINATION			
Alesse ^{2,3}	0.1 mg levonorgestrel	20 mcg	\$35.00
Loestrin 1/20 ²	1 mg norethindrone acetate	20 mcg	\$28.56
Mircette ²	0.15 mg desogestrel	20 mcg	\$59.92
Yaz	3 mg drospirenone	20 mcg	\$70.84
Loestrin 1.5/30 ²	1.5 mg norethindrone acetate	30 mcg	\$28.98
Lo-Ovral ²	0.3 mg norgestrel	30 mcg	\$30.52
Levlen ²	0.15 mg levonorgestrel	30 mcg	\$36.40
Ortho-Cept ² Desogen ²	0.15 mg desogestrel	30 mcg	\$30.52
Yasmin	3 mg drospirenone	30 mcg	\$76.44
Brevicon ² Modicon ²	0.5 mg norethindrone	35 mcg	\$32.20
Demulen 1/35 ²	1 mg ethynodiol diacetate	35 mcg	\$29.96
Ortho-Novum 1/35 ²	1 mg norethindrone	35 mcg	\$29.40
Ortho-Cyclen ²	0.25 mg norgestimate	35 mcg	\$31.64
Ovcon 35 ²	0.4 mg norethindrone	35 mcg	\$44.80
COMBINATION: EXTENDED-CYCLE			
Seasonale	0.15 mg levonorgestrel	30 mcg	\$51.00
Seasonique	0.15 mg levonorgestrel (days 1-84)/ 0 mg levonorgestrel (days 85-91)	30 mcg (84 days)/10 mcg (7 days)	\$66.90
LoSeasonique	0.10 mg levonorgestrel (days 1-84)/ 0 mg levonorgestrel (days 85-91)	20 mcg (84 days)/10 mcg (7 days)	\$99.00
Lybrel	90 mcg levonorgestrel	20 mcg	\$78.40
TRIPHASIC			
Estrostep	1 mg norethindrone acetate (days 1-5) 1 mg norethindrone acetate (days 6-12) 1 mg norethindrone acetate (days 13-21)	20 mcg 30 mcg 35 mcg	\$98.84
Cyclessa ²	0.1 mg desogestrel (days 1-7) 0.125 mg desogestrel (days 8-14) 0.15 mg desogestrel (days 15-21)	25 mcg	\$33.60
Ortho-Tri-Cyclen Lo	0.18 norgestimate (days 1-7) 0.21 norgestimate (days 8-14) 0.25 norgestimate (days 15-21)	25 mcg	\$104.44
Triphasil ^{2,3}	0.05 mg levonorgestrel (days 1-6) 0.075 mg levonorgestrel (days 7-11) 0.125 mg levonorgestrel (days 12-21)	30 mcg 40 mcg 30 mcg	\$27.44
Ortho-Novum 7/7/7 ^{2,3}	0.5 mg norethindrone (days 1-7) 0.75 mg norethindrone (days 8-14) 1 mg norethindrone (days 15-21)	35 mcg	\$31.36
Ortho-Tri-Cyclen ^{2,3}	0.18 mg norgestimate (days 1-7) 0.215 mg norgestimate (days 8-14) 0.25 mg norgestimate (days 15-21)	35 mcg	\$31.64

(continued)

Table 18-3. Commonly used low-dose oral contraceptives. (continued)

Name	Progestin	Estrogen (Ethinyl Estradiol)	Cost per Month ¹
Tri-Norinyl ^{2,3}	0.5 mg norethindrone (days 1-7) 1 mg norethindrone (days 8-16) 0.5 mg norethindrone (days 17-21)	35 mcg	\$39.20
PROGESTIN-ONLY MINIPILL			
Ortho Micronor ^{2,3}	0.35 mg norethindrone to be taken continuously	None	\$36.96

¹Average wholesale price (AWP, for AB-rated generic when available) for quantity listed. Source: *Red Book Online*, 2012, Thomson Reuters (Healthcare), Inc. AWP may not accurately represent the actual pharmacy cost because wide contractual variations exist among institutions.

²Generic equivalent available.

³Multiple other brands available.

D. CARCINOMA—A relationship between long-term (3–4 years) oral contraceptive use and occurrence of cervical dysplasia and cancer has been found in various studies. A 2002 study showed that there is no increased risk of breast cancer in women aged 35–64 who are current or former users of oral contraceptives. Women with a family history of breast cancer or women who started oral contraceptive use at a young age are not at increased risk. Combination oral contraceptives reduce the risk of endometrial carcinoma by 40% after 2 years of use and 60% after 4 or more years of use. The risk of ovarian cancer is reduced by 30% with pill use for < 4 years, by 60% with use for 5–11 years, and by 80% after 12 or more years. Rarely, oral contraceptives have been associated with the development of benign

or malignant hepatic tumors; this may lead to rupture of the liver, hemorrhage, and death. The risk increases with higher dosage, longer duration of use, and older age.

E. HYPERTENSION—Oral contraceptives may cause hypertension in some women; the risk is increased with longer duration of use and older age. Women in whom hypertension develops while using oral contraceptives should use other contraceptive methods. However, with regular blood pressure monitoring, nonsmoking women under the age of 40 with well-controlled mild hypertension may use oral contraceptives.

F. HEADACHE—Migraine or other vascular headaches may occur or worsen with pill use. If severe or frequent headaches develop while using this method, it should be discontinued. Women with migraine headaches with an aura should not use oral contraceptives.

G. LACTATION—Combined oral contraceptives can impair the quantity and quality of breast milk. While it is preferable to avoid the use of combination oral contraceptives during lactation, the effects on milk quality are small and are not associated with developmental abnormalities in infants. Combination oral contraceptives should be started no earlier than 6 weeks postpartum to allow for establishment of lactation. Progestin-only pills, levonorgestrel implants, and depot medroxyprogesterone acetate are alternatives with no adverse effects on milk quality.

H. OTHER DISORDERS—Depression may occur or be worsened with oral contraceptive use. Fluid retention may occur. Patients who had cholestatic jaundice during pregnancy may develop it while taking birth control pills.

6. Minor side effects—Nausea and dizziness may occur in the first few months of pill use. A weight gain of 2–5 lb (0.9–2.25 kg) commonly occurs. Spotting or breakthrough bleeding between menstrual periods may occur, especially if a pill is skipped or taken late; this may be helped by switching to a pill of slightly greater potency (see section 3, above) or by switching to a triphasic regimen. Missed menstrual periods may occur, especially with low-dose pills. A pregnancy test should be performed if pills have been skipped or if two or more expected menstrual periods are

Table 18-4. Contraindications to use of oral contraceptives.**Absolute contraindications**

Pregnancy
Thrombophlebitis or thromboembolic disorders (past or present)
Stroke or coronary artery disease (past or present)
Cancer of the breast (known or suspected)
Undiagnosed abnormal vaginal bleeding
Estrogen-dependent cancer (known or suspected)
Benign or malignant tumor of the liver (past or present)
Uncontrolled hypertension
Diabetes mellitus with vascular disease
Age over 35 and smoking > 15 cigarettes daily
Known thrombophilia
Migraine with aura
Active hepatitis
Surgery or orthopedic injury requiring prolonged immobilization

Relative contraindications

Migraine without aura
Hypertension
Heart or kidney disease
Diabetes mellitus
Gallbladder disease
Cholestasis during pregnancy
Sickle cell disease (S/S or S/C type)
Lactation

missed. Fatigue and decreased libido can occur. Chloasma may occur, as in pregnancy, and is increased by exposure to sunlight.

B. Progestin Minipill

1. Efficacy and methods of use—A formulation containing 0.35 mg of norethindrone is available in the United States. The efficacy is similar to that of combined oral contraceptives. The minipill is believed to prevent conception by causing thickening of the cervical mucus to make it hostile to sperm, alteration of ovum transport (which may account for the slightly higher rate of ectopic pregnancy with these pills), and inhibition of implantation. Ovulation is inhibited inconsistently with this method. The minipill is begun on the first day of a menstrual cycle and then taken continuously for as long as contraception is desired.

2. Advantages—The low dose and absence of estrogen make the minipill safe during lactation; it may increase the flow of milk. It is often tried by women who want minimal doses of hormones and by patients who are over age 35. They lack the cardiovascular side effects of combination pills. The minipill can be safely used by women with sickle cell disease (S/S or S/C).

3. Complications and contraindications—Minipill users often have bleeding irregularities (eg, prolonged flow, spotting, or amenorrhea); such patients may need regular pregnancy tests. Ectopic pregnancies are more frequent, and complaints of abdominal pain should be investigated with this in mind. Many of the absolute contraindications and relative contraindications listed in Table 18–4 apply to the minipill; however, the contraceptive benefit of the minipill may outweigh the risks for patients who smoke, who are over age 35, or who have such conditions as superficial deep venous thrombosis or known thromboembolic disorders or diabetes with vascular disease. Minor side effects of combination oral contraceptives such as weight gain and mild headache may also occur with the minipill.

Centers for Disease Control and Prevention (CDC). U.S. medical eligibility criteria for contraceptive use, 2010. *MMWR Recomm Rep*. 2010 Jun 18;59(No.RR-4):1–85. [PMID: 20559203]

Cremer M et al. Recent innovations in oral contraception. *Semin Reprod Med*. 2010 Mar;28(2):140–6. [PMID: 20391327]

2. Contraceptive Injections & Implants (Long-Acting Progestins)

The injectable progestin DMPA is approved for contraceptive use in the United States. There is extensive worldwide experience with this method over the past 3 decades. The medication is given as a deep intramuscular injection of 150 mg every 3 months and has a contraceptive efficacy of 99.7%. A subcutaneous preparation, containing 104 mg of DMPA is available in the United States. Common side effects include irregular bleeding, amenorrhea, weight gain, and headache. It is associated with bone mineral loss that is usually reversible after discontinuation of the method. Users commonly have irregular bleeding initially

and subsequently develop amenorrhea. Ovulation may be delayed after the last injection. Contraindications are similar to those for the minipill.

A single-rod, subdermal progestin implant, Implanon, is approved for use in the United States. Implanon is a 40-mm by 2-mm rod containing 68 mg of the progestin etonogestrel that is inserted in the inner aspect of the non-dominant arm. Insertion and removal are much simpler and faster than with the original Norplant subdermal system. Hormone levels drop rapidly after removal, and there is no delay in the return of fertility. In clinical trials, the pregnancy rate was 0.0% with 3 years of use. The side effect profile is similar to minipills, DMPA, and Norplant. Irregular bleeding has been the most common reason for discontinuation.

McDonald-Mosley R et al. Contraceptive implants. *Semin Reprod Med*. 2010 Mar;28(2):110–17. [PMID: 20352560]

Roy G. Injectable contraception. *Semin Reprod Med*. 2010 Mar;28(2):126–32. [PMID: 20352562]

3. Other Hormonal Methods

A transdermal contraceptive patch containing 150 mcg norelgestromin and 20 mcg ethinyl estradiol and measuring 20 cm² is available. The patch is applied to the lower abdomen, upper torso, or buttock once a week for 3 consecutive weeks, followed by 1 week without the patch. It appears that the average steady-state concentration of ethinyl estradiol with the patch is approximately 60% higher than with a 35 mcg pill. However, there is currently no evidence for an increased incidence of estrogen-related side effects. The mechanism of action, side effects, and efficacy are similar to those associated with oral contraceptives, although compliance may be better. However, discontinuation for side effects is more frequent.

A contraceptive vaginal ring that releases 120 mcg of etonogestrel and 15 mcg of ethinyl estradiol daily is available. The ring is soft and flexible and is placed in the upper vagina for 3 weeks, removed, and replaced 1 week later. The efficacy, mechanism of action, and systemic side effects are similar to those associated with oral contraceptives. Ring users may experience an increased incidence of vaginal discharge.

Lopez LM et al. Skin patch and vaginal ring versus combined oral contraceptives for contraception. *Cochrane Database Syst Rev*. 2010 Mar 17;(3):CD003552. [PMID: 20238323]

4. Intrauterine Devices

IUDs available in the United States include the Mirena (which releases levonorgestrel) and the copper-bearing TCu380A. The mechanism of action of IUDs is thought to involve either spermicidal or inhibitory effects on sperm capacitation and transport. IUDs are not abortifacients.

The Mirena is effective for 5 years, and the TCu380A for 10 years. The hormone-containing IUDs have the advantage of reducing cramping and menstrual flow.

The IUD is an excellent contraceptive method for most women. The devices are highly effective, with failure rates

similar to those achieved with surgical sterilization. Nulliparity is not a contraindication to IUD use. Women who are not in mutually monogamous relationships should use condoms for protection from sexually transmitted diseases. The Mirena may have a protective effect against upper tract infection similar to that of the oral contraceptives.

A. Insertion

Insertion can be performed during or after the menses, at midcycle to prevent implantation, or later in the cycle if the patient has not become pregnant. Both types of IUDs may be inserted up to 48 hours after vaginal delivery, or prior to closure of the uterus at the time of cesarean section. Insertion immediately following abortion is acceptable if there is no sepsis and if follow-up insertion a month later will not be possible; otherwise, it is wise to wait until 4 weeks post abortion. Misoprostol (200 mcg the night before) and NSAIDs given as premedications may help insertions in nulliparous patients or when insertion is not performed during menses.

B. Contraindications & Complications

Contraindications to use of IUDs are outlined in Table 18–5.

1. Pregnancy—A copper-containing IUD can be inserted within 5 days following a single episode of unprotected mid-cycle coitus as a postcoital contraceptive. An IUD should not be inserted into a pregnant uterus. If pregnancy occurs as an IUD failure, there is a greater chance of spontaneous abortion if the IUD is left in situ (50%) than if it is removed (25%). Spontaneous abortion with an IUD in place is associated with a high risk of severe sepsis, and death can occur rapidly. Women using an IUD who become pregnant should have the IUD removed if the string is visible. It can be removed at the time of abortion if this is desired. If the string is not visible and the patient wants to continue the pregnancy, she should be informed of the serious risk of sepsis and, occasionally, death with such pregnancies. She should be informed that any flu-like symptoms such as fever, myalgia, headache, or nausea warrant immediate medical attention for possible septic abortion.

Table 18–5. Contraindications to IUD use.

Absolute contraindications

- Pregnancy
- Acute or subacute pelvic inflammatory disease or purulent cervicitis
- Significant anatomic abnormality of uterus
- Unexplained uterine bleeding
- Active liver disease (Mirena only)

Relative contraindications

- History of pelvic inflammatory disease since the last pregnancy
- Lack of available follow-up care
- Menorrhagia or severe dysmenorrhea (copper IUD)
- Cervical or uterine neoplasia

IUD, intrauterine device.

Since the ratio of ectopic to intrauterine pregnancies is increased among IUD wearers, clinicians should search for adnexal masses in early pregnancy and should always check the products of conception for placental tissue following abortion.

2. Pelvic infection—There is an increased risk of pelvic infection during the first month following insertion. The subsequent risk of pelvic infection appears to be primarily related to the risk of acquiring sexually transmitted infections. Infertility rates do not appear to be increased among women who have previously used the currently available IUDs. At the time of insertion, women with an increased risk of sexually transmitted diseases should be screened for gonorrhea and *Chlamydia*. Women with a history of recent or recurrent pelvic infection are not good candidates for IUD use.

3. Menorrhagia or severe dysmenorrhea—The copper IUD can cause heavier menstrual periods, bleeding between periods, and more cramping, so it is generally not suitable for women who already suffer from these problems. Alternatively, the hormone-releasing IUD Mirena has been approved by the FDA to treat heavy menstrual bleeding. NSAIDs are also helpful in decreasing bleeding and pain in IUD users.

4. Complete or partial expulsion—Spontaneous expulsion of the IUD occurs in 10–20% of cases during the first year of use. Any IUD should be removed if the body of the device can be seen or felt in the cervical os.

5. Missing IUD strings—If the transcervical tail cannot be seen, this may signify unnoticed expulsion, perforation of the uterus with abdominal migration of the IUD, or simply retraction of the string into the cervical canal or uterus owing to movement of the IUD or uterine growth with pregnancy. Once pregnancy is ruled out, a cervical speculum may be used to visualize the IUD string in the cervical canal. If not visualized, one should probe for the IUD with a sterile sound or forceps designed for IUD removal after administering a paracervical block. If the IUD cannot be detected, pelvic ultrasound will demonstrate the IUD if it is in the uterus. Alternatively, obtain anteroposterior and lateral radiographs of the pelvis with another IUD or a sound in the uterus as a marker, to confirm an extrauterine IUD. If the IUD is in the abdominal cavity, it should generally be removed by laparoscopy or laparotomy. Perforations of the uterus are less likely if insertion is performed slowly, with meticulous care taken to follow directions applicable to each type of IUD.

Shimoni N. Intrauterine contraceptives: a review of uses, side effects and candidates. *Semin Reprod Med.* 2010 Mar;28(2): 118–25. [PMID: 20352561]

5. Diaphragm & Cervical Cap

The diaphragm (with contraceptive jelly) is a safe and effective contraceptive method with features that make it acceptable to some women and not others. Failure rates range from 6% to 16%, depending on the motivation of the woman and the care with which the diaphragm is used.

The advantages of this method are that it has no systemic side effects and gives significant protection against pelvic infection and cervical dysplasia as well as pregnancy. The disadvantages are that it must be inserted near the time of coitus and that pressure from the rim predisposes some women to cystitis after intercourse.

The cervical cap (with contraceptive jelly) is similar to the diaphragm but fits snugly over the cervix only (the diaphragm stretches from behind the cervix to behind the pubic symphysis). The cervical cap is more difficult to insert and remove than the diaphragm. The main advantages are that it can be used by women who cannot be fitted for a diaphragm because of a relaxed anterior vaginal wall or by women who have discomfort or develop repeated bladder infections with the diaphragm. However, failure rates are 9% (perfect use) and 16% (typical use) in nulliparous women and 26% (perfect use) and 32% (typical use) in parous women.

Because of the small risk of toxic shock syndrome, a cervical cap or diaphragm should not be left in the vagina for over 12–18 hours, nor should these devices be used during the menstrual period.

6. Contraceptive Foam, Cream, Film, Sponge, Jelly, & Suppository

These products are available without prescription, are easy to use, and are fairly effective, with typical failure rates of 10–22%. All contain the spermicide nonoxynol-9, which also has some virucidal and bactericidal activity. Nonoxynol-9 does not appear to adversely affect the vaginal colonization of hydrogen peroxide-producing lactobacilli. A 2002 study suggests that nonoxynol-9 is not protective against HIV infection, particularly in women who have frequent intercourse. The FDA now requires products containing nonoxynol-9 to include a warning that the products do not protect against HIV or other sexually transmitted diseases and that use of these products can irritate the vagina and rectum and may increase the risk of getting the AIDS virus from an infected partner. Recent data suggest that low-risk women using a nonoxynol-9 product, with coital activity two to three times per week, are not at increased risk for epithelial disruption, compared with couples using condoms alone.

7. Condom

The male condom of latex or animal membrane affords good protection against pregnancy—equivalent to that of a diaphragm and spermicidal jelly; latex (but not animal membrane) condoms also offer protection against many sexually transmitted diseases, including HIV. When a spermicide, such as vaginal foam, is used with the condom, the failure rate (approximately 2% with perfect use and 15% with typical use) approaches that of oral contraceptives. The disadvantages of condoms are dulling of sensation and spillage of semen due to tearing, slipping, or leakage with detumescence of the penis.

Two female condoms, one made of polyurethane and the other of synthetic nitrile, are available in the United States. The reported failure rates range from 5% to 21%;

the efficacy is comparable to that of the diaphragm. These are the only female-controlled method that offers significant protection from both pregnancy and sexually transmitted diseases.

8. Contraception Based on Awareness of Fertile Periods

These methods are most effective when the couple restricts intercourse to the post ovular phase of the cycle or uses a barrier method at other times. Well-instructed, motivated couples may be able to achieve low pregnancy rates with fertility awareness methods. However, properly done randomized clinical trials comparing the efficacy of most of these methods with other contraceptive methods do not exist.

A. “Symptothermal” Natural Family Planning

The basis for this approach is patient-observed increase in clear elastic cervical mucus, brief abdominal midcycle discomfort (“mittelschmerz”), and a sustained rise of the basal body temperature about 2 weeks after onset of menstruation. Unprotected intercourse is avoided from shortly after the menstrual period, when fertile mucus is first identified, until 48 hours after ovulation, as identified by a sustained rise in temperature and the disappearance of clear elastic mucus.

B. Calendar Method

After the length of the menstrual cycle has been observed for at least 8 months, the following calculations are made: (1) The first fertile day is determined by subtracting 18 days from the shortest cycle, and (2) the last fertile day is determined by subtracting 11 days from the longest cycle. For example, if the observed cycles run from 24 to 28 days, the fertile period would extend from the sixth day of the cycle (24 minus 18) through the 17th day (28 minus 11). Day 1 of the cycle is the first day of menses.

C. Basal Body Temperature Method

This method indicates the safe time for intercourse after ovulation has passed. The temperature must be taken immediately upon awakening, before any activity. A slight drop in temperature often occurs 12–24 hours before ovulation, and a rise of about 0.4°C occurs 1–2 days after ovulation. The elevated temperature continues throughout the remainder of the cycle. Data suggest that the risk of pregnancy increases starting 5 days prior to the day of ovulation, peaks on the day of ovulation, and then rapidly decreases to zero by the day after ovulation.

D. Standard Days Method

This fertility awareness method requires the use of a set of beads that reminds the couple to avoid intercourse (or use a barrier method of contraception) during days 8 through 19 of the menstrual cycle. The beads are in a circle and color-coded to show the days when a woman is likely to become pregnant and the days that are “safe” during the cycle. A movable ring is repositioned to a new bead each day starting

on the first day of menses. In a small multicenter trial, the perfect use failure rate was 5% and the typical use failure rate was 12%. The method is applicable to women with a history of menstrual cycles between 29 and 32 days.

E. TwoDay Method

The TwoDay method requires that women be able to identify cervical secretions by observation or touching them in underwear or toilet paper, by touching the genitals, or by the sensation of wetness in the genital area or on underwear. The woman then uses a two-question algorithm to determine whether she is fertile. She asks herself: (1) Did I note secretions today? and (2) Did I note secretions yesterday? If the answer to either of these questions is “yes,” she should consider herself fertile. In a multicenter study of 450 women, effectiveness with perfect use was 96.5% and with typical use 76.3%.

Pallone SR et al. Fertility awareness-based methods: another option for family planning. *J Am Board Fam Med.* 2009 Mar-Apr;22(2):147–57. [PMID: 19264938]

9. Emergency Contraception

If unprotected intercourse occurs in midcycle and if the woman is certain she has not inadvertently become pregnant earlier in the cycle, the following regimens are effective in preventing implantation. These methods should be started as soon as possible and within 120 hours after unprotected coitus. (1) Levonorgestrel, 1.5 mg orally as a single dose (available in the United States prepackaged as Plan B and available over-the-counter for women aged 17 years and above), has a 1% failure rate, when taken within 72 hours. It remains efficacious up to 120 hours after intercourse, though less so compared with earlier use. (2) If the levonorgestrel regimen is not available, a combination oral contraceptive containing ethinyl estradiol and levonorgestrel given in a regimen of two to six tablets initially, followed by two to six tablets 12 hours later may be used. At least 20 brands of pills may be used in this way. For specific instructions for each pill brand, consult www.not-2-late.com. Used within 72 hours, the failure rate of these regimens is approximately 3%, but anti-nausea medication is often necessary. (3) Ulipristal, 30 mg orally as a single dose, has been shown to be more effective than levonorgestrel, particularly when used between 72 and 120 hours. It is available by prescription in the United States and Western Europe. (4) IUD insertion within 5 days after one episode of unprotected midcycle coitus will also prevent pregnancy; copper-bearing IUDs have been tested for this purpose.

Information on clinics or individual clinicians providing emergency contraception in the United States may be obtained by calling 1-888-668-2528.

Glasier AF et al. Ulipristal acetate versus levonorgestrel for emergency contraception: a randomized non-inferiority trial and meta-analysis. *Lancet.* 2010 Feb 13;375(9714):555–62. [PMID: 20116841]

10. Abortion

Since the legalization of abortion in the United States in 1973, the related maternal mortality rate has fallen markedly, because illegal and self-induced abortions have been replaced by safer medical procedures. Abortions in the first trimester of pregnancy are performed by vacuum aspiration under local anesthesia or with medical regimens. Dilation and evacuation, a variation of vacuum aspiration is generally used in the second trimester. Techniques utilizing intra-amniotic instillation of hypertonic saline solution or various prostaglandins regimens, along with medical or osmotic dilators are occasionally used after 18 weeks. Several medical abortion regimens utilizing mifepristone and multiple doses of misoprostol have been reported as being effective in the second trimester. Overall, legal abortion in the United States has a mortality rate of < 1:100,000. Rates of morbidity and mortality rise with length of gestation. Currently in the United States, 88% of abortions are performed before 13 weeks' gestation and only 1.3% are performed after 20 weeks. If abortion is chosen, every effort should be made to encourage the patient to seek an early procedure. While numerous state laws limiting access to abortion and a federal law banning a rarely used variation of dilation and evacuation have been enacted, abortion remains legal and available until fetal viability, between 24 and 28 weeks gestation, under *Roe v. Wade*.

Complications resulting from abortion include retained products of conception (often associated with infection and heavy bleeding) and unrecognized ectopic pregnancy. Immediate analysis of the removed tissue for placenta can exclude or corroborate the diagnosis of ectopic pregnancy. Women who have fever, bleeding, or abdominal pain after abortion should be examined; use of broad-spectrum antibiotics and reaspiration of the uterus are frequently necessary. Hospitalization is advisable if acute salpingitis requires intravenous administration of antibiotics. Complications following illegal abortion often need emergency care for hemorrhage, septic shock, or uterine perforation.

Rh immune globulin should be given to all Rh-negative women following abortion. Prophylactic antibiotics are indicated for surgical abortion; for example a one-dose regimen of doxycycline, 200 mg orally 1 hour before the procedure. Many clinics prescribe tetracycline, 500 mg orally four times daily for 5 days after the procedure, as presumptive treatment for *Chlamydia*.

Mifepristone (RU 486) is approved by the FDA as an oral abortifacient at a dose of 600 mg on day 1, followed by 400 mcg orally of misoprostol on day 3. This combination is 95% successful in terminating pregnancies of up to 9 weeks' duration with minimum complications. A more commonly used, evidence-based regimen is mifepristone, 200 mg orally on day 1, followed by misoprostol, 800 mcg vaginally either immediately or within 6–8 hours. Although not approved by the FDA for this indication, a combination of intramuscular methotrexate, 50 mg/m² of body surface area, followed 3–7 days later by vaginal misoprostol, 800 mcg, is 98% successful in terminating pregnancy at 8 weeks or less. Minor side effects, such as nausea, vomiting, and diarrhea, are common with these regimens. There

is a 5–10% incidence of hemorrhage or incomplete abortion requiring curettage. Medical abortion is generally considered as safe as surgical abortion in the first trimester but is associated with more pain and a lower success rate (requiring surgical abortion). Overall, the risk of uterine infection is lower with medical than with surgical abortion. As of 2010, there have been reports of eight deaths occurring within 1 week of medical abortion, associated with endometritis and toxic shock caused by *Clostridium sordellii* or *Clostridium perfringens* for a rate of 0.58 per 100,000 medical abortions in the United States. To improve early diagnosis and treatment of this entity, clinicians should be aware of the constellation of presenting symptoms of tachycardia, hypotension, edema, hemoconcentration, profound leukocytosis, and absence of fever.

Lièvre M et al. Meta-analysis of 200 or 600 mg mifepristone in association with two prostaglandins for termination of early pregnancy. *Contraception*. 2009 Jul;80(1):95–100. [PMID: 19501223]

Zane S et al. Gynecologic clostridial toxic shock in women of reproductive age. *Curr Infect Dis Rep*. 2011 Dec;13(6):561–70. [PMID: 21882086]

11. Sterilization

In the United States, sterilization is the most popular method of birth control for couples who want no more children. Although sterilization is reversible in some instances, reversal surgery in both men and women is costly, complicated, and not always successful. Therefore, patients should be counseled carefully before sterilization and should view the procedure as permanent.

Vasectomy is a safe, simple procedure in which the vas deferens is severed and sealed through a scrotal incision under local anesthesia. Long-term follow-up studies on vasectomized men show no excess risk of cardiovascular disease. Several studies have shown a possible association with prostate cancer, but the evidence is weak and inconsistent.

Female sterilization procedures include laparoscopic bipolar electrocoagulation, or plastic ring application on the uterine tubes, or minilaparotomy with Pomeroy tubal resection. The advantages of laparoscopy are minimal postoperative pain, small incisions, and rapid recovery. The advantages of minilaparotomy are that it can be performed with standard surgical instruments under local or general anesthesia. However, there is more postoperative pain and a longer recovery period. The cumulative 10-year failure rate for all methods combined is 1.85%, varying from 0.75% for postpartum partial salpingectomy and laparoscopic unipolar coagulation to 3.65% for spring clips; this fact should be discussed with women preoperatively. Some studies have found an increased risk of menstrual irregularities as a long-term complication of tubal ligation, but findings in different studies have been inconsistent. Two methods of transcervical sterilization, Essure and Adiana, can be performed as outpatient procedures. Essure involves the placement of an expanding microcoil of titanium into the proximal uterine tube under hysteroscopic guidance. The efficacy rate at 1 year is 99.8%. Adiana involves hysteroscopically guided superficial radiofrequency damage to

the tubal lumen and immediate placement of a nonabsorbable silicone elastomer matrix in the tube to allow tissue in-growth. The efficacy rate at 1 year is 98.9%. Both procedures should have tubal occlusion confirmed at 3 months with a hysterosalpingogram.

▶ When to Refer

Refer to experienced clinicians for Implanon or other subcutaneous insertion, IUD insertion, tubal occlusion or ligation, vasectomy, or therapeutic abortion.

Castañó PM et al. Transcervical sterilization. *Semin Reprod Med*. 2010 Mar;28(2):103–9. [PMID: 20352559]

RAPE



ESSENTIALS OF DIAGNOSIS

- ▶ Women neither secretly want to be raped nor do they expect, encourage, or enjoy rape.
- ▶ Rape is always a terrifying experience in which most victims fear for their lives.
- ▶ The rapist is usually a hostile man who uses sexual intercourse to terrorize and humiliate a woman.
- ▶ Knowledge of state laws and collection of evidence requirements are essential for clinicians evaluating possible rape victims.

▶ General Considerations

Rape, or sexual assault, is legally defined in different ways in various jurisdictions. Clinicians and emergency department personnel who deal with rape victims should be familiar with the laws pertaining to sexual assault in their own state. From a medical and psychological viewpoint, it is essential that persons treating rape victims recognize the nonconsensual and violent nature of the crime. About 95% of reported rape victims are women. Penetration may be vaginal, anal, or oral and may be by the penis, hand, or a foreign object. The absence of genital injury does not imply consent by the victim. The assailant may be unknown to the victim or, more frequently, may be an acquaintance or even the spouse.

“Unlawful sexual intercourse,” or statutory rape, is intercourse with a female before the age of majority even with her consent.

Rape represents an expression of anger, power, and sexuality on the part of the rapist. The rapist is usually a hostile man who uses sexual intercourse to terrorize and humiliate a woman. Women neither secretly want to be raped nor do they expect, encourage, or enjoy rape.

Rape involves severe physical injury in 5–10% of cases and is always a terrifying experience in which most victims fear for their lives. Consequently, all victims suffer some psychological aftermath. Moreover, some rape victims may acquire sexually transmissible disease or become pregnant.

Because rape is a personal crisis, each patient will react differently, but anxiety disorders and posttraumatic stress disorder (PTSD) are common sequelae. The rape trauma syndrome comprises two principal phases. (1) Immediate or acute: Shaking, sobbing, and restless activity may last from a few days to a few weeks. The patient may experience anger, guilt, or shame or may repress these emotions. Reactions vary depending on the victim's personality and the circumstances of the attack. (2) Late or chronic: Problems related to the attack may develop weeks or months later. The lifestyle and work patterns of the individual may change. Sleep disorders or phobias often develop. Loss of self-esteem can rarely lead to suicide.

Clinicians and emergency department personnel who deal with rape victims should work with community rape crisis centers or other sources of ongoing psychological support and counseling.

► General Office Procedures

The clinician who first sees the alleged rape victim should be empathetic. Begin with a statement such as, "This is a terrible thing that has happened to you. I want to help."

1. Secure written consent from the patient, guardian, or next of kin for gynecologic examination and for photographs if they are likely to be useful as evidence. If police are to be notified, do so, and obtain advice on the preservation and transfer of evidence.
2. Obtain and record the history in the patient's own words. The sequence of events, ie, the time, place, and circumstances, must be included. Note the date of the LMP, whether or not the woman is pregnant, and the time of the most recent coitus prior to the sexual assault. Note the details of the assault such as body cavities penetrated, use of foreign objects, and number of assailants. Note whether the victim is calm, agitated, or confused (drugs or alcohol may be involved). Record whether the patient came directly to the hospital or whether she bathed or changed her clothing. Record findings but do not issue even a tentative diagnosis lest it be erroneous or incomplete.
3. Have the patient disrobe while standing on a white sheet. Hair, dirt, and leaves, underclothing, and any torn or stained clothing should be kept as evidence. Scrape material from beneath fingernails and comb pubic hair for evidence. Place all evidence in separate clean paper bags or envelopes and label carefully.
4. Examine the patient, noting any traumatized areas that should be photographed. Examine the body and genitals with a Wood light to identify semen, which fluoresces; positive areas should be swabbed with a premoistened swab and air-dried in order to identify acid phosphatase. Colposcopy can be used to identify small areas of trauma from forced entry especially at the posterior fourchette.
5. Perform a pelvic examination, explaining all procedures and obtaining the patient's consent before proceeding gently with the examination. Use a narrow speculum lubricated with water only. Collect material with sterile cotton swabs from the vaginal walls and cervix and

make two air-dried smears on clean glass slides. Wet and dry swabs of vaginal secretions should be collected and refrigerated for subsequent acid phosphatase and DNA evaluation. Swab the mouth (around molars and cheeks) and anus in the same way, if appropriate. Label all slides carefully. Collect secretions from the vagina, anus, or mouth with a premoistened cotton swab, place at once on a slide with a drop of saline, and cover with a coverslip. Look for motile or nonmotile sperm under high, dry magnification, and record the percentage of motile forms.

6. Perform appropriate laboratory tests as follows. Culture the vagina, anus, or mouth (as appropriate) for *N gonorrhoeae* and *Chlamydia*. Perform a Papanicolaou smear of the cervix, a wet mount for *T vaginalis*, a baseline pregnancy test, and VDRL test. A confidential test for HIV viral load or antibody can be obtained if desired by the patient. Antibody testing can be repeated in 2–4 months if initially negative. Repeat the pregnancy test if the next menses is missed, and repeat the VDRL test in 6 weeks. Obtain blood (10 mL without anticoagulant) and urine (100 mL) specimens if there is a history of forced ingestion or injection of drugs or alcohol.
7. Transfer clearly labeled evidence, eg, laboratory specimens, directly to the clinical pathologist in charge or to the responsible laboratory technician, in the presence of witnesses (never via messenger), so that the rules of evidence will not be breached.

► Treatment

Give analgesics or sedatives if indicated. Administer tetanus toxoid if deep lacerations contain soil or dirt particles.

Give ceftriaxone, 125 mg intramuscularly, to prevent gonorrhea. In addition, give metronidazole, 2 g as a single dose, and azithromycin 1 g orally or doxycycline, 100 mg orally twice daily for 7 days to treat chlamydia infection. Incubating syphilis will probably be prevented by these medications, but the VDRL test should be repeated 6 weeks after the assault.

Prevent pregnancy by using one of the methods discussed under Emergency Contraception, if necessary (this chapter).

Vaccinate against hepatitis B. Consider HIV prophylaxis (see Chapter 31).

Because women who are sexually assaulted are at increased risk for long-term psychological sequelae, such as PTSD and anxiety disorders, it is critical that the patient and her family and friends have a source of ongoing counseling and psychological support.

► When to Refer

All women who seek care for sexual assault should be referred to a facility that has expertise in the management of victims of sexual assault and is capable of performing expert forensic examination, if requested.

Vickerman KA et al. Rape treatment outcome research: empirical findings and state of the literature. *Clin Psychol Rev*. 2009 Jul;29(5):431–48. [PMID: 19442425]

MENOPAUSAL SYNDROME



ESSENTIALS OF DIAGNOSIS

- ▶ Cessation of menses due to aging or to bilateral oophorectomy.
- ▶ Elevation of FSH and LH levels.
- ▶ Hot flushes and night sweats (in 80% of women).
- ▶ Decreased vaginal lubrication; thinned vaginal mucosa with or without dyspareunia.

▶ General Considerations

The term “menopause” denotes the final cessation of menstruation, either as a normal part of aging or as the result of surgical removal of both ovaries. In a broader sense, as the term is commonly used, it denotes a 1- to 3-year period during which a woman adjusts to a diminishing and then absent menstrual flow and the physiologic changes that may be associated—hot flushes, night sweats, and vaginal dryness.

The average age at menopause in Western societies today is 51 years. Premature menopause is defined as ovarian failure and menstrual cessation before age 40; this often has a genetic or autoimmune basis. Surgical menopause due to bilateral oophorectomy is common and can cause more severe symptoms owing to the sudden rapid drop in sex hormone levels.

There is no objective evidence that cessation of ovarian function is associated with severe emotional disturbance or personality changes. However, mood changes toward depression and anxiety can occur at this time. Furthermore, the time of menopause often coincides with other major life changes, such as departure of children from the home, a midlife identity crisis, or divorce. These events, coupled with a sense of the loss of youth, may exacerbate the symptoms of menopause and cause psychological distress.

▶ Clinical Findings

A. Symptoms and Signs

1. Cessation of menstruation—Menstrual cycles generally become irregular as menopause approaches. Anovular cycles occur more often, with irregular cycle length and occasional menorrhagia. Menstrual flow usually diminishes in amount owing to decreased estrogen secretion, resulting in less abundant endometrial growth. Finally, cycles become longer, with missed periods or episodes of spotting only. When no bleeding has occurred for 1 year, the menopausal transition can be said to have occurred. Any bleeding after this time warrants investigation by endometrial curettage or aspiration to rule out endometrial cancer.

2. Hot flushes—Hot flushes (feelings of intense heat over the trunk and face, with flushing of the skin and sweating) occur in > 80% of women as a result of the decrease in

ovarian hormones. Hot flushes can begin before the cessation of menses. The etiology of hot flushes is unknown. They typically persist for 2 to 3 years, but up to 16% of women aged 67 may continue to experience symptoms. Hot flushes are more severe in women who undergo surgical menopause. Occurring at night, they often cause sweating and insomnia and result in fatigue on the following day.

3. Vaginal atrophy—With decreased estrogen secretion, thinning of the vaginal mucosa and decreased vaginal lubrication occur and may lead to dyspareunia. The introitus decreases in diameter. Pelvic examination reveals pale, smooth vaginal mucosa and a small cervix and uterus. The ovaries are not normally palpable after the menopause. Continued sexual activity will help prevent tissue shrinkage.

4. Osteoporosis—Osteoporosis may occur as a late sequela of menopause.

B. Laboratory Findings

Serum FSH and LH levels are elevated. Vaginal cytologic examination will show a low estrogen effect with predominantly parabasal cells, indicating lack of epithelial maturation due to hypoestrogenism.

▶ Treatment

A. Natural Menopause

Education and support from health providers, midlife discussion groups, and reading material will help most women having difficulty adjusting to the menopause. Physiologic symptoms can be treated as follows.

1. Vasomotor symptoms—For women with moderate to severe vasomotor symptoms, estrogen or estrogen/progestin regimens are the most effective approach to symptom relief. Conjugated estrogens, 0.3 mg, 0.45 mg, or 0.625 mg; 17-beta-estradiol, 0.5 or 1 mg; or estrone sulfate, 0.625 mg can be given once daily orally; or estradiol can be given transdermally as skin patches that are changed once or twice weekly and secrete 0.05–0.1 mg of hormone daily. Unless the patient has undergone hysterectomy, a combination regimen of an estrogen with a progestin such as medroxyprogesterone, 1.5 or 2.5 mg, or norethindrone, 0.1, 0.25, or 0.5 mg, should be used to prevent endometrial hyperplasia or cancer. There is also a patch available containing estradiol and the progestin levonorgestrel. The oral hormones can be given in several differing regimens. Give estrogen on days 1–25 of each calendar month, with 5–10 mg of oral medroxyprogesterone acetate added on days 14–25. Withhold hormones from day 26 until the end of the month, when the endometrium will be shed, producing a light, generally painless monthly period. Alternatively, give the estrogen along with a progestin daily, without stopping. This regimen causes some initial bleeding or spotting, but within a few months it produces an atrophic endometrium that will not bleed. If the patient has had a hysterectomy, a progestin need not be used.

Data from the Women’s Health Initiative (WHI) study suggest that women should not use combination

progestin-estrogen therapy for more than 3 or 4 years. In this study, the increased risk of cardiovascular disease, cerebrovascular disease, and breast cancer with this regimen outweighed the benefits. Women who cannot find relief with alternative approaches may wish to consider continuing use of combination therapy after a thorough discussion of the risks and benefits. Alternatives to hormone therapy for vasomotor symptoms include SSRIs such as paroxetine, 12.5 mg or 25 mg/d orally, or venlafaxine, 75 mg/d orally. Gabapentin, an antiseizure medication, is also effective at 900 mg/d orally. Clonidine given orally or transdermally, 100–150 mcg daily, may also reduce the frequency of hot flashes, but its use is limited by side effects, including dry mouth, drowsiness, and hypotension. There is some evidence that soy isoflavones may be effective in treating menopausal symptoms. Other compounds including red clover and black cohosh have not been shown to be effective. Because little is known about adverse effects, particularly with long-term use, dietary supplements should be used with caution.

2. Vaginal atrophy—A vaginal ring containing 2 mg of estradiol can be left in place for 3 months and is suitable for long-term use. Short-term use of estrogen vaginal cream will relieve symptoms of atrophy, but because of variable absorption, therapy with either the vaginal ring or systemic hormone replacement is preferable. A low-dose estradiol tablet (10 mcg) is available and is inserted in the vagina daily for 2 weeks and then twice a week for long-term use. Testosterone propionate 1–2%, 0.5–1 g, in a vanishing cream base used in the same manner is also effective if estrogen is contraindicated. A bland lubricant such as unscented cold cream or water-soluble gel can be helpful at the time of coitus.

3. Osteoporosis—(See also discussion in Chapter 26.) Women should ingest at least 800 mg of calcium daily throughout life. In addition, 1200 mg of elemental calcium should be taken as a daily supplement at the time of the menopause and thereafter; calcium supplements should be taken with meals to increase their absorption. Vitamin D, 800 international units/d from food, sunlight, or supplements, is necessary to enhance calcium absorption and maintain bone mass. A daily program of energetic walking and exercise to strengthen the arms and upper body helps maintain bone mass.

Women most at risk for osteoporotic fractures should consider bisphosphonates, raloxifene, or hormone replacement therapy. This includes white and Asian women, especially if they have a family history of osteoporosis, are thin, short, cigarette smokers, have a history of hyperthyroidism, use corticosteroid medications long-term, or are physically inactive.

B. Risks of Hormone Therapy

Double-blinded randomized, controlled trials have shown no overall cardiovascular benefit with estrogen-progestin

replacement therapy in a group of postmenopausal women with or without established coronary disease. Both in the WHI trial and the Heart and Estrogen/Progestin Replacement Study (HERS), the overall health risks (increased risk of coronary heart events; strokes; thromboembolic disease; gallstones; and breast cancer, including an increased risk of mortality from breast cancer) exceeded the benefits from the use of combination estrogen and progesterone. An ancillary study of the WHI study showed that not only did estrogen-progestin hormone replacement therapy not benefit cognitive function but there was a small increased risk of cognitive decline in that group compared with women in the placebo group. The unopposed estrogen arm of the WHI trial demonstrated a decrease in the risk of hip fracture, a small but nonsignificant decrease in breast cancer, but an increased risk of stroke and no evidence of protection from coronary heart disease. The study also showed a small increase in the combined risk of mild cognitive impairment and dementia with estrogen use compared with placebo, similar to the estrogen-progestin arm. Women who have been receiving long-term estrogen-progestin hormone replacement therapy, even in the absence of complications, should be encouraged to stop, especially if they do not have menopausal symptoms. However, the risks appear to be lower in women starting therapy at the time of menopause and higher in previously untreated women starting therapy long after menopause. Therapy should be individualized as the risk-benefit profile varies with age and individual risk factors. (See also discussions of estrogen and progestin replacement therapy in Chapter 26.)

C. Surgical Menopause

The abrupt hormonal decrease resulting from oophorectomy generally results in severe vasomotor symptoms and rapid onset of dyspareunia and osteoporosis unless treated. If not contraindicated, estrogen replacement is generally started immediately after surgery. Conjugated estrogens 1.25 mg orally, estrone sulfate 1.25 mg orally, or estradiol 2 mg orally is given for 25 days of each month. After age 45–50 years, this dose can be tapered to 0.625 mg of conjugated estrogens or equivalent.

North American Menopause Society. Estrogen and progestogen use in postmenopausal women: 2010 position statement of The North American Menopause Society. *Menopause*. 2010 Mar;17(2):242–55. [PMID: 20154637]

Shen W et al. Treatment strategies for hot flashes. *Expert Opin Pharmacother*. 2009 May;10(7):1133–44. [PMID: 19405789]

Wren BG. The benefits of oestrogen following menopause: why hormone replacement therapy should be offered to postmenopausal women. *Med J Aust*. 2009 Mar 16;190(6):321–5. [PMID: 19296814]

Obstetrics & Obstetric Disorders

Vanessa L. Rogers, MD
Kevin C. Worley, MD

19

DIAGNOSIS OF PREGNANCY

It is advantageous to diagnose pregnancy as promptly as possible when a sexually active woman misses a menstrual period or has symptoms suggestive of pregnancy. In the event of a desired pregnancy, prenatal care can begin early, and potentially harmful medications and activities such as drug and alcohol use, smoking, and occupational chemical exposure can be halted. In the event of an unwanted pregnancy, counseling about adoption or termination of the pregnancy can be provided at an early stage.

► Pregnancy Tests

All urine or blood pregnancy tests rely on the detection of human chorionic gonadotropin (hCG) produced by the placenta. hCG levels increase shortly after implantation, approximately double every 48 hours, reach a peak at 50–75 days, and fall to lower levels in the second and third trimesters. Laboratory and home pregnancy tests use monoclonal antibodies specific for hCG. These tests are performed on serum or urine and are accurate at the time of the missed period or shortly after it.

Compared with intrauterine pregnancies, **ectopic pregnancies** may show lower levels of hCG that plateau or fall in serial determinations. Quantitative assays of hCG repeated at 48-hour intervals are used in the diagnosis of ectopic pregnancy as well as in cases of molar pregnancy, threatened abortion, and missed abortion. Comparison of hCG levels between laboratories may be misleading in a given patient because different international standards may produce results that vary by as much as twofold. hCG levels can also be problematic because they require a series of measurements. Progesterone levels, however, remain relatively stable in the first trimester. A single measurement of progesterone is the best indicator of whether a pregnancy is viable, although there is a broad indeterminate zone. A value < 5 ng/mL (16 nmol/L) predicts pregnancy failure while a value > 25 ng/mL (80 nmol/L) indicates a pregnancy will be successful. There is uncertainty when the value is between these two points. Combining several serum biomarkers may provide a better prediction of pregnancy viability. **Pregnancy of unknown location** is a term used to describe a situation where a woman has a positive

pregnancy test but the location and viability of the pregnancy is not known because nothing is seen on ultrasound.

Kirk E et al. Pregnancies of unknown location. *Best Pract Res Clin Obstet Gynaecol.* 2009 Aug;23(4):493–9. [PMID: 19345646]

► Manifestations of Pregnancy

The following symptoms and signs are usually due to pregnancy, but none are diagnostic. A record of the time and frequency of coitus is helpful for diagnosing and dating a pregnancy.

A. Symptoms

Amenorrhea, nausea and vomiting, breast tenderness and tingling, urinary frequency and urgency, “quickening” (perception of first movement noted at about the 18th week), weight gain.

B. Signs (in Weeks from Last Menstrual Period)

Breast changes (enlargement, vascular engorgement, colostrum) start to occur very early in pregnancy and continue until the postpartum period. Cyanosis of the vagina and cervical portio and softening of the cervix occur in about the seventh week. Softening of the cervicouterine junction takes place in the eighth week, and generalized enlargement and diffuse softening of the corpus occurs after the eighth week. When a woman’s abdomen will start to enlarge depends on her body habitus but typically starts in the sixteenth week.

The uterine fundus is palpable above the pubic symphysis by 12–15 weeks from the last menstrual period and reaches the umbilicus by 20–22 weeks. Fetal heart tones can be heard by Doppler at 10–12 weeks of gestation.

► Differential Diagnosis

The nonpregnant uterus enlarged by myomas can be confused with the gravid uterus, but it is usually very firm and irregular. An ovarian tumor may be found midline, displacing the nonpregnant uterus to the side or posteriorly. Ultrasonography and a pregnancy test will provide accurate diagnosis in these circumstances.

ESSENTIALS OF PRENATAL CARE

The first prenatal visit should occur as early as possible after the diagnosis of pregnancy and should include the following: history, physical examination, laboratory tests, advice to the patient, and tests and procedures.

► History

The patient's age, ethnic background, and occupation should be obtained. The onset of the last menstrual period and its normality, possible conception dates, bleeding after the last menstruation, medical history, all prior pregnancies (duration, outcome, and complications), and symptoms of present pregnancy should be documented. The patient's nutritional habits should be discussed with her, as well as any use of caffeine, tobacco, alcohol, or drugs (Table 19–1 and 19–2). Whether there is any family history of congenital anomalies and heritable diseases, a personal history of childhood varicella, prior sexually transmitted diseases (STDs), or risk factors for HIV infection should be determined.

► Physical Examination

Height, weight, and blood pressure should be measured, and a general physical examination should be done, including a breast examination. Abdominal and pelvic

Table 19–1. Common drugs that are teratogenic or fetotoxic.¹

ACE inhibitors	Lithium
Alcohol	Methotrexate
A-II antagonists	Misoprostol
Androgens	NSAIDs (third trimester)
Antiepileptics (phenytoin, valproic acid, carbamazepine)	Opioids (prolonged use)
Benzodiazepines	Progestins
Carbarsone (amebicide)	Radioiodine (antithyroid)
Chloramphenicol (third trimester)	Reserpine
Cyclophosphamide	Ribavirin
Diazoxide	Sulfonamides (third trimester)
Diethylstilbestrol	SSRIs
Disulfiram	Tetracycline (third trimester)
Ergotamine	Thalidomide
Estrogens	Tobacco smoking
Griseofulvin	Trimethoprim (third trimester)
Isotretinoin	Warfarin and other coumarin anticoagulants

¹Many other drugs are also contraindicated during pregnancy. Evaluate any drug for its need versus its potential adverse effects. Further information can be obtained from the manufacturer or from any of several teratogenic registries around the country. ACE, angiotensin-converting enzyme; A-II antagonists, angiotensin II receptor blocking agents; NSAIDs, nonsteroidal anti-inflammatory drugs; SSRIs, selective serotonin reuptake inhibitors.

Table 19–2. Drugs and substances that require a careful assessment of risk before they are prescribed for breastfeeding women.

Category of Drug	Specific Drug	Concern
ACE inhibitors	Lisinopril	Unknown effects.
Alkylating agents	Cyclophosphamide	Neonatal neutropenia. No breastfeeding.
Analgesic	Aspirin	High doses associated with neonatal salicylate toxicity.
Antibiotics	Ciprofloxacin	Case of neonatal <i>Clostridium difficile</i> pseudomembranous colitis.
	Nitrofurantoin	Avoid if family history of glucose-6-phosphate dehydrogenase deficiency.
Antiepileptics	Carbamazepine, diazepam	Neonatal hepatitis, dose-dependent effects.
Antidepressants	Fluoxetine, sertraline	Present in breast milk. Watch for adverse effects.
Antihistamine	Cetirizine, diphenhydramine	Irritability of the newborn.
Antihypertensives	Methyldopa	Possible neonatal hypoglycemia.
Antimetabolites	Methotrexate	Unknown effects. No breastfeeding.
Anticholinergic	Atropine	Unknown effects.
Hormones	Danazol	Unknown effects. No breastfeeding.
Mood stabilizer	Lithium	High circulating level in the neonate.
Retinoids	Isotretinoin	Unknown effects. No breastfeeding.
Radioactive compounds	Radioiodine	No breastfeeding.

The above list is not all-inclusive. For additional information, see the below references from which this information is adapted or the online drug and lactation database, Lactmed, at <http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT>. Data from Buhimschi CS et al. Medications in pregnancy and lactation: part 1. Teratology. Obstet Gynecol. 2009 Jan;113(1):166-88; and Buhimschi CS et al. Medications in pregnancy and lactation: Part 2. Drugs with minimal or unknown human teratogenic effect. Obstet Gynecol. 2009 Feb;113(2 Pt 1):417-32.

examination should include the following: (1) estimate of uterine size or measure of fundal height; (2) evaluation of bony pelvis for symmetry and adequacy; (3) evaluation of cervix for structural anatomy, infection, effacement, dilation; (4) detection of fetal heart tones by Doppler device after 10 weeks.

► Laboratory Tests

Urinalysis; culture of a clean-voided midstream urine sample; random blood glucose; complete blood count with red cell indices; serologic test for syphilis, rubella antibody titer; varicella immunity; blood group; Rh type; antibody screening for anti-Rh₀(D), hepatitis B surface antigen (HBsAg), and the HIV should be performed. Cervical cultures are usually obtained for Chlamydia and possibly *Neisseria gonorrhoeae*, along with a Papanicolaou smear of the cervix. All black women should have sickle cell screening. Women of African, Asian, or Mediterranean ancestry with anemia or low mean corpuscular volume (MCV) values should have hemoglobin electrophoresis performed to identify abnormal hemoglobins (Hb S, C, F, α -thalassemia, β -thalassemia). Tuberculosis skin testing is indicated for high-risk populations. Fetal aneuploidy screening is available in the first and second trimester and should be offered to all women, ideally before 20 weeks gestation. Noninvasive first trimester screening for Down syndrome includes ultrasonographic nuchal translucency and serum levels of PAPP-A (pregnancy-associated plasma protein A) and the free β subunit of hCG. In the second trimester, a “quad screen” blood test can be performed; it measures serum alpha-fetoprotein (msAFP), β -hCG, unconjugated estriol, and inhibin A. First and second trimester tests have similar detection rates. When first and second trimester screening are combined (integrated screening), the detection rates are even higher. Women at increased risk for aneuploidy can then be offered chorionic villus sampling or genetic amniocentesis, depending on gestational age and availability. Blood screening for Tay-Sachs, Canavan disease, and familial dysautonomia is offered to couples who are of Eastern European Jewish (Ashkenazi) descent. Couples of French-Canadian or Cajun ancestry should also be screened as possible Tay-Sachs carriers. Screening for cystic fibrosis is offered to all pregnant women. Hepatitis C antibody screening should be offered to pregnant women who are at high risk for infection.

► Advice to Patients

A. Prenatal Visits

Prenatal care should begin early and maintain a schedule of regular prenatal visits: 0–28 weeks, every 4 weeks; 28–36 weeks, every 2 weeks; 36 weeks on, weekly.

B. Diet

The patient should be counseled to eat a balanced diet containing the major food groups.

1. Prenatal vitamins with iron and folic acid should be prescribed. Supplements that are not specified for pregnant women should be avoided as they may contain dangerous amounts of certain vitamins.

2. The average weight pregnant woman should be expected to gain is 20–40 lb. A pregnant woman should not diet to lose weight during pregnancy, although obese women do seem to benefit from gaining less weight, perhaps 10–15 lb.
3. Caffeine intake should be decreased to 0–1 cup of coffee, tea, or caffeinated cola daily.
4. The patient should be advised to avoid eating raw or rare meat as well as fish known to contain elevated levels of mercury.
5. Patients should be encouraged to eat fresh fruits and vegetables (washed before eating).

C. Medications

Only medications prescribed or authorized by the obstetric provider should be taken.

D. Alcohol and Other Drugs

Patients should be encouraged to abstain from alcohol, tobacco, and all recreational (“street”) drugs. No safe level of alcohol intake has been established for pregnancy. Fetal effects are manifest in the **fetal alcohol syndrome**, which includes growth restriction; facial, skeletal, and cardiac abnormalities; and serious central nervous system dysfunction. These effects are thought to result from direct toxicity of ethanol as well as of its metabolites such as acetaldehyde.

Cigarette smoking results in fetal exposure to carbon monoxide and nicotine, and this is thought to eventuate in a number of adverse pregnancy outcomes. An increased risk of abruptio placentae, placenta previa, and premature rupture of the membranes is documented among women who smoke. Preterm delivery, low birth weight, and ectopic pregnancy are also more likely among smokers. Women who smoke should quit smoking or at least reduce the number of cigarettes smoked per day to as few as possible. Clinicians should ask all pregnant women about their smoking history and offer smoking cessation counseling during pregnancy, since women are more motivated to change at this time. Pregnant women should also avoid exposure to environmental smoke (“passive smoking”) and smokeless tobacco.

Sometimes compounding the above effects on pregnancy outcome are the independent adverse effects of illicit drugs. Cocaine use in pregnancy is associated with an increased risk of premature rupture of membranes, preterm delivery, placental abruption, intrauterine growth restriction, neurobehavioral deficits, and sudden infant death syndrome. Similar adverse pregnancy effects are associated with amphetamine use, perhaps reflecting the vasoconstrictive potential of both amphetamines and cocaine. Adverse effects associated with opioid use include intrauterine growth restriction, prematurity, and fetal death.

E. Radiographs and Noxious Exposures

Radiographs should be avoided unless essential and approved by a clinician. Abdominal shielding should be used whenever possible. The patient should be told to inform her dentist and providers that she is pregnant.

Chemical or radiation hazards should be avoided as should excessive heat in hot tubs or saunas. Patients should be told to avoid handling cat feces or cat litter and to wear gloves when gardening.

F. Rest and Activity

The patient should be encouraged to obtain adequate rest each day. She should abstain from strenuous physical work or activities, particularly when heavy lifting or weight bearing is required. Regular exercise can be continued at a mild to moderate level; however exhausting or hazardous exercises or new athletic training programs should be avoided during pregnancy. Exercises that require a great deal of balance should also be done with caution.

G. Birth Classes

The patient should be encouraged to enroll in a childbirth preparation class with her partner well before her due date.

▶ Tests & Procedures

A. Each Visit

Weight, blood pressure, fundal height, and fetal heart rate are measured, and a urine specimen is obtained and tested for protein and glucose. Any concerns the patient may have about pregnancy, health, and nutrition should be reviewed.

B. 6–12 Weeks

Confirm uterine size and growth by pelvic examination. Document fetal heart tones (audible at 10–12 weeks of gestation by Doppler). First trimester screening and a discussion of choices of aneuploidy screening should be discussed at this time (see Laboratory Tests, above). Chorionic villus sampling is performed during this period (11–13 weeks).

C. 16–20 Weeks

The “quad screen” and amniocentesis are performed as indicated and requested by the patient during this time (see Laboratory Tests, above). Fetal ultrasound examination to determine pregnancy dating and evaluate fetal anatomy is also done. An earlier examination provides the most accurate dating, and a later examination demonstrates fetal anatomy in greatest detail. The best compromise is at 18–20 weeks of gestation.

D. 20–24 Weeks

Instruct the patient about symptoms and signs of preterm labor and rupture of membranes. Consider cervical length measurement by ultrasound after 18 weeks with history of prior preterm delivery (> 2.5 cm is normal).

E. 24 Weeks to Delivery

Ultrasound examination is performed as indicated. Typically, fetal size and growth are evaluated when fundal height is 3 cm less than or more than expected for gestational age. In multiple pregnancies, ultrasound should be performed every 4–6 weeks to evaluate for discordant growth.

F. 24–28 Weeks

Screening for gestational diabetes is performed using a 50-g glucose load (Glucola) and a 1-hour post-Glucola blood glucose determination. Abnormal values (≥ 140 mg/dL) should be followed up with a 3-hour glucose tolerance test (see Table 19–4).

G. 28 Weeks

If initial antibody screen for anti-Rh₀(D) is negative, repeat antibody testing for Rh-negative patients is performed, but the result is not required before Rh₀(D) immune globulin is administered (see below).

H. 28–32 Weeks

A complete blood count is done to evaluate for anemia of pregnancy. Screening for syphilis and possibly HIV is also frequently performed at this time. Providers should familiarize themselves with the laws in their state since testing requirements vary.

I. 28 Weeks to Delivery

Fetal position and presentation are determined. The patient is asked about symptoms or signs of preterm labor or rupture of membranes at each visit. Maternal perception of fetal movement should be assessed at each visit. Antepartum fetal testing can be performed as medically indicated.

J. 36 Weeks to Delivery

Repeat syphilis and HIV testing (depending on state laws), cervical cultures for *N gonorrhoeae* and *Chlamydia trachomatis* should be performed in at-risk patients. The indicators of onset of labor, admission to the hospital, management of labor and delivery, and options for analgesia and anesthesia should be discussed with the patient. Weekly cervical examinations are not necessary unless indicated to assess a specific clinical situation. Elective delivery (whether by induction or cesarean section) prior to 39 weeks of gestation requires confirmation of fetal lung maturity.

The CDC recommends universal prenatal culture-based screening for group B streptococcal colonization in pregnancy. A single standard culture of the distal vagina and anorectum is collected at 35–37 weeks. No prophylaxis is needed if the screening culture is negative. Patients whose cultures are positive receive intrapartum penicillin prophylaxis during labor. Except when group B streptococci are found in urine, asymptomatic colonization is not to be treated before labor. Patients who have had a previous infant with invasive group B streptococcal disease or who have group B streptococcal bacteriuria during this pregnancy should receive intrapartum prophylaxis regardless, so rectovaginal cultures are not needed. Patients whose cultures at 35–37 weeks were not done or whose results are not known should receive prophylaxis if they have a risk factor for early-onset neonatal disease, including intrapartum temperature $\geq 38^{\circ}\text{C}$, membrane rupture > 18 hours, or delivery before 37 weeks gestation.

The routine recommended regimen for prophylaxis is penicillin G, 5 million units intravenously as a loading dose and then 2.5 million units intravenously every 4 hours until delivery. In penicillin-allergic patients not at high risk for anaphylaxis, 2 g of cefazolin can be given intravenously as an initial dose and then 1 g intravenously every 8 hours until delivery. In patients at high risk for anaphylaxis, vancomycin 1 g intravenously every 12 hours until delivery is used or, after confirmed susceptibility testing of group B streptococcal isolate, clindamycin 900 mg intravenously every 8 hours or erythromycin 500 mg intravenously every 6 hours until delivery.

K. 41 Weeks

The patient should have a cervical examination to determine the probability of successful induction of labor. Based on this, induction of labor is undertaken if the cervix is favorable (generally, cervix ≥ 2 cm dilated $\geq 50\%$ effaced, vertex at -1 station, soft cervix, and midposition); if unfavorable, antepartum fetal testing is begun. Induction is performed at 42 weeks gestation regardless of the cervical examination findings; some providers elect induction at 41 weeks regardless of the cervical examination findings.

ACOG Committee on Genetics. ACOG Committee Opinion No. 442: Preconception and prenatal carrier screening for genetic diseases in individuals of Eastern European Jewish descent. *Obstet Gynecol.* 2009 Oct;114(4):950–53. [PMID: 19888064]
 Driscoll DA et al. Screening for fetal aneuploidy and neural tube defects. *Genet Med.* 2009 Nov;11(11):818–21. [PMID: 19915395]
 Phelan ST. Components and timing of prenatal care. *Obstet Gynecol Clin North Am.* 2008 Sep;35(3):339–53. [PMID: 18760223]

NUTRITION IN PREGNANCY

Nutrition in pregnancy can affect maternal health and infant size and well-being. Pregnant women should have nutrition counseling early in prenatal care and access to supplementary food programs if necessary. Counseling should stress abstinence from alcohol, smoking, and recreational drugs. Caffeine and artificial sweeteners should be used only in small amounts. “Empty calories” should be avoided, and the diet should contain the following foods: protein foods of animal and vegetable origin, milk and milk products, whole-grain cereals and breads, and fruits and vegetables—especially green leafy vegetables.

Weight gain in pregnancy should be 20–40 lb, which includes the added weight of the fetus, placenta, and amniotic fluid and of maternal reproductive tissues (fluid, blood, increased fat stores, and increased lean body mass). Maternal fat stores are a caloric reserve for pregnancy and lactation; weight restriction in pregnancy to avoid developing such fat stores may affect the development of other fetal and maternal tissues and is not advisable. Obese women can have normal infants with less weight gain (15–20 lb) but should be encouraged to eat high-quality foods. Normally, a pregnant woman gains 2–5 lb in the first trimester and slightly <1 lb/wk thereafter. She needs

approximately an extra 200–300 kcal/d (depending on energy output) and 30 g/d of additional protein for a total protein intake of about 75 g/d. Appropriate caloric intake in pregnancy helps prevent the problems associated with low birth weight.

Rigid salt restriction is not necessary. While consumption of highly salted snack foods and prepared foods is not desirable, 2–3 g/d of sodium is permissible. The increased calcium needs of pregnancy (1200 mg/d) can be met with milk, milk products, green vegetables, soybean products, corn tortillas, and calcium carbonate supplements.

The increased need for iron and folic acid should be met with foods as well as vitamin and mineral supplements. (See section on Anemia in pregnancy.) Megavitamins should not be taken in pregnancy, as they may result in fetal malformation or disturbed metabolism. However, a balanced prenatal supplement containing 30–60 mg of elemental iron, 0.5–0.8 mg of folate, and the recommended daily allowances of various vitamins and minerals is widely used in the United States and is probably beneficial to many women with marginal diets. There is evidence that periconceptional folic acid supplements can decrease the risk of neural tube defects in the fetus. For this reason, the United States Public Health Service recommends the consumption of 0.4 mg of folic acid per day for all pregnant and reproductive age women. Women with a prior pregnancy complicated by neural tube defect may require higher supplemental doses as determined by their providers. Lactovegetarians and ovo-lactovegetarians do well in pregnancy; vegetarian women who eat neither eggs nor milk products should have their diets assessed for adequate calories and protein and should take oral vitamin B₁₂ supplements during pregnancy and lactation.

De-Regil LM et al. Effects and safety of periconceptional folate supplementation for preventing birth defects. *Cochrane Database Syst Rev.* 2010 Oct 6;(10):CD007950. [PMID: 20927767]

Rasmussen KM et al. Recommendations for weight gain during pregnancy in the context of the obesity epidemic. *Obstet Gynecol.* 2010 Nov;116(5):1191–5. [PMID: 20966705]

PREVENTION OF RHESUS ALLOIMMUNIZATION

The antibody anti-Rh₀(D) is responsible for most severe instances of hemolytic disease of the newborn. About 15% of whites and much lower proportions of blacks and Asians are Rh₀(D)–negative. If an Rh₀(D)–negative woman carries an Rh₀(D)–positive fetus, antibodies against Rh₀(D) may develop in the mother when fetal red cells enter her circulation during small fetomaternal bleeding episodes in the early third trimester or during delivery, abortion, ectopic pregnancy, abruptio placentae, or other instances of antepartum bleeding. This antibody, once produced, remains in the woman’s circulation and poses the threat of hemolytic disease for subsequent Rh-positive fetuses.

Passive immunization against hemolytic disease of the newborn is achieved with Rh₀(D) immune globulin, a purified concentrate of antibodies against Rh₀(D) antigen. The Rh₀(D)

immune globulin (one vial of 300 mcg intramuscularly) is given to the mother within 72 hours after delivery (or spontaneous or induced abortion or ectopic pregnancy). The antibodies in the immune globulin destroy fetal Rh-positive cells so that the mother will not produce anti-Rh₀(D). During her next Rh-positive gestation, erythroblastosis will be prevented. An additional safety measure is the routine administration of the immune globulin at the 28th week of pregnancy. The passive antibody titer that results is too low to significantly affect an Rh-positive fetus. The maternal clearance of the globulin is slow enough that protection will continue for 12 weeks.

Hemolytic disease of varying degrees, from mild to serious, continues to occur in association with Rh subgroups (C, c, or E) or Kell, Kidd, and other factors. Therefore, the presence of atypical antibodies should be checked in the third trimester of all pregnancies.

Moise KJ Jr. Management of rhesus alloimmunization in pregnancy. *Obstet Gynecol.* 2008 Jul;112(1):164–76. [PMID: 18591322]

LACTATION

Breastfeeding should be encouraged by education throughout pregnancy and the puerperium. Mothers should be told the benefits of breastfeeding, including infant immunity, emotional satisfaction, mother-infant bonding, and economic savings. The period of amenorrhea associated with frequent and consistent breastfeeding provides some (although not completely reliable) birth control until menstruation begins at 6–12 months postpartum or the intensity of breastfeeding diminishes. If the mother must return to work, even a brief period of nursing is beneficial. Transfer of immunoglobulins in colostrum and breast milk protects the infant against many systemic and enteric infections. Macrophages and lymphocytes transferred to the infant from breast milk play an immunoprotective role. The intestinal flora of breastfed infants inhibits the growth of pathogens. Breastfed infants have fewer bacterial and viral infections, less severe diarrhea, and fewer allergy problems than bottle-fed infants. Furthermore, they are less apt to be obese as children and adults.

Frequent breastfeeding on an infant-demand schedule enhances milk flow and successful breastfeeding. Mothers breastfeeding for the first time need help and encouragement from providers, nurses, and other nursing mothers. Milk supply can be increased by increased suckling and increased rest.

Nursing mothers should have a fluid intake of over 2 L/d. The United States RDA calls for 21 g of extra protein (over the 44 g/d baseline for an adult woman) and 550 extra kcal/d in the first 6 months of nursing. Calcium intake should be 1200 mg/d. Continuation of a prenatal vitamin and mineral supplement is wise. Strict vegetarians who eschew both milk and eggs should always take vitamin B₁₂ supplements during pregnancy and lactation.

1. Effects of Drugs in a Nursing Mother

Drugs taken by a nursing mother may accumulate in milk and be transmitted to the infant (Table 19–2). The amount of drug entering the milk depends on the drug's lipid solubility, mechanism of transport, and degree of ionization.

2. Suppression of Lactation

A. Mechanical Suppression

The simplest and safest method of suppressing lactation after it has started is to gradually transfer the baby to a bottle or a cup over a 3-week period. Milk supply will decrease with decreased demand, and minimal discomfort ensues. If nursing must be stopped abruptly, the mother should avoid nipple stimulation, refrain from expressing milk, and use a snug brassiere. Ice packs and analgesics can be helpful. This same technique can be used in cases where suppression is desired before nursing has begun. Engorgement will gradually recede over a 2- to 3-day period.

B. Hormonal Suppression

Oral and long-acting injections of hormonal preparations were used at one time to suppress lactation. Because of their questionable efficacy and particularly because of associated side effects such as thromboembolic episodes and hair growth, their use for this purpose has been abandoned. Similarly, lactation suppression with bromocriptine is to be avoided because of reports of severe hypertension, seizures, strokes, and myocardial infarctions associated with its use.

Rautava S et al. Academy of Breastfeeding Medicine founder's lecture 2008: breastfeeding—an extrauterine link between mother and child. *Breastfeed Med.* 2009 Mar;4(1):3–10. [PMID: 19292608]

TRAVEL & IMMUNIZATIONS DURING PREGNANCY

During an otherwise normal low-risk pregnancy, travel can be planned most safely up to the 32nd week. Commercial flying in pressurized cabins does not pose a threat to the fetus. An aisle seat will allow frequent walks. Adequate fluids should be taken during the flight.

It is not advisable to travel to endemic areas of yellow fever in Africa or Latin America; similarly, it is inadvisable to travel to areas of Africa or Asia where chloroquine-resistant falciparum malaria is a hazard, since complications of malaria are more common in pregnancy.

Ideally, all immunizations should precede pregnancy. Live virus products are contraindicated during pregnancy (measles, rubella, yellow fever and smallpox.) Inactivated polio vaccine (IPV) should be given subcutaneously instead of the oral live-attenuated vaccine. The varicella vaccine should be given 1–3 months before becoming pregnant. Vaccines against pneumococcal pneumonia, meningococcal meningitis, and hepatitis A can be used as indicated. Pregnant women who are considered to be at high-risk for hepatitis B and who have not been previously vaccinated should be vaccinated during pregnancy.

Annual influenza vaccination is indicated in all women who are pregnant or will be pregnant during “flu season.” It can be given in the first trimester. The CDC lists pregnant women as a high-risk group. Pregnant women who have not previously received the tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) immunization should be given the vaccine after 20 weeks gestation or immediately postpartum. Further, any teenagers or adults not previously vaccinated who will have close contact with the infant should also receive it, ideally 2 weeks before exposure to the child. This vaccination strategy is referred to as “cocooning,” and its purpose is to protect the infant aged < 12 months who is at particularly high risk for lethal pertussis.

Hepatitis A vaccine contains formalin-inactivated virus and can be given in pregnancy when needed. Chloroquine can be used for malaria prophylaxis in pregnancy, and proguanil is also safe. Pooled immune globulin to prevent hepatitis A is safe and does not carry a risk of HIV-transmission.

Water should be purified by boiling, since iodine purification may provide more iodine than is safe during pregnancy.

Prophylactic antibiotics or bismuth subsalicylate should not be used during pregnancy to prevent diarrhea. Oral rehydration and treatment of bacterial diarrhea with erythromycin or ampicillin if necessary is preferred.

Centers for Disease Control and Prevention (CDC). Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine (Tdap) in pregnant women and persons who have or anticipate having close contact with an infant aged < 12 months—Advisory Committee on Immunization Practices (ACIP), 2011. *MMWR Morb Mortal Wkly Rep.* 2011 Oct 21;60(41):1424–6. [PMID: 22012116]

OBSTETRIC COMPLICATIONS OF THE FIRST & SECOND TRIMESTERS

VOMITING OF PREGNANCY (Morning Sickness) & HYPEREMESIS GRAVIDARUM (Pernicious Vomiting of Pregnancy)

ESSENTIALS OF DIAGNOSIS

- ▶ Morning or evening nausea and vomiting.
- ▶ Persistent vomiting severe enough to result in weight loss, dehydration, starvation ketosis, hypochloremic alkalosis, hypokalemia.
- ▶ May have transient elevation of liver enzymes.
- ▶ Appears related to high or rising serum hCG.
- ▶ More common with multiple gestation or hydatidiform mole.

▶ General Considerations

Nausea and vomiting begin soon after the first missed period and cease by the fifth month of gestation. Up to three-fourths of women complain of nausea and vomiting

during early pregnancy, with the vast majority noting nausea throughout the day. This problem exerts no adverse effects on the pregnancy and does not presage other complications.

Persistent, severe vomiting during pregnancy—hyperemesis gravidarum—can be disabling and require hospitalization. Thyroid dysfunction can be associated with hyperemesis gravidarum, so it is advisable to determine thyroid-stimulating hormone (TSH) and free thyroxine (T_4) values in these patients.

▶ Treatment

A. Mild Nausea and Vomiting of Pregnancy

In most instances, only reassurance and dietary advice are required. Because of possible teratogenicity, drugs used during the first half of pregnancy should be restricted to those of major importance to life and health. Antiemetics, antihistamines, and antispasmodics are generally unnecessary to treat nausea of pregnancy. Vitamin B_6 (pyridoxine), 50–100 mg/d orally, is nontoxic and may be helpful in some patients.

B. Hyperemesis Gravidarum

With more severe nausea and vomiting, it may become necessary to hospitalize the patient. In this case, a private room with limited activity is preferred. Give nothing by mouth for 48 hours, and maintain hydration and electrolyte balance by giving appropriate parenteral fluids and vitamin supplements as indicated. Antiemetics such as promethazine (25 mg orally, rectally, or intravenously every 4–6 hours), metoclopramide (10 mg orally or intravenously every 6 hours), or ondansetron (4–8 mg orally or intravenously every 8 hours) should be started. Antiemetics will likely need to be given intravenously initially. Rarely, total parenteral nutrition may become necessary. As soon as possible, place the patient on a dry diet consisting of six small feedings daily plus clear liquids 1 hour after eating. Antiemetics may be continued orally as needed. After in-patient stabilization, the patient can be maintained at home even if she requires intravenous fluids in addition to her oral intake. There are conflicting studies regarding the use of corticosteroids for the control of hyperemesis gravidarum. Therefore, this treatment should be withheld until more accepted treatments have been exhausted.

▶ When to Refer

- Patient is unable to tolerate any food or water.
- There is concern for other pathology (ie, hydatidiform mole).
- Patient requires hospitalization.

▶ When to Admit

- Patient is unable to tolerate any food or water.
- Condition precludes the patient from ingesting necessary medications.
- Weight loss.
- Presence of a hydatidiform mole.

Niebyl JR. Clinical practice. Nausea and vomiting in pregnancy. *N Engl J Med.* 2010 Oct 14;363(16):1544–50. [PMID: 20942670]
 Sonkusare S. The clinical management of hyperemesis gravidarum. *Arch Gynecol Obstet.* 2011 Jun;283(6):1183–92. [PMID: 21424548]

SPONTANEOUS ABORTION



ESSENTIALS OF DIAGNOSIS

- ▶ Intrauterine pregnancy at < 20 weeks.
- ▶ Low or falling levels of hCG.
- ▶ Bleeding, midline cramping pain.
- ▶ Open cervical os.
- ▶ Complete or partial expulsion of products of conception.

▶ General Considerations

About three-fourths of spontaneous abortions occur before the 16th week; of these, three-fourths occur before the eighth week. Almost 20% of all clinically recognized pregnancies terminate in spontaneous abortion.

More than 60% of spontaneous abortions result from chromosomal defects due to maternal or paternal factors; about 15% appear to be associated with maternal trauma, infections, dietary deficiencies, diabetes mellitus, hypothyroidism, the lupus anticoagulant-anticardiolipin-antiphospholipid antibody syndrome, or anatomic malformations. There is no reliable evidence that abortion may be induced by psychic stimuli such as severe fright, grief, anger, or anxiety. In about one-fourth of cases, the cause of abortion cannot be determined. There is no evidence that video display terminals or associated electromagnetic fields are related to an increased risk of spontaneous abortion.

It is important to distinguish women with a history of incompetent cervix from those with more typical early abortion. Characteristically, incompetent cervix presents as “silent” cervical dilation (ie, with minimal uterine contractions) in the second trimester. Women with incompetent cervix often present with significant cervical dilation (2 cm or more) and minimal symptoms. When the cervix reaches 4 cm or more, active uterine contractions or rupture of the membranes may occur secondary to the degree of cervical dilation. This does not change the primary diagnosis. Factors that predispose to incompetent cervix are a history of incompetent cervix with a previous pregnancy, cervical conization or surgery, cervical injury, diethylstilbestrol (DES) exposure, and anatomic abnormalities of the cervix. Prior to pregnancy or during the first trimester, there are no methods for determining whether the cervix will eventually be incompetent. After 14–16 weeks, ultrasound may be used to evaluate the internal anatomy of the lower uterine segment and cervix for the funneling and shortening abnormalities consistent with cervical incompetence.

▶ Clinical Findings

A. Symptoms and Signs

1. Threatened abortion—Bleeding or cramping occurs, but the pregnancy continues. The cervix is not dilated.

2. Inevitable abortion—The cervix is dilated and the membranes may be ruptured, but passage of the products of conception has not yet occurred. Bleeding and cramping persist, and passage of the products of conception is considered inevitable.

3. Complete abortion—Products of conception are completely expelled. Pain ceases, but spotting may persist. Cervical os is closed.

4. Incomplete abortion—The cervix is dilated. Some portion of the products of conception (usually placental) remain in the uterus. Only mild cramps are reported, but bleeding is persistent and often excessive.

5. Missed abortion—The pregnancy has ceased to develop, but the conceptus has not been expelled. Symptoms of pregnancy disappear. There may be a brownish vaginal discharge but no free bleeding. Pain does not develop. The cervix is semifirm and slightly patulous; the uterus becomes smaller and irregularly softened; the adnexa are normal.

B. Laboratory Findings

Pregnancy tests show low or falling levels of hCG. A complete blood count should be obtained if bleeding is heavy. Determine Rh type, and give Rh₀(D) immune globulin if Rh-negative. All tissue recovered should be assessed by a pathologist and may be sent for genetic analysis in selected cases.

C. Ultrasonographic Findings

The gestational sac can be identified at 5–6 weeks from the last menstruation, a fetal pole at 6 weeks, and fetal cardiac activity at 6–7 weeks by transvaginal ultrasound. Serial observations are often required to evaluate changes in size of the embryo. A small, irregular sac without a fetal pole with accurate dating is diagnostic of an abnormal pregnancy.

▶ Differential Diagnosis

The bleeding that occurs in abortion of a uterine pregnancy must be differentiated from the abnormal bleeding of an ectopic pregnancy and anovular bleeding in a non-pregnant woman. The passage of hydropic villi in the bloody discharge is diagnostic of hydatidiform mole.

▶ Treatment

A. General Measures

1. Threatened abortion—The patient should be placed on bed rest for 24–48 hours followed by gradual resumption of usual activities, with abstinence from coitus and douching. Hormonal treatment is contraindicated. Antibiotics should be used only if there are signs of infection.

2. Missed abortion—This calls for counseling regarding the fate of the pregnancy and planning for its elective

termination at a time chosen by the patient and clinician. Insertion of laminaria to dilate the cervix followed by aspiration has historically been the method of choice for a missed abortion. Medically induced first-trimester termination with prostaglandins (ie, misoprostol given vaginally or orally in a dose of 200–800 mcg) combined with an antiprogesterone (ie, mifepristone 600 mg orally) has grown in popularity because it has been shown to be safe, effective, less invasive, and more private. If it is unsuccessful or if there is excessive bleeding, a surgical procedure may still be needed. Patients must be counseled about the different therapeutic options with a thorough explanation of all risks and benefits.

B. Surgical Measures

1. Incomplete or inevitable abortion—Prompt removal of any products of conception remaining within the uterus is required to stop bleeding and prevent infection. Analgesia and a paracervical block are useful, followed by uterine exploration with ovum forceps or uterine aspiration. Regional anesthesia may be required.

2. Cerclage and restriction of activities—A cerclage is the treatment of choice for incompetent cervix, but a viable intrauterine pregnancy should be confirmed prior to placement of the cerclage.

A variety of suture materials including a 5-mm Mersilene band can be used to create a purse-string type of stitch around the cervix, using either the McDonald or Shirodkar method. Cerclage should be undertaken with caution when there is advanced cervical dilation or when the membranes are prolapsed into the vagina. Rupture of the membranes and infection are specific contraindications to cerclage. Cervical cultures for *N gonorrhoeae*, *Chlamydia*, and group B streptococci should be obtained before elective placement of a cerclage. *N gonorrhoeae* and *Chlamydia* should be treated before placement.

► When to Refer

- Patient with history of two second-trimester losses.
- Vaginal bleeding in a pregnant patient that resembles menstruation in a nonpregnant woman.
- Patient with an open cervical os.
- No signs of uterine growth in serial examinations of a pregnant patient.
- Leakage of amniotic fluid.

► When to Admit

- Open cervical os.
- Heavy vaginal bleeding.
- Leakage of amniotic fluid.

Deutchman M et al. First trimester bleeding. *Am Fam Physician*. 2009 Jun;79(11):985–94. [PMID: 19514696]

Hamoda H et al. Medical and surgical options for induced abortion in first trimester. *Best Pract Res Clin Obstet Gynaecol*. 2010 Aug;24(4):503–16. [PMID: 20418168]

RECURRENT (Habitual) ABORTION

Recurrent abortion has been defined as the loss of three or more previsible (<20 weeks gestation or 500 g) pregnancies in succession. Recurrent abortion occurs in about 1% of all couples. Abnormalities related to recurrent abortion can be identified in approximately half of these instances. If a woman has lost three previous pregnancies without identifiable cause, she still has at least a 65% chance of carrying a fetus to viability.

Recurrent abortion is a clinical rather than pathologic diagnosis. The clinical findings are similar to those observed in other types of abortion (see above).

► Treatment

A. Preconception Therapy

Preconception therapy is aimed at detection of maternal or paternal defects that may contribute to abortion. A thorough history and examination is essential. A random blood glucose test and thyroid function studies (including thyroid antibodies) can be done if history indicates a possible predisposition to diabetes mellitus or thyroid disease. Detection of lupus anticoagulant and other hemostatic abnormalities (proteins S and C and antithrombin deficiency, hyperhomocysteinemia, anticardiolipin antibody, factor V Leiden mutations) and an antinuclear antibody test may be indicated. Hysteroscopy or hysterothorography can be used to exclude submucosal myomas and congenital anomalies of the uterus. In women with recurrent losses, resection of a uterine septum, if present, has been recommended. Chromosomal (karyotype) analysis of both partners can be done to rule out balanced translocations (found in 5% of infertile couples), but karyotyping is expensive and may not be helpful.

Many therapies have been tried to prevent recurrent pregnancy loss from immunologic causes. Low-molecular-weight heparin (LMWH), aspirin, intravenous immunoglobulin, and corticosteroids have all been used but the definitive treatment has not yet been determined. LMWH and low-dose aspirin have been recommended for women with antiphospholipid antibodies and recurrent pregnancy loss.

Shetty S et al. Anti-phospholipid antibodies and other immunological causes of recurrent fetal loss—a review of literature of various therapeutic protocols. *Am J Reprod Immunol*. 2009 Jul;62(1):9–24. [PMID: 19527228]

B. Postconception Therapy

The patient should be provided early prenatal care and scheduled frequent office visits. Bed rest is justified only for bleeding or pain. Empiric sex steroid hormone therapy is contraindicated.

► Prognosis

The prognosis is excellent if the cause of abortion can be corrected or treated.

Branch DW et al. Clinical practice. Recurrent miscarriage. *N Engl J Med.* 2010 Oct;363(18):1740–7. [PMID: 20979474]

ECTOPIC PREGNANCY



ESSENTIALS OF DIAGNOSIS

- ▶ Amenorrhea or irregular bleeding and spotting.
- ▶ Pelvic pain, usually adnexal.
- ▶ Adnexal mass by clinical examination or ultrasound.
- ▶ Failure of serum level of β -hCG to double every 48 hours.
- ▶ No intrauterine pregnancy on transvaginal ultrasound with serum β -hCG > 2000 mU/mL.

▶ General Considerations

Ectopic implantation occurs in about one out of 150 live births. About 98% of ectopic pregnancies are tubal. Other sites of ectopic implantation are the peritoneum or abdominal viscera, the ovary, and the cervix. Any condition that prevents or retards migration of the fertilized ovum to the uterus can predispose to an ectopic pregnancy, including a history of infertility, pelvic inflammatory disease, ruptured appendix, and prior tubal surgery. Combined intrauterine and extrauterine pregnancy (heterotopic) may occur rarely. In the United States, undiagnosed or undetected ectopic pregnancy is currently the most common cause of maternal death during the first trimester.

▶ Clinical Findings

A. Symptoms and Signs

Severe lower quadrant pain occurs in almost every case. It is sudden in onset, stabbing, intermittent, and does not radiate. Backache may be present during attacks. Shock occurs in about 10%, often after pelvic examination. At least two-thirds of patients give a history of abnormal menstruation; many have been infertile.

Blood may leak from the tubal ampulla over a period of days, and considerable blood may accumulate in the peritoneum. Slight but persistent vaginal spotting is usually reported, and a pelvic mass may be palpated. Abdominal distention and mild paralytic ileus are often present.

B. Laboratory Findings

Blood studies may show anemia and slight leukocytosis. Quantitative serum pregnancy tests will show levels generally lower than expected for normal pregnancies of the same duration. If β -hCG levels are followed over a few days, there may be a slow rise or a plateau rather than the near doubling every 2 days associated with normal early intrauterine pregnancy or the falling levels that occur with spontaneous abortion. A progesterone level can also be measured to assess the viability of the pregnancy.

C. Imaging

Ultrasonography can reliably demonstrate a gestational sac 5–6 weeks from the last menstruation and a fetal pole at 6 weeks if located in the uterus. An empty uterine cavity raises a strong suspicion of extrauterine pregnancy, which can occasionally be revealed by transvaginal ultrasound. Specified levels of serum β -hCG have been reliably correlated with ultrasound findings of an intrauterine pregnancy. For example, a β -hCG level of 6500 mU/mL with an empty uterine cavity by transabdominal ultrasound is highly suspicious for an ectopic pregnancy. Similarly, a β -hCG value of 2000 mU/mL or more can be indicative of an ectopic pregnancy if no products of conception are detected within the uterine cavity by transvaginal ultrasound. Serum β -hCG values can vary by laboratory.

D. Special Examinations

With the advent of high-resolution transvaginal ultrasound, culdocentesis is rarely used in evaluation of possible ectopic pregnancy. Laparoscopy is the surgical procedure of choice both to confirm an ectopic pregnancy and in most cases to permit removal of the ectopic pregnancy without the need for exploratory laparotomy.

▶ Differential Diagnosis

Clinical and laboratory findings suggestive or diagnostic of pregnancy will distinguish ectopic pregnancy from many acute abdominal illnesses such as acute appendicitis, acute pelvic inflammatory disease, ruptured corpus luteum cyst or ovarian follicle, and urinary calculi. Uterine enlargement with clinical findings similar to those found in ectopic pregnancy is also characteristic of an aborting uterine pregnancy or hydatidiform mole. Ectopic pregnancy should be suspected when postabortal tissue examination fails to reveal chorionic villi. Steps must be taken for immediate diagnosis, including prompt microscopic tissue examination, ultrasonography, and serial β -hCG titers every 48 hours.

▶ Treatment

Patients must be warned about the complications of an ectopic pregnancy and monitored closely. In a stable patient, methotrexate (50 mg/m²) intramuscularly—given as single or multiple doses—is acceptable medical therapy for early ectopic pregnancy. Favorable criteria are that the pregnancy should be < 3.5 cm in largest dimension and unruptured, with no active bleeding and no fetal heart tones.

When a patient with an ectopic pregnancy is unstable or when surgical therapy is planned, the patient is hospitalized. Blood is typed and cross-matched. Ideally, diagnosis and operative treatment should precede frank rupture of the tube and intra-abdominal hemorrhage. The use of methotrexate in an unstable patient is absolutely contraindicated.

Surgical treatment is definitive. In most patients, diagnostic laparoscopy is the initial surgical procedure performed. Depending on the size of the ectopic pregnancy

and whether or not it has ruptured, salpingostomy with removal of the ectopic or a partial or complete salpingectomy can usually be performed. Clinical conditions permitting, patency of the contralateral tube can be established by injection of indigo carmine into the uterine cavity and flow through the contralateral tube confirmed visually by the surgeon.

Iron therapy for anemia may be necessary during convalescence. Rh₀(D) immune globulin (300 mcg) should be given to Rh-negative patients.

► Prognosis

Repeat tubal pregnancy occurs in about 10% of cases. This should not be regarded as a contraindication to future pregnancy, but the patient requires careful observation and early ultrasound confirmation of an intrauterine pregnancy.

► When to Refer

- Severe abdominal pain.
- Palpation of an adnexal mass on pelvic examination.
- Abdominal pain and vaginal bleeding in a pregnant patient.

► When to Admit

- Presence of symptoms or signs of a ruptured ectopic pregnancy.

Barnhart KT. Clinical practice. Ectopic pregnancy. *N Engl J Med*. 2009 Jul 23;361(4):379–87. [PMID: 19625718]

GESTATIONAL TROPHOBLASTIC DISEASE (Hydatidiform Mole & Choriocarcinoma)



ESSENTIALS OF DIAGNOSIS

Hydatidiform mole.

- ▶ Amenorrhea.
- ▶ Irregular uterine bleeding.
- ▶ Serum β -hCG > 40,000 mU/mL.
- ▶ Passage of grapelike clusters of enlarged edematous villi per vagina.
- ▶ Ultrasound of uterus shows characteristic heterogeneous echogenic image and no fetus or placenta.
- ▶ Cytogenetic composition is 46, XX (85%), completely of paternal origin.

Choriocarcinoma.

- ▶ Persistence of detectable β -hCG after mole evacuation.

► General Considerations

Gestational trophoblastic disease is a spectrum of disorders that includes hydatidiform mole (partial and complete),

invasive mole (local extension into the uterus or vagina), choriocarcinoma (a malignant tumor often complicated by distant metastases), and placental site trophoblastic tumor. Complete moles show no evidence of a fetus on ultrasonography. The majority are 46, XX with all chromosomes of paternal origin. Partial moles generally show evidence of an embryo or gestational sac; are triploid, slower-growing, and less symptomatic; and often present clinically as a missed abortion. Partial moles tend to follow a benign course, while complete moles have a greater tendency to become choriocarcinomas.

The highest rates of gestational trophoblastic disease occur in Asians. In the United States, the frequency is 1:1500 pregnancies. Risk factors include prior spontaneous abortion, a history of mole, and age younger than 21 or older than 35. Approximately 10% of women require further treatment after evacuation of the mole; choriocarcinoma develops in 2–3% of women.

► Clinical Findings

A. Symptoms and Signs

Uterine bleeding, beginning at 6–16 weeks, is observed in most instances. In some cases, the uterus is larger than would be expected in a normal pregnancy of the same duration. Excessive nausea and vomiting may occur. Bilaterally enlarged cystic ovaries are sometimes palpable. They are the result of ovarian hyperstimulation due to excess β -hCG.

Preeclampsia-eclampsia may develop during the second trimester of an untreated molar pregnancy, but this is unusual because most are diagnosed early.

Choriocarcinoma may be manifested by continued or recurrent uterine bleeding after evacuation of a mole or following delivery, abortion, or ectopic pregnancy. The presence of an ulcerative vaginal tumor, pelvic mass, or evidence of distant metastatic tumor may be the presenting observation.

B. Laboratory Findings

Hydatidiform moles are generally characterized by high serum β -hCG values, which can range from high normal to the millions. Levels are higher with complete moles than with partial moles. Serum β -hCG values, if extremely high, can assist in making the diagnosis, but they are more helpful in managing response to treatment. Hematocrit, creatinine, blood type, liver function tests, and thyroid function tests should also be measured. High β -hCG levels can cause the release of thyroid hormone, and rarely, symptoms of hyperthyroidism will be present. Patients with hyperthyroidism may require β -blocker therapy until the mole has been evacuated.

C. Imaging

Ultrasound has virtually replaced all other means of preoperative diagnosis of hydatidiform mole. Placental vesicles can be easily seen on transvaginal ultrasound. A preoperative chest film is indicated to rule out pulmonary metastases of the trophoblast.

► Treatment

A. Specific (Surgical) Measures

The uterus should be emptied as soon as the diagnosis of hydatidiform mole is established, preferably by suction curettage. Ovarian cysts should not be resected nor ovaries removed; spontaneous regression of theca lutein cysts will occur with elimination of the mole. The products of conception removed from the uterus should be sent to a pathologist for review. In patients who have completed their childbearing, hysterectomy is an acceptable alternative. Hysterectomy does not preclude the need for follow up of β -hCG levels.

B. Follow-Up Measures

Weekly quantitative β -hCG level measurements are initially required. Following successful surgical evacuation, moles show a progressive decline in β -hCG. After three negative weekly tests (< 5 mU/mL), the interval may be increased to every 3 months for an additional 6 months. The purpose of this follow up is to identify persistent metastatic and nonmetastatic disease, including choriocarcinoma, which is more likely to occur if the initial β -hCG is high and the uterus is large. If levels plateau or begin to rise, the patient should be evaluated by repeat laboratory tests, chest film, and dilatation and curettage (D&C) before the initiation of chemotherapy. Effective contraception (preferably birth control pills) should be prescribed to avoid the hazard and confusion of elevated β -hCG from a new pregnancy. The β -hCG levels should be negative for 6 months before pregnancy is attempted again. Because the risk of recurrence of a molar pregnancy is 1%, an ultrasound should be performed in the first trimester of the pregnancy following a mole to ensure that the pregnancy is normal. In addition, a β -hCG level should then be checked 6 weeks postpartum (after the subsequent normal pregnancy) to ensure there is no persistent trophoblastic tissue, and the placenta should be examined by a pathologist.

C. Antitumor Chemotherapy

If malignant tissue is discovered at surgery or during the follow-up examination, chemotherapy is indicated. For low-risk patients with a good prognosis, methotrexate is considered first-line therapy followed by actinomycin (see Table 39–11). The side effects—anorexia, nausea and vomiting, stomatitis, rash, diarrhea, and bone marrow suppression—usually are reversible in about 3 weeks and can be ameliorated by the administration of folinic acid (0.1 mg/kg) intramuscularly. Repeated courses of methotrexate 2 weeks apart generally are required to destroy the trophoblast and maintain a zero chorionic gonadotropin titer, as indicated by β -hCG determination. Patients with a poor prognosis should be referred to a cancer center, where multiple-agent chemotherapy probably will be given.

► Prognosis

Five-year survival after courses of chemotherapy, even when metastases have been demonstrated, can be expected in at least 85% of cases of choriocarcinoma.

► When to Refer

- Uterine size exceeds that anticipated for gestational age.
- Vaginal bleeding similar to menstruation.
- Pregnant patient with a history of a molar pregnancy.

► When to Admit

- Confirmed molar pregnancy by ultrasound and laboratory studies.
- Heavy vaginal bleeding in a pregnant patient under evaluation.

Lurain JR. Gestational trophoblastic disease I: epidemiology, pathology, clinical presentation and diagnosis of gestational trophoblastic disease, and management of hydatidiform mole. *Am J Obstet Gynecol.* 2010 Dec; 203(6):531–9. [PMID: 20728069]

Seckl MJ et al. Gestational trophoblastic disease. *Lancet.* 2010 Aug 28;376(9742):717–29. [PMID: 20673583]

OBSTETRIC COMPLICATIONS OF THE SECOND & THIRD TRIMESTERS

PREECLAMPSIA-ECLAMPSIA

ESSENTIALS OF DIAGNOSIS

Preeclampsia

- Blood pressure of ≥ 140 mm Hg systolic or ≥ 90 mm Hg diastolic after 20 weeks of gestation.
- Proteinuria of ≥ 0.3 g in 24 hours.

Severe Preeclampsia

- Blood pressure of ≥ 160 mm Hg systolic or ≥ 110 mm Hg diastolic.
- Proteinuria ≥ 5 g in 24 hours or 4+ on dipstick.
- Thrombocytopenia.
- Hemolysis, elevated liver enzymes, low platelets (HELLP).
- Pulmonary edema.
- Fetal growth restriction.

Eclampsia

- Seizures in a patient with evidence of preeclampsia.

► General Considerations

Preeclampsia is defined as the presence of newly elevated blood pressure and proteinuria during pregnancy. Eclampsia is diagnosed when seizures develop in a patient with evidence of preeclampsia. Historically, the presence of three elements was required for the diagnosis of preeclampsia: hypertension, proteinuria, and edema. Edema was difficult to objectively quantify and is no longer a required element.

Preeclampsia-eclampsia can occur any time after 20 weeks of gestation and up to 6 weeks postpartum. It is a disease unique to pregnancy, with the only cure being delivery of the fetus and placenta. Preeclampsia-eclampsia develops in approximately 7% of pregnant women in the United States. Primiparas are most frequently affected; however, the incidence of preeclampsia-eclampsia is increased with multiple gestation pregnancies, chronic hypertension, diabetes, kidney disease, collagen-vascular and autoimmune disorders, and gestational trophoblastic disease. Five percent of women with preeclampsia progress to eclampsia. Uncontrolled eclampsia is a significant cause of maternal death.

The cause of preeclampsia-eclampsia is not known, but it is likely a multifactorial, two-stage process. The first stage is thought to be a disturbance in placental implantation involving the spiral arteries very early in gestation. The abnormal placental perfusion that results leads to the formation of noxious free radicals. The second stage is characterized by excessive inflammation causing endothelial damage, vasospasm, and finally clinical signs and symptoms. An immunologic component to preeclampsia-eclampsia has been proposed, citing the increased incidence in primigravidas. This entire process is likely enhanced by environmental factors, genetic predisposition, and preexisting maternal disease.

► Clinical Findings

Clinically, the severity of preeclampsia-eclampsia can be measured with reference to the six major sites in which it exerts its effects: the central nervous system, the kidneys, the liver, the hematologic and vascular systems, and the fetal-placental unit. By evaluating each of these areas for the presence of mild to severe preeclampsia, the degree of involvement can be assessed, and an appropriate management plan can be formulated that balances the severity of disease and gestational age (Table 19–3).

A. Preeclampsia

1. Mild—Patients usually have few complaints, and the diastolic blood pressure is < 110 mm Hg. Edema may be present. The platelet count is over 100,000/mcL, antepartum fetal testing is reassuring, central nervous system irritability is minimal, epigastric pain is not present, and liver enzymes are not elevated.

2. Severe—Symptoms are more dramatic and persistent. Patients may complain of headache and vision changes. The blood pressure is often quite high, with readings at or above 160/110 mm Hg. Thrombocytopenia (platelet counts < 100,000/mcL) may be present and progress to disseminated intravascular coagulation. Severe epigastric pain may

Table 19–3. Indicators of mild versus severe preeclampsia-eclampsia.

Site	Indicator	Mild to Moderate	Severe
Central nervous system	Symptoms and signs	Hyperreflexia	Seizures Blurred vision Scotomas Headache Clonus Irritability
Kidney	Proteinuria Uric acid Urinary output	0.3-5 g/24 h > 4.5 mg/dL > 30 mL/h	> 5 g/24 h or catheterized urine with 4+ protein > 4.5 mg/dL < 30 mL/h
Liver	AST, ALT, LD	Normal	Elevated LFTs Epigastric pain Ruptured liver
Hematologic	Platelets Hemoglobin	> 100,000/mcL Normal range	< 100,000/mcL Elevated
Vascular	Blood pressure Retina	< 160/110 mm Hg Arteriolar spasm	> 160/110 mm Hg Retinal hemorrhages
Fetal-placental unit	Growth restriction Oligohydramnios Fetal distress	Absent Absent Absent	Present Present Present

ALT, alanine aminotransferase; AST, aspartate aminotransferase; LD, lactate dehydrogenase; LFTs, liver function tests.

be present from hepatic subcapsular hemorrhage with significant stretch or rupture of the liver capsule. HELLP syndrome (hemolysis, elevated liver enzymes, low platelets) is a form of severe preeclampsia.

B. Eclampsia

The occurrence of seizures defines eclampsia. It is a manifestation of severe central nervous system involvement. Other findings of preeclampsia are observed.

► Differential Diagnosis

Preeclampsia-eclampsia can mimic and be confused with many other diseases, including chronic hypertension, chronic kidney disease, primary seizure disorders, gallbladder and pancreatic disease, immune thrombocytopenia, thrombotic thrombocytopenic purpura, and hemolytic-uremic syndrome. It must always be considered a possibility in any pregnant woman beyond 20 weeks of gestation. It is particularly difficult to diagnose when a preexisting disease such as hypertension is present. Uric acid values can be quite helpful in such situations, since hyperuricemia is uncommon in pregnancy except with gout, kidney disease, or preeclampsia-eclampsia.

► Treatment

The use of diuretics, dietary restriction or enhancement, sodium restriction, aspirin, and vitamin-mineral supplements such as calcium or vitamin C and E have not been confirmed to be useful in clinical studies. The only cure is delivery of the fetus at a time as favorable as possible for its survival.

A. Preeclampsia

Early recognition is the key to treatment. This requires careful attention to the details of prenatal care—especially subtle changes in blood pressure and weight. The objectives are to prolong pregnancy if possible, to allow fetal lung maturity while preventing progression to severe disease and eclampsia. The critical factors are the gestational age of the fetus, fetal pulmonary maturity, and the severity of maternal disease. Preeclampsia-eclampsia at term is managed by delivery. Prior to term, severe preeclampsia-eclampsia requires delivery with very few exceptions. Epigastric pain, severe range blood pressures, thrombocytopenia, and visual disturbances are strong indications for delivery of the fetus. Severe disease by protein alone can be managed more conservatively.

For mild preeclampsia, bed rest is the cornerstone of therapy. This increases central blood flow to the kidneys, heart, brain, liver, and placenta and may stabilize or even improve the degree of preeclampsia-eclampsia for a period of time.

Bed rest may be attempted at home or in the hospital. Prior to making this decision, the clinician should evaluate the six sites of involvement listed in Table 19-3 and make an assessment about the severity of disease.

1. Home management—Home management with bed rest may be attempted for patients with mild preeclampsia and a stable home situation. This requires assistance at

home, rapid access to the hospital, a reliable patient, and the ability to obtain frequent blood pressure readings. A home health nurse can often provide frequent home visits and assessment.

2. Hospital care—Hospitalization is required for women with severe preeclampsia or those with unreliable home situations. Regular assessment of blood pressure, reflexes, urine protein, and fetal heart tones and activity are required. A complete blood count, platelet count, and electrolyte panel including liver enzymes should be checked regularly, with frequency dependent on severity. A 24-hour urine collection for creatinine clearance and total protein should be obtained on admission and repeated as indicated. Magnesium sulfate is not used until the diagnosis of severe preeclampsia is made and delivery planned (see Eclampsia, below).

Fetal evaluation should be obtained as part of the workup. If the patient is being admitted to the hospital, fetal testing should be performed on the same day to assess fetal wellbeing. This may be done by fetal heart rate testing with nonstress testing or by biophysical profile. A regular schedule of fetal surveillance must then be followed. Daily fetal kick counts can be recorded by the patient herself. Consideration can be given to amniocentesis to evaluate fetal lung maturity if hospitalization occurs at 30–37 weeks of gestation. If immaturity is suspected, corticosteroids (betamethasone 12 mg intramuscularly every 24 h for two doses, or dexamethasone 6 mg intramuscularly every 12 h for four doses) can be administered to the mother. Fetuses between 26 and 30 weeks of gestation can be presumed to be immature, and corticosteroids should be given.

The method of delivery is determined by the maternal and fetal status. A vaginal delivery is preferred because it has less blood loss than a cesarean section and requires less coagulation factors. Cesarean section is reserved for the usual fetal indications.

B. Eclampsia

1. Emergency care—If the patient is convulsing, she is turned on her side to prevent aspiration and to improve blood flow to the placenta. Fluid or food is aspirated from the glottis or trachea. The seizure may be stopped by giving an intravenous bolus of either magnesium sulfate, 4–6 g, or lorazepam, 2–4 mg over 4 minutes or until the seizure stops. Magnesium sulfate is the preferred agent, and alternatives should only be used if magnesium sulfate is unavailable. A continuous intravenous infusion of magnesium sulfate is then started at a rate of 2–3 g/h unless the patient is known to have significantly reduced kidney function. Magnesium blood levels are then checked every 4–6 hours and the infusion rate adjusted to maintain a therapeutic blood level (4–6 mEq/L). Urinary output is checked hourly and the patient assessed for signs of possible magnesium toxicity such as loss of deep tendon reflexes or decrease in respiratory rate and depth, which can be reversed with calcium gluconate, 1 g intravenously over 2 minutes.

2. General care—Magnesium sulfate should be given intravenously, 4- to 6-g load over 15–20 minutes followed by 2–3 g/h maintenance, for seizure prophylaxis in patients with severe preeclampsia. The occurrence of eclampsia

necessitates delivery once the patient is stabilized. It is important, however, that assessment of the status of the patient and fetus take place first. Continuous fetal monitoring must be performed and blood typed and cross-matched quickly. A urinary catheter is inserted to monitor urinary output, and blood is tested for complete blood count, platelets, liver enzymes, uric acid, creatinine, and electrolytes. If hypertension is present with systolic values of ≥ 160 mm Hg or diastolic values ≥ 110 mm Hg, antihypertensive medications should be administered to reduce the blood pressure to 140–150/90–100 mm Hg. Lower blood pressures than this may induce placental insufficiency through reduced perfusion. Hydralazine given in 5- to 10-mg increments intravenously every 20 minutes is frequently used to lower blood pressure. Labetalol, 10–20 mg intravenously, every 20 minutes as needed, can also be used.

3. Delivery—Delivery is mandated once eclampsia has occurred. Vaginal delivery is preferred. The rapidity with which delivery must be achieved depends on the fetal and maternal status following the seizure and the availability of laboratory data on the patient. Oxytocin, given intravenously and titrated to a dose that results in adequate contractions, may be used to induce or augment labor. Oxytocin should only be administered by a clinician specifically trained in its use. Regional analgesia or general anesthesia is acceptable. Cesarean section is used for the usual obstetric indications.

4. Postpartum—Magnesium sulfate infusion (2–3 g/h) should be continued until preeclampsia-eclampsia has begun to resolve postpartum (which may take 1–7 days), but in any case for at least 24 hours. The most reliable indicator of this resolution is the onset of diuresis with urinary output of over 100–200 mL/h. When this occurs, magnesium sulfate can be discontinued. Late-onset preeclampsia-eclampsia can occur during the postpartum period. It is usually manifested by either hypertension or seizures. Treatment is the same as prior to delivery—ie, with hydralazine and magnesium sulfate.

► When to Refer

- New onset of hypertension and proteinuria in a pregnant patient > 20 weeks' gestation.
- New onset of seizure activity in a pregnant patient.
- Symptoms of severe preeclampsia in a pregnant patient with elevated blood pressure above baseline.

► When to Admit

- Evidence of severe preeclampsia or eclampsia.
- Evaluation for preeclampsia when severe disease is suspected.
- Evaluation for preeclampsia in a patient with an unstable home environment.

Sibai BM. Hypertensive disorders of pregnancy: the United States perspective. *Curr Opin Obstet Gynecol*. 2008 Apr;20(2):102–6. [PMID: 18388806]

Steegers EA et al. Pre-eclampsia. *Lancet*. 2010 Aug 21;376(9741):631–44. [PMID: 20598363]

ACUTE FATTY LIVER OF PREGNANCY

Acute fatty liver of pregnancy is a disorder limited to the gravid state. It occurs in the third trimester of pregnancy and involves acute hepatic failure. With improved recognition and immediate delivery, the mortality rate is now 7–23%. The disorder is usually seen after the 35th week of gestation and is more common in primigravidas and those with twins. The incidence is about 1:14,000 deliveries.

The cause of acute fatty liver of pregnancy is just now being elucidated, and it likely is the result of poor placental mitochondrial function. Many cases may be due to a homozygous fetal deficiency of long-chain acyl coenzyme A dehydrogenase (LCHAD).

► Clinical Findings

Pathologic findings are unique to the disorder, with fatty engorgement of hepatocytes. Clinical onset is gradual, with flu-like symptoms that progress to the development of abdominal pain, jaundice, encephalopathy, disseminated intravascular coagulation, and death. On examination, the patient shows signs of hepatic failure.

Laboratory findings show marked elevation of alkaline phosphatase but only moderate elevations of alanine aminotransferase (ALT) and aspartate aminotransferase (AST). Prothrombin time and bilirubin are also elevated. The white blood cell count is elevated, and the platelet count is depressed. Hypoglycemia may be extreme.

► Differential Diagnosis

The differential diagnosis is that of fulminant hepatitis. However, liver aminotransferases for fulminant hepatitis are higher (> 1000 units/mL) than those for acute fatty liver of pregnancy (usually 500–1000 units/mL). It is also important to review the appropriate history and perform the appropriate tests for toxins that cause liver failure. Preeclampsia may involve the liver but typically does not cause jaundice. The elevations in liver function tests in patients with preeclampsia usually do not reach the levels seen in patients with acute fatty liver of pregnancy.

► Treatment

Diagnosis of acute fatty liver of pregnancy mandates immediate delivery. Supportive care during labor includes administration of glucose, platelets, and fresh frozen plasma as needed. Vaginal delivery is preferred. Resolution of encephalopathy occurs over days, and supportive care with a low-protein diet is needed.

► Prognosis

Recurrence rates for this liver disorder are unclear but probably increased in families with proven LCHAD deficiency. Most authorities advise against subsequent pregnancy, but there have been reported cases of successful outcomes in later pregnancies.

Pan C et al. Pregnancy-related liver diseases. *Clin Liver Dis*. 2011 Feb;15(1):199–208. [PMID: 21112001]

PRETERM LABOR



ESSENTIALS OF DIAGNOSIS

- ▶ Regular uterine contractions approximately 5 minutes apart.
- ▶ Cervical dilatation or effacement, or both.

▶ General Considerations

Preterm birth is defined as delivery prior to 37 weeks gestation, and spontaneous preterm labor with or without premature rupture of the fetal membranes is responsible for at least two-thirds or all preterm births. Prematurity is the largest single contributor to infant mortality. Recognized risk factors for spontaneous preterm labor include a past history of spontaneous preterm delivery, premature rupture of the membranes, multiple gestation, black race, intrauterine infections, müllerian anomalies (including those caused by exposure to DES), bacterial vaginosis, and certain socioeconomic conditions (such as limited access to prenatal care). It has also been consistently demonstrated that women with a shortened cervical length as measured by transvaginal ultrasound in the midtrimester are at increased risk for spontaneous preterm delivery. Strategies aimed at preventing preterm birth in high-risk women—principally those with a history of preterm birth or a shortened cervix (or both)—have focused on the administration of progesterone. Prospective randomized controlled trials have demonstrated reductions in rates of preterm birth in women with singleton pregnancies who received progesterone supplementation, although the optimal dose and route of administration (intramuscular injection versus vaginal suppository) is unclear. In twin pregnancies, however, progesterone administration has not been effective at prolonging pregnancy, suggesting that the mechanism for preterm birth may be different in multiple gestations. Although somewhat controversial, there is also evidence to suggest that women with shortened cervixes may benefit from placement of a cervical cerclage. The use of cervical cerclage in conjunction with progesterone supplementation has not been adequately studied.

▶ Clinical Findings

Cervical softening and remodeling likely precede symptoms of uterine contractions in preterm labor. Symptoms such as pelvic pressure, cramping, or vaginal discharge may be the first complaints in high-risk patients who later develop preterm labor. Because these complaints may be vague and irregular uterine contractions are common, distinguishing which patients merit further evaluation can be problematic. In some cases, this distinction can be facilitated by the use of fetal fibronectin measurement in cervicovaginal specimens. This test is most useful when it is negative (<50 ng/mL), since the negative predictive value for delivery within 7–14 days is 93–97%. A negative test, therefore, usually means the patient can be reassured and discharged home.

▶ Treatment

Patients must be educated to identify symptoms associated with preterm labor to avoid unnecessary delay in their evaluation. In high-risk patients who become symptomatic, limited activity and bed rest continues to be recommended despite limited evidence to support such recommendations.

Numerous pharmacologic agents (eg, tocolytics) have been given in an attempt to forestall preterm birth, although none are completely effective. **Magnesium sulfate** is commonly used, and there is evidence that it may also be protective against cerebral palsy. Magnesium sulfate is given intravenously as a 4- to 6-g bolus followed by a continuous infusion of 2–3 g/h. Magnesium levels should be determined every 4–6 hours to monitor for evidence of toxicity. Magnesium sulfate is entirely cleared by the kidney and must, therefore, be used with caution in women with any degree of kidney injury. After contractions have ceased for 12–24 hours, magnesium can be stopped and the situation reassessed.

β-Adrenergic drugs such as **terbutaline** have also been used. Terbutaline can be given as an intravenous infusion starting at 2.5 mcg/min or as a subcutaneous injection starting at 250 mcg given every 30 minutes. Oral terbutaline therapy following parenteral treatment is often elected and consists of giving 2.5–5 mg every 4–6 hours. With terbutaline, a dose-related elevation of heart rate of 20–40 beats/min may occur. If maternal tachycardia is significant (>120 beats/min) or it is accompanied by chest pain or palpitations, cessation of therapy should be considered. Pulmonary edema is also a well-documented serious side effect and occurs with increased frequency with concomitant administration of corticosteroids, large volume intravenous fluid infusion, maternal sepsis, or prolonged tocolysis. Unfortunately, these serious side effects are idiosyncratic and not dose-related. Certain metabolic derangements have also been associated with β-adrenergic drugs, most commonly hyperglycemia and hypokalemia.

Nifedipine, 20 mg orally every 6 hours, and **indomethacin**, 50 mg orally once then 25 mg orally every 6 hours up to 48 hours, have also been used with limited success. Nifedipine should not be given in conjunction with magnesium sulfate.

Before attempts are made to prevent preterm delivery with tocolytic agents, the patient should be assessed for conditions in which delivery would be indicated. Severe preeclampsia, lethal fetal anomalies, placental abruption, and intrauterine infection are all examples of indications for preterm delivery. In these cases, attempts to forestall delivery would be inappropriate.

In pregnancies between 24 and 34 weeks gestation where preterm birth is anticipated, betamethasone, 12 mg intramuscularly repeated once 24 hours later, or dexamethasone, 6 mg intramuscularly repeated every 12 hours for four doses, is administered to hasten fetal lung maturation. Repeat courses are not recommended. Women in preterm labor should also receive antimicrobial prophylaxis against group B streptococcus. Recommendations for group B streptococcus prophylaxis are discussed above.

► When to Refer

- Symptoms of increased pelvic pressure or cramping in high-risk patients.
- Regular uterine contractions.
- Rupture of membranes.
- Vaginal bleeding.

► When to Admit

- Cervical dilation of ≥ 2 cm prior to 34 weeks gestation.
- Contractions that cause cervical change.
- Rupture of membranes.

Berghella V et al. Effectiveness of cerclage according to severity of cervical length shortening: a meta-analysis. *Ultrasound Obstet Gynecol.* 2010 Apr;35(4):468–73. [PMID: 20052661]

Combs CA et al. 17-hydroxyprogesterone caproate for twin pregnancy: a double-blind, randomized clinical trial. *Am J Obstet Gynecol.* 2011 Mar;204(3):221.e1–8. [PMID: 21376161]

Hassan SS et al. Vaginal progesterone reduces the rate of preterm birth in women with a sonographic short cervix: a multicenter, randomized, double-blind, placebo-controlled trial. *Ultrasound Obstet Gynecol.* 2011 Jul;38(1):18–31. [PMID: 21472815]

Iams JD et al. Care for women with prior preterm birth. *Am J Obstet Gynecol.* 2010 Aug;203(2):89–100. [PMID: 20417491]

THIRD-TRIMESTER BLEEDING

Five to 10 percent of women have vaginal bleeding in late pregnancy. The clinician must distinguish between placental causes (placenta previa, placental abruption, vasa previa) and nonplacental causes (labor, infection, disorders of the lower genital tract, systemic disease). The approach to bleeding in late pregnancy generally should be conservative and expectant unless fetal distress or excessive maternal hemorrhage occurs.

► Treatment

A. General Measures

The patient should be hospitalized and placed on bed rest. Initially, continuous fetal monitoring is indicated to assess for fetal distress. A complete blood count (including platelets) should be obtained and repeated serially if the bleeding continues. If the hemorrhage is significant, the need for blood replacement should be anticipated and two to four units of red cells typed and cross-matched. Coagulation studies can be ordered as clinically indicated. Ultrasound examination should be performed to determine placental location. Digital pelvic examinations are done only after ultrasound examination has ruled out placenta previa.

B. Placenta Previa

Placenta previa occurs when the placenta implants over the internal cervical os. Risk factors for this condition include previous cesarean delivery, increasing maternal age, multiparity, and smoking. If the diagnosis is initially made in the first or second trimester, the ultrasound should be repeated

in the third trimester. Persistence of placenta previa at this point is an indication for cesarean as the route of delivery. Painless vaginal bleeding is the characteristic symptom in placenta previa and can range from light spotting to profuse hemorrhage. Hospitalization for extended evaluation is the appropriate initial management approach. For pregnancies that have reached 37 weeks gestation or beyond with continued bleeding, delivery is generally indicated. Pregnancies at 36 weeks or earlier are candidates for expectant management provided the bleeding is not prodigious, and a subset of these women can be discharged if the bleeding and contractions completely subside.

Women with a placenta previa who have one or more previous cesarean deliveries are at increased risk for placenta accreta. In this condition, the placental implantation is abnormally invaded into the endometrium (accreta), myometrium (increta), or beyond the uterine serosa (percreta). After delivery, the placenta does not separate normally, and hysterectomy is required to stop the postpartum hemorrhage, which can be massive. If this condition is suspected antenatally based on ultrasound findings and clinical risk assessment, delivery should be planned at an institution with appropriate personnel and facilities to manage complex surgical cases and severe postpartum hemorrhage.

C. Placental Abruption

Placental abruption is the premature separation of the placenta from its implantation site before delivery. Hypertension is a known risk factor for abruption, and the patient should be assessed for hypertension. Other risk factors include multiparity, cocaine use, smoking, previous abruption, and thrombophilias. Classic symptoms are vaginal bleeding, uterine tenderness and frequent contractions, but the clinical presentation is highly variable. Ultrasound may be helpful to exclude placenta previa, but failure to identify a retroplacental clot does not exclude abruption. In most cases, abruption is an indication for immediate delivery because of the high risk of fetal death.

Publications Committee, Society for Maternal Fetal Medicine, Belfort, MA. Placenta accreta. *Am J Obstet Gynecol.* 2010 Nov;203(5):430–9. [PMID: 21055510]

OBSTETRIC COMPLICATIONS OF THE PERIPARTUM PERIOD

PUERPERAL MASTITIS (See Also Chapter 17)

Postpartum mastitis occurs sporadically in nursing mothers, usually with symptom onset after discharge from the hospital, or it may occur in epidemic form in the hospital. *Staphylococcus aureus* is usually the causative agent. Inflammation is generally unilateral, and women nursing for the first time are more often affected. Rarely, inflammatory carcinoma of the breast can be mistaken for puerperal mastitis.

Mastitis frequently begins within 3 months after delivery and may start with an engorged breast and a sore or fissured nipple. Cellulitis is usually obvious in the affected area of breast with redness, tenderness, and local warmth. Fever and chills are common complaints as well. Treatment consists of antibiotics effective against penicillin-resistant staphylococci (dicloxacillin 500 mg orally every 6 hours or a cephalosporin for 10–14 days) and regular emptying of the breast by nursing or by using a mechanical suction device. Although nursing of the infected breast is safe for the infant, local inflammation of the nipple may complicate latching. Failure to respond to usual antibiotics within 3 days may represent an organizing abscess or infection with a resistant organism. When the causative organism is methicillin-resistant *S aureus* (MRSA), the risk for abscess formation is increased when compared with infection caused by nonresistant staphylococcal species. If an abscess is suspected, ultrasound of the breast can help confirm the diagnosis. In these cases, surgical evacuation is usually required.

Lee IW et al. Puerperal mastitis requiring hospitalization during a nine-year period. *Am J Obstet Gynecol.* 2010 Oct;203(4):332.e1–6. [PMID: 20599181]
 Stafford I et al. Community-acquired methicillin-resistant *Staphylococcus aureus* among patients with puerperal mastitis requiring hospitalization. *Obstet Gynecol.* 2008 Sep;112(3):533–7. [PMID: 18757649]

CHORIOAMNIONITIS & METRITIS

ESSENTIALS OF DIAGNOSIS

- ▶ Fever not attributable to another source.
- ▶ Uterine tenderness.
- ▶ Foul smelling vaginal discharge.
- ▶ Tachycardia in the mother, fetus, or both.

▶ General Considerations

Peripartum infection of the uterus is a common problem encountered during labor and the puerperium. Uterine infection in pregnancy is referred to as chorioamnionitis, since the infection involves the chorion. Uterine infection after delivery is often called endometritis or endomyometritis, but the term “metritis” is probably most accurate to emphasize that the infection extends throughout the uterine tissue. These infections are polymicrobial and are most commonly attributed to urogenital pathogens. Risk factors include cesarean delivery, prolonged labor, use of internal monitors, multiple pelvic examinations, prolonged rupture of membranes, and lower genital tract infections.

▶ Clinical Findings

Chorioamnionitis and metritis are diagnosed by the presence of fever ($\geq 38^\circ\text{C}$) in the absence of any other source and one or more of the following signs: maternal tachycardia,

fetal tachycardia, foul-smelling lochia, and uterine tenderness. Cultures of the cervix are not done because of the polymicrobial nature of the infection.

▶ Treatment

Treatment is with broad-spectrum antibiotics that will cover gram-positive organisms and gram-negative organisms if still pregnant and gram-negative organisms and anaerobes if postpartum. A common regimen for chorioamnionitis is ampicillin, 2 g intravenously every 6 hours, and gentamicin, 2 mg/kg intravenous load then 1.5 mg/kg intravenously every 8 hours. A common regimen for metritis is gentamicin, 2 mg/kg intravenous load then 1.5 mg/kg intravenously every 8 hours, and clindamycin, 900 mg intravenously every 8 hours. Antibiotics are stopped when the patient has been afebrile for 24 hours. No oral antibiotics are subsequently needed. Patients with metritis who do not respond in the first 24–48 hours may have enterococcus and require additional gram-positive coverage (such as ampicillin) to the regimen.

MEDICAL CONDITIONS COMPLICATING PREGNANCY

ANEMIA

Normal pregnancy is characterized by an increase in maternal plasma volume of about 50% and in increase in red cell volume of about 25%. Because of these changes, the mean hemoglobin and hematocrit values are lower than in the nonpregnant state. Anemia in pregnancy is often defined as a hemoglobin measurement below 11 g/dL or hematocrit below 33%. Symptoms such as fatigue and dyspnea that would otherwise suggest the presence of anemia in nonpregnant women are normal in pregnant women; therefore, periodic measurement of blood counts in pregnancy is essential so that anemia can be identified and treated.

A. Iron Deficiency Anemia

The increased requirement for iron over the course of pregnancy is appreciable in order to support fetal growth and expansion of maternal blood volume. Dietary intake of iron is generally insufficient to meet this demand, and it is recommended that all pregnant women receive about 30 mg of elemental iron per day in the second and third trimesters. If supplementation is inadequate, iron deficiency anemia develops. The usual findings of hypochromic and microcytic red cells may not initially be evident on the complete blood count, but iron studies can confirm the diagnosis if necessary. Abnormally low ferritin levels ($< 10\text{--}15$ mcg/L) have the highest sensitivity and specificity for diagnosing iron deficiency anemia. However, a serum iron level below 40 mcg/dL and transferrin saturation $< 10\%$ are also consistent with the diagnosis (see Chapter 13). Treatment consists of supplements with 60–100 mg of elemental iron and a diet containing iron-rich foods. Iron is best absorbed if taken with a dietary source of vitamin C (raw fruits or lightly cooked greens).

B. Folic Acid Deficiency Anemia

Megaloblastic anemia in pregnancy is almost always caused by folic acid deficiency, since vitamin B₁₂ deficiency is extremely uncommon in the childbearing years. The daily requirement of folic acid increases in pregnancy, and supplementation with 0.4 mg of folate is recommended. Importantly, this dose taken during the periconceptional period has also been shown to reduce the risk of neural tube defects in the offspring. Multiple gestation, infections, malabsorption, and use of anticonvulsant drugs such as phenytoin can precipitate folic acid deficiency, and additional folate supplementation should be considered in these settings. Lactating women continue to have increased demand for folate, and the diagnosis is sometimes made in the puerperium.

The diagnosis is made by finding macrocytic red cells and hypersegmented neutrophils in a blood smear (see Chapter 13). However, blood smears in pregnancy may be difficult to interpret, since they frequently show iron deficiency changes as well. With established folate deficiency, a supplemental dose of 1 mg/d and a diet with increased folic acid is generally sufficient to correct the anemia.

C. Sickle Cell Anemia

Women with sickle cell anemia are subject to serious complications in pregnancy. The anemia becomes more severe, and acute pain crises often occur more frequently. When compared with women who do not have hemoglobinopathies, women with hemoglobin SS are at increased risk for infections (especially pulmonary and urinary tract), thromboembolic events, pregnancy-related hypertension, transfusion, cesarean delivery, preterm birth, and fetal growth restriction. There also continues to be an increased rate of maternal mortality, despite an increased recognition of the high-risk nature of these pregnancies. Intensive medical treatment may improve the outcomes for both mother and fetus. Prophylactically transfusing packed red cells to lower the level of hemoglobin S and elevate the level of hemoglobin A is a controversial practice without clear benefit. Management decisions should be made in conjunction with a maternal fetal medicine specialist and a hematologist.

Genetic counseling should be offered to patients with sickle cell disease or sickle trait (hemoglobin AS). If the father is a carrier of the sickle cell gene (or his status is unknown), the parents may wish to undergo prenatal diagnosis to determine whether the fetus is affected.

Contraceptive counseling postpartum is important, although the safest and most effective method in women with sickle cell disease is unclear. Progestin-only compounds may be ideal because progesterone has long been recognized to help prevent pain crises in some women. Intrauterine devices carry a risk of infection and combination oral contraceptives are a concern because of the thrombogenic potential; these forms of contraception have not been adequately studied in these patients.

Women with hemoglobin SC disease are also at increased risk for complications, but the morbidity does not appear to be as great as in women with SS disease.

Women with either SC or SS disease are managed similarly. Women with sickle cell trait alone usually have an uncomplicated pregnancy course except for an increased risk of urinary tract infection.

American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 95: Anemia in pregnancy. *Obstet Gynecol.* 2008 Jul;112(1):201–7. [PMID: 18591330]
 Rogers DT et al. Sickle cell disease in pregnancy. *Obstet Gynecol Clin North Am.* 2010 Jun;37(2):223–37. [PMID: 20685550]
 Villers MS et al. Morbidity associated with sickle cell disease in pregnancy. *Am J Obstet Gynecol.* 2008 Aug;199(2):125:e1–5. [PMID: 18533123]

ANTIPHOSPHOLIPID SYNDROME

The antiphospholipid syndrome (APS) is characterized by the presence of specific autoantibodies in association with certain clinical conditions, most notably arterial and venous thrombosis and adverse pregnancy outcomes. Clinically, the diagnosis can be suspected after any of the following outcomes: an episode of thrombosis, three or more consecutive spontaneous abortions prior to 10 weeks gestation, one fetal loss after 10 weeks gestation, or a preterm delivery at less than 34 weeks due to preeclampsia. In addition to these clinical features, laboratory criteria include the identification of at least one of the following antiphospholipid antibodies: the lupus anticoagulant, anticardiolipin antibodies, or anti- β_2 -glycoprotein I antibodies. The lupus anticoagulant cannot be directly assayed, but it is tested for in several different phospholipid-dependent clotting tests and is interpreted as either present or absent. Anticardiolipin antibodies may be detected with enzyme-linked immunosorbent assay (ELISA) testing but should only be considered diagnostic when the IgG or IgM isotypes are present in medium to high titer (40 GPL or MPL, respectively). Likewise, anti- β_2 -glycoprotein I antibodies are detected with ELISA but should only be considered positive when they are present in a titer that is greater than 99th percentile for a normal population. The diagnosis of APS requires two positive antiphospholipid antibody test results at least 12 weeks apart since transient positive results can occur.

Treatment for APS in pregnancy generally involves administration of a heparin compound and low-dose aspirin (81 mg). In women with recurrent pregnancy loss and APS, it has been demonstrated that unfractionated heparin and low-dose aspirin can reduce the risk for spontaneous abortion. Outside of the first trimester, heparin is generally continued through pregnancy and the early postpartum period for thromboprophylaxis. LMWH is also commonly used for this indication; however, it is not clear that LMWH has the same effect on reducing the risk of recurrent abortion as unfractionated heparin. Either prophylactic or therapeutic dosing strategies may be appropriate depending on the patient's history and clinical risk factors. Infusions of intravenous immunoglobulin are of unclear benefit in these patients, and this treatment is not recommended.

ACOG Committee on Practice Bulletins-Obstetrics. ACOG Practice Bulletin No. 118: Antiphospholipid syndrome. *Obstet Gynecol.* 2011 Jan;117(1):192–9. [PMID: 21173671]

Bates SM et al; American College of Chest Physicians. Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). *Chest*. 2008 Jun;133(6 suppl):844S–86S. [PMID: 18574280]

Ziakas PD et al. Heparin treatment in antiphospholipid syndrome with recurrent pregnancy loss: a systematic review and meta-analysis. *Obstet Gynecol*. 2010 Jun;115(6):1256–62. [PMID: 20502298]

THYROID DISEASE

Thyroid disease is relatively common in pregnancy, and in their overt states, both hypothyroidism and hyperthyroidism have been consistently associated with adverse pregnancy outcomes. Fortunately, these risks are mitigated by adequate treatment of the thyroid condition. The impact of pregnancy on thyroid physiology is appreciable. It is essential to understand the gestational age-specific effects that pregnancy has on thyroid function tests, since these biochemical markers are required to make the diagnosis of thyroid dysfunction. Failure to recognize these alterations can result in misclassification or misdiagnosis.

Overt hypothyroidism is defined by an elevated serum thyrotropin level with a depressed thyroxine level. The condition in pregnancy has been associated with an increase in complications such as preterm birth, preeclampsia, placental abruption, and impaired neuropsychological development in the offspring. The most common etiology is Hashimoto (autoimmune) thyroiditis. Many of the symptoms of hypothyroidism mimic those of normal pregnancy, making its clinical identification difficult. Initial treatment is empiric with levothyroxine started at 75–100 mcg/d. Thyroid function tests can be repeated at 4–6 weeks and the dose adjusted as necessary with the goal of normalizing the TSH level. An increase in the dose of levothyroxine may be required in the second and third trimesters.

Subclinical hypothyroidism is defined as an increased TSH and a normal thyroxine level. There is insufficient data at this time to recommend screening for or treating subclinical hypothyroidism in pregnancy.

Overt hyperthyroidism, defined as excessive production of thyroxine with a depressed (usually undetectable) serum thyrotropin level, is also associated with increased risks in pregnancy. Spontaneous abortion, preterm birth, preeclampsia, and maternal heart failure occur with increased frequency with untreated thyrotoxicosis. Thyroid storm, although rare, can be a life-threatening complication. Medical treatment of thyrotoxicosis is usually accomplished with the antithyroid drugs propylthiouracil or methimazole. Although teratogenicity has not been clearly established, in utero exposure to methimazole has been associated with aplasia cutis and choanal and esophageal atresia in the offspring of pregnancies so treated. Propylthiouracil is not believed to be teratogenic, but it has been associated with the rare complications of hepatotoxicity and agranulocytosis. Recommendations by the American Thyroid Association are to treat with propylthiouracil in the first trimester and convert to methimazole for the remainder of the pregnancy. The therapeutic target for

the free T_4 level is the upper limit of the normal reference range. The TSH levels generally stay suppressed even with adequate treatment. A β -blocker can be used for such symptoms as palpitations or tremors. Fetal hypothyroidism or hyperthyroidism is uncommon but can occur with maternal Graves disease, which is the most common cause of hyperthyroidism in pregnancy. Radioiodine ablation is absolutely contraindicated in pregnancy because it may destroy the fetal thyroid as well.

Transient autoimmune thyroiditis can occur in the postpartum period and is evident within the first year after delivery. The first phase, occurring up to 4 months postpartum, is a hyperthyroid state. Over the next few months, there is a transition to a hypothyroid state, which may require treatment with levothyroxine. Spontaneous resolution to a euthyroid state is the rule in most cases.

Bahn RS et al. The role of propylthiouracil in the management of Graves' disease in adults: report of a meeting jointly sponsored by the American Thyroid Association and the Food and Drug Administration. *Thyroid*. 2009 Jul;19(7):673–4. [PMID: 19583480]

Fitzpatrick DL et al. Diagnosis and management of thyroid disease in pregnancy. *Obstet Gynecol Clin North Am*. 2010 Jun;37(2): 73–93. [PMID: 20685547]

Negro R et al. Thyroid disease in pregnancy. *Best Pract Res Clin Endocrinol Metab*. 2011 Dec;25(6):927–43. [PMID: 22115167]

DIABETES MELLITUS

Normal pregnancy can be characterized as a state of increased insulin resistance that helps ensure a steady stream of glucose delivery to the developing fetus. Thus, both mild fasting hypoglycemia and postprandial hyperglycemia are physiologic. These metabolic changes are felt to be hormonally mediated with likely contributions from human placental lactogen, estrogen, and progesterone.

A. Gestational Diabetes

Gestational diabetes is abnormal glucose tolerance in pregnancy and is generally believed to be an exaggeration of the pregnancy-induced physiologic changes in carbohydrate metabolism. Alternatively, pregnancy may unmask an underlying propensity for glucose intolerance, which will be evident in the nonpregnant state at some future time if not in the immediate postpartum period. Indeed, at least 50% of women with gestational diabetes are diagnosed with overt diabetes at some point in their lifetime. During the pregnancy, the principal concern in women identified to have gestational diabetes is excessive fetal growth, which can result in increased maternal and perinatal morbidity. Shoulder dystocia occurs more frequently in infants of diabetic mothers because of fetal overgrowth and increased fat deposition on the shoulders. Cesarean delivery and preeclampsia are also significantly increased in women with diabetes, both gestational and overt.

Although the diagnostic thresholds for glucose tolerance tests vary somewhat by region, most practitioners elect to offer testing to all pregnant women. A screening 50-g glucose load is administered at 24–28 weeks' gestation, and if this

Table 19-4. Screening and diagnostic criteria for gestational diabetes mellitus.**Screening for gestational diabetes mellitus**

1. 50-g oral glucose load, administered between the 24th and 28th weeks, without regard to time of day or time of last meal. Universal blood glucose screening is indicated for patients who are of Hispanic, African, Native American, South or East Asian, Pacific Island, or indigenous Australian ancestry. Screening may be omitted for women of a low-prevalence ethnic group who have no family history of diabetes, are under 25 years of age, have normal weight before pregnancy, and have no history of abnormal glucose metabolism or poor obstetric outcome.
2. Venous plasma glucose measure 1 hour later.
3. Value of 140 mg/dL (7.8 mmol/L) or above in venous plasma indicates the need for a full diagnostic glucose tolerance test.

Diagnosis of gestational diabetes mellitus

1. 100-g oral glucose load, administered in the morning after overnight fast lasting at least 8 hours but not more than 14 hours, and following at least 3 days of unrestricted diet (> 150 g carbohydrate) and physical activity.
2. Venous plasma glucose is measured fasting and at 1, 2, and 3 hours. Subject should remain seated and should not smoke throughout the test.
3. Two or more of the following venous plasma concentrations must be equal or exceeded for a diagnosis of gestational diabetes: fasting, 95 mg/dL (5.3 mmol/L); 1 hour, 180 mg/dL (10 mmol/L); 2 hours, 155 mg/dL (8.6 mmol/L); 3 hours, 140 mg/dL (7.8 mmol/L).

test is abnormal, the diagnostic test is a 100-g oral glucose tolerance test (Table 19-4). Women in whom gestational diabetes is diagnosed should undergo nutrition counseling, and insulin should be given to those with persistent fasting hyperglycemia. Insulin can be injected in a split dose mix of NPH and regular, administered twice daily. Insulin has long been regarded as the standard care for women who require medical management. Experience is increasing, however, with the use of oral hypoglycemic agents, such as glyburide and metformin. Randomized controlled trials comparing insulin to oral therapy have identified generally similar maternal and neonatal outcomes with either approach, although the long-term safety of oral agents has not been adequately studied in the women so treated or in their infants. Capillary blood glucose monitoring is checked four times per day, once fasting and three times after meals. Euglycemia is considered to be 60–90 mg/dL while fasting and < 120 mg/dL 2 hours postprandially. Intensive therapy with dietary modifications or insulin therapy, or both, has been demonstrated to decrease rates of macrosomia, shoulder dystocia, and preeclampsia. Because of the increased prevalence of overt diabetes in these women, they should be evaluated 6–12 weeks postpartum by a 2-hour oral glucose tolerance test (75-g glucose load).

B. Overt Diabetes

Overt diabetes is diabetes mellitus that antedates the pregnancy. As in gestational diabetes, fetal overgrowth from inadequately controlled hyperglycemia remains a significant concern because of the increased maternal and

perinatal morbidity that accompany macrosomia. Women with overt diabetes are subject to a number of other complications as well. Spontaneous abortions and third trimester stillbirths occur with increased frequency in these women. There is also a twofold to threefold increased risk for fetal malformations, as hyperglycemia during organogenesis is teratogenic. The most common malformations in offspring of diabetic women are cardiac, skeletal, and neural tube defects. For the mother, the likelihood of infections and pregnancy-related hypertension is increased.

Preconception counseling and evaluation in a diabetic woman is ideal to maximize the pregnancy outcomes. This provides an opportunity to optimize glycemic control and evaluate for evidence of end-organ damage. The initial evaluation of diabetic women should include a complete chemistry panel, HbA_{1c} determination, 24-hour urine collection for total protein and creatinine clearance, fundoscopic examination, and an ECG. Hypertension is common and should be addressed. Euglycemia should be established before conception and maintained during pregnancy with daily home glucose monitoring by the patient. There is an inverse relationship between glycemic control and the occurrence of fetal malformations, and women whose periconceptional glycosylated hemoglobin levels are at or near normal levels have rates of malformations that approach baseline. A well-planned dietary program is a key component, with an intake of 1800–2200 kcal/d divided into three meals and three snacks. Insulin is given subcutaneously in a split-dose regimen as described above for women with gestational diabetes. The use of continuous insulin pump therapy has been found to be very useful during pregnancy in women with type 1 diabetes mellitus.

Throughout the pregnancy, diabetic women should be seen every 2–3 weeks and more frequently depending on the clinical condition. Adjustments in the insulin regimen may be necessary as the pregnancy progresses. A specialized ultrasound is often performed around 20 weeks to detect fetal malformations. Signs and symptoms of infections should be evaluated and promptly treated. In the third trimester, fetal surveillance is indicated, and women with diabetes should receive serial antenatal testing (usually in the form of a nonstress test or biophysical profile). The timing of delivery is dictated by the quality of diabetic control, the presence or absence of medical complications, and fetal status. The goal is to reach 39 weeks (38 completed weeks) and then proceed with delivery. Confirmation of lung maturity may be appropriate if preterm delivery is contemplated.

Ali S et al. Diabetes in pregnancy: health risks and management. *Postgrad Med J.* 2011 Jun;87(1028):417–27. [PMID: 21368321]

Landon MB et al. Gestational diabetes mellitus. *Obstet Gynecol.* 2011 Dec;118(6):1379–93. [PMID: 22105269]

Mathiesen ER et al. Insulin treatment in diabetic pregnancy. *Diabetes Metab Res Rev.* 2008 May–Jun;24(Suppl 2):S3–20. [PMID: 18429332]

Nicholson W et al. Benefits and risks of oral diabetes agents compared with insulin in women with gestational diabetes: a systematic review. *Obstet Gynecol.* 2009 Jan;113(1):193–205. [PMID: 19104375]

CHRONIC HYPERTENSIVE DISEASE

Chronic hypertension is estimated to complicate approximately 3% of pregnancies. To establish this diagnosis, hypertension should antedate the pregnancy or be evident before 20 weeks' gestation to differentiate it from pregnancy-related hypertension. This distinction can be problematic when the initial presentation is after 20 weeks, but chronic hypertension is confirmed if the blood pressure remains elevated beyond 12 weeks postpartum. Risk factors for chronic hypertension include older maternal age, African American race, and obesity. While essential hypertension is by far the most common etiology, secondary causes should be sought when clinically indicated.

Women with chronic hypertension are at increased risk for adverse maternal and perinatal outcomes. Superimposed preeclampsia develops in up to 25% of women with chronic hypertension, and the risk appears to increase with greater degrees of baseline hypertension. In these situations, there is a tendency for preeclampsia to occur at an earlier gestational age, be more severe, and be associated with fetal growth restriction. Women with chronic hypertension are also at increased risk for placental abruption and preterm birth.

Pregnant women with chronic hypertension require medication only if the blood pressure is sustained at or above 150/100 mm Hg. Treatment of hypertension has not been demonstrated to improve pregnancy outcomes, but it is indicated in women with significant hypertension for long-term maternal cardiovascular health. For initiation of treatment, methyldopa has the longest record of safety at a starting dosage of 250 mg orally two to three times daily. Therapy with β -blockers or calcium channel blockers is also acceptable (see Tables 11–7, 11–9). Care must be taken not to excessively reduce the blood pressure, as this may decrease uteroplacental perfusion. The goal is a modest reduction in blood pressure and avoidance of severe hypertension ($\geq 160/110$ mm Hg).

If a woman with chronic hypertension is stable on a medical regimen when she becomes pregnant, it is usually appropriate to continue this therapy. Angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers, however, are contraindicated in all trimesters of pregnancy. In addition to causing fetal hypocalcemia and renal failure with exposure in the second and third trimesters, it is now recognized that these medications are teratogenic in the first trimester. Diuretics, although not typically initiated in pregnancy, may be continued in patients who are taking them when they become pregnant.

When there is sustained severe hypertension despite multiple medications or significant end-organ damage from hypertensive disease, pregnancy is not likely to be tolerated well. In these situations, therapeutic abortion may be appropriate. If the pregnancy is continued, the woman must be counseled that the maternal and perinatal risks are appreciable, and complications such as superimposed preeclampsia and fetal growth restriction should be anticipated.

Jim B et al. Hypertension in pregnancy: a comprehensive update. *Cardiol Rev.* 2010 Jul–Aug;18(4):178–89. [PMID: 20539101]
Seely EW et al. Chronic hypertension in pregnancy. *N Engl J Med.* 2011 Aug 4;365(5):439–46. [PMID: 21812673]

HEART DISEASE

Normal pregnancy physiology is characterized by cardiovascular adaptations in the mother. Cardiac output increases markedly as a result of both augmented stroke volume and an increase in the resting heart rate, and the maternal blood volume expands by up to 50%. These changes may not be tolerated well in women with functional or structural abnormalities of the heart. Thus, although only a small number of pregnancies are complicated by cardiac disease, these contribute disproportionately to overall rates of maternal morbidity and mortality. Most heart disease seen in women of childbearing age in the United States is caused by congenital heart disease.

For practical purposes, the functional capacity of the heart is the best single measurement of cardiopulmonary status (see box, Functional Cardiac Assessment). Most pregnant women with cardiac disease have class I or II functional disability, and although good outcomes are generally anticipated in this group, complications such as preeclampsia, preterm birth, and low birth weight appear to occur with increased frequency. Women with more severe disability (class III or IV) are rare in contemporary obstetrics; however, the maternal mortality is markedly increased in this setting and is usually the result of congestive heart failure. Because of these risks, therapeutic abortion for maternal health should be considered in women who are severely disabled from cardiac disease. Specific conditions that have been associated with a particularly high risk for maternal death include Eisenmenger syndrome, primary pulmonary hypertension, Marfan syndrome with aortic root dilatation, and severe aortic or mitral stenosis. In general, these conditions should be considered contraindications to pregnancy.

Pregnant women with cardiac disease are best treated by a team of practitioners with experience in caring for such patients. Symptoms of volume overload should be evaluated and treated promptly. Labor management may

FUNCTIONAL CARDIAC ASSESSMENT

Class I	Uncompromised: No limitation on physical activity.
Class II	Slightly limited: Symptoms present with ordinary physical activity but asymptomatic at rest.
Class III	Markedly limited: Symptoms present with less than ordinary activity but asymptomatic at rest.
Class IV	Severely compromised: Inability to perform any activity without developing symptoms, which may also develop at rest.

differ slightly depending on the specific cardiac lesion, but cesarean section is generally reserved for obstetric indications. The early postpartum period is a critical time for fluid management. Patients who are predisposed to heart failure should be monitored closely during the puerperium.

Infective endocarditis prophylaxis is not recommended for a vaginal or cesarean delivery in the absence of infection, except in the very small subset of patients at highest risk for adverse outcomes from endocarditis. The women at highest risk include those with cyanotic heart disease, prosthetic valves, or both. If infection is present, such as chorioamnionitis, the underlying infection should be treated with the usual regimen and additional agents are not needed specifically for endocarditis prophylaxis. Prophylaxis, if required, should be given intravenously (see Table 33–6).

American College of Obstetricians and Gynecologists ACOG Practice Bulletin No. 120: Use of prophylactic antibiotics in labor and delivery. *Obstet Gynecol.* 2011 Jun;117(6):1472–83. [PMID: 21606770]

Drenthen W et al; ZAHARA Investigators. Predictors of pregnancy complications in women with congenital heart disease. *Eur Heart J.* 2010 Sep;31(17):2124–32. [PMID: 20584777]

Ford AA et al. Maternal congenital cardiac disease: outcomes of pregnancy in a single tertiary care center. *Obstet Gynecol.* 2008 Oct;112(4):828–33. [PMID: 18827125]

ASTHMA

Asthma is one of the most common medical conditions encountered in pregnancy. Women with mild to moderate asthma can generally expect excellent pregnancy outcomes, but severe or poorly controlled asthma has been associated with adverse maternal and perinatal outcomes. The effects of pregnancy on asthma are likely minimal as asthma severity in the pregnancy has been reported to be similar to its severity during the year preceding the pregnancy. Strategies for treatment are similar to that in nonpregnant women. Patients should be educated about symptom management and avoidance of asthma triggers. Baseline pulmonary function tests can provide an objective assessment of lung function and may help the patient with self-monitoring of her asthma severity using a peak flow meter. Medications used commonly in the nonpregnant population are acceptable in pregnancy, and none are absolutely contraindicated. Inhaled β_2 -agonists are indicated for all asthma patients, and inhaled corticosteroids are added for persistent symptoms when a rescue inhaler alone is inadequate. Budesonide is the preferred inhaled corticosteroid based on its documented safety in pregnancy. The primary goals of management in pregnancy include minimizing symptoms and avoiding hypoxic episodes to the fetus.

Belanger K et al. Effect of pregnancy on maternal asthma symptoms and medication use. *Obstet Gynecol.* 2010 Mar;115(3):559–67. [PMID: 20177287]

Dombrowski MP et al; ACOG Committee on Practice Bulletins—Obstetrics. ACOG practice bulletin: Clinical management guidelines for obstetrician-gynecologists number 90, February 2008: asthma in pregnancy. *Obstet Gynecol.* 2008 Feb;111(2 Pt 1):457–64. [PMID: 18238988]

SEIZURE DISORDERS

Epilepsy is one of the most common serious neurologic disorders in pregnant women. Many of the commonly used antiepileptic drugs are known human teratogens. Therefore, the principal objectives in managing pregnancy in epileptic women are achieving adequate control of seizures while minimizing exposure to medications that can cause congenital malformations. Women contemplating pregnancy who have not had a seizure for 5 years should consider a prepregnancy trial of withdrawal from antiepileptic therapy. For those who continue to require treatment, therapy with one medication is preferred. Selecting a regimen should be based on the type of seizure disorder and the risks associated with each medication. Valproic acid should not be considered first-line therapy because it has consistently been associated with higher rates of malformations than most other commonly used antiepileptic drugs, and there are data to suggest that it is also associated with impairments of cognitive development in the offspring. Phenytoin and carbamazepine are also older medications that are still used, and both have established patterns of associated fetal malformations. Concerns about teratogenicity have prompted increasing use of the newer antiepileptic drugs such as lamotrigine, topiramate, oxcarbazepine, and levetiracetam. Although the safety of these medications in pregnancy continues to be evaluated, experiences from large, population-based studies suggest that in utero exposure to the newer antiepileptic drugs in the first trimester of pregnancy does not appear to increase the risk for major birth defects. Supplemental folate may decrease the risk of congenital malformations, and it is recommended that pregnant women with epilepsy be given at least 0.4 mg/d of folic acid. It is unclear if higher doses of folate offer greater protective benefit.

Buhimschi CS et al. Medication in pregnancy and lactation: Part 1. Teratology. *Obstet Gynecol.* 2009 Jan;113(1):166–88. [PMID: 19104374]

Harden CL et al. Practice parameter update: management issues for women with epilepsy—focus on pregnancy (an evidence-based review): vitamin K, folic acid, blood levels, and breastfeeding: report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and American Epilepsy Society. *Neurology.* 2009 Jul 14;73(2):142–9. [PMID: 19398680]

Jentink J et al. Valproic acid monotherapy in pregnancy and major congenital malformations. *N Engl J Med.* 2010 Jun 10;362(23):2185–93. [PMID: 20558369]

Molgaard-Nielsen D et al. Newer-generation antiepileptic drugs and the risk of major birth defects. *JAMA.* 2011 May 18;305(19):1996–2002. [PMID: 21586715]

Vajda FJ et al. Teratogenicity of the newer antiepileptic drugs—the Australian experience. *J Clin Neurosci.* 2012 Jan;19(1):57–9. [PMID: 22104350]

INFECTIOUS CONDITIONS COMPLICATING PREGNANCY

URINARY TRACT INFECTION

The urinary tract is especially vulnerable to infections during pregnancy because the altered secretions of steroid sex

hormones and the pressure exerted by the gravid uterus on the ureters and bladder cause hypotonia and congestion and predispose to urinary stasis. Labor and delivery and urinary retention postpartum also may initiate or aggravate infection. *Escherichia coli* is the offending organism in over two-thirds of cases.

From 2% to 8% of pregnant women have asymptomatic bacteriuria, which some believe to be associated with an increased risk of preterm birth. It is estimated that pyelonephritis will develop in 20–40% of these women if untreated.

An evaluation for asymptomatic bacteriuria at the first prenatal visit is recommended for all pregnant women. If a urine culture is positive, treatment should be initiated. Nitrofurantoin (100 mg orally twice daily), ampicillin (250 mg orally four times daily), and cephalexin (250 mg orally four times daily) are acceptable medications for 3–7 days. Sulfonamides should be avoided in the third trimester because they may interfere with bilirubin binding and thus impose a risk of neonatal hyperbilirubinemia and kernicterus. Fluoroquinolones are also contraindicated because of their potential teratogenic effects on fetal cartilage and bone. Patients with recurrent bacteriuria should receive suppressive medication (once daily dosing of an appropriate antibiotic) for the remainder of the pregnancy. Acute pyelonephritis requires hospitalization for intravenous administration of antibiotics and crystalloids until the patient is afebrile; this is followed by a full course of oral antibiotics.

Schnarr J et al. Asymptomatic bacteriuria and symptomatic urinary tract infections in pregnancy. *Eur J Clin Invest*. 2008 Oct;38(Suppl 2):50–7. [PMID: 18826482]

GROUP B STREPTOCOCCAL INFECTION

Group B streptococci frequently colonize the lower female genital tract, with an asymptomatic carriage rate in pregnancy of 10–30%. This rate depends on maternal age, gravidity, and geographic variation. Vaginal carriage is asymptomatic and intermittent, with spontaneous clearing in approximately 30% and recolonization in about 10% of women. Adverse perinatal outcomes associated with group B streptococcal colonization include urinary tract infection, intrauterine infection, premature rupture of membranes, preterm delivery, and postpartum metritis.

Women with postpartum metritis due to infection with group B streptococci, especially after cesarean section, develop fever, tachycardia, and abdominal pain, usually within 24 hours after delivery. Approximately 35% of these women are bacteremic.

Group B streptococcal infection is a common cause of neonatal sepsis. Transmission rates are high, yet the rate of neonatal sepsis is surprisingly low at < 1:1000 live births. Unfortunately, the mortality rate associated with early-onset disease can be as high as 20–30% in premature infants. In contrast, it is approximately 2–3% in those at term. Moreover, these infections can contribute markedly to chronic morbidity, including mental retardation and neurologic disabilities. Late-onset disease develops through contact with hospital nursery personnel. Up to 45% of

these health care workers can carry the bacteria on their skin and transmit the infection to newborns.

CDC recommendations for screening and prophylaxis for group B streptococcal colonization are set forth in this chapter in the section on Essentials of Prenatal Care: Tests and Procedures.

Verani JR et al; Division of Bacterial Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention (CDC). Prevention of perinatal group B streptococcal disease—revised guidelines from CDC, 2010. *MMWR Recomm Rep*. 2010 Nov 19;59(RR-10):1–36. [PMID: 21088663]

VARICELLA

Commonly known as chickenpox, varicella-zoster virus (VZV) infection has a fairly benign course when incurred during childhood but may result in serious illness in adults, particularly during pregnancy. Infection results in lifelong immunity. Approximately 95% of women born in the United States have VZV antibodies by the time they reach reproductive age. The incidence of VZV infection during pregnancy has been reported as up to 7:10,000.

► Clinical Findings

A. Symptoms and Signs

The incubation period for this infection is 10–20 days. A primary infection follows and is characterized by a flu-like syndrome with malaise, fever, and development of a pruritic maculopapular rash on the trunk which becomes vesicular and then crusts. Pregnant women are prone to the development of VZV pneumonia, often a fulminant infection sometimes requiring respiratory support. After primary infection, the virus becomes latent, ascending to dorsal root ganglia. Subsequent reactivation can occur as zoster, often under circumstances of immunocompromise, although this is rare during pregnancy.

Two types of fetal infection have been documented. The first is congenital VZV syndrome, which typically occurs in 0.4–2% of fetuses exposed to primary VZV infection during the first trimester. Anomalies include limb and digit abnormalities, microphthalmos, and microcephaly.

Infection during the second and third trimesters is less threatening. Maternal IgG crosses the placenta, protecting the fetus. The only infants at risk for severe infection are those born after maternal viremia but before development of maternal protective antibody. Maternal infection manifesting 5 days before or up to 2 days after delivery is the time period believed to be most hazardous for transmission to the fetus.

B. Laboratory Findings

Diagnosis is commonly made on clinical grounds. Laboratory verification of recent infection is made most often by antibody detection techniques, including ELISA, fluorescent antibody, and hemagglutination inhibition. Serum obtained by cordocentesis may be tested for VZV IgM to document fetal infection.

► Treatment

Varicella-zoster immune globulin (VZIG) has been shown to prevent or modify the symptoms of infection in some women but is no longer readily available. Treatment success depends on identification of susceptible women at or just following exposure. Women with a questionable or negative history of chickenpox should be checked for antibody, since the overwhelming majority will have been previously exposed. If the antibody is negative, VZIG (625 units intramuscularly) should be given within 96 hours after exposure. There are no known adverse effects of VZIG administration during pregnancy, although the incubation period for disease can be lengthened. Infants born within 5 days after onset of maternal infection should also receive VZIG (125 units).

Infected pregnant women should be closely observed and hospitalized at the earliest signs of pulmonary involvement. Intravenous acyclovir (10 mg/kg intravenously every 8 hours) is recommended in the treatment of VZV pneumonia.

Lamont RF et al. Varicella-zoster virus (chickenpox) infection in pregnancy. *BJOG*. 2011 Sep;118(10):1155–62. [PMID: 21585641]

TUBERCULOSIS

The diagnosis of tuberculosis in pregnancy is made by history taking, physical examination, and skin testing, with special attention to women in high-risk groups. Women at high risk include those who are from endemic areas, those infected with HIV, drug users, health care workers, and close contacts of people with tuberculosis. Chest radiographs should not be obtained as a routine screening measure in pregnancy but should be used only in patients with a skin test conversion or with suggestive findings in the history and physical examination. Abdominal shielding must be used if a chest radiograph is obtained.

Decisions on treatment depend on whether the patient has active disease or is at high risk for progression to active disease. Women who are purified protein derivative (PPD)–positive but not at high risk for disease progression can receive treatment postpartum, which does not preclude breastfeeding. The concentration of medication in breast milk is neither toxic nor adequate for treatment of the newborn. Treatment is with isoniazid and ethambutol or isoniazid and rifampin (see Chapters 9 and 33). Because isoniazid therapy may result in vitamin B₆ deficiency, a supplement of 50 mg/d of vitamin B₆ should be given simultaneously. Isoniazid, particularly in pregnant women, can cause hepatitis. Liver function tests should be performed regularly in pregnant women who receive treatment. Streptomycin, ethionamide, and most other antituberculous drugs should be avoided in pregnancy. If adequately treated, tuberculosis in pregnancy has an excellent prognosis.

Nhan-Chang CL et al. Tuberculosis in pregnancy. *Clin Obstet Gynecol*. 2010 Jun;53(2):311–21. [PMID: 20436306]

HIV/AIDS DURING PREGNANCY

Heterosexual acquisition and injection drug use are the principal identified modes of HIV infection in women. Asymptomatic infection is associated with a normal pregnancy rate and no increased risk of adverse pregnancy outcomes. There is no evidence that pregnancy causes AIDS progression.

Previously, two-thirds of HIV-positive neonates acquired their infection close to, or during, the time of delivery. Routine HIV screening in pregnancy, including the use of rapid HIV tests in Labor and Delivery units, and the use of highly active antiretroviral therapy (HAART) therapy has markedly reduced this transmission risk. Zidovudine alone (500 mg/d orally) given to the mother antenatally starting at 14 weeks of gestation and during labor (1 mg/kg/h intravenously) and then to the infant (4 mg/kg orally two times daily) for the first 6 weeks of life reduces the transmission rate from 25% to 8%. HAART reduced the risk even further, to approximately 2%, and is the standard of care. In an HIV-positive pregnant woman, a CD4 count, plasma RNA level, and resistance testing (if virus is detectable) should be obtained at the first prenatal visit. Prior or current antiretroviral use should be reviewed. A woman already taking and tolerating an acceptable HAART regimen does not have to discontinue it in the first trimester. Patients should also be tested for hepatitis C, toxoplasmosis, and cytomegalovirus.

Women not receiving therapy should be offered HAART with three drugs (commonly two nucleoside analogues and one protease inhibitor, including zidovudine whenever possible) after counseling regarding the potential impact of therapy on both mother and fetus. HAART should be offered regardless of viral load and CD4 count, and it should be started in the second trimester unless there is a maternal indication to start earlier. The majority of drugs used to treat HIV/AIDS have thus far proven to be safe in pregnancy with an acceptable risk/benefit ratio. Efavirenz has been clearly linked with anomalies (myelomeningocele) and should not be used in pregnancy, specifically the first trimester.

The use of prophylactic elective cesarean section before the onset of labor or rupture of the membranes to prevent vertical transmission of HIV infection from mother to fetus has been shown to further reduce the transmission rate. There is limited information on the impact of elective cesarean section on transmission rates in infants of mothers on HAART or with viral loads <1000 copies/mL. However, with HAART therapy and undetectable viral loads (< 50 copies/mL), the transmission risk has been estimated to be 1% or less, and there may be no additional benefit of cesarean delivery. Women with viral loads < 1000 copies/mL on HAART can be offered a vaginal delivery. Amniotomy should not be performed, and internal monitors, particularly the fetal scalp electrode, should be avoided. HIV-infected women should be advised not to breastfeed their infants.

The Public Health Task Force provides guidelines for the management of HIV/AIDS in pregnancy that are regularly updated and available at <http://www.aidsinfo.nih.gov/>. In addition, there is the National Perinatal HIV

Hotline, which provides free consultation regarding perinatal HIV care (1-888-448-8765).

Anderson BL et al. Pregnancy and optimal care of HIV-infected patients. *Clin Infect Dis*. 2009 Feb 15;48(4):449–55. [PMID: 19133799]

Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission. Recommendations for use of antiretroviral drugs in pregnant HIV-1 infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States. 2011 Sep 14:1–207. <http://aidsinfo.nih.gov/ContentFiles/PerinatalGL.pdf>

MATERNAL HEPATITIS B & C CARRIER STATE

There are an estimated 350 million chronic carriers of **hepatitis B virus** worldwide. Among these people, there is an increased incidence of chronic active hepatitis, cirrhosis, and hepatocellular carcinoma. In the United States, 1.4 million people are infected, with the highest rate among Asian Americans. All pregnant women should be screened for HBsAg. Transmission of the virus to the baby after delivery is likely if both surface antigen and e antigen are positive. Vertical transmission can be blocked by the immediate postdelivery administration to the newborn of hepatitis B immunoglobulin and hepatitis B vaccine intramuscularly. The vaccine dose is repeated at 1 and 6 months of age. Successful, but limited, experience has also been reported with lamivudine during the third trimester to prevent vertical transmission of hepatitis B in mothers with high HBV viral loads. Pregnant women with chronic hepatitis B should have liver function tests during the pregnancy. Hepatitis B infection is not a contraindication to breastfeeding.

Hepatitis C virus infection is the most common chronic blood-borne infection in the United States. Risk factors for transmission include blood transfusion, injection drug use, employment in patient care or clinical laboratory work, exposure to a sex partner or household member who has had a history of hepatitis, exposure to multiple sex partners, and low socioeconomic level. The average rate of hepatitis C virus (HCV) infection among infants born to HCV-positive, HIV-negative women is 5–6%. However, the average infection rate increases to 14% when mothers are coinfecting with HCV and HIV. The principal factor associated with transmission is the presence of HCV RNA in the mother at the time of birth.

Esposti SD et al. Hepatitis B in pregnancy: challenges and treatment. *Gastroenterol Clin North Am*. 2011 Jun;40(2):355–72. [PMID: 21601784]

HERPES GENITALIS

Infection of the lower genital tract by herpes simplex virus type 2 (HSV-2) (see also Chapter 6) is a common STD with potentially serious consequences to pregnant women and their newborn infants. Although up to 20% of women in an obstetric practice may have antibodies to

HSV-2, a history of the infection is unreliable and the incidence of neonatal infection is low (8–60/100,000 live births). Most infected neonates are born to women with no symptoms, signs, or history of infection.

Women who have had *primary* herpes infection late in pregnancy are at high risk for shedding virus at delivery. Some authors suggest use of prophylactic acyclovir, 400 mg orally two to three times daily, to decrease the likelihood of active lesions at the time of labor and delivery.

Women with a history of *recurrent* genital herpes have a lower neonatal attack rate than women infected during the pregnancy, but they should still be monitored with clinical observation and culture of any suspicious lesions. Since asymptomatic viral shedding is not predictable by antepartum cultures, current recommendations do not include routine cultures in individuals with a history of herpes without active disease. However, when labor begins, vulvar and cervical inspection should be performed. Cesarean section is indicated at the time of labor if there are prodromal symptoms, active genital lesions, or a positive cervical culture obtained within the preceding week.

For treatment, see Chapter 32. The use of acyclovir in pregnancy is acceptable, and prophylaxis starting at 36 weeks gestation has been shown to decrease the number of cesarean sections performed for active disease.

Anzivino E et al. Herpes simplex virus infection in pregnancy and in neonate: status of art of epidemiology, diagnosis, therapy, and prevention. *Virology*. 2009 April 6;6:40. [PMID: 19348670]

Corey L et al. Maternal and neonatal herpes simplex virus infections. *N Engl J Med*. 2009 Oct 1;361(14):1376–85. [PMID: 19797284]

SYPHILIS, GONORRHEA, & CHLAMYDIA TRACHOMATIS INFECTION (See also Chapters 33 and 34)

These STDs have significant consequences for mother and child. Untreated syphilis in pregnancy can cause late abortion, stillbirth, transplacental infection, and congenital syphilis. Gonorrhea can produce large-joint arthritis by hematogenous spread as well as ophthalmia neonatorum. Maternal chlamydial infections are largely asymptomatic but are manifested in the newborn by inclusion conjunctivitis and, at age 2–4 months, by pneumonia. The diagnosis of each can be reliably made by appropriate laboratory tests. All women should be tested for syphilis and *Chlamydia* as part of their routine prenatal care. Repeat testing is dependent on risk factors, prevalence, and state laws. Women at risk should be tested for gonorrhea. The sexual partners of women with STDs should be identified and treated also if possible; the local health department can assist with this process.

Workowski KA et al; Centers for Disease Control and Prevention (CDC). Sexually transmitted diseases treatment guidelines, 2010. *MMWR Recomm Rep*. 2010 Dec 17;59(RR-12):1–110. [PMID: 21160459]

SURGICAL COMPLICATIONS DURING PREGNANCY

Although purely elective surgery should be avoided during pregnancy, women who undergo surgical procedures for an urgent or emergent indication during pregnancy do not appear to be at increased risk for adverse outcomes. Obstetric complications, when they occur, are more likely to be associated with the underlying maternal illness. Recommendations have held that the optimal time for semi-elective surgery is the second trimester to avoid exposure to anesthesia in the first trimester and the enlarged uterus in the third. Importantly, however, there is no convincing evidence that general anesthesia induces malformations or increases the risk for abortion.

CHOLELITHIASIS, CHOLECYSTITIS, & INTRAHEPATIC CHOLESTASIS OF PREGNANCY

Cholelithiasis is common in pregnancy as physiologic changes such as incomplete gallbladder emptying predispose to gallstone formation. The diagnosis is usually suspected based on classic symptoms of right upper quadrant pain, usually after meals, and is confirmed with right upper quadrant ultrasound. Symptomatic cholelithiasis without cholecystitis is usually managed conservatively, but recurrent symptoms are common. Cholecystitis results from obstruction of the cystic duct and often is accompanied by bacterial infection. Medical management with antibiotics is reasonable in selected cases, but definitive treatment with cholecystectomy will help prevent complications such as gallbladder perforation and pancreatitis. Cholecystectomy has successfully been performed in all trimesters of pregnancy and should not be withheld based on the stage of pregnancy if clinically indicated. Laparoscopy is preferred in the first half of pregnancy but becomes technically difficult in the last trimester due to the enlarged uterus and cephalad displacement of abdominal contents.

Obstruction of the common duct can lead to cholangitis requiring surgical removal of gallstones and establishment of biliary drainage. Endoscopic retrograde cholangiopancreatography (ERCP) and endoscopic retrograde sphincterotomy can be performed safely in pregnant women if precautions are taken to minimize exposure to radiation. There does, however, appear to be a slightly higher rate of post-procedure pancreatitis in pregnant women who undergo ERCP.

Intrahepatic cholestasis of pregnancy is characterized by incomplete clearance of bile acids in genetically susceptible women. The main symptom of generalized pruritus usually occurs in the third trimester. Laboratory studies reveal hepatic dysfunction with elevations in serum bile acids. Hepatic transaminase levels may also be modestly elevated, and mild bilirubin elevations may even result in clinical jaundice. Ursodeoxycholic acid (8–10 mg/kg/d) is the treatment of choice and results in decreased pruritus in most women. Cholestyramine has also been used, but it does not appear to be as effective and impairs absorption of fat-soluble vitamins. Vitamin K supplementation is therefore required to help prevent hemorrhagic disease in the fetus. Symptoms ultimately resolve after delivery but

often recur in subsequent pregnancies. Adverse fetal outcomes, particularly fetal distress, meconium-stained amniotic fluid, and stillbirth, have been reported in women with cholestasis of pregnancy. Because of these risks, many clinicians recommend antenatal testing in the third trimester and delivery around 38 weeks gestation. Evidence-based recommendations, however, are not available.

Geenes V et al. Intrahepatic cholestasis of pregnancy. *World J Gastroenterol.* 2009 May 7;15(17):2049–66. [PMID: 19418576]
Tang SJ et al. Safety and utility of ERCP during pregnancy. *Gastrointest Endosc.* 2009 Mar;69(3 Pt 1):453–61. [PMID: 19136111]

APPENDICITIS

Appendicitis occurs in about 1 of 1500 pregnancies. The diagnosis is often difficult to make clinically since the appendix is displaced cephalad from McBurney point. Furthermore, nausea, vomiting, and mild leukocytosis occur in normal pregnancy, so with or without these findings, any complaint of right-sided pain should raise suspicion. CT scanning can help confirm the diagnosis when clinical findings are equivocal, and proper shielding can minimize radiation exposure to the fetus. MRI is also being increasingly used to evaluate for appendicitis in pregnant women and appears to be a reasonable alternative to CT scanning. Unfortunately, the diagnosis of appendicitis is not made until the appendix has ruptured in at least 20% of obstetric patients. Peritonitis in these cases can lead to preterm labor or abortion. With early diagnosis and appendectomy, the prognosis is good for mother and baby.

Blumenfeld YJ et al. MR imaging in cases of antenatal suspected appendicitis—a meta-analysis. *J Matern Fetal Neonatal Med.* 2011 Mar;24(3):485–8. [PMID: 20695758]
Parangi S et al. Surgical gastrointestinal disorders during pregnancy. *Am J Surg.* 2007 Feb;193(2):223–32. [PMID: 17236852]

CARCINOMA OF THE BREAST

Carcinoma of the breast (see also Chapter 17) is one of the most commonly diagnosed cancers in pregnancy. Although the effects of pregnancy on breast cancer progression are unclear, it has been consistently reported that breast cancers diagnosed during pregnancy are more likely to have higher grade disease with associated nodal involvement when compared with those diagnosed in nonpregnant women. This observation underscores the importance of expeditious evaluation of any breast mass in a pregnant woman. Although breast enlargement and glandular hyperplasia during pregnancy and the puerperium may limit the radiographic evaluation, both ultrasonography and mammography are useful for characterizing a mass. Ultimately, however, biopsy is required for any suspicious lesion. If breast biopsy confirms the diagnosis of cancer, surgery should not be withheld based on the stage of the pregnancy. If chemotherapy is indicated and the pregnancy is early, termination can be considered. If the pregnancy is more advanced, it may be appropriate to

administer chemotherapeutic agents during the pregnancy to avoid a delay in treatment. Cases need to be individualized and should be managed by a multidisciplinary team with experience in treating both patients with cancer and high-risk pregnancies.

Guidroz JA et al. Management of pregnant women with breast cancer. *J Surg Oncol.* 2011 Mar 15;103(4):337–40. [PMID: 21337568]

OVARIAN TUMORS

The management of an adnexal mass in pregnancy depends on the gestational age at which it is diagnosed and the likelihood that complications will develop. In early pregnancy, the corpus luteum is frequently observed using transvaginal ultrasound and appears as a simple cyst. The corpus luteum provides progesterone support of the pregnancy until the placenta assumes this role in the latter part of the first trimester. Although uncommon, corpus luteum cysts may enlarge and undergo hemorrhage or torsion and become symptomatic. If resection is required prior to 10 weeks gestation, supplementation with progesterone should be given through the 10th week.

The management of asymptomatic adnexal masses identified in early pregnancy depends on the size and

sonographic appearance of the mass. In general, masses that are small (< 5 cm), cystic, and simple require no follow-up. Larger masses or those with complex features are usually followed with repeat ultrasound in the early second trimester. Those that persist may require surgical resection, particularly if they are large (≥ 5 cm) or have features that are suspicious for malignancy, such as thick internal septations or papillary excrescences. Larger masses, even when benign, increase the risk for ovarian torsion, which can result in adnexal necrosis, peritonitis and preterm labor. The risk for ovarian torsion appears to be greatest in the first half of pregnancy as the gravid uterus grows out of the pelvis. Elective removal in the early second trimester can prevent this complication. It should be emphasized, however, that the optimal management of persistent masses of intermediate size (5–10 cm) that are believed to be benign is unclear, and decisions should be made on an individual basis. If there is suspicion for ovarian cancer, preoperative consultation with a practitioner experienced in treating gynecologic malignancies is appropriate.

Glanc P et al. Adnexal masses in the pregnant patient: a diagnostic and management challenge. *Ultrasound Q.* 2008 Dec;24(4):225–40. [PMID: 19060689]

Yen CF et al. Risk analysis of torsion and malignancy for adnexal masses during pregnancy. *Fertil Steril.* 2009 May;91(5):1895–902. [PMID: 18359024]

Musculoskeletal & Immunologic Disorders

David B. Hellmann, MD, MACP
John B. Imboden, Jr., MD

20

► Diagnosis & Evaluation

A. Examination of the Patient

In the patient with arthritis, the two clinical clues most helpful for diagnosis are the **joint pattern** and the **presence or absence of extra-articular manifestations**. The joint pattern is defined by the answers to three questions: (1) Is inflammation present? (2) How many joints are involved? and (3) What joints are affected? Joint inflammation manifests as redness, warmth, swelling, and morning stiffness of at least 30 minutes' duration. Both the number of affected joints and the specific sites of involvement affect the differential diagnosis (Table 20–1). Some diseases—gout, for example—are characteristically monoarticular, whereas other diseases, such as rheumatoid arthritis, are usually polyarticular. The location of joint involvement can also be distinctive. Only two diseases frequently cause prominent involvement of the distal interphalangeal (DIP) joint: osteoarthritis and psoriatic arthritis. Extra-articular manifestations such as fever (eg, gout, Still disease, endocarditis), rash (eg, systemic lupus erythematosus, psoriatic arthritis, Still disease), nodules (eg, rheumatoid arthritis, gout), or neuropathy (eg, polyarteritis nodosa, granulomatosis with polyangiitis [formerly Wegener granulomatosis]) narrow the differential diagnosis further.

B. Arthrocentesis and Examination of Joint Fluid

If the diagnosis is uncertain, synovial fluid should be examined whenever possible (Table 20–2). Most large joints are easily aspirated, and contraindications to arthrocentesis are few. The aspirating needle should never be passed through an overlying cellulitis or psoriatic plaque because of the risk of introducing infection. For patients who are receiving long-term anticoagulation therapy with warfarin, joints can be aspirated with a small-gauge needle (eg, 22F) if the international normalized ratio (INR) is < 3.0.

1. Types of studies

A. GROSS EXAMINATION—Clarity is an approximate guide to the degree of inflammation. Noninflammatory fluid is transparent, mild inflammation produces translucent fluid, and purulent effusions are opaque. Bleeding disorders,

trauma, and traumatic taps are the most common causes of bloody effusions.

B. CELL COUNT—The synovial fluid white cell count discriminates between **noninflammatory** (< 2000 white cells/mcL), **inflammatory** (2000–75,000 white cells/mcL), and **purulent** (> 100,000 white cells/mcL) joint effusions. Synovial fluid glucose and protein levels add little information and should not be ordered.

C. MICROSCOPIC EXAMINATION—Compensated polarized light microscopy identifies and distinguishes monosodium urate (gout, negatively birefringent) and calcium pyrophosphate (pseudogout, positive birefringent) crystals. Gram stain has specificity but limited sensitivity (50%) for septic arthritis.

D. CULTURE—Bacterial cultures as well as special studies for gonococci, tubercle bacilli, or fungi are ordered as appropriate.

2. Interpretation—Synovial fluid analysis is diagnostic in infectious or microcrystalline arthritis. Although the severity of inflammation in synovial fluid can overlap among various conditions, the synovial fluid white cell count is a helpful guide to diagnosis (Table 20–3).

DEGENERATIVE & CRYSTAL-INDUCED ARTHRITIS

DEGENERATIVE JOINT DISEASE (Osteoarthritis)

ESSENTIALS OF DIAGNOSIS

- ▶ A degenerative disorder with minimal articular inflammation.
- ▶ No systemic symptoms.
- ▶ Pain relieved by rest; morning stiffness brief.
- ▶ Radiographic findings: narrowed joint space, osteophytes, increased density of subchondral bone, bony cysts.

Table 20-1. Diagnostic value of the joint pattern.

Characteristic	Status	Representative Disease
Inflammation	Present	Rheumatoid arthritis, systemic lupus erythematosus, gout
	Absent	Osteoarthritis
Number of involved joints	Monarticular	Gout, trauma, septic arthritis, Lyme disease, osteoarthritis
	Oligoarticular (2-4 joints)	Reactive arthritis, psoriatic arthritis, inflammatory bowel disease
	Polyarticular (≥ 5 joints)	Rheumatoid arthritis, systemic lupus erythematosus
Site of joint involvement	Distal interphalangeal	Osteoarthritis, psoriatic arthritis (not rheumatoid arthritis)
	Metacarpophalangeal, wrists	Rheumatoid arthritis, systemic lupus erythematosus, calcium pyrophosphate deposition disease (not osteoarthritis)
	First metatarsal phalangeal	Gout, osteoarthritis

► General Considerations

Osteoarthritis, the most common form of joint disease, is chiefly a disease of aging. Ninety percent of all people have radiographic features of osteoarthritis in weight-bearing joints by age 40. Symptomatic disease also increases with age. Gender is also a risk factor, because osteoarthritis develops in women more frequently than in men.

This arthropathy is characterized by degeneration of cartilage and by hypertrophy of bone at the articular margins. Inflammation is usually minimal. Hereditary and mechanical factors may be involved in the pathogenesis.

Obesity is a risk factor for osteoarthritis of the knee, hand, and probably of the hip. Recreational running does

not increase the incidence of osteoarthritis, but participation in competitive contact sports does. Jobs requiring frequent bending and carrying increase the risk of knee osteoarthritis.

► Clinical Findings

A. Symptoms and Signs

Degenerative joint disease is divided into two types: (1) primary, which most commonly affects some or all of the following: the DIP and the proximal interphalangeal (PIP) joints of the fingers, the carpometacarpal joint of the thumb, the hip, the knee, the metatarsophalangeal (MTP) joint of the big toe, and the cervical and lumbar spine; and (2) secondary, which may occur in any joint as a sequela to articular injury resulting from either intra-articular (including rheumatoid arthritis) or extra-articular causes. The injury may be acute, as in a fracture; or chronic, as that due to occupational overuse of a joint, metabolic disease (eg, hyperparathyroidism, hemochromatosis, ochronosis), or neurologic disorders (syringomyelia; see below).

The onset is insidious. Initially, there is articular stiffness, seldom lasting more than 15 minutes; this develops later into pain on motion of the affected joint and is made worse by activity or weight bearing and relieved by rest. Flexion contracture or varus deformity of the knee is not unusual, and bony enlargements of the DIP (Heberden nodes) and PIP (Bouchard nodes) are occasionally prominent (Figure 20-1). There is no ankylosis, but limitation of motion of the affected joint or joints is common. Crepitus may often be felt over the knee. Joint effusion and other articular signs of inflammation are mild. There are no systemic manifestations.

B. Laboratory Findings

Osteoarthritis does not cause elevation of the erythrocyte sedimentation rate (ESR) or other laboratory signs of inflammation. Synovial fluid is noninflammatory.

Table 20-2. Examination of joint fluid.

Measure	(Normal)	Group I (Noninflammatory)	Group II (Inflammatory)	Group III (Purulent)
Volume (mL) (knee)	< 3.5	Often > 3.5	Often > 3.5	Often > 3.5
Clarity	Transparent	Transparent	Translucent to opaque	Opaque
Color	Clear	Yellow	Yellow to opalescent	Yellow to green
WBC (per mL)	< 200	< 2000	2000-75,000 ¹	> 100,000 ²
Polymorphonuclear leukocytes	< 25%	< 25%	50% or more	75% or more
Culture	Negative	Negative	Negative	Usually positive ²

¹Gout, rheumatoid arthritis, and other inflammatory conditions occasionally have synovial fluid WBC counts > 75,000/mL but rarely > 100,000/mL.

²Most purulent effusions are due to septic arthritis. Septic arthritis, however, can present with group II synovial fluid, particularly if infection is caused by organisms of low virulence (eg, *Neisseria gonorrhoeae*) or if antibiotic therapy has been started.

WBC, white blood cell count.

Table 20-3. Differential diagnosis by joint fluid groups.

Group I (Noninflammatory) (< 2000 white cells/mcl)	Group II (Inflammatory) (2000 – $75,000$ white cells/mcl)	Group III (Purulent) ($> 100,000$ white cells/mcl)	Hemorrhagic
Degenerative joint disease Trauma ¹ Osteochondritis dissecans Osteochondromatosis Neuropathic arthropathy ¹ Subsiding or early inflammation Hypertrophic osteoarthropathy ² Pigmented villonodular synovitis ¹	Rheumatoid arthritis Acute crystal-induced synovitis (gout and pseudogout) Reactive arthritis Ankylosing spondylitis Rheumatic fever ² Tuberculosis	Pyogenic bacterial infections	Hemophilia or other hemorrhagic diathesis Trauma with or without fracture Neuropathic arthropathy Pigmented villonodular synovitis Synovioma Hemangioma and other benign neoplasms

¹May be hemorrhagic.

²Noninflammatory or inflammatory group.

Reproduced, with permission, from Rodnan GP (editor). Primer on the rheumatic diseases, 7th ed. JAMA. 1973;224(Suppl):662.

C. Imaging

Radiographs may reveal narrowing of the joint space; osteophyte formation and lipping of marginal bone; and thickened, dense subchondral bone. Bone cysts may also be present.

► Differential Diagnosis

Because articular inflammation is minimal and systemic manifestations are absent, degenerative joint disease should seldom be confused with other arthritides. The distribution of joint involvement in the hands also helps distinguish osteoarthritis from rheumatoid arthritis. Osteoarthritis chiefly affects the DIP and PIP joints and spares the wrist and metacarpophalangeal (MCP) joints; rheumatoid arthritis involves the wrists and MCP joints and spares the DIP joints. Furthermore, the joint enlargement is bony-hard and



▲ **Figure 20-1.** Osteoarthritis with bony enlargement of the distal interphalangeal (DIP) joints (Heberden nodes) and proximal interphalangeal (PIP) joints (Bouchard nodes). (Courtesy of Richard P. Usatine, MD; used, with permission, from Usatine RP, Smith MA, Mayeaux EJ Jr, Chumley H, Tysinger J. *The Color Atlas of Family Medicine*. McGraw-Hill, 2009.)

cool in osteoarthritis but spongy and warm in rheumatoid arthritis. Skeletal symptoms due to degenerative changes in joints—especially in the spine—may cause coexistent metastatic neoplasia, osteoporosis, multiple myeloma, or other bone disease to be overlooked.

► Prevention

Weight reduction reduces the risk of developing symptomatic knee osteoarthritis. Correcting leg length discrepancy of > 1 cm with shoe modification may prevent knee osteoarthritis from developing in the shorter leg. Maintaining normal vitamin D levels may reduce the occurrence and progression of osteoarthritis, in addition to being important for bone health.

► Treatment

A. General Measures

For patients with mild to moderate osteoarthritis of weight-bearing joints, moderate physical activity (eg, a supervised walking program, hydrotherapy classes, or Tai Chi classes), and use of assistive devices (eg, a cane on the contralateral side) may result in clinical improvement of functional status without aggravating the joint pain. Weight loss can also improve the symptoms.

B. Analgesic and Anti-inflammatory Drugs

Nonsteroidal anti-inflammatory drugs (NSAIDs) (see Table 5-3) are more effective (and more toxic) than acetaminophen for osteoarthritis of the knee or hip. Their superiority is most convincing in persons with severe disease. Patients with mild disease should start with acetaminophen (2.6–4 g/d). NSAIDs should be considered for patients who do not respond to acetaminophen. (See discussion of NSAID toxicity in the section on treatment of rheumatoid arthritis.) High doses of NSAIDs, as used in the inflammatory arthritides, are unnecessary. A topical NSAID—diclofenac gel 1% is approved by the US Food and Drug Administration (FDA) for treatment of osteoarthritis; the recommended dose is 4 g applied to the affected

joint four times daily. Topical diclofenac appears more effective than placebo for knee and hand osteoarthritis. Rates of systemic side effects are lower with topical than with oral diclofenac. Few studies have compared the efficacy of oral and topical NSAIDs. Chondroitin sulfate and glucosamine, alone or in combination, are no better than placebo in reducing pain in patients with knee or hip osteoarthritis.

For many patients, it is possible eventually to reduce the dosage or limit use of drugs to periods of exacerbation. For patients with knee osteoarthritis and effusion, intra-articular injection of triamcinolone (20–40 mg) may obviate the need for analgesics or NSAIDs. Corticosteroid injections up to four times a year appear to be safe. Intra-articular injections of sodium hyaluronate reduce symptoms moderately in some patients. Capsaicin cream 0.025–0.075% applied three or four times a day can also reduce knee pain without NSAIDs.

C. Surgical Measures

Total hip and knee replacements provide excellent symptomatic and functional improvement when involvement of that joint severely restricts walking or causes pain at rest, particularly at night. Arthroscopic surgery for knee osteoarthritis is ineffective.

► Prognosis

Marked disability is less common in patients with osteoarthritis than in those with rheumatoid arthritis, but symptoms may be quite severe and limit activity considerably (especially with involvement of the hips, knees, and cervical spine).

► When to Refer

- Refer patients to an orthopedic surgeon when recalcitrant symptoms or functional impairment, or both, warrant consideration of joint replacement surgery of the hip or knee.

Altman R et al. Topical therapy for osteoarthritis: clinical and pharmacologic perspectives. *Postgrad Med.* 2009 Mar; 121(2):139–47. [PMID: 19332972]

Aran S et al. A double-blind randomized controlled trial appraising the symptom-modifying effects of colchicine on osteoarthritis of the knee. *Clin Exp Rheumatol.* 2011 May–Jun; 29(3):513–8. [PMID: 21640042]

Chan FK et al. Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial. *Lancet.* 2010 Jul 17;376(9736): 173–9. Erratum in: *Lancet.* 2011 Jul 16;378(9787):228. [PMID: 20638563]

Harvey WF et al. Association of leg-length inequality with knee osteoarthritis: a cohort study. *Ann Intern Med.* 2010 Mar 2; 152(5):287–95. [PMID: 20194234]

Losina E et al. Impact of obesity and knee osteoarthritis on morbidity and mortality in older Americans. *Ann Intern Med.* 2011 Feb 15;154(4):217–26. [PMID: 21320937]

Wandel S et al. Effects of glucosamine, chondroitin, or placebo in patients with osteoarthritis of hip or knee: network meta-analysis. *BMJ.* 2010 Sep 16;341:c4675. [PMID: 20847017]

CRYSTAL DEPOSITION ARTHRITIS

1. Gouty Arthritis

ESSENTIALS OF DIAGNOSIS

- ▶ Acute onset, usually monarticular, recurring attacks, often involving the first MTP joint.
- ▶ Polyarticular involvement more common in patients with long-standing disease.
- ▶ Identification of urate crystals in joint fluid or tophi is diagnostic.
- ▶ Dramatic therapeutic response to NSAIDs.
- ▶ With chronicity, urate deposits in subcutaneous tissue, bone, cartilage, joints, and other tissues.

► General Considerations

Gout is a metabolic disease of a heterogeneous nature, often familial, associated with abnormal amounts of urates in the body and characterized early by a recurring acute arthritis, usually monarticular, and later by chronic deforming arthritis. The associated hyperuricemia is due to overproduction or underexcretion of uric acid—sometimes both. The disease is especially common in Pacific islanders, eg, Filipinos and Samoans. Primary gout has a heritable component, and genome-wide surveys have linked risk of gout to several genes whose products regulate urate handling by the kidney. Secondary gout, which may have a heritable component, is related to acquired causes of hyperuricemia, eg, medication use (especially diuretics, low-dose aspirin, cyclosporine, and niacin), myeloproliferative disorders, multiple myeloma, hemoglobinopathies, chronic kidney disease, hypothyroidism, psoriasis, sarcoidosis, and lead poisoning (Table 20–4). Alcohol ingestion promotes hyperuricemia by increasing urate production and decreasing the renal excretion of uric acid. Finally, hospitalized patients frequently suffer attacks of gout because of changes in diet, fluid intake, or medications that lead either to rapid reductions or increases in the serum urate level.

About 90% of patients with primary gout are men, usually over 30 years of age. In women, the onset is typically postmenopausal. The characteristic lesion is the tophus, a nodular deposit of monosodium urate monohydrate crystals with an associated foreign body reaction. Tophi are found in cartilage, subcutaneous and periarticular tissues, tendon, bone, the kidneys, and elsewhere. Urates have been demonstrated in the synovial tissues (and fluid) during acute arthritis; indeed, the acute inflammation of gout is believed to be initiated by the ingestion of uncoated urate crystals by monocytes and synoviocytes. Once inside the cells, the gout crystals are processed through Toll-like receptors and activate NALP-3 inflammasomes which in turn release a variety of chemotactic agents and cytokines capable of mediating inflammation. The precise relationship of hyperuricemia to gouty arthritis is still obscure, since chronic hyperuricemia is found in people who never

Table 20-4. Origin of hyperuricemia.**Primary hyperuricemia**

- A. Increased production of purine
 1. Idiopathic
 2. Specific enzyme defects (eg, Lesch-Nyhan syndrome, glycogen storage diseases)
- B. Decreased renal clearance of uric acid (idiopathic)

Secondary hyperuricemia

- A. Increased catabolism and turnover of purine
 1. Myeloproliferative disorders
 2. Lymphoproliferative disorders
 3. Carcinoma and sarcoma (disseminated)
 4. Chronic hemolytic anemias
 5. Cytotoxic drugs
 6. Psoriasis
- B. Decreased renal clearance of uric acid
 1. Intrinsic kidney disease
 2. Functional impairment of tubular transport
 - a. Drug-induced (eg, thiazides, low-dose aspirin)
 - b. Hyperlactacidemia (eg, lactic acidosis, alcoholism)
 - c. Hyperketoacidemia (eg, diabetic ketoacidosis, starvation)
 - d. Diabetes insipidus (vasopressin-resistant)
 - e. Bartter syndrome

Modified, with permission, from Rodnan GP. Gout and other crystalline forms of arthritis. *Postgrad Med.* 1975 Oct;58(5):6-14.

develop gout or uric acid stones. Rapid fluctuations in serum urate levels, either increasing or decreasing, are important factors in precipitating acute gout. The mechanism of the late, chronic stage of gouty arthritis is better understood. This is characterized pathologically by tophaceous invasion of the articular and periarticular tissues, with structural derangement and secondary degeneration (osteoarthritis).

Uric acid kidney stones are present in 5–10% of patients with gouty arthritis. Hyperuricemia correlates highly with the likelihood of developing stones, with the risk of stone formation reaching 50% in patients with a serum urate level > 13 mg/dL. Chronic urate nephropathy is caused by the deposition of monosodium urate crystals in the renal medulla and pyramids. Although progressive chronic kidney disease occurs in a substantial percentage of patients with chronic gout, the role of hyperuricemia in causing this outcome is controversial, because many patients with gout have numerous confounding risk factors for chronic kidney disease (eg, hypertension, alcohol use, lead exposure, and other risk factors for vascular disease).

► Clinical Findings

A. Symptoms and Signs

Acute gouty arthritis is sudden in onset and frequently nocturnal. It may develop without apparent precipitating cause or may follow rapid increases or decreases in serum urate levels. Common precipitants are alcohol excess (particularly beer), changes in medications that affect urate metabolism, and, in the hospitalized patient, fasting before medical procedures. The MTP joint of the great toe is the most susceptible

joint (“podagra”), although others, especially those of the feet, ankles, and knees, are commonly affected. Gouty attacks may develop in periarticular soft tissues such as the arch of the foot. Hips and shoulders are rarely affected. More than one joint may occasionally be affected during the same attack; in such cases, the distribution of the arthritis is usually asymmetric. As the attack progresses, the pain becomes intense. The involved joints are swollen and exquisitely tender and the overlying skin tense, warm, and dusky red. Fever is common and may reach 39°C. Local desquamation and pruritus during recovery from the acute arthritis are characteristic of gout but are not always present. Tophi may be found in the external ears, feet, olecranon and prepatellar bursae, and hands (Figure 20–2). They usually develop years after the initial attack of gout.

Asymptomatic periods of months or years commonly follow the initial acute attack. After years of recurrent severe monoarthritis attacks of the lower extremities and untreated hyperuricemia, gout can evolve into a chronic, deforming polyarthritis of upper and lower extremities that mimics rheumatoid arthritis.

B. Laboratory Findings

The serum uric acid is elevated (> 7.4 mg/dL) in 95% of patients who have serial measurements during the course of an attack. However, a single uric acid determination is normal in up to 25% of cases, so it does not exclude gout,



▲ **Figure 20-2.** Acute gouty arthritis superimposed on tophaceous gout. (Courtesy of the Western Journal of Medicine and JM Geiderman, MD; used, with permission, from Usatine RP, Smith MA, Mayeaux EJ, Jr, Chumley H, Tysinger J. *The Color Atlas of Family Medicine*. McGraw-Hill, 2009.)

especially in patients taking urate-lowering drugs. During an acute attack, the peripheral blood white cell count is frequently elevated. Identification of sodium urate crystals in joint fluid or material aspirated from a tophus establishes the diagnosis. The crystals, which may be extracellular or found within neutrophils, are needle-like and negatively birefringent when examined by polarized light microscopy.

C. Imaging

Early in the disease, radiographs show no changes. Later, punched-out erosions with an overhanging rim of cortical bone (“rat bite”) develop. When these are adjacent to a soft tissue tophus, they are diagnostic of gout.

► Differential Diagnosis

Acute gout is often confused with cellulitis. Bacteriologic studies usually exclude acute pyogenic arthritis. Pseudogout is distinguished by the identification of calcium pyrophosphate crystals (positive birefringence) in the joint fluid, usually normal serum uric acid, and the radiographic appearance of chondrocalcinosis.

Chronic tophaceous arthritis may resemble chronic rheumatoid arthritis; gout is suggested by an earlier history of monarthritis and is established by the demonstration of urate crystals in a suspected tophus. Likewise, hips and shoulders are generally spared in tophaceous gout. Biopsy may be necessary to distinguish tophi from rheumatoid nodules. A radiographic appearance similar to that of gout may be found in rheumatoid arthritis, sarcoidosis, multiple myeloma, hyperparathyroidism, or Hand-Schüller-Christian disease. Chronic lead intoxication may result in attacks of gouty arthritis (saturnine gout).

► Treatment

A. Asymptomatic Hyperuricemia

Asymptomatic hyperuricemia should not be treated; uric acid-lowering drugs need not be instituted until arthritis, renal calculi, or tophi become apparent.

B. Acute Attack

Arthritis is treated first and hyperuricemia weeks or months later, if at all. Sudden reduction of serum uric acid often precipitates further episodes of gouty arthritis.

1. NSAIDs—These drugs (see Table 5–3) are the treatment of choice for acute gout. Traditionally, indomethacin has been the most frequently used agent, but all of the other newer NSAIDs are probably equally effective. Indomethacin is initiated at a dosage of 25–50 mg orally every 8 hours and continued until the symptoms have resolved (usually 5–10 days). Active peptic ulcer disease, impaired kidney function, and a history of allergic reaction to NSAIDs are contraindications. For patients at high risk for upper gastrointestinal bleeding, celecoxib (200 mg twice a day on day 1 then 100 mg twice daily until resolution), a cyclooxygenase type 2 (COX-2) inhibitor, may be an appropriate first choice for management of an acute gout attack. Long-term

use of COX-2 inhibitors is not advised because of the association with increased risk of cardiovascular events, which has led to the removal of some drugs (eg, rofecoxib and valdecoxib) from the US market.

2. Colchicine—Neither oral nor intravenous colchicine should be used for the treatment of acute gout flares. A patient who is taking prophylactic doses of colchicine may continue it through the flare. The use of oral colchicine during the intercritical period to prevent gout attacks is discussed below.

3. Corticosteroids—Corticosteroids often give dramatic symptomatic relief in acute episodes of gout and will control most attacks. They are most useful in patients with contraindications to the use of NSAIDs. Corticosteroids may be given intravenously (eg, methylprednisolone, 40 mg/d tapered over 7 days) or orally (eg, prednisone, 40–60 mg/d tapered over 7 days). If the patient’s gout is monarticular, intra-articular administration (eg, triamcinolone, 10–40 mg depending on the size of the joint) is very effective. Because gouty and septic arthritis can coexist, albeit rarely, joint aspiration and Gram stain with culture of synovial fluid should be performed when intra-articular corticosteroids are given.

4. Anakinra—Uncontrolled studies suggest that this interleukin-1 receptor antagonist has efficacy for the management of acute gout.

C. Management between Attacks

Treatment during symptom-free periods is intended to minimize urate deposition in tissues, which causes chronic tophaceous arthritis, and to reduce the frequency and severity of recurrences. Patients with a single episode of gout who are willing to lose weight and stop drinking alcohol are at low risk for another attack and unlikely to benefit from long-term medical therapy. In contrast, older individuals with mild chronic kidney disease who require diuretic use and have a history of multiple attacks of gout are more likely to benefit from pharmacologic treatment. In general, the higher the uric acid level and the more frequent the attacks, the more likely that long-term medical therapy will be beneficial.

1. Diet—Potentially reversible causes of hyperuricemia are a high-purine diet, obesity, alcohol consumption, and use of certain medications (see below). Beer consumption appears to confer a higher risk of gout than does whiskey or wine. Higher levels of meat and seafood consumption are associated with increased risks of gout, whereas a higher level of dairy products consumption is associated with a decreased risk. Although dietary purines usually contribute only 1 mg/dL to the serum uric acid level, moderation in eating foods with high purine content is advisable (Table 20–5). A high liquid intake and, more importantly, a daily urinary output of 2 L or more will aid urate excretion and minimize urate precipitation in the urinary tract.

2. Avoidance of hyperuricemic medications—Thiazide and loop diuretics inhibit renal excretion of uric acid and

Table 20-5. The purine content of foods.¹**Low-purine foods**

Refined cereals and cereal products, cornflakes, white bread, pasta, flour, arrowroot, sago, tapioca, cakes
Milk, milk products, and eggs
Sugar, sweets, and gelatin
Butter, polyunsaturated margarine, and all other fats
Fruit, nuts, and peanut butter
Lettuce, tomatoes, and green vegetables (except those listed below)
Cream soups made with low-purine vegetables but without meat or meat stock
Water, fruit juice, cordials, and carbonated drinks

High-purine foods

All meats, including organ meats, and seafood
Meat extracts and gravies
Yeast and yeast extracts, beer, and other alcoholic beverages
Beans, peas, lentils, oatmeal, spinach, asparagus, cauliflower, and mushrooms

¹The purine content of a food reflects its nucleoprotein content and turnover. Foods containing many nuclei (eg, liver) have many purines, as do rapidly growing foods such as asparagus. The consumption of large amounts of a food containing a small concentration of purines may provide a greater purine load than consumption of a small amount of a food containing a large concentration of purines.

Reproduced, with permission, from Emmerson BT. The management of gout. *N Engl J Med.* 1996 Feb 15;334(7):445-51.

should be avoided in patients with gout. Similarly, low doses of aspirin aggravate hyperuricemia, as does niacin.

3. Colchicine—There are two indications for daily colchicine administration. First, colchicine can be used to prevent future attacks. For the person who has mild hyperuricemia and occasional attacks of gouty arthritis, long-term colchicine prophylaxis may be all that is needed. Second, colchicine can also be used when uricosuric drugs or allopurinol (see below) are started, to suppress attacks precipitated by abrupt changes in the serum uric acid level. For either indication, the usual dose is 0.6 mg either once or twice a day. Colchicine is renally cleared. Patients who have coexisting moderate chronic kidney disease should take colchicine only once a day or once every other day in order to avoid the peripheral neuromyopathy and other complications of colchicine toxicity.

4. Reduction of serum uric acid—Indications for a urate lowering intervention include frequent acute arthritis not controlled by colchicine prophylaxis, tophaceous deposits, or kidney damage. Hyperuricemia with infrequent attacks of arthritis may not require treatment. If instituted, the goal of medical treatment is to maintain the serum uric acid at or below 6 mg/dL, which allows urate crystals to solubilize.

Three classes of agents may be used to lower the serum uric acid—the uricosuric drugs, xanthine oxidase inhibitors (allopurinol or febuxostat), and uricase (pegloticase); none is of value in the treatment of acute gout. Choosing between uricosuric drugs and allopurinol depends on the

result of a 24-hour urine uric acid determination. A value under 800 mg/d indicates undersecretion of uric acid, which is amenable to uricosuric agents if kidney function is preserved or to a xanthine oxidase inhibitor (allopurinol or febuxostat) if kidney function is limited. Patients with > 800 mg of uric acid in a 24-hour urine collection are overproducers and require a xanthine oxidase inhibitor. The uricase, pegloticase, requires intravenous administration and is indicated only in patients with chronic gout refractory to other treatments.

A. URICOSURIC DRUGS—Uricosuric drugs, which block the tubular reabsorption of filtered urate thereby reducing the metabolic urate pool, prevent the formation of new tophi and reduce the size of those already present. When administered concomitantly with colchicine, they may lessen the frequency of recurrences of acute gout. The indication for uricosuric treatment is the increasing frequency or severity of acute attacks. Uricosuric agents are ineffective in patients with an estimated glomerular filtration rate of < 60 mL/min.

The following uricosuric drugs may be used: (1) Probenecid, 0.5 g orally daily initially, with gradual increase to 1–2 g daily; or (2) sulfinpyrazone, 50–100 mg orally twice daily initially, with gradual increase to 200–400 mg twice daily. Hypersensitivity to either with fever and rash occurs in 5% of cases; gastrointestinal complaints are observed in 10%. Probenecid also inhibits the excretion of penicillin, indomethacin, dapsone, and acetazolamide.

Precautions with uricosuric drugs include maintaining a daily urinary output of 2000 mL or more in order to minimize the precipitation of uric acid in the urinary tract. This can be further prevented by giving alkalinizing agents (eg, potassium citrate, 30–80 mEq/d orally) to maintain a urine pH of > 6.0. Uricosuric drugs should not be used in patients with a history of uric acid nephrolithiasis. Aspirin in moderate doses antagonizes the action of uricosuric agents, but low doses (325 mg or less per day) do not; doses of aspirin > 3 g daily are themselves uricosuric.

B. XANTHINE OXIDASE INHIBITORS—The xanthine oxidase inhibitors promptly lower plasma urate and urinary uric acid concentrations and facilitate tophus mobilization. Inhibitors of xanthine oxidase are of special value in uric acid overproducers; in tophaceous gout; in patients unresponsive to the uricosuric regimen; and in gouty patients with uric acid renal calculi. Asymptomatic hyperuricemia should not be treated. Two xanthine oxidase inhibitors are available for treating chronic gout: allopurinol and febuxostat. One or the other should be chosen; allopurinol and febuxostat are not to be used together. The most frequent adverse effect with either medication is the precipitation of an acute gouty attack; thus, patients generally should be receiving prophylactic doses of colchicine and should not be experiencing an acute flare when xanthine oxidase inhibitors are initiated. Hypersensitivity to allopurinol occurs in 2% of cases and can be life-threatening. The most common sign of hypersensitivity is a pruritic rash that may progress to toxic epidermal necrolysis, particularly if allopurinol is continued; vasculitis and hepatitis are other manifestations. Patients should be instructed to stop

allopurinol immediately if a rash develops. Febuxostat apparently does not cause the hypersensitivity reactions seen with allopurinol and can be given without dose adjustment to patients with mild to moderate renal disease. However, 2–3% of patients taking febuxostat may develop abnormal liver function tests. In addition, one clinical study showed that febuxostat was associated with a slightly higher rate of fatal and non-fatal cardiovascular events than allopurinol (0.97 vs 0.58 per 100 patient-years).

The initial daily dose of allopurinol is 300 mg/d orally for most patients who have normal kidney function; the dose of allopurinol should be increased in 100-mg increments to achieve the desired serum uric acid level of ≤ 6.0 mg/dL. Successful treatment usually requires a dose of 300–400 mg of allopurinol daily. The maximum daily dose is 800 mg. Allopurinol can be used in chronic kidney disease, but the dose must be reduced to decrease the chance of side effects. For patients with renal impairment, the initial dose should be 50–100 mg daily.

Allopurinol interacts with other drugs. The combined use of allopurinol and ampicillin causes a drug rash in 20% of patients. Allopurinol can increase the half-life of probenecid, while probenecid increases the excretion of allopurinol. Thus, a patient taking both drugs may need to use slightly higher than usual doses of allopurinol and lower doses of probenecid. The initial dose of febuxostat is 40 mg/d orally. If the target serum uric acid is not reached within 2 weeks, then the dose of febuxostat can be increased to its maximum of 80 mg/d.

C. URICASE—Nonprimate mammals do not develop gout because they have an enzyme—uricase—that ensures that purine metabolism does not end with urate but the much more soluble metabolite, allantoin. In humans, the gene for uricase has been inactivated by a missense mutation, so purine metabolism dead ends with the production of uric acid, which becomes insoluble above a level of 6.8 mg/dL. Pegloticase, a recombinant uricase that must be administered intravenously (8 mg every 2 weeks), is indicated for the rare patient with chronic tophaceous gout who is refractory to all other therapies. Pegloticase carries a “Black Box Warning,” which advises administering the drug only in healthcare settings and by healthcare professionals prepared to manage anaphylactic and other serious infusion reactions.

D. Chronic Tophaceous Arthritis

With rigorous medical compliance, allopurinol or febuxostat or pegloticase shrinks tophi and in time can lead to their disappearance. Resorption of extensive tophi requires maintaining a serum uric acid below 6 mg/dL. Surgical excision of large tophi offers mechanical improvement in selected deformities.

E. Gout in the Transplant Patient

Hyperuricemia and gout commonly develop in many transplant patients because they have decreased kidney function and require drugs that inhibit uric acid excretion (especially cyclosporine and diuretics). Treating acute gout in these patients is challenging; NSAIDs are usually

contraindicated because of underlying chronic kidney disease; intravenous colchicine should not be used because of its narrow therapeutic index (particularly in kidney dysfunction); and corticosteroids are already being used. Often the best approach for monarticular gout—after excluding infection—is injecting corticosteroids into the joint (see above). For polyarticular gout, increasing the dose of systemic corticosteroid may be the only alternative. Since transplant patients often have multiple attacks of gout, long-term relief requires lowering the serum uric acid with allopurinol or febuxostat. (Kidney dysfunction seen in many transplant patients makes uricosuric agents ineffective.) Both allopurinol and febuxostat inhibit the metabolism of azathioprine and should be avoided in patients who must take azathioprine.

▶ Prognosis

Without treatment, the acute attack may last from a few days to several weeks. The intervals between acute attacks vary up to years, but the asymptomatic periods often become shorter if the disease progresses. Chronic gouty arthritis occurs after repeated attacks of acute gout, but only after inadequate treatment. The younger the patient at the onset of disease, the greater the tendency to a progressive course. Destructive arthropathy is rarely seen in patients whose first attack is after age 50.

Patients with gout are anecdotally thought to have an increased incidence of hypertension, kidney disease (eg, nephrosclerosis, interstitial nephritis, pyelonephritis), diabetes mellitus, hypertriglyceridemia, and atherosclerosis.

Burns CM et al. Gout therapeutics: new drugs for an old disease. *Lancet*. 2011 Jan 8;377(9760):165–77. [PMID: 20719377]
 Choi HK et al. Fructose-rich beverages and risk of gout in women. *JAMA*. 2010 Nov 24;304(20):2270–8. [PMID: 21068145]
 Neogi T. Clinical practice. Gout. *N Engl J Med*. 2011 Feb 3; 364(5):443–52. [PMID: 21288096]
 Stamp LK et al. Using allopurinol above the dose based on creatinine clearance is effective and safe in patients with chronic gout, including those with renal impairment. *Arthritis Rheum*. 2011 Feb;63(2):412–21. [PMID: 21279998]
 Sundy J et al. Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials. *JAMA*. 2011 Aug 17;306(7):711–20. [PMID: 21846852]

2. Chondrocalcinosis & Pseudogout

Chondrocalcinosis is the presence of calcium-containing salts in articular cartilage. Diagnosed radiologically, it may be familial and is commonly associated with a wide variety of metabolic disorders (eg, hemochromatosis, hyperparathyroidism, ochronosis, diabetes mellitus, hypothyroidism, Wilson disease, and gout). Pseudogout (also called calcium pyrophosphate dihydrate [CPPD] deposition disease) is most often seen in persons age 60 or older, is characterized by acute, recurrent and rarely chronic arthritis involving large joints (most commonly the knees and the wrists) and is almost always accompanied by chondrocalcinosis of the affected joints. Other joints frequently affected are the

MCPs, hips, shoulders, elbows, and ankles. Involvement of the DIP and PIP joints is no more common in CPPD deposition disease than in other age-matched controls. Pseudogout, like gout, frequently develops 24–48 hours after major surgery. Identification of calcium pyrophosphate crystals in joint aspirates is diagnostic of pseudogout. With light microscopy, the rhomboid-shaped crystals differ from the needle-shaped gout crystals. A red compensator is used for positive identification, since pseudogout crystals are blue when parallel and yellow when perpendicular to the axis of the compensator. Urate crystals give the opposite pattern. X-ray examination shows not only calcification (usually symmetric) of cartilaginous structures but also signs of degenerative joint disease (osteoarthritis). Unlike gout, pseudogout is usually associated with normal serum urate levels.

NSAIDs (salicylates, indomethacin, naproxen, and other drugs) are helpful in the treatment of acute episodes. Patients at increased risk for upper gastrointestinal bleeding may use a COX-2 inhibitor to treat acute attacks of pseudogout. Long-term use of COX-2 inhibitors is not advised because of the association with increased risk of cardiovascular events. Colchicine, 0.6 mg orally twice daily, is more effective for prophylaxis than for acute attacks. Aspiration of the inflamed joint and intra-articular injection of triamcinolone, 10–40 mg, depending on the size of the joint, are also of value in resistant cases.

Pascual E et al. Synovial fluid analysis for crystals. *Curr Opin Rheumatol.* 2011 Mar;23(2):161–9. [PMID: 21285711]
 Richette P et al. An update on the epidemiology of calcium pyrophosphate dihydrate crystal deposition disease. *Rheumatology (Oxford).* 2009 Jul;48(7):711–5. [PMID: 19398486]

PAIN SYNDROMES

NECK PAIN



ESSENTIALS OF DIAGNOSIS

- ▶ Most chronic neck pain is caused by degenerative joint disease and responds to conservative approaches.
- ▶ Whiplash is the most common type of traumatic injury to the neck.
- ▶ Serious erosive disease of the atlantoaxial joint (C1–2) may lead to neurologic complications in patients with rheumatoid arthritis and ankylosing spondylitis.

▶ General Considerations

At any point in time, about 15% of adults are experiencing neck pain, which develops more commonly in women than in men. The prevalence of neck pain peaks at age 50. A large group of articular and extra-articular disorders are characterized by pain that may involve simultaneously the

neck, shoulder girdle, and upper extremity. Diagnostic differentiation may be difficult. Some represent primary disorders of the cervicobrachial region; others are local manifestations of systemic disease. It is frequently not possible to make a specific diagnosis.

▶ Clinical Findings

A. Symptoms and Signs

Neck pain may be limited to the posterior region or, depending on the level of the symptomatic joint, may radiate segmentally to the occiput, anterior chest, shoulder girdle, arm, forearm, and hand. It may be intensified by active or passive neck motions. The general distribution of pain and paresthesias corresponds roughly to the involved dermatome in the upper extremity. Radiating pain in the upper extremity is often intensified by hyperextension of the neck and deviation of the head to the involved side. Limitation of cervical movements is the most common objective finding. Neurologic signs depend on the extent of compression of nerve roots or the spinal cord. Compression of the spinal cord may cause paraparesis or paraplegia.

B. Imaging

The radiographic findings depend on the cause of the pain; many plain radiographs are completely normal in patients who have suffered an acute cervical strain. Loss of cervical lordosis is often seen but is nonspecific. In osteoarthritis, comparative reduction in height of the involved disk space is a frequent finding. The most common late radiographic finding is osteophyte formation anteriorly, adjacent to the disk; other chronic abnormalities occur around the apophysial joint clefts, chiefly in the lower cervical spine.

Use of advanced imaging techniques is indicated in the patient who has severe pain of unknown cause that fails to respond to conservative therapy or in the patient who has evidence of myelopathy. MRI is more sensitive than CT in detecting disk disease, extradural compression, and intramedullary cord disease. CT is preferable for demonstration of fractures.

▶ Differential Diagnosis & Treatment

The causes of neck pain include acute and chronic cervical strain or sprains, herniated nucleus pulposus, osteoarthritis, ankylosing spondylitis, rheumatoid arthritis, fibromyalgia, osteomyelitis, neoplasms, polymyalgia rheumatica, compression fractures, pain referred from visceral structures (eg, angina), and functional disorders.

A. Nonspecific Neck Pain

In the absence of trauma or evidence of infection, malignancy, neurologic findings, or systemic inflammation, the patient can be treated conservatively. Conservative therapy can include rest, analgesics, or physical therapy.

B. Acute Cervical Musculotendinous Strain

Cervical strain is generally caused by mechanical postural disorders, overexertion, or injury (eg, whiplash). Acute

episodes are associated with pain, decreased cervical spine motion, and paraspinal muscle spasm, resulting in stiffness of the neck and loss of motion. Muscle trigger points can often be localized. After whiplash injury, patients often experience not only neck pain but also shoulder girdle discomfort and headache. Management includes administration of analgesics. Soft cervical collars are commonly recommended, but evidence suggests they may delay recovery. Acupuncture, manipulation, or physical therapy can help some patients, but the precise role of these treatments is not well established. Corticosteroid injection into cervical facet joints is ineffective. Gradual return to full activity is encouraged.

C. Herniated Nucleus Pulposus

Rupture or prolapse of the nucleus pulposus of the cervical disks into the spinal canal causes pain radiating at a C6–7 level. When intra-abdominal pressure is increased by coughing, sneezing, or other movements, symptoms are aggravated, and cervical muscle spasm may occur. Neurologic abnormalities include decreased reflexes of the deep tendons of the biceps and triceps and decreased sensation and muscle atrophy or weakness in the forearm or hand. Cervical traction, bed rest, and other conservative measures are usually successful. Radicular symptoms usually respond to conservative therapy, including NSAIDs, activity modification, intermittent cervical traction, and neck immobilization. Cervical epidural corticosteroid injections may help those who fail conservative therapy. Surgery is indicated for unremitting pain and progressive weakness despite a full trial of conservative therapy and if a surgically correctable abnormality is identified by MRI or CT myelography. Surgical decompression achieves excellent results in 70–80% of such patients.

D. Arthritic Disorders

Cervical spondylosis (degenerative arthritis) is a collective term describing degenerative changes that occur in the apophysial joints and intervertebral disk joints, with or without neurologic signs. Osteoarthritis of the articular facets is characterized by progressive thinning of the cartilage, subchondral osteoporosis, and osteophytic proliferation around the joint margins. Degeneration of cervical disks and joints may occur in adolescents but is more common after age 40. Degeneration is progressive and is marked by gradual narrowing of the disk space, as demonstrated by radiography. Osteocartilaginous proliferation occurs around the margin of the vertebral body and gives rise to osteophytic ridges that may encroach upon the intervertebral foramina and spinal canal, causing compression of the neurovascular contents.

Osteoarthritis of the cervical spine is often asymptomatic but may cause diffuse neck pain. A minority of patients with neck pain also suffer from radicular pain or myelopathy. Myelopathy develops insidiously and is manifested by sensory dysfunction and clumsy hands. Some patients also complain of unsteady walking, urinary frequency and urgency, or electrical shock sensations with neck flexion or extension (Lhermitte sign). Weakness, sensory loss, and

spasticity with exaggerated reflexes develop below the level of spinal cord compression. Amyotrophic lateral sclerosis, multiple sclerosis, syringomyelia, spinal cord tumors, and tropical spastic paresis from HTLV-1 infection can mimic myelopathy from cervical arthritis. The mainstay of conservative therapy is immobilizing the cervical spine with a collar. With moderate to severe neurologic symptoms, surgical treatment is indicated.

Atlantoaxial subluxation may occur in patients with either rheumatoid arthritis or ankylosing spondylitis. Inflammation of the synovial structures resulting from erosion and laxity of the transverse ligament can lead to neurologic signs of spinal cord compression. Treatment may vary from use of a cervical collar or more rigid bracing to operative treatment, depending on the degree of subluxation and neurologic progression. Surgical treatment for stabilization of the cervical spine is a last resort.

E. Other Disorders

Osteomyelitis and neoplasms are discussed below. Osteoporosis is discussed in Chapter 26.

- Aas RW et al. Workplace interventions for neck pain in workers. *Cochrane Database Syst Rev*. 2011 Apr 13;(4):CD008160. [PMID: 21491405]
- Benjamin RM et al. Systematic review of the effectiveness of cervical epidurals in the management of chronic neck pain. *Pain Physician*. 2009 Jan–Feb;12(1):137–57. [PMID: 19165300]
- Eubanks JD. Cervical radiculopathy: nonoperative management of neck pain and radicular symptoms. *Am Fam Physician*. 2010 Jan 1;81(1):33–40. [PMID: 20052961]
- Goode AP et al. Prevalence, practice patterns, and evidence for chronic neck pain. *Arthritis Care Res (Hoboken)*. 2010 Nov; 62(11):1594–601. [PMID: 20521306]
- Haines T et al; Cervical Overview Group (COG). A Cochrane review of patient education for neck pain. *Spine J*. 2009 Oct; 9(10):859–71. [PMID: 19596214]

THORACIC OUTLET SYNDROMES

Thoracic outlet syndromes result from compression of the neurovascular structures supplying the upper extremity. Symptoms and signs arise from intermittent or continuous pressure on elements of the brachial plexus (> 90% of cases) or the subclavian or axillary vessels (veins or arteries) by a variety of anatomic structures of the shoulder girdle region. The neurovascular bundle can be compressed between the anterior or middle scalene muscles and a normal first thoracic rib or a cervical rib. Most commonly thoracic outlet syndromes are caused by scarred scalene neck muscle secondary to neck trauma or sagging of the shoulder girdle resulting from aging, obesity, or pendulous breasts. Faulty posture, occupation, or thoracic muscle hypertrophy from physical activity (eg, weight-lifting, baseball pitching) may be other predisposing factors.

Thoracic outlet syndromes present in most patients with some combination of four symptoms involving the upper extremity, namely pain, numbness, weakness, and swelling. The predominant symptoms depend on whether the compression chiefly affects neural or vascular structures. The onset of symptoms is usually gradual but can be

sudden. Some patients spontaneously notice aggravation of symptoms with specific positioning of the arm. Pain radiates from the point of compression to the base of the neck, the axilla, the shoulder girdle region, arm, forearm, and hand. Paresthesias are common and distributed to the volar aspect of the fourth and fifth digits. Sensory symptoms may be aggravated at night or by prolonged use of the extremities. Weakness and muscle atrophy are the principal motor abnormalities. Vascular symptoms consist of arterial ischemia characterized by pallor of the fingers on elevation of the extremity, sensitivity to cold, and, rarely, gangrene of the digits or venous obstruction marked by edema, cyanosis, and engorgement.

The symptoms of thoracic outlet syndromes can be provoked within 60 seconds over 90% of the time by having a patient elevate the arms in a “stick-em-up” position (ie, abducted 90 degrees in external rotation). Reflexes are usually not altered. Obliteration of the radial pulse with certain maneuvers of the arm or neck, once considered a highly sensitive sign of thoracic outlet obstruction, does not occur in most cases.

Chest radiography will identify patients with cervical rib (although most patients with cervical ribs are asymptomatic). MRI with the arms held in different positions is useful in identifying sites of impaired blood flow. Intra-arterial or venous obstruction is confirmed by angiography. Determination of conduction velocities of the ulnar and other peripheral nerves of the upper extremity may help localize the site of their compression.

Thoracic outlet syndrome must be differentiated from osteoarthritis of the cervical spine, tumors of the superior pulmonary sulcus, cervical spinal cord, or nerve roots, and periarthritis of the shoulder.

Treatment is directed toward relief of compression of the neurovascular bundle. Greater than 95% of patients can be treated successfully with conservative therapy consisting of physical therapy and avoiding postures or activities that compress the neurovascular bundle. Some women will benefit from a support bra. Operative treatment, required by < 5% of patients, is more likely to relieve the neurologic rather than the vascular component that causes symptoms.

Brooke BS et al. Contemporary management of thoracic outlet syndrome. *Curr Opin Cardiol*. 2010 Nov;25(6):535–40. [PMID: 20838336]

Fugate MW et al. Current management of thoracic outlet syndrome. *Curr Treat Options Cardiovasc Med*. 2009 Apr;11(2):176–83. [PMID: 19289030]

Povlsen B et al. Treatment for thoracic outlet syndrome. *Cochrane Database Syst Rev*. 2010 Jan 20;(1):CD007218. [PMID: 20091624]

LOW BACK PAIN

Up to 80% of the population experience low back pain at some time. The differential diagnosis is broad and includes muscular strain, primary spine disease (eg, disk herniation, degenerative arthritis), systemic diseases (eg, metastatic cancer), and regional diseases (eg, aortic aneurysm). A

precise diagnosis cannot be made in the majority of cases. Even when anatomic defects—such as vertebral osteophytes or a narrowed disk space—are present, causality cannot be assumed since such defects are common in asymptomatic patients. Most patients with acute onset of low back pain will improve in 1–4 weeks and need no evaluation beyond the initial history and physical examination. The diagnostic challenge is to identify those patients who require more extensive or urgent evaluation. In practice, this means identifying those patients with pain caused by (1) infection, (2) cancer, (3) inflammatory back disease such as ankylosing spondylitis, or (4) pain referred from abdominal or pelvic processes, such as an expanding aortic aneurysm. Significant or progressive neurologic deficits also require identification. If there is no evidence of these problems, conservative therapy is called for.

1. Clinical Approach to Diagnosis

▶ General History & Physical Examination

Low back pain is a final common pathway of many processes; the pain of vertebral osteomyelitis, for example, is not very different in quality and intensity from that due to back strain of the weekend gardener. Historical factors of importance include smoking, weight loss, age over 50, and cancer, all of which are risk factors for vertebral body metastasis. Osteomyelitis most frequently occurs in adults with a history of recurrent urinary tract infections and is especially common in diabetics and injection drug users. A history of a cardiac murmur should raise concern about endocarditis, since back pain is not an uncommon manifestation. A background of renal calculi might indicate another cause of referred back pain.

▶ History of Back Pain

Certain qualities of a patient's pain can indicate a specific diagnosis. Low back pain radiating down the buttock and below the knee suggests a herniated disk causing nerve root irritation. Other conditions—including sacroiliitis, facet joint degenerative arthritis, spinal stenosis, or irritation of the sciatic nerve from a wallet—also cause this pattern.

The diagnosis of disk herniation is further suggested by physical examination (see below) and confirmed by imaging techniques. Disk herniation can be asymptomatic, so its presence does not invariably link it to the symptom.

Low back pain at night, unrelieved by rest or the supine position, suggests the possibility of malignancy, either vertebral body metastasis (chiefly from prostate, breast, lung, multiple myeloma, or lymphoma) or a cauda equina tumor. Similar pain can also be caused by compression fractures (from osteoporosis or myeloma).

Symptoms of large or rapidly evolving neurologic deficits identify patients who need urgent evaluation for possible cauda equina tumor, epidural abscess or, rarely, massive disk herniation. When a herniated disk impinges a nerve root, pain is the most prominent symptom; numbness and weakness are less common and, when present, are of the magnitude consistent with compression of a single

nerve root. Symptoms of bilateral leg weakness (from multiple lumbar nerve root compressions) or of saddle area anesthesia, bowel or bladder incontinence, or impotence (indicating multiple sacral nerve root compressions) indicate a cauda equina process.

Low back pain that worsens with rest and improves with activity is characteristic of ankylosing spondylitis or other seronegative spondyloarthropathies, especially when the onset is insidious and begins before age 40. Most degenerative back diseases produce precisely the opposite pattern, with rest alleviating and activity aggravating the pain. Low back pain causing the patient to writhe occurs in renal colic but can also indicate a leaking aneurysm. The pain associated with pseudoclaudication from lumbar spinal stenosis is discussed below.

► Physical Examination of the Back

Several physical findings should be sought because they help identify those few patients who need more than conservative management.

Neurologic examination of the lower extremities will detect the small deficits produced by disk disease and the large deficits complicating such problems as cauda equina tumors. A positive straight leg raising test indicates nerve root irritation. The examiner performs the test on the supine patient by passively raising the patient's ipsilateral leg. The test is positive if radicular pain is produced with the leg raised 60 degrees or less. It has a specificity of 40% but is 95% sensitive in patients with herniation at the L4–5 or L5–S1 level (the sites of 95% of disk herniations). It can be falsely negative, especially in patients with herniation above the L4–5 level. The crossed straight leg sign is positive when raising the contralateral leg reproduces the sciatica. It has a sensitivity of 25% but is 90% specific for disk herniation.

Detailed examination of the sacral and lumbar nerve roots, especially L5 and S1, is essential for detecting neurologic deficits associated with back pain. Disk herniation produces deficits predictable for the site involved (Table 20–6). Deficits of multiple nerve roots suggest a cauda equina tumor or an epidural abscess, both requiring urgent evaluation and treatment.

Measurement of spinal motion in the patient with acute pain is rarely of diagnostic utility and usually simply confirms that pain limits motion. An exception is the decreased range of motion in multiple regions of the spine (cervical, thoracic, and lumbar) in a diffuse spinal disease such as

ankylosing spondylitis. By the time the patient has such limits, however, the diagnosis is usually straightforward.

If back pain is not severe and does not itself limit motion, the modified Schober test of lumbar motion is helpful in early diagnosis of ankylosing spondylitis. To perform this test, two marks are made with the patient upright: one 10 cm above the sacral dimples and another 5 cm below. The patient then bends forward as far as possible, and the distance between the points is measured. Normally, the distance increases from 15 cm to at least 20 cm. Anything less indicates reduced lumbar motion.

Palpation of the spine usually does not yield diagnostic information. Point tenderness over a vertebral body is reported to suggest osteomyelitis, but this association is uncommon. A step-off noted between the spinous process of adjacent vertebral bodies may indicate spondylolisthesis, but the sensitivity of this finding is extremely low. Tenderness of the soft tissues overlying the greater trochanter of the hip is a manifestation of trochanteric bursitis.

Inspection of the spine is not often of value in identifying serious causes of low back pain. The classic posture of ankylosing spondylitis is a late finding. Scoliosis of mild degree is not associated with an increased risk of clinical back disease. Cutaneous neurofibromas can identify the rare patient with nerve root encasement.

Examination of the hips should be part of the complete examination. While hip arthritis usually produces pain chiefly in the groin area, some patients have buttock or low back symptoms.

► Further Examination

If the history and physical examination do not suggest the presence of infection, cancer, inflammatory back disease, major neurologic deficits, or pain referred from abdominal or pelvic disease, further evaluation can be deferred while conservative therapy is tried. The great majority of patients will improve with conservative care over 1–4 weeks.

Regular radiographs of the lumbosacral spine give 20 times the radiation dose of a chest radiograph and provide limited, albeit important, information. Oblique films double the radiation dose and are not routinely needed. Radiographs can provide evidence of vertebral body osteomyelitis, cancer, fractures, or ankylosing spondylitis. Degenerative changes in the lumbar spine are ubiquitous in patients over 40 and do not prove clinical disease. Plain radiographs have very low sensitivity or specificity for disk disease. Thus, plain radiographs are warranted promptly for patients suspected of having infection, cancer, or fractures; selected other patients who do not improve after 2–4 weeks of conservative therapy are also candidates. The Agency for Healthcare Research and Quality guidelines for obtaining lumbar radiographs are summarized in Table 20–7.

MRI provides exquisite anatomic detail but is reserved for patients who are considering surgery or have evidence of a systemic disease. For example, MRI is needed urgently for any patient in whom an epidural mass or cauda equina tumor is suspected but not for a patient believed to have a routine disk herniation, since most will improve over 4–6 weeks of conservative therapy. Noncontrast CT does not

Table 20–6. Neurologic testing of lumbosacral nerve disorders.

Nerve Root	Motor	Reflex	Sensory Area
L4	Dorsiflexion of foot	Knee jerk	Medial calf
L5	Dorsiflexion of great toe	None	Medial forefoot
S1	Plantar flexion of foot	Ankle jerk	Lateral foot

Table 20-7. AHRQ criteria for lumbar radiographs in patients with acute low back pain.**Possible fracture**

Major trauma
 Minor trauma in patients > 50 years
 Long-term corticosteroid use
 Osteoporosis
 > 70 years

Possible tumor or infection

> 50 years
 < 20 years
 History of cancer
 Constitutional symptoms
 Recent bacterial infection
 Injection drug use
 Immunosuppression
 Supine pain
 Nocturnal pain

AHRQ, Agency for Healthcare Research and Quality. Reproduced, with permission, from Suarez-Almazor et al. Use of lumbar radiographs for the early diagnosis of low back pain. Proposed guidelines would increase utilization. *JAMA*. 1997 Jun; 277:1782-6.

image cauda equina tumors or other intradural lesions, and if used instead of MRI it must include intrathecal contrast.

Radionuclide bone scanning has limited usefulness. It is most useful for early detection of vertebral body osteomyelitis or osteoblastic metastases. The bone scan is normal in multiple myeloma because lytic lesions do not take up isotope.

2. Management

While any management plan must be individualized, key elements of most conservative treatments for back pain include analgesia and education. Analgesia can usually be provided with NSAIDs (see Table 5-3), but severe pain may require opioids (see Table 5-4). Rarely does the need for opioids extend beyond 1-2 weeks.

Diazepam, cyclobenzaprine, carisoprodol, and methocarbamol have been prescribed as muscle relaxants, though their sedative effects may limit their use. They should be reserved for patients who do not respond to NSAIDs and usually are needed only for 1-2 weeks, which reduces the chance of dependence. Their use should be avoided in older patients, who are at risk for falling. All patients should be taught how to protect the back in daily activities—ie, not to lift heavy objects, to use the legs rather than the back when lifting, to use a chair with arm rests, and to rise from bed by first rolling to one side and then using the arms to push to an upright position. Back manipulation for benign, mechanical low back pain appears safe and as effective as therapies provided by clinicians.

Rest and back exercises, once thought to be cornerstones of conservative therapy, are now known to be ineffective for acute back pain. Advice to rest in bed is less effective than advice to remain active. No bed rest with

continuation of ordinary activities as tolerated is superior to 2 days of bed rest, 7 days of bed rest, and back mobilizing exercises. Similarly, for acute back pain, exercise therapy is not effective. The value of corsets or traction is dubious. Epidural corticosteroid injections can provide short-term relief of sciatica but do not improve functional status or reduce the need for surgery. In double-blind studies, repeated injections have been no more effective than a single injection. For chronic low back pain, yoga is as effective as a back exercise program and more effective than a self-care book. Corticosteroid injections into facet joints are ineffective for chronic low back pain. Massage therapy is effective for treatment of chronic back pain, with benefits lasting at least 6 months.

Surgical consultation is needed urgently for any patient with a major or evolving neurologic deficit. Randomized controlled trials have shown that for sciatica caused by disk herniation, conservative treatment and surgery achieve similar 1-year outcomes; however, pain relief and perceived recovery were obtained more quickly with surgery. Surgery tends to ameliorate leg pain more quickly and fully than back pain.

Complaints without objective findings suggest a psychological role in symptom formation. Treatment includes reassurance and nonopioid analgesics.

▶ When to Refer

- Suspected malignancy.
- Inflammatory low back pain.

▶ When to Admit

- Neurologic signs indicative of cauda equina syndrome.
- Vertebral osteomyelitis.

Cherkin DC et al. A comparison of the effects of 2 types of massage and usual care on chronic low back pain: a randomized, controlled trial. *Ann Intern Med*. 2011 Jul 5;155(1):1-9. [PMID: 21727288]

Chou R et al; Clinical Guidelines Committee of the American College of Physicians. Diagnostic imaging for low back pain: advice for high-value health care from the American College of Physicians. *Ann Intern Med*. 2011 Feb 1;154(3):181-9. [PMID: 21282698]

Chou R et al. Nonsurgical interventional therapies for low back pain: a review of the evidence for an American Pain Society clinical practice guideline. *Spine (Phila Pa 1976)*. 2009 May 1;34(10):1078-93. [PMID: 19363456]

Chou R et al. Will this patient develop persistent disabling low back pain? *JAMA*. 2010 Apr 7;303(13):1295-302. [PMID: 20371789]

Hildreth CJ et al. JAMA patient page. Sciatica. *JAMA*. 2009 Jul 8;302(2):216. [PMID: 19584353]

Weinstein JN et al. Surgical compared with nonoperative treatment for lumbar degenerative spondylolisthesis: four-year results in the Spine Patient Outcomes Research Trial (SPORT) randomized and observational cohorts. *J Bone Joint Surg Am*. 2009 Jun;91(6):1295-304. [PMID: 19487505]

Wilkens P et al. Effect of glucosamine on pain-related disability in patients with chronic low back pain and degenerative lumbar osteoarthritis: a randomized controlled trial. *JAMA*. 2010 Jul 7;304(1):45-52. [PMID: 20606148]

LUMBAR SPINAL STENOSIS



ESSENTIALS OF DIAGNOSIS

- ▶ Most patients are older than 60 years.
- ▶ Presenting symptom is often back pain radiating to the buttocks and thighs.
- ▶ Pain often interferes with walking, worsens with lumbar extension, and improves with lumbar flexion.
- ▶ Back and leg pain often associated with numbness and paresthesias.
- ▶ Preservation of pedal pulses helps exclude vascular claudication.
- ▶ Diagnosis best confirmed by MRI.

▶ General Considerations

Lumbar spinal stenosis, defined as narrowing of the spinal canal with compression of the nerve roots, may be congenital or (more commonly) acquired. It most frequently results from enlarging osteophytes at the facet joints, hypertrophy of the ligamentum flavum, and protrusion or bulging of intervertebral disks. Lumbar spinal stenosis may produce symptoms by directly compressing nerve roots or by compressing nutrient arterioles that supply the nerve roots.

▶ Clinical Findings

A. Symptoms and Signs

Most patients with lumbar spinal stenosis are over 60 years old and complain of either leg pain or trouble walking. The pain may originate in the low back but will extend below the buttock into the thigh in nearly 90% of patients. In approximately 50% of patients, the pain will extend below the knee. The pain is often a combination of aching and numbness, which characteristically worsens with walking. The pain can also be brought on by prolonged standing. Not infrequently the symptoms are bilateral. Many patients are more troubled by poor balance, unsteadiness of gait, or leg weakness that develops as they walk. Some describe these neuroclaudication symptoms as developing “spaghetti legs” or “walking like a drunk sailor.” Because the lumbar spinal canal volume increases with back flexion and decreases with extension, some patients observe that they have fewer symptoms walking uphill than down. The back and lower extremity examination in patients with lumbar spinal stenosis is often unimpressive. Less than 10% have a positive straight leg raise sign, 25% have diminished deep tendon reflexes, and 60% have slight proximal weakness. Walking with the patient may reveal unsteadiness, although usually the patient’s perception of gait disturbance is greater than that of an observer.

B. Imaging

The diagnosis of spinal stenosis in a patient with symptoms is best confirmed by MRI.

▶ Differential Diagnosis

The onset of symptoms with standing, the location of the maximal discomfort to the thighs, and the preservation of pedal pulses help distinguish the “pseudoclaudication” of spinal stenosis from true claudication caused by vascular insufficiency. Distinguishing spinal stenosis from disk herniation can be challenging since both conditions can produce pain radiating down the back of the leg. Features that favor spinal stenosis are the gradual onset of symptoms, the marked exacerbation with walking, and the amelioration of symptoms with sitting or lumbar flexion. Complaints of bilateral aching in the buttocks associated with stiffness may make some practitioners consider the diagnosis of polymyalgia rheumatica. However, patients with lumbar spinal stenosis do not have the shoulder or neck symptoms characteristic of polymyalgia rheumatica.

▶ Treatment

Weight loss and exercises aimed at reducing lumbar lordosis, which aggravates symptoms of spinal stenosis, can help. Lumbar epidural corticosteroid injections provide some immediate relief for about 50% of patients and more sustained relief for approximately 25%. When disabling symptoms persist, surgery will reduce pain and improve function substantially in approximately 75% of patients at 1 and 2 years; only about 25% of patients treated conservatively will experience a similar improvement.

Genevay S et al. Lumbar spinal stenosis. *Best Pract Res Clin Rheumatol.* 2010 Apr;24(2):253–65. [PMID: 20227646]

Tran de QH et al. Lumbar spinal stenosis: a brief review of the nonsurgical management. *Can J Anaesth.* 2010 Jul;57(7):694–703. [PMID: 20428988]

Weinstein JN et al. Surgical compared with nonoperative treatment for lumbar degenerative spondylolisthesis: four-year results in the Spine Patient Outcomes Research Trial (SPORT) randomized and observational cohorts. *J Bone Joint Surg Am.* 2009 Jun;91(6):1295–304. [PMID: 19487505]

FIBROMYALGIA



ESSENTIALS OF DIAGNOSIS

- ▶ Most frequent in women aged 20–50.
- ▶ Chronic widespread musculoskeletal pain syndrome with multiple tender points.
- ▶ Fatigue, headaches, numbness common.
- ▶ Objective signs of inflammation absent; laboratory studies normal.

▶ General Considerations

Fibromyalgia is one of the most common rheumatic syndromes in ambulatory general medicine affecting 3–10% of the general population. It shares many features with the chronic fatigue syndrome, namely, an increased frequency

among women aged 20–50, absence of objective findings, and absence of diagnostic laboratory test results. While many of the clinical features of the two conditions overlap, musculoskeletal pain predominates in fibromyalgia whereas lassitude dominates the chronic fatigue syndrome.

The cause is unknown, but aberrant perception of painful stimuli, sleep disorders, depression, and viral infections have all been proposed. Fibromyalgia can be a rare complication of hypothyroidism, rheumatoid arthritis or, in men, sleep apnea.

► Clinical Findings

The patient complains of chronic aching pain and stiffness, frequently involving the entire body but with prominence of pain around the neck, shoulders, low back, and hips. Fatigue, sleep disorders, subjective numbness, chronic headaches, and irritable bowel symptoms are common. Even minor exertion aggravates pain and increases fatigue. Physical examination is normal except for “trigger points” of pain produced by palpation of various areas such as the trapezius, the medial fat pad of the knee, and the lateral epicondyle of the elbow.

► Differential Diagnosis

Fibromyalgia is a diagnosis of exclusion. A detailed history and repeated physical examination can obviate the need for extensive laboratory testing. Rheumatoid arthritis and systemic lupus erythematosus (SLE) present with objective physical findings or abnormalities on routine testing. Thyroid function tests are useful, since hypothyroidism can produce a secondary fibromyalgia syndrome. Polymyositis produces weakness rather than pain. The diagnosis of fibromyalgia probably should be made hesitantly in a patient over age 50 and should never be invoked to explain fever, weight loss, or any other objective signs. Polymyalgia rheumatica produces shoulder and pelvic girdle pain, is associated with anemia and an elevated ESR, and occurs after age 50. Hypophosphatemic states, such as oncogenic osteomalacia, should also be included in the differential diagnosis of musculoskeletal pain unassociated with physical findings. In contrast to fibromyalgia, oncogenic osteomalacia usually produces pain in only a few areas and is associated with a low serum phosphate level.

► Treatment

A multidisciplinary approach is most effective. Patient education is essential. Patients can be comforted that they have a diagnosable syndrome treatable by specific though imperfect therapies and that the course is not progressive. Cognitive behavioral therapy, including programs that emphasize mindfulness meditation is often helpful. There is modest efficacy of amitriptyline, fluoxetine, duloxetine, milnacipran, chlorpromazine, cyclobenzaprine, pregabalin, or gabapentin. Amitriptyline is initiated at a dosage of 10 mg orally at bedtime and gradually increased to 40–50 mg depending on efficacy and toxicity. Less than 50% of the patients experience a sustained improvement. Exercise programs are also beneficial. NSAIDs are generally ineffective. Tramadol and

acetaminophen combinations have ameliorated symptoms modestly in short-term trials. Opioids and corticosteroids are ineffective and should not be used to treat fibromyalgia. Acupuncture is also ineffective.

► Prognosis

All patients have chronic symptoms. With treatment, however, many do eventually resume increased activities. Progressive or objective findings do not develop.

Arnold LM et al. Flexible dosed duloxetine in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled trial. *J Rheumatol.* 2010 Dec;37(12):2578–86. [PMID: 20843911]

Häuser W et al. Efficacy of multicomponent treatment in fibromyalgia syndrome: a meta-analysis of randomized controlled clinical trials. *Arthritis Rheum.* 2009 Feb 15;61(2):216–24. [PMID: 19177530]

Moore RA et al. Gabapentin for chronic neuropathic pain and fibromyalgia in adults. *Cochrane Database Syst Rev.* 2011 Mar 16;(3):CD007938. [PMID: 21412914]

van Koulil S et al. Tailored cognitive-behavioral therapy and exercise training for high-risk patients with fibromyalgia. *Arthritis Care Res (Hoboken).* 2010 Oct;62(10):1377–85. [PMID: 20521308]

CARPAL TUNNEL SYNDROME

ESSENTIALS OF DIAGNOSIS

- Begins as pain, burning, and tingling in the distribution of the median nerve.
- Symptoms initially most bothersome at night.
- Weakness or atrophy, especially of the thenar eminence, appears later.
- Common in occupations that require repetitive wrist motion and in pregnancy, diabetes, and rheumatoid arthritis.

► General Considerations

An entrapment neuropathy, carpal tunnel syndrome is a painful disorder caused by compression of the median nerve between the carpal ligament and other structures within the carpal tunnel. The contents of the tunnel can be compressed by synovitis of the tendon sheaths or carpal joints, recent or malhealed fractures, tumors, and occasionally congenital anomalies. Even though no anatomic lesion is apparent, flattening or even circumferential constriction of the median nerve may be observed during operative section of the ligament. The disorder may occur in pregnancy, is seen in individuals with a history of repetitive use of the hands, and may follow injuries of the wrists. There is a familial type of carpal tunnel syndrome in which no etiologic factor can be identified.

Carpal tunnel syndrome can also be a feature of many systemic diseases: rheumatoid arthritis and other rheumatic disorders (inflammatory tenosynovitis); myxedema,

localized amyloidosis in chronic kidney disease, sarcoidosis, and leukemia (tissue infiltration); acromegaly; and hyperparathyroidism.

► Clinical Findings

The initial symptoms are pain, burning, and tingling in the distribution of the median nerve (the palmar surfaces of the thumb, the index and long fingers, and the radial half of the ring finger). Aching pain may radiate proximally into the forearm and occasionally proximally to the shoulder and over the neck and chest. Pain is exacerbated by manual activity, particularly by extremes of volar flexion or dorsiflexion of the wrist. It is most bothersome at night. Impairment of sensation in the median nerve distribution may or may not be demonstrable. Subtle disparity between the affected and opposite sides can be shown by testing for two-point discrimination or by requiring the patient to identify different textures of cloth by rubbing them between the tips of the thumb and the index finger. Tinel or Phalen sign may be positive. (Tinel sign is tingling or shock-like pain elicited by tapping the volar surface of the wrist; Phalen sign is pain or paresthesia in the distribution of the median nerve when the patient flexes both wrists to 90 degrees for 60 seconds.) The carpal compression test, in which numbness and tingling are induced by the direct application of pressure over the carpal tunnel, may be more sensitive and specific than the Tinel and Phalen tests. Muscle weakness or atrophy, especially of the thenar eminence, appears later than sensory disturbances. Specific examinations include electromyography and determinations of segmental sensory and motor conduction delay. Sensory conduction delay is evident before motor delay.

► Differential Diagnosis

This syndrome should be differentiated from other cervicobrachial pain syndromes, from compression syndromes of the median nerve in the forearm or arm, and from mononeuritis multiplex. When left-sided, it may be confused with angina pectoris.

► Treatment

Treatment is directed toward relief of pressure on the median nerve. When a causative lesion is discovered, it is treated appropriately. Otherwise, patients in whom carpal tunnel syndrome is suspected should modify their hand activities and have the affected wrist splinted for 2–6 weeks. NSAIDs can also be added. Patients should be referred to a specialist for injection of corticosteroid into the carpal tunnel or for operation when they do not improve or when thenar muscle atrophy or weakness develops. Muscle strength returns gradually, but complete recovery cannot be expected when atrophy is pronounced.

► When to Refer

- Refer to a hand surgeon if symptoms persist despite the use of wrist splints.
- Refer to a hand surgeon if weakness or thenar atrophy develops.

Atroshi I et al. Incidence of physician-diagnosed carpal tunnel syndrome in the general population. *Arch Intern Med.* 2011 May 23;171(10):943–4. [PMID: 21606100]

Huisstede BM et al. Carpal tunnel syndrome. Part I: effectiveness of nonsurgical treatments—a systematic review. *Arch Phys Med Rehabil.* 2010 Jul;91(7):981–1004. [PMID: 20599038]

Huisstede BM et al. Carpal tunnel syndrome. Part II: effectiveness of surgical treatments—a systematic review. *Arch Phys Med Rehabil.* 2010 Jul;91(7):1005–24. [PMID: 20599039]

Jarvik JG et al. Surgery versus non-surgical therapy for carpal tunnel syndrome: a randomised parallel-group trial. *Lancet.* 2009 Sep 26;374(9695):1074–81. [PMID: 19782873]

DUPUYTREN CONTRACTURE

This relatively common disorder is characterized by hyperplasia of the palmar fascia and related structures, with nodule formation and contracture of the palmar fascia. The cause is unknown, but the condition has a genetic predisposition and occurs primarily in white men over 50 years of age. The incidence is higher among alcoholic patients and those with chronic systemic disorders (especially cirrhosis). It is also associated with systemic fibrosing syndrome, which includes Peyronie disease, mediastinal and retroperitoneal fibrosis, and Riedel struma. The onset may be acute, but slowly progressive chronic disease is more common.

Dupuytren contracture manifests itself by nodular or cord-like thickening of one or both hands, with the fourth and fifth fingers most commonly affected. The patient may complain of tightness of the involved digits, with inability to satisfactorily extend the fingers, and on occasion there is tenderness. The resulting cosmetic problems may be unappealing, but in general the contracture is well tolerated since it exaggerates the normal position of function of the hand. Fasciitis involving other areas of the body may lead to plantar fibromatosis (10% of patients) or Peyronie disease (1–2%).

If the palmar nodule is growing rapidly, injections of triamcinolone or collagenase into the nodule may be of benefit. Surgical intervention is indicated in patients with significant flexion contractures, depending on the location, but recurrence is not uncommon.

Hurst LC et al; CORD I Study Group. Injectable collagenase clostridium histolyticum for Dupuytren's contracture. *N Engl J Med.* 2009 Sep 3;361(10):968–79. [PMID: 19726771]

COMPLEX REGIONAL PAIN SYNDROME

Complex regional pain syndrome (formerly called reflex sympathetic dystrophy) is a rare disorder of the extremities characterized by autonomic and vasomotor instability. The cardinal symptoms and signs are pain localized to an arm or leg, swelling of the involved extremity, disturbances of color and temperature in the affected limb, dystrophic changes in the overlying skin and nails, and limited range of motion. Strikingly, the findings are not limited to the distribution of a single peripheral nerve. Most cases are preceded by direct physical trauma, often of relatively

minor nature, to the soft tissues, bone, or nerve. Early mobilization after injury or surgery reduces the likelihood of developing the syndrome. Vitamin C, 500 mg/d orally, is effective in reducing the risk of complex regional pain syndrome following wrist fracture. Any extremity can be involved, but the syndrome most commonly occurs in the hand and is associated with ipsilateral restriction of shoulder motion (shoulder-hand syndrome). The syndrome proceeds through phases: pain, swelling, and skin color and temperature changes develop early and, if untreated, lead to atrophy and dystrophy. The swelling in complex regional pain syndrome is diffuse (“catcher’s mitt hand”) and not restricted to joints. Pain is often burning in quality, intense, and often greatly worsened by minimal stimuli such as light touch. The shoulder-hand variant of this disorder sometimes complicates myocardial infarction or injuries to the neck or shoulder. Complex regional pain syndrome may occur after a knee injury or after arthroscopic knee surgery. There are no systemic symptoms. In the early phases of the syndrome, bone scans are sensitive, showing diffuse increased uptake in the affected extremity. Radiographs eventually reveal severe generalized osteopenia. In the posttraumatic variant, this is known as Sudeck atrophy. Symptoms and findings are bilateral in some. This syndrome should be differentiated from other cervicobrachial pain syndromes, rheumatoid arthritis, thoracic outlet obstruction, and scleroderma, among others.

Early treatment offers the best prognosis for recovery. For mild cases, NSAIDs (eg, naproxen 250–500 mg twice daily orally) can be effective. For more severe cases associated with edema, prednisone, 30–60 mg/d orally for 2 weeks and then tapered over 2 weeks, can be effective. Pain management is important and facilitates physical therapy, which plays a critical role in efforts to restore function. Some patients will also benefit from antidepressant agents (eg, nortriptyline initiated at a dosage of 10 mg orally at bedtime and gradually increased to 40–75 mg at bedtime) or from anticonvulsants (eg, gabapentin 300 mg three times daily orally). Bisphosphonates, calcitonin, intravenous immunoglobulin, regional nerve blocks and dorsal-column stimulation have also been demonstrated to be helpful. Patients who have restricted shoulder motion may benefit from the treatment described for scapulohumeral periarthritis. The prognosis partly depends on the stage in which the lesions are encountered and the extent and severity of associated organic disease.

Bruehl S. An update on the pathophysiology of complex regional pain syndrome. *Anesthesiology*. 2010 Sep;113(3):713–25. [PMID: 20693883]

Goebel A et al. Intravenous immunoglobulin treatment of the complex regional pain syndrome: a randomized trial. *Ann Intern Med*. 2010 Feb 2;152(3):152–8. [PMID: 20124231]

BURSITIS

Inflammation of bursae—the synovium-like cellular membranes overlying bony prominences—may be secondary to trauma, infection, or arthritic conditions such as gout, rheumatoid arthritis, or osteoarthritis. The most common



▲ **Figure 20-3.** Aseptic olecranon bursitis secondary to repetitive trauma. (Courtesy of Richard P. Usatine, MD; used, with permission, from Usatine RP, Smith MA, Mayeaux EJ Jr, Chumley H, Tysinger J. *The Color Atlas of Family Medicine*. McGraw-Hill, 2009.)

locations are the subdeltoid, olecranon (Figure 20-3), ischial, trochanteric, semimembranosus-gastrocnemius (Baker cyst), and prepatellar bursae.

There are several ways to distinguish bursitis from arthritis. Bursitis is more likely than arthritis to cause focal tenderness and swelling and less likely to affect range of motion of the adjacent joint. Olecranon bursitis, for example, causes an oval (or, if chronic, bulbous) swelling at the tip of the elbow and does not affect elbow motion, whereas an elbow joint inflammation produces more diffuse swelling and reduces range of motion. Similarly, a patient with prepatellar bursitis has a small focus of swelling over the kneecap but no distention of the knee joint itself and preserved knee motion. A patient with trochanteric bursitis will have tenderness over the greater trochanter and normal internal rotation of the hip; a patient with hip arthritis usually will have reduced internal rotation. Bursitis caused by trauma responds to local heat, rest, NSAIDs, and local corticosteroid injections.

Bursitis can result from infection. The two most common sites are the olecranon and prepatellar bursae. Acute swelling and redness at either of these two sites calls for aspiration to rule out infection. The absence of fever does not exclude infection; one-third of those with septic olecranon bursitis are afebrile. A bursal fluid white blood cell count of >1000/mcL indicates inflammation from infection, rheumatoid arthritis, or gout. In septic bursitis, the white cell count averages over 50,000/mcL. Most cases are caused by *Staphylococcus aureus*; the Gram stain is positive in two-thirds. Treatment involves antibiotics and aspiration for tense effusions.

Chronic, stable olecranon bursa swelling usually does not require aspiration. Aspiration of the olecranon bursa runs the risk of creating a chronic drainage site, which can be reduced by using a “zig-zag” approach with a small needle (25-gauge if possible) and pulling the skin over the bursa before introducing it. Applying a pressure bandage may also help prevent chronic drainage. Surgical removal of the bursa is indicated only for cases in which repeated infections occur. Repetitive minor trauma to the olecranon bursa should be eliminated by avoiding resting the elbow on a hard surface or by wearing an elbow pad.

A bursa can also become symptomatic when it ruptures. This is particularly true for Baker cyst, whose rupture can cause calf pain and swelling that mimic thrombophlebitis. Ruptured Baker cysts are imaged easily by sonography or MRI. In most cases, imaging is unnecessary because the cyst and an associated knee effusion are detectable on physical examination. It may be important to exclude a deep venous thrombosis, which can be mimicked by a ruptured Baker cyst. Treatment of a ruptured cyst includes rest, leg elevation, and injection of triamcinolone, 20–40 mg into the knee anteriorly (the knee compartment communicates with the cyst). Rarely, Baker cyst can compress vascular structures and cause leg edema and true thrombophlebitis.

Rowand M et al. Clinical inquiries. How should you treat trochanteric bursitis? *J Fam Pract.* 2009 Sep;58(9):494–500. [PMID: 19744419]

AUTOIMMUNE DISEASES

RHEUMATOID ARTHRITIS

ESSENTIALS OF DIAGNOSIS

- ▶ Usually insidious onset with morning stiffness and pain in affected joints.
- ▶ Symmetric polyarthritis with predilection for small joints of the hands and feet; deformities common with progressive disease.
- ▶ Radiographic findings: juxta-articular osteoporosis, joint erosions, and joint space narrowing.
- ▶ Rheumatoid factor and antibodies to cyclic citrullinated peptides (anti-CCP) are present in 70–80%.
- ▶ Extra-articular manifestations: subcutaneous nodules, interstitial lung disease, pleural effusion, pericarditis, splenomegaly with leukopenia, and vasculitis.

▶ General Considerations

Rheumatoid arthritis is a chronic systemic inflammatory disease whose major manifestation is synovitis of multiple joints. It has a prevalence of 1% and is more common in women than men (female:male ratio of 3:1). Rheumatoid

arthritis can begin at any age, but the peak onset is in the fourth or fifth decade for women and the sixth to eighth decades for men. The cause is not known. Susceptibility to rheumatoid arthritis is genetically determined with multiple genes contributing. Inheritance of class II HLA molecules with a distinctive five-amino-acid sequence known as the “shared epitope” is the best characterized genetic risk factor. Untreated, rheumatoid arthritis causes joint destruction with consequent disability and shortens life expectancy. Early, aggressive treatment is the standard of care.

The pathologic findings in the joint include chronic synovitis with formation of a pannus, which erodes cartilage, bone, ligaments, and tendons. In the acute phase, effusion and other manifestations of inflammation are common. In the late stage, organization may result in fibrous ankylosis; true bony ankylosis is rare.

▶ Clinical Findings

A. Symptoms and Signs

1. Joint symptoms—The clinical manifestations of rheumatoid disease are highly variable, but joint symptoms usually predominate. Although acute presentations may occur, the onset of articular signs of inflammation is usually insidious, with prodromal symptoms of vague periarticular pain or stiffness. Symmetric swelling of multiple joints with tenderness and pain is characteristic. Monarticular disease is occasionally seen initially. Stiffness persisting for > 30 minutes (and usually many hours) is prominent in the morning. Stiffness may recur after daytime inactivity and be much more severe after strenuous activity. Although any diarthrodial joint may be affected, PIP joints of the fingers, MCP joints (Figure 20–4), wrists, knees, ankles, and MTP joints



▲ **Figure 20–4.** Rheumatoid arthritis with ulnar deviation at the metacarpophalangeal (MCP) joints. (Courtesy of Richard P. Usatine, MD; used, with permission, from Usatine RP, Smith MA, Mayeaux EJ Jr, Chumley H, Tysinger J. *The Color Atlas of Family Medicine.* McGraw-Hill, 2009.)

are most often involved. Synovial cysts and rupture of tendons may occur. Entrapment syndromes are not unusual—particularly of the median nerve at the carpal tunnel of the wrist. Rheumatoid arthritis can affect the neck but spares the other components of the spine and does not involve the sacroiliac joints. In advanced disease, atlantoaxial (C1–C2) subluxation can lead to myelopathy.

2. Rheumatoid nodules—Twenty percent of patients have subcutaneous rheumatoid nodules, most commonly situated over bony prominences but also observed in the bursae and tendon sheaths (Figure 20–5). Nodules are occasionally seen in the lungs, the sclerae, and other tissues. Nodules correlate with the presence of rheumatoid factor in serum (“seropositivity”), as do most other extra-articular manifestations.

3. Ocular symptoms—Dryness of the eyes, mouth, and other mucous membranes is found especially in advanced disease (see Sjögren syndrome). Other ocular manifestations include episcleritis, scleritis, and scleromalacia due to scleral nodules.

4. Other symptoms—Interstitial lung disease is not uncommon (estimates of prevalence vary widely according to method of detection) and manifests clinically as cough and progressive dyspnea. Pericarditis and pleural disease, when present, are usually silent clinically. Patients with active joint disease often have palmar erythema. Occasionally, a small vessel vasculitis develops and manifests as tiny hemorrhagic infarcts in the nail folds or finger pulps. Although necrotizing arteritis is well reported, it is



▲ **Figure 20–5.** Rheumatoid nodules over the extensor surface of the forearm. (Courtesy of Richard P. Usatine, MD; used, with permission, from Usatine RP, Smith MA, Mayeaux EJ Jr, Chumley H, Tysinger J. *The Color Atlas of Family Medicine*. McGraw-Hill, 2009.)

rare. A small subset of patients with rheumatoid arthritis have Felty syndrome, the occurrence of splenomegaly and neutropenia, usually in the setting of severe, destructive arthritis. Felty syndrome must be distinguished from the large granular lymphocyte syndrome, with which it shares many features.

Aortitis is a rare late complication that can result in aortic regurgitation or rupture and is usually associated with evidence of rheumatoid vasculitis elsewhere in the body.

B. Laboratory Findings

Anti-CCP antibodies and rheumatoid factor, an IgM antibody directed against the Fc fragment of IgG, are present in 70–80% of patients with established rheumatoid arthritis but have sensitivities of only 50% in early disease. Anti-CCP antibodies are the most specific blood test for rheumatoid arthritis (specificity ~95%). Rheumatoid factor can occur in other autoimmune disease and in chronic infections, including hepatitis C, syphilis, subacute bacterial endocarditis, and tuberculosis. The prevalence of rheumatoid factor positivity also rises with age in healthy individuals. Approximately 20% of rheumatoid patients have antinuclear antibodies.

The ESR and levels of C-reactive protein are typically elevated in proportion to disease activity. A moderate hypochromic normocytic anemia is common. The white cell count is normal or slightly elevated, but leukopenia may occur, often in the presence of splenomegaly (eg, Felty syndrome). The platelet count is often elevated, roughly in proportion to the severity of overall joint inflammation. Initial joint fluid examination confirms the inflammatory nature of the arthritis. (See Table 20–2.) Arthrocentesis is needed to diagnose superimposed septic arthritis, which is a common complication of rheumatoid arthritis and should be considered whenever a patient with rheumatoid arthritis has one joint inflamed out of proportion to the rest.

C. Imaging

Of all the laboratory tests, radiographic changes are the most specific for rheumatoid arthritis. Radiographs obtained during the first 6 months of symptoms, however, are usually normal. The earliest changes occur in the wrists or feet and consist of soft tissue swelling and juxta-articular demineralization. Later, diagnostic changes of uniform joint space narrowing and erosions develop. The erosions are often first evident at the ulnar styloid and at the juxta-articular margin, where the bony surface is not protected by cartilage. Diagnostic changes also occur in the cervical spine, with C1–2 subluxation, but these changes usually take many years to develop. Although both MRI and ultrasonography are more sensitive than radiographs in detecting bony and soft tissue changes in rheumatoid arthritis, their value in early diagnosis relative to that of plain radiographs has not been established.

► Differential Diagnosis

The differentiation of rheumatoid arthritis from other joint conditions and immune-mediated disorders can be difficult.

In 2010, the American College of Rheumatology updated their classification criteria for rheumatoid arthritis. In contrast to rheumatoid arthritis, osteoarthritis spares the wrist and the MCP joints. Osteoarthritis is not associated with constitutional manifestations, and the joint pain is characteristically relieved by rest, unlike the morning stiffness of rheumatoid arthritis. Signs of articular inflammation, prominent in rheumatoid arthritis, are usually minimal in degenerative joint disease. CPPD deposition disease can cause a degenerative arthropathy of the MCPs and wrists; radiographs are usually diagnostic. Although gouty arthritis is almost always intermittent and monoarticular in the early years, it may evolve with time into a chronic polyarticular process that mimics rheumatoid arthritis. Gouty tophi can resemble rheumatoid nodules both in typical location and appearance. The early history of intermittent monoarthritis and the presence of synovial urate crystals are distinctive features of gout. Spondyloarthropathies, particularly earlier in their course, can be a source of diagnostic uncertainty; predilection for lower extremities and involvement of the spine and sacroiliac joints point to the correct diagnosis. Chronic Lyme arthritis typically involves only one joint, most commonly the knee, and is associated with positive serologic tests (see Chapter 34). Human parvovirus B19 infection in adults can mimic early rheumatoid arthritis. However, arthralgias are more prominent than arthritis, fever is common, IgM antibodies to parvovirus B19 are present, and the arthritis usually resolves within weeks. Infection with hepatitis C can cause a chronic nonerosive polyarthritis associated with rheumatoid factor; tests for anti-CCP antibodies are negative.

Malar rash, photosensitivity, discoid skin lesions, alopecia, high titer antibodies to double-stranded DNA, glomerulonephritis, and central nervous system abnormalities point to the diagnosis of SLE. Polymyalgia rheumatica occasionally causes polyarthralgias in patients over age 50, but these patients remain rheumatoid factor–negative and have chiefly proximal muscle pain and stiffness, centered on the shoulder and hip girdles. Rheumatic fever is characterized by the migratory nature of the arthritis, an elevated antistreptolysin titer, and a more dramatic and prompt response to aspirin; carditis and erythema marginatum may occur in adults, but chorea and subcutaneous nodules virtually never do. Finally, a variety of cancers produce paraneoplastic syndromes, including polyarthritis. One form is hypertrophic pulmonary osteoarthropathy most often produced by lung and gastrointestinal carcinomas, characterized by a rheumatoid-like arthritis associated with clubbing, periosteal new bone formation, and a negative rheumatoid factor. Diffuse swelling of the hands with palmar fasciitis occurs in a variety of cancers, especially ovarian carcinoma.

► Treatment

The primary objectives in treating rheumatoid arthritis are reduction of inflammation and pain, preservation of function, and prevention of deformity. Success requires early, effective pharmacologic intervention. Disease-modifying antirheumatic drugs (DMARDs) should be started as soon as the diagnosis of rheumatoid disease is certain and then

adjusted with the aim of suppressing disease activity. The American College of Rheumatology recommends using standardized assessments, such as the Disease Activity Score 28 Joints (DAS28), to gauge therapeutic responses, with the target of mild disease activity or remission by these measures. In advanced disease, surgical intervention may help improve function of damaged joints and to relieve pain.

A. Nonsteroidal Anti-inflammatory Drugs

NSAIDs provide some symptomatic relief in rheumatoid arthritis but do not prevent erosions or alter disease progression. They are not appropriate for monotherapy and should only be used in conjunction with DMARDs. A large number of NSAIDs are available; all appear equivalent in terms of efficacy (see Table 5–3).

Celecoxib, a selective COX-2 inhibitor, is FDA-approved for the treatment of osteoarthritis and rheumatoid arthritis. Compared with traditional NSAIDs, COX-2 inhibitors are as effective for treating rheumatoid arthritis but less likely in some circumstances to cause upper gastrointestinal tract adverse events (eg, obstruction, perforation, hemorrhage, or ulceration). Long-term use of COX-2 inhibitors, particularly in the absence of concomitant aspirin use, has been associated with an increased risk of cardiovascular events, leading to the removal of some COX-2 inhibitors from the US market and intense scrutiny of all drugs in that class.

1. Gastrointestinal side effects—For traditional NSAIDs that inhibit both COX-1 and COX-2, gastrointestinal side effects, such as gastric ulceration, perforation, and gastrointestinal hemorrhage, are the most common serious side effects. The overall rate of bleeding with NSAID use in the general population is low (1:6000 users or less) but is increased by long-term use, higher NSAID dose, concomitant corticosteroids or anticoagulants, the presence of rheumatoid arthritis, history of peptic ulcer disease or alcoholism, and age over 70. Twenty-five percent of all hospitalizations and deaths from peptic ulcer disease result from traditional NSAID therapy. Each year, 1:1000 patients with rheumatoid arthritis will require hospitalization for NSAID-related gastrointestinal bleeding or perforation. Although all traditional NSAIDs can cause massive gastrointestinal bleeding, the risk may be higher with indomethacin and piroxicam, probably because these drugs preferentially inhibit COX-1 in the stomach.

One approach to reducing the gastrointestinal toxicity of traditional NSAIDs is to add a proton pump inhibitor (eg, omeprazole 20 mg orally daily). Sucralfate, antacids, and H₂-blockers (such as ranitidine) either do not work or do not work as well as proton pump inhibitors. The expense of proton pump inhibitors and misoprostol dictates that their use should be reserved for patients with risk factors for NSAID-induced gastrointestinal toxicity (noted above). Patients who have recently recovered from an NSAID-induced bleeding gastric ulcer appear to be at high risk for rebleeding (about 5% in 6 months) when an NSAID is reintroduced, even if prophylactic measures such as proton pump inhibitors are used. NSAIDs can also affect

the lower intestinal tract, causing perforation or aggravating inflammatory bowel disease.

Acute liver injury from NSAIDs is rare, occurring in about 1 of every 25,000 patients using these agents. Having rheumatoid arthritis or taking sulindac may increase the risk.

2. Renal side effects—All of the NSAIDs, including aspirin and the COX-2 inhibitors, can produce renal toxicity, including interstitial nephritis, nephrotic syndrome, prerenal azotemia, and aggravation of hypertension. Hyperkalemia due to hyporeninemic hypoaldosteronism may also be seen rarely. The risk of renal toxicity is low but is increased by age over 60, a history of kidney disease, congestive heart failure, ascites, and diuretic use. COX-2 inhibitors appear to cause as much nephrotoxicity as traditional NSAIDs.

3. Platelet effects—All NSAIDs except the nonacetylated salicylates and the COX-2 inhibitors interfere with platelet function and prolong bleeding time. For all older NSAIDs except aspirin, the effect on bleeding time resolves as the drug is cleared. Aspirin irreversibly inhibits platelet function, so the bleeding time effect resolves only as new platelets are made. Concomitant administration of a traditional NSAID can interfere with the ability of aspirin to acetylate platelets and thus may interfere with the cardioprotective effects of low-dose aspirin. COX-2 inhibitors, which differ from other NSAIDs in not inhibiting platelet function, do not increase the risk of bleeding with surgical procedures as most NSAIDs do. Unfortunately, this failure to inhibit platelets is now known to lead to increased risks of myocardial infarction and stroke, particularly when the medications are used in high doses for prolonged periods of time. Patients requiring low-dose aspirin who are not compliant have a greater risk of developing a thrombotic event while taking a COX-2 inhibitor than while taking a traditional NSAID. Whether combination therapy with low-dose aspirin and a COX-2 inhibitor maintains the gastrointestinal advantage of selective COX-2 inhibitors is not yet known.

Although groups of patients with rheumatoid arthritis respond similarly to NSAIDs, individuals may respond differently—an NSAID that works for one patient may not work for another. Thus, if the first NSAID chosen is not effective after 2–3 weeks of use, another should be tried.

B. Corticosteroids

Low-dose corticosteroids (eg, oral prednisone 5–10 mg daily) produce a prompt anti-inflammatory effect in rheumatoid arthritis and slow the rate of articular erosion. However, their multiple side effects limit their long-term use.

Low-dose corticosteroids often are used as a “bridge” to reduce disease activity until the slower acting DMARDs take effect or as adjunctive therapy for active disease that persists despite treatment with DMARDs. No more than 10 mg of prednisone or equivalent per day is appropriate for articular disease. Many patients do reasonably well on 5–7.5 mg daily. (The use of 1 mg tablets, to facilitate doses of < 5 mg/d, is encouraged.) Higher doses are used to manage serious extra-articular manifestations (eg, pericarditis,

necrotizing scleritis). When the corticosteroids are to be discontinued, they should be tapered gradually on a planned schedule appropriate to the duration of treatment. All patients receiving long-term corticosteroid therapy should take measures to prevent osteoporosis.

Intra-articular corticosteroids may be helpful if one or two joints are the chief source of difficulty. Intra-articular triamcinolone, 10–40 mg depending on the size of the joint to be injected, may be given for symptomatic relief but not more than four times a year.

C. Synthetic DMARDs

1. Methotrexate—Methotrexate is usually the initial synthetic DMARD of choice for patients with rheumatoid arthritis. It is generally well tolerated and often produces a beneficial effect in 2–6 weeks. The usual initial dose is 7.5 mg of methotrexate orally once weekly. If the patient has tolerated methotrexate but has not responded in 1 month, the dose can be increased to 15 mg orally once per week. The maximal dose is usually 20–25 mg/wk. The most frequent side effects are gastric irritation and stomatitis. Cytopenia, most commonly leukopenia or thrombocytopenia but rarely pancytopenia, due to bone marrow suppression is another important potential problem. The risk of developing pancytopenia is much higher in patients with elevation of the serum creatinine (≥ 2 mg/dL). Hepatotoxicity with fibrosis and cirrhosis is an important toxic effect that correlates with cumulative dose and is uncommon with appropriate monitoring of liver function tests. Methotrexate is contraindicated in a patient with any form of chronic hepatitis. Heavy alcohol use increases the hepatotoxicity, so patients should be advised to drink alcohol in extreme moderation, if at all. Diabetes, obesity, and kidney disease also increase the risk of hepatotoxicity. Liver function tests should be monitored at least every 12 weeks, along with a complete blood count. The dose of methotrexate should be reduced if aminotransferase levels are elevated, and the drug should be discontinued if abnormalities persist despite dosage reduction. Gastric irritation, stomatitis, cytopenias, and hepatotoxicity are reduced by prescribing either daily folate (1 mg orally) or weekly leucovorin calcium (2.5–5 mg taken orally 24 hours after the dose of methotrexate). Hypersensitivity to methotrexate can cause an acute or subacute interstitial pneumonitis that can be life-threatening but which usually responds to cessation of the drug and institution of corticosteroids. Because methotrexate is teratogenic, women of child-bearing age as well as men must use effective contraception while taking the medication. Methotrexate is associated with an increased risk of B cell lymphomas, some of which resolve following the discontinuation of the medication. The combination of methotrexate and other folate antagonists, such as trimethoprim-sulfamethoxazole, should be used cautiously, since pancytopenia can result. Probenecid should also be avoided since it increases methotrexate drug levels and toxicity.

2. Sulfasalazine—This drug is a second-line agent for rheumatoid arthritis. It is usually introduced at a dosage of 0.5 g orally twice daily and then increased each week by

0.5 g until the patient improves or the daily dose reaches 3 g. Side effects, particularly neutropenia and thrombocytopenia, occur in 10–25% and are serious in 2–5%. Sulfasalazine also causes hemolysis in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency, so a G6PD level should be checked before initiating sulfasalazine. Patients with aspirin sensitivity should not be given sulfasalazine. Patients taking sulfasalazine should have complete blood counts monitored every 2–4 weeks for the first 3 months, then every 3 months.

3. Leflunomide—Leflunomide, a pyrimidine synthesis inhibitor, is also FDA-approved for treatment of rheumatoid arthritis and is administered as a single oral daily dose of 20 mg. The most frequent side effects are diarrhea, rash, reversible alopecia, and hepatotoxicity. Some patients experience dramatic unexplained weight loss. The drug is carcinogenic, teratogenic, and has a half-life of 2 weeks. Thus, it is contraindicated in premenopausal women or in men who wish to father children.

4. Antimalarials—Hydroxychloroquine sulfate is the antimalarial agent most often used against rheumatoid arthritis. Monotherapy with hydroxychloroquine should be reserved for patients with mild disease because only a small percentage will respond and in some of those cases only after 3–6 months of therapy. Hydroxychloroquine is often used in combination with other conventional DMARDs, particularly methotrexate and sulfasalazine. The advantage of hydroxychloroquine is its comparatively low toxicity, especially at a dosage of 200–400 mg/d orally (not to exceed 6.5 mg/kg/d). The most important reaction, pigmentary retinitis causing visual loss, is rare at this dose. Ophthalmologic examinations every 12 months are required when this drug is used for long-term therapy. Other reactions include neuropathies and myopathies of both skeletal and cardiac muscle, which usually improve when the drug is withdrawn.

5. Minocycline—Minocycline is more effective than placebo for rheumatoid arthritis. It is reserved for early, mild cases, since its efficacy is modest, and it works better during the first year of rheumatoid arthritis. The mechanism of action is not clear, but tetracyclines do have anti-inflammatory properties, including the ability to inhibit destructive enzymes such as collagenase. The dosage of minocycline is 200 mg orally daily. Adverse effects are uncommon except for dizziness, which occurs in about 10%.

D. Biologic DMARDs

1. Tumor necrosis factor inhibitors—Inhibitors of tumor necrosis factor (TNF)—a pro-inflammatory cytokine—are fulfilling the aim of targeted therapy for rheumatoid arthritis. These medications are frequently added to the treatment of patients who have not responded adequately to methotrexate and are increasingly used as initial therapy in combination with methotrexate for patients with poor prognostic factors.

Five inhibitors are in use: etanercept, infliximab, adalimumab, golimumab, and certolizumab pegol. Etanercept, a soluble recombinant TNF receptor:Fc fusion protein, is

usually administered at a dosage of 50 mg subcutaneously once per week. Infliximab, a chimeric monoclonal antibody, is administered at a dosage of 3–10 mg/kg intravenously; infusions are repeated after 2, 6, 10, and 14 weeks and then are administered every 8 weeks. Adalimumab, a human monoclonal antibody that binds to TNF, is given at a dosage of 40 mg subcutaneously every other week. The dose for golimumab, a human anti-TNF monoclonal antibody, is 50 mg subcutaneously once monthly. Certolizumab pegol is a PEGylated monoclonal antibody TNF inhibitor; the dose is 200–400 mg subcutaneously every 2 to 4 weeks. Each drug produces substantial improvement in more than 60% of patients. Each is usually very well tolerated. Minor irritation at injection sites is the most common side effect of etanercept and adalimumab. Rarely, nonrecurrent leukopenia develops in patients. TNF plays a physiologic role in combating many types of infection; TNF inhibitors have been associated with a several-fold increased risk of serious bacterial infections and a striking increase in granulomatous infections, particularly reactivation of tuberculosis. Screening for latent tuberculosis (see Chapter 9) is mandatory before the initiation of TNF blockers. It is prudent to suspend TNF blockers when a fever or other manifestations of a clinically important infection develops in a patient. Demyelinating neurologic complications that resemble multiple sclerosis have been reported rarely in patients taking etanercept, but the true magnitude of this risk—likely quite small—has not been determined with precision. While there are conflicting data with respect to increased risk of malignancy, in 2009, the FDA issued a safety alert about case reports of malignancies, including leukemias, in patients treated with TNF inhibitors. Contrary to expectation, TNF inhibitors were not effective in the treatment of congestive heart failure. The use of infliximab, in fact, was associated with increased morbidity in a congestive heart failure trial. Consequently, TNF inhibitors should be used with extreme caution in patients with congestive heart failure. Infliximab can rarely cause anaphylaxis and induce anti-DNA antibodies (but rarely clinically evident SLE). A final concern about TNF inhibitors is the expense, which is more than \$10,000 per year.

2. Abatacept—Abatacept, a recombinant protein made by fusing a fragment of the Fc domain of human IgG with the extracellular domain of a T cell inhibitory receptor (CTLA4), blocks T-cell costimulation. It is approved by the FDA for use in rheumatoid arthritis and produces clinically meaningful responses in approximately 50% of individuals whose disease is active despite the combination of methotrexate and a TNF inhibitor.

3. Rituximab—Rituximab is a humanized mouse monoclonal antibody that depletes B cells. It is approved by the FDA to be used in combination with methotrexate for patients whose disease has been refractory to treatment with a TNF inhibitor.

4. Tocilizumab—Tocilizumab is a monoclonal antibody that blocks the receptor for IL-6, an inflammatory cytokine involved in the pathogenesis of rheumatoid arthritis. It also is approved by the FDA to be used in combination with

methotrexate for patients whose disease has been refractory to treatment with a TNF inhibitor.

E. DMARD Combinations

As a general rule, DMARDs have greater efficacy when administered in combination than when used individually. Currently, the most commonly used combination is that of methotrexate with one of the TNF inhibitors, which clearly is superior to methotrexate alone. The urge to use combination therapies with TNF inhibitors as the initial treatment for rheumatoid arthritis, however, has been tempered by concerns about their safety and cost. The American College of Rheumatology has published detailed recommendations on the initiation of DMARD combinations.

► Course & Prognosis

After months or years, deformities may occur; the most common are ulnar deviation of the fingers, boutonnière deformity (hyperextension of the DIP joint with flexion of the PIP joint), “swan-neck” deformity (flexion of the DIP joint with extension of the PIP joint), valgus deformity of the knee, and volar subluxation of the MTP joints. The excess mortality associated with rheumatoid arthritis is largely due to cardiovascular disease that is unexplained by traditional risk factors and that appears to be a result of deleterious effects of chronic systemic inflammation on the vascular system.

► When to Refer

Early referral to a rheumatologist is essential for appropriate diagnosis and the timely introduction of effective pharmacologic and nonpharmacologic (physical and occupational) therapy.

Aletaha D et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. *Arthritis Rheum.* 2010 Sep;62(9):2569–81. [PMID: 20872595]

Chan FK et al. Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial. *Lancet.* 2010 Jul 17;376(9736):173–9. Erratum in: *Lancet.* 2011 Jul 16;378(9787):228. [PMID: 20638563]

Emery P et al; Combination of Methotrexate and Etanercept in Early Rheumatoid Arthritis Trial Group. Two-year clinical and radiographic results with combination etanercept-methotrexate therapy versus monotherapy in early rheumatoid arthritis: a two-year, double-blind, randomized study. *Arthritis Rheum.* 2010 Mar;62(3):674–82. Erratum in: *Arthritis Rheum.* 2010 Oct;62(10):3005. [PMID: 20187135]

Huizinga TW et al. In the clinic. Rheumatoid arthritis. *Ann Intern Med.* 2010 Jul 6;153(1):ITC1–15. [PMID: 20621898]

Klarenbeek NB et al. Discontinuing treatment in patients with rheumatoid arthritis in sustained clinical remission: exploratory analyses from the BeSt study. *Ann Rheum Dis.* 2011 Feb;70(2):315–9. [PMID: 21068104]

van Vollenhoven RF et al. Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial. *Lancet.* 2009 Aug 8;374(9688):459–66. [PMID: 19665644]

ADULT STILL DISEASE

Still disease is a systemic form of juvenile chronic arthritis in which high spiking fevers are much more prominent, especially at the outset, than arthritis. This syndrome also occurs in adults. Most adults are in their 20s or 30s; onset after age 60 is rare. The fever is dramatic, often with daily spikes to 40°C, associated with sweats and chills, and then plunging to normal or several degrees below normal in the absence of antipyretics. Many patients initially complain of sore throat. An evanescent salmon-colored nonpruritic rash, chiefly on the chest and abdomen, is a characteristic feature. The rash can easily be missed since it often appears only with the fever spike. Many patients also have lymphadenopathy and pericardial effusions. Joint symptoms are mild or absent in the beginning, but a destructive arthritis, especially of the wrists, may develop months later. Anemia and leukocytosis, with white blood counts sometimes exceeding 40,000/mcL, are the rule. Ferritin levels are exceptionally high (> 3000 mg/mL) in more than 70% of cases of adult Still disease—for reasons that are not clear. A low percentage (< 20%) of serum ferritin that is glycosylated may be even more specific for adult Still disease. Although there must be exclusion of other causes of fever, the diagnosis of adult Still disease is strongly suggested by the fever pattern, sore throat, and the classic rash. About half of the patients respond to high-dose aspirin (eg, 1 g three times orally daily) or other NSAIDs, and half require prednisone, sometimes in doses > 60 mg/d orally. TNF inhibitors may be helpful for some patients with refractory adult Still disease, but most patients treated with these agents achieve only partial remissions. More complete and dramatic responses have been achieved with the IL-1 receptor antagonist anakinra.

Bagnari V et al. Adult-onset Still's disease. *Rheumatol Int.* 2010 May;30(7):855–62. [PMID: 20020138]

SYSTEMIC LUPUS ERYTHEMATOSUS



ESSENTIALS OF DIAGNOSIS

- Occurs mainly in young women.
- Rash over areas exposed to sunlight.
- Joint symptoms in 90% of patients. Multiple system involvement.
- Anemia, leukopenia, thrombocytopenia.
- Glomerulonephritis, central nervous system disease, and complications of antiphospholipid antibodies are major sources of disease morbidity.
- Serologic findings: antinuclear antibodies (100%), anti-double-stranded DNA antibodies (approximately two-thirds), and low serum complement levels (particularly during disease flares).

► General Considerations

SLE is an inflammatory autoimmune disorder characterized by autoantibodies to nuclear antigens. It can affect multiple organ systems. Many of its clinical manifestations are secondary to the trapping of antigen-antibody complexes in capillaries of visceral structures or to autoantibody-mediated destruction of host cells (eg, thrombocytopenia). The clinical course is marked by spontaneous remission and relapses. The severity may vary from a mild episodic disorder to a rapidly fulminant, life-threatening illness.

The incidence of SLE is influenced by many factors, including gender, race, and genetic inheritance. About 85% of patients are women. Sex hormones appear to play some role; most cases develop after menarche and before menopause. Among older individuals, the gender distribution is more equal. Race is also a factor, as SLE occurs in 1:1000 white women but in 1:250 black women. Familial occurrence of SLE has been repeatedly documented, and the disorder is concordant in 25–70% of identical twins. If a mother has SLE, her daughters' risks of developing the disease are 1:40 and her sons' risks are 1:250. Aggregation of serologic abnormalities (positive antinuclear antibody) is seen in asymptomatic family members, and the prevalence of other rheumatic diseases is increased among close relatives of patients. The importance of specific genes in SLE is emphasized by the high frequency of certain HLA haplotypes, especially DR2 and DR3, and null complement alleles.

Before making a diagnosis of SLE, it is imperative to ascertain that the condition has not been induced by a drug (Table 20–8). Procainamide, hydralazine, and isoniazid are the best-studied drugs. While antinuclear antibody tests

and other serologic findings become positive in many persons receiving these agents, clinical manifestations occur in only a few.

Four features of **drug-induced lupus** separate it from SLE: (1) the sex ratio is nearly equal; (2) nephritis and central nervous system features are not ordinarily present; (3) hypocomplementemia and antibodies to double-stranded DNA are absent; and (4) the clinical features and most laboratory abnormalities usually revert toward normal when the offending drug is withdrawn.

The diagnosis of SLE should be suspected in patients having a multisystem disease with a positive test for antinuclear antibodies. Differential diagnosis includes rheumatoid arthritis, systemic vasculitis, scleroderma, inflammatory myopathies, viral hepatitis, sarcoidosis, acute drug reactions, and drug-induced lupus.

The diagnosis of SLE can be made with reasonable probability if 4 of the 11 criteria set forth in Table 20–9 are met. These criteria, developed as guidelines for the inclusion of patients in research studies, do not supplant clinical judgment in the diagnosis of SLE.

► Clinical Findings

A. Symptoms and Signs

The systemic features include fever, anorexia, malaise, and weight loss. Most patients have skin lesions at some time;

Table 20–8. Drugs associated with lupus erythematosus.

Definite association	
Chlorpromazine	Minocycline
Hydralazine	Procainamide
Isoniazid	Quinidine
Methyldopa	
Possible association	
β-Blockers	Nitrofurantoin
Captopril	Penicillamine
Carbamazepine	Phenytoin
Cimetidine	Propylthiouracil
Ethosuximide	Sulfasalazine
Levodopa	Sulfonamides
Lithium	Trimethadione
Methimazole	
Unlikely association	
Allopurinol	Penicillin
Chlorthalidone	Phenylbutazone
Gold salts	Reserpine
Griseofulvin	Streptomycin
Methysergide	Tetracyclines
Oral contraceptives	

Modified and reproduced, with permission, from Hess EV et al. Drug-related lupus. *Bull Rheum Dis.* 1991;40(4):1–8.

Table 20–9. Criteria for the classification of SLE.

(A patient is classified as having SLE if any 4 or more of 11 criteria are met.)

- Malar rash
- Discoid rash
- Photosensitivity
- Oral ulcers
- Arthritis
- Serositis
- Kidney disease
 - > 0.5 g/d proteinuria, or
 - ≥ 3⁺ dipstick proteinuria, or
 - Cellular casts
- Neurologic disease
 - Seizures, or
 - Psychosis (without other cause)
- Hematologic disorders
 - Hemolytic anemia, or
 - Leukopenia (< 4000/mcl), or
 - Lymphopenia (< 1500/mcl), or
 - Thrombocytopenia (< 100,000/mcl)
- Immunologic abnormalities
 - Positive LE cell preparation, or
 - Antibody to native DNA, or
 - Antibody to Sm, or
 - False-positive serologic test for syphilis
- Positive ANA

ANA, antinuclear antibody; SLE, systemic lupus erythematosus. Modified and reproduced, with permission, from Tan EM et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. *Arthritis Rheum.* 1982 Nov;25(11):1271–7.

the characteristic “butterfly” (malar) rash affects less than half of patients. Other cutaneous manifestations are, discoid lupus, typical fingertip lesions, periungual erythema, nail fold infarcts, and splinter hemorrhages. Alopecia is common. Mucous membrane lesions tend to occur during periods of exacerbation. Raynaud phenomenon, present in about 20% of patients, often antedates other features of the disease.

Joint symptoms, with or without active synovitis, occur in over 90% of patients and are often the earliest manifestation. The arthritis can lead to reversible swan-neck deformities, but erosive changes are almost never noted on radiographs. Subcutaneous nodules are rare.

Ocular manifestations include conjunctivitis, photophobia, transient or permanent monocular blindness, and blurring of vision. Cotton-wool spots on the retina (cytoid bodies) represent degeneration of nerve fibers due to occlusion of retinal blood vessels.

Pleurisy, pleural effusion, bronchopneumonia, and pneumonitis are frequent. Restrictive lung disease can develop. Alveolar hemorrhage is rare but life-threatening.

The pericardium is affected in the majority of patients. Cardiac failure may result from myocarditis and hypertension. Cardiac arrhythmias are common. Atypical verrucous endocarditis of Libman-Sacks is usually clinically silent but occasionally can produce acute or chronic valvular incompetence—most commonly mitral regurgitation.

Mesenteric vasculitis occasionally occurs in SLE and may closely resemble polyarteritis nodosa, including the presence of aneurysms in medium-sized blood vessels. Abdominal pain (particularly postprandial), ileus, peritonitis, and perforation may result.

Neurologic complications of SLE include psychosis, cognitive impairment, seizures, peripheral and cranial neuropathies, transverse myelitis, and strokes. Severe depression and

psychosis are sometimes exacerbated by the administration of large doses of corticosteroids.

Several forms of glomerulonephritis may occur, including mesangial, focal proliferative, diffuse proliferative, and membranous (see Chapter 22). Some patients may also have interstitial nephritis. With appropriate therapy, the survival rate even for patients with serious chronic kidney disease (proliferative glomerulonephritis) is favorable, albeit a substantial portion of patients with severe lupus nephritis still eventually require renal replacement therapy.

B. Laboratory Findings

(Tables 20–10 and 20–11.) SLE is characterized by the production of many different autoantibodies. Antinuclear antibody tests based on immunofluorescence assays are sensitive but not specific for SLE—ie, they are positive in virtually all patients with lupus but are positive also in many patients with nonlupus conditions such as rheumatoid arthritis, autoimmune thyroid disease, scleroderma, and Sjögren syndrome. False-negative results can occur with tests for antinuclear antibodies based on enzyme-linked immunosorbent assays (ELISA). Therefore, SLE should not be excluded on the basis of a negative ELISA for antinuclear antibodies. Antibodies to double-stranded DNA and to Sm are specific for SLE but not sensitive, since they are present in only 60% and 30% of patients, respectively. Depressed serum complement—a finding suggestive of disease activity—often returns toward normal in remission. Anti-double-stranded DNA antibody levels also correlate with disease activity in some patients; anti-Sm levels do not.

Three types of antiphospholipid antibodies occur (Table 20–11). The first causes the biologic false-positive tests for syphilis; the second is the lupus anticoagulant, which despite

Table 20–10. Frequency (%) of autoantibodies in rheumatic diseases.¹

	ANA	Anti-Native DNA	Rheumatoid Factor	Anti-Sm	Anti-SS-A	Anti-SS-B	Anti-SCL-70	Anti-Centromere	Anti-Jo-1	ANCA
Rheumatoid arthritis	30–60	0–5	70	0	0–5	0–2	0	0	0	0
Systemic lupus erythematosus	95–100	60	20	10–25	15–20	5–20	0	0	0	0–1
Sjögren syndrome	95	0	75	0	65	65	0	0	0	0
Diffuse scleroderma	80–95	0	30	0	0	0	33	1	0	0
Limited scleroderma (CREST syndrome)	80–95	0	30	0	0	0	20	50	0	0
Polymyositis/dermatomyositis	80–95	0	33	0	0	0	0	0	20–30	0
Granulomatosis with polyangiitis (formerly Wegener granulomatosis)	0–15	0	50	0	0	0	0	0	0	93–96 ¹

¹Frequency for generalized, active disease.

ANA, antinuclear antibodies; Anti-Sm, anti-Smith antibody; anti-SCL-70, anti-scleroderma antibody; ANCA, antineutrophil cytoplasmic antibody; CREST, calcinosis cutis, Raynaud phenomenon, esophageal motility disorder, sclerodactyly, and telangiectasia.

Table 20-11. Frequency (%) of laboratory abnormalities in systemic lupus erythematosus.

Anemia	60%
Leukopenia	45%
Thrombocytopenia	30%
Biologic false-positive tests for syphilis	25%
Antiphospholipid antibodies	
Lupus anticoagulant	7%
Anti-cardiolipin antibody	25%
Direct Coombs-positive	30%
Proteinuria	30%
Hematuria	30%
Hypocomplementemia	60%
ANA	95-100%
Anti-native DNA	50%
Anti-Sm	20%

ANA, antinuclear antibody; Anti-Sm, anti-Smith antibody. Modified and reproduced, with permission, from Hochberg MC et al. Systemic lupus erythematosus: a review of clinicolaboratory features and immunologic matches in 150 patients with emphasis on demographic subsets. *Medicine* (Baltimore). 1985 Sep;64(5):285-95.

its name is a risk factor for venous and arterial thrombosis and for miscarriage. The lupus anticoagulant often causes prolongation of the activated partial thromboplastin time, and its presence is confirmed by an abnormal Russell viper venom time (RVVT) that corrects with the addition of phospholipid but not normal plasma. Anticardiolipin antibodies are the third type of antiphospholipid antibodies. In many cases, the “antiphospholipid antibody” appears to be directed at a serum cofactor (β_2 -glycoprotein-I) rather than at phospholipid itself. Abnormality of urinary sediment is almost always found in association with renal lesions. Showers of red blood cells, with or without casts, and proteinuria (varying from mild to nephrotic range) are frequent during exacerbation of the disease.

► Treatment

Patient education and emotional support, are especially important for patients with lupus. Since the various manifestations of SLE affect prognosis differently and since SLE activity often waxes and wanes, drug therapy—both the choice of agents and the intensity of their use—must be tailored to match disease severity. Patients with photosensitivity should be cautioned against sun exposure and should apply a protective lotion to the skin while out of doors. Skin lesions often respond to the local administration of corticosteroids. Minor joint symptoms can usually be alleviated by rest and NSAIDs.

Antimalarials (hydroxychloroquine) may be helpful in treating lupus rashes or joint symptoms and appear to reduce the incidence of severe disease flares. The dose of

hydroxychloroquine is 200 or 400 mg/d orally and should not exceed 6.5 mg/kg/d; annual monitoring for retinal changes is recommended. Drug-induced neuropathy and myopathy may be erroneously ascribed to the underlying disease. The androgenic corticosteroid danazol may be effective therapy for thrombocytopenia not responsive to corticosteroids. Although dehydroepiandrosterone (DHEA) can improve a patient's sense of well being, the drug is not used often because it has little to no impact on other measures of disease activity and frequently causes troubling side effects (particularly acne and hirsutism).

Corticosteroids are required for the control of certain complications. (Systemic corticosteroids are not usually given for minor arthritis, skin rash, leukopenia, or the anemia associated with chronic disease.) Glomerulonephritis, hemolytic anemia, pericarditis or myocarditis, alveolar hemorrhage, central nervous system involvement, and thrombotic thrombocytopenic purpura all require corticosteroid treatment and often other interventions as well. Forty to 60 mg of oral prednisone is often needed initially; however, the lowest dose of corticosteroid that controls the condition should be used. Central nervous system lupus may require higher doses of corticosteroids than are usually given; however, corticosteroid psychosis may mimic lupus cerebritis, in which case reduced doses are appropriate. Immunosuppressive agents such as cyclophosphamide, mycophenolate mofetil, and azathioprine are used in cases resistant to corticosteroids. Treatment of severe lupus nephritis includes an induction phase and a maintenance phase. Cyclophosphamide, which improves renal survival but not patient survival, has been for many years the standard treatment for both phases of lupus nephritis. Mycophenolate mofetil appears to be an effective alternative treatment for many patients with lupus nephritis. Very close follow-up is needed to watch for potential side effects when immunosuppressants are given; these agents should be administered by clinicians experienced in their use. When cyclophosphamide is required, gonadotropin-releasing hormone analogs can be given to protect a woman against the risk of premature ovarian failure. Belimumab, a monoclonal antibody that inhibits the activity of a B cell growth factor, has received FDA approval for treating antibody-positive SLE patients with active disease who have not responded to standard therapies (eg, NSAIDs, antimalarials, or immunosuppressive therapies). However, the precise indications for its use have not been defined, and its efficacy in severe disease activity is unknown. Belimumab appears less effective in blacks. While observations studies suggested that rituximab was effective in SLE, one large randomized-controlled trial demonstrated it was no more effective than placebo. For patients with the **antiphospholipid syndrome**—the presence of antiphospholipid antibodies and compatible clinical events—anticoagulation is the treatment of choice (see Antiphospholipid Antibody Syndrome, below). Moderate intensive anticoagulation with warfarin to achieve an INR of 2.0–3.0 is as effective as more intensive regimens. Pregnant patients with recurrent fetal loss associated with antiphospholipid antibodies should be treated with low-molecular-weight heparin plus aspirin.

▶ Course & Prognosis

Ten-year survival rates exceeding 85% are routine. In most patients, the illness pursues a relapsing and remitting course. Prednisone, often needed in doses of 40 mg/d orally or more during severe flares, can usually be tapered to low doses (5–10 mg/d) when the disease is inactive. However, there are some in whom the disease pursues a virulent course, leading to serious impairment of vital structures such as lung, heart, brain, or kidneys, and the disease may lead to death. With improved control of lupus activity and with increasing use of corticosteroids and immunosuppressive drugs, the mortality and morbidity patterns in lupus have changed. Mortality in SLE shows a bimodal pattern. In the early years after diagnosis, infections—especially with opportunistic organisms—are the leading cause of death, followed by active SLE, chiefly due to kidney or central nervous system disease. In later years, accelerated atherosclerosis, linked to chronic inflammation, becomes a major cause of death. Indeed, the incidence of myocardial infarction is five times higher in persons with SLE than in the general population. Therefore, it is especially important for SLE patients to avoid smoking and to minimize other conventional risk factors for atherosclerosis (eg, hypercholesterolemia, hypertension, obesity, and inactivity). Patients with SLE should receive influenza vaccination every year and pneumococcal vaccination every 5 years. Since SLE patients have a higher risk of developing malignancy (especially lymphoma, lung cancer, and cervical cancer), preventive cancer screening recommendations should be followed assiduously. With more patients living longer, it has become evident that avascular necrosis of bone, affecting most commonly the hips and knees, is responsible for substantial morbidity. Nonetheless, the outlook for most patients with SLE has become increasingly favorable.

▶ When to Refer

- Appropriate diagnosis and management of SLE requires the active participation of a rheumatologist.
- The severity of organ involvement dictates referral to other subspecialists, such as nephrologists and pulmonologists.

▶ When to Admit

- Rapidly progressive glomerulonephritis, pulmonary hemorrhage, transverse myelitis, and other severe organ-threatening manifestations of lupus usually require inpatient assessment and management.
- Severe infections, particularly in the setting of immunosuppressant therapy, should prompt admission.

Dooley MA et al. Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. *N Engl J Med*. 2011 Nov 17;365(20):1886–95. [PMID: 22087680]

Haque S et al. Risk factors for clinical coronary heart disease in systemic lupus erythematosus: the lupus and atherosclerosis evaluation of risk (LASER) study. *J Rheumatol*. 2010 Feb; 37(2):322–9. [PMID: 19955047]

Lateef A et al. Biologics in the treatment of systemic lupus erythematosus. *Curr Opin Rheumatol*. 2010 Sep;22(5):504–9. [PMID: 20502332]

Merrill JT et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. *Arthritis Rheum*. 2010 Jan; 62(1):222–33. [PMID: 20039413]

Navarra SV et al; BLISS-52 Study Group. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. *Lancet*. 2011 Feb 26;377(9767):721–31. [PMID: 21296403]

Petri M et al. High-dose cyclophosphamide versus monthly intravenous cyclophosphamide for systemic lupus erythematosus: a prospective randomized trial. *Arthritis Rheum*. 2010 May;62(5):1487–93. [PMID: 20131296]

ANTIPHOSPHOLIPID SYNDROME



ESSENTIALS OF DIAGNOSIS

- ▶ Hypercoagulability, with recurrent thromboses in either the venous or arterial circulation.
- ▶ Thrombocytopenia is common.
- ▶ Pregnancy complications, specifically pregnancy losses after the first trimester.
- ▶ Lifelong anticoagulation with warfarin is recommended currently for patients with serious complications of this syndrome because recurrent events are common.

▶ General Considerations

A primary **antiphospholipid syndrome** (APS) is diagnosed in patients who have venous or arterial occlusions, recurrent fetal loss, or thrombocytopenia in the presence of persistent antiphospholipid antibodies but not other features of SLE. In < 1% of patients with antiphospholipid antibodies, a potentially devastating syndrome known as the “catastrophic antiphospholipid syndrome” occurs, leading to diffuse thromboses, thrombotic microangiopathy, and multiorgan system failure.

▶ Clinical Findings

A. Symptoms and Signs

Patients are often asymptomatic until suffering a thrombotic complication of this syndrome or a pregnancy loss. Thrombotic events may occur in either the arterial or venous circulations. Thus, deep venous thromboses, pulmonary emboli, cerebrovascular accidents are typical clinical events among patients with the APS. Budd-Chiari syndrome, cerebral sinus vein thrombosis, myocardial or digital infarctions, and other thrombotic events also occur. A variety of other symptoms and signs are often attributed to the APS, including mental status changes, livedo reticularis, skin ulcers, microangiopathic nephropathy, and cardiac valvular dysfunction—typically mitral regurgitation

that may mimic Libman-Sacks endocarditis. Livedo reticularis is strongly associated with the subset of patients with APS in whom arterial ischemic events develop. Pregnancy losses that are associated with APS include unexplained fetal death after the first trimester, one or more premature births before 34 weeks because of eclampsia or preeclampsia, or three or more unexplained miscarriages during the first trimester.

B. Laboratory Findings

As noted in the discussion of SLE, three types of antiphospholipid antibody are believed to contribute to this syndrome: (1) anti-cardiolipin antibodies; (2) a “lupus anticoagulant” that prolongs certain coagulation tests (see below); and (3) an antibody associated with a biologic false-positive test for syphilis. Anti-cardiolipin antibodies are typically measured with enzyme immunoassays for either IgG or IgM. In general, IgG anti-cardiolipin antibodies are believed to be more pathologic than IgM. A clue to the presence of a lupus anticoagulant, which may occur in individuals who do not have SLE, may be detected by a prolongation of the partial thromboplastin time (which, paradoxically, is associated with a thrombotic tendency rather than a bleeding risk). A finding more sensitive for a lupus anticoagulant, however, is prolongation of the coagulation assay known as the Russell viper venom time (RVVT). In the presence of a lupus anticoagulant, the RVVT is prolonged and does not correct with mixing studies but does with the addition of excess phospholipid. With the last type of antiphospholipid antibody, the patient has a positive rapid plasma reagin (RPR), but negative specific anti-treponemal assays.

► Differential Diagnosis

The exclusion of other autoimmune disorders, particularly those in the SLE spectrum, is essential because such disorders may be associated with additional complications requiring alternative treatments. Other genetic or acquired conditions associated with hypercoagulability such as protein C, protein S, factor V Leiden, and antithrombin deficiency should be excluded. Catastrophic APS has a broad differential, including sepsis, pulmonary-renal syndromes, systemic vasculitis, disseminated intravascular coagulation, and thrombotic thrombocytopenic purpura.

► Treatment

Present recommendations for anticoagulation are to treat patients with warfarin to maintain an INR of 2.0–3.0. Patients who have recurrent thrombotic events on this level of anticoagulation may require higher INRs (> 3.0), but the bleeding risk increases substantially with this degree of anticoagulation. Guidelines indicate that patients with APS should be treated with anticoagulation for life. Because of the teratogenic effects of warfarin, subcutaneous heparin and low dose aspirin (81 mg) is the usual approach to prevent pregnancy complications in women with APS. In patients with catastrophic APS, a three-pronged approach is taken in the acute setting: intravenous heparin, high doses of corticosteroids, and either intravenous immune globulin or plasmapheresis.

Cervera R. Update on the diagnosis, treatment, and prognosis of the catastrophic antiphospholipid syndrome. *Curr Rheumatol Rep.* 2010 Feb;12(1):70–6. [PMID: 20425537]

Ruiz-Irastorza G et al. Antiphospholipid syndrome. *Lancet.* 2010 Oct 30;376(9751):1498–509. [PMID: 20822807]

Ziakas PD et al. Heparin treatment in antiphospholipid syndrome with recurrent pregnancy loss: a systematic review and meta-analysis. *Obstet Gynecol.* 2010 Jun;115(6):1256–62. [PMID: 20502298]

Zuily S et al. Increased risk for heart valve disease associated with antiphospholipid antibodies in patients with systemic lupus erythematosus: meta-analysis of echocardiographic studies. *Circulation.* 2011 Jul 12;124(2):215–24. [PMID: 21690492]

RAYNAUD PHENOMENON



ESSENTIALS OF DIAGNOSIS

- Paroxysmal bilateral digital pallor and cyanosis followed by rubor.
- Precipitated by cold or emotional stress; relieved by warmth.
- Primarily affects young women.
- Primary form benign; secondary form can cause digital ulceration or gangrene.

► General Considerations

Raynaud phenomenon (RP) is a syndrome of paroxysmal digital ischemia, most commonly caused by an exaggerated response of digital arterioles to cold or emotional stress. The initial phase of RP, mediated by excessive vasoconstriction, consists of well-demarcated digital pallor or cyanosis; the subsequent (recovery) phase of RP, caused by vasodilation, leads to intense hyperemia and rubor. Although RP chiefly affects fingers, it can also affect toes and other acral areas such as the nose and ears. RP is classified as primary (idiopathic or Raynaud disease) or secondary. Nearly one-third of the population reports being “sensitive to the cold” but does not experience the paroxysms of digital pallor, cyanosis, and erythema characteristic of RP. Primary RP occurs in 2–6% of adults, is especially common in young women, and poses more of a nuisance than a threat to good health. In contrast, secondary RP is less common, is chiefly associated with rheumatic diseases (especially scleroderma), and is frequently severe enough to cause digital ulceration or gangrene.

► Clinical Findings

In early attacks of RP, only one or two fingertips may be affected; as it progresses, all fingers down to the distal palm may be involved. The thumbs are rarely affected. During recovery there may be intense rubor, throbbing, paresthesia, pain, and slight swelling. Attacks usually terminate spontaneously or upon returning to a warm room or putting the extremity in warm water. The patient is usually asymptomatic between attacks. Sensory changes that often accompany vasomotor manifestations include numbness, stiffness, diminished sensation, and aching pain.

Primary RP appears first between ages 15 and 30, almost always in women. It tends to be mildly progressive and, unlike secondary RP (which may be unilateral and may involve only one or two fingers), symmetric involvement of the fingers of both hands is the rule. Spasm becomes more frequent and prolonged. Unlike secondary RP, primary RP does not cause digital pitting, ulceration, or gangrene.

Nailfold capillary abnormalities are among the earliest clues that a person has secondary rather than primary RP. The nailfold capillary pattern can be visualized by placing a drop of grade B immersion oil at the patient's cuticle and then viewing the area with an ophthalmoscope set to 20–40 diopters. Dilation or dropout of the capillary loops indicates the patient has a secondary form of RP, most commonly scleroderma (Table 20–12). While highly specific for secondary RP, nailfold capillary changes have a low sensitivity. Digital pitting or ulceration or other abnormal physical findings (eg, skin tightening, loss of extremity pulse, rash, swollen joints) can also provide evidence of secondary RP.

Primary RP must be differentiated from the numerous causes of secondary RP (Table 20–12). The history and examination may suggest the diagnosis of systemic sclerosis (including its CREST variant), SLE, and mixed connective tissue disease; RP is occasionally the first manifestation of these disorders. The diagnosis of many of these rheumatic diseases can be confirmed with specific serologic tests (see Table 20–10).

Table 20–12. Causes of secondary Raynaud phenomenon.

Rheumatic diseases
Scleroderma
Systemic lupus erythematosus
Dermatomyositis/polymyositis
Sjögren syndrome
Vasculitis (polyarteritis nodosa, Takayasu disease, Buerger disease)
Neurovascular compression and occupational
Carpal tunnel syndrome
Thoracic outlet obstruction
Vibration injury
Medications
Serotonin agonists (sumatriptan)
Sympathomimetic drugs (decongestants)
Chemotherapy (bleomycin, vinblastine)
Ergotamine
Caffeine
Nicotine
Hematologic disorders
Cryoglobulinemia
Polycythemia vera
Paraproteinemia
Cold agglutinins
Endocrine disorders
Hypothyroidism
Pheochromocytoma
Miscellaneous
Atherosclerosis
Embolic disease
Migraine
Exposure to epoxy resins
Sequela of frostbite

RP may occur in patients with the thoracic outlet syndromes. In these disorders, involvement is generally unilateral, and symptoms referable to brachial plexus compression tend to dominate the clinical picture. Carpal tunnel syndrome should also be considered, and nerve conduction tests are appropriate in selected cases.

A particularly severe form of RP occurs in up to one-third of patients receiving bleomycin and vincristine in combination, often for testicular cancer. Treatment is unsuccessful, and the problem persists even with discontinuation of the drugs.

► Differential Diagnosis

The differentiation from Buerger disease (thromboangiitis obliterans) is usually not difficult, since thromboangiitis obliterans is generally a disease of men, particularly smokers; peripheral pulses are often diminished or absent; and, when RP occurs in association with thromboangiitis obliterans, it is usually in only one or two digits.

In acrocyanosis, cyanosis of the hands is permanent and diffuse; the sharp and paroxysmal line of demarcation with pallor does not occur with acrocyanosis. Frostbite may lead to chronic RP. Ergot poisoning, particularly due to prolonged or excessive use of ergotamine, must also be considered but is unusual.

RP may be mimicked by type I cryoglobulinemia, in which a monoclonal antibody cryoprecipitates in the cooler distal circulation. Type I cryoglobulinemia is usually associated with multiple myeloma or with lymphoproliferative disorders.

Erythromelalgia can mimic the rubor phase of RP; exacerbation by heat and relief with cold readily distinguish erythromelalgia from RP.

► Treatment

A. General Measures

Patients should wear gloves or mittens whenever outside in temperatures that precipitate attacks. Keeping the body warm is also a cornerstone of initial therapy. Wearing warm shirts, coats, and hats will help prevent the exaggerated vasospasm that causes RP and that is not prevented by warming only the hands. The hands should be protected from injury at all times; wounds heal slowly, and infections are consequently hard to control. Softening and lubricating lotion to control the fissured dry skin should be applied to the hands frequently. Smoking should be stopped and sympathomimetic drugs (eg, decongestants, diet pills, and amphetamines) should be avoided. For most patients with primary RP, general measures alone are sufficient to control symptoms. Medical or surgical therapy should be considered in patients who have severe symptoms or are experiencing tissue injury from digital ischemia.

B. Medications

Calcium channel blockers are first-line therapy for RP. Calcium channel blockers produce a modest benefit and are more effective in primary RP than secondary RP. Slow release nifedipine (30–180 mg/d orally), amlodipine (5–20 mg/d orally), felodipine, or nisoldipine are popular and more effective than verapamil and diltiazem. Other medications that are sometimes effective in treating RP

include angiotensin-converting enzyme inhibitors, sympatholytic agents (eg, prazosin), topical nitrates, phosphodiesterase inhibitors (eg, sildenafil, tadalafil, and vardenafil), selective serotonin reuptake inhibitors (fluoxetine), endothelin-receptor inhibitors (ie, bosentan), statins, parenteral prostaglandins (prostaglandin E₁), and oral prostaglandins (misoprostol).

C. Surgical Measures

Sympathectomy may be indicated when attacks have become frequent and severe, when they interfere with work and well being, and particularly when trophic changes have developed and medical measures have failed. Cervical sympathectomy is modestly effective for primary but not secondary RP. Digital sympathectomy may improve secondary RP.

► Prognosis

Primary RP is benign and largely a nuisance for affected individuals who are exposed to cold winters or excessive air conditioning. The prognosis of secondary RP depends on the severity of the underlying disease. Unfortunately, severe pain from ulceration and gangrene are not rare with scleroderma, especially the CREST variant.

► When to Refer

- Appropriate management of patients with secondary RP often requires consultation with a rheumatologist.

► When to Admit

- Patients with severe digital ischemia as evidenced by demarcation should be admitted for intensive therapy.

Chatterjee S. Management of Raynaud's phenomenon in the patient with connective tissue disease. *Curr Treat Options Cardiovasc Med.* 2010 Apr;12(2):185–204. [PMID: 20842555]
 Huisstede BM et al. Effectiveness of interventions for secondary Raynaud's phenomenon: a systematic review. *Arch Phys Med Rehabil.* 2011 Jul;92(7):1166–80. [PMID: 21704799]
 Shenoy PD et al. Efficacy of tadalafil in secondary Raynaud's phenomenon resistant to vasodilator therapy: a double blind randomized cross-over trial. *Rheumatology (Oxford).* 2010 Dec;49(12):2420–8. [PMID: 20837499]

SCLERODERMA (Systemic Sclerosis)



ESSENTIALS OF DIAGNOSIS

- Limited disease (80% of patients): thickening of skin confined to the face, neck, and distal extremities.
- Diffuse disease (20%): widespread thickening of skin, including truncal involvement, with areas of increased pigmentation and depigmentation.
- Raynaud phenomenon and antinuclear antibodies are present in virtually all patients.
- Systemic features of gastroesophageal reflux, hypomotility of gastrointestinal tract, pulmonary fibrosis, pulmonary hypertension, and renal involvement.

► General Considerations

Scleroderma (systemic sclerosis) is a rare chronic disorder characterized by diffuse fibrosis of the skin and internal organs. Symptoms usually appear in the third to fifth decades, and women are affected two to three times as frequently as men.

Two forms of scleroderma are generally recognized: limited (80% of patients) and diffuse (20%). In limited scleroderma, which is also known as the CREST syndrome (representing calcinosis cutis, Raynaud phenomenon, esophageal motility disorder, sclerodactyly, and telangiectasia), the hardening of the skin (scleroderma) is limited to the face and hands. In contrast, in diffuse scleroderma, the skin changes also involve the trunk and proximal extremities. Tendon friction rubs over the forearms and shins occur uniquely (but not universally) in diffuse scleroderma. In general, patients with limited scleroderma have better outcomes than those with diffuse disease, largely because kidney disease or interstitial lung disease rarely develops in patients with limited disease. Cardiac disease is also more characteristic of diffuse scleroderma. Patients with limited disease, however, are more susceptible to digital ischemia, leading to finger loss, and to life-threatening pulmonary hypertension. Small and large bowel hypomotility, which may occur in either form of scleroderma, can cause constipation alternating with diarrhea, malabsorption due to bacterial overgrowth, pseudoobstruction, and severe bowel distension with rupture.

► Clinical Findings

A. Symptoms and Signs

Raynaud phenomenon is usually the initial manifestation and can precede other signs and symptoms by years in cases of limited scleroderma. Polyarthralgia, weight loss, and malaise are common early features of diffuse scleroderma but are infrequent in limited scleroderma. Cutaneous disease usually, but not always, develops before visceral involvement and can manifest initially as non-pitting subcutaneous edema associated with pruritus. With time the skin becomes thickened and hidebound, with loss of normal folds. Telangiectasia, pigmentation, and depigmentation are characteristic. Ulceration about the fingertips and subcutaneous calcification are seen. Dysphagia and symptoms of reflux due to esophageal dysfunction are common and result from abnormalities in motility and later from fibrosis. Fibrosis and atrophy of the gastrointestinal tract cause hypomotility. Large-mouthed diverticuli occur in the jejunum, ileum, and colon. Diffuse pulmonary fibrosis and pulmonary vascular disease are reflected in restrictive lung physiology and low diffusing capacities. Cardiac abnormalities include pericarditis, heart block, myocardial fibrosis, and right heart failure secondary to pulmonary hypertension. Scleroderma renal crisis, resulting from intimal proliferation of smaller renal arteries and usually associated with hypertension, is a marker for a poor outcome even though many cases can be treated effectively with angiotensin-converting enzyme inhibitors.

B. Laboratory Findings

Mild anemia is often present. In scleroderma renal crisis, the peripheral blood smear shows findings consistent with a microangiopathic hemolytic anemia (due to mechanical damage to red cells from diseased small vessels). Elevation of the ESR is unusual. Proteinuria appears in association with renal involvement. Antinuclear antibody tests are nearly always positive, frequently in high titers (Table 20–10). The scleroderma antibody (anti-SCL-70), directed against topoisomerase III, is found in one-third of patients with diffuse systemic sclerosis and in 20% of those with CREST syndrome. Although present in only a small number of patients with diffuse scleroderma, anti-SCL-70 antibodies may portend a poor prognosis, with a high likelihood of serious internal organ involvement (eg, interstitial lung disease). Anticentromere antibodies are seen in 50% of those with CREST syndrome and in 1% of individuals with diffuse scleroderma (Table 20–10). Anticentromere antibodies are highly specific for limited scleroderma, but they also occur occasionally in overlap syndromes. Anti-RNA polymerase III antibodies develop in 10–20% of scleroderma patients overall and correlate with the development of diffuse skin disease and renal hypertensive crisis.

► Differential Diagnosis

Early in its course, scleroderma can cause diagnostic confusion with other causes of Raynaud phenomenon, particularly SLE, mixed connective tissue disease, and the inflammatory myopathies. Scleroderma can be mistaken for other disorders characterized by skin hardening. Eosinophilic fasciitis is a rare disorder presenting with skin changes that resemble diffuse scleroderma. The inflammatory abnormalities, however, are limited to the fascia rather than the dermis and epidermis. Moreover, patients with eosinophilic fasciitis are distinguished from those with scleroderma by the presence of peripheral blood eosinophilia, the absence of Raynaud phenomenon, the good response to prednisone, and an association (in some cases) with paraproteinemias. Diffuse skin thickening and visceral involvement are features of scleromyxedema; the presence of a paraprotein, the absence of Raynaud phenomenon, and distinct skin histology point to scleromyxedema. Diabetic cheiropathy typically develops in long-standing, poorly controlled diabetes and can mimic sclerodactyly. Nephrogenic fibrosing dermopathy produces thickening and hardening of the skin of the trunk and extremities in patients with chronic kidney disease; exposure to gadolinium may play a pathogenic role. Morphea and linear scleroderma cause sclerodermatous changes limited to circumscribed areas of the skin and usually have excellent outcomes.

► Treatment

Treatment of scleroderma is symptomatic and supportive and focuses on the organ systems involved. There is no effective therapy for the underlying disease process. However, interventions for management of specific organ manifestations of this disease have improved substantially. Severe

Raynaud syndrome may respond to calcium channel blockers, eg, long-acting nifedipine, 30–120 mg/d orally, or to losartan, 50 mg/d orally, or to sildenafil 50 mg orally twice daily. Patients with esophageal disease should take medications in liquid or crushed form. Esophageal reflux can be reduced and the risk of scarring diminished by avoidance of late-night meals and by the use of proton pump inhibitors (eg, omeprazole, 20–40 mg/d orally), which achieve near-complete inhibition of gastric acid production and are remarkably effective for refractory esophagitis. Patients with delayed gastric emptying maintain their weight better if they eat small, frequent meals and remain upright for at least 2 hours after eating. Long-term octreotide (0.1 mg subcutaneously twice daily), a somatostatin analog, helps some patients with bacterial overgrowth and pseudoobstruction. Malabsorption due to bacterial overgrowth also responds to antibiotics, eg, tetracycline, 500 mg four times orally daily, often prescribed cyclically. The hypertensive crises associated with systemic sclerosis renal crisis must be treated early and aggressively (in the hospital) with angiotensin-converting enzyme inhibitors, eg, captopril, initiated at 25 mg orally every 6 hours and titrated up as tolerated to a maximum of 100 mg every 6 hours. Apart from the patient with myositis, prednisone has little or no role in the treatment of scleroderma; high doses (> 15 mg daily) have been associated with scleroderma renal crisis. Cyclophosphamide improves dyspnea and pulmonary function tests modestly in patients with severe interstitial lung disease; this highly toxic drug should only be administered by physicians familiar with its use. Mycophenolate mofetil, 1 g twice daily, stabilized lung function in small, uncontrolled studies of patients with interstitial lung disease. Bosentan, an endothelin receptor antagonist, improves exercise capacity and cardiopulmonary hemodynamics in patients with pulmonary hypertension and helps prevent digital ulceration. Sildenafil or prostaglandins (delivered by continuous intravenous infusion or intermittent inhalation) may also be useful in treating pulmonary hypertension. At an experimental level, immunoablative therapy with or without stem cell rescue has achieved promising results for some patients with severe, rapidly progressive diffuse scleroderma.

The 9-year survival rate in scleroderma averages approximately 40%. The prognosis tends to be worse in those with diffuse scleroderma, in blacks, in males, and in older patients. Lung disease—in the form of pulmonary fibrosis or pulmonary arterial hypertension—is now the number one cause of mortality. Death from advanced heart failure or chronic kidney disease is also common. Those persons in whom severe internal organ involvement does not develop in the first 3 years have a substantially better prognosis, with 72% surviving at least 9 years. Breast and lung cancer may be more common in patients with scleroderma.

► When to Refer

- Appropriate management of scleroderma requires frequent consultations with a rheumatologist.
- Severity of organ involvement dictates referral to other subspecialists, such as pulmonologists or gastroenterologists.

Manno R et al. Immunotherapy of systemic sclerosis. *Immunotherapy*. 2010 Nov;2(6):863–78. [PMID: 21091117]
 Ong VH et al. Innovative therapies for systemic sclerosis. *Curr Opin Rheumatol*. 2010 May;22(3):264–72. [PMID: 20190640]
 Simeón-Aznar CP et al. Effect of mycophenolate sodium in scleroderma-related interstitial lung disease. *Clin Rheumatol*. 2011 Nov;30(11):1393–8. [PMID: 21881859]

IDIOPATHIC INFLAMMATORY MYOPATHIES (Polymyositis & Dermatomyositis)



ESSENTIALS OF DIAGNOSIS

- ▶ Bilateral proximal muscle weakness.
- ▶ Characteristic cutaneous manifestations in dermatomyositis (Gottron papules, heliotrope rash).
- ▶ Diagnostic tests: elevated creatine kinase, muscle biopsy, electromyography, MRI.
- ▶ Increased risk of malignancy, particularly in dermatomyositis.
- ▶ Inclusion body myositis can mimic polymyositis but is less responsive to treatment.

▶ General Considerations

Polymyositis and dermatomyositis are systemic disorders of unknown cause whose principal manifestation is muscle weakness. Although their clinical presentations (aside from the presence of certain skin findings in dermatomyositis, some of which are pathognomonic) and treatments are similar, the two diseases are pathologically quite distinct. They affect persons of any age group, but the peak incidence is in the fifth and sixth decades of life. Women are affected twice as commonly as men, and the diseases (particularly polymyositis) also occur more often among blacks than whites. There is an increased risk of malignancy in adult patients with dermatomyositis. Indeed, up to one patient in four with dermatomyositis has an occult malignancy. Malignancies may be evident at the time of presentation with the muscle disease but may not be detected until months afterward in some cases. Rare patients with dermatomyositis have skin disease without overt muscle involvement, a condition termed “dermatomyositis sine myositis.” Myositis may also be associated with other connective tissue diseases, especially scleroderma, lupus, mixed connective tissue disease, and Sjögren syndrome.


▶ Clinical Findings

A. Symptoms and Signs

Polymyositis may begin abruptly, but the usual presentation is one of gradual and progressive muscle weakness. The weakness chiefly involves proximal muscle groups of the upper and lower extremities as well as the neck. Leg weakness (eg, difficulty in rising from a chair or climbing stairs) typically precedes arm symptoms. In contrast to myasthenia

gravis, polymyositis and dermatomyositis do not cause facial or ocular muscle weakness. Pain and tenderness of affected muscles occur in one-fourth of cases, but these are rarely the chief complaints. About one-fourth of patients have dysphagia. In contrast to scleroderma, which affects the smooth muscle of the lower esophagus and can cause a “sticking” sensation below the sternum, polymyositis or dermatomyositis involves the striated muscles of the upper pharynx and can make initiation of swallowing difficult. Muscle atrophy and contractures occur as late complications of advanced disease. Clinically significant myocarditis is uncommon even though there is often creatine kinase-MB elevation. Patients who are bed-bound from myositis should be screened for respiratory muscle weakness that can be severe enough to cause CO₂ retention and can progress to require mechanical ventilation.

The characteristic rash of **dermatomyositis** is dusky red and may appear in a malar distribution mimicking the classic rash of SLE. Facial erythema beyond the malar distribution is also characteristic of dermatomyositis. Erythema also occurs over other areas of the face, neck, shoulders, and upper chest and back (“shawl sign”). Periorbital edema and a purplish (heliotrope) suffusion over the eyelids are typical signs (Figure 20–6). Coloration of the heliotrope and other rashes of dermatomyositis can be affected by skin tone. In blacks, the rashes may appear more hyperpigmented than erythematous or violaceous. Periungual erythema, dilations of nailbed capillaries, and scaly patches over the dorsum of PIP and MCP joints (Gottron sign) are highly suggestive. Scalp involvement by dermatomyositis may mimic psoriasis. Infrequently, the cutaneous findings of this disease precede the muscle inflammation by weeks or months. Diagnosing polymyositis in patients over age 70 years can be difficult because weakness may be overlooked or attributed erroneously to idiopathic frailty. Polymyositis can remain undiagnosed or will be misdiagnosed as hepatitis because of elevations in alanine aminotransferase (ALT) and aspartate



▲ **Figure 20–6.** Heliotrope (violaceous) rash around the eyes in a patient with dermatomyositis. (Courtesy of Richard P. Usatine, MD; used, with permission, from Usatine RP, Smith MA, Mayeaux EJ Jr, Chumley H, Tysinger J. *The Color Atlas of Family Medicine*. McGraw-Hill, 2009.)

aminotransferase (AST) levels. A subset of patients with polymyositis and dermatomyositis develop the “**antisynthetase syndrome**,” a group of findings including inflammatory arthritis, fever, Raynaud phenomenon, “mechanic’s hands” (hyperkeratosis along the radial and palmar aspects of the fingers) interstitial lung disease, and often severe muscle disease associated with certain autoantibodies (eg, anti-Jo1 antibodies).

B. Laboratory Findings

Measurement of serum levels of muscle enzymes, especially creatine kinase and aldolase, is most useful in diagnosis and in assessment of disease activity. Anemia is uncommon. The ESR and C-reactive protein are often normal and are not reliable indicators of disease activity. Rheumatoid factor is found in a minority of patients. Antinuclear antibodies are present in many patients, especially those who have an associated connective tissue disease (Table 20–10). A number of autoantibodies are seen exclusively in patients with myositis and are associated with distinctive clinical features. The most common myositis-specific antibody, anti-Jo-1 antibody, is seen in the subset of patients who have associated interstitial lung disease (Table 20–10). The other myositis-specific autoantibodies are anti-Mi-2, associated with dermatomyositis; anti-SRP (anti-signal recognition particle), associated with rapidly progressive, severe polymyositis, and dysphagia; and anti-155/140, strongly associated with dermatomyositis with malignancy (malignancy in 71% with versus 11% without this antibody). In the absence of the anti-synthetase syndrome, chest radiographs are usually normal. Electromyographic abnormalities consisting of polyphasic potentials, fibrillations, and high-frequency action potentials point toward a myopathic, rather than a neurogenic, cause of weakness. MRI can detect early and patchy muscle involvement, can guide biopsies, and often is more useful than electromyography. The malignancies most commonly associated with dermatomyositis in descending order of frequency are ovarian, lung, pancreatic, stomach, colorectal, and non-Hodgkin lymphoma. The search for an occult malignancy should begin with a history and physical examination, supplemented with a complete blood count, comprehensive biochemical panel, serum protein electrophoresis, and urinalysis, and should include age- and risk-appropriate cancer screening tests. Given the especially strong association of ovarian carcinoma and dermatomyositis, transvaginal ultrasonography, CT scanning, and CA-125 levels may be useful in women. No matter how extensive the initial screening, some malignancies will not become evident for months after the initial presentation.

C. Muscle Biopsy

Biopsy of clinically involved muscle is the only specific diagnostic test. The pathology findings in polymyositis and dermatomyositis are distinct. Although both include lymphoid inflammatory infiltrates, the findings in dermatomyositis are localized to perivascular regions and there is evidence of humoral and complement-mediated destruction of microvasculature associated with the

muscle. In addition to its vascular orientation, the inflammatory infiltrate in dermatomyositis centers on the interfascicular septa and is located around, rather than in, muscle fascicles. A pathologic hallmark of dermatomyositis is perifascicular atrophy. In contrast, the pathology of polymyositis characteristically includes endomysial infiltration of the inflammatory infiltrate. Owing to the sometimes patchy distribution of pathologic abnormalities, however, false-negative biopsies sometimes occur in both disorders.

► Differential Diagnosis

Muscle inflammation may occur as a component of SLE, scleroderma, Sjögren syndrome, and overlap syndromes. In those cases, associated findings usually permit the precise diagnosis of the primary condition.

Inclusion body myositis, because of its tendency to mimic polymyositis, is a common cause of “treatment-resistant polymyositis.” In contrast to the epidemiologic features of polymyositis, however, the typical inclusion body myositis patient is white, male, and over the age of 50. The onset of inclusion body myositis is more insidious than that of polymyositis or dermatomyositis (eg, occurring over years rather than months), and asymmetric distal motor weakness is common in inclusion body myositis. Creatine kinase levels in inclusion body myositis are often minimally elevated and are normal in 25%. Electromyography may show a mixed picture of myopathic and neurogenic abnormalities. Muscle biopsy shows characteristic intracellular vacuoles by light microscopy and either tubular or filamentous inclusions in the nucleus or cytoplasm by electron microscopy. Inclusion body myositis is less likely to respond to therapy.

Hypothyroidism is a common cause of proximal muscle weakness associated with elevations of serum creatine kinase. Hyperthyroidism and Cushing disease may both be associated with proximal muscle weakness with normal levels of creatine kinase. Patients with polymyalgia rheumatica are over the age of 50 and—in contrast to patients with polymyositis—have pain but no objective weakness; creatine kinase levels are normal. Disorders of the peripheral and central nervous systems (eg, chronic inflammatory polyneuropathy, multiple sclerosis, myasthenia gravis, Eaton-Lambert disease, and amyotrophic lateral sclerosis) can produce weakness but are distinguished by characteristic symptoms and neurologic signs and often by distinctive electromyographic abnormalities. A number of systemic vasculitides (polyarteritis nodosa, microscopic polyangiitis, the Churg-Strauss syndrome, granulomatosis with polyangiitis, and mixed cryoglobulinemia) can produce profound weakness through vasculitic neuropathy. The muscle weakness associated with these disorders, however, is typically distal and asymmetric, at least in the early stages.

Many drugs, including corticosteroids, alcohol, clofibrate, penicillamine, tryptophan, and hydroxychloroquine, can produce proximal muscle weakness. Long-term use of colchicine at doses as low as 0.6 mg twice a day in patients with moderate chronic kidney disease can produce a mixed neuropathy-myopathy that mimics polymyositis. The weakness and muscle enzyme elevation reverse

with cessation of the drug. Polymyositis can occur as a complication of HIV or HTLV-1 infection and with zidovudine therapy as well.

HMG-CoA reductase inhibitors can cause myopathy and rhabdomyolysis. Although only about 0.1% of patients taking a statin drug alone develop myopathy, concomitant administration of other drugs (especially gemfibrozil, cyclosporine, niacin, macrolide antibiotics, azole antifungals, and protease inhibitors) increases the risk. Statin use has also been linked to the development of an autoimmune-mediated necrotizing myositis, which persists after the statin has been discontinued and is associated with autoantibodies to HMG-CoA reductase.

► Treatment

Most patients respond to corticosteroids. Often a daily dose of 40–60 mg or more of oral prednisone is required initially. The dose is then adjusted downward while monitoring muscle strength and serum levels of muscle enzymes. Long-term use of corticosteroids is often needed, and the disease may recur or reemerge when they are withdrawn. Patients with an associated neoplasm have a poor prognosis, although remission may follow treatment of the tumor; corticosteroids may or may not be effective in these patients. In patients resistant or intolerant to corticosteroids, therapy with methotrexate or azathioprine may be helpful. Intravenous immune globulin is effective for dermatomyositis resistant to prednisone. Mycophenolate mofetil (1–1.5 g orally twice daily) may be useful as a steroid-sparing agent. Rituximab has achieved encouraging results in some patients with inflammatory myositis unresponsive to prednisone. Since the rash of dermatomyositis is often photosensitive, patients should limit sun exposure. Hydroxychloroquine (200–400 mg/d orally not to exceed 6.5 mg/kg) can also help ameliorate the skin disease.

► When to Refer

- Appropriate management of myositis usually requires frequent consultations with a rheumatologist or neurologist.
- Severe lung disease may require consultation with a pulmonologist.

► When to Admit

- Signs of rhabdomyolysis.
- Respiratory insufficiency with hypoxia or carbon dioxide retention.

Katzap E et al. Antisynthetase syndrome. *Curr Rheumatol Rep.* 2011 Jun;13(3):175–81. [PMID: 21455765]

Labirua A et al. Interstitial lung disease and idiopathic inflammatory myopathies: progress and pitfalls. *Curr Opin Rheumatol.* 2010 Nov;22(6):633–8. [PMID: 20827201]

Mammen AL et al. Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathy. *Arthritis Rheum.* 2011 Mar; 63(3): 713–21. [PMID: 21360500]

MIXED CONNECTIVE TISSUE DISEASE & OVERLAP SYNDROMES

Many patients with symptoms and signs compatible with a connective tissue disease have features consistent with more than one type of rheumatic disease. Special attention has been drawn to antinuclear antibody–positive patients who have overlapping features of SLE, scleroderma, and inflammatory myopathy together with autoantibodies to ribonuclear protein (RNP). Some consider these patients to have a distinct entity (“mixed connective tissue disease”), and others view this as a subset of SLE characterized by a higher prevalence of Raynaud phenomenon, polyarthritides, myositis, and pulmonary hypertension and a lower incidence of renal involvement. Other patients have features of more than one connective tissue disease (eg, rheumatoid arthritis and SLE, SLE and scleroderma) in the absence of anti-RNP antibodies and are referred to as having an “overlap syndrome.” Treatments are guided more by the distribution and severity of patients’ organ system involvement than by therapies specific to these overlap syndromes.

Tsai YY et al. Fifteen-year experience of pediatric-onset mixed connective tissue disease. *Clin Rheumatol.* 2010 Jan;29(1): 53–8. [PMID: 19756834]

SJÖGREN SYNDROME



ESSENTIALS OF DIAGNOSIS

- Women are 90% of patients; the average age is 50 years.
- Dryness of eyes and dry mouth (sicca components) are the most common features; they occur alone or in association with rheumatoid arthritis or other connective tissue disease.
- Rheumatoid factor and other autoantibodies are common.
- Increased incidence of lymphoma.

► General Considerations

Sjögren syndrome is a systemic autoimmune disorder whose clinical presentation is usually dominated by dryness of the eyes and mouth due to immune-mediated dysfunction of the lacrimal and salivary glands. The disorder is predominantly seen in women, with a ratio of 9:1; most cases develop between the ages of 40 and 60 years. Sjögren syndrome can occur in isolation (“primary” Sjögren syndrome) or in association with another rheumatic disease. Sjögren syndrome is most frequently associated with rheumatoid arthritis but also occurs with SLE, primary biliary cirrhosis, scleroderma, polymyositis, Hashimoto thyroiditis, polyarteritis, and interstitial pulmonary fibrosis.

► Clinical Findings

A. Symptoms and Signs

Keratoconjunctivitis sicca results from inadequate tear production caused by lymphocyte and plasma cell infiltration of the lacrimal glands. Ocular symptoms are usually mild. Burning, itching, and the sensation of having a foreign body or a grain of sand in the eye occur commonly. For some patients, the initial manifestation is the inability to tolerate wearing contact lenses. Many patients with more severe ocular dryness notice ropy secretions across their eyes, especially in the morning. Photophobia may signal corneal ulceration resulting from severe dryness. For most patients, symptoms of dryness of the mouth (xerostomia) dominate those of dry eyes. Patients frequently complain of a “cotton mouth” sensation and difficulty swallowing foods, especially dry foods like crackers, unless they are washed down with liquids. The persistent oral dryness causes most patients to carry water bottles or other liquid dispensers from which they sip constantly. A few patients have such severe xerostomia that they have difficulty speaking. Persistent xerostomia results often in rampant dental caries; caries at the gum line strongly suggest Sjögren syndrome. Some patients are most troubled by loss of taste and smell. Parotid enlargement, which may be chronic or relapsing, develops in one-third of patients. Desiccation may involve the nose, throat, larynx, bronchi, vagina, and skin.

Systemic manifestations include dysphagia, small vessel vasculitis, pleuritis, obstructive airways disease and interstitial lung disease (in the absence of smoking), neuropsychiatric dysfunction (most commonly peripheral neuropathies), and pancreatitis; they may be related to the associated diseases noted above. Renal tubular acidosis (type I, distal) occurs in 20% of patients. Chronic interstitial nephritis, which may result in impaired kidney function, may be seen.

B. Laboratory Findings

Laboratory findings include mild anemia, leukopenia, and eosinophilia. Polyclonal hypergammaglobulinemia, rheumatoid factor positivity (70%), and antinuclear antibodies (95%) are all common findings. Antibodies against the cytoplasmic antigens SS-A and SS-B (also called Ro and La, respectively) are often present in primary Sjögren syndrome and tend to correlate with the presence of extraglandular manifestations (Table 20–10). Thyroid-associated autoimmunity is a common finding among patients with Sjögren syndrome.

Useful ocular diagnostic tests include the Schirmer test, which measures the quantity of tears secreted. Lip biopsy, a simple procedure, reveals characteristic lymphoid foci in accessory salivary glands. Biopsy of the parotid gland should be reserved for patients with atypical presentations such as unilateral gland enlargement that suggest a neoplastic process.

► Differential Diagnosis

Isolated complaints of dry mouth are most commonly due to medication side effects. Chronic hepatic C can cause sicca symptoms and rheumatoid factor positivity. Minor

salivary gland biopsies reveal lymphocytic infiltrates but not to the extent of Sjögren syndrome, and tests for anti-SS-A and anti-SS-B are negative. Diffuse infiltration of CD8 T cells producing parotid gland enlargement can develop in HIV-infected individuals. Involvement of the lacrimal or salivary glands, or both in sarcoidosis can mimic Sjögren syndrome; biopsies reveal noncaseating granulomas. Rarely, amyloid deposits in the lacrimal and salivary glands produce sicca symptoms. IgG4-related systemic disease (characterized by high serum IgG₄ levels and infiltration of tissues with IgG₄ plasma cells) can result in lacrimal and salivary gland enlargement that mimics Sjögren syndrome.

► Treatment & Prognosis

Treatment of sicca symptoms is symptomatic and supportive. Artificial tears applied frequently will relieve ocular symptoms and avert further desiccation. Topical ocular 0.05% cyclosporine also improves ocular symptoms and signs of dryness. The mouth should be kept well lubricated. Sipping water frequently or using sugar-free gums and hard candies usually relieves dry mouth symptoms. Pilocarpine (5 mg orally four times daily) and the acetylcholine derivative cevimeline (30 mg orally three times daily) may improve xerostomia symptoms. Atropinic drugs and decongestants decrease salivary secretions and should be avoided. A program of oral hygiene, including fluoride treatment, is essential in order to preserve dentition. If there is an associated rheumatic disease, its systemic treatment is not altered by the presence of Sjögren syndrome.

Although Sjögren syndrome may compromise patients' quality of life significantly, the disease is usually consistent with a normal life span. Poor prognoses are influenced mainly by the presence of systemic features associated with underlying disorders, the development in some patients of lymphocytic vasculitis, the occurrence of a painful peripheral neuropathy, and the complication (in a minority of patients) of lymphoma. Severe systemic inflammatory manifestations are treated with prednisone or various immunosuppressive medications. The patients (3–10% of the total Sjögren population) at greatest risk for developing lymphoma are those with severe exocrine dysfunction, marked parotid gland enlargement, splenomegaly, vasculitis, peripheral neuropathy, anemia, and mixed monoclonal cryoglobulinemia.

► When to Refer

- Presence of systemic symptoms or signs.
- Symptoms or signs of ocular dryness not responsive to artificial tears.

► When to Admit

- Presence of severe systemic signs such as vasculitis unresponsive to outpatient management.

Chai J et al. Neurological manifestations of primary Sjögren's syndrome. *Curr Opin Neurol*. 2010 Oct;23(5):509–13. [PMID: 20689426]

Kokosi M et al. Pulmonary involvement in Sjögren syndrome. *Clin Chest Med.* 2010 Sep;31(3):489–500. [PMID: 20692541]
 Ramos-Casals M et al. Treatment of primary Sjögren syndrome: a systematic review. *JAMA.* 2010 Jul 28;304(4):452–60. [PMID: 20664046]

RHABDOMYOLYSIS

ESSENTIALS OF DIAGNOSIS

- ▶ Associated with crush injuries to muscle, prolonged immobility, drug toxicities, hypothermia, and other causes.
- ▶ Massive acute elevations of muscle enzymes that peak quickly and usually resolve within days once the inciting injury has been identified and removed.

▶ General Considerations

Rhabdomyolysis is a syndrome of acute necrosis of skeletal muscle associated with myoglobinuria and markedly elevated creatine kinase levels. Acute tubular necrosis is a common complication of rhabdomyolysis and is due to the toxic effects of filtering excessive quantities of myoglobin in the setting of hypovolemia (See Acute Tubular Necrosis in Chapter 22). Many patients in whom rhabdomyolysis develops are volume-contracted and, therefore, oliguric renal failure is encountered routinely.

Rhabdomyolysis was first recognized as a complication of crush injuries to muscle among victims of the London Blitz during the World War II. Cocaine use and alcohol intoxication, particularly in the setting of prolonged immobility and exposure hypothermia, are leading causes of admissions due to rhabdomyolysis on the medical services of inner city hospitals. Use of statins is another important cause of rhabdomyolysis. The presence of compromised kidney and liver function, diabetes mellitus, and hypothyroidism as well as concomitant use of other medications increase the risk of rhabdomyolysis in patients taking statins. The cytochrome P450 liver enzymes metabolize all statins except for pravastatin and rosuvastatin. Drugs that block the action of cytochrome P450 include protease inhibitors, erythromycin, itraconazole, clarithromycin, diltiazem, and verapamil. Use of these drugs concomitantly with the statins (but not pravastatin or rosuvastatin) can increase the risk of development of rhabdomyolysis. The likelihood of rhabdomyolysis also increases when statins are used with niacin and fibric acids (gemfibrozil, clofibrate, and fenofibrate). Rhabdomyolysis is an uncommon complication of polymyositis, dermatomyositis, and the myopathy of hypothyroidism, despite the high levels of creatine kinase often seen in these conditions.

Often there is little evidence for muscle injury on clinical assessment of the patients with rhabdomyolysis—specifically, myalgias and weakness are usually absent. The first clue to muscle necrosis in such individuals may be a

urinary dipstick testing positive for “blood” (actually myoglobin) in the absence of red cells in the sediment. This positive finding is due to myoglobinuria, which results in a false-positive reading for hemoglobin. Such an abnormality should prompt determination of the serum creatine kinase level, which invariably is elevated (usually markedly so). Other commonly encountered laboratory abnormalities in rhabdomyolysis include elevated serum levels of ALT and lactate dehydrogenase due to release of these enzymes from skeletal muscle.

▶ Treatment

Vigorous fluid resuscitation (4–6 L/d, with careful monitoring for volume overload) is indicated. Infusion of mannitol (100 mg/d) and urine alkalinization (to minimize precipitation of myoglobin within tubules) have been recommended as measures to reduce kidney injury, but definitive evidence for the efficacy of these measures is lacking. Myopathic complications of statins usually resolve within several weeks of discontinuing the drug.

Bosch X et al. Rhabdomyolysis and acute kidney injury. *N Engl J Med.* 2009 Jul 2;361(1):62–72. [PMID: 19571284]
 Cervellin G et al. Rhabdomyolysis: historical background, clinical, diagnostic and therapeutic features. *Clin Chem Lab Med.* 2010 Jun;48(6):749–56. [PMID: 20298139]

VASCULITIS SYNDROMES

“Vasculitis” is a heterogeneous group of disorders characterized by inflammation within the walls of affected blood vessels. The major forms of primary systemic vasculitis are listed in Table 20–13. The first consideration in classifying cases of vasculitis is the size of the major vessels involved: large, medium, or small. The presence of the clinical signs and symptoms shown in Table 20–14 help distinguish among these three groups. After determining the size of the major vessels involved, other issues that contribute to the classification include the following:

- Does the process involve arteries, veins, or both?
- What are the patient’s demographic characteristics (age, gender, ethnicity, smoking status)?
- Which organs are involved?
- Is there hypocomplementemia or other evidence of immune complex deposition?
- Is there granulomatous inflammation on tissue biopsy?
- Are antineutrophil cytoplasmic antibodies (ANCA) present?

In addition to the disorders considered to be primary vasculitides, there are also multiple forms of vasculitis that are associated with other known underlying conditions. These “secondary” forms of vasculitis occur in the setting of chronic infections (eg, hepatitis B or C, subacute bacterial endocarditis), connective tissue disorders, inflammatory bowel disease, malignancies, and reactions to medications. Only the major primary forms of vasculitis are discussed here.

Table 20-13. Classification scheme of primary vasculitides according to size of predominant blood vessels involved.

<p>Predominantly large-vessel vasculitides</p> <ul style="list-style-type: none"> Takayasu arteritis Giant cell arteritis (temporal arteritis) Behçet disease¹ <p>Predominantly medium-vessel vasculitides</p> <ul style="list-style-type: none"> Polyarteritis nodosa Buerger disease Primary angiitis of the central nervous system <p>Predominantly small-vessel vasculitides</p> <ul style="list-style-type: none"> Immune-complex mediated <ul style="list-style-type: none"> Cutaneous leukocytoclastic angiitis (“hypersensitivity vasculitis”) Henoch-Schönlein purpura Essential cryoglobulinemia² “ANCA-associated” disorders³ Granulomatosis with polyangiitis (formerly Wegener granulomatosis)² Microscopic polyangiitis² Churg-Strauss syndrome²
--

¹May involve small, medium, and large-sized blood vessels.
²Frequent overlap of small and medium-sized blood vessel involvement.
³Not all forms of these disorders are always associated with ANCA. ANCA, antineutrophil cytoplasmic antibodies.

Langford CA. Vasculitis. *J Allergy Clin Immunol.* 2010 Feb;125 (2 Suppl 2):S216–25. [PMID: 19932919]

POLYMYALGIA RHEUMATICA & GIANT CELL ARTERITIS

ESSENTIALS OF DIAGNOSIS

- ▶ Age over 50 years.
- ▶ Giant cell (temporal) arteritis is characterized by headache, jaw claudication, polymyalgia rheumatica, visual abnormalities, and a markedly elevated ESR.
- ▶ The hallmark of polymyalgia rheumatica is pain and stiffness in shoulders and hips lasting for several weeks without other explanation.

▶ General Considerations

Polymyalgia rheumatica and giant cell arteritis probably represent a spectrum of one disease: Both affect the same population (patients over the age of 50), show preference for the same HLA haplotypes, and show similar patterns of cytokines in blood and arteries. Polymyalgia rheumatica and giant cell arteritis also frequently coexist. The important differences between the two conditions are that polymyalgia rheumatica alone does not cause blindness and responds to low-dose (10–20 mg/d orally) prednisone

Table 20-14. Typical clinical manifestations of large-, medium-, and small-vessel involvement by vasculitis.

Large	Medium	Small
Constitutional symptoms: fever, weight loss, malaise, arthralgias/arthrits		
Limb claudication	Cutaneous nodules	Purpura
Asymmetric blood pressures	Ulcers	Vesiculobullous lesions
Absence of pulses	Livedo reticularis	Urticaria
Bruits	Digital gangrene	Glomerulonephritis
Aortic dilation	Mononeuritis multiplex	Alveolar hemorrhage
	Microaneurysms	Cutaneous extravascular necrotizing granulomas
		Splinter hemorrhages
		Uveitis
		Episcleritis
		Scleritis

therapy, whereas giant cell arteritis can cause blindness and large artery complications and requires high-dose (40–60 mg/d) prednisone.

▶ Clinical Findings

A. Polymyalgia Rheumatica

Polymyalgia rheumatica is a clinical diagnosis based on pain and stiffness of the shoulder and pelvic girdle areas, frequently in association with fever, malaise, and weight loss. In approximately two-thirds of cases, polymyalgia occurs in the absence of giant cell arteritis. Because of the stiffness and pain in the shoulders, hips, and lower back, patients have trouble combing their hair, putting on a coat, or rising from a chair. In contrast to polymyositis and polyarteritis nodosa, polymyalgia rheumatica does not cause muscular weakness either through primary muscle inflammation or secondary to nerve infarction. A few patients have joint swelling, particularly of the knees, wrists, and sternoclavicular joints.

B. Giant Cell Arteritis

Giant cell arteritis is a systemic panarteritis affecting medium-sized and large vessels in patients over the age of 50. The incidence of this disease increases with each decade of life. The mean age at onset is approximately 79 years. Giant cell arteritis is also called temporal arteritis because that artery is frequently involved, as are other extracranial branches of the carotid artery. About 50% of patients with giant cell arteritis also have polymyalgia rheumatica. The classic symptoms suggesting that a patient has arteritis are headache, scalp tenderness, visual symptoms (particularly amaurosis fugax or diplopia), jaw claudication, or throat pain. Of these symptoms, jaw claudication has the highest positive predictive value. The temporal artery is usually normal on physical examination but may be nodular, enlarged, tender, or pulseless. Blindness usually results from the syndrome of anterior ischemic optic neuropathy, caused by occlusive arteritis of the posterior ciliary branch

of the ophthalmic artery. The ischemic optic neuropathy of giant cell arteritis may produce no fundoscopic findings for the first 24–48 hours after the onset of blindness.

Asymmetry of pulses in the arms, a murmur of aortic regurgitation, or bruits heard near the clavicle resulting from subclavian artery stenoses identify patients in whom giant cell arteritis has affected the aorta or its major branches. Clinically evident large vessel involvement—characterized chiefly by aneurysm of the thoracic aorta or stenosis of the subclavian, vertebral, carotid, and basilar arteries—occurs in approximately 25% of patients with giant cell arteritis, sometimes years after the diagnosis. Subclinical large artery disease is the rule: positron emission tomography scans reveal inflammation in the aorta and its major branches in nearly 85% of untreated patients. Forty percent of patients with giant cell arteritis have non-classic symptoms at presentation, chiefly respiratory tract problems (most frequently dry cough), mononeuritis multiplex (most frequently with painful paralysis of a shoulder), or fever of unknown origin. Giant cell arteritis accounts for 15% of all cases of fever of unknown origin in patients over the age of 65. The fever can be as high as 40°C and is frequently associated with rigors and sweats. In contrast to patients with infection, patients with giant cell arteritis and fever usually have normal white blood cell counts (before prednisone is started). Thus, in an older patient with fever of unknown origin, marked elevations of acute phase reactants, and a normal white blood count, giant cell arteritis must be considered even in the absence of specific features such as headache or jaw claudication. In some cases, instead of having the well-known symptom of jaw claudication, patients complain of vague pain affecting other locations, including the tongue, nose, or ears. Indeed, unexplained head or neck pain in an older patient may signal the presence of giant cell arteritis.

C. Laboratory Findings

1. Polymyalgia rheumatica—Anemia and elevated acute phase reactants (often markedly elevated ESRs, for example) are present in the most cases, but cases of polymyalgia rheumatica occurring with normal acute phase reactants are well documented.

2. Giant cell arteritis—Nearly 90% of patients with giant cell arteritis have ESRs > 50 mm/h. The ESR in this disorder is often > 100 mm/h, but cases in which the ESR is low or even normal do occur. In one series, 5% of patients with biopsy-proven giant cell arteritis had ESRs < 40 mm/h. Although the C-reactive protein is slightly more sensitive, patients with biopsy-proven giant cell arteritis with normal C-reactive proteins have also been described. Most patients also have a mild normochromic, normocytic anemia and thrombocytosis. The alkaline phosphatase (liver source) is elevated in 20% of patients with giant cell arteritis.

► Differential Diagnosis

The differential diagnosis of malaise, anemia, and striking acute phase reactant elevations includes rheumatic diseases (such as rheumatoid arthritis, other systemic vasculitides,

multiple myeloma, and other malignant disorders) and chronic infections (such as bacterial endocarditis and osteomyelitis).

► Treatment

A. Polymyalgia Rheumatica

Patients with isolated polymyalgia rheumatica (ie, those not having “above the neck” symptoms of headache, jaw claudication, scalp tenderness, or visual symptoms) are treated with prednisone, 10–20 mg/d orally. If the patient does not experience a dramatic improvement within 72 hours, the diagnosis should be revisited. Usually after 2–4 weeks of treatment, slow tapering of the prednisone can be attempted. Most patients require some dose of prednisone for a minimum of approximately 1 year; 6 months is too short in most cases. Disease flares are common (50% or more) as prednisone is tapered. The addition of weekly methotrexate may increase the chance of successfully tapering prednisone in some patients.

B. Giant Cell Arteritis

The urgency of early diagnosis and treatment in giant cell arteritis relates to the prevention of blindness. Once blindness develops, it is usually permanent. Therefore, when a patient has symptoms and findings suggestive of temporal arteritis, therapy with prednisone (60 mg/d orally) should be initiated immediately and a temporal artery biopsy performed promptly. For patients who seek medical attention for visual loss, intravenous pulse methylprednisolone (eg, 1 g daily for 3 days) has been advocated; unfortunately, few patients recover vision no matter what the initial treatment. One study—too small and too preliminary to change the standard therapy recommendations mentioned above—suggested that initiating treatment with intravenous pulse methylprednisolone may increase the chance that a patient with giant cell arteritis will achieve remission and be able to taper off of prednisone. Retrospective studies suggest that low-dose aspirin (~81 mg/d orally) may reduce the chance of visual loss or stroke in patients with giant cell arteritis and should be added to prednisone in the initial treatment. Although it is prudent to obtain a temporal artery biopsy as soon as possible after instituting treatment, diagnostic findings of giant cell arteritis may still be present 2 weeks (or even considerably longer) after starting corticosteroids. Typically, a positive biopsy shows inflammatory infiltrate in the media and adventitia with lymphocytes, histiocytes, plasma cells, and giant cells. An adequate biopsy specimen is essential (at least 2 cm in length is ideal), because the disease may be segmental. Unilateral temporal artery biopsies are positive in approximately 80–85% of patients, but bilateral biopsies add incrementally to the yield (10–15% in some studies, less in others). Ultrasonography can detect abnormalities in inflamed temporal arteries, but it has not displaced temporal artery biopsy as the gold standard for diagnosis in most cases because results are highly operator dependent. Temporal artery biopsy is abnormal in only 50% of patients with large artery disease (eg, arm claudication and unequal upper extremity blood pressures). In these

patients, magnetic resonance angiography or CT angiography will establish the diagnosis by demonstrating long stretches of narrowing of the subclavian and axillary arteries. Prednisone should be continued in a dosage of 60 mg/d orally for about 1 month before tapering. When only the symptoms of polymyalgia rheumatica are present, temporal artery biopsy is not necessary.

After 1 month of high-dose prednisone, almost all patients will have a normal ESR. When tapering and adjusting the dosage of prednisone, the ESR (or C-reactive protein) is a useful but not absolute guide to disease activity. A common error is treating the ESR rather than the patient. The ESR often rises slightly as the prednisone is tapered, even as the disease remains quiescent. Because elderly individuals often have baseline ESRs that are above the normal range, mild ESR elevations should not be an occasion for renewed treatment with prednisone in patients who are asymptomatic. Unfortunately, no highly effective prednisone-sparing therapy has been identified. Methotrexate was modestly effective in one double-blind, placebo-controlled treatment trial but ineffective in another. Anti-TNF therapies do not work in giant cell arteritis. Thoracic aortic aneurysms occur 17 times more frequently in patients with giant cell arteritis than in normal individuals and can result in aortic regurgitation, dissection, or rupture. The aneurysms can develop at any time but typically occur 7 years after the diagnosis of giant cell arteritis is made.

Gonzalez-Gay MA et al. Medical management of polymyalgia rheumatica. *Expert Opin Pharmacother*. 2010 May;11(7):1077–87. [PMID: 20367535]

Scheurer RA et al. Treatment of vision loss in giant cell arteritis. *Curr Treat Options Neurol*. 2012 Feb;14(1):84–92. [PMID: 22037998]

POLYARTERITIS NODOSA



ESSENTIALS OF DIAGNOSIS

- ▶ Medium-sized arteries are always affected; smaller arterioles are sometimes involved; lung is spared but kidney often affected, causing renin-mediated hypertension.
- ▶ Clinical findings depend on the arteries involved.
- ▶ Common features include fever, abdominal pain, extremity pain, livedo reticularis, mononeuritis multiplex, anemia, and elevated acute phase reactants (ESR or C-reactive protein or both).
- ▶ Associated with hepatitis B (10% of cases).

▶ General Considerations

Polyarteritis nodosa, described in 1866, is acknowledged widely as the first form of vasculitis reported in the medical literature. For many years, all forms of inflammatory vascular disease were termed “polyarteritis nodosa.” In recent

decades, numerous subtypes of vasculitis have been recognized, greatly narrowing the spectrum of vasculitis called polyarteritis nodosa. Currently, the term is reserved for necrotizing arteritis of medium-sized vessels that has a predilection for involving the skin, peripheral nerves, mesenteric vessels (including renal arteries), heart, and brain, but polyarteritis nodosa can actually involve almost any organ. Polyarteritis nodosa is relatively rare, with a prevalence of about 30 per 1 million people. Approximately 10% of cases of polyarteritis nodosa are caused by hepatitis B. Most cases of hepatitis B–associated disease occur within 6 months of hepatitis B infection.

▶ Clinical Findings

A. Symptoms and Signs

The clinical onset is usually insidious, with fever, malaise, weight loss, and other symptoms developing over weeks to months. Pain in the extremities is often a prominent early feature caused by arthralgia, myalgia (particularly affecting the calves), or neuropathy. The combination of mononeuritis multiplex (with the most common finding being foot-drop) and features of a systemic illness is one of the earliest specific clues to the presence of an underlying vasculitis. Polyarteritis nodosa is among the forms of vasculitis most commonly associated with vasculitic neuropathy.

In polyarteritis nodosa, the typical skin findings—livedo reticularis, subcutaneous nodules, and skin ulcers—reflect the involvement of deeper, medium-sized blood vessels. Digital gangrene is not an unusual occurrence. The most common cutaneous presentation is lower extremity ulcerations, usually occurring near the malleoli. Involvement of the renal arteries leads to a renin-mediated hypertension (much less characteristic of vasculitides involving smaller blood vessels). For unclear reasons, classic polyarteritis nodosa seldom (if ever) involves the lung, with the occasional exception of the bronchial arteries.

Abdominal pain—particularly diffuse periumbilical pain precipitated by eating—is common but often difficult to attribute to mesenteric vasculitis in the early stages. Nausea and vomiting are common symptoms. Infarction compromises the function of major viscera and may lead to acalculous cholecystitis or appendicitis. Some patients present dramatically with an acute abdomen caused by mesenteric vasculitis and gut perforation or with hypotension resulting from rupture of a microaneurysm in the liver, kidney, or bowel.

Subclinical cardiac involvement is common in polyarteritis nodosa, and overt cardiac dysfunction occasionally occurs (eg, myocardial infarction secondary to coronary vasculitis, or myocarditis).

B. Laboratory Findings

Most patients with polyarteritis nodosa have a slight anemia, and leukocytosis is common. Acute phase reactants are often (but not always) strikingly elevated. A major challenge in making the diagnosis of polyarteritis nodosa, however, is the absence of a disease-specific serologic test (eg, an autoantibody). Patients with classic polyarteritis nodosa are

ANCA-negative and may have low titers of rheumatoid factor or antinuclear antibodies, both of which are nonspecific findings. In patients with polyarteritis nodosa, appropriate serologic tests for active hepatitis B infection must be performed.

C. Biopsy and Angiography

The diagnosis of polyarteritis nodosa requires confirmation with either a tissue biopsy or an angiogram. Biopsies of symptomatic sites such as skin (from the edge of an ulcer or the center of a nodule), nerve, or muscle have sensitivities of approximately 70%. The least invasive tests should usually be obtained first, but biopsy of an involved organ is essential. If performed by experienced clinicians, tissue biopsies normally have high benefit-risk ratios because of the importance of establishing the diagnosis. Patients in whom polyarteritis nodosa is suspected—eg, on the basis of mesenteric ischemia or new-onset hypertension occurring in the setting of a systemic illness—may be diagnosed by the angiographic finding of aneurysmal dilations in the renal, mesenteric, or hepatic arteries. Angiography must be performed cautiously in patients with baseline renal dysfunction.

▶ Treatment

For polyarteritis nodosa, corticosteroids in high doses (up to 60 mg of oral prednisone daily) may control fever and constitutional symptoms and heal vascular lesions. Pulse methylprednisolone (eg, 1 g intravenously daily for 3 days) may be necessary for patients who are critically ill at presentation. Immunosuppressive agents, especially cyclophosphamide, lower the risk of disease-related death and morbidity among patients who have severe disease. For patients with polyarteritis nodosa associated with hepatitis B, the preferred treatment regimen is a short course of prednisone accompanied by antiviral therapy and plasmapheresis (three times a week for up to 6 weeks).

▶ Prognosis

Without treatment, the 5-year survival rate in these disorders is poor—on the order of 10%. With appropriate therapy, remissions are possible in many cases and the 5-year survival rate has improved to 60–90%. Poor prognostic factors are chronic kidney disease with serum creatinine > 1.6 mg/dL, proteinuria > 1 g/d, gastrointestinal ischemia, central nervous system disease, and cardiac involvement. In the absence of any of these five factors, 5-year survival is nearly 90%. Survival at 5 years drops to 75% with one poor prognostic factor present and to about 50% with two or more factors. Substantial morbidity and even death may result from adverse effects of cyclophosphamide and corticosteroids. Consequently, these therapies require careful monitoring and expert management. In contrast to many other forms of systemic vasculitis, disease relapses in polyarteritis following the successful induction of remission are the exception rather than the rule, occurring in only about 20% of cases.

de Menthon M et al. Treating polyarteritis nodosa: current state of the art. *Clin Exp Rheumatol*. 2011 Jan–Feb;29(1 Suppl 64):S110–6. [PMID: 21586205]

Morgan AJ et al. Cutaneous polyarteritis nodosa: a comprehensive review. *Int J Dermatol*. 2010 Jul;49(7):750–6. [PMID: 20618492]

Pagnoux C et al. Clinical features and outcomes in 348 patients with polyarteritis nodosa: a systematic retrospective study of patients diagnosed between 1963 and 2005 and entered into the French Vasculitis Study Group Database. *Arthritis Rheum*. 2010 Feb;62(2):616–26. [PMID: 20112401]

GRANULOMATOSIS WITH POLYANGIITIS (Formerly Wegener Granulomatosis)

ESSENTIALS OF DIAGNOSIS

- ▶ Classic triad of upper and lower respiratory tract disease and glomerulonephritis.
- ▶ Suspect if mild respiratory symptoms (eg, nasal congestion, sinusitis) are refractory to usual treatment.
- ▶ Pathology defined by the triad of small vessel vasculitis, granulomatous inflammation, and necrosis.
- ▶ ANCA, usually directed against proteinase-3 (less commonly against myeloperoxidase present in severe, active disease) (90% of patients).
- ▶ Kidney disease often rapidly progressive without treatment.


▶ General Considerations

Granulomatosis with polyangiitis, which has an estimated incidence of approximately 12 cases per million individuals per year, is the prototype of diseases associated with antineutrophil cytoplasmic antibodies (ANCA). (Other “ANCA-associated vasculitides” include microscopic polyangiitis and the Churg-Strauss syndrome.) Granulomatosis with polyangiitis is characterized in its full expression by vasculitis of small arteries, arterioles, and capillaries, necrotizing granulomatous lesions of both upper and lower respiratory tract, glomerulonephritis, and other organ manifestations. Without treatment, generalized disease is invariably fatal, with most patients surviving < 1 year after diagnosis. It occurs most commonly in the fourth and fifth decades of life and affects men and women with equal frequency.

▶ Clinical Findings

A. Symptoms and Signs

The disorder usually develops over 4–12 months. Upper respiratory tract symptoms develop in 90% of patients and lower respiratory tract symptoms develop in 60% of patients; some patients may have both upper and lower respiratory tract symptoms. Upper respiratory tract symptoms can include nasal congestion, sinusitis, otitis media, mastoiditis, inflammation of the gums, or stridor due to subglottic stenosis. Since many of these symptoms are common, the



▲ **Figure 20-7.** Scleritis in a patient with granulomatosis with polyangiitis (formerly Wegener granulomatosis). (Courtesy of Everett Allen, MD; used, with permission, from Usatine RP, Smith MA, Mayeaux EJ Jr, Chumley H, Tysinger J. *The Color Atlas of Family Medicine*. McGraw-Hill, 2009.)

underlying disease is not often suspected until the patient develops systemic symptoms or the original problem is refractory to treatment. The lungs are affected initially in 40% and eventually in 80%, with symptoms including cough, dyspnea, and hemoptysis. Other early symptoms can include a migratory oligoarthritis with a predilection for large joints; a variety of symptoms related to ocular disease (unilateral proptosis from orbital pseudotumor; red eye from scleritis [Figure 20-7], episcleritis, anterior uveitis, or peripheral ulcerative keratitis); purpura or other skin lesions; and dysesthesia due to neuropathy. Renal involvement, which develops in three-fourths of the cases, may be subclinical until kidney disease is advanced. Fever, malaise, and weight loss are common.

Physical examination can be remarkable for congestion, crusting, ulceration, bleeding, and even perforation of the nasal septum. Destruction of the nasal cartilage with “saddle nose” deformity occurs late. Otitis media, proptosis, scleritis, episcleritis, and conjunctivitis are other common findings. Newly acquired hypertension, a frequent feature of polyarteritis nodosa, is rare in granulomatosis with polyangiitis. Venous thrombotic events (eg, deep venous thrombosis and pulmonary embolism) are a common occurrence in granulomatosis with polyangiitis, at least in part because of the tendency of the disease to involve veins as well as arteries. Although limited forms of granulomatosis with polyangiitis have been described in which the kidney is spared initially, kidney disease will develop in the majority of untreated patients.

B. Laboratory Findings

1. Serum tests and urinalysis—Most patients have slight anemia, mild leukocytosis, and elevated acute phase reactants.

If there is renal involvement, there is proteinuria and the urinary sediment contains red cells, with or without white cells, and often has red cell casts.

Serum tests for ANCA help in the diagnosis of granulomatosis with polyangiitis and related forms of vasculitis (Table 20-10). Several different types of ANCA are recognized, but the two subtypes relevant to systemic vasculitis are those directed against proteinase-3 (PR3) and myeloperoxidase (MPO). Antibodies to these two antigens are termed “PR3-ANCA” and “MPO-ANCA,” respectively. The cytoplasmic pattern of immunofluorescence (c-ANCA) caused by PR3-ANCA has a high specificity (> 90%) for either granulomatosis with polyangiitis or a closely related disease, microscopic polyangiitis (or, less commonly, the Churg-Strauss syndrome). In the setting of active disease, particularly cases in which the disease is severe and generalized to multiple organ systems, the sensitivity of PR3-ANCA is > 95%. A substantial percentage of patients with “limited” granulomatosis with polyangiitis—disease that does not pose an immediate threat to life and is often confined to the respiratory tract—are ANCA-negative. Although ANCA testing may be very helpful when used properly, it does not eliminate the need in most cases for confirmation of the diagnosis by tissue biopsy. Furthermore, ANCA levels correlate erratically with disease activity, and changes in titer should not dictate changes in therapy in the absence of supporting clinical data. The perinuclear (p-ANCA) pattern, caused by MPO-ANCA, is more likely to occur in microscopic polyangiitis or Churg-Strauss but may also be found in granulomatosis with polyangiitis. Approximately 10–25% of patients with classic granulomatosis with polyangiitis have MPO-ANCA. All positive immunofluorescence assays for ANCA should be confirmed by enzyme immunoassays for the specific autoantibodies directed against PR3 or MPO.

2. Histologic findings—Histologic features of granulomatosis with polyangiitis include vasculitis, granulomatous inflammation, geographic necrosis, and acute and chronic inflammation. The full range of pathologic changes is usually evident only on thoracoscopic lung biopsy. Granulomas, observed only rarely in renal biopsy specimens, are found much more commonly on lung biopsy specimens. Nasal biopsies often do not show vasculitis but may show chronic inflammation and other changes which, interpreted by an experienced pathologist, can serve as convincing evidence of the diagnosis. Renal biopsy discloses a segmental necrotizing glomerulonephritis with multiple crescents; this is characteristic but not diagnostic. Pathologists characterize the renal lesion of granulomatosis with polyangiitis (and other forms of “ANCA-associated vasculitis”) as a pauci-immune glomerulonephritis because of the relative absence (compared with immune complex-mediated disorders) of immunoreactants—IgG, IgM, IgA, and complement proteins—within glomeruli.

C. Imaging

Chest CT is more sensitive than chest radiography; lesions include infiltrates, nodules, masses, and cavities. Pleural effusions are uncommon. Often the radiographs prompt

concern about lung cancer. Hilar adenopathy is unusual in granulomatosis with polyangiitis; if present, sarcoidosis, tumor, or infection is more likely. Other common radiographic abnormalities include extensive sinusitis and even bony sinus erosions.

► Differential Diagnosis

In most patients with granulomatosis with polyangiitis, refractory sinusitis or otitis media is initially suspected. When upper respiratory tract inflammation persists and is accompanied by additional systemic inflammatory signs (eg, red eye from scleritis, joint pain and swelling), the diagnosis of granulomatosis with polyangiitis should be considered. Rheumatoid arthritis will wrongly be suspected in a substantial minority of patients who chiefly complain of joint pain. Arriving at the correct diagnosis is aided by awareness that rheumatoid arthritis typically involves small joints of the hand, whereas granulomatosis with polyangiitis favors large joints, such as the hip, knee, elbow, and shoulder. Lung cancer may be the first diagnostic consideration for some middle-aged patients in whom cough, hemoptysis, and lung masses are presenting symptoms and signs; typically, evidence of glomerulonephritis, a positive ANCA or, ultimately, the lung biopsy findings will point to the proper diagnosis. Granulomatosis with polyangiitis shares with SLE, anti-glomerular basement membrane disease, and microscopic polyangiitis the ability to cause an acute pulmonary-renal syndrome. Approximately 10–25% of patients with classic granulomatosis with polyangiitis have MPO-ANCA. Owing to involvement of the same types of blood vessels, similar patterns of organ involvement, and the possibility of failing to identify granulomatous pathology on tissue biopsies because of sampling error, granulomatosis with polyangiitis is often difficult to differentiate from microscopic polyangiitis. The crucial distinctions between the two disorders are the tendencies for granulomatosis with polyangiitis to involve the upper respiratory tract (including the ears) and to cause granulomatous inflammation.

► Treatment

Early treatment is crucial in preventing the devastating end-organ complications of this disease, and often in preserving life. While granulomatosis with polyangiitis may involve the sinuses or lung for months, once proteinuria or hematuria develops, progression to advanced chronic kidney disease can be rapid (over several weeks). For patients with severe disease, the combination of cyclophosphamide and prednisone is the standard of care. Remissions can be induced in more than 90% of patients treated with prednisone (1 mg/kg daily) plus cyclophosphamide (2 mg/kg/d orally with adjustments required for renal insufficiency and age > 70 years old). Cyclophosphamide is best given daily by mouth; intermittent high-dose intravenous cyclophosphamide is less effective. The current approach to remission induction in severe cases is to use cyclophosphamide for 3–6 months, followed by a switch to a regimen more likely to be tolerated well. Unfortunately, disease relapses occur in a substantial proportion of those patients who achieve remission. In

patients with remission induced by 3–6 months of cyclophosphamide and corticosteroids, azathioprine (up to 2 mg/kg/d orally) has been shown to be as effective as cyclophosphamide in maintaining disease remissions (at least for up to 12–15 months). Before the institution of azathioprine, patients should be tested (through a commercially available blood test) for deficiencies in the level of thiopurine methyltransferase, an enzyme essential to the metabolism of azathioprine. Another option for remission maintenance is methotrexate, 20–25 mg/wk (administered either orally or intramuscularly). Because of its superior side-effect profile, methotrexate is viewed as an appropriate substitute for cyclophosphamide for initial treatment in patients who do not have significant renal dysfunction (of any cause) or immediately life-threatening disease. Treatment with TNF inhibitors, particularly etanercept, is not effective. Rituximab, a B-cell-depleting monoclonal antibody, has been shown to be as effective as cyclophosphamide for patients who have never been treated and may be more effective than cyclophosphamide for treating relapses. However, rituximab's high cost, its undefined long-term health effects, and its association with opportunistic infections (including progressive multifocal leukoencephalopathy [PML]) indicate that defining rituximab's precise role in treating ANCA-associated vasculitis requires additional study.

Hiemstra TF et al; European Vasculitis Study Group (EUVAS). Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized controlled trial. *JAMA*. 2010 Dec 1; 304(21):2381–8. [PMID: 21060104]
 Stone JH et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. *N Engl J Med*. 2010 Jul 15;363(3):221–32. [PMID: 20647199]
 Walsh M et al; European Vasculitis Study Group. Risk factors for relapse of ANCA associated vasculitis. *Arthritis Rheum*. 2012 Feb; 64(2):542–8. [PMID: 21953279]

MICROSCOPIC POLYANGIITIS

ESSENTIALS OF DIAGNOSIS

- Necrotizing vasculitis of small- and medium-sized arteries and veins.
- Most common cause of pulmonary-renal syndrome: diffuse alveolar hemorrhage and glomerulonephritis.
- Associated with ANCA in 75% of cases, usually anti-myeloperoxidase antibodies (MPO-ANCA) that cause a p-ANCA pattern on immunofluorescence testing. ANCA directed against proteinase-3 (PR3-ANCA) can also be observed.

► General Considerations

Microscopic polyangiitis is a pauci-immune nongranulomatous necrotizing vasculitis that (1) affects small blood vessels (capillaries, venules, or arterioles), (2) often causes

glomerulonephritis and pulmonary capillaritis, and (3) is often associated with ANCA on immunofluorescence testing (directed against MPO, a constituent of neutrophil granules). Because microscopic polyangiitis may involve medium-sized as well as small blood vessels and because it tends to affect capillaries within the lungs and kidneys, its spectrum overlaps those of both polyarteritis nodosa and granulomatosis with polyangiitis.

In rare instances, medications, particularly propylthiouracil, hydralazine, allopurinol, penicillamine, minocycline, and sulfasalazine, induce a systemic vasculitis associated with high titers of MPO-ANCA and features of microscopic polyangiitis.

► Clinical Findings

A. Symptoms and Signs

A wide variety of findings suggesting vasculitis of small blood vessels may develop in microscopic polyangiitis. These include “palpable” (or “raised”) purpura and other signs of cutaneous vasculitis (ulcers, splinter hemorrhages, vesiculobullous lesions).

Microscopic polyangiitis is the most common cause of pulmonary-renal syndromes, being several times more common than anti-glomerular basement membrane disease. Interstitial lung fibrosis that mimics usual interstitial pneumonitis is the presenting condition. Pulmonary hemorrhage may occur. The pathologic findings in the lung are typically those of capillaritis.

Vasculitic neuropathy (mononeuritis multiplex) is also common in microscopic polyangiitis.

B. Laboratory Findings

As noted, three-fourths of patients with microscopic polyangiitis are ANCA-positive. Elevated acute phase reactants are also typical of active disease. Microscopic hematuria, proteinuria, and red blood cell casts in the urine may occur. The renal lesion is a segmental, necrotizing glomerulonephritis, often with localized intravascular coagulation and the observation of intraglomerular thrombi upon renal biopsy.

► Differential Diagnosis

Distinguishing this disease from granulomatosis with polyangiitis may be challenging in some cases. Microscopic polyangiitis is not associated with the chronic destructive upper respiratory tract disease often found in granulomatosis with polyangiitis. Moreover, as noted, a critical difference between the two diseases is the absence of granulomatous inflammation in microscopic polyangiitis. Because their treatments may differ, microscopic polyangiitis must also be differentiated from polyarteritis nodosa.

► Treatment

In microscopic polyangiitis, patients are likely to require prednisone and cyclophosphamide because of the urgency in treating pulmonary hemorrhage and glomerulonephritis. Cyclophosphamide may be administered either in an oral

daily regimen or via intermittent (usually monthly) intravenous pulses. Whenever cyclophosphamide is used, *Pneumocystis jiroveci* prophylaxis with either single-strength oral trimethoprim-sulfamethoxazole or dapsone 100 mg/d is essential. Following the induction of remission, azathioprine is a reasonable choice to replace cyclophosphamide. In cases of drug-induced MPO-ANCA-associated vasculitis, the offending medication should be discontinued; significant organ involvement (eg, pulmonary hemorrhage, glomerulonephritis) requires immunosuppressive therapy. Rituximab has been shown to be as effective as cyclophosphamide in treating ANCA-associated vasculitis.

► Prognosis

The key to effecting good outcomes is early diagnosis. Compared with patients who have granulomatosis with polyangiitis, those who have microscopic polyangiitis are more likely to have significant fibrosis on renal biopsy because of later diagnosis. The likelihood of disease recurrence following remission in microscopic polyangiitis is about 33%.

Corral-Gudino L et al. Overall survival, renal survival and relapse in patients with microscopic polyangiitis: a systematic review of current evidence. *Rheumatology (Oxford)*. 2011 Aug;50(8):1414–23. [PMID: 21406467]

Silva F et al. Mycophenolate mofetil for induction and maintenance of remission in microscopic polyangiitis with mild to moderate renal involvement—a prospective, open-label pilot trial. *Clin J Am Soc Nephrol*. 2010 Mar;5(3):445–53. [PMID: 20093349]

CRYOGLOBULINEMIA

Cryoglobulinemia can be associated with an immune-complex mediated, small-vessel vasculitis. Chronic infection with hepatitis C is the most common underlying condition; cryoglobulinemic vasculitis also can occur in the setting of other chronic infections, such as subacute bacterial endocarditis and osteomyelitis, and with connective tissue diseases, especially Sjögren syndrome. The cryoglobulins associated with vasculitis are cold-precipitable immune complexes consisting of rheumatoid factor and IgG (rheumatoid factor is an autoantibody to the constant region of IgG). The rheumatoid factor component can be monoclonal (type II cryoglobulins) or polyclonal (type III cryoglobulins). (Type I cryoglobulins are cryoprecipitable monoclonal proteins that lack rheumatoid factor activity; these cause cold-induced hyperviscosity syndromes, not vasculitis, and are associated with lymphoproliferative disease.)

► Clinical Findings

Cryoglobulinemic vasculitis typically manifests as recurrent palpable purpura and peripheral neuropathy. A proliferative glomerulonephritis can develop and can manifest as rapidly progressive glomerulonephritis. Abnormal liver function tests, abdominal pain, and pulmonary disease may also occur. The diagnosis is based on a compatible

clinical picture and a positive serum test for cryoglobulins. The presence of a disproportionately low C4 level can be a diagnostic clue to the presence of cryoglobulinemia.

► Treatment

Asymptomatic cryoglobulinemia is common in hepatitis C–infected individuals and does not in itself warrant treatment. The optimal approach to treatment of hepatitis C–associated cryoglobulinemic vasculitis is viral suppression with pegylated forms of interferon- α and ribavirin. Because immunosuppressive agents may facilitate viral replication, corticosteroids, cyclophosphamide, and other interventions (including plasmapheresis) should be reserved for organ-threatening complications. B cell depletion using rituximab appears to be a promising avenue of therapy.

Ferri C et al. Treatment with rituximab in patients with mixed cryoglobulinemia syndrome: results of multicenter cohort study and review of the literature. *Autoimmun Rev.* 2011 Nov;11(1):48–55. [PMID: 21821153]

Iannuzzella F et al. Management of hepatitis C virus-related mixed cryoglobulinemia. *Am J Med.* 2010 May;123(5):400–8. [PMID: 20399313]

HENOCH-SCHÖNLEIN PURPURA

Henoch-Schönlein purpura, the most common systemic vasculitis in children, occurs in adults as well. Typical features are palpable purpura (Figure 20–8), arthritis, and hematuria. Abdominal pain occurs less frequently in adults than in children. Pathologic features include leukocytoclastic vasculitis with IgA deposition. The cause is not known.

The purpuric skin lesions are typically located on the lower extremities but may also be seen on the hands, arms, trunk, and buttocks. Joint symptoms are present in the majority of patients, the knees and ankles being most commonly involved. Abdominal pain secondary to vasculitis of the intestinal tract is often associated with gastrointestinal bleeding. Hematuria signals the presence of a renal lesion that is usually reversible, although it occasionally may progress to chronic kidney disease. Children tend to have more frequent and more serious gastrointestinal vasculitis, whereas adults more often suffer from chronic kidney disease. Biopsy of the kidney reveals segmental glomerulonephritis with crescents and mesangial deposition of IgA.

Chronic courses with persistent or intermittent skin disease are more likely to occur in adults than in children. The value of corticosteroids has been controversial. In children or adults, prednisone (1 mg/kg/d orally) may benefit those with severe extrarenal manifestations and with evidence of kidney disease. The incremental efficacy of steroid-sparing drugs such as azathioprine and mycophenolate mofetil—often used in the setting of kidney disease—is not known.

Jithpratuck W et al. The clinical implications of adult-onset Henoch-Schönlein purpura. *Clin Mol Allergy.* 2011 May 27; 9(1):9. [PMID: 21619657]

McCarthy HJ et al. Clinical practice: diagnosis and management of Henoch-Schönlein purpura. *Eur J Pediatr.* 2010 Jun;169(6): 643–50. [PMID: 20012647]



▲ **Figure 20–8.** Palpable purpura in a woman with leukocytoclastic vasculitis. (Courtesy of Eric Kraus, MD; used, with permission, from Usatine RP, Smith MA, Mayeaux EJ Jr, Chumley H, Tysinger J. *The Color Atlas of Family Medicine.* McGraw-Hill, 2009.)

RELAPSING POLYCHONDritis

This disease is characterized by inflammatory destructive lesions of cartilaginous structures, principally the ears, nose, trachea, and larynx. Nearly 40% of cases are associated with another disease, especially either other immunologic disorders (such as SLE, rheumatoid arthritis, or Hashimoto thyroiditis) or cancers (such as multiple myeloma) or hematologic disorders (such as myelodysplastic syndrome). The disease, which is usually episodic, affects males and females equally. The cartilage is painful, swollen, and tender during an attack and subsequently becomes atrophic, resulting in permanent deformity. Biopsy of the involved cartilage shows inflammation and chondrolysis. Noncartilaginous manifestations of the disease include fever, episcleritis, uveitis, deafness, aortic insufficiency, and rarely glomerulonephritis. In 85% of patients, a migratory, asymmetric, and seronegative arthropathy occurs, affecting both large and small joints and the costochondral junctions. Diagnosing this uncommon disease is especially difficult since the signs of cartilage inflammation (such as red ears or nasal pain) may be more subtle than the fever, arthritis, rash, or other systemic manifestations.

Prednisone, 0.5–1 mg/kg/d orally, is often effective. Dapsone (100–200 mg/d orally) or methotrexate (7.5–20 mg orally per week) may also have efficacy, sparing the need for long-term high-dose corticosteroid treatment. Involvement

of the tracheobronchial tree, leading to tracheomalacia, may lead to difficult management issues.

Lahmer T et al. Relapsing polychondritis: An autoimmune disease with many faces. *Autoimmun Rev*. 2010 Jun;9(8):540–6. [PMID: 20215048]

Yoo JH et al. Relapsing polychondritis: systemic and ocular manifestations, differential diagnosis, management, and prognosis. *Semin Ophthalmol*. 2011 Jul–Sep;26(4–5):261–9. [PMID: 21958172]

BEHÇET SYNDROME



ESSENTIALS OF DIAGNOSIS

- ▶ Most commonly occurs among persons of Asian, Turkish, or Middle Eastern background, but may affect persons of any demographic profile.
- ▶ Recurrent, painful aphthous ulcers of the mouth and genitals.
- ▶ Erythema nodosum-like lesions; a follicular rash; and the pathergy phenomenon (formation of a sterile pustule at the site of a needle stick).
- ▶ Either anterior or posterior uveitis. Posterior uveitis may be asymptomatic until significant damage to the retina has occurred.
- ▶ Variety of neurologic lesions that can mimic multiple sclerosis, particularly through involvement of the white matter of the brainstem.

▶ General Considerations

Named after the Turkish dermatologist who first described it, this disease is of unknown cause. Its protean manifestations are believed to result from vasculitis that may involve all types of blood vessels: small, medium, and large, on both the arterial and venous side of the circulation.

▶ Clinical Findings

A. Symptoms and Signs

The hallmark of Behçet disease is painful aphthous ulceration in the mouth (see Figure 8–7). These lesions, which usually occur multiply, may be found on the tongue, gums, and inner surfaces of the oral cavity. Genital lesions, similar in appearance, are also common but do not occur in all patients. Other cutaneous lesions of Behçet disease include tender, erythematous, papular lesions that resemble erythema nodosum. (On biopsy, however, many of these lesions are shown to be secondary to vasculitis rather than septal panniculitis.) These erythema nodosum-like lesions have a tendency to ulcerate, a major difference between the lesions of Behçet disease and the erythema nodosum seen in cases of sarcoidosis and inflammatory bowel disease. An erythematous follicular rash that occurs frequently on the upper extremities may be a subtle feature of the disease. The pathergy phenomenon is frequently underappreciated

(unless the patient is asked); in this phenomenon, sterile pustules develop at sites where needles have been inserted into the skin (eg, for phlebotomy) in some patients.

A nonerosive arthritis occurs in about two-thirds of patients, most commonly affecting the knees and ankles. Eye involvement may be one of the most devastating complications of Behçet disease. Posterior uveitis, in essence a retinal venulitis, may lead to the insidious destruction of large areas of the retina before the patient becomes aware of visual problems. Anterior uveitis, associated with photophobia and a red eye, is intensely symptomatic. This complication may lead to a hypopyon, the accumulation of pus in the anterior chamber. If not treated properly with mydriatic agents to dilate the pupil and corticosteroid eye-drops to diminish inflammation, the anterior uveitis may lead to synechial formation between the iris and lens, resulting in permanent pupillary distortion.

Central nervous system involvement is another cause of major potential morbidity. The central nervous system lesions that may mimic multiple sclerosis radiologically often result in serious disability or death. Findings include sterile meningitis (recurrent meningeal headaches associated with a lymphocytic pleocytosis), cranial nerve palsies, seizures, encephalitis, mental disturbances, and spinal cord lesions. Aphthous ulcerations of the ileum and cecum and other forms of gastrointestinal involvement develop in approximately a quarter of patients. Large vessel vasculitis can lead to pulmonary artery aneurysms and life-threatening pulmonary hemorrhage. Finally, patients have a hypercoagulable tendency that may lead to complicated venous thrombotic events, particularly multiple deep venous thrombosis, pulmonary emboli, cerebral sinus thrombosis, and other problems associated with clotting.

The clinical course may be chronic but is often characterized by remissions and exacerbations.

B. Laboratory Findings

There are no pathognomonic laboratory features of Behçet disease. Although acute phase reactants are often elevated, there is no autoantibody or other assay that is distinctive. No markers of hypercoagulability specific to Behçet have been identified.

▶ Treatment

Corticosteroids (1 mg/kg/d of oral prednisone) are a mainstay of therapy for severe disease manifestations. Azathioprine (2 mg/kg/d orally) may be an effective steroid-sparing agent. Cyclophosphamide (2 mg/kg/d orally) or chlorambucil (0.1–0.2 mg/kg/d orally) is indicated for severe ocular and central nervous system complications of Behçet disease. Both colchicine (0.6 mg once to three times daily orally) and thalidomide (100 mg/d orally) help ameliorate the mucocutaneous findings. TNF inhibition and interferon alfa-2a demonstrates some promise as a therapeutic approach, but large studies are lacking to date.

Ideguchi H et al. Behçet disease: evolution of clinical manifestations. *Medicine (Baltimore)*. 2011 Mar;90(2):125–32. [PMID: 21358436]

PRIMARY ANGIITIS OF THE CENTRAL NERVOUS SYSTEM

Primary angiitis of the central nervous system is a syndrome with several possible causes that produces small and medium-sized vasculitis limited to the brain and spinal cord. Biopsy-proved cases have predominated in men who have a history of weeks to months of headaches, encephalopathy, and multifocal strokes. Systemic signs and symptoms are absent, and routine laboratory tests are usually normal. MRI of the brain is almost always abnormal, and the spinal fluid often reveals a mild lymphocytosis and a modest increase in protein level. Angiograms classically reveal a “string of beads” pattern produced by alternating segments of arterial narrowing and dilation. However, neither the MRI nor the angiogram appearance is specific for vasculitis. Indeed, in one study, none of the patients who had biopsy-proved central nervous system vasculitis had an angiogram showing “the string of beads,” and none of the patients with the classic angiographic findings had a positive brain biopsy for vasculitis. Many conditions, including vasospasm, can produce the same angiographic pattern as vasculitis. Definitive diagnosis requires a compatible clinical picture; exclusion of infection, neoplasm, or metabolic disorder or drug exposure (eg, cocaine) that can mimic primary angiitis of the central nervous system; and a positive brain biopsy. In contrast to biopsy-proved cases, patients with angiographically defined central nervous system vasculopathy are chiefly women who have had an abrupt onset of headaches and stroke (often in the absence of encephalopathy) with normal spinal fluid findings. Many patients who fit this clinical profile may have reversible cerebral vasoconstriction rather than true vasculitis. Such cases may best be treated with calcium channel blockers (such as nimodipine or verapamil) and possibly a short course of corticosteroids. Biopsy-proved cases usually improve with prednisone therapy and often require cyclophosphamide. In recent years, cases of central nervous system vasculitis associated with cerebral amyloid angiopathy have been reported. These cases often respond well to corticosteroids, albeit the long-term natural history remains poorly defined.

Berlit P. Diagnosis and treatment of cerebral vasculitis. *Ther Adv Neurol Disord*. 2010 Jan;3(1):29–42. [PMID: 21180634]

LIVEDO RETICULARIS

Livedo reticularis produces a mottled, purplish discoloration of the skin with reticulated cyanotic areas surrounding paler central cores. This distinctive “fishnet” pattern is caused by spasm or obstruction of perpendicular arterioles, combined with pooling of blood in surrounding venous plexuses. Livedo reticularis can be idiopathic or a manifestation of a serious underlying condition.

Idiopathic livedo reticularis is a benign condition that worsens with cold exposure, improves with warming, and primarily affects the extremities. Apart from cosmetic concerns, it is usually asymptomatic. Systemic symptoms or the development of cutaneous ulcerations point to the presence of an underlying disease.

Secondary livedo reticularis occurs in association with a variety of diseases that cause vascular obstruction or inflammation. Of particular importance is the link with antiphospholipid antibody syndrome. Livedo reticularis is the presenting manifestation of 25% of patients with antiphospholipid antibody syndrome and is strongly associated with the subgroup that has arterial thromboses, including those with Sneddon syndrome (livedo reticularis and cerebrovascular events). Other underlying causes of livedo reticularis include the vasculitides (particularly polyarteritis nodosa), cholesterol emboli syndrome, thrombocytopenia, cryoglobulinemia, cold agglutinin disease, primary hyperoxaluria (due to vascular deposits of calcium oxalate), and disseminated intravascular coagulation.

Frances C. Dermatological manifestations of Hughes’ antiphospholipid antibody syndrome. *Lupus*. 2010 Aug;19(9):1071–7. [PMID: 20693200]

SERONEGATIVE SPONDYLOARTHROPATHIES

The seronegative spondyloarthropathies are ankylosing spondylitis, psoriatic arthritis, reactive arthritis, the arthritis associated with inflammatory bowel disease, and undifferentiated spondyloarthropathy. These disorders are noted for male predominance, onset usually before age 40, inflammatory arthritis of the spine and sacroiliac joints, asymmetric oligoarthritis of large peripheral joints, enthesopathy (inflammation of where ligaments, tendons, and joint capsule insert into bone), uveitis in a significant minority, the absence of autoantibodies in the serum, and a striking association with HLA-B27. Present in only 8% of normal whites and 4% of normal blacks, HLA-B27 is positive in 90% of patients with ankylosing spondylitis and 75% with reactive arthritis. HLA-B27 also occurs in 50% of the psoriatic and inflammatory bowel disease patients who have sacroiliitis. Patients with only peripheral arthritis in these latter two syndromes do not show an increase in HLA-B27.

ANKYLOSING SPONDYLITIS



ESSENTIALS OF DIAGNOSIS

- ▶ Chronic low backache in young adults, generally worst in the morning.
- ▶ Progressive limitation of back motion and of chest expansion.
- ▶ Transient (50%) or persistent (25%) peripheral arthritis.
- ▶ Anterior uveitis in 20–25%.
- ▶ Diagnostic radiographic changes in sacroiliac joints.
- ▶ Negative serologic tests for rheumatoid factor and anti-CCP antibodies.
- ▶ HLA-B27 testing is most helpful when there is an intermediate probability of disease.

► General Considerations

Ankylosing spondylitis is a chronic inflammatory disease of the joints of the axial skeleton, manifested clinically by pain and progressive stiffening of the spine. The age at onset is usually in the late teens or early 20s. The incidence is greater in males than in females, and symptoms are more prominent in men, with ascending involvement of the spine more likely to occur.

► Clinical Findings

A. Symptoms and Signs

The onset is usually gradual, with intermittent bouts of back pain that may radiate into the buttocks. The back pain is worse in the morning and usually associated with stiffness that lasts hours. The pain and stiffness improve with activity, in contrast to back pain due to mechanical causes and degenerative disease, which improves with rest and worsens with activity. As the disease advances, symptoms progress in a cephalad direction, and back motion becomes limited, with the normal lumbar curve flattened and the thoracic curvature exaggerated. Chest expansion is often limited as a consequence of costovertebral joint involvement. In advanced cases, the entire spine becomes fused, allowing no motion in any direction. Transient acute arthritis of the peripheral joints occurs in about 50% of cases, and permanent changes in the peripheral joints—most commonly the hips, shoulders, and knees—are seen in about 25%. Enthesopathy, a hallmark of the spondyloarthropathies, can manifest as swelling of the Achilles tendon at its insertion, plantar fasciitis (producing heel pain), or “sausage” swelling of a finger or toe (less common in ankylosing spondylitis than in psoriatic arthritis).

Anterior uveitis is associated in as many as 25% of cases and may be a presenting feature. Spondylitic heart disease, characterized chiefly by atrioventricular conduction defects and aortic regurgitation occurs in 3–5% of patients with long-standing severe disease. Constitutional symptoms similar to those of rheumatoid arthritis are absent in most patients.

B. Laboratory Findings

The ESR is elevated in 85% of cases, but serologic tests for rheumatoid factor and anti-CCP antibodies are negative. Anemia may be present but is often mild. HLA-B27 is found in 90% of white patients and 50% of black patients with ankylosing spondylitis. Because this antigen occurs in 8% of the healthy white population (and 2% of healthy blacks), it is not a specific diagnostic test.

C. Imaging

The earliest radiographic changes are usually in the sacroiliac joints. In the first 2 years of the disease process, the sacroiliac changes may be detectable only by MRI. Later, erosion and sclerosis of these joints are evident on plain radiographs; the sacroiliitis of ankylosing spondylitis is bilateral and symmetric. Inflammation where the annulus fibrosus attaches to the vertebral bodies initially causes

sclerosis (“the shiny corner sign”) and then characteristic squaring of the vertebral bodies. The term “bamboo spine” describes the late radiographic appearance of the spinal column in which the vertebral bodies are fused by vertically oriented, bridging syndesmophytes formed by the ossification of the annulus fibrosus and calcification of the anterior and lateral spinal ligaments. Fusion of the posterior facet joints of the spine is also common.

Additional radiographic findings include periosteal new bone formation on the iliac crest, ischial tuberosities and calcanei, and alterations of the pubic symphysis and sternomanubrial joint similar to those of the sacroiliacs. Radiologic changes in peripheral joints, when present, tend to be asymmetric and lack the demineralization and erosions seen in rheumatoid arthritis.

► Differential Diagnosis

Low back pain due to mechanical causes, disk disease, and degenerative arthritis is very common. Onset of back pain prior to age 30 and an “inflammatory” quality of the back pain (ie, morning stiffness and pain that improve with activity) should raise the possibility of ankylosing spondylitis. In contrast to ankylosing spondylitis, rheumatoid arthritis predominantly affects multiple, small, peripheral joints of the hands and feet. Rheumatoid arthritis spares the sacroiliac joints and only affects the cervical component of the spine. Bilateral sacroiliitis indistinguishable from ankylosing spondylitis is seen with the spondylitis associated with inflammatory bowel disease. Sacroiliitis associated with reactive arthritis and psoriasis, on the other hand, is often asymmetric or even unilateral. Osteitis condensans ilii (sclerosis on the iliac side of the sacroiliac joint) is an asymptomatic, postpartum radiographic finding that is occasionally mistaken for sacroiliitis. Diffuse idiopathic skeletal hyperostosis (DISH) causes exuberant osteophytes of the spine that occasionally are difficult to distinguish from the syndesmophytes of ankylosing spondylitis. The osteophytes of DISH are thicker and more anterior than the syndesmophytes of ankylosing spondylitis, and the sacroiliac joints are normal in DISH.

► Treatment

NSAIDs remain first-line treatment of ankylosing spondylitis and may slow radiographic progression of spinal disease. Because individual patients differ in their response to particular NSAIDs, empiric trials of several different NSAIDs are warranted if the response to any given NSAID is not satisfactory. TNF inhibitors have established efficacy for NSAID-resistant axial disease; responses are often substantial and durable. Etanercept (50 mg subcutaneously once a week), adalimumab (40 mg subcutaneously every other week), or infliximab (5 mg/kg every other month by intravenous infusion) is reasonable for patients whose symptoms are refractory to NSAIDs. Sulfasalazine (1000 mg orally twice daily) is sometimes useful for peripheral arthritis but lacks effectiveness for spinal and sacroiliac joint disease. Corticosteroids have minimal impact on the arthritis—particularly the spondylitis—of ankylosing spondylitis and can worsen osteopenia. All patients should

be referred to a physical therapist for instruction in postural exercises.

► Prognosis

Almost all patients have persistent symptoms over decades; rare individuals experience long-term remissions. The severity of disease varies greatly, with about 10% of patients having work disability after 10 years. Developing hip disease within the first 2 years of disease onset presages a worse prognosis. The availability of TNF inhibitors has provided symptomatic relief and improved quality of life for many patients with ankylosing spondylitis.

Heldmann F et al. The European ankylosing spondylitis infliximab cohort (EASIC): a European multicentre study of long term outcomes in patients with ankylosing spondylitis treated with infliximab. *Clin Exp Rheumatol*. 2011 Jul–Aug;29(4):672–80. [PMID: 21906431]

Jang JH et al. Ankylosing spondylitis: patterns of radiographic involvement—a re-examination of accepted principles in a cohort of 769 patients. *Radiology*. 2011 Jan;258(1):192–8. [PMID: 20971774]

PSORIATIC ARTHRITIS



ESSENTIALS OF DIAGNOSIS

- ▶ Psoriasis precedes onset of arthritis in 80% of cases.
- ▶ Arthritis usually asymmetric, with “sausage” appearance of fingers and toes but a polyarthritis that resembles rheumatoid arthritis also occurs.
- ▶ Sacroiliac joint involvement common; ankylosis of the sacroiliac joints may occur.
- ▶ Radiographic findings: osteolysis; pencil-in-cup deformity; relative lack of osteoporosis; bony ankylosis; asymmetric sacroiliitis and atypical syndesmophytes.

► General Considerations

Although psoriasis usually precedes the onset of arthritis, arthritis precedes (by up to 2 years) or occurs simultaneously with the skin disease in approximately 20% of cases.

► Clinical Findings

A. Symptoms and Signs

The patterns or subsets of psoriatic arthritis include the following:

1. A symmetric polyarthritis that resembles rheumatoid arthritis. Usually, fewer joints are involved than in rheumatoid arthritis.
2. An oligoarticular form that may lead to considerable destruction of the affected joints.

3. A pattern of disease in which the DIP joints are primarily affected. Early, this may be monoarticular, and often the joint involvement is asymmetric. Pitting of the nails and onycholysis frequently accompany DIP involvement.
4. A severe deforming arthritis (arthritis mutilans) in which osteolysis is marked.
5. A spondylitic form in which sacroiliitis and spinal involvement predominate; 50% of these patients are HLA-B27-positive.

Arthritis is at least five times more common in patients with severe skin disease than in those with only mild skin findings. Occasionally, however, patients may have a single patch of psoriasis (typically hidden in the scalp, gluteal cleft, or umbilicus) and are unaware of its presence. Thus, a detailed search for cutaneous lesions is essential in patients with arthritis of new onset. Also, the psoriatic lesions may have cleared when arthritis appears—in such cases, the history is most useful in diagnosing previously unexplained cases of mono- or oligoarthritis. Nail pitting is sometimes a clue. “Sausage” swelling of one or more digits is a common manifestation of enthesopathy in psoriatic arthritis.

B. Laboratory Findings

Laboratory studies show an elevation of the ESR, but rheumatoid factor is not present. Uric acid levels may be high, reflecting the active turnover of skin affected by psoriasis. There is a correlation between the extent of psoriatic involvement and the level of uric acid, but gout is no more common than in patients without psoriasis. Desquamation of the skin may also reduce iron stores.

C. Imaging

Radiographic findings are most helpful in distinguishing the disease from other forms of arthritis. There are marginal erosions of bone and irregular destruction of joint and bone, which, in the phalanx, may give the appearance of a sharpened pencil. Fluffy periosteal new bone may be marked, especially at the insertion of muscles and ligaments into bone. Such changes will also be seen along the shafts of metacarpals, metatarsals, and phalanges. Psoriatic spondylitis causes asymmetric sacroiliitis and syndesmophytes, which are coarser than those seen in ankylosing spondylitis.

► Treatment

NSAIDs are usually sufficient for mild cases. Methotrexate (7.5–20 mg orally once a week) is generally considered the drug of choice for patients who have not responded to NSAIDs; methotrexate can improve both the cutaneous and arthritic manifestations. For cases with disease that is refractory to methotrexate, the addition of TNF inhibitors (at doses similar to the treatment of ankylosing spondylitis) is usually effective for both arthritis and psoriatic skin disease. Corticosteroids are less effective in psoriatic arthritis than in other forms of inflammatory arthritis and may precipitate pustular psoriasis during tapers. Antimalarials may also exacerbate psoriasis. Successful treatment directed at the skin lesions alone (eg, by PUVA

therapy) occasionally is accompanied by an improvement in peripheral articular symptoms.

Gladman DD et al. Risk factors for radiographic progression in psoriatic arthritis: subanalysis of the randomized controlled trial ADEPT. *Arthritis Res Ther.* 2010;12(3):R113. [PMID: 20537151]

McGonagle D et al. The early phase of psoriatic arthritis. *Ann Rheum Dis.* 2011 Mar;70 (Suppl 1):i71–6. [PMID: 21339224]

Mease PJ. Psoriatic arthritis: update on pathophysiology, assessment and management. *Ann Rheum Dis.* 2011 Mar;70(Suppl 1):i77–84. [PMID: 21339225]

REACTIVE ARTHRITIS (Formerly Reiter Syndrome)



ESSENTIALS OF DIAGNOSIS

- ▶ Fifty to eighty percent of patients are HLA-B27-positive.
- ▶ Oligoarthritis, conjunctivitis, urethritis, and mouth ulcers most common features.
- ▶ Usually follows dysentery or a sexually transmitted infection.

▶ General Considerations

Reactive arthritis is precipitated by antecedent gastrointestinal and genitourinary infections and manifests as an asymmetric sterile oligoarthritis, typically of the lower extremities. It is frequently associated with enthesitis. Extra-articular manifestations are common and include urethritis, conjunctivitis, uveitis, and mucocutaneous lesions. Reactive arthritis occurs most commonly in young men and is associated with HLA-B27 in 80% of white patients and 50–60% of blacks.

▶ Clinical Findings

A. Symptoms and Signs

Most cases of reactive arthritis develop within 1–4 weeks after either a gastrointestinal infection (with *Shigella*, *Salmonella*, *Yersinia*, *Campylobacter*) or a sexually transmitted infection (with *Chlamydia trachomatis* or perhaps *Ureaplasma urealyticum*). Whether the inciting infection is sexually transmitted or dysenteric does not affect the subsequent manifestations but does influence the gender ratio: The ratio is 1:1 after enteric infections but 9:1 with male predominance after sexually transmitted infections. Synovial fluid from affected joints is culture-negative. A clinically indistinguishable syndrome can occur without an apparent antecedent infection, suggesting that subclinical infection can precipitate reactive arthritis or that there are other, as yet unrecognized, triggers.

The arthritis is most commonly asymmetric and frequently involves the large weight-bearing joints (chiefly the knee and ankle); sacroiliitis or ankylosing spondylitis is



▲ **Figure 20-9.** Circinate balanitis due to reactive arthritis (Reiter syndrome). (Courtesy of Susan Lindsley, Dr. M. F. Rein, Public Health Image Library, CDC.)

observed in at least 20% of patients, especially after frequent recurrences. Systemic symptoms including fever and weight loss are common at the onset of disease. The mucocutaneous lesions may include balanitis (Figure 20-9), stomatitis, and keratoderma blennorrhagicum (Figure 20-10), indistinguishable from pustular psoriasis. Involvement of the fingernails in reactive arthritis also mimics psoriatic changes. When present, conjunctivitis is mild and occurs early in the disease course. Anterior uveitis, which can develop at any time in HLA-B27-positive patients, is a more clinically significant ocular complication. Carditis and aortic regurgitation may occur. While most signs of the disease disappear within days or weeks, the arthritis may persist for several months or become chronic. Recurrences involving any combination of the clinical manifestations are common and are sometimes followed by permanent sequelae, especially in the joints (eg, articular destruction).



▲ **Figure 20-10.** Keratoderma blennorrhagica of the soles due to reactive arthritis (Reiter syndrome). (Courtesy of Susan Lindsley, Public Health Image Library, CDC.)

B. Imaging

Radiographic signs of permanent or progressive joint disease may be seen in the sacroiliac as well as the peripheral joints.

► Differential Diagnosis

Gonococcal arthritis can initially mimic reactive arthritis, but the marked improvement after 24–48 hours of antibiotic administration and the culture results distinguish the two disorders. Rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis must also be considered. By causing similar oral, ocular, and joint lesions, Behçet disease may also mimic reactive arthritis. The oral lesions of reactive arthritis, however, are typically painless, in contrast to those of Behçet disease.

The association of reactive arthritis and HIV has been debated, but evidence now indicates that it is equally common in sexually active men regardless of HIV status.

► Treatment

NSAIDs have been the mainstay of therapy. Antibiotics given at the time of a nongonococcal sexually transmitted infection reduce the chance that the individual will develop this disorder. For chronic reactive arthritis associated with chlamydial infection, combination antibiotics taken for 6 months are more effective than placebo. Patients who do not respond to NSAIDs may respond to sulfasalazine, 1000 mg orally twice daily, or to methotrexate, 7.5–20 mg orally per week. For those patients with recent-onset disease that is refractory to NSAIDs and these DMARDs, anti-TNF agents, which are effective in the other spondyloarthropathies, may be effective.

Meyer A et al; Club Rhumatisme et Inflammation. Safety and efficacy of anti-tumor necrosis factor α therapy in ten patients with recent-onset refractory reactive arthritis. *Arthritis Rheum.* 2011 May;63(5):1274–80. [PMID: 21538314]

ARTHRITIS & INFLAMMATORY INTESTINAL DISEASES

One-fifth of patients with **inflammatory bowel disease** have arthritis, which complicates **Crohn disease** somewhat more frequently than it does **ulcerative colitis**. In both diseases, two distinct forms of arthritis occur. The first is peripheral arthritis—usually a nondeforming asymmetric oligoarthritis of large joints—in which the activity of the joint disease parallels that of the bowel disease. The arthritis usually begins months to years after the bowel disease, but occasionally the joint symptoms develop earlier and may be prominent enough to cause the patient to overlook intestinal symptoms. The second form of arthritis is a spondylitis that is indistinguishable by symptoms or radiographs from ankylosing spondylitis and follows a course independent of the bowel disease. About 50% of these patients are HLA-B27-positive.

Controlling the intestinal inflammation usually eliminates the peripheral arthritis. The spondylitis often requires

NSAIDs, which need to be used cautiously since these agents may activate the bowel disease in a few patients. Range-of-motion exercises as prescribed for ankylosing spondylitis can be helpful.

About two-thirds of patients with **Whipple disease** experience arthralgia or arthritis, most often an episodic, large-joint polyarthritis. The arthritis usually precedes the gastrointestinal manifestations by years. In fact, the arthritis resolves as the diarrhea develops. Thus, Whipple disease should be considered in the differential diagnosis of unexplained episodic arthritis.

Papamichael K et al. Low prevalence of antibodies to cyclic citrullinated peptide in patients with inflammatory bowel disease regardless of the presence of arthritis. *Eur J Gastroenterol Hepatol.* 2010 Jun;22(6):705–9. [PMID: 19525851]

INFECTIOUS ARTHRITIS*

NONGONOCOCCAL ACUTE BACTERIAL (Septic) ARTHRITIS

ESSENTIALS OF DIAGNOSIS

- Acute onset of inflammatory monoarticular arthritis, most often in large weight-bearing joints and wrists.
- Common risk factors include previous joint damage and injection drug use.
- Infection with causative organisms commonly found elsewhere in body.
- Joint effusions are usually large, with white blood counts commonly > 50,000/mcL.

► General Considerations

Nongonococcal acute bacterial arthritis is often a disease that occurs when there is an underlying abnormality. The key risk factors are bacteremia (eg, injection drug use, endocarditis, infection at other sites), damaged or prosthetic joints (eg, rheumatoid arthritis), compromised immunity (eg, diabetes, advanced chronic kidney disease, alcoholism, cirrhosis, and immunosuppressive therapy), and loss of skin integrity (eg, cutaneous ulcer or psoriasis). *Staphylococcus aureus* is the most common cause of nongonococcal septic arthritis, accounting for about 50% of all cases. Methicillin-resistant *S aureus* (MRSA) and group B streptococcus have become increasing frequent and important causes of septic arthritis. Gram-negative septic arthritis causes about 10% of cases and is especially common in injection drug users and in immunocompromised persons. *Escherichia coli* and *Pseudomonas aeruginosa* are the most common gram-negative

*Lyme disease is discussed in Chapter 34.

isolates in adults. Pathologic changes include varying degrees of acute inflammation, with synovitis, effusion, abscess formation in synovial or subchondral tissues, and, if treatment is not adequate, articular destruction.

► Clinical Findings

A. Symptoms and Signs

The onset is usually acute, with pain, swelling, and heat of the affected joint worsening over hours. The knee is most frequently involved; other commonly affected sites are the hip, wrist, shoulder, and ankle. Unusual sites, such as the sternoclavicular or sacroiliac joint, can be involved in injection drug users. Chills and fever are common but are absent in up to 20% of patients. Infection of the hip usually does not produce apparent swelling but results in groin pain greatly aggravated by walking. More than one joint is involved in 15% of cases of septic arthritis; risk factors for multiple joint involvement include rheumatoid arthritis, associated endocarditis, and infection with group B streptococci.

B. Laboratory Findings

Synovial fluid analysis is critical for diagnosis. The leukocyte count of the synovial fluid usually exceeds 50,000/mcL and often is > 100,000/mcL, with 90% or more polymorphonuclear cells (Table 20–2). Gram stain of the synovial fluid is positive in 75% of staphylococcal infections and in 50% of gram-negative infections. Synovial fluid cultures are positive in 70–90% of cases; administration of antibiotics prior to arthrocentesis reduces the likelihood of a positive culture result. Blood cultures are positive in approximately 50% of patients.

C. Imaging

Imaging tests generally add little to the diagnosis of septic arthritis. Indeed, other than demonstrating joint effusion, radiographs are usually normal early in the disease; in fact, evidence of demineralization may develop within days of onset. MRI and CT are more sensitive in detecting fluid in joints that are not accessible to physical examination (eg, the hip). Bony erosions and narrowing of the joint space followed by osteomyelitis and periostitis may be seen within 2 weeks.

► Differential Diagnosis

Gout and pseudogout can cause acute, very inflammatory monoarticular arthritis and high-grade fever; the failure to find crystals on synovial fluid analysis excludes these diagnoses. A well-recognized but uncommon initial presentation of rheumatoid arthritis is an acute inflammatory monoarthritis (“pseudoseptic”). Acute rheumatic fever commonly involves several joints; Still disease may mimic septic arthritis, but laboratory evidence of infection is absent. Pyogenic arthritis may be superimposed on other types of joint disease, notably rheumatoid arthritis. Indeed, septic arthritis must be excluded (by joint fluid examination)

in any patient with rheumatoid arthritis who has a joint strikingly more inflamed than the other joints.

► Prevention

There is no evidence that patients with prosthetic joints undergoing procedures should receive antibiotic prophylaxis to prevent joint infection. However, the topic remains controversial. The American Academy of Orthopedic Surgeons advocates prescribing antibiotic prophylaxis for any patient with a prosthetic joint replacement undergoing a procedure that can cause bacteremia.

► Treatment

The effective treatment of septic arthritis requires appropriate antibiotic therapy together with drainage of the infected joint. Hospitalization is always necessary. If the likely causative organism cannot be determined clinically or from the synovial fluid Gram stain, treatment should be started with broad-spectrum antibiotic coverage effective against staphylococci, streptococci, and gram-negative organisms. The recommendation for initial treatment is to give a third-generation cephalosporin: ceftriaxone, 1 g intravenously daily (or every 12 hours if concomitant meningitis or endocarditis is suspected); or cefotaxime, 1 g intravenously every 8 hours; or ceftizoxime, 1 g intravenously every 8 hours. Vancomycin (1 g intravenously every 12 hours, adjusted for age, weight, and renal function) should be used whenever MRSA is reasonably likely. Antibiotic therapy should be adjusted when culture results become available; the duration of antibiotic therapy is usually 4–6 weeks.

Early orthopedic consultation is essential. Effective drainage is usually achieved through early arthroscopic lavage and debridement together with drain placement. Open surgical drainage should be performed when conservative treatment fails, when there is concomitant osteomyelitis requiring debridement, or when the involved joint (eg, hip, shoulder, sacroiliac joint) cannot be drained by more conservative means. Immobilization with a splint and elevation are used at the onset of treatment. Early active motion exercises within the limits of tolerance will hasten recovery.

► Prognosis

The outcome of septic arthritis depends largely on the antecedent health of the patient, the causative organism (eg, *S aureus* bacterial arthritis is associated with a poor functional outcome in about 40% of cases), and the promptness of treatment. Five to 10 percent of patients with an infected joint die of respiratory complications of sepsis. The mortality rate is 30% for patients with polyarticular sepsis. Bony ankylosis and articular destruction commonly also occur if treatment is delayed or inadequate.

Galloway JB et al. Risk of septic arthritis in patients with rheumatoid arthritis and the effect of anti-TNF therapy: results from the British Society for Rheumatology Biologics Register. *Ann Rheum Dis*. 2011 Oct;70(10):1810–4. [PMID: 21784730]
Mathews CJ et al. Bacterial septic arthritis in adults. *Lancet*. 2010 Mar 6;375(9717):846–55. [PMID: 20206778]

GONOCOCCAL ARTHRITIS



ESSENTIALS OF DIAGNOSIS

- ▶ Prodromal migratory polyarthralgias.
- ▶ Tenosynovitis is the most common sign.
- ▶ Purulent monoarthritis in 50%.
- ▶ Characteristic skin lesions.
- ▶ Most common in young women during menses or pregnancy.
- ▶ Symptoms of urethritis frequently absent.
- ▶ Dramatic response to antibiotics.

▶ General Considerations

In contrast to nongonococcal bacterial arthritis, gonococcal arthritis usually occurs in otherwise healthy individuals. Host factors, however, influence the expression of the disease: gonococcal arthritis is two to three times more common in women than in men, is especially common during menses and pregnancy, and is rare after age 40. Gonococcal arthritis is also common in men who have sex with men, whose high incidence of asymptomatic gonococcal pharyngitis and proctitis predisposes them to disseminated gonococcal infection. Recurrent disseminated gonococcal infection should prompt testing of the patient's CH50 level to evaluate for a congenital deficiency of a terminal complement component (C5, C6, C7, or C8).

▶ Clinical Findings

A. Symptoms and Signs

One to 4 days of migratory polyarthralgias involving the wrist, knee, ankle, or elbow are common at the outset. Thereafter, two patterns emerge. The first pattern is characterized by tenosynovitis that most often affects wrists, fingers, ankles, or toes and is seen in 60% of patients. The second pattern is purulent monoarthritis that most frequently involves the knee, wrist, ankle, or elbow and is seen in 40% of patients. Less than half of patients have fever, and less than one-fourth have any genitourinary symptoms. Most patients will have asymptomatic but highly characteristic skin lesions that usually consist of two to ten small necrotic pustules distributed over the extremities, especially the palms and soles.

B. Laboratory Findings

The peripheral blood leukocyte count averages about 10,000 cells/mcL and is elevated in less than one-third of patients. The synovial fluid white blood cell count usually ranges from 30,000 to 60,000 cells/mcL. The synovial fluid Gram stain is positive in one-fourth of cases and culture in less than half. Positive blood cultures are uncommon. Urethral, throat, cervical, and rectal cultures should be done in all patients, since they are often positive in the absence of local symptoms. Urinary nucleic acid amplification tests have excellent sensitivity and specificity for the detection of *Neisseria gonorrhoeae* in genitourinary sites.

C. Imaging

Radiographs are usually normal or show only soft tissue swelling.

▶ Differential Diagnosis

Reactive arthritis can produce acute monoarthritis, urethritis, and fever in a young person but is distinguished by negative cultures and failure to respond to antibiotics. Lyme disease involving the knee is less acute, does not show positive cultures, and may be preceded by known tick exposure and characteristic rash. The synovial fluid analysis will exclude gout, pseudogout, and nongonococcal bacterial arthritis. Rheumatic fever and sarcoidosis can produce migratory tenosynovitis but have other distinguishing features. Infective endocarditis with septic arthritis can mimic disseminated gonococcal infection. Meningococcemia occasionally presents with a clinical picture that resembles disseminated gonococcal infection; blood cultures establish the correct diagnosis.

▶ Treatment

In most cases, patients in whom gonococcal arthritis is suspected should be admitted to the hospital to confirm the diagnosis, to exclude endocarditis, and to start treatment. While outpatient treatment has been recommended in the past, the rapid rise in gonococci resistant to penicillin makes initial inpatient treatment advisable. Approximately 4–5% of all gonococcal isolates produce a β -lactamase that confers penicillin resistance. An additional 15–20% of gonococcal species have chromosomal mutations that result in relative resistance to penicillin. The recommendation for initial treatment is to give a third-generation cephalosporin: ceftriaxone, 1 g intravenously daily (or every 12 hours if concomitant meningitis or endocarditis is suspected); or cefotaxime, 1 g intravenously every 8 hours; or ceftizoxime, 1 g intravenously every 8 hours. Once improvement from parenteral antibiotics has been achieved for 24–48 hours, patients can be switched to cefixime, 400 mg orally twice daily, or cefpodoxime, 400 mg orally twice daily, to complete a 7- to 10-day course. Recently, however, cephalosporin-resistant strains of gonococci have been identified; treatment with gentamicin or the new fluoroketolide, solithromycin (not yet approved by the United States FDA) has been suggested. Fluoroquinolone antibiotics are also not recommended for the initial treatment of gonococcal infections unless because of drug resistance culture results show antibiotic sensitivity.

▶ Prognosis

Generally, gonococcal arthritis responds dramatically in 24–48 hours after initiation of antibiotics, and drainage of the infected joint(s) is required infrequently. Complete recovery is the rule.

Bolan GA et al. The emerging threat of untreatable gonococcal infection. *N Engl J Med*. 2012 Feb 9; 366(6):485–7.
 García-De La Torre I et al. Gonococcal and nongonococcal arthritis. *Rheum Dis Clin North Am*. 2009 Feb;35(1):63–73. [PMID: 19480997]

RHEUMATIC MANIFESTATIONS OF HIV INFECTION

Infection with HIV has been associated with various rheumatic disorders, most commonly arthralgias and arthritis. HIV painful articular syndrome causes severe arthralgias in an oligoarticular, asymmetric pattern that resolve within 24 hours; the joint examination is normal. HIV-associated arthritis is an asymmetric oligoarticular process with objective findings of arthritis and a self-limited course that ranges from weeks to months. Psoriatic arthritis and reactive arthritis occur in HIV-infected individuals and can be severe; it remains uncertain whether the incidence of these disorders is increased in HIV-infected populations. These spondyloarthropathies can respond to NSAIDs, though many cases are unresponsive. In the era of highly active antiretroviral therapies, immunosuppressive medications can be used if necessary in HIV patients, though with caution. Muscle weakness associated with an elevated creatine kinase can be due to nucleoside reverse transcriptase inhibitor-associated myopathy or HIV-associated myopathy; the clinical presentations of each resemble idiopathic polymyositis but the muscle biopsies show minimal inflammation. Less commonly, an inflammatory myositis indistinguishable from idiopathic polymyositis occurs.

Kaddu-Mukasa M et al. Rheumatic manifestations among HIV positive adults attending the Infectious Disease Clinic at Mulago Hospital. *Afr Health Sci*. 2011 Mar;11(1):24–9. [PMID: 21572853]

VIRAL ARTHRITIS

Arthralgias occur frequently in the course of acute infections with many viruses, but frank arthritis is uncommon. A notable exception is acute parvovirus B19 infection, which leads to acute polyarthritides in 50–60% of adult cases (infected children develop the febrile exanthem known as “slapped cheek fever”). The arthritis can mimic rheumatoid arthritis but is almost always self-limited and resolves within several weeks. The diagnosis is established by the presence of IgM antibodies specific for parvovirus B19. Self-limited polyarthritides is also common in acute hepatitis B infection and typically occurs before the onset of jaundice. Urticaria or other types of skin rash may be present. Indeed, the clinical picture resembles that of serum sickness (see Atopic Disease below). Serum transaminase levels are elevated, and tests for hepatitis B surface antigen are positive. Serum complement levels are often low during active arthritis and become normal after remission of arthritis. The incidence of hepatitis B–associated polyarthritides has fallen substantially with the introduction of hepatitis B vaccination. Effective vaccination programs in the United States have eliminated acute rubella infections, formerly a common cause of virally induced polyarthritides. Changes in the rubella vaccine (an attenuated live vaccine) have greatly reduced the incidence of rubella vaccine–induced polyarthritides as well.

Chronic infection with hepatitis C is associated with chronic polyarthralgia in up to 20% of cases and with

chronic polyarthritides in 3–5%. Both can mimic rheumatoid arthritis, and the presence of rheumatoid factor in most hepatitis C–infected individuals leads to further diagnostic confusion. Indeed, hepatitis C–associated arthritis is frequently misdiagnosed as rheumatoid arthritis. Distinguishing hepatitis C–associated arthritis/arthralgias from the co-occurrence of hepatitis C and rheumatoid arthritis can be difficult. Rheumatoid arthritis always causes objective arthritis (not just arthralgias) and can be erosive (hepatitis C–associated arthritis is nonerosive). The presence of anti-CCP antibodies points to the diagnosis of rheumatoid arthritis.

Ezzat WM et al. Anti-cyclic citrullinated peptide antibodies as a discriminating marker between rheumatoid arthritis and chronic hepatitis C-related polyarthropathy. *Rheumatol Int*. 2011 Jan;31(1):65–9. [PMID: 19882340]

INFECTIONS OF BONES

ACUTE PYOGENIC OSTEOMYELITIS

ESSENTIALS OF DIAGNOSIS

- ▶ Fever and chills associated with pain and tenderness of involved bone.
- ▶ Diagnosis usually requires culture of bone biopsy.
- ▶ ESR often extremely high (eg, > 100 mm/h).
- ▶ Radiographs early in the course are typically negative.

▶ General Considerations

Osteomyelitis is a serious infection that is often difficult to diagnose and treat. Infection of bone occurs as a consequence of (1) hematogenous dissemination of bacteria, (2) invasion from a contiguous focus of infection, and (3) skin breakdown in the setting of vascular insufficiency.

▶ Clinical Findings

A. Symptoms and Signs

1. Hematogenous osteomyelitis—Osteomyelitis resulting from bacteremia is a disease associated with sickle cell disease, injection drug users, diabetes mellitus, or the elderly. Patients with this form of osteomyelitis often present with sudden onset of high fever, chills, and pain and tenderness of the involved bone. The site of osteomyelitis and the causative organism depend on the host. Among patients with hemoglobinopathies such as sickle cell anemia, osteomyelitis is caused most often by salmonellae; *S aureus* is the second most common cause. Osteomyelitis in injection drug users develops most commonly in the spine. Although in this setting *S aureus* is most common, gram-negative infections, especially *P aeruginosa* and *Serratia* species, are also frequent pathogens. Rapid progression to epidural abscess causing

fever, pain, and sensory and motor loss is not uncommon. In older patients with hematogenous osteomyelitis, the most common sites are the thoracic and lumbar vertebral bodies. Risk factors for these patients include diabetes, intravenous catheters, and indwelling urinary catheters. These patients often have more subtle presentations, with low-grade fever and gradually increasing bone pain.

2. Osteomyelitis from a contiguous focus of infection—Prosthetic joint replacement, decubitus ulcer, neurosurgery, and trauma most frequently cause soft tissue infections that can spread to bone. *S aureus* and *Staphylococcus epidermidis* are the most common organisms. Localized signs of inflammation are usually evident, but high fever and other signs of toxicity are usually absent. Septic arthritis and cellulitis can also spread to contiguous bone.

3. Osteomyelitis associated with vascular insufficiency—Patients with diabetes and vascular insufficiency are susceptible to developing a very challenging form of osteomyelitis. The foot and ankle are the most commonly affected sites. Infection originates from an ulcer or other break in the skin that is usually still present when the patient presents but may appear disarmingly unimpressive. Bone pain is often absent or muted by the associated neuropathy. Fever is also commonly absent. Two of the best bedside clues that the patient has osteomyelitis are the ability to easily advance a sterile probe through a skin ulcer to bone and an ulcer area > 2 cm².

B. Imaging and Laboratory Findings

The plain film is the most readily available imaging procedure to establish the diagnosis of osteomyelitis, but it can be falsely negative early. Early radiographic findings may include soft tissue swelling, loss of tissue planes, and peri-articular demineralization of bone. About 2 weeks after onset of symptoms, erosion of bone and alteration of cancellous bone appear, followed by periostitis.

MRI, CT, and nuclear medicine bone scanning are more sensitive than conventional radiography. MRI is the most sensitive and is particularly helpful in demonstrating the extent of soft tissue involvement. Radionuclide bone scanning is most valuable when osteomyelitis is suspected but no site is obvious. Nuclear medicine studies may also detect multifocal sites of infection. Ultrasound is useful in diagnosing the presence of effusions within joints and extra-articular soft tissue fluid collections but not in detecting bone infections.

Identifying the offending organism is a crucial step in selection of antibiotic therapy. Bone biopsy for culture is required except in those with hematogenous osteomyelitis, who have positive blood cultures. Cultures from overlying ulcers, wounds, or fistulas are unreliable.

► Differential Diagnosis

Acute hematogenous osteomyelitis should be distinguished from suppurative arthritis, rheumatic fever, and cellulitis. More subacute forms must be differentiated from tuberculosis or mycotic infections of bone and Ewing sarcoma or, in the case of vertebral osteomyelitis, from metastatic tumor.

When osteomyelitis involves the vertebrae, it commonly traverses the disk—a finding not observed in tumor.

► Complications

Inadequate treatment of bone infections results in chronicity of infection, and this possibility is increased by delaying diagnosis and treatment. Extension to adjacent bone or joints may complicate acute osteomyelitis. Recurrence of bone infections often results in anemia, a markedly elevated ESR, weight loss, weakness and, rarely, amyloidosis or nephrotic syndrome. Pseudoepitheliomatous hyperplasia, squamous cell carcinoma, or fibrosarcoma may occasionally arise in persistently infected tissues.

► Treatment

Most patients require both debridement of necrotic bone and prolonged administration of antibiotics. Patients with vertebral body osteomyelitis and epidural abscess may require urgent neurosurgical decompression. Depending on the site and extent of debridement, surgical procedures to stabilize, fill in, cover, or revascularize may be needed. Oral therapy with quinolones (eg, ciprofloxacin, 750 mg twice daily) for 6–8 weeks has been shown to be as effective as standard parenteral antibiotic therapy for chronic osteomyelitis with susceptible organisms. When treating osteomyelitis caused by *S aureus*, quinolones are usually combined with rifampin, 300 mg orally twice daily.

► Prognosis

If sterility of the lesion is achieved within 2–4 days, a good result can be expected in most cases if there is no compromise of the patient's immune system. However, progression of the disease to a chronic form may occur. It is especially common in the lower extremities and in patients in whom circulation is impaired (eg, diabetics).

Howell WR et al. Osteomyelitis: an update for hospitalists. *Hosp Pract (Minneap)*. 2011 Feb;39(1):153–60. [PMID: 21441771]
Zimmerli W. Clinical practice. Vertebral osteomyelitis. *N Engl J Med*. 2010 Mar 18;362(11):1022–9. [PMID: 20237348]

MYCOTIC INFECTIONS OF BONES & JOINTS

Fungal infections of the skeletal system are usually secondary to a primary infection in another organ, frequently the lungs (see Chapter 36). Although skeletal lesions have a predilection for the cancellous portions of long bones and vertebral bodies, the predominant lesion—a granuloma with varying degrees of necrosis and abscess formation—does not produce a characteristic clinical picture.

Differentiation from other chronic focal infections depends on culture studies of synovial fluid or tissue obtained from the local lesion. Serologic tests provide presumptive support of the diagnosis.

1. Candidiasis

Candidal osteomyelitis most commonly develops in debilitated, malnourished patients undergoing prolonged

hospitalization for cancer, neutropenia, trauma, complicated abdominal surgical procedures, or injection drug use. Infected intravenous catheters frequently serve as a hematogenous source. Prosthetic joints can also be infected by *Candida*.

For susceptible *Candida* species, fluconazole, 200 mg orally twice daily, is probably as effective as amphotericin B (see Chapter 36).

Dailey NJ et al. *Candida glabrata* spinal osteomyelitis. *Am J Med Sci*. 2011 Jan;341(1):78–82. [PMID: 21030857]

2. Coccidioidomycosis

Coccidioidomycosis of bones and joints is usually secondary to primary pulmonary infection. Arthralgia with periarticular swelling, especially in the knees and ankles, occurring as a nonspecific manifestation of systemic coccidioidomycosis, should be distinguished from actual bone or joint infection. Osseous lesions commonly occur in cancellous bone of the vertebrae or near the ends of long bones at tendinous insertions. These lesions are initially osteolytic and thus may mimic metastatic tumor or myeloma.

The precise diagnosis depends on recovery of *Coccidioides immitis* from the lesion or histologic examination of tissue obtained by open biopsy. Rising titers of complement-fixing antibodies also provide evidence of the disseminated nature of the disease.

Oral azole antifungal agents (fluconazole 200–400 mg daily, or itraconazole 200 mg twice daily) are the treatment of choice for bone and joint coccidioidomycosis. Chronic infection is rarely cured with antifungal agents and may require operative excision of infected bone and soft tissue; amputation may be the only solution for stubbornly progressive infections. Immobilization of joints by plaster casts and avoidance of weight bearing provide benefit. Synovectomy, joint debridement, and arthrodesis are reserved for more advanced joint infections.

Ampel NM. Coccidioidomycosis: a review of recent advances. *Clin Chest Med*. 2009 Jun;30(2):241–51. [PMID: 19375631]
Blair JE. State-of-the-art treatment of coccidioidomycosis skeletal infections. *Ann N Y Acad Sci*. 2007 Sep;1111:422–33. [PMID: 17395727]

3. Histoplasmosis

Focal skeletal or joint involvement in histoplasmosis is rare and generally represents dissemination from a primary focus in the lungs. Skeletal lesions may be single or multiple and are not characteristic.

Kauffman CA. Histoplasmosis. *Clin Chest Med*. 2009 Jun;30(2):217–25. [PMID: 19375629]
Knox KS et al. Histoplasmosis. *Proc Am Thorac Soc*. 2010 May;7(3):169–72. [PMID: 20463244]

TUBERCULOSIS OF BONES & JOINTS

SPINAL TUBERCULOSIS (Pott Disease)

ESSENTIALS OF DIAGNOSIS

- ▶ Seen primarily in immigrants from developing countries or immunocompromised patients.
- ▶ Back pain and gibbus deformity.
- ▶ Radiographic evidence of vertebral involvement.
- ▶ Evidence of *Mycobacterium tuberculosis* in aspirates or biopsies of spinal lesions.

▶ General Considerations

In the developing world, children primarily bear the burden of musculoskeletal tuberculosis. In the United States, however, musculoskeletal infection is more often seen in adult immigrants from countries where tuberculosis is prevalent, or it develops in the setting of immunosuppression (eg, HIV infection, therapy with TNF inhibitors). Spinal tuberculosis (Pott disease) accounts for about 50% of musculoskeletal infection due to *M tuberculosis* (see Chapter 9). Seeding of the vertebrae may occur through hematogenous spread from the respiratory tract at the time of primary infection, with clinical disease developing years later as a consequence of reactivation. The thoracic and lumbar vertebrae are the most common sites of spinal involvement; vertebral infection is associated with paravertebral cold abscesses in 75% of cases.

▶ Clinical Findings

A. Symptoms and Signs

Patients complain of back pain, often present for months and sometimes associated with radicular pain and lower extremity weakness. Constitutional symptoms are usually absent, and < 20% have active pulmonary disease. Destruction of the anterior aspect of the vertebral body can produce the characteristic gibbus deformity.

B. Laboratory Findings

Most patients have a positive reaction to purified protein derivative (PPD) or a positive interferon-gamma release assay. Cultures of paravertebral abscesses and biopsies of vertebral lesions are positive in up to 70–90%. Biopsies reveal characteristic caseating granulomas in most cases. Isolation of *M tuberculosis* from an extraspinal site is sufficient to establish the diagnosis in the proper clinical setting.

C. Imaging

Radiographs can reveal lytic and sclerotic lesions and bony destruction of vertebrae but are normal early in the disease course. CT scanning can demonstrate paraspinous soft tissue extensions of the infection; MRI is the imaging technique of choice to detect compression of the spinal cord or cauda equina.

► Differential Diagnosis

Spinal tuberculosis must be differentiated from subacute and chronic spinal infections due to pyogenic organisms, *Brucella*, and fungi as well as from malignancy.

► Complications

Paraplegia due to compression of the spinal cord or cauda equina is the most serious complication of spinal tuberculosis.

► Treatment

Antimicrobial therapy should be administered for 6–9 months, usually in the form of isoniazid, rifampin, pyrazinamide, and ethambutol for 2 months followed by isoniazid and rifampin for an additional 4–7 months (see also Chapter 9). Medical management alone is often sufficient. Surgical intervention, however, may be indicated when there is neurologic compromise or severe spinal instability.

Jain AK. Tuberculosis of the spine: a fresh look at an old disease. *J Bone Joint Surg Br.* 2010 Jul;92(7):905–13. [PMID: 20595106]
Kumar R et al. Role of interferon gamma release assay in the diagnosis of Pott disease. *J Neurosurg Spine.* 2010 May;12(5):462–6. [PMID: 20433293]

and ankles are most commonly involved, but any joint may be affected. Distribution of joint involvement is usually polyarticular and symmetric. The arthritis is commonly self-limited, resolving after several weeks or months and rarely resulting in chronic arthritis, joint destruction, or significant deformity. Sarcoid arthropathy is often associated with erythema nodosum, but the diagnosis is contingent on the demonstration of other extra-articular manifestations of sarcoidosis and, notably, biopsy evidence of noncaseating granulomas. Despite the clinical appearance of an inflammatory arthritis, synovial fluid often is noninflammatory (ie, < 2000 leukocytes/mL). In chronic arthritis, radiographs show typical changes in the bones of the extremities with intact cortex and cystic changes.

Treatment of arthritis in sarcoidosis is usually symptomatic and supportive. Colchicine may be of value. A short course of corticosteroids may be effective in patients with severe and progressive joint disease.

Sweiss NJ et al. Rheumatologic manifestations of sarcoidosis. *Semin Respir Crit Care Med.* 2010 Aug;31(4):463–73. [PMID: 20665396]
Gnanasegaran G et al. Multislice SPECT/CT in benign and malignant bone disease: when the ordinary turns into the extraordinary. *Semin Nucl Med.* 2009 Nov;39(6):431–42. [PMID: 19801222]

TUBERCULOUS ARTHRITIS

Infection of peripheral joints by *M tuberculosis* usually presents as a monoarticular arthritis lasting for weeks to months (or longer), but less often, it can have an acute presentation that mimics septic arthritis. Any joint can be involved; the hip and knee are most commonly affected. Constitutional symptoms and fever are present in only a small number of cases. Tuberculosis also can cause a chronic tenosynovitis of the hand and wrist. Joint destruction occurs far more slowly than in septic arthritis due to pyogenic organisms. Synovial fluid is inflammatory but not to the degree seen in pyogenic infections, with synovial white cell counts in the range of 10,000–20,000 cells/mL. Smears of synovial fluid are positive for acid-fast bacilli in a minority of cases; synovial fluid cultures, however, are positive in 80% of cases. Because culture results may take weeks, the diagnostic procedure of choice usually is synovial biopsy, which yields characteristic pathologic findings and positive cultures in > 90%. Antimicrobial therapy is the mainstay of treatment. Rarely, a reactive, sterile polyarthritis associated with erythema nodosum (Poncet disease) develops in patients with active pulmonary tuberculosis.

Shu CC et al. Mycobacterial arthritis of large joints. *Ann Rheum Dis.* 2009 Sep;(9):1504–5. [PMID: 19674984]

ARTHRITIS IN SARCOIDOSIS

The frequency of arthritis among patients with sarcoidosis is variously reported between 10% and 35%. It is usually acute in onset, but articular symptoms may appear insidiously and often antedate other manifestations of the disease. Knees

OTHER RHEUMATIC DISORDERS

RHEUMATIC MANIFESTATIONS OF CANCER

Rheumatologic syndromes may be the presenting manifestations for a variety of cancers. Dermatomyositis in adults, for example, is often associated with cancer (see Table 39–2). Hypertrophic pulmonary osteoarthropathy, which is characterized by the triad of polyarthritis, new onset of clubbing, and periosteal new bone formation, is associated with both malignant diseases (eg, lung and intrathoracic cancers) and nonmalignant ones (eg, cyanotic heart disease, cirrhosis, and lung abscess). Cancer-associated polyarthritis is rare, has both oligoarticular and polyarticular forms, and should be considered when “seronegative rheumatoid arthritis” develops abruptly in an elderly patient. Palmar fasciitis manifests as bilateral palmar swelling with finger contractures and may be the first indication of cancer, particularly ovarian carcinoma. Remitting seronegative synovitis with non-pitting edema (“RS3PE”) presents with a symmetric small joint polyarthritis associated with non-pitting edema of the hands; it can be idiopathic or associated with malignancy. Palpable purpura due to leukocytoclastic vasculitis may be the presenting complaint in myeloproliferative disorders. Hairy cell leukemia can be associated with medium-sized vessel vasculitis such as polyarteritis nodosa. Acute leukemia can produce joint pains that are disproportionately severe in comparison to the minimal swelling and heat that are present. Leukemic arthritis complicates approximately 5% of cases. Rheumatic manifestations of myelodysplastic syndromes include cutaneous vasculitis, lupus-like syndromes, neuropathy, and episodic

intense arthritis. Erythromelalgia, a painful warmth and redness of the extremities that (unlike Raynaud) improves with cold exposure or with elevation of the extremity, is often associated with myeloproliferative diseases, particularly essential thrombocythemia.

Naschitz JE et al. Musculoskeletal syndromes associated with malignancy (excluding hypertrophic osteoarthropathy). *Curr Opin Rheumatol.* 2008 Jan;20(1):100–5. [PMID: 18281865]

NEUROGENIC ARTHROPATHY (Charcot Joint)

Neurogenic arthropathy is joint destruction resulting from loss or diminution of proprioception, pain, and temperature perception. Although initially described in the knees of patients with tabes dorsalis, it is more frequently seen in association with diabetic neuropathy (foot and ankle) or syringomyelia (shoulder). As normal muscle tone and protective reflexes are lost, secondary degenerative joint disease ensues, resulting in an enlarged, boggy, relatively painless joint with extensive cartilage erosion, osteophyte formation, and multiple loose joint bodies. Radiographs can reveal striking osteolysis that mimics osteomyelitis or dramatic destruction of the joint with subluxation, fragmentation of bone, and bony sclerosis.

Treatment is directed toward the primary disease; mechanical devices are used to assist in weight bearing and prevention of further trauma. In some instances, amputation becomes unavoidable.

Thompson P et al. Diabetic foot: Charcot neuropathic osteoarthropathy. *Adv Skin Wound Care.* 2009 Feb;22(2):72–3. [PMID: 19155710]

PALINDROMIC RHEUMATISM

Palindromic rheumatism is a disease of unknown cause characterized by frequent recurring attacks (at irregular intervals) of acutely inflamed joints. Periarticular pain with swelling and transient subcutaneous nodules may also occur. The attacks cease within several hours to several days. The knee and finger joints are most commonly affected, but any peripheral joint may be involved. Systemic manifestations other than fever do not occur. Although hundreds of attacks may take place over a period of years, there is no permanent articular damage. Laboratory findings are usually normal. Palindromic rheumatism must be distinguished from acute gouty arthritis and an atypical acute onset of rheumatoid arthritis. In some patients, palindromic rheumatism is a prodrome of rheumatoid arthritis.

Symptomatic treatment with NSAIDs is usually all that is required during the attacks. Hydroxychloroquine may be of value in preventing recurrences.

OSTEONECROSIS (Avascular Necrosis of Bone)

Osteonecrosis is a complication of corticosteroid use, alcoholism, trauma, SLE, pancreatitis, gout, sickle cell disease,

dysbaric syndromes (eg, “the bends”), knee meniscectomy, and infiltrative diseases (eg, Gaucher disease). The most commonly affected sites are the proximal and distal femoral heads, leading to hip or knee pain. Other commonly affected sites include the ankle, shoulder, and elbow. Osteonecrosis of the jaw has been rarely associated with use of bisphosphonate therapy, almost always when the bisphosphonate is used for treating metastatic cancer or multiple myeloma rather than osteoporosis. Initially, radiographs are often normal; MRI, CT scan, and bone scan are all more sensitive techniques. Treatment involves avoidance of weight bearing on the affected joint for at least several weeks. The value of surgical core decompression is controversial. For osteonecrosis of the hip, a variety of procedures designed to preserve the femoral head have been developed for early disease, including vascularized and nonvascularized bone grafting procedures. These procedures are most effective in avoiding or forestalling the need for total hip arthroplasty in young patients who do not have advanced disease. Without a successful intervention of this nature, the natural history of avascular necrosis is usually progression of the bony infarction to cortical collapse, resulting in significant joint dysfunction. Total hip replacement is the usual outcome for all patients who are candidates for that procedure.

Babis GC et al. Osteonecrosis of the femoral head. *Orthopedics.* 2011 Jan;34(1):39. [PMID: 21210589]

Smith TO et al. The clinical and radiological outcomes of hip resurfacing versus total hip arthroplasty: a meta-analysis and systematic review. *Acta Orthop.* 2010 Dec;81(6):684–95. [PMID: 21067432]

Turun S et al. A systematic review of rivaroxaban versus enoxaparin in the prevention of venous thromboembolism after hip or knee replacement. *Thromb Res.* 2011 Jun;127(6):525–34. [PMID: 21397931]

ALLERGIC DISEASES

Allergy is an immunologically mediated hypersensitivity reaction to a foreign antigen manifested by tissue inflammation and organ dysfunction. These responses have a genetic basis, but the clinical expression of disease depends on both immunologic responsiveness and antigen exposure. Allergic disorders may be local or systemic. Because the allergen is foreign (ie, environmental), the skin and respiratory tract are the organs most frequently involved in allergic disease. Allergic reactions may also localize to the vasculature, gastrointestinal tract, or other visceral organs. Anaphylaxis is the most extreme form of systemic allergy.

▶ Immunologic Classification

An immunologic classification for hypersensitivity reactions serves as a rational basis for diagnosis and treatment. The classification follows.

A. Type I—IgE-Mediated (Immediate) Hypersensitivity

IgE antibodies occupy receptor sites on mast cells. Within minutes after exposure to the allergen, a multivalent

antigen links adjacent IgE molecules, activating and degranulating mast cells. Clinical manifestations depend on the effects of released mediators on target end organs. Both preformed and newly generated mediators cause vasodilation, visceral smooth muscle contraction, mucous secretory gland stimulation, vascular permeability, and tissue inflammation. Arachidonic acid metabolites, cytokines, and other mediators induce a late-phase inflammatory response that appears several hours later. There are two clinical subgroups of IgE-mediated allergy: atopy and anaphylaxis.

1. Atopy—The term “atopy” is applied to a group of diseases (allergic rhinitis, allergic asthma, atopic dermatitis, and allergic gastroenteropathy) occurring in persons with an inherited tendency to develop antigen-specific IgE reaction to environmental allergens or food antigens. Aeroallergens such as pollens, mold spores, animal danders, and house dust mite antigen are common triggers for allergic conjunctivitis, allergic rhinitis, and allergic asthma. The allergic origin of atopic dermatitis is less well understood, but some patients’ symptoms can be triggered by exposure to dust mite antigen and ingestion of certain foods. There is a strong familial tendency toward the development of atopy.

2. Anaphylaxis—Certain allergens—especially drugs, insect venoms, latex, and foods—may induce an IgE antibody response, causing a generalized release of mediators from mast cells and resulting in systemic anaphylaxis. This is characterized by (1) hypotension or shock from widespread vasodilation, (2) bronchospasm, (3) gastrointestinal and uterine muscle contraction, and (4) urticaria or angioedema. The condition is potentially fatal and can affect both nonatopic and atopic persons. Isolated urticaria and angioedema are cutaneous forms of anaphylaxis, are much more common, and have a better prognosis.

B. Type II—Antibody-Mediated (Cytotoxic) Hypersensitivity

Cytotoxic reactions involve the specific reaction of either IgG or IgM antibody to cell-bound antigens. This results in activation of the complement cascade and the destruction of the cell to which the antigen is bound. Examples include immune hemolytic anemia and Rh hemolytic disease in the newborn.

C. Type III—Immune Complex-Mediated Hypersensitivity

Immune complex-mediated reactions occur when antigen and IgG or IgM antibodies form circulating immune complexes. Deposition of these complexes in tissues or in vascular endothelium can produce immune complex-mediated tissue injury through activation of the complement cascade, anaphylatoxin generation, and chemotaxis of polymorphonuclear leukocytes. Serum sickness is the classic example of type III hypersensitivity. Immune complex disease also can develop in the setting of chronic infections such as subacute bacterial endocarditis and hepatitis B.

D. Type IV—T Cell-Mediated Hypersensitivity (Delayed Hypersensitivity, Cell-Mediated Hypersensitivity)

Type IV delayed hypersensitivity is mediated by activated T cells, which accumulate in areas of antigen deposition. The most common expression of delayed hypersensitivity is allergic contact dermatitis, which develops when a low-molecular-weight sensitizing substance haptens with dermal proteins, becoming a complete antigen. Sensitized T cells release cytokines, activating macrophages and promoting the subsequent dermal inflammation; this occurs 1–2 days after the time of contact. Common topical agents associated with allergic contact dermatitis include nickel, formaldehyde, potassium dichromate, thiurams, mercaptos, parabens, quaternium-15, and ethylenediamine. Rhus (poison oak and ivy) contact dermatitis is caused by cutaneous exposure to oils from the toxicodendron plants. Acute contact dermatitis is characterized by erythema and induration with vesicle formation, often with pruritus, with exudation and crusting in more severe cases. Chronic allergic contact dermatitis may be associated with fissuring, lichenification, or dyspigmentation and may be mistaken for other forms of dermatitis. To diagnose allergic contact dermatitis, patch testing can be performed.

ATOPIC DISEASE

Clinical manifestations resembling allergic hypersensitivity can also occur in the absence of an immunologic mechanism. Therefore, the diagnosis of allergy requires answers to the following questions: (1) What is the nature of the disease? (2) Is the disease caused by an IgE-mediated mechanism? (3) What specific allergens are responsible?

The relevant history includes a survey of allergen exposure associated with home, work, hobbies, and habits as well as medications. Physical examination is most useful if performed during exposure. Demonstration of allergic hypersensitivity by *in vivo* or *in vitro* testing confirms clinical suspicions of allergic disease.

► Specific IgE Antibody Tests

To maximize the positive predictive value of allergy testing, a positive test result must be correlated with the history. Patients selected for testing include those with moderate to severe disease, those who are potential candidates for allergen immunotherapy, and those with strong predisposing factors for atopic diatheses, eg, a strong family history of atopy or ongoing exposure to potential sources of allergen. Since the development of rhinitis precedes the presentation of asthma in over half of cases, early intervention may decrease the risk of more severe clinical allergic disease. The type of immune response must be consistent with the nature of the disease. IgE antibody causes allergic rhinitis but not allergic contact dermatitis. IgE antibodies are detected by *in vivo* (skin tests) or *in vitro* methods.

Bischoff SC. Food allergy and eosinophilic gastroenteritis and colitis. *Curr Opin Allergy Clin Immunol.* 2010 Jun;10(3):238–45. [PMID: 20431371]

Novak N. New insights into the mechanism and management of allergic diseases: atopic dermatitis. *Allergy*. 2009 Feb;64(2):265–75. [PMID: 19178406]

Ong PY. Emerging drugs for atopic dermatitis. *Expert Opin Emerg Drugs*. 2009 Mar;14(1):165–79. [PMID: 19216704]

Sicherer SH et al. Advances in allergic skin disease, anaphylaxis, and hypersensitivity reactions to foods, drugs, and insects in 2008. *J Allergy Clin Immunol*. 2009 Feb;123(2):319–27. [PMID: 19203656]

SERUM SICKNESS



ESSENTIALS OF DIAGNOSIS

- ▶ Fever, pruritic rash, arthralgias, and arthritis; nephritis in severe cases.
- ▶ Occurs 7–10 days following administration of an exogenous antigen (eg, heterologous gamma globulin) when specific IgG antibodies develop against the antigen.
- ▶ Immune complex-mediated small vessel vasculitis and tissue injury.

▶ General Considerations

Serum sickness occurs when an antibody response to exogenously administered antigens results in the formation of immune complexes. Deposition of these complexes in vascular endothelium and tissues produces immune complex-mediated small vessel vasculitis and tissue injury through activation of complement, generation of anaphylatoxins, and chemoattraction of polymorphonuclear leukocytes. The skin, joints, and kidneys are commonly affected. It is self-limited and resolves after the antigen is cleared. First observed in the preantibiotic era when heterologous serum preparations were used for passive immunization, serum sickness is now less common but still occurs with the use of heterologous anti-thymocyte globulin for transplant rejection and, infrequently, after the administration of murine monoclonal antibodies or even non-protein drugs.

▶ Clinical Findings

A. Symptoms and Signs

Sustained high fever (> 101°F) is typical. The earliest manifestation is often a maculopapular or urticarial pruritic rash. Angioedema can occur. Polyarthralgias, frank polyarthritis, and lymphadenopathy are common. Nephritis is usually mild but can progress to acute renal failure.

B. Laboratory Findings

The ESR is increased, and leukocytosis is common. Other nonspecific laboratory findings include elevated hepatic aminotransferases. When nephritis is present, the urinalysis

reveals proteinuria, hematuria, and red cell casts. Hypocomplementemia is usually present in cases due to administration of heterologous gamma globulin but not in milder cases precipitated by non-protein drugs. Circulating immune complexes may be found, but current assays are limited in sensitivity.

▶ Treatment

This disease is self-limited, and treatment is usually conservative for mild cases. NSAIDs help relieve the arthralgias, and antihistamines and topical corticosteroids can be of benefit for the skin manifestation. A high-dose course of corticosteroids is administered for serious reactions, especially those complicated by glomerulonephritis and other manifestations of vasculitis. Plasma exchange may be of benefit for cases refractory to corticosteroids.

PSEUDOALLERGIC REACTIONS

These reactions resemble immediate hypersensitivity reactions but are not mediated by allergen-IgE interaction. Instead, direct mast cell activation occurs. Examples of pseudoallergic or “anaphylactoid” reactions include radiocontrast reactions, direct mast cell activation by opioids, and the now rare “red man syndrome” from rapid infusion of vancomycin. In contrast to IgE-mediated reactions, these can often be prevented by prophylactic medical regimens.

Radiocontrast Media Reactions

Reactions to radiocontrast media do not appear to be mediated by IgE antibodies, yet clinically they are similar to anaphylaxis. If a patient has had an anaphylactoid reaction to conventional radiocontrast media, the risk for a second reaction upon reexposure may be as high as 30%. Patients with asthma or those being treated with β -adrenergic blocking medications may be at increased risk. The management of patients at risk for radiocontrast medium reactions includes use of the low-osmolality contrast preparations and prophylactic administration of prednisone (50 mg orally every 6 hours beginning 18 hours before the procedure) and diphenhydramine (25–50 mg intramuscularly 60 minutes before the procedure). The use of the lower-osmolality radiocontrast media in combination with the pretreatment regimen decreases the incidence of reactions to < 1%.

Liccardi G et al; Cardarelli Hospital Radiocontrast Media and Anesthetic-Induced Anaphylaxis Prevention Working Group. Strategies for the prevention of asthmatic, anaphylactic and anaphylactoid reactions during the administration of anesthetics and/or contrast media. *J Investig Allergol Clin Immunol*. 2008;18(1):1–11. [PMID: 18361095]

Vermeire S et al. Serum sickness, encephalitis and other complications of anti-cytokine therapy. *Best Pract Res Clin Gastroenterol*. 2009;23(1):101–12. [PMID: 19258190]

PRIMARY IMMUNODEFICIENCY DISORDERS

The primary immunologic deficiency diseases include congenital and acquired disorders of humoral immunity (B cell function) or cell-mediated immunity (T cell function). Most of these diseases are rare and, because they are genetically determined, usually present in childhood. Nonetheless, several immunodeficiency disorders can present in adulthood, most notably selective IgA deficiency and common variable immunodeficiency.

Arason GJ et al. Primary immunodeficiency and autoimmunity: lessons from human diseases. *Scand J Immunol.* 2010 May; 71(5):317–28. [PMID: 20500682]

Bussone G et al. Autoimmune manifestations in primary immune deficiencies. *Autoimmun Rev.* 2009 Feb;8(4):332–6. [PMID: 19028607]

Fried AJ et al. Pathogenesis, diagnosis, and management of primary antibody deficiencies and infections. *Clin Microbiol Rev.* 2009 Jul;22(3):396–414. [PMID: 19597006]

Slatter MA et al. Primary immunodeficiency syndromes. *Adv Exp Med Biol.* 2010;685:146–65. [PMID: 20687503]

SELECTIVE IMMUNOGLOBULIN A DEFICIENCY

Selective IgA deficiency is the most common primary immunodeficiency disorder and is characterized by serum IgA levels < 15 mg/dL with normal levels of IgG and IgM; its prevalence is about 1:500 individuals. Most persons are asymptomatic because of compensatory increases in secreted IgG and IgM. Some affected patients have frequent and recurrent infections, such as sinusitis, otitis, and bronchitis. Some cases of IgA deficiency may spontaneously remit. When IgG₂ subclass deficiency occurs in combination with IgA deficiency, affected patients are more susceptible to encapsulated bacteria and the degree of immune impairment can be more severe. Patients with a combined IgA and IgG subclass deficiency should be assessed for functional antibody responses to glycoprotein antigen immunization.

Atopic disease and autoimmune disorders can be associated with IgA deficiency. Occasionally, a sprue-like syndrome with steatorrhea has been associated with an isolated IgA deficit. Treatment with commercial immune globulin is ineffective, since IgA and IgM are present only in trace quantities in these preparations.

Individuals with selective IgA deficiency may have high titers of anti-IgA antibodies and are at risk for anaphylactic reactions following exposure to IgA through infusions of plasma (or blood transfusions). These anti-IgA antibodies develop in the absence of prior exposure to human plasma or blood, possibly due to crossreactivity to bovine IgA in cow's milk or prior sensitization to maternal IgA in breast milk.

Yel L. Selective IgA deficiency. *J Clin Immunol.* 2010 Jan;30(1): 10–6. [PMID: 20101521]

COMMON VARIABLE IMMUNODEFICIENCY

ESSENTIALS OF DIAGNOSIS

- ▶ Defect in terminal differentiation of B cells, with absent plasma cells and deficient synthesis of secreted antibody.
- ▶ Frequent sinopulmonary infections secondary to humoral immune deficiency.
- ▶ Confirmation by evaluation of serum immunoglobulin levels and deficient functional antibody responses.

▶ General Considerations

The most common cause of panhypogammaglobulinemia in adults is common variable immunodeficiency, a heterogeneous immunodeficiency disorder clinically characterized by an increased incidence of recurrent infections, autoimmune phenomena, and neoplastic diseases. The onset generally is during adolescence or early adulthood but can occur at any age. The prevalence of common variable immunodeficiency is about 1:80,000 in the United States. Most cases are sporadic; 10–20% are familial.

▶ Clinical Findings

A. Symptoms and Signs

Increased susceptibility to pyogenic infections is the hallmark of the disease. Virtually all patients suffer from recurrent sinusitis, with bronchitis, otitis, pharyngitis, and pneumonia also being common infections. Infections may be prolonged or associated with unusual complications such as meningitis or sepsis.

Gastrointestinal disorders are commonly associated with common variable immunodeficiency, and a sprue-like syndrome, with diarrhea, steatorrhea, malabsorption, protein-losing enteropathy, and hepatosplenomegaly, may develop in patients. Paradoxically, there is an increased incidence of autoimmune disease (20%), although patients may not display the usual serologic markers. Autoimmune cytopenias are most common, but autoimmune endocrinopathies, seronegative rheumatic disease, and gastrointestinal disorders are also commonly seen. Lymph nodes may be enlarged in these patients, yet biopsies show marked reduction in plasma cells. Noncaseating granulomas are frequently found in the spleen, liver, lungs, or skin. There is an increased propensity for the development of B cell neoplasms (50- to 400-fold increase risk of lymphoma), gastric carcinomas, and skin cancers.

B. Laboratory Findings

The pattern of immunoglobulin isotype deficiency is variable. Most patients present with significantly depressed IgG levels, but over time all antibody classes (IgG, IgA, and IgM) may be affected. Diagnosis is confirmed in patients

with recurrent infections by demonstration of functional or quantitative defects in antibody production. Serum IgG levels are usually < 250 mg/dL; serum IgA and IgM levels are also subnormal. Decreased to absent functional antibody responses to protein antigen immunizations establish the diagnosis.

The causes of the panhypogammaglobulinemia in common variable immunodeficiency patients include intrinsic B cell defects that prevent terminal maturation into antibody-secreting plasma cells. The absolute B cell count in the peripheral blood in most patients, despite the underlying cellular defect, is normal. A subset of these patients have concomitant T cell immunodeficiency with increased numbers of activated CD8 cells, splenomegaly, and decreased delayed-type hypersensitivity.

▶ Treatment

Patients may be treated aggressively with antibiotics at the first sign of infection. Since antibody deficiency predisposes patients to high-risk pyogenic infections, antibiotic coverage should be sure to cover encapsulated bacteria.

Only after the development of bronchiectasis or after sinus surgery do patients become significantly affected by more virulent organisms such as *S aureus* or *P aeruginosa*. Maintenance intravenous immune globulin therapy is indicated, with infusions of 300–500 mg/kg of intravenous immune globulin given at about monthly intervals. Adjustment of dosage or of the infusion interval is made on the basis of clinical responses and steady-state trough serum IgG levels. Such therapy is effective in decreasing the incidence of potentially life-threatening infections and increasing quality of life. The yearly cost of monthly infusions can be in excess of \$20,000–\$30,000.

Deane S et al. Common variable immunodeficiency: etiological and treatment issues. *Int Arch Allergy Immunol.* 2009; 150(4):311–24. Erratum in: *Int Arch Allergy Immunol.* 2010;151(4):284. [PMID: 19571563]

van de Ven AA et al. B-cell defects in common variable immunodeficiency: BCR signaling, protein clustering and hardwired gene mutations. *Crit Rev Immunol.* 2011;31(2):85–98. [PMID: 21542788]

21

Electrolyte & Acid-Base Disorders

Kerry C. Cho, MD

ASSESSMENT OF THE PATIENT

The diagnosis and treatment of fluid and electrolyte disorders are based on (1) careful history, (2) physical examination and assessment of total body water and its distribution, (3) serum electrolyte concentrations, (4) urine electrolyte concentrations, and (5) serum osmolality. The pathophysiology of electrolyte disorders is rooted in basic principles of total body water and its distribution across fluid compartments.

A. Body Water and Fluid Distribution

Total body water is different in men than in women, and it decreases with aging (Table 21–1). Approximately 50–60% of total body weight is water; two-thirds (40% of body weight) is intracellular, while one-third (20% of body weight) is extracellular. One-fourth of extracellular fluid (5% of body weight) is intravascular. Water may be lost from either or both compartments (intracellular and extracellular). Changes in total body water content are best evaluated by documenting changes in body weight. Effective circulating volume may be assessed by physical examination (eg, blood pressure, pulse, jugular venous distention). Quantitative measurements of effective circulating volume and intravascular volume may be invasive (ie, central venous pressure or pulmonary wedge pressure) or non-invasive (ie, inferior vena cava diameter and right atrial pressure by echocardiography) but still require careful interpretation.

B. Serum Electrolytes

The cause of electrolyte disorders may be determined by reviewing the history, underlying diseases, and medications.

C. Evaluation of Urine

The urine concentration of an electrolyte indicates renal handling of the electrolyte and whether the kidney is appropriately excreting or retaining the electrolyte. A 24-hour urine collection for daily electrolyte excretion is the gold standard for renal electrolyte handling, but it is slow and onerous. A more convenient method is the fractional

excretion (FE) of an electrolyte X (FE_x) calculated from a spot urine sample:

$$FE_x(\%) = \frac{\text{Urine X/Serum X}}{\text{Urine Cr/Serum Cr}} \times 100$$

A low fractional excretion indicates renal reabsorption (high avidity or electrolyte retention), while a high fractional excretion indicates renal wasting (low avidity or electrolyte excretion). Thus, the fractional excretion helps the clinician determine whether the kidney's response is appropriate for a specific electrolyte disorder.

D. Serum Osmolality

Solute concentration is measured by osmolality. Osmoles per kilogram of water is *osmolality*; osmoles per liter of solution is *osmolarity*. At physiological solute concentrations (normally 285–295 mosm/kg), the two measurements are clinically interchangeable. Tonicity refers to osmolytes that are impermeable to cell membranes. Differences in osmolyte concentration across cell membranes lead to osmosis and fluid shifts, stimulation of thirst, and secretion of antidiuretic hormone (ADH). Substances that easily permeate cell membranes (eg, urea, ethanol) are ineffective osmoles that do not cause fluid shifts across fluid compartments.

Serum osmolality can be estimated from the following formula:

Osmolality =

$$2(\text{Na}^+ \text{ mEq/L}) + \frac{\text{Glucose mg/dL}}{18} + \frac{\text{BUN mg/dL}}{2.8}$$

(1 mosm/L of glucose equals 180 mg/L and 1 mosm/L of urea nitrogen equals 28 mg/L). Sodium is the major extracellular cation; doubling the serum sodium in the formula for estimated osmolality accounts for counterbalancing anions. A discrepancy between measured and estimated osmolality of > 10 mosm/kg suggests an osmol gap, which is the presence of other unmeasured osmoles such as ethanol, methanol, isopropanol, and ethylene glycol (see Table 38–5).

Table 21-1. Total body water (as percentage of body weight) in relation to age and sex.

Age	Male	Female
18-40	60%	50%
41-60	60-50%	50-40%
Over 60	50%	40%

DISORDERS OF SODIUM CONCENTRATION

HYPONATREMIA



ESSENTIALS OF DIAGNOSIS

- ▶ Volume status and serum osmolality are essential to determine etiology.
- ▶ Hyponatremia usually reflects excess water retention relative to sodium rather than sodium deficiency.
- ▶ Hypotonic fluids commonly cause hyponatremia in hospitalized patients.

General Considerations


Defined as a serum sodium concentration < 135 mEq/L, hyponatremia is the most common electrolyte abnormality in hospitalized patients. The clinician should be wary about hyponatremia since mismanagement can result in neurologic catastrophes from cerebral osmotic demyelination. Indeed, iatrogenic complications from aggressive or inappropriate therapy can be more harmful than hyponatremia itself.

A common misperception is that the sodium concentration is a reflection of total body sodium or total body water. In fact, total body water and sodium can be low, normal, or high in hyponatremia since the kidney can regulate sodium and water homeostasis independently. Most cases of hyponatremia reflect water imbalance and abnormal water handling, not sodium imbalance, indicating the primary role of ADH in the pathophysiology of hyponatremia. A diagnostic algorithm using serum osmolality and volume status separates the causes of hyponatremia into therapeutically useful categories (Figure 21-1).

Etiology

A. Isotonic & Hypertonic Hyponatremia

Serum osmolality identifies isotonic and hypertonic hyponatremia, although these cases can often be identified by careful history or previous laboratory tests.



▲ **Figure 21-1.** Evaluation of hyponatremia using serum osmolality and extracellular fluid volume status.

ACE, angiotensin-converting enzyme; SIADH, syndrome of inappropriate antidiuretic hormone. (Adapted, with permission, from Narins RG et al. Diagnostic strategies in disorders of fluid, electrolyte and acid-base homeostasis. *Am J Med.* 1982 Mar;72(3):496-520.)

Isotonic hyponatremia is seen with severe hyperlipidemia and hyperproteinemia. Lipids (including chylomicrons, triglycerides, and cholesterol) and proteins (> 10 g/dL, eg, paraproteinemias and intravenous immunoglobulin therapy) interfere with the measurement of serum sodium, causing pseudohyponatremia. Serum osmolality is isotonic because lipids and proteins do not affect osmolality measurement. Newer sodium assays using ion-specific electrodes will not produce pseudohyponatremia.

Hypertonic hyponatremia occurs with hyperglycemia and mannitol administration for increased intracranial pressure. Glucose and mannitol osmotically pull intracellular water into the extracellular space. The translocation of water lowers the serum sodium concentration. Translocational hyponatremia is not pseudohyponatremia or an artifact of sodium measurement. The sodium concentration falls 2 mEq/L for every 100 mg/dL (or 5.56 mmol/L) rise in glucose when the glucose concentration is between 200 mg/dL and 400 mg/dL (11.1 mmol/L and 22.2 mmol/L). If the glucose concentration is > 400 mg/dL, the sodium concentration falls 4 mEq/L for every 100 mg/dL rise in glucose. There is some controversy about the correction factor for the serum sodium in the presence of hyperglycemia. Many guidelines recommend a correction factor, whereby the serum sodium concentration decreases by 1.6 mEq/L for every 100 mg/dL (5.56 mmol/L) rise in plasma glucose above normal, but there is evidence that the decrease may be greater when patients have more severe hyperglycemia (> 400 mg/dL or 22.2 mmol/L) or volume depletion, or both. One group has suggested (based on short-term exposure of normal volunteers to markedly elevated glucose levels) that when the serum glucose is > 200 mg/dL, the serum sodium concentration decreases by at least 2.4 mEq/L.

B. Hypotonic Hyponatremia

Most cases of hyponatremia are hypotonic, highlighting sodium's role as the predominant extracellular osmole. The next step is classifying hypotonic cases by the patient's volume status.

1. Hypovolemic hypotonic hyponatremia—Hypovolemic hyponatremia occurs with renal or extrarenal volume loss and hypotonic fluid replacement (Figure 21–1). Total body sodium and total body water are decreased. To maintain intravascular volume, the pituitary increases ADH secretion, causing free water retention from hypotonic fluid replacement. The body sacrifices serum osmolality to preserve intravascular volume. In short, losses of water and salt are replaced by water alone. Without ongoing hypotonic fluid intake, the renal or extrarenal volume loss would produce hypovolemic hypernatremia.

Cerebral salt wasting is a distinct and rare subset of hypovolemic hyponatremia seen in patients with intracranial disease (eg, infections, cerebrovascular accidents, tumors, and neurosurgery). Clinical features include refractory hypovolemia and hypotension, often requiring continuous infusion of isotonic or hypertonic saline and ICU monitoring. The exact pathophysiology is unclear but includes renal sodium wasting possibly through

brain natriuretic peptide, ADH release, and decreased aldosterone secretion.

2. Euvolemic hypotonic hyponatremia—Euvolemic hyponatremia has the broadest differential diagnosis. Most processes are mediated directly or indirectly through ADH, including hypothyroidism, adrenal insufficiency, medications, and the syndrome of inappropriate ADH (SIADH). The exceptions are primary polydipsia, beer potomania, and reset osmostat.

A. HORMONAL ABNORMALITIES—Hypothyroidism and adrenal insufficiency can cause hyponatremia. Exactly how hypothyroidism induces hyponatremia is unclear but may be related to ADH. Adrenal insufficiency may be associated with the hyperkalemia and metabolic acidosis of hypoaldosteronism. Cortisol provides feedback inhibition for ADH release.

B. THIAZIDE DIURETICS AND OTHER MEDICATIONS—Thiazides induce hyponatremia typically in older female patients within days of initiating therapy. The mechanism appears to be a combination of mild diuretic-induced volume contraction, ADH effect, and intact urinary concentrating ability resulting in water retention and hyponatremia. Loop diuretics do not cause hyponatremia as frequently because of disrupted medullary concentrating gradient and impaired urine concentration.

Nonsteroidal anti-inflammatory drugs (NSAIDs) increase ADH by inhibiting prostaglandin formation. Prostaglandins and selective serotonin reuptake inhibitors (eg, fluoxetine, paroxetine, and citalopram) can cause hyponatremia, especially in geriatric patients. Enhanced secretion or action of ADH may result from increased serotonergic tone. Angiotensin-converting enzyme (ACE) inhibitors do not block the conversion of angiotensin I to angiotensin II in the brain. Angiotensin II stimulates thirst and ADH secretion. Hyponatremia during amiodarone-loading has been reported; it usually improves with dose reduction.

Abuse of 3,4-methylenedioxymethamphetamine (MDMA, also known as Ecstasy) can lead to hyponatremia and severe neurologic symptoms, including seizures, cerebral edema, and brainstem herniation. MDMA and its metabolites increase ADH release from the hypothalamus. Primary polydipsia may contribute to hyponatremia since MDMA users typically increase fluid intake to prevent hyperthermia.

C. NAUSEA, PAIN, SURGERY, AND MEDICAL PROCEDURES—Nausea and pain are potent stimulators of ADH release. Severe hyponatremia can develop after elective surgery in healthy patients, especially premenopausal women. Hypotonic fluids in the setting of elevated ADH levels can produce severe, life-threatening hyponatremia. Medical procedures such as colonoscopy have also been associated with hyponatremia.

D. HIV INFECTION—Hyponatremia is seen in up to 50% of hospitalized HIV patients and 20% of ambulatory HIV patients. The differential diagnosis is broad: medication effect, adrenal insufficiency, hypoaldosteronism, central nervous system or pulmonary disease, SIADH, malignancy, and volume depletion.

E. ENDURANCE EXERCISE HYPONATREMIA—Hyponatremia after endurance exercise (eg, triathlon events and marathons) may be caused by a combination of excessive hypotonic fluid intake and continued ADH secretion. Reperfusion of the exercise-induced ischemic splanchnic bed causes delayed absorption of excessive quantities of hypotonic fluid ingested during exercise. Sustained elevation of ADH prevents water excretion in this setting. Current guidelines suggest that endurance athletes drink water according to thirst rather than according to specified hourly rates of fluid intake.

F. SYNDROME OF INAPPROPRIATE ANTIDIURETIC HORMONE SECRETION—Under normal circumstances, hypovolemia and hyperosmolality stimulate ADH secretion. ADH release is inappropriate without these physiological cues. Normal regulation of ADH release occurs from both the central nervous system and the chest via baroreceptors and neural input. The major causes of SIADH (Table 21–2) are disorders affecting the central nervous system (structural, metabolic, psychiatric, or pharmacologic processes) or the lungs (infectious, mechanical, oncologic). Medications commonly cause SIADH by increasing ADH or its action. Some carcinomas, especially small cell lung carcinoma, can autonomously secrete ADH.

G. PSYCHOGENIC POLYDIPSIA AND BEER POTOMANIA—Marked free water intake (generally > 10 L/d) may produce hyponatremia. Euvolemia is maintained through renal excretion of sodium. Urine sodium is therefore generally elevated (> 20 mEq/L), and ADH levels are appropriately suppressed. As the increased free water is excreted, the urine osmolality approaches the minimum of 50 mosm/kg. Polydipsia occurs in psychiatric patients. Psychiatric medications may interfere with water excretion or increase thirst through anticholinergic side effects, further increasing water intake. The hyponatremia of beer potomania occurs in patients who consume large amounts of beer. Free water excretion is decreased because of decreased solute consumption and production; muscle wasting and malnutrition are contributing factors. Without enough solute, these patients have decreased free water excretory capacity even if they maximally dilute the urine.

H. RESET OSMOSTAT—Reset osmostat is a rare cause of hyponatremia characterized by appropriate ADH regulation in response to water deprivation and fluid challenges. Patients with reset osmostat regulate serum sodium and serum osmolality around a lower set point, concentrating or diluting urine in response to hyperosmolality and hypo-osmolality. The mild hypo-osmolality of pregnancy is a form of reset osmostat.

3. Hypervolemic hypotonic hyponatremia—Hypervolemic hyponatremia occurs in the edematous states of cirrhosis, heart failure, nephrotic syndrome, and advanced kidney disease (Figure 21–1). In cirrhosis and heart failure, effective circulating volume is decreased due to peripheral vasodilation or decreased cardiac output. Increased renin-angiotensin-aldosterone system activity and ADH secretion result in water retention. Note the pathophysiological

Table 21–2. Causes of syndrome of inappropriate ADH secretion (SIADH).

Central nervous system disorders

- Head trauma
- Stroke
- Subarachnoid hemorrhage
- Hydrocephalus
- Brain tumor
- Encephalitis
- Guillain-Barré syndrome
- Meningitis
- Acute psychosis
- Acute intermittent porphyria

Pulmonary lesions

- Tuberculosis
- Bacterial pneumonia
- Aspergillosis
- Bronchiectasis
- Neoplasms
- Positive pressure ventilation

Malignancies

- Bronchogenic carcinoma
- Pancreatic carcinoma
- Prostatic carcinoma
- Renal cell carcinoma
- Adenocarcinoma of colon
- Thymoma
- Osteosarcoma
- Lymphoma
- Leukemia

Drugs

- Increased ADH production
 - Antidepressants: tricyclics, monoamine oxidase inhibitors, SSRIs
 - Antineoplastics: cyclophosphamide, vincristine
 - Carbamazepine
 - Methylenedioxymethamphetamine (MDMA; Ecstasy)
 - Clofibrate
 - Neuroleptics: thiothixene, thioridazine, fluphenazine, haloperidol, trifluoperazine
- Potentiated ADH action
 - Carbamazepine
 - Chlorpropamide, tolbutamide
 - Cyclophosphamide
 - NSAIDs
 - Somatostatin and analogs
 - Amiodarone

Others

- Postoperative
- Pain
- Stress
- AIDS
- Pregnancy (physiologic)
- Hypokalemia

ADH, antidiuretic hormone; NSAIDs, nonsteroidal anti-inflammatory drugs; SSRIs, selective serotonin reuptake inhibitors.

similarity to hypovolemic hyponatremia—the body sacrifices osmolality in an attempt to restore effective circulating volume.

The pathophysiology of hyponatremia in nephrotic syndrome is not completely understood, but the primary disturbance may be renal sodium retention, resulting in overfilling of the intravascular space and secondary edema

formation as fluid enters the interstitial space. Previously, it was thought that the decreased oncotic pressure of hypoalbuminemia caused fluid shifts from the intravascular space to the interstitial compartment. Intravascular underfilling led to secondary renal sodium retention. However, patients receiving therapy for glomerular disease and nephrotic syndrome often have edema resolution prior to normalization of the serum albumin.

Patients with advanced kidney disease typically have sodium retention and decreased free water excretory capacity, resulting in hypervolemic hyponatremia.

► Clinical Findings

A. Symptoms and Signs

Whether hyponatremia is symptomatic depends on its severity and acuity. Chronic disease can be severe (sodium concentration < 110 mEq/L), yet remarkably asymptomatic because the brain has adapted by decreasing its tonicity over weeks to months. Acute disease that has developed over hours to days can be severely symptomatic with relatively modest hyponatremia. Mild hyponatremia (sodium concentrations of 130–135 mEq/L) is usually asymptomatic.

Mild symptoms of nausea and malaise progress to headache, lethargy, and disorientation as the sodium concentration drops. The most serious symptoms are respiratory arrest, seizure, coma, permanent brain damage, brainstem herniation, and death. Premenopausal women are much more likely than menopausal women to die or suffer permanent brain injury from hyponatremic encephalopathy, suggesting a hormonal role in the pathophysiology.

Evaluation starts with a careful history for new medications, changes in fluid intake (polydipsia, anorexia, intravenous fluid rates and composition), fluid output (nausea and vomiting, diarrhea, ostomy output, polyuria, oliguria, insensible losses). The physical examination should help categorize the patient's volume status into hypovolemia, euvolemia, or hypervolemia.

B. Laboratory Findings

Laboratory assessment should include serum electrolytes, serum creatinine, serum osmolality, and urine sodium. The etiology of most cases of hyponatremia will be apparent from the history, physical, and basic laboratory tests. Additional tests of thyroid and adrenal function will occasionally be necessary.

SIADH is a clinical diagnosis characterized by (1) hyponatremia; (2) decreased osmolality (< 280 mosm/kg); (3) absence of heart, kidney, or liver disease; (4) normal thyroid and adrenal function (see Chapter 26); and (5) urine sodium usually over 20 mEq/L. In clinical practice, ADH levels are not measured. Patients with SIADH may have low blood urea nitrogen (BUN) (< 10 mg/dL [or < 3.6 mmol/L]) and hypouricemia (< 4 mg/dL [or < 238 μmol/L]), which are not only dilutional but result from increased urea and uric acid clearances in response to the volume-expanded state. Azotemia may reflect volume contraction, ruling out SIADH, which is seen in euvolemic patients.

► Complications

The most serious complication of hyponatremia is iatrogenic cerebral osmotic demyelination from overly rapid sodium correction. Also called central pontine myelinolysis, cerebral osmotic demyelination may occur outside the brainstem. Demyelination may occur days after sodium correction or initial neurologic recovery from hyponatremia. Hypoxic episodes during hyponatremia may contribute to demyelination. The neurologic effects are generally catastrophic and irreversible.

► Treatment

Regardless of the patient's volume status, another common feature is to restrict free water and hypotonic fluid intake, since these solutions will exacerbate hyponatremia. Free water intake from oral intake and intravenous fluids should generally be < 1–1.5 L/d.

Hypovolemic patients require adequate fluid resuscitation from isotonic fluids (either normal saline or lactated Ringer solution) to suppress the hypovolemic stimulus for ADH release. Patients with **cerebral salt wasting** may require hypertonic saline to prevent circulatory collapse; some may respond to fludrocortisone. **Hypervolemic** patients may require loop diuretics or dialysis, or both, to correct increased total body water and sodium. **Euvolemic** patients may respond to free water restriction alone.

Pseudohyponatremia from hypertriglyceridemia or hyperproteinemia requires no therapy except confirmation with the clinical laboratory. **Translocational hyponatremia** from glucose or mannitol can be managed with glucose correction or mannitol discontinuation (if possible). No specific therapy is necessary in patients with **reset osmostat** since they successfully regulate their serum sodium with fluid challenges and water deprivation.

Symptomatic and severe hyponatremia generally require hospitalization for careful monitoring of fluid balance and weights, treatment, and frequent sodium checks. Inciting medications should be discontinued if possible.

There is no consensus about the optimal rate of sodium correction in symptomatic hyponatremic patients. A reasonable rate is 10–12 mEq/L/d in mildly to moderately symptomatic patients. A more aggressive rate of 1–1.5 mEq/L/h (to a maximum correction of 10–12 mEq/L) has been used in severely symptomatic patients. Sodium concentration should be monitored as frequently as every 1–2 hours. As symptoms improve or resolve, the correction rate should be reduced to roughly 0.5 mEq/L/h. To avoid overcorrection, the clinician should stabilize the sodium around 125 mEq/L to 130 mEq/L.

In severely symptomatic patients, the clinician should calculate the sodium deficit and deliver 3% **hypertonic saline**. The sodium deficit can be calculated by the following formula:

$$\text{Sodium deficit} = \text{Total body water (TBW)} \\ \times (\text{Desired serum Na} - \text{Actual serum Na})$$

where TBW is typically 50% of total mass in women and 55% of total mass in men. For example, a nonedematous, severely symptomatic 70 kg woman with a serum sodium

of 122 mEq/L should have her serum sodium corrected to approximately 132 mEq/L in the first 24 hours. Her sodium deficit is calculated as:

$$\begin{aligned}\text{Sodium deficit} &= 70 \text{ kg} \times 0.5 \times (132 \text{ mEq/L} - 122 \text{ mEq/L}) \\ &= 350 \text{ mEq}\end{aligned}$$

3% hypertonic saline has a sodium concentration of 514 mEq/1000 mL. The delivery rate for hypertonic saline can be calculated as:

$$\begin{aligned}\text{Delivery rate} &= \text{Sodium deficit} / 514 \text{ mEq} / 1000 \\ &\quad \text{mL} / 24 \text{ hours} \\ &= 350 \text{ mEq} / 514 \text{ mEq} / 1000 \text{ mL} / 24 \text{ hours} \\ &= 28 \text{ mL} / \text{hour}\end{aligned}$$

In general, the 3% hypertonic saline infusion rate should not exceed 0.5 mL/kg body weight/h; higher rates may represent a miscalculated sodium deficit or a mathematical error. The goal is not to correct the serum sodium by more than 10–12 mEq/L over the first 24 hours. Hypertonic saline in hypervolemic patients can be hazardous, resulting in worsening volume overload, pulmonary edema, and ascites.

For patients who cannot adequately restrict free water or have an inadequate response to conservative measures, demeclocycline (300–600 mg orally twice daily) inhibits the effect of ADH on the distal tubule. Onset of action may require 1 week, and urinary concentrating ability may be permanently impaired, resulting in nephrogenic diabetes insipidus (DI) and even hypernatremia. Cirrhosis may increase the nephrotoxicity of demeclocycline.

Vasopressin antagonists may revolutionize the treatment of euvolemic and hypervolemic hyponatremia, especially in heart failure. Lixivaptan, tolvaptan, and satavaptan are oral selective vasopressin-2 receptor antagonists. V₂ receptors mediate the diuretic effect of ADH. For hospitalized patients with euvolemic SIADH, conivaptan is given as an intravenous loading dose of 20 mg delivered over 30 minutes, then as 20 mg continuously over 24 hours. Subsequent infusions may be administered every 1–3 days at 20–40 mg/d by continuous infusion. Tolvaptan and conivaptan are available in the United States. (Lixivaptan and satavaptan are not yet approved by the Food and Drug Administration [FDA] for use in the United States.)

▶ When to Refer

- Nephrology or endocrinology consultation should be considered in severe, symptomatic, refractory, or complicated cases of hyponatremia.
- Aggressive therapies with hypertonic saline, demeclocycline, vasopressin antagonists, or dialysis mandate specialist consultation.
- Consultation may be necessary with end-stage liver or heart disease.

▶ When to Admit

Hospital admission is necessary for symptomatic patients or those requiring aggressive therapies for close monitoring and frequent laboratory testing.

Graff-Radford J et al. Clinical and radiologic correlations of central pontine myelinolysis syndrome. *Mayo Clin Proc.* 2011 Nov;86(11):1063–7. [PMID: 21997578]

Leung AA et al. Risk of thiazide-induced hyponatremia in patients with hypertension. *Am J Med.* 2011 Nov;124(11):1064–72. [PMID: 22017784]

Robertson GL. Vaptans for the treatment of hyponatremia. *Nat Rev Endocrinol.* 2011 Mar;7(3):151–61. [PMID: 21283124]

Sterns RH et al. Treatment of hyponatremia. *Curr Opin Nephrol Hypertens.* 2010 Sep;19(5):493–8. [PMID: 20539224]

HYPERNATREMIA



ESSENTIALS OF DIAGNOSIS

- ▶ Increased thirst and water intake is the first defense against hypernatremia.
- ▶ Urine osmolality helps differentiate renal from nonrenal water loss.

▶ General Considerations

Hypernatremia is defined as a sodium concentration > 145 mEq/L. All patients with hypernatremia have hyperosmolality, unlike hyponatremic patients who can have a low, normal, or high serum osmolality. The hypernatremic patient is typically hypovolemic due to free water losses, although hypervolemia is frequently seen, often as an iatrogenic complication in hospitalized patients with impaired access to free water. Rarely, excessive sodium intake may cause hypernatremia. Hypernatremia in primary aldosteronism is mild and usually does not cause symptoms.

An intact thirst mechanism and access to water are the primary defense against hypernatremia. The hypothalamus can sense minimal changes in serum osmolality, triggering the thirst mechanism and increased water intake. Thus, whatever the underlying disorder (eg, dehydration, lactulose or mannitol therapy, central and nephrogenic DI), excess water loss can cause hypernatremia only when adequate water intake is not possible.

▶ Clinical Findings

A. Symptoms and Signs

When the patient is dehydrated, orthostatic hypotension and oliguria are typical findings. Because water shifts from the cells to the intravascular space to protect volume status, these symptoms may be delayed. Lethargy, irritability, and weakness are early signs. Hyperthermia, delirium, seizures, and coma may be seen with severe hypernatremia (ie, sodium > 158 mEq/L). Symptoms in the elderly may not be specific; a recent change in consciousness is associated with a poor prognosis. Osmotic demyelination is an uncommon but reported consequence of severe hypernatremia.

B. Laboratory Findings

1. Urine osmolality > 400 mosm/kg—Renal water-conserving ability is functioning.

A. NONRENAL LOSSES—Hypertremia will develop if water intake falls behind hypotonic fluid losses from excessive sweating, the respiratory tract, or bowel movements. Lactulose causes an osmotic diarrhea with loss of free water.

B. RENAL LOSSES—While severe hyperglycemia can cause translocational hyponatremia (see above), progressive volume depletion from glucosuria can result in hypertremia. Osmotic diuresis can occur with the use of mannitol or urea.

2. Urine osmolality < 250 mosm/kg—Hypertremia with a dilute urine (osmolality < 250 mosm/kg) is characteristic of DI. Central DI results from inadequate ADH release. Nephrogenic DI results from renal insensitivity to ADH; common causes include lithium, demeclocycline, relief of urinary obstruction, interstitial nephritis, hypercalcemia, and hypokalemia.

▶ Treatment

Treatment of hypertremia includes correcting the cause of the fluid loss, replacing water, and replacing electrolytes (as needed). In response to increases in plasma osmolality, brain cells synthesize solutes called idiogenic osmoles, which cause intracellular fluid shifts. Osmole production begins 4–6 hours after dehydration and takes several days to reach steady state. If hypertremia is rapidly corrected, the osmotic imbalance may cause cerebral edema and potentially severe neurologic impairment. Fluids should be administered over a 48-hour period, aiming for serum sodium correction of approximately 1 mEq/L/h (1 mmol/L/h). There is no consensus about the optimal rates of sodium correction in hypertremia and hyponatremia.

A. Choice of Type of Fluid for Replacement

1. Hypertremia with hypovolemia—Hypovolemic patients should receive isotonic 0.9% normal saline to restore euvolemia and to treat hyperosmolality, since isotonic 0.9% normal saline (308 mosm/kg) is often hypo-osmolar compared with plasma. After adequate volume resuscitation with normal saline, 0.45% saline or 5% dextrose (or both) can be used to replace any remaining free water deficit. Milder volume deficits may be treated with 0.45% saline and 5% dextrose.

2. Hypertremia with euvolemia—Water ingestion or intravenous 5% dextrose will result in the excretion of excess sodium in the urine. If the glomerular filtration rate (GFR) is decreased, diuretics will increase urinary sodium excretion but may impair renal concentrating ability, increasing the quantity of water that needs to be replaced.

3. Hypertremia with hypervolemia—Treatment includes 5% dextrose solution to reduce hyperosmolality. Loop diuretics may be necessary to promote natriuresis and lower total body sodium. In severe rare cases with kidney disease, hemodialysis may be necessary to correct the excess total body sodium and water.

B. Calculation of Water Deficit

Fluid replacement should include the free water deficit and additional maintenance fluid to replace ongoing and anticipated fluid losses.

1. Acute hypertremia—In acute dehydration without much solute loss, free water loss is similar to the weight loss. Initially, a 5% dextrose solution may be used. As correction of water deficit progresses, therapy should continue with 0.45% saline with dextrose.

2. Chronic hypertremia—The water deficit is calculated to restore normal sodium concentration, typically 140 mEq/L. Total body water (TBW) (Table 21–1) correlates with muscle mass and therefore decreases with advancing age, cachexia, and dehydration and is lower in women than in men. Current TBW equals 40–60% current body weight.

$$\text{Volume (in L) to be replaced} = \text{Current TBW} \times \frac{[\text{Na}^+] - 140}{140}$$

▶ When to Refer

Patients with refractory or unexplained hypertremia should be referred for subspecialist consultation.

▶ When to Admit

- Patients with symptomatic hypertremia require hospitalization for evaluation and treatment.
- Significant comorbidities or concomitant acute illnesses, especially if contributing to hypertremia, may necessitate hospitalization.

Adroge HJ et al. Hypertremia. *N Engl J Med*. 2000 May 18;342(20):1493–9. [PMID: 10816188]
 Alshayeb HM et al. Severe hypertremia correction rate and mortality in hospitalized patients. *Am J Med Sci*. 2011 May;341(5):356–60. [PMID: 21358313]
 Nguyen MK. Quantitative approaches to the analysis and treatment of the dysnatremias. *Semin Nephrol*. 2009 May; 29(3):216–26. [PMID: 19523570]
 O'Donoghue SD et al. Acquired hypernatraemia is an independent predictor of mortality in critically ill patients. *Anaesthesia*. 2009 May;64(5):514–20. [PMID: 19413821]
 Reynolds RM et al. Disorders of sodium balance. *BMJ*. 2006 Mar 25;332(7543):702–5. [PMID: 16565125]

VOLUME OVERLOAD

ESSENTIALS OF DIAGNOSIS

- ▶ Disorder of excessive sodium retention in the setting of low arterial underfilling (eg, congestive heart failure or cirrhosis).
- ▶ Hyponatremia from water retention in edematous states is associated with sodium retention.

The hallmark of a volume overloaded state is sodium retention. Abnormally low arterial filling, such as from congestive heart failure or cirrhosis, activates the neurohumoral axis, which stimulates the renin-angiotensin-aldosterone system, the sympathetic nervous system, and ADH (vasopressin) release. Sodium retention with edema results. The stimulus for vasopressin release is nonosmotic. Released in response to baroreceptor activation, vasopressin stimulates renal V_2 receptors, resulting in water reabsorption, edema formation, and hyponatremia.

Bagshaw SM et al. Disorders of sodium and water balance in hospitalized patients. *Can J Anaesth*. 2009 Feb;56(2):151–67. [PMID: 19247764]

Rosner MH et al. Dysnatremias in the intensive care unit. *Contrib Nephrol*. 2010;165:292–8. [PMID: 20427980]

HYPEROSMOLAR DISORDERS & OSMOLAR GAPS

HYPEROSMOLALITY WITH TRANSIENT OR NO SIGNIFICANT SHIFT IN WATER

Urea and alcohol readily cross cell membranes and can produce hyperosmolality. Urea is an ineffective osmole with little effect on osmotic water movement across cell membranes. Alcohol quickly equilibrates between the intra-cellular and extracellular compartments, adding 22 mosm/L for every 100 mg/dL (or 21.7 mmol/L) of ethanol. Ethanol ingestion should be considered in any case of stupor or coma with an elevated osmol gap (measured osmolality – calculated osmolality > 10 mosm/kg). Other toxic alcohols such as methanol and ethylene glycol cause an osmol gap and a metabolic acidosis with an increased anion gap (see Chapter 38). The combination of an increased anion gap metabolic acidosis and an osmol gap exceeding 10 mosm/kg is not specific for toxic alcohol ingestion and may occur with alcoholic ketoacidosis or lactic acidosis (see Metabolic Acidosis).

HYPEROSMOLALITY ASSOCIATED WITH SIGNIFICANT SHIFTS IN WATER

Increased concentrations of solutes that do not readily enter cells cause a shift of water from intracellular to extracellular. Hyperosmolality of effective osmoles such as sodium and glucose causes symptoms, primarily neurologic. The severity of symptoms depends on the degree of hyperosmolality and rapidity of development. In acute hyperosmolality, somnolence and confusion can appear when the osmolality exceeds 320–330 mosm/kg; coma, respiratory arrest, and death can result when osmolality exceeds 340–350 mosm/kg.

Kraut JA et al. Approach to the evaluation of a patient with an increased serum osmolal gap and high-anion-gap metabolic acidosis. *Am J Kidney Dis*. 2011 Sep;58(3):480–4. [PMID: 21794966]

Whittington JE et al. The osmolal gap: what has changed? *Clin Chem*. 2010 Aug;56(8):1353–5. [PMID: 20530730]

DISORDERS OF POTASSIUM CONCENTRATION

HYPOKALEMIA

ESSENTIALS OF DIAGNOSIS

- ▶ Severe hypokalemia may induce dangerous arrhythmias and rhabdomyolysis.
- ▶ Transtubular potassium concentration gradient (TTKG) can distinguish renal from nonrenal loss of potassium.

▶ General Considerations

Hypokalemia can result from insufficient dietary potassium intake, intracellular shifting of potassium from the extracellular space, extrarenal potassium loss, or renal potassium loss (Table 21–3). Cellular uptake of potassium is increased by insulin and β -adrenergic stimulation

Table 21–3. Causes of hypokalemia.

Decreased potassium intake Potassium shift into the cell

- Increased postprandial secretion of insulin
- Alkalosis
- Trauma (via β -adrenergic stimulation?)
- Periodic paralysis (hypokalemic)
- Barium intoxication

Renal potassium loss

- Increased aldosterone (mineralocorticoid) effects
 - Primary hyperaldosteronism
 - Secondary aldosteronism (dehydration, heart failure)
- Renovascular hypertension
- Malignant hypertension
- Ectopic ACTH-producing tumor
- Gitelman syndrome
- Bartter syndrome
- Cushing syndrome
- Licorice (European)
- Renin-producing tumor
- Congenital abnormality of steroid metabolism (eg, adrenogenital syndrome, 17α -hydroxylase defect, apparent mineralocorticoid excess, 11β -hydroxylase deficiency)
- Increased flow to distal nephron
 - Diuretics (furosemide, thiazides)
 - Salt-losing nephropathy
- Hypomagnesemia
 - Unreabsorbable anion
 - Carbenicillin, penicillin
- Renal tubular acidosis (type I or II)
 - Fanconi syndrome
 - Interstitial nephritis
 - Metabolic alkalosis (bicarbonaturia)
- Congenital defect of distal nephron
 - Liddle syndrome

Extrarenal potassium loss

- Vomiting, diarrhea, laxative abuse
- Villous adenoma, Zollinger-Ellison syndrome

and blocked by α -adrenergic stimulation. Aldosterone is an important regulator of total body potassium, increasing potassium secretion in the distal renal tubule. The most common cause of hypokalemia, especially in developing countries, is gastrointestinal loss from infectious diarrhea. The potassium concentration in intestinal secretion is ten times higher (80 mEq/L) than in gastric secretions. Hypokalemia in the presence of acidosis suggests profound potassium depletion and requires urgent treatment. Self-limited hypokalemia occurs in 50–60% of trauma patients, perhaps related to enhanced release of epinephrine.

Hypokalemia increases the likelihood of digitalis toxicity. In patients with heart disease, hypokalemia induced by β_2 -adrenergic agonists and diuretics may substantially increase the risk of arrhythmias. Numerous genetic mutations affect fluid and electrolyte metabolism, including disorders of potassium metabolism (Table 21–4).

Magnesium is an important cofactor for potassium uptake and maintenance of intracellular potassium levels. Loop diuretics (eg, furosemide) cause substantial renal potassium and magnesium losses. Magnesium depletion should be considered in refractory hypokalemia.

► Clinical Findings

A. Symptoms and Signs

Muscular weakness, fatigue, and muscle cramps are frequent complaints in mild to moderate hypokalemia. Gastrointestinal smooth muscle involvement may result in constipation or ileus. Flaccid paralysis, hyporeflexia, hypercapnia, tetany, and rhabdomyolysis may be seen with severe hypokalemia (< 2.5 mEq/L). The presence of hypertension may be a clue to the diagnosis of hypokalemia from aldosterone or mineralocorticoid excess (Table 21–4). Renal manifestations include nephrogenic DI and interstitial nephritis.

B. Laboratory Findings

Urinary potassium concentration is low (< 20 mEq/L) as a result of extrarenal loss (eg, diarrhea, vomiting) and inappropriately high (> 40 mEq/L) with renal loss (eg, mineralocorticoid excess, Bartter syndrome, Liddle syndrome) (Table 21–3).

The transtubular $[K^+]$ gradient (TTKG) is a simple and rapid evaluation of net potassium secretion. TTKG is calculated as follows:

$$\text{TTKG} = \frac{\text{Urine } K^+ / \text{Plasma } K^+}{\text{Urine osm} / \text{Plasma osm}}$$

Hypokalemia with a TTKG > 4 suggests renal potassium loss with increased distal K^+ secretion. In such cases, plasma renin and aldosterone levels are helpful in differential diagnosis. The presence of nonabsorbed anions, such as bicarbonate, increases the TTKG.

Table 21–4. Genetic disorders associated with electrolyte metabolism disturbances.

Disease	Site of Mutation
Potassium	
Hypokalemia	
Hypokalemic periodic paralysis	Dihydropyridine-sensitive skeletal muscle voltage-gated calcium channel
Bartter syndrome	Na^+ - K^+ - $2Cl^-$ cotransporter, K^+ channel (ROMK), or Cl^- channel of thick ascending limb of Henle (hypofunction), barttin
Gitelman syndrome	Thiazide-sensitive Na^+ - Cl^- cotransporter
Liddle syndrome	β or γ subunit of amiloride-sensitive Na^+ channel (hyperfunction)
Apparent mineralocorticoid excess	11 β -hydroxysteroid dehydrogenase (failure to inactivate cortisol)
Glucocorticoid-remediable hyperaldosteronism	Regulatory sequence of 11 β -hydroxylase controls aldosterone synthase inappropriately
Hyperkalemia	
Hyperkalemic periodic paralysis	α subunit of calcium channel
Pseudohypoaldosteronism type I	β or γ subunit of amiloride-sensitive Na^+ channel (hypofunction)
Pseudohypoaldosteronism type II (Gordon syndrome)	HNK2, HNK4
Calcium	
Familial hypocalciuric hypercalcemia	Ca^{2+} -sensing protein (hypofunction)
Familial hypocalcemia	Ca^{2+} -sensing protein (hyperfunction)
Phosphate	
Hypophosphatemic rickets	PEX gene, FGF23
Magnesium	
Hypomagnesemia-hypercalciuria syndrome	Paracellin-1
Water	
Nephrogenic diabetes insipidus	Vasopressin receptor-2 (Type 1), aquaporin-2
Acid-base	
Proximal RTA	Na^+ HCO_3^- cotransporter
Distal RTA	Cl^- HCO_3^- exchanger H^+ -ATPase
Proximal and distal RTA	Carbonic anhydrase II

FGF23, fibroblast growth factor 23; RTA, renal tubular acidosis.

C. Electrocardiogram

The electrocardiogram (ECG) shows decreased amplitude and broadening of T waves, prominent U waves, premature ventricular contractions, and depressed ST segments.

▶ Treatment

Oral potassium supplementation is the safest and easiest treatment for mild to moderate deficiency. Dietary potassium is almost entirely coupled to phosphate—rather than chloride—and is therefore not effective in correcting potassium loss associated with chloride depletion from diuretics or vomiting. In the setting of abnormal kidney function and mild to moderate diuretic dosage, 20 mEq/d of oral potassium is generally sufficient to prevent hypokalemia, but 40–100 mEq/d over a period of days to weeks is needed to treat hypokalemia and fully replete potassium stores.

Intravenous potassium is indicated for patients with severe hypokalemia and for those who cannot take oral supplementation. For severe deficiency, potassium may be given through a peripheral intravenous line in a concentration up to 40 mEq/L and at rates up to 10 mEq/h. Concentrations of up to 20 mEq/h may be given through a central venous catheter. Continuous ECG monitoring is indicated, and the serum potassium level should be checked every 3–6 hours. Avoid glucose-containing fluid to prevent further shifts of potassium into the cells. Magnesium deficiency should be corrected, particularly in refractory hypokalemia.

▶ When to Refer

Patients with unexplained hypokalemia, refractory hyperkalemia, or clinical features suggesting alternative diagnoses (eg, aldosteronism or hypokalemic periodic paralysis) should be referred for endocrinology or nephrology consultation.

▶ When to Admit

Patients with symptomatic or severe hypokalemia, especially with cardiac manifestations, require cardiac monitoring, frequent laboratory testing, and potassium supplementation.

Born-Frontsberg E et al. Cardiovascular and cerebrovascular comorbidities of hypokalemic and normokalemic primary aldosteronism: results of the German Conn's Registry. *J Clin Endocrinol Metab.* 2009 Apr;94(4):1125–30. [PMID: 19190103]

Greenlee M et al. Narrative review: evolving concepts in potassium homeostasis and hypokalemia. *Ann Intern Med.* 2009 May 5;150(9):619–25. [PMID: 19414841]

Huang CL et al. Mechanism of hypokalemia in magnesium deficiency. *J Am Soc Nephrol.* 2007 Oct;18(10):2649–52. [PMID: 17804670]

Palmer BF. A physiologic-based approach to the evaluation of a patient with hypokalemia. *Am J Kidney Dis.* 2010 Dec;56(6):1184–90. [PMID: 20828906]

HYPERKALEMIA



ESSENTIALS OF DIAGNOSIS

- ▶ Serum potassium level > 5.0 mEq/L (> 5.0 mmol/L).
- ▶ Hyperkalemia may develop in patients taking ACE inhibitors, angiotensin-receptor blockers, potassium-sparing diuretics, or their combination, even with no or only mild kidney dysfunction.
- ▶ The ECG may show peaked T waves, widened QRS and biphasic QRS-T complexes, or may be normal despite life-threatening hyperkalemia.
- ▶ Measurement of plasma potassium level differentiates potassium leak from blood cells in cases of clotting, leukocytosis, and thrombocytosis from elevated serum potassium.
- ▶ Rule out extracellular potassium shift from the cells in acidosis and assess renal potassium excretion.

▶ General Considerations

Hyperkalemia usually occurs in patients with advanced kidney disease but can also develop with normal kidney function (Table 21–5). Acidosis causes intracellular potassium to shift extracellularly. Serum potassium concentration rises about 0.7 mEq/L for every decrease of 0.1 pH unit during acidosis. Fist clenching during venipuncture may raise the potassium concentration by 1–2 mEq/L by causing acidosis and potassium shift from cells. In the absence of acidosis, serum potassium concentration rises about 1 mEq/L when there is a total body potassium excess of 1–4 mEq/kg. However, the higher the serum potassium concentration, the smaller the excess necessary to raise the potassium levels further.

Mineralocorticoid deficiency from Addison disease or chronic kidney disease (CKD) is another cause of hyperkalemia with decreased renal excretion of potassium. Mineralocorticoid resistance due to genetic disorders, interstitial kidney disease, or urinary tract obstruction also leads to hyperkalemia.

ACE inhibitors or angiotensin-receptor blockers (ARBs), commonly used in patients with congestive heart failure or CKD, may cause hyperkalemia. The concomitant use of spironolactone, eplerenone, or β -blockers further increases the risk of hyperkalemia. Thiazide or loop diuretics and sodium bicarbonate may minimize hyperkalemia. Persistent mild hyperkalemia in the absence of ACE inhibitor or ARB therapy is usually due to type IV renal tubular acidosis (RTA). Heparin inhibits aldosterone production in the adrenal glands, causing hyperkalemia.

Trimethoprim is structurally similar to amiloride and triamterene, and all three drugs inhibit renal potassium excretion through suppression of sodium channels in the distal nephron.

Cyclosporine and tacrolimus can induce hyperkalemia in organ transplant recipients, especially kidney transplant patients, partly due to suppression of the basolateral $\text{Na}^+ - \text{K}^+$ -ATPase in

Table 21-5. Causes of hyperkalemia.**Spurious/Pseudohyperkalemia**

Leakage from erythrocytes when separation of serum from clot is delayed (plasma K⁺ normal)
 Marked thrombocytosis or leukocytosis with release of intracellular K⁺ (plasma K⁺ normal)
 Repeated fist clenching during phlebotomy, with release of K⁺ from forearm muscles
 Specimen drawn from arm with intravenous K⁺ infusion

Decreased K⁺ excretion

Kidney disease, acute and chronic
 Renal secretory defects (may or may not have reduced kidney function): kidney transplant, interstitial nephritis, systemic lupus erythematosus, sickle cell disease, amyloidosis, obstructive nephropathy
 Hyporeninemic hypoaldosteronism (often in diabetic patients with mild to moderate nephropathy) or selective hypoaldosteronism (eg, AIDS patients)
 Drugs that inhibit potassium excretion: spironolactone, eplerenone, drosipironone, NSAIDs, ACE inhibitors, angiotensin II receptor blockers, triamterene, amiloride, trimethoprim, pentamidine, cyclosporine, tacrolimus)

Shift of K⁺ from within the cell

Massive release of intracellular K⁺ in burns, rhabdomyolysis, hemolysis, severe infection, internal bleeding, vigorous exercise
 Metabolic acidosis (in the case of organic acid accumulation—eg, lactic acidosis—a shift of K⁺ does not occur since organic acid can easily move across the cell membrane)
 Hypertonicity (solvent drag)
 Insulin deficiency (metabolic acidosis may not be apparent)
 Hyperkalemic periodic paralysis
 Drugs: succinylcholine, arginine, digitalis toxicity, β-adrenergic antagonists
 α-Adrenergic stimulation?

Excessive intake of K⁺

Especially in patients taking medications that decrease potassium secretion (see above)

ACE, angiotensin-converting enzyme; NSAIDs, nonsteroidal anti-inflammatory drugs.

principal cells. Hyperkalemia is commonly seen in HIV patients and has been attributed to impaired renal excretion of potassium due to pentamidine or trimethoprim-sulfamethoxazole or to hyporeninemic hypoaldosteronism.

► Clinical Findings

Hyperkalemia impairs neuromuscular transmission, causing muscle weakness, flaccid paralysis, and ileus. Electrocardiography is not a sensitive method for detecting hyperkalemia, since nearly half of patients with a serum potassium level > 6.5 mEq/L will not manifest ECG changes. ECG changes in hyperkalemia include bradycardia, PR interval prolongation, peaked T waves, QRS widening, and biphasic QRS-T complexes. Conduction disturbances, such as bundle branch block and atrioventricular block, may occur. Ventricular fibrillation and cardiac arrest are terminal events.

► Prevention

Inhibitors of the renin-angiotensin-aldosterone axis (ie, ACE inhibitors, ARBs, and spironolactone) and potassium-sparing

diuretics (eplerenone, triamterene) should be used cautiously in patients with heart failure, liver failure, and kidney disease. Laboratory monitoring should be performed within 1 week of drug initiation or dosage increase.

► Treatment

The diagnosis should be confirmed by repeat laboratory testing to rule out spurious hyperkalemia, especially in the absence of medications that cause hyperkalemia or in patients without kidney disease or a previous history of hyperkalemia. Plasma potassium concentration can be measured to avoid hyperkalemia due to potassium leakage out of red cells, white cells, and platelets. Kidney dysfunction should be ruled out at the initial assessment.

Treatment consists of withholding exogenous potassium, identifying the cause, reviewing the patient's medications and dietary potassium intake, and correcting the hyperkalemia. Emergent treatment is indicated when cardiac toxicity, muscle paralysis, or severe hyperkalemia (potassium > 6.5 mEq/L) is present, even in the absence of ECG changes. Insulin, bicarbonate, and β-agonists shift potassium intracellularly within minutes of administration (Table 21-6). Intravenous calcium may be given to antagonize the cell membrane effects of potassium, but its use should be restricted to life-threatening hyperkalemia in patients taking digitalis because hypercalcemia may cause digitalis toxicity. Hemodialysis may be required to remove potassium in patients with acute or chronic kidney injury.

► When to Refer

- Patients with hyperkalemia from kidney disease and reduced renal potassium excretion should see a nephrologist.
- Transplant patients may need adjustment of their immunosuppression regimen by transplant specialists.

► When to Admit

Patients with severe hyperkalemia > 6 mEq/L, any degree of hyperkalemia associated with ECG changes, or concomitant illness (eg, tumor lysis, rhabdomyolysis, metabolic acidosis) should be sent to the emergency department for immediate treatment.

Aronson PS et al. Effects of pH on potassium: new explanations for old observations. *J Am Soc Nephrol.* 2011 Nov;22(11):1981–9. [PMID: 21980112]

Elliott MJ et al. Management of patients with acute hyperkalemia. *CMAJ.* 2010 Oct 19;182(15):1631–5. [PMID: 20855477]

Palmer BF. A physiologic-based approach to the evaluation of a patient with hyperkalemia. *Am J Kidney Dis.* 2010 Aug; 56(2):387–93. [PMID: 20493606]

Shingarev R et al. A physiologic-based approach to the treatment of acute hyperkalemia. *Am J Kidney Dis.* 2010 Sep; 56(3):578–84. [PMID: 20570423]

Watson M et al. Damned if you do, damned if you don't: potassium binding resins in hyperkalemia. *Clin J Am Soc Nephrol.* 2010 Oct;5(10):1723–6. [PMID: 20798253]

Table 21-6. Treatment of hyperkalemia.

IMMEDIATE					
Modality	Mechanism of Action	Onset	Duration	Prescription	K ⁺ Removed from Body
Calcium	Antagonizes cardiac conduction abnormalities	0-5 minutes	1 hour	Calcium gluconate 10%, 5-30 mL intravenously; or calcium chloride 5%, 5-30 mL intravenously	0
Bicarbonate	Distributes K ⁺ into cells	15-30 minutes	1-2 hours	NaHCO ₃ , 44-88 mEq (1-2 ampules) intravenously Note: Sodium bicarbonate may not be effective in end-stage renal disease patients; dialysis is more expedient and effective. Some patients may not tolerate the additional sodium load of bicarbonate therapy.	0
Insulin	Distributes K ⁺ into cells	15-60 minutes	4-6 hours	Regular insulin, 5-10 units intravenously, plus glucose 50%, 25 g intravenously	0
Albuterol	Distributes K ⁺ into cells	15-30 minutes	2-4 hours	Nebulized albuterol, 10-20 mg in 4 mL normal saline, inhaled over 10 minutes Note: Much higher doses are necessary for hyperkalemia therapy (10-20 mg) than for airway disease (2.5 mg).	0
URGENT					
Modality	Mechanism of Action	Onset of Action		Prescription	K ⁺ Removed from Body
Loop diuretic	Renal K ⁺ excretion	0.5-2 hours		Furosemide, 40-160 mg intravenously Note: Diuretics may not be effective in patients with acute and chronic kidney diseases.	Variable
Sodium polystyrene sulfonate (Kayexalate)	Ion-exchange resin binds K ⁺	1-3 hours		Oral: 15-60 g in 20% sorbitol (60-240 mL) Rectal: 30-60 g in 20% sorbitol Note: Resins with sorbitol may cause bowel necrosis and intestinal perforation, especially in postoperative patients.	0.5-1 mEq/g resin
Hemodialysis ¹	Extracorporeal K ⁺ removal	1-8 hours		Dialysate [K ⁺] 0-1 mEq/L Note: A fast and effective therapy for hyperkalemia, hemodialysis can be delayed by vascular access placement and equipment and/or staffing availability. Serum K can be rapidly corrected within minutes, but post-dialysis rebound can occur.	25-50 mEq/h
Peritoneal dialysis	Peritoneal K ⁺ removal	1-4 hours		Frequent exchanges	200-300 mEq

¹Can be both acute immediate and urgent treatment of hyperkalemia.

Modified and reproduced, with permission, from Cogan MG. *Fluid and Electrolytes: Physiology and Pathophysiology*. McGraw-Hill, 1991.

DISORDERS OF CALCIUM CONCENTRATION

The normal total plasma (or serum) calcium concentration is 8.5-10.5 mg/dL (or 2.1-2.6 mmol/L). Ionized calcium (normal: 4.6-5.3 mg/dL [or 1.15-1.32 mmol/L]) is physiologically active and necessary for muscle contraction and nerve function.

The calcium-sensing receptor, a transmembrane protein that detects the extracellular calcium concentration, has been identified in the parathyroid gland and the kidney. Functional defects in this protein are associated with diseases of abnormal calcium metabolism such as familial hypocalcemia and familial hypocalciuric hypercalcemia (Table 21-4).

HYPOCALCEMIA



ESSENTIALS OF DIAGNOSIS

- ▶ Often mistaken as a neurologic disorder.
- ▶ Check for decreased parathyroid hormone (PTH), vitamin D, or magnesium depletion.
- ▶ If the ionized calcium level is normal despite a low total serum calcium, calcium metabolism is usually normal.

▶ General Considerations

The most common cause of low total serum calcium is hypoalbuminemia. When serum albumin concentration is lower than 4 g/dL (40 g/L), serum Ca^{2+} concentration is reduced by 0.8–1 mg/dL (0.20–0.25 mmol/L) for every 1 g/dL (10 g/L) of albumin.

The most accurate measurement of serum calcium is the ionized calcium concentration. True hypocalcemia (decreased ionized calcium) implies insufficient action of PTH or active vitamin D. Important causes of hypocalcemia are listed in Table 21–7.

The most common cause of hypocalcemia is advanced CKD, in which decreased production of active vitamin D_3 (1,25 dihydroxyvitamin D_3) and hyperphosphatemia both play a role (see Chapter 22). Some cases of primary hypoparathyroidism are due to mutations of the calcium-sensing

Table 21–7. Causes of hypocalcemia.

Decreased intake or absorption

- Malabsorption
- Small bowel bypass, short bowel
- Vitamin D deficit (decreased absorption, decreased production of 25-hydroxyvitamin D or 1,25-dihydroxyvitamin D)

Increased loss

- Alcoholism
- Chronic kidney disease
- Diuretic therapy

Endocrine disease

- Hypoparathyroidism (genetic, acquired; including hypomagnesemia and hypermagnesemia)
- Post-parathyroidectomy (hungry bone syndrome)
- Pseudohypoparathyroidism
- Calcitonin secretion with medullary carcinoma of the thyroid
- Familial hypocalcemia

Associated diseases

- Pancreatitis
- Rhabdomyolysis
- Septic shock

Physiologic causes

- Associated with decreased serum albumin¹
- Decreased end-organ response to vitamin D
- Hyperphosphatemia
- Induced by aminoglycoside antibiotics, plicamycin, loop diuretics, foscarnet

receptor in which inappropriate suppression of PTH release leads to hypocalcemia (see Chapter 26). Magnesium depletion reduces both PTH release and tissue responsiveness to PTH, causing hypocalcemia. Hypocalcemia in pancreatitis is a marker of severe disease. Elderly hospitalized patients with hypocalcemia and hypophosphatemia, with or without an elevated PTH level, are likely vitamin D deficient.

▶ Clinical Findings

A. Symptoms and Signs

Hypocalcemia increases excitation of nerve and muscle cells, primarily affecting the neuromuscular and cardiovascular systems. Spasm of skeletal muscle causes cramps and tetany. Laryngospasm with stridor can obstruct the airway. Convulsions, perioral and peripheral paresthesias, and abdominal pain can develop. Classic physical findings include Chvostek sign (contraction of the facial muscle in response to tapping the facial nerve) and Trousseau sign (carpal spasm occurring with occlusion of the brachial artery by a blood pressure cuff). QT prolongation predisposes to ventricular arrhythmias. In chronic hypoparathyroidism, cataracts and calcification of basal ganglia may appear (see Chapter 26).

B. Laboratory Findings

Serum calcium concentration is low (< 8.5 mg/dL [or < 2.1 mmol/L]). In true hypocalcemia, the ionized serum calcium concentration is also low (< 4.6 mg/dL [or < 1.15 mmol/L]). Serum phosphate is usually elevated in hypoparathyroidism or in advanced CKD, whereas it is suppressed in early CKD or vitamin D deficiency.

Serum magnesium concentration is commonly low. In respiratory alkalosis, total serum calcium is normal but ionized calcium is low. The ECG shows a prolonged QT interval.

▶ Treatment¹

A. Severe, Symptomatic Hypocalcemia

In the presence of tetany, arrhythmias, or seizures, intravenous calcium gluconate is indicated. Because of the short duration of action, continuous calcium infusion is usually required. Ten to 15 milligrams of calcium per kilogram body weight, or six to eight 10-mL vials of 10% calcium gluconate (558–744 mg of calcium), is added to 1 L of D_5W and infused over 4–6 hours. By monitoring the serum calcium level frequently (every 4–6 hours), the infusion rate is adjusted to maintain the serum calcium level at 7–8.5 mg/dL.

B. Asymptomatic Hypocalcemia

Oral calcium (1–2 g) and vitamin D preparations, including active vitamin D sterols, are used. Calcium carbonate is well tolerated and less expensive than many other calcium tablets. A check of urinary calcium excretion is recommended after the initiation of therapy because hypercalciuria (urine calcium excretion > 300 mg or > 7.5 mmol per day)

¹Ionized calcium concentration is normal.

¹See also Chapter 26 for discussion of the treatment of hypoparathyroidism.

or urine calcium:creatinine ratio > 0.3 may impair kidney function in these patients. The low serum calcium associated with hypoalbuminemia does not require replacement therapy. If serum Mg^{2+} is low, therapy must include magnesium replacement, which by itself will usually correct hypocalcemia.

► When to Refer

Patients with complicated hypocalcemia from hypoparathyroidism, familial hypocalcemia, or CKD require referral to an endocrinologist or nephrologist.

► When to Admit

Patients with tetany, arrhythmias, seizures, or other symptoms of hypocalcemia require immediate evaluation and therapy.

Bosworth M et al. Clinical inquiries: what is the best workup for hypocalcemia? *J Fam Pract.* 2008 Oct;57(10):677–9. [PMID: 18842196]

Peacock M. Calcium metabolism in health and disease. *Clin J Am Soc Nephrol.* 2010 Jan;5(Suppl 1):S23–30. [PMID: 20089499]

Piccoli GB et al. Severe hypocalcemia caused by intravascular calcium phosphate precipitation after sodium phosphate-containing bowel preparation. *Am J Kidney Dis.* 2010 Feb; 55(2):A35–7. [PMID: 20116677]

Shoback D. Clinical practice. Hypoparathyroidism. *N Engl J Med.* 2008 Jul 24;359(4):391–403. [PMID: 18650515]

HYPERCALCEMIA



ESSENTIALS OF DIAGNOSIS

- Primary hyperparathyroidism and malignancy-associated hypercalcemia are the most common causes.
- Hypercalciuria usually precedes hypercalcemia.
- Most often, asymptomatic, mild hypercalcemia (≥ 10.5 mg/dL [or 2.6 mmol/L]) is due to primary hyperparathyroidism, whereas the symptomatic, severe hypercalcemia (≥ 14 mg/dL [or 3.5 mmol/L]) is due to hypercalcemia of malignancy.

► General Considerations

Important causes of hypercalcemia are listed in Table 21–8. Primary hyperparathyroidism and malignancy account for 90% of cases. Primary hyperparathyroidism is the most common cause of hypercalcemia (usually mild) in ambulatory patients. Chronic hypercalcemia (over 6 months) or some manifestation such as nephrolithiasis also suggests a benign cause. Tumor production of PTH-related proteins (PTHrP) is the most common paraneoplastic endocrine syndrome, accounting for most cases of hypercalcemia in inpatients (see Table 39–2). The neoplasm is clinically apparent in nearly all cases when the hypercalcemia is detected, and the prognosis

Table 21–8. Causes of hypercalcemia.

Increased intake or absorption

- Milk-alkali syndrome
- Vitamin D or vitamin A excess

Endocrine disorders

- Primary hyperparathyroidism
- Secondary or tertiary hyperparathyroidism (usually associated with hypocalcemia)
- Acromegaly
- Adrenal insufficiency
- Pheochromocytoma
- Thyrotoxicosis

Neoplastic diseases

- Tumors producing PTH-related proteins (ovary, kidney, lung)
- Multiple myeloma (elaboration of osteoclast-activating factor)
- Lymphoma (occasionally from production of calcitriol)

Miscellaneous causes

- Thiazide diuretic use
- Granulomatous diseases (production of calcitriol)
- Paget disease of bone
- Hypophosphatasia
- Immobilization
- Familial hypocalciuric hypercalcemia
- Complications of kidney transplantation
- Lithium intake

PTH, parathyroid hormone.

is poor. Granulomatous diseases, such as sarcoidosis and tuberculosis, cause hypercalcemia via overproduction of active vitamin D_3 (1,25 dihydroxyvitamin D_3).

Milk-alkali syndrome has had a resurgence due to calcium ingestion for prevention of osteoporosis. Heavy calcium carbonate intake causes hypercalcemic acute kidney injury, likely from renal vasoconstriction. The decreased GFR impairs bicarbonate excretion, while hypercalcemia stimulates proton secretion and bicarbonate reabsorption. Metabolic alkalosis decreases calcium excretion, maintaining hypercalcemia.

Hypercalcemia causes nephrogenic DI through activation of calcium-sensing receptors in collecting ducts, which reduces ADH-induced water permeability. Volume depletion further worsens hypercalcemia.

► Clinical Findings

A. Symptoms and Signs

The history and physical examination should focus on the duration of hypercalcemia and evidence for a neoplasm. Hypercalcemia may affect gastrointestinal, kidney, and neurologic function. Mild hypercalcemia is often asymptomatic. Symptoms usually occur if the serum calcium is > 12 mg/dL (or > 3 mmol/L) and tend to be more severe if hypercalcemia develops acutely. Symptoms include constipation and polyuria, except in hypocalciuric hypercalcemia, in which polyuria is absent. Other symptoms include nausea, vomiting, anorexia, peptic ulcer disease, renal colic, and hematuria from nephrolithiasis. Polyuria from hypercalciuria-induced nephrogenic DI can result in volume depletion and acute kidney injury. Neurologic manifestations range from mild drowsiness to weakness, depression, lethargy, stupor, and coma in severe

hypercalcemia. Ventricular ectopy and idioventricular rhythm occur and can be accentuated by digitalis.

B. Laboratory Findings

The ionized calcium exceeds 1.32 mmol/L. A high serum chloride concentration and a low serum phosphate concentration in a ratio $> 33:1$ (or > 102 if SI units are utilized) suggests primary hyperparathyroidism where PTH decreases proximal tubular phosphate reabsorption. A low serum chloride concentration with a high serum bicarbonate concentration, along with elevated BUN and creatinine, suggests milk-alkali syndrome. Severe hypercalcemia (> 15 mg/dL [or > 3.75 mmol/L]) generally occurs in malignancy. More than 300 mg (or > 7.5 mmol) per day of urinary calcium excretion suggests hypercalciuria; < 100 mg (or < 2.5 mmol) per day suggests hypocalciuria. Hypercalciuric patients—such as those with malignancy or those receiving oral active vitamin D therapy—may easily develop hypercalcemia in case of volume depletion. Serum phosphate may or may not be low, depending on the cause. Hypocalciuric hypercalcemia occurs in milk-alkali syndrome, thiazide diuretic use, and familial hypocalciuric hypercalcemia.

The chest radiograph may reveal malignancy or granulomatous disease. The ECG shows a shortened QT interval. Measurements of PTH and PTHrP help distinguish between hyperparathyroidism (elevated PTH) and malignancy-associated hypercalcemia (suppressed PTH, elevated PTHrP).

▶ Treatment

Until the primary cause can be identified and treated, renal excretion of calcium is promoted through aggressive hydration and forced calciuresis. The tendency in hypercalcemia is hypovolemia from nephrogenic DI. In dehydrated patients with normal cardiac and kidney function, 0.45% saline or 0.9% saline can be given rapidly (250–500 mL/h). A meta-analysis questioned the efficacy and safety profile of intravenous furosemide for hypercalcemia. Thiazides can worsen hypercalcemia.

Bisphosphonates are the treatment of choice for hypercalcemia of malignancy. Although they are safe, effective, and normalize calcium in $> 70\%$ of patients, bisphosphonates may require up to 48–72 hours before reaching full therapeutic effect. Calcitonin may be helpful in the short-term until bisphosphonates reach therapeutic levels. In emergency cases, dialysis with low calcium dialysate may be needed. The calcimimetic agent cinacalcet hydrochloride suppresses PTH secretion and decreases serum calcium concentration and holds promise as a treatment option. See Chapter 39 for a discussion of the treatment of hypercalcemia of malignancy and Chapter 26 for a discussion of the treatment of hypercalcemia of hyperparathyroidism.

Typically, if dialysis patients do not receive proper supplementation of calcium and active vitamin D, hypocalcemia and hyperphosphatemia develop. On the other hand, hypercalcemia can sometimes develop, particularly in the setting of severe secondary hyperparathyroidism,

characterized by high PTH levels and subsequent release of calcium from bone. Therapy may include intravenous vitamin D, which further increases the serum calcium concentration. Another type of hypercalcemia occurs when PTH levels are low. Bone turnover is decreased, which results in a low buffering capacity for calcium. When calcium is administered in calcium-containing phosphate binders or dialysate, or when vitamin D is administered, hypercalcemia results. Hypercalcemia in dialysis patients usually occurs in the presence of hyperphosphatemia, and metastatic calcification may occur. Malignancy should be considered as a cause of the hypercalcemia.

▶ When to Refer

- Patients may require referral to an oncologist or endocrinologist depending on the underlying cause of hypercalcemia.
- Patients with granulomatous diseases (eg, tuberculosis and other chronic infections, granulomatosis with polyangiitis [formerly Wegener granulomatosis], sarcoidosis) may require assistance from infectious disease specialists, rheumatologists, or pulmonologists.

▶ When to Admit

- Patients with symptomatic or severe hypercalcemia require immediate treatment.
- Unexplained hypercalcemia with associated conditions, such as acute kidney injury or suspected malignancy, may require urgent treatment and expedited evaluation.

Kallas M et al. Rare causes of calcitriol-mediated hypercalcemia: a case report and literature review. *J Clin Endocrinol Metab.* 2010 Jul;95(7):3111–7. [PMID: 20427501]

LeGrand SB et al. Narrative review: furosemide for hypercalcemia: an unproven yet common practice. *Ann Intern Med.* 2008 Aug 19;149(4):259–63. [PMID: 18711156]

Medarov BI. Milk-alkali syndrome. *Mayo Clin Proc.* 2009 Mar;84(3):261–7. [PMID: 19252114]

Pellitteri PK. Evaluation of hypercalcemia in relation to hyperparathyroidism. *Otolaryngol Clin North Am.* 2010 Apr;43(2):389–97. [PMID: 20510722]

DISORDERS OF PHOSPHORUS CONCENTRATION

Plasma phosphorus is mainly inorganic phosphate and represents a small fraction ($< 0.2\%$) of total body phosphate.

Important determinants of plasma inorganic phosphate are renal excretion, intestinal absorption, and shift between the intracellular and extracellular spaces. The kidney is the most important regulator of the serum phosphate level. PTH decreases reabsorption of phosphate in the proximal tubule while 1,25-dihydroxyvitamin D₃ increases reabsorption. Renal proximal tubular reabsorption of phosphate is decreased by volume expansion, corticosteroids, and proximal tubular dysfunction (as in Fanconi syndrome). Fibroblast growth factor 23 (FGF23) is a potent phosphaturic hormone. Intestinal absorption

of phosphate is facilitated by active vitamin D. PTH stimulates phosphate release from bone and renal phosphate excretion; primary hyperparathyroidism can lead to hypophosphatemia and depletion of bone phosphate stores. By contrast, growth hormone augments proximal tubular reabsorption of phosphate. Cellular phosphate uptake is stimulated by various factors and conditions, including alkalemia, insulin, epinephrine, feeding, hungry bone syndrome, and accelerated cell proliferation.

Phosphorus metabolism and homeostasis are intimately related to calcium metabolism. See sections on metabolic bone disease in Chapter 26.

HYPOPHOSPHATEMIA



ESSENTIALS OF DIAGNOSIS

- ▶ Severe hypophosphatemia may cause tissue hypoxia and rhabdomyolysis.
- ▶ Renal loss of phosphate can be diagnosed by measuring urinary phosphate excretion and by calculating maximal tubular phosphate reabsorption rate (TmP/GFR).
- ▶ PTH and FGF23 are the major factors that decrease TmP/GFR, leading to renal loss of phosphate.

▶ General Considerations

The leading causes of hypophosphatemia are listed in Table 21–9. Hypophosphatemia may occur in the presence of normal phosphate stores. Serious depletion of body phosphate stores may exist with low, normal, or high serum phosphate concentrations.

Serum phosphate levels decrease transiently after food intake, thus fasting samples are recommended for accuracy. **Moderate hypophosphatemia** (1.0–2.4 mg/dL [or 0.32–0.79 mmol/L]) occurs commonly in hospitalized patients and may not reflect decreased phosphate stores.

In **severe hypophosphatemia** (< 1 mg/dL [or < 0.32 mmol/L]), the affinity of hemoglobin for oxygen increases through a decrease in the erythrocyte 2,3-diphosphoglycerate concentration, impairing tissue oxygenation and cell metabolism and resulting in muscle weakness or even rhabdomyolysis. Severe hypophosphatemia is common and multifactorial in alcoholic patients. In acute alcohol withdrawal, increased plasma insulin and epinephrine along with respiratory alkalosis promote intracellular shift of phosphate. Vomiting, diarrhea, and poor dietary intake contribute to hypophosphatemia. Chronic alcohol use results in a decrease in the renal threshold of phosphate excretion. This renal tubular dysfunction reverses after a month of abstinence. Patients with chronic obstructive pulmonary disease and asthma commonly have hypophosphatemia, attributed to xanthine derivatives causing shifts of phosphate intracellularly and the phosphaturic effects of β -adrenergic agonists, loop diuretics, xanthine derivatives, and corticosteroids. The metabolic syndrome, a major

Table 21–9. Causes of hypophosphatemia.

Diminished supply or absorption

Starvation

Parenteral alimentation with inadequate phosphate content
Malabsorption syndrome, small bowel bypass
Absorption blocked by oral antacids with aluminum or magnesium
Vitamin D-deficient and vitamin D-resistant osteomalacia

Increased loss

Phosphaturic drugs: theophylline, diuretics, bronchodilators, corticosteroids
Hyperparathyroidism (primary or secondary)
Hyperthyroidism
Renal tubular defects with excessive phosphaturia (congenital, induced by monoclonal gammopathy, heavy metal poisoning), alcoholism
Hypokalemic nephropathy
Inadequately controlled diabetes mellitus
Hypophosphatemic rickets
Phosphatonins of oncogenic osteomalacia (eg, FGF23 production)

Intracellular shift of phosphorus

Administration of glucose
Anabolic steroids, estrogen, oral contraceptives, β -adrenergic agonists, xanthine derivatives
Hungry bone syndrome
Respiratory alkalosis
Salicylate poisoning

Electrolyte abnormalities

Hypercalcemia
Hypomagnesemia
Metabolic alkalosis

Abnormal losses followed by inadequate repletion

Diabetes mellitus with acidosis, particularly during aggressive therapy
Recovery from starvation or prolonged catabolic state
Chronic alcoholism, particularly during restoration of nutrition; associated with hypomagnesemia
Recovery from severe burns

FGF23, fibroblast growth factor 23.

contributor to coronary heart disease risk, is associated with low phosphate (and magnesium) levels but the clinical significance of these disturbances is unclear. Refeeding or glucose administration to phosphate-depleted patients may cause fatal hypophosphatemia.

▶ Clinical Findings

A. Symptoms and Signs

Acute, severe hypophosphatemia (< 1.0 mg/dL [or < 0.32 mmol/L]) can lead to rhabdomyolysis, paresthesias, and encephalopathy (irritability, confusion, dysarthria, seizures, and coma). Respiratory failure or failure to wean from mechanical ventilation may occur as a result of diaphragmatic weakness. Arrhythmias and heart failure are uncommon but serious manifestations. Hematologic manifestations include acute hemolytic anemia from erythrocyte fragility, platelet dysfunction with petechial hemorrhages, and impaired chemotaxis of leukocytes (leading to increased susceptibility to gram-negative sepsis).

Chronic severe depletion may cause anorexia, pain in muscles and bones, and fractures.

B. Laboratory Findings

Urine phosphate excretion is a useful clue in the evaluation of hypophosphatemia. The normal renal response to hypophosphatemia is decreased urinary phosphate excretion to < 100 mg/day. The fractional excretion of phosphate ($F_E\text{PO}_4$) should be < 5%. The main factors regulating $F_E\text{PO}_4$ are PTH and phosphate intake. Increased PTH or phosphate intake decreases $F_E\text{PO}_4$ (ie, more phosphate is excreted into the urine).

Measurement of plasma PTH or PTHrP levels may be helpful. The clinical utility of serum FGF levels is undetermined except in uncommon diseases.

Other clinical features may be suggestive of hypophosphatemia, such as hemolytic anemia and rhabdomyolysis. Fanconi syndrome may present with any combination of uricosuria, aminoaciduria, normoglycemic glucosuria, normal anion gap metabolic acidosis, and phosphaturia. In chronic hypophosphatemia, radiographs and bone biopsies show changes resembling osteomalacia.

▶ Treatment

Hypophosphatemia can be prevented by including phosphate in repletion and maintenance fluids. A rapid decline in calcium levels can occur with parenteral administration of phosphate; oral replacement of phosphate is preferable. Moderate hypophosphatemia (1.0–2.5 mg/dL [or 0.32–0.79 mmol/L]) is usually asymptomatic and does not require treatment. The hypophosphatemia in patients with diabetic ketoacidosis (DKA) will usually correct with normal dietary intake. Chronic hypophosphatemia can be treated with oral phosphate repletion. Mixtures of sodium and potassium phosphate salts may be given to provide 0.5–1 g (16–32 mmol) of phosphate per day. For severe, symptomatic hypo-phosphatemia (< 1 mg/dL [or < 0.32 mmol/L]), an infusion should provide 279–310 mg/12 h (or 9–10 mmol/12 h) until the serum phosphorus exceeds 1 mg/dL and the patient can be switched to oral therapy. The infusion rate should be decreased if hypotension occurs. Monitoring of plasma phosphate, calcium, and potassium every 6 hours is necessary because the response to phosphate supplementation is not predictable. Magnesium deficiency often coexists and should be treated.

Contraindications to phosphate replacement include hypoparathyroidism, advanced CKD, tissue damage and necrosis, and hypercalcemia. When an associated hyperglycemia is treated, phosphate accompanies glucose into cells, and hypophosphatemia may ensue.

▶ When to Refer

- Patients with refractory hypophosphatemia with increased urinary phosphate excretion may require evaluation by an endocrinologist (for such conditions as hyperparathyroidism and vitamin D disorders) or a nephrologist (for such conditions as renal tubular defects).
- Patients with decreased gastrointestinal absorption may require referral to a gastroenterologist.

▶ When to Admit

Patients with severe or refractory hypophosphatemia will require intravenous phosphate.

Bergwitz C et al. Case records of the Massachusetts General Hospital. Case 33-2011. A 56-year-old man with hypophosphatemia. *N Engl J Med.* 2011 Oct 27;365(17):1625–35. [PMID: 22029985]

Brunelli SM et al. Hypophosphatemia: clinical consequences and management. *J Am Soc Nephrol.* 2007 Jul;18(7):1999–2003. [PMID: 17568018]

Geerse DA et al. Treatment of hypophosphatemia in the intensive care unit: a review. *Crit Care.* 2010;14(4):R147. [PMID: 20682049]

Liamis G et al. Medication-induced hypophosphatemia: a review. *QJM.* 2010 Jul;103(7):449–59. [PMID: 20356849]

HYPERPHOSPHATEMIA



ESSENTIALS OF DIAGNOSIS

- ▶ Advanced CKD is the most common cause.
- ▶ Hyperphosphatemia in the presence of hypercalcemia imposes a high risk of metastatic calcification

▶ General Considerations

Advanced CKD with decreased urinary excretion of phosphate is the most common cause of hyperphosphatemia. Other causes are listed in Table 21–10.

Table 21–10. Causes of hyperphosphatemia.

Massive load of phosphate into the extracellular fluid

Exogenous sources

Hypervitaminosis D

Laxatives or enemas containing phosphate

Intravenous phosphate supplement

Endogenous sources

Rhabdomyolysis (especially if chronic kidney disease coexists)

Cell lysis by chemotherapy of malignancy, particularly lymphoproliferative diseases

Metabolic acidosis (lactic acidosis, ketoacidosis)

Respiratory acidosis (phosphate incorporation into cells is disturbed)

Decreased excretion into urine

Chronic kidney disease

Acute kidney injury

Hypoparathyroidism

Pseudohypoparathyroidism

Acromegaly

Pseudohyperphosphatemia

Multiple myeloma

Hyperbilirubinemia

Hypertriglyceridemia

Hemolysis in vitro

► Clinical Findings

A. Symptoms and Signs

The clinical manifestations are those of the underlying disorder or associated condition.

B. Laboratory Findings

In addition to elevated phosphate, blood chemistry abnormalities are those of the underlying disease.

► Treatment

Treatment is directed at the underlying cause. Exogenous sources of phosphate, including enteral or parenteral nutrition and medications, should be reduced or eliminated. Dietary phosphate absorption can be reduced by oral phosphate binders, such as calcium carbonate, calcium acetate, sevelamer carbonate, lanthanum carbonate, and aluminum hydroxide. Sevelamer, lanthanum, and aluminum may be used in patients with hypercalcemia, although aluminum use should be limited to a few days because of the risk of aluminum accumulation and neurotoxicity. In acute kidney injury and advanced CKD, dialysis will reduce serum phosphate.

► When to Admit

Patients with acute severe hyperphosphatemia require hospitalization for emergent therapy, possibly including dialysis. Concomitant illnesses, such as acute kidney injury or cell lysis, may necessitate admission.

Lee R et al. Disorders of phosphorus homeostasis. *Curr Opin Endocrinol Diabetes Obes.* 2010 Dec;17(6):561–7. [PMID: 20962635]

Orrego JJ et al. Hyperphosphatemia. *Endocr Pract.* 2010 May–Jun;16(3):524–5. [PMID: 20551010]

Prié D et al. Genetic disorders of renal phosphate transport. *N Engl J Med.* 2010 Jun 24;362(25):2399–409. [PMID: 20573928]

Tonelli M et al. Oral phosphate binders in patients with kidney failure. *N Engl J Med.* 2010 Apr 8;362(14):1312–24. [PMID: 20375408]

DISORDERS OF MAGNESIUM CONCENTRATION

Normal plasma magnesium concentration is 1.8–3.0 mg/dL (or 0.75–1.25 mmol/L), with about one-third bound to protein and two-thirds existing as free cation. Magnesium excretion is via the kidney. Magnesium's physiologic effects on the nervous system resemble those of calcium.

Altered magnesium concentration usually provokes an associated alteration of Ca^{2+} . Both hypomagnesemia and hypermagnesemia can decrease PTH secretion or action. Severe hypermagnesemia (> 5 mg/dL [or 2.1 mmol/L]) suppresses PTH secretion with consequent hypocalcemia; this disorder is typically seen only in patients receiving magnesium therapy for preeclampsia. Severe hypomagnesemia causes PTH resistance in end-organs and eventually decreased PTH secretion in severe cases.

HYPOMAGNESEMIA



ESSENTIALS OF DIAGNOSIS

- Serum concentration of magnesium may not be decreased even in the presence of magnesium depletion. Check urinary magnesium excretion if renal magnesium wasting is suspected.
- Causes neurologic symptoms and arrhythmias.
- Impairs release of PTH.

► General Considerations

Causes of hypomagnesemia are listed in Table 21–11. Normomagnesemia does not exclude magnesium depletion because only 1% of total body magnesium is in the extracellular fluid (ECF). Hypomagnesemia and hypokalemia share many etiologies, including diuretics, diarrhea, alcoholism, aminoglycosides, and amphotericin. Renal potassium wasting also occurs from hypomagnesemia, and is refractory to potassium replacement until magnesium is repleted. Hypomagnesemia also suppresses PTH release and causes end-organ resistance to PTH and low 1,25-dihydroxyvitamin D_3 levels. The resultant hypocalcemia is refractory to calcium replacement until the magnesium is normalized. Molecular mechanisms of magnesium wasting have been revealed in some hereditary disorders. The FDA has issued a warning about hypomagnesemia for patients taking proton pump inhibitors. The presumed mechanism is decreased

Table 21–11. Causes of hypomagnesemia.

Diminished absorption or intake

- Malabsorption, chronic diarrhea, laxative abuse
- Proton pump inhibitors
- Prolonged gastrointestinal suction
- Small bowel bypass
- Malnutrition
- Alcoholism
- Total parenteral alimentation with inadequate Mg^{2+} content

Increased renal loss

- Diuretic therapy (loop diuretics, thiazide diuretics)
- Hyperaldosteronism, Gitelman syndrome (a variant of Bartter syndrome)
- Hyperparathyroidism, hyperthyroidism
- Hypercalcemia
- Volume expansion
- Tubulointerstitial diseases
- Transplant kidney
- Drugs (aminoglycoside, cetuximab, cisplatin, amphotericin B, pentamidine)

Others

- Diabetes mellitus
- Post-parathyroidectomy (hungry bone syndrome)
- Respiratory alkalosis
- Pregnancy

intestinal magnesium absorption, but it is not clear why this complication develops in only a small fraction of patients taking these medications.

► Clinical Findings

A. Symptoms and Signs

Common symptoms are those of hypokalemia and hypocalcemia, with weakness and muscle cramps. Marked neuromuscular and central nervous system hyperirritability may produce tremors, athetoid movements, jerking, nystagmus, a Babinski response, confusion, and disorientation. Cardiovascular manifestations include hypertension, tachycardia, and ventricular arrhythmias.

B. Laboratory Findings

Urinary excretion of magnesium exceeding 10–30 mg/day or a fractional excretion > 2% indicates renal magnesium wasting. Hypocalcemia and hypokalemia are often present. The ECG shows a prolonged QT interval, due to lengthening of the ST segment. PTH secretion is often suppressed (see Hypocalcemia, above).

► Treatment

Magnesium oxide, 250–500 mg orally once or twice daily, is useful for treating chronic hypomagnesemia. Symptomatic hypomagnesemia requires intravenous magnesium sulfate 1–2 g over 5–60 minutes mixed in either dextrose 5% or 0.9% normal saline. Torsades de pointes in the setting of hypomagnesemia can be treated with 1–2 g of magnesium sulfate in 10 mL of dextrose 5% solution pushed intravenously over 15 minutes. Severe, non-life-threatening deficiency can be treated at a rate to 1–2 g/h over 3–6 hours. Magnesium sulfate may also be given intramuscularly in a dosage of 200–800 mg/day (8–33 mmol/day) in four divided doses. Serum levels must be monitored daily and dosage adjusted to keep the concentration from rising above 3 mg/dL. Tendon reflexes may be checked for hyporeflexia of hypermagnesemia. K^+ and Ca^{2+} replacement may be required, but patients with hypokalemia and hypocalcemia of hypomagnesemia do not recover without magnesium supplementation.

Patients with normal kidney function can excrete excess magnesium; hypermagnesemia should not develop with replacement dosages. In patients with CKD, magnesium replacement should be done cautiously to avoid hypermagnesemia. Reduced doses (50–75% dose reduction) and more frequent monitoring (at least twice daily) are indicated.

Musso CG. Magnesium metabolism in health and disease. *Int Urol Nephrol*. 2009;41(2):357–62. [PMID: 19274487]
 Naderi AS et al. Hereditary etiologies of hypomagnesemia. *Nat Clin Pract Nephrol*. 2008 Feb;4(2):80–9. [PMID: 18227801]
 Regolisti G et al. Severe hypomagnesemia during long-term treatment with a proton pump inhibitor. *Am J Kidney Dis*. 2010 Jul;56(1):168–74. [PMID: 20493607]

HYPERMAGNESEMIA



ESSENTIALS OF DIAGNOSIS

- Often associated with advanced CKD and chronic intake of magnesium-containing drugs.

► General Considerations

Hypermagnesemia is almost always the result of advanced CKD and impaired magnesium excretion. Antacids and laxatives are underrecognized sources of magnesium. Pregnant patients may have severe hypermagnesemia from intravenous magnesium for preeclampsia and eclampsia. Magnesium replacement should be done cautiously in patients with CKD; dose reductions up to 75% may be necessary to avoid hypermagnesemia.

► Clinical Findings

A. Symptoms and Signs

Muscle weakness, decreased deep tendon reflexes, mental obtundation, and confusion are characteristic manifestations. Weakness, flaccid paralysis, ileus, urinary retention, and hypotension are noted. Serious findings include respiratory muscle paralysis and cardiac arrest.

B. Laboratory Findings

Serum Mg^{2+} is elevated. In the common setting of CKD, BUN, creatinine, potassium, phosphate, and uric acid may all be elevated. Serum Ca^{2+} is often low. The ECG shows increased PR interval, broadened QRS complexes, and peaked T waves, probably related to associated hyperkalemia.

► Treatment

Exogenous sources of magnesium should be discontinued. Calcium antagonizes Mg^{2+} and may be given intravenously as calcium chloride, 500 mg or more at a rate of 100 mg (4.1 mmol) per minute. Hemodialysis or peritoneal dialysis may be necessary to remove magnesium, particularly with severe kidney disease.

Long-term use of magnesium hydroxide and magnesium sulfate should be avoided in patients with advanced stages of CKD.

Moe SM. Disorders involving calcium, phosphorus, and magnesium. *Prim Care*. 2008 Jun;35(2):215–37. [PMID: 18486714]
 Topf JM et al. Hypomagnesemia and hypermagnesemia. *Rev Endocr Metab Disord*. 2003 May;4(2):195–206. [PMID: 12766548]


ACID–BASE DISORDERS

Assessment of a patient's acid–base status requires measurement of arterial pH, PCO_2 , and plasma bicarbonate (HCO_3^-). Blood gas analyzers directly measure pH and

PCO_2 . The HCO_3^- value is calculated from the Henderson-Hasselbalch equation:

$$\text{pH} = 6.1 + \log \frac{\text{HCO}_3^-}{0.03 \times \text{PCO}_2}$$

The total venous CO_2 measurement is a more direct determination of HCO_3^- . Because of the dissociation characteristics of carbonic acid (H_2CO_3) at body pH, dissolved CO_2 is almost exclusively in the form of HCO_3^- , and for clinical purposes the total carbon dioxide content is equivalent (± 3 mEq/L) to the HCO_3^- concentration:



Venous blood gases can provide useful information for acid-base assessment since the arteriovenous differences in pH and PCO_2 are small and relatively constant. Venous blood pH is usually 0.03–0.04 units lower than arterial blood pH, and venous blood PCO_2 is 7 or 8 mm Hg higher than arterial blood PCO_2 . Calculated HCO_3^- concentration in venous blood is at most 2 mEq/L higher than arterial blood HCO_3^- . Arterial and venous blood gases will not be equivalent during a cardiopulmonary arrest; arterial samples should be obtained for the most accurate measurements of pH and PCO_2 .

TYPES OF ACID-BASE DISORDERS

There are two types of acid-base disorders: acidosis and alkalosis. These disorders can be either metabolic (decreased or increased HCO_3^-) or respiratory (decreased or increased PCO_2). Primary respiratory disorders affect blood acidity by changes in PCO_2 , and primary metabolic disorders are disturbances in HCO_3^- concentration. A primary disturbance is usually accompanied by a compensatory response, but the compensation does not fully correct the pH disturbance of the primary disorder. If the pH is < 7.40 , the primary process is acidosis, either respiratory

STEP-BY-STEP ANALYSIS OF ACID-BASE STATUS

- Step 1:** Determine the primary (or main) disorder—whether it is metabolic or respiratory—from blood pH, HCO_3^- , and PCO_2 values.
- Step 2:** Determine the presence of mixed acid-base disorders by calculating the range of compensatory responses (Table 21-12).
- Step 3:** Calculate the anion gap (Table 21-13).
- Step 4:** Calculate the corrected HCO_3^- concentration if the anion gap is increased (see above).
- Step 5:** Examine the patient to determine whether the clinical signs are compatible with the acid-base analysis.

($\text{PCO}_2 > 40$ mm Hg) or metabolic ($\text{HCO}_3^- < 24$ mEq/L). If the pH is higher than 7.40, the primary process is alkalosis, either respiratory ($\text{PCO}_2 < 40$ mm Hg) or metabolic ($\text{HCO}_3^- > 24$ mEq/L). One respiratory or metabolic disorder with its appropriate compensatory response is a simple acid-base disorder.

MIXED ACID-BASE DISORDERS

Two or three simultaneous disorders can be present in a mixed acid-base disorder, but there can never be two primary respiratory disorders. Uncovering a mixed acid-base disorder is clinically important, but requires a methodical approach to acid-base analysis (see box, Step-by-Step Analysis of Acid-Base Status). Once the primary disturbance has been determined, the clinician should assess whether the compensatory response is appropriate (Table 21-12). An inadequate or an exaggerated response indicates the presence of another primary acid-base disturbance.

The anion gap should always be calculated for two reasons. First, it is possible to have an abnormal anion

Table 21-12. Primary acid-base disorders and expected compensation.

Disorder	Primary Defect	Compensatory Response	Magnitude of Compensation
Respiratory acidosis			
Acute	$\uparrow \text{PCO}_2$	$\uparrow \text{HCO}_3^-$	$\uparrow \text{HCO}_3^-$ 1 mEq/L per 10 mm Hg $\uparrow \text{PCO}_2$
Chronic	$\uparrow \text{PCO}_2$	$\uparrow \text{HCO}_3^-$	$\uparrow \text{HCO}_3^-$ 3.5 mEq/L per 10 mm Hg $\uparrow \text{PCO}_2$
Respiratory alkalosis			
Acute	$\downarrow \text{PCO}_2$	$\downarrow \text{HCO}_3^-$	$\downarrow \text{HCO}_3^-$ 2 mEq/L per 10 mm Hg $\downarrow \text{PCO}_2$
Chronic	$\downarrow \text{PCO}_2$	$\downarrow \text{HCO}_3^-$	$\downarrow \text{HCO}_3^-$ 5 mEq/L per 10 mm Hg $\downarrow \text{PCO}_2$
Metabolic acidosis	$\downarrow \text{HCO}_3^-$	$\downarrow \text{PCO}_2$	$\downarrow \text{PCO}_2$ 1.3 mm Hg per 1 mEq/L $\downarrow \text{HCO}_3^-$
Metabolic alkalosis	$\uparrow \text{HCO}_3^-$	$\uparrow \text{PCO}_2$	$\uparrow \text{PCO}_2$ 0.7 mm Hg per 1 mEq/L $\uparrow \text{HCO}_3^-$

gap even if the sodium, chloride, and bicarbonate levels are normal. Second, a large anion gap (> 20 mEq/L) suggests a primary metabolic acid-base disturbance regardless of the pH or serum bicarbonate level because a markedly abnormal anion gap is never a compensatory response to a respiratory disorder. In patients with an increased anion gap metabolic acidosis, clinicians should calculate the corrected bicarbonate. In increased anion gap acidoses, there should be a mole for mole decrease in HCO_3^- as the anion gap increases. A corrected HCO_3^- value higher or lower than normal (24 mEq/L) indicates the concomitant presence of metabolic alkalosis or normal anion gap metabolic acidosis, respectively.

Adrogue HJ et al. Assessing acid-base disorders. *Kidney Int.* 2009 Dec;76(12):1239–47. [PMID: 19812535]
 Kellum JA. Disorders of acid-base balance. *Crit Care Med.* 2008 Nov;35(11):2630–6. [PMID: 17893626]
 Rastegar A. Clinical utility of Stewart's method in diagnosis and management of acid-base disorders. *Clin J Am Soc Nephrol.* 2009 Jul;4(7):1267–74. [PMID: 19520748]

METABOLIC ACIDOSIS



ESSENTIALS OF DIAGNOSIS

- ▶ Decreased HCO_3^- with acidemia.
- ▶ Classified into increased anion gap acidosis and normal anion gap acidosis.
- ▶ Lactic acidosis, ketoacidosis, and toxins produce metabolic acidoses with the largest anion gaps.
- ▶ Normal anion gap acidosis is mainly caused by gastrointestinal HCO_3^- loss or RTA. Urinary anion gap may help distinguish between these causes.

▶ General Considerations

The hallmark of metabolic acidosis is decreased HCO_3^- . Metabolic acidoses are classified by the anion gap, either normal or increased (Table 21–13). The anion gap is the difference between readily measured anions and cations.

In plasma,

$$[\text{Na}^+] + \frac{\text{Unmeasured cations}}{\text{anions}} = \text{HCO}_3^- + \text{Cl}^- + \frac{\text{Unmeasured anions}}{\text{anions}}$$

$$\text{Anion gap} = \text{Na}^+ - (\text{HCO}_3^- + \text{Cl}^-)$$

Major unmeasured cations are calcium (2 mEq/L), magnesium (2 mEq/L), γ -globulins, and potassium (4 mEq/L). Major unmeasured anions are albumin (2 mEq/L per g/dL), phosphate (2 mEq/L), sulfate (1 mEq/L), lactate (1–2 mEq/L), and other organic anions (3–4 mEq/L). Traditionally, the normal anion gap has been 12 ± 4 mEq/L. With current auto-analyzers, the reference range may be lower (6 ± 1 mEq/L), primarily from an increase in Cl^- values. Despite its usefulness, the anion gap can be misleading. Non-acid-base disorders may cause errors in

Table 21–13. Anion gap in metabolic acidosis.¹

Decreased (< 6 mEq)

Hypoalbuminemia (decreased unmeasured anion)
 Plasma cell dyscrasias
 Monoclonal protein (cationic paraprotein) (accompanied by chloride and bicarbonate)

Bromide intoxication

Increased (> 12 mEq)

Metabolic anion

Diabetic ketoacidosis

Alcoholic ketoacidosis

Lactic acidosis

Chronic kidney disease (advanced stages) (PO_4^{3-} , SO_4^{2-})

Starvation

Metabolic alkalosis (increased number of negative charges on protein)

Drug or chemical anion

Salicylate intoxication

Sodium carbenicillin therapy

Methanol (formic acid)

Ethylene glycol (oxalic acid)

Normal (6–12 mEq)

Loss of HCO_3^-

Diarrhea

Recovery from diabetic ketoacidosis

Pancreatic fluid loss ileostomy (unadapted)

Carbonic anhydrase inhibitors

Chloride retention

Renal tubular acidosis

Ileal loop bladder

Administration of HCl equivalent or NH_4Cl

Arginine and lysine in parenteral nutrition

¹Reference ranges for anion gap may vary based on differing laboratory methods.

anion gap interpretation; these disorders including hypoalbuminemia, hypernatremia, or hyponatremia; antibiotics (eg, carbenicillin is an unmeasured anion; polymyxin is an unmeasured cation) may also cause errors in anion gap interpretation. Although not usually associated with metabolic acidosis, a decreased anion gap can occur because of a reduction in unmeasured anions or an increase in unmeasured cations. In hypoalbuminemia, a 2 mEq/L decrease in anion gap will occur for every 1 g/dL decline in serum albumin.

INCREASED ANION GAP ACIDOSIS (Increased Unmeasured Anions)

Normochloremic metabolic acidosis generally results from addition of organic acids such as lactate, acetoacetate, β -hydroxybutyrate, and exogenous toxins. Other anions such as isocitrate, α -ketoglutarate, malate and D-lactate, may contribute to the anion gap of lactic acidosis, DKA, and acidosis of unknown etiology. Uremia causes an increased anion gap metabolic acidosis from unexcreted organic acids and anions.

A. Lactic Acidosis

Lactic acid is formed from pyruvate in anaerobic glycolysis, typically in tissues with high rates of glycolysis, such as gut (responsible for over 50% of lactate production), skeletal muscle, brain, skin, and erythrocytes. Normally, lactate levels

remain low (1 mEq/L) because of metabolism of lactate principally by the liver through gluconeogenesis or oxidation via the Krebs cycle. The kidneys metabolize about 30% of lactate.

In lactic acidosis, lactate levels are at least 4–5 mEq/L but commonly 10–30 mEq/L. There are two basic types of lactic acidosis.

Type A (hypoxic) lactic acidosis is more common, resulting from decreased tissue perfusion; cardiogenic, septic, or hemorrhagic shock; and carbon monoxide or cyanide poisoning. These conditions increase peripheral lactic acid production and decrease hepatic metabolism of lactate as liver perfusion declines.


Type B lactic acidosis may be due to metabolic causes (eg, diabetes, ketoacidosis, liver disease, kidney disease, infection, leukemia, or lymphoma) or toxins (eg, ethanol, methanol, salicylates, isoniazid, or metformin). Propylene glycol can cause lactic acidosis from decreased liver metabolism; it is used as a vehicle for intravenous drugs, such as nitroglycerin, etomidate, and diazepam. Parenteral nutrition without thiamine causes severe refractory lactic acidosis from deranged pyruvate metabolism. Patients with short bowel syndrome may develop D-lactic acidosis with encephalopathy due to carbohydrate malabsorption and subsequent fermentation by colonic bacteria.

Nucleoside analog reverse transcriptase inhibitors can cause type B lactic acidosis due to mitochondrial toxicity.

Idiopathic lactic acidosis, usually in debilitated patients, has an extremely high mortality rate. (For treatment of lactic acidosis, see below and Chapter 27.)


B. Diabetic Ketoacidosis (DKA)

DKA is characterized by hyperglycemia and metabolic acidosis with an increased anion gap:



where B^- is β -hydroxybutyrate or acetoacetate, the ketones responsible for the increased anion gap. The anion gap should be calculated from the measured serum electrolytes; correction of the serum sodium for the dilutional effect of hyperglycemia will exaggerate the anion gap. Diabetics with ketoacidosis may have lactic acidosis from tissue hypoperfusion and increased anaerobic metabolism.

During the recovery phase of DKA, a hyperchloremic non-anion gap acidosis can develop because saline resuscitation results in chloride retention, restoration of GFR, and ketoaciduria. Ketone salts (NaB) are formed as bicarbonate is consumed:



The kidney reabsorbs ketone anions poorly but can compensate for the loss of anions by increasing the reabsorption of Cl^- .

Patients with DKA and normal kidney function may have marked ketonuria and severe metabolic acidosis but only a mildly increased anion gap. Thus, the size of the anion gap correlates poorly with the severity of the DKA; the urinary loss of Na^+ or K^+ salts of β -hydroxybutyrate will lower the anion gap without altering the H^+ excretion or the severity of

the acidosis. Urine dipsticks for ketones test primarily for acetoacetate and, to a lesser degree, acetone but not the predominant ketoacid, β -hydroxybutyrate. Dipstick tests for ketones may become more positive even as the patient improves due to the metabolism of hydroxybutyrate. Thus, the patient's clinical status and pH are better markers of improvement than the anion gap or ketone levels.

C. Alcoholic Ketoacidosis

Chronically malnourished patients who consume large quantities of alcohol daily may develop alcoholic ketoacidosis. Most of these patients have mixed acid–base disorders (10% have a triple acid–base disorder). Although decreased HCO_3^- is usual, 50% of the patients may have normal or alkalemic pH. Three types of metabolic acidosis are seen in alcoholic ketoacidosis: (1) Ketoacidosis is due to β -hydroxybutyrate and acetoacetate excess. (2) Lactic acidosis: Alcohol metabolism increases the NADH:NAD ratio, causing increased production and decreased utilization of lactate. Accompanying thiamine deficiency, which inhibits pyruvate carboxylase, further enhances lactic acid production in many cases. Moderate to severe elevations of lactate (> 6 mmol/L) are seen with concomitant disorders such as sepsis, pancreatitis, or hypoglycemia. (3) Hyperchloremic acidosis from bicarbonate loss in the urine is associated with ketonuria (see above). Metabolic alkalosis occurs from volume contraction and vomiting. Respiratory alkalosis results from alcohol withdrawal, pain, or associated disorders such as sepsis or liver disease. Half of the patients have hypoglycemia or hyperglycemia. When serum glucose levels are > 250 mg/dL, the distinction from DKA is difficult. The absence of a diabetic history and normoglycemia after initial therapy support the diagnosis of alcoholic ketoacidosis.

D. Toxins

(See also Chapter 38.) Multiple toxins and drugs increase the anion gap by increasing endogenous acid production. Common examples include methanol (metabolized to formic acid), ethylene glycol (glycolic and oxalic acid), and salicylates (salicylic acid and lactic acid). The latter can cause a mixed disorder of metabolic acidosis with respiratory alkalosis. In toluene poisoning, a metabolite hippurate is rapidly excreted by the kidney and may present as a normal anion gap acidosis. Isopropanol, which is metabolized to acetone, increases the osmolar gap, but not the anion gap.

E. Uremic Acidosis

As the GFR drops below 15–30 mL/min, the kidneys are increasingly unable to excrete H^+ and organic acids, such as phosphate and sulfate, resulting in an increased anion gap acidosis. Hyperchloremic normal anion gap acidosis develops in earlier stages of CKD.

NORMAL ANION GAP ACIDOSIS (Table 21-14)

The two major causes are gastrointestinal HCO_3^- loss and defects in renal acidification (renal tubular acidoses). The urinary anion gap can differentiate between these causes (see below).

Table 21-14. Hyperchloremic, normal anion gap metabolic acidoses.

	Renal Defect	Serum [K ⁺]	Distal H ⁺ Secretion		Urinary Anion Gap	Treatment
			Urinary NH ₄ ⁺ Plus Minimal Urine pH	Titratable Acid		
Gastrointestinal HCO ₃ ⁻ loss	None	↓	< 5.5	↑↑	Negative	Na ⁺ , K ⁺ , and HCO ₃ ⁻ as required
Renal tubular acidosis						
I. Classic distal	Distal H ⁺ secretion	↓	> 5.5	↓	Positive	NaHCO ₃ (1-3 mEq/kg/d)
II. Proximal secretion	Proximal H ⁺	↓	< 5.5	Normal	Positive	NaHCO ₃ or KHCO ₃ (10-15 mEq/kg/d), thiazide
IV. Hyporeninemic hypoaldosteronism	Distal Na ⁺ reabsorption, K ⁺ secretion, and H ⁺ secretion	↑	< 5.5	↓	Positive	Fludrocortisone (0.1-0.5 mg/d), dietary K ⁺ restriction, furosemide (40-160 mg/d), NaHCO ₃ (1-3 mEq/kg/d)

Modified and reproduced, with permission, from Cogan MG. *Fluid and Electrolytes: Physiology and Pathophysiology*. McGraw-Hill, 1991.

A. Gastrointestinal HCO₃⁻ Loss

The gastrointestinal tract secretes bicarbonate at multiple sites. Small bowel and pancreatic secretions contain large amounts of HCO₃⁻; massive diarrhea or pancreatic drainage can result in HCO₃⁻ loss. Hyperchloremia occurs because the ileum and colon secrete HCO₃⁻ in exchange for Cl⁻ by countertransport. The resultant volume contraction causes increased Cl⁻ retention by the kidney in the setting of decreased HCO₃⁻. Patients with ureterosigmoidostomies can develop hyperchloremic metabolic acidosis because the colon secretes HCO₃⁻ in the urine in exchange for Cl⁻.

B. Renal Tubular Acidosis (RTA)

Hyperchloremic acidosis with a normal anion gap and normal (or near normal) GFR, and in the absence of diarrhea, defines RTA. The defect is either inability to excrete H⁺ (inadequate generation of new HCO₃⁻) or inappropriate reabsorption of HCO₃⁻. Three major types can be differentiated by the clinical setting, urinary pH, urinary anion gap (see below), and serum K⁺ level. The pathophysiologic mechanisms of RTA have been elucidated by identifying the responsible molecules and gene mutations.

1. Classic distal RTA (type I)—This disorder is characterized by selective deficiency in H⁺ secretion in α intercalated cells in the collecting tubule. Despite acidosis, urinary pH cannot be acidified and is above 5.5, which retards the binding of H⁺ to phosphate (H⁺ + HPO₄²⁻ → H₂PO₄) and inhibits titratable acid excretion. Furthermore, urinary excretion of NH₄⁺Cl⁻ is decreased, and the urinary anion gap is positive (see below). Enhanced K⁺ excretion occurs probably because there is less competition from H⁺ in the distal nephron transport system. Furthermore, hyperaldosteronism occurs in response to renal salt wasting, which will increase potassium excretion. Nephrocalcinosis and nephrolithiasis are often seen in patients with distal RTA since chronic acidosis decreases tubular calcium reabsorption. Hypercalciuria, alkaline urine,

and lowered level of urinary citrate cause calcium phosphate stones and nephrocalcinosis.

Distal RTA develops as a consequence of paraproteinemias, autoimmune disease, and drugs and toxins such as amphotericin.

2. Proximal RTA (type II)—Proximal RTA is due to a selective defect in the proximal tubule's ability to reabsorb filtered HCO₃⁻. Carbonic anhydrase inhibitors (acetazolamide) can cause proximal RTA. About 90% of filtered HCO₃⁻ is absorbed by the proximal tubule. A proximal defect in HCO₃⁻ reabsorption will overwhelm the distal tubule's limited capacity to reabsorb HCO₃⁻, resulting in bicarbonaturia and metabolic acidosis. Distal delivery of HCO₃⁻ declines as the plasma HCO₃⁻ level decreases. When the plasma HCO₃⁻ level drops to 15–18 mEq/L, the distal nephron can reabsorb the diminished filtered load of HCO₃⁻. Bicarbonaturia resolves, and the urinary pH can be acidic. Thiazide-induced volume contraction can be used to enhance proximal HCO₃⁻ reabsorption, leading to the decrease in distal HCO₃⁻ delivery and improvement of bicarbonaturia and renal acidification. The increased delivery of HCO₃⁻ to the distal nephron increases K⁺ secretion, and hypokalemia results if a patient is loaded with excess HCO₃⁻ and K⁺ is not adequately supplemented. Proximal RTA can exist with other proximal reabsorption defects, such as Fanconi syndrome, resulting in glucosuria, aminoaciduria, phosphaturia, and uricosuria. Causes include multiple myeloma and nephrotoxic drugs.

3. Hyporeninemic hypoaldosteronemic RTA (type IV)—Type IV is the most common RTA in clinical practice. The defect is aldosterone deficiency or antagonism, which impairs distal nephron Na⁺ reabsorption and K⁺ and H⁺ excretion. Renal salt wasting and hyperkalemia are frequently present. Common causes are diabetic nephropathy, tubulointerstitial renal diseases, hypertensive nephrosclerosis, and AIDS. In patients with these disorders, drugs, such as ACE inhibitors, spironolactone, and NSAIDs, can exacerbate the hyperkalemia.

C. Dilutional Acidosis

Rapid dilution of plasma volume by 0.9% NaCl may cause hyperchloremic acidosis.

D. Recovery from DKA

See earlier section, Increased Anion Gap Acidosis (Increased Unmeasured Anion).

E. Posthypocapnia

In prolonged respiratory alkalosis, HCO_3^- decreases and Cl^- increases from decreased renal NH_4^+Cl^- excretion. If the respiratory alkalosis is corrected quickly, HCO_3^- will remain low until the kidneys can generate new HCO_3^- , which generally takes several days. In the meantime, the increased Pco_2 with low HCO_3^- causes metabolic acidosis.

F. Hyperalimentation

Hyperalimentation fluids may contain amino acid solutions that acidify when metabolized, such as arginine hydrochloride and lysine hydrochloride.

► Assessment of Hyperchloremic Metabolic Acidosis by Urinary Anion Gap

Increased renal NH_4^+Cl^- excretion to enhance H^+ removal is the normal physiologic response to metabolic acidosis. The daily urinary excretion of NH_4Cl can be increased from 30 mEq to 200 mEq in response to acidosis.

The urinary anion gap ($\text{Na}^+ + \text{K}^+ - \text{Cl}^-$) reflects the ability of the kidney to excrete NH_4Cl . The urinary anion gap differentiates between gastrointestinal and renal causes of hyperchloremic acidosis. If the cause is gastrointestinal HCO_3^- loss (diarrhea), renal acidification remains normal and NH_4Cl excretion increases, and the urinary anion gap is negative. If the cause is distal RTA, the urinary anion gap is positive, since the basic lesion in the disorder is the inability of the kidney to excrete H^+ as NH_4Cl . In proximal (type II) RTA, the kidney has defective HCO_3^- reabsorption, leading to increased HCO_3^- excretion rather than decreased NH_4Cl excretion; the urinary anion gap is often negative.

Urinary pH may not readily differentiate between the two causes. Despite acidosis, if volume depletion from diarrhea causes inadequate Na^+ delivery to the distal nephron and therefore decreased exchange with H^+ , urinary pH may not be lower than 5.3. In the presence of this relatively high urinary pH, however, H^+ excretion continues due to buffering of NH_3 to NH_4^+ , since the pK of this reaction is as high as 9.1. Potassium depletion, which can accompany diarrhea (and surreptitious laxative abuse), may also impair renal acidification. Thus, when volume depletion is present, the urinary anion gap is a better measure of ability to acidify the urine than urinary pH.

When large amounts of other anions are present in the urine, the urinary anion gap may not be reliable. In such a situation, NH_4^+ excretion can be estimated using the urinary osmolar gap.

$$\text{NH}_4^+ \text{ excretion (mmol/L)} = 0.5 \times \text{Urinary osmolar gap} \\ = 0.5 [\text{U osm} - 2(\text{U Na}^+ + \text{U K}^+) + \text{U urea} + \text{U glucose}]$$

where urine concentrations and osmolality are in mmol/L.

► Clinical Findings

A. Symptoms and Signs

Symptoms of metabolic acidosis are mainly those of the underlying disorder. Compensatory hyperventilation is an important clinical sign and may be misinterpreted as a primary respiratory disorder; Kussmaul breathing (deep, regular, sighing respirations) may be seen with severe metabolic acidosis.

B. Laboratory Findings

Blood pH, serum HCO_3^- , and PCO_2 are decreased. Anion gap may be normal (hyperchloremic) or increased (normochloremic). Hyperkalemia may be seen (see above).

► Treatment

A. Increased Anion Gap Acidosis

Treatment is aimed at the underlying disorder, such as insulin and fluid therapy for diabetes and appropriate volume resuscitation to restore tissue perfusion. The metabolism of lactate will produce HCO_3^- and increase pH. Supplemental HCO_3^- is indicated for treatment of hyperkalemia (Table 21-6) and some forms of normal anion gap acidosis but has been controversial for treatment of increased anion gap metabolic acidosis with respect to efficacy and safety. Large amounts of HCO_3^- may have deleterious effects, including hypernatremia, hyperosmolality, volume overload, and worsening of intracellular acidosis.

In addition, alkali administration stimulates phosphofructokinase activity, thus exacerbating lactic acidosis via enhanced lactate production. Ketogenesis is also augmented by alkali therapy.

In salicylate intoxication, alkali therapy must be started unless blood pH is already alkalinized by respiratory alkalosis, since an increased pH converts salicylate to more impermeable salicylic acid, decreasing central nervous system damage. In alcoholic ketoacidosis, thiamine should be given with glucose to avoid Wernicke encephalopathy. The bicarbonate deficit can be calculated as follows:

$$\text{HCO}_3^- \text{ deficit} = 0.5 \times \text{body weight in kg} \times (24 - \text{HCO}_3^-)$$

Half of the calculated deficit should be administered within the first 3–4 hours to avoid overcorrection and volume overload. In methanol intoxication, ethanol had been used as a competitive substrate for alcohol dehydrogenase, which metabolizes methanol to formaldehyde. Inhibition of alcohol dehydrogenase by fomepizole is the standard of care.

B. Normal Anion Gap Acidosis

Treatment of RTA is mainly achieved by administration of alkali (either as bicarbonate or citrate) to correct metabolic abnormalities and prevent nephrocalcinosis and CKD.

Large amounts of oral alkali (10–15 mEq/kg/d) (Table 21–14) may be required to treat proximal RTA because most of the alkali is excreted into the urine, which exacerbates hypokalemia. Thus, a mixture of sodium and potassium salts is preferred. Thiazides may reduce the amount of alkali required, but hypokalemia may develop. Treatment of type 1 distal RTA requires less alkali (1–3 mEq/kg/d) than proximal RTA. Potassium supplementation may be necessary.

For type IV RTA, dietary potassium restriction may be necessary and potassium-retaining drugs should be withdrawn. Fludrocortisone may be effective in cases with hypoaldosteronism, but should be used with care, preferably in combination with loop diuretics. In some cases, oral alkali supplementation (1–3 mEq/kg/d) may be required.

▶ When to Refer

Most clinicians will refer patients with renal tubular acidoses to a nephrologist for evaluation and possible alkali therapy.

▶ When to Admit

Patients will require emergency department evaluation or hospital admission depending on the severity of the acidosis and underlying conditions.

Kraut JA et al. Approach to the evaluation of a patient with an increased serum osmolal gap and high-anion-gap metabolic acidosis. *Am J Kidney Dis.* 2011 Sep;58(3):480–4. [PMID: 21794966]

Kraut JA et al. Metabolic acidosis: pathophysiology, diagnosis and management. *Nat Rev Nephrol.* 2010 May;6(5):274–85. [PMID: 20308999]

Liamis G et al. Pharmacologically-induced metabolic acidosis: a review. *Drug Saf.* 2010 May 1;33(5):371–91. [PMID: 20397738]

METABOLIC ALKALOSIS



ESSENTIALS OF DIAGNOSIS

- ▶ High HCO_3^- with alkalemia.
- ▶ Evaluate effective circulating volume by physical examination.
- ▶ Check urinary chloride concentration to differentiate saline-responsive alkalosis from saline-unresponsive alkalosis.

▶ Classification

Metabolic alkalosis is characterized by high HCO_3^- . Abnormalities that generate HCO_3^- are called “initiation factors,” whereas abnormalities that promote renal conservation of HCO_3^- are called “maintenance factors.” Metabolic alkalosis may remain even after the initiation factors have resolved.

The causes of metabolic alkalosis are classified into two groups based on “saline responsiveness” using the urine Cl^- as a marker for volume status (Table 21–15). Saline-responsive metabolic alkalosis is a sign of extracellular volume contraction, and saline-unresponsive alkalosis implies excessive total body bicarbonate with either euvolemia or hypervolemia. The compensatory increase in PCO_2 rarely exceeds 55 mm Hg; higher PCO_2 values imply a superimposed primary respiratory acidosis.

A. Saline-Responsive Metabolic Alkalosis

Much more common than saline-unresponsive alkalosis, saline-responsive alkalosis is characterized by normotensive extracellular volume contraction and hypokalemia.

Table 21–15. Metabolic alkalosis.

Saline-Responsive ($U_{\text{Cl}} < 25$ mEq/L)	Saline-Unresponsive ($U_{\text{Cl}} > 40$ mEq/L)
Excessive body bicarbonate content Renal alkalosis Diuretic therapy Poorly reabsorbable anion therapy: carbenicillin, penicillin, sulfate, phosphate Posthypercapnia Gastrointestinal alkalosis Loss of HCl from vomiting or nasogastric suction Intestinal alkalosis: chloride diarrhea NaHCO_3 (baking soda) Sodium citrate, lactate, gluconate, acetate Transfusions Antacids Normal body bicarbonate content “Contraction alkalosis”	Excessive body bicarbonate content Renal alkalosis Normotensive Bartter syndrome (renal salt wasting and secondary hyperaldosteronism) Severe potassium depletion Refeeding alkalosis Hypercalcemia and hypoparathyroidism Hypertensive Endogenous mineralocorticoids Primary aldosteronism Hyperreninism Adrenal enzyme deficiency: 11- and 17-hydroxylase Liddle syndrome Exogenous alkali Exogenous mineralocorticoids Licorice

Modified and reproduced, with permission, from Narins RG et al. Diagnostic strategies in disorders of fluid, electrolyte and acid-base homeostasis. *Am J Med.* 1982 Mar;72(3):496–520.

Hypotension and orthostasis may be seen. In vomiting or nasogastric suction, loss of acid (HCl) initiates the alkalosis, but volume contraction from Cl^- loss maintains the alkalosis because the kidney avidly reabsorbs Na^+ to restore the ECF. Increased sodium reabsorption necessitates increased HCO_3^- reabsorption proximally, and the urinary pH remains acidic despite alkalemia (paradoxical aciduria). Renal Cl^- reabsorption is high, and urine Cl^- is low ($< 10\text{--}20$ mEq/L). In alkalosis, bicarbonaturia may force Na^+ excretion as the accompanying cation even if volume depletion is present. Therefore, urine Cl^- is preferred to urine Na^+ as a measure of extracellular volume. Diuretics may limit the utility of urine chloride by increasing urine chloride and sodium excretion, even in the setting of volume contraction.

Metabolic alkalosis is generally associated with hypokalemia due to the direct effect of alkalosis on renal potassium excretion and secondary hyperaldosteronism from volume depletion. Hypokalemia exacerbates the metabolic alkalosis by increasing bicarbonate reabsorption in the proximal tubule and hydrogen ion secretion in the distal tubule. Administration of KCl will correct the disorder.

1. Contraction alkalosis—Diuretics decrease extracellular volume from urinary loss of NaCl and water. The plasma HCO_3^- concentration increases because the extracellular fluid volume contracts around a stable total body bicarbonate. Contraction alkalosis is the opposite of dilutional acidosis.

2. Posthypercapnia alkalosis—In chronic respiratory acidosis, the kidney decreases bicarbonate excretion, increasing plasma HCO_3^- concentration (Table 21–12). Hypercapnia directly affects the proximal tubule to decrease NaCl reabsorption, which can cause extracellular volume depletion. If PCO_2 is rapidly corrected, metabolic alkalosis will exist until the kidney excretes the retained bicarbonate. Many patients with chronic respiratory acidosis receive diuretics, which further exacerbates the metabolic alkalosis.

B. Saline-Unresponsive Alkalosis

1. Hyperaldosteronism—Primary hyperaldosteronism causes extracellular volume expansion and hypertension by increasing distal sodium reabsorption. Aldosterone increases H^+ and K^+ excretion, producing metabolic alkalosis and hypokalemia. In an attempt to decrease extracellular volume, high levels of NaCl are excreted with a high urine Cl^- (> 20 mEq/L). Therapy with NaCl will increase volume expansion and hypertension and will not treat the underlying problem of mineralocorticoid excess.

2. Alkali administration with decreased GFR—The normal kidney has a substantial capacity for bicarbonate excretion, protecting against metabolic alkalosis even with large HCO_3^- intake. However, urinary excretion of bicarbonate is inadequate in CKD. If large amounts of HCO_3^- are consumed, as with intensive antacid therapy, metabolic alkalosis will occur. Lactate, citrate, and gluconate can also cause metabolic alkalosis because they are metabolized to bicarbonate. In milk-alkali syndrome, sustained heavy ingestion of absorbable antacids and milk causes hypercalcemic

kidney injury and metabolic alkalosis. Volume contraction from renal hypercalcemic effects exacerbates the alkalosis.

► Clinical Findings

A. Symptoms and Signs

There are no characteristic symptoms or signs. Orthostatic hypotension may be encountered. Concomitant hypokalemia may cause weakness and hyporeflexia. Tetany and neuromuscular irritability occur rarely.

B. Laboratory Findings

The arterial blood pH and bicarbonate are elevated. With respiratory compensation, the arterial Pco_2 is increased. Serum potassium and chloride are decreased. There may be an increased anion gap. The urine chloride can differentiate between saline-responsive (< 25 mEq/L) and unresponsive (> 40 mEq/L) causes.

► Treatment

Mild alkalosis is generally well tolerated. Severe or symptomatic alkalosis (pH > 7.60) requires urgent treatment.

A. Saline-Responsive Metabolic Alkalosis

Therapy for saline-responsive metabolic alkalosis is correction of the extracellular volume deficit with isotonic saline. Diuretics should be discontinued. H_2 -blockers or proton pump inhibitors may be helpful in patients with alkalosis from nasogastric suctioning. If pulmonary or cardiovascular disease prohibits adequate resuscitation, acetazolamide will increase renal bicarbonate excretion. Hypokalemia may develop because bicarbonate excretion may induce kaliuresis. Severe cases, especially those with reduced kidney function, may require dialysis with low-bicarbonate dialysate.

B. Saline-Unresponsive Metabolic Alkalosis

Therapy for saline-unresponsive metabolic alkalosis includes surgical removal of a mineralocorticoid-producing tumor and blockage of aldosterone effect with an ACE inhibitor or with spironolactone. Metabolic alkalosis in primary aldosteronism can be treated only with potassium repletion.

Boscaro M et al. Diagnosis and management of primary aldosteronism. *Curr Opin Endocrinol Diabetes Obes.* 2008 Aug; 15(4):332–8. [PMID: 18594273]

Gennari FJ et al. Acid-base disturbances in gastrointestinal disease. *Clin J Am Soc Nephrol.* 2008 Nov;3(6):1861–8. [PMID: 18922984]

Gennari FJ et al. An unusual case of metabolic alkalosis. *Am J Kidney Dis.* 2010 Jun;55(6):1130–5. [PMID: 20400219]

Medarov BI. Milk-alkali syndrome. *Mayo Clin Proc.* 2009 Mar; 84(3):261–7. [PMID: 19252114]

RESPIRATORY ACIDOSIS (HYPERCAPNIA)

Respiratory acidosis results from hypoventilation and subsequent hypercapnia. Pulmonary and extrapulmonary disorders can cause hypoventilation.

Acute respiratory failure is associated with severe acidosis and only a small increase in the plasma bicarbonate. After 6–12 hours, the primary increase in PCO_2 evokes a renal compensation to excrete more acid and to generate more HCO_3^- ; complete metabolic compensation by the kidney takes several days.

Chronic respiratory acidosis is generally seen in patients with underlying lung disease, such as chronic obstructive pulmonary disease. Renal excretion of acid as NH_4Cl results in hypochloremia. When chronic respiratory acidosis is corrected suddenly, posthypercapnic metabolic alkalosis ensues until the kidneys excrete the excess bicarbonate over 2–3 days.

► Clinical Findings

A. Symptoms and Signs

With acute onset, somnolence, confusion, mental status changes, asterixis, and myoclonus may develop. Severe hypercapnia increases cerebral blood flow, cerebrospinal fluid pressure, and intracranial pressure; papilledema and pseudotumor cerebri may be seen.

B. Laboratory Findings

Arterial pH is low and PCO_2 is increased. Serum HCO_3^- is elevated but does not fully correct the pH. If the disorder is chronic, hypochloremia is seen.

► Treatment

If opioid overdose is a possible diagnosis or there is no other obvious cause for hypoventilation, the clinician should consider a diagnostic and therapeutic trial of intravenous naloxone (see Chapter 38). In all forms of respiratory acidosis, treatment is directed at the underlying disorder to improve ventilation.

Adrogué HJ. Diagnosis and management of severe respiratory acidosis. *Am J Kidney Dis.* 2010 Nov;56(5):994–1000. [PMID: 20673604]

Brown LK. Hypoventilation syndromes. *Clin Chest Med.* 2010 Jun;31(2):249–70. [PMID: 20488285]

Schwartzstein RM et al. Rising PaCO_2 in the ICU: using a physiologic approach to avoid cognitive biases. *Chest.* 2011 Dec;140(6):1638–42. [PMID: 22147823]

RESPIRATORY ALKALOSIS (HYPOCAPNIA)

Respiratory alkalosis occurs when hyperventilation reduces the PCO_2 , increasing serum pH. The most common cause of respiratory alkalosis is hyperventilation syndrome (Table 21–16), but bacterial septicemia and cirrhosis are other common causes. In pregnancy, progesterone stimulates the respiratory center, producing an average PCO_2 of 30 mm Hg and respiratory alkalosis. Symptoms of acute respiratory alkalosis are related to decreased cerebral blood flow induced by the disorder.

Determination of appropriate metabolic compensation may reveal an associated metabolic disorder (see above under Mixed Acid–Base Disorders).

Table 21–16. Causes of respiratory alkalosis.

Hypoxia

- Decreased inspired oxygen tension
- High altitude
- Ventilation/perfusion inequality
- Hypotension
- Severe anemia

CNS-mediated disorders

- Voluntary hyperventilation
- Anxiety-hyperventilation syndrome
- Neurologic disease
- Cerebrovascular accident (infarction, hemorrhage)
- Infection
- Trauma
- Tumor
- Pharmacologic and hormonal stimulation
- Salicylates
- Nicotine
- Xanthines
- Pregnancy (progesterone)

- Hepatic failure
- Gram-negative septicemia
- Recovery from metabolic acidosis
- Heat exposure

Pulmonary disease

- Interstitial lung disease
- Pneumonia
- Pulmonary embolism
- Pulmonary edema

Mechanical overventilation

Adapted, with permission, from Gennari FJ. Respiratory acidosis and alkalosis. In: *Maxwell and Kleeman's Clinical Disorders of Fluid and Electrolyte Metabolism*, 5th ed. Narins RG (editor). McGraw-Hill, 1994.

As in respiratory acidosis, the metabolic compensation is greater if the respiratory alkalosis is chronic (Table 21–12). Although serum HCO_3^- is frequently < 15 mEq/L in metabolic acidosis, such a low level in respiratory alkalosis is unusual and may represent a concomitant primary metabolic acidosis.

► Clinical Findings

A. Symptoms and Signs

In acute cases (hyperventilation), there is light-headedness, anxiety, perioral numbness, and paresthesias. Tetany occurs from a low ionized calcium, since severe alkalosis increases calcium binding to albumin.

B. Laboratory Findings

Arterial blood pH is elevated, and PCO_2 is low. Serum bicarbonate is decreased in chronic respiratory alkalosis.

► Treatment

Treatment is directed toward the underlying cause. In acute hyperventilation syndrome from anxiety, the traditional treatment of breathing into a paper bag should be discouraged because it does not correct PCO_2 and may decrease PO_2 . Reassurance may be sufficient for the

Table 21-17. Replacement guidelines for sweat and gastrointestinal fluid losses.

	Average Electrolyte Composition				Replacement Guidelines per Liter Lost				
	Na ⁺ (mEq/L)	K ⁺ (mEq/L)	Cl ⁻ (mEq/L)	HCO ₃ ⁻ (mEq/L)	0.9% Saline (mL)	0.45% Saline (mL)	D ₃ W (mL)	KCl (mEq/L)	7.5% NaHCO ₃ (45 mEq HCO ₃ ⁻ /amp)
Sweat	30-50	5	50			500	500	5	
Gastric secretions	20	10	10			300	700	20	
Pancreatic juice	130	5	35	115		400	600	5	2 amps
Bile	145	5	100	25	600		400	5	0.5 amp
Duodenal fluid	60	15	100	10		1000		15	0.25 amp
Ileal fluid	100	10	60	60		600	400	10	1 amp
Colonic diarrhea	140 ¹	10	85	60		1000		10	1 amp

¹In the absence of diarrhea, colonic fluid Na⁺ levels are low (40 mEq/L).

anxious patient, but sedation may be necessary if the process persists. Hyperventilation is usually self-limited since muscle weakness caused by the respiratory alkalemia will suppress ventilation. Rapid correction of chronic respiratory alkalosis may result in metabolic acidosis as PCO₂ is increased in the setting of a previous compensatory decrease in HCO₃⁻.

Curley G et al. Bench-to-bedside review: carbon dioxide. *Crit Care*. 2010;14(2):220. [PMID: 20497620]
Laffey JG et al. Hypocapnia. *N Engl J Med*. 2002 Jul 4;347(1):43-53. [PMID: 12097540]

FLUID MANAGEMENT

Daily parenteral maintenance fluids and electrolytes for an average adult would include 2500–3000 mL of 5% dextrose in 0.2% saline solution (34 mEq Na⁺ plus 34 mEq Cl⁻/L)

with 30 mEq/L of KCl. Guidelines for gastrointestinal fluid losses are shown in Table 21-17.

Weight loss or gain is the best indication of water balance. Insensible water loss should be considered in febrile patients. Water loss increases by 100–150 mL/d for each degree of body temperature over 37°C.

In patients requiring maintenance and possibly replacement of fluid and electrolytes by parenteral infusion, the total daily ration should be administered continuously over 24 hours to ensure optimal utilization.

If intravenous fluids are the only source of water, electrolytes, and calories for longer than a week, parenteral nutrition containing amino acids, lipids, trace metals, and vitamins may be indicated. (See Chapter 29.)

For parenteral alimentation, 620 mg (20 mmol) of phosphorus is required for every 1000 nonprotein kcal to maintain phosphate balance and to ensure anabolic function. For prolonged parenteral fluid maintenance, a daily ration is 620–1240 mg (20–40 mmol) of phosphorus.

22

Kidney Disease

Suzanne Watnick, MD
Tonja Dirx, MD

Kidney disease can be discovered incidentally during a routine medical evaluation or with evidence of kidney dysfunction, such as hypertension, edema, nausea, or hematuria. The initial approach in both situations should be to assess the cause and severity of renal abnormalities. In all cases this evaluation includes (1) an estimation of disease duration, (2) a careful urinalysis, and (3) an assessment of the glomerular filtration rate (GFR). The history and physical examinations, though equally important, are variable among renal syndromes—thus, specific symptoms and signs are discussed under each disease entity.

ASSESSMENT OF KIDNEY DISEASE

Disease Duration

Kidney disease may be acute or chronic. Acute kidney injury, also known as acute renal failure, is worsening of kidney function over hours to days, resulting in the retention of nitrogenous wastes (such as urea nitrogen) and creatinine in the blood. Retention of these substances is called azotemia. Chronic kidney disease (CKD) results from an abnormal loss of kidney function over months to years. Differentiating between the two is important for diagnosis, treatment, and outcome. Oliguria is unusual in CKD. Anemia (from low kidney erythropoietin production) is rare in the initial period of acute kidney disease. Small kidneys are most consistent with CKD, whereas normal to large-size kidneys can be seen with both chronic and acute disease.

Urinalysis

A urinalysis can provide information similar to a renal biopsy in a way that is cost-effective and, of course, noninvasive. The urine is collected in midstream or, if that is not feasible, by bladder catheterization. The urine should be examined within 1 hour after collection to avoid destruction of formed elements. Urinalysis includes a dipstick examination followed by microscopic assessment if the dipstick has positive findings. The dipstick examination measures urinary pH, protein, hemoglobin, glucose,

ketones, bilirubin, nitrites, and leukocyte esterase. Urinary specific gravity is often reported, too. Microscopy searches for all formed elements—crystals, cells, casts, and infecting organisms.

Various findings on the urinalysis are indicative of certain patterns of kidney disease. A bland (normal) urinary sediment is common, especially in CKD and acute disorders that are not intrinsic to the kidney, such as limited effective blood flow to the kidney or obstruction of outflow of urine. Casts are composed of Tamm-Horsfall urinary mucoprotein in the shape of the nephron segment where they were formed. Heavy proteinuria and lipiduria are consistent with the nephrotic syndrome. The presence of hematuria with dysmorphic red blood cells, red blood cell casts, and proteinuria is indicative of glomerulonephritis. Dysmorphic red blood cells are misshapen during abnormal passage from the capillary through the glomerular basement membrane (GBM) into the urinary space of Bowman capsule. Pigmented granular casts and renal tubular epithelial cells alone or in casts suggest acute tubular necrosis. White blood cells, including neutrophils and eosinophils, white blood cell casts (Table 22–1), red blood cells, and small amounts of protein can be found in interstitial nephritis and pyelonephritis; Wright and Hansel stains can detect eosinophiluria. Pyuria alone can indicate a urinary tract infection. Hematuria and proteinuria are discussed more thoroughly below.

A. Proteinuria

Proteinuria is defined as excessive protein excretion in the urine, generally > 150–160 mg/24 h in adults. Significant proteinuria is a sign of an underlying kidney abnormality, usually glomerular in origin when > 1 g/d to < 2 g/d. Less than 1 g/d can be due to multiple causes along the nephron segment, as listed below. Proteinuria can be accompanied by other clinical abnormalities—elevated blood urea nitrogen (BUN) and serum creatinine levels, abnormal urinary sediment, or evidence of systemic illness (eg, fever, rash, vasculitis).

There are several reasons for development of proteinuria: (1) **Functional proteinuria** is a benign process stemming from stressors such as acute illness, exercise, and

Table 22-1. Significance of specific urinary casts.

Type	Significance
Hyaline casts	Concentrated urine, febrile disease, after strenuous exercise, in the course of diuretic therapy (not indicative of renal disease)
Red cell casts	Glomerulonephritis
White cell casts	Pyelonephritis, interstitial nephritis (indicative of infection or inflammation)
Renal tubular cell casts	Acute tubular necrosis, interstitial nephritis
Coarse, granular casts	Nonspecific; can represent acute tubular necrosis
Broad, waxy casts	Chronic kidney disease (indicative of stasis in enlarged collecting tubules)

“orthostatic proteinuria.” The latter condition, generally found in people under age 30 years, usually results in urinary protein excretion of < 1 g/d. The orthostatic nature of the proteinuria is confirmed by measuring an 8-hour overnight supine urinary protein excretion, which should be < 50 mg. (2) **Overload proteinuria** can result from overproduction of circulating, filterable plasma proteins (monoclonal gammopathies), such as Bence Jones proteins associated with multiple myeloma. Urinary protein electrophoresis will exhibit a discrete protein peak. Other examples of overload proteinuria include myoglobinuria in rhabdomyolysis and hemoglobinuria in hemolysis. (3) **Glomerular proteinuria** results from effacement of epithelial cell foot processes and altered glomerular permeability with an increased filtration fraction of normal plasma proteins. Glomerular diseases exhibit some degree of proteinuria. The urinary protein electrophoresis will have a pattern exhibiting a large albumin spike indicative of increased permeability of albumin across a damaged GBM. (4) **Tubular proteinuria** occurs as a result of faulty reabsorption of normally filtered proteins in the proximal tubule, such as β_2 -microglobulin and immunoglobulin light chains. Causes include acute tubular necrosis, toxic injury (lead, aminoglycosides), drug-induced interstitial nephritis, and hereditary metabolic disorders (Wilson disease and Fanconi syndrome).

Evaluation of proteinuria by urinary dipstick primarily detects albumin, while overlooking positively charged light chains of immunoglobulins. These proteins can be detected by the addition of sulfosalicylic acid to the urine specimen. Precipitation without dipstick detection of albumin indicates the presence of paraproteins.

The next step is an estimation of proteinuria from a 24-hour urine collection. A finding of > 150–160 mg/24 h is abnormal, and > 3.5 g/24 h is consistent with nephrotic-range proteinuria. The simplest method is to collect a random urine sample. The ratio of urinary protein concentration to urinary creatinine concentration ($[U_{\text{protein}}]/[U_{\text{creatinine}}]$) correlates with 24-hour urine protein collection (< 0.2 is normal and corresponds to excretion of < 200

mg/24 h). The benefit of a urine protein-to-creatinine ratio is the ease of collection and the lack of error from overcollection or undercollection of urine. If a patient has proteinuria with or without loss of kidney function, kidney biopsy may be indicated, particularly if the kidney disease is acute in onset. The clinical consequences of proteinuria are discussed in the section Nephrotic Spectrum Glomerular Diseases below.

B. Hematuria

Hematuria is significant if there are more than three red cells per high-power field on at least two occasions. It is usually detected incidentally by the urine dipstick examination or clinically following an episode of macroscopic hematuria. The diagnosis must be confirmed via microscopic examination, as false-positive dipstick tests can be caused by myoglobin, oxidizing agents, beets and rhubarb, hydrochloric acid, and bacteria. Transient hematuria is common, but in patients younger than 40 years, it is less often of clinical significance due to lower concern for malignancy.

Hematuria may be due to renal or extrarenal causes. Extrarenal causes are addressed in Chapters 23 and 39; most worrisome are urologic malignancies. Renal causes account for approximately 10% of cases and are best considered anatomically as glomerular or nonglomerular. The most common extraglomerular sources include cysts, calculi, interstitial nephritis, and renal neoplasia. Glomerular causes include immunoglobulin A (IgA) nephropathy, thin GBM disease, membranoproliferative glomerulonephritis (MPGN), other hereditary glomerular diseases (eg, Alport syndrome), and systemic nephritic syndromes.

Currently, the United States Health Preventive Services Task Force does not recommend screening for hematuria. See Chapter 23 for evaluation of hematuria.

▶ Estimation of GFR

The GFR provides a useful index of kidney function at the level of the glomerulus. Patients with kidney disease can have a decreased GFR from any process that causes loss of nephron (and thus glomerular) mass. However, they can also have a normal or increased GFR, either from hyperfiltration at the glomerulus or disease at a different segment of the nephron, interstitium, or vascular supply. The GFR measures the amount of plasma ultrafiltered across the glomerular capillaries and correlates with the ability of the kidneys to filter fluids and various substances. Daily GFR in normal individuals is variable, with a range of 150–250 L/24 h or 100–120 mL/min/1.73 m² of body surface area. GFR can be measured indirectly by determining the renal clearance of plasma substances that are not bound to plasma proteins, are freely filterable across the glomerulus, and are neither secreted nor reabsorbed along the renal tubules. The formula used to determine the renal clearance of a substance is

$$C = \frac{U \times \dot{V}}{P}$$

where C is the clearance, U and P are the urine and plasma concentrations of the substance (mg/dL), and \dot{V} is the urine

flow rate (mL/min). In clinical practice, the clearance rate of endogenous creatinine, the creatinine clearance, is one way of estimating GFR. Creatinine is a product of muscle metabolism produced at a relatively constant rate and cleared by renal excretion. It is freely filterable by the glomerulus and not reabsorbed by the renal tubules. With stable kidney function, creatinine production and excretion are equal; thus, plasma creatinine concentrations remain constant. However, it is not a perfect indicator of GFR for the following reasons: (1) A small amount is normally eliminated by tubular secretion, and the fraction secreted progressively increases as GFR declines (overestimating GFR); (2) with severe kidney failure, gut microorganisms degrade creatinine; (3) an individual's meat intake and muscle mass affect baseline plasma creatinine levels; (4) commonly used drugs such as aspirin, cimetidine, probenecid, and trimethoprim reduce tubular secretion of creatinine, increasing the plasma creatinine concentration and falsely indicating kidney dysfunction; and (5) the accuracy of the measurement necessitates a stable plasma creatinine concentration over a 24-hour period, so that during the development of and recovery from acute kidney injury, when the serum creatinine is changing, the creatinine clearance is of questionable value (Table 22–2). Of note, the creatinine clearance is the traditional estimation equation used for consideration of drug dosing in patients with kidney disease.

One way to measure creatinine clearance is to collect a timed urine sample and determine the plasma creatinine level midway through the collection. An incomplete or prolonged urine collection is a common source of error. One way of estimating the completeness of the collection is to calculate a 24-hour creatinine excretion; the amount should be constant:

$$U_{cr} \times \dot{V} = 15\text{--}20 \text{ mg/kg for healthy young women}$$

$$U_{cr} \times \dot{V} = 20\text{--}25 \text{ mg/kg for healthy young men}$$

The creatinine clearance (C_{cr}) is approximately 100 mL/min/1.73 m² in healthy young women and 120 mL/min/1.73 m² in healthy young men. The C_{cr} declines by an

average of 0.8 mL/min/yr after age 40 years as part of the aging process, but 35% of subjects in one study had no decline in kidney function over 10 years.

C_{cr} can be estimated from the formula of Cockcroft and Gault, which incorporates age, sex, and weight to estimate C_{cr} from plasma creatinine levels without any urinary measurements:

$$C_{cr} = \frac{(140 - \text{Age}) \times \text{Weight (kg)}}{P_{cr} \times 72}$$

For women, the creatinine clearance is multiplied by 0.85 because muscle mass is less. This formula overestimates GFR in patients who are obese or edematous and is most accurate when normalized for body surface area of 1.73 m².

BUN is another index used in assessing kidney function. It is synthesized mainly in the liver and is the end product of protein catabolism. Urea is freely filtered by the glomerulus, and about 30–70% is reabsorbed in the renal tubules. Unlike creatinine clearance, which overestimates GFR, urea clearance underestimates GFR. Urea reabsorption may be decreased in volume replete patients, whereas volume depletion causes increased urea reabsorption, in conjunction with increased sodium reabsorption, from the kidney, increasing BUN. A normal BUN:creatinine ratio is 10:1, although this can vary between individuals. With volume depletion, the ratio can increase to 20:1 or higher. Other causes of increased BUN include increased catabolism (gastrointestinal [GI] bleeding, cell lysis, and corticosteroid usage), increased dietary protein, and decreased renal perfusion (congestive heart failure, renal artery stenosis) (Table 22–3). Reduced BUN is seen in liver disease and in the syndrome of inappropriate antidiuretic hormone (SIADH) secretion.

As patients approach end-stage renal disease (ESRD), a more accurate measure of GFR than creatinine clearance is the average of the creatinine and urea clearances. The creatinine clearance overestimates GFR, as mentioned above, while the urea clearance underestimates GFR. Therefore, an average of the two more accurately approximates the true GFR.

The four-variable estimated GFR is a complex equation, including serum creatinine, age, weight, and race, that is often reported alongside serum creatinine measurements

Table 22–2. Conditions affecting serum creatinine independently of glomerular filtration rate.

Condition	Mechanism
Conditions elevating creatinine	
Ketoacidosis, cephalothin, cefoxitin, flucytosine	Noncreatinine chromogen
Other drugs: aspirin, cimetidine, probenecid, trimethoprim	Inhibition of tubular creatinine secretion
Conditions decreasing creatinine	
Advanced age	Physiologic decrease in muscle mass
Cachexia	Pathologic decrease in muscle mass
Liver disease	Decreased hepatic creatine synthesis and cachexia

Table 22–3. Conditions affecting BUN independently of GFR.

Increased BUN
Reduced effective circulating blood volume (prerenal azotemia)
Catabolic states (gastrointestinal bleeding, corticosteroid use)
High-protein diets
Tetracycline
Decreased BUN
Liver disease
Malnutrition
Sickle cell anemia
SIADH

BUN, blood urea nitrogen; GFR, glomerular filtration rate; SIADH, syndrome of inappropriate antidiuretic hormone.

and more accurate than creatinine or urea clearance. This was derived from data collected for the Modification of Diet and Renal Disease (MDRD) study and has been validated in several other populations. Many laboratories will report a value for the estimated GFR in addition to a serum creatinine. Several web-based calculators will calculate this; one location is www.nephron.com.

Other useful, well-validated estimators of GFR include the CKD-EPI formula. This is more accurate and precise than the MDRD equation at higher levels of true GFR, possibly decreasing false-positive results. This formula may perform better in elderly populations; however, this estimation equation did not include large numbers of nonwhite patients.

Cystatin C is another endogenous marker of GFR, filtered freely at the glomerulus and produced at a relatively constant rate, irrespective of muscle mass. It is reabsorbed and partially metabolized in the renal tubular epithelial cells. Studies show less variability with age, gender, or race for cystatin C versus serum creatinine.

RENAL BIOPSY

Indications for percutaneous needle biopsy include (1) unexplained acute kidney injury or CKD; (2) acute nephritic syndromes; (3) unexplained proteinuria and hematuria; (4) previously identified and treated lesions to plan future therapy; (5) systemic diseases associated with kidney dysfunction, such as systemic lupus erythematosus, Goodpasture syndrome, and granulomatosis with polyangiitis (formerly Wegener granulomatosis), to confirm the extent of renal involvement and to guide management; (6) suspected transplant rejection, to differentiate it from other causes of acute kidney injury; and (7) to guide treatment. If a patient is unwilling to accept therapy based on biopsy findings, the risk of biopsy may outweigh its benefit. Relative contraindications include a solitary or ectopic kidney (exception: transplant allografts), horseshoe kidney, ESRD, congenital anomalies, and multiple cysts. Absolute contraindications include an uncorrected bleeding disorder, severe uncontrolled hypertension, renal infection, renal neoplasm, hydronephrosis, or an uncooperative patient.

Prior to biopsy, patients should not use medications that prolong clotting times and should have well-controlled blood pressure. Blood work should include a hemoglobin, platelet count, prothrombin time, and partial thromboplastin time. After biopsy, hematuria occurs in nearly all patients. Less than 10% will have macroscopic hematuria. Patients should remain supine for 4–6 hours postbiopsy. A patient with a 6-hour postbiopsy hematocrit > 3% lower than baseline should be closely monitored.

Percutaneous kidney biopsies are generally safe. Approximately 1% of patients will experience significant bleeding requiring blood transfusions. More than half of patients will have at least a small hematoma. Risk of major bleeding persists up to 72 hours after the biopsy. Any type of anticoagulation therapy should be held for 5–7 days postbiopsy if possible. The risks of nephrectomy and mortality are about 0.06–0.08%. When a percutaneous needle biopsy is technically not feasible and

renal tissue is deemed clinically essential, a closed renal biopsy via interventional radiologic techniques or open renal biopsy under general anesthesia can be done.

- Bairy M et al. Safety of outpatient kidney biopsy: one center's experience with 178 native kidney biopsies. *Am J Kidney Dis.* 2008 Sep;52(3):631–2. [PMID: 18725027]
- Campbell KH et al. Kidney disease in the elderly: update on recent literature. *Curr Opin Nephrol Hypertens.* 2008 May;17(3):298–303. [PMID: 18408482]
- Nguyen MT et al. Misapplications of commonly used kidney equations: renal physiology in practice. *Clin J Am Soc Nephrol.* 2009 Mar;4(3):528–34. [PMID: 19261813]
- Patel JV et al. Hematuria: etiology and evaluation for the primary care physician. *Can J Urol.* 2008 Aug;15(Suppl 1):54–61. [PMID: 18700066]
- Stevens LA et al. Comparative performance of the CKD Epidemiology Collaboration (CKD-EPI) and the Modification of Diet in Renal Disease (MDRD) Study equations for estimating GFR levels above 60 mL/min/1.73 m². *Am J Kidney Dis.* 2010 Sep;56(3):486–95. [PMID: 20557989]

ACUTE KIDNEY INJURY (ACUTE RENAL FAILURE)

ESSENTIALS OF DIAGNOSIS

- ▶ Sudden increase in BUN or serum creatinine.
- ▶ Oliguria can be associated.
- ▶ Symptoms and signs depend on cause.

▶ General Considerations

Acute kidney injury, also known as acute renal failure, is defined as a sudden decrease in kidney function, resulting in an inability to maintain acid-base, fluid and electrolyte balance and to excrete nitrogenous wastes. Serum creatinine is a convenient marker. A clinically applicable definition of acute kidney injury has been developed. The RIFLE criteria describe three progressive levels of acute kidney injury (risk, injury, and failure) based on the elevation in serum creatinine or decline in urinary output with two outcome measures (loss and ESRD). Risk, injury, and failure are defined, respectively, as a 1.5-fold increase in serum creatinine, a twofold or threefold increase in serum creatinine, or a decline in urinary output to 0.5 mL/kg/h over 6, 12, or 24 hours. These definitions were created by an international consensus panel and correlate with prognosis. The AKIN criteria are also predictive of outcomes, and closely follow the RIFLE criteria, with the addition of a change in serum creatinine of ≥ 0.3 mg/day qualifying as a risk for injury. In the absence of functioning kidneys, serum creatinine concentration will typically increase by 1–1.5 mg/dL daily, although with certain conditions, such as rhabdomyolysis, serum creatinine can increase more rapidly. On average, 5% of hospital admissions and 30% of intensive care unit (ICU) admissions carry a diagnosis of acute kidney injury, and it will develop in 25% of hospitalized patients. Patients with

acute kidney injury of any type are at higher risk for all-cause mortality according to recent prospective cohorts, whether or not there is substantial renal recovery.

► Clinical Findings

A. Symptoms and Signs

The uremic milieu of acute kidney injury can cause nonspecific symptoms. When present, symptoms are often due to uremia or its underlying cause. Uremia can cause nausea, vomiting, malaise, and altered sensorium. Hypertension can occur, and fluid homeostasis is often altered. Hypovolemia can cause states of low blood flow to the kidneys, sometimes termed “prerenal” states, whereas hypervolemia can result from intrinsic or “postrenal” disease. Pericardial effusions can occur with uremia, and a pericardial friction rub can be present. Effusions may result in cardiac tamponade. Arrhythmias occur, especially with hyperkalemia. The lung examination may show rales in the presence of hypervolemia. Acute kidney failure can cause nonspecific diffuse abdominal pain and ileus as well as platelet dysfunction; thus, bleeding and clotting disorders are more common in these patients. The neurologic examination reveals encephalopathic changes with asterixis and confusion; seizures may ensue.

B. Laboratory Findings

Elevated BUN and serum creatinine levels are present, though these elevations do not distinguish acute kidney disease from CKD. Hyperkalemia can occur from impaired renal potassium excretion. With hyperkalemia, the ECG can reveal peaked T waves, PR prolongation, and QRS widening. A long QT segment can occur with hypocalcemia. Anion gap and non-gap metabolic acidosis (due to decreased organic and nonorganic acid clearance) is often noted. Hyperphosphatemia occurs when phosphorus

cannot be secreted by damaged tubules either with or without increased cell catabolism. Metastatic calcium phosphate deposition may be observed when the product of calcium and phosphorus is elevated (eg, exceeding $55\text{--}65\text{ mg}^2/\text{dL}^2$). Anemia can occur as a result of decreased erythropoietin production over weeks, and associated platelet dysfunction is typical.

► Classification & Etiology

Acute kidney injury can be divided into three categories: prerenal causes (renal hypoperfusion leading to lower GFR), intrinsic renal disease, and postrenal causes (obstructive uropathy). Identifying the cause is the first step toward treating the patient (Table 22–4).

A. Prerenal Causes

Prerenal causes are the most common reason for acute kidney insults and injury, accounting for 40–80% of cases, depending on the population studied. Prerenal azotemia is due to renal hypoperfusion, which is an appropriate physiologic change. If it can be immediately reversed with restoration of renal blood flow, renal parenchymal damage often does not occur. If hypoperfusion persists, ischemia can result, causing intrinsic kidney injury.

Decreased renal perfusion can occur in several ways, such as a decrease in intravascular volume, a change in vascular resistance, or low cardiac output. Causes of volume depletion include hemorrhage, GI losses, dehydration, excessive diuresis, extravascular space sequestration, pancreatitis, burns, trauma, and peritonitis.

Changes in vascular resistance can occur systemically with sepsis, anaphylaxis, anesthesia, and afterload-reducing drugs. Blockers of the renin-angiotensin-aldosterone system, such as angiotensin-converting enzyme (ACE) inhibitors, prevent efferent renal arteriolar constriction out of

Table 22–4. Classification and differential diagnosis of acute kidney injury.

	Prerenal Azotemia	Postrenal Azotemia	Intrinsic Renal Disease		
			Acute Tubular Necrosis (Oliguric or Polyuric)	Acute Glomerulonephritis	Acute Interstitial Nephritis
Etiology	Poor renal perfusion	Obstruction of the urinary tract	Ischemia, nephrotoxins	Immune complex-mediated, pauci-immune, anti-GBM related	Allergic reaction; drug reaction; infection, collagen vascular disease
Serum BUN:Cr ratio	> 20:1	> 20:1	< 20:1	> 20:1	< 20:1
Urinary indices					
U _{Na} (mEq/L)	< 20	Variable	> 20	< 20	Variable
FE _{Na} (%)	< 1	Variable	> 1 (when oliguric)	< 1	< 1; > 1
Urine osmolality (mosm/kg)	> 500	< 400	250–300	Variable	Variable
Urinary sediment	Benign or hyaline casts	Normal or red cells, white cells, or crystals	Granular (muddy brown) casts, renal tubular casts	Red cells, dysmorphic red cells and red cell casts	White cells, white cell casts, with or without eosinophils

BUN:Cr, blood urea nitrogen:creatinine ratio; FE_{Na}, fractional excretion of sodium; U_{Na}, urinary concentration of sodium.

proportion to the afferent arteriolar constriction; thus, GFR will decrease with these medications. Nonsteroidal anti-inflammatory drugs (NSAIDs) prevent afferent arteriolar vasodilation by inhibiting prostaglandin-mediated signals. Thus, in cirrhosis and congestive heart failure, when prostaglandins are recruited to increase renal blood flow, NSAIDs will have particularly deleterious effects. Epinephrine, norepinephrine, high-dose dopamine, anesthetic agents, and cyclosporine also can cause renal vasoconstriction. Renal artery stenosis causes increased resistance and decreased renal perfusion.

Low cardiac output is a state of low effective renal arterial blood flow. This occurs in states of cardiogenic shock, congestive heart failure, pulmonary embolism, and pericardial tamponade. Arrhythmias and valvular disorders can also reduce cardiac output. In the ICU setting, positive pressure ventilation will decrease venous return, also decreasing cardiac output.

When GFR falls acutely, it is important to determine whether acute kidney injury is due to prerenal or intrinsic renal causes. The history and physical examination are important, and urinalysis can be helpful. The BUN:creatinine ratio will typically exceed 20:1 due to increased urea reabsorption. In an oliguric patient, another useful index is the fractional excretion of sodium (FE_{NA}). With decreased GFR, the kidney will reabsorb salt and water avidly if there is no intrinsic tubular dysfunction. Thus, patients with prerenal causes should have a low fractional excretion percent of sodium (< 1%). Oliguric patients with intrinsic kidney dysfunction typically have a high fractional excretion of sodium (> 1–2%). The FE_{NA} is calculated as follows: FE_{NA} = clearance of Na^+ /GFR = clearance of Na^+ / C_{cr} :

$$FE_{NA} = \frac{\text{Urine}_{NA} \times \text{Serum}_{cr}}{\text{Urine}_{cr} \times \text{Serum}_{NA}} \times 100$$

Renal sodium handling is more accurately assessed by the FE_{NA} in oliguric states than in nonoliguric states because the FE_{NA} could be relatively low in nonoliguric acute tubular necrosis if sodium intake and excretion are relatively low. (Oliguria is defined as urinary output < 400–500 mL/d, or < 20 mL/h.) Diuretics can cause increased sodium excretion. Thus, if the FE_{NA} is high within 12–24 hours after diuretic administration, the cause of acute kidney injury may not be accurately predicted. Acute kidney injury due to glomerulonephritis can have a low FE_{NA} because sodium reabsorption and tubular function may not be compromised.

Treatment of prerenal insults depends entirely on the causes, but maintenance of euvolemia, attention to serum potassium, and avoidance of nephrotoxic drugs are benchmarks of therapy. This involves careful assessment of volume status, cardiac function, diet, and drug usage.

B. Postrenal Causes

Postrenal causes are the least common reason for acute kidney injury, accounting for approximately 5–10% of cases, but important to detect because of their reversibility. Postrenal azotemia occurs when urinary flow from both kidneys, or a single functioning kidney, is obstructed. Occasionally,

postrenal uropathies can occur when a single kidney is obstructed if the contralateral kidney cannot adjust for the loss in function, (eg, in a patient with advanced CKD). Obstruction leads to elevated intraluminal pressure, causing kidney parenchymal damage, with marked effects on renal blood flow and tubular function, and a decrease in GFR.

Postrenal causes include urethral obstruction, bladder dysfunction or obstruction, and obstruction of both ureters or renal pelvises. In men, benign prostatic hyperplasia is the most common cause. Patients taking anticholinergic drugs are particularly at risk. Obstruction can also be caused by bladder, prostate, and cervical cancers; retroperitoneal fibrosis and other processes; and neurogenic bladder. Less common causes are blood clots, bilateral ureteral stones, urethral stones or stricture, and bilateral papillary necrosis.

Patients may be anuric or polyuric and may complain of lower abdominal pain. Polyuria can occur in the setting of partial obstructions with resultant tubular dysfunction and an inability to appropriately reabsorb salt and water loads. Obstruction can be constant or intermittent and partial or complete. On examination, the patient may have an enlarged prostate, distended bladder, or mass detected on pelvic examination.

Laboratory examination may initially reveal high urine osmolality, low urine sodium, high BUN:creatinine ratio, and low FE_{NA} (as tubular function may not be compromised initially). These indices are similar to a prerenal picture because extensive intrinsic renal damage has not occurred. After several days, the urine sodium increases as the kidneys fail and are unable to concentrate the urine—thus, isosthenuria is present. The urine sediment is generally benign.

Patients with acute kidney injury and suspected postrenal insults should undergo bladder catheterization and ultrasonography to assess for hydronephrosis and hydronephrosis. After reversal of the underlying process, these patients often undergo a postobstructive saluresis and diuresis, and care should be taken to avoid volume depletion. Rarely, obstruction is not diagnosed by ultrasonography. For example, patients with retroperitoneal fibrosis from tumor or radiation may not show dilation of the urinary tract. If suspicion does exist, a CT scan or MRI can establish the diagnosis. Prompt treatment of obstruction within days by catheters, stents, or other surgical procedures can result in partial or complete reversal of the acute process.

C. Intrinsic Acute Kidney Injury

Intrinsic renal disorders account for up to 50% of all cases of acute kidney injury. Intrinsic dysfunction is considered after prerenal and postrenal causes have been excluded. The sites of injury are the tubules, interstitium, vasculature, and glomeruli.

▶ When to Refer

- If a patient has signs of acute kidney injury that have not reversed over 1–2 weeks, but no signs of acute uremia, the patient can usually be referred to a nephrologist rather than admitted.
- If a patient has signs of persistent urinary tract obstruction, the patient should be referred to a urologist.

▶ When to Admit

The patient should be admitted if there is sudden loss of kidney function resulting in abnormalities that cannot be handled expeditiously in an outpatient setting (eg, hyperkalemia, volume overload, uremia) or other requirements for acute intervention, such as emergent urologic intervention or dialysis.

Jun M et al. Intensities of renal replacement therapy in acute kidney injury: a systematic review and meta-analysis. *Clin J Am Soc Nephrol*. 2010 Jun;5(6):956–63. [PMID: 20395356]

Kinsey GR et al. Pathogenesis of acute kidney injury: foundation for clinical practice. *Am J Kidney Dis*. 2011 Aug;58(2):291–301. [PMID: 21530035]

Lafrance JP et al. Acute kidney injury associates with increased long-term mortality. *J Am Soc Nephrol*. 2010 Feb;21(2):345–52. [PMID: 20019168]

Stevens LM et al. JAMA patient page. Kidney failure. *JAMA*. 2009 Feb 11;301(6):686. [PMID: 19211477]

ACUTE TUBULAR NECROSIS



ESSENTIALS OF DIAGNOSIS

- ▶ Acute kidney injury.
- ▶ Ischemic or toxic insult.
- ▶ Urine sediment with pigmented granular casts and renal tubular epithelial cells is pathognomonic but not essential.

▶ General Considerations

Acute kidney injury due to tubular damage is termed “acute tubular necrosis” and accounts for approximately 85% of intrinsic acute kidney injury. The two major causes of acute tubular necrosis are ischemia and nephrotoxin exposure. Ischemia causes tubular damage from states of prolonged low kidney perfusion, often termed a “prerenal” state, with resultant tubular necrosis and apoptosis. Ischemic acute kidney injury is characterized not only by inadequate GFR but also by renal blood flow inadequate to maintain parenchymal cellular formation. This occurs in the setting of prolonged hypotension or hypoxemia, such as volume depletion, shock, and sepsis. Major surgical procedures can involve prolonged periods of hypoperfusion, which are exacerbated by vasodilating anesthetic agents. Aside from the serum creatinine, other urinary and serum biomarkers, including neutrophil gelatinase-associated lipocalin and cystatin C, are being investigated in order to diagnose and treat acute kidney injury earlier in its course, with the potential for better outcomes.

Exogenous nephrotoxins more commonly cause damage than endogenous nephrotoxins.

A. Exogenous Nephrotoxins

Aminoglycosides cause some degree of acute tubular necrosis in up to 25% of hospitalized patients receiving

therapeutic levels of the drugs. Nonoliguric kidney injury typically starts to occur after 5–10 days of exposure. Predisposing factors include underlying kidney damage, volume depletion, and advanced age. Aminoglycosides can remain in renal tissues for up to a month, so kidney function may not recover for some time after stopping the medication. Monitoring of peak and trough levels is important, but trough levels are more helpful in predicting renal toxicity. Gentamicin is as nephrotoxic as tobramycin; streptomycin is the least nephrotoxic of the aminoglycosides, likely due to the number of cationic amino side chains present on each molecule.

Amphotericin B is typically nephrotoxic after a dose of 2–3 g. This causes a type I renal tubular acidosis with severe vasoconstriction and distal tubular damage, which can lead to hypokalemia and nephrogenic diabetes insipidus. **Vancomycin**, intravenous **acyclovir**, and several **cephalosporins** have been known to cause acute tubular necrosis.

Radiographic contrast media may be directly nephrotoxic. Contrast nephropathy is the third leading cause of new acute kidney injury in hospitalized patients. It probably results from the synergistic combination of direct renal tubular epithelial cell toxicity and renal medullary ischemia. Predisposing factors include advanced age, preexisting kidney disease (serum creatinine >2 mg/dL), volume depletion, diabetic nephropathy, congestive heart failure, multiple myeloma, repeated doses of contrast, and recent exposure to other nephrotoxic agents, including NSAIDs and ACE inhibitors. The combination of preexisting diabetes mellitus and kidney dysfunction poses the greatest risk (15–50%) for contrast nephropathy. Lower volumes of contrast with lower osmolality are recommended in high-risk patients. Toxicity usually occurs within 24–48 hours after the radiocontrast study. Nonionic contrast media may be less toxic, but this has not been well proven. Prevention should be the goal when using these agents. The mainstay of therapy is a liter of intravenous 0.9% saline over 10–12 hours both before and after the contrast administration—cautiously in patients with preexisting cardiac dysfunction. Neither mannitol nor furosemide offers benefit over 0.9% (normal) saline administration. In fact, furosemide may lead to increased rates of renal dysfunction in this setting. In some but not all studies, *N*-acetylcysteine given before and after contrast decreases the incidence of dye-induced nephrotoxicity. Acetylcysteine is a thiol-containing antioxidant with little toxicity whose mechanism of action is unclear. It is rarely given unless a patient has a preexisting risk factor. With little harm and possible benefit, administering acetylcysteine 600 mg orally every 12 hours twice, before and after a dye load, for patients at risk for acute kidney injury, is a reasonable strategy. Intravenous *N*-acetylcysteine, 1200 mg prior to an emergent procedure, has shown benefit compared with placebo and may be a good option if a patient needs contrast dye urgently. One large prospective randomized controlled trial showed no benefit of *N*-acetylcysteine in over 2300 patients randomized to either 1200 mg orally twice versus placebo prior to and after angiographic procedures. The primary endpoint was a 25% increase in serum creatinine within 48–96 hours after the procedure. Some

investigators have shown a benefit using sodium bicarbonate (154 mEq/L, intravenously at 3 mL/kg/h for 1 hour before the procedure, then 1 mL/kg/h for 6 hours after the procedure) over a more conventional regimen of normal saline as the isotonic volume expander. However, others have shown sodium bicarbonate was not superior to sodium chloride when using similar administration regimens. Other nephrotoxic agents should be avoided during the day before and after dye administration.

Cyclosporine toxicity is usually dose dependent. It causes distal tubular dysfunction (a type 4 renal tubular acidosis) from severe vasoconstriction. Regular blood level monitoring is important to prevent both acute and chronic nephrotoxicity. With patients who are taking cyclosporine for renal transplant rejection, kidney biopsy is often necessary to distinguish transplant rejection from cyclosporine toxicity. Renal function usually improves after reducing the dose or stopping the drug.

Other exogenous nephrotoxins include antineoplastics, such as cisplatin and organic solvents, and heavy metals such as mercury, cadmium, and arsenic.

B. Endogenous Nephrotoxins

Endogenous nephrotoxins include heme-containing products, uric acid, and paraproteins. **Myoglobinuria** as a consequence of rhabdomyolysis leads to acute tubular necrosis. Necrotic muscle releases large amounts of myoglobin, which is freely filtered across the glomerulus. The myoglobin is reabsorbed by the renal tubules, and direct damage can occur. Distal tubular obstruction from pigmented casts and intrarenal vasoconstriction can also cause damage. This type of kidney injury occurs in the setting of crush injury, or muscle necrosis from prolonged unconsciousness, seizures, cocaine, and alcohol abuse. Dehydration and acidosis predispose to the development of myoglobinuric acute kidney injury. Patients may complain of muscular pain and often have signs of muscle injury. Rhabdomyolysis of clinical importance commonly occurs with a serum creatine kinase (CK) >20,000–50,000 international units/L. One study showed that 58% of patients with acute kidney injury from rhabdomyolysis had CK levels >16,000 international units/L. Only 11% of patients without kidney injury had CK values >16,000 international units/L. The globin moiety of myoglobin will cause the urine dipstick to read falsely positive for hemoglobin: the urine appears dark brown, but no red cells are present. With lysis of muscle cells, patients also become hyperkalemic, hyperphosphatemic, and hyperuricemic. Hypocalcemia may ensue due to phosphorus and calcium precipitation. The mainstay of treatment is volume repletion. Other adjunctive treatments include mannitol for free radical clearance and diuresis as well as alkalization of the urine. These modalities have not been proved to change outcomes in human trials. Hypocalcemia should not be treated unless the patient is symptomatic. As the patient recovers, calcium can move back from tissues to plasma, so early exogenous calcium administration is not recommended unless the patient has symptoms or the level becomes exceedingly low in an unconscious patient because

such repletion could result in hypercalcemia later in the course of the illness.

Hemoglobin can cause a similar form of acute tubular necrosis. Massive intravascular hemolysis is seen in transfusion reactions and in certain hemolytic anemias. Reversal of the underlying disorder and hydration are the mainstays of treatment.

Hyperuricemia can occur in the setting of rapid cell turnover and lysis. Chemotherapy for germ cell neoplasms and leukemia and lymphoma are the primary causes. Acute kidney injury occurs with intratubular deposition of uric acid crystals; serum uric acid levels are often >15–20 mg/dL and urine uric acid levels >600 mg/24 h. A urine uric acid to urine creatinine ratio >1.0 indicates risk of acute kidney injury.

Bence Jones protein seen in conjunction with multiple myeloma can cause direct tubular toxicity and tubular obstruction. Other renal complications from multiple myeloma include hypercalcemia and renal tubular dysfunction, including proximal renal tubular acidosis (see Multiple Myeloma, below).

► Clinical Findings

A. Symptoms and Signs

See Acute Kidney Injury.

B. Laboratory Findings

Hyperkalemia and hyperphosphatemia are commonly encountered. BUN:creatinine ratio is usually <20:1 because tubular function is not intact, per the mechanisms described in the general section on acute kidney injury (Table 22–4). Urinalysis may show evidence of acute tubular damage. The urine may be brown. Urinary output can be either oliguric or nonoliguric, with oliguria portending a worse prognosis. Urine sodium concentration is typically elevated, but the FE_{Na} is more indicative of tubular function, as discussed above. On microscopic examination, an active sediment may show pigmented granular casts or “muddy brown” casts. Renal tubular epithelial cells and epithelial cell casts can be present (see Table 22–1).

► Treatment

Treatment is aimed at hastening recovery and avoiding complications. Preventive measures should be taken to avoid volume overload and hyperkalemia. Loop diuretics have been used in large doses (eg, furosemide in doses ranging from 20 mg to 160 mg orally or intravenously twice daily, or as a continuous infusion) to affect adequate diuresis and may help convert oliguric to nonoliguric renal failure. Such a conversion has never been shown to affect outcomes such as mortality, though. One retrospective study has shown potentially worse outcomes in patients who receive doses of furosemide, including non-recovery of renal function and an increased risk of death. A prospective randomized controlled trial has shown no difference between the administration of large doses of diuretics versus placebo on either recovery from acute kidney injury or death. Widespread use of diuretics in

critically ill patients with acute kidney injury should thus be discouraged. Disabling side effects of supranormal dosing include hearing loss and cerebellar dysfunction. This is mainly due to peak furosemide levels; this risk can be minimized by the use of a furosemide drip. A starting dose of 0.1–0.3 mg/kg/h is appropriate, increasing to a maximum of 0.5–1 mg/kg/h. A bolus of 1–1.5 mg/kg should be administered at the beginning of each dose escalation. Intravenous thiazide diuretics can be used to augment urinary output; chlorothiazide, 250–500 mg intravenously every 8–12 hours, is a reasonable choice. Another good choice to augment diuresis is metolazone at doses of 2.5–5 mg given orally once to twice daily, 30 minutes prior to loop diuretics. It is less expensive than intravenous chlorothiazide and has reasonable bioavailability. Short-term effects of loop diuretics include activation of the renin–angiotensin system. One prospective randomized trial showed the long-term benefits of plasma ultrafiltration over the use of intravenous diuretics in patients with decompensated heart failure. This intervention can be considered in ICU patients with acute kidney injury in need of volume removal who are nonresponsive to diuretics. Nutritional support should maintain adequate intake while preventing excessive catabolism. Dietary protein restriction of 0.6 g/kg/d helps prevent metabolic acidosis. Hypocalcemia and hyperphosphatemia can be improved with diet and phosphate-binding agents, such as aluminum hydroxide (500 mg orally with meals) over the short term, and calcium carbonate (500–1500 mg orally three times daily), calcium acetate (667 mg, two or three tablets, orally before meals), sevelamer carbonate (800–1600 mg orally three times daily), and lanthanum carbonate (1000 mg orally with meals) over longer periods. Hypocalcemia should not be treated in patients with rhabdomyolysis unless they are symptomatic. Hypermagnesemia can occur because of reduced magnesium excretion by the renal tubules, so magnesium-containing antacids and laxatives should be avoided in these patients. Dosages of all medications must be adjusted according to the estimated degree of renal impairment for drugs eliminated by the kidney.

Indications for dialysis in acute kidney injury from acute tubular necrosis or other intrinsic disorders include life-threatening electrolyte disturbances (such as hyperkalemia), volume overload unresponsive to diuresis, worsening acidosis, and uremic complications (eg, encephalopathy, pericarditis, and seizures). In gravely ill patients, less severe but worsening abnormalities may also be indications for dialytic support. Two prospective randomized control trials, each with more than 1100 patients, showed that an intensive dialysis dose was not superior to a more conventional dose.

▶ Course & Prognosis

The clinical course of acute tubular necrosis is often divided into three phases: initial injury, maintenance, and recovery. The maintenance phase is expressed as either oliguric (urinary output < 500 mL/d) or nonoliguric. Nonoliguric acute tubular necrosis has a better outcome. Conversion from oliguric to nonoliguric states may be attempted but has not been shown to change the prognosis. Drugs such as dopamine and diuretics are sometimes used

for this purpose but have not been shown to improve outcomes. In numerous studies, dopamine use in this setting has no benefit. Average duration of the maintenance phase is 1–3 weeks but may be several months. Cellular repair and removal of tubular debris occur during this period. The recovery phase can be heralded by diuresis. GFR begins to rise; BUN and serum creatinine fall.

The mortality rate associated with acute kidney injury is 20–50% in hospitalized settings, and up to 70% with additional comorbid illnesses. Increased mortality is associated with advanced age, severe underlying disease, and multi-system organ failure. Leading causes of death are infections, fluid and electrolyte disturbances, and worsening of underlying disease. Mortality rates may be starting to improve slightly according to two retrospective cohort studies conducted within the last 10 years.

▶ When to Refer

- A patient with acute tubular necrosis should be referred to a nephrologist when the etiology is unclear or renal function continues to worsen despite intervention.
- Also, referral is appropriate if fluid, electrolyte, and acid-base abnormalities are recalcitrant to interventions.
- Studies have shown that nephrology referral improves outcome in acute kidney injury.

▶ When to Admit

Admission is appropriate when a patient has symptoms or signs of acute kidney injury that require immediate intervention, such as intravenous fluids, dialytic therapy, or that requires a team approach that cannot be coordinated as an outpatient.

INTERSTITIAL NEPHRITIS



ESSENTIALS OF DIAGNOSIS

- ▶ Fever.
- ▶ Transient maculopapular rash.
- ▶ Acute or chronic kidney injury.
- ▶ Pyuria (including eosinophiluria), white blood cell casts, and hematuria.

▶ General Considerations

Acute interstitial nephritis accounts for 10–15% of cases of intrinsic renal failure. An interstitial inflammatory response with edema and possible tubular cell damage is the typical pathologic finding. Cell-mediated immune reactions prevail over humoral responses. T lymphocytes can cause direct cytotoxicity or release lymphokines that recruit monocytes and inflammatory cells.

Although drugs account for over 70% of cases, acute interstitial nephritis also occurs in infectious diseases, immunologic disorders, or as an idiopathic condition. The most common drugs are penicillins and cephalosporins,

sulfonamides and sulfonamide-containing diuretics, NSAIDs, rifampin, phenytoin, and allopurinol. Proton pump inhibitors have also been recognized as a cause of acute interstitial nephritis. Infectious causes include streptococcal infections, leptospirosis, cytomegalovirus, histoplasmosis, and Rocky Mountain spotted fever. Immunologic entities are more commonly associated with glomerulonephritis, but systemic lupus erythematosus, Sjögren syndrome, sarcoidosis, and cryoglobulinemia can cause interstitial nephritis.

► Clinical Findings

Clinical features can include fever (> 80%), rash (25–50%), arthralgias, and peripheral blood eosinophilia (80%). The classic triad of fever, rash, and arthralgias is present in only 10–15% of cases. The urine often contains red cells (95%), white cells, and white cell casts. Proteinuria can be a feature, particularly in NSAID-induced interstitial nephritis, but is usually modest (< 2 g/24 h). Eosinophiluria is neither very sensitive nor specific and can be detected by Wright or Hansel stain.

► Treatment & Prognosis

Acute interstitial nephritis often carries a good prognosis. Recovery occurs over weeks to months, but urgent dialytic therapy may be necessary in up to one-third of all referred patients before resolution. Patients rarely progress to ESRD. Those with prolonged courses of oliguric failure and advanced age have a worse prognosis. Treatment consists of supportive measures and removal of the inciting agent. If kidney injury persists after these steps, a short course of corticosteroids can be given, although the data to support use of corticosteroids are not substantial. Short-term, high-dose methylprednisolone (0.5–1 g/d intravenously for 1–4 days) or prednisone (60 mg/d orally for 1–2 weeks) followed by a prednisone taper can be used in these more severe cases of drug-induced interstitial nephritis.

GLOMERULONEPHRITIS



ESSENTIALS OF DIAGNOSIS

- ▶ Hematuria, dysmorphic red cells, red cell casts, and mild proteinuria.
- ▶ Dependent edema and hypertension.
- ▶ Acute renal insufficiency.

► General Considerations

Acute glomerulonephritis is a relatively uncommon cause of acute kidney injury, accounting for about 5% of cases. Pathologically, inflammatory glomerular lesions are seen. These include mesangioproliferative, focal and diffuse proliferative, and crescentic lesions. The larger the percentage of glomeruli involved and the more severe the lesion, the more likely it is that the patient will have a poor clinical outcome.

Categorization of acute glomerulonephritis can be done by serologic analysis. Markers include anti-GBM antibodies, antineutrophil cytoplasmic antibodies (ANCA), and other immune markers of disease.

Immune complex deposition usually occurs when moderate antigen excess over antibody production occurs. Complexes formed with marked antigen excess tend to remain in the circulation. Antibody excess with large antigen–antibody aggregates usually results in phagocytosis and clearance of the precipitates by the mononuclear phagocytic system in the liver and spleen. Causes include IgA nephropathy (Berger disease), peri-infectious or post-infectious glomerulonephritis, endocarditis, lupus nephritis, cryoglobulinemic glomerulonephritis (often associated with hepatitis C virus), and MPGN.

Anti-GBM-associated acute glomerulonephritis is either confined to the kidney or associated with pulmonary hemorrhage. The latter is termed “Goodpasture syndrome.” Injury is related to autoantibodies aimed against type IV collagen in the GBM rather than to immune complex deposition.

Pauci-immune acute glomerulonephritis is a form of small-vessel vasculitis associated with ANCA, causing primary and secondary kidney diseases that do not have direct immune complex deposition or antibody binding. Tissue injury is believed to be due to cell-mediated immune processes. An example is granulomatosis with polyangiitis, a systemic necrotizing vasculitis of small arteries and veins associated with intravascular and extravascular granuloma formation. In addition to glomerulonephritis, these patients can have upper airway, pulmonary, and skin manifestations of disease. Cytoplasmic ANCA (c-ANCA) is a common pattern. Microscopic polyangiitis is another pauci-immune vasculitis causing acute glomerulonephritis. Perinuclear staining (p-ANCA) is the common pattern. ANCA-associated and anti-GBM-associated acute glomerulonephritis can evolve to crescentic glomerulonephritis and often have poor outcomes unless treatment is started early. Both are described more fully below.

Other vascular causes of acute glomerulonephritis include hypertensive emergencies and the thrombotic microangiopathies such as hemolytic-uremic syndrome and thrombotic thrombocytopenic purpura (see Chapter 14).

► Clinical Findings

A. Symptoms and Signs

Patients with acute glomerulonephritis are often hypertensive and edematous, and have an abnormal urinary sediment. The edema is found first in body parts with low tissue tension, such as the periorbital and scrotal regions.

B. Laboratory Findings

Serum creatinine can rise over days to months, depending on the rapidity of the underlying process. The BUN:creatinine ratio is not a reliable marker of kidney function and is more reflective of the underlying volume status of the patient. Dipstick and microscopic evaluation will reveal evidence of hematuria, moderate proteinuria (usually < 3 g/d), and cellular elements such as red cells, red cell casts, and white cells. Red cell casts are specific for glomerulonephritis, and a

detailed search is warranted. Either spot urinary protein-creatinine ratios or 24-hour urine collections can quantify protein excretion; the latter can quantify creatinine clearance when renal function is stable. However, in cases of rapidly changing serum creatinine values, the urinary creatinine clearance is an unreliable marker of GFR. The FE_{NA} is usually low unless the renal tubulo-interstitial space is affected, and renal dysfunction is marked (see Table 22–4).

Further tests include complement levels (C3, C4, CH50), ASO titer, anti-GBM antibody levels, ANCAs, antinuclear antibody titers, cryoglobulins, hepatitis serologies, blood cultures, renal ultrasound, and occasionally renal biopsy.

► Treatment

Depending on the nature and severity of disease, treatment can consist of high-dose corticosteroids and cytotoxic agents such as cyclophosphamide. Plasma exchange can be used in Goodpasture disease and pauci-immune glomerulonephritis as a temporizing measure until chemotherapy can take effect. Treatment and prognosis for specific diseases are discussed more fully below.

- Cruz DN et al. Clinical review: RIFLE and AKIN—time for reappraisal. *Crit Care*. 2009;13(3):211. [PMID: 19638179]
 Hoste EA et al. Epidemiology of acute kidney injury. *Contrib Nephrol*. 2010;165:1–8. [PMID: 20427949]
 Lafrance JP et al. Acute kidney injury associates with increased long-term mortality. *J Am Soc Nephrol*. 2010 Feb;21(2):345–52. [PMID: 20019168]
 Navaneethan SD et al. Sodium bicarbonate therapy for prevention of contrast-induced nephropathy: a systematic review and meta-analysis. *Am J Kidney Dis*. 2009 Apr;53(4):617–27. [PMID: 19027212]
 Perazella MA et al. Diagnostic value of urine microscopy for differential diagnosis of acute kidney injury in hospitalized patients. *Clin J Am Soc Nephrol*. 2008 Nov;3(6):1615–9. [PMID: 18784207]
 Vaidya VS et al. Urinary biomarkers for sensitive and specific detection of acute kidney injury in humans. *Clin Transl Sci*. 2008 Dec;1(3):200–8. [PMID: 19212447]

CARDIORENAL SYNDROME



ESSENTIALS OF DIAGNOSIS

- Cardiac dysfunction: signs or symptoms of heart failure, ischemic injury or arrhythmias.
- Kidney disease: acute or chronic, depending on type of cardiorenal syndrome.

► General Considerations

Cardiorenal syndrome is a pathophysiologic disorder of the heart and kidneys wherein the acute or chronic deterioration of one organ results in the acute or chronic deterioration of the other. This syndrome has been classified into five types.

Type 1 consists of acute kidney injury stemming from acute cardiac disease. Type 2 is CKD due to chronic cardiac disease. Type 3 is acute cardiac disease as a result of acute

kidney injury. Type 4 is chronic cardiac decompensation from CKD. Type 5 consists of heart and kidney dysfunction due to other acute or chronic systemic disorders (such as sepsis). Identifying and defining this common syndrome may assist in the future with treatments to improve its morbidity and mortality.

CHRONIC KIDNEY DISEASE



ESSENTIALS OF DIAGNOSIS

- Decline in the GFR over months to years
- Persistent proteinuria or abnormal renal morphology.
- Symptoms and signs of uremia when nearing end-stage disease.
- Hypertension in most cases.
- Bilateral small kidneys on ultrasound in advanced disease.

► General Considerations

CKD affects more than 20 million Americans, or one in nine adults. Most are unaware of the condition because they remain asymptomatic until the disease has significantly progressed. The National Kidney Foundation's staging system helps clinicians formulate practice plans (Table 22–5). Over 70% of cases of late-stage CKD (stage 5 CKD and ESRD) in the United States are due to diabetes mellitus or hypertension. Glomerulonephritis, cystic diseases, and other urologic diseases account for another 12%, and 15% of patients have other or unknown causes (Table 22–6). Recently, genetic polymorphisms of the *APOL-1* gene has been shown to be associated with an increased risk of the development of CKD in African Americans.

CKD is rarely reversible and usually leads to a progressive decline in kidney function even after the inciting event has been removed. Destruction of nephrons (inciting event) leads to compensatory hypertrophy of the remaining nephrons, which must increase their individual GFRs to supranormal in order to maintain overall homeostasis. One consequence of this compensatory hyperfiltration is that the serum creatinine may remain relatively normal even in the face of significant loss of renal mass; therefore, it is a relatively insensitive marker for renal damage and scarring. In addition, compensatory hyperfiltration leads to overwork injury in the remaining nephrons, which in turn causes progressive glomerular sclerosis and interstitial fibrosis. Angiotensin receptor blockers (ARBs) and ACE inhibitors can help reduce hyperfiltration injury and are particularly helpful in slowing the progression of proteinuric CKD. Fortunately, an individual's decreased renal mass as a result of kidney donation is not associated with the development of CKD later in life.

CKD is an independent risk factor for cardiovascular disease; proteinuric CKD confers an even higher risk of cardiovascular mortality.

Table 22-5. Stages of chronic kidney disease: A clinical action plan.^{1,2}

Stage	Description	GFR (mL/min/1.73 m ²)	Action ³
1	Kidney damage with normal or ↑ GFR	≥ 90	Diagnosis and treatment. Treatment of comorbid conditions. Slowing of progression. Cardiovascular disease risk reduction.
2	Kidney damage with mildly ↓ GFR	60-89	Estimating progression.
3	Moderately ↓ GFR	30-59	Evaluating and treating complications.
4	Severely ↓ GFR	15-29	Preparation for kidney replacement therapy.
5	End-stage renal disease (ESRD)	< 15 (or dialysis)	Replacement (if uremia is present).

¹From National Kidney Foundation, KDOQI, Chronic Kidney Disease Guidelines.

²Chronic kidney disease is defined as either kidney damage or GFR < 60 mL/min/1.73 m² for 3 or more months. Kidney damage is defined as pathologic abnormalities or markers of damage, including abnormalities in blood or urine tests or imaging studies.

³Includes actions from preceding stages.

GFR, glomerular filtration rate.

Clinical Findings

A. Symptoms and Signs

In the early stages, CKD is asymptomatic. Symptoms develop slowly with the progressive decline in GFR, are nonspecific, and do not manifest until kidney disease is far advanced (GFR < 10–15 mL/min/1.73 m²). At this point, the build-up of metabolic waste products, or uremic toxins, can result in the uremic syndrome (Table 22-7). General

Table 22-6. Major causes of chronic kidney disease.

Glomerular diseases
Primary glomerular diseases
Focal and segmental glomerulosclerosis
Membranoproliferative glomerulonephritis
IgA nephropathy
Membranous nephropathy
Alport syndrome (hereditary nephritis)
Secondary glomerular diseases
Diabetic nephropathy
Amyloidosis
Postinfectious glomerulonephritis
HIV-associated nephropathy
Collagen-vascular diseases (eg, SLE)
HCV-associated membranoproliferative glomerulonephritis
Tubulointerstitial nephritis
Drug hypersensitivity
Heavy metals
Analgesic nephropathy
Reflux/chronic pyelonephritis
Sickle cell nephropathy
Idiopathic
Cystic diseases
Polycystic kidney disease
Medullary cystic disease
Obstructive nephropathies
Prostatic disease
Nephrolithiasis
Retroperitoneal fibrosis/tumor
Congenital
Vascular diseases
Hypertensive nephrosclerosis
Renal artery stenosis

HCV, hepatitis C virus; SLE, systemic lupus erythematosus.

Table 22-7. Symptoms and signs of uremia.

Organ System	Symptoms	Signs
General	Fatigue, weakness	Sallow-appearing, chronically ill
Skin	Pruritus, easy bruisability	Pallor, ecchymoses, excoriations, edema, xerosis
ENT	Metallic taste in mouth, epistaxis	Urinous breath
Eye		Pale conjunctiva
Pulmonary	Shortness of breath	Rales, pleural effusion
Cardiovascular	Dyspnea on exertion, retrosternal pain on inspiration (pericarditis)	Hypertension, cardiomegaly, friction rub
Gastrointestinal	Anorexia, nausea, vomiting, hiccups	
Genitourinary	Nocturia, erectile dysfunction	Isosthenuria
Neuromuscular	Restless legs, numbness and cramps in legs	
Neurologic	Generalized irritability and inability to concentrate, decreased libido	Stupor, asterixis, myoclonus, peripheral neuropathy

symptoms of uremia may include fatigue, weakness, and malaise. GI symptoms, such as anorexia, nausea, vomiting, and a metallic taste in the mouth, are common. Neurologic problems may include irritability, difficulty in concentrating, insomnia, subtle memory defects, restless legs, paresthesias, and twitching. Pruritus is common and difficult to treat. Alterations in sexual function, including decreased libido, and menstrual irregularities are common. Chest pain is rare but can occur with pericarditis. Drug toxicity can develop as renal clearance worsens; in particular, hypoglycemia may become problematic, and even life-threatening, in diabetics since insulin is eliminated by the kidneys.

The most common physical finding in CKD is hypertension. It is often present in early stages of CKD and may worsen with CKD progression. The uremic patient (CKD stage 5) appears chronically ill. The skin may be sallow, with easy bruisability. Rarely seen in the current era is uremic frost, a cutaneous reflection of ESRD. Uremic fetor is the characteristic fishy odor of the breath. Cardiopulmonary signs may include rales, cardiomegaly, jugular venous distention, edema, and a pericardial friction rub (rarely). Mental status can vary from decreased concentration to confusion, stupor, and coma. Myoclonus and asterixis may be signs of uremia.

Symptoms and signs of uremia warrant immediate hospital admission and nephrology consultation for initiation of dialysis. The uremic syndrome resolves or lessens significantly with dialytic therapy.


In any patient with kidney disease, it is important to identify and correct all possibly reversible insults or exacerbating factors (Table 22–8). Urinary tract infections, obstruction, extracellular fluid volume depletion, hypotension, nephrotoxins (such as NSAIDs), severe or emergent hypertension, and congestive heart failure should be excluded. Any of the above can worsen underlying CKD.

Table 22–8. Reversible causes of kidney injury.

Reversible Factors	Diagnostic Clues
Infection	Urine culture and sensitivity tests
Obstruction	Bladder catheterization, then renal ultrasound
Extracellular fluid volume depletion or significant hypotension relative to baseline	Blood pressure and pulse, including orthostatic pulse
Hypokalemia, hypercalcemia, and hyperuricemia (usually > 15 mg/dL)	Serum electrolytes, calcium, phosphate, uric acid
Nephrotoxic agents	Drug history
Severe/urgent hypertension	Blood pressure, chest radiograph
Congestive heart failure	Physical examination, chest radiograph

B. Laboratory Findings

The diagnosis of CKD is made by documenting elevations of the serum creatinine over at least 3 months. Persistent proteinuria or abnormalities on renal imaging (eg, polycystic kidneys) are also diagnostic of CKD, even when estimated GFR is normal. It is helpful to plot the inverse of serum creatinine ($1/S_{Cr}$) versus time or estimated GFR (if reported by the laboratory) versus time. If three or more prior measurements are available, the time to ESRD can thus be estimated (Figure 22–1). If the slope of the line acutely declines, new and potentially reversible renal insults should be excluded as outlined above. Anemia, hyperphosphatemia, hypocalcemia, hyperkalemia, and metabolic acidosis can occur with both acute kidney disease and CKD. The urinalysis shows isosthenuria if tubular concentrating and diluting ability are impaired. The urinary sediment can show broad waxy casts as a result of dilated, hypertrophic nephrons. Proteinuria may be present. If so, it should be quantified as described above. Quantification of urinary protein is important for several reasons. First, it helps narrow the differential diagnosis of the etiology of the CKD (Table 22–6); for example, glomerular diseases tend to present with protein excretion of > 1 g/d. Second, the presence of proteinuria is associated with more rapid progression of CKD and cardiovascular mortality.



¹ Value of serum creatinine level = 1.0 mg/dL

² Value of serum creatinine level = 2.0 mg/dL

³ Value of serum creatinine level = 5.0 mg/dL

▲ **Figure 22–1.** Decline in kidney function (expressed as the reciprocal of serum creatinine as shown here, or as estimated glomerular filtration rate [eGFR]) plotted against time to end-stage renal disease (ESRD). The solid line indicates the linear decline in kidney function over time. The dotted line indicates the approximate time to ESRD.

C. Imaging

The finding of small echogenic kidneys bilaterally (<9–10 cm) by ultrasonography supports a diagnosis of CKD, although normal or even large kidneys can be seen with adult polycystic kidney disease, diabetic nephropathy, HIV-associated nephropathy, multiple myeloma, amyloidosis, and obstructive uropathy.

► Complications

The complications of CKD tend to occur at relatively predictable stages of disease as noted in Figure 22–2.

A. Cardiovascular Complications


Patients with CKD experience greater morbidity and mortality from cardiovascular disease in comparison to the general population. Death from cardiovascular causes accounts for 45% of all deaths of patients receiving dialysis. Eighty to 90 percent of patients with CKD die, primarily of cardiovascular disease, before reaching need for dialysis. The precise biologic mechanisms for this enhanced mortality are unclear but may have to do with the uremic milieu including abnormal phosphorus and calcium homeostasis, increased burden of oxidative stress, increased vascular reactivity, increased left ventricular hypertrophy, and underlying coexistent comorbidities such as hypertension and diabetes mellitus.

1. Hypertension—Hypertension is the most common complication of CKD. As kidney disease progresses, hypertension due to salt and water retention usually develops. Hyperreninemic states and exogenous erythropoietin administration can also exacerbate hypertension.

As with other patient populations, control of hypertension should focus on both nonpharmacologic therapy (eg, diet, exercise, weight loss, treatment of obstructive sleep apnea) and pharmacologic therapy. CKD results in disturbed sodium homeostasis such that the ability of the

kidney to adjust to variations in sodium and water intake becomes limited as GFR declines. The clinician should recommend institution of a diet with mildly decreased salt intake (3 g/d), and salt intake should be reduced to 2 g/d if hypertension persists or signs of CHF develop. Diuretics are nearly always needed to help control hypertension. However, volume contraction as a result of very low sodium intake or over-diuresis in the presence of impaired sodium homeostasis can result in further impairment of the GFR. In addition to diuretics, initial drug therapy should include ACE inhibitors or ARBs as recommended by national guidelines (if serum potassium permits). When an ACE inhibitor or an ARB is initiated or uptitrated, patients should have serum creatinine and potassium checked within 5–14 days. Hyperkalemia or a rise in serum creatinine > 30% from baseline mandates reduction or cessation of the drug. Second-line antihypertensive agents include calcium channel-blocking agents and β -blocking agents. Because of the difficulty in controlling hypertension in CKD, additional agents from other classes are often needed. Current guidelines suggest a blood pressure goal of 130/80 mm Hg for patients with CKD; a goal of 125/75 mm Hg is recommended for patients with proteinuria. It should be noted that treatment of blood pressure significantly below these goals is not supported by current data and may be dangerous in some populations, such as the elderly. Ongoing randomized controlled trials are looking at the benefit of systolic blood pressure goals of < 120 mm Hg versus < 140 mm Hg regarding outcomes such as ESRD and cardiac death in high-risk populations.

2. Coronary artery disease—Patients with CKD are at higher risk for death from cardiovascular disease than the general population. Traditional modifiable risk factors for cardiovascular disease, such as hypertension, tobacco use, and hyperlipidemia, should be aggressively treated in patients with CKD. Uremic vascular calcification involving disordered phosphorus homeostasis and other mediators may also be a cardiovascular risk factor in these patients.




▲ **Figure 22–2.** Complications of chronic kidney disease (CKD) by stage and glomerular filtration rate (GFR). Complications arising from CKD tend to occur at the stages depicted, although there is considerable variability noted in clinical practice. HTN, hypertension; PTH, parathyroid hormone. (Adapted, with permission, from William Bennett, MD.)

3. Congestive heart failure—The complications of CKD result in increased cardiac workload via underlying hypertensive disease, volume overload, and anemia. Patients with CKD may also have accelerated rates of atherosclerosis, and vascular calcification resulting in vessel stiffness. All of these factors contribute to left ventricular hypertrophy and diastolic dysfunction, which are present in most patients starting dialysis. Over time, systolic dysfunction may also develop. Water and salt restriction is usually necessary. Diuretics are of value if they can affect an increased urine volume, although thiazides are ineffective by themselves when the GFR is $< 20\text{--}30$ mL/min/1.73 m². Loop diuretics are commonly used, potentially in combination with thiazide diuretics, and higher doses are required as renal function declines. Digoxin is excreted by the kidney, and its toxicity is exacerbated in the presence of electrolyte disturbances which are common in CKD. The proven efficacy of ACE inhibitors in congestive heart failure holds true for patients with CKD. Despite the risks of hyperkalemia and worsening renal function, ACE inhibitors and ARBs can be used for patients with a serum creatinine > 3 mg/dL with close supervision and laboratory test monitoring.

4. Pericarditis—Pericarditis may develop in uremic patients but is rare. Symptoms include chest pain and fever. Pulsus paradoxus can be present; a friction rub may be auscultated, but the lack of a rub does not rule out a significant pericardial effusion. The chest radiograph can show an enlarged cardiac silhouette, and the ECG, generalized ST and T wave changes, characteristically a progression from diffuse ST elevation followed by a return to baseline and then T wave inversion. If pericardial effusion occurs, the ECG often shows nonspecific T wave changes and low QRS voltage; electrical alternans is a pathognomonic finding. Cardiac tamponade can occur; patients with tamponade have signs of poor cardiac output, with jugular venous distention and lungs clear to auscultation. Uremic pericarditis is a mandatory indication for hospitalization and initiation of hemodialysis.

B. Disorders of Mineral Metabolism

The metabolic bone disease of CKD refers to the complex disturbances of calcium and phosphorus metabolism, parathyroid hormone (PTH), active vitamin D, and possibly fibroblast growth factor-23 (FGF-23) homeostasis (see Chapter 21 and Figure 22–3). A typical pattern seen as early as CKD stage 3 is hyperphosphatemia, hypocalcemia, hypovitaminosis D, and secondary hyperparathyroidism as a result of the first three abnormalities. Traditionally, the emphasis on treating these disturbances centered around concern for the consequential bone disease and increased fracture risk noted in CKD patients. Now it is recognized that such disturbances also lead to vascular calcification and may be partly responsible for the accelerated cardiovascular disease and excess mortality seen in the CKD population. Epidemiologic studies in humans show an association between elevated phosphorus levels and increased risk of cardiovascular mortality in early CKD through ESRD. As yet, there are no intervention trials suggesting the best course of treatment in these patients; control of mineral and PTH levels per current guidelines is discussed below.



▲ **Figure 22-3.** Mineral abnormalities of chronic kidney disease (CKD). Decline in glomerular filtration rate (GFR) and loss of renal mass lead directly to increased serum phosphorus and hypovitaminosis D. Both of these abnormalities result in hypocalcemia and hyperparathyroidism. Many CKD patients also have nutritional 25(OH) vitamin D deficiency. PTH, parathyroid hormone.

Bone disease, or **renal osteodystrophy**, in advanced CKD is common and there are several types of lesions. Renal osteodystrophy can only be diagnosed by bone biopsy, which is rarely done. The most common bone disease, **osteitis fibrosa cystica**, is a result of secondary hyperparathyroidism and the osteoclast-stimulating effects of PTH. This is a high-turnover disease with osteoclastic bone resorption and subperiosteal lesions. **Metastatic calcifications**, such as tumoral calcinosis, can occur. Radiographically, lesions are most prominent in the phalanges and lateral ends of the clavicles. Adynamic bone disease, or low-bone turnover, is becoming more common and results from relatively low PTH levels or activity; it may result iatrogenically from suppression of PTH or via spontaneously low PTH production. **Osteomalacia**, or lack of bone mineralization, is another lesion associated with CKD. In the past, osteomalacia was associated with aluminum toxicity—either as a result of chronic ingestion of prescribed aluminum-containing phosphorus binders or from high levels of aluminum in untreated dialysate. Currently, osteomalacia is more likely to result from hypovitaminosis D; there is also theoretical risk of osteomalacia associated with use of bisphosphonates in advanced CKD.

All of the above entities can cause bony pain, proximal muscle weakness, and higher risk for fractures. Treatment involves correction of calcium, phosphorus, and 25-OH vitamin D levels toward normal values, along with treatment of hyperparathyroidism. Understanding the interplay between these abnormalities can help target therapy (Figure 22–3). Declining GFR leads to phosphorus retention. This results in hypocalcemia as phosphorus complexes with calcium, deposits in soft tissues, and stimulates PTH. Loss of renal mass, and low 25-OH vitamin D levels often seen in CKD patients results in low 1,25(OH) vitamin D production by the kidney. Because 1,25(OH) vitamin D is a suppressor of PTH production, hypovitaminosis D also leads to secondary hyperparathyroidism.

The first step in treatment of metabolic bone disease is control of hyperphosphatemia (defined as a serum phosphorus of ≤ 4.5 mg/dL in pre-ESRD CKD, or ≤ 5.5 mg/dL in ESRD patients). This involves dietary phosphorus

restriction initially, followed by the administration of oral phosphorus binders if targets are not achieved (see below). Dietary phosphorus restriction to 1000 mg/d can be challenging as many phosphorus sources are also rich in protein; care must be taken to avoid protein malnutrition. Oral phosphorus binders, such as calcium carbonate (650 mg/tablet) or calcium acetate (667 mg/capsule), block absorption of dietary phosphorus in the gut and are given three or four times daily at the beginning of meals. These should be titrated to a serum phosphorus of < 4.6 mg/dL in stage 3–4 of CKD (GFR of 15–59 mL/min) and < 4.6–5.5 mg/dL in ESRD patients. National guidelines recommend maximal elemental calcium doses of 1500 mg/d (eg, nine tablets of calcium acetate); doses should be decreased if serum calcium rises above 10 mg/dL. Phosphorus-binding agents that do not contain calcium are sevelamer and lanthanum. Sevelamer, 800 mg orally, and lanthanum carbonate, 1000 mg orally, are given at the beginning of meals. Aluminum hydroxide is a highly effective phosphorus binder but can cause osteomalacia and neurologic complications when used long-term. While it can be used in the acute setting for serum phosphorus > 7 mg/dL or for short periods (eg, 3 weeks) in CKD patients, long-term use should be avoided.

Once serum phosphorus levels are controlled, active vitamin D (1,25[OH] vitamin D, or calcitriol) or active vitamin D analogs are recommended to treat secondary hyperparathyroidism in stage 3–5 CKD. Serum 25-OH vitamin D levels should be measured and brought to normal (see Chapter 26) prior to considering administration of active vitamin D. Active vitamin D (calcitriol) increases serum calcium and phosphorus levels; both need to be monitored closely during calcitriol therapy, and its dose should be decreased if hypercalcemia or hyperphosphatemia occurs. Typical calcitriol dosing is 0.25 or 0.5 mcg orally daily or every other day initially. Cinacalcet is a calcimimetic agent that targets the calcium-sensing receptor on the chief cells of the parathyroid gland and suppresses PTH production. Cinacalcet, 30–90 mg orally once a day, can be used if elevated serum phosphorus or calcium levels prohibit the use of vitamin D analogs; cinacalcet can cause hypocalcemia. Optimal PTH levels in CKD are not known, but because skeletal resistance to PTH develops with uremia, relatively high levels are targeted in advanced CKD to avoid adynamic bone disease. Expert guidelines generally suggest goal PTH levels near or just above the upper limit of normal for moderate CKD, and at least twofold and up to ninefold the upper limit of normal for ESRD.

C. Hematologic Complications

1. Anemia—The anemia of CKD is primarily due to decreased erythropoietin production, which often becomes clinically significant during stage 3 CKD. Many patients are iron deficient as well due to impaired GI iron absorption.

Erythropoiesis-stimulating agents (eg, recombinant erythropoietin [epoetin] and darbepoetin) are FDA-approved in CKD for a goal hemoglobin (Hgb) of 10–11 g/dL if no other treatable causes for anemia are present. One study in patients with CKD showed no benefit of starting erythropoietin-like agents before Hgb values were < 9 g/dL. The dose needed can vary; the starting dose of epoetin is

50 units/kg (3000–4000 units/dose) once or twice a week. Darbepoetin is started at 0.45 mcg/kg and can be administered every 2–4 weeks. These agents can be given intravenously (eg, to the hemodialysis patient) or subcutaneously (eg, to the predialysis or dialysis patient); subcutaneous dosing of erythropoietin is roughly 30% more effective than intravenous dosing. Erythropoiesis-stimulating agents should be titrated to a Hgb of 10–11 g/dL for optimal safety; studies show that targeting a higher Hgb increases risk of stroke and possibly other cardiovascular events. When titrating doses, Hgb levels should rise no more than 1 g/dL every 3–4 weeks. Hypertension is a complication of erythropoietin or darbepoetin therapy in about 20% of patients. The dosage may require adjustment, or antihypertensive drugs may need to be given.

Iron stores must be adequate to ensure response to erythropoiesis-stimulating agents. Patients with CKD tend to have progressively increasing level of hepcidin, a molecule that blocks GI iron absorption and mobilization of iron from body stores. Therefore, traditional measures of iron stores are measured in CKD patients but are considered abnormal at a higher reference level. In CKD, a serum ferritin < 100–200 ng/mL or iron saturation < 20% is suggestive of iron deficiency. Iron stores should be replenished with oral or parenteral iron prior to the initiation of erythropoietic agents. Iron therapy should be withheld if the serum ferritin is > 500–800 ng/mL, even if the iron saturation is < 20%. Oral therapy with ferrous sulfate, gluconate, or fumarate (the latter two tend to be better tolerated), 325 mg once to three times daily, is the initial therapy for patients who are not yet receiving dialysis. For those that do not respond due to poor GI absorption or lack of tolerance, intravenous iron may be necessary.

The preliminary investigation of anemia in any CKD patient should also include assessment of thyroid function tests, serum vitamin B₁₂, and red blood cell folate stores, and fecal occult blood testing prior to initiating erythropoiesis-stimulating agent therapy.

2. Coagulopathy—The coagulopathy of CKD is mainly caused by platelet dysfunction. Platelet counts may be mildly decreased, and the bleeding time is prolonged due to abnormal adhesiveness and aggregation. Clinically, patients can have petechiae, purpura, and an increased tendency for bleeding during surgery.

Treatment is required only in patients who are symptomatic. Raising the Hgb to 9–10 g/dL in anemic patients can reduce bleeding time via increased blood viscosity. Desmopressin (25 mcg intravenously every 8–12 hours for two doses) is a short-lived but effective treatment for platelet dysfunction and it is often used in preparation for surgery. Conjugated estrogens, 2.5–5 mg orally for 5–7 days, may have an effect for several weeks but is very seldom used. Dialysis improves the bleeding time but does not normalize it. Cryoprecipitate (10–15 bags) is rarely used and lasts < 24 hours.

D. Hyperkalemia

Potassium balance generally remains intact in CKD until stages 4–5. However, hyperkalemia may occur at earlier stages

when certain conditions are present, such as type 4 renal tubular acidosis (seen in patients with diabetes mellitus), high potassium diets, or medications that decrease renal potassium secretion (amiloride, triamterene, spironolactone, eplerenone, NSAIDs, ACE inhibitors, ARBs) or block cellular potassium uptake (β -blockers). Other causes include acidic states, and any type of cellular destruction causing release of intracellular contents (which are high in potassium), such as hemolysis and rhabdomyolysis.

Treatment of acute hyperkalemia is discussed in Chapter 21 (see Table 21–6). Cardiac monitoring is indicated for any ECG changes seen with hyperkalemia or a serum potassium level > 6.0 – 6.5 mEq/L. The ion exchange resin sodium polystyrene sulfonate exchanges sodium for potassium and results in GI potassium excretion and is often used to treat acute hyperkalemia in addition to β -agonists, insulin plus glucose, and calcium gluconate as indicated. Chronic hyperkalemia is best treated with dietary potassium restriction (2 g/d) and minimization or elimination of any medications that may impair renal potassium excretion, as noted above. Loop diuretics may also be administered for their kaliuretic effect as long as the patient is not volume-depleted.

E. Acid-Base Disorders

Damaged kidneys are unable to excrete the 1 mEq/kg/d of acid generated by metabolism of dietary animal proteins in the typical Western diet. The resultant metabolic acidosis is primarily due to loss of renal mass; distal tubular defects may contribute to or worsen the acidosis. Although patients with CKD are in positive hydrogen ion balance, the arterial blood pH is maintained at 7.33–7.37 and serum bicarbonate concentration rarely falls below 15 mEq/L. The excess hydrogen ions are buffered by the large calcium carbonate and calcium phosphate stores in bone. This results in leaching of calcium and phosphorus from the bone and contributes to the metabolic bone disease described above. To help mitigate damage to bone and encourage normal growth, the serum bicarbonate level should be maintained at > 21 mEq/L. The most commonly used alkali salt is sodium bicarbonate. Administration should begin with 20–30 mEq/d divided into two doses per day and titrated as needed. Citrate salts increase the absorption of dietary aluminum and should be avoided in CKD patients.

F. Neurologic Complications

Uremic encephalopathy, resulting from the aggregation of uremic toxins, does not occur until GFR falls below 5–10 mL/min/1.73 m². Symptoms begin with difficulty in concentrating and can progress to lethargy, confusion, and coma. Physical findings may include nystagmus, weakness, asterix, and hyperreflexia. These symptoms and signs improve after initiation of dialysis.

Neuropathy is found in 65% of CKD stage 5 and ESRD patients but can also be seen in patients with CKD stage 4. Peripheral neuropathies manifest themselves as sensorimotor polyneuropathies (stocking-glove distribution) and isolated or multiple isolated mononeuropathies; other

CKD-associated neuropathies result in erectile dysfunction and autonomic dysfunction. Patients may have restless leg syndrome, loss of deep tendon reflexes, and distal pain. The earlier initiation of dialysis may prevent peripheral neuropathies, although the response to dialysis is variable.

G. Endocrine Disorders

In advanced CKD, circulating insulin levels are higher because of decreased renal insulin clearance, and, in diabetics, there is risk of developing dangerous hypoglycemia if this phenomenon is not anticipated. Doses of oral hypoglycemics and insulin may need reduction. Metformin is associated with risk of lactic acidosis when estimated GFR is < 60 mL/min/1.73 m² and should be discontinued at this point.

Decreased libido and erectile dysfunction are common in advanced CKD. Men have decreased testosterone levels; women are often anovulatory. Women with serum creatinine < 1.4 mg/dL are not at increased risk for poor outcomes in pregnancy; however, those with serum creatinine > 1.4 mg/dL may experience faster progression of CKD with pregnancy. Fetal survival is not compromised, however, unless CKD is advanced. Despite a high degree of infertility in patients with ESRD, pregnancy can occur in this setting—particularly in women who are well dialyzed and well nourished. However, fetal mortality approaches 50%, and babies who survive are often premature. In female patients with ESRD, renal transplantation with a well-functioning allograft affords the best chances for a successful pregnancy.

► Treatment

A. Slowing Progression

Treatment of the underlying cause of CKD is vital. Control of diabetes should be aggressive in early CKD; risk of hypoglycemia increases in advanced CKD as described above, and glycemic targets may need to be relaxed to avoid this dangerous complication. Blood pressure control is vital to slow progression of all forms of CKD; agents that block the renin-angiotensin-aldosterone system are particularly important in proteinuric disease (see section on hypertension). Several small studies suggest a possible benefit of oral alkali therapy in slowing CKD progression when acidemia is present (see above); there is also theoretic value in lowering uric acid levels in those with concomitant hyperuricemia, but clinical data are lacking at this time. Management of traditional cardiovascular risk factors should also be emphasized.

B. Dietary Management

Every patient with CKD should be evaluated by a renal nutritionist. Specific recommendations should be made concerning protein, salt, water, potassium, and phosphorus intake to help manage CKD progression and complications.

1. Protein restriction—Experimental models have shown that protein restriction slows the progression to ESRD;

however, this has not been consistently proved in clinical trials. The questionable benefits of protein restriction in slowing the rate of decline of GFR must be weighed against the risk of cachexia upon the initiation of dialysis; low serum albumin at the start of dialysis is one of the strongest predictors of mortality in this population.

2. Salt and water restriction—In advanced CKD, the kidney is unable to adapt to large changes in sodium intake. Intake > 3–4 g/d can lead to edema, hypertension, and congestive heart failure, whereas intake of < 1 g/d can lead to volume depletion and hypotension. For the nondialysis patient approaching ESRD, 2 g/d of sodium is an initial recommendation. A daily intake of 2 L of fluid maintains water balance.

3. Potassium restriction—Restriction is needed once the GFR has fallen below 10–20 mL/min/1.73 m², or earlier if the patient is hyperkalemic. Patients should receive detailed lists concerning potassium content of foods and should limit their intake to < 50–60 mEq/d (2 g); this is about half of normal intake.

4. Phosphorus restriction—The phosphorus level should be kept in the ‘normal’ range (<4.5 mg/dL) predialysis, and between 3.5 and 5.5 mg/dL when on dialysis, with a dietary restriction of 800–1000 mg/d. Foods rich in phosphorus such as cola beverages, eggs, dairy products, nuts, beans, and meat should be limited, although care must be taken to avoid protein malnutrition. Below a GFR of 20–30 mL/min/1.73 m², dietary restriction is rarely sufficient to reach target levels, and phosphorus binders are usually required. The treatment of hyperphosphatemia is discussed above in the section on disorders of mineral metabolism.

C. Medication Management

Many drugs are excreted by the kidney; dosages should be adjusted for GFR. Insulin doses may need to be adjusted as noted above. Magnesium-containing medications, such as laxatives or antacids, should be avoided as should phosphorus-containing medicines, particularly cathartics. Morphine metabolites are active and can accrue in advanced CKD; this problem is not encountered with other opioid agents. Drugs with potential nephrotoxicity (NSAIDs, intravenous contrast, as well as others noted in the Acute Kidney Injury section) should be avoided.

D. Treatment of End-Stage Renal Disease

When GFR declines to 5–10 mL/min/1.73 m² (with or without overt uremic symptoms), renal replacement therapy (hemodialysis, peritoneal dialysis, or kidney transplantation) is required to sustain life. Select patients with limited life expectancy because of very advanced age or comorbid conditions may choose not to pursue dialysis therapy. Patient education is very important in understanding which mode of therapy is most suitable; timely preparation for treatment is also key. Referral to a nephrologist for consideration of ESRD treatment should take place in late stage 3 CKD, or when the GFR is declining rapidly.

1. Dialysis—Dialysis initiation should be considered when GFR is 10 mL/min/1.73 m². Recent studies suggest that the well-selected patient without overt uremic symptoms may wait to initiate dialysis until GFR is closer to 7 mL/min/1.73 m². Other indications for dialysis, which may occur when GFR is 10–15 mL/min/1.73 m² include (1) uremic symptoms, (2) fluid overload unresponsive to diuresis, (3) refractory hyperkalemia, and (4) severe metabolic acidosis (pH < 7.20). Preparation for dialysis requires a team approach. Dietitians and social workers should be involved as well as primary care clinicians and nephrologists. The patient and family need early counseling regarding the risks and benefits of therapy. For very elderly patients, or those with multiple debilitating or life-limiting comorbidities, dialysis therapy may not meaningfully prolong life, and the option of not starting dialysis with the development of ESRD should be discussed with the patient and family. Conversely, for patients who are otherwise relatively healthy, evaluation for possible kidney transplantation should be considered prior to initiation of dialysis.

A. HEMODIALYSIS—Hemodialysis requires a constant flow of blood along one side of a semipermeable membrane with a cleansing solution, or dialysate, along the other. Diffusion and convection allow the dialysate to remove unwanted substances from the blood while adding back needed components. Vascular access for hemodialysis can be accomplished by an arteriovenous fistula (the preferred method) or prosthetic graft; creation of dialysis access should be considered well before dialysis initiation. An indwelling catheter is used when there is no useable vascular access; because catheters confer a high risk of bloodstream infection, they should be considered a temporary measure. Native fistulas typically last longer than prosthetic grafts but require a longer time (6–8 weeks or more after surgical construction) for maturation. Infection, thrombosis, and aneurysm formation are complications seen more often in grafts than fistulas. *Staphylococcus* species are the most common cause of soft-tissue infections and bacteremia.

Dialysis at a hemodialysis center occurs three times a week. Sessions last 3–5 hours depending on patient size, type of dialyzer used, and other factors. Other hemodialysis schedules can be considered depending on available resources and patient preferences. Results from nocturnal dialysis trials have not been uniform but have shown improvements over thrice weekly dialysis for blood pressure control, mineral metabolism, and quality of life. Home hemodialysis is often performed more frequently (3–6 days per week for shorter sessions) and requires a trained helper, and large equipment. The availability of these quotidian modalities (nocturnal and frequent home hemodialysis) is becoming more widespread; results of trials comparing these to conventional in-center dialysis have not thus far shown significant mortality differences.

B. PERITONEAL DIALYSIS—With peritoneal dialysis, the peritoneal membrane is the “dialyzer.” Dialysate is instilled into the peritoneal cavity through an indwelling catheter; water and solutes move across the capillary bed that lies between the visceral and parietal layers of the membrane

into the dialysate during a “dwell.” After equilibration, the dialysate is drained, and fresh dialysate is instilled—this is an “exchange.”

There are three kinds of peritoneal dialysis: continuous ambulatory peritoneal dialysis (CAPD), in which the patient exchanges the dialysate four to six times a day manually; continuous cyclic peritoneal dialysis (CCPD), which utilizes a cyclor machine to automatically perform exchanges at night; and nocturnal intermittent peritoneal dialysis (NIPD), where patients use a cyclor machine at night without any fluid in the peritoneum during the day. As with hemodialysis, peritoneal dialysis prescriptions are guided by adequacy measurements (ie, dialytic clearance of urea).

Peritoneal dialysis permits significant patient autonomy. Its continuous nature minimizes the symptomatic volume and electrolyte shifts observed in hemodialysis patients, and poorly dialyzable compounds (such as phosphates) are better cleared, which permits less dietary restriction. However, peritoneal dialysate removes large amounts of albumin, and nutritional status must be closely watched.

The most common complication of peritoneal dialysis is peritonitis. Rates are improving (< 0.5 episodes per patient-year). Peritonitis may present with nausea and vomiting, abdominal pain, diarrhea or constipation, and fever. The dialysate is usually cloudy; and a diagnostic peritoneal fluid cell count is > 100 white blood cells/mCL of which over 50% are polymorphonuclear neutrophils. *Staphylococcus aureus* is the most common infecting organism, but streptococci and gram-negative species are also common.

2. Kidney transplantation—Up to 50% of all patients with ESRD are otherwise healthy enough to be suitable for transplantation. Older age is becoming less of a barrier, as long as reasonable life expectancy is anticipated. Two-thirds of kidney allografts come from deceased donors, with the remainder from living related or unrelated donors. There are over 90,000 patients on the active waiting list for a deceased donor transplant in the United States; the average wait is 2–6 years, depending on geographic location and recipient blood type.

The 1- and 3-year kidney graft survival rates are approximately 96% and 91%, respectively, for living donor transplants and 91% and 81%, respectively, for deceased donor transplants. Factors that determine outcome include antigenic disparity (ABO blood groups and major histocompatibility or HLA) between donor and recipient, the type of immunologic response mounted by the host, and the immunosuppressive regimen used to prevent graft rejection. Nonimmunologic factors that affect the risk of chronic rejection include age and race of recipient; donor age; length of time on dialysis; and coexisting hyperlipidemia, hypertension, or cytomegalovirus infection.

Immunosuppressive regimens to prevent allograft rejection generally include a combination of a corticosteroid, an antimetabolite (azathioprine or mycophenolate mofetil), and a calcineurin inhibitor (tacrolimus or cyclosporine) or mTOR inhibitor (sirolimus). Maintenance doses are lower than doses given at the time of transplant, with the aim of preventing recurrent rejection and chronic allograft

nephropathy, prolonging graft survival, and minimizing potentially serious medication side effects. Aside from medication use, the life of a transplant recipient can return to nearly normal, although these patients are at higher risk for certain cancers and infections.

3. Medical management of ESRD—As noted above, some patients are not candidates for transplantation and may not benefit from dialysis. Recent studies suggest that very elderly persons who do not die soon after dialysis initiation rapidly lose functional status in the first year of treatment. The decision to initiate dialysis in patients with limited life expectancy should be weighed against possible deleterious changes in quality of life. For patients with ESRD who elect not to undergo dialysis, death occurs within days to weeks. In general, uremia develops and patients lose consciousness prior to death. Arrhythmias can occur as a result of electrolyte imbalance. Volume overload and dyspnea can be managed by volume restriction and opioids as described in Chapter 5. Involvement of a palliative care team is essential.

► Prognosis in ESRD

Compared with kidney transplant recipients and age-matched controls, mortality is higher for patients undergoing dialysis. There is likely little difference in survival for well-matched peritoneal versus hemodialysis patients.

Survival rates on dialysis depend on the underlying disease process. Five-year Kaplan-Meier survival rates vary from 36% for patients with diabetes to 53% for patients with glomerulonephritis. Overall 5-year survival is currently estimated at 42%. Patients undergoing dialysis have an average life-expectancy of 3–5 years, but survival for as long as 25 years may be achieved depending on comorbidities. The most common cause of death is cardiac disease (50%). Other causes include infection (12%), cerebrovascular disease (15%), and malignancy (6%). Diabetes, advanced age, a low serum albumin, lower socioeconomic status, and inadequate dialysis are all significant predictors of mortality; high fibroblast growth factor (FGF)-23 levels have emerged as a novel marker for mortality in ESRD.

► When to Refer

- A patient with stage 3–5 CKD should be referred to a nephrologist for management in conjunction with the primary care provider.
- A patient with other forms of CKD such as those with significant proteinuria (>1 g/d) or polycystic kidney disease should be referred to a nephrologist at earlier stages.

► When to Admit

- Admission should be considered for patients with decompensation of problems related to CKD, such as worsening of acid-base status, electrolyte abnormalities, and volume status that cannot be appropriately treated in the outpatient setting.
- Admission is appropriate when a patient needs to start dialysis and is not stable for outpatient initiation.

- Abbound H et al. Clinical practice. Stage IV chronic kidney disease. *N Engl J Med.* 2010 Jan 7;362(1):56–65. [PMID: 20054047]
- Chrysant SG et al. Current status of aggressive blood glucose and blood pressure control in diabetic hypertensive subjects. *Am J Cardiol.* 2011 Jun 15;107(12):1856–61. [PMID: 21481823]
- FHN Trial Group; Chertow GM et al. In-center hemodialysis six times per week versus three times per week. *N Engl J Med.* 2010 Dec 9;362(24):2287–300. [PMID: 21091062]
- Galliford J et al. Modern renal transplantation: present challenges and future prospects. *Postgrad Med J.* 2009 Feb;85(1000):91–101. [PMID: 19329704]
- Himmelfarb J et al. Hemodialysis. *N Engl J Med.* 2010 Nov 4;363(19):1833–45. [PMID: 21047227]
- James MT et al. Early recognition and prevention of chronic kidney disease. *Lancet.* 2010;375(9722):1296–309. [PMID: 20382326]
- Kuritzky L et al. Identification and management of albuminuria in the primary care setting. *J Clin Hypertens.* 2011 Jun;13(6):438–49. [PMID: 21649844]
- Matzke GR et al. Drug dosing consideration in patients with acute and chronic kidney disease—a clinical update from Kidney Disease: Improving Global Outcomes (KDIGO). *Kidney Int.* Dec;80(11):1122–37. [PMID: 21918498]
- Power A et al. Management of the dialysis patient for the hospital physician. *Postgrad Med J.* 2009 Jul;85(1005):376–381. [PMID: 19581248]

RENAL ARTERY STENOSIS



ESSENTIALS OF DIAGNOSIS

- ▶ Produced by atherosclerotic occlusive disease (80–90% of patients) or fibromuscular dysplasia (10–15%).
- ▶ Hypertension.
- ▶ Acute kidney injury in patients starting ACE inhibitor therapy.

▶ General Considerations

Atherosclerotic ischemic renal disease accounts for nearly all cases of renal artery stenosis. Fibromuscular dysplasia is a rare cause of renal artery stenosis. Approximately 5% of Americans with hypertension suffer from renal artery stenosis. It occurs most commonly in those over 45 years of age with a history of atherosclerotic disease. Other risk factors include CKD, diabetes mellitus, tobacco use, and hypertension.

▶ Clinical Findings

A. Symptoms and Signs

Patients with atherosclerotic ischemic renal disease may have refractory hypertension, new-onset hypertension (in an older patient), pulmonary edema with poorly controlled blood pressure, and acute kidney injury upon starting an ACE inhibitor. In addition to hypertension, physical examination may reveal an audible abdominal bruit on the affected side. Fibromuscular dysplasia primarily affects young women. Unexplained hypertension in a woman younger than 40 years is reason to screen for this disorder.

B. Laboratory Findings

Laboratory values can show elevated BUN and serum creatinine levels in the setting of significant renal ischemia.

C. Imaging

Abdominal ultrasound can reveal asymmetric kidney size when one renal artery is affected out of proportion to the other.

Three prevailing methods used for screening are Doppler ultrasonography, CT angiography, and magnetic resonance angiography (MRA). **Doppler ultrasonography** is highly sensitive and specific (> 90% with an experienced ultrasonographer) and relatively inexpensive. However, this method is extremely operator and patient dependent. Measurements of blood flow must be made at the aorta and along each third of the renal artery in order to assess the disease. This test is a poor choice for patients who are obese, unable to lie supine, or have interfering bowel gas patterns.

CT angiography consists of intravenous digital subtraction angiography with arteriography and is a noninvasive procedure. The procedure uses a spiral (helical) CT scan with intravenous contrast injection. The sensitivities from various studies range from 77% to 98%, with less varying specificities in a range of 90–94%.

MRA is an excellent but expensive way to screen for renal artery stenosis, particularly in those with atherosclerotic disease. Sensitivity is 77–100%, although one study with particular flaws showed a sensitivity of only 62%. Specificity ranges from 71% to 96%. Turbulent blood flow can cause false-positive results. The imaging agent for MRA (gadolinium) has been associated with nephrogenic systemic fibrosis, which occurs primarily in patients with a GFR of < 15 mL/min/1.73 m², and rarely in patients with a GFR of 15–30 mL/min/1.73 m². It has also been seen in those with acute kidney injury and kidney transplants.

Renal angiography is the gold standard for diagnosis. CO₂ subtraction angiography can be used in place of dye when the risk of dye nephropathy exists—eg, in diabetic patients with kidney injury. Lesions are most commonly found in the proximal third or ostial region of the renal artery. The risk of atheroembolic phenomena after angiography ranges from 5% to 10%. Fibromuscular dysplasia has a characteristic “beads-on-a-string” appearance on angiography.

▶ Treatment

Treatment of atherosclerotic ischemic renal disease is controversial. Options include medical management, angioplasty with or without stenting, and surgical bypass. A 2009 study has shown that intervention is no better than optimal medical management in typical patients in whom renal artery stenosis was diagnosed via gold-standard mechanisms. Angioplasty might reduce the number of antihypertensive medications but does not significantly change the progression of kidney dysfunction in comparison to patients medically managed. Stenting produces significantly better angioplastic results. However, blood pressure is equally improved, and serum creatinines are similar at

6 months of observation compared with both angioplasty and stents. Angioplasty is equally as effective as, and safer than, surgical revision. Treatment of **fibromuscular dysplasia** with percutaneous transluminal angioplasty is often curative.

ASTRAL Investigators; Wheatley K et al. Revascularization versus medical therapy for renal-artery stenosis. *N Engl J Med*. 2009 Nov 12;361(20):1953–62. [PMID: 19907042]
 Balk E et al. Effectiveness of management strategies for renal artery stenosis: a systematic review. *Ann Intern Med*. 2006 Dec 19;145(12):901–12. [PMID: 17062633]
 Hildreth CJ et al. JAMA patient page. Renal artery stenosis. *JAMA*. 2008 Nov 5;300(17):2084. [PMID: 18984899]
 Textor SC et al. Renovascular hypertension and ischemic nephropathy. *Am J Hypertens*. 2010 Nov;23(11):1159–69. [PMID: 20864945]

GLOMERULAR DISEASES


Abnormalities of glomerular function can be caused by damage to the major components of the glomerulus: the epithelium (podocytes), basement membrane, capillary endothelium, or mesangium. The damage may be caused by overwork injury, such as in CKD; by an inflammatory process, such as systemic lupus erythematosus; by a podocyte

protein mutation, such as in hereditary focal and segmental glomerulosclerosis; or a deposition disease, such as diabetes or amyloidosis. A specific histologic pattern of glomerular injury results from this damage and can be seen on renal biopsy.

Classification

Clinically, a glomerular disease can be classified as being in one of two spectra—either in the nephritic spectrum or the nephrotic spectrum (Figure 22–4). In the “least severe” end of the **nephritic spectrum**, the findings of glomerular hematuria (ie, dysmorphic red blood cells) are characteristic. The nephritic syndrome, comprising glomerular hematuria, subnephrotic proteinuria (<3 g/d), edema, and elevated creatinine, falls in the mid-portion of the spectrum. The rapidly progressive glomerulonephritides are at the “most severe” and clinically urgent end of the nephritic spectrum.

The **nephrotic spectrum** comprises diseases that present with primarily proteinuria of at least 0.5–1 g/d and a bland urine sediment (no cells or cellular casts). The more severe end of the nephrotic spectrum comprises the nephrotic syndrome, which is characterized by the constellation of nephrotic-range proteinuria of > 3 g/d, hypoalbuminuria, edema, and hyperlipidemia. Differentiating between a clinical presentation within the nephritic spectrum versus the



▲ **Figure 22–4.** Glomerular diseases present within one of the clinical spectra shown, the exact presentation is determined by the severity of the underlying disease and the pattern of injury. Nephritic diseases are characterized by the presence of an active urine sediment with glomerular hematuria and often with proteinuria. Nephrotic spectrum diseases are proteinuric with bland urine sediments (no cells or cellular casts). All glomerular diseases may progress to a chronic, scarred state. (Adapted, with permission, from Megan Troxell, MD, PhD.)

Table 22-9. Classification and findings in glomerulonephritis: Nephritic spectrum presentations.

	Typical presentation	Association/notes	Serology
Postinfectious glomerulonephritis	Children: abrupt onset of nephritic syndrome and acute kidney injury but can present anywhere in nephritic spectrum	Streptococci, other bacterial infections (eg, staphylococci, endocarditis, shunt infections)	Rising ASO titers, low complement levels
IgA nephropathy (Berger disease) and Henoch-Schönlein purpura, systemic IgA vasculitis	Classically: gross hematuria with upper respiratory tract infection; can present anywhere in nephritic spectrum; Henoch-Schönlein purpura with vasculitic rash and gastrointestinal hemorrhage	Abnormal IgA glycosylation in both primary (familial predisposition) and secondary disease (associated with cirrhosis, HIV, celiac disease) Henoch-Schönlein purpura in children after an inciting infection	No serologic tests helpful; complement levels are normal
Pauci-immune (granulomatosis with polyangiitis, Churg-Strauss, polyarteritis, idiopathic crescentic glomerulonephritis)	Classically as crescentic or RPGN, but can present anywhere in nephritic spectrum; may have respiratory tract/sinus symptoms in granulomatosis with polyangiitis	See Figure 22-5	ANCAs: MPO or PR3 titers high; complement levels normal
Anti-glomerular basement membrane glomerulonephritis; Goodpasture syndrome	Classically as crescentic or RPGN, but can present anywhere in nephritic spectrum; with pulmonary hemorrhage in Goodpasture syndrome	May develop as a result of respiratory irritant exposure (chemicals or tobacco use)	Anti-GBM antibody titers high; complement levels normal
Cryoglobulin-associated glomerulonephritis	Often acute nephritic syndrome; often with systemic vasculitis including rash and arthritis	Most commonly associated with chronic hepatitis C; may occur with other chronic infections or some connective tissue diseases	Cryoglobulins positive; rheumatoid factor may be elevated; complement levels low
Idiopathic MPGN	Classically presents with acute nephritic syndrome, but can see nephrotic syndrome features in addition	Most patients are < 30 years old Type I most common Type II (dense deposit disease) associated with C3 nephritic factor	Low complement levels
Hepatitis C infection	Anywhere in nephritic spectrum	Can cause MPGN pattern of injury or cryoglobulinemic glomerulonephritis; membranous nephropathy pattern of injury uncommon	Low complement levels; positive hepatitis C serology; rheumatoid factor may be elevated
Systemic lupus erythematosus	Anywhere in nephritic spectrum, depending on pattern/severity of injury	Treatment depends on clinical course and International Society of Nephrology and Renal Pathology Society (ISN/RPS) classification on biopsy	High ANA and anti-double-stranded DNA titers; low complement levels

ANA, antinuclear; ANCAs: antineutrophil cytoplasmic antibodies; GBM, glomerular basement membrane; MPGN, membranoproliferative glomerulonephritis; RPGN, rapidly progressive glomerulonephritis.

nephrotic spectrum is important because it helps narrow the differential diagnosis of the underlying glomerular disease (Tables 22-9 and 22-10).

Glomerular diseases can also be classified according to whether they cause only renal abnormalities (primary renal disease) or whether the renal abnormalities result from a systemic disease (secondary renal disease).

Further evaluation prior to renal biopsy may include serologic testing for systemic diseases that can result in glomerular damage (Figure 22-5).

- Beck LH Jr et al. Glomerular and tubulointerstitial diseases. *Prim Care*. 2008 Jun;35(2):265-96. [PMID: 18486716]
- Chiang CK et al. Glomerular diseases: genetic causes and future therapeutics. *Nat Rev Nephrol*. 2010 Sep;6(9):539-54. [PMID: 20644582]
- El Nahas M. Cardio-Kidney-Damage: a unifying concept. *Kidney Int*. 2010 Jul;78(1):14-8. [PMID: 20445499]
- McGrogan A et al. The incidence of primary glomerulonephritis worldwide: a systematic review of the literature. *Nephrol Dial Transplant*. 2011 Feb;26(2):414-30. [PMID: 21068142]

Table 22-10. Classification and findings in glomerulonephritis: Nephrotic spectrum presentations.

Disease	Typical presentation	Association/notes
Minimal change disease (nil disease; lipid nephrosis)	Child with sudden onset of full nephrotic syndrome	Children: associated with allergy or viral infection Adults: associated with Hodgkin disease, NSAIDs
Membranous nephropathy	Anywhere in nephrotic spectrum, but nephrotic syndrome not uncommon; particular predisposition to hypercoagulable state	Primary (idiopathic) may be associated with antibodies to PLA ₂ R Associated with non-Hodgkin lymphoma, carcinoma (gastrointestinal, renal, bronchogenic, thyroid), gold therapy, penicillamine, SLE, chronic hepatitis B or C infection
Focal and segmental glomerulosclerosis	Anywhere in nephrotic spectrum; children with congenital disease have nephrotic syndrome	Children: congenital disease with podocyte gene mutation, or in spectrum of disease with minimal change disease Adults: Associated with heroin abuse, HIV infection, reflux nephropathy, obesity, pamidronate, podocyte protein mutations
Amyloidosis	Anywhere in nephrotic spectrum	AL: plasma cell dyscrasia with Ig light chain over-production and deposition; check SPEP and UPEP AA: serum amyloid protein A over-production and deposition in response to chronic inflammatory disease (rheumatoid arthritis, inflammatory bowel disease, chronic infection)
Diabetic nephropathy	High GFR (hyperfiltration) → microalbuminuria → frank proteinuria → decline in GFR	Diabetes diagnosis precedes diagnosis of nephropathy by years
HIV-associated nephropathy	Heavy proteinuria, often nephrotic syndrome, progresses to ESRD relatively quickly	Usually seen in antiviral treatment-naïve patients (rare in HAART era), predilection for those of African descent
Membranoproliferative glomerulonephropathy	Can present with nephrotic syndrome, but usually with nephritic features as well (glomerular hematuria)	See Table 22-9

ESRD, end-stage renal disease; GFR, glomerular filtration rate; HAART, highly active antiretroviral therapy; NSAIDs, nonsteroidal anti-inflammatory drugs; PLA₂R, phospholipase A₂ receptor; SLE, systemic lupus erythematosus; SPEP/UPEP: serum and urine protein electrophoresis.

NEPHRITIC SPECTRUM GLOMERULAR DISEASES



ESSENTIALS OF DIAGNOSIS

- ▶ Glomerular hematuria (dysmorphic red blood cells), possibly red blood cell urinary casts.
- ▶ Less than nephrotic range proteinuria (0.3–3 g/d).
- ▶ Hypertension is common.
- ▶ Entity classified into one of three groups: asymptomatic glomerular hematuria, acute nephritic syndrome, or rapidly progressive glomerulonephritis.
- ▶ Edema, if present, in dependent (eg, periorbital or scrotal) areas.

▶ General Considerations


Glomerulonephritis is a term given to those diseases that present in the nephritic spectrum and usually signifies an

inflammatory process causing renal dysfunction. It can be acute, developing over days to weeks, with or without resolution, or may be more chronic and indolent with progressive scarring. As noted above, diseases that cause a nephritic spectrum presentation may present with glomerular hematuria with some proteinuria, with nephritic syndrome, or with rapidly progressive glomerulonephritis (Figure 22-4). The presentation depends on the severity of the underlying inflammation and the pattern of injury caused by the disease process.

▶ Clinical Findings

A. Symptoms and Signs

If the nephritic syndrome is present, edema is first seen in regions of low tissue pressure such as the periorbital and scrotal areas. Hypertension in the nephritic syndrome is due to sodium retention resulting from acute decrease in GFR. Heavy glomerular bleeding from inflammation may result in gross hematuria (smoky or cola-colored urine).



▲ **Figure 22-5.** Serologic analysis of patients with glomerulonephritis. MPGN, membranoproliferative glomerulonephritis. (Reproduced, with permission, from Greenberg A et al. *Primer on Kidney Diseases*. Academic Press, 1994 and Jennette JC, Falk RJ). Diagnosis and management of glomerulonephritis and vasculitis presenting as acute renal failure. *Med Clin North Am*. 1990;74(4):893-908. © Elsevier.)

B. Laboratory Findings

1. Serologic testing—Serologic tests, including complement levels, antinuclear antibodies, cryoglobulins, hepatitis serologies, ANCA, anti-GBM antibodies, and antistreptolysin O (ASO) titers (Figure 22–5), are done based on the history and physical examination to narrow the differential diagnosis of the nephritic spectrum disorder.

2. Urinalysis—The urinalysis shows protein and red blood cells. On microscopy, these cells are misshapen from traversing a damaged capillary membrane—so-called dysmorphic red blood cells. Red blood cell casts are seen with heavy glomerular bleeding and tubular stasis. When quantified, proteinuria is usually subnephrotic (<3 g/d).

3. Biopsy—Renal biopsy should be considered if there are no contraindications (eg, bleeding disorders, thrombocytopenia, uncontrolled hypertension). Light microscopy delineates the pattern of injury; underlying disease process can be further categorized according to the immunofluorescence pattern and appearance on electron microscopy.

► Treatment

General measures for all include aggressive treatment of hypertension and fluid overload if present. Dialysis may be needed as discussed in the acute kidney injury section. The inflammatory glomerular injury may require corticosteroids or cytotoxic agents, or both. (See specific diseases discussed below.)

► When to Refer

Any patient in whom a glomerulonephritis is suspected should be referred to a nephrologist.

► When to Admit

Any suspicion of acute nephritic syndrome or rapidly progressive glomerulonephritis warrants consideration of immediate hospitalization.

POSTINFECTIOUS GLOMERULONEPHRITIS



ESSENTIALS OF DIAGNOSIS

- ▶ Proteinuria.
- ▶ Glomerular hematuria.
- ▶ Symptoms 1–3 weeks after infection (often pharyngitis or impetigo).

► General Considerations

Postinfectious glomerulonephritis is most often due to infection with nephritogenic group A β -hemolytic streptococci. It can occur sporadically or in clusters and during epidemics. It commonly appears after pharyngitis or impetigo with onset 1–3 weeks after infection (average 7–10 days).

Other infections have been associated with postinfectious glomerulonephritis including bacteremic states

(especially with *S aureus*), bacterial pneumonias, deep-seated abscesses, gram-negative infections, infective endocarditis, and shunt infections. Viral, fungal, and parasitic causes of postinfectious glomerulonephritis pattern of glomerular injury include hepatitis B or C, HIV, cytomegalovirus infection, infectious mononucleosis, coccidioidomycosis, malaria, mycobacteria, syphilis, and toxoplasmosis.

► Clinical Findings

A. Symptoms and Signs

Disease presentation can vary widely across the nephritic spectrum from asymptomatic glomerular hematuria (especially in epidemic cases) to nephritic syndrome with hypertension, oliguria, edema, and perhaps cola-colored urine.

B. Laboratory Findings

Serum complement levels are low; in postinfectious glomerulonephritis due to group A streptococcal infection, antistreptolysin O (ASO) titers can be high unless the immune response has been blunted with previous antibiotic treatment. Glomerular hematuria and subnephrotic proteinuria are present; severe cases may demonstrate elevated serum creatinine and red cell casts in the urine. Renal biopsy shows a diffuse proliferative pattern of injury on light microscopy. Immunofluorescence shows IgG and C3 in a granular pattern in the mesangium and along the capillary basement membrane. Electron microscopy shows large, dense subepithelial deposits or “humps.”

► Treatment

The underlying infection should be identified and treated appropriately, but otherwise, treatment for postinfectious glomerulonephritis is supportive. Antihypertensives, salt restriction, and diuretics should be used if needed. Corticosteroids have not been shown to improve outcome. Prognosis depends on the severity of the glomerular injury and age of the patient. Children are more likely to fully recover; adults are more prone to the development of severe disease (rapidly progressive glomerulonephritis with crescent formation) and CKD.

Kanjanabuch T et al. An update on acute postinfectious glomerulonephritis worldwide. *Nat Rev Nephrol.* 2009 May; 5(5):259–69. [PMID: 19384327]

IGA NEPHROPATHY



ESSENTIALS OF DIAGNOSIS

- ▶ Proteinuria: minimal to nephrotic range.
- ▶ Glomerular hematuria: microscopic is common; macroscopic (gross) after infection.
- ▶ Positive IgA staining on renal biopsy.

► General Considerations

IgA nephropathy (Berger disease) is a primary renal disease of IgA deposition in the glomerular mesangium. The inciting cause is unknown but is likely due to abnormal glycosylation of IgA subclass 1 molecules. IgA nephropathy can be a primary (renal-limited) disease, or it can be secondary to hepatic cirrhosis, celiac disease, and infections such as HIV and cytomegalovirus. Susceptibility to IgA nephropathy seems to be inheritable.

IgA nephropathy is the most common primary glomerular disease worldwide, particularly in Asia. It is most commonly seen in children and young adults, with males affected two to three times more commonly than females.

► Clinical Findings

An episode of gross hematuria is the most common presenting symptom. Frequently, this is associated with an upper respiratory infection (50%), GI symptoms (10%), or a flu-like illness (15%). The urine becomes red or cola-colored 1–2 days after illness onset. In contrast to postinfectious glomerulonephritis, this feature has been called “synpharyngitic hematuria” since there is no significant latent period. IgA nephropathy can present as any of the nephritic syndromes from asymptomatic microscopic hematuria to rapidly progressive glomerulonephritis. Rarely, it can present as a nephrotic syndrome.

There are no serologic tests that aid in the diagnosis of IgA nephropathy; serum IgA subclass 1 testing may be a possibility in the future. Serum complements are normal. The typical pattern of injury seen on renal biopsy is a focal glomerulonephritis with mesangial proliferation; immunofluorescence demonstrates diffuse mesangial IgA and C3 deposits.

► Treatment

The disease course of primary IgA nephropathy varies widely among patients; treatment approach needs to be tailored to risk for progression. Patients with low risk for progression (no hypertension, normal GFR, minimal proteinuria) can be monitored annually. Patients at medium to high risk (proteinuria > 0.5 g/d, decreased GFR, or hypertension, or any combination of these three conditions) should be given an initial course of conservative treatment, including ACE inhibitor or ARB therapy and blood pressure control to 130/80 mm Hg. For those in this risk category who have nephrotic syndrome or a rapid decline in GFR, or those in whom proteinuria is not suppressed to < 1 g/d but have relatively preserved GFR (stage 3 CKD or less), immunosuppressive therapy should be considered. In patients with proteinuria of 1.0–3.5 g/d and GFR > 70 mL/min/1.73 m², corticosteroid therapy has proven beneficial. One such regimen (methylprednisolone, 1 g/d intravenously for 3 days during months 1, 3, and 5, plus prednisone in a dosage of 0.5 mg/kg orally every other day for 6 months) showed a 2% doubling of creatinine after 6 years in the treatment group versus a 21% doubling of creatinine in the control group. For patients with a GFR < 70 mL/min/1.73 m² and a predicted progression to ESRD in < 5 years, some experts have suggested a trial of low-dose cyclophosphamide followed by maintenance azathioprine. Kidney transplantation is an

excellent option for patients with ESRD, but recurrent disease has been documented in 30% of patients 5–10 years post-transplant. Fortunately, recurrent disease rarely leads to failure of the allograft.

► Prognosis

Approximately one-third of patients experience spontaneous clinical remission. Progression to ESRD occurs in 20–30% of patients. The remaining patients show chronic microscopic hematuria and a stable serum creatinine. The most unfavorable prognostic indicator is proteinuria > 1 g/d; other unfavorable prognostic indicators include hypertension, persistent microscopic hematuria and proteinuria, glomerulosclerosis or glomerular crescents on biopsy, and abnormal GFR on presentation.

Floege J et al. Current therapy for IgA nephropathy. *J Am Soc Nephrol.* 2011 Oct;22(10):1785–94. [PMID: 21903997]

Suzuki H et al. The pathophysiology of IgA nephropathy. *J Am Soc Nephrol.* 2011 Oct;22(10):1795–803. [PMID: 21949093]

HENOCH-SCHÖNLEIN PURPURA

Henoch-Schönlein purpura is a small-vessel leukocytoclastic vasculitis associated with IgA subclass 1 deposition in vessel walls. It is most common in children and is often associated with an inciting infection, such as group A streptococcus or other exposure. There is a male predominance. It classically presents with palpable purpura in the lower extremities and buttock area; arthralgias; and abdominal symptoms, such as nausea, colic, and melena. A decrease in GFR is common with a nephritic presentation. The renal lesions are considered by most experts to be identical to those found in IgA nephropathy. Most patients with microscopic hematuria and minimal proteinuria recover fully over several weeks. Progressive CKD and possibly ESRD are more likely to develop in those with the nephrotic syndrome and the presence of both nephritic and nephrotic syndrome poses the worst renal prognosis. Histologic classification of the lesions in children may also provide prognostic information. To date, although several treatment regimens of various immunosuppressive agents have been clinically tested, none have been definitively proven to alter the course of severe Henoch-Schönlein purpura nephritis. Rituximab treatment and plasma exchange have been successful for severe disease according to several case reports, but clinical trials are lacking.

Further details about Henoch-Schönlein purpura are provided in Chapter 20.

Davin JC. Henoch-Schönlein purpura nephritis: pathophysiology, treatment, and future strategy. *Clin J Am Soc Nephrol.* 2011 Mar;6(3):679–89. [PMID: 21393485]

Pillebout E et al; CESAR study group. Addition of cyclophosphamide to steroids provides no benefit compared with steroids alone in treating adult patients with severe Henoch-Schönlein purpura. *Kidney Int.* 2010 Sep;78(5):495–502. [PMID: 20505654]

Saulsbury FT. Henoch-Schönlein purpura. *Curr Opin Rheumatol.* 2010 Sep;22(5):598–602. [PMID: 20473173]

Xia Y et al. Clinical outcomes in children with Henoch-Schönlein purpura nephritis grade IIIa or IIIb. *Pediatr Nephrol.* 2011 Jul;26(7):1083–8. [PMID: 21387156]

PAUCI-IMMUNE GLOMERULONEPHRITIS (ANCA-Associated)

Pauci-immune necrotizing glomerulonephritis is caused by the following systemic ANCA-associated small-vessel vasculitides: granulomatosis with polyangiitis, microscopic polyangiitis, and Churg-Strauss disease (see Chapter 20). ANCA-associated glomerulonephritis can also present as a primary renal lesion without systemic involvement; this is termed “idiopathic crescentic glomerulonephritis.” The precise pathogenesis of these entities is unknown; it is likely that ANCAs are responsible for neutrophil activation and consequent vascular damage. Immunofluorescence of renal biopsy specimens do not reveal any evidence of immunoglobulin or complement deposition, hence the term “pauci-immune.” Renal involvement classically presents as a rapidly progressive glomerulonephritis.

► Clinical Findings

A. Symptoms and Signs

Symptoms of a systemic inflammatory disease, including fever, malaise, and weight loss may be present and usually precede initial presentation by several months. In addition to hematuria and proteinuria from glomerular inflammation, some patients exhibit purpura from dermal capillary involvement and mononeuritis multiplex from nerve arteriolar involvement. Ninety percent of patients with granulomatosis with polyangiitis have upper (especially sinus) or lower respiratory tract symptoms with nodular lesions that can cavitate and bleed. Hemoptysis is a concerning sign and usually warrants hospitalization.

B. Laboratory Findings

Serologically, ANCA subtype analysis is done. A c-ANCA is specific for antiproteinase-3 antibodies (PR3-ANCA), while a p-ANCA is specific for antimyeloperoxidase antibodies (MPO-ANCA). Most patients with granulomatosis with polyangiitis are c-ANCA positive; the remainder can have a p-ANCA pattern or rarely do not demonstrate ANCA serologically. Microscopic angiitis has either a p-ANCA or c-ANCA pattern about 80% of the time. As noted above, the small vessels and glomeruli lack immune deposits on immunofluorescence. Necrotizing lesions and crescents are the pattern of injury associated with this rapidly progressive glomerulonephritis.

► Treatment

Treatment should be instituted early. Induction therapy of high-dose corticosteroids (methylprednisolone, 1–2 g/d intravenously for 3 days, followed by prednisone, 1 mg/kg orally for 1 month, with a slow taper over the next 6 months) and cytotoxic agents (cyclophosphamide, 0.5–1 g/m² intravenously per month or 1.5–2 mg/kg orally for 3–6 months) is followed by long-term azathioprine or mycophenolate mofetil. Plasma exchange has been shown to be beneficial in conjunction with induction therapy; however, a recent meta-analysis calls into question the strength of this benefit. Rituximab has recently been shown to be noninferior to cyclophosphamide for induction.

► Prognosis

Without treatment, prognosis is extremely poor. However, with aggressive treatment, complete remission can be achieved in about 75% of patients. Prognosis depends on the extent of renal involvement before treatment is started. ANCA titers should be monitored to follow treatment efficacy; rising titers herald relapse. Patients receiving cyclophosphamide should receive prophylaxis for *Pneumocystis jiroveci*, such as trimethoprim-sulfamethoxazole double-strength orally 3 days per week.

Hiemstra TF et al; European Vasculitis Study Group (EUVAS). Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized controlled trial. *JAMA*. 2010 Dec 1;304(21):2381–8. [PMID: 21060104]
 Kallenberg CG. Pathogenesis of ANCA-associated vasculitides. *Ann Rheum Dis*. 2011 Mar;70(Suppl 1):i59–63. [PMID: 21339221]
 Rutgers A et al. Pauci-immune necrotizing glomerulonephritis. *Rheum Dis Clin North Am*. 2010 Aug;36(3):559–72. [PMID: 20688250]
 Walsh M et al. Plasma exchange for renal vasculitis and idiopathic rapidly progressive glomerulonephritis: a meta-analysis. *Am J Kidney Dis*. 2011 Apr;57(4):566–74. [PMID: 21194817]

ANTI-GLOMERULAR BASEMENT MEMBRANE GLOMERULONEPHRITIS & GOODPASTURE SYNDROME

Goodpasture syndrome is defined by the clinical constellation of glomerulonephritis and pulmonary hemorrhage; injury to both is mediated by antibodies to epitopes in the GBM (Figure 22–5). Up to one-third of patients with anti-GBM glomerulonephritis have no evidence of concomitant lung injury. Anti-GBM-associated glomerulonephritis accounts for 10–20% of patients with rapidly progressive acute glomerulonephritis. The incidence peaks in the second and third decades of life during which time males are predominantly affected and lung involvement is more common, and again in the sixth and seventh decades with less gender predominance. Lung involvement has been associated with pulmonary infection, tobacco use, and hydrocarbon solvent exposure; HLA-DR2 and -B7 antigens may predispose as well.

► Clinical Findings

A. Symptoms and Signs

The onset of disease is preceded by an upper respiratory tract infection in 20–60% of cases; hemoptysis, dyspnea, and possible respiratory failure may ensue. Other findings are consistent with a rapidly progressive acute glomerulonephritis, although some cases may present with much milder forms of the nephritic spectrum of disease (eg, glomerular hematuria and proteinuria with minimal renal dysfunction).

B. Laboratory Findings

Laboratory evaluation can show iron deficiency anemia if pulmonary hemorrhage has been prolonged. Serum

complement levels are normal. Sputum may contain hemosiderin-laden macrophages. Chest radiographs can show shifting pulmonary infiltrates due to pulmonary hemorrhage. The diffusion capacity of carbon monoxide is markedly increased. Diagnosis is confirmed by finding circulating anti-GBM antibodies, which are positive in over 90% of patients. About 15% of patients also have elevated ANCA titers; these patients should be treated with plasma exchange as for anti-GBM disease. Renal biopsy typically shows crescent formation on light microscopy, with linear IgG staining along the GBM on immunofluorescence.

▶ Treatment

The treatment of choice is a combination of plasma exchange therapy to remove circulating antibodies, and administration of immunosuppressive drugs to prevent formation of new antibodies and control the inflammatory response. Corticosteroids are typically given initially in pulse doses of methylprednisolone, 1–2 g/d for 3 days, then prednisone orally 1 mg/kg/d. Cyclophosphamide is administered intravenously at a dose of 0.5–1 g/m² per month or orally at a dosage of 2–3 mg/kg/d. Daily plasma exchange is performed for up to 2 weeks. A poorer prognosis exists in patients with oliguria and a serum creatinine > 6–7 mg/dL, or requiring dialysis upon presentation. Anti-GBM antibody titers should decrease as the clinical course improves.

Cui Z et al. Advances in human antiglomerular basement membrane disease. *Nat Rev Nephrol.* 2011 Jul 19;7(12):697–705. [PMID: 21769105]

CRYOGLOBULIN-ASSOCIATED GLOMERULONEPHRITIS

Essential (mixed) cryoglobulinemia is a disorder associated with cold-precipitable immunoglobulins (cryoglobulins). Glomerular disease results from the precipitation of cryoglobulins in glomerular capillaries (Figure 22–5). The cause is typically hepatitis C infection, but other infections (such as hepatitis B) or other occult or clinically apparent viral, bacterial, and fungal infections can be causative; it is also associated with some connective tissue diseases.

Patients exhibit purpuric and necrotizing skin lesions in dependent areas, arthralgias, fever, and hepatosplenomegaly. Serum complement levels are depressed. Rheumatoid factor is often elevated when cryoglobulins are present. Renal biopsy may show several different patterns of injury; there may be crescent formation, glomerular capillary thrombi, or MPGN (see below). Treatment consists of aggressively targeting the causative infection. Pulse corticosteroids, plasma exchange, and cytotoxic agents have been used when risk of exacerbating the underlying infection is resolved. Interferon- α (IFN- α) has been shown to benefit patients with hepatitis C–related cryoglobulinemia; in patients who do not respond to such treatment or for whom antiviral treatment is not indicated, there is some suggestion that rituximab may improve renal outcomes.

Colucci G et al. Cryoglobulinemic membranoproliferative glomerulonephritis: beyond conventional therapy. *Clin Nephrol.* 2011 Apr;75(4):374–9. [PMID: 21426893]

IDIOPATHIC MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS

MPGN in its primary form is an idiopathic renal disease that usually presents with nephritic features ranging from asymptomatic glomerular hematuria and proteinuria, to episodes of gross hematuria, to the acute nephritic syndrome. MPGN may also present with the nephrotic syndrome. Most patients are under 30 years of age, and a recent history of upper respiratory tract infection is present in nearly half. At least two major subgroups are recognized: type I and type II. Both are characterized by hypocomplementemia; in type I MPGN, the classic complement pathway is activated, leading to low or normal C3 with low C4, whereas in type II disease, the alternative complement pathway is activated and C3 is low while C4 is normal. Prognosis is worse in type II disease.

Renal biopsy in **type I MPGN** demonstrates a thickened GBM due to immune complex deposition and abnormal mesangial cell proliferation between the GBM and the endothelial cells. This gives a characteristic “splitting” or “tram-track” appearance to the capillary wall. Immunofluorescence shows IgG, IgM, and granular deposits of C3, C1q, and C4. Subendothelial deposits are seen on electron microscopy.

Type II MPGN (dense deposit disease) is less common than type I and is associated with C3 nephritic factor, a circulating IgG antibody. Light microscopy is similar to type I. Electron microscopy shows a characteristic ribbon-like deposit of homogeneous material that replaces part of the GBM.

Treatment of idiopathic MPGN is controversial. After ruling out secondary or systemic causes, treatment of children with nephrotic syndrome consists of corticosteroids at 40 mg/m² every other day for a prolonged duration. Uncontrolled studies suggest that there may be some role for other immunosuppressive regimens, including cyclophosphamide, cyclosporine, and mycophenolate mofetil. ACE inhibitors and ARBs should be used to treat hypertension and proteinuria. Adults are less likely to respond to corticosteroid treatment. In the past, 50% of patients progressed to ESRD in 10 years; this rate may now be slightly lower with the introduction of more aggressive therapy. Less favorable prognostic findings include type II MPGN, early renal insufficiency, hypertension, and persistent nephrotic syndrome. Both types of MPGN will recur after renal transplantation; however, type II recurs more commonly. Plasma exchange has been used with mixed results to treat post-transplant recurrence of MPGN.

Alchi B et al. Membranoproliferative glomerulonephritis. *Pediatr Nephrol.* 2010 Aug;25(8):1409–18. [PMID: 19908070]
Yuan M et al. Combination therapy with mycophenolate mofetil and prednisone in steroid-resistant idiopathic membranoproliferative glomerulonephritis. *Clin Nephrol.* 2010 May; 73(5):354–9. [PMID: 20420795]

HEPATITIS C VIRUS INFECTION

Renal disease in the setting of hepatitis C viral infection was not well-recognized until 1993. Now it accounts for approximately 8% of patients with ESRD. The three patterns of renal injury associated with hepatitis C are secondary MPGN, cryoglobulinemic glomerulonephritis, and membranous nephropathy. A type I MPGN (see section above) is the most common lesion found on kidney biopsy. These patients typically have hematuria and proteinuria, hypertension, and anemia. Occasionally, they also exhibit features of the nephrotic syndrome. Many patients have elevated serum transaminases and an elevated rheumatoid factor. Hypocomplementemia is very common, with C4 typically more reduced than C3. Cryoglobulinemic disease is discussed above. Membranous glomerulopathy is the least common of the three and presents with a typical nephrotic picture; neither cryoglobulins nor rheumatoid factor is present.

▶ Treatment

In patients with hepatitis C virus–associated MPGN not receiving treatment for liver disease, the question arises whether to initiate therapy for kidney disease. The main indications for therapy are poor renal function, nephrotic syndrome, new or worsening hypertension, fibrosis or tubulointerstitial disease on biopsy, and progressive disease. IFN- α may result in suppression of viremia and improvement in hepatic function. Renal function rarely improves unless viral suppression occurs; however, renal function often worsens when therapy is abated. Ribavirin is relatively contraindicated in kidney disease because of the dose-related hemolysis that occurs with renal dysfunction. Despite this, some case series have shown benefit with combined IFN- α and ribavirin in closely monitored settings.

Perico N et al. Hepatitis C infection and chronic renal diseases. *Clin J Am Soc Nephrol.* 2009 Jan;4(1):207–20. [PMID: 19129320]

SYSTEMIC LUPUS ERYTHEMATOSUS

Systemic lupus erythematosus is an autoimmune disease in which renal involvement is common. In various series, renal involvement ranges from 35% to 90% (see Chapter 20), with the higher estimates encompassing subclinical disease.

Lupus nephritis may present as any entity in the spectrum of clinical glomerular disease, although most presentations are as glomerulonephritis. Nonglomerular syndromes include tubulointerstitial nephritis and vasculitis. All patients with systemic lupus erythematosus should have routine urinalyses to monitor for the appearance of hematuria or proteinuria. If urinary abnormalities are detected, renal biopsy is often performed. The 2003 International Society of Nephrology and Renal Pathology Society (ISN/RPS) classification of renal glomerular lesions is class I, minimal mesangial nephritis; class II, mesangial proliferative nephritis; class III, focal (< 50% of glomeruli affected with capillary involvement) proliferative nephritis;

class IV, diffuse (> 50% of glomeruli affected with capillary involvement) proliferative nephritis; class V, membranous nephropathy; and class VI, advanced sclerosis without residual disease activity. Classes III and IV, the most severe forms of lupus nephritis, are further classified as active or chronic, and global or segmental, which confers additional prognostic value.

▶ Treatment

Individuals with **class I** and **class II lesions** require no treatment. Transformation of these types to a more active lesion may occur and is usually accompanied by an increase in lupus serologic activity and evidence of deteriorating renal function (eg, rising serum creatinine, increasing proteinuria). Repeat biopsy to confirm the transformation in these patients is recommended. Patients with extensive **class III lesions** and all **class IV lesions** should receive aggressive immunosuppressive therapy. The features signifying the poorest prognosis in patients with class III or IV lesions include elevated serum creatinine, lower complement levels, male sex, presence of antiphospholipid antibodies, nephrotic-range proteinuria, black race, and poor response to therapy. Indications for treatment of **class V lesions** are unclear; however, if superimposed proliferative lesions exist, aggressive therapy should be instituted.

Treatment of **proliferative lupus nephritis** consists of induction therapy, followed by maintenance treatment. All induction therapy includes corticosteroids (eg, methylprednisolone 1 g intravenously daily for 3 days followed by prednisone, 1 mg/kg orally daily with subsequent taper over 4–6 weeks) in combination with either cyclophosphamide or mycophenolate mofetil. Current data suggest that blacks and Hispanics respond more favorably to mycophenolate mofetil rather than cyclophosphamide; in addition, mycophenolate mofetil has a more favorable side-effect profile than does cyclophosphamide. Cyclophosphamide induction regimens vary but usually involve monthly intravenous pulse doses (500–750 mg/m²) for 4–8 months. Induction is followed by daily oral mycophenolate mofetil or azathioprine maintenance therapy. A recent trial showed that mycophenolate mofetil was superior to azathioprine maintenance and caused few adverse effects. Mycophenolate mofetil induction is typically given at 2–3 g/d, then tapered to 1–2 g/d for maintenance. Tacrolimus or cyclosporine may also be considered, but the relapse rate is high upon discontinuation of these agents. Rituximab has also been used for induction therapy, but clinical trial data are lacking. Remission rates with induction vary from 80% for partial remission to 50–60% for full remission; it may take more than 6 months to see these effects. Relapse is common and rates of disease flare are higher in those who do not experience complete remission; similarly, progression to ESRD is more common in those who relapse more frequently, or in whom no remission has been achieved.

The normalization of various laboratory tests (double-stranded DNA antibodies, serum C3, C4, CH₅₀ levels) can be useful in monitoring treatment. Urinary protein levels and sediment activity are also helpful markers. Patients with systemic lupus erythematosus who undergo dialysis have a

favorable prospect for long-term survival; interestingly, systemic lupus symptoms may become quiescent with the development of ESRD. Patients with systemic lupus erythematosus undergoing kidney transplants have recurrent renal disease in 8% of cases.

Dooley MA et al. Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. *N Engl J Med*. 2011 Nov 17; 365(20):1886–95. [PMID: 22087680]

Ortega LM et al. Lupus nephritis: pathologic features, epidemiology and a guide to therapeutic decisions. *Lupus*. 2010 Apr; 19(5):557–74. [PMID: 20089610]

Tesar V et al. Treatment of proliferative lupus nephritis: a slowly changing landscape. *Nat Rev Nephrol*. 2011 Feb;7(2):96–109. [PMID: 21173789]

NEPHROTIC SPECTRUM GLOMERULAR DISEASES



ESSENTIALS OF DIAGNOSIS

- ▶ Bland urine sediment (few if any cells or cellular casts).
- ▶ Full-blown nephrotic syndrome consists of the following:
 - -Urine protein excretion > 3 g per 24 hours.
 - -Hypoalbuminemia (albumin < 3 g/dL).
 - -Peripheral edema.
 - -Hyperlipidemia.
 - -Oval fat bodies in the urine.

▶ General Considerations

In adults, about one-third of patients with nephrotic syndrome have a systemic disease such as diabetes mellitus, amyloidosis, or systemic lupus erythematosus. With the current epidemic of type 2 diabetes mellitus, the proportion with diabetes is slowly increasing. The remainder have proteinuria due to primary renal disease. The most common causes are minimal change disease, focal segmental glomerulosclerosis, membranous nephropathy, and MPGN (see above). Any of these disease processes can present on the less severe end of the spectrum with a bland urinalysis and proteinuria, or with the full-blown nephrotic syndrome. Serum creatinine may or may not be abnormal at the time of presentation, depending on the severity, acuity and chronicity of the disease.

▶ Clinical Findings

A. Symptoms and Signs

Peripheral edema is a hallmark of the nephrotic syndrome, occurring when the serum albumin concentration is < 3 g/dL (30 g/L). Edema is most likely due to sodium retention and, at albumin levels < 2 g/dL (20 g/L), arterial underfilling from low plasma oncotic pressure. Initially, this presents in

the dependent areas of the body subject to gravity, such as the lower extremities; however, such edema can become generalized, including notable periorbital edema. Patients can experience dyspnea due to pulmonary edema, pleural effusions, and diaphragmatic compromise with ascites. Complaints of abdominal fullness may also be present in patients with ascites.

Patients with the nephrotic syndrome may also have an increase incidence of infection owing to loss of immunoglobulins and certain complement moieties in the urine; similarly, there can be increased risk of venous thrombosis secondary to loss of anticoagulant factors.

B. Laboratory Findings

1. Urinalysis—Proteinuria occurs as a result of effacement of podocytes (foot processes) and an alteration of the negative charge of the GBM. The screening test for proteinuria is the urinary dipstick analysis; however, this test indicates albumin only. The addition of sulfosalicylic acid to the urine sediment allows abnormal paraproteins to be detected. A spot urine protein to urine creatinine ratio gives a reasonable approximation of grams of protein excreted per day.

Microscopically, the urinary sediment has relatively few cellular elements or casts. However, if marked hyperlipidemia is present, the urine can have oval fat bodies resulting from lipid deposits in sloughed renal tubular epithelial cells. They appear as “grape clusters” under light microscopy and “Maltese crosses” under polarized light.

2. Blood chemistries—The nephrotic syndrome results in hypoalbuminemia (< 3 g/dL [30 g/L]) and hypoproteinemia (< 6 g/dL [60 g/L]). Hyperlipidemia occurs in over 50% of patients with early nephrotic syndrome, and becomes more frequent and worsens in degree as the severity of the nephritic syndrome increases. A fall in oncotic pressure triggers increased hepatic production of lipids (cholesterol and apolipoprotein B). There is also decreased clearance of very low-density lipoproteins, causing hypertriglyceridemia. Patients may also have an elevated erythrocyte sedimentation rate as a result of alterations in some plasma components such as increased levels of fibrinogen. Patients may become deficient in vitamin D, zinc, and copper from loss of binding proteins in the urine.

Laboratory testing to determine the underlying cause may include complement levels, serum and urine protein electrophoresis, antinuclear antibodies, and serologic tests for hepatitis.

3. Renal biopsy—Renal biopsy is often performed in adults with new-onset idiopathic nephrotic syndrome if a primary renal disease that may require drug therapy (eg, corticosteroids, cytotoxic agents) is suspected. Chronically and significantly elevated creatinine levels may indicate irreversible kidney disease mitigating the usefulness of kidney biopsy. In the setting of long-standing diabetes mellitus type 1 or 2, proteinuric renal disease is rarely biopsied unless atypical features (such as significant glomerular hematuria or cellular casts) are also present, or if there is other reason to suspect a second renal lesion.

► Treatment

A. Protein Loss

The daily total dietary protein intake should replace the daily urinary protein losses so as to avoid negative nitrogen balance. Protein malnutrition often occurs with urinary protein losses > 10 g/d. In the past, protein restriction was suggested for patients with kidney disease. The largest human trial to date (the MDRD Study) did not show a significant benefit, but two meta-analyses in 1999 and 2001 have shown a mild renal benefit. For this reason, the KDOQI recommends protein restriction to 0.6–0.8 g/kg/d in patients with a GFR < 25 mL/min/1.73 m² prior to starting dialysis. However, great care must be taken to avoid malnutrition in these patients.

In both diabetic and nondiabetic patients, therapy that is aimed at reducing proteinuria may also reduce progression of renal disease. ACE inhibitors and ARBs lower urine protein excretion by lowering efferent arteriolar resistance, thereby reducing glomerular capillary pressure; they also have antifibrotic effects. ACE inhibitors and ARBs can be used in patients with reduced GFR as long as significant hyperkalemia (potassium > 5.2–5.5 mEq/L) does not occur and serum creatinine rises < 30%; these patients should be monitored closely to avoid acute kidney injury and hyperkalemia. The combination of an ACE inhibitor and ARB versus ARB alone for slowing the progression of diabetic nephropathy is being tested in a multicenter, prospective randomized study.

B. Edema

Dietary salt restriction is essential for managing edema; most patients also require diuretic therapy. Commonly used diuretics include thiazide and loop diuretics (both are highly protein bound). With hypoalbuminemia and decreased GFR, diuretic delivery to the kidney is reduced, and patients often require larger doses. A combination of loop and thiazide diuretics can potentiate the diuretic effect. This may be needed for patients with refractory fluid retention.

C. Hyperlipidemia

Hypercholesterolemia and hypertriglyceridemia occur as noted above. Dietary modification and exercise should be advocated; however, effective lipid-lowering usually also requires pharmacologic treatment (see Chapter 28). Statins are hepatically cleared, so dosage is not altered for CKD. Rhabdomyolysis, however, is more common in patients with CKD who take gemfibrozil in combination with statins; combining fenofibrate or niacin with a statin poses less risk of rhabdomyolysis.

D. Hypercoagulable State

Patients with serum albumin < 2 g/dL can become hypercoagulable. Nephrotic patients have urinary losses of antithrombin, protein C, and protein S and increased platelet activation. Patients are prone to renal vein thrombosis and other venous thromboemboli, particularly with membranous glomerulopathy. Anticoagulation therapy is

warranted for at least 3–6 months in patients with evidence of thrombosis in any location. Patients with renal vein thrombosis or recurrent thromboemboli require indefinite anticoagulation.

► When to Refer

Any patient noted to have nephrotic syndrome should be referred immediately to a nephrologist for aggressive volume and blood pressure management, assessment for renal biopsy, and treatment of the underlying disease. Proteinuria of > 1 g/d without the nephrotic syndrome also merits nephrology referral, though with less urgency.

► When to Admit

Patients with edema refractory to outpatient therapy or rapidly worsening kidney function that may require inpatient interventions should be admitted.

Haider DG et al. Kidney biopsy in patients with diabetes mellitus. *Clin Nephrol.* 2011 Sep;76(3):180–5. [PMID: 21888854]
Kodner C. Nephrotic syndrome in adults: diagnosis and management. *Am Fam Physician.* 2009 Nov 15;80(10):1129–34. [PMID: 19904897]

NEPHROTIC SPECTRUM DISEASE IN PRIMARY RENAL DISORDERS

MINIMAL CHANGE DISEASE



ESSENTIALS OF DIAGNOSIS

- Nephrotic range proteinuria.
- Kidney biopsy shows no changes on light microscopy.
- Characteristic foot-process effacement on electron microscopy.

► General Considerations

Minimal change disease is the most common cause of proteinuric renal disease in children, accounting for about 80% of cases. It often remits upon treatment with a course of corticosteroids. Indeed, children with nephrotic syndrome are often treated for minimal change disease empirically without a biopsy diagnosis. Biopsy should be considered for children with nephrotic syndrome who exhibit unusual features (such as signs of other systemic illness), who are steroid-resistant (see below), or who relapse frequently upon withdrawal of corticosteroid therapy. Minimal change disease is less common in adults, accounting for 20–25% of cases of primary nephrotic syndrome in those over age 40 years. This entity can be idiopathic but also occurs following viral upper respiratory infections (especially in children), in association with tumors such as Hodgkin disease, with drugs (lithium), and with hypersensitivity reactions (especially to NSAIDs and bee stings).

► Clinical Findings

A. Symptoms and Signs

Patients often exhibit the manifestations of full-blown nephrotic syndrome. They are more susceptible to infection, especially with gram-positive organisms, have a tendency toward thromboembolic events, develop severe hyperlipidemia, and experience protein malnutrition. Minimal change disease can rarely cause acute kidney injury due to tubular changes and interstitial edema.

B. Histologic Findings

Glomeruli show no changes on light microscopy or immunofluorescence. On electron microscopy, there is a characteristic effacement of podocyte foot processes. A subgroup of patients also shows mesangial cell proliferation; such patients have more hematuria and hypertension and poor response to standard corticosteroid treatment.

► Treatment

Treatment is with prednisone, 60 mg/m²/d orally. Adults often require longer courses of therapy than children. It can take up to 16 weeks to achieve a response to corticosteroids. Treatment should be continued for several weeks after complete remission of proteinuria. A significant number of patients will relapse and require further corticosteroid treatment. Steroid-resistant nephrotic syndrome is defined as persistent proteinuria after a 4-week course of prednisone. Patients with frequent relapses or corticosteroid resistance may need cyclophosphamide or cyclosporine to induce subsequent remissions; tacrolimus or rituximab may also be considered, although controlled trials are lacking. Progression to ESRD is rare. Complications most often arise from prolonged corticosteroid use.

Palmer SC et al. Interventions for minimal change disease in adults with nephrotic syndrome. *Cochrane Database Syst Rev.* 2008 Jan 23;(1):CD001537. [PMID: 18253993]

Roberti I et al. Long-term outcome of children with steroid-resistant nephrotic syndrome treated with tacrolimus. *Pediatr Nephrol.* 2010 Jun;25(6):1117–24. [PMID: 20217433]

van Husen M et al. New therapies in steroid-sensitive and steroid-resistant idiopathic nephrotic syndrome. *Pediatr Nephrol.* 2011 Jun;26(6):881–92. [PMID: 21229269]

MEMBRANOUS NEPHROPATHY

ESSENTIALS OF DIAGNOSIS

- Nephrotic range proteinuria.
- Associated with coagulopathy, eg, renal vein thrombosis, if nephrotic syndrome present.
- “Spike and dome” pattern on kidney biopsy from subepithelial deposits.
- Secondary causes notably include hepatitis B virus and carcinomas.

► General Considerations

Membranous nephropathy is the most common cause of primary nephrotic syndrome in adults, usually presenting in the fifth and sixth decades. It is an immune-mediated disease characterized by immune complex deposition in the subepithelial portion of glomerular capillary walls. The antigen in the primary form of the disease appears to be a phospholipase A₂ receptor (PLA₂R) on the podocyte in 70–80% of patients. Secondary disease is associated with underlying carcinomas; infections, such as hepatitis B, endocarditis, and syphilis; autoimmune disease, such as systemic lupus erythematosus, mixed connective tissue disease, and thyroiditis; and certain drugs, such as penicillamine and captopril. The course of disease is variable, with about 50% of patients progressing to ESRD over 3–10 years. Poorer outcome is associated with concomitant tubulointerstitial fibrosis, male sex, elevated serum creatinine, hypertension, and heavy proteinuria (> 10 g/d).

► Clinical Findings

A. Symptoms and Signs

Patients with membranous nephropathy and nephrotic syndrome have a higher risk of hypercoagulable state than those with nephrosis from other etiologies; there is a particular predisposition to renal vein thrombosis in these patients. There may be symptoms or signs of an underlying infection or neoplasm (especially lung, stomach, breast, and colon cancers) in secondary membranous nephropathy.

B. Laboratory Findings

See above for laboratory findings in the nephrotic syndrome. Serum evaluation for circulating PLA₂R antibodies to assess for idiopathic membranous nephropathy may be available in the future. By light microscopy, capillary wall thickness is increased without inflammatory changes or cellular proliferation; when stained with silver methenamine, a “spike and dome” pattern may be observed owing to projections of excess GBM between the subepithelial deposits. Immunofluorescence shows IgG and C3 uniformly along capillary loops. Electron microscopy shows a discontinuous pattern of dense deposits along the subepithelial surface of the basement membrane.

► Treatment

Treatment is controversial. After underlying causes are excluded, treatment depends on the risk of renal disease progression. One algorithm is based on the degree of proteinuria. In patients with proteinuria < 3.5 g/d, the risk of progression is low. These individuals should be closely monitored with a low-salt diet, strict blood pressure control, and an ACE inhibitor or ARB for reduction of proteinuria. Patients with proteinuria of 3.5–8 g/d but normal renal function are at moderate risk. They should follow the above suggestions and can elect immunosuppressive regimens with corticosteroids and chlorambucil or cyclophosphamide for 6 months, although only 65% of these patients experience partial or complete remission within 3–4 years.

Cyclosporine is a second choice. The highest-risk patients—those with > 8 g/d of proteinuria and possible renal dysfunction—might receive corticosteroids with a cytotoxic agent as first-line immunosuppressant therapy, though the choice of cyclosporine is also reasonable. Mycophenolate mofetil and rituximab are becoming more widely accepted as possible first-line agents of treatment or for patients who relapse or do not tolerate other immunosuppressive agents. Patients with primary membranous nephropathy are excellent candidates for transplant.

Cravedi P et al. Efficacy and safety of rituximab second-line therapy for membranous nephropathy: a prospective, matched-cohort study. *Am J Nephrol.* 2011;33(5):461–8. [PMID: 21508634]

Hofstra JM et al. Anti-phospholipase A₂ receptor antibodies correlate with clinical status in idiopathic membranous nephropathy. *Clin J Am Soc Nephrol.* 2011 Jun;6(6):1286–91. [PMID: 21474589]

Hofstra JM et al. Management of patients with membranous nephropathy. *Nephrol Dial Transplant.* 2012 Jan; 27(1):6–9. [PMID: 21737514]

FOCAL SEGMENTAL GLOMERULOSCLEROSIS

This lesion can present as idiopathic disease or secondary to such conditions as heroin use, morbid obesity, chronic urinary reflux, and HIV infection. Idiopathic disease may be related to heritable abnormalities of any of several podocyte proteins. Clinically, patients with nephrotic spectrum findings may have overt nephrotic syndrome. Decreased kidney function is present in 25–50% at time of diagnosis. Patients with focal segmental glomerulosclerosis and nephrotic syndrome typically progress to ESRD in 6–8 years.

Diagnosis requires renal biopsy. Light microscopy shows sclerosis of portions (or segments) of some, but not all glomeruli (thus, focal and not diffuse disease). IgM and C3 are seen in the sclerotic lesions on immunofluorescence, although it is presumed that these immune components are simply trapped in the sclerotic glomeruli and are not participating in the pathogenesis of the disease. Electron microscopy shows fusion of epithelial foot processes as seen in minimal change disease.

Treatment for primary focal segmental glomerulosclerosis is controversial, although supportive care for nephrotic patients is indicated (diuretics for edema, ACE inhibitors or ARBs to target proteinuria and hypertension, statins or niacin for hyperlipidemia). High-dose oral prednisone (1–1.5 mg/kg/d) for 2–3 months followed by a slow taper can induce remission within 5–9 months in over half of patients. Other cytotoxic drug therapy can be considered for steroid-resistant patients, including calcineurin inhibitors and mycophenolate mofetil. For those patients with primary focal segmental glomerulosclerosis who progress to ESRD and undergo renal transplantation, relapse rate and graft loss is relatively high; plasma exchange therapy just prior to transplant and with early signs of relapse appear to be beneficial in lowering risk of these outcomes.

Gbadegesin R et al. Pathogenesis and therapy of focal segmental glomerulosclerosis: an update. *Pediatr Nephrol.* 2011 Jul; 26(7):1001–15. [PMID: 21110043]

Meyrier A. Focal and segmental glomerulosclerosis: multiple pathways are involved. *Semin Nephrol.* 2011 Jul;31(4):326–32. [PMID: 21839365]

Uliniski T. Recurrence of focal segmental glomerulosclerosis after kidney transplantation: strategies and outcome. *Curr Opin Organ Transplant.* 2010 Oct;15(5):628–32. [PMID: 20733489]

NEPHROTIC SPECTRUM DISEASE FROM SYSTEMIC DISORDERS

AMYLOIDOSIS

Amyloidosis is caused by extracellular deposition of the fibrous protein amyloid in one or more sites in the body. The amyloid fibrils are composed of proteins that have formed characteristic β -pleated sheets. Primary renal amyloidosis (AL amyloidosis) may occur in the absence of systemic disease or associated with multiple myeloma; indeed, both are plasma cell dyscrasias, which overproduce immunoglobulin light chain (the amyloid protein). Serum and urine protein electrophoresis can be helpful in delineating the light chain present in such cases. Secondary amyloidosis (AA amyloidosis) is due to a chronic inflammatory disease, such as rheumatoid arthritis, inflammatory bowel disease, or chronic infection. In these cases, acute phase reactant serum amyloid A is synthesized in the liver and deposited in the tissues. Amyloid-affected kidneys can be enlarged as a result of this deposition disease. Pathologically, glomeruli are filled with amorphous deposits that stain positive with Congo red and show green birefringence.

Treatment options are few. Remissions can occur in secondary amyloidosis if the inciting agent is removed. Primary amyloidosis of the kidney progresses to ESRD in an average of 2–3 years. Five-year overall survival is <20%, with death occurring from ESRD and heart disease. The use of alkylating agents and corticosteroids—eg, melphalan and prednisone—can reduce proteinuria and improve renal function in a small percentage of patients. Significant reduction in free light chain burden (>90%) has been shown to correlate with improved renal outcomes. Melphalan and stem cell transplantation are associated with high toxicity (45% mortality) but induce remission in 80% of the remaining patients. Renal transplant is an option in patients with secondary amyloid.

Pinney JH et al. Outcome in renal AL amyloidosis after chemotherapy. *J Clin Oncol.* 2011 Feb 20;29(6):674–81. [PMID: 21220614]

Qu Z et al. Clinical and pathological features of renal amyloidosis: an analysis of 32 patients in a single Chinese centre. *Nephrology (Carlton).* 2010 Feb;15(1):102–7. [PMID: 20377777]

DIABETIC NEPHROPATHY



ESSENTIALS OF DIAGNOSIS

- ▶ Prior evidence of diabetes mellitus, typically over 10 years.
- ▶ Albuminuria (microscopic or macroscopic) precedes decline in GFR.
- ▶ Signs of diabetic nephropathy on renal biopsy, if done.
- ▶ Other end-organ damage, such as retinopathy, is common.

▶ General Considerations

Diabetic nephropathy is the most common cause of ESRD in the United States (about 4000 cases a year). Type 1 diabetes mellitus carries a 30–40% risk of nephropathy after 20 years, whereas type 2 has a 15–20% risk after 20 years. ESRD is much more likely to develop in persons with type 1 diabetes mellitus, in part due to fewer comorbidities and deaths before ESRD ensues. With the current epidemic of obesity and type 2 diabetes mellitus, rates of diabetic nephropathy are projected to continue to increase. Patients at higher risk include males, African Americans, and Native Americans.

▶ Clinical Findings

The first stage of diabetic nephropathy is hyperfiltration, with an increase in GFR, followed by the development of microalbuminuria (30–300 mg/d). As the nephropathy progresses, (macro)albuminuria (> 300 mg/d, or enough to be detected on regular dipstick) is seen, and the GFR returns to normal and then goes on to decrease. Yearly screening for the development of microalbuminuria is recommended for all diabetic patients. In patients prone to nephropathy, microalbuminuria develops within 10–15 years after onset of diabetes and progresses over the next 3–7 years to overt proteinuria (> 300 mg of albuminuria per day).

The most common lesion in diabetic nephropathy is diffuse glomerulosclerosis, but nodular glomerulosclerosis (Kimmelstiel-Wilson nodules) is pathognomonic. The kidneys in these patients are usually enlarged as a result of cellular hypertrophy and proliferation.

Patients with diabetes are prone to other renal disease. These include papillary necrosis, chronic interstitial nephritis, and type 4 (hyporeninemic hypoaldosteronemic) renal tubular acidosis. Patients are more susceptible to acute kidney injury from many insults, including intravenous contrast material and concomitant use of renin-angiotensin blockers (eg, ACE inhibitors) and NSAIDs. In diabetic patients with consequent comorbidities, there is a poor prognosis once dialysis is begun.

▶ Treatment

With the onset of microalbuminuria, aggressive treatment is necessary. Strict glycemic control and treatment of

hypertension have been proven to slow progression of disease; current guidelines support a goal blood pressure of 130/80 mm Hg in most patients, and possibly 120/75 mm Hg in overtly proteinuric patients. In particular, ACE inhibitors and ARBs lower the rate of progression to clinical proteinuria and slow progression to ESRD by reducing intraglomerular pressure as well as by treating hypertension; they may also have antifibrotic effects. Even in the subset of patients with markedly diminished GFR, these agents seem to provide renal benefit if patients can avoid hyperkalemia and as long as GFR does not decline more than 30% with the initiation of this therapy. Some experts have advocated for combination ACE inhibitor and ARB therapy as a way to maximally target proteinuria; however, the ONTARGET trial suggested great caution in using combination therapy because of the development of hyperkalemia and worsening kidney function in the group given both telmisartan and ramipril.

de Boer IH et al. Temporal trends in the prevalence of diabetic kidney disease in the United States. *JAMA*. 2011 Jun 22; 305(24):2532–9. [PMID: 21693741]

Rossing P et al. Need for better diabetes treatment for improved renal outcome. *Kidney Int Suppl*. 2011 Mar;(120):S28–32. [PMID: 21358699]

Ruggenti P et al. The RAAS in the pathogenesis and treatment of diabetic nephropathy. *Nat Rev Nephrol*. 2010 Jun;6(6): 319–30. [PMID: 20440277]

Seaquist ER et al. Approach to the patient with type 2 diabetes and progressive kidney disease. *J Clin Endocrinol Metab*. 2010 Jul;95(7):3103–10. [PMID: 20610606]

Ting RZ et al. Treatment and landmark clinical trials for renoprotection. *Contrib Nephrol*. 2011;170:184–95. [PMID: 21659771]

HIV-ASSOCIATED NEPHROPATHY

HIV-associated nephropathy can present as the nephrotic syndrome in patients with HIV infection. Decline in GFR can progress rapidly. Most patients are black, possibly because of a genetic predisposition. Often, patients have low CD4 counts and have advanced HIV disease, but HIV-associated nephropathy can also be the initial presentation of disease.

Light microscopy shows focal segmental glomerulosclerosis as described above. Lesions are often of the collapsing variety, and renal biopsy specimens also exhibit severe tubulointerstitial damage.

Small, uncontrolled studies have shown that highly active antiretroviral therapy (HAART) for a prolonged course can slow progression of disease. Despite this minimal evidence, HAART has been recommended for use in these patients given the therapy's other beneficial effects and reasonable toxicity profile. Either ACE inhibitors or ARBs can be used to control blood pressure and slow disease progression. Corticosteroid treatment has been used with variable success at a dosage of 1 mg/kg/d, along with cyclosporine.

Atta MG. Diagnosis and natural history of HIV-associated nephropathy. *Adv Chronic Kidney Dis*. 2010 Jan;17(1):52–8. [PMID: 20005489]

Kalayjian RC. The treatment of HIV-associated nephropathy. *Adv Chronic Kidney Dis*. 2010 Jan;17(1):59–71. [PMID: 20005490]

TUBULOINTERSTITIAL DISEASES

Tubulointerstitial disease may be acute or chronic. Acute disease is most commonly associated with medications, infectious agents, and systemic rheumatologic disorders. Interstitial edema, infiltration with polymorphonuclear neutrophils, and tubular cell necrosis can be seen. (See Acute Kidney Injury, above, and Table 22–11.) Chronic disease is associated with insults from an acute factor or progressive insults without any obvious acute cause. Interstitial fibrosis and tubular atrophy are present, with a mononuclear cell predominance. The chronic disorders are described below.

CHRONIC TUBULOINTERSTITIAL DISEASES



ESSENTIALS OF DIAGNOSIS

- ▶ Kidney size is small and contracted.
- ▶ Decreased urinary concentrating ability.
- ▶ Hyperchloremic metabolic acidosis.
- ▶ Reduced GFR.

Table 22–11. Causes of acute tubulointerstitial nephritis (abbreviated list).

Drug reactions	
Antibiotics	
β-Lactam antibiotics: methicillin, penicillin, ampicillin, cephalosporins	
Ciprofloxacin	
Erythromycin	
Sulfonamides	
Tetracycline	
Vancomycin	
Trimethoprim-sulfamethoxazole	
Ethambutol	
Rifampin	
Nonsteroidal anti-inflammatory drugs	
Diuretics	
Thiazides	
Furosemide	
Miscellaneous	
Allopurinol	
Cimetidine	
Phenytoin	
Systemic infections	
Bacteria	
<i>Streptococcus</i>	
<i>Corynebacterium diphtheriae</i>	
<i>Legionella</i>	
Viruses	
Epstein-Barr	
Others	
Mycoplasma	
<i>Rickettsia rickettsii</i>	
<i>Leptospira icterohaemorrhagiae</i>	
<i>Toxoplasma</i>	
Idiopathic	
Tubulointerstitial nephritis-uveitis (TIN-U)	

General Considerations

The primary causes of chronic tubulointerstitial disease are discussed below. Other causes include multiple myeloma and gout, which are discussed in the section on multisystem disease with variable kidney involvement.

A. Obstructive Uropathy

The most common cause of chronic tubulointerstitial disease is prolonged obstruction of the urinary tract. In partial obstruction, patients can exhibit polyuria (possibly due to vasopressin insensitivity and poor ability to concentrate the urine) or oliguria (due to decreased GFR). Azotemia and hypertension (due to increased renin-angiotensin production) are usually present. The major causes are prostatic disease in men; ureteral calculus in a single functioning kidney; bilateral ureteral calculi; carcinoma of the cervix, colon, or bladder; and retroperitoneal tumors or fibrosis.

Abdominal, rectal, and genitourinary examinations are helpful. Urinalysis can show hematuria, pyuria, and bacteriuria but is often benign. Abdominal ultrasound may detect mass lesions, hydronephrosis, and hydronephrosis. CT scanning and MRI provide more detailed information.

B. Vesicoureteral Reflux

Reflux nephropathy is primarily a disorder of childhood and occurs when urine passes retrograde from the bladder to the kidneys during voiding. It is the second most common cause of chronic tubulointerstitial disease. It occurs as a result of an incompetent vesicoureteral sphincter. Urine can extravasate into the interstitium; an inflammatory response develops, and fibrosis occurs. The inflammatory response is due to either bacteria or normal urinary components.

Patients are typically diagnosed as young children with a history of recurrent urinary tract infections. This entity can be detected before birth via screening fetal ultrasonography. After birth, a voiding cystourethrogram can be done. Less commonly, this entity is not diagnosed until adolescence or young adulthood when patients present with hypertension and substantial proteinuria, unusual in most tubular diseases. At this point, renal ultrasound or IVP can show renal scarring and hydronephrosis. IVP is relatively contraindicated in patients with kidney dysfunction who are at higher risk for contrast nephropathy. On renal biopsy, focal glomerulosclerosis can be seen in those with kidney damage. Although most damage occurs before age 5 years, progressive renal deterioration to ESRD continues as a result of the early insults.

C. Analgesics

Analgesic nephropathy is most commonly seen in patients who ingest large quantities of analgesic combinations. The drugs of concern are phenacetin, paracetamol, aspirin, and NSAIDs, with acetaminophen a possible but less certain culprit. Ingestion of at least 1 g/d for 3 years of these

analgesics is considered necessary for kidney dysfunction to develop. This disorder occurs most frequently in individuals who are using analgesics for chronic headaches, muscular pains, and arthritis. Most patients grossly underestimate their analgesic use.

Tubulointerstitial inflammation and papillary necrosis are seen on pathologic examination. Papillary tip and inner medullary concentrations of some analgesics are tenfold higher than in the renal cortex. Phenacetin—once a common cause of this disorder and now rarely available—is metabolized in the papillae by the prostaglandin hydroperoxidase pathway to reactive intermediates that bind covalently to interstitial cell macromolecules, causing necrosis. Aspirin and other NSAIDs can cause damage by their metabolism to active intermediates which can result in cell necrosis. These drugs also decrease medullary blood flow (via inhibition of prostaglandin synthesis) and decrease glutathione levels, which are necessary for detoxification.

Patients can exhibit hematuria, mild proteinuria, polyuria (from tubular damage), anemia (from GI bleeding or erythropoietin deficiency), and sterile pyuria. As a result of papillary necrosis, sloughed papillae can be found in the urine. An IVP may be helpful for detecting these—contrast will fill the area of the sloughed papillae, leaving a “ring shadow” sign at the papillary tip. However, IVP is rarely used in patients with significant kidney dysfunction, given the need for dye and associated acute kidney injury.

D. Heavy Metals

Environmental exposure to heavy metals—such as lead and cadmium—is seen infrequently now in the United States. Chronic lead exposure can lead to tubulointerstitial disease. Individuals at risk are those with occupational exposure (eg, welders who work with lead-based paint) and drinkers of alcohol distilled in automobile radiators (“moonshine” whiskey users). Lead is filtered by the glomerulus and is transported across the proximal convoluted tubules, where it accumulates and causes cell damage. Fibrosed arterioles and cortical scarring also lead to damaged kidneys. Proximal tubular damage leads to decreased secretion of uric acid, resulting in hyperuricemia and saturnine gout. Patients commonly are hypertensive. Diagnosis is most reliably performed with a calcium disodium edetate (EDTA) chelation test. Urinary excretion of > 600 mg of lead in 24 hours following 1 g of EDTA indicates excessive lead exposure.

Occupational exposure to cadmium also causes proximal tubular dysfunction. Hypercalciuria and nephrolithiasis can be seen. Other heavy metals that can cause tubulointerstitial disease include mercury and bismuth.

▶ Clinical Findings

A. Symptoms and Signs

Polyuria is common because tubular damage leads to inability to concentrate the urine. Volume depletion can also occur as a result of a salt-wasting defect in some individuals.

B. Laboratory Findings

Patients can become hyperkalemic both because the GFR is lower and the distal tubules become aldosterone resistant. A hyperchloremic renal tubular acidosis is characteristic from a component of type 4 or type 1 renal tubular acidosis. Less commonly, a proximal renal tubular acidosis is seen due to direct proximal tubular damage. The cause of the renal tubular acidosis is threefold: (1) reduced ammonia production, (2) inability to acidify the distal tubules, and (3) proximal tubular bicarbonate wasting. The urinalysis is nonspecific, as opposed to that seen in acute interstitial nephritis. Proteinuria is typically < 2 g/d (owing to inability of the proximal tubule to reabsorb freely filterable proteins); a few cells may be seen; and broad waxy casts are often present.

▶ Treatment

Treatment depends first on identifying the disorder responsible for kidney dysfunction. The degree of interstitial fibrosis that has developed can help predict recovery of renal function. Once there is evidence for loss of parenchyma (small shrunken kidneys or interstitial fibrosis on biopsy), little can prevent the progression toward ESRD. Treatment is then directed at medical management. Tubular dysfunction may require potassium and phosphorus restriction and sodium, calcium, or bicarbonate supplements.

If hydronephrosis is present, relief of obstruction should be accomplished promptly. Prolonged obstruction leads to further tubular damage—particularly in the distal nephron—which may be irreversible despite relief of obstruction. Neither surgical correction of reflux nor medical therapy with antibiotics can prevent deterioration toward ESRD once renal scarring has occurred.

Patients in whom lead nephropathy is suspected should continue chelation therapy with EDTA if there is no evidence of irreversible renal damage (eg, renal scarring or small kidneys). Continued exposure should be avoided.

Treatment of analgesic nephropathy requires withdrawal of all analgesics. Stabilization or improvement of renal function may occur if significant interstitial fibrosis is not present. Hydration during exposure to analgesics may also have some beneficial effects.

▶ When to Refer

- Patients with stage 3–5 CKD should be referred to a nephrologist when tubulointerstitial diseases are suspected. Other select cases of stage 1–2 CKD should also be referred.
- Patients with urologic abnormalities should be referred to a urologist.

Gooch K et al. NSAID use and progression of chronic kidney disease. *Am J Med.* 2007 Mar;120(3):280.e1–7. [PMID: 17349452]

CYSTIC DISEASES OF THE KIDNEY

Renal cysts are epithelium-lined cavities filled with fluid or semisolid material. They develop primarily from renal

Table 22-12. Clinical features of renal cystic disease.

	Simple Renal Cysts	Acquired Renal Cysts	Autosomal Dominant Polycystic Kidney Disease	Medullary Sponge Kidney	Medullary Cystic Kidney
Prevalence	Common	Dialysis patients	1:1000	1:5000	Rare
Inheritance	None	None	Autosomal dominant	None	Autosomal dominant
Age at onset	20-40	40-60	Adulthood
Kidney size	Normal	Small	Large	Normal	Small
Cyst location	Cortex and medulla	Cortex and medulla	Cortex and medulla	Collecting ducts	Corticomedullary junction
Hematuria	Occasional	Occasional	Common	Rare	Rare
Hypertension	None	Variable	Common	None	None
Associated complications	None	Adenocarcinoma in cysts	Urinary tract infections, renal calculi, cerebral aneurysms 10-15%, hepatic cysts 40-60%	Renal calculi, urinary tract infections	Polyuria, salt wasting
Kidney failure	Never	Always	Frequently	Never	Always

tubular elements. One or more simple cysts are found in 50% of individuals over the age of 50 years. They are rarely symptomatic and have little clinical significance. In contrast, generalized cystic diseases are associated with cysts scattered throughout the cortex and medulla of both kidneys and can progress to ESRD (Table 22-12).

SIMPLE OR SOLITARY CYSTS

Simple cysts account for 65-70% of all renal masses. They are generally found at the outer cortex and contain fluid that is consistent with an ultrafiltrate of plasma. Most are found incidentally on ultrasonographic examination. Simple cysts are typically asymptomatic but can become infected.

The main concern with simple cysts is to differentiate them from malignancy, abscess, or polycystic kidney disease. Renal cystic disease can develop in dialysis patients. These cysts have a potential for progression to malignancy. Ultrasound and CT scanning are the recommended procedures for evaluating these masses. Simple cysts must meet three sonographic criteria to be considered benign: (1) echo free, (2) sharply demarcated mass with smooth walls, and (3) an enhanced back wall (indicating good transmission through the cyst). Complex cysts can have thick walls, calcifications, solid components, and mixed echogenicity. On CT scan, the simple cyst should have a smooth thin wall that is sharply demarcated. It should not enhance with contrast media. A renal cell carcinoma will enhance but typically is of lower density than the rest of the parenchyma. Arteriography can also be used to evaluate a mass preoperatively. A renal cell carcinoma is hypervascular in 80%, hypovascular in 15%, and avascular in 5% of cases.

If a cyst meets the criteria for being benign, periodic reevaluation is the standard of care. If the lesion is not consistent with a simple cyst, follow-up with a urologic consultant and possible surgical exploration is recommended.

Terada N et al. Risk factors for renal cysts. *BJU Int.* 2004 Jun;93(9):1300-2. [PMID: 15180627]

AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE



ESSENTIALS OF DIAGNOSIS

- ▶ Multiple cysts in bilateral kidneys; total number depends on age.
- ▶ Large, palpable kidneys on examination.
- ▶ Combination of hypertension and abdominal mass suggestive of disease.
- ▶ Family history is compelling but not necessary.
- ▶ Chromosomal abnormalities present in some patients.

▶ General Considerations

This disorder is among the most common hereditary diseases in the United States, affecting 500,000 individuals, or 1 in 800 live births. Fifty percent of patients will have ESRD by age 60 years. The disease has variable penetrance but accounts for 10% of dialysis patients in the United States. At least two genes account for this disorder: *ADPKD1* on the short arm of chromosome 16 (85-90% of patients) and *ADPKD2* on chromosome 4 (10-15%). Patients with the *PKD2* mutation have slower progression of disease and longer life expectancy than those with *PKD1*. Other sporadic cases without these mutations have also been recognized.

▶ Clinical Findings

Abdominal or flank pain and microscopic or gross hematuria are present in most patients. A history of urinary tract

infections and nephrolithiasis is common. A family history is positive in 75% of cases, and > 50% of patients have hypertension (see below) that may antedate the clinical manifestations of the disease. Patients have large kidneys that may be palpable on abdominal examination. The combination of hypertension and an abdominal mass should suggest the disease. Forty to 50 percent have concurrent hepatic cysts. Pancreatic and splenic cysts occur also. Hemoglobin and hematocrit tend to be maintained as a result of erythropoietin production by the cysts. The urinalysis may show hematuria and mild proteinuria. In patients with *PKD1*, ultrasonography confirms the diagnosis—two or more cysts in patients under age 30 years (sensitivity of 88.5%), two or more cysts in each kidney in patients age 30–59 years (sensitivity of 100%), and four or more cysts in each kidney in patients age 60 years or older are diagnostic for autosomal dominant polycystic kidney disease. If sonographic results are unclear, CT scan is recommended and highly sensitive.

► Complications & Treatment

A. Pain

Abdominal or flank pain is caused by infection, bleeding into cysts, and nephrolithiasis. Bed rest and analgesics are recommended. Cyst decompression can help with chronic pain.

B. Hematuria

Gross hematuria is most commonly due to rupture of a cyst into the renal pelvis, but it can also be caused by a kidney stone or urinary tract infection. Hematuria typically resolves within 7 days with bed rest and hydration. Recurrent bleeding should suggest the possibility of underlying renal cell carcinoma, particularly in men over age 50 years.

C. Renal Infection

An infected renal cyst should be suspected in patients who have flank pain, fever, and leukocytosis. Blood cultures may be positive, and urinalysis may be normal because the cyst does not communicate directly with the urinary tract. CT scans can be helpful because an infected cyst may have an increased wall thickness. Bacterial cyst infections are difficult to treat. Antibiotics with cystic penetration should be used, eg, fluoroquinolones or trimethoprim-sulfamethoxazole and chloramphenicol. Treatment may require 2 weeks of parenteral therapy followed by long-term oral therapy.

D. Nephrolithiasis

Up to 20% of patients have kidney stones, primarily calcium oxalate. Hydration (2–3 L/d) is recommended.

E. Hypertension

Fifty percent of patients have hypertension at time of presentation, and it will develop in most patients during the course of the disease. Cyst-induced ischemia appears to cause activation of the renin-angiotensin system, and cyst decompression can lower blood pressure temporarily. Hypertension should be treated aggressively, as this may prolong the time to ESRD. (Diuretics should be used cautiously since the effect on renal cyst formation is unknown.)

F. Cerebral Aneurysms

About 10–15% of these patients have arterial aneurysms in the circle of Willis. Screening arteriography is not recommended unless the patient has a family history of aneurysms or is undergoing elective surgery with a high risk of developing moderate to severe hypertension.

G. Other Complications

Vascular problems include mitral valve prolapse in up to 25% of patients, aortic aneurysms, and aortic valve abnormalities. Colonic diverticula are more common in patients with polycystic kidneys.

► Prognosis

Significant research is ongoing regarding therapy. Vasopressin receptor antagonists have been successful in animal models but have not yet been shown to be helpful in slowing down progression of disease in humans. These agents lower renal epithelial cell intracellular cyclic AMP (cAMP) levels, and in vitro evidence suggests that intracellular cAMP plays a significant role in cystogenesis in polycystic kidney disease. Other agents, octreotide and sirolimus, have shown a decreased rate of cyst growth but no decrease in the rate of decline in kidney function. Avoidance of caffeine may prevent cyst formation due to effects on G-coupled proteins. Treatment of hypertension and a low-protein diet may slow the progression of disease, although this is not well proven.

Grantham JJ. Clinical practice. Autosomal dominant polycystic kidney disease. *N Engl J Med*. 2008 Oct 2;359(14):1477–85. [PMID: 18832246]
 Schrier RW. Randomized intervention studies in human polycystic kidney and liver disease. *J Am Soc Nephrol*. 2010 Jun;21(6):891–3. [PMID: 20431043]
 Torres VE et al. Rationale and design of the TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and its Outcomes) 3-4 Study. *Am J Kidney Dis*. 2011 May;57(5):692–9. [PMID: 21333426]
 Watnick T et al. mTOR inhibitors in polycystic kidney disease. *N Engl J Med*. 2010 Aug 26;363(9):879–81. [PMID: 20581393]

MEDULLARY SPONGE KIDNEY

This disease is a relatively common and benign disorder that is present at birth and not usually diagnosed until the fourth or fifth decade. It is caused by autosomal dominant mutations in the *MCKD1* or *MCKD2* genes on chromosomes 1 and 16, respectively. Kidneys have a marked irregular enlargement of the medullary and interpapillary collecting ducts. This is associated with medullary cysts that are diffuse, giving a “Swiss cheese” appearance in these regions.

► Clinical Findings

Medullary sponge kidney presents with gross or microscopic hematuria, recurrent urinary tract infections, or nephrolithiasis. Common abnormalities are a decreased urinary concentrating ability and nephrocalcinosis; less common is incomplete type I distal renal tubular acidosis. The diagnosis can be made by CT, which shows cystic dilatation of the

distal collecting tubules, a striated appearance in this area, and calcifications in the renal collecting system.

► Treatment

There is no known therapy. Adequate fluid intake (2 L/d) helps prevent stone formation. If hypercalciuria is present, thiazide diuretics are recommended because they decrease calcium excretion. Alkali therapy is recommended if renal tubular acidosis is present.

► Prognosis

Renal function is well maintained unless there are complications from recurrent urinary tract infections and nephrolithiasis.

MULTISYSTEM DISEASES WITH VARIABLE KIDNEY INVOLVEMENT¹

MULTIPLE MYELOMA

Multiple myeloma is a malignancy of plasma cells (see Chapter 13). Renal involvement occurs in about 25% of all patients. “Myeloma kidney” is the presence of light chain immunoglobulins (Bence Jones protein) in the urine causing renal toxicity. Bence Jones protein causes direct renal tubular toxicity and results in tubular obstruction by precipitating in the tubules. The earliest tubular damage results in Fanconi syndrome (a type II proximal renal tubular acidosis). The proteinuria seen with multiple myeloma is primarily due to light chains that are not detected on urine dipstick, which mainly detects albumin. Hypercalcemia and hyperuricemia are frequently seen. Glomerular amyloidosis can develop in patients with multiple myeloma; in these patients, dipstick protein determinations are positive due to glomerular epithelial cell foot process effacement and albumin “spilling” into Bowman capsule with resultant albuminuria. Other conditions resulting in renal dysfunction include plasma cell infiltration of the renal parenchyma and a hyperviscosity syndrome compromising renal blood flow. Therapy for acute kidney injury attributed to multiple myeloma includes correction of hypercalcemia, volume repletion, and chemotherapy for the underlying malignancy. Plasmapheresis had been considered appropriate to decrease the burden of existing monoclonal proteins while awaiting chemotherapeutic regimens to take effect. However, in the largest randomized prospective trial to date, plasmapheresis did not provide any renal benefit to these patients. Pheresis therapy still remains controversial.

Clark WF et al. Plasma exchange for myeloma kidney: cast(s) away? *Kidney Int.* 2008 Jun;73(11):1211–3. [PMID: 18480853]
Roussou M et al. Reversibility of renal failure in newly diagnosed patients with multiple myeloma and the role of novel agents. *Leuk Res.* 2010 Oct;34(10):1395–7. [PMID: 20510452]

¹Other diseases with variable involvement described elsewhere in this chapter include systemic lupus erythematosus, diabetes mellitus, and the vasculitides such as granulomatosis with polyangiitis and Goodpasture disease.

SICKLE CELL DISEASE

Renal dysfunction associated with sickle cell disease is most commonly due to sickling of red blood cells in the renal medulla because of low oxygen tension and hypertonicity. Congestion and stasis lead to hemorrhage, interstitial inflammation, and papillary infarcts. Clinically, hematuria is common. Damage to renal capillaries also leads to diminished concentrating ability. Isosthenuria (urine osmolality equal to that of serum) is routine, and patients can easily become dehydrated. Papillary necrosis occurs as well. These abnormalities are commonly encountered in sickle cell trait. Sickle cell glomerulopathy is less common but will inexorably progress to ESRD. Its primary clinical manifestation is proteinuria. Optimal treatment requires adequate hydration and control of the sickle cell disease.

Davenport A et al. Sickle cell kidney. *J Nephrol.* 2008 Mar–Apr; 21(2):253–5. [PMID: 18446721]

Maigne G et al. Glomerular lesions in patients with sickle cell disease. *Medicine (Baltimore).* 2010 Jan;89(1):18–27. [PMID: 20075701]

TUBERCULOSIS

The classic renal manifestation of tuberculosis is the presence of microscopic pyuria with a sterile urine culture—or “sterile pyuria.” More often, other bacteria are also present. Microscopic hematuria is often present with pyuria. Urine cultures are the gold standard for diagnosis. Three to six first morning midstream specimens should be performed to improve sensitivity. Papillary necrosis and cavitation of the renal parenchyma occur less frequently, as do ureteral strictures and calcifications. Adequate drug therapy can result in resolution of renal involvement.

Chapagain A et al. Presentation, diagnosis, and treatment outcome of tuberculous-mediated tubulointerstitial nephritis. *Kidney Int.* 2011 Mar;79(6):671–7. [PMID: 21160461]

Figueiredo AA et al. Epidemiology of urogenital tuberculosis worldwide. *Int J Urol.* 2008 Sep;15(9):827–32. [PMID: 18637157]

GOUT & THE KIDNEY

The kidney is the primary organ for excretion of uric acid. Patients with proximal tubular dysfunction have decreased excretion of uric acid and are more prone to gouty attacks. Depending on the pH and uric acid concentration, deposition can occur in the tubules, the interstitium, or the urinary tract. The more alkaline pH of the interstitium causes urate salt deposition, whereas the acidic environment of the tubules and urinary tract causes uric acid crystal deposition at high concentrations.

Three disorders are commonly seen: (1) uric acid nephrolithiasis, (2) acute uric acid nephropathy, and (3) chronic urate nephropathy. Kidney dysfunction with uric acid nephrolithiasis stems from obstructive nephropathy. Acute uric acid nephropathy presents similarly to acute tubulointerstitial nephritis with direct toxicity

from uric acid crystals. Chronic urate nephropathy is caused by deposition of urate crystals in the alkaline medium of the interstitium; this can lead to fibrosis and atrophy. Epidemiologically, hyperuricemia and gout have been associated with worsening cardiovascular outcomes.

Treatment between gouty attacks involves avoidance of food and drugs causing hyperuricemia, aggressive hydration, and pharmacotherapy aimed at reducing serum uric acid levels. These disorders are seen in both “overproducers” and “underexcretors” of uric acid. The latter situation may seem counterintuitive; however, these patients have hyperacidic urine, which explains the deposition of relatively insoluble uric acid crystals. For those with uric acid nephrolithiasis, fluid intake should exceed 3 L/d, and use of a urinary alkalinizing agent can be considered.

Edwards NL. The role of hyperuricemia and gout in kidney and cardiovascular disease. *Cleve Clin J Med.* 2008 Jul;75(Suppl 5):S13–6. [PMID: 18822470]

Goicoechea M et al. Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. *Clin J Am Soc Nephrol.* 2010 Aug;5(8):1388–93. [PMID: 20538833]

NEPHROGENIC SYSTEMIC FIBROSIS

Nephrogenic systemic fibrosis is a multisystem disorder seen only in patients with CKD (primarily with a GFR < 15 mL/min/1.73 m², but rarely with a GFR of 15–29 mL/min/1.73 m²), acute kidney injury, and after kidney transplantation. Histopathologically, there is an increase in dermal

spindle cells positive for CD34 and procollagen I. Collagen bundles with mucin and elastic fibers are also noted.

Nephrogenic systemic fibrosis was first recognized in hemodialysis patients in 1997 and has been strongly linked to use of contrast agents containing gadolinium. Incidence is projected to be 1–4% in the highest risk (ESRD) population that has received gadolinium, and lower in patients with less severe kidney dysfunction. The FDA has issued a warning regarding avoidance of exposure to this agent for patients with GFR < 30 mL/min/1.73 m².

▶ Clinical Findings

Nephrogenic systemic fibrosis affects several organ systems, including the skin, muscles, lungs, and cardiovascular system. The most common manifestation is a debilitating fibrosing skin disorder that can range from skin-colored to erythematous papules, which coalesce to brawny patches. The skin can be thick and woody in areas and is painful out-of-proportion to findings on examination.

▶ Treatment

Several case reports and series have described benefit for patients after treatment with corticosteroids, photopheresis, plasmapheresis, and sodium thiosulfate. The true effectiveness of these interventions is still unclear. Alternative or no imaging agents should be used for patients requiring MR with contrast at risk for nephrogenic systemic fibrosis.

Agarwal R et al. Gadolinium-based contrast agents and nephrogenic systemic fibrosis: a systematic review and meta-analysis. *Nephrol Dial Transplant.* 2009 Mar;24(3):856–63. [PMID: 18952698]

23

Urologic Disorders

Maxwell V. Meng, MD, FACS
 Marshall L. Stoller, MD
 Thomas J. Walsh, MD, MS

HEMATURIA

ESSENTIALS OF DIAGNOSIS

- ▶ Both gross and microscopic hematuria require evaluation.
- ▶ The upper urinary tract should be imaged, and cystoscopy should be performed if there is hematuria in the absence of infection.

▶ General Considerations

An **upper tract source** (kidneys and ureters) can be identified in 10% of patients with gross or microscopic hematuria. For upper tract sources, stone disease accounts for 40%, medical kidney disease (medullary sponge kidney, glomerulonephritis, papillary necrosis) for 20%, renal cell carcinoma for 10%, and urothelial cell carcinoma of the ureter or renal pelvis for 5%. Drug ingestion and associated medical problems may provide diagnostic clues. Analgesic use (papillary necrosis), cyclophosphamide (chemical cystitis), antibiotics (interstitial nephritis), diabetes mellitus, sickle cell trait or disease (papillary necrosis), a history of stone disease, or malignancy should all be investigated. The **lower tract source** of gross hematuria (in the absence of infection) is most commonly from urothelial cell carcinoma of the bladder. Microscopic hematuria in the male is most commonly from benign prostatic hyperplasia. The presence of hematuria in patients receiving anticoagulation therapy cannot be ascribed to the anticoagulation; a complete evaluation is warranted consisting of upper tract imaging, cystoscopy, and urine cytology (see Chapter 39 for Bladder Cancer, Cancers of the Ureter and Renal Pelvis, Renal Cell Carcinoma, and Kidney and Testis Tumors).

▶ Clinical Findings

A. Symptoms and Signs

If gross hematuria occurs, a description of the timing (initial, terminal, total) may provide a clue to the localization

of disease. Associated symptoms (ie, renal colic, irritative voiding symptoms, constitutional symptoms) should be investigated. Physical examination should emphasize signs of systemic disease (fever, rash, lymphadenopathy, abdominal or pelvic masses) as well as signs of medical kidney disease (hypertension, volume overload). Urologic evaluation may demonstrate an enlarged prostate, flank mass, or urethral disease.

B. Laboratory Findings

Initial laboratory investigations include a urinalysis and urine culture. Proteinuria and casts suggest renal origin. Irritative voiding symptoms, bacteriuria, and a positive urine culture in the female suggest urinary tract infection, but follow-up urinalysis is important after treatment to ensure resolution of the hematuria.

Further evaluation may include urinary cytology to assist in the diagnosis of bladder neoplasm.

C. Imaging

Upper tract imaging (usually abdominal and pelvic CT scanning without and with contrast) may identify neoplasms of the kidney or ureter as well as benign conditions such as urolithiasis, obstructive uropathy, papillary necrosis, medullary sponge kidney, or polycystic kidney disease. CT urography and MRI have replaced intravenous urography when imaging the upper tracts for sources of hematuria. The role of ultrasonographic evaluation of the urinary tract for hematuria is unclear. Although it may provide adequate information for the kidney, its sensitivity in detecting ureteral disease is lower. In addition, its higher degree of operator dependence may further confound the issue.

D. Cystoscopy

Cystoscopy can be used to assess for bladder or urethral neoplasm, benign prostatic enlargement, and radiation or chemical cystitis. For gross hematuria, cystoscopy is ideally performed while the patient is actively bleeding to allow better localization (ie, lateralize to one side of the upper tracts, bladder, or urethra).

▶ Follow-up

In patients with negative evaluations, repeat evaluations may be warranted to avoid a missed malignancy; however, the ideal frequency of such evaluations is not defined. Urinary cytology can be repeated in 3–6 months, and cystoscopy and upper tract imaging after a year.

▶ When to Refer

In the absence of infection, hematuria (either gross or microscopic) requires evaluation.

Grossfeld G et al. Evaluation of asymptomatic microscopic hematuria in adults: the American Urological Association best practice policy—part I: definition, detection, prevalence, and etiology. *Urology*. 2001 Apr;57(4):599–603. [PMID: 11306356]

Kelly JD et al. Assessment and management of non-visible haematuria in primary care. *BMJ*. 2009 Jan;16(338):a3021. [PMID: 19151065]

Margulis V et al. Assessment of hematuria. *Med Clin North Am*. 2011 Jan;95(1):153–9. [PMID: 21095418]

Rao PK et al. How to evaluate “dipstick hematuria”: what to do before you refer. *Cleve Clin J Med*. 2008 Mar;75(3):227–33. [PMID: 18383931]

Rodgers MA et al. Diagnostic tests used in the investigation of adult haematuria: A systematic review. *BJU Int*. 2006 Dec;98(6):1154–60. [PMID: 16879444]

GENITOURINARY TRACT INFECTIONS

1. Acute Cystitis



ESSENTIALS OF DIAGNOSIS

- ▶ Irritative voiding symptoms.
- ▶ Patient usually afebrile.
- ▶ Positive urine culture; blood cultures may also be positive.

▶ General Considerations

Acute cystitis is an infection of the bladder most commonly due to the coliform bacteria (especially *Escherichia coli*) and occasionally gram-positive bacteria (enterococci). The route of infection is typically ascending from the urethra. Viral cystitis due to adenovirus is sometimes seen in children but is rare in adults. Cystitis in men is rare and implies a pathologic process such as infected stones, prostatitis, or chronic urinary retention requiring further investigation.

▶ Clinical Findings

A. Symptoms and Signs

Irritative voiding symptoms (frequency, urgency, dysuria) and suprapubic discomfort are common. Women may

experience gross hematuria, and symptoms may often appear following sexual intercourse. Physical examination may elicit suprapubic tenderness, but examination is often unremarkable. Systemic toxicity is absent.

B. Laboratory Findings

Urinalysis shows pyuria and bacteriuria and varying degrees of hematuria. The degree of pyuria and bacteriuria does not necessarily correlate with the severity of symptoms. Urine culture is positive for the offending organism, but colony counts exceeding 10^5 /mL are not essential for the diagnosis.

C. Imaging

Because uncomplicated cystitis is rare in men, elucidation of the underlying problem with appropriate investigations, such as abdominal ultrasonography or cystoscopy (or both), is warranted. Follow-up imaging using CT scanning is warranted if pyelonephritis, recurrent infections, or anatomic abnormalities are suspected.

▶ Differential Diagnosis

In women, infectious processes such as vulvovaginitis and pelvic inflammatory disease can usually be distinguished by pelvic examination and urinalysis. In men, urethritis and prostatitis may be distinguished by physical examination (urethral discharge or prostatic tenderness).

Noninfectious causes of cystitis-like symptoms include pelvic irradiation, chemotherapy (cyclophosphamide), bladder carcinoma, interstitial cystitis, voiding dysfunction disorders, and psychosomatic disorders.

▶ Prevention

Women who have more than three episodes of cystitis per year are considered candidates for prophylactic antibiotic therapy to prevent recurrence after treatment of urinary tract infection. Prior to institution of therapy, a thorough urologic evaluation is warranted to exclude any anatomic abnormality (eg, stones, reflux, fistula). The three most commonly used oral agents for prophylaxis are trimethoprim-sulfamethoxazole (40 mg/200 mg), nitrofurantoin (100 mg), and cephalexin (250 mg). Single dosing at bedtime or at the time of intercourse is the recommended schedule.

The risk of acquiring a catheter-associated urinary tract infection in hospitalized patients can be minimized by using indwelling catheters only when necessary, implementing systems to ensure removal of catheters when no longer needed, using antimicrobial catheters in high-risk patients, using external collection devices in select men, identifying significant postvoid residuals by ultrasound, maintaining proper insertion techniques, and utilizing alternatives such as intermittent catheterization. The cost of treating a catheter-associated urinary tract infection acquired by a hospitalized patient is one of the complications that is not reimbursed by the Centers for Medicare & Medicaid Services.

► Treatment

Uncomplicated cystitis in women can be treated with short-term antimicrobial therapy, which consists of single-dose therapy or 1–3 days of therapy. Fluoroquinolones and nitrofurantoin are the drugs of choice for uncomplicated cystitis (Table 23–1). Trimethoprim-sulfamethoxazole can be ineffective because of the emergence of resistant organisms. In men, uncomplicated urinary tract infection is rare, and thus, the duration of antibiotic therapy depends on the underlying etiology. Hot sitz baths or urinary analgesics (phenazopyridine, 200 mg orally three times daily) may provide symptomatic relief.

► Prognosis

Infections typically respond rapidly to therapy, and failure to respond suggests resistance to the selected drug or anatomic abnormalities requiring further investigation.

► When to Refer

- Suspicion or radiographic evidence of anatomic abnormality.
- Evidence of urolithiasis.
- Recurrent cystitis due to bacterial persistence.

Lo E et al. Strategies to prevent catheter-associated urinary tract infection in acute care hospitals. *Infect Control Hosp Epidemiol.* 2008 Oct;29(S1):S41–50. [PMID: 18840088]

Norris DL 2nd et al. Urinary tract infections: diagnosis and management in the emergency department. 2008 May;26(2):413–30. [PMID: 18406981]

Saint S et al. Catheter-associated urinary tract infection and the Medicare rule changes. *Ann Intern Med.* 2009 Jun 16;150(12):877–84. [PMID: 19528567]

Saint S et al. Preventing hospital-acquired urinary tract infection in the United States: a national study. *Clin Infect Dis.* 2008 Jan 15;46(2):243–50. [PMID: 18171256]

Table 23–1. Empiric therapy for urinary tract infections.

Diagnosis	Antibiotic	Route	Duration	Cost per Duration Noted ¹
Acute pyelonephritis	Ampicillin, 1 g every 6 hours, and gentamicin, 1 mg/kg every 8 hours	Intravenous	21 days	\$567.00 not including intravenous supplies
	Ciprofloxacin, 750 mg every 12 hours	Oral	21 days	\$236.50
	Ofloxacin, 200–300 mg every 12 hours	Oral	21 days	\$239.00 (300 mg)
	Trimethoprim-sulfamethoxazole, 160/800 mg every 12 hours ²	Oral	21 days	\$45.80
Chronic pyelonephritis	Same as for acute pyelonephritis, but duration of therapy is 3–6 months			
Acute cystitis	Cephalexin, 250–500 mg every 6 hours	Oral	1–3 days	\$16.60/3 days (500 mg)
	Ciprofloxacin, 250–500 mg every 12 hours	Oral	1–3 days	\$32.00/3 days (500 mg)
	Nitrofurantoin (macrocrystals), 100 mg every 12 hours	Oral	7 days	\$26.00
	Norfloxacin, 400 mg every 12 hours	Oral	1–3 days	\$26.40/3 days
	Ofloxacin, 200 mg every 12 hours	Oral	1–3 days	\$28.70/3 days
	Trimethoprim-sulfamethoxazole, 160/800 mg, two tablets ²	Oral	Single dose	\$2.20
Acute bacterial prostatitis	Same as for acute pyelonephritis		21 days	
Chronic bacterial prostatitis	Ciprofloxacin, 250–500 mg every 12 hours	Oral	1–3 months	\$322.00/1 month (500 mg)
	Ofloxacin, 200–400 mg every 12 hours	Oral	1–3 months	\$360.00/1 month (400 mg)
	Trimethoprim-sulfamethoxazole, 160/800 mg every 12 hours ²	Oral	1–3 months	\$65.40/1 month
Acute epididymitis	Ceftriaxone, 250 mg as single dose, plus Doxycycline, 100 mg every 12 hours	Intramuscular	Once	\$2.00/250 mg
		Oral	10 days	\$10.40
Non-sexually transmitted	Same as for chronic bacterial prostatitis	Oral	3 weeks	

¹Average wholesale price, (AWP, for AB-rated generic when available) for quantity listed. Source: *Red Book Online, 2012*, Thomson Reuters (Healthcare) Inc. AWP may not accurately represent the actual pharmacy cost because wide contractual variations exist among institutions.

²Increasing resistance noted (up to 20%).

2. Acute Pyelonephritis



ESSENTIALS OF DIAGNOSIS

- ▶ Fever.
- ▶ Flank pain.
- ▶ Irritative voiding symptoms.
- ▶ Positive urine culture.

▶ General Considerations

Acute pyelonephritis is an infectious inflammatory disease involving the kidney parenchyma and renal pelvis. Gram-negative bacteria are the most common causative agents including *E coli*, *Proteus*, *Klebsiella*, *Enterobacter*, and *Pseudomonas*. Gram-positive bacteria are less commonly seen but include *Enterococcus faecalis* and *Staphylococcus aureus*. The infection usually ascends from the lower urinary tract—with the exception of *S aureus*, which usually is spread by a hematogenous route.

▶ Clinical Findings

A. Symptoms and Signs

Symptoms include fever, flank pain, shaking chills, and irritative voiding symptoms (urgency, frequency, dysuria). Associated nausea and vomiting, and diarrhea are common. Signs include fever and tachycardia. Costovertebral angle tenderness is usually pronounced.

B. Laboratory Findings

Complete blood count shows leukocytosis and a left shift. Urinalysis shows pyuria, bacteriuria, and varying degrees of hematuria. White cell casts may be seen. Urine culture demonstrates heavy growth of the offending agent, and blood culture may also be positive.

C. Imaging

In complicated pyelonephritis, renal ultrasound may show hydronephrosis from a stone or other source of obstruction.

▶ Differential Diagnosis

Acute intra-abdominal disease such as appendicitis, cholecystitis, pancreatitis, or diverticulitis must be distinguished from pyelonephritis. A normal urinalysis is usually seen in gastrointestinal disorders; however, on occasion, inflammation from adjacent bowel (appendicitis or diverticulitis) may result in hematuria or sterile pyuria. Abnormal liver function tests or elevated amylase levels may assist in the differentiation. Lower lobe pneumonia is distinguishable by the abnormal chest radiograph.

In males, the main differential diagnosis for acute pyelonephritis includes acute epididymitis, acute prostatitis, and acute cystitis. Physical examination and the location of the pain should permit this distinction.

▶ Complications

Sepsis with shock can occur with acute pyelonephritis. In diabetic patients, emphysematous pyelonephritis resulting from gas-producing organisms may be life threatening if not adequately treated. Healthy adults usually recover complete kidney function, yet if coexistent kidney disease is present, scarring or chronic pyelonephritis may result. Inadequate therapy could result in abscess formation.

▶ Treatment

Urine and blood cultures are obtained to identify the causative agent and to determine antimicrobial sensitivity. In the inpatient setting, intravenous ampicillin and an aminoglycoside are initiated prior to obtaining sensitivity results (Table 23–1). In the outpatient setting, quinolones may be initiated (Table 23–1). Antibiotics are adjusted according to sensitivities. Fevers may persist for up to 72 hours; failure to respond warrants imaging (CT or ultrasound) to exclude complicating factors that may require intervention. Catheter drainage may be necessary in the face of urinary retention and nephrostomy drainage if there is ureteral obstruction. In inpatients, intravenous antibiotics are continued for 24 hours after the fever resolves, and oral antibiotics are then given to complete a 14-day course of therapy. Follow-up urine cultures are mandatory following the completion of treatment.

▶ Prognosis

With prompt diagnosis and appropriate treatment, acute pyelonephritis carries a good prognosis. Complicating factors, underlying kidney disease, and increasing patient age may lead to a less favorable outcome.

▶ When to Refer

- Evidence of complicating factors (urolithiasis, obstruction).
- Absence of clinical improvement in 48 hours.

▶ When to Admit

- Severe infections or complicating factors, evidence of sepsis or need for parenteral antibiotics.
- Need for radiographic imaging or drainage of urinary tract obstruction.

Gupta K et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Disease Society of America and the European Society for Microbiology and Infectious Diseases. *Clin Infect Dis*. 2011 Mar 1;52(5):e103–20. [PMID: 21292654]

Meng MV. Infection of the upper urinary tract. In: Wessells H (editor). *Urological Emergencies: A Practical Guide*. New York: Humana Press, 2012.

3. Acute Bacterial Prostatitis



ESSENTIALS OF DIAGNOSIS

- ▶ Fever.
- ▶ Irritative voiding symptoms.
- ▶ Perineal or suprapubic pain; exquisite tenderness common on rectal examination.
- ▶ Positive urine culture.

▶ General Considerations

Acute bacterial prostatitis is usually caused by gram-negative rods, especially *E coli* and *Pseudomonas* species and less commonly by gram-positive organisms (eg, enterococci). The most likely routes of infection include ascent up the urethra and reflux of infected urine into the prostatic ducts. Lymphatic and hematogenous routes are probably rare.

▶ Clinical Findings

A. Symptoms and Signs

Perineal, sacral, or suprapubic pain, fever, and irritative voiding complaints are common. Varying degrees of obstructive symptoms may occur as the acutely inflamed prostate swells, which may lead to urinary retention. High fevers and a warm and often exquisitely tender prostate are detected on examination. Care should be taken to perform a gentle rectal examination, since vigorous manipulations may result in septicemia. Prostatic massage is contraindicated.

B. Laboratory Findings

Complete blood count shows leukocytosis and a left shift. Urinalysis shows pyuria, bacteriuria, and varying degrees of hematuria. Urine cultures will demonstrate the offending pathogen (Table 23–2).

▶ Differential Diagnosis

Acute pyelonephritis or acute epididymitis should be distinguishable by the location of pain as well as by physical examination. Acute diverticulitis is occasionally confused

with acute prostatitis; however, the history and urinalysis should permit clear distinction. Urinary retention from benign or malignant prostatic enlargement is distinguishable by initial or follow-up rectal examination.

▶ Treatment

Hospitalization may be required, and parenteral antibiotics (ampicillin and aminoglycoside) should be initiated until organism sensitivities are available (Table 23–1). After the patient is afebrile for 24–48 hours, oral antibiotics (eg, quinolones) are used to complete 4–6 weeks of therapy. If urinary retention develops, urethral catheterization or instrumentation is contraindicated, and a percutaneous suprapubic tube is required. Follow-up urine culture and examination of prostatic secretions should be performed after the completion of therapy to ensure eradication.

▶ Prognosis

With effective treatment, chronic bacterial prostatitis is rare.

▶ When to Refer

- Evidence of urinary retention.
- Evidence of chronic prostatitis.

▶ When to Admit

- Signs of sepsis.
- Need for surgical drainage of bladder or prostatic abscess.

Benway BM et al. Bacterial prostatitis. *Urol Clin North Am*. 2008 Feb;35(1):23–32. [PMID: 18061021]

4. Chronic Bacterial Prostatitis



ESSENTIALS OF DIAGNOSIS

- ▶ Irritative voiding symptoms.
- ▶ Perineal or suprapubic discomfort, often dull and poorly localized.
- ▶ Positive expressed prostatic secretions and culture.

Table 23–2. Clinical characteristics of prostatitis and prostaticodynia syndromes.

Findings	Acute Bacterial Prostatitis	Chronic Bacterial Prostatitis	Nonbacterial Prostatitis	Prostaticodynia
Fever	+	–	–	–
Urinalysis	+	–	–	–
Expressed prostate secretions	Contraindicated	+	+	–
Bacterial culture	+	+	–	–

▶ General Considerations

Although chronic bacterial prostatitis may evolve from acute bacterial prostatitis, many men have no history of acute infection. Gram-negative rods are the most common etiologic agents, but only one gram-positive organism (*Enterococcus*) is associated with chronic infection. Routes of infection are the same as discussed for acute infection.

▶ Clinical Findings

A. Symptoms and Signs

Clinical manifestations are variable. Some patients are asymptomatic, but most have varying degrees of irritative voiding symptoms. Low back and perineal pain are not uncommon. Many patients report a history of urinary tract infections. Physical examination is often unremarkable, although the prostate may feel normal, boggy, or indurated.

B. Laboratory Findings

Urinalysis is normal unless a secondary cystitis is present. Expressed prostatic secretions demonstrate increased numbers of leukocytes (>10 per high-power field), especially lipid-laden macrophages. However, this finding is consistent with inflammation and is not diagnostic of bacterial prostatitis (Table 23–2). Leukocyte and bacterial counts from expressed prostatic secretions do not correlate with severity of symptoms. Culture of the secretions or the post-prostatic massage urine specimen is necessary to make the diagnosis.

C. Imaging

Imaging tests are not necessary, although pelvic radiographs or transrectal ultrasound may demonstrate prostatic calculi.

▶ Differential Diagnosis

Chronic urethritis may mimic chronic prostatitis, though cultures of the fractionated urine may localize the source of infection to the initial specimen, which would come from the urethra. Cystitis may be secondary to prostatitis, but urine samples after prostatic massage may localize the infection to the prostate. Anal disease may share some of the symptoms of prostatitis, but physical examination should permit a distinction between the two.

▶ Treatment

Few antimicrobial agents attain therapeutic intraprostatic levels in the absence of acute inflammation. Trimethoprim does diffuse into the prostate, and trimethoprim-sulfamethoxazole is associated with the best cure rates (Table 23–1). However, increasing resistance up to 20% has been noted. Other effective agents include carbenicillin, erythromycin, cephalexin, and the quinolones. The optimal duration of therapy remains controversial, ranging from 6 to 12 weeks. Symptomatic relief may be provided by anti-inflammatory agents (indomethacin, ibuprofen) and hot sitz baths.


▶ Prognosis

Chronic bacterial prostatitis is difficult to cure, but its symptoms and tendency to cause recurrent urinary tract infections can be controlled by suppressive antibiotic therapy.

▶ When to Refer

- Persistent symptoms.
- Consideration of enrollment in clinical trials.

5. Nonbacterial Prostatitis



ESSENTIALS OF DIAGNOSIS

- ▶ Irritative voiding symptoms.
- ▶ Perineal or suprapubic discomfort, similar to that of chronic bacterial prostatitis.
- ▶ Positive expressed prostatic secretions, but culture is negative.

▶ General Considerations

Nonbacterial prostatitis is the most common of the prostatitis syndromes, and its cause is unknown. Speculation implicates chlamydiae, mycoplasmas, ureaplasmas, and viruses, but no substantial proof exists. In some cases, nonbacterial prostatitis may represent a noninfectious inflammatory or autoimmune disorder. Because the cause of nonbacterial prostatitis remains unknown, the diagnosis is usually one of exclusion.

▶ Clinical Findings

A. Symptoms and Signs

The clinical presentation is identical to that of chronic bacterial prostatitis; however, no history of urinary tract infections is present. The National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI) (<http://www2.nidk.nih.gov/NR/rdonlyres/93B6388F-B429-4603-9C3C-6765BDEB49A1/0/NIHCPSIEnglish.pdf>) has been validated to quantify symptoms of chronic nonbacterial prostatitis or chronic pelvic pain syndrome.

B. Laboratory Findings

Increased numbers of leukocytes are seen on expressed prostatic secretions, but all cultures are negative.

▶ Differential Diagnosis

The major distinction is from chronic bacterial prostatitis. The absence of a history of urinary tract infection and of positive cultures makes the distinction (Table 23–2). In older men with irritative voiding symptoms and negative cultures, the possibility of bladder cancer must be excluded. Urinary cytologic examination and cystoscopy are warranted.

► Treatment

Because of the uncertainty regarding the etiology of non-bacterial prostatitis, a trial of antimicrobial therapy directed against *Ureaplasma*, *Mycoplasma*, or *Chlamydia* is warranted. Erythromycin (250 mg orally four times daily) can be initiated for 14 days yet should be continued for 3–6 weeks only if a favorable clinical response ensues. Some symptomatic relief may be obtained with nonsteroidal anti-inflammatory agents or sitz baths. Dietary restrictions are not necessary unless the patient relates a history of symptom exacerbation by certain substances such as alcohol, caffeine, and perhaps certain foods.

► Prognosis

Annoying, recurrent symptoms are common, but serious sequelae have not been identified.

Dhar NB et al. New therapies in chronic prostatitis. 2007 Jul;8(4):313–8. [PMID: 18519016]

Nickel JC et al. Phenotypic approach to the management of chronic prostatitis/chronic pelvic pain syndrome. *Curr Urol Rep.* 2009 Jul;10(4):307–12. [PMID: 19570493]

6. Prostatodynia

Prostatodynia is a noninflammatory disorder that affects young and middle-aged men and has variable causes, including voiding dysfunction and pelvic floor musculature dysfunction. The term “prostatodynia” is a misnomer, as the prostate is actually normal.

► Clinical Findings

A. Symptoms and Signs

Symptoms are the same as those seen with chronic prostatitis, yet there is no history of urinary tract infection. Additional symptoms may include hesitancy and interruption of flow. Patients may relate a lifelong history of voiding difficulty. Physical examination is unremarkable, but increased anal sphincter tone and periprostatic tenderness may be observed.

B. Laboratory Findings

Urinalysis is normal. Expressed prostatic secretions show normal numbers of leukocytes (Table 23–2). Urodynamic testing may show signs of dysfunctional voiding (detrusor contraction without urethral relaxation, high urethral pressures, spasms of the urinary sphincter) and is indicated in patients failing empiric trials of α -blockers or anticholinergics.

► Differential Diagnosis

Normal urinalysis will distinguish it from acute infectious processes. Examination of expressed prostatic secretions will distinguish this entity from prostatitis syndromes (Table 23–2).

► Treatment

Bladder neck and urethral spasms can be treated by α -blocking agents (terazosin, 1–10 mg orally once a day, or doxazosin, 1–8 mg orally once a day). Pelvic floor muscle dysfunction may respond to diazepam and biofeedback techniques. Sitz baths may contribute to symptomatic relief.

► Prognosis


Prognosis is variable depending on the specific cause.

Anothaisintawee T et al. Management of chronic prostatitis/chronic pelvic pain syndrome: a systematic review and network meta-analysis. *JAMA.* 2011 Jan 5;305(1):78–86. [PMID: 21205969]

Pontari MA. Chronic prostatitis/chronic pelvic pain syndrome. *Urol Clin North Am.* 2008 Feb;35(1):81–9. [PMID: 18061026]

Rodriguez MA et al. Evidence for overlap between urological and nonurological unexplained clinical conditions. *J Urol.* 2009 Nov;182(5):2123–31. [PMID: 19758633]

7. Acute Epididymitis



ESSENTIALS OF DIAGNOSIS

- Fever.
- Irritative voiding symptoms.
- Painful enlargement of epididymis.

► General Considerations

Most cases of acute epididymitis are infectious and can be divided into one of two categories that have different age distributions and etiologic agents. **Sexually transmitted forms** typically occur in men under age 40 years, are associated with urethritis, and result from *Chlamydia trachomatis* or *Neisseria gonorrhoeae*. **Non-sexually transmitted forms** typically occur in older men, are associated with urinary tract infections and prostatitis, and are caused by gram-negative rods. The route of infection is probably via the urethra to the ejaculatory duct and then down the vas deferens to the epididymis. Amiodarone has been associated with self-limited epididymitis, which is a dose-dependent phenomenon.

► Clinical Findings

A. Symptoms and Signs

Symptoms may follow acute physical strain (heavy lifting), trauma, or sexual activity. Associated symptoms of urethritis (pain at the tip of the penis and urethral discharge) or cystitis (irritative voiding symptoms) may occur. Pain develops in the scrotum and may radiate along the spermatic cord or to the flank. Fever and scrotal swelling are usually apparent. Early in the course, the epididymis may be distinguishable from the testis; however, later the two

may appear as one enlarged, tender mass. The prostate may be tender on rectal examination.

B. Laboratory Findings

Complete blood count shows leukocytosis and a left shift. In the sexually transmitted variety, Gram staining of a smear of urethral discharge may be diagnostic of gram-negative intracellular diplococci (*N gonorrhoeae*). White cells without visible organisms on urethral smear represent non-gonococcal urethritis, and *C trachomatis* is the most likely pathogen. In the non-sexually transmitted variety, urinalysis shows pyuria, bacteriuria, and varying degrees of hematuria. Urine cultures will demonstrate the offending pathogen.

C. Imaging

Scrotal ultrasound may aid in the diagnosis if examination is difficult because of the presence of a large hydrocele or because questions exist regarding the diagnosis.

► Differential Diagnosis

Tumors generally cause painless enlargement of the testis. Urinalysis is negative, and examination reveals a normal epididymis. Scrotal ultrasound is helpful to define the pathology. Testicular torsion usually occurs in prepubertal males but is occasionally seen in young adults. Acute onset of symptoms and a negative urinalysis favor testicular torsion or torsion of one of the testicular or epididymal appendages. Prehn sign (elevation of the scrotum above the pubic symphysis improves pain from epididymitis) may be helpful but is not reliable.

► Treatment

Bed rest with scrotal elevation is important in the acute phase. Treatment is directed toward the identified pathogen (Table 23–1). The sexually transmitted variety is treated with 10–21 days of antibiotics, and the sexual partner must be treated as well. Non-sexually transmitted forms are treated for 21–28 days with appropriate antibiotics, at which time evaluation of the urinary tract is warranted to identify underlying disease.

► Prognosis

Prompt treatment usually results in a favorable outcome. Delayed or inadequate treatment may result in epididymo-orchitis, decreased fertility, or abscess formation.

► When to Refer

- Persistent symptoms and infection despite antibiotic therapy.
- Signs of sepsis or abscess formation.

Tracy CR et al. Diagnosis and management of epididymitis. *Urol Clin North Am.* 2008 Feb;35(1):101–8. [PMID: 18061028]

INTERSTITIAL CYSTITIS



ESSENTIALS OF DIAGNOSIS

- Pain with a full bladder or urinary urgency.
- Submucosal petechiae or ulcers on cystoscopic examination.
- Diagnosis of exclusion.

► General Considerations

Interstitial cystitis (painful bladder syndrome) is characterized by pain with bladder filling that is relieved by emptying and is often associated with urgency and frequency. This is a diagnosis of exclusion, and patients must have a negative urine culture and cytology and no other obvious cause such as radiation cystitis, chemical cystitis (cyclophosphamide), vaginitis, urethral diverticulum, or genital herpes. Up to 40% of patients referred to urologists for interstitial cystitis may actually be found to have a different diagnosis after careful evaluation.

Population-based studies have demonstrated a prevalence of between 18 and 40 per 100,000 people. Both sexes are involved, but most patients are women, with a mean age of 40 years at onset. Patients with interstitial cystitis are more likely to report bladder problems in childhood, and there appears to be a higher prevalence in women. Up to 50% of patients may experience spontaneous remission of symptoms, with a mean duration of 8 months without treatment.

The etiology of interstitial cystitis is unknown, and it is most likely not a single disease but rather several diseases with similar symptoms. Associated diseases include severe allergies, irritable bowel syndrome, or inflammatory bowel disease. Theories regarding the cause of interstitial cystitis include increased epithelial permeability, neurogenic causes (sensory nervous system abnormalities), and autoimmunity.

► Clinical Findings

A. Symptoms and Signs

Pain with bladder filling that is relieved with urination or urgency, frequency, and nocturia are the most common symptoms. Patients should be asked about exposure to pelvic radiation or treatment with cyclophosphamide. Examination should exclude genital herpes, vaginitis, or a urethral diverticulum.

B. Laboratory Findings

Urinalysis, urine culture, and urinary cytologies are obtained to examine for infectious causes and bladder malignancy. Urodynamic testing assesses bladder sensation and compliance and excludes detrusor instability.

C. Cystoscopy

The bladder is distended with fluid (hydrodistention) to detect glomerulations (submucosal hemorrhage), which

may or may not be present. Biopsy should be performed to exclude other causes such as carcinoma, eosinophilic cystitis, and tuberculous cystitis. The presence of submucosal mast cells is not needed to make the diagnosis of interstitial cystitis.

► Differential Diagnosis

Exposures to radiation or cyclophosphamide are obtained by the history. Bacterial cystitis, genital herpes, or vaginitis can be excluded by urinalysis, culture, and physical examination. A urethral diverticulum may be suspected if palpation of the urethra demonstrates an indurated mass that results in the expression of pus from the urethral meatus. Urethral carcinoma presents as a firm mass on palpation.

► Treatment

There is no cure for interstitial cystitis, but most patients achieve symptomatic relief from one of several approaches, including hydrodistention, which is usually done as part of the diagnostic evaluation. Approximately 20–30% of patients notice symptomatic improvement following this maneuver. Also of importance is the measurement of bladder capacity during hydrodistention, since patients with very small bladder capacities (< 200 mL) are unlikely to respond to medical therapy.

Amitriptyline (10–75 mg/d orally) is often used as first-line medical therapy in patients with interstitial cystitis. Both central and peripheral mechanisms may contribute to its activity. Nifedipine (30–60 mg/d orally) and other calcium channel blockers have also demonstrated some activity in patients with interstitial cystitis. Pentosan polysulfate sodium (Elmiron) is an oral synthetic sulfated polysaccharide that helps restore integrity to the epithelium of the bladder in a subset of patients and has been evaluated in a placebo-controlled trial. Other options include intravesical instillation of dimethyl sulfoxide (DMSO) and heparin. Intravesical bacillus Calmette-Guérin (BCG) is not beneficial.

Further treatment modalities include transcutaneous electric nerve stimulation (TENS) and acupuncture. Surgical therapy for interstitial cystitis should be considered only as a last resort and may require cystourethrectomy with urinary diversion.

► When to Refer

Persistent and bothersome symptoms in the absence of identifiable cause.

Bogart LM et al. Symptoms of interstitial cystitis, painful bladder syndrome and similar disease in women: a systematic review. *J Urol.* 2007 Feb;177(2):450–6. [PMID: 17222607]

Dawson TE et al. Intravesical treatment for painful bladder syndrome/interstitial cystitis. *Cochrane Database Syst Rev.* 2007 Oct;17(4):CD006113. [PMID: 17943887]

Fall M et al. Treatment of bladder pain syndrome/interstitial cystitis 2008: can we make evidence-based decisions? *Eur Urol.* 2008 Jul;54(1):65–75. [PMID: 18403099]

Hanno PM et al. AUA guideline for the diagnosis and treatment of interstitial cystitis/bladder pain syndrome. *J Urol.* 2011 Jun;185(6):2162–70. [PMID: 21497847]

Marinkovic SP et al. The management of interstitial cystitis or painful bladder syndrome in women. *BMJ.* 2009 Jul 31;339:b2707. [PMID: 19648180]

Theoharides TC et al. Interstitial cystitis: bladder pain and beyond. *Expert Opin Pharmacother.* 2008 Dec;9(17):2979–94. [PMID: 19006474]

URINARY STONE DISEASE



ESSENTIALS OF DIAGNOSIS

- Severe flank pain.
- Nausea and vomiting.
- Identification on noncontrast CT or ultrasonography.

► General Considerations

Urinary stone disease is exceeded in frequency as a urinary tract disorder only by infections and prostatic disease and is estimated to afflict 240,000–720,000 Americans per year. Men are more frequently affected by urolithiasis than women, with a ratio of 2.5:1. Initial presentation predominates in the third and fourth decades. The ratio of men to women approaches parity in the sixth and seventh decades.

Urinary calculi are polycrystalline aggregates composed of varying amounts of crystalloid and a small amount of organic matrix. Stone formation requires saturated urine that is dependent on pH, ionic strength, solute concentration, and complexation. There are five major types of urinary stones: calcium oxalate, calcium phosphate, struvite (magnesium ammonium phosphate), uric acid, and cystine. The most common types are composed of calcium, and for that reason most urinary stones (85%) are radiopaque (as seen on plain abdominal radiographs). Uric acid stones can be radiolucent yet frequently are composed of a combination of uric acid and calcium oxalate and thus are frequently radiopaque. Cystine stones frequently have a smooth-edged ground-glass appearance.

Geographic factors contribute to the development of stones. Areas of high humidity and elevated temperatures appear to be contributing factors, and the incidence of symptomatic ureteral stones is greatest during hot summer months. Persons in sedentary occupations have a higher incidence of stones than manual laborers. Increasing evidence is revealing that urinary stone disease may be a precursor to subsequent cardiovascular disease.

High protein and high salt intake may be important factors in the development of urinary stones while carbohydrates and fats have not been proven to have an impact on urinary stone disease.

Genetic factors may contribute to urinary stone formation. Cystinuria is an autosomal recessive disorder. Homozygous individuals have markedly increased excretion of cystine and frequently have numerous recurrent episodes of urinary stones despite attempts to optimize medical treatment. Distal renal tubular acidosis may be

transmitted as a hereditary trait, and urolithiasis occurs in up to 75% of patients affected with this disorder.

► Clinical Findings

A. Symptoms and Signs

Obstructing urinary stones usually present with acute and severe colic. Pain usually occurs suddenly and may awaken patients from sleep. It is localized to the flank, is usually severe, and may be associated with nausea and vomiting. Patients are constantly moving trying to find a comfortable position—in sharp contrast to those with an acute abdomen. The pain may occur episodically and may radiate anteriorly over the abdomen. As the stone progresses down the ureter, the pain may be referred into the ipsilateral testis or labium. If the stone becomes lodged at the ureterovesicular junction, patients will complain of marked urinary urgency and frequency and in men, pain may radiate to the tip of the penis. After the stone passes into the bladder, there typically is minimal pain with passage through the urethra. Stone size does not correlate with the severity of the symptoms.

B. Laboratory Findings

Urinalysis usually reveals microscopic or gross hematuria (~90%). However, the absence of microhematuria does not exclude urinary stones. Infection must be excluded, because the combination of infection and urinary tract obstruction requires prompt intervention as described below. Urinary pH is a valuable clue to the cause of the possible stone. Normal urine pH is 5.8–5.9. There is a normal postprandial urinary alkaline tide. Numerous dipstick measurements are valuable in the complete workup of a patient in whom urinary stones are suspected. Persistent urinary pH below 5.5 is suggestive of uric acid or cystine stones, both relatively radiolucent as seen on plain abdominal radiographs. In contrast, a persistent urinary pH > 7.2 is suggestive of a struvite infection stone, which is radiopaque on

plain radiographs. Patients with calcium-based stones typically have a urinary pH between 5.5 and 6.8.

C. Metabolic Evaluation

Patients should strain their urine through cheesecloth or a urine strainer. Stone analysis should be performed on recovered stones. Controversy exists in deciding which patients need a thorough metabolic evaluation for stone disease. Patients with uncomplicated first-time stones should probably undergo blood screening for abnormalities of serum calcium, electrolytes, and uric acid as a baseline.

More extensive evaluation is required in patients who have recurrent stones or those with a family history of nephrolithiasis. Patients are encouraged to change their diet to reduce sodium intake, reduce their animal protein intake during individual meals, and to ingest adequate fluid intake to achieve a voided volume of 1.5–2.0 L of urine. After these dietary changes have been initiated, a 24-hour urine collection should be obtained to ascertain urinary volume, pH, calcium, uric acid, oxalate, phosphate, sodium, and citrate excretion. Serum parathyroid hormone (PTH) and calcium can be obtained if the 24-hour urine collection reveals hypercalciuria. Table 23–3 demonstrates the diagnostic criteria for the hypercalciuric states. (See discussion below.)

D. Imaging

A plain abdominal radiograph (KUB, kidney-ureter-bladder) and renal ultrasound examination will diagnose most stones. More than 60% of patients with acute renal colic will have with a stone in the distal 4 cm of the ureter; attention should be directed to that region when examining plain radiographs and abdominal ultrasonographic studies. Spiral CT is frequently the first-line tool in evaluating flank pain. Repeated CT scans should be avoided due to the substantial radiation exposure to these patients who have recurrent stones at a young age. CT scans should be obtained in the prone position to help differentiate distal

Table 23–3. Diagnostic criteria of different types of hypercalciuria.

	Absorptive Type I	Absorptive Type II	Absorptive Type III	Resorptive	Renal
Serum					
Calcium	N	N	N	↑	N
Phosphorus	N	N	↓	↓	N
PTH	N	N	N	↑	↑
Vitamin D	N	N	↑	↑	↑
Urinary calcium					
Fasting	N	N	↑	↑	↑
Restricted	↑	N	↑	↑	↑
After calcium load	↑	↑	↑	↑	↑

PTH, parathyroid hormone; ↑, elevated; ↓, low; N, normal.

ureterovesicular stones from those that have already passed into the urinary bladder. Stone density can be estimated with Hounsfield units (HU) on CT scans to help determine stone type. Stones with low HU (< 450) are typically composed of uric acid, while those with high HU (> 1200) are typically composed of calcium oxalate monohydrate. All stones whether radiopaque or radiolucent on plain abdominal radiographs will be visible on noncontrast CT except the rare calculi due to the protease inhibitor indinavir.

► Medical Treatment & Prevention

To reduce the recurrence rate of urinary stones, one must attempt to achieve a stone-free status. Small stone fragments may serve as a nidus for future stone development. Selected patients must be thoroughly evaluated to reduce stone recurrence rates. Patients who have formed uric acid stones may have recurrences within months if appropriate therapy is not initiated. If no medical treatment is provided after surgical stone removal, stones will generally recur in 50% of patients within 5 years. Of greatest importance in reducing stone recurrence is an increased fluid intake. Absolute volumes are not established, but increasing fluid intake to ensure a voided volume of 1.5–2.0 L/d is recommended (average voided volume is 1.6 L/d). Patients are encouraged to ingest fluids during meals, 2 hours after each meal (when the body is most dehydrated), and prior to going to sleep in the evening—enough to awaken the patient to void—and to ingest additional fluids during the night. Increasing fluids only during daylight hours may not dilute a supersaturated urine overnight and thus initiate a new stone.

A. Diet

Sodium intake should be restricted to keep urinary sodium levels < 150 mEq/d. Increased sodium intake will increase sodium and calcium excretion, increase monosodium urates (that can act as a nidus for stone growth), increase the relative saturation of calcium phosphate, and decrease urinary citrate excretion. All of these factors encourage stone growth. Animal protein intake should be spread out through the day and not consumed during any individual meal and is best limited to 1 g/kg/d. An increased protein load during an individual meal can also increase calcium, oxalate, and uric acid excretion and decrease urinary citrate excretion.

Bran can significantly decrease urinary calcium excretion by increasing bowel transit time and mechanically binding to calcium. Excess intake of oxalate and purines can increase the incidence of stones in predisposed individuals. Dietary calcium or calcium supplements should not be routinely decreased. In fact, decreased calcium consumption has been found to increase stone recurrence. Only type II absorptive hypercalciuric patients (see below) benefit from a low calcium diet.

B. Calcium Nephrolithiasis

1. Hypercalciuric—Hypercalciuric calcium nephrolithiasis (>250 mg/24 h; >4 mg/kg/24 h) can be caused by absorptive, resorptive, and renal disorders.

Absorptive hypercalciuria is secondary to increased absorption of calcium at the level of the small bowel, predominantly in the jejunum, and can be further subdivided into types I, II, and III. Type I absorptive hypercalciuria is independent of calcium intake. There is increased urinary calcium on a regular or even a calcium-restricted diet. Treatment is centered on decreasing bowel absorption of calcium. Cellulose phosphate, a chelating agent, is an effective form of therapy. An average dose is 10–15 g in three divided doses. It binds to the calcium and impedes small bowel absorption due to its increased bulk. Cellulose phosphate does not change the intestinal transport mechanism. It should be given with meals so it will be available to bind to the dietary calcium. Taking this chelating agent prior to bedtime is ineffective. Postmenopausal women should be treated with caution. It is interesting, however, that there is no enhanced decline in bone density after long-term use. Inappropriate use may result in a negative calcium balance and a secondary parathyroid stimulation. Long-term use without follow-up metabolic surveillance may result in hypomagnesuria and secondary hyperoxaluria and recurrent calculi. Routine follow-up every 6–8 months will help encourage medical compliance and permit adjustments in medical therapy based on repeat metabolic studies.

Thiazide therapy is more commonly used and is an alternative to cellulose phosphate in the treatment of type I absorptive hypercalciuria. Thiazides decrease renal calcium excretion but have no impact on intestinal absorption. This therapy results in increased bone density of approximately 1% per year. Thiazides have limited long-term utility (< 5 years) since they may lose their hypocalciuric effect with continued therapy.

Type II absorptive hypercalciuria is diet dependent and fortunately rare. Decreasing calcium intake by 50% (approximately 400 mg/d) will decrease the hypercalciuria to normal values (150–200 mg/24 h). There is no specific medical therapy.

Type III absorptive hypercalciuria is secondary to a renal phosphate leak. This results in increased vitamin D synthesis and secondarily increased small bowel absorption of calcium. This can be readily reversed by orthophosphates (250 mg orally three to four times per day), presently available without need for a prescription. Orthophosphates do not change intestinal absorption but rather inhibit vitamin D synthesis.

Resorptive hypercalciuria is secondary to hyperparathyroidism. Hypercalcemia, hypophosphatemia, hypercalciuria, and an elevated serum PTH value are found. Appropriate surgical resection of the parathyroid adenoma cures the disease and recurrent urinary stones are decreased by > 90%. Medical management is invariably a failure.

Renal hypercalciuria occurs when the renal tubules are unable to efficiently reabsorb filtered calcium, and hypercalciuria results. Spilling calcium in the urine results in secondary hyperparathyroidism. Serum calcium typically is normal. Thiazides are effective long-term therapy in patients with this disorder.

2. Hyperuricosuric—Hyperuricosuric calcium nephrolithiasis is secondary to dietary purine excess or endogenous uric acid metabolic defects. Most cases (85%) can be

treated with purine dietary restrictions; those that are not reversed with dietary modification are successfully treated with allopurinol. In contrast to uric acid nephrolithiasis, patients with hyperuricosuric calcium stones typically maintain a urinary pH > 5.5. Monosodium urates adsorb and adsorb inhibitors and promote heterogeneous nucleation. Hyperuricosuric calcium nephrolithiasis is initiated with epitaxy, or heterogeneous nucleation. In such situations, similar crystal structures (ie, uric acid and calcium oxalate) can grow together with the aid of a protein matrix infrastructure.

3. Hyperoxaluric—Hyperoxaluric calcium nephrolithiasis (> 40 mg oxalate/24h urine) is usually due to primary intestinal disorders. Patients usually have a history of chronic diarrhea frequently associated with inflammatory bowel disease. In these situations, increased bowel fat or bile (or both) combine with intraluminal calcium to form a soap-like product. Calcium is therefore unavailable to bind to oxalate, which is then freely and rapidly absorbed. A small increase in oxalate absorption will significantly increase stone formation. If the diarrhea or steatorrhea cannot be effectively curtailed, oral calcium should be taken with meals; the calcium can be obtained by either ingesting milk products or taking calcium carbonate supplements (250–500 mg). Excess ascorbic acid (> 2 g/d) will substantially increase urinary oxalate levels. Rare enzymatic liver defects can lead to primary hyperoxaluria that is routinely fatal without a combined liver and kidney transplantation.

4. Hypocitraturic—Hypocitraturic calcium nephrolithiasis may be secondary to chronic diarrhea, type I (distal) renal tubular acidosis, chronic hydrochlorothiazide treatment, or in any other condition that results in a metabolic acidosis. The metabolic acidosis will encourage citrate transport into the proximal tubular cells and be consumed by the citric acid cycle in their mitochondria and result in hypocitraturia (< 450 mg/24h). Hypocitraturia is frequently associated with most forms of calcium stone formation. Urinary citrate binds to calcium in solution, thereby decreasing available calcium for precipitation and subsequent stone formation. Potassium citrate supplements are usually effective treatment in these situations. Urinary citrate is decreased in acidosis and is increased during alkalosis. The potassium will supplement the frequently associated hypokalemic states, and citrate will help correct the acidosis. A typical dose is 20 mEq three times a day (available in 10-mEq waxed tablets or in solution), or 30 mEq of crystal formulations twice a day. Alternatively, oral lemonade has been shown to increase urinary citrate by about 150 mg/24h.

C. Uric Acid Calculi

The average normal urinary pH is 5.8–5.9. Urinary pH is consistently < 5.5 in persons who form uric acid stones. The pK of uric acid is 5.75, at which point half of the uric acid is ionized as a urate salt and is soluble, while the other half is insoluble. Increasing the urinary pH above 6.2 dramatically increases uric acid solubility and can effectively

dissolve large calculi at a rate of 1 cm per month as seen on plain abdominal radiographs, and effectively prevents future uric acid stone formation. Urinary alkalization is the key to stone dissolution and prophylaxis. Potassium citrate is the most frequently used medication to increase urinary pH. It can be given in liquid preparation, as crystals that need to be taken with fluids, or as tablets (10 mEq), two by mouth three or four times daily. Patients with uric acid calculi should be given nitrazine pH paper with which to monitor the effectiveness of their urinary alkalization; the goal is a urinary pH > 6.2 and < 6.5 (to avoid calcium phosphate precipitation). Other contributing factors include hyperuricemia, myeloproliferative disorders, malignancy with increased uric acid production, abrupt and dramatic weight loss, and uricosuric medications. If hyperuricemia is present, allopurinol (300 mg/d orally) may be given. Although pure uric acid stones are relatively radiolucent, most have some calcium components and can be visualized on plain abdominal radiographs. Renal ultrasonography is a helpful adjunct for appropriate diagnosis and long-term management.

D. Struvite Calculi

Struvite stones are synonymous with magnesium-ammonium-phosphate or infection stones. They are most commonly seen in women with recurrent urinary tract infections recalcitrant to appropriate antibiotics. They rarely present as ureteral stones with colic without prior upper tract endourologic intervention. Frequently, a struvite stone is discovered as a large staghorn configured calculus forming a cast of the renal collecting system. Struvite stones are radiodense. Urinary pH is high, routinely above 7.2. These stones are formed secondary to urease-producing organisms, including *Proteus*, *Pseudomonas*, *Providencia* and, less commonly, *Klebsiella*, *Staphylococcus*, and *Mycoplasma*. An *E coli* urinary tract infection is not consistent with an infectious reservoir originating from a struvite calculus. These frequently large stones are relatively soft and amenable to percutaneous nephrolithotomy. Appropriate perioperative antibiotics are required. They can recur rapidly, and efforts should be taken to render the patient stone-free. Postoperative irrigation through nephrostomy tubes can eliminate small fragments. Acetohydroxamic acid is an effective urease inhibitor, but it is poorly tolerated by most patients because of its gastrointestinal toxicity.

E. Cystine Calculi

Cystine stones are a result of abnormal excretion of cystine, ornithine, lysine, and arginine. Cystine is the only amino acid that becomes insoluble in urine. These stones are particularly difficult to manage medically. Prevention is centered around marked increased fluid intake during the day and evening to achieve a urinary volume of 3–4 L/d, urinary alkalization with a urinary pH > 7.0 (monitored with Nitrazine pH paper), and disulfide inhibitors such as tiopronin (α -mercaptopyrionylglycine) or penicillamine. There are no known inhibitors of cystine calculi.

► Surgical Treatment

Forced intravenous fluids will not push stones down the ureter. Effective peristalsis directing a bolus of urine down the ureter requires opposing ureteral walls to approach each other and touch, which large dilated systems cannot do. In fact, forced diuresis is counterproductive and will exacerbate the pain; a euvoletic state should be achieved. Associated fever may represent infection, a medical emergency requiring prompt drainage by a ureteral catheter or a percutaneous nephrostomy tube. Antibiotics alone are inadequate unless the obstruction is drained.

A. Ureteral Stones

Impediment to urine flow by ureteral stones usually occurs at two sites: at the ureteropelvic junction and at the ureterovesicular junction as the ureter enters the bladder. Prediction of spontaneous stone passage is difficult. Stones < 5–6 mm in diameter as seen on a plain abdominal radiograph usually pass spontaneously. Medical expulsive therapy with α -blockers (such as tamsulosin, 0.4 mg orally once daily) in combination with a nonsteroidal anti-inflammatory agent (such as ibuprofen 600 mg orally three times per day with a full stomach), with or without a short course of a low-dose oral corticosteroid dramatically increases the rate of spontaneous stone passage. Active medical expulsive therapy with appropriate pain medications is appropriate for the first few weeks. If stone passage fails, with or without medical expulsive therapy, or the patient has intolerable pain or persistent nausea or vomiting, therapeutic intervention is indicated. Distal ureteral stones are best managed with ureteroscopic stone extraction or in situ extracorporeal shock wave lithotripsy (SWL). Ureteroscopic stone extraction involves placement of a small endoscope through the urethra and into the ureter. Under direct vision, basket extraction or stone laser fragmentation followed by extraction is performed. Complications during endoscopic retrieval increase as the duration of attempted medical expulsive therapy increases beyond 6 weeks. Indications for earlier intervention include severe pain unresponsive to medications, fever, persistent nausea and vomiting requiring intravenous hydration, social requirements requiring return to work, or anticipated travel. Most upper tract stones that enter the bladder can exit the urethra with minimal discomfort.

In situ SWL, an alternative, utilizes an external energy source that is focused on the stone. This focused energy is additive, resulting in minimal tissue insult except at the focus where the stone is positioned with the aid of fluoroscopy or ultrasonography. This can be performed under anesthesia as an outpatient procedure and has a high stone fragmentation rate. Most stone fragments will pass uneventfully within 2 weeks, but those that have not passed within 6 weeks are unlikely to pass without intervention. Women of childbearing age are best not treated with SWL for a stone in the lower ureter because the impact on the ovary is unknown.

Proximal and midureteral stones—those above the inferior margin of the sacroiliac joint—can be treated with SWL or ureteroscopy. SWL is delivered directly to the stone

(in situ) without the need to push the stone back into the renal pelvis. To help ensure adequate drainage after SWL, a double J ureteral stent may be placed, but it does not ensure passage of stone fragments. Occasionally, stone fragments will obstruct the ureter after SWL. Conservative management will usually result in spontaneous resolution with eventual passage of the stone fragments. If this is unsuccessful, adequate proximal drainage through a percutaneous nephrostomy tube will facilitate passage. In rare instances, ureteroscopic extraction will be required.

B. Renal Calculi

Patients with renal calculi presenting without pain, urinary tract infections, or obstruction need not be treated. They should be monitored with serial abdominal radiographs or renal ultrasonographic examinations. If calculi are growing or become symptomatic, intervention should be undertaken. Renal calculi < 1.5 cm in diameter are best treated with SWL. Calculi located in the inferior calyx frequently result in suboptimal stone-free rates as measured at 3 months by x-ray. Such calculi and others of larger diameter are best treated via percutaneous nephrolithotomy. Percutaneous nephrolithotomy is performed by inserting a needle into the appropriate renal calyx and dilating a tract large enough to allow a nephroscope to pass and inspect, fragment, and remove stone and stone fragments. Perioperative antibiotic coverage should be given on the basis of preoperative urine cultures.

► When to Refer

- Evidence of urinary obstruction.
- Urinary stone with fever.
- Anatomic abnormalities or solitary kidney.
- Concomitant pyelonephritis.

► When to Admit

- Intractable nausea and vomiting or pain.
- Fever.

Fink HA et al. Diet, fluid, or supplements for secondary prevention of nephrolithiasis: a systematic review and meta-analysis of randomized trials. *Eur Urol*. 2009 Jul;56(1):72–80. [PMID: 19321253]

Nouvenne A et al. Effects of a low-salt diet on idiopathic hypercalciuria in calcium-oxalate stone formers: a 3-mo randomized controlled trial. *Am J Clin Nutr*. 2010 Mar;91(3):565–70. [PMID: 20042524]

Preminger GM et al; EAU/AUA Nephrolithiasis Guideline Panel. 2007 guideline for the management of ureteral calculi. *J Urol*. 2007 Dec;178(6):2418–34. [PMID: 17993340]

Reiner AP et al. Kidney stones and subclinical atherosclerosis in young adults: the CARDIA study. *J Urol*. 2011 Mar;185(3):920–5. [PMID: 21251678]

Stoller ML et al. The primary stone event: a new hypothesis involving a vascular etiology. *J Urol*. 2004 May;171(5):1920–4. [PMID: 15076312]

Tracy CR et al. Update on the medical management of stone disease. *Curr Opin Urol*. 2009 Mar;19(2):200–4. [PMID: 19188774]

MALE ERECTILE DYSFUNCTION & SEXUAL DYSFUNCTION



ESSENTIALS OF DIAGNOSIS

- ▶ Erectile dysfunction can have organic and psychogenic etiologies.
- ▶ Organic erectile dysfunction may be an early sign of cardiovascular disease and requires evaluation.
- ▶ Peyronie disease is a common fibrotic disorder of the penile erectile bodies that causes penile deformity and sexual dysfunction.

▶ General Considerations

Erectile dysfunction is the consistent inability to attain or maintain a sufficiently rigid penile erection for sexual performance. The condition affects nearly 30 million American men, and its incidence is age related. Approximately 52% of men aged 40–70 years experience erectile dysfunction. Most cases of erectile dysfunction have an organic rather than a psychogenic cause. Normal male erection is a neurovascular event relying on an intact autonomic and somatic nerve supply to the penis, smooth and striated musculature of the corpora cavernosa and pelvic floor, and arterial blood flow supplied by the paired pudendal arteries. Erection is caused and maintained by an increase in arterial flow, active relaxation of the smooth muscle within the sinusoids of the paired corpora cavernosa of the penis, and an increase in venous resistance. Contraction of the bulbocavernosus and ischiocavernosus muscles results in further rigidity of the penis with intracavernosal pressures far exceeding systolic blood pressure. Nitric oxide is a pivotal neurotransmitter that initiates and sustains erections; however, other molecules contribute, including acetylcholine, prostaglandins, and vasoactive intestinal peptide.

Male sexual dysfunction may be manifested in a variety of ways, and patient history is critical to the proper classification and treatment. Androgens have a strong influence on the sexual desire of men. A **loss of libido** may indicate androgen deficiency on the basis of either hypothalamic, pituitary, or testicular disease. **Loss of erections** may result from arterial, venous, neurogenic, or psychogenic causes. Concurrent medical problems may damage one or more of the mechanisms. Of particular concern is endothelial dysfunction, defined as the decreased bioavailability of nitric oxide with subsequent impairment of arterial vasodilation. Erectile dysfunction may be an early manifestation of endothelial dysfunction, which precedes more severe, systemic atherosclerotic, cardiovascular disease. In addition, many medications, especially antihypertensive and antidepressant agents, are associated with erectile dysfunction. **Peyronie disease** is a fibrotic disorder of the tunica albuginea of the penis resulting in varying degrees of penile curvature or deformity and sexual dysfunction. Peyronie disease develops in approximately 5% of men older than 50 years, but this may be an underestimate related to embarrassment in seeking care. After onset of the disease, 10% of men improve

spontaneously. If left untreated, the disease progresses in half of the remainder and the rest stabilize. Deformity of the penis can be severe enough to impair normal sexual function. The etiology of Peyronie disease is not fully understood and is likely multifactorial. The most promising hypothesis is that subtle penile trauma is followed by abnormal wound healing, although other potential disease modulators may include vascular disease and hypogonadism.

Priapism is the occurrence of penile erection unrelated to sexual stimulation, generally lasting longer than 4 hours, and potentially leading to irreversible damage to the erectile mechanisms. Priapism can be due to unregulated high blood flow, but more commonly, it is due to trapping of blood within the erectile bodies resulting in penile ischemia and infarction of the sinusoidal tissue. Priapism may be caused by any of the treatments for erectile dysfunction, drug use, and red blood cell dyscrasias.

Anejaculation is the loss of seminal emission and may result from androgen deficiency by decreasing prostate and seminal vesicle secretions as well as sympathetic denervation as a result of diabetes mellitus or pelvic or retroperitoneal surgery or radiation. **Retrograde ejaculation** may occur as a result of mechanical disruption of the bladder neck, especially following transurethral resection of the prostate, pelvic radiation, treatment with α -blockers, or due to sympathetic denervation. If libido and erection are intact, the **loss of orgasm** is usually of psychological origin. **Premature ejaculation** is the persistent or recurrent ejaculation with minimal stimulation before a person desires (associated with distress) and may be primary or secondary. The former is usually psychogenic in origin and additional history may elucidate the presence of a new partner, unreasonable expectations about performance, or emotional disorders. The latter is caused by erectile dysfunction and may be corrected with erectile dysfunction treatment.

▶ Clinical Findings

A. Symptoms and Signs

Erectile dysfunction should be distinguished from problems of penile deformity, ejaculation, libido, and orgasm. The severity of the dysfunction (maintaining vs attaining; chronic, occasional, or situational) as well as its timing should be noted. The history should include inquiries about dyslipidemia, hypertension, depression, neurologic disease, diabetes mellitus, chronic kidney disease, and endocrine disorders as well as cardiac or peripheral vascular disease. Pelvic trauma, surgery, or irradiation identifies patients at increased risk for erectile dysfunction. Penile deformity or curvature that prevents normal intercourse should be noted because this may indicate the presence of Peyronie disease, which may complicate treatment. The history should clarify the severity of curvature, loss of penile length, and other deformities that may prevent normal, painless sexual intercourse. It is important to determine whether the patient has any normal erections in the early morning or during sleep. If normal erections occur, an organic cause is less likely. The ability to attain but not maintain an erection may be the first sign of **endothelial dysfunction**, which is the decreased responsiveness of the

penile vasculature to nitric oxide released from pelvic parasympathetic nerves. The gradual loss of erections over time is more suggestive of an organic cause with the exception of erectile dysfunction that immediately follows pelvic surgery or trauma. Medication use should be noted, since 25% of all cases of sexual dysfunction may be drug related. The use of alcohol, tobacco, and recreational drugs should be recorded, since each is associated with an increased risk of sexual dysfunction.

During the physical examination, secondary sexual characteristics should be assessed. Motor and sensory examination should be performed as well as palpation and quantification of lower extremity vascular pulsations. The genitalia should be examined, noting the presence of penile scarring or plaque formation (Peyronie disease) and any abnormalities in size or consistency of either testicle.

B. Laboratory Findings

Laboratory evaluation should consist of a fasting lipid profile and glucose, testosterone, and prolactin. Patients with abnormalities of testosterone or prolactin require further evaluation with measurement of free testosterone and luteinizing hormone (LH) to distinguish hypothalamic-pituitary dysfunction from testes failure.

C. Special Tests

Further testing is based on the patient's history and is performed when etiology is unclear. Organic and psychogenic erectile dysfunction frequently occur in tandem, given that erectile dysfunction can contribute to emotional stress. Erectile dysfunction that is primarily psychogenic can generally be differentiated by patient history, whereby men will describe normal nocturnal or morning erections, or situational erectile dysfunction. If the distinction remains unclear, clarity may be gained with the use of nocturnal penile tumescence testing, where the frequency and rigidity of erections are recorded by a tension meter attached to the penis before sleep. Patients with psychogenic erectile dysfunction will have nocturnal erections of adequate frequency and rigidity.

Treatment of patients with oral medications (sildenafil, vardenafil, and tadalafil) provides insight into the etiology and severity of erectile dysfunction. Patients with inadequate response to oral medications may undergo further evaluation with direct injection of vasoactive medications into the penis. These medications (prostaglandin E_1 , papaverine, phentolamine or a combination of drugs) induce erections in men with intact vascular systems. Patients who respond with a rigid erection require no further vascular evaluation.

Additional vascular testing is indicated in select patients who do not achieve an erection after penile injection and who are candidates for vascular reconstructive surgery. Duplex ultrasound, penile cavernosography, and pudendal arteriography can distinguish arterial from venous erectile dysfunction and help predict which patients may benefit from vascular surgery.

► Treatment

Treatment of men suffering from sexual dysfunction should be patient centered and goal oriented, since the

disease is generally not life-threatening. Most men can be treated successfully with one of the approaches outlined below. Men who have psychogenic erectile dysfunction will probably benefit from behaviorally oriented sex therapy.

A. Hormonal Replacement

Testosterone replacement therapy may be offered to men with documented biochemical hypogonadism who have undergone endocrinologic evaluation and in whom there is no evidence of prostate cancer or other contraindication to treatment. Restoration of normal testosterone levels may improve libido and effectiveness of oral erectile medications.

B. Vasoactive Therapy

Sexual stimulation with subsequent nitric oxide release from the parasympathetic nerves and endothelium initiates penile erection. Nitric oxide enters smooth muscles cells, increases cyclic guanosine monophosphate (cGMP) production, which mediates calcium sequestration and cellular hyperpolarization. Phosphodiesterase-5 (PDE-5) degrades cGMP and fosters penile detumescence. Activation of pelvic sympathetic nerves causes ejaculation, contraction of the smooth muscle within the corpora cavernosa and complete penile detumescence.

1. Oral agents—Sildenafil, vardenafil, and tadalafil inhibit PDE-5, preventing the degradation of cGMP, thereby sustaining inflow of blood into the erect penis. The drugs are similarly effective; some patients who do not respond to one PDE-5 inhibitor may respond to one of the other agents. Because of differences in receptor binding affinity and pharmacokinetics, the drugs have variable durations of activity and side effects. Each drug should be initiated at the lowest dose and titrated to effect. There is no effect on libido, and priapism is exceedingly rare. The additive effect of nitrate medications may lead to exaggerated cardiac preload reduction and hypotension; therefore, these drugs are contraindicated in patients taking nitroglycerin or nitrates. The greatest risk for this effect is within the first hour after taking sildenafil but this risk period may be longer for tadalafil due to increased drug half-life. All patients being evaluated for acute chest pain should be asked if they are taking a PDE-5 inhibitor before administering nitroglycerin and close monitoring of blood pressure is warranted if there is concern regarding drug overlap. Fixed atherosclerotic disease in the aortoiliac system is associated with diminished efficacy.

The combination of PDE-5 inhibitors and α -receptor blockers (which may be prescribed for lower urinary tract symptoms) may cause a larger reduction in systemic blood pressure than when PDE-5 inhibitors are used alone. However, these two classes of medication may be safely used in combination if they are started in a stepwise fashion, with escalation of dose when there is no evidence of syncope. In select men, combined treatment with PDE-5 inhibitors and testosterone replacement may be warranted, since adequate androgen levels may be required for the penile vasculature to be fully responsive to vasoactive drugs.

2. Injectable agents—Direct injection of vasoactive prostaglandins with or without papaverine or phentolamine into the penis is an acceptable form of treatment for many men

with erectile dysfunction. Injections are performed using a tuberculin syringe or a metered-dose injection device. The base and lateral aspect of the penis is used as the injection site to avoid injury to the superficial blood supply located anteriorly. Complications are rare and include bruising, dizziness, local pain, fibrosis, priapism, and infection. Vasoactive prostaglandins (alprostadil) can also be delivered via a urethral suppository with slightly less effectiveness.

The presence of a prolonged erection (priapism) requires immediate medical attention to prevent erectile dysfunction and fibrosis of the cavernosal tissues. Initial management may include aspiration of blood from the penis or injection of sympathomimetic drugs (epinephrine or phenylephrine); if these maneuvers fail, surgical shunts may need to be performed to drain blood from the corpora cavernosa.

C. Vacuum Erection Device

The vacuum erection device causes erection by creating a vacuum chamber around the penis, whereby blood is drawn into the corpora cavernosa. Once adequate tumescence has been achieved, an elastic constriction band is placed around the proximal penile shaft to prevent loss of erection, and the vacuum cylinder is removed. Such devices are highly effective, regardless of the cause of erectile dysfunction; however, the devices are cumbersome with a high rate of discontinued use. Complications are rare.

D. Penile Prosthesis

Prosthetic devices may be implanted directly into the paired corporal bodies. Penile prostheses may be semi-rigid (malleable) or inflatable. Each is manufactured in a variety of sizes and is custom-fit to the individual. Even for men with normal erectile function, the penis is flaccid 90% of time; therefore, inflatable devices may result in a more natural appearance and better functionality. Complications are rare but include mechanical failure, infection, and injury to adjacent anatomic structures during surgery. For men who elect this treatment, personal and partner satisfaction rates exceed 90%.

E. Vascular Reconstruction

Patients with disorders of the arterial system are candidates for various forms of arterial reconstruction, including endarterectomy and balloon dilation for proximal arterial occlusion and arterial bypass procedures utilizing arterial (epigastric) or venous (deep dorsal vein) segments for distal occlusion. Patients with venous disorders may be managed with ligation of certain veins (deep dorsal or emissary veins) or the crura of the corpora cavernosa. Experience with vascular reconstructive procedures is limited, and many patients so treated still fail to achieve a rigid erection.

F. Medical and Surgical Therapy for Peyronie Disease

A wide range of medical and surgical treatments have been used to treat the disorder. There are no oral therapies for Peyronie disease that are approved by the FDA; however, evidence from randomized controlled trials supports the use of pentoxifylline, coenzyme Q10, colchicine, potassium

aminobenzoate (Potaba), and L-carnitine. The intraplaque injection of verapamil or interferon improves penile deformity in some patients. Surgical treatment is an alternative for men with compromised sexual function due to severe curvature or lesions causing penile instability. The choice of corrective procedure should be tailored to each patient after a detailed evaluation of disease severity and sexual function.

▶ When to Refer

- Patients with inadequate response to oral medications or who are unable to tolerate side effects.
- Patients with Peyronie disease (penile curvature) or other penile deformity.
- Patients with a history of pelvic or perineal trauma, surgery, or radiation.
- Young patients or those with lifelong erectile dysfunction.
- Ischemic priapism is a medical emergency and requires immediate referral to a urologist or the emergency department for intervention to allow restoration of penile blood perfusion.

Corona G et al. Phosphodiesterase type 5 (PDE5) inhibitors in erectile dysfunction: the proper drug for the proper patient. *J Sex Med.* 2011 Dec;8(12):3418–32. [PMID: 21995676]

McVary KT. Clinical practice. Erectile dysfunction. *N Engl J Med.* 2007 Dec 13;357(24):2472–81. [PMID: 18077811]

Meuleman EJ et al. Diagnostic tests for male erectile dysfunction revisited. Committee Consensus Report of the International Consultation in Sexual Medicine. *J Sex Med.* 2010 Jul;7(7):2375–81. [PMID: 20487240]

Porst H. An overview of pharmacotherapy in premature ejaculation. *J Sex Med.* 2011 Oct;8(Suppl 4):335–41. [PMID: 21967395]

Shin D et al. Erectile dysfunction: a disease marker for cardiovascular disease. *Cardiol Rev.* 2011 Jan–Feb;19(1):5–11. [PMID: 21135596]

Smith JF et al. Peyronie's disease: a critical appraisal of current diagnosis and treatment. *Int J Impot Res.* 2008 Sep–Oct;20(5):445–59. [PMID: 18650828]

Tsertsvadze A et al. Oral phosphodiesterase-5 inhibitors and hormonal treatments for erectile dysfunction: a systematic review and meta-analysis. *Ann Intern Med.* 2009 Nov 3;151(9):650–61. [PMID: 19884626]

MALE INFERTILITY

ESSENTIALS OF DIAGNOSIS

- ▶ Couple infertility is related to the male partner in 50% of cases.
- ▶ Causes include decreased or absent sperm production or function, or obstruction of the male genital tract.
- ▶ Detailed history, physical examination, and repeated semen analysis are the cornerstones of diagnosis and treatment.
- ▶ In select men, abnormal semen quality may indicate poor somatic health and increased risk for certain health conditions.

► General Considerations

Infertility, the inability of a couple to conceive a child after 1 year of sexual intercourse without contraceptive use, affects 15–20% of US couples. Approximately one-third of cases result from male factors, one-third from female factors, and one-third from combined factors; therefore, evaluation of both partners is critical. Clinical evaluation is warranted following 6 months of unprotected intercourse in select couples. Following a detailed history and physical examination, a semen analysis is essential for diagnosis and should be performed at least twice, on two separate occasions (Figure 23–1). Because spermatogenesis takes approximately 74 days, it is important to review events from the past 3 months. Some types of male infertility put men at higher risk for the later development of testicular germ cell cancer; thus, they should be counseled appropriately and taught self testicular exam.


► Clinical Findings

A. Symptoms and Signs

The history should include prior testicular insults (torsion, cryptorchidism, trauma), infections (mumps orchitis,

epididymitis), environmental factors (excessive heat, radiation, chemotherapy, prolonged pesticide exposure), medications (anabolic steroids, cimetidine, and spironolactone may affect spermatogenesis; phenytoin may lower FSH; sulfasalazine and nitrofurantoin affect sperm motility), and drugs (alcohol, tobacco, marijuana). Sexual habits, frequency and timing of intercourse, use of lubricants, and each partner's previous fertility experiences are important. Loss of libido and headaches, visual disturbances, or galactorrhea may indicate a pituitary tumor. The past medical or surgical history may reveal thyroid or liver disease (abnormalities of spermatogenesis), diabetic neuropathy (retrograde or anejaculation), radical pelvic or retroperitoneal surgery (absent seminal emission secondary to sympathetic nerve injury), or hernia repair (damage to the vas deferens or testicular blood supply).

Physical examination should pay particular attention to features of hypogonadism: underdeveloped secondary sexual characteristics, diminished male pattern hair distribution (axillary, body, facial, pubic), body habitus, and gynecomastia. The scrotal contents should be carefully evaluated. Testicular size should be noted (normal size approximately 4.5 × 2.5 cm, volume 18 mL). **Varicoceles**



▲ **Figure 23-1.** Couple based approach to evaluation and treatment of male factor infertility. FNA, fine-needle aspiration.

are abnormally dilated and refluxing veins of the pampiniform plexus that can be identified in the standing position by gentle palpation of the spermatic cord and, on occasion, may only be appreciated with the Valsalva maneuver. The vas deferens, epididymis, and prostate should be palpated (absence of all or part of the vas deferens may indicate the presence a cystic fibrosis variant, congenital bilateral or unilateral absence of the vas deferens).

B. Laboratory Findings

Semen analysis should be performed after 2 to 3 days of ejaculatory abstinence. The specimen should be analyzed within 1 hour after collection. Abnormal sperm concentrations are <15 million/mL (**oligozoospermia** is the presence of <15 million sperm/mL in the ejaculate; **azoospermia** is the absence of sperm). Normal semen volumes range between 1.5 mL and 5 mL (volumes <1.5 mL may result in inadequate buffering of the vaginal acidity and may be due to retrograde ejaculation, ejaculatory duct obstruction, or androgen insufficiency). Normal sperm motility and morphology demonstrate $>45\%$ motile cells and $>4\%$ normal morphology (World Health Organization). Abnormal motility may result from varicocele, antisperm antibodies, infection, abnormalities of the sperm flagella, or partial ejaculatory duct obstruction. Abnormal morphology may result from a varicocele, infection, or exposure to gonadotoxins (eg, tobacco smoke).

Endocrine evaluation is warranted if sperm counts are low (<15 million/mL) or if there is a basis from the history and physical examination for suspecting an endocrinologic origin. Initial testing should include serum FSH and testosterone. Specific abnormalities in these hormones should prompt additional testing, including LH and prolactin. Elevated FSH and LH levels and low testosterone levels (hypergonadotropic hypogonadism) are associated with primary testicular failure. Low FSH and LH associated with low testosterone occur in secondary testicular failure (hypogonadotropic hypogonadism) and may be of hypothalamic or pituitary origin. Elevation of serum prolactin may indicate the presence of pituitary prolactinoma.

C. Genetic Testing

Men with sperm concentrations <10 million/mL should undergo testing for Y chromosome microdeletions and karyotypic abnormalities. Gene deletions from the long arm of the Y chromosome may cause azoospermia or oligozoospermia with age-related decline in spermatogenesis that is transmissible to male offspring. Karyotyping may reveal Klinefelter syndrome. Partial or complete absence of the vas deferens should prompt testing for cystic fibrosis mutations.

D. Imaging

Scrotal ultrasound may detect a subclinical varicocele. Vasography may be required in patients with suspected genital duct obstruction. Men with low ejaculate volume and no evidence of retrograde ejaculation should undergo transrectal ultrasound to evaluate the prostate and seminal vesicles. MRI of the sella turcica should be performed in

men with markedly elevated prolactin or hypogonadotropic hypogonadism to evaluate the anterior pituitary gland. MRI of the pelvis and scrotum should be considered in men for whom the testes cannot be identified in the scrotum by physical examination or ultrasound.

E. Special Tests

Patients with low volume ejaculate should have post-ejaculation urine samples centrifuged and analyzed for sperm to evaluate for retrograde ejaculation. In cases of disproportionately low motility, sperm vitality and the presence of autoantibodies should be assessed. Rounds cells in concentrations >1 million/mL should prompt leukocyte esterase or peroxidase staining (immature germ cells are found normally, but inflammatory cells may require treatment).

▶ Treatment

A. General Measures

Education about the proper timing for intercourse in relation to the woman's ovulatory cycle as well as the avoidance of spermicidal lubricants should be discussed. In cases of gonadotoxic exposure or medication-related factors, the offending agent should be removed. Patients with active genitourinary tract infections should be treated with appropriate antibiotics. Healthy lifestyle habits, including healthy diet, moderate exercise, and avoidance of gonadotoxins (such as tobacco smoke) should be reinforced.

B. Varicocele

Varicocelectomy is performed by stopping retrograde blood flow in spermatic cord veins. Surgical ligation may be accomplished via subinguinal, inguinal, retroperitoneal, or laparoscopic approaches. Percutaneous venographic embolization of varicoceles is feasible but may have a higher recurrence rate.

C. Endocrine Therapy

Hypogonadotropic hypogonadism may be treated with chorionic gonadotropin once primary pituitary disease has been excluded or treated. Dosage is usually 2000 international units intramuscularly three times a week. If sperm counts fail to rise after 12 months, FSH therapy should be initiated.

D. Ejaculatory Dysfunction Therapy

Patients with retrograde ejaculation may benefit from α -adrenergic agonists (pseudoephedrine, 60 mg orally three times a day) or imipramine (25 mg orally three times a day). Medical failures may require the collection of post-ejaculation urine for intrauterine insemination. Anejaculation can be treated with vibratory stimulation or electroejaculation in select cases.

E. Ductal Obstruction

Obstruction of the ejaculatory ducts may be corrected by transurethral resection of the ducts in the prostatic urethra.

If obstruction of the vas deferens or epididymis is suspected, the level of obstruction must be determined via a vasogram prior to operative treatment, with the exception of prior vasectomy. Obstruction of the vas deferens is best managed by microsurgical vasovasostomy or vasoepididymostomy.

F. Assisted Reproductive Techniques

Intrauterine insemination, in vitro fertilization, and intracytoplasmic sperm injection (ICSI) are alternatives for patients in whom other means of treating reduced sperm concentration, motility, or functionality has failed. With the use of ICSI, azoospermic men can father their genetic progeny by surgical retrieval of sperm from the testicle, epididymis, or vas deferens.

▶ When to Refer

- Couples with clinical infertility or concern about fertility potential.
- Men with known genital insults, genetic diagnoses, or syndromes that preclude natural fertility.
- Reproductive-aged men with newly diagnosed cancer or other disease that may require cytotoxic therapies with interest in fertility preservation.

Lopushnyan NA et al. Surgical techniques for the management of male infertility. *Asian J Androl.* 2012 Jan;14(1):94–102. [PMID: 22120932]

Patel ZP et al. Male factor assessment in infertility. *Med Clin North Am.* 2011 Jan;95(1):223–34. [PMID: 21095425]

Practice Committee of American Society for Reproductive Medicine in collaboration with Society for Male Reproduction and Urology. Evaluation of the azoospermic male. *Fertil Steril.* 2008 Nov;90(5 Suppl):S74–7. [PMID: 19007652]

Walsh TJ et al. Increased risk of testicular germ cell cancer among infertile men. *Arch Intern Med.* 2009 Feb 23;169(4):351–6. [PMID: 19237718]

Walsh TJ et al. The genetics of male infertility. *Semin Reprod Med.* 2009 Mar;27(2):124–36. [PMID: 19247914]

BENIGN PROSTATIC HYPERPLASIA



ESSENTIALS OF DIAGNOSIS

- ▶ Obstructive or irritative voiding symptoms.
- ▶ May have enlarged prostate on rectal examination.
- ▶ Absence of urinary tract infection, neurologic disorder, stricture disease, prostatic or bladder malignancy.

▶ General Considerations

Benign prostatic hyperplasia is the most common benign tumor in men, and its incidence is age related. The prevalence of histologic benign prostatic hyperplasia in autopsy studies rises from approximately 20% in men aged 41–50 years, to 50% in men aged 51–60, and to over 90% in men

over 80 years of age. Although clinical evidence of disease occurs less commonly, symptoms of prostatic obstruction are also age related. At age 55 years, approximately 25% of men report obstructive voiding symptoms. At age 75 years, 50% of men report a decrease in the force and caliber of the urinary stream.

Risk factors for the development of benign prostatic hyperplasia are poorly understood. Some studies have suggested a genetic predisposition and some have noted racial differences. Approximately 50% of men under age 60 years who undergo surgery for benign prostatic hyperplasia may have a heritable form of the disease. This form is most likely an autosomal dominant trait, and first-degree male relatives of such patients carry an increased relative risk of approximately fourfold.

▶ Clinical Findings

A. Symptoms

The symptoms of benign prostatic hyperplasia can be divided into obstructive and irritative complaints. **Obstructive symptoms** include hesitancy, decreased force and caliber of the stream, sensation of incomplete bladder emptying, double voiding (urinating a second time within 2 hours), straining to urinate, and postvoid dribbling. **Irritative symptoms** include urgency, frequency, and nocturia.

The American Urological Association (AUA) symptom index (Table 23–4) is perhaps the single most important tool used in the evaluation of patients with this disorder and should be calculated for all patients before starting therapy. The answers to seven questions quantitate the severity of obstructive or irritative complaints on a scale of 0–5. Thus, the score can range from 0 to 35, in increasing severity of symptoms.

A detailed history focusing on the urinary tract should be obtained to exclude other possible causes of symptoms such as prostate cancer or disorders unrelated to the prostate such as urinary tract infection, neurogenic bladder, or urethral stricture.

B. Signs

A physical examination, digital rectal examination (DRE), and a focused neurologic examination should be performed on all patients. The size and consistency of the prostate should be noted, but prostate size does not correlate with the severity of symptoms or the degree of obstruction. Benign prostatic hyperplasia usually results in a smooth, firm, elastic enlargement of the prostate. Induration, if detected, must alert the clinician to the possibility of cancer, and further evaluation is needed (ie, prostate-specific antigen [PSA] testing, transrectal ultrasound, and biopsy). Examination of the lower abdomen should be performed to assess for a distended bladder.

C. Laboratory Findings

Urinalysis should be performed to exclude infection or hematuria. A serum PSA is considered optional, yet most clinicians will include it in the initial evaluation, particularly if life expectancy is > 10 years. PSA certainly increases

Table 23-4. American Urological Association symptom index for benign prostatic hyperplasia.¹

Questions to Be Answered	Not at All	Less Than One Time in Five	Less Than Half the Time	About Half the Time	More Than Half the Time	Almost Always
1. Over the past month, how often have you had a sensation of not emptying your bladder completely after you finish urinating?	0	1	2	3	4	5
2. Over the past month, how often have you had to urinate again less than 2 hours after you finished urinating?	0	1	2	3	4	5
3. Over the past month, how often have you found you stopped and started again several times when you urinated?	0	1	2	3	4	5
4. Over the past month, how often have you found it difficult to postpone urination?	0	1	2	3	4	5
5. Over the past month, how often have you had a weak urinary stream?	0	1	2	3	4	5
6. Over the past month, how often have you had to push or strain to begin urination?	0	1	2	3	4	5
7. Over the past month, how many times did you most typically get up to urinate from the time you went to bed at night until the time you got up in the morning?	0	1	2	3	4	5

¹Sum of seven circled numbers equals the symptom score. See text for explanation.

Reproduced, with permission, from Barry MJ et al. The American Urological Association symptom index for benign prostatic hyperplasia. *J Urol.* 1992 Nov;148(5):1549-57.

the ability to detect prostate cancer over DRE alone; however, because there is much overlap between levels seen in benign prostatic hyperplasia and prostate cancer, its use remains controversial (see below in the section on screening for prostate cancer).

D. Imaging

Upper tract imaging (CT or renal ultrasound) is recommended only in the presence of concomitant urinary tract disease or complications from benign prostatic hyperplasia (ie, hematuria, urinary tract infection, chronic kidney disease, history of stone disease).

E. Cystoscopy

Cystoscopy is not recommended to determine the need for treatment but may assist in determining the surgical approach in patients opting for invasive therapy.

F. Additional Tests

Cystometrograms and urodynamic profiles should be reserved for patients with suspected neurologic disease or those who have failed prostate surgery. Flow rates, postvoid residual urine determination, and pressure-flow studies are considered optional.


► Differential Diagnosis

A history of prior urethral instrumentation, urethritis, or trauma should be elucidated to exclude urethral stricture or bladder neck contracture. Hematuria and pain are

commonly associated with bladder stones. Carcinoma of the prostate may be detected by abnormalities on the DRE or an elevated PSA (see Chapter 39 for Prostate Cancer). A urinary tract infection can mimic the irritative symptoms of benign prostatic hyperplasia and can be readily identified by urinalysis and culture; however, a urinary tract infection can also be a complication of benign prostatic hyperplasia. Carcinoma of the bladder, especially carcinoma in situ, may also present with irritative voiding complaints; however, urinalysis usually shows evidence of hematuria (see Chapter 39 for Bladder Cancer). Patients with a neurogenic bladder may also have many of the same symptoms and signs as those with benign prostatic hyperplasia; however, a history of neurologic disease, stroke, diabetes mellitus, or back injury may be obtained, and diminished perineal or lower extremity sensation or alterations in rectal sphincter tone or the bulbocavernosus reflex might be observed on examination. Simultaneous alterations in bowel function (constipation) might also suggest the possibility of a neurologic disorder.

► Treatment

Clinical practice guidelines exist for the evaluation and treatment of patients with benign prostatic hyperplasia (Figure 23-2). Following evaluation as outlined above, patients should be offered various forms of therapy for benign prostatic hyperplasia. Patients are advised to consult with their primary care clinicians and make an educated decision on the basis of the relative efficacy and side effects of the treatment options (Table 23-5).



▲ **Figure 23-2.** Benign prostatic hyperplasia decision diagram. DRE, digital rectal examination; PSA, prostate-specific antigen; BPH, benign prostatic hyperplasia; TUIP, transurethral incision of the prostate; TURP, transurethral resection of the prostate.

Table 23-5. Summary of benign prostatic hyperplasia treatment outcomes.¹

Outcome	TUIP	Open Surgery	TURP	Watchful Waiting	α -Blockers	Finasteride ²
Chance for improvement ¹	78–83%	94–99.8%	75–96%	31–55%	59–86%	54–78%
Degree of symptom improvement (% reduction in symptom score)	73%	79%	85%	Unknown	51%	31%
Morbidity and complications ¹	2.2–33.3%	7–42.7%	5.2–30.7%	1–5%	2.9–43.3%	13.6–8.8%
Death within 30–90 days ¹	0.2–1.5%	1–4.6%	0.5–3.3%	0.8%	0.8%	0.8%
Total incontinence ¹	0.1–1.1%	0.3–0.7%	0.7–1.4%	2%	2%	2%
Need for operative treatment for surgical complications ¹	1.3–2.7%	0.6–14.1%	0.7–10.1%	0	0	0
Erectile dysfunction ¹	3.9–24.5%	4.7–39.2%	3.3–34.8%	3%	3%	2.5–5.3%
Retrograde ejaculation	6–55%	36–95%	25–99%	0	4–11%	0
Loss of work in days	7–21	21–28	7–21	1	3.5	1.5%
Hospital stay in days	1–3	5–10	3–5	0	0	0

¹90% confidence interval.

²Most of the data reviewed for finasteride are derived from three trials that have required an enlarged prostate for entry. The chance of improvement in men with symptoms yet minimally enlarged prostates may be much less, as noted from the VA Cooperative Trial.

TUIP, transurethral incision of the prostate; TURP, transurethral resection of the prostate.

Patients with mild symptoms (AUA scores 0–7) should be managed by watchful waiting only. Absolute surgical indications are refractory urinary retention (failing at least one attempt at catheter removal), large bladder diverticula, or any of the following sequelae of benign prostatic hyperplasia: recurrent urinary tract infection, recurrent gross hematuria, bladder stones, or chronic kidney disease.

A. Watchful Waiting

The risk of progression or complications is uncertain. However, in men with symptomatic disease, it is clear that progression is not inevitable and that some men undergo spontaneous improvement or resolution of their symptoms.

Retrospective studies on the natural history of benign prostatic hyperplasia are inherently subject to bias, relating in part to patient selection and also to the type and extent of follow-up. Very few prospective studies addressing the natural history have been reported. One small series demonstrated that approximately 10% of symptomatic men may progress to urinary retention while 50% of patients demonstrate marked improvement or resolution of symptoms. A large randomized study compared finasteride with placebo in men with moderate to severely symptomatic disease and enlarged prostates on DRE. Patients in the placebo arm demonstrated a 7% risk of developing urinary retention over 4 years.

Men with moderate or severe symptoms can also be observed if they so choose. The optimal interval for follow-up is not defined, nor are the specific end points for intervention.

B. Medical Therapy

1. α -Blockers— α -Blockers can be classified according to their receptor selectivity as well as their half-life (Table 23–6).

Prazosin is effective; however, it requires dose titration and twice daily dosing. Typical side effects include orthostatic hypotension, dizziness, tiredness, retrograde ejaculation, rhinitis, and headache.

Long-acting α -blockers allow for once-a-day dosing, but dose titration is still necessary because side effects similar to those seen with prazosin may occur. Terazosin improves symptoms and in numerous studies is superior to placebo or finasteride. Terazosin is started at a dosage of 1 mg orally daily for 3 days, increased to 2 mg orally daily for 11 days, then 5 mg orally daily. Additional dose escalation to 10 mg orally daily can be performed if necessary. Doxazosin is started at a dosage of 1 mg orally daily for 7 days, increased to 2 mg orally daily for 7 days, then 4 mg orally daily. Additional dose escalation to 8 mg orally daily can be performed if necessary. Alfuzosin is a long-acting α -blocker; its dose is 10 mg orally once daily and does not require titration.

α_{1a} -Receptors are localized to the prostate and bladder neck. Selective blockade of these receptors results in fewer systemic side effects than α -blocker therapy (orthostatic hypotension, dizziness, tiredness, rhinitis, and headache), thus obviating the need for dose titration. The typical dose of tamsulosin is 0.4 mg orally daily taken 30 minutes after a meal. Several randomized, double-blind, placebo-controlled trials have been performed comparing terazosin, doxazosin, tamsulosin, and alfuzosin with placebo. All agents have demonstrated safety and efficacy. However, floppy eye syndrome, a complication of cataract surgery, can occur in patients taking α -blockers and α_{1a} -blockers.

2. 5 α -Reductase inhibitors—Finasteride is a 5 α -reductase inhibitor that blocks the conversion of testosterone to dihydrotestosterone. This drug impacts upon the epithelial component of the prostate, resulting in reduction in size of the gland and improvement in symptoms. Six months of therapy is required for maximum effects on prostate size (20% reduction) and symptomatic improvement.

Several randomized, double-blind, placebo-controlled trials have been performed comparing finasteride with placebo. Efficacy, safety, and durability are well established. However, symptomatic improvement is seen only in men with enlarged prostates (> 40 mL by ultrasonographic examination). Side effects include decreased libido, decrease in volume of ejaculate, and erectile dysfunction. Serum PSA is reduced by approximately 50% in patients receiving finasteride therapy. Therefore, in order to compare with pre-finasteride levels, the serum PSA of a patient taking finasteride should be doubled.

A report suggests that finasteride therapy may decrease the incidence of urinary retention and the need for operative treatment in men with enlarged prostates and moderate to severe symptoms. The larger the prostate over 40 mL, the greater the relative-risk reduction. However, optimal identification of appropriate patients for prophylactic therapy remains to be determined. Dutasteride is a dual 5 α -reductase inhibitor that appears to be similar to finasteride in its effectiveness; its dose is 0.5 mg orally daily.

Both finasteride and dutasteride have been shown to be effective chemopreventive agents for prostate cancer in large, randomized clinical trials. The 25% risk reduction was observed in men with both low and high risk for prostate cancer. However, despite the strength of the evidence for 5 α -reductase inhibitors in reducing the risk of prostate

Table 23–6. α -Blockade for benign prostatic hyperplasia.

Agent	Action	Oral Dose
Alfuzosin	α_1 -Blockade	10 mg daily
Doxazosin	α_1 -Blockade	1–8 mg daily
Phenoxybenzamine	α_1 - and α_2 -Blockade	5–10 mg twice daily
Prazosin	α_1 -Blockade	1–5 mg twice daily
Silodosin	α_{1a} -Blockade	4 or 8 mg daily
Tadalafil	Phosphodiesterase type 5 inhibitor	5 mg daily
Tamsulosin	α_{1a} -Blockade	0.4 or 0.8 mg daily
Terazosin	α_1 -Blockade	1–10 mg daily

cancer, an FDA advisory committee recommended against labeling these agents for prostate cancer chemoprevention, citing the potential increased risk of high-grade tumors in these studies, isolated risk reduction in low-grade tumors, and inability to apply the findings to the general population. Moreover, the FDA has included the increased risk of being diagnosed with high-grade prostate cancer in the labels of all 5 α -reductase inhibitors.

3. Phosphodiesterase-5 inhibitor—The FDA approved the use of tadalafil to treat the signs and symptoms of benign prostatic hyperplasia in 2011; it is also approved for use in men with both urinary symptoms and erectile dysfunction. The data from two randomized, double-blind, placebo-controlled trials demonstrated significant improvements in standardized measurements of urinary function between 2 and 4 weeks after initiating treatment at 5 mg, with minimal adverse effects.

4. Combination therapy—The four-arm Veterans Administration Cooperative Trial compared placebo, finasteride alone, terazosin alone, and combination of finasteride and terazosin. Over 1200 patients participated, and significant decreases in symptom scores and increases in urinary flow rates were seen only in the arms containing terazosin. However, enlarged prostates were not an entry criterion; in fact, prostate size in this study was much smaller than in previous controlled trials using finasteride (32 versus 52 mL). Other randomized, placebo-controlled trials comparing finasteride with placebo in men with lower urinary tract symptoms and large prostates showed finasteride to be beneficial for reducing symptoms, increasing urinary flow rate, and reducing the risk of complications due to benign prostatic hyperplasia as well as reducing the number of men who required surgery for benign prostatic hyperplasia. The Medical Therapy of Prostatic Symptoms (MTOPs) trial is a large, randomized, placebo-controlled trial comparing finasteride, doxazosin, the combination of the two, and placebo in 3047 men observed for a mean of 4.5 years. Long-term combination therapy with doxazosin and finasteride was safe and reduced the risk of overall clinical progression of benign prostatic hyperplasia significantly more than did treatment with either drug alone. Combination therapy and finasteride alone reduced the long-term risk of acute urinary retention and the need for invasive therapy. Combination therapy had the risks of additional side effects and the cost of two medications.

5. Phytotherapy—Phytotherapy is the use of plants or plant extracts for medicinal purposes. Its use in benign prostatic hyperplasia has been popularized by patient-driven enthusiasm. Several plant extracts have been popularized, including the saw palmetto berry, the bark of *Pygeum africanum*, the roots of *Echinacea purpurea* and *Hypoxis rooperi*, pollen extract, and the leaves of the trembling poplar. The mechanisms of action of these agents are unknown. A 2006 prospective, randomized, double-blind, placebo-controlled trial revealed no improvement in symptoms, urinary flow rate, or quality of life for men with benign prostatic hyperplasia with saw palmetto treatment compared with placebo.

C. Conventional Surgical Therapy

1. Transurethral resection of the prostate (TURP)

Ninety-five percent of simple prostatectomies can be performed endoscopically (TURP). Most of these procedures are performed under a spinal anesthetic and require a 1- to 2-day hospital stay. Symptom scores and flow rate improvement are superior following TURP relative to any minimally invasive therapy; however, the length of the hospital stay is greater. Much controversy revolves around possible higher rates of morbidity and mortality associated with TURP in comparison with open surgery, but the higher rates observed in one study probably related to more significant comorbidities in the TURP patients compared with the patients who received open surgical treatment. Several other studies could not confirm the difference in mortality when controlling for age and comorbidities. The risks of TURP include retrograde ejaculation (75%), erectile dysfunction (5–10%), and urinary incontinence (< 1%). Complications include bleeding, urethral stricture or bladder neck contracture, perforation of the prostate capsule with extravasation, and, if severe, transurethral resection syndrome, a hypervolemic, hyponatremic state resulting from absorption of the hypotonic irrigating solution. Clinical manifestations of the syndrome include nausea, vomiting, confusion, hypertension, bradycardia, and visual disturbances. The risk of transurethral resection syndrome increases with resection times over 90 minutes. Treatment includes diuresis and, in severe cases, hypertonic saline administration (see Hyponatremia, Chapter 21).

2. Transurethral incision of the prostate (TUIP)

Men with moderate to severe symptoms and small prostates often have posterior commissure hyperplasia or an “elevated bladder neck.” These patients will often benefit from incision of the prostate. The procedure is more rapid and less morbid than TURP. Outcomes in well-selected patients are comparable, though a lower rate of retrograde ejaculation has been reported (25%).

3. Open simple prostatectomy—When the prostate is too large to remove endoscopically, open enucleation is necessary. What size is “too large” depends upon the surgeon's experience with TURP. Glands over 100 g are usually considered for open enucleation. In addition to size, other relative indications for open prostatectomy include concomitant bladder diverticulum or bladder stone and whether dorsal lithotomy positioning is or is not possible.

Open prostatectomies can be performed with either a suprapubic or retropubic approach. Simple suprapubic prostatectomy is performed transvesically and is the operation of choice if there is concomitant bladder pathology. After the adenoma is removed, both a urethral and a suprapubic catheter are inserted prior to closure.

In simple retropubic prostatectomy, the bladder is not entered but rather a transverse incision is made in the surgical capsule of the prostate and the adenoma is enucleated as described above; only a urethral catheter is needed at the end of the case.

D. Minimally Invasive Therapy

1. Laser therapy—Several coagulation necrosis techniques have been utilized. Transurethral laser-induced prostatectomy (TULIP) is performed under transrectal ultrasound guidance. The instrument is placed in the urethra and transrectal ultrasound is used to direct the device as it is slowly pulled from the bladder neck to the apex. The depth of treatment is monitored with ultrasound.

Most urologists prefer to use visually directed laser techniques. Visual coagulative necrosis is performed under cystoscopic control, and the laser fiber is pulled through the prostate at several designated areas depending upon the size and configuration of the gland. Four-quadrant and sextant approaches have been described for lateral lobes, with additional treatments directed at enlarged median lobes. Coagulative techniques do not create an immediate visual defect in the prostatic urethra—tissue is sloughed over the course of several weeks up to 3 months following the procedure.

Visual contact ablative techniques take longer in the operating room because the fiber is placed in direct contact with the prostate tissue, which is vaporized. Photovaporization of the prostate (PVP), an alternative laser technique, uses a high-power KTP laser. An immediate defect is obtained in the prostatic urethra, similar to that seen during TURP.

Interstitial laser therapy places fibers directly into the prostate, usually under cystoscopic control. Irritative voiding symptoms may be less in these patients as the urethral mucosa is spared and prostate tissue is resorbed by the body rather than sloughed.

Advantages to laser surgery include minimal blood loss, rare occurrence of transurethral resection syndrome, the ability to treat patients while on anticoagulation therapy, and outpatient surgery. Disadvantages are the lack of tissue for pathologic examination, the longer postoperative catheterization time, the more frequent irritative voiding complaints, and the expense of laser fibers and generators.

Large multicenter, randomized studies with long-term follow-up are needed in comparing laser prostate surgery with TURP and other forms of minimally invasive surgery.

2. Transurethral needle ablation of the prostate (TUNA)—This procedure uses a specially designed urethral catheter that is passed into the urethra. Interstitial radiofrequency needles are then deployed from the tip of the catheter, piercing the mucosa of the prostatic urethra. Radiofrequencies are then used to heat the tissue, resulting in coagulative necrosis. Bladder neck and median lobe enlargement are not well treated by TUNA. Subjective and

objective improvement in voiding occurs. In randomized trials comparing TUNA to TURP, similar improvement was seen when comparing life scores, peak urinary flow rates, and postvoid residual urine.

3. Transurethral electrovaporization of the prostate—

This technique uses the standard resectoscope. High current densities result in heat vaporization of tissue, creating a cavity in the prostatic urethra. Because the device requires slower sweeping speeds over the prostatic urethra and the depth of vaporization is approximately one-third of a standard loop, this procedure usually takes longer than a standard TURP. Long-term comparative data are needed.

4. Hyperthermia—Microwave hyperthermia is most commonly delivered with a transurethral catheter. Some devices cool the urethral mucosa to decrease the risk of injury. However, if temperatures do not go above 45 °C, cooling is unnecessary. Symptom score and flow rate improvement are obtained, but (as with laser surgery) large randomized studies with long-term follow-up are needed to assess durability and cost-effectiveness.

▶ When to Refer

- Progression to urinary retention.
- Patient dissatisfaction with medical therapy.
- Need for surgical intervention or further evaluation (cystoscopy).

Andriole GL et al; REDUCE Study Group. Effect of dutasteride on the risk of prostate cancer. *N Engl J Med*. 2010 Apr 1;362(13):1192–202. [PMID: 20357281]

Kaplan SA. Update on the American urological association guidelines for the treatment of benign prostatic hyperplasia. *Rev Urol*. 2006;8(Suppl 4):S10–7. [PMID: 17215996]

McConnell JD et al; Medical Therapy of Prostatic Symptoms (MTOPS) Research Group. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. *N Engl J Med*. 2003 Dec 18;349(25):2387–98. [PMID: 14681504]

McVary KT et al. American Urological Association Guideline: Management of Benign Prostatic Hyperplasia (BPH). <http://www.auanet.org/content/clinical-practice-guidelines/clinical-guidelines.cfm?sub=bph>

Roehrborn CG. BPH progression: concept and key learning from MTOPS, ALTESS, COMBAT, and ALF-ONCE. *BJU Int*. 2008 Mar;101(Suppl 3):17–21. [PMID: 18307681]

Selius BA et al. Urinary retention in adults: diagnosis and initial management. *Am Fam Physician*. 2008 Mar 1;77(5):643–50. [PMID: 18350762]

Thompson IM et al. Chemoprevention of prostate cancer. *J Urol*. 2009 Aug;182(2):499–507. [PMID: 19524966]

24

Nervous System Disorders

Michael J. Aminoff, MD, DSc, FRCP

Geoffrey A. Kerchner, MD, PhD

HEADACHE

Headache is such a common complaint and can occur for so many different reasons that its proper evaluation may be difficult. New, severe, or acute headaches are more likely than chronic headaches to relate to an intracranial disorder; the approach to such headaches is discussed in Chapter 2. Chronic headaches may be primary or secondary to another disorder. Common primary headache syndromes include migraine, tension-type headache, and cluster headache. Important secondary causes to consider include intracranial lesions, head injury, cervical spondylosis, dental or ocular disease, temporomandibular joint dysfunction, sinusitis, hypertension, depression, and a wide variety of general medical disorders. Although underlying structural lesions are not present in most patients presenting with headache, it is nevertheless important to bear this possibility in mind. About one-third of patients with brain tumors, for example, present with a primary complaint of headache.

The intensity, quality, and site of pain—and especially the duration of the headache and the presence of associated neurologic symptoms—may provide clues to the underlying cause. Migraine headaches are often described as pulsating or throbbing; a sense of tightness or pressure is common with tension headache. Sharp lancinating pain suggests a neuritic cause; ocular or periorbital icpick-like pains occur with migraine or cluster headache; and a dull or steady headache is typical of an intracranial mass lesion. Ocular or periocular pain suggests an ophthalmologic disorder; band-like pain is common with tension headaches; and lateralized headache is common with migraine or cluster headache. In patients with sinusitis, there may be tenderness of overlying skin and bone. With intracranial mass lesions, headache may be focal or generalized; in patients with trigeminal or glossopharyngeal neuralgia, the pain is localized to one of the divisions of the trigeminal nerve or to the pharynx and external auditory meatus, respectively.

Inquiry should be made of precipitating factors. Recent sinusitis, dental surgery, head injury, or symptoms suggestive of a systemic viral infection may suggest the underlying cause. Migraine may be exacerbated by emotional stress, fatigue, foods containing nitrite or tyramine, or the menstrual period. Alcohol may precipitate cluster headache.

Temporomandibular joint dysfunction causes headache or facial pain that comes on with chewing; trigeminal or glossopharyngeal neuralgia may also be precipitated by chewing, and masticatory claudication sometimes occurs with giant cell arteritis. Cough-induced headache occurs with structural lesions of the posterior fossa, but in many instances no specific cause can be found.

The timing of symptoms is important. Headaches are typically worse on awakening in patients with an intracranial mass or sleep apnea. Cluster headaches tend to occur at the same time each day or night. Tension headaches are worse with stress or at the end of the day.

Associated symptoms may also be helpful. Nausea; sensitivity to light, sound, and exertion; and a proclivity to retreat to a dark, quiet room typify migraine. Anxiety, agitation, and even suicidality may accompany cluster headache. Other accompanying symptoms may point to specific disorders.

A progressive headache disorder, new onset of headache in middle or later life, headaches that disturb sleep or are related to exertion, and headaches that are associated with neurologic symptoms or a focal neurologic deficit usually require cranial MRI or CT scan to exclude an intracranial mass lesion. Signs of meningeal irritation and impairment of consciousness also indicate the need for further investigation (cranial CT scan or MRI and examination of the cerebrospinal fluid) to exclude subarachnoid hemorrhage or meningeal infection. The diagnosis and treatment of primary neurologic disorders associated with headache are considered separately under these disorders.

1. Migraine



ESSENTIALS OF DIAGNOSIS

- ▶ Headache, usually pulsatile.
- ▶ Pain is typically, but not always, unilateral.
- ▶ Nausea, vomiting, photophobia, and phonophobia are common accompaniments.
- ▶ An aura of transient neurologic symptoms (commonly visual) may precede head pain.
- ▶ Commonly, head pain occurs with no aura.

► General Considerations

The pathophysiology of migraine probably relates to neurovascular dysfunction. Headache results from the dilatation of blood vessels innervated by the trigeminal nerve caused by release of neuropeptides from parasympathetic nerve fibers approximating these vessels. The probable underlying mechanism is activation of the trigeminal nucleus caudalis, nucleus tractus solitarius, and dorsal raphe nucleus. Imaging studies have revealed changes in brainstem regions involved in sensory modulation, suggesting that migraine relates to a failure of normal sensory processing. Before or simultaneous with symptom onset, regional cerebral blood flow is decreased in the cortex corresponding to the clinically affected area; after one to several hours, hyperemia occurs in this same region. Cortical spreading depression of Leão has been implicated.

► Clinical Findings

Classic migrainous headache is a lateralized throbbing headache that occurs episodically following its onset in adolescence or early adult life. In many cases, however, the headaches do not conform to this pattern, although their associated features and response to antimigrainous preparations nevertheless suggest that they have a similar basis. In this broader sense, migrainous headaches may be lateralized or generalized, may be dull or throbbing, and are sometimes associated with anorexia, nausea, vomiting, photophobia, phonophobia, osmophobia, cognitive impairment, and blurring of vision. They usually build up gradually and may last for several hours or longer. Focal disturbances of neurologic function may precede or accompany the headaches and have been attributed to constriction of branches of the internal carotid artery. Visual disturbances occur commonly and may consist of field defects; of luminous visual hallucinations such as stars, sparks, unformed light flashes (photopsia), geometric patterns, or zigzags of light; or of some combination of field defects and luminous hallucinations (scintillating scotomas). Other focal disturbances such as aphasia or numbness, paresthesias, clumsiness, dysarthria, dysequilibrium, or weakness in a circumscribed distribution may also occur.

In rare instances, the neurologic or somatic disturbance accompanying typical migrainous headaches becomes the sole manifestation of an attack ("migraine equivalent"). Very rarely, the patient may be left with a permanent neurologic deficit following a migrainous attack, and migraine with aura may be a risk factor for stroke.

Patients often give a family history of migraine. Attacks may be triggered by emotional or physical stress, lack or excess of sleep, missed meals, specific foods (eg, chocolate), alcoholic beverages, bright lights, loud noise, menstruation, or use of oral contraceptives.

An uncommon variant is **basilar artery migraine**, in which blindness or visual disturbances throughout both visual fields are initially accompanied or followed by dysarthria, dysequilibrium, tinnitus, and perioral and distal paresthesias and are sometimes followed by transient loss or impairment of consciousness or by a confusional state.

This, in turn, is followed by a throbbing (usually occipital) headache, often with nausea and vomiting.

In **ophthalmoplegic migraine**, lateralized pain—often about the eye—is accompanied by nausea, vomiting, and diplopia due to transient external ophthalmoplegia. The ophthalmoplegia is due to third nerve palsy, sometimes with accompanying sixth nerve involvement, and may outlast the orbital pain by several days or even weeks. The ophthalmic division of the fifth nerve has also been affected in some patients. Ophthalmoplegic migraine is rare; more common causes of a painful ophthalmoplegia are internal carotid artery aneurysms and diabetes.

Migraine often exhibits a complex, polygenic pattern of inheritance. Sometimes, an autosomal dominant inheritance pattern is apparent, as in **familial hemiplegic migraine** (FHM), in which attacks of lateralized weakness represent the aura. Mutations in three associated genes—*ATP1A2*, *CACNA1A*, and *SCN1A*—account for about three-quarters of cases.

► Treatment

Management of migraine consists of avoidance of any precipitating factors, together with prophylactic or symptomatic pharmacologic treatment if necessary.

A. Symptomatic Therapy

During acute attacks, many patients find it helpful to rest in a quiet, darkened room until symptoms subside. A simple analgesic (eg, aspirin, acetaminophen, ibuprofen, or naproxen) taken right away often provides relief, but treatment with prescription therapy is sometimes necessary. To prevent medication overuse, use of simple analgesics should be limited to 15 days or less per month, and combination analgesics should be limited to no more than 10 days per month.

Cafergot, a combination of ergotamine tartrate (1 mg) and caffeine (100 mg), is often particularly helpful; one or two tablets are taken at the onset of headache or warning symptoms, followed by one tablet every 30 minutes, if necessary, up to six tablets per attack and no more than 10 days per month. Because of impaired absorption or vomiting during acute attacks, oral medication sometimes fails to help. Cafergot given rectally as suppositories (one-half to one suppository containing 2 mg of ergotamine) or dihydroergotamine mesylate (0.5–1 mg intravenously or 1–2 mg subcutaneously or intramuscularly) may be useful in such cases. Ergotamine-containing preparations should be avoided in pregnancy and when cardiovascular disease or risk factors are present. Prochlorperazine, administered rectally (25 mg suppository) or intravenously or orally (5–10 mg) can be an effective alternative, as can the various butalbital-containing combination analgesics available.

Sumatriptan, which has a high affinity for 5-HT₁ receptors, is a rapidly effective agent for aborting attacks when given subcutaneously by an autoinjection device (4–6 mg once subcutaneously, may repeat once after 2 hours if needed; maximum dose 12 mg/24 h). Nasal and oral preparations are available but may be less effective due to slower absorption. Zolmitriptan, another selective 5-HT₁ receptor

agonist, has high bioavailability after oral administration and is also effective for the immediate treatment of migraine. The optimal initial oral dose is 5 mg, and relief usually occurs within 1 hour; may repeat once after 2 hours. It is also available in a nasal formulation, which has a rapid onset of action; the dose is 5 mg in one nostril once and it may be repeated once after 2 hours. The maximum dose for both formulations is 10 mg/24 h. A number of other triptans are available, including rizatriptan (5–10 mg orally at onset, may repeat every 2 hours twice [maximum dose 30 mg/24 h]); naratriptan (1–2.5 mg orally at onset, may repeat once after 4 hours [maximum dose 5 mg/24 h]); almotriptan (6.25–12.5 mg orally at onset, may repeat dose once after 2 hours [maximum dose 25 mg/24 h]); frovatriptan (2.5 mg orally at onset, may repeat after 2 hours once [maximum dose 7.5 mg/24]); and eletriptan (20–40 mg orally at onset; may repeat after 2 hours once [maximum dose 80 mg/24 h]). Eletriptan is useful for immediate therapy and frovatriptan, which has a longer half-life, may be worthwhile for patients with prolonged attacks or attacks provoked by menstrual periods.

Triptans may cause nausea and vomiting. They should probably be avoided in women who are pregnant, in patients with hemiplegic or basilar migraine, and in patients with risk factors for stroke (such as hypertension, prior stroke or transient ischemic attack, diabetes mellitus, hypercholesterolemia, obesity). Triptans are contraindicated in

patients with coronary or peripheral vascular disease. Patients often experience greater benefit when the triptan is combined with naproxen (500 mg).

Several non-triptan abortive therapies, including telcagepant (a calcitonin gene-related peptide antagonist) and lasmiditan (a serotonin 1F receptor agonist), are currently in clinical trials and may be better tolerated than triptans.

The neuroleptic droperidol is also helpful in aborting acute attacks, particularly in an emergency setting in opioid-tolerant patients. Intravenous metoclopramide and prochlorperazine are effective. Opioid analgesics are sometimes required when other therapies fail. Intravenous propofol in subanesthetic doses may help in intractable cases.

B. Preventive Therapy

Preventive treatment may be necessary if migraine headaches occur more frequently than two or three times a month or significant disability is associated with attacks. Some of the more common drugs used for this purpose are listed in Table 24–1. Their mode of action is unclear but may involve alteration of central neurotransmission. Several drugs may have to be tried in turn before the headaches are brought under control. Once a drug has been found to help, it should be continued for several months. If

Table 24–1. Prophylactic treatment of migraine.

Drug	Usual Adult Oral Daily Dose	Common Side Effects
Antiepileptic¹		
Topiramate	100 mg (divided twice daily)	Somnolence, nausea, dyspepsia, irritability, dizziness, ataxia, nystagmus, diplopia, glaucoma, renal calculi, weight loss, hypohidrosis, hyperthermia.
Valproic acid ^{2,3}	500–1000 mg (divided twice daily)	Nausea, vomiting, diarrhea, drowsiness, alopecia, weight gain, hepatotoxicity, thrombocytopenia, tremor, pancreatitis.
Cardiovascular		
Candesartan ³	8–32 mg	Dizziness, cough, diarrhea, fatigue.
Propranolol	80–240 mg (divided twice to four times daily)	Fatigue, dizziness, hypotension, bradycardia, depression, insomnia, nausea, vomiting, constipation.
Timolol	10–30 mg	Similar to propranolol.
Verapamil ⁴	80–240 mg (divided three times daily)	Headache, hypotension, flushing, edema, constipation. May aggravate atrioventricular nodal heart block and congestive heart failure.
Antidepressant⁵		
Amitriptyline ⁶	10–150 mg	Sedation, dry mouth, constipation, weight gain, blurred vision, edema, hypotension, urinary retention.
Other		
Botulinum toxin A	Intramuscular injection by trained clinician	Injection site reaction, hypersensitivity, muscle weakness.

¹Gabapentin and possibly other antiepileptics have also been used successfully.

²Avoid during pregnancy.

³Not FDA-approved for this indication.

⁴Other calcium channel antagonists (eg, nimodipine, nifedipine, and diltiazem) may also help.

⁵Depression is commonly comorbid with migraine disorder and may warrant separate treatment.

⁶Other tricyclic antidepressants (eg, nortriptyline and imipramine) may similarly help.

the patient remains headache-free, the dose may be tapered and the drug eventually withdrawn. Botulinum toxin type A was approved by the US Food and Drug Administration (FDA) for migraine prevention in late 2010, despite conflicting results regarding its efficacy among randomized, placebo-controlled trials. Although acupuncture has been widely used in the prophylaxis of migraine, a randomized controlled trial failed to show any difference between it and sham acupuncture. Some neurostimulation techniques look promising, including occipital nerve stimulation.

2. Tension-type Headache

This is the most common type of primary headache disorder. Patients frequently complain of pericranial tenderness, poor concentration, and other nonspecific symptoms, in addition to constant daily headaches that are often vise-like or tight in quality but are not pulsatile. Headaches may be exacerbated by emotional stress, fatigue, noise, or glare. The headaches are usually generalized, may be most intense about the neck or back of the head, and are not associated with focal neurologic symptoms. There is diagnostic overlap with migraine.

The therapeutic approach is similar to that in migraine, except that triptan drugs are not indicated. Treatment of comorbid anxiety or depression is important. Techniques to induce relaxation are sometimes useful and include massage, hot baths, and biofeedback.

3. Cluster Headache

Cluster headache affects predominantly middle-aged men. The pathophysiology is unclear but may relate to activation of cells in the ipsilateral hypothalamus, triggering the trigeminal autonomic vascular system. There is often no family history of headache or migraine. Episodes of severe unilateral periorbital pain occur daily for several weeks and are often accompanied by one or more of the following: ipsilateral nasal congestion, rhinorrhea, lacrimation, redness of the eye, and Horner syndrome (ptosis of the eyelid, meiosis or constriction of the pupil, and anhidrosis or reduced sweat secretion). During attacks, patients are often restless and agitated. Episodes often occur at night, awaken the patient, and last for between 15 minutes and 3 hours. Spontaneous remission then occurs, and the patient remains well for weeks or months before another bout of closely spaced attacks occurs. Bouts may last for 4 to 8 weeks and may occur up to several times per year. During a bout, many patients report that alcohol triggers an attack; others report that stress, glare, or ingestion of specific foods occasionally precipitates attacks. In occasional patients, remission does not occur. This variant has been referred to as chronic cluster headache. **Hemicrania continua** is a separate primary headache syndrome with unilateral head pain and associated autonomic symptoms; unlike cluster headache, the pain is continuous without pain-free periods, and it completely resolves with indomethacin.

Examination reveals no abnormality apart from Horner syndrome that either occurs transiently during an attack or, in longstanding cases, remains as a residual deficit between attacks.

Treatment of an individual attack with oral drugs is generally unsatisfactory, but subcutaneous (6 mg dose) or intranasal (20-mg/spray) sumatriptan or inhalation of 100% oxygen (12–15 L/min for 15 minutes via a non-rebreather mask) may be effective. Zolmitriptan (5- and 10-mg nasal spray) is also effective. Dihydroergotamine (0.5–1 mg intramuscularly or intravenously) is sometimes used. Viscous lidocaine (1 mg of 4–6% solution) intranasally is sometimes effective.

Various prophylactic agents that have been found to be effective in individual patients include civamide (not available in the United States), lithium carbonate (monitored by plasma lithium determination), verapamil (240–960 mg daily), topiramate (100–400 mg daily), valproate (750–1500 mg daily), and suboccipital corticosteroid injection about the greater occipital nerve. As there is often a delay before these medications are effective, transitional therapy is often used. Ergotamine tartrate is effective and can be given as rectal suppositories (0.5–1 mg at night or twice daily), by mouth (2 mg daily), or by subcutaneous injection (0.25 mg three times daily for 5 days per week). Other options include prednisone (60 mg daily for 5 days followed by gradual withdrawal), or dihydroergotamine (9.25 mg intravenously over several days or 0.5 mg intramuscularly twice daily). Stimulation of the occipital nerve may be helpful.

4. Posttraumatic Headache

A variety of nonspecific symptoms may follow closed head injury, regardless of whether consciousness is lost. Headache is often a conspicuous feature.

The headache itself usually appears within a day or so following injury, may worsen over the ensuing weeks, and then gradually subsides. It is usually a constant dull ache, with superimposed throbbing that may be localized, lateralized, or generalized. It is sometimes accompanied by nausea, vomiting, or scintillating scotomas. Headaches occurring more than 1–2 weeks after the inciting event are probably not directly attributable to the head injury.

Dysequilibrium, sometimes with a rotatory component, may also occur and is often enhanced by postural change or head movement. Impaired memory, poor concentration, emotional instability, and increased irritability are other common complaints and occasionally are the sole manifestations of the syndrome. The duration of symptoms relates in part to the severity of the original injury, but even trivial injuries are sometimes followed by symptoms that persist for months.

Special investigations are usually not helpful. The electroencephalogram may show minor nonspecific changes, while the electronystagmogram sometimes suggests either peripheral or central vestibulopathy. CT scans or MRI of the head usually show no abnormal findings.

Treatment is difficult, but optimistic encouragement and graduated rehabilitation, depending on the occupational circumstances, are advised as symptoms often resolve spontaneously within several months. Headaches often respond to simple analgesics, but severe headaches may necessitate preventive treatment as outlined for migraine.

5. Primary Cough Headache

Severe head pain may be produced by coughing (and by straining, sneezing, and laughing) but, fortunately, usually lasts for only a few minutes or less. The pathophysiologic basis of the complaint is not known, and often there is no underlying structural lesion. However, intracranial lesions, usually in the posterior fossa (eg, Arnold-Chiari malformation), are present in about 10% of cases, and brain tumors or other space-occupying lesions may present in this way. Accordingly, CT scanning or MRI should be undertaken in all patients and repeated annually for several years, since a small structural lesion may not show up initially.

The disorder is usually self-limited, although it may persist for several years. For unknown reasons, symptoms sometimes clear completely after lumbar puncture. Indomethacin (75–150 mg daily orally) may provide relief. Similar activity-triggered headache syndromes include **primary exertional headache** and **primary headache associated with sexual activity**.

6. Headache Due to Giant Cell (Temporal or Cranial) Arteritis

The superficial temporal, vertebral, ophthalmic, and posterior ciliary arteries are often the most severely affected pathologically. Most patients are elderly. The major symptom is lateralized headache, often associated with or preceded by myalgia, malaise, anorexia, weight loss, and other nonspecific complaints. Loss of vision is the most feared manifestation and occurs quite commonly. Clinical examination often reveals tenderness of the scalp and over the temporal arteries. Further details, including approaches to treatment, are given in Chapter 20.

7. Headache Due to Intracranial Mass Lesions

Intracranial mass lesions of all types may cause headache owing to displacement of vascular structures and other pain-sensitive tissues. Posterior fossa tumors often cause occipital pain, and supratentorial lesions lead to bifrontal headache, but such findings are too inconsistent to be of value in attempts at localizing a pathologic process. The headaches are nonspecific in character and may vary in severity from mild to severe. They may be worsened by exertion or postural change and may be associated with nausea and vomiting, but this is true of migraine also. Headaches are also a feature of pseudotumor cerebri (idiopathic intracranial hypertension) (see below). Signs of focal or diffuse cerebral dysfunction or of increased intracranial pressure will indicate the need for further investigation. Similarly, a progressive headache disorder or the new onset of headaches in middle or later life merits investigation if no cause is apparent.

8. Medication Overuse (Analgesic Rebound) Headache

In approximately half of all patients with chronic daily headaches, medication overuse is responsible. They present with chronic pain or with complaints of severe headache

unresponsive to medication. Early initiation of a migraine preventive therapy (see above) permits withdrawal of analgesics and eventual relief of headache.

9. Headache Due to Other Neurologic Causes

Cerebrovascular disease may be associated with headache, but the mechanism is unclear. Headache may occur with internal carotid artery occlusion or carotid dissection and after carotid endarterectomy. Diagnosis is facilitated by the clinical accompaniments and the circumstances in which the headache developed.

Acute severe headache accompanies subarachnoid hemorrhage and meningeal infections; accompanying signs of impairment of consciousness and sign of meningeal irritation indicate the need for further investigations.

Dull or throbbing headache is a frequent sequela of lumbar puncture and may last for several days. It is aggravated by the erect posture and alleviated by recumbency. The exact mechanism is unclear, but it is commonly attributed to leakage of cerebrospinal fluid through the dural puncture site. Its incidence may be reduced if a small-diameter needle is used for the spinal tap, and perhaps also if the patient lies prone or supine after the procedure.

▶ When to Refer

- Acute onset of “worst headache in my life.”
- Increasing headache unresponsive to simple measures.
- History of trauma, hypertension, fever, visual changes.
- Presence of neurologic signs or of scalp tenderness.

▶ When to Admit

- Suspected subarachnoid hemorrhage or structural intracranial lesion.
- Depends on underlying cause.

- Ailani J et al. The role of nerve blocks and botulinum toxin injections in the management of cluster headaches. *Curr Pain Headache Rep.* 2009 Apr;13(2):164–7. [PMID: 19272284]
- Bartolini M et al. A double-blind, randomized, multicenter, Italian study of frovatriptan versus almotriptan for the acute treatment of migraine. *J Headache Pain.* 2011 Jun;12(3):361–8. [PMID: 21437714]
- Bendtsen L et al. EFNS guideline on the treatment of tension-type headache—report of an EFNS task force. *Eur J Neurol.* 2010 Nov;17(11):1318–25. [PMID: 20482606]
- Broner SW et al. Epidemiology of cluster headache. *Curr Pain Headache Rep.* 2009 Apr;13(2):141–6. [PMID: 19272280]
- Formisano R et al. Post-traumatic headache: facts and doubts. *J Headache Pain.* 2009 Jun;10(3):145–52. [PMID: 19294482]
- Grover PJ et al. Deep brain stimulation for cluster headache. *J Clin Neurosci.* 2009 Jul;16(7):861–6. [PMID: 19398342]
- Hagen K et al. Management of medication overuse headache: 1-year randomized multicentre open-label trial. *Cephalalgia.* 2009 Feb;29(2):221–32. [PMID: 18823363]
- Hewitt DJ et al. Randomized controlled trial of the CGRP receptor antagonist MK-3207 in the acute treatment of migraine. *Cephalalgia.* 2011 Apr;31(6):712–22. [PMID: 21383045]
- Jackson JL et al. Tricyclic antidepressants and headaches: systematic review and meta-analysis. *BMJ.* 2010 Oct 20;341:c5222. [PMID: 20961988]

Kale N et al. Diagnosis and management of giant cell arteritis: a review. *Curr Opin Ophthalmol*. 2010 Nov;21(6):417–22. [PMID: 20811283]

Katsarava Z et al. Migraine and stroke. *J Neurol Sci*. 2010 Dec 15;299(1–2):42–4. [PMID: 20858559]

Magis D et al. Treatment of migraine: update on new therapies. *Curr Opin Neurol*. 2011 Jun;24(3):203–10. [PMID: 21464715]

Shuhendler AJ et al. Efficacy of botulinum toxin type A for the prophylaxis of episodic migraine headaches: a meta-analysis of randomized, double-blind, placebo-controlled trials. *Pharmacotherapy*. 2009 Jul;29(7):784–91. [PMID: 19558252]

FACIAL PAIN

1. Trigeminal Neuralgia



ESSENTIALS OF DIAGNOSIS

- ▶ Brief episodes of stabbing facial pain.
- ▶ Pain is in the territory of the second and third division of the trigeminal nerve.
- ▶ Pain exacerbated by touch.

▶ General Considerations

Trigeminal neuralgia (“tic douloureux”) is most common in middle and later life. It affects women more frequently than men.

▶ Clinical Findings

Momentary episodes of sudden lancinating facial pain occur and commonly arise near one side of the mouth and shoot toward the ear, eye, or nostril on that side. The pain may be triggered or precipitated by such factors as touch, movement, drafts, and eating. Indeed, in order to lessen the likelihood of triggering further attacks, many patients try to hold the face still while talking. Spontaneous remissions for several months or longer may occur. As the disorder progresses, however, the episodes of pain become more frequent, remissions become shorter and less common, and a dull ache may persist between the episodes of stabbing pain. Symptoms remain confined to the distribution of the trigeminal nerve (usually the second or third division) on one side only.

▶ Differential Diagnosis

The characteristic features of the pain in trigeminal neuralgia usually distinguish it from other causes of facial pain. Neurologic examination shows no abnormality except in a few patients in whom trigeminal neuralgia is symptomatic of some underlying lesion, such as multiple sclerosis or a brainstem neoplasm, in which case the finding will depend on the nature and site of the lesion. Similarly, CT scans and radiologic contrast studies are often normal in patients with classic trigeminal neuralgia.

In a young patient presenting with trigeminal neuralgia, multiple sclerosis must be suspected even if there are no

other neurologic signs. In such circumstances, findings on evoked potential testing and examination of cerebrospinal fluid may be corroborative. When the facial pain is due to a posterior fossa tumor, CT scanning and MRI generally reveal the lesion.

▶ Treatment

The drugs most helpful for treatment are oxcarbazepine (although not approved by the FDA for this indication) or carbamazepine, with monitoring by serial blood counts and liver function tests. If these medications are ineffective or cannot be tolerated, phenytoin should be tried. (Doses and side effects of these drugs are shown in Table 24–3). Baclofen (10–20 mg three or four times daily) or lamotrigine (400 mg orally daily) may also be helpful, either alone or in combination with one of these other agents. Gabapentin may also relieve pain, especially in patients who do not respond to conventional medical therapy and those with multiple sclerosis. Depending on response and tolerance, up to 2400 mg daily orally is given in divided doses.

In the past, alcohol injection of the affected nerve, rhizotomy, or tractotomy was recommended if pharmacologic treatment was unsuccessful. More recently, however, posterior fossa exploration has frequently revealed some structural cause for the neuralgia (despite normal findings on CT scans, MRI, or arteriograms), such as an anomalous artery or vein impinging on the trigeminal nerve root. In such cases, simple decompression and separation of the anomalous vessel from the nerve root produce lasting relief of symptoms. In elderly patients with a limited life expectancy, radiofrequency rhizotomy is sometimes preferred because it is easy to perform, has few complications, and provides symptomatic relief for a period of time. Gamma radiosurgery to the trigeminal root is another noninvasive approach that appears to be successful in most patients, with essentially no side effects other than facial paresthesias in a few instances; up to one-third of patients achieved a pain-free state without need for medication after the procedure. Surgical exploration generally reveals no abnormality and is inappropriate in patients with trigeminal neuralgia due to multiple sclerosis.

Gronseth G et al. Practice Parameter: the diagnostic evaluation and treatment of trigeminal neuralgia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology and the European Federation of Neurological Societies. *Neurology*. 2008 Oct 7;71(15):1183–90. [PMID: 18716236]

Riesenburger RI et al. Outcomes following single-treatment gamma knife surgery for trigeminal neuralgia with a minimum 3-year follow-up. *J Neurosurg*. 2010 Apr;112(4):766–71. [PMID: 19780644]

2. Atypical Facial Pain

Facial pain without the typical features of trigeminal neuralgia is generally a constant, often burning pain that may have a restricted distribution at its onset but soon spreads to the rest of the face on the affected side and sometimes

involves the other side, the neck, or the back of the head as well. The disorder is especially common in middle-aged women, many of them depressed, but it is not clear whether depression is the cause of or a reaction to the pain. Simple analgesics should be given a trial, as should tricyclic antidepressants, carbamazepine, oxcarbazepine, and phenytoin; the response is often disappointing. Opioid analgesics pose a danger of addiction in patients with this disorder. Attempts at surgical treatment are not indicated.

Cornelissen P et al. Evidence-based interventional pain medicine according to clinical diagnoses. 3. Persistent idiopathic facial pain. *Pain Pract.* 2009 Nov–Dec;9(6):443–8. [PMID: 19874535]

3. Glossopharyngeal Neuralgia

Glossopharyngeal neuralgia is an uncommon disorder in which pain similar in quality to that in trigeminal neuralgia occurs in the throat, about the tonsillar fossa, and sometimes deep in the ear and at the back of the tongue. The pain may be precipitated by swallowing, chewing, talking, or yawning and is sometimes accompanied by syncope. In most instances, no underlying structural abnormality is present; multiple sclerosis is sometimes responsible. Oxcarbazepine and carbamazepine (see Table 24–3) are the treatments of choice and should be tried before any surgical procedures are considered. Microvascular decompression is generally preferred over destructive surgical procedures such as partial rhizotomy in medically refractory cases and is often effective without causing severe complications.

4. Postherpetic Neuralgia

Herpes zoster (shingles) is due to reactivation of a latent varicella-zoster virus infection in a sensory nerve ganglion. Postherpetic neuralgia develops in about 15% of patients who have shingles. This complication seems especially likely to occur in elderly or immunocompromised persons, when the rash is severe, and when the first division of the trigeminal nerve is affected. It also relates to the duration of the rash before medical consultation. A history of shingles and the presence of cutaneous scarring resulting from shingles aid in the diagnosis. Severe pain with shingles correlates with the intensity of postherpetic symptoms.

The incidence of postherpetic neuralgia may be reduced by the treatment of shingles with oral acyclovir or famciclovir, but this is disputed; systemic corticosteroids do not help. Management of the established complication is essentially medical. If simple analgesics fail to help, a trial of a tricyclic antidepressant (eg, amitriptyline, up to 100–150 mg daily orally) is often effective. Other patients respond to carbamazepine (up to 1200 mg daily orally), phenytoin (300 mg daily orally), gabapentin (up to 3600 mg daily orally), or pregabalin (up to 600 mg/daily orally). A combination of gabapentin and morphine taken orally may provide better analgesia at lower doses of each agent than either taken alone. Topical application of capsaicin cream (eg, Zostrix, 0.025%) may be helpful, but a transdermal patch (8%) had no effect. Topical lidocaine (5%) is also worthy of trial. The administration of live-attenuated

zoster vaccine to patients over the age of 60 years is important in preventing the occurrence of herpes zoster, although it does not reduce the incidence of postherpetic neuralgia.

Chen N et al. Corticosteroids for preventing postherpetic neuralgia. *Cochrane Database Syst Rev.* 2010 Dec 8;(12):CD005582. [PMID: 21154361]

Chen N et al. Vaccination for preventing postherpetic neuralgia. *Cochrane Database Syst Rev.* 2011 Mar 16;(3):CD007795. [PMID: 21412911]

Wiffen PJ et al. Carbamazepine for acute and chronic pain in adults. *Cochrane Database Syst Rev.* 2011 Jan 19;(1):CD005451. [PMID: 21249671]

5. Facial Pain Due to Other Causes

Facial pain may be caused by temporomandibular joint dysfunction in patients with malocclusion, abnormal bite, or faulty dentures. There may be tenderness of the masticatory muscles, and an association between pain onset and jaw movement is sometimes noted. This pattern differs from that of jaw (masticatory) claudication, a symptom of giant cell arteritis, in which pain develops progressively with mastication. Treatment of the underlying joint dysfunction relieves symptoms.

A relationship of facial pain to chewing or temperature changes may suggest a dental disturbance. The cause is sometimes not obvious, and diagnosis requires careful dental examination and radiographs. Sinusitis and ear infections causing facial pain are usually recognized by the history of respiratory tract infection, fever and, in some instances, nasal or aural discharge. There may be localized tenderness. Radiologic evidence of sinus infection or mastoiditis is confirmatory.

Glaucoma is an important ocular cause of facial pain, usually localized to the periorbital region.

On occasion, pain in the jaw may be the principal manifestation of angina pectoris. Precipitation by exertion and radiation to more typical areas establish the cardiac origin.

▶ When to Refer

- Worsening pain unresponsive to simple measures.
- Continuing pain of uncertain cause.
- For consideration of surgical treatment (trigeminal or glossopharyngeal neuralgia).

EPILEPSY



ESSENTIALS OF DIAGNOSIS

- ▶ Recurrent seizures.
- ▶ Characteristic electroencephalographic changes accompany seizures.
- ▶ Mental status abnormalities or focal neurologic symptoms may persist for hours postictally.

► General Considerations

The term “epilepsy” denotes any disorder characterized by recurrent unprovoked seizures. A seizure is a transient disturbance of cerebral function due to an abnormal paroxysmal neuronal discharge in the brain. Epilepsy is common, affecting approximately 0.5% of the population in the United States.

► Etiology

According to the International League Against Epilepsy classification system, the many etiologies of seizures can be grouped into three categories.

A. Genetic Epilepsy

This category encompasses a broad range of disorders, for which the age at onset ranges from the neonatal period to adolescence or even later in life. Monogenic disorders tend to exhibit an autosomal dominant pattern of inheritance, and where the mutation is known, the responsible gene often encodes a neuronal ion channel.

B. Structural/Metabolic Epilepsy

There are many causes for recurrent seizures.

1. Pediatric age groups—Congenital abnormalities and perinatal injuries may result in seizures presenting in infancy or childhood.

2. Metabolic disorders—Withdrawal from alcohol or drugs is a common cause of recurrent seizures, and other metabolic disorders (such as uremia and hypoglycemia or hyperglycemia) may also be responsible. Since these seizures are provoked by a readily reversible cause, this would not be considered epilepsy.

3. Trauma—Trauma is an important cause of seizures at any age, but especially in young adults. Posttraumatic epilepsy is more likely to develop if the dura mater was penetrated and generally becomes manifest within 2 years following the injury. However, seizures developing in the first week after head injury do not necessarily imply that future attacks will occur. There is no clear evidence that prophylactic anticonvulsant drug treatment reduces the incidence of posttraumatic epilepsy.

4. Tumors and other space-occupying lesions—Neoplasms may lead to seizures at any age, but they are an especially important cause of seizures in middle and later life, when the incidence of neoplastic disease increases. The seizures are commonly the initial symptoms of the tumor and often are focal in character. They are most likely to occur with structural lesions involving the frontal, parietal, or temporal regions. Tumors must be excluded by imaging studies (MRI preferred over CT) in all patients with onset of seizures after 30 years of age, focal seizures or signs, or a progressive seizure disorder.

5. Vascular diseases—Vascular diseases become increasingly frequent causes of seizures with advancing age and are the most common cause of seizures with onset at age 60 years or older.

6. Degenerative disorders—Alzheimer disease and other degenerative disorders are a cause of seizures in later life.

7. Infectious diseases—Infectious diseases must be considered in all age groups as potentially reversible causes of seizures. Seizures may occur with an acute infective or inflammatory illness, such as bacterial meningitis or herpes encephalitis, or in patients with more longstanding or chronic disorders, such as neurosyphilis or cerebral cysticercosis. In patients with AIDS, they may result from central nervous system toxoplasmosis, cryptococcal meningitis, secondary viral encephalitis, or other infective complications. Seizures are a common sequela of supra-tentorial brain abscess, developing most frequently in the first year after treatment.

C. Unknown

In many cases, the cause of epilepsy cannot be determined.

► Classification of Seizures

The International League Against Epilepsy distinguishes seizures affecting only part of the brain (focal seizures) from those that are generalized (Table 24–2).

A. Focal Seizures

The initial clinical and electroencephalographic manifestations of partial seizures indicate that only a restricted part of one cerebral hemisphere has been activated. The ictal manifestations depend on the area of the brain involved. Focal seizures sometimes involve impairment of consciousness and may evolve to convulsive seizures, in a process previously called secondary generalization.

1. Without impairment of consciousness—Seizures may be manifested by focal motor symptoms (convulsive jerking) or somatosensory symptoms (eg, paresthesias or tingling) that spread (or “march”) to different parts of the limb or body depending on their cortical representation; such seizures were previously described as “simple partial” seizures. In other instances, special sensory symptoms (eg, light flashes or buzzing) indicate involvement of visual, auditory, olfactory, or gustatory regions of the brain, or there may be autonomic symptoms or signs (eg, abnormal epigastric sensations, sweating, flushing, pupillary dilation). The sole manifestations of some seizures are phenomena such as dysphasia, dysmnestic symptoms (eg, déjà vu, jamais vu), affective disturbances, illusions, or structured hallucinations, but such symptoms are usually accompanied by impairment of consciousness.

2. With impairment of consciousness—Impaired consciousness or responsiveness may be preceded, accompanied, or followed by the various symptoms mentioned above, and automatisms may occur. Such seizures were previously called “complex partial” seizures.

B. Generalized Seizures

There are several different varieties of generalized seizures, as outlined below. In some circumstances, seizures cannot be classified because of incomplete information or because they do not fit into any category.

Table 24-2. Seizure classification.

Seizure Type	Key Features	Other Associated Features
Focal seizures	Involvement of only a restricted part of brain; may evolve to a bilateral, convulsive seizure	
Without impairment of consciousness		Observable focal motor or autonomic symptoms, or subjective sensory or psychic symptoms may occur
With impairment of consciousness		Above symptoms may precede, accompany, or follow the period of altered responsiveness
Generalized seizures	Diffuse involvement of brain at onset	
Absence (petit mal)	Consciousness impaired briefly; patient often unaware of attacks	May have clonic, tonic, or atonic (ie, loss of postural tone) components; autonomic components (eg, enuresis); or accompanying automatisms Almost always begin in childhood and frequently cease by age 20
Atypical absences	May be more gradual in onset and termination than typical absence	More marked changes in tone may occur
Myoclonic	Single or multiple myoclonic jerks	
Tonic-clonic (grand mal)	Tonic phase: Sudden loss of consciousness, with rigidity and arrest of respiration, lasting < 1 minute Clonic phase: Jerking occurs, usually for < 2-3 minutes Flaccid coma: Variable duration	May be accompanied by tongue biting, incontinence, or aspiration; commonly followed by postictal confusion variable in duration
Status epilepticus	Repeated seizures without recovery between them; a fixed and enduring epileptic condition lasting ≥ 30 minutes	

1. Absence seizures—These are characterized by impairment of consciousness, sometimes with mild clonic, tonic, or atonic components (ie, reduction or loss of postural tone), autonomic components (eg, enuresis), or accompanying automatisms. Onset and termination of attacks are abrupt. If attacks occur during conversation, the patient may miss a few words or may break off in midsentence for a few seconds. The impairment of external awareness is so brief that the patient is unaware of it. Absence (“petit mal”) seizures almost always begin in childhood and frequently cease by the age of 20 years, although occasionally they are then replaced by other forms of generalized seizure. Electroencephalographically, such attacks are associated with bursts of bilaterally synchronous and symmetric 3-Hz spike-and-wave activity. A normal background in the electroencephalogram and normal or above-normal intelligence imply a good prognosis for the ultimate cessation of these seizures.

2. Atypical absence seizures—There may be more marked changes in tone, or attacks may have a more gradual onset and termination than in typical absence seizures. They commonly occur in patients with multiple seizure types, may be accompanied by developmental delay or mental retardation, and are associated with slower spike-wave discharges than those in typical absence attacks.

3. Myoclonic seizures—Myoclonic seizures consist of single or multiple myoclonic jerks.

4. Tonic-clonic (“grand mal”) seizures—In these seizures, which are characterized by sudden loss of

consciousness, the patient becomes rigid and falls to the ground, and respiration is arrested. This tonic phase, which usually lasts for < 1 minute, is followed by a clonic phase in which there is jerking of the body musculature that may last for 2 or 3 minutes and is then followed by a stage of flaccid coma. During the seizure, the tongue or lips may be bitten, urinary or fecal incontinence may occur, and the patient may be injured. Immediately after the seizure, the patient may recover consciousness, drift into sleep, have a further convulsion without recovery of consciousness between the attacks (**status epilepticus**), or after recovering consciousness have a further convulsion (**serial seizures**). In other cases, patients will behave in an abnormal fashion in the immediate postictal period, without subsequent awareness or memory of events (**postepileptic automatism**). Headache, disorientation, confusion, drowsiness, nausea, soreness of the muscles, or some combination of these symptoms commonly occurs postictally.

5. Tonic, clonic, or atonic seizures—Loss of consciousness may occur with either the tonic or clonic accompaniments described above, especially in children. Atonic seizures (**epileptic drop attacks**) have also been described.

▶ Clinical Findings

A. Symptoms and Signs

Nonspecific changes such as headache, mood alterations, lethargy, and myoclonic jerking alert some patients to an impending seizure hours before it occurs. These prodromal

symptoms are distinct from the aura; the aura that may precede a generalized seizure by a few seconds or minutes is itself a part of the attack and it arises locally from a restricted part of the brain.

In most patients, seizures occur unpredictably at any time and without any relationship to posture or ongoing activities. Occasionally, however, they occur at a particular time (eg, during sleep) or in relation to external precipitants such as lack of sleep, missed meals, emotional stress, menstruation, alcohol ingestion (or alcohol withdrawal; see below), or use of certain drugs. Fever and nonspecific infections may also precipitate seizures in epileptic patients. In a few patients, seizures are provoked by specific stimuli such as flashing lights or a flickering television set (**photosensitive epilepsy**), music, or reading.

Clinical examination between seizures shows no abnormality in patients with idiopathic epilepsy, but in the immediate postictal period, extensor plantar responses may be seen. The presence of lateralized or focal signs postictally suggests that seizures may have a focal origin. In patients with symptomatic epilepsy, the findings on examination will reflect the underlying cause.

B. Imaging

MRI is indicated for patients with focal neurologic symptoms or signs, focal seizures, or electroencephalographic findings of a focal disturbance; some clinicians routinely order MRI for all patients with new-onset seizure disorders. CT is generally less sensitive than MRI to small structural brain abnormalities but may be used when MRI is contraindicated (eg, in a patient with a metallic implant). Such studies should be performed in patients with clinical evidence of a progressive disorder and in those with new onset of seizures after the age of 20 years because of the possibility of an underlying neoplasm.

C. Laboratory and Other Studies

Initial investigations should include hematologic and biochemical screening tests (eg, complete blood count, serum glucose, electrolytes, creatinine, calcium, magnesium, and liver function tests). The hematologic and biochemical screening tests are important both to exclude various causes of seizures and to provide a baseline for subsequent monitoring of long-term effects of treatment. A lumbar puncture may be necessary when any sign of infection is present or in the evaluation of new-onset seizures in the acute setting.

Electroencephalography may support the clinical diagnosis of epilepsy (by demonstrating paroxysmal abnormalities containing spikes or sharp waves), may provide a guide to prognosis, and may help classify the seizure disorder. Classification of the disorder is important for determining the most appropriate anticonvulsant drug with which to start treatment. For example, absence and focal seizures with impairment of consciousness may be difficult to distinguish clinically, but the electroencephalographic findings and treatment of choice differ in these two conditions. Finally, by localizing the epileptogenic source, the electroencephalographic findings are important in evaluating candidates for surgical treatment.

► Differential Diagnosis

The distinction between the various disorders likely to be confused with generalized seizures is usually made on the basis of the history. The importance of obtaining an eyewitness account of the attacks cannot be overemphasized.

A. Differential Diagnosis of Focal Seizures

1. Transient ischemic attacks—These attacks are distinguished from seizures by their longer duration, lack of spread, and symptoms. Level of consciousness, which is unaltered, does not distinguish them. There is a loss of motor or sensory function (eg, weakness or numbness) with transient ischemic attacks, whereas positive symptoms (eg, convulsive jerking or paresthesias) characterize seizures.

2. Rage attacks—Rage attacks are usually situational and lead to goal-directed aggressive behavior.

3. Panic attacks—These may be hard to distinguish from focal seizures unless there is evidence of an anxiety disorder between attacks and the attacks have a clear relationship to external circumstances.

B. Differential Diagnosis of Generalized Seizures

1. Syncope—Syncope episodes usually occur in relation to postural change, emotional stress, instrumentation, pain, or straining. They are typically preceded by pallor, sweating, nausea, and malaise and lead to loss of consciousness accompanied by flaccidity; recovery occurs rapidly with recumbency, and there is no postictal headache or confusion. In some instances, however, motor accompaniments may simulate a seizure. Serum creatine kinase measured about 3 hours after the event is generally normal after syncopal episodes but markedly elevated after tonic-clonic seizures.

2. Cardiac disease—Cerebral hypoperfusion due to a disturbance of cardiac rhythm should be suspected in patients with known cardiac or vascular disease or in elderly patients who present with episodic loss of consciousness. Prodromal symptoms are typically absent. Repeated Holter monitoring may be necessary to establish the diagnosis; monitoring initiated by the patient (“event monitor”) may be valuable if the disturbances of consciousness are rare. A relationship of attacks to physical activity and the finding of a systolic murmur are suggestive of aortic stenosis.

3. Brainstem ischemia—Loss of consciousness is preceded or accompanied by other brainstem signs. Basilar artery migraine and vertebrobasilar vascular disease are discussed elsewhere in this chapter.

4. Psychogenic nonepileptic seizure (PNES)—Simulating an epileptic seizure, a PNES may occur due to a conversion disorder or malingering. Many patients also have true seizures or a family history of epilepsy. Although a PNES tends to occur at times of emotional stress, this may also be the case with true seizures.

Clinically, the attacks superficially resemble tonic-clonic seizures, but there may be obvious preparation before a PNES occurs. Moreover, there is usually no tonic phase; instead, there may be an asynchronous thrashing of the limbs, which increases if restraints are imposed and rarely leads to injury. Consciousness may be normal or “lost,” but in the latter context the occurrence of goal-directed behavior or of shouting, swearing, etc, indicates that it is feigned. Postictally, there are no changes in behavior or neurologic findings.

Often, clinical observation is insufficient to discriminate epileptic from nonepileptic seizures. Video electroencephalographic monitoring may be quite helpful: epileptic seizures, especially those involving altered consciousness, commonly involve scalp electroencephalographic signs that coincide with a behavioral spell, whereas a PNES does not. The serum level of prolactin has been found to increase dramatically between 15 and 30 minutes after a tonic-clonic convulsion in most patients, whereas it is unchanged after a PNES. Serum creatine kinase levels also increase after a convulsion but not a PNES.

► Treatment

A. General Measures

For patients with epilepsy, drug treatment is prescribed with the goal of preventing further attacks and is usually continued until there have been no seizures for at least 3 years. Epileptic patients should be advised to avoid situations that could be dangerous or life-threatening if further seizures should occur. Legislation may require clinicians to report to the state authorities any patients with seizures or other episodic disturbances of consciousness; driving cessation for 6 months or as legislated is appropriate following an unprovoked seizure.

1. Choice of medication—Drug selection depends on seizure type (Table 24–3). The dose of the selected drug is gradually increased until seizures are controlled or side effects prevent further increases. If seizures continue despite treatment at the maximal tolerated dose, a second drug is added and the dose increased depending on tolerance; the first drug is then gradually withdrawn. In treatment of focal seizures, the success rate is higher with carbamazepine, phenytoin, or valproic acid than with phenobarbital or primidone. Gabapentin, topiramate, lamotrigine, oxcarbazepine, levetiracetam, zonisamide, lacosamide, ezogabine, and tiagabine are newer antiepileptic drugs used to treat focal seizures. Felbamate is also effective for such seizures but, because it may cause aplastic anemia or fulminant hepatic failure, should be used only in selected patients unresponsive to other measures. Rufinamide is currently approved only for seizures in patients with Lennox-Gastaut syndrome, but it may be effective against seizures in a broader range of refractory patients. For generalized or unclassified seizures, valproate is better tolerated than topiramate and more efficacious than lamotrigine and is thus preferred for many patients; however, the teratogenic potential of valproate makes its use undesirable in women of childbearing age. All antiepileptics are potentially teratogenic, although the

teratogenicity of the newer antiseizure medications is less clear. Nevertheless, antiepileptic medication must be given to pregnant women with epilepsy to prevent seizures, which can pose serious risk to the fetus from trauma, hypoxia, or other factors. In most patients with seizures of a single type, satisfactory control can be achieved with a single anticonvulsant drug. Treatment with two drugs may further reduce seizure frequency or severity but usually only at the cost of greater toxicity. Treatment with more than two drugs is almost always unhelpful unless the patient is having seizures of different types.

2. Monitoring—Monitoring serum drug levels has led to major advances in the management of seizure disorders. Individual differences in drug metabolism cause a given dose of a drug to produce different blood concentrations in different patients, and this will affect the therapeutic response. In general, the dose of an antiepileptic agent is increased depending on the clinical response regardless of the serum drug level. The trough drug level is then measured to provide a reference point for the maximum tolerated dose. Dosing should not be based simply on serum levels because some patients require levels that exceed the therapeutic range (“toxic levels”) but tolerate these without ill effect. Steady-state drug levels in the blood should be measured after treatment is initiated, dosage is changed, or another drug is added to the therapeutic regimen and when seizures are poorly controlled. Dose adjustments are then guided by the laboratory findings. The most common cause of a lower concentration of drug than expected for the prescribed dose is poor patient compliance. Compliance can be improved by limiting to a minimum the number of daily doses. Recurrent seizures or status epilepticus may result if drugs are taken erratically, and in some circumstances noncompliant patients may be better off without any medication.

All anticonvulsant drugs have side effects, and some of these are shown in Table 24–3.

In most patients, a complete blood count should be performed at least annually because of the risk of anemia or blood dyscrasia. Treatment with certain drugs may require more frequent monitoring or use of additional screening tests. For example, periodic tests of hepatic function are necessary if valproic acid, carbamazepine, or felbamate is used, and serial blood counts are important with carbamazepine, ethosuximide, or felbamate. Detailed medication-specific recommendations should be sought from a drug reference source before prescribing, since baseline studies are often necessary.

3. Discontinuance of medication—Only when adult patients have been seizure-free for 2 years should withdrawal of medication be considered. Unfortunately, there is no way of predicting which patients can be managed successfully without treatment, although seizure recurrence is more likely in patients who initially did not respond to therapy, those with seizures having focal features or of multiple types, and those with continuing electroencephalographic abnormalities. Dose reduction should be gradual (over weeks or months), and drugs should be withdrawn one at a time. If seizures recur, treatment is reinstated with the previously effective drug regimen.

Table 24-3. Drug treatment for seizures in adults.

Drug	Usual Adult Daily Oral Dose	Minimum No. of Daily Doses	Time to Steady State Drug Levels	Optimal Drug Level	Selected Side Effects and Idiosyncratic Reactions
Generalized or focal seizures					
Phenytoin	200–400 mg	1	5–10 days	10–20 mcg/mL	Nystagmus, ataxia, dysarthria, sedation, confusion, gingival hyperplasia, hirsutism, megaloblastic anemia, blood dyscrasias, skin rashes, fever, systemic lupus erythematosus, lymphadenopathy, peripheral neuropathy, dyskinesias.
Carbamazepine extended-release (ER) formulation	400–1600 mg ER	2	3–4 days	4–8 mcg/mL	Nystagmus, dysarthria, diplopia, ataxia, drowsiness, nausea, blood dyscrasias, hepatotoxicity, hyponatremia. May exacerbate myoclonic seizures.
Valproic acid	1500–2000 mg	2–3	2–4 days	50–100 mcg/mL	Nausea, vomiting, diarrhea, drowsiness, alopecia, weight gain, hepatotoxicity, thrombocytopenia, tremor, pancreatitis.
Phenobarbital	100–200 mg	1	14–21 days	10–40 mcg/mL	Drowsiness, nystagmus, ataxia, skin rashes, learning difficulties, hyperactivity.
Primidone	750–1500 mg	3	4–7 days	5–15 mcg/mL	Sedation, nystagmus, ataxia, vertigo, nausea, skin rashes, megaloblastic anemia, irritability.
Lamotrigine ^{1,2,5}	100–500 mg	2	4–5 days	?	Sedation, skin rash, visual disturbances, dyspepsia, ataxia.
Topiramate ^{1–4}	200–400 mg	2	4 days	?	Somnolence, nausea, dyspepsia, irritability, dizziness, ataxia, nystagmus, diplopia, glaucoma, renal calculi, weight loss, hypohidrosis, hyperthermia.
Oxcarbazepine ^{1,3}	900–1800 mg	2	2–3 days	?	As for carbamazepine.
Levetiracetam ^{1,2}	1000–3000 mg	2	2 days	?	Somnolence, ataxia, headache, behavioral changes.
Zonisamide ¹	200–600 mg	1	14 days	?	Somnolence, ataxia, anorexia, nausea, vomiting, rash, confusion, renal calculi. Do not use in patients with sulfonamide allergy.
Tiagabine ¹	32–56 mg	2	2 days	?	Somnolence, anxiety, dizziness, poor concentration, tremor, diarrhea.
Pregabalin ¹	150–300 mg	2	2–4 days	?	Somnolence, dizziness, poor concentration, weight gain, thrombocytopenia, skin rashes, anaphylactoid reactions.
Gabapentin ¹	900–3600 mg	3	1 day	?	Sedation, fatigue, ataxia, nystagmus, weight loss.
Felbamate ^{1,3,6}	1200–3600 mg	3	4–5 days	?	Anorexia, nausea, vomiting, headache, insomnia, weight loss, dizziness, hepatotoxicity, aplastic anemia.
Lacosamide ¹	100–400 mg	2	3 days	?	Vertigo, diplopia, nausea, headache, fatigue, ataxia, tremor, anaphylactoid reactions, PR prolongation, cardiac dysrhythmia, suicidality.
Ezogabine ¹	300–1200 mg	3	2–3 days	?	Dizziness, somnolence, confusion, vertigo, nausea, ataxia, psychiatric disturbances.
Absence seizures					
Ethosuximide	100–1500 mg	2	5–10 days	40–100 mcg/mL	Nausea, vomiting, anorexia, headache, lethargy, unsteadiness, blood dyscrasias, systemic lupus erythematosus, urticaria, pruritus.
Valproic acid	1500–2000 mg	3	2–4 days	50–100 mcg/mL	See above.
Clonazepam	0.04–0.2 mg/kg	2	?	20–80 ng/mL	Drowsiness, ataxia, irritability, behavioral changes, exacerbation of tonic-clonic seizures.
Myoclonic seizures					
Valproic acid	1500–2000 mg	3	2–4 days	50–100 mcg/mL	See above.
Clonazepam	0.04–0.2 mg/kg	2	?	20–80 ng/mL	See above.

¹Approved as adjunctive therapy for focal-onset seizures.²Approved as adjunctive therapy for primary generalized tonic-clonic seizures.³Approved as initial monotherapy for focal-onset seizures.⁴Approved as initial monotherapy for primary generalized tonic-clonic seizures.⁵Approved as monotherapy (after conversion from another drug) in focal-onset seizures.⁶Not to be used as a first-line drug; when used, blood counts should be performed regularly (every 2–4 weeks). Should be used only in selected patients because of risk of aplastic anemia and hepatic failure. It is advisable to obtain written informed consent before use.

4. Surgical treatment—Patients with seizures refractory to pharmacologic management may be candidates for operative treatment. Surgical resection is most efficacious when there is a single well-defined seizure focus, particularly in the temporal lobe. Among well-chosen patients, up to 70% remain seizure-free after extended follow-up. Using a different approach, a recent trial showed benefits of bilateral deep brain stimulation of the anterior thalamus for medically refractory focal-onset seizures.

5. Vagal nerve stimulation—Treatment by chronic vagal nerve stimulation for adults and adolescents with medically refractory focal seizures is approved in the United States and provides an alternative approach for patients who are not optimal candidates for surgical treatment. The mechanism of therapeutic action is unknown. Adverse effects consist mainly of transient hoarseness during stimulus delivery.

B. Special Circumstances

1. Solitary seizures—In patients who have had only one seizure or a flurry of seizures over a brief period of several hours, investigation as outlined above should exclude an underlying cause requiring specific treatment. An electroencephalogram should also be obtained, preferably within 24 hours after the seizure, because the findings may influence management—especially when focal abnormalities are present. Prophylactic anticonvulsant drug treatment is generally not required unless further attacks occur or investigations reveal some underlying pathology. The risk of seizure recurrence varies in different series between about 30% and 70%. Epilepsy should not be diagnosed on the basis of a solitary seizure. If seizures occur in the context of transient, nonrecurrent systemic disorders such as acute cerebral anoxia, the diagnosis of epilepsy is inaccurate, and long-term prophylactic anticonvulsant drug treatment is unnecessary.

2. Alcohol withdrawal seizures—One or more generalized tonic-clonic seizures may occur within 48 hours or so of withdrawal from alcohol after a period of high or prolonged intake. Patients should be hospitalized for at least 24 hours for observation and to follow the severity of withdrawal symptoms. If the seizures have consistently focal features, the possibility of an associated structural abnormality, often traumatic in origin, must be considered. Head CT scan or MRI should be performed in patients with new onset of generalized seizures and whenever there are focal features. Treatment with anticonvulsant drugs is generally not required for alcohol withdrawal seizures, since they are self-limited. Benzodiazepines (diazepam or lorazepam, dosed as needed to reduce withdrawal symptoms and to avoid oversedation) are effective and safe for preventing further seizures. Status epilepticus may rarely follow alcohol withdrawal and is managed along conventional lines (see below). Further attacks will not occur if the patient abstains from alcohol.

3. Tonic-clonic status epilepticus—Poor compliance with the anticonvulsant drug regimen is the most common cause; others include alcohol withdrawal, intracranial

infection or neoplasms, metabolic disorders, and drug overdose. The mortality rate may be as high as 20%, and among survivors the incidence of neurologic and cognitive sequelae may be high. The prognosis relates to the length of time between onset of status epilepticus and the start of effective treatment.

Status epilepticus is a medical emergency. Initial management includes maintenance of the airway and 50% dextrose (25–50 mL) intravenously in case hypoglycemia is responsible. If seizures continue, an intravenous bolus of lorazepam, 4 mg, is given at a rate of 2 mg/min and repeated once after 10 minutes if necessary; alternatively, 10 mg of diazepam is given intravenously over the course of 2 minutes, and again after 10 minutes if necessary. Diazepam can also be given rectally as a gel (0.2 mg/kg). These measures are usually effective in halting seizures for a brief period. Respiratory depression and hypotension may complicate the treatment of status epilepticus and are treated as in other circumstances; this treatment may include intubation and mechanical ventilation and admission to an intensive care unit.

Regardless of the response to lorazepam or diazepam, phenytoin (18–20 mg/kg) is given intravenously at a rate of 50 mg/min; this provides initiation of long-term seizure control. The drug is best injected directly but can also be given in saline; it precipitates, however, if injected into glucose-containing solutions. Because arrhythmias may develop during rapid administration of phenytoin, electrocardiographic monitoring is prudent. Hypotension may complicate phenytoin administration, especially if diazepam has also been given. In many countries, injectable phenytoin has been replaced by fosphenytoin, which is rapidly and completely converted to phenytoin following intravenous administration. No dosing adjustments are necessary because fosphenytoin is expressed in terms of phenytoin equivalents (PE); fosphenytoin is less likely to cause reactions at the infusion site, can be given with all common intravenous solutions, and may be administered at a faster rate (150 mg PE/min). It is also more expensive.

If seizures continue, phenobarbital is then given in a loading dose of 10–20 mg/kg intravenously by slow or intermittent injection (50 mg/min). Respiratory depression and hypotension are especially common with this therapy. Alternatively or additionally, intravenous valproate is used for status epilepticus (loading dose 25–30 mg/kg over 15 min; then 100 mg/h); although valproate has not yet been approved by the FDA for this indication, it has been used with success.

If these measures fail, general anesthesia with ventilatory assistance may be required. Intravenous midazolam may provide control of refractory status epilepticus; the suggested loading dose is 0.2 mg/kg, followed by 0.05–0.2 mg/kg/h. Propofol (1–2 mg/kg as an intravenous bolus, followed by infusion at 2–15 mg/kg/h depending on response) may also be used, as may pentobarbital (15 mg/kg intravenously, followed by 0.5–4 mg/kg/h).

After status epilepticus is controlled, an oral drug program for the long-term management of seizures is started, and investigations into the cause of the disorder are pursued.

4. Nonconvulsive status epilepticus—In some cases, status epilepticus presents not with convulsions, but with a fluctuating abnormal mental status, confusion, impaired responsiveness, and automatism. Electroencephalography is helpful in establishing the diagnosis. The treatment approach outlined above applies to any type of status epilepticus, although intravenous anesthesia is usually not necessary. The prognosis is a reflection of the underlying cause rather than of continuing seizures.

▶ When to Refer

- Behavioral episodes are of uncertain nature.
- Seizures are difficult to control or have focal features.
- There are accompanying neurologic signs.
- There is a progressive neurologic disorder.
- Status epilepticus.

▶ When to Admit

- Status epilepticus.
- For monitoring, when PNES are suspected.
- If surgery is contemplated.

Bauer G et al. Nonconvulsive status epilepticus and coma. *Epilepsia*. 2010 Feb;51(2):177–90. [PMID: 19744116]

Berg AT et al. Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE Commission on Classification and Terminology, 2005–2009. *Epilepsia*. 2010 Apr;51(4):676–85. [PMID: 20196795]

Bonnett LJ et al. Risk of recurrence after a first seizure and implications for driving: further analysis of the Multicentre study of early Epilepsy and Single Seizures. *BMJ*. 2010 Dec 7;341:c6477. [PMID: 21147743]

Fisher R et al; SANTE Study Group. Electrical stimulation of the anterior nucleus of thalamus for treatment of refractory epilepsy. *Epilepsia*. 2010 May;51(5):899–908. [PMID: 20331461]

French JA et al. Randomized, double-blind, placebo-controlled trial of ezogabine (retigabine) in partial epilepsy. *Neurology*. 2011 May 3;76(18):1555–63. [PMID: 21451152]

Johnston A et al. Epilepsy in the elderly. *Expert Rev Neurother*. 2010 Dec;10(12):1899–910. [PMID: 21384700]

Perucca E et al. The pharmacological treatment of epilepsy in adults. *Lancet Neurol*. 2011 May;10(5):446–56. [PMID: 21511198]

Rabinstein AA. Management of status epilepticus in adults. *Neurol Clin*. 2010 Nov;28(4):853–62. [PMID: 20816266]

Spencer S et al. Outcomes of epilepsy surgery in adults and children. *Lancet Neurol*. 2008 Jun;7(6):525–37. [PMID: 18485316]

DYSAUTONOMIA



ESSENTIALS OF DIAGNOSIS

- ▶ Abnormalities of blood pressure or heart rate regulation, sweating, intestinal motility, sphincter control, sexual function, respiration, or ocular function, occurring in isolation or any combination.

▶ General Considerations

Dysautonomia may occur as a result of central or peripheral pathologic processes. It is manifested by a variety of symptoms that may occur in isolation or in various combinations and relate to abnormalities of blood pressure regulation, thermoregulatory sweating, gastrointestinal function, sphincter control, sexual function, respiration, and ocular function. Syncope, a symptom of dysautonomia, is characterized by a transient loss of consciousness, usually accompanied by hypotension and bradycardia. It may occur in response to emotional stress, postural hypotension, vigorous exercise in a hot environment, obstructed venous return to the heart, acute pain or its anticipation, fluid loss, and a variety of other circumstances.

A. Central Neurologic Causes

Disease at certain sites in the central nervous system, regardless of its nature, may lead to dysautonomic symptoms. Postural hypotension, which is usually the most troublesome and disabling symptom, may result from spinal cord transection and other myelopathies (eg, due to tumor or syringomyelia) above the T6 level or from brainstem lesions such as syringobulbia and posterior fossa tumors. Sphincter or sexual disturbances may result from cord lesions below T6. Certain primary degenerative disorders are responsible for dysautonomia occurring in isolation (**pure autonomic failure**) or in association with more widespread abnormalities (**multisystem atrophy** or **Shy-Drager syndrome**) that may include parkinsonian, pyramidal symptoms, and cerebellar deficits.

B. Peripheral Neurologic Causes

A pure autonomic neuropathy may occur acutely or subacutely after a viral infection or as a paraneoplastic disorder related usually to small cell lung cancer, particularly in association with certain antibodies, such as anti-Hu or those directed at neuronal nicotinic acetylcholine receptors. Typically, presenting symptoms include postural hypotension, impaired thermoregulatory sweating, xerostomia or xerophthalmia, abnormal gastrointestinal motility, dilated pupils, or acute urinary retention. Dysautonomia is often conspicuous in patients with Guillain-Barré syndrome, manifesting with marked hypotension or hypertension or cardiac arrhythmias that may have a fatal outcome. It may also occur with diabetic, uremic, amyloidotic, and various other metabolic or toxic neuropathies; in association with leprosy or Chagas disease; and as a feature of certain hereditary neuropathies with autosomal dominant or recessive inheritance or an X-linked pattern. Autonomic symptoms are prominent in the crises of hepatic porphyria. Patients with botulism or the Lambert-Eaton myasthenic syndrome may have constipation, urinary retention, and a sicca syndrome as a result of impaired cholinergic function.

▶ Clinical Findings

A. Symptoms and Signs

Dysautonomic symptoms include syncope, postural hypotension, paroxysmal hypertension, persistent tachycardia

without other cause, facial flushing, hypohidrosis or hyperhidrosis, vomiting, constipation, diarrhea, dysphagia, abdominal distention, disturbances of micturition or defecation, erectile dysfunction, apneic episodes, and declining night vision. In syncope, prodromal malaise, nausea, headache, diaphoresis, pallor, visual disturbance, loss of postural tone, and a sense of weakness and impending loss of consciousness are followed by actual loss of consciousness. Although the patient is usually flaccid, some motor activity is not uncommon, and urinary (and rarely fecal) incontinence may also occur, thereby simulating a seizure. Recovery is rapid once the patient becomes recumbent, but headache, nausea, and fatigue are common postictally.

B. Evaluation of the Patient

Clinical evaluation is important to exclude reversible, non-neurologic causes of symptoms. Postural hypotension and syncope, for example, may relate to a reduced cardiac output (eg, from aortic stenosis or cardiomyopathy), paroxysmal cardiac dysrhythmias, volume depletion, various medications, and endocrine and metabolic disorders such as Addison disease, hypothyroidism or hyperthyroidism, pheochromocytoma, and carcinoid syndrome. Testing of autonomic function helps establish the diagnosis of dysautonomia, to exclude other causes of symptoms, to assess the severity of involvement, and to guide prognostication. Such testing includes evaluating the cardiovascular response to the Valsalva maneuver, startle, mental stress, postural change, and deep respiration, and the sudomotor (sweating) responses to warming or a deep inspiratory gasp. Tilt-table testing may reproduce syncopal or presyncopal symptoms. Pharmacologic studies to evaluate the pupillary responses, radiologic studies of the bladder or gastrointestinal tract, uroflowmetry and urethral pressure profiles, and recording of nocturnal penile tumescence may also be necessary in selected cases. Further investigation depends on the presence of other associated neurologic abnormalities. In patients with a peripheral cause, work-up for peripheral neuropathy may be required as discussed below and should include testing for ganglionic acetylcholine receptor antibody. For those with evidence of a central lesion, imaging studies will exclude a treatable structural cause.

► Treatment

The most disabling symptom of dysautonomia is usually postural hypotension and syncope. Abrupt postural change, prolonged recumbency, and other precipitants should be avoided. Medications associated with postural hypotension should be discontinued or reduced in dose. Treatment may include wearing waist-high elastic hosiery, salt supplementation, sleeping in a semierect position (which minimizes the natriuresis and diuresis that occur during recumbency), and fludrocortisone (0.1–0.2 mg daily). Vasoconstrictor agents may be helpful and include midodrine (2.5–10 mg three times daily) and ephedrine (15–30 mg three times daily). Other agents that have been used occasionally or experimentally are dihydroergotamine,

yohimbine, pyridostigmine, and clonidine; refractory cases may respond to erythropoietin (epoetin alfa) or desmopressin. Patients must be monitored for recumbent hypertension. Postprandial hypotension is helped by caffeine. There is no satisfactory treatment for disturbances of sweating, but an air-conditioned environment is helpful in avoiding extreme swings in body temperature.

► When to Refer

- When the diagnosis is uncertain.
- When symptoms persist despite conventional treatment.

Klein CM. Evaluation and management of autonomic nervous system disorders. *Semin Neurol.* 2008 Apr;28(2):195–204. [PMID: 18351521]

Shibao C et al. Comparative efficacy of yohimbine against pyridostigmine for the treatment of orthostatic hypotension in autonomic failure. *Hypertension.* 2010 Nov;56(5):847–51. [PMID: 20837887]

Vaddadi G et al. Management strategies for recurrent vasovagal syncope. *Intern Med J.* 2010 Aug;40(8):554–60. [PMID: 20718882]

SENSORY DISTURBANCES

Patients may complain of either lost or abnormal sensations. The term “numbness” is often used by patients to denote loss of feeling, but the word also has other meanings and the patient’s intention must be clarified. Abnormal spontaneous sensations are generally called paresthesias, and unpleasant or painful sensations produced by a stimulus that is usually painless are called dysesthesias.

Sensory symptoms may be due to disease located anywhere along the peripheral or central sensory pathways. The character, site, mode of onset, spread, and temporal profile of sensory symptoms must be established and any precipitating or relieving factors identified. These features—and the presence of any associated symptoms—help identify the origin of sensory disturbances, as do the physical signs as well. Sensory symptoms or signs may conform to the territory of individual peripheral nerves or nerve roots. Involvement of one side of the body—or of one limb in its entirety—suggests a central lesion. Distal involvement of all four extremities suggests polyneuropathy, a cervical cord or brainstem lesion, or—when symptoms are transient—a metabolic disturbance such as hyperventilation syndrome. Short-lived sensory complaints may be indicative of sensory seizures or cerebral ischemic phenomena as well as metabolic disturbances. In patients with cord lesions, there may be a transverse sensory level. “Dissociated sensory loss” is characterized by loss of some sensory modalities with preservation of others. Such findings may be encountered in patients with either peripheral or central disease and must therefore be interpreted in the clinical context in which they are found.

The absence of sensory signs in patients with sensory symptoms does not mean that symptoms have a nonorganic basis. Symptoms are often troublesome before signs of sensory dysfunction have had time to develop.

WEAKNESS & PARALYSIS

Loss of muscle power may result from central disease involving the upper or lower motor neurons; from peripheral disease involving the roots, plexus, or peripheral nerves; from disorders of neuromuscular transmission; or from primary disorders of muscle. The clinical findings help localize the lesion and thus reduce the number of diagnostic possibilities.

Weakness due to upper motor neuron lesions is characterized by selective involvement of certain muscle groups and is associated with spasticity, increased tendon reflexes, and extensor plantar responses. The site of upper motor neuron (pyramidal) involvement may be indicated by the presence of other clinical signs or by the distribution of the motor deficit. Lower motor neuron lesions lead to muscle wasting as well as weakness, with flaccidity and loss of tendon reflexes, but no change in the plantar responses unless the neurons subserving them are directly involved. Fasciculations may be evident over affected muscles. In distinguishing between a root, plexus, or peripheral nerve lesion, the distribution of the motor deficit and of any sensory changes is of particular importance. In patients with disturbances of neuromuscular transmission, weakness is patchy in distribution, often fluctuates over short periods of time, and is not associated with sensory changes. In myopathic disorders, weakness is usually most marked proximally in the limbs, is not associated with sensory loss or sphincter disturbance, and is not accompanied by muscle wasting or loss of tendon reflexes—at least not until an advanced stage.

TRANSIENT ISCHEMIC ATTACKS



ESSENTIALS OF DIAGNOSIS

- ▶ Focal neurologic deficit of acute onset.
- ▶ Clinical deficit resolves completely within 24 hours.
- ▶ Risk factors for vascular disease often present.

▶ General Considerations

Transient ischemic attacks are characterized by focal ischemic cerebral neurologic deficits that last for < 24 hours (usually < 1–2 hours). About 30% of patients with stroke have a history of transient ischemic attacks, and proper treatment of the attacks is an important means of prevention. The incidence of stroke does not relate to either the number or the duration of individual attacks but is increased in patients with hypertension or diabetes mellitus. The risk of stroke is highest in the month after a transient ischemic attack (particularly in the first 48 hours) and progressively declines thereafter.

▶ Etiology

An important cause of transient cerebral ischemia is embolization. In many patients with these attacks, a source is readily apparent in the heart or a major

extracranial artery to the head, and emboli sometimes are visible in the retinal arteries. Moreover, an embolic phenomenon explains why separate attacks may affect different parts of the territory supplied by the same major vessel. Cardiac causes of embolic ischemic attacks include atrial fibrillation, rheumatic heart disease, mitral valve disease, infective endocarditis, atrial myxoma, and mural thrombi complicating myocardial infarction. Atrial septal defects and patent foramen ovale may permit emboli from the veins to reach the brain (“paradoxical emboli”). An ulcerated plaque on a major artery to the brain may serve as a source of emboli. In the anterior circulation, atherosclerotic changes occur most commonly in the region of the carotid bifurcation extracranially, and these changes may cause a bruit. In some patients with transient ischemic attacks or strokes, an acute or recent hemorrhage is found to have occurred into this atherosclerotic plaque, and this finding may have pathologic significance. Patients with AIDS have an increased risk of developing transient ischemic deficits or strokes.

Less common abnormalities of blood vessels that may cause transient ischemic attacks include fibromuscular dysplasia, which affects particularly the cervical internal carotid artery; atherosclerosis of the aortic arch; inflammatory arterial disorders such as giant cell arteritis, systemic lupus erythematosus, polyarteritis, and granulomatous angiitis; and meningovascular syphilis. Hypotension may cause a reduction of cerebral blood flow if a major extracranial artery to the brain is markedly stenosed, but this is a rare cause of transient ischemic attack.

Hematologic causes of ischemic attacks include polycythemia, sickle cell disease, and hyperviscosity syndromes. Severe anemia may also lead to transient focal neurologic deficits in patients with preexisting cerebral arterial disease.

The **subclavian steal syndrome** may lead to transient vertebrobasilar ischemia. Symptoms develop when there is localized stenosis or occlusion of one subclavian artery proximal to the source of the vertebral artery, so that blood is “stolen” from this artery. A bruit in the supraclavicular fossa, unequal radial pulses, and a difference of 20 mm Hg or more between the systolic blood pressures in the arms should suggest the diagnosis in patients with vertebrobasilar transient ischemic attacks.

▶ Clinical Findings

A. Symptoms and Signs

The symptoms of transient ischemic attacks vary markedly among patients; however, the symptoms in a given individual tend to be constant in type. Onset is abrupt and without warning, and recovery usually occurs rapidly, often within a few minutes. The specific symptoms depend on the arterial distribution affected, as outlined in the subsequent section on stroke.

The natural history of attacks is variable. Some patients will have a major stroke after only a few attacks, whereas others may have frequent attacks for weeks or months without having a stroke. The risk of stroke is high in the

first 3 months after an attack, particularly in the first month and especially within the first 48 hours. Attacks may occur intermittently over a long period of time, or they may stop spontaneously. In general, carotid ischemic attacks are more liable than vertebrobasilar ischemic attacks to be followed by stroke. The stroke risk is greater in patients older than 60 years, in diabetics, or after transient ischemic attacks that last longer than 10 minutes and with symptoms or signs of weakness, speech impairment, or gait disturbance.

B. Imaging

CT or MRI scan is indicated within 24 hours of symptom onset, in part to exclude the possibility of a small cerebral hemorrhage or a cerebral tumor masquerading as a transient ischemic attack; MRI with diffusion-weighted sequences is particularly sensitive for revealing acute or subacute infarction. Noninvasive imaging of the cervical vasculature should also be performed. Carotid duplex ultrasonography is useful for detecting significant stenosis of the internal carotid artery, and MR or CT angiography permits broader visualization of cervical and intracranial vasculature. When noninvasive studies fail to reveal an etiology for transient ischemic attacks, conventional cerebral arteriography may be indicated. This technique is the gold standard for investigating the integrity of the cervical and cerebral vasculature, and allows for angioplasty or other interventions, if necessary.

C. Laboratory and Other Studies

Clinical and laboratory evaluation must include assessment for hypertension, heart disease, hematologic disorders, diabetes mellitus, hyperlipidemia, and peripheral vascular disease. It should include complete blood count, fasting blood glucose and serum cholesterol and homocysteine determinations, serologic tests for syphilis, and an ECG and chest radiograph. Echocardiography with bubble contrast is performed if a cardiac source is likely, and blood cultures are obtained if endocarditis is suspected. Holter monitoring is indicated if a transient, paroxysmal disturbance of cardiac rhythm is suspected.

Differential Diagnosis

Focal seizures usually cause abnormal motor or sensory phenomena such as clonic limb movements, paresthesias, or tingling, rather than weakness or loss of feeling. Symptoms generally spread (“march”) up the limb and may lead to a generalized tonic-clonic seizure.

Classic migraine is easily recognized by the visual premonitory symptoms, followed by nausea, headache, and photophobia, but less typical cases may be hard to distinguish. The patient’s age and medical history (including family history) may be helpful in this regard. Patients with migraine commonly have a history of episodes since adolescence and report that other family members have a similar disorder.

Focal neurologic deficits may occur during periods of hypoglycemia in diabetic patients receiving insulin or oral hypoglycemic agent therapy.

Treatment

Hospitalization should be considered for patients seen within 72 hours of the attack, when they are at increased risk for early recurrence. One commonly used method to assess recurrence risk is the ABCD² score; points are assigned for each of the following criteria: age 60 years or older (1 point), blood pressure $\geq 140/90$ mm Hg (1 point), clinical symptoms of focal weakness (2 points) or speech impairment without weakness (1 point), duration ≥ 60 minutes (2 points) or 10–59 minutes (1 point), or diabetes mellitus (1 point). An ABCD² score of 3 or more points has been suggested as a threshold for hospital admission. Admission is also advisable for patients with crescendo attacks, symptomatic carotid stenosis, or known cardiac source of emboli or hypercoagulable state; such hospitalization facilitates early intervention for any recurrence and rapid institution of secondary prevention measures. When arteriography reveals a surgically accessible high-grade stenosis (70–99% in luminal diameter) on the side appropriate to carotid ischemic attacks and there is relatively little atherosclerosis elsewhere in the cerebrovascular system, operative treatment (carotid endarterectomy) or endovascular intervention reduces the risk of ipsilateral carotid stroke, especially when transient ischemic attacks are of recent onset (<1 month). Some evidence suggests that transluminal angioplasty and stenting is inferior to aggressive medical management alone. There is a more moderate benefit for patients with 50–69% stenosis, and surgery is not indicated for mild stenosis (<50%); its benefits are unclear with severe stenosis plus diffuse intracranial atherosclerotic disease. In patients with carotid ischemic attacks who are poor operative candidates (and thus have not undergone arteriography) or who are found to have extensive vascular disease, medical treatment should be instituted. Similarly, patients with vertebrobasilar ischemic attacks are treated medically and are not subjected to arteriography unless there is clinical evidence of stenosis or occlusion in the carotid or subclavian arteries.

Medical treatment is aimed at preventing further attacks and stroke. Treat diabetes mellitus; hematologic disorders; and hypertension, preferably with an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker. Consider starting a statin medication regardless of the current low-density lipoprotein level; in addition to reducing stroke risk, antecedent statin use may improve the outcome if an ischemic stroke does occur. Cigarette smoking should be stopped, and cardiac sources of embolization should be treated appropriately. Weight reduction and regular physical activity should be encouraged when appropriate.

A. Embolization from the Heart

Cardioembolism, especially in the setting of atrial fibrillation, is an indication for anticoagulation as a preventive treatment for stroke. If anticoagulants are indicated for the treatment of embolism from the heart, they should be started immediately, provided that the area of cerebral infarct is small and there is no contraindication to their use. There is no advantage in delay, and the common fear of causing hemorrhage into a previously infarcted area is

misplaced, since there is a far greater risk of further embolism to the cerebral circulation if treatment is withheld. Treatment with warfarin sodium is introduced in a daily dose of 5–15 mg orally, then adjusted based on the international normalized ratio (INR). Warfarin is more effective than aspirin in reducing the incidence of cardioembolic events, but when its use is contraindicated, aspirin (325 mg daily orally) may be used in patients with nonrheumatic atrial fibrillation to reduce the risk of stroke. (See Chapter 14.) Compared with warfarin, the direct thrombin inhibitor dabigatran (150 mg twice daily) offers improved reduction of stroke risk, similar or lower risk of hemorrhage, easier dosing, and no requirement for monitoring.

B. Noncardioembolic Attacks

Treatment with low-dose aspirin (81 mg daily orally) significantly reduces the frequency of transient ischemic attacks and the incidence of stroke. For patients who continue to experience transient ischemic attacks on low-dose aspirin, higher doses of aspirin show no additional benefit. However, low-dose aspirin combined with sustained-release dipyridamole (200 mg twice daily orally) has been shown to be more effective in preventing stroke than aspirin alone. Clopidogrel (75 mg daily orally) alone is marginally more efficacious than aspirin alone; combining clopidogrel with aspirin is not clearly better than clopidogrel alone but does increase the risk of bleeding complications. Cilostazol, another antiplatelet medication, appears to offer similar efficacy at stroke prevention as aspirin, and possibly less risk of hemorrhage. Anticoagulant drugs are not recommended, as they offer no benefit over antiplatelet therapy, and the risk of serious hemorrhagic adverse effects is greater.

► When to Refer

All patients should be referred for urgent investigation and treatment to prevent stroke.

► When to Admit

If seen within 72 hours of a transient ischemic attack, patients should be considered for admission when they have an ABCD² score of 3 points or more, when outpatient evaluation is impractical, or when there are crescendo attacks or other concern for early recurrence or stroke.

Chimowitz MI et al; SAMMPRIS Trial Investigators. Stenting versus aggressive medical therapy for intracranial arterial stenosis. *N Engl J Med.* 2011 Sep 15;365(11):993–1003. [PMID: 21899409]

Connolly SJ et al; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. *N Engl J Med.* 2009 Sep 17;361(12):1139–51. [PMID: 19717844]

Easton JD et al. Definition and evaluation of transient ischemic attack. *Stroke.* 2009 Jun;40(6):2276–93. [PMID: 19423857]

Ederle J et al. Endovascular treatment with angioplasty or stenting versus endarterectomy in patients with carotid artery stenosis in the Carotid and Vertebral Artery Transluminal Angioplasty Study (CAVATAS): long-term follow-up of a randomized trial. *Lancet Neurol.* 2009 Oct;8(10):898–907. [PMID: 19717345]

Hankey GJ et al. Antithrombotic drugs for patients with ischemic stroke and transient ischaemic attack to prevent recurrent major vascular events. *Lancet Neurol.* 2010 Mar;9(3):273–84. [PMID: 20170841]

Olivot JM et al. Diffusion-perfusion MRI for triaging transient ischemic attack and acute cerebrovascular syndromes. *Curr Opin Neurol.* 2011 Feb;24(1):44–9. [PMID: 21157338]

Shinohara Y et al. Cilostazol for prevention of secondary stroke (CSPS 2): an aspirin-controlled, double-blind, randomised non-inferiority trial. *Lancet Neurol.* 2010 Oct;9(10):959–68. [PMID: 20833591]

Tsivgoulis G et al. Multicenter external validation of the ABCD² score in triaging TIA patients. *Neurology.* 2010 Apr 27;74(17):1351–7. [PMID: 20421579]

STROKE



ESSENTIALS OF DIAGNOSIS

- Sudden onset of characteristic neurologic deficit.
- Patient often has history of hypertension, diabetes mellitus, valvular heart disease, or atherosclerosis.
- Distinctive neurologic signs reflect the region of the brain involved.

► General Considerations

In the United States, stroke remains the third leading cause of death, despite a general decline in the incidence of stroke in the last 30 years. The precise reasons for this decline are uncertain, but increased awareness of risk factors (hypertension, diabetes mellitus, hyperlipidemia, cigarette smoking, cardiac disease, AIDS, recreational drug abuse, heavy alcohol consumption, family history of stroke) and improved prophylactic measures and surveillance of those at increased risk have been contributory. Elevation of the blood homocysteine level is also a risk factor for stroke, but it is unclear whether this risk is reduced by treatment to lower the level. A previous stroke makes individual patients more susceptible to additional strokes.

For years, strokes have been subdivided pathologically into infarcts (thrombotic or embolic) and hemorrhages, and clinical criteria for distinguishing between these possibilities have been emphasized. However, it is often difficult to determine on clinical grounds the pathologic basis for stroke (Table 24–4).

1. Lacunar Infarction

Lacunar infarcts are small lesions (usually <5 mm in diameter) that occur in the distribution of short penetrating arterioles in the basal ganglia, pons, cerebellum, internal capsule, thalamus and, less commonly, the deep cerebral white matter. Lacunar infarcts are associated with poorly controlled hypertension or diabetes and have been found in several clinical syndromes, including contralateral pure motor or pure sensory deficit, ipsilateral ataxia with crural paresis, and dysarthria with clumsiness of the hand. The neurologic deficit may progress over 24–36 hours before stabilizing.

Table 24-4. Features of the major stroke subtypes.

Stroke Type and Subtype	Clinical Features	Diagnosis	Treatment
Ischemic stroke			
Lacunar infarct	Small (< 5 mm) lesions in the basal ganglia, pons, cerebellum, or internal capsule; less often in deep cerebral white matter; prognosis generally good; clinical features depend on location, but may worsen over first 24-36 hours.	MRI with diffusion-weighted sequences usually defines the area of infarction; CT is insensitive acutely but can be used to exclude hemorrhage.	Aspirin; long-term management is to control risk factors (hypertension and diabetes mellitus).
Carotid circulation obstruction	See text—signs vary depending on occluded vessel.	Noncontrast CT to exclude hemorrhage but findings may be normal during first 6-24 hours of an ischemic stroke; diffusion-weighted MRI is gold standard for identifying acute stroke; electrocardiography, echocardiography, blood glucose, complete blood count, and tests for hypercoagulable states, hyperlipidemia are indicated; Holter monitoring in selected instances; carotid duplex studies, CTA, MRA, or conventional angiography in selected cases.	Select patients for intravenous thrombolytics or intra-arterial mechanical thrombolysis; aspirin is first-line therapy; anticoagulation with heparin for cardioembolic strokes when no contraindications exist.
Vertebrobasilar occlusion	See text—signs vary based on location of occluded vessel.	As for carotid circulation obstruction.	As for carotid circulation obstruction.
Hemorrhagic stroke			
Spontaneous intracerebral hemorrhage	Commonly associated with hypertension; also with bleeding disorders, amyloid angiopathy. Hypertensive hemorrhage is located commonly in the basal ganglia and less commonly in the pons, thalamus, cerebellum, or cerebral white matter.	Noncontrast CT is superior to MRI for detecting bleeds of < 48 hours duration; laboratory tests to identify bleeding disorder: angiography may be indicated to exclude aneurysm or AVM. Do not perform lumbar puncture.	Most managed supportively, but cerebellar bleeds or hematomas with gross mass effect may require urgent surgical evacuation.
Subarachnoid hemorrhage	Present with sudden onset of worst headache of life, may lead rapidly to loss of consciousness; signs of meningeal irritation often present; etiology usually aneurysm or AVM, but 20% have no source identified.	CT to confirm diagnosis, but may be normal in rare instances; if CT negative and suspicion high, perform lumbar puncture to look for red blood cells or xanthochromia; angiography to determine source of bleed in candidates for treatment.	See sections on AVM and aneurysm.
Intracranial aneurysm	Most located in the anterior circle of Willis and are typically asymptomatic until subarachnoid bleed occurs; 20% rebleed in first 2 weeks.	CT indicates subarachnoid hemorrhage, and angiography then demonstrates aneurysms; angiography may not reveal aneurysm if vasospasm present.	Prevent further bleeding by clipping aneurysm or coil embolization; nimodipine helps prevent vasospasm; reverse vasospasm by intravenous fluids and induced hypertension after aneurysm has been obliterated, if no other aneurysms are present; angioplasty may also reverse symptomatic vasospasm.
AVMs	Focal deficit from hematoma or AVM itself.	CT reveals bleed, and may reveal the AVM; may be seen by MRI. Angiography demonstrates feeding vessels and vascular anatomy.	Surgery indicated if AVM has bled or to prevent further progression of neurologic deficit; other modalities to treat nonoperable AVMs are available at specialized centers.

AVMs, arteriovenous malformations; CTA, computed tomography angiography; MRA, magnetic resonance angiography.

Lacunar infarcts are sometimes visible on CT scans as small, punched-out, hypodense areas, but in other patients no abnormality is seen. In some instances, patients with a clinical syndrome suggestive of lacunar infarction are found on CT scanning to have a severe hemispheric infarct. Diffusion-weighted MRI is sensitive to acute lesions, which later evolve into areas of T2 hyperintensity and eventually into small, punched-out, cerebrospinal fluid-filled spaces.

Early mortality and risk of stroke recurrence is higher for patients with nonlacunar than lacunar infarcts. The prognosis for recovery from the deficit produced by a lacunar infarct is usually good, with partial or complete resolution occurring over the following 4–6 weeks in many instances.

Donnan GA et al. Lacunes and lacunar syndromes. *Handb Clin Neurol*. 2008;93:559–75. [PMID: 18804668]

2. Cerebral Infarction

Thrombotic or embolic occlusion of a major vessel leads to cerebral infarction. Causes include the disorders predisposing to transient ischemic attacks (see above) and atherosclerosis of cerebral arteries. The resulting deficit depends on the particular vessel involved and the extent of any collateral circulation. Cerebral ischemia leads to release of excitatory and other neuropeptides that may augment calcium flux into neurons, thereby leading to cell death and increasing the neurologic deficit.

► Clinical Findings

A. Symptoms and Signs

Onset is usually abrupt, and there may then be very little progression except that due to brain swelling. Clinical evaluation should always include examination of the heart and auscultation over the subclavian and carotid vessels to determine whether there are any bruits.

1. Obstruction of carotid circulation—Occlusion of the ophthalmic artery is probably symptomless in most cases because of the rich orbital collaterals, but its transient embolic obstruction can lead to amaurosis fugax—sudden and brief loss of vision in one eye.

Occlusion of the anterior cerebral artery distal to its junction with the **anterior communicating artery** causes weakness and cortical sensory loss in the contralateral leg and sometimes mild weakness of the arm, especially proximally. There may be a contralateral grasp reflex, paratonic rigidity, and abulia (lack of initiative) or frank confusion. Urinary incontinence is not uncommon, particularly if behavioral disturbances are conspicuous. Bilateral anterior cerebral infarction is especially likely to cause marked behavioral changes and memory disturbances. Unilateral anterior cerebral artery occlusion proximal to the junction with the anterior communicating artery is generally well tolerated because of the collateral supply from the other side.

Middle cerebral artery occlusion leads to contralateral hemiplegia, hemisensory loss, and homonymous hemianopia (ie, bilaterally symmetric loss of vision in half of the visual

fields), with the eyes deviated to the side of the lesion. If the dominant hemisphere is involved, global aphasia is also present. It may be impossible to distinguish this clinically from occlusion of the internal carotid artery. With occlusion of either of these arteries, there may also be considerable swelling of the hemisphere, leading to drowsiness, stupor, and coma in extreme cases. Occlusions of different branches of the middle cerebral artery cause more limited findings. For example, involvement of the anterior main division leads to a predominantly expressive dysphasia and to contralateral paralysis and loss of sensations in the arm, the face and, to a lesser extent, the leg. Posterior branch occlusion produces a receptive (Wernicke) aphasia and a homonymous visual field defect. With involvement of the nondominant hemisphere, speech and comprehension are preserved, but there may be a left hemispatial neglect syndrome or constructional and visuospatial deficits.

2. Obstruction of vertebrobasilar circulation—Occlusion of the **posterior cerebral artery** may lead to a thalamic syndrome in which contralateral hemisensory disturbance occurs, followed by the development of spontaneous pain and hyperpathia. There is often a macular-sparing homonymous hemianopia and sometimes a mild, usually temporary, hemiparesis. Depending on the site of the lesion and the collateral circulation, the severity of these deficits varies and other deficits may also occur, including involuntary movements and alexia. Occlusion of the main artery beyond the origin of its penetrating branches may lead solely to a macular-sparing hemianopia.

Vertebral artery occlusion distally, below the origin of the anterior spinal and posterior inferior cerebellar arteries, may be clinically silent because the circulation is maintained by the other vertebral artery. If the remaining vertebral artery is congenitally small or severely atherosclerotic, however, a deficit similar to that of basilar artery occlusion is seen unless there is good collateral circulation from the anterior circulation through the circle of Willis. When the small paramedian arteries arising from the vertebral artery are occluded, contralateral hemiplegia and sensory deficit occur in association with an ipsilateral cranial nerve palsy at the level of the lesion. An obstruction of the **posterior inferior cerebellar artery** or an obstruction of the vertebral artery just before it branches to this vessel leads to ipsilateral spinothalamic sensory loss involving the face, ninth and tenth cranial nerve lesions, limb ataxia and numbness, and Horner syndrome, combined with contralateral spinothalamic sensory loss involving the limbs.

Occlusion of both **vertebral arteries** or the **basilar artery** leads to coma with pinpoint pupils, flaccid quadriplegia and sensory loss, and variable cranial nerve abnormalities. With partial basilar artery occlusion, there may be diplopia, visual loss, vertigo, dysarthria, ataxia, weakness or sensory disturbances in some or all of the limbs, and discrete cranial nerve palsies. In patients with hemiplegia of pontine origin, the eyes are often deviated to the paralyzed side, whereas in patients with a hemispheric lesion, the eyes commonly deviate from the hemiplegic side.

Occlusion of any of the major **cerebellar arteries** produces vertigo, nausea, vomiting, nystagmus, ipsilateral limb ataxia, and contralateral spinothalamic sensory loss in the

limbs. If the superior cerebellar artery is involved, the contralateral spinothalamic loss also involves the face; with occlusion of the anterior inferior cerebellar artery, there is ipsilateral spinothalamic sensory loss involving the face, usually in conjunction with ipsilateral facial weakness and deafness. Massive cerebellar infarction may lead to coma, tonsillar herniation, and death.

3. Coma—Infarction in either the carotid or vertebrobasilar territory may lead to loss of consciousness. For example, an infarct involving one cerebral hemisphere may lead to such swelling that the function of the other hemisphere or the rostral brainstem is disturbed and coma results. Similarly, coma occurs with bilateral brainstem infarction when this involves the reticular formation, and it occurs with brainstem compression after cerebellar infarction.

B. Imaging

A CT scan of the head (without contrast) should be performed immediately, before the administration of aspirin or other antithrombotic agents, to exclude cerebral hemorrhage. CT is relatively insensitive to acute ischemic stroke, and subsequent MRI with diffusion-weighted sequences should be performed to define the distribution and extent of infarction as well as to exclude tumor or other differential considerations. Perfusion-weighted MRI sequences can be useful for outlining any additional areas at risk for infarction, thus guiding treatment decisions; specific guidelines are still being determined. Imaging of the cervical vasculature is indicated as part of a search to identify the source of the stroke.

C. Laboratory and Other Studies

Investigations should include a complete blood count, erythrocyte sedimentation rate, blood glucose determination, and serologic tests for syphilis. Screening for antiphospholipid antibodies (lupus anticoagulants and anticardiolipin antibodies); the factor V Leiden mutation; abnormalities of protein C, protein S, or antithrombin; or a prothrombin gene mutation is indicated if a hypercoagulable disorder is suspected (eg, a young patient without apparent risk factors for stroke). Similarly, elevated serum cholesterol and lipids and serum homocysteine may indicate an increased risk of thrombotic stroke. Electrocardiography or continuous cardiac monitoring for at least 24 hours will help exclude a recent myocardial infarction or a cardiac arrhythmia that might be serving as a source of embolization. Blood cultures should be performed if endocarditis is suspected, echocardiography (bubble contrast study) if heart disease—especially valvular disease, left-to-right shunting, or cardiac thrombus—is a concern, and Holter monitoring if paroxysmal cardiac arrhythmia requires exclusion. Examination of the cerebrospinal fluid is not always necessary but may be helpful if cerebral vasculitis or another inflammatory or infectious cause of stroke is suspected, but it should be delayed until after CT or MRI to exclude any risk for herniation due to mass effect.

▶ Treatment

Prophylactic measures were considered earlier in discussing transient ischemic attacks. The management of acute

stroke should be in a stroke care unit, when feasible. Intravenous thrombolytic therapy with recombinant tissue plasminogen activator (rtPA; 0.9 mg/kg to a maximum of 90 mg, with 10% given as a bolus over 1 minute and the remainder over 1 hour) is effective in reducing the neurologic deficit in selected patients without CT evidence of intracranial hemorrhage when administered as soon as possible, but not more than 4.5 hours after the onset of ischemic symptoms. Treatment within 3 hours has the strongest evidence for benefit (and has FDA approval), but more recent data suggest that extending the treatment window to 4.5 hours still results in reduced disability at 90 days. Based on those data and the recommendations of professional societies, many emergency hospitals have adopted this longer treatment window. Recent hemorrhage, increased risk of hemorrhage (eg, treatment with anticoagulants), arterial puncture at a noncompressible site, and systolic pressure >185 mm Hg or diastolic pressure >110 mm Hg are among the contraindications to this treatment. In selected patients with thrombotic stroke, percutaneous procedures, including endovascular intra-arterial rtPA administration or mechanical removal of an embolus or clot from an occluded cerebral artery using an intra-arterial mechanical thrombolytic device, are also effective relative to non-thrombolytic medical treatment, despite an increased risk of intracranial hemorrhage; it is not clear how these invasive approaches compare to intravenous thrombolytic therapy.

Early management of a completed stroke otherwise requires general supportive measures. During the acute stage, there may be marked brain swelling and edema, with symptoms and signs of increasing intracranial pressure, an increasing neurologic deficit, or herniation syndrome. Elevated intracranial pressure is managed by head elevation and osmotic agents such as mannitol. Maintenance of an adequate cerebral perfusion pressure helps prevent further ischemia. Decompressive hemicraniectomy for malignant middle cerebral artery infarctions may reduce mortality and improve functional outcome in some instances. Attempts to lower the blood pressure of hypertensive patients during the acute phase (ie, within 2 weeks) of a stroke should generally be avoided, as there is loss of cerebral autoregulation, and lowering the blood pressure may further compromise ischemic areas. However, if the systolic pressure exceeds 220 mm Hg, it can be lowered using intravenous labetalol or nicardipine with continuous monitoring to 170–200 mm Hg and then, after 2 weeks, it can be reduced further to <140/90 mm Hg.

In patients not eligible for thrombolytic therapy, and in whom hemorrhage has been excluded by CT, the immediate administration of aspirin 325 mg orally daily is indicated. Anticoagulant drugs should be started in the setting of atrial fibrillation or other source of cardioembolism. Treatment is with warfarin (target INR 2.0–3.0) or dabigatran (150 mg twice daily). If the CT scan shows no evidence of hemorrhage and the cerebrospinal fluid is clear, anticoagulant treatment may be started without delay.

Physical therapy has an important role in the management of patients with impaired motor function. Passive movements at an early stage will help prevent contractures.

As cooperation increases and some recovery begins, active movements will improve strength and coordination. In all cases, early mobilization and active rehabilitation are important. Occupational therapy may improve morale and motor skills, while speech therapy may be beneficial in patients with expressive dysphasia or dysarthria. Because of the risk for dysphagia following stroke, access to food and drink is typically restricted until an appropriate swallowing evaluation. When there is a severe and persisting motor deficit, a device such as a leg brace, toe spring, frame, or cane may help the patient move about, and the provision of other aids to daily living may improve the quality of life.

► Prognosis

The prognosis for survival after cerebral infarction is better than after cerebral or subarachnoid hemorrhage. The only proved effective therapy for acute stroke requires initiation within 3–4.5 hours after stroke onset, and the prognosis therefore depends on the time that elapses before arrival at the hospital. Patients receiving such treatment with rtPA are at least 30% more likely to have minimal or no disability at 3 months than those not treated by this means. Loss of consciousness after a cerebral infarct implies a poorer prognosis than otherwise. The extent of the infarct governs the potential for rehabilitation. Patients who have had a cerebral infarct are at risk for additional strokes and for myocardial infarcts. Statin therapy to lower serum lipid levels may reduce this risk. Antiplatelet therapy reduces the recurrence rate by 30% among patients without a cardiac cause for the stroke who are not candidates for carotid endarterectomy. Nevertheless, the cumulative risk of recurrence of noncardioembolic stroke is still 3–7% annually.

Patients with massive strokes from which meaningful recovery is unlikely should receive palliative care (see Chapter 5).

► When to Refer

All patients should be referred.

► When to Admit

All patients should be hospitalized, preferably in a stroke care unit.

Amarenco P et al; SPARCL Investigators. Relative and cumulative effects of lipid and blood pressure control in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels trial. *Stroke*. 2009 Jul;40(7):2486–92. [PMID: 19461031]

Biffi A et al. Statin treatment and functional outcome after ischemic stroke: case-control and meta-analysis. *Stroke*. 2011 May;42(5):1314–9. [PMID: 21415396]

Ederle J et al; CAVATAS collaborators. Long-term outcome of endovascular treatment versus medical care for carotid artery stenosis in patients not suitable for surgery and randomised in the Carotid and Vertebral Artery Transluminal Angioplasty study (CAVATAS). *Cerebrovasc Dis*. 2009;28(1):1–7. [PMID: 19420915]

Ferro JM et al. Aetiological diagnosis of ischaemic stroke in young adults. *Lancet Neurol*. 2010 Nov;9(11):1085–96. [PMID: 20965437]

Hofmeijer J et al; HAMLET investigators. Surgical decompression for space-occupying cerebral infarction (the Hemicraniectomy After Middle Cerebral Artery infarction with Life-threatening Edema Trial [HAMLET]): a multicentre, open, randomised trial. *Lancet Neurol*. 2009 Apr;8(4):326–33. [PMID: 19269254]

Lansberg MG et al. Efficacy and safety of tissue plasminogen activator 3 to 4.5 hours after acute ischemic stroke: a meta-analysis. *Stroke*. 2009 Jul;40(7):2438–41. [PMID: 19478213]

O'Donnell MJ et al. Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study. *Lancet*. 2010 Jul 10;376(9735):112–23. [PMID: 20561675]

O'Rourke K et al. Percutaneous vascular interventions for acute ischaemic stroke. *Cochrane Database Syst Rev*. 2010 Oct 6;(10):CD007574. [PMID: 20927761]

3. Intracerebral Hemorrhage

Spontaneous, nontraumatic intracerebral hemorrhage in patients with no angiographic evidence of an associated vascular anomaly (eg, aneurysm or angioma) is usually due to hypertension. The pathologic basis for hemorrhage is probably the presence of microaneurysms that develop on perforating vessels in hypertensive patients. Hypertensive intracerebral hemorrhage occurs most frequently in the basal ganglia and less commonly in the pons, thalamus, cerebellum, and cerebral white matter. Hemorrhage may extend into the ventricular system or subarachnoid space, and signs of meningeal irritation are then found. Hemorrhages usually occur suddenly and without warning, often during activity. In the elderly, cerebral amyloid angiopathy is another important and frequent cause of hemorrhage, which is usually lobar in distribution, sometimes recurrent, and associated with a better prognosis than hypertensive hemorrhage.

Other causes of nontraumatic intracerebral hemorrhage include hematologic and bleeding disorders (eg, leukemia, thrombocytopenia, hemophilia, or disseminated intravascular coagulation), anticoagulant therapy, liver disease, high alcohol intake, and primary or secondary brain tumors. There is also an association with advancing age and male sex. Bleeding is primarily into the subarachnoid space when it occurs from an intracranial aneurysm or arteriovenous malformation (see below), but it may be partly intraparenchymal as well. In some cases, no specific cause for cerebral hemorrhage can be identified.

► Clinical Findings

A. Symptoms and Signs

With hemorrhage into the cerebral hemisphere, consciousness is initially lost or impaired in about one-half of patients. Vomiting occurs very frequently at the onset of bleeding, and headache is sometimes present. Focal symptoms and signs then develop, depending on the site of the hemorrhage. With hypertensive hemorrhage, there is generally a rapidly evolving neurologic deficit with hemiplegia or hemiparesis. A hemisensory disturbance is also present with more deeply placed lesions. With lesions of the putamen, loss of conjugate lateral gaze may be conspicuous. With thalamic hemorrhage, there may be a loss of upward gaze, downward or skew deviation of the eyes, lateral gaze palsies, and pupillary inequalities.

Cerebellar hemorrhage may present with sudden onset of nausea and vomiting, dysequilibrium, headache, and loss of consciousness that may terminate fatally within 48 hours. Less commonly, the onset is gradual and the course episodic or slowly progressive—clinical features suggesting an expanding cerebellar lesion. In yet other cases, however, the onset and course are intermediate, and examination shows lateral conjugate gaze palsies to the side of the lesion; small reactive pupils; contralateral hemiplegia; peripheral facial weakness; ataxia of gait, limbs, or trunk; periodic respiration; or some combination of these findings.

B. Imaging

CT scanning (without contrast) is important not only in confirming that hemorrhage has occurred but also in determining the size and site of the hematoma. It is superior to MRI for detecting intracranial hemorrhage of < 48 hours duration. If the patient's condition permits further intervention, CT angiography, MR angiography, or cerebral angiography may be undertaken thereafter to determine whether an aneurysm or arteriovenous malformation is present (see below). Follow-up imaging during the hospitalization may reveal hematoma expansion, a predictor of poor outcome.

C. Laboratory and Other Studies

A complete blood count, platelet count, bleeding time, prothrombin and partial thromboplastin times, and liver and kidney function tests may reveal a predisposing cause for the hemorrhage. Lumbar puncture is contraindicated because it may precipitate a herniation syndrome in patients with a large hematoma, and CT scanning is superior in detecting intracerebral hemorrhage.

▶ Treatment

Neurologic management is generally conservative and supportive, regardless of whether the patient has a profound deficit with associated brainstem compression, in which case the prognosis is grim, or a more localized deficit not causing increased intracranial pressure or brainstem involvement. Such therapy may include ventilatory support, blood pressure regulation, seizure prophylaxis, control of fever, osmotherapy, and nutritional supplementation. Intracranial pressure may require monitoring. Ventricular drainage may be required in patients with intraventricular hemorrhage and acute hydrocephalus. Decompression may be helpful when a superficial hematoma in cerebral white matter is exerting a mass effect and causing incipient herniation. In patients with cerebellar hemorrhage, prompt surgical evacuation of the hematoma is appropriate, because spontaneous unpredictable deterioration may otherwise lead to a fatal outcome and because operative treatment may lead to complete resolution of the clinical deficit. The treatment of underlying structural lesions or bleeding disorders depends on their nature. Hemostatic therapy with recombinant activated factor VII has not improved survival or functional outcome. There is no specific treatment for cerebral amyloid angiopathy.

▶ When to Refer

All patients should be referred.

▶ When to Admit

All patients should be hospitalized.

Biffi A et al. Statin use and outcome after intracerebral hemorrhage: case-control study and meta-analysis. *Neurology*. 2011 May 3;76(18):1581–8. [PMID: 21451150]
 Dowlatsahi D et al. Defining hematoma expansion in intracerebral hemorrhage: relationship with patient outcomes. *Neurology*. 2011 Apr 5;76(14):1238–44. [PMID: 21346218]
 Fischbein NJ et al. Nontraumatic intracranial hemorrhage. *Neuroimaging Clin N Am*. 2010 Nov;20(4):469–92. [PMID: 20974372]
 Runchey S et al. Does this patient have a hemorrhagic stroke?: clinical findings distinguishing hemorrhagic stroke from ischemic stroke. *JAMA*. 2010 Jun 9;303(22):2280–6. [PMID: 20530782]

4. Spontaneous Subarachnoid Hemorrhage

ESSENTIALS OF DIAGNOSIS

- ▶ Sudden severe headache.
- ▶ Signs of meningeal irritation usually present.
- ▶ Obtundation is common.
- ▶ Focal deficits frequently absent.

▶ General Considerations

Between 5% and 10% of strokes are due to subarachnoid hemorrhage. Trauma is the most common cause of subarachnoid hemorrhage, the prognosis of which depends on the severity of the head injury. Spontaneous (nontraumatic) subarachnoid hemorrhage frequently results from the rupture of an arterial saccular (“berry”) aneurysm or from an arteriovenous malformation. Occasional patients with aneurysms have headaches, sometimes accompanied by nausea and neck stiffness, a few hours or days before massive subarachnoid hemorrhage occurs. This has been attributed to “warning leaks” of a small amount of blood from the aneurysm.

▶ Clinical Findings

A. Symptoms and Signs

Subarachnoid hemorrhage has a characteristic clinical picture. Its onset is with sudden headache of a severity never experienced previously by the patient. This may be followed by nausea and vomiting and by a loss or impairment of consciousness that can either be transient or progress inexorably to deepening coma and death. If consciousness is regained, the patient is often confused and irritable and may show other symptoms of an altered mental status. Neurologic examination generally reveals nuchal rigidity and other signs of meningeal irritation, except in deeply comatose patients.

Aneurysms may cause a focal neurologic deficit by compressing adjacent structures. However, most are asymptomatic or produce only nonspecific symptoms until they rupture, at which time subarachnoid hemorrhage results. A higher risk of subarachnoid hemorrhage is associated with older age, female sex, “nonwhite” ethnicity, hypertension, tobacco smoking, high alcohol consumption (exceeding 150 g per week), previous symptoms, posterior circulation aneurysms, and larger aneurysms. Focal neurologic signs are usually absent but, when present, may relate either to a focal intracerebral hematoma (from arteriovenous malformations) or to ischemia in the territory of the vessel with a ruptured aneurysm.

B. Imaging

A CT scan (preferably with CT angiography) should be performed immediately to confirm that hemorrhage has occurred and to search for clues regarding its source. It is preferable to MRI because it is faster and more sensitive in detecting hemorrhage in the first 24 hours. CT findings sometimes are normal in patients with suspected hemorrhage, and the cerebrospinal fluid must then be examined for the presence of blood or xanthochromia before the possibility of subarachnoid hemorrhage is discounted.

Cerebral arteriography is undertaken to determine the source of bleeding. In general, bilateral carotid and vertebral arteriography are necessary because aneurysms are often multiple, while arteriovenous malformations may be supplied from several sources. The procedure allows an interventional radiologist to treat an underlying aneurysm or arteriovenous malformation by various techniques. If arteriograms show no abnormality, the examination should be repeated after 2 weeks because vasospasm or thrombus may have prevented detection of an aneurysm or other vascular anomaly during the initial study. CT or MR angiography may also be revealing but is less sensitive than conventional arteriography.

C. Laboratory and Other Studies

The cerebrospinal fluid is bloodstained. Electrocardiographic evidence of arrhythmias or myocardial ischemia has been well described and probably relates to excessive sympathetic activity. Peripheral leukocytosis and transient glycosuria are also common findings.

► Treatment

All patients should be admitted to hospital and seen by a neurologist. The measures outlined below in the section on stupor and coma are applied to comatose patients. Conscious patients are confined to bed, advised against any exertion or straining, treated symptomatically for headache and anxiety, and given laxatives or stool softeners. If there is severe hypertension, the blood pressure can be lowered gradually, but not below a diastolic level of 100 mm Hg. Phenytoin is generally prescribed routinely to prevent seizures. If no cause for the hemorrhage can be identified, medical management is continued for about 6 weeks and is followed by gradual mobilization.

The major aim of treatment is to prevent further hemorrhage. The risk of further hemorrhage from a ruptured aneurysm is greatest within a few days of the first hemorrhage; approximately 20% of patients will have further bleeding within 2 weeks and 40% within 6 months. Definitive treatment, ideally within 2 days of the hemorrhage, requires surgical clipping of the aneurysm base or endovascular treatment by interventional radiologists; the latter is sometimes feasible even for inoperable aneurysms and has a lower morbidity than surgery.

► Complications

Spontaneous subarachnoid hemorrhage may result in severe complications, so monitoring is necessary, usually in an intensive care unit. Intrathecal thrombolytic therapy, presumably by speeding clearance of extravasated blood, appears to reduce the rate of these complications. Hemiplegia or other focal deficit sometimes may follow aneurysmal bleeding after a delay of 2–14 days due to focal arterial spasm. The etiology of vasospasm is uncertain and likely multifactorial, and it sometimes leads to significant cerebral ischemia or infarction and may further aggravate any existing increase in intracranial pressure. Transcranial Doppler ultrasound may be used to screen noninvasively for vasospasm, but conventional arteriography is required to document and treat vasospasm when the clinical suspicion is high. Calcium channel-blocking agents have helped reduce or reverse vasospasm experimentally, and nimodipine has been shown to reduce, in neurologically normal patients, the incidence of ischemic deficits from arterial spasm without producing any side effects. The dose of nimodipine is 60 mg every 4 hours orally for 21 days. Clazosentan, an endothelin receptor antagonist, has failed to affect vasospasm-related morbidity or mortality; the drug has not yet been approved by the US FDA. After surgical obliteration of all aneurysms, symptomatic vasospasm may also be treated by intravascular volume expansion and induced hypertension; transluminal balloon angioplasty of involved intracranial vessels is also helpful. Aspirin provides no benefit. Results from a randomized trial suggest that the prophylactic administration of intravenous magnesium sulfate, sufficient to achieve serum levels of 4.9–6.1 mg/dL (2–2.5 mmol/L), reduced the risk of transcranial ultrasound-detectable vasospasm and of vasospasm-induced cerebral infarction but did not change overall clinical outcomes.

Acute hydrocephalus, which sometimes occurs due to cerebrospinal fluid outflow disruption by the subarachnoid blood, should be suspected if the patient deteriorates clinically and a repeat CT scan should be done. Acute hydrocephalus frequently causes intracranial hypertension severe enough to require temporary, and less commonly prolonged or permanent, intraventricular cerebrospinal fluid shunting. Renal salt-wasting is another complication of subarachnoid hemorrhage that may develop abruptly during the first several days of hospitalization. The resulting hyponatremia and cerebral edema may exacerbate intracranial hypertension and may require carefully titrated treatment with oral sodium chloride or intravenous hyperosmotic sodium solution. Daily measurement of the serum

sodium level allows for the early detection of this complication. Hypopituitarism may occur as a late complication of subarachnoid hemorrhage.

Kramer AH et al. Locally-administered intrathecal thrombolytics following aneurysmal subarachnoid hemorrhage: a systematic review and meta-analysis. *Neurocrit Care*. 2011 Jun;14(3):489–99. [PMID: 20740327]

Kronvall E et al. Nimodipine in aneurysmal subarachnoid hemorrhage: a randomized study of intravenous or peroral administration. *J Neurosurg*. 2009 Jan;110(1):58–63. [PMID: 18847340]

Macdonald RL et al. Clazosentan, an endothelin receptor antagonist, in patients with aneurysmal subarachnoid haemorrhage undergoing surgical clipping: a randomised, double-blind, placebo-controlled phase 3 trial (CONSCIOUS-2). *Lancet Neurol*. 2011 Jul;10(7):618–25.

Mahaney KB et al. Variation of patient characteristics, management, and outcome with timing of surgery for aneurysmal subarachnoid hemorrhage. *J Neurosurg*. 2011 Apr;114(4):1045–53. [PMID: 21250801]

Rabinstein AA et al. Multidisciplinary management and emerging therapeutic strategies in aneurysmal subarachnoid haemorrhage. *Lancet Neurol*. 2010 May;9(5):504–19. [PMID: 20398858]

Westermaier T et al. Prophylactic intravenous magnesium sulfate for treatment of aneurysmal subarachnoid hemorrhage: a randomized, placebo-controlled, clinical study. *Crit Care Med*. 2010 May;38(5):1284–90. [PMID: 20228677]

5. Intracranial Aneurysm



ESSENTIALS OF DIAGNOSIS

- ▶ Subarachnoid hemorrhage or focal deficit.
- ▶ Abnormal imaging studies.

▶ General Considerations

Saccular aneurysms (“berry” aneurysms) tend to occur at arterial bifurcations, are frequently multiple (20% of cases), and are usually asymptomatic. They may be associated with polycystic kidney disease and coarctation of the aorta. Risk factors for aneurysm formation include smoking, hypertension, and hypercholesterolemia. Most aneurysms are located on the anterior part of the circle of Willis—particularly on the anterior or posterior communicating arteries, at the bifurcation of the middle cerebral artery, and at the bifurcation of the internal carotid artery. Mycotic aneurysms resulting from septic embolism occur in more distal vessels and often at the cortical surface. The most significant complication of intracranial aneurysms is a subarachnoid hemorrhage, which is discussed in the preceding section. A higher risk of subarachnoid hemorrhage is associated with older age, female sex, “non-white” ethnicity, hypertension, tobacco smoking, high alcohol consumption (exceeding 150 g per week), previous symptoms, posterior circulation aneurysms, and larger aneurysms.

▶ Clinical Findings

A. Symptoms and Signs

Aneurysms may cause a focal neurologic deficit by compressing adjacent structures. However, most are asymptomatic or produce only nonspecific symptoms until they rupture, at which time subarachnoid hemorrhage results. Its manifestations, complications, and management were outlined in the preceding section.

B. Imaging

Definitive evaluation is by angiography (bilateral carotid and vertebral studies), which generally indicates the size and site of the lesion, sometimes reveals multiple aneurysms, and may show arterial spasm if rupture has occurred. Visualization by CT or MR angiography is not usually adequate if operative treatment is under consideration because lesions may be multiple and small lesions are sometimes missed.

▶ Treatment

The major aim of treatment is to prevent hemorrhages. Management of ruptured aneurysms was described in the section on subarachnoid hemorrhage. Symptomatic but unruptured aneurysms merit prompt treatment, either surgically or by endovascular techniques, whereas small asymptomatic ones discovered incidentally are often monitored arteriographically and corrected only if they increase in size to over 10 mm.

▶ When to Refer

All patients should be referred.

▶ When to Admit

- All patients with a subarachnoid hemorrhage.
- All patients for detailed imaging.
- All patients undergoing surgical or endovascular treatment.

Clarke M. Systematic review of reviews of risk factors for intracranial aneurysms. *Neuroradiology*. 2008 Aug;50(8):653–64. [PMID: 18560819]

Ducruet AF et al. Intracranial infectious aneurysms: a comprehensive review. *Neurosurg Rev*. 2010 Jan;33(1):37–46. [PMID: 19838745]

Ferns SP et al. De novo aneurysm formation and growth of untreated aneurysms: a 5-year MRA follow-up in a large cohort of patients with coiled aneurysms and review of the literature. *Stroke*. 2011 Feb;42(2):313–8. [PMID: 21164110]

Pritz MB. Cerebral aneurysm classification based on angioarchitecture. *J Stroke Cerebrovasc Dis*. 2011 Mar–Apr;20(2):162–7. [PMID: 20621522]

Raja PV et al. Microsurgical clipping and endovascular coiling of intracranial aneurysms: a critical review of the literature. *Neurosurgery*. 2008 Jun;62(6):1187–202. [PMID: 18824986]

6. Arteriovenous Malformations

ESSENTIALS OF DIAGNOSIS

- ▶ Sudden onset of subarachnoid and intracerebral hemorrhage.
- ▶ Distinctive neurologic signs reflect the region of the brain involved.
- ▶ Signs of meningeal irritation in patients presenting with subarachnoid hemorrhage.
- ▶ Seizures or focal deficits may occur.

▶ General Considerations

Arteriovenous malformations are congenital vascular malformations that result from a localized maldevelopment of part of the primitive vascular plexus and consist of abnormal arteriovenous communications without intervening capillaries. They vary in size, ranging from massive lesions that are fed by multiple vessels and involve a large part of the brain to lesions so small that they are hard to identify at arteriography, surgery, or autopsy. In approximately 10% of cases, there is an associated arterial aneurysm, while 1–2% of patients presenting with aneurysms have associated arteriovenous malformations. Clinical presentation may relate to hemorrhage from the malformation or an associated aneurysm or may relate to cerebral ischemia due to diversion of blood by the anomalous arteriovenous shunt or due to venous stagnation. Regional maldevelopment of the brain, compression or distortion of adjacent cerebral tissue by enlarged anomalous vessels, and progressive gliosis due to mechanical and ischemic factors may also be contributory. In addition, communicating or obstructive hydrocephalus may occur and lead to symptoms.

▶ Clinical Findings

A. Symptoms and Signs

1. Supratentorial lesions—Most cerebral arteriovenous malformations are supratentorial, usually lying in the territory of the middle cerebral artery. Initial symptoms consist of hemorrhage in 30–60% of cases, recurrent seizures in 20–40%, headache in 5–25%, and miscellaneous complaints (including focal deficits) in 10–15%. Up to 70% of arteriovenous malformations bleed at some point in their natural history, most commonly before the patient reaches the age of 40 years. This tendency to bleed is unrelated to the lesion site or to the patient's sex, but small arteriovenous malformations are more likely to bleed than large ones. Arteriovenous malformations that have bled once are more likely to bleed again. Hemorrhage is commonly intracerebral as well as into the subarachnoid space, and it has a fatal outcome in about 10% of cases. Focal or generalized seizures may accompany or follow hemorrhage, or they may be the initial presentation, especially with frontal or parietal arteriovenous malformations. Headaches are especially

likely when the external carotid arteries are involved in the malformation. These sometimes simulate migraine but more commonly are nonspecific in character, with nothing about them to suggest an underlying structural lesion.

In patients presenting with subarachnoid hemorrhage, examination may reveal an abnormal mental status and signs of meningeal irritation. Additional findings may help localize the lesion and sometimes indicate that intracranial pressure is increased. A cranial bruit always suggests the possibility of a cerebral arteriovenous malformation, but bruits may also be found with aneurysms, meningiomas, acquired arteriovenous fistulas, and arteriovenous malformations involving the scalp, calvarium, or orbit. Bruits are best heard over the ipsilateral eye or mastoid region and are of some help in lateralization but of no help in localization. Absence of a bruit in no way excludes the possibility of arteriovenous malformation.

2. Infratentorial lesions—Brainstem arteriovenous malformations are often clinically silent, but they may hemorrhage, cause obstructive hydrocephalus, or lead to progressive or relapsing brainstem deficits. Cerebellar arteriovenous malformations may also be clinically inconspicuous but sometimes lead to cerebellar hemorrhage.

B. Imaging

In patients presenting with suspected hemorrhage, CT scanning indicates whether subarachnoid or intracerebral bleeding has recently occurred, helps localize its source, and may reveal the arteriovenous malformation. If the CT scan shows no evidence of bleeding but subarachnoid hemorrhage is diagnosed clinically, the cerebrospinal fluid should be examined.

When intracranial hemorrhage is confirmed but the source of hemorrhage is not evident on the CT scan, arteriography is necessary to exclude aneurysm or arteriovenous malformation. MR and CT angiography are not sensitive enough for this purpose. Even if the findings on CT scan suggest arteriovenous malformation, arteriography is required to establish the nature of the lesion with certainty and to determine its anatomic features so that treatment can be planned. The examination must generally include bilateral opacification of the internal and external carotid arteries and the vertebral arteries. Arteriovenous malformations typically appear as a tangled vascular mass with distended tortuous afferent and efferent vessels, a rapid circulation time, and arteriovenous shunting.

In patients presenting without hemorrhage, CT scan or MRI usually reveals the underlying abnormality, and MRI frequently also shows evidence of old or recent hemorrhage that may have been asymptomatic. The nature and detailed anatomy of any focal lesion identified by these means are delineated by angiography, especially if operative treatment is under consideration.

C. Laboratory and Other Studies

Electroencephalography is usually indicated in patients presenting with seizures and may show consistently focal or lateralized abnormalities resulting from the underlying

cerebral arteriovenous malformation. This should be followed by CT scanning.

► Treatment

Surgical treatment to prevent further hemorrhage is justified in patients with arteriovenous malformations that have bled, provided that the lesion is accessible and the patient has a reasonable life expectancy. Surgical treatment is also appropriate if intracranial pressure is increased and to prevent further progression of a focal neurologic deficit. In patients presenting solely with seizures, anticonvulsant drug treatment is usually sufficient, and operative treatment is unnecessary unless there are further developments.

Definitive operative treatment consists of excision of the arteriovenous malformation if it is surgically accessible. Arteriovenous malformations that are inoperable because of their location are sometimes treated solely by embolization; although the risk of hemorrhage is not reduced, neurologic deficits may be stabilized or even reversed by this procedure. Two other techniques for the treatment of intracerebral arteriovenous malformations are injection of a vascular occlusive polymer through a flow-guided microcatheter and permanent occlusion of feeding vessels by positioning detachable balloon catheters in the desired sites and then inflating them with quickly solidifying contrast material. Stereotactic radiosurgery with the gamma knife or related approaches is also useful in the management of inoperable cerebral arteriovenous malformations.

► When to Refer

All patients should be referred.

► When to Admit

- All patients with a subarachnoid or cerebral hemorrhage.
- All patients for detailed imaging.
- All patients undergoing surgical or endovascular treatment.

Sandalcioglu IE et al. The management of arteriovenous malformations. *J Neurosurg Sci.* 2011 Mar;55(1):57–69. [PMID: 21464810]

7. Intracranial Venous Thrombosis

Intracranial venous thrombosis may occur in association with intracranial or maxillofacial infections, hypercoagulable states, polycythemia, sickle cell disease, and cyanotic congenital heart disease and in pregnancy or during the puerperium. There is a genetic component to risk. It is characterized by headache, focal or generalized convulsions, drowsiness, confusion, increased intracranial pressure, and focal neurologic deficits—and sometimes by evidence of meningeal irritation. The diagnosis is confirmed by CT scanning, MRI, MR venography, or angiography.

Treatment includes anticonvulsant drugs if seizures have occurred and antiedema agents (eg, dexamethasone,

4 mg four times daily intravenously or intramuscularly and continued as necessary) or other measures to reduce intracranial pressure. Anticoagulation with dose-adjusted intravenous heparin or weight-adjusted subcutaneous low-molecular-weight heparin, followed by oral warfarin anticoagulation for 6 months reduces morbidity and mortality of venous sinus thrombosis. Concomitant intracranial hemorrhage related to the venous thrombosis does not contraindicate heparin therapy. In cases refractory to heparin, endovascular techniques including catheter-directed thrombolytic therapy (urokinase) and thrombectomy, are sometimes helpful but may increase risk for major hemorrhage.

Bentley JN et al. From presentation to follow-up: diagnosis and treatment of cerebral venous thrombosis. *Neurosurg Focus.* 2009 Nov;27(5):E4. [PMID: 19877795]
Marjot T et al. Genes associated with adult cerebral venous thrombosis. *Stroke.* 2011 Apr;42(4):913–8. [PMID: 21350198]

► When to Refer

All patients should be referred.

► When to Admit

All patients should be hospitalized.

8. Spinal Cord Vascular Diseases



ESSENTIALS OF DIAGNOSIS

- Sudden onset of back or limb pain and neurologic deficit in limbs.
- Motor, sensory, or reflex changes in limbs depending on level of lesion.
- Imaging studies distinguish between infarct and hematoma.

► Infarction of the Spinal Cord

Infarction of the spinal cord is rare. It typically occurs in the territory of the anterior spinal artery because this vessel, which supplies the anterior two-thirds of the cord, is itself supplied by only a limited number of feeders. Infarction usually results from interrupted flow in one or more of these feeders, eg, with aortic dissection, aortography, polyarteritis, or severe hypotension, or after surgical resection of the thoracic aorta. The paired posterior spinal arteries, by contrast, are supplied by numerous arteries at different levels of the cord. Spinal cord hypoperfusion may lead to a central cord syndrome with distal weakness of lower motor neuron type and loss of pain and temperature appreciation, with preserved posterior column function.

Since the anterior spinal artery receives numerous feeders in the cervical region, infarcts almost always occur caudally. Clinical presentation is characterized by acute onset of flaccid, areflexive paraplegia that evolves after a

few days or weeks into a spastic paraplegia with extensor plantar responses. There is an accompanying dissociated sensory loss, with impairment of appreciation of pain and temperature but preservation of sensations of vibration and position. Treatment is symptomatic.

Novy J et al. Spinal cord ischemia: clinical and imaging patterns, pathogenesis, and outcomes in 27 patients. *Arch Neurol.* 2006 Aug;63(8):1113–20. [PMID: 16908737]

► Epidural or Subdural Hemorrhage

Epidural or subdural hemorrhage may lead to sudden severe back pain followed by an acute compressive myelopathy necessitating urgent spinal MRI or myelography and surgical evacuation. It may occur in patients with bleeding disorders or those who are taking anticoagulant drugs, sometimes following trauma or lumbar puncture. Epidural hemorrhage may also be related to a vascular malformation or tumor deposit.

► Spinal Dural Arteriovenous Fistulae

Spinal dural arteriovenous fistulae are congenital lesions that present with spinal subarachnoid hemorrhage or myeloradiculopathy. Since most of these malformations are located in the thoracolumbar region, they lead to motor and sensory disturbances in the legs and to sphincter disorders. Pain in the legs or back is often severe. Examination reveals an upper, lower, or mixed motor deficit in the legs; sensory deficits are also present and are usually extensive, although occasionally they are confined to radicular distribution. Cervical spinal dural arteriovenous fistulae lead also to symptoms and signs in the arms. Spinal MRI may not detect the spinal dural arteriovenous fistulae, and negative findings do not exclude the diagnosis. Myelography (performed with the patient prone and supine) detects serpiginous filling defects due to enlarged vessels. Selective spinal arteriography confirms the diagnosis. Most lesions are extramedullary, are posterior to the cord (lying either intradurally or extradurally), and can easily be treated by ligation of feeding vessels and excision of the fistulous anomaly or by embolization procedures. Delay in treatment may lead to increased and irreversible disability or to death from recurrent subarachnoid hemorrhage.

► When to Refer

All patients should be referred.

► When to Admit

All patients should be hospitalized.

Narvid J et al. Spinal dural arteriovenous fistulae: clinical features and long-term results. *Neurosurgery.* 2008 Jan;62(1):159–67. [PMID: 18300903]

INTRACRANIAL & SPINAL MASS LESIONS

1. Primary Intracranial Tumors



ESSENTIALS OF DIAGNOSIS

- Generalized or focal disturbance of cerebral function, or both.
- Increased intracranial pressure in some patients.
- Neuroradiologic evidence of space-occupying lesion.

► General Considerations

Half of all primary intracranial neoplasms (Table 24–5) are gliomas and the remainder are meningiomas, pituitary adenomas (see Chapter 26), neurofibromas, and other tumors. Certain tumors, especially neurofibromas, hemangioblastomas, and retinoblastomas, may have a familial basis, and congenital factors bear on the development of craniopharyngiomas. Tumors may occur at any age, but certain gliomas show particular age predilections (Table 24–5).

► Clinical Findings

A. Symptoms and Signs

Intracranial tumors may lead to a generalized disturbance of cerebral function and to symptoms and signs of increased intracranial pressure. In consequence, there may be personality changes, intellectual decline, emotional lability, seizures, headaches, nausea, and malaise. If the pressure is increased in a particular cranial compartment, brain tissue may herniate into a compartment with lower pressure. The most familiar syndrome is herniation of the temporal lobe uncus through the tentorial hiatus, which causes compression of the third cranial nerve, midbrain, and posterior cerebral artery. The earliest sign of this is ipsilateral pupillary dilation, followed by stupor, coma, decerebrate posturing, and respiratory arrest. Another important herniation syndrome consists of displacement of the cerebellar tonsils through the foramen magnum, which causes medullary compression leading to apnea, circulatory collapse, and death. Other herniation syndromes are less common and of less clear clinical importance.

Intracranial tumors also lead to focal deficits depending on their location.

1. Frontal lobe lesions—Tumors of the frontal lobe often lead to progressive intellectual decline, slowing of mental activity, personality changes, and contralateral grasp reflexes. They may lead to expressive aphasia if the posterior part of the left inferior frontal gyrus is involved. Anosmia may also occur as a consequence of pressure on the olfactory nerve. Precentral lesions may cause focal motor seizures or contralateral pyramidal deficits.

2. Temporal lobe lesions—Tumors of the uncinate region may be manifested by seizures with olfactory or

Table 24-5. Primary intracranial tumors.

Tumor	Clinical Features	Treatment and Prognosis
Glioblastoma multiforme	Presents commonly with nonspecific complaints and increased intracranial pressure. As it grows, focal deficits develop.	Course is rapidly progressive, with poor prognosis. Total surgical removal is usually not possible. Radiation therapy and chemotherapy may prolong survival.
Astrocytoma	Presentation similar to glioblastoma multiforme but course more protracted, often over several years. Cerebellar astrocytoma may have a more benign course.	Prognosis is variable. By the time of diagnosis, total excision is usually impossible; tumor may be radiosensitive and chemotherapy may also be helpful. In cerebellar astrocytoma, total surgical removal is often possible.
Medulloblastoma	Seen most frequently in children. Generally arises from roof of fourth ventricle and leads to increased intracranial pressure accompanied by brainstem and cerebellar signs. May seed subarachnoid space.	Treatment consists of surgery combined with radiation therapy and chemotherapy.
Ependymoma	Glioma arising from the ependyma of a ventricle, especially the fourth ventricle; leads to early signs of increased intracranial pressure. Arises also from central canal of cord.	Tumor is best treated surgically if possible. Radiation therapy may be used for residual tumor.
Oligodendroglioma	Slow-growing. Usually arises in cerebral hemisphere in adults. Calcification may be visible on skull radiograph.	Treatment is surgical and usually successful. Radiation and chemotherapy may be used if tumor has malignant features.
Brainstem glioma	Presents during childhood with cranial nerve palsies and then with long tract signs in the limbs. Signs of increased intracranial pressure occur late.	Tumor is inoperable; treatment is by irradiation and shunt for increased intracranial pressure.
Cerebellar heman-gioblastoma	Presents with dysequilibrium, ataxia of trunk or limbs, and signs of increased intracranial pressure. Sometimes familial. May be associated with retinal and spinal vascular lesions, polycythemia, and renal cell carcinoma.	Treatment is surgical. Radiation is used for residual tumor.
Pineal tumor	Presents with increased intracranial pressure, sometimes associated with impaired upward gaze (Parinaud syndrome) and other deficits indicative of midbrain lesion.	Ventricular decompression by shunting is followed by surgical approach to tumor; irradiation is indicated if tumor is malignant. Prognosis depends on histopathologic findings and extent of tumor.
Craniopharyngioma	Originates from remnants of Rathke pouch above the sella, depressing the optic chiasm. May present at any age but usually in childhood, with endocrine dysfunction and bitemporal field defects.	Treatment is surgical, but total removal may not be possible. Radiation may be used for residual tumor.
Acoustic neurinoma	Ipsilateral hearing loss is most common initial symptom. Subsequent symptoms may include tinnitus, headache, vertigo, facial weakness or numbness, and long tract signs. (May be familial and bilateral when related to neurofibromatosis.) Most sensitive screening tests are MRI and brainstem auditory evoked potential.	Treatment is excision by translabyrinthine surgery, craniectomy, or a combined approach. Outcome is usually good.
Meningioma	Originates from the dura mater or arachnoid; compresses rather than invades adjacent neural structures. Increasingly common with advancing age. Tumor size varies greatly. Symptoms vary with tumor site—eg, unilateral proptosis (sphenoidal ridge); anosmia and optic nerve compression (olfactory groove). Tumor is usually benign and readily detected by CT scanning; may lead to calcification and bone erosion visible on plain radiographs of skull.	Treatment is surgical. Tumor may recur if removal is incomplete.
Primary cerebral lymphoma	Associated with AIDS and other immunodeficient states. Presentation may be with focal deficits or with disturbances of cognition and consciousness. May be indistinguishable from cerebral toxoplasmosis.	Treatment is high-dose methotrexate followed by radiation therapy. Prognosis depends on CD4 count at diagnosis.

gustatory hallucinations, motor phenomena such as licking or smacking of the lips, and some impairment of external awareness without actual loss of consciousness. Temporal lobe lesions also lead to depersonalization, emotional changes, behavioral disturbances, sensations of déjà vu or jamais vu, micropsia or macropsia (objects appear

smaller or larger than they are), visual field defects (crossed upper quadrantanopia), and auditory illusions or hallucinations. Left-sided lesions may lead to dysnomia and receptive aphasia, while right-sided involvement sometimes disturbs the perception of musical notes and melodies.

3. Parietal lobe lesions—Tumors in this location characteristically cause contralateral disturbances of sensation and may cause sensory seizures, sensory loss or inattention, or some combination of these symptoms. The sensory loss is cortical in type and involves postural sensibility and tactile discrimination, so that the appreciation of shape, size, weight, and texture is impaired. Objects placed in the hand may not be recognized (astereognosis). Extensive parietal lobe lesions may produce contralateral hyperpathia and spontaneous pain (thalamic syndrome). Involvement of the optic radiation leads to a contralateral homonymous field defect that sometimes consists solely of lower quadrantanopia. Lesions of the left angular gyrus cause Gerstmann syndrome (a combination of alexia, agraphia, acalculia, right-left confusion, and finger agnosia), whereas involvement of the left submarginal gyrus causes ideational apraxia. Anosognosia (the denial, neglect, or rejection of a paralyzed limb) is seen in patients with lesions of the non-dominant (right) hemisphere. Constructional apraxia and dressing apraxia may also occur with right-sided lesions.

4. Occipital lobe lesions—Tumors of the occipital lobe characteristically produce crossed homonymous hemianopia or a partial field defect. With left-sided or bilateral lesions, there may be visual agnosia both for objects and for colors, while irritative lesions on either side can cause unformed visual hallucinations. Bilateral occipital lobe involvement causes cortical blindness in which there is preservation of pupillary responses to light and lack of awareness of the defect by the patient. There may also be loss of color perception, prosopagnosia (inability to identify a familiar face), simultagnosia (inability to integrate and interpret a composite scene as opposed to its individual elements), and Balint syndrome (failure to turn the eyes to a particular point in space, despite preservation of spontaneous and reflex eye movements). The denial of blindness or a field defect constitutes Anton syndrome.

5. Brainstem and cerebellar lesions—Brainstem lesions lead to cranial nerve palsies, ataxia, incoordination, nystagmus, and pyramidal and sensory deficits in the limbs on one or both sides. Intrinsic brainstem tumors, such as gliomas, tend to produce an increase in intracranial pressure only late in their course. Cerebellar tumors produce marked ataxia of the trunk if the vermis cerebelli is involved and ipsilateral appendicular deficits (ataxia, incoordination and hypotonia of the limbs) if the cerebellar hemispheres are affected.

6. False localizing signs—Tumors may lead to neurologic signs other than by direct compression or infiltration, thereby leading to errors of clinical localization. These false localizing signs include third or sixth nerve palsy and bilateral extensor plantar responses produced by herniation syndromes, and an extensor plantar response occurring ipsilateral to a hemispheric tumor as a result of compression of the opposite cerebral peduncle against the tentorium.

B. Imaging

MRI with gadolinium enhancement is the preferred method to detect the lesion and to define its location,

shape, and size; the extent to which normal anatomy is distorted; and the degree of any associated cerebral edema or mass effect. CT scanning with radiocontrast enhancement could be performed; however, it is less helpful than MRI for small lesions or tumors in the posterior fossa. The characteristic appearance of meningiomas on MRI or CT scanning is virtually diagnostic, ie, a lesion in a typical site (parasagittal and sylvian regions, olfactory groove, sphenoidal ridge, tuberculum sellae) that appears as a homogeneous area of increased density in noncontrast scans and enhances uniformly with contrast. Newer neuroimaging techniques may help identify brain tumors by increased blood perfusion (perfusion-weighted MRI, single photon-emission computed tomography, positron-emission tomography) and high metabolism or cell turnover (magnetic resonance spectroscopy, positron-emission tomography), but non-neoplastic diseases, such as stroke and inflammatory or infectious diseases, are sometimes associated with hyperperfusion and hypermetabolism. Diffusion-weighted MRI may also be helpful. Arteriography may show stretching or displacement of normal cerebral vessels by the tumor and the presence of tumor vascularity. The presence of an avascular mass is a nonspecific finding that could be due to tumor, hematoma, abscess, or any space-occupying lesion. In patients with normal hormone levels and an intrasellar mass, angiography is necessary to distinguish with confidence between a pituitary adenoma and an arterial aneurysm.

C. Laboratory and Other Studies

The electroencephalogram provides supporting information concerning cerebral function and may show either a focal disturbance due to the neoplasm or a more diffuse change reflecting altered mental status. Lumbar puncture is rarely necessary; the findings are seldom diagnostic, and the procedure carries the risk of causing a herniation syndrome.

► Treatment

Treatment depends on the type and site of the tumor (Table 24–5) and the condition of the patient. Some benign tumors, especially meningiomas discovered incidentally during brain imaging for another purpose, may be monitored with serial annual imaging. For symptomatic tumors, complete surgical removal may be possible if the tumor is extra-axial (eg, meningioma, acoustic neuroma) or is not in a critical or inaccessible region of the brain (eg, cerebellar hemangioblastoma). Surgery also permits the diagnosis to be verified and may be beneficial in reducing intracranial pressure and relieving symptoms even if the neoplasm cannot be completely removed. Clinical deficits are sometimes due in part to obstructive hydrocephalus, in which case simple surgical shunting procedures often produce dramatic benefit. In patients with malignant gliomas, radiation therapy increases median survival rates regardless of any preceding surgery, and its combination with chemotherapy provides additional benefit. Indications for irradiation in the treatment of patients with other primary intracranial neoplasms depend on tumor type

and accessibility and the feasibility of complete surgical removal. Temozolomide is a commonly used oral and intravenous chemotherapeutic for gliomas, and there is an increasing trend to use monoclonal antibodies as a component of therapy. Corticosteroids help reduce cerebral edema and are usually started before surgery. Herniation is treated with intravenous dexamethasone (10–20 mg as a bolus, followed by 4 mg every 6 hours) and intravenous mannitol (20% solution given in a dose of 1.5 g/kg over about 30 minutes). Anticonvulsants are also commonly administered in standard doses (see Table 24–3) but are not indicated for prophylaxis in patients who have no history of seizures. Long-term neurocognitive deficits may complicate radiation therapy. For those patients whose disease deteriorates despite treatment, palliative care is important (see Chapter 5).

► When to Refer

All patients should be referred.

► When to Admit

- All patients with increased intracranial pressure.
- All patients requiring biopsy, surgical treatment, or shunting procedures.

Buckner JC et al. Central nervous system tumors. *Mayo Clin Proc.* 2007 Oct;82(10):1271–86. [PMID: 17908533]
 Colman H et al. Molecular predictors in glioblastoma. *Arch Neurol.* 2008 July;65(7):877–83. [PMID: 18625854]
 Daly FN et al. Supportive management of patients with brain tumors. *Expert Rev Neurother.* 2007 Oct;7(10):1327–36. [PMID: 17939770]
 Mrugala MM et al. Temozolomide: expanding its role in brain cancer. *Drugs Today (Barc).* 2010 Nov;46(11):833–46. [PMID: 21225022]
 Soffietti R et al. New developments in the treatment of malignant gliomas. *Expert Rev Neurother.* 2007 Oct;7(10):1313–26. [PMID: 17939769]

2. Metastatic Intracranial Tumors

Cerebral Metastases

Metastatic brain tumors present in the same way as other cerebral neoplasms, ie, with increased intracranial pressure, with focal or diffuse disturbance of cerebral function, or with both of these manifestations. Indeed, in patients with a single cerebral lesion, the metastatic nature of the lesion may only become evident on histopathologic examination. In other patients, there is evidence of widespread metastatic disease, or an isolated cerebral metastasis develops during treatment of the primary neoplasm.

The most common source of intracranial metastasis is carcinoma of the lung; other primary sites are the breast, kidney, skin (melanoma), and gastrointestinal tract. Most cerebral metastases are located supratentorially. Laboratory and radiologic studies used to evaluate patients with metastases are those described for primary neoplasms. They include MRI and CT scanning performed both with and without contrast material. Lumbar puncture is necessary only in patients with suspected carcinomatous meningitis

(see below). In patients with verified cerebral metastasis from an unknown primary, investigation is guided by symptoms and signs. In women, mammography is indicated; in men under 50, germ cell origin is sought since both have therapeutic implications.

In patients with only a single, surgically accessible cerebral metastasis who are otherwise well (ie, a high level of functioning and little or no evidence of extracranial disease), it may be possible to remove the lesion and then treat with irradiation; the latter may also be selected as the sole treatment. In patients with multiple metastases or widespread systemic disease, the prognosis is poor; stereotactic radiosurgery, whole-brain radiotherapy, or both, may help in some instances, but in others treatment is palliative only.

Chang EL et al. Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. *Lancet Oncol.* 2009 Nov;10(11):1037–44. [PMID: 19801201]
 Eichler AF et al. Brain metastases. *Curr Treat Options Neurol.* 2008 Jul;10(4):308–14. [PMID: 18579017]
 Kanner AA et al. Surgical therapies in brain metastasis. *Semin Oncol.* 2007 Jun;34(3):197–205. [PMID: 17560981]
 Mintz A et al. Management of single brain metastasis: a practice guideline. *Curr Oncol.* 2007 Aug;14(4):131–43. [PMID: 17710205]
 Patil CG et al. Whole brain radiation therapy (WBRT) alone versus WBRT and radiosurgery for the treatment of brain metastases. *Cochrane Database Syst Rev.* 2010 Jun 16;(6):CD006121. [PMID: 20556764]

Leptomeningeal Metastases (Carcinomatous Meningitis)

The neoplasms metastasizing most commonly to the leptomeninges are carcinoma of the breast, lymphomas, and leukemia. Leptomeningeal metastases lead to multifocal neurologic deficits, which may be associated with infiltration of cranial and spinal nerve roots, direct invasion of the brain or spinal cord, obstructive hydrocephalus, or some combination of these factors.

The diagnosis is confirmed by examination of the cerebrospinal fluid. Findings may include elevated cerebrospinal fluid pressure, pleocytosis, increased protein concentration, and decreased glucose concentration. Cytologic studies may indicate that malignant cells are present; if not, lumbar puncture should be repeated at least twice to obtain further samples for analysis.

CT scans showing contrast enhancement in the basal cisterns or showing hydrocephalus without any evidence of a mass lesion support the diagnosis. Gadolinium-enhanced MRI frequently shows enhancing foci in the leptomeninges. Myelography may show deposits on multiple nerve roots.

Treatment is by irradiation to symptomatic areas, combined with intrathecal methotrexate. The long-term prognosis is poor—only about 10% of patients survive for 1 year—and palliative care is therefore important (see Chapter 5).

3. Intracranial Mass Lesions in AIDS Patients

Primary cerebral lymphoma is a common complication in patients with AIDS. This leads to disturbances in

cognition or consciousness, focal motor or sensory deficits, aphasia, seizures, and cranial neuropathies. Similar clinical disturbances may result from **cerebral toxoplasmosis**, which is also a common complication in patients with AIDS (see Chapters 31 and 35). Neither CT nor MRI findings distinguish these two disorders, and serologic tests for toxoplasmosis are unreliable in AIDS patients. Accordingly, for neurologically stable patients, a trial of treatment for toxoplasmosis with sulfadiazine (100 mg/kg/d up to 8 g/d in four divided doses orally daily) and pyrimethamine (75 mg orally daily for 3 days, then 25 mg orally daily) is recommended for 3 weeks; the imaging studies are then repeated, and if any lesion has improved, the regimen is continued indefinitely. If any lesion does not improve, cerebral biopsy is necessary. Primary cerebral lymphoma is treated with whole-brain irradiation.

Cryptococcal meningitis is a common opportunistic infection in AIDS patients. Clinically, it may resemble cerebral toxoplasmosis or lymphoma, but cranial CT scans are usually normal. The diagnosis is made on the basis of cerebrospinal fluid studies, with positive India ink staining in 75–80% and cryptococcal antigen tests in 95% of cases. Treatment is with amphotericin B plus flucytosine, as set forth in Table 36–1, followed by fluconazole.

4. Primary & Metastatic Spinal Tumors

Approximately 10% of spinal tumors are intramedullary. Ependymoma is the most common type of intramedullary tumor; the remainder are other types of glioma. Extramedullary tumors may be extradural or intradural in location. Among the primary extramedullary tumors, neurofibromas and meningiomas are relatively common, are benign, and may be intradural or extradural. Carcinomatous metastases, lymphomatous or leukemic deposits, and myeloma are usually extradural; in the case of metastases, the prostate, breast, lung, and kidney are common primary sites.

Tumors may lead to spinal cord dysfunction by direct compression, by ischemia secondary to arterial or venous obstruction and, in the case of intramedullary lesions, by invasive infiltration.

► Clinical Findings

A. Symptoms and Signs

Symptoms usually develop insidiously. Pain is often conspicuous with extradural lesions; is characteristically aggravated by coughing or straining; may be radicular, localized to the back, or felt diffusely in an extremity; and may be accompanied by motor deficits, paresthesias, or numbness, especially in the legs. Bladder, bowel, and sexual dysfunction may occur. When sphincter disturbances occur, they are usually particularly disabling. Pain, however, often precedes specific neurologic symptoms from epidural metastases.

Examination may reveal localized spinal tenderness. A segmental lower motor neuron deficit or dermatomal sensory changes (or both) are sometimes found at the

level of the lesion, while an upper motor neuron deficit and sensory disturbance are found below it.

B. Imaging

CT myelography or, preferably, MRI with contrast is used to identify and localize the lesion. The combination of known tumor elsewhere in the body, back pain, and either abnormal plain films of the spine or neurologic signs of cord compression is an indication to perform these studies on an urgent basis. Some clinicians proceed to MRI or CT myelography based solely on new back pain in a cancer patient.

C. Laboratory Findings

The cerebrospinal fluid is often xanthochromic and contains a greatly increased protein concentration with normal cell content and glucose concentration.

► Treatment

Intramedullary tumors are treated by decompression and surgical excision (when feasible) and by irradiation. The prognosis depends on the cause and severity of cord compression before it is relieved.

Treatment of epidural spinal metastases consists of irradiation, irrespective of cell type. Dexamethasone is also given in a high dosage (eg, 25 mg four times daily for 3 days orally or intravenously, followed by rapid tapering of the dosage, depending on response) to reduce cord swelling and relieve pain. Surgical decompression is reserved for patients with tumors that are unresponsive to irradiation or have previously been irradiated and for cases in which there is some uncertainty about the diagnosis. The long-term outlook is poor, but radiation treatment may at least delay the onset of major disability.

Grimm S et al. Adult primary spinal cord tumors. *Expert Rev Neurother.* 2009 Oct;9(10):1487–95. [PMID: 19831838]
Harel R et al. Spine metastases: current treatments and future directions. *Eur J Cancer.* 2010 Oct;46(15):2696–707. [PMID: 20627705]

5. Brain Abscess



ESSENTIALS OF DIAGNOSIS

- Symptoms and signs of expanding intracranial mass.
- Signs of primary infection or congenital heart disease are sometimes present.
- Fever may be absent.

► General Considerations

Brain abscess presents as an intracranial space-occupying lesion and arises as a sequela of disease of the ear or nose, may be a complication of infection elsewhere in the body, or may result from infection introduced intracranially by

trauma or surgical procedures. The most common infective organisms are streptococci, staphylococci, and anaerobes; mixed infections are not uncommon.

► Clinical Findings

A. Symptoms and Signs

Headache, drowsiness, inattention, confusion, and seizures are early symptoms, followed by signs of increasing intracranial pressure and then a focal neurologic deficit. There may be little or no systemic evidence of infection.

B. Imaging and Other Investigations

A CT scan of the head characteristically shows an area of contrast enhancement surrounding a low-density core. Similar abnormalities may be found in patients with metastatic neoplasms. MRI findings often permit earlier recognition of focal cerebritis or an abscess. Arteriography indicates the presence of a space-occupying lesion, which appears as an avascular mass with displacement of normal cerebral vessels. Stereotactic needle aspiration may enable a specific etiologic organism to be identified. Examination of the cerebrospinal fluid does not help in diagnosis and may precipitate a herniation syndrome. Peripheral leukocytosis is sometimes present.

► Treatment

Treatment consists of intravenous antibiotics, combined with surgical drainage (aspiration or excision) if necessary to reduce the mass effect, or sometimes to establish the diagnosis. Abscesses smaller than 2 cm can often be cured medically. Broad-spectrum antibiotics, selected based on risk factors and likely organisms, are used if the infecting organism is unknown (see Chapter 33). Initial empiric antibiotic regimens typically include ceftriaxone (2 g intravenously every 12 hours), metronidazole (15 mg/kg intravenous loading dose, followed by 7.5 mg/kg intravenously every 6 hours), and vancomycin (1 g intravenously every 12 hours). The regimen is altered once culture and sensitivity data are available. Antimicrobial treatment is usually continued parenterally for 6–8 weeks, followed by orally for 2–3 months. The patient should be monitored by serial CT scans or MRI every 2 weeks and at deterioration. Dexamethasone (4–25 mg four times daily intravenously or orally, depending on severity, followed by tapering of dose, depending on response) may reduce any associated edema, but intravenous mannitol is sometimes required.

Carpenter J et al. Retrospective analysis of 49 cases of brain abscess and review of the literature. *Eur J Clin Microbiol Infect Dis.* 2007 Jan;26(1):1–11. [PMID: 17180609]

NONMETASTATIC NEUROLOGIC COMPLICATIONS OF MALIGNANT DISEASE

A variety of nonmetastatic neurologic complications of malignant disease (see Table 39–2) can be recognized. Metabolic encephalopathy due to electrolyte abnormalities, infections, drug overdose, or the failure of some vital

organ may be reflected by drowsiness, lethargy, restlessness, insomnia, agitation, confusion, stupor, or coma. The mental changes are usually associated with tremor, asterixis, and multifocal myoclonus. The electroencephalogram is generally diffusely slowed. Laboratory studies are necessary to detect the cause of the encephalopathy, which must then be treated appropriately.

Immune suppression resulting from either the malignant disease or its treatment (eg, by chemotherapy) predisposes patients to brain abscess, progressive multifocal leukoencephalopathy, meningitis, herpes zoster infection, and other opportunistic infectious diseases. Moreover, an overt or occult cerebrospinal fluid fistula, as occurs with some tumors, may also increase the risk of infection. MRI or CT scanning aids in the early recognition of a brain abscess, but metastatic brain tumors may have a similar appearance. Examination of the cerebrospinal fluid is essential in the evaluation of patients with meningitis but is of no help in the diagnosis of brain abscess.

Cerebrovascular disorders that cause neurologic complications in patients with systemic cancer include nonbacterial thrombotic endocarditis and septic embolization. Cerebral, subarachnoid, or subdural hemorrhages may occur in patients with myelogenous leukemia and may be found in association with metastatic tumors, especially malignant melanoma. Spinal subdural hemorrhage sometimes occurs after lumbar puncture in patients with marked thrombocytopenia.

Disseminated intravascular coagulation occurs most commonly in patients with acute promyelocytic leukemia or with some adenocarcinomas and is characterized by a fluctuating encephalopathy, often with associated seizures, that frequently progresses to coma or death. There may be few accompanying neurologic signs. Venous sinus thrombosis, which usually presents with convulsions and headaches, may also occur in patients with leukemia or lymphoma. Examination commonly reveals papilledema and focal or diffuse neurologic signs. Anticonvulsants, anticoagulants, and drugs to lower the intracranial pressure may be of value.

Autoimmune paraneoplastic disorders occur when the immune system reacts against neuronal antigens expressed by tumor cells. The clinical manifestations depend on the autoantibody. Symptoms may precede those due to the neoplasm itself. Several distinct syndromes are common, including paraneoplastic cerebellar degeneration, limbic encephalitis, encephalomyelitis, anti-NMDA receptor-associated encephalitis, opsoclonus/myoclonus, sensory neuronopathy, and dermatomyositis.

Paraneoplastic cerebellar degeneration occurs most commonly in association with carcinoma of the lung, but also in breast and gynecologic cancers and Hodgkin lymphoma. Typically, there is a pancerebellar syndrome causing dysarthria, nystagmus, and ataxia of the trunk and limbs. The disorder is associated with anti-Yo, -Tr, -voltage-gated calcium channel (VGCC), and -Zic antibodies. Treatment is of the underlying malignant disease. **Limbic encephalitis**, characterized by impaired recent memory, disturbed affect, hallucinations, and seizures, occurs in some patients with tumors of the lungs, breast, thymus, and germ cells.

Associated antibodies include anti-Hu, -Ma2, -CV2/CRMP5, -voltage-gated potassium channel (VGKC), -AMPA receptor, and -GABA_B receptor. A more generalized **encephalomyelitis** occurs with anti-Hu, -CV2/CRMP5, -Ma2, and -amphiphysin antibodies in the context of a similar spectrum of tumors. **Anti-NMDA receptor-associated encephalitis** causes a characteristic syndrome of severe psychiatric symptoms, dyskinesias, dysautonomia, and hypoventilation, and is frequently associated with ovarian teratoma. **Opsoclonus/myoclonus**, a syndrome of involuntary, erratic, and conjugate saccadic eye movements and myoclonic movements of the limbs, occurs in patients with lung, breast, and gynecologic tumors, often without an identifiable antibody. **Sensory neuronopathy**, typically caused by anti-Hu antibodies in small cell lung cancer or other carcinomas, manifests itself with asymmetric, multifocal sensory nerve root deficits leading to pain, numbness, sensory ataxia, and sometimes hearing loss. **Dermatomyositis** (see Chapter 20) or the **Lambert-Eaton myasthenic syndrome** (discussed below) may be seen in patients with underlying carcinoma. Identification of an antibody is not always possible in a suspected autoimmune paraneoplastic condition, and a search for an underlying neoplasm should not be deterred. Treatment of the neoplasm takes priority and offers the best hope for stabilization or improvement of the neurologic symptoms, which often are not completely reversible. Specific treatment of the antibody-mediated symptoms by intravenous immunoglobulin (IVIG) administration, plasmapheresis, corticosteroids, or other immunosuppressive regimens, is frequently attempted despite limited efficacy. Encephalitides involving antibodies directed against neuronal cell surface antigens, such as VGKC or AMPA, NMDA, or GABA_B receptors, can occur either as paraneoplastic phenomena or in isolation, and typically respond well to immunotherapy.

Dalmau J et al. Paraneoplastic syndromes of the CNS. *Lancet Neurol*. 2008 Apr;7(4):327–40. [PMID: 18339348]
 Rosenfeld MR et al. Update on paraneoplastic and autoimmune disorders of the central nervous system. *Semin Neurol*. 2010 Jul;30(3):320–31. [PMID: 20577938]

PSEUDOTUMOR CEREBRI (Benign Intracranial Hypertension)



ESSENTIALS OF DIAGNOSIS

- ▶ Headache, worse on straining.
- ▶ Visual obscurations or diplopia may occur.
- ▶ Examination reveals papilledema.
- ▶ Abducens palsy is commonly present.

▶ General Considerations

There are many causes of pseudotumor cerebri. Thrombosis of the transverse venous sinus as a noninfectious complication

of otitis media or chronic mastoiditis is one cause, and sagittal sinus thrombosis may lead to a clinically similar picture. Other causes include chronic pulmonary disease, systemic lupus erythematosus, uremia, endocrine disturbances such as hypoparathyroidism, hypothyroidism, or Addison disease, vitamin A toxicity, and the use of tetracycline or oral contraceptives. Cases have also followed withdrawal of corticosteroids after long-term use. In most instances, however, no specific cause can be found, and the disorder remits spontaneously after several months. This idiopathic variety—known as **idiopathic intracranial hypertension**—occurs most commonly among overweight women aged 20–44. In all cases, screening for a space-occupying lesion of the brain is important.

▶ Clinical Findings

A. Symptoms and Signs

Symptoms consist of headache, diplopia, and other visual disturbances due to papilledema and abducens nerve dysfunction. Pulse-synchronous tinnitus may also occur. Examination reveals the papilledema and some enlargement of the blind spots, but patients otherwise look well.

B. Imaging

Investigations reveal no evidence of a space-occupying lesion. CT scan shows small or normal ventricles. MR venography is helpful in screening for thrombosis of the intracranial venous sinuses.

C. Laboratory Findings

Lumbar puncture confirms the presence of intracranial hypertension, but the cerebrospinal fluid is normal. Laboratory studies help exclude some of the other causes mentioned earlier.

▶ Treatment

Untreated intracranial hypertension sometimes leads to secondary optic atrophy and permanent visual loss. Acetazolamide (250–500 mg orally three times daily, increasing slowly to a maintenance dose of 1000–2000 mg daily, divided two to four times daily) reduces formation of cerebrospinal fluid and can be used to start treatment. Like acetazolamide, the antiepileptic drug topiramate (Table 24–3) is a carbonic anhydrase inhibitor and was shown to be similarly effective in an open label study; topiramate has the added benefit of causing weight loss. Corticosteroids (eg, prednisone, 60–80 mg daily) may also be necessary. Obese patients should be advised to lose weight. Repeated lumbar puncture to lower the intracranial pressure by removal of cerebrospinal fluid is effective as a temporizing measure, but pharmacologic approaches to treatment provide better long-term relief. Treatment is monitored by checking visual acuity and visual fields, funduscopic appearance, and pressure of the cerebrospinal fluid. The disorder may worsen after a period of stability, indicating the need for long-term follow-up.

If medical treatment fails to control the intracranial pressure, surgical placement of a lumboperitoneal or

ventriculoperitoneal shunt or optic nerve sheath fenestration should be undertaken to preserve vision.

In addition to the above measures, any specific cause of intracranial hypertension requires appropriate treatment. Thus, hormone therapy should be initiated if there is an underlying endocrine disturbance. Discontinuing the use of tetracycline, oral contraceptives, or vitamin A will allow for resolution of intracranial hypertension due to these agents. If corticosteroid withdrawal is responsible, the medication should be reintroduced and then tapered more gradually.

▶ When to Refer

All patients should be referred.

▶ When to Admit

All patients requiring shunt placement or optic nerve sheath fenestration should be hospitalized.

Abubaker K et al. Idiopathic intracranial hypertension: lumbo-peritoneal shunts versus ventriculoperitoneal shunts—case series and literature review. *Br J Neurosurg.* 2011 Feb;25(1):94–9. [PMID: 21323404]

Dhungana S et al. Idiopathic intracranial hypertension. *Acta Neurol Scand.* 2010 Feb;121(2):71–82. [PMID: 19930211]

Friesner D et al. Idiopathic intracranial hypertension in the USA: the role of obesity in establishing prevalence and healthcare costs. *Obes Rev.* 2011 May;12(5):e372–80. [PMID: 20804521]

Shah VA et al. Long-term follow-up of idiopathic intracranial hypertension: the Iowa experience. *Neurology.* 2008 Feb 19;70(8):634–40. [PMID: 18285538]

SELECTED NEURO CUTANEOUS DISEASES

Because the nervous system develops from the epithelial layer of the embryo, a number of congenital diseases include both neurologic and cutaneous manifestations. Among these disorders, three are discussed below, and **von Hippel–Lindau** disease is discussed in Chapter 26.

1. Tuberous Sclerosis

Tuberous sclerosis may occur sporadically or on a familial basis with autosomal dominant inheritance. The disease is caused by mutations that inactivate either the *TSC1* (hamartin) gene on chromosome 9 or the *TSC2* (tuberin) gene on chromosome 16, resulting in constitutive expression of mTOR (mammalian target of rapamycin) and impaired tumor suppression in multiple tissues. Neurologic presentation is with seizures and progressive psychomotor retardation beginning in early childhood. The cutaneous abnormality, adenoma sebaceum, becomes manifest usually between 5 and 10 years of age and typically consists of reddened nodules on the face (cheeks, nasolabial folds, sides of the nose, and chin) and sometimes on the forehead and neck. Other typical cutaneous lesions include subungual fibromas, shagreen patches (leathery plaques of subepidermal fibrosis, situated usually on the trunk), and leaf-shaped hypopigmented spots. Associated abnormalities include retinal lesions and tumors, benign rhabdomyomas of the heart, lung cysts, benign tumors in the viscera, and bone cysts.

The disease is slowly progressive and leads to increasing mental deterioration. There is no specific treatment, but anticonvulsant drugs may help in controlling seizures.

Franz DN et al. Tuberous sclerosis complex: neurological, renal and pulmonary manifestations. *Neuropediatrics.* 2010 Oct;41(5):199–208. [PMID: 21210335]

2. Neurofibromatosis

Neurofibromatosis may occur either sporadically or on a familial basis with autosomal dominant inheritance. Two distinct forms are recognized: **Type 1 (Recklinghausen disease)** is characterized by multiple hyperpigmented macules and neurofibromas, and results from mutations in the *NF1* gene on chromosome 17. **Type 2** is characterized by **eighth nerve tumors**, often accompanied by other intracranial or intraspinal tumors, and is associated with mutations in the *NF2* (merlin) gene on chromosome 22.

Neurologic presentation is usually with symptoms and signs of tumor. Multiple neurofibromas characteristically are present and may involve spinal or cranial nerves, especially the eighth nerve (Figure 24–1). Examination of the superficial cutaneous nerves usually reveals palpable mobile nodules. In some cases, there is an associated marked overgrowth of subcutaneous tissues (plexiform neuromas), sometimes with an underlying bony abnormality. Associated cutaneous lesions include axillary freckling and patches of cutaneous pigmentation (café au lait spots). Malignant degeneration of neurofibromas occasionally occurs and may lead to peripheral sarcomas. Meningiomas, gliomas (especially optic nerve gliomas), bone cysts, pheochromocytomas, scoliosis, and obstructive hydrocephalus may also occur.

Asthagiri AR et al. Neurofibromatosis type 2. *Lancet.* 2009 Jun 6;373(9679):1974–86. [PMID: 19476995]

Gerber PA et al. Neurofibromatosis. *Eur J Med Res.* 2009 Mar 17;14(3):102–5. [PMID: 19380279]



▲ **Figure 24–1.** Neurofibromatosis. (Courtesy of Jack Resnick, Sr, MD; used, with permission, from Usatine RP, Smith MA, Mayeaux EJ, Jr, Chumley H, Tysinger J. *The Color Atlas of Family Medicine.* McGraw-Hill, 2009.)

3. Sturge-Weber Syndrome

Sturge-Weber syndrome consists of a congenital, usually unilateral, cutaneous capillary angioma involving the upper face, leptomeningeal angiomatosis and, in many patients, choroidal angioma. It has no sex predilection and usually occurs sporadically. The cutaneous angioma sometimes has a more extensive distribution over the head and neck and is often quite disfiguring, especially if there is associated overgrowth of connective tissue. Focal or generalized seizures are the usual neurologic presentation and may commence at any age. There may be contralateral homonymous hemianopia, hemiparesis and hemisensory disturbance, ipsilateral glaucoma, and mental subnormality. Skull radiographs taken after the first 2 years of life usually reveal gyriform (“tramline”) intracranial calcification, especially in the parieto-occipital region, due to mineral deposition in the cortex beneath the intracranial angioma.

Treatment is aimed at controlling seizures pharmacologically, but surgical treatment may be necessary. Ophthalmologic advice should be sought concerning the management of choroidal angioma and of increased intraocular pressure.

Pascual-Castroviejo I et al. Sturge-Weber syndrome: study of 55 patients. *Can J Neurol Sci.* 2008 Jul;35(3):301–7. [PMID: 18714797]

Tsipursky MS et al. Photodynamic therapy of choroidal hemangioma in Sturge-Weber syndrome, with a review of treatments for diffuse and circumscribed choroidal hemangiomas. *Surv Ophthalmol.* 2011 Jan–Feb;56(1):68–85. [PMID: 21074819]

MOVEMENT DISORDERS

1. Benign Essential (Familial) Tremor



ESSENTIALS OF DIAGNOSIS

- ▶ Postural tremor of hands, head, or voice.
- ▶ Family history common.
- ▶ May improve temporarily with alcohol.
- ▶ No abnormal findings other than tremor.

▶ General Considerations

The cause of benign essential tremor is uncertain, but it is sometimes inherited in an autosomal dominant manner. Responsible genes have been identified at 3q13, 2p22-p25, and 6p23.

▶ Clinical Findings

Tremor may begin at any age and is enhanced by emotional stress. The tremor usually involves one or both hands, the head, or the hands and head, while the legs tend to be spared. Examination reveals no other abnormalities. Ingestion of a small quantity of alcohol commonly provides remarkable but short-lived relief by an unknown mechanism.

Although the tremor may become more conspicuous with time, it generally leads to little disability. Occasionally, it interferes with manual skills and leads to impairment of handwriting. Speech may also be affected if the laryngeal muscles are involved.

▶ Treatment

Treatment is often unnecessary. When it is required because of disability, propranolol may be helpful but will need to be continued indefinitely in doses of 60–240 mg daily orally. However, intermittent therapy is sometimes useful in patients whose tremor becomes exacerbated in specific predictable situations. Primidone may be helpful when propranolol is ineffective, but patients with essential tremor are often very sensitive to it. Therefore, the starting dose is 50 mg daily orally, and the daily dose is increased by 50 mg every 2 weeks depending on the patient’s response; a maintenance dose of 125 mg three times daily orally is commonly effective. Occasional patients do not respond to these measures but are helped by alprazolam (up to 3 mg daily in divided doses), topiramate (titrated up to a dose of 400 mg daily orally in divided doses over about 8 weeks), gabapentin (1800 mg daily orally in divided doses), mirtazapine (15 or 30 mg at night orally), or clozapine (30–50 mg twice daily orally). Other antiepileptic agents including levetiracetam and zonisamide are reportedly sometimes effective. Botulinum toxin A may reduce tremor, but adverse effects include dose-dependent weakness of the injected muscles. Pregabalin was recently shown to be ineffective.

Disabling tremor unresponsive to medical treatment may be helped by high-frequency thalamic stimulation to one or both hemispheres, according to the laterality of symptoms. Subdural motor cortex stimulation has also been effective in a small trial.

▶ When to Refer

All patients should be referred.

▶ When to Admit

Patients requiring surgical treatment (deep brain stimulation placement) should be hospitalized.

Deng H et al. Genetics of essential tremor. *Brain.* 2007 Jun;130 (Pt 6):1456–64. [PMID: 17353225]

Elble RJ et al. An update on essential tremor. *Curr Neurol Neurosci Rep.* 2009 Jul;9(4):273–7. [PMID: 19515278]

Moro E et al. Unilateral subdural motor cortex stimulation improves essential tremor but not Parkinson’s disease. *Brain.* 2011 Jul;134(Pt 7):2096–105. [PMID: 21646329]

2. Parkinsonism



ESSENTIALS OF DIAGNOSIS

- ▶ Any combination of tremor, rigidity, bradykinesia, and progressive postural instability.
- ▶ Cognitive impairment is sometimes prominent.

► General Considerations

Parkinsonism is a relatively common disorder that occurs in all ethnic groups, with an approximately equal sex distribution. The most common variety, idiopathic Parkinson disease, begins most often between 45 and 65 years of age and is a progressive disease.

► Etiology

Parkinsonism may rarely occur on a familial basis, and the parkinsonian phenotype may result from mutations of several different genes (alpha-synuclein, parkin, *LRRK2*, *DJ1*, and *PINK1*). Mutations in *LRRK2* also account for some cases of apparently sporadic Parkinson disease. Postencephalitic parkinsonism is becoming increasingly rare. Exposure to certain toxins (eg, manganese dust, carbon disulfide) and severe carbon monoxide poisoning may lead to parkinsonism. Typical parkinsonism has occurred in individuals who have taken 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP) for recreational purposes. This compound is converted in the body to a neurotoxin that selectively destroys dopaminergic neurons in the substantia nigra. Reversible parkinsonism may develop in patients receiving neuroleptic drugs (see Chapter 25), reserpine, or metoclopramide. Only rarely is hemiparkinsonism the presenting feature of a progressive space-occupying lesion.

In idiopathic Parkinson disease, dopamine depletion due to degeneration of the dopaminergic nigrostriatal system leads to an imbalance of dopamine and acetylcholine, which are neurotransmitters normally present in the corpus striatum. Treatment is directed at redressing this imbalance by blocking the effect of acetylcholine with anticholinergic drugs or by the administration of levodopa, the precursor of dopamine. The serum urate level may be a prognostic indicator—the rate of progression declines as the urate level increases. Prior use of ibuprofen is associated with a decreased risk of developing Parkinson disease.

► Clinical Findings

Tremor, rigidity, bradykinesia, and postural instability are the cardinal features of parkinsonism and may be present in any combination. There may also be a mild decline in intellectual function. The tremor of about four to six cycles per second is most conspicuous at rest, is enhanced by emotional stress, and is often less severe during voluntary activity. Although it may ultimately be present in all limbs, the tremor is commonly confined to one limb or to the limbs on one side for months or years before it becomes more generalized. In some patients, tremor is absent.

Rigidity (an increase in resistance to passive movement) is responsible for the characteristically flexed posture seen in many patients, but the most disabling symptoms of parkinsonism are due to bradykinesia, manifested as a slowness of voluntary movement and a reduction in automatic movements such as swinging of the arms while walking. Curiously, however, effective voluntary activity may briefly be regained during an emergency (eg, the patient is able to leap aside to avoid an oncoming motor vehicle).

Clinical diagnosis of the well-developed syndrome is usually simple. The patient has a relatively immobile face

with widened palpebral fissures, infrequent blinking, and a certain fixity of facial expression. Seborrhea of the scalp and face is common. There is often mild blepharoclonus, and a tremor may be present about the mouth and lips. Repetitive tapping (about twice per second) over the bridge of the nose produces a sustained blink response (Myerson sign). Other findings may include saliva drooling from the mouth, perhaps due to impairment of swallowing; soft and poorly modulated voice; a variable rest tremor and rigidity in some or all of the limbs; slowness of voluntary movements; impairment of fine or rapidly alternating movements; and micrographia. There is typically no muscle weakness (provided that sufficient time is allowed for power to be developed) and no alteration in the tendon reflexes or plantar responses. It is difficult for the patient to arise from a sitting position and begin walking. The gait itself is characterized by small shuffling steps and a loss of the normal automatic arm swing; there may be unsteadiness on turning, difficulty in stopping, and a tendency to fall.

► Differential Diagnosis

Diagnostic problems may occur in mild cases, especially if tremor is minimal or absent. For example, mild hypokinesia or slight tremor is commonly attributed to old age. Depression, with its associated expressionless face, poorly modulated voice, and reduction in voluntary activity, can be difficult to distinguish from mild parkinsonism, especially since the two disorders may coexist; in some cases, a trial of antidepressant drug therapy is necessary. The family history, the character of the tremor, and lack of other neurologic signs should distinguish essential tremor from parkinsonism. **Wilson disease** can be distinguished by its early age at onset, the presence of other abnormal movements, Kayser-Fleischer rings, and chronic hepatitis, and by increased concentrations of copper in the tissues. **Huntington disease** presenting with rigidity and bradykinesia may be mistaken for parkinsonism unless the family history and accompanying dementia are recognized. In **multisystem atrophy** (previously called the **Shy-Drager syndrome**), autonomic insufficiency (leading to postural hypotension, anhidrosis, disturbances of sphincter control, erectile dysfunction, etc) may be accompanied by parkinsonism, pyramidal deficits, lower motor neuron signs, or cerebellar dysfunction. In **progressive supranuclear palsy**, bradykinesia and rigidity are accompanied by a supranuclear disorder of eye movements, pseudobulbar palsy, pseudo-emotional lability (pseudobulbar affect), and axial dystonia. **Jakob-Creutzfeldt disease** may be accompanied by features of parkinsonism, but dementia is usual, myoclonic jerking is common, ataxia and pyramidal signs may be conspicuous, and the electroencephalographic findings are usually characteristic. In **corticobasal degeneration**, asymmetric parkinsonism is accompanied by conspicuous signs of cortical dysfunction (eg, apraxia, sensory inattention, dementia, aphasia).

► Treatment

Treatment is symptomatic. There is great interest in developing disease-modifying therapies, and trials of several

putative neuroprotective agents are in progress, as are various trials of gene therapy.

A. Medical Measures

Drug treatment is not required early in the course of Parkinson disease, but the nature of the disorder and the availability of medical treatment for use when necessary should be discussed with the patient.

1. Amantadine—Patients with mild symptoms but no disability may be helped by amantadine. This drug improves all of the clinical features of parkinsonism, but its mode of action is unclear. Side effects include restlessness, confusion, depression, skin rashes, edema, nausea, constipation, anorexia, postural hypotension, and disturbances of cardiac rhythm. However, these are relatively uncommon with the usual dose (100 mg twice daily orally). It also ameliorates dyskinesias resulting from chronic levodopa therapy.

2. Anticholinergic drugs—Anticholinergics are more helpful in alleviating tremor and rigidity than bradykinesia. Treatment is started with a small dose (Table 24-6) and gradually increased until benefit occurs or side effects limit further increments. If treatment is ineffective, the drug is gradually withdrawn and another preparation then tried.

Common side effects include dryness of the mouth, nausea, constipation, palpitations, cardiac arrhythmias, urinary retention, confusion, agitation, restlessness, drowsiness, mydriasis, increased intraocular pressure, and defective accommodation.

Anticholinergic drugs are contraindicated in patients with prostatic hyperplasia, narrow-angle glaucoma, or obstructive gastrointestinal disease and are often tolerated poorly by the elderly. They are best avoided whenever cognitive impairment or a predisposition to delirium exists.

3. Levodopa—Levodopa, which is converted in the body to dopamine, improves all of the major features of parkinsonism, including bradykinesia, but does not stop progression of the disorder. The most common early side effects of levodopa are nausea, vomiting, and hypotension, but cardiac arrhythmias may also occur. Dyskinesias, restlessness, confusion, and other behavioral changes tend to occur

somewhat later and become more common with time. Levodopa-induced dyskinesias may take any conceivable form, including chorea, athetosis, dystonia, tremor, tics, and myoclonus. An even later complication is the “on-off phenomenon,” in which abrupt but transient fluctuations in the severity of parkinsonism occur unpredictably but frequently during the day. The “off” period of marked bradykinesia has been shown to relate in some instances to falling plasma levels of levodopa. During the “on” phase, dyskinesias are often conspicuous but mobility is increased.

Carbidopa, which inhibits the enzyme responsible for the breakdown of levodopa to dopamine, does not cross the blood-brain barrier. When levodopa is given in combination with carbidopa, the extracerebral breakdown of levodopa is diminished. This reduces the amount of levodopa required daily for beneficial effects, and it lowers the incidence of nausea, vomiting, hypotension, and cardiac irregularities. Such a combination does not prevent the development of the “on-off phenomenon,” and the incidence of other side effects (dyskinesias or psychiatric complications) may actually be increased.

Sinemet, a commercially available preparation that contains carbidopa and levodopa in a fixed ratio (1:10 or 1:4), is generally used. Treatment is started with a small dose—eg, one tablet of Sinemet 25/100 (containing 25 mg of carbidopa and 100 mg of levodopa) three times daily—and gradually increased depending on the response. Sinemet CR is a controlled-release formulation (containing 25 or 50 mg of carbidopa and 100 or 200 mg of levodopa). It is sometimes helpful in reducing fluctuations in clinical response to treatment and in reducing the frequency with which medication must be taken. The commercially available combination of levodopa with both carbidopa and entacapone (Stalevo) may also be helpful in this context and is discussed in the following section on COMT inhibitors. Response fluctuations are also reduced by keeping the daily intake of protein at the recommended minimum and taking the main protein meal as the last meal of the day.

The dyskinesias and behavioral side effects of levodopa are dose-related, but reduction in dose may eliminate any therapeutic benefit. Levodopa-induced dyskinesias may also respond to amantadine or possibly levetiracetam.

Levodopa therapy is contraindicated in patients with psychotic illness or narrow-angle glaucoma. It should not be given to patients taking monoamine oxidase A inhibitors or within 2 weeks of their withdrawal, because hypertensive crises may result. Levodopa should be used with care in patients with suspected malignant melanomas or with active peptic ulcers because of concerns that it may exacerbate these disorders.

4. Dopamine agonists—Dopamine agonists act directly on dopamine receptors, and their use in parkinsonism is associated with a lower incidence of the response fluctuations and dyskinesias that occur with long-term levodopa therapy. They were previously reserved for patients who had either become refractory to levodopa or developed the “on-off phenomenon.” However, they are now best given either before the introduction of levodopa or with a low dose of Sinemet 25/100 (carbidopa 25 mg and levodopa

Table 24-6. Some anticholinergic antiparkinsonian drugs.

Drug	Usual Daily Dose
Benztropine mesylate (Cogentin)	1-6 mg
Biperiden (Akineton)	2-12 mg
Orphenadrine (Disipal, Norflex)	150-400 mg
Procyclidine (Kemadrin)	7.5-30 mg
Trihexyphenidyl (Artane)	6-20 mg

Modified, with permission, from Aminoff MJ. Pharmacologic management of parkinsonism and other movement disorders. In: *Basic & Clinical Pharmacology*, 11th ed. Katzung BG (editor). McGraw-Hill, 2009.

100 mg), one tablet three times daily when dopaminergic therapy is first introduced; the dose of Sinemet is kept constant, while the dose of the agonist is gradually increased. Bromocriptine, an ergot derivative is not widely used in the United States because of side effects, including anorexia; nausea; vomiting; constipation; postural hypotension; digital vasospasm; cardiac arrhythmias; various dyskinesias and mental disturbances; headache; nasal congestion; erythromelalgia; pulmonary infiltrates; and pericardial, pleural, or pulmonary fibrosis. In 2007, the manufacturer of pergolide, another ergot derivative and dopamine agonist, withdrew the drug from the US market after two studies showed that serious cardiac valvular abnormalities developed in some patients while taking the drug.

Pramipexole and ropinirole are two newer dopamine agonists that are not ergot derivatives. They are effective in early Parkinson disease as well as in advanced stages of the disease. In each case, the daily dose is built up gradually. Pramipexole is started at a dosage of 0.125 mg three times daily orally, and the dose is doubled after 1 week and again after another week; the daily dose is then increased by 0.75 mg at weekly intervals depending on response and tolerance. Most patients require between 0.5 and 1.5 mg three times daily orally. Ropinirole is begun in a dosage of 0.25 mg three times daily orally, and the total daily dose is increased at weekly intervals by 0.75 mg until the fourth week and by 1.5 mg thereafter. Most patients require between 2 and 8 mg three times daily for benefit. Adverse effects include fatigue, somnolence, nausea, peripheral edema, dyskinesias, confusion, and postural hypotension. Less commonly, an irresistible urge to sleep may occur, sometimes in inappropriate and hazardous circumstances. Impulse control disorders involving gambling, shopping, or sexual activity have also been related to use of dopamine agonists. Extended-release, once-daily formulations of pramipexole and ropinirole are now available with similar efficacy and tolerability as the immediate release versions.

5. Selective monoamine oxidase inhibitors—Rasagiline, a selective monoamine oxidase B inhibitor, has a clear symptomatic benefit in a daily oral dose of 1 mg, taken in the morning; it may also be used for adjunctive therapy in patients with response fluctuations to levodopa. Selegiline (5 mg orally with breakfast and lunch) is another monoamine oxidase B inhibitor that is sometimes used as adjunctive treatment for parkinsonism. By inhibiting the metabolic breakdown of dopamine, these drugs may improve fluctuations or declining response to levodopa. Although it is sometimes advised that tyramine-rich foods be avoided when either rasagiline or selegiline is taken because of the theoretical possibility of a hypertensive (“cheese”) effect, there is no clinical evidence to support the need for such dietary precautions when they are taken at the recommended dosage.

Studies have suggested (but failed to show conclusively) that rasagiline may slow the progression of Parkinson disease, and it appears to delay the need for other symptomatic therapies. For these reasons, rasagiline is often started early, particularly for patients who are young or have mild disease. However, the FDA has rejected an expansion of rasagiline’s indication to include disease modification.

6. COMT inhibitors—Catecholamine-*O*-methyltransferase inhibitors reduce the metabolism of levodopa to 3-*O*-methyl-dopa and thereby alter the plasma pharmacokinetics of levodopa, leading to more sustained plasma levels and more constant dopaminergic stimulation of the brain. Two such agents, tolcapone and entacapone, are currently available and may be used as an adjunct to levodopa-carbidopa in patients with response fluctuations or an otherwise inadequate response. Treatment results in reduced response fluctuations, with a greater period of responsiveness to administered levodopa; however, the use of these agents does not delay the eventual development of levodopa-induced dyskinesias. Tolcapone is given in a dosage of 100 mg or 200 mg three times daily orally, and entacapone is given as 200 mg with each dose of Sinemet (levodopa-carbidopa). With either preparation, the dose of Sinemet taken concurrently may have to be reduced by up to one-third to avoid side effects such as dyskinesias, confusion, hypotension, and syncope. Diarrhea is sometimes troublesome. Because rare cases of fulminant hepatic failure have followed its use, tolcapone should be avoided in patients with preexisting liver disease. Serial liver function tests should be performed at 2-week intervals for the first year and at longer intervals thereafter in patients receiving the drug—as recommended by the manufacturer. Hepatotoxicity has not been reported with entacapone, which is therefore the preferred agent, and serial liver function tests are not required.

Stalevo is the commercial preparation of levodopa combined with both carbidopa and entacapone. It is best used in patients already stabilized on equivalent doses of carbidopa/levodopa and entacapone. It is priced at or below the price of the individual ingredients (ie, carbidopa/levodopa and entacapone) and has the added convenience of requiring fewer tablets to be taken daily. It is available in three strengths: Stalevo 50 (12.5 mg of carbidopa, 50 mg of levodopa, and 200 mg of entacapone), Stalevo 100 (25 mg of carbidopa, 100 mg of levodopa, and 200 mg of entacapone), and Stalevo 150 (37.5 mg of carbidopa, 150 mg of levodopa, and 200 mg of entacapone).

7. Atypical antipsychotics—Confusion and psychotic symptoms may occur as a side effect of dopaminergic therapy or as a part of the underlying illness. They often respond to atypical antipsychotic agents, which have few extrapyramidal side effects and do not block the effects of dopaminergic medication. Olanzapine, quetiapine, and risperidone may be tried, but the most effective of these agents is clozapine, a dibenzodiazepine derivative. Clozapine may rarely cause marrow suppression, and weekly blood counts are therefore necessary for patients taking it. The patient is started on 6.25 mg at bedtime and the dosage increased to 25–100 mg/d as needed. In low doses, it may also improve iatrogenic dyskinesias.

B. General Measures

Physical therapy or speech therapy helps many patients. Cognitive impairment and psychiatric symptoms may be helped by a cholinesterase inhibitor, such as rivastigmine (3–12 mg orally daily or 4.6 or 9.5 mg/24 hours transdermally daily). The quality of life can often be improved by

the provision of simple aids to daily living, eg, rails or banisters placed strategically about the home, special table cutlery with large handles, nonslip rubber table mats, and devices to amplify the voice.

C. Surgical Measures

Thalamotomy or pallidotomy may help patients who become unresponsive to medical treatment or have intolerable side effects from antiparkinsonian agents, especially if they have no evidence of diffuse vascular disease or significant cognitive decline. Ablative surgery should generally be confined to one side because the morbidity is considerably greater after bilateral procedures. Because of their morbidity, ablative procedures have generally been supplanted by deep brain stimulation.

D. Brain Stimulation

High-frequency stimulation of the subthalamic nuclei or globus pallidus internus may benefit all the major features of the disease. Electrical stimulation of the brain has the advantage over ablative procedures of being reversible and of causing minimal or no damage to the brain, and is therefore the preferred surgical approach to treatment. There is no evidence that the natural history of Parkinson disease is affected. Deep brain stimulation is reserved for patients without cognitive impairment or psychiatric disorder who have a good response to levodopa but in whom dyskinesias or response fluctuations are problematic. It frequently takes 3–6 months after surgery to adjust stimulator programming and to achieve optimal results. Side effects include depression, apathy, impulsivity, executive dysfunction, and decreased verbal fluency in a subset of patients.

E. Gene Therapy

Injections of adeno-associated viruses encoding various human genes have been made into the subthalamic nucleus or putamen in various phase I and phase II trials. These trials are currently ongoing, but the procedure appears to be safe. Early evidence suggests that transfer of the gene for glutamic acid decarboxylase (the enzyme that produces the inhibitory neurotransmitter GABA) into the subthalamic nucleus improves motor function in patients with Parkinson disease, but it is unclear whether there is any greater benefit than subthalamic deep-brain stimulation.

► When to Refer

All patients should be referred.

► When to Admit

Patients requiring surgical treatment should be admitted.

Follett KA et al; CSP 468 Study Group. Pallidal versus subthalamic deep-brain stimulation for Parkinson's disease. *N Engl J Med*. 2010 Jun 3;362(22):2077–91. [PMID: 20519680]

Gao X et al. Use of ibuprofen and risk of Parkinson disease. *Neurology*. 2011 Mar 8;76(10):863–9. [PMID: 21368281]

Gottwald MD, Aminoff MJ. Therapies for dopaminergic-induced dyskinesias in Parkinson disease. *Ann Neurol*. 2011 Jun;69(6):919–27. [PMID: 21681795]

Lees AJ et al. Parkinson's disease. *Lancet*. 2009 Jun 13;373(9680):2055–66. [PMID: 19524782]

LeWitt PA et al. AAV2-GAD gene therapy for advanced Parkinson's disease: a double-blind, sham-surgery controlled, randomised trial. *Lancet Neurol*. 2011 Apr;10(4):309–19. [PMID: 21419704]

Rascol O et al. A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes. *Lancet Neurol*. 2011 May;10(5):415–23. [PMID: 21482191]

Rascol O et al. Efficacy, safety, and tolerability of overnight switching from immediate- to once daily extended-release pramipexole in early Parkinson's disease. *Mov Disord*. 2010 Oct 30;25(14):2326–32. [PMID: 20669265]

Williams A et al. Deep brain stimulation plus best medical therapy versus best medical therapy alone for advanced Parkinson's disease (PD SURG trial): a randomised, open-label trial. *Lancet Neurol*. 2010 Jun;9(6):581–91. [PMID: 20434403]

3. Huntington Disease



ESSENTIALS OF DIAGNOSIS

- Gradual onset and progression of chorea and dementia or behavioral change.
- Family history of the disorder.
- Responsible gene identified on chromosome 4.

► General Considerations

Huntington disease is characterized by chorea and dementia. It is inherited in an autosomal dominant manner and occurs throughout the world, in all ethnic groups, with a prevalence rate of about 5 per 100,000. There is an expanded and unstable CAG trinucleotide repeat in the huntingtin gene at 4p16.3; longer repeat lengths correspond to an earlier age of onset and faster disease progression.

► Clinical Findings

A. Symptoms and Signs

Clinical onset is usually between 30 and 50 years of age. The disease is progressive and usually leads to a fatal outcome within 15–20 years. The initial symptoms may consist of either abnormal movements or intellectual changes, but ultimately both occur. The earliest mental changes are often behavioral, with irritability, moodiness, antisocial behavior, or a psychiatric disturbance, but a more obvious dementia subsequently develops. The dyskinesia may initially be no more than an apparent fidgetiness or restlessness, but eventually choreiform movements and some dystonic posturing occur. Progressive rigidity and akinesia (rather than chorea) sometimes occur in association with dementia, especially in cases with childhood onset.

B. Imaging

CT scanning or MRI usually demonstrates cerebral atrophy and atrophy of the caudate nucleus in established cases.

Positron emission tomography (PET) has shown reduced striatal metabolic rate.

► Differential Diagnosis

The diagnosis is established with a widely available genetic test, although such testing should be pursued under the guidance of a licensed genetic counselor. Chorea developing with no family history of choreoathetosis should not be attributed to Huntington disease, at least not until other causes of chorea have been excluded clinically and by appropriate laboratory studies. Nongenetic causes of chorea include stroke, systemic lupus erythematosus and related disorders, paraneoplastic syndromes, infection with HIV, and various medications. In younger patients, self-limiting Sydenham chorea develops after group A streptococcal infections on rare occasions. If a patient presents solely with progressive intellectual failure, it may not be possible to distinguish Huntington disease from other causes of dementia unless there is a characteristic family history or a dyskinesia develops.

Huntington disease–like (HDL) disorders resemble Huntington disease but the CAG trinucleotide repeat number of the huntingtin gene is normal. There are autosomal dominant (HDL1, a familial prion disease involving a mutation in the *PRNP* gene on chromosome 20; and HDL2, a triplet repeat disease involving the gene for junctophilin-3 on chromosome 16) and recessive forms (HDL3, 4p15.3).

A clinically similar autosomal dominant disorder (**dentatorubral-pallidoluysian atrophy**), manifested by chorea, dementia, ataxia, and myoclonic epilepsy, is uncommon except in persons of Japanese ancestry. It is due to a mutation in the *ATN1* gene mapping to 12p13.31. Treatment is as for Huntington disease.

► Treatment

There is no cure for Huntington disease; progression cannot be halted; and treatment is purely symptomatic. The reported biochemical changes suggest a relative underactivity of neurons containing gamma-aminobutyric acid (GABA) and acetylcholine or a relative overactivity of dopaminergic neurons. Tetrabenazine, a drug that interferes with the vesicular storage of biogenic amines, is widely used to treat the dyskinesia. The starting dose is 12.5 mg twice or three times daily orally, increasing by 12.5 mg every 5 days depending on response and tolerance; the usual maintenance dose is 25 mg three times daily. Side effects include depression, postural hypotension, drowsiness, and parkinsonian features; tetrabenazine should not be given within 14 days of taking monoamine oxidase inhibitors and is not indicated for the treatment of levodopa-induced dyskinesias. Reserpine is similar in depleting central monoamines but has more peripheral effects and a worse side-effect profile, making its use problematic in Huntington disease; if utilized, the dose is built up gradually to between 2 mg and 5 mg orally daily, depending on the response. Treatment with drugs blocking dopamine receptors, such as phenothiazines or haloperidol, may control the dyskinesia and any behavioral disturbances.

Haloperidol treatment is usually begun with a dose of 1 mg once or twice daily orally, which is then increased every 3 or 4 days depending on the response; alternatively, atypical antipsychotic agents such as quetiapine (increasing from 25 mg daily orally up to 100 mg twice daily orally as tolerated) may be tried. Amantadine in a dose of 200 mg to 400 mg daily orally is sometimes helpful for chorea. Behavioral disturbances may respond to clozapine. Attempts to compensate for the relative GABA deficiency by enhancing central GABA activity or to compensate for the relative cholinergic underactivity by giving choline chloride have not been therapeutically helpful. Neuroprotective strategies are being explored.

Offspring should be offered genetic counseling. Genetic testing permits presymptomatic detection and definitive diagnosis of the disease.

► When to Refer

All patients should be referred.

Adam OR et al. Symptomatic treatment of Huntington disease. *Neurotherapeutics*. 2008 Apr;5(2):181–97. [PMID: 18394562]

Biglan KM et al. Motor abnormalities in premanifest persons with Huntington's disease: the PREDICT-HD study. *Mov Disord*. 2009 Sep 15;24(12):1763–72. [PMID: 19562761]

Frank S. Tetrabenazine as anti-chorea therapy in Huntington disease: an open-label continuation study. *Huntington Study Group/TETRA-HD Investigators. BMC Neurol*. 2009 Dec 18;9:62. [PMID: 20021666]

Kiebertz K et al; Huntington Disease Study Group DIMOND Investigators. A randomized, placebo-controlled trial of latrepirdine in Huntington disease. *Arch Neurol*. 2010 Feb; 67(2):154–60. [PMID: 20142523]

Roze E et al. Pathophysiology of Huntington's disease: from huntingtin functions to potential treatments. *Curr Opin Neurol*. 2008 Aug;21(4):497–503. [PMID: 18607213]

4. Idiopathic Torsion Dystonia



ESSENTIALS OF DIAGNOSIS

- Dystonic movements and postures.
- Normal birth and developmental history. No other neurologic signs.
- Investigations (including CT scan or MRI) reveal no cause of dystonia.

► General Considerations

Idiopathic torsion dystonia may occur sporadically or on a hereditary basis, with autosomal dominant, autosomal recessive, and X-linked recessive modes of transmission. One responsible gene is located at 9q34 (and has been named *DYT1*) and involves a unique mutation consisting of a GAG deletion in the major dominantly inherited disorder, and maps to the long arm of the X chromosome in the X-linked recessive form; the responsible gene in the autosomal recessive disorder is unknown. Symptoms may begin in childhood or later and persist throughout life.

► Clinical Findings

The disorder is characterized by the onset of abnormal movements and postures in a patient with a normal birth and developmental history, no relevant past medical illness, and no other neurologic signs. Investigations (including CT scan) reveal no cause for the abnormal movements. Dystonic movements of the head and neck may take the form of torticollis, blepharospasm, facial grimacing, or forced opening or closing of the mouth. The limbs may also adopt abnormal but characteristic postures. The age at onset influences both the clinical findings and the prognosis. With onset in childhood, there is usually a family history of the disorder, symptoms commonly commence in the legs, and progression is likely until there is severe disability from generalized dystonia. In contrast, when onset is later, a positive family history is unlikely, initial symptoms are often in the arms or axial structures, and severe disability does not usually occur, although generalized dystonia may ultimately develop in some patients. If all cases are considered together, about one-third of patients eventually become so severely disabled that they are confined to chair or bed, while another one-third are affected only mildly.

► Differential Diagnosis

Before a diagnosis of idiopathic torsion dystonia is made, it is imperative to exclude other causes of dystonia. Perinatal anoxia, birth trauma, and kernicterus are common causes of dystonia, but abnormal movements usually then develop before the age of 5, the early development of the patient is usually abnormal, and a history of seizures is not unusual. Moreover, examination may reveal signs of mental retardation or pyramidal deficit in addition to the movement disorder. Dystonic posturing may also occur in Wilson disease, Huntington disease, or parkinsonism; as a sequela of encephalitis lethargica or previous neuroleptic drug therapy; and in certain other disorders. In these cases, diagnosis is based on the history and accompanying clinical manifestations.

► Treatment

Idiopathic torsion dystonia usually responds poorly to drugs. Levodopa, diazepam, baclofen, carbamazepine, amantadine, or anticholinergic medication (in high dosage) is occasionally helpful; if not, a trial of treatment with tetrabenazine, phenothiazines, or haloperidol may be worthwhile. In each case, the dose has to be individualized, depending on response and tolerance. However, the doses of these latter drugs that are required for benefit lead usually to mild parkinsonism. Pallidal deep brain stimulation is helpful for medically refractory dystonia and has a lower morbidity than stereotactic thalamotomy, which is sometimes helpful in patients with predominantly unilateral limb dystonia. Potential adverse events of deep brain stimulation include cerebral infection or hemorrhage, broken leads, affective changes, and dysarthria.

A distinct variety of dominantly inherited dystonia, caused by a mutation in the gene for GTP cyclohydrolase I on chromosome 14q, is remarkably responsive to levodopa.

► When to Refer

All patients should be referred.

► When to Admit

Patients requiring surgical treatment should be admitted.

Lyons MK et al. Long-term follow-up of deep brain stimulation for Meige syndrome. *Neurosurg Focus*. 2010 Aug;29(2):E5. [PMID: 20672922]

Ostrem JL et al. Treatment of dystonia with deep brain stimulation. *Neurotherapeutics*. 2008 Apr;5(2):320–30. [PMID: 18394573]

5. Focal Torsion Dystonia

A number of the dystonic manifestations that occur in idiopathic torsion dystonia may also occur as isolated phenomena. They are best regarded as focal dystonias that either occur as formes frustes of idiopathic torsion dystonia in patients with a positive family history or represent a focal manifestation of the adult-onset form of that disorder when there is no family history. Mapping of responsible genes to chromosome 8 (*DYT6*) and chromosome 18 (*DYT7*) has been reported in some instances of cervical or cranial dystonia. Medical treatment is generally unsatisfactory. A trial of the drugs used in idiopathic torsion dystonia is worthwhile, however, since a few patients do show some response. In addition, with restricted dystonias such as blepharospasm or torticollis, local injection of botulinum A toxin into the overactive muscles may produce worthwhile benefit for several weeks or months and can be repeated as needed.

Both blepharospasm and oromandibular dystonia may occur as an isolated focal dystonia. The former is characterized by spontaneous involuntary forced closure of the eyelids for a variable interval. Oromandibular dystonia is manifested by involuntary contraction of the muscles about the mouth causing, for example, involuntary opening or closing of the mouth, roving or protruding tongue movements, and retraction of the platysma.

Spasmodic torticollis, usually with onset between 25 and 50 years of age, is characterized by a tendency for the neck to twist to one side. This initially occurs episodically, but eventually the neck is held to the side. Spontaneous resolution may occur in the first year or so. The disorder is otherwise usually lifelong. Selective section of the spinal accessory nerve and the upper cervical nerve roots is sometimes helpful if medical treatment is unsuccessful. Local injection of botulinum A toxin provides benefit in most cases.

Writer's cramp is characterized by dystonic posturing of the hand and forearm when the hand is used for writing and sometimes when it is used for other tasks, eg, playing the piano or using a screwdriver or eating utensils. Drug treatment is usually unrewarding, and patients are often best advised to learn to use the other hand for activities requiring manual dexterity. Injections of botulinum A toxin are helpful in some instances.

6. Myoclonus

Occasional myoclonic jerks may occur in anyone, especially when drifting into sleep. General or multifocal myoclonus

is common in patients with idiopathic epilepsy and is especially prominent in certain hereditary disorders characterized by seizures and progressive intellectual decline, such as the lipid storage diseases. It is also a feature of various rare degenerative disorders, notably Ramsay Hunt syndrome, and is common in subacute sclerosing panencephalitis and Jakob-Creutzfeldt disease. Generalized myoclonic jerking may accompany uremic and other metabolic encephalopathies, result from therapy with levodopa or cyclic antidepressants, occur in alcohol or drug withdrawal states, or follow anoxic brain damage. It also occurs on a hereditary or sporadic basis as an isolated phenomenon in otherwise healthy subjects.

Segmental myoclonus is a rare manifestation of a focal spinal cord lesion. It may also be the clinical expression of **epilepsia partialis continua**, a disorder in which a repetitive focal epileptic discharge arises in the contralateral sensorimotor cortex, sometimes from an underlying structural lesion. An electroencephalogram is often helpful in clarifying the epileptic nature of the disorder, and CT or MRI scan may reveal the causal lesion.

Myoclonus may respond to certain anticonvulsant drugs, especially valproic acid, or to one of the benzodiazepines, particularly clonazepam (see Table 24–3). It may also respond to piracetam (up to 16.8 g daily). Myoclonus following anoxic brain damage is often responsive to oxitriptan (5-hydroxytryptophan), an investigational agent that is the precursor of serotonin, and sometimes to clonazepam. Oxitriptan is given in gradually increasing doses up to 1–1.5 mg daily. In patients with segmental myoclonus, a localized lesion should be searched for and treated appropriately.

Chang VC et al. Myoclonus. *Curr Treat Options Neurol*. 2008 May;10(3):222–9. [PMID: 18579026]

7. Wilson Disease

In this metabolic disorder, abnormal movement and posture may occur with or without coexisting signs of liver involvement. Psychiatric and neuropsychological manifestations are common. Wilson disease is discussed in Chapter 16.

Lorincz MT. Neurologic Wilson's disease. *Ann N Y Acad Sci*. 2010 Jan;1184:173–87. [PMID: 20146697]

8. Drug-Induced Abnormal Movements

Phenothiazines, butyrophenones, and metoclopramide may produce a wide variety of abnormal movements, including parkinsonism, akathisia (ie, motor restlessness), acute dystonia, chorea, and tardive dyskinesias or dystonia; several of these are also produced by aripiprazole. These complications are discussed in Chapter 25. Chorea may also develop in patients receiving levodopa, bromocriptine, anticholinergic drugs, phenytoin, carbamazepine, lithium, amphetamines, or oral contraceptives, and it resolves with withdrawal of the offending substance. Similarly, dystonia may be produced by levodopa, bromocriptine, lithium, or carbamazepine; and parkinsonism

by reserpine and tetrabenazine. Postural tremor may occur with a variety of drugs, including epinephrine, isoproterenol, theophylline, caffeine, lithium, thyroid hormone, tricyclic antidepressants, and valproic acid.

9. Restless Legs Syndrome

This disorder may occur as a primary (idiopathic) disorder or in relation to Parkinson disease, pregnancy, iron deficiency anemia, peripheral neuropathy (especially uremic or diabetic), or periodic leg movements of sleep. It may have a hereditary basis, and several genetic loci have been associated with the disorder (12q12–q21, 14q13–q21, 9p24–p22, 2q33, 20p13, 6p21, and 2p14–p13). Restlessness and curious sensory disturbances lead to an irresistible urge to move the limbs, especially during periods of relaxation. Disturbed nocturnal sleep and excessive daytime somnolence may result. Therapy is with nonergot dopamine agonists, such as pramipexole (0.125–0.5 mg once daily or ropinirole (0.25–4 mg once daily) 2 to 3 hours before bedtime, or with benzodiazepines, such as clonazepam. Gabapentin (starting with 300 mg daily, increasing to approximately 1800 mg daily depending on response and tolerance), pregabalin (150–300 mg divided twice to three times daily), or gabapentin enacarbil (600 mg extended release daily) are related drugs that improve symptoms. Levodopa is helpful but may lead to an augmentation of symptoms, so that its use is generally reserved for those who do not respond to other measures. In some instances, opioids are required to control symptoms.

Ellenbogen AL et al. A 52-week study of gabapentin enacarbil in restless legs syndrome. *Clin Neuropharmacol*. 2011 Jan–Feb;34(1):8–16. [PMID: 21242741]

Garcia-Borreguero D et al. Treatment of restless legs syndrome with pregabalin: a double-blind, placebo-controlled study. *Neurology*. 2010 Jun 8;74(23):1897–904. [PMID: 20427750]

Manconi M et al. Pramipexole versus ropinirole: polysomnographic acute effects in restless legs syndrome. *Mov Disord*. 2011 Apr;26(5):892–5. [PMID: 21370262]

Oertel W et al; SP710 Study Group. Long-term safety and efficacy of rotigotine transdermal patch for moderate-to-severe idiopathic restless legs syndrome: a 5-year open-label extension study. *Lancet Neurol*. 2011 Aug;10(8):710–20. [PMID: 21705273]

10. Gilles de la Tourette Syndrome



ESSENTIALS OF DIAGNOSIS

- ▶ Multiple motor and phonic tics.
- ▶ Symptoms begin before age 21 years.
- ▶ Tics occur frequently for at least 1 year.
- ▶ Tics vary in number, frequency, and nature over time.

▶ Clinical Findings

Motor tics are the initial manifestation in 80% of cases and most commonly involve the face, whereas in the remaining

20%, the initial symptoms are phonic tics; ultimately a combination of different motor and phonic tics develop in all patients. These are noted first in childhood, generally between the ages of 2 and 15. Motor tics occur especially about the face, head, and shoulders (eg, sniffing, blinking, frowning, shoulder shrugging, head thrusting, etc). Phonic tics commonly consist of grunts, barks, hisses, throat-clearing, coughs, etc, but sometimes also of verbal utterances including coprolalia (obscene speech). There may also be echolalia (repetition of the speech of others), echopraxia (imitation of others' movements), and palilalia (repetition of words or phrases). Some tics may be self-mutilating in nature, such as nail-biting, hair-pulling, or biting of the lips or tongue. The disorder is chronic, but the course may be punctuated by relapses and remissions. Obsessive-compulsive behaviors are commonly associated and may be more disabling than the tics themselves. A family history is sometimes obtained, and a mutation in the histidine decarboxylase gene on chromosome 15 was recently reported in one family with an autosomal dominant form of the disease. Prior reports of a linkage to chromosome 13q have been called into question.

Examination usually reveals no abnormalities other than the tics. In addition to obsessive-compulsive behavior disorders, psychiatric disturbances may occur because of the associated cosmetic and social embarrassment. The diagnosis of the disorder is often delayed for years, the tics being interpreted as psychiatric illness or some other form of abnormal movement. Patients are thus often subjected to unnecessary treatment before the disorder is recognized. The tic-like character of the abnormal movements and the absence of other neurologic signs should differentiate this disorder from other movement disorders presenting in childhood. Wilson disease, however, can simulate the condition and should be excluded.

▶ Treatment

Treatment is symptomatic and may need to be continued indefinitely. Cognitive behavioral therapy or other forms of behavioral intervention can be effective alone or in combination with pharmacotherapy. α -Adrenergic agonists, such as clonidine (start 0.05 mg orally at bedtime, titrating to 0.3–0.4 mg orally daily, divided three to four times per day) or guanfacine (start 0.5 mg orally at bedtime, titrating to a maximum of 3–4 mg orally daily, divided twice daily) are first-line therapies because of a favorable side-effect profile compared with typical antipsychotics, which are the only FDA-approved therapies for the disorder. Topiramate has shown promise in a double-blind, placebo-controlled study, and the use of tetrabenazine has been described but not rigorously tested. Atypical antipsychotics, including risperidone and aripiprazole, have shown possible efficacy and may be tried before the typical antipsychotic agents. When a typical antipsychotic is required in cases of severe tics, haloperidol is generally regarded as the drug of choice. It is started in a low dose (0.25 mg daily orally) that is gradually increased (by 0.25 mg every 4 or 5 days) until there is maximum benefit with a minimum of side effects or until side effects limit further increments. A total daily oral dose

of between 2 mg and 8 mg is usually optimal, but higher doses are sometimes necessary. Fluphenazine (2–15 mg orally daily) or pimozide (1–10 mg orally daily) are alternatives. Typical antipsychotics can cause significant weight gain and carry a risk of tardive dyskinesias and other long-term, potentially irreversible motor side effects.

Injection of botulinum toxin type A at the site of the most distressing tics is sometimes worthwhile. Bilateral high-frequency deep brain stimulation at various sites has been helpful in some, otherwise intractable, cases.

▶ When to Refer

All patients with Gilles de la Tourette syndrome should be referred.

▶ When to Admit

Patients undergoing surgical (deep brain stimulation) treatment should be admitted.

Jankovic J et al. A randomised, double-blind, placebo-controlled study of topiramate in the treatment of Tourette syndrome. *J Neurol Neurosurg Psychiatry*. 2010 Jan;81(1):70–3. [PMID: 19726418]

Sassi M et al. Deep brain stimulation therapy for treatment-refractory Tourette's syndrome: a review. *Acta Neurochir (Wien)*. 2011 Mar;153(3):639–45. [PMID: 20853121]

DEMENTIA



ESSENTIALS OF DIAGNOSIS

- ▶ Progressive intellectual decline.
- ▶ Not due to delirium or psychiatric disease.
- ▶ Age is the main risk factor, followed by family history and vascular disease risk factors.

▶ General Considerations

Dementia is a progressive decline in intellectual function that is severe enough to compromise social or occupational functioning. “Mild cognitive impairment” describes a decline that has not resulted in a change in the level of function. Although a few patients identify a precipitating event, most experience an insidious onset and gradual progression of symptoms.

Dementia typically begins after age 60, and the prevalence doubles approximately every 5 years thereafter; in persons aged 85 and older, around half have dementia. In most, the cause of dementia is acquired, either as a sporadic primary neurodegenerative disease or as the result of another disorder, such as stroke. Other risk factors for dementia include family history, diabetes mellitus and other vascular disease risk factors, and a history of significant head injury. Dementia is more prevalent among women, but this is accounted for by their longer life expectancy. Education and ongoing intellectual stimulation may

be protective, perhaps by promoting a “cognitive reserve,” an improved capacity to compensate for insidious neurodegeneration.

Dementia is distinct from delirium and psychiatric disease. **Delirium** is an acute confusional state that often occurs in response to an identifiable trigger, such as drug or alcohol intoxication or withdrawal (eg, Wernicke encephalopathy, described below); medication side effects (especially drugs with anticholinergic properties, antihistamines, benzodiazepines, sleeping aids, opioids, neuroleptics, corticosteroids, and other sedative or psychotropic agents), infection (consider occult urinary tract infection or pneumonia in elderly patients), metabolic disturbance (including an electrolyte abnormality; hypoglycemia or hyperglycemia; or a nutritional, endocrine, renal, or hepatic disorder), sleep deprivation, or other neurologic disease (seizure, including a postictal state, or stroke). A delirium typically involves fluctuating level of arousal, including drowsiness or agitation, and it improves after removal or treatment of the precipitating factor. Patients with dementia are especially susceptible to episodes of delirium, but recognition of the dementia is not possible until the delirium lifts. For this reason, dementia is typically diagnosed in outpatients who are otherwise medically stable, rather than in acutely ill patients in the hospital.

Psychiatric disease sometimes leads to complaints of impaired cognition. Impaired attention is usually to blame, and in some patients with depression or anxiety, poor focus and concentration may even be a primary complaint. The symptoms should improve with appropriate psychiatric treatment. Mood disorders are commonly seen in patients with neurodegenerative disease and in some cases are an early symptom. There is some evidence that a persistent, untreated mood disorder may predispose to the development of an age-related dementia, and psychiatric symptoms can clearly exacerbate cognitive impairment in patients who already have dementia; therefore, suspicion of dementia should not distract from appropriate screening for and treatment of depression or anxiety.

► Clinical Findings

A. Symptoms and Signs

Physicians should be aware that a patient’s insight into a cognitive change may be vague or absent, and collateral history is essential to a proper evaluation. As patients age, primary care clinicians should inquire periodically about the presence of any cognitive symptoms.

Symptoms depend on the area of the brain affected. **Short-term memory loss**, involving the repeating of questions or stories and a diminished ability to recall the details of recent conversations or events, frequently results from pathologic changes in the hippocampus. **Word-finding difficulty** often involves difficulty recalling the names of people, places, or objects, with low-frequency words affected first, eventually resulting in speech laden with pronouns and circumlocutions. This problem is thought to arise from pathology at the temporoparietal junction of the left hemisphere. Problems with articulation, fluency, comprehension, or word meaning are anatomically distinct and

less common. **Visuospatial dysfunction** may result in poor navigation and getting lost in familiar places, impaired recognition of previously familiar faces and buildings, or trouble discerning an object against a background. The right parietal lobe is one of the brain areas implicated in such symptoms. **Executive dysfunction** may manifest by easy distractibility, impulsivity, mental inflexibility, concrete thought, slowed processing speed, poor planning and organization, or impaired judgment. Localization may vary and could include the frontal lobes or subcortical areas like the basal ganglia or cerebral white matter. **Apathy** or indifference, separate from depression, is common and may have a similar anatomy as executive dysfunction. **Apraxia**, or the loss of learned motor behaviors, may result from dysfunction of the frontal or parietal lobes, especially the left parietal lobe.

The time of symptom onset must be established, but subtle, early symptoms are often apparent only in retrospect. Another event, such as an illness or hospitalization, may lead to a new recognition of existing symptoms. Symptoms often accumulate over time, and the nature of the earliest symptom is most helpful in forming the differential diagnosis. The history should establish risk factors for dementia, including family history, other chronic illnesses, and vascular disease risk factors. Finally, it is important to document the patient’s current capacity to perform basic and instrumental activities of daily living (see Chapter 4) and to note the extent of decline from the premorbid level of function. Indeed, it is this functional assessment that defines the presence and severity of a dementia.

The physical examination is important to identify any occult medical illness. In addition, eye movement abnormalities, parkinsonism (see above), or other motor abnormalities may help identify an underlying neurologic condition. The workup should prioritize the exclusion of conditions that are reversible or require separate therapy. Screening for depression is necessary, along with imaging and laboratory workup, as indicated below.

B. Neuropsychological Assessment

Brief quantification of cognitive impairment is indicated in a patient complaining of cognitive symptoms. The Folstein Mini Mental State Exam (MMSE) is commonly used, and can be administered in approximately 5 minutes. The Montreal Cognitive Assessment takes slightly longer and may be slightly more sensitive. These tests are useful because they are objective and widely used, but both have important limitations: they are insensitive to mild cognitive impairment, they may be biased negatively by the presence of language or attention problems, and they do not correlate with functional capacity.

An evaluation by a trained neuropsychologist or psychometrician may be appropriate. The goal of such testing is to enhance localization by defining the cognitive domains that are impaired as well as to quantify the degree of impairment. There is no standard battery of tests, but a variety of metrics are commonly used to assess all of the symptom types highlighted above. Assessments are most accurate when a patient is well-rested, comfortable, and otherwise medically stable.

In an asymptomatic patient, there is no screening guideline. Because occult cognitive impairment can lead to morbidity through isolation and poor attentiveness to basic needs (for instance, in an elderly individual living alone), periodic screening is prudent for patients in their 70s and older: Ask the patient to repeat three simple nouns (not referring to objects in the room), then to draw a clock face with numbers in the correct place and the hands indicating a time of 11:10, and finally to recall the three nouns; recall of fewer than three words or any abnormality in the clock drawing may signify the need to continue with the full MMSE and to pursue further questioning and workup.

C. Imaging

Brain imaging is indicated in any patient with a new, progressive cognitive complaint. The goal is to exclude occult cerebrovascular disease, tumor, or other identifiable structural abnormality, rather than to provide positive evidence of a neurodegenerative disease. Global or focal brain atrophy may be worse than expected for age and could suggest a particular neurodegenerative process, but such findings are rarely specific. MRI is preferred, but CT scan will suffice; no contrast is necessary. If MRI is obtained, then diffusion-weighted sequences may be helpful if acute stroke or prion disease is a consideration.

Positron-emission tomography (PET) with fluorodeoxyglucose (FDG) may identify particular brain structures that are hypometabolic and thus likely to harbor pathology. PET imaging does not confirm or exclude any specific cause of dementia but may be useful as an element of the workup in specific clinical circumstances, such as discriminating between Alzheimer disease and frontotemporal dementia in a patient with some symptoms of each. PET imaging with a radiolabeled ligand for β -amyloid, one of the pathologic proteins in Alzheimer disease, is nearing FDA approval and may soon be available. This technique may be quite helpful in diagnosing Alzheimer disease in younger patients. However, after age 60 or 70, amyloid plaques can accumulate in the absence of cognitive impairment; thus, the specificity of a positive amyloid scan diminishes with age. Single photon-emission computed tomography offers similar information as FDG-PET but is less sensitive.

D. Laboratory Findings

Serum levels of vitamin B₁₂, free T₄, and thyroid-stimulating hormone should be measured for any patient with cognitive symptoms. A serum rapid plasma regain (RPR) used to be obtained routinely, but now is done only if there is a risk factor or suspicion for a remote, untreated syphilis infection. Other testing should be driven by clinical suspicion, and often includes a complete blood count, serum electrolytes, glucose, and lipid profile. Also prudent is age-appropriate cancer screening.

Other tests are available if Alzheimer disease is a consideration: ApoE genotyping is clinically available, and the presence of one or two ApoE ϵ 4 alleles indicates an increased risk of Alzheimer disease. Importantly, the gene does not cause Alzheimer disease; familial Alzheimer disease is rare and is caused by mutations in the amyloid

precursor protein or presenilin genes. Finding an ApoE ϵ 4 allele in a young patient with dementia might raise the index of suspicion for Alzheimer disease. Obtaining a genotype in an elderly patient is unlikely to be helpful, and doing so in an asymptomatic patient as a marker of risk for Alzheimer disease is inappropriate until a preventive therapy becomes available. Spinal fluid protein measurements are also now clinically available. Levels of β -amyloid decrease and tau protein increase in Alzheimer disease, but the sensitivity and specificity at discriminating from other causes of dementia is uncertain.

► Differential Diagnosis

In elderly patients with gradually progressive cognitive symptoms and no other complaint or sign, a neurodegenerative disease is likely (Table 24–7). Decline beginning before age 60, rapid progression, fluctuating course, unintended weight loss, systemic complaints, or other unexplained symptoms or signs raise suspicion for another process. In this case, the differential is broad and includes infection or inflammatory disease (consider a lumbar puncture to screen for cells or antibodies in the spinal fluid), neoplasm or a paraneoplastic condition, endocrine or metabolic disease, drugs or toxins, or other conditions. **Normal pressure hydrocephalus** is a difficult diagnosis to establish. Symptoms include gait apraxia (sometimes described as a “magnetic” gait, as if the feet are stuck to the floor), urinary incontinence, and dementia. CT scanning or MRI of the brain reveals ventricles that are enlarged in obvious disproportion to sulcal widening and overall brain atrophy. When drainage of a large volume (30–50 mL) of cerebrospinal fluid by lumbar puncture results in objective improvement of gait (such as in the time to walk 20 feet), then consideration is often given to the placement of a lumboperitoneal shunt. Unfortunately, gait disorders, incontinence, and cognitive dysfunction often occur together nonspecifically in elderly patients, and distinguishing normal pressure hydrocephalus from cerebral atrophy is not straightforward. Because of the surgical risks associated with shunt placement, as well as a strong risk for future shunt malfunction requiring further surgical intervention, the procedure should be avoided except in clear-cut cases. In general, it is the gait apraxia that is most likely to improve after surgery; the cognitive impairment is least likely to respond.

► Treatment

A. Nonpharmacologic Approaches

Aerobic exercise (45 minutes most days of the week) and frequent mental stimulation may reduce the rate of functional decline and decrease the demented patient's caregiving needs, and these interventions may reduce the risk of dementia in normal individuals. The most efficacious manner of mental stimulation is a matter of debate: maintaining as active a role in the family and community as practically possible is most likely to be of benefit, emphasizing activities at which the patient feels confident. Patients with neurodegenerative diseases have a limited capacity to regain lost skills; for instance, memory drills in a patient

Table 24-7. Common causes of age-related dementia.

Disorder	Pathology	Clinical Features
Alzheimer disease	Plaques containing β -amyloid peptide, and neurofibrillary tangles containing tau protein, occur throughout the neocortex	<ul style="list-style-type: none"> • Most common age-related neurodegenerative disease; incidence doubles every 5 years after age 60 • Short-term memory impairment is early and prominent in most cases • Variable deficits of executive function, visuospatial function, and language
Vascular dementia	Multifocal ischemic change	<ul style="list-style-type: none"> • Stepwise or progressive accumulation of cognitive deficits in association with repeated strokes • Symptoms depend on localization of strokes
Dementia with Lewy bodies	Histologically indistinguishable from Parkinson disease: α -synuclein-containing Lewy bodies occur in the brainstem, midbrain, olfactory bulb, and neocortex. Alzheimer pathology may coexist.	<ul style="list-style-type: none"> • Cognitive dysfunction, with prominent visuospatial and executive deficits • Psychiatric disturbance, with anxiety, visual hallucinations, and fluctuating delirium • Parkinsonian motor deficits with or after other features • Cholinesterase inhibitors lessen delirium; poor tolerance of many psychoactive medications, including neuroleptics and dopaminergics
Frontotemporal dementia (FTD)	Neuropathology is variable and defined by the protein found in intraneuronal aggregates. Tau protein, TAR DNA-binding protein 43 (TDP-43), or fused-in-sarcoma (FUS) protein account for most cases.	<ul style="list-style-type: none"> • Peak incidence in the sixth decade; approximately equal to Alzheimer disease as a cause of dementia in patients under 60 years old. • Familial cases result from mutations in genes for tau, progranulin, or others <p>Behavioral variant FTD</p> <ul style="list-style-type: none"> • Deficits in empathy, social comportment, insight, abstract thought, and executive function • Behavior is disinhibited, impulsive, and ritualistic, with prominent apathy and increased interest in sex or sweet/fatty foods • Relative preservation of memory • Focal right frontal atrophy • Association with amyotrophic lateral sclerosis <p>Semantic dementia</p> <ul style="list-style-type: none"> • Deficits in word-finding, single word comprehension, object and category knowledge, and face recognition • Behaviors may be rigid, ritualistic, or similar to behavioral variant FTD • Focal, asymmetric temporal pole atrophy <p>Progressive nonfluent aphasia</p> <ul style="list-style-type: none"> • Speech is effortful with dysarthria, phonemic errors, sound distortions, and poor grammar • Focal extrapyramidal signs and apraxia of the right arm and leg are common • On a diagnostic and pathological continuum with corticobasal degeneration • Focal left frontal atrophy

with Alzheimer disease are more likely to lead to frustration than benefit and studies show that computerized cognitive training does not improve cognition or function in demented patients.

B. Cognitive Symptoms

Cholinesterase inhibitors are first-line therapy for Alzheimer disease and dementia with Lewy bodies. They provide mild, symptomatic treatment for cognitive dysfunction and may prolong the capacity for independence. However, they do

not prevent disease progression. Commonly used medications include donepezil (start at 5 mg orally daily for 4 weeks, then increase to 10 mg daily; a 23 mg daily dose is newly approved for moderate to severe Alzheimer disease, although its additional efficacy over the 10-mg dose is modest); rivastigmine (start at 1.5 mg orally twice daily, then increasing every 2 weeks by 1.5 mg twice daily to a goal of 3–6 mg twice daily); and galantamine (start at 4 mg orally twice daily, then increasing every 4 weeks by 4 mg twice daily to a goal of 8–12 mg twice daily). Cholinesterase inhibitors are not given for frontotemporal dementia because they may

worsen behavioral symptoms. Nausea and diarrhea are common side effects; syncope and cardiac dysrhythmia are uncommon but more serious. An ECG is often obtained before and after starting therapy, particularly in a patient with cardiac disease or a history of syncope.

Memantine (start at 5 mg orally daily, then increase by 5 mg per week up to a target of 10 mg twice daily) is approved for the treatment of moderate to severe Alzheimer disease. In frontotemporal dementia, some open-label studies support its use, and blinded, placebo-controlled trials are underway. There is some evidence that memantine may improve cognition and behavior among patients with dementia with Lewy bodies.

Disease-modifying drugs are not yet available for Alzheimer disease. Active and passive immunotherapy directed against β -amyloid is currently being explored. Such treatment appears to increase the risk for meningeal inflammation or brain edema, especially in patients with an ApoE ϵ 4 allele, and it remains to be seen whether a counterbalancing benefit exists; phase III trials are ongoing.

C. Mood and Behavioral Disturbances

Selective serotonin reuptake inhibitors are generally safe and well-tolerated in elderly, cognitively impaired patients, and they may be efficacious for the treatment of depression, anxiety, or agitation. However, paroxetine should be avoided because it has anticholinergic effects. Other antidepressant agents, such as bupropion or venlafaxine, may also be tried. Studies on the efficacy of antidepressant therapy in this population are conflicting, but these medications are better tolerated than some alternatives (discussed here).

Insomnia is common, and trazodone (25–50 mg orally at bedtime as needed) can be safe and effective. Over-the-counter antihistamine hypnotics must be avoided, along with benzodiazepines, because of their tendency to worsen cognition and precipitate delirium. Other prescription hypnotics such as zolpidem may result in similar adverse reactions.

For agitation, impulsivity, and other behaviors that interfere with safe caregiving, causes of delirium (detailed above) should first be considered. When no reversible trigger is identified, treatment should be approached in a staged manner. Behavioral interventions, such as reorientation and distraction from anxiety-provoking stimuli, are first-line. Ensure that the patient is kept active during the day with both physical exercise and mentally stimulating activities, and that there is adequate sleep at night. Reassess the level of caregiving, and consider increasing the time spent directly with an attendant. Next, ensure that appropriate pharmacologic treatment of cognition and mood is maximized. Finally, as a last resort, when other measures prove insufficient and the patient's behaviors raise safety concerns, consider low doses of an atypical antipsychotic medication, such as quetiapine (start 25 mg orally daily as needed, increasing to two to three times daily as needed); even though atypical agents cause extrapyramidal side effects less frequently than typical antipsychotics, they should be used with particular

caution in a patient at risk for falls, especially if parkinsonian signs are already present. Regularly scheduled dosing is not recommended, and if implemented should be reassessed on a frequent basis (eg, weekly), with attempts to taper off as tolerated. There is an FDA black box warning against the use of all antipsychotic medications in demented patients because of an association with death from cardiovascular and infectious diseases, and other causes. Benzodiazepines, such as lorazepam (0.5 mg as needed, up to one to two times daily) may be used as an alternative, but they may sometimes worsen rather than ameliorate agitation.

Finally, psychostimulants like methylphenidate have been studied as a means to treat apathy in dementia. While such treatment may be of benefit to selected patients, the possibility of causing agitation or cardiovascular strain limits routine use.

► Special Circumstances

A. Rapidly Progressive Dementia

When dementia develops quickly, with obvious decline over a few weeks to a few months, the syndrome may be classified as a rapidly progressive dementia. The differential diagnosis for typical dementias is still relevant, but additional etiologies must be considered, including prion disease; infections; toxins; neoplasms; and autoimmune and inflammatory diseases, including corticosteroid-responsive (Hashimoto) encephalopathy and antibody-mediated paraneoplastic syndromes. Workup should begin with brain MRI with contrast and diffusion-weighted imaging, routine laboratory studies (serum vitamin B₁₂, free T₄, and thyroid-stimulating hormone levels), serum RPR, HIV antibody, Lyme serology, rheumatologic tests (erythrocyte sedimentation rate, C-reactive protein, and antinuclear antibody), anti-thyroglobulin and anti-thyroperoxidase antibody levels, paraneoplastic autoimmune antibodies, and cerebrospinal fluid studies (cell count and differential; protein and glucose levels; protein electrophoresis for oligoclonal bands; IgG index [spinal-fluid-to-serum gamma-globulin level] ratio; and VDRL). Depending on the clinical context, it may be necessary to exclude Wilson disease (24-hour urine copper level), heavy metal intoxication (24-hour urine heavy metal panel), and infectious encephalitis (cerebrospinal fluid polymerase chain reaction for Whipple disease, herpes simplex virus, cytomegalovirus, varicella-zoster virus, and other viruses).

Jakob-Creutzfeldt disease is a relatively common cause of rapidly progressive dementia (see Chapter 32). Family history is important since mutations in *PRNP*, the gene for the prion protein, account for around 15% of cases. Diffusion-weighted MRI is the most helpful diagnostic tool, classically revealing cortical ribboning (a gyral pattern of hyperintensity) as well as restricted diffusion in the caudate and anterior putamen. Reflecting the high rate of neuronal death, cerebrospinal fluid levels of the intraneuronal proteins tau, 14-3-3, and neuron-specific enolase are often elevated, although this finding is neither sensitive nor specific. An electroencephalogram often shows periodic complexes.

B. Driving and Dementia

It is recommended that any patient with mild dementia or worse should discontinue driving. Most states have laws regulating driving among cognitively impaired individuals, and many require the physician to report the patient's diagnosis to the public health department or department of motor vehicles. There is no evidence that driving classes help patients with neurodegenerative diseases.

▶ When to Refer

All patients with new, unexplained cognitive decline should be referred.

▶ When to Admit

Dementia alone is not an indication for admission, but admission is sometimes necessary when a superimposed delirium poses safety risks at home.

Carr DB et al. The older adult driver with cognitive impairment: "It's a very frustrating life". *JAMA*. 2010 Apr 28;303(16):1632–41. [PMID: 20424254]
 Geschwind MD et al. Rapidly progressive dementia. *Ann Neurol*. 2008 Jul;64(1):97–108. [PMID: 18668637]
 Kerchner GA et al. Bapineuzumab. *Expert Opin Biol Ther*. 2010 Jul;10(7):1121–30. [PMID: 20497044]
 Mayeux R. Clinical practice. Early Alzheimer's disease. *N Engl J Med*. 2010 Jun 10;362(23):2194–201. [PMID: 20558370]
 Petersen RC et al. Mild cognitive impairment: ten years later. *Arch Neurol*. 2009 Dec;66(12):1447–55. [PMID: 20008648]
 Schmitt FA et al. Efficacy of rivastigmine on executive function in patients with Parkinson's disease dementia. *CNS Neurosci Ther*. 2010 Dec;16(6):330–6. [PMID: 20950329]
 Seitz DP et al. Antidepressants for agitation and psychosis in dementia. *Cochrane Database Syst Rev*. 2011 Feb 16;(2):CD008191. [PMID: 21328305]

MULTIPLE SCLEROSIS



ESSENTIALS OF DIAGNOSIS

- ▶ Episodic neurologic symptoms.
- ▶ Patient usually under 55 years of age at onset.
- ▶ Single pathologic lesion cannot explain clinical findings.
- ▶ Multiple foci best visualized by MRI.

▶ General Considerations

This common neurologic disorder, which probably has an autoimmune basis, has its greatest incidence in young adults. Epidemiologic studies indicate that multiple sclerosis is much more common in persons of western European lineage who live in temperate zones. No population with a high risk for multiple sclerosis exists between latitudes 40° N and 40° S. A genetic susceptibility to the disease is present, based on twin studies, familial cases, and an association with specific HLA antigens (HLA-DR2) and alleles of

IL2RA (the interleukin-2 receptor α gene) and *IL7RA* (the interleukin-7 receptor α gene). Pathologically, focal—often perivenular—areas of demyelination with reactive gliosis are found scattered in the white matter of brain and spinal cord and in the optic nerves. Axonal damage also occurs.

▶ Clinical Findings

A. Symptoms and Signs

The common initial presentation is weakness, numbness, tingling, or unsteadiness in a limb; spastic paraparesis; retrobulbar optic neuritis; diplopia; dysequilibrium; or a sphincter disturbance such as urinary urgency or hesitancy. Symptoms may disappear after a few days or weeks, although examination often reveals a residual deficit.

Several forms of the disease are recognized. In most patients, there is an interval of months or years after the initial episode before new symptoms develop or the original ones recur (**relapsing-remitting disease**). Eventually, however, relapses and usually incomplete remissions lead to increasing disability, with weakness, spasticity, and ataxia of the limbs, impaired vision, and urinary incontinence. The findings on examination at this stage commonly include optic atrophy; nystagmus; dysarthria; and pyramidal, sensory, or cerebellar deficits in some or all of the limbs. In some of these patients, the clinical course changes so that a steady deterioration occurs, unrelated to acute relapses (**secondary progressive disease**). Less commonly, symptoms are steadily progressive from their onset, and disability develops at a relatively early stage (**primary progressive disease**). The diagnosis cannot be made with confidence unless the total clinical picture indicates involvement of different parts of the central nervous system at different times. Fatigue is common in all forms of the disease.

A number of factors (eg, infection) may precipitate or trigger exacerbations. Relapses are reduced in pregnancy but are more likely during the 2 or 3 months following pregnancy, possibly because of the increased demands and stresses that occur in the postpartum period.

B. Imaging

MRI of the brain or cervical cord has a major role in demonstrating the presence of multiple lesions. In T1-weighted images, hypointense "black holes" probably represent areas of permanent axonal damage; hyperintense lesions are also found. Gadolinium-enhanced T1-weighted images may highlight areas of inflammation with breakdown of the blood-brain barrier, which helps identify newer lesions. T2-weighted images provide information about disease burden or total number of lesions, which typically appear as areas of high signal intensity. CT scans are less helpful than MRI.

In patients with myelopathy alone and in whom there is no clinical or laboratory evidence of more widespread disease, MRI or myelography may be necessary to exclude a congenital or acquired surgically treatable lesion. The foramen magnum region must be visualized to exclude the possibility of Arnold-Chiari malformation, in which parts of the cerebellum and the lower brainstem are displaced

into the cervical canal and produce mixed pyramidal and cerebellar deficits in the limbs.

C. Laboratory and Other Studies

A definitive diagnosis can never be based solely on the laboratory findings. If there is clinical evidence of only a single lesion in the central nervous system, multiple sclerosis cannot properly be diagnosed unless it can be shown that other regions are affected subclinically. The electrocerebral responses evoked by monocular visual stimulation with a checkerboard pattern stimulus, by monaural click stimulation, and by electrical stimulation of a sensory or mixed peripheral nerve have been used to detect subclinical involvement of the visual, brainstem auditory, and somatosensory pathways, respectively. Other disorders may also be characterized by multifocal electrophysiologic abnormalities.

There may be mild lymphocytosis or a slightly increased protein concentration in the cerebrospinal fluid, especially soon after an acute relapse. Elevated IgG in cerebrospinal fluid and discrete bands of IgG (oligoclonal bands) are present in many patients. The presence of such bands is not specific, however, since they have been found in a variety of inflammatory neurologic disorders and occasionally in patients with vascular or neoplastic disorders of the nervous system.

D. Diagnosis

Multiple sclerosis should not be diagnosed unless there is evidence that two or more different regions of the central white matter have been affected at different times. A diagnosis of clinically definite disease can be made in patients with a relapsing-remitting course and evidence on examination of at least two lesions involving different regions of the central white matter. The diagnosis is probable in patients with multifocal white matter disease but only one clinical attack, or with a history of at least two clinical attacks but signs of only a single lesion. Imaging may reveal involvement of the nervous system at different times if a gadolinium-enhancing lesion is present at least 3 months after an initial clinical event at a different site than one corresponding to that event or if a new T2 lesion is found at any time compared with a baseline scan obtained at least 30 days after the initial clinical event. Dissemination in space requires three of the following: (1) at least one gadolinium-enhancing lesion or nine T2 hyperintense lesions if there is no enhancing lesion; (2) one or more infratentorial (or spinal cord) lesions; (3) one or more juxtacortical lesions; and (4) at least three periventricular lesions.

In patients with a single clinical event who do not satisfy criteria for multiple sclerosis, a diagnosis of a **clinically isolated syndrome (CIS)** is made. Such patients are at risk for developing multiple sclerosis and are sometimes offered β -interferon or glatiramer acetate therapy, which may delay progression to clinically definite disease. Follow-up MRI should be considered 6–12 months later to assess for the presence of any new lesion.

► Treatment

At least partial recovery from acute exacerbations can reasonably be expected, but further relapses may occur

without warning, and there is no means of preventing progression of the disorder. Some disability is likely to result eventually, but about half of all patients are without significant disability even 10 years after onset of symptoms.

Recovery from acute relapses may be hastened by treatment with corticosteroids, but the extent of recovery is unchanged. Intravenous therapy is given first—typically methylprednisolone 1 g daily for 3 days—followed by oral prednisone at 60–80 mg daily for 1 week with a taper over the ensuing 2–3 weeks. Long-term treatment with corticosteroids provides no benefit and does not prevent further relapses.

In patients with relapsing-remitting or secondary progressive disease, indefinite treatment with β -interferon (interferon β -1a 30 mcg intramuscularly once weekly, or 44 mcg subcutaneously three times per week; or interferon β -1b 0.25 mg subcutaneously every other day) or with subcutaneous administration of glatiramer acetate (20 mg daily) reduces the frequency of exacerbations with equal efficacy. Natalizumab, an α 4 integrin antagonist that reduces the development of brain lesions in experimental models, reduces the relapse rate when given intravenously once monthly. However, natalizumab treatment is associated with an increased risk of the development of progressive multifocal leukoencephalopathy. Its use is therefore restricted to patients with relapsing-remitting disease who have not responded to other therapies or who have a particularly aggressive initial disease course. It should be used alone and not in combination with β -interferon, glatiramer acetate, or other immune-modifying therapies. Fingolimod (0.5 mg orally daily) reduces the relapse rate in multiple sclerosis, possibly with more efficacy than interferon β -1a. Cladribine and alemtuzumab are being investigated for this indication. Several studies have suggested that immunosuppressive therapy with cyclophosphamide, azathioprine, methotrexate, or mitoxantrone may help arrest the course of secondary progressive multiple sclerosis. The evidence of benefit is incomplete, however. Plasmapheresis is sometimes helpful in patients with severe relapses unresponsive to corticosteroids. Intravenous immunoglobulins (IVIGs) may reduce the clinical attack rate in relapsing-remitting disease, but the available studies are inadequate to permit treatment recommendations. Statins may have immunomodulatory effects, and their possible role in the treatment of multiple sclerosis is being studied.

Symptomatic therapy for spasticity (see below), neurogenic bladder, or fatigue may be required. Fatigue is especially common in multiple sclerosis, and modafinil (200 mg orally every morning) is an effective and FDA-approved therapy for this indication. Dalfampridine (an extended-release formulation of 4-aminopyridine administered as 10 mg orally twice daily) is efficacious at improving timed gait in multiple sclerosis. Depression and even suicidality can occur in multiple sclerosis and may worsen with interferon β -1a therapy; screening and conventional treatment of such symptoms are appropriate.

► When to Refer

All patients, but especially those with progressive disease despite standard therapy, should be referred.

▶ When to Admit

- Patients requiring plasma exchange.
- During severe relapses.
- Patient unable to manage at home.

Coles AJ et al. Alemtuzumab versus interferon beta-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes. *Lancet Neurol.* 2011 Apr;10(4):338–48. [PMID: 21397567]

Comi G et al; PreCISe study group. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome: a randomised, double-blind, placebo-controlled trial. *Lancet.* 2009 Oct 31;374(9700):1503–11. [PMID: 19815268]

Fragoso YD et al. Severe depression, suicide attempts, and ideation during the use of interferon beta by patients with multiple sclerosis. *Clin Neuropharmacol.* 2010 Nov–Dec;33(6):312–6. [PMID: 21079457]

Giovannoni G et al; CLARITY Study Group. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. *N Engl J Med.* 2010 Feb 4;362(5):416–26. [PMID: 20089960]

Goodman AD et al. A phase 3 trial of extended release oral dalfampridine in multiple sclerosis. *Ann Neurol.* 2010 Oct;68(4):494–502. [PMID: 20976768]

Kappos L et al; FREEDOMS Study Group. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. *N Engl J Med.* 2010 Feb 4;362(5):387–401. [PMID: 20089952]

Khatri B et al. Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study. *Lancet Neurol.* 2011 Jun;10(6):520–9. [PMID: 21571593]

Lange R et al. Modafinil effects in multiple sclerosis patients with fatigue. *J Neurol.* 2009 Apr;256(4):645–50. [PMID: 19367356]

Naismith RT et al. Rituximab add-on therapy for breakthrough relapsing multiple sclerosis: a 52-week phase II trial. *Neurology.* 2010 Jun 8;74(23):1860–7. [PMID: 20530322]

NEUROMYELITIS OPTICA

This disorder is characterized by optic neuritis and acute myelitis with MRI changes that extend over at least three segments of the spinal cord. An isolated myelitis or optic neuritis may also occur. Previously known as Devic disease and once regarded as a variant of multiple sclerosis, neuromyelitis optica is associated with a specific antibody marker (NMO-IgG) targeting the water channel aquaporin-4. MRI of the brain typically does not show widespread white matter involvement, but such changes do not exclude the diagnosis. Treatment is by long-term immunosuppression. Rituximab may help in reducing the risk of relapses and is undergoing clinical trials; no standard dosing regimen is yet available.

Cree B. Neuromyelitis optica: diagnosis, pathogenesis, and treatment. *Curr Neurol Neurosci Rep.* 2008 Sep;8(5):427–33. [PMID: 18713580]

Jacob A et al. Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients. *Arch Neurol.* 2008 Nov;65(11):1443–8. [PMID: 18779415]

VITAMIN E DEFICIENCY

Vitamin E deficiency may produce a disorder somewhat similar to Friedreich ataxia (see below). There is

spinocerebellar degeneration involving particularly the posterior columns of the spinal cord and leading to limb ataxia, sensory loss, absent tendon reflexes, slurring of speech and, in some cases, pigmentary retinal degeneration. The disorder may occur as a consequence of malabsorption or on a hereditary basis (eg, abetalipoproteinemia). Treatment is with α -tocopheryl acetate as discussed in Chapter 29.

SPASTICITY

The term “spasticity” is commonly used for an upper motor neuron deficit, but it properly refers to a velocity-dependent increase in resistance to passive movement that affects different muscles to a different extent, is not uniform in degree throughout the range of a particular movement, and is commonly associated with other features of pyramidal deficit. It is often a major complication of stroke, cerebral or spinal injury, static perinatal encephalopathy, and multiple sclerosis.

Physical therapy with appropriate stretching programs is important during rehabilitation after the development of an upper motor neuron lesion and in subsequent management of the patient. The aim is to prevent joint and muscle contractures and perhaps to modulate spasticity.

Drug management is important also, but treatment may increase functional disability when increased extensor tone is providing additional support for patients with weak legs. Dantrolene weakens muscle contraction by interfering with the role of calcium. It is best avoided in patients with poor respiratory function or severe myocardial disease. Treatment is begun with 25 mg once daily, and the daily dose is built up by 25 mg increments every 3 days, depending on tolerance, to a maximum of 100 mg four times daily. Side effects include diarrhea, nausea, weakness, hepatic dysfunction (that may rarely be fatal, especially in women older than 35), drowsiness, light-headedness, and hallucinations.

Baclofen is an effective drug for treating spasticity of spinal origin and painful flexor (or extensor) spasms. The maximum recommended daily oral dose is 80 mg; treatment is started with a dose of 5 or 10 mg twice daily orally and then built up gradually. Side effects include gastrointestinal disturbances, lassitude, fatigue, sedation, unsteadiness, confusion, and hallucinations. Diazepam may modify spasticity by its action on spinal interneurons and perhaps also by influencing supraspinal centers, but effective doses often cause intolerable drowsiness and vary with different patients. Tizanidine, a centrally acting α_2 -adrenergic agonist, is as effective as these other agents and is probably better tolerated. The daily dose is built up gradually, usually to 8 mg taken three times daily. Side effects include sedation, lassitude, hypotension, and dryness of the mouth.

Intramuscular injection of botulinum toxin has been used to relax targeted muscles.

In patients with severe spasticity that is unresponsive to other therapies and is associated with marked disability, intrathecal injection of phenol or alcohol may be helpful. Surgical options include implantation of an intrathecal baclofen pump, rhizotomy, or neurectomy. Severe contractures may be treated by surgical tendon release.

Spasticity may be exacerbated by decubitus ulcers, urinary or other infections, and nociceptive stimuli.

Maanum G et al. Effects of botulinum toxin A in ambulant adults with spastic cerebral palsy: a randomized double-blind placebo controlled-trial. *J Rehabil Med*. 2011 Mar;43(4):338–47. [PMID: 21305227]

Simpson DM et al. Botulinum neurotoxin versus tizanidine in upper limb spasticity: a placebo-controlled study. *J Neurol Neurosurg Psychiatry*. 2009 Apr;80(4):380–5. [PMID: 18977811]

MYELOPATHIES IN AIDS

A variety of myelopathies may occur in patients with AIDS. These are discussed in Chapter 31.

MYELOPATHY OF HUMAN T CELL LEUKEMIA VIRUS INFECTION

Human T cell leukemia virus (HTLV-1), a human retrovirus, is transmitted by breast-feeding, sexual contact, blood transfusion, and contaminated needles. Most patients are asymptomatic, but after a variable latent period (which may be as long as several years) a myelopathy develops in some instances. The MRI, electrophysiologic, and cerebrospinal fluid findings are similar to those of multiple sclerosis, but HTLV-1 antibodies are present in serum and spinal fluid. There is no specific treatment, but intravenous or oral corticosteroids may help in the initial inflammatory phase of the disease. Prophylactic measures are important. Needles or syringes should not be shared; infected patients should not breastfeed their infants or donate blood, semen, or other tissue. Infected patients should use condoms to prevent sexual transmission.

Biswas HH et al. Neurologic abnormalities in HTLV-I- and HTLV-II-infected individuals without overt myelopathy. *Neurology*. 2009 Sep 8;73(10):781–9. [PMID: 19738173]

SUBACUTE COMBINED DEGENERATION OF THE SPINAL CORD

Subacute combined degeneration of the spinal cord is due to vitamin B₁₂ deficiency, such as occurs in pernicious anemia. It is characterized by myelopathy with predominant pyramidal and posterior column deficits, sometimes in association with polyneuropathy, mental changes, or optic neuropathy. Megaloblastic anemia may also occur, but this does not parallel the neurologic disorder, and the former may be obscured if folic acid supplements have been taken. Treatment is with vitamin B₁₂. For pernicious anemia, a convenient therapeutic regimen is 100 mg cyanocobalamin intramuscularly daily for 1 week, then weekly for 1 month, and then monthly for the remainder of the patient's life.

WERNICKE ENCEPHALOPATHY & KORSAKOFF SYNDROME

Wernicke encephalopathy is characterized by confusion, ataxia, and nystagmus leading to ophthalmoplegia (lateral rectus muscle weakness, conjugate gaze palsies); peripheral neuropathy may also be present. It is due to thiamine deficiency and in the United States occurs most commonly in alcoholics. It may also occur in patients with AIDS or hyperemesis gravidarum, and after surgery for obesity. In suspected cases, thiamine (100 mg) is given intravenously immediately and then intramuscularly on a daily basis until a satisfactory diet can be ensured. Intravenous glucose given before thiamine may precipitate the syndrome or worsen the symptoms. The diagnosis is confirmed by the response in 1 or 2 days to treatment, which must not be delayed while awaiting laboratory confirmation of thiamine deficiency from a blood sample obtained prior to thiamine administration. **Korsakoff syndrome** occurs in more severe cases; it includes anterograde and retrograde amnesia and sometimes confabulation, and may not be recognized until after the initial delirium has lifted.

Santos Andrade C et al. Non-alcoholic Wernicke's encephalopathy: broadening the clinicoradiological spectrum. *Br J Radiol*. 2010 May;83(989):437–46. [PMID: 20223908]

Sechi G et al. Wernicke's encephalopathy: new clinical settings and recent advances in diagnosis and management. *Lancet Neurol*. 2007 May;6(5):442–55. [PMID: 17434099]

STUPOR & COMA



ESSENTIALS OF DIAGNOSIS

- ▶ Level of consciousness is depressed.
- ▶ Stuporous patients respond only to repeated vigorous stimuli.
- ▶ Comatose patients are unarousable and unresponsive.

▶ General Considerations

The patient who is stuporous is unresponsive except when subjected to repeated vigorous stimuli, while the comatose patient is unarousable and unable to respond to external events or inner needs, although reflex movements and posturing may be present.

Coma is a major complication of serious central nervous system disorders. It can result from seizures, hypothermia, metabolic disturbances, or structural lesions causing bilateral cerebral hemispheric dysfunction or a disturbance of the brainstem reticular activating system. A mass lesion involving one cerebral hemisphere may cause coma by compression of the brainstem. All comatose patients should be admitted to hospital and referred to a neurologist or neurosurgeon.

▶ Assessment & Emergency Measures

The diagnostic workup of the comatose patient must proceed concomitantly with management. Supportive therapy

for respiration or blood pressure is initiated; in hypothermia, all vital signs may be absent and all such patients should be rewarmed before the prognosis is assessed.

The patient can be positioned on one side with the neck partly extended, dentures removed, and secretions cleared by suction; if necessary, the patency of the airways is maintained with an oropharyngeal airway. Blood is drawn for serum glucose, electrolyte, and calcium levels; arterial blood gases; liver and kidney function tests; and toxicologic studies as indicated. Dextrose 50% (25 g), naloxone (0.4–1.2 mg), and thiamine (100 mg) are given intravenously without delay.

Further details are then obtained from attendants of the patient's medical history, the circumstances surrounding the onset of coma, and the time course of subsequent events. Abrupt onset of coma suggests subarachnoid hemorrhage, brainstem stroke, or intracerebral hemorrhage, whereas a slower onset and progression occur with other structural or mass lesions. Urgent noncontrast CT scanning of the head is appropriate if it can be obtained directly from the emergency department, in order to identify intracranial hemorrhage, brain herniation, or other structural lesion that may require immediate neurosurgical intervention. A metabolic cause is likely with a preceding intoxicated state or agitated delirium. On examination, attention is paid to the behavioral response to painful stimuli, the pupils and their response to light, the position of the eyes and their movement in response to passive movement of the head and ice-water caloric stimulation, and the respiratory pattern.

A. Response to Painful Stimuli

Purposive limb withdrawal from painful stimuli implies that sensory pathways from and motor pathways to the stimulated limb are functionally intact. Unilateral absence of responses despite application of stimuli to both sides of the body in turn implies a corticospinal lesion; bilateral absence of responsiveness suggests brainstem involvement, bilateral pyramidal tract lesions, or psychogenic unresponsiveness. Inappropriate responses may also occur. Decorticate posturing may occur with lesions of the internal capsule and rostral cerebral peduncle, decerebrate posturing with dysfunction or destruction of the midbrain and rostral pons, and decerebrate posturing in the arms accompanied by flaccidity or slight flexor responses in the legs in patients with extensive brainstem damage extending down to the pons at the trigeminal level.

B. Ocular Findings

1. Pupils—Hypothalamic disease processes may lead to unilateral Horner syndrome, while bilateral diencephalic involvement or destructive pontine lesions may lead to small but reactive pupils. Ipsilateral pupillary dilation with no direct or consensual response to light occurs with compression of the third cranial nerve, eg, with uncal herniation. The pupils are slightly smaller than normal but responsive to light in many metabolic encephalopathies; however, they may be fixed and dilated following overdose

with atropine or scopolamine, and pinpoint (but responsive) with opioids. Pupillary dilation for several hours following cardiopulmonary arrest implies a poor prognosis.

2. Eye movements—Conjugate deviation of the eyes to the side suggests the presence of an ipsilateral hemispheric lesion or a contralateral pontine lesion. A mesencephalic lesion leads to downward conjugate deviation. Dysconjugate ocular deviation in coma implies a structural brainstem lesion unless there was preexisting strabismus.

The oculomotor responses to passive head turning and to caloric stimulation relate to each other and provide complementary information. In response to brisk rotation of the head from side to side and to flexion and extension of the head, normally conscious patients with open eyes do not exhibit contraversive conjugate eye deviation (doll's-head eye response) unless there is voluntary visual fixation or bilateral frontal pathology. With cortical depression in lightly comatose patients, a brisk doll's-head eye response is seen. With brainstem lesions, this oculocephalic reflex becomes impaired or lost, depending on the site of the lesion.

The oculovestibular reflex is tested by caloric stimulation using irrigation with ice water. In normal subjects, jerk nystagmus is elicited for about 2 or 3 minutes, with the slow component toward the irrigated ear. In unconscious patients with an intact brainstem, the fast component of the nystagmus disappears, so that the eyes tonically deviate toward the irrigated side for 2–3 minutes before returning to their original position. With impairment of brainstem function, the response becomes perverted and finally disappears. In metabolic coma, oculocephalic and oculovestibular reflex responses are preserved, at least initially.

C. Respiratory Patterns

Diseases causing coma may lead to respiratory abnormalities. Cheyne-Stokes respiration (in which episodes of deep breathing alternate with periods of apnea) may occur with bihemispheric or diencephalic disease or in metabolic disorders. Central neurogenic hyperventilation occurs with lesions of the brainstem tegmentum; apneustic breathing (in which there are prominent end-inspiratory pauses) suggests damage at the pontine level (eg, due to basilar artery occlusion); and atactic breathing (a completely irregular pattern of breathing with deep and shallow breaths occurring randomly) is associated with lesions of the lower pontine tegmentum and medulla.

1. Stupor & Coma Due to Structural Lesions

Supratentorial mass lesions tend to affect brain function in an orderly way. There may initially be signs of hemispheric dysfunction, such as hemiparesis. As coma develops and deepens, cerebral function becomes progressively disturbed, producing a predictable progression of neurologic signs that suggest rostrocaudal deterioration.

Thus, as a supratentorial mass lesion begins to impair the diencephalon, the patient becomes drowsy, then

stuporous, and finally comatose. There may be Cheyne-Stokes respiration; small but reactive pupils; doll's-head eye responses with side-to-side head movements but sometimes an impairment of reflex upward gaze with brisk flexion of the head; tonic ipsilateral deviation of the eyes in response to vestibular stimulation with cold water; and initially a positive response to pain but subsequently only decorticate posturing. With further progression, midbrain failure occurs. Motor dysfunction progresses from decorticate to bilateral decerebrate posturing in response to painful stimuli; Cheyne-Stokes respiration is gradually replaced by sustained central hyperventilation; the pupils become middle-sized and fixed; and the oculocephalic and oculovestibular reflex responses become impaired, perverted, or lost. As the pons and then the medulla fail, the pupils remain unresponsive; oculovestibular responses are unobtainable; respiration is rapid and shallow; and painful stimuli may lead only to flexor responses in the legs. Finally, respiration becomes irregular and stops, the pupils often then dilating widely.

In contrast, a subtentorial (ie, brainstem) lesion may lead to an early, sometimes abrupt disturbance of consciousness without any orderly rostrocaudal progression of neurologic signs. Compressive lesions of the brainstem, especially cerebellar hemorrhage, may be clinically indistinguishable from intraparenchymal processes.

A structural lesion is suspected if the findings suggest focality. In such circumstances, a CT scan should be performed before, or instead of, a lumbar puncture in order to avoid any risk of cerebral herniation. Further management is of the causal lesion and is considered separately under the individual disorders.

In some cases of traumatic brain injury, swelling may be diffuse rather than focal. Decompressive craniectomy may reduce otherwise refractory intracranial hypertension but does not improve neurologic outcome. Hypothermic therapy is controversial.

Clifton GL et al. Very early hypothermia induction in patients with severe brain injury (the National Acute Brain Injury Study: Hypothermia II): a randomised trial. *Lancet Neurol*. 2011 Feb;10(2):131–9. [PMID: 21169065]

Cooper DJ et al. Decompressive craniectomy in diffuse traumatic brain injury. *N Engl J Med*. 2011 Apr 21;364(16):1493–502. [PMID: 21434843]

2. Stupor & Coma Due to Metabolic Disturbances

Patients with a metabolic cause of coma generally have signs of patchy, diffuse, and symmetric neurologic involvement that cannot be explained by loss of function at any single level or in a sequential manner, although focal or lateralized deficits may occur in hypoglycemia. Moreover, pupillary reactivity is usually preserved, while other brainstem functions are often grossly impaired. Comatose patients with meningitis, encephalitis, or subarachnoid hemorrhage may also exhibit little in the way of

focal neurologic signs, however, and clinical evidence of meningeal irritation is sometimes very subtle in comatose patients. Examination of the cerebrospinal fluid in such patients is essential to establish the correct diagnosis.

In patients with coma due to cerebral ischemia and hypoxia, the absence of pupillary light reflexes at the time of initial examination indicates that there is little chance of regaining independence; by contrast, preserved pupillary light responses, the development of spontaneous eye movements (roving, conjugate, or better), and extensor, flexor, or withdrawal responses to pain at this early stage imply a relatively good prognosis.

Treatment of metabolic encephalopathy is of the underlying disturbance and is considered in other chapters. If the cause of the encephalopathy is obscure, all drugs except essential ones may have to be withdrawn in case they are responsible for the altered mental status.

Stevens RD et al. Approach to the comatose patient. *Crit Care Med*. 2006 Jan;34(1):31–41. [PMID: 16374153]

Wijdicks EF et al. Practice parameter: Prediction of outcome in comatose survivors after cardiopulmonary resuscitation (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology. *Neurology*. 2006 Jul 25;67(2):203–10. [PMID: 16864809]

3. Brain Death

The definition of brain death is controversial, and diagnostic criteria have been published by many different professional organizations. In order to establish brain death, the irreversibly comatose patient must be shown to have lost all brainstem reflex responses, including the pupillary, corneal, oculovestibular, oculocephalic, oropharyngeal, and respiratory reflexes, and should have been in this condition for at least 6 hours. Spinal reflex movements do not exclude the diagnosis, but ongoing seizure activity or decerebrate or decorticate posturing is not consistent with brain death. The apnea test (presence or absence of spontaneous respiratory activity at a $Paco_2$ of at least 60 mm Hg) serves to determine whether the patient is capable of respiratory activity.

Reversible coma simulating brain death may be seen with hypothermia (temperature $<32^\circ C$) and overdosage with central nervous system depressant drugs, and these conditions must be excluded. Certain ancillary tests may assist the determination of brain death but are not essential. An isoelectric electroencephalogram, when the recording is made according to the recommendations of the American Electroencephalographic Society, may help in confirming the diagnosis. Alternatively, the demonstration of an absent cerebral circulation by intravenous radioisotope cerebral angiography or by four-vessel contrast cerebral angiography is confirmatory.

Wijdicks EF. The case against confirmatory tests for determining brain death in adults. *Neurology*. 2010 Jul 6;75(1):77–83. [PMID: 20603486]

4. Persistent Vegetative State

Patients with severe bilateral hemispheric disease may show some improvement from an initially comatose state, so that, after a variable interval, they appear to be awake but lie motionless and without evidence of awareness or higher mental activity. This persistent vegetative state has been variously referred to as akinetic mutism, apallic state, or coma vigil. Most patients in this persistent vegetative state will die in months or years, but partial recovery has occasionally occurred and in rare instances has been sufficient to permit communication or even independent living.

5. Minimally Conscious State

In this state, patients exhibit inconsistent evidence of consciousness. There is some degree of functional recovery of behaviors suggesting self- or environmental awareness, such as basic verbalization or context-appropriate gestures, emotional responses (eg, smiling) to emotional but not neutral stimuli, or purposive responses to environmental stimuli (eg, a finger movement or eye blink apparently to command). Further improvement is manifest by the restoration of communication with the patient. The minimally conscious state may be temporary or permanent. Little information is available about its natural history or long-term outlook, which reflect the underlying cause. The likelihood of useful functional recovery diminishes with time; after 12 months, patients are likely to remain severely disabled and without a reliable means of communication. Prognostication is difficult.

6. Locked-In Syndrome (De-efferented State)

Acute destructive lesions (eg, infarction, hemorrhage, demyelination, encephalitis) involving the ventral pons and sparing the tegmentum may lead to a mute, quadriparetic but conscious state in which the patient is capable of blinking and of voluntary eye movement in the vertical plane, with preserved pupillary responses to light. Such a patient can mistakenly be regarded as comatose. Physicians should recognize that “locked-in” individuals are fully aware of their surroundings. The prognosis is usually poor, but recovery has occasionally been reported in some cases, including resumption of independent daily life.

Wilson BA et al. A case study of locked-in-syndrome: psychological and personal perspectives. *Brain Inj*. 2011;25(5):526–38. [PMID: 21457000]

HEAD INJURY

Trauma is the most common cause of death in young people, and head injury accounts for almost half of these trauma-related deaths. The incidence of head injury can be reduced by, for example, using bicycle helmets and protective equipment in sports.

The prognosis following head injury depends on the site and severity of brain damage. Some guide to prognosis

is provided by the mental status, since loss of consciousness implies a worse prognosis than otherwise. Similarly, the degree of retrograde and posttraumatic amnesia provides an indication of the severity of injury and thus of the prognosis. Absence of skull fracture does not exclude the possibility of severe head injury. During the physical examination, special attention should be given to the level of consciousness and extent of any brainstem dysfunction.

Note: Patients (especially elderly, >65 years) who are intoxicated with drugs or alcohol or have evidence of soft-tissue injury above the clavicles following head injury should be admitted to the hospital for observation, as should patients with recurrent vomiting, persistent anterograde amnesia, retrograde amnesia for more than 30 minutes, focal neurologic deficits, lethargy, or skull fractures. If admission is declined, responsible family members should be given clear instructions about the need for, and manner of, checking on them at regular (hourly) intervals and for obtaining additional medical help if necessary.

Skull radiographs or CT scans may provide evidence of fractures. Because injury to the spine may have accompanied head trauma, cervical spine radiographs (especially in the lateral projection) should always be obtained in comatose patients and in patients with severe neck pain or a deficit possibly related to cord compression.

CT scanning has an important role in demonstrating intracranial hemorrhage and may also provide evidence of cerebral edema and displacement of midline structures.

1. Cerebral Injuries

These are summarized in Table 24–8. Increased intracranial pressure may result from ventilatory obstruction, abnormal neck position, seizures, dilutional hyponatremia, or cerebral edema; an intracranial hematoma requiring surgical evacuation may also be responsible. Other measures that may be necessary to reduce intracranial pressure include induced hyperventilation, intravenous mannitol infusion, and intravenous furosemide; corticosteroids provide no benefit in this context. Overall, treatment is mainly supportive. The role of induced hypothermia in reducing long-term neurologic deficits is currently under investigation.

2. Scalp Injuries & Skull Fractures

Scalp lacerations and depressed or compound depressed skull fractures should be treated surgically as appropriate. Simple skull fractures require no specific treatment.

The clinical signs of basilar skull fracture include bruising about the orbit (raccoon sign), blood in the external auditory meatus (Battle sign), and leakage of cerebrospinal fluid (which can be identified by its glucose content) from the ear or nose. Cranial nerve palsies (involving especially the first, second, third, fourth, fifth, seventh, and eighth nerves in any combination) may also occur. If there is any leakage of cerebrospinal fluid, conservative treatment, with elevation of the head, restriction of fluids, and administration of acetazolamide (250 mg four times daily), is often helpful; but if the leak continues for more than a few days, lumbar subarachnoid drainage may be necessary.

Table 24-8. Acute cerebral sequelae of head injury.

Sequelae	Clinical Features	Pathology
Concussion	A transient, trauma-induced alteration in mental status that may or may not involve loss of consciousness. Symptoms and signs include headache, nausea, disorientation, irritability, amnesia, clumsiness, visual disturbances, and focal neurologic deficit.	Bruising on side of impact (coup injury) or contralaterally (contrecoup injury).
Cerebral contusion or laceration	Loss of consciousness longer than with concussion. Focal neurologic deficits are often present. May lead to death or severe residual neurologic deficit.	Vasogenic edema, multiple petechial hemorrhages, and mass effect. May have subarachnoid bleeding. Herniation may occur in severe cases. Cerebral laceration specifically involves tearing of the cerebral tissue and pia-arachnoid overlying a contusion.
Acute epidural hemorrhage	Headache, confusion, somnolence, seizures, and focal deficits occur several hours after injury and lead to coma, respiratory depression, and death unless treated by surgical evacuation.	Tear in meningeal artery, vein, or dural sinus, leading to hematoma visible on CT scan.
Acute subdural hemorrhage	Similar to epidural hemorrhage, but interval before onset of symptoms is longer. Treatment is by surgical evacuation.	Hematoma from tear in veins from cortex to superior sagittal sinus or from cerebral laceration, visible on CT scan.
Cerebral hemorrhage	Generally develops immediately after injury. Clinically resembles hypertensive hemorrhage. Surgical evacuation is sometimes helpful.	Hematoma, visible on CT scan.
Diffuse axonal injury	Persistent loss of consciousness, coma, or persistent vegetative state resulting from severe rotational shearing forces or deceleration.	Imaging may be normal or may show tiny, scattered white matter hemorrhages. Histology reveals torn axons.

Antibiotics are given if infection occurs, based on culture and sensitivity studies. Only very occasional patients require intracranial repair of the dural defect because of persistence of the leak or recurrent meningitis.

3. Late Complications of Head Injury

The relationship of chronic subdural hemorrhage to head injury is not always clear. In many elderly persons there is no history of trauma, but in other cases a head injury, often trivial, precedes the onset of symptoms by several weeks. The clinical presentation is usually with mental changes such as slowness, drowsiness, headache, confusion, memory disturbances, personality change, or even dementia. Focal neurologic deficits such as hemiparesis or hemisensory disturbance may also occur but are less common. CT scan is an important means of detecting the hematoma, which is sometimes bilateral. Treatment is by surgical evacuation to prevent cerebral compression and tentorial herniation. There is no clear evidence that prophylactic anticonvulsant therapy reduces the incidence of post-traumatic seizures.

After major head injury causing severe, acute mental status changes, cognitive deficits may persist indefinitely. Memory training may be a helpful component of rehabilitation. In addition, there is an association between head trauma and the later development of a neurodegenerative disease, such as Alzheimer or Parkinson disease and amyotrophic lateral sclerosis.

Normal-pressure hydrocephalus may follow head injury, subarachnoid hemorrhage, or meningoencephalitis. Other late complications of head injury include posttraumatic seizure disorder, headache, vertigo, and hyposmia.

▶ When to Refer

- Patients with focal neurologic deficits, altered consciousness, or skull fracture.
- Patients with late complications of head injury, eg, post-traumatic seizure disorder or normal pressure hydrocephalus.

▶ When to Admit

- Patients (especially elderly, >65 years) who are intoxicated with drugs or alcohol or have evidence of soft-tissue injury above the clavicles should be admitted for observation.
- Patients with recurrent vomiting, focal neurologic deficits, persistent anterograde amnesia, retrograde amnesia for more than 30 minutes, altered consciousness, or skull fracture.
- Patients with acute epidural, subdural, or cerebral hematoma.
- Patients requiring shunt placement for normal pressure hydrocephalus.

- Maas AI et al. Moderate and severe traumatic brain injury in adults. *Lancet Neurol.* 2008 Aug;7(8):728–41. [PMID: 18635021]
- Ropper AH et al. Clinical practice. Concussion. *N Engl J Med.* 2007 Jan 11;356(2):166–72. [PMID: 17215534]
- Shum D et al. A randomized controlled trial of prospective memory rehabilitation in adults with traumatic brain injury. *J Rehabil Med.* 2011 Feb;43(3):216–23. [PMID: 21305237]

SPINAL TRAUMA



ESSENTIALS OF DIAGNOSIS

- ▶ History of preceding trauma.
- ▶ Development of acute neurologic deficit.
- ▶ Signs of myelopathy on examination.

▶ General Considerations

While spinal cord damage may result from whiplash injury, severe injury usually relates to fracture-dislocation causing compression or angular deformity of the cord either cervically or in the lower thoracic and upper lumbar regions. Extreme hypotension following injury may also lead to cord infarction.

▶ Clinical Findings

Total cord transection results in immediate flaccid paralysis and loss of sensation below the level of the lesion. Reflex activity is lost for a variable period, and there is urinary and fecal retention. As reflex function returns over the following days and weeks, spastic paraplegia or quadriplegia develops, with hyperreflexia and extensor plantar responses, but a flaccid atrophic (lower motor neuron) paralysis may be found depending on the segments of the cord that are affected. The bladder and bowels also regain some reflex function, permitting urine and feces to be expelled at intervals. As spasticity increases, flexor or extensor spasms (or both) of the legs become troublesome, especially if the patient develops bed sores or a urinary tract infection. Paraplegia with the legs in flexion or extension may eventually result.

With lesser degrees of injury, patients may be left with mild limb weakness, distal sensory disturbance, or both. Sphincter function may also be impaired, urinary urgency and urgency incontinence being especially common. More particularly, a unilateral cord lesion leads to an ipsilateral motor disturbance with accompanying impairment of proprioception and contralateral loss of pain and temperature appreciation below the lesion (Brown-Séquard syndrome). A central cord syndrome may lead to a lower motor neuron deficit and loss of pain and temperature appreciation, with sparing of posterior column functions. A radicular deficit may occur at the level of the injury—or, if the cauda equina is involved, there may be evidence of disturbed function in several lumbosacral roots.

▶ Treatment

Treatment of the injury consists of immobilization and—if there is cord compression—early decompressive laminectomy and fusion (within 24 hours). Early treatment with high doses of corticosteroids (eg, methylprednisolone, 30 mg/kg by intravenous bolus, followed by 5.4 mg/kg/h for 23 hours) may improve neurologic recovery if commenced within 8 hours after injury; the findings from various studies are conflicting, however, and evaluation of the published evidence suggest that significant benefit is unlikely. Anatomic realignment of the spinal cord by traction and other orthopedic procedures is important. Subsequent care of the residual neurologic deficit—paraplegia or quadriplegia—requires treatment of spasticity and care of the skin, bladder, and bowels.

▶ When to Refer

All patients with focal neurologic deficits should be referred.

▶ When to Admit

- Patients with neurologic deficits.
- Patients with spinal cord injury, compression, or acute epidural or subdural hematoma.
- Patients with vertebral fracture-dislocation likely to compress the cord.

Fehlings MG et al. Current practice in the timing of surgical intervention in spinal cord injury. *Spine (Phila Pa 1976).* 2010 Oct 1;35(21 Suppl):S166–73. [PMID: 20881458]

Furlan JC et al. The impact of age on mortality, impairment, and disability among adults with acute traumatic spinal cord injury. *J Neurotrauma.* 2009 Oct;26(10):1707–17. [PMID: 19413491]

Lenahan B et al. The urgency of surgical decompression in acute central cord injuries with spondylosis and without instability. *Spine (Phila Pa 1976).* 2010 Oct 1;35(21 Suppl):S180–6. [PMID: 20881460]

SYRINGOMYELIA

Destruction or degeneration of gray and white matter adjacent to the central canal of the cervical spinal cord leads to cavitation and accumulation of fluid within the spinal cord. The precise pathogenesis is unclear, but many cases are associated with Arnold-Chiari malformation, in which there is displacement of the cerebellar tonsils, medulla, and fourth ventricle into the spinal canal, sometimes with accompanying meningocele. In such circumstances, the cord cavity connects with and may merely represent a dilated central canal. In other cases, the cause of cavitation is less clear. There is a characteristic clinical picture, with segmental atrophy, areflexia and loss of pain and temperature appreciation in a “cape” distribution, owing to the destruction of fibers crossing in front of the central canal in the mid-cervical spinal cord. Thoracic kyphoscoliosis is usually present. With progression, involvement of the long motor and sensory tracts occurs as well, so that a pyramidal and sensory deficit develops in the legs. Upward extension

of the cavitation (syringobulbia) leads to dysfunction of the lower brainstem and thus to bulbar palsy, nystagmus, and sensory impairment over one or both sides of the face.

Syringomyelia, ie, cord cavitation, may also occur in association with an intramedullary tumor or following severe cord injury, and the cavity then does not communicate with the central canal.

In patients with Arnold-Chiari malformation, CT scans reveal a small posterior fossa and enlargement of the foramen magnum, along with other associated skeletal abnormalities at the base of the skull and upper cervical spine. MRI reveals the syrinx as well as the characteristic findings of the Arnold-Chiari malformation, including the caudal displacement of the fourth ventricle and herniation of the cerebellar tonsils through the foramen magnum. Focal cord enlargement is found at myelography or by MRI in patients with cavitation related to past injury or intramedullary neoplasms.

Treatment of Arnold-Chiari malformation with associated syringomyelia is by suboccipital craniectomy and upper cervical laminectomy, with the aim of decompressing the malformation at the foramen magnum. The cord cavity should be drained, and if necessary an outlet for the fourth ventricle can be made. In cavitation associated with intra-medullary tumor, treatment is surgical, but radiation therapy may be necessary if complete removal is not possible. Posttraumatic syringomyelia is also treated surgically if it leads to increasing neurologic deficits or to intolerable pain.

Aghakhani N et al. Long-term follow-up of Chiari-related syringomyelia in adults: analysis of 157 surgically treated cases. *Neurosurgery*. 2009 Feb;64(2):308–15. [PMID: 19190458]

DEGENERATIVE MOTOR NEURON DISEASES



ESSENTIALS OF DIAGNOSIS

- ▶ Weakness.
- ▶ No sensory loss or sphincter disturbance.
- ▶ Progressive course.
- ▶ No identifiable underlying cause other than genetic basis in familial cases.

▶ General Considerations

This group of degenerative disorders is characterized clinically by weakness and variable wasting of affected muscles, without accompanying sensory changes.

Motor neuron disease in adults generally commences between 30 and 60 years of age. There is degeneration of the anterior horn cells in the spinal cord, the motor nuclei of the lower cranial nerves, and the corticospinal and corticobulbar pathways. The disorder is usually sporadic, but familial cases may occur and several genetic mutations or loci have been identified. Cigarette smoking may be one risk factor.

▶ Classification

Five varieties have been distinguished on clinical grounds.

A. Progressive Bulbar Palsy

Bulbar involvement predominates owing to disease processes affecting primarily the motor nuclei of the cranial nerves.

B. Pseudobulbar Palsy

Bulbar involvement predominates in this variety also, but it is due to bilateral corticobulbar disease and thus reflects upper motor neuron dysfunction. There may be a “pseudobulbar affect,” with uncontrollable episodes of laughing or crying to stimuli that would not normally have elicited such marked reactions.

C. Progressive Spinal Muscular Atrophy

This is characterized primarily by a lower motor neuron deficit in the limbs due to degeneration of the anterior horn cells in the spinal cord.

D. Primary Lateral Sclerosis

There is a purely upper motor neuron deficit in the limbs.

E. Amyotrophic Lateral Sclerosis

A mixed upper and lower motor neuron deficit is found in the limbs. This disorder is sometimes associated with cognitive decline (in a pattern consistent with frontotemporal dementia), a pseudobulbar affect, or parkinsonism.

▶ Clinical Findings

A. Symptoms and Signs

Difficulty in swallowing, chewing, coughing, breathing, and talking (dysarthria) occur with bulbar involvement. In progressive bulbar palsy, there is drooping of the palate; a depressed gag reflex; pooling of saliva in the pharynx; a weak cough; and a wasted, fasciculating tongue. In pseudobulbar palsy, the tongue is contracted and spastic and cannot be moved rapidly from side to side. Limb involvement is characterized by motor disturbances (weakness, stiffness, wasting, fasciculations) reflecting lower or upper motor neuron dysfunction; there are no objective changes on sensory examination, although there may be vague sensory complaints. The sphincters are generally spared. Cognitive changes or pseudobulbar affect may be present. The disorder is progressive, and amyotrophic lateral sclerosis is usually fatal within 3–5 years; death usually results from pulmonary infections. Patients with bulbar involvement generally have the poorest prognosis, while patients with primary lateral sclerosis often have a longer survival despite profound quadriparesis and spasticity.

B. Laboratory and Other Studies

Electromyography may show changes of chronic partial denervation, with abnormal spontaneous activity in the resting muscle and a reduction in the number of motor

units under voluntary control. In patients with suspected spinal muscular atrophy or amyotrophic lateral sclerosis, the diagnosis should not be made with confidence unless such changes are found in at least three spinal regions (cervical, thoracic, lumbosacral) or two spinal regions and the bulbar musculature. Motor conduction velocity is usually normal but may be slightly reduced, and sensory conduction studies are also normal. Biopsy of a wasted muscle shows the histologic changes of denervation. The serum creatine kinase may be slightly elevated but never reaches the extremely high values seen in some of the muscular dystrophies. The cerebrospinal fluid is normal.

Approximately 10% of cases of amyotrophic lateral sclerosis are familial and have been associated with mutations at several different genetic loci. The spinal muscular atrophies (SMAs) are inherited syndromes caused most often by mutations of the survival motor neuron (SMN) gene on chromosome 5. Different mutations result in more or less severe disruptions of the protein, resulting in an age of onset that ranges from infancy (SMA type I; Werdnig-Hoffmann disease), to early (type II) or late childhood (type III; Kugelberg-Welander syndrome), to adulthood (type IV). X-linked bulbosplinal neuronopathy (Kennedy syndrome) is associated with an expanded trinucleotide repeat sequence on the androgen receptor gene and carries a more benign prognosis than other forms of motor neuron disease. There have been recent reports of juvenile spinal muscular atrophy due to hexosaminidase deficiency, with abnormal findings on rectal biopsy and reduced hexosaminidase A in serum and leukocytes. Pure motor syndromes resembling motor neuron disease may also occur in association with monoclonal gammopathy or multifocal motor neuropathies with conduction block. A motor neuropathy may also develop in Hodgkin disease and has a relatively benign prognosis. Infective anterior horn cell diseases (polio virus or West Nile virus infection) can generally be distinguished by the acute onset and monophasic course of the illness, as discussed in Chapter 32.

► Treatment

Riluzole, 50 mg orally twice daily, which reduces the pre-synaptic release of glutamate, may slow progression of amyotrophic lateral sclerosis. There is otherwise no specific treatment except in patients with gammopathy, in whom plasmapheresis and immunosuppression may lead to improvement. Therapeutic trials of various neurotrophic factors and other agents to slow disease progression have yielded generally disappointing results. Symptomatic and supportive measures may include prescription of anticholinergic drugs (such as trihexyphenidyl, amitriptyline, or atropine) or use of a portable suction machine if drooling is troublesome, braces or a walker to improve mobility, and physical therapy to prevent contractures. Behavioral modification (eg, exercising facial muscles and encouraging frequent swallowing) or over-the-counter decongestants may also help mild drooling. Spasticity may be helped by baclofen or diazepam. A semiliquid diet or nasogastric tube feeding may be needed if dysphagia is severe. Gastrostomy or cricopharyngomyotomy is sometimes resorted to in extreme cases of predominant bulbar involvement, and

tracheostomy may be necessary if respiratory muscles are severely affected; however, in the terminal stages of these disorders, the aim of treatment should be to keep patients as comfortable as possible. Information on palliative care is provided in Chapter 5.

► When to Refer

All patients (to exclude other treatable causes of symptoms and signs) should be referred.

► When to Admit

Patients should be admitted during the terminal stages of the disorders for palliative care.

Billingham MC. A review of the neural mechanisms of action and clinical efficiency of riluzole in treating amyotrophic lateral sclerosis: what have we learned in the last decade? *CNS Neurosci Ther.* 2011 Feb;17(1):4–31. [PMID: 20236142]
 Lomen-Hoerth C. Amyotrophic lateral sclerosis from bench to bedside. *Semin Neurol.* 2008 Apr;28(2):205–11. [PMID: 18351522]
 Mitchell JD et al. Amyotrophic lateral sclerosis. *Lancet.* 2007 Jun 16;369(9578):2031–41. [PMID: 17574095]
 Phukan J et al. Cognitive impairment in amyotrophic lateral sclerosis. *Lancet Neurol.* 2007 Nov;6(11):994–1003. [PMID: 17945153]
 Wang H et al. Smoking and risk of amyotrophic lateral sclerosis: a pooled analysis of 5 prospective cohorts. *Arch Neurol.* 2011 Feb;68(2):207–13. [PMID: 21320987]

PERIPHERAL NEUROPATHIES

Peripheral neuropathies can be categorized on the basis of the structure primarily affected. The predominant pathologic feature may be axonal degeneration (axonal or neuronal neuropathies) or paranodal or segmental demyelination. The distinction may be possible on the basis of neurophysiologic findings. Motor and sensory conduction velocity can be measured in accessible segments of peripheral nerves. In axonal neuropathies, conduction velocity is normal or reduced only mildly and needle electromyography provides evidence of denervation in affected muscles. In demyelinating neuropathies, conduction may be slowed considerably in affected fibers, and in more severe cases, conduction is blocked completely, without accompanying electromyographic signs of denervation.

Nerves may be injured or compressed by neighboring anatomic structures at any point along their course. Common **mononeuropathies** of this sort are considered below. They lead to a sensory, motor, or mixed deficit that is restricted to the territory of the affected nerve. A similar clinical disturbance is produced by peripheral nerve tumors, but these are rare except in patients with neurofibromatosis type 1. Multiple mononeuropathies suggest a patchy multifocal disease process such as vasculopathy (eg, diabetes, arteritis), an infiltrative process (eg, leprosy, sarcoidosis), radiation damage, or an immunologic disorder (eg, brachial plexopathy). Diffuse **polyneuropathies** lead to a symmetric sensory, motor, or mixed deficit, often marked distally. They include the hereditary, metabolic,

and toxic disorders; idiopathic inflammatory polyneuropathy (Guillain-Barré syndrome); and the peripheral neuropathies that may occur as a nonmetastatic complication of malignant diseases. Involvement of motor fibers leads to flaccid weakness that is most marked distally; dysfunction of sensory fibers causes impaired sensory perception. Tendon reflexes are depressed or absent. Paresthesias, pain, and muscle tenderness may also occur.

POLYNEUROPATHIES & MONONEURITIS MULTIPLEX



ESSENTIALS OF DIAGNOSIS

- ▶ Weakness, sensory disturbances, or both in the extremities.
- ▶ Pain sometimes common.
- ▶ Depressed or absent tendon reflexes.
- ▶ May be family history of neuropathy.
- ▶ May be history of systemic illness or toxic exposure.

The cause of polyneuropathy or mononeuritis multiplex is suggested by the history, mode of onset, and predominant clinical manifestations. Laboratory workup includes a complete blood count and erythrocyte sedimentation rate, serum protein electrophoresis, and immunophoresis, determination of plasma urea and electrolytes, liver and thyroid function tests, tests for rheumatoid factor and anti-nuclear antibody, HBsAg determination, a serologic test for syphilis, fasting blood glucose level, urinary heavy metal levels, cerebrospinal fluid examination, and chest radiography. These tests should be ordered selectively, as guided by symptoms and signs. Measurement of nerve conduction velocity is important in confirming the peripheral nerve origin of symptoms and providing a means of following clinical changes, as well as indicating the likely disease process (ie, axonal or demyelinating neuropathy). Cutaneous nerve biopsy may help establish a precise diagnosis (eg, polyarteritis, amyloidosis). In about half of cases, no specific cause can be established; of these, slightly less than half are subsequently found to be familial.

Treatment is of the underlying cause, when feasible, and is discussed below under the individual disorders. Physical therapy helps prevent contractures, and splints can maintain a weak extremity in a position of useful function. Anesthetic extremities must be protected from injury. To guard against burns, patients should check the temperature of water and hot surfaces with a portion of skin having normal sensation, measure water temperature with a thermometer, and use cold water for washing or lower the temperature setting of their hot-water heaters. Shoes should be examined frequently during the day for grit or foreign objects in order to prevent pressure lesions.

Patients with polyneuropathies or mononeuritis multiplex are subject to additional nerve injury at pressure points and should therefore avoid such behavior as leaning on elbows or sitting with crossed legs for lengthy periods.

Neuropathic, burning pain is sometimes troublesome and may respond to simple analgesics, such as aspirin or nonsteroidal anti-inflammatory agents, and to gabapentin (300 mg orally three times daily, titrated up to a maximum of 1200 mg orally three times daily as necessary). Duloxetine (60 mg orally daily) or venlafaxine (start 37.5 mg orally twice daily, and titrate up to 75 mg orally two to three times daily) may be helpful, especially in painful diabetic neuropathy. Opioids may be necessary for severe hyperpathia or pain induced by minimal stimuli, but their use should be avoided as much as possible. The use of a frame or cradle to reduce contact with bedclothes may be helpful. Many patients experience episodic stabbing pains, which may respond to gabapentin, pregabalin (100 mg orally three times daily), carbamazepine (start 100 mg orally twice daily, and titrate up to 400 mg orally twice daily), or tricyclic antidepressants (eg, amitriptyline 10–150 mg orally at bedtime daily).

Symptoms of autonomic dysfunction are occasionally troublesome. Postural hypotension is often helped by wearing waist-high elastic stockings and sleeping in a semierect position at night. Fludrocortisone reduces postural hypotension, but doses as high as 1 mg/d are sometimes necessary in diabetics and may lead to recumbent hypertension. Midodrine, an α -agonist, is sometimes helpful in a dose of 2.5–10 mg three times daily. Erectile dysfunction and diarrhea are difficult to treat; a flaccid neuropathic bladder may respond to parasympathomimetic drugs such as bethanechol chloride, 10–50 mg three or four times daily.

Freeman R. Autonomic peripheral neuropathy. *Neurol Clin.* 2007 Feb;25(1):277–301. [PMID: 17324728]

Kanji JN et al. Does this patient with diabetes have large-fiber peripheral neuropathy? *JAMA.* 2010 Apr 21;303(15):1526–32. [PMID: 20407062]

Moore RA et al. Pregabalin for acute and chronic pain in adults. *Cochrane Database Syst Rev.* 2009 Jul 8;(3):CD007076. [PMID: 19588419]

Torpy JM et al. JAMA patient page. Peripheral neuropathy. *JAMA.* 2008 Mar 5;299(9):1096. [PMID: 18319421]

1. Inherited Neuropathies

A. Charcot-Marie-Tooth Disease (HMSN Type I, II)

Several distinct varieties of Charcot-Marie-Tooth disease can be recognized. There is usually an autosomal dominant mode of inheritance, but occasional cases occur on a sporadic, recessive, or X-linked basis. The responsible gene is commonly located on the short arm of chromosome 17 and less often shows linkage to chromosome 1 or the X chromosome. It has also been linked to several other chromosomes, emphasizing the genetic heterogeneity of the disorder. Clinical presentation may be with foot deformities or gait disturbances in childhood or early adult life. Slow progression leads to the typical features of polyneuropathy, with distal weakness and wasting that begin in the legs, a variable amount of distal sensory loss, and depressed or absent tendon reflexes. Tremor is a conspicuous feature

in some instances. Electrodiagnostic studies show a marked reduction in motor and sensory conduction velocity (hereditary motor and sensory neuropathy [HMSN] type I).

In other instances (HMSN type II), motor conduction velocity is normal or only slightly reduced, sensory nerve action potentials may be absent, and signs of chronic partial denervation are found in affected muscles electromyographically. The predominant pathologic change is axonal loss rather than segmental demyelination.

A similar disorder may occur in patients with progressive distal spinal muscular atrophy, but there is no sensory loss; electrophysiologic investigation reveals that motor conduction velocity is normal or only slightly reduced, and nerve action potentials are normal.

B. Dejerine-Sottas Disease (HMSN Type III)

The disorder may occur on a sporadic, autosomal dominant or, less commonly, autosomal recessive basis. Onset in infancy or childhood leads to a progressive motor and sensory polyneuropathy with weakness, ataxia, sensory loss, and depressed or absent tendon reflexes. The peripheral nerves may be palpably enlarged and are characterized pathologically by segmental demyelination, Schwann cell hyperplasia, and thin myelin sheaths. Electrophysiologically, there is slowing of conduction, and sensory action potentials may be unrecordable.

C. Friedreich Ataxia

This disorder, the only known autosomal recessive trinucleotide repeat disease, is caused by expansion of a poly-GAA locus in the gene for frataxin on chromosome 9, leading to symptoms in childhood or early adult life. The gait becomes ataxic, the hands become clumsy, and other signs of cerebellar dysfunction develop accompanied by weakness of the legs and extensor plantar responses. Involvement of peripheral sensory fibers leads to sensory disturbances in the limbs and depressed tendon reflexes. There is bilateral pes cavus. Pathologically, there is a marked loss of cells in the posterior root ganglia and degeneration of peripheral sensory fibers. In the central nervous system, changes are conspicuous in the posterior and lateral columns of the cord. Electrophysiologically, conduction velocity in motor fibers is normal or only mildly reduced, but sensory action potentials are small or absent. Cardiac disease is the most common cause of death.

In the differential diagnosis for Friedreich ataxia are other spinocerebellar ataxias, a growing group of at least 29 inherited disorders, each involving a different identified gene. These heterogeneous disorders, which frequently (but not exclusively) exhibit an autosomal dominant inheritance pattern and poly-CAG expansion of the affected gene, typically cause cerebellar ataxia and varying combinations of other symptoms (such as peripheral neuropathy, ophthalmoparesis, dysarthria, and pyramidal and extrapyramidal signs).

Koeppen AH. Friedreich's ataxia: pathology, pathogenesis, and molecular genetics. *J Neurol Sci.* 2011 Apr 15;303(1-2):1-12. [PMID: 21315377]

D. Refsum Disease (HMSN Type IV)

This autosomal recessive disorder is due to a disturbance in phytanic acid metabolism. Clinically, pigmentary retinal degeneration is accompanied by progressive sensorimotor polyneuropathy and cerebellar signs. Auditory dysfunction, cardiomyopathy, and cutaneous manifestations may also occur. Motor and sensory conduction velocity are reduced, often markedly, and there may be electromyographic evidence of denervation in affected muscles. Dietary restriction of phytanic acid and its precursors may be helpful therapeutically. Plasmapheresis to reduce stored phytanic acid may help at the initiation of treatment.

E. Porphyria

Peripheral nerve involvement may occur during acute attacks in both variegate porphyria and acute intermittent porphyria. Motor symptoms usually occur first, and weakness is often most marked proximally and in the upper limbs rather than the lower. Sensory symptoms and signs may be proximal or distal in distribution. Autonomic involvement is sometimes pronounced. The electrophysiologic findings are in keeping with the results of neuropathologic studies suggesting that the neuropathy is axonal in type. Hematin (4 mg/kg intravenously over 15 minutes once or twice daily) may lead to rapid improvement. A high-carbohydrate diet and, in severe cases, intravenous glucose or levulose may also be helpful. Propranolol (up to 100 mg orally every 4 hours) may control tachycardia and hypertension in acute attacks.

2. Neuropathies Associated with Systemic & Metabolic Disorders

A. Diabetes Mellitus

In this disorder, involvement of the peripheral nervous system may lead to symmetric sensory or mixed polyneuropathy, asymmetric motor radiculoneuropathy or plexopathy (diabetic amyotrophy), thoracoabdominal radiculopathy, autonomic neuropathy, or isolated lesions of individual nerves. These may occur singly or in any combination and are discussed in Chapter 27.

Bansal D et al. Amitriptyline vs. pregabalin in painful diabetic neuropathy: a randomized double blind clinical trial. *Diabet Med.* 2009 Oct;26(10):1019-26. [PMID: 19900234]
Zochodne DW. Diabetic polyneuropathy: an update. *Curr Opin Neurol.* 2008 Oct;21(5):527-33. [PMID: 18769245]

B. Uremia

Uremia may lead to a symmetric sensorimotor polyneuropathy that tends to affect the lower limbs more than the upper limbs and is more marked distally than proximally (see Chapter 22). The diagnosis can be confirmed electrophysiologically, for motor and sensory conduction velocity is moderately reduced. The neuropathy improves both clinically and electrophysiologically with kidney transplantation and to a lesser extent with chronic dialysis.

Krishnan AV et al. Uremic neuropathy: clinical features and new pathophysiological insights. *Muscle Nerve*. 2007 Mar;35(3):273–90. [PMID: 17195171]

C. Alcoholism and Nutritional Deficiency

Many alcoholics have an axonal distal sensorimotor polyneuropathy that is frequently accompanied by painful cramps, muscle tenderness, and painful paresthesias and is often more marked in the legs than in the arms. Symptoms of autonomic dysfunction may also be conspicuous. Motor and sensory conduction velocity may be slightly reduced, even in subclinical cases, but gross slowing of conduction is uncommon. A similar distal sensorimotor polyneuropathy is a well-recognized feature of beriberi (thiamine deficiency). In vitamin B₁₂ deficiency, distal sensory polyneuropathy may develop but is usually overshadowed by central nervous system manifestations (eg, myelopathy, optic neuropathy, or intellectual changes).

D. Paraproteinemias

A symmetric sensorimotor polyneuropathy that is gradual in onset, progressive in course, and often accompanied by pain and dysesthesias in the limbs may occur in patients (especially men) with multiple myeloma. The neuropathy is of the axonal type in classic lytic myeloma, but segmental demyelination (primary or secondary) and axonal loss may occur in sclerotic myeloma and lead to predominantly motor clinical manifestations. Both demyelinating and axonal neuropathies are also observed in patients with paraproteinemias without myeloma. A small fraction will develop myeloma if serially followed. The demyelinating neuropathy in these patients may be due to the monoclonal protein's reacting to a component of the nerve myelin. The neuropathy of classic multiple myeloma is poorly responsive to therapy. The polyneuropathy of benign monoclonal gammopathy may respond to immunosuppressant drugs and plasmapheresis.

Polyneuropathy may also occur in association with macroglobulinemia and cryoglobulinemia and sometimes responds to plasmapheresis. Entrapment neuropathy, such as carpal tunnel syndrome, is more common than polyneuropathy in patients with (nonhereditary) generalized amyloidosis. With polyneuropathy due to amyloidosis, sensory and autonomic symptoms are especially conspicuous, whereas distal wasting and weakness occur later; there is no specific treatment.

3. Neuropathies Associated with Infectious & Inflammatory Diseases

A. Leprosy

Leprosy is an important cause of peripheral neuropathy in certain parts of the world. Sensory disturbances are mainly due to involvement of intracutaneous nerves. In tuberculoid leprosy, they develop at the same time and in the same distribution as the skin lesion but may be more extensive if nerve trunks lying beneath the lesion are also involved. In lepromatous leprosy, there is more extensive sensory loss, and this develops earlier and to a greater extent in the

coolest regions of the body, such as the dorsal surfaces of the hands and feet, where the bacilli proliferate most actively. Motor deficits result from involvement of superficial nerves where their temperature is lowest, eg, the ulnar nerve in the region proximal to the olecranon groove, the median nerve as it emerges from beneath the forearm flexor muscle to run toward the carpal tunnel, the peroneal nerve at the head of the fibula, and the posterior tibial nerve in the lower part of the leg; patchy facial muscular weakness may also occur owing to involvement of the superficial branches of the seventh cranial nerve.

Motor disturbances in leprosy are suggestive of multiple mononeuropathy, whereas sensory changes resemble those of distal polyneuropathy. Examination, however, relates the distribution of sensory deficits to the temperature of the tissues; in the legs, for example, sparing frequently occurs between the toes and in the popliteal fossae, where the temperature is higher. Treatment is with antileprotic agents (see Chapter 33).

B. AIDS

A variety of neuropathies occur in HIV-infected patients (see Chapter 31). Patients with AIDS may develop a chronic symmetric sensorimotor axonal **polyneuropathy** associated usually with no abnormal cerebrospinal fluid findings. Treatment is symptomatic. AIDS patients may also develop progressive **polyradiculopathy** or radiculomyelopathy that leads to leg weakness and urinary retention; sensory loss is less conspicuous than in polyneuropathy. The cerebrospinal fluid may show mononuclear pleocytosis and increased protein and low glucose concentrations. Cytomegalovirus is responsible in at least some cases. The prognosis is generally poor, but some patients respond to intravenous ganciclovir (2.5 mg/kg every 8 hours for 10 days, then 7.5 mg/kg daily 5 days per week).

An inflammatory **demyelinating polyradiculoneuropathy** sometimes occurs in HIV-seropositive patients without AIDS and may follow an acute, subacute, or chronic course. Weakness is usually more conspicuous distally than proximally and tends to overshadow sensory symptoms. Tendon reflexes are depressed or absent. The cerebrospinal fluid shows an increased cell count and protein concentration. Treatment with plasmapheresis has helped some patients. Spontaneous improvement may also occur. Seropositive patients without AIDS may also develop a **mononeuropathy multiplex** that sometimes responds to treatment with plasmapheresis.

Evans SR et al. Peripheral neuropathy in HIV: prevalence and risk factors. *AIDS*. 2011 Apr 24;25(7):919–28. [PMID: 21330902]

C. Lyme Borreliosis

The neurologic manifestations of Lyme disease include meningitis, meningoencephalitis, polyradiculoneuropathy, mononeuropathy multiplex, and cranial neuropathy. Serologic tests establish the underlying disorder. Lyme disease and its treatment are discussed in depth in Chapter 34.

D. Sarcoidosis

Cranial nerve palsies (especially facial palsy), multiple mononeuropathy and, less commonly, symmetric polyneuropathy may all occur, the latter sometimes preferentially affecting either motor or sensory fibers. Improvement may occur with use of corticosteroids.

E. Polyarteritis

Involvement of the vasa nervorum by the vasculitic process may result in infarction of the nerve. Clinically, one encounters an asymmetric sensorimotor polyneuropathy (mononeuritis multiplex) that pursues a waxing and waning course. Corticosteroids and cytotoxic agents—especially cyclophosphamide—may be of benefit in severe cases.

F. Rheumatoid Arthritis

Compressive or entrapment neuropathies, ischemic neuropathies, mild distal sensory polyneuropathy, and severe progressive sensorimotor polyneuropathy can occur in rheumatoid arthritis.

4. Neuropathy Associated with Critical Illness

Patients in intensive care units with sepsis and multiorgan failure sometimes develop polyneuropathies. This may be manifested initially by unexpected difficulty in weaning patients from a mechanical ventilator and in more advanced cases by wasting and weakness of the extremities and loss of tendon reflexes. Sensory abnormalities are relatively inconspicuous. The neuropathy is axonal in type. Its pathogenesis is obscure, and treatment is supportive. The prognosis is good provided patients recover from the underlying critical illness.

5. Toxic Neuropathies

Axonal polyneuropathy may follow exposure to industrial agents or pesticides such as acrylamide, organophosphorus compounds, hexacarbon solvents, methyl bromide, and carbon disulfide; metals such as arsenic, thallium, mercury, and lead; and drugs such as phenytoin, perhexiline, isoniazid, nitrofurantoin, vincristine, and pyridoxine in high doses. Detailed occupational, environmental, and medical histories and recognition of clusters of cases are important in suggesting the diagnosis. Treatment is by preventing further exposure to the causal agent. Isoniazid neuropathy is prevented by pyridoxine supplementation.

Diphtheritic neuropathy results from a neurotoxin released by the causative organism and is common in many areas. Palatal weakness may develop 2–4 weeks after infection of the throat, and infection of the skin may similarly be followed by focal weakness of neighboring muscles. Disturbances of accommodation may occur about 4–5 weeks after infection and distal sensorimotor demyelinating polyneuropathy after 1–3 months.

6. Neuropathies Associated with Malignant Diseases

Both a sensorimotor and a purely sensory polyneuropathy may occur as a nonmetastatic complication of malignant diseases, and have been associated with circulating anti-MAG or anti-Hu antibodies that can be detected by a paraneoplastic antibody panel that is available commercially. The sensorimotor polyneuropathy may be mild and occur in the course of known malignant disease, or it may have an acute or subacute onset, lead to severe disability, and occur before there is any clinical evidence of the cancer, occasionally following a remitting course. An autonomic neuropathy may also occur as a paraneoplastic disorder related to the presence of anti-Hu antibodies or to an antibody against ganglionic acetylcholine receptors (anti-nAChR).

7. Acute Idiopathic Polyneuropathy (Guillain-Barré Syndrome)



ESSENTIALS OF DIAGNOSIS

- ▶ Acute or subacute progressive polyradiculoneuropathy.
- ▶ Weakness is more severe than sensory disturbances.
- ▶ Acute dysautonomia may be life-threatening.

▶ General Considerations

This acute or subacute polyradiculoneuropathy sometimes follows infective illness, inoculations, or surgical procedures. There is an association with preceding *Campylobacter jejuni* enteritis. The disorder probably has an immunologic basis, but the precise mechanism is unclear.

▶ Clinical Findings

A. Symptoms and Signs

The main complaint is of weakness that varies widely in severity in different patients and often has a proximal emphasis and symmetric distribution. It usually begins in the legs, spreading to a variable extent but frequently involving the arms and often one or both sides of the face. The muscles of respiration or deglutition may also be affected. Sensory symptoms are usually less conspicuous than motor ones, but distal paresthesias and dysesthesias are common, and neuropathic or radicular pain is present in many patients. Autonomic disturbances are also common, may be severe, and are sometimes life-threatening; they include tachycardia, cardiac irregularities, hypotension or hypertension, facial flushing, abnormalities of sweating, pulmonary dysfunction, and impaired sphincter control. The axonal subtypes of the syndrome (acute motor axonal neuropathy [AMAN] and acute motor and sensory axonal neuropathy [AMSAN]) are caused by antibodies to gangliosides on the axon membrane, including

anti-GM1, anti-GM1b, anti-GD1a, anti-GD1b, and (in AMAN) anti-GalNAC-GD1a antibodies. The Miller Fisher syndrome, another subtype, is characterized by the clinical triad of ophthalmoplegia, ataxia, and areflexia, and is associated with anti-GQ1b antibodies.

B. Laboratory Findings

The cerebrospinal fluid characteristically contains a high protein concentration with a normal cell content, but these changes may take 2 or 3 weeks to develop. Electrophysiologic studies may reveal marked abnormalities, which do not necessarily parallel the clinical disorder in their temporal course. Pathologic examination shows primary demyelination or, less commonly, axonal degeneration.

► Differential Diagnosis

When the diagnosis is made, the history and appropriate laboratory studies should exclude the possibility of porphyric, diphtheritic, or toxic (heavy metal, hexacarbon, organophosphate) neuropathies. The temporal course excludes other peripheral neuropathies. Poliomyelitis, botulism, and tick paralysis must also be considered as they cause weakness of acute onset. The presence of pyramidal signs, a markedly asymmetric motor deficit, a sharp sensory level, or early sphincter involvement should suggest a focal cord lesion.

► Treatment

Treatment with prednisone is ineffective and may prolong recovery time. Plasmapheresis is of value; it is best performed within the first few days of illness and is particularly useful for clinically severe or rapidly progressive cases or those with ventilatory impairment. IVIG (400 mg/kg/d for 5 days) is equally helpful and imposes less stress on the cardiovascular system than plasmapheresis. Patients should be admitted to intensive care units if their forced vital capacity is declining, and intubation is considered if the forced vital capacity reaches 15 mL/kg, the mean inspiratory force reaches -40 mm Hg, dyspnea becomes evident, or the oxygen saturation declines. Respiratory toilet and chest physical therapy help prevent atelectasis. Marked hypotension may respond to volume replacement or pressor agents. Low-dose heparin to prevent pulmonary embolism should be considered.

Approximately 3% of patients with acute idiopathic polyneuropathy have one or more clinically similar relapses, sometimes several years after the initial illness. Plasma exchange therapy may produce improvement in chronic and relapsing inflammatory polyneuropathy.

► Prognosis

Most patients eventually make a good recovery, but this may take many months, and about 20% of patients are left with persisting disability.

► When to Refer

All patients should be referred.

► When to Admit

All patients should be hospitalized until their condition is stable and there is no respiratory compromise.

- Haber P et al. Vaccines and Guillain-Barré syndrome. *Drug Saf.* 2009;32(4):309–23. [PMID: 19388722]
- Hughes RA et al. Corticosteroids for Guillain-Barré syndrome. *Cochrane Database Syst Rev.* 2010 Feb 17;2:CD001446. [PMID: 20166061]
- Hughes RA et al. Intravenous immunoglobulin for Guillain-Barré syndrome. *Cochrane Database Syst Rev.* 2010 Jun 16;(6):CD002063. [PMID: 20556755]
- Lo YL. Clinical and immunological spectrum of the Miller Fisher syndrome. *Muscle Nerve.* 2007 Nov;36(5):615–27. [PMID: 17657801]
- van Doorn PA et al. Clinical features, pathogenesis, and treatment of Guillain-Barré syndrome. *Lancet Neurol.* 2008 Oct;7(10):939–50. [PMID: 18848313]
- Yuki N. Ganglioside mimicry and peripheral nerve disease. *Muscle Nerve.* 2007 Jun;35(6):691–711. [PMID: 17373701]

8. Chronic Inflammatory Polyneuropathy

Chronic inflammatory demyelinating polyneuropathy, an acquired immunologically mediated disorder, is clinically similar to Guillain-Barré syndrome except that it has a relapsing or steadily progressive course over months or years and that autonomic dysfunction is generally less common. It may present as an exclusively motor disorder or with a mixed sensorimotor disturbance. In the relapsing form, partial recovery may occur after some relapses, but in other instances there is no recovery between exacerbations. Although remission may occur spontaneously with time, the disorder frequently follows a progressive downhill course leading to severe functional disability.

Electrodiagnostic studies show marked slowing of motor and sensory conduction, and focal conduction block. Signs of partial denervation may also be present owing to secondary axonal degeneration. Nerve biopsy may show chronic perivascular inflammatory infiltrates in the endoneurium and epineurium, without accompanying evidence of vasculitis. However, a normal nerve biopsy result or the presence of nonspecific abnormalities does not exclude the diagnosis.

Corticosteroids may arrest or reverse the downhill course. Treatment is usually begun with prednisone, 60–80 mg daily, continued for 2–3 months or until a definite response has occurred. If no response has occurred despite 3 months of treatment, a higher dose may be tried. In responsive cases, the dose is gradually tapered, but most patients become corticosteroid-dependent, often requiring prednisone, 20 mg daily on alternate days, on a long-term basis. IVIG can be used in place of, or in addition to corticosteroids and is best used as the initial treatment in pure motor syndromes. When both IVIG and corticosteroids are ineffective, plasma exchange may be worthwhile. Consistent with the notion that the condition is antibody mediated, rituximab has shown promise. Immunosuppressant or immunomodulatory drugs (such as azathioprine) may be added when the response to other

measures is unsatisfactory or to enable maintenance doses of corticosteroids to be lowered. Symptomatic treatment is also important.

Benedetti L et al. Rituximab in patients with chronic inflammatory demyelinating polyradiculoneuropathy: a report of 13 cases and review of the literature. *J Neurol Neurosurg Psychiatry*. 2011 Mar;82(3):306–8. [PMID: 20639381]

Latov N et al; IGIV-C CIDP Efficacy (ICE) Study Group. Timing and course of clinical response to intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy. *Arch Neurol*. 2010 Jul;67(7):802–7. [PMID: 20457948]

Rajabally YA et al. Validity of diagnostic criteria for chronic inflammatory demyelinating polyneuropathy: a multicentre European study. *J Neurol Neurosurg Psychiatry*. 2009 Dec;80(12):1364–8. [PMID: 19622522]

van Schaik IN et al. Pulsed high-dose dexamethasone versus standard prednisolone treatment for chronic inflammatory demyelinating polyradiculoneuropathy (PREDICT study): a double-blind, randomised, controlled trial. *Lancet Neurol*. 2010 Mar;9(3):245–53. [PMID: 20133204]

MONONEUROPATHIES



ESSENTIALS OF DIAGNOSIS

- ▶ Focal motor or sensory deficit.
- ▶ Deficit is in territory of an individual peripheral nerve.

An individual nerve may be injured along its course or may be compressed, angulated, or stretched by neighboring anatomic structures, especially at a point where it passes through a narrow space (entrapment neuropathy). The relative contributions of mechanical factors and ischemia to the local damage are not clear. With involvement of a sensory or mixed nerve, pain is commonly felt distal to the lesion. Symptoms never develop with some entrapment neuropathies, resolve rapidly and spontaneously in others, and become progressively more disabling and distressing in yet other cases. The precise neurologic deficit depends on the nerve involved. Percussion of the nerve at the site of the lesion may lead to paresthesias in its distal distribution.

Entrapment neuropathy may be the sole manifestation of subclinical polyneuropathy, and this must be borne in mind and excluded by nerve conduction studies. Such studies are also indispensable for the accurate localization of the focal lesion.

In patients with acute compression neuropathy such as may occur in intoxicated individuals (“Saturday night palsy”), no treatment is necessary. Complete recovery generally occurs, usually within 2 months, presumably because the underlying pathology is demyelination. However, axonal degeneration can occur in severe cases, and recovery then takes longer and may never be complete.

In chronic compressive or entrapment neuropathies, avoidance of aggravating factors and correction of any underlying systemic conditions are important. Local

infiltration of the region about the nerve with corticosteroids may be of value; in addition, surgical decompression may help if there is a progressively increasing neurologic deficit or if electrodiagnostic studies show evidence of partial denervation in weak muscles.

Peripheral nerve tumors are uncommon, except in neurofibromatosis type 1, but also give rise to mononeuropathy. This may be distinguishable from entrapment neuropathy only by noting the presence of a mass along the course of the nerve and by demonstrating the precise site of the lesion with appropriate electrophysiologic studies. Treatment of symptomatic lesions is by surgical removal if possible.

1. Carpal Tunnel Syndrome

See Chapter 20.

2. Pronator Teres or Anterior Interosseous Syndrome

The median nerve gives off its motor branch, the anterior interosseous nerve, below the elbow as it descends between the two heads of the pronator teres muscle. A lesion of either nerve may occur in this region, sometimes after trauma or owing to compression from, for example, a fibrous band. With anterior interosseous nerve involvement, there is no sensory loss, and weakness is confined to the pronator quadratus, flexor pollicis longus, and the flexor digitorum profundus to the second and third digits. Weakness is more widespread and sensory changes occur in an appropriate distribution when the median nerve itself is affected. The prognosis is variable. If improvement does not occur spontaneously, decompressive surgery may be helpful.

3. Ulnar Nerve Lesions

Ulnar nerve lesions are likely to occur in the elbow region as the nerve runs behind the medial epicondyle and descends into the cubital tunnel. In the condylar groove, the ulnar nerve is exposed to pressure or trauma. Moreover, any increase in the carrying angle of the elbow, whether congenital, degenerative, or traumatic, may cause excessive stretching of the nerve when the elbow is flexed. Ulnar nerve lesions may also result from thickening or distortion of the anatomic structures forming the cubital tunnel, and the resulting symptoms may also be aggravated by flexion of the elbow, because the tunnel is then narrowed by tightening of its roof or inward bulging of its floor. A severe lesion at either site causes sensory changes in the medial 1½ digits and along the medial border of the hand. There is weakness of the ulnar-innervated muscles in the forearm and hand. With a cubital tunnel lesion, however, there may be relative sparing of the flexor carpi ulnaris muscle. Electrophysiologic evaluation using nerve stimulation techniques allows more precise localization of the lesion.

If conservative measures are unsuccessful in relieving symptoms and preventing further progression, surgical treatment may be necessary. This consists of nerve transposition if the lesion is in the condylar groove, or a release procedure if it is in the cubital tunnel.

Ulnar nerve lesions may also develop at the wrist or in the palm of the hand, usually owing to repetitive trauma or to compression from ganglia or benign tumors. They can be subdivided depending on their presumed site. Compressive lesions are treated surgically. If repetitive mechanical trauma is responsible, this is avoided by occupational adjustment or job retraining.

Watts AC et al. Patient-rated outcome of ulnar nerve decompression: a comparison of endoscopic and open in situ decompression. *J Hand Surg Am.* 2009 Oct;34(8):1492–8. [PMID: 19695795]

4. Radial Nerve Lesions

The radial nerve is particularly liable to compression or injury in the axilla (eg, by crutches or by pressure when the arm hangs over the back of a chair). This leads to weakness or paralysis of all the muscles supplied by the nerve, including the triceps. Sensory changes may also occur but are often surprisingly inconspicuous, being marked only in a small area on the back of the hand between the thumb and index finger. Injuries to the radial nerve in the spiral groove occur characteristically during deep sleep, as in intoxicated individuals (Saturday night palsy), and there is then sparing of the triceps muscle, which is supplied more proximally. The nerve may also be injured at or above the elbow; its purely motor posterior interosseous branch, supplying the extensors of the wrist and fingers, may be involved immediately below the elbow, but then there is sparing of the extensor carpi radialis longus, so that the wrist can still be extended. The superficial radial nerve may be compressed by handcuffs or a tight watch strap.

5. Femoral Neuropathy

The clinical features of femoral nerve palsy consist of weakness and wasting of the quadriceps muscle, with sensory impairment over the anteromedian aspect of the thigh and sometimes also of the leg to the medial malleolus, and a depressed or absent knee jerk. Isolated femoral neuropathy may occur in diabetics or from compression by retroperitoneal neoplasms or hematomas (eg, expanding aortic aneurysm). Femoral neuropathy may also result from pressure from the inguinal ligament when the thighs are markedly flexed and abducted, as in the lithotomy position.

6. Meralgia Paresthetica

The lateral femoral cutaneous nerve, a sensory nerve arising from the L2 and L3 roots, may be compressed or stretched in obese or diabetic patients and during pregnancy. The nerve usually runs under the outer portion of the inguinal ligament to reach the thigh, but the ligament sometimes splits to enclose it. Hyperextension of the hip or increased lumbar lordosis—such as occurs during pregnancy—leads to nerve compression by the posterior fascicle of the ligament. However, entrapment of the nerve at any point along its course may cause similar symptoms, and several other anatomic variations predispose the nerve to damage when it is stretched. Pain, paresthesia, or

numbness occurs about the outer aspect of the thigh, usually unilaterally, and is sometimes relieved by sitting. Examination shows no abnormalities except in severe cases when cutaneous sensation is impaired in the affected area. Symptoms are usually mild and commonly settle spontaneously. Hydrocortisone injections medial to the antero-superior iliac spine often relieve symptoms temporarily, while nerve decompression by transposition may provide more lasting relief.

7. Sciatic & Common Peroneal (Fibular) Nerve Palsies

Misplaced deep intramuscular injections are probably still the most common cause of sciatic nerve palsy. Trauma to the buttock, hip, or thigh may also be responsible. The resulting clinical deficit depends on whether the whole nerve has been affected or only certain fibers. In general, the peroneal (fibular) fibers of the sciatic nerve are more susceptible to damage than those destined for the tibial nerve. A sciatic nerve lesion may therefore be difficult to distinguish from peroneal (fibular) neuropathy unless there is electromyographic evidence of involvement of the short head of the biceps femoris muscle. The common peroneal (fibular) nerve itself may be compressed or injured in the region of the head and neck of the fibula, eg, by sitting with crossed legs or wearing high boots. There is weakness of dorsiflexion and eversion of the foot, accompanied by numbness or blunted sensation of the anterolateral aspect of the calf and dorsum of the foot.

8. Tarsal Tunnel Syndrome

The tibial nerve, the other branch of the sciatic, supplies several muscles in the lower extremity, gives origin to the sural nerve, and then continues as the posterior tibial nerve to supply the plantar flexors of the foot and toes. It passes through the tarsal tunnel behind and below the medial malleolus, giving off calcaneal branches and the medial and lateral plantar nerves that supply small muscles of the foot and the skin on the plantar aspect of the foot and toes. Compression of the posterior tibial nerve or its branches between the bony floor and ligamentous roof of the tarsal tunnel leads to pain, paresthesias, and numbness over the bottom of the foot, especially at night, with sparing of the heel. Muscle weakness may be hard to recognize clinically. Compressive lesions of the individual plantar nerves may also occur more distally, with clinical features similar to those of the tarsal tunnel syndrome. Treatment is surgical decompression.

9. Facial Neuropathy

An isolated facial palsy is most often idiopathic (Bell palsy) but may occur in patients with HIV seropositivity, sarcoidosis, Lyme disease (Figure 24–2; also see Chapter 34) or with any process causing an inflammatory reaction in the subarachnoid space, such as meningitis. Whenever facial palsies occur bilaterally, or a facial palsy occurs in conjunction with other neurologic deficits, MRI brain imaging should be undertaken and other investigations considered.



▲ **Figure 24-2.** Facial palsy caused by an infection with *Borrelia burgdorferi* (Lyme disease). (Public Health Image Library, CDC.)

▶ When to Refer

- If there is uncertainty about the diagnosis.
- Symptoms or signs are progressing despite treatment.

▶ When to Admit

When a patient should be hospitalized depends on the cause and treatment.

BELL PALSY



ESSENTIALS OF DIAGNOSIS

- ▶ Sudden onset of lower motor neuron facial palsy.
- ▶ Hyperacusis or impaired taste may occur.
- ▶ No other neurologic abnormalities.

▶ General Considerations

Bell palsy is an idiopathic facial paresis of lower motor neuron type that has been attributed to an inflammatory reaction involving the facial nerve near the stylomastoid foramen or in the bony facial canal. Increasing evidence incriminates reactivation of herpes simplex or varicella zoster virus infection in the geniculate ganglion at least in

some instances. The disorder is more common in pregnant women or in persons with diabetes mellitus.

▶ Clinical Findings

The facial paresis (Figure 24–2) generally comes on abruptly, but it may worsen over the following day or so. Pain about the ear precedes or accompanies the weakness in many cases but usually lasts for only a few days. The face itself feels stiff and pulled to one side. There may be ipsilateral restriction of eye closure and difficulty with eating and fine facial movements. A disturbance of taste is common, owing to involvement of chorda tympani fibers, and hyperacusis due to involvement of fibers to the stapedius occurs occasionally.

▶ Treatment

Other disorders that can produce a facial palsy and require specific treatment, such as tumors, Lyme disease, AIDS, sarcoidosis, and herpes zoster infection of the geniculate ganglion, must be excluded. The management of Bell palsy is controversial. Approximately 60% of cases recover completely without treatment, presumably because the lesion is so mild that it leads merely to conduction block. Considerable improvement occurs in most other cases, and only about 10% of all patients have permanent disfigurement or other long-term sequelae. Treatment is unnecessary in most cases but is indicated for patients in whom an unsatisfactory outcome can be predicted. The best clinical guide to prognosis is the severity of the palsy during the first few days after presentation. Patients with clinically complete palsy when first seen are less likely to make a full recovery than those with an incomplete one. A poor prognosis for recovery is also associated with advanced age, hyperacusis, and severe initial pain. Electromyography and nerve excitability or conduction studies provide a guide to prognosis but not early enough to aid in the selection of patients for treatment.

The only medical treatment that may influence the outcome is administration of corticosteroids, but this must be commenced within 5 days of onset. Treatment with prednisone, 60–80 mg orally daily for 4 or 5 days, followed by tapering of the dose over the next 7–10 days, is a satisfactory regimen; prednisolone (50 mg daily orally) for 10 days is another acceptable alternative. It is helpful to protect the eye with lubricating drops (or lubricating ointment at night) and a patch if eye closure is not possible. Acyclovir does not confer any additional benefit. There is no evidence that surgical procedures to decompress the facial nerve are of benefit.

de Almeida JR et al. Combined corticosteroid and antiviral treatment for Bell palsy: a systematic review and meta-analysis. *JAMA*. 2009 Sep 2;302(9):985–93. [PMID: 19724046]
 Quant EC et al. The benefits of steroids versus steroids plus antivirals for treatment of Bell's palsy: a meta-analysis. *BMJ*. 2009 Sep 7;339:b3354. [PMID: 19736282]
 Sullivan FM et al. A randomised controlled trial of the use of aciclovir and/or prednisolone for the early treatment of Bell's palsy: the BELLS study. *Health Technol Assess*. 2009 Oct;13(47):1–130. [PMID: 19833052]

DISCOGENIC NECK PAIN



ESSENTIALS OF DIAGNOSIS

- ▶ Neck pain, sometimes radiating to arms.
- ▶ Restricted neck movements.
- ▶ Motor, sensory, or reflex changes in arms with root involvement.
- ▶ Neurologic deficit in legs, gait disorder, or sphincter disturbance with cord involvement.

▶ General Considerations

A variety of congenital abnormalities may involve the cervical spine and lead to neck pain; these include hemivertebrae, fused vertebrae, basilar impression, and instability of the atlantoaxial joint. Traumatic, degenerative, infective, and neoplastic disorders may also lead to pain in the neck. When rheumatoid arthritis involves the spine, it tends to affect especially the cervical region, leading to pain, stiffness, and reduced mobility; displacement of vertebrae or atlantoaxial subluxation may lead to cord compression that can be life-threatening if not treated by fixation. Further details are given in Chapter 20 (including a discussion on low back pain), and discussion here is restricted to disk disease.

1. Acute Cervical Disk Protrusion

Acute cervical disk protrusion leads to pain in the neck and radicular pain in the arm, exacerbated by head movement. With lateral herniation of the disk, motor, sensory, or reflex changes may be found in a radicular (usually C6 or C7) distribution on the affected side (Figure 24–3); with more centrally directed herniations, the spinal cord may also be involved, leading to spastic paraparesis and sensory disturbances in the legs, sometimes accompanied by impaired sphincter function. The diagnosis is confirmed by MRI or CT myelography. In mild cases, bed rest or intermittent neck traction may help, followed by immobilization of the neck in a collar for several weeks. If these measures are unsuccessful or the patient has a significant neurologic deficit, surgical removal of the protruding disk may be necessary.

2. Cervical Spondylosis

Cervical spondylosis results from chronic cervical disk degeneration, with herniation of disk material, secondary calcification, and associated osteophytic outgrowths. One or more of the cervical nerve roots may be compressed, stretched, or angulated; and myelopathy may also develop as a result of compression, vascular insufficiency, or recurrent minor trauma to the cord. Patients present with neck pain and restricted head movement, occipital headaches, radicular pain and other sensory disturbances in the arms, weakness of the arms or legs, or some combination of these symptoms. Examination generally reveals that lateral

flexion and rotation of the neck are limited. A segmental pattern of weakness or dermatomal sensory loss (or both) may be found unilaterally or bilaterally in the upper limbs, and tendon reflexes mediated by the affected root or roots are depressed. The C5 and C6 nerve roots are most commonly involved, and examination frequently then reveals weakness of muscles supplied by these roots (eg, deltoids, supraspinatus and infraspinatus, biceps, brachioradialis), pain or sensory loss about the shoulder and outer border of the arm and forearm, and depressed biceps and brachioradialis reflexes. Spastic paraparesis may also be present if there is an associated myelopathy, sometimes accompanied by posterior column or spinothalamic sensory deficits in the legs.

Plain radiographs of the cervical spine show osteophyte formation, narrowing of disk spaces, and encroachment on the intervertebral foramina, but such changes are common in middle-aged persons and may be unrelated to the presenting complaint. CT or MRI helps confirm the diagnosis and exclude other structural causes of the myelopathy.

Restriction of neck movements by a cervical collar may relieve pain. Operative treatment may be necessary to prevent further progression if there is a significant neurologic deficit or if root pain is severe, persistent, and unresponsive to conservative measures.

▶ When to Refer

- Pain unresponsive to simple measures.
- Patients with neurologic deficits.
- Patients in whom surgical treatment is under consideration.

▶ When to Admit

- Patients with progressive or significant neurologic deficit.
- Patients with sphincter involvement (from cord compression).
- Patients requiring surgical treatment.

Matz PG et al; Joint Section on Disorders of the Spine and Peripheral Nerves of the American Association of Neurological Surgeons and Congress of Neurological Surgeons. The natural history of cervical spondylotic myelopathy. *J Neurosurg Spine*. 2009 Aug;11(2):104–11. [PMID: 19769489]

BRACHIAL & LUMBAR PLEXUS LESIONS


1. Brachial Plexus Neuropathy

Brachial plexus neuropathy may be idiopathic, sometimes occurring in relationship to a number of different nonspecific illnesses or factors. In other instances, brachial plexus lesions follow trauma or result from congenital anomalies, neoplastic involvement, or injury by various physical agents. In rare instances, the disorder occurs on a familial basis.

Idiopathic brachial plexus neuropathy (neuralgic amyotrophy) characteristically begins with severe pain about the shoulder, followed within a few days by weakness,

Peripheral nerve

Nerve root




▲ **Figure 24-3.** Cutaneous innervation. The segmental or radicular (root) distribution is shown on the left side of the body and the peripheral nerve distribution on the right side. Above: anterior view; facing page: posterior view. (Reproduced, with permission, from Simon RP et al. *Clinical Neurology*, 7th ed. McGraw-Hill, 2009.)

reflex changes, and sensory disturbances involving especially the C5 and C6 segments but affecting any nerve in the brachial plexus. Symptoms and signs are usually unilateral but may be bilateral. Wasting of affected muscles is sometimes profound. The disorder relates to disturbed function of cervical roots or part of the brachial plexus,

but its precise cause is unknown. Recovery occurs over the ensuing months but may be incomplete. Treatment is purely symptomatic.

van Alfen N et al. The clinical spectrum of neuralgic amyotrophy in 246 cases. *Brain*. 2006 Feb;129(Pt 2):438–50. [PMID: 16371410]



▲ Figure 24-3. (Continued)

2. Cervical Rib Syndrome

Compression of the C8 and T1 roots or the lower trunk of the brachial plexus by a cervical rib or band arising from the seventh cervical vertebra leads to weakness and wasting of intrinsic hand muscles, especially those in the thenar eminence, accompanied by pain and numbness in the medial two fingers and the ulnar border of the hand and forearm. The subclavian artery may also be compressed,

and this forms the basis of Adson test for diagnosing the disorder; the radial pulse is diminished or obliterated on the affected side when the seated patient inhales deeply and turns the head to one side or the other. Electromyography, nerve conduction studies, and somatosensory evoked potential studies may help confirm the diagnosis. MRI may be especially helpful in revealing the underlying compressive structure. Plain radiographs or CT scanning sometimes shows the cervical rib or a large

transverse process of the seventh cervical vertebra, but normal findings do not exclude the possibility of a cervical band. Treatment of the disorder is by surgical excision of the rib or band.

3. Lumbosacral Plexus Lesions

A lumbosacral plexus lesion may develop in association with diseases such as diabetes, cancer, or bleeding disorders or in relation to injury. It occasionally occurs as an isolated phenomenon similar to idiopathic brachial plexopathy, and pain and weakness then tend to be more conspicuous than sensory symptoms. The distribution of symptoms and signs depends on the level and pattern of neurologic involvement.

Wilbourn AJ. Plexopathies. *Neurol Clin.* 2007 Feb;25(1):139–71. [PMID: 17324724]

DISORDERS OF NEUROMUSCULAR TRANSMISSION

1. Myasthenia Gravis



ESSENTIALS OF DIAGNOSIS

- ▶ Fluctuating weakness of commonly used voluntary muscles, producing symptoms such as diplopia, ptosis, and difficulty in swallowing.
- ▶ Activity increases weakness of affected muscles.
- ▶ Short-acting anticholinesterases transiently improve the weakness.

▶ General Considerations

Myasthenia gravis occurs at all ages, sometimes in association with a thymic tumor or thyrotoxicosis, as well as in rheumatoid arthritis and lupus erythematosus. It is most common in young women with HLA-DR3; if thymoma is associated, older men are more commonly affected. Onset is usually insidious, but the disorder is sometimes unmasked by a coincidental infection that leads to exacerbation of symptoms. Exacerbations may also occur before the menstrual period and during or shortly after pregnancy. Symptoms are due to a variable degree of block of neuromuscular transmission caused by autoantibodies binding to acetylcholine receptors; these are found in most patients with the disease and have a primary role in reducing the number of functioning acetylcholine receptors. Additionally, cellular immune activity against the receptor is found. Clinically, this leads to weakness; initially powerful movements fatigue readily. The external ocular muscles and certain other cranial muscles, including the masticatory, facial, and pharyngeal muscles, are especially likely to be affected, and the respiratory and limb muscles may also be involved.

▶ Clinical Findings

A. Symptoms and Signs

Patients present with ptosis, diplopia, difficulty in chewing or swallowing, respiratory difficulties, limb weakness, or some combination of these problems. Weakness may remain localized to a few muscle groups, especially the ocular muscles, or may become generalized. Symptoms often fluctuate in intensity during the day, and this diurnal variation is superimposed on a tendency to longer-term spontaneous relapses and remissions that may last for weeks. Nevertheless, the disorder follows a slowly progressive course and may have a fatal outcome owing to respiratory complications such as aspiration pneumonia.

Clinical examination confirms the weakness and fatigability of affected muscles. In most cases, the extraocular muscles are involved, and this leads to ocular palsies and ptosis, which are commonly asymmetric. Pupillary responses are normal. The bulbar and limb muscles are often weak, but the pattern of involvement is variable. Sustained activity of affected muscles increases the weakness, which improves after a brief rest. Sensation is normal, and there are usually no reflex changes.

Life-threatening exacerbations of myasthenia (so-called **myasthenic crisis**) may lead to respiratory weakness requiring immediate admission to the intensive care unit, where respiratory function can be monitored and ventilator support is readily available.

B. Imaging

A CT scan of the chest with and without contrast should be obtained to demonstrate a coexisting thymoma, but a normal study does not exclude this possibility.

C. Laboratory and Other Studies

Electrophysiologic demonstration of a decrementing muscle response to repetitive 2- or 3-Hz stimulation of motor nerves indicates a disturbance of neuromuscular transmission. Such an abnormality may even be detected in clinically strong muscles with certain provocative procedures. Needle electromyography of affected muscles shows a marked variation in configuration and size of individual motor unit potentials, and single-fiber electromyography reveals an increased jitter, or variability, in the time interval between two muscle fiber action potentials from the same motor unit.

Assay of serum for elevated levels of circulating acetylcholine receptor antibodies is useful because it has a sensitivity of 80–90% for the diagnosis of myasthenia gravis. Certain patients without antibodies to acetylcholine receptors have serum antibodies to muscle-specific tyrosine kinase (MuSK), which should therefore be determined; these patients are more likely to have facial, respiratory, and proximal muscle weakness than those with antibodies to acetylcholine receptors.

▶ Treatment

Medication such as aminoglycosides that may exacerbate myasthenia gravis should be avoided. Anticholinesterase

drugs provide symptomatic benefit without influencing the course of the disease. Neostigmine, pyridostigmine, or both can be used, the dose being determined on an individual basis. The usual dose of neostigmine is 7.5–30 mg (average, 15 mg) orally taken four times daily; of pyridostigmine, 30–180 mg (average, 60 mg) orally four times daily. Overmedication may temporarily increase weakness.

Thymectomy usually leads to symptomatic benefit or remission and should be considered in all patients younger than age 60, unless weakness is restricted to the extraocular muscles. If the disease is of recent onset and only slowly progressive, operation is sometimes delayed for a year or so, in the hope that spontaneous remission will occur.

Treatment with corticosteroids is indicated for patients who have responded poorly to anticholinesterase drugs and have already undergone thymectomy. It is often introduced with the patient in the hospital, since weakness may initially be aggravated. Once weakness has stabilized after 2–3 weeks or any improvement is sustained, further management can be on an outpatient basis. Alternate-day treatment is usually well tolerated, but if weakness is enhanced on the nontreatment day it may be necessary for medication to be taken daily. The dose of corticosteroids is determined on an individual basis, but an initial high daily dose (eg, prednisone, 60–100 mg orally daily) can gradually be tapered to a relatively low maintenance level as improvement occurs; total withdrawal is difficult, however. Treatment with azathioprine may also be effective. The usual dose is 2–3 mg/kg orally daily after a lower initial dose.

In patients with major disability, plasmapheresis or IVIG therapy may be beneficial and have similar efficacy. It is also useful for stabilizing patients before thymectomy and for managing acute crisis. Mycophenolate mofetil, an immunosuppressant, may provide symptomatic benefit and allow the corticosteroid dose to be reduced.

▶ When to Refer

All patients should be referred.

▶ When to Admit

- Patients with acute exacerbation or respiratory involvement.
- Patients requiring plasmapheresis.
- Patients who are starting corticosteroid therapy.
- For thymectomy.

Barth D et al. Comparison of IVIg and PLEX in patients with myasthenia gravis. *Neurology*. 2011 Jun 7;76(23):2017–23. [PMID: 21562253]

Benatar M et al. Evidence report: the medical treatment of ocular myasthenia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. *Neurology*. 2007 Jun 12;68(24):2144–9. [PMID: 17460154]

Chaudhuri A et al. Myasthenic crisis. *QJM*. 2009 Feb;102(2):97–107. [PMID: 19060020]

Meriggioli MN et al. Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity. *Lancet Neurol*. 2009 May;8(5):475–90. [PMID: 19375665]

Okumura M et al. Biological implications of thymectomy for myasthenia gravis. *Surg Today*. 2010;40(2):102–7. [PMID: 20107947]

2. Myasthenic Syndrome (Lambert-Eaton Syndrome)



ESSENTIALS OF DIAGNOSIS

- ▶ Variable weakness, typically improving with activity.
- ▶ Dysautonomic symptoms may also be present.
- ▶ A history of malignant disease may be obtained.

▶ General Considerations

Myasthenic syndrome may be associated with small-cell carcinoma, sometimes developing before the tumor is diagnosed, and occasionally occurs with certain autoimmune diseases. There is defective release of acetylcholine in response to a nerve impulse, caused by P/Q-type voltage-gated calcium-channel antibody, and this leads to weakness, especially of the proximal muscles of the limbs. Unlike myasthenia gravis, however, power steadily increases with sustained contraction. The diagnosis can be confirmed electrophysiologically, because the muscle response to stimulation of its motor nerve increases remarkably if the nerve is stimulated repetitively at high rates, even in muscles that are not clinically weak.

Treatment with plasmapheresis and immunosuppressive drug therapy (prednisone and azathioprine) may lead to clinical and electrophysiologic improvement, in addition to therapy aimed at tumor when present. Prednisone is usually initiated in a daily dose of 60–80 mg and azathioprine in a daily dose of 2 mg/kg. Symptomatic therapy includes the use of potassium channel antagonists; of these, 3,4-diaminopyridine (60–80 mg/d orally in three divided doses) has been best studied and appears efficacious. Guanidine hydrochloride (25–50 mg/kg/d orally in divided doses) is an alternative and is occasionally helpful in seriously disabled patients, but adverse effects of the drug include marrow suppression. The response to treatment with anticholinesterase drugs such as pyridostigmine or neostigmine is usually disappointing.

Pourmand R. Lambert-Eaton myasthenic syndrome. *Front Neurol Neurosci*. 2009;26:120–5. [PMID: 19349709]

Quartel A et al. Current therapy for Lambert-Eaton myasthenic syndrome: development of 3,4-diaminopyridine phosphate salt as first-line symptomatic treatment. *Curr Med Res Opin*. 2010 Jun;26(6):1363–75. [PMID: 20377318]

3. Botulism

The toxin of *Clostridium botulinum* prevents the release of acetylcholine at neuromuscular junctions and autonomic synapses. Botulism occurs most commonly following the ingestion of contaminated home-canned food and should be suggested by the development of sudden, fluctuating, severe weakness in a previously healthy person. Symptoms begin within 72 hours following ingestion of the toxin and may progress for several days. Typically, there is diplopia, ptosis, facial weakness, dysphagia, and nasal

speech, followed by respiratory difficulty and finally by weakness that appears last in the limbs. Blurring of vision (with unreactive dilated pupils) is characteristic, and there may be dryness of the mouth, constipation (paralytic ileus), and postural hypotension. Sensation is preserved, and the tendon reflexes are not affected unless the involved muscles are very weak. If the diagnosis is suspected, the local health authority should be notified and a sample of serum and contaminated food (if available) sent to be assayed for toxin. Support for the diagnosis may be obtained by electrophysiologic studies; with repetitive stimulation of motor nerves at fast rates, the muscle response increases in size progressively.

Patients should be hospitalized in case respiratory assistance becomes necessary. Treatment is with trivalent antitoxin, once it is established that the patient is not allergic to horse serum. Potassium channel antagonists may provide symptomatic relief as they do in Lambert-Eaton myasthenic syndrome (see above). Anticholinesterase drugs are of no value. Respiratory assistance and other supportive measures should be provided as necessary. Further details are provided in Chapter 33.

4. Disorders Associated with Use of Aminoglycosides

Aminoglycoside antibiotics, eg, gentamicin, may produce a clinical disturbance similar to botulism by preventing the release of acetylcholine from nerve endings, but symptoms subside rapidly as the responsible drug is eliminated from the body. These antibiotics are particularly dangerous in patients with preexisting disturbances of neuromuscular transmission and are therefore best avoided in patients with myasthenia gravis.

MYOPATHIC DISORDERS

1. Muscular Dystrophies



ESSENTIALS OF DIAGNOSIS

- ▶ Muscle weakness, often in a characteristic distribution.
- ▶ Age at onset and inheritance pattern depend on the specific dystrophy.

▶ General Considerations

These inherited myopathic disorders are characterized by progressive muscle weakness and wasting. They are subdivided by mode of inheritance, age at onset, and clinical features, as shown in Table 24–9. In the Duchenne type, pseudohypertrophy of muscles frequently occurs at some stage; intellectual retardation is common; and there may be skeletal deformities, muscle contractures, and cardiac involvement. The serum creatine kinase level is increased, especially in the Duchenne and Becker varieties, and mildly

increased also in limb-girdle dystrophy. Electromyography may help confirm that weakness is myopathic rather than neurogenic. Similarly, histopathologic examination of a muscle biopsy specimen may help confirm that weakness is due to a primary disorder of muscle and to distinguish between various muscle diseases.

A genetic defect on the short arm of the X chromosome has been identified in Duchenne dystrophy. The affected gene codes for the protein dystrophin, which is markedly reduced or absent from the muscle of patients with the disease. Dystrophin levels are generally normal in the Becker variety, but the protein is qualitatively altered.

Duchenne muscular dystrophy can now be recognized early in pregnancy in about 95% of women by genetic studies; in late pregnancy, DNA probes can be used on fetal tissue obtained for this purpose by amniocentesis. The genes causing some of the other muscular dystrophies are listed in Table 24–9.

There is no specific treatment for the muscular dystrophies, but it is important to encourage patients to lead as normal lives as possible. Prednisone (0.75 mg/kg orally daily) improves muscle strength and function in boys with Duchenne dystrophy, but side effects need to be monitored. Prolonged bed rest must be avoided, as inactivity often leads to worsening of the underlying muscle disease. Physical therapy and orthopedic procedures may help counteract deformities or contractures.

Angelini C. The role of corticosteroids in muscular dystrophy: a critical appraisal. *Muscle Nerve*. 2007 Oct;36(4):424–35. [PMID: 17541998]
 Guglieri M et al. Limb-girdle muscular dystrophies. *Curr Opin Neurol*. 2008 Oct;21(5):576–84. [PMID: 18769252]
 Tawil R et al. Facioscapulohumeral muscular dystrophy. *Muscle Nerve*. 2006 Jul;34(1):1–15. [PMID: 16508966]

2. Myotonic Dystrophy

Myotonic dystrophy, a slowly progressive, dominantly inherited disorder, usually manifests itself in the third or fourth decade but occasionally appears early in childhood. Myotonic dystrophy type 1 results from an expanded CTG repeat in a protein kinase gene on chromosome 19; in type 2, the defect is a CCTG repeat expansion in the gene for zinc-finger protein-9 on chromosome 3. Myotonia leads to complaints of muscle stiffness and is evidenced by the marked delay that occurs before affected muscles can relax after a contraction. This can often be demonstrated clinically by delayed relaxation of the hand after sustained grip or by percussion of the belly of a muscle. In addition, there is weakness and wasting of the facial, sternocleidomastoid, and distal limb muscles. Associated clinical features include cataracts, frontal baldness, testicular atrophy, diabetes mellitus, cardiac abnormalities, and intellectual changes. Electromyographic sampling of affected muscles reveals myotonic discharges in addition to changes suggestive of myopathy.

It is difficult to determine whether drug therapy for myotonia is safe or effective. When myotonia is disabling, treatment with a sodium channel blocker—such as phenytoin

Table 24-9. The muscular dystrophies.¹

Disorder	Inheritance	Age at Onset (years)	Distribution	Prognosis	Genetic Association
Duchenne type	X-linked recessive	1-5	Pelvic, then shoulder girdle; later, limb and respiratory muscles.	Rapid progression. Death within about 15 years after onset.	Xp21 Dystrophin (loss of functional expression)
Becker	X-linked recessive	5-25	Pelvic, then shoulder girdle.	Slow progression. May have normal life span.	Xp21 Dystrophin (reduced functional expression)
Limb-girdle (Erb)	Autosomal recessive, dominant or sporadic	10-30	Pelvic or shoulder girdle initially, with later spread to the other.	Variable severity and rate of progression. Possible severe disability in middle life.	Multiple
Facioscapulohumeral	Autosomal dominant	Any age	Face and shoulder girdle initially; later, pelvic girdle and legs.	Slow progression. Minor disability. Usually normal life span.	4q35
Emery-Dreifuss	X-linked recessive or autosomal dominant	5-10	Humeroperoneal or scapuloperoneal.	Variable.	Xq28; Emerin (X-linked) 1q21.2; Laminin A/C (chromosome 1) Others
Distal	Autosomal dominant or recessive	40-60	Onset distally in extremities; proximal involvement later.	Slow progression.	14q12; Myosin heavy chain 7 2p13 Dysferlin
Ocular	Autosomal dominant (may be recessive)	Any age (usually 5-30)	External ocular muscles; may also be mild weakness of face, neck, and arms.		
Oculopharyngeal	Autosomal dominant	Any age	As in the ocular form but with dysphagia.		14q11.2-q13 Poly (A)-binding protein-2
Myotonic dystrophy	Autosomal dominant	Any age (usually 20-40)	Face, neck, distal limbs.	Slow progression.	19q13.2-q13.3; Dystrophia myotonica protein kinase 3q13.3-q24; Zinc-finger protein-9

¹Not all possible genetic loci are shown.

(100 mg orally three times daily), procainamide (0.5–1 g orally four times daily), or mexiletine (150–200 mg orally three times daily)—may be helpful, but the associated side effects, particularly for antiarrhythmic drugs, are often limiting. Neither the weakness nor the course of the disorder is influenced by treatment.

Gagnon C et al; DMI Expert Panel. Health supervision and anticipatory guidance in adult myotonic dystrophy type 1. *Neuromuscul Disord.* 2010 Dec;20(12):847–51. [PMID: 20884209]

Logigian EL et al. Mexiletine is an effective antimyotonia treatment in myotonic dystrophy type 1. *Neurology.* 2010 May 4;74(18):1441–8. [PMID: 20439846]

Miller TM. Differential diagnosis of myotonic disorders. *Muscle Nerve.* 2008 Mar;37(3):293–9. [PMID: 18067134]

3. Myotonia Congenita

Myotonia congenita is commonly inherited as a dominant trait. The responsible gene on chromosome 7 encodes a voltage-gated chloride channel. Generalized myotonia

without weakness is usually present from birth, but symptoms may not appear until early childhood. Patients complain of muscle stiffness that is enhanced by cold and inactivity and relieved by exercise. Muscle hypertrophy, at times pronounced, is also a feature. A recessive form with later onset is associated with slight weakness and atrophy of distal muscles. Treatment with procainamide, tocainide, mexiletine, or phenytoin may help the myotonia, as in myotonic dystrophy.

4. Polymyositis & Dermatomyositis

See Chapter 20.

5. Inclusion Body Myositis

This disorder, of unknown cause, begins insidiously, usually after middle age, with progressive proximal weakness of first the lower and then the upper extremities, and affecting facial and pharyngeal muscles. Weakness often begins in the quadriceps femoris in the lower limbs and the forearm flexors in the upper limbs. Distal weakness is usually mild. Serum creatine kinase levels may be normal or increased. The diagnosis is confirmed by muscle biopsy. Corticosteroid and immunosuppressive therapy is usually ineffective, but IVIG therapy is occasionally of mild benefit.

Lloyd TE. Novel therapeutic approaches for inclusion body myositis. *Curr Opin Rheumatol*. 2010 Nov;22(6):658–64. [PMID: 20827206]

Machado P et al. Sporadic inclusion body myositis: an unsolved mystery. *Acta Rheumatol Port*. 2009 Apr–Jun;34(2A):161–82. [PMID: 19474772]

6. Mitochondrial Myopathies

The mitochondrial myopathies are a clinically diverse group of disorders that on pathologic examination of skeletal muscle with the modified Gomori stain show characteristic “ragged red fibers” containing accumulations of abnormal mitochondria. Patients may present with progressive external ophthalmoplegia or with limb weakness that is exacerbated or induced by activity. Other patients present with central neurologic dysfunction, eg, myoclonic epilepsy (**myoclonic epilepsy**, ragged red fiber syndrome, or **MERRF**), or the combination of myopathy, encephalopathy, lactic acidosis, and **stroke-like episodes** (**MELAS**). These disorders result from separate abnormalities of mitochondrial DNA. (See also Chapter 20.) Treatment is symptomatic and palliative, but various experimental approaches are being explored.

A mitochondrial myopathy may develop in patients receiving zidovudine for treatment of AIDS, and patients receiving highly active antiretroviral therapy (HAART) for HIV-1 infection may develop a **lipodystrophy**, with fat accumulating in muscle.

Rahman S et al. Diagnosis and therapy in neuromuscular disorders: diagnosis and new treatments in mitochondrial diseases. *J Neurol Neurosurg Psychiatry*. 2009 Sep;80(9):943–53. [PMID: 19684231]

7. Myopathies Associated with Other Disorders

Myopathy may occur in association with chronic hypokalemia, any endocrinopathy, and in patients taking corticosteroids, chloroquine, colchicine, clofibrate, emetine, aminocaproic acid, lovastatin, bretylium tosylate, or drugs causing potassium depletion. Weakness is mainly proximal, and serum creatine kinase is typically normal, except in hypothyroidism and some of the toxic myopathies. Treatment is of the underlying cause. Myopathy also occurs with chronic alcoholism, whereas acute reversible muscle necrosis may occur shortly after acute alcohol intoxication. Inflammatory myopathy may occur in patients taking penicillamine; myotonia may be induced by clofibrate, and preexisting myotonia may be exacerbated or unmasked by depolarizing muscle relaxants (eg, suxamethonium), β -blockers (eg, propranolol), fenoterol, ritodrine and, possibly, certain diuretics.

▶ When to Refer

All patients should be referred (to establish the diagnosis and underlying cause).

▶ When to Admit

- For respiratory assistance.
- For rhabdomyolysis.

PERIODIC PARALYSIS SYNDROMES

Periodic paralysis may have a familial (dominant inheritance) basis. The syndromes to be described are channelopathies that manifest as abnormal, often potassium-sensitive, muscle-membrane excitability and lead clinically to episodes of flaccid weakness or paralysis, sometimes in association with abnormalities of the plasma potassium level. Strength is normal between attacks. Mutations in genes encoding three ion channels [*CACNA1S* (1q32), *SCN4A* (17q23.1-q25.3), and *KCNJ2* (17q23.1-q24.2)] account for most cases. **Hypokalemic periodic paralysis** has been related to mutations in the *CACNL1A3*, *SCN4A*, or *KCNE3* (11q13-q14) gene and is characterized by attacks that tend to occur on awakening, after exercise, or after a heavy meal and may last for several days. Patients should avoid excessive exertion. A low-carbohydrate and low-salt diet may help prevent attacks, as may acetazolamide, 250–750 mg/d. Nonselective β -adrenergic blockers may also prevent recurrent paralytic attacks. An ongoing attack may be aborted by potassium chloride given orally or by intravenous drip, provided the ECG can be monitored and kidney function is satisfactory. In young Asian men, it is commonly associated with hyperthyroidism and has been related to polymorphism in the *CACNA1S* gene; treatment of the endocrine disorder prevents recurrences. In **hyperkalemic periodic paralysis**, which is mostly associated with

mutations in the *SCN4A* gene, attacks also tend to occur after exercise but usually last for < 1 hour. They may be terminated by intravenous calcium gluconate (1–2 g) or by intravenous diuretics (furosemide, 20–40 mg), glucose, or glucose and insulin; daily acetazolamide or chlorothiazide may prevent recurrences. **Normokalemic periodic paralysis** is similar clinically to the hyperkalemic variety, but the plasma potassium level remains normal during attacks; treatment is with acetazolamide.

▶ When to Refer

All patients should be referred.

Abbasi B et al. Hypokalemic thyrotoxic periodic paralysis with thyrotoxic psychosis and hypercapnic respiratory failure. *Am J Med Sci.* 2010 Aug;340(2):147–53. [PMID: 20581656]
Alkaabi JM et al. Hypokalemic periodic paralysis: a case series, review of the literature and update of management. *Eur J Emerg Med.* 2010 Feb;17(1):45–7. [PMID: 20201128]

25

Psychiatric Disorders

Stuart J. Eisendrath, MD

Jonathan E. Lichtmacher, MD

COMMON PSYCHIATRIC DISORDERS

STRESS & ADJUSTMENT DISORDERS (Situational Disorders)

ESSENTIALS OF DIAGNOSIS

- ▶ Anxiety or depression clearly secondary to an identifiable stress.
- ▶ Subsequent symptoms of anxiety or depression commonly elicited by similar stress of lesser magnitude.
- ▶ Alcohol and other drugs are commonly used in self-treatment.

▶ General Considerations

Stress exists when the adaptive capacity of the individual is overwhelmed by events. The event may be an insignificant one objectively considered, and even favorable changes (eg, promotion and transfer) requiring adaptive behavior can produce stress. For each individual, stress is subjectively defined, and the response to stress is a function of each person's personality and physiologic endowment.

Opinion differs about what events are most apt to produce stress reactions. The causes of stress are different at different ages—eg, in young adulthood, the sources of stress are found in the marriage or parent-child relationship, the employment relationship, and the struggle to achieve financial stability; in the middle years, the focus shifts to changing spousal relationships, problems with aging parents, and problems associated with having young adult offspring who themselves are encountering stressful situations; in old age, the principal concerns are apt to be retirement, loss of physical capacity, major personal losses, and thoughts of death.

▶ Clinical Findings

An individual may react to stress by becoming anxious or depressed, by developing a physical symptom, by running

away, having a drink, overeating, starting an affair, or in limitless other ways. Common subjective responses are fear (of repetition of the stress-inducing event), rage (at frustration), guilt (over aggressive impulses), and shame (over helplessness). Acute and reactivated stress may be manifested by restlessness, irritability, fatigue, increased startle reaction, and a feeling of tension. Inability to concentrate, sleep disturbances (insomnia, bad dreams), and somatic preoccupations often lead to self-medication, most commonly with alcohol or other central nervous system depressants. Maladaptive behavior in response to stress is called adjustment disorder, with the major symptom specified (eg, "adjustment disorder with depressed mood").

▶ Differential Diagnosis

Adjustment disorders must be distinguished from anxiety disorders, affective disorders, and personality disorders exacerbated by stress and from somatic disorders with psychic overlay. Adjustment disorders may have symptoms that overlap with other disorders, such as anxiety symptoms, but they occur in reaction to an identifiable life stressor such as a difficult work situation or romantic breakup. Adjustment disorders are diagnosed when the symptoms do not fit with a more specific diagnosis such as major depressive disorder which requires at least five criteria. Patients with adjustment disorders have marked distress after a stressor and significant impairment in social or occupational functioning. Adjustment disorders are regarded as acute if less than 6 months or chronic if longer.

▶ Treatment

A. Behavioral

Stress reduction techniques include immediate symptom reduction (eg, rebreathing in a bag for hyperventilation) or early recognition and removal from a stress source before full-blown symptoms appear. It is often helpful for the patient to keep a daily log of stress precipitators, responses, and alleviators. Relaxation, mindfulness-based stress reduction, and exercise techniques are also helpful in reducing the reaction to stressful events.

B. Social

The stress reactions of life crisis problems are a function of psychosocial upheaval, and patients frequently present with somatic symptoms. While it is not easy for the patient to make necessary changes (or they would have been made long ago), it is important for the clinician to establish the framework of the problem, since the patient's denial system may obscure the issues. Clarifying the problem allows the patient to begin viewing it within the proper context and facilitates the sometimes difficult decisions the patient eventually must make (eg, change of job or relocation of adult-dependent offspring).

C. Psychological

Prolonged in-depth psychotherapy is seldom necessary in cases of isolated stress response or adjustment disorder. Supportive psychotherapy (see above) with an emphasis on the here and now and strengthening of existing coping mechanisms is a helpful approach so that time and the patient's own resiliency can restore the previous level of function.

D. Medical

Judicious use of sedatives (eg, lorazepam, 0.5–1 mg two or three times daily orally) for a limited time and as part of an overall treatment plan can provide relief from acute anxiety symptoms. Problems arise when the situation becomes chronic through inappropriate treatment or when the treatment approach supports the development of chronicity.

► Prognosis

Return to satisfactory function after a short period is part of the clinical picture of this syndrome. Resolution may be delayed if others' responses to the patient's difficulties are thoughtlessly harmful or if the secondary gains outweigh the advantages of recovery. The longer the symptoms persist, the worse the prognosis.

Birnie K et al. Psychological benefits for cancer patients and their partners participating in mindfulness-based stress reduction (MBSR). *Psychooncology*. 2010 Sep;19(9):1004–9. [PMID: 19918956]

POSTTRAUMATIC STRESS DISORDER



ESSENTIALS OF DIAGNOSIS

- ▶ Exposure to traumatic (life-threatening) event.
- ▶ Symptoms, such as flashbacks, intrusive images, and nightmares, often represent reexperiencing the event.
- ▶ Avoidance symptoms, including numbing, social withdrawal, and avoidance of stimuli associated with the event.
- ▶ Increased vigilance, such as startle reactions and difficulty falling asleep.
- ▶ Symptoms impair functioning.

► General Considerations

Posttraumatic stress disorder (PTSD)—included among the anxiety disorders in the Diagnostic Statistical Manual-IV (*DSM-IV*)—is a syndrome characterized by “reexperiencing” a traumatic event (eg, rape, severe burns, military combat) and decreased responsiveness and avoidance of current events associated with the trauma. The National Veterans Vietnam Readjustment Survey indicated that 53.4% of male and 48.1% of female Vietnam war veterans experienced some symptoms of PTSD, with approximately 60% of these affected veterans experiencing the full syndrome. Of the male veterans, 44.7% experienced a lifetime prevalence of alcohol or drug abuse, with 13% experiencing current abuse or dependence. Data indicate that 13% of veterans who served in Iraq and 6% of those who served in Afghanistan have experienced PTSD. The 2005 National Comorbidity Survey Report estimated the lifetime prevalence of PTSD among adult Americans at 6.8% with a current prevalence of 3.6% and with women having rates twice as high as men. PTSD is more common when the event is associated with physical injury than when it is not. Many individuals with PTSD (20–40%) have experienced other associated problems, including divorce, parenting problems, difficulties with the law, and substance abuse. Since the terrorist attacks in the United States on September 11, 2001, estimates of PTSD have ranged from 4.7% to 10.2% in those witnessing the live attacks and have been associated with functional impairment as well as increased rates of substance use.

► Clinical Findings

Patients with PTSD experience physiologic hyperarousal, including startle reactions, intrusive thoughts, illusions, overgeneralized associations, sleep problems, nightmares, dreams about the precipitating event, impulsivity, difficulties in concentration, and hyperalertness. The symptoms may be precipitated or exacerbated by events that are a reminder of the original stress. Symptoms frequently arise after a long latency period (eg, child abuse can result in later-onset posttraumatic stress disorder).

► Differential Diagnosis

In 75% of cases, PTSD occurs with comorbid depression or panic disorder, and there is considerable overlap in the symptom complexes of all three conditions. The key to establishing the PTSD diagnosis lies in the history of exposure to a life-threatening event followed by intrusive (eg, flashbacks, nightmares) or avoidance (eg, withdrawal) symptoms. Acute stress disorder occurs during or shortly after a traumatic event and has many of the same symptoms as PTSD but lasts between 2 and 28 days. Some individuals with dissociative features, such as borderline personality disorders, may mimic some of the symptoms of PTSD, but those disorders are typically more related to chronic childhood maltreatment not a specific traumatic event.

► Treatment

A. Psychotherapy

Psychotherapy should be initiated as soon as possible after the traumatic event, and it should be brief (typically 8-12 sessions), once the individual is in a safe environment. Cognitive behavior therapy, exposure therapy, and eye-movement desensitization reprocessing have been effective in significantly reducing the duration of symptoms. In all of these approaches, the individual confronts the traumatic situation and learns to view it with less reactivity. Psychological debriefing in a single session, once a mainstay in prevention of PTSD, is now considered to be ineffective and possibly harmful. Posttraumatic stress syndromes respond to interventions that help patients integrate the event in an adaptive way with some sense of mastery in having survived the trauma. Marital problems are a major area of concern, and it is important that the clinician have available a dependable referral source when marriage counseling is indicated.

Treatment initiated later, when symptoms have crystallized, includes programs for cessation of alcohol and other drug abuse, group and individual psychotherapy, and improved social support systems. The therapeutic approach is to facilitate the normal recovery that was blocked at the time of the trauma.

B. Medication

Early treatment of anxious arousal with β -blockers (eg, propranolol, 80–160 mg orally daily) may lessen the peripheral symptoms of anxiety (eg, tremors, palpitations) but has not been shown to help prevent development of PTSD. Antidepressant medications—particularly selective serotonin reuptake inhibitors (SSRIs)—in full dosage are helpful in ameliorating depression, panic attacks, sleep disruption, and startle responses in chronic PTSD. Sertraline and paroxetine are approved by the US Food and Drug Administration (FDA) for this purpose. Antiseizure medications such as carbamazepine (400–800 mg orally daily) will often mitigate impulsivity and difficulty with anger management. Benzodiazepines, such as clonazepam (1–4 mg daily orally, divided into one or two doses), will reduce anxiety and panic attacks when used in adequate dosage, but dependency problems are a concern, particularly when the patient has had such problems in the past. The α -adrenergic blocking agent prazosin (2–10 mg orally at bedtime) has been successfully used to decrease nightmares and improve quality of sleep in PTSD.

► Prognosis

The sooner therapy is initiated after the trauma, the better the prognosis. Approximately half of patients experience chronic symptoms. Prognosis is best in those with good premorbid psychiatric functioning. Individuals experiencing an acute stress disorder typically do better than those experiencing a delayed posttraumatic disorder. Individuals who experience trauma resulting from a natural disaster (eg, earthquake or hurricane) tend to do better than those who experience a traumatic interpersonal encounter (eg, rape or combat).

Cloitre M et al. Treatment of complex PTSD: results of the ISTSS expert clinician survey on best practices. *J Trauma Stress*. 2011 Dec;24(6):615–27. [PMID: 22147449]

Hetrick SE et al. Combined pharmacotherapy and psychological therapies for posttraumatic stress disorder (PTSD). *Cochrane Database Syst Rev*. 2010 Jul 7;(7):CD007316. [PMID: 20614457]

ANXIETY DISORDERS & DISSOCIATIVE DISORDERS



ESSENTIALS OF DIAGNOSIS

- Overt anxiety or an overt manifestation of a coping mechanism (such as a phobia), or both.
- Not limited to an adjustment disorder.
- Somatic symptoms referable to the autonomic nervous system or to a specific organ system (eg, dyspnea, palpitations, paresthesias).
- Not a result of physical disorders, psychiatric conditions (eg, schizophrenia), or drug abuse (eg, cocaine).

► General Considerations

Stress, fear, and anxiety all tend to be interactive. The principal components of anxiety are **psychological** (tension, fears, difficulty in concentration, apprehension) and **somatic** (tachycardia, hyperventilation, palpitations, tremor, sweating). Other organ systems (eg, gastrointestinal) may be involved in multiple-system complaints. Fatigue and sleep disturbances are common. Sympathomimetic symptoms of anxiety are both a response to a central nervous system state and a reinforcement of further anxiety. Anxiety can become self-generating, since the symptoms reinforce the reaction, causing it to spiral. This is often the case when the anxiety is an epiphenomenon of other medical or psychiatric disorders.

Anxiety may be free-floating, resulting in acute anxiety attacks, occasionally becoming chronic. When one or several coping mechanisms (see above) are functioning, the consequences are well-known problems such as phobias, conversion reactions, dissociative states, obsessions, and compulsions. Lack of structure is frequently a contributing factor, as noted in those people who have “Sunday neuroses.” They do well during the week with a planned work schedule but cannot tolerate the unstructured weekend. Planned-time activities tend to bind anxiety, and many people have increased difficulties when this is lost, as in retirement.

Some believe that various manifestations of anxiety are not a result of unconscious conflicts but are “habits”—persistent patterns of nonadaptive behavior acquired by learning. The “habits,” being nonadaptive, are unsatisfactory ways of dealing with life’s problems—hence the resultant anxiety. Help is sought only when the anxiety becomes too painful. Exogenous factors such as stimulants (eg, caffeine, cocaine) must be considered as a contributing factor.

► Clinical Findings

A. Generalized Anxiety Disorder

This is the most common of the clinically significant anxiety disorders. Initial manifestations appear at age 20–35 years, and there is a slight predominance in women. The anxiety symptoms of apprehension, worry, irritability, difficulty in concentrating, insomnia, and somatic complaints are present more days than not for at least 6 months. Manifestations can include cardiac (eg, tachycardia, increased blood pressure), gastrointestinal (eg, increased acidity, nausea, epigastric pain), and neurologic (eg, headache, near-syncope) systems. The focus of the anxiety may be a number of everyday activities.

B. Panic Disorder

This is characterized by short-lived, recurrent, unpredictable episodes of intense anxiety accompanied by marked physiologic manifestations. **Agoraphobia**, fear of being in places where escape is difficult, such as open spaces or public places where one cannot easily hide, may be present and may lead the individual to confine his or her life to the home environment. Distressing symptoms and signs such as dyspnea, tachycardia, palpitations, headaches, dizziness, paresthesias, choking, smothering feelings, nausea, and bloating are associated with feelings of impending doom (alarm response). Although these symptoms may lead to overlap with some of the same bodily complaints found in the somatoform disorders, the key to the diagnosis of panic disorder is the psychic pain and suffering the individual expresses. Recurrent **sleep panic attacks** (not nightmares) occur in about 30% of panic disorders. Anticipatory anxiety develops in all these patients and further constricts their daily lives. Panic disorder tends to be familial, with onset usually under age 25; it affects 3–5% of the population, and the female-to-male ratio is 2:1. The premenstrual period is one of heightened vulnerability. Patients frequently undergo emergency medical evaluations (eg, for “heart attacks” or “hypoglycemia”) before the correct diagnosis is made. Gastrointestinal symptoms are especially common, occurring in about one-third of cases. Myocardial infarction, pheochromocytoma, hyperthyroidism, and various recreational drug reactions can mimic panic disorder. Mitral valve prolapse may be present but is not usually a significant factor. Patients who have recurrent panic disorder often become **demoralized, hypochondriacal, agoraphobic, and depressed**. These individuals are at increased risk for major depression and the suicide attempts associated with that disorder. Alcohol abuse (in about 20%) results from self-treatment and is not infrequently combined with dependence on sedatives. Some patients have atypical panic attacks associated with seizure-like symptoms that often include psychosensory phenomena (a history of stimulant abuse often emerges). About 25% of panic disorder patients also have obsessive-compulsive disorder (OCD).

C. Obsessive-Compulsive Disorder

In the obsessive-compulsive reaction, the irrational idea or the impulse persistently intrudes into awareness. Obsessions

(constantly recurring thoughts such as fears of exposure to germs) and compulsions (repetitive actions such as washing the hands many times) are recognized by the individual as absurd and are resisted, but anxiety is alleviated only by ritualistic performance of the action or by deliberate contemplation of the intruding idea or emotion. Many patients do not mention the symptoms and must be asked about them. These patients are usually predictable, orderly, conscientious, and intelligent—traits that are seen in many compulsive behaviors such as food binging and purging and compulsive exercise. There is an overlapping of OCD and other behaviors (“OCD spectrum”), including tics, trichotillomania (hair pulling), onychophagia (nail biting), hypochondriasis, Tourette syndrome, and eating disorders (see Chapter 29). The 2–3% incidence of OCD in the general population is much higher than was previously recognized. In addition, there is a high comorbidity of OCD and major depression; two-thirds of OCD patients will develop major depression during their lifetime. Male to female ratios are similar, with the highest rates occurring in the young, divorced, separated, and unemployed (all high-stress categories). Neurologic abnormalities of fine motor coordination and involuntary movements are common. Under extreme stress, these patients sometimes exhibit paranoid and delusional behaviors, often associated with depression, and can mimic schizophrenia.

D. Phobic Disorder

Phobic ideation can be considered a form of “displacement” in which patients transfer feelings of anxiety from their true object to one that can be avoided. However, since phobias are ineffective coping mechanisms, there tends to be an increase in their scope, intensity, and number. Social phobias are global or specific; in the former, all social situations are poorly tolerated, while the latter group includes performance anxiety or well-delineated phobias (eg, fear of bridges). Agoraphobia is frequently associated with severe panic attacks, and it often develops in early adult life, making a normal lifestyle difficult.

E. Dissociative Disorder

Fugue (the sudden, unexpected travel away from one's home with inability to recall one's past), amnesia, somnambulism, dissociative identity disorder (multiple personality disorder), and depersonalization are all dissociative states. The reaction is precipitated by emotional crisis. The symptom produces anxiety reduction and a temporary solution of the crisis. Mechanisms include repression and isolation as well as particularly limited scope of attention as seen in hypnotic states. Dissociative symptoms are similar in many ways to symptoms seen in patients with temporal lobe dysfunction.

► Treatment

In all cases, underlying medical disorders must be ruled out (eg, cardiovascular, endocrine, respiratory, and neurologic disorders and substance-related syndromes, both intoxication and withdrawal states). These and other disorders can coexist with panic disorder.

A. Medical

1. Generalized anxiety—Benzodiazepines are the anxiolytics of choice in the acute management of generalized anxiety (Table 25–1). They are almost immediately effective. Antidepressants can be efficacious for the long-term treatment of generalized anxiety disorder, panic disorder, social phobia, and OCD.

All of the benzodiazepines may be given orally, and several are available in parenteral formulations. Benzodiazepines such as lorazepam are absorbed rapidly when given intramuscularly. In psychiatric disorders, the

benzodiazepines are usually given orally; in controlled medical environments (eg, the ICU), where the rapid onset of respiratory depression can be assessed, they are often given intravenously. Onset of action is a function of the rate of absorption (related to lipophilic property) and varies, with diazepam and clonazepam being the most rapidly absorbed orally. This characteristic, along with high lipid solubility, may explain the popularity of diazepam. In the average case of anxiety, diazepam, 5–10 mg orally twice daily as needed, is a reasonable starting regimen.

The duration of action of the benzodiazepines varies as a function of the active metabolites they produce.

Table 25–1. Commonly used antianxiety and hypnotic agents.

Drug	Usual Daily Oral Doses	Usual Daily Maximum Doses	Cost for 30 Days Treatment Based on Maximum Dosage ¹
Benzodiazepines (used for anxiety)			
Alprazolam (Xanax) ²	0.5 mg	4 mg	\$115.20
Chlordiazepoxide (Librium) ³	10–20 mg	100 mg	\$46.80
Clonazepam (Klonopin) ³	1–2 mg	10 mg	\$169.50
Clorazepate (Tranxene) ³	15–30 mg	60 mg	\$260.40
Diazepam (Valium) ³	5–15 mg	30 mg	\$18.00
Lorazepam (Ativan) ²	2–4 mg	4 mg	\$73.20
Oxazepam (Serax) ²	10–30 mg	60 mg	\$95.40
Benzodiazepines (used for sleep)			
Estazolam (Prosom) ²	1 mg	2 mg	\$29.70
Flurazepam (Dalmane) ³	15 mg	30 mg	\$10.50
Midazolam (Versed IV) ⁴	5 mg IV		\$1.04/dose
Quazepam (Doral) ³	7.5 mg	15 mg	\$138.00
Temazepam (Restoril) ²	15 mg	30 mg	\$26.40
Triazolam (Halcion) ⁵	0.125 mg	0.25 mg	\$20.10
Miscellaneous (used for anxiety)			
Buspirone (Buspar) ²	10–30 mg	60 mg	\$218.40
Phenobarbital ³	15–30 mg	90 mg	\$3.30
Miscellaneous (used for sleep)			
Chloral hydrate (Noctec) ²	500 mg	1000 mg	\$85.20
Eszopiclone (Lunesta) ⁵	2–3 mg	3 mg	\$235.50
Hydroxyzine (Vistaril) ²	50 mg	100 mg	\$66.60
Ramelteon (Rozerem)	8 mg	8 mg	\$189.60
Zaleplon (Sonata) ⁶	5–10 mg	10 mg	\$112.50
Zolpidem (Ambien) ⁵	5–10 mg	10 mg	\$138.60

¹Average wholesale price (AWP, for AB-rated generic when available) for quantity listed. Source: *Red Book Online, 2012*, Thomson Reuters (Healthcare Inc.). AWP may not accurately represent the actual pharmacy cost because wide contractual variations exist among institutions.

²Intermediate physical half-life (10–20 hours).

³Long physical half-life (> 20 hours).

⁴Intravenously for procedures.

⁵Short physical half-life (1–6 hours).

⁶Short physical half-life (about 1 hour).

Benzodiazepines such as lorazepam do not produce active metabolites and have intermediate half-lives of 10–20 hours, characteristics useful in treating elderly patients. Ultra-short-acting agents such as triazolam have half-lives of 1–3 hours and may lead to rebound withdrawal anxiety. Longer-acting benzodiazepines such as flurazepam and diazepam produce active metabolites, have half-lives of 20–120 hours, and should be avoided in the elderly. Since people vary widely in their response and since the medications are long-lasting, the dosage must be individualized. Once this is established, an adequate dose early in the course of symptom development will obviate the need for “pill popping,” which contributes to dependency problems. Panic disorder does not usually respond to benzodiazepines other than clonazepam and alprazolam. Those high-potency benzodiazepines and the antidepressants are most commonly used for panic disorder. Notably, alprazolam has a relatively short half-life and over time can lead to interdose rebound anxiety, although the extended release form is available and obviates this difficulty.

Whether the indications for benzodiazepines are anxiety or insomnia, the medications should be used judiciously. The longer-acting benzodiazepines are used for the treatment of alcohol withdrawal and anxiety symptoms; the intermediate medications are useful as sedatives for insomnia (eg, lorazepam), while short-acting agents (eg, midazolam) are used for medical procedures such as endoscopy.

The side effects of all the benzodiazepine antianxiety agents are patient and dose dependent. As the dosage exceeds the levels necessary for sedation, the side effects include disinhibition, ataxia, dysarthria, nystagmus, and delirium. (The patient should be told not to operate machinery until he or she is well stabilized without side effects.)

Paradoxical agitation, anxiety, psychosis, confusion, mood lability, and anterograde amnesia have been reported, particularly with the shorter-acting benzodiazepines. These agents produce cumulative clinical effects with repeated dosage (especially if the patient has not had time to metabolize the previous dose), additive effects when given with other classes of sedatives or alcohol (many apparently “accidental” deaths are the result of concomitant use of sedatives and alcohol), and residual effects after termination of treatment (particularly in the case of medications that undergo slow biotransformation).

Overdosage results in respiratory depression, hypotension, shock syndrome, coma, and death. Flumazenil, a benzodiazepine antagonist, is effective in overdosage. Overdosage (see Chapter 38) and withdrawal states are medical emergencies. Serious side effects of chronic excessive dosage are development of tolerance, resulting in increasing dose requirements, and physiologic dependence, resulting in withdrawal symptoms similar in appearance to alcohol and barbiturate withdrawal (withdrawal effects must be distinguished from reemergent anxiety). Abrupt withdrawal of sedative medications may cause serious and even fatal convulsive seizures. Psychosis, delirium, and autonomic dysfunction have also been described. Both duration of action and duration of exposure are major factors related to likelihood of withdrawal.

Table 25–2. Benzodiazepine interactions with other medications.

Drug	Effects
Antacids	Decreased absorption of benzodiazepines
Cimetidine	Increased half-life of diazepam and triazolam
Contraceptives	Increased levels of diazepam and triazolam
Digoxin	Alprazolam and diazepam raise digoxin level
Disulfiram	Increased duration of action of sedatives
Isoniazid	Increased plasma diazepam
Levodopa	Inhibition of antiparkinsonism effect
Propoxyphene	Impaired clearance of diazepam
Rifampin	Decreased plasma diazepam
Warfarin	Decreased prothrombin time

Common withdrawal symptoms after low to moderate daily use of benzodiazepines are classified as **somatic** (disturbed sleep, tremor, nausea, muscle aches), **psychological** (anxiety, poor concentration, irritability, mild depression), or **perceptual** (poor coordination, mild paranoia, mild confusion). The presentation of symptoms will vary depending on the half-life of the drug. There are no significant side effects on organ systems other than the brain, and the medications are safe in most medical conditions. Benzodiazepine interactions with other medications are listed in Table 25–2.

Antidepressants are the first-line medications for sustained treatment of generalized anxiety disorder, having the advantage of not causing serious physiologic dependency problems. At initiation of treatment, antidepressants can themselves be anxiogenic—thus, an initial dose, in conjunction with short-term treatment with a benzodiazepine, is often indicated. Venlafaxine and duloxetine (serotonin and norepinephrine reuptake inhibitors) are FDA-approved for the treatment of generalized anxiety disorder in usual antidepressant doses. Initial daily dosing should start low (37.5–75 mg for venlafaxine and 30 mg for duloxetine) and be titrated upward as needed. SSRIs, such as paroxetine, are also used. Similarly, buspirone, sometimes used as an augmenting agent in the treatment of depression and compulsive behaviors, is also effective for generalized anxiety. Buspirone is usually given in a total dosage of 15–60 mg/d in three divided doses. Higher doses tend to be counterproductive and produce gastrointestinal symptoms and dizziness. There is a 2- to 4-week delay before antidepressants and buspirone take effect, and patients require education regarding this lag. Sleep is sometimes negatively affected. β -Blockers such as propranolol may help reduce peripheral somatic symptoms. Alcohol is the most frequently self-administered drug and should be interdicted. The highly addicting medications with a narrow margin of safety such as glutethimide, ethchlorvynol, methprylon, meprobamate, and the barbiturates (with the exception of phenobarbital) should be

avoided. Phenobarbital, in addition to its anticonvulsant properties, is a reasonably safe and very inexpensive sedative but has the disadvantage of causing hepatic microsomal enzyme stimulation (not the case with benzodiazepines), which may affect the metabolism of other medications.

2. Panic attacks—Panic attacks may be treated in several ways. A sublingual dose of alprazolam (0.5–1 mg) is often effective for urgent treatment. For sustained treatment, SSRIs are the initial medications of choice (adequate blood levels will require dosages similar to those used in the treatment of depression). For example, sertraline starting at 25 mg/d and increased after 1 week to 50 mg/d may be effective. Because of initial agitation in response to antidepressants, doses should start low and be very gradually increased. High-potency benzodiazepines may be used for symptomatic treatment as the antidepressant dose is titrated upward. Clonazepam (1–6 mg/d orally) and alprazolam (0.5–6 mg/d orally) are effective alternatives to antidepressants. Both medications may produce marked withdrawal if stopped abruptly and should always be tapered. Because of chronicity of the disorders and the problem of dependency with benzodiazepine medications, it is generally desirable to use antidepressant medications as the principal pharmacologic approach. Antidepressants have been used in conjunction with β -blockers in resistant cases. Propranolol (40–160 mg/d orally) can mute the peripheral symptoms of anxiety without significantly affecting motor and cognitive performance. They block symptoms mediated by sympathetic stimulation (eg, palpitations, tremulousness) but not nonadrenergic symptoms (eg, diarrhea, muscle tension). Contrary to a common misunderstanding, they usually do not cause depression as a side effect and can be used cautiously in patients with depression. Valproate has been found to be as effective in panic disorder as the antidepressants and is another useful alternative.

3. Phobic disorder—Phobic disorder may be part of the panic disorder and is treated within that framework. Global social phobias may be treated with SSRIs, such as paroxetine, sertraline, and fluvoxamine, or monoamine oxidase (MAO) inhibitors in the same dosage as used for depression. Gabapentin, an anticonvulsant with anxiolytic properties, may be an alternative to antidepressants in the treatment of social phobia in a dosage of 300–3600 mg/d, depending on response versus sedation. Specific phobias such as performance anxiety may respond to moderate doses of β -blockers, such as propranolol, 20–40 mg 1 hour prior to exposure. D-cycloserine (DCS), an antituberculosis drug, has been investigated as an augmenting agent in exposure treatment. As a partial agonist at the NMDA receptor in the amygdala, DCS appears to slightly speed up in vivo reduction of fear responses. Importantly, such medications must be used in combination with cognitive behavioral exposure strategies.

4. Obsessive-compulsive disorder—OCD responds to serotonergic medications in about 60% of cases and usually requires a longer response time than for depression (up to 12 weeks). Clomipramine has proved effective in doses equivalent to those used for depression. Fluoxetine (an SSRI drug) has been widely used in this disorder but in

doses higher than those used in depression (up to 60–80 mg/d). The other SSRI medications such as sertraline, paroxetine, and fluvoxamine are being used with comparable efficacy, each with its own side-effect profile. Buspirone in doses of 15–60 mg/d appears to be effective primarily as an anti-obsessional augmenting agent for the SSRI medications. There is some evidence that antipsychotics may be helpful as adjuncts to the SSRIs in treatment-resistant cases. Psychosurgery has a limited place in selected cases of severe unremitting OCD. The stereotactic techniques now being used, including modified cingulotomy, are great improvements over the crude methods of the past. Experimental work has suggested a role for deep brain stimulation in OCD.

B. Behavioral

Behavioral approaches are widely used in various anxiety disorders, often in conjunction with medication. Any of the behavioral techniques can be used beneficially in altering the contingencies (precipitating factors or rewards) supporting any anxiety-provoking behavior. Relaxation techniques can sometimes be helpful in reducing anxiety. Desensitization, by exposing the patient to graded doses of a phobic object or situation, is an effective technique and one that the patient can practice outside the therapy session. Emotive imagery, wherein the patient imagines the anxiety-provoking situation while at the same time learning to relax, helps decrease the anxiety when the patient faces the real-life situation. Physiologic symptoms in panic attacks respond well to relaxation training. Exposure techniques with response prevention are useful for OCD.

C. Psychological

Cognitive behavioral approaches have been effective in treatment of panic disorders, phobias, and OCD when erroneous beliefs need correction. These approaches share a common behavioral technique of exposing the individual to the feared object or situation. The combination of medical and cognitive behavioral therapy is more effective than either alone. Group therapy is the treatment of choice when the anxiety is clearly a function of the patient's difficulties in dealing with social settings. Acceptance and commitment therapy is a new psychotherapy that has been used with some success in anxiety disorders. It encourages individuals to keep focused on life goals while they "accept" the presence of anxiety in their lives.

D. Social

Peer support groups for panic disorder and agoraphobia have been particularly helpful. Social modification may require measures such as family counseling to aid acceptance of the patient's symptoms and avoid counterproductive behavior in behavioral training. Any help in maintaining the social structure is anxiety-alleviating, and work, school, and social activities should be maintained. School and vocational counseling may be provided by professionals, who often need help from the clinician in defining the patient's limitations.

► Prognosis

Anxiety disorders are usually long-standing and may be quite difficult to treat. All can be relieved to varying degrees with medications and behavioral techniques. The prognosis is much better if the commonly observed anxiety-panic-phobia-depression cycle can be broken with a combination of the therapeutic interventions discussed above.

Blanco C et al. A placebo-controlled trial of phenelzine, cognitive behavioral group therapy, and their combination for social anxiety disorder. *Arch Gen Psychiatry*. 2010 Mar;67(3):286–95. [PMID: 20194829]

Hayes SC et al. Open, aware, and active: contextual approaches as an emerging trend in the behavioral and cognitive therapies. *Annu Rev Clin Psychol*. 2011 Apr;7:141–68. [PMID: 21219193]

Roy-Byrne P et al. Delivery of evidence-based treatment for multiple anxiety disorders in primary care: a randomized controlled trial. *JAMA*. 2010 May 19;303(19):1921–8. [PMID: 20483968]

Siegmund A et al. D-cycloserine does not improve but might slightly speed up the outcome of in-vivo exposure therapy in patients with severe agoraphobia and panic disorder in a randomized double blind clinical trial. *J Psychiatr Res*. 2011 Aug;45(8):1042–7. [PMID: 21377691]

SOMATOFORM DISORDERS (Abnormal Illness Behaviors)

ESSENTIALS OF DIAGNOSIS

- Physical symptoms may involve one or more organ systems and are not intentional.
- Subjective complaints exceed objective findings.
- Correlations of symptom development and psychosocial stresses.
- Combination of biogenetic and developmental patterns.

► General Considerations

Somatoform disorders can occur focused on any organ system. Vulnerability in one or more organ systems and exposure to family members with somatization problems play a major role in the development of particular symptoms, and the “functional” versus “organic” dichotomy is a hindrance to good treatment. Clinicians should suspect psychiatric disorders in a number of conditions. For example, 45% of patients complaining of palpitations had lifetime psychiatric diagnoses including generalized anxiety, depression, panic, and somatization disorders. Similarly, 33–44% of patients who undergo coronary angiography for chest pain but have negative results have been found to have panic disorder.

In any patient presenting with a condition judged to be somatoform, depression must be considered in the diagnosis.

► Clinical Findings

A. Conversion Disorder

“Conversion” (formerly “hysterical conversion”) of psychic conflict into physical symptoms in parts of the body innervated by the sensorimotor system (eg, paralysis, aphonia) is a disorder that is more common in individuals from lower socioeconomic classes and certain cultures. The coping mechanisms used in this condition are repression (a barring from consciousness) and isolation (a splitting of the affect from the idea). The somatic manifestation that takes the place of anxiety is often paralysis, and in some instances the organ dysfunction may have symbolic meaning (eg, arm paralysis in marked anger so the individual cannot use the arm to strike someone). Pseudoepileptic (“hysterical”) seizures are often difficult to differentiate from intoxication states or panic attacks. Retention of consciousness, random flailing with asynchronous movements of the right and left sides, and resistance to having the nose and mouth pinched closed during the attack, all point toward a pseudoepileptic event. Electroencephalography, particularly in a video-electroencephalography assessment unit, during the attack is the most helpful diagnostic aid in excluding genuine seizure states. Serum prolactin levels rise abruptly in the postictal state only in true epilepsy. La belle indifférence (an unconcerned affect) is not a significant identifying characteristic, as commonly believed, since individuals even with genuine medical illness, may exhibit a high level of denial. Important conversion disorder criteria include a history of conversion or somatization disorder, modeling the symptom after someone else who had a similar presentation, a serious precipitating emotional event, associated psychopathology (eg, depression, schizophrenia, personality disorders), a temporal correlation between the precipitating event and the symptom, and a temporary “solving of the problem” by the conversion. It is important to identify physical disorders with unusual presentations (eg, multiple sclerosis, systemic lupus erythematosus).

B. Somatization Disorder (Briquet Syndrome, Hysteria)

This is characterized by multiple physical complaints referable to several organ systems. Anxiety, panic disorder, and depression are often present, and **major depression** is an important consideration in the differential diagnosis. There is a significant relationship (20%) to a lifetime history of panic-agoraphobia-depression. It usually occurs before age 30 and is ten times more common in women. Polysurgery is often a feature of the history. Preoccupation with medical and surgical therapy becomes a lifestyle that excludes most other activities. The symptoms indicate maladaptive coping techniques and there is often evidence of long-standing somatic complaints, including multiple pain and gastrointestinal symptoms (such as dyspareunia, dysmenorrhea, headache, backache, abdominal pain, vomiting, bloating) and pseudoneurologic symptoms (such as amnesia or pseudoepileptic seizures), often with a history of similar organ system involvement in other family members. Multiple symptoms that constantly change and the

inability of more than three doctors to make a diagnosis are strong clues to the problem.

C. Pain Disorder Associated with Psychological Factors (Formerly Somatoform Pain Disorder)

This involves a long history of complaints of severe pain out of proportion to any biomedical findings that are present. This diagnosis must not be one of exclusion and should be made only after extended evaluation has established a clear correlation of psychogenic factors with exacerbations and remissions of complaints.

D. Hypochondriasis

This is a fear of disease and preoccupation with the body, with perceptual amplification and heightened responsiveness. A process of social learning is usually involved, frequently with a role model who was a member of the family and may be a part of the underlying psychodynamic causation. It is common in panic disorders.

E. Factitious Disorders

These disorders, in which symptom production is intentional, are not somatoform conditions in that symptoms are produced consciously, in contrast to the unconscious process of the above conditions. They are characterized by self-induced symptoms or false physical and laboratory findings for the purpose of deceiving clinicians or other hospital personnel. The deceptions may involve self-mutilation, fever, hemorrhage, hypoglycemia, seizures, and an almost endless variety of manifestations—often presented in an exaggerated and dramatic fashion (**Munchausen syndrome**). “Munchausen by proxy” is the term used when a parent creates an illness in a child so the adult (usually the mother) can maintain a relationship with clinicians. The duplicity may be either simple or extremely complex and difficult to recognize. The patients are frequently connected in some way with the health professions; they are often migratory; and there is no apparent external motivation other than achieving the patient role.

► Complications

A poor clinician-patient relationship, with iatrogenic disorders and “doctor shopping,” tends to exacerbate the problem. Sedative and analgesic dependency is the most common iatrogenic complication.

► Treatment

A. Medical

Medical support with careful attention to building a therapeutic practitioner-patient relationship is the mainstay of treatment. It must be accepted that the patient's distress is real. Every problem not found to have an organic basis is not necessarily a mental disease. Diligent attempts should be made to relate symptoms to adverse developments in the patient's life. It may be useful to have the patient keep a meticulous diary, paying particular attention to various pertinent factors evident in the history. Regular, frequent,

short appointments that are not symptom-contingent may be helpful. Medications (frequently abused) should not be prescribed to replace appointments. One person should be the primary clinician, and consultants should be used mainly for evaluation. An empathic, realistic, optimistic approach must be maintained in the face of the expected ups and downs. Ongoing reevaluation is necessary, since somatization can coexist with a concurrent physical illness.

B. Psychological

Psychological approaches can be used by the primary clinician when it is clear that the patient is ready to make some changes in lifestyle in order to achieve symptomatic relief. This is often best approached on a here-and-now basis and oriented toward pragmatic changes rather than an exploration of early experiences that the patient frequently fails to relate to current distress. Group therapy with other individuals who have similar problems is sometimes of value to improve coping, allow ventilation, and focus on interpersonal adjustment. Hypnosis or lorazepam interviews used early are helpful in resolving conversion disorders. If the primary clinician has been working with the patient on psychological problems related to the physical illness, the groundwork is often laid for successful psychiatric referral.

For patients who have been identified as having a factitious disorder, early psychiatric consultation is indicated. There are two main treatment strategies for these patients. One consists of a conjoint confrontation of the patient by both the primary clinician and the psychiatrist. The patient's disorder is portrayed as a cry for help, and psychiatric treatment is recommended. The second approach avoids direct confrontation and attempts to provide a face-saving way to relinquish the symptom without overt disclosure of the disorder's origin. Techniques such as biofeedback and self-hypnosis may foster recovery using this strategy. Another face-saving approach is to use a double bind with the patient. For example, the patient is told there are two possible diagnoses: (1) an organic disease that should respond to the next medical intervention (usually modest and noninvasive), or (2) factitious disorder for which the patient will need psychiatric treatment. Given these options, many patients will choose to recover and not have to admit the origin of their problem.

C. Behavioral

Behavioral therapy is probably best exemplified by biofeedback techniques. In biofeedback, the particular abnormality (eg, increased peristalsis) must be recognized and monitored by the patient and therapist (eg, by an electronic stethoscope to amplify the sounds). This is immediate feedback, and after learning to recognize it, the patient can then learn to identify any change thus produced (eg, a decrease in bowel sounds) and so become a conscious originator of the feedback instead of a passive recipient. Relief of the symptom operantly conditions the patient to utilize the maneuver that relieves symptoms (eg, relaxation causing a decrease in bowel sounds). With emphasis on this

type of learning, the patient is able to identify symptoms early and initiate the countermeasures, thus decreasing the symptomatic problem. Migrainoid and tension headaches have been particularly responsive to biofeedback methods.

D. Social

Social endeavors include family, work, and other interpersonal activity. Family members should come for some appointments with the patient so they can learn how best to live with the patient. This is particularly important in treatment of somatization and pain disorders. Peer support groups provide a climate for encouraging the patient to accept and live with the problem. Ongoing communication with the employer may be necessary to encourage long-term continued interest in the employee. Employers can become just as discouraged as clinicians in dealing with employees who have chronic problems.

► Prognosis

The prognosis is much better if the primary clinician is able to intervene early before the situation has deteriorated. After the problem has crystallized into chronicity, it is very difficult to effect change.

Asmundson GJ et al. Health anxiety: current perspectives and future directions. *Curr Psychiatry Rep.* 2010 Aug;12(4):306–12. [PMID: 20549396]

Gordon-Elliott JS et al. An approach to the patient with multiple physical symptoms or chronic disease. *Med Clin North Am.* 2010 Nov;94(6):1207–16. [PMID: 20951278]

Schweitzer PJ et al. Long-term follow-up of hypochondriasis after selective serotonin reuptake inhibitor treatment. *J Clin Psychopharmacol.* 2011 Jun;31(3):365–8. [PMID: 21508861]

CHRONIC PAIN DISORDERS



ESSENTIALS OF DIAGNOSIS

- ▶ Chronic complaints of pain.
- ▶ Symptoms frequently exceed signs.
- ▶ Minimal relief with standard treatment.
- ▶ History of having seen many clinicians.
- ▶ Frequent use of several nonspecific medications.

► General Considerations

A problem in the management of pain is the lack of distinction between acute and chronic pain syndromes. Most clinicians are adept at dealing with acute pain problems but have difficulty handling the patient with a chronic pain disorder. This type of patient frequently takes too many medications, stays in bed a great deal, has seen many clinicians, has lost skills, and experiences little joy in either work or play. All relationships suffer (including those with clinicians), and life becomes a constant search for succor. The

search results in complex clinician-patient relationships that usually include many drug trials, particularly sedatives, with adverse consequences (eg, irritability, depressed mood) related to long-term use. Treatment failures provoke angry responses and depression from both the patient and the clinician, and the pain syndrome is exacerbated. When frustration becomes too great, a new clinician is found, and the cycle is repeated. The longer the existence of the pain disorder, the more important become the psychological factors of anxiety and depression. As with all other conditions, it is counterproductive to speculate about whether the pain is “real.” It is real to the patient, and acceptance of the problem must precede a mutual endeavor to alleviate the disturbance.

► Clinical Findings


Components of the chronic pain syndrome consist of anatomic changes, chronic anxiety and depression, anger, and changed lifestyle. Usually, the anatomic problem is irreversible, since it has already been subjected to many interventions with increasingly unsatisfactory results. An algorithm for assessing chronic pain and differentiating it from other psychiatric conditions is illustrated in Figure 25–1.

Chronic anxiety and depression produce heightened irritability and overreaction to stimuli. A marked decrease in pain threshold is apparent. This pattern develops into a hypochondriacal preoccupation with the body and a constant need for reassurance. The pressure on the clinician becomes wearing and often leads to covert rejection of the patient, such as not being available or making referrals to other clinicians.

This is perceived by the patient, who then intensifies the effort to find help, and the typical cycle is repeated. Anxiety and depression are seldom discussed, almost as if there is a tacit agreement not to deal with these issues.

Changes in lifestyle involve some of the pain behaviors. These usually take the form of a family script in which the patient accepts the role of being sick, and this role then becomes the focus of most family interactions and may become important in maintaining the family, so that neither the patient nor the family wants the patient’s role to change. Demands for attention and efforts to control the behavior of others revolve around the central issue of control of other people (including clinicians). Cultural factors frequently play a role in the behavior of the patient and how the significant people around the patient cope with the problem. Some cultures encourage demonstrative behavior, while others value the stoic role.

Another secondary gain that frequently maintains the patient in the sick role is financial compensation or other benefits. Frequently, such systems are structured so that they reinforce the maintenance of sickness and discourage any attempts to give up the role. Clinicians unwittingly reinforce this role because of the very nature of the practice of medicine, which is to respond to complaints of illness. Helpful suggestions from the clinician are often met with responses like, “Yes, but . . .” Medications then become the principal approach, and drug dependency problems may develop.



▲ **Figure 25-1.** Algorithm for assessing psychiatric component of chronic pain. (Adapted and reproduced, with permission, from Eisendrath SJ. Psychiatric aspects of chronic pain. *Neurology*. 1995 Dec;45(12 Suppl 9):S26–34.)

► Treatment

A. Behavioral

The cornerstone of a unified approach to chronic pain syndromes is a comprehensive behavioral program. This is necessary to identify and eliminate pain reinforcers, to decrease drug use, and to use effectively those positive reinforcers that shift the focus from the pain. It is critical that the patient be made a partner in the effort to manage and function better in the setting of ongoing pain symptoms. The clinician must shift from the idea of biomedical cure to ongoing care of the patient. The patient should agree to discuss the pain only with the clinician and not with family members; this tends to stabilize the patient's personal life, since the family is usually tired of the subject. At the beginning of treatment, the patient should be assigned self-help tasks graded up to maximal activity as a means of positive reinforcement. The tasks should not exceed capability. The patient can also be asked to keep a self-rating chart to log accomplishments, so that progress can be measured and remembered. Instruct the patient to record degrees of pain on a self-rating scale in relation to various situations and

mental attitudes so that similar circumstances can be avoided or modified.

Avoid positive reinforcers for pain such as marked sympathy and attention to pain. Emphasize a positive response to productive activities, which remove the focus of attention from the pain. Activity is also desensitizing, since the patient learns to tolerate increasing activity levels.

Biofeedback techniques (see Somatoform Disorders, above) and hypnosis have been successful in ameliorating some pain syndromes. Hypnosis tends to be most effective in patients with a high level of denial, who are more responsive to suggestion. Hypnosis can be used to lessen anxiety, alter perception of the length of time that pain is experienced, and encourage relaxation. Mindfulness-based stress reduction programs have been useful in helping individuals develop an enhanced capacity to live a higher quality life with persistent pain.

B. Medical

A *single clinician* in charge of the comprehensive treatment approach is the highest priority. Consultations as indicated

and technical procedures done by others are appropriate, but the care of the patient should remain in the hands of the primary clinician. Referrals should not be allowed to raise the patient's hopes unrealistically or to become a way for the clinician to reject the case. The attitude of the clinician should be one of honesty, interest, and hopefulness—not for a cure but for control of pain and improved function. If the patient manifests opioid addiction, detoxification may be an early treatment goal.

Nonsteroidal anti-inflammatory medications are often the first-line of treatment for pain. If opioid analgesics or sedatives are prescribed, they should not be given on an “as-needed” schedule (see Chapter 5). A fixed schedule lessens the conditioning effects of these medications. Tricyclic antidepressants (TCAs) (eg, nortriptyline), venlafaxine, and duloxetine in doses up to those used in depression may be helpful, particularly in neuropathic pain syndromes. In other conditions, their effects on pain may be less clear, but ameliorating depression is usually important nonetheless. Gabapentin, an anticonvulsant with possible applications in the treatment of anxiety disorders, has been shown to be useful in postherpetic and diabetic neuropathy and somatoform disorders.

In addition to medications, a variety of nonpharmacologic strategies may be offered, including physical therapy and acupuncture.

C. Social

Involvement of family members and other significant persons in the patient's life should be an early priority. The best efforts of both patient and therapists can be unwittingly sabotaged by other persons who may feel that they are “helping” the patient. They frequently tend to reinforce the negative aspects of the chronic pain disorder. The patient becomes more dependent and less active, and the pain syndrome becomes an immutable way of life. The more destructive pain behaviors described by many experts in chronic pain disorders are the results of well-meaning but misguided efforts of family members. Ongoing therapy with the family can be helpful in the early identification and elimination of these behavior patterns.

D. Psychological

In addition to group therapy with family members and others, groups of patients can be helpful if properly led. The major goal, whether of individual or group therapy, is to gain patient involvement. A group can be a powerful instrument for achieving this goal, with the development of group loyalties and cooperation. People will frequently make efforts with group encouragement that they would never make alone. Individual therapy should be directed toward strengthening existing coping mechanisms and improving self-esteem. For example, teaching patients to challenge expectations induced by chronic pain may lead to improved functioning. As an illustration, many chronic pain patients, making assumptions more derived from acute injuries, incorrectly believe they will damage themselves by attempting to function. The rapport between patient and clinician, as in all psychotherapeutic efforts, is the major factor in therapeutic success.

Morley S. Efficacy and effectiveness of cognitive behaviour therapy for chronic pain: Progress and some challenges. *Pain*. 2011 Mar;152(3 Suppl):S99–106. [PMID: 21159433]
Vitiello MV et al. Cognitive behavioral therapy for insomnia improves sleep and decreases pain in older adults with comorbid insomnia and osteoarthritis. *J Clin Sleep Med*. 2009 Aug;5(4):363–4. [PMID: 19968014]

PSYCHOSEXUAL DISORDERS

The stages of sexual activity include **excitement** (arousal), **orgasm**, and **resolution**. The precipitating excitement or arousal is psychologically determined. Arousal response leading to plateau is a physiologic and psychological phenomenon of vasocongestion, a parasympathetic reaction causing erection in men and labial-clitoral congestion in women. The orgasmic response includes emission in men and clonic contractions of the analogous striated perineal muscles of both men and women. Resolution is a gradual return to normal physiologic status.

While the arousal stimuli—vasocongestive and orgasmic responses—constitute a single response in a well-adjusted person, they can be considered as separate stages that can produce different syndromes responding to different treatment procedures.

► Clinical Findings

There are three major groups of sexual disorders.

A. Paraphilias (Sexual Arousal Disorders)

In these conditions, formerly called “deviations” or “variations,” the excitement stage of sexual activity is associated with sexual objects or orientations different from those usually associated with adult sexual stimulation. The stimulus may be a woman's shoe, a child, animals, instruments of torture, or incidents of aggression. The pattern of sexual stimulation is usually one that has early psychological roots. Poor experiences with sexual activity frequently reinforce this pattern over time.

Exhibitionism is the impulsive behavior of exposing the genitalia to unsuspecting strangers in order to achieve sexual excitation. It is a childhood sexual behavior carried into adult life.

Transvestism consists of recurrent cross-dressing behavior in a heterosexual man for the purpose of sexual excitation. Such fetishistic behavior can be part of masturbation foreplay. Transvestism in homosexuality and transsexualism is not for the purpose of sexual excitement but is a function of preference or gender identity disorder.

Voyeurism involves the achievement of sexual arousal by watching the activities of an unsuspecting person, usually in various stages of undress or sexual activity. In both exhibitionism and voyeurism, excitation leads to masturbation as a replacement for sexual activity.

Pedophilia is the use of a child of either sex to achieve sexual arousal and, in many cases, gratification. Contact is frequently oral, with either participant being dominant, but pedophilia includes intercourse of any type. Adults of both sexes engage in this behavior, but because of social and cultural factors it is more commonly identified with men.

The pedophile has difficulty in adult sexual relationships, and men who perform this act are frequently impotent.

Incest involves a sexual relationship with a person in the immediate family, most frequently a child. In many ways it is similar to pedophilia (intrafamilial pedophilia). Incestuous feelings are fairly common, but cultural mores are usually sufficiently strong to act as a barrier to the expression of sexual feelings.

Sexual sadism is the attainment of sexual arousal by inflicting pain upon the sexual object. Much sexual activity has aggressive components (eg, biting, scratching). However, forced sexual acquiescence (eg, rape) is considered to be primarily an act of aggression.

Sexual masochism is the achievement of erotic pleasure by being humiliated, enslaved, physically bound, and restrained. It may be life-threatening, since neck binding or partial asphyxiation usually forms part of the ritual. The practice is much more common in men than in women.

B. Gender Identity Disorder

Core gender identity reflects a biologic self-image—the conviction that “I am a boy” or “I am a girl” that is usually well developed by age 3 or 4. Gender dysphoria refers to the development of a sexual identity that is the opposite of the biologic one.

Transsexualism is an attempt to deny and reverse biologic sex by maintaining sexual identity with the opposite gender. Transsexuals do not alternate between gender roles; rather, they assume a fixed role of attitudes, feelings, fantasies, and choices consonant with those of the opposite sex, all of which clearly date back to early development. For example, male to female transsexuals in early childhood behave, talk, and fantasize as if they were girls. They do not grow out of feminine patterns; they do not work in professions traditionally considered to be masculine; and they have no interest in their own penises either as evidence of maleness or as organs for erotic behavior. The desire for sex change starts early and may culminate in assumption of a feminine lifestyle, hormonal treatment, and use of surgical procedures, eg, castration and vaginoplasty.

C. Psychosexual Dysfunction

This category includes a large group of vasocongestive and orgasmic disorders. Often, they involve problems of sexual adaptation, education, and technique that are often initially discussed with, diagnosed by, and treated by the primary care provider.

There are two conditions common in men: erectile dysfunction and ejaculation disturbances.

Erectile dysfunction is inability to achieve or maintain an erection firm enough for satisfactory intercourse; patients sometimes use the term to mean premature ejaculation. Careful questioning is necessary, since causes of this vasocongestive disorder can be psychological, physiologic, or both. The majority are pathophysiologic and, to varying degrees, treatable. After onset of the problem, a history of occasional erections—especially nocturnal penile tumescence, which may be evaluated by a simple monitoring device, or a sleep study in the sleep laboratory—is usually evidence that the dysfunction is psychological in origin,

with the caveat that decreased nocturnal penile tumescence occurs in some depressed patients. **Psychological erectile dysfunction** is caused by interpersonal or intrapsychic factors (eg, marital disharmony, depression). **Organic factors** are discussed in Chapter 23.

Ejaculation disturbances include premature ejaculation, inability to ejaculate, and retrograde ejaculation. (Ejaculation is possible in patients with erectile dysfunction.) Ejaculation is usually connected with orgasm, and ejaculatory control is an acquired behavior that is minimal in adolescence and increases with experience. Pathogenic factors are those that interfere with learning control, most frequently sexual ignorance. Intrapsychic factors (anxiety, guilt, depression) and interpersonal maladaptation (marital problems, unresponsiveness of mate, power struggles) are also common. Organic causes include interference with sympathetic nerve distribution (often due to surgery or trauma) and the effects of pharmacologic agents (eg, SSRIs or sympatholytics).

In women, the two most common forms of sexual dysfunction are vaginismus and frigidity.

Vaginismus is a conditioned response in which a spasm of the perineal muscles occurs if there is any stimulation of the area. The desire is to avoid penetration. Sexual responsiveness and vasocongestion may be present, and orgasm can result from clitoral stimulation.

Frigidity is a complex condition in which there is a general lack of sexual responsiveness. The woman has difficulty in experiencing erotic sensation and does not have the vasocongestive response. Sexual activity varies from active avoidance of sex to an occasional orgasm. Orgasmic dysfunction—in which a woman has a vasocongestive response but varying degrees of difficulty in reaching orgasm—is sometimes differentiated from frigidity. Causes for the dysfunctions include poor sexual techniques, early traumatic sexual experiences, interpersonal disharmony (marital struggles, use of sex as a means of control), and intrapsychic problems (anxiety, fear, guilt). Organic causes include any conditions that might cause pain in intercourse, pelvic pathology, mechanical obstruction, and neurologic deficits.

Disorders of sexual desire consist of diminished or absent libido in either sex and may be a function of organic or psychological difficulties (eg, anxiety, phobic avoidance). Any chronic illness can reduce desire. Hormonal disorders, including hypogonadism or use of antiandrogen compounds such as cyproterone acetate, and chronic kidney disease contribute to deterioration in sexual desire. Although menopause may lead to diminution of sexual desire in some women, the relationship between menopause and libido is complicated and may be influenced by sociocultural factors. Alcohol, sedatives, opioids, marijuana, and some medications may affect sexual drive and performance.

▶ Treatment

A. Paraphilias and Gender Identity Disorders

1. Psychological—Sexual arousal disorders involving variant sexual activity (paraphilia), particularly those of a more superficial nature (eg, voyeurism) and those of recent onset, are responsive to psychotherapy in a moderate

percentage of cases. The prognosis is much better if the motivation comes from the individual rather than the legal system; unfortunately, however, judicial intervention is frequently the only stimulus to treatment, because the condition persists and is reinforced until conflict with the law occurs. Therapies frequently focus on barriers to normal arousal response; the expectation is that the variant behavior will decrease as normal behavior increases.

2. Behavioral—Aversive and operant conditioning techniques have been tried frequently in gender role disorders but have only occasionally been successful. In some cases, the sexual arousal disorders improve with modeling, role-playing, and conditioning procedures. Emotive imagery is occasionally helpful in lessening anxiety in fetish problems.

3. Social—Although they do not produce a change in sexual arousal patterns or gender role, self-help groups have facilitated adjustment to an often hostile society. Attention to the family is particularly important in helping persons in such groups to accept their situation and alleviate their guilt about the role they think they had in creating the problem.

4. Medical—Medroxyprogesterone acetate, a suppressor of libidinal drive, is used to mute disruptive sexual behavior in men of all ages. Onset of action is usually within 3 weeks, and the effects are generally reversible. Fluoxetine or other SSRIs at depression doses (see Table 25–8) may reduce some of the compulsive sexual behaviors including the paraphilias. A focus of study in the treatment of severe paraphilia has been agonists of luteinizing hormone–releasing hormone. Although some transsexuals are treated with genital reconstructive surgery, many others are screened out by trial periods of living as the other sex prior to operation.

B. Psychosexual Dysfunction

1. Medical—Identification of a contributory reversible cause is most important. Even if the condition is not reversible, identification of the specific cause helps the patient to accept the condition. Marital disharmony, with its exacerbating effects, may thus be avoided. Of all the sexual dysfunctions, erectile dysfunction is the condition most likely to have an organic basis. Sildenafil, tadalafil, and vardenafil are phosphodiesterase type 5 inhibitors that are effective oral agents for the treatment of penile erectile dysfunction (eg, sildenafil 25–100 mg orally 1 hour prior to intercourse). These agents are effective for SSRI-induced erectile dysfunction in men and in some cases for SSRI-associated sexual dysfunction in women. Use of the medications in conjunction with any nitrates, particularly in individuals with coronary artery disease, can have significant hypotensive effects leading to death in some cases. The medication, which does not appear to impact sexual desire, should be used only once a day. Because of their common effect in delaying ejaculation, the SSRIs have been effective in premature ejaculation.

2. Behavioral—Syndromes resulting from conditioned responses have been treated by conditioning techniques, with excellent results. Vaginismus responds well to desensitization with graduated Hegar dilators along with relaxation techniques. Masters and Johnson have used behavioral

approaches in all of the sexual dysfunctions, with concomitant supportive psychotherapy and with improvement of the communication patterns of the couple.

3. Psychological—The use of psychotherapy by itself is best suited for those cases in which interpersonal difficulties or intrapsychic problems predominate. Anxiety and guilt about parental injunctions against sex may contribute to sexual dysfunction. Even in these cases, however, a combined behavioral-psychological approach usually produces results most quickly.

4. Social—The proximity of other people (eg, a mother-in-law) in a household is frequently an inhibiting factor in sexual relationships. In such cases, some social engineering may alleviate the problem.

Eardley I et al. Pharmacotherapy for erectile dysfunction. *J Sex Med.* 2010 Jan;7(1 Pt 2):524–40. [PMID: 20092451]

PERSONALITY DISORDERS



ESSENTIALS OF DIAGNOSIS

- ▶ Long history dating back to childhood.
- ▶ Recurrent maladaptive behavior.
- ▶ Low self-esteem and lack of confidence.
- ▶ Minimal introspective ability with a tendency to blame others for all problems.
- ▶ Major difficulties with interpersonal relationships or society.
- ▶ Depression with anxiety when maladaptive behavior fails.

▶ General Considerations

An individual's personality structure, or character, is an integral part of self-image. It reflects genetics, interpersonal influences, and recurring patterns of behavior adopted in order to cope with the environment. The classification of subtypes of personality disorders depends on the predominant symptoms and their severity. The most severe disorders—those that bring the patient into greatest conflict with society—tend to be classified as antisocial (psychopathic) or borderline.

Personality disorders can be considered a matrix for some of the more severe psychiatric problems (eg, schizotypal, relating to schizophrenia, and avoidance types, relating to some anxiety disorders).

▶ Classification & Clinical Findings

See Table 25–3.

▶ Differential Diagnosis

Patients with personality disorders tend to show anxiety and depression when pathologic coping mechanisms fail, and their symptoms can be similar to those disorders.

Table 25-3. Personality disorders: Classification and clinical findings.

Personality Disorder	Clinical Findings
Antisocial	Selfish, callous, promiscuous, impulsive, unable to learn from experience, often has legal problems.
Avoidant	Fears rejection, hyperreacts to rejection and failure, with poor social endeavors and low self-esteem.
Borderline	Impulsive; has unstable and intense interpersonal relationships; is suffused with anger, fear, and guilt; lacks self-control and self-fulfillment; has identity problems and affective instability; is suicidal (a serious problem—up to 80% of hospitalized borderline patients make an attempt at some time during treatment, and the incidence of completed suicide is as high as 5%); aggressive behavior, feelings of emptiness, and occasional psychotic decompensation. This group has a high drug abuse rate, which plays a role in symptoms. There is extensive overlap with other diagnostic categories, particularly mood disorders and posttraumatic stress disorder.
Dependent	Passive, overaccepting, unable to make decisions, lacks confidence, with poor self-esteem.
Histrionic (hysterical)	Dependent, immature, seductive, egocentric, vain, emotionally labile.
Narcissistic	Exhibitionist, grandiose, preoccupied with power, lacks interest in others, with excessive demands for attention.
Obsessive compulsive	Perfectionist, egocentric, indecisive, with rigid thought patterns and need for control.
Paranoid	Defensive, oversensitive, secretive, suspicious, hyperalert, with limited emotional response.
Schizoid	Shy, introverted, withdrawn, avoids close relationships.
Schizotypal	Superstitious, socially isolated, suspicious, with limited interpersonal ability, eccentric behaviors, and odd speech.

Occasionally, the more severe cases may decompensate into psychosis under stress and mimic other psychotic disorders.

► Treatment

A. Social

Social and therapeutic environments such as day hospitals, halfway houses, and self-help communities utilize peer pressures to modify the self-destructive behavior. The patient with a personality disorder often has failed to profit from experience, and difficulties with authority impair the learning experience. The use of peer relationships and the repetition possible in a structured setting of a helpful community enhance the behavioral treatment opportunities and increase learning. When problems are detected early, both the school and the home can serve as foci of intensified social pressure to change the behavior, particularly with the use of behavioral techniques.

B. Behavioral

The behavioral techniques used are principally operant conditioning and aversive conditioning. The former simply emphasizes the recognition of acceptable behavior and its reinforcement with praise or other tangible rewards. Aversive responses usually mean punishment, although this can range from a mild rebuke to some specific punitive responses such as deprivation of privileges. Extinction plays a role in that an attempt is made not to respond to inappropriate behavior, and the lack of response eventually causes the person to abandon that type of behavior. Pouting and tantrums, for example, diminish quickly when such behavior elicits no reaction. Dialectical behavioral therapy is a program of individual and group therapy specifically designed for patients with chronic suicidality and borderline personality disorder. It blends mindfulness and a

cognitive-behavioral model to address self-awareness, interpersonal functioning, affective lability, and reactions to stress.

C. Psychological

Psychological intervention is best conducted in group settings. Group therapy is helpful when specific interpersonal behavior needs to be improved. This mode of treatment also has a place with so-called “acting-out” patients, ie, those who frequently act in an impulsive and inappropriate way. The peer pressure in the group tends to impose restraints on rash behavior. The group also quickly identifies the patient’s types of behavior and helps improve the validity of the patient’s self-assessment, so that the antecedents of the unacceptable behavior can be effectively handled, thus decreasing its frequency. Individual therapy should initially be supportive, ie, helping the patient to restabilize and mobilize coping mechanisms. If the individual has the ability to observe his or her own behavior, a longer-term and more introspective therapy may be warranted. The therapist must be able to handle countertransference feelings (which are frequently negative), maintain appropriate boundaries in the relationship (no physical contacts, however well-meaning), and refrain from premature confrontations and interpretations.

D. Medical

Hospitalization is indicated in the case of serious suicidal or homicidal danger. In most cases, treatment can be accomplished in the day treatment center or self-help community. Antipsychotics may be required for short periods in conditions that have temporarily decompensated into transient psychoses (eg, olanzapine [2.5–10 mg/d orally], risperidone [0.5–2 mg/d orally], or haloperidol [0.5–2 mg/d orally, split into two doses]). In some cases, these medications are required only for several days and can be

discontinued after the patient has regained a previously established level of adjustment; they can also provide ongoing support. Carbamazepine, 400–800 mg orally daily in divided doses, decreases the severity of behavioral dyscontrol. Antidepressants have improved anxiety, depression, and sensitivity to rejection in some borderline patients. SSRIs may have a role in reducing aggressive behavior in impulsive aggressive patients.

► Prognosis

Antisocial and borderline categories generally have a guarded prognosis. Those patients with a history of parental abuse and a family history of mood disorder tend to have the most challenging treatments.

Ingenhoven T et al. Effectiveness of pharmacotherapy for severe personality disorders: meta-analyses of randomized controlled trials. *J Clin Psychiatry*. 2010 Jan;71(1):14–25. [PMID: 19778496]

McMain SF et al. A randomized trial of dialectical behavior therapy versus general psychiatric management for borderline personality disorder. *Am J Psychiatry*. 2009 Dec;166(12):1365–74. [PMID: 19755574]

SCHIZOPHRENIA & OTHER PSYCHOTIC DISORDERS



ESSENTIALS OF DIAGNOSIS

- ▶ Social withdrawal, usually slowly progressive, often with deterioration in personal care.
- ▶ Loss of ego boundaries, with inability to perceive oneself as a separate entity.
- ▶ Loose thought associations, often with slowed thinking or overinclusive and rapid shifting from topic to topic.
- ▶ Autistic absorption in inner thoughts and frequent sexual or religious preoccupations.
- ▶ Auditory hallucinations, often of a derogatory nature.
- ▶ Delusions, frequently of a grandiose or persecutory nature.
- ▶ Symptoms of at least 6 months' duration.

Frequent additional signs:

- ▶ Flat affect and rapidly alternating mood shifts irrespective of circumstances.
- ▶ Hypersensitivity to environmental stimuli, with a feeling of enhanced sensory awareness.
- ▶ Variability or changeable behavior incongruent with the external environment.
- ▶ Concrete thinking with inability to abstract; inappropriate symbolism.
- ▶ Impaired concentration worsened by hallucinations and delusions.
- ▶ Depersonalization, wherein one behaves like a detached observer of one's own actions.

► General Considerations

The schizophrenic disorders are a group of syndromes manifested by massive disruption of thinking, mood, and overall behavior as well as poor filtering of stimuli. The characterization and nomenclature of the disorders are quite arbitrary and are influenced by sociocultural factors and schools of psychiatric thought.

It is currently believed that the schizophrenic disorders are of multifactorial cause, with genetic, environmental, and neurotransmitter pathophysiologic components. At present, there is no laboratory method for confirming the diagnosis of schizophrenia. There may or may not be a history of a major disruption in the individual's life (failure, loss, physical illness) before gross psychotic deterioration is evident.

Schizophrenic symptoms have been classified into positive and negative categories. Positive symptoms include hallucinations, delusions, and formal thought disorders; these symptoms appear to be related to increased dopaminergic (D₂) activity in the mesolimbic region. Negative symptoms include diminished sociability, restricted affect, and poverty of speech; these symptoms appear to be related to decreased D₂ activity in the mesocortical system.

“Other psychotic disorders” are conditions that are similar to schizophrenic disorders in their acute symptoms but have a less pervasive influence over the long term. The patient usually attains higher levels of functioning. The acute psychotic episodes tend to be less disruptive of the person's lifestyle, with a fairly quick return to previous levels of functioning.

► Classification

A. Schizophrenic Disorders

Schizophrenic disorders are subdivided on the basis of certain prominent phenomena that are frequently present. **Disorganized (hebephrenic) schizophrenia** is characterized by marked incoherence and an incongruous or silly affect. **Catatonic schizophrenia** is distinguished by a marked psychomotor disturbance of either excitement (purposeless and stereotyped) or rigidity with mutism. Infrequently, there may be rapid alternation between excitement and stupor (see under catatonic syndrome, below). **Paranoid schizophrenia** includes marked persecutory or grandiose delusions often consonant with hallucinations of similar content and with less marked disorganization of speech and behavior. **Undifferentiated schizophrenia** denotes a category in which symptoms are not specific enough to warrant inclusion of the illness in the other subtypes. **Residual schizophrenia** is a classification that includes persons who have clearly had an episode warranting a diagnosis of schizophrenia but who at present have no overt psychotic symptoms, although they show milder signs such as social withdrawal, flat affect, and eccentric behaviors.

B. Delusional Disorders

Delusional disorders are psychoses in which the predominant symptoms are persistent, nonbizarre delusions with

minimal impairment of daily functioning. (The schizophrenic disorders show significant impairment.) Intellectual and occupational activities are little affected, whereas social and marital functioning tend to be markedly involved. Hallucinations are not usually present. Common delusional themes include paranoid delusions of persecution, delusions of being related to or loved by a well-known person, and delusions that one's partner is unfaithful.

C. Schizoaffective Disorders

Schizoaffective disorders are those cases that fail to fit comfortably either in the schizophrenic or in the affective categories. They are usually cases with affective symptoms that precede or develop concurrently with psychotic manifestations. There has been increasing interest in studying prodromal schizophrenia with a goal of prevention or early treatment.

D. Schizophreniform Disorders

Schizophreniform disorders are similar in their symptoms to schizophrenic disorders except that the duration of prodromal, acute, and residual symptoms is > 1 week but < 6 months.

E. Brief Psychotic Disorders

These disorders last < 1 week. They are the result of psychological stress. The shorter duration is significant and correlates with a more acute onset and resolution as well as a much better prognosis.

F. Late Life Psychosis

Brain abnormalities occur in 40% of patients who develop psychotic symptoms after age 60. The psychotic symptoms are typical, and there are other findings such as low IQ scores and diminished cognitive function.

G. Atypical Psychoses

This group includes a wide range of conditions with psychotic symptoms. The cause is often not clear, but later events (eg, new symptoms) may clarify the diagnosis. The most common example is chronic psychosis developing either during periods of heavy abuse of drugs or at some time after the drug use has ceased. Other conditions include temporal lobe dysfunction, HIV infection, and a number of the conditions noted in the differential diagnosis (see below). They often have a good premorbid history, a precipitous onset, and an episodic course with symptom-free intervals.

► Clinical Findings

A. Symptoms and Signs

The symptoms and signs of schizophrenia vary markedly among individuals as well as in the same person at different times. The patient's **appearance** may be bizarre, although the usual finding is a mild to moderate unkempt blandness. **Motor activity** is generally reduced, although extremes

ranging from catatonic stupor to frenzied excitement occur. **Social behavior** is characterized by marked withdrawal coupled with disturbed interpersonal relationships and a reduced ability to experience pleasure. Dependency and a poor self-image are common. **Verbal utterances** are variable, the language being concrete yet symbolic, with unassociated rambling statements (at times interspersed with mutism) during an acute episode. Neologisms (made-up words or phrases), echolalia (repetition of words spoken by others), and verbigeration (repetition of senseless words or phrases) are occasionally present. **Affect** is usually flattened, with occasional inappropriateness. **Depression** is present in almost all cases but may be less apparent during the acute psychotic episode and more obvious during recovery. Depression is sometimes confused with akinetic side effects of antipsychotic medications. It is also related to **boredom**, which increases symptoms and decreases the response to treatment. Work is generally unavailable and time unfilled, providing opportunities for counterproductive activities such as drug abuse, withdrawal, and increased psychotic symptoms.

Thought content may vary from a paucity of ideas to a rich complex of delusional fantasy with archaic thinking. One frequently notes after a period of conversation that little if any information has actually been conveyed. Incoming stimuli produce varied responses. In some cases a simple question may trigger explosive outbursts, whereas at other times there may be no overt response whatsoever (catatonia). When paranoid ideation is present, the patient is often irritable and less cooperative. **Delusions** (false beliefs) are characteristic of paranoid thinking, and they usually take the form of a preoccupation with the supposedly threatening behavior exhibited by other individuals. This ideation may cause the patient to adopt active countermeasures such as locking doors and windows, taking up weapons, covering the ceiling with aluminum foil to counteract radar waves, and other bizarre efforts. Somatic delusions revolve around issues of bodily decay or infestation. **Perceptual distortions** usually include auditory hallucinations—visual hallucinations are more commonly associated with organic mental states—and may include illusions (distortions of reality) such as figures changing in size or lights varying in intensity. Cenesthetic hallucinations (eg, a burning sensation in the brain, feeling blood flowing in blood vessels) occasionally occur. Lack of humor, feelings of dread, depersonalization (a feeling of being apart from the self), and fears of annihilation may be present. Any of the above symptoms generate higher anxiety levels, with heightened arousal and occasional panic and suicidal ideation, as the individual fails to cope.

The development of the acute episode in schizophrenia frequently is the end product of a gradual decompensation. Frustration and anxiety appear early, followed by depression and alienation, along with progressive ineffectiveness in day-to-day coping. This often leads to feelings of panic and increasing disorganization, with loss of the ability to test and evaluate the reality of perceptions. The stage of so-called psychotic resolution includes delusions, autistic pre-occupations, and psychotic insight, with acceptance of the decompensated state. The process is frequently complicated

by the use of caffeine, alcohol, and other recreational drugs. Life expectancy of schizophrenic patients is as much as 20% shorter than that of cohorts in the general population and is often associated with comorbid conditions such as the metabolic syndrome.

Polydipsia may produce water intoxication with hyponatremia—characterized by symptoms of confusion, lethargy, psychosis, seizures, and occasionally death—in any psychiatric disorder, but most commonly in schizophrenia. These problems exacerbate the schizophrenic symptoms and can be confused with them. Possible pathogenetic factors in polydipsia include a hypothalamic defect, inappropriate antidiuretic hormone (ADH) secretion, neuroleptic medications (anticholinergic effects, stimulation of hypothalamic thirst center, effect on ADH), smoking (nicotine and syndrome of inappropriate antidiuretic hormone [SIADH]), psychotic thought processes (delusions), and other medications (eg, diuretics, antidepressants, lithium, alcohol). Other causes of polydipsia must be ruled out (eg, diabetes mellitus, diabetes insipidus, kidney disease).

B. Imaging

Ventricular enlargement and cortical atrophy, as seen on CT scan, have been correlated with chronic course, severe cognitive impairment, and nonresponsiveness to neuroleptic medications. Decreased frontal lobe activity seen on PET scan has been associated with negative symptoms.

► Differential Diagnosis

One should not hesitate to reconsider the diagnosis of schizophrenia in any person who has received that diagnosis in the past, particularly when the clinical course has been atypical. A number of these patients have been found to actually have atypical episodic affective disorders that have responded well to lithium. Manic episodes often mimic schizophrenia. Furthermore, schizophrenia has been diagnosed in many individuals because of inadequacies in psychiatric nomenclature. Thus, schizophrenia was often inappropriately diagnosed in persons with brief reactive psychoses, OCD, paranoid disorders, and schizophreniform disorders.

Psychotic depressions, psychotic organic mental states, and any illness with psychotic ideation tend to be confused with schizophrenia, partly because of the regrettable tendency to use the terms interchangeably. Adolescent phases of growth and counterculture behaviors constitute another area of diagnostic confusion. It is particularly important to avoid a misdiagnosis in these groups, because of the long-term implications arising from having such a serious diagnosis made in a formative stage of life.

Medical disorders such as thyroid dysfunction, adrenal and pituitary disorders, reactions to toxic materials (eg, mercury, PCBs), and almost all of the organic mental states in the early stages must be ruled out. Postpartum psychosis is discussed under Mood Disorders. **Complex partial seizures**, especially when psychosensory phenomena are present, are an important differential consideration. Toxic drug states arising from prescription, over-the-counter, herbal and street drugs may mimic all of the psychotic disorders.

The chronic use of amphetamines, cocaine, and other stimulants frequently produces a psychosis that is almost identical to the acute paranoid schizophrenic episode. The presence of formication (sensation of insects crawling on or under the skin) and stereotypy suggests the possibility of stimulant abuse. Phencyclidine (see below), a very common street drug, may cause a reaction that is difficult to distinguish from other psychotic disorders. Cerebellar signs, excessive salivation, dilated pupils, and increased deep tendon reflexes should alert the clinician to the possibility of a toxic psychosis. Industrial chemical toxicity (both organic and metallic), degenerative disorders, and metabolic deficiencies must be considered in the differential diagnosis.

Catatonic syndrome, frequently assumed to exist solely as a component of schizophrenic disorders, is actually the end product of a number of illnesses, including various organic conditions. Neoplasms, viral and bacterial encephalopathies, central nervous system hemorrhage, metabolic derangements such as diabetic ketoacidosis, sedative withdrawal, and hepatic and renal malfunction have all been implicated. It is particularly important to realize that drug toxicity (eg, overdoses of antipsychotic medications such as fluphenazine or haloperidol) can cause catatonic syndrome, which may be misdiagnosed as a catatonic schizophrenic disorder and inappropriately treated with more antipsychotic medication.

► Treatment

A. Medical

Hospitalization is often necessary, particularly when the patient's behavior shows gross disorganization. The presence of competent family members lessens the need for hospitalization, and each case should be judged individually. The major considerations are to prevent self-inflicted harm or harm to others and to provide the patient's basic needs. A full medical evaluation and CT scan or MRI of the brain should be considered in first episodes of schizophreniform disorder and other psychotic episodes of unknown cause.

Antipsychotic medications (see below) are the treatment of choice. The relapse rate can be reduced by 50% with proper maintenance neuroleptic therapy. Long-acting, injectable depot neuroleptics are used in noncompliant patients or nonresponders to oral medication.

Antipsychotic medications include the **"typical"** neuroleptics phenothiazines, thioxanthenes (both similar in structure), butyrophenones, dihydroindolones, dibenzoxazepines, and benzisoxazoles, and the newer **"atypical"** neuroleptics clozapine, risperidone, olanzapine, quetiapine, aripiprazole, ziprasidone, paliperidone, iloperidone, and lurasidone (Table 25–4). Generally, increasing milligram potency of the typical neuroleptics is associated with decreasing anticholinergic and adrenergic side effects and increasing extrapyramidal symptoms (Table 25–5). For example, chlorpromazine has lower potency and more severe anticholinergic and adrenergic side effects. The increased anticholinergic effect of chlorpromazine, however, lowers the risk of extrapyramidal symptoms.

Table 25-4. Commonly used antipsychotics and medications.

Drug	Usual Daily Oral Dose	Usual Daily Maximum Dose ¹	Cost per Unit	Cost for 30 Days Treatment Based on Maximum Dosage ²
Aripiprazole (Abilify)	10-15 mg	30 mg	\$30.95/30 mg	\$928.50
Asenapine (Saphris)	10-20 mg	20 mg	\$11.53/10 mg	\$691.80
Chlorpromazine (Thorazine; others)	100-400 mg	1 g	\$2.90/200 mg	\$435.00
Clozapine (Clozaril)	300-450 mg	900 mg	\$3.33/100 mg	\$899.10
Fluphenazine (Permitil, Prolixin) ³	2-10 mg	60 mg	\$1.15/10 mg	\$207.00
Haloperidol (Haldol)	2-5 mg	60 mg	\$2.76/20 mg	\$248.40
Iloperidone (Fanapt)	12-24 mg	24 mg	\$12.68/12 mg	\$760.80
Loxapine (Loxitane)	20-60 mg	200 mg	\$2.57/50 mg	\$308.40
Lurasidone (Latuda)	40-80 mg	80 mg	\$18.46/80 mg	\$553.80
Olanzapine (Zyprexa)	5-10 mg	15 mg	\$20.97/10 mg	\$927.90
Paliperidone (Invega)	6-12 mg	12 mg	\$14.31/6 mg	\$858.46
Perphenazine (Trilafon) ³	16-32 mg	64 mg	\$1.95/16 mg	\$234.00
Quetiapine (Seroquel)	200-400 mg	800 mg	\$14.37/200 mg	\$1329.00
Risperidone (Risperdal) ⁴	2-6 mg	10 mg	\$7.59/2 mg	\$946.16
Thioridazine (Mellaril)	100-400 mg	600 mg	\$.67/100 mg	\$120.60
Thiothixene (Navane) ³	5-10 mg	80 mg	\$0.65/10 mg	\$156.00
Trifluoperazine (Stelazine)	5-15 mg	60 mg	\$1.58/10 mg	\$284.40
Ziprasidone (Geodon)	40-160 mg	160 mg	\$12.08/80 mg	\$724.80

¹Can be higher in some cases.

²Average wholesale price (AWP, for AB-rated generic when available) for quantity listed. Source: *Red Book Online*, 2012, Thomson Reuters (Healthcare Inc.). AWP may not accurately represent the actual pharmacy cost because wide contractual variations exist among institutions.

³Indicates piperazine structure.

⁴For risperidone, daily doses above 6 mg increase the risk of extrapyramidal syndrome. Risperidone 6 mg is approximately equivalent to haloperidol 20 mg.

The Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study compared “atypical” and “typical” neuroleptic medications. Although it was not definitive, it suggested similar antipsychotic efficacy for both classes and a tendency for the atypicals, particularly olanzapine, to be better tolerated leading to enhanced compliance. It also highlighted lack of patient adherence as a major factor in treatments.

The phenothiazines comprise the bulk of the currently used “typical” neuroleptic medications. The only butyrophenone commonly used in psychiatry is haloperidol, which is different in structure but similar in action and side effects to the piperazine phenothiazines such as fluphenazine, perphenazine, and trifluoperazine. These medications and haloperidol (dopamine [D₂] receptor blockers) have high potency and a paucity of autonomic side effects and act to markedly lower arousal levels. Molindone and loxapine, while less potent, are similar in action, side effects, and safety to the piperazine phenothiazines.

The first “atypical” (novel) antipsychotic drug developed, clozapine, a dibenzodiazepine derivative, has dopamine (D₄) receptor-blocking activity as well as central serotonergic, histaminergic, and α -noradrenergic receptor-blocking activity. It is effective in the treatment of about 30% of psychoses resistant to other neuroleptic medications. Research suggests that clozapine may have specific efficacy in decreasing suicidality in patients with schizophrenia. It is associated with a 1% risk of agranulocytosis, which requires weekly white blood cell count monitoring for the first 6 months followed by monitoring every other week. Weekly monitoring for 1 month after discontinuation of the medication is recommended. Because of an association between clozapine and myocarditis, the drug is contraindicated in patients with severe heart disease. Risperidone is an antipsychotic that blocks some serotonin receptors (5-HT₂) and dopamine receptors (D₂). Risperidone causes fewer extrapyramidal side effects than the typical antipsychotics at doses < 6 mg.

Table 25-5. Relative potency and side effects of antipsychotic medications.

Drug	Chlorpromazine: Drug Potency Ratio	Anticholinergic Effects ¹	Extrapyramidal Effect ¹
Aripiprazole	1:20	1	0
Chlorpromazine	1:1	4	1
Clozapine	1:1	4	—
Fluphenazine	1:50	1	4
Haloperidol	1:50	1	4
lloperidone	1:25	1	1
Loxapine	1:10	2	3
Lurasidone	1:5	1	2
Olanzapine	1:20	1	1
Perphenazine	1:10	2	3
Quetiapine	1:1	1	—
Risperidone	1:50	1	1
Thioridazine	1:1	4	1
Thiothixene	1:20	1	4
Trifluoperazine	1:20	1	4
Ziprasidone	1:1	1	1

¹1, weak effect; 4, strong effect.

It appears to be as effective as haloperidol and possibly as effective as clozapine in treatment-resistant patients without requiring weekly white cell counts. Risperidone-induced hyperprolactinemia, even on low doses, has been reported, and that effect is thought to be more common with risperidone than with other atypical antipsychotics. Risperidone is available in a long-acting injectable preparation.

Olanzapine is a potent blocker of muscarinic, anticholinergic, 5-HT₂, and dopamine D₁, D₂, and D₄ receptors. High doses of olanzapine (12.5–17.5 mg daily) appear to be more effective than lower doses. The drug appears to be more effective than haloperidol in the treatment of negative symptoms, such as withdrawal, psychomotor retardation, and poor interpersonal relationships. It is available in an orally disintegrating form for patients who are unable to tolerate standard oral dosing and in an injectable form for the management of acute agitation associated with schizophrenia and bipolar disorder. Olanzapine tends to result in elevations of serum alanine aminotransferase more commonly than does haloperidol. Olanzapine is associated with a much lower incidence of dystonic reaction than haloperidol and is perhaps less likely to induce tardive dyskinesia. Its most common side effects include somnolence, agitation, nervousness, headache, insomnia, dizziness, and significant weight gain. Multiple case reports have linked olanzapine and clozapine to new-onset type 2 diabetes, and all atypical medications should be monitored

for this adverse effect as well. The manufacturer has alerted physicians to an association between olanzapine and a significantly higher risk of stroke and death in elderly patients, which has also been noted with other atypical and typical agents (see below).

Quetiapine is a neuroleptic with greater 5-HT₂ relative to D₂ receptor blockade as well as a relatively high affinity for α_1 - and α_2 -adrenergic receptors. It appears to be as efficacious as haloperidol in treating positive and negative symptoms of schizophrenia, with less extrapyramidal side effects even at high doses. More common side effects include somnolence, dizziness, and postural hypotension. Because of an association with lens changes seen in patients on long-term treatment, an eye examination to detect cataract formation is recommended at initiation of treatment and then at 6-month intervals during treatment. Quetiapine may cause QT prolongation particularly when prescribed with other medications that effect the QT interval and in overdose.

Ziprasidone has both anti-dopamine receptor and antiserotonin receptor effects, with good efficacy for both positive and negative symptoms of schizophrenia. In one study of 146 treatment-resistant schizophrenic patients, ziprasidone was as effective as clozapine. Ziprasidone is not associated with significant weight gain, hyperlipidemia, or new-onset diabetes and offers a good alternative for some patients. It has been implicated in QTc interval delay of > 500 ms in some patients, although in several cases of

overdose there were no incidents of torsades de pointes or sudden death. Patients taking ziprasidone should be screened for cardiac risk factors. A pretreatment ECG is indicated for patients at risk for cardiac sequelae (including patients taking other medications that might prolong the QTc interval).

Aripiprazole is the first neuroleptic that is a dopamine stabilizer. A partial agonist at the dopamine D₂ and serotonin 5-HT₁ receptors and an antagonist at 5-HT₂ receptors, it is effective against positive and negative symptoms of schizophrenia. It functions as an antagonist or agonist, depending on the dopaminergic activity at the dopamine receptors. This may help decrease side effects. More activating than sedating, aripiprazole is thought to impose a low risk of extrapyramidal symptoms, weight gain, hyperprolactinemia, and delayed QT interval. Aripiprazole has been approved as an augmentation agent for treatment-resistant depression even when psychosis is not present. Asenapine, approved for the treatment of schizophrenia and bipolar disorder (mixed or manic state), appears to be particularly helpful in treating negative symptoms of schizophrenia. Paliperidone, the active metabolite of risperidone, is available as a capsule and a monthly injection. It has the advantage of low associations with diabetes mellitus, weight gain, and dyslipidemia. Both asenapine and paliperidone increase the risk of QT interval prolongation and should be avoided in patients with risk factors for this ECG finding. Asenapine can cause hyperprolactinemia and weight gain. Asenapine carries a warning of possible serious allergic reaction, even after the first dose including anaphylaxis, low blood pressure, and difficulty breathing. Patients should be appropriately cautioned. Iloperidone has low incidence of extrapyramidal side effects that is similar to the other atypical agents but requires careful initial titration due to the risk of orthostatic hypotension and possibility of lengthening the QT interval. When coadministered with paroxetine or clarithromycin, the dose of iloperidone must be halved because of decreased hepatic metabolism by the cytochrome P450 CYP2D6 and CYP3A4 isozymes. Lurasidone, approved by the FDA in 2011 has been shown to be effective in treating acute decompensation in patients with chronic schizophrenia. This medication is distinguished by low incidence of weight gain, increased lipids or prolonged QT interval, but clinicians should be mindful of side effects of akathisia, elevated prolactin and in higher doses, somnolence. None of the antipsychotics produce true physical dependency. All decrease adrenergic responses. Despite higher costs, atypical neuroleptics are often considered preferable to traditional antipsychotics because they are thought to be associated with reduced extrapyramidal symptoms and a lesser risk of tardive dyskinesia.

► Clinical Indications

The antipsychotics are used to treat all forms of the schizophrenias as well as psychotic ideation in organic brain psychoses, delirium and dementia, drug-induced psychoses, psychotic depression, and mania. They are also

effective in Tourette disorder. They quickly lower the arousal (activity) level and, perhaps indirectly, gradually improve socialization and thinking. The improvement rate is about 80%. Patients whose behavioral symptoms worsen with use of antipsychotic medications may have an undiagnosed organic condition such as anticholinergic toxicity.

Symptoms that are ameliorated by these medications include hyperactivity, hostility, aggression, delusions, hallucinations, irritability, and poor sleep. Individuals with acute psychosis and good premorbid function respond quite well. The most common cause of failure in the treatment of acute psychosis is inadequate dosage, and the most common cause of relapse is noncompliance.

Although typical antipsychotics are efficacious in the treatment of positive symptoms of schizophrenia, such as hallucinations and delusions, atypical antipsychotics are thought to have efficacy in reducing both positive and negative symptoms. Antidepressant medications may be used in conjunction with neuroleptics if significant depression is present. Resistant cases may require concomitant use of lithium, carbamazepine, or valproic acid. The addition of a benzodiazepine drug to the neuroleptic regimen may prove helpful in treating the agitated or catatonic psychotic patient who has not responded to neuroleptics alone—lorazepam, 1–2 mg orally, can produce a rapid resolution of catatonic symptoms and may allow maintenance with a lower neuroleptic dose. Electroconvulsive therapy (ECT) has also been effective in treating catatonia.

► Dosage Forms & Patterns

The dosage range is quite broad. For example, risperidone, 0.25–1 mg orally at bedtime, may be sufficient for the elderly person with mild dementia with psychosis (especially in view of the increased risk of stroke and death in the elderly), whereas up to 6 mg/d may be used in a young patient with acute schizophrenia. For quick response, an atypical antipsychotic may be started in combination with a benzodiazepine (eg, risperidone oral solution, 2 mg, or olanzapine, 10 mg orally, and lorazepam, 2 mg orally, every 2–4 hours as needed). In an acutely distressed, psychotic patient one might use haloperidol, 10 mg intramuscularly, which is absorbed rapidly and achieves an initial tenfold plasma level advantage over equal oral doses. Psychomotor agitation, racing thoughts, and general arousal are quickly reduced. The dose can be repeated every 3–4 hours; when the patient is less symptomatic, oral doses can replace parenteral administration in most cases. In the elderly, both atypical (eg, risperidone 0.25 mg–0.5 mg daily or olanzapine 1.25 mg daily) and typical (eg haloperidol 0.5 mg daily or perphenazine 2 mg daily) antipsychotics, often used effectively in small doses for behavioral control, have been linked to premature death in some cases.

Absorption of oral medications may be increased or decreased by concomitant administration of other medications (eg, antacids tend to decrease the absorption of

antidepressants). Previous gastrointestinal surgery may alter pH, motility, and surface areas available for drug absorption. There are racial differences in metabolizing the neuroleptic medications—eg, many Asians require only about half the usual dosage. Bioavailability is influenced by other factors such as smoking or hepatic microsomal enzyme stimulation with alcohol or barbiturates and enzyme-altering medications such as carbamazepine or methylphenidate. Neuroleptic plasma drug level determinations are not currently of major clinical assistance.

Divided daily doses are not necessary after a maintenance dose has been established, and most patients can then be maintained on a single daily dose, usually taken at bedtime. This is particularly appropriate in a case where the sedative effect of the drug is desired for nighttime sleep, and undesirable sedative effects can be avoided during the day. Risperidone is an exception, being given twice daily. First-episode patients especially should be tapered off medications after about 6 months of stability and carefully monitored; their rate of relapse is lower than that of multiple-episode patients.

Psychiatric patients—particularly paranoid individuals—often neglect to take their medication. In these cases and in nonresponders to oral medication, the enanthate and decanoate (the latter is slightly longer-lasting and has fewer extrapyramidal side effects) forms of fluphenazine or the decanoate form of haloperidol may be given by deep subcutaneous injection or intramuscularly to achieve an effect that will usually last 7–28 days. A patient who cannot be depended on to take oral medication (or who overdoses on minimal provocation) will generally agree to come to the clinician's office for a "shot." The usual dose of the fluphenazine long-acting preparations is 25 mg every 2 weeks. Dosage and frequency of administration vary from about 100 mg weekly to 12.5 mg monthly. Use the smallest effective amount as infrequently as possible. A monthly injection of 25 mg of fluphenazine decanoate is equivalent to about 15–20 mg of oral fluphenazine daily. Risperidone is the first atypical neuroleptic available in a long-acting injectable form (25–50 mg intramuscularly every 2 weeks). Concomitant use of a benzodiazepine (eg, lorazepam, 2 mg orally twice daily) may permit reduction of the required dosage of oral or parenteral antipsychotic drug.

Intravenous haloperidol, the neuroleptic most commonly used by this route, is often used in critical care units in the management of agitated, delirious patients. Intravenous haloperidol should be given no faster than 1 mg/min to reduce cardiovascular side effects, such as torsades de pointes. Current practice indicates that ECG monitoring should be used whenever haloperidol is being administered intravenously.

► Side Effects

For both typical and atypical neuroleptic agents, a range of side effects has been reported. The most common anticholinergic side effects include **dry mouth** (which can lead to ingestion of caloric liquids and weight gain or hyponatremia),

blurred near vision, urinary retention (particularly in elderly men with enlarged prostates), **delayed gastric emptying, esophageal reflux, ileus, delirium**, and precipitation of **acute glaucoma** in patients with narrow anterior chamber angles. Other autonomic effects include **orthostatic hypotension** and **sexual dysfunction**—problems in achieving erection, ejaculation (including retrograde ejaculation), and orgasm in men (approximately 50% of cases) and women (approximately 30%). Delay in achieving orgasm is often a factor in medication noncompliance. **Electrocardiographic changes** occur frequently, but clinically significant arrhythmias are much less common. Elderly patients and those with preexisting cardiac disease are at greater risk. The most frequently seen electrocardiographic changes include diminution of the T wave amplitude, appearance of prominent U waves, depression of the ST segment, and prolongation of the QT interval. Thioridazine has been given an FDA warning for dose-related QTc delay and risk of fatal cardiac arrhythmias. As noted above, ziprasidone can produce QTc prolongation. An ECG prior to treatment in some patients may be indicated. In some critical care patients, torsades de pointes has been associated with the use of high-dose intravenous haloperidol (usually > 30 mg/24 h).

Associations have been suggested between the atypical neuroleptics and **new-onset diabetes, hyperlipidemia, QTc prolongation**, and **weight gain** (Table 25–6). The FDA has particularly noted the risk of hyperglycemia and new-onset diabetes in this class of medication that is not related to weight gain. The risk of diabetes mellitus is increased in patients taking clozapine and olanzapine. Monitoring of weight, fasting blood sugar and lipids prior to initiation of treatment and at regular intervals thereafter is an important part of medication monitoring. Early research suggests that the addition of metformin to olanzapine may improve drug-induced weight gain in patients with drug-naïve, first-episode schizophrenia. Neuroleptic medications in general may have **metabolic** and **endocrine effects**, including weight gain, hyperglycemia, impaired temperature regulation in hot weather, and water intoxication, that may be due to inappropriate ADH secretion. Lactation and menstrual irregularities are common (antipsychotic medications should be avoided, if possible, in breast cancer patients because of potential trophic effects of elevated prolactin levels on the breast). Both antipsychotic and antidepressant medications inhibit sperm motility. **Bone marrow depression** and **cholestatic jaundice** occur rarely; these are hypersensitivity reactions, and they usually appear in the first 2 months of treatment. They subside on discontinuance of the drug. There is cross-sensitivity among all of the phenothiazines, and a drug from a different group should be used when allergic reactions occur.

Clozapine is associated with a 1.6% risk of **agranulocytosis** (higher in persons of Ashkenazi Jewish ancestry), and its use must be strictly monitored with weekly blood counts during the first 6 months of treatment, with monitoring every other week thereafter. Discontinuation of the medication requires weekly monitoring of the white blood cell count for 1 month. Clozapine has been associated with

Table 25-6. Adverse factors associated with atypical antipsychotic medications.

	Weight Gain	Hyperlipidemia	New-Onset Diabetes Mellitus	QTc Prolongation ¹
Asenapine	+/-	+/-	+/-	+++
Aripiprazole	+/-	-	-	++
Clozapine	+++	+++	+++	+/-
Lurasidone	-	-	-	-
Olanzapine	+++	+++	+++	+/-
Paliperidone	+	+/-	+/-	+++
Quetiapine	++	++	++	+++
Risperidone	++	++	++	+
Ziprasidone	+/-	-	-	+++

¹QTc prolongation is a side effect of many medications and suggests a possible risk for arrhythmia. Prescriber's Letter 2011; 18(12):271207.

fatal myocarditis and is contraindicated in patients with severe heart disease. In addition, clozapine lowers the seizure threshold and has many side effects, including sedation, hypotension, increased liver enzyme levels, hypersalivation, respiratory arrest, weight gain, and changes in both the ECG and the electroencephalogram.

Photosensitivity, retinopathy, and hyperpigmentation are associated with use of fairly high dosages of chlorpromazine and thioridazine. The appearance of particulate melanin deposits in the lens of the eye is related to the total dose given, and patients on long-term medication should have periodic eye examinations. Teratogenicity has not been causally related to these medications, but prudence is indicated particularly in the first trimester of pregnancy. The seizure threshold is lowered, but it is safe to use these medications in epileptics who take anticonvulsants.

The **neuroleptic malignant syndrome (NMS)** is a catatonia-like state manifested by extrapyramidal signs, blood pressure changes, altered consciousness, and hyperpyrexia; it is an uncommon but serious complication of neuroleptic treatment. Muscle rigidity, involuntary movements, confusion, dysarthria, and dysphagia are accompanied by pallor, cardiovascular instability, fever, pulmonary congestion, and diaphoresis and may result in stupor, coma, and death. The cause may be related to a number of factors, including poor dosage control of neuroleptic medication, affective illness, decreased serum iron, dehydration, and increased sensitivity of dopamine receptor sites. Lithium in combination with a neuroleptic drug may increase vulnerability, which is already increased in patients with an affective disorder. In most cases, the symptoms develop within the first 2 weeks of antipsychotic drug treatment. The syndrome may occur with small doses of the medications. Intramuscular administration is a risk factor. Elevated creatine kinase and leukocytosis with a shift to the left are present early in about half of cases. Treatment includes controlling fever and providing fluid support. Dopamine agonists such as bromocriptine,

2.5–10 mg orally three times a day, and amantadine, 100–200 mg orally twice a day, have also been useful. Dantrolene, 50 mg intravenously as needed, is used to alleviate rigidity (do not exceed 10 mg/kg/d due to hepatotoxicity risk). There is ongoing controversy about the efficacy of these three agents as well as the use of calcium channel blockers and benzodiazepines. ECT has been used effectively in resistant cases. Clozapine has been used with relative safety and fair success as an antipsychotic drug for patients who have had NMS. The syndrome must be differentiated from acute lethal catatonia, malignant hyperthermia, neurotoxic syndromes (including AIDS), and a variety of other conditions such as viral encephalitis, Wilson disease, central anticholinergic syndrome, and hypertonic states (eg, tetany, strychnine poisoning).

Akathisia is the most common (about 20%) extrapyramidal symptom. It usually occurs early in treatment (but may persist after neuroleptics are discontinued) and is frequently mistaken for anxiety or exacerbation of psychosis. It is characterized by a subjective desire to be in constant motion followed by an inability to sit or stand still and consequent pacing. It may induce suicidality or feelings of fright, rage, terror, or sexual torment. Insomnia is often present. It is crucial to educate patients in advance about these potential side effects so that the patients do not misinterpret them as signs of increased illness. In all cases, reevaluate the dosage requirement or the type of neuroleptic drug. One should inquire also about cigarette smoking, which in women has been associated with an increased incidence of akathisia. Antiparkinsonism medications (such as trihexyphenidyl, 2–5 mg orally three times daily) may be helpful, but first-line treatment often includes a benzodiazepine (such as clonazepam 0.5–1 mg orally three times daily). In resistant cases, symptoms may be alleviated by propranolol, 30–80 mg/d orally, diazepam, 5 mg orally three times daily, or amantadine, 100 mg orally three times daily.

Acute dystonias usually occur early, although a late (tardive) occurrence is reported in patients (mostly men

after several years of therapy) who previously had early severe dystonic reactions and a mood disorder (see below). Younger patients are at higher risk for acute dystonias. The most common signs are bizarre muscle spasms of the head, neck, and tongue. Frequently present are torticollis, oculogyric crises, swallowing or chewing difficulties, and masseter spasms. Laryngospasm is particularly dangerous. Back, arm, or leg muscle spasms are occasionally reported. Diphenhydramine, 50 mg intramuscularly, is effective for the acute crisis; one should then give benztropine mesylate, 2 mg orally twice daily, for several weeks, and then discontinue gradually, since few of the extrapyramidal symptoms require long-term use of the antiparkinsonism medications (all of which are about equally efficacious—though trihexyphenidyl tends to be mildly stimulating and benztropine mildly sedating).

Drug-induced parkinsonism is indistinguishable from idiopathic parkinsonism, but it is reversible, occurs later in treatment than the preceding extrapyramidal symptoms, and in some cases appears after neuroleptic withdrawal. The condition includes the typical signs of apathy and reduction of facial and arm movements (akinesia, which can mimic depression), festinating gait, rigidity, loss of postural reflexes, and pill-rolling tremor. AIDS patients seem particularly vulnerable to extrapyramidal side effects. High-potency neuroleptics often require antiparkinsonism medications (see Table 24–6). The neuroleptic dosage should be reduced, and immediate relief can be achieved with antiparkinsonism medications in the same dosages as above. After 4–6 weeks, these antiparkinsonism medications can often be discontinued with no recurrent symptoms. In any of the extrapyramidal symptoms, amantadine, 100–400 mg orally daily, may be used instead of the antiparkinsonism medications. Neuroleptic-induced catatonia is similar to catatonic stupor with rigidity, drooling, urinary incontinence, and cogwheeling. It usually responds slowly to withdrawal of the offending medication and use of antiparkinsonism agents.

Tardive dyskinesia is a syndrome of abnormal involuntary stereotyped movements of the face, mouth, tongue, trunk, and limbs that may occur after months or (usually) years of treatment with neuroleptic agents. The syndrome affects 20–35% of patients who have undergone long-term neuroleptic therapy. Predisposing factors include older age, many years of treatment, cigarette smoking, and diabetes mellitus. Pineal calcification is higher in this condition by a margin of 3:1. There are no clearcut differences among the antipsychotic medications in the development of tardive dyskinesia. (Although the atypical antipsychotics appear to offer a lower risk of tardive dyskinesia, long-term effects have not been investigated.) Early manifestations of tardive dyskinesia include fine worm-like movements of the tongue at rest, difficulty in sticking out the tongue, facial tics, increased blink frequency, or jaw movements of recent onset. Later manifestations may include bucco-linguo-masticatory movements, lip smacking, chewing motions, mouth opening and closing, disturbed gag reflex, puffing of the cheeks, disrupted speech, respiratory distress, or choreoathetoid movements of the

extremities (the last being more prevalent in younger patients). The symptoms do not necessarily worsen and in rare cases may lessen even though neuroleptic medications are continued. The dyskinesias do not occur during sleep and can be voluntarily suppressed for short periods. Stress and movements in other parts of the body will often aggravate the condition.

Early signs of dyskinesia must be differentiated from those reversible signs produced by ill-fitting dentures or nonneuroleptic medications such as levodopa, TCAs, antiparkinsonism agents, anticonvulsants, and antihistamines. Other neurologic conditions such as Huntington chorea can be differentiated by history and examination.

The emphasis should be on prevention of side effects. Use the least amount of neuroleptic drug necessary to mute the psychotic symptoms, and use atypical antipsychotics as first line agents. Detect early manifestations of dyskinesias. When these occur, stop anticholinergic medications and gradually discontinue neuroleptic medications, if clinically feasible. Weight loss and cachexia sometimes appear on withdrawal of neuroleptics. In an indeterminate number of cases, the dyskinesias will remit. Keep the patient off the medications until reemergent psychotic symptoms dictate their resumption, at which point they are restarted in low doses and gradually increased until there is clinical improvement. If neuroleptic medications are restarted, clozapine and olanzapine appear to offer less risk of recurrence. The use of adjunctive agents such as benzodiazepines or lithium may help directly or indirectly by allowing control of psychotic symptoms with a low dosage of neuroleptics. If the dyskinesic syndrome recurs and it is necessary to continue neuroleptic medications to control psychotic symptoms, informed consent should be obtained. Benzodiazepines, buspirone (in doses of 15–60 mg/d orally), phosphatidylcholine, clonidine, calcium channel blockers, vitamin E, omega-3 fatty acids, and propranolol all have had limited usefulness in treating the dyskinetic side effects.

B. Social

Environmental considerations are most important in the individual with a chronic illness, who usually has a history of repeated hospitalizations, a continued low level of functioning, and symptoms that never completely remit. Family rejection and work failure are common. In these cases, board and care homes staffed by personnel experienced in caring for psychiatric patients are most important. There is frequently an inverse relationship between stability of the living situation and the amounts of required antipsychotic medications, since the most salutary environment is one that reduces stimuli. Nonresidential self-help groups such as Recovery, Inc., should be utilized whenever possible. They provide a setting for sharing, learning, and mutual support and are frequently the only social involvement with which this type of patient is comfortable. Vocational rehabilitation and work agencies (eg, Goodwill Industries, Inc.) provide assessment, training, and job opportunities at a level commensurate with the person's clinical condition.

C. Psychological

The need for psychotherapy varies markedly depending on the patient's current status and history. In a person with a single psychotic episode and a previously good level of adjustment, supportive psychotherapy may help the patient reintegrate the experience, gain some insight into antecedent problems, and become a more self-observant individual who can recognize early signs of stress. Insight-oriented psychotherapy is often counterproductive in this type of disorder. Research suggests that cognitive behavioral therapy—in conjunction with medication management—may have some efficacy in the treatment of symptoms of schizophrenia. Cognitive behavioral therapy for schizophrenia involves helping the individual challenge psychotic thinking and alters response to hallucinations. Similarly, a form of psychotherapy called acceptance and commitment therapy has shown value in helping prevent hospitalizations in schizophrenia. Cognitive remediation therapy is another approach to treatment that shows promise in helping schizophrenics become better able to focus their disorganized thinking. Family therapy may also help alleviate the patient's stress and to assist relatives in coping with the patient.

D. Behavioral

Behavioral techniques (see above) are most frequently used in therapeutic settings such as day treatment centers, but there is no reason why they cannot be incorporated into family situations or any therapeutic setting. Many behavioral techniques (eg, positive reinforcement—whether it be a word of praise or an approving nod—after some positive behavior), can be a powerful instrument for helping a person learn behaviors that will facilitate social acceptance. Music from portable digital players with earphones is one of many ways to divert the patient's attention from auditory hallucinations.

► Prognosis

In any psychosis, in the large majority of patients the prognosis is excellent for alleviation of positive symptoms such as hallucinations or delusions treated with medication. Negative symptoms such as diminished affect and sociability are much more difficult to treat but appear responsive to atypical antipsychotics. Unavailability of structured work situations and lack of family therapy are two other reasons why the prognosis is so guarded in such a large percentage of schizophrenic patients. Psychosis connected with a history of serious drug abuse has a guarded prognosis because of the central nervous system damage, usually from the medications themselves and associated medical illnesses.

Ellinger LK et al. Efficacy of metformin and topiramate in prevention and treatment of second-generation antipsychotic-induced weight gain. *Ann Pharmacother*. 2010 Apr;44(4):668–79. [PMID: 20233913]

Hasnain M et al. Metabolic syndrome associated with schizophrenia and atypical antipsychotics. *Curr Diab Rep*. 2010 Jun;10(3):209–16. [PMID: 20425584]

Ray WA et al. Atypical antipsychotic drugs and the risk of sudden cardiac death. *N Engl J Med*. 2009 Jan 15;360(3):225–35. [PMID: 19144938]

MOOD DISORDERS (Depression & Mania)

ESSENTIALS OF DIAGNOSIS

Present in most depressions:

- ▶ Mood varies from mild sadness to intense feelings of guilt, worthlessness, and hopelessness.
- ▶ Difficulty in thinking, including inability to concentrate, ruminations, and lack of decisiveness.
- ▶ Loss of interest, with diminished involvement in work and recreation.
- ▶ Somatic complaints such as headache; disrupted, lessened, or excessive sleep; loss of energy; change in appetite; decreased sexual drive.
- ▶ Anxiety.

Present in some severe depressions:

- ▶ Psychomotor retardation or agitation.
- ▶ Delusions of a hypochondriacal or persecutory nature.
- ▶ Withdrawal from activities.
- ▶ Physical symptoms of major severity, eg, anorexia, insomnia, reduced sexual drive, weight loss, and various somatic complaints.
- ▶ Suicidal ideation.

Present in mania:

- ▶ Mood ranging from euphoria to irritability.
- ▶ Sleep disruption.
- ▶ Hyperactivity.
- ▶ Racing thoughts.
- ▶ Grandiosity.
- ▶ Variable psychotic symptoms.

► General Considerations

Depression is extremely common, with up to 30% of primary care patients having depressive symptoms. Depression may be the final expression of (1) genetic factors (neurotransmitter dysfunction), (2) developmental problems (personality problems, childhood events), or (3) psychosocial stresses (divorce, unemployment). It frequently presents in the form of somatic complaints with negative medical workups. Although sadness and grief are normal responses to loss, depression is not. Patients experiencing normal grief tend to produce sympathy and sadness in the clinician caregiver; depression often produces frustration and irritation in the clinician. Grief is usually accompanied by intact self-esteem, whereas depression is marked by a sense of guilt and worthlessness.

Mania is often combined with depression and may occur alone, together with depression in a mixed episode, or in cyclic fashion with depression.

► Clinical Findings

In general, there are four major types of depressions, with similar symptoms in each group.

A. Adjustment Disorder with Depressed Mood

Depression may occur in reaction to some identifiable stressor or adverse life situation, usually loss of a person by death (grief reaction), divorce, etc; financial reversal (crisis); or loss of an established role, such as being needed. Anger is frequently associated with the loss, and this in turn often produces a feeling of guilt. The disorder occurs within 3 months of the stressor and causes significant impairment in social or occupational functioning. The symptoms range from mild sadness, anxiety, irritability, worry, lack of concentration, discouragement, and somatic complaints to the more severe symptoms of frank depression. When the full criteria for major depressive disorder are present (see below), then that diagnosis should be made and treatment instituted even when there is a known stressor. The presence of a stressor is not the determining diagnostic driver, it is the resultant syndromal complex. One should not neglect treatment for major depression simply because it may appear to be an understandable reaction to a particular stress or difficulty.

B. Depressive Disorders

The subclassifications include major depressive disorder and dysthymia.

1. Major depressive disorder—A major depressive disorder (eg, “endogenous” unipolar disorder, melancholia) consists of at least one episode of serious mood depression that occurs at any time of life. Many consider a physiologic or metabolic aberration to be causative. Complaints vary widely but most frequently include a loss of interest and pleasure (anhedonia), withdrawal from activities, and feelings of guilt. Also included are inability to concentrate, some cognitive dysfunction, anxiety, chronic fatigue, feelings of worthlessness, somatic complaints (unexplained somatic complaints frequently indicate depression), loss of sexual drive, and thoughts of death. Diurnal variation with improvement as the day progresses is common. Vegetative signs that frequently occur are insomnia, anorexia with weight loss, and constipation. Occasionally, severe agitation and psychotic ideation (paranoid thinking, somatic delusions) are present. These symptoms are more common in depressed persons who are older than 50 years. Paranoid symptoms may range from general suspiciousness to ideas of reference with delusions. The somatic delusions frequently revolve around feelings of impending annihilation or hypochondriacal beliefs (eg, that the body is rotting away with cancer). Hallucinations are uncommon.

Subcategories include **major depression with atypical features** characterized by hypersomnia, overeating, lethargy, and rejection sensitivity. **Major depression with a seasonal onset (seasonal affective disorder)** is a dysfunction of circadian rhythms that occurs more commonly in the winter months and is believed to be due to decreased

exposure to full-spectrum light. Common symptoms include carbohydrate craving, lethargy, hyperphagia, and hypersomnia. **Major depression with postpartum onset** usually occurs 2 weeks to 6 months postpartum.

Most women (up to 80%) experience some mild let-down of mood in the postpartum period. For some of these (10–15%), the symptoms are more severe and similar to those usually seen in serious depression, with an increased emphasis on concerns related to the baby (obsessive thoughts about harming it or inability to care for it). When psychotic symptoms occur, there is frequently associated sleep deprivation, volatility of behavior, and manic-like symptoms. Postpartum psychosis is much less common (< 2%), often occurs within the first 2 weeks, and requires early and aggressive management. Biologic vulnerability with hormonal changes and psychosocial stressors all play a role. The chances of a second episode are about 25% and may be reduced with prophylactic treatment.

2. Dysthymia—Dysthymia is a chronic depressive disturbance. Sadness, loss of interest, and withdrawal from activities over a period of 2 or more years with a relatively persistent course is necessary for this diagnosis. Generally, the symptoms are milder but longer-lasting than those in a major depressive episode.

3. Premenstrual dysphoric disorder—Depressive symptoms occur during the late luteal phase (last 2 weeks) of the menstrual cycle. (See also chapter 18)

C. Bipolar Disorders

Bipolar disorders consist of episodic mood shifts into mania, major depression, hypomania, and mixed mood states. The ability of bipolar disorder to mimic aspects of many other coincident major mental health disorders and a high comorbidity with substance abuse can make the initial diagnosis of bipolar disorder difficult. Bipolar I is diagnosed when an individual has both depressive and manic episodes. For individuals who experience depressive and hypomanic episodes without frank mania, the diagnosis would be Bipolar II. Individuals who become manic when treated with an antidepressant for a depressive episode are often regarded as Bipolar III.

1. Mania—A manic episode is a mood change characterized by elation with hyperactivity, overinvolvement in life activities, increased irritability, flight of ideas, easy distractibility, and little need for sleep. The overenthusiastic quality of the mood and the expansive behavior initially attract others, but the irritability, mood lability with swings into depression, aggressive behavior, and grandiosity usually lead to marked interpersonal difficulties. Activities may occur that are later regretted, eg, excessive spending, resignation from a job, a hasty marriage, sexual acting out, and exhibitionistic behavior, with alienation of friends and family. Atypical manic episodes can include gross delusions, paranoid ideation of severe proportions, and auditory hallucinations usually related to some grandiose perception. The episodes begin abruptly (sometimes precipitated by life stresses) and may last from several days to months. Spring and summer tend to be the peak periods.

Generally, the manic episodes are of shorter duration than the depressive episodes. In almost all cases, the manic episode is part of a broader bipolar (manic-depressive) disorder. Patients with four or more discrete episodes of a mood disturbance in 1 year are called “rapid cyclers.” (Substance abuse, particularly cocaine, can mimic rapid cycling.) These patients have a higher incidence of hypothyroidism. Manic patients differ from patients with schizophrenia in that the former use more effective interpersonal maneuvers, are more sensitive to the social maneuvers of others, and are more able to utilize weakness and vulnerability in others to their own advantage. Creativity has been positively correlated with mood disorders, but the best work done is between episodes of mania and depression.

2. Cyclothymic disorders—These are chronic mood disturbances with episodes of depression and hypomania. The symptoms must have at least a 2-year duration and are milder than those that occur in depressive or manic episodes. Occasionally, the symptoms will escalate into a full-blown manic or depressive episode, in which case reclassification as bipolar I would be warranted.

D. Mood Disorders Secondary to Illness and Medications

Any illness, severe or mild, can cause significant depression. Conditions such as rheumatoid arthritis, multiple sclerosis, stroke, and chronic heart disease are particularly likely to be associated with depression, as are other chronic illnesses. Depression is common in cancer, as well, with a particularly high degree of comorbidity in pancreatic cancer. Hormonal variations clearly play a role in some depressions. Varying degrees of depression occur at various times in schizophrenic disorders, central nervous system disease, and organic mental states. **Alcohol dependency** frequently coexists with serious depression.

The classic model of **drug-induced depression** occurs with the use of reserpine, both in clinical settings and as a pharmacologic probe in research settings. Corticosteroids and oral contraceptives are commonly associated with affective changes. Antihypertensive medications such as methyl dopa, guanethidine, and clonidine have been associated with the development of depressive syndromes, as have digitalis and antiparkinsonism medications (eg, levodopa). Interferons are strongly associated with depressed mood as a side effect; consultation with a psychiatrist prior to prescribing these agents is indicated in cases where there is a history of depression. It is unusual for β -blockers to produce depression when given for short periods, such as in the treatment of performance anxiety. Sustained use of β -blockers for medical conditions such as hypertension may produce depression in some patients, although most individuals do not suffer this adverse effect and the data supporting this association remain inconclusive. Infrequently, disulfiram and anticholinesterase medications may be associated with symptoms of depression. All stimulant use results in a depressive syndrome when the drug is withdrawn. Alcohol, sedatives, opiates, and most of the psychedelic drugs are depressants and, paradoxically, are often used in self-treatment of depression.

► Differential Diagnosis

Since depression may be a part of any illness—either reactively or as a secondary symptom—careful attention must be given to personal life adjustment problems and the role of medications (eg, reserpine, corticosteroids, levodopa). Schizophrenia, partial complex seizures, organic brain syndromes, panic disorders, and anxiety disorders must be differentiated. Subtle thyroid dysfunction must be ruled out.

► Complications

The most important complication is **suicide**, which often includes some elements of aggression. Suicide rates in the general population vary from 9 per 100,000 in Spain to 20 per 100,000 in the United States to 58 per 100,000 in Hungary. In individuals with depression, the lifetime risk rises to 10–15%. In patients with bipolar disorder, the risk is higher, with up to 20% of individuals dying of suicide. Men tend toward successful suicide, particularly in older age groups, whereas women make more attempts with lower mortality rates. An increased suicide rate is being observed in the younger population, ages 15–35. Patients with cancer, respiratory illnesses, AIDS, and those being maintained on hemodialysis have higher suicide rates. Alcohol use is a significant factor in many suicide attempts.

There are several groups of people who make suicide attempts. One group includes those individuals with acute situational problems. These individuals may be acutely distressed by a recent breakup in a relationship or another type of disappointment. This group also includes those who may not be diagnosed as having depression but who are overwhelmed by a stressful situation often with an aspect of public humiliation (eg, the man charged with child molestation who hangs himself in his cell). A suicide attempt in such cases may be an impulsive or aggressive act not associated with significant depression. In such cases, a suicide attempt is clearly a stratagem for controlling or hurting others or an attempted escape.

Another high-risk group includes individuals with severe depression. Severe depression may be due to conditions such as medical illness (eg, AIDS, whose victims have a suicide rate over 20 times that of the general population) or comorbid psychiatric disorders (eg, panic disorders). Anxiety, panic, and fear are major findings in suicidal behavior. A patient may seem to make a dramatic improvement, but the lifting of depression may be due to the patient's decision to commit suicide. Another high-risk group are individuals with psychotic illness who tend not to verbalize their concerns, are unpredictable, and are often successful in their suicide attempt, although they make up only a small percentage of the total.

Finally, suicide is 10 times more prevalent in patients with schizophrenia than in the general population, and jumping from bridges is a more common means of attempted suicide by schizophrenics than by others. In one study of 100 “jumpers,” 47% had schizophrenia.

The immediate goal of psychiatric evaluation is to assess the current suicidal risk and the need for hospitalization versus outpatient management. Perhaps the one most useful question is to ask the person how many hours per

day he or she thinks about suicide. If it is more than 1 hour, the individual is at high risk. Further assessing the risk by inquiring about intent, plans, means, and suicide-inhibiting factors (eg, strong ties to children or the church) is essential. The intent is less likely to be truly suicidal, for example, if small amounts of poison or medication were ingested or scratching of wrists was superficial, if the act was performed in the vicinity of others or with early notification of others, or if the attempt was arranged so that early detection would be anticipated. Alcohol, hopelessness, delusional thoughts, and complete or nearly complete loss of interest in life or ability to experience pleasure are all positively correlated with suicide attempts. Other risk factors are previous attempts, a family history of suicide, medical or psychiatric illness (eg, anxiety, depression, psychosis), male sex, older age, contemplation of violent methods, a humiliating social stressor, and drug use (including long-term sedative or alcohol use), which contributes to impulsiveness or mood swings. Successful treatment of the patient at risk for suicide cannot be achieved if the patient continues to abuse drugs.

The patient's current mood status is best evaluated by direct evaluation of plans and concerns about the future, personal reactions to the attempt, and thoughts about the reactions of others. Measurement of mood is often facilitated by using a standardized instrument such as the Hamilton or Montgomery-Asberg clinician-administered rating scales or the self-administered Patient Health Questionnaire-9. Such measures allow for initial assessment as well as ongoing treatment tracking. The patient's immediate resources should also be assessed—people who can be significantly involved (most important), family support, job situation, financial resources, etc. Suicide risk can be specifically assessed using an instrument such as the Columbia-Suicide Severity Risk Scale.

If hospitalization is not indicated (eg, gestures, impulsive attempts; see above), the clinician must formulate and institute a treatment plan or make an adequate referral. (The National Suicide Prevention Lifeline, 1-800-273-8255, may be of assistance.) Medication should be dispensed in small amounts to at-risk patients. Although TCAs and SSRIs are associated with an equal incidence of suicide attempts, the risk of successful suicide is higher with TCA overdose. Guns and medications should be removed from the patient's household. Driving should be interdicted until the patient improves. The problem is often worsened by the long-term complications of the suicide attempt, eg, brain damage due to hypoxia, peripheral neuropathies caused by staying for long periods in one position causing nerve compressions, and medical or surgical problems such as esophageal strictures and tendon dysfunctions.

The reasons for **self-mutilation**, most commonly wrist cutting (but also autocastration, autoamputation, and autoenucleation, which are associated with psychoses), may be very different from the reasons for a suicide attempt. The initial treatment plan, however, should presume suicidal ideation, and conservative treatment should be initiated.

Sleep disturbances in the depressions are discussed below.

► Treatment of Depression

A. Medical


Depression associated with reactive disorders usually does not call for drug therapy and can be managed by psychotherapy and the passage of time. In severe cases—particularly when vegetative signs are significant and symptoms have persisted for more than a few weeks—antidepressant drug therapy is often effective. Drug therapy is also suggested by a family history of major depression in first-degree relatives or a past history of prior episodes.

The antidepressant medications may be conveniently classified into three groups: (1) the newer antidepressants, including the SSRIs and bupropion, duloxetine, venlafaxine, nefazodone, vilazodone, and mirtazapine, (2) the TCAs and clinically similar medications, and (3) the MAO inhibitors (see Table 25–8). These groups are described in greater detail below. ECT is effective in all types of depression and will also rapidly resolve a manic episode. It is also very effective for postpartum depression. Megavitamin treatment, acupuncture, and electrosleep are of unproved usefulness for any psychiatric condition. Repetitive transcranial magnetic stimulation has been approved by the FDA for individuals who have not responded to one trial of an antidepressant and is being evaluated for wider application but is still not covered by most insurers as a first-line treatment.

Hospitalization is necessary if suicide is a major consideration or if complex treatment modalities are required.

Medication selection is influenced by the history of previous responses if that information is available. If a relative has responded to a particular drug, this suggests that the patient may respond similarly. If no background information is available, a drug such as sertraline, 25 mg orally daily and increasing gradually up to 200 mg, or desipramine, starting with 50 mg orally and gradually increasing to 150 mg, can be selected and a *full trial* instituted. The medication trial should be monitored for worsening mood or suicidal ideation with patient assessments every 1–2 weeks until week 6. If successful, the medication should be continued for 6–12 months at the full therapeutic dose before tapering is considered. Antidepressants should usually be continued indefinitely at full dosage in individuals with a first episode of depression before the age of 20 or after the age of 50, with more than two episodes after age 40, at least one episode after age 50, or with three or more total episodes. The STAR*D trial suggests that if the response to the first medication is inadequate, the best alternatives are to switch to a second agent that may be from the same or different class of antidepressant; another option is to try augmenting the first agent with lithium (eg, 600–900 mg/d orally), buspirone (eg, 30–60 mg/d orally), or thyroid medication (eg, liothyronine, 25–50 mcg/d orally). The latter course is often taken when there has been at least a partial response to the initial drug. Dysthymia is also treated in this way. The Agency for Health Care Policy and Research has produced clinical practice guidelines that outline one algorithm of treatment decisions (Figure 25–2).

Psychotic depression should be treated with a combination of an antipsychotic such as olanzapine and an



¹Times of assessment (weeks 6 and 12) rest on very modest data. It may be necessary to revise the treatment plan earlier for patients not responding at all.

▲ **Figure 25-2.** Overview of treatment for depression. (Reproduced from Agency for Health Care Policy and Research: Depression in Primary Care. Vol. 2: Treatment of Major Depression. United States Department of Health and Human Services, 1993.)

antidepressant such as an SSRI at their usual doses. Mifepristone may have specific and early activity against psychotic depression.

Major depression with atypical features or seasonal onset can be treated with an MAO inhibitor or an SSRI with good results.

Stimulants such as dextroamphetamine (5–30 mg/d orally) and methylphenidate (10–45 mg/d orally) have enjoyed a resurgence of interest for the short-term treatment of depression in medically ill and geriatric patients. Their 50–60% efficacy rate is slightly below that of other agents. The stimulants are notable for rapid onset of action

(hours) and a paucity of side effects (tachycardia, agitation) in most patients. They are usually given in two divided doses early in the day (eg, 7 am and noon) so as to avoid interfering with sleep. These agents may also be useful as adjunctive agents in refractory depression. Although not useful in routine clinical practice, ketamine can have antidepressant properties and highlights possible therapeutic pathways.

Caution: Depressed patients may have suicidal thoughts, and the amount of drug dispensed should be appropriately controlled. It appears that in children and adolescent populations, antidepressants may be associated with some slightly increased risk of suicidality, but this diminishes by age 25. After that, antidepressants have neutral or possibly protective effects until age 65 years or older when they have protective effects. The older TCAs have a narrow therapeutic index, and one advantage of the newer medications is their wider margin of safety. Nonetheless, even with newer agents, because of the possibility of suicidality early in antidepressant treatment, close follow-up is indicated. This increase is primarily evident in individuals younger than 25 years and may be due to increased energy to act on suicidal impulses or to early agitation. In all cases of pharmacologic management of depressed states, caution is indicated until the risk of suicide is considered minimal.

1. SSRIs and atypical antidepressants—The SSRIs include fluoxetine, sertraline, paroxetine, fluvoxamine, citalopram and its enantiomer escitalopram. The chief advantages of these agents are that they do not generally cause significant cardiovascular or anticholinergic side effects, and they have much lower lethality in overdose compared to TCAs. (Notably, citalopram now carries a warning regarding QT prolongation in doses above 40 mg, and caution should be used in prescribing in patients at risk for arrhythmia. This is not the case for escitalopram.) The atypical antidepressants are bupropion, which appears to exert its effect through the dopamine neurotransmitter system; venlafaxine and duloxetine, both of which inhibit the reuptake of both serotonin and norepinephrine; nefazodone, which blocks the reuptake of serotonin but also inhibits the 5-HT₂ postsynaptic receptors; vilazodone, which inhibits the reuptake of serotonin and is a partial agonist at the 5HT_{1A} receptors; and mirtazapine, which selectively blocks presynaptic α_2 -adrenergic receptors and enhances both noradrenergic and serotonergic transmission. All of these antidepressants are effective in the treatment of depression, both typical and atypical. The SSRI medications have been effective in the treatment of panic attacks, bulimia, generalized anxiety disorder, OCD, and PTSD. They do not seem to be as clearly effective in some pain syndromes as the TCAs, although venlafaxine may have some efficacy in the treatment of neuropathic pain, and duloxetine is FDA-approved for the treatment of diabetic peripheral neuropathy and fibromyalgia.

Most of the medications in this group tend to be activating and are given in the morning so as not to interfere with sleep. Some patients, however, may have sedation, requiring that the drug be given at bedtime. This reaction occurs most commonly with paroxetine, fluvoxamine, and mirtazapine. The SSRIs can be given in once-daily dosage. Nefazodone and venlafaxine are usually given twice daily. Bupropion

and venlafaxine are available in extended-release formulations and can be given once daily. There is usually some delay in response; fluoxetine, for example, requires 2–6 weeks to act in depression, 4–8 weeks to be effective in panic disorder, and 6–12 weeks in treatment of OCD. The starting dose (10 mg) is given for 1 week before increasing to the average daily oral dose of 20 mg for depression, while OCD may require up to 80 mg daily. Some patients, particularly the elderly, may tolerate and benefit from as little as 10 mg/d or every other day. The other SSRIs have shorter half-lives and a lesser effect on hepatic enzymes, which reduces their impact on the metabolism of other medications (thus not increasing significantly the serum concentrations of other medications as much as fluoxetine). The shorter half-lives also allow for more rapid clearing if adverse side effects appear. Venlafaxine appears to be more effective with doses > 200 mg/d orally, although some individuals respond to doses as low as 75 mg/d.

The **side effects** common to all of these medications are headache, nausea, tinnitus, insomnia, and nervousness. Akathisia has been common with the SSRIs; other extrapyramidal symptoms (eg, dystonias) have occurred infrequently but particularly in withdrawal states. Because SSRIs affect platelet serotonin levels, abnormal bleeding can occur. Sertraline and citalopram appear to be the safest agents in this class when used with warfarin. Sexual side effects of erectile dysfunction, retrograde ejaculation, and dysorgasmia are very common with the SSRIs. Oral phosphodiesterase-5 inhibitors (such as sildenafil, 25–50 mg; tadalafil, 5–20 mg; or vardenafil, 10–20 mg taken 1 hour prior to sexual activity) can improve erectile dysfunction in some patients. Adjunctive bupropion (75–150 mg orally daily) may also help with restoring erectile function. Cyproheptadine, 4 mg orally prior to sexual activity, may be helpful in countering drug-induced anorgasmia. The SSRIs are strong serotonin uptake blockers and may in high dosage or in combination with MAO inhibitors, including the antiparkinsonian drug selegiline, cause a “**serotonin syndrome**.” This syndrome is manifested by rigidity, hyperthermia, autonomic instability, myoclonus, confusion, delirium, and coma. This syndrome can be a particularly troublesome problem in the elderly. Several cases of angina have been reported in association with SSRIs. However, current research indicates that SSRIs are safer agents to use than TCAs in patients with cardiac disease. A study has found that sertraline is a safe and effective antidepressant treatment in patients with acute myocardial infarction or unstable angina.

Withdrawal syndromes have been reported for the SSRIs and venlafaxine. These include dysphoric mood, agitation, and a flu-like state. These medications should be discontinued gradually over a period of weeks or months to reduce the risk of withdrawal phenomena.

Fluoxetine, fluvoxamine, sertraline, venlafaxine, and citalopram in customary antidepressant doses may increase the risk of major fetal malformation when used during pregnancy; however, the absolute risk of congenital defects is considered low. Paroxetine may be associated with a twofold increased risk of cardiac abnormalities. Postpartum developmental effects of antidepressants have been thought

to be minimal, however, this question calls for ongoing investigation. A 2010 study of depressed women in their third trimester of pregnancy, comparing those who were treated with an SSRI versus those who were untreated, suggests the SSRI may have relatively delayed gross motor development at 6 months. Peripartum effects may be a concern and are documented anecdotally in the literature. At the same time, maternal major mood disorder in pregnancy by itself carries its own risks to the mother and fetus and has been linked to low birth weight and preterm delivery. Postpartum effects of prenatal depression have not been studied. The decision to use SSRIs and other psychotropic agents during pregnancy and postpartum must be a collaborative decision based on a thorough risk-benefit analysis for each individual.

Venlafaxine is reported to be well-tolerated without significant anticholinergic or cardiovascular side effects. Nausea, nervousness, and profuse sweating appear to be the major side effects. Venlafaxine appears to have few drug-drug interactions. It does require monitoring of blood pressure because dose-related hypertension may develop in some individuals. Desvenlafaxine, a newer form of the drug, is started at its target dose of 50 mg/d orally and does not require upward titration. Duloxetine may also result in small increases in blood pressure. Common side effects include dry mouth, dizziness, and fatigue. Inhibitors of 1A2 and 2D6 may increase duloxetine levels with a risk of toxicity.

Nefazodone appears to lack the anticholinergic effects of the TCAs and the agitation sometimes induced by SSRIs. Nefazodone should not be given with terfenadine, astemizole, or cisapride. (Terfenadine, astemizole, and cisapride are not commercially available in the United States.) Because nefazodone inhibits the liver's cytochrome P450 3A4 isoenzymes, concurrent use of these medications can lead to serious QT prolongation, ventricular tachycardia, or death. Through the same mechanism of enzyme inhibition, nefazodone can elevate cyclosporine levels sixfold to tenfold. Nefazodone has been given an FDA warning because it has been implicated in liver failure in rare cases. Pretreatment and ongoing monitoring of liver enzymes are indicated.

Mirtazapine is thought to enhance central noradrenergic and serotonergic activity with minimal sexual side effects compared with the SSRIs. Its action as a potent antagonist of histaminergic receptors may make it a useful agent for patients with depression and insomnia. It is also an effective antiemetic due to its antagonism of the 5-HT₃ receptor. Its most common adverse side effects include somnolence, increased appetite, weight gain, lipid abnormalities, and dizziness. There have been reports of agranulocytosis in 2 of 2796 patients. Although it is metabolized by P450 isoenzymes, it is not an inhibitor of this system. It is given in a single oral dose at bedtime starting at 15 mg and increasing in 15-mg increments every week or every other week up to 45 mg.

2. Tricyclic antidepressants (TCAs) and clinically similar medications—TCAs were the mainstay of drug therapy for depression for many years. They have also been effective in panic disorders, pain syndromes, and anxiety states. Specific ones have been effective in OCD

(clomipramine), enuresis (imipramine), psychotic depression (amoxapine), and reduction of craving in cocaine withdrawal (desipramine).

TCAs are characterized more by their similarities than by their differences. There is a lag in clinical response for up to several weeks, largely the result of anticholinergic side effects that prevent rapid increase in dosage. They tend to affect both serotonin and norepinephrine reuptake; some medications act mainly on the former and others principally on the latter neurotransmitter system. Individuals receiving the same dosages vary markedly in therapeutic drug levels achieved (elderly patients require smaller doses), and determination of plasma drug levels is helpful when clinical response has been disappointing. Nortriptyline is usually effective when plasma levels are between 50 and 150 ng/mL; imipramine at plasma levels of 200–250 ng/mL; and desipramine at plasma levels of 100–250 ng/mL. High blood levels are not more effective than moderate levels and may be counterproductive (eg, delirium, seizures). Patients with gastrointestinal side effects benefit from plasma level monitoring to assess absorption of the drug. Most TCAs can be given in a single dose at bedtime, starting at fairly low doses (eg, nortriptyline 25 mg orally) and increasing by 25 mg every several days as tolerated until the therapeutic response is achieved (eg, nortriptyline, 100–150 mg) or to maximum dose if necessary (eg, nortriptyline, 150 mg). The most common cause of treatment failure is an inadequate trial. A full trial consists of giving maximum daily dosage for at least 6 weeks. Because of marked anticholinergic and sedating side effects, clomipramine is started at a low dose (25 mg/d orally) and increased slowly in divided doses up to 100 mg/d, held at that level for several days, and then gradually increased as necessary up to 250 mg/d. Any of the TCA-like medications should be started at very low doses (eg, 10–25 mg/d) and increased slowly in the treatment of panic disorder.

The TCAs have anticholinergic side effects to varying degrees (amitriptyline 100 mg is equivalent to atropine 5 mg). One must be particularly wary of the effect in elderly men with prostatic hyperplasia. The anticholinergic effects also predispose to other medical problems such as constipation, heat stroke, or dental problems from xerostomia. Orthostatic hypotension is fairly common, is not dose-dependent and may not remit with time on medication; this may predispose to falls and hip fractures in the elderly. Cardiac effects of the TCAs are functions of the anticholinergic effect, direct myocardial depression (quinidine-like effect), and interference with adrenergic neurons. These factors may produce altered rate, rhythm, and contractility, particularly in patients with preexisting cardiac disease, such as bundle-branch or bifascicular block. Electrocardiographic changes range from benign ST segment and T wave changes and sinus tachycardia to a variety of complex and serious arrhythmias, the latter requiring a change in medication. Because TCAs have class I antiarrhythmic effects, they should be used with caution in patients with ischemic heart disease, arrhythmias, or conduction disturbances. SSRIs or the atypical antidepressants are better initial choices for this population. TCAs lower

the seizure threshold so this is of particular concern in patients with a propensity for seizures (eg, previous head injury, alcohol withdrawal). Loss of libido and erectile, ejaculatory, and orgasmic dysfunction are fairly common and can compromise compliance. Trazodone rarely causes priapism (1 in 9000), but when it occurs, it requires treatment within 12 hours (epinephrine 1:1000 injected into the corpus cavernosum). Delirium, agitation, and mania are infrequent complications of the TCAs but can occur. Sudden discontinuation of some of these medications can produce “cholinergic rebound,” manifested by headaches and nausea with abdominal cramps. Overdoses of TCAs are often serious because of the narrow therapeutic index and quinidine-like effects (see Chapter 38).

3. Monoamine oxidase inhibitors—The MAO inhibitors are generally used as third-line medications for depression (after a failure of SSRIs, TCAs, or the atypical antidepressants) because of the dietary and other restrictions required (see below and Table 25–7). They should be considered third-line medications for refractory panic disorder as well as depression; however, this hierarchy has become more flexible since MAO inhibitor skin patches (selegiline) have become available. They deliver the MAO inhibitor to the bloodstream bypassing the gastrointestinal tract so that dietary restrictions are not necessary in the lowest dosage strength (6 mg/24 h).

Oral MAO inhibitors are administered in gradual stepwise dosage and may be given in the morning or evening, depending upon their effect on sleep. They tend to take effect in a fairly low dosage range (Table 25–8). Blood levels are not congruent with therapeutic response.

The MAO inhibitors commonly cause symptoms of orthostatic hypotension (which may persist) and sympathomimetic effects of tachycardia, sweating, and tremor. Nausea, insomnia (often associated with intense afternoon drowsiness), and sexual dysfunction are common. Trazodone, 25–75 mg orally at bedtime, may ameliorate the MAO-induced insomnia. Central nervous system effects include agitation and toxic psychoses. Dietary limitations (see Table 25–7) and abstinence from drug products containing phenylpropanolamine, phenylephrine, meperidine, dextromethorphan, and pseudoephedrine are mandatory for MAO-A type inhibitors (those marketed for treatment of depression), since the reduction of available MAO leaves the patient vulnerable to exogenous amines (eg, tyramine in foodstuffs).

Treatment for a resultant hypertensive crisis has been the same as for pheochromocytoma (see Chapter 26), but

there have been reports of success with nifedipine, 10 mg chewed and placed under the tongue, normalizing blood pressure in 1–5 minutes. The restrictions on the proscribed foodstuffs and sympathomimetic medications are in effect during treatment and for 2–3 weeks after cessation of therapy. Termination of therapy with MAO inhibitors may be associated with anxiety, agitation, cognitive slowing, and headache. Very gradual withdrawal and short-term benzodiazepine therapy will ameliorate symptoms.

4. Switching and combination therapy—If the therapeutic response has been poor after an adequate trial with the chosen drug, the diagnosis should be reassessed. Assuming that the trial has been adequate and the diagnosis is correct, a trial with a second drug is appropriate. In switching from one group to another, an adequate “wash-out time” must be allowed. This is critical in certain situations—eg, in switching from an MAO inhibitor to a TCA, allow 2–3 weeks between stopping one drug and starting another; in switching from an SSRI to an MAO inhibitor, allow 4–5 weeks. In switching within groups—eg, from one TCA to another (amitriptyline to desipramine, etc)—no washout time is needed, and one can rapidly decrease the dosage of one drug while increasing the other. In clinical practice, adjunctive treatment with lithium, buspirone, or thyroid hormone may be helpful in depression. The adjunctive use of low-dose atypical antipsychotics such as aripiprazole, olanzapine, and risperidone in the treatment of patients with refractory depression is supported by research. The side effect risk is the same as when treating psychosis. The FDA has approved aripiprazole for this purpose. Adding an atypical agent requires monitoring body mass index, lipids, and glucose. Combining two antidepressants, or adding an antipsychotic to an antidepressant, requires caution and is usually reserved for clinicians who feel comfortable managing this or after psychiatric consultation.

5. Maintenance and tapering—When clinical relief of symptoms is obtained, medication is continued for 12 months in the effective maintenance dosage, which is the dosage required in the acute stage. The full dosage should be continued indefinitely when the individual has a first episode before age 20 or after age 50, is over age 40 with two episodes, at least one episode after age 50, or has had three episodes at any age. Major depression should often be considered a chronic disease. If the medication is being tapered, it should be done gradually over several months, monitoring closely for relapse.

6. Drug interactions—Interactions with other medications are listed in Table 25–9.

7. Electroconvulsive therapy—ECT causes a generalized central nervous system seizure (peripheral convulsion is not necessary) by means of electric current. The key objective is to exceed the seizure threshold, which can be accomplished by a variety of means. The mechanism of action is not known, but it is thought to involve major neurotransmitter responses at the cell membrane. Electrical current insufficient to cause a seizure produces no therapeutic benefit.

ECT is the most effective (about 70–85%) treatment of severe depression—particularly the delusions and agitation

Table 25-7. Principal dietary restrictions in MAOI use.

1. Cheese, except cream cheese and cottage cheese and fresh yogurt
2. Fermented or aged meats such as bologna, salami
3. Broad bean pods such as Chinese bean pods
4. Liver of all types
5. Meat and yeast extracts
6. Red wine, sherry, vermouth, cognac, beer, ale
7. Soy sauce, shrimp paste, sauerkraut

MAOI, monoamine oxidase inhibitor.

Table 25-8. Commonly used antidepressants.

Drug	Usual Daily Oral Dose (mg)	Usual Daily Maximum Dose (mg)	Sedative Effects ¹	Anticholinergic Effects ¹	Cost per Unit	Cost for 30 Days Treatment Based on Maximum Dosage ²
SSRIs						
Citalopram (Celexa)	20	40	< 1	1	\$2.53/40 mg	\$75.90
Escitalopram (Lexapro)	10	20	< 1	1	\$5.02/20 mg	\$150.60
Fluoxetine (Prozac, Sarafem)	5-40	80	< 1	< 1	\$2.67/20 mg	\$320.40
Fluvoxamine (Luvox)	100-300	300	1	< 1	\$2.64/100 mg	\$237.60
Nefazodone (Serzone)	300-600	600	2	< 1	\$1.92/200 mg	\$172.80
Paroxetine (Paxil)	20-30	50	1	1	\$2.65/20 mg	\$159.00
Sertraline (Zoloft)	50-150	200	< 1	< 1	\$2.85/100 mg	\$171.00
Vilazodone (Viibryd)	40	40	< 1	< 1	\$4.74/20 mg	\$147.20
Tricyclic and clinically similar compounds						
Amitriptyline (Elavil)	150-250	300	4	4	\$1.16/150 mg	\$69.60
Amoxapine (Asendin)	150-200	400	2	2	\$1.67/100 mg	\$200.40
Clomipramine (Anafranil)	100	250	3	3	\$1.40/75 mg	\$149.70
Desipramine (Norpramin)	100-250	300	1	1	\$1.50/100 mg	\$135.00
Doxepin (Sinequan)	150-200	300	4	3	\$1.15/100 mg	\$103.50
Imipramine (Tofranil)	150-200	300	3	3	\$1.22/50 mg	\$219.60
Maprotiline (Ludiomil)	100-200	300	4	2	\$1.60/75 mg	\$192.00
Nortriptyline (Aventyl, Pamelor)	100-150	150	2	2	\$1.46/50 mg	\$131.40
Protriptyline (Vivactil)	15-40	60	1	3	\$3.07/10 mg	\$552.60
Monoamine oxidase inhibitors						
Phenelzine (Nardil)	45-60	90	\$0.84/15 mg	\$151.20
Selegiline transdermal (Emsam)	6 (skin patch)	12	\$23.77/6 mg patch	\$713.02
Tranlycypromine (Parnate)	20-30	50	\$1.25/10 mg	\$187.50
Other compounds						
Bupropion SR (Wellbutrin SR)	300	400 ³		< 1	\$3.59/200 mg	\$215.40
Bupropion XL (Wellbutrin XL)	300 ⁴	450 ⁴		< 1	\$4.77/300 mg	\$286.20
Desvenlafaxine (Pristiq)	50	100	1	< 1	\$5.41/100 mg	\$162.30
Duloxetine (Cymbalta)	40	60	2	3	\$6.65/60 mg	\$199.50
Mirtazapine (Remeron)	15-45	45	4	2	\$2.80/30 mg	\$85.53
Trazodone (Desyrel)	100-300	400	4	< 1	\$0.73/100 mg	\$87.60
Trimipramine (Surmontil)	75-200	200	4	4	\$5.78/100 mg	\$346.80
Venlafaxine XR (Effexor)	150-225	225	1	< 1	\$4.67/75 mg	\$420.30

¹1, weak effect; 4, strong effect.

²Average wholesale price (AWP, for AB-rated generic when available) for quantity listed. Source: *Red Book Online, 2012*, Thomson Reuters (Healthcare Inc.). AWP may not accurately represent the actual pharmacy cost because wide contractual variations exist among institutions.

³200 mg twice daily.

⁴Wellbutrin XL is a once-daily form of bupropion. Bupropion is still available as immediate release, and, if used, no single dose should exceed 150 mg.

SSRIs, serotonin selective reuptake inhibitors.

Table 25-9. Antidepressant drug interactions with other medications.

Drug	Effects
Tricyclic and other non-MAOI antidepressants	
Antacids	Decreased absorption of antidepressants
Anticoagulants	Increased hypoprothrombinemic effect
Cimetidine	Increased antidepressant blood levels and psychosis
Clonidine	Decreased antihypertensive effect
Digitalis	Increased incidence of heart block
Disulfiram	Increased antidepressant blood levels
Guanethidine	Decreased antihypertensive effect
Haloperidol	Increased antidepressant levels
Insulin	Decreased blood sugar
Lithium	Increased lithium levels with fluoxetine
Methyl dopa	Decreased antihypertensive effect
Other anticholinergic medications	Marked anticholinergic responses
Phenytoin	Increased blood levels
Procainamide	Decreased ventricular conduction
Procarbazine	Hypertensive crisis
Propranolol	Increased hypotension
Quinidine	Decreased ventricular conduction
Rauwolfia derivatives	Increased stimulation
Sedatives	Increased sedation
Sympathomimetic medications	Increased vasopressor effect
Terfenadine, ¹ astemizole, ¹ cisapride ¹	Torsades de pointes
MAOIs	
Antihistamines	Increased sedation
Belladonna-like medications	Increased blood pressure
Dextromethorphan	Same as meperidine
Guanethidine	Decreased blood pressure
Insulin	Decreased blood sugar
Levodopa	Increased blood pressure
Meperidine	Increased agitation, seizures, coma, death
Methyl dopa	Decreased blood pressure
Pseudoephedrine	Hypertensive crisis (increased blood pressure)
Reserpine	Increased blood pressure and temperature
Succinylcholine	Increased neuromuscular blockade
Sulfonylureas	Decreased blood sugar
Sympathomimetic medications	Increased blood pressure

¹Terfenadine, astemizole, and cisapride are not commercially available in the United States.

MAOIs, monoamine oxidase inhibitors.

commonly seen with depression in the elderly. It is indicated when medical conditions preclude the use of antidepressants, nonresponsiveness to these medications, and extreme suicidality. Comparative controlled studies of ECT in severe depression show that it is more effective than pharmacotherapy. It is also effective in the manic disorders and psychoses during pregnancy (when medications may be contraindicated). It has not been shown to be helpful in chronic schizophrenic disorders, and it is generally not used in acute schizophrenic episodes unless medications are not effective and it is urgent that the psychosis be controlled (eg, a catatonic stupor complicating an acute medical condition).

The most common side effects are memory disturbance and headache. Memory loss or confusion is usually related to the number and frequency of ECT treatments and proper oxygenation during treatment. Unilateral ECT is associated with less memory loss than bilateral ECT. Some memory loss is occasionally permanent, but most memory faculties return to full capacity within several weeks. There have been reports that lithium administration concurrent with ECT resulted in greater memory loss.

Increased intracranial pressure is a serious contraindication. Other problems such as cardiac disorders, aortic aneurysms, bronchopulmonary disease, and venous thrombosis are relative contraindications and must be evaluated in light of the severity of the medical problem versus the need for ECT. Serious complications arising from ECT occur in < 1 in 1000 cases. Most of these problems are cardiovascular or respiratory in nature (eg, aspiration of gastric contents). Poor patient understanding and lack of acceptance of the technique by the public are the biggest obstacles to the use of ECT.

8. Phototherapy—Phototherapy is used in major depression with seasonal onset. It consists of exposure (at a 3-foot distance) to a light source of 2500 lux for 2 hours daily. Light visors are an adaptation that provides greater mobility and an adjustable light intensity. The dosage varies, with some patients requiring morning and night exposure. One effect is alteration of biorhythm through melatonin mechanisms.

9. Experimental treatments—In preliminary studies, transcranial magnetic stimulation appears to be effective in nonpsychotic depression. Its use in this condition has been approved by the FDA for individuals who have not responded to an antidepressant. It is usually delivered in a course of 16–20 sessions over 1 month. Vagal nerve stimulation has shown some promise in extremely refractory cases and is approved by the FDA but has not been approved by many insurers.

B. Psychological

It is seldom possible to engage an individual in penetrating psychotherapeutic endeavors during the acute stage of a severe depression. While medications may be taking effect, a supportive approach to strengthen existing coping mechanisms and appropriate consideration of the patient's continuing need to function at work, to engage in recreational activities, etc, are necessary as the severity of the

depression lessens. If the patient is not seriously depressed, it is often quite appropriate to initiate intensive psychotherapeutic efforts, since flux periods are a good time to effect change. A catharsis of repressed anger and guilt may be beneficial. Therapy during or just after the acute stage may focus on coping techniques, with some practice of alternative choices. Depression-specific psychotherapies help improve self-esteem, increase assertiveness, and lessen dependency. Interpersonal psychotherapy for depression has shown efficacy in the treatment of acute depression, helping patients master interpersonal stresses and develop new coping strategies. Cognitive behavioral therapy for depression addresses patients' patterns of negative thoughts, called cognitive distortions, that lead to feelings of depression and anxiety. Treatment usually includes homework assignments such as keeping a journal of cognitive distortions and of positive responses to them. The combination of drug therapy plus interpersonal psychotherapy or cognitive behavioral therapy is more effective than either modality alone. It is usually helpful to involve the spouse or other significant family members early in treatment. Mindfulness-based cognitive therapy has reduced relapse rates in several randomized controlled trials. In two studies, it was as effective as maintenance medication in preventing relapse. This therapy incorporates meditation and teaches patients to distance themselves from depressive thinking. It may be a preferable alternative for individuals who wish to have an alternative to long-term medications to stay free of depressive episodes.

C. Social

Flexible use of appropriate social services can be of major importance in the treatment of depression. Since alcohol is often associated with depression, early involvement in alcohol treatment programs such as Alcoholics Anonymous can be important to future success (see Alcohol Dependency and Abuse, below). The structuring of daily activities during severe depression is often quite difficult for the patient, and loneliness is often a major factor. The help of family, employer, or friends is often necessary to mobilize the patient who experiences no joy in daily activities and tends to remain uninvolved and to deteriorate. Insistence on sharing activities will help involve the patient in simple but important daily functions. In some severe cases, the use of day treatment centers or support groups of a specific type (eg, mastectomy groups) is indicated. It is not unusual for a patient to have multiple legal, financial, and vocational problems requiring legal and vocational assistance.

D. Behavioral

When depression is a function of self-defeating coping techniques such as passivity, the role-playing approach can be useful. Behavioral techniques, including desensitization, may be used in problems such as phobias where depression is a by-product. When depression is a regularly used interpersonal style, behavioral counseling to family members or others can help in extinguishing the behavior in the patient. Behavioral activation, a technique of motivating depressed patients to begin engaging in pleasurable activities, has been shown to be a useful depression-specific psychotherapy.

► Treatment of Mania

Acute manic or hypomanic symptoms will respond to lithium or valproic acid after several days of treatment, but it is increasingly common to use atypical neuroleptics as adjunctive treatment or monotherapy. High-potency benzodiazepines (eg, clonazepam) may also be useful adjuncts in managing acute cases. Some schizoaffective disorders and some cases of so-called schizophrenia are probably atypical bipolar affective disorder, for which lithium treatment may be effective.

A. Neuroleptics

Acute manic symptoms of agitation and psychosis may be treated initially with the atypical antipsychotic olanzapine, (eg, 5–20 mg orally), risperidone (2–3 mg orally), or aripiprazole (15–30 mg) in conjunction with a benzodiazepine if indicated. Alternatively, when behavioral control is immediately necessary, olanzapine in an injectable form (2.5–10 mg intramuscularly) or haloperidol, 5–10 mg orally or intramuscularly repeated as needed until symptoms subside, may be used. The dosage of the neuroleptic may be gradually reduced after lithium or another mood stabilizer is started (see below). Olanzapine is approved as a maintenance treatment for bipolar disorder.

B. Clonazepam

Clonazepam can be an alternative or adjunct to a neuroleptic in controlling acute behavioral symptoms. Clonazepam has the advantage of causing no extrapyramidal side effects. Although 1–2 mg orally every 4–6 hours may be effective, up to 16 mg/d may be necessary.

C. Lithium

As a prophylactic drug for bipolar affective disorder, lithium significantly decreases the frequency and severity of both manic and depressive attacks in about 70% of patients. A positive response is more predictable if the patient has a low frequency of episodes (no more than two per year with intervals free of psychopathology). A positive response occurs more frequently in individuals who have blood relatives with a diagnosis of manic or hypomanic attacks. Patients who swing rapidly back and forth between manic and depressive attacks (at least four cycles per year) usually respond poorly to lithium prophylaxis initially, but some improve with continued long-term treatment. Carbamazepine (see below) has been used with success in this group.

In addition to its use in manic states, lithium is sometimes useful in the prophylaxis of recurrent unipolar depressions (perhaps undiagnosed bipolar disorder). Lithium may ameliorate nonspecific aggressive behaviors and dyscontrol syndromes. The dosages are the same as used in bipolar disorder. Most patients with bipolar disease can be managed long-term with lithium alone, although some will require continued or intermittent use of a neuroleptic, antidepressant, or carbamazepine. An excellent resource for information is the Lithium Information Center, Madison Institute of Medicine, 7617

Mineral Point Road, Suite 300, Madison, WI 53717-1914, <http://www.miminc.org/aboutlithinfoctr.html>.

Before treatment, the clinical workup should include a medical history and physical examination; complete blood count; T4, thyroid-stimulating hormone, blood urea nitrogen (BUN), serum creatinine, and serum electrolyte determinations; urinalysis; and electrocardiography (in patients over age 45 or with a history of cardiac disease).

1. Dosage—The common starting dosage of lithium carbonate is 300 mg orally two or three times daily, with trough blood levels measured after 5 days of treatment. In a small minority of patients, a slow release form or units of different dosage may be required. Lithium citrate is available as a syrup. The dosage is that required to maintain blood levels in the therapeutic range. For acute attacks, this ranges from 1 to 1.5 mEq/L. Although there is controversy about the optimal long-term maintenance dose, many clinicians reduce the acute level to 0.6–1 mEq/L in order to reduce side effects. The dose required to meet this need will vary in different individuals. For acute mania, doses of 1200–1800 mg/d are generally recommended. Augmentation of antidepressants is usually achieved with half of these doses. Once-a-day dosage is acceptable, but most patients have less nausea when they take the drug in divided doses with meals.

Lithium is readily absorbed, with peak serum levels occurring within 1–3 hours and complete absorption in 8 hours. Half of the total body lithium is excreted in 18–24 hours (95% in the urine). Blood for lithium levels should be drawn 12 hours after the last dose. Serum levels should be measured 5–7 days after initiation of treatment and changes in dose. For maintenance treatment, lithium levels should be monitored initially every 1–2 months but may be measured every 6–12 months in stable, long-term patients. Levels should be monitored more closely when there is any condition that causes volume depletion (eg, diarrhea, dehydration, use of diuretics).

2. Side effects—Mild gastrointestinal symptoms (take lithium with food and in divided doses), fine tremors (treat with propranolol, 20–60 mg/d orally, only if persistent), slight muscle weakness, and some degree of somnolence are early side effects that are usually transient. Moderate polyuria (reduced renal responsiveness to ADH) and polydipsia (associated with increased plasma renin concentration) are often present. Potassium administration can blunt this effect, as may once-daily dosing of lithium. Weight gain (often a result of calories in fluids taken for polydipsia) and leukocytosis not due to infection are fairly common.

Other side effects include goiter (3%; often euthyroid), hypothyroidism (10%; concomitant administration of lithium and iodide or lithium and carbamazepine enhances the hypothyroid and goitrogenic effect of either drug), changes in the glucose tolerance test toward a diabetes-like curve, nephrogenic diabetes insipidus (usually resolving about 8 weeks after cessation of lithium therapy), nephrotic syndrome, edema, folate deficiency, and pseudotumor cerebri (ophthalmoscopy is indicated if there are complaints of headache or blurred vision). A metallic taste, hair

loss, and Raynaud phenomenon have been reported in a few cases. Thyroid and kidney function should be checked at 3- to 4-month intervals. Most of these side effects subside when lithium is discontinued; when residual side effects exist, they are usually not serious. Most clinicians treat lithium-induced hypothyroidism (more common in women) with thyroid hormone while continuing lithium therapy. Hypercalcemia and elevated parathyroid hormone levels occur in some patients. Electrocardiographic abnormalities (principally T wave flattening or inversion) may occur during lithium administration but are not of major clinical significance. Sinoatrial block may occur, particularly in the elderly. Other medications that prolong intraventricular conduction, such as TCAs, must be used cautiously in conjunction with lithium. Lithium impairs ventilatory function in patients with airway obstruction. Lithium alone does not have a significant effect on sexual function, but when combined with benzodiazepines (clonazepam in most symptomatic patients) it causes sexual dysfunction in about 50% of men. Lithium may precipitate or exacerbate psoriasis in some patients.

Patients receiving long-term lithium therapy may have cogwheel rigidity and, occasionally, other extrapyramidal signs. Lithium potentiates the parkinsonian effects of haloperidol. Long-term lithium therapy has also been associated with a relative lowering of the level of memory and perceptual processing (affecting compliance in some cases). Some impairment of attention and emotional reactivity has also been noted. Lithium-induced delirium with therapeutic lithium levels is an infrequent complication usually occurring in the elderly and may persist for several days after serum levels have become negligible. Encephalopathy has occurred in patients receiving combined lithium and neuroleptic therapy and in those who have cerebrovascular disease, thus requiring careful evaluation of patients who develop neurotoxic signs at subtoxic blood levels.

Some reports have suggested that the long-term use of lithium may have adverse effects on kidney function (with interstitial fibrosis, tubular atrophy, or nephrogenic diabetes insipidus). Persistent polyuria should require an investigation of the kidney's ability to concentrate urine. A rise in serum creatinine levels is an indication for in-depth evaluation of kidney function and consideration of alternative treatments if the individual can tolerate a change. Incontinence has been reported in women, apparently related to changes in bladder cholinergic-adrenergic balance.

Prospective studies suggest that the overall risk imposed by lithium in pregnancy may be overemphasized. However, lithium exposure in early pregnancy does increase the frequency of congenital anomalies, especially Ebstein and other major cardiovascular anomalies. For women who take psychotropic medications who become pregnant, the decision to make a change in medication is complex and requires informed consent regarding the relative risks to the patient and fetus. Indeed, the risk of untreated bipolar disorder carries its own risks for pregnancy. Formula feeding should be considered in mothers taking lithium, since concentration in breast milk is one-third to half that in serum.

Frank toxicity usually occurs at blood lithium levels > 2 mEq/L. Because sodium and lithium are reabsorbed at the same loci in the proximal renal tubules, any sodium loss (diarrhea, use of diuretics, or excessive perspiration) results in increased lithium levels. Symptoms and signs include vomiting and diarrhea, the latter exacerbating the problem since more sodium is lost and more lithium is absorbed. Other symptoms and signs, some of which may not be reversible, include tremors, marked muscle weakness, confusion, dysarthria, vertigo, choreoathetosis, ataxia, hyperreflexia, rigidity, lack of coordination, myoclonus, seizures, opisthotonos, and coma. Toxicity is more severe in the elderly, who should be maintained on slightly lower serum levels. Lithium overdosage may be accidental or intentional or may occur as a result of poor monitoring.

Patients with massive ingestions of lithium or blood lithium levels > 2.5 mEq/L should be treated with induced emesis and gastric lavage. If kidney function is normal, osmotic and saline diuresis increases renal lithium clearance. Urinary alkalization is also helpful, since sodium bicarbonate decreases lithium reabsorption in the proximal tubule, as does acetazolamide. Aminophylline potentiates the diuretic effect by increasing the clearance of lithium. Medications affecting the distal loop have no effect on lithium reabsorption. Blood lithium levels > 2.5 mEq/L (confirmed by cerebrospinal fluid lithium levels) should be considered an indication for hemodialysis.

Compliance with lithium therapy is adversely affected by the loss of some hypomanic experiences valued by the patient. These include social extroversion and a sense of heightened enjoyment in many activities such as sex and business dealings, often with increased productivity in the latter.

3. Drug interactions—Patients receiving lithium should use diuretics with caution and only under close medical supervision. The thiazide diuretics cause increased lithium reabsorption from the proximal renal tubules, resulting in increased serum lithium levels (Table 25–10), and adjustment of lithium intake must be made to compensate for this. Reduce lithium dosage by 25–40% when the patient is receiving 50 mg of hydrochlorothiazide daily. Potassium-sparing diuretics (spironolactone, amiloride, triamterene) may also increase serum lithium levels and require careful monitoring of lithium levels. Loop diuretics (furosemide, ethacrynic acid, bumetanide) do not appear to alter serum lithium levels. Concurrent use of lithium and angiotensin-converting enzyme inhibitors requires a 50–75% reduction in lithium intake to achieve therapeutic lithium levels.

D. Valproic Acid

Valproic acid (divalproex) is an antiseizure drug whose activity is at least partially related to GABA neurotransmission. It is a first-line treatment for mania because it has a broader index of safety than lithium. This issue is particularly important in AIDS or other medically ill patients prone to dehydration or malabsorption with wide swings in serum lithium levels. Valproic acid has also been used effectively in panic disorder and migraine headache. Treatment is often started at a dose of 750 mg/d orally in divided doses, and dosage is then titrated to achieve therapeutic

Table 25–10. Lithium interactions with other medications.

Drug	Effects
ACE inhibitors	↑ Lithium levels
Fluoxetine	↑ Lithium levels
Ibuprofen	↑ Lithium levels
Indomethacin	↑ Lithium levels
Methyl dopa	Rigidity, mutism, fascicular twitching
Osmotic diuretics (urea, mannitol)	↑ Lithium excretion
Phenylbutazone	↑ Lithium levels
Potassium-sparing diuretics (spironolactone, amiloride, triamterene)	↑ Lithium levels
Sodium bicarbonate	↑ Lithium excretion
Succinylcholine	↑ Duration of action of succinylcholine
Theophylline, aminophylline	↑ Lithium excretion
Thiazide diuretics	↑ Lithium levels
Valproic acid	↓ Lithium levels
COX-2 inhibitors	↑ Lithium levels

ACE, angiotensin-converting enzyme; COX-2, cyclooxygenase-2.

serum levels. Oral loading in acutely manic bipolar patients in an inpatient setting (initiated at a dosage of 20 mg/kg/d) can safely achieve serum therapeutic levels in 2–3 days. Concomitant use of aspirin may increase valproate levels, carbamazepine or phenytoin may decrease valproate levels, while warfarin levels may be elevated by valproate. Gastrointestinal symptoms and weight gain are the main side effects. Liver function tests, complete blood counts, glucose levels, and weight should be monitored at 2 weeks, 4 weeks, and at 3 months initially and annually or more frequently thereafter based on clinical judgment. Significant teratogenic effects are a concern so pregnancy should be ruled out prior to initiation.

E. Carbamazepine

Carbamazepine, an antiseizure drug that stabilizes the activity of cell membranes, has been used with increasing frequency in the treatment of bipolar patients who cannot be satisfactorily treated with lithium (nonresponsive, excessive side effects, or rapid cycling). It is often effective at 800–1600 mg/d orally. It has also been used in the treatment of resistant depressions, alcohol withdrawal, and hallucinations (in conjunction with neuroleptics) and in patients with behavioral dyscontrol or panic attacks. It suppresses some phases of kindling (see Stimulants) and has been used to treat residual symptoms in previous stimulant abusers (eg, PTSD with impulse control problems). Dose-related side effects include sedation and ataxia. Dosages

start at 400–600 mg orally daily and are increased slowly to therapeutic levels. Skin rashes and a mild reduction in white count are common. SIADH occurs rarely. Non-steroidal anti-inflammatory medications (except aspirin), the antibiotics erythromycin and isoniazid, the calcium channel blockers verapamil and diltiazem (but not nifedipine), fluoxetine, propoxyphene, and cimetidine all increase carbamazepine levels. Carbamazepine can be effective in conjunction with lithium, although there have been reports of reversible neurotoxicity with the combination. Carbamazepine stimulates hepatic microsomal enzymes and so tends to decrease levels of haloperidol and oral contraceptives. It also lowers T_4 , free T_4 , and T_3 levels. Cases of fetal malformation (particularly spina bifida) have been reported along with growth deficiency and developmental delay. Liver tests and complete blood counts should be monitored in patients taking carbamazepine. Genetic studies suggest that screening for the HLA-B1502 allele in the Han Chinese population and the HLA-A3101 allele in northern Europeans may help target individuals more susceptible to a serious rash. **Oxcarbazepine**, a derivative of carbamazepine, does not appear to induce its own metabolism and is associated with fewer drug interactions, although it may impose a higher risk of hyponatremia. FDA-approved for partial seizures, oxcarbazepine may have efficacy in acute mania. It appears to be a safer alternative to carbamazepine due to its lower risk of hepatotoxicity.

F. Lamotrigine

Lamotrigine is thought to inhibit neuronal sodium channels and the release of the excitatory amino acids, glutamate and aspartate. It is FDA approved for long-term maintenance of bipolar disorder. Two double-blind studies support its efficacy in the treatment of acute bipolar depression as adjunctive therapy or as monotherapy. Its metabolism is inhibited by coadministration of valproic acid—doubling its half-life—and accelerated by hepatic enzyme-inducing agents such as carbamazepine. More frequent mild side effects include headache, dizziness, nausea, and diplopia. Rash occurring in 10% of patients is an indication for immediate cessation of dosing, since lamotrigine has been associated with Stevens-Johnson syndrome (1:1000) and, rarely, toxic epidermal necrolysis. Dosing starts at 25–50 mg/d orally and is titrated upward slowly to decrease the likelihood of rash. Slower titration and a lower total dose are indicated for patients taking valproic acid.

► Prognosis

Reactive depressions are usually time-limited, and the prognosis with treatment is good if a pathologic pattern of adjustment does not intervene. Major affective disorders frequently respond well to a full trial of drug treatment.

Mania and bipolar disorder have a good prognosis with adequate treatment, although patient adherence to treatment is often quite challenging.

Ansari A et al. The psychopharmacology algorithm project at the Harvard South Shore Program: an update on bipolar depression. *Harv Rev Psychiatry*. 2010;18(1):36–55. [PMID: 20047460]

Banerjee S et al. Sertraline or mirtazapine for depression in dementia (HTA-SADD): a randomised, multicentre, double-blind, placebo-controlled trial. *Lancet*. 2011 Jul 30;378(9789):403–11. [PMID: 21764118]

Parikh S et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. II. Psychotherapy alone or in combination with antidepressant medication. *J Affect Disord*. 2009 Oct;117(Suppl 1):S15–25. [PMID: 19682749]

Stewart DE. Clinical practice. Depression during pregnancy. *N Engl J Med*. 2011 Oct 27;365(17):1605–11. [PMID: 22029982]

Tess AV et al. Medical evaluation of patients undergoing electroconvulsive therapy. *N Engl J Med*. 2009 Apr 2;360(14):1437–44. [PMID: 19339723]

Torpy JM et al. JAMA patient page. Bipolar Disorder. *JAMA*. 2009 Feb 4;301(5):564. [PMID: 19190322]

Yonkers KA et al. The management of depression during pregnancy: a report from the American Psychiatric Association and the American College of Obstetricians and Gynecologists. *Gen Hosp Psychiatry*. 2009 Sep–Oct;31(5):403–13. [PMID: 19703633]

SLEEP DISORDERS

Sleep consists of two distinct states as shown by electroencephalographic studies: (1) REM (rapid eye movement) sleep, also called dream sleep, D state sleep, paradoxical sleep, and (2) NREM (non-REM) sleep, also called S stage sleep, which is divided into stages 1, 2, 3, and 4 and is recognizable by different electroencephalographic patterns. Stages 3 and 4 are “delta” sleep. Dreaming occurs mostly in REM and to a lesser extent in NREM sleep.

Sleep is a cyclic phenomenon, with four or five REM periods during the night accounting for about one-fourth of the total night's sleep (1.5–2 hours). The first REM period occurs about 80–120 minutes after onset of sleep and lasts about 10 minutes. Later REM periods are longer (15–40 minutes) and occur mostly in the last several hours of sleep. Most stage 4 (deepest) sleep occurs in the first several hours.

Age-related changes in normal sleep include an unchanging percentage of REM sleep and a marked decrease in stage 3 and stage 4 sleep, with an increase in wakeful periods during the night. These normal changes, early bedtimes, and daytime naps play a role in the increased complaints of insomnia in older people. Variations in sleep patterns may be due to circumstances (eg, “jet lag”) or to idiosyncratic patterns (“night owls”) in persons who perhaps because of different “biologic rhythms” habitually go to bed late and sleep late in the morning. Creativity and rapidity of response to unfamiliar situations are impaired by loss of sleep. There are also rare individuals who have chronic difficulty in adapting to a 24-hour sleep-wake cycle (desynchronization sleep disorder), which can be resynchronized by altering exposure to light.

The three major sleep disorders are discussed below.

1. Dyssomnias (Insomnia)

► Classification & Clinical Findings

Patients may complain of difficulty getting to sleep or staying asleep, intermittent wakefulness during the night, early

morning awakening, or combinations of any of these. Transient episodes are usually of little significance. Stress, caffeine, physical discomfort, daytime napping, and early bedtimes are common factors.

Psychiatric disorders are often associated with persistent insomnia. **Depression** is usually associated with fragmented sleep, decreased total sleep time, earlier onset of REM sleep, a shift of REM activity to the first half of the night, and a loss of slow wave sleep—all of which are non-specific findings. In **manic disorders**, sleeplessness is a cardinal feature and an important early sign of impending mania in bipolar cases. Total sleep time is decreased, with shortened REM latency and increased REM activity. Sleep-related panic attacks occur in the transition from stage 2 to stage 3 sleep in some patients with a longer REM latency in the sleep pattern preceding the attacks.

Abuse of alcohol may cause or be secondary to the sleep disturbance. There is a tendency to use alcohol as a means of getting to sleep without realizing that it disrupts the normal sleep cycle. Acute alcohol intake produces a decreased sleep latency with reduced REM sleep during the first half of the night. REM sleep is increased in the second half of the night, with an increase in total amount of slow wave sleep (stages 3 and 4). Vivid dreams and frequent awakenings are common. Chronic alcohol abuse increases stage 1 and decreases REM sleep (most medications delay or block REM sleep), with symptoms persisting for many months after the individual has stopped drinking. Acute alcohol or other sedative withdrawal causes delayed onset of sleep and REM rebound with intermittent awakening during the night.

Heavy smoking (more than a pack a day) causes difficulty falling asleep—apparently independently of the often associated increase in coffee drinking. Excess intake near bedtime of caffeine, cocaine, and other stimulants (eg, over-the-counter cold remedies) causes decreased total sleep time—mostly NREM sleep—with some increased sleep latency.

Sedative-hypnotics—specifically, the benzodiazepines, which are the most commonly prescribed medications to promote sleep—tend to increase total sleep time, decrease sleep latency, and decrease nocturnal awakening, with variable effects on NREM sleep. Withdrawal causes just the opposite effects and results in continued use of the drug for the purpose of preventing withdrawal symptoms. Antidepressants decrease REM sleep (with marked rebound on withdrawal in the form of nightmares) and have varying effects on NREM sleep. The effect on REM sleep correlates with reports that REM sleep deprivation produces improvement in some depressions.

Persistent insomnias are also related to a wide variety of medical conditions, particularly delirium, pain, respiratory distress syndromes, uremia, asthma, thyroid disorders, and nocturia due to benign prostatic hyperplasia. Sleep apnea and restless leg movement are described below. Adequate analgesia and proper treatment of medical disorders will reduce symptoms and decrease the need for sedatives.

► Treatment

In general, there are two broad classes of treatment for insomnia, and the two may be combined: psychological

(cognitive-behavioral) and pharmacologic. In situations of acute distress, such as a grief reaction, pharmacologic measures may be most appropriate. With primary insomnia, however, initial efforts should be psychologically based. This is particularly true in the elderly to avoid the potential adverse reactions of medications. The elderly population is at risk for complaints of insomnia because sleep becomes lighter and more easily disrupted with aging. Medical disorders that become more common with age may also predispose to insomnia.

A. Psychological

Psychological strategies should include educating the patient regarding good **sleep hygiene**: (1) Go to bed only when sleepy. (2) Use the bed and bedroom only for sleeping and sex. (3) If still awake after 20 minutes, leave the bedroom, pursue a restful activity (such as a bath or meditation), and only return when sleepy. (4) Get up at the same time every morning regardless of the amount of sleep during the night. (5) Discontinue caffeine and nicotine, at least in the evening if not completely. (6) Establish a daily exercise regimen. (7) Avoid alcohol as it may disrupt continuity of sleep. (8) Limit fluids in the evening. (9) Learn and practice relaxation techniques. (10) Establish a bedtime ritual and a routine time for going to sleep. A 2009 study suggests that cognitive behavioral therapy for insomnia was as effective as zolpidem with benefits sustained 1 year after treatment.

B. Medical

When the above measures are insufficient, medications may be useful. Lorazepam (0.5 mg orally nightly), temazepam (7.5–15 mg orally nightly) and the nonbenzodiazepine hypnotics, zolpidem (5–10 mg orally nightly), and zaleplon (5–10 mg orally nightly), are often effective for the elderly population and can be given in larger doses—twice what is prescribed for the elderly—in younger patients. A nonbenzodiazepine hypnotic, eszopiclone (2–3 mg orally), is similar in action to zolpidem and zaleplon but dissimilar in that it is not restricted to short-term use. A lower dose of 1 mg is indicated in the elderly or those with hepatic impairment. It is important to note that short-acting agents like triazolam or zolpidem may lead to amnesic episodes if used on a daily ongoing basis. Longer-acting agents such as flurazepam (half-life of > 48 hours) may accumulate in the elderly and lead to cognitive slowing, ataxia, falls, and somnolence. In general, it is appropriate to use medications for short courses of 1–2 weeks. The medications described above have largely replaced barbiturates as hypnotic agents because of their greater safety in overdose and their lesser hepatic enzyme induction effects. Antihistamines such as diphenhydramine (25 mg orally nightly) or hydroxyzine (25 mg orally nightly) may also be useful for sleep, as they produce no pharmacologic dependency; their anticholinergic effects may, however, produce confusion or urinary symptoms in the elderly. Trazodone, an atypical antidepressant, is a non-habit-forming, effective sleep medication in lower than antidepressant doses (25–150 mg orally at bedtime). Priapism is a rare side effect

requiring emergent treatment. Ramelteon, 8 mg orally at bedtime, is a melatonin receptor agonist that helps with sleep onset and does not appear to have abuse potential. It appears to be safe for ongoing use without the development of tolerance.

Triazolam has achieved popularity as a hypnotic drug because of its very short duration of action. However, because it has been associated with dependency, transient psychotic reactions, anterograde amnesia, and rebound anxiety, it has been removed from the market in several European countries. If used, it must be prescribed only for short periods of time.

2. Hypersomnias (Disorders of Excessive Sleepiness)

► Classification & Clinical Findings

A. Sleep Apnea

This disorder is characterized by cessation of breathing for at least 30 episodes (each lasting about 10 seconds) during the night. There are two types: obstructive and central. (See Chapter 9.)

B. Narcolepsy

Narcolepsy consists of a tetrad of symptoms: (1) Sudden, brief (about 15 minutes) sleep attacks that may occur during any type of activity; (2) cataplexy—sudden loss of muscle tone involving specific small muscle groups or generalized muscle weakness that may cause the person to slump to the floor, unable to move, often associated with emotional reactions and sometimes confused with seizure disorder; (3) sleep paralysis—a generalized flaccidity of muscles with full consciousness in the transition zone between sleep and waking; and (4) hypnagogic hallucinations, visual or auditory, which may precede sleep or occur during the sleep attack. The attacks are characterized by an abrupt transition into REM sleep—a necessary criterion for diagnosis. The disorder begins in early adult life, affects both sexes equally, and usually levels off in severity at about 30 years of age.

REM sleep behavior disorder, characterized by motor dyscontrol and often violent dreams during REM sleep, may be related to narcolepsy.

C. Kleine-Levin Syndrome

This syndrome, which occurs mostly in young men, is characterized by hypersomnic attacks three or four times a year lasting up to 2 days, with hyperphagia, hypersexuality, irritability, and confusion on awakening. It has often been associated with antecedent neurologic insults. It usually remits after age 40.

D. Periodic Limb Movement Disorder (Formerly Called Nocturnal Myoclonus)

Periodic lower leg movements occur only during sleep with subsequent daytime sleepiness, anxiety, depression, and cognitive impairment. Restless leg syndrome includes movements while awake as well.

E. Shift Work Sleep Disorder

Shift work sleep disorder occurs when there is excessive fatigue as a consequence of work occurring during the normal sleep period.

► Treatment

Narcolepsy can be managed by daily administration of a stimulant such as dextroamphetamine sulfate, 10 mg orally in the morning, with increased dosage as necessary. Modafinil is a schedule IV medication FDA-approved for treating the excessive daytime fatigue of narcolepsy as well as for shift work sleep disorder. Usual dosing is 200 mg orally each morning. Its mechanism of action is unknown, yet it is thought to be less of an abuse risk than stimulants that are primarily dopaminergic. Common side effects include headache and anxiety; however, modafinil appears to be generally well tolerated. Modafinil may reduce the efficacy of cyclosporine, oral contraceptives, and other medications by inducing their hepatic metabolism. Imipramine, 75–100 mg orally daily, has been effective in treatment of cataplexy but not narcolepsy.

Periodic limb movement disorder and REM sleep behavior disorder can be treated with clonazepam with variable results. There is no treatment for Kleine-Levin syndrome.

Treatment of sleep apnea is discussed in Chapter 9.

3. Parasomnias (Abnormal Behaviors during Sleep)

These disorders are fairly common in children and less so in adults.

► Classification & Clinical Findings

A. Sleep Terror

Sleep terror (pavor nocturnus) is an abrupt, terrifying arousal from sleep, usually in preadolescent boys although it may occur in adults as well. It is distinct from sleep panic attacks. Symptoms are fear, sweating, tachycardia, and confusion for several minutes, with amnesia for the event.

B. Nightmares

Nightmares occur during REM sleep; sleep terrors in stage 3 or stage 4 sleep.

C. Sleepwalking

Sleepwalking (somnambulism) includes ambulation or other intricate behaviors while still asleep, with amnesia for the event. It affects mostly children aged 6–12 years, and episodes occur during stage 3 or stage 4 sleep in the first third of the night and in REM sleep in the later sleep hours. Sleepwalking in elderly people may be a feature of dementia. Idiosyncratic reactions to drugs (eg, marijuana, alcohol) and medical conditions (eg, partial complex seizures) may be causative factors in adults.

D. Enuresis

Enuresis is involuntary micturition during sleep in a person who usually has voluntary control. Like other parasomnias,

it is more common in children, usually in the 3–4 hours after bedtime, but is not limited to a specific stage of sleep. Confusion during the episode and amnesia for the event are common.

► Treatment

Treatment for sleep terrors is with benzodiazepines (eg, diazepam, 5–20 orally mg at bedtime), since it will suppress stage 3 and stage 4 sleep. Somnambulism responds to the same treatment for the same reason, but simple safety measures should not be neglected. Enuresis may respond to imipramine, 50–100 mg orally at bedtime, although desmopressin nasal spray (an ADH preparation) has increasingly become the treatment of choice for nocturnal enuresis. Behavioral approaches (eg, bells that ring when the pad gets wet) have also been successful.

Bagai K. Obstructive sleep apnea, stroke, and cardiovascular diseases. *Neurologist*. 2010 Nov;16(6):329–39. [PMID: 21150380]
 Morin CM et al. Cognitive behavioral therapy, singly and combined with medication, for persistent insomnia: a randomized controlled trial. *JAMA*. 2009 May 20;301(19):2005–15. [PMID: 19454639]
 Parmet S et al. JAMA patient page. Insomnia. *JAMA*. 2006 Jun 28;295(24):2952. [PMID: 16804158]

DISORDERS OF AGGRESSION

Aggression and violence are symptoms rather than diseases, and most frequently they are not associated with an underlying medical condition. Clinicians are unable to predict dangerous behavior with greater than chance accuracy. Depression, schizophrenia, personality disorders, mania, paranoia, temporal lobe dysfunction, and organic mental states may be associated with acts of aggression. Impulse control disorders are characterized by physical abuse (usually of the aggressor's domestic partner or children), by pathologic intoxication, by impulsive sexual activities, and by reckless driving. Anabolic steroid usage by athletes has been associated with increased tendencies toward violent behavior.

In the United States, a significant proportion of all violent deaths are alcohol-related. The ingestion of even small amounts of alcohol can result in pathologic intoxication that resembles an acute organic mental condition. Amphetamines, crack cocaine, and other stimulants are frequently associated with aggressive behavior. Phencyclidine is a drug commonly associated with violent behavior that is occasionally of a bizarre nature, partly due to lowering of the pain threshold. Domestic violence and rape are much more widespread than previously recognized. Awareness of the problem is to some degree due to increasing recognition of the rights of women and the understanding by women that they do not have to accept abuse. Acceptance of this kind of aggressive behavior inevitably leads to more, with the ultimate aggression being murder—20–50% of murders in the United States occur within the family. Police are called for more domestic disputes than all other criminal incidents combined. Children living in such family situations frequently become victims of abuse.

Features of individuals who have been subjected to long-term physical or sexual abuse are as follows: trouble expressing anger, staying angry longer, general passivity in relationships, feeling “marked for life” with an accompanying feeling of deserving to be victimized, lack of trust, and dissociation of affect from experiences. They are prone to express their psychological distress with somatization symptoms, often pain complaints. They may also have symptoms related to posttraumatic stress, as discussed above. The clinician should be suspicious about the origin of any injuries not fully explained, particularly if such incidents recur.

► Treatment

A. Psychological

Management of any violent individual includes appropriate psychological maneuvers. Move slowly, talk slowly with clarity and reassurance, and evaluate the situation. Strive to create a setting that is minimally disturbing, and eliminate people or things threatening to the violent individual. Do not threaten or abuse, and do not touch or crowd the person. Allow no weapons in the area (an increasing problem in hospital emergency departments). Proximity to a door is comforting to both the patient and the examiner. Use a negotiator the violent person can relate to comfortably. Food and drink are helpful in defusing the situation (as are cigarettes for those who smoke). Honesty is important. Make no false promises, bolster the patient's self-esteem, and continue to engage the subject verbally until the situation is under control. This type of individual does better with strong external controls to replace the lack of inner controls over the long term. Close probationary supervision and judicially mandated restrictions can be most helpful. There should be a major effort to help the individual avoid drug use (eg, Alcoholics Anonymous). Victims of abuse are essentially treated as any victim of trauma and, not infrequently, have evidence of PTSD.

B. Pharmacologic

Pharmacologic means are often necessary whether or not psychological approaches have been successful. This is particularly true in the agitated or psychotic patient. The drug of choice in psychotic aggressive states is haloperidol, 5–10 mg intramuscularly every hour until symptoms are alleviated. Benzodiazepine sedatives (eg, diazepam, 5 mg orally or intravenously every several hours) can be used for mild to moderate agitation, but an antipsychotic drug is preferred for management of the seriously violent and psychotic patient. Chronic aggressive states, particularly in retardation and brain damage (rule out causative organic conditions and medications such as anticholinergic medications in amounts sufficient to cause confusion), have been ameliorated with risperidone, 0.5–2 mg/d orally, propranolol, 40–240 mg/d orally, or pindolol, 5 mg twice daily orally (pindolol causes less bradycardia and hypotension than propranolol). Carbamazepine and valproic acid are effective in the treatment of aggression and explosive disorders, particularly when associated with known or suspected brain lesions. Lithium and SSRIs are also effective

for some intermittent explosive outbursts. Buspirone (10–45 mg/d orally) is helpful for aggression, particularly in mentally retarded patients.

C. Physical

Physical management is necessary if psychological and pharmacologic means are not sufficient. It requires the active and visible presence of an adequate number of personnel (five or six) to reinforce the idea that the situation is under control despite the patient's lack of inner controls. Such an approach often precludes the need for actual physical restraint. When adequate personnel are not available, however, two people shielded by a mattress (single-bed size) can usually corner and subdue the patient without injury to anyone. Seclusion rooms and restraints should be used only when necessary (ambulatory restraints are an alternative), and the patient must then be observed at frequent intervals. Design of corridors and seclusion rooms is important. Narrow corridors, small spaces, and crowded areas exacerbate the potential for violence in an anxious patient.

D. Other Interventions

The treatment of victims (eg, battered women) is challenging and often complicated by their reluctance to leave the situation. Reasons for staying vary, but common themes include the fear of more violence because of leaving, the hope that the situation may ameliorate (in spite of steady worsening), and the financial aspects of the situation, which are seldom to the woman's advantage. Concerns for the children often finally compel the woman to seek help. An early step is to get the woman into a therapeutic situation that provides the support of others in similar straits. Al-Anon is frequently a valuable asset and quite appropriate when alcohol is a factor. The group can support the victim while she gathers strength to consider alternatives without being paralyzed by fear. Many cities now offer temporary emergency centers and counseling. Use the available resources, attend to any medical or psychiatric problems, and maintain a compassionate interest. Some states now require physicians to report injuries caused by abuse or suspected abuse to police authorities.

Johnson DM et al. Cognitive behavioral treatment of PTSD in residents in battered women's shelters: results of a randomized clinical trial. *J Consult Clin Psychol*. 2011 Aug; 79(4): 542–51. [PMID: 21787052]

Rees S et al. Lifetime prevalence of gender-based violence in women and the relationship with mental disorders and psychosocial function. *JAMA*. 2011 Aug 3;305(5):513–21. [PMID: 21813429]

SUBSTANCE USE DISORDERS (DRUG DEPENDENCY, DRUG ABUSE)

The term "drug dependency" is used in a broad sense here to include both addictions and habituations. It involves the triad of compulsive drug use referred to as drug addiction, which includes: (1) a **psychological dependence** or craving

and the behavior involved in procurement of the drug; (2) **physiologic dependence**, with withdrawal symptoms on discontinuance of the drug; and (3) **tolerance**, ie, the need to increase the dose to obtain the desired effects. Drug dependency is a function of the amount of drug used and the duration of usage. The amount needed to produce dependency varies with the nature of the drug and the idiosyncratic nature of the user. The frequency of use is usually daily, and the duration is inevitably > 2–3 weeks. Polydrug abuse is very common. Transgenerational continuity of drug abuse is also common.

There is accumulating evidence that an impairment syndrome exists in many former (and current) drug users. It is believed that drug use produces damaged neurotransmitter receptor sites and that the consequent imbalance produces symptoms that may mimic other psychiatric illnesses. "**Kindling**"—repeated stimulation of the brain—renders the individual more susceptible to focal brain activity with minimal stimulation. Stimulants and depressants can produce kindling, leading to relatively spontaneous effects no longer dependent on the original stimulus. These effects may be manifested as mood swings, panic, psychosis, and occasionally overt seizure activity. The imbalance also results in frequent job changes, marital problems, and generally erratic behavior. Patients with PTSD frequently have treated themselves with a variety of drugs. Chronic abusers of a wide variety of drugs exhibit cerebral atrophy on CT scans, a finding that may relate to the above symptoms. Early recognition is important, mainly to establish realistic treatment programs that are chiefly symptom-directed.

The clinician faces three problems with substance abuse: (1) the prescribing of substances such as sedatives, stimulants, or opioids that might produce dependency; (2) the treatment of individuals who have already abused drugs, most commonly alcohol; and (3) the detection of illicit drug use in patients presenting with psychiatric symptoms. The usefulness of urinalysis for detection of drugs varies markedly with different drugs and under different circumstances (pharmacokinetics is a major factor). Water-soluble drugs (eg, alcohol, stimulants, opioids) are eliminated in a day or so. Lipophilic substances (eg, barbiturates, tetrahydrocannabinol) appear in the urine over longer periods of time: several days in most cases, 1–2 months in chronic marijuana users. Sedative drug determinations are quite variable, amount of drug and duration of use being important determinants. False-positives can be a problem related to ingestion of some legitimate medications (eg, phenytoin for barbiturates, phenylpropanolamine for amphetamines, chlorpromazine for opioids) and some foods (eg, poppy seeds for opioids, coca leaf tea for cocaine). Manipulations can alter the legitimacy of the testing. Dilution, either in vivo or in vitro, can be detected by checking urine specific gravity. Addition of ammonia, vinegar, or salt may invalidate the test, but odor and pH determinations are simple. Hair analysis can determine drug use over longer periods, particularly sequential drug-taking patterns. The sensitivity and reliability of such tests are considered good, and the method may be complementary to urinalysis.

Kosten TR et al. Management of drug and alcohol withdrawal. *N Engl J Med.* 2003 May 1;348(18):1786–95. [PMID: 12724485]
 Marlatt GA. Update on harm-reduction policy and intervention research. *Annu Rev Clin Psychol.* 2010 Apr 27;6:591–606. [PMID: 20192791].

ALCOHOL DEPENDENCY & ABUSE (Alcoholism)



ESSENTIALS OF DIAGNOSIS

Major criteria:

- ▶ Physiologic dependence as manifested by evidence of withdrawal when intake is interrupted.
- ▶ Tolerance to the effects of alcohol.
- ▶ Evidence of alcohol-associated illnesses, such as alcoholic liver disease, cerebellar degeneration.
- ▶ Continued drinking despite strong medical and social contraindications and life disruptions.
- ▶ Impairment in social and occupational functioning.
- ▶ Depression.
- ▶ Blackouts.

Other signs:

- ▶ Alcohol stigmas: alcohol odor on breath, alcoholic facies, flushed face, scleral injection, tremor, ecchymoses, peripheral neuropathy.
- ▶ Surreptitious drinking.
- ▶ Unexplained work absences.
- ▶ Frequent accidents, falls, or injuries of vague origin; in smokers, cigarette burns on hands or chest.
- ▶ Laboratory tests: elevated values of liver function tests, mean corpuscular volume, serum uric acid, and triglycerides.

▶ General Considerations

Alcoholism (also known as alcohol dependence) is a syndrome consisting of two phases: at-risk drinking and alcohol addiction. At-risk drinking is the repetitive use of alcohol, often to alleviate anxiety or solve other emotional problems. Alcohol addiction is a true addiction, similar to that which occurs following the repeated use of other sedative-hypnotics, and is characterized by recurrent use of alcohol despite disruption in social roles (family and work), alcohol-related legal problems, and taking safety risks by oneself and with others. The National Institute on Alcohol Abuse and Alcoholism formally defines at-risk drinking as more than 4 drinks per day or 14 drinks per week for men or more than 3 drinks per day or 7 drinks per week for women. These individuals are at an increased risk for developing or are developing alcohol addiction. Alcohol and other drug abuse patients have a much higher prevalence of lifetime psychiatric disorders. While male-to-female ratios in alcoholic treatment agencies remain at 4:1,

there is evidence that the rates are converging. Women delay seeking help, and when they do they tend to seek it in medical or mental health settings. Adoption and twin studies indicate some genetic influence. Ethnic distinctions are important—eg, 40% of Japanese have aldehyde dehydrogenase deficiency and are more susceptible to the effects of alcohol. Depression is often present and should be evaluated carefully. The majority of suicides and intrafamily homicides involve alcohol. Alcohol is a major factor in rapes and other assaults.

There are several screening instruments that may help identify alcoholism. One of the most useful is the CAGE questionnaire (see Table 1–7).

▶ Clinical Findings

A. Acute Intoxication

The signs of alcoholic intoxication are the same as those of overdose with any other central nervous system depressant: drowsiness, errors of commission, psychomotor dysfunction, disinhibition, dysarthria, ataxia, and nystagmus. For a 70-kg person, an ounce of whiskey, a 4- to 6-oz glass of wine, or a 12-oz bottle of beer (roughly 15, 11, and 13 grams of alcohol, respectively) may raise the level of alcohol in the blood by 25 mg/dL. For a 50-kg person, the blood alcohol level would rise even higher (35 mg/dL) with the same consumption. Blood alcohol levels below 50 mg/dL rarely cause significant motor dysfunction (the legal limit for driving under the influence is commonly 80 mg/dL). Intoxication as manifested by ataxia, dysarthria, and nausea and vomiting indicates a blood level > 150 mg/dL, and lethal blood levels range from 350 to 900 mg/dL. In severe cases, overdose is marked by respiratory depression, stupor, seizures, shock syndrome, coma, and death. Serious overdoses are frequently due to a combination of alcohol with other sedatives.

B. Withdrawal

There is a wide spectrum of manifestations of alcoholic withdrawal, ranging from anxiety, decreased cognition, and tremulousness through increasing irritability and hyperreactivity to full-blown delirium tremens. Symptoms of mild withdrawal, including tremor, elevated vital signs, and anxiety, begin within about 8 hours after the last drink and usually have passed by day 3. Generalized seizures occur within the first 24–38 hours and are more prevalent in persons who have a history of withdrawal syndromes. Delirium tremens is an acute organic psychosis that is usually manifest within 24–72 hours after the last drink (but may occur up to 7–10 days later). It is characterized by mental confusion, tremor, sensory hyperacuity, visual hallucinations (often of snakes, bugs, etc), autonomic hyperactivity, diaphoresis, dehydration, electrolyte disturbances (hypokalemia, hypomagnesemia), seizures, and cardiovascular abnormalities. The acute withdrawal syndrome is often completely unexpected and occurs when the patient has been hospitalized for some unrelated problem and presents as a diagnostic problem. Suspect alcohol withdrawal in every unexplained delirium. The mortality rate from delirium tremens has steadily decreased with early diagnosis and improved treatment.

In addition to the immediate withdrawal symptoms, there is evidence of persistent longer-term ones, including sleep disturbances, anxiety, depression, excitability, fatigue, and emotional volatility. These symptoms may persist for 3–12 months, and in some cases they become chronic.

C. Alcoholic (Organic) Hallucinosis

This syndrome occurs either during heavy drinking or on withdrawal and is characterized by a paranoid psychosis without the tremulousness, confusion, and clouded sensorium seen in withdrawal syndromes. The patient appears normal except for the auditory hallucinations, which are frequently persecutory and may cause the patient to behave aggressively and in a paranoid fashion.

D. Chronic Alcoholic Brain Syndromes

These encephalopathies are characterized by increasing erratic behavior, memory and recall problems, and emotional instability—the usual signs of organic brain injury due to any cause. Wernicke-Korsakoff syndrome due to thiamine deficiency may develop with a series of episodes. Wernicke encephalopathy consists of the triad of confusion, ataxia, and ophthalmoplegia (typically sixth nerve). Early recognition and treatment with thiamine can minimize damage. One of the possible sequelae is Korsakoff psychosis, characterized by both anterograde and retrograde amnesia, with confabulation early in the course. Early recognition and treatment of the alcoholic with intravenous thiamine and B complex vitamins can minimize damage.

E. Laboratory Findings

Ethanol may contribute to the presence of an otherwise unexplained osmolar gap. There may also be elevated liver function tests, increased serum uric acid and triglycerides, and decreased serum potassium and magnesium. The most definitive biologic marker for chronic alcoholism is carbohydrate deficient transferrin, which can detect heavy use (60 mg/d over 7–10 days) with high specificity. Two other tests that may provide clues to an alcohol problem are γ -glutamyl transpeptidase measurement (levels > 30 units/L are suggestive of heavy drinking) and mean corpuscular volume (> 95 fL in men and > 100 fL in women). If both are elevated, a serious drinking problem is likely. Use of other recreational drugs with alcohol skews and negates the significance of these tests. High-density lipoprotein cholesterol elevations combined with elevated γ -glutamyl transpeptidase concentrations also can help identify heavy drinkers.

► Differential Diagnosis

The differential diagnosis of alcoholism is essentially between primary alcoholism (when no other major psychiatric diagnosis exists) and secondary alcoholism (when alcohol is used as self-medication for major underlying psychiatric problems such as schizophrenia or affective disorder). The differentiation is important, since the latter group requires treatment for the specific psychiatric problem. In primary and secondary alcoholism, at-risk drinking can be distinguished from alcohol addiction by taking a careful psychiatric history and evaluating the degree to

which recurrent drinking impacts the social role functioning and physical safety of the individual.

The differential diagnosis of alcohol withdrawal includes other sedative withdrawals and other causes of delirium. Acute alcoholic hallucinosis must be differentiated from other acute paranoid states such as amphetamine psychosis or paranoid schizophrenia. The history and laboratory test results are the most important features in differentiating chronic organic brain syndromes due to alcohol from those due to other causes. The form of the brain syndrome is of little help—eg, chronic brain syndromes from lupus erythematosus may be associated with confabulation similar to that resulting from long-standing alcoholism.

► Complications

The medical, economic, and psychosocial problems of alcoholism are staggering. The central and peripheral nervous system complications include chronic brain syndromes, cerebellar degeneration, cardiomyopathy, and peripheral neuropathies. Direct effects on the liver include cirrhosis, esophageal varices, and eventual hepatic failure. Indirect effects include protein abnormalities, coagulation defects, hormone deficiencies, and an increased incidence of liver neoplasms.

Fetal alcohol syndrome includes one or more of the following developmental defects in the offspring of alcoholic women: (1) low birth weight and small size with failure to catch up in size or weight, (2) mental retardation, with an average IQ in the 60s, and (3) a variety of birth defects, with a large percentage of facial and cardiac abnormalities. The fetuses are very quiet in utero, and there is an increased frequency of breech presentations. There is a higher incidence of delayed postnatal growth and behavior development. The risk is appreciably higher the more alcohol ingested by the mother each day. Cigarette and marijuana smoking as well as cocaine use can produce similar effects on the fetus.

► Treatment of At-Risk Drinking

A. Psychological

The most important consideration for the clinician is to suspect the problem early and take a nonjudgmental attitude, although this does not mean a passive one. The problem of **denial** must be faced, preferably with significant family members at the first meeting. This means dealing from the beginning with any enabling behavior of the spouse or other significant people. Enabling behavior allows the alcoholic to avoid facing the consequences of his or her behavior.

There must be an emphasis on the things that can be done. This approach emphasizes the fact that the clinician cares and strikes a positive and hopeful note early in treatment. Valuable time should not be wasted trying to find out why the patient drinks; come to grips early with the immediate problem of how to stop the drinking. Although total abstinence should be the ultimate goal, a harm reduction model indicates that gradual progress toward abstinence can be a useful treatment stratagem.

Motivational interviewing, a model of counseling that addresses both the patient's ambivalence and motivation for change, may contribute to reduced consumption over time.

B. Social

Get the patient into Alcoholics Anonymous and the spouse into Al-Anon. Success is usually proportionate to the utilization of Alcoholics Anonymous, religious counseling, and other resources. The patient should be seen frequently for short periods and charged an appropriate fee.

Do not underestimate the importance of religion, particularly since the alcoholic is often a dependent person who needs a great deal of support. Early enlistment of the help of a concerned religious adviser can often provide the turning point for a personal conversion to sobriety.

One of the most important considerations is the patient's job—fear of losing a job is one of the most powerful motivations for giving up drink. The business community has become painfully aware of the problem, with the result that about 70% of the Fortune 500 companies offer programs to their employees to help with the problem of alcoholism. In the latter case, some specific recommendations to employers can be offered: (1) Avoid placement in jobs where the alcoholic must be alone, eg, as a traveling buyer or sales executive. (2) Use supervision but not surveillance. (3) Keep competition with others to a minimum. (4) Avoid positions that require quick decision-making on important matters (high-stress situations). In general, commitment to abstinence and avoidance of situations that might be conducive to drinking are most predictive of a good outcome.

C. Medical

Hospitalization is not usually necessary. It is sometimes used to dramatize a situation and force the patient to face the problem of alcoholism, but generally it should be used for medical indications.

Because of the many medical complications of alcoholism, a complete physical examination with appropriate laboratory tests is mandatory, with special attention to the liver and nervous system. Use of sedatives as a replacement for alcohol is not desirable. The usual result is concomitant use of sedatives and alcohol and worsening of the problem. Lithium is not helpful in the treatment of alcoholism.

Disulfiram (250–500 mg/d orally) has been used for many years as an aversive drug to discourage alcohol use. Disulfiram inhibits alcohol dehydrogenase, causing toxic reactions when alcohol is consumed. The results have generally been of limited effectiveness and depend on the motivation of the individual to be compliant.

Naltrexone, an opiate antagonist, in a dosage of 50 mg orally daily, has been helpful in lowering relapse rates over the 3–6 months after cessation of drinking, apparently by lessening the pleasurable effects of alcohol. One study suggests that naltrexone is most effective when given during periods of drinking in combination with therapy that supports abstinence but accepts the fact that relapses occur. Naltrexone is FDA-approved for maintenance therapy. Studies indicate that it reduces alcohol craving when used as part of a comprehensive treatment program. Acamprosate (333–666 mg orally three times daily) helps reduce craving and maintain abstinence, and can be continued even during periods of relapse.

D. Behavioral

Conditioning approaches historically have been used in some settings in the treatment of alcoholism, most commonly as a type of aversion therapy. For example, the patient is given a drink of whiskey and then a shot of apomorphine, and proceeds to vomit. In this way a strong association is built up between the drinking and vomiting. Although this kind of treatment has been successful in some cases, after appropriate informed consent, many people do not sustain the learned aversive response.

▶ Treatment of Hallucinoses & Withdrawal

A. Medical

1. Alcoholic hallucinosis—Alcoholic hallucinosis, which can occur either during or on cessation of a prolonged drinking period, is not a typical withdrawal syndrome and is handled differently. Since the symptoms are primarily those of a psychosis in the presence of a clear sensorium, they are handled like any other psychosis: hospitalization (when indicated) and adequate amounts of antipsychotic medications. Haloperidol, 5 mg orally twice a day for the first day or so, usually ameliorates symptoms quickly, and the drug can be decreased and discontinued over several days as the patient improves. It then becomes necessary to deal with the chronic alcohol abuse, which has been discussed.

2. Withdrawal symptoms—The onset of withdrawal symptoms is usually 8–12 hours and the peak intensity of symptoms is 48–72 hours after alcohol consumption is stopped. Providing adequate central nervous system depressants (eg, benzodiazepines) is important to counteract the excitability resulting from sudden cessation of alcohol intake. The choice of a specific sedative is less important than using adequate doses to bring the patient to a level of moderate sedation, and this will vary from person to person. Mild dependency requires “drying out.” In some instances for outpatients, a short course of tapering long-acting benzodiazepines—eg, diazepam, 20 mg orally daily initially, decreasing by 5 mg daily—may be a useful adjunct. In moderate to severe withdrawal, hospitalize the patient and use diazepam orally in a dosage of 5–10 mg hourly depending on the clinical need as judged by withdrawal symptoms, including nausea, tremor, autonomic hyperactivity, agitation; tactile, visual, and auditory hallucinations; and disorientation. This type of symptom-driven medication regimen for withdrawal appears to reduce total benzodiazepine usage over fixed-dose schedules. Antipsychotic medications should not be used. Monitoring of vital signs and fluid and electrolyte levels is essential for the severely ill patient.

In very severe withdrawal, intravenous administration is necessary. After stabilization, the amount of diazepam required to maintain a sedated state may be given orally every 8–12 hours. If restlessness, tremulousness, and other signs of withdrawal persist, the dosage is increased until moderate sedation occurs. The dosage is then gradually reduced by 20% every 24 hours until withdrawal is complete. This usually requires a week or so of treatment. Clonidine, 5 mcg/kg orally every 2 hours, or the patch

formulation of appropriate dosage strength, suppresses cardiovascular signs of withdrawal and has some anxiolytic effect. Carbamazepine, 400–800 mg daily orally, compares favorably with benzodiazepines for alcohol withdrawal.

Atenolol, as an adjunct to benzodiazepines, can reduce symptoms of alcohol withdrawal. The daily oral atenolol dose is 100 mg when the heart rate is above 80 beats per minute and 50 mg for a heart rate between 50 and 80 beats per minute. Atenolol should not be used when bradycardia is present.

Meticulous examination for other medical problems is necessary. Alcoholic hypoglycemia can occur with low blood alcohol levels (see Chapter 27). Alcoholics commonly have liver disease and associated clotting problems and are also prone to injury—and the combination all too frequently leads to undiagnosed subdural hematoma.

Phenytoin does not appear to be useful in managing alcohol withdrawal seizures *per se*. Sedating doses of benzodiazepines are effective in treating alcohol withdrawal seizures. Thus, other anticonvulsants are not usually needed unless there is a preexisting seizure disorder.

A general diet should be given, and vitamins in high doses: thiamine, 50 mg intravenously initially, then intramuscularly on a daily basis; pyridoxine, 100 mg/d; folic acid, 1 mg/d; and ascorbic acid, 100 mg twice a day. Intravenous glucose solutions should not be given prior to thiamine for fear of precipitating Wernicke syndrome. Thiamine is necessary as a ketolase enzyme cofactor. Concurrent administration of vitamins is satisfactory, and hydration should be meticulously assessed on an ongoing basis.

Chronic brain syndromes secondary to a long history of alcohol intake are not clearly responsive to thiamine and vitamin replenishment. Attention to the social and environmental care of this type of patient is paramount.

B. Psychological and Behavioral

The comments in the section on problem drinking apply here also; these methods of treatment become the primary consideration after successful treatment of withdrawal or alcoholic hallucinosis. Psychological and social measures should be initiated in the hospital prior to discharge. This increases the possibility of continued post-hospitalization treatment.

Apodaca TR et al. Mechanisms of change in motivational interviewing: a review and preliminary evaluation of the evidence. *Addiction*. 2009 May;104(5):716–7. [PMID: 19413785]
 de Wit M et al. Alcohol-use disorders in the critically ill patient. *Chest*. 2010 Oct;138(4):994–1003. [PMID: 20923804]
 Johnson BA. Medication treatment of different types of alcoholism. *Am J Psychiatry*. 2010 Jun;167(6):630–9. [PMID: 20516163]
 Ringold S et al. JAMA patient page. Alcohol abuse and alcoholism. *JAMA*. 2006 May 3;295(17):2100. [PMID: 16670424]

OTHER DRUG & SUBSTANCE DEPENDENCIES

1. Opioids

While the terms “opioids” and “narcotics” both refer to a group of drugs with actions that mimic those of morphine, the term “opioids” is used when discussing medications

prescribed in a controlled manner by a clinician, and the term “narcotics” is used to connote illicit drug use. The group includes natural derivatives of opium (opiates), synthetic surrogates (opioids), and a number of polypeptides, some of which have been discovered to be natural neurotransmitters. The principal narcotic of abuse is heroin (metabolized to morphine), which is not used as a legitimate medication. The other common opioids are prescription medications that differ in milligram potency, duration of action, and agonist and antagonist capabilities (see Chapter 5). All of the opioid analgesics can be reversed by the opioid antagonist naloxone.

The clinical symptoms and signs of mild narcotic intoxication include changes in mood, with feelings of euphoria; drowsiness; nausea with occasional emesis; needle tracks; and miosis. The incidence of snorting and inhaling heroin (“smoking”) is increasing, particularly among cocaine users. This coincides with a decrease in the availability of methaqualone (no longer marketed) and other sedatives used to temper the cocaine “high” (see discussion of cocaine under Stimulants, below). Overdosage causes respiratory depression, peripheral vasodilation, pinpoint pupils, pulmonary edema, coma, and death.

Dependency is a major concern when continued use of opioids occurs, although withdrawal causes only moderate morbidity (similar in severity to a bout of “flu”). Addicted patients sometimes consider themselves more addicted than they really are and may not require a withdrawal program. Grades of withdrawal are categorized from 0 to 4: grade 0 includes craving and anxiety; grade 1, yawning, lacrimation, rhinorrhea, and perspiration; grade 2, previous symptoms plus mydriasis, piloerection, anorexia, tremors, and hot and cold flashes with generalized aching; grades 3 and 4, increased intensity of previous symptoms and signs, with increased temperature, blood pressure, pulse, and respiratory rate and depth. In withdrawal from the most severe addiction, vomiting, diarrhea, weight loss, hemoconcentration, and spontaneous ejaculation or orgasm commonly occur. Complications of heroin administration include infections (eg, pneumonia, septic emboli, hepatitis, and HIV infection from using nonsterile needles), traumatic insults (eg, arterial spasm due to drug injection, gangrene), and pulmonary edema.

Treatment for overdosage (or suspected overdosage) is naloxone, 2 mg intravenously. If an overdose has been taken, the results are dramatic and occur within 2 minutes. Since the duration of action of naloxone is much shorter than that of the opioids, the patient must be under close observation. Hospitalization, supportive care, repeated naloxone administration, and observation for withdrawal from other drugs should be maintained for as long as necessary.

Treatment for withdrawal begins if grade 2 signs develop. If a withdrawal program is necessary, use methadone, 10 mg orally (use parenteral administration if the patient is vomiting), and observe. If signs (piloerection, mydriasis, cardiovascular changes) persist for > 4–6 hours, give another 10 mg; continue to administer methadone at 4- to 6-hour intervals until signs are not present (rarely > 40 mg of methadone in 24 hours). Divide the total amount of drug required over the first 24-hour period by 2

and give that amount every 12 hours. Each day, reduce the total 24-hour dose by 5–10 mg. Thus, a moderately addicted patient initially requiring 30–40 mg of methadone could be withdrawn over a 4- to 8-day period. Clonidine, 0.1 mg orally several times daily over a 10- to 14-day period, is both an alternative and an adjunct to methadone detoxification; it is not necessary to taper the dose. Clonidine is helpful in alleviating cardiovascular symptoms but does not significantly relieve anxiety, insomnia, or generalized aching. There is a protracted abstinence syndrome of metabolic, respiratory, and blood pressure changes over a period of 3–6 months.

Opioid antagonists (eg, naltrexone) can also be used successfully for treatment of the patient who has been free of opioids for 7–10 days. Naltrexone blocks the narcotic “high” of heroin when 50 mg is given orally every 24 hours initially for several days and then 100 mg is given every 48–72 hours. A monthly injectable form of naltrexone has become available and may enhance compliance. Liver disorders are a major contraindication. Buprenorphine, a partial agonist, has become a mainstay of office-based treatment of opiate dependency. Its use requires certified training.

Alternative strategies for the treatment of opioid withdrawal have included rapid and ultrarapid detoxification techniques. However, recent data do not support the use of either method. Methadone maintenance programs are of some value in chronic recidivism. Under carefully controlled supervision, the narcotic addict is maintained on fairly high doses of methadone (40–120 mg/d) that satisfy craving and block the effects of heroin to a great degree.

2. Sedatives (Anxiolytics)

See Anxiety Disorders, this chapter.

3. Psychedelics

About 6000 species of plants have psychoactive properties. All of the common psychedelics (LSD, mescaline, psilocybin, dimethyltryptamine, and other derivatives of phenylalanine and tryptophan) can produce similar behavioral and physiologic effects. An initial feeling of tension is followed by emotional release such as crying or laughing (1–2 hours). Later, perceptual distortions occur, with visual illusions and hallucinations, and occasionally there is fear of ego disintegration (2–3 hours). Major changes in time sense and mood lability then occur (3–4 hours). A feeling of detachment and a sense of destiny and control occur (4–6 hours). Of course, reactions vary among individuals, and some of the drugs produce markedly different time frames. Occasionally, the acute episode is terrifying (a “bad trip”), which may include panic, depression, confusion, or psychotic symptoms. Preexisting emotional problems, the attitude of the user, and the setting where the drug is used affect the experience.

Treatment of the acute episode primarily involves protection of the individual from erratic behavior that may lead to injury or death. A structured environment is usually sufficient until the drug is metabolized. In severe cases, antipsychotic medications with minimal side effects (eg, haloperidol, 5 mg intramuscularly) may be given every

several hours until the individual has regained control. In cases where “flashbacks” occur (mental imagery from a “bad trip” that is later triggered by mild stimuli such as marijuana, alcohol, or psychic trauma), a short course of an antipsychotic drug—eg, olanzapine, 5–10 mg/d, or risperidone, 2 mg/d, initially, and up to 20 mg/d and 6 mg/d, respectively—is usually sufficient. Lorazepam, 1–2 mg orally or intramuscularly every 2 hours as needed for acute agitation, may be a useful adjunct. An occasional patient may have “flashbacks” for much longer periods and require small doses of neuroleptic medications over the longer term.

4. Phencyclidine

Phencyclidine (PCP, angel dust, peace pill, hog), developed as an anesthetic agent, first appeared as a street drug deceptively sold as tetrahydrocannabinol (THC). Because it is simple to produce and mimics to some degree the traditional psychedelic drugs, PCP has become a common deceptive substitute for LSD, THC, and mescaline. It is available in crystals, capsules, and tablets to be inhaled, injected, swallowed, or smoked (it is commonly sprinkled on marijuana).

Absorption after smoking is rapid, with onset of symptoms in several minutes and peak symptoms in 15–30 minutes. Mild intoxication produces euphoria accompanied by a feeling of numbness. Moderate intoxication (5–10 mg) results in disorientation, detachment from surroundings, distortion of body image, combativeness, unusual feats of strength (partly due to its anesthetic activity), and loss of ability to integrate sensory input, especially touch and proprioception. Physical symptoms include dizziness, ataxia, dysarthria, nystagmus, retracted upper eyelid with blank stare, hyperreflexia, and tachycardia. There are increases in blood pressure, respiration, muscle tone, and urine production. Usage in the first trimester of pregnancy is associated with an increase in spontaneous abortion and congenital defects. Severe intoxication (20 mg or more) produces an increase in degree of moderate symptoms, with the addition of seizures, deepening coma, hypertensive crisis, and severe psychotic ideation. The drug is particularly long-lasting (several days to several weeks) owing to high lipid solubility, gastroenteric recycling, and the production of active metabolites. Overdosage may be fatal, with the major causes of death being hypertensive crisis, respiratory arrest, and convulsions. Acute rhabdomyolysis has been reported and can result in myoglobinuric kidney failure.

Differential diagnosis involves the whole spectrum of street drugs, since in some ways phencyclidine mimics sedatives, psychedelics, and marijuana in its effects. Blood and urine testing can detect the acute problem.

Treatment is discussed in Chapter 38.

5. Marijuana

Cannabis sativa, a hemp plant, is the source of marijuana. The parts of the plant vary in potency. The resinous exudate of the flowering tops of the female plant (hashish, charas) is the most potent, followed by the dried leaves and flowering shoots of the female plant (bhanga) and the resinous mass from small leaves of inflorescence (ganja). The least potent

parts are the lower branches and the leaves of the female plant and all parts of the male plant. Mercury may be a contaminant in marijuana grown in volcanic soil. The drug is usually inhaled by smoking. Effects occur in 10–20 minutes and last 2–3 hours. “Joints” of good quality contain about 500 mg of marijuana (which contains approximately 5–15 mg of tetrahydrocannabinol with a half-life of 7 days). Marijuana soaked in formaldehyde and dried (“AMP”) has produced unusual effects, including autonomic discharge and severe though transient cognitive impairment.

With moderate dosage, marijuana produces two phases: mild euphoria followed by sleepiness. In the acute state, the user has an altered time perception, less inhibited emotions, psychomotor problems, impaired immediate memory, and conjunctival injection. High doses produce transient psychotomimetic effects. No specific treatment is necessary except in the case of the occasional “bad trip,” in which case the person is treated in the same way as for psychedelic usage. Marijuana frequently aggravates existing mental illness and adversely affects motor performance.

Studies of long-term effects have conclusively shown abnormalities in the pulmonary tree. Laryngitis and rhinitis are related to prolonged use, along with chronic obstructive pulmonary disease. Electrocardiographic abnormalities are common, but no chronic cardiac disease has been linked to marijuana use. Long-term usage has resulted in depression of plasma testosterone levels and reduced sperm counts. Abnormal menstruation and failure to ovulate have occurred in some women. Cognitive impairments are common. Health care utilization for a variety of health problems is increased in long-term marijuana smokers. Sudden withdrawal produces insomnia, nausea, myalgia, and irritability. Psychological effects of long-term marijuana usage are still unclear. Urine testing is reliable if samples are carefully collected and tested. Detection periods span 4–6 days in short-term users and 20–50 days in long-term users.

6. Stimulants: Amphetamines & Cocaine

Stimulant abuse is quite common, either alone or in combination with abuse of other drugs. The stimulants include illicit drugs such as methamphetamine (“speed”)—one variant is a smokable form called “ice,” which gives an intense and fairly long-lasting high—and methylphenidate and dextroamphetamine, which are under prescription control. Street availability of amphetamines remains high. Moderate usage of any of the stimulants produces hyperactivity, a sense of enhanced physical and mental capacity, and sympathomimetic effects. The clinical picture of acute stimulant intoxication includes sweating, tachycardia, elevated blood pressure, mydriasis, hyperactivity, and an acute brain syndrome with confusion and disorientation. Tolerance develops quickly, and, as the dosage is increased, hypervigilance, paranoid ideation (with delusions of parasitosis), stereotypy, bruxism, tactile hallucinations of insect infestation, and full-blown psychoses occur, often with persecutory ideation and aggressive responses. Stimulant withdrawal is characterized by depression with symptoms of hyperphagia and hypersomnia.

People who have used stimulants chronically (eg, anorexigenics) occasionally become sensitized (“**kindling**”) to future use of stimulants. In these individuals, even small amounts of mild stimulants such as caffeine can cause symptoms of paranoia and auditory hallucinations.

Cocaine is a stimulant. It is a product of the coca plant. The derivatives include seeds, leaves, coca paste, cocaine hydrochloride, and the free base of cocaine. Cocaine hydrochloride is the salt and the most commonly used form. Free base, a purer (and stronger) derivative called “**crack**,” is prepared by simple extraction from cocaine hydrochloride.

There are various modes of use. Coca leaf chewing involves toasting the leaves and chewing with alkaline material (eg, the ash of other burned leaves) to enhance buccal absorption. One achieves a mild high, with onset in 5–10 minutes and lasting for about an hour. Intranasal use is simply snorting cocaine through a straw. Absorption is slowed somewhat by vasoconstriction (which may eventually cause tissue necrosis and septal perforation); the onset of action is in 2–3 minutes, with a moderate high (euphoria, excitement, increased energy) lasting about 30 minutes. The purity of the cocaine is a major determinant of the high. Intravenous use of cocaine hydrochloride or “free-base” is effective in 30 seconds and produces a short-lasting, fairly intense high of about 15 minutes’ duration. The combined use of cocaine and ethanol results in the metabolic production of cocaethylene by the liver. This substance produces more intense and long-lasting cocaine-like effects. Smoking freebase (volatilized cocaine because of the lower boiling point) acts in seconds and results in an intense high lasting several minutes. The intensity of the reaction is related to the marked lipid solubility of the freebase form and produces by far the most severe medical and psychiatric symptoms.

Cardiovascular collapse, arrhythmias, myocardial infarction, and transient ischemic attacks have been reported. Seizures, strokes, migraine symptoms, hyperthermia, and lung damage may occur, and there are several obstetric complications, including spontaneous abortion, abruptio placentae, teratogenic effects, delayed fetal growth, and prematurity. Cocaine can cause anxiety, mood swings, and delirium, and chronic use can cause the same problems as other stimulants (see above).

Clinicians should be alert to cocaine use in patients presenting with unexplained nasal bleeding, headaches, fatigue, insomnia, anxiety, depression, and chronic hoarseness. Sudden withdrawal of the drug is not life-threatening but usually produces craving, sleep disturbances, hyperphagia, lassitude, and severe depression (sometimes with suicidal ideation) lasting days to weeks.

Treatment is imprecise and difficult. Since the high is related to blockage of dopamine reuptake, the dopamine agonist bromocriptine, 1.5 mg orally three times a day, alleviates some of the symptoms of craving associated with acute cocaine withdrawal. Other dopamine agonists such as apomorphine, levodopa, and amantadine are under study for this purpose. Carbamazepine may be a useful adjunct in treating symptoms of alcohol withdrawal, and desipramine in moderate doses has been useful in helping maintain abstinence in the early stages of treatment.

Treatment of psychosis is the same as that of any psychosis: antipsychotic medications in dosages sufficient to alleviate the symptoms. Any medical symptoms (eg, hyperthermia, seizures, hypertension) are treated specifically. These approaches should be used in conjunction with a structured program, most often based on the Alcoholics Anonymous model. Hospitalization may be required if self-harm or violence toward others is a perceived threat (usually indicated by paranoid delusions).

7. Caffeine

Caffeine, along with nicotine and alcohol, is one of the most commonly used drugs worldwide. About 10 billion pounds of coffee (the richest source of caffeine) are consumed yearly throughout the world. Tea, cocoa, and cola drinks also contribute to an intake of caffeine that is often astoundingly high in a large number of people. Low to moderate doses (30–200 mg/d) tend to improve some aspects of performance (eg, vigilance). The approximate content of caffeine in a (180-mL) cup of beverage is as follows: brewed coffee, 80–140 mg; instant coffee, 60–100 mg; decaffeinated coffee, 1–6 mg; black leaf tea, 30–80 mg; tea bags, 25–75 mg; instant tea, 30–60 mg; cocoa, 10–50 mg; and 12-oz cola drinks, 30–65 mg. A 2-oz chocolate candy bar has about 20 mg. Some herbal teas (eg, “morning thunder”) contain caffeine. Caffeine-containing analgesics usually contain approximately 30 mg per unit. Symptoms of caffeinism (usually associated with ingestion of over 500 mg/d) include anxiety, agitation, restlessness, insomnia, a feeling of being “wired,” and somatic symptoms referable to the heart and gastrointestinal tract. It is common for a case of caffeinism to present as an anxiety disorder. It is also common for caffeine and other stimulants to precipitate severe symptoms in compensated schizophrenic and manic-depressive patients. Chronically depressed patients often use caffeine drinks as self-medication. This diagnostic clue may help distinguish some major affective disorders. Withdrawal from caffeine (> 250 mg/d) can produce headaches, irritability, lethargy, and occasional nausea.

8. Miscellaneous Drugs, Solvents

The principal over-the-counter drugs of concern have been phenylpropanolamine and an assortment of antihistaminic agents, frequently in combination with a mild analgesic promoted as cold remedies. Medications containing phenylpropanolamine have been removed from sale in the United States due to an FDA ban. The major problem in use of phenylpropanolamine relates to its side effects as a stimulant, including precipitation of anxiety states, increased blood pressure effects, auditory and visual hallucinations, paranoid ideation, and occasionally delirium. Aggressiveness and some loss of impulse control were reported as well as sleep disturbances even with small doses.

Antihistamines usually produce some central nervous system depression—thus their use as over-the-counter sedatives. Practically all of the so-called sleep aids are antihistamines. The mixture of antihistamines with alcohol usually exacerbates the central nervous system effects. Scopolamine and bromides have generally been removed from over-the-counter products.

The abuse of laxatives sometimes can lead to electrolyte disturbances that may contribute to the manifestations of a delirium. The greatest use of laxatives tends to be in the elderly and in those with eating disorders, both of whom are the most vulnerable to physiologic changes.

Anabolic steroids are being abused by people who wish to increase muscle mass for cosmetic reasons or for greater strength. In addition to the medical problems, the practice is associated with significant mood swings, aggressiveness, and paranoid delusions. Alcohol and stimulant use is higher in these individuals. Withdrawal symptoms of steroid dependency include fatigue, depressed mood, restlessness, and insomnia.

Amyl nitrite has been used as an “orgasm expander.” The changes in time perception, “rush,” and mild euphoria caused by the drug prompted its nonmedical use, and popular lore concerning the effects of inhalation just prior to orgasm has led to increased use. Subjective effects last from 5 seconds to 15 minutes. Tolerance develops readily, but there are no known withdrawal symptoms. Abstinence for several days reestablishes the previous level of responsiveness. Long-term effects may include damage to the immune system and respiratory difficulties.

Sniffing of solvents and inhaling of gases (including aerosols) produce a form of inebriation similar to that of the volatile anesthetics. Agents include gasoline, toluene, petroleum ether, lighter fluids, cleaning fluids, paint thinners, and solvents that are present in many household products (eg, nail polish, typewriter correction fluid). Typical intoxication states include euphoria, slurred speech, hallucinations, and confusion, and with high doses, acute manifestations are unconsciousness and cardiorespiratory depression or failure; chronic exposure produces a variety of symptoms related to the liver, kidney, bone marrow, or heart. Lead encephalopathy can be associated with sniffing leaded gasoline. In addition, studies of workers chronically exposed to jet fuel showed significant increases in neuroathenic symptoms, including fatigue, anxiety, mood changes, memory difficulties, and somatic complaints. These same problems have been noted in long-term solvent abuse.

The so-called designer drugs are synthetic substitutes for commonly used recreational drugs and are produced in small, clandestine laboratories. The most common designer drugs have been methyl analogues of fentanyl and have been used as heroin substitutes. MDMA (methylenedioxymethamphetamine), an amphetamine derivative sometimes called “ecstasy,” is also a designer drug with high abuse potential and neurotoxicity. Often not detected by standard toxicology screens, these substances can present a vexing problem for clinicians faced with symptoms from a totally unknown cause.

Alford DP et al. Collaborative care of opioid-addicted patients in primary care using buprenorphine: five-year experience. *Arch Intern Med.* 2011 Mar 14;171(5):425–31. [PMID: 21403039]

Hoch E et al. Efficacy of a targeted cognitive-behavioral treatment program for cannabis use disorders (CANDIS®). *Eur Neuropsychopharmacol.* 2012 Apr; 22(4):267–80. [PMID: 21865014]

DELIRIUM & OTHER COGNITIVE DISORDERS (FORMERLY: ORGANIC BRAIN SYNDROME)

ESSENTIALS OF DIAGNOSIS

- ▶ Transient or permanent brain dysfunction.
- ▶ Cognitive impairment to varying degrees.
- ▶ Impaired recall and recent memory, inability to focus attention, random psychomotor activity such as stereotypy, and problems in perceptual processing, often with psychotic ideation.
- ▶ Emotional disorders frequently present: depression, anxiety, irritability.
- ▶ Behavioral disturbances: impulse control, sexual acting-out, attention deficits, aggression, and exhibitionism.

▶ General Considerations

The organic problem may be a primary brain disease or a secondary manifestation of some general disorder. All of

the cognitive disorders show some degree of impaired thinking depending on the site of involvement, the rate of onset and progression, and the duration of the underlying brain lesion. Emotional disturbances (eg, depression) are often present as significant comorbidities. The behavioral disturbances tend to be more common with chronicity, more directly related to the underlying personality or central nervous system vulnerability to drug side effects, and not necessarily correlated with cognitive dysfunction.

The causes of cognitive disorders are listed in Table 25–11.

▶ Clinical Findings

The manifestations are many and varied and include problems with orientation, short or fluctuating attention span, loss of recent memory and recall, impaired judgment, emotional lability, lack of initiative, impaired impulse control, inability to reason through problems, depression (worse in mild to moderate types), confabulation (not limited to alcohol organic brain syndrome), constriction of intellectual functions, visual and auditory hallucinations, and delusions. Physical findings will naturally vary according to the cause. The electroencephalogram usually shows generalized slowing in delirium.

Table 25–11. Etiology of delirium and other cognitive disorders.

Disorder	Possible Causes
Intoxication	Alcohol, sedatives, bromides, analgesics (eg, pentazocine), psychedelic drugs, stimulants, and household solvents.
Drug withdrawal	Withdrawal from alcohol, sedative-hypnotics, corticosteroids.
Long-term effects of alcohol	Wernicke-Korsakoff syndrome.
Infections	Septicemia; meningitis and encephalitis due to bacterial, viral, fungal, parasitic, or tuberculous organisms or to central nervous system syphilis; acute and chronic infections due to the entire range of microbiologic pathogens.
Endocrine disorders	Thyrotoxicosis, hypothyroidism, adrenocortical dysfunction (including Addison disease and Cushing syndrome), pheochromocytoma, insulinoma, hypoglycemia, hyperparathyroidism, hypoparathyroidism, panhypopituitarism, diabetic ketoacidosis.
Respiratory disorders	Hypoxia, hypercapnia.
Metabolic disturbances	Fluid and electrolyte disturbances (especially hyponatremia, hypomagnesemia, and hypercalcemia), acid-base disorders, hepatic disease (hepatic encephalopathy), kidney failure, porphyria.
Nutritional deficiencies	Deficiency of vitamin B ₁ (beriberi), vitamin B ₁₂ (pernicious anemia), folic acid, nicotinic acid (pellagra); protein-calorie malnutrition.
Trauma	Subdural hematoma, subarachnoid hemorrhage, intracerebral bleeding, concussion syndrome.
Cardiovascular disorders	Myocardial infarctions, cardiac arrhythmias, cerebrovascular spasms, hypertensive encephalopathy, hemorrhages, embolisms, and occlusions indirectly cause decreased cognitive function.
Neoplasms	Primary or metastatic lesions of the central nervous system, cancer-induced hypercalcemia.
Seizure disorders	Ictal, interictal, and postictal dysfunction.
Collagen-vascular and immunologic disorders	Autoimmune disorders, including systemic lupus erythematosus, Sjögren syndrome, and AIDS.
Degenerative diseases	Alzheimer disease, Pick disease, multiple sclerosis, parkinsonism, Huntington chorea, normal pressure hydrocephalus.
Medications	Anticholinergic medications, antidepressants, H ₂ -blocking agents, digoxin, salicylates (long-term use), and a wide variety of other over-the-counter and prescribed medications.

A. Delirium

Delirium (acute confusional state) is a transient global disorder of attention, with clouding of consciousness, usually a result of systemic problems (eg, medications, hypoxemia). Onset is usually rapid. The mental status fluctuates (impairment is usually least in the morning), with varying inability to concentrate, maintain attention, and sustain purposeful behavior. There is a marked deficit of short-term memory and recall. Anxiety and irritability are common. Amnesia is retrograde (impaired recall of past memories) and anterograde (inability to recall events after the onset of the delirium). Orientation problems follow the inability to retain information. Perceptual disturbances (often visual hallucinations) and psychomotor restlessness with insomnia are common. Autonomic changes include tachycardia, dilated pupils, and sweating. The average duration is about 1 week, with full recovery in most cases. Delirium can coexist with dementia. Delirium may be hypoactive, hyperactive, or mixed. “Sundowning”—mild to moderate delirium at night—is more common in patients with preexisting dementia and may be precipitated by hospitalization, medications, and sensory deprivation.

Terminal delirium occurs commonly at the end of life. The delirium may be related to multiple medical causes, including organ failure, and may be unrecognized. Treatment must be based on a careful evaluation of the underlying etiology and the risks and benefits of available medical and nonmedical interventions.

B. Dementia

(See Chapters 4 and 24.) Dementia is characterized by chronicity and deterioration of selective mental functions. Specific cognitive assessment must be performed, since many patients are able to cover a deficit in routine conversation. The Mini-Mental State Examination produces a numerical score with up to 30 points given for correct answers to questions (likely organic < 27 points).

In all types of dementia, loss of impulse control (sexual and language) is common. The tenuous level of functioning makes the individual most susceptible to minor physical and psychological stresses. **Pseudodementia** is a term applied to depressed patients who appear to be demented. These patients are often identifiable by their tendency to complain about memory problems vociferously rather than try to cover them up. They usually say they cannot complete cognitive tasks but with encouragement can often do so. They can be considered to have depression-induced reversible dementia that remits when the depression resolves.

C. Amnestic Syndrome

This is a memory disturbance without delirium or dementia. It is usually associated with thiamine deficiency and chronic alcohol use (eg, Korsakoff syndrome). There is an impairment in the ability to learn new information or recall previously learned information.

D. Substance-Induced Hallucinosis

This condition is characterized by persistent or recurrent hallucinations (usually auditory) without the other symptoms

usually found in delirium or dementia. Alcohol or hallucinogens are often the cause. There does not have to be any other mental disorder, and there may be complete spontaneous resolution.

E. Personality Changes Due to a General Medical Condition (Formerly Organic Personality Syndrome)

This syndrome is characterized by emotional lability and loss of impulse control along with a general change in personality. Cognitive functions are preserved. Social inappropriateness is common. Loss of interest and lack of concern with the consequences of one's actions are often present. The course depends on the underlying cause (eg, frontal lobe contusion may resolve completely).

► Differential Diagnosis

The differential diagnosis consists mainly of schizophrenia and the other psychoses, which are sometimes confused with cognitive disorders and are often accompanied by psychotic symptoms.

► Complications

Chronicity may result from delayed correction of the defect, eg, subdural hematoma, low-pressure hydrocephalus. Accidents secondary to impulsive behavior and poor judgment are a major consideration. Secondary depression and impulsive behavior not infrequently lead to suicide attempts. Medications—particularly sedatives—may worsen thinking abilities and contribute to the overall problems.

► Treatment

A. Medical

Delirium should be considered a syndrome of acute brain dysfunction analogous to acute kidney failure. The first aim of treatment is to identify and correct the etiologic medical problem. Evaluation should consist of a comprehensive physical examination including a search for neurologic abnormalities, infection, or hypoxia. Routine laboratory tests may include serum electrolytes, serum glucose, BUN, serum creatinine, liver function tests, thyroid function tests, arterial blood gases, complete blood count, serum calcium, phosphorus, magnesium, vitamin B₁₂, folate, blood cultures, urinalysis, and cerebrospinal fluid analysis. Discontinue medications that may be contributing to the problem (eg, analgesics, corticosteroids, cimetidine, lidocaine, anticholinergic medications, central nervous system depressants, mefloquine). Do not overlook any possibility of reversible organic disease. Electroencephalography, CT, and MRI evaluations of the brain may be helpful in diagnosis. Ideally, the patient should be monitored without further medications while the evaluation is carried out. There are, however, two indications for medication in delirious states: behavioral control (eg, pulling out lines) and subjective distress (eg, pronounced fear due to hallucinations). If these indications are present, medications may be used. If there is any

hint of alcohol or substance withdrawal (the most common cause of delirium in the general hospital), a benzodiazepine such as lorazepam (1–2 mg every hour) can be given parenterally. If there is little likelihood of withdrawal syndrome, haloperidol is often used in doses of 1–10 mg every hour. Given intravenously under ECG monitoring, it appears to impose slight risk of extrapyramidal side effects. In addition to the medication, a pleasant, comfortable, nonthreatening, and physically safe environment with adequate nursing or attendant services should be provided. Once the underlying condition has been identified and treated, adjunctive medications can be tapered.

Treatment of the behavioral manifestations of the **dementia syndrome** usually involve trying to positively reinforce healthy behaviors and not reinforcing maladaptive behaviors (such as aggression). Arranging the physical environment to maximize autonomy as much as feasible and promote regularity of routine, helps the individual cope with their limited intellectual reserves. Simple, direct statements are more easily comprehended by these individuals. Understanding how their decreased cognitive function limits their abilities is important. For example, one elderly man in a residential apartment kept complaining that someone was stealing his ice cream at night. Realizing that he was unable to recall eating it himself, his “delusion” made a certain sense. Once his caregivers understood this, they were able to be more compassionate in listening to his complaints and less worried about an ice cream burglar.

Aggressiveness and rage states in dementia can be reduced with lipophilic β -blockers (eg, propranolol, metoprolol) in moderate doses. Since the serotonergic system has been implicated in arousal conditions, medications that affect serotonin have been found to be of some benefit in aggression and agitation. Included in this group are lithium, trazodone, buspirone, and clonazepam. Dopamine blockers (eg, the neuroleptic medications such as haloperidol) have been used for many years to attenuate aggression. Atypical neuroleptics may have a role in selected geriatric patients; however, there are reports of increased mortality in some studies related to the use of atypical neuroleptics (equaling the elevated mortality of the typical agents) in this population. There are also reports of reduced agitation in Alzheimer disease from carbamazepine, 100–400 mg/d orally (with slow increase as needed). Emotional lability in some cases responds to small doses of imipramine (25 mg orally one to three times per day) or fluoxetine (5–20 mg/d orally); depression, which often occurs early in the course of Alzheimer dementia, responds to the usual doses of antidepressant medications, preferably those with the least anticholinergic side effects (eg, SSRIs and MAO inhibitors).

Ergotoxine alkaloids (ergoloid mesylates: Hydergine, others) have been studied with mixed results; improvement in ambulatory self-care and depressed mood has been noted, but there has been no improvement of cognitive functioning on any standardized tests. Stimulant medications (eg, methylphenidate) do not change cognitive function but can improve affect and mood, which helps the caretakers cope with the problem.

B. Social

Substitute home care, board and care, or convalescent home care may be most useful when the family is unable to care for the patient. The setting should include familiar people and objects, lights at night, and a simple schedule. Counseling may help the family to cope with problems and may help keep the patient at home as long as possible. Information about local groups can be obtained from the Alzheimer's Disease and Related Disorders Association, 70 East Lake Street, Suite 600, Chicago, IL 60601. Volunteer services, including homemakers, visiting nurses, and adult protective services, may be helpful in maintaining the patient at home.

C. Behavioral

Behavioral techniques include operant responses that can be used to induce positive behaviors, eg, paying attention to the patient who is trying to communicate appropriately, and extinction by ignoring inappropriate responses. Patients with Alzheimer disease can learn skills and retain them but do not recall the circumstances in which they were learned.

D. Psychological

Formal psychological therapies are not usually helpful and may make things worse by taxing the patient's limited cognitive resources.

► Prognosis

The prognosis is good for recovery of mental functioning in delirium when the underlying condition is reversible. For most dementia syndromes, the prognosis is for gradual deterioration, although new drug treatments may prove helpful.

- Lavretsky H et al. Association of depressed mood and mortality in older adults with and without cognitive impairment in a prospective naturalistic study. *Am J Psychiatry*. 2010 May;167(5):589–97. [PMID: 20160005]
- Torpy JM et al. JAMA patient page. Dementia. *JAMA*. 2009 Aug 12;302(6):704. [PMID: 19671914]
- Torpy JM et al. JAMA patient page. Mild cognitive impairment. *JAMA*. 2009 Jul 22;302(4):452. [PMID: 19622827]
- Trifiro G et al. Association of community-acquired pneumonia with antipsychotic drug use in elderly patients: a nested case-control study. *Ann Intern Med*. 2010 Apr 6;152(7):418–25. [PMID: 20368647]

PSYCHIATRIC PROBLEMS ASSOCIATED WITH HOSPITALIZATION & ILLNESS

► Diagnostic Categories

A. Acute Problems

1. Delirium with psychotic features secondary to the medical or surgical problem, or compounded by effect of treatment.
2. Acute anxiety, often related to ignorance and fear of the immediate problem as well as uncertainty about the future.

3. Anxiety as an intrinsic aspect of the medical problem (eg, hyperthyroidism).
4. Denial of illness, which may present during acute or intermediate phases of illness.

B. Intermediate Problems

1. Depression as a function of the illness or acceptance of the illness, often associated with realistic or fantasied hopelessness about the future.
2. Behavioral problems, often related to denial of illness and, in extreme cases, causing the patient to leave the hospital against medical advice.

C. Recuperative Problems

1. Decreasing cooperation as the patient sees that improvement and compliance are not compelled.
2. Readjustment problems with family, job, and society.

► General Considerations

A. Acute Problems

1. “Intensive care unit psychosis”—The stressful ICU environment may be a cause of delirium. Critical care unit factors include sleep deprivation, increased arousal, mechanical ventilation, and social isolation. Other causes include those common to delirium and require vigorous investigation (see Delirium, above).

2. Presurgical and postsurgical anxiety states—Such problems are common and commonly ignored. Presurgical anxiety is very common and is principally a fear of death (many surgical patients make out their wills). Patients may be fearful of anesthesia (improved by the preoperative anesthesia interview), the mysterious operating room, and the disease processes that might be uncovered by the surgeon. Such fears frequently cause people to delay examinations that might result in earlier surgery and a greater chance of cure.

The opposite of this is **surgery proneness**, the quest for surgery to escape from overwhelming life stresses. Polysurgery patients may be classified as having factitious disorders. Dynamic motivations include the need to get medical care as a way of getting dependency needs met, the desire to outwit authority figures, unconscious guilt, or a masochistic need to suffer. Frequent surgery may also be related to a somatoform disorder, particularly body dysmorphic disorder (an obsession that a body part is disfigured). More apparent reasons may include an attempt to get relief from pain and a lifestyle that has become almost exclusively medically oriented, with all of the risks entailed in such an endeavor.

Postsurgical anxiety states are usually related to pain, procedures, and loss of body image. Acute pain problems are quite different from chronic pain disorders (see Chronic Pain Disorders, this chapter); the former are readily handled with adequate analgesic medication (see Chapter 5). Alterations in body image, as with amputations, ostomies, and mastectomies, often raise concerns about relationships with others.

3. Iatrogenic problems—These usually pertain to medications, complications of diagnostic and treatment procedures, and impersonal and unsympathetic staff behavior. Polypharmacy is often a factor. Patients with unsolved diagnostic problems are at higher risk. They are desirous of relief, and the quest engenders more diagnostic procedures with a higher incidence of complications. The upset patient and family may be very demanding. Excessive demands usually result from anxiety. Such behavior is best handled with calm and measured responses.

B. Intermediate Problems

1. Prolonged hospitalization—Prolonged hospitalization presents unique problems in certain hospital services, eg, burn units, orthopedic services, and tuberculosis wards. The acute problems of the severely burned patient are discussed in Chapter 37. The problems often are behavioral difficulties related to length of hospitalization and necessary procedures. For example, in burn units, pain is a major problem in addition to anxiety about procedures. Disputes with staff are common and often concern pain medication or ward privileges. Some patients regress to infantile behavior and dependency. Staff members must agree about their approach to the patient in order to ensure the smooth functioning of the unit.

Denial of illness may present in some patients. Intervention by an authority figure (eg, immediate work supervisor) may help the patient accept treatment and eventually abandon the coping mechanism of denial.

2. Depression—Mood disorders ranging from mild adjustment disorder to major depressive disorder frequently occur during prolonged hospitalizations. A key to the diagnosis of depression in the medical setting is the individual's loss of self-esteem; they often think of themselves as worthless and are guilt ridden. Therapeutic medications (eg, corticosteroids) may be a factor. Depression can contribute to irritability and overt anger. Severe depression can lead to anorexia, which further complicates healing and metabolic balance. It is during this period that the issue of disfigurement arises—relief at survival gives way to concern about future function and appearance.

C. Recuperative Problems

1. Anxiety—Anxiety about return to the posthospital environment can cause regression to a dependent position. Complications increase, and staff forbearance again is tested. Anxiety occurring at this stage usually is handled more easily than previous behavior problems.

2. Posthospital adjustment—Adjustment difficulties after discharge are related to the severity of the deficits and the use of outpatient facilities (eg, physical therapy, rehabilitation programs, psychiatric outpatient treatment). Some patients may experience posttraumatic stress symptoms (eg, from traumatic injuries or even from necessary medical treatments). Lack of appropriate follow-up can contribute to depression in the patient, who may feel that he or she is making poor progress and may have thoughts of “giving up.” Reintegration into work, educational, and

social endeavors may be slow. Life is simply much more difficult when one is disfigured, disabled, or disenfranchised.

► Clinical Findings

The symptoms that occur in these patients are similar to those discussed in previous sections of this chapter, eg, delirium, stress and adjustment disorders, anxiety, and depression. Behavior problems may include lack of cooperation, increased complaints, demands for medication, sexual approaches to nurses, threats to leave the hospital, and actual signing out against medical recommendations. The underlying personality structure of the individual is a major factor in coping styles (eg, the compulsive individual increases indecision, the hysterical individual increases dramatic behavior).

► Differential Diagnosis

Delirium and dementia (including cases associated with HIV infection and drug abuse) must always be ruled out, since they often present with symptoms resembling anxiety, depression, or psychosis. Personality disorders existing prior to hospitalization often underlie the various behavior problems, but particularly the management problems.

► Complications

Prolongation of hospitalization causes increased expense, deterioration of patient-staff relationships, and increased probabilities of iatrogenic and legal problems. The possibility of increasing posthospital treatment problems is enhanced.

► Treatment

A. Medical

The most important consideration by far is to have one clinician in charge, a clinician whom the patient trusts and who is able to oversee multiple treatment approaches (see Somatoform Disorders, above). In acute problems, attention must be paid to metabolic imbalance, alcohol withdrawal, and previous drug use—prescribed, recreational, or over-the-counter. Adequate sleep and analgesia are important in the prevention of delirium. When absolute behavioral control is urgently needed, agents such as propofol, dexmedetomidine, opioids, and midazolam have been used.

Many clinicians are attuned to the early detection of the surgery-prone patient. Plastic and orthopedic surgeons are at particular risk. Appropriate consultations may help detect some problems and mitigate future ones.

Postsurgical anxiety states can be alleviated by personal attention from the surgeon. Anxiety is not so effectively lessened by ancillary medical personnel, whom the patient perceives as lesser authorities, until after the clinician has reassured the patient. Inappropriate use of “as needed” analgesia places an unfair burden on the nurse. “Patient-controlled analgesia” can improve pain control, decrease anxiety, and minimize side effects.

Depression should be recognized early. If severe, it may be treated by antidepressant medications (see Antidepressant Medications, above). High levels of anxiety can be lowered with judicious use of anxiolytic agents. Unnecessary medications tend to reinforce the patient's impression that there must be a serious illness or medication would not be required.

B. Psychological

Prepare the patient and family for what is to come. This includes the types of units where the patient will be quarantined, the procedures that will be performed, and any disfigurements that will result from surgery. Repetition improves understanding. The nursing staff can be helpful, since patients frequently confide a lack of understanding to a nurse but are reluctant to do so to the physician.

Denial of illness is frequently a block to acceptance of treatment. This too should be handled with family members present (to help the patient face the reality of the situation) in a series of short interviews (for reinforcement). Dependency problems resulting from long hospitalization are best handled by focusing on the changes to come as the patient makes the transition to the outside world. Key figures are teachers, vocational counselors, and physical therapists. Challenges should be realistic and practical and handled in small steps.

Depression is usually related to the loss of familiar hospital supports, and the outpatient therapists and counselors help to lessen the impact of the loss. Some of the impact can be alleviated by anticipating, with the patient and family, the signal features of the common depression to help prevent the patient from assuming a permanent sick role (invalidism).

Suicide is always a concern when a patient is faced with despair. An honest, compassionate, and supportive approach will help sustain the patient during this trying period.

C. Behavioral

Prior desensitization can significantly allay anxiety about medical procedures. A “dry run” can be done to reinforce the oral description. Cooperation during acute problem periods can be enhanced by the use of appropriate reinforcers such as a favorite nurse or helpful family member. People who are positive reinforcers are even more helpful during the intermediate phases when the patient becomes resistant to the seemingly endless procedures (eg, debridement of burned areas).

Specific situations (eg, psychological dependency on the respirator) can be corrected by weaning with appropriate reinforcers (eg, watching a favorite movie on a DVD player when disconnected from the ventilator). Behavioral approaches should be used in a positive and optimistic way for maximal reinforcement.

Relaxation techniques and attentional distraction can be used to block side effects of a necessary treatment (eg, nausea in cancer chemotherapy).

D. Social

A change in environment requires adaptation. Because of the illness, admission and hospitalization may be more easily handled than discharge. Reintegration into society

can be difficult. In some cases, the family is a negative influence. A pre-discharge evaluation must be made to determine whether the family will be able to cope with the physical or mental changes in the patient. Working with the family while the patient is in the acute stage may presage a successful transition later on.

Development of a new social life can be facilitated by various self-help organizations (eg, the stoma club). Sharing problems with others in similar circumstances eases the return to a social life, which may be quite different from that prior to the illness.

► Prognosis

The prognosis is good in all patients who have reversible medical and surgical conditions. It is guarded when there

is serious functional loss that impairs vocational, educational, or societal possibilities—especially in the case of progressive and ultimately life-threatening illness.

Davydow DS et al. Psychiatric morbidity and functional impairments in survivors of burns, traumatic injuries and ICU stays for other critical illnesses: a review of the literature. *Int Rev Psychiatry*. 2009 Dec;21(6):531–8. [PMID: 19919206]

Katon WJ et al. Collaborative care for patients with depression and chronic illnesses. *N Engl J Med*. 2010 Dec 30;363(27):2611–20. [PMID: 21190455]

Milani RV et al. Impact of exercise training and depression on survival in heart failure due to coronary heart disease. *Am J Cardiol*. 2011 Jan;107(1):64–8. [PMID: 21146688]

Endocrine Disorders

Paul A. Fitzgerald, MD

26

DISEASES OF THE HYPOTHALAMUS & PITUITARY GLAND

ANTERIOR HYPOPITUITARISM

ESSENTIALS OF DIAGNOSIS

- ▶ Partial or complete deficiency of one or any combination of anterior pituitary hormones.
- ▶ **Adrenocorticotrophic hormone deficiency:** reduced adrenal secretion of cortisol, testosterone, and epinephrine; aldosterone secretion remains intact.
- ▶ **Growth hormone (GH) deficiency:** short stature in children; asthenia, obesity, and increased cardiac mortality in adults.
- ▶ **Prolactin deficiency:** inhibition of postpartum lactation.
- ▶ **Thyroid-stimulating hormone (TSH) deficiency:** secondary hypothyroidism.
- ▶ **Luteinizing hormone (LH) and follicle-stimulating hormone (FSH) deficiency:** hypogonadism and infertility in men and women.

General Considerations

Hypopituitarism can be caused by either hypothalamic or pituitary dysfunction. Patients with hypopituitarism may have single or multiple hormonal deficiencies (Table 26–1). When one hormonal deficiency is discovered, others may be present.

1. Hypopituitarism caused by mass lesions—Lesions in the hypothalamus, pituitary stalk, or pituitary can cause hypopituitarism. Pituitary adenomas are usually sporadic but are sometimes part of multiple endocrine neoplasia type 1 (MEN 1). Pituitary tumors that arise in MEN 1 usually secrete prolactin (63%), GH (9%), or both (10%) and are more aggressive than sporadic adenomas. Pituitary tumors rarely cause diabetes insipidus.

Other types of mass lesions include granulomas (eg, granulomatosis with polyangiitis [formerly Wegener granulomatosis], tuberculosis), Rathke cleft cysts, apoplexy, metastatic carcinomas, aneurysms, and brain tumors (craniopharyngioma, meningioma, dysgerminoma, glioma, chondrosarcoma, chordoma of the clivus). Autoimmune hypophysitis, postpartum pituitary necrosis (Sheehan syndrome), eclampsia–preeclampsia, sickle cell disease, and African trypanosomiasis are rare causes. Langerhans cell histiocytosis usually presents in youth with diabetes insipidus or hypopituitarism; osteolytic bone lesions are noted on radiographs.

2. Hypopituitarism without mass lesions—This may be congenital in syndromes such as septo-optic dysplasia (de Morsier syndrome). Congenital hypopituitarism also develops in patients with *PROPI* and other gene mutations. Hypopituitarism may also be caused by cranial radiation, surgery, encephalitis, hemochromatosis, or autoimmunity. It may also occur after coronary artery bypass grafting. At least one pituitary hormone deficiency develops in about 25–30% of survivors of moderate to severe traumatic brain injury (Glasgow Coma Scale \leq 13/15) and in about 55% of survivors of aneurysmal subarachnoid hemorrhage. Some degree of hypopituitarism occurs in one-third of ischemic stroke patients, most commonly GH deficiency and hypogonadotropic hypogonadism. Mitotane, given for adrenal cortical carcinoma, can suppress TSH secretion and cause reversible secondary hypothyroidism. Therapy with exogenous corticosteroids (parenteral, oral, inhaled, or topical) can suppress adrenocorticotrophic hormone (ACTH) secretion and causes functional isolated secondary adrenal insufficiency.

Congenital isolated hypogonadotropic hypogonadism can be caused by various gene mutations that control the production or release of gonadotropin-releasing hormone (GnRH), LH, or FSH. **Congenital adrenal hypoplasia** (see below) is one cause of isolated hypogonadotropic **hypogonadism**. It may be autosomal recessive or X-linked; the X-linked form is caused by a mutation in the *DAX 1* gene. Adrenal insufficiency, caused by failure to form the adrenal cortex, can present during infancy or childhood in boys with *DAX 1* gene mutations. **Prader-Willi syndrome**

Table 26-1. Pituitary hormones.

Anterior pituitary	
Growth hormone (GH) ¹	
Prolactin (PRL)	
Adrenocorticotropic hormone (ACTH)	
Thyroid-stimulating hormone (TSH)	
Luteinizing hormone (LH) ²	
Follicle-stimulating hormone (FSH)	
Posterior pituitary	
Arginine vasopressin (AVP) ³	
Oxytocin	

¹GH closely resembles human placental lactogen (hPL).

²LH closely resembles human chorionic gonadotropin (hCG).

³AVP is identical with antidiuretic hormone (ADH).

(see below) is a genetic disorder where genes on the paternal chromosome 15 are deleted or unexpressed. The incidence of this disorder is 1:15,000; both sexes are affected equally. **Kallmann syndrome** (see below) is caused by various gene mutations that impair the development or migration of GnRH-synthesizing neurons from the olfactory bulb to the hypothalamus. Kallmann syndrome is usually sporadic but may be familial and inherited as X-linked recessive (*Kal 1*), autosomal dominant (*Kal 2, 3, 4, 5, or 6*), or autosomal recessive (*Kal 3, 4, or 6*). Kallmann syndrome has an incidence of 1:10,000 males and 1:50,000 females.

► Clinical Findings

A. Symptoms and Signs

1. Gonadotropin deficiency—Also known as hypogonadotropic hypogonadism, gonadotropin deficiency is caused by insufficiencies in LH and FSH, which cause hypogonadism and infertility. **Congenital gonadotropin deficiency** is characterized by partial or complete lack of pubertal development. (See discussion of primary amenorrhea.) Patients with **Kallmann syndrome** have hypogonadism and anosmia or hyposmia. Half of these patients have unilateral renal agenesis. Some patients with Kallmann syndrome may also exhibit cryptorchidism, micropenis, color blindness, sensorineural deafness, cerebellar ataxia, cognitive problems, bimanual synkinesis, cleft lip or palate, or high-arched palate. Some affected women have menarche followed by secondary amenorrhea.

Patients with **congenital adrenal hypoplasia** have congenital normosmic idiopathic hypogonadotropic hypogonadism. Boys with congenital adrenal hypoplasia who survive beyond childhood usually do not enter puberty as a result of their hypogonadotropic hypogonadism. However, hypogonadotropic hypogonadism and subtle signs of adrenal failure can present in adulthood in males with partial loss-of-function mutations in *DAX 1*. Patients with **Prader-Willi syndrome** have variable features of both gonadotropin deficiency and primary gonadal dysfunction; boys have cryptorchidism. Other features of Prader-Willi syndrome can include mental retardation, short stature, hyperflexibility, autonomic dysregulation, cognitive impairment, and hyperphagia with obesity.

Acquired gonadotropin deficiency is characterized by the loss of axillary, pubic, and body hair. This occurs gradually but becomes particularly prominent in patients who are also hypoadrenal. Men may note diminished beard growth. Libido is diminished. Women have amenorrhea; men note decreased erections. Most patients are infertile. Androgen deficiency predisposes patients to osteopenia and muscle atrophy. (See sections on male hypogonadism and secondary amenorrhea.) Advancing age, obesity, and poor health also cause partial male hypogonadism. (See Male Hypogonadism.)

2. TSH deficiency—TSH deficiency causes hypothyroidism with manifestations such as fatigue, weakness, weight change, and hyperlipidemia. Bexarotene is a retinoid chemotherapeutic agent that suppresses TSH secretion and circulating levels of T₄ and T₃, thereby inducing reversible secondary hypothyroidism. (See Hypothyroidism and Myxedema.)

3. ACTH deficiency—This results in diminished cortisol secretion (see Adrenocortical Hypofunction). Symptoms may include weakness, fatigue, weight loss, and hypotension. Patients with partial ACTH deficiency continue to have some cortisol secretion and may not have symptoms until stressed by illness or surgery. Adrenal mineralocorticoid secretion continues, so manifestations of adrenal insufficiency in hypopituitarism are usually less striking than in bilateral adrenal gland destruction (Addison disease); hyponatremia may occur, especially when ACTH and TSH deficiencies are both present.

4. GH deficiency—When GH deficiency is congenital, it presents with hypoglycemia in infancy and short stature in childhood. GH deficiency in adulthood tends to cause mild to moderate central obesity, increased systolic blood pressure, increased low-density lipoprotein (LDL) cholesterol, and reduced cardiac output. Affected patients may also have reduced muscle and bone mass, reduced physical and mental energy, impaired concentration and memory, and depression. **Laron syndrome** is an autosomal recessive disorder that is mainly associated with mutations in GH receptor gene. This causes resistance to GH and severe insulin-like growth factor-I (IGF-I) deficiency, resulting in short stature (dwarfism). Affected individuals have a prominent forehead, depressed nasal bridge, small mandible, and central obesity. They may have recurrent hypoglycemic seizures. Partial resistance to GH may cause some cases of idiopathic short stature without features of Laron syndrome.

5. Combined pituitary hormone deficiency and panhypopituitarism—The conditions refer to a deficiency of several or all pituitary hormones. Combined pituitary hormone deficiency gradually develops in patients with *PROP 1* gene mutations, usually presenting with short stature and growth failure due to GH and TSH deficiency; lack of pubertal development occurs due to deficiencies in FSH and LH. ACTH-cortisol deficiency also gradually develops in patients with *PROP 1* gene mutations; these patients typically require corticosteroid replacement therapy by age 18 years. In addition to the

manifestations noted above, patients with long-standing hypopituitarism tend to have dry, pale, finely textured skin. The face has fine wrinkles and an apathetic countenance.

6. Other manifestations—Hypothalamic damage can cause obesity and cognitive impairment. Local tumor effects can cause headache or optic nerve compression with visual field impairment.

B. Laboratory Findings

The fasting blood glucose may be low. Hyponatremia is often present due to hypothyroidism or hypoadrenalism. Hyperkalemia usually does not occur, since aldosterone production is not affected.

For men, an accurate serum total testosterone measurement must be obtained. For older men, free testosterone is best measured by calculation, using accurate assays for testosterone and sex hormone binding globulin. Serum gonadotropins (FSH and LH) are obtained if the serum testosterone is low in order to distinguish primary hypogonadism from pituitary dysfunction.

The free thyroxine (FT₄) level is low, and TSH is usually not elevated. However, hypothyroidism with a paradoxically increased serum TSH has been reported in some patients with hypothalamic hypopituitarism. Plasma levels of sex steroids (testosterone and estradiol) are low or low normal, as are the serum gonadotropins. Elevated prolactin (PRL) levels are found in patients with prolactinomas, acromegaly, and hypothalamic disease.

ACTH deficiency usually causes functional atrophy of the adrenal cortex within 2 weeks of pituitary destruction. Therefore, the diagnosis of secondary hypoadrenalism can usually be confirmed with cosyntropin testing. For the cosyntropin test, patients should be either taking no corticosteroids or a short-acting corticosteroid (such as hydrocortisone), which is held after midnight on the morning of the test. At 8 AM, blood is drawn for serum cortisol, ACTH, and dehydroepiandrosterone (DHEA); then 0.25 mg of cosyntropin (synthetic ACTH₁₋₂₄) is administered intramuscularly or intravenously. Another blood sample is obtained 45 minutes after the cosyntropin injection to remeasure serum cortisol levels. A stimulated serum cortisol of < 20 mcg/dL (550 nmol/mL) indicates adrenal insufficiency. With gradual pituitary damage and early in the course of ACTH deficiency, patients can have a stimulated serum cortisol of ≥ 20 mcg/dL but a baseline 8 AM serum cortisol < 5 mcg/dL (137.5 nmol/L), which is suspicious for adrenal insufficiency. Serum DHEA levels are usually low in patients with adrenal deficiency, helping confirm the diagnosis. A baseline ACTH level is low or normal in secondary hypoadrenalism, distinguishing it from primary adrenal disease. For patients with symptoms of secondary adrenal insufficiency (hyponatremia, hypotension, pituitary tumor) but borderline cosyntropin testing, treatment can be instituted empirically. The cosyntropin test may be repeated at a later date. Insulin tolerance testing and metyrapone testing are usually unnecessary.

Deficiency of epinephrine occurs with secondary adrenal insufficiency, since high local concentrations of cortisol are required to induce the production of the enzyme

phenylethanolamine *N*-methyltransferase (PNMT) in the adrenal medulla that catalyzes the conversion of norepinephrine to epinephrine.

The diagnosis of GH deficiency is difficult since normal GH secretion is pulsatile and serum GH levels are nearly undetectable for most of the day. Also, adults normally tend to produce less GH as they age. Therefore, GH deficiency is often inferred by symptoms of GH deficiency in the presence of pituitary destruction or other pituitary hormone deficiencies. GH deficiency is present in 96% of patients with three or more other pituitary hormone deficiencies. GH stimulates the production of IGF-I. Unfortunately, serum IGF-I is not sensitive for GH deficiency since IGF-I levels are in the normal range in about 50% of adults with GH deficiency. Low serum IGF-I levels are not specific for GH deficiency; however, a very low level of IGF-I (< 84 mcg/L) is indicative of GH deficiency, except in conditions that naturally suppress serum IGF-I (eg, malnutrition, prolonged fasting, oral estrogen, hypothyroidism, uncontrolled diabetes mellitus, liver failure). In GH deficiency, exercise-stimulated serum GH levels remain at < 5 ng/mL and usually fail to rise; however, by age 40 years, most normal adults have lost their GH response to exercise.

Provocative GH-stimulation tests are commonly used but are poor tests for GH deficiency. The insulin hypoglycemia test is now rarely used. Other GH stimulation tests require the administration of intravenous arginine and growth hormone-releasing hormone (GHRH) and oral clonidine or carbidopa/levodopa (combination) in patients pretreated with propranolol or estrogen. However, these tests do not discriminate well between normal individuals and patients with presumed GH deficiency (patients with three or more other pituitary hormone deficiencies). Also, normal overweight adults (body mass index [BMI] ≥ 25 kg/m²) typically have blunted peak GH levels after arginine-GHRH administration.

Despite the limitations of intravenous GHRH/arginine stimulation testing, some insurance companies insist that patients have an abnormal test before covering the costs of GH replacement therapy. However, the latter test has a sensitivity of only 66% for GH deficiency. Therefore, when patients have a serum IGF-I < 84 mcg/L or three other pituitary hormone deficiencies, the likelihood of GH deficiency is so high that symptomatic patients should have a therapeutic trial of GH therapy.

The differential diagnosis of GH deficiency is congenital GH resistance with deficiency of IGF-I; at its worst, IGF-I deficiency results in Laron dwarfism that is resistant to GH therapy.

Patients with hypopituitarism without an established etiology should be screened for hemochromatosis with a serum iron and transferrin saturation or ferritin since hemochromatosis can cause hypopituitarism.

C. Imaging

MRI provides the best visualization of pituitary and hypothalamic tumors. Thickening of the pituitary stalk can be caused by sarcoidosis or hypophysitis.

► Differential Diagnosis

The failure to enter puberty may simply reflect delayed puberty, also known as constitutional delay in growth and puberty. Reversible hypogonadotropic hypogonadism may occur with serious illness, malnutrition, anorexia nervosa, or morbid obesity. Men typically develop partial secondary hypogonadism with aging. The clinical situation and the presence of normal adrenal and thyroid function allow ready distinction from hypopituitarism. Profound hypogonadotropic hypogonadism develops in men who receive GnRH analog therapy (leuprolide) for prostate cancer; it usually persists following cessation of therapy. Hypogonadotropic hypogonadism usually develops in patients receiving opioid therapy, including high-dose methadone or long-term intrathecal infusion of opioids; both GH deficiency and secondary adrenal insufficiency occur in 15% of such patients. Secondary adrenal insufficiency may persist for many months following high-dose corticosteroid therapy.

Severe illness causes functional suppression of TSH and T_4 . Hyperthyroxinemia reversibly suppresses TSH. Administration of triiodothyronine (Cytomel) suppresses TSH and T_4 . Bexarotene, used to treat cutaneous T cell lymphoma, suppresses TSH secretion, resulting in temporary central hypothyroidism. Corticosteroids or megestrol treatment reversibly suppresses endogenous ACTH and cortisol secretion.

GH deficiency normally occurs with aging. Physiologic GH deficiency that develops in obese patients may return to normal with sufficient weight loss.

► Complications

Among patients with craniopharyngiomas, diabetes insipidus is found in 16% preoperatively and in 60% postoperatively. Hyponatremia often presents abruptly during the first 2 weeks following pituitary surgery. Visual field impairment may occur. Hypothalamic damage may result in morbid obesity as well as cognitive and emotional problems. Conventional radiation therapy results in an increased incidence of small vessel ischemic strokes and second tumors.

Patients with untreated hypoadrenalism and a stressful illness may become febrile and die in shock and coma.

Adults with GH deficiency have experienced an increased cardiovascular morbidity. Rarely, acute hemorrhage may occur in large pituitary tumors, manifested by rapid loss of vision, headache, and evidence of acute pituitary failure (pituitary apoplexy) requiring emergency decompression of the sella.

► Treatment

Transsphenoidal removal of pituitary tumors will sometimes reverse hypopituitarism. Postoperative hyponatremia often occurs; serum sodium must be checked frequently for 2 weeks after pituitary surgery. Hypogonadism due to PRL excess usually resolves during treatment with dopamine agonists. Endocrine substitution therapy must be given before, during and, often, permanently after such procedures.

GH-secreting tumors may respond to octreotide (see section on acromegaly). Radiation therapy with x-ray,

gamma knife, or heavy particles may be necessary but increases the likelihood of hypopituitarism.

The mainstay of substitution therapy for pituitary insufficiency remains lifetime hormone replacement.

A. Corticosteroids

Hydrocortisone tablets, 15–35 mg/d orally in divided doses, should be given. Most patients do well with 10–20 mg in the morning and 5–15 mg in the late afternoon. Patients with partial ACTH deficiency (basal morning serum cortisol above 8 mg/dL [220 mmol/L]) require hydrocortisone replacement in lower doses of about 5 mg orally twice daily. Some patients feel better taking prednisone, 3–7.5 mg/d orally. A mineralocorticoid is rarely needed. To determine the optimal corticosteroid replacement dosage, it is necessary to monitor patients carefully for manifestations of overreplacement (Cushing syndrome) or underreplacement. A serum white blood cell count (WBC) with a relative differential can be useful, since a relative neutrophilia and lymphopenia can indicate overreplacement with corticosteroid, and vice versa. Additional corticosteroids must be given during states of stress, eg, during infection, trauma, or surgical procedures. For mild illness, corticosteroid doses are doubled or tripled. For trauma or surgical stress, hydrocortisone is given in doses of 50 mg intramuscularly or intravenously every 6 hours and then reduced to normal doses as the stress subsides. Patients with adrenal insufficiency are advised to wear a medical alert bracelet describing their condition and treatment.

Patients with secondary adrenal insufficiency due to treatment with corticosteroids at supraphysiologic doses require their usual daily dose of corticosteroid during surgery and acute illness; supplemental hydrocortisone is not usually required.

B. Thyroid

Levothyroxine is given to correct hypothyroidism only after the patient is assessed for cortisol deficiency or is already receiving corticosteroids. (See Hypothyroidism.) The typical maintenance dose is about 1.6 mcg/kg body weight. However, dosage requirements vary widely, averaging 125 mcg daily with a range of 25–300 mcg daily. The optimal replacement dose of thyroxine for each patient must be carefully assessed clinically on an individual basis. Serum FT_4 levels usually need to be in the high-normal range for adequate replacement. Assessment of serum TSH is useless for monitoring patients, since levels are always low with TSH deficiency.

C. Sex Hormones

Hypogonadotropic hypogonadism often develops in patients with hyperprolactinemia; it may be reversed with treatment of the hyperprolactinemia. (See Hyperprolactinemia.)

Androgen replacement is discussed in the section on male hypogonadism. Estrogen replacement is discussed in the section on female hypogonadism. Patients with idiopathic hypogonadotropic hypogonadism, who have received several years of hormone replacement therapy

(HRT), may have a trial off hormonal therapy to assess whether spontaneous sexual maturation may have occurred.

Women with hypopituitarism and secondary adrenal insufficiency whose serum DHEA levels are < 400 ng/mL may be treated with compounded DHEA in doses of about 25–50 mg/d orally. DHEA therapy tends to increase pubic and axillary hair and may modestly improve libido, alertness, stamina, and overall psychological well being after 6 months of therapy.

To improve spermatogenesis, human chorionic gonadotropin (hCG) (equivalent to LH) may be given at a dosage of 2000–3000 units intramuscularly three times weekly and testosterone replacement is discontinued. The dose of hCG is adjusted to normalize serum testosterone levels. After 6–12 months of hCG treatment, if the sperm count remains low, hCG injections are continued along with injections of FSH: follitropin- β (synthetic recombinant FSH) or urofollitropins (urine-derived FSH). An alternative for patients with an intact pituitary (eg, Kallmann syndrome) is the use of leuprolide (GnRH analog) by intermittent subcutaneous infusion. With either treatment, testicular volumes double within 5–12 months, and spermatogenesis occurs in most cases. With persistent treatment and the help of intracytoplasmic sperm injection for some cases, the total pregnancy success rate is about 70%. Clomiphene, 25–50 mg orally daily, can sometimes stimulate a man's own pituitary gonadotropins (when his pituitary is intact), thereby increasing testosterone and sperm production.

For fertility induction in females, ovulation may be induced with clomiphene, 50 mg daily for 5 days every 2 months. Follitropins and hCG can induce multiple births and should be used only by those experienced with their administration. (See Hypogonadism.)

D. Human Growth Hormone (hGH)

Symptomatic adults with severe GH deficiency (serum IGF-I < 85 mcg/L) may be treated with a subcutaneous recombinant human growth hormone (rhGH) injection starting at a dosage of about 0.2 mg/d (0.6 international units/d), administered three or four times weekly. The dosage of rhGH is increased every 2–4 weeks by increments of 0.1 mg (0.3 international units) until side effects occur or a sufficient salutary response and a normal serum IGF-I level are achieved. A sustained-release injectable suspension of depot GH is available (Nutropin Depot). It can be given twice monthly and is therefore more convenient than standard rhGH preparations. In a study of 20 Brazilian GH-deficient adults, depot GH, given in doses of 13.5 mg subcutaneously twice monthly over 6 months, improved body morphology and lipid profiles but was associated with an increase in carotid plaque. If the desired effects (eg, improved energy and mentation, reduction in visceral adiposity) are not seen within 3–6 months at maximum tolerated dosage, rhGH therapy is discontinued.

During pregnancy, rhGH may be safely administered to women with hypopituitarism at their usual pregestational dose during the first trimester, tapering the dose

during the second trimester, and discontinuing rhGH during the third trimester.

Oral estrogen replacement reduces hepatic IGF-I production. Therefore, prior to commencing rhGH therapy, oral estrogen is changed to a transdermal or transvaginal estradiol.

Side effects of rhGH therapy may include peripheral edema, hand stiffness, arthralgias, myalgias, headache, pseudotumor cerebri, gynecomastia, carpal tunnel syndrome, tarsal tunnel syndrome, hypertension, and proliferative retinopathy. Side effects are more common in older patients, those with greater weight and higher BMI, and those with adult-onset GH deficiency. Such symptoms usually remit promptly after a sufficient reduction in dosage. Excessive doses of rhGH could cause acromegaly; patients receiving long-term therapy require careful clinical monitoring. Serum IGF-I levels should be kept in the normal range and periodic determinations of serum IGF-I levels are helpful in guiding therapeutic dosing.

GH should not be administered during critical illness since, in one study, administration of very high doses of rhGH to patients in an intensive care unit was shown to increase overall mortality. There is no role for GH replacement in the somatopause of aging.

IGF-I (mecasermin) is available to treat patients with Laron syndrome.

E. Other Treatment

Selective transsphenoidal resection of pituitary adenomas can often restore normal pituitary function. Cabergoline, bromocriptine, or quinagolide may reverse the hypogonadism seen in hyperprolactinemia. (See Disorders of Prolactin Secretion.) Disseminated Langerhans cell histiocytosis may be treated with bisphosphonates to improve bone pain; treatment with 2-chlorodeoxyadenosine (cladribine) has been reported to produce remissions.

► Prognosis

The prognosis depends on the primary cause. Hypopituitarism resulting from a pituitary tumor may be reversible with dopamine agonists or with careful selective resection of the tumor. Spontaneous recovery from hypopituitarism associated with pituitary stalk thickening has been reported. Patients can also recover from functional hypopituitarism, eg, hypogonadism due to starvation or severe illness, suppression of ACTH by corticosteroids, or suppression of TSH by hyperthyroidism. Spontaneous reversal of isolated idiopathic hypogonadotropic hypogonadism occurs in about 10% of patients after several years of hormone replacement therapy.

Functionally, most patients with hypopituitarism do very well with hormone replacement. Men with infertility who are treated with hCG/FSH or GnRH are likely to resume spermatogenesis if they have a history of sexual maturation, descended testicles, and a baseline serum inhibin level over 60 pg/mL. Women under age 40 years, with infertility due to hypogonadotropic hypogonadism, can usually have successful induction of ovulation.

- Binder G et al; South German Working Group for Pediatric Endocrinology. Effects of dehydroepiandrosterone therapy on pubic hair growth and psychological well-being in adolescent girls and young women with central adrenal insufficiency: a double-blind, randomized, placebo-controlled phase III trial. *J Clin Endocrinol Metab.* 2009 Apr;94(4):1182–90. [PMID: 19126625]
- Bry-Gauillard H et al. Congenital hypogonadotropic hypogonadism in females: clinical spectrum, evaluation, and genetics. *Ann Endocrinol (Paris).* 2010 May;71(3):158–62. [PMID: 20363464]
- Chanson P et al. Comparative validation of the growth hormone-releasing hormone and arginine test for the diagnosis of adult growth hormone deficiency using a growth hormone assay conforming to recent international recommendations. *J Clin Endocrinol Metab.* 2010 Aug;95(8):3684–92. [PMID: 20484474]
- Clemmons DR. The diagnosis and treatment of growth hormone deficiency in adults. *Curr Opin Endocrinol Diabetes Obes.* 2010 Aug;17(4):377–83. [PMID: 20588115]
- Grossman AB. The diagnosis and management of central hypoadrenalism. *J Clin Endocrinol Metab.* 2010 Nov;95(6):4855–63. [PMID: 20525912]
- Root AW. Reversible isolated hypogonadotropic hypogonadism due to mutations in the neurokinin B regulation of gonadotropin-releasing hormone release. *J Clin Endocrinol Metab.* 2010 Jun;95(6):2625–9. [PMID: 20525912]
- Santhanam P et al. Diagnostic predicament of secondary adrenal insufficiency. *Endocr Pract.* 2010 Jul–Aug;16(4):689–9. [PMID: 20439244]
- Tessnow AH et al. The changing face of Sheehan's syndrome. *Am J Med Sci.* 2010 Nov;340(5):402–6. [PMID: 20944496]

DIABETES INSIPIDUS



ESSENTIALS OF DIAGNOSIS

- ▶ Antidiuretic hormone (ADH) deficiency causes central diabetes insipidus with polyuria (2–20 L/d) and polydipsia.
- ▶ Hyponatremia occurs if fluid intake is inadequate.

▶ General Considerations

Diabetes insipidus is an uncommon disease characterized by an increase in thirst and the passage of large quantities of urine of low specific gravity (usually < 1.006 with ad libitum fluid intake). The urine is otherwise normal. It is caused by a deficiency of vasopressin or resistance to vasopressin.

Primary central diabetes insipidus (without an identifiable lesion noted on MRI of the pituitary and hypothalamus) accounts for about one-third of all cases of diabetes insipidus. Many such cases appear to be due to autoimmunity against hypothalamic arginine vasopressin (AVP)-secreting cells; pituitary stalk thickening can often be detected on pituitary MRI scanning. The cause may also be genetic. Familial diabetes insipidus occurs as a dominant genetic trait with symptoms developing at about 2 years of age. Diabetes insipidus also occurs in Wolfram syndrome, a rare autosomal recessive disorder that is also known by

the acronym DIDMOAD (diabetes insipidus, type 1 diabetes mellitus, optic atrophy, and deafness). DIDMOAD manifestations usually present in childhood but may not occur until adulthood, along with depression and cognitive problems. Diabetes insipidus can also occur in the preleukemic phase of acute myelogenous leukemia associated with myelodysplasia. **Secondary central diabetes insipidus** is due to damage to the hypothalamus or pituitary stalk by tumor, hypophysitis, anoxic encephalopathy, surgical or accidental trauma, infection (eg, encephalitis, tuberculosis, syphilis), sarcoidosis, or multifocal Langerhans cell (eosinophilic) granulomatosis (“histiocytosis X”). Metastases to the pituitary are more likely to cause diabetes insipidus (33%) than are pituitary adenomas (1%).

Vasopressinase-induced diabetes insipidus may be seen in the last trimester of pregnancy and in the puerperium. A circulating enzyme destroys native vasopressin; however, synthetic desmopressin is unaffected. **Nephrogenic diabetes insipidus** is a disorder caused by a defect in the kidney tubules that interferes with water reabsorption. These patients have normal secretion of vasopressin, and the polyuria is unresponsive to it. **Congenital nephrogenic diabetes insipidus** is present from birth and is due to defective expression of renal vasopressin V2 receptors or vasopressin-sensitive water channels. It occurs as a familial X-linked trait; adults often have hyperuricemia as well. **Acquired forms of vasopressin-resistant diabetes insipidus** are usually less severe and are seen in pyelonephritis, renal amyloidosis, myeloma, potassium depletion, Sjögren syndrome, sickle cell anemia, or chronic hypercalcemia. The disorder may occur also as a corticosteroid effect or as an acute side effect of diuretics. Certain drugs (eg, demeclocycline, lithium, foscarnet, or methicillin) may induce nephrogenic diabetes insipidus. The recovery from acute tubular necrosis may also be associated with transient nephrogenic diabetes insipidus. (See Kidney Disorders.)

▶ Clinical Findings

A. Symptoms and Signs

The symptoms of the disease are intense thirst, especially with a craving for ice water, and polyuria, the volume of ingested fluid varying from 2 L to 20 L daily, with correspondingly large urine volumes. Partial diabetes insipidus presents with less intense symptoms and should be suspected in patients with unremitting enuresis. Most patients with diabetes insipidus are able to maintain fluid balance by continuing to ingest large volumes of water. However, diabetes insipidus may present with hypernatremia and dehydration in patients without free access to water, or with a damaged hypothalamic thirst center and altered thirst sensation. Diabetes insipidus is aggravated by administration of high-dose corticosteroids, which increases renal free water clearance. Vasopressin-induced diabetes insipidus during pregnancy is often associated with oligohydramnios, preeclampsia, or hepatic dysfunction.

B. Laboratory Findings

The diagnosis of diabetes insipidus as a cause of polyuria or hypernatremia requires clinical judgment. There is no

single diagnostic laboratory test. Evaluation for diabetes insipidus should include an accurate 24-hour urine collection that is measured for volume and creatinine. A urine volume of < 2 L/24 h (in the absence of hypernatremia) essentially rules out diabetes insipidus. Serum is assayed for glucose, urea nitrogen, calcium, potassium, sodium, and uric acid. Hyperuricemia occurs in many patients with diabetes insipidus, since reduced vasopressin stimulation of the renal V1 receptor causes a reduction in the renal tubular clearance of urate.

A supervised “vasopressin challenge test” may be given: Desmopressin acetate is given in an initial dose of 0.05–0.1 mL (5–10 mcg) intranasally (or 1 mcg subcutaneously or intravenously), with measurement of urine volume for 12 hours before and 12 hours after administration. Serum sodium must be obtained immediately in the event of symptoms of hyponatremia. The dosage of desmopressin is doubled if the response is marginal. Patients with central diabetes insipidus notice a distinct reduction in thirst and polyuria; serum sodium stays normal except in some salt-losing conditions.

In **nonfamilial central diabetes insipidus**, MRI of the pituitary and hypothalamus and of the skull is done to look for mass lesions. The pituitary stalk may be thickened, which may be a manifestation of Langerhans cell histiocytosis, sarcoidosis, or lymphocytic hypophysitis. When **nephrogenic diabetes insipidus** is a diagnostic consideration, measurement of serum vasopressin is done during modest fluid restriction; typically, the vasopressin level is high.

► Differential Diagnosis

Central diabetes insipidus must be distinguished from polyuria caused by psychogenic polydipsia, diabetes mellitus, Cushing syndrome or corticosteroid treatment, lithium, hypercalcemia, hypokalemia, and the nocturnal polyuria of Parkinson disease. It must also be distinguished from vasopressinase-induced diabetes insipidus and nephrogenic diabetes insipidus.

► Complications

If water is not readily available, the excessive output of urine will lead to severe dehydration. Patients with an impaired thirst mechanism are very prone to hypernatremia, particularly since they usually also have impaired mentation and forget to take their desmopressin. All the complications of the primary disease may eventually become evident. In patients who are receiving desmopressin acetate therapy, there is a danger of induced water intoxication.

► Treatment

Mild cases of diabetes insipidus require no treatment other than adequate fluid intake. Reduction of aggravating factors (eg, corticosteroids, which directly increase renal free water clearance) will improve polyuria.

Desmopressin acetate is the treatment of choice for central diabetes insipidus. It is also useful in diabetes insipidus associated with pregnancy or the puerperium, since desmopressin is resistant to degradation by the circulating vasopressinase.

Desmopressin is given orally in a starting dose of 0.05 mg twice daily and increased to a maximum of 0.4 mg every 8 hours, if required. Oral desmopressin is particularly useful for patients with sinusitis from the nasal preparation. Gastrointestinal symptoms, asthenia, and mild increases in hepatic enzymes can occur with the oral preparation.

The nasal preparation (100 mcg/mL solution) is given every 12–24 hours as needed for thirst and polyuria. It may be administered via metered-dose nasal inhaler containing 0.1 mL/spray or via a plastic calibrated tube. The starting dose is 0.05–0.1 mL every 12–24 hours, and the dose is then individualized according to response. Nasal desmopressin may cause nasal irritation.

Desmopressin can also be given intravenously, intramuscularly, or subcutaneously in doses of 1–4 mcg every 12–24 hours as needed to treat thirst or hypernatremia.

Desmopressin may cause hyponatremia, which is uncommon if minimum effective doses are used and the patient allows thirst to occur periodically. Desmopressin can sometimes cause emotional changes, such as depression or agitation and there is an increased risk of suicide among patients starting desmopressin treatment. Erythromelalgia occurs rarely. All desmopressin preparations, including tablets, are subject to heat degradation and should be refrigerated.

Both central and nephrogenic diabetes insipidus respond partially to hydrochlorothiazide, 50–100 mg/d orally (with potassium supplement or amiloride). Nephrogenic diabetes insipidus may respond to combined treatments of indomethacin-hydrochlorothiazide, indomethacin-desmopressin, or indomethacin-amiloride. Indomethacin, 50 mg orally every 8 hours, is effective in acute cases.

Psychotherapy is required for most patients with psychogenic polydipsia. Thioridazine and lithium are best avoided if psychiatric drug therapy is needed, since they cause polyuria.

► Prognosis

Central diabetes insipidus appearing after pituitary surgery usually remits after days to weeks but may be permanent if the upper pituitary stalk is cut.

Chronic central diabetes insipidus is ordinarily more an inconvenience than a dire medical condition. Treatment with desmopressin allows normal sleep and activity. Hypernatremia can occur, especially when the thirst center is damaged, but diabetes insipidus does not otherwise reduce life expectancy, and the prognosis is that of the underlying disorder.

Alexandrov N et al. Gestational diabetes insipidus: a review of an underdiagnosed condition. *J Obstet Gynaecol Can.* 2010 Mar; 32(3):225–31. [PMID: 20500966]

Ananthkrishnan S. Diabetes insipidus in pregnancy: etiology, evaluation, and management. *Endocr Pract.* 2009 Jul–Aug; 15(4):377–82. [PMID: 19454377]

Kristof RA et al. Incidence, clinical manifestations, and course of water and electrolyte metabolism disturbances following transphenoidal pituitary adenoma surgery: a prospective observational study. *J Neurosurg.* 2009 Sep;111(3):555–62. [PMID: 19199508]

Loh JA et al. Disorders of water and salt metabolism associated with pituitary disease. *Endocrinol Metab Clin North Am.* 2008 Mar;37(1):213–34. [PMID: 18226738]

ACROMEGALY & GIGANTISM



ESSENTIALS OF DIAGNOSIS

- ▶ Pituitary tumor.
- ▶ Excessive growth of hands, feet, jaw, and internal organs; or gigantism before closure of epiphyses.
- ▶ Amenorrhea, headaches, visual field loss, weakness.
- ▶ Soft, doughy, sweaty handshake.
- ▶ Elevated IGF-I.
- ▶ Serum GH not suppressed following oral glucose.

▶ General Considerations

GH exerts much of its growth-promoting effects by stimulating the release of IGF-I from the liver and other tissues.

Acromegaly is nearly always caused by a pituitary adenoma. These tumors may be locally invasive, particularly into the cavernous sinus. Less than 1% are malignant. Most are macroadenomas (over 1 cm in diameter). Acromegaly is usually sporadic but may rarely be familial. The disease may also be associated with endocrine tumors of the parathyroids or pancreas (MEN 1). Acromegaly may also be seen in McCune–Albright syndrome and as part of Carney syndrome (atrial myxoma, acoustic neuroma, lentiginos, adrenal hypercortisolism). Acromegaly is rarely caused by ectopic secretion of GHRH or GH secreted by a lymphoma, hypothalamic tumor, bronchial carcinoid, or pancreatic tumor.

▶ Clinical Findings

A. Symptoms and Signs

Excessive GH causes tall stature and gigantism if it occurs in youth, before closure of epiphyses. Afterward, acromegaly develops. The term “acromegaly,” meaning extremity enlargement, seriously understates the manifestations. The hands enlarge and a doughy, moist handshake is characteristic. The fingers widen, causing patients to enlarge their rings. Carpal tunnel syndrome is common. The feet also grow, particularly in shoe width. Facial features coarsen since the bones and sinuses of the skull enlarge; hat size increases. The mandible becomes more prominent, causing prognathism and malocclusion. Tooth spacing widens. Older photographs of the patient can be a useful comparison.

Macroglossia occurs, as does hypertrophy of pharyngeal and laryngeal tissue; this causes a deep, coarse voice and sometimes makes intubation difficult. Obstructive sleep apnea may occur. A goiter may be noted. Hypertension (50%) and cardiomegaly are common. At diagnosis, about 10% of acromegalic patients have overt heart failure, with a dilated left ventricle and a reduced ejection fraction. Weight gain is typical, particularly of muscle and bone. Insulin resistance is usually present and frequently causes diabetes mellitus (30%). Arthralgias and degenerative arthritis occur. Overgrowth of vertebral bone can cause

spinal stenosis. Colon polyps are common, especially in patients with skin papillomas. The skin may also manifest hyperhidrosis, thickening, cystic acne, skin tags, and areas of acanthosis nigricans.

GH-secreting pituitary tumors usually cause some degree of hypogonadism, either by cosecretion of PRL or by direct pressure upon normal pituitary tissue. Decreased libido and erectile dysfunction are common. Women with acromegaly may experience irregular menses or amenorrhea; those who become pregnant have an increased risk of gestational diabetes and hypertension. Secondary hypothyroidism sometimes occurs; hypoadrenalism is unusual. Headaches are frequent. Temporal hemianopia may occur as a result of the optic chiasm being impinged by a suprasellar growth of the tumor.

B. Laboratory Findings

For screening purposes, a random serum IGF-I can be obtained. If it is normal for age, acromegaly is ruled out. For further evaluation, the patient should be fasting for at least 8 hours (except for water), not acutely ill, and should not have exercised on the day of testing. Assay for the following: IGF-I (increased to over five times normal in most acromegalic patients), PRL (cosecreted by many GH-secreting tumors), glucose (diabetes is common in acromegaly), liver enzymes and blood urea nitrogen (BUN) (liver failure or kidney disease can misleadingly elevate GH), serum calcium (to screen for hyperparathyroidism), serum inorganic phosphorus (frequently elevated), serum free T_4 , and TSH (secondary hypothyroidism is common in acromegaly; primary hypothyroidism may increase PRL; hyperthyroidism may occur as a result of excess TSH).

Glucose syrup (75 g) is then administered orally, and serum GH is measured 60 minutes afterward; acromegaly is excluded if the serum GH is < 1 ng/mL (immunoradiometric assay [IRMA] or chemiluminescent assays). For ultrasensitive GH assays, GH should be suppressed to < 0.3 ng/mL to exclude acromegaly. The serum IGF-I and glucose-suppressed GH are usually complementary tests; however, disparities between GH and IGF-I levels occur in up to 30% of patients.

C. Imaging

MRI shows a pituitary tumor in 90% of acromegalic patients. These tumors ordinarily involve the sella and cavernous sinus; rare ectopic tumors may arise in the sphenoid bone. MRI is generally superior to CT scanning, especially in the postoperative setting. Radiographs of the skull may show an enlarged sella and thickened skull. Radiographs may also show tufting of the terminal phalanges of the fingers and toes. A lateral view of the foot shows increased thickness of the heel pad.

▶ Differential Diagnosis

Active acromegaly must be distinguished from familial coarse features, large hands and feet, and isolated prognathism and from inactive (“burned-out”) acromegaly in which there has been a spontaneous remission due to infarction of the pituitary adenoma. GH-induced gigantism

must be differentiated from familial tall stature and from aromatase deficiency. (See Osteoporosis.)

Misleadingly high serum GH levels can be caused by exercise or eating just prior to the test; acute illness or agitation; liver failure or kidney disease; malnourishment; diabetes mellitus; or concurrent treatment with estrogens, β -blockers, or clonidine. During normal adolescence, serum IGF-I is usually elevated and GH may fail to be suppressed.

► Complications

Complications include hypopituitarism, hypertension, glucose intolerance or frank diabetes mellitus, cardiac enlargement, and cardiac failure. Carpal tunnel syndrome may cause thumb weakness and thenar atrophy. Arthritis of hips, knees, and spine can be troublesome. Cord compression may be seen. Visual field defects may be severe and progressive. Acute loss of vision or cranial nerve palsy may occur if the tumor undergoes spontaneous hemorrhage and necrosis (pituitary apoplexy). Colon polyps are more likely to develop in patients with acromegaly.

► Treatment

Pituitary microsurgery is the treatment of choice for patients with acromegaly. Many patients have an apparent surgical cure and a remission in all clinical symptoms but continue to have a mildly elevated serum GH or IGF-I postoperatively. If no residual tumor is apparent on MRI, the patient may elect to be monitored closely, rather than embark on adjuvant medical therapy that is expensive and carries its own risks (see below).

A. Pituitary Microsurgery

Endoscopic transnasal, transsphenoidal pituitary microsurgery removes the adenoma while preserving anterior pituitary function in most patients. Surgical remission is achieved in about 70% of patients followed over 3 years. GH levels fall immediately; diaphoresis and carpal tunnel syndrome often improve within a day after surgery. Transsphenoidal surgery is usually well tolerated, but complications occur in about 10% of patients, including infection, cerebrospinal fluid leak, and hypopituitarism. Transsphenoidal pituitary surgery may be difficult in patients with McCune–Albright syndrome because of fibrous dysplasia of the skull base.

Fluid and electrolyte disturbances occur in most patients postoperatively. Diabetes insipidus can occur within 2 days postoperatively but is usually mild and self-correcting. Hyponatremia can occur abruptly 4–13 days postoperatively in 21% of patients; symptoms may include nausea, vomiting, headache, malaise, or seizure. It is treated with fluid restriction and salt supplements. It is prudent to monitor serum sodium levels postoperatively. Dietary salt supplements for 2 weeks postoperatively may help prevent this complication.

Corticosteroids are administered perioperatively and tapered to replacement doses over 1 week; hydrocortisone is discontinued and cosyntropin stimulation test is performed about 6 weeks after surgery. At that time, a serum T_4 can be checked (to screen for secondary hypothyroidism) and the patient is screened for secondary hypogonadism (see above).

B. Medications

Patients who do not have a clinical or biochemical remission after surgery may be treated with a dopamine agonist (eg, cabergoline), somatostatin analogs, pegvisomant, or a combination of these medications. **Cabergoline** may be used first, since it is an oral medication. Cabergoline therapy is most successful for tumors that secrete both PRL and GH but can also be effective for patients with normal serum PRL levels. Therapy with cabergoline will shrink one-third of such tumors by more than 50%. The initial dose is 0.25 mg orally twice weekly, which is gradually increased to a maximum dosage of 1 mg twice weekly, if tolerated by the patient based on serum GH and IGF-I levels. Side effects of cabergoline include nausea, fatigue, constipation, abdominal pain, and dizziness. Long-term therapy with dopamine agonists (cabergoline, bromocriptine, or pergolide) for pituitary tumors has not caused the cardiac valve problems that can occur when much higher doses are used for Parkinson disease.

Octreotide and **lanreotide** are somatostatin analogs that are given by subcutaneous injection. Octreotide (Sandostatin LAR depot) is given at a dose of 20–40 mg intragluteally monthly. Lanreotide acetate (Somatuline Depot) is given by subcutaneous intragluteal injection at a dosage of 60–120 mg monthly. Whichever preparation is used, the dosage can be adjusted to achieve serum GH levels under 2 ng/mL. Such long-acting somatostatin analogs can achieve serum GH levels under 2 ng/mL in 79% of patients and normal serum IGF-I levels in 53% of patients. Headaches often improve, and tumor shrinkage of about 30% may be expected. Acromegalic patients with pretreatment serum GH levels exceeding 20 ng/mL are less likely to respond to octreotide or lanreotide therapy. Side effects are experienced by about one-third of patients and include injection site pain, loose acholic stools, abdominal discomfort, or cholelithiasis. All somatostatin analogs are expensive and must be continued indefinitely or until other treatment has been effective.

Pegvisomant is a GH receptor antagonist that blocks hepatic IGF-I production. Pegvisomant therapy produces symptomatic relief and normalizes serum IGF-I levels in over 90% of patients. The starting dosage is 10 mg subcutaneously daily. The maintenance dosage can be increased by 5–10 mg every 4–6 weeks, based on serum IGF-I levels and liver transaminase levels; the maximum dosage is 40 mg subcutaneously daily. Pegvisomant does not shrink GH-secreting tumors. Patients need to be monitored carefully with visual field examinations, GH levels, and MRI scanning of the pituitary. Side effects of pegvisomant, including hepatitis and liver injury, have occurred in a patient with Gilbert syndrome. Other adverse effects include edema, flulike syndrome, nausea, and hypertension. Lipohypertrophy can occur at injection sites, so injection sites must be diligently rotated and inspected. In acromegalic diabetics, hypoglycemic drugs are reduced to avoid hypoglycemia during pegvisomant therapy. The effectiveness of pegvisomant is reduced by coadministration of opioids. Pegvisomant is detected in some GH assays, which could overestimate serum GH levels. Pegvisomant is extremely expensive.

C. Stereotactic Radiosurgery

Acromegalic patients who have not had a complete remission with transsphenoidal surgery or medical therapy may be treated with **stereotactic radiosurgery** administered by gamma knife, heavy particle radiation, or adapted linear accelerator. Gamma knife radiosurgery is preferred, since it has become more widely available and normalization of serum IGF-I has been reported in up to 80% of treated patients. Radiosurgery precisely radiates the pituitary tumor in a single session and reduces radiation to the normal brain. However, it cannot be used for pituitary tumors with suprasellar extension due to the risk of damaging the optic chiasm. Radiosurgery can be used for pituitary tumors invading the cavernous sinus, since cranial nerves III, IV, V, and VI are less susceptible to radiation damage. Radiosurgery can also be used for patients who have not responded to conventional radiation therapy. Following any pituitary radiation therapy, patients are advised to take lifelong daily low-dose aspirin because of the increased risk of small-vessel stroke.

► Prognosis

Patients with acromegaly have increased morbidity and mortality from cardiovascular disorders and progressive acromegalic symptoms. Those who are treated and have a random serum GH under 1.0 ng/mL or a glucose-suppressed serum GH under 0.4 ng/mL with a normal age-adjusted serum IGF-I level have reduced morbidity and mortality. Transsphenoidal pituitary surgery is successful in 80% of patients with tumors < 2 cm in diameter and GH levels < 50 ng/mL. Extrasellar extension of the pituitary tumor, particularly cavernous sinus invasion, reduces the likelihood of surgical cure.

Adjuvant medical therapy has been quite successful in treating patients who are not cured by pituitary surgery. Postoperatively, normal pituitary function is usually preserved. Soft tissue swelling regresses but bone enlargement is permanent. Hypertension frequently persists despite successful surgery. Conventional radiation therapy (alone) produces a remission in about 40% of patients by 2 years and 75% of patients by 5 years after treatment. Gamma knife or cyberknife radiosurgery reduces GH levels an average of 77%, with 20% of patients having a full remission after 12 months. Patients with pituitary adenomas that abut the optic chiasm can be treated with cyberknife radiosurgery, controlling tumor growth and preserving vision in most patients. Heavy particle pituitary radiation produces a remission in about 70% of patients by 2 years and 80% of patients by 5 years. Radiation therapy eventually produces some degree of hypopituitarism in most patients. Conventional radiation therapy may cause some degree of organic brain syndrome and predisposes to small strokes. Patients must receive lifelong follow-up, with regular monitoring of serum GH and IGF-I levels. Serum GH levels over 5 ng/mL and rising IGF-I levels usually indicate a recurrent tumor.

Hypopituitarism may occur, due to the tumor itself, pituitary surgery, or radiation therapy. Hypopituitarism may develop years following radiation therapy, so patients must have regular clinical monitoring of their pituitary function.

- Caron P et al. Acromegaly and pregnancy: a retrospective multicenter study of 59 pregnancies in 46 women. *J Clin Endocrinol Metab.* 2010 Oct;95(10):4680–7. [PMID: 20660047]
- Giustina A et al. Current management practices for acromegaly: an international survey. *Pituitary.* 2011 Jun;14(2):125–33. [PMID: 21063787]
- Jane JA Jr et al. Endoscopic transsphenoidal surgery for acromegaly: remission using modern criteria, complications, and predictors of outcome. *J Clin Endocrinol Metab.* 2011 Sep;96(9):2732–40. [PMID: 21715544]
- Katznelson L. Approach to the patient with persistent acromegaly after pituitary surgery. *J Clin Endocrinol Metab.* 2010 Sep;95(9):4114–23. [PMID: 20823464]
- Rowland NC et al. Radiation treatment strategies for acromegaly. *Neurosurg Focus.* 2010 Oct;29(4):E12. [PMID: 20887122]
- Sandret L et al. Place of cabergoline in acromegaly: a meta-analysis. *J Clin Endocrinol Metab.* 2011 May;96(5):1327–35. [PMID: 21325455]
- Sherlock M et al. Medical therapy in acromegaly. *Nat Rev Endocrinol.* 2011 May;7(5):291–300. [PMID: 21448141]

HYPERPROLACTINEMIA



- **Women:** Oligomenorrhea, amenorrhea; galactorrhea; infertility.
- Prolactin normally elevated during pregnancy.
- **Men:** Hypogonadism; decreased libido and erectile dysfunction; infertility.
- Elevated serum PRL.
- CT scan or MRI often demonstrates pituitary adenoma.

► General Considerations

Non-gestational elevations in serum PRL can be caused by numerous conditions (Table 26–2). PRL-secreting pituitary tumors are more common in women than in men and are usually sporadic but may rarely be familial as part of MEN 1. Most are microadenomas (< 1 cm in diameter) that do not grow even with pregnancy or oral contraceptives. However, some giant prolactinomas (over 3 cm in diameter) can spread into the cavernous sinuses and suprasellar areas; rarely, they may erode the floor of the sella to invade the sinuses.

► Clinical Findings

A. Symptoms and Signs

Hyperprolactinemia may result in hypogonadotropic hypogonadism and reduced fertility. Men usually have erectile dysfunction and diminished libido; gynecomastia sometimes occurs but rarely with galactorrhea. Women may note oligomenorrhea or amenorrhea, although some women continue to menstruate normally. Galactorrhea, defined as lactation in the absence of nursing, is common. During pregnancy, clinically significant enlargement of a microprolactinoma (diameter < 1 cm) occurs in < 3%;

Table 26-2. Causes of hyperprolactinemia.

Physiologic Causes	Pharmacologic Causes	Pathologic Causes
Exercise	Amoxapine	Acromegaly
Idiopathic	Amphetamines	Chronic chest wall stimulation
Macroprolactinemia ("big prolactin")	Anesthetic agents	(postthoracotomy, postmastectomy, herpes zoster, breast problems, chest acupuncture, nipple rings, etc)
Pregnancy	Antipsychotics (conventional and atypical)	Cirrhosis
Puerperium	Butyrophenones	Hypothalamic disease
Sleep (REM phase)	Cimetidine and ranitidine (not famotidine or nizatidine)	Hypothyroidism
Stress (trauma, surgery)	Estrogens	Kidney disease (especially with zinc deficiency)
Suckling	Hydroxyzine	Multiple sclerosis
	Methyldopa	Optic neuromyelitis
	Metoclopramide	Pituitary stalk section
	Opioids	Prolactin-secreting tumors
	Nicotine	Pseudocyesis (false pregnancy)
	Phenothiazines	Spinal cord lesions
	Protease inhibitors	Systemic lupus erythematosus
	Progestins	
	Reserpine	
	Risperidone	
	Selective serotonin reuptake inhibitors	
	Testosterone	
	Tricyclic antidepressants	
	Verapamil	

clinically significant enlargement of a macroprolactinoma (diameter ≥ 1 cm) occurs in about 30%.

Pituitary prolactinomas may cosecrete GH and cause acromegaly (see above). Large tumors may cause headaches, visual symptoms, and pituitary insufficiency.

Aside from pituitary tumors, some women secrete an abnormal form of prolactin that appears to cause peripartum cardiomyopathy (see Chapter 10). Suppression of prolactin secretion with dopamine agonists can reverse the cardiomyopathy.

B. Laboratory Findings

Evaluate for conditions known to cause hyperprolactinemia, particularly pregnancy (serum hCG), hypothyroidism (serum FT₄ and TSH), kidney disease (BUN and serum creatinine), cirrhosis (liver function tests) and hyperparathyroidism (serum calcium). Men are evaluated for hypogonadism with determinations of serum total and free testosterone, LH, and FSH. Women who have amenorrhea are assessed for hypogonadism with determinations of serum estradiol, LH, and FSH. Patients with pituitary macroadenomas (> 3 cm in diameter) should have PRL measured on serial dilutions of serum, since IRMA assays may otherwise report falsely low titers, the "high-dose hook effect." Patients with macroprolactinomas or manifestations of possible hypopituitarism should be evaluated for

hypopituitarism as described above. An assay for macroprolactinemia should be considered for patients with hyperprolactinemia who are relatively asymptomatic and have no apparent cause for hyperprolactinemia.

C. Imaging

Patients with hyperprolactinemia not induced by drugs, hypothyroidism, or pregnancy should be examined by pituitary MRI. Small prolactinomas may thus be demonstrated, but clear differentiation from normal variants is not always possible. In the event that a woman with a macroprolactinoma becomes pregnant and elects not to take dopamine agonists during her pregnancy, MRI is usually not performed since the normal pituitary grows during pregnancy. However, if visual-field defects or other neurologic symptoms develop in a pregnant woman, a limited MRI study should be done, focusing on the pituitary without gadolinium contrast.

► Differential Diagnosis

The causes of hyperprolactinemia are shown in Table 26-2. Chronic nipple stimulation, nipple piercing, augmentation or reduction mammoplasty, and mastectomy may stimulate PRL secretion. The pituitary tumor of acromegaly can cosecrete GH and PRL. Hyperprolactinemia may also be idiopathic. Increased pituitary size is a normal variant in young women. About 10% of hyperprolactinemic patients are found to be secreting macroprolactin, a relatively inactive "big prolactin"; pituitary MRI is normal in 78% of cases.

The differential diagnosis for galactorrhea includes the small amount of breast milk that can be expressed from the nipple in many parous women that is not cause for concern. Nipple stimulation from nipple rings, chest surgery, or acupuncture can cause galactorrhea; serum PRL levels may be normal or minimally elevated. Some women can have galactorrhea with normal serum PRL levels and no discernible cause (idiopathic). Normal breast milk may be various colors besides white. Bloody galactorrhea requires an evaluation for breast malignancy.

► Treatment

Medications known to increase PRL should be stopped if possible. Hyperprolactinemia due to hypothyroidism is corrected by thyroxine.

Women with microprolactinomas who have amenorrhea or are desirous of contraception may safely take oral contraceptives or estrogen replacement—there is minimal risk of stimulating enlargement of the microadenoma. Patients with infertility and hyperprolactinemia may be treated with a dopamine agonist in an effort to improve fertility. Women with amenorrhea who elect to receive no treatment have an increased risk of developing osteoporosis; such women require periodic bone densitometry.

Pituitary macroprolactinomas (> 10 mm in diameter) have a higher risk of progressive growth, particularly during treatment with estrogen or testosterone replacement therapy or during pregnancy. Therefore, patients with macroprolactinomas should not be treated with sex HRT unless they are in remission with dopamine agonist medication or surgery. Pregnant women with macroprolactinomas

should continue to receive treatment with dopamine agonists throughout the pregnancy to prevent tumor growth. If dopamine agonists are not used during pregnancy in a woman with a macroprolactinoma, visual-field testing is required each trimester. During pregnancy, measurement of prolactin is not useful surveillance for tumor growth due to the fact that prolactin increases greatly during normal pregnancy.

A. Dopamine Agonists

Dopamine agonists are the initial treatment of choice for patients with giant prolactinomas and those with hyperprolactinemia desiring restoration of normal sexual function and fertility. Cabergoline is usually the best tolerated ergot-derived dopamine agonist. The beginning dosage is 0.25 mg orally once weekly for 1 week, then 0.25 mg twice weekly for the next week, then 0.5 mg twice weekly. Further dosage increases may be required monthly, based on serum PRL levels, up to a maximum of 1.5 mg twice weekly. Bromocriptine (1.25–20 mg/d orally) is an alternative drug. Women who experience nausea with oral preparations may find relief with deep vaginal insertion of cabergoline or bromocriptine tablets; vaginal irritation sometimes occurs. Quinagolide (Norprolac; not available in the United States) is a non-ergot-derived dopamine agonist for patients intolerant or resistant to ergot-derived medications; the starting dosage is 0.075 mg/d orally, increasing as needed and tolerated to a maximum of 0.6 mg/d. Patients whose tumor is resistant to one dopamine agonist may be switched to another in an effort to induce a tolerable remission.

Dopamine agonists are given at bedtime to minimize side effects of fatigue, nausea, dizziness, and orthostatic hypotension. These symptoms usually improve with dosage reduction and continued use. Erythromelalgia is rare. Dopamine agonists can cause a variety of psychiatric side effects that are not dose related and may take weeks to resolve once the dopamine agonist is discontinued. Therefore, dopamine agonists should be used judiciously in psychiatric patients whose antipsychotic medications have caused hyperprolactinemia. Long-term therapy with dopamine agonists (cabergoline, bromocriptine, or pergolide) for pituitary tumors has not caused the cardiac valve problems that can occur when much higher doses are used for Parkinson disease.

With dopamine agonist treatment, 90% of patients with prolactinomas experience a fall in serum PRL to 10% or less of pretreatment levels; about 80% of treated patients achieve a normal serum PRL level. Shrinkage of a pituitary adenoma occurs early, but the maximum effect may take up to a year. Nearly half of prolactinomas—even massive tumors—shrink more than 50%. Such shrinkage of giant prolactinomas can result in spinal fluid rhinorrhea. Discontinuing therapy after months or years usually results in the reappearance of hyperprolactinemia and galactorrhea-amenorrhea. After 2 years of cabergoline therapy, the percentage of patients who maintain a normal serum prolactin after withdrawal of the drug are as follows: 32% with idiopathic hyperprolactinemia, 21% with microprolactinomas, and 16% with macroprolactinomas.

Because dopamine agonists usually restore fertility promptly, many pregnancies have resulted; no teratogenicity

has been noted with any of the dopamine agonists. However, women with microadenomas may have treatment withdrawn during pregnancy. Macroadenomas may enlarge significantly during pregnancy; if therapy is withdrawn, such patients must be monitored clinically with serum PRL determinations and with computer-assisted visual fields. Women with macroprolactinomas who have responded to dopamine agonists may safely receive oral contraceptive agents as long as they continue receiving therapy.

B. Surgical Treatment

Transsphenoidal pituitary surgery may be urgently required for large tumors undergoing apoplexy or those severely compromising visual fields. It is also used electively for patients who do not tolerate or respond to dopamine agonists. Pituitary transsphenoidal surgery is generally well-tolerated, with a surgical mortality rate of < 0.5%. Complications, such as cerebrospinal fluid leakage, meningitis, stroke, or visual loss, occur in about 3% of cases; sinusitis, nasal septal perforation, or infection complicates about 6.5% of surgeries. Postoperative hyponatremia occurs quite commonly, and it is advisable to monitor serum sodium levels for the first 2 weeks postoperatively. For pituitary microprolactinomas, skilled neurosurgeons are successful in normalizing prolactin in 87% of patients; the 10-year recurrence rate is 13%. Pituitary function can be preserved in over 95% of cases. However, the surgical success rate for macroprolactinomas is much lower, and the complication rates are higher. Craniotomy is rarely indicated, since even large tumors can usually be decompressed via the transsphenoidal approach.

Fluid and electrolyte disturbances occur in most patients postoperatively. Diabetes insipidus can occur within 2 days postoperatively but is usually mild and self-correcting. Hyponatremia can occur abruptly 4–13 days postoperatively in 21% of patients; symptoms may include nausea, vomiting, headache, malaise, or seizure. It is treated with fluid restriction and salt supplements. It is prudent to monitor serum sodium levels postoperatively. Dietary salt supplements for 2 weeks postoperatively may help prevent this complication.

C. Radiation Therapy

Radiation therapy is reserved for patients with macroadenomas that are growing despite treatment with dopamine agonists. A single gamma knife or cyberknife treatment is preferable for certain patients whose optic chiasm is clear of tumor, since it is generally safer and more convenient than conventional radiation therapy. Conventional radiation therapy must be given over 5 weeks and carries a high risk of eventual hypopituitarism. Other possible side effects include some degree of memory impairment and an increased long-term risk of second tumors and small vessel ischemic strokes. After radiation therapy, patients are advised to take low-dose aspirin daily for life to reduce their stroke risk.

D. Chemotherapy

Some patients with aggressive pituitary macroadenomas or carcinomas are not surgical candidates and do not respond to dopamine agonists or radiation therapy. Temozolomide

may be administered, 150–200 mg/m² orally daily for 5 days of each 28-day cycle; after three cycles, treatment efficacy is determined by prolactin measurement and MRI scanning. A minority of such patients respond to temozolomide.

Coker F et al. Antidepressant-induced hyperprolactinaemia: incidence, mechanisms and management. *CNS Drugs*. 2010 Jul;24(7):563–74. [PMID: 20527996]
 Dekkers OM et al. Recurrence of hyperprolactinemia after withdrawal of dopamine agonists: systematic review and meta-analysis. *J Clin Endocrinol Metab*. 2010 Jan;95(1):43–51. [PMID: 19880787]
 Kars M et al. Update in prolactinomas. *Neth J Med*. 2010 Mar;68(3):104–12. [PMID: 20308704]
 Klibanski A. Clinical practice. Prolactinomas. *N Engl J Med*. 2010 Apr 1;362(13):1219–26. [PMID: 20357284]
 Melmed S et al. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. *J Clin Endocrinol Metab*. 2011 Feb;96(2):273–88. [PMID: 21296991]
 Milano W et al. Recent clinical aspects of hyperprolactinemia induced by antipsychotics. *Rev Recent Clin Trials*. 2011 Jan;6(1):52–63. [PMID: 20868350]

DISEASES OF THE THYROID GLAND

THYROID TESTING

Assays for FT₄, total triiodothyronine (T₃), and free triiodothyronine (FT₃) have largely supplanted measurements

of total T₄, resin T₃ uptake (RT₃U), and free thyroxine index (FT₄I). It is particularly important to determine “free” serum levels (FT₄ and FT₃) in conditions associated with high circulating levels of thyroxine-binding globulin, such as during therapy with oral estrogen. Ultrasensitive assays for serum TSH have largely replaced older TSH assays. Table 26–3 shows the appropriate use of thyroid tests.

HYPOTHYROIDISM & MYXEDEMA



ESSENTIALS OF DIAGNOSIS

- ▶ Weakness, fatigue, cold intolerance, constipation, weight change, depression, menorrhagia, hoarseness.
- ▶ Dry skin, bradycardia, delayed return of deep tendon reflexes.
- ▶ Anemia, hyponatremia, hyperlipidemia.
- ▶ FT₄ level is usually low.
- ▶ TSH elevated in primary hypothyroidism.

▶ General Considerations

Hypothyroidism is common, affecting over 1% of the general population and about 5% of individuals over age

Table 26–3. Appropriate use of thyroid tests.

	Test	Comment
Screening	Serum thyroid-stimulating hormone (TSH) (sensitive assay) Free thyroxine (FT ₄)	Most sensitive test for primary hypothyroidism and hyperthyroidism Excellent test
For hypothyroidism	Serum TSH Antithyroglobulin and antithyroperoxidase antibodies	High in primary and low in secondary hypothyroidism Elevated in Hashimoto thyroiditis
For hyperthyroidism	Serum TSH (sensitive assay) Triiodothyronine (T ₃) or free triiodothyronine (FT ₃) ¹²³ I uptake and scan Antithyroglobulin and antimicrosomal antibodies Thyroid-stimulating immunoglobulin; TSH receptor antibody (TSH-R Ab [stim])	Suppressed except in TSH-secreting pituitary tumor or pituitary hyperplasia (rare) Elevated Increased uptake; diffuse versus “hot” areas on scan Elevated in Graves disease Usually (65%) positive in Graves disease
For thyroid nodules	Fine-needle aspiration (FNA) biopsy ¹²³ I uptake and scan ^{99m} Tc scan Ultrasonography	Best diagnostic method for thyroid cancer Cancer is usually “cold”; less reliable than FNA biopsy Vascular versus avascular Useful to assist FNA biopsy. Useful in assessing the risk of malignancy (multinodular goiter or pure cysts are less likely to be malignant). Useful to monitor nodules and patients after thyroid surgery for carcinoma.

60 years. Thyroid hormone deficiency affects almost all body functions. The degree of severity ranges from mild and unrecognized hypothyroid states to striking myxedema. The fluid retention seen in myxedema is caused by the interstitial accumulation of hydrophilic mucopolysaccharides, which leads to lymphedema. Hyponatremia is the result of impaired renal tubular sodium reabsorption due to reductions in Na^+ - K^+ -ATPase.

Hypothyroidism may be due to failure or resection of the thyroid gland itself or deficiency of pituitary TSH (see Hypopituitarism, above). The condition must be distinguished from the functional hypothyroidism that occurs in severe nonthyroidal illness, which does not require treatment with thyroxine (see Euthyroid Sick Syndrome).

Maternal hypothyroidism during pregnancy results in offspring with IQ scores that are an average 7 points lower than those of euthyroid mothers.

Goiter may be present with thyroiditis, iodide deficiency, genetic thyroid enzyme defects, drug goitrogens (lithium, iodide, propylthiouracil or methimazole, phenylbutazone, sulfonamides, amiodarone, interferon- α , interferon- β , interleukin-2), food goitrogens in iodide-deficient areas (eg, turnips, cassavas) or, rarely, peripheral resistance to thyroid hormone or infiltrating diseases (eg, cancer, sarcoidosis). A hypothyroid phase occurs in subacute (de Quervain) viral thyroiditis following initial hyperthyroidism. Hashimoto thyroiditis is the most common cause of hypothyroidism (see Thyroiditis section).

Goiter is usually absent when hypothyroidism is due to destruction of the gland by surgery, radiation therapy (to the head, neck, chest, and shoulder region), or ^{131}I . Chemotherapy can reduce thyroid function, causing hypothyroidism. Sunitinib, a protein-tyrosine kinase inhibitor used to treat gastrointestinal stromal malignancies, causes transient primary hypothyroidism in about 50% of treated patients.

Amiodarone, because of its high iodine content, causes clinically significant hypothyroidism in about 15–20% of patients who receive it. Hypothyroidism occurs most often in patients with preexisting autoimmune thyroiditis and in patients who are not iodine-deficient. The T_4 level is normal or low, and the TSH is elevated, usually over 20 ng/dL. Another 17% of patients have milder elevations of TSH and are asymptomatic. Low-dose amiodarone is less likely to cause hypothyroidism. Cardiac patients with amiodarone-induced symptomatic hypothyroidism are treated with just enough thyroxine to relieve symptoms. Hypothyroidism usually resolves over several months if amiodarone is discontinued. Hypothyroidism may also develop in patients with a high iodine intake from other sources, especially if they have underlying lymphocytic thyroiditis.

Hepatitis C is associated with an increased risk of autoimmune thyroiditis, with 21% of affected patients having antithyroid antibodies and 13% having hypothyroidism. The risk of thyroid dysfunction is even higher when patients are treated with interferon. Interferon- α and interferon- β treatment can induce thyroid dysfunction (usually hypothyroidism, sometimes hyperthyroidism) in 6% of patients. Spontaneous resolution occurs in over 50% of cases once interferon is discontinued.

► Clinical Findings

A. Symptoms and Signs

1. Common manifestations—Mild hypothyroidism often escapes detection without screening (ie, serum TSH). Common symptoms of hypothyroidism include weight gain, fatigue, lethargy, depression, weakness, dyspnea on exertion, arthralgias or myalgias, muscle cramps, menorrhagia, constipation, dry skin, headache, paresthesias, carpal tunnel syndrome, cold intolerance, and Raynaud syndrome. Physical findings can include bradycardia; diastolic hypertension; thin, brittle nails; thinning of hair; peripheral edema; puffy face and eyelids; and skin pallor or yellowing (carotenemia). Delayed relaxation of deep tendon reflexes may be present. Patients often have a palpably enlarged thyroid (goiter) that arises due to elevated serum TSH levels or the underlying thyroid pathology, such as Hashimoto thyroiditis.

2. Less common manifestations—Less common symptoms of hypothyroidism include diminished appetite and weight loss, hoarseness, decreased sense of taste and smell, and diminished auditory acuity. Some patients may complain of dysphagia or neck discomfort. Although most menstruating women have menorrhagia, some women have scant menses or amenorrhea. Physical findings may include thinning of the outer halves of the eyebrows; thickening of the tongue; hard pitting edema; and effusions into the pleural and peritoneal cavities as well as into joints. Galactorrhea may also be present. Cardiac enlargement (“myxedema heart”) and pericardial effusions may occur. Psychosis (myxedema madness) can occur from severe hypothyroidism or from toxicity of other drugs whose metabolism is slowed in hypothyroidism. Hypothermia and stupor or myxedema coma, which is often associated with infection (especially pneumonia), may develop in patients with severe hypothyroidism. Pituitary enlargement due to hyperplasia of TSH-secreting cells, which is reversible following thyroid therapy, may be seen in long-standing hypothyroidism.

Some hypothyroid patients with Hashimoto thyroiditis have symptoms that are not due to hypothyroidism but rather to other autoimmune disease. Some autoimmune conditions that occur more commonly in patients with Hashimoto thyroiditis include Addison disease, hypoparathyroidism, diabetes mellitus, pernicious anemia, Sjögren syndrome, vitiligo, biliary cirrhosis, and celiac disease.

Celiac disease occurs in at least 5% of patients with hypothyroidism due to Hashimoto thyroiditis. Affected patients often have weight loss and gastrointestinal symptoms. However, many patients with celiac disease have minimal gastrointestinal symptoms but may have systemic manifestations such as fatigue, depression, osteoporosis or osteomalacia, iron deficiency anemia, short stature, delayed puberty, amenorrhea, or reduced fertility. Intestinal malabsorption may cause vitamin deficiencies with bruising due to vitamin K deficiency, hyperkeratosis due to vitamin A deficiency, bone pain due to vitamin D deficiency, or neuropathy and ataxia due to vitamin E or vitamin B_{12} deficiency.

B. Laboratory Findings

Hypothyroidism is a common disorder and thyroid function tests should be obtained for any patient with the non-specific symptoms or signs of hypothyroidism. The single best screening test for hypothyroidism is the serum TSH (Table 26–3). Serum TSH is increased with primary hypothyroidism but is low or normal with pituitary insufficiency. The FT₄ may be low or low-normal. Other laboratory abnormalities may often be seen: increased serum LDL cholesterol, triglycerides, lipoprotein (a), liver enzymes, and creatine kinase; increased serum PRL; and hyponatremia, hypoglycemia, and anemia (with normal or increased mean corpuscular volume). Semen analysis shows an increase in abnormal sperm morphology. In patients with autoimmune thyroiditis, titers of antibodies against thyroperoxidase and thyroglobulin are high; serum antinuclear antibodies (ANA) may be present and are not usually indicative of lupus.

The normal range for ultrasensitive TSH levels is generally stated to be 0.4–4.0 mU/L. However, the normal range of TSH varies with age such that newborns have a much higher normal range; children and elderly patients have a mildly higher normal range. Over 95% of normal adults have serum TSH concentrations under 3.0 mU/L. There is a high risk of finding antithyroid antibodies in patients with serum TSH in the upper range of normal, but most such patients are asymptomatic. TSH may be mildly elevated in some euthyroid individuals, especially elderly women (10% incidence). Such patients with normal FT₄ levels are considered to have “subclinical hypothyroidism,” but can have subtle manifestations of hypothyroidism (eg, fatigue, depression, hyperlipidemia) that may improve with thyroid hormone replacement. Patients who are completely asymptomatic with a mildly elevated serum TSH and normal serum FT₄ do not require levothyroxine replacement; in fact, mildly decreased thyroid function was associated with familial longevity in the Leiden Longevity Study. About 18% of patients with subclinical hypothyroidism later become definitely hypothyroid; many such patients have Hashimoto thyroiditis.

C. Imaging

Radiologic imaging is usually not necessary for patients with hypothyroidism. However, on CT or MRI, a goiter may be noted in the neck or in the mediastinum (retrosternal goiter). An enlarged thymus is frequently seen in the mediastinum in cases of autoimmune thyroiditis. In primary hypothyroidism with elevated serum TSH levels, MRI of the head will frequently show an enlargement of the pituitary gland from thyrotrope hyperplasia; such enlargement can be mistaken for a pituitary tumor.

► Differential Diagnosis

Many clinical manifestations of hypothyroidism (see above) are common in the general population without thyroid illness. The differential diagnoses are the conditions and drugs that can cause aberrations in laboratory tests, resulting in a low serum T₄ or T₃ or high serum TSH in

Table 26–4. Factors that may cause aberrations in laboratory tests that may be mistaken for primary hypothyroidism.¹

Low Serum T ₄ or T ₃	High Serum TSH
Laboratory error	Laboratory error
Acute psychiatric problems	Autoimmune disease (assay interference)
Cirrhosis	Heterophile antibodies
Nephrotic syndrome	Anti-mouse antibodies
Familial thyroid-binding globulin deficiency	Strenuous exercise (acute)
Severe illness	Sleep deprivation (acute)
Drugs	Recovery from nonthyroidal illness (transient)
Androgens	Acute psychiatric admissions (14% transient)
Asparaginase	Elderly—especially women (10%, mild elevations)
Carbamazepine	
Chloral hydrate	
Corticosteroids	
Diclofenac (T ₃)	
Didanosine	
Fenclofenac	
5-Fluorouracil	
Halofenate	
Mitotane	
Naproxen (T ₃)	
Nicotinic acid	
Oxcarbazepine	
Phenobarbital	
Phenytoin (total T ₄ may be as low as 2 mcg/dL)	
Salicylates—large doses (T ₃ and T ₄)	
Sertraline	
Stavudine	
T ₃ therapy (T ₄)	

¹True primary hypothyroidism may coexist.

T₄, levothyroxine; T₃, triiodothyronine; TSH, thyroid-stimulating hormone.

the absence of hypothyroidism (Table 26–4). The pituitary is often quite enlarged in primary hypothyroidism, due to reversible hyperplasia of TSH-secreting cells; the concomitant hyperprolactinemia seen in hypothyroidism can lead to the mistaken diagnosis of a TSH-secreting or PRL-secreting pituitary adenoma.

Euthyroid sick syndrome should be considered in patients with abnormal thyroid function tests (eg, low serum T₄ and low levels of FT₄) without thyroid disease; conditions that can result in this syndrome include severe illness, caloric deprivation, or major surgery. Patients who have undergone major surgery may have accelerated peripheral metabolism of serum T₄ to reverse T₃ (rT₃). Furthermore, in most patients who are critically ill, there is a circulating inhibitor of thyroid hormone binding to serum thyroxine-binding proteins (TBPs). This causes the RT₃U to be misleadingly low, causing the computed FT₄I to be very low. The presence of a very low serum T₄ in severe nonthyroidal illness indicates a poor prognosis. Serum TSH tends to be suppressed in severe nonthyroidal illness, making the diagnosis of concurrent primary hypothyroidism quite difficult, although the presence of a goiter suggests the diagnosis.

The clinician must decide whether such severely ill patients (with a low serum T_4 but no elevated TSH) might have hypothyroidism due to pituitary insufficiency. Patients without symptoms of prior brain lesion or hypopituitarism are very unlikely to suddenly develop hypopituitarism during an unrelated illness. Patients with diabetes insipidus, hypopituitarism, or other signs of a central nervous system lesion may be given T_4 empirically.

True secondary hypothyroidism due to direct dopamine suppression of TSH-secreting cells may develop in patients receiving prolonged dopamine infusions.

Certain antiseizure medications cause low serum FT_4 levels by accelerating hepatic conversion of T_4 to T_3 ; serum TSH levels are normal.

► Complications

Cardiac complications may occur as a result of preexistent coronary artery disease and congestive heart failure, which may be exacerbated by levothyroxine therapy. Patients with severe hypothyroidism have an increased susceptibility to bacterial pneumonia. Megacolon has been described in long-standing hypothyroidism. Organic psychoses with paranoid delusions may occur (“myxedema madness”). Rarely, adrenal crisis may be precipitated by thyroid therapy. Hypothyroidism is a rare cause of infertility, which may respond to thyroid medication. Pregnancy in a woman with untreated hypothyroidism often results in miscarriage. Sellar enlargement and even well-defined TSH-secreting tumors may develop in untreated cases. These tumors decrease in size after replacement therapy is instituted.

Myxedema crisis refers to severe, life-threatening hypothyroidism. The manifestations of hypothyroidism are present and more severe. Affected patients have impaired cognition, ranging from confusion to somnolence to coma (myxedema coma). Convulsions and abnormal central nervous system signs may occur. Patients have severe hypothermia, hypoventilation, hyponatremia, hypoglycemia, and hypotension. Rhabdomyolysis and acute kidney injury may occur. Myxedema coma is most often seen in elderly women who have had a stroke or who have stopped taking their thyroxine medication. It is often induced by an underlying infection; cardiac, respiratory, or central nervous system illness; cold exposure; or drug use. The mortality rate from myxedema coma is high. Myxedematous patients are unusually sensitive to opioids and average doses may result in death. Patients with severe myxedema may have hyponatremia that is severe and refractory to treatment.

► Treatment

Before therapy with thyroid hormone is commenced, the hypothyroid patient requires at least a clinical assessment for adrenal insufficiency and angina, for which the patient would require evaluation and treatment.

A. Beginning Treatment for Hypothyroidism

Levothyroxine is the preferred preparation for treating hypothyroid patients. However, patients (as a group) receiving levothyroxine replacement do not have the same sense of well-being as their peers. In response, some clinicians

prescribe mixed T_4/T_3 preparations such as Armour thyroid, but levothyroxine alone renders patients clinically euthyroid as long as it is given in sufficient doses (see below).

Otherwise healthy young and middle-age adults with hypothyroidism may be treated initially with levothyroxine in doses of 25–75 mcg orally daily. The lower doses are used for very mild hypothyroidism, while higher doses are given for more symptomatic hypothyroidism. Women who are pregnant with significant hypothyroidism may begin therapy with levothyroxine at higher doses of 100–150 mcg orally daily. The levothyroxine dosage may be increased according to clinical response and serum TSH, initially trying to keep the serum TSH level between 0.4 mU/L and 2.0 mU/L. The levothyroxine dose required to render patients clinically euthyroid varies considerably, with higher doses required during pregnancy and with certain medications (see below). Since food interferes slightly with the absorption of levothyroxine, it is advisable to take levothyroxine with water in the morning after an overnight fast. The selected time should become a regular daily habit for the patient. After beginning daily administration, significant increases in serum T_4 levels are seen within 1–2 weeks, and near-peak levels are seen within 3–4 weeks.

Patients with coronary disease or those who are over age 60 years are treated with smaller initial doses of levothyroxine, 25–50 mcg orally daily; higher initial doses may be used if such patients are severely hypothyroid. The dose can be increased by 25 mcg every 1–3 weeks until the patient is euthyroid. Patients with hypothyroidism and known ischemic heart disease may begin thyroxine therapy following restoration of coronary perfusion by coronary artery angioplasty or bypass.

Myxedema crisis requires larger initial doses of levothyroxine intravenously, since myxedema itself can interfere with levothyroxine intestinal absorption. Levothyroxine sodium 400 mcg is given intravenously as a loading dose, followed by 50–100 mcg intravenously daily; the lower dose is given to patients with suspected coronary insufficiency. In patients with myxedema coma, liothyronine (T_3 , Triostat) can be given intravenously in doses of 5–10 mcg every 8 hours for the first 48 hours. The hypothermic patient is warmed only with blankets, since faster warming can precipitate cardiovascular collapse. Patients with hypercapnia require intubation and assisted mechanical ventilation. Infections must be detected and treated aggressively. Patients in whom concomitant adrenal insufficiency is suspected are treated with hydrocortisone, 100 mg intravenously, followed by 25–50 mcg every 8 hours.

B. Monitoring & Optimizing Treatment of Hypothyroidism

Every hypothyroid patient requires regular clinical assessments that must include interim histories and physical examinations. Clinical judgment is critical to determine the optimal levothyroxine dose for each patient. Laboratory assays supplement clinical judgment. An elevated serum TSH usually indicates the need for a higher dose of levothyroxine (see below). Unfortunately, normal serum TSH and FT_4 levels do not accurately determine that the patient is euthyroid (see below). The patient should be prescribed sufficient levothyroxine to restore a clinically euthyroid state,

while maintaining the serum T_3 within the reference range. For most patients with hypothyroidism, a stable maintenance dose of levothyroxine can usually be found.

Levothyroxine doses may need to be titrated upward after patients commence taking medications that increase the hepatic metabolism of levothyroxine (eg, carbamazepine, phenobarbital, primidone, phenytoin, rifabutin, rifampin, sunitinib, and imatinib [Gleevec]). Amiodarone can cause an increase or decrease in thyroxine dose requirements, making it necessary to closely monitor serum TSH and adjust the thyroxine dosage accordingly in these patients. Malabsorption of thyroxine can be caused by coadministration of binding substances, such as iron preparations (including iron found in multivitamins), fiber, raloxifene, sucralfate, aluminum hydroxide antacids, sevelamer, orlistat, calcium and magnesium supplements, and soy milk or soy protein supplements. Bile acid-binding resins, such as cholestyramine and colestevam, can bind T_4 and impair its absorption even when administered 5 hours before the T_4 . Proton pump inhibitors reduce gastric acidity, which interferes slightly with the absorption of levothyroxine. Gastrointestinal disorders can interfere with thyroxine absorption, including celiac disease, inflammatory bowel disease, lactose intolerance, *Helicobacter pylori* gastritis, and atrophic gastritis.

Different thyroxine preparations vary in their bioavailability by up to 14%. Such differences in the bioavailability of different T_4 formulations may have a subtle but significant clinical impact. It is therefore recommended that patients always continue to take the same brand name of thyroxine or the same manufacturer's generic thyroxine. There is no standardized optimal dose of levothyroxine, so each patient's dose must be based on careful clinical assessment. Although serum TSH levels can be helpful in determining optimal dosing, it is important to consider clinical response and to not rely entirely on serum TSH levels to determine the patient's optimal thyroxine dosage.

Women with hypothyroidism typically require increased doses of T_4 during therapy with oral estrogen as well as during pregnancy (see below). Conversely, T_4 dosage requirements for women often decrease with delivery, cessation of oral estrogen, and menopause.

1. During pregnancy—Administering adequate levothyroxine to a hypothyroid woman is critical. The fetus is at least partially dependent on maternal T_4 for central nervous system development—particularly in the second trimester. It is therefore important to carefully monitor hypothyroid women with serum TSH (FT_4I or FT_4 concentrations in hypopituitarism) determinations every 4–6 weeks and to increase T_4 replacement progressively as required (see Chapter 19).

There is considerable individual variation in the requirement for additional T_4 replacement during pregnancy. An increase in levothyroxine requirement has been noted as early as the fifth week of pregnancy. Therefore, for women receiving replacement thyroxine, it is prudent to increase levothyroxine dosages by approximately 30% as soon as pregnancy is confirmed. By mid pregnancy, women require an average of 47% increase in their levothyroxine dosage.

The increased T_4 dosage requirements during pregnancy are believed to be due to several factors: (1) Rising estrogen

levels during pregnancy increase thyroxine binding globulin (TBG) serum concentrations, reducing FT_4 levels. (2) Placental deiodinase promotes the turnover of T_4 . (3) Supplemental iron and prenatal multivitamins containing iron can bind to oral T_4 and reduce its intestinal absorption. Similarly, supplemental calcium can also reduce T_4 absorption. Therefore, it is important that patients take their T_4 replacement at least 4 hours before or after such dietary supplements. Postpartum, T_4 replacement requirements ordinarily return to prepregnancy levels.

Serum TSH levels normally drop while FT_4I rises during the first trimester of pregnancy. This probably results from high levels of hCG (with structural homology to TSH) that stimulates thyroid hormone production. Most women with a low serum TSH in the first trimester are euthyroid. Serum FT_4I is helpful in evaluating the thyroid status of pregnant women, particularly in the first trimester. Following delivery, levothyroxine dose requirements decline.

2. Elevated serum TSH levels—This usually indicates underreplacement with levothyroxine. However, before increasing the T_4 dosage, it is important to confirm that the patient is indeed taking the medication as directed and does not have angina. It is also important to consider the following: A high TSH in a patient receiving standard replacement doses of T_4 may indicate malabsorption of levothyroxine due to concurrent administration with binding substances (see above) or with food (instead of fasting). Malabsorption of T_4 can also occur in short bowel syndrome; therapy with medium chain triglyceride oil may improve absorption. Impaired absorption of T_4 can also be caused by diarrhea of any cause or malabsorption due to concurrent celiac disease (sprue), regional enteritis, liver disease, or pancreatic exocrine insufficiency. Serum TSH may be elevated transiently in acute psychiatric illness and during recovery from nonthyroidal illness. Autoimmune disease can cause false elevations of TSH by interfering with the assay. A high TSH can also be caused by thyrotropin-secreting pituitary tumors. TSH may be increased by phenothiazines and atypical antipsychotics.

3. Normal serum TSH levels—Patients are treated with sufficient levothyroxine to achieve normal serum TSH levels of 0.4–2.0 mU/L. Patients who continue to feel hypothyroid despite a normal serum TSH may have a suboptimal serum T_3 ; they may respond well to higher replacement doses of levothyroxine.

4. Low or suppressed serum TSH levels—Serum TSH levels (using a sensitive assay) that are below the reference range (0.4–4.0 mU/L) are considered “low” (0.04–0.4 mU/L) or “suppressed” (≤ 0.03 mU/L). It has generally been assumed that since TSH is a sensitive test for hyperthyroidism in Graves disease, a low serum TSH in patients taking levothyroxine reliably indicates overreplacement; that assumption is proving incorrect. Certainly, if a patient taking levothyroxine has a suppressed serum TSH and manifestations of hyperthyroidism, the dosage of levothyroxine must be reduced. However, many patients with low serum TSH levels exhibit no symptoms of hyperthyroidism. For such patients, it is important to determine whether hypopituitarism or severe nonthyroidal illness is present, which can result

in low serum TSH levels without hyperthyroidism. TSH can also be reduced by certain medications, such as nonsteroidal anti-inflammatory drugs; opioids; nifedipine; verapamil; and high-dose, short-term administration of corticosteroids. Absent such conditions, a clinically euthyroid patient with a suppressed serum TSH should be given a lower dosage of levothyroxine. Patients who exhibit hypothyroid symptoms on the reduced dosage of levothyroxine may have the higher dose resumed.

Some hypothyroid patients receiving levothyroxine have hypothyroid-type symptoms, particularly persistent fatigue or weight gain, despite having low serum TSH levels. Such patients require careful assessment for concurrent illnesses such as adrenal insufficiency, hypogonadism, anemia, celiac disease, or depression. If such conditions are not present or are treated and hypothyroid-type symptoms persist despite low-normal or low TSH levels, a serum T_3 level (FT_3 in pregnancy and women receiving oral estrogens) is often helpful. If the serum T_3 level is low or low normal, the patient may benefit from an increase in levothyroxine dosage; if a definite clinical benefit is achieved, the higher dose is continued. Patients with a low serum TSH (0.04–0.4 mU/L) on replacement levothyroxine do not have any long-term increased risk of cardiovascular disease, dysrhythmias, or fractures. However, patients with suppressed serum TSH (≤ 0.03 mU/L) do have an increased risk of such side effects and long-term monitoring for atrial arrhythmias and osteoporosis is recommended.

► Prognosis

Hypothyroidism caused by interferon- α resolves within 17 months of stopping the drug in 50% of patients. Patients with mild hypothyroidism caused by Hashimoto thyroiditis have a remission rate of 11%. With early treatment of hypothyroidism, striking transformations take place both in appearance and mental function. Return to a normal state is usually the rule, but relapses will occur if treatment is interrupted. On the whole, response to thyroid treatment is most satisfactory. However, untreated hypothyroid patients with myxedema crisis have a mortality rate approaching 100%. Even with optimal treatment, patients with myxedema crisis have a mortality rate of 20–50%.

Kim BW et al. For some: L-thyroxine replacement might not be enough: a genetic rationale. *J Clin Endocrinol Metab.* 2009 May;94(5):1521–3. [PMID: 19420275]

Liwanpo L et al. Conditions and drugs interfering with thyroxine absorption. *Best Pract Res Clin Endocrinol Metab.* 2009 Dec;23(6):781–92. [PMID: 19942153]

Nygaard B et al. Effect of combination therapy with thyroxine (T_4) and 3,5,3'-triiodothyronine versus T_4 monotherapy in patients with hypothyroidism, a double-blind, randomized cross-over study. *Eur J Endocrinol.* 2009 Dec;161(6):895–902. [PMID: 19666698]

O'Reilly DS. Thyroid hormone replacement: an iatrogenic problem. *Int J Clin Pract.* 2010 Jun;64(7):991–4. [PMID: 20584231]

Padmanabhan H. Amiodarone and thyroid dysfunction. *South Med J.* 2010 Sep;103(9):922–30. [PMID: 20689491]

Reid SM et al. Interventions for clinical and subclinical hypothyroidism in pregnancy. *Cochrane Database Syst Rev.* 2010 Jul 7;(7):CD007752. [PMID: 20614463]

HYPERTHYROIDISM (THYROTOXICOSIS)



ESSENTIALS OF DIAGNOSIS

- Sweating, weight loss or gain, anxiety, palpitations, loose stools, heat intolerance, irritability, fatigue, weakness, menstrual irregularity.
- Tachycardia; warm, moist skin; stare; tremor.
- In Graves disease: goiter (often with bruit); ophthalmopathy.
- Suppressed TSH in primary hyperthyroidism; increased T_4 , FT_4 , T_3 , FT_3 .

► General Considerations

The term “thyrotoxicosis” refers to the clinical manifestations associated with serum levels of T_4 or T_3 that are excessive for the individual (hyperthyroidism). Serum TSH levels are suppressed in primary hyperthyroidism. However, certain drugs and conditions can affect laboratory tests and lead to the erroneous diagnosis of hyperthyroidism in euthyroid individuals (Table 26–5). The causes of hyperthyroidism are many and diverse, as described below.

A. Graves Disease

Graves disease (known as Basedow disease in Europe) is the most common cause of thyrotoxicosis. It is an autoimmune disorder affecting the thyroid gland, characterized by an increase in synthesis and release of thyroid hormones. Graves disease is much more common in women than in men (8:1), and its onset is usually between the ages of 20 and 40 years. It may be accompanied by infiltrative ophthalmopathy (Graves exophthalmos) and, less commonly, by infiltrative dermopathy (pretibial myxedema). The thymus gland is typically enlarged and serum ANA levels are usually elevated, reflecting the underlying autoimmunity. Graves disease has a familial tendency, and many patients have a family history of Graves disease or hypothyroidism from Hashimoto thyroiditis. Histocompatibility studies have shown an association with group HLA-B8 and HLA-DR3. The pathogenesis of the hyperthyroidism of Graves disease involves the formation of autoantibodies that bind to the TSH receptor in thyroid cell membranes and stimulate the gland to hyperfunction. Such antibodies are called thyroid-stimulating immunoglobulins (TSI) or TSH receptor antibodies (TSHrAb).

Dietary iodine supplementation can trigger Graves disease. An increased incidence of Graves disease occurs in countries that have embarked on national programs to fortify commercial salt with potassium iodide; the increase in Graves disease lasts about 4 years. Similarly, patients being treated with potassium iodide or amiodarone (which contains iodine) have an increased risk of developing Graves disease.

Patients with Graves disease have an increased risk of other systemic autoimmune disorders. Affected patients are at increased risk for Sjögren syndrome, pernicious anemia,

Table 26-5. Factors that can cause aberrations in laboratory tests that may be mistaken for spontaneous clinical primary hyperthyroidism.¹

High Serum T ₄ or T ₃	Low Serum TSH
Laboratory error	Laboratory error
Collecting serum in vial with gel barrier for T ₃	Autonomous thyroid or thyroid nodule
Acute psychiatric problems (30%)	Acute corticosteroid administration
Acute medical illness (eg, acute intermittent porphyria)	Elderly euthyroid
AIDS (increased thyroid-binding globulin)	Nonthyroidal illness (severe)
Autoimmunity	Pregnancy (especially with morning sickness)
Hepatitis: acute or chronic active	hCG-secreting trophoblastic tumors
Primary biliary cirrhosis	Drugs
Pregnancy (especially with morning sickness)	Thyroid hormone
Hyperemesis gravidarum	Amphetamines
Familial thyroid-binding abnormalities	Dopamine
Familial generalized resistance to thyroid (Refetoff syndrome)	Dopamine agonists
Drugs	Calcium channel blockers (nifedipine, verapamil)
Amiodarone	
Amphetamines	
Clofibrate	
Estrogens (oral)	
Heparin (dialysis method)	
Heroin	
Thyroid hormone therapy	
Methadone	
Perphenazine	
Tamoxifen	

¹True clinical hyperthyroidism may coexist.

hCG, human chorionic gonadotropin; NSAIDs, nonsteroidal anti-inflammatory drugs; T₄, levothyroxine; T₃, triiodothyronine; TSH, thyroid-stimulating hormone.

Addison disease, alopecia areata, vitiligo, celiac disease, autoimmune diabetes mellitus type 1, hypoparathyroidism, myasthenia gravis, and cardiomyopathy.

B. Toxic Multinodular Goiter and Thyroid Adenomas

Autonomous toxic adenomas of the thyroid may be single (Plummer disease) or multiple (toxic multinodular goiter).

Jod-Basedow disease, or iodine-induced hyperthyroidism, may occur in patients with multinodular goiters after intake of large amounts of iodine in the diet or in the form of radiographic contrast materials or drugs, especially amiodarone. This condition is not associated with infiltrative ophthalmopathy or dermopathy.

C. Subacute (de Quervain) Thyroiditis

Subacute thyroiditis typically presents with a moderately enlarged, tender thyroid, and hyperthyroidism. It is thought to be due to a viral infection. If the gland is nontender, the disorder is called “silent thyroiditis.” Hyperthyroidism is

followed by hypothyroidism. Patients taking lithium may rarely experience thyrotoxicosis due to silent thyroiditis. Symptoms mimic a manic episode such that the diagnosis is often missed.

D. Thyrotoxicosis Factitia

Thyrotoxicosis factitia is due to ingestion of excessive amounts of exogenous thyroid hormone. Isolated epidemics of thyrotoxicosis have been caused by consumption of ground beef contaminated with bovine thyroid gland.

E. Struma Ovarii

Thyroid tissue is contained in about 3% of ovarian dermoid tumors and teratomas. This thyroid tissue may autonomously secrete thyroid hormone due to a toxic nodule or in concert with the woman's thyroid gland in Graves disease or toxic multinodular goiter.

F. Pituitary Tumor

TSH hypersecretion by the pituitary may be caused by a tumor or thyrotrophe cell hyperplasia and is a rare cause of hyperthyroidism. Serum TSH is elevated or normal in the presence of true thyrotoxicosis. Pituitary hyperplasia may be detected on MRI scan as pituitary enlargement without a discrete adenoma being visible. This condition appears to be due to a diminished feedback effect of T₄ upon the pituitary. Some cases are familial. Prolonged untreated hypothyroidism causes pituitary enlargement due to thyrotrophe hyperplasia; thyrotrophe tumors are rare.

G. Thyroiditis

Hashimoto thyroiditis may cause transient hyperthyroidism during the initial destructive phase. This is also seen in some patients receiving interferon- α , interferon- β , and interleukin-2. Postpartum thyroiditis refers to Hashimoto thyroiditis that occurs in the first 6 months after delivery. It is common, occurring postpartum in 5–10% of women in the United States. Hyperthyroidism results from the release of stored thyroid hormone following damage to the thyroid. Thyroiditis and hyperthyroidism can also develop in patients receiving sunitinib chemotherapy.

H. Pregnancy and Trophoblastic Tumors

The prevalence of hyperthyroidism in pregnancy—most commonly due to Graves disease—is about 0.2%. Struma ovarii is rare. Newborns have an increased risk of intrauterine growth retardation, prematurity, and transient thyrotoxicosis from transplacental transfer of thyrotropin receptor antibody (TRAb).

Although hCG generally has a low affinity for the thyroid's TSH receptors, very high serum levels of hCG may cause sufficient receptor activation to cause thyrotoxicosis. Mild gestational hyperthyroidism may occur during the first 4 months of pregnancy, when hCG levels are very high. Pregnant women are more likely to have thyrotoxicosis and hyperemesis gravidarum if they have high serum levels of asialo-hCG, a subfraction of hCG with greater affinity for TSH receptors.

High levels of hCG can also cause thyrotoxicosis in some cases of molar pregnancy, choriocarcinoma, and testicular malignancies.

I. Thyroid Carcinoma

Metastatic functioning thyroid carcinoma is a rare cause of thyrotoxicosis. Hyperthyroidism can be induced by recombinant human thyroid-stimulating hormone (rhTSH) that is given prior to radioiodine therapy or scanning. (See Thyroid Cancer section.)

J. Iodine-Induced Hyperthyroidism

Iodine-induced hyperthyroidism is also known as Jod-Basedow disease. The recommended iodine intake for nonpregnant adults is 150 mcg/d. Higher iodine intake can precipitate hyperthyroidism, particularly in patients with nodular goiters, autonomous thyroid nodules, or asymptomatic Graves disease. Iodine-induced hyperthyroidism also occurs in patients with no detectable underlying thyroid disorder. Common sources of excess iodine include intravenous iodinated radiocontrast dye, certain foods (eg, kelp, nori), topical iodinated antiseptics (eg, povidine iodine), and medications (eg, potassium iodide or amiodarone). Intravenous iodinated radiocontrast dye can also precipitate thyrotoxicosis by inducing a destructive subacute thyroiditis that may be painful and is similar to type 2 amiodarone-induced thyrotoxicosis.

K. Amiodarone-Induced Thyrotoxicosis

Amiodarone is a widely used antiarrhythmic drug. The half-life of amiodarone and its metabolites is about 100 days. By weight, amiodarone is 37% iodine and thyroid dysfunction develops in about 15–20% of patients taking amiodarone. In the United States, amiodarone-induced thyrotoxicosis develops in about 3% of patients taking the drug; the incidence of amiodarone-induced thyrotoxicosis is higher in Europe and in iodine-deficient geographic areas (20%). Hyperthyroidism can occur 4 months to 3 years after initiation of amiodarone and may develop several months after amiodarone has been discontinued.

Type 1 amiodarone-induced thyrotoxicosis is caused by active elaboration of excessive thyroid hormone and may occur by either of two mechanisms: (1) Free iodine may cause toxic multinodular goiter in iodine-deficient patients with preexisting autonomous thyroid nodules. Thyroid radioactive iodine (RAI) uptake ranges from low to high. (2) Excessive free iodine can trigger an immunologic attack on the thyroid; this may cause Graves disease, commonly with diffuse thyroid enlargement and antithyroid peroxidase antibodies (70%). Color flow Doppler sonography shows increased vascularity and blood flow velocity. Thyroidal radioiodine uptake may be low, normal, or increased.

Type 2 amiodarone-induced thyrotoxicosis is caused by destructive thyroiditis, which releases stored thyroid hormone from damaged cells; hyperthyroidism can last 1–3 months and may be followed by hypothyroidism. On ultrasound, the thyroid gland is normal in size, and on color flow Doppler sonography there is no increase in vascularity. Thyroidal radioiodine uptake is usually very low (< 3%).

► Clinical Findings

A. Symptoms and Signs

Thyrotoxicosis due to any cause produces many different manifestations of variable intensity among different individuals. Patients may complain of nervousness, restlessness, heat intolerance, increased sweating, pruritus, fatigue, weakness, muscle cramps, frequent bowel movements, or weight change (usually loss). There may be palpitations or angina pectoris. Women frequently report menstrual irregularities.

Signs of thyrotoxicosis also include fine resting finger tremors, moist warm skin, fever, hyperreflexia, fine hair, and onycholysis. Chronic thyrotoxicosis may cause osteoporosis. Clubbing and swelling of the fingers (acropachy) develop in a small number of patients.

In patients with Graves disease, physical examination usually reveals a diffusely enlarged thyroid, frequently asymmetric, often with a bruit. However, some patients have no palpable thyroid enlargement. The thyroid gland in subacute thyroiditis is usually moderately enlarged and tender. In patients with toxic multinodular goiter, the thyroid usually has palpable nodules.

Cardiopulmonary manifestations of thyrotoxicosis commonly include a forceful heartbeat, premature atrial contractions, and sinus tachycardia. Patients often have exertional dyspnea. Atrial fibrillation or atrial tachycardia occurs in about 8% of patients with thyrotoxicosis, more commonly in men, the elderly, and those with ischemic or valvular heart disease. The ventricular response from the atrial fibrillation may be difficult to control. Thyrotoxicosis itself can cause a thyrotoxic cardiomyopathy, and the onset of atrial fibrillation can precipitate congestive heart failure. Echocardiogram reveals pulmonary hypertension in 49% of patients with hyperthyroidism; of these, 71% have pulmonary artery hypertension while 29% have pulmonary venous hypertension. Hemodynamic abnormalities and pulmonary hypertension are reversible with restoration of euthyroidism.

Graves eye manifestations, which can occur with hyperthyroidism of any etiology, include upper eyelid retraction (Dalrymple sign), lid lag with downward gaze (von Graefe sign), and a staring appearance (Kocher sign). **Ophthalmopathy** is clinically apparent in 20–40% of patients with Graves disease and type 1 amiodarone-induced thyrotoxicosis, but in no other conditions causing hyperthyroidism. It usually consists of conjunctival edema (chemosis), conjunctivitis, and mild exophthalmos (proptosis). About 5–10% of patients experience more severe exophthalmos, with the eye being pushed forward by increased retro-orbital fat and eye muscles that have been thickened by lymphocytic infiltration. Such patients can experience diplopia from extraocular muscle entrapment. There may be weakness of upward gaze (Stellwag sign). The optic nerve may be compressed in severe cases, causing progressive loss of color vision, visual fields, and visual acuity. Corneal drying may occur with inadequate lid closure. Eye changes may sometimes be asymmetric or unilateral. The severity of the eye disease is not closely correlated with the severity of the thyrotoxicosis. Some patients with Graves ophthalmopathy are clinically euthyroid.

Exophthalmometry should be performed on all patients with Graves disease to document their degree of exophthalmos and detect progression of orbitopathy. The protrusion of the eye beyond the orbital rim is measured with a prism instrument (Hertel exophthalmometer). Maximum normal eye protrusion varies between kindreds and races, being about 22 mm for blacks, 20 mm for whites, and 18 mm for Asians.

The differential diagnosis for Graves ophthalmopathy includes diplopia caused by coexistent **ocular myasthenia gravis**, which is more common in Graves disease and is usually mild, often with selective eye involvement. Acetylcholinesterase receptor antibody (AChR Ab) levels are elevated in only 36% of such patients, and a thymoma is present in 9%. Orbital lymphoma can also masquerade as Graves ophthalmopathy.

Graves dermopathy (pretibial myxedema) occurs in about 3% of patients with Graves disease, usually in the pretibial region. It is more common in patients with high levels of serum thyroid-stimulating immunoglobulin and in those with severe Graves ophthalmopathy. Glycosaminoglycans accumulation and lymphoid infiltration occur in affected skin, which becomes erythematous with a thickened, rough texture. Elephantiasis of the legs is a rare complication.

Thyroid acropachy is an extreme and unusual manifestation of Graves disease. It presents with digital clubbing, swelling of fingers and toes, and a periosteal reaction of extremity bones. It is ordinarily associated with ophthalmopathy and thyroid dermopathy. Most patients are smokers. The presence of thyroid acropachy is an indication of the severity of the autoimmunity; most patients have high serum titers of thyroid-stimulating immunoglobulin. Patients with thyroid acropachy are at greater risk for having concurrent Graves dermopathy and severe ophthalmopathy. However, acropachy itself does not usually cause clinical complaints.

Tetany is a rare presenting feature. In hyperthyroidism, the renal excretion of magnesium is increased and hypomagnesemia is common. Severe magnesium depletion causes hypoparathyroidism that can result in hypocalcemia.

Hyperthyroidism during pregnancy shares many of the features of normal pregnancy: tachycardia, warm skin, heat intolerance, increased sweating, and a palpable thyroid. Pregnancy can have a beneficial effect on the thyrotoxicosis of Graves disease. However, there is an increased risk of thyroid storm, preeclampsia–eclampsia, congestive heart failure, premature delivery, and abruptio placentae. TSI (or TSHrAb) crosses the placenta; if maternal serum TSI (or TSHrAb) levels reach > 500% in the third trimester, the risk of transient neonatal Graves disease in the newborn is increased.

Hypokalemic periodic paralysis occurs in about 15% of Asian or Native American men with thyrotoxicosis. It usually presents abruptly with symmetric flaccid paralysis (and few thyrotoxic symptoms), often after intravenous dextrose, oral carbohydrate, or vigorous exercise. Attacks last 7–72 hours.

B. Laboratory Findings

Serum FT_4 , T_3 , FT_3 , T_4 , thyroid resin uptake, and FT_4 index are all usually increased. Sometimes the FT_4 level may be

normal but with an elevated serum T_3 (T_3 toxicosis). Serum T_3 can be misleadingly elevated when blood is collected in tubes using a gel barrier, which causes certain immunoassays (eg, Immulite but not AxSYM analyzers) to report serum total T_3 levels that are falsely elevated in 24% of normal patients. Serum T_4 or T_3 can be elevated in other nonthyroidal conditions (Table 26–5).

Serum TSH is suppressed in hyperthyroidism, except in the very rare cases of pituitary inappropriate secretion of thyrotropin. Serum TSH may be misleadingly low in other nonthyroidal conditions (Table 26–5). The term “**subclinical hyperthyroidism**” is used to describe asymptomatic individuals with a low serum TSH but normal serum levels of FT_4 and T_3 ; progression to symptomatic thyrotoxicosis occurs at a rate of 1–2% per year in patients without a goiter and at a rate of 5% per year in patients with a multinodular goiter.

Hyperthyroidism can cause other laboratory abnormalities, including hypercalcemia, increased alkaline phosphatase, anemia, and decreased granulocytes. Hypokalemia and hypophosphatemia occur in thyrotoxic periodic paralysis.

Problems of diagnosis occur in patients with acute psychiatric disorders; about 30% of these patients have elevated serum T_4 levels without clinical thyrotoxicosis. The TSH is not usually suppressed, distinguishing psychiatric disorder from true hyperthyroidism. T_4 levels return to normal gradually.

In **Graves disease**, serum TSI (or TSHrAb) is usually detectable (65%). Antithyroglobulin or antithyroperoxidase antibodies are usually elevated but are nonspecific. Serum ANA and anti-double-stranded DNA antibodies are also usually elevated without any evidence of lupus erythematosus or other collagen-vascular disease.

With **subacute thyroiditis**, patients often have an increased erythrocyte sedimentation rate (ESR) but antithyroid antibodies are usually not present in the plasma, and tests for TSI (or TSHrAb) are negative. Patients with **iodine-induced hyperthyroidism** also have undetectable serum TSI (or TSHrAb), an absence of serum antithyroperoxidase antibodies, and an elevated urinary iodine concentration. In **thyrotoxicosis factitia**, serum thyroglobulin levels are low, distinguishing it from other causes of hyperthyroidism.

With **hyperthyroidism during pregnancy**, women have an elevated FT_4 while the TSH is suppressed. However, apparent lack of full TSH suppression can be seen due to misidentification of hCG as TSH in certain assays. Although the total T_4 is elevated in most pregnant women, values over 20 mcg/dL are encountered only in hyperthyroidism. The T_3 resin uptake, which is low in normal pregnancy because of high TBG concentration, is normal or high in thyrotoxic persons. Pregnancy can have a beneficial effect on the thyrotoxicosis of Graves disease, with decreasing antibody titers and decreasing FT_4 levels as the pregnancy advances.

Since high levels of T_4 and FT_4 are normally seen in patients taking **amiodarone**, suppressed TSH (sensitive assay) must be present along with a greatly elevated T_4 (> 20 mcg/dL) or T_3 (> 200 ng/dL) in order to diagnose hyperthyroidism. (**Note:** Hypothyroidism occurs in an additional 6% of patients receiving amiodarone after

2–39 weeks of therapy.) In **type 1 amiodarone-induced thyrotoxicosis**, the presence of proptosis, thyroid-stimulating immunoglobulin is diagnostic. In **type 2 amiodarone-induced thyrotoxicosis**, serum levels of interleukin-6 (IL-6) are usually quite elevated.

C. Imaging

RAI should never be administered to pregnant women. In others, RAI scanning and uptake may be helpful to determine the cause for hyperthyroidism. RAI uptake and scanning is not necessary for patients with obvious Graves disease who have elevated serum thyroid-stimulating immunoglobulin or associated Graves ophthalmopathy. Women with hyperthyroidism due to Graves disease should ideally have the RAI scan extended to include the pelvis in order to screen for concomitant struma ovarii (rare). A high RAI uptake is seen in **Graves disease** and **toxic nodular goiter**. Patients with **type 1 amiodarone-induced thyrotoxicosis** have RAI uptake that is usually detectable but typically below the normal range, although some patients may have elevated RAI uptake. A low RAI uptake is characteristic of **subacute thyroiditis** and iodine-induced hyperthyroidism. Low RAI uptake is also seen with interleukin-2 therapy and after neck surgery for hyperparathyroidism. In **type 2 amiodarone-induced thyrotoxicosis**, thyroid RAI uptake is usually below 3%.

Thyroid ultrasound can be helpful in patients with hyperthyroidism, particularly in patients with palpable thyroid nodules. **Color flow Doppler sonography** is helpful to distinguish type 1 amiodarone-induced thyrotoxicosis, with its increased blood flow velocity and vascularity, from type 2 amiodarone-induced thyrotoxicosis (reduced vascularity).

MRI and CT scanning of the orbits are the imaging methods of choice to visualize Graves ophthalmopathy affecting the extraocular muscles. Imaging is required only in severe or unilateral cases or in euthyroid exophthalmos that must be distinguished from orbital pseudotumor, tumors, and other lesions.

► Differential Diagnosis

True thyrotoxicosis must be distinguished from those conditions that elevate serum T_4 and T_3 or suppress serum TSH without affecting clinical status (see Table 26–5).

Some states of hypermetabolism without thyrotoxicosis—notably severe anemia, leukemia, polycythemia, and cancer—rarely cause confusion. Pheochromocytoma is often associated with hypermetabolism, tachycardia, weight loss, and profuse sweating. Acromegaly may also produce tachycardia, sweating, and thyroid enlargement. Appropriate laboratory tests will easily distinguish these entities.

Cardiac disease (eg, atrial fibrillation, angina) refractory to treatment suggests the possibility of underlying (“apathetic”) hyperthyroidism. Other causes of ophthalmoplegia (eg, myasthenia gravis) and exophthalmos (eg, orbital tumor, pseudotumor) must be considered. Thyrotoxicosis must also be considered in the differential diagnosis of muscle weakness and osteoporosis. Diabetes mellitus and Addison disease may coexist with thyrotoxicosis.

► Complications

Hypercalcemia, osteoporosis, and nephrocalcinosis may occur. Decreased libido, erectile dysfunction, diminished sperm motility, and gynecomastia may be noted in men with hyperthyroidism. Other complications include cardiac arrhythmias and heart failure, thyroid crisis, ophthalmopathy, dermatopathy, and thyrotoxic hypokalemic periodic paralysis (see below).

► Treatment

A. Graves Disease

The treatment of Graves disease involves a choice of methods rather than a method of choice.

1. Propranolol—Propranolol is generally used for symptomatic relief until the hyperthyroidism is resolved. It effectively relieves the tachycardia, tremor, diaphoresis, and anxiety that occur with hyperthyroidism due to any cause. It is the initial treatment of choice for thyroid storm. The periodic paralysis seen in association with thyrotoxicosis is also effectively treated with β -blockade. It has no effect on thyroid hormone secretion. Treatment is usually begun with propranolol ER 60 mg orally once or twice daily, with dosage increases every 2–3 days to a maximum daily dose of 320 mg. Propranolol ER is initially given every 12 hours for patients with severe hyperthyroidism, due to accelerated metabolism of the propranolol; it may be given once daily as hyperthyroidism improves.

2. Thiourea drugs—Methimazole or propylthiouracil is generally used for young adults or patients with mild thyrotoxicosis, small goiters, or fear of isotopes. Carbimazole is another thiourea that is converted to methimazole in vivo and is available outside the United States. Elderly patients usually respond particularly well. These drugs are also useful for preparing hyperthyroid patients for surgery and elderly patients for RAI treatment. The drugs do not permanently damage the thyroid and are associated with a lower chance of posttreatment hypothyroidism (compared with RAI or surgery). When thiourea therapy is discontinued, there is a high recurrence rate for hyperthyroidism (about 50%). A better likelihood of long-term remission is seen in patients with small goiters or mild hyperthyroidism and those requiring small doses of thiourea. Patients whose thyroperoxidase and thyroglobulin antibodies remain high after 2 years of therapy have been reported to have only a 10% rate of relapse. Thiourea therapy may be continued long-term for patients who are tolerating it well.

Agranulocytosis occurs in about 0.3% of patients taking methimazole and about 0.4% of patients taking propylthiouracil. Agranulocytosis usually occurs in the first 60 days of therapy, and it develops in a few patients after 5 months of therapy. There is a genetic tendency to develop agranulocytosis with thiourea therapy; if a close relative has had this adverse reaction, other therapies should be considered for the patient. Patients are warned that if a sore throat or febrile illness develops, they should seek medical attention and have a WBC determined immediately. The agranulocytosis is generally reversible; recovery is not

improved by filgrastim (granulocyte colony-stimulating factor [G-CSF]). Periodic surveillance of the WBC during treatment has been advocated, but the onset of agranulocytosis is generally abrupt.

Other side effects common to thiourea drugs include pruritus, allergic dermatitis, nausea, and dyspepsia. Antihistamines may control mild pruritus without discontinuation of the drug. Since the two thiourea drugs are similar, patients who have had a major allergic reaction from one should not be given the other.

Primary hypothyroidism may occur. The patient may become clinically hypothyroid for 2 weeks or more before TSH levels rise, having been suppressed by the preceding hyperthyroidism. Therefore, the patient's changing thyroid status is best monitored clinically and with serum levels of FT₄. Rapid growth of the goiter usually occurs if prolonged hypothyroidism is allowed to develop; the goiter may sometimes become massive but usually regresses rapidly with reduction or cessation of thiourea therapy or with thyroid hormone replacement.

A. METHIMAZOLE—Methimazole is generally preferred over propylthiouracil since methimazole is more convenient to use and is less likely to cause fulminant hepatic necrosis. Methimazole therapy is also less likely to cause ¹³¹I treatment failure. Rare complications peculiar to methimazole include serum sickness, cholestatic jaundice, loss of taste, alopecia, nephrotic syndrome, and hypoglycemia. Methimazole is given orally in initial doses of 30–60 mg once daily. Some patients with very mild hyperthyroidism may respond well to smaller initial doses of methimazole (10–20 mg daily). Methimazole may also be administered twice daily to reduce the likelihood of gastrointestinal upset. Methimazole use in pregnancy has been associated with a possibly increased risk of fetal anomalies such as aplasia cutis, esophageal atresia, and coanal atresia. However, methimazole may be used if the patient cannot tolerate propylthiouracil (see below). If methimazole is used during pregnancy or breastfeeding, the dose should not exceed 20 mg daily. The dosage is reduced as manifestations of hyperthyroidism resolve and as the FT₄ level falls toward normal. For patients who have elected to receive ¹³¹I therapy, methimazole is discontinued 4 days prior to receiving the ¹³¹I and is resumed at a lower dose 3 days afterwards to avoid recurrence of hyperthyroidism. About 4 weeks after ¹³¹I therapy, methimazole may be discontinued if the patient is euthyroid.

B. PROPYLTHIOURACIL—Propylthiouracil has been the drug of choice during breastfeeding since it is not concentrated in the milk as much as methimazole. Propylthiouracil is also favored during pregnancy, possibly causing fewer problems in the newborn. Rare complications peculiar to propylthiouracil include arthritis, lupus, aplastic anemia, thrombocytopenia, and hypoprothrombinemia. Acute hepatitis occurs rarely and is treated with prednisone but may progress to liver failure. Propylthiouracil is given orally in initial doses of 300–600 mg daily in four divided doses. The dosage and frequency of administration are reduced as symptoms of hyperthyroidism resolve and the FT₄ level approaches normal. During pregnancy, the dose of propylthiouracil is kept below 200 mg/d to avoid goitrous

hypothyroidism in the infant; the patient may be switched to methimazole in the second trimester.

3. Iodinated contrast agents—These agents provide effective temporary treatment for thyrotoxicosis of any cause. Iopanoic acid (Telepaque) or ipodate sodium (Bilivist, Oragrafin) is given orally in a dosage of 500 mg twice daily for 3 days, then 500 mg once daily. These agents inhibit peripheral 5'-monodeiodination of T₄, thereby blocking its conversion to active T₃. Within 24 hours, serum T₃ levels fall an average of 62%. For patients with Graves disease, methimazole is begun first to block iodine organification; the next day, ipodate sodium or iopanoic acid may be added. The iodinated contrast agents are particularly useful for patients who are very symptomatically thyrotoxic (see Thyroid Storm). They offer a therapeutic option for patients with T₄ overdosage, subacute thyroiditis, and amiodarone-induced thyrotoxicosis and for those intolerant to thioureas and for newborns with thyrotoxicosis (due to maternal Graves disease). Treatment periods of 8 months or more are possible, but efficacy tends to wane with time. In Graves disease, thyroid RAI uptake may be suppressed during treatment but typically returns to pretreatment uptake by 7 days after discontinuation of the drug, allowing ¹³¹I treatment.

4. Radioactive iodine (¹³¹I, RAI)—The administration of ¹³¹I is an excellent method of destroying overactive thyroid tissue (either diffuse or toxic nodular goiter). There are ample data to conclude that patients who are treated with RAI in adulthood do not have an increased risk of subsequent thyroid cancer, leukemia, or other malignancies. Similarly, individuals who were treated with RAI as teenagers have not shown any increased risk of malignancy in a 36-year retrospective study. Children born to parents previously treated with ¹³¹I show normal rates of congenital abnormalities.

Because fetal radiation is harmful, *RAI should not be given to pregnant women*. A sensitive pregnancy test (serum β-hCG) should be obtained on all women of reproductive age prior to ¹³¹I therapy.

Most patients may receive ¹³¹I while being symptomatically treated with propranolol ER, which is then reduced in dosage as hyperthyroxinemia resolves. However, some patients (those with coronary disease, the elderly, or those with severe hyperthyroidism) are usually rendered euthyroid with a thiouracil drug (see above) while the dosage of propranolol is reduced. A higher rate of ¹³¹I treatment failure has been reported in patients with Graves disease who have been receiving methimazole or propylthiouracil. However, therapy with ¹³¹I will usually be effective if the methimazole is discontinued at least 4 days before RAI therapy and if the therapeutic dosage of ¹³¹I is adjusted (upward) according to RAI uptake on the pretherapy scan. Prior to ¹³¹I therapy, patients are instructed against receiving intravenous iodinated contrast or ingesting large quantities of dietary iodine, but severe restriction of dietary iodine is not usually necessary.

Following ¹³¹I treatment for hyperthyroidism, Graves ophthalmopathy appears or worsens in 15% of patients (23% in smokers and 6% in nonsmokers) and improves in

none, whereas during treatment with methimazole, ophthalmopathy worsens in 3% and improves in 2% of patients. Among patients receiving prednisone following ^{131}I treatment, preexistent ophthalmopathy worsens in none and improves in 67%. Therefore, patients with Graves ophthalmopathy who are to be treated with radioiodine should be considered for prophylactic prednisone (20–40 mg/d) for 2 months following administration of ^{131}I , particularly in patients who have severe orbital involvement.

Smoking increases the risk of having a flare in ophthalmopathy following ^{131}I treatment and also reduces the effectiveness of prednisone treatment. Therefore, patients who smoke are strongly encouraged to quit prior to ^{131}I treatment.

FT_4 levels may sometimes drop within 2 months after ^{131}I treatment, but then rise again to thyrotoxic levels, at which time thyroid RAI uptake is low. This phenomenon is caused by a release of stored thyroid hormone from injured thyroid cells and does not indicate a treatment failure. In fact, serum FT_4 then falls abruptly to hypothyroid levels.

There is a high incidence of hypothyroidism in the months to years after ^{131}I , even when small doses are given. Patients with Graves disease treated with ^{131}I also have an increased lifetime risk of developing hyperparathyroidism, particularly when radioiodine therapy was administered in childhood or adolescence. Lifelong clinical follow-up is mandatory, with measurements of serum TSH, FT_4 , and calcium when indicated.

5. Thyroid surgery—Thyroidectomy may be performed for pregnant women whose thyrotoxicosis is not controlled with low doses of thioureas, and for women who desire to become pregnant in the very near future. Surgery is also an option for nodular goiters, when there is a suspicion for malignancy.

The Hartley–Dunhill operation is the procedure of choice for patients with Graves disease having surgery; this operation consists of a total resection of one lobe and a subtotal resection of the other lobe, leaving about 4 g of thyroid tissue. Subtotal thyroidectomy of both lobes is often used, but ultimately results in a 9% recurrence rate for hyperthyroidism. Total thyroidectomy of both lobes poses an increased risk of hypoparathyroidism and damage to the recurrent laryngeal nerves.

Patients are ordinarily rendered euthyroid preoperatively with a thiourea drug. Iodate sodium or iopanoic acid (500 mg orally twice daily) may be used in addition to a thiourea to accelerate the decline in serum T_3 . Propranolol ER is given orally at initial doses of 60–80 mg twice daily and increased every 2–3 days until the heart rate is < 90 beats per minute. Propranolol is continued until the serum T_3 (or free T_3) is normal preoperatively. Thyroid vascularity is reduced by preoperative treatment with either iodate sodium or iopanoic acid (500 mg twice orally daily for 3 days) or iodine (eg, Lugol solution, two or three drops orally daily for several days). If a patient undergoes surgery while thyrotoxic, larger doses of propranolol are given perioperatively to reduce the likelihood of thyroid crisis.

Morbidity includes possible damage to the recurrent laryngeal nerve, with resultant vocal cord paralysis. If both recurrent laryngeal nerves are damaged, airway obstruction

may develop, and the patient may require intubation and tracheostomy. Hypoparathyroidism also occurs, which means that calcium levels must be checked postoperatively. When a competent, experienced neck surgeon performs a thyroidectomy, surgical complications are uncommon. Thyroid surgery should be performed as an inpatient, with at least an overnight observational period.

B. Toxic Solitary Thyroid Nodules

Toxic solitary thyroid nodules are usually benign but may rarely be malignant. If a nonsurgical therapy is elected, the nodule should be evaluated with a fine-needle aspiration biopsy (FNA). Hyperthyroidism caused by a single hyperfunctioning thyroid nodule may be treated symptomatically with propranolol ER and methimazole or propylthiouracil, as in Graves disease (see above). Patients who tolerate methimazole well may elect to continue it for long-term therapy. The dose of methimazole should be adjusted to keep the TSH slightly suppressed, so the risk of TSH-stimulated growth of the nodule is reduced. For patients under age 40 years and for healthy older patients, surgery is usually recommended; patients are made euthyroid with a thiourea preoperatively and given several days of iodine, ipodate sodium, or iopanoic acid before surgery as in Graves disease (see above). Transient postoperative hypothyroidism resolves spontaneously. Permanent hypothyroidism occurs in about 14% of patients by 6 years after surgery. Patients with a toxic solitary nodule who are over age 40 years or in poor health may be offered ^{131}I therapy. If the patient has been receiving methimazole preparatory to ^{131}I , the TSH should be kept slightly suppressed in order to reduce the uptake of ^{131}I by the normal thyroid. Nevertheless, permanent hypothyroidism occurs in about one-third of patients after 8 years of ^{131}I therapy. The nodule remains palpable in 50% and may grow in 10% of patients after ^{131}I .

C. Toxic Multinodular Goiter

Hyperthyroidism caused by a toxic multinodular goiter may also be treated with propranolol ER and methimazole, as in Graves disease. Methimazole does reverse hyperthyroidism, but there is a 95% recurrence rate if it is stopped. Definitive treatment for large multinodular goiters is surgery, prior to which patients are rendered euthyroid. Surgery is particularly indicated to relieve pressure symptoms or for cosmetic indications. Patients with toxic multinodular goiter are prepared for surgery the same as those with Graves disease. Patients who are to receive ^{131}I treatment are rendered nearly euthyroid with methimazole, which is stopped at least 4 days before RAI treatment. Meanwhile, the patient follows a low-iodine diet; this is done to enhance the thyroid gland's uptake of RAI, which may be relatively low in this condition (compared to Graves disease). Relatively high doses of ^{131}I are usually required; recurrent thyrotoxicosis and hypothyroidism are common, so patients must be monitored closely. Peculiarly, in about 5% of patients with diffusely nodular toxic goiter, the administration of ^{131}I therapy may induce Graves disease. Also, Graves eye disease has occurred rarely following ^{131}I therapy for multinodular goiter.

D. Subacute (de Quervain) Thyroiditis

Patients with hyperthyroidism due to subacute thyroiditis are treated symptomatically with oral propranolol ER at initial doses of about 60–80 mg twice daily and increased every 2–3 days until the heart rate is < 90 beats per minute. Iodate sodium or iopanoic acid, 500 mg orally daily, promptly corrects elevated T_3 levels and is continued for 15–60 days until the serum FT_4 level normalizes. The condition subsides spontaneously within weeks to months. Thioureas are ineffective, since thyroid hormone production is actually low in this condition. RAI is ineffective, since the thyroid's iodine uptake is low. Since periods of hypothyroidism may occur following the initial inflammatory episode, patients should have close clinical follow-up, with serum FT_4 measurement when necessary. Prompt treatment of the transient hypothyroidism may reduce the incidence of recurrent thyroiditis. Pain can usually be managed with non-aspirin nonsteroidal anti-inflammatory drugs.

E. Hashimoto Thyroiditis (Hashitoxicosis)

Rarely, hyperthyroidism develops as a result of release of stored thyroid hormone during severe Hashimoto thyroiditis. Serum thyroperoxidase or thyroglobulin antibodies are usually high, but RAI uptake is low, thus distinguishing it from Graves disease. This is especially common in postpartum women, in whom it may be transient. Treatment is with propranolol ER. Iodate sodium or iopanoic acid may also be used as described above. Patients are monitored carefully for the development of hypothyroidism and treated.

F. Hyperthyroidism during Pregnancy and Lactation

There may be a slightly increased risk of fetal anomalies associated with methimazole in the first trimester. Therefore, pregnant women with hyperthyroidism are treated with propylthiouracil in the first trimester and then may be switched to methimazole. Either thiourea should be given in the smallest dose possible, permitting mild subclinical hyperthyroidism to occur since it is usually well tolerated. Both propylthiouracil and methimazole cross the placenta and can induce hypothyroidism, with fetal TSH hypersecretion and goiter. Thyroid hormone administration to the mother does not prevent hypothyroidism in the fetus, since T_4 and T_3 do not freely cross the placenta. Fetal hypothyroidism is rare if the mother's hyperthyroidism is controlled with small daily doses of propylthiouracil (50–150 mg/d orally) or methimazole (5–15 mg/d orally). Thyroidectomy is reserved for women who are allergic or resistant to antithyroid drugs (usually due to noncompliance) or who have very large goiters. Fetal ultrasound at 32 weeks gestation can visualize any fetal goiter, so fetal thyroid dysfunction can be diagnosed and treated.

Both methimazole and propylthiouracil are secreted in breast milk, but not in amounts that affect the infant's thyroid hormone levels. No adverse reactions to these drugs (eg, rash, hepatic dysfunction, leukopenia) have been reported in breast-fed infants. Recommended doses are 20 mg orally daily or less for methimazole and 450 mg

orally daily or less for propylthiouracil. It is recommended that the medication be taken just after breast-feeding.

G. Treatment of Other Causes of Hyperthyroidism

Patients with thyrotoxicosis from **thyrotrope pituitary hyperplasia** are treated with propranolol ER as described above. Definitive treatment is with RAI or thyroid surgery. Patients with thyrotoxicosis caused by a **thyrotrope pituitary adenoma** are treated with propranolol ER and methimazole, followed by transsphenoidal resection of the pituitary tumor, when possible.

Patients with **type 1 amiodarone-induced thyrotoxicosis** usually require propranolol ER. Therapy with ^{131}I may be successful in some patients with sufficient RAI uptake. If radioiodine therapy is not an option (due to insufficient RAI uptake), treatment with methimazole is begun. If radioiodine is administered, methimazole may be started several days afterward. After two doses of methimazole, iopanoic acid or sodium ipodate may be added to the regimen to further block conversion of T_4 to T_3 ; the recommended dosage for each is 500 mg orally twice daily for 3 days, followed by 500 mg once daily until thyrotoxicosis is resolved. If iopanoic acid or sodium ipodate is not available, the alternative is potassium perchlorate; it is given in doses of ≤ 1000 mg daily (in divided doses) for a course not to exceed 30 days in order to avoid the complication of aplastic anemia. Amiodarone may be withdrawn but this does not have a significant therapeutic effect for several months. Thyroidectomy is reserved for resistant cases.

Patients with **type 2 amiodarone-induced thyrotoxicosis** usually require propranolol ER. Prednisone is given at an initial dose of about 0.5–0.7 mg/kg; that dose of prednisone is continued for about 2 weeks and then slowly tapered and finally withdrawn after about 3 months. Iopanoic acid or ipodate sodium may also be used (see above). Withdrawal of amiodarone is not usually necessary. Methimazole is ineffective. Thyroidectomy is rarely required, since the condition is transient. Most patients become euthyroid within 30–40 days, except in cases of very severe thyrotoxicosis.

Some cases of **amiodarone-induced thyrotoxicosis** cannot be strictly categorized as either type 1 or type 2. Such patients usually have negligible radioiodine uptake, so treatment is usually commenced with propranolol ER and a 1-month trial of methimazole. Iopanoic acid or ipodate sodium can be added to methimazole as noted above. Prednisone is given for severe thyrotoxicosis or when methimazole fails to correct the thyrotoxicosis. Amiodarone is discontinued, when feasible.

H. Treatment of Complications

1. Graves ophthalmopathy—The risk of having a “flare” of ophthalmopathy following ^{131}I treatment for hyperthyroidism is about 6% for nonsmokers and 23% for smokers. Graves ophthalmopathy can also be aggravated by thiazolidinediones (eg, pioglitazone, rosiglitazone); these oral diabetic agents should be avoided or withdrawn in patients with Graves disease. Patients with mild ophthalmopathy

may be treated with selenium 100 mcg orally twice daily, which slows the progression of the disease. For acute, progressive exophthalmos, intravenous methylprednisolone, begun promptly, is superior to oral prednisone, possibly due to improved compliance. Methylprednisolone is given intravenously, 500 mg weekly for 6 weeks, then 250 mg weekly for 6 weeks. If oral prednisone is chosen for treatment, it must be given promptly in daily doses of 40–60 mg/d orally, with dosage reduction over several weeks. Higher initial prednisone doses of 80–120 mg/d are used when there is optic nerve compression. Prednisone alleviates acute eye symptoms in 64% of nonsmokers, but only 14% of smokers respond well.

Progressive active exophthalmos may be treated with retrobulbar radiation therapy using a supervoltage linear accelerator (4–6 MeV) to deliver 20 Gy over 2 weeks to the extraocular muscles, avoiding the cornea and lens. Prednisone in high doses is given concurrently. Patients who respond well to orbital radiation include those with signs of acute inflammation, recent exophthalmos (< 6 months), or optic nerve compression. Patients with chronic proptosis and orbital muscle restriction respond less well. Retrobulbar radiation does not cause cataracts or tumors; however, it can cause radiation-induced retinopathy (usually subclinical) in about 5% of patients overall, mostly in diabetics.

For severe cases, orbital decompression surgery may save vision, though diplopia often persists postoperatively. General eye protective measures include wearing glasses to protect the protruding eye and taping the lids shut during sleep if corneal drying is a problem. Methylcellulose drops and gels (“artificial tears”) may also help. Tarsorrhaphy or canthoplasty can frequently help protect the cornea and provide improved appearance. Hypothyroidism and hyperthyroidism must be treated promptly.

2. Cardiac complications—

A. SINUS TACHYCARDIA—Treatment consists of treating the thyrotoxicosis. A β -blocker (as described above) such as propranolol is used in the interim unless there is an associated cardiomyopathy.

B. ATRIAL FIBRILLATION—Hyperthyroidism must be treated immediately (see above). Other drugs, including digoxin, β -blockers, anticoagulants, may be required. Electrical cardioversion is unlikely to convert atrial fibrillation to normal sinus rhythm while the patient is thyrotoxic. Spontaneous conversion to normal sinus rhythm occurs in 62% of patients with return of euthyroidism, but that likelihood decreases with age. Following conversion to euthyroidism, there is a 60% chance that atrial fibrillation will recur, despite normal thyroid function tests. Those with persistent atrial fibrillation may have elective cardioversion 4 months after resolution of hyperthyroidism.

(1) **Digoxin**—Digoxin is used to slow a fast ventricular response to thyrotoxic atrial fibrillation; it must be used in larger than normal doses because of increased clearance and an increased number of cardiac cellular sodium pumps requiring inhibition. Digoxin doses are reduced as hyperthyroidism is corrected.

(2) **β -Blockers**— β -Blockers may also reduce the ventricular rate, but they must be used with caution—particularly

in patients with cardiomegaly or signs of heart failure—since their negative inotropic effect may precipitate congestive heart failure. Therefore, an initial trial of a short-duration β -blocker should be considered, such as esmolol intravenously. If a β -blocker is used, doses of digoxin must be reduced.

(3) **Anticoagulants**—Anticoagulation is indicated in the following situations: left atrial enlargement on echocardiogram, global left ventricular dysfunction, recent congestive heart failure, hypertension, recurrent atrial fibrillation, or a history of previous thromboembolism. The doses of warfarin required in thyrotoxicosis are smaller than normal because of an accelerated plasma clearance of vitamin K–dependent clotting factors. Higher warfarin doses are usually required as hyperthyroidism subsides.

C. HEART FAILURE—Heart failure due to thyrotoxicosis may be caused by extreme tachycardia, cardiomyopathy, or both. Very aggressive treatment of the hyperthyroidism is required in either case (see Thyroid Crisis, below). The tachycardia from atrial fibrillation is treated with digoxin as above. Intravenous furosemide is typically required. Oral spironolactone or eplerenone may be helpful. If tachycardia appears to be the main cause of the failure, β -blockers are administered cautiously as described above.

Congestive heart failure may occur as a result of low-output dilated cardiomyopathy in the setting of hyperthyroidism. It is uncommon and may be caused by an idiosyncratic severe toxic effect of hyperthyroidism upon certain hearts. Cardiomyopathy may occur at any age and without preexisting cardiac disease. β -Blockers and calcium channel blockers are avoided. Emergency treatment may include afterload reduction, diuretics, digoxin, and other inotropic agents while the patient is being rendered euthyroid. Heart failure usually persists despite correction of hyperthyroidism.

D. APATHETIC HYPERTHYROIDISM—Apathetic hyperthyroidism may present with angina pectoris. Treatment is directed at reversing the hyperthyroidism as well as providing standard antianginal therapy. Coronary angioplasty or bypass grafting can often be avoided by prompt diagnosis and treatment.

3. Thyroid crisis or “storm”—This disorder, rarely seen today, is an extreme form of thyrotoxicosis that may be triggered by stressful illness, thyroid surgery, or RAI administration. Its manifestations often include marked delirium, severe tachycardia, vomiting, diarrhea, dehydration and very high fever. The mortality rate is high.

A thiourea drug is given (eg, methimazole, 15–25 mg orally every 6 hours or propylthiouracil, 150–250 mg orally every 6 hours). Iodate sodium (500 mg/d orally) can be helpful if begun 1 hour after the first dose of thiourea. Iodide is given 1 hour later as Lugol solution (10 drops three times daily orally) or as sodium iodide (1 g intravenously slowly). Propranolol is given (cautiously in the presence of heart failure; see above) in a dosage of 0.5–2 mg intravenously every 4 hours or 20–120 mg orally every 6 hours. Hydrocortisone is usually given in doses of 50 mg orally every 6 hours, with rapid dosage reduction as the clinical situation improves. Aspirin is avoided since it

displaces T_4 from TBG, raising FT_4 serum levels. Definitive treatment with ^{131}I or surgery is delayed until the patient is euthyroid.

4. Hyperthyroidism from postpartum thyroiditis—

Propranolol ER is given during the hyperthyroid phase followed by levothyroxine during the hypothyroidism phase (see Thyroiditis, below).

5. Graves dermopathy—

Treatment involves application of a topical corticosteroid (eg, fluocinolone) with nocturnal plastic occlusive dressings.

6. Thyrotoxic hypokalemic periodic paralysis—

Sudden symmetric flaccid paralysis, along with hypokalemia and hypophosphatemia can occur with hyperthyroidism. There are often few classic signs of thyrotoxicosis. It is most prevalent in Asian and Native Americans with hyperthyroidism and is 30 times more common in men than women. Therapy with oral propranolol, 3 mg/kg, normalizes the serum potassium and phosphate levels and reverses the paralysis within 2–3 hours. No intravenous potassium or phosphate is ordinarily required. Intravenous dextrose and oral carbohydrate aggravate the condition and are to be avoided. Therapy is continued with propranolol, 60–80 mg orally every 8 hours (or sustained-action propranolol ER daily at equivalent daily dosage), along with a thiourea drug such as methimazole to treat the hyperthyroidism.

► Prognosis

Graves disease may rarely subside spontaneously, particularly when it is mild or subclinical. Graves disease that presents in early pregnancy has a 30% chance of spontaneous remission before the third trimester. The ocular, cardiac, and psychological complications can become serious and persistent even after treatment. Permanent hypoparathyroidism and vocal cord palsy are risks of surgical thyroidectomy. Recurrences are common following thiourea therapy but also occur after low-dose ^{131}I therapy or subtotal thyroidectomy. With adequate treatment and long-term follow-up, the results are usually good. However, despite treatment for their hyperthyroidism, women experience an increased long-term risk of death from thyroid disease, cardiovascular disease, stroke, and fracture of the femur. Posttreatment hypothyroidism is common. It may occur within a few months or up to several years after RAI therapy or subtotal thyroidectomy. Malignant exophthalmos has a poor prognosis unless treated aggressively.

Subclinical hyperthyroidism refers to a condition in which asymptomatic individuals have a low serum TSH and normal FT_4 and T_3 . Most such patients do well without treatment. In one series, clinical hyperthyroidism developed in only one of seven patients after 2 years. In most patients, the serum TSH may revert to normal within 2 years. Most such patients do not have accelerated bone loss. However, if a baseline bone density shows significant osteopenia, bone densitometry may be performed periodically. In persons over age 60 years, serum TSH is very low (< 0.1 mU/L) in 3% and mildly low (0.1–0.4 mU/L) in 9%. The chance of developing atrial fibrillation is 2.8% yearly in elderly patients with very low TSH and 1.1% yearly in those with mildly low TSH. Asymptomatic persons with

very low TSH are monitored closely but are not treated unless atrial fibrillation or other manifestations of hyperthyroidism develop.

Bahn RS et al. Hyperthyroidism and other causes of thyrotoxicosis: management of guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. *Thyroid*. 2011 Jun;21(6):593–646. [PMID: 21510801]

Bogazzi F et al. Approach to the patient with amiodarone-induced thyrotoxicosis. *J Clin Endocrinol Metab*. 2010 Jun;95(6):2529–35. [PMID: 20525904]

Calvi L et al. Acute thyrotoxicosis secondary to destructive thyroiditis associated with cardiac catheterization contrast dye. *Thyroid*. 2011 Apr;21(4):443–9. [PMID: 21385076]

Ghandour A et al. Hyperthyroidism: a stepwise approach to management. *J Fam Pract*. 2011 Jul;60(7):388–95. [PMID: 21731916]

Kim TD et al. Thyroid dysfunction caused by second-generation tyrosine kinase inhibitors in Philadelphia chromosome-positive chronic myeloid leukemia. *Thyroid*. 2010 Nov;20(11):1209–14. [PMID: 20929406]

Marococchi C et al; European Group on Graves' Orbitopathy. Selenium and the course of mild Graves' orbitopathy. *N Engl J Med*. 2011 May 19;364(20):1920–31. [PMID: 21591944]

Pantalone KM et al. Approach to a low TSH level: patience is a virtue. *Cleve Clin J Med*. 2010 Nov;77(11):803–11. [PMID: 21048053]

Pramyothin P et al. Clinical problem solving. A hidden solution. *N Engl J Med*. 2011 Dec;365(22):2123–7. [PMID: 22129257]

Ross DS. Radioiodine therapy for hyperthyroidism. *N Engl J Med*. 2011 Feb 10;364(6):542–50. [PMID: 21306240]

THYROIDITIS



ESSENTIALS OF DIAGNOSIS

- ▶ **Acute and subacute forms:** thyroid gland swelling, sometimes causing pressure symptoms.
- ▶ **Chronic form:** thyroid gland may or may not be enlarged with rubbery firmness.
- ▶ Thyroid function tests variable.
- ▶ Serum antithyroperoxidase and antithyroglobulin antibody levels usually elevated in Hashimoto thyroiditis.

► General Considerations

Thyroiditis may be classified as follows: (1) chronic lymphocytic thyroiditis due to autoimmunity (also called Hashimoto thyroiditis), (2) subacute thyroiditis, (3) suppurative thyroiditis, and (4) Riedel thyroiditis.

Hashimoto thyroiditis is an autoimmune condition and the most common thyroid disorder in the United States. B-lymphocytes invade the thyroid gland, such that the condition is also known as **chronic lymphocytic thyroiditis**. Detectable levels of antithyroid antibodies are usually present: antithyroperoxidase (antimitochondrial) antibodies or antithyroglobulin antibodies, or both. Elevated serum levels of antithyroid antibodies are found in 3% of men and 13% of women. Women over the age of 60 years have a 25%

incidence of elevated serum levels of antithyroid antibodies. However, only a small subset of individuals with elevated antithyroid antibody levels ever develops thyroid dysfunction. One percent of the population has serum antithyroid antibody titers > 1:6400 and they are at particular risk for thyroid dysfunction. The incidence of Hashimoto thyroiditis varies by kindred, race, and by sex; in persons older than 12 years of age in the United States, elevated levels of antithyroid antibodies are found in 14.3% of whites, 10.9% of Mexican-Americans, and 5.3% of blacks.

Hashimoto thyroiditis tends to be familial and is six times more common in women than in men. Its frequency is increased by dietary iodine supplementation. Certain drugs (amiodarone, interferon- α , interferon- β , interleukin-2, G-CSF) frequently induce thyroid autoantibodies. Childhood or occupational exposure to head-neck external beam radiation increases the lifetime risk of Hashimoto thyroiditis. Subclinical thyroiditis is extremely common, as evidenced in autopsy series that have found focal thyroiditis in about 40% of women and 20% of men.

Hashimoto thyroiditis often progresses to hypothyroidism, which may be linked to thyrotropin receptor-blocking antibodies, detected in 10% of patients with Hashimoto thyroiditis. Hypothyroidism is more likely to develop in smokers than in nonsmokers, possibly due to the thiocyanates in cigarette smoke. High serum levels of thyroid peroxidase antibody also predict progression from subclinical hypothyroidism to symptomatic hypothyroidism. Although the hypothyroidism is usually permanent, up to 11% of patients experience a remission after several years. There are two possible causes for such remissions: (1) the Hashimoto thyroiditis may improve spontaneously; and (2) thyroid-stimulating immunoglobulin is produced in sufficient quantities to overwhelm the destructive effects of concurrent Hashimoto thyroiditis, causing the thyroid to produce more thyroid hormone. Rarely, if the thyroid gland goes on to produce *excessive* thyroid hormone, the result is an autoimmune hyperthyroidism (see Graves disease).

Hashimoto thyroiditis is sometimes associated with other endocrine deficiencies as part of polyglandular autoimmunity (PGA). Adults with type 2 PGA are prone to autoimmune thyroiditis, diabetes mellitus type 1, autoimmune gonadal failure, hypoparathyroidism, and adrenal insufficiency (see Adrenal Insufficiency). Thyroiditis is associated with other autoimmune conditions, such as pernicious anemia, Sjögren syndrome, vitiligo, inflammatory bowel disease, and celiac disease. The incidence of celiac disease in patients with Hashimoto thyroiditis is about 5%. Hashimoto thyroiditis is very rarely associated with other autoimmune conditions such as myocarditis, hypophysitis, alopecia areata, encephalitis, primary pulmonary hypertension, or membranous nephropathy. Women with gonadal dysgenesis (Turner syndrome) have a 15% incidence of significant thyroid dysfunction by age 40 years. Thyroiditis is also commonly seen in patients with hepatitis C.

Painless postpartum thyroiditis refers to autoimmune thyroiditis that occurs soon after delivery in 7.2% of women. There is some evidence that the autoimmunity may be triggered by the accumulation of fetal cells in the maternal thyroid during pregnancy, a condition known as

microchimerism. Women in whom postpartum thyroiditis develops have a 70% chance of recurrence after subsequent pregnancies. It occurs most commonly in women who have high levels of thyroid peroxidase antibody in the first trimester of pregnancy or immediately after delivery. It is also more common in women with other autoimmunity or a family history of Hashimoto thyroiditis.

Painless sporadic thyroiditis is thought to be a subacute form of Hashimoto thyroiditis that is similar to painless postpartum thyroiditis (see above), except that it is not related to pregnancy. It accounts for about 1% of cases of thyrotoxicosis.

Subacute thyroiditis—also called de Quervain thyroiditis, granulomatous thyroiditis, and giant cell thyroiditis—is relatively common. It is believed to be caused by a viral infection and often follows an upper respiratory tract infection. Its incidence peaks in the summer. It accounts for up to 5% of clinical thyroid disease and young and middle-aged women are most commonly affected.

Suppurative thyroiditis refers to a nonviral infection of the thyroid gland. It is usually bacterial. However, mycobacterial, fungal, and parasitic infections can occur, particularly in immunosuppressed individuals. Suppurative thyroiditis is quite rare, since the thyroid is resistant to infection, largely due to its high iodine content. It tends to affect patients with preexistent thyroid disease. Congenital pyriform sinus fistulas are a cause for recurrent suppurative thyroiditis in otherwise normal individuals.

Riedel thyroiditis is also called invasive fibrous thyroiditis, Riedel struma, woody thyroiditis, ligneous thyroiditis, and invasive thyroiditis. It is the rarest form of thyroiditis and is found most frequently in middle-aged or elderly women. It is usually a manifestation of a multifocal systemic fibrosis syndrome.

▶ Clinical Findings

A. Symptoms and Signs

In **Hashimoto thyroiditis**, the thyroid gland is usually diffusely enlarged, firm, and finely nodular. One thyroid lobe may be asymmetrically enlarged, raising concerns about neoplasm. Although patients may complain of neck tightness, pain and tenderness are not usually present. About 10% of cases are atrophic, the gland being fibrotic, particularly in elderly women.

Systemic manifestations are mostly related to ambient levels of thyroid hormone. However, depression and chronic fatigue are more common in such patients, even after correction of hypothyroidism. About one-third of patients have mild dry mouth (xerostomia) or dry eyes (keratoconjunctivitis sicca) of an autoimmune nature related to Sjögren syndrome. It may be associated with myasthenia gravis, which is usually of mild severity, mainly affecting the extraocular muscles and having a relatively low incidence of detectable AChR Ab or thymic disease. Associated celiac disease can produce fatigue or depression, often in the absence of gastrointestinal symptoms.

Postpartum thyroiditis is typically manifested by hyperthyroidism that begins 1–6 months after delivery and persists for only 1–2 months. Then, hypothyroidism tends to develop in affected women beginning 4–8 months after delivery.

Thyrotoxic symptoms in **painless sporadic thyroiditis** are usually mild; a small, nontender goiter may be palpated in about 50% of such patients. High serum thyroid peroxidase antibody concentrations are found in only 50% of such patients. The course is similar to painless postpartum thyroiditis.

Subacute thyroiditis presents with an acute, usually painful enlargement of the thyroid gland, often with dysphagia. The pain may radiate to the ears. Patients usually have a low-grade fever and fatigue. The manifestations may persist for weeks or months and may be associated with malaise. If there is no pain, it is called **silent thyroiditis**. Thyrotoxicosis develops in 50% of affected patients and tends to last for several weeks. Subsequently, hypothyroidism develops that lasts 4–6 months. Normal thyroid function typically returns within 12 months, but persistent hypothyroidism develops in 5% of patients.

Patients with **suppurative thyroiditis** usually are febrile and have severe pain, tenderness, redness, and fluctuation in the region of the thyroid gland. In **Riedel thyroiditis**, thyroid enlargement is often asymmetric; the gland is stony hard and adherent to the neck structures, causing signs of compression and invasion, including dysphagia, dyspnea, pain, and hoarseness. Related conditions include retroperitoneal fibrosis, fibrosing mediastinitis, sclerosing cervicitis, subretinal fibrosis, and biliary tract sclerosis. It may respond to therapy with tamoxifen (see Treatment).

B. Laboratory Findings

In Hashimoto thyroiditis with clinically evident disease, there are usually increased circulating levels of antithyroid peroxidase (90%) or antithyroglobulin (40%) antibodies. Antithyroid antibodies decline during pregnancy and are often undetectable in the third trimester. Once Hashimoto thyroiditis has been diagnosed, monitoring of these antibody levels is not necessary. The serum TSH level is elevated if thyroid hormone is not elaborated in adequate amounts by the thyroid gland.

Patients with Hashimoto thyroiditis have a 15% incidence of having serum antibodies associated with celiac disease (sprue, gluten-sensitive enteropathy). At least 5% of patients with Hashimoto thyroiditis are found to have clinically significant celiac disease. Although most patients with celiac disease have gastrointestinal complaints such as bloating or diarrhea, vague symptoms such as fatigue or ennui may predominate. Serum levels of IgA endomysial antibody or IgA tissue transglutaminase (tTG) antibody may be elevated. However, these antibody levels decline on a low gluten diet. Many patients with mild celiac disease have negative serology and a trial of a gluten-free diet is the most sensitive test.

In subacute thyroiditis, the ESR is markedly elevated while antithyroid antibody titers are low, distinguishing it from autoimmune thyroiditis. In **suppurative thyroiditis**, both the leukocyte count and ESR are usually elevated.

With hyperthyroidism due to Hashimoto thyroiditis or subacute thyroiditis, serum FT₄ levels tend to be proportionally higher than T₃ levels, since the hyperthyroidism is due to the passive release of stored thyroid hormone, which is predominantly T₄; this is in contrast to Graves disease

and toxic nodular goiter, where T₃ is relatively more elevated. Because T₄ is less active than T₃, the hyperthyroidism seen in thyroiditis is usually less severe. Serum levels of TSH are suppressed in hyperthyroidism due to thyroiditis.

C. Imaging

Ultrasound in cases of Hashimoto thyroiditis typically shows a gland with characteristic diffuse heterogeneous density and hypoechoogenicity. Ultrasonography of the thyroid helps distinguish thyroiditis from multinodular goiter or thyroid nodules that are suspicious for malignancy. It is also helpful in guiding FNA biopsy of small suspicious thyroid nodules. Color-flow Doppler ultrasonography can help distinguish thyroiditis from Graves disease, since patients with Graves disease have a hypervascular thyroid gland, whereas in thyroiditis there is normal or reduced vascularity.

RAI uptake and scan may be helpful in determining the cause of hyperthyroidism, distinguishing thyroiditis from Graves disease, since patients with subacute thyroiditis exhibit a very low RAI uptake. In patients with chronic Hashimoto thyroiditis (euthyroid or hypothyroid), RAI uptake may be normal or high with uneven uptake on the scan; scanning is not useful in making the diagnosis.

[¹⁸F]Fluorodeoxyglucose positron emission tomography (¹⁸FDG-PET) scanning frequently shows diffuse thyroid uptake of isotope in cases of thyroiditis. About 3% of all ¹⁸FDG-PET scans shows such uptake. However, discrete thyroid nodules can also be discovered on ¹⁸FDG-PET scanning and are known as “thyroid PET incidentalomas,” of which 50% are malignant.

D. Fine-Needle Aspiration Biopsy

Patients with **Hashimoto thyroiditis** who have a thyroid nodule should have an ultrasound-guided FNA biopsy, since the risk of papillary thyroid cancer is about 8% in such nodules. When **suppurative thyroiditis** is suspected, an FNA biopsy with Gram stain and culture is required. FNA biopsy is usually not required for subacute thyroiditis but shows characteristic giant multinucleated cells.

► Complications

Hashimoto thyroiditis may lead to hypothyroidism or transient thyrotoxicosis. Perimenopausal women with high serum levels of antithyropoxidase antibodies have a higher relative risk of depression independently of ambient thyroid hormone levels.

Pregnant women with Hashimoto thyroiditis have an increased risk of spontaneous miscarriage in the first trimester of pregnancy. Hyperthyroidism may develop in patients with Hashimoto thyroiditis, either due to the emergence of Graves disease or due to the release of stored thyroid hormone, which is caused by inflammation. The latter condition has variably been termed “hashitoxicosis” or “painless sporadic thyroiditis;” it is known as postpartum painless thyroiditis when it occurs in women after delivery.

Patients with Hashimoto thyroiditis have an increased risk of other autoimmune conditions, such as Addison disease, hypoparathyroidism, diabetes, pernicious anemia, biliary cirrhosis, vitiligo, and celiac disease.

In the suppurative forms of thyroiditis, any of the complications of infection may occur; the subacute and chronic forms of the disease are complicated by the effects of pressure on the neck structures: dyspnea and, in Riedel struma, vocal cord palsy. Papillary thyroid carcinoma or thyroid lymphoma may rarely be associated with chronic thyroiditis and must be considered in the diagnosis of uneven painless enlargements that continue in spite of treatment; such patients require FNA biopsy.

► Differential Diagnosis

Thyroiditis must be considered in the differential diagnosis of all types of goiters, especially if enlargement is rapid. The very low RAI uptake in subacute thyroiditis with elevated T_4 and T_3 is helpful. Thyroid autoantibody tests have been of help in the diagnosis of Hashimoto thyroiditis, but the tests are not specific and may also be positive in patients with multinodular goiters, malignancy (eg, thyroid carcinoma, lymphoma), and concurrent Graves disease. The subacute and suppurative forms of thyroiditis may resemble any infectious process in or near the neck structures. Chronic thyroiditis, especially if the enlargement is uneven and if there is pressure on surrounding structures, may resemble carcinoma, and both disorders may be present in the same gland.

► Treatment

A. Hashimoto Thyroiditis

If hypothyroidism is present, levothyroxine should be given in the usual replacement doses (0.05–0.2 mg orally daily). In patients with a large goiter and normal or elevated serum TSH, an attempt is made to shrink the goiter by administering levothyroxine in doses sufficient to drive the serum TSH below the reference range while maintaining clinical euthyroidism. Suppressing doses of T_4 tend to shrink the goiter an average of 30% over 6 months. If the goiter does not regress, lower replacement doses of levothyroxine may be given. If the thyroid gland is only minimally enlarged and the patient is euthyroid, regular observation is in order, since hypothyroidism may develop subsequently—often years later. (See Hypothyroidism section.)

In one study involving 21 patients with Hashimoto thyroiditis and subclinical hypothyroidism, simvastatin (20 mg orally daily) improved thyroid function over 8 weeks, possibly by stimulating apoptosis of certain types of lymphocytes. In another study, selenium (200 mcg daily orally for 3 months) reduced the serum levels of anti-thyroperoxidase antibodies by 49% versus a 10% reduction in the placebo arm. The long-term effectiveness of simvastatin or selenium therapy on the course of Hashimoto thyroiditis is unknown.

B. Subacute Thyroiditis

All treatment is empiric and must be continued for several weeks. Recurrence is common. The drug of choice is aspirin, which relieves pain and inflammation. Thyrotoxic symptoms are treated with propranolol, 10–40 mg every 6 hours. Iodinated contrast agents cause a prompt fall in

serum T_3 levels and a dramatic improvement in thyrotoxic symptoms. Sodium ipodate (Oragrafin, Bilivist) or iopanoic acid (Telepaque) is given orally in doses of 500 mg orally daily until serum FT_4 levels return to normal. Transient hypothyroidism is treated with T_4 (0.05–0.1 mg orally daily) if symptomatic.

C. Suppurative Thyroiditis

Treatment is with antibiotics and with surgical drainage when fluctuation is marked.

D. Riedel Struma

The treatment of choice is tamoxifen, 20 mg orally twice daily, which must be continued for years. Tamoxifen can induce partial to complete remissions in most patients within 3–6 months. Its mode of action appears to be unrelated to its antiestrogen activity. Short-term corticosteroid treatment may be added for partial alleviation of pain and compression symptoms. Surgical decompression usually fails to permanently alleviate compression symptoms; such surgery is difficult due to dense fibrous adhesions, making surgical complications more likely.

► Prognosis

Hashimoto thyroiditis is occasionally associated with other autoimmune disorders (diabetes mellitus, Addison disease, pernicious anemia, etc). In general, however, patients with Hashimoto thyroiditis have an excellent prognosis, since the condition either remains stable for years or progresses slowly to hypothyroidism, which is easily treated. Although 80% of women with postpartum thyroiditis subsequently recover normal thyroid function, permanent hypothyroidism eventually develops in about 50% within 7 years. Permanent hypothyroidism is more common in women who are multiparous or who have had a spontaneous abortion. In subacute thyroiditis, spontaneous remissions and exacerbations are common; the disease process may smolder for months. Papillary thyroid carcinoma carries a relatively good prognosis when it occurs in patients with Hashimoto thyroiditis.

- Boelaert K et al. Prevalence and relative risk of other autoimmune diseases in subjects with autoimmune thyroid disease. *Am J Med.* 2010 Feb;123(2):183.e1–9. [PMID: 20103030]
- Desailloud R et al. Viruses and thyroiditis: an update. *Virology.* 2009 Jan 12;6:5. [PMID: 19138419]
- Duntas LH. Environmental factors and autoimmune thyroiditis. *Nat Clin Pract Endocrinol Metab.* 2008 Aug;4(8):454–60. [PMID: 18607401]
- Eschler DC et al. Cutting edge: the etiology of autoimmune thyroid disease. *Clin Rev Allergy Immunol.* 2011 Oct;41(2):190–7. [PMID: 21234711]
- Li Y et al. Hashimoto's thyroiditis: old concepts and new insights. *Curr Opin Rheumatol.* 2011 Jan;23(1):102–7. [PMID: 21124092]
- Tomer Y. Genetic susceptibility to autoimmune thyroid disease: past, present, and future. *Thyroid.* 2010 Jul;20(7):715–25. [PMID: 20604685]
- Tran HA et al. The natural history of interferon-alpha induced thyroiditis in chronic hepatitis C patients: a long term study. *Thyroid Res.* 2011 Jan 8;4(1):2. [PMID: 21214950]

THYROID NODULES & MULTINODULAR GOITER



ESSENTIALS OF DIAGNOSIS

- ▶ Single or multiple thyroid nodules are commonly found with careful thyroid examinations.
- ▶ Thyroid function tests mandatory.
- ▶ Thyroid biopsy for single or dominant nodules or for a history of prior head-neck or chest-shoulder radiation.
- ▶ Ultrasound examination useful for biopsy and follow-up.
- ▶ Clinical follow-up required.

▶ General Considerations

Thyroid nodules are extremely common. In Germany, neck ultrasound screening of adults found a 20% incidence of thyroid nodules > 1 cm in diameter. Palpable nodules are found in 5% of women and 1% of men in iodine-sufficient areas of the world. Palpable thyroid nodules are even more common in iodine-deficient geographic areas (see Iodine Deficiency Disorder & Endemic Goiter). Each year in the United States, about 275,000 thyroid nodules are detected by palpation, of which 10% are malignant. Palpable thyroid nodules are increasingly prevalent with age. On high-resolution thyroid ultrasound, about 50% of palpable “solitary nodules” are found to be just one nodule in a multinodular goiter.

In recent years, an increased general use of scanning (CT, MRI, ultrasound, PET) has led to an increased rate of incidentally detecting nonpalpable thyroid nodules. In fact, thyroid ultrasound detects thyroid nodules in about 20% of randomly screened healthy adults.

Although 90% of thyroid nodules are benign, the presence of a thyroid nodule ≥ 1 cm diameter warrants follow-up and further testing for function and malignancy. An occasional nodule < 1 cm diameter requires follow-up if it has high-risk characteristics on ultrasound or if the patient has had prior head-neck radiation therapy. Thyroid nodules that are incidentally discovered on ^{18}F -FDG-PET scanning have a 33% risk for being malignant and definitely require biopsy.

Most patients with a thyroid nodule are euthyroid, but there is a high incidence of hypothyroidism or hyperthyroidism. Goiter may be caused by numerous conditions, including multinodular goiter, iodine deficiency, pregnancy (in areas of iodine deficiency), Graves disease, Hashimoto thyroiditis, subacute thyroiditis, or infections. About 90% of thyroid nodules are benign adenoma, colloid nodule, or cyst but may sometimes be a primary thyroid malignancy or (less frequently) a metastatic neoplasm. Patients with multiple thyroid nodules have the same overall risk of thyroid cancer as patients with solitary nodules. The risk of a thyroid nodule being malignant is higher among patients with a history of head-neck radiation, total body radiation for bone marrow transplantation, exposure

to radioactive fallout as a child or teen, a family history of thyroid cancer or a thyroid cancer syndrome (eg, Cowden syndrome, multiple endocrine neoplasia type 2, familial polyposis, Carney syndrome), or a personal history of another malignancy. The risk of malignancy is also higher if there is hoarseness or vocal fold paralysis, and if the thyroid nodule is large, adherent to the trachea or strap muscles, or associated with lymphadenopathy. The presence of Hashimoto thyroiditis does not reduce the risk of malignancy; a nodule of ≥ 1 cm in a gland with thyroiditis carries an 8% chance of malignancy.

▶ Clinical Findings

Table 26–6 illustrates the approach to the evaluation of thyroid nodules based on the index of suspicion for malignancy.

A. Symptoms and Signs

Most small thyroid nodules cause no symptoms. They may sometimes be detected only by having the patient swallow during careful inspection and palpation of the thyroid.

A thyroid nodule or multinodular goiter can grow to become visible and of concern to the patient. Particularly large nodular goiters can become a cosmetic embarrassment. Nodules can grow large enough to cause discomfort, hoarseness, or dysphagia. Retrosternal large multinodular goiters can cause dyspnea due to tracheal compression. Large substernal goiters may cause superior vena cava syndrome, manifested by facial erythema and jugular vein distention that progress to cyanosis and facial edema when both arms are kept raised over the head (Pemberton sign).

Depending on their cause, goiters and thyroid nodules may be associated with hypothyroidism (Hashimoto thyroiditis, endemic goiter) or hyperthyroidism (Graves disease, toxic nodular goiter, subacute thyroiditis, and thyroid cancer with metastases).

B. Laboratory Findings

A serum TSH level (sensitive assay) should be obtained for all patients with a thyroid nodule. Patients with a subnormal serum TSH must have further assessment for hyperthyroidism and have a radionuclide thyroid scan (^{123}I or $^{99\text{m}}\text{Tc}$ pertechnetate) to determine whether the nodule is hyperfunctioning; hyperfunctioning nodules are rarely malignant. Tests for antithyroperoxidase antibodies and antithyroglobulin antibodies may also be helpful. Very high antibody levels are found in Hashimoto thyroiditis. However, thyroiditis frequently coexists with malignancy, so suspicious nodules should always be biopsied. Serum calcitonin is obtained if a medullary thyroid carcinoma is suspected in a family member with a history of familial medullary thyroid carcinoma or MEN type 2.

C. Imaging

Neck ultrasonography should be performed to measure the size of a nodule and to determine whether a palpable nodule is part of a multinodular goiter. The following ultrasound characteristics of thyroid nodules increase the

Table 26-6. Clinical evaluation of thyroid nodules.¹

Clinical Evidence	Low Index of Suspicion	High Index of Suspicion
History	Family history of goiter; residence in area of endemic goiter	Previous therapeutic radiation of head, neck, or chest; hoarseness
Physical characteristics	Older women; soft nodule; multinodular goiter	Young adults, men; solitary, firm nodule; vocal cord paralysis; enlarged lymph nodes; distant metastatic lesions
Serum factors	High titer of antithyroid antibody; hypothyroidism; hyperthyroidism	Elevated serum calcitonin
Fine-needle aspiration biopsy	Colloid nodule or adenoma	Papillary carcinoma, follicular lesion, medullary or anaplastic carcinoma
Scanning techniques		
Uptake of ¹²³ I	Hot nodule	Cold nodule
Ultrasonogram	Cystic lesion	Solid lesion
Roentgenogram	Shell-like calcification	Punctate calcification
Response to thyroxine therapy	Regression after 0.05-0.1 mg/d for 6 months or more	Increase in size

¹Clinically suspicious nodules should be evaluated with fine-needle aspiration biopsy.

likelihood of malignancy: irregular or indistinct margins, heterogenous nodule echogenicity, intranodular vascular images, microcalcifications, complex cyst, or diameter over 1 cm. Ultrasound is also useful for long-term surveillance of thyroid nodules and multinodular goiter. Ultrasonography is generally preferred over CT and MRI because of its accuracy, ease of use, and lower cost.

RAI (¹²³I or ¹³¹I) scans have limited usefulness in the evaluation of thyroid nodules. Hypofunctioning (cold) nodules have a somewhat increased risk of being malignant but most are benign. Hyperfunctioning (hot) nodules are ordinarily benign but may sometimes be malignant. RAI uptake and scanning is helpful if a patient is found to have evidence of hyperthyroidism. (See Hyperthyroidism)

CT scanning is helpful for larger thyroid nodules and multinodular goiter; it can determine the degree of tracheal compression and the degree of extension into the mediastinum.

D. Incidentally Discovered Thyroid Nodules

Thyroid nodules are frequently discovered as an incidental finding, with an incidence that depends on the imaging modality: MRI, 50%; CT, 13%; and ¹⁸FDG-PET, 2%. When such scanning detects a thyroid nodule, an ultrasound is performed to better determine the nodule's risk for malignancy and the need for FNA biopsy, and to establish a baseline for ultrasound follow-up. The malignancy risk is about 17% for nodules discovered incidentally on CT or MRI, and 25–50% for nodules discovered incidentally by ¹⁸FDG-PET. For incidentally discovered thyroid nodules of borderline concern, follow-up thyroid ultrasound in 3–6 months may be helpful; growing lesions may be biopsied or resected.

E. Fine-Needle Aspiration Biopsy

Fine-needle aspiration (FNA) biopsy is the best method to assess a thyroid nodule for malignancy. FNA biopsy can be done while patients continue taking anticoagulants or aspirin. For multinodular goiters, the four largest nodules (≥ 1 cm diameter) should be biopsied to minimize the risk of missing a malignancy. For solitary thyroid nodules, FNA biopsy is indicated for the following: (1) nodules > 5 mm diameter with a suspicious appearance on ultrasound; (2) nodules associated with abnormal cervical lymph nodes; (3) nodules ≥ 1 cm diameter that are solid or have microcalcifications; (4) mixed cystic-solid nodules ≥ 1.5 cm diameter with any suspicious features on ultrasound or ≥ 2 cm diameter with benign features on ultrasound; (5) spongiform nodules ≥ 2 cm diameter. Pure cystic nodules are benign and do not require FNA biopsy. Using ultrasound guidance for FNA biopsy improves the diagnostic accuracy for both palpable and nonpalpable thyroid nodules. The chance of an optimal tissue sampling is also improved by having an experienced clinician perform the FNA biopsy and by having the aspirate interpreted by a skilled cytopathologist.

In one review of thyroid FNA biopsies, about 70% were benign, 5% were malignant, 10% were “suspicious,” and 15% were “nondiagnostic.” Nondiagnostic, bloody, or hypocellular FNA biopsies should be repeated under ultrasound guidance; nodules that continue to have nondiagnostic cytology should be monitored closely; those that are solid or that grow should be resected.

When FNA cytology is “suspicious” for papillary thyroid carcinoma or Hürthle cell neoplasm, the risk of malignancy is 57%. When FNA cytology yields a “suspicious” follicular lesion, the overall risk of the lesion being malignant

is about 20–25%. The risk that a follicular lesion is malignant increases for patients who are much younger or older than age 50. Most patients with suspicious FNA cytology are advised to have surgery.

Cystic nodules yielding serous fluid are usually benign, but the aspirate should be submitted for cytologic testing. Cystic nodules yielding bloody fluid have a higher chance of being malignant.

False-positive thyroid FNA biopsy results occur at a rate of about 4%. False-negative thyroid FNA biopsy results also occur at an overall rate of about 4%, less commonly when performed under ultrasound guidance and interpreted by cytopathologists. False-negative results delay surgical excision and lead to an increased risk of vascular and capsular invasion by the malignancy. Some false-negative FNA biopsy results may not have actually been inaccurate, since truly benign thyroid nodules can later become malignant. Patients who have a negative thyroid FNA should have observational follow-up, ideally with both palpation and ultrasound; nodules that continue to grow should be rebiopsied or excised.

▶ Treatment

All thyroid nodules, including those that are benign, need to be monitored by regular periodic palpation and ultrasound and rebiopsied if growth occurs. A toxic multinodular goiter and hyperthyroidism, associated with the ingestion or intravenous administration of large amounts of iodine, may develop in patients with multinodular goiters. It is therefore prudent to minimize excessive dietary iodine intake and intravenous iodinated contrast. Patients found to have hyperthyroidism may have a RAI uptake and scan for additional evaluation, especially if ^{131}I is a therapeutic consideration. Patients with toxic multinodular goiters may also be treated with methimazole, propranolol, or surgery (see Hyperthyroidism section).

A. Levothyroxine Suppression Therapy

Patients with elevated levels of serum TSH are treated with levothyroxine replacement. Otherwise, for small benign thyroid nodules, levothyroxine suppression therapy is not recommended. For larger nodules (> 2 cm), if TSH levels are elevated or normal, TSH suppression with levothyroxine (starting doses of 50 mcg orally daily) can be considered. Thyroxine suppression therapy is most successful in iodine-deficient areas of the world and less successful in iodine-sufficient regions. Long-term levothyroxine suppression of TSH tends to keep nodules from enlarging, but only 20% shrink more than 50%. In one 5-year study, thyroid nodule size increased in 29% of patients treated with levothyroxine, compared to growth in 56% of nodules in patients not receiving levothyroxine. Levothyroxine suppression also reduces the emergency of new nodules: 8% with levothyroxine and 29% without levothyroxine. Levothyroxine suppression therapy is not usually given to patients with cardiac disease, since it increases the risk for angina and atrial fibrillation. Levothyroxine suppression causes a small loss of bone density, particularly in postmenopausal women if the serum TSH is suppressed to

< 0.05 mU/L. Such patients are advised to have bone density testing every 3–5 years. Levothyroxine should not be administered if the baseline TSH is low, since that is an indication of autonomous thyroid secretion, such that levothyroxine therapy will be ineffective and liable to cause clinical thyrotoxicosis.

Levothyroxine suppression needs to be carefully monitored, since it carries a 17% risk of inducing symptoms of hyperthyroidism. This can occur due to excessive levothyroxine dosing, the emergence of an autonomous or toxic nodule or Graves disease, or a reduction in thyroid binding globulin seen in early menopause or with discontinuing oral estrogen therapy. Therefore, coronary insufficiency and cardiac arrhythmias are relative contraindications to levothyroxine suppression. All patients receiving levothyroxine suppression therapy should have serum TSH levels monitored regularly, with the dose of levothyroxine adjusted to keep the serum TSH mildly suppressed between 0.2 mU/L and 0.8 mU/L. Thyroid nodules require careful clinical evaluation and thyroid palpation or ultrasound examinations about every 6 months initially. After several years of stability, yearly examinations are sufficient.

B. Potassium Iodide

Additional suppression of thyroid nodules may be obtained by adding oral potassium iodide, 150 mcg daily, to levothyroxine suppression therapy (see above) for patients with thyroid nodules ≥ 1 cm in diameter. In a German study, the addition of potassium iodide to levothyroxine further decreased thyroid nodule size over the course of 1 year. However, the study excluded children; pregnant women; non-whites; and patients with autoimmune thyroid disease, autonomous nodules, consumption of other iodine-containing medications, dermatitis herpetiformis, or iodine allergy. The long-term risk of administering potassium iodide to iodine-sufficient patients is unknown.

C. Surgery

Total thyroidectomy is required for thyroid nodules that are malignant on FNA biopsy (see Thyroid Cancer section). More limited thyroid surgery is indicated for benign nodules with indeterminate or suspicious cytologic test results, compression symptoms, discomfort, or cosmetic embarrassment. Surgery may also be used to remove hyperfunctioning “hot” thyroid adenomas or toxic multinodular goiter causing hyperthyroidism (see Hyperthyroidism section).

D. Percutaneous Ethanol Injection

Thyroid cysts can be aspirated, but cystic fluid recurs in 75% of patients. Percutaneous ethanol injection has been used to shrink pure cysts; it must often be repeated, but the success rate is 80%. Percutaneous ethanol injection can also be used to shrink benign (biopsy proven) thyroid nodules. The complication rate is about 9%, but serious or permanent complications are rare.

E. Radioiodine (^{131}I) Therapy

Radioactive ^{131}I is a treatment option for hyperthyroid patients with toxic thyroid adenomas, multinodular goiter,

or Graves disease (see Hyperthyroidism section). It may also be used to shrink benign nontoxic thyroid nodules. Thyroid nodules shrink an average of 40% by 1 year and 59% by 2 years after ^{131}I therapy. Nodules that shrink after ^{131}I therapy generally remain palpable and become firmer; they may develop unusual cytologic characteristics on FNA biopsy. ^{131}I therapy may be used to shrink large multinodular goiter but may rarely induce Graves disease. Hypothyroidism is a risk and may occur years after ^{131}I therapy, so it is advisable to assess thyroid function every 3 months for the first year, every 6 months thereafter, and immediately for symptoms of hypothyroidism or hyperthyroidism.

► Prognosis

The great majority of thyroid nodules are benign. Benign thyroid nodules may involute but usually persist or grow slowly. About 90% of thyroid nodules will increase their volume by $\geq 15\%$ over 5 years; cystic nodules are less likely to grow. Cytologically benign nodules that grow are unlikely to be malignant; in one series, only 1 of 78 rebiopsied nodules was found to be malignant. The prognosis for patients with thyroid nodules that prove to be malignant is determined by the histologic type and other factors (see below). Multinodular goiters tend to persist or grow slowly, even in iodine-deficient areas where iodine repletion usually does not shrink established goiters. Patients with very small, incidentally discovered, nonpalpable thyroid nodules do require follow-up with thyroid ultrasound every 1–2 years but are at low risk for malignancy. Nodules that are malignant have a minor effect on morbidity and mortality.

- Bahn RS et al. Approach to the patient with nontoxic multinodular goiter. *J Clin Endocrinol Metab.* 2011 May;96(5):1201–12. [PMID: 21543434]
- Bastin S et al. Role of ultrasound in the assessment of nodular thyroid disease. *J Med Imaging Radiat Oncol.* 2009 Apr;53(2):177–87. [PMID: 19527364]
- Grussendorf M et al. Reduction of thyroid nodule volume by levothyroxine and iodine alone and in combination: a randomized, placebo-controlled trial. *J Clin Endocrinol Metab.* 2011 Sept;96(9):2786–95. [PMID: 21715542]
- Kim DW et al. Ultrasound-guided fine-needle aspiration biopsy of thyroid nodules: comparison in efficacy according to nodule size. *Thyroid.* 2009 Jan;19(1):27–31. [PMID: 19021460]
- Mihai R et al. One in four patients with follicular thyroid cytology (THY3) has a thyroid carcinoma. *Thyroid.* 2009 Jan;19(1):33–7. [PMID: 18976164]

THYROID CANCER

ESSENTIALS OF DIAGNOSIS

- Painless swelling in region of thyroid.
- Thyroid function tests usually normal.
- Past history of irradiation to head and neck region may be present.
- Positive thyroid needle aspiration.

► General Considerations

The incidence of papillary and follicular (differentiated) thyroid carcinomas increases with age. The overall female:male ratio is 3:1. The yearly incidence of thyroid cancer has been increasing in the United States, with the number of cases diagnosed annually reaching 37,200, probably as a result of the wider use of CT, MRI, PET, and ultrasound that incidentally find small thyroid malignancies. Thyroid cancer mortality has been stable, accounting for about 1500 deaths in the United States annually. Thyroid microcarcinoma (≤ 10 mm diameter) is found with the surprising frequency of 35%. Clearly, most thyroid cancers remain microscopic and indolent. However, larger thyroid cancers (palpable or ≥ 1 cm in diameter) are more malignant and require treatment.

Papillary thyroid carcinoma is the most common thyroid malignancy (Table 26–7).

Pure papillary and mixed papillary-follicular carcinoma represent about 80% of all thyroid cancers. It usually presents as a single thyroid nodule, but it can arise out of a multinodular goiter. Papillary thyroid carcinoma is commonly multifocal within the gland, with other foci usually arising de novo rather than representing intraglandular metastases. About 10% of cases present with palpable cervical lymph node metastases from a small thyroid cancer. Papillary thyroid carcinomas tend to grow slowly and often remain confined to the thyroid and regional lymph nodes for years. However, they may become more aggressive, especially in patients over age 45 years, and most particularly in the elderly. The cancer may invade the trachea and local muscles and may spread to the lungs.

Papillary thyroid carcinoma is caused by genetic mutations or translocations. Activating mutations of the *ras* oncogene can cause benign thyroid adenomas or nodular goiter. Additional activating mutations in *BRAF* or *TRK* genes can lead to papillary carcinoma. About 45% of papillary thyroid carcinomas are caused by over expression of the *ret* oncogene by the translocation of certain gene promoters to it, producing *retPTC-1*, *retPTC-2*, or *retPTC-3*. Radiation treatments to the head and neck region tend to cause *retPTC-1*. Nuclear fallout exposure tends to cause *retPTC-3*, resulting in more aggressive papillary thyroid carcinomas. Additional loss of the *p53* tumor suppressor gene can cause progression of papillary thyroid carcinoma to anaplastic thyroid carcinoma.

Exposure to head and neck radiation therapy poses a particular threat to children who then have an increased lifetime risk of developing thyroid pathology, including papillary thyroid carcinoma; thyroid malignancy may emerge between 10 and 40 years after exposure, with a peak occurrence 20–25 years later. After an explosion at the Chernobyl Nuclear Plant in the Ukraine in 1986, the risk of developing papillary thyroid carcinoma was highest among children who were under age 5 at the time of exposure to radiation; emergence of more aggressive papillary thyroid carcinoma occurred within 6–7 years after exposure.

Papillary thyroid carcinoma can occur in familial syndromes as an autosomal dominant trait, caused by loss of various tumor suppressor genes. Such syndromes (with associated features) include familial papillary carcinoma

Table 26-7. Some characteristics of thyroid cancer.

	Papillary	Follicular	Medullary	Undifferentiated
Incidence	Most common	Common	Uncommon	Uncommon
Average age	42	50	50	57
Females	70%	72%	56%	56%
Invasion				
Juxtanodal	+++++	+	+++++	+++
Blood vessels	+	+++	+++	+++++
Distant sites	+	+++	++	+++++
¹²³ I uptake	+	++++	0	0
Mortality	+	++ to +++	+ to ++++	+++++++

(with papillary renal carcinoma); familial nonmedullary thyroid carcinoma; familial polyposis (with large intestine polyps and gastrointestinal tumors); Gardner syndrome (with small and large intestine polyps, fibromas, lipomas, osteomas); and Turcot syndrome (with large intestine polyps and brain tumors). Older patients with multinodular goiter may rarely develop a papillary thyroid carcinoma. Papillary carcinoma can sometimes undergo a late anaplastic transformation into an aggressive carcinoma.

Generally speaking, papillary carcinoma is the least aggressive thyroid malignancy. However, the tumor spreads via lymphatics within the thyroid, appearing to be multifocal in 60% of patients and involving both lobes in 30% of patients. About 80% of patients have microscopic metastases to cervical lymph nodes. Unlike other forms of cancer, patients with papillary thyroid carcinoma who have palpable lymph node metastases do not have a particularly increased mortality rate; however, their risk of local recurrence is increased.

Occult metastases to the lung occur in 10–15% of papillary thyroid cancer. About 70% of small lung metastases resolve following ¹³¹I therapy; however, larger pulmonary metastases have only a 10% remission rate.

Microscopic “micropapillary” carcinoma (≤ 1 mm and invisible even on thyroid ultrasound) is a variant of normal, being found in 24% of thyroidectomies performed for benign thyroid disease when 2-mm sections were carefully examined. It thus appears that the overwhelming majority of these microscopic foci never become clinically significant. The surgical pathology report of such a tiny papillary carcinoma that is otherwise benign does not justify aggressive follow-up or treatment because a cancer diagnosis is unwarranted and harmful. All that may be required is yearly follow-up with palpation of the neck and mild TSH suppression by thyroxine.

Follicular thyroid carcinoma and its variants (eg, Hürthle cell carcinoma) account for about 14% of thyroid malignancies; follicular thyroid carcinoma is generally more aggressive than papillary carcinoma. Rarely, some follicular carcinomas secrete enough T_4 to cause thyrotoxicosis if the tumor load becomes significant. Metastases commonly

are found in neck nodes, bones, and lungs. Most follicular thyroid carcinomas avidly absorb iodine, making possible diagnostic scanning and treatment with ¹³¹I after total thyroidectomy. The follicular histopathologic features that are associated with a high risk of metastasis and recurrence are poorly differentiated and Hürthle cell (oncocyctic) variants. The latter variants do not take up RAI.

Follicular carcinoma results from certain gene mutations or translocations. Aberrant DNA methylation, activation of the *ras* oncogene, and mutations of the *MEN1* gene can result in benign follicular adenomas. Loss of function of *PPAR γ* or the *3P* tumor suppressor gene can lead to follicular carcinoma, and additional loss of the *p53* tumor suppressor gene can produce anaplastic carcinoma.

Follicular thyroid carcinoma and adenomas develop in patients with Cowden disease, a rare autosomal dominant familial syndrome caused by loss of a tumor suppressor gene; such patients tend to have macrocephaly, multiple hamartomas, early-onset breast cancer, intestinal polyps, facial papules, and other skin and mucosal lesions.

Medullary thyroid carcinoma represents about 3% of thyroid cancers. About one-third of cases are sporadic, one-third are familial, and one-third are associated with MEN type 2. Medullary thyroid carcinoma is often caused by an activating mutation of the *ret* oncogene on chromosome 10. Mutation analysis of the *ret* oncogene exons 10, 11, 13, and 14 detects 95% of the mutations causing MEN 2A and 90% of the mutations causing familial medullary thyroid carcinoma. Patients with MEN 2B have activating mutations in exon 16 of the *ret* oncogene. These germline mutations can be detected by DNA analysis of peripheral WBCs. Therefore, discovery of a medullary thyroid carcinoma makes genetic analysis mandatory. If a gene defect is discovered, related family members must have genetic screening for that specific gene defect. When a family member with MEN 2A or familial medullary thyroid carcinoma does not have an identifiable *ret* oncogene mutation, gene carriers may still be identified using family linkage analysis. Even when no gene defect is detectable, family members should have thyroid surveillance every 6 months. Somatic mutations of the *ret* oncogene can be identified in

the tumors of 30% of patients with sporadic (nonfamilial) medullary thyroid carcinoma. (See Multiple Endocrine Neoplasia.)

Medullary thyroid carcinoma arises from parafollicular thyroid cells that can secrete calcitonin, prostaglandins, serotonin, ACTH, corticotropin-releasing hormone (CRH), and other peptides. These peptides can cause symptoms and can be used as tumor markers. Early local metastases are usually present, usually to adjacent muscle and trachea as well as to local and mediastinal lymph nodes. Eventually, late metastases may appear in the bones, lungs, adrenals, or liver. Medullary thyroid carcinoma does not concentrate iodine.

Anaplastic thyroid carcinoma represents about 2% of thyroid cancers. It usually presents in an older patient as a rapidly enlarging mass in a multinodular goiter. It is the most aggressive thyroid carcinoma and metastasizes early to surrounding nodes and distant sites. Local pressure symptoms include dysphagia or vocal cord paralysis. This tumor does not concentrate iodine.

Anaplastic thyroid carcinoma is caused by certain gene mutations, including inactivating mutations of the *p53* tumor suppressor gene, as described above for papillary and follicular thyroid carcinomas.

Other thyroid malignancies together represent about 3% of thyroid cancers. **Lymphoma** of the thyroid is more common in older women. Thyroid lymphomas are most commonly B cell lymphomas (50%) or mucosa-associated lymphoid tissue (MALT; 23%); other types include follicular, small lymphocytic, and Burkitt lymphoma and Hodgkin disease. Thyroidectomy is rarely required. **Other cancers** may sometimes metastasize to the thyroid, particularly bronchogenic, breast, and renal carcinomas and malignant melanoma.

► Clinical Findings

A. Symptoms and Signs

Thyroid carcinoma usually presents as a palpable, firm, nontender nodule in the thyroid. Most thyroid carcinomas are asymptomatic, but large thyroid cancers can cause neck discomfort, dysphagia, or hoarseness (due to pressure on the recurrent laryngeal nerve). About 3% of thyroid malignancies present with a metastasis, usually to local lymph nodes but sometimes to distant sites such as bone or lung. Palpable lymph node involvement is present in 15% of adults and 60% of youths. Metastatic functioning differentiated thyroid carcinoma can sometimes secrete enough thyroid hormone to produce thyrotoxicosis. **Anaplastic thyroid carcinoma** is more apt to be advanced at the time of diagnosis, presenting with dysphagia, hoarseness, dyspnea, and metastases to the lungs. Occasionally, such carcinomas may be discovered while they are still relatively small and localized.

Medullary thyroid carcinoma frequently causes flushing and persistent diarrhea (30%), which may be the initial clinical feature. Patients with metastases often experience fatigue as well as other symptoms. Cushing syndrome develops in about 5% of patients from secretion of ACTH or CRH. Signs of pressure or invasion of surrounding tissues

are present in anaplastic or large tumors; recurrent laryngeal nerve palsy can occur.

Lymphoma usually presents as a rapidly enlarging, painful mass arising out of a multinodular or diffuse goiter affected by autoimmune thyroiditis, with which it may be confused microscopically. About 20% of cases have concomitant hypothyroidism.

B. Laboratory Findings

(FNA biopsy is discussed above in the section on Thyroid Nodules.) Thyroid function tests are generally normal unless there is concomitant thyroiditis. Follicular carcinoma may secrete enough T_4 to suppress TSH and cause clinical hyperthyroidism.

Serum thyroglobulin is high in most metastatic papillary and follicular tumors, making this a useful marker for recurrent or metastatic disease. Caution must be exercised for the following reasons: (1) Circulating antithyroglobulin antibodies can cause erroneous thyroglobulin determinations. (2) Thyroglobulin levels may be misleadingly elevated in thyroiditis, which often coexists with carcinoma. (3) Certain thyroglobulin assays falsely report the continued presence of thyroglobulin after total thyroidectomy and tumor resection, causing undue concern about possible metastases. Therefore, unexpected thyroglobulin levels should prompt a repeat assay in another reference laboratory.

Serum calcitonin levels are usually elevated in medullary thyroid carcinoma, making this a marker for metastatic disease. However, serum calcitonin may be elevated in many other conditions, such as thyroiditis; pregnancy; azotemia; hypercalcemia; and other malignancies, including pheochromocytomas, carcinoid tumors, and carcinomas of the lung, pancreas, breast, and colon.

In patients with **medullary thyroid carcinoma**, serum calcitonin and carcinoembryonic antigen (CEA) determinations should be obtained before surgery, then regularly in postoperative follow-up: every 4 months for 5 years, then every 6 months for life. In patients with extensive metastases, serum calcitonin should be measured in the laboratory with serial dilutions. Calcitonin levels remain elevated in patients with persistent tumor but also in some patients with apparent cure or indolent disease. Therefore, rising levels of calcitonin (or CEA) are the best indication for recurrence. Serum calcitonin levels > 250 pg/mL are also an indication for recurrent or metastatic medullary thyroid carcinoma. Serum CEA levels are usually elevated with medullary carcinoma, making this a useful second marker; however, it is not specific for this carcinoma.

C. Imaging

1. Ultrasound of the neck—Ultrasound of the neck should be performed routinely on all patients with thyroid cancer for the initial diagnosis and for follow-up. Ultrasound is useful in determining the size and location of the malignancy as well as the location of any neck metastases.

2. Radioactive iodine scanning—RAI (^{131}I or ^{123}I) thyroid and whole-body scanning is used after thyroidectomy for surveillance as described below, supplanting its previous

use to determine whether a nodule was “cold” as a sign of malignancy.

3. CT and MRI scanning—CT scanning may demonstrate metastases and is particularly useful for localizing and monitoring lung metastases. However, CT scanning is less sensitive than ultrasound for detecting metastases within the neck. Iodinated contrast should never be given prior to RAI scanning or RAI therapy, since the large amounts of iodine in contrast media competitively inhibit the uptake of RAI by the thyroid, greatly reducing the effectiveness of subsequent RAI scanning and therapy. Medullary carcinoma in the thyroid, nodes, and liver may calcify, but lung metastases rarely do so. MRI is particularly useful for imaging bone metastases.

4. PET scanning—PET scanning is particularly useful for detecting thyroid cancer metastases that do not have sufficient iodine uptake to be visible on RAI scans. Metastases are best detected using ^{18}F FDG-PET whole-body scanning. The sensitivity of ^{18}F FDG-PET scanning for differentiated thyroid cancer is enhanced if the patient is hypothyroid or receiving thyrotropin, which increases the metabolic activity of differentiated thyroid cancer. Disadvantages of PET scanning include its lack of specificity for thyroid cancer as well as its expense and lack of availability in some locations. ^{18}F FDG-PET scanning has prognostic implications, since differentiated thyroid cancer metastases with low standard uptake value (SUV) scores are associated with a better prognosis.

► Differential Diagnosis

Neuroendocrine carcinomas may metastasize to the thyroid and be confused with medullary thyroid carcinoma.

False-positive ^{131}I scans are common with normal residual thyroid tissue and have been reported with Zenker diverticulum, struma ovarii, pleuropericardial cyst, gastric pull-up, and ^{131}I -contaminated bodily secretions. False-negative ^{131}I scans are common in early metastatic differentiated thyroid carcinoma but occur also in more advanced disease, including 14% of bone metastases.

► Complications

The complications vary with the type of carcinoma. Differentiated thyroid carcinomas may have local or distant metastases. One-third of medullary carcinomas may secrete serotonin and prostaglandins, producing flushing and diarrhea, and may be complicated by the coexistence of pheochromocytomas or hyperparathyroidism. The risks of radical neck surgery include permanent hypoparathyroidism and vocal cord palsy due to recurrent laryngeal nerve damage; permanent hypothyroidism is expected after thyroidectomy and should always be treated adequately.

► Treatment of Differentiated Thyroid Carcinoma

A. Surgical Treatment

Surgical removal is the treatment of choice for thyroid carcinomas. Neck ultrasound is obtained preoperatively, since

suspicious cervical lymphadenopathy is detected in about 25%. Intraoperative thyroid ultrasound by the surgeon also helps assess the extent of the tumor and lymph node involvement, altering surgical treatment in many cases. For differentiated papillary and follicular carcinoma > 1 cm diameter, total thyroidectomy is performed with limited removal of cervical lymph nodes. For medullary thyroid carcinoma, repeated neck dissections are often required.

For indeterminate nodules, surgery consists of a thyroid lobectomy for an indeterminate “follicular lesion” that is ≤ 4 cm diameter. If malignancy is diagnosed on pathology, a completion thyroidectomy is performed. For indeterminate follicular lesions > 4 cm diameter that are at higher risk for being malignant, a bilateral thyroidectomy is performed as the initial surgery. Higher risk lesions include those with a FNA biopsy that shows marked atypia or that are suspicious for papillary carcinoma and those that occur in patients with a history of radiation exposure or a family history of thyroid carcinoma.

For biopsies that are diagnostic of malignancy, surgery involves lobectomy alone for papillary thyroid carcinomas < 1 cm diameter in patients under age 45 years who have no history of head and neck irradiation and no evidence of lymph node metastasis on ultrasonography. Other patients should have a total or near total thyroidectomy. The advantage of near-total thyroidectomy for differentiated thyroid carcinoma is that multicentric foci of carcinoma are more apt to be resected. Also, there is less normal thyroid tissue to compete with cancer for ^{131}I administered later for scans or treatment. A central neck lymph node dissection is performed at the time of thyroidectomy for patients with nodal metastases that are clinically evident. A lateral neck dissection is performed for patients with biopsy-proven lateral cervical lymphadenopathy. Neck muscle resections are usually avoided for differentiated thyroid carcinoma. However, patients with the Hürthle cell variant of follicular carcinoma may benefit from a modified radical neck dissection. Metastases to the brain are best treated surgically, since treatment with radiation or RAI is ineffective. Levothyroxine is prescribed in doses of 0.05–0.1 mg orally daily immediately postoperatively (see Thyroxine Suppression and Chemotherapy, below). About 2–4 months after surgery, patients require reevaluation and often require therapy with ^{131}I (see below).

Permanent injury to one recurrent laryngeal nerve occurs in between 1–2% and 7% of patients, depending on the experience of the surgeon. Bilateral nerve palsies are rare. Temporary recurrent laryngeal nerve palsies occur in another 5% but often resolve within 6 months. After total thyroidectomy, temporary hypoparathyroidism occurs in 20% and becomes permanent in about 2%. The incidence of hypoparathyroidism may be reduced if accidentally resected parathyroids are immediately autotransplanted into the neck muscles. Thyroidectomy requires at least an overnight hospital admission, since late bleeding, airway problems, and tetany can occur. Ambulatory thyroidectomy is potentially dangerous and should not be done. Following surgery, staging (Table 26–8) should be done to help determine prognosis and to plan therapy and follow-up.

Table 26-8. Pathologic tumor-node-metastasis (pTNM) staging and tumor-related approximate survival rates for adults with appropriately treated differentiated (papillary) thyroid carcinoma based upon patient age, primary tumor size and invasiveness (T), lymph node involvement (N), and distant metastases (M).¹

Stage	Description	Five-Year Survival	Ten-Year Survival
I	Under 45: any T, any N, no M Over 45: T ≤ 1 cm, no N, no M	99%	98%
II	Under 45: any T, any N, any M Over 45: T > 1 cm limited to thyroid, no N, no M	99%	90%
III	Over 45: T > 4 cm limited to thyroid, no N, no M; or any T limited to thyroid, regional N, no M	95%	75%
IV	Over 45: T local invasion, any N, any M; or T extensive invasion, any N, no M; or any T, any N, distant M	85%	65%

¹Patients having a relatively worse prognosis include those with familial differentiated thyroid carcinoma.

In pregnant women with thyroid cancer, surgery is usually delayed until after delivery, except for fast-growing tumors that may be resected after 24 weeks gestation; there has been no difference in survival or tumor recurrence rates in women who underwent surgery during or after their pregnancy. Differentiated thyroid carcinoma does not behave more aggressively during pregnancy. But there is a higher risk of complications in pregnant women undergoing thyroid surgery, compared to nonpregnant women.

B. Thyroxine Suppression and Chemotherapy

Patients who have had a thyroidectomy for differentiated thyroid cancer must take thyroxine replacement for life. Oral thyroxine should be given in doses that suppress serum TSH without causing clinical thyrotoxicosis. An ultrasensitive TSH assay should be used; serum TSH should be suppressed below 0.1 mU/L for patients with stage II disease and below 0.05 mU/L for patients with stage III–IV disease. (See Table 26-8.) Although patients receiving thyroxine suppression therapy (TSH < 0.05 mU/L) are at risk for a lower bone density than age-matched controls, the adverse effect upon bone density and fracture risk is relatively minor for patients who remain clinically euthyroid. Nevertheless, patients receiving thyroxine suppression therapy are advised to have periodic bone densitometry.

Zoledronic acid, an intravenous bisphosphonate, has proven useful for osteolytic metastases from other solid tumors and has been used for patients with thyroid bone metastases, but its effectiveness is unknown.

Thyroid carcinomas are extraordinarily resistant to chemotherapy. Sorafenib and sunitinib are tyrosine kinase inhibitors that have shown some activity against metastatic differentiated thyroid carcinomas that are radioiodine-resistant, with partial responses in 20% and stable disease in 60%.

C. Radioactive Iodine (¹³¹I) Therapy

Differentiated thyroid cancers variably retain the normal thyroid's ability to respond to TSH, secrete thyroglobulin, and concentrate iodine. There are two reasons to treat

patients with ¹³¹I after thyroidectomy: (1) thyroid remnant ablation and (2) treatment of known or suspected thyroid cancer. ¹³¹I is usually administered 2–4 months after surgery. Treatment with ¹³¹I is repeated 9–12 months later if surveillance RAI scanning shows evidence of metastatic disease. (See Surveillance, below.)

Before starting ¹³¹I therapy, patients follow a low iodine diet for at least 2 weeks. The low iodine diet consists of avoiding the following: iodized table salt, sea salt, fish, shellfish, seaweed, commercial bread, dairy products, processed meats, canned or dried fruit, canned fruit juices, highly salted soups and snack foods, black tea, instant coffee, food coloring with Red Dye #3, egg yolks, multivitamins with iodine, or topical iodine. Patients must not be given amiodarone or intravenous radiologic contrast dyes containing iodine.

1. Thyroid remnant ablation—A small dose of 30 mCi (1110 MBq) ¹³¹I is given for “remnant ablation” of residual normal thyroid tissues after surgery for differentiated thyroid cancer. This small dose of ¹³¹I is given to patients with no lymph node involvement who are at low risk for metastases. There are several advantages for giving thyroid remnant ablation: (1) There is usually remnant normal tissue that can produce thyroglobulin (a useful tumor marker); (2) Remnant ablation using ¹³¹I may destroy microscopic deposits of cancer; (3) The post-therapy scan may visualize metastatic cancer that would otherwise have been invisible. However, ¹³¹I remnant ablation has not been useful for patients with stage I papillary thyroid carcinomas < 1 cm diameter that are unifocal or multifocal. Such very low-risk patients may have close surveillance without receiving remnant ablation.

2. Treatment of metastases—RAI therapy improves survival and reduces recurrence rates for patients with stage III–IV cancer and those with stage II cancer having gross extrathyroidal extension. RAI therapy is also given to patients with stage II cancer who have distant metastases, a primary tumor > 4 cm diameter, or primary tumors 1–4 cm diameter with lymph node metastases or other high-risk features. Brain metastases do not usually respond

to ^{131}I and are best resected or treated with gamma knife radiosurgery (Table 26–8). A post-therapy whole-body scan is performed 2–10 days after ^{131}I therapy.

Staging with RAI scanning or ^{18}F -FDG-PET/CT scanning assists dosing decisions for ^{131}I therapy. Radioiodine doses of 50–100 mCi are given to patients with large primary tumors or tumors at the surgical margin. Patients with local lymph node involvement typically receive 100 mCi of ^{131}I ; patients with more extensive neck node involvement, regional or distant metastases receive ^{131}I at a dose of 125–200 mCi (4625–7400 MBq). Unfortunately, about 35% of patients with differentiated thyroid carcinoma have poor uptake of ^{131}I into metastases. Patients with asymptomatic, stable, radioiodine-resistant metastases may be carefully monitored for tumor progression.

Some patients have elevated serum thyroglobulin levels but a negative whole-body radioiodine scan and a negative neck ultrasound. In such patients, an ^{18}F -FDG PET/CT scan is obtained. If all scans are negative, empiric therapy with ^{131}I is not useful.

Doses of ^{131}I over 100 mCi (3800 MBq) can cause gastritis, temporary oligospermia, sialadenitis, and xerostomia. RAI therapy can cause neurologic decompensation in patients with brain metastases; it is advisable to treat such patients with prednisone 30–40 mg orally daily for several days before and after ^{131}I therapy. Cumulative doses of ^{131}I over 500 mCi can cause infertility, pancytopenia (4%), and leukemia (0.3%). Pulmonary fibrosis can occur in patients with diffuse lung metastases after receiving cumulative ^{131}I activities of > 600 mCi (22 GBq). The kidneys excrete RAI, so patients receiving dialysis for kidney disease require a dosage reduction to only 20% of the usual dose of ^{131}I .

3. rhTSH-stimulated ^{131}I therapy, thyroglobulin, and scan—Recombinant human thyroid stimulating hormone (rhTSH, Thyrogen) is given to increase the sensitivity of serum thyroglobulin for residual cancer and to increase the uptake of ^{131}I into residual thyroid tissue (thyroid remnant “ablation”) or cancer. Thyrogen must be kept refrigerated and is administered according to the following protocol: Thyroxine replacement is held for 2 days before rhTSH and for 3 days afterward. rhTSH 0.9 mg is administered intragluteally (not intravenously) daily for 2 consecutive days. On the third day, blood is drawn: serum TSH is assayed to confirm that it is > 30 mCU/mL; serum hCG is measured in reproductive-age women to screen for pregnancy; and serum thyroglobulin is measured as a tumor marker. RAI is then administered at the prescribed dose (see above).

Thyrogen should not be administered to patients with an intact thyroid gland because it can cause severe thyroid swelling and hyperthyroidism. Hyperthyroidism can also occur in patients with significant metastases or residual normal thyroid. Other side effects include nausea (11%) and headache (7%). Thyrotropin has caused neurologic deterioration in 7% of patients with central nervous system metastases.

4. Thyroxine-withdrawal stimulated ^{131}I therapy, thyroglobulin, and scan—Thyroxine withdrawal is sometimes used because of its lower cost, despite the discomforts of becoming hypothyroid. Thyroxine is withdrawn for

14 days and the patient is allowed to become hypothyroid; high levels of endogenous TSH stimulate the uptake of RAI and production of thyroglobulin by thyroid cancer or residual thyroid. Just prior to ^{131}I therapy, the following blood tests are obtained: serum TSH to confirm it is > 30 mCU/mL, serum hCG in reproductive-age women to screen for pregnancy, serum thyroglobulin as a tumor marker. Three days after ^{131}I therapy, thyroxine therapy may be resumed at full replacement dose.

5. Side effects and contraindications—National Cancer Institute surveillance data for thousands of patients with thyroid cancer indicate that patients with differentiated thyroid cancer, treated with only surgery, have a 5% increased risk of developing a second non-thyroid malignancy (especially breast cancer). Patients with thyroid cancer who received ^{131}I therapy have a 20% increased risk of developing a second non-thyroid malignancy (especially leukemia and lymphoma). The greatest risk of second cancers appeared within 5 years of ^{131}I therapy and was most significant for younger patients.

Pregnant women may not receive RAI therapy. Women are advised to avoid pregnancy for at least 4 months following ^{131}I therapy. Men have been found to have abnormal spermatozoa for up to 6 months following ^{131}I therapy and are advised to use contraceptive methods during that time.

▶ Treatment of Other Thyroid Malignancies

Patients with anaplastic thyroid carcinoma are treated with local resection and radiation. Lovastatin has been demonstrated to cause differentiation and apoptosis of anaplastic thyroid carcinoma cells in vitro; however, clinical studies have not been performed. Anaplastic thyroid carcinoma does not respond to ^{131}I therapy and is resistant to chemotherapy.

Patients with thyroid MALT lymphomas have a low risk of recurrence after simple thyroidectomy. Patients with other thyroid lymphomas are best treated with external radiation therapy; chemotherapy is added for extensive lymphoma. Patients with systemic lymphomas involving the thyroid are usually treated with chemotherapy.

Patients with a *ret* protooncogene mutation should have a prophylactic total thyroidectomy, ideally by age 6 years (MEN 2A) or at age 6 months (MEN 2B). Medullary thyroid carcinoma is best treated with surgery for the primary tumor and metastases. It does not respond to ^{131}I therapy and is generally resistant to chemotherapy. In one study, vandetanib (100 mg orally once daily) produced a partial remission in 16% and stable disease in 53% of patients with locally advanced or metastatic medullary thyroid carcinoma.

A. External Radiation Therapy

External radiation may be delivered to bone metastases, especially those without radioiodine uptake. Local neck radiation therapy may also be given to patients with anaplastic thyroid carcinoma. Brain metastases can be treated with gamma knife radiosurgery.

► Surveillance

Patients with differentiated thyroid carcinoma must be observed long-term for recurrent or metastatic disease. Patients with **differentiated thyroid carcinoma** have traditionally required at least two annual consecutively negative stimulated serum thyroglobulin determinations < 1 ng/mL and normal RAI scans (if done) and neck ultrasound before they are considered to be in remission. The first surveillance occurs with stimulated postoperative serum thyroglobulin, ¹³¹I therapy, and post-therapy scanning about 2–4 months after surgery. (See Treatment, above.) At 9–12 months postoperatively, patients usually receive another stimulated serum thyroglobulin and radioiodine scan. Patients with persistent RAI uptake restricted to the thyroid bed need not have repeated ¹³¹I therapies if the neck ultrasound appears normal and stimulated serum thyroglobulin is < 2 ng/mL. Further radioiodine or other scans may be required for patients with more aggressive differentiated thyroid cancer, prior metastases, rising serum thyroglobulin levels, or other evidence of metastases.

1. Serum TSH suppression—Patients with differentiated thyroid cancer are treated with thyroxine doses that are sufficient to suppress the serum TSH below the normal range. For intermediate- or high-risk patients, the serum TSH should be suppressed below 0.1 mU/L, while the target TSH for low-risk patients is 0.1–0.5 mU/mL. Patients who are considered cured should nevertheless be treated with sufficient thyroxine to keep the serum TSH < 2 mU/L. Follow-up must include physical examinations and laboratory testing to ensure that patients remain clinically euthyroid with serum TSH levels in the target range. To achieve suppression of serum TSH, the required dose of thyroxine may be such that serum FT₄ levels may be slightly elevated; in that case, measurement of serum T₃ or free T₃ can be useful to ensure the patient is not frankly hyperthyroid. Thyrotoxicosis can be caused by overreplacement with thyroxine or by the growth of functioning metastases.

2. Serum thyroglobulin—Thyroglobulin is produced by normal thyroid tissue and by most differentiated thyroid carcinomas. It is only after a total or near-total thyroidectomy and ¹³¹I remnant ablation that thyroglobulin becomes a useful tumor marker for patients with differentiated papillary or follicular thyroid cancer, particularly for patients who do not have serum antithyroglobulin antibodies.

Detectable thyroglobulin levels do not necessarily indicate the presence of residual or metastatic thyroid cancer. Conversely, baseline serum thyroglobulin levels are insensitive markers for disease recurrence. However, baseline or stimulated serum thyroglobulin levels ≥ 2 ng/mL indicate the need for a repeat neck ultrasound and further scanning with RAI or ¹⁸FDG-PET. If serum thyroglobulin levels remain ≥ 2 ng/mL in the presence of normal scanning, it is prudent to repeat the serum thyroglobulin in a national reference laboratory. In one series of patients with differentiated thyroid cancer following thyroidectomy, there was a 21% incidence of metastases in patients with serum thyroglobulin < 1 ng/mL (while receiving thyroxine for TSH suppression). Therefore, *baseline* serum thyroglobulin

levels are inadequately sensitive and *stimulated* serum thyroglobulin measurements should be used and *always* with neck ultrasound. The usefulness of routinely doing a radioiodine scan (see below) in low-risk patients is controversial but continues to be done in many centers during stimulation following either rhTSH or thyroid hormone withdrawal, according to described protocols.

3. Neck ultrasound—Neck ultrasound should be used in all patients with thyroid carcinoma to supplement neck palpation; it should be performed preoperatively, 3 months postoperatively, and regularly thereafter. Ultrasound is more sensitive for lymph node metastases than either CT or MRI scanning. Small inflammatory nodes may be detected postoperatively and do not necessarily indicate metastatic disease, but follow-up is necessary. Ultrasound-guided FNA biopsy should be performed on suspicious lesions.

4. Radioactive iodine (RAI: ¹³¹I or ¹²³I) neck and whole-body scanning—Despite its limitations, RAI scanning has traditionally been used to detect metastatic differentiated thyroid cancer and to determine whether the cancer is amenable to treatment with ¹³¹I. RAI scanning is particularly useful for high-risk patients and those with persistent antithyroglobulin antibodies that make serum thyroglobulin determinations unreliable.

The ¹³¹I isotope may be used in scanning doses, given < 2 weeks before scheduled ¹³¹I treatment to avoid “stunning” metastases such that they take up less of the RAI therapy dose. The radioisotope ¹²³I may also be used and does not stun tumors; it allows single-photon emission computed tomography (SPECT) to better localize metastases. Initial RAI scanning is typically performed about 2–4 months following surgery for differentiated thyroid carcinoma. Whole-body scanning should be performed for at least 30 minutes for at least 140,000 counts and spot views of the neck should be obtained for at least 35,000 counts.

About 65% of metastases are detectable by RAI scanning, but only after optimal preparation: Patients should ideally have a total or near-total thyroidectomy, since any residual normal thyroid competes for RAI with metastases, which are less avid for iodine. It is reasonable to perform a rhTSH-stimulated scan and thyroglobulin level 2–3 months after the initial neck surgery; if the scan is negative and the serum thyroglobulin is < 2 ng/mL, low-risk patients may not require further scanning but should continue to be monitored with neck ultrasound and serum thyroglobulin levels every 6–12 months. For higher-risk patients, the rhTSH-stimulated thyroglobulin and RAI scan may be repeated about 1 year after surgery and then again if warranted. Serum thyroglobulin and radioiodine scanning are stimulated by either rhTSH or thyroid hormone withdrawal according to the protocols described above for ¹³¹I treatment.

The combination of rhTSH-stimulated scanning and thyroglobulin levels detects a thyroid remnant or cancer with a sensitivity of 84%. However, the presence of antithyroglobulin antibodies renders the serum thyroglobulin determination uninterpretable. In about 21% of low-risk patients, rhTSH stimulates serum thyroglobulin to above 2 ng/mL; such patients have a 23% risk of local neck

metastases and a 13% risk of distant metastases. The rhTSH-stimulated radioiodine neck and whole-body scan detects only about half of these metastases because they are small or not avid for iodine. Some patients have persistent radioiodine uptake in the neck on diagnostic scanning but have no visible tumor on neck ultrasound; such patients do not require additional radioiodine therapy, especially if the serum thyroglobulin level is very low.

5. Positron emission tomography scanning— ^{18}F FDG-PET scanning is particularly useful for detecting thyroid cancer metastases in patients with a detectable serum thyroglobulin (especially serum thyroglobulin levels >10 ng/mL and rising) who have a normal whole-body RAI scan and an unrevealing neck ultrasound. The patient should be fasting at least 6 hours prior to ^{18}F FDG-PET scanning; water is allowed, but no sweetened beverages. Diabetic patients with blood sugars <200 mg/dL may be scanned. ^{18}F FDG-PET scanning can be combined with a CT scan; the resultant ^{18}F FDG-PET/CT fusion scan is 60% sensitive for detecting metastases that are not visible by other methods. This scan is less sensitive for small brain metastases. ^{18}F FDG-PET scanning detects the metabolic activity of tumor tissue; for differentiated thyroid carcinoma, this scan is more sensitive when the patient's thyroid cancer is stimulated with rhTSH (Thyrogen) as described above. One problem with ^{18}F FDG-PET scanning is its lack of specificity. False-positives can occur with benign hepatic tumors, sarcoidosis, radiation therapy, suture granulomas, reactive lymph nodes, or inflammation at surgical sites that can persist for months. False-positive uptake can also occur in muscles and brown fat.

^{18}F FDG-PET scanning predicts survival better than standard staging; the number, location, and SUV_{max} of metastases are all significant prognostic factors. (See Prognosis.) ^{18}F FDG-PET scanning is particularly sensitive for detecting medullary thyroid carcinoma metastases, and prescan thyrotropin does not improve the PET scan sensitivity for medullary thyroid carcinoma.

6. Other scanning—Thallium-201 (^{201}Tl) scans may be useful for detecting metastatic differentiated thyroid carcinoma when the ^{131}I scan is normal but serum thyroglobulin is elevated. MRI scanning is particularly useful for imaging metastases in the brain, mediastinum, or bones. CT scanning is useful for imaging and monitoring pulmonary metastases.

► Prognosis

Papillary thyroid cancer staging and survival data are shown on Table 26–8. ^{18}F FDG-PET scanning independently predicts survival, with patients having few PET-avid metastases and low SUV_{max} (highest image-pixel standardized uptake value) having a better prognosis. There is generally a good prognosis, particularly for adults under age 45 years, despite the fact that up to 40% of these patients are found to harbor lymph node metastases when extensive lymph node dissections are performed. The following characteristics imply a worse prognosis: age over 45 years, male sex, bone or brain metastases, macronodular (>1 cm) pulmonary metastases, and lack of ^{131}I uptake into metastases. Younger patients with pulmonary metastases tend to

respond better to ^{131}I therapy than do older adults. Certain papillary histologic types are associated with a higher risk of recurrence and reduced survival: tall cell, columnar cell, and diffuse sclerosing types. Brain metastases are detected in 1%; they reduce median survival to 12 months, but the patient's prognosis is improved by surgical resection. Patients with a **follicular variant of papillary carcinoma** have a prognosis somewhere between that of papillary and follicular thyroid carcinoma.

Patients with **follicular carcinoma** have a cancer mortality rate that is 3.4 times higher than patients with papillary carcinoma. The **Hürthle cell variant** of follicular carcinoma is even more aggressive. Both follicular carcinoma and its Hürthle cell variant tend to present at a more advanced stage than papillary carcinoma. However, at a given stage, the different types of differentiated thyroid carcinoma have a similar prognosis. Patients with primary tumors >1 cm in diameter who undergo limited thyroid surgery (subtotal thyroidectomy or lobectomy) have a 2.2-fold increased mortality over those having total or near-total thyroidectomies. Patients who have not received ^{131}I ablation have mortality rates that are increased twofold by 10 years and threefold by 25 years (over those who have received ablation). The risk of cancer recurrence is twofold higher in men than in women and 1.7-fold higher in multifocal than in unifocal tumors.

Patients with a normal ^{18}F FDG-PET scan have a 98% 5-year survival, while those having >10 metastases have a 20% 5-year survival. Those with a SUV_{max} of 0.1–4.6 have a 5-year survival of 85%, while those with a $\text{SUV}_{\text{max}} >13.3$ have a 5-year survival of 20%. Patients with only local metastases have a 5-year survival of 95%, while those with regional (supraclavicular, mediastinal) metastases have a 5-year survival of 70%, and those with distant metastases have a 5-year survival of 35%.

Medullary thyroid carcinoma is more aggressive than differentiated thyroid cancer but is typically fairly indolent. The overall 10-year survival rate is 90% when the tumor is confined to the thyroid, 70% for those with metastases to cervical lymph nodes, and 20% for those with distant metastases. Patients with sporadic disease usually have lymph node involvement noted at the time of diagnosis, whereas distal metastases may not be noted for years. For patients with medullary thyroid carcinoma who have metastases to lymph nodes, modified radical neck dissection is recommended. Familial cases or those associated with MEN 2A tend to be less aggressive; the 10-year survival rate is higher, in part due to earlier detection. Medullary thyroid carcinoma that is seen in MEN 2B is more aggressive, arises earlier in life, and carries a worse overall prognosis, especially when associated with a germline *M918T* mutation. The elderly tend to have more aggressive medullary thyroid carcinomas. Women with medullary thyroid carcinoma who are under age 40 years have a better prognosis. A better prognosis is also obtained in patients undergoing total thyroidectomy and neck dissection; radiation therapy reduces recurrence in patients with metastases to neck nodes. The mortality rate is increased 4.5-fold when primary or metastatic tumor tissue stains heavily for myelomonocytic antigen M-1. Conversely,

tumors with heavy immunoperoxidase staining for calcitonin are associated with prolonged survival even in the presence of significant metastases.

Anaplastic thyroid carcinoma carries a 1-year survival rate of about 10% and a 5-year survival rate of about 5%. Patients with fully localized tumors on MRI have a better prognosis.

Localized lymphoma carries a 5-year survival of nearly 100%. Those with disease outside the thyroid have a 63% 5-year survival. However, the prognosis is better for those with the MALT type. Patients presenting with stridor, pain, laryngeal nerve palsy, or mediastinal extension tend to fare worse.

Bible KC et al. Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study. *Lancet Oncol.* 2010 Oct 11;11(10):962–72. [PMID: 20851682]

Brierley JD. Update on external beam radiation therapy in thyroid cancer. *J Clin Endocrinol Metab.* 2011 Aug;96(8):2289–95. [PMID: 21816795]

Cabanillas ME et al. Challenges associated with tyrosine kinase inhibitor therapy for metastatic thyroid cancer. *J Thyroid Res.* 2011;2011:985780. [PMID: 22007339]

Cox AE et al. Diagnosis and treatment of differentiated thyroid carcinoma. *Radiol Clin North Am.* 2011 May;49(3):453–62. [PMID: 21569904]

Jasim S et al. Multiple endocrine neoplasia type 2B with RET proto-oncogene A883F mutation displays a more indolent form of medullary thyroid carcinoma compared with a RET M918T mutation. *Thyroid.* 2011 Feb;21(2):189–92. [PMID: 21186952]

Johnson NA et al. Imaging surveillance of differentiated thyroid cancer. *Radiol Clin North Am.* 2011 May;49(3):473–87. [PMID: 21569906]

Kim WG et al. Empiric high-dose 131-iodine therapy lacks efficacy for treated papillary thyroid cancer patients with detectable serum thyroglobulin, but negative cervical sonography and ¹⁸F-fluorodeoxyglucose positron emission tomography scan. *J Clin Endocrinol Metab.* 2010 Mar;95(3):1169–73. [PMID: 20080852]

Kojic SL et al. Anaplastic thyroid cancer: a comprehensive review of novel therapy. *Expert Rev Anticancer Ther.* 2011 Mar;11(3):387–402. [PMID: 21417853]

Pitt SC et al. Medullary, anaplastic, and metastatic cancers of the thyroid. *Semin Oncol.* 2010 Dec;37(6):567–79. [PMID: 21167376]

Tala H et al. Contemporary post surgical management of differentiated thyroid carcinoma. *Clin Oncol (R Coll Radiol).* 2010 Aug;22(6):419–29. [PMID: 20605708]

IODINE DEFICIENCY DISORDER & ENDEMIC GOITER

ESSENTIALS OF DIAGNOSIS

- ▶ Common in regions with low-iodine diets.
- ▶ High rate of congenital hypothyroidism and cretinism.
- ▶ Goiters may become multinodular and enlarge.
- ▶ Most adults with endemic goiter are found to be euthyroid; however, some are hypothyroid or hyperthyroid.

General Considerations

About 1 billion people are iodine deficient, having no access to iodized salt and living in areas with iodine-depleted soil. Severe iodine deficiency increases the risk of miscarriage and stillbirth. About 0.5% of live births in iodine-deficient areas have full-blown cretinism. Moderate iodine deficiency during gestation and infancy cause other manifestations of congenital hypothyroidism, such as deafness and short stature and permanently lowers a child's IQ by 10–15 points.

Populations in areas of iodine deficiency have a high incidence of goiter. One such area is Pescopagano, Italy, where 60% of adults have goiters. Hyperthyroidism (present or past) occurred in 2.9%; hypothyroidism was overt in 0.2% and subclinical in 3.8%.

Although iodine deficiency is the most common cause of endemic goiter, certain foods (eg, sorghum, millet, maize, cassava), mineral deficiencies (selenium, iron), and water pollutants can themselves cause goiter or aggravate a goiter proclivity caused by iodine deficiency. In iodine-deficient patients, smoking can induce goiter growth. Pregnancy aggravates iodine deficiency and is associated with an increase in size of thyroid nodules and the emergence of new nodules. Some individuals are particularly susceptible to goiter owing to congenital partial defects in thyroid enzyme activity.

Clinical Findings

A. Symptoms and Signs

Endemic goiters may become multinodular and very large. Growth often occurs during pregnancy and may cause compressive symptoms.

Substernal goiters are usually asymptomatic but can cause tracheal compression, respiratory distress and failure, dysphagia, superior vena cava syndrome, gastrointestinal bleeding from esophageal varices, palsies of the phrenic or recurrent laryngeal nerves, or Horner syndrome. Cerebral ischemia and stroke can result from arterial compression or thyrocervical steal syndrome. Substernal goiters can rarely cause pleural or pericardial effusions. The incidence of significant malignancy is < 1%.

Some patients with endemic goiter may become hypothyroid. Others may become thyrotoxic as the goiter grows and becomes more autonomous, especially if iodine is added to the diet.

B. Laboratory Findings

The serum T₄ and TSH are generally normal. TSH falls in the presence of hyperthyroidism if a multinodular goiter has become autonomous in the presence of sufficient amounts of iodine for thyroid hormone synthesis. TSH rises with hypothyroidism. Thyroid RAI uptake is usually elevated, but it may be normal if iodine intake has improved. Serum levels of anti-thyroid antibodies are usually either undetectable or in low titers. Serum thyroglobulin is often elevated.

Differential Diagnosis

Endemic goiter must be distinguished from all other forms of nodular goiter that may coexist in an endemic region (see above).

► Prevention

Adding iodine to commercial salt prevents iodine deficiency. In the United States, potassium iodide is used. Some tropical countries use potassium iodate, since it is more stable than potassium iodide in hot and humid climates. Iodized salt contains iodine at about 20 mg per kg salt. The minimum dietary requirement for iodine is about 50 mcg daily, with optimal iodine intake being 150–300 mcg daily. Iodine sufficiency is assessed by measurement of urinary iodide excretion, the target being more than 10 mcg/dL. Initiating iodine supplementation in an iodine-deficient area greatly reduces the emergence of new goiters but causes an increased frequency of hyperthyroidism during the first year.

► Treatment

The addition of potassium iodide to table salt greatly reduces the prevalence of endemic goiter and cretinism but is less effective in shrinking established goiter. Concurrent deficiencies in both vitamin A and iodine increase the risk of endemic goiter and concurrent repletion of both iodide and vitamin A reduces goiter in endemic goiter regions.

Adults with large multinodular goiter may require thyroidectomy for cosmesis, compressive symptoms, or thyrotoxicosis. Following partial thyroidectomy in iodine-deficient geographic areas, there is a high goiter recurrence rate, so near-total thyroidectomy is preferred when surgery is indicated. Certain patients may be treated with ¹³¹I for large compressive goiters.

► Complications

Dietary iodine supplementation increases the risk of autoimmune thyroid dysfunction, which may cause hypothyroidism or hyperthyroidism. Excessive iodine supplementation increases the risk of goiter. Suppression of TSH by administering thyroxine carries the risk of inducing hyperthyroidism, particularly in patients with autonomous multinodular goiters; therefore, thyroxine suppression should not be started in patients with a low TSH level. Rarely, Graves disease can develop 3–10 months after ¹³¹I treatment in patients with large multinodular goiters.

Laurberg P et al. Iodine intake as a determinant of thyroid disorders in populations. *Best Pract Res Clin Endocrinol Metab.* 2010 Feb;24(1):13–27. [PMID: 20172467]

Untoro J et al. The challenges of iodine supplementation: a public health programme perspective. *Best Pract Res Clin Endocrinol Metab.* 2010 Feb;24(1):89–99. [PMID: 20172473]

Zimmermann MB. Iodine deficiency. *Endocr Rev.* 2009 Jun;30(4):376–408. [PMID: 19460960]

▼ DISEASES OF THE PARATHYROIDS

Parathyroid hormone (PTH) increases osteoclastic activity in bone, increases the renal tubular reabsorption of calcium, and stimulates the synthesis of 1,25-dihydroxycholecalciferol by the kidney. Meanwhile, PTH inhibits the

absorption of phosphate and bicarbonate by the renal tubule. All of these actions cause a net increase in serum calcium.

HYPOPARATHYROIDISM & PSEUDOHYPOPARATHYROIDISM

ESSENTIALS OF DIAGNOSIS

- ▶ Tetany, carpopedal spasms, tingling of lips and hands, muscle and abdominal cramps, psychological changes.
- ▶ Positive Chvostek sign and Trousseau phenomenon.
- ▶ Serum calcium low; serum phosphate high; alkaline phosphatase normal; urine calcium excretion reduced.
- ▶ Low or low-normal serum PTH in presence of hypocalcemia.
- ▶ Serum magnesium may be low.

► General Considerations

Acquired hypoparathyroidism is most commonly seen following thyroidectomy, when it is usually transient but may be permanent. It may also occur after multiple parathyroidectomies. Hypoparathyroidism may occur transiently after surgical removal of a parathyroid adenoma for primary hyperparathyroidism due to suppression of the remaining normal parathyroids and accelerated remineralization of the skeleton (hungry bone syndrome). Neck irradiation may rarely cause hypoparathyroidism.

Autoimmune hypoparathyroidism may be isolated or combined with other endocrine deficiencies in polyglandular autoimmunity (PGA), which is also known as autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED). PGA type 1 presents in childhood with at least two of the following manifestations: candidiasis, hypoparathyroidism, or Addison disease. Cataracts, uveitis, alopecia, vitiligo, or autoimmune thyroid disease may also develop. Fat malabsorption occurs in 20% of patients with PGA-1 and may present as weight loss; diarrhea; or malabsorption of vitamin D, a fat-soluble vitamin used to treat the hypoparathyroidism. The fat malabsorption may be due to a deficiency in the jejunal enteroendocrine cells that produce cholecystokinin, causing a reduction in bile acid secretion. Hypoparathyroidism can also occur in systemic lupus erythematosus, caused by antiparathyroid antibodies.

Parathyroid deficiency may also be the result of damage from heavy metals such as copper (Wilson disease) or iron (hemochromatosis, transfusion hemosiderosis), granulomas, Riedel thyroiditis, tumors, or infection.

Functional hypoparathyroidism may also occur as a result of magnesium deficiency (malabsorption, chronic alcoholism), which prevents the secretion of PTH. Correction of hypomagnesemia results in rapid disappearance

of the condition. Hypermagnesemia can also suppress PTH secretion; it may occur in patients with kidney disease who take magnesium supplements, laxatives, or antacids.

In **congenital hypoparathyroidism**, parathyroid cells have calcium-sensing receptors (CaSR) that sense the serum calcium concentration and suppress PTH secretion by way of G-protein-coupled mechanisms. Gain-of-function mutations (constitutive activation) of the *CaSR* gene suppress the parathyroid glands, resulting in hypocalcemia without elevations in serum PTH levels. Such mutations cause “autosomal dominant hypocalcemia with hypercalciuria” from deficient secretion of PTH. The prevalence of autosomal dominant hypocalcemia with hypercalciuria in the population is about 1 in 70,000, and it typically presents in infancy with hypocalcemic seizures.

Hypoparathyroidism, deafness, and renal dysplasia (HDR or Barakat) syndrome is an autosomal dominant condition caused by haploinsufficiency or mutations of the gene *GATA3*; the condition is autosomal dominant. Hypocalcemia is present from birth but may not be detected until the occurrence of mental retardation or hypocalcemic tetany. Hypoparathyroidism may also be seen in DiGeorge syndrome, along with congenital cardiac and facial anomalies; hypocalcemia usually presents with tetany in infancy, but some cases are not detected until adulthood.

Familial isolated hypoparathyroidism is caused by mutations in various genes that encode the secretion of PTH or the embryologic development of the parathyroid glands. Mutations in the *TBCE* gene cause autosomal recessive hypoparathyroidism with other phenotypic abnormalities that are known as the Kenny-Caffey syndrome or the Sanjad-Sakati syndrome. Various mutations in genes that encode mitochondria have maternal inheritance and cause hypoparathyroidism in association with other syndromes: Kearns-Sayre (ophthalmoplegia, retinopathy, cardiomyopathy, diabetes) and MELAS (mitochondrial encephalopathy, lactic acidosis, stroke).

► Clinical Findings

A. Symptoms and Signs

Acute hypoparathyroidism and hypocalcemia can occur spontaneously or may be precipitated when a patient with untreated hypoparathyroidism receives a proton pump inhibitor. Manifestations of hypocalcemia include tetany, muscle cramps, carpal spasm, irritability, altered mental status, convulsions, and stridor; tingling of the circumoral area, hands, and feet is almost always present. Symptoms of the chronic disease are lethargy, personality changes, anxiety state, blurring of vision due to premature cataracts, Parkinsonism, and mental retardation. Some patients with chronic hypocalcemia are asymptomatic, even with very low levels of serum calcium.

Chvostek sign (facial muscle contraction on tapping the facial nerve in front of the ear) is positive, and Trousseau phenomenon (carpal spasm after application of a sphygmomanometer cuff) is present. Cataracts may occur; the nails may be thin and brittle; the skin is dry and scaly, at times with fungus infection (candidiasis), and there may be loss of eyebrows; and deep tendon reflexes may be hyperactive.

Papilledema and elevated cerebrospinal fluid pressure are occasionally seen. Teeth may be defective if the onset of the disease occurs in childhood.

B. Laboratory Findings

Serum calcium is low, serum phosphate high, urinary calcium low, and alkaline phosphatase normal. Serum calcium is largely bound to albumin. In hypoalbuminemia, the serum ionized calcium may be determined, but it has had surprisingly poor clinical utility. Alternatively, the serum calcium level can be corrected for serum albumin level as follows:

$$\text{“Corrected” serum Ca}^{2+} = \text{Serum Ca}^{2+} \text{ mg/dL} \\ + (0.8 \times [4.0 - \text{Albumin g/dL}])$$

PTH levels are low. Hypomagnesemia may exacerbate symptoms and decrease parathyroid function.

C. Imaging

Radiographs or CT scans of the skull may show basal ganglia calcifications; the bones may be denser than normal. Cutaneous calcification may occur.

D. Other Examinations

Slit-lamp examination may show early posterior lenticular cataract formation. The electrocardiogram (ECG) shows prolonged QT intervals and T wave abnormalities. Patients with chronic hypoparathyroidism tend to have increased bone mineral density, particularly in the lumbar spine.

► Complications

Acute tetany with stridor, especially if associated with vocal cord palsy, may lead to respiratory obstruction requiring tracheostomy. Pseudotumor cerebri has been reported. Congestive heart failure may rarely occur. The complications of chronic hypoparathyroidism largely depend on the duration of the disease. There may be associated autoimmunity causing sprue syndrome, pernicious anemia, or Addison disease. In long-standing cases, cataract formation and calcification of the basal ganglia are seen. Occasionally, parkinsonian symptoms or choreoathetosis develop. Ossification of the paravertebral ligaments may occur with nerve root compression; surgical decompression may be required. Seizures are common in untreated patients. Overtreatment with vitamin D and calcium may produce nephrocalcinosis and impairment of kidney function. Chronic hypocalcemia can cause heart failure.

► Differential Diagnosis

Paresthesias, muscle cramps, or tetany due to respiratory alkalosis, in which the serum calcium is normal, can be confused with hypocalcemia. In fact, hyperventilation tends to accentuate hypocalcemic symptoms.

At times hypoparathyroidism is misdiagnosed as idiopathic epilepsy, choreoathetosis, or brain tumor (on the basis of brain calcifications, convulsions, choked disks) or, more rarely, as “asthma” (on the basis of stridor and dyspnea).

In patients with hypoalbuminemia, serum levels of ionized calcium are normal.

Hypocalcemia may also be due to malabsorption of calcium, magnesium, or vitamin D; patients do not always have diarrhea. Hypocalcemia may also be caused by certain drugs: loop diuretics, plicamycin, phenytoin, alendronate, and foscarnet. In addition, hypocalcemia may be seen in cases of rapid intravascular volume expansion or due to chelation from transfusions of large volumes of citrated blood. It is also observed in patients with acute pancreatitis. Hypocalcemia may develop in some patients with certain osteoblastic metastatic carcinomas (especially breast, prostate) instead of the expected hypercalcemia. Hypocalcemia with hyperphosphatemia (simulating hypoparathyroidism) is seen in azotemia but may also be caused by large doses of intravenous, oral, or rectal phosphate preparations and by chemotherapy of responsive lymphomas or leukemias.

Hypocalcemia with hypercalciuria may be due to a familial syndrome involving a mutation in the calcium-sensing receptor; such patients have levels of serum PTH that are in the normal range, distinguishing it from hypoparathyroidism. It is transmitted as an autosomal dominant disorder. Such patients are hypercalciuric; treatment with calcium and vitamin D may cause nephrocalcinosis.

Congenital pseudohypoparathyroidism is a group of disorders characterized by resistance to PTH. There are several subtypes caused by different mutations involving the PTH receptor or its G protein or adenyl cyclase. Renal tubular resistance to PTH causes hypercalciuria with resultant hypocalcemia. PTH levels are high and the PTH receptors in bone are typically not involved, such that bony changes of hyperparathyroidism may be evident. In pseudohypoparathyroidism type 1a, patients have hypocalcemia and hyperphosphatemia with additional features known as Albright hereditary osteodystrophy: mental retardation, short stature, obesity, round face, short fourth metacarpals, ectopic bone formation, hypothyroidism, and hypogonadism. Patients without hypocalcemia but sharing the phenotypic abnormalities are said to have "pseudopseudohypoparathyroidism."

► Treatment

A. Emergency Treatment for Acute Attack (Hypoparathyroid Tetany)

This usually occurs after surgery and requires immediate treatment.

1. Airway—Be sure an adequate airway is present.

2. Intravenous calcium gluconate—Calcium gluconate, 10–20 mL of 10% solution intravenously, may be given *slowly* until tetany ceases. Ten to 50 mL of 10% calcium gluconate may be added to 1 L of 5% glucose in water or saline and administered by slow intravenous drip. The rate should be adjusted so that the serum calcium is maintained between 8 mg/dL and 9 mg/dL.

3. Oral calcium—Calcium salts should be given orally as soon as possible to supply 1–2 g of calcium daily. Liquid calcium carbonate, 500 mg/5 mL, may be especially useful. The dosage is 1–3 g calcium daily. Calcium citrate contains 21% calcium, but a higher proportion is absorbed with less gastrointestinal intolerance.

4. Vitamin D preparations—(Table 26–9.) Therapy should be started as soon as oral calcium is begun. The active metabolite of vitamin D, 1,25-dihydroxycholecalciferol (calcitriol), has a very rapid onset of action and is not long-lasting if hypercalcemia occurs. It is of great use in the treatment of acute hypocalcemia. Therapy is commenced at a dosage of 0.25 mcg orally each morning with upward dosage titration to near normocalcemia. Ultimately, doses of 0.5–2 mcg/d are usually required. Calcifediol (25-hydroxyvitamin D₃), another option for treatment, has an intermediate onset and duration of action; the usual starting dose is 20 mcg/d orally.

5. Magnesium—If hypomagnesemia is present (chronic alcoholism, malnutrition, renal loss, drugs such as cisplatin, etc), it must be corrected to treat the resulting hypocalcemia. Acutely, magnesium sulfate is given intravenously, 1–2 g every 6 hours. Long-term magnesium replacement may be given as magnesium oxide tablets (600 mg), one or two per day, or as a combined magnesium and calcium preparation (CalMag, others).

6. Transplantation of cryopreserved parathyroid tissue removed during prior surgery—Transplantation restores normocalcemia in about 23% of cases.

B. Maintenance Treatment

The goal should be to maintain the serum calcium in a slightly low but asymptomatic range (8–8.6 mg/dL). This

Table 26–9. Vitamin D preparations used in the treatment of hypoparathyroidism.

	Available Preparations	Daily Dose	Duration of Action
Ergocalciferol ergosterol, (vitamin D ₂ , Calciferol)	Capsules of 50,000 international units; 8000 international units/mL oral solution	2000–200,000 units	1–2 weeks
Cholecalciferol (vitamin D ₃)	Capsules of 50,000 international units not available commercially in United States; may be compounded	10,000–50,000 units	4–8 weeks
Calcitriol (Rocaltrol)	Capsules of 0.25 and 0.5 mcg; 1 mcg/mL oral solution; 1 mcg/mL for injection	0.25–4 mcg	½–2 weeks

will minimize the hypercalciuria that would otherwise occur and provides a margin of safety against overdosage and hypercalcemia, which may produce permanent damage to kidney function. Patients with mild, asymptomatic hypocalcemia require no therapy. For others, calcium supplementation (1 g/d) is given, along with a vitamin D preparation.

Patients with chronic hypoparathyroidism must usually be treated with some type of vitamin D (Table 26–9). Monitoring of serum calcium at regular intervals (at least every 3 months) is mandatory. **Calcitriol**, a short-acting preparation, is given in doses that range from 0.25 mcg/d to 2.0 mcg orally daily. **Ergocalciferol** (vitamin D₂) is derived from plants and is commercially available. The usual dose ranges from 25,000 to 150,000 units/d. It is a slow-acting preparation that is stored in fat, giving it a long duration of action. If toxicity develops, hypercalcemia—treatable with hydration and prednisone—may persist for weeks after it is discontinued. Despite this risk, ergocalciferol usually produces a more stable serum calcium level than do the shorter-acting preparations.

Teriparatide (Forteo) is a recombinant preparation of human PTH 1–34. Teriparatide is effective in treating patients with hypoparathyroidism when given by subcutaneous injection at an initial dose of 0.4 mcg/kg twice daily. The dose is adjusted to produce normal serum calcium levels. The disadvantages of teriparatide therapy include its extremely high cost and the necessity for injections. Furthermore, teriparatide is not approved by the US Food and Drug Administration (FDA) for this indication because prolonged high doses in rats caused osteosarcoma. Therefore, teriparatide therapy is reserved for patients with severe hypoparathyroidism that fails to respond to vitamin D.

Target serum calcium levels (albumin-corrected) should be 8.0–8.5 mg/dL; these levels are mildly low to avoid hypercalciuria. It is prudent to monitor urine calcium with “spot” urine determinations and keep the level below 30 mg/dL if possible. Hypercalciuria may respond to oral hydrochlorothiazide, usually given with a potassium supplement.

Caution: Phenothiazine drugs should be administered with caution, since they may precipitate extrapyramidal symptoms in hypocalcemic patients. Furosemide should be avoided, since it may worsen hypocalcemia.

► Prognosis

The outlook is good if the diagnosis is made promptly and treatment instituted. Any dental changes, cataracts, and brain calcifications are permanent. Periodic blood chemical evaluation is required, since changes in calcium levels may call for modification of the treatment schedule. Hypercalcemia that develops in patients with seemingly stable, treated hypoparathyroidism may be a presenting sign of Addison disease.

Despite optimal therapy, patients with hypoparathyroidism have been reported to have an overall reduced quality of life. Affected patients have a high risk of having mood and psychiatric disorders along with a reduced overall sense of well-being.

Bosworth M et al. Clinical inquiries: what is the best workup for hypocalcemia? *J Fam Pract.* 2008 Oct;57(10):677–9. [PMID: 18842196]

Khan MI et al. Medical management of postsurgical hypoparathyroidism. *Endocr Pract.* 2010 Dec;6:1–19. [PMID: 21134871]

Milman S et al. Proton pump inhibitor-induced hypocalcemic seizure in a patient with hypoparathyroidism. *Endocr Pract.* 2011 Jan–Feb;17(1):104–7. [PMID: 21041166]

Puig-Domingo M et al. Successful treatment of vitamin D unresponsive hypoparathyroidism with multipulse subcutaneous infusion of teriparatide. *Eur J Endocrinol.* 2008 Nov;159(5):653–7. [PMID: 18703565]

Shoback D. Clinical practice. Hypoparathyroidism. *N Engl J Med.* 2008 Jul;359(4):391–403. [PMID: 18650515]

Sikjaer T et al. PTH treatment in hypoparathyroidism. *Curr Drug Saf.* 2011 Apr;6(2):89–99. [PMID: 21524246]

Wen HY et al. Parathyroid disease. *Rheum Dis Clin North Am.* 2010 Nov;36(4):647–64. [PMID: 21092844]

Winer KK et al. Long-term treatment of 12 children with chronic hypoparathyroidism: a randomized trial comparing synthetic human parathyroid hormone 1–34 versus calcitriol and calcium. *J Clin Endocrinol Metab.* 2010 Jun;95(6):2680–8. [PMID: 20392870]

HYPERPARATHYROIDISM

ESSENTIALS OF DIAGNOSIS

- Frequently detected incidentally by screening.
- Renal calculi, polyuria, hypertension, constipation, fatigue, mental changes.
- Bone pain; rarely, cystic lesions and pathologic fractures.
- Serum and urine calcium elevated; urine phosphate high with low to normal serum phosphate; alkaline phosphatase normal to elevated.
- Elevated PTH.

► General Considerations

Primary hyperparathyroidism is the most common cause of hypercalcemia, with a prevalence of 1–4 cases per 1000 persons. It occurs at all ages but most commonly in the seventh decade and in women (74%). Before age 45, the prevalence is similar in men and women.

The disease is caused by hypersecretion of PTH, usually by a single parathyroid adenoma (80%), and less commonly by hyperplasia by two or more parathyroid glands (20%), or carcinoma ($\leq 1\%$). However, when hyperparathyroidism presents before age 30 years, there is a higher incidence of multiglandular disease (36%) and parathyroid carcinoma (5%). The size of the parathyroid adenoma correlates with the serum PTH level.

Hyperparathyroidism is familial in about 10% of cases. Parathyroid hyperplasia may arise in MEN types 1, 2A, and 2B. In MEN 1, multiglandular hyperparathyroidism is usually the initial manifestation and ultimately occurs in 90% of affected individuals. Hyperparathyroidism in MEN 2A is less frequent than in MEN 1 and is usually

milder. Familial hyperparathyroidism can also occur in the hyperparathyroidism-jaw tumor syndrome, a rare autosomal dominant familial condition in which parathyroid cystic adenomas or carcinomas are associated with ossifying fibromas of the mandible and maxilla as well as renal lesions (cysts, hamartomas, Wilms tumors). Affected individuals usually present with severe hypercalcemia as teenagers or young adults; the pathology is usually a single parathyroid adenoma. (See Table 26–17.)

Hyperparathyroidism results in the excessive excretion of calcium and phosphate by the kidneys. PTH stimulates renal tubular reabsorption of calcium; however, hyperparathyroidism causes hypercalcemia and an increase in calcium in the glomerular filtrate that overwhelms tubular reabsorption capacity, resulting in hypercalciuria. At least 5% of renal calculi are associated with this disease. Diffuse parenchymal calcification (nephrocalcinosis) is seen less commonly. Excessive PTH can cause cortical demineralization that is particularly evident at the wrist and hip; trabecular bone is usually spared as evidenced by relatively higher spinal bone density compared to the wrist. Severe, chronic hyperparathyroidism can cause diffuse demineralization, pathologic fractures, and cystic bone lesions throughout the skeleton, a condition known as **osteitis fibrosa cystica**.

In chronic kidney disease, hyperphosphatemia and decreased renal production of 1,25-dihydroxycholecalciferol ($1,25[\text{OH}]_2\text{D}_3$) initially produce a decrease in ionized calcium. The parathyroid glands are stimulated (secondary hyperparathyroidism) and may enlarge, becoming autonomous (tertiary hyperparathyroidism). The bone disease seen in this setting is known as **renal osteodystrophy**. Parathyroid hyperplasia in uremia can result in extremely high serum PTH levels that are associated with uremic vascular calcification. Hypercalcemia often occurs after kidney transplant.

Parathyroid carcinoma is a rare cause of hyperparathyroidism but is more common in patients with serum calcium levels ≥ 14.0 mcg/dL. About 50% of parathyroid carcinomas are palpable.

► Clinical Findings

A. Symptoms and Signs

In the developed world, hypercalcemia of hyperparathyroidism is typically discovered accidentally by routine chemistry panels. Many patients are asymptomatic or have mild symptoms that may be elicited only upon questioning. Parathyroid adenomas are usually so small and deeply located in the neck that they are almost never palpable; when a mass is palpated, it usually turns out to be an incidental thyroid nodule.

Symptomatic patients are said to have problems with “bones, stones, abdominal groans, psychic moans, with fatigue overtones.” The manifestations are categorized as skeletal, urinary tract, and those associated with hypercalcemia.

1. Skeletal manifestations—Hyperparathyroidism causes a loss of cortical bone and a gain of trabecular bone. Low bone density is typically most prominent at the wrist.


Postmenopausal women are prone to asymptomatic vertebral fractures. Although significant bone demineralization is uncommon in mild hyperparathyroidism, osteitis fibrosa cystica may present as pathologic fractures or as “brown tumors” or cysts of the jaw. More commonly, patients have bone pain and arthralgias.

2. Manifestations of hypercalcemia—Mild hypercalcemia may be asymptomatic. However, hypercalcemia usually causes a variety of manifestations whose severity is not entirely predictable by the level of serum calcium or PTH in patients with hyperparathyroidism. In fact, patients with only mild hypercalcemia can have significant symptoms, particularly depression, constipation, and bone and joint pain. Paresthesias, muscular weakness, and diminished deep tendon reflexes are examples of **neuromuscular manifestations**. **Central nervous system** manifestations include malaise, fatigue, intellectual weariness, depression, increased sleep requirement, progressing to cognitive impairment, disorientation, psychosis, or stupor. **Cardiovascular symptoms** include hypertension, prolonged P-R interval, shortened Q-T interval, sensitivity to arrhythmic effects of digitalis, bradyarrhythmias, heart block, and asystole. **Renal** manifestations include polyuria and polydipsia, caused by hypercalcemia-induced nephrogenic diabetes insipidus. Among all patients with newly discovered hyperparathyroidism, calcium-containing kidney stones have occurred or are detectable in about 18%. Patients with asymptomatic hyperparathyroidism have a 7% incidence of asymptomatic calcium nephrolithiasis, compared to 1.6% incidence in age-matched controls. Gastrointestinal symptoms include anorexia, nausea, vomiting, abdominal pain, weight loss, constipation, and obstipation. Pancreatitis occurs in 3%. **Pruritus** may be present. **Calcium** may precipitate in the corneas (“band keratopathy”). Calcium may also precipitate in extravascular tissues as well as in small arteries, causing small vessel thrombosis and skin necrosis (calciophylaxis).

3. Hyperparathyroidism during pregnancy—About 67% of women with primary hyperparathyroidism during pregnancy experience complications such as nephrolithiasis, hyperemesis, pancreatitis, muscle weakness, cognitive changes, and hypercalcemic crisis. About 80% of fetuses experience complications of maternal hyperparathyroidism, including fetal demise, preterm delivery, low birth weight, postpartum neonatal tetany, and permanent hypoparathyroidism.

B. Laboratory Findings

The hallmark of primary hyperparathyroidism is hypercalcemia, with the serum adjusted total calcium > 10.5 mg/dL (Figure 26–1). The adjusted total calcium = measured serum calcium in mg/dL + $[0.8 \times (4.0 - \text{patient's serum albumin in g/dL})]$. Serum ionized calcium determinations have not proven very helpful clinically, except in hyperproteinemic states (such as hyperalbuminemia, Waldenström macroglobulinemia, myeloma, or thrombocytosis); in such patients with hyperparathyroidism, the serum ionized calcium is usually > 5.4 mg/dL (1.4 mmol/L).



▲ **Figure 26-1.** Parathyroid hormone and calcium nomogram. Relationship between serum intact parathyroid hormone (PTH) and serum calcium levels in patients with hypoparathyroidism, pseudohypoparathyroidism, nonparathyroid hypercalcemia, primary hyperparathyroidism (HPT), and secondary hyperparathyroidism. (Used with permission from GJ Strewler, MD.)

The urine calcium excretion may be high or normal (averaging 250 mg/g creatinine) but it is usually low for the degree of hypercalcemia. The serum phosphate is often low (< 2.5 mg/dL). There is an excessive loss of phosphate in the urine in the presence of hypophosphatemia (25% of cases), whereas in secondary hyperparathyroidism due to kidney disease, the serum phosphate may be high. The alkaline phosphatase is elevated only if bone disease is present. The plasma chloride and uric acid levels may be elevated. Vitamin D deficiency is common in patients with hyperparathyroidism, and it is prudent to screen for vitamin D deficiency with a serum 25-OH vitamin D determination. Low serum 25-OH vitamin D levels (< 20 mcg/L; < 50 nmol/L) can aggravate hyperparathyroidism and its bone manifestations; vitamin D replacement may be helpful in treating such patients with hyperparathyroidism.

Elevated serum levels of intact PTH (IRMA assay) confirm the diagnosis of hyperparathyroidism. Patients with apparent hyperparathyroidism should be screened for familial benign hypocalciuric hypercalcemia with a 24-hour urine for calcium and creatinine. Patients should discontinue thiazide diuretics prior to this test. Calcium excretion of < 50 mg/24 hours (or < 5 mg/dL on a random urine) is not typical for primary hyperparathyroidism and indicates possible familial benign hypocalciuric hypercalcemia.

Patients with low bone density who have an elevated serum PTH but a normal serum calcium must be evaluated for causes of secondary hyperparathyroidism (eg,

vitamin D or calcium deficiency, hyperphosphatemia, renal failure). In the absence of secondary hyperparathyroidism, patients with an elevated serum PTH but normal serum calcium are determined to have normocalcemic hyperparathyroidism. Such individuals require monitoring, since hypercalcemia develops in about 19% of patients over 3 years of follow-up.

C. Imaging

Preoperative sestamibi-iodine subtraction scanning and neck ultrasonography can locate parathyroid adenomas preoperatively in an effort to improve the outcome and limit the invasiveness of neck surgery. Parathyroid imaging is crucial for patients who have had prior neck surgery. However, the usefulness of preoperative parathyroid localizing imaging studies for first neck explorations remains controversial. Preoperative scanning does not improve the outcome of initial bilateral neck explorations performed by a surgeon with special expertise in parathyroid surgery. Therefore, preoperative imaging has been used mainly to improve the outcome for limited neck exploration, with only modest success. (See Surgery.) Imaging is not useful for the diagnosis of hyperparathyroidism, which must be made by serum calcium and PTH determinations. Small benign thyroid nodules are discovered incidentally in nearly 50% of patients with hyperparathyroidism who have imaging with ultrasound or MRI.

CT and MRI scanning of the neck are not ordinarily required or useful for initial preoperative parathyroid localizing studies, since these scanning techniques are less sensitive for identifying tiny parathyroid adenomas. However, for repeat neck operations and when ectopic parathyroid glands are suspected, MRI is preferred since it offers better soft tissue contrast than CT scanning and is less adversely affected by postoperative changes in the neck.

Patients with hyperparathyroidism have a high risk of calcium nephrolithiasis. Therefore, it has been suggested that all patients with hyperparathyroidism have noncontrast-enhanced CT scanning of the kidneys to determine whether calcium-containing stones are present. For patients with apparently asymptomatic hyperparathyroidism, the presence or absence of calcium nephrolithiasis can be a deciding factor about whether to have parathyroidectomy surgery.

Bone density measurements by dual energy x-ray absorptiometry (DXA) are helpful in determining the amount of bone loss in patients with hyperparathyroidism. Bone loss occurs mostly in long bones, and DXA should ideally include three areas: lumbar spine, hip, and distal radius.

Bone radiographs are usually normal and are not required to make the diagnosis of hyperparathyroidism. There may be demineralization, subperiosteal resorption of bone (especially in the radial aspects of the fingers), or loss of the lamina dura of the teeth. There may be cysts throughout the skeleton, mottling of the skull (“salt-and-pepper appearance”), or pathologic fractures. Articular cartilage calcification (chondrocalcinosis) is sometimes found.

Patients with renal osteodystrophy may have ectopic calcifications around joints or in soft tissue. Such patients may exhibit radiographic changes of osteopenia, osteitis fibrosa, or osteosclerosis, alone or in combination. Osteosclerosis of the vertebral bodies is known as “rugger jersey spine.”

► Complications

Pathologic long bone fractures are more common in patients with hyperparathyroidism than in the general population. Urinary tract infection due to stone and obstruction may lead to kidney disease and uremia. If the serum calcium level rises rapidly, clouding of sensorium, kidney disease, and rapid precipitation of calcium throughout the soft tissues may occur. Peptic ulcer and pancreatitis may be intractable before surgery. Insulinomas or gastrinomas may be associated, as well as pituitary tumors (MEN type 1). Pseudogout may complicate hyperparathyroidism both before and after surgical removal of tumors. Hypercalcemia during gestation produces neonatal hypocalcemia.

In tertiary hyperparathyroidism due to chronic kidney disease, high serum calcium and phosphate levels may cause disseminated calcification in the skin, soft tissues, and arteries (calciophylaxis); this can result in painful ischemic necrosis of skin and gangrene, cardiac arrhythmias, and respiratory failure. The actual serum levels of calcium and phosphate have not correlated well with calciophylaxis, but a calcium (mg/dL) \times phosphate (mg/dL) product over 70 is usually present.

► Differential Diagnosis

A. Artifact

A report of hypercalcemia may be due to laboratory error or excess tourniquet time and should always be repeated. Hypercalcemia may be due to high serum protein concentrations; in the presence of very high or low serum albumin concentrations, a serum ionized calcium is more dependable than the total serum calcium concentration. Hypercalcemia may also be seen with dehydration; spurious elevations in serum calcium have been reported with severe hypertriglyceridemia, when the calcium assay uses spectrophotometry.

B. Hypercalcemia of Malignancy

Many malignant tumors (breast, lung, pancreas, uterus, hypernephroma, paraganglioma, etc) can produce hypercalcemia. In some cases (breast carcinoma especially), bony metastases are present. In others, no metastases to bone can be demonstrated. Most of these tumors secrete PTH-related protein (PTHrP), which has tertiary structural homologies to PTH and causes bone resorption and hypercalcemia similar to those of PTH. The clinical features of the hypercalcemia of cancer can closely simulate hyperparathyroidism. Serum phosphate is often low, but the plasma level of PTH is low. Serum PTHrP may be elevated.

Multiple myeloma is a common cause of hypercalcemia in the older population. Many other hematologic cancers, such as monocytic leukemia, T cell leukemia and lymphoma, and Burkitt lymphoma, have also been associated with hypercalcemia. Multiple myeloma causes kidney dysfunction; resultant increased levels of carboxyl terminal PTH may cause it to be confused with hyperparathyroidism if a carboxyl terminal PTH assay is used.

C. Sarcoidosis and Other Granulomatous Disorders

Macrophages and perhaps other cells present in granulomatous tissue have the ability to synthesize $1,25(\text{OH})_2\text{D}_3$. Hypercalcemia has been reported in patients with sarcoidosis, tuberculosis, berylliosis, histoplasmosis, coccidioidomycosis, leprosy, and even foreign-body granuloma. Increased intestinal calcium absorption and hypercalciuria are more common than hypercalcemia. Serum levels of $1,25(\text{OH})_2\text{D}_3$ are elevated. Sarcoid granulomas can also secrete PTHrP.

D. Calcium or Vitamin D Ingestion

Ingestion of large amounts of calcium or vitamin D can cause hypercalcemia, especially in patients who concurrently take thiazide diuretics, which reduce urinary calcium loss. Hypercalcemia is reversible following withdrawal of calcium and vitamin D supplements. If hypercalcemia persists, the possibility of associated hyperparathyroidism should be strongly considered.

In vitamin D intoxication, patients may be taking large amounts of vitamin D for unclear reasons, so a thorough review of all medications is important. Hypercalcemia may persist for several weeks. Serum levels of 25-hydroxycholecalciferol ($25[\text{OH}]\text{D}_3$) are helpful to confirm the

diagnosis. A brief course of corticosteroid therapy may be necessary if hypercalcemia is severe.

E. Familial Benign Hypocalciuric Hypercalcemia

Familial benign hypocalciuric hypercalcemia can be easily mistaken for mild hyperparathyroidism. It is a common autosomal dominant inherited disorder (prevalence: 1 in 16,000) caused by a loss-of-function mutation in the gene encoding the CaSR. CaSRs are found on the surface of the parathyroid glands and allow the parathyroid glands to vary PTH secretion according to serum calcium levels. Reduced function of the CaSR causes the parathyroid glands to falsely “sense” hypocalcemia and inappropriately release slightly excessive amounts of PTH. At the same time, the renal tubule CaSRs are also affected, causing hypocalciuria. Familial benign hypocalciuric hypercalcemia is characterized by hypercalcemia, hypocalciuria (usually < 50 mg/24 h), variable hypermagnesemia, and normal or minimally elevated levels of PTH. These patients do not normalize their hypercalcemia after subtotal parathyroid removal and should not be subjected to surgery. The condition has an excellent prognosis and is easily diagnosed with a family history and urinary calcium clearance determination.

F. Vitamin D Deficiency

Secondary hyperparathyroidism predictably develops in patients with a deficiency in vitamin D. Serum calcium levels are typically in the normal range, but may rise to become borderline elevated with time, due to parathyroid glandular hyperplasia. (See Osteomalacia section.)

G. Adrenal Insufficiency

Hypercalcemia is common in untreated Addison disease. This is partly due to disinhibition of calcium uptake by the renal tubule and gut. Additionally, Addison disease can cause dehydration and hyperproteinemia, resulting in higher levels of nonionized calcium.

H. Immobilization Hypercalcemia

Prolonged immobilization at bed rest commonly causes hypercalcemia, particularly in adolescents, critically ill patients, and patients with extensive Paget disease of bone. Hypercalcemia develops in about one-third of acutely ill patients being treated in intensive care units, particularly patients with acute kidney injury. Serum calcium elevations are typically mild but may reach 15 mg/dL. Serum PTH levels are usually slightly elevated, consistent with mild hyperparathyroidism, but may be suppressed or normal.

I. Other Causes of Hypercalcemia

Other causes of hypercalcemia are shown in Table 21–8. Modest hypercalcemia is occasionally seen in patients taking thiazide diuretics or lithium; such patients may have an inappropriately nonsuppressed PTH level with hypercalcemia. Hypercalcemia occurs frequently in

infants with Williams syndrome. Hyperthyroidism causes increased turnover of bone and occasional hypercalcemia. Bisphosphonates can increase serum calcium in 20% and serum PTH becomes high in 10%, mimicking hyperparathyroidism.

► Treatment

A. Asymptomatic Primary Hyperparathyroidism

Patients with mild asymptomatic hyperparathyroidism may not need therapy. Such patients are advised to keep active, avoid immobilization, and drink adequate fluids. For postmenopausal women with hyperparathyroidism, estrogen replacement therapy reduces serum calcium by an average of 0.75 mg/dL and slightly improves bone density.

Affected patients must avoid thiazide diuretics, large doses of vitamin A, and calcium-containing antacids or supplements. Serum calcium and albumin are checked about twice yearly, kidney function and urine calcium once yearly, and three-site bone density (distal radius, hip, and spine) every 2 years. Rising serum calcium should prompt further evaluation and determination of PTH levels.

B. Surgical Parathyroidectomy

Parathyroidectomy is recommended for patients with symptomatic hyperparathyroidism, kidney stones, bone disease, and pregnancy.

Some patients with seemingly asymptomatic hyperparathyroidism may be surgical candidates for other reasons such as (1) serum calcium 1 mg/dL (0.25 mmol/L) above the upper limit of normal with urine calcium excretion > 50 mg/24 h (off thiazide diuretics), (2) urine calcium excretion over 400 mg/24 h, (3) creatinine clearance < 60 mL/min, (4) cortical bone density (wrist, hip) ≥ 2.5 SD below normal or previous fragility bone fracture, (5) relative youth (under age 50–60 years), (6) difficulty ensuring medical follow-up, or (7) pregnancy. During pregnancy, parathyroidectomy is performed in the second trimester. Surgery for patients with “asymptomatic” hyperparathyroidism may confer modest benefits in social and emotional function, with improvements in anxiety and phobias being reported in comparison to similar patients who are monitored without surgery.

Preoperative parathyroid imaging has been used in an attempt to allow unilateral minimally invasive neck surgery. The reported success rates vary considerably. The usefulness of preoperative parathyroid imaging was evaluated in a series of 350 patients with sporadic primary hyperparathyroidism. A single gland was predicted by sestamibi in 83%, by ultrasound in 85%, and by concordance of both in 59% of patients. Unilateral neck exploration, directed by these studies, resulted in success rate of only 73%, 77%, and 82%, respectively, despite the intraoperative quick PTH assay predicting success. Even in patients with concordant sestamibi and ultrasound scans, and an intraoperative PTH drop of $> 50\%$, at least one additional abnormal parathyroid gland is left behind in the contralateral neck in 15% of patients.

Without preoperative localization studies, bilateral neck exploration is usually advisable for the following:

(1) patients with a family history of hyperparathyroidism, (2) patients with a personal or family history of MEN, and (3) patients wanting an optimal chance of success with a single surgery. Patients undergoing unilateral neck exploration can have the incision widened for bilateral neck exploration if two abnormal glands are found or if the serum quick PTH falls by < 50% within 10 minutes of the parathyroid resection. Parathyroid glands are not uncommonly supernumerary (five or more) or ectopic (eg, intrathyroidal, carotid sheath, mediastinum). The optimal surgical management for patients with MEN type 1 is subtotal parathyroidectomy that usually results in a cure, although recurrent hyperparathyroidism develops in 18% and the rate of postoperative hypoparathyroidism is high.

Parathyroid hyperplasia is commonly seen with secondary or tertiary hyperparathyroidism associated with uremia. Cinacalcet is an alternative to surgery. When surgery is performed, a subtotal parathyroidectomy is optimal; three and one-half glands are usually removed, and a metal clip is left to mark the location of residual parathyroid tissue.

Parathyroid carcinoma can cause severe hypercalcemia associated with very high serum levels of PTH. Preoperative localizing studies usually detect a large invasive tumor. Therapy consists of en bloc resection of the tumor and the ipsilateral thyroid lobe. Metastases to local and to distant sites occur in about 50% of patients. Reoperation for neck recurrence is usually necessary. Adjuvant treatment includes radiation therapy. Cinacalcet is administered initially in doses of 30 mg twice daily and increased as needed up to 90 mg four times daily. Intravenous bisphosphonate (zoledronic acid) is used as needed.

Complications—Serum PTH levels fall below normal in 70% of patients within hours after successful surgery, commonly causing hypocalcemic paresthesias or even tetany. Hypocalcemia tends to occur the evening after surgery or on the next day. Therefore, frequent postoperative monitoring of serum calcium (or serum calcium plus albumin) is advisable beginning the evening after surgery. Once hypercalcemia has resolved, liquid or chewable calcium carbonate is given orally to reduce the likelihood of hypocalcemia. Symptomatic hypocalcemia is treated with larger doses of calcium; calcitriol (0.25–1 mcg daily orally) may be added, with the dosage depending on symptom severity. Magnesium salts are sometimes required postoperatively, since adequate magnesium is required for functional recovery of the remaining suppressed parathyroid glands.

In about 12% of patients having successful parathyroid surgery, PTH levels rise above normal (while serum calcium is normal or low) by 1 week postoperatively. This secondary hyperparathyroidism is probably due to “hungry bones” and is treated with calcium and vitamin D preparations. Such therapy is usually needed only for 3–6 months but is required long-term by some patients.

Hyperthyroidism commonly occurs immediately following parathyroid surgery. It is caused by release of stored thyroid hormone during surgical manipulation of the thyroid. In symptomatic patients, short-term treatment with propranolol may be required for several days.

C. Medical Measures

1. Fluids—Hypercalcemia is treated with a large fluid intake unless contraindicated. Severe hypercalcemia requires hospitalization and intensive hydration with intravenous saline. (See Chapter 21.)

2. Bisphosphonates—Intravenous bisphosphonates are potent inhibitors of bone resorption and can temporarily treat the hypercalcemia of hyperparathyroidism. Pamidronate in doses of 30–90 mg (in 0.9% saline) is administered intravenously over 2–4 hours. Zoledronic acid 2–4 mg is administered intravenously over 15 to 20 minutes. These drugs cause a gradual decline in serum calcium over several days that may last for weeks to months. Such intravenous bisphosphonates are used generally for patients with severe hyperparathyroidism in preparation for surgery. Oral bisphosphonates, such as alendronate, are not effective for treating the hypercalcemia or hypercalciuria of hyperparathyroidism. However, oral alendronate has been shown to improve bone mineral density in the lumbar spine and hip (not distal radius) and may be used for asymptomatic patients with hyperparathyroidism who have a low bone mineral density.

3. Vitamin D and vitamin D analogs—

A. PRIMARY HYPERPARATHYROIDISM—For patients with vitamin D deficiency, careful vitamin D replacement may be beneficial to patients with hyperparathyroidism. Aggravation of hypercalcemia does not ordinarily occur. Serum PTH levels may fall with vitamin D replacement in doses of 800–2000 international units daily. Occasionally, larger doses are required to achieve normal 25-OH vitamin D levels.

B. SECONDARY AND TERTIARY HYPERPARATHYROIDISM ASSOCIATED WITH AZOTEMIA—**Calcitriol**, given orally or intravenously after dialysis, suppresses parathyroid hyperplasia of kidney disease. For patients with normal serum calcium levels, it is given orally in starting doses of 0.25 mcg on alternate days or daily. Calcitriol often causes hypercalcemia, so that serum levels of calcium and phosphate must be monitored to ensure that the serum $\text{Ca}^{2+} \times \text{PO}_4$ product remains ≤ 70 . When that occurs, the dose of calcitriol is decreased or the patient is switched to therapy with vitamin D analogs or cinacalcet.

The vitamin D analogs **paricalcitol** and **doxercalciferol** suppress PTH secretion and cause less hypercalcemia than calcitriol; however, they are very expensive. The doses are adjusted to keep serum PTH levels between 150 pg/mL and 300 pg/mL. **Paricalcitol** (Zemlar) is administered intravenously during dialysis three times weekly in starting doses of 0.04–0.1 mcg/kg to a maximum dose of 0.24 mcg/kg three times weekly. Alternatively, paricalcitol may be administered orally at doses of 1–2 mcg daily for serum PTH levels < 500 pg/mL or 2–4 mcg daily for serum PTH levels > 500 pg/mL. Dialysis patients receiving paricalcitol have improved survival compared with patients receiving calcitriol. **Doxercalciferol** (Hectorol) is administered intravenously three times weekly during hemodialysis to patients with azotemic secondary hyperparathyroidism in starting doses of 4 mcg three times weekly to a maximum dose of 18 mcg three times weekly. Alternatively, doxercalciferol may be administered orally three times weekly at dialysis,

starting with 10 mcg three times weekly at dialysis to a maximum of 60 mcg/wk.

4. Cinacalcet—Cinacalcet hydrochloride is a calcimimetic agent that binds to sites of the parathyroid glands' extracellular CaSRs to increase the glands' affinity for extracellular calcium, thereby decreasing PTH secretion. About 50% of azotemic patients with secondary or tertiary hyperparathyroidism are resistant to vitamin D analogs (see above). Cinacalcet is given orally in starting doses of 30 mg daily to a maximum of 250 mg daily, with dosage adjustments to keep the serum PTH in the range of 150–300 pg/mL. Patients with primary hyperparathyroidism have also been treated successfully with cinacalcet in oral doses of 30–50 mg twice daily, with 73% of patients achieving normocalcemia. Cinacalcet is given to patients with severe hypercalcemia due to parathyroid carcinoma at initial doses of 30 mg orally twice daily and increased progressively to 60 mg twice daily, then 90 mg twice daily to a maximum of 90 mg every 6–8 hours. Cinacalcet is usually well tolerated but may cause nausea and vomiting, which are usually transient. It is very expensive.

5. Other measures—Estrogen replacement, given to postmenopausal women, reduces hypercalcemia slightly. Similarly, raloxifene also reduces the hypercalcemia of hyperparathyroidism, reducing serum calcium levels an average of 0.4 mg/dL. Propranolol may be useful for preventing the adverse cardiac effects of hypercalcemia.

Renal osteodystrophy is caused by secondary or tertiary hyperparathyroidism during kidney disease. It can be prevented or delayed by reducing hyperphosphatemia with phosphate binding medication and dietary phosphate restriction.

► Prognosis

Patients with symptomatic hyperparathyroidism usually experience worsening disease (eg, nephrolithiasis) unless they have treatment. Conversely, the majority of completely asymptomatic patients with mild hypercalcemia (serum calcium <11.0 mg/dL) remain stable with follow-up. However, worsening hypercalcemia, hypercalciuria, and reductions in cortical bone mineral density develop in about one-third of asymptomatic patients. Therefore, asymptomatic patients must be monitored carefully and treated with oral hydration and mobilization.

Surgical removal of apparently single sporadic parathyroid adenomas is successful in 94%. Patients with MEN 1 undergoing subtotal parathyroidectomy may experience long remissions, but hyperparathyroidism frequently recurs. Despite treatment for hyperparathyroidism, patients remain at increased risk for all-cause mortality, cardiovascular disease, kidney stones, and renal failure. These increased risks are likely the residuals of pretreatment hypertension and nephrolithiasis.

Spontaneous cure due to necrosis of the tumor has been reported but is exceedingly rare. The bones, in spite of severe cyst formation, deformity, and fracture, will heal if a parathyroid tumor is successfully removed. The presence of pancreatitis increases the mortality rate. Acute pancreatitis usually resolves with correction of hypercalcemia,

whereas subacute or chronic pancreatitis tends to persist. Significant renal damage may progress even after removal of an adenoma.

Parathyroid carcinoma tends to invade local structures and may sometimes metastasize; repeat surgical resections and radiation therapy can prolong life. Aggressive surgical and medical management of parathyroid carcinoma can result in a median overall survival of 14.3 years (range 10.5–25.7 years) from the date of diagnosis. Factors associated with a worsened mortality rate include lymph node or distant metastases, high number of recurrences, and higher serum calcium levels at recurrence.

- Bargren AE et al. Can biochemical abnormalities predict symptomatology in patients with primary hyperparathyroidism? *J Am Coll Surg.* 2011 Sep;213(3):410–4. [PMID: 21723154]
- Duntas LH et al. Cinacalcet as alternative treatment of primary hyperparathyroidism: achievements and prospects. *Endocrine.* 2011 Jun;39(3):199–204. [PMID: 21442382]
- Harari A et al. Parathyroid carcinoma: a 43-year outcome and survival analysis. *J Clin Endocrinol Metab.* 2011 Dec;96(12):3679–86. [PMID: 21937626]
- Marcocci C et al. Clinical practice. Primary hyperparathyroidism. *N Engl J Med.* 2011 Dec 22;365(25):2389–97. [PMID: 22187986]
- McVeigh T et al. Changing practices in the surgical management of hyperparathyroidism. *Surgeon.* 2011 Nov 19. [Epub ahead of print] [PMID: 22105046]
- Morris GS et al. Parathyroidectomy improves functional capacity in “asymptomatic” older patients with primary hyperparathyroidism: a randomized control trial. *Ann Surg.* 2010 May;251(5):832–7. [PMID: 20395857]
- Rejzmark L et al. Nephrolithiasis and renal calcifications in primary hyperparathyroidism. *J Clin Endocrinol Metab.* 2011 Aug;96(8):2377–85. [PMID: 21646371]
- Sprague SM et al. Control of secondary hyperparathyroidism by vitamin D receptor agonists in chronic kidney disease. *Clin J Am Soc Nephrol.* 2010 Mar;5(3):512–8. [PMID: 20133492]
- Vestergaard P et al. Medical treatment of primary, secondary, and tertiary hyperparathyroidism. *Curr Drug Saf.* 2011 Apr;6(2):108–13. [PMID: 21524244]

METABOLIC BONE DISEASE

The term “metabolic bone disease” denotes those conditions producing diffusely decreased bone density and diminished bone strength. It is categorized by histologic appearance: osteoporosis (bone matrix and mineral both decreased) and osteomalacia (bone matrix intact, mineral decreased). Osteoporosis and osteomalacia often coexist in the same patient.

OSTEOPOROSIS



ESSENTIALS OF DIAGNOSIS

- Fracture propensity of spine, hip, pelvis, and wrist from demineralization.
- Serum PTH, calcium, phosphorus, and alkaline phosphatase usually normal.
- Serum 25-hydroxyvitamin D levels often low as a comorbid condition.

► General Considerations

Osteoporosis is a skeletal disorder characterized by a loss of bone osteoid that reduces bone integrity, resulting in an increased risk of fractures. In the United States, osteoporosis causes about 2 million fractures annually, including 547,000 vertebral fractures, 300,000 hip fractures, and 135,000 pelvic fractures. White women have a 40% lifetime risk of sustaining one or more osteoporotic fractures. The morbidity and indirect mortality rates are very high. The rate of bone formation is often normal, whereas the rate of bone resorption is increased.

Osteoporosis can be caused by a variety of factors, which are listed in Table 26–10. The most common causes are aging; high-dose corticosteroid administration; alcoholism; and sex hormone deficiency, particularly menopause in women.

Osteogenesis imperfecta is caused by a major mutation in the gene encoding for type I collagen, the major collagen constituent of bone. This causes severe osteoporosis; spontaneous fractures occur in utero or during childhood. Blue sclerae may be present. Certain polymorphisms in the genes encoding type I collagen are common, particularly in whites, resulting in collagen disarray and predisposing to hypogonadal (eg, menopausal) or idiopathic osteoporosis.

► Clinical Findings

A. Symptoms and Signs

Osteoporosis is usually asymptomatic until fractures occur. It may present as backache of varying degrees of severity or as a spontaneous fracture or collapse of a vertebra. Loss of height is common. Once osteoporosis is identified, a

carefully directed history and physical examination must be performed to determine its cause (Table 26–10).

B. Laboratory Findings

Serum calcium, phosphate, and PTH are normal. The alkaline phosphatase is usually normal but may be slightly elevated, especially following a fracture. Vitamin D deficiency is very common and serum determination of 25-hydroxyvitamin D should be obtained for every individual with low bone density. Serum 25-hydroxyvitamin D levels below 20 ng/mL are considered frank vitamin D deficiency. Lesser degrees of vitamin D deficiency (serum 25-hydroxyvitamin D levels between 20 ng/mL and 30 ng/mL) may also increase the risk for hip fracture. (See Osteomalacia, below.) Testing for thyrotoxicosis and hypogonadism may be required. Celiac disease may be screened for with serum immunoglobulin A (IgA) endomysial antibody and tissue transglutaminase antibody determinations.

C. Bone Densitometry

DXA is used to determine the bone density of the lumbar spine and hip. Bone densitometry should be performed on all patients who are at risk for osteoporosis or osteomalacia or have pathologic fractures or radiographic evidence of diminished bone density. This test delivers negligible radiation, and the measurements are quite accurate. However, bone densitometry cannot distinguish osteoporosis from osteomalacia; in fact, both are often present. Also, the bone mineral density does not directly measure bone quality and is only fairly successful at predicting fractures. Vertebral bone mineral density may be misleadingly high in compressed vertebrae and in patients with extensive arthritis. DXA also overestimates the bone mineral density of taller persons and underestimates the bone mineral density of smaller persons. Quantitative CT delivers more radiation but is more accurate in the latter situations.

Bone mineral density is typically expressed in g/cm^2 , for which there are different normal ranges for each bone and for each type of DXA-measuring machine. The “T score” is a simplified way of reporting bone density in which the patient’s bone mineral density is compared to the young normal mean and expressed as a standard deviation score. The World Health Organization has established criteria for defining osteoporosis in postmenopausal white women, based on T score:

T score ≥ -1.0 : Normal.

T score -1.0 to -2.5 : Osteopenia (“low bone density”).

T score < -2.5 : Osteoporosis.

T score < -2.5 with a fracture: Severe osteoporosis.

This classification is somewhat arbitrary and there really is no bone mineral density fracture threshold; instead, the fracture risk increases about twofold for each standard deviation drop in bone mineral density. In fact, most women with fragility fractures have bone densities above -2.5 . Surveillance DXA bone densitometry is recommended for postmenopausal women with a frequency according to their T scores: obtain DXA every 5 years for

Table 26–10. Causes of osteoporosis.¹

Hormone deficiency	Genetic disorders
Estrogen (women)	Aromatase deficiency
Androgen (men)	Type I collagen mutations
Hormone excess	Osteogenesis imperfecta
Cushing syndrome or corticosteroid administration	Idiopathic juvenile and adult osteoporosis
Thyrotoxicosis	Ehlers-Danlos syndrome
Hyperparathyroidism	Marfan syndrome
Immobilization and microgravity	Homocystinuria
Tobacco	Miscellaneous
Alcoholism	Celiac disease
Malignancy, especially multiple myeloma	Anorexia nervosa
Medications	Hyponatremia (chronic)
Excessive vitamin D intake	Protein-calorie malnutrition
Excessive vitamin A intake	Vitamin C deficiency
Heparin therapy	Copper deficiency
Selective serotonin reuptake inhibitors	Liver disease
Rosiglitazone	Rheumatoid arthritis
	Uncontrolled diabetes mellitus
	Systemic mastocytosis

¹See Table 26–11 for causes of osteomalacia.

T scores -1.0 to -1.5 , every 3–5 years for scores -1.5 to -2.0 , and every 1–2 years for scores under -2.0 .

The “Z score” is used to express bone density in premenopausal women, younger men, and children. The Z score is a statistical term that is used for expressing an individual’s bone density as standard deviation from age-matched, race-matched, and sex-matched means.

► Differential Diagnosis

Osteopenia and fractures can be caused by osteomalacia (see below) and bone marrow neoplasia such as myeloma or metastatic bone disease. These conditions coexist in many patients.

► Treatment

A. General Measures

For prevention and treatment of osteoporosis, the diet should be adequate in protein, total calories, calcium, and vitamin D. Pharmacologic corticosteroid doses should be reduced or discontinued if possible. Thiazides may be useful if hypercalciuria is present. High-impact physical activity (eg, jogging) significantly increases bone density in men and women. Stair-climbing increases bone density in women. Patients who cannot exercise vigorously should be encouraged to engage in other exercise regularly, thereby increasing strength and reducing the risk of falling. Weight training is helpful to increase muscle strength as well as bone density. Measures should be taken to avoid falls at home (eg, adequate lighting, handrails on stairs, handholds in bathrooms). Patients who have weakness or balance problems must use a cane or a walker; rolling walkers should have a brake mechanism. Balance exercises can reduce the risk of falls. Patients should be kept active; bedridden patients should be given active or passive exercises. The spine may be adequately supported (though braces or corsets are usually not well tolerated), but rigid or excessive immobilization must be avoided. Alcohol and smoking should be avoided.

B. Specific Measures

Several treatment options are available, so a regimen is tailored to each patient. Generally, treatment is indicated for all women with osteoporosis (T scores below -2.5) and for all patients who have had fragility fractures. Prophylactic treatment should also be considered for patients with advanced osteopenia (T scores between -2.0 and -2.5).

1. Vitamin D and calcium—Osteoporosis and osteomalacia often coexist (see Osteomalacia section). Sun exposure and vitamin D supplementation are useful in preventing and treating osteomalacia but not osteoporosis. Vitamin D supplementation reduces the incidence of vertebral fractures by 37% and may slightly reduce the incidence of nonvertebral fractures. Oral vitamin D is given in doses of 800–2000 international units daily. Vitamin D supplementation is especially required during winter months and for patients having prolonged hospitalization or nursing home care, for patients with serum levels of 25-hydroxyvitamin D below 20 ng/mL, and those with intestinal malabsorption.

Calcium supplementation does not reduce the fracture risk in otherwise healthy postmenopausal women. One meta-analysis concluded that calcium supplementation is associated with a 27% increased risk of myocardial infarction; however, methodologic shortcomings in that study have raised doubts about its validity. Conversely, the Women’s Health Initiative found that myocardial infarction rates were not significantly higher among postmenopausal women taking calcium. Calcium supplements may increase the risk of calcium-containing kidney stones, unless taken with meals. Some patients experience gastrointestinal upset with calcium supplements. Therefore, calcium supplementation should probably be given only to those patients whose diets are low in calcium. More important is the assurance of adequate vitamin D through sun exposure or oral vitamin D supplementation. If calcium supplementation is given, it should include vitamin D. Calcium supplementation may be given as calcium citrate (0.4–0.7 g elemental calcium per day) or calcium carbonate (1–1.5 g elemental calcium per day).

2. Bisphosphonates—Bisphosphonates all work similarly, inhibiting osteoclast-induced bone resorption. They increase bone density significantly and reduce the incidence of both vertebral and nonvertebral fractures. Bisphosphonates have also been effective in preventing corticosteroid-induced osteoporosis. To ensure intestinal absorption, oral bisphosphonates must be taken in the morning with at least 8 oz of plain water at least 40 minutes before consumption of anything else. The patient must remain upright after taking bisphosphonates to reduce the risk of esophagitis. These medications are excreted in the urine. However, no dosage adjustments are required for patients with creatinine clearances above 35 mL/min. There has been little experience giving bisphosphonates to patients with severe kidney disease; if given, the dose would need to be greatly reduced and serum phosphate levels monitored.

Bisphosphonates may be given orally once monthly or weekly. Available oral preparations include **alendronate**, 70 mg orally once weekly (tablet or solution), and **risedronate**, 35 mg orally once weekly. Both these medications reduce the risk of both vertebral and nonvertebral fractures. Studies sponsored by the manufacturer of alendronate found that alendronate was significantly more potent than risedronate and equally well tolerated. Another bisphosphonate, **ibandronate sodium**, is taken once monthly in a dose of 150 mg orally. Once-monthly ibandronate is convenient and reduces the risk of vertebral fractures but not nonvertebral fractures; its effectiveness has not been directly compared with other bisphosphonates. Oral bisphosphonates can cause nausea, chest pain, and hoarseness. Erosive esophagus can occur, particularly in patients with hiatal hernia and gastroesophageal reflux.

For patients who cannot tolerate oral bisphosphonates or for whom oral bisphosphonates are contraindicated, intravenous bisphosphonates are available. **Zoledronic acid** is a third-generation bisphosphonate and a potent osteoclast inhibitor. It can be given every 12 months in doses of 2–4 mg intravenously over at least 15–30 minutes. **Pamidronate** can be given in doses of 30–60 mg by

slow intravenous infusion in normal saline solution every 3–6 months.

Bisphosphonate therapy can cause several side effects that are collectively known as the **acute-phase response**. Such a response occurs in 42% of patients following the first infusion of zoledronic acid and usually starts within the first few days following the infusion. Among patients receiving their first infusion of zoledronic acid, these adverse side effects have included fever, chills, or flushing (20%); musculoskeletal pain (20%); nausea, vomiting, or diarrhea (8%); nonspecific symptoms, such as fatigue, dyspnea, edema, headache, or dizziness (22%); and eye inflammation (0.6%). The acute-phase response is most commonly seen after the first dose of bisphosphonate (particularly zoledronic acid) and tends to diminish with time. Symptoms are transient, lasting several days and usually resolving spontaneously but typically recurring with subsequent doses. For patients experiencing a severe acute-phase response with zoledronic acid, intravenous pamidronate can substitute for zoledronic acid for subsequent treatment. Additionally, patients who experience an especially severe acute-phase response can be given prophylactic corticosteroids and ondansetron prior to subsequent bisphosphonate infusions.

Osteonecrosis of the jaw is a rare complication of bisphosphonate therapy for osteoporosis. A painful, necrotic, nonhealing lesion of the jaw occurs, particularly after tooth extraction. About 95% of jaw osteonecrosis cases have occurred with high-dose therapy with zoledronic acid or pamidronate for patients with myeloma or solid tumor osteolytic metastases. Only about 5% of cases have occurred in patients receiving oral (or, less frequently, intravenous) bisphosphonate doses for osteoporosis. The incidence of osteonecrosis is estimated to be about 1:100,000 patients treated for osteoporosis and 1:100 patients being treated for cancer. In a prospective 3-year trial of 7714 women who received intravenous zoledronic acid 5 mg/year, there were no cases of osteonecrosis. For patients with painful osteonecrotic exposed bone, treatment is 90% effective (without resolution of the exposed bone) using antibiotics along with 0.12% chlorhexidine antiseptic mouthwash. Patients receiving bisphosphonates must receive regular dental care and try to avoid dental extraction.

Atypical “chalkstick” fractures of the femur occur rarely in patients taking bisphosphonates. Bisphosphonate use for more than 5 years is associated with 2.7-fold risk in subtrochanteric or shaft fractures; but the absolute risk is low at about 1 fracture per 1000 bisphosphonate users yearly. In one study, atypical femoral fractures developed in 4 of 327 patients after receiving at least 24 intravenous bisphosphonate infusions for bone metastases. Atypical fractures are subtrochanteric or diaphyseal, occur with little trauma, and are usually transverse as opposed to the more typical comminuted or spiral femoral shaft fractures. Bilateral femoral fractures occur in 27%. About 70% of affected patients have had prodromal thigh pain prior to the fracture. The risk for atypical femoral fractures is particularly increased among patients concurrently taking high-dose corticosteroids and those receiving treatment for more than 5 years. Teriparatide may be helpful to promote

healing of such fractures. Despite this rare complication, the overall risk of hip fracture is reduced among patients taking bisphosphonates for up to 5 years.

Patients taking oral bisphosphonates have an increased risk of developing esophageal cancer. In North America and Europe, the incidence of esophageal cancer at age 60–79 is about 1 per 1000 population over 5 years; this risk is estimated to increase to about 2 per 1000 with administration of oral bisphosphonates for 5 years or longer.

In patients taking bisphosphonates, hypercalcemia is seen in 20% and serum PTH levels increase above normal in 10%, mimicking primary hyperparathyroidism. Hypocalcemia occurs frequently, resulting in secondary hyperparathyroidism.

The half-life of alendronate in bone is 10 years. Therefore, bisphosphonates may be discontinued after a 5-year course of therapy. Repeat bone densitometry may be obtained after 3 years of bisphosphonate therapy. Bone density falls in 18% of patients during their first year of treatment with bisphosphonates, but 80% of such patients have gain in bone density with continued bisphosphonate treatment.

3. Sex hormones—Hypogonadal women who take estrogen replacement therapy (ERT) have a lower risk of developing osteoporosis. Postmenopausal estrogen replacement is valuable as an osteoporosis prevention measure and this should be one factor in the complex decision about whether to take ERT. Low doses of estrogen appear to be adequate to prevent postmenopausal osteoporosis (see Estrogen Replacement Therapy). Once osteoporosis has developed, estrogen replacement is not an effective treatment. Men with hypogonadism may be treated with testosterone (see Male Hypogonadism).

4. Selective estrogen receptor modulators—Raloxifene, 60 mg/d orally, can be used by postmenopausal women in place of estrogen for prevention of osteoporosis. Bone density increases about 1% over 2 years in postmenopausal women versus 2% increases with estrogen replacement. It reduces the risk of vertebral fractures by about 40% but does not appear to reduce the risk of nonvertebral fractures. Raloxifene produces a reduction in LDL cholesterol but not the rise in high-density lipoprotein (HDL) cholesterol seen with estrogen. It has no direct effect on coronary plaque. Unlike estrogen, raloxifene does not reduce hot flashes; in fact, it often intensifies them. It does not relieve vaginal dryness. Unlike estrogen, raloxifene does not cause endometrial hyperplasia, uterine bleeding, or cancer, nor does it cause breast soreness. The risk of breast cancer is reduced 76% in women taking raloxifene for 3 years. Since it is a potential teratogen, it is relatively contraindicated in women capable of pregnancy.

Raloxifene increases the risk for thromboembolism and should not be used by women with such a history. Leg cramps can also occur.

5. Teriparatide—Teriparatide (Forteo, Parathar) is an analog of PTH. Teriparatide stimulates the production of new collagenous bone matrix that must be mineralized. Patients receiving teriparatide must have sufficient intake of vitamin D and calcium. When administered to patients

with osteoporosis in doses of 20 mcg/d subcutaneously for 2 years, teriparatide dramatically improves bone density in most bones except the distal radius. Teriparatide may also be used to promote healing of atypical femoral chalkstick fractures associated with bisphosphonate therapy. The recommended dose should not be exceeded, since teriparatide has caused osteosarcoma in rats when administered in very high doses. Patients with Paget disease of bone or patients with open epiphyses or hypercalcemia should not use the drug. Patients with a past history of osteosarcoma or chondrosarcoma should not use this medication. Side effects may include dizziness and leg cramps. Teriparatide is approved only for a 2-year course of treatment.

Teriparatide should be used with caution in patients if they are also taking corticosteroids and thiazide diuretics along with oral calcium supplementation because hypercalcemia may develop.

Following a course of teriparatide, a course of bisphosphonates should be considered in order to retain the improved bone density.

6. Calcitonin—A nasal spray of calcitonin-salmon (Miacalcin) is available that contains 2200 units/mL in 2-mL metered-dose bottles. The usual dose is one puff (0.09 mL, 200 international units) once daily, alternating nostrils. Nasal administration causes significantly less nausea and flushing than the parenteral route. However, nasal symptoms such as rhinitis and epistaxis occur commonly; other less common adverse reactions include flu-like symptoms, allergy, arthralgias, back pain, and headache. Five years of therapy increases bone 2–3% and reduces the number of new vertebral fractures. Both nasal and parenteral calcitonin have analgesic effects on bone pain from fractures; reduction of pain may be noted within 2–4 weeks after commencing therapy. Calcitonin reduces the incidence of vertebral fractures, but its effect upon nonvertebral fractures has not been established.

7. Denosumab—This is a monoclonal antibody that inhibits the proliferation and maturation of preosteoclasts into mature osteoclast bone-resorbing cells. It does this by binding to the osteoclast receptor activator of nuclear factor- κ B ligand (RANKL). Denosumab is administered in doses of 60 mg subcutaneously every 6 months. It increases bone mineral density more than oral alendronate. It has been relatively well tolerated, with an 8% incidence of flu-like symptoms. It can decrease serum calcium and should not be administered to patients with hypocalcemia. Other side effects include the development of eczema and dermatitis, serious infections, new malignancies, and pancreatitis. Its efficacy is comparable to bisphosphonates. However, its long-term safety remains unknown, so it is reserved for patients with severe osteoporosis who have not tolerated or not responded to bisphosphonates. It is extremely expensive.

► Prognosis

Bone mineral density densitometries can detect whether progressive osteopenia or frank osteoporosis is developing. Hypogonadal women, especially those not receiving HRT, must ensure sufficient intake of vitamin D to prevent

osteomalacia. Bisphosphonates and raloxifene can reverse progressive osteopenia and osteoporosis and decrease fracture risk.

Hypogonadal men are also at risk for developing osteoporosis. Testosterone administration can prevent osteoporosis. Men with prostate cancer may not receive testosterone replacement and should be monitored with bone densitometries. Bisphosphonate therapy can reverse progressive osteopenia and osteoporosis in men.

- Bolland MJ et al. Effect of calcium supplements on risk of myocardial infarctions and cardiovascular events: metaanalysis. *BMJ*. 2010 Jul;341:c3691. [PMID: 20671013]
- Cauley JA et al. Once-yearly zoledronic acid and days of disability, bed rest and back pain: randomised controlled HORIZON pivotal fracture trial. *J Bone Miner Res*. 2011 May;26(5):984–92. [PMID: 21089141]
- Charopoulos I et al. The role and efficacy of denosumab in the treatment of osteoporosis: an update. *Expert Opin Drug Saf*. 2011 Mar;10(2):205–17. [PMID: 21208140]
- Hollick RJ et al. Role of bisphosphonates in the management of postmenopausal osteoporosis: an update on recent safety anxieties. *Menopause Int*. 2011 Jun;17(2):66–72. [PMID: 21693503]
- Howe TE et al. Exercise for preventing and treating osteoporosis in postmenopausal women. *Cochrane Database Syst Rev*. 2011 Jul 6;(7):CD000333. [PMID: 21735380]
- Mazziotti G et al. Drug-induced osteoporosis: mechanisms and clinical implications. *Am J Med*. 2010 Oct;123(10):877–84. [PMID: 20920685]
- Moen MD et al. Denosumab: a review of its use in the treatment of postmenopausal osteoporosis. *Drugs Aging*. 2011 Jan;28(1):63–82. [PMID: 21174488]
- Puhaindran ME et al. Atypical subtrochanteric femoral fractures in patients with skeletal malignant involvement treated with intravenous bisphosphonates. *J Bone Joint Surg Am*. 2011 Jul 6;93(13):1235–42. [PMID: 21776577]
- Ryan CS et al. Osteoporosis in men: the value of laboratory testing. *Osteoporos Int*. 2011 June;22(6):1845–53. [PMID: 20936403]

OSTEOMALACIA



ESSENTIALS OF DIAGNOSIS

- ▶ Painful proximal muscle weakness (especially pelvic girdle); bone pain and tenderness.
- ▶ Decreased bone density from defective mineralization.
- ▶ Laboratory abnormalities may include increased alkaline phosphatase, decreased 25-hydroxyvitamin D, hypocalcemia, hypocalciuria, hypophosphatemia, secondary hyperparathyroidism.
- ▶ Classic radiologic features may be present.

► General Considerations

Defective mineralization of the growing skeleton in childhood causes permanent bone deformities (rickets). Defective skeletal mineralization in adults is known as osteomalacia. It is caused by any condition that results in

inadequate calcium or phosphate mineralization of bone osteoid.

► Etiology (Table 26–11)

A. Vitamin D Deficiency and Resistance

Vitamin D is predominantly synthesized in the skin during exposure to ultraviolet B light. Vitamin D is also consumed in the diet from plants (ergocalciferol, D₂) or animals/fish (cholecalciferol, D₃). Both forms of vitamin D are converted in the liver to 25-hydroxyvitamin D (25OHD); 25OHD is subsequently converted in various tissues (mainly kidney) to 1,25-dihydroxyvitamin D (1,25[OH]₂D), the active hormone whose production is regulated by serum calcium, phosphorus, and PTH. 1,25(OH)₂D binds to cytoplasmic vitamin D receptors, increasing the absorption of dietary calcium from the intestine and increasing the reabsorption of calcium in the renal tubule, thereby reducing calcium loss in the urine. 1,25(OH)₂D also stimulates bone osteoblasts to release RANKL that stimulates osteoclasts, which release calcium from bone.

Unexpectedly, vitamin D receptors have been found in most tissues in the body (eg, brain, heart, breast, prostate) that have nothing to do with calcium homeostasis. The function of these vitamin D receptors is unknown. Much of the recent interest in vitamin D has been sparked by

epidemiology studies relating an increased prevalence of cancer, diabetes mellitus, cardiovascular disease, and multiple sclerosis to lower serum levels of 25OHD. Such association studies suffer from the fact that healthy individuals have more sun exposure and a better diet, such that low serum 25OHD levels may be the result of the disease rather than the cause of it.

Vitamin D deficiency is the most common cause of osteomalacia and its incidence is increasing throughout the world as a result of diminished exposure to sunlight caused by urbanization, automobile and public transportation, modest clothing, and sunscreen use. Significant vitamin D deficiency (serum 25OHD < 50 nmol/L or < 20 ng/mL) was found in 24.3% of postmenopausal women from 25 countries in the Multiple Outcomes of Raloxifene Evaluation (MORE) study. The incidence varied: < 1% in Southeast Asia, 29% in the United States, and 36% in Italy. Severe vitamin D deficiency (serum 25OHD < 25 nmol/L or < 10 ng/mL) was found in 4% of these women; 3.5% in the United States and 12.5% in Italy. Among US men over age 65 years, 25% have serum 25OHD levels below 20 ng/mL; men over age 75 with such low vitamin D levels have particularly accelerated bone loss. Vitamin D deficiency is particularly common in the institutionalized elderly, with the incidence exceeding 60% in some groups not receiving vitamin D supplementation. Deficiency of vitamin D may arise from insufficient sun exposure, malnutrition, or malabsorption (due to pancreatic insufficiency, cholestatic liver disease, sprue, inflammatory bowel disease, jejunoileal bypass, Billroth type II gastrectomy). Orlistat is a weight-loss medication that causes fat malabsorption and reduced serum 25OHD levels. Cholestyramine binds bile acids necessary for vitamin D absorption. Patients with severe nephrotic syndrome lose large amounts of vitamin D-binding protein in the urine, and osteomalacia may also develop.

Anticonvulsants (eg, phenytoin, carbamazepine, valproate, phenobarbital) inhibit the hepatic production of 25OHD and sometimes cause osteomalacia. Phenytoin can also directly inhibit bone mineralization. Serum levels of 1,25(OH)₂D are usually normal.

Vitamin D–dependent rickets type I is caused by a rare autosomal recessive disorder with a defect in the renal enzyme 1- α -hydroxylase leading to defective synthesis of 1,25(OH)₂D. It presents in childhood with rickets and alopecia; osteomalacia develops in adults with this condition unless treated with oral calcitriol in doses of 0.5–1 mcg daily.

Vitamin D–dependent rickets type II (better known as hereditary 1,25(OH)₂D-resistant rickets) is caused by a genetic defect in the 1,25(OH)₂D receptor. Patients have hypocalcemia with childhood rickets and adult osteomalacia. Alopecia is common. These patients respond variably to oral calcitriol in very large doses (2–6 mcg daily).

Table 26–11. Causes of osteomalacia.¹

Vitamin disorders
Decreased availability of vitamin D
Insufficient sunlight exposure
Nutritional deficiency of vitamin D
Malabsorption; aging, excess wheat bran, bariatric surgery, pancreatic enzyme deficiency
Nephrotic syndrome
Vitamin D–dependent rickets type I
Liver disease
Chronic kidney disease
Kidney transplantation
Phenytoin, carbamazepine, valproate, or barbiturate therapy
Dietary calcium deficiency
Phosphate deficiency
Decreased intestinal absorption
Nutritional deficiency of phosphorus
Phosphate-binding antacid therapy
Increased renal loss
X-linked hypophosphatemic rickets
Tumoral hypophosphatemic osteomalacia
Association with other disorders, including paraproteinemias, glycogen storage diseases, neurofibromatosis, Wilson disease, Fanconi syndrome, renal tubular acidosis, and alcoholism
Inhibitors of mineralization
Aluminum
Bisphosphonates
Disorders of bone matrix
Hypophosphatasia
Fibrogenesis imperfecta
Axial osteomalacia

¹See Table 26–10 for causes of osteoporosis.

B. Deficient Calcium Intake

Rickets and osteomalacia continue to be common problems in many tropical countries despite adequate exposure to sunlight. A nutritional deficiency of calcium can occur in any severely malnourished patient. Some degree of calcium deficiency is common in the elderly, since intestinal

calcium absorption declines with age. Ingestion of excessive wheat bran also causes calcium malabsorption.

C. Phosphate Deficiency

Clinical symptoms of phosphate deficiency include severe muscle weakness and bone pain. Phosphate deficiency in childhood causes classic rickets, whereas phosphate deficiency in adulthood causes osteomalacia.

1. Genetic disorders—Fibroblast growth factor-23 (FGF23) is a phosphaturic factor (phosphatonin) that is secreted by bone osteoblasts in response to elevated serum phosphate levels. Families with autosomal dominant hypophosphatemic rickets have a gain-of-function mutation in the gene encoding FGF23 that makes it resistant to proteolytic cleavage, thereby increasing serum FGF23 levels. In X-linked hypophosphatemic rickets, there is a mutation in the gene encoding PHEX endopeptidase, which fails to cleave FGF23, resulting in elevated serum FGF23 levels. An autosomal recessive form of hypophosphatemic rickets is caused by mutations in *DMPI1*, a transcription factor that regulates FGF23 production in bone. All three conditions have high serum FGF23 levels causing hypophosphatemia and bone mineral depletion.

Sodium-phosphate cotransporters (NPT2a or NPT2c) reabsorb phosphate from the proximal renal tubule. Mutations in the genes encoding them or in *NHERF1* cause hypophosphatemia, bone mineral depletion, and calcium-phosphate kidney stones.

2. Tumor-induced osteomalacia—A variety of mesenchymal tumors (87% benign) secrete fibroblast growth factor-23 (FGF23, see above) and cause marked hypophosphatemia due to renal phosphate wasting. Such tumors are usually small and are often difficult to locate. The condition is characterized by hypophosphatemia, excessive phosphaturia, reduced or normal serum $1,25(\text{OH})_2\text{D}$ concentrations, and osteomalacia. Serum levels of FGF23 are elevated. Such tumors are often small and difficult to find, frequently lying in extremities. Imaging with ^{111}In -octreotide or ^{18}F FDG-PET should include the entire body and may be helpful in localizing these tumors.

3. Other causes of hypophosphatemia—Osteomalacia from hypophosphatemia can be caused by poor nutrition, and severe hypophosphatemia can occur with refeeding after starvation. Other causes of hypophosphatemic osteomalacia include alcoholism and chelation of phosphate in the gut by aluminum hydroxide antacids, calcium acetate (Phos-Lo), or sevelamer hydrochloride (Renagel). Excessive renal phosphate losses are also seen in proximal renal tubular acidosis and Fanconi syndrome.

D. Aluminum Toxicity

Bone mineralization is inhibited by aluminum. Osteomalacia may occur in patients receiving long-term renal hemodialysis with tap water dialysate or from aluminum-containing antacids used to reduce phosphate levels. Osteomalacia may develop in patients being maintained on long-term total parenteral nutrition if the casein hydrolysate used for amino acids contains high levels of aluminum.

E. Hypophosphatasia

Hypophosphatasia, a deficiency of bone alkaline phosphatase effect, is a rare genetic cause of osteomalacia that is commonly misdiagnosed as osteoporosis. The incidence in the United States is about 1 in 100,000 live births; about 1 in 300 adults is a carrier. Many different mutations in the gene (designated *ALPL*) encoding bone alkaline phosphatase have been described, and transmission can be either autosomal recessive or autosomal dominant. The phenotypic presentation of hypophosphatasia is extremely variable. At its worst extreme, it can present as a stillborn without dentition or calcified bones. At its mildest, hypophosphatasia can present in middle age with premature loss of teeth, foot pain (due to metatarsal stress fractures), thigh pain (due to femoral pseudofractures), or arthritis (due to chondrocalcinosis). Serum alkaline phosphatase (collected in a non-EDTA tube) is low for age in patients with hypophosphatasia. To confirm the diagnosis, a 24-hour urine should be assayed for phosphoethanolamine, a substrate for tissue-nonspecific alkaline phosphatase, whose excretion is always elevated in patients with hypophosphatasia. Prenatal genetic testing, by way of chorionic villus biopsy, is available for the infantile form of hypophosphatasia. There is no proven therapy for hypophosphatasia, except for supportive care. Teriparatide, a useful therapy for osteoporosis, has been administered to some patients with hypophosphatasia, but its long-term efficacy is unknown.

F. Fibrogenesis Imperfecta Ossium

This rare condition sporadically affects middle-aged patients, who present with progressive bone pain and pathologic fractures. Bones have a dense “fishnet” appearance on radiographs. Serum alkaline phosphatase levels are elevated. Some patients have a monoclonal gammopathy, indicating a possible plasma cell dyscrasia causing an impairment in osteoblast function and collagen disarray. Remission has been reported after repeated courses of melphalan, corticosteroids, and vitamin D analog over 3 years.

▶ Clinical Findings

The clinical manifestations of defective bone mineralization depend on the age at onset and the severity. In infants and children, vitamin D deficiency can cause severe hypocalcemia with muscle weakness; heart failure; laryngospasm; and rickets with bone pain, fractures, bone deformities, and dental problems. In adults, osteomalacia is typically asymptomatic at first. Eventually, bone pain occurs, along with muscle weakness due to calcium deficiency. Pathologic fractures may occur with little or no trauma. Vitamin D deficiency has also been associated with a possible increased risk of multiple sclerosis, rheumatoid arthritis, diabetes mellitus (types 1 and 2), and other conditions, but the causal relationship is uncertain.

▶ Diagnostic Tests

Serum is obtained for calcium, albumin, phosphate, alkaline phosphatase, PTH, and $25[\text{OH}]_2\text{D}_3$ determinations. Bone densitometry helps document the degree of osteopenia. Radiographs may show diagnostic features.

In one series of biopsy-proved osteomalacia, alkaline phosphatase was elevated in 94% of patients; the calcium or phosphorus was low in 47% of patients; $25(\text{OH})\text{D}_3$ was low in 29% of patients; pseudofractures were seen in 18% of patients; and urinary calcium was low in 18% of patients. $1,25(\text{OH})_2\text{D}_3$ may be low even when $25(\text{OH})\text{D}_2$ levels are normal.

Bone biopsy is not usually necessary but is diagnostic of osteomalacia if there is significant unmineralized osteoid.

► Differential Diagnosis

Osteomalacia is often seen together with osteoporosis, and its presence can be inferred by finding low serum levels of $25(\text{OH})$ vitamin D, low serum calcium, or low serum phosphate. A high serum alkaline phosphatase may be present in severe osteomalacia but not osteoporosis. The relative contribution of the two entities to diminished bone density may not be apparent until treatment, since a dramatic rise in bone density is often seen with therapy for osteomalacia. Phosphate deficiency must be distinguished from hypophosphatemia seen in hyperparathyroidism.

► Prevention & Treatment

To obtain adequate sunshine vitamin D, the face, arms, hands, or back must have sun exposure without sunscreen for 15 minutes at least twice weekly. The main natural food source of vitamin D is fish, particularly salmon, mackerel, cod liver oil, and sardines or tuna canned in oil. Most commercial cow's milk is fortified with vitamin D at about 400 international units per quart; however, skim milk and other dairy products contain much less vitamin D.

Many vitamin supplements contain plant-derived vitamin D_2 , which has less biologic availability than once believed. Over-the-counter multivitamin/mineral supplements contain variable amounts of vitamin D, and vitamin D toxicity has occurred from two different multivitamins sold in the United States. Therefore, it is prudent to recommend that patients take a dedicated vitamin D supplement from a reliable manufacturer.

In sunlight-deprived individuals (eg, veiled women, confined patients, or residents of higher latitudes during winter), the recommended daily allowance should be vitamin D_3 1000 international units daily. In such individuals, vitamin D_3 supplements should be given prophylactically. Patients receiving long-term phenytoin therapy may be treated prophylactically with vitamin D, 50,000 international units orally every 2–4 weeks.

Frank vitamin D deficiency is treated with ergocalciferol (D_2), 50,000 international units orally once weekly for 8 weeks. Following that, vitamin D_3 (cholecalciferol) supplementation is used at a dose of 2000 international units daily. Vitamin D_3 is more effective than vitamin D_2 in raising serum levels of $25(\text{OH})\text{D}$. Some patients require long-term supplementation with ergocalciferol of up to 50,000 international units weekly. In patients with intestinal malabsorption, oral doses of 25,000–100,000 international units of vitamin D_3 daily may be required. Some patients with steatorrhea respond better to oral $25(\text{OH})\text{D}_3$ (calcifediol), 50–100 mcg/d. Serum levels of $25(\text{OH})\text{D}$ should be

monitored and the dosage of vitamin D adjusted to maintain serum $25(\text{OH})\text{D}$ levels above 30 ng/mL. During treatment with high-dose vitamin D, serum calcium should also be monitored to avoid hypercalcemia.

Beyond increasing the intestinal absorption of calcium, vitamin D supplementation may have additional effects. Vitamin D supplementation has been associated with improved muscle strength and a reduced fall risk, factors that reduce the risk of bone fracture.

The addition of calcium supplements to vitamin D is probably not necessary for the prevention of osteomalacia in the majority of otherwise well-nourished patients. However, patients with malabsorption or poor nutrition should receive calcium supplementation. Recommended doses of calcium are as follows: calcium citrate (eg, Citracal), 0.4–0.6 g elemental calcium per day, or calcium carbonate (eg, OsCal, Tums), 1–1.5 g elemental calcium per day. Calcium supplements are best administered with meals.

In **hypophosphatemic osteomalacia**, nutritional deficiencies are corrected, aluminum-containing antacids are discontinued, and patients with renal tubular acidosis are given bicarbonate therapy. In patients with sporadic adult-onset hypophosphatemia, hyperphosphaturia, and low serum $1,25(\text{OH})_2\text{D}$ levels, a search is conducted for occult tumors that may be resected; whole-body MRI scanning may be required.

For those with X-linked or idiopathic hypophosphatemia and hyperphosphaturia, oral phosphate supplements must be given long-term; calcitriol, 0.25–0.5 mcg/d, is given also to improve the impaired calcium absorption caused by the oral phosphate. If necessary, rhGH may be added to the above regimen to reduce phosphaturia.

Patients with **hypophosphatasia** have been treated with teriparatide with improvement in bone pain and fracture healing.

- Araki T et al. Vitamin D intoxication with severe hypercalcemia due to manufacturing and labeling errors of two dietary supplements made in the United States. *J Clin Endocrinol Metab.* 2011 Dec;96(12):3603–8. [PMID: 21917864]
- Bell DS. Protean manifestations of vitamin D deficiency, part 1: the epidemic of deficiency. *South Med J.* 2011 May;104(5):331–4. [PMID: 21606711]
- Bergwitz C et al. Case records of the Massachusetts General Hospital. Case 33-2011. A 56-year-old man with hypophosphatemia. *N Engl J Med.* 2011 Oct;365(17):1625–35. [PMID: 22029985]
- Cehade H et al. Acute life-threatening presentation of vitamin D deficiency rickets. *J Clin Endocrinol Metab.* 2011 Sep;96(9):2681–3. [PMID: 21795457]
- Chong WH et al. The importance of whole body imaging in tumor-induced osteomalacia. *J Clin Endocrinol Metab.* 2011 Dec;96(12):3599–600. [PMID: 22143830]
- Heaney RP et al. Vitamin D_3 is more potent than vitamin D_2 in humans. *J Clin Endocrinol Metab.* 2011 Mar;96(3):E447–52. [PMID: 21177785]
- Hollick MF et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. *J Clin Endocrinol Metab.* 2011 Jul;96(7):1911–30. [PMID: 21646368]
- Russell LA. Osteoporosis and osteomalacia. *Rheum Dis Clin North Am.* 2010 Nov;36(4):665–80. [PMID: 21092845]

PAGET DISEASE OF BONE (Osteitis Deformans)

ESSENTIALS OF DIAGNOSIS

- ▶ Often asymptomatic.
- ▶ Bone pain may be the first symptom.
- ▶ Kyphosis, bowed tibias, large head, deafness, and frequent fractures.
- ▶ Serum calcium and phosphate normal; alkaline phosphatase elevated; urinary hydroxyproline elevated.
- ▶ Dense, expanded bones on radiographs.

▶ General Considerations

Paget disease of bone is a common condition manifested by one or more bony lesions having high bone turnover and disorganized osteoid formation. Involved bones become vascular, weak, and deformed. Paget disease is most common in the United Kingdom but is also common in other areas of the world, particularly in those with British ancestry. It is uncommon in Africa, Asia, and Scandinavia. Paget disease is present in 1–2% of the population of the United States and affects men more commonly than women. It is usually diagnosed in patients over age 40 years and its prevalence doubles with each decade thereafter, reaching an incidence of about 10% after age 80. It is usually discovered incidentally during radiology imaging or because of incidentally discovered elevations in serum alkaline phosphatase. The cause of Paget disease is unknown. However, there is often a genetic component since about 15% of affected patients have a first-degree relative with the disease. Similar familial disorders occur at an earlier age and their genetics has been established.

▶ Clinical Findings

A. Symptoms and Signs

Paget disease is often mild and asymptomatic. Only 27% of affected individuals are symptomatic at the time of diagnosis. It can involve just one bone (monostotic) or multiple bones (polyostotic), particularly the skull, femur, tibia, pelvis, and humerus. The affected bones are typically involved right away and the disease tends not to involve additional bones during its course. Pain is the usual first symptom. It may occur in the involved bone or in an adjacent joint, which can be involved with degenerative arthritis. The bones can become soft, leading to bowed tibias, kyphosis, and frequent “chalkstick” fractures with slight trauma. If the skull is involved, the patient may report headaches and an increased hat size. Deafness may occur. Increased vascularity over the involved bones causes increased warmth and can cause vascular “steal” syndromes.

B. Laboratory Findings

Serum alkaline phosphatase is usually markedly elevated. However, some patients with limited monostotic involvement

may have serum alkaline phosphatase levels within the normal range. A serum bone-specific alkaline phosphatase determination can be useful for patients with a normal serum total alkaline phosphatase level and to distinguish the source of an elevated serum alkaline phosphatase as being from bone (rather than liver). Other markers of bone turnover may be elevated. Serum C-telopeptide (CTX) is usually high. Urinary hydroxyproline is also elevated in active disease. Serum calcium may be elevated, particularly if the patient is at bed rest. A serum 25-OH vitamin D determination should be obtained to screen for vitamin D deficiency, which can also present with an increased alkaline phosphatase and bone pain. Also, any vitamin D deficiency should be corrected before prescribing a bisphosphonate.

C. Imaging

On radiographs, the initial lesions are typically osteolytic, with focal radiolucencies (“osteoporosis circumscripta”) in the skull or advancing flame-shaped lytic lesions in long bones. Bone lesions may subsequently become sclerotic and have a mixed lytic and sclerotic appearance. The affected bones eventually become thickened and deformed. Technetium pyrophosphate bone scans are helpful in delineating activity of bone lesions even before any radiologic changes are apparent.

▶ Differential Diagnosis

Certain rare familial osteoclastic bone disorders share phenotypic homologies with Paget disease of bone. Familial expansile osteolysis, familial early-onset Paget disease, and familial skeletal hyperphosphatasia are autosomal dominant disorders caused by different tandem duplications of the gene encoding RANK, resulting in its constitutive activation. Juvenile Paget disease is an autosomal recessive disorder caused by an inactivating mutation in the gene encoding osteoprotegerin. The syndrome of Paget disease, inclusion body myopathy, and frontotemporal dementia is caused by a mutation in the gene that encodes valosin-containing protein.

Paget disease must be differentiated from primary bone lesions such as osteogenic sarcoma, multiple myeloma, and fibrous dysplasia and from secondary bone lesions such as metastatic carcinoma and osteitis fibrosa cystica. Fibrogenesis imperfecta ossium is a rare symmetric disorder that can mimic the features of Paget disease; alkaline phosphatase is likewise elevated. If serum calcium is elevated, hyperparathyroidism may be present in some patients as well.

▶ Complications

If immobilization occurs, hypercalcemia and renal calculi may develop. Vertebral collapse may lead to spinal cord compression. The increased vascularity may give rise to high-output cardiac failure. Arthritis frequently develops in joints adjacent to involved bone.

Extensive skull involvement may cause cranial nerve palsies from impingement of the neural foramina. Involvement of the petrous temporal bone frequently causes hearing loss (mixed sensorineural and conductive)

and occasionally tinnitus or vertigo. Vertebral involvement can cause compression of spinal nerves, resulting in radiculopathy or paralysis. The affected bones have a high blood flow and can thereby cause a vascular “steal” syndrome. Skull involvement can cause a vascular steal syndrome with somnolence or ischemic neurologic events; the optic nerve may be affected, resulting in loss of vision. Vertebral involvement can cause a vascular steal syndrome with paralysis. Jaw involvement can cause the teeth to spread intraorally and become misaligned.

Osteosarcoma may develop in long-standing lesions but is rare (< 1%). Sarcomatous change is suggested by a marked increase in bone pain, sudden rise in alkaline phosphatase, and appearance of a new lytic lesion.

► Treatment

Asymptomatic patients may require only clinical surveillance and no treatment. However, treatment should be considered for asymptomatic patients who have extensive involvement of the skull, long bones, or vertebrae. Patients must be monitored carefully before, during, and after treatment with clinical examinations and serial serum alkaline phosphatase determinations.

A. Bisphosphonates

Bisphosphonates are the treatment of choice for Paget disease. Bisphosphonates are usually given cyclically. Therapy is given until a therapeutic response occurs, as evidenced by normalization of the serum alkaline phosphatase. After a course of therapy, patients are given a break for about 3 months or until the serum alkaline phosphatase begins rising again; another cycle is then commenced.

Patients frequently experience a paradoxical increase in pain soon after commencing bisphosphonate therapy; this is the “first dose effect” and the pain usually subsides with further treatment. Flu-like symptoms occur fairly frequently. Osteonecrosis, particularly of the jaw, is rare but can occur spontaneously or after tooth extraction.

The oral bisphosphonates should all be taken with 8 oz of plain water only; they are relatively contraindicated in patients with a history of esophagitis, esophageal stricture, dysphagia, hiatal hernia, or achalasia. **Alendronate**, 40 mg orally daily for 3–6 month cycles, must be taken in the morning with water only, at least 30–40 minutes before any other food, liquids, or medications. Patients should not lie down for at least 30 minutes after taking alendronate to reduce the risk of esophagitis. **Tiludronate**, 400 mg orally daily for 3-month cycles, should not be taken within 2 hours of meals, aspirin, indomethacin, calcium, magnesium, or aluminum-containing antacids. Esophagitis is uncommon, but it is still advisable to avoid recumbency for 30 minutes after dosing; but the drug may be taken in the evening as well as during the day. The most common side effects have been gastrointestinal, including abdominal pain in 13% and nausea in 9%. **Risedronate**, 30 mg orally daily for 2-month cycles, must be taken in the morning with water only, at least 30–40 minutes before any other food, liquids, or medications. Patients should not lie down for at least 30 minutes after taking risedronate to reduce the risk of esophagitis.

Parenteral bisphosphonates are particularly useful for patients who cannot tolerate oral bisphosphonates. Intravenous bisphosphonates can produce clinical improvements that last several months. Serum alkaline phosphatase levels may continue to drop for 6 months after treatment. They appear to be more effective than oral bisphosphonates but have more systemic side effects. Postinfusion fever, fatigue, myalgia, bone pain, and ocular problems occur commonly and may sometimes be severe. Serious side effects are rare but include uveitis and acute kidney disease. Hypocalcemia is common and may be severe, especially if intravenous bisphosphonates are given along with loop diuretics. It is advisable to administer calcium and vitamin D supplements, especially during the first 2 weeks following treatment. Asthma may occur in aspirin-sensitive patients. **Pamidronate**, 30–60 mg is infused intravenously over 2–4 hours. Depending on the disease severity, one to three additional doses may be given days or weeks apart. **Zoledronic acid** can be given every 6–12 months in doses of 2–5 mg intravenously over 20 minutes. Six months following a single infusion of zoledronic acid, patients had a clinical response rate of 96%, compared with 74% in patients receiving daily oral risedronate. Intravenous zoledronic acid has been demonstrated to be significantly more effective than daily risedronate. Bisphosphonates have significant side effects (see Osteoporosis, above).

B. Nasal Calcitonin-Salmon

Calcitonin-salmon, 200 international units/unit dose spray, is administered as one spray daily, alternating nostrils. It is just as effective as the parenteral preparation and is associated with fewer side effects. Nasal irritation may occur, as may occasional epistaxis. However the use of calcitonin has declined dramatically with the introduction of more potent bisphosphonates.

► Prognosis

The prognosis in general is good, but sarcomatous changes (in 1–3%) can alter it unfavorably. In general, the prognosis is worse the earlier in life the disease starts. Fractures usually heal well. In the severe forms, marked deformity, intractable pain, and cardiac failure are found. These complications should become rare with prompt bisphosphonate treatment.

- Colina M et al. Paget's disease of bone: a review. *Rheumatol Int*. 2008 Sep;28(11):1069–75. [PMID: 18592244]
- Mahmood W et al. Proposed new approach for treating Paget's disease of bone. *Ir J Med Sci*. 2011 Mar;180(1):121–4. [PMID: 21132539]
- Michou L et al. Emerging strategies and therapies for treatment of Paget's disease of bone. *Drug Des Devel Ther*. 2011;5:225–39. [PMID: 21607019]
- Reid IR et al. Bisphosphonates in Paget's disease. *Bone*. 2011 Jul;49(1):89–94. [PMID: 20832512]
- Roodman GD. Insights into the pathogenesis of Paget's disease. *Ann N Y Acad Sci*. 2010 Mar;1192:176–80. [PMID: 20392234]
- Silverman SL. Paget disease of bone: therapeutic options. *J Clin Rheumatol*. 2008 Oct;14(5):299–305. [PMID: 18838910]

DISEASES OF THE ADRENAL CORTEX

ACUTE ADRENOCORTICAL INSUFFICIENCY
(Adrenal Crisis)

ESSENTIALS OF DIAGNOSIS

- ▶ Weakness, abdominal pain, fever, confusion, nausea, vomiting, and diarrhea.
- ▶ Low blood pressure, dehydration; skin pigmentation may be increased.
- ▶ Serum potassium high, sodium low, BUN high.
- ▶ Cosyntropin (ACTH₁₋₂₄) unable to stimulate an increase in serum cortisol to ≥ 20 mcg/dL.

▶ General Considerations

Acute adrenal insufficiency is an emergency caused by insufficient cortisol. Crisis may occur in the course of treatment of chronic insufficiency, or it may be the presenting manifestation of adrenal insufficiency. Acute adrenal crisis is more commonly seen in primary adrenal insufficiency (Addison disease) than in disorders of the pituitary gland causing secondary adrenocortical hypofunction.

Adrenal crisis may occur in the following situations: (1) during stress, (eg, trauma, surgery, infection, hyperthyroidism, or prolonged fasting) in a patient with latent or treated adrenal insufficiency; (2) following sudden withdrawal of adrenocortical hormone in a patient with chronic insufficiency or in a patient with temporary insufficiency due to suppression by exogenous corticosteroids or megestrol; (3) following bilateral adrenalectomy or removal of a functioning adrenal tumor that had suppressed the other adrenal; (4) following sudden destruction of the pituitary gland (pituitary necrosis), or when thyroid hormone is given to a patient with hypoadrenalism; and (5) following injury to both adrenals by trauma, hemorrhage, anticoagulant therapy, thrombosis, infection or, rarely, metastatic carcinoma; (6) following administration of etomidate, which is used intravenously for rapid anesthesia induction or intubation.

▶ Clinical Findings

A. Symptoms and Signs

The patient complains of headache, lassitude, nausea and vomiting, abdominal pain, and often diarrhea. Confusion or coma may be present. Fever may be 40.6 °C or more. The blood pressure is low. Recurrent hypoglycemia and reduced insulin requirements may present in patients with preexisting type 1 diabetes mellitus. Other signs may include cyanosis, dehydration, skin hyperpigmentation, and sparse axillary hair (if hypogonadism is also present). Meningococemia may be associated with purpura and adrenal insufficiency secondary to adrenal infarction (Waterhouse–Friderichsen syndrome).

B. Laboratory Findings

The eosinophil count may be high. Hyponatremia or hyperkalemia (or both) are usually present. Hypoglycemia is frequent. Hypercalcemia may be present. Blood, sputum, or urine culture may be positive if bacterial infection is the precipitating cause of the crisis.

The diagnosis is made by a simplified cosyntropin stimulation test, which is performed as follows: (1) Synthetic ACTH₁₋₂₄ (cosyntropin), 0.25 mg, is given intramuscularly. (2) Serum is obtained for cortisol between 30 and 60 minutes after cosyntropin is administered. Normally, serum cortisol rises to at least 20 mcg/dL. For patients receiving corticosteroid treatment, hydrocortisone must not be given for at least 8 hours before the test. Other corticosteroids (eg, prednisone, dexamethasone) do not interfere with specific assays for cortisol.

Plasma ACTH is markedly elevated if the patient has primary adrenal disease (generally > 200 pg/mL).

▶ Differential Diagnosis

Acute adrenal insufficiency must be distinguished from other causes of shock (eg, septic, hemorrhagic, cardiogenic). Hyperkalemia is also seen with gastrointestinal bleeding, rhabdomyolysis, hyperkalemic paralysis, and certain drugs (eg, angiotensin-converting enzyme [ACE] inhibitors, spironolactone). Hyponatremia is seen in many other conditions (eg, hypothyroidism, diuretic use, heart failure, cirrhosis, vomiting, diarrhea, severe illness, or major surgery). Acute adrenal insufficiency must be distinguished from an acute abdomen in which neutrophilia is the rule, whereas adrenal insufficiency is characterized by a relative lymphocytosis and eosinophilia.

More than 90% of serum cortisol is protein bound and low serum levels of binding proteins result in misleadingly low serum cortisol determinations by most assays. Nearly 40% of critically ill patients, with serum albumin < 2.5 g/dL, have low serum total cortisol levels but normal serum free cortisol or salivary cortisol levels and normal adrenal function.

▶ Treatment

A. Acute Phase

If the diagnosis is suspected, draw a blood sample for cortisol determination and treat with hydrocortisone, 100–300 mg intravenously, and saline *immediately*, without waiting for the results. Thereafter, give hydrocortisone phosphate or hydrocortisone sodium succinate, 100 mg intravenously immediately, and continue intravenous infusions of 50–100 mg every 6 hours for the first day. Give the same amount every 8 hours on the second day and then adjust the dosage in view of the clinical picture.

Since bacterial infection frequently precipitates acute adrenal crisis, broad-spectrum antibiotics should be administered empirically while waiting for the results of initial cultures. Hypoglycemia should be vigorously treated while serum electrolytes, BUN, and creatinine are monitored.

B. Convalescent Phase

When the patient is able to take food by mouth, give oral hydrocortisone, 10–20 mg every 6 hours, and reduce dosage

to maintenance levels as needed. Most patients ultimately require hydrocortisone twice daily (AM, 10–20 mg; PM, 5–10 mg). Mineralocorticoid therapy is not needed when large amounts of hydrocortisone are being given, but as the dose is reduced it is usually necessary to add fludrocortisone acetate, 0.05–0.2 mg orally daily. Some patients never require fludrocortisone or become edematous at doses of more than 0.05 mg once or twice weekly. Once the crisis has passed, the patient must be evaluated to assess the degree of permanent adrenal insufficiency and to establish the cause if possible.

► Prognosis

Rapid treatment will usually be lifesaving. However, acute adrenal insufficiency is frequently unrecognized and untreated since its manifestations mimic more common conditions; lack of treatment leads to shock that is unresponsive to volume replacement and vasopressors, resulting in death.

Hahner S et al. Therapeutic management of adrenal insufficiency. *Best Pract Res Clin Endocrinol Metab.* 2009 Apr;23(2):167–79. [PMID: 19500761]
 Marik PE. Critical illness-related corticosteroid insufficiency. *Chest.* 2009 Jan;135(1):181–93. [PMID: 19136406]
 Marik PE et al. Requirement of perioperative stress doses of corticosteroids: a systematic review of the literature. *Arch Surg.* 2008 Dec;143(12):1222–6. [PMID: 19075176]
 Maxime V et al. Adrenal insufficiency in septic shock. *Clin Chest Med.* 2009 Mar;30(1):17–27. [PMID: 19186278]

CHRONIC ADRENOCORTICAL INSUFFICIENCY (Addison Disease)

ESSENTIALS OF DIAGNOSIS

- ▶ Weakness, fatigability, anorexia, weight loss; nausea and vomiting, diarrhea; abdominal pain, muscle and joint pains; amenorrhea.
- ▶ Sparse axillary hair; increased skin pigmentation, especially of creases, pressure areas, and nipples.
- ▶ Hypotension, small heart.
- ▶ Serum sodium may be low; potassium, calcium, and BUN may be elevated; neutropenia, mild anemia, eosinophilia, and relative lymphocytosis may be present.
- ▶ Plasma cortisol levels are low or fail to rise after administration of corticotropin.
- ▶ Plasma ACTH level is elevated.

► General Considerations

Addison disease refers to primary adrenal insufficiency caused by dysfunction or absence of the adrenal cortices. It is distinct from secondary adrenal insufficiency caused by deficient secretion of ACTH. (See Anterior Hypopituitarism.)

Addison disease is an uncommon disorder with a prevalence of about 140 per million and an annual incidence of about 4 per million in the United States. Addison disease is characterized by chronic deficiency of cortisol, with consequent elevation of serum ACTH causing skin pigmentation that can be subtle or strikingly dark. Patients with destruction of the adrenal cortices or with classic 21-hydroxylase deficiency also have mineralocorticoid deficiency with hyponatremia, volume depletion, and hyperkalemia. In contrast, mineralocorticoid deficiency is not present in patients with familial glucocorticoid deficiency and Allgrove syndrome (see below).

► Etiology

Autoimmune destruction of the adrenals is the most common cause of Addison disease in the United States (accounting for about 80% of spontaneous cases). With such autoimmunity, adrenal function decreases over several years as it progresses to overt adrenal insufficiency. It may occur alone or as part of a **polyglandular autoimmune (PGA) syndrome**. **Type 1 PGA** is also known as autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) syndrome and is caused by a defect in T cell-mediated immunity inherited as an autosomal recessive trait. Type 1 PGA usually presents in early childhood with mucocutaneous candidiasis, followed by hypoparathyroidism and dystrophy of the teeth and nails; Addison disease usually appears by age 15 years. Partial or late expression of the syndrome is common. A varied spectrum of associated diseases may be seen in adulthood, including hypogonadism, hypothyroidism, pernicious anemia, alopecia, vitiligo, hepatitis, malabsorption, and Sjögren syndrome.

Type 2 PGA usually presents in young adults age 20–40 years, usually women (female:male ratio is 3:1). The following conditions may be presentations of type 2 PGA: autoimmune adrenal insufficiency, type 1 diabetes mellitus, or autoimmune thyroid disease (usually hypothyroidism, sometimes hyperthyroidism). The combination of Addison disease and hypothyroidism is known as Schmidt syndrome. Patients may also have vitiligo, alopecia areata, Sjögren syndrome, or celiac sprue. Type 2 PGA is also associated with autoimmune primary ovarian failure; testicular failure (5%); pernicious anemia (4%); and, rarely, autoimmune hypophysitis, encephalitis, or hypoparathyroidism (late-onset).

Tuberculosis as a leading cause of Addison disease is relatively rare in the United States but common where tuberculosis is more prevalent.

Bilateral **adrenal hemorrhage** may occur during sepsis, heparin-associated thrombocytopenia or anticoagulation, or with antiphospholipid antibody syndrome. It may occur in association with major surgery or trauma, presenting about 1 week later with pain, fever, and shock. It may also occur spontaneously and present with flank pain; MRI may show adrenal enlargement with increased T2-weighted imaging.

Adrenoleukodystrophy is an X-linked peroxisomal disorder causing accumulation of very long-chain fatty acids in the adrenal cortex, testes, brain, and spinal cord. It may present at any age and accounts for one-third of cases of Addison disease in boys. Aldosterone deficiency occurs in 9%. Hypogonadism is common. Psychiatric symptoms

often include mania, psychosis, or cognitive impairment. Neurologic deterioration may be severe or mild (particularly in heterozygote women), mimics symptoms of multiple sclerosis, and can occur years after the onset of adrenal insufficiency.

Rare causes of adrenal insufficiency include lymphoma, metastatic carcinoma, coccidioidomycosis, histoplasmosis, cytomegalovirus infection (more frequent in patients with AIDS), syphilitic gummas, scleroderma, amyloid disease, and hemochromatosis.

Congenital adrenal insufficiency occurs in several conditions. **Familial glucocorticoid deficiency** is an autosomal recessive disease that is caused by mutations in the adrenal ACTH receptor (melanocortin 2 receptor, MC2R). It is characterized by isolated cortisol deficiency and ACTH resistance and may present with neonatal hypoglycemia, frequent infections, and dark skin pigmentation. **Triple A (Allgrove) syndrome** is caused by a mutation in the *AAAS* gene that encodes a protein known as *ALADIN* (alacrima, achalasia, adrenal insufficiency, neurologic disorder). It is characterized by variable expression of the following: adrenal ACTH resistance with cortisol deficiency, achalasia, alacrima, nasal voice, autonomic dysfunction, and neuromuscular disease of varying severity (hyperreflexia to spastic paraplegia). Cortisol deficiency usually presents in infancy but may not occur until the third decade of life. **Congenital adrenal hypoplasia** causes adrenal insufficiency due to absence of the adrenal cortex; patients may also have hypogonadotropic hypogonadism, myopathy, and high-frequency hearing loss.

Patients with hereditary defects in adrenal enzymes for cortisol synthesis develop **congenital adrenal hyperplasia** due to ACTH stimulation. The most common enzyme defect is P450c21 (21-hydroxylase). Patients with severely defective P450c21 enzymes manifest deficiency of mineralocorticoids (salt wasting) in addition to deficient cortisol and excessive androgens. Women with milder enzyme defects have adequate cortisol but develop hirsutism in adolescence or adulthood and are said to have “late-onset” congenital adrenal hyperplasia. (See Hirsutism section.) Patients with deficient P450c17 (17 hydroxylase) have varying degrees of adrenocortical deficiency with associated hypertension, hypokalemia, and primary hypogonadism.

Drugs that cause primary adrenal insufficiency include mitotane and abiraterone acetate (Zytiga), which inhibits P450c17 for the treatment of men with prostate cancer but causes adrenocortical deficiency with hypertension and hyperkalemia.

► Clinical Findings

A. Symptoms and Signs

The symptoms may include weakness and fatigability, weight loss, myalgias, arthralgias, fever, anorexia, nausea and vomiting, anxiety, and mental irritability. Some of these symptoms may be due to high serum levels of IL-6. Pigmentary changes consist of diffuse tanning over nonexposed as well as exposed parts or multiple freckles; hyperpigmentation is especially prominent over the knuckles, elbows, knees, and posterior neck and in palmar creases. Nail beds may develop longitudinal pigmented bands. Nipples and

areolas tend to darken. The skin in pressure areas such as the belt or brassiere lines and the buttocks also darkens. New scars are pigmented. Some patients have associated vitiligo (10%). Emotional changes are common. Hypoglycemia, when present, may worsen the patient's weakness and mental functioning, rarely leading to coma. Manifestations of other autoimmune disease (see above) may be present. Patients tend to be hypotensive and orthostatic; about 90% have systolic blood pressures under 110 mm Hg; blood pressure over 130 mm Hg is rare. Other findings may include a small heart, hyperplasia of lymphoid tissues, and scant axillary and pubic hair (especially in women).

Patients with adult-onset adrenoleukodystrophy may present with neuropsychiatric symptoms, sometimes without adrenal insufficiency.

B. Laboratory Findings

The WBC count usually shows moderate neutropenia, lymphocytosis, and a total eosinophil count over 300/mcL. Among patients with *chronic* Addison disease, the serum sodium is usually low (90%) while the potassium is elevated (65%). Patients with diarrhea may not be hyperkalemic. Fasting blood glucose may be low. Hypercalcemia may be present. Young men with idiopathic Addison disease are screened for adrenoleukodystrophy by determining plasma very long-chain fatty acid levels; affected patients have high levels.

Low plasma cortisol (< 3 mcg/dL) at 8 AM is diagnostic, especially if accompanied by simultaneous elevation of the plasma ACTH level (usually > 200 pg/mL). The diagnosis is made by a simplified cosyntropin stimulation test, which is performed as follows: (1) Synthetic ACTH₁₋₂₄ (cosyntropin), 0.25 mg, is given intramuscularly. (2) Serum is obtained for cortisol 45 minutes after cosyntropin is administered. Normally, serum cortisol rises to at least 20 mcg/dL. For patients receiving corticosteroid treatment, hydrocortisone must not be given for at least 8 hours before the test. Other corticosteroids (eg, prednisone, dexamethasone) do not interfere with specific assays for cortisol.

Serum DHEA levels are under 1000 ng/mL in 100% of patients with Addison disease and a serum DHEA above 1000 ng/mL excludes the diagnosis. However, serum DHEA levels below 1000 ng/mL are not helpful, since about 15% of the general population have such low DHEA levels, particularly children and elderly individuals. Antiadrenal antibodies are found in the serum in about 50% of cases of autoimmune Addison disease. Antibodies to thyroid (45%) and other tissues may be present.

Salt-wasting congenital adrenal hyperplasia due to 21-hydroxylase deficiency is usually diagnosed at birth in females due to ambiguous genitalia. Males and patients with milder enzyme defects may present later. The diagnosis of adrenal insufficiency is made as above. The specific diagnosis requires elevated serum levels of 17-OH progesterone.

Elevated plasma renin activity (PRA) indicates the presence of depleted intravascular volume and the need for higher doses of fludrocortisone replacement. Serum epinephrine levels are low in patients with adrenal insufficiency, since these patients do not have the high local concentrations of cortisol that are required to induce the enzyme PNMT in adrenal medulla for the synthesis of epinephrine from norepinephrine.

C. Imaging

When Addison disease is not clearly autoimmune, a chest radiograph is obtained to look for tuberculosis, fungal infection, or cancer as possible causes. CT scan of the abdomen will show small noncalcified adrenals in autoimmune Addison disease. The adrenals are enlarged in about 85% of cases due to metastatic or granulomatous disease. Calcification is noted in about 50% of cases of tuberculous Addison disease but is also seen with hemorrhage, fungal infection, pheochromocytoma, and melanoma.

► Differential Diagnosis

Patients with secondary adrenal insufficiency (hypopituitarism) lack ACTH and have normal skin pigmentation, in contrast to patients with Addison disease who have elevated levels of ACTH that can increase skin pigmentation. Patients with ACTH deficiency have normal mineralocorticoid production and do not develop hyperkalemia. Addison disease should be considered in any patient with unexplained hypotension, but shock is usually caused by more common conditions such as gastrointestinal bleeding or sepsis. Hyponatremia or hyperkalemia may be seen in numerous other conditions (see Chapter 21). Drospirenone, the progestin component in certain oral contraceptives, may cause hyperkalemia.

Unexplained weight loss, weakness, and anorexia may be mistaken for occult cancer. Nausea, vomiting, diarrhea, and abdominal pain may be misdiagnosed as intrinsic gastrointestinal disease. The hyperpigmentation may be confused with that due to ethnic or racial factors. Weight loss may simulate anorexia nervosa. The neurologic manifestations of Allgrove syndrome and adrenoleukodystrophy (especially in women) may mimic multiple sclerosis. Hemochromatosis also enters the differential diagnosis of skin hyperpigmentation, but it should be remembered that it may truly be a cause of Addison disease as well as diabetes mellitus and hypoparathyroidism. Serum ferritin is increased in most cases of hemochromatosis and is a useful screening test. About 17% of patients with AIDS have symptoms of cortisol resistance. AIDS can also cause frank adrenal insufficiency.

Hyperkalemia can be caused by isolated hypoaldosteronism and is seen in various conditions. Hyporeninemic hypoaldosteronism can be caused by renal tubular acidosis type IV and is commonly seen with diabetic nephropathy, hypertensive nephrosclerosis, tubulointerstitial diseases, and AIDS (see Chapter 21). Hyperreninemic hypoaldosteronism can be seen in patients with myotonic dystrophy, aldosterone synthase deficiency, and congenital adrenal hyperplasia. Hyperkalemia, hypertension, and hypogonadism may present as delayed adolescence or in adulthood in some patients with congenital adrenal hyperplasia (CYP17 deficiency); cortisol deficiency is also usually present but may not be clinically evident.

► Complications

Any of the complications of the underlying disease (eg, tuberculosis) are more likely to occur, and the patient is susceptible to intercurrent infections that may precipitate crisis. Associated autoimmune diseases are common (see above).

► Treatment

A. General Measures

Patients with Addison disease must be thoroughly informed about their condition. All infections should be treated immediately and vigorously, with the dose of hydrocortisone increased appropriately (see below). Patients are advised to wear a medical alert bracelet or medal reading, “Adrenal insufficiency—takes hydrocortisone.”

B. Specific Therapy

Replacement therapy should include a combination of corticosteroids and mineralocorticoids. In mild cases, hydrocortisone alone may be adequate.

Hydrocortisone is the drug of choice. Most Addisonian patients are well maintained on 15–30 mg of hydrocortisone orally daily in two divided doses, two-thirds in the morning and one-third in the late afternoon or early evening. Some patients respond better to prednisone in a dosage of about 2–4 mg orally in the morning and 1–2 mg in the evening. Adjustments in dosage are made according to the clinical response. A proper dose usually results in a normal WBC count differential.

The dose of corticosteroid should be raised in case of infection, trauma, surgery, stressful diagnostic procedures, or other forms of stress. The maximum hydrocortisone dose for severe stress is 50 mg intravenously or intramuscularly every 6 hours. Lower doses, oral or parenteral, are used for less severe stress. The dose is reduced back to normal as the stress subsides.

Fludrocortisone acetate has a potent sodium-retaining effect. The dosage is 0.05–0.3 mg orally daily or every other day. In the presence of postural hypotension, hyponatremia, or hyperkalemia, the dosage is increased. Similarly, in patients with fatigue, elevated PRA indicates the need for a higher replacement dose of fludrocortisone. If edema, hypokalemia, or hypertension ensues, the dose is decreased.

DHEA is given to some patients with adrenal insufficiency. In a double-blind clinical trial, patients taking DHEA 50 mg orally each morning experienced an improved sense of well-being, increased muscle mass, and a reversal in bone loss at the femoral neck. DHEA replacement did not improve fatigue, cognitive problems, or sexual dysfunction; however, its placebo effect may be significant in that regard. Older women who receive DHEA should be monitored for androgenic effects. Because over-the-counter preparations of DHEA have variable potencies, it is best to have the pharmacy formulate this with pharmaceutical-grade micronized DHEA.

► Prognosis

The life expectancy of patients with Addison disease has been considered reasonably normal, as long as they are very compliant with taking their medications and are knowledgeable about their condition. However, a retrospective Swedish study of 1675 patients with Addison disease found an unexpected increase in all-cause mortality, mostly from cardiovascular disease, malignancy, and infectious causes. Associated conditions can pose additional health risks. For example, patients with adrenoleukodystrophy or Allgrove

syndrome may suffer from neurologic disease. Patients with adrenal tuberculosis may have a serious systemic infection that requires treatment. Adrenal crisis can occur in patients who stop their medication or who experience stress such as infection, trauma, or surgery without appropriately higher doses of corticosteroids. Patients who take excessive doses of corticosteroid replacement can develop Cushing syndrome, which imposes its own risks.

Many patients with treated Addison disease complain of chronic low-grade fatigue.

Many patients with Addison disease do not feel entirely normal, despite glucocorticoid and mineralocorticoid replacement. This may be due, in part, to the inadequacy of oral replacement to duplicate cortisol's normal circadian rhythm. Also, patients with Addison disease are deficient in epinephrine, but replacement epinephrine is not available. Fatigue may also be an indication of suboptimal dosing of medication, electrolyte imbalance, or concurrent problems such as hypothyroidism or diabetes mellitus. However, most patients with Addison disease are able to live fully active lives.

Arlt W. The approach to the adult with newly diagnosed adrenal insufficiency. *J Clin Endocrinol Metab.* 2009 Apr;94(4):1059–67. [PMID: 19349469]

Betterle C et al. Autoimmune Addison's disease. *Endocr Dev.* 2011;20:161–72. [PMID: 21164269]

Bornstein SR. Predisposing factors for adrenal insufficiency. *N Engl J Med.* 2009 May 28;360(22):2328–39. [PMID: 19474430]

Chakera AJ et al. Addison disease in adults: diagnosis and management. *Am J Med.* 2010 May;123(5):409–13. [PMID: 20399314]

Gurnell EM et al. Long-term DHEA replacement in primary adrenal insufficiency: a randomized, controlled trial. *J Clin Endocrinol Metab.* 2008 Feb;93(2):400–9. [PMID: 18000094]

Koetz K et al. Management of steroid replacement in adrenal insufficiency. *Minerva Endocrinol.* 2010 Jun;35(2):61–72. [PMID: 20595936]

Neary N et al. Adrenal insufficiency: etiology, diagnosis and treatment. *Curr Opin Endocrinol Diabetes Obes.* 2010 Jun;17(3):217–23. [PMID: 20375886]

Speiser PW et al. Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: an Endocrine Society clinical practice guideline. *J Clin Endocrinol Metab.* 2010 Sep;95(9): 4133–60. [PMID: 20823466]

CUSHING SYNDROME (Hypercortisolism)



ESSENTIALS OF DIAGNOSIS

- ▶ Central obesity, muscle wasting, thin skin, hirsutism, purple striae.
- ▶ Psychological changes.
- ▶ Osteoporosis, hypertension, poor wound healing.
- ▶ Hyperglycemia, glycosuria, leukocytosis, lymphocytopenia, hypokalemia.
- ▶ Elevated serum cortisol and urinary free cortisol. Lack of normal suppression by dexamethasone.

▶ General Considerations

The term Cushing “syndrome” refers to the manifestations of excessive corticosteroids, commonly due to supra-physiologic doses of corticosteroid drugs and rarely due to spontaneous production of excessive corticosteroids by the adrenal cortex. Cases of spontaneous Cushing syndrome are rare (2.6 new cases yearly per million population) and have several possible causes.

About 40% of cases are due to Cushing “disease,” by which is meant the manifestations of hypercortisolism due to ACTH hypersecretion by the pituitary. Cushing disease is caused by a benign pituitary adenoma that is typically very small (< 5 mm) and usually located in the anterior pituitary (98%) or in the posterior pituitary (2%). It is at least three times more frequent in women than men. Excessive ingestion of gamma-hydroxybutyric acid (GHB, Xyrem) can also induce ACTH-dependent Cushing syndrome that resolves after the drug is stopped.

About 10% of cases are due to nonpituitary ACTH-secreting neoplasms (eg, small cell lung carcinoma), which produce excessive amounts of ectopic ACTH. Hypokalemia and hyperpigmentation are commonly found in this group.

About 15% of cases are due to ACTH from a source that cannot be initially located.

About 30% of cases are due to excessive autonomous secretion of cortisol by the adrenals—independently of ACTH, serum levels of which are usually low. Most such cases are due to a unilateral adrenal tumor. Benign adrenal adenomas are generally small and produce mostly cortisol; adrenocortical carcinomas are usually large when discovered and can produce excessive cortisol as well as androgens, with resultant hirsutism and virilization. ACTH-independent macronodular adrenal hyperplasia can also produce hypercortisolism due to the adrenal cortex cells' abnormal stimulation by hormones such as catecholamines, arginine vasopressin, serotonin, hCG/LH, or gastric inhibitory polypeptide; in the latter case, hypercortisolism may be intermittent and food dependent and serum ACTH may not be completely suppressed. Pigmented bilateral adrenal macronodular adrenal hyperplasia is a rare cause of Cushing syndrome in children and young adults; it may be an isolated condition or part of the Carney complex.

▶ Clinical Findings

A. Symptoms and Signs

Patients with Cushing syndrome usually have central obesity with a plethoric “moon face,” “buffalo hump,” supraclavicular fat pads, protuberant abdomen, and thin extremities. Muscle atrophy causes weakness, with difficulty standing up from a seated position or climbing stairs. Patients may also experience oligomenorrhea or amenorrhea (or erectile dysfunction in the male), backache, headache, hypertension, osteoporosis, avascular necrosis of bone, acne, and superficial skin infections. Patients may have thirst and polyuria (with or without glycosuria), renal calculi, glaucoma, purple striae (especially around the thighs, breasts, and abdomen), and easy bruisability. Unusual bacterial or fungal infections are common. Wound healing is impaired. Mental symptoms may range from diminished ability to concentrate to

increased lability of mood to frank psychosis. Patients are susceptible to opportunistic infections.

B. Laboratory Findings

Glucose tolerance is impaired as a result of insulin resistance. Polyuria is present as a result of increased free water clearance; diabetes mellitus with glycosuria may worsen it. Patients with Cushing syndrome often have leukocytosis with relative granulocytosis and lymphopenia. Hypokalemia may be present, particularly in cases of ectopic ACTH secretion.

▶ Tests for Hypercortisolism

The easiest screening test for Cushing syndrome is the dexamethasone suppression test: dexamethasone 1 mg is given orally at 11 pm and serum is collected for cortisol determination at about 8 AM the next morning; a cortisol level < 5 mcg/dL (< 135 nmol/L, fluorometric assay) or < 1.8 mcg/dL (< 49 nmol/L, high-performance liquid chromatography [HPLC] assay) excludes Cushing syndrome with some certainty. However, 8% of established patients with pituitary Cushing disease have dexamethasone-suppressed cortisol levels < 2 mcg/dL. Therefore, when other clinical criteria suggest hypercortisolism, further evaluation is warranted even in the face of normal dexamethasone-suppressed serum cortisol. Antiseizure drugs (eg, phenytoin, phenobarbital, primidone) and rifampin accelerate the metabolism of dexamethasone, causing a lack of cortisol suppression by dexamethasone. Estrogens—during pregnancy or as oral contraceptives or ERT—may also cause lack of dexamethasone suppressibility.

Patients with an abnormal dexamethasone suppression test require further investigation, which includes a 24-hour urine collection for free cortisol and creatinine. An abnormally high 24-hour urine free cortisol (or free cortisol to creatinine ratio of > 95 mcg cortisol/g creatinine) helps confirm hypercortisolism. A misleadingly high urine free cortisol excretion occurs with high fluid intake. In pregnancy, urine free cortisol is increased, while 17-hydroxycorticosteroids remain normal and diurnal variability of serum cortisol is normal. Carbamazepine and fenofibrate cause false elevations of urine free cortisol when determined by HPLC.

A midnight serum cortisol level > 7.5 mcg/dL is indicative of Cushing syndrome and distinguishes it from other conditions associated with a high urine free cortisol (pseudo-Cushing states). Requirements for this test include being in the same time zone for at least 3 days, being without food for at least 3 hours, and having an indwelling intravenous line established in advance for the blood draw.

Late-night salivary cortisol assays are useful due to the inconvenience of obtaining a midnight blood specimen for serum cortisol. Assays are available that use liquid chromatography-tandem mass spectrometry. Midnight salivary cortisol levels are normally < 0.15 mcg/dL (4.0 nmol/L). Midnight salivary cortisol levels that are consistently > 0.25 mcg/dL (7.0 nmol/L) are considered very abnormal. The late-night salivary cortisol test has a high sensitivity and specificity for Cushing syndrome, but false-positive and false-negative tests have occurred.

Interestingly, hypercortisolism without Cushing syndrome can occur in several conditions, such as severe depression, anorexia nervosa, alcoholism, and familial cortisol resistance.

▶ Finding the Cause of Hypercortisolism

Once hypercortisolism is confirmed, a plasma or serum ACTH is obtained. It must be collected properly in a plastic tube on ice and processed quickly by a laboratory with a reliable, sensitive assay. A level of ACTH below about 20 pg/mL indicates a probable adrenal tumor, whereas higher levels are produced by pituitary or ectopic ACTH-secreting tumors.

▶ Localizing Techniques

In ACTH-independent Cushing syndrome, CT of the adrenals usually detects a mass lesion. Most such lesions are benign adrenal adenomas, but an adrenal carcinoma is suspected in the following circumstances: (1) diameter ≥ 4 cm; (2) nodule growth; or (3) atypical imaging: density on noncontrast CT > 10 Hounsfield units (HU) or CT contrast washout $\geq 60\%$ or relative contrast washout $\geq 40\%$ at 15 minutes after intravenous administration.

In ACTH-dependent Cushing syndrome, MRI of the pituitary demonstrates a pituitary lesion in about 50% of cases. Premature cerebral atrophy is often noted. When the pituitary MRI is normal or shows a tiny (< 5 mm diameter) irregularity that may be incidental, selective catheterization of the inferior petrosal sinus veins draining the pituitary is performed. ACTH levels in the inferior petrosal sinus that are more than twice the simultaneous peripheral venous ACTH levels are indicative of pituitary Cushing disease. Inferior petrosal sinus sampling is also done during CRH administration, which ordinarily causes the ACTH levels in the inferior petrosal sinus to be over three times the peripheral ACTH level when the pituitary is the source of ACTH.

When inferior petrosal sinus ACTH concentrations are not above the requisite levels, a search for an ectopic source of ACTH is undertaken. Location of ectopic sources of ACTH commences with CT scanning of the chest and abdomen, with special attention to the lungs (for carcinoid or small cell carcinomas), the thymus, the pancreas, and the adrenals. In patients with ACTH-dependent Cushing syndrome, chest masses should not be assumed to be the source of ACTH, since opportunistic infections are common, so it is prudent to biopsy a chest mass to confirm the pathologic diagnosis prior to resection.

CT scanning fails to detect the source of ACTH in about 40% of patients with ectopic ACTH secretion.¹¹¹ In-octreotide (OCT, somatostatin receptor scintigraphy) scanning is also useful in detecting occult tumors. A low-dose scan with 6 mCi OCT is used first; a high-dose scan with 12 mCi OCT may be used if the low-dose scan gives equivocal results.¹⁸FDG-PET scanning is not usually helpful. Some ectopic ACTH-secreting tumors elude discovery, necessitating bilateral adrenalectomy. The ectopic source of ACTH should continue to be sought, since it may become detectable by OCT or CT scanning at a later date.

In non-ACTH-dependent Cushing syndrome, a CT scan of the adrenals can localize the adrenal tumor in most cases.

► Differential Diagnosis

Alcoholic patients can have hypercortisolism and many clinical manifestations of Cushing syndrome. Pregnant women have elevated serum ACTH levels, increased urine free cortisol, and high serum cortisol levels due to high serum levels of cortisol-binding globulin. Regular use of the “party drug” gamma hydroxybutyrate (GHB, sodium oxybate) has been reported to cause reversible ACTH-dependent Cushing syndrome. Depressed patients also have hypercortisolism that can be nearly impossible to distinguish biochemically from Cushing syndrome but without clinical signs of Cushing syndrome. Some adolescents develop violaceous striae on the abdomen, back, and breasts; these are known as “striae distensae” and are not indicative of Cushing syndrome. Cushing syndrome can be misdiagnosed as anorexia nervosa (and vice versa) owing to the muscle wasting and extraordinarily high urine free cortisol levels found in anorexia. Patients with severe obesity frequently have an abnormal dexamethasone suppression test, but the urine free cortisol is usually normal, as is diurnal variation of serum cortisol. Patients with familial cortisol resistance have hyperandrogenism, hypertension, and hypercortisolism without actual Cushing syndrome. Patients with familial partial lipodystrophy type I develop central obesity and moon facies, along with thin extremities due to atrophy of subcutaneous fat. However, these patients’ muscles are strong and may be hypertrophic, distinguishing this condition from Cushing syndrome. Patients receiving antiretroviral therapy for HIV-1 infection frequently develop partial lipodystrophy with thin extremities and central obesity with a dorsocervical fat pad (“buffalo hump”) that may mimic Cushing syndrome.

► Complications

Cushing syndrome, if untreated, produces serious morbidity and even death. The patient may suffer from any of the complications of hypertension or of diabetes mellitus. Susceptibility to infections is increased. Compression fractures of the osteoporotic spine and aseptic necrosis of the femoral head may cause marked disability. Nephrolithiasis and psychosis may occur. Following bilateral adrenalectomy for Cushing disease, a pituitary adenoma may enlarge progressively, causing local destruction (eg, visual field impairment) and hyperpigmentation; this complication is known as Nelson syndrome.

► Treatment

Cushing disease is best treated by transsphenoidal selective resection of the pituitary adenoma. After pituitary surgery, the rest of the pituitary usually returns to normal function; however, the pituitary corticotrophs remain suppressed and require 6–36 months to recover normal function. Hydrocortisone or prednisone replacement therapy is necessary in the meantime. Patients who do not have a remission (or who have a recurrence) may be considered for

treatment with cabergoline 0.5–3.5 mg orally twice weekly, which was successful in 40% of patients in one small study. Laparoscopic adrenalectomy should be offered to unresponsive patients. Another treatment option for patients with ACTH-secreting pituitary tumors is stereotactic pituitary radiosurgery (gamma knife or cyberknife), which normalizes urine free cortisol in two-thirds of patients within 12 months. Conventional radiation therapy results in a 23% cure rate. Pasireotide, a novel multireceptor-targeting somatostatin analog that has not yet received approval by the US FDA, is a potential treatment for refractory Cushing disease. Pasireotide (600–900 mcg subcutaneously twice daily) normalizes the urine free cortisol in at least 17% of patients with Cushing disease.

Pituitary radiosurgery can also be used to treat Nelson syndrome, the progressive enlargement of ACTH-secreting pituitary tumors following bilateral adrenalectomy. Patients who are not surgical candidates may be given a trial of ketoconazole in doses of about 200 mg orally every 6 hours; liver enzymes must be monitored for progressive elevation.

Adrenal neoplasms secreting cortisol are resected laparoscopically, if they are < 6 cm diameter. Postoperatively, the contralateral adrenal’s cortisol secretion is deficient, due to ACTH suppression, so postoperative hydrocortisone replacement is required until recovery occurs.

Patients with metastatic adrenocortical carcinoma have detectable cortisol levels following removal of the primary tumor. Metastases may not be visible on scanning. Patients with adrenal carcinoma should be treated postoperatively with mitotane for a course of 2–5 years, since it appears to improve prognosis (see below). Mitotane is given, beginning with 0.5 g twice daily with meals and increasing to 1 g twice daily within 2 weeks. The doses of mitotane are adjusted every 2–3 weeks ideally to reach serum levels of 14–20 mcg/mL; however, only about half the patients can tolerate mitotane levels above 14 mcg/mL. Mitotane side effects include CNS depression, lethargy, hypogonadism, hypercholesterolemia, hypocalcemia, hepatotoxicity, leukopenia, hypertension, nausea, rash, TSH suppression with hypothyroidism, and primary adrenal insufficiency. Replacement hydrocortisone or prednisone should be started when mitotane doses reach 2 g daily. The replacement dose of hydrocortisone starts at 15 mg in the morning and 10 mg in the afternoon, but must often be doubled or tripled because mitotane increases cortisol metabolism and cortisol binding globulin levels; the latter can artifactually raise serum cortisol levels. Ketoconazole or metyrapone can help suppress hypercortisolism in unresectable adrenal carcinoma.

Ectopic ACTH-secreting tumors should be located, when possible, and surgically resected. If that cannot be done, laparoscopic bilateral adrenalectomy is usually recommended. Medical treatment with a combination of mitotane (3–5 g/24 h), ketoconazole (0.4–1.2 g/24 h), and metyrapone (3–4.5 g/24 h) often suppresses the hypercortisolism. Octreotide LAR, 20–40 mg injected intramuscularly every 28 days, suppresses ACTH secretion in about one-third of such cases.

Patients who are successfully treated for Cushing syndrome typically develop “cortisol withdrawal syndrome,” even when given replacement corticosteroids for adrenal

insufficiency. Manifestations can include hypotension, nausea, fatigue, arthralgias, myalgias, pruritus, and flaking skin. Increasing the hydrocortisone replacement to 30 mg orally twice daily can improve these symptoms; the dosage is then reduced slowly as tolerated. Patients with Cushing syndrome are prone to develop osteoporosis. Bone densitometry is recommended for all patients and treatment is commenced for patients with osteoporosis. (See Osteoporosis section, above.)

► Prognosis

The manifestations of Cushing syndrome regress with time, but patients are often left with residual mild cognitive impairment, muscle weakness, osteoporosis, and sequelae from vertebral fractures. Younger patients have a better chance for recovery and children with short stature may have catch-up growth following cure.

Patients with Cushing syndrome from a benign adrenal adenoma experience a 5-year survival of 95% and a 10-year survival of 90%, following a successful adrenalectomy. Patients with Cushing disease from a pituitary adenoma experience a similar survival if their pituitary surgery is successful, which can be predicted if the postoperative nonsuppressed serum cortisol is < 2 mcg/dL. However, transsphenoidal surgery incurs a failure rate of about 10–20%, often due to the adenoma's ectopic position or invasion of the cavernous sinus. Those patients who have a complete remission after transsphenoidal surgery have about a 15–20% chance of recurrence over the next 10 years. Patients with failed pituitary surgery may require pituitary radiation therapy, which has its own morbidity. Laparoscopic bilateral adrenalectomy may be required; recurrence of hypercortisolism may occur as a result of growth of an adrenal remnant stimulated by high levels of ACTH. The prognosis for patients with ectopic ACTH-producing tumors depends on the aggressiveness and stage of the particular tumor. Patients with ACTH of unknown source have a 5-year survival rate of 65% and a 10-year survival rate of 55%.

In patients with adrenocortical carcinoma, the prognosis depends on the stage of the tumor at the time of surgery. In patients with stage I–II disease, confined to the adrenal by surgical inspection and scan, the median 5-year survival is about 60% and long-term survival does occur. However, despite apparent complete resection in stage I–III tumors, visible metastases develop in about 40% of patients within 2 years. Adjuvant therapy with mitotane appears to improve the prognosis, with patients receiving mitotane having a 5-year survival of 87% versus 53% in those not receiving mitotane. Patients with advanced stage IV disease at the time of surgery have a poorer prognosis, but debulking surgery and therapy with mitotane may be beneficial.

AbdelMannan D et al. Peri-operative management of Cushing's disease. *Rev Endocr Metab Disord*. 2010 Jun;11(2):127–34. [PMID: 20556520]

Doi M et al. Clinical features and management of ectopic ACTH syndrome at a single institute in Japan. *Endocr J*. 2010; 57(12):1061–9. [PMID: 21076235]

Feelders RA et al. Medical treatment of Cushing's syndrome: adrenal-blocking drugs and ketoconazole. *Neuroendocrinology*. 2010;92(Suppl 1):111–5. [PMID: 20829630]

Kamenický P et al. Mitotane, metyrapone, and ketoconazole combination therapy as an alternative to rescue adrenalectomy for severe ACTH-dependent Cushing's syndrome. *J Clin Endocrinol Metab*. 2011 Sep;96(9):2796–804. [PMID: 21752886]

Lacroix A. Approach to the patient with adrenocortical carcinoma. *J Clin Endocrinol Metab*. 2010 Nov;95(11):4812–22. [PMID: 21051577]

Pedroncelli AM. Medical treatment of Cushing's disease: somatostatin analogues and pasireotide. *Neuroendocrinology*. 2010;92(Suppl 1):120–4. [PMID: 20829632]

Pivonello R et al. The medical treatment of Cushing's disease: effectiveness of chronic treatment with the dopamine agonist cabergoline in patients unsuccessfully treated by surgery. *J Clin Endocrinol Metab*. 2009 Jan;94(1):223–30. [PMID: 18957500]

Tritos NA et al. Management of Cushing disease. *Nat Rev Endocrinol*. 2011 May;7(5):279–89. [PMID: 21301487]

Yip L et al. The adrenal mass: correlation of histopathology with imaging. *Ann Surg Oncol*. 2010 Mar;17(3):846–52. [PMID: 19960266]

HIRSUTISM & VIRILIZATION



ESSENTIALS OF DIAGNOSIS

- Hirsutism, acne, menstrual disorders.
- Virilization: increased muscularity, androgenic alopecia, deepening of the voice, clitoromegaly.
- Rarely, a palpable pelvic tumor.
- Urinary 17-ketosteroids and serum DHEAS and androstenedione elevated in adrenal disorders; variable in others.
- Serum testosterone is often elevated.

► General Considerations

Hirsutism is defined as cosmetically unacceptable terminal hair growth that appears in women in a male pattern. Some degree of hirsutism affects about 5–10% of non-Asian women of reproductive age. The amount of hair growth deemed unacceptable depends on a woman's ethnicity and familial and cultural norms. Hirsutism is quantitated using the Ferriman-Gallwey score in which hirsutism is graded from 0 (none) to 4 (severe) in nine areas of the body with a maximum possible score of 36; scores 8–15 indicate moderate hirsutism, while scores over 15 indicate severe hirsutism.

► Etiology

Hirsutism may be idiopathic or familial or be caused by the following disorders: polycystic ovary syndrome (PCOS), steroidogenic enzyme defects, neoplastic disorders; or rarely by medications, acromegaly, or ACTH-induced Cushing disease.

A. Idiopathic or Familial

Most women with hirsutism or androgenic alopecia have no detectable hyperandrogenism. Patients often have a

strong familial predisposition to hirsutism that may be considered normal in the context of their genetic background. Such patients may have elevated serum levels of androstenediol glucuronide, a metabolite of dihydrotestosterone that is produced by skin in cosmetically unacceptable amounts.

B. Polycystic Ovary Syndrome (Hyperthecosis, Stein-Leventhal Syndrome)

PCOS is a common functional disorder of the ovaries, affecting about 4–6% of premenopausal women in the United States and accounting for at least 50% of all cases of hirsutism associated with elevated testosterone levels. It is familial and transmitted as a modified autosomal dominant trait. Affected women have elevated serum testosterone or free testosterone levels. Affected women have signs of androgen excess, including hirsutism, acne, and male-pattern thinning of scalp hair. About 50% of affected women have oligomenorrhea or amenorrhea with anovulation. Despite the syndrome's name, the presence of ovarian cysts is not helpful diagnostically and is actually a misnomer, since about 30% of women with PCOS do *not* have cystic ovaries and 25–30% of normal menstruating women *have* cystic ovaries. Obesity and high serum insulin levels (due to insulin resistance) contribute to the syndrome in 70% of women. The serum LH:FSH ratio is often > 2.0 . Both adrenal and ovarian androgen hypersecretion are commonly present. Women with PCOS have a 35% risk of depression, compared with 11% in age-matched controls. Diabetes mellitus is present in about 13% of cases. Obstructive sleep apnea is particularly common, even in slender women with PCOS. Untreated women with amenorrhea have a slightly increased risk of endometrial carcinoma. Hypertension and hyperlipidemia are often present, increasing the risk of cardiovascular disease. Women frequently regain normal menstrual cycles with aging.

C. Steroidogenic Enzyme Defects

Baby girls with “classic” 21-hydroxylase deficiency have ambiguous genitalia and may become virilized unless treated with corticosteroid replacement; about 50% of such patients have clinically evident mineralocorticoid deficiency (salt-wasting) as well.

About 2% of patients with adult-onset hirsutism have been found to have a partial defect in adrenal 21-hydroxylase. The condition is more common in Ashkenazi Jews, Yupic Alaskans, and natives of La Reunion Island. The phenotypic expression is delayed until adolescence or adulthood; such patients do not have salt-wasting. Polycystic ovaries and adrenal adenomas are more likely to develop in these women.

Some rare patients with hyperandrogenism and hypertension have 11-hydroxylase deficiency. This is distinguished from cortisol resistance by high cortisol serum levels in the latter and by high serum 11-deoxycortisol levels in the former.

Patients with an XY karyotype and a deficiency in 17 β -hydroxysteroid dehydrogenase-3 or a deficiency in 5 α -reductase-2 may present as phenotypic girls in whom virilization develops at puberty.

D. Neoplastic Disorders

Ovarian tumors are very uncommon causes of hirsutism (0.8%) and include arrhenoblastomas, Sertoli-Leydig cell tumors, dysgerminomas, and hilar cell tumors. Adrenal carcinoma is a rare cause of Cushing syndrome and hyperandrogenism that can be quite virilizing. Pure androgen-secreting adrenal tumors occur very rarely; about 50% are malignant.

E. Rare Causes of Hirsutism

Acromegaly and ACTH-induced Cushing syndrome can cause hirsutism. Porphyria cutanea tarda can cause periorbital hair growth in addition to dermatitis in sun-exposed areas. Maternal virilization during pregnancy may occur as a result of a luteoma of pregnancy, hyperreactio luteinalis, or polycystic ovaries. In postmenopausal women, diffuse stromal Leydig cell hyperplasia is a rare cause of hyperandrogenism. Acquired hypertrichosis lanuginosa is manifested by the appearance of diffuse fine lanugo hair growth on the face and body along with stomatologic symptoms; the disorder is usually associated with an internal malignancy, especially colorectal cancer, and may regress after tumor removal. Pharmacologic causes include minoxidil, cyclosporine, phenytoin, anabolic steroids, diazoxide, and certain progestins.

► Clinical Findings

A. Symptoms and Signs

Modest androgen excess from any source increases sexual hair (chin, upper lip, abdomen, and chest) and increases sebaceous gland activity, producing acne. Menstrual irregularities, anovulation, and amenorrhea are common. If androgen excess is pronounced, defeminization (decrease in breast size, loss of feminine adipose tissue) and virilization (frontal balding, muscularity, clitoromegaly, and deepening of the voice) occur. Virilization points to the presence of an androgen-producing neoplasm.

Hypertension may be seen in rare patients with Cushing syndrome, adrenal 11-hydroxylase deficiency, or cortisol resistance syndrome.

A pelvic examination may disclose clitoromegaly or ovarian enlargement that may be cystic or neoplastic.

B. Laboratory Testing and Imaging

Serum androgen testing is mainly useful to screen for rare occult adrenal or ovarian neoplasms. Some general guidelines are presented here, though exceptions are common.

Serum is assayed for total testosterone and free testosterone. A serum testosterone level > 200 ng/dL or free testosterone > 40 ng/dL indicates the need for pelvic examination and ultrasound. If that is negative, an adrenal CT scan is performed.

Most radioimmunoassays and enzyme-linked immunosorbent assay (ELISA) for testosterone are inaccurate below serum testosterone levels of 300 ng/dL. The more accurate testosterone assays rely upon extraction and chromatography, followed by mass spectrometry or immunoassay. Free testosterone is best measured by calculation, using

accurate assays for testosterone and sex hormone binding globulin.

A serum androstenedione level > 1000 ng/dL also points to an ovarian or adrenal neoplasm.

Patients with milder elevations of serum testosterone or androstenedione usually are treated with an oral contraceptive.

Patients with very elevated serum DHEAS (> 700 mcg/dL) have an adrenal source of androgen. This usually is due to adrenal hyperplasia and rarely to adrenal carcinoma. An adrenal CT scan is performed.

No firm guidelines exist as to which patients (if any) with hyperandrogenism should be screened for “late-onset” 21-hydroxylase deficiency. The evaluation requires levels of serum 17-hydroxyprogesterone to be drawn at baseline and at 30–60 minutes after the intramuscular injection of 0.25 mg of cosyntropin (ACTH_{1–24}). This test should ideally be done during the follicular phase of a woman’s menstrual cycle. Patients with congenital adrenal hyperplasia will usually have a baseline 17-hydroxyprogesterone level over 300 ng/dL or a stimulated level over 1000 ng/dL. Patients with any clinical signs of Cushing syndrome should receive a screening test. (See Cushing Syndrome.)

Serum levels of FSH and LH are elevated if amenorrhea is due to ovarian failure. An LH:FSH ratio > 2.0 is common in patients with PCOS. On abdominal ultrasound, about 25–30% of normal young women have polycystic ovaries, so the appearance of ovarian cysts on ultrasound is not helpful. Pelvic ultrasound or MRI can usually detect virilizing tumors of the ovary. However, small virilizing ovarian tumors may not be detectable on imaging studies; selective venous sampling for testosterone may be used for diagnosis in such patients.

► Treatment

Postmenopausal women with severe hyperandrogenism should undergo laparoscopic bilateral oophorectomy (if CT scan of the adrenals and ovaries is normal), since small hilar cell tumors of the ovary may not be visible on scans. Girls with classic salt-wasting congenital adrenal hyperplasia and infertility or treatment-resistant hyperandrogenism may be treated with laparoscopic bilateral adrenalectomy. Any drugs causing hirsutism are stopped.

Spironolactone may be taken in doses of 50–100 mg orally twice daily on days 5–25 of the menstrual cycle or daily if used concomitantly with an oral contraceptive. Hyperkalemia and other side effects are uncommon.

Finasteride inhibits 5 α -reductase, the enzyme that converts testosterone to active dihydrotestosterone in the skin. Given as 2.5-mg doses orally daily, it provides modest reduction in hirsutism over 6 months—somewhat less than that achieved with spironolactone. Finasteride is ineffective for androgenic alopecia in women. Side effects are rare.

Flutamide inhibits testosterone binding to androgen receptors and also suppresses serum testosterone. It is given orally in a dosage of 250 mg/d for the first year and then 125 mg/d for maintenance. Used with an oral contraceptive, it appears to be more effective than spironolactone in improving hirsutism, acne, and male pattern baldness. Women with congenital adrenal hyperplasia who take

replacement hydrocortisone experience decreased renal cortisol clearance when treated with flutamide, resulting in lower hydrocortisone dosage requirements; corticosteroid replacement doses should be reduced when flutamide is added for treatment of hirsutism. Hepatotoxicity has been reported but is rare.

Oral contraceptives stimulate menses (if that is desired) and reduce acne vulgaris. They are not very effective for hirsutism, but increase serum sex hormone binding globulin and thereby slightly reduce serum free testosterone levels. Oral contraceptives containing antiandrogen progestins include desogestrel (Azurette, Kariva), drospirenone (Gianvi), or norgestimate (Ortho Tri-Cyclen Lo). Cyproterone is a particularly potent antiandrogen that is not available in the United States but is available as Diane-35 in Canada and the United Kingdom. These preparations may be more effective for treating hirsutism but are associated with an increased risk of deep venous thrombosis.

Metformin may improve menstrual function in women with PCOS and amenorrhea or oligomenorrhea but is less effective than oral contraceptives. Metformin is not effective in promoting fertility or in improving hirsutism in women with PCOS. Metformin therapy is usually given with meals and is started at a dose of 500 mg/d with breakfast for 1 week, then 500 mg with breakfast and dinner for 1 week, then 500 mg with breakfast and 1000 mg with dinner for 1 week, then 850–1000 mg with breakfast and dinner. The most common side effects are dose-related gastrointestinal upset and diarrhea. Patients are advised to take the highest tolerated dosage. Metformin appears to be nonteratogenic. Although metformin reduces insulin resistance, it does not cause hypoglycemia in nondiabetics. Metformin is contraindicated in renal and hepatic disease.

Simvastatin can reduce hirsutism in women with PCOS. In one study, simvastatin 20 mg orally daily was given to women receiving an oral contraceptive for PCOS. Besides improving their serum lipid profiles, women receiving simvastatin had greater decreases in hirsutism and serum free testosterone levels than the women receiving an oral contraceptive alone.

Clomiphene is the treatment of choice for women with PCOS and infertility. Over 6 months, clomiphene therapy resulted in a 22.5% rate of conception with live births. The rate of pregnancy with multiple fetuses is 6%.

Women with classic congenital adrenal hyperplasia (21-hydroxylase deficiency) have hirsutism and adrenal insufficiency that requires glucocorticoid and mineralocorticoid replacement. However, women with partial “late onset” 21-hydroxylase deficiency do not require hormone replacement. Treating such women with dexamethasone risks iatrogenic Cushing syndrome and is not particularly more effective than the other treatments for hirsutism listed below.

Local treatment by shaving or depilatories, waxing, electrolysis, or bleaching should be encouraged. **Eflornithine** (Vaniqa 13.9%) topical cream retards hair growth when applied twice daily to unwanted facial hair; improvement is noted within 4–8 weeks. However, local skin irritation may occur. Hirsutism returns with discontinuation. **Laser therapy** (photoepilation) is a fairly effective treatment for facial hirsutism, particularly for women with dark hair and

light skin; longer-wavelength lasers are used for women with darker skin. Complications of laser therapy include skin hypopigmentation (rare) and hyperpigmentation, which occurs in 20% but usually resolves; a paradoxical increase in hair growth occurs infrequently. Repeated laser treatments are usually required.

Topical minoxidil, 2% solution applied twice daily to a dry scalp, may be used to effectively treat women with androgenic alopecia. Hypertrichosis is an unwanted side effect of topical minoxidil, occurring in 3–5% of treated women; it may affect the forehead, cheeks, upper lip, or chin. Hypertrichosis resolves within 1–6 months after the drug is stopped.

Antiandrogen treatments *must* be given only to non-pregnant women. Women must be counseled to take oral contraceptives, when indicated, and avoid pregnancy, since use during pregnancy causes malformations and pseudohermaphroditism in male infants.

Banaszewska B et al. Effects of simvastatin and oral contraceptive agent on polycystic ovary syndrome: prospective, randomized, crossover trial. *J Clin Endocrinol Metab.* 2007 Feb;92(2):456–61. [PMID: 17105841]

Castelo-Branco C et al. Comprehensive clinical management of hirsutism. *Gynecol Endocrinol.* 2010 Jul;26(7):484–93. [PMID: 20218823]

Escobar-Morreale HF. Diagnosis and management of hirsutism. *Ann NY Acad Sci.* 2010 Sep;1205:166–74. [PMID: 20840269]

Harrison S et al. Update on the management of hirsutism. *Cleve Clin J Med.* 2010 Jun;77(6):388–98. [PMID: 20516250]

Koulouri O et al. Management of hirsutism. *BMJ.* 2009 Mar 27;338:b847. [PMID: 19329515]

Nestler JE. Metformin for the treatment of the polycystic ovary syndrome. *N Engl J Med.* 2008 Jan;358(1):47–54. [PMID: 18172174]

Nouri K et al. Photoepilation: a growing trend in laser-assisted cosmetic dermatology. *J Cosmet Dermatol.* 2008 Mar;7(1):61–7. [PMID: 18254814]

PRIMARY ALDOSTERONISM



ESSENTIALS OF DIAGNOSIS

- ▶ Hypertension that may be severe or drug-resistant.
- ▶ Hypokalemia (in minority of patients) may cause polyuria, polydipsia, muscle weakness.
- ▶ Elevated plasma and urine aldosterone levels and low plasma renin level.

▶ General Considerations

Primary aldosteronism (hyperaldosteronism) causes hypertension by an inappropriately high aldosterone secretion that does not suppress adequately with sodium loading. Primary aldosteronism is believed to account for 8% of all cases of hypertension and 20% of cases of resistant hypertension. It may be difficult to distinguish primary aldosteronism from cases of low renin essential hypertension, with which it may overlap. Patients of all ages may be affected,

but the peak incidence is between 30 years and 60 years. Excessive aldosterone production increases sodium retention and suppresses plasma renin. It increases renal potassium excretion, which can lead to hypokalemia. Cardiovascular events are more prevalent in patients with aldosteronism (35%) than in those with essential hypertension (11%). Primary aldosteronism may be caused by an aldosterone-producing adrenal adenoma (Conn syndrome), 40% of which have been found to have somatic mutations in a gene involved with the potassium channel. Primary aldosteronism is also commonly caused by unilateral or bilateral adrenal hyperplasia. Bilateral aldosteronism may be corticosteroid suppressible, due to an autosomal-dominant genetic defect allowing ACTH stimulation of aldosterone production.

▶ Clinical Findings

A. Symptoms and Signs

Patients have hypertension that is typically moderate. Some patients have only diastolic hypertension, without other symptoms and signs. Edema is rarely seen in primary aldosteronism. About 37% of patients have hypokalemia and may consequently have symptoms of muscular weakness (at times with paralysis simulating periodic paralysis), paresthesias with frank tetany, headache, polyuria, and polydipsia.

B. Laboratory Findings

Screening for hyperaldosteronism is usually with PRA. About 20% of hypertensive patients have a low PRA, and a significant portion of these patients have primary aldosteronism. Initial screening can also include both aldosterone and plasma renin activity to determine an aldosterone to renin ratio (see below).

Plasma potassium should also be determined in hypertensive individuals. However, hypokalemia, once thought to be the hallmark of hyperaldosteronism, is present in only 37% of affected patients: 50% of those with an adrenal adenoma and 17% of those with adrenal hyperplasia. Proper phlebotomy technique is important to avoid spurious increases in potassium. The blood should be drawn slowly with a syringe and needle (rather than a vacutainer) at least 5 seconds after tourniquet release and without fist-clenching. Plasma potassium, rather than the routine serum potassium, should be measured in cases of unexpected hyperkalemia, with the separation of plasma from cells within 30 minutes of collection. Besides hypokalemia, many patients with primary aldosteronism have metabolic alkalosis with an elevated serum bicarbonate (HCO_3^-) concentration.

Testing for primary aldosteronism should be done for all hypertensive patients with hypokalemia, whether spontaneous or diuretic induced. But since only a minority of affected patients have hypokalemia, testing should also be considered for normokalemic hypertensive patients with (1) treatment-resistant hypertension (despite three drugs); (2) severe hypertension: > 160 mm Hg systolic or > 100 mm Hg diastolic; (3) early-onset hypertension; (4) low-renin hypertension; (5) hypertension with an adrenal mass; and (6) family history of aldosteronism.

For a patient to be properly tested for primary aldosteronism, certain antihypertensive medications should ideally be held. Diuretics should be discontinued for 3 weeks. Dihydropyridine calcium channel blockers can normalize aldosterone secretion, thus interfering with the diagnosis. β -Blockers suppress PRA in patients with essential hypertension. Antihypertensive medications that have minimal effects on the plasma aldosterone:renin ratio include ACE inhibitors, α -blockers, verapamil, hydralazine, prazosin, doxazosin, and terazosin. However, it may be impractical to hold or change antihypertensive medicines; in such cases, testing should proceed.

During the testing period, the patient should have an unrestricted high sodium intake. The patient should be out of bed for at least 2 hours and seated for 5–15 minutes before the blood draw, which should preferably be obtained between 8 AM and 10 AM. Renin is measured as either PRA or direct renin concentration. Serum aldosterone should ideally be measured with a tandem mass spectrometry assay.

For patients who have not been receiving diuretics for at least 3 weeks, a plasma renin activity (PRA) that is normal or elevated makes primary aldosteronism very unlikely. However, a low PRA alone cannot establish the diagnosis of primary aldosteronism, since it occurs in many patients with essential hypertension. An aldosterone:renin ratio is a sensitive screening test. Serum aldosterone (ng/dL):PRA (ng/mL/h) ratios < 24 exclude primary aldosteronism, whereas ratios between 24 and 67 are suspicious and ratios > 67 are very suggestive of primary aldosteronism. Such elevated ratios are not diagnostic; rather, they indicate the need to document increased aldosterone secretion with a 24-hour urine collection. Another problem with the aldosterone:renin ratio is the use of different units and measurements. For aldosterone, 1 ng/dL converts to 27.7 pmol/L. For renin, a PRA of 1 ng/mL/h (12.8 pmol/L/min) converts to a direct renin concentration of 5.2 ng/L (8.2 mU/L).

When the aldosterone:renin ratio is high, a 24-hour urine collection is assayed for aldosterone, free cortisol, and creatinine. A low PRA (< 5 mcg/L/h) with a urine aldosterone over 20 mcg/24 h indicates primary aldosteronism.

Once primary aldosteronism is diagnosed, unilateral adrenal aldosteronism may be distinguished from bilateral adrenal aldosteronism by adrenal vein sampling and by further biochemical testing. Plasma may be assayed for 18-hydroxycorticosterone; a level > 100 ng/dL is seen with adrenal neoplasms, whereas levels < 100 ng/dL are non-diagnostic. In addition, a posture stimulation test may be performed, but this requires overnight hospitalization. The test is performed by drawing blood for aldosterone at 8 AM while the patient is supine after overnight recumbency and again after the patient is upright for 4 hours. Patients with a unilateral adrenal adenoma usually have a baseline plasma aldosterone level > 20 ng/dL that does not rise. Patients with bilateral adrenal hyperplasia typically have a baseline plasma aldosterone level < 20 ng/dL that rises during upright posture. The accuracy of the posture stimulation test is about 85%.

C. Imaging

All patients with biochemically confirmed primary aldosteronism require a thin-section CT scan of the adrenals to

screen for a rare adrenal carcinoma. In the absence of a large adrenal carcinoma, adrenal CT scanning cannot reliably distinguish unilateral from bilateral aldosterone excess, having a sensitivity of 78% and a specificity of 78% for unilateral aldosteronism. Therefore, the decision to perform a unilateral adrenalectomy should not be based solely on an adrenal CT scan. Instead, patients with primary aldosteronism should be considered for a trial of medical therapy with spironolactone or eplerenone. If medical therapy is ineffective or if surgery is desired for an apparent adrenal adenoma, further evaluation for surgical candidacy should be done with laboratory testing. However, since CT scanning and laboratory testing are often inconclusive, adrenal vein sampling is often required.

D. Adrenal Vein Sampling

Bilateral selective adrenal vein sampling is the most accurate way to determine whether primary aldosteronism is due to unilateral aldosterone excess, which can be treated by adrenalectomy. It is indicated only to direct the surgeon to the correct adrenal and should be performed only if surgery is contemplated. It is particularly useful for patients who are not hypokalemic, who are over age 40 years, or who have an adrenal adenoma < 1 cm diameter. It is particularly difficult to catheterize the right adrenal vein. Therefore, the venous samples are assayed for both aldosterone and cortisol during a cosyntropin (ACTH_{1-24}) infusion to be sure that the sampling has included both adrenal veins. The procedure has a sensitivity of 95% and a specificity of 100% but only when performed by an experienced radiologist. The complication rate is 2.5%. Risks can be minimized if the radiologist avoids adrenal venography and limits the use of contrast.

► Screening

Hyperaldosteronism is the most common cause of refractory hypertension in youth and middle-aged adults. The Endocrine Society's Clinical Practice Guidelines recommend screening for hyperaldosteronism in patients who have any of the following: (1) blood pressure > 160/100 mm Hg; (2) drug-resistant hypertension; (3) hypertension with spontaneous or diuretic-induced hypokalemia; (4) hypertension with adrenal incidentaloma; (5) hypertension with a family history of early-onset hypertension or cerebrovascular accident before age 40 years; (6) hypertension and a first-degree relative with primary aldosteronism.

► Differential Diagnosis

The differential diagnosis of primary aldosteronism includes other causes of hypokalemia (see Chapter 21) in patients with essential hypertension, especially diuretic therapy. Chronic depletion of intravascular volume stimulates renin secretion and secondary hyperaldosteronism. Thus, it is important to discontinue diuretics and ensure adequate hydration and sodium intake when assessing a patient for primary hyperaldosteronism.

Excessive ingestion of real licorice (black and derived from anise) or Sambuca (an Italian liqueur) can cause hypertension and hypokalemia. Real licorice and anise-flavored

drinks (sambuca, pastis) contain glycyrrhizic acid, which has a metabolite that inhibits the adrenal enzyme 11β -hydroxysteroid dehydrogenase type 2 that normally inactivates cortisol in the renal tubule. Higher renal tubular cortisol levels activate aldosterone receptors, resulting in renal tubular absorption of sodium and excretion of potassium. Oral contraceptives may increase aldosterone secretion in some patients. Renal vascular disease can cause severe hypertension with hypokalemia; PRA is high, distinguishing it from primary aldosteronism.

Excessive adrenal secretion of other corticosteroids (besides aldosterone) may also cause hypertension with hypokalemia. This occurs with certain congenital adrenal enzyme disorders such as P450c11 deficiency (increased deoxycorticosterone with virilization and deficient cortisol) or P450c17 deficiency (increased deoxycorticosterone, corticosterone, and progesterone but deficient estradiol and testosterone). P450c17 deficiency results from a defect in the 17-hydroxylase enzyme in both the adrenal and ovarian steroidogenic pathways. Presenting signs include hypertension and ambiguous genitalia or primary amenorrhea. Urinary aldosterone secretion is < 20 mcg/24 h and plasma renin is low in both P450c11 and P450c17 deficiencies. Primary cortisol resistance can cause hypertension and hypokalemia; renin and aldosterone are suppressed, while plasma levels of cortisol, ACTH, and deoxycorticosterone are high. Liddle syndrome is an autosomal dominant cause of hypertension and hypokalemia resulting from excessive sodium absorption from the renal tubule; renin and aldosterone levels are low. Thyrotoxicosis and familial periodic paralysis may also present with hypokalemia. Hyperaldosteronism may rarely be due to a malignant ovarian tumor.

► Complications

The incidence of cardiovascular complications from hypertension are higher in primary aldosteronism than in idiopathic hypertension. Following unilateral adrenalectomy for Conn syndrome, suppression of the contralateral adrenal may result in temporary postoperative hypoaldosteronism, characterized by hyperkalemia and hypotension.

► Treatment

Conn syndrome (unilateral aldosterone-secreting adrenal adenoma) is treated by laparoscopic adrenalectomy, though long-term therapy with spironolactone or eplerenone is an option. Bilateral adrenal hyperplasia is best treated with spironolactone or eplerenone. Spironolactone also has antiandrogen activity and frequently causes breast tenderness, gynecomastia, or reduced libido; it is given at initial doses of 12.5–25 mg orally once daily; the dose may be titrated upward to 200 mg daily. Eplerenone is becoming favored for men, since it does not have antiandrogen effects; however, it has a short half-life and must be given twice daily in oral doses of 25–50 mg. Blood pressure must be monitored daily when beginning these anti-mineralocorticoid medications; significant drops in blood pressure have occurred when these drugs are added to other antihypertensives. Other antihypertensive drugs may

also be required. Glucocorticoid-remediable aldosteronism is very rare but may respond well to suppression with low-dose dexamethasone.

► Prognosis

The hypertension is reversible in about two-thirds of cases but persists or returns in spite of surgery in the remainder. The prognosis is much improved by early diagnosis and treatment. Only 2% of aldosterone-secreting adrenal tumors are malignant.

- Carey RM. Adrenal disease update 2011. 2011 Dec;96(12):3583–91. [PMID: 22143828]
- Choi M et al. K^+ channel mutations in adrenal aldosterone-producing adenomas and hereditary hypertension. *Science*. 2011 Feb;331(6018):768–72. [PMID: 21311022]
- Quinkler M et al. Treatment of primary aldosteronism. *Best Pract Res Clin Endocrinol Metab*. 2010 Dec;24(6):923–32. [PMID: 21115161]
- Rossi GP. Diagnosis and treatment of primary aldosteronism. *Rev Endocr Metab Disord*. 2011 Mar;12(1):27–36. [PMID: 21369868]
- Schwartz GL. Screening for adrenal-endocrine hypertension: overview of accuracy and cost-effectiveness. *Endocrinol Metab Clin North Am*. 2011 Jun;40(2):279–94. [PMID: 21565667]
- Tomaschitz A et al. Aldosterone to renin ratio—a reliable screening tool for primary aldosteronism? *Horm Metab Res*. 2010 Jun;43(6):382–91. [PMID: 20225167]

PHEOCHROMOCYTOMA & PARAGANGLIOMA

ESSENTIALS OF DIAGNOSIS

- “Attacks” of headache, perspiration, palpitations, anxiety.
- Hypertension, frequently sustained but often paroxysmal, especially during surgery or delivery.
- Elevated urinary catecholamines or their metabolites. Normal serum T_4 and TSH.

► General Considerations

Both pheochromocytomas and non-head-neck paragangliomas are tumors of the sympathetic nervous system. Pheochromocytomas arise from the adrenal medulla and usually secrete both epinephrine and norepinephrine. Paragangliomas (“extra-adrenal pheochromocytomas”) arise from sympathetic paraganglia, often metastasize, and secrete norepinephrine or are nonsecretory. Excessive levels of norepinephrine or neuropeptide Y cause hypertension, while epinephrine causes tachyarrhythmias. These tumors may be located in either or both adrenals or anywhere along the sympathetic nervous chain, and rarely in such aberrant locations as the mediastinum, heart, or bladder.

These rare tumors are deceptive and deadly. They are a rare cause of hypertension, being found in $< 0.3\%$ of hypertensive individuals. The incidence is higher in patients

with moderate to severe hypertension. About two to three new cases per million population are diagnosed annually. However, in autopsy cases, the incidence of pheochromocytoma is 250–1300 cases per million, indicating that most cases are not diagnosed during life.

About 25% of patients with pheochromocytomas/paragangliomas harbor germline mutations making them prone to develop the tumor. The chance of harboring a germline mutation is nearly 100% in patients with a family history of pheochromocytomas/paragangliomas and 17% in patients without any known family history of pheochromocytomas/paragangliomas.

Pheochromocytomas develop in about 20% of patients with type 2 von Hippel–Lindau (VHL) disease (hemangiomas of the retina, cerebellum, brainstem, and spinal cord; hyperparathyroidism; pancreatic cysts; endolymphatic sac tumors; cystadenomas of the adnexa or epididymis; renal cysts, adenomas, and carcinomas); inheritance is autosomal dominant. Patients with VHL develop pheochromocytomas that are less likely to be extra-adrenal, less likely to be malignant (3.5%), more likely to be bilateral, and more likely to present at an early age. Pheochromocytomas that arise in patients with VHL secrete exclusively norepinephrine and its metabolite normetanephrine. Therefore, individuals who carry type 2 VHL mutations should be screened for pheochromocytoma with plasma normetanephrine levels.

MEN 2A is associated with pheochromocytomas and medullary thyroid carcinoma. **MEN 2B** is associated with pheochromocytomas, aggressive medullary thyroid carcinoma, mucosal neuromas, and marfanoid habitus. **von Recklinghausen neurofibromatosis type 1 (NF-1)** is associated with an increased risk of pheochromocytomas/paragangliomas as well as cutaneous neurofibromas, optic gliomas, vascular anomalies, hamartomas, malignant nerve sheath tumors, and smooth-bordered café au lait spots. **Familial paraganglioma** can be caused by mutations in the genes encoding succinate dehydrogenase (SDH) subunits B, C, or D. Patients with such germline mutations are more apt to have bilateral pheochromocytomas or multicentric paragangliomas.

► Clinical Findings

A. Symptoms and Signs (Table 26–12)

Pheochromocytomas can be lethal unless they are diagnosed and treated appropriately. Catastrophic hypertensive crisis and fatal cardiac arrhythmias can occur spontaneously or may be triggered by intravenous contrast dye or glucagon injection, needle biopsy of the mass, anesthesia, or surgical procedures. Paroxysms can be triggered by exercise, bending, lifting, or emotional stress. Certain drugs can precipitate attacks: monoamine oxidase (MAO) inhibitors, caffeine, nicotine, decongestants, amphetamines, cocaine, ionic intravenous contrast, and epinephrine. Bladder paragangliomas may present with paroxysms during micturition.

Paroxysms typically produce hypertension (90%) and such symptoms as severe headache (80%), perspiration (70%), and palpitations (60%); other symptoms may include anxiety (50%), a sense of impending doom, or

tremor (40%). Vasomotor changes during an attack cause mottled cyanosis and facial pallor; as the attack subsides, facial flushing may occur as a result of reflex vasodilation. Epinephrine secretion by an adrenal pheochromocytoma may cause episodic tachyarrhythmias, hypotension, or even syncope. Acute coronary syndrome can be caused by coronary vasoconstriction. Confusion, psychosis, seizures, transient ischemic attacks, or stroke may occur with cerebrovascular vasoconstriction or hemorrhagic stroke. Aortic aneurysms may dissect and rupture. Abdominal pain, nausea, vomiting, and even ischemic bowel can be due to splanchnic vasoconstriction. Large or hemorrhagic abdominal tumors can also cause abdominal pain. Peripheral vasoconstriction can cause Raynaud phenomenon or even gangrene. Patients may experience nervousness and irritability, increased appetite, and loss of weight. Other patients have pulmonary edema and heart failure due to cardiomyopathy. Cytokine release can cause nephrotic syndrome or acute respiratory distress syndrome (ARDS). Although most patients are symptomatic, some patients are normotensive and asymptomatic, particularly when the tumor is nonsecretory or discovered at an early stage.

B. Laboratory Findings

Plasma fractionated free metanephrines is the single most sensitive test for secretory pheochromocytomas and paragangliomas. Normal levels rule out pheochromocytoma and paraganglioma with some certainty and the work-up can usually end there. However, misleading elevations in metanephrines or normetanephrines can be caused by factors such as physical or emotional stress, sleep apnea, and MAO inhibitors. Therefore, patients with elevated plasma metanephrines or normetanephrines levels require further evaluation.

Assay of urinary fractionated metanephrines and creatinine effectively confirms most pheochromocytomas that were detected by elevated plasma fractionated metanephrines. A 24-hour urine specimen is usually obtained, although an overnight or shorter collection may be used; patients with pheochromocytomas generally have more than 2.2 mcg of total metanephrine per milligram of creatinine, and more than 135 mcg total catecholamines per gram creatinine. Urinary assay for total metanephrines is about 97% sensitive for detecting functioning pheochromocytomas. Urinary assay for vanillylmandelic acid (VMA) is not usually required.

Some drugs and foods can interfere with certain assays for catecholamines, and stresses can also cause misleading elevations in catecholamine excretion (Table 26–13). About 10% of hypertensive patients have a misleadingly elevated level of one or more tests.

Serum chromogranin A is elevated in 90% of patients with pheochromocytoma and the levels correlate with tumor size, being higher in patients with metastatic disease. Serum chromogranin A levels can be misleadingly elevated in patients with azotemia or hypergastrinemia, and in those treated with corticosteroids or proton pump inhibitors. Serum may also be assayed for neuron-specific enolase; high levels implicate a malignant pheochromocytoma, while normal levels are nonspecific.

Table 26-12. Clinical manifestations of pheochromocytoma and paraganglioma.

Blood pressure	Hypertension: severe or mild, paroxysmal or sustained; orthostasis; hypotension/shock; normotension
Vasospasm	Cyanosis, Raynaud syndrome, gangrene; severe radial artery vasospasm with thready pulse; falsely low blood pressure by radial artery transducer
Multisystem crisis	Severe hypertension/hypotension, fever, encephalopathy, ARDS, renal failure, hepatic failure, death
Cardiovascular	Palpitations, dysrhythmias, chest pain, acute coronary syndrome, cardiomyopathy, heart failure, cardiac paragangliomas
Gastrointestinal	Abdominal pain, nausea, vomiting, weight loss, intestinal ischemia; pancreatitis, cholecystitis, jaundice; rupture of abdominal aneurysm; constipation, toxic megacolon
Metabolic	Hyperglycemia/diabetes, lactic acidosis, fevers
Neurologic	Headache, paresthesias, numbness, dizziness, CVA, TIA, hemiplegia, hemianopsia, seizures, hemorrhagic stroke; skull metastases may impinge on brain structures, optic nerve, or other cranial nerves; spinal metastases may impinge on cord or nerve roots
Pulmonary	Dyspnea; hypoxia from ARDS
Psychiatric	Anxiety attacks or constant anxiety; depression; chronic fatigue; psychosis
Renal	Renal insufficiency, nephrotic syndrome, malignant nephrosclerosis; large tumors often involve the kidneys and renal vessels
Skin	Apocrine sweating during paroxysms, drenching sweats as attack subsides; eczema; mottled cyanosis during paroxysm
Thyroid	Paroxysmal thyroid swelling
Ectopic hormones	ACTH (Cushing syndrome); VIP (Verner-Morrison syndrome); PTHrP (hypercalcemia); erythropoietin (erythrocytosis)
Children	More commonly have sustained hypertension, diaphoresis, visual changes, polyuria/polydipsia, seizures, edematous or cyanotic hands; more commonly harbor germline mutations, multiple tumors, and paragangliomas
Women	More symptomatic than men: more frequent headache, weight loss, numbness, dizziness, tremor, anxiety, and fatigue
Pregnancy	Hypertension mimicking eclampsia; hypertensive multisystem crisis during vaginal delivery; postpartum shock or fever; high mortality
General laboratory	Leukocytosis, erythrocytosis, eosinophilia

ACTH, adrenocorticotropic hormone; ARDS, acute respiratory distress syndrome; CVA, cerebrovascular accident; PTHrP, parathyroid hormone-related protein; TIA, transient ischemic attack; VIP, vasoactive intestinal peptide.

Used, with permission, from Gardner D, Shoback D (editors). *Greenspan's Basic and Clinical Endocrinology*. 9th edition, McGraw-Hill, NY, 2011.

Pharmacologic provocative and suppressive tests that evaluate the rise or fall in blood pressure are usually not required or recommended.

Hyperglycemia is present in about 35% of patients but is usually mild. Leukocytosis is common. The ESR is sometimes elevated. PRA may be increased by catecholamines.

Genetic testing should ideally be performed on all patients with pheochromocytoma or paraganglioma. Testing for VHL, *ret* protooncogene, and SDHB/SDHD mutations is advisable. Family members may then be screened for the specific gene mutation.

C. Imaging

1. CT and MRI scanning—Imaging should not usually replace biochemical testing, since incidental adrenal adenomas are common (2–4% of scans) and can be misleading. When a pheochromocytoma is suspected because of biochemical testing or a genetic condition predisposing to

pheochromocytoma, a CT scan of the abdomen is performed, with thin sections through the adrenals. *A noncontrast CT should be followed by a CT scan using nonionic contrast, which reduces the risk of catecholamine release from a pheochromocytoma and a hypertensive crisis.* Glucagon should not be used during scanning, since it can provoke hypertensive crisis; similarly, intravenous contrast can precipitate hypertensive crisis, particularly in patients whose hypertension is uncontrolled.

MRI scanning has the advantage of not requiring intravenous contrast dye; its lack of radiation makes it the imaging of choice during pregnancy and childhood. Both CT and MRI scanning have a sensitivity of about 90% for adrenal pheochromocytoma and a sensitivity of 95% for adrenal tumors over 0.5 cm in diameter. However, both CT and MRI are less sensitive for detecting recurrent tumors, metastases, and extra-adrenal paragangliomas. If no adrenal tumor is found, the scan is extended to include the entire abdomen, pelvis, and chest.

Table 26-13. Factors potentially causing misleading catecholamine results: High-performance liquid chromatography with electrochemical detection (HPLC-ECD).

Drugs	Foods	Conditions
Acetaminophen ²	Bananas ¹	Amyotrophic lateral sclerosis ¹
Aldomet ²	Caffeine ¹	Brain lesions ¹
Amphetamines ¹	Coffee ²	Carcinoid ¹
Bronchodilators ¹	Peppers ²	Eclampsia ¹
Bupirone ²	Pineapples ¹	Emotion, severe ¹
Captopril ²	Walnuts ¹	Exercise, vigorous ¹
Cimetidine ²		Guillain-Barré syndrome ¹
Cocaine ¹		Hypoglycemia ¹
Codeine ²		Kidney disease ³
Decongestants ¹		Lead poisoning ¹
Ephedrine ¹		Myocardial infarct, acute ¹
Fenfluramine ³		Pain, severe ¹
Isoproterenol ¹		Porphyria, acute ¹
Labetalol ^{1,2}		Psychosis, acute ¹
Levodopa ²		Quadriplegia ¹
Mandelamine ²		Sleep apnea
Metoclopramide ²		
Nitroglycerin ¹		
Phenoxybenzamine		
Tricyclic antidepressants		
Viloxazine ²		

¹Increases catecholamine excretion.

²May cause confounding peaks on HPLC chromatograms.

³Decreases catecholamine excretion.

2. Nuclear imaging—A whole-body ¹²³I-*meta*-iodobenzylguanidine (¹²³I-MIBG) scan can localize tumors with a sensitivity of 94% and a specificity of 92%. It is less sensitive for MEN 2A- or MEN 2B-related pheochromocytomas and for metastases. Preoperative ¹²³I-MIBG scanning is not usually required to confirm that a unilateral adrenal mass is a pheochromocytoma in a patient with classic clinical and biochemical presentation. Preoperative whole-body ¹²³I-MIBG scanning can be useful when the CT scan cannot locate a suspected pheochromocytoma, making a paraganglioma more likely; it can also be useful when the CT scan is ambiguous for pheochromocytoma. It is prudent to perform a whole-body ¹²³I-MIBG scan about 3 months postoperatively to determine if metastatic or recurrent tumor is present. Drugs that reduce ¹²³I-MIBG uptake should be avoided, including tricyclic antidepressants and cyclobenzaprine (6 weeks), amphetamines, nasal decongestants, phenothiazines, haloperidol, diet pills, labetalol, and cocaine (2 weeks).

Somatostatin receptor imaging using ¹¹¹In-labeled octreotide is only 25% sensitive for detecting an adrenal pheochromocytoma. However, ¹¹¹In-labeled octreotide scanning is quite sensitive for detecting extra-adrenal pheochromocytomas (paragangliomas) and metastatic pheochromocytomas, sometimes locating tumors that were missed by ¹²³I-MIBG scanning.

PET scanning usually detects tumors using ¹⁸F-labeled deoxyglucose (¹⁸FDG-PET) or ¹⁸F-labeled dopamine (¹⁸FDA-PET), and may demonstrate tumors that are not visible on ¹²³I-MIBG scanning. Combining PET scan with

noncontrast CT produces a PET/CT fusion scan with exceptional sensitivity.

► Differential Diagnosis

Certain conditions mimic pheochromocytoma: thyrotoxicosis, essential hypertension, myocarditis, glomerulonephritis or other renal lesions, eclampsia, and psychoneurosis (anxiety attack). Toxemia of pregnancy is associated with hypertension and increased catecholamine production.

Conditions that have manifestations similar to those of pheochromocytoma include the following: essential labile hypertension, renal hypertension, anxiety attacks, thyrotoxicosis, toxemia of pregnancy, acute intermittent porphyria, hypogonadal vascular instability (hot flushes), cocaine or amphetamine use, and clonidine withdrawal. Patients taking nonselective MAO inhibitor antidepressants can have hypertensive crisis after eating foods that contain tyramine (eg, fermented cheeses, aged wines, certain beers, fava beans, vegemite, marmite). Patients with erythromelalgia can have hypertensive crises; their episodic painful flushing and leg swelling are relieved by cold, distinguishing this condition from pheochromocytoma. Pheochromocytomas can cause chest pain and ECG changes that mimic acute cardiac ischemia. Renal artery stenosis can cause severe hypertension and may coexist with pheochromocytoma.

False-positive testing for catecholamines and metabolites occurs in about 10% of hypertensives, but levels are usually < 50% above normal and typically normalize with repeat testing.

► Complications

All of the complications of severe hypertension may be encountered. In addition, a catecholamine-induced cardiomyopathy may develop. Severe heart failure and cardiovascular collapse may develop in patients during a paroxysm. Sudden death may occur due to cardiac arrhythmia. ARDS has been reported. Hypertensive crises with sudden blindness or cerebrovascular accidents are not uncommon. Paroxysms may be spontaneous or precipitated by sudden movement, exertion, manipulation, vaginal delivery, emotional stress, trauma, or surgical removal of the tumor. Decongestant medications, fluoxetine, and other selective serotonin reuptake inhibitors may induce hypertensive paroxysms and death. Occasionally, the initial manifestation of pheochromocytoma may be hypotension or even shock.

After removal of the tumor, a state of severe hypotension and shock (resistant to epinephrine and norepinephrine) may ensue with precipitation of kidney disease or myocardial infarction. Hypotension and shock may occur from spontaneous infarction or hemorrhage of the tumor.

On rare occasions, a patient dies as a result of the complications of diagnostic tests or during surgery. During surgery, pheochromocytoma cells may be seeded within the peritoneum, resulting in multifocal recurrent tumors.

► Medical Treatment

Patients must receive adequate treatment for hypertension and tachyarrhythmias prior to surgery for pheochromocytoma/paraganglioma. Patients are advised

to use a portable sphyngomanometer and measure their blood pressures daily and immediately during paroxysms. Some patients with pheochromocytoma or paraganglioma are not hypertensive and do not require preoperative antihypertensive management.

α -Blockers are typically administered preparatory to surgery. Phenoxybenzamine is a long-acting nonselective α -blocker with a half-life of 24 hours; it is given initially in a dosage of 10 mg orally every 12 hours, increasing gradually by about 10 mg/d about every 3 days until hypertension is controlled. Maintenance doses range from 10 mg/d to 120 mg/d. Selective α_1 -blockers may be used: doxazosin (half-life 22 hours), terazosin (half-life 12 hours), or prazosin (half-life 3 hours). Patients given preoperative phenoxybenzamine experience less intraoperative hypertension but greater post-resection hypotension than patients given preoperative selective α_1 -blockers. Optimal α -blockade is achieved when supine arterial pressure is below 140/90 mm Hg or as low as possible for the patient to have a standing arterial pressure above 80/45 mm Hg.

Calcium channel blockers (nifedipine ER or nicaldipine ER) are very effective and may be used with or without α -blockers. They are superior to phenoxybenzamine for long-term use, since they cause less fatigue, nasal congestion, and orthostatic hypotension. For acute hypertensive crisis (systolic blood pressure > 170 mm Hg) a nifedipine 10-mg capsule may be chewed and swallowed. Nifedipine is quite successful for treating acute hypertension in patients with pheochromocytoma/paraganglioma, even at home; it is reasonably safe as long as the blood pressure is monitored.

β -Blockers (eg, metoprolol XL) are often required after institution of α -blockade or calcium channel blockade. The use of a β -blocker as initial antihypertensive therapy has resulted in an “unopposed alpha” that causes paradoxical worsening of hypertension. Labetalol has combined α - and β -blocking activity and is an effective agent but can cause paradoxical hypertension if used as the initial antihypertensive agent. Labetalol can also interfere with catecholamine determinations in some laboratories and reduces the tumor’s uptake of radioisotopes, such that it must be discontinued for at least 4–7 days before diagnostic scanning with ^{123}I -MIBG or ^{18}F FDG-PET or ^{131}I -MIBG therapy.

► Surgical Treatment

Surgical removal of pheochromocytomas or abdominal paragangliomas is the treatment of choice. For surgery, a team approach—endocrinologist, anesthesiologist, and surgeon—is critically important. Laparoscopic surgery is preferred, but large and invasive tumors require open laparotomy. Patients with small familial or bilateral pheochromocytomas may undergo selective resection of the tumors, sparing the adrenal cortex; however, there is a recurrence rate of 10% over 10 years.

Prior to surgery, blood pressure control should be maintained for a minimum of 4–7 days or until optimal cardiac status is established. The ECG should be monitored until it becomes stable. (It may take a week or even months to correct ECG changes in patients with catecholamine

myocarditis, and it may be prudent to defer surgery until then in such cases.) Patients must be very closely monitored during surgery to promptly detect sudden changes in blood pressure or cardiac arrhythmias.

Intraoperative severe hypertension is managed with continuous intravenous nicardipine (a short-acting calcium channel blocker), 2–6 mcg/kg/min, or nitroprusside, 0.5–10 mcg/kg/min. Prolonged nitroprusside administration can cause cyanide toxicity. Tachyarrhythmia is treated with intravenous atenolol (1 mg boluses), esmolol, or lidocaine.

Autotransfusion of 1–2 units of blood at 12 hours preoperatively plus generous intraoperative volume replacement reduces the risk of postresection hypotension caused by desensitization of the vascular α_1 -receptors. Shock may therefore occur following removal of the pheochromocytoma. It is treated with intravenous saline or colloid and high doses of intravenous norepinephrine. Intravenous 5% dextrose is infused postoperatively to prevent hypoglycemia.

► Managing Metastatic Pheochromocytoma & Paraganglioma

Surgical histopathology for pheochromocytoma or paraganglioma cannot reliably determine whether a tumor is malignant. Therefore, all pheochromocytomas and paragangliomas must be approached as possibly malignant. Even if no metastases are visible at the time of surgery, they may become apparent years later. So all patients require lifetime follow-up. Therefore, it is essential to recheck plasma fractionated metanephrine levels postoperatively, at least 2–4 weeks after surgery and when the patient has minimal residual pain. It is also prudent to perform a whole-body ^{123}I -MIBG scan about 3 months postoperatively, since previously undetected metastases may become visible. Thereafter, blood pressure and symptoms must be rechecked regularly for life; plasma fractionated metanephrines are also rechecked regularly, at least every 6 months for 5 years, then once yearly for life and immediately if hypertension or symptoms recur or if metastases become evident. Since some metastases are indolent, it is important to tailor treatment to each individual according to their tumor’s aggressiveness. Most surgeons resect the main tumor and larger metastases (debulking). Indolent metastases may be kept under close surveillance. Patients with osteolytic bone metastases may be treated with external beam radiation therapy, which is often helpful in relieving pain and stabilizing local osseous disease. Intravenous zoledronic acid may also be administered to patients with osteolytic bone metastases. Various chemotherapy regimens have been used, but there have been no controlled clinical trials to prove the effectiveness of one regimen over another or whether any regimen actually improves overall survival. The most common chemotherapy regimen combines cyclophosphamide, vincristine, and dacarbazine in cycles that are repeated every 3 weeks. About one-third of patients experience some degree of temporary remission. Another chemotherapy regimen uses temozolomide, 250 mg/d orally for 5 days, repeating the cycle every 28 days. Sunitinib, a tyrosine kinase inhibitor, can also produce remissions, given in doses of 50 mg/d for 4 weeks on and then 2 weeks off; alternatively, a dose of 37.5 mg/d can be

given continuously. Each chemotherapy regimen has toxicities.

About 60% of patients with metastatic pheochromocytoma or paraganglioma have tumors with sufficient uptake of ^{123}I -MIBG on diagnostic scanning to allow for therapy with high-activity ^{131}I -MIBG. Activities of 125–500 mCi are infused, with many centers administering repeated infusions of 2 mCi/kg to cumulative activities of at least 500–800 mCi. Radioisotope therapy can suppress the bone marrow temporarily. Myelodysplastic syndrome and leukemia can develop several years after ^{131}I -MIBG therapy, with the risk proportional to the cumulative amount of isotope. ARDS and multisystem failure can occur rarely after ^{131}I -MIBG therapy, particularly in patients with pretreatment proteinuria.

For inoperable or metastatic secretory tumors, metyrosine reduces catecholamine synthesis but does not impede the progressive growth of metastases; the initial metyrosine dosage is 250 mg four times daily, increased daily by increments of 250–500 mg to a maximum of 4 g/d. Metyrosine causes central nervous system side effects and crystalluria; hydration must be ensured. Metastatic pheochromocytomas may be treated with combination chemotherapy (eg, cyclophosphamide, vincristine, and dacarbazine) or with high doses of ^{131}I -MIBG.

► Prognosis

The malignancy of a pheochromocytoma or sympathetic paraganglioma cannot be determined by its size or histologic examination. A tumor is considered malignant if metastases are present; this may take many years to become clinically evident. Therefore, lifetime surveillance is required. Malignancy is more likely for larger tumors and for sympathetic paragangliomas. The prognosis is good for patients with pheochromocytomas that are resected before causing cardiovascular damage. Hypertension usually resolves after successful surgery but may persist or return in 25% of patients despite successful surgery. Although this may be essential hypertension, biochemical reevaluation is then required, looking for a second or metastatic pheochromocytoma.

Formerly, the surgical mortality was as high as 30%, but the development of laparoscopic surgical techniques, improved anesthesia, intraoperative monitoring, and preoperative blood pressure control with α -blockers or calcium channel blockers has reduced surgical mortality to < 3%.

Patients with metastatic pheochromocytoma and paraganglioma have an extremely variable prognosis. Patients with a heavy and progressive tumor burden and distant metastases have a worse prognosis; patients with multiple pulmonary metastases have limited survival. Patients harboring *SDHB* germline mutations often have more aggressive tumors. Those with metastases limited to the abdomen or bone tend to have a better prognosis. Patients who receive surgery and chemotherapy have a median survival of about 44%. Patients undergoing surgery and high-dose ^{131}I -MIBG therapy have been reported to have a 5-year survival rate of 75%. It is important to note that some patients have an indolent malignancy and prolonged survivals of up to 30 years have been reported with no treatment.

Ayala-Ramirez M et al. Clinical risk factors for malignancy and overall survival in patients with pheochromocytomas and sympathetic paragangliomas: primary tumor size and primary tumor location as prognostic indicators. *J Clin Endocrinol Metab.* 2011 Mar;96(3):717–25. [PMID: 21190975]

De Jong WH et al. Elevated urinary free and deconjugated catecholamines after consumption of a catecholamine-rich diet. *J Clin Endocrinol Metab.* 2010 Jun;95(6):2851–5. [PMID: 20382681]

Gonias S et al. Phase II study of high-dose [^{131}I]metaiodobenzylguanidine therapy for patients with metastatic pheochromocytoma and paraganglioma. *J Clin Oncol.* 2009 Sep;27(25):4162–8. [PMID: 19636009]

Lenders JW. Biochemical diagnosis of pheochromocytoma and paraganglioma. *Ann Endocrinol (Paris).* 2009 Jun;70(3):161–5. [PMID: 19296926]

Shao Y et al. Preoperative alpha blockade for normotensive pheochromocytoma: is it necessary? *J Hypertens.* 2011 Dec;29(12):2429–32. [PMID: 22025238]

Shen WT et al. One hundred two patients with pheochromocytoma treated at a single institution since the introduction of laparoscopic adrenalectomy. *Arch Surg.* 2010 Sep;145(9):893–7. [PMID: 20855761]

Weingarten TN et al. Comparison of two preoperative medical management strategies for laparoscopic resection of pheochromocytoma. *Urology.* 2010 Aug;76(2):508.e6–11. [PMID: 20546874]

PANCREATIC & DUODENAL NEUROENDOCRINE TUMORS*

ISLET CELL TUMORS

ESSENTIALS OF DIAGNOSIS

- Half the tumors are nonsecretory; weight loss, abdominal pain, or jaundice may be presenting signs.
- Secretory tumors cause a variety of manifestations depending on the hormones secreted.

► General Considerations

The pancreatic islets are composed of several types of cells, each with distinct chemical and microscopic features: the A cells (20%) secrete glucagon, the B cells (70%) secrete insulin, and the D cells (5%) secrete somatostatin or gastrin. F cells secrete “pancreatic polypeptide.”

Pancreatic neuroendocrine tumors constitute < 5% of all pancreatic tumors. Pancreatic neuroendocrine tumors are rare, with an incidence of about 10 per million yearly. About 40% are functional, producing hormones that are tumor markers, which are important for diagnosis and follow-up. Although most pancreatic and duodenal neuroendocrine tumors arise spontaneously, they may occur as part four different inherited disorders: MEN 1,

*Diabetes mellitus and hyperglycemia are discussed in Chapter 27.

von Hippel-Lindau disease (VHL), neurofibromatosis 1 (NF-1) and the rare tuberous sclerosis complex (TSC).

Insulinomas are usually benign (about 90%) and secrete excessive amounts of insulin that causes hypoglycemia. Insulinomas also produce proinsulin and C-peptide. Insulinomas are solitary in 95% of sporadic cases but are multiple in about 90% of cases arising in MEN 1. (See Chapter 27.)

Gastrinomas secrete excessive quantities of the hormone gastrin (as well as “big” gastrin), which stimulates the stomach to hypersecrete acid, thereby causing hyperplastic gastric rugae and peptic ulceration (Zollinger–Ellison syndrome). About 50% of gastrinomas are malignant and metastasize to the liver. Gastrinomas are typically found in the duodenum (49%), pancreas (24%), or lymph nodes (11%). Sporadic Zollinger–Ellison syndrome is rarely suspected at the onset of symptoms; typically, there is a 5-year delay in diagnosis. About 22% of patients have MEN 1. In patients with MEN 1, gastrinomas usually present at a younger age; hyperparathyroidism may occur from 14 years preceding the Zollinger–Ellison diagnosis to 38 years afterward.

Glucagonomas are usually malignant; liver metastases are ordinarily present by the time of diagnosis. They usually secrete other hormones besides glucagon, often gastrin.

Somatostatinomas are very rare and are associated with weight loss, diabetes mellitus, malabsorption, and hypochlorhydria.

VIPomas are rare pancreatic neuroendocrine tumors that produce vasoactive intestinal polypeptide (VIP), a substance that causes profuse watery diarrhea and profound hypokalemia (Verner–Morrison syndrome).

Nonfunctional pancreatic neuroendocrine tumors produce no significant hormones and usually grow to large size prior to detection. They typically present with symptoms caused by mass effect.

Carcinoid pancreatic neuroendocrine tumors are typically indolent but usually metastasize to local and distant sites, particularly to other endocrine organs.

► Clinical Findings

A. Symptoms and Signs

Presenting symptoms and signs of **gastrinomas** include abdominal pain (75%), diarrhea (73%), heartburn (44%), bleeding (25%), or weight loss (17%). Endoscopy usually discovers prominent gastric folds (94%).

The 5-, 10-, and 20-year survival rates with MEN 1 are 94%, 75%, and 58%, respectively, while the survival rates for sporadic Zollinger–Ellison syndrome are 62%, 50%, and 31%, respectively. (See Chapter 15.)

Initial symptoms of **glucagonoma** often include weight loss, diarrhea, nausea, peptic ulcer, or necrolytic migratory erythema. About 35% of patients ultimately develop diabetes mellitus. The median survival is 34 months after diagnosis.

Carcinoid pancreatic neuroendocrine tumors secrete serotonin and can produce an atypical carcinoid syndrome manifested by pain, diarrhea, and weight loss; skin flushing occurs in 39% of patients. Islet cell tumors can secrete ectopic hormones in addition to native hormones, often in

combinations that produce various clinical syndromes. They may secrete ACTH and cause Cushing syndrome.

B. Imaging

Localization of noninsulinoma pancreatic islet cell tumors and their metastases is best done with somatostatin receptor scintigraphy (SRS); SRS detects about 75% of noninsulinomas. CT and MRI are also useful. Insulinomas can usually be located preoperatively by endoscopic ultrasonography. For insulinomas, preoperative localization studies are less successful and have the following sensitivities: ultrasonography 25%, CT 25%, endoscopic ultrasonography 27%, transhepatic portal vein sampling 40%, arteriography 45%, intraoperative palpation 55%, and intraoperative pancreatic ultrasound 75%. Nearly all insulinomas can be successfully located at surgery by intraoperative palpation and ultrasound. An abdominal CT scan is usually obtained, but extensive preoperative localization procedures, especially with invasive methods, are not required. Tumors may be located in the pancreatic head or neck (57%), body (15%), or tail (19%) or in the duodenum (9%).

► Treatment

Direct resection of the tumor (or tumors), which often spread locally, is the primary form of therapy for all types of islet cell neoplasms. In Zollinger–Ellison syndrome, gastrinomas are most commonly found in the duodenum but also in the pancreas. Gastric hyperacidity in Zollinger–Ellison syndrome is treated with a proton pump inhibitor at quadruple the usual doses. Proton pump inhibitors increase serum gastrin, which is the tumor marker for gastrinomas; hypercalcemia also stimulates gastrin release.

Insulinomas must be localized with biphasic thin section helical CT and endoscopic ultrasound. Surgery must be guided, either by preoperative endoscopic ultrasound tattooing or by laparoscopic intraoperative ultrasound. Surgery is usually successful for sporadic insulinomas. However, in MEN 1, insulinomas are rarely cured by surgery, with the exception of total pancreatectomy. The hypoglycemia caused by insulinomas may be counteracted by verapamil or diazoxide.

Ocreotide LAR is useful in the therapy of islet cell tumors with the exception of insulinoma; subcutaneous injections of 20–30 mg are required every 4 weeks. Treatment with ocreotide LAR improves the symptoms caused by excessive VIP but does not halt tumor growth. Selective radioembolization of hepatic metastases can be accomplished with the use of yttrium-90(Y)-labeled resin or glass microspheres. The use of streptozocin, doxorubicin, and asparaginase, especially for malignant insulinoma, has produced some encouraging results, though these drugs are quite toxic. Combined chemotherapy with 5-fluorouracil, dacarbazine, and epirubicin has also been effective (see Table 39–12).

The prognosis in these neoplasms is variable. The surgical complication rate is about 40%, with patients commonly developing fistulas and infections. Extensive pancreatic resection may cause diabetes mellitus. The overall 5-year survival is higher with functional tumors (77%) than with

nonfunctional ones (55%) and higher with benign tumors (91%) than with malignant ones (55%).

Batcher E et al. Pancreatic neuroendocrine tumors. *Endocr Res.* 2011;36(1):35–43. [PMID: 21226566]
 Eehalt F et al. Neuroendocrine tumors of the pancreas. *Oncologist.* 2009 May;14(5):456–67. [PMID: 19411317]
 Ekeblad S. Islet cell tumours. *Adv Exp Med Biol.* 2010;654:771–89. [PMID: 20217524]
 Imamura M. Recent standardization of treatment strategy for pancreatic neuroendocrine tumors. *World J Gastroenterol.* 2010 Sep 28;16(36):4519–25. [PMID: 20857521]
 Lewis RB et al. Pancreatic endocrine tumors: radiologic-clinicopathologic correlation. *Radiographics.* 2010 Oct;30(6): 1445–64. [PMID: 21071369]
 Smith JK et al. Complications after pancreatectomy for neuroendocrine tumors: a national study. *J Surg Res.* 2010 Sep;163(1): 63–8. [PMID: 20599224]
 Walter T et al. Evaluation of the combination of 5-fluorouracil, dacarbazine, and epirubicin in patients with advanced well-differentiated neuroendocrine tumors. *Clin Colorectal Cancer.* 2010 Oct;9(4):248–54. [PMID: 20920998]

DISEASES OF THE TESTES & MALE BREAST

MALE HYPOGONADISM

ESSENTIALS OF DIAGNOSIS

- ▶ Diminished libido and erections.
- ▶ Fatigue, depression, reduced exercise endurance.
- ▶ Decreased growth of body hair.
- ▶ Testes may be small or normal in size.
- ▶ Serum testosterone or free testosterone is decreased.
- ▶ Serum gonadotropins (LH and FSH) are decreased or normal in hypogonadotropic hypogonadism; they are increased in testicular failure (hypergonadotropic hypogonadism).

▶ General Considerations

Male hypogonadism is caused by deficient testosterone secretion by the testes. It may be classified according to whether it is due to (1) insufficient gonadotropin secretion by the pituitary (hypogonadotropic); (2) pathology in the testes themselves (hypergonadotropic); or (3) both (Table 26–14). Partial male hypogonadism may be difficult to distinguish from the physiologic reduction in serum testosterone seen in normal aging, obesity, and illness.

▶ Etiology

A. Hypogonadotropic Hypogonadism (Low Testosterone with Normal or Low LH)

A deficiency in FSH and LH may be isolated or associated with other pituitary hormonal abnormalities. (See

Table 26–14. Causes of male hypogonadism.

Hypogonadotropic (Low or Normal LH)	Hypergonadotropic (High LH)
Aging	Aging
Alcohol	Antitumor chemotherapy
Chronic illness	Bilateral anorchia
Congenital syndromes	Idiopathic
Constitutional delay	Klinefelter syndrome
Cushing syndrome	Leprosy
Drugs	Lymphoma
Estrogen	Male climacteric
GnRH agonist (leuprolide)	Mumps
Ketoconazole	Myotonic dystrophy
Marijuana	Noonan syndrome
Prior androgens	Orchitis
Spironolactone	Radiation therapy
Hemochromatosis	Sertoli cell-only syndrome
Hypopituitarism	Testicular trauma
Hypothyroidism	Tuberculosis
Idiopathic	Uremia
Kallmann syndrome	
17-Ketosteroid reductase deficiency	
Major medical or surgical illnesses	
Malnourishment	
Obesity (BMI > 30)	
Prader-Willi syndrome	

BMI, body mass index; GnRH, gonadotropin-releasing hormone; LH, luteinizing hormone.

Hypopituitarism.) Hypogonadotropic hypogonadism can be primary, with a failure to enter puberty by age 14; the differential diagnosis is isolated hypogonadotropic hypogonadism, hypopituitarism, or simply delayed puberty (constitutional delay of growth and puberty). Hypogonadotropic hypogonadism may also be acquired. Causes of acquired hypogonadotropic hypogonadism include pituitary or hypothalamic tumors, granulomatous diseases, lymphocytic hypophysitis, or hemochromatosis. Other causes of acquired hypogonadotropic hypogonadism include Cushing syndrome, adrenal insufficiency, and thyroid hormone excess or deficiency. Genetic conditions (eg, Kallman syndrome or *PROKR2* mutations) account for about 40% of cases of acquired hypogonadotropic hypogonadism that is isolated, severe (serum testosterone < 150 ng/dL), and apparently idiopathic.

The main causes of male partial acquired hypogonadotropic hypogonadism (serum testosterone 150–300 ng/dL) are functional and include obesity, poor health, or normal aging. Spermatogenesis is usually preserved. After age 40, serum total testosterone declines variably by an average of 1–2% per year; serum free testosterone levels decline even faster, since sex hormone binding globulin increases with age. After age 70 years, 28% of men have low serum total testosterone and 68% have low serum free testosterone levels, compared with the levels found in young men. Serum levels of free testosterone are lower in men aged 40–70 compared with younger men, without any increase in serum LH. After age 70, LH levels tend to rise, indicating a contribution of primary gonadal dysfunction with advanced age.

There is considerable clinical and laboratory overlap between patients with partial hypogonadotropic hypogonadism and those with normal aging, obesity, or illness. A multicenter European study concluded that the diagnosis of testosterone deficiency in older men should include a serum testosterone < 320 ng/mL and at least three of the following six symptoms: erectile dysfunction, poor morning erection, low libido, depression, fatigue, and inability to perform vigorous activity. Such men are most likely to benefit from testosterone replacement.

B. Hypergonadotropic Hypogonadism (Testicular Failure with High LH)

A failure in testicular secretion of testosterone causes a rise in LH. If testicular Sertoli cell function is deficient, FSH will be elevated. Conditions that can cause testicular failure include viral infection (eg, mumps), irradiation, cancer chemotherapy or radioisotope therapy, autoimmunity, myotonic dystrophy, uremia, XY gonadal dysgenesis, partial 17-ketosteroid reductase deficiency, Klinefelter syndrome, and male climacteric. In men who have had a unilateral orchiectomy for cancer, the remaining testicle can fail even in the absence of radiation or chemotherapy. Male hypogonadism can also be caused by a congenital partial deficiency in the steroidogenic enzyme CYP17 (17-hydroxylase). CYP17 may be deliberately inhibited by abiraterone acetate (Zytiga), a drug for prostate cancer. CYP17 inhibition also causes adrenocortical insufficiency, hypertension, and hypokalemia.

Klinefelter syndrome (47,XXY and its variants) is the most common chromosomal abnormality among males, with an incidence of about 1:500. It is caused by the expression of an abnormal karyotype, classically 47,XXY. Other forms are common, eg, 46,XY/47,XXY mosaicism, 48,XXYY, 48,XXXYY, or 46,XX males.

The manifestations of Klinefelter syndrome are variable. Testes feel normal during childhood, but during adolescence they usually become firm, fibrotic, small, and nontender to palpation. Although puberty occurs at the normal time, the degree of virilization is variable. About 85% of patients have some gynecomastia at puberty. Other causes of gynecomastia (Table 26–15) must be excluded. Other common findings include tall stature and abnormal body proportions that are unusual for hypogonadal men (height greater than arm span; crown-pubis length greater than pubis-floor). Patients with multiple X or Y chromosomes are more apt to have mental deficiency and other abnormalities such as clinodactyly or synostosis. They may also exhibit problems with coordination and social skills. Other problems include a higher incidence of breast cancer, chronic pulmonary disease, varicosities of the legs, and diabetes mellitus (8% of patients); impaired glucose tolerance occurs in an additional 19% of patients.

The diagnosis of Klinefelter syndrome is confirmed by karyotyping or by determining the presence of RNA for X-inactive-specific transcriptase (XIST) in peripheral blood leukocytes by polymerase chain reaction.

On semen analysis, most men (about 95%) with classic Klinefelter syndrome have azoospermia, although some

Table 26–15. Causes of gynecomastia.

Idiopathic	Busulfan Chorionic gonadotropin Cimetidine Clomiphene Cyclophosphamide Diazepam Diethylstilbestrol Digitalis preparations Dutasteride Estrogens (oral or topical) Ethionamide Famotidine (rare) Finasteride Flutamide Goserelin Growth hormone HAART (highly active antiretroviral therapy) Haloperidol Hydroxyzine Isoniazid Ketoconazole Lavender oil (topical) Leuprolide Marijuana Meprobamate Methadone Methyldopa Metoclopramide Metronidazole Mirtazapine Nilutamide Omeprazole Opioids Penicillamine Phenothiazines Progestins Protease inhibitors Proton pump inhibitors (uncommon) Ranitidine (rare) Reserpine Risperidone Somatropin (growth hormone) Soy ingestion Spironolactone Tea tree oil (topical) Testosterone Thioridazine Tricyclic antidepressants Verapamil
Physiologic causes	
Neonatal period	
Puberty	
Aging	
Obesity	
Endocrine diseases	
Androgen resistance syndromes	
Aromatase excess syndrome (sporadic or familial)	
Diabetic lymphocytic mastitis	
Hyperprolactinemia	
Hyperthyroidism	
Klinefelter syndrome	
Male hypogonadism	
Partial 17-ketosteroid reductase deficiency	
Systemic diseases	
Androgen insensitivity	
Chronic liver disease	
Chronic kidney disease	
Neurologic disorders	
Refeeding after starvation	
Spinal cord injury	
Neoplasms	
Adrenal tumors	
Bronchogenic carcinoma	
Carcinoma of the breast	
Ectopic hCG: lung, hepatocellular, gastric, renal carcinomas	
Pituitary prolactinoma	
Testicular tumors	
Drugs (partial list)	
Alcohol	
Alkylating agents	
Amiodarone	
Anabolic steroids	
Androgens	
Bicalutamide	

sperm production is often present in their early teens. Men with 46,XY/47,XXY mosaicism may have spontaneous fertility. Also, testicular biopsy reveals sperm in up to 50% of affected patients, allowing some of them to be fertile with the use of in vitro fertilization using intracytoplasmic sperm injection (ICSI).

XY gonadal dysgenesis describes several conditions that result in the failure of the testes to develop normally.

SRY is a gene on the Y chromosome that initiates male sexual development. Mutations in *SRY* result in testicular dysgenesis. Affected individuals lack testosterone, which results in sex reversal: female external genitalia with a blind vaginal pouch, no uterus, and intra-abdominal dysgenetic gonads. Affected individuals are raised as girls and appear normal until their lack of pubertal development and amenorrhea leads to the diagnosis. Intra-abdominal rudimentary testes have an increased risk of developing a malignancy and are usually resected. Patients are considered women and receive estrogen replacement therapy.

C. Androgen Insensitivity

Partial resistance to testosterone is a rare condition in which phenotypic males have variable degrees of apparent hypogonadism, hypospadias, cryptorchism, and gynecomastia. Serum testosterone levels are normal.

► Clinical Findings

A. Symptoms and Signs

Hypogonadism that is congenital or acquired during childhood presents as delayed puberty. Men with acquired hypogonadism have variable manifestations. Most men experience decreased libido. Others complain of erectile dysfunction, poor morning erection, or hot sweats. Men often have depression, fatigue, or decreased ability to perform vigorous physical activity. The presenting complaint may also be infertility, gynecomastia, headache, fracture, or other symptoms related to the cause or result of the hypogonadism. The patient's history often gives a clue to the cause (Table 26–14).

Physical signs associated with hypogonadism may include decreased body, axillary, beard, or pubic hair; such diminished sexual hair growth is not reliably present except after years of severe hypogonadism. Men in whom hypogonadism develops tend to lose muscle mass and gain weight due to an increase in subcutaneous fat. Examination should include measurements of arm span and height. Testicular size should be assessed with an orchidometer (normal volume is about 10–25 mL; normal length is usually over 6 cm). Testicular size may decrease but usually remains within the normal range in men with postpubertal hypogonadotropic hypogonadism, but it may be diminished with testicular injury or Klinefelter syndrome. The testes must also be carefully palpated for masses, since Leydig cell tumors may secrete estrogen and present with hypogonadism. The testicles must be carefully examined for evidence of trauma, infiltrative lesions (eg, lymphoma), or ongoing infection (eg, leprosy, tuberculosis).

B. Laboratory Findings

The evaluation for hypogonadism begins with a morning serum testosterone or free testosterone measurement (or both) using a reliable assay. Most radioimmunoassays and ELISAs for testosterone are inaccurate when serum testosterone levels are < 300 ng/dL. More accurate testosterone assays rely on extraction and chromatography, followed by mass spectrometry or immunoassay. Serum testosterone

levels are considered low if they are confirmed to be < 320 ng/dL (11 nmol/L). Free testosterone is best measured by calculation, using accurate assays for testosterone and sex hormone binding globulin. Serum free testosterone levels are considered low if they are confirmed to be < 64 pg/mL (220 pmol/L).

Normal ranges for serum testosterone have been derived from nonfasting morning blood specimens, which tend to be the highest of the day. Later in the day, serum testosterone levels can be 25–50% lower. Therefore, a serum testosterone drawn fasting or late in the day may be misleadingly below the “normal range.” Serum testosterone levels in men are highest at age 20–30 years and slightly lower at age 30–40 years; testosterone falls gradually but progressively after age 40 years. Testing for serum free testosterone is especially important for detecting hypogonadism in elderly men, who generally have high levels of sex hormone binding globulin. A low serum testosterone should be verified with a repeat assay and further evaluated with serum LH and FSH levels. LH and FSH tend to be high in patients with hypergonadotropic hypogonadism but low or inappropriately normal in men with hypogonadotropic hypogonadism or normal aging. Patients with low gonadotropins may be further evaluated for other pituitary abnormalities, including hyperprolactinemia.

Testosterone stimulates erythropoiesis in men, causing the normal red blood count range to be higher in men than in women; mild anemia is common in men with hypogonadism, with red blood counts below the normal male range. For men with long-standing male hypogonadism, bone densitometry is recommended. Men with severe osteoporosis may require treatment with bisphosphonates and vitamin D, in addition to testosterone replacement therapy. (See Osteoporosis section.)

1. Hypogonadotropic hypogonadism—A serum PRL determination is obtained but may be elevated for many reasons (see Table 26–2). Men with gynecomastia may be screened for partial 17-ketosteroid reductase deficiency with serum determinations for androstenedione and estrone, which are elevated in this condition. X-linked congenital adrenal hypoplasia is a rare condition in which a *DAX-1* gene mutation causes hypogonadotropic hypogonadism and azoospermia, which usually presents in adolescence; the associated primary adrenal insufficiency usually presents in childhood, but it may remain undiagnosed into adulthood. The serum estradiol level may be elevated in patients with cirrhosis and in rare cases of estrogen-secreting tumors (testicular Leydig cell tumor or adrenal carcinoma). Men with no discernible definite cause for hypogonadotropic hypogonadism should be screened for hemochromatosis and have an MRI of the pituitary and hypothalamic region to look for a tumor or other lesion. (See Hypopituitarism.)

2. Hypergonadotropic hypogonadism—Men with hypergonadotropic hypogonadism have low serum testosterone levels with a compensatory increase in FSH and LH. Klinefelter syndrome can be confirmed by karyotyping or by measurement of leukocyte XIST. Testicular biopsy is usually reserved for younger patients in whom the reason for primary hypogonadism is unclear.

► Treatment

Testosterone replacement is reasonable for boys who have not begun puberty by age 14. It is beneficial to most men with hypergonadotropic hypogonadism or severe hypogonadotropic hypogonadism. Men with symptoms of hypogonadism (see above) and a repeatedly low serum testosterone or free testosterone can also benefit from testosterone replacement. For men with borderline low serum testosterone levels and marginal hypogonadal symptoms, the decision to treat should consider the potential benefits versus risks (see below). Such men may be given a trial of testosterone therapy for several months while monitoring their response.

Testosterone therapy should not be administered to men with active prostate or breast cancer, or erythrocytosis. In men over age 50 years, a digital prostate examination and serum prostate-specific antigen (PSA) level should be done before beginning testosterone therapy. Men with symptoms of prostatic hypertrophy, a palpable prostate nodule, or a PSA > 4 ng/mL (> 3 ng/mL in men of African ancestry) should have a urologic evaluation prior to treatment. Serum PSA should be measured yearly during therapy. Similarly, testosterone therapy is not given to men with untreated sleep apnea or congestive heart failure. In men who have coronary risk factors or are over age 65, special attention should be given to improving cardiac risk factors (eg, controlling hypertension or hyperlipidemia) and administering low-dose aspirin while receiving testosterone replacement.

Drug interactions can occur. Testosterone should be administered cautiously to men receiving coumadin, since the combination can increase the INR and risk of bleeding. Similarly, testosterone therapy can increase serum levels of cyclosporine, tacrolimus, and tolvaptan. Testosterone can predispose to hypoglycemia in diabetic men receiving insulin or oral hypoglycemic agents, so close monitoring of blood sugars is advisable during initiation of testosterone therapy.

Oral androgen therapy with methyltestosterone is not advisable due to the potential for causing liver tumors, peliosis hepatis, and cholestatic jaundice (see below).

A. Formulations of Testosterone Replacement Therapy

1. Topical testosterone—Testosterone is best administered topically. Topical administration yields more stable serum testosterone levels than intramuscular administration. Topical testosterone is usually applied once daily in the morning after showering. Topical testosterone should not be applied to the breast or genitals. **AndroGel** 1% gel is available in 2.5-g packets (25 mg testosterone) and 5-g packets (50 mg testosterone) and in a pump that dispenses 12.5 mg testosterone per pump actuation: the recommended dose is 50–100 mg applied daily to the shoulders. **AndroGel** 1.6% gel is available in a pump that dispenses 20.25 mg testosterone per pump actuation; the recommended dose is 40.5–81 mg daily. **Testim** 1% gel is available in 5-g tubes (50 mg testosterone); the recommended dose is 50–100 mg applied daily. **Fortesta** 2% gel is available in a pump that dispenses 10 mg testosterone per pump

actuation; the recommended dose is 40–70 mg daily. **Testogel** is distributed in 5-g sachets (50 mg testosterone); this brand is not available in the United States. **Testim**, **Fortesta**, and **Testogel** may be applied to both shoulders, upper arms, or abdomen. **Axiron** 2% solution is available in a pump that dispenses 30 mg per actuation; the recommended dose is 30–60 mg applied to each axilla daily.

The skin serves as a reservoir that slowly releases about 10% of the testosterone into the blood; serum testosterone levels reach a steady state in 1–3 days. The serum testosterone level should be determined about 14 days after starting therapy; if the level remains below normal or the clinical response is inadequate, the daily dose may be increased to 1.5 to 2 times the initial dose. After the application of topical testosterone, the hands should be washed. The application site should be allowed to dry for 5–10 minutes before dressing. Before close contact with women or children, a shirt must be worn or the areas of application washed with soap and water to prevent transfer of testosterone to them.

2. Transdermal testosterone—Testosterone transdermal systems (skin patches) are available in two formulations for application to nongenital skin. **Testoderm** II, 5 mg/d leaves a sticky residue but causes little skin irritation. **Androderm** (2 or 4 mg/24 h) patches may be applied at bedtime in doses of 4–8 mg; it adheres more tightly to the skin but may cause more skin irritation. Both produce reliable serum levels of testosterone that are somewhat lower than those achieved with injections. The patch systems also suffer from being rather inconvenient and expensive.

3. Parenteral testosterone—Testosterone cypionate and testosterone enanthate are intramuscular testosterone formulations that are available in solutions containing 200 mg/mL. Their main advantage is low cost. The usual dose is 200 mg every 2 weeks or 300 mg every 3 weeks. The dose and injection intervals are adjusted according to the patient's response. These preparations are oil-based and are usually given intramuscularly in the gluteal area.

Testosterone undecanoate (**Nebido**) is a long-lasting depot testosterone formulation that is administered in doses of 1000 mg (4 mL) by slow intramuscular injection. The initial injection is followed by another 1000 mg injection 6 weeks later and maintenance doses of 1000 mg every 3 months. A serum testosterone level is measured before the fourth dose; if the serum testosterone remains low, the dosing interval is shortened to every 10 weeks. It is not available in the United States or Canada.

4. Buccal testosterone—Testosterone buccal tablets (**Striant**) are placed between the upper lip and gingivae. One or two 30-mg tablets are thus retained and changed every 12 hours. They should not be chewed or swallowed.

5. Oral testosterone—Oral androgen preparations include methyltestosterone and fluoxymesterone. Another oral preparation is testosterone undecanoate; it is not approved in the United States. These oral preparations can cause liver tumors or peliosis hepatis with long-term use. Cholestatic jaundice occurs in 1–2% of patients but usually remits after the medication is discontinued. Oral androgens are not as effective as topical or parenteral testosterone.

B. Benefits of Testosterone Replacement Therapy

Testosterone therapy usually benefits men with low serum testosterone and at least three manifestations of hypogonadism as noted above. Testosterone therapy can improve overall mood, sense of well-being, sexual desire, and erectile function. It also increases physical vigor and muscle strength as manifested in measurements of leg-press and chest-press strength. Testosterone replacement also improves exercise endurance and stair climbing ability.

C. Risks of Testosterone Replacement Therapy

Testosterone replacement therapy appears to increase the risk of cardiovascular events in men older than age 65 with cardiac risk factors or preexisting angina. This increased risk may be due to the decrease in serum HDL that can occur with testosterone therapy.

Testosterone therapy can aggravate benign prostatic hypertrophy (BPH). However, aggravation of voiding problems is uncommon. In men with BPH, finasteride may be coadministered with testosterone to reduce prostate size. The incidence of prostate cancer does not appear to be increased by testosterone therapy. However, testosterone therapy is contraindicated in the presence of active prostate cancer. Hypogonadal men who have had a prostatectomy for low-grade prostate cancer, and who have remained in complete remission for several years, may have testosterone therapy given cautiously while monitoring sensitive serum PSA levels.

Erythrocytosis develops in some men who are treated with testosterone. Erythrocytosis is more common with intramuscular injections of testosterone enanthate than with transcutaneous testosterone. However, no increase in the incidence of thromboembolic events has been reported.

Testosterone therapy tends to aggravate sleep apnea in older men, likely through central nervous system effects. Surveillance for sleep apnea is recommended during testosterone therapy and a formal evaluation with nocturnal pulse oximetry recording is recommended for all high-risk patients with snoring, obesity, partner's report of apneic episodes, nocturnal awakening, unrefreshing sleep with daytime fatigue, or hypertension.

Men who are treated with testosterone frequently experience some increase in acne that is usually mild and tolerated; topical antiacne therapy or a reduction in testosterone replacement dosage may be required. Increases in intraocular pressure have occurred during testosterone therapy. During the initiation of testosterone replacement therapy, gynecomastia develops in some men, which usually is mild and tends to resolve spontaneously; switching from testosterone injections to testosterone transdermal gel may help this condition.

► Prognosis of Male Hypogonadism

If hypogonadism is due to a pituitary lesion, the prognosis is that of the primary disease (eg, tumor, necrosis). The prognosis for restoration of virility is good if testosterone is given.

Basaria S et al. Adverse events associated with testosterone administration. *N Engl J Med.* 2010 Jul 8;363(2):109–22. [PMID: 20592293]

Bhasin S et al. Testosterone therapy in men with androgen deficiency syndrome: an Endocrine Society clinical practice guideline. *J Clin Endocrinol Metab.* 2010 Jun;95(6):2536–59. [PMID: 20525905]

Cunningham GR et al. Clinical review: why is androgen replacement in males controversial? *J Clin Endocrinol Metab.* 2011 Jan;96(1):38–52. [PMID: 20881265]

Dwyer AA et al. The long-term clinical follow-up and natural history of men with adult-onset idiopathic hypogonadotropic hypogonadism. *J Clin Endocrinol Metab.* 2010 Sep;95(9):4235–43. [PMID: 20591981]

Mäkinen JI et al. Androgen replacement therapy in late-onset hypogonadism: current concepts and controversies. *Gerontology.* 2011;57(3):193–202. [PMID: 20689266]

Traish AM et al. Testosterone deficiency. *Am J Med.* 2011 Jul;124(7):578–87. [PMID: 21683825]

Wu FC et al; EMAS Group. Identification of late-onset hypogonadism in middle-aged and elderly men. *N Engl J Med.* 2010 Jul 8;363(2):125–35. [PMID: 20554979]

TESTICULAR TUMORS IN ADULTS (See also Chapter 39)

About 95% of testicular tumors are germ cell tumors (seminomas or nonseminomas). Seminomas do not produce α -fetoprotein, but about 5–10% produce some hCG. Nonseminomas, on the other hand, produce increased serum levels of one or both of these markers in about 90% of cases. Men with liver disease may have misleadingly high levels of α -fetoprotein. Most germ cell tumors are sensitive to cisplatin-based combined pre-chemotherapy. Sperm banking is advised.

About 5% of testicular tumors are Leydig or Sertoli cell tumors. Leydig cell tumors tend to produce estrogen (75%) and cause gynecomastia and impotence on that basis; they may sometimes produce androgens that can cause pseudo-precocious puberty in boys. Sertoli cell tumors may also produce estrogen (30%) with feminization; gynecomastia may be due to hCG secretion (25%).

Some testicular tumors may be small and nonpalpable yet may secrete sufficient amounts of hCG or estrogen to cause gynecomastia or impotence. Testicular ultrasound may help reveal small tumors.

After unilateral orchiectomy for testicular cancer, an elevated FSH level prior to further treatment indicates a patient at higher risk for cancer in the remaining testis.

CRYPTORCHISM

One or both testes may be absent from the scrotum at birth in about 20% of premature or low-birth-weight male infants and in 3–6% of full term infants. Cryptorchism is found in 1–2% of males after 1 year of age but must be distinguished from retractile testes, which require no treatment. Cryptorchism should be corrected before age 12–24 months in an attempt to reduce the risk of infertility, which occurs in up to 75% of men with bilateral cryptorchism and in 50% of men with unilateral cryptorchism.

Some patients have underlying hypogonadism, including hypogonadotropic hypogonadism.

If the testes are not palpable, ultrasound or MRI can be used to locate them. Alternatively, hCG, 1500 units intramuscularly daily for 3 days, causes a significant rise in testosterone if the testes are present. Therapy with hCG results in a testicular descent rate of about 25%.

Compared to an incidence of 0.002% in normal males, cryptorchid testes increase the lifetime risk of testicular neoplasia to about 0.06%, and intra-abdominal testes, to 5%. Orchiopexy decreases the risk of neoplasia when performed before 10 years of age. Orchiectomy after puberty is an option for intra-abdominal testes.

Husmann DA. Testicular descent: a hypothesis and review of current controversies. *Pediatr Endocrinol Rev.* 2009 Jun; 6(4):491–5. [PMID: 19550384]

Kurpisz M et al. Cryptorchidism and long-term consequences. *Reprod Biol.* 2010 Mar;10(1):19–35. [PMID: 20349021]

Travis LB et al. Testicular cancer survivorship: research strategies and recommendations. *J Natl Cancer Inst.* 2010 Aug 4;102(15): 1114–30. [PMID: 20585105]

Wood HM et al. Cryptorchidism and testicular cancer: separating fact from fiction. *J Urol.* 2009 Feb;181(2):452–61. [PMID: 19084853]

GYNECOMASTIA

ESSENTIALS OF DIAGNOSIS

- ▶ Palpable enlargement of the male breast, often asymmetric or unilateral.
- ▶ Glandular gynecomastia characterized by tenderness.
- ▶ Fatty gynecomastia typically nontender.
- ▶ Must be distinguished from carcinoma or mastitis.

▶ General Considerations

Gynecomastia refers to a female-appearing male breast. In practice, it is defined as the presence of palpable glandular breast tissue in males. Pubertal gynecomastia develops in about 60% of boys; the swelling usually subsides spontaneously within a year. Gynecomastia is particularly common in teenagers who are very tall or overweight. Gynecomastia develops in about 50% of athletes who abuse androgens and anabolic steroids. It is seen in Klinefelter syndrome, which affects 1:500 men. (See section on Klinefelter syndrome.) Gynecomastia can develop in HIV-infected patients treated with highly active antiretroviral therapy (HAART), especially in men receiving efavirenz or didanosine; breast enlargement resolves spontaneously in 73% of patients within 9 months. Gynecomastia is common among elderly men, particularly when there is associated weight gain. However, it can be the first sign of a serious disorder.

The causes of gynecomastia are multiple and diverse (Table 26–15).

▶ Clinical Findings

A. Symptoms and Signs

The male breasts must be palpated carefully to distinguish true glandular gynecomastia from fatty pseudogynecomastia in which only adipose tissue is felt. The breasts are best examined both seated and supine. Using the thumb and forefinger as pincers, the subareolar tissue is compared to nearby adipose tissue. Fatty gynecomastia is usually diffuse and nontender. Glandular enlargement beneath the areola may be tender. Pubertal gynecomastia is characterized by tender discoid enlargement of breast tissue 2–3 cm in diameter beneath the areola. The following characteristics are worrisome for malignancy: asymmetry; location not immediately below the areola; unusual firmness; or nipple retraction, bleeding, or discharge. Gynecomastia is graded according to severity: I, mild; II, moderate; III, severe.

B. Laboratory Findings

Obtain plasma levels of PRL (see Hyperprolactinemia) and the β -subunit of hCG (β -hCG). Detectable levels of β -hCG implicate a testicular tumor (germ cell or Sertoli cell) or other malignancy (usually lung or liver). Detectable low levels of serum β -hCG (< 5 mU/mL) may be reported in men with primary hypogonadism and high serum LH levels if the assay for β -hCG cross-reacts with LH. Measurements of serum free testosterone and LH are valuable in the diagnosis of primary or secondary hypogonadism. A low serum free testosterone and high LH are seen in primary hypogonadism. High testosterone levels plus high LH levels characterize partial androgen resistance. Serum estradiol is determined but is usually normal; increased levels may result from testicular tumors, increased β -hCG, liver disease, obesity, adrenal tumors (rare), true hermaphroditism (rare), or gain of function mutations affecting the aromatase gene (rare). Many estrogens and substances with estrogenic activity are not detected by estradiol assays. Serum TSH (sensitive) and FT₄ levels are also determined. A karyotype (for Klinefelter syndrome) is obtained in men with persistent gynecomastia without obvious cause.

Investigation of unclear cases should include a chest radiograph to search for metastatic or bronchogenic carcinoma. Needle biopsy with cytologic examination may be performed on suspicious areas of male breast enlargement (especially when unilateral or asymmetric) to distinguish gynecomastia from tumor or mastitis.

▶ Treatment

Pubertal gynecomastia often resolves spontaneously within 1–2 years. Drug-induced gynecomastia resolves after the offending drug is removed. Spironolactone can be stopped, with substitution of a selective aldosterone antagonist such as eplerenone. Patients with painful or persistent gynecomastia may be treated with medical therapy, which is usually continued for 9–12 months. Generally, it is prudent to treat patients for gynecomastia only when it becomes a troubling and continuing problem for them.

Selective estrogen receptor modulator (SERM) therapy is much more effective for glandular (“lumpy”) gynecomastia than for diffuse fatty gynecomastia. Raloxifene, 60 mg orally daily, may be somewhat more effective than tamoxifen, 10–20 mg orally daily.

Aromatase inhibitor (AI) therapy, such as anastrozole and letrozole, is reasonably effective for gynecomastia. Anastrozole, 1 mg orally daily, reduces breast volume significantly in adolescent boys over a 6-month course of therapy. Serum levels of estrogen fall slightly while testosterone levels rise significantly. Concerns about long-term AI therapy in adolescents include the possibility of inducing osteoporosis and delaying epiphyseal fusion, which could cause an increase in adult height.

Testosterone therapy for men with hypogonadism may improve or worsen preexistent gynecomastia.

Radiation therapy has been used prophylactically to prevent gynecomastia in men with prostate cancer being treated with antiandrogen therapy. Low-dose radiation therapy reduces the incidence of gynecomastia from 85% to 52%.

Surgical correction is reserved for patients with persistent or severe gynecomastia, since results can be disappointing. For best results, the procedure should be performed by a plastic surgeon who has experience with this surgery.

Carlson HE. Approach to the patient with gynecomastia. *J Clin Endocrinol Metab.* 2011 Jan;96(1):15–21. [PMID: 21209041]
 Devalia HL et al. Current concepts in gynecomastia. *Surgeon.* 2009 Apr;7(2):114–9. [PMID: 19408804]
 Hammond DC. Surgical correction of gynecomastia. *Plast Reconstr Surg.* 2009 Jul;124(1 Suppl):61e–68e. [PMID: 19568140]
 Johnson RE et al. Gynecomastia: pathophysiology, evaluation, and management. *Mayo Clin Proc.* 2009 Nov;84(11):1010–5. [PMID: 19880691]
 Mauras N et al. Pharmacokinetics and pharmacodynamics of anastrozole in pubertal boys with recent-onset gynecomastia. *J Clin Endocrinol Metab.* 2009 Aug;94(8):2975–8. [PMID: 19470631]

AMENORRHEA & MENOPAUSE (SEE ALSO CHAPTER 18)

PRIMARY AMENORRHEA

Menarche ordinarily occurs between ages 11 and 15 years (average in the United States: 12.7 years). The failure of any menses to appear is termed “primary amenorrhea,” and evaluation is commenced (1) at age 14 years if neither menarche nor any breast development has occurred or if height is in the lowest 3%, or (2) at age 16 years if menarche has not occurred.

► Etiology of Primary Amenorrhea

The causes of primary amenorrhea include hypothalamic-pituitary causes, hyperandrogenism, ovarian causes, pseudohermaphroditism, uterine causes, and pregnancy.

A. Hypothalamic-Pituitary Causes (with Low or Normal FSH)

A genetic deficiency of GnRH and gonadotropins may be isolated or associated with other pituitary deficiencies or diminished olfaction (Kallmann syndrome). Hypothalamic lesions, particularly craniopharyngioma, may be present. Pituitary tumors may be nonsecreting or may secrete PRL or GH. Cushing syndrome may be caused by corticosteroid treatment, a cortisol-secreting adrenal tumor, or an ACTH-secreting pituitary tumor. Hypothyroidism can delay adolescence. Head trauma or encephalitis can cause gonadotropin deficiency. Primary amenorrhea may also be caused by constitutional delay of adolescence, organic illness, vigorous exercise (eg, ballet dancing, running), stressful life events, dieting, or anorexia nervosa; however, these conditions should not be assumed to account for amenorrhea without a full physical and endocrinologic evaluation. (See section on Hypopituitarism.)

B. Hyperandrogenism (with Low or Normal FSH)

Excess testosterone may be secreted by adrenal tumors or by adrenal hyperplasia caused by steroidogenic enzyme defects such as P450c21 deficiency (salt-wasting) or P450c11 deficiency (hypertension). Ovarian tumors or polycystic ovaries may also secrete excess testosterone. Androgenic steroids may also cause this syndrome.

C. Ovarian Causes (with High FSH)

Gonadal dysgenesis (Turner syndrome and variants; see below) is a frequent cause of primary amenorrhea. Ovarian failure due to autoimmunity is a common cause. Rare deficiencies in certain ovarian steroidogenic enzymes are causes of primary hypogonadism without virilization: 3β-hydroxysteroid dehydrogenase deficiency (adrenal insufficiency with low serum 17-hydroxyprogesterone) and P450c17 deficiency (hypertension and hypokalemia with high serum 17-hydroxyprogesterone). A whole-body deficiency in P450 aromatase (P450arom) activity produces female hypogonadism associated with polycystic ovaries, tall stature, osteoporosis, and virilization.

D. Pseudohermaphroditism (with High LH)

An enzymatic defect in testosterone synthesis may present as a sexually immature phenotypic girl with primary amenorrhea. Complete androgen resistance (testicular feminization) presents as a phenotypic young woman without sexual hair but with normal breast development and primary amenorrhea. In both cases, the uterus is absent and testes are intra-abdominal or cryptorchid. Intra-abdominal testes are surgically resected. Such patients are treated as normal but infertile, hypogonadal women.

E. Uterine Causes (with Normal FSH)

Congenital absence or malformation of the uterus may be responsible for primary amenorrhea, as may an unresponsive or atrophic endometrium. An imperforate hymen is occasionally the reason for the absence of visible menses.

F. Pregnancy (with High hCG)

Pregnancy may be the cause of primary amenorrhea even when the patient denies ever having had sexual intercourse.

► Clinical Findings

A. Symptoms and Signs

Patients with primary amenorrhea require a thorough history and physical examination to look for signs of the conditions noted above. Headaches or visual field abnormalities implicate a hypothalamic or pituitary tumor. Signs of pregnancy may be present. Blood pressure abnormalities, acne, and hirsutism should be noted. Short stature may be seen with an associated GH or thyroid hormone deficiency. Short stature with manifestations of gonadal dysgenesis indicates Turner syndrome (see below). Olfaction testing screens for Kallmann syndrome. Obesity and short stature may be signs of Cushing syndrome. Tall stature may be due to eunuchoidism or gigantism. Hirsutism or virilization suggests excessive testosterone.

An external pelvic examination plus a rectal examination should be performed to assess hymen patency and the presence of a uterus.

B. Laboratory and Radiologic Findings

The initial endocrine evaluation should include serum determinations of FSH, LH, PRL, testosterone, TSH, FT₄, and hCG (pregnancy test). Patients who are virilized or hypertensive require serum electrolyte determinations and further hormonal evaluation. MRI of the hypothalamus and pituitary is used to evaluate teens with primary amenorrhea and low or normal FSH and LH—especially those with high PRL levels. Pelvic duplex/color sonography is very useful. Girls who have a normal uterus and high FSH without the classic features of Turner syndrome may require a karyotype to diagnose X chromosome mosaicism.

► Treatment

Treatment of primary amenorrhea is directed at the underlying cause. Girls with permanent hypogonadism are treated with ERT (see below).

Deligeoroglou E et al. Evaluation and management of adolescent amenorrhea. *Ann NY Acad Sci.* 2010 Sep;1205:23–32. [PMID: 20840249]

Gamboa S et al. Clinical inquiries. What's the best way to manage athletes with amenorrhea? *J Fam Pract.* 2008 Nov;57(11):749–50. [PMID: 19006626]

Rosenberg HK. Sonography of the pelvis in patients with primary amenorrhea. *Endocrinol Metab Clin North Am.* 2009 Dec;38(4):739–60. [PMID: 19944290]

SECONDARY AMENORRHEA & MENOPAUSE

Secondary amenorrhea is defined as the absence of menses for 3 consecutive months in women who have passed menarche. Menopause is defined as the terminal episode of naturally occurring menses; it is a retrospective diagnosis, usually made after 6 months of amenorrhea.

► Etiology

The causes of secondary amenorrhea include pregnancy, hypothalamic-pituitary causes, hyperandrogenism, uterine causes, premature ovarian failure, and menopause.

A. Pregnancy (High hCG)

Pregnancy is the most common cause for secondary amenorrhea in women of childbearing age. The differential diagnosis includes rare ectopic secretion of hCG by a choriocarcinoma or bronchogenic carcinoma.

B. Hypothalamic-Pituitary Causes (with Low or Normal FSH)

The hypothalamus must release GnRH in a pulsatile manner for the pituitary to secrete gonadotropins. GnRH pulses occurring more than once per hour favor LH secretion, while less frequent pulses favor FSH secretion. In normal ovulatory cycles, GnRH pulses in the follicular phase are rapid and favor LH synthesis and ovulation; ovarian luteal progesterone is then secreted that slows GnRH pulses, causing FSH secretion during the luteal phase. Most women with hypothalamic amenorrhea have a persistently low frequency of GnRH pulses.

Secondary “hypothalamic” amenorrhea may be caused by stressful life events such as school examinations or leaving home. Such women usually have a history of normal sexual development and irregular menses since menarche. Amenorrhea may also be the result of strict dieting, vigorous exercise, organic illness, or anorexia nervosa. Intrathecal infusion of opioids causes amenorrhea in most women. These conditions should not be assumed to account for amenorrhea without a full physical and endocrinologic evaluation. Young women in whom the results of evaluation and progestin withdrawal test are normal have non-cyclic secretion of gonadotropins resulting in anovulation. Such women typically recover spontaneously but should have regular evaluations and a progestin withdrawal test about every 3 months to detect loss of estrogen effect.

PRL elevation due to any cause (see section on hyperprolactinemia) may cause amenorrhea. Pituitary tumors or other lesions may cause hypopituitarism. Corticosteroid excess of any cause suppresses gonadotropins.

C. Hyperandrogenism (with Low-Normal FSH)

Elevated serum levels of testosterone can cause hirsutism, virilization, and amenorrhea. In PCOS, GnRH pulses are persistently rapid, favoring LH synthesis with excessive androgen secretion; reduced FSH secretion impairs follicular maturation. Progesterone administration can slow the GnRH pulses, thus favoring FSH secretion that induces follicular maturation. Rare causes include adrenal P450c21 deficiency, ovarian or adrenal malignancies, ectopic ACTH secretion by a malignancy, and Cushing disease. Anabolic steroids also cause amenorrhea.

D. Uterine Causes (with Normal FSH)

Infection of the uterus commonly occurs following delivery or D&C but may occur spontaneously. Endometritis

due to tuberculosis or schistosomiasis should be suspected in endemic areas. Endometrial scarring may result, causing amenorrhea (Asherman syndrome). Such women typically continue to have monthly premenstrual symptoms. The vaginal estrogen effect is normal.

E. Early and Premature Menopause (with High FSH)

Early menopause refers to primary ovarian failure that occurs before age 45. It affects approximately 5% of women. About 1% of women experience **premature menopause** that is defined as ovarian failure before age 40; about 30% of such cases are due to autoimmunity against the ovary. X chromosome mosaicism accounts for 8% of cases of premature menopause. Other causes include surgical bilateral oophorectomy, radiation therapy for pelvic malignancy, and chemotherapy. Women who have undergone hysterectomy are prone to premature ovarian failure even though the ovaries were left intact. Myotonic dystrophy, galactosemia, and mumps oophoritis are additional causes. Early or premature menopause is frequently familial. Ovarian failure is usually irreversible.

F. Normal Menopause (with High FSH)

Normal menopause refers to primary ovarian failure that occurs after age 45. "Climacteric" is defined as the period of natural physiologic decline in ovarian function, generally occurring over about 10 years. By about age 40 years, the remaining ovarian follicles are those that are the least sensitive to gonadotropins. Increasing titers of FSH are required to stimulate estradiol secretion. Estradiol levels may actually rise during early climacteric.

The normal age for menopause in the United States ranges between 48 and 55 years, with an average of about 51.5 years. Serum estradiol levels fall and the remaining estrogen after menopause is estrone, derived mainly from peripheral aromatization of adrenal androstenedione. Such peripheral production of estrone is enhanced by obesity and liver disease. Individual differences in estrone levels partly explain why the symptoms noted above may be minimal in some women but severe in others.

► Clinical Findings

A. Symptoms and Signs

Vasomotor instability (hot flashes) is experienced by 80% of women, lasting seconds to many minutes. Hot flashes with drenching sweats may be most severe at night or may be triggered by emotional stress. Women may also experience fatigue, insomnia, headache, diminished libido, or rheumatologic symptoms. Psychological symptoms of the "climacteric" include depression and irritability. Some women continue to menstruate for many months despite symptoms of estrogen deficiency. The acute symptoms of estrogen deficiency noted above tend to gradually decline in severity. However, the median duration of moderate to severe hot flashes is about 10 years. Hot flashes tend to continue longer in thin versus obese women and in black

versus white women. The late manifestations of estrogen deficiency include urogenital atrophy with vaginal dryness and dyspareunia; dysuria, frequency, and incontinence may occur. Increased bone osteoclastic activity increases the risk for osteoporosis and fractures. The skin becomes more wrinkled. Increases in the LDL:HDL cholesterol ratio cause an increased risk for arteriosclerosis.

A careful pelvic examination is always required to check for uterine or adnexal enlargement and to obtain a Papanicolaou smear and a vaginal smear for assessment of estrogen effect. Various life stresses, vigorous exercise, and "crash" dieting all predispose to amenorrhea; however, such factors should not be assumed to account for amenorrhea without a complete workup to screen for other causes.

B. Laboratory Findings

Since pregnancy is the most common cause of amenorrhea, women of childbearing age are immediately screened with a serum or urine hCG (pregnancy test). An elevated hCG overwhelmingly indicates pregnancy; false-positive testing may occur very rarely with ectopic hCG secretion (eg, choriocarcinoma or bronchogenic carcinoma). Women without an elevated hCG receive further laboratory evaluation including serum PRL, FSH, LH, and TSH. Hyperprolactinemia or hypopituitarism (without obvious cause; see section on Hypopituitarism) should prompt an MRI study of the pituitary region. Routine testing for kidney and liver function (eg, BUN, serum creatinine, bilirubin, alkaline phosphatase, and alanine aminotransferase) is also performed. A serum testosterone level is obtained in hirsute or virilized women. Patients with manifestations of hypercortisolism receive a 1-mg overnight dexamethasone suppression test for initial screening (see section on Cushing syndrome). Nonpregnant women without any laboratory abnormality may receive a 10-day course of a progestin (eg, medroxyprogesterone acetate, 10 mg/d); absence of withdrawal menses typically indicates a lack of estrogen or a uterine abnormality.

► Treatment

Therapy of symptomatic hypogonadism generally consists of estrogen replacement therapy (see below). Slow, deep breathing can ameliorate hot flashes. For women with severe hot flashes who cannot take estrogen, gabapentin is quite effective in oral doses titrated up to 200–800 mg every 8 hours. However, gabapentin is frequently associated with side effects such as fatigue, headache, dizziness, and cognitive impairment; such symptoms are most pronounced during the first 2 weeks of therapy but often improve within 4 weeks. An herb, black cohosh, may possibly relieve hot flashes. Tamoxifen and raloxifene offer bone protection but aggravate hot flashes. Treatment or prevention of postmenopausal osteoporosis with bisphosphonates such as alendronate, risedronate, or intravenous zoledronic acid (see section on Osteoporosis) is another therapeutic option. Women with low serum testosterone levels may experience hypoactive sexual desire disorder (HSDD) that may respond to low-dose testosterone replacement.

► Hormone Replacement Therapy

Two large, prospective studies have evaluated the effect of HRT on postmenopausal women. The Women's Health Initiative (WHI) monitored 16,606 mostly-older postmenopausal women in the United States in a prospective, double-blinded, placebo-controlled study of postmenopausal HRT. A control group of women taking a daily placebo was compared with (1) women receiving daily conventional-dose oral combined HRT (conjugated equine estrogens [CEE] 0.625 mg/d with medroxyprogesterone acetate 2.5 mg/d) and (2) women, having had a hysterectomy, receiving only CEE 0.625 mg/d. The California Teachers Study prospectively followed up 71,237 postmenopausal women of all ages (mean age 63 years, range 36–94 years) for mortality, breast cancer, and other outcomes.

The WHI and California Teachers Study risk–benefit findings (described below) have dramatically changed postmenopausal HRT. The overall use of HRT has declined. When HRT is prescribed, lower-dose estrogen regimens are preferred over conventional-dose therapy. Estrogen preparations other than CEE have become increasingly favored. Transdermal and vaginal estrogen preparations are widely preferred over oral estrogen replacement. Also, the potential adverse effects of progestins are now recognized, such that women taking very low-dose estrogen replacement may not require progestins or may receive progestin therapy only periodically, if at all. For moderate- to high-dose estrogen therapy, progestins are being used in lower doses. Also, clinicians are now tending to prescribe progesterone-eluting intrauterine devices and oral progestins other than medroxyprogesterone acetate.

A. Benefits of Estrogen Replacement Therapy

In the California Teachers Study, HRT in women under age 60 was associated with a dramatic 46% reduction in all-cause mortality, particularly cardiovascular disease. This association of HRT and lower mortality may suffer from self-selection bias. Nevertheless, there appears to be a survival advantage of HRT in women under age 60 that diminishes with age; no reduction in mortality was noted in the group of women aged 85–94 years. The reduction in cardiovascular disease among younger postmenopausal women taking HRT may be explained by the reduction in serum levels of atherogenic lipoprotein(a) with HRT, with or without a progestin. Improvement in serum HDL cholesterol is greatest with unopposed estrogen but is also seen with the addition of a progestin.

Estrogen replacement improves or eliminates postmenopausal hot flashes and diaphoretic episodes. Vaginal moisture is improved and libido is enhanced in some women. Estradiol vaginal rings can improve symptoms of an overactive bladder. Sleep disturbances are common in menopause and can be reversed with estrogen replacement. Some women notice a mild impairment in memory and cognitive function at menopause that can improve with HRT. Sex hormone replacement may also improve the body pain and reduced physical function experienced by some women at the time of menopause. Many women taking HRT experience a significantly improved quality of life. Estrogen

replacement does not prevent facial skin wrinkling; however, it may improve facial skin moisture and thickness, reducing seborrhea and atrophy. Estrogen therapy does not appear to reduce the risk of Alzheimer dementia.

1. Estrogen replacement without progestin (unopposed HRT)

—Interestingly, the WHI study found that postmenopausal women taking unopposed estrogen had a 23% reduction in breast cancer risk. The WHI study also found that women who received estrogen therapy experienced a reduced number of hip fractures (six fewer fractures/year per 10,000 women) compared with placebo. Even “microdose” transdermal estradiol (0.014 mg/d) improves bone density. Unopposed oral conjugated estrogens have no discernible effect upon cognitive function, overall mortality, or the risk for heart attacks, or colorectal cancer. Unopposed estrogen replacement improves glyce-mic control in women with type 2 diabetes mellitus. Perimenopause-related depression is improved by unopposed estrogen replacement; the addition of a progestin may negate this effect. A 20-year study of 8801 women living in a retirement community found that estrogen use was associated with improved survival. Age-adjusted mortality rates were 56.4 (per 1000 person-years) among nonusers and 50.4 among women who had used estrogen for 15 years or longer.

2. Estrogen replacement therapy with progestins (combined HRT)

—Women receiving conventional-dose daily conjugated estrogen and medroxyprogesterone acetate (0.625 mg and 2.5 mg, respectively) for an average of 5.6 years, experienced a lower risk of developing diabetes mellitus (3.5%) versus those taking a placebo (4.2%).

B. Risks of Estrogen Replacement Therapy

The risks of estrogen replacement depend on the dose. Conventional doses (eg, oral conjugated estrogens \geq 0.625 mg/d or transdermal estradiol \geq 0.05 mg/d) carry higher risks than lower doses (eg, oral conjugated estrogens, \leq 0.3 mg/d or transdermal estradiol \leq 0.025 mg/d). Route of administration also affects risks, since oral estrogens pass through the liver and increase hepatic production of clotting factors (thereby increasing the risks of thrombotic stroke), whereas transdermal or vaginal administration of estrogen does not significantly increase clotting proclivity. The risks for HRT also depend on whether estrogen is administered alone (unopposed HRT) or with a progestin (combined HRT).

1. Estrogen replacement without progestin (unopposed HRT)

—Surprisingly, the WHI study found that postmenopausal women who received conventional-dose estrogen-only therapy had a reduced risk of breast cancer (seven fewer cases/year per 10,000 women) compared with a placebo group. However, the California Teachers Study monitored women for a longer period; a group of 37,000 women who had been taking conventional-dose estrogen-only therapy for \geq 20 years did have a slightly increased risk of breast cancer. Women taking lower-dose unopposed estrogen therapy would be expected to have lower long-term risk of breast cancer.

Conventional-dose unopposed estrogen replacement (0.625–1.25 mg daily) increases the risk of endometrial hyperplasia and dysfunctional uterine bleeding, which often prompts patients to stop the estrogen. However, lower-dose unopposed estrogen confers a much lower risk of dysfunctional uterine bleeding. Recurrent dysfunctional bleeding necessitates a pelvic examination and possibly an endometrial biopsy. There has been considerable concern that unopposed estrogen replacement might increase the risk for endometrial carcinoma. However, a Cochrane Database Review found no increased risk of endometrial carcinoma in a review of 30 randomized controlled trials. Therefore, lower-dose unopposed estrogen replacement does not appear to confer any increased risk for endometrial cancer.

Long-term conventional-dose unopposed estrogen increases the mortality risk from ovarian cancer, although the absolute risk is small. The annual age-adjusted ovarian cancer death rates for women taking estrogen replacement for ≥ 10 years are 64:100,000 for current users, 38:100,000 for former users, and 26:100,000 for women who had never taken estrogen. Lower-dose estrogen replacement is believed to confer a negligible increased risk for ovarian cancer.

The WHI trial was stopped in 2002 because of an increased risk of stroke among women taking conjugated oral estrogens in doses of 0.625 mg daily; the risk was about 44 strokes per 10,000 person-years versus about 32 per 10,000 person-years in women taking placebo. Transdermal or transvaginal estrogen is not expected to increase the risk of stroke.

Conventional-dose therapy with oral estrogen alone had been thought to increase the risk of deep venous thrombosis and stroke, but the WHI follow-up study found no such increased risk for deep venous thrombosis or stroke. Oral estrogens can cause hypertriglyceridemia, particularly in women with preexistent hyperlipidemia, rarely resulting in pancreatitis. Postmenopausal estrogen therapy also slightly increases the risk of gallstones and cholecystitis. Oral estrogens reduce the effectiveness of GH replacement. These side effects can be reduced or avoided by using non-oral estrogen replacement.

Elderly women, receiving long-term conventional-dose estrogen replacement, experience an increased risk of urinary incontinence. Some women complain of estrogen-induced edema or mastalgia. Estrogen replacement has been reported to lower the seizure threshold in some women with epilepsy. Untreated large pituitary prolactinomas may enlarge if exposed to estrogen.

2. Estrogen replacement with a progestin (combined HRT)—The WHI study found that women who received long-term conventional oral doses of combined HRT (conjugated estrogens 0.625 mg/d plus medroxyprogesterone acetate 2.5 mg/d) had an increased risk of deep venous thrombosis (3.5 per 1000 person-years) compared with women receiving placebo (1.7 per 1000 person-years).

Conventional-dose oral combined HRT results in an increased risk of myocardial infarction (24% or six additional heart attacks per 10,000 women), mostly in older women with high-risk LDL levels or preexistent coronary disease. Most of the risk for myocardial infarction occurs in

the first year of therapy. This increased risk is attributable to the progestin component, since the estrogen-only arm of the WHI study found no increased risk of myocardial infarction.

Long-term conventional-dose oral combined HRT increases breast density and the risk for abnormal mammograms (9.4% versus 5.4% for placebo). There is also a higher risk of breast cancer (8 cases per 10,000 women/year versus 6.5 cases per 10,000 women/year for placebo); no increased risk of breast cancer has been found with estrogen-only HRT. This increased risk for breast cancer appears to mostly affect relatively thin women with a BMI < 24.4 . The Iowa Women's Health Study reported an increase in breast cancer with HRT only in women consuming more than 1 oz of alcohol weekly. No accelerated risk of breast cancer has been seen in users of HRT who have benign breast disease or a family history of breast cancer. Women in whom new-onset breast tenderness develops with combined HRT have an increased risk of breast cancer, compared with women without breast tenderness.

The Women's Health Initiative Mental Study (WHIMS) followed the effect of combined conventional-dose oral HRT on cognitive function in women 65–79 years old. HRT did not protect these older women from cognitive decline. In fact, they experienced an increased risk for severe dementia at a rate of 23 more cases/year for every 10,000 women over age 65 years.

In the WHI study, women receiving conventional-dose combined oral HRT experienced an increased risk of stroke (31 strokes per 10,000 women/year versus 26 strokes per 10,000 women/year for placebo). Stroke risk was also increased by hypertension, diabetes, and smoking.

Women taking combined estrogen–progestin replacement do not experience an increased risk of ovarian cancer. They do experience an increased risk of developing asthma.

Progestins may cause moodiness, particularly in women with a history of premenstrual dysphoric disorder. Cycled progestins may trigger migraines in certain women. Many other adverse reactions have been reported, including breast tenderness, alopecia, and fluid retention. Contraindications to the use of progestins include thromboembolic disorders, liver disease, breast cancer, and pregnancy.

C. Hormone Replacement Therapy Agents

1. Transdermal estradiol—Estradiol can be delivered systemically with different systems of skin patches, mists, and gels. Transdermal estradiol works for most women, but some women have poor transdermal absorption or skin reactions to the product.

A. ESTRADIOL PATCHES MIXED WITH ADHESIVE—These systems tend to cause minimal skin irritation. Of the following preparations, the Vivelle-Dot patches are the smallest and least obtrusive. Generic estradiol transdermal (0.025, 0.0375, 0.05, 0.06, 0.075, 0.1 mg/d) is replaced once weekly. Brand products include Esclim, Vivelle, and Vivelle-Dot (0.025, 0.0375, 0.05, 0.075, or 0.1 mg/d), replaced twice weekly; Alora (0.025, 0.05, 0.075, or 0.1 mg/d), replaced twice weekly; Climara (0.025, 0.0375, 0.05, 0.06, 0.075, or 0.1 mg/d), replaced weekly; FemPatch (0.025 mg/d), replaced

weekly; and Menostar (0.014 mg/d), replaced weekly. This type of estradiol skin patch can be cut in half and applied to the skin without proportionately greater loss of potency.

B. ESTRADIOL PATCHES WITH DRUG RESERVOIR—These systems cause significant skin irritation in some women. Available preparations include Estraderm (0.05 or 0.1 mg/d), applied to the trunk, abdomen, or buttocks and replaced twice weekly.

C. ESTRADIOL PATCHES WITH PROGESTIN MIXED WITH ADHESIVE—These preparations mix estradiol with either norethindrone acetate or levonorgestrel. Combipatch (0.05 mg E and 0.14 mg norethindrone acetate daily or 0.05 mg E and 0.25 mg norethindrone acetate daily) is replaced twice weekly. Climara Pro (0.45 mg E and 0.0125 mg levonorgestrel daily) is replaced once weekly. The addition of a progestin reduces the risk of endometrial hyperplasia but increases the risk of breast cancer and side effects, compared with estrogen therapy alone.

D. ESTRADIOL GELS AND MISTS—EstroGel 0.06% is available in a metered-dose pump that dispenses 0.05 mg estradiol per actuation; estradiol doses are 0.05–0.1 mg/d. Elestrin 0.06% is available in a metered-dose pump that dispenses 0.5 mg estradiol per activation; estradiol doses are 0.5–1 mg/d. These gels are applied daily to one arm from the wrist to the shoulder after bathing. Divigel 1% gel (0.025, 0.5, 1 g/packet) is applied to upper thigh daily. Estrasorb 1.7 g pouches (0.025 mg estradiol) is available in doses of 0.025–0.05 mg estradiol applied to the leg daily. Evamist is available as a topical mister that dispenses 1.53 mg estradiol/spray; doses are 1–3 sprays to the forearm daily. To avoid spreading the estradiol to others, the hands should be washed and precautions taken to avoid prolonged skin contact with children. Application of sunscreen prior to estradiol gel has been reported to *increase* the transdermal absorption of estradiol.

2. Oral estrogen—

A. ORAL ESTROGEN-ONLY PREPARATIONS—These preparations include conjugated equine estrogens (CEE 0.3, 0.45, 0.625, 0.9, 1.25 mg), conjugated plant-derived estrogens (eg, Menest, Estratab, 0.3, 0.625, and 2.5 mg), and conjugated synthetic estrogens (eg, Cenestin, 0.3, 0.625, 0.9, and 1.25 mg). Other preparations include ethinyl estradiol (20 and 50 mcg), estradiol (0.5, 1, and 2 mg), estropipate (0.75, 1.5, 3, and 6 mg), and estradiol acetate (eg, Femtrace 0.45, 0.9, and 1.8 mg).

B. ORAL ESTROGEN PLUS PROGESTIN PREPARATIONS—These include CEE with medroxyprogesterone acetate (Prempro 0.3/1.5, 0.45/1.5, 0.625/2.5, and 0.625 mg/5 mg), CEE for 14 days cycled with CEE plus medroxyprogesterone acetate for 14 days (Premphase 0.625/0 and 0.625 mg/5 mg), estradiol with norethindrone acetate (Activella 0.5/0 and 1 mg/0.5 mg), ethinyl estradiol with norethindrone acetate (Femhrt 2.5/5 and 5 mcg/1 mg), and estradiol with norgestimate (Prefest, sequences of estradiol 1 mg/d for 3 days, alternating with a combination of 1 mg estradiol/0.09 mg norgestimate daily for 3 days). Oral contraceptives can also be used for combined HRT.

3. Vaginal estrogen—Urogenital atrophy commonly develops in postmenopausal women and can cause dryness of the vagina, genital itching, burning, dyspareunia, and recurrent urinary tract infections. Urinary symptoms can include urgency and dysuria. Vaginal estrogen is intended to deliver estrogen directly to local tissues and is moderately effective in reducing these symptoms, while minimizing systemic estrogen exposure. Some estrogen is absorbed systemically and can relieve menopausal symptoms. Systemically absorbed estrogen avoids first-pass liver metabolism, causing less hypertriglyceridemia and prothrombotic effects than oral estrogen. Manufacturers recommend that these preparations be used for only 3–6 months in women with an intact uterus, since vaginal estrogen can cause endometrial proliferation. However, most clinicians use them for longer periods. Vaginal estrogen can be administered in three different ways: creams, tablets, and rings.

A. ESTROGEN VAGINAL CREAMS—These creams are administered intravaginally with a measured-dose applicator daily for 2 weeks for atrophic vaginitis, then administered one to three times weekly. Available preparations include CEEs (Premarin, 0.626 mg/g cream), dosed as 0.25–0.5 g cream vaginally; dienestrol (Ortho Dienestrol, 10 mg/g cream), 0.25–0.5 g cream vaginally; estradiol (Estrace, 0.1 mg/g cream), 1 g cream vaginally; and estropipate (Ogen, 1.5 mg/g cream), 0.25–0.5 g vaginally.

B. ESTRADIOL VAGINAL TABLETS—These tablets are sold prepackaged in a disposable applicator and can be administered deep intravaginally daily for 2 weeks for atrophic vaginitis, then twice weekly. The tablets dissolve into a gel that gradually releases estradiol. Available preparations include vaginal estradiol tablets (Vagifem, 25 mcg/tablet).

C. ESTRADIOL VAGINAL RINGS—These rings are inserted manually into the upper third of the vagina, worn continuously, and replaced every 90 days. Only a small amount of the released estradiol enters the systemic circulation. Vaginal rings do not usually interfere with sexual intercourse. If a ring is removed or descends into the introitus, it may be washed in warm water and reinserted. Available preparations include Estring (2 mg estradiol/ring, releasing 7.5 mcg/d) and Femring (12.4 mg estradiol/ring, releasing 0.05 mg/d, or 24.8 mg estradiol/ring, releasing 0.10 mg/d). For women with postmenopausal urinary urgency and frequency, even the low-dose Estring can successfully reduce urinary symptoms.

D. ESTRADIOL WITH PROGESTIN VAGINAL RINGS—NuvaRing contains a mixture of estradiol and etonogestrel. It is a contraceptive vaginal ring that is placed in the vagina for 3 weeks, removed for 1 week, then replaced.

4. Estradiol intramuscular—Parenteral estradiol should be used only for particularly severe menopausal symptoms when other measures have failed or are contraindicated. Estradiol cypionate (DepoEstradiol 5 mg/mL) may be administered intramuscularly in doses of 1–5 mg every 3–4 weeks. Estradiol valerate (20 mg/mL) may be administered intramuscularly in doses of 10–20 mg every 4 weeks. Women with an intact uterus should receive a progestin for the last 10 days of each cycle.

5. Oral progestins—For a woman with an intact uterus, long-term conventional-dose unopposed systemic estrogen therapy can cause endometrial hyperplasia, which typically results in dysfunctional uterine bleeding and might rarely lead to endometrial cancer. Progestin therapy transforms proliferative into secretory endometrium, causing a menses when given intermittently or no bleeding when given continuously.

The type of progestin preparation, its dosage, and the timing of administration may be tailored to the given situation. Progestins may be given daily, monthly, or at longer intervals. When given episodically, progestins are usually administered for 7–14 day periods. Progestins are available in different formulations: Micronized progesterone (Prometrium, 100 mg/capsule), medroxyprogesterone acetate (Provera, Amen, Cycrin; 2.5, 5.0, and 10 mg/scored tablet), norethindrone acetate (Aygestin, 5 mg/tablet), and norethindrone (Micronor, Nor-QD; 0.35 mg/tablet).

Topical progesterone (20–50 mg/d) may reduce hot flashes in women who are intolerant to oral HRT. It may be applied to the upper arms, thighs, or inner wrists daily. It may be compounded as micronized progesterone 250 mg/mL in a transdermal gel. Its effects upon the breast and endometrium are unknown.

6. Progestin-releasing intrauterine devices—

Intrauterine devices (IUDs) that release progestins can be useful for women receiving ERT, since they can reduce the incidence of dysfunctional uterine bleeding and endometrial carcinoma without exposing women to the significant risks of systemic progestins. The Mirena IUD releases levonorgestrel and is inserted into the uterus by a clinician within 7 days of the onset of menses. It remains effective for up to 5 years. Parous women are generally better able to tolerate the Mirena IUD than nulliparous women.

7. Selective estrogen receptor modulators—

SERMs (eg, raloxifene, tamoxifen) are an alternative to estrogen replacement for hypogonadal women at risk for osteoporosis who prefer not to take estrogens because of their contraindications (eg, breast or uterine cancer) or side effects. Raloxifene does not reduce hot flashes, vaginal dryness, skin wrinkling, or breast atrophy; it does not improve cognition. However, in doses of 60 mg/d orally, it inhibits bone loss without stimulating effects upon the breasts or endometrium. Because raloxifene may slightly increase the risk of venous thromboembolism, it should not be used by women at prolonged bed rest or by those prone to thrombosis. In contrast with the use of ERT, concomitant progesterone therapy is not needed, and raloxifene does not increase the risk of development of breast cancer.

Tibolone (Livial) is an SERM whose metabolites have mixed estrogenic, progestogenic, and weak androgenic activity. It is comparable to HRT for the treatment of climacteric-related complaints. It does not appear to significantly stimulate proliferation of breast or endometrial tissue. It depresses both serum triglycerides and HDL cholesterol. Long-term studies are lacking. It is not available in the United States.

8. Phytoestrogens—These substances are found in plants that bind to estrogen receptors. Phytoestrogens, found in

soy and red clover extracts, do not appear to significantly improve menopausal hot flashes, cognitive function, bone density, or plasma lipids.

9. Testosterone replacement therapy in women—In premenopausal women, serum testosterone levels decline with age. Between 25 and 45 years of age, women's testosterone levels fall 50%. After natural menopause, the ovaries remain a significant source for testosterone. In fact, following natural menopause, serum testosterone levels do not fall abruptly and serum free testosterone levels may actually rise. In contrast, very low serum testosterone levels are found in women after bilateral oophorectomy, autoimmune ovarian failure, adrenalectomy, and in hypopituitarism. Testosterone deficiency contributes to hot flashes, loss of sexual hair, muscle atrophy, osteoporosis, and diminished libido, also known as hypoactive sexual desire disorder.

In women, diminished libido is common and multifactorial. Although low serum testosterone levels may contribute to hypoactive sexual desire disorder, hysterectomy and sexual isolation are major causes. Low serum testosterone levels may also cause fatigue, a diminished sense of well-being, and a dulled enthusiasm for life. Androgen replacement may improve these problems.

Testosterone therapy is often effective, while DHEA therapy is not. Selected women may be treated with low-dose testosterone. Methyltestosterone can be taken orally in doses of 1.25–2.5 mg daily. Testosterone can also be compounded as a cream containing 1 mg/mL, with 1 mL applied to the low abdomen daily. Methyltestosterone is also available in combination with conjugated estrogens (eg, Estratest). This formulation is convenient but carries the same disadvantage as oral estrogen—increased risk of thromboembolism. Tablets contain either 1.25 mg conjugated estrogens with 2.5 mg methyltestosterone or 0.625 mg conjugated estrogens with 1.25 mg methyltestosterone. Estratest is usually started at the lowest strength. It should be given cyclically at the lowest dose that controls symptoms.

Women receiving testosterone therapy must be monitored for the appearance of any acne or hirsutism, and serum testosterone levels are determined periodically if women feel that they are benefitting and long-term testosterone therapy is instituted. Side effects of low-dose testosterone therapy are usually minimal but may include polycythemia, emotional changes, hirsutism, acne, an adverse effect on lipids, and potentiation of warfarin anticoagulation therapy. Testosterone replacement tends to reduce both triglyceride and HDL cholesterol levels. Hepatocellular neoplasms and peliosis hepatis, rare complications of oral androgens at higher doses, have not been reported with methyltestosterone at lower doses of 2.5 mg orally daily. Androgens should not be given to women with liver disease or during pregnancy or breast-feeding. Testosterone replacement therapy for women should be used judiciously, since long-term prospective clinical trials are lacking. An analysis of the Nurses' Health Study found that women who had been taking CEEs plus methyltestosterone experienced an increased risk of breast cancer. Yearly mammography is recommended for all women over 40 years of age.

D. Other Treatments for Menopausal Hot Flashes

Lifestyle changes, such as dressing coolly, keeping the ambient room temperature cool, sleeping with light bedclothes, sipping cold beverages, and stress reduction may help reduce hot flashes. Women may try avoiding known triggers for hot flashes, such as smoking, alcohol, caffeine, and hot spicy foods. Idiosyncratic triggers for hot flashes may be discerned and avoided. **Gabapentin** can relieve hot flashes when estrogen replacement therapy is contraindicated or not desired and when lifestyle changes are insufficient. Women with moderate to severe postmenopausal hot flashes may obtain relief with gabapentin 600–2400 mg daily in divided doses. Side effects are most prominent in the first 2 weeks of treatment and may include somnolence, unsteadiness, and dizziness.

- Canonica M et al. Further evidence for promoting transdermal estrogens in the management of postmenopausal symptoms. *Menopause*. 2011 Oct;18(10):1038–9. [PMID: 21946050]
- Deligeorgiou E et al. Evaluation and management of adolescent amenorrhea. *Ann NY Acad Sci*. 2010 Sep;1205:23–32. [PMID: 20840249]
- Freeman EW et al. Duration of menopausal hot flashes and associated risk factors. *Obstet Gynecol*. 2001 May;117(5):1095–104. [PMID: 21508748]
- Hayes LP et al. Use of gabapentin for the management of natural or surgical menopausal hot flashes. *Ann Pharmacother*. 2011 Mar;45(3):388–94. [PMID: 21343402]
- Nappi RE et al. Menopause and sexual desire: the role of testosterone. *Menopause Int*. 2010 Dec;16(4):162–8. [PMID: 21156854]
- Nelken RS et al. Randomized trial of estradiol vaginal ring versus oral oxybutynin for the treatment of overactive bladder. *Menopause*. 2011 Sep;18(9):926–6. [PMID: 21532512]
- Rosenberg HK. Sonography of the pelvis in patients with primary amenorrhea. *Endocrinol Metab Clin North Am*. 2009 Dec;38(4):739–60. [PMID: 19944290]
- Santoro N. Update in hyper- and hypogonadotropic amenorrhea. *J Clin Endocrinol Metab*. 2011 Nov;96(11):3281–8. [PMID: 22058375]
- Stram DO et al. Age-specific effects of hormone therapy use on overall mortality and ischemic heart disease mortality among women in the California Teachers Study. *Menopause*. 2011 Mar;18(3):253–61. [PMID: 20881652]
- Taylor HS et al. Update in hormone therapy use in menopause. *J Clin Endocrinol Metab*. 2011 Feb;96(2):255–64. [PMID: 21296989]
- Warren MP. Hormone therapy for menopausal symptoms: putting benefits and risks into perspective. *J Fam Pract*. 2010 Dec;59(12):E1–7. [PMID: 21135919]

TURNER SYNDROME (Gonadal Dysgenesis)



ESSENTIALS OF DIAGNOSIS

- ▶ Short stature with normal GH levels.
- ▶ Primary amenorrhea or early ovarian failure.
- ▶ Epicanthal folds, webbed neck, short fourth metacarpals.
- ▶ Renal and cardiovascular anomalies.

Turner syndrome comprises a group of X chromosome disorders that are associated with spontaneous abortion, primary hypogonadism, short stature, and other phenotypic anomalies. It affects 1–2% of fetuses, of which about 97% abort, accounting for about 10% of all spontaneous abortions. Nevertheless, it affects about 1 in every 2500 live female births. Patients with the classic syndrome (about 50% of cases) lack one of the two chromosomes (45,XO karyotype). Other patients with Turner syndrome have X chromosome abnormalities, such as ring X or Xq (X/abnormal X) or X chromosome deletions affecting all or some somatic cells (mosaicism, XX/XO). Turner syndrome may be diagnosed in infant girls at birth, since they tend to be small and may exhibit severe lymphedema. Evaluation for childhood short stature often leads to the diagnosis. Girls and women with Turner syndrome have an increased risk of aortic coarctation (11%) and bicuspid aortic valves (16%); these cardiac abnormalities are more common in patients with webbed necks.

1. Classic Turner Syndrome (45,XO Gonadal Dysgenesis)

▶ Clinical Findings

A. Symptoms and Signs

Features of Turner syndrome are variable and may be subtle in girls with mosaicism. Typical manifestations in adulthood include short stature, hypogonadism, webbed neck, high-arched palate, wide-spaced nipples, hypertension, and renal abnormalities (Table 26–16). Emotional disorders are common.

Hypogonadism presents as “delayed adolescence” (primary amenorrhea, 80%) or early ovarian failure (20%); girls with 45,XO Turner (blood karyotyping) who enter puberty are typically found to have mosaicism if other tissues are karyotyped.

B. Laboratory Findings

Hypogonadism is confirmed in girls who have high serum levels of FSH and LH. A blood karyotype showing 45,XO (or X chromosome abnormalities or mosaicism) establishes the diagnosis. GH and IGF-1 levels are normal.

C. Imaging

An ultrasound and MRI scan of the chest and abdomen should be done in all patients with Turner syndrome to determine whether cardiac, aortic, and renal abnormalities are present.

▶ Treatment

Treatment of short stature with daily injections of GH (0.1 unit/kg/d) plus an androgen (eg, oxandrolone) for at least 4 years before epiphyseal fusion increases final height by a mean of about 10.3 cm over the mean predicted height of 144.2 cm. Such GH treatment rarely causes pseudotumor cerebri. After age 12 years, estrogen therapy is begun with

Table 26-16. Manifestations of Turner syndrome.

Short stature
Distinctive facial features
Ptosis
Micrognathia
Low-set ears
Epicanthal folds
Sexual infantilism due to gonadal dysgenesis with primary amenorrhea (80%)
Early ovarian failure with secondary amenorrhea (20%)
Webbed neck (40%)
Low hairline
High-arched palate
Cubitus valgus
Short fourth metacarpals (50%)
Lymphedema of hands and feet (30%)
Hypoplastic widely spaced nipples
Hyperconvex nails
Pigmented nevi
Keloid formation (eg, surgical scars or after ear piercing)
Recurrent otitis media
Renal abnormalities (60%)
Horseshoe kidney
Hydronephrosis
Hypertension (idiopathic or due to coarctation or kidney disease)
Gastrointestinal disorders
Telangiectasis with bleeding
Celiac disease
Inflammatory bowel disease
Colon carcinoma
Liver disease
Impaired space-form recognition, direction sense, and mathematical reasoning
Cardiovascular anomalies
Coarctation of the aorta (10–20%)
Partial anomalous pulmonary venous connection
Bicuspid aortic valve (with aortic stenosis or insufficiency)
Aortic dissection due to coarctation and cystic medial necrosis of the aorta
Associated conditions
Obesity
Diabetes mellitus (types 1 and 2)
Dyslipidemia
Hyperuricemia
Hashimoto thyroiditis
Achlorhydria
Cataracts, corneal opacities
Neuroblastoma (1%)
Rheumatoid arthritis

low doses of conjugated estrogens (0.3 mg) or ethinyl estradiol (5 mcg) given on days 1–21 per month. When growth stops, HRT is begun with estrogen and progestin; transdermal estrogen may be used to initiate pubertal development.

► Complications & Surveillance

Bicuspid aortic valves are associated with an increased risk of infective endocarditis, aortic valvular stenosis or insufficiency, and ascending aortic aneurysm and dissection.

Partial anomalous pulmonary vein connections occur in 13% and can lead to left-to-right shunting of blood. Adults with Turner syndrome have a high incidence of ECG abnormalities.

Women with Turner syndrome have a reduced life expectancy due in part to their increased risk of diabetes mellitus (types 1 and 2), hypertension, dyslipidemia, and osteoporosis.

Diagnostic vigilance and aggressive treatment of these conditions reduce the risk of aortic aneurysm dissection, ischemic heart disease, stroke, and fracture. Patients are prone to keloid formation after surgery or ear piercing. Yearly ocular examinations and periodic thyroid evaluations are recommended.

Repeat cardiovascular evaluations should be done every 3–4 years. Patients with the classic 45,XO karyotype have a high risk of renal structural abnormalities, whereas those with 46 X/abnormal X are more prone to malformations of the urinary collecting system. The risk of aortic dissection is increased more than 100-fold in women with Turner syndrome, particularly those with pronounced neck webbing and shield chest. Patients with aortic root enlargement are usually treated with β -blockade and serial imaging. Women with Turner syndrome who are able to become pregnant are strongly advised to deliver via cesarean section due to the risk of aortic aneurysm rupture during vaginal delivery.

2. Turner Syndrome Variants

A. 46,X (Abnormal X) Karyotype

Patients with small distal short arm deletions of the X chromosome (Xp^-) that include the *SHOX* gene often have short stature and skeletal abnormalities but have a low risk of ovarian failure. Transmission of Turner syndrome from mother to daughter can occur. There may be an increased risk of trisomy 21 in the conceptuses of women with Turner syndrome. Patients with deletions of the long arm of the X chromosome (distal to Xq24) often have amenorrhea without short stature or other features of Turner syndrome. Abnormalities or deletions of other genes located on both the long and short arms of the X chromosome can produce gonadal dysgenesis with few other somatic features.

B. 45,XO/46,XX Mosaicism

This karyotype results in a modified form of Turner syndrome. Such girls tend to be taller and may have more gonadal function and fewer other manifestations of Turner syndrome.

C. Other Variants

45,XO/46,XY mosaicism can produce some manifestations of Turner syndrome. Patients may have ambiguous genitalia or male infertility with an otherwise normal phenotype. Germ cell tumors, such as gonadoblastomas and seminomas, develop in about 10% of patients with 45,XO/46,XY mosaicism; most such tumors are benign.

- Bondy CA. Turner syndrome 2008. *Horm Res.* 2009 Jan;71 (Suppl 1):52–6. [PMID: 19153507]
- Conway GS et al. How do you monitor the patient with Turner's syndrome in adulthood? *Clin Endocrinol (Oxf)*. 2010 Dec; 73(6):696–9. [PMID: 20718775]
- Davenport ML. Approach to the patient with Turner syndrome. *J Clin Endocrinol Metab.* 2010 Apr;95(4):1487–95. [PMID: 20375216]
- Mazzanti L et al. Developmental syndromes: growth hormone deficiency and treatment. *Endocr Dev.* 2009;14:114–34. [PMID: 19293579]
- Ross JL et al. Growth hormone plus childhood low-dose estrogen in Turner's syndrome. *N Engl J Med.* 2011 Mar 31;364(13): 1230–42. [PMID: 21449786]
- Thomas J et al. Management of cardiovascular disease in Turner syndrome. *Expert Rev Cardiovasc Ther.* 2009 Dec;7(12): 1631–41. [PMID: 19954324]
- Zeger MP et al. Prospective study confirms oxandrolone-associated improvement in height in growth hormone-treated adolescent girls with Turner syndrome. *Horm Res Paediatr.* 2011;75(1):38–46. [PMID: 20733274]

MULTIPLE ENDOCRINE NEOPLASIA

ESSENTIALS OF DIAGNOSIS

- ▶ MEN 1: tumors of the parathyroid glands, endocrine pancreas and duodenum, pituitary, adrenal, thyroid; lipomas and facial angiofibromas.
- ▶ MEN 2A: medullary thyroid cancers, pheochromocytomas, Hirschsprung disease.
- ▶ MEN 2B: medullary thyroid cancers, pheochromocytomas, Marfan-like habitus, mucosal neuromas, intestinal ganglioneuroma, delayed puberty.

Syndromes of MEN are inherited as autosomal dominant traits and cause a predisposition to the development of tumors in different tissues, particularly involving endocrine glands (Table 26–17).

1. MEN 1 (Wermer Syndrome)

MEN 1 is a familial multiglandular endocrine tumor syndrome, with a prevalence of 2–10 per 100,000 people. The presentation of MEN 1 is quite variable, even in the same kindred. Parathyroid, enteropancreatic, and pituitary tumors can be present in one individual, though not necessarily at the same time. Nonendocrine tumors also occur, such as subcutaneous lipomas, facial angiofibromas, and collagenomas. In some affected individuals, tumors may start developing in childhood, whereas in others, tumors develop late in adult life.

About 90% of patients with MEN 1 have germline mutations that are inherited as an autosomal dominant trait. Patients with MEN 1 usually have detectable mutations in the *menin* gene, located on the long arm of chromosome 11 (11q13). MEN 1 gene testing is available at a few centers and is able to detect the specific mutation in 60–95% of cases. If no mutation is detected, genetic linkage analysis can be done if there are several affected members in the kindred. Gene testing permits the rest of the kindred to be tested for the specific gene defect and allows informed genetic counseling.

With close endocrine surveillance of affected individuals, the initial biochemical manifestations (usually hypercalcemia) can often be detected as early as age 14–18 years in patients with a MEN 1 gene mutation, although clinical manifestations do not usually present until the third or fourth decade.

Hyperparathyroidism is the first clinical manifestation of MEN 1 in two-thirds of affected patients, but it may present at any time of life. Patients with the MEN 1 mutation have a > 90% lifetime risk of developing hyperparathyroidism. The hyperparathyroidism of MEN 1 is notoriously difficult to treat surgically, due to multiple gland involvement and the frequency of supernumerary glands and ectopic parathyroid tissue. Typically, three and one-half glands are resected, leaving one-half of the most normal-appearing gland intact. Also, during neck surgery, a thymectomy is performed to resect any intrathymic parathyroid glands or

Table 26–17. Multiple endocrine neoplasia (MEN) syndromes: Incidence of tumor types.

Tumor Type	MEN 1 (Wermer Syndrome)	MEN 2A (Sipple Syndrome)	MEN 2B
Parathyroid	95%	20–50%	Rare
Pancreatic	54%		
Pituitary	42%		
Medullary thyroid carcinoma		> 90%	80%
Pheochromocytoma	Rare	20–35%	60%
Mucosal and gastrointestinal ganglioneuromas		Rare	> 90%
Subcutaneous lipoma	30%		
Adrenocortical adenoma	30%		
Thoracic carcinoid	15%		
Thyroid adenoma	55%		
Facial angiofibromas and collagenomas	85%		

occult thymic carcinoid tumors. Nevertheless, the surgical failure rate is about 38%, and there is a recurrence rate of about 16%, with hypercalcemia often recurring many years after neck surgery. Aggressive parathyroid resection can cause permanent hypoparathyroidism. Patients with persistent or recurrent hyperparathyroidism should avoid oral calcium supplements and thiazide diuretics; oral therapy with calcimimetic drug, such as cinacalcet, is effective but expensive. The diagnosis and treatment of hyperparathyroidism is described earlier in this chapter.

Enteropancreatic tumors occur in about 75% of patients with MEN 1. **Nonsecretory neuroendocrine tumors** occur and do not secrete hormones; they tend to be large and very aggressive. **Gastrinomas** occur in about 35% of patients with MEN 1; they secrete gastrin, thereby causing severe gastric hyperacidity (Zollinger–Ellison syndrome) with peptic ulcer disease or diarrhea. Concurrent hypercalcemia, due to hyperparathyroidism (see above), stimulates gastrin and gastric acid secretion; control of the hypercalcemia often reduces gastric acid secretion and serum gastrin levels. These gastrinomas tend to be small, multiple, and ectopic; they are frequently found outside the pancreas, usually in the duodenum. Gastrinomas of MEN 1 can metastasize to the liver; but in patients with MEN 1, depending upon the kindred, hepatic metastases tend to be less aggressive than those from sporadic gastrinomas. Treatment of patients with gastrinomas in MEN 1 is usually conservative, utilizing long-term high-dose proton pump inhibitor therapy and control of hypercalcemia; surgery is palliative and usually reserved for aggressive gastrinomas and those tumors arising in the duodenum. Zollinger–Ellison syndrome is also discussed in Chapter 15.

Insulinomas cause hyperinsulinism and fasting hypoglycemia. They occur in about 15% of patients with MEN 1. Surgery is usually attempted, but the tumors can be small, multiple, and difficult to detect. The diagnosis and treatment of insulinomas are described in Chapter 27. Glucagonomas (1.6%) secrete glucagon and cause diabetes and migratory necrolytic erythema. VIPomas (1%) secrete VIP and cause profuse watery diarrhea, hypokalemia, and achlorhydria (WDHA, Verner-Morrison syndrome). Somatostatinomas (0.7%) can cause diabetes mellitus, steatorrhea, and cholelithiasis.

Pituitary adenomas occur in about 42% of patients with MEN 1. They are more common in women (50%) than men (31%) and are the presenting tumor in 17% of patients with MEN 1. These tumors tend to be more aggressive macroadenomas (> 1 cm diameter, 85%) compared to sporadic pituitary tumors (42%). Of MEN 1–associated pituitary tumors, about 62% secrete PRL, 8% secrete GH, 13% secrete both PRL and GH, and 13% are nonsecretory; only 4% secrete ACTH and cause Cushing disease. The diagnosis and treatment of pituitary tumors and Cushing disease were described earlier in this chapter. These pituitary tumors can produce local pressure effects and hypopituitarism.

Adrenal adenomas or hyperplasia occurs in about 37% of patients with MEN 1 and 50% are bilateral. They are generally benign and nonfunctional. In one series, one out of 12 of these patients developed a feminizing adrenal carcinoma. These adrenal lesions are pituitary independent.

Nonendocrine tumors occur commonly in MEN 1. Small facial angiofibromas and subcutaneous lipomas are common. Collagenomas can present as firm dermal nodules. Malignant melanomas have been reported.

The differential diagnosis of MEN 1 includes sporadic or familial tumors of the pituitary, parathyroids, or pancreatic islets. Hypercalcemia (from any cause) may cause gastrointestinal symptoms and increased gastrin levels, simulating a gastrinoma. Routine suppression of gastric acid secretion with H₂-blockers or proton pump inhibitors causes a physiologic increase in serum gastrin that can be mistaken for a gastrinoma. H₂-blockers and metoclopramide cause hyperprolactinemia, simulating a pituitary prolactinoma.

Variants of MEN 1 also occur. Kindreds with MEN 1 Burin variant have a high prevalence of prolactinomas, late-onset hyperparathyroidism, and carcinoid tumors, but rarely enteropancreatic tumors.

2. MEN 2A (Sipple Syndrome)

MEN 2A is a rare familial multiglandular syndrome that is inherited as an autosomal dominant trait. Patients with MEN 2A should have genetic testing for a *ret* protooncogene (RET) mutation. Their first-degree relatives may then be tested for the specific RET mutation. Patients with MEN 2A may have **medullary thyroid carcinoma** (> 90%); hyperparathyroidism (20–50%), due to hyperplasia or multiple adenomas in over 70% of cases; **pheochromocytomas** (20–35%), which are often bilateral; or **Hirschsprung disease**. The medullary thyroid carcinoma is of mild to moderate aggressiveness. Children harboring an MEN 2A RET gene mutation are advised to have a prophylactic total thyroidectomy by age 6 years.

Siblings or children of patients with MEN 2A should have genetic testing to determine if they have a mutation of the *ret* protooncogene (RET) on chromosome 10cen-10q11.2; this identifies about 95% of affected individuals. Each kindred has a certain *ret* codon mutation that correlates with the particular variation in the MEN 2 syndrome, such as the age of onset and aggressiveness of medullary thyroid cancer. The specific mutation as well as case histories of family members should guide the timing for prophylactic thyroidectomy. Before any surgical procedure, MEN 2 carriers should be screened for pheochromocytoma. There is incomplete penetrance, and about 30% of those with such mutations never manifest endocrine tumors.

Patients may be screened for medullary thyroid carcinoma with a serum calcitonin drawn after 3 days of omeprazole, 20 mg orally twice daily; calcitonin levels rise in the presence of medullary thyroid carcinoma to above 80 pg/mL in women or above 190 pg/mL in men.

3. MEN 2B

MEN 2B is a familial, autosomal dominant multiglandular syndrome that is caused by a mutation of the *ret* protooncogene (RET) on chromosome 10. MEN 2B is characterized by mucosal neuromas (> 90%) with bumpy and enlarged lips and tongue, Marfan-like habitus (75%), adrenal pheochromocytomas (60%) that are rarely malignant and often bilateral, and medullary thyroid carcinoma

(80%). Patients also have intestinal abnormalities (75%) such as intestinal ganglioneuromas, skeletal abnormalities (87%), and delayed puberty (43%). Medullary thyroid carcinoma is aggressive and presents early in life. Therefore, infants having a parent with MEN 2B receive genetic screening; those carrying the RET mutation undergo a prophylactic total thyroidectomy by age 6 months.

OTHER SYNDROMES OF MULTIPLE ENDOCRINE NEOPLASIA

Patients with **Carney complex** develop tumors in the adrenal cortex, pituitary, thyroid, and gonads as well as cardiac myxomas and hyperpigmentation. Patients with **Cowden disease** develop thyroid abnormalities (66%) such as benign adenomas and follicular adenocarcinomas, along with breast cancer (20–36% in women), and multiple hamartomas that affect the skin and multiple other organs. Patients with **McCune-Albright syndrome** may develop precocious puberty (particularly girls) due to gonadal hypersecretion, Cushing syndrome caused by multiple adrenal nodules, hyperthyroidism from hypersecretory thyroid nodules, and acromegaly caused by GH-secreting pituitary tumors. Patients have fibrous dysplasia of bones and hypophosphatemia, with bone fractures being common. Sudden death has been reported. It is caused by a postzygotic somatic mutation in the gene encoding the stimulatory G_s protein, resulting in constitutive activation of affected cells.

Daly AF et al. Update on familial pituitary tumors: from multiple endocrine neoplasia type 1 to familial isolated pituitary adenoma. *Horm Res.* 2009 Jan;71(Suppl 1):105–11. [PMID: 19153518]

Pieterman CR et al. Care for patients with multiple endocrine neoplasia type 1: the current evidence base. *Fam Cancer.* 2011 Mar;10(1):151–71. [PMID: 21061174]

Romei C et al. Multiple endocrine neoplasia type 2 syndromes (MEN 2): results from the ItaMEN network analysis on the prevalence of different genotypes and phenotypes. *Eur J Endocrinol.* 2010 Aug;163(2):301–8. [PMID: 20516206]

Thakker RV. Multiple endocrine neoplasia type 1 (MEN1). *Best Pract Res Clin Endocrinol Metab.* 2010 Jun;24(3):355–70. [PMID: 20833329]

Wohllk N et al. Multiple endocrine neoplasia type 2. *Best Pract Res Clin Endocrinol Metab.* 2010 Jun;24(3):371–87. [PMID: 20833330]

CLINICAL USE OF CORTICOSTEROIDS

Mechanisms of Action

Cortisol is a steroid hormone that is normally secreted by the adrenal cortex in response to ACTH. It exerts its action by binding to nuclear receptors, which then act upon chromatin to regulate gene expression, producing effects throughout the body.

Relative Potencies (Table 26–18)

Hydrocortisone and cortisone acetate, like cortisol, have mineralocorticoid effects that become excessive at higher

Table 26–18. Systemic versus topical activity of corticosteroids.¹

	Systemic Activity	Topical Activity
Prednisone	4–5	1–2
Triamcinolone	5	1
Triamcinolone acetonide	5	40
Dexamethasone	30–120	10
Betamethasone	30	5–10
Betamethasone valerate	—	50–150
Methylprednisolone	5	5
Fluocinolone acetonide	—	40–100
Flurandrenolide	—	20–50
Deflazacort	3–4	—

¹Hydrocortisone = 1 in potency.

doses. Other synthetic corticosteroids such as prednisone, dexamethasone, and deflazacort (an oxazoline derivative of prednisolone) have minimal mineralocorticoid activity. Anticonvulsant drugs (eg, phenytoin, carbamazepine, phenobarbital) accelerate the metabolism of corticosteroids other than hydrocortisone, making them significantly less potent. Megestrol, a synthetic progestin, has slight corticosteroid activity that becomes significant when administered in high doses for appetite stimulation.

Adverse Effects

Prolonged treatment with systemic high-dose corticosteroids causes a variety of adverse effects that can be life-threatening. Patients should be thoroughly informed of the major possible side effects of treatment such as insomnia, cognitive and personality changes, weight gain with central obesity, bruising, striae, muscle weakness, polyuria, kidney stones, diabetes mellitus, glaucoma, cataracts, sex hormone suppression, candidiasis and opportunistic infections. High-dose corticosteroids have adverse cardiovascular effects, increasing the risk of hypertension, dyslipidemia, myocardial infarction, stroke, atrial fibrillation or flutter, and heart failure. Bone fractures (especially spine and hip) ultimately occur in about 40% of patients receiving long-term corticosteroid therapy. Osteoporotic fractures can also occur in patients who receive extensive topical, inhaled, or intermittent oral corticosteroids (eg, prednisone ≥ 10 mg daily and cumulative dose > 1 g). Osteoporotic fractures can occur even in patients receiving long-term corticosteroid therapy at relatively low doses (eg, 5–7.5 mg prednisone daily). Patients at increased risk for corticosteroid osteoporotic fractures include those who are over age 60 or who have a low body mass index, pretreatment osteoporosis, a family history of osteoporosis, or concurrent disease that limits mobility. Avascular necrosis of bone (especially hips) develops in about 15% of patients who

Table 26–19. Management of patients receiving systemic corticosteroids.**Recommendations for prescribing**

- Do not administer corticosteroids unless absolutely indicated or more conservative measures have failed.
- Keep dosage and duration of administration to the minimum required for adequate treatment.

Monitoring recommendations

- Screen for tuberculosis with a purified protein derivative (PPD) test or chest radiograph before commencing long-term corticosteroid therapy.
- Screen for diabetes mellitus before treatment and at each clinician visit.
 - Have patient test urine weekly for glucose.
 - Teach patient about the symptoms of hyperglycemia.
- Screen for hypertension before treatment and at each clinician visit.
- Screen for glaucoma and cataracts before treatment, 3 months after treatment inception, and then at least yearly.
- Monitor plasma potassium for hypokalemia and treat as indicated.
- Obtain bone densitometry before treatment and then periodically. Treat osteoporosis.
- Weigh daily. Use dietary measures to avoid obesity and optimize nutrition.
- Measure height frequently to document the degree of axial spine demineralization and compression.
- Watch for fungal or yeast infections of skin, nails, mouth, vagina, and rectum, and treat appropriately.
- With dosage reduction, watch for signs of adrenal insufficiency or corticosteroid withdrawal syndrome.

Patient information

- Prepare the patient and family for possible adverse effects on mood, memory, and cognitive function.
- Inform the patient about other possible side effects, particularly weight gain, osteoporosis, and aseptic necrosis of bone.
- Counsel to avoid smoking and excessive ethanol consumption.

Prophylactic measures

- Institute a vigorous physical exercise and isometric regimen tailored to each patient's disabilities.
- Administer calcium (1 g elemental calcium) and vitamin D₃, 400–800 international units orally daily.
 - Check spot morning urines for calcium, and alter dosage to keep urine calcium concentration below 30 mg/dL.
 - If the patient is receiving thiazide diuretics, check for hypercalcemia, and administer only 500 mg elemental calcium daily.
 - Consider a bisphosphonate such as alendronate (70 mg orally weekly) or periodic intravenous infusions of pamidronate or zoledronic acid.
- Avoid prolonged bed rest that will accelerate muscle weakness and bone mineral loss. Ambulate early after fractures.
- Avoid elective surgery, if possible. Vitamin A in a daily dose of 20,000 units orally for 1 week may improve wound healing, but it is not prescribed in pregnancy.
- Avoid activities that could cause falls or other trauma.
- For ulcer prophylaxis, if administering corticosteroids with nonsteroidals, prescribe a proton pump inhibitor (not required for corticosteroids alone). Avoid large doses of antacids containing aluminum hydroxide (many popular brands) because aluminum hydroxide binds phosphate and may cause a hypophosphatemic osteomalacia that can compound corticosteroid osteoporosis.
- Treat hypogonadism.
- Treat infections aggressively. Consider unusual pathogens.
- Treat edema as indicated.

receive corticosteroids at high doses (eg, prednisone \geq 15 mg daily) for more than 1 month with cumulative prednisone doses of \geq 10 g.

Bisphosphonates (eg, alendronate, 70 mg orally weekly) prevent the development of osteoporosis among patients receiving prolonged courses of corticosteroids. For patients who are unable to tolerate oral bisphosphonates (due to esophagitis, hiatal hernia, or gastritis), periodic intravenous infusions of pamidronate, 60–90 mg, or zoledronic acid, 2–4 mg, should also be effective. Teriparatide, 20 mcg subcutaneously daily for up to 2 years, is also effective against corticosteroid-induced osteoporosis. (See further discussion in Osteoporosis section.) It is wise to follow an organized treatment plan such as the one outlined in Table 26–19.

Christiansen CF et al. Glucocorticoid use and risk of atrial fibrillation or flutter: a population-based, case-control study. *Arch Intern Med.* 2009 Oct 12;169(18):1677–83. [PMID: 19822824]

Leib ES et al. Official positions for FRAX® clinical regarding glucocorticoids: the impact of the use of glucocorticoids on the estimate by FRAX® of the 10 year risk of fracture from Joint Official Positions Development Conference of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX®. *J Clin Densitom.* 2011 Jul–Sep;14(3):212–9. [PMID: 21810527]

Strohmayer EA et al. Glucocorticoids and cardiovascular risk factors. *Endocrinol Metab Clin North Am.* 2001 Jun;40(2):409–17. [PMID: 21565675]

Weinstein RS. Clinical practice. Glucocorticoid-induced bone disease. *N Engl J Med.* 2011 Jul 7;365(1):62–70. [PMID: 21732837]

27

Diabetes Mellitus & Hypoglycemia

Umesh Masharani, MB, BS, MRCP(UK)

DIABETES MELLITUS

ESSENTIALS OF DIAGNOSIS

Type 1 diabetes:

- ▶ Polyuria, polydipsia, and weight loss associated with random plasma glucose ≥ 200 mg/dL (11.1 mmol/L).
- ▶ Plasma glucose of ≥ 126 mg/dL (7.0 mmol/L) after an overnight fast, documented on more than one occasion.
- ▶ Ketonemia, ketonuria, or both.
- ▶ Islet autoantibodies are frequently present.

Type 2 diabetes:

- ▶ Most patients are over 40 years of age and obese.
- ▶ Polyuria and polydipsia. Ketonuria and weight loss generally are uncommon at time of diagnosis. Candidal vaginitis in women may be an initial manifestation. Many patients have few or no symptoms.
- ▶ Plasma glucose of ≥ 126 mg/dL after an overnight fast on more than one occasion. Two hours after 75 g oral glucose, diagnostic values are ≥ 200 mg/dL (11.1 mmol).
- ▶ Hypertension, dyslipidemia, and atherosclerosis are often associated.

▶ Epidemiologic Considerations

In 2010, an estimated 25.8 million people (8.3%) in the United States had diabetes mellitus, of which approximately 1 million have type 1 diabetes and most of the rest have type 2 diabetes. A third group that was designated as “other specific types” by the American Diabetes Association (ADA) (Table 27–1) number only in the thousands. Among these are the rare monogenic defects of either B cell function or of insulin action, primary diseases of the exocrine pancreas, endocrinopathies,

and medication-induced diabetes. Updated information about the prevalence of diabetes in the United States is available from the Centers for Disease Control and Prevention (<http://www.cdc.gov/diabetes/pubs/estimates.htm#prev>).

▶ Classification & Pathogenesis

Diabetes mellitus is a syndrome with disordered metabolism and inappropriate hyperglycemia due to either a deficiency of insulin secretion or to a combination of insulin resistance and inadequate insulin secretion to compensate. Type 1 diabetes is due to pancreatic islet B cell destruction predominantly by an autoimmune process, and these patients are prone to ketoacidosis. Type 2 diabetes is the more prevalent form and results from insulin resistance with a defect in compensatory insulin secretion.

A. Type 1 Diabetes Mellitus

This form of diabetes is immune-mediated in over 95% of cases (type 1a) and idiopathic in < 5% (type 1b). The rate of pancreatic B cell destruction is quite variable, being rapid in some individuals and slow in others. Type 1 diabetes is usually associated with ketosis in its untreated state. It occurs at any age but most commonly arises in children and young adults with a peak incidence before school age and again at around puberty. It is a catabolic disorder in which circulating insulin is virtually absent, plasma glucagon is elevated, and the pancreatic B cells fail to respond to all insulinogenic stimuli. Exogenous insulin is therefore required to reverse the catabolic state, prevent ketosis, reduce the hyperglucagonemia, and reduce blood glucose.

1. Immune-mediated type 1 diabetes mellitus (type 1A)—The highest incidence of immune-mediated type 1 diabetes mellitus is in Scandinavia and northern Europe, where the annual incidence is as high as 40 per 100,000 children aged 14 years or younger in Finland, 31 per 100,000 in Sweden, 22 per 100,000 in Norway, and 20 per 100,000 in England. The annual incidence of type 1 diabetes decreases across the rest of Europe to 11 per 100,000 in Greece and 9 per 100,000 in France. Surprisingly, the island of Sardinia has as high an annual incidence as Finland

Table 27-1. Other specific types of diabetes mellitus.

Genetic defects of pancreatic B cell function
MODY 1 (HNF-4 α); rare
MODY 2 (glucokinase); less rare
MODY 3 (HNF-1 α); accounts for two-thirds of all MODY
MODY 4 (PDX1); very rare
MODY 5 (HNF-1 β); very rare
MODY 6 (neuroD1); very rare
Mitochondrial DNA
Genetic defects in insulin action
Type A insulin resistance
Leprechaunism
Rabson-Mendenhall syndrome
Lipoatrophic diabetes
Diseases of the exocrine pancreas
Endocrinopathies
Drug- or chemical-induced diabetes
Other genetic syndromes (Down, Klinefelter, Turner, others) sometimes associated with diabetes

MODY, maturity-onset diabetes of the young.

(40 per 100,000) even though in the rest of Italy, including the island of Sicily, it is only 11 per 100,000 per year. In the United States, the annual incidence of type 1 diabetes averages 16 per 100,000, with higher rates in states more densely populated with persons of Scandinavian descent such as Minnesota. Worldwide, the lowest incidence of type 1 diabetes (< 1 case per 100,000 per year) is in China and parts of South America. The global incidence of type 1 diabetes is increasing (approximately 3% each year). In Europe, the highest annual incidence increase was seen in low prevalence countries in Eastern Europe, especially Romania and Poland. Changes in environmental factors most likely explain this increased incidence.

Approximately one-third of the disease susceptibility is due to genes and two-thirds to environmental factors. Genes that are related to the HLA locus contribute about 40% of the genetic risk. About 95% of patients with type 1 diabetes possess either HLA-DR3 or HLA-DR4, compared with 45–50% of white controls. *HLA-DQ* genes are even more specific markers of type 1 susceptibility, since a particular variety (*HLA-DQB1*0302*) is found in the DR4 patients with type 1, while a “protective” gene (*HLA-DQB1*0602*) is often present in the DR4 controls. The other important gene that contributes to about 10% of the genetic risk is found at the 5′ polymorphic region of the insulin gene. This polymorphic region affects the expression of the insulin gene in the thymus and results in depletion of insulin-specific T lymphocytes. In linkage studies, 16 other genetic regions of the human genome have been identified as being important to pathogenesis. Many of the genes linked to these additional loci play important roles in the function and regulation of the immune response. Mutations in genes associated with T cell tolerance can also cause autoimmune diabetes. The autoimmune regulatory gene (*AIRE*) product regulates the expression of several proteins in the thymus causing the deletion of self-reactive T cells. Type 1 diabetes mellitus as well as other autoimmune disorders

Table 27-2. Diagnostic sensitivity and specificity of autoimmune markers in patients with newly diagnosed type 1 diabetes mellitus.

	Sensitivity	Specificity
Glutamic acid decarboxylase (GAD65)	70–90%	99%
Insulin (IAA)	40–70%	99%
Tyrosine phosphatase (IA-2)	50–70%	99%
Zinc transporter 8 (ZnT8)	50–70%	99%

(autoimmune polyglandular syndrome 1) develop in 20% of individuals with homozygote mutations in *AIRE*. *FOXP3*, an X chromosome gene, encodes a transcription factor required for the formation of regulatory T cells. Mutations in *FOXP3* lead to very early type 1 diabetes mellitus and other autoimmune endocrinopathies (immuno-dysregulation polyendocrinopathy enteropathy X-linked [IPEX] syndrome). Most patients with type 1 diabetes mellitus have circulating antibodies to islet cells (ICA), insulin (IAA), glutamic acid decarboxylase 65 (GAD65), tyrosine phosphatase IA2 (ICA-512), and zinc transporter 8 (ZnT8) at the time the diagnosis is made (Table 27–2). These antibodies facilitate screening for an autoimmune cause of diabetes, particularly screening siblings of affected children, as well as adults with atypical features of type 2 diabetes mellitus. Screening with GAD65, ICA-512, IAA, and ZnT8 autoantibodies may identify about 98% of people who have an autoimmune basis for their beta cell loss. Antibody levels decline with increasing duration of disease. Also, low levels of anti-insulin antibodies develop in almost all patients once they are treated with insulin.

Family members of diabetic probands are at increased lifetime risk for developing type 1 diabetes mellitus. A child whose mother has type 1 diabetes has a 3% risk of developing the disease and a 6% risk if the child’s father has it. The risk in siblings is related to the number of HLA haplotypes that the sibling shares with the diabetic proband. If one haplotype is shared, the risk is 6% and if two haplotypes are shared, the risk increases to 12–25%. The highest risk is for identical twins, where the concordance rate is 25–50%.

Some patients with a milder expression of type 1 diabetes mellitus initially retain enough B cell function to avoid ketosis, but as their B cell mass diminishes later in life, dependence on insulin therapy develops. Islet cell antibody surveys among northern Europeans indicate that up to 15% of “type 2” diabetic patients may actually have this mild form of type 1 diabetes (latent autoimmune diabetes of adulthood; LADA). Evidence for environmental factors playing a role in the development of type 1 diabetes include the observation that the disease is more common in Scandinavian countries and becomes progressively less frequent in countries nearer and nearer to the equator. Also, the risk for type 1 diabetes increases when individuals who normally have a low risk emigrate to the Northern Hemisphere. For example, it was recently shown that Pakistani children born and raised in Bradford, England have a higher risk for

developing type 1 diabetes compared with children who lived in Pakistan all their lives.

Which environmental factor is responsible for the increased risk is not known. There have been a number of different hypotheses including infections with certain viruses (mumps, rubella, Cocksackie B4) and consumption of cow's milk. Also, in developed countries, childhood infections have become less frequent and so perhaps the immune system becomes dysregulated with development of autoimmunity and conditions such as asthma and diabetes. This theory is referred to as the hygiene hypothesis. None of these factors has so far been confirmed as the culprit. Part of the difficulty is that autoimmune injury undoubtedly starts many years before clinical diabetes mellitus develops.

2. Idiopathic type 1 diabetes mellitus (type 1B)—

Approximately 5% of subjects have no evidence of pancreatic B cell autoimmunity to explain their insulinopenia and ketoacidosis. This subgroup has been classified as "idiopathic type 1 diabetes" and designated as "type 1B." Although only a minority of patients with type 1 diabetes fall into this group, most of these are of Asian or African origin. It was recently reported that about 4% of the West Africans with ketosis-prone diabetes are homozygous for a mutation in *PAX-4 (Arg133Trp)*—a transcription factor that is essential for the development of pancreatic islets.

B. Type 2 Diabetes Mellitus

This represents a heterogeneous group of conditions that used to occur predominantly in adults, but it is now more frequently encountered in children and adolescents. More than 90% of all diabetic persons in the United States are included under this classification. Circulating endogenous insulin is sufficient to prevent ketoacidosis but is inadequate to prevent hyperglycemia in the face of increased needs owing to tissue insensitivity (insulin resistance).

Genetic and environmental factors combine to cause both the insulin resistance and the beta cell loss. Most epidemiologic data indicate strong genetic influences, since in monozygotic twins over 40 years of age, concordance develops in over 70% of cases within a year whenever type 2 diabetes develops in one twin. Genome-wide association studies have made considerable progress in identifying the at-risk genes. So far, 19 different genetic loci have been associated with an increased risk of type 2 diabetes. A significant number of the identified loci appear to code for proteins that have a role in beta cell function or development. One of the genetic loci with the largest risk effect is *TCF7L2*. This gene codes for a transcription factor involved in the WNT signaling pathway that is required for normal pancreatic development. Alleles at other genetic loci (*CDKAL1*, *SLC30A8*, *HHEX-IDE*, *CDKN2A/B*, *KCNJ11*, and *IGF2BP2*) are thought to affect insulin secretion. Two loci (*FTO* and *MC4R*) affect fat mass and obesity risk. The *PPARG* locus has been implicated in insulin resistance. The loci identified to date still explain only some of the heritable risk for diabetes; clearly, other loci remain to be discovered.

Early in the disease process, hyperplasia of pancreatic B cells occurs and probably accounts for the fasting hyperinsulinism and exaggerated insulin and proinsulin responses

to glucose and other stimuli. With time, chronic deposition of amyloid in the islets may combine with inherited genetic defects progressively to impair B cell function.

Obesity is the most important environmental factor causing insulin resistance. The degree and prevalence of obesity varies among different racial groups with type 2 diabetes. While obesity is apparent in no more than 30% of Chinese and Japanese patients with type 2, it is found in 60–70% of North Americans, Europeans, or Africans with type 2 and approaches 100% of patients with type 2 among Pima Indians or Pacific Islanders from Nauru or Samoa.

Visceral obesity, due to accumulation of fat in the omental and mesenteric regions, correlates with insulin resistance; subcutaneous abdominal fat seems to have less of an association with insulin insensitivity. There are many patients with type 2 diabetes who, while not overtly obese, have increased visceral fat; they are termed the "metabolically obese." Exercise may affect the deposition of visceral fat as suggested by CT scans of Japanese wrestlers, whose extreme obesity is predominantly subcutaneous. Their daily vigorous exercise program prevents accumulation of visceral fat, and they have normal serum lipids and euglycemia despite daily intakes of 5000–7000 kcal and development of massive subcutaneous obesity. Several **adipokines**, secreted by fat cells, can affect insulin action in obesity. Two of these, **leptin** and **adiponectin**, seem to increase sensitivity to insulin, presumably by increasing hepatic responsiveness. Two others—**tumor necrosis factor**, which inactivates insulin receptors, and **resistin**, which interferes with insulin action on glucose metabolism—have been reported to be elevated in obese animal models. Abnormal levels of these adipokines may contribute to the development of insulin resistance in human obesity.

Hyperglycemia per se can impair insulin action by causing accumulation of hexosamines in muscle and fat tissue and by inhibiting glucose transport (acquired glucose toxicity). Correction of hyperglycemia reverses this acquired insulin resistance.

C. Other Specific Types of Diabetes Mellitus

1. Maturity-onset diabetes of the young (MODY)—

This subgroup is a relatively rare monogenic disorder characterized by non-insulin-dependent diabetes with **autosomal dominant inheritance** and an age at onset of 25 years or younger. Patients are nonobese, and their hyperglycemia is due to impaired glucose-induced secretion of insulin. Six types of MODY have been described. Except for MODY 2, in which a glucokinase gene is defective, all other types involve mutations of a nuclear transcription factor that regulates islet gene expression.

The enzyme glucokinase is a rate-limiting step in glycolysis and determines the rate of adenosine triphosphate (ATP) production from glucose and the insulin secretory response in the beta cell. MODY 2, due to glucokinase mutations, is usually quite mild, associated with only slight fasting hyperglycemia and few if any microvascular diabetic complications. It generally responds well to hygienic measures or low doses of oral hypoglycemic agents. MODY 3, due to mutations in hepatic nuclear factor 1 α is the most common form, accounting for two-thirds of all MODY

cases. The clinical course is of progressive beta cell failure and need for insulin therapy. Mutations in both alleles of glucokinase present with more severe neonatal diabetes. Mutation in one allele of the pancreatic duodenal homeobox 1 (PDX1) causes diabetes usually at a later age (~ 35 years) than other forms of MODY; mutations in both alleles of PDX1 causes pancreatic agenesis.

2. Diabetes due to mutant insulins—This is a very rare subtype of nonobese type 2 diabetes, with no more than ten families having been described. Since affected individuals were heterozygous and possessed one normal insulin gene, diabetes was mild, did not appear until middle age, and showed autosomal dominant genetic transmission. There is generally no evidence of clinical insulin resistance, and these patients respond well to standard therapy.

3. Diabetes due to mutant insulin receptors—Defects in one of their insulin receptor genes have been found in more than 40 people with diabetes, and most have extreme insulin resistance associated with acanthosis nigricans (Figures 27–1 and 27–2). In very rare instances when both insulin receptor genes are abnormal, newborns present with a leprechaun-like phenotype and seldom live through infancy.

4. Diabetes mellitus associated with a mutation of mitochondrial DNA—Since sperm do not contain mitochondria, only the mother transmits mitochondrial genes to her offspring. Diabetes due to mutations of mitochondrial DNA occurs in < 2% of patients with diabetes. The most common cause is the A3243G mutation in the gene coding for the tRNA (Leu,UUR). Diabetes occurs even when a small percentage of the mitochondria in the cell carry the mutation; the heteroplasmy levels in the leukocytes range from 1% to 40%. Diabetes usually develops in these patients in their late 30s, and characteristically, they also have hearing



▲ **Figure 27-1.** Acanthosis nigricans of the axilla, with typical dark coloration and velvety appearance and texture. (Used with permission from Umesh Masharani, MB, BS, MRCP(UK).)



▲ **Figure 27-2.** Acanthosis nigricans of the nape of the neck, with typical dark and velvety appearance. (Used with permission from Umesh Masharani, MB, BS, MRCP(UK).)

loss (maternally inherited diabetes and deafness [MIDD]). In some patients, the beta cell failure can be rapidly progressive and patients require insulin soon after diagnosis. Other patients can be managed by diet or oral agents for a while but most eventually require insulin. MIDD patients are not usually overweight; they resemble patients with type 1 diabetes mellitus but without evidence for autoimmunity.

5. Wolfram syndrome—Wolfram syndrome is an autosomal recessive neurodegenerative disorder first evident in childhood. It consists of diabetes insipidus, diabetes mellitus, optic atrophy, and deafness, hence the acronym DIDMOAD. It is due to mutations in a gene named *WFS1*, which encodes a 100.3 kDa transmembrane protein localized in the endoplasmic reticulum. The *WFS1* protein forms part of the unfolding protein response and helps protect the beta cells from endoplasmic reticulum stress and apoptosis especially during periods of high insulin demand. Diabetes develops in mice with mutated form of this protein; and isolated islets from these mice show impairment in insulin secretion to glucose stimulus and increased apoptosis. The diabetes mellitus usually presents in the first decade together with the optic atrophy. Cranial diabetes insipidus and sensorineural deafness develop during the second decade in 60–75% of patients. Ureterohydronephrosis, neurogenic bladder, cerebellar ataxia, peripheral neuropathy, and psychiatric illness develop later in many patients.

6. Autosomal recessive syndromes—Homozygous mutations in a number of pancreatic transcription factors, *NEUROG3*, *PTF1A*, *RFX6*, and *GLI-similar 3 (GLIS3)*, cause neonatal or childhood diabetes. Homozygous *PTF1A* mutations result in absent pancreas and cerebellar atrophy; *NEUROG3* mutations cause severe malabsorption and diabetes before puberty. Homozygous mutations in *RFX6* cause the Mitchell-Riley syndrome characterized by absence of all islet cell types apart from pancreatic polypeptide cells, hypoplasia of the pancreas and gallbladder, and intestinal atresia. *GLIS3* gene plays a role in transcription of insulin

Table 27-3. Secondary causes of hyperglycemia.**Hyperglycemia due to tissue insensitivity to insulin**

Hormonal tumors (acromegaly, Cushing syndrome, glucagonoma, pheochromocytoma)

Pharmacologic agents (corticosteroids, sympathomimetic drugs, niacin)

Liver disease (cirrhosis, hemochromatosis)

Muscle disorders (myotonic dystrophy)

Adipose tissue disorders (lipodystrophy, truncal obesity)

Insulin receptor disorders (acanthosis nigricans syndromes, leprechaunism)

Hyperglycemia due to reduced insulin secretion

Hormonal tumors (somatostatinoma, pheochromocytoma)

Pancreatic disorders (pancreatitis, hemosiderosis, hemochromatosis)

Pharmacologic agents (thiazide diuretics, phenytoin, pentamidine)

gene, and homozygous mutations cause neonatal diabetes and congenital hypothyroidism. The gene *EIF2AK3* encodes PERK-like ER kinase (PERK), which controls one of the pathways of the unfolded protein response. Absence of PERK leads to inadequate response to ER stress and accelerated beta cell apoptosis. Patients with mutation in this gene have neonatal diabetes, epiphyseal dysplasia, developmental delay, and hepatic and renal dysfunction (Wolcott-Rallison syndrome).

7. Diabetes mellitus secondary to other causes—

Endocrine tumors secreting growth hormone, glucocorticoids, catecholamines, glucagon, or somatostatin can cause glucose intolerance (Table 27-3). In the first four of these situations, peripheral responsiveness to insulin is impaired. With excess of glucocorticoids, catecholamines, or glucagon, increased hepatic output of glucose is a contributory factor; in the case of catecholamines, decreased insulin release is an additional factor in producing carbohydrate intolerance, and with somatostatin, inhibition of insulin secretion is the major factor. Diabetes mainly occurs in individuals with underlying defects in insulin secretion, and hyperglycemia typically resolves when the hormone excess is resolved.

A rare syndrome of extreme insulin resistance associated with acanthosis nigricans (Figures 27-1 and 27-2) afflicts either young women with androgenic features as well as insulin receptor mutations or older individuals, mostly women, in whom a circulating immunoglobulin binds to insulin receptors and reduces their affinity to insulin.

Many medications (calcineurin inhibitors, sirolimus, thiazides, β -blockers, corticosteroids, niacin, atypical antipsychotics) are associated with carbohydrate intolerance or frank diabetes. The medications act by decreasing insulin secretion or by increasing insulin resistance or both. Cyclosporine and tacrolimus impair insulin secretion; sirolimus principally increases insulin resistance. These agents contribute to the development of new-onset diabetes after transplantation. Corticosteroids increase insulin resistance but may also have an effect on beta cell function; in a case control study and a large population cohort study, oral corticosteroids doubled the risk for development of

diabetes. Thiazide diuretics and β -blockers modestly increase the risk for diabetes. Treating the hypokalemia due to thiazides may reverse the hyperglycemia. Atypical antipsychotics, particularly olanzapine and clozapine, have been associated with increased risk of glucose intolerance. These medications cause weight gain and insulin resistance but may also impair beta cell function; an increase in rates of diabetic ketoacidosis has been reported.

Chronic pancreatitis or subtotal pancreatectomy reduces the number of functioning B cells and can result in a metabolic derangement very similar to that of genetic type 1 diabetes except that a concomitant reduction in pancreatic A cells may reduce glucagon secretion so that relatively lower doses of insulin replacement are needed.

► Insulin Resistance Syndrome (Syndrome X; Metabolic Syndrome)

Twenty-five percent of the general nonobese, nondiabetic population has insulin resistance of a magnitude similar to that seen in type 2 diabetes. These insulin-resistant nondiabetic individuals are at much higher risk for developing type 2 diabetes than insulin-sensitive persons. In addition to diabetes, these individuals have increased risk for elevated plasma triglycerides, lower high-density lipoproteins (HDLs), and higher blood pressure—a cluster of abnormalities termed syndrome X or metabolic syndrome. These associations have now been expanded to include small, dense, low-density lipoprotein (LDL), hyperuricemia, abdominal obesity, prothrombotic state with increased levels of plasminogen activator inhibitor type 1 (PAI-1), and proinflammatory state. These clusters of abnormalities significantly increase the risk of atherosclerotic disease.

It has been postulated that hyperinsulinemia and insulin resistance play a direct role in these metabolic abnormalities, but supportive evidence is inconclusive. Although hyperinsulinism and hypertension often coexist in whites, that is not the case in blacks or Pima Indians. Moreover, patients with hyperinsulinism due to insulinoma are not hypertensive, and there is no fall in blood pressure after surgical removal of the insulinoma restores normal insulin levels. The main value of grouping these disorders as a syndrome, however, is to remind clinicians that the therapeutic goals are not only to correct hyperglycemia but also to manage the elevated blood pressure and dyslipidemia that result in increased cerebrovascular and cardiac morbidity and mortality in these patients.

American Diabetes Association. Diagnosis and classification of diabetes mellitus. *Diabetes Care*. 2011 Jan;34(Suppl 1):S62-9. [PMID: 21193628]

Simmons RK et al. The metabolic syndrome: useful concept or clinical tool? Report of a WHO Expert Consultation. *Diabetologia*. 2010 Apr;53(4):600-5. [PMID: 20012011]

► Clinical Findings

The principal clinical features of the two major types of diabetes mellitus are listed for comparison in Table 27-4.

Table 27-4. Clinical features of diabetes at diagnosis.

	Type 1 Diabetes	Type 2 Diabetes
Polyuria and thirst	++	+
Weakness or fatigue	++	+
Polyphagia with weight loss	++	–
Recurrent blurred vision	+	++
Vulvovaginitis or pruritus	+	++
Peripheral neuropathy	+	++
Nocturnal enuresis	++	–
Often asymptomatic	–	++

Patients with type 1 diabetes have a characteristic symptom complex. An absolute deficiency of insulin results in accumulation of circulating glucose and fatty acids, with consequent hyperosmolality and hyperketonemia.

Patients with type 2 diabetes may or may not have characteristic features. The presence of obesity or a strongly positive family history for mild diabetes suggests a high risk for the development of type 2 diabetes.

A. Symptoms and Signs

1. Type 1 diabetes—Increased urination is a consequence of osmotic diuresis secondary to sustained hyperglycemia. This results in a loss of glucose as well as free water and electrolytes in the urine. Thirst is a consequence of the hyperosmolar state, as is blurred vision, which often develops as the lenses are exposed to hyperosmolar fluids.

Weight loss despite normal or increased appetite is a common feature of type 1 when it develops subacutely. The weight loss is initially due to depletion of water, glycogen, and triglycerides; thereafter, reduced muscle mass occurs as amino acids are diverted to form glucose and ketone bodies.

Lowered plasma volume produces symptoms of postural hypotension. Total body potassium loss and the general catabolism of muscle protein contribute to the weakness.

Paresthesias may be present at the time of diagnosis, particularly when the onset is subacute. They reflect a temporary dysfunction of peripheral sensory nerves, which clears as insulin replacement restores glycemic levels closer to normal, suggesting neurotoxicity from sustained hyperglycemia.

When absolute insulin deficiency is of acute onset, the above symptoms develop abruptly. Ketoacidosis exacerbates the dehydration and hyperosmolality by producing anorexia and nausea and vomiting, interfering with oral fluid replacement.

The patient's level of consciousness can vary depending on the degree of hyperosmolality. When insulin deficiency develops relatively slowly and sufficient water intake is maintained, patients remain relatively alert and physical findings may be minimal. When vomiting occurs in response to worsening ketoacidosis, dehydration progresses and compensatory mechanisms become inadequate to keep

serum osmolality below 320–330 mosm/L. Under these circumstances, stupor or even coma may occur. The fruity breath odor of acetone further suggests the diagnosis of diabetic ketoacidosis.

Hypotension in the recumbent position is a serious prognostic sign. Loss of subcutaneous fat and muscle wasting are features of more slowly developing insulin deficiency. In occasional patients with slow, insidious onset of insulin deficiency, subcutaneous fat may be considerably depleted.

2. Type 2 diabetes—While increased urination and thirst may be presenting symptoms in some patients with type 2 diabetes, many other patients have an insidious onset of hyperglycemia and are asymptomatic initially. This is particularly true in obese patients, whose diabetes may be detected only after glycosuria or hyperglycemia is noted during routine laboratory studies. Occasionally, when the disease has been occult for some time, patients with type 2 diabetes may have evidence of neuropathic or cardiovascular complications at the time of presentation. Chronic skin infections are common. Generalized pruritus and symptoms of vaginitis are frequently the initial complaints of women. Diabetes should be suspected in women with chronic candidal vulvovaginitis as well as in those who have delivered large babies (> 9 lb, or 4.1 kg) or have had polyhydramnios, preeclampsia, or unexplained fetal losses. Balanoposthitis (inflammation of the foreskin and glans in uncircumcised males) may occur.

Many patients with type 2 diabetes are overweight or obese. Even those who are not significantly obese often have characteristic localization of fat deposits on the upper segment of the body (particularly the abdomen, chest, neck, and face) and relatively less fat on the appendages, which may be quite muscular. This centripetal fat distribution is characterized by a high waist circumference; a waist circumference > 40 inches (102 cm) in men and 35 inches (88 cm) in women is associated with an increased risk of diabetes. Some patients may have acanthosis nigricans, which is associated with significant insulin resistance; the skin in the axilla, groin, and back of neck is hyperpigmented and hyperkeratotic (Figures 27-1 and 27-2). Mild hypertension is often present in obese diabetics. Eruptive xanthomas on the flexor surface of the limbs and on the buttocks and lipemia retinalis due to hyperchylomicronemia can occur in patients with uncontrolled type 2 diabetes who also have a familial form of hypertriglyceridemia.

Hyperglycemic hyperosmolar coma can also be present; in these cases, patients are profoundly dehydrated, hypotensive, lethargic or comatose but without Kussmaul respirations.

B. Laboratory Findings

1. Urinalysis

A. GLUCOSURIA—A specific and convenient method to detect glucosuria is the paper strip impregnated with glucose oxidase and a chromogen system (Clinistix, Diastix), which is sensitive to as little as 100 mg/dL (5.5 mmol) glucose in urine. Diastix can be directly applied to the urinary

stream, and differing color responses of the indicator strip reflect glucose concentration.

A normal renal threshold for glucose as well as reliable bladder emptying is essential for interpretation.

Nondiabetic glycosuria (renal glycosuria) is a benign asymptomatic condition wherein glucose appears in the urine despite a normal amount of glucose in the blood, either basally or during a glucose tolerance test. Its cause may vary from mutations in the *SGLT2* gene coding for sodium-glucose transporter 2 (familial renal glycosuria) to one associated with dysfunction of the proximal renal tubule (Fanconi syndrome, chronic kidney disease), or it may merely be a consequence of the increased load of glucose presented to the tubules by the elevated glomerular filtration rate during pregnancy. As many as 50% of pregnant women normally have demonstrable sugar in the urine, especially during the third and fourth months. This sugar is practically always glucose except during the late weeks of pregnancy, when lactose may be present.

B. KETONURIA—Qualitative detection of ketone bodies can be accomplished by nitroprusside tests (Acetest or Ketostix). Although these tests do not detect β -hydroxybutyric acid, which lacks a ketone group, the semiquantitative estimation of ketonuria thus obtained is nonetheless usually adequate for clinical purposes. Many laboratories now measure β -hydroxybutyric acid, and there is a meter available (Precision Xtra, Abbott Diabetes Care) for patient use that measures β -hydroxybutyric acid levels in capillary glucose samples. β -Hydroxybutyrate levels > 0.6 mmol/L require evaluation. Patients with levels > 3.0 mmol/L, equivalent to very large urinary ketones, require hospitalization.

2. Blood testing procedures

A. PLASMA OR SERUM GLUCOSE—Plasma or serum from venous blood samples has the advantage over whole blood of providing values for glucose that are independent of hematocrit and that reflect the glucose concentration to which body tissues are exposed. Venous samples should be collected in tubes containing sodium fluoride to prevent glycolysis, placed on ice and the plasma separated from cells within 60 minutes. In the absence of fluoride, the rate of disappearance of glucose in presence of blood cells has been reported to be approximately 10 mg/dL/h (0.56 mmol/L). The glucose concentration is 10–15% higher in plasma or serum than in whole blood because structural components of blood cells are absent. A plasma glucose level of 126 mg/dL (7 mmol/L) or higher on more than one occasion after at least 8 hours of fasting is diagnostic of diabetes mellitus (Table 27–5). Fasting plasma glucose levels of 100–125 mg/dL (5.6–6.9 mmol/L) are associated with increased risk of diabetes (impaired fasting glucose tolerance).

B. ORAL GLUCOSE TOLERANCE TEST—If the fasting plasma glucose level is < 126 mg/dL (7 mmol/L) when diabetes is nonetheless suspected, then a standardized oral glucose tolerance test may be done (Table 27–5). In order to optimize insulin secretion and effectiveness, especially when patients have been on a low-carbohydrate diet, a minimum of 150–200 g of carbohydrate per day should be included in the diet for 3 days preceding the test. The patient should eat

Table 27–5. Criteria for the diagnosis of diabetes.

	Normal Glucose Tolerance	Impaired Glucose Tolerance	Diabetes Mellitus ²
Fasting plasma glucose mg/dL (mmol/L)	< 100 (5.6)	100–125 (5.6–6.9)	≥ 126 (7.0)
Two hours after glucose load ¹ mg/dL (mmol/L)	< 140 (7.8)	≥ 140 –199 (7.8–11.0)	≥ 200 (11.1)
HbA _{1c} (%)	< 5.7	5.7–6.4	≥ 6.5

¹Give 75 g of glucose dissolved in 300 mL of water after an overnight fast in persons who have been receiving at least 150–200 g of carbohydrate daily for 3 days before the test.

²A fasting plasma glucose ≥ 126 mg/dL (7.0 mmol) or HbA_{1c} of $\geq 6.5\%$ is diagnostic of diabetes if confirmed by repeat testing.

nothing after midnight prior to the test day. On the morning of the test, adults are then given 75 g of glucose in 300 mL of water; children are given 1.75 g of glucose per kilogram of ideal body weight. The glucose load is consumed within 5 minutes. The test should be performed in the morning because there is some diurnal variation in oral glucose tolerance, and patients should not smoke or be active during the test.

Blood samples for plasma glucose are obtained at 0 and 120 minutes after ingestion of glucose. An oral glucose tolerance test is normal if the fasting venous plasma glucose value is < 100 mg/dL (5.6 mmol/L) and the 2-hour value falls below 140 mg/dL (7.8 mmol/L). A fasting value of 126 mg/dL (7 mmol/L) or higher or a 2-hour value of > 200 mg/dL (11.1 mmol/L) is diagnostic of diabetes mellitus. Patients with 2-hour value of 140–199 mg/dL (7.8–11.1 mmol/L) have impaired glucose tolerance. False-positive results may occur in patients who are malnourished, bedridden, or afflicted with an infection or severe emotional stress. Diuretics, oral contraceptives, corticosteroids, excess thyroxine, phenytoin, nicotinic acid, and some psychotropic medications may also cause false-positive results.

C. GLYCATED HEMOGLOBIN (HEMOGLOBIN A_{1c}) MEASUREMENTS—Hemoglobin becomes glycosylated by ketoamine reactions between glucose and other sugars and the free amino groups on the α and β chains. Only glycation of the N-terminal valine of the beta chain imparts sufficient negative charge to the hemoglobin molecule to allow separation by charge dependent techniques. These charge separated hemoglobins are collectively referred to as hemoglobin A_{1c} (HbA_{1c}). The major form of HbA_{1c} is hemoglobin A_{1c} (HbA_{1c}) where glucose is the carbohydrate. HbA_{1c} comprises 4–6% of total hemoglobin A_{1c}. The remaining HbA_{1c} species contain fructose-1,6 diphosphate (HbA_{1a1}); glucose-6-phosphate (HbA_{1a2}); and unknown carbohydrate moiety (HbA_{1b}). The hemoglobin A_{1c} fraction is abnormally elevated in diabetic persons with chronic hyperglycemia. Methods for measuring HbA_{1c} include electrophoresis, cation-exchange chromatography, boronate affinity chromatography, and immunoassays. Office-based immunoassays using capillary blood give a result in about 9 minutes

and this allows for nearly immediate feedback to the patients regarding their glycemic control.

Since glycohemoglobins circulate within red blood cells whose life span lasts up to 120 days, they generally reflect the state of glycemia over the preceding 8–12 weeks, thereby providing an improved method of assessing diabetic control. The HbA_{1c} value, however, is weighted to more recent glucose levels (previous month) and this explains why significant changes in HbA_{1c} are observed with short-term (1 month) changes in mean plasma glucose levels. Measurements should be made in patients with either type of diabetes mellitus at 3- to 4-month intervals so that adjustments in therapy can be made if HbA_{1c} is either subnormal or if it is more than 2% above the upper limits of normal for a particular laboratory. In patients monitoring their own blood glucose levels, HbA_{1c} values provide a valuable check on the accuracy of monitoring. In patients who do not monitor their own blood glucose levels, HbA_{1c} values are essential for adjusting therapy. There is a linear relationship between the HbA_{1c} and the average glucose levels in the previous 3 months as determined from continuous glucose monitoring data and from seven-point capillary blood glucose profiles (preprandial, postprandial, and bedtime). Table 27–6 gives the mean capillary glucose values for HbA_{1c} values ranging from 5% to 12%.

The accuracy of HbA_{1c} values can be affected by hemoglobin variants or traits; the effect depends on the specific hemoglobin variant or derivative and the specific assay used. Immunoassays that use an antibody to the glycated amino terminus of β globin do not recognize the terminus of the γ globin of hemoglobin F. Thus, in patients with high levels of hemoglobin F, immunoassays give falsely low values of HbA_{1c}. Cation-exchange chromatography separates hemoglobin species by charge differences. Hemoglobin

variants that co-elute with HbA_{1c} can lead to an overestimation of the HbA_{1c} value. Chemically modified derivatives of hemoglobin such as carbamoylation (in end-stage chronic kidney disease) or acetylation (high-dose aspirin therapy) can similarly co-elute with HbA_{1c} by some assay methods. The National Glycohemoglobin Standardization Program website (www.ngsp.org) has information on the impact of frequently encountered hemoglobin variants and traits on the results obtained with the commonly used HbA_{1c} assays.

Any condition that shortens erythrocyte survival or decreases mean erythrocyte age (eg, recovery from acute blood loss, hemolytic anemia) will falsely lower HbA_{1c} irrespective of the assay method used. Alternative methods such as fructosamine (see below) should be considered for these patients. Vitamins C and E are reported to falsely lower test results possibly by inhibiting glycation of hemoglobin.

The ADA has endorsed using the HbA_{1c} as a diagnostic test for diabetes (Table 27–5). A cutoff value of 6.5% was chosen because the risk for retinopathy increases substantially above this value. The advantages of using the HbA_{1c} to diagnose diabetes is that there is no need to fast; it has lower intraindividual variability than the fasting glucose test and the oral glucose tolerance test; and it provides an estimate of glucose control for the preceding 2–3 months. People with HbA_{1c} levels of 5.7–6.4% should be considered at high risk for developing diabetes (prediabetes). The diagnosis should be confirmed with a repeat HbA_{1c} test, unless the patient is symptomatic with plasma glucose levels > 200 mg/dL (11.1 mmol/L). This test is not appropriate to use in populations with high prevalence of hemoglobinopathies or in conditions with increased red cell turnover. Also, the testing should be performed using a National Glycohemoglobin Standardization Program certified method and standardized to the Diabetes Control and Complications Trial assay.

D. SERUM FRUCTOSAMINE—Serum fructosamine is formed by nonenzymatic glycosylation of serum proteins (predominantly albumin). Since serum albumin has a much shorter half-life than hemoglobin, serum fructosamine generally reflects the state of glycemic control for only the preceding 1–2 weeks. Reductions in serum albumin (eg, nephrotic state or hepatic disease) will lower the serum fructosamine value. When abnormal hemoglobins or hemolytic states affect the interpretation of glycohemoglobin or when a narrower time frame is required, such as for ascertaining glycemic control at the time of conception in a diabetic woman who has recently become pregnant, serum fructosamine assays offer some advantage. Normal values vary in relation to the serum albumin concentration and are 200–285 μ mol/L when the serum albumin level is 5 g/dL. HbA_{1c} values and serum fructosamine are highly correlated. The following relationship between serum fructosamine levels and HbA_{1c} has been reported based on linear regression analysis:

$$\text{HbA}_{1c} = 0.017 \times \text{serum fructosamine level (}\mu\text{mol/L)} + 1.61$$

Thus, serum fructosamine levels of 317, 375, and 435 μ mol/L are equivalent to HbA_{1c} values of 7%, 8%, and 9%.

Table 27–6. Correlations of HbA_{1c} levels with average of capillary glucose measurements (preprandial, postprandial and bedtime) in the previous 3 months.

HbA _{1c} Value (%) Determined Using DCCT Aligned Assays	Mean Capillary Blood Glucose Levels (mg/dL) [mmol/L]
5	97 [5.4]
6	126 [7.0]
7	154 [8.6]
8	183 [10.2]
9	212 [11.8]
10	240 [13.3]
11	269 [14.9]
12	298 [16.6]

DCCT, Diabetes Complications and Control Trial.

Adapted, with permission, from Nathan DM et al. Translating the A_{1c} assay into estimated average glucose values. *Diabetes Care* 2008 Aug; 31(8):1473–8. © 2008 American Diabetes Association.

E. SELF-MONITORING OF BLOOD GLUCOSE—Capillary blood glucose measurements performed by patients themselves, as outpatients, are extremely useful. In type 1 patients in whom “tight” metabolic control is attempted, they are indispensable. There are several paper strip (glucose oxidase, glucose dehydrogenase, or hexokinase) methods for measuring glucose on capillary blood samples. A reflectance photometer or an amperometric system is then used to measure the reaction that takes place on the reagent strip. A large number of blood glucose meters are now available. All are accurate, but they vary with regard to speed, convenience, size of blood samples required, reporting capability, and cost. Popular models include those manufactured by LifeScan (One Touch), Bayer Corporation (Breeze, Contour), Roche Diagnostics (Accu-Chek), and Abbott Laboratories (Precision, FreeStyle). These blood glucose meters are relatively inexpensive, ranging from \$50 to \$100 each. Test strips remain a major expense, costing \$.50 to \$.75 apiece. Each glucose meter also comes with a lancet device and disposable 26- to 33-gauge lancets. The accuracy of data obtained by home glucose monitoring does require education of the patient in sampling and measuring procedures as well as in properly calibrating the instruments.

The clinician should be aware of the limitations of the self-monitoring glucose systems. First, some older meters require input of a code for each batch of strips; failure to enter the code can result in misleading results. Many of the newer meters no longer require this step. Second, increases or decreases in hematocrit can decrease or increase the measured glucose values. The mechanism underlying this effect is not known but presumably it is due to the impact of red cells on the diffusion of plasma into the reagent layer. Third, the meters and the test strips are calibrated over the glucose concentrations ranging from 60 mg/dL (3.3 mmol/L) to 160 mg/dL (8.9 mmol/L) and the accuracy is not as good for higher and lower glucose levels. When the glucose is < 60 mg/dL (3.3 mmol/L), the difference between the meter and the laboratory value may be as much as 20%. Fourth, glucose oxidase–based amperometric systems underestimate glucose levels in the presence of high oxygen tension. This may be important in the critically ill who are receiving supplemental oxygen; under these circumstances, a glucose dehydrogenase–based system may be preferable. Fifth, glucose-dehydrogenase pyrroloquinoline quinone (GDH-PQQ) systems may report falsely high glucose levels in patients who are receiving parenteral products containing nonglucose sugars such as maltose, galactose, or xylose or their metabolites. Patients have been given falsely high glucose values resulting in life-threatening hypoglycemia. Sixth, some meters have been approved for measuring glucose in blood samples obtained at alternative sites such as the forearm and thigh. There is, however, a 5- to 20-minute lag in the glucose response on the arm with respect to the glucose response on the finger. Forearm blood glucose measurements could therefore result in a delay in detection of rapidly developing hypoglycemia.

F. CONTINUOUS GLUCOSE MONITORING SYSTEMS—A number of continuous glucose monitoring systems are available for clinical use. The systems manufactured by Medtronic

Minimed, DexCom systems, and Abbott Diagnostics (outside United States), involve inserting a subcutaneous sensor (rather like an insulin pump cannula) that measures glucose concentrations in the interstitial fluid for 3–7 days. The data are transmitted to a separate pager-like device with a screen. The MiniMed system also has the option to wirelessly transmit the data to the screen of their insulin pump. The systems allow the patient to set “alerts” for low and high glucose values and rate of change of glucose levels. Patients still have to calibrate the devices with periodic fingerstick glucose levels, and since there are concerns regarding reliability, it is still necessary to confirm the displayed glucose level with a fingerstick glucose before making interventions such as injecting extra insulin or eating extra carbohydrates. A 6-month randomized controlled study of type 1 patients showed that adults (25 years and older) using these systems had improved glycemic control without an increase in the incidence of hypoglycemia. A randomized controlled study of continuous glucose monitoring during pregnancy showed improved glycemic control in the third trimester, lower birth weight, and reduced risk of macrosomia. The individual glucose values are not that critical—what matters is the direction and the rate at which the glucose is changing, allowing the user to take corrective action. The wearer also gains insight into the way particular foods and activities affect their glucose levels. The other main benefit is the low glucose alert warning. The MiniMed insulin pump marketed in Europe can be programmed to automatically suspend insulin delivery for 2 hours when the glucose levels on the continuous glucose monitoring device falls to a preset level. Increasingly, these systems are being covered by insurance. The initial cost is about \$800 to \$1000, and the sensor, which has to be changed every 3 to 7 days, costs \$35 to \$60. This adds up to an out-of-pocket expense of about \$4000 annually.

There is great interest in using the data obtained from these continuous glucose monitoring systems to automatically deliver insulin by continuous subcutaneous insulin infusion pump. Algorithms have been devised to link continuous glucose monitoring to insulin delivery and preliminary clinical studies appear promising.

3. Lipoprotein abnormalities in diabetes—Circulating lipoproteins are just as dependent on insulin as is the plasma glucose. In type 1 diabetes, moderately deficient control of hyperglycemia is associated with only a slight elevation of LDL cholesterol and serum triglycerides and little if any change in HDL cholesterol. Once the hyperglycemia is corrected, lipoprotein levels are generally normal. However, in patients with type 2 diabetes, a distinct “diabetic dyslipidemia” is characteristic of the insulin resistance syndrome. Its features are a high serum triglyceride level (300–400 mg/dL [3.4–4.5 mmol/L]), a low HDL cholesterol (< 30 mg/dL [0.8 mmol/L]), and a qualitative change in LDL particles, producing a smaller dense particle whose membrane carries supranormal amounts of free cholesterol. These smaller dense LDL particles are more susceptible to oxidation, which renders them more atherogenic. Since a low HDL cholesterol is a major feature predisposing to macrovascular disease, the term “dyslipidemia” has preempted the term “hyperlipidemia,” which mainly denoted the elevated triglycerides. Measures designed to correct the obesity and

hyperglycemia, such as exercise, diet, and hypoglycemic therapy, are the treatment of choice for diabetic dyslipidemia, and in occasional patients in whom normal weight was achieved, all features of the lipoprotein abnormalities cleared. Since primary disorders of lipid metabolism may coexist with diabetes, persistence of lipid abnormalities after restoration of normal weight and blood glucose should prompt a diagnostic workup and possible pharmacotherapy of the lipid disorder. Chapter 28 discusses these matters in detail.

Handelsman Y et al. American Association of Clinical Endocrinologists Medical Guidelines for clinical practice for developing a diabetes mellitus comprehensive care plan: executive summary. *Endocr Pract.* 2011 Mar-Apr;17(2):287–302. [PMID: 21474421]

Malkani S et al. Implications of using hemoglobin A1C for diagnosing diabetes mellitus. *Am J Med.* 2011 May;124(5):395–401. [PMID: 21531226]

Pickup JC et al. Glycaemic control in type 1 diabetes during real time continuous glucose monitoring compared with self monitoring of blood glucose: meta-analysis of randomised controlled trials using individual patient data. *BMJ.* 2011 Jul 7;343:d3805. [PMID: 21737469]

Sacks DB et al; National Academy of Clinical Biochemistry; Evidence-Based Laboratory Medicine Committee of the American Association for Clinical Chemistry. Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. *Diabetes Care.* 2011 Jun;34(6):e61–99. [PMID: 21617108]

Screening for type 2 diabetes mellitus in adults: U.S. Preventive Services Task Force recommendation statement. *Ann Intern Med.* 2008 Jun 3;148(11):846–54. [PMID: 18519930]

► Clinical Trials in Diabetes

Findings of the Diabetes Complications and Control Trial (DCCT) and of the United Kingdom Prospective Diabetes Study (UKPDS), have confirmed the beneficial effects of improved glycemic control in both type 1 and type 2 diabetes, respectively (see below). In addition, with increased understanding of the pathophysiology of both type 1 and type 2 diabetes, large prospective studies—Diabetes Prevention Trial 1 (DPT-1) and the Diabetes Prevention Program (DPP)—have been performed in attempts to prevent onset of these disorders (see below).

A. Clinical Trials in Type 1 Diabetes

1. Diabetes Prevention Trial-1—This multicenter study sponsored by the National Institutes of Health was designed to determine whether the development of type 1 diabetes mellitus could be prevented or delayed by immune intervention therapy. Daily low-dose insulin injections were administered for up to 8 years in first-degree relatives of type 1 diabetic patients who were selected as being at high risk for development of type 1 diabetes because of detectable islet cell antibodies and reduced early-insulin release. Unfortunately, this immune intervention failed to affect the onset of type 1 diabetes compared with a randomized untreated group. A related study using oral insulin in lower risk first-degree relatives who have islet cell antibodies but

whose early insulin release remains intact also failed to show an effect on the onset of type 1 diabetes. After an average of 4.3 years of observation, type 1 diabetes developed in about 35% of persons in both the oral insulin and the placebo groups.

2. The Diabetes Control and Complications Trial—This long-term therapeutic study involving 1441 patients with type 1 diabetes mellitus reported that “near” normalization of blood glucose resulted in a delay in the onset and a major slowing of the progression of established microvascular and neuropathic complications of diabetes during a follow-up period of up to 10 years. Multiple insulin injections (66%) or insulin pumps (34%) were used in the intensively treated group, who were trained to modify their therapy in response to frequent glucose monitoring. The conventionally treated groups used no more than two insulin injections, and clinical well-being was the goal with no attempt to modify management based on HbA_{1c} determinations or the glucose results.

In half of the patients, a mean hemoglobin A_{1c} of 7.2% (normal: < 6%) and a mean blood glucose of 155 mg/dL (8.6 mmol/L) were achieved using intensive therapy, while in the conventionally treated group HbA_{1c} averaged 8.9% with an average blood glucose of 225 mg/dL (12.5 mmol/L). Over the study period, which averaged 7 years, there was an approximately 60% reduction in risk between the two groups in regard to diabetic retinopathy, nephropathy, and neuropathy. The intensively treated group also had a non-significant reduction in the risk of macrovascular disease of 41% (95% CI, –10 to 68). Intensively treated patients had a threefold greater risk of serious hypoglycemia as well as a greater tendency toward weight gain. However, there were no deaths definitely attributable to hypoglycemia in any persons in the DCCT study, and no evidence of posthypoglycemic cognitive damage was detected.

Subjects participating in the DCCT study were subsequently enrolled in a follow-up observational study, the Epidemiology of Diabetes Interventions and Complications (EDIC) study. Even though the between-group differences in mean HbA_{1c} narrowed over 4 years, the group assigned to intensive therapy had a lower risk of retinopathy at 4 years, microalbuminuria at 7 to 8 years, and impaired glomerular filtration rate (< 60 mL/min/1.73 m²) at 22 years of continued study follow-up. Moreover, by the end of the 11-year follow-up period, the intensive therapy group had significantly reduced their risk of any cardiovascular disease events by 42% (95% CI, 9% to 23%; *P* = 0.02). Thus, it seems that the benefits of good glucose control persist even if control deteriorates at a later date.

The general consensus of the ADA is that intensive insulin therapy associated with comprehensive self-management training should become standard therapy in patients with type 1 diabetes mellitus after the age of puberty. Exceptions include those with advanced chronic kidney disease and the elderly, since in these groups the detrimental risks of hypoglycemia outweigh the benefits of tight glycemic control.

3. Immune intervention trials in new-onset type 1 diabetes—At the time of diagnosis of type 1 diabetes, patients still have significant B cell function. This explains

why soon after diagnosis patients go into a partial clinical remission (“honeymoon”) requiring little or no insulin. This clinical remission is short-lived, however, and eventually patients lose all B cell function and have more labile glucose control. Attempts have been made to prolong this partial clinical remission using medications such as cyclosporine, azathioprine, prednisone, and antithymocyte globulin. These medications have had limited efficacy, and there are concerns about toxicity and the need for continuous treatment.

Newer agents that may induce immune tolerance and appear to have few side effects have been used in patients with new-onset type 1 diabetes mellitus. The CD3 complex is the major signal transducing element of the T cell receptor and the anti-CD3 antibodies are believed to modulate the autoimmune response by selectively inhibiting the pathogenic T cells or by inducing regulatory T cells. Phase I/II and II/III clinical trials using the humanized monoclonal antibodies against CD3, hOKT3 γ (Ala-Ala) (teplizumab) and ChAglyCD3 (otelixizumab) delayed but did not completely arrest the decline in insulin production in patients with newly diagnosed type 1 diabetes. Studies are ongoing to identify which individuals may benefit from this therapy. A study using anti-CD3 antibody prior to clinical onset of diabetes is also under consideration. These and other approaches that selectively modulate the autoimmune T cell response hold promise that type 1 diabetes may eventually be preventable without prolonged immunosuppression.

Bluestone JA et al. Genetics, pathogenesis and clinical interventions in type 1 diabetes. *Nature*. 2010 Apr 29;464(7293):1293–300. [PMID: 20432533]

Diabetes Prevention Trial—Type 1 Diabetes Study Group. Effects of insulin in relatives of patients with type 1 diabetes mellitus. *N Engl J Med*. 2002 May 30;346(22):1685–91. [PMID: 12037147]

Nathan DM et al; Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. *N Engl J Med*. 2005 Dec 22;353(25):2643–53. [PMID: 16371630]

The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. *N Engl J Med*. 1993 Sep 30;329(14):977–86. [PMID: 8366922]

B. Clinical Trials in Type 2 Diabetes

1. The Diabetes Prevention Program—This study was aimed at discovering whether treatment with either diet and exercise or metformin could prevent the onset of type 2 diabetes in people with impaired glucose tolerance; 3234 overweight men and women aged 25–85 years with impaired glucose tolerance participated in the study. Intervention with a low-fat diet and 150 minutes of moderate exercise (equivalent to a brisk walk) per week reduced the risk of progression to type 2 diabetes by 71% compared with a matched control group. Participants taking 850 mg of metformin twice a day reduced their risk of developing type 2 diabetes by 31%, but this intervention was relatively ineffective in those who were either less obese or in the older age group.

With the demonstration that intervention can be successful in preventing progression to diabetes in these subjects, a recommendation has been made to change the terminology from the less comprehensible “impaired glucose tolerance” to “prediabetes.” The latter is a term that the public can better understand and thus respond to by implementing healthier diet and exercise habits.

2. Kumamoto study—The Kumamoto study involved a relatively small number of patients with type 2 diabetes ($n = 110$) who were nonobese and only slightly insulin-resistant, requiring < 30 units of insulin per day for intensive therapy. Over a 6-year period, it was shown that intensive insulin therapy, achieving a mean HbA_{1c} of 7.1%, significantly reduced microvascular end points compared with conventional insulin therapy achieving a mean HbA_{1c} of 9.4%. Cardiovascular events were neither worsened nor improved by intensive therapy, and weight changes were likewise not influenced by either form of treatment.

3. The United Kingdom Prospective Diabetes Study—

This multicenter study was designed to establish, in type 2 diabetic patients, whether the risk of macrovascular or microvascular complications could be reduced by intensive blood glucose control with oral hypoglycemic agents or insulin and whether any particular therapy was of advantage. A total of 3867 patients aged 25–65 years with newly diagnosed diabetes were recruited between 1977 and 1991, and studied over 10 years. The median age at baseline was 54 years; 44% were overweight ($> 120\%$ over ideal weight); and baseline HbA_{1c} was 9.1%. Therapies were randomized to include a control group on diet alone and separate groups intensively treated with either insulin or sulfonylurea (chlorpropamide, glyburide, or glipizide). Metformin was included as a randomization option in a subgroup of 342 overweight or obese patients, and much later in the study an additional subgroup of both normal-weight and overweight patients who were responding unsatisfactorily to sulfonylurea therapy were randomized to either continue on their sulfonylurea therapy alone or to have metformin combined with it. In 1987, an additional modification was made to evaluate whether tight control of blood pressure with stepwise antihypertensive therapy would prevent macrovascular and microvascular complications in 758 hypertensive patients among this UKPDS population compared with 390 of them whose blood pressure was treated less intensively. The tight control group was randomly assigned to treatment with either an angiotensin-converting enzyme (ACE) inhibitor (captopril) or a β -blocker (atenolol). Both medications were stepped up to maximum dosages of 100 mg/d and then, if blood pressure remained higher than the target level of $< 150/85$ mm Hg, more medications were added in the following stepwise sequence: a diuretic, slow-release nifedipine, methyl-dopa, and prazosin—until the target level of tight control was achieved. In the control group, hypertension was conventionally treated to achieve target levels $< 180/105$ mm Hg, but these patients were not prescribed either ACE inhibitors or β -blockers.

Intensive treatment with either sulfonylureas, metformin, combinations of those two, or insulin achieved

mean HbA_{1c} levels of 7%. This level of glycemic control decreased the risk of microvascular complications (retinopathy and nephropathy) in comparison with conventional therapy (mostly diet alone), which achieved mean levels of HbA_{1c} of 7.9%. Weight gain occurred in intensively treated patients except when metformin was used as monotherapy. No cardiovascular benefit and no adverse cardiovascular outcomes were noted regardless of the therapeutic agent. Hypoglycemic reactions occurred in the intensive treatment groups, but only one death from hypoglycemia was documented during 27,000 patient-years of intensive therapy.

When therapeutic subgroups were analyzed, some unexpected and paradoxical results were noted. Among the obese patients, intensive treatment with insulin or sulfonylureas did not reduce microvascular complications compared with diet therapy alone. This was in contrast to the significant benefit of intensive therapy with these medications in the total group. Furthermore, intensive therapy with metformin was more beneficial in the overweight or obese persons than diet alone with regard to fewer myocardial infarctions, strokes, and diabetes-related deaths, but there was no significant reduction by metformin of diabetic microvascular complications as compared with the diet group. Moreover, in the subgroup of obese and non-obese patients in whom metformin was added to sulfonylurea failures, rather than showing a benefit, there was a 96% increase in diabetes-related deaths compared with the matched cohort of patients with unsatisfactory glycemic control on sulfonylureas who remained on their sulfonylurea therapy. Chlorpropamide also came out poorly on subgroup analysis in that those receiving it as intensive therapy did less well regarding progression to retinopathy than those conventionally treated with diet.

Tight control of blood pressure (median value 144/82 mm Hg vs 154/87 mm Hg) substantially reduced the risk of microvascular disease and stroke but not myocardial infarction. In fact, reducing blood pressure by this amount had substantially greater impact on microvascular outcomes than that achieved by lowering HbA_{1c} from 7.9% to 7%. An epidemiologic analysis of the UKPDS data did show that every 10 mm Hg decrease in updated mean systolic blood pressure was associated with 11% reduction in risk for myocardial infarction. More than half of the patients needed two or more medications for adequate therapy of their hypertension, and there was no demonstrable advantage of ACE inhibitor therapy over therapy with β -blockers with regard to diabetes end points. Use of a calcium channel blocker added to both treatment groups appeared to be safe over the long term in this diabetic population despite some controversy in the literature about its safety in diabetics.

Like the DCCT trialists, the UKPDS researchers performed post-trial monitoring to determine whether there were long-term benefits of having been in the intensively treated glucose and blood pressure arms of the study. The between-group differences in HbA_{1c} were lost within the first year of follow-up, but the reduced risk (24%, $P = 0.001$) of development or progression of microvascular complications in the intensively treated group persisted for 10 years. The intensively treated group also had significantly reduced

risk of myocardial infarction (15%, $P = 0.01$) and death from any cause (13%, $P = 0.007$) during the follow-up period. The subgroup of overweight or obese subjects who were initially randomized to metformin therapy showed sustained reduction in risk of myocardial infarction and death from any cause in the follow-up period. The between-group blood pressure differences disappeared within 2 years of the end of the trial. Unlike the sustained benefits seen with glucose control, there were no sustained benefits from having been in the more tightly controlled blood pressure group. Both blood pressure groups were at similar risk for microvascular events and diabetes-related end points during the follow-up period.

Thus, the follow-up of the UKPDS type 2 diabetes cohort showed that, as in type 1 diabetes, the benefits of good glucose control persist even if control deteriorates at a later date. Blood pressure benefits, however, last only as long as the blood pressure is well controlled.

4. The Steno-2 study—The Steno-2 study was designed in 1990 to validate the efficacy of targeting multiple concomitant risk factors for both microvascular and macrovascular disorders in type 2 diabetes. A prospective, randomized, open, blinded end point design was used where 160 patients with type 2 diabetes and microalbuminuria were assigned to conventional therapy with their general practitioner or to intensive care at the Steno Diabetes Center. The intensively treated group had step-wise introduction of lifestyle and pharmacologic interventions aimed at keeping glycated hemoglobin < 6.5%, blood pressure < 130/80 mm Hg; total cholesterol < 175 mg/dL (4.5 mmol/L), and triglycerides < 150 mg/dL (1.7 mmol/L). All the intensively treated group received ACE inhibitors and if intolerant, an angiotensin II-receptor blocker. The lifestyle component of intensive intervention included reduction in dietary fat intake to < 30% of total calories; smoking cessation program; light to moderate exercise; daily vitamin-mineral supplement of vitamin C, E, and chromium picolinate. Initially, aspirin was only given as secondary prevention to patients with a history of ischemic cardiovascular disease; later, all patients received aspirin. After a mean follow-up of 7.8 years, cardiovascular events (eg, myocardial infarction, angioplasties, coronary bypass grafts, strokes, amputations, vascular surgical interventions) developed in 44% of patients in the conventional arm and only in 24% in the intensive multifactorial arm—about a 50% reduction. Rates of nephropathy, retinopathy, and autonomic neuropathy were also lower in the multifactorial intervention arm by 62% and 63%, respectively.

The persons who participated in this trial were subsequently enrolled in an observational follow-up study for an average of 5.5 years. Even though the significant differences in glycemic control and levels of risk factors of cardiovascular disease between the groups had disappeared by the end of the follow-up period, the interventional group continued to have a lower risk of retinal photocoagulation, renal failure, cardiovascular end points, and cardiovascular mortality.

The data from the UKPDS and this study provide support for guidelines recommending vigorous treatment of

concomitant microvascular and cardiovascular risk factors in patients with type 2 diabetes.

5. ACCORD, ADVANCE, and VADT studies—The ACCORD study was a randomized controlled study designed to determine whether normal HbA_{1c} levels would reduce the risk of cardiovascular events in middle-aged or older individuals with type 2 diabetes. About 35% of the 10,251 recruited subjects had established cardiovascular disease at study entry. The intensive arm of the study was discontinued after 3.5 years of follow-up because of more unexplained deaths in the intensive arm when compared with the control arm (22%, $P = .020$). Analysis of the data at time of discontinuation showed that the intensively treated group (mean HbA_{1c} 6.4%) had a 10% reduction in cardiovascular event rate compared with the standard treated group (mean HbA_{1c} 7.5%), but this difference was not statistically significant.

The ADVANCE trial randomly assigned 11,140 patients with type 2 diabetes to standard or intensive glucose control. The primary outcomes were major macrovascular cardiovascular events (nonfatal myocardial infarction or stroke or death from cardiovascular causes) or microvascular events. Overall, one-third (32%) of the subjects had established cardiovascular disease at study entry. After a median follow-up of 5 years, there was a nonsignificant reduction (6%) in major macrovascular event rate in the intensively treated group (mean HbA_{1c} 6.5%) compared with the standard therapy group (HbA_{1c} 7.3%).

The Veteran Administration Diabetes Trial (VADT) randomly assigned 1791 patients from age 50 to 69 years with type 2 diabetes to standard or intensive glucose control. Overall, 97% of the subjects were men. The primary outcome was a composite of myocardial infarction, death from cardiovascular causes, congestive heart failure, vascular surgery, inoperable coronary artery disease, and amputation for gangrene. All the patients had optimized blood pressure and lipid levels. After a median follow-up of 5.6 years, there was no significant difference in the primary outcome in the intensively treated group (HbA_{1c} 6.9%) compared with the standard therapy (HbA_{1c} 8.4%). Within this larger study, there was an embedded study evaluating the impact of the intensive therapy on patients who were subcategorized as having low, moderate, and high coronary calcium scores on CT scans. Patients with low coronary calcium score showed a reduced number of cardiovascular events with intensive therapy.

Thus, the ACCORD, ADVANCE, and VADT results do not provide support for the hypothesis that near-normal glucose control in patients with type 2 diabetes will reduce cardiovascular events. It is, however, important not to overinterpret the results of these three studies. The results do not exclude the possibility that cardiovascular benefits might accrue with longer duration of near-normal glucose control. In the UKPDS, risk reductions for myocardial infarction and death from any cause were only observed during 10 years of post-trial follow-up. Specific subgroups of type 2 diabetic patients may also have different outcomes. The ACCORD, ADVANCE, and VADT studies recruited patients who had diabetes for 8–10 years and one-third of them already had established cardiovascular

disease. Patients in the UKPDS, in contrast, had newly diagnosed diabetes and only 7.5% had a history of macrovascular disease. It is possible that the benefits of tight glycemic control on macrovascular events are attenuated in patients with longer duration of diabetes or with established vascular disease. Specific therapies used to lower glucose may also affect cardiovascular event rate or mortality. Severe hypoglycemia occurred more frequently in the intensively treated groups of the ACCORD, ADVANCE, and VADT studies; the ACCORD investigators were not able to exclude undiagnosed hypoglycemia as a potential cause for the increased death rate in the intensive treatment group.

A formal meta-analysis performed of the raw trial data from the ACCORD, ADVANCE, VADT, and UKPDS studies found that allocation to more intensive glucose control reduced the risk of myocardial infarction by 15% (hazard ratio 0.85, 95% CI 0.76–0.94). This benefit occurred in patients who did not have preexisting macrovascular disease.

ACCORD Study Group; Gerstein HC et al. Effects of intensive glucose lowering in type 2 diabetes. *N Engl J Med.* 2008 Jun 12;358(24):2545–59. [PMID: 18539917]

ADVANCE Collaborative Group; Patel A et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. *N Engl J Med.* 2008 Jun 12;358(24):2560–72. [PMID: 18539916]

Duckworth W et al; VADT Investigators. Glucose control and vascular complications in veterans with type 2 diabetes. *N Engl J Med.* 2009 Jan 8;360(2):129–39. [PMID: 19092145]

Gaede P et al. Effect of a multifactorial intervention on mortality in type 2 diabetes. *N Engl J Med.* 2008 Feb 7;358(6):580–91. [PMID: 18256393]

Holman RR et al. 10-year follow-up of intensive glucose control in type 2 diabetes. *N Engl J Med.* 2008 Oct 9;359(15):1577–89. [PMID: 18784090]

Turnbull FM et al. Intensive glucose control and macrovascular outcomes in type 2 diabetes. *Diabetologia.* 2009 Nov;52(11):2288–98. [PMID: 19655124]

UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). *Lancet.* 1998 Sep 12;352(9131):837–53. [PMID: 9742976]

UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. *BMJ.* 1998 Sep 12; 317(7160):703–13. [PMID: 9732337]

▶ Treatment Regimens

A. Diet

A well-balanced, nutritious diet remains a fundamental element of therapy. The American Diabetes Association (ADA) recommends about 45–65% of total daily calories in the form of carbohydrates; 25–35% in the form of fat (of which < 7% are from saturated fat), and 10–35% in the form of protein. In patients with type 2 diabetes, limiting the carbohydrate intake and substituting some of the calories with monounsaturated fats, such as olive oil, rapeseed (canola) oil, or the oils in nuts and avocados, can lower triglycerides and increase HDL cholesterol. In addition, in those patients

with obesity and type 2 diabetes, weight reduction by caloric restriction is an important goal of the diet. Patients with type 1 diabetes or type 2 diabetes who take insulin should be taught “carbohydrate counting,” so they can administer their insulin bolus for each meal based on its carbohydrate content. In obese individuals with diabetes, an additional goal is weight reduction by caloric restriction (see Chapter 29).

The current recommendations for both types of diabetes continue to limit cholesterol to 300 mg daily, and individuals with LDL cholesterol more than 100 mg/dL (2.6 mmol/L) should limit dietary cholesterol to 200 mg daily. High protein intake may cause progression of kidney disease in patients with diabetic nephropathy; for these individuals, a reduction in protein intake to 0.8 kg/day (or about 10% of total calories daily) is recommended.

Exchange lists for meal planning can be obtained from the American Diabetes Association and its affiliate associations or from the American Dietetic Association (<http://www.eatright.org>), 216 W. Jackson Blvd., Chicago, IL 60606 (312-899-0040).

1. Dietary fiber—Plant components such as cellulose, gum, and pectin are indigestible by humans and are termed dietary “fiber.” Insoluble fibers such as cellulose or hemicellulose, as found in bran, tend to increase intestinal transit and may have beneficial effects on colonic function. In contrast, soluble fibers such as gums and pectins, as found in beans, oatmeal, or apple skin, tend to retard nutrient absorption rates so that glucose absorption is slower and hyperglycemia may be slightly diminished. Although its recommendations do not include insoluble fiber supplements such as added bran, the ADA recommends food such as oatmeal, cereals, and beans with relatively high soluble fiber content as staple components of the diet in diabetics. High soluble fiber content in the diet may also have a favorable effect on blood cholesterol levels.

2. Glycemic index—The glycemic index of a carbohydrate containing food is determined by comparing the glucose excursions after consuming 50 g of test food with glucose excursions after consuming 50 g of reference food (white bread):

$$\text{glycemic index} = \frac{\text{Blood glucose area under the curve (3h) for test food}}{\text{Blood glucose area under the curve (3h) for reference food}} \times 100$$

Eating low glycemic index foods results in lower glucose levels after meals. Low glycemic index foods have values of 55 or less and include many fruits, vegetables, grainy breads, pasta, and legumes. High glycemic index foods have values of 70 or greater and include baked potato, white bread, and white rice. Glycemic index is lowered by presence of fats and protein when food is consumed in a mixed meal. Even though it may not be possible to accurately predict the glycemic index of a particular food in the context of a meal, it is reasonable to choose foods with low glycemic index.

3. Artificial and other sweeteners—Aspartame (Nutra Sweet) consists of two major amino acids, aspartic acid and phenylalanine, which combine to produce a sweetener 180 times as sweet as sucrose. A major limitation is that it is not heat stable, so it cannot be used in cooking. Saccharin (Sweet 'N Low), Sucralose (Splenda), Acesulfame potassium (Sweet One), and rebiana (Truvia) are other “artificial” sweeteners that can be used in cooking and baking.

Fructose represents a “natural” sugar substance that is a highly effective sweetener, induces only slight increases in plasma glucose levels, and does not require insulin for its metabolism. However, because of potential adverse effects of large amounts of fructose on raising serum cholesterol, triglycerides, and LDL cholesterol, it does not have any advantage as a sweetening agent in the diabetic diet. This does not preclude, however, ingestion of fructose-containing fruits and vegetables or fructose-sweetened foods in moderation.

Sugar alcohols, also known as polyols or polyalcohol, are commonly used as sweeteners and bulking agents. They occur naturally in a variety of fruits and vegetables but are also commercially made from sucrose, glucose, and starch. Examples are sorbitol, xylitol, mannitol, lactitol, isomalt, maltitol, and hydrogenated starch hydrolysates (HSH). They are not as easily absorbed as sugar, so they do not raise blood glucose levels as much. Therefore, sugar alcohols are often used in food products that are labeled as “sugar free,” such as chewing gum, lozenges, hard candy, and sugar-free ice cream. However, if consumed in large quantities, they will raise blood glucose and can cause bloating and diarrhea.

B. Medications for Treating Hyperglycemia

The medications for treating type 2 diabetes (Table 27–7) fall into several categories: (1) Medications that primarily stimulate insulin secretion by binding to the sulfonylurea receptor: Sulfonylureas remain the most widely prescribed medications for treating hyperglycemia. The meglitinide analog repaglinide and the D-phenylalanine derivative nateglinide also bind the sulfonylurea receptor and stimulate insulin secretion. (2) Medications that primarily lower glucose levels by their actions on the liver, muscle, and adipose tissue: Metformin works in the liver. The thiazolidinediones appear to have their main effect on skeletal muscle and adipose tissue. (3) Medications that principally affect absorption of glucose: The α -glucosidase inhibitors acarbose and miglitol are such currently available therapies. (4) Medications that mimic incretin effect or prolong incretin action: Glucagon-like peptide 1 (GLP1) receptor agonists and DPP IV inhibitors fall into this category. (5) Other: Pramlintide lowers glucose by suppressing glucagon and slowing gastric emptying.

1. Medications that primarily stimulate insulin secretion by binding to the sulfonylurea receptor on the beta cell—

A. SULFONYLUREAS—The primary mechanism of action of the sulfonylureas is to stimulate insulin release from pancreatic B cells. Specific receptors on the surface of pancreatic B cells bind sulfonylureas in the rank order of their

Table 27-7. Drugs for treatment of type 2 diabetes mellitus.

Drug	Tablet Size	Daily Dose	Duration of Action
Sulfonylureas			
Tolbutamide (Orinase)	250 and 500 mg	0.5-2 g in two or three divided doses	6-12 hours
Tolazamide (Tolinase)	100, 250, and 500 mg	0.1-1 g as single dose or in two divided doses	Up to 24 hours
Acetohexamide (Dymelor)	250 and 500 mg	0.25-1.5 g as single dose or in two divided doses	8-24 hours
Chlorpropamide (Diabinese)	100 and 250 mg	0.1-0.5 g as single dose	24-72 hours
Glyburide			
(DiaBeta, Micronase)	1.25, 2.5, and 5 mg	1.25-20 mg as single dose or in two divided doses	Up to 24 hours
(Glynase)	1.5, 3, and 6 mg	1.5-12 mg as single dose or in two divided doses	Up to 24 hours
Glipizide			
(Glucotrol)	5 and 10 mg	2.5-40 mg as a single dose or in two divided doses 30 minutes before meals	6-12 hours
(Glucotrol XL)	2.5, 5, and 10 mg	2.5 to 10 mg once a day is usual dose; 20 mg once a day is maximal dose	Up to 24 hours
Gliclazide (not available in United States)	80 mg	40-80 mg as single dose; 160-320 mg as divided dose	12 hours
Glimepiride (Amaryl)	1, 2, and 4 mg	1-4 mg once a day is usual dose; 8 mg once a day is maximal dose	Up to 24 hours
Meglitinide analogs			
Repaglinide (Prandin)	0.5, 1, and 2 mg	0.5 to 4 mg three times a day before meals	3 hours
Mitiglinide (available in Japan)	5 and 10 mg	5 or 10 mg three times a day before meals	2 hours
D-Phenylalanine derivative			
Nateglinide (Starlix)	60 and 120 mg	60 or 120 mg three times a day before meals	1.5 hours
Biguanides			
Metformin (Glucophage)	500, 850, and 1000 mg	1-2.5 g; 1 tablet with meals two or three times daily	7-12 hours
Extended-release metformin (Glucophage XR)	500 and 750 mg	500-2000 mg once a day	Up to 24 hours
Thiazolidinediones			
Rosiglitazone (Avandia) ¹	2, 4, and 8 mg	4-8 mg daily (can be divided)	Up to 24 hours
Pioglitazone (Actos)	15, 30, and 45 mg	15-45 mg daily	Up to 24 hours
α-Glucosidase inhibitors			
Acarbose (Precose)	50 and 100 mg	25-100 mg three times a day just before meals	4 hours
Miglitol (Glyset)	25, 50, and 100 mg	25-100 mg three times a day just before meals	4 hours
Voglibose (not available in United States)	0.2 and 0.3 mg	0.2-0.3 mg three times a day just before meals	4 hours
GLP-1 receptor agonists			
Exenatide (Byetta)	1.2 mL and 2.4 mL prefilled pens containing 5 mcg and 10 mcg (subcutaneous injection)	5 mcg subcutaneously twice a day within 1 hour of breakfast and dinner. Increase to 10 mcg subcutaneously twice a day after about a month. Do not use if calculated creatinine clearance is < 30 mL/min.	6 hours
Exenatide, long-acting release (Byetta LAR, Bydureon)	2 mg (powder)	Suspend in provided diluent and inject subcutaneously	1 week
Liraglutide (Victoza)	Pre-filled, multi-dose pen that delivers doses of 0.6 mg, 1.2 mg, or 1.8 mg	0.6 mg subcutaneously once a day (starting dose). Increase to 1.2 mg after a week if no adverse reactions. Dose can be further increased to 1.8 mg, if necessary.	24 hours

(continued)

Table 27-7. Drugs for treatment of type 2 diabetes mellitus. (continued)

Drug	Tablet Size	Daily Dose	Duration of Action
DPP-4 inhibitors			
Sitagliptin (Januvia)	25, 50, and 100 mg	100 mg once daily is usual dose; dose is 50 mg once daily if calculated creatinine clearance is 30 to 50 mL/min and 25 mg once daily if clearance is < 30 mL/min.	24 hours
Saxagliptin (Onglyza)	2.5 and 5 mg	2.5 mg or 5 mg once daily. Use 2.5 mg dose if calculated creatinine clearance is \leq 50 mL/min or if also taking drugs that are strong CYP3A4/5 inhibitors such as ketoconazole.	24 hours
Vildagliptin (Galvus) (not available in United States)	50 mg	50 mg once or twice daily. Contraindicated in patients with calculated creatinine clearance \leq 60 mL/min or AST/ALT three times upper limit of normal	24 hours
Linagliptin (Tradjenta)	5 mg	5 mg daily	24 hours
Others			
Pramlintide (Symlin)	5 mL vial containing 0.6 mg/mL; also available as prefilled pens. Symlin pen 60 or Symlin pen 120 (subcutaneous injection)	For insulin-treated type 2 patients, start at 60 mcg dose three times a day (10 units on U100 insulin syringe). Increase to 120 mcg three times a day (20 units on U100 insulin syringe) if no nausea for 3-7 days. Give immediately before meal. For type 1 patients, start at 15 mcg three times a day (2.5 units on U100 insulin syringe) and increase by increments of 15 mcg to a maximum of 60 mcg three times a day, as tolerated. To avoid hypoglycemia, lower insulin dose by 50% on initiation of therapy.	2 hours

¹Restricted Distribution Program in place in the United States.

insulinotropic potency (glyburide with the greatest affinity and tolbutamide with the least affinity). It has been shown that activation of these receptors closes potassium channels, resulting in depolarization of the B cell. This depolarized state permits calcium to enter the cell and actively promote insulin release.

Sulfonylureas are not indicated for use in type 1 diabetes patients since these medications require functioning pancreatic B cells to produce their effect on blood glucose. These medications are used in patients with type 2 diabetes, in whom acute administration improves the early phase of insulin release that is refractory to acute glucose stimulation. Sulfonylureas are metabolized by the liver and apart from acetohexamide, whose metabolite is more active than the parent compound, the metabolites of all the other sulfonylureas are weakly active or inactive. The metabolites are excreted by the kidney and, in the case of the second-generation sulfonylureas, partly excreted in the bile. Sulfonylureas are generally contraindicated in patients with severe liver or kidney impairment. Idiosyncratic reactions are rare, with skin rashes or hematologic toxicity (leukopenia, thrombocytopenia) occurring in < 0.1% of users.

(1) **First-generation sulfonylureas (tolbutamide, tolazamide, acetohexamide, chlorpropamide)**—**Tolbutamide** is supplied as 500 mg tablets. It is rapidly oxidized in the liver to inactive metabolites, and its approximate duration of effect is relatively short (6–10 hours). Tolbutamide is probably best administered in divided doses (eg, 500 mg before each meal and at bedtime); however, some patients require

only one or two tablets daily with a maximum dose of 3000 mg/d. Because of its short duration of action, which is independent of kidney function, tolbutamide is relatively safe to use in renal impairment. Prolonged hypoglycemia has been reported rarely with tolbutamide, mostly in patients receiving certain antibacterial sulfonamides (sulfisoxazole), phenylbutazone for arthralgias, or the oral azole antifungal medications to treat candidiasis. These medications apparently compete with tolbutamide for oxidative enzyme systems in the liver, resulting in maintenance of high levels of unmetabolized, active sulfonylurea in the circulation.

Tolazamide, acetohexamide, and chlorpropamide are rarely used. Chlorpropamide has a prolonged biologic effect, and severe hypoglycemia can occur especially in the elderly as their renal clearance declines with aging. Its other side effects include alcohol-induced flushing and hyponatremia due to its effect on vasopressin secretion and action.

(2) **Second-generation sulfonylureas (glyburide, glipizide, gliclazide, glimepiride)**—Glyburide, glipizide, gliclazide, and glimepiride are 100–200 times more potent than tolbutamide. These medications should be used with caution in patients with cardiovascular disease or in elderly patients, in whom prolonged hypoglycemia would be especially dangerous.

Glyburide is available in 1.25 mg, 2.5 mg, and 5 mg tablets. The usual starting dose is 2.5 mg/d, and the average maintenance dose is 5–10 mg/d given as a single morning dose; maintenance doses higher than 20 mg/d are not recommended. Some reports suggest that 10 mg is a maximum daily

therapeutic dose, with 15–20 mg having no additional benefit in poor responders and doses over 20 mg actually worsening hyperglycemia. Glyburide is metabolized in the liver into products with hypoglycemic activity, which probably explains why assays specific for the unmetabolized compound suggest a plasma half-life of only 1–2 hours, yet the biologic effects of glyburide are clearly persistent 24 hours after a single morning dose in diabetic patients. Glyburide is unique among sulfonylureas in that it not only binds to the pancreatic B cell membrane sulfonylurea receptor but also becomes sequestered within the B cell. This may also contribute to its prolonged biologic effect despite its relatively short circulating half-life. A “Press Tab” formulation of “micronized” glyburide—easy to divide in half with slight pressure if necessary—is available in tablet sizes of 1.5 mg, 3 mg, and 6 mg.

Glyburide has few adverse effects other than its potential for causing hypoglycemia, which at times can be prolonged. Flushing has rarely been reported after ethanol ingestion. It does not cause water retention, as chlorpropamide does, but rather slightly enhances free water clearance. Glyburide should not be used in patients with liver failure and renal failure because of the risk of hypoglycemia. Elderly patients are at particular risk for hypoglycemia even with relatively small daily doses.

Glipizide is available in 5 and 10 mg tablets. For maximum effect in reducing postprandial hyperglycemia, this agent should be ingested 30 minutes before meals, since rapid absorption is delayed when the medication is taken with food. The recommended starting dose is 5 mg/d, with up to 15 mg/d given as a single daily dose before breakfast. When higher daily doses are required, they should be divided and given before meals. The maximum dose recommended by the manufacturer is 40 mg/d, although doses above 10–15 mg probably provide little additional benefit in poor responders and may even be less effective than smaller doses.

At least 90% of glipizide is metabolized in the liver to inactive products, and 10% is excreted unchanged in the urine. Glipizide therapy should therefore not be used in patients with liver failure. Because of its lower potency and shorter duration of action, it is preferable to glyburide in elderly patients. Glipizide has also been marketed as Glucotrol-XL in 2.5, 5, and 10 mg tablets. It provides extended release during transit through the gastrointestinal tract with greater effectiveness in lowering prebreakfast hyperglycemia than the shorter-duration immediate-release standard glipizide tablets. However, this formulation appears to have sacrificed its lower propensity for severe hypoglycemia compared with longer-acting glyburide without showing any demonstrable therapeutic advantages over glyburide.

Gliclazide (not available in the United States) is another intermediate duration sulfonylurea with a duration of action of about 12 hours. It is available as 80 mg tablets. The recommended starting dose is 40–80 mg/d with a maximum dose of 320 mg. Doses of 160 mg and above are given as divided doses before breakfast and dinner. The medication is metabolized by the liver; the metabolites and conjugates have no hypoglycemic effect. An extended release preparation is available.

Glimepiride is available as 1, 2 and 4 mg tablets. It has a long duration of effect with a half-life of 5 hours allowing once or twice daily dosing. Glimepiride achieves blood glucose lowering with the lowest dose of any sulfonylurea compound. A single daily dose of 1 mg/d has been shown to be effective, and the maximal recommended dose is 8 mg. It is completely metabolized by the liver to relatively inactive metabolic products.

B. MEGLITINIDE ANALOGS—Repaglinide is structurally similar to glyburide but lacks the sulfonic acid-urea moiety. It acts by binding to the sulfonylurea receptor and closing the ATP-sensitive potassium channel. It is rapidly absorbed from the intestine and then undergoes complete metabolism in the liver to inactive biliary products, giving it a plasma half-life of < 1 hour. The medication therefore causes a brief but rapid pulse of insulin. The starting dose is 0.5 mg three times a day 15 minutes before each meal. The dose can be titrated to a maximal daily dose of 16 mg. Like the sulfonylureas, repaglinide can be used in combination with metformin. Hypoglycemia is the main side effect. In clinical trials, when the medication was compared with a long-duration sulfonylurea (glyburide), there was a trend toward less hypoglycemia. Like the sulfonylureas also, repaglinide causes weight gain. Metabolism is by cytochrome P450 3A4 isoenzyme, and other medications that induce or inhibit this isoenzyme may increase or inhibit (respectively) the metabolism of repaglinide. The medication may be useful in patients with kidney impairment or in the elderly.

Mitiglinide is a benzylsuccinic acid derivative that binds to the sulfonylurea receptor and is similar to repaglinide in its clinical effects. It has been approved for use in Japan.

C. D-PHENYLALANINE DERIVATIVE—Nateglinide stimulates insulin secretion by binding to the sulfonylurea receptor and closing the ATP-sensitive potassium channel. This compound is rapidly absorbed from the intestine, reaching peak plasma levels within 1 hour. It is metabolized in the liver and has a plasma half-life of about 1.5 hours. Like repaglinide, it causes a brief rapid pulse of insulin, and when given before a meal it reduces the postprandial rise in blood glucose. The medication is available as 60 and 120 mg tablets. The 60 mg dose is used in patients who have mild elevations in HbA_{1c}. For most patients, the recommended starting and maintenance dose is 120 mg three times a day before meals. Like the other insulin secretagogues, its main side effects are hypoglycemia and weight gain.

2. Medications that primarily lower glucose levels by their actions on the liver, muscle, and adipose tissue—

A. METFORMIN—Metformin (1,1-dimethylbiguanide hydrochloride) is used, either alone or in conjunction with other oral agents or insulin, in the treatment of patients with type 2 diabetes.

Metformin activates adenosine monophosphate-activated protein kinase (AMPK) by uncoupling mitochondrial oxidative phosphorylation and increasing cellular AMP levels. Metformin's therapeutic effects primarily derive from the

increasing hepatic AMPK activity, which reduces hepatic gluconeogenesis and lipogenesis. Metformin is a substrate for organic cation transporter 1, which is abundantly expressed in hepatocytes and in the gut.

Metformin has a half-life of 1.5–3 hours, is not bound to plasma proteins, and is not metabolized in humans, being excreted unchanged by the kidneys.

Metformin is the first-line therapy for patients with type 2 diabetes. The current recommendation is to start this medication at diagnosis. A side benefit of metformin therapy is its tendency to improve both fasting and postprandial hyperglycemia and hypertriglyceridemia in obese diabetics without the weight gain associated with insulin or sulfonylurea therapy. Metformin is ineffective in patients with type 1 diabetes. Patients with chronic kidney disease (calculated glomerular filtration rate < 50 mL/min) should not be given this medication because failure to excrete it would produce high blood and tissue levels of metformin that could stimulate lactic acid overproduction. Likewise, patients with liver failure or persons who abuse alcohol should not receive this medication; lactic acid production from the gut and other tissues, which rises during metformin therapy, could result in lactic acidosis when defective hepatocytes cannot remove the lactate or when alcohol-induced reduction of nucleotides interferes with lactate clearance.

Metformin is dispensed as 500 mg, 850 mg, and 1000 mg tablets. A 500 mg and 750 mg extended-release preparation is also available. Although the maximal dosage is 2.55 g, little benefit is seen above a total dose of 2000 mg. It is important to begin with a low dose and increase the dosage very gradually in divided doses—taken with meals—to reduce minor gastrointestinal upsets. A common schedule would be one 500 mg tablet three times a day with meals or one 850 mg or 1000 mg tablet twice daily at breakfast and dinner. Up to 2000 mg of the extended-release preparation can be given once a day.

The most frequent side effects of metformin are gastrointestinal symptoms (anorexia, nausea, vomiting, abdominal discomfort, diarrhea), which occur in up to 20% of patients. These effects are dose-related, tend to occur at onset of therapy, and often are transient. However, in 3–5% of patients, therapy may have to be discontinued because of persistent diarrheal discomfort. In a retrospective analysis, it has been reported that patients switched from immediate-release metformin to comparable dose of extended-release metformin experienced fewer gastrointestinal side effects.

Hypoglycemia does not occur with therapeutic doses of metformin, which permits its description as a “euglycemic” or “antihyperglycemic” medication rather than an oral hypoglycemic agent. Dermatologic or hematologic toxicity is rare. Absorption of vitamin B₁₂ appears to be reduced during long-term metformin therapy, but the serum vitamin B₁₂ levels usually remain in the normal range. However, periodic screening with serum vitamin B₁₂ levels should be considered, especially in patients with symptoms of peripheral neuropathy or if a macrocytic anemia develops.

Lactic acidosis has been reported as a side effect but is uncommon with metformin in contrast to phenformin. While therapeutic doses of metformin reduce lactate

uptake by the liver, serum lactate levels rise only minimally if at all, since other organs such as the kidney can remove the slight excess. However, if tissue hypoxia occurs, the metformin-treated patient is at higher risk for lactic acidosis due to compromised lactate removal. Similarly, when kidney function deteriorates, affecting not only lactate removal by the kidney but also metformin excretion, plasma levels of metformin rise far above the therapeutic range and block hepatic uptake enough to provoke lactic acidosis without associated increases in lactic acid production. Almost all reported cases have involved subjects with associated risk factors that should have contraindicated its use (kidney, liver, or cardiorespiratory insufficiency, alcoholism, advanced age). Acute kidney failure can occur rarely in certain patients receiving radiocontrast agents. Metformin therapy should therefore be temporarily halted on the day of radiocontrast administration and restarted a day or two later after confirmation that renal function has not deteriorated.

B. THIAZOLIDINEDIONES—Medications of this class of antihyperglycemic agents sensitize peripheral tissues to insulin. They bind a nuclear receptor called peroxisome proliferator-activated receptor gamma (PPAR- γ) and affect the expression of a number of genes. Observed effects of thiazolidinediones include increased glucose transporter expression (GLUT 1 and GLUT 4), decreased free fatty acid levels, decreased hepatic glucose output, increased adiponectin and decreased release of resistin from adipocytes, and increased differentiation of preadipocytes into adipocytes. They have also been demonstrated to decrease levels of plasminogen activator inhibitor type 1, matrix metalloproteinase 9, C-reactive protein, and interleukin 6. Like the biguanides, this class of medications does not cause hypoglycemia.

Troglitazone, the first medication in this class to go into widespread clinical use, was withdrawn from clinical use because of medication-associated fatal liver failure. Two other medications of this class, rosiglitazone and pioglitazone, are available for clinical use. Both are effective as monotherapy and in combination with sulfonylureas or metformin or insulin, lowering HbA_{1c} by 1% to 2%. When used in combination with insulin, they can result in a 30–50% reduction in insulin dosage, and some patients can come off insulin completely. The dosage of rosiglitazone is 4–8 mg daily and of pioglitazone, 15–45 mg daily, and the medications do not have to be taken with food. Rosiglitazone is primarily metabolized by the CYP 2C8 isoenzyme and pioglitazone is metabolized by CYP 2C8 and CYP 3A4.

The combination of a thiazolidinedione and metformin has the advantage of not causing hypoglycemia. Patients inadequately managed on sulfonylureas can do well on a combination of sulfonylurea and rosiglitazone or pioglitazone. About 25% of patients in clinical trials fail to respond to these medications, presumably because they are significantly insulinopenic.

These medications have some additional effects apart from glucose lowering. Rosiglitazone therapy is associated with increases in total cholesterol, LDL-cholesterol (15%),

and HDL-cholesterol (10%). There is a reduction in free fatty acids of about 8–15%. The changes in triglycerides were generally not different from placebo. Pioglitazone in clinical trials lowered triglycerides (9%) and increased HDL-cholesterol (15%), but did not cause a consistent change in total cholesterol and LDL-cholesterol levels. A prospective randomized comparison of the metabolic effects of pioglitazone and rosiglitazone on patients who had previously taken troglitazone (now withdrawn from the US market) showed similar effects on HbA_{1c} and weight gain. Pioglitazone-treated persons, however, had lower total cholesterol, LDL-cholesterol, and triglycerides when compared with rosiglitazone-treated persons. Small prospective studies have demonstrated that treatment with these medications leads to improvements in the biochemical and histologic features of nonalcoholic fatty liver disease. The thiazolidinediones also may limit vascular smooth muscle proliferation after injury, and there are reports that pioglitazone and troglitazone (subsequently withdrawn from the US market) reduced neointimal proliferation after coronary stent placement. Finally, in one double-blind, placebo-controlled study, rosiglitazone was shown to be associated with a decrease in the ratio of urinary albumin to creatinine excretion.

Safety concerns and some troublesome side effects have emerged about this class of medications that significantly limit their use.

A meta-analysis of 42 randomized clinical trials with rosiglitazone suggested that this medication increases the risk of angina pectoris or myocardial infarction. A meta-analysis of clinical trials with pioglitazone did not show similar findings. Although conclusive data are lacking, the European Medicines Agency has suspended the use of rosiglitazone in Europe. In the United States, the FDA has established a restricted distribution program, and prescribers and patients must enroll in the Avandia-Rosiglitazone Medicine Access Program at 1-800-282-6342 or www.avandia.com. The patients are required to review statements regarding the cardiovascular safety of rosiglitazone and acknowledge that they understand the risks. Since pioglitazone and rosiglitazone are therapeutically equivalent and side effects, apart from the myocardial infarction risk, are identical, there is no clinical reason why any patient should be prescribed rosiglitazone.

Edema occurs in about 3–4% of patients receiving monotherapy with rosiglitazone or pioglitazone. The edema occurs more frequently (10–15%) in patients receiving concomitant insulin therapy and may result in congestive heart failure. The medications are contraindicated in diabetic individuals with New York Heart Association class III and IV cardiac status. Thiazolidinediones have also been reported as being associated with new onset or worsening macular edema. Apparently, this is a rare side effect, and most of these patients also had peripheral edema. The macular edema resolved or improved once the medication was discontinued.

In experimental animals, rosiglitazone stimulates bone marrow adipogenesis at the expense of osteoblastogenesis resulting in a decrease in bone density. An increase in fracture risk in women (but not men) has been reported with

both rosiglitazone and pioglitazone. The fracture risk is in the range of 1.9 per 100 patient-years with the thiazolidinedione compared to 1.1 per 100 patient years on comparison treatment. In at least one study of rosiglitazone, the fracture risk was increased in premenopausal as well as postmenopausal women.

Other side effects include anemia, which occurs in 4% of patients treated with these medications; it may be due to a dilutional effect of increased plasma volume rather than a reduction in red cell mass. Weight gain occurs, especially when the medication is combined with a sulfonylurea or insulin. Some of the weight gain is fluid retention, but there is also an increase in total fat mass. In preclinical studies with pioglitazone, bladder tumors were observed in male rats receiving clinically relevant doses of the medication. In a planned 5-year interim analysis of data from a long-term observational cohort study of patients taking pioglitazone, there was no overall increased risk of bladder cancer with pioglitazone. However, increased bladder cancer risk was observed with increasing dose and duration of pioglitazone use, reaching statistical significance after 24 months of exposure.

Although rosiglitazone and pioglitazone have not been reported to cause liver injury, the FDA recommends that they should not be used in patients with clinical evidence of active liver disease or pretreatment elevation of the alanine aminotransferase (ALT) level that is 2.5 times greater than the upper limit of normal. Obviously, caution should be used in initiation of therapy in patients with even mild ALT elevations. Liver biochemical tests should be performed prior to initiation of treatment and periodically thereafter.

3. Medications that affect absorption of glucose—

α -Glucosidase inhibitors competitively inhibit the α -glucosidase enzymes in the gut that digest dietary starch and sucrose. Two of these medications—acarbose and miglitol—are available for clinical use in the United States. Voglibose, another α -glucosidase inhibitor is available in Japan, Korea, and India. Acarbose and miglitol are potent inhibitors of glucoamylase, α -amylase, and sucrase but have less effect on isomaltase and hardly any on trehalase and lactase. Acarbose binds 1000 times more avidly to the intestinal disaccharidases than do products of carbohydrate digestion or sucrose. A fundamental difference between acarbose and miglitol is in their absorption. Acarbose has the molecular mass and structural features of a tetrasaccharide, and very little (about 2%) crosses the microvillar membrane. Miglitol, however, has a structural similarity with glucose and is absorbable. Both medications delay the absorption of carbohydrate and lower postprandial glycemic excursion.

A. ACARBOSE—Acarbose is available as 50 mg and 100 mg tablets. The recommended starting dose of acarbose is 50 mg twice daily, gradually increasing to 100 mg three times daily. For maximal benefit on postprandial hyperglycemia, acarbose should be given with the first mouthful of food ingested. In diabetic patients, it reduces postprandial hyperglycemia by 30–50%, and its overall effect is to lower the HbA_{1c} by 0.5–1%.

The principal adverse effect, seen in 20–30% of patients, is flatulence. This is caused by undigested carbohydrate reaching the lower bowel, where gases are produced by bacterial flora. In 3% of cases, troublesome diarrhea occurs. This gastrointestinal discomfort tends to discourage excessive carbohydrate consumption and promotes improved compliance of type 2 patients with their diet prescriptions. When acarbose is given alone, there is no risk of hypoglycemia. However, if combined with insulin or sulfonylureas, it might increase the risk of hypoglycemia from these agents. A slight rise in hepatic aminotransferases has been noted in clinical trials with acarbose (5% versus 2% in placebo controls, and particularly with doses > 300 mg/d). The levels generally return to normal on stopping the medication.

In the UKPDS, approximately 2000 patients on diet, sulfonylurea, metformin, or insulin therapy were randomized to acarbose or placebo therapy. By 3 years, 60% of the patients had discontinued the medication, mostly because of gastrointestinal symptoms. If one looked only at the 40% who remained on the medication, they had an 0.5% lower HbA_{1c} compared with placebo.

B. MIGLITOL—Miglitol is similar to acarbose in terms of its clinical effects. It is indicated for use in diet- or sulfonylurea-treated patients with type 2 diabetes. Therapy is initiated at the lowest effective dosage of 25 mg three times a day. The usual maintenance dose is 50 mg three times a day, although some patients may benefit from increasing the dose to 100 mg three times a day. Gastrointestinal side effects occur as with acarbose. The medication is not metabolized and is excreted unchanged by the kidney. Theoretically, absorbable α -glucosidase inhibitors could induce a deficiency of one or more of the α -glucosidases involved in cellular glycogen metabolism and biosynthesis of glycoproteins. This does not occur in practice because, unlike the intestinal mucosa, which sees a high concentration of the medication, the blood level is 200-fold to 1000-fold lower than the concentration needed to inhibit intracellular α -glucosidases. Miglitol should not be used in end-stage chronic kidney disease, when its clearance would be impaired.

4. Incretins—Oral glucose provokes a threefold to fourfold higher insulin response than an equivalent dose of glucose given intravenously. This is because the oral glucose causes a release of gut hormones, principally glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), that amplify the glucose-induced insulin release. This “incretin effect” is reduced in patients with type 2 diabetes. GLP-1 secretion (but not GIP secretion) is impaired in patients with type 2 diabetes and when GLP-1 is infused in patients with type 2 diabetes, it stimulates insulin secretion and lowers glucose levels. GLP-1, unlike the sulfonylureas, has only a modest insulin stimulatory effect at normoglycemic concentrations. This means that GLP-1 has a lower risk for hypoglycemia than the sulfonylureas.

In addition to its insulin stimulatory effect, GLP-1 also has a number of other pancreatic and extrapancreatic effects. It suppresses glucagon secretion and so may ameliorate the hyperglucagonemia that is present in people

with diabetes and improve postprandial hyperglycemia. GLP-1 preserves islet integrity and reduces apoptotic cell death of human islet cells in culture. In mice, streptozotocin-induced apoptosis is significantly reduced by coadministration of exendin-4 or exenatide, a GLP-1 receptor agonist. GLP-1 acts on the stomach delaying gastric emptying; the importance of this effect on glucose lowering is illustrated by the observation that antagonizing the deceleration of gastric emptying markedly reduces the glucose lowering effect of GLP-1. GLP-1 receptors are present in the central nervous system, and intracerebroventricular administration of GLP-1 in wild type mice, but not in GLP-1 receptor knockout mice, inhibits feeding. Type 2 diabetic patients undergoing GLP-1 infusion are less hungry; it is unclear whether this is mainly due to a deceleration of gastric emptying or whether there is a central nervous system effect as well.

A. GLP-1 RECEPTOR AGONISTS—GLP-1 is rapidly proteolyzed by dipeptidyl peptidase 4 (DPP-4) and by other enzymes, such as endopeptidase 24.11, and is also cleared rapidly by the kidney. As a result, GLP-1's half-life is only 1–2 minutes. The native peptide, therefore, cannot be used therapeutically and the approach taken has been to develop metabolically stable analogs or derivatives of GLP-1 that are not subject to the same enzymatic degradation or renal clearance. Two GLP-1 receptor agonists, exenatide and liraglutide, are currently available for clinical use.

Exenatide (Exendin 4) is a GLP-1 receptor agonist isolated from the saliva of the Gila Monster (a venomous lizard) that is more resistant to DPP-4 action and cleared by the kidney. Its half-life is 2.4 hours, and its glucose lowering effect is about 6 hours. When this medication is given to patients with type 2 diabetes by subcutaneous injection twice daily, it lowers blood glucose and HbA_{1c} levels. Exenatide appears to have the same effects as GLP-1 on glucagon suppression and gastric emptying. In clinical trials, adding exenatide therapy to patients with type 2 diabetes already taking metformin or a sulfonylurea, or both, further lowered the HbA_{1c} value by 0.4% to 0.6% over a 30-week period. These patients also experienced a weight loss of 3–6 pounds. In an open label extension study up to 80 weeks, the HbA_{1c} reduction was sustained, and there was further weight loss (to a total loss of about 10 pounds). The main side effect was nausea, affecting over 40% of the patients. The nausea was dose-dependent and declined with time. The risk of hypoglycemia was higher in persons taking sulfonylureas. The FDA has received 30 post-marketing reports of acute pancreatitis in patients taking exenatide. The pancreatitis was severe (hemorrhagic or necrotizing) in 6 instances, and two of these patients died. Many of these patients had other risk factors for pancreatitis, but the possibility remains that the medication was causally responsible for some cases. Patients taking exenatide should be advised to seek immediate medical care if they experience unexplained persistent severe abdominal pain. The FDA also reported 16 cases of renal impairment and 62 cases of acute renal failure in patients taking exenatide. Some of these patients had preexisting kidney disease, and others had one or more risk factors for kidney disease. A number of patients reported nausea,

vomiting, and diarrhea; it is possible that these side effects cause volume depletion and contributed to the development of the renal failure. The delay in gastric emptying may affect the absorption of some other medications; therefore, antibiotics and oral contraceptives should be taken 1 hour before exenatide doses. Low-titer antibodies against exenatide develop in over one-third (38%) of patients, but the clinical effects are not attenuated. High-titer antibodies develop in a subset of patients (~6%), and in about half of these cases, an attenuation of glycemic response has been seen. Exenatide stimulates C-cell tumors in rodents and the drug is therefore contraindicated in patients with a personal or family history of medullary thyroid cancer or multiple endocrine neoplasia (MEN) syndrome type 2.

Exenatide is dispensed as two fixed-dose pens (5 mcg and 10 mcg). It is injected 60 minutes before breakfast and before dinner. Patients should be prescribed the 5 mcg pen for the first month and, if tolerated, the dose can then be increased to 10 mcg twice a day. The medication is not recommended in patients with glomerular filtration rate < 30 mL/min.

Exenatide LAR is a once weekly preparation that is dispensed as a powder (2 mg). It is suspended in the provided diluent just prior to injection. In comparative clinical trials, the long-acting drug lowers the HbA_{1c} level a little more than the twice daily drug. It is as well tolerated, with nausea being the predominant side effect.

Liraglutide is a soluble fatty acid acylated GLP-1 analog (with replacement of lysine with arginine at position 34 and the attachment of a C16 acyl chain to a lysine at position 26). The fatty-acyl GLP-1 retains affinity for GLP-1 receptors but the addition of the C 16 acyl chain allows for non-covalent binding to albumin, both hindering DPP-4 access to the molecule and contributing to a prolonged half-life and duration of action. The half-life is approximately 12 hours, allowing the medication to be injected once a day.

In clinical trials lasting 26 and 52 weeks, adding liraglutide to the therapeutic regimen (metformin, sulfonylurea, thiazolidinedione) of patients with type 2 diabetes further lowered the HbA_{1c} value. Depending on the dose and design of the study, the HbA_{1c} decline was in the range of 0.6% to 1.5%. The patients had sustained weight loss of 1–6 pounds.

Like exenatide, the most frequent side effects were nausea (28%) and vomiting (10%). There was also an increased incidence of diarrhea. About 2–5% of participants withdrew from the studies because of the gastrointestinal symptoms. In clinical trials, there were seven cases of pancreatitis in the liraglutide treated group with one case in the comparison group (2.2 vs. 0.6 cases per 1000 patient-years). Liraglutide stimulates C-cell neoplasia and causes medullary thyroid carcinoma in rats. Human C-cells express very few GLP1-receptors, and the relevance to human therapy is unclear; however, because of the animal data, the medication should not be used in patients with personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia (MEN) syndrome type 2.

The dosing is initiated at 0.6 mg daily, increased after 1 week to 1.2 mg daily. If needed, an additional increase in

dose to 1.8 mg is recommended for optimal glycemic control. Titration is also based on tolerability. There is limited experience using the medication in renal failure but no dose adjustment is recommended.

B. DPP-4 INHIBITORS—An alternate approach to the use of GLP-1 receptor agonists is to inhibit the enzyme DPP-4 and prolong the action of endogenously released GLP-1 and GIP. Three oral DPP-4 inhibitors, sitagliptin, saxagliptin, and linagliptin, are available for the treatment of type 2 diabetes in the United States. An additional DPP4 inhibitor, vildagliptin, is available in Europe.

Sitagliptin in clinical trials was shown to be effective in lowering glucose when used alone and in combination with metformin and pioglitazone. In various clinical trials, improvements in HbA_{1c} ranged from 0.5% to 1.4%. The usual dose of sitagliptin is 100 mg once daily, but the dose is reduced to 50 mg daily if the calculated creatinine clearance is 30–50 mL/min and to 25 mg for clearances < 30 mL/min. Unlike exenatide, sitagliptin does not cause nausea or vomiting. It also does not result in weight loss. The main adverse effect appears to be a predisposition to nasopharyngitis or upper respiratory tract infection. A small increase in neutrophil count of ~200 cells/mcL has also occurred. Since its FDA approval and clinical use, there have been reports of serious allergic reactions to sitagliptin, including anaphylaxis, angioedema, and exfoliative skin conditions including Stevens-Johnson syndrome. There have also been reports of pancreatitis (88 cases including 2 cases of hemorrhagic or necrotizing pancreatitis). The frequency of these events is unclear. A number of neuropeptides, growth factors, cytokines, and chemokines are potential DPP-4 substrates; DPP-4 inhibitors prolong the actions of neuropeptide Y and substance P. It is unknown whether the effects of DPP-4 inhibitors on the actions of neuropeptide Y and substance P over a long-term period will have negative consequences.

Saxagliptin, when added to the therapeutic regimen (metformin, sulfonylurea, thiazolidinedione) of patients with type 2 diabetes, further lowered the HbA_{1c} value by about 0.7–0.9%. The dose is 2.5 mg or 5 mg once a day. The 2.5-mg dose should be used in patients with calculated creatinine clearance < 50 mL/min. It lowers HbA_{1c} by about 0.6% when added to metformin or glyburide or thiazolidine in various 24-week clinical trials. The medication does not cause weight gain or loss. The main adverse reactions were upper respiratory tract infection, nasopharyngitis, headache, and urinary tract infection. There is also small reversible dose-dependent reduction in absolute lymphocyte count, which remains within normal limits. Hypersensitivity reactions, such as urticaria and facial edema, occurred in 1.5% of patients taking the medication compared with 0.4% receiving placebo. The metabolism of saxagliptin is by CYP3A4/5; thus, strong inhibitors or inducers of CYP3A4/5 will affect the pharmacokinetics of saxagliptin and its active metabolite.

Linagliptin lowers HbA_{1c} by about 0.4–0.6% when added to metformin, sulfonylurea, or pioglitazone. The dose is 5 mg daily and, since it is primarily excreted unmetabolized via the bile, no dose adjustment is needed in

patients with renal failure. The adverse reactions include nasopharyngitis and hypersensitivity reactions (urticaria, angioedema, localized skin exfoliation, bronchial hyperreactivity). In one study, there were eight cases of pancreatitis in 4687 patients exposed to drug (4311 patient years) with 0 cases in 1183 patients receiving placebo (433 patient years).

Vildagliptin lowers HbA_{1c} by about 0.5–1% when added to the therapeutic regimen of patients with type 2 diabetes. The dose is 50 mg once or twice daily. Adverse reactions include upper respiratory tract infections, nasopharyngitis, dizziness, and headache. Rare cases of hepatic dysfunction, including hepatitis, have been reported. Liver function testing is recommended quarterly during the first year of use and periodically thereafter.

5. Others—Pramlintide is a synthetic analog of islet amyloid polypeptide (IAPP or amylin). When given subcutaneously, it delays gastric emptying, suppresses glucagon secretion, and decreases appetite. It is approved for use both in type 1 diabetes and in insulin-treated type 2 diabetes. In 6-month clinical studies with type 1 and insulin-treated type 2 patients, those taking the medication had an approximately 0.4% reduction in HbA_{1c} and about 1.7 kg weight loss compared with placebo. The HbA_{1c} reduction was sustained for 2 years but some of the weight was regained. The medication is given by injection immediately before the meal. Hypoglycemia can occur, and it is recommended that the short-acting or premixed insulin doses be reduced by 50% when the medication is started. Since the medication slows gastric emptying, recovery from hypoglycemia can be a problem because of delay in absorption of fast-acting carbohydrates. Nausea was the other main side effect, affecting 30–50% of persons but tended to improve with time. In patients with type 1 diabetes, the initial dose of pramlintide is 15 mcg before each meal and titrated up by 15 mcg increments to a maintenance dose of 30 mcg or 60 mcg before each meal. In patients with type 2 diabetes, the starting dose is 60 mcg premeals increased to 120 mcg in 3 to 7 days if no significant nausea occurs.

6. Medication combinations—Several medication combinations are available in different dose sizes, including glyburide and metformin (GlucoVance); glipizide and metformin (Metaglip); repaglinide and metformin (Prandi-Met); rosiglitazone and metformin (Avandamet); pioglitazone and metformin (ACTOplus Met); rosiglitazone and glimepiride (Avandaryl); pioglitazone and glimepiride (Duetact); sitagliptin and metformin (Janumet); saxagliptin and metformin XR (Kombiglyze XR); and linagliptin and metformin (Jentadueto). These medication combinations, however, limit the clinician's ability to optimally adjust dosage of the individual medications and for that reason are not recommended.

C. Insulin

Insulin is indicated for type 1 diabetes as well as for type 2 diabetic patients with insulinopenia whose hyperglycemia does not respond to diet therapy either alone or combined with other hypoglycemic medications.

Table 27–8. Summary of bioavailability characteristics of the insulins.

Insulin Preparations	Onset of Action	Peak Action	Effective Duration
Insulins lispro, aspart, glulisine	5–15 minutes	1–1.5 hours	3–4 hours
Human regular	30–60 minutes	2 hours	6–8 hours
Human NPH	2–4 hours	6–7 hours	10–20 hours
Insulin glargine	1.5 hours	Flat	~24 hours
Insulin detemir	1 hour	Flat	17 hours

With the development of highly purified human insulin preparations, immunogenicity has been markedly reduced, thereby decreasing the incidence of therapeutic complications such as insulin allergy, immune insulin resistance, and localized lipoatrophy at the injection site. However, the problem of achieving optimal insulin delivery remains unsolved with the present state of technology. It has not been possible to reproduce the physiologic patterns of intraportal insulin secretion with subcutaneous injections of short-acting or longer-acting insulin preparations. Even so, with the help of appropriate modifications of diet and exercise and careful monitoring of capillary blood glucose levels at home, it has often been possible to achieve acceptable control of blood glucose by using various mixtures of short- and longer-acting insulins injected at least twice daily or portable insulin infusion pumps.

1. Characteristics of available insulin preparations—

Commercial insulin preparations differ with respect to the time of onset and duration of their biologic action (Table 27–8).

A. SPECIES OF INSULIN—Human insulin is produced by recombinant DNA techniques (biosynthetic human insulin) as Humulin (Eli Lilly) and as Novolin (Novo Nordisk). It is dispensed as either regular (R) or NPH (N) formulations. Five analogs of human insulin—three rapidly acting (insulin lispro, insulin aspart, insulin glulisine) and two long-acting (insulin glargine and insulin detemir)—have been approved by the FDA for clinical use (Table 27–9). Animal insulins are no longer available in the United States.

B. PURITY OF INSULIN—“Purified” insulin is defined by FDA regulations as the degree of purity wherein proinsulin contamination is < 10 ppm. All insulins presently available contain < 10 ppm of proinsulin and are labeled as “purified.” These purified insulins seem to preserve their potency quite well, so that refrigeration is recommended but not crucial. During travel, reserve supplies of insulin can thus be readily transported for weeks without losing potency if protected from extremes of heat or cold.

C. CONCENTRATION OF INSULIN—At present, insulins in the United States are available in a concentration of 100 units/mL (U100), and all are dispensed in 10-mL vials. With the

Table 27-9. Insulin preparations available in the United States.¹**Rapidly acting human insulin analogs**

Insulin lispro (Humalog, Lilly)
 Insulin aspart (Novolog, Novo Nordisk)
 Insulin glulisine (Apidra, Sanofi Aventis)

Short-acting regular insulin

Regular insulin (Lilly, Novo Nordisk)

Intermediate-acting insulins

NPH insulin (Lilly, Novo Nordisk)

Premixed insulins

70% NPH/30% regular (70/30 insulin—Lilly, Novo Nordisk)
 70% NPL/25% insulin lispro (Humalog Mix 75/25—Lilly)
 50% NPL/50% insulin lispro (Humalog Mix 50/50—Lilly)
 70% insulin aspart protamine/30% insulin aspart (Novolog Mix 70/30—Novo Nordisk)

Long-acting human insulin analogs


Insulin glargine (Lantus, Sanofi Aventis)
 Insulin detemir (Levemir, Novo Nordisk)

¹All insulins available in the United States are recombinant human or human insulin analog origin. All the above insulins are dispensed at U100 concentration. There is an additional U500 preparation of regular insulin.

NPH, neutral protamine Hagedorn.

popularity of “low-dose” (0.5- or 0.3-mL) disposable insulin syringes, U100 can be measured with acceptable accuracy in doses as low as 1–2 units. For use in rare cases of severe insulin resistance in which large quantities of insulin are required, U500 regular human insulin (Humulin R) is available from Eli Lilly.

2. Insulin preparations—Insulins are classified into short-acting and long-acting insulin preparations. The short-acting preparations are regular insulin and the rapidly acting insulin analogs (Figure 27-3). They are dispensed as clear solutions at neutral pH and contain small amounts of zinc to improve their stability and shelf life. The long-acting preparations are NPH insulin and the long-acting insulin analogs. NPH insulin is dispensed as a turbid suspension at neutral pH with protamine in phosphate buffer. The long-acting insulin analogs are also dispensed as clear solutions; insulin glargine is at acidic pH and insulin detemir is at neutral pH. The rapidly acting insulin analogs and the long-acting insulins are designed for subcutaneous administration, while regular insulin can also be given intravenously. While insulin aspart has been approved for intravenous use (eg, in hyperglycemic emergencies), there is no advantage in using insulin aspart over regular insulin by this route.



▲ Figure 27-3. Extent and duration of action of various types of insulin-euglycemic hyperinsulinemic clamps in normal volunteers. **A.** Intermediate neutral protamine Hagedorn (NPH) insulin and long-acting insulin analogs. **B.** Regular insulin and rapidly acting insulin analogs.

A. SHORT-ACTING INSULIN PREPARATIONS—

(1) *Regular insulin*—Regular insulin is a short-acting soluble crystalline zinc insulin whose effect appears within 30 minutes after subcutaneous injection and lasts 5–7 hours when usual quantities are administered. Intravenous infusions of regular insulin are particularly useful in the treatment of diabetic ketoacidosis and during the perioperative management of insulin-requiring diabetics. Regular insulin is indicated when the subcutaneous insulin requirement is changing rapidly, such as after surgery or during acute infections—although the rapidly acting insulin analogs may be preferable in these situations.

For markedly insulin-resistant persons who would otherwise require large volumes of insulin solution, a U500 preparation of human regular insulin is available. Since a U500 syringe is not available, when U500 insulin is required in cases of severe insulin resistance, a U100 insulin syringe or tuberculin syringe must be used to measure doses. The clinician should carefully note dosages in both units and volume to avoid overdosage.

(2) *Rapidly acting insulin analogs*—Insulin lispro (Humalog) is an insulin analog produced by recombinant technology, wherein two amino acids near the carboxyl terminal of the B chain have been reversed in position: Proline at position B28 has been moved to B29 and lysine has been moved from B29 to B28. Insulin aspart (Novolog) is a single substitution of proline by aspartic acid at position B28. Insulin glulisine (Apidra) differs from human insulin in that the amino acid asparagine at position B3 is replaced by lysine and the lysine in position B29 by glutamic acid. These changes result in these three analogs having less tendency to form hexamers, in contrast to human insulin. When injected subcutaneously, the analogs quickly dissociate into monomers and are absorbed very rapidly, reaching peak serum values in as soon as 1 hour—in contrast to regular human insulin, whose hexamers require considerably more time to dissociate and become absorbed. The amino acid changes in these analogs do not interfere with their binding to the insulin receptor, with the circulating half-life, or with their immunogenicity, which are all identical with those of human regular insulin.

Clinical trials have demonstrated that the optimal times of preprandial subcutaneous injection of comparable doses of the rapidly acting insulin analogs and of regular human insulin are 20 minutes and 60 minutes, respectively, before the meal. While this more rapid onset of action has been welcomed as a great convenience by diabetic patients who object to waiting as long as 60 minutes after injecting regular human insulin before they can begin their meal, patients must be taught to ingest adequate absorbable carbohydrate early in the meal to avoid hypoglycemia during the meal. Another desirable feature of rapidly acting insulin analogs is that their duration of action remains at about 4 hours irrespective of dosage. This contrasts with regular insulin, whose duration of action is prolonged when larger doses are used.

The rapidly acting analogs are also commonly used in pumps. In a double-blind crossover study comparing insulin lispro with regular insulin in insulin pumps, persons using insulin lispro had lower HbA_{1c} values and improved

postprandial glucose control with the same frequency of hypoglycemia. The concern remains that in the event of pump failure, users of the rapidly acting insulin analogs will have more rapid onset of hyperglycemia and ketosis.

B. LONG-ACTING INSULIN PREPARATIONS—

(1) *NPH (neutral protamine Hagedorn or isophane) insulin*—NPH is an intermediate-acting insulin whose onset of action is delayed by combining 2 parts soluble crystalline zinc insulin with 1 part protamine zinc insulin. This produces equivalent amounts of insulin and protamine, so that neither is present in an uncomplexed form (“isophane”).

Its onset of action is delayed to 2–4 hours, and its peak response is generally reached in about 8–10 hours. Because its duration of action is often < 24 hours (with a range of 10–20 hours), most patients require at least two injections daily to maintain a sustained insulin effect. Occasional vials of NPH insulin have tended to show unusual clumping of their contents or “frosting” of the container, with considerable loss of bioactivity. This instability is rare and occurs less frequently if NPH human insulin is refrigerated when not in use and if bottles are discarded after 1 month of use.

(2) *Insulin glargine*—Insulin glargine is an insulin analog in which the asparagine at position 21 of the A chain of the human insulin molecule is replaced by glycine and two arginines are added to the carboxyl terminal of the B chain. The arginines raise the isoelectric point of the molecule closer to neutral, making it more soluble in an acidic environment. In contrast, human insulin has an isoelectric point of pH 5.4. Insulin glargine is a clear insulin which, when injected into the neutral pH environment of the subcutaneous tissue, forms microprecipitates that slowly release the insulin into the circulation. It lasts for about 24 hours without any pronounced peaks and is given once a day to provide basal coverage. This insulin cannot be mixed with the other human insulins because of its acidic pH. When this insulin was given as a single injection at bedtime to type 1 patients, fasting hyperglycemia was better controlled when compared with bedtime NPH insulin. The clinical trials also suggest that there may be less nocturnal hypoglycemia with this insulin when compared with NPH insulin.

In one clinical trial involving type 2 patients, insulin glargine was associated with a slightly higher progression of retinopathy when compared with NPH insulin. The frequency was 7.5% with the analog and 2.7% with the NPH. However, this observation was not confirmed in a 5-year open-label prospective study of 1024 persons randomized to NPH or insulin glargine. Insulin glargine does have a sixfold greater affinity for IGF-1 receptor compared with the human insulin. There has also been a report that insulin glargine had increased mitogenicity compared with human insulin in a human osteosarcoma cell line. The significance of these observations is not yet clear. An observational study from Germany of 127,031 patients who had exposure to regular insulin, short-acting insulin analogs, and insulin glargine reported a strong correlation between increased insulin dose and cancer risk. Moreover, insulin glargine, dose for dose, appeared to carry a higher risk of

cancer than regular insulin. Additional studies are needed to confirm or refute this observation. Because of lack of safety data, use of insulin glargine during pregnancy is not recommended.

(3) Insulin detemir—Insulin detemir is an insulin analog in which the tyrosine at position 30 of the β chain has been removed and a 14-C fatty acid chain (tetradecanoic acid) is attached to the lysine at position 29 by acylation. The fatty acid chain makes the molecule more lipophilic than native insulin and the addition of zinc stabilizes the molecule and leads to formation of hexamers. After injection, self-association at the injection site and albumin binding in the circulation via the fatty acid side chain, leads to slower distribution to peripheral target tissues and prolonged duration of action. The affinity of insulin detemir is fourfold to fivefold lower than that of human soluble insulin and therefore the U100 formulation of insulin detemir has an insulin concentration of 2400 nmol/mL compared with 600 nmol/mL for NPH. The duration of action for insulin detemir is about 17 hours at therapeutically relevant doses. It is recommended that the insulin be injected once or twice a day to achieve a stable basal coverage. This insulin has been reported to have lower within-subject pharmacodynamic variability compared with NPH insulin and insulin glargine. In vitro studies do not suggest any clinically relevant albumin binding interactions between insulin detemir and fatty acids or protein-bound medications. Since there is a vast excess (~400,000) of albumin binding sites available in plasma per insulin detemir molecule, it is unlikely that hypoalbuminemic disease states will affect the ratio of bound to free insulin detemir.

C. MIXED INSULIN PREPARATIONS—Since intermediate insulins require several hours to reach adequate therapeutic levels, their use in patients with type 1 diabetes requires supplements of regular or rapidly acting insulin analogs preprandially. For convenience, regular or rapidly acting insulin analogs and NPH insulin may be mixed together in the same syringe and injected subcutaneously in split dosage before breakfast and supper. It is recommended that the regular insulin or rapidly acting insulin analog be withdrawn first, then the NPH insulin and that the injection be given immediately after loading the syringe. Stable premixed insulins (70% NPH and 30% regular) are available as a convenience to patients who have difficulty mixing insulin because of visual problems or impairment of manual dexterity. Premixed preparations of insulin lispro and NPH insulins are unstable because of exchange of insulin lispro with the human insulin in the protamine complex. Consequently, the soluble component becomes over time a mixture of regular and insulin lispro at varying ratios. In an attempt to remedy this, an intermediate insulin composed of isophane complexes of protamine with insulin lispro was developed called NPL (neutral protamine lispro). This insulin has the same duration of action as NPH insulin. Premixed combinations of NPL and insulin lispro—(75% NPL/25% insulin lispro mixture [Humalog Mix 75/25] and 50% NPL/50% insulin lispro mixture [Humalog Mix 50/50]) are available for clinical use. Similarly, a 70% insulin aspart protamine/30% insulin aspart (NovoLog Mix 70/30) is available. The main advantages of

these mixtures are that they can be given within 15 minutes of starting a meal and they are superior in controlling the postprandial glucose rise after a carbohydrate rich meal. These benefits have not translated into improvements in HbA_{1c} levels when compared with the usual 70% NPH/30% regular mixture.

The longer-acting insulin analogs cannot be mixed with either regular insulin or the rapidly acting insulin analogs.

3. Methods of insulin administration

A. INSULIN SYRINGES AND NEEDLES—Plastic disposable syringes are available in 1 mL, 0.5 mL, and 0.3 mL sizes. The “low-dose” 0.3 mL syringes have become increasingly popular, because many diabetics do not take more than 30 units of insulin in a single injection except in rare instances of extreme insulin resistance. Two lengths of needles are available: short (8 mm) and long (12.7 mm). Long needles are preferable in obese patients to reduce variability of insulin absorption. Ultrafine needles as small as 31 gauge reduce the pain of injections. “Disposable” syringes may be reused until blunting of the needle occurs (usually after three to five injections). Sterility adequate to avoid infection with reuse appears to be maintained by recapping syringes between uses. Cleansing the needle with alcohol may not be desirable since it can dissolve the silicone coating and can increase the pain of skin puncturing.

Any part of the body covered by loose skin can be used, such as the abdomen, thighs, upper arms, flanks, and upper buttocks. Preparation with alcohol is no longer required prior to injection as long as the skin is clean. Rotation of sites continues to be recommended to avoid delayed absorption when fibrosis or lipohypertrophy occurs from repeated use of a single site. However, considerable variability of absorption rates from different sites, particularly with exercise, may contribute to the instability of glycemic control in certain type 1 patients if injection sites are rotated too frequently in different areas of the body. Consequently, it is best to limit injection sites to a single region of the body and rotate sites within that region. The abdomen is recommended for subcutaneous injections, since regular insulin has been shown to absorb more rapidly from there than from other subcutaneous sites. The effect of anatomic regions appears to be much less pronounced with the analog insulins.

B. INSULIN PEN INJECTOR DEVICES—Insulin pens eliminate the need for carrying insulin vials and syringes. Cartridges of insulin lispro, insulin aspart, and insulin glargine are available for reusable pens (Eli Lilly, Novo Nordisk, Owen Mumford, and Sanofi Aventis pens). Disposable prefilled pens are also available for insulin lispro, insulin aspart, insulin glulisine, insulin detemir, insulin glargine, NPH, 70% NPH/30% regular, 75% NPL/25% insulin lispro, 50% NPL/50% insulin lispro, and 70% insulin aspart protamine/30% insulin aspart. Thirty-one gauge needles (5, 6, and 8 mm long) for these pens make injections almost painless.

C. INSULIN PUMPS—In the United States, Medtronic Mini-Med, Animas, Insulet, and Roche make insulin infusion pumps for subcutaneous delivery of insulin. These pumps are small (about the size of a pager) and very easy to

program. They offer many features, including the ability to set a number of different basal rates throughout the 24 hours and to adjust the time over which bolus doses are given. They also are able to detect pressure build-up if the catheter is kinked. Improvements have also been made in the infusion sets. The catheter connecting the insulin reservoir to the subcutaneous cannula can be disconnected, allowing the patient to remove the pump temporarily (eg, for bathing). Ominpod (Insulet Corporation) is an insulin infusion system in which the insulin reservoir and infusion set are integrated into one unit (pod), so there is no catheter. The pod, placed on the skin, delivers subcutaneous basal and bolus insulin based on wirelessly transmitted instructions from a personal digital assistant. The great advantage of continuous subcutaneous insulin infusion (CSII) is that it allows for establishment of a basal profile tailored to the patient. The patient therefore is able to eat with less regard to timing because the basal insulin infusion should maintain constant blood glucose between meals. Also the ability to adjust the basal insulin infusion makes it easier for the patient to manage glycemic excursions that occur with exercise. The pumps also have software that can assist the patient to calculate boluses based on glucose reading and carbohydrates to be consumed. They keep track of the time elapsed since last insulin bolus and the patient is reminded of this when he or she attempts to give additional correction bolus before the effect of the previous bolus has worn off ("insulin on board" feature). This feature reduces the risk of overcorrecting and subsequent hypoglycemia.

CSII therapy is appropriate for patients with type 1 diabetes who are motivated, mechanically inclined, educated about diabetes (diet, insulin action, treatment of hypoglycemia and hyperglycemia), and willing to monitor their blood glucose four to six times a day. Known complications of CSII include ketoacidosis, which can occur when insulin delivery is interrupted, and skin infections. Another disadvantage is its cost and the time demanded of physicians and staff in initiating therapy.

D. INHALED INSULIN—Exubera, the first inhaled insulin preparation approved by the FDA is no longer available; the manufacturer stopped marketing it because of lack of demand. In clinical trials, Exubera was as effective as subcutaneous regular insulin in controlling postprandial glucose excursions. Physicians, however, were reluctant to prescribe Exubera for a number of reasons, including a lack of long-term safety data on pulmonary function, awkward dosing schedule, availability of other insulin delivery systems, cost, and lack of insurance coverage. The manufacturer also subsequently reported that there were six cases of lung cancer in patients who used inhaled insulin and one case in the comparison treatment patients. All the patients in whom lung cancer developed had a history of cigarette smoking. There is currently only one pharmaceutical company conducting clinical trials with inhaled insulin (Technosphere insulin, MannKind Corporation).

D. Transplantation

Pancreas transplantation at the time of kidney transplantation is becoming more widely accepted. Patients

undergoing simultaneous pancreas and kidney transplantation have an 85% chance of pancreatic graft survival and a 92% chance of kidney graft survival after 1 year. Solitary pancreatic transplantation in the absence of a need for kidney transplantation should be considered only in those rare patients who fail all other insulin therapeutic approaches and who have frequent severe hypoglycemia or who have life-threatening complications related to their lack of metabolic control.

Islet cell transplantation is a minimally invasive procedure, and investigators in Edmonton, Canada, have reported initial insulin independence in a small number of patients with type 1 diabetes who underwent this procedure. Using islets from multiple donors and corticosteroid-free immunosuppression, percutaneous transhepatic portal vein transplantation of islets was achieved in over 20 subjects. Although all of the initial cohort was able to achieve insulin independence posttransplantation (some for more than 2 years of follow-up), a decline in insulin secretion has occurred over time and the subjects have again required supplemental insulin. All patients had complete correction of severe hypoglycemic reactions, leading to a marked improvement in overall quality of life. Islet cell transplant trials with different kinds and combinations of immunosuppressive agents are currently underway. Even if long-term insulin independence is demonstrated, wide application of this procedure for the treatment of type 1 diabetes is limited by the dependence on multiple donors and the requirement for potent long-term immunotherapy.

Bennett WL et al. Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations. *Ann Intern Med.* 2011 May 3;154(9):602–13. [Erratum in: *Ann Intern Med.* 2011 Jul 5;155(1):67–8. [PMID: 21403054]

Drucker DJ et al. Incretin-based therapies for the treatment of type 2 diabetes: evaluation of the risks and benefits. *Diabetes Care.* 2010 Feb;33(2):428–33. [PMID: 20103558]

Jeitler K et al. Continuous subcutaneous insulin infusion versus multiple daily insulin injections in patients with diabetes mellitus: systematic review and meta-analysis. *Diabetologia.* 2008 Jun;51(6):941–51. [PMID: 18351320]

Shapiro AM. Strategies toward single-donor islets of Langerhans transplantation. *Curr Opin Organ Transplant.* 2011 Dec; 16(6):627–31. [PMID: 22068022]

Tahrani AA et al. Glycaemic control in type 2 diabetes: targets and new therapies. *Pharmacol Ther.* 2010 Feb;125(2):328–61. [PMID: 19931305]

Waugh N et al. Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation. *Health Technol Assess.* 2010 Jul;14(36):1–248. [PMID: 20646668]

White SA et al. Pancreas transplantation. *Lancet.* 2009 May 23; 373(9677):1808–17. [PMID: 19465236]

► Steps in the Management of the Diabetic Patient

A. Diagnostic Examination

Any features of the clinical picture that suggest end-organ insensitivity to insulin, such as visceral obesity, must be identified. The family history should document not only the incidence of diabetes in other members of the family

but also the age at onset, whether it was associated with obesity, and whether insulin was required. An attempt should be made to characterize the diabetes as type 1 or type 2, based on the clinical features present and on whether or not ketonuria accompanies the glycosuria. For the occasional patient, measurement of ICA, GAD65, IAA, and ICA 512 antibodies can help distinguish between type 1 and type 2 diabetes. Many patients with newly diagnosed type 1 diabetes still have significant endogenous insulin production, and C peptide levels do not reliably distinguish between type 1 and type 2 diabetes. Other factors that increase cardiac risk, such as smoking history, presence of hypertension or hyperlipidemia, or oral contraceptive pill use, should be recorded.

Laboratory diagnosis should document fasting plasma glucose levels above 126 mg/dL (7 mmol/L) or postprandial values consistently above 200 mg/dL (11.1 mmol/L) and whether ketonuria accompanies the glycosuria. A glycohemoglobin measurement is useful for assessing the effectiveness of future therapy. Some flexibility of clinical judgment is appropriate when diagnosing diabetes mellitus in the elderly patient with borderline hyperglycemia.

Baseline values include fasting plasma triglycerides, total cholesterol and HDL-cholesterol, electrocardiography, kidney function studies, peripheral pulses, and neurologic, podiatric, and ophthalmologic examinations to help guide future assessments.

B. Patient Education (Self-Management Training)

Since diabetes is a lifelong disorder, education of the patient and the family is probably the most important obligation of the clinician who provides initial care. The best persons to manage a disease that is affected so markedly by daily fluctuations in environmental stress, exercise, diet, and infections are the patients themselves and their families. The “teaching curriculum” should include explanations by the physician or nurse of the nature of diabetes and its potential acute and chronic hazards and how they can be recognized early and prevented or treated. Self-monitoring of blood glucose should be emphasized, especially in insulin-requiring diabetic patients, and instructions must be given on proper testing and recording of data.

Patients taking insulin should have an understanding of the actions of basal and bolus insulins. They should be taught to determine whether the basal dose is appropriate and how to adjust the rapidly acting insulin dose for the carbohydrate content of a meal. Patients and their families and friends should be taught to recognize signs and symptoms of hypoglycemia and how to treat low glucose reactions. Strenuous exercise can precipitate hypoglycemia, and patients must therefore be taught to reduce their insulin dosage in anticipation of strenuous activity or to take supplemental carbohydrate. Injection of insulin into a site farthest away from the muscles most involved in the exercise may help ameliorate exercise-induced hypoglycemia, since insulin injected in the proximity of exercising muscle may be more rapidly mobilized. Exercise training also increases the effectiveness of insulin and insulin doses should be adjusted accordingly. Infections can cause

insulin resistance, and patients should be instructed on how to manage the hyperglycemia with supplemental rapidly acting insulin.

The targets for blood glucose control should be elevated appropriately in elderly patients since they have the greatest risk if subjected to hypoglycemia and the least long-term benefit from more rigid glycemic control. Advice on personal hygiene, including detailed instructions on foot and dental care, should be provided. All infections (especially pyogenic ones) provoke the release of high levels of insulin antagonists, such as catecholamines or glucagon, and thus bring about a marked increase in insulin requirements. Patients who are taking oral agents may decompensate and temporarily require insulin. Patients should be told about community agencies, such as Diabetes Association chapters, that can serve as a continuing source of instruction.

Finally, vigorous efforts should be made to persuade new diabetics who smoke to give up the habit, since large vessel peripheral vascular disease and debilitating retinopathy are less common in nonsmoking diabetic patients.

C. Therapy

Treatment must be individualized on the basis of the type of diabetes and specific needs of each patient. However, certain general principles of management can be outlined for hyperglycemic states of different types.

1. Type 1 diabetes—Traditional once- or twice-daily insulin regimens are usually ineffective in type 1 patients without residual endogenous insulin. In these patients, information and counseling based on the findings of the DCCT (see above) should be provided about the advantages of taking multiple injections of insulin in conjunction with self-blood glucose monitoring. If near-normalization of blood glucose is attempted, at least four measurements of capillary blood glucose and three or four insulin injections are necessary.

A combination of rapidly acting insulin analogs and long-acting insulin analogs allows for more physiologic insulin replacement. The rapidly acting insulin analogs have been advocated as a safer and much more convenient alternative to regular human insulin for preprandial use. In a study comparing regular insulin with insulin lispro, daily insulin doses and HbA_{1c} levels were similar, but insulin lispro improved postprandial control, reduced hypoglycemic episodes, and improved patient convenience compared with regular insulin. However, because of their relatively short duration (no more than 3–4 hours), the rapidly acting insulin analogs need to be combined with longer-acting insulins to provide basal coverage and avoid hyperglycemia prior to the next meal. In addition to carbohydrate content of the meal, the effect of simultaneous fat ingestion must also be considered a factor in determining the rapidly acting insulin analog dosage required to control the glycemic increment during and just after the meal. With low-carbohydrate content and high-fat intake, there is an increased risk of hypoglycemia from insulin lispro within 2 hours after the meal. Table 27–10 illustrates a regimen with a rapidly acting insulin analog and insulin detemir or insulin glargine

Table 27-10. Examples of intensive insulin regimens using rapidly acting insulin analogs (insulin lispro, aspart, or glulisine) and insulin detemir, or insulin glargine in a 70-kg man with type 1 diabetes.¹⁻³

	Pre-Breakfast	Pre-Lunch	Pre-Dinner	At Bedtime
Rapidly acting insulin analog	5 units	4 units	6 units	
Insulin detemir	6-7 units			8-9 units
OR				
Rapidly acting insulin analog	5 units	4 units	6 units	—
Insulin glargine		—		15-16 units

¹Assumes that patient is consuming approximately 75 g carbohydrate at breakfast, 60 g at lunch, and 90 g at dinner.

²The dose of rapidly acting insulin can be raised by 1 or 2 units if extra carbohydrate (15-30 g) is ingested or if premeal blood glucose is > 170 mg/dL (9.4 mmol/L).

³Insulin glargine or insulin detemir must be given as a separate injection.

that might be appropriate for a 70-kg person with type 1 diabetes eating meals providing standard carbohydrate intake and moderate to low fat content.

Insulin glargine is usually given once in the evening to provide 24-hour coverage. This insulin *cannot be mixed* with any of the other insulins and must be given as a separate injection. There are occasional patients in whom insulin glargine does not seem to last for 24 hours, and in such cases it needs to be given twice a day. As shown, insulin detemir may also need to be given twice a day to get adequate 24-hour basal coverage. Alternatively, small doses of NPH (~ 3-4 units) can be given with each meal to provide daytime basal coverage with a larger dose at night. Unlike the long-acting insulin analogs, NPH can be mixed in the same syringe as the insulin lispro, insulin aspart, and insulin glulisine.

Continuous subcutaneous insulin infusion (CSII) by portable battery-operated “open loop” devices currently

provides the most flexible approach, allowing the setting of different basal rates throughout the 24 hours and permitting patients to delay or skip meals and vary meal size and composition. The dosage is usually based on providing 50% of the estimated insulin dose as basal and the remainder as intermittent boluses prior to meals. For example, a 70-kg man requiring 35 units of insulin per day may require a basal rate of 0.7 units per hour throughout the 24 hours with the exception of 3 AM to 8 AM, when 0.8 units per hour might be appropriate (given the “dawn phenomenon”—reduced tissue sensitivity to insulin between 5 AM and 8 AM). The meal bolus would depend on the carbohydrate content of the meal and the premeal blood glucose value. One unit per 15 g of carbohydrate plus 1 unit for 50 mg/dL (2.8 mmol/L) of blood glucose above a target value (eg, 120 mg/dL [6.7 mmol/L]) is a common starting point. Further adjustments to basal and bolus dosages would depend on the results of blood glucose monitoring. The majority of patients use the rapidly acting insulin analogs in the pumps. One of the more difficult therapeutic problems in managing patients with type 1 diabetes is determining the proper adjustment of insulin dose when the prebreakfast blood glucose level is high. Occasionally, the prebreakfast hyperglycemia is due to the Somogyi effect, in which nocturnal hypoglycemia leads to a surge of counter-regulatory hormones to produce high blood glucose levels by 7 AM. However, a more common cause for prebreakfast hyperglycemia is the waning of circulating insulin levels by the morning. Also, the dawn phenomenon is present in as many as 75% of type 1 patients and can aggravate the hyperglycemia.

Table 27-11 shows that diagnosis of the cause of prebreakfast hyperglycemia can be facilitated by self-monitoring of blood glucose at 3 AM in addition to the usual bedtime and 7 AM measurements. This is required for only a few nights, and when a particular pattern emerges from monitoring blood glucose levels overnight, appropriate therapeutic measures can be taken. The Somogyi effect can be treated by eliminating the dose of intermediate insulin at dinnertime and giving it at a lower dosage at bedtime or by supplying more food at bedtime. When a waning insulin level is the cause, then either increasing the evening dose or shifting it from dinnertime to bedtime (or both) can be

Table 27-11. Prebreakfast hyperglycemia: Classification by blood glucose and insulin levels.

	Blood Glucose (mg/dL) [mmol/L]			Free Immunoreactive Insulin (microunit/mL)		
	10:00 PM	3:00 AM	7:00 AM	10:00 PM	3:00 AM	7:00 AM
Somogyi effect	90 [5]	40 [2.2]	200 [11.1]	High	Slightly high	Normal
Dawn phenomenon	110 [6.1]	110 [6.1]	150 [8.3]	Normal	Normal	Normal
Waning of insulin dose plus dawn phenomenon	110 [6.1]	190 [10.6]	220 [12.2]	Normal	Low	Low
Waning of insulin dose plus dawn phenomenon plus Somogyi effect	110 [6.1]	40 [2.2]	380 [21.1]	High	Normal	Low

effective. A bedtime dose either of insulin glargine or insulin detemir provides more sustained overnight insulin levels than human NPH and may be effective in managing refractory prebreakfast hyperglycemia. If this fails, insulin pump therapy may be required. When the dawn phenomenon alone is present, the dosage of intermediate insulin can be divided between dinnertime and bedtime; when insulin pumps are used, the basal infusion rate can be increased (eg, from 0.8 unit/h to 0.9 unit/h from 6 AM until breakfast).

2. Type 2 diabetes—Therapeutic recommendations are based on the relative contributions of beta cell insufficiency and insulin insensitivity in individual patients. The possibility that the individual patient has a specific etiologic cause for their diabetes should always be considered, especially when the patient does not have a family history of type 2 diabetes or does not have any evidence of central obesity or insulin resistance. Such patients should be evaluated for other types of diabetes such as LADA or MODY. Patients with LADA should be prescribed insulin when the disease is diagnosed and treated like patients with type 1 diabetes. It is also important to note that many patients with type 2 diabetes mellitus have a progressive loss of beta cell function and will require additional therapeutic interventions with time.

A. WEIGHT REDUCTION—One of the primary modes of therapy in the obese patient with type 2 diabetes is weight reduction. Normalization of glycemia can be achieved by weight loss and improvement in tissue sensitivity to insulin. A combination of caloric restriction, increased exercise, and behavior modification is required if a weight reduction program is to be successful. Understanding the risks associated with the diagnosis of diabetes may motivate the patient to lose weight.

For selected patients, medical or surgical options for weight loss should be considered (see Chapter 29). Sibutramine, a combined serotonin-norepinephrine reuptake inhibitor, was moderately effective in promoting weight loss, but it was withdrawn from the US market because of its association with increased cardiovascular risk. Orlistat is a reversible inhibitor of gastric and pancreatic lipases and prevents the hydrolysis and absorption of dietary triglycerides. It is available over-the-counter and in prescription strength. In 1-year studies in obese patients with type 2 diabetes, those taking orlistat had lost more weight, had lower HbA_{1c} values, and had improved lipid profiles. The main adverse reactions were gastrointestinal, with oily spotting, oily stool, flatus, and fecal urgency and frequency. Malabsorption of fat-soluble vitamins also occurs, and patients should take a multivitamin tablet containing fat-soluble vitamins at least 2 hours before or 2 hours after the administration of orlistat. Cases of severe liver injury have been reported with this medication, although a cause and effect relationship has not been established.

Bariatric surgery (Roux-en-Y, gastric banding, gastric sleeve, biliopancreatic diversion/duodenal switch) typically results in substantial weight loss and improvement in glucose levels. A meta-analysis examining the impact of bariatric surgery on patients with diabetes and BMI of 40 kg/m²

or greater noted that 82% of patients had resolution of clinical and laboratory manifestations of diabetes in the first 2 years after surgery and 62% remained free of diabetes more than 2 years after surgery. The improvement was most marked in the procedure that caused the greatest weight loss (biliopancreatic diversion/duodenal switch). There was, however, a high attrition of patients available for follow-up, and there was little information about different ethnic types. Weight regain does occur after bariatric surgery, and it can be expected that 20–25% of the lost weight will be regained over 10 years. The impact of this weight gain on diabetes recurrence depends principally on the degree of beta cell dysfunction. Also anatomic changes imposed by malabsorptive surgery can result in protein malnutrition, vitamin and mineral deficiencies. Clinically significant deficiencies in calcium; folic acid; iron; and vitamins D, B₁₂, A, and K are common. Thus, patients undergoing malabsorptive procedures require lifelong supplementation and monitoring by a team familiar with possible deficiencies. Both early and late dumping symptoms can also occur.

Nonobese patients with type 2 diabetes frequently have increased visceral adiposity—the so-called metabolically obese normal weight patient. There is less emphasis on weight loss, but exercise remains an important aspect of treatment.

B. GLUCOSE LOWERING AGENTS—The current recommendation is to start metformin therapy at diagnosis and not wait to see whether the patient can achieve target glycemic control with weight management and exercise. **Metformin** is advantageous because, apart from lowering glucose without the risk of hypoglycemia, it also lowers serum triglycerides and promotes some modest weight loss. In the UKPDS study, metformin use in the obese participants was associated with reduction in risk of cardiovascular events. The medication, however, cannot be used in patients with end-stage renal disease, and sometimes gastrointestinal side effects develop at even the lowest doses and persist over time. Under these circumstances the choice of the initial agent depends on a number of factors, including comorbid conditions, adverse reactions to the medications, ability of the patient to monitor for hypoglycemia, medication cost, and patient and clinician preferences. **Sulfonylureas** have been available for many years and their use in combination with metformin is well established. They do, however, have the propensity of causing hypoglycemia and weight gain. **Pioglitazone** improves peripheral insulin resistance and lowers glucose without causing hypoglycemia. Troublesome adverse reactions include weight gain, fluid retention and heart failure, increased fracture risk in women, and possible increased risk of bladder cancer. Pioglitazone is contraindicated in patients with active liver disease and in patients with liver enzymes ≥ 2.5 times the upper limit of normal. The **α -glucosidase inhibitors** have modest glucose lowering effects and have gastrointestinal side effects. The **GLP-1 receptor agonists (exenatide and liraglutide)** have a lower risk of hypoglycemia than the sulfonylureas and they promote weight loss. However, they need to be given by injection, cause nausea, may cause pancreatitis, and are contraindicated in patients

with gastroparesis. The **DPP-4 inhibitors (sitagliptin and saxagliptin)** also have a low risk of hypoglycemia, and they do not cause nausea or vomiting. They can also be used in patients with kidney impairment. There are, however, reports of serious allergic reactions, including anaphylaxis, angioedema, and Stevens-Johnson syndrome. There is also concern that they may, like the GLP-1 receptor agonists, cause pancreatitis.

When diabetes is not well controlled with initial therapy (usually metformin), then a second agent should be added. In patients who experience hyperglycemia after a carbohydrate-rich meal (such as dinner), a short-acting secretagogue before meals may suffice to get the glucose levels into the target range. Patients with severe insulin resistance may be candidates for pioglitazone. Patients who are very concerned about weight gain may benefit from a trial of GLP-1 receptor agonist or DPP-4 inhibitor. If two agents are inadequate, then a third agent is added, although data regarding efficacy of such combined therapy are limited.

When the combination of oral agents (and injectable GLP-1 receptor agonists) fail to achieve euglycemia in patients with type 2 diabetes, then insulin treatment should be instituted. Various insulin regimens may be effective. One proposed regimen is to continue the oral combination therapy and then simply add a bedtime dose of NPH or long-acting insulin analog (insulin glargine or insulin detemir) to reduce excessive nocturnal hepatic glucose output and improve fasting glucose levels. If the patient does not achieve target glucose levels during the day, then daytime insulin treatment can be initiated. A convenient insulin regimen under these circumstances is a split dose of 70/30 NPH/regular mixture (or Humalog Mix 75/25 or NovoLogMix 70/30) before breakfast and before dinner. If this regimen fails to achieve satisfactory glycemic goals or is associated with unacceptable frequency of hypoglycemic episodes, then a more intensive regimen of multiple insulin injections can be instituted as in patients with type 1 diabetes. Metformin principally reduces hepatic glucose output, and it is reasonable to continue with this medication when insulin therapy is instituted. Pioglitazone, which improves peripheral insulin sensitivity, can be used together with insulin but this combination is associated with more weight gain and peripheral edema. The sulfonylureas also continue to be of benefit. There is limited information on the benefits of continuing the GLP-1-receptor agonists or the DPP-4 inhibitors once insulin therapy is initiated. Weight-reducing interventions should continue even after initiation of insulin therapy and may allow for simplification of the therapeutic regimen in the future.

D. Acceptable Levels of Glycemic Control

A reasonable aim of therapy is to approach normal glycemic excursions without provoking severe or frequent hypoglycemia. What has been considered “acceptable” control includes blood glucose levels of 90–130 mg/dL (5–7.2 mmol/L) before meals and after an overnight fast, and levels no higher than 180 mg/dL (10 mmol/L) 1 hour after meals and 150 mg/dL (8.3 mmol/L) 2 hours after meals. HbA_{1c} levels < 7% are a reasonable goal for nonpregnant adults.

Less stringent HbA_{1c} goals may be appropriate in children, those with a history of severe hypoglycemia, limited life expectancy, and advanced microvascular and macrovascular disease. In the elderly frail patient, an HbA_{1c} target of approximately 8% may be reasonable although formal evidence is lacking. It should be emphasized that the value of blood pressure control was as great as or greater than glycemic control in type 2 patients as regards microvascular as well as macrovascular complications.

Buchwald H et al. Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. *Am J Med.* 2009 Mar;122(3):248–256.e5. [PMID: 19272486]

Heber D et al. Endocrine and nutritional management of the post-bariatric surgery patient: an Endocrine Society Clinical Practice Guideline. *J Clin Endocrinol Metab.* 2010 Nov;95(11): 4823–43. [PMID: 21051578]

Karra E et al. Mechanisms facilitating weight loss and resolution of type 2 diabetes following bariatric surgery. *Trends Endocrinol Metab.* 2010 Jun;21(6):337–44. [PMID: 20133150]

Mooradian AD et al. Narrative review: a rational approach to starting insulin therapy. *Ann Intern Med.* 2006 Jul 18;145(2): 125–34. [PMID: 16847295]

Nathan DM et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. *Diabetes Care.* 2009 Jan;32(1):193–203. [PMID: 18945920]

Zinman B et al; American Diabetes Association. Physical activity/exercise and diabetes. *Diabetes Care.* 2004 Jan;27(Suppl 1): S58–62. [PMID: 14693927]

E. Complications of Insulin Therapy

1. Hypoglycemia—Hypoglycemic reactions are the most common complications that occur in patients with diabetes who are treated with insulin. Hypoglycemia may result from delay in taking a meal or from unusual physical exertion without supplemental calories or decrease in insulin dose. In addition, hypoglycemia can occur in patient taking sulfonylureas, repaglinide, and nateglinide, particularly if the patient is elderly, has kidney or liver disease, or is taking certain other medications that alter metabolism of the sulfonylureas (eg, phenylbutazone, sulfonamides, or warfarin). It occurs more frequently with the use of long-acting sulfonylureas than when shorter-acting agents are used.

The signs and symptoms of hypoglycemia may be divided into those resulting from stimulation of the autonomic nervous system and those from neuroglycopenia (insufficient glucose for normal central nervous system function). When the blood glucose falls to around 54 mg/dL (3 mmol/L), the patient starts to experience both sympathetic (tachycardia, palpitations, sweating, tremulousness) and parasympathetic (nausea, hunger) nervous system symptoms. If these autonomic symptoms are ignored and the glucose levels fall further (to around 50 mg/dL [2.8 mmol/L]), then neuroglycopenic symptoms appear, including irritability, confusion, blurred vision, tiredness, headache, and difficulty speaking. A further decline in glucose can then lead to loss of consciousness or even a seizure. With repeated episodes of hypoglycemia, there is

adaptation, and autonomic symptoms do not occur until the blood glucose levels are much lower and so the first symptoms are often due to neuroglycopenia. This condition is referred to as “hypoglycemic unawareness.” It has been shown that hypoglycemic unawareness can be reversed by keeping glucose levels high for a period of several weeks. Except for sweating, most of the sympathetic symptoms of hypoglycemia are blunted in patients receiving β -blocking agents for angina pectoris or hypertension. Though not absolutely contraindicated, these medications must be used with caution in insulin-requiring diabetics, and β_1 -selective blocking agents are preferred.

Hypoglycemia in insulin-treated patients with diabetes occurs as a consequence of three factors: behavioral issues, impaired counterregulatory systems, and complications of diabetes.

Behavioral issues include injecting too much insulin for the amount of carbohydrates ingested. Drinking alcohol in excess, especially on an empty stomach, can also cause hypoglycemia. In patients with type 1 diabetes, hypoglycemia can occur during or even several hours after exercise, and so glucose levels need to be monitored and food and insulin adjusted. Some patients do not like their glucose levels to be high, and they treat every high glucose level aggressively. These individuals who “stack” their insulin—that is, give another dose of insulin before the first injection has had its full action—can develop hypoglycemia.

Counterregulatory issues resulting in hypoglycemia include impaired glucagon response, sympatho-adrenal responses, and cortisol deficiency. Patients with diabetes of > 5 years duration lose their glucagon response to hypoglycemia. As a result, they are at a significant disadvantage in protecting themselves against falling glucose levels. Once the glucagon response is lost, their sympatho-adrenal responses take on added importance. Unfortunately, aging, autonomic neuropathy, or hypoglycemic unawareness due to repeated low glucose levels further blunts the sympatho-adrenal responses. Occasionally, Addison disease develops in persons with type 1 diabetes mellitus; when this happens, insulin requirements fall significantly, and unless insulin dose is reduced, recurrent hypoglycemia will develop.

Complications of diabetes that increase the risk for hypoglycemia include autonomic neuropathy, gastroparesis, and end-stage chronic kidney disease. The sympathetic nervous system is an important system alerting the individual that the glucose level is falling by causing symptoms of tachycardia, palpitations, sweating, and tremulousness. Failure of the sympatho-adrenal responses increases the risk of hypoglycemia. In addition, in patients with gastroparesis, if insulin is given before a meal, the peak of insulin action may occur before the food is absorbed causing the glucose levels to fall. Finally, in end-stage chronic kidney disease, hypoglycemia can occur presumably because of decreased insulin clearance as well as loss of renal contribution to gluconeogenesis in the postabsorptive state.

To prevent and treat insulin-induced hypoglycemia, the diabetic patient should carry glucose tablets or juice at all times. For most episodes, ingestion of 15 grams of carbohydrate is sufficient to reverse the hypoglycemia. The patient should be instructed to check the blood glucose in

15 minutes and treat again if the glucose level is still low. A parenteral glucagon emergency kit (1 mg) should be provided to every patient with diabetes who is receiving insulin therapy. Family or friends should be instructed how to inject it subcutaneously or intramuscularly into the buttock, arm, or thigh in the event that the patient is unconscious or refuses food. The medication can occasionally cause vomiting, and the unconscious patient should be turned on his or her side to protect the airway. The glucagon mobilizes glycogen from the liver, raising the blood glucose by about 36 mg/dL (2 mmol/L) in about 15 minutes. After the patient recovers consciousness, additional oral carbohydrate should be given. People with diabetes receiving hypoglycemic medication therapy should also wear an identification MedicAlert bracelet or necklace or carry a card in his or her wallet. The telephone number for the MedicAlert Foundation International in Turlock, California, is 1-800-ID-ALERT and the Internet address is www.medicalert.org.

Medical personnel treating severe hypoglycemia can give 50 mL of 50% glucose solution by rapid intravenous infusion. If intravenous access is not available, 1 mg of glucagon can be injected intramuscularly.

2. Immunopathology of insulin therapy—At least five molecular classes of insulin antibodies are produced during the course of insulin therapy in diabetes, including IgA, IgD, IgE, IgG, and IgM. With the increased therapeutic use of purified pork and especially human insulin, the various immunopathologic syndromes such as insulin allergy, immune insulin resistance, and lipoatrophy have become quite rare since the titers and avidity of these induced antibodies are generally quite low.

A. INSULIN ALLERGY—Insulin allergy, or immediate-type hypersensitivity, is a rare condition in which local or systemic urticaria is due to histamine release from tissue mast cells sensitized by adherence of anti-insulin IgE antibodies. In severe cases, anaphylaxis results. When only human insulin has been used from the onset of insulin therapy, insulin allergy is exceedingly rare. Antihistamines, corticosteroids, and even desensitization may be required, especially for systemic hypersensitivity. There have been case reports of successful use of insulin lispro in those rare patients who have a generalized allergy to human insulin or insulin resistance due to a high titer of insulin antibodies.

B. IMMUNE INSULIN RESISTANCE—A low titer of circulating IgG anti-insulin antibodies that neutralize the action of insulin to a small extent develops in most insulin-treated patients. With the old animal insulins, a high titer of circulating antibodies sometimes developed, resulting in extremely high insulin requirements—often more than 200 units daily. This is now rarely seen with the switch to highly purified pork or human insulins and has not been reported with the analogs.

C. LIPODYSTROPHY—Atrophy of subcutaneous fatty tissue leading to disfiguring excavations and depressed areas may rarely occur at the site of injection. This complication results from an immune reaction, and it has become rarer with the development of pure and human insulin

preparations. Lipohypertrophy, on the other hand, is a consequence of the pharmacologic effects of insulin being deposited in the same location repeatedly. It can occur with purified insulins as well. Rotation of injection sites will prevent lipohypertrophy. There is a case report of a patient who had intractable lipohypertrophy with human insulin but no longer had the problem when he switched to insulin lispro.

Cryer PE. Elimination of hypoglycemia from the lives of people affected by diabetes. *Diabetes*. 2011 Jan;60(1):24–7. [PMID: 21193736]

► Chronic Complications of Diabetes

Late clinical manifestations of diabetes mellitus include a number of pathologic changes that involve small and large blood vessels, cranial and peripheral nerves, the skin, and the lens of the eye. These lesions lead to hypertension, end-stage chronic kidney disease, blindness, autonomic and peripheral neuropathy, amputations of the lower extremities, myocardial infarction, and cerebrovascular accidents. These late manifestations correlate with the duration of the diabetic state subsequent to the onset of puberty. In type 1 diabetes, end-stage chronic kidney disease develops in up to 40% of patients, compared with < 20% of patients with type 2 diabetes. As regards proliferative retinopathy, it ultimately develops in both types of diabetes but has a slightly higher prevalence in type 1 patients (25% after 15 years' duration). In patients with type 1 diabetes, complications from end-stage chronic kidney disease are a major cause of death, whereas patients with type 2 diabetes are more likely to have macrovascular diseases leading to myocardial infarction and stroke as the main causes of death. Cigarette use adds significantly to the risk of both microvascular and macrovascular complications in diabetic patients.

A. Ocular Complications

1. Diabetic cataracts—Premature cataracts occur in diabetic patients and seem to correlate with both the duration of diabetes and the severity of chronic hyperglycemia. Nonenzymatic glycosylation of lens protein is twice as high in diabetic patients as in age-matched nondiabetic persons and may contribute to the premature occurrence of cataracts.

2. Diabetic retinopathy—After 10 to 15 years, 25–50% of patients with type 1 diabetes show some signs of retinopathy. After 15 years, prevalence increases to 75–95%, and after 30 years, the prevalence approaches 100%. In patients with type 2 diabetes, the prevalence of nonproliferative retinopathy is 60% after 16 years.

There are two main categories of diabetic retinopathy: nonproliferative and proliferative. Diabetic macular edema can occur at any stage. **Nonproliferative** (“background”) retinopathy represents the earliest stage of retinal involvement by diabetes and is characterized by such changes as microaneurysms, dot hemorrhages, exudates, and retinal edema. During this stage, the retinal capillaries leak proteins, lipids, or red cells into the retina. When this process occurs in the macula (clinically significant macular edema),

the area of greatest concentration of visual cells, there is interference with visual acuity; this is the most common cause of visual impairment in patients with type 2 diabetes. **Proliferative retinopathy** involves the growth of new capillaries and fibrous tissue within the retina and into the vitreous chamber. It is a consequence of small vessel occlusion, which causes retinal hypoxia; this in turn stimulates new vessel growth. New vessel formation may occur at the optic disc or elsewhere on the retina. Proliferative retinopathy can occur in both types of diabetes but is more common in type 1, developing about 7–10 years after onset of symptoms, with a prevalence of 25% after 15 years' duration. Prior to proliferation of new capillaries, a preproliferative phase often occurs in which arteriolar ischemia is manifested as cotton-wool spots (small infarcted areas of retina). Vision is usually normal until vitreous hemorrhage or retinal detachment occurs.

Proliferative retinopathy is a leading cause of blindness in the United States, particularly since it increases the risk of retinal detachment. Vision-threatening retinopathy virtually never appears in type 1 patients in the first 3–5 years of diabetes or before puberty. Up to 20% of patients with type 2 diabetes have retinopathy at the time of diagnosis. Annual consultation with an ophthalmologist should be arranged for patients who have had type 1 diabetes for more than 3–5 years and for all patients with type 2 diabetes, because many were probably diabetic for an extensive period of time before diagnosis. Patients with any macular edema, severe nonproliferative retinopathy, or any proliferative retinopathy require the care of an ophthalmologist. Extensive “scatter” xenon or argon photocoagulation and focal treatment of new vessels reduce severe visual loss in those cases in which proliferative retinopathy is associated with recent vitreous hemorrhages or in which extensive new vessels are located on or near the optic disk. Macular edema, which is more common than proliferative retinopathy in patients with type 2 diabetes (up to 20% prevalence), has a guarded prognosis, but it has also responded to scatter therapy with improvement in visual acuity if detected early. Injection of bevacizumab (Avastin), an anti-vascular endothelial growth factor (anti-VEGF), into the eye has been shown to stop the growth of the new blood vessels in diabetic eye disease. Avoiding tobacco use and correction of associated hypertension are important therapeutic measures in the management of diabetic retinopathy. There is no contraindication to using aspirin in patients with proliferative retinopathy.

3. Glaucoma—Glaucoma occurs in approximately 6% of persons with diabetes. It is responsive to the usual therapy for open-angle disease. Neovascularization of the iris in diabetics can predispose to closed-angle glaucoma, but this is relatively uncommon except after cataract extraction, when growth of new vessels has been known to progress rapidly, involving the angle of the iris and obstructing outflow.

B. Diabetic Nephropathy

As many as 4000 cases of end-stage chronic kidney disease occur each year among diabetic people in the United States. This is about one-third of all patients being treated for

end-stage chronic kidney disease and represents a considerable national health expense.

The cumulative incidence of nephropathy differs between the two major types of diabetes. Patients with type 1 diabetes have a 30–40% chance of having nephropathy after 20 years—in contrast to the much lower frequency in type 2 diabetes patients, in whom only about 15–20% develop clinical kidney disease. However, since there are many more individuals affected with type 2 diabetes, end-stage chronic kidney disease is much more prevalent in type 2 than in type 1 diabetes in the United States and especially throughout the rest of the world. Improved glycemic control and more effective therapeutic measures to correct hypertension—and with the beneficial effects of ACE inhibitors—can reduce the development of end-stage chronic kidney disease among diabetics.

Diabetic nephropathy is initially manifested by proteinuria; subsequently, as kidney function declines, urea and creatinine accumulate in the blood. Sensitive radioimmunoassay methods of detecting small amounts of urinary albumin have permitted detection of microgram concentrations—in contrast to the less sensitive dipstick strips, whose minimal detection limit is 0.3–0.5%. Conventional 24-hour urine collections, in addition to being inconvenient for patients, also show wide variability of albumin excretion, since several factors such as sustained erect posture, dietary protein, and exercise tend to increase albumin excretion rates. For these reasons, an albumin-creatinine ratio in an early morning spot urine collected upon awakening is preferable. In the early morning spot urine, a ratio of albumin (mcg/L) to creatinine (mg/L) of < 30 mcg/mg creatinine is normal, and a ratio of 30–300 mcg/mg creatinine suggests abnormal microalbuminuria. At least two early morning spot urine collections over a 3- to 6-month period should be abnormal before a diagnosis of microalbuminuria is justified. Short-term hyperglycemia, exercise, urinary tract infections, heart failure, and acute febrile illness can cause transient albuminuria and so testing for microalbuminuria should be postponed until resolution of these problems.

Subsequent end-stage chronic kidney disease can be predicted by persistent urinary albumin excretion rates exceeding 30 mcg/min. Glycemic control as well as a low-protein diet (0.8 g/kg/d) may reduce both the hyperfiltration and the elevated microalbuminuria in patients in the early stages of diabetes and those with incipient diabetic nephropathy. Antihypertensive therapy also decreases microalbuminuria. Evidence from some studies—but not the UKPDS—supports a specific role for ACE inhibitors in reducing intraglomerular pressure in addition to their lowering of systemic hypertension. An ACE inhibitor (captopril, 50 mg twice daily) in normotensive diabetics impedes progression to proteinuria and prevents the increase in albumin excretion rate. Since microalbuminuria has been shown to correlate with elevated *nocturnal* systolic blood pressure, it is possible that “normotensive” diabetic patients with microalbuminuria have slightly elevated systolic blood pressure during sleep, which is lowered during antihypertensive therapy. This action may contribute to the reported efficacy of ACE inhibitors in reducing microalbuminuria in “normotensive” patients.

If treatment is inadequate, then the disease progresses with proteinuria of varying severity occasionally leading to nephrotic syndrome with hypoalbuminemia, edema, and an increase in circulating LDL cholesterol, as well as progressive azotemia. In contrast to all other kidney disorders, the proteinuria associated with diabetic nephropathy does not diminish with progressive end-stage chronic kidney disease (patients continue to excrete 10–11 g daily as creatinine clearance diminishes). As end-stage chronic kidney disease progresses, there is an elevation in the renal threshold at which glycosuria appears.

Patients with diabetic nephropathy should be evaluated and monitored by a nephrologist. There has been gradual improvement in quality of life of diabetic patients receiving dialysis. The cumulative survival for diabetic patients is about 22% compared with about 37% for dialysis patients without diabetes. Diabetic nephropathy accounts for about 20% of kidney transplantations performed annually in the United States. Survival rates have also improved for diabetic patients after kidney transplantation.

C. Diabetic Neuropathy

Diabetic neuropathies are the most common complications of diabetes affecting up to 50% of older patients with type 2 diabetes.

1. Peripheral neuropathy—

A. DISTAL SYMMETRIC POLYNEUROPATHY—This is the most common form of diabetic peripheral neuropathy where loss of function appears in a stocking-glove pattern and is due to an axonal neuropathic process. Longer nerves are especially vulnerable, hence the impact on the foot. Both motor and sensory nerve conduction is delayed in the peripheral nerves, and ankle jerks may be absent.

Sensory involvement usually occurs first and is generally bilateral, symmetric, and associated with dulled perception of vibration, pain, and temperature. The pain can range from mild discomfort to severe incapacitating symptoms (see below). The sensory deficit may eventually be of sufficient degree to prevent patients from feeling pain. Patients who have a sensory neuropathy should therefore be examined with a 5.07 Semmes Weinstein filament and those who cannot feel the filament must be considered at risk for unperceived neuropathic injury.

The denervation of the small muscles of the foot result in clawing of the toes and displacement of the submetatarsal fat pads anteriorly. These changes, together with the joint and connective tissue changes, alter the biomechanics of the foot and increase plantar pressures. This combination of decreased pain threshold, abnormally high foot pressures, and repetitive stress (such as from walking) can lead to calluses and ulcerations in the high-pressure areas such as over the metatarsal heads (Figure 27–4). Peripheral neuropathy, autonomic neuropathy, and trauma also predisposes to the development of Charcot arthropathy. An acute case of Charcot foot arthropathy presents with pain and swelling, and if left untreated, leads to a “rocker bottom” deformity and ulceration. The early radiologic changes show joint subluxation and periarticular fractures. As the



▲ **Figure 27-4.** Neuropathic ulcer under the head of the third metatarsal on the foot of a diabetic patient. (Courtesy of Javier La Fontaine, DPM; used, with permission, from Usatine RP, Smith MA, Mayeaux EJ Jr, Chumley H, Tysinger J. *The Color Atlas of Family Medicine*. McGraw-Hill, 2009.)

process progresses, there is frank osteoclastic destruction leading to deranged and unstable joints particularly in the midfoot. Not surprisingly, the key issue for the healing of neuropathic ulcers in a foot with good vascular supply is mechanical unloading. In addition, any infection should be treated with debridement and appropriate antibiotics; healing duration of 8–10 weeks is typical. Occasionally, when healing appears refractory, **platelet-derived growth factor** (becaplermin [Regranex]) should be considered for local application. A post-marketing epidemiologic study showed increased cancer deaths in patients who had used three or more tubes of becaplermin on their leg or feet ulcers, and there is now a “black box” warning on the medication label. Once ulcers are healed, therapeutic footwear is key to preventing recurrences. Custom molded shoes are reserved for patients with significant foot deformities. Other patients with neuropathy may require accommodative insoles that distribute the load over as wide an area as possible. Patients with foot deformities and loss of their protective threshold should get regular care from a podiatrist. Patients should be educated on appropriate footwear and those with loss of their protective threshold should be instructed to inspect their feet daily for reddened areas, blisters, abrasions, or lacerations.

B. ISOLATED PERIPHERAL NEUROPATHY—Involvement of the distribution of only one nerve (“mononeuropathy”) or of several nerves (“mononeuropathy multiplex”) is characterized by sudden onset with subsequent recovery of all or most of the function. This neuropathology has been attributed to vascular ischemia or traumatic damage. Cranial and femoral nerves are commonly involved, and motor abnormalities predominate. The patient with cranial nerve involvement usually has diplopia and single third, fourth, or sixth nerve weakness on examination but the pupil is spared. A full recovery of function occurs in 6–12 weeks. Diabetic amyotrophy presents with onset of severe pain in the front of the thigh. Within a few days or weeks of the onset of pain, weakness and wasting of the quadriceps develops. As the weakness appears, the pain tends to improve. Management includes analgesia and improved diabetes control. The symptoms improve over 6–18 months.

C. PAINFUL DIABETIC NEUROPATHY—Hypersensitivity to light touch and occasionally severe “burning” pain, particularly at night, can become physically and emotionally disabling. Amitriptyline, 25–75 mg at bedtime, has been recommended for pain associated with diabetic neuropathy. Dramatic relief has often resulted within 48–72 hours. This rapid response is in contrast to the 2 or 3 weeks required for an antidepressive effect. Patients often attribute the benefit to having a full night’s sleep. Mild to moderate morning drowsiness is a side effect that generally improves with time or can be lessened by giving the medication several hours before bedtime. This medication should not be continued if improvement has not occurred after 5 days of therapy. If amitriptyline’s anticholinergic effects are too troublesome, then nortriptyline can be used. Desipramine in doses of 25–150 mg/d seems to have the same efficacy as amitriptyline. Tricyclic antidepressants, in combination with the phenothiazine, fluphenazine, have been shown in two studies to be efficacious in painful neuropathy, with benefits unrelated to relief of depression. Gabapentin (900–1800 mg/d in three divided doses) has also been shown to be effective in the treatment of painful neuropathy and should be tried if the tricyclic medications prove ineffective. Pregabalin, a congener of gabapentin, has been shown in an 8-week study to be more effective than placebo in treating painful diabetic peripheral neuropathy. However, this medication was not compared with an active control. Also, because of its abuse potential, it has been categorized as a schedule V controlled substance. Duloxetine, a serotonin and norepinephrine reuptake inhibitor, has been approved for the treatment of painful diabetic neuropathy. In clinical trials, this medication reduced the pain sensitivity score by 40–50%. Capsaicin, a topical irritant, has been found to be effective in reducing local nerve pain; it is dispensed as a cream (Zostrix 0.025%, Zostrix-HP 0.075%) to be rubbed into the skin over the painful region two to four times daily. Gloves should be used for application since hand contamination could result in discomfort if the cream comes in contact with eyes or sensitive areas such as the genitalia. Application of a 5% lidocaine patch over an area of maximal pain has been reported to be of benefit. It is approved for

treatment of postherpetic neuralgia and is in clinical trials for the treatment of painful diabetic neuropathy.

Diabetic neuropathic cachexia is a syndrome characterized by a symmetric peripheral neuropathy associated with profound weight loss (up to 60% of total body weight) and painful dysesthesias affecting the proximal lower limbs, the hands, or the lower trunk. Treatment is usually with insulin and analgesics. The prognosis is generally good, and patients typically recover their baseline weight with resolution of the painful sensory symptoms within 1 year.

2. Autonomic neuropathy—Neuropathy of the autonomic system occurs principally in patients with diabetes of long duration. It affects many diverse visceral functions including blood pressure and pulse, gastrointestinal activity, bladder function, and erectile dysfunction. Treatment is directed specifically at each abnormality.

Involvement of the gastrointestinal system may be manifested by nausea, vomiting, postprandial fullness, reflux or dysphagia, constipation or diarrhea (or both), and fecal incontinence. Gastroparesis should be considered in type 1 diabetic patients in whom unexpected fluctuations and variability in their blood glucose levels develops after meals. Radioisotope studies show marked delay in gastric emptying. Metoclopramide has been of some help in treating diabetic gastroparesis. It is a dopamine antagonist that has central antiemetic effects as well as a cholinergic action to facilitate gastric emptying. It is given in a dose of 10 mg orally three or four times a day, 30 minutes before meals and at bedtime. Drowsiness, restlessness, fatigue, and lassitude are common adverse effects. Tardive dyskinesia and extrapyramidal effects can occur, especially when used for longer than 3 months, and the FDA has cautioned against the long-term use of metoclopramide.

Erythromycin appears to bind to motilin receptors in the stomach and has been found to improve gastric emptying over the short term in doses of 250 mg three times daily, but its effectiveness seems to diminish over time. Tegaserod (Zelnorm), the partial 5-HT₄ agonist, has been withdrawn from the US market by the FDA, so it is no longer used for this indication. In selected patients, injections of botulinum toxin into the pylorus can reduce pylorus sphincter resistance and enhance gastric emptying. Gastric electrical stimulation has been reported to improve symptoms and quality of life indices in patients with gastroparesis refractory to pharmacologic therapy.

Diarrhea associated with autonomic neuropathy has occasionally responded to broad-spectrum antibiotic therapy, although it often undergoes spontaneous remission. Refractory diabetic diarrhea is often associated with impaired sphincter control and fecal incontinence. Therapy with loperamide, 4–8 mg daily, or diphenoxylate with atropine, two tablets up to four times a day, may provide relief. In more severe cases, tincture of paregoric or codeine (60 mg tablets) may be required to reduce the frequency of diarrhea and improve the consistency of the stools. Clonidine has been reported to lessen diabetic diarrhea; however, its usefulness is limited by its tendency to lower blood pressure in these patients who already have autonomic neuropathy,

resulting in orthostatic hypotension. Constipation usually responds to stimulant laxatives such as senna.

Incomplete emptying of the bladder can sometimes occur. Bethanechol in doses of 10–50 mg three times a day has occasionally improved emptying of the atonic urinary bladder. Catheter decompression of the distended bladder has been reported to improve its function, and considerable benefit has been reported after surgical severing of the internal vesicle sphincter.

Use of Jobst fitted stockings, tilting the head of the bed, and arising slowly from the supine position can be helpful in treating symptoms of orthostatic hypotension. When such measures are inadequate, then treatment with fludrocortisone 0.1–0.2 mg daily can be considered. This medication, however, can result in supine hypertension and hypokalemia. Midodrine (10 mg three times a day), an α -agonist, can also be used.

Erectile dysfunction can result from neurologic, psychological or vascular causes, or a combination of these causes. There are medical, mechanical, and surgical treatments available for treatment of erectile dysfunction. Penile erection depends on relaxation of the smooth muscle in the arteries of the corpus cavernosum, and this is mediated by nitric oxide-induced cyclic 3',5'-guanosine monophosphate (cGMP) formation. cGMP-specific phosphodiesterase type 5 (PDE5) inhibitors impair the breakdown of cGMP and improve the ability to attain and maintain an erection. Sildenafil (Viagra), vardenafil (Levitra), and tadalafil (Cialis) have been shown in placebo-controlled clinical trials to improve erections in response to sexual stimulation. The recommended dose of sildenafil for most patients is one 50-mg tablet taken approximately 1 hour before sexual activity. The peak effect is at 1.5–2 hours, with some effect persisting for 4 hours. Patients with diabetes mellitus using sildenafil reported 50–60% improvement in erectile function. The maximum recommended dose is 100 mg. The recommended dose of both vardenafil and tadalafil is 10 mg. The doses may be increased to 20 mg or decreased to 5 mg based on efficacy and side effects. Tadalafil has been shown to improve erectile function for up to 36 hours after dosing. Low doses are now available for daily use. In clinical trials, only a few adverse effects have been reported—transient mild headache, flushing, dyspepsia, and some altered color vision. Priapism can occur with these medications, and patients should be advised to seek immediate medical attention if an erection persists for longer than 4 hours. The PDE5 inhibitors potentiate the hypotensive effects of nitrates and their use is contraindicated in patients who are concurrently using organic nitrates in any form. Caution is advised for men who have suffered a heart attack, stroke, or life-threatening arrhythmia within the previous 6 months; men who have resting hypotension or hypertension; and men who have a history of cardiac failure or have unstable angina. Rarely, a decrease in vision or permanent visual loss has been reported after PDE5 inhibitor use.

Intracorporeal injection of vasoactive medications causes penile engorgement and erection. Medications most commonly used include papaverine alone, papaverine with phentolamine, and alprostadil (prostaglandin E₁). Alprostadil injections are relatively painless, but careful instruction is

essential to prevent local trauma, priapism, and fibrosis. Intraurethral pellets of alprostadil avoid the problem of injection of the medication.

External vacuum therapy (Erec-Aid System) is a nonsurgical treatment consisting of a suction chamber operated by a hand pump that creates a vacuum around the penis. This draws blood into the penis to produce an erection that is maintained by a specially designed tension ring inserted around the base of the penis and which can be kept in place for up to 20–30 minutes. While this method is generally effective, its cumbersome nature limits its appeal.

In view of the recent development of nonsurgical approaches to therapy of erectile dysfunction, resort to surgical implants of penile prostheses is becoming less common.

D. Cardiovascular Complications

1. Heart disease—Microangiopathy occurs in the heart and may explain the etiology of congestive cardiomyopathies in diabetic patients who do not have demonstrable coronary artery disease. More commonly, however, heart disease in patients with diabetes is due to coronary atherosclerosis. Myocardial infarction is three to five times more common in diabetic patients and is the leading cause of death in patients with type 2 diabetes. Cardiovascular disease risk is increased in patients with type 1 diabetes as well, although the absolute risk is lower than in patients with type 2 diabetes. Premenopausal women who normally have lower rates of coronary artery disease lose this protection once diabetes develops. The increased risk in patients with type 2 diabetes reflects the combination of hyperglycemia, hyperlipidemia, abnormalities of platelet adhesiveness, coagulation factors, hypertension, oxidative stress, and inflammation. Large intervention studies of risk factor reduction in diabetes are lacking, but it is reasonable to assume that reducing these risk factors would have a beneficial effect. Lowering LDL cholesterol reduces first events in patients without known coronary disease and secondary events in patients with known coronary disease. These intervention studies included some patients with diabetes, and the benefits of LDL cholesterol lowering was apparent in this group. The National Cholesterol Education Program clinical practice guidelines have designated diabetes as a coronary risk equivalent and have recommended that patients with diabetes should have an LDL cholesterol goal of < 100 mg/dL (2.6 mmol/L). Lowering LDL cholesterol to 70 mg/dL (1.8 mmol/L) may have additional benefit and is a reasonable target for most patients with type 2 diabetes who have multiple risk factors for cardiovascular disease.

The ADA also recommends lowering blood pressure to 130/80 mm Hg or less. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) randomized 33,357 persons (age 55 years and older) with hypertension and at least one other coronary artery disease risk factor to receive treatment with chlorthalidone, amlodipine, or lisinopril. Chlorthalidone appeared to be superior to amlodipine and lisinopril in lowering blood pressure, reducing the incidence of cardiovascular events, tolerability, and cost. The study included 12,063 individuals with type 2 diabetes. The Heart Outcomes Prevention Evaluation (HOPE) study randomized 9297 high-risk patients who had

evidence of vascular disease or diabetes plus one other cardiovascular risk factor to receive ramipril or placebo for a mean of 5 years. Treatment with ramipril resulted in a 25% reduction of the risk of myocardial infarction, stroke, or death from cardiovascular disease. The mean difference between the placebo and ramipril group was 2.2 mm Hg systolic and 1.4 mm Hg diastolic blood pressure. The reduction in cardiovascular event rate remained significant after adjustment for this small difference in blood pressure. The mechanism underlying this protective effect of ramipril is unknown. Patients with type 2 diabetes who already have cardiovascular disease or microalbuminuria should therefore be considered for treatment with an ACE inhibitor. More clinical studies are needed to address the question of whether patients with type 2 diabetes who do not have cardiovascular disease or microalbuminuria would specifically benefit from ACE inhibitor treatment.

Aspirin at a dose of 81–325 mg daily has been shown to effectively inhibit thromboxane synthesis by platelets and is effective in reducing cardiovascular morbidity and mortality in patients who have a history of myocardial infarction or stroke (secondary prevention). It is unclear if aspirin prevents primary cardiovascular events in people with diabetes. The current recommendation is to give aspirin to people with diabetes who have a greater than 10% 10-year risk of cardiovascular events. Typically, this includes most diabetic men aged 50 years or older and diabetic women aged 60 years or older with one or more additional risk factors (smoking, hypertension, dyslipidemia, family history of premature cardiovascular disease, or albuminuria). Contraindications for aspirin therapy are patients with aspirin allergy, bleeding tendency, recent gastrointestinal bleeding, or active hepatic disease. The Early Treatment Diabetic Retinopathy Study (ETDRS) showed that aspirin does not influence the course of proliferative retinopathy. There was no statistically significant difference in the severity of vitreous/preretinal hemorrhages or their rate of resolution between the aspirin and placebo groups. Thus, it appears that there is no contraindication to aspirin use to achieve cardiovascular benefit in diabetic patients who have proliferative retinopathy.

2. Peripheral vascular disease—Atherosclerosis is markedly accelerated in the larger arteries. It is often diffuse, with localized enhancement in certain areas of turbulent blood flow, such as at the bifurcation of the aorta or other large vessels. Clinical manifestations of peripheral vascular disease include ischemia of the lower extremities, erectile dysfunction, and intestinal angina.

The incidence of **gangrene of the feet** in diabetics is 30 times that in age-matched controls. The factors responsible for its development, in addition to peripheral vascular disease, are small vessel disease, peripheral neuropathy with loss of both pain sensation and neurogenic inflammatory responses, and secondary infection. In two-thirds of patients with ischemic gangrene, pedal pulses are not palpable. In the remaining one-third who have palpable pulses, reduced blood flow through these vessels can be demonstrated by plethysmographic or Doppler ultrasound examination. Prevention of foot injury is imperative. Agents that reduce peripheral blood flow such as

tobacco and propranolol should be avoided. Control of other risk factors such as hypertension is essential. Cholesterol-lowering agents are useful as adjunctive therapy when early ischemic signs are detected and when dyslipidemia is present. Patients should be advised to seek immediate medical care if a diabetic foot ulcer develops. Improvement in peripheral blood flow with endarterectomy and bypass operations is possible in certain patients.

E. Skin and Mucous Membrane Complications

Chronic pyogenic infections of the skin may occur, especially in poorly controlled diabetic patients. **Candidal infection** can produce erythema and edema of intertriginous areas below the breasts, in the axillas, and between the fingers. It causes vulvovaginitis in women with chronically uncontrolled diabetes who have persistent glucosuria and is a frequent cause of pruritus. While antifungal creams containing miconazole or clotrimazole offer immediate relief of vulvovaginitis, recurrence is frequent unless glucosuria is reduced.

In some patients with type 2 diabetes, poor glycemic control can cause a severe hypertriglyceridemia, which can present as **eruptive cutaneous xanthomas** and pancreatitis. The skin lesions appear as yellow morbilliform eruptions 2–5 mm in diameter with erythematous areolae. They occur on extensor surfaces (elbows, knees, buttocks) and disappear after triglyceride levels are reduced.

Necrobiosis lipoidica diabetorum is usually located over the anterior surfaces of the legs or the dorsal surfaces of the ankles. They are oval or irregularly shaped plaques with demarcated borders and a glistening yellow surface and occur in women two to four times more frequently than in men. Pathologically, the lesions show degeneration of collagen, granulomatous inflammation of subcutaneous tissues and blood vessels, capillary basement membrane thickening and obliteration of vessel lumina. The condition is associated with type 1 diabetes, although it can occur in patients with type 2 diabetes, and also in patients without diabetes. First-line therapy includes topical and subcutaneous corticosteroids. Improving glycemic control may help the condition.

“Shin spots” are not uncommon in adult diabetics. They are brownish, rounded, painless atrophic lesions of the skin in the pretibial area.

F. Bone and Joint Complications

A number of bone and joint complications occur in people with diabetes. Long-standing diabetes can cause progressive stiffness of the hand secondary to contracture and tightening of skin over the joints (diabetic cheiroarthropathy), frozen shoulder (adhesive capsulitis), carpal tunnel syndrome, and Dupuytren contractures. These complications are believed to be due to glycosylation of collagen and perhaps other proteins in connective tissue. There may also be an inflammatory component.

Data on bone mineral density and fracture risk in people with diabetes are contradictory. Patients with type 2 diabetes do appear to be at increased risk for nonvertebral

fractures. Women with type 1 diabetes have an increased risk of fracture when compared with women without diabetes. Other factors, such as duration of diabetes, and diabetes complications, such as neuropathy and renal disease, likely affect both the bone mineral density and fracture risk.

Diffuse idiopathic skeletal hyperostosis (DISH) is characterized by ossification of the anterior longitudinal ligaments of the spine and various extraspinal ligaments. It causes stiffness and decreased range of spinal motion. The peripheral joints most commonly affected are the metacarpophalangeal joints, elbows, and shoulders. Diabetes, obesity, hypertension, and dyslipidemia are risk factors for this condition.

Hyperuricemia is more common in type 2 diabetes, so it is not surprising that these patients are at increased risk for acute and tophaceous gout.

Bursitis, particularly of the shoulders and hips occurs more frequently than expected in patients with diabetes.

- Albersen M et al. Evaluation and treatment of erectile dysfunction. *Med Clin North Am.* 2011 Jan;95(1):201–12. [PMID: 21095423]
- Boscia F. Current approaches to the management of diabetic retinopathy and diabetic macular oedema. *Drugs.* 2010 Nov 12;70(16):2171–200. [PMID: 20964459]
- Howard IM. The prevention of foot ulceration in diabetic patients. *Phys Med Rehabil Clin N Am.* 2009 Nov;20(4):595–609. [PMID: 19781501]
- Jude EB et al. Peripheral arterial disease in diabetes—a review. *Diabet Med.* 2010 Jan;27(1):4–14. [PMID: 20121883]
- McGill JB. Improving microvascular outcomes in patients with diabetes through management of hypertension. *Postgrad Med.* 2009 Mar;121(2):89–101. [PMID: 19332966]
- Mohamed Q et al. Management of diabetic retinopathy: a systematic review. *JAMA.* 2007 Aug 22;298(8):902–16. [PMID: 17712074]
- Schwartz SG et al. Pharmacotherapy for diabetic retinopathy. *Expert Opin Pharmacother.* 2009 May;10(7):1123–31. [PMID: 19405788]
- Shields J et al. Managing diabetic nephropathy. *Clin Med.* 2010 Oct;10(5):500–4. [PMID: 21117388]
- Tesfaye S et al; Toronto Diabetic Neuropathy Expert Group. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. *Diabetes Care.* 2010 Oct;33(10):2285–93. [PMID: 20876709]
- Van Buren PN et al. Hypertension in diabetic nephropathy: epidemiology, mechanisms, and management. *Adv Chronic Kidney Dis.* 2011 Jan;18(1):28–41. [PMID: 21224028]

► Special Situations

A. Diabetes Management in the Hospital

Most patients with diabetes are hospitalized for reasons other than their diabetes. Indeed, up to 10–15% of all hospitalized patients have diabetes. Audits suggest that as many as a 30% of these hospitalized patients have inappropriate management of their diabetes, with such errors as being given metformin where contraindicated, failure to act on high blood glucose levels, omission of diabetes medication, no record of diabetes complications, and inappropriate insulin management or blood glucose monitoring. It is challenging using outpatient oral therapies or

insulin regimens in the hospital because patients are not eating as usual; they are often fasting for procedures; clinical events increase adverse reactions associated with diabetes medicines, eg, thiazolidinediones can cause fluid retention and worsen heart failure; metformin should not be used in patients with significant chronic kidney or liver disease, or those getting contrast for radiographic studies. Subcutaneous or intravenous insulin therapy is frequently substituted for other diabetes medicines because the insulin dose can be adjusted to match changing inpatient needs and it is safe to use insulin in patients with heart, kidney, and liver disease.

Surgery represents a stress situation during which most of the insulin antagonists (eg, catecholamines, growth hormone, and corticosteroids) are mobilized. In the diabetic patient, this can lead to a worsening of hyperglycemia and perhaps even ketoacidosis. The aim of medical management of people with diabetes during the perioperative period is to minimize these stress-induced changes. Recommendations for management depend both on the patient's usual diabetic regimen and on the type of surgery (major or minor) to be done (see also Chapter 3).

For people with diabetes controlled with diet alone, no special precautions must be taken unless diabetic control is markedly disturbed by the procedure. If this occurs, small doses of short-acting insulin as needed will correct the hyperglycemia.

Patients taking oral agents should not take them on the day of surgery. If there is significant hyperglycemia, small doses of short-acting insulin are given as needed. If this approach does not provide adequate control, an insulin infusion should be started in the manner indicated below. The oral agents can be restarted once the patient is eating normally after the operation. It is important to order a postoperative serum creatinine level to ensure adequate kidney function prior to restarting metformin therapy.

Patients taking insulin represent the only serious challenge to management of diabetes when surgery is necessary. However, with careful attention to changes in the clinical or laboratory picture, glucose control can be managed successfully. The protocol used to control the glucose depends on the kind of diabetes (type 1 or type 2); whether it is minor surgery (lasting < 2 hours and patient eating afterwards) or major surgery (lasting > 2 hours, with invasion of a body

cavity, and patient not eating afterwards); and the preoperative insulin regimen (basal bolus or premixed insulin twice a day or premeal bolus only or regular insulin before meals and NPH at bedtime). Patients with type 1 diabetes must be receiving some insulin to prevent the development of diabetic ketoacidosis. Many patients with type 2 diabetes who are taking insulin do well perioperatively without insulin for a few hours. Ideally, patients with diabetes should undergo surgery early in the morning. Table 27–12 summarizes the approach for these patients.

One insulin infusion method adds 10 units of regular insulin to 1 L of 5% dextrose in 0.45% saline, and this is infused intravenously at a rate of 100–180 mL/h. This gives the patient 1–1.8 units of insulin per hour which, except in the most severe cases, generally keeps the blood glucose within the range of 100–250 mg/dL (5.5–13.9 mmol/L). The infusion may be continued for several days, if necessary. Perioperatively, plasma glucose or blood glucose should be determined every 2–4 hours to be sure metabolic control is adequate. If it is not, adjustments in the ratio of insulin to dextrose in the intravenous solution can be made.

An alternative method, which is gaining increasing popularity, consists of separate infusions of insulin and glucose delivered by pumps to permit independent adjustments of each infusion rate, depending on hourly variation of blood glucose values. There are a number of different algorithms available for insulin infusions.

After surgery, when the patient has resumed an adequate oral intake, subcutaneous administration of insulin can be resumed and intravenous administration of insulin and dextrose can be stopped 30 minutes after the first subcutaneous dose. Insulin needs may vary in the first several days after surgery because of continuing postoperative stresses and because of variable caloric intake. In this situation, multiple doses of short-acting insulin plus some long-acting basal insulin, guided by blood glucose determinations, can keep the patient in acceptable metabolic control.

In the **intensive care units (ICUs)**, glucose levels are controlled most frequently using insulin infusions. Patients receiving total parenteral nutrition can have insulin added to the bag. Standard total parenteral nutrition contains 25% dextrose so an infusion rate of 50 mL/h delivers 12.5 g of dextrose per hour.

Table 27–12. Recommendations for management of insulin-treated diabetes during surgery.

Type of Diabetes	Minor Surgical Procedures (< 2 hours; eating afterwards)	Major surgical procedures (> 2 hours; invasion of body cavity; not eating immediately after recovery)
Type 2: Patients taking basal bolus insulin regimen; twice daily premixed insulin	No insulin on the day of operation. Start 5% dextrose infusion; monitor fingerstick blood glucose and give subcutaneous short-acting insulin every 4 or 6 hours	Same regimen as minor procedure. If control is not satisfactory, then intravenous insulin infusion
Type 1: Patients taking basal bolus insulin regimen or using insulin pump	Patients using pump should discontinue the pump the evening before procedure and given 24 hour basal insulin. On day of procedure, start 5% dextrose; monitor blood glucose and give subcutaneous short-acting insulin every 4 or 6 hours	Initiate insulin infusion on morning of procedure and transition back to usual regimen when eating

On the **general surgical and medical wards**, most patients are treated with subcutaneous insulin regimens. Limited cross-sectional and prospective studies suggest that the best glucose control is achieved on a combination of basal and bolus regimen with 50% of daily insulin needs provided by intermediate- or long-acting insulins. Standardized order sets prompt medical personnel to write more physiologic insulin orders; they can reduce errors; and they often include algorithms for recognition and treatment of hypoglycemia.

The morbidity and mortality in diabetic patients is twice that of nondiabetic patients. Those with new-onset hyperglycemia (ie, those without a preadmission diagnosis of diabetes) have even higher mortality—almost eightfold that of nondiabetic patients in one study. These observations have led to the question of whether tight glycemic control in the hospital improves outcomes.

A prospective trial in surgical ICU patients (Leuven 1 study) reported that aggressive treatment of hyperglycemia (defined as blood glucose > 110 mg/dL [6.1 mmol/L]) reduced mortality and morbidity. Only a small number of persons in this study (204 of 1548) had a diagnosis of diabetes preoperatively, and so this study suggests that controlling hyperglycemia per se (independent of a diagnosis of diabetes) was beneficial. The benefits, however, were principally seen in patients who were in the ICU for longer than 5 days, and it is unclear whether the benefits also apply to most surgical patients who stay in the ICU for only 1 to 2 days.

The same investigators performed a similar prospective trial among 1200 medical ICU patients (Leuven 2 study) and reported that aggressive treatment of hyperglycemia reduced morbidity (decreased acquired kidney injury and increased early weaning from mechanical ventilation) but not mortality. Again, as in the surgical ICU study, only a small number of persons (16.9%) had a diagnosis of diabetes at admission.

The findings of the Leuven studies, however, have not been confirmed by other prospective studies. Two other ICU-based studies (Glucontrol and VISEP) that attempted to confirm the findings were unable to do so. Both studies were stopped prematurely, however. The Glucontrol study was stopped because an interim analysis (falsely) suggested increased mortality in the test group; and the VISEP study was stopped because of seven-fold increase in hypoglycemic events in the intensively treated group. A large multicenter, multinational study (NICE-SUGAR) recruited 6104 surgical and medical ICU patients with hyperglycemia (20% had diabetes) and randomized them to tight control (blood glucose levels of 81–108 mg/dL [4.5–6 mmol/L]) or less tight control (glucose levels < 180 mg/dL [< 10 mmol/L]). The tight group achieved blood glucose levels of 115 ± 18 mg/dL (6.4 ± 1.0 mmol/L) and the conventional group, 144 ± 23 mg/dL (8 ± 1.3 mmol/L). There were more deaths (829 versus 751 deaths) in the tight glucose control group compared with the less tight glucose control group ($P = .02$). The excess deaths in the intensive group were due to cardiovascular events. The intensively treated group also had more cases of severe hypoglycemia (206 versus 15 cases).

A study on tight intraoperative glycemic control during cardiac surgery also failed to show any benefit; if anything, the intensively treated group had more events. The United Kingdom Glucose Insulin in Stroke Trial (GIST-UK) failed to show beneficial effect of tight glycemic control in stroke patients; however, the investigators acknowledged that, because of slow recruitment, the study was underpowered.

Thus, based on the evidence available so far, ICU patients with diabetes and new-onset hyperglycemia with blood glucose levels above 180 mg/dL (10 mmol/L) should be treated with insulin, aiming for target glucose levels between 140 mg/dL (7.8 mmol/L) and 180 mg/dL (10 mmol/L). In the ICU setting, aiming for blood glucose levels close to 100 mg/dL (5.6 mmol/L) is not beneficial and may even be harmful. When patients leave the ICU, target glucose values between 100 mg/dL (5.6 mmol/L) and 180 mg/dL (10 mmol/L) may be appropriate, although this view is based on clinical observations rather than conclusive evidence.

B. Pregnancy and the Diabetic Patient

Tight glycemic control with normal HbA_{1c} levels is very important during pregnancy. Early in pregnancy, poor control increases the risk of spontaneous abortion and congenital malformations. Late in pregnancy, poor control can result in polyhydramnios, preterm labor, stillbirth, and fetal macrosomia with its associated problems. Diabetes complications can impact both maternal and fetal health. Diabetic retinopathy can first develop during pregnancy or retinopathy that is already present can worsen. Diabetic women with microalbuminuria can have worsening albuminuria during pregnancy and are at higher risk for preeclampsia. Patients who have preexisting kidney failure (pregnancy creatinine clearance < 80 mL/min) are at high risk for further decline in kidney function during the pregnancy, and this may not reverse after delivery. Diabetic gastroparesis can severely exacerbate the nausea and vomiting of pregnancy and some patients may require fluid and nutritional support.

Although there is evidence that glyburide is safe during pregnancy, the current practice is to control diabetes with insulin therapy. Every effort should be made, utilizing multiple injections of insulin or a continuous infusion of insulin by pump, to maintain near-normalization of fasting and preprandial blood glucose values while avoiding hypoglycemia. The fast-acting insulin analogs insulin aspart and insulin lispro can be used, but data on using the long-acting insulin analogs are limited. A small study using insulin glargine in 32 pregnancies did not reveal any problems. There are no data on insulin detemir use in pregnancy. NPH is currently the preferred intermediate insulin for basal coverage during pregnancy.

Unless there are fetal or maternal complications, diabetic women should be able to carry the pregnancy to full-term, delivering at 38 to 41 weeks. Induction of labor before 39 weeks may be considered if there is concern about increasing fetal weight. See Chapter 19 for further details.

Boinpally T et al. Management of type 2 diabetes and gestational diabetes in pregnancy. *Mt Sinai J Med.* 2009 Jun;76(3):269–80. [PMID: 19421970]

Castorino K et al. Pregnancy and diabetes management: advances and controversies. *Clin Chem.* 2011 Feb;57(2):221–30. [PMID: 21148303]

Griesdale DE et al. Intensive insulin therapy and mortality among critically ill patients: a meta-analysis including NICE-SUGAR study data. *CMAJ.* 2009 Apr 14;180(8):821–7. [PMID: 19318387]

Scurlock C et al. Critique of normoglycemia in intensive care evaluation: survival using glucose algorithm regulation (NICE-SUGAR)—a review of recent literature. *Curr Opin Clin Nutr Metab Care.* 2010 Mar;13(2):211–4. [PMID: 20010098]

► Prognosis

The DCCT showed that the previously poor prognosis for as many as 40% of patients with type 1 diabetes is markedly improved by optimal care. DCCT participants were generally young and highly motivated and were cared for in academic centers by skilled diabetes educators and endocrinologists who were able to provide more attention and services than are usually available. Improved training of primary care providers may be beneficial.

For type 2 diabetes, the UKPDS documented a reduction in microvascular disease with glycemic control, although this was not apparent in the obese subgroup. Cardiovascular outcomes were not improved by glycemic control, although antihypertensive therapy showed benefit in reducing the number of adverse cardiovascular complications as well as in reducing the occurrence of microvascular disease among hypertensive patients. In patients with visceral obesity, successful management of type 2 diabetes remains a major challenge in the attempt to achieve appropriate control of hyperglycemia, hypertension, and dyslipidemia. Once safe and effective methods are devised to prevent or manage obesity, the prognosis of type 2 diabetes with its high cardiovascular risks should improve considerably.

In addition to poorly understood genetic factors relating to differences in individual susceptibility to development of long-term complications of hyperglycemia, it is clear that in both types of diabetes, the diabetic patient's intelligence, motivation, and awareness of the potential complications of the disease contribute significantly to the ultimate outcome.

► When to Refer

- All patients should receive self-management education when diabetes is diagnosed and at intervals thereafter. The instructional team must include a registered dietitian and registered nurse; they must be Certified Diabetes Educators (CDEs).
- Patients with type 1 diabetes should be referred to an endocrinologist for comanagement with a primary care provider.
- Patients with type 2 diabetes should be referred to an endocrinologist if treatment goals are not met or if the patient requires an increasingly complex regimen to maintain glycemic control.

- Patients with type 2 diabetes should be referred to an ophthalmologist or optometrist for a dilated eye examination when the diabetes is diagnosed, and patients with type 1 diabetes should be referred 5 years after the diagnosis is made.
- Patients with peripheral neuropathy, especially those with loss of protective threshold (unable to detect 5.07 Semmes-Weinstein filament) or structural foot problems, should be referred to a podiatrist.
- Referrals to other specialists may be required for management of chronic complications of diabetes.

American Association of Diabetes Educators <http://www.aadenet.org/>

American Diabetes Association <http://www.diabetes.org/home>
American Diabetes Association. Standards of Medical Care in Diabetes—2012 *Diabetes Care.* 2012 Jan;35(Suppl 1):S11–63. [PMID: 22187469]

American Dietetic Association <http://www.eatright.org>

Juvenile Diabetes Foundation <http://www.jdf.org/index.html>

DIABETIC COMA

Coma may be due to a variety of causes not directly related to diabetes. Certain causes directly related to diabetes require differentiation: (1) Hypoglycemic coma resulting from excessive doses of insulin or oral hypoglycemic agents. (2) Hyperglycemic coma associated with either severe insulin deficiency (diabetic ketoacidosis) or mild to moderate insulin deficiency (hyperglycemic hyperosmolar state). (3) Lactic acidosis associated with diabetes, particularly in diabetics stricken with severe infections or with cardiovascular collapse.

DIABETIC KETOACIDOSIS



ESSENTIALS OF DIAGNOSIS

- ▶ Hyperglycemia > 250 mg/dL (13.9 mmol/L).
- ▶ Acidosis with blood pH < 7.3.
- ▶ Serum bicarbonate < 15 mEq/L.
- ▶ Serum positive for ketones.

► General Considerations

Diabetic ketoacidosis may be the initial manifestation of type 1 diabetes or may result from increased insulin requirements in type 1 diabetes patients during the course of infection, trauma, myocardial infarction, or surgery. It is a life-threatening medical emergency with a mortality rate just under 5% in individuals under 40 years of age, but with a more serious prognosis in the elderly, who have mortality rates over 20%. The National Data Group reports an annual incidence of five to eight episodes of diabetic ketoacidosis per 1000 diabetic persons. Ketoacidosis may develop in patients with type 2 diabetes when severe stress such as sepsis or trauma is present. Diabetic ketoacidosis

has been found to be one of the more common serious complications of insulin pump therapy, occurring in approximately 1 per 80 patient-months of treatment. Many patients who monitor capillary blood glucose regularly ignore urine ketone measurements, which would signal the possibility of insulin leakage or pump failure before serious illness develops. Poor compliance, either for psychological reasons or because of inadequate education, is one of the most common causes of diabetic ketoacidosis, particularly when episodes are recurrent.

► Clinical Findings

A. Symptoms and Signs

The appearance of diabetic ketoacidosis is usually preceded by a day or more of polyuria and polydipsia associated with marked fatigue, nausea, and vomiting. If untreated, mental stupor ensues that can progress to coma. Drowsiness is fairly common but frank coma only occurs in about 10% of patients. On physical examination, evidence of dehydration in a stuporous patient with rapid deep breathing and a “fruity” breath odor of acetone would strongly suggest the diagnosis. Hypotension with tachycardia indicates profound fluid and electrolyte depletion, and mild hypothermia is usually present. Abdominal pain and even tenderness may be present in the absence of abdominal disease. Conversely, cholecystitis or pancreatitis may occur with minimal symptoms and signs.

B. Laboratory Findings

(Table 27–13.) Typically, the patient with moderately severe diabetic ketoacidosis has a plasma glucose of 350–900 mg/dL (19.4–50 mmol/L), serum ketones at a dilution of 1:8 or greater, hyperkalemia (serum potassium level of 5–8 mEq/L), slight hyponatremia (serum sodium of approximately 130 mEq/L), hyperphosphatemia (serum phosphate level of 6–7 mg/dL [1.9–2.3 mmol/L]), and elevated blood urea nitrogen and serum creatinine levels. Acidosis may be severe (pH ranging from 6.9 to 7.2, and serum bicarbonate ranging

from 5 mEq/L to 15 mEq/L); PCO_2 is low (15–20 mm Hg) related to hyperventilation. Fluid depletion is marked, typically about 100 mL/kg.

The hyperkalemia occurs despite total body potassium depletion because of the shift of potassium from the intracellular to extracellular spaces that occurs in systemic acidosis. The average total body potassium deficit resulting from osmotic diuresis, acidosis, and gastrointestinal losses is about 3–5 mEq/kg body weight. Similarly, despite the elevated serum phosphate, total body phosphate is generally depleted. Serum sodium is generally reduced due to loss of sodium ions (7–10 mEq/kg) by polyuria and vomiting and because severe hyperglycemia shifts intracellular water into the interstitial compartment. There is some controversy about the correction factor for the serum sodium in the presence of hyperglycemia. Many guidelines recommend a correction factor, whereby the serum sodium concentration decreases by 1.6 mEq/L for every 100 mg/dL (5.56 mmol/L) rise in plasma glucose above normal, but there is evidence that the decrease may be greater when patients have more severe hyperglycemia (greater than 400 mg/dL or 22.2 mmol/L) and/or volume depletion. One group has suggested (based on short-term exposure of normal volunteers to markedly elevated glucose levels) that, when the serum glucose is greater than 200 mg/dL (11.1 mmol/L), the serum sodium concentration decreases by at least 2.4 mEq/L. Serum osmolality can be directly measured by standard tests of freezing point depression or can be estimated by calculating the molarity of sodium, chloride, and glucose in the serum. A convenient method of estimating effective serum osmolality is as follows (normal values in humans are 280–300 mosm/kg):

$$\text{mosm/kg} = 2 [\text{measured Na}^+] + \frac{\text{Glucose (mg/dL)}}{18}$$

These calculated estimates are usually 10–20 mosm/kg lower than values measured by standard cryoscopic techniques. Central nervous system depression or coma occurs when the effective serum osmolality exceeds 320–330

Table 27–13. Laboratory diagnosis of coma in diabetic patients.

	Urine Glucose	Acetone	Plasma Glucose	Bicarbonate	Acetone
Related to diabetes					
Hypoglycemia	0 ¹	0 or +	Low	Normal	0
Diabetic ketoacidosis	++++	++++	High	Low	++++
Hyperglycemic hyperosmolar state coma	++++	0	High	Normal or slightly low	0
Lactic acidosis	0 or +	0 or +	Normal or low or high	Low	0 or +
Unrelated to diabetes					
Alcohol or other toxic drugs	0 or +	0 or +	May be low	Normal or low ²	0 or +
Cerebrovascular accident or head trauma	+ or 0	0	Often high	Normal	0
Uremia	0 or +	0	High or normal	Low	0 or +

¹Leftover urine in bladder might still contain glucose from earlier hyperglycemia.

²Alcohol can elevate plasma lactate as well as keto acids to reduce pH.

mosm/L. Coma in a diabetic patient with a lower osmolality should prompt a search for cause of coma other than hyperosmolality (see Chapter 21).

Blood urea nitrogen and serum creatinine are invariably elevated because of dehydration. In some automated creatinine assays, serum creatinine can be falsely elevated by nonspecific chromogenicity of keto acids and glucose. Most laboratories, however, now routinely eliminate this interference.

Ketoacidemia represents the effect of insulin lack at multiple enzyme loci. Insulin lack associated with elevated levels of growth hormone, catecholamines, and glucagon contributes to increases in lipolysis from adipose tissue and in hepatic ketogenesis. In addition, reduced ketolysis by insulin-deficient peripheral tissues contributes to the ketoacidemia. The only true “keto” acid present is acetoacetic acid which, along with its by-product acetone, is measured by nitroprusside reagents (Acetest and Ketostix). The sensitivity for acetone, however, is poor, requiring over 10 mmol/L, which is seldom reached in the plasma of ketoacidotic patients—although this detectable concentration is readily achieved in urine. Thus, in the plasma of ketotic patients, only acetoacetate is measured by these reagents. The more prevalent β -hydroxybutyric acid has no ketone group and is therefore not detected by conventional nitroprusside tests. This takes on special importance in the presence of circulatory collapse during diabetic ketoacidosis, wherein an increase in lactic acid can shift the redox state to increase β -hydroxybutyric acid at the expense of the readily detectable acetoacetic acid. Bedside diagnostic reagents are then unreliable, suggesting no ketonemia in cases where β -hydroxybutyric acid is a major factor in producing the acidosis. A combined glucose and ketone meter (Precision Xtra, Abbott Diabetes Care) that is able to measure blood β -hydroxybutyrate concentration on capillary blood is now available. Many clinical laboratories also offer direct blood β -hydroxybutyrate measurement.

Elevation of serum amylase is common but often represents salivary as well as pancreatic amylase. Thus, in this setting, an elevated serum amylase is not specific for acute pancreatitis. Serum lipase may be useful if the diagnosis of acute pancreatitis is being seriously considered. Leukocytosis as high as 25,000/mcL with a left shift may occur with or without associated infection. The presence of an elevated or even a normal temperature would suggest the presence of an infection, since patients with diabetic ketoacidosis are generally hypothermic if uninfected.

► Treatment

Patients with mild diabetic ketoacidosis are alert and have pH levels between 7.25 and 7.30; those with moderate ketoacidosis have pH levels between 7.0 and 7.24 and are either alert or little drowsy; and those with severe ketoacidosis are stuporose and have a pH < 7.0. Those with mild ketoacidosis can be treated in the emergency department, but those with moderate or severe ketoacidosis require admission to the ICU or step-down unit. Therapeutic goals are to restore plasma volume and tissue perfusion, reduce blood glucose and osmolality toward normal,

correct acidosis, replenish electrolyte losses, and identify and treat precipitating factors. Gastric intubation is recommended in the comatose patient to prevent vomiting and aspiration that may occur as a result of gastric atony, a common complication of diabetic ketoacidosis. An indwelling catheter may also be necessary. In patients with preexisting cardiac or renal failure or those in severe cardiovascular collapse, a central venous pressure catheter or a Swan-Ganz catheter should be inserted to evaluate the degree of hypovolemia and to monitor subsequent fluid administration.

A comprehensive flow sheet that includes vital signs, serial laboratory data, and therapeutic interventions (eg, fluids, insulin) should be meticulously maintained by the clinician responsible for the patient's care. Plasma glucose should be recorded hourly and electrolytes and pH at least every 2–3 hours during the initial treatment period. Bedside glucose meters should be used to titrate the insulin therapy. The patient should not receive sedatives or opioids.

A. Fluid Replacement

In most patients, the fluid deficit is 4–5 L. Initially, 0.9% saline solution is the solution of choice to help reexpand the contracted vascular volume and should be started in the emergency department as soon as the diagnosis is established. The saline should be infused rapidly to provide 1 L/h over the first 1–2 hours. After the first 2 L of fluid have been given, the intravenous infusion should be at the rate of 300–400 mL/h. Use 0.9% (“normal”) saline unless the serum sodium is > 150 mEq/L, when 0.45% (“half normal”) saline solution should be used. The volume status should be very carefully monitored. Failure to give enough volume replacement (at least 3–4 L in 8 hours) to restore normal perfusion is one of the most serious therapeutic shortcomings adversely influencing satisfactory recovery. Excessive fluid replacement (more than 5 L in 8 hours) may contribute to acute respiratory distress syndrome or cerebral edema. When blood glucose falls to approximately 250 mg/dL (13.9 mmol/L), the fluids should be changed to a 5% glucose-containing solution to maintain serum glucose in the range of 250–300 mg/dL (13.9–16.7 mmol/L). This will prevent the development of hypoglycemia and will also reduce the likelihood of cerebral edema, which could result from too rapid decline of blood glucose.

B. Insulin Replacement

Immediately after initiation of fluid replacement, regular insulin should be given intravenously in a loading dose of 0.1 unit/kg as an intravenous bolus to prime the tissue insulin receptors. Following the initial bolus, intravenous doses of insulin as low as 0.1 unit/kg/h are continuously infused or given hourly as an intramuscular injection; this is sufficient to replace the insulin deficit in most patients. A recent prospective randomized study showed that a bolus dose is not required if patients are given hourly insulin infusion at 0.14 unit/kg. Replacement of insulin deficiency helps correct the acidosis by reducing the flux of fatty acids to the liver, reducing ketone production by the liver, and also improving removal of ketones from the blood. Insulin treatment

reduces the hyperosmolality by reducing the hyperglycemia. It accomplishes this by increasing removal of glucose through peripheral utilization as well as by decreasing production of glucose by the liver. This latter effect is accomplished by direct inhibition of gluconeogenesis and glycogenolysis as well as by lowered amino acid flux from muscle to liver and reduced hyperglucagonemia.

The insulin dose should be “piggy-backed” into the fluid line so the rate of fluid replacement can be changed without altering the insulin delivery rate. If the plasma glucose level fails to fall at least 10% in the first hour, a repeat loading dose (0.1 or 0.14 unit/kg) is recommended. The availability of bedside glucometers and of laboratory instruments for rapid and accurate glucose analysis (Beckman or Yellow Springs glucose analyzer) has contributed much to achieving optimal insulin replacement. Rarely, a patient with immune insulin resistance is encountered, and this requires doubling the insulin dose every 2–4 hours if hyperglycemia does not improve after the first two doses of insulin. The insulin dose should be adjusted to lower the glucose concentration by about 50–70 mg/dL (2.8–3.9 mmol/L).

C. Potassium

Total body potassium loss from polyuria and vomiting may be as high as 200 mEq. However, because of shifts of potassium from cells into the extracellular space as a consequence of acidosis, serum potassium is usually normal to slightly elevated prior to institution of treatment. As the acidosis is corrected, potassium flows back into the cells, and hypokalemia can develop if potassium replacement is not instituted. If the patient is not uremic and has an adequate urinary output, potassium chloride in doses of 10–30 mEq/h should be infused during the second and third hours after beginning therapy as soon as the acidosis starts to resolve. Replacement should be started sooner if the initial serum potassium is inappropriately normal or low and should be delayed if serum potassium fails to respond to initial therapy and remains above 5 mEq/L, as in cases of chronic kidney disease. Occasionally, a patient may present with a serum potassium level < 3.5 mEq/L, in which case insulin therapy should be delayed until the potassium level is corrected to > 3.5 mEq/L. An ECG can be of help in monitoring the patient’s potassium status: High peaked T waves are a sign of hyperkalemia, and flattened T waves with U waves are a sign of hypokalemia. Foods high in potassium content should be prescribed when the patient has recovered sufficiently to take food orally. Tomato juice has 14 mEq of potassium per 240 mL, and a medium-sized banana provides about 10 mEq.

D. Sodium Bicarbonate

The use of sodium bicarbonate in management of diabetic ketoacidosis has been questioned since clinical benefit was not demonstrated in one prospective randomized trial and because of the following potentially harmful consequences: (1) development of hypokalemia from rapid shift of potassium into cells if the acidosis is overcorrected; (2) tissue anoxia from reduced dissociation of oxygen from

hemoglobin when acidosis is rapidly reversed (leftward shift of the oxygen dissociation curve); and (3) cerebral acidosis resulting from lowering of cerebrospinal fluid pH. It must be emphasized, however, that these considerations are less important when very severe acidosis exists. Therefore, it is recommended that bicarbonate be administered to diabetic patients in ketoacidosis if the arterial blood pH is 7.0 or less, with careful monitoring to prevent overcorrection. One or two ampules of sodium bicarbonate (one ampule contains 44 mEq/50 mL) should be added to 1 L of 0.45% saline. (**Note:** Addition of sodium bicarbonate to 0.9% saline would produce a markedly hypertonic solution that could aggravate the hyperosmolar state already present.) This should be administered rapidly (over the first hour). It can be repeated until the arterial pH reaches 7.1, but *it should not be given if the pH is 7.1 or greater* since additional bicarbonate would increase the risk of rebound metabolic alkalosis as ketones are metabolized. Alkalosis shifts potassium from serum into cells, which could precipitate a fatal cardiac arrhythmia.

E. Phosphate

Phosphate replacement is seldom required in treating diabetic ketoacidosis. However, if severe hypophosphatemia of < 1 mg/dL (< 0.32 mmol/L) develops during insulin therapy, a small amount of phosphate can be replaced per hour as the potassium salt. Correction of hypophosphatemia helps restore the buffering capacity of the plasma, thereby facilitating renal excretion of hydrogen. It also corrects the impaired oxygen dissociation from hemoglobin by regenerating 2,3-diphosphoglycerate. However, three randomized studies in which phosphate was replaced in only half of a group of patients with diabetic ketoacidosis did not show any apparent clinical benefit from phosphate administration. Moreover, attempts to use potassium phosphate as the sole means of replacing potassium have led to a number of reported cases of severe hypocalcemia with tetany. To minimize the risk of inducing tetany from too-rapid replacement of phosphate, the average deficit of 40–50 mmol of phosphate should be replaced intravenously at a rate *no* > 3–4 mmol/h in a 60–70-kg person. A stock solution (Abbott) provides a mixture of 1.12 g KH_2PO_4 and 1.18 g K_2HPO_4 in a 5-mL single-dose vial (this equals 22 mmol of potassium and 15 mmol of phosphate). One-half of this vial (2.5 mL) should be added to 1 L of either 0.45% saline or 5% dextrose in water. Two liters of this solution, infused at a rate of 400 mL/h, will correct the phosphate deficit at the optimal rate of 3 mmol/h while providing 4.4 mEq of potassium per hour. (Additional potassium should be administered as potassium chloride to provide a total of 10–30 mEq of potassium per hour, as noted above.) If the serum phosphate remains below 2.5 mg/dL (0.8 mmol/L) after this infusion, a repeat 5-hour infusion can be given.

F. Hyperchloremic Acidosis During Therapy

Because of the considerable loss of keto acids in the urine during the initial phase of therapy, substrate for subsequent regeneration of bicarbonate is lost and correction of the total bicarbonate deficit is hampered. A portion of the

bicarbonate deficit is replaced with chloride ions infused in large amounts as saline to correct the dehydration. In most patients, as the ketoacidosis clears during insulin replacement, a hyperchloremic, low-bicarbonate pattern emerges with a normal anion gap. This is a relatively benign condition that reverses itself over the subsequent 12–24 hours once intravenous saline is no longer being administered. Using a balanced electrolyte solution similar to serum in chloride concentration and pH during resuscitation instead of normal saline has been reported to prevent the hyperchloremic acidosis.

G. Treatment of Associated Infection

Antibiotics are prescribed as indicated. Cholecystitis and pyelonephritis may be particularly severe in these patients.

H. Transition to Subcutaneous Insulin Regimen

Once the diabetic ketoacidosis is controlled and the patient is awake and able to eat, subcutaneous insulin therapy can be initiated. The patient with type 1 diabetes may have persistent significant tissue insulin resistance and may require a total daily insulin dose of approximately 0.6 units/kg. The amount of insulin required in the previous 8 hours can also be helpful in estimating the initial insulin doses. Half the total daily dose can be given as a long-acting basal insulin and the other half as short-acting insulin premeals. The patient should receive subcutaneous basal insulin and rapid-acting insulin analog with the first meal and the insulin infusion discontinued an hour later. The overlap of the subcutaneous insulin action and insulin infusion is necessary to prevent relapse of the diabetic ketoacidosis. The increased insulin resistance is only present for a few days, and it is important to reduce both the basal and bolus insulins to avoid hypoglycemia. A patient with new-onset type 1 diabetes usually still has significant beta cell function and may not need any basal insulin and only very low doses of rapid-acting insulin before meals after recovery from the ketoacidosis. Patients with type 2 diabetes and diabetes ketoacidosis due to severe illness may initially require insulin therapy but can often transition back to oral agents during outpatient follow-up.

► Prognosis

Low-dose insulin infusion and fluid and electrolyte replacement combined with careful monitoring of patients' clinical and laboratory responses to therapy have dramatically reduced the mortality rates of diabetic ketoacidosis to < 5%. However, this complication remains a significant risk in the aged who have mortality rates > 20% and in patients in profound coma in whom treatment has been delayed. Acute myocardial infarction and infarction of the bowel following prolonged hypotension worsen the outlook. A serious prognostic sign is end-stage chronic kidney disease, and prior kidney dysfunction worsens the prognosis considerably because the kidney plays a key role in compensating for massive pH and electrolyte abnormalities. Symptomatic cerebral edema occurs primarily in the

pediatric population. Risk factors for its development include severe baseline acidosis, rapid correction of hyperglycemia, and excess volume administration in the first 4 hours. Onset of headache or deterioration in mental status during treatment should lead to consideration of this complication. Intravenous mannitol at a dosage of 1–2 g/kg given over 15 minutes is the mainstay of treatment. Excess crystalloid infusion can precipitate pulmonary edema. Acute respiratory distress syndrome is a rare complication of treatment of diabetic ketoacidosis.

After recovery and stabilization, patients should be instructed on how to recognize the early symptoms and signs of ketoacidosis. Urine ketones or capillary blood β -hydroxybutyrate should be measured in patients with signs of infection or in insulin pump-treated patients when capillary blood glucose remains unexpectedly and persistently high. When heavy ketonuria and glycosuria persist on several successive examinations, supplemental rapid acting insulin should be administered and liquid foods such as lightly salted tomato juice and broth should be ingested to replenish fluids and electrolytes. The patient should be instructed to contact the clinician if ketonuria persists, and especially if there is vomiting and inability to keep down fluids. Recurrent episodes of severe ketoacidosis often indicate poor compliance with the insulin regimen, and these patients will require intensive counseling.

Kitabchi AE et al. Hyperglycemic crises in adult patients with diabetes. *Diabetes Care*. 2009 Jul;32(7):1335–43. [PMID: 19564476]

Savage MW et al. Joint British Diabetes Societies guideline for the management of diabetic ketoacidosis. *Diabet Med*. 2011 May;28(5):508–15. [PMID: 21255074]

Weber C et al. Prevention of diabetic ketoacidosis and self-monitoring of ketone bodies: an overview. *Curr Med Res Opin*. 2009 May;25(5):1197–207. [PMID: 19327102]

HYPERGLYCEMIC HYPEROSMOLAR STATE



ESSENTIALS OF DIAGNOSIS

- ▶ Hyperglycemia > 600 mg/dL (33.3 mmol/L).
- ▶ Serum osmolality > 310 mosm/kg.
- ▶ No acidosis; blood pH above 7.3.
- ▶ Serum bicarbonate > 15 mEq/L.
- ▶ Normal anion gap (< 14 mEq/L).

► General Considerations

This second most common form of hyperglycemic coma is characterized by severe hyperglycemia in the absence of significant ketosis, with hyperosmolality and dehydration. It occurs in patients with mild or occult diabetes, and most patients are typically middle-aged to elderly. Accurate figures are not available as to its true incidence, but from data on hospital discharges it is rarer than diabetic ketoacidosis

even in older age groups. Lethargy and confusion develop as serum osmolality exceeds 310 mosm/kg, and coma can occur if osmolality exceeds 320–330 mosm/kg. Underlying chronic kidney disease or congestive heart failure is common, and the presence of either worsens the prognosis. A precipitating event such as infection, myocardial infarction, stroke, or recent operation is often present. Certain medications such as phenytoin, diazoxide, corticosteroids, and diuretics have been implicated in its pathogenesis, as have procedures associated with glucose loading such as peritoneal dialysis.

▶ Pathogenesis

A partial or relative insulin deficiency may initiate the syndrome by reducing glucose utilization of muscle, fat, and liver while inducing hyperglucagonemia and increasing hepatic glucose output. With massive glycosuria, obligatory water loss ensues. If a patient is unable to maintain adequate fluid intake because of an associated acute or chronic illness or has suffered excessive fluid loss, marked dehydration results. As plasma volume contracts, chronic kidney disease develops, and the resultant limitation of renal glucose loss leads to increasingly higher blood glucose concentrations. Severe hyperosmolality develops that causes mental confusion and finally coma. It is not clear why ketosis is virtually absent under these conditions of insulin insufficiency, although reduced levels of growth hormone may be a factor, along with portal vein insulin concentrations sufficient to restrain ketogenesis.

▶ Clinical Findings

A. Symptoms and Signs

Onset may be insidious over a period of days or weeks, with weakness, polyuria, and polydipsia. The lack of features of ketoacidosis may retard recognition of the syndrome and delay therapy until dehydration becomes more profound than in ketoacidosis. Reduced intake of fluid is not an uncommon historical feature, due to either inappropriate lack of thirst, nausea, or inaccessibility of fluids to elderly, bedridden patients. Lethargy and confusion develop, progressing to convulsions and deep coma. Physical examination confirms the presence of profound dehydration in a lethargic or comatose patient without Kussmaul respirations.

B. Laboratory Findings

(Table 27–13.) Severe hyperglycemia is present, with blood glucose values ranging from 800 mg/dL to 2400 mg/dL (44.4 mmol/L to 133.2 mmol/L). In mild cases, where dehydration is less severe, dilutional hyponatremia as well as urinary sodium losses may reduce serum sodium to 120–125 mEq/L, which protects to some extent against extreme hyperosmolality. However, as dehydration progresses, serum sodium can exceed 140 mEq/L, producing serum osmolality readings of 330–440 mosm/kg. Ketosis and acidosis are usually absent or mild. Prerenal azotemia is the rule, with serum urea nitrogen elevations over 100 mg/dL (35.7 mmol/L) being typical.

▶ Treatment

A. Fluid Replacement

Fluid replacement is of paramount importance in treating nonketotic hyperglycemic coma. The onset of hyperosmolality is more insidious in elderly people without ketosis than in younger individuals with high serum ketone levels, which provide earlier indicators of severe illness (vomiting, rapid deep breathing, acetone odor, etc). Consequently, diagnosis and treatment are often delayed until fluid deficit has reached levels of 6–10 L.

If hypovolemia is present as evidenced by hypotension and oliguria, fluid therapy should be initiated with 0.9% saline. In all other cases, 0.45% saline appears to be preferable as the initial replacement solution because the body fluids of these patients are markedly hyperosmolar. As much as 4–6 L of fluid may be required in the first 8–10 hours. Careful monitoring of the patient is required for proper sodium and water replacement. Once blood glucose reaches 250 mg/dL (13.9 mmol/L), fluid replacement should include 5% dextrose in either water, 0.45% saline solution, or 0.9% saline solution. The rate of dextrose infusion should be adjusted to maintain glycemic levels of 250–300 mg/dL (13.9–16.7 mmol/L) in order to reduce the risk of cerebral edema. An important end point of fluid therapy is to restore urinary output to 50 mL/h or more.

B. Insulin

Less insulin may be required to reduce the hyperglycemia in nonketotic patients as compared to those with diabetic ketoacidotic coma. In fact, fluid replacement alone can reduce hyperglycemia considerably by correcting the hypovolemia, which then increases both glomerular filtration and renal excretion of glucose. An initial insulin dose of 0.1 unit/kg is followed by an insulin infusion of 0.1 units/kg/h (or just an infusion of 0.14 units/kg/h without a bolus), which is titrated to lower blood glucose levels by 50–70 mg/dL per hour (2.8–3.9 mmol/L/h). Once the patient has stabilized and the blood glucose falls to around 250 mg/dL (13.9 mmol/L), insulin can be given subcutaneously.

C. Potassium

With the absence of acidosis, there may be no initial hyperkalemia unless associated end-stage chronic kidney disease is present. This results in less severe total potassium depletion than in diabetic ketoacidosis, and less potassium replacement is therefore needed. However, because initial serum potassium is usually not elevated and because it declines rapidly as a result of insulin's effect on driving potassium intracellularly, it has been recommended that potassium replacement be initiated earlier than in ketotic patients, assuming that no chronic kidney disease or oliguria is present. Potassium chloride (10 mEq/L) can be added to the initial bottle of fluids administered if the patient's serum potassium is not elevated.

D. Phosphate

If severe hypophosphatemia (serum phosphate < 1 mg/dL [< 0.32 mmol/L]) develops during insulin therapy, phosphate

replacement can be given as described for ketoacidotic patients (at 3 mmol/h).

► Prognosis

The severe dehydration and low output state may predispose the patient to complications such as myocardial infarction, stroke, pulmonary embolism, mesenteric vein thrombosis, and disseminated intravascular coagulation. Fluid replacement remains the primary approach to the prevention of these complications. Low-dose heparin prophylaxis is reasonable but benefits of routine anticoagulation remain doubtful. Rhabdomyolysis is a recognized complication and should be looked for and treated.

The overall mortality rate of hyperglycemic hyperosmolar state coma is more than ten times that of diabetic ketoacidosis, chiefly because of its higher incidence in older patients, who may have compromised cardiovascular systems or associated major illnesses and whose dehydration is often excessive because of delays in recognition and treatment. (When patients are matched for age, the prognoses of these two hyperglycemic emergencies are reasonably comparable.) When prompt therapy is instituted, the mortality rate can be reduced from nearly 50% to that related to the severity of coexistent disorders.

After the patient is stabilized, the appropriate form of long-term management of the diabetes must be determined. Insulin treatment should be continued for a few weeks but patients usually recover sufficient endogenous insulin secretion to make a trial of diet or diet plus oral agents worthwhile. When the episode occurs in a patient who has known diabetes, then education of the patient and caregivers should be instituted. They should be taught how to recognize situations (nausea and vomiting, infection) that predispose to recurrence of the hyperglycemic, hyperosmolar state, as well as detailed information on how to prevent the escalating dehydration that culminates in hyperosmolar coma (small sips of sugar-free liquids, increase in usual hypoglycemic therapy, or early contact with the clinician).

American Diabetes Association. Hyperglycemic crises in patients with diabetes mellitus. *Diabetes Care*. 2001 Jan;24(1):154–61. [PMID: 11221603]

Nyenwe EA et al. Evidence-based management of hyperglycemic emergencies in diabetes mellitus. *Diabetes Res Clin Pract*. 2011 Dec;94(3):340–51. [PMID: 21978840]

LACTIC ACIDOSIS



ESSENTIALS OF DIAGNOSIS

- Severe acidosis with hyperventilation.
- Blood pH below 7.30.
- Serum bicarbonate < 15 mEq/L.
- Anion gap > 15 mEq/L.
- Absent serum ketones.
- Serum lactate > 5 mmol/L.

► General Considerations

Lactic acidosis is characterized by accumulation of excess lactic acid in the blood. Normally, the principal sources of this acid are the erythrocytes (which lack enzymes for aerobic oxidation), skeletal muscle, skin, and brain. Conversion of lactic acid to glucose and its oxidation principally by the liver but also by the kidneys represent the chief pathways for its removal. Overproduction of lactic acid (tissue hypoxia), deficient removal (hepatic failure), or both (circulatory collapse) can cause accumulation. Lactic acidosis is not uncommon in any severely ill patient suffering from cardiac decompensation, respiratory or hepatic failure, septicemia, or infarction of bowel or extremities. With the discontinuance of phenformin therapy in the United States, lactic acidosis in patients with diabetes mellitus has become uncommon but occasionally occurs in metformin-treated patients (see above) and it still must be considered in the acidotic diabetic, especially if the patient is seriously ill. Most cases of metformin-associated lactic acidosis occur in patients in whom there were contraindications to the use of metformin, in particular renal failure.

► Clinical Findings

A. Symptoms and Signs

The main clinical feature of lactic acidosis is marked hyperventilation. When lactic acidosis is secondary to tissue hypoxia or vascular collapse, the clinical presentation is variable, being that of the prevailing catastrophic illness. However, in the idiopathic, or spontaneous, variety, the onset is rapid (usually over a few hours), blood pressure is normal, peripheral circulation is good, and there is no cyanosis.

B. Laboratory Findings

Plasma bicarbonate and blood pH are quite low, indicating the presence of severe metabolic acidosis. Ketones are usually absent from plasma and urine or at least not prominent. The first clue may be a high anion gap (serum sodium minus the sum of chloride and bicarbonate anions [in mEq/L] should be no > 15). A higher value indicates the existence of an abnormal compartment of anions. If this cannot be clinically explained by an excess of keto acids (diabetes), inorganic acids (uremia), or anions from medication overdosage (salicylates, methyl alcohol, ethylene glycol), then lactic acidosis is probably the correct diagnosis. (See also Chapter 21.) In the absence of azotemia, hyperphosphatemia may be a clue to the presence of lactic acidosis for reasons that are not clear. The diagnosis is confirmed by demonstrating, in a sample of blood that is promptly chilled and separated, a plasma lactic acid concentration of 5 mmol/L or higher (values as high as 30 mmol/L have been reported). Normal plasma values average 1 mmol/L, with a normal lactate/pyruvate ratio of 10:1. This ratio is greatly exceeded in lactic acidosis.¹

¹In collecting samples, it is essential to rapidly chill and separate the blood in order to remove red cells, whose continued glycolysis at room temperature is a common source of error in reports of high plasma lactate. Frozen plasma remains stable for subsequent assay.

► Treatment

Aggressive treatment of the precipitating cause of lactic acidosis is the main component of therapy, such as ensuring adequate oxygenation and vascular perfusion of tissues. Empiric antibiotic coverage for sepsis should be given after culture samples are obtained in any patient in whom the cause of the lactic acidosis is not apparent.

Alkalinization with intravenous sodium bicarbonate to keep the pH above 7.2 has been recommended by some in the emergency treatment of lactic acidosis; as much as 2000 mEq in 24 hours has been used. However, there is no evidence that the mortality rate is favorably affected by administering bicarbonate, and its use remains controversial. Hemodialysis may be useful in cases where large sodium loads are poorly tolerated and in cases associated with metformin toxicity.

► Prognosis

The mortality rate of spontaneous lactic acidosis is high. The prognosis in most cases is that of the primary disorder that produced the lactic acidosis.

Fitzgerald E et al. Metformin associated lactic acidosis. *BMJ*. 2009 Sep 16;339:b3660. [PMID: 19759079]

Goergen SK et al. Systematic review of current guidelines, and their evidence base, on risk of lactic acidosis after administration of contrast medium for patients receiving metformin. *Radiology*. 2010 Jan;254(1):261–9. [PMID: 20032157]

Jansen TC et al. Blood lactate monitoring in critically ill patients: a systematic health technology assessment. *Crit Care Med*. 2009 Oct;37(10):2827–39. [PMID: 19707124]

Salpeter SR et al. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. *Cochrane Database Syst Rev*. 2010 Jan 20;(1):CD002967. [PMID: 20091535]

▼ THE HYPOGLYCEMIC STATES

Spontaneous hypoglycemia in adults is of two principal types: fasting and postprandial. Symptoms begin at plasma glucose levels in the range of 60 mg/dL (3.3 mmol/L) and impairment of brain function at approximately 50 mg/dL (2.8 mmol/L). Fasting hypoglycemia is often subacute or chronic and usually presents with neuroglycopenia as its principal manifestation; postprandial hypoglycemia is relatively acute and is often heralded by symptoms of neurogenic autonomic discharge (sweating, palpitations, anxiety, tremulousness).

► Differential Diagnosis (Table 27-14)

Fasting hypoglycemia may occur in certain endocrine disorders, such as hypopituitarism, Addison disease, or myxedema; in disorders related to liver malfunction, such as acute alcoholism or liver failure; and in instances of end-stage chronic kidney disease, particularly in patients requiring dialysis. These conditions are usually obvious, with hypoglycemia being only a secondary feature. When fasting hypoglycemia is a primary manifestation developing in adults without apparent endocrine disorders or inborn metabolic diseases from childhood, the principal diagnostic possibilities include: (1) hyperinsulinism, due to either

Table 27-14. Common causes of hypoglycemia in adults.¹

Fasting hypoglycemia
Pancreatic B cell tumor
Surreptitious administration of insulin or sulfonylureas
Extrapancreatic tumors
Postprandial hypoglycemia
Alimentary
Noninsulinoma pancreatogenous hypoglycemia syndrome
Functional
Occult diabetes mellitus
Alcohol-related hypoglycemia
Immunopathologic hypoglycemia
Idiopathic anti-insulin antibodies (which release their bound insulin)
Antibodies to insulin receptors (which act as agonists)
Drug-induced hypoglycemia

¹In the absence of clinically obvious endocrine, renal, or hepatic disorders and exclusive of diabetes mellitus treated with hypoglycemic agents.

pancreatic B cell tumors, iatrogenic or surreptitious administration of insulin or sulfonylurea and (2) hypoglycemia due to extrapancreatic tumors.

Postprandial (reactive) hypoglycemia may be seen after gastrointestinal surgery and is particularly associated with the dumping syndrome after gastrectomy and Roux-en-Y gastric bypass surgery. Occult diabetes very occasionally present with postprandial hypoglycemia. Rarely, it occurs with islet cell hyperplasia—the so-called noninsulinoma pancreatogenous hypoglycemia syndrome.

Alcohol-related hypoglycemia is due to hepatic glycogen depletion combined with alcohol-mediated inhibition of gluconeogenesis. It is most common in malnourished alcohol abusers but can occur in anyone who is unable to ingest food after an acute alcoholic episode followed by gastritis and vomiting.

Immunopathologic hypoglycemia is an extremely rare condition in which anti-insulin antibodies or antibodies to insulin receptors develop spontaneously. In the former case, the mechanism appears to relate to increasing dissociation of insulin from circulating pools of bound insulin. When antibodies to insulin receptors are found, most patients do not have hypoglycemia but rather severe insulin-resistant diabetes and acanthosis nigricans. However, during the course of the disease in these patients, certain anti-insulin receptor antibodies with agonist activity mimicking insulin action may develop, producing severe hypoglycemia.

HYPOGLYCEMIA DUE TO PANCREATIC B CELL TUMORS



ESSENTIALS OF DIAGNOSIS

- Hypoglycemic symptoms—frequently neuroglycopenic (confusion, blurred vision, diplopia, anxiety, convulsions).

- ▶ Immediate recovery upon administration of glucose.
- ▶ Blood glucose < 45 mg/dL (2.5 mmol/L) with a serum insulin level of 6 microunit/mL or more.

▶ General Considerations

Fasting hypoglycemia in an otherwise healthy, well-nourished adult is rare and is most commonly due to an adenoma of the islets of Langerhans. Ninety percent of such tumors are single and benign, but multiple adenomas can occur as well as malignant tumors with functional metastases. Adenomas may be familial, and multiple adenomas have been found in conjunction with tumors of the parathyroids and pituitary (MEN type 1 [MEN 1]). Over 99% of them are located within the pancreas and less than 1% in ectopic pancreatic tissue.

▶ Clinical Findings

A. Symptoms and Signs

The most important prerequisite to diagnosing an insulinoma is simply to consider it, particularly in relatively healthy-appearing persons who have fasting hypoglycemia associated with some degree of central nervous system dysfunction such as confusion or abnormal behavior. A delay in diagnosis can result in unnecessary treatment for psychomotor epilepsy or psychiatric disorders and may cause irreversible brain damage. In longstanding cases, obesity can result as a consequence of overeating to relieve symptoms.

The so-called **Whipple triad** is characteristic of hypoglycemia regardless of the cause. It consists of: (1) a history of hypoglycemic symptoms; (2) an associated fasting blood glucose of 45 mg/dL (2.5 mmol/L) or less; and (3) immediate recovery upon administration of glucose. The hypoglycemic symptoms in insulinoma often develop in the early morning or after missing a meal. Occasionally, they occur after exercise. They typically begin with evidence of central nervous system glucose lack and can include blurred vision or diplopia, headache, feelings of detachment, slurred speech, and weakness. Personality and mental changes vary from anxiety to psychotic behavior, and neurologic deterioration can result in convulsions or coma. Sweating and palpitations may not occur.

Hypoglycemic unawareness is very common in patients with insulinoma. They adapt to chronic hypoglycemia by increasing their efficiency in transporting glucose across the blood-brain barrier, which masks awareness that their blood glucose is approaching critically low levels. Counterregulatory hormonal responses as well as neurogenic symptoms such as tremor, sweating, and palpitations are therefore blunted during hypoglycemia. If lack of these warning symptoms prevents recognition of the need to eat to correct the problem, patients can lapse into severe hypoglycemic coma. However, symptoms and normal hormone responses during experimental insulin-induced hypoglycemia have been shown to be restored after successful surgical removal of the insulinoma. Presumably with return of euglycemia, adaptive

Table 27–15. Diagnostic criteria for insulinoma after a 72-hour fast.

Laboratory Test	Result
Plasma glucose	< 45mg/dL (2.5 mmol/L)
Plasma insulin (RIA) ¹	≥ 6 microunit/mL
Plasma insulin (ICMA) ¹	≥ 3 microunit/mL
Plasma C-peptide	≥ 200 pmol/L (0.2nmol/L)
Plasma proinsulin	≥ 5 pmol/L
β-hydroxybutyrate	≤ 2.7 mmol/L
Sulfonylurea screen (including repaglinide and nateglinide)	Negative

¹Conversion factors: insulin microunit/mL × 6.0 = nmol/L; C-peptide ng/mL × 0.333 = nmol/L

effects on glucose transport into the brain are corrected, and thresholds of counterregulatory responses and neurogenic autonomic symptoms are therefore restored to normal.

B. Laboratory Findings

B cell adenomas do not reduce secretion in the presence of hypoglycemia, and the critical diagnostic test is to demonstrate inappropriately elevated serum insulin levels at a time when hypoglycemia is present. A reliable serum insulin level (radioimmunoassay) of 6 microunit/mL or more in the presence of blood glucose values below 45 mg/dL (2.5 mmol/L) is diagnostic of inappropriate hyperinsulinism (Table 27–15). Immunochemiluminometric assays (ICMA) have sensitivities of < 1 microunit/mL, and with these assays, the cutoffs for insulinomas is insulin level of 3 microunit/mL or higher. Other causes of hyperinsulinemic hypoglycemia must be considered, including factitious administration of insulin or sulfonylureas. Factitious use of insulin will result in suppression of endogenous insulin secretion and a low C-peptide levels. An elevated circulating proinsulin level in the presence of fasting hypoglycemia is characteristic of most B cell adenomas and does not occur in factitious hyperinsulinism. Thus, C-peptide and proinsulin levels (by ICMA) of > 200 pmol/L and > 5 pmol/L, respectively, are characteristic of insulinomas. In patients with insulinoma, plasma β-hydroxybutyrate levels are suppressed to 2.7 mmol/L or less.

In patients with epigastric distress, a history of renal calculi, or menstrual or erectile dysfunction, a serum calcium, gastrin, or prolactin level may be useful in screening for MEN 1 associated with insulinoma.

C. Diagnostic Tests

If the history is consistent with episodic spontaneous hypoglycemia, patients should be given a home blood glucose monitor and advised to monitor blood glucose levels at the time of symptoms and before consumption of carbohydrates, if this can be done safely. Patients with insulinomas frequently report fingerstick blood glucose levels between 40 mg/dL (2.2 mmol/L) and 50 mg/dL (2.8 mmol/L) at the time of symptoms. The diagnosis,

however, cannot be made based on a fingerstick blood glucose. It is necessary to have a low laboratory glucose concomitantly with elevated plasma insulin, proinsulin, and C-peptide levels and a negative sulfonylurea screen. When patients give a history of symptoms after only a short period of food withdrawal or with exercise, then an outpatient assessment can be attempted. The patient should be brought by a family member to the office after an overnight fast and observed in the office. Activity such as walking should be encouraged and fingerstick blood glucose measured repeatedly during observation. If symptoms occur or fingerstick blood glucose is below 50 mg/dL (2.8 mmol/L) then samples for plasma glucose, insulin, C-peptide, proinsulin, sulfonylurea screen, serum ketones, and antibodies to insulin should be sent. If outpatient observation does not result in symptoms or hypoglycemia and if the clinical suspicion remains high, then the patient should undergo an inpatient supervised 72-hour fast. A suggested protocol for the supervised fast is shown in Table 27–16.

In 30% of patients with insulinoma, the blood glucose levels often drop below 45 mg/dL (2.5 mmol/L) after an overnight fast, but some patients require up to 72 hours to develop symptomatic hypoglycemia. However, the term “72-hour fast” is actually a misnomer in most cases since the fast should be immediately terminated as soon as symptoms appear and laboratory confirmation of hypoglycemia is available. In normal male subjects, the blood glucose does not fall below 55–60 mg/dL (3.1–3.3 mmol/L) during a 3-day fast. In contrast, in normal premenopausal women who have fasted for only 24 hours, the plasma glucose may fall normally to such an extent that it can reach values as low as 35 mg/dL (1.9 mmol/L). In these cases,

Table 27–16. Suggested hospital protocol for supervised fast in diagnosis of insulinoma.

- (1) Obtain baseline serum glucose, insulin, proinsulin, and C-peptide measurements at onset of fast and place intravenous cannula.
- (2) Permit only calorie-free and caffeine-free fluids and encourage supervised activity (such as walking).
- (3) Measure urine for ketones at the beginning and every 12 hours and at end of fast.
- (4) Obtain capillary glucose measurements with a reflectance meter every 4 hours until values < 60 mg/dL are obtained. Then increase the frequency of fingersticks to each hour, and when capillary glucose value is < 49 mg/dL send a venous blood sample to the laboratory for serum glucose, insulin, proinsulin, and C-peptide measurements. Check frequently for manifestations of neuroglycopenia.
- (5) If symptoms of hypoglycemia occur or if a laboratory value of serum glucose is < 45 mg/dL, or if 72 hours have elapsed then conclude the fast with a final blood sample for serum glucose, insulin, proinsulin, C-peptide, β -hydroxybutyrate and sulfonylurea measurements. Then give oral fast-acting carbohydrate followed by a meal. If the patient is confused or unable to take oral agents, then administer 50 mL of 50% dextrose intravenously over 3 to 5 minutes. Do not conclude a fast based simply on a capillary blood glucose measurement—wait for the laboratory glucose value—unless the patient is very symptomatic and it would be dangerous to wait.

however, the women are not symptomatic, presumably owing to the development of sufficient ketonemia to supply energy needs to the brain. Insulinoma patients, on the other hand, become symptomatic when plasma glucose drops to subnormal levels, since inappropriate insulin secretion restricts ketone formation. Moreover, the demonstration of a nonsuppressed insulin level ≥ 6 microunit/mL using a RIA assay (> 3 microunit/mL using an ICMA assay) in the presence of hypoglycemia suggests the diagnosis of insulinoma. If hypoglycemia does not develop in a male patient after fasting for up to 72 hours—and particularly when this prolonged fast is terminated with a period of moderate exercise—insulinoma must be considered an unlikely diagnosis.

Stimulation with pancreatic B cell secretagogues such as tolbutamide, glucagon, or leucine has been devised to demonstrate exaggerated and prolonged insulin secretion in the presence of insulinomas. However, because insulin-secreting tumors have a wide range of granule content and degrees of differentiation, they are variably responsive to these secretagogues; and a negative response does not necessarily rule out an insulinoma. For these reasons, stimulation tests are not recommended in the diagnostic work-up of insulinoma.

An oral glucose tolerance test is of no value in the diagnosis of insulin secreting tumors. HbA_{1c} levels may be low but there is considerable overlap with normal patients and no particular value is diagnostic.

D. Preoperative Localization of B Cell Tumors

After the diagnosis of insulinoma has been unequivocally made by clinical and laboratory findings, studies to localize the tumor should be initiated. The focus of attention should be directed to the pancreas since that is where virtually all insulinomas originate.

Because of the small size of these tumors (averaging 1.5 cm in diameter in one large series), imaging studies do not necessarily identify all of them. A pancreatic dual phase helical CT scan with thin section can identify 82–94% of the lesions. MRI scans with gadolinium can be helpful in detecting a tumor in 85% of cases. One case report suggests that diffusion-weighted MRI can be useful for detecting and localizing small insulinomas, especially for those with no hypervascular pattern. The imaging study used will depend on local availability and local radiologic skill. If the imaging study is normal, then an endoscopic ultrasound should be performed. In experienced hands, about 80–90% of tumors can be detected with this procedure. Fine-needle aspiration of the identified lesion can be attempted to confirm the presence of a neuroendocrine tumor. If the tumor is not identified or the imaging result is equivocal, then the patient should undergo selective calcium-stimulated angiography, which has been reported to localize the tumor to a particular region of the pancreas approximately about 90% of the time. In this test, angiography is combined with injections of calcium gluconate into the gastroduodenal, splenic, and superior mesenteric arteries, and insulin levels are measured in the hepatic vein effluent. The procedure is performed after an overnight fast. Calcium gluconate 10% solution diluted to a volume of 5 mL with 0.95% saline is bolused into the selected artery at a dose of 0.0125 mmol

calcium/kg (0.005 mmol calcium/kg for obese patients). Small samples of blood (5 mL) are taken from the hepatic effluent at times 0, 30, 60, 90, 120, and 180 seconds after the calcium injection. Fingerstick blood glucose levels are measured at intervals and a dextrose infusion is maintained throughout the procedure to prevent hypoglycemia. Calcium stimulates insulin release from insulinomas but not normal islets, and so a step-up from baseline in insulin levels at 30 or 60 seconds (twofold or greater) regionalizes the source of the hyperinsulinism to the head of the pancreas for the gastroduodenal artery, the uncinate process for the superior mesenteric artery, and the body and tail of the pancreas for the splenic artery calcium infusions. A less than twofold elevation of insulin in the 120-second sample may represent effects of recirculating calcium and is not considered a positive localization. In a single insulinoma, the response is in one artery alone unless the tumor resides in an area fed by two arteries or if there are multiple insulinomas (eg, in MEN 1). Patients who have diffuse islet hyperplasia (the noninsulinoma pancreatogenous hypoglycemia syndrome) will have positive responses in multiple arteries. Because diazoxide may interfere with this test, it should be discontinued for at least 48–72 hours before sampling. Patients should be closely monitored during the procedure to avoid hypoglycemia (as well as hyperglycemia, which could affect insulin gradients). These studies combined with careful intraoperative ultrasonography and palpation by a surgeon experienced in insulinoma surgery identifies up to 98% of tumors.

► Treatment

The treatment of choice for insulin-secreting tumors is surgical resection. While waiting for surgery, patients should be given oral diazoxide. Divided doses of 300–400 mg/d usually suffice although an occasional patient may require up to 800 mg/d. Side effects include edema due to sodium retention, gastric irritation, and mild hirsutism. Hydrochlorothiazide, 25–50 mg daily, can be used to counteract the sodium retention and edema as well potentiate diazoxide's hyperglycemic effect.

Tumor resection should be performed by a surgeon with previous experience in removing pancreatic B cell tumors. In patients with a single benign adenoma, 90–95% have a successful cure at the first surgical attempt when intraoperative ultrasound is used by a skilled surgeon. Diazoxide should be administered on the day of the surgery because it reduces the risk of hypoglycemia during surgery. Typically, it does not mask the glycemic rise indicative of surgical cure. Blood glucose should be monitored throughout surgery, and 5% or 10% dextrose infusion should be used to maintain euglycemia. In cases where the diagnosis has been established but no adenoma is located after careful palpation and use of intraoperative ultrasound, it is no longer advisable to blindly resect the body and tail of the pancreas, since a nonpalpable tumor missed by ultrasound is most likely embedded within the fleshy head of the pancreas that is left behind with subtotal resections. Most surgeons prefer to close the incision and schedule a selective arterial calcium stimulation with hepatic venous sampling

to locate the tumor site prior to a repeat operation. Laparoscopy using ultrasound and enucleation has been successful with a single tumor of the body or tail of the pancreas, but open surgery remains necessary for tumors in the head of the pancreas.

In patients with inoperable functioning islet cell carcinoma and in approximately 5–10% of MEN 1 cases when subtotal removal of the pancreas has failed to produce cure, diazoxide is treatment of choice. Frequent carbohydrate feedings (every 2 to 3 hours) can also be helpful although weight gain may become a problem. If patients are unable to tolerate diazoxide because of gastrointestinal upset, hirsutism, or edema, the calcium channel blocker verapamil may be beneficial in view of its inhibitory effect on insulin release from insulinoma cells. Octreotide, a potent long-acting synthetic octapeptide analog of somatostatin, has been used to inhibit release of hormones from a number of endocrine tumors. A dose of 50 mcg of octreotide injected subcutaneously twice daily has been tried in cases where surgery failed to remove the source of hyperinsulinism. However, its effectiveness is limited since its affinity for somatostatin receptors of the pancreatic B cell is very much less than for those of the anterior pituitary somatotrophs for which it was originally designed as treatment for acromegaly. When hypoglycemia persists after attempted surgical removal of the insulinoma and if diazoxide or verapamil is poorly tolerated or ineffective, multiple small feedings may be the only recourse. Streptozocin can decrease insulin secretion in islet cell carcinomas and increase survival. With selective arterial administration, effective cytotoxic doses have been achieved without undue renal toxicity that characterized early experience. Benign tumors appear to respond poorly, if at all.

Cryer PE et al. Evaluation and management of adult hypoglycemic disorders: an Endocrine Society Clinical Practice Guideline. *J Clin Endocrinol Metab.* 2009 Mar;94(3):709–28. [PMID: 19088155]

Kapoor RR et al. Advances in the diagnosis and management of hyperinsulinemic hypoglycemia. *Nat Clin Pract Endocrinol Metab.* 2009 Feb;5(2):101–12. [PMID: 19165222]

Mathur A et al. Insulinoma. *Surg Clin North Am.* 2009 Oct; 89(5):1105–21. [PMID: 19836487]

NONISLET CELL TUMOR HYPOGLYCEMIA

These rare causes of hypoglycemia include mesenchymal tumors such as retroperitoneal sarcomas, hepatocellular carcinomas, adrenocortical carcinomas, and miscellaneous epithelial-type tumors. The tumors are frequently large and readily palpated or visualized on CT scans or MRI.

In many cases the hypoglycemia is due to the expression and release of an incompletely processed insulin-like growth factor 2 (IGF-2) by the tumor. This immature form of the IGF-II molecule (pro-IGF-2 or “big IGF-2”) binds IGF-binding protein-3 (IGFBP-3) but not to the acid-labile subunit. As a consequence, this pro-IGF-II remains active and binds to insulin receptors in muscle to promote glucose transport and to insulin receptors in liver and kidney to reduce glucose output. It also binds to receptors for IGF-1

in the pancreatic B cell to inhibit insulin secretion and in the pituitary to suppress growth hormone release. With the reduction of growth hormone, there is a consequent lowering of IGF-1 levels as well as IGFBP-3 and acid-labile subunit.

The diagnosis is supported by laboratory documentation of serum insulin levels below 5 microunit/mL with plasma glucose levels of 45 mg/dL (2.5 mmol/L) or lower. Values for growth hormone and IGF-1 are also decreased. Levels of IGF-2 may be increased but often are “normal” in quantity, despite the presence of the immature, higher-molecular-weight form of IGF-2, which can only be detected by special laboratory techniques.

Not all the patients with nonislet cell tumor hypoglycemia have elevated pro-IGF-II. Ectopic insulin production has been described in bronchial carcinoma, ovarian carcinoma, and small cell carcinoma of the cervix. Hypoglycemia due to IgF-1 released from a metastatic large cell carcinoma of the lung has also been reported.

The prognosis for these tumors is generally poor, and surgical removal should be attempted when feasible. Dietary management of the hypoglycemia is the mainstay of medical treatment, since diazoxide is usually ineffective.

de Groot JW et al. Non-islet cell tumour-induced hypoglycaemia: a review of the literature including two new cases. *Endocr Relat Cancer*. 2007 Dec;14(4):979–93. [PMID: 18045950]

POSTPRANDIAL HYPOGLYCEMIA

1. Hypoglycemia Following Gastric Surgery

Hypoglycemia sometimes develops in patients who have undergone gastric surgery (eg, gastrectomy, vagotomy, pyloroplasty, gastrojejunostomy, Nissan fundoplication, Bilioth II procedure and Roux-en-Y), especially when they consume foods containing high levels of carbohydrates. This late dumping syndrome occurs about 1–3 hours after a meal and is a result of rapid delivery of high concentration of carbohydrates in the proximal small bowel and rapid absorption of glucose. The hyperinsulinemic response to the high carbohydrate load causes hypoglycemia. The symptoms include lightheadedness, sweating, confusion and even loss of consciousness after eating a high carbohydrate meal. It is possible that gastrointestinal hormones such as GLP-1 play a role in the hyperinsulinemic response. The incidence of secondary dumping syndrome declined with the advent of medical therapy for peptic ulcer disease. There has been resurgence of cases, however, with the popularity of Roux-en-Y gastric bypass surgery for the treatment of morbid obesity. Patients typically complain of symptoms that are more severe after consumption of large amounts of readily absorbable carbohydrates. In terms of documenting hypoglycemia, it is reasonable to request the patient to consume a meal that leads to symptoms during everyday life. An oral glucose tolerance test is not recommended because many normal persons have false-positive test results. There have been case reports of insulinoma and noninsulinoma pancreatogenous hypoglycemia syndrome

in patients with hypoglycemia post Roux-en-Y surgery. It is unclear how often this occurs. A careful history may identify patients who have a history of hypoglycemia with exercise or meals, and these individuals may require a formal 72-hour fast to rule out an insulinoma.

Treatment for secondary dumping includes dietary modification, but this may be difficult to sustain. Patients can try more frequent meals with smaller portions of less rapidly digested carbohydrates. α -Glucosidase therapy may be a useful adjunct to a low carbohydrate diet. Octreotide 50 mcg administered subcutaneously two or three times a day 30 minutes prior to each meal has been reported to improve symptoms due to late dumping syndrome. Various surgical procedures to delay gastric emptying have been reported to improve symptoms but long-term efficacy studies are lacking.

2. Noninsulinoma Pancreatogenous Hypoglycemia Syndrome (Islet Cell Hyperplasia)

In a very small number of patients with organic hyperinsulinism, islet cell hyperplasia is present rather than an adenoma. This condition is referred to as noninsulinoma pancreatogenous hypoglycemia syndrome. These patients typically have documented hyperinsulinemic hypoglycemia after meals but not with fasting up to 72 hours. The patients have a positive response to calcium-stimulated angiography. A gradient-guided partial pancreatectomy leads to clinical remission, and the pathology of the pancreas shows evidence of islet cell hyperplasia and nesidioblastosis. These patients do not have mutations in the pancreatic islet beta-cell ATP-sensitive potassium channel inward rectifier (*Kir 6.2*) and the sulfonylurea receptor-1 (*SUR1*) genes, which have been reported in children with familial hyperinsulinemic hypoglycemia.

3. Functional Alimentary Hypoglycemia

Patients have symptoms suggestive of increased sympathetic activity, including anxiety, weakness, tremor, sweating or palpitations after meals. Physical examination and laboratory tests are normal. Previously, many of these patients underwent a 5-hour oral glucose tolerance test and the detection of glucose levels in the 50–60 mg/dL (2.8–3.3 mmol/L) range was thought to be responsible for the symptoms; the recommended treatment was dietary modification. It is now recognized that at least 10% of normal patients who do not have any symptoms have nadir glucose levels < 50 mg/dL (2.8 mmol/L) during a 4- to 6-hour oral glucose tolerance test. In a study comparing responses to oral glucose tolerance test with a mixed meal test, none of the patients who had plasma glucose levels < 50 mg/dL on oral glucose had low glucose values with the mixed meal. Thus, it is not recommended that these patients with symptoms suggestive of increased sympathetic activity undergo either a prolonged oral glucose tolerance test or a mixed meal test. Instead, the patients should be given home blood glucose monitors (with memories) and instructed to monitor fingerstick glucose levels at the time of symptoms. Only patients who have symptoms when

their fingerstick blood glucose is low (< 50 mg/dL) and who have resolution of symptoms when the glucose is raised by eating rapidly released carbohydrate need additional evaluation. Patients who do not have evidence for low glucose levels at time of symptoms are generally reassured by their findings. Counseling and support should be the mainstays in therapy, with dietary manipulation only an adjunct.

4. Occult Diabetes

This condition is characterized by a delay in early insulin release from pancreatic B cells, resulting in initial exaggeration of hyperglycemia during a glucose tolerance test. In response to this hyperglycemia, an exaggerated insulin release produces a late hypoglycemia 4–5 hours after ingestion of glucose. These patients are often obese and frequently have a family history of diabetes mellitus.

Patients with this type of postprandial hypoglycemia often respond to reduced intake of refined sugars with multiple, spaced, small feedings high in dietary fiber. In the obese, treatment is directed at weight reduction to achieve ideal weight. These patients should be considered to have prediabetes or early diabetes (type 1 or 2) and advised to have periodic medical evaluations.

5. Autoimmune Hypoglycemia

Patients with autoimmune hypoglycemia have early postprandial hyperglycemia followed by hypoglycemia 3–4 hours later. The hypoglycemia is attributed to a dissociation of insulin-antibody immune complexes, releasing free insulin.

The disorder is associated with methimazole treatment for Graves disease, although it can also occur in patients treated with various other sulfhydryl-containing medications (captopril, penicillamine) as well as other drugs such as hydralazine, isoniazid, and procainamide. In addition, it has been reported in patients with autoimmune disorders such as rheumatoid arthritis, systemic lupus erythematosus, and polymyositis as well as in multiple myeloma and other plasma cell dyscrasias where paraproteins or antibodies cross-react with insulin. There is also an association with the HLA class II alleles (DRB1*0406, DQA1*0301, and DQB1*0302). These alleles are 10 to 20 times more common in Japanese and Korean populations, which explains why the disorder has been reported mostly in Japanese patients.

High titers of insulin autoantibodies, usually IgG class, can be detected. Insulin, proinsulin, and C-peptide levels may be elevated, but the results may be erroneous because of the interference of the insulin antibodies with the immunoassays for these peptides.

In most cases, the hypoglycemia is transient and usually resolves spontaneously within 3–6 months of diagnosis, particularly when the offending medications are stopped. The most consistent therapeutic benefit in management of this syndrome has been achieved by dietary treatment with small, frequent low-carbohydrate meals. Prednisone (30–60 mg orally daily) has been used to lower the titer of insulin antibodies.

Kellogg TA et al. Postgastric bypass hyperinsulinemic hypoglycemia syndrome: characterization and response to a modified diet. *Surg Obes Relat Dis.* 2008 Jul–Aug;4(4):492–9. [PMID: 18656831]

Lupsa BC et al. Autoimmune forms of hypoglycemia. *Medicine (Baltimore).* 2009 May;88(3):141–53. [PMID: 19440117]

FACTITIOUS HYPOGLYCEMIA

Factitious hypoglycemia may be difficult to document. A suspicion of self-induced hypoglycemia is supported when the patient is associated with the health professions or has access to insulin or sulfonylurea medications taken by a diabetic member of the family. The triad of hypoglycemia, high immunoreactive insulin, and suppressed plasma C peptide immunoreactivity is pathognomonic of exogenous insulin administration. Demonstration of circulating insulin antibodies supports this diagnosis in suspected cases. When sulfonylureas, repaglinide and nateglinide are suspected as a cause of factitious hypoglycemia, a plasma level of these medications to detect their presence may be required to distinguish laboratory findings from those of insulinoma.

Charlton R et al. Munchausen's syndrome manifesting as factitious hypoglycaemia. *Diabetologia.* 2001 Jun;44(6):784–5. [PMID: 11440375]

Hirshberg B et al. Repaglinide-induced factitious hypoglycemia. *J Clin Endocrinol Metab.* 2001 Feb;86(2):475–7. [PMID: 11157993]

Trenque T et al. Prevalence of factitious hypoglycaemia associated with sulphonylurea drugs in France in the year 2000. *Br J Clin Pharmacol.* 2002 Nov;54(5):548. [PMID: 12445037]

HYPOGLYCEMIA DUE TO INSULIN RECEPTOR ANTIBODIES

Hypoglycemia due to insulin receptor autoantibodies is also an extremely rare syndrome; most cases have occurred in women often with a history of autoimmune disease. Almost all of these patients have also had episodes of insulin-resistant diabetes and acanthosis nigricans. Their hypoglycemia may be either fasting or postprandial and is often severe and is attributed to an agonistic action of the antibody on the insulin receptor. Balance between the antagonistic and agonistic effects of the antibodies determines whether insulin-resistant diabetes or hypoglycemia occurs. Hypoglycemia was found to respond to corticosteroid therapy but not to plasmapheresis or immunosuppression.

Kim CH et al. Autoimmune hypoglycemia in a type 2 diabetic patient with anti-insulin and insulin receptor antibodies. *Diabetes Care.* 2004 Jan;27(1):288–9. [PMID: 14694017]

Yaturu S et al. Severe autoimmune hypoglycemia with insulin antibodies necessitating plasmapheresis. *Endocr Pract.* 2004 Jan–Feb;10(1):49–54. [PMID: 15251622]

MEDICATION-INDUCED HYPOGLYCEMIA

A number of medications apart from the sulfonylureas can occasionally cause hypoglycemia. Common offenders

include the fluoroquinolones such as gatifloxacin and levofloxacin, pentamidine, quinine, ACE inhibitors, salicylates and β -adrenergic blocking agents. The fluoroquinolones, particularly gatifloxacin, has been associated with both hypoglycemia and hyperglycemia. It is thought that the drug acts on the ATP sensitive potassium channels in the beta cell. Hypoglycemia is an early event, and hyperglycemia occurs several days into therapy. Intravenous pentamidine is cytotoxic to beta cells and causes acute hyperinsulinemia and hypoglycemia followed by insulinopenia and hyperglycemia. Fasting patients taking non-cardioselective β -blockers can have an exaggerated hypoglycemic response to starvation. The β -blockade inhibits fatty acids and gluconeogenesis substrate release and reduces plasma glucagon response. Therapy with ACE inhibitors increases the risk of hypoglycemia in patients who are taking insulin or sulfonylureas presumably because these drugs increase sensitivity to circulating insulin by increasing blood flow to the muscle.

Ethanol-associated hypoglycemia may be due to hepatic depletion of NADH and altered NADH:NAD⁺ ratio. This in turn limits conversion of lactate to pyruvate, the main substrate for hepatic gluconeogenesis. With prolonged starvation, glycogen reserves become depleted within

18–24 hours and hepatic glucose output becomes totally dependent on gluconeogenesis. Under these circumstances, a blood concentration of ethanol as low as 45 mg/dL (9.8 mmol/L) can induce profound hypoglycemia by blocking gluconeogenesis. Neuroglycopenia in a patient whose breath smells of alcohol may be mistaken for alcoholic stupor. Prevention consists of adequate food intake during ethanol ingestion. Therapy consists of glucose administration to replenish glycogen stores until gluconeogenesis resumes.

When sugar-containing soft drinks are used as mixers to dilute alcohol in beverages (gin and tonic, rum and cola), there seems to be a greater insulin release than when the soft drink alone is ingested and a tendency for more of a late hypoglycemic overswing to occur 3–4 hours later. Prevention would consist of avoiding sugar mixers while ingesting alcohol and ensuring supplementary food intake to provide sustained absorption.

Rave K et al. Enhancement of blood glucose lowering effect of a sulfonylurea when coadministered with an ACE inhibitor: results of a glucose-clamp study. *Diab Metabol Res Rev*. 2005 Sep–Oct;21(5):459–64. [PMID: 15915547]

Lipid Disorders

Robert B. Baron, MD, MS

28

For patients with known cardiovascular disease (secondary prevention), cholesterol lowering leads to a consistent reduction in total mortality and recurrent cardiovascular events in men and women and in middle-aged and older patients. Among patients without cardiovascular disease (primary prevention), the data are less conclusive, with rates of cardiovascular events, heart disease mortality, and all-cause mortality differing among studies. Nonetheless, treatment algorithms have been designed to assist clinicians in selecting patients for cholesterol-lowering therapy based on their lipid levels and their overall risk of developing cardiovascular disease.

LIPOPROTEINS & ATHEROGENESIS

The plaques in the arterial walls of patients with atherosclerosis contain large amounts of cholesterol. The higher the level of low-density lipoproteins (LDL) cholesterol, the greater the risk of atherosclerotic heart disease; conversely, the higher the high-density lipoproteins (HDL) cholesterol, the lower the risk of coronary heart disease (CHD). This is true in men and women, in different racial and ethnic groups, and at all ages up to age 75 years. Because most cholesterol in serum is LDL, high total cholesterol levels are also associated with an increased risk of CHD. Middle-aged men whose serum cholesterol levels are in the highest quintile for age (above about 230 mg/dL or 5.95 mmol/L) have a risk of coronary death before age 65 years of about 10%; men in the lowest quintile (below about 170 mg/dL or 4.40 mmol/L) have a 3% risk. Death from CHD before age 65 years is less common in women, with equivalent risks one-third those of men. In men, each 10-mg/dL or 0.26-mmol/L increase in cholesterol (or LDL cholesterol) increases the risk of CHD by about 10%; each 5-mg/dL or 0.13-mmol/L increase in HDL reduces the risk by about 10%. The effect of HDL cholesterol is greater in women, whereas the effects of total and LDL cholesterol are smaller.

There are several genetic disorders that provide insight into the pathogenesis of lipid-related diseases. **Familial hypercholesterolemia**, rare in the homozygous state (about one per million) is a condition in which the cell-surface receptors for the LDL molecule are absent or defective,

resulting in unregulated synthesis of LDL. Patients with two abnormal genes (homozygotes) have extremely high levels—up to eight times normal—and present with atherosclerotic disease in childhood. Homozygotes may require liver transplantation to correct their severe lipid abnormalities. Those with one defective gene (heterozygotes) have LDL concentrations twice normal; persons with this condition may develop CHD in their 30s or 40s.

Another rare condition is caused by an abnormality of lipoprotein lipase, the enzyme that enables peripheral tissues to take up triglyceride from chylomicrons and very-low-density lipoproteins (VLDL) particles. Patients with this condition, one cause of **familial hyperchylomicronemia**, have marked hypertriglyceridemia with recurrent pancreatitis and hepatosplenomegaly in childhood.

Numerous other genetic abnormalities of lipid metabolism are named for the abnormality noted when serum is electrophoresed (eg, dysbetalipoproteinemia) or from combinations of lipid abnormalities in families (eg, familial combined hyperlipidemia). Thus, family members of patients with severe lipid disorders are appropriately studied. Other patients have abnormalities in the production of apoproteins, such as increased apoprotein B and its affiliated lipoproteins, LDL and VLDL; reduced apoprotein AII and its affiliated particle; or excess lipoprotein(a). Other mutations occur in lipoprotein lipase and in the gene encoding for cholesterol efflux regulatory protein. Genome-wide association studies have identified additional genetic variants responsible for differences in serum lipids.

▶ When to Refer

- Known genetic lipid disorders.
- Striking family history of hyperlipidemia or premature atherosclerosis.
- Extremely high serum LDL cholesterol or triglyceride, or extremely low serum HDL cholesterol.

Alwaili K et al. High-density lipoproteins and cardiovascular disease: 2010 update. *Expert Rev Cardiovasc Ther.* 2010 Mar;8(3):413–23. [PMID: 20222819]

Kathiresan S et al. Polymorphisms associated with cholesterol and risk of cardiovascular events. *N Engl J Med*. 2008 Mar 20;358(12):1240–9. [PMID: 18354102]
 Pencina MJ et al. Predicting the 30-year risk of cardiovascular disease: the Framingham Heart Study. *Circulation*. 2009 Jun 23;119(24):3078–84. [PMID: 19506114]
 Pirruccello J et al. Genetics of lipid disorders. *Curr Opin Cardiol*. 2010 May;25(3):238–42. [PMID: 20224388]

LIPID FRACTIONS & THE RISK OF CORONARY HEART DISEASE

In fasting serum, cholesterol is carried primarily on three different lipoproteins—the VLDL, LDL, and HDL molecules. Total cholesterol equals the sum of these three components:

$$\text{Total cholesterol} = \text{HDL cholesterol} + \text{VLDL cholesterol} + \text{LDL cholesterol}$$

Most clinical laboratories measure the total cholesterol, the total triglycerides, and the amount of cholesterol found in the HDL fraction, which is easily precipitated from serum. Most triglyceride is found in VLDL particles, which contain five times as much triglyceride by weight as cholesterol. The amount of cholesterol found in the VLDL fraction can be estimated by dividing the triglyceride by 5:

$$\text{VLDL cholesterol} = \frac{\text{Triglycerides}}{5}$$

Because the triglyceride level is used as a proxy for the amount of VLDL, this formula works only in fasting samples and when the triglyceride level is <400 mg/dL or <4.52 mmol/L. At higher triglyceride levels, LDL and VLDL cholesterol levels can be determined after ultracentrifugation or by direct chemical measurement.

The total cholesterol is reasonably stable over time; however, measurements of HDL and especially triglycerides may vary considerably because of analytic error in the laboratory and biologic variation in a patient's lipid level. Thus, the LDL should always be estimated as the mean of at least two determinations; if those two estimates differ by more than 10%, a third lipid profile is obtained. The LDL is estimated as follows:

$$\text{LDL cholesterol} = \text{Total cholesterol} - \text{HDL cholesterol} - \frac{\text{Triglycerides (mg/dL)}}{5}$$

When using SI units, the formula becomes

$$\text{LDL cholesterol} = \text{Total cholesterol} - \text{HDL cholesterol} - \frac{\text{Triglycerides (mmol/L)}}{2.2}$$

Understanding the relationships of the different lipid fractions leads to a more accurate understanding of a

patient's lipid-related coronary risk than the total cholesterol. Two persons with the same total cholesterol of 275 mg/dL (7.11 mmol/L) may have very different lipid profiles. One may have an HDL cholesterol of 110 mg/dL (2.84 mmol/L) with a triglyceride of 150 mg/dL (1.69 mmol/L), giving an estimated LDL cholesterol of 135 mg/dL (3.49 mmol/L); the other may have an HDL cholesterol of 25 mg/dL (0.65 mmol/L) with a triglyceride of 200 mg/dL (2.26 mmol/L) and an LDL cholesterol of 210 mg/dL (5.43 mmol/L). The second would have more than a tenfold higher CHD risk than the first, assuming no differences in other factors. Because of high HDL cholesterol levels in women, many with apparently high total cholesterol levels have favorable lipid profiles. Thus, evaluation of the lipid fractions is essential before therapy is initiated.

Some authorities use the ratio of the total to HDL cholesterol as an indicator of lipid-related coronary risk: the lower this ratio is, the better. Although ratios are useful predictors within populations of patients, they may obscure important information in individual patients. (A total cholesterol of 300 mg/dL [7.76 mmol/L] and an HDL of 60 mg/dL [1.56 mmol/L] result in the same ratio as a total cholesterol of 150 mg/dL [3.88 mmol/L] with an HDL of 30 mg/dL [0.78 mmol/L].) Moreover, the total cholesterol-to-HDL cholesterol ratio will magnify the importance of variations in HDL measurement.

There is no true "normal" range for serum lipids. In Western populations, cholesterol values are about 20% higher than in Asian populations and exceed 300 mg/dL (7.76 mmol/L) in nearly 5% of adults. About 10% of adults have LDL cholesterol levels above 200 mg/dL (5.17 mmol/L). Total and LDL cholesterol levels tend to rise with age in persons who are otherwise in good health.

Declines are seen in acute illness, and lipid studies in such patients are of little value with the exception of the serum triglyceride level in a patient with pancreatitis. Cholesterol levels (even when expressed as an age-matched percentile rank, such as the highest 20%) do not remain constant over time, especially from childhood through adolescence and young adulthood. Thus, children and young adults with relatively high cholesterol may have lower levels later in life, whereas those with low cholesterol may show increases.

THERAPEUTIC EFFECTS OF LOWERING CHOLESTEROL

Reducing cholesterol levels in healthy middle-aged men without CHD (primary prevention) reduces their risk in proportion to the reduction in LDL cholesterol and the increase in HDL cholesterol. Treated patients have statistically significant and clinically important reductions in the rates of myocardial infarctions, new cases of angina, and need for coronary artery bypass procedures. The West of Scotland Study showed a 31% decrease in myocardial infarctions in middle-aged men treated with pravastatin compared with placebo. The Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS) study showed similar results with lovastatin. As with any

primary prevention interventions, large numbers of healthy patients need to be treated to prevent a single event. The numbers of patients needed to treat (NNT) to prevent a nonfatal myocardial infarction or a coronary artery disease death in these two studies were 46 and 50, respectively. The Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) study of atorvastatin in subjects with hypertension and other risk factors but without CHD also demonstrated a convincing 36% reduction in CHD events. The Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) showed a 44% reduction in a combined end point of myocardial infarction, stroke, revascularization, hospitalization for unstable angina, or death from cardiovascular causes. The NNT for 1 year to prevent one event was 169.

Primary prevention studies have found a less consistent effect on total mortality. The West of Scotland study found a 20% decrease in total mortality, tending toward statistical significance. The AFCAPS/TexCAPS study with lovastatin showed no difference in total mortality. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT) also showed no reduction either in all-cause mortality or in CHD events when pravastatin was compared with usual care. Subjects treated with atorvastatin in the ASCOT study had a 13% reduction in mortality, but the result was not statistically significant. This study, however, was stopped early due to the marked reduction in CHD events. The JUPITER trial demonstrated a statistically significant 20% reduction in death from any cause. The NNT for 1 year was 400.

In patients with CHD, the benefits of cholesterol lowering are clearer. Major studies with statins have shown significant reductions in cardiovascular events, cardiovascular deaths, and all-cause mortality in men and women with coronary artery disease. The NNT to prevent a nonfatal myocardial infarction or a coronary artery disease death in these three studies were between 12 and 34. Aggressive cholesterol lowering with these agents causes regression of atherosclerotic plaques in some patients, reduces the progression of atherosclerosis in saphenous vein grafts, and can slow or reverse carotid artery atherosclerosis. Meta-analysis suggests that this latter effect results in a significant decrease in strokes. Results with other classes of medications have been less consistent. For example, gemfibrozil treatment subjects had fewer cardiovascular events, but there was no benefit in all-cause mortality when compared with placebo.

The disparities in results between primary and secondary prevention studies highlight several important points. The benefits and adverse effects of cholesterol lowering may be specific to each type of drug; the clinician cannot assume that the effects will generalize to other classes of medication. Second, the net benefits from cholesterol lowering depend on the underlying risk of CHD and of other disease. In patients with atherosclerosis, morbidity and mortality rates associated with CHD are high, and measures that reduce it are more likely to be beneficial even if they have no effect—or even slightly harmful effects—on other diseases.

- Baigent C et al; SHARP Investigators. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. *Lancet*. 2011 Jun 25;377(9784):2181–92. [PMID: 21663949]
- Bayturan O et al. The metabolic syndrome, its component risk factors, and progression of coronary atherosclerosis. *Arch Intern Med*. 2010 Mar 8;170(5):478–84. [PMID: 20212186]
- Brugts JJ et al. The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials. *BMJ*. 2009;338:b2376. [PMID: 19567909]
- Cholesterol Treatment Trialists' (CTT) Collaboration; Collins R et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. *Lancet*. 2010 Nov 13;376(9753):1670–81. [PMID: 21067804]
- Cooney MT et al; SCORE investigators. HDL cholesterol protects against cardiovascular disease in both genders, at all ages and at all levels of risk. *Atherosclerosis*. 2009 Oct;206(2):611–6. [PMID: 19375079]
- Cui Y et al. Effects of increasing high-density lipoprotein cholesterol and decreasing low-density lipoprotein cholesterol on the incidence of first acute coronary events (from the Air Force/Texas Coronary Atherosclerosis Prevention Study). *Am J Cardiol*. 2009 Sep 15;104(6):829–34. [PMID: 19733719]
- Pletcher MJ et al. Comparing impact and cost-effectiveness of primary prevention strategies for lipid-lowering. *Ann Intern Med*. 2009 Feb 17;150(4):243–54. [PMID: 19221376]

SECONDARY CONDITIONS THAT AFFECT LIPID METABOLISM

Several factors, including drugs, can influence serum lipids (Table 28–1). These are important for two reasons: abnormal lipid levels (or changes in lipid levels) may be the presenting sign of some of these conditions, and correction of the underlying condition may obviate the need to treat an apparent lipid disorder. Diabetes and alcohol use, in particular, are commonly associated with high triglyceride levels that decline with improvements in glycemic control or reduction in alcohol use, respectively. Thus, secondary causes of high blood lipids should be considered in each patient with a lipid disorder before lipid-lowering therapy is started. In most instances, special testing is not needed: a history and physical examination are sufficient. However, screening for hypothyroidism in patients with hyperlipidemia is cost effective.

CLINICAL PRESENTATIONS

Most patients with high cholesterol levels have no specific symptoms or signs. The vast majority of patients with lipid abnormalities are detected by the laboratory, either as part of the workup of a patient with cardiovascular disease or as part of a preventive screening strategy. Extremely high levels of chylomicrons or VLDL particles (triglyceride level above 1000 mg/dL or 10 mmol/L) result in the formation of **eruptive xanthomas** (Figure 28–1) (red-yellow papules, especially on the buttocks). High LDL concentrations result in **tendinous xanthomas** on certain tendons (Achilles,

Table 28-1. Secondary causes of lipid abnormalities.

Cause	Associated Lipid Abnormality
Obesity	Increased triglycerides, decreased HDL cholesterol
Sedentary lifestyle	Decreased HDL cholesterol
Diabetes mellitus	Increased triglycerides, increased total cholesterol
Alcohol use	Increased triglycerides, increased HDL cholesterol
Hypothyroidism	Increased total cholesterol
Hyperthyroidism	Decreased total cholesterol
Nephrotic syndrome	Increased total cholesterol
Chronic kidney disease	Increased total cholesterol, increased triglycerides
Cirrhosis	Decreased total cholesterol
Obstructive liver disease	Increased total cholesterol
Malignancy	Decreased total cholesterol
Cushing disease (or corticosteroid use)	Increased total cholesterol
Oral contraceptives	Increased triglycerides, increased total cholesterol
Diuretics ¹	Increased total cholesterol, increased triglycerides
β -Blockers ^{1,2}	Increased total cholesterol, decreased HDL

¹Short-term effects only.

² β -Blockers with intrinsic sympathomimetic activity, such as pindolol and acebutolol, do not affect lipid levels.



▲ **Figure 28-1.** Eruptive xanthoma on the arm of a man with untreated hyperlipidemia and diabetes mellitus. (Courtesy of Richard P. Usatine, MD; used, with permission, from Usatine RP, Smith MA, Mayeaux EJ Jr, Chumley H, Tysinger J. *The Color Atlas of Family Medicine*. McGraw-Hill, 2009.)

patella, back of the hand). Such xanthomas usually indicate one of the underlying genetic hyperlipidemias. **Lipemia retinalis** (cream-colored blood vessels in the fundus) is seen with extremely high triglyceride levels (above 2000 mg/dL or 20 mmol/L).

SCREENING FOR HIGH BLOOD CHOLESTEROL

All patients with CHD or CHD risk equivalents (other clinical forms of atherosclerosis such as peripheral artery disease, abdominal aortic aneurysm, and symptomatic carotid artery disease; patients with diabetes mellitus; and patients with multiple risk factors that confer a >20% 10-year risk for developing CHD [Table 28-2]) should be screened for elevated lipids. The only exceptions are patients in whom lipid lowering is not indicated or desirable for other reasons. Patients who already have evidence of atherosclerosis are the group at highest risk of suffering additional manifestations in the near term and thus have the most to gain from reduction of blood lipids. Additional risk reduction measures for atherosclerosis are discussed in Chapter 10; lipid lowering should be just one aspect of a program to reduce the progression and effects of the disease.

In patients with cardiovascular disease, a complete lipid profile (total cholesterol, HDL cholesterol, and triglyceride levels) after an overnight fast should be obtained as a screening test. Those whose estimated LDL cholesterol level is high should have at least one repeat measurement. Specific treatments for high LDL cholesterol levels are discussed below. The goal of therapy should be to reduce the LDL cholesterol to below 100 mg/dL (2.59 mmol/L) or optimally to below 70 mg/dL (1.81 mmol/L). Evidence suggests that treatment with a statin is effective even if the starting LDL cholesterol is below 100 mg/dL (2.59 mmol/L). These data suggest that most patients with CHD or CHD risk equivalents should be treated with statin therapy.

The best screening and treatment strategy for adults who do not have atherosclerotic cardiovascular disease is less clear. Several algorithms have been developed to guide the clinician in treatment decisions, but management decisions are individualized based on the patient's risk.

Although the National Cholesterol Education Program (NCEP) recommends screening of all adults aged 20 years or older for high blood cholesterol, the United States Preventive Services Task Force (USPSTF) suggests beginning at age 20 years only if there is increased risk of CHD. For men without increased risk, screening is recommended beginning at age 35 years. For women and for men aged 20 to 35 without increased risk, the USPSTF makes no recommendation for or against routine screening for lipid disorders. Although there is no established interval for screening, screening can be repeated every 5 years for those with average or low risk and more often for those whose levels are close to therapeutic thresholds. This strategy focuses cholesterol screening on those at the greatest risk of coronary artery disease and increases the cost effectiveness of cholesterol screening.

Individuals without cardiovascular disease can then be stratified according to risk factors as defined by the NCEP. Those with two or more risk factors are considered

Table 28-2. Framingham 10-year coronary heart disease risk projections. Calculate the number of points for each risk factor. Sum the total risk score and estimate the 10-year risk.

MEN			WOMEN		
Age	Points		Age	Points	
20-34	-9		20-34	-7	
35-39	-4		35-39	-3	
40-44	0		40-44	0	
45-49	3		45-49	3	
50-54	6		50-54	6	
55-59	8		55-59	8	
60-64	10		60-64	10	
65-69	11		65-69	12	
70-74	12		70-74	14	
75-79	13		75-79	16	

Total Cholesterol	Points				
	Age 20-39	Age 40-49	Age 50-59	Age 60-69	Age 70-79
<160	0	0	0	0	0
160-199	4	3	2	1	0
200-239	7	5	3	1	0
240-279	9	6	4	2	1
≥ 280	11	8	5	3	1

Total Cholesterol	Points				
	Age 20-39	Age 40-49	Age 50-59	Age 60-69	Age 70-79
<160	0	0	0	0	0
160-199	4	3	2	1	0
200-239	8	6	4	2	1
240-279	11	8	5	3	2
≥ 280	13	10	7	4	2

Age	Points				
	20-39	40-49	50-59	60-69	70-79
Nonsmoker	0	0	0	0	0
Smoker	8	5	3	1	1

Age	Points				
	20-39	40-49	50-59	60-69	70-79
Nonsmoker	0	0	0	0	0
Smoker	9	7	4	2	1

HDL (mg/dL)	Points
≥ 60	-1
50-59	0
40-49	1
<40	2

HDL (mg/dL)	Points
≥ 60	-1
50-59	0
40-49	1
<40	2

Systolic BP (mm Hg)	Points if Untreated	Points if Treated
	<120	0
120-129	0	1
130-139	1	2
140-159	1	2
≥ 160	2	3

Systolic BP (mm Hg)	Points if Untreated	Points if Treated
	<120	0
120-129	1	3
130-139	2	4
140-159	3	5
≥ 160	4	6

(continued)

Table 28-2. Framingham 10-year coronary heart disease risk projections. Calculate the number of points for each risk factor. Sum the total risk score and estimate the 10-year risk. (continued)

MEN		WOMEN	
Point Total	10-Year Risk %	Point Total	10-Year Risk %
<0	<1	<9	<1
0	1	9	1
1	1	10	1
2	1	11	1
3	1	12	1
4	1	13	2
5	2	14	2
6	2	15	3
7	3	16	4
8	4	17	5
9	5	18	6
10	6	19	8
11	8	20	11
12	10	21	14
13	12	22	17
14	16	23	22
15	20	24	27
16	25	≥ 25	≥ 30
≥ 17	≥ 30		

Ten-Year Risk
%

Ten-Year Risk
%

to be at intermediate risk of coronary artery disease, and those with less than two are at low risk. These risks include age and gender (men aged 45 years or older, women aged 55 years or older), a family history of premature CHD (myocardial infarction or sudden cardiac death before age 55 years in a first-degree male relative or before age 65 years in a first-degree female relative), hypertension (whether treated or not), current cigarette smoking (10 or more cigarettes per day), and low HDL cholesterol (<40 mg/dL). Because HDL cholesterol is protective against CHD, a risk factor is subtracted if the level is >60 mg/dL. Patients with two or more risk factors are then further stratified by evaluating their 10-year risk of developing CHD using Framingham projections of 10-year risk (Table 28-2). Because risk factors alone are an imprecise measure of CHD risk, estimating the 10-year risk using Framingham data is helpful even in patients with one or no risk factors.

Numerous other risk factors have been studied in an attempt to better predict future CHD events. These include high-sensitivity C-reactive protein (hs-CRP), electron beam computed tomography (EBCT), homocysteine, fibrinogen, lipoprotein a, LDL subfractions, ankle-brachial index, and others. Several of these, particularly hs-CRP and EBCT, may add additional prognostic ability after accounting for traditional risk factors, but no clinical trials have yet examined the effect of these on health outcomes. Clinical guidelines suggest limiting the use of additional risk factors such as hs-CRP to patients at intermediate risk (by Framingham projections) if additional data is likely to change a therapeutic decision.

Several strategies for obtaining the initial cholesterol measurement have been proposed, including: (1)

measuring total cholesterol alone, (2) measuring total cholesterol and HDL cholesterol, or (3) measuring LDL and HDL cholesterol. Each is acceptable, but treatment decisions are based on the LDL and HDL cholesterol levels. Measurement of the total cholesterol alone is the least expensive strategy and is adequate for low-risk individuals; those with total cholesterol >200 mg/dL (>6.0 mmol/L) should then be reevaluated with a fasting LDL and HDL cholesterol measurement. Measurement of the total cholesterol and HDL cholesterol allows for better characterization of the risk factor profile but also requires reevaluation if the total cholesterol is >200 mg/dL (>5.17 mmol/L) as recommended by the USPSTF. Initial measurement of the LDL and HDL cholesterol is least likely to lead to patient misinformation and misclassification and is the strategy recommended by the NCEP.

Treatment decisions are based on the LDL cholesterol, and the patient's risk factor profile (including the HDL cholesterol level) and estimated 10-year risk. Patients in the intermediate-risk group (two or more risk factors) are selected for diet therapy (therapeutic lifestyle changes) if LDL cholesterol is >130 mg/dL (>3.36 mmol/L). If the 10-year risk of CHD is <10%, drug treatment is recommended if LDL is >160 mg/dL (>4.14 mmol/L); if the 10-year CHD risk is between 10% and 20%, drug treatment is recommended if LDL is >130 mg/dL (>3.36 mmol/L). Low-risk individuals with one or no risk factors and estimated 10-year CHD risk <10% are selected for diet therapy if LDL cholesterol is >160 mg/dL (>4.14 mmol/L) and for drug therapy if it is >190 mg/dL (>4.91 mmol/L) (Table 28-3).

Table 28-3. LDL goals and treatment cutpoints: Recommendations of the NCEP Adult Treatment Panel III.

Risk Category	LDL Goal (mg/dL)	LDL Level at Which to Initiate Lifestyle Changes (mg/dL)	LDL Level at Which to Consider Drug Therapy ¹ (mg/dL)
High risk: CHD ² or CHD risk equivalents ³ (10-year risk >20%)	<100 (optional goal: <70 mg/dL) ⁴	≥ 100 ⁵	≥ 100 (<100: consider drug options) ⁶
Moderately high risk: 2+ risk factors ⁷ (10-year risk 10% to 20%) ⁸	<130 ⁹	≥ 130 ⁵	≥ 130 (100-129; consider drug options) ¹⁰
Moderate risk: 2+ risk factors ⁷ (10-year risk <10%) ⁸	<130	≥ 130	≥ 160
Low risk: 0-1 risk factors ¹¹	<160	≥ 160	≥ 190 (160-189: LDL-lowering drug optional)

¹When LDL-lowering drug therapy is used, it is advised that intensity of therapy be sufficient to achieve at least a 30-40% reduction in LDL cholesterol levels.

²CHD includes history of myocardial infarction, unstable angina, coronary artery procedures (angioplasty or bypass surgery), or evidence of clinically significant myocardial ischemia.

³CHD risk equivalents include clinical manifestations of noncoronary forms of atherosclerotic disease (peripheral arterial disease, abdominal aortic aneurysm, and carotid artery disease [transient ischemic attacks or stroke of carotid origin with >50% obstruction of a carotid artery]), diabetes mellitus, and ≥ 2 risk factors with 10-year risk for CHD >20%.

⁴Very high risk favors the optional LDL cholesterol goal of <70 mg/dL, or in patients with high triglycerides, non-high density lipoprotein (HDL) cholesterol <100 mg/dL.

⁵Any person at high risk or moderately high risk who has lifestyle-related risk factors (eg, obesity, physical inactivity, elevated triglyceride, low HDL cholesterol, or metabolic syndrome) is a candidate for therapeutic lifestyle changes to modify these risk factors regardless of LDL cholesterol.

⁶If baseline LDL cholesterol is <100 mg/dL, institution of an LDL-lowering drug is a therapeutic option on the basis of available clinical trial results. If a high-risk person has high triglycerides or low HDL cholesterol, combining a fibrate or nicotinic acid with an LDL-lowering drug can be considered.

⁷Risk factors include cigarette smoking, hypertension (blood pressure ≥ 140/90 mm Hg or on antihypertensive medication), low HDL cholesterol (<40 mg/dL), family history of premature CHD (CHD in male first-degree relative <55 years of age; CHD in female first-degree relative <65 years of age), and age (men ≥ 45 years; women ≥ 55 years).

⁸Electronic 10-year risk calculators are available at www.nhlbi.nih.gov/guidelines/cholesterol.

⁹Optional LDL cholesterol goal <100 mg/dL.

¹⁰For moderately high-risk persons, when the LDL cholesterol level is 100-129 mg/dL at baseline or on lifestyle therapy, initiation of an LDL-lowering drug to achieve an LDL cholesterol level <100 mg/dL is a therapeutic option on the basis of available clinical trial results.

¹¹Almost all people with zero or one risk factor have a 10-year CHD risk <10%, and 10-year risk assessment in these people is thus not necessary.

LDL, low-density lipoprotein; NCEP, National Cholesterol Education Program; CHD, coronary heart disease.

Reproduced, with permission, from Grundy SM et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. *Circulation*. 2004 Jul 13;110(2):227-39.

► Screening in Women

The foregoing screening and treatment guidelines, based largely on LDL cholesterol levels, are designed for both men and women. Yet several observational studies suggest that a low HDL cholesterol is a more important risk factor for CHD in women than a high LDL cholesterol. Meta-analysis of studies including women with known heart disease, however, has found that medications that primarily lower LDL cholesterol do prevent recurrent myocardial infarctions in women. There is insufficient evidence to be certain of a similar effect from LDL-lowering therapy in women without evidence of CHD. Although most experts recommend application of the same primary prevention guidelines for women as for men, clinicians should be aware of the uncertainty in this area. Using estimates of 10-year CHD risk may be particularly helpful in women since a larger percentage of women than men will have

estimated 10-year CHD risks below 10% per year and thus women are less likely to benefit from therapy unless their LDL cholesterol is extremely high (>190 mg/dL or 4.91 mmol/L).

► Screening in Older Patients

Meta-analysis of evidence relating cholesterol to CHD in the elderly suggests that cholesterol is not a risk factor for CHD for persons over age 75 years. Clinical trials have rarely included such individuals. One exception is the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER). In this study, elderly patients with cardiovascular disease (secondary prevention) benefited from statin therapy, whereas those without cardiovascular disease (primary prevention) did not. Although the NCEP recommends continuing treatment in the elderly, many clinicians will prefer to stop screening and treatment in patients age

75 years or older who do not have CHD. In patients age 75 years or older who have CHD, LDL-lowering therapy can be continued as recommended for younger patients with the disease. Decisions to discontinue therapy should be based on overall functional status and life expectancy, comorbidities, and patient preference and should be made in context with overall therapeutic goals and end-of-life decisions.

Bonow RO. Clinical practice. Should coronary calcium screening be used in cardiovascular prevention strategies? *N Engl J Med*. 2009 Sep 3;361(10):990–7. [PMID: 19726773]
 Emerging Risk Factors Collaboration. Major lipids, apolipoproteins, and risk of vascular disease. *JAMA*. 2009 Nov 11;302(18):1993–2000. [PMID: 19903920]
 Helfand M et al. Screening for lipid disorders in adults: selective update of 2001 US Preventive Services Task Force Review [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2008 Jun. Report No.: 08-05114-EF-1. [PMID: 20722146]
 Kuklina EV et al. Prevalence of coronary heart disease risk factors and screening for high cholesterol levels among young adults, United States, 1999–2006. *Ann Fam Med*. 2010 Jul-Aug;8(4):327–33. [PMID: 20644187]

TREATMENT OF HIGH LOW-DENSITY LIPOPROTEIN CHOLESTEROL

Reduction of LDL cholesterol is just one part of a program to reduce the risk of cardiovascular disease. Other measures—including smoking cessation, hypertension control, and aspirin—are also of central importance. Less well studied but of potential value is raising the HDL cholesterol level. Quitting smoking reduces the effect of other cardiovascular risk factors (such as a high cholesterol level); it may also increase the HDL cholesterol level. Exercise (and weight loss) may reduce the LDL cholesterol and increase the HDL. Modest alcohol use (1–2 ounces a day) also raises HDL levels and appears to have a salutary effect on CHD rates.

Several classes of medications are being actively tested to raise HDL cholesterol levels. One such class of these medications, the cholesteryl ester transfer protein inhibitors, raises HDL cholesterol levels. However, studies to date of one agent in this class, torcetrapib, have shown adverse effects on cardiovascular outcomes. A second drug, anacetrapib, is in clinical trials. Results show reductions of LDL cholesterol as well as increases in HDL cholesterol and no significant adverse experiences compared with placebo. Larger and longer trials are planned to assess the impact of this drug on clinical outcomes.

► Diet Therapy

Studies of nonhospitalized adults have reported only modest cholesterol-lowering benefits of dietary therapy, typically in the range of a 5–10% decrease in LDL cholesterol, with even less in the long term. The effect of diet therapy, however, varies considerably among individuals, as some patients will have striking reductions in LDL cholesterol—up to a 25–30% decrease—whereas others will have clinically important increases. Thus, the results of diet therapy should be assessed about 4 weeks after initiation.

Cholesterol-lowering diets may also have a variable effect on lipid fractions. Diets very low in total fat or in

saturated fat may lower HDL cholesterol as much as LDL cholesterol. It is not known how these diet-induced changes affect coronary risk.

Several nutritional approaches to diet therapy are available. Most Americans currently eat over 35% of calories as fat, of which 15% is saturated fat. Dietary cholesterol intake averages 400 mg/d. A cholesterol-lowering diet recommends reducing total fat to 25–30% and saturated fat to <7% of calories. Dietary cholesterol should be limited to <200 mg/d. These diets replace fat, particularly saturated fat, with carbohydrate. In most instances, this approach will also result in fewer total calories consumed and will facilitate weight loss in overweight patients. Other diet plans, including the Dean Ornish Diet, the Pritikin Diet, and most vegetarian diets, restrict fat even further. Low-fat, high-carbohydrate diets may, however, result in reductions in HDL cholesterol.

An alternative strategy is the “Mediterranean diet,” which maintains total fat at approximately 35–40% of total calories but replaces saturated fat with monounsaturated fat such as that found in canola oil and in olives, peanuts, avocados, and their oils. This diet is equally effective at lowering LDL cholesterol but is less likely to lead to reductions in HDL cholesterol. Several studies have suggested that this approach may also be associated with reductions in endothelial dysfunction, insulin resistance, and markers of vascular inflammation and may result in better resolution of the metabolic syndrome than traditional cholesterol-lowering diets.

Other dietary changes may also result in beneficial changes in blood lipids. Soluble fiber, such as that found in oat bran or psyllium, may reduce LDL cholesterol by 5–10%. Garlic, soy protein, vitamin C, pecans, and plant sterols may also result in reduction of LDL cholesterol. Because oxidation of LDL cholesterol is a potential initiating event in atherogenesis, diets rich in antioxidants, found primarily in fruits and vegetables, may be helpful (see Chapter 29). Studies have suggested that when all of these elements are combined into a single dietary prescription, the impact of diet on LDL cholesterol may approach that of statin medications, lowering LDL cholesterol by close to 30%.

Cannon CP et al. Safety of anacetrapib in patients with or at high risk for coronary heart disease. *N Engl J Med*. 2010 Dec 16;363(25):2406–15. [PMID: 21082868]
 Ferdowsian HR et al. Effects of plant-based diets on plasma lipids. *Am J Cardiol*. 2009 Oct 1;104(7):947–56. [PMID: 19766762]
 Kelley GA et al. Comparison of aerobic exercise, diet or both on lipids and lipoproteins in adults: a meta-analysis of randomized controlled trials. *Clin Nutr*. 2011 Dec 9. [Epub ahead of print] [PMID: 22154987]
 Nordmann AJ et al. Meta-analysis comparing Mediterranean to low-fat diets for modification of cardiovascular risk factors. *Am J Med*. 2011 Sep;124(9):841–51. [PMID: 21854893]
 Rumawas ME et al. Mediterranean-style dietary pattern, reduced risk of metabolic syndrome traits, and incidence in the Framingham Offspring Cohort. *Am J Clin Nutr*. 2009 Dec; 90(6):1608–14. [PMID: 19828705]
 Talati R et al. The comparative efficacy of plant sterols and stanols on serum lipids: a systematic review and meta-analysis. *J Am Diet Assoc*. 2010 May;110(5):719–26. [PMID: 20430133]
 Walker C et al. Diets for cardiovascular disease prevention: what is the evidence? *Am Fam Physician*. 2009 Apr 1;79(7):571–8. [PMID: 19378874]

► Pharmacologic Therapy

Most patients whose risk from CHD is considered high enough to warrant pharmacologic therapy of an elevated LDL cholesterol should be given aspirin prophylaxis at a dose of 81 mg/d unless there are contraindications such as aspirin sensitivity, bleeding diatheses, or active peptic ulcer disease. The benefit of aspirin in reducing the risk of CHD in men is equivalent to that of cholesterol lowering. Other CHD risk factors, such as hypertension and smoking, should also be controlled.

If the decision to treat a patient with an LDL-lowering drug is made, a goal for treatment is set. The National Cholesterol Education Program's Adult Treatment Panel III (NCEP ATP III) guidelines remain the mainstay of clinical practice. For patients with CHD or CHD risk equivalents, the goal is LDL <100 mg/dL (<2.59 mmol/L), but for patients with very high risk, a goal of LDL <70 mg/dL (<1.81 mmol/L) is a therapeutic option (see Table 28–3). This goal may also be appropriate for patients with very high risk who have a baseline LDL <100 mg/dL (<2.59 mmol/L). For patients with two or more risk factors and a 10-year CHD risk of 10–20%, the recommended goal is LDL <130 mg/dL (<3.36 mmol/L), but a goal of <100 mg/dL (<2.59 mmol/L) is optional. For those with two or more risk factors and a 10-year CHD risk of <10%, the goal is <130 mg/dL (<3.36 mmol/L). For those with zero or one risk factor, the goal is LDL <160 mg/dL (<4.14 mmol/L) (see Table 28–3). In most instances, intensity of therapy should be sufficient to achieve a 30–40% reduction in LDL cholesterol. Once the goal is reached, the lipid profile should be monitored periodically (every 6–12 months), with consideration given to periodic reductions in drug dose.

A. Niacin (Nicotinic Acid)

Niacin was the first lipid-lowering agent that was associated with a reduction in total mortality. Long-term follow-up of a secondary prevention trial of middle-aged men with previous myocardial infarction disclosed that about half of those who had been previously treated with niacin had died, compared with nearly 60% of the placebo group. This favorable effect on mortality was not seen during the trial itself, though there was a reduction in the incidence of recurrent coronary events.

Niacin reduces the production of VLDL particles, with secondary reduction in LDL and increases in HDL cholesterol levels. The average effect of full-dose niacin therapy, 3–4.5 g/d, is a 15–25% reduction in LDL cholesterol and a 25–35% increase in HDL cholesterol. Full doses are required to obtain the LDL effect, but the HDL effect is observed at lower doses, eg, 1 g/d. Niacin will also reduce triglycerides by half and will lower lipoprotein(a) (Lp[a]) levels and will increase plasma homocysteine levels. Intolerance to niacin is common; only 50–60% of patients can take full doses. Niacin causes a prostaglandin-mediated flushing that patients may describe as “hot flashes” or pruritus and that can be decreased with aspirin (81–325 mg/d) or other non-steroidal anti-inflammatory agents taken during the same day. Flushing may also be decreased by initiating niacin therapy with a very small dose, eg, 100 mg with the evening

meal. The dose can be doubled each week until 1.5 g/d is tolerated. After rechecking blood lipids, the dose is increased and divided over three meals until the goal of 3–4.5 g/d is reached (eg, 1 g with each meal). Extended-release niacin is better tolerated by most patients. It is not known whether routine monitoring of liver enzymes results in early detection and thus reduced severity of this side effect. Niacin can also exacerbate gout and peptic ulcer disease. Although niacin may increase blood sugar in some patients, clinical trials have shown that niacin can be safely used in diabetic patients.

B. Bile Acid-Binding Resins

The bile acid-binding resins include cholestyramine, colestelam, and colestipol. Treatment with these agents reduces the incidence of coronary events in middle-aged men by about 20%, with no significant effect on total mortality. The resins work by binding bile acids in the intestine. The resultant reduction in the enterohepatic circulation causes the liver to increase its production of bile acids, using hepatic cholesterol to do so. Thus, hepatic LDL receptor activity increases, with a decline in plasma LDL levels. The triglyceride level tends to increase slightly in some patients treated with bile acid-binding resins; they should be used with caution in those with elevated triglycerides and probably not at all in patients who have triglyceride levels above 500 mg/dL. The clinician can anticipate a reduction of 15–25% in the LDL cholesterol level, with insignificant effects on the HDL level.

The usual dose of cholestyramine is 12–36 g of resin per day in divided doses with meals, mixed in water or, more palatably, juice. Doses of colestipol are 20% higher (each packet contains 5 g of resin). The dose of colestelam is 625 mg, 6–7 tablets per day.

These agents often cause gastrointestinal symptoms, such as constipation and gas. They may interfere with the absorption of fat-soluble vitamins (thereby complicating the management of patients receiving warfarin) and may bind other drugs in the intestine. Concurrent use of psyllium may ameliorate the gastrointestinal side effects.

C. Hydroxymethylglutaryl-Coenzyme A (HMG-CoA) Reductase Inhibitors (Statins)

The HMG-CoA reductase inhibitors (statins) include atorvastatin, fluvastatin, lovastatin, pitavastatin, pravastatin, rosuvastatin, and simvastatin. These agents work by inhibiting the rate-limiting enzyme in the formation of cholesterol. They reduce myocardial infarctions and total mortality in secondary prevention, as well as in older middle-aged men free of CHD. A meta-analysis has demonstrated significant reduction in risk of stroke. Cholesterol synthesis in the liver is reduced, with a compensatory increase in hepatic LDL receptors (presumably so that the liver can take more of the cholesterol that it needs from the blood) and a reduction in the circulating LDL cholesterol level by up to 35%. There are also modest increases in HDL levels and decreases in triglyceride levels.

Oral doses are as follows: atorvastatin, 10–80 mg/d; fluvastatin, 20–40 mg/d; lovastatin, 10–80 mg/d; pitavastatin

2–4 mg/d; pravastatin, 10–40 mg/d; rosuvastatin, 5–40 mg/d; and simvastatin, 5–40 mg/d. There is no clear superiority of one HMG-CoA reductase inhibitor over others. These agents are given once daily. The most common side effects are muscle aches, occurring in up to 10% of patients, and mild gastrointestinal effects. More serious, but extremely uncommon, side effects include liver failure and muscle disease including myositis and rhabdomyolysis. Liver disease is more common in patients also taking fibrates or niacin. Muscle disease is more common with statins and fibrates and niacin as well as with erythromycin, antifungal medications, nefazadone, and cyclosporine. Manufacturers of HMG-CoA reductase inhibitors recommend regular monitoring of liver and muscle enzymes.

D. Fibric Acid Derivatives

The fibrates are peroxisome proliferative-activated receptor- α (PPAR- α) agonists that result in potent reductions of plasma triglycerides and increases in HDL cholesterol. They reduce LDL levels by about 10–15%, although the result is quite variable, and triglyceride levels by about 40% and raise HDL levels by about 15–20%. The fibric acid derivatives or fibrates approved for use in the United States are gemfibrozil and fenofibrate. Ciprofibrate and bezafibrate are also available for use internationally.

Gemfibrozil reduced CHD rates in hypercholesterolemic middle-aged men free of coronary disease in the Helsinki Heart Study. The effect was observed only among those who also had lower HDL cholesterol levels and high triglyceride levels. In a VA study, gemfibrozil was also shown to reduce cardiovascular events in men with existing CHD whose primary lipid abnormality was a low HDL cholesterol. There was no effect on all-cause mortality.

The usual dose of gemfibrozil is 600 mg once or twice a day. Side effects include cholelithiasis, hepatitis, and myositis. The incidence of the latter two conditions may be higher among patients also taking other lipid-lowering agents. In the largest clinical trial that used clofibrate, there were significantly more deaths—especially due to cancer—in the treatment group; it should not be used.

E. Ezetimibe

Ezetimibe is a lipid-lowering drug that inhibits the intestinal absorption of dietary and biliary cholesterol by blocking passage across the intestinal wall by inhibiting a cholesterol transporter. The usual dose of ezetimibe is 10 mg/d orally. Ezetimibe reduces LDL cholesterol between 15% and 20% when used as monotherapy and can further reduce LDL in patients taking statins who are not yet at therapeutic goal.

However, the effects of ezetimibe on CHD and its long-term safety are not yet known. Results from one small clinical trial, ENHANCE (a study of 720 persons with heterozygous familial hypercholesterolemia), showed no significant difference of intimal media thickness with ezetimibe plus an HMG-CoA reductase inhibitor compared with an HMG-CoA reductase inhibitor alone. A second study compared a statin plus ezetimibe with a statin plus extended-release niacin. The statin plus niacin

caused a significant regression of carotid intima-media thickness and was superior to the statin plus ezetimibe combination.

► Initial Selection of Medication

At present there are no absolute guidelines for selection of available lipid-modifying medications in particular patients. Nonetheless, clinical trials provide guidance (Table 28–4). For most patients who require a lipid-modifying medication, an HMG-CoA reductase inhibitor is preferred. Although niacin will also have beneficial effects on lipids in both men and women with CHD, there is less evidence demonstrating the desired effects on CHD and all-cause mortality. Resins are the only lipid-modifying medication considered safe in pregnancy.

Combination therapy may be used to meet lipid targets in some patients or to achieve other therapeutic goals. For example, low-dose niacin (0.5–1 g/d), will substantially increase the HDL cholesterol when added to an HMG-CoA reductase inhibitor. Despite improvements in the lipid profile, however, there are few data demonstrating improved clinical outcomes of combination therapy when compared with HMG-CoA reductase inhibitors alone. Combinations may also increase the risk of complications of drug therapy. The combination of gemfibrozil and HMG-CoA reductase inhibitors increases the risk of muscle and liver disease more than either drug alone.

Abourbih S et al. Effect of fibrates on lipid profiles and cardiovascular outcomes: a systematic review. *Am J Med.* 2009 Oct; 122(10):962.e1–8. [PMID: 19698935]

ACCORD Study Group et al. Effects of combination lipid therapy in type 2 diabetes mellitus. *N Engl J Med.* 2010 Apr 29;362(17):1563–74. [PMID: 20228404]

AIM-HIGH Investigators; Boden WE et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. *N Engl J Med.* 2011 Dec 15;365(24):2255–67. [PMID: 22085343]

Athyros VG et al. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis. *Lancet.* 2010 Dec 4;376(9756):1916–22. [PMID: 21109302]

Hsia J et al. Cardiovascular event reduction and adverse events among subjects attaining low-density lipoprotein cholesterol <50 mg/dl with rosuvastatin. The JUPITER trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin). *J Am Coll Cardiol.* 2011 Apr 19;57(16):1666–75. [PMID: 21492764]

Jun M et al. Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. *Lancet.* 2010 May 29;375(9729):1875–84. [PMID: 20462635]

Karalis DG. Intensive lowering of low-density lipoprotein cholesterol levels for primary prevention of coronary artery disease. *Mayo Clin Proc.* 2009 Apr;84(4):345–52. [PMID: 19339653]

Ladenson PW. Use of the thyroid hormone analogue eprotirome in statin-treated dyslipidemia. *N Engl J Med.* 2010 Mar 11; 362(10):906–16. [PMID: 20220185]

Mikhailidis DP et al. Comparative efficacy of the addition of ezetimibe to statin vs statin titration in patients with hypercholesterolemia: systematic review and meta-analysis. *Curr Med Res Opin.* 2011 Jun;27(6):1191–210. [PMID: 21473671]

Table 28-4. Effects of selected lipid-modifying drugs.

Drug	Lipid-Modifying Effects		Triglyceride	Initial Daily Dose	Maximum Daily Dose	Cost for 30 Days Treatment with Dose Listed ¹
	LDL	HDL				
Atorvastatin (Lipitor)	-25 to -40%	+5 to 10%	↓↓	10 mg once	80 mg once	\$158.04 (20 mg once)
Cholestyramine (Questran, others)	-15 to -25%	+5%	±	4 g twice a day	24 g divided	\$127.00 (8 g divided)
Colesevelam (WelChol)	-10 to -20%	+10%	±	625 mg, 6-7 tablets once	625 mg, 6-7 tablets once	\$270.00 (6 tablets once)
Colestipol (Colestid)	-15 to -25%	+5%	±	5 g twice a day	30 g divided	\$150.00 (10 g divided)
Ezetimibe (Zetia)	-20%	+5%	±	10 mg once	10 mg once	\$146.10 (10 mg once)
Fenofibrate (Tricor, others)	-10 to -15%	+15 to 25%	↓↓	48 mg once	145 mg once	\$180.00 (145 mg once)
Fenofibric Acid (Trilipix)	-10 to -15%	+15 to 25%	↓↓	45 mg once	135 mg once	\$171.60 (135 mg once)
Fluvastatin (Lescol)	-20 to -30%	+5 to 10%	↓	20 mg once	40 mg once	\$126.00 (20 mg once)
Gemfibrozil (Lopid, others)	-10 to -15%	+15 to 20%	↓↓	600 mg once	1200 mg divided	\$73.20 (600 mg twice a day)
Lovastatin (Mevacor, others)	-25 to -40%	+5 to 10%	↓	10 mg once	80 mg divided	\$71.10 (20 mg once)
Niacin (OTC, Niaspan)	-15 to -25%	+25 to 35%	↓↓	100 mg once	3-4.5 g divided	\$9.00 (1.5 g twice a day, OTC) \$320.40 (2 g Niaspan)
Pitavastatin (Livalo)	-30 to 40%	+10 to 25%	↓↓	2 mg once	4 mg once	\$128.40 (2 mg once)
Pravastatin (Pravachol)	-25 to -40%	+5 to 10%	↓	20 mg once	40 mg once	\$98.10 (20 mg once)
Rosuvastatin (Crestor)	-40 to -50%	+10 to 15%	↓↓	10 mg once	40 mg once	\$169.50 (20 mg once)
Simvastatin (Zocor, others)	-25 to -40%	+5 to 10%	↓↓	5 mg once	80 mg once	\$84.60 (10 mg once)

¹Average wholesale price (AWP, for AB-rated generic when available) for quantity listed. Source: *Red Book Online, 2012*, Thomson Reuters (Healthcare) Inc. AWP may not accurately represent the actual pharmacy cost because wide contractual variations exist among institutions.

LDL, low-density lipoprotein; HDL, high-density lipoprotein; ± variable, if any; others, indicates availability of less expensive generic preparations; OTC, over the counter.

Nicholls SJ et al. Effect of two intensive statin regimens on progression of coronary disease. *N Engl J Med.* 2011 Dec 1;365(22):2078-87. [PMID: 22085316]

Raal FJ et al. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. *Lancet.* 2010 Mar 20;375(9719):998-1006. [PMID: 20227758]

Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH) Collaborative Group. Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-blind randomised trial. *Lancet.* 2010 Nov 13;376(9753):1658-69. [PMID: 21067805]

Taylor AJ et al. Extended-release niacin or ezetimibe and carotid-media thickness. *N Engl J Med.* 2009 Nov 26;361(22):2113-22. [PMID: 19915217]

HIGH BLOOD TRIGLYCERIDES

Patients with very high levels of serum triglycerides (>1000 mg/dL) are at risk for pancreatitis. The pathophysiology is not certain, since pancreatitis never develops in some

patients with very high triglyceride levels. Most patients with congenital abnormalities in triglyceride metabolism present in childhood; hypertriglyceridemia-induced pancreatitis first presenting in adults is more commonly due to an acquired problem in lipid metabolism.

Although there are no clear triglyceride levels that predict pancreatitis, most clinicians treat fasting levels above 500 mg/dL (5 mmol/L). The risk of pancreatitis may be more related to the triglyceride level following consumption of a fatty meal. Because postprandial increases in triglyceride are inevitable if fat-containing foods are eaten, fasting triglyceride levels in persons prone to pancreatitis should be kept well below that level.

The primary therapy for high triglyceride levels is dietary, avoiding alcohol, simple sugars, refined starches, saturated and trans fatty acids, and restricting total calories. Control of secondary causes of high triglyceride levels (see Table 28-1) may also be helpful. In patients with fasting triglycerides \geq 500 mg/dL (\geq 5 mmol/L) despite adequate dietary compliance—and certainly in those with a previous episode of pancreatitis—therapy with a triglyceride-lowering drug (eg, niacin, a fibric acid

derivative, omega-3-acid ethyl esters, or an HMG-CoA reductase inhibitor) is indicated. Combinations of these medications may also be used.

Whether patients with elevated triglycerides (>150 mg/dL or 1.5 mmol/L) should be treated to prevent CHD is not known. Meta-analysis of 17 observational studies suggests that after adjustment for other risk factors, elevated triglycerides increased CHD risk in men by 14% and in women by 37%. Triglyceride-rich lipoproteins have been found in human atheromas, and elevated triglycerides are associated with small dense LDL in most instances. Elevated triglycerides are also an important feature of the metabolic syndrome, found in an estimated 25% of Americans—defined by three or more of the following five abnormalities: waist circumference >102 cm in men or >88 cm in women, serum triglyceride level of at least 150 mg/dL, HDL level of <40 mg/dL in men or <50 mg/dL in women, blood pressure of at least 130/85 mm Hg, and serum glucose level of at least 110 mg/dL. Other data, however, suggest that triglyceride measurements do not improve discrimination between those with and without CHD events, and clinical trial data are not available to support the routine treatment of high triglycerides in all patients.

The NCEP ATP III guidelines, however, recommend an aggressive approach to triglyceride management. For those with borderline levels (150–199 mg/dL or 1.5–1.99 mmol/L), emphasis is placed on calorie restriction and exercise. For patients with high triglycerides (>200 mg/dL), the non-HDL cholesterol should be measured (total cholesterol – HDL cholesterol). The ATP III report recommends that non-HDL cholesterol should be treated with diet and

medications to result in levels 30 mg/dL higher than the LDL goal. The ATP III report does not differentiate between primary and secondary prevention. It is reasonable to use this approach for patients with CHD and risk equivalents for that disease but not for lower-risk patients.

AbouRjaili G et al. Current concepts in triglyceride metabolism, pathophysiology, and treatment. *Metabolism*. 2010 Aug;59(8):1210–20. [PMID: 20060141]

Ballantyne CM et al. Long-term efficacy of adding fenofibrate acid to moderate-dose statin therapy in patients with persistent elevated triglycerides. *Cardiovasc Drugs Ther*. 2011 Feb;25(1):59–67. [PMID: 21416219]

Bays HE et al. Long-term up to 24-month efficacy and safety of concomitant prescription omega-3-acid ethyl esters and simvastatin in hypertriglyceridemic patients. *Curr Med Res Opin*. 2010 Apr;26(4):907–15. [PMID: 20156032]

Faergeman O et al; Steering Committees of IDEAL and TNT Trials. Plasma triglycerides and cardiovascular events in the Treating to New Targets and Incremental Decrease in End-Points through Aggressive Lipid Lowering trials of statins in patients with coronary artery disease. *Am J Cardiol*. 2009 Aug 15;104(4):459–63. [PMID: 19660594]

Roth EM et al. Efficacy and safety of rosuvastatin and fenofibrate acid combination therapy versus simvastatin monotherapy in patients with hypercholesterolemia and hypertriglyceridemia: a randomized, double-blind study. *Am J Cardiovasc Drugs*. 2010;10(3):175–86. [PMID: 20524719]

Watts GF et al. Triglycerides and atherogenic dyslipidaemia: extending treatment beyond statins in the high-risk cardiovascular patient. *Heart*. 2011 Mar;97(5):350–6. [PMID: 21296781]

Nutritional Disorders

Robert B. Baron, MD, MS

29

PROTEIN-ENERGY MALNUTRITION



ESSENTIALS OF DIAGNOSIS

- ▶ Decreased intake of energy or protein, increased nutrient losses, or increased nutrient requirements.
- ▶ Weight loss and growth failure.
- ▶ **Kwashiorkor:** caused by protein deficiency.
- ▶ **Marasmus:** caused by combined protein and energy deficiency.
- ▶ In severe cases, virtually all organ systems are affected.
- ▶ Protein loss correlates with weight loss: 35–40% total body weight loss is usually fatal.

General Considerations

Protein–energy malnutrition occurs as a result of a relative or absolute deficiency of energy and protein. It may be primary, due to inadequate food intake, or secondary, as a result of other illness. For most developing nations, primary protein–energy malnutrition remains among the most significant health problems. Protein–energy malnutrition has been described as two distinct syndromes. **Kwashiorkor**, caused by a deficiency of protein in the presence of adequate energy, is typically seen in weaning infants at the birth of a sibling in areas where foods containing protein are insufficiently abundant. **Marasmus**, caused by combined protein and energy deficiency, is most commonly seen where adequate quantities of food are not available.

In industrialized societies, protein–energy malnutrition is most often secondary to other diseases. **Kwashiorkor-like secondary protein–energy malnutrition** occurs primarily in association with hypermetabolic acute illnesses such as trauma, burns, and sepsis. **Marasmus-like secondary protein–energy malnutrition** typically results from

chronic diseases such as chronic obstructive pulmonary disease (COPD), congestive heart failure, cancer, or AIDS. These syndromes have been estimated to be present in at least 20% of hospitalized patients. A substantially greater number of patients have risk factors that could result in these syndromes. In both syndromes, protein–energy malnutrition is caused either by decreased intake of energy and protein, increased nutrient losses, or increased nutrient requirements dictated by the underlying illness. For example, diminished oral intake may result from poor dentition or various gastrointestinal disorders. Loss of nutrients results from malabsorption and diarrhea as well as from glycosuria. Nutrient requirements are increased by fever, surgery, neoplasia, and burns.

▶ Pathophysiology

Protein–energy malnutrition affects every organ system. The most obvious results are loss of body weight, adipose stores, and skeletal muscle mass. Weight losses of 5–10% are usually tolerated without loss of physiologic function; losses of 35–40% of body weight usually result in death. Loss of protein from skeletal muscle and internal organs is usually proportionate to weight loss. Protein mass is lost from the liver, gastrointestinal tract, kidneys, and heart.

As protein–energy malnutrition progresses, organ dysfunction develops. Hepatic synthesis of serum proteins decreases, and depressed levels of circulating proteins are observed. Cardiac output and contractility are decreased, and the electrocardiogram (ECG) may show decreased voltage and a rightward axis shift. Autopsies of patients who die with severe undernutrition show myofibrillar atrophy and interstitial edema of the heart.

Respiratory function is affected primarily by weakness and atrophy of the muscles of respiration. Vital capacity and tidal volume are depressed, and mucociliary clearance is abnormal. The gastrointestinal tract is affected by mucosal atrophy and loss of villi of small intestine, resulting in malabsorption. Intestinal disaccharidase deficiency and mild pancreatic insufficiency also occur.

Changes in immunologic function are among the most important changes seen in protein–calorie undernutrition. T lymphocyte number and function are depressed. Changes

in B cell function are more variable. Impaired complement activity, granulocyte function, and anatomic barriers to infection are noted, and wound healing is poor.

► Clinical Findings

The clinical manifestations of protein–energy malnutrition range from mild growth retardation and weight loss to a number of distinct clinical syndromes. Children in the developing world manifest marasmus and kwashiorkor. In secondary protein–energy malnutrition as seen in industrialized nations, clinical manifestations are affected by the degree of protein and energy deficiency, the underlying illness that resulted in the deficiency, and the patient's nutritional status prior to illness.

Progressive wasting that begins with weight loss and proceeds to more severe cachexia typically develops in most patients with marasmus-like secondary protein–energy malnutrition. In the most severe form of this disorder, most body fat stores disappear and muscle mass decreases, most noticeably in the temporalis and interosseous muscles. Laboratory studies may be unremarkable—serum albumin, for example, may be normal or slightly decreased, rarely decreasing to < 2.8 g/dL (< 28 g/L). In contrast, owing to its rapidity of onset, kwashiorkor-like secondary protein–energy malnutrition may develop in patients with normal subcutaneous fat and muscle mass or, if the patient is obese, in patients with excess fat and muscle. The serum protein level, however, typically declines and the serum albumin is often < 2.8 g/dL (< 28 g/L). Dependent edema, ascites, or anasarca may develop. As with primary protein–energy malnutrition, combinations of the marasmus-like and kwashiorkor-like syndromes can occur simultaneously, typically in patients with progressive chronic disease in whom a superimposed acute illness develops.

► Treatment

The treatment of severe protein–energy malnutrition is a slow process requiring great care. Initial efforts should be directed at correcting fluid and electrolyte abnormalities and infections. Of particular concern are depletion of potassium, magnesium, and calcium and acid–base abnormalities. The second phase of treatment is directed at repletion of protein, energy, and micronutrients. Treatment is started with modest quantities of protein and calories calculated according to the patient's actual body weight. Adult patients are given 1 g/kg of protein and 30 kcal/kg of calories. Concomitant administration of vitamins and minerals is obligatory. Either the enteral or parenteral route can be used, although the former is preferable. Enteral fat and lactose are withheld initially. Patients with less severe protein–calorie undernutrition can be given calories and protein simultaneously with the correction of fluid and electrolyte abnormalities. Similar quantities of protein and calories are recommended for initial treatment.

Patients treated for protein–energy malnutrition require close follow-up. In adults, both calories and protein are advanced as tolerated, adults to 1.5 g/kg/d of protein and 40 kcal/kg/d of calories.

Patients who are re-fed too rapidly may develop a number of untoward clinical sequelae. During refeeding, circulating

potassium, magnesium, phosphorus, and glucose move intracellularly and can result in low serum levels of each. The administration of water and sodium with carbohydrate refeeding can result in congestive heart failure in persons with depressed cardiac function. Enteral refeeding can lead to malabsorption and diarrhea due to abnormalities in the gastrointestinal tract.

Refeeding edema is a benign condition to be differentiated from congestive heart failure. Changes in renal sodium reabsorption and poor skin and blood vessel integrity result in the development of dependent edema without other signs of heart disease. Treatment includes reassurance, elevation of the dependent area, and modest sodium restriction. Diuretics are usually ineffective, may aggravate electrolyte deficiencies, and should not be used.

The prevention and early detection of protein–energy malnutrition in hospitalized patients require awareness of its risk factors and early symptoms and signs. Patients at risk require formal assessment of nutritional status and close observation of dietary intake, body weight, and nutritional requirements during the hospital stay.

- Bonanni A et al. Protein-energy wasting and mortality in chronic kidney disease. *Int J Environ Res Public Health*. 2011 May;8(5):1631–54. [PMID: 21655142]
- Grover Z et al. Protein energy malnutrition. *Pediatr Clin North Am*. 2009 Oct;56(5):1055–68. [PMID: 19931063]
- Kovesdy CP et al. Outcome predictability of biomarkers of protein-energy wasting and inflammation in moderate and advanced chronic kidney disease. *Am J Clin Nutr*. 2009 Aug;90(2):407–14. [PMID: 19535427]
- Meijers JM et al. Defining malnutrition: mission or mission impossible? *Nutrition*. 2010 Apr;26(4):432–40. [PMID: 19954929]
- Milne AC et al. Protein and energy supplementation in elderly people at risk from malnutrition. *Cochrane Database Syst Rev*. 2009 Apr 15;(2):CD003288. [PMID: 19370584]
- Mueller C et al. A.S.P.E.N. clinical guidelines: nutrition screening, assessment, and intervention in adults. *JPEN J Parenter Enteral Nutr*. 2011 Jan;35(1):16–24. [PMID: 21224430]
- Pencharz PB. Protein and energy requirements for 'optimal' catch-up growth. *Eur J Clin Nutr*. 2010 May;64(Suppl 1):S5–7. [PMID: 20442723]

OBESITY



ESSENTIALS OF DIAGNOSIS

- Excess adipose tissue; body mass index (BMI) > 30 .
- Upper body obesity (abdomen and flank) of greater health consequence than lower body obesity (buttocks and thighs).
- Associated with health consequences, including diabetes mellitus, hypertension, and hyperlipidemia.

► General Considerations

Obesity is one of the most common disorders in medical practice and among the most frustrating and difficult to

manage. Little progress has been made in prevention or treatment, yet major changes have occurred in our understanding of its causes and its implications for health.

► Definition & Measurement

Obesity is defined as an excess of adipose tissue. Accurate quantification of body fat requires sophisticated techniques not usually available in clinical practice. Physical examination is usually sufficient to detect excess body fat. More quantitative evaluation is performed by calculating the BMI.

The **BMI** closely correlates with excess adipose tissue. It is calculated by dividing measured body weight in kilograms by the height in meters squared.

The National Institutes of Health (NIH) define a normal BMI as 18.5–24.9. Overweight is defined as BMI = 25–29.9. Class I obesity is 30–34.9, class II obesity is 35–39.9, and class III (extreme) obesity is BMI > 40. Factors other than total weight, however, are also important. Upper body obesity (excess fat around the waist and flank) is a greater health hazard than lower body obesity (fat in the thighs and buttocks). Obese patients with increased abdominal circumference (> 102 cm in men and 88 cm in women) or with high waist–hip ratios (> 1.0 in men and > 0.85 in women) have a greater risk of diabetes mellitus, stroke, coronary artery disease, and early death than equally obese patients with lower ratios. Further differentiation of the location of excess fat suggests that visceral fat within the abdominal cavity is more hazardous to health than subcutaneous fat around the abdomen.

Current U.S. survey data demonstrate that 68% of Americans are overweight and 33.8% are obese. Women in the United States are more apt to be obese than men, and African-American and Mexican-American women are more obese than whites. The poor are more obese than the rich regardless of race.

► Health Consequences of Obesity

Obesity is associated with significant increases in both morbidity and mortality. A great many disorders occur with greater frequency in obese people. The most important and common of these are hypertension, type 2 diabetes mellitus, hyperlipidemia, coronary artery disease, degenerative joint disease, and psychosocial disability. Approximately 60% of individuals with obesity in the United States have the metabolic syndrome (including three or more of the following factors: elevated abdominal circumference, blood pressure, blood triglycerides, and fasting blood sugar, and low high-density lipoprotein [HDL] cholesterol). Certain cancers (colon, ovary, and breast), thromboembolic disorders, digestive tract diseases (gallbladder disease, gastroesophageal reflux disease), and skin disorders are also more prevalent in the obese. Surgical and obstetric risks are greater. Obese patients also have a greater risk of pulmonary functional impairment including sleep apnea, endocrine abnormalities, proteinuria, and increased hemoglobin concentration. Patients with obesity have increased rates of major depression and binge eating disorder. Several studies have documented

that obese individuals are also subject to various forms of social discrimination.

In young and middle-aged adults, mortality from all causes and mortality from cardiovascular disease increase in proportion to the degree of obesity. The relative risk associated with obesity, however, decreases with age, and weight is no longer a risk factor in adults over age 75 years. Analysis of data from the National Health and Nutrition Examination Survey (NHANES) has suggested that lesser amounts of excess weight (BMI between 25 and 29.9) may not be associated with excess mortality.

► Etiology

Until recently, obesity was considered to be the direct result of a sedentary lifestyle plus chronic ingestion of excess calories. Although these factors are undoubtedly the principal cause in many cases, there is evidence for strong genetic influences on the development of obesity. Adopted children demonstrate a close relationship between their BMI and that of their biologic parents. No such relationship is found between the children and their adoptive parents. Twin studies also demonstrate substantial genetic influences on BMI with little influence from the childhood environment. As much as 40–70% of obesity may be explained by genetic influences.

Genetic determinants of some types of obesity have now been established. Five genes affecting control of appetite have been identified in mice. Mutations of each gene result in obesity, and each has a human homolog. One gene codes for a protein expressed by adipose tissue—leptin—and another for the leptin receptor in the brain. The other three genes affect brain pathways downstream from the leptin receptor. Numerous other candidate genes for human obesity have been identified. Only a small percentage (4–6%) of human obesity is thought to be due to single gene mutations. Most human obesity undoubtedly develops from the interactions of multiple genes, environmental factors, and behavior. The rapid increase in obesity in the last several decades clearly points to a major role of environmental factors in the development of obesity.

► Medical Evaluation of the Obese Patient

Historical information should be obtained about age at onset, recent weight changes, family history of obesity, occupational history, eating and exercise behavior, cigarette and alcohol use, previous weight loss experience, and psychosocial factors including assessment for depression and eating disorders. Particular attention should be directed at use of laxatives, diuretics, hormones, nutritional supplements, and over-the-counter medications.

Physical examination should assess the BMI, the degree and distribution of body fat, overall nutritional status, and signs of secondary causes of obesity.

Less than 1% of obese patients have an identifiable secondary, nonpsychiatric, cause of obesity. Hypothyroidism and Cushing syndrome are important examples that can usually be diagnosed by physical examination in patients with unexplained recent weight gain. Such patients require

further endocrinologic evaluation, including serum thyroid-stimulating hormone (TSH) determination and dexamethasone suppression testing (see Chapter 26).

All obese patients should be assessed for medical consequences of their obesity by screening for the metabolic syndrome. Blood pressure, waist circumference, fasting glucose, low-density lipoprotein (LDL) and HDL cholesterol, and triglycerides should be measured.

► Treatment

Using conventional dietary techniques, only 20% of patients will lose 20 lb and maintain the loss for over 2 years; 5% will maintain a 40-lb loss. Average weight loss is approximately 7% of baseline weight. Continued close provider–patient contact appears to be more important for success of treatment than the specific features of any given treatment regimen. Careful patient selection will improve success rates and decrease frustration of both patients and therapists. Only sufficiently motivated patients should enter active treatment programs. Specific attempts to identify motivated patients—eg, requesting a 3-day diet record—are often useful.

Most successful programs employ a multidisciplinary approach to weight loss, with hypocaloric diets, behavior modification to change eating behavior, aerobic exercise, and social support. Emphasis must be on *maintenance* of weight loss.

Dietary instructions for most patients incorporate the same principles that apply to healthy people who are not obese. This is achieved by emphasizing intake of a wide variety of predominantly “unprocessed” foods. Special attention is usually paid to limiting foods that provide large amounts of calories without other nutrients, ie, fat, sucrose, and alcohol. There is no physiologic advantage to diets that restrict carbohydrates, advocate relatively larger amounts of protein or fats, or recommend ingestion of foods one at a time. Diets that are restricted in carbohydrates (such as the Atkins and South Beach diets), however, can be effective in achieving a lower total calorie intake. Several studies have demonstrated that low-carbohydrate diets can be used safely and effectively for weight loss without adverse effects on lipids or other metabolic parameters. Meal replacement diets can also be used effectively and safely to achieve weight loss.

Long-term changes in eating behavior are required to maintain weight loss. Although formal **behavior modification** programs are available to which patients can be referred, the clinician caring for obese patients can teach a number of useful behavioral techniques. The most important technique is to emphasize planning and record keeping. Patients can be taught to plan menus and exercise sessions and to record their actual behavior. Record keeping not only aids in behavioral change, but also helps the provider to make specific suggestions for problem solving. Patients can be taught to recognize “eating cues” (emotional, situational, etc) and how to avoid or control them. Regular self-monitoring of weight is also associated with improved long-term weight maintenance.

Exercise offers a number of advantages to patients trying to lose weight and keep it off. Aerobic exercise directly

increases the daily energy expenditure and is particularly useful for long-term weight maintenance. Exercise will also preserve lean body mass and partially prevent the decrease in basal energy expenditure (BEE) seen with semistarvation. When compared with no treatment, exercise alone results in small amounts of weight loss. Exercise plus diet results in greater weight loss than diet alone. A greater intensity of exercise is associated with a greater amount of weight loss. Up to 1 hour of moderate exercise per day is associated with long-term weight maintenance in individuals who have successfully lost weight. **Social support** is essential for a successful weight loss program. Continued close contact with clinicians and involvement of the family and peer group are useful techniques for reinforcing behavioral change and preventing social isolation.

Patients with severe obesity may require more aggressive treatment regimens. **Very-low-calorie diets** (≤ 800 kcal/d) result in rapid weight loss and marked initial improvement in obesity-related metabolic complications. Patients are commonly maintained on such programs for 4–6 months. Patients who adhere to the program lose an average of 2 lb per week. Average maximum weight loss is approximately 15% of initial weight. Most programs use meal replacement diets to achieve the very-low-calorie intake. Long-term weight maintenance following meal replacement programs is less predictable and requires concurrent behavior modification, long-term use of low-calorie diets, careful self-monitoring, and regular exercise. Side effects such as fatigue, orthostatic hypotension, cold intolerance, and fluid and electrolyte disorders are observed in proportion to the degree of calorie reduction and require regular supervision by a clinician. Other less common complications include gout, gallbladder disease, and cardiac arrhythmias. Although weight loss is more rapidly achieved with very-low-calorie diets as compared with traditional diets, long-term outcomes are equivalent.

Medications for the treatment of obesity are available both over the counter and by prescription. Considerable controversy exists as to the appropriate use of medications for obesity. NIH clinical obesity guidelines state that obesity drugs may be used as part of a comprehensive weight loss program for patients with BMI > 30 or those with BMI > 27 with obesity-related risk factors. There are few data, however, to suggest that medications can improve long-term outcomes associated with obesity.

Several medications are approved by the US Food and Drug Administration (FDA) for treatment of obesity. Catecholaminergic medications (eg, phentermine, diethylpropion, mazindol) are approved for short-term use only and have limited utility. Sibutramine, previously approved for the treatment of obesity, was withdrawn from the United States market in 2010 following the publication of a large study demonstrating an increased risk of strokes and myocardial infarctions.

Orlistat works in the gastrointestinal tract rather than the central nervous system. By inhibiting intestinal lipase, orlistat reduces fat absorption. As expected, orlistat may result in diarrhea, gas, and cramping and perhaps also reduced absorption of fat-soluble vitamins. In randomized trials with up to 2 years of follow-up, orlistat has resulted in

2–4 kg greater weight loss than placebo. Orlistat (120 mg orally up to three times daily with each fat-containing meal) is the only medication approved for longer-term treatment of obesity in the United States. A lower dose formulation (Alli 60 mg, one capsule orally up to three times daily with each fat-containing meal; maximum of three capsules per day) is available without a prescription. Long-term clinical benefits have not been demonstrated. Although orlistat results in some additional weight loss at the end of 1- and 2-year clinical trials and, in some studies, improved obesity-related metabolic parameters, a beneficial impact on obesity-related clinical outcomes has not been established.

Several new medications and combinations of existing medications are also being investigated, but none have yet been approved for use in the United States. Lorcaserin, a selective serotonin receptor agonist, was not approved by the FDA due to increased mammary adenocarcinoma in animal studies. The combination of phentermine and topiramate was not approved due to excess psychiatric events, increased heart rate, and teratogenicity. Bupropion and naltrexone resulted in short-term weight loss but was not approved due to ongoing concerns of increased cardiovascular risk. Bupropion and zonisamide, exenatide and other incretins, and cetilistat (another pancreatic lipase inhibitor) are all being investigated.

Bariatric surgery is an increasingly prevalent treatment option for patients with severe obesity. In the United States, gastric operations are considered the procedures of choice. Most popular is the Roux-en-Y gastric bypass (RYGB). In most centers, the operation can be done laparoscopically. RYGB typically results in substantial amounts of weight loss—over 30% of initial body weight in some studies. Complications occur in up to 40% of persons undergoing RYGB surgery and include peritonitis due to anastomotic leak; abdominal wall hernias; staple line disruption; gallstones; neuropathy; marginal ulcers; stomal stenosis; wound infections; thromboembolic disease; gastrointestinal symptoms; and nutritional deficiencies, including iron, vitamin B₁₂, folate, calcium, and vitamin D. Operative mortality rates within 30 days are nil to 1% in low-risk populations but have been reported to be substantially higher in Medicare beneficiaries. One-year mortality rates have been reported as high as 7.5% in men with Medicare. The surgical volume (the number of cases performed by the surgeon or hospital) has been demonstrated to be an important predictor of outcome. Gastric banding (GB) surgeries are increasing as an alternative procedure. GB results in less dramatic weight loss than RYGB but with fewer short-term complications. Frequent follow-up is required to adjust the gastric band. Longer-term follow-up suggests that both procedures are associated with significant regaining of weight. NIH consensus panel recommendations are to limit obesity surgery to patients with BMIs over 40, or over 35 if obesity-related comorbidities are present. The procedure is cost-effective for patients with severe obesity and most third-party payers cover the procedure in selected patients. Outcomes studies have suggested that bariatric surgery is associated with a significant reduction in deaths at 11-year follow-up. In one prospective study, the number needed to treat to prevent one death in 11 years was 77 operations.

▶ When to Refer

Patients with BMI over 40 (or over 35 with obesity-related morbidities) who are interested in considering weight loss surgery.

- Al-Benna S. Perioperative management of morbid obesity. *J Perioper Pract.* 2011 Jul;21(7):225–33. [PMID: 21874986]
- Benotti PN et al. Preoperative weight loss before bariatric surgery. *Arch Surg.* 2009 Dec;144(12):1150–5. [PMID: 20026834]
- Boltri JM et al. Clinical inquiries. Which strategies work best to prevent obesity in adults? *J Fam Pract.* 2009 Dec;58(12):668–76. [PMID: 19961823]
- Chen L et al. Reduction in consumption of sugar-sweetened beverages is associated with weight loss: the PREMIER trial. *Am J Clin Nutr.* 2009 May;89(5):1299–306. [PMID: 19339405]
- Corsica JA et al. Food addiction: true or false? *Curr Opin Gastroenterol.* 2010 Mar;26(2):165–9. [PMID: 20042860]
- Farrell TM et al. Clinical application of laparoscopic bariatric surgery: an evidence-based review. *Surg Endosc.* 2009 May;23(5):930–49. [PMID: 19125308]
- Field BC et al. Obesity treatment: novel peripheral targets. *Br J Clin Pharmacol.* 2009 Dec;68(6):830–43. [PMID: 20002077]
- Flegal KM et al. Prevalence and trends in obesity among US adults, 1999–2008. *JAMA.* 2010 Jan 20;303(3):235–41. [PMID: 20071471]
- Foster GD et al. Weight and metabolic outcomes after 2 years on a low-carbohydrate versus low-fat diet: a randomized trial. *Ann Intern Med.* 2010 Aug 3;153(3):147–57. [PMID: 20679559]
- Gortmaker SL et al. Changing the future of obesity: science, policy, and action. *Lancet.* 2011 Aug 27;378(9793):838–47. [PMID: 21872752]
- Hite AH et al. Low-carbohydrate diet review: shifting the paradigm. *Nutr Clin Pract.* 2011 Jun;26(3):300–8. [PMID: 21586415]
- Idelevich E et al. Current pharmacotherapeutic concepts for the treatment of obesity in adults. *Ther Adv Cardiovasc Dis.* 2009 Feb;3(1):75–90. [PMID: 19144669]
- James WP et al; SCOUT Investigators. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. *N Engl J Med.* 2010 Sep 2;363(10):905–17. [PMID: 20818901]
- King DE et al. Adherence to healthy lifestyle habits in US adults, 1988–2006. *Am J Med.* 2009 Jun;122(6):528–34. [PMID: 19486715]
- Kirk SF et al. Effective weight management practice: a review of the lifestyle intervention evidence. *Int J Obes (Lond).* 2012 Feb;36(2):178–85. [PMID: 21487396]
- Longitudinal Assessment of Bariatric Surgery (LABS) Consortium; Flum DR et al. Perioperative safety in the longitudinal assessment of bariatric surgery. *N Engl J Med.* 2009 Jul 30;361(5):445–54. [PMID: 19641201]
- Puhl MR et al. The stigma of obesity: a review and update. *Obesity (Silver Spring).* 2009 May;17(5):941–64. [PMID: 19165161]
- Rao G. Office-based strategies for the management of obesity. *Am Fam Physician.* 2010 Jun 15;81(12):1449–56. [PMID: 20540483]
- Sacks FM et al. Comparison of weight-loss diets with different compositions of fat, protein, and carbohydrates. *N Engl J Med.* 2009 Feb 26;360(9):859–73. [PMID: 19246357]
- Tice JA et al. Gastric banding or bypass? A systematic review comparing the two most popular bariatric procedures. *Am J Med.* 2008 Oct;121(10):885–93. [PMID: 18823860]
- Tsai AG et al. Treatment of obesity in primary care practice in the United States: a systematic review. *J Gen Intern Med.* 2009 Sep;24(9):1073–9. [PMID: 19562419]
- Wang YC et al. Health and economic burden of the projected obesity trends in the USA and the UK. *Lancet.* 2011 Aug 27;378(9793):815–25. [PMID: 21872750]
- Yancy WS Jr et al. A randomized trial of a low-carbohydrate diet vs orlistat plus a low-fat diet for weight loss. *Arch Intern Med.* 2010 Jan 25;170(2):136–45. [PMID: 20101008]

EATING DISORDERS

ANOREXIA NERVOSA

 ESSENTIALS OF DIAGNOSIS

- ▶ Disturbance of body image and intense fear of becoming fat.
- ▶ Weight loss leading to body weight 15% below expected.
- ▶ In females, absence of three consecutive menstrual cycles.

▶ General Considerations

Anorexia nervosa typically begins in the years between adolescence and young adulthood. Ninety percent of patients are females, most from the middle and upper socioeconomic strata. The diagnosis is based on weight loss leading to body weight 15% below expected, a distorted body image, fear of weight gain or of loss of control over food intake and, in females, the absence of at least three consecutive menstrual cycles. Other medical or psychiatric illnesses that can account for anorexia and weight loss must be excluded.

The prevalence of anorexia nervosa is greater than previously suggested. In Rochester, Minnesota, for example, the prevalence per 100,000 population is estimated to be 270 for females and 22 for males. Many other adolescent girls have features of the disorder without the severe weight loss.

The cause of anorexia nervosa is not known. Although multiple endocrinologic abnormalities exist in these patients, most authorities believe they are secondary to malnutrition and not primary disorders. Most experts favor a primary psychiatric origin, but no hypothesis explains all cases. The patient characteristically comes from a family whose members are highly goal and achievement oriented. Interpersonal relationships may be inadequate or destructive. The parents are usually overly directive and concerned with slimness and physical fitness, and much of the family conversation centers around dietary matters. One theory holds that the patient's refusal to eat is an attempt to regain control of her body in defiance of parental control. The patient's unwillingness to inhabit an "adult body" may also represent a rejection of adult responsibilities and the implications of adult interpersonal relationships. Patients are commonly perfectionistic in behavior and exhibit obsessional personality characteristics. Marked depression or anxiety may be present.

▶ Clinical Findings

A. Symptoms and Signs

Patients with anorexia nervosa may exhibit severe emaciation and may complain of cold intolerance or constipation.

Amenorrhea is almost always present. Bradycardia, hypotension, and hypothermia may be present in severe cases. Examination demonstrates loss of body fat, dry and scaly skin, and increased lanugo body hair. Parotid enlargement and edema may also occur.

B. Laboratory Findings

Laboratory findings are variable but may include anemia, leukopenia, electrolyte abnormalities, and elevations of blood urea nitrogen (BUN) and serum creatinine. Serum cholesterol levels are often increased. Endocrine abnormalities include depressed levels of luteinizing and follicle-stimulating hormones and impaired response of luteinizing hormone to luteinizing hormone-releasing hormone.

▶ Diagnosis & Differential Diagnosis

The diagnosis can be difficult, since many common social and cultural factors promote and maintain anorexic behavior. The diagnosis depends on identification of the common behavioral features and exclusion of medical disorders that would account for weight loss.

Behavioral features required for the diagnosis include intense fear of becoming obese, disturbance of body image, weight loss of at least 15%, and refusal to exceed a minimal normal weight.

The differential diagnosis includes endocrine and metabolic disorders, such as panhypopituitarism, Addison disease, hyperthyroidism, and diabetes mellitus; gastrointestinal disorders, such as Crohn disease and celiac sprue; chronic infections and cancers, such as tuberculosis and lymphoma; and rare central nervous system disorders, such as hypothalamic tumors.

▶ Treatment

The goal of treatment is restoration of normal body weight and resolution of psychological difficulties. Hospitalization may be necessary. Treatment programs conducted by experienced teams are successful in about two-thirds of cases, restoring normal weight and menstruation. One-half continue to experience difficulties with eating behavior and psychiatric problems. Occasional patients with anorexia develop obesity after treatment. Two to 6% of patients die of the complications of the disorder or commit suicide.

Various treatment methods have been used without clear evidence of superiority of one over another. Supportive care by clinicians and nurses is probably the most important feature of therapy. Structured behavioral therapy, intensive psychotherapy, and family therapy may be tried. A variety of medications including tricyclic antidepressants, selected serotonin reuptake inhibitors (SSRIs), and lithium carbonate are effective in some cases; overall, however, clinical trial results have been disappointing. Patients with severe malnutrition must be hemodynamically stabilized and may require enteral or parenteral feeding. Forced feedings should be

reserved for life-threatening situations, since the goal of treatment is to reestablish normal eating behavior.

▶ When to Refer

- Adolescents and young adults with otherwise unexplained weight loss should be evaluated by a psychiatrist.
- All patients with diagnosed anorexia nervosa should be co-managed with a psychiatrist.

▶ When to Admit

- Signs of hypovolemia, major electrolyte disorders, and severe protein-energy malnutrition.
- Failure to improve with outpatient management.

Arcelus J et al. Mortality rates in patients with anorexia nervosa and other eating disorders. A meta-analysis of 36 studies. *Arch Gen Psychiatry*. 2011 Jul;68(7):724–31. [PMID: 21727255]

Attia E. Anorexia nervosa: current status and future directions. *Annu Rev Med*. 2010;61:425–35. [PMID: 19719398]

Attia E et al. Behavioral management for anorexia nervosa. *N Engl J Med*. 2009 Jan 29;360(5):500–6. [PMID: 19179317]

Mehler PS et al. Nutritional rehabilitation: practical guidelines for refeeding the anorectic patient. *J Nutr Metab*. 2010;2010. pii: 625782 [PMID: 20798756]

Norrington A et al. Medical management of acute severe anorexia nervosa. *Arch Dis Child Educ Pract Ed*. 2011 Jul 15. [Epub ahead of print] [PMID: 21764823]

Ozier AD et al. Position of the American Dietetic Association: nutrition intervention in the treatment of eating disorders. *J Am Diet Assoc*. 2011 Aug;111(8):1236–41. [PMID: 21802573]

Sim LA et al. Identification and treatment of eating disorders in the primary care setting. *Mayo Clin Proc*. 2010 Aug;85(8):746–51. [PMID: 20605951]

Treasure J et al. Eating disorders. *Lancet*. 2010 Feb 13;375(9714):583–93. [PMID: 19931176]

BULIMIA NERVOSA



ESSENTIALS OF DIAGNOSIS

- ▶ Uncontrolled episodes of binge eating at least twice weekly for 3 months.
- ▶ Recurrent inappropriate compensation to prevent weight gain such as self-induced vomiting, laxatives, diuretics, fasting, or excessive exercise.
- ▶ Overconcern with weight and body shape.

▶ General Considerations

Bulimia nervosa is the episodic uncontrolled ingestion of large quantities of food followed by recurrent inappropriate compensatory behavior to prevent weight gain such as self-induced vomiting, diuretic or cathartic use, or strict dieting or vigorous exercise.

Like anorexia nervosa, bulimia nervosa is predominantly a disorder of young, white, middle- and upper-class

women. It is more difficult to detect than anorexia, and some studies have estimated that the prevalence may be as high as 19% in college-aged women.

▶ Clinical Findings

Patients with bulimia nervosa typically consume large quantities of easily ingested high-calorie foods, usually in secrecy. Some patients may have several such episodes a day for a few days; others report regular and persistent patterns of binge eating. Binging is usually followed by vomiting, cathartics, or diuretics and is usually accompanied by feelings of guilt or depression. Periods of binging may be followed by intervals of self-imposed starvation. Body weights may fluctuate but generally are within 20% of desirable weights.

Some patients with bulimia nervosa also have a cryptic form of anorexia nervosa with significant weight loss and amenorrhea. Family and psychological issues are generally similar to those encountered among patients with anorexia nervosa. Bulimic patients, however, have a higher incidence of premorbid obesity, greater use of cathartics and diuretics, and more impulsive or antisocial behavior. Menstruation is usually preserved.

Medical complications are numerous. Gastric dilatation and pancreatitis have been reported after binges. Vomiting can result in poor dentition, pharyngitis, esophagitis, aspiration, and electrolyte abnormalities. Cathartic and diuretic abuse also cause electrolyte abnormalities or dehydration. Constipation and hemorrhoids are common.

▶ Treatment

Treatment of bulimia nervosa requires supportive care and psychotherapy. Individual, group, family, and behavioral therapy have all been utilized. Antidepressant medications may be helpful. The best results have been with fluoxetine hydrochloride and other SSRIs. Although death from bulimia is rare, the long-term psychiatric prognosis in severe bulimia is worse than that in anorexia nervosa.

▶ When to Refer

All patients with diagnosed bulimia should be co-managed with a psychiatrist.

Crow SJ et al. Increased mortality in bulimia nervosa and other eating disorders. *Am J Psychiatry*. 2009 Dec;166(12):1342–6. [PMID: 19833789]

Ozier AD et al. Position of the American Dietetic Association: nutrition intervention in the treatment of eating disorders. *J Am Diet Assoc*. 2011 Aug;111(8):1236–41. [PMID: 21802573]

Mehler PS. Medical complications of bulimia nervosa and their treatments. *Int J Eat Disord*. 2011 Mar;44(2):95–104. [PMID: 21312201]

Mitchell JE et al. Stepped care and cognitive-behavioural therapy for bulimia nervosa: randomized trial. *Br J Psychiatry*. 2011 May;198(5):391–7. [PMID: 21415046]

Reiter CS et al. Nutrition therapy for eating disorders. *Nutr Clin Pract*. 2010 Apr;25(2):122–36. [PMID: 20413693]

Steinhausen HC et al. The outcome of bulimia nervosa: findings from one-quarter century of research. *Am J Psychiatry*. 2009 Dec;166(12):1331–41. [PMID: 19884225]

DISORDERS OF VITAMIN METABOLISM

THIAMINE (B₁) DEFICIENCY



ESSENTIALS OF DIAGNOSIS

- ▶ Most common in patients with chronic alcoholism.
- ▶ Early symptoms of anorexia, muscle cramps, paresthesias, irritability.
- ▶ Advanced syndromes of high output heart failure (“wet beriberi”), peripheral nerve disorders, and Wernicke-Korsakoff syndrome (“dry beriberi”).

▶ General Considerations

Most thiamine deficiency in the United States is due to alcoholism. Patients with chronic alcoholism may have poor dietary intakes of thiamine and impaired thiamine absorption, metabolism, and storage. Thiamine deficiency is also associated with malabsorption, dialysis, and other causes of chronic protein–calorie undernutrition. Thiamine deficiency can be precipitated in patients with marginal thiamine status with intravenous dextrose solutions.

▶ Clinical Findings

Early manifestations of thiamine deficiency include anorexia, muscle cramps, paresthesias, and irritability. Advanced deficiency primarily affects the cardiovascular system (“wet beriberi”) or the nervous system (“dry beriberi”). Wet beriberi occurs in thiamine deficiency accompanied by severe physical exertion and high carbohydrate intakes. Dry beriberi occurs in thiamine deficiency accompanied by inactivity and low calorie intake.

Wet beriberi is characterized by marked peripheral vasodilation resulting in high-output heart failure with dyspnea, tachycardia, cardiomegaly, and pulmonary and peripheral edema, with warm extremities mimicking cellulitis.

Dry beriberi involves both the peripheral and the central nervous systems. Peripheral nerve involvement is typically a symmetric motor and sensory neuropathy with pain, paresthesias, and loss of reflexes. The legs are affected more than the arms. Central nervous system involvement results in Wernicke–Korsakoff syndrome. Wernicke encephalopathy consists of nystagmus progressing to ophthalmoplegia, truncal ataxia, and confusion. Korsakoff syndrome includes amnesia, confabulation, and impaired learning.

▶ Diagnosis

A variety of biochemical tests are available to assess thiamine deficiency. In most instances, however, the clinical response to empiric thiamine therapy is used to support a diagnosis of thiamine deficiency. The most commonly used biochemical tests measure erythrocyte transketolase

activity and urinary thiamine excretion. A transketolase activity coefficient > 15–20% suggests thiamine deficiency.

▶ Treatment

Thiamine deficiency is treated with large parenteral doses of thiamine. Fifty to 100 mg/d is administered intravenously for the first few days, followed by daily oral doses of 5–10 mg/d. All patients should simultaneously receive therapeutic doses of other water-soluble vitamins. Although treatment results in complete resolution in half of patients (one-fourth immediately and another one-fourth over days), the other half obtain only partial resolution or no benefit.

▶ When to Refer

Patients with signs of beriberi or Wernicke-Korsakoff syndrome should be referred to a neurologist.

THIAMINE TOXICITY

There is no known toxicity of thiamine.

- Galvin R et al. EFNS guidelines for diagnosis, therapy and prevention of Wernicke encephalopathy. *Eur J Neurol*. 2010 Dec;17(12):1408–18. [PMID: 20642790]
- Kumar N. Neurologic presentations of nutritional deficiencies. *Neurol Clin*. 2010 Feb;28(1):107–70. [PMID: 19932379]
- Wedisinghe L et al. Wernicke’s encephalopathy: a preventable cause of maternal death. *Br J Hosp Med (Lond)*. 2011 Jan;72(1):31–4. [PMID: 21240115]
- Zahr NM et al. Clinical and pathological features of alcohol-related brain damage. *Nat Rev Neurol*. 2011 May;7(5):284–94. [PMID: 21487421]

RIBOFLAVIN (B₂) DEFICIENCY

▶ Clinical Findings

Riboflavin deficiency almost always occurs in combination with deficiencies of other vitamins. Dietary inadequacy, interactions with a variety of medications, alcoholism, and other causes of protein–calorie undernutrition are the most common causes of riboflavin deficiency.

Manifestations of riboflavin deficiency include cheilosis, angular stomatitis, glossitis, seborrheic dermatitis, weakness, corneal vascularization, and anemia.

▶ Diagnosis

Riboflavin deficiency can be confirmed by measuring the riboflavin-dependent enzyme erythrocyte glutathione reductase. Activity coefficients > 1.2–1.3 are suggestive of riboflavin deficiency. Urinary riboflavin excretion and serum levels of plasma and red cell flavins can also be measured.

▶ Treatment

Riboflavin deficiency is usually treated empirically when the diagnosis is suspected. It is easily treated with foods such as meat, fish, and dairy products or with oral preparations of the vitamin. Administration of 5–15 mg/d until

clinical findings are resolved is usually adequate. Riboflavin can also be given parenterally, but it is poorly soluble in aqueous solutions.

RIBOFLAVIN TOXICITY

There is no known toxicity of riboflavin.

Hoey L et al. Studies of biomarker responses to intervention with riboflavin: a systematic review. *Am J Clin Nutr.* 2009 Jun;89(6):1960S–1980S. [PMID: 19403631]
Koch TR et al. Postoperative metabolic and nutritional complications of bariatric surgery. *Gastroenterol Clin North Am.* 2010 Mar;39(1):109–24. [PMID: 20202584]

NIACIN DEFICIENCY

► General Considerations

Niacin is a generic term for nicotinic acid and other derivatives with similar nutritional activity. Unlike most other vitamins, niacin can be synthesized from the amino acid tryptophan. Niacin is an essential component of the co-enzymes nicotinamide adenine dinucleotide (NAD) and nicotinamide adenine dinucleotide phosphate (NADP), which are involved in many oxidation-reduction reactions. The major food sources of niacin are protein foods containing tryptophan and numerous cereals, vegetables, and dairy products.

Niacin in the form of nicotinic acid is used therapeutically for the treatment of hypercholesterolemia and hypertriglyceridemia. Daily doses of 3–6 g can result in significant reductions in levels of LDL and very-low-density lipoproteins (VLDL) and in elevation of HDL. Niacinamide (the form of niacin usually used to treat niacin deficiency) does not exhibit the lipid-lowering effects of nicotinic acid. Historically, niacin deficiency occurred when corn, which is relatively deficient in both tryptophan and niacin, was the major source of calories. Currently, niacin deficiency is more commonly due to alcoholism and nutrient–drug interactions. Niacin deficiency can also occur in inborn errors of metabolism.

► Clinical Findings

As with other B vitamins, the early manifestations of niacin deficiency are nonspecific. Common complaints include anorexia, weakness, irritability, mouth soreness, glossitis, stomatitis, and weight loss. More advanced deficiency results in the classic triad of pellagra: dermatitis, diarrhea, and dementia. The dermatitis is symmetric, involving sun-exposed areas. Skin lesions are dark, dry, and scaling. The dementia begins with insomnia, irritability, and apathy and progresses to confusion, memory loss, hallucinations, and psychosis. The diarrhea can be severe and may result in malabsorption due to atrophy of the intestinal villi. Advanced pellagra can result in death.

► Diagnosis

In early deficiency, diagnosis requires a high index of suspicion and attempts at confirmation of niacin deficiency.

Niacin metabolites, particularly *N*-methylnicotinamide, can be measured in the urine. Low levels suggest niacin deficiency but may also be found in patients with generalized under-nutrition. Serum and red cell levels of NAD and NADP are also low but are similarly nonspecific. In advanced cases, the diagnosis of pellagra can be made on clinical grounds.

► Treatment

Niacin deficiency can be effectively treated with oral niacin, usually given as nicotinamide. Doses ranging from 10 mg/d to 150 mg/d have been used without difficulty.

NIACIN TOXICITY

At the high doses of niacin used to treat hyperlipidemia, side effects are common. These include cutaneous flushing (partially prevented by pretreatment with aspirin, 325 mg/d, and use of extended-release preparations) and gastric irritation. Elevation of liver enzymes, hyperglycemia, and gout are less common untoward effects.

Brown TM. Pellagra: an old enemy of timeless importance. *Psychosomatics.* 2010 Mar;51(2):93–7. [PMID: 20332283]
Hiraga A et al. Hoarseness in pellagra. *J Clin Neurosci.* 2011 Jun;18(6):870–1. [PMID: 21507655]

VITAMIN B₆ DEFICIENCY

Vitamin B₆ deficiency most commonly occurs as a result of interactions with medications—especially isoniazid, cycloserine, penicillamine, and oral contraceptives—or of alcoholism. A number of inborn errors of metabolism and other pyridoxine-responsive syndromes, particularly pyridoxine-responsive anemia, are not clearly due to vitamin deficiency but commonly respond to high doses of the vitamin. Patients with common variable immunodeficiency may have concomitant vitamin B₆ deficiency.

► Clinical Findings

Vitamin B₆ deficiency results in a clinical syndrome similar to that seen with deficiencies of other B vitamins, including mouth soreness, glossitis, cheilosis, weakness, and irritability. Severe deficiency can result in peripheral neuropathy, anemia, and seizures. Studies have suggested a potential relationship of low vitamin B₆ levels and a variety of clinical conditions including cardiovascular diseases, inflammatory diseases, and certain cancers.

► Diagnosis

The diagnosis of vitamin B₆ deficiency can be confirmed by measurement of pyridoxal phosphate in blood. Normal levels are > 50 ng/mL.

► Treatment

Vitamin B₆ deficiency can be effectively treated with oral vitamin B₆ supplements. Doses of 10–20 mg/d are usually

adequate, though some patients taking medications that interfere with pyridoxine metabolism may need doses as high as 100 mg/d. Inborn errors of metabolism and the pyridoxine-responsive syndromes often require doses up to 600 mg/d.

Vitamin B₆ should be routinely prescribed for patients receiving medications (such as isoniazid) that interfere with pyridoxine metabolism to prevent vitamin B₆ deficiency. This is particularly true for patients who are more likely to have diets marginally adequate in vitamin B₆, such as the elderly, alcoholic patients, or the urban poor. Clinical trials have shown that vitamin B₆ supplementation, combined with other B vitamins, has no benefit on cardiovascular disease outcomes.

VITAMIN B₆ TOXICITY

A sensory neuropathy, at times irreversible, occurs in patients receiving large doses of vitamin B₆. Although most patients have taken 2 g or more per day, some patients have taken only 200 mg/d.

Hisano M et al. Vitamin B₆ deficiency and anemia in pregnancy.

Eur J Clin Nutr. 2010 Feb;64(2):221–3. [PMID: 19920848]

Keith ME et al. B-vitamin deficiency in hospitalized patients with heart failure. *J Am Diet Assoc.* 2009 Aug;109(8):1406–10. [PMID: 19631047]

Larsson SC et al. Vitamin B6 and risk of colorectal cancer: a meta-analysis of prospective studies. *JAMA.* 2010 Mar 17;303(11):1077–83. [PMID: 20233826]

Skarupski KA et al. Longitudinal association of vitamin B-6, folate, and vitamin B-12 with depressive symptoms among older adults over time. *Am J Clin Nutr.* 2010 Aug;92(2):330–5. [PMID: 20519557]

VITAMIN B₁₂ & FOLATE

Vitamin B₁₂ (cobalamin) and folate are discussed in Chapter 13.

VITAMIN C (Ascorbic Acid) DEFICIENCY

Most cases of vitamin C deficiency seen in the United States are due to dietary inadequacy in the urban poor, the elderly, and patients with chronic alcoholism. Patients with chronic illnesses such as cancer and chronic kidney disease and individuals who smoke cigarettes are also at risk.

► Clinical Findings

Early manifestations of vitamin C deficiency are nonspecific and include malaise and weakness. In more advanced stages, the typical features of scurvy develop. Manifestations include perifollicular hemorrhages, perifollicular hyperkeratotic papules, petechiae and purpura, splinter hemorrhages, bleeding gums, hemarthroses, and subperiosteal hemorrhages. Periodontal signs do not occur in edentulous patients. Anemia is common, and wound healing is impaired. The late

stages of scurvy are characterized by edema, oliguria, neuropathy, intracerebral hemorrhage, and death.

► Diagnosis

The diagnosis of advanced scurvy can be made clinically on the basis of the skin lesions in the proper clinical situation. Atraumatic hemarthrosis is also highly suggestive. The diagnosis can be confirmed with decreased plasma ascorbic acid levels, typically below 0.1 mg/dL.

► Treatment

Adult scurvy can be treated orally with 300–1000 mg of ascorbic acid per day. Improvement typically occurs within days. Clinical trials have shown that supplemental vitamin C has no benefit on cardiovascular disease or cancer outcomes.

VITAMIN C TOXICITY

Very large doses of vitamin C can cause gastric irritation, flatulence, or diarrhea. Oxalate kidney stones are of theoretic concern because ascorbic acid is metabolized to oxalate, but stone formation has not been frequently reported. Vitamin C can also confound common diagnostic tests by causing false-negative tests for fecal occult blood and both false-negative and false-positive tests for urine glucose.

Berger MM. Vitamin C requirements in parenteral nutrition. *Gastroenterology.* 2009 Nov;137(5 Suppl):S70–8. [PMID: 19874953]

Choh CT et al. Unrecognised scurvy. *BMJ.* 2009 Sep 17;339:b3580. [PMID: 19762412]

Magiorkinis E et al. Scurvy: past, present and future. *Eur J Intern Med.* 2011 Apr;22(2):147–52. [PMID: 21402244]

Pemberton J. Unrecognised scurvy. Signs and requirements. *BMJ.* 2010 Feb 2;340:c590. [PMID: 20124375]

Popovich D et al. Scurvy: forgotten but definitely not gone. *J Pediatr Health Care.* 2009 Nov–Dec;23(6):405–15. [PMID: 19875028]

VITAMIN A DEFICIENCY

► Clinical Findings

Vitamin A deficiency is one of the most common vitamin deficiency syndromes, particularly in developing countries. In many such regions, it is the most common cause of blindness. In the United States, vitamin A deficiency is usually due to fat malabsorption syndromes or mineral oil laxative abuse and occurs most commonly in the elderly and urban poor.

Night blindness is the earliest symptom. Dryness of the conjunctiva (xerosis) and the development of small white patches on the conjunctiva (Bitot spots) are early signs. Ulceration and necrosis of the cornea (keratomalacia), perforation, endophthalmitis, and blindness are late manifestations. Xerosis and hyperkeratinization of the skin and loss of taste may also occur.

▶ Diagnosis

Abnormalities of dark adaptation are strongly suggestive of vitamin A deficiency. Serum levels below the normal range of 30–65 mg/dL are commonly seen in advanced deficiency.

▶ Treatment

Night blindness, poor wound healing, and other signs of early deficiency can be effectively treated orally with 30,000 international units of vitamin A daily for 1 week. Advanced deficiency with corneal damage calls for administration of 20,000 international units/kg orally for at least 5 days. The potential antioxidant effects of β -carotene can be achieved with supplements of 25,000–50,000 international units of β -carotene.

VITAMIN A TOXICITY

Excess intake of β -carotenes (hypercarotenosis) results in staining of the skin a yellow-orange color but is otherwise benign. Skin changes are most marked on the palms and soles, while the scleras remain white, clearly distinguishing hypercarotenosis from jaundice.

Excessive vitamin A (hypervitaminosis A), on the other hand, can be quite toxic. Chronic toxicity usually occurs after ingestion of daily doses of over 50,000 international units/d for > 3 months. Early manifestations include dry, scaly skin, hair loss, mouth sores, painful hyperostoses, anorexia, and vomiting. More serious findings include hypercalcemia; increased intracranial pressure, with papilledema, headaches, and decreased cognition; and hepatomegaly, occasionally progressing to cirrhosis. Excessive vitamin A has also recently been related to increased risk of hip fracture. Acute toxicity can result from ingestion of massive doses of vitamin A, such as in drug overdoses or consumption of polar bear liver. Manifestations include nausea, vomiting, abdominal pain, headache, papilledema, and lethargy.

The diagnosis can be confirmed by elevations of serum vitamin A levels. The only treatment is withdrawal of vitamin A from the diet. Most symptoms and signs improve rapidly.

Bello S et al. Routine vitamin A supplementation for the prevention of blindness due to measles infection in children. *Cochrane Database Syst Rev*. 2011 Apr 13;(4):CD007719. [PMID: 21491401]

Braunstein A et al. Vitamin A deficiency in New York City. *Lancet*. 2010 Jul 24;376(9737):267. [PMID: 20663549]

Checkley W et al. Maternal vitamin A supplementation and lung function in offspring. *N Engl J Med*. 2010 May 13;362(19):1784–94. [PMID: 20463338]

Tanumihardjo SA. Vitamin A: biomarkers of nutrition for development. *Am J Clin Nutr*. 2011 Aug;94(2):658S–65S. [PMID: 21715511]

VITAMIN D

Vitamin D is discussed in Chapter 26. The major food source of vitamin D is fortified milk, but sunlight on the skin is a prime resource as well.

VITAMIN E DEFICIENCY

▶ Clinical Findings

Clinical deficiency of vitamin E is most commonly due to severe malabsorption, the genetic disorder abetalipoproteinemia, or, in children with chronic cholestatic liver disease, biliary atresia or cystic fibrosis. Manifestations of deficiency include areflexia, disturbances of gait, decreased proprioception and vibration, and ophthalmoplegia.

▶ Diagnosis

Plasma vitamin E levels can be measured; normal levels are 0.5–0.7 mg/dL or higher. Since vitamin E is normally transported in lipoproteins, the serum level should be interpreted in relation to circulating lipids.

▶ Treatment

The optimum therapeutic dose of vitamin E has not been clearly defined. Large doses, often administered parenterally, can be used to improve the neurologic complications seen in abetalipoproteinemia and cholestatic liver disease. The potential antioxidant benefits of vitamin E can be achieved with supplements of 100–400 international units/d. Clinical trials of supplemental vitamin E to prevent cardiovascular disease, however, have shown no beneficial effects.

VITAMIN E TOXICITY

Vitamin E has been thought to be the least toxic of the fat-soluble vitamins. Large doses—many times the recommended daily requirement—have been taken for extended periods of time without apparent harm, though nausea, flatulence, and diarrhea have been reported. Clinical trials, however, have suggested an increase in all-cause mortality with high dose (≥ 400 international units/d) vitamin E supplements. Large doses of vitamin E can also increase the vitamin K requirement and can result in bleeding in patients taking oral anticoagulants.

Biesalski HK. Vitamin E requirements in parenteral nutrition. *Gastroenterology*. 2009 Nov;137(5 Suppl):S92–104. [PMID: 19874955]

Brewer GJ. Why vitamin E therapy fails for treatment of Alzheimer's disease. *J Alzheimers Dis*. 2010 Jan;19(1):27–30. [PMID: 20061623]

Devore EE et al. Dietary antioxidants and long-term risk of dementia. *Arch Neurol*. 2010 Jul;67(7):819–25. [PMID: 20625087]

McCance DR et al; Diabetes and Pre-eclampsia Intervention Trial (DAPIT) Study Group. Vitamins C and E for prevention of pre-eclampsia in women with type 1 diabetes (DAPIT): a randomised placebo-controlled trial. *Lancet*. 2010 Jul 24;376(9737):259–66. [PMID: 20580423]

Sanyal AJ et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. *N Engl J Med*. 2010 May 6;362(18):1675–85. [PMID: 20427778]

Suksomboon N et al. Effects of vitamin E supplementation on glycaemic control in type 2 diabetes: systematic review of randomized controlled trials. *J Clin Pharm Ther*. 2011 Feb;36(1):53–63. [PMID: 21198720]

VITAMIN K

Vitamin K is discussed in Chapter 14. Vitamin K is synthesized by intestinal bacteria.

DIET THERAPY

Specific therapeutic diets can be designed to facilitate the medical management of most common illnesses. In most cases, consultation with a registered dietitian is necessary in order to design and implement major dietary changes. Clinicians should be familiar with the indications for special diets and their basic composition to facilitate patient referrals and to maximize patient compliance. Diet therapy is a difficult process, and not all patients are able to cooperate fully. Requesting the patient to record dietary intake for 3–5 days may provide useful insight into the patient's motivation as well as providing nutrient information about the current diet.

Therapeutic diets can be divided into three groups: (1) diets that alter the consistency of food, (2) diets that restrict or otherwise modify dietary components, and (3) diets that supplement dietary components.

DIETS THAT ALTER CONSISTENCY

▶ Clear Liquid Diet

This diet provides adequate water, 500–1000 kcal as simple sugar, and some electrolytes. It is fiber free and requires minimal digestion or intestinal motility.

A clear liquid diet is useful for patients with resolving postoperative ileus, acute gastroenteritis, partial intestinal obstruction, and as preparation for diagnostic gastrointestinal procedures. It is commonly used as the first diet for patients who have been taking nothing by mouth for long periods. Because of the low calorie and minimal protein content of the clear liquid diet, it is used only for short periods.

▶ Full Liquid Diet

The full liquid diet provides adequate water and can be designed to provide adequate calories and protein. Vitamins and minerals—especially folic acid, iron, and vitamin B₆—may be inadequate and should be provided in the form of supplements. Dairy products, soups, eggs, and soft cereals are used to supplement clear liquids. Commercial oral supplements can also be incorporated into the diet or used alone.

This diet is low in residue and can be used in many instances instead of the clear liquid diet described above—especially in patients with difficulty in chewing or swallowing, with partial obstructions, or in preparation for some diagnostic procedures. Full liquid diets are commonly used following clear liquid diets to advance diets in patients who have been taking nothing by mouth for long periods.

▶ Soft Diets

Soft diets are designed for patients unable to chew or swallow hard or coarse food. Tender foods are used, and most

raw fruits and vegetables and coarse breads and cereals are eliminated. Soft diets are commonly used to assist in progression from full liquid diets to regular diets in postoperative patients, in patients who are too weak or those whose dentition is too poor to handle a general diet, in head and neck surgical patients, in patients with esophageal strictures, and in other patients who have difficulty with chewing or swallowing.

The soft diet can be designed to meet all nutritional requirements.

DIETS THAT RESTRICT NUTRIENTS

Diets can be designed to restrict (or eliminate) virtually any nutrient or food component. The most commonly used restricted diets are those that limit sodium, fat, and protein. Other restrictive diets include gluten restriction in sprue, potassium and phosphate reduction in chronic kidney disease, and various elimination diets for food allergies.

▶ Sodium-Restricted Diets

Low-sodium diets are useful in the management of hypertension and in conditions in which sodium retention and edema are prominent features, particularly congestive heart failure, chronic liver disease, and chronic kidney disease. Sodium restriction is beneficial with or without diuretic therapy. When used in conjunction with diuretics, sodium restriction allows lower dosage of the diuretic medication and may prevent side effects. Potassium excretion, in particular, is directly related to distal renal tubule sodium delivery, and sodium restriction will decrease diuretic-related potassium losses.

Typical American diets contain a minimum of 4–6 g (175–260 mEq) of sodium per day. A no-added-salt diet contains approximately 3 g (132 mEq) of sodium per day. Further restriction can be achieved with sodium diets of 2 or 1 g/d. Diets with more severe restriction are poorly accepted by patients and are rarely used.

Dietary sodium includes sodium naturally occurring in foods, sodium added during food processing, and sodium added by the consumer during cooking and at the table. About a third of current dietary intake is derived from each. Diets that allow 2000 mg of sodium daily are easiest to design and implement. Such diets generally eliminate added salt, most processed foods, and selected foods with particularly high sodium content. Patients who follow such diets for 2–3 months lose their craving for salty foods and can often continue to restrict their sodium intake indefinitely. Many patients with mild hypertension will achieve significant reductions in blood pressure (approximately 5 mm Hg diastolic) with this degree of sodium restriction. Other patients require more severe sodium restriction (approximately 1000 mg of sodium per day) for reduction in blood pressure.

Diets allowing 1000 mg of sodium require further restriction of commonly eaten foods. Special “low-sodium” products are now available to facilitate such diets. These diets are difficult for most people to follow and are generally reserved for hospitalized patients and highly motivated outpatients—most commonly those with severe liver disease and ascites.

► Fat-Restricted Diets

Traditional fat-restricted diets are useful in the treatment of fat malabsorption syndromes. Such diets will improve the symptoms of diarrhea with steatorrhea independently of the primary physiologic abnormality by limiting the quantity of fatty acids that reach the colon. The degree of fat restriction necessary to control symptoms must be individualized. Patients with severe malabsorption can be limited to 40–60 g of fat per day. Diets containing 60–80 g of fat per day can be designed for patients with less severe abnormalities.

In general, fat-restricted diets require broiling, baking, or boiling meat and fish; discarding the skin of poultry and fish and using those foods as the main protein source; using nonfat dairy products; and avoiding desserts, sauces, and gravies.

► Low-Cholesterol, Low-Saturated-Fat Diets

Fat-restricted diets that specifically restrict saturated fats and dietary cholesterol are the mainstay of dietary treatment of hyperlipidemia (see Chapter 28). Similar diets are recommended also for diabetes mellitus (see Chapter 27) and for the prevention of coronary artery disease (see Chapter 10). Current recommendations for the prevention of cancer by dietary modification also include fat restriction. The large Women's Health Initiative Dietary Modification Trial, however, did not show any significant benefit of a low-fat diet on weight control or prevention of cardiovascular disease or cancer.

The aim of these diets is to restrict total fat to < 30% of calories and to achieve a normal body weight by caloric restriction and increased physical activity. Saturated fat is restricted to 7% of calories and dietary cholesterol to 200 mg/d. Saturated fat can be replaced either with complex carbohydrates or, if energy balance permits, with monounsaturated fats. Saturated fat, total fat, and dietary cholesterol can be restricted further, but studies suggest that more extreme restriction offers little further advantage in overall modification of serum lipids. Cholesterol-lowering diets can be further augmented with the addition of plant stanols and sterols and with soluble dietary fiber.

► Protein-Restricted Diets

Protein-restricted diets are most commonly used in patients with hepatic encephalopathy due to chronic liver disease and in patients with advanced chronic kidney disease to slow the progression of early disease and to decrease symptoms of uremia in more severe disease. Patients with selected inborn errors of amino acid metabolism and other abnormalities resulting in hyperammonemia also require restriction of protein or of specific amino acids.

Protein restriction is intended to limit the production of nitrogenous waste products. Energy intake must be adequate to facilitate the efficient use of dietary protein. Proteins must be of high biologic value and be provided in sufficient quantity to meet minimal requirements. For most patients, the diet should contain at least 0.6 g/kg/d of

protein. Patients with encephalopathy who do not respond to this degree of restriction are unlikely to respond to more severe restriction.

DIETS THAT SUPPLEMENT NUTRIENTS

► High-Fiber Diet

Dietary fiber is a diverse group of plant constituents that is resistant to digestion by the human digestive tract. Typical American diets contain about 5–10 g of dietary fiber per day. Epidemiologic evidence has suggested that populations consuming greater quantities of fiber have a lower incidence of certain gastrointestinal disorders, including diverticulitis and colon cancer. Most authorities currently recommend higher intakes of dietary fiber for health maintenance.

Diets high in dietary fiber (20–35 g/d) are also commonly used in the management of a variety of gastrointestinal disorders, particularly irritable bowel syndrome and recurrent diverticulitis. Diets high in fiber may also be useful to reduce blood sugar in patients with diabetes and to reduce cholesterol levels in patients with hypercholesterolemia. Such diets include greater intakes of fresh fruits and vegetables, whole grains, legumes and seeds, and bran products. For some patients, the addition of psyllium seed (2 tsp per day) or natural bran (one-half cup per day) may be preferable.

► High-Potassium Diets

Potassium-supplemented diets are used most commonly to compensate for potassium losses caused by diuretics. Although potassium losses can be partially prevented by using lower doses of diuretics, concurrent sodium restriction, and potassium-sparing diuretics, some patients require additional potassium to prevent hypokalemia. High-potassium diets may also have a direct antihypertensive effect. Typical American diets contain about 3 g (80 mEq) of potassium per day. High-potassium diets commonly contain 4.5–7 g (120–180 mEq) of potassium per day.

Most fruits, vegetables, and their juices contain high concentrations of potassium. Supplemental potassium can also be provided with potassium-containing salt substitutes (up to 20 mEq in one-quarter tsp) or as potassium chloride in solution or capsules, but this is rarely necessary if the above measures are followed to prevent potassium losses and supplement dietary potassium.

► High-Calcium Diets

Additional intakes of dietary calcium have been recommended for the prevention of postmenopausal osteoporosis, the prevention and treatment of hypertension, and the prevention of colon cancer. The Women's Health Initiative, however, suggested that calcium and vitamin D supplementation did not prevent fractures or colon cancer. Nonetheless, many authorities recommend intakes of 1 g of calcium per day for most adults and 1.5 g/d for postmenopausal women. Average American daily intakes are approximately 700 mg/d.

Dairy products are the primary dietary sources of calcium in the United States. Patients with lactose intolerance who cannot tolerate liquid dairy products may be able to use lactose-free milk, take supplemental lactase enzyme supplements, or tolerate nonliquid products such as cheese and yogurt. Leafy green vegetables and canned fish with bones also contain high concentrations of calcium, although the latter is also high in sodium.

- Esposito K et al. Effects of a Mediterranean-style diet on the need for antihyperglycemic drug therapy in patients with newly diagnosed type 2 diabetes: a randomized trial. *Ann Intern Med.* 2009 Sep 1;151(5):306–14. [PMID: 19721018]
- Hooper L et al. Reduced or modified dietary fat for preventing cardiovascular disease. *Cochrane Database Syst Rev.* 2011 Jul 6;(7):CD002137. [PMID: 21735388]
- Ho-Pham LT et al. Effect of vegetarian diets on bone mineral density: a Bayesian meta-analysis. *Am J Clin Nutr.* 2009 Oct;90(4):943–50. [PMID: 19571226]
- Jenkins DJ et al. Effect of a dietary portfolio of cholesterol-lowering foods given at 2 levels of intensity of dietary advice on serum lipids in hyperlipidemia: a randomized controlled trial. *JAMA.* 2011 Aug 24;306(8):831–9. [PMID: 21862744]
- Kelly RB. Diet and exercise in the management of hyperlipidemia. *Am Fam Physician.* 2010 May 1;81(9):1097–102. [PMID: 20433126]
- Mente A et al. A systematic review of the evidence supporting a causal link between dietary factors and coronary heart disease. *Arch Intern Med.* 2009 Apr 13;169(7):659–69. [PMID: 19364995]
- Sacks FM et al. Comparison of weight-loss diets with different compositions of fat, protein, and carbohydrates. *N Engl J Med.* 2009 Feb 26;360(9):859–73. [PMID: 19246357]
- Sacks FM et al. Dietary therapy in hypertension. *N Engl J Med.* 2010 Jun 3;362(22):2102–12. [PMID: 20519681]
- Shikany JM et al. Effects of a low-fat dietary intervention on glucose, insulin, and insulin resistance in the Women's Health Initiative (WHI) Dietary Modification trial. *Am J Clin Nutr.* 2011 Jul;94(1):75–85. [PMID: 21562091]

NUTRITIONAL SUPPORT

Nutritional support is the provision of nutrients to patients who cannot meet their nutritional requirements by eating standard diets. Nutrients may be delivered enterally, using oral nutritional supplements, nasogastric and nasoduodenal feeding tubes, and tube enterostomies, or parenterally, using lines or catheters placed in peripheral or central veins, respectively. Current nutritional support techniques permit adequate nutrient delivery to most patients. Nutrition support should be utilized, however, only if it is likely to improve the patient's clinical outcome. The financial costs and risks of side effects must be balanced against the potential advantages of improved nutritional status in each clinical situation.

INDICATIONS FOR NUTRITIONAL SUPPORT

The precise indications for nutritional support remain controversial. Most authorities agree that nutritional support is indicated for at least four groups of adult patients: (1) those with inadequate bowel syndromes, (2) those

with severe prolonged hypercatabolic states (eg, due to extensive burns, multiple trauma, mechanical ventilation), (3) those requiring prolonged therapeutic bowel rest, and (4) those with severe protein-calorie undernutrition with a treatable disease who have sustained a loss of over 25% of body weight.

It has been difficult to prove the efficacy of nutritional support in the treatment of most other conditions. In most cases it has not been possible to show a clear advantage of treatment by means of nutritional support over treatment without such support.


The American Society for Parenteral and Enteral Nutrition (ASPEN) has published recommendations for the rational use of nutritional support. The recommendations emphasize the need to individualize the decision to begin nutritional support, weighing the risks and costs against the benefits to each patient. They also reinforce the need to identify high-risk malnourished patients by nutritional assessment.

NUTRITIONAL SUPPORT METHODS

Selection of the most appropriate nutritional support method involves consideration of gastrointestinal function, the anticipated duration of nutritional support, and the ability of each method to meet the patient's nutritional requirements. The method chosen should meet the patient's nutritional needs with the lowest risk and lowest cost possible. For most patients, enteral feeding is safer and cheaper and offers significant physiologic advantages. An algorithm for selection of the most appropriate nutritional support method is presented in Figure 29–1.

Prior to initiating specialized enteral nutritional support, efforts should be made to supplement food intake. Attention to patient preferences, timing of meals and diagnostic procedures and use of medications, and the use of foods brought to the hospital by family and friends can often increase oral intake. Patients unable to eat enough at regular mealtimes to meet nutritional requirements can be given **oral supplements** as snacks or to replace low-calorie beverages. Oral supplements of differing nutritional composition are available for the purpose of individualizing the diet in accordance with specific clinical requirements. Fiber and lactose content, caloric density, protein level, amino acid profiles, vitamin K, and calcium can all be modified as necessary.

Patients unable to take adequate oral nutrients who have functioning gastrointestinal tracts and who meet the criteria for nutritional support are candidates for **tube feedings**. Small-bore feeding tubes are placed via the nose into the stomach or duodenum. Patients able to sit up in bed who can protect their airways can be fed into the stomach. Because of the increased risk of aspiration, patients who cannot adequately protect their airways should be fed nasoduodenally. Feeding tubes can usually be passed into the duodenum by leaving an extra length of tubing in the stomach and placing the patient in the right decubitus position. Metoclopramide, 10 mg intravenously, can be given 20 minutes prior to insertion and continued every 6 hours thereafter to facilitate passage through the pylorus.



▲ **Figure 29-1.** Nutritional support method decision tree.

Occasionally patients will require fluoroscopic or endoscopic guidance to insert the tube distal to the pylorus. Placement of nasogastric and, particularly, nasoduodenal tubes should be confirmed radiographically before delivery of feeding solutions.

Feeding tubes can also be placed directly into the gastrointestinal tract using **tube enterostomies**. Most tube enterostomies are placed in patients who require long-term enteral nutritional support. Gastrostomies have the advantage of allowing bolus feedings, while jejunostomies require continuous infusions. Gastrostomies—like nasogastric feeding—should be used only in patients at low risk for aspiration. Gastrostomies can also be placed percutaneously with the aid of endoscopy. These tubes can then be advanced to jejunostomies. Tube enterostomies can also be placed surgically.

Patients who require nutritional support but whose gastrointestinal tracts are nonfunctional should receive **parenteral nutritional support**. Most patients receive parenteral feedings via a central vein—most commonly the subclavian vein. Peripheral veins can be used in some patients, but because of the high osmolality of parenteral solutions this is rarely tolerated for more than a few weeks.

Peripheral vein nutritional support is most commonly used in patients with nonfunctioning gastrointestinal tracts who require immediate support but whose clinical status is expected to improve within 1–2 weeks, allowing enteral feeding. Peripheral vein nutritional support is administered via standard intravenous lines. Solutions should always include lipid and dextrose in combination with amino acids to provide adequate nonprotein calories. Serious side effects are infrequent, but there is a high incidence of phlebitis and infiltration of intravenous lines.

Central vein nutritional support is delivered via intravenous catheters placed percutaneously using aseptic technique. Proper placement in the superior vena cava is documented radiographically before the solution is infused. Catheters must be carefully maintained by experienced nursing personnel and used solely for nutritional support to prevent infection and other catheter-related complications.

NUTRITIONAL REQUIREMENTS

Each patient's nutritional requirements should be determined independently of the method of nutritional support. In most situations, solutions of equal nutrient value can be designed for delivery via enteral and parenteral routes, but differences in absorption must be considered. A complete nutritional support solution must contain water, energy, amino acids, electrolytes, vitamins, minerals, and essential fatty acids.

▶ Water

For most patients, water requirements can be calculated by allowing 1500 mL for the first 20 kg of body weight plus 20 mL for every kilogram over 20. Additional losses should be replaced as they occur. For average-sized adult patients, fluid needs are about 30–35 mL/kg, or approximately 1 mL/kcal of energy required (see below).

▶ Energy

Energy requirements can be estimated by one of three methods: (1) by using standard equations to calculate BEE plus additional calories for activity and illness, (2) by applying a simple calculation based on calories per kilogram of body weight, or (3) by measuring energy expenditure with indirect calorimetry.

BEE can be estimated by the **Harris-Benedict equation**: for men, $BEE = 666 + (13.7 \times \text{weight in kg}) + (5 \times \text{height in cm}) - (6.8 \times \text{age in years})$. For women, $BEE = 655 + (9.5 \times \text{weight in kg}) + (1.8 \times \text{height in cm}) - (4.7 \times \text{age in years})$. For undernourished patients, actual body weight should be used; for obese patients, ideal body weight should be used. For most patients, an additional 20–50% of BEE is administered as nonprotein calories to accommodate energy expenditures during activity or relating to the illness. Occasional patients are noted to have energy expenditures > 150% of BEE.

Energy requirements can be estimated also by multiplying actual body weight in kilograms (for obese patients, ideal body weight) by 30–35 kcal.

Both of these methods provide imprecise estimates of actual energy expenditures, especially for the markedly underweight, overweight, and critically ill patient. Studies using indirect calorimetry have demonstrated that as many as 30–40% of patients will have measured expenditures 10% above or below estimated values. For accurate determination of energy expenditure, indirect calorimetry should be used.

► Protein

Protein and energy requirements are closely related. If adequate calories are provided, most patients can be given 0.8–1.2 g of protein per kilogram per day. Patients undergoing moderate to severe stress should receive up to 1.5 g/kg/d. As in the case of energy requirements, actual weights should be used for normal and underweight patients and ideal weights for patients with significant obesity.

Patients who are receiving protein without adequate calories will catabolize protein for energy rather than utilizing it for protein synthesis. Thus, when energy intake is low, excess protein is needed for nitrogen balance. If both energy and protein intakes are low, extra energy will have a more significant positive effect on nitrogen balance than extra protein.

► Electrolytes & Minerals

Requirements for sodium, potassium, and chloride vary widely. Most patients require 45–145 mEq/d of each. The actual requirement in individual patients will depend on the patient's cardiovascular, renal, endocrine, and gastrointestinal status as well as measurements of serum concentration.

Patients receiving enteral nutritional support should receive adequate vitamins and minerals according to the recommended daily allowances. Most premixed enteral solutions provide adequate vitamins and minerals as long as adequate calories are administered.

Patients receiving parenteral nutritional support require smaller amounts of minerals: calcium, 10–15 mEq/d; phosphorus, 15–20 mEq per 1000 nonprotein calories; and magnesium, 16–24 mEq/d. Most patients receiving nutritional support do not require supplemental iron because body stores are adequate. Iron nutrition should be monitored closely by following the hemoglobin concentration, mean corpuscular volume, and iron studies. Parenteral administration of iron is associated with a number of adverse effects and should be reserved for iron-deficient patients unable to take oral iron.

Patients receiving parenteral nutritional support should be given the trace elements zinc (about 5 mg/d) and copper (about 2 mg/d). Patients with diarrhea will require additional zinc to replace fecal losses. Additional trace elements—especially chromium, manganese, and selenium—are provided to patients receiving long-term parenteral nutrition.

Parenteral vitamins are provided daily. Standardized multivitamin solutions are currently available to provide

adequate quantities of vitamins A, B₁₂, C, D, E, thiamine, riboflavin, niacin, pantothenic acid, pyridoxine, folic acid, and biotin. Vitamin K is not given routinely but administered when the prothrombin time becomes abnormal.

► Essential Fatty Acids

Patients receiving nutritional support should be given 2–4% of their total calories as linoleic acid to prevent essential fatty acid deficiency. Most prepared enteral solutions contain adequate linoleic acid. Patients receiving parenteral nutrition should be given at least 250 mL of a 20% intravenous fat (emulsified soybean or safflower oil) about two or three times a week. Intravenous fat can also be used as an energy source in place of dextrose.

ENTERAL NUTRITIONAL SUPPORT SOLUTIONS

Most patients who require enteral nutritional support can be given commercially prepared enteral solutions (Table 29–1). Nutritionally complete solutions have been designed to provide adequate proportions of water, energy,

Table 29–1. Enteral solutions.

Complete
Blenderized (eg, Compleat Regular, Compleat Modified, ¹ Vitaneed ¹)
Whole protein, lactose-containing (eg, Mentene, Carnation and Delmark Instant Breakfast, Forta Shake)
Whole protein, lactose-free, low-residue:
1 kcal/mL (eg, Ensure, Isocal, Osmolite, Nutren 1.0, ¹ Nutrilan, Isolan, ¹ Sustacal, Resource)
1.5 kcal/mL (eg, Ensure Plus, Sustacal HC, Comply, Nutren 1.5, Resource Plus)
2 kcal/mL (eg, Isocal HCN, Magnacal, TwoCal HN)
High-nitrogen: > 15% total calories from protein (eg, Ensure HN, Attain, ¹ Osmolite HN, ¹ Replete, Entrition HN, ¹ Isolan, ¹ Isocal HN, ¹ Sustacal HC, Isosource HN, ¹ Ultralan)
Whole protein, lactose-free, high-residue:
1 kcal/mL (eg, Jevity, ¹ Profiber, ¹ Nutren 1.0 with fiber, ¹ Fiberian, ¹ Sustacal with fiber, Ultracal, ¹ Ensure with fiber, Fibersource)
Chemically defined peptide- or amino acid-based (eg, Accupeg HPF, Criticare HN, Peptamen, ¹ Reabfin, Vital HN, AlitraQ, Tolerex, Vivonex TEN)
“Disease-specific” formulas
Advanced chronic kidney disease: with essential amino acids (eg, Amin-Aid, Travasorb Renal, Aminess)
Malabsorption: with medium-chain triglycerides (eg, Portagen, ¹ Travasorb MCT)
Respiratory failure: with > 50% calories from fat (eg, Pulmocare, NutriVent)
Hepatic encephalopathy: with high amounts of branched-chain amino acids (eg, Hepatic-Acid II, Travasorb Hepatic)
Incomplete (modular)
Protein (eg, Nutrisource Protein, Promed, Propac)
Carbohydrate (eg, Nutrisource Carbohydrate, Polycose, Sumacal)
Fat (eg, MCT Oil, Microlipid, Nutrisource Lipid)
Vitamins (eg, Nutrisource Vitamins)
Minerals (eg, Nutrisource Minerals)

¹Isotonic.

protein, and micronutrients. Nutritionally incomplete solutions are also available to provide specific macronutrients (eg, protein, carbohydrate, and fat) to supplement complete solutions for patients with unusual requirements or to design solutions that are not available commercially.

Nutritionally complete solutions are characterized as follows: (1) by osmolality (isotonic or hypertonic), (2) by lactose content (present or absent), (3) by the molecular form of the protein component (intact proteins; peptides or amino acids), (4) by the quantity of protein and calories provided, and (5) by fiber content (present or absent). For most patients, isotonic solutions containing no lactose or fiber are preferable. Such solutions generally contain moderate amounts of fat and intact protein. Most commercial isotonic solutions contain 1000 kcal and about 37–45 g of protein per liter.

Solutions containing hydrolyzed proteins or crystalline amino acids and with no significant fat content are called elemental solutions, since macronutrients are provided in their most “elemental” form. These solutions have been designed for patients with malabsorption, particularly pancreatic insufficiency and limited fat absorption. Elemental diets are extremely hypertonic and often result in more severe diarrhea. Their use should be limited to patients who cannot tolerate isotonic solutions.

Although formulas have been designed for specific clinical situations—solutions containing primarily essential amino acids (for advanced chronic kidney disease), medium-chain triglycerides (for fat malabsorption), more fat (for respiratory failure and CO₂ retention), and more branched-chain amino acids (for hepatic encephalopathy and severe trauma)—they have not been shown to be superior to standard formulas for most patients.

Enteral solutions should be administered via continuous infusion, preferably with an infusion pump. Isotonic feedings should be started at full strength at about 25–33% of the estimated final infusion rate. Feedings can be advanced by similar amounts every 12 hours as tolerated. Hypertonic feedings should be started at half strength. The strength and the rate can then be advanced every 6 hours as tolerated.

COMPLICATIONS OF ENTERAL NUTRITIONAL SUPPORT

Minor complications of tube feedings occur in 10–15% of patients. Gastrointestinal complications include diarrhea (most common), inadequate gastric emptying, emesis, esophagitis, and occasionally gastrointestinal bleeding. Diarrhea associated with tube feeding may be due to intolerance to the osmotic load or to one of the macronutrients (eg, fat, lactose) in the solution. Patients being fed in this way may also have diarrhea from other causes (as side effects of antibiotics or other drugs, associated with infection, etc), and these possibilities should always be investigated in appropriate circumstances.

Mechanical complications of tube feedings are potentially the most serious. Of particular importance is aspiration. All patients receiving nasogastric tube feedings are at risk for this life-threatening complication. Limiting nasogastric feedings to those patients who can adequately protect their airway and careful monitoring of patients being fed by tube should limit these serious complications to

1–2% of cases. Minor mechanical complications are common and include tube obstruction and dislodgment.

Metabolic complications during enteral nutritional support are common but in most cases are easily managed. The most important problem is hypernatremic dehydration, most commonly seen in elderly patients given excessive protein intake who are unable to respond to thirst. Abnormalities of potassium, glucose, CO₂ production, and acid–base balance may also occur.

PARENTERAL NUTRITIONAL SUPPORT SOLUTIONS

Parenteral nutritional support solutions can be designed to deliver adequate nutrients to most patients. The basic parenteral solution is composed of dextrose, amino acids, and water. Electrolytes, minerals, trace elements, vitamins, and medications can also be added. Most commercial solutions contain the monohydrate form of dextrose that provides 3.4 kcal/g. Crystalline amino acids are available in a variety of concentrations, so that a broad range of solutions can be made up that will contain specific amounts of dextrose and amino acids as required.

Typical solutions for central vein nutritional support contain 25–35% dextrose and 2.75–6% amino acids depending upon the patient’s estimated nutrient and water requirements. These solutions typically have osmolalities in excess of 1800 mosm/L and require infusion into a central vein. A typical formula for patients without organ failure is shown in Table 29–2.

Table 29–2. Typical parenteral nutrition solution (for stable patients without organ failure).

Dextrose (3.4 kcal/g)	25%
Amino acids (4 kcal/g)	6%
Na ⁺	50 mEq/L
K ⁺	40 mEq/L
Ca ²⁺	5 mEq/L
Mg ²⁺	8 mEq/L
Cl ⁻	60 mEq/L
P	12 mEq/L
Acetate	Balance
MVI-12 (vitamins)	10 mL/d
MTE (trace elements)	5 mL/d
Fat emulsion 20%	250 mL five times a week
Typical rate	Day 1: 30 mL/h Day 2: 60 mL/h
By day 2, solution provides:	Calories: 1925 kcal total Protein: 86 g Fat: 19% of total kcal Fluid: 1690 mL

Solutions with lower osmolalities can also be designed for infusion into peripheral veins. Typical solutions for peripheral infusion contain 5–10% dextrose and 2.75–4.25% amino acids. These solutions have osmolalities between 800 and 1200 mosm/L and result in a high incidence of thrombophlebitis and line infiltration. These solutions will provide adequate protein for most patients but inadequate energy. Additional energy must be provided in the form of emulsified soybean or safflower oil. Such intravenous fat solutions are currently available in 10% and 25% solutions providing 1.1 and 2.2 kcal/mL, respectively. Intravenous fat solutions are isosmotic and well tolerated by peripheral veins.

Typical patients are given 200–500 mL of a 20% solution each day. As much as 60% of total calories can be administered in this manner.

Intravenous fat can also be provided to patients receiving central vein nutritional support. In this instance, dextrose concentrations should be decreased to provide a fixed concentration of energy. Intravenous fat has been shown to be equivalent to intravenous dextrose in providing energy to spare protein. Intravenous fat is associated with less glucose intolerance, less production of carbon dioxide, and less fatty infiltration of the liver and has been increasingly utilized in patients with hyperglycemia, respiratory failure, and liver disease. Intravenous fat has also been increasingly used in patients with large estimated energy requirements. The maximum glucose utilization rate is approximately 5–7 mg/min/kg. Patients who require additional calories can be given them as fat to prevent excess administration of dextrose. Intravenous fat can also be used to prevent essential fatty acid deficiency. The optimal ratio of carbohydrate and fat in parenteral nutritional support has not been determined.

Infusion of parenteral solutions should be started slowly to prevent hyperglycemia and other metabolic

complications. Typical solutions are given initially at a rate of 50 mL/h and advanced by about the same amount every 24 hours until the desired final rate is reached.

COMPLICATIONS OF PARENTERAL NUTRITIONAL SUPPORT

Complications of central vein nutritional support occur in up to 50% of patients. Although most are minor and easily managed, significant complications will develop in about 5% of patients. Complications of central vein nutritional support can be divided into catheter-related complications and metabolic complications.

Catheter-related complications can occur during insertion or while the catheter is in place. Pneumothorax, hemothorax, arterial laceration, air emboli, and brachial plexus injury can occur during catheter placement. The incidence of these complications is inversely related to the experience of the physician performing the procedure but will occur in at least 1–2% of cases even in major medical centers. Each catheter placement should be documented by chest radiograph prior to initiation of nutritional support.

Catheter thrombosis and catheter-related sepsis are the most important complications of indwelling catheters. Patients with indwelling central vein catheters in whom fever develops without an apparent source should have their lines changed over a wire or removed immediately, the tip quantitatively cultured, and antibiotics begun empirically. Quantitative tip cultures and blood cultures will help guide further antibiotic therapy. Catheter-related sepsis occurs in 2–3% of patients even if maximal efforts are made to prevent infection.

Metabolic complications of central vein nutritional support occur in over 50% of patients (Table 29–3). Most

Table 29–3. Metabolic complications of parenteral nutritional support.

Complication	Common Causes	Possible Solutions
Hyperglycemia	Too rapid infusion of dextrose, “stress,” corticosteroids	Decrease glucose infusion; insulin; replacement of dextrose with fat
Hyperosmolar nonketotic dehydration	Severe, undetected hyperglycemia	Insulin, hydration, potassium
Hyperchloremic metabolic acidosis	High chloride administration	Decrease chloride
Azotemia	Excessive protein administration	Decrease amino acid concentration
Hyperphosphatemia, hypokalemia, hypomagnesemia	Extracellular to intracellular shifting with refeeding	Increase solution concentration
Liver enzyme abnormalities	Lipid trapping in hepatocytes, fatty liver	Decrease dextrose
Acalculous cholecystitis	Biliary stasis	Oral fat
Zinc deficiency	Diarrhea, small bowel fistulas	Increase concentration
Copper deficiency	Biliary fistulas	Increase concentration

are minor and easily managed, and termination of support is seldom necessary.

PATIENT MONITORING DURING NUTRITIONAL SUPPORT

Every patient receiving enteral or parenteral nutritional support should be monitored closely. Formal nutritional support teams composed of a physician, a nurse, a dietitian, and a pharmacist have been shown to decrease the rate of complications.

Patients should be monitored both for the adequacy of treatment and to prevent complications or detect them early when they occur. Because estimates of nutritional requirements are imprecise, frequent reassessment is necessary. Daily intakes should be recorded and compared with estimated requirements. Body weight, hydration status, and overall clinical status should be followed. Patients who do not appear to be responding as anticipated can be evaluated for nitrogen balance by means of the following equation:

$$\text{Nitrogen balance} = \frac{\text{24-hour protein intake (g)}}{6.25} - \left(\frac{\text{24-hour urinary nitrogen (g)}}{\text{nitrogen (g)}} + 4 \right)$$

Patients with positive nitrogen balances can be continued on their current regimens; patients with negative balances should receive moderate increases in calorie and protein intake and then be reassessed. Monitoring for metabolic complications includes daily measurements of electrolytes; serum glucose, phosphorus, magnesium, calcium, and creatinine; and BUN until the patient is stabilized. Once the patient is stabilized, electrolytes, phosphorus,

calcium, magnesium, and glucose should be obtained at least twice weekly. Red blood cell folate, zinc, and copper should be checked at least once a month.

- Bankhead R et al. A.S.P.E.N. Board of Directors. Enteral Nutrition Practice Recommendations. *JPEN J Parenter Enteral Nutr.* 2009 Mar-Apr;33(2):122-67. [PMID: 19171692]
- Cahill NE et al. Nutrition therapy in the critical care setting: what is "best achievable" practice? An international multicenter observational study. *Crit Care Med.* 2010 Feb;38(2):395-401. [PMID: 19851094]
- Calder PC et al. Lipid emulsions in parenteral nutrition of intensive care patients: current thinking and future directions. *Intensive Care Med.* 2010 May;36(5):735-49. [PMID: 20072779]
- Casaer MP et al. Early versus late parenteral nutrition in critically ill adults. *N Engl J Med.* 2011 Aug 11;365(6):506-17. [PMID: 21714640]
- Koretz RL. Enteral nutrition: a hard look at some soft evidence. *Nutr Clin Pract.* 2009 Jun-Jul;24(3):316-24. [PMID: 19483061]
- Murray SM et al. Nutrition support for bone marrow transplant patients. *Cochrane Database Syst Rev.* 2009 Jan 21;(1):CD002920. [PMID: 19160213]
- Oertel MF et al. Parenteral and enteral nutrition in the management of neurosurgical patients in the intensive care unit. *J Clin Neurosci.* 2009 Sep;16(9):1161-7. [PMID: 19570684]
- Sampson EL et al. Enteral tube feeding for older people with advanced dementia. *Cochrane Database Syst Rev.* 2009 Apr 15;(2):CD007209. [PMID: 19370678]
- Singer P et al. Considering energy deficit in the intensive care unit. *Curr Opin Clin Nutr Metab Care.* 2010 Mar;13(2):170-6. [PMID: 20019607]
- Tappenden KA. Emerging therapies for intestinal failure. *Arch Surg.* 2010 Jun;145(6):528-32. [PMID: 20566971]
- Wanten G et al. Managing adult patients who need home parenteral nutrition. *BMJ.* 2011 Mar 18;342:d1447. [PMID: 21421667]
- Ziegler TR. Parenteral nutrition in the critically ill patient. *N Engl J Med.* 2009 Sep 10;361(11):1088-97. [PMID: 19741230]

30

Common Problems in Infectious Diseases & Antimicrobial Therapy

Peter V. Chin-Hong, MD
B. Joseph Guglielmo, PharmD

COMMON PROBLEMS IN INFECTIOUS DISEASES

FEVER OF UNKNOWN ORIGIN (FUO)

ESSENTIALS OF DIAGNOSIS

- ▶ Illness of at least 3 weeks duration.
- ▶ Fever over 38.3°C on several occasions.
- ▶ Diagnosis has not been made after three outpatient visits or 3 days of hospitalization.

▶ General Considerations

The intervals specified in the criteria for the diagnosis of FUO are arbitrary ones intended to exclude patients with protracted but self-limited viral illnesses and to allow time for the usual radiographic, serologic, and cultural studies to be performed. Because of costs of hospitalization and the availability of most screening tests on an outpatient basis, the original criterion requiring 1 week of hospitalization has been modified to accept patients in whom a diagnosis has not been made after three outpatient visits or 3 days of hospitalization.

Several additional categories of FUO have been added: (1) **Hospital-associated FUO** refers to the hospitalized patient with fever of 38.3°C or higher on several occasions, due to a process not present or incubating at the time of admission, in whom initial cultures are negative and the diagnosis remains unknown after 3 days of investigation (see Health care-associated Infections below). (2) **Neutropenic FUO** includes patients with fever of 38.3°C or higher on several occasions with < 500 neutrophils per microliter in whom initial cultures are negative and the diagnosis remains uncertain after 3 days (see Chapter 2 and Infections in the Immunocompromised Patient, below). (3) **HIV-associated FUO** pertains to HIV-positive patients with fever of 38.3°C or higher who have been febrile for 4 weeks or more as an outpatient or 3 days as an inpatient, in whom the diagnosis remains uncertain after 3 days of investigation

with at least 2 days for cultures to incubate (see Chapter 31). Although not usually considered separately, FUO in solid organ transplant recipients is a common scenario with a unique differential diagnosis and is discussed below.

For a general discussion of fever, see the section on fever and hyperthermia in Chapter 2.

A. Common Causes

Most cases represent unusual manifestations of common diseases and not rare or exotic diseases—eg, tuberculosis, endocarditis, gallbladder disease, and HIV (primary infection or opportunistic infection) are more common causes of FUO than Whipple disease or familial Mediterranean fever.

B. Age of Patient

In adults, infections (25–40% of cases) and cancer (25–40% of cases) account for the majority of FUOs. In children, infections are the most common cause of FUO (30–50% of cases) and cancer a rare cause (5–10% of cases). Autoimmune disorders occur with equal frequency in adults and children (10–20% of cases), but the diseases differ. Juvenile rheumatoid arthritis is particularly common in children, whereas systemic lupus erythematosus, granulomatosis with polyangiitis (formerly Wegener granulomatosis), and polyarteritis nodosa are more common in adults. Still disease, giant cell arteritis, and polymyalgia rheumatica occur exclusively in adults. In the elderly (over 65 years of age), multisystem immune-mediated diseases such as temporal arteritis, polymyalgia rheumatica, sarcoidosis, rheumatoid arthritis, and granulomatosis with polyangiitis (formerly Wegener granulomatosis) account for 25–30% of all FUOs.

C. Duration of Fever

The cause of FUO changes dramatically in patients who have been febrile for 6 months or longer. Infection, cancer, and autoimmune disorders combined account for only 20% of FUOs in these patients. Instead, other entities such as granulomatous diseases (granulomatous hepatitis, Crohn disease, ulcerative colitis) and factitious fever become important causes. One-fourth of patients who say they have been febrile for 6 months or longer actually have

no true fever or underlying disease. Instead, the usual normal circadian variation in temperature (temperature 0.5–1°C higher in the afternoon than in the morning) is interpreted as abnormal. Patients with episodic or recurrent fever (ie, those who meet the criteria for FUO but have fever-free periods of 2 weeks or longer) are similar to those with prolonged fever. Infection, malignancy, and autoimmune disorders account for only 20–25% of such fevers, whereas various miscellaneous diseases (Crohn disease, familial Mediterranean fever, allergic alveolitis) account for another 25%. Approximately 50% of cases remain undiagnosed but have a benign course with eventual resolution of symptoms.

D. Immunologic Status

In the neutropenic patient, fungal infections and occult bacterial infection are important causes of FUO. In the patient taking immunosuppressive medications (particularly organ transplant patients), cytomegalovirus (CMV) infections are a frequent cause of fever, as are fungal infections, nocardiosis, *Pneumocystis jiroveci* (formerly *P carinii*) pneumonia, and mycobacterial infections.

E. Classification of Causes of FUO

Most patients with FUO will fit into one of five categories.

1. Infection—Both systemic and localized infections can cause FUO. Tuberculosis and endocarditis are the most common systemic infections, but mycoses, viral diseases (particularly infection with Epstein-Barr virus and CMV), toxoplasmosis, brucellosis, Q fever, cat-scratch disease, salmonellosis, malaria, and many other less common infections have been implicated. Primary infection with HIV or opportunistic infections associated with AIDS—particularly mycobacterial infections—can also present as FUO. The most common form of localized infection causing FUO is an occult abscess. Liver, spleen, kidney, brain, and bone abscesses may be difficult to detect. A collection of pus may form in the peritoneal cavity or in the subdiaphragmatic, subhepatic, paracolic, or other areas. Cholangitis, osteomyelitis, urinary tract infection, dental abscess, or paranasal sinusitis may cause prolonged fever.

2. Neoplasms—Many cancers can present as FUO. The most common are lymphoma (both Hodgkin and non-Hodgkin) and leukemia. Posttransplant lymphoproliferative disorders may also present with fever. Other diseases of lymph nodes, such as angioimmunoblastic lymphoma and Castleman disease, can also cause FUO. Primary and metastatic tumors of the liver are frequently associated with fever, as are renal cell carcinomas. Atrial myxoma is an often forgotten neoplasm that can result in fever. Chronic lymphocytic leukemia and multiple myeloma are rarely associated with fever, and the presence of fever in patients with these diseases should prompt a search for infection.

3. Autoimmune disorders—Still disease, systemic lupus erythematosus, cryoglobulinemia, and polyarteritis nodosa are the most common causes of autoimmune-associated FUO. Giant cell arteritis and polymyalgia rheumatica are seen almost exclusively in patients over 50 years of age and

are nearly always associated with an elevated erythrocyte sedimentation rate (> 40 mm/h).

4. Miscellaneous causes—Many other conditions have been associated with FUO but less commonly than the foregoing types of illness. Examples include thyroiditis, sarcoidosis, Whipple disease, familial Mediterranean fever, recurrent pulmonary emboli, alcoholic hepatitis, drug fever, and factitious fever.

5. Undiagnosed FUO—Despite extensive evaluation, the diagnosis remains elusive in 15% or more of patients. Of these patients, the fever abates spontaneously in about 75% with no diagnosis; in the remainder, more classic manifestations of the underlying disease appear over time.

► Clinical Findings

Because the evaluation of a patient with FUO is costly and time-consuming, it is imperative to first document the presence of fever. This is done by observing the patient while the temperature is being taken to ascertain that fever is not factitious (self-induced). Associated findings that accompany fever include tachycardia, chills, and piloerection. A thorough history—including family, occupational, social (sexual practices, use of injection drugs), dietary (unpasteurized products, raw meat), exposures (animals, chemicals), and travel—may give clues to the diagnosis. Repeated physical examination may reveal subtle, evanescent clinical findings essential to diagnosis.

A. Laboratory Tests

In addition to routine laboratory studies, blood cultures should always be obtained, preferably when the patient has not taken antibiotics for several days, and should be held by the laboratory for 2 weeks to detect slow-growing organisms. Cultures on special media are requested if *Legionella*, *Bartonella*, or nutritionally deficient streptococci are possible pathogens. “Screening tests” with immunologic or microbiologic serologies (“febrile agglutinins”) are of low yield and should not be done. If the history or physical examination suggests a specific diagnosis, specific serologic tests with an associated fourfold rise or fall in titer may be useful. Because infection is the most common cause of FUO, other body fluids are usually cultured, ie, urine, sputum, stool, cerebrospinal fluid, and morning gastric aspirates (if one suspects tuberculosis). Direct examination of blood smears may establish a diagnosis of malaria or relapsing fever (*Borrelia*).

B. Imaging

All patients with FUO should have a chest radiograph. Studies such as sinus films, upper gastrointestinal series with small bowel follow-through, barium enema, proctosigmoidoscopy, and evaluation of gallbladder function are reserved for patients who have symptoms, signs, or a history that suggest disease in these body regions. CT scan of the abdomen and pelvis is also frequently performed and is particularly useful for looking at the liver, spleen, and retroperitoneum. When the CT scan is abnormal, the findings often lead to a specific diagnosis. A normal CT scan is not

quite as useful; more invasive procedures such as biopsy or exploratory laparotomy may be needed. The role of MRI in the investigation of FUO has not been evaluated. In general, however, MRI is better than CT for detecting lesions of the nervous system and is useful in diagnosing various vasculitides. Ultrasound is sensitive for detecting lesions of the kidney, pancreas, and biliary tree. Echocardiography should be used if one is considering endocarditis or atrial myxoma. Transesophageal echocardiography is more sensitive than surface echocardiography for detecting valvular lesions, but even a negative transesophageal study does not exclude endocarditis (10% false-negative rate). The usefulness of radionuclide studies in diagnosing FUO is variable. Some experts use positron emission tomography (PET) in conjunction with CT scans early in the investigation of FUO. However, more studies are needed before this practice can be more fully integrated into clinical practice. Theoretically, a gallium or PET scan would be more helpful than an indium-labeled white blood cell scan because gallium and fluorodeoxyglucose may be useful for detecting infection, inflammation, and neoplasm whereas the indium scan is useful only for detecting infection. Indium-labeled immunoglobulin may prove to be useful in detecting infection and neoplasm and can be used in the neutropenic patient. It is not sensitive for lesions of the liver, kidney, and heart because of high background activity. In general, radionuclide scans are plagued by high rates of false-positive and false-negative results that are not useful when used as screening tests and, if done at all, are limited to those patients whose history or examination suggests local inflammation or infection.

C. Biopsy

Invasive procedures are often required for diagnosis. Any abnormal finding should be aggressively evaluated: Headache calls for lumbar puncture to rule out meningitis; skin rash should be biopsied for cutaneous manifestations of collagen vascular disease or infection; and enlarged lymph nodes should be aspirated or biopsied for neoplasm and sent for culture. Bone marrow aspiration with biopsy is a relatively low-yield procedure (15–25%; except in HIV-positive patients, in whom mycobacterial infection is a common cause of FUO), but the risk is low and the procedure should be done if other less invasive tests have not yielded a diagnosis, particularly in persons with hematologic abnormalities. Liver biopsy will yield a specific diagnosis in 10–15% of patients with FUO and should be considered in any patient with abnormal liver function tests even if the liver is normal in size. CT scanning and MRI have decreased the need for exploratory laparotomy; however, surgical visualization and biopsies should be considered when there is continued deterioration or lack of diagnosis.

▶ Treatment

An empiric course of antimicrobials for possible cystitis (eg, ciprofloxacin, 500 mg orally twice daily for 3 days) should be considered if an infectious diagnosis is strongly suspected. However, if there is no clinical response, it is

imperative to stop therapy and reevaluate. Once definitive culture results return, streamlining therapy to the most narrow-spectrum antimicrobial should take place.

Empiric administration of corticosteroids should be discouraged because they can suppress fever and exacerbate many infections.

▶ When to Refer

- Any patient with FUO and progressive weight loss and other constitutional signs.
- Any immunocompromised patient (eg, transplant recipients and HIV-infected patients).
- Infectious diseases specialists may also be able to coordinate and interpret specialized testing (eg, Q fever serologies) with outside agencies, such as the US Centers for Disease Control and Prevention.

▶ When to Admit

- Any patient who is rapidly declining with weight loss where hospital admission may expedite work-up.
- If FUO is present in immunocompromised patients, such as those who are neutropenic from recent chemotherapy or those who have undergone transplantation (particularly in the previous 6 months).

Ben-Baruch S et al. Predictive parameters for a diagnostic bone marrow biopsy specimen in the work-up of Fever of unknown origin. *Mayo Clin Proc.* 2012 Feb;87(2):136–42. [PMID: 22226833]

Cunha BA. Fever of unknown origin: clinical overview of classic and current concepts. *Infect Dis Clin North Am.* 2007;21(4):867–915. [PMID: 18061081]

Hot A et al. Yield of bone marrow examination in diagnosing the source of fever of unknown origin. *Arch Intern Med.* 2009 Nov 23;169(21):2018–23. [PMID: 19933965]

Pedersen TI et al. Fever of unknown origin: a retrospective study of 52 cases with evaluation of the diagnostic utility of FDG-PET/CT. *Scand J Infect Dis.* 2012 Jan;44(1):18–23. [PMID: 21888563]

INFECTIONS IN THE IMMUNOCOMPROMISED PATIENT

ESSENTIALS OF DIAGNOSIS

- ▶ Fever and other symptoms may be blunted because of immunosuppression.
- ▶ A contaminating organism in an immunocompetent individual may be a pathogen in an immunocompromised one.
- ▶ The interval since transplantation and the degree of immunosuppression can narrow the differential diagnosis.
- ▶ Empiric broad-spectrum antibiotics may be appropriate in high-risk patients whether or not symptoms are localized.

► General Considerations

Immunocompromised patients have defects in their natural defense mechanisms resulting in an increased risk for infection. In addition, infection is often severe, rapidly progressive, and life threatening. Organisms that are not usually problematic in the immunocompetent person may be important pathogens in the compromised patient (eg, *Staphylococcus epidermidis*, *Corynebacterium jeikeium*, *Propionibacterium acnes*, *Bacillus* species). Therefore, culture results must be interpreted with caution, and isolates should not be disregarded as merely contaminants. Although the type of immunodeficiency is associated with specific infectious disease syndromes, any pathogen can cause infection in any immunosuppressed patient at any time. Thus, a systematic evaluation is required to identify a specific organism.

A. Impaired Humoral Immunity

Defects in humoral immunity are often congenital, although hypogammaglobulinemia can occur in multiple myeloma, chronic lymphocytic leukemia, and in patients who have undergone splenectomy. Patients with ineffective humoral immunity lack opsonizing antibodies and are at particular risk for infection with encapsulated organisms, such as *Haemophilus influenzae*, *Neisseria meningitidis* and *Streptococcus pneumoniae*.

B. Granulocytopenia (Neutropenia)

Granulocytopenia is common following hematopoietic cell transplantation (“stem cell transplantation”) and among patients with solid tumors—as a result of myelosuppressive chemotherapy—and in acute leukemias. The risk of infection begins to increase when the absolute granulocyte count falls below 1000/mcL, with a dramatic increase in frequency and severity when the granulocyte count falls below 100/mcL. The infection risk is also increased with a rapid rate of decline of neutrophils and with a prolonged period of neutropenia. The granulocytopenic patient is particularly susceptible to infections with gram-negative enteric organisms, *Pseudomonas*, gram-positive cocci (particularly *Staphylococcus aureus*, *S epidermidis*, and viridans streptococci), *Candida*, *Aspergillus*, and other fungi that have recently emerged as pathogens such as *Trichosporon*, *Scedosporium*, *Fusarium*, and the mucormycoses.

C. Impaired Cellular Immunity

Patients with cellular immune deficiency encompass a large and heterogeneous group, including patients with HIV infection (see Chapter 31); patients with lymphoreticular malignancies, such as Hodgkin disease; and patients receiving immunosuppressive medications, such as corticosteroids, cyclosporine, tacrolimus, and other cytotoxic drugs. This latter group—those who are immunosuppressed as a result of medications—includes patients who have undergone solid organ transplantation, many patients receiving therapy for solid tumors, and patients receiving prolonged high-dose corticosteroid treatment (eg, for asthma, temporal arteritis, systemic lupus). Patients taking

tumor necrosis factor (TNF) inhibitors, such as etanercept and infliximab, are also included in this category. Patients with cellular immune dysfunction are susceptible to infections by a large number of organisms, particularly ones that replicate intracellularly. Examples include bacteria, such as *Listeria*, *Legionella*, *Salmonella*, and *Mycobacterium*; viruses, such as herpes simplex, varicella, and CMV; fungi, such as *Cryptococcus*, *Coccidioides*, *Histoplasma*, and *Pneumocystis*; and protozoa, such as *Toxoplasma*. Patients taking TNF inhibitors have specific defects that increase risk of bacterial, mycobacterial (particularly tuberculosis), and fungal infections (primary and reactivation).

D. Hematopoietic Cell Transplant Recipients

The length of time it takes for complications to occur in hematopoietic cell transplant recipients can be helpful in determining the etiologic agent. In the early (preengraftment) posttransplant period (day 1–21), patients will become severely neutropenic for 7–21 days. Patients are at risk for gram-positive (particularly catheter-related) and gram-negative bacterial infections, as well as herpes simplex virus, respiratory syncytial virus, and fungal infections. In contrast to solid organ transplant recipients, the source of fever is unknown in 60–70% of hematopoietic cell transplant patients. Between 3 weeks and 3 months posttransplant, infections with CMV, adenovirus, *Aspergillus*, and *Candida* are most common. *P jiroveci* pneumonia is possible, particularly in patients who receive additional immunosuppression for treatment of graft-versus-host disease. Patients continue to be at risk for infectious complications beyond 3 months following transplantation, particularly those who have received allogeneic transplantation and those who are taking immunosuppressive therapy for chronic graft-versus-host disease. Varicella-zoster is common, and *Aspergillus* and CMV infections are increasingly seen in this period as well.

E. Solid Organ Transplant Recipients

The length of time it takes for infection to occur following solid organ transplantation can also be helpful in determining the infectious origin. Immediate postoperative infections often involve the transplanted organ. Following lung transplantation, pneumonia and mediastinitis are particularly common; following liver transplantation, intra-abdominal abscess, cholangitis, and peritonitis may be seen; after kidney transplantation, urinary tract infections, perinephric abscesses, and infected lymphoceles can occur.

Most infections that occur in the first 2–4 weeks posttransplant are related to the operative procedure and to hospitalization itself (wound infection, intravenous catheter infection, urinary tract infection from a Foley catheter) or are related to the transplanted organ. In rare instances, donor derived infections (eg, West Nile virus, tuberculosis) may present during this time period. Infections that occur between the first and sixth months are often related to immunosuppression. During this period, reactivation of viruses, such as herpes simplex, varicella-zoster, and CMV is quite common. Opportunistic infections with fungi

(eg, *Candida*, *Aspergillus*, *Cryptococcus*, *Pneumocystis*), *Listeria monocytogenes*, *Nocardia*, and *Toxoplasma* are also common. After 6 months, if immunosuppression has been reduced to maintenance levels, infections that would be expected in any population occur. Patients with poorly functioning allografts receiving long-term immunosuppression therapy continue to be at risk for opportunistic infections.

F. Other Immunocompromised States

A large group of patients who are not specifically immunodeficient are at increased risk for infection due to debilitating injury (eg, burns or severe trauma), invasive procedures (eg, chronic central intravenous catheters, Foley catheters, dialysis catheters), central nervous system dysfunction (which predisposes patients to aspiration pneumonia and decubitus ulcers), obstructing lesions (eg, pneumonia due to an obstructed bronchus, pyelonephritis due to nephrolithiasis, cholangitis secondary to cholelithiasis), and use of broad-spectrum antibiotics. Patients with diabetes mellitus have alterations in cellular immunity, resulting in mucormycosis, emphysematous pyelonephritis, and foot infections.

► Clinical Findings

A. Laboratory Findings

Routine evaluation includes complete blood count with differential, chest radiograph, and blood cultures; urine and respiratory cultures should be obtained if indicated clinically or radiographically. Any focal complaints (localized pain, headache, rash) should prompt imaging and cultures appropriate to the site.

Patients who remain febrile without an obvious source should be evaluated for viral infection (serum CMV antigen test or polymerase chain reaction), abscesses (which usually occur near previous operative sites), candidiasis involving the liver or spleen, or aspergillosis. Serologic evaluation may be helpful if toxoplasmosis or an endemic fungal infection (coccidioidomycosis, histoplasmosis) is a possible cause. Antigen based assays may be useful for the diagnosis of aspergillosis (detected by galactomannan level in serum or bronchoalveolar lavage fluid), or other invasive fungal disease, including *Pneumocystis* infection (serum $(1\rightarrow\beta\text{-D-glucan level})$).

B. Special Diagnostic Procedures

Special diagnostic procedures should also be considered. The cause of pulmonary infiltrates can be easily determined with simple techniques in some situations—eg, induced sputum yields a diagnosis of *Pneumocystis* pneumonia in 50–80% of AIDS patients with this infection. In other situations, more invasive procedures may be required (bronchoalveolar lavage, transbronchial biopsy, open lung biopsy). Skin, liver, or bone marrow biopsy may be helpful in establishing a diagnosis.

► Differential Diagnosis

Transplant rejection, organ ischemia and necrosis, thrombophlebitis, and lymphoma (posttransplant lymphoproliferative disease) may all present as fever and must be considered in the differential diagnosis.

► Prevention

There is great interest in preventing infection with prophylactic antimicrobial regimens but no uniformity of opinion about optimal drugs or dosage regimens. Hand washing is the simplest and most effective means of decreasing hospital-associated infections, especially in the compromised patient. Invasive devices such as central and peripheral lines and Foley catheters are potential sources of infection. Some centers use laminar airflow isolation or high-efficiency particulate air (HEPA) filtering in hematopoietic cell transplant patients. Rates of infection and episodes of febrile neutropenia, but not mortality, are decreased if colony-stimulating factors are used during chemotherapy or during stem-cell transplantation.

A. *Pneumocystis* & Herpes Simplex Infections

Trimethoprim-sulfamethoxazole (TMP-SMZ), one double-strength tablet orally three times a week, one double-strength tablet twice daily on weekends, or one single-strength tablet daily for 3–6 months, is frequently used to prevent *Pneumocystis* infections in transplant patients. In patients allergic to TMP-SMZ, dapsone, 50 mg orally daily or 100 mg three times weekly, is recommended. Glucose-6-phosphate dehydrogenase (G6PD) levels should be determined before therapy when the latter is instituted. Acyclovir prevents herpes simplex infections in bone marrow and solid organ transplant recipients and is given to seropositive patients who are not receiving acyclovir or ganciclovir for CMV prophylaxis. The usual dose is 200 mg orally three times daily for 4 weeks (hematopoietic cell transplants) to 12 weeks (other solid organ transplants).

B. CMV

No uniformly accepted approach has been adopted for prevention of CMV. Prevention strategies often depend on the serologic status of the donor and recipient and the organ transplanted, which determines the level of immunosuppression after transplant. In solid organ transplants (liver, kidney, heart, lung), the greatest risk of developing CMV disease is in seronegative patients who receive organs from seropositive donors. These high-risk patients usually receive oral valganciclovir, 900 mg daily for 3–6 months (longer in lung transplant recipients). Other solid organ transplant recipients (seropositive recipients) are at lower risk for developing CMV disease but still usually receive oral valganciclovir for 3 months. The lowest risk group for the development of CMV disease is in seronegative patients who receive organs from seronegative donors. Typically, no CMV prophylaxis is used in this group. Ganciclovir and valganciclovir also prevent herpes virus reactivation. Because immunosuppression is increased during periods of rejection, patients treated for rejection usually receive CMV prophylaxis during rejection therapy.

Recipients of hematopoietic cell transplants are more severely immunosuppressed than recipients of solid organ transplants, are at greater risk for developing serious CMV infection (usually CMV reactivation), and thus usually receive more aggressive prophylaxis. Two approaches have been used: universal prophylaxis or preemptive therapy.

In the former, all high-risk patients (seropositive patients who receive allogeneic transplants) may receive oral valganciclovir, 900 mg daily to day 100. This method is costly and associated with significant bone marrow toxicity. Alternatively, patients can be monitored without specific prophylaxis and have blood sampled weekly for the presence of CMV. If CMV is detected by an antigenemia assay or by polymerase chain reaction, preemptive therapy is instituted with oral valganciclovir, 900 mg twice daily for a minimum of 2–3 weeks followed by oral valganciclovir at 900 mg daily until day 100. This preemptive approach is effective but does miss a small number of patients in whom CMV disease would have been prevented had prophylaxis been used. Other preventive strategies include use of CMV-negative or leukocyte-depleted blood products for CMV-seronegative recipients.

C. Other Organisms

Routine decontamination of the gastrointestinal tract to prevent bacteremia in the neutropenic patient is not recommended. Prophylactic administration of antibiotics in the afebrile, asymptomatic neutropenic patient is controversial, although many centers have adopted this strategy. Rates of bacteremia are decreased, but overall mortality is not affected and emergence of resistant organisms is a risk. Use of intravenous immunoglobulin is reserved for the small number of patients with severe hypogammaglobulinemia following bone marrow transplantation and should not be routinely administered to all transplant patients.

Prophylaxis with antifungal agents to prevent invasive mold (primarily *Aspergillus*) and yeast (primarily *Candida*) infections is routinely used, but the optimal agent, dose, and duration have not been standardized. Lipid-based preparations of amphotericin B, aerosolized amphotericin B, intravenous and oral fluconazole or voriconazole, and oral posaconazole solution are all prophylactic options in the neutropenic patient. Because voriconazole is superior to amphotericin for documented *Aspergillus* infections and because posaconazole prophylaxis (compared with fluconazole) has been shown to result in fewer cases of invasive aspergillosis among allogeneic stem cell transplant recipients with graft-versus-host disease, one approach to prophylaxis is to use oral fluconazole (400 mg/d) for patients at low risk for developing fungal infections (those who receive autologous bone marrow transplants) and oral voriconazole (200 mg twice daily) or oral posaconazole (200 mg solution three times daily) for those at high risk (allogeneic transplants, graft-versus-host disease) at least until engraftment (usually 30 days). In solid organ transplant recipients, the risk of invasive fungal infection varies considerably (1–2% in liver, pancreas, and kidney transplants and 6–8% in heart and lung transplants). Whether universal prophylaxis or observation with preemptive therapy is the best approach has not been determined. Although fluconazole is effective in preventing yeast infections, emergence of fluconazole-resistant *Candida* and molds (*Fusarium*, *Aspergillus*, *Mucor*) has raised concerns about its routine use as a prophylactic agent.

Given the high risk of reactivation of tuberculosis in patients taking TNF inhibitors, all patients should be

screened for latent tuberculosis infection (LTBI) with a tuberculin skin test or an interferon-gamma release assay prior to the start of therapy. If LTBI is diagnosed, treatment with the TNF inhibitors should be delayed until treatment for LTBI is completed. There is also a marked risk of reactivation of hepatitis B and hepatitis C in patients taking TNF inhibitors; patients should also be screened for these viruses when TNF inhibitor treatment is being considered.

► Treatment

A. General Measures

Because infections in the immunocompromised patient can be rapidly progressive and life-threatening, diagnostic procedures must be performed promptly, and empiric therapy is usually instituted.

While reduction or discontinuation of immunosuppressive medication may jeopardize the viability of the transplanted organ, this measure may be necessary if the infection is life-threatening. Hematopoietic growth factors (granulocyte and granulocyte-macrophage colony-stimulating factors) stimulate proliferation of bone marrow stem cells, resulting in an increase in peripheral leukocytes. These agents shorten the period of neutropenia and have been associated with reduction in infection.

B. Specific Measures

Antimicrobial drug therapy ultimately should be tailored to culture results. While combinations of antimicrobials may be used to provide synergy or to prevent resistance, the primary reason for empiric combination therapy is broad-spectrum coverage of multiple pathogens (since infections in these patients are often polymicrobial).

Empiric therapy is often instituted at the earliest sign of infection in the immunosuppressed patient because prompt therapy favorably affects outcome. The antibiotic or combination of antibiotics used depends on the degree of immune compromise and the site of infection. For example, in the febrile neutropenic patient, an algorithmic approach to therapy is often used. Febrile neutropenic patients should be empirically treated with broad-spectrum agents active against gram-positive organisms, *Pseudomonas aeruginosa*, and other gram-negative bacilli (such as cefepime 2 g every 8 hours intravenously). The addition of vancomycin, 10–15 mg/kg/dose intravenously every 12 hours, should be considered in those patients with suspected infection due to methicillin-resistant *Staphylococcus aureus* (MRSA), *S epidermidis*, and enterococcus. Continued neutropenic fever necessitates broadening of antibacterial coverage from cefepime to agents such as imipenem 500 mg every 6 hours or meropenem 1 g every 8 hours intravenously with or without tobramycin 5 mg/kg intravenously every 24 hours. Antifungal agents (such as voriconazole, 200 mg intravenously or orally every 12 hours, or caspofungin, 50 mg daily intravenously) should be added if fevers continue after 5–7 days of broad-spectrum antibacterial therapy. Regardless of whether the patient becomes afebrile, therapy is continued until resolution of neutropenia. Failure to continue antibiotics through the period of neutropenia has been associated with increased morbidity and mortality.

Patients with fever and low-risk neutropenia (neutropenia expected to persist for < 10 days, no comorbid complications requiring hospitalization, and cancer adequately treated) can be treated with oral antibiotic regimens, such as ciprofloxacin, 750 mg every 12 hours, plus amoxicillin-clavulanic acid, 500 mg every 8 hours. Antibiotics are continued as long as the patient is neutropenic even if a source is not identified. In the organ transplant patient with interstitial infiltrates, the main concern is infection with *Pneumocystis* or *Legionella* species, so that empiric treatment with a macrolide (or fluoroquinolone) and TMP-SMZ, 15 mg/kg/d orally or intravenously (based on trimethoprim component) would be reasonable in those patients not receiving TMP-SMZ prophylaxis. If the patient does not respond to empiric treatment, a decision must be made to add more antimicrobial agents or perform invasive procedures (see above) to make a specific diagnosis. By making a definite diagnosis, therapy can be specific, thereby reducing selection pressure for resistance and superinfection.

▶ When to Refer

- Any immunocompromised patient with an opportunistic infection.
- Patients with potential drug toxicities and drug interactions related to antimicrobials where alternative agents are sought.
- Patients with LTBI in whom therapy with TNF inhibitors is planned.

▶ When to Admit

Immunocompromised patients who are febrile, or those without fevers in whom an infection is suspected, particularly in the following groups: solid-organ or hematopoietic stem cell transplant recipient (particularly in the first 6 months), neutropenic patients, patients receiving TNF inhibitors, transplant recipients who have had recent rejection episodes (including graft-versus-host disease).

Fishman JA. Infection in solid-organ transplant recipients. *N Engl J Med*. 2007;357(25):2601–14. [PMID: 18094380]

Freifeld AG et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. *Clin Infect Dis*. 2011 Feb 15;52(4):e56–93. [PMID: 21258094]

Grijalva CG et al. Initiation of tumor necrosis factor- α antagonists and the risk of hospitalization for infection in patients with autoimmune diseases. *JAMA*. 2011 Dec 7;306(21):2331–9. [PMID: 22056398]

Morris MI et al. Infections transmitted by transplantation. *Infect Dis Clin North Am*. 2010 Jun;24(2):497–514. [PMID: 20466280]

Neofytos D et al. Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry. *Clin Infect Dis*. 2009 Feb 1;48(3):265–73. [PMID: 19115967]

Palmer SM et al. Extended valganciclovir prophylaxis to prevent cytomegalovirus after lung transplantation: a randomized, controlled trial. *Ann Intern Med*. 2010 Jun 15;152(12):761–9. [PMID: 20547904]

Sax PE et al; AIDS Clinical Trials Group Study A5164 Team. Blood (1 \rightarrow 3)-beta-D-glucan as a diagnostic test for HIV-related *Pneumocystis jirovecii* pneumonia. *Clin Infect Dis*. 2011 Jul 15;53(2):197–202. [PMID: 21690628]

Walsh TJ et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. *Clin Infect Dis*. 2008 Feb 1;46(3):327–60. [PMID: 18177225]

Winthrop KL et al. Mycobacterial and other serious infections in patients receiving anti-tumor necrosis factor and other newly approved biologic therapies: case finding through the Emerging Infections Network. *Clin Infect Dis*. 2008 Jun 1;46(11):1738–40. [PMID: 18419421]

HEALTH CARE–ASSOCIATED INFECTIONS



ESSENTIALS OF DIAGNOSIS

- ▶ Health care–associated infections are acquired during the course of receiving health care treatment for other conditions.
- ▶ Hospital-associated infections are a subset of health care–associated infections defined as those not present or incubating at the time of hospital admission and developing 48 hours or more after admission.
- ▶ Most health care–associated infections are preventable.
- ▶ Hand washing is the most effective means of preventing health care–associated infections and should be done routinely even when gloves are worn.

▶ General Considerations

In the United States, approximately 5% of patients acquire a health care–associated infection, resulting in prolongation of the hospital stay, increase in cost of care, significant morbidity, and a 5% mortality rate. The most common infections are urinary tract infections, usually associated with Foley catheters or urologic procedures; bloodstream infections, most commonly from indwelling catheters but also from secondary sites, such as surgical wounds, abscesses, pneumonia, the genitourinary tract, and the gastrointestinal tract; pneumonia in intubated patients or those with altered levels of consciousness; surgical wound infections; MRSA infections; and *Clostridium difficile* colitis.

Some general principles are helpful in preventing, diagnosing, and treating health care–associated infections:

1. Many infections are a direct result of the use of invasive devices for monitoring or therapy, such as intravenous catheters, Foley catheters, shunts, surgical drains, catheters placed by interventional radiology for drainage, nasogastric tubes, and orotracheal or nasotracheal tubes for ventilatory support. Early removal of such devices reduces the possibility of infection.
2. Patients in whom health care–associated infections develop are often critically ill, have been hospitalized for extended periods, and have received several courses

of broad-spectrum antibiotic therapy. As a result, health care–associated infections are often due to multidrug resistant pathogens and are different from those encountered in community-acquired infections. For example, *S aureus* and *S epidermidis* (a frequent cause of prosthetic device infection) are often resistant to nafcillin and cephalosporins and require vancomycin for therapy; *Enterococcus faecium* resistant to ampicillin and vancomycin; gram-negative infections caused by *Pseudomonas*, *Citrobacter*, *Enterobacter*, *Acinetobacter*, and *Stenotrophomonas*, which may be resistant to most antibacterials. When choosing antibiotics to treat the seriously ill patient with a health care–associated infection, antimicrobial history and the “local ecology” must be considered. In the most seriously ill patients, broad-spectrum coverage with vancomycin and a carbapenem with or without an aminoglycoside is recommended. Once a pathogen is isolated and susceptibilities are known, the most narrow spectrum, least toxic, most cost-effective drug should be used.

Widespread use of antimicrobial drugs contributes to the selection of drug-resistant organisms, thus every effort should be made to limit the spectrum of coverage and unnecessary duration. All too often, unreliable or uninterpretable specimens are obtained for culture that result in unnecessary use of antibiotics. The best example of this principle is the diagnosis of line-related or bloodstream infection in the febrile patient (see below). To avoid unnecessary use of antibiotics, thoughtful consideration of culture results is mandatory. A positive wound culture without signs of inflammation or infection, a positive sputum culture without pulmonary infiltrates on chest radiograph, or a positive urine culture in a catheterized patient without symptoms or signs of pyelonephritis are all likely to represent colonization, not infection.

► Clinical Findings

A. Symptoms and Signs

Catheter-associated infections have a variable presentation, depending on the type of catheter used (peripheral or central venous catheters, nontunneled or tunneled). Local signs of infection may be present at the insertion site, with pain, erythema, and purulence. Fever is often absent in uncomplicated infections and if present, may indicate more disseminated disease such as bacteremia, cellulitis and septic thrombophlebitis. Often signs of infection at the insertion site are absent.

1. Fever in an intensive care unit patient—Fever complicates up to 70% of patients in intensive care units, and the etiology of the fever may be infectious or noninfectious. Common infectious causes include catheter-associated infections, hospital-acquired and ventilator-associated pneumonia (see Chapter 9), surgical site infections, urinary tract infections, and sepsis. Clinically relevant sinusitis is relatively uncommon in the patient in the intensive care unit.

An important noninfectious cause is thromboembolic disease. Fever in conjunction with refractory hypotension and shock may suggest sepsis; however, adrenal insufficiency,

thyroid storm, and transfusion reaction may have a similar clinical presentation. Drug fever is difficult to diagnose and is usually a diagnosis of exclusion unless there are other signs of hypersensitivity, such as a typical maculopapular rash.

2. Fever in the postoperative patient—Postoperative fever is very common and in many cases resolves spontaneously. Etiologies are both infectious and noninfectious. Timing of the fever in relation to the surgery and the nature of the surgical procedure may help diagnostically.

A. IMMEDIATE FEVER (IN THE FIRST FEW HOURS AFTER SURGERY)—Immediate fever can be due to medications that were given perioperatively, to the trauma of surgery itself, or to infections that were present before surgery. Necrotizing fasciitis due to group A streptococci or mixed organisms may present in this period. Malignant hyperthermia is rare and presents 30 minutes to several hours following inhalational anesthesia and is characterized by extreme hyperthermia, muscle rigidity, rhabdomyolysis, electrolyte abnormalities, and hypotension. Aggressive cooling and dantrolene are the mainstays of therapy. Aspiration of acidic gastric contents during surgery can cause a chemical pneumonitis (Mendelson syndrome) that rapidly develops but is transient and does not require antibiotics. Fever due to the trauma of surgery itself usually resolves in 2–3 days, longer in more complicated operative cases and in patients with head trauma.

B. ACUTE FEVER (WITHIN 1 WEEK OF SURGERY)—Acute fever is usually due to common causes of hospital-associated infections, such as ventilator-associated pneumonia (including aspiration pneumonia in patients with decreased gag reflex) and line infections. Noninfectious causes include alcohol withdrawal, gout, pulmonary embolism, and pancreatitis. Atelectasis following surgery is commonly invoked as a cause of postoperative fever but there is no good evidence to support a causal association between the presence or degree of atelectasis and fever.

C. SUBACUTE FEVER (AT LEAST 1 WEEK AFTER SURGERY)—Surgical site infections commonly present at least 1 week after surgery. The type of surgery that was performed predicts specific infectious etiologies. Patients undergoing cardiothoracic surgery may be at higher risk for pneumonia and deep and superficial sternal wound infections. Meningitis without typical signs of meningismus may complicate neurosurgical procedures. Abdominal surgery may result in deep abdominal abscesses that require drainage.

B. Laboratory Findings

Blood cultures are universally recommended, and chest radiographs are frequently obtained. A properly prepared sputum Gram stain and semi-quantitative sputum cultures may be useful in selected patients where there is a high pretest probability of pneumonia but multiple exclusion criteria probably limit generalizability in most patients, such as immunocompromised patients and those with drug resistance. Other diagnostic strategies will be dictated by the clinical context (eg, transesophageal echocardiogram in a patient with *S aureus* bacteremia).

Any fever in a patient with a central venous catheter should prompt the collection of blood. The best method to evaluate bacteremia is to gather at least two peripherally obtained blood cultures. Blood cultures from unidentified sites, a single blood culture from any site, or a blood culture through an existing line will often be positive for *S epidermidis*, resulting in the inappropriate use of vancomycin. Unless two separate venipuncture cultures are obtained—not through catheters—interpretation of results is impossible and unnecessary therapy may be given. Every such “pseudobacteremia” increases laboratory costs, antibiotic use, and length of stay. Microbiologic evaluation of the removed catheter can sometimes be helpful, but only in addition to (not instead of) blood cultures drawn from peripheral sites. The differential time to positivity measures the difference in time that cultures simultaneously drawn through a catheter and a peripheral site become positive. A positive test (about 120 minutes difference in time) supports a catheter-related bloodstream infection, and a negative test may permit catheters to be retained.

► Complications

Patients who have persistent bacteremia and fever despite removal of the infected catheter may have complications such as septic thrombophlebitis, endocarditis, or metastatic foci of infection (particularly with *S aureus*). Additional studies such as venous Doppler studies, transesophageal echocardiogram, and chest radiographs may be indicated, and 4–6 weeks of antibiotics may be needed. In the case of septic thrombophlebitis, anticoagulation with heparin is also recommended if there are no contraindications.

► Differential Diagnosis

Although most fevers are due to infections, about 25% of patients will have fever of noninfectious origin, including drug fever, nonspecific postoperative fevers (tissue damage or necrosis), hematoma, pancreatitis, pulmonary embolism, myocardial infarction, and ischemic bowel disease.

► Prevention

The concept of universal precautions emphasizes that all patients are treated as though they have a potential blood-borne transmissible disease, and thus all body secretions are handled with care to prevent spread of disease. Body substance isolation requires use of gloves whenever a health care worker anticipates contact with blood or other body secretions. Even though gloves are worn, health care workers should routinely wash their hands, since it is the easiest and most effective means of preventing hospital-associated infections. Application of a rapid drying, alcohol-based antiseptic is simple, takes less time than traditional hand washing with soap and water, is more effective at reducing hand colonization, and promotes compliance with hand decontamination.

Peripheral intravenous lines should be replaced every 3 days. Arterial lines and lines in the central venous circulation (including those placed peripherally) can be left in place indefinitely and are changed or removed when they

are clinically suspected of being infected, when they are nonfunctional, or when they are no longer needed. Using sterile barrier precautions (including cap, mask, gown, gloves, and drape) is recommended while inserting central venous catheters. Silver alloy–impregnated Foley catheters reduce the incidence of catheter-associated bacteriuria, and antibiotic-impregnated (minocycline plus rifampin or chlorhexidine plus silver sulfadiazine) venous catheters reduce line infections and bacteremia. Silver-coated endotracheal tubes may reduce the incidence of ventilator-associated pneumonia. Whether the increased cost of these devices justifies their routine use should be determined by individual institutions. Catheter-related urinary tract infections and intravenous catheter-associated infections are not Medicare-reimbursable conditions. Preoperative skin preparation with chlorhexidine and alcohol (versus povidone-iodine) has been shown to reduce the incidence of infection following surgery. Another strategy that can prevent surgical-site infections is the identification and treatment of *S aureus* nasal carriers with 2% mupirocin nasal ointment and chlorhexidine soap. Daily bathing of ICU patients with chlorhexidine-impregnated washcloths versus soap and water may result in lower risk of catheter-associated bloodstream infections. Selective decontamination of the digestive tract with nonabsorbable or parenteral antibiotics, or both, may prevent hospital-acquired pneumonia and decrease mortality.

Attentive nursing care (positioning to prevent decubitus ulcers, wound care, elevating the head during tube feedings to prevent aspiration) is critical in preventing hospital-associated infections. In addition, monitoring of high-risk areas by hospital epidemiologists is critical in the prevention of infection. Some guidelines advocate rapid screening for MRSA on admission to acute care facilities among certain subpopulations of patients (eg, those recently hospitalized, admission to the intensive care unit, patients undergoing hemodialysis). However, it is not clear whether this strategy decreases the incidence of hospital-associated MRSA infections.

Vaccines, including hepatitis A, hepatitis B, and the varicella, pneumococcal, and influenza vaccinations, are important adjuncts. (See section below on Immunization against Infectious Diseases.)

► Treatment

A. Fever in an Intensive Care Unit Patient

Unless the patient has a central neurologic injury with elevated intracranial pressure or has a temperature > 41°C, there is less physiologic need to maintain euthermia. Empiric broad-spectrum antibiotics (see Table 30–5) are recommended for neutropenic and other immunocompromised patients and in patients who are clinically unstable.

B. Catheter-Associated Infections

Factors that inform treatment decisions include the type of catheter, the causative pathogen, the availability of alternate catheter access sites, the need for ongoing intravascular access, and the severity of disease.

In general, catheters should be removed if there is purulence at the exit site; if the organism is *S aureus*, gram-negative rods, or *Candida* species; if there is persistent bacteremia (> 48 hours while receiving antibiotics); or if complications, such as septic thrombophlebitis, endocarditis, or other metastatic disease exist. Central venous catheters may be exchanged over a guidewire provided there is no erythema or purulence at the exit site and the patient does not appear to be septic. Methicillin-resistant, coagulase-negative staphylococci are the most common pathogens; thus, empiric therapy with vancomycin, 15 mg/kg intravenously twice daily, should be given assuming normal kidney function. Empiric gram-negative coverage may be considered in patients who are immunocompromised or who are critically ill (see Table 30–5).

Antibiotic treatment duration depends on the pathogen and the extent of disease. For uncomplicated bacteremia, 5–7 days of therapy is usually sufficient for coagulase-negative staphylococci, even if the original catheter is retained. Fourteen days of therapy is generally recommended for uncomplicated bacteremia caused by gram-negative rods, *Candida* species, and *S aureus*. Antibiotic lock therapy involves the instillation of supratherapeutic concentrations of antibiotics with heparin in the lumen of catheters. The purpose is to achieve adequate concentrations of antibiotics to kill microbes in the biofilm. Antibiotic lock therapy can be used for catheter-related bloodstream infections caused by coagulase-negative staphylococci or enterococci and when the catheter is being retained in a salvage situation.

▶ When to Refer

- Any patient with multidrug-resistant infection.
- Any patient with fungemia or persistent bacteremia.
- Patients with multisite infections.
- Patients with impaired or fluctuating kidney function for assistance with dosing of antimicrobials.
- Patients with refractory or recurrent *C difficile* colitis.

Bode LG et al. Preventing surgical-site infections in nasal carriers of *Staphylococcus aureus*. *N Engl J Med*. 2010 Jan 7;362(1):9–17. [PMID: 20054045]

Climo MW et al. The effect of daily bathing with chlorhexidine on the acquisition of methicillin-resistant *Staphylococcus aureus*, vancomycin-resistant *Enterococcus*, and healthcare-associated bloodstream infections: results of a quasi-experimental multicenter trial. *Crit Care Med*. 2009 Jun;37(6):1858–65. [PMID: 19384220]

Darouiche RO et al. Chlorhexidine-alcohol versus povidone-iodine for surgical-site antisepsis. *N Engl J Med*. 2010 Jan 7;362(1):18–26. [PMID: 20054046]

Harbarth S et al. Universal screening for methicillin-resistant *Staphylococcus aureus* at hospital admission and nosocomial infection in surgical patients. *JAMA*. 2008 Mar 12;299(10):1149–57. [PMID: 18334690]

Kollef MH et al. Silver-coated endotracheal tubes and incidence of ventilator-associated pneumonia: the NASCENT randomized trial. *JAMA*. 2008 Aug 20;300(7):805–13. [PMID: 18714060]

Louie TJ et al. Fidaxomicin versus vancomycin for *Clostridium difficile* infection. *N Engl J Med*. 2011 Feb 3;364(5):422–31. [PMID: 21288078]

Mermel LA et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 update by the Infectious Diseases Society of America. *Clin Infect Dis*. 2009 Jul 1;49(1):1–45. [PMID: 19489710]

Peleg AY et al. Hospital-acquired infections due to gram-negative bacteria. *N Engl J Med*. 2010 May 13;362(19):1804–13. [PMID: 20463340]

Yokoe DS et al. A compendium of strategies to prevent healthcare-associated infections in acute care hospitals. *Infect Control Hosp Epidemiol*. 2008 Oct;29(Suppl 1):S12–21. [PMID: 18840084]

INFECTIONS OF THE CENTRAL NERVOUS SYSTEM

ESSENTIALS OF DIAGNOSIS

- ▶ Central nervous system infection is a medical emergency.
- ▶ Symptoms and signs common to all central nervous system infections include headache, fever, sensorial disturbances, neck and back stiffness, positive Kernig and Brudzinski signs, and cerebrospinal fluid abnormalities.

▶ General Considerations

Infections of the central nervous system can be caused by almost any infectious agent, including bacteria, mycobacteria, fungi, spirochetes, protozoa, helminths, and viruses.

▶ Etiologic Classification

Central nervous system infections can be divided into several categories that usually can be readily distinguished from each other by cerebrospinal fluid examination as the first step toward etiologic diagnosis (Table 30–1).

A. Purulent Meningitis

Patients with bacterial meningitis usually seek medical attention within hours or 1–2 days after onset of symptoms. The organisms responsible depend primarily on the age of the patient as summarized in Table 30–2. The diagnosis is usually based on the Gram-stained smear (positive in 60–90%) or culture (positive in over 90%) of the cerebrospinal fluid.

B. Chronic Meningitis

The presentation of chronic meningitis is less acute than purulent meningitis. Patients with chronic meningitis usually have a history of symptoms lasting weeks to months. The most common pathogens are *Mycobacterium tuberculosis*, atypical mycobacteria, fungi (*Cryptococcus*, *Coccidioides*, *Histoplasma*), and spirochetes (*Treponema pallidum* and *Borrelia burgdorferi*, the cause of Lyme disease). The diagnosis is made by culture or in some cases by serologic tests (cryptococcosis, coccidioidomycosis, syphilis, Lyme disease).

Table 30-1. Typical cerebrospinal fluid findings in various central nervous system diseases.

Diagnosis	Cells/mcL	Glucose (mg/dL)	Protein (mg/dL)	Opening Pressure
Normal	0-5 lymphocytes	45-85 ¹	15-45	70-180 mm H ₂ O
Purulent meningitis (bacterial) ² community-acquired	200-20,000 polymorphonuclear neutrophils	Low (< 45)	High (> 50)	Markedly elevated
Granulomatous meningitis (mycobacterial, fungal) ³	100-1000, mostly lymphocytes ³	Low (< 45)	High (> 50)	Moderately elevated
Spirochetal meningitis	100-1000, mostly lymphocytes ³	Normal	Moderately high (> 50)	Normal to slightly elevated
Aseptic meningitis, viral or meningoencephalitis ⁴	25-2000, mostly lymphocytes ³	Normal or low	High (> 50)	Slightly elevated
"Neighborhood reaction" ⁵	Variably increased	Normal	Normal or high	Variable

¹Cerebrospinal fluid glucose must be considered in relation to blood glucose level. Normally, cerebrospinal fluid glucose is 20-30 mg/dL lower than blood glucose, or 50-70% of the normal value of blood glucose.

²Organisms in smear or culture of cerebrospinal fluid; counterimmunoelectrophoresis or latex agglutination may be diagnostic.

³Polymorphonuclear neutrophils may predominate early.

⁴Viral isolation from cerebrospinal fluid early; antibody titer rise in paired specimens of serum; polymerase chain reaction for herpesvirus.

⁵May occur in mastoiditis, brain abscess, epidural abscess, sinusitis, septic thrombus, brain tumor. Cerebrospinal fluid culture results usually negative.

C. Aseptic Meningitis

Aseptic meningitis—a much more benign and self-limited syndrome than purulent meningitis—is caused principally by viruses, especially herpes simplex virus and the enterovirus group (including coxsackieviruses and echoviruses). Infectious mononucleosis may be accompanied by aseptic meningitis. Leptospirosis is also usually placed in the aseptic group because of the lymphocytic cellular response and its relatively benign course. This type of meningitis also occurs during secondary syphilis and disseminated Lyme disease. Prior to the routine administration of measles-mumps-rubella (MMR) vaccines, mumps was the most common cause of viral meningitis. Drug-induced aseptic meningitis has been reported with nonsteroidal anti-inflammatory drugs, sulfonamides and certain solid organ transplant agents, including muromonab-CD3 (OKT3).

D. Encephalitis

Encephalitis (due to herpesviruses, arboviruses, rabies virus, flaviviruses [West Nile encephalitis, Japanese encephalitis]), and many others, produces disturbances of the sensorium, seizures, and many other manifestations. Patients are more ill than those with aseptic meningitis. Cerebrospinal fluid may be entirely normal or may show some lymphocytes and in some instances (eg, herpes simplex) red cells as well. Influenza has been associated with encephalitis, but the relationship is not clear.

E. Partially Treated Bacterial Meningitis

Previous effective antibiotic therapy given for 12-24 hours will decrease the rate of positive Gram stain results by 20% and culture by 30-40% of the cerebrospinal fluid but will have little effect on cell count, protein, or glucose.

Table 30-2. Initial antimicrobial therapy for purulent meningitis of unknown cause.

Population	Common Microorganisms	Standard Therapy
18-50 years	<i>Streptococcus pneumoniae</i> , <i>Neisseria meningitidis</i>	Vancomycin ¹ plus cefotaxime or ceftriaxone ²
Over 50 years	<i>S pneumoniae</i> , <i>N meningitidis</i> , <i>Listeria monocytogenes</i> , gram-negative bacilli	Vancomycin ¹ plus ampicillin, ³ plus cefotaxime or ceftriaxone ²
Impaired cellular immunity	<i>L monocytogenes</i> , gram-negative bacilli, <i>S pneumoniae</i>	Vancomycin ¹ plus ampicillin ³ plus cefepime ⁴
Postsurgical or posttraumatic	<i>Staphylococcus aureus</i> , <i>S pneumoniae</i> , gram-negative bacilli	Vancomycin ¹ plus cefepime ⁴

¹The dose of vancomycin is 10-15 mg/kg/dose intravenously every 6 hours.

²The usual dose of cefotaxime is 2 g intravenously every 6 hours and that of ceftriaxone is 2 g intravenously every 12 hours. If the organism is sensitive to penicillin, 3-4 million units intravenously every 4 hours is given.

³The dose of ampicillin is usually 2 g intravenously every 4 hours.

⁴Cefepime is given in a dose of 50-100 mg/kg intravenously every 8 hours.

Occasionally, previous antibiotic therapy will change a predominantly polymorphonuclear response to a lymphocytic pleocytosis, and some of the cerebrospinal fluid findings may be similar to those seen in aseptic meningitis.

F. Neighborhood Reaction

As noted in Table 30–1, this term denotes a purulent infectious process in close proximity to the central nervous system that spills some of the products of the inflammatory process—white blood cells or protein—into the cerebrospinal fluid. Such an infection might be a brain abscess, osteomyelitis of the vertebrae, epidural abscess, subdural empyema, or bacterial sinusitis or mastoiditis.

G. Noninfectious Meningeal Irritation

Carcinomatous meningitis, sarcoidosis, systemic lupus erythematosus, chemical meningitis, and certain drugs—nonsteroidal anti-inflammatory drugs, OKT3, TMP-SMZ, and others—can also produce symptoms and signs of meningeal irritation with associated cerebrospinal fluid pleocytosis, increased protein, and low or normal glucose. Meningismus with normal cerebrospinal fluid findings occurs in the presence of other infections such as pneumonia and shigellosis.

H. Brain Abscess

Brain abscess presents as a space-occupying lesion; symptoms may include vomiting, fever, change of mental status, or focal neurologic manifestations. When brain abscess is suspected, a CT scan should be performed. If positive, lumbar puncture should *not* be performed since results rarely provide clinically useful information and herniation can occur. The bacteriology of brain abscess is usually polymicrobial and includes *S aureus*, gram-negative bacilli, streptococci, and anaerobes (including anaerobic streptococci and *Prevotella* species).

I. Amebic Meningoencephalitis

These infections are caused by free-living amebas and present as two distinct syndromes. The diagnosis is confirmed by culture (*Acanthamoeba* species and *Balamuthia mandrillaris*) or identification of the organism in a wet mount of cerebrospinal fluid (*Naegleria fowleri*) or on biopsy specimens. No effective therapy is available.

Primary amebic meningoencephalitis is caused by *N fowleri* and is an acute fulminant disease, usually seen in children and young adults with recent fresh water exposure, and is characterized by signs of meningeal irritation that rapidly progresses to encephalitis and death. Rare cures have been reported with intravenous and intraventricular administration of amphotericin B.

Granulomatous amebic encephalitis is caused by *Acanthamoeba* species. It is an indolent disease, frequently seen in immunocompromised patients and associated with cutaneous lesions. Central nervous system disease is characterized by headache, nausea, vomiting, cranial neuropathies, seizures, and hemiparesis. Infections with *Balamuthia* are similar to *Acanthamoeba* in that the course is subacute

to chronic, but unlike *Acanthamoeba* both immunocompromised and immunocompetent persons can be affected.

J. Health Care–Associated Meningitis

This infection may arise as a result of invasive neurosurgical procedures (eg, craniotomy, internal or external ventricular catheters, external lumbar catheters), complicated head trauma, or from hospital-acquired bloodstream infections. In general, the microbiology is distinct from community-acquired meningitis, with gram-negative organisms (eg, *Pseudomonas*), *S aureus*, and coagulase-negative staphylococci playing a larger role.

▶ Clinical Findings

A. Symptoms and Signs

The classic triad of fever, stiff neck, and altered mental status has a low sensitivity (44%) for bacterial meningitis. However, nearly all patients with bacterial meningitis have at least two of the following symptoms—fever, headache, stiff neck, or altered mental status.

B. Laboratory Tests

Evaluation of a patient with suspected meningitis includes a blood count, blood culture, lumbar puncture followed by careful study and culture of the cerebrospinal fluid, and a chest film. The fluid must be examined for cell count, glucose, and protein, and a smear stained for bacteria (and acid-fast organisms when appropriate) and cultured for pyogenic organisms and for mycobacteria and fungi when indicated. Latex agglutination tests can detect antigens of encapsulated organisms (*S pneumoniae*, *H influenzae*, *N meningitidis*, and *Cryptococcus neoformans*) but are rarely used except for detection of *Cryptococcus* or in partially treated patients. Polymerase chain reaction (PCR) testing of cerebrospinal fluid has been used to detect bacteria (*S pneumoniae*, *H influenzae*, *N meningitidis*, *M tuberculosis*, *B burgdorferi*, and *Tropheryma whippelii*) and viruses (herpes simplex, varicella-zoster, CMV, Epstein-Barr virus, and enteroviruses) in patients with meningitis. The greatest experience is with PCR for herpes simplex and varicella-zoster, and the tests are very sensitive (> 95%) and specific. Tests to detect the other organisms may not be any more sensitive than culture, but the real value is the rapidity with which results are available, ie, hours compared with days or weeks.

C. Lumbar Puncture and Imaging

Since performing a lumbar puncture in the presence of a space-occupying lesion (brain abscess, subdural hematoma, subdural empyema, necrotic temporal lobe from herpes encephalitis) may result in brainstem herniation, a CT scan is performed prior to lumbar puncture if a space-occupying lesion is suspected on the basis of papilledema, seizures, or focal neurologic findings. Other indications for CT scan are an immunocompromised patient or moderate to severely impaired level of consciousness. If delays are encountered in obtaining a CT scan and bacterial meningitis is suspected, blood cultures should be drawn and

antibiotics and corticosteroids administered even before cerebrospinal fluid is obtained for culture to avoid delay in treatment (Table 30–1). Antibiotics given within 4 hours before obtaining cerebrospinal fluid probably do not affect culture results.

▶ Treatment

Although it is difficult to prove with existing clinical data that early antibiotic therapy improves outcome in bacterial meningitis, prompt therapy is still recommended. In purulent meningitis, the identity of the causative microorganism may remain unknown or doubtful for a few days and initial antibiotic treatment as set forth in Table 30–2 should be directed against the microorganisms most common for each age group.

The duration of therapy for bacterial meningitis varies depending on the etiologic agent: *H influenzae*, 7 days; *N meningitidis*, 3–7 days; *S pneumoniae*, 10–14 days; *L monocytogenes*, 14–21 days; and gram-negative bacilli, 21 days.

Dexamethasone therapy is recommended for adults with pneumococcal meningitis. Ten milligrams of dexamethasone administered intravenously 15–20 minutes before or simultaneously with the first dose of antibiotics and continued every 6 hours for 4 days decreases morbidity and mortality. Patients most likely to benefit from corticosteroids are those infected with gram-positive organisms (*Streptococcus pneumoniae* or *S suis*), and those who are HIV negative. It is unknown whether patients with meningitis due to *N meningitidis* and other bacterial pathogens benefit from the use of adjunctive corticosteroids. Increased intracranial pressure due to brain edema often requires therapeutic attention. Hyperventilation, mannitol (25–50 g as a bolus intravenous infusion), and even drainage of cerebrospinal fluid by repeated lumbar punctures or by placement of ventricular catheters have been used to control cerebral edema and increased intracranial pressure. Dexamethasone (4 mg intravenously every 4–6 hours) may also decrease cerebral edema.

Therapy of brain abscess consists of drainage (excision or aspiration) in addition to 3–4 weeks of systemic antibiotics directed against organisms isolated. An empiric regimen often includes metronidazole, 500 mg intravenously or orally every 8 hours, plus ceftriaxone, 2 g intravenously every 12 hours, with or without vancomycin, 10–15 mg/kg/dose intravenously every 12 hours. In cases where abscesses are < 2 cm in size, where there are multiple abscesses that cannot be drained, or if an abscess is located in an area where significant neurologic sequelae would result from drainage, antibiotics for 6–8 weeks without drainage can be used.

In addition to antibiotics, in cases of health care-associated meningitis associated with an external ventricular catheter, the probability of cure is increased if the catheter is removed. In infections associated with internal ventricular catheters, removal of the internal components and insertion of an external drain is recommended.

Therapy of other types of meningitis is discussed elsewhere in this book (fungal meningitis, Chapter 36; syphilis and Lyme borreliosis, Chapter 34; tuberculous meningitis, Chapter 33; herpes encephalitis, Chapter 32).

▶ When to Refer

- Patients with acute meningitis, particularly if culture negative or atypical (eg, fungi, syphilis, Lyme disease, *M tuberculosis*), or if the patient is immunosuppressed.
- Patients with chronic meningitis.
- All patients with brain abscesses and encephalitis.
- Patients with suspected hospital-acquired meningitis (eg, in patients who have undergone recent neurosurgery).
- Patients with recurrent meningitis.

▶ When to Admit

- Patients with suspected acute meningitis, encephalitis, and brain abscess should be admitted for urgent evaluation and treatment.
- There is less urgency to admit patients with chronic meningitis; these patients may be admitted to expedite diagnostic procedures and coordinate care, particularly if no diagnosis has been made in the outpatient setting.

Glaser CA et al. Beyond viruses: clinical profiles and etiologies associated with encephalitis. *Clin Infect Dis*. 2006 Dec 15;43(12):1565–77. [PMID: 17109290]

Granerod J et al; UK Health Protection Agency (HPA) Aetiology of Encephalitis Study Group. Causes of encephalitis and differences in their clinical presentations in England: a multi-centre, population-based prospective study. *Lancet Infect Dis*. 2010 Dec;10(12):835–44. [PMID: 20952256]

Honda H et al. Central nervous system infections: meningitis and brain abscess. *Infect Dis Clin North Am*. 2009 Sep;23(3): 609–23. [PMID: 19665086]

Logan SA et al. Viral meningitis. *BMJ*. 2008 Jan 5;336(7634):36–40. [PMID: 18174598]

Thigpen MC et al; Emerging Infections Programs Network. Bacterial meningitis in the United States, 1998–2007. *N Engl J Med*. 2011 May 26;364(21):2016–25. [PMID: 21612470]

van de Beek D et al. Nosocomial bacterial meningitis. *N Engl J Med*. 2010 Jan 14;362(2):146–54. [PMID: 20071704]

ANIMAL & HUMAN BITE WOUNDS



ESSENTIALS OF DIAGNOSIS

- ▶ Cat and human bites have higher rates of infection than dog bites.
- ▶ Hand bites are particularly concerning for the possibility of closed-space infection.
- ▶ Antibiotic prophylaxis indicated for noninfected bites of the hand and hospitalization required for infected hand bites.
- ▶ All infected wounds need to be cultured to direct therapy.

▶ General Considerations

About 1000 dog bite injuries require emergency department attention each day, most often in urban areas. Dog bites occur most commonly in the summer months. Biting animals are usually known by their victims, and most

biting incidents are provoked (ie, bites occur while playing with the animal or after surprising the animal or waking it abruptly from sleep). Failure to elicit a history of provocation is important, because an unprovoked attack raises the possibility of rabies. Human bites are usually inflicted by children while playing or fighting; in adults, bites are associated with alcohol use and closed-fist injuries that occur during fights.

The animal inflicting the bite, the location of the bite, and the type of injury inflicted are all important determinants of whether they become infected. Cat bites are more likely to become infected than human bites—between 30% and 50% of all cat bites become infected. Infections following human bites are variable. Bites inflicted by children rarely become infected because they are superficial, and bites by adults become infected in 15–30% of cases, with a particularly high rate of infection in closed-fist injuries. “Through and through” bites (eg involving the mucosa and the skin) have an infection rate similar to closed-fist injuries. Dog bites, for unclear reasons, become infected only 5% of the time. Bites of the head, face, and neck are less likely to become infected than bites on the extremities. Puncture wounds become infected more frequently than lacerations, probably because the latter are easier to irrigate and debride.

The bacteriology of bite infections is polymicrobial. Following dog and cat bites, over 50% of infections are caused by aerobes and anaerobes and 36% are due to aerobes alone. Pure anaerobic infections are rare. *Pasteurella* species are the single most common isolate (75% of cat bites and 50% of dog bites). Other common aerobic isolates include streptococci, staphylococci, *Moraxella*, and *Neisseria*; the most common anaerobes are *Fusobacterium*, *Bacteroides*, *Porphyromonas*, and *Prevotella*. The median number of isolates following human bites is four (three aerobes and one anaerobe). Like dog and cat bites, most human bites are a mixture of aerobes and anaerobes (54%) or are due to aerobes alone (44%). Streptococci and *S aureus* are the most common aerobes. *Eikenella corrodens* (found in up to 30% of patients), *Prevotella* and *Fusobacterium* are the most common anaerobes. Although the organisms noted are the most common, innumerable others have been isolated—including *Capnocytophaga* (dog and cats), *Pseudomonas*, and *Haemophilus*—emphasizing the point that all infected bites should be cultured to define the microbiology.

HIV can be transmitted from bites (either from biting or receiving a bite from an HIV-infected patient) but has rarely been reported.

► Treatment

A. Local Care

Vigorous cleansing and irrigation of the wound as well as debridement of necrotic material are the most important factors in decreasing the incidence of infections. Radiographs should be obtained to look for fractures and the presence of foreign bodies. Careful examination to assess the extent of the injury (tendon laceration, joint space penetration) is critical to appropriate care.

B. Suturing

If wounds require closure for cosmetic or mechanical reasons, suturing can be done. However, one should never suture an infected wound, and wounds of the hand should generally not be sutured since a closed-space infection of the hand can result in loss of function.

C. Prophylactic Antibiotics

Prophylaxis is indicated in high-risk bites and in high-risk patients. Cat bites in any location and hand bites by any animal, including humans, should receive prophylaxis. Individuals with certain comorbidities (diabetes, liver disease) are at increased risk for severe complications and should receive prophylaxis even for low-risk bites, as should patients without functional spleens who are at increased risk for overwhelming sepsis (primarily with *Capnocytophaga* species). Amoxicillin-clavulanate (Augmentin) 500 mg orally three times daily for 5–7 days is the regimen of choice. For patients with serious allergy to penicillin, a combination of clindamycin 300 mg orally three times daily plus doxycycline 100 mg orally twice daily, or double-strength TMP-SMZ orally twice daily, or a fluoroquinolone (ciprofloxacin 500 mg orally twice daily or levofloxacin 500–750 mg orally once daily) is recommended for 5–7 days. Moxifloxacin, a fluoroquinolone with good aerobic and anaerobic activity, may be suitable as monotherapy at 400 mg orally once daily for 5–7 days. Agents such as dicloxacillin, cephalexin, erythromycin, and clindamycin should not be used alone because they lack activity against *Pasteurella* species. Doxycycline and TMP-SMZ have poor activity against anaerobes and should only be used in combination with clindamycin.

Because the risk of HIV transmission is so low following a bite, routine postexposure prophylaxis is not recommended. Each case should be evaluated individually and consideration for prophylaxis should be given to those who present within 72 hours of the incident, the source is known to be HIV infected, and the exposure is high risk.

D. Antibiotics for Documented Infection

For wounds that are infected, antibiotics are clearly indicated. How they are given (orally or intravenously) and the need for hospitalization are individualized clinical decisions. The most commonly encountered pathogens require treatment with either a combination of a β -lactam plus a β -lactamase inhibitor (ampicillin-sulbactam [Unasyn], 1.5–3.0 g intravenously every 6–8 hours; piperacillin-tazobactam [Zosyn], 3.375 g intravenously every 6–8 hours; or amoxicillin-clavulanate [Augmentin], 500 mg orally three times daily) or with a carbapenem (ertapenem, 1 g intravenously daily; imipenem, 500 mg intravenously every 6–8 hours; meropenem, 1 g intravenously every 8 hours). For the patient with severe penicillin allergy, a combination of clindamycin 600–900 mg intravenously every 8 hours plus a fluoroquinolone (ciprofloxacin, 400 mg intravenously every 12 hours; levofloxacin, 500–750 mg intravenously once daily) or TMP-SMZ (10 mg/kg of trimethoprim daily in two or three divided doses) is indicated. Duration of therapy is usually 2–3 weeks unless

complications such as septic arthritis or osteomyelitis are present; if these complications are present, therapy should be extended to 4 and 6 weeks, respectively.

E. Tetanus and Rabies

All patients must be evaluated for the need for tetanus (see Chapter 33) and rabies (see Chapter 32) prophylaxis.

▶ When to Refer

- If septic arthritis or osteomyelitis is suspected.
- For exposure to bites by dogs, cats, reptiles, amphibians, and rodents.
- When rabies is a possibility.

▶ When to Admit

- Patients with infected hand bites.
- Deep bites, particularly if over joints.

Oehler RL et al. Bite-related and septic syndromes caused by cats and dogs. *Lancet Infect Dis*. 2009 Jul;9(7):439–47. [PMID: 19555903]

Stevens DL et al; Infectious Diseases Society of America. Practice guidelines for the diagnosis and management of skin and soft-tissue infections. *Clin Infect Dis*. 2005 Nov 15;41(10):1373–406. [PMID: 16231249]

Warrell MJ. Emerging aspects of rabies infection: with a special emphasis on children. *Curr Opin Infect Dis*. 2008 Jun;21(3):251–7. [PMID: 18448969]

SEXUALLY TRANSMITTED DISEASES



ESSENTIALS OF DIAGNOSIS

- ▶ All sexually transmitted diseases (STDs) have subclinical or latent periods, and patients may be asymptomatic.
- ▶ Simultaneous infection with several organisms is common.
- ▶ All patients who seek STD testing should be screened for syphilis and HIV.
- ▶ Partner notification and treatment are important to prevent further transmission and reinfection in the index case.

▶ General Considerations

The most common STDs are gonorrhea,* syphilis,* human papillomavirus (HPV)-associated condyloma acuminatum, chlamydial genital infections,* herpesvirus genital infections, trichomonas vaginitis, chancroid,* granuloma inguinale, scabies, louse infestation, and bacterial vaginosis (among women who have sex with women). However,

shigellosis*; hepatitis A, B, and C*; amebiasis; giardiasis*; cryptosporidiosis*; salmonellosis*; and campylobacteriosis may also be transmitted by sexual (oral-anal) contact, especially in men who have sex with men. Both homosexual and heterosexual contact are risk factors for the transmission of HIV (see Chapter 31). All STDs have subclinical or latent phases that play an important role in long-term persistence of the infection or in its transmission from infected (but largely asymptomatic) persons to other contacts. Simultaneous infection by several different agents is common.

Infections typically present in one of several ways, each of which has a defined differential diagnosis, which should prompt appropriate diagnostic tests.

A. Genital Ulcers

Common etiologies include herpes simplex virus, primary syphilis, and chancroid. Other possibilities include lymphogranuloma venereum (see Chapter 33), granuloma inguinale caused by *Klebsiella granulomatis* (see Chapter 33), as well as lesions caused by infection with Epstein-Barr virus and HIV. Noninfectious causes are Behçet disease (see Chapter 20), neoplasm, trauma, drugs, and irritants.

B. Urethritis with or without Urethral Discharge

The most common infections causing urethral discharge are *Neisseria gonorrhoeae* and *Chlamydia trachomatis*. *N gonorrhoeae* and *C trachomatis* are also frequent causes of prostatitis among sexually active men. Other sexually transmitted infections that can cause urethritis include *Mycoplasma genitalium*, *Ureaplasma urealyticum*, and *Trichomonas vaginalis*. Noninfectious causes of urethritis includes reactive arthritis with associated urethritis (Reiter syndrome).

C. Vaginal Discharge

Common causes of vaginitis are bacterial vaginosis (caused by overgrowth of anaerobes such as *Gardnerella vaginalis*), candidiasis, and *T vaginalis* (see Chapter 18). Less common infectious causes of vaginitis include HPV-associated condyloma acuminata and group A streptococcus. Noninfectious causes are physiologic changes related to the menstrual cycle, irritants, and lichen planus. Even though *N gonorrhoeae* and *C trachomatis* are frequent causes of cervicitis, they rarely produce vaginal discharge.

▶ Screening & Prevention

All persons who seek STD testing should undergo routine screening for HIV infection, using rapid HIV-testing (if patients may not follow-up for results obtained by standard methods) or nucleic acid amplification followed by confirmatory serology (if primary HIV infection may be a possibility) as indicated. Patients in whom STDs have been diagnosed and treated (in particular, chlamydia or gonorrhea) are at a high risk for reinfection and should be encouraged to be rescreened for STDs at 3 months following the initial STD diagnosis.

*Reportable to public health authorities.

Asymptomatic patients often request STD screening at the time of initiating a new sexual relationship. Routine HIV testing and hepatitis B serology testing should be offered to all such patients. In sexually active women who have not been recently screened, cervical Papanicolaou testing and nucleic acid amplification testing of a urine specimen for gonorrhea and chlamydia are recommended. Among men who have sex with men, additional screening is recommended for syphilis; hepatitis A; urethral, pharyngeal, and rectal gonorrhea; as well as urethral and rectal chlamydia. Nucleic acid amplification testing is FDA-approved for testing urine for gonorrhea or chlamydia. However, the use of nucleic acid amplification testing of secretions in the rectum and pharynx has not been validated in many laboratories. There are no recommendations to screen heterosexual men for urethral chlamydia but this could be considered in STD clinics, adolescent clinics, or in correctional facilities. The periodicity of screening thereafter depends on sexual risk, but most screening should be offered at least annually to sexually active adults (particularly to those 25-years-old and under). If not immune, hepatitis B vaccination is recommended for all sexually active adults, and hepatitis A vaccination in men who have sex with men. Persons between the ages of 9 and 26 may be offered vaccination against HPV.

The risk of developing an STD following a **sexual assault** is difficult to accurately ascertain given high rates of baseline infections and poor follow-up. Victims of assault have a high baseline rate of infection (*N gonorrhoeae*, 6%; *C trachomatis*, 10%; *T vaginalis*, 15%; and bacterial vaginosis, 34%), and the risk of acquiring infection as a result of the assault is significant but is often lower than the preexisting rate (*N gonorrhoeae*, 6–12%; *C trachomatis*, 4–17%; *T vaginalis*, 12%; syphilis, 0.5–3%; and bacterial vaginosis, 19%). Victims should be evaluated within 24 hours after the assault, and nucleic acid amplification tests for *N gonorrhoeae* and *C trachomatis* should be performed. Vaginal secretions are obtained for *Trichomonas* wet mount and culture, or point-of-care testing. If a discharge is present, if there is itching, or if secretions are malodorous, a wet mount should be examined for *Candida* and bacterial vaginosis. In addition, a blood sample should be obtained for immediate serologic testing for syphilis, hepatitis B, and HIV. Follow-up examination for STD should be repeated within 1–2 weeks, since concentrations of infecting organisms may not have been sufficient to produce a positive test at the time of initial examination. If prophylactic treatment was given (may include postexposure hepatitis B vaccination without hepatitis B immune globulin; treatment for chlamydial, gonorrheal, or trichomonal infection; and emergency contraception), tests should be repeated only if the victim has symptoms. If prophylaxis was not administered, the individual should be seen in 1 week so that any positive tests can be treated. Follow-up serologic testing for syphilis and HIV infection should be performed in 6, 12, and 24 weeks if the initial tests are negative. The usefulness of presumptive therapy is controversial, some feeling that all patients should receive it and others that it should be limited to those in whom follow-up cannot be ensured or to patients who request it.

Although seroconversion to HIV has been reported following sexual assault when this was the only known risk, this risk is believed to be low. The likelihood of HIV transmission from vaginal or anal receptive intercourse when the source is known to be HIV positive is 1 per 1000 and 5 per 1000, respectively. Although prophylactic antiretroviral therapy has not been studied in this setting, the Department of Health and Human Services recommends the prompt institution of postexposure prophylaxis with highly active antiretroviral therapy if the person seeks care within 72 hours of the assault, the source is known to be HIV positive, and the exposure presents a substantial risk of transmission.

In addition to screening asymptomatic patients with STDs, other strategies for preventing further transmission include evaluating sex partners and administering preexposure vaccination of preventable STDs to individuals at risk; other strategies include the consistent use of male and female condoms. For each patient, there are one or more sexual contacts who require diagnosis and treatment. Prompt treatment of contacts by giving antibiotics to the index case to distribute to all sexual contacts (patient-delivered therapy) is an important strategy for preventing further transmission and to prevent reinfection in the index case.

Note that vaginal spermicides and condoms containing nonoxynol-9 provide no additional protection against STDs. Male circumcision has been demonstrated to protect against HIV and HPV acquisition in heterosexual men with HIV-infected partners. Early initiation of antiretroviral therapy in HIV-infected individuals can prevent HIV acquisition in an uninfected sex partner. Also, preexposure prophylaxis with a once-daily pill containing tenofovir plus emtricitabine has been shown to be effective in preventing HIV infection among high-risk men who have sex with men.

▶ When to Refer

- Patients with a new diagnosis of HIV.
- Patients with persistent, refractory or recurrent STDs, particularly when drug resistance is suspected.

Cohen MS et al; HPTN 052 Study Team. Prevention of HIV-1 infection with early antiretroviral therapy. *N Engl J Med*. 2011 Aug 11;365(6):493–505. [PMID: 21767103]

Grant RM et al; iPrEx Study Team. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. *N Engl J Med*. 2010 Dec 30;363(27):2587–99. [PMID: 21091279]

Jena AB et al. Sexually transmitted diseases among users of erectile dysfunction drugs: analysis of claims data. *Ann Intern Med*. 2010 Jul 6;153(1):1–7. [PMID: 20621899]

Ohnishi M et al. Is *Neisseria gonorrhoeae* initiating a future era of untreatable gonorrhea?: detailed characterization of the first strain with high-level resistance to ceftriaxone. *Antimicrob Agents Chemother*. 2011 Jul;55(7):3538–45. [PMID: 21576437]

Smith DK et al. Antiretroviral postexposure prophylaxis after sexual, injection-drug use, or other nonoccupational exposure to HIV in the United States: recommendations from the U.S. Department of Health and Human Services. *MMWR Recomm Rep*. 2005 Jan 21;54(RR-2):1–20. [PMID: 15660015]

Tobian AA et al. Male circumcision for the prevention of HSV-2 and HPV infections and syphilis. *N Engl J Med*. 2009 Mar 26;360(13):1298–309. [PMID: 19321868]

Workowski KA et al; Centers for Disease Control and Prevention (CDC). Sexually transmitted diseases treatment guidelines, 2010. *MMWR Recomm Rep*. 2010 Dec 17;59(RR-12):1–110. Erratum in: *MMWR Recomm Rep*. 2011 Jan 14;60(1):18. [PMID: 21160459]

INFECTIONS IN DRUG USERS



ESSENTIALS OF DIAGNOSIS

Common infections that occur with greater frequency in drug users include:

- ▶ Skin infections, aspiration pneumonia, tuberculosis.
- ▶ Hepatitis A, B, C, D; STDs; AIDS.
- ▶ Pulmonary septic emboli, infective endocarditis.
- ▶ Osteomyelitis and septic arthritis.

▶ General Considerations

There is a high incidence of infection among drug users, particularly those who inject drugs. Increased risk of infection is likely associated with poor hygiene and colonization with potentially pathogenic organisms, contamination of drugs and equipment, increased sexual risk behaviors, and impaired immune defenses. The use of parenterally administered recreational drugs has increased enormously in recent years. There are now an estimated 300,000 or more injection drug users in the United States.

Skin infections are associated with poor hygiene and use of nonsterile technique when injecting drugs. *S aureus* (including community-acquired methicillin-resistant strains) and oral flora (streptococci, *Eikenella*, *Fusobacterium*, *Peptostreptococcus*) are the most common organisms, with enteric gram-negatives generally more likely seen in those who inject into the groin. Cellulitis and subcutaneous abscesses occur most commonly, particularly in association with subcutaneous (“skin-popping”) or intramuscular injections and the use of cocaine and heroin mixtures (probably due to ischemia). Myositis, clostridial myonecrosis, and necrotizing fasciitis occur infrequently but are life-threatening. Wound botulism in association with black tar heroin occurs sporadically but often in clusters.

Aspiration pneumonia and its complications (lung abscess, empyema, brain abscess) result from altered consciousness associated with drug use. Mixed aerobic and anaerobic mouth flora are usually involved.

Tuberculosis also occurs in drug users, and infection with HIV has fostered the spread of tuberculosis in this population. Morbidity and mortality rates are increased in HIV-infected individuals with tuberculosis. Classic radiographic findings are often absent; tuberculosis is suspected in any patient with infiltrates who does not respond to antibiotics.

Hepatitis is very common among habitual drug users and is transmissible both by the parenteral (hepatitis B, C, and D) and by the fecal-oral route (hepatitis A). Multiple episodes of hepatitis with different agents can occur.

Pulmonary septic emboli may originate from venous thrombi or right-sided endocarditis.

STDs are not directly related to drug use, but the practice of exchanging sex for drugs has resulted in an increased frequency of STDs. Syphilis, gonorrhea, and chancroid are the most common.

AIDS has a high incidence among injection drug users and their sexual contacts and among the offspring of infected women (see Chapter 31).

Infective endocarditis in persons who use drugs intravenously is most commonly caused by *S aureus*, *Candida* (usually *C albicans* or *C parapsilosis*), *Enterococcus faecalis*, other streptococci, and gram-negative bacteria (especially *Pseudomonas* and *Serratia marcescens*). See Chapter 33.

Other vascular infections include septic thrombophlebitis and mycotic aneurysms. Mycotic aneurysms resulting from direct trauma to a vessel with secondary infection most commonly occur in femoral arteries and less commonly in arteries of the neck. Aneurysms resulting from hematogenous spread of organisms frequently involve intracerebral vessels and thus are seen in association with endocarditis.

Osteomyelitis and septic arthritis involving vertebral bodies, sternoclavicular joints, the pubic symphysis, the sacroiliac joints, and other sites usually results from hematogenous distribution of injected organisms or septic venous thrombi. Pain and fever precede radiographic changes, sometimes by several weeks. While staphylococci—often methicillin-resistant—are common organisms, *Serratia*, *Pseudomonas*, *Candida* (often not *C albicans*), and other pathogens rarely encountered in spontaneous bone or joint disease are found in injection drug users.

▶ Treatment

A common and difficult clinical problem is management of the parenteral drug user who presents with fever. In general, after obtaining appropriate cultures (blood, urine, and sputum if the chest radiograph is abnormal), empiric therapy is begun. If the chest radiograph is suggestive of a community-acquired pneumonia (consolidation), therapy for outpatient pneumonia is begun with a third-generation cephalosporin, such as ceftriaxone, 1 g intravenously every 24 hours, plus azithromycin, 500 mg orally or intravenously every 24 hours, or doxycycline, 100 mg orally or intravenously twice daily. If the chest radiograph is suggestive of septic emboli (nodular infiltrates), therapy for presumed endocarditis is initiated, usually with vancomycin 15 mg/kg/dose every 12 hours intravenously (due to the high prevalence of MRSA and the possibility of enterococcus). If the chest radiograph is normal and no focal site of infection can be found, endocarditis is presumed. While awaiting the results of blood cultures, empiric treatment with vancomycin is started. If blood cultures are positive for organisms that frequently cause endocarditis in drug users (see above), endocarditis is presumed to be present

and treated accordingly. If blood cultures are positive for an organism that is an unusual cause of endocarditis, evaluation for an occult source of infection should go forward. In this setting, a transesophageal echocardiogram may be quite helpful since it is 90% sensitive in detecting vegetations and a negative study is strong evidence against endocarditis. If blood cultures are negative and the patient responds to antibiotics, therapy should be continued for 7–14 days (oral therapy can be given once an initial response has occurred). In every patient, careful examination for an occult source of infection (eg, genitourinary, dental, sinus, gallbladder) should be done.

▶ When to Refer

- Any patient with suspected or proven infective endocarditis.
- Patients with persistent bacteremia.

▶ When to Admit

- Injection drug users with fever.
- Patients with abscesses or progressive skin and soft tissue infection that require debridement.

Deiss RG et al. Tuberculosis and illicit drug use: review and update. *Clin Infect Dis*. 2009 Jan 1;48(1):72–82. [PMID: 19046064]

Gordon RJ et al. Bacterial infections in drug users. *N Engl J Med*. 2005 Nov 3;353(18):1945–54. [PMID: 16267325]

Paintsil E et al. Survival of hepatitis C virus in syringes: implication for transmission among injection drug users. *J Infect Dis*. 2010 Oct 1;202(7):984–90. [PMID: 20726768]

Jain V et al. Infective endocarditis in an urban medical center: association of individual drugs with valvular involvement. *J Infect*. 2008 Aug;57(2):132–8. [PMID: 18597851]

ACUTE INFECTIOUS DIARRHEA



ESSENTIALS OF DIAGNOSIS

- ▶ **Acute diarrhea:** lasts < 2 weeks
- ▶ **Chronic diarrhea:** lasts > 2 weeks.
- ▶ **Mild diarrhea:** ≤ 3 stools per day.
- ▶ **Moderate diarrhea:** ≥ 4 stools per day with local symptoms (abdominal cramps, nausea, tenesmus).
- ▶ **Severe diarrhea:** ≥ 4 stools per day with systemic symptoms (fever, chills, dehydration).

▶ General Considerations

Acute diarrhea can be caused by a number of different factors, including emotional stress, food intolerance, inorganic agents (eg, sodium nitrite), organic substances (eg, mushrooms, shellfish), drugs, and infectious agents (including viruses, bacteria, and protozoa) (Table 30–3). From a diagnostic and therapeutic standpoint, it is helpful to classify infectious diarrhea into syndromes that produce inflammatory or bloody diarrhea and those that are

noninflammatory, nonbloody, or watery. In general, the term “inflammatory diarrhea” suggests colonic involvement by invasive bacteria or parasites or by toxin production. Patients complain of frequent bloody, small-volume stools, often associated with fever, abdominal cramps, tenesmus, and fecal urgency. Common causes of this syndrome include *Shigella*, *Salmonella*, *Campylobacter*, *Yersinia*, invasive strains of *Escherichia coli*, *E coli* O157:H7 and other Shiga-toxin-producing strains of *E coli* (STEC), *Entamoeba histolytica*, and *C difficile*. Tests for fecal leukocytes or the neutrophil marker lactoferrin are frequently positive, and definitive etiologic diagnosis requires stool culture. Noninflammatory diarrhea is generally milder and is caused by viruses or toxins that affect the small intestine and interfere with salt and water balance, resulting in large-volume watery diarrhea, often with nausea, vomiting, and cramps. Common causes of this syndrome include viruses (eg, rotavirus, norovirus, astrovirus, enteric adenoviruses), vibrios (*Vibrio cholerae*, *Vibrio parahaemolyticus*), enterotoxin-producing *E coli*, *Giardia lamblia*, cryptosporidia, and agents that can cause food-borne gastroenteritis. In developed countries, viruses (particularly norovirus) are an important cause of hospitalizations due to acute gastroenteritis among adults.

The term “food poisoning” denotes diseases caused by toxins present in consumed foods. When the incubation period is short (1–6 hours after consumption), the toxin is usually preformed. Vomiting is usually a major complaint, and fever is usually absent. Examples include intoxication from *S aureus* or *Bacillus cereus*, and toxin can be detected in the food. When the incubation period is longer—between 8 hours and 16 hours—the organism is present in the food and produces toxin after being ingested. Vomiting is less prominent, abdominal cramping is frequent, and fever is often absent. The best example of this disease is that due to *Clostridium perfringens*. Toxin can be detected in food or stool specimens.

The inflammatory and noninflammatory diarrheas discussed above can also be transmitted by food and water and usually have incubation periods between 12 and 72 hours. *Cyclospora*, cryptosporidia, and *Isospora* are protozoans capable of causing disease in both immunocompetent and immunocompromised patients. Characteristics of disease include profuse watery diarrhea that is prolonged but usually self-limited (1–2 weeks) in the immunocompetent patient but can be chronic in the compromised host. Epidemiologic features may be helpful in determining etiology. Recent hospitalization or antibiotic use suggests *C difficile*; recent foreign travel suggests *Salmonella*, *Shigella*, *Campylobacter*, *E coli*, or *V cholerae*; undercooked hamburger suggests *E coli*, especially O157:H7; outbreak in long-term care facility, school, or cruise ship suggests norovirus; and fried rice consumption is associated with *B cereus* toxin. Prominent features of some of these causes of diarrhea are listed in Table 30–3.

▶ Treatment

A. General Measures

In general, most cases of acute gastroenteritis are self-limited and do not require therapy other than supportive

Table 30-3. Acute bacterial diarrheas and “food poisoning.”

Organism	Incubation Period	Vomiting	Diarrhea	Fever	Associated Foods	Diagnosis	Clinical Features and Treatment
<i>Staphylococcus</i> (preformed toxin)	1-8 hours	+++	±	±	Staphylococci grow in meats, dairy, and bakery products and produce enterotoxin.	Clinical. Food and stool can be tested for toxin.	Abrupt onset, intense nausea and vomiting for up to 24 hours, recovery in 24-48 hours. Supportive care.
<i>Bacillus cereus</i> (preformed toxin)	1-8 hours	+++	±	-	Reheated fried rice causes vomiting or diarrhea.	Clinical. Food and stool can be tested for toxin.	Acute onset, severe nausea and vomiting lasting 24 hours. Supportive care.
<i>B. cereus</i> (diarrheal toxin)	10-16 hours	±	+++	-	Toxin in meats, stews, and gravy.	Clinical. Food and stool can be tested for toxin.	Abdominal cramps, watery diarrhea, and nausea lasting 24-48 hours. Supportive care.
<i>Clostridium perfringens</i>	8-16 hours	±	+++	-	Clostridia grow in rewarmed meat and poultry dishes and produce an enterotoxin.	Stools can be tested for enterotoxin or cultured.	Abrupt onset of profuse diarrhea, abdominal cramps, nausea; vomiting occasionally. Recovery usual without treatment in 24-48 hours. Supportive care; antibiotics not needed.
<i>Clostridium botulinum</i>	12-72 hours	±	-	-	Clostridia grow in anaerobic acidic environment eg, canned foods, fermented fish, foods held warm for extended periods.	Stool, serum, and food can be tested for toxin. Stool and food can be cultured.	Diplopia, dysphagia, dysphonia, respiratory embarrassment. Treatment requires clear airway, ventilation, and intravenous polyvalent antitoxin (see text). Symptoms can last for days to months.
<i>Clostridium difficile</i>	Usually occurs after 7-10 days of antibiotics. Can occur after a single dose or several weeks after completion of antibiotics.	-	+++	++	Associated with antimicrobial drugs; clindamycin and β-lactams most commonly implicated. Fluoroquinolones associated with hypervirulent strains.	Stool tested for toxin.	Abrupt onset of diarrhea that may be bloody; fever. Oral metronidazole for mild to moderate cases. Oral vancomycin for more severe disease.
Enterohemorrhagic <i>Escherichia coli</i> , including <i>E. coli</i> O157:H7 and other Shiga-toxin producing strains (STEC)	1-8 days	+	+++	-	Undercooked beef, especially hamburger; unpasteurized milk and juice; raw fruits and vegetables.	<i>E. coli</i> O157:H7 can be cultured on special medium. Other toxins can be detected in stool.	Usually abrupt onset of diarrhea, often bloody; abdominal pain. In adults, it is usually self-limited to 5-10 days. In children, it is associated with hemolytic-uremic syndrome (HUS). Antibiotic therapy may increase risk of HUS. Plasma exchange may help patients with STEC-associated HUS.
Enterotoxigenic <i>E. coli</i> (ETEC)	1-3 days	±	+++	±	Water, food contaminated with feces.	Stool culture. Special tests required to identify toxin-producing strains.	Watery diarrhea and abdominal cramps, usually lasting 3-7 days. In travelers, fluoroquinolones shorten disease.
<i>Vibrio parahaemolyticus</i>	2-48 hours	+	+	±	Undercooked or raw seafood.	Stool culture on special medium.	Abrupt onset of watery diarrhea, abdominal cramps, nausea and vomiting. Recovery is usually complete in 2-5 days.

<i>Vibrio cholerae</i>	24-72 hours	+	+++	-	Contaminated water, fish, shellfish, street vendor food.	Stool culture on special medium.	Abrupt onset of liquid diarrhea in endemic area. Needs prompt intravenous or oral replacement of fluids and electrolytes. Tetracyclines and azithromycin shorten excretion of vibrios.
<i>Campylobacter jejuni</i>	2-5 days	±	+++	+	Raw or undercooked poultry, unpasteurized milk, water.	Stool culture on special medium.	Fever, diarrhea that can be bloody, cramps. Usually self-limited in 2-10 days. Treat with azithromycin or fluoroquinolones for severe disease. May be associated with Guillain-Barré syndrome.
<i>Shigella</i> species (mild cases)	24-48 hours	±	+	+	Food or water contaminated with human feces. Person to person spread.	Routine stool culture.	Abrupt onset of diarrhea, often with blood and pus in stools, cramps, tenesmus, and lethargy. Stool cultures are positive. Therapy depends on sensitivity testing, but the fluoroquinolones are most effective. Do not give opioids. Often mild and self-limited.
<i>Salmonella</i> species	1-3 days	-	++	+	Eggs, poultry, unpasteurized milk, cheese, juices, raw fruits and vegetables.	Routine stool culture.	Gradual or abrupt onset of diarrhea and low-grade fever. No antimicrobials unless high risk (see text) or systemic dissemination is suspected, in which case give a fluoroquinolone. Prolonged carriage can occur.
<i>Yersinia enterocolitica</i>	24-48 hours	±	+	+	Undercooked pork, contaminated water, unpasteurized milk, tofu.	Stool culture on special medium.	Severe abdominal pain, (appendicitis-like symptoms) diarrhea, fever. Polyarthritits, erythema nodosum in children. If severe, give tetracycline or fluoroquinolone. Without treatment, self-limited in 1-3 weeks.
Rotavirus	1-3 days	++	+++	+	Fecally contaminated foods touched by infected food handlers.	Immunoassay on stool.	Acute onset, vomiting, watery diarrhea that lasts 4-8 days. Supportive care.
Noroviruses and other caliciviruses	12-48 hours	++	+++	+	Shell fish and fecally contaminated foods touched by infected food handlers.	Clinical diagnosis with negative stool cultures. PCR available on stool.	Nausea, vomiting (more common in children) diarrhea (more common in adults), fever, myalgias, abdominal cramps. Lasts 12-60 hours. Supportive care.

PCR, polymerase chain reaction.

measures. Treatment usually consists of replacement of fluids and electrolytes and, very rarely, management of hypovolemic shock and respiratory compromise. In mild diarrhea, increasing ingestion of juices and clear soups is adequate. In more severe cases of dehydration (postural lightheadedness, decreased urination), oral glucose-based rehydration solutions can be used (Ceralyte, Pedialyte).

B. Specific Measures

When symptoms persist beyond 3–4 days, initial presentation is accompanied by fever or bloody diarrhea, or if the patient is immunocompromised, cultures of stool are usually obtained. Symptoms have often resolved by the time cultures are completed. In this case, even if a pathogen is isolated, therapy is not needed (except for *Shigella*, since the infecting dose is so small that therapy to eradicate organisms from the stool is indicated for epidemiologic reasons). If symptoms persist and a pathogen is isolated, it is reasonable to institute specific treatment even though therapy has not been conclusively shown to alter the natural history of disease for most pathogens. Exceptions include infection with *Shigella* where antibiotic therapy has been shown to shorten the duration of symptoms by 2–3 days, and *Campylobacter* infections (early therapy, within 4 days of onset of symptoms, shortens the course of disease). Conversely, antibiotic therapy for infections with *E coli* O157:H7 does not ameliorate symptoms and may increase the risk of developing hemolytic-uremic syndrome. Uncomplicated gastroenteritis due to *Salmonella* does not require therapy because the disease is usually self-limited and therapy may prolong carriage and perhaps increase relapses. Because bacteremia with complications can occur in high-risk patients, some experts have recommended therapy for *Salmonella* in patients over the age of 50, in organ transplant recipients, in those with HIV, in patients taking corticosteroids, in those with lymphoproliferative diseases, and in those with vascular grafts. Ciprofloxacin, 500 mg orally every 12 hours for 5 days, is effective in shortening the course of illness compared with placebo in patients presenting with diarrhea, whether a pathogen is isolated or not. However, because of concerns about selecting for resistant organisms (especially *Campylobacter*, where increasing resistance to fluoroquinolones has been documented and erythromycin is the drug of choice) coupled with the fact that most infectious diarrhea is self-limited, routine use of antibiotics for all patients with diarrhea is not recommended. Antibiotics should be considered in patients with evidence of invasive disease (white cells in stool, dysentery), with symptoms 3–4 days or more in duration, with multiple stools (eight to ten or more per day), and in those with impaired immune responses. Antimotility drugs are useful in mild cases. Their use should be limited to patients without fever and without dysentery (bloody stools), and they should be used in low doses because of the risk of producing toxic megacolon.

Therapeutic recommendations for specific agents can be found elsewhere in this book.

ASGE Standards of Practice Committee; Shen B et al. The role of endoscopy in the management of patients with diarrhea. *Gastrointest Endosc.* 2010 May;71(6):887–92. [PMID: 20346452]

Colic E et al. Management of an acute outbreak of diarrhoea-associated haemolytic uraemic syndrome with early plasma exchange in adults from southern Denmark: an observational study. *Lancet.* 2011 Sep 17;378(9796):1089–93. [PMID: 21871657]

DuPont HL. Clinical practice. Bacterial diarrhea. *N Engl J Med.* 2009 Oct 15;361(16):1560–9. [PMID: 19828533]

Frank C et al; HUS Investigation Team. Epidemic profile of Shiga-toxin-producing *Escherichia coli* O104:H4 outbreak in Germany. *N Engl J Med.* 2011 Nov 10;365(19):1771–80. [PMID: 21696328]

Lopman BA et al. Increasing rates of gastroenteritis hospital discharges in US adults and the contribution of norovirus, 1996–2007. *Clin Infect Dis.* 2011 Feb 15;52(4):466–74. [PMID: 21258098]

Prince Christopher RH et al. Antibiotic therapy for *Shigella* dysentery. *Cochrane Database Syst Rev.* 2010 Jan 10;(1):CD006784. [PMID: 20091606]

INFECTIOUS DISEASES IN THE RETURNING TRAVELER



ESSENTIALS OF DIAGNOSIS

- ▶ Most infections are common and self-limited.
- ▶ Identify patients with transmissible diseases that require isolation.
- ▶ The incubation period may be helpful in diagnosis.
- ▶ Less than 3 weeks following exposure may suggest dengue, leptospirosis and yellow fever; >3 weeks suggest typhoid fever, malaria, and tuberculosis.

▶ General Considerations

The differential diagnosis of fever in the returning traveler is broad, ranging from self-limited viral infections to life-threatening illness. The evaluation is best done by identifying whether a particular syndrome is present, then refining the differential diagnosis based on an exposure history. The travel history should include directed questions regarding geography (rural versus urban), animal or arthropod contact, unprotected sexual intercourse, ingestion of untreated water or raw foods, historical or pretravel immunizations, and adherence to malaria prophylaxis.

▶ Etiologies

The most common infectious causes of fever—excluding simple causes such as upper respiratory infections, bacterial pneumonia and urinary tract infections—in returning travelers are malaria (see Chapter 35), diarrhea (see next section), and dengue (see Chapter 32). Others include respiratory infections, including seasonal influenza, influenza A/H1N1 ‘swine’ influenza, and influenza A/H5N1

'avian' influenza (see Chapter 32); leptospirosis (see Chapter 34); typhoid fever (see Chapter 33); and rickettsial infections (see Chapter 32). Foreign travel is increasingly recognized as a risk factor for colonization and disease with resistant pathogens, such as extended-spectrum β -lactamases (ESBL)-producing gram-negative organisms. Systemic febrile illnesses without a diagnosis also occurs commonly, particularly in travelers returning from sub-Saharan Africa or Southeast Asia.

A. Fever and Rash

Potential etiologies include dengue, Chikungunya, viral hemorrhagic fever, leptospirosis, meningococemia, yellow fever, typhus, *Salmonella typhi*, and acute HIV infection.

B. Pulmonary Infiltrates

Tuberculosis, ascaris, *Paragonimus*, and *Strongyloides* can all cause pulmonary infiltrates.

C. Meningoencephalitis

Etiologies include *N meningitidis*, leptospirosis, arboviruses, rabies, and (cerebral) malaria.

D. Jaundice

Consider hepatitis A, yellow fever, hemorrhagic fever, leptospirosis, and malaria.

E. Fever without Localizing Symptoms or Signs

Malaria, typhoid fever, acute HIV infection, rickettsial illness, visceral leishmaniasis, trypanosomiasis, and dengue are possible etiologies.

F. Traveler's Diarrhea

See next section.

▶ Clinical Findings

Fever and rash in the returning traveler should prompt blood cultures and serologic tests based on the exposure history. The work-up of a **pulmonary infiltrate** should include the placement of a PPD, examination of sputum for acid-fast bacilli and possibly for ova and parasites. Patients with evidence of **meningoencephalitis** should receive lumbar puncture, blood cultures, thick/thin smears of peripheral blood, history-guided serologies, and a nape biopsy (if rabies is suspected). **Jaundice** in a returning traveler should be evaluated for hemolysis (for malaria), and the following tests should be performed: liver function tests, thick/thin smears of peripheral blood, and directed serologic testing. The work-up of **traveler's diarrhea** is presented in the following section. Finally, patients with **fever** but no localizing signs or symptoms should have blood cultures performed. Routine laboratory studies usually include complete blood count with differential, electrolytes, liver function tests, urinalysis, and blood cultures. Thick and thin peripheral blood smears should be done (and repeated in 12–24 hours if clinical suspicion remains high) for malaria if there has been travel to endemic areas.

Other studies are directed by the results of history, physical examination, and initial laboratory tests. They may include stool for ova and parasites, chest radiograph, HIV test, and specific serologies (eg, dengue, leptospirosis, rickettsial disease, schistosomiasis, *Strongyloides*). Bone marrow biopsy to diagnose typhoid fever could be helpful in the appropriate patient.

▶ When to Refer

Travelers with fever, particularly if immunocompromised.

▶ When to Admit

Any evidence of hemorrhage, respiratory distress, hemodynamic instability, and neurologic deficits.

Centers for Disease Control and Prevention (CDC). Detection of *Enterobacteriaceae* isolates carrying metallo-beta-lactamase—United States, 2010. MMWR Morb Mortal Wkly Rep. 2010 Jun 25;59(24):750. [PMID: 20577157]

Gregory CJ et al. Clinical and laboratory features that differentiate dengue from other febrile illnesses in an endemic area—Puerto Rico, 2007–2008. Am J Trop Med Hyg. 2010 May;82(5):922–9. [PMID: 20439977]

Griffith KS et al. Treatment of malaria in the United States: a systematic review. JAMA. 2007 May 23;297(20):2264–77. [PMID: 17519416]

Hochedez P et al. Management of travelers with fever and exanthema, notably dengue and chikungunya infections. Am J Trop Med Hyg. 2008 May;78(5):710–3. [PMID: 18458301]

Monsel G et al. Recent developments in dermatological syndromes in returning travelers. Curr Opin Infect Dis. 2008 Oct;21(5):495–9. [PMID: 18725799]

Mukherjee P et al. Epidemiology of travel-associated pandemic (H1N1) 2009 infection in 116 patients, Singapore. Emerg Infect Dis. 2010 Jan;16(1):21–6. [PMID: 20031038]

Taylor WR et al. Avian influenza—a review for doctors in travel medicine. Travel Med Infect Dis. 2010 Jan;8(1):1–12. [PMID: 20188299]

TRAVELER'S DIARRHEA



ESSENTIALS OF DIAGNOSIS

- ▶ Usually a benign, self-limited disease occurring about 1 week into travel.
- ▶ Prophylaxis not recommended unless there is a comorbid disease (inflammatory bowel syndrome, HIV, immunosuppressive medication).
- ▶ Single-dose therapy of a fluoroquinolone usually effective if significant symptoms develop.

▶ General Considerations

Whenever a person travels from one country to another—particularly if the change involves a marked difference in climate, social conditions, or sanitation standards and facilities—diarrhea may develop within 2–10 days. Bacteria cause 80% of cases of traveler's diarrhea, with enterotoxigenic *E coli*, *Shigella* species, and *Campylobacter jejuni* being the

most common pathogens. Less common are *Aeromonas*, *Salmonella*, noncholera vibrios, *E histolytica*, and *G lamblia*. Contributory causes include unusual food and drink, change in living habits, occasional viral infections (adenoviruses or rotaviruses), and change in bowel flora. Chronic watery diarrhea may be due to amebiasis or giardiasis or, rarely, tropical sprue.

► Clinical Findings

A. Symptoms and Signs

There may be up to ten or even more loose stools per day, often accompanied by abdominal cramps and nausea, occasionally by vomiting, and rarely by fever. The stools are usually watery and not associated with fever when caused by enterotoxigenic *E coli*. With invasive bacterial pathogens (*Shigella*, *Campylobacter*, *Salmonella*) stools can be bloody and fever may be present. The illness usually subsides spontaneously within 1–5 days, although 10% remain symptomatic for 1 week or longer, and symptoms persist for longer than 1 month in 2%. Traveler's diarrhea is also a significant risk factor for developing irritable bowel syndrome.

B. Laboratory Findings

In patients with fever and bloody diarrhea, stool culture is indicated, but in most cases, cultures are reserved for those who do not respond to antibiotics.

► Prevention

A. General Measures

Avoidance of fresh foods and water sources that are likely to be contaminated is recommended for travelers to developing countries, where infectious diarrheal illnesses are endemic.

B. Specific Measures

Because not all travelers will have diarrhea and because most episodes are brief and self-limited, the currently recommended approach is to provide the traveler with a supply of antimicrobials to be taken if significant diarrhea occurs during the trip. In areas where toxin-producing bacteria are the major cause of diarrhea (Latin America and Africa), loperamide (4 mg oral loading dose, then 2 mg after each loose stool to a maximum of 16 mg/d) with a single oral dose of ciprofloxacin (750 mg), levofloxacin (500 mg), or ofloxacin (200 mg), cures most cases of traveler's diarrhea. If diarrhea is associated with bloody stools or persists despite a single dose of a fluoroquinolone, 1000 mg of azithromycin should be taken. In pregnant women and in areas where invasive bacteria more commonly cause diarrhea (Indian subcontinent, Asia, especially Thailand where fluoroquinolone-resistant *Campylobacter* is prevalent), azithromycin is the drug of choice. Rifaximin, a nonabsorbable agent, is also approved for therapy of traveler's diarrhea at a dose of 200 mg orally three times per day or 400 mg twice a day for 3 days. Because luminal concentrations are high, but tissue levels are insufficient, it should not be used in situations where there is a high likelihood of invasive disease (eg, fever, systemic toxicity, or bloody stools). Prophylaxis is recommended for those with

significant underlying disease (inflammatory bowel disease, AIDS, diabetes, heart disease in the elderly, conditions requiring immunosuppressive medications) and for those whose full activity status during the trip is so essential that even short periods of diarrhea would be unacceptable.

Prophylaxis is started upon entry into the destination country and is continued for 1 or 2 days after leaving. For stays of more than 3 weeks, prophylaxis is not recommended because of the cost and increased toxicity. For prophylaxis, numerous oral antimicrobial once-daily regimens are effective, such as norfloxacin, 400 mg; ciprofloxacin, 500 mg; or rifaximin, 200 mg. Bismuth subsalicylate is effective but turns the tongue and the stools black and can interfere with doxycycline absorption, which may be needed for malaria prophylaxis; it is rarely used.

► Treatment

For most individuals, the affliction is short-lived, and symptomatic therapy with loperamide is all that is required, provided the patient is not systemically ill (fever $\geq 39^{\circ}\text{C}$) and does not have dysentery (bloody stools), in which case antimotility agents should be avoided. Packages of oral rehydration salts to treat dehydration are available over the counter in the United States (Infalyte, Pedialyte, others) and in many foreign countries.

► When to Refer

- Cases refractory to treatment.
- Persistent infection.
- Immunocompromised patient.

► When to Admit

Patients who are severely dehydrated or hemodynamically unstable should be admitted to the hospital.

- Hill DR et al. Management of travellers' diarrhoea. *BMJ*. 2008 Oct 6;337:a1746. [PMID: 18838421]
- Hill DR et al. The practice of travel medicine: guidelines by the Infectious Disease Society of America. *Clin Infect Dis*. 2006 Dec 15;43(12):1499–539. [PMID: 17109284]
- Mohamed JA et al. Single nucleotide polymorphisms in the promoter of the gene encoding the lipopolysaccharide receptor CD14 are associated with bacterial diarrhea in US and Canadian travelers to Mexico. *Clin Infect Dis*. 2011 Jun;52(11):1332–41. [PMID: 21596674]
- Tuteja AK et al. Development of functional diarrhea, constipation, irritable bowel syndrome, and dyspepsia during and after traveling outside the USA. *Dig Dis Sci*. 2008 Jan;53(1):271–6. [PMID: 17549631]

ANTIMICROBIAL THERAPY

SELECTED PRINCIPLES OF ANTIMICROBIAL THERAPY

Specific steps (outlined below) are required when considering antibiotic therapy for patients. Drugs within classes, drugs of first choice, and alternative drugs are presented in Table 30–4.

Table 30-4. Drugs of choice for suspected or proved microbial pathogens, 2012.¹

Suspected or Proved Etiologic Agent	Drug(s) of First Choice	Alternative Drug(s)
Gram-negative cocci		
<i>Moraxella catarrhalis</i>	Cefuroxime, a fluoroquinolone ²	Cefotaxime, ceftriaxone, cefuroxime axetil, an erythromycin, ³ a tetracycline, ⁴ azithromycin, amoxicillin-clavulanic acid, clarithromycin, TMP-SMZ ⁵
<i>Neisseria gonorrhoeae</i> (gonococcus)	Cefixime, ceftriaxone	Cefpodoxime proxetil
<i>Neisseria meningitidis</i> (meningococcus)	Penicillin ⁶	Cefotaxime, ceftriaxone, ampicillin
Gram-positive cocci		
<i>Streptococcus pneumoniae</i> ⁷ (pneumococcus)	Penicillin ⁶	An erythromycin, ³ a cephalosporin, ⁸ vancomycin, clindamycin, azithromycin, clarithromycin, a tetracycline, ⁴ respiratory fluoroquinolones ²
<i>Streptococcus</i> , hemolytic, groups A, B, C, G	Penicillin ⁶	An erythromycin, ³ a cephalosporin, ⁸ vancomycin, clindamycin, azithromycin, clarithromycin
Viridans streptococci	Penicillin ⁶ ± gentamicin	Cephalosporin, ⁸ vancomycin
<i>Staphylococcus</i> , methicillin-resistant	Vancomycin	TMP-SMZ, ⁵ doxycycline, minocycline, linezolid, daptomycin, quinupristin-dalfopristin, tigecycline, televancin
<i>Staphylococcus</i> , non-penicillinase-producing	Penicillin ⁶	A cephalosporin, ⁸ clindamycin
<i>Staphylococcus</i> , penicillinase-producing	Penicillinase-resistant penicillin ⁹	Vancomycin, a cephalosporin, ⁸ clindamycin, amoxicillin-clavulanic acid, ampicillin-sulbactam, piperacillin-tazobactam, TMP-SMZ ⁵
<i>Enterococcus faecalis</i>	Ampicillin ± gentamicin ¹⁰	Vancomycin ± gentamicin
<i>Enterococcus faecium</i>	Vancomycin ± gentamicin ¹⁰	Linezolid, ¹¹ quinupristin-dalfopristin, ¹¹ daptomycin, ¹¹ tigecycline ¹¹
Gram-negative rods		
<i>Acinetobacter</i>	Imipenem, meropenem	Tigecycline, ertapenem, minocycline, doxycycline, aminoglycosides, ¹² colistin
<i>Prevotella</i> , oropharyngeal strains	Clindamycin	Metronidazole
<i>Bacteroides</i> , gastrointestinal strains	Metronidazole	Ticarcillin-clavulanate, ampicillin-sulbactam, piperacillin-tazobactam, carbapenem
<i>Brucella</i>	Doxycycline + rifampin ⁴	TMP-SMZ ⁵ ± gentamicin; ciprofloxacin + rifampin
<i>Campylobacter jejuni</i>	Erythromycin ³ or azithromycin	Tetracycline, ⁴ a fluoroquinolone ²
<i>Enterobacter</i>	Ertapenem, imipenem, meropenem, cefepime	Aminoglycoside, a fluoroquinolone, ² TMP-SMZ ⁵
<i>Escherichia coli</i> (sepsis) ¹³	Cefotaxime, ceftriaxone	Imipenem ¹³ or meropenem, ¹³ aminoglycosides, ¹² a fluoroquinolone, ² aztreonam, ticarcillin-clavulanate, ampicillin-sulbactam, piperacillin-tazobactam
<i>Escherichia coli</i> (uncomplicated outpatient urinary infection)	Fluoroquinolones, ² nitrofurantoin	TMP-SMZ, ⁵ oral cephalosporin
<i>Haemophilus</i> (meningitis and other serious infections)	Cefotaxime, ceftriaxone	Aztreonam
<i>Haemophilus</i> (respiratory infections, otitis)	TMP-SMZ ⁵	Doxycycline, azithromycin, clarithromycin, cefotaxime, ceftriaxone, cefuroxime, cefuroxime axetil, ampicillin-clavulanate
<i>Helicobacter pylori</i>	Amoxicillin + clarithromycin + proton pump inhibitor (PPI)	Bismuth subsalicylate + tetracycline + metronidazole + PPI
<i>Klebsiella</i> ¹³	A cephalosporin	TMP-SMZ, ⁵ aminoglycoside, ¹² imipenem ¹³ or meropenem, ¹³ a fluoroquinolone, ² aztreonam, ticarcillin-clavulanate, ampicillin-sulbactam, piperacillin-tazobactam
<i>Legionella</i> species (pneumonia)	Azithromycin, or fluoroquinolones ² ± rifampin	Doxycycline ± rifampin

(continued)

Table 30-4. Drugs of choice for suspected or proved microbial pathogens, 2012.¹ (continued)

Suspected or Proved Etiologic Agent	Drug(s) of First Choice	Alternative Drug(s)
<i>Proteus mirabilis</i>	Ampicillin	An aminoglycoside, ¹² TMP-SMZ, ⁵ a fluoroquinolone, ² a cephalosporin ⁸
<i>Proteus vulgaris</i> and other species (<i>Morganella</i> , <i>Providencia</i>)	Cefotaxime, ceftriaxone	Aminoglycoside, ¹² imipenem, TMP-SMZ, ⁵ a fluoroquinolone ²
<i>Pseudomonas aeruginosa</i>	Piperacillin-tazobactam or ceftazidime or cefepime, or imipenem or meropenem or doripenem ± aminoglycoside ¹²	Ciprofloxacin (or levofloxacin) ± piperacillin-tazobactam; ciprofloxacin (or levofloxacin) ± ceftazidime; ciprofloxacin (or levofloxacin) ± cefepime; piperacillin-tazobactam + tobramycin; ceftazidime + tobramycin; cefepime + tobramycin; meropenem (imipenem, doripenem) + tobramycin
<i>Burkholderia pseudomallei</i> (melioidosis)	Ceftazidime	Tetracycline, ⁴ TMP-SMZ, ⁵ amoxicillin-clavulanic acid, imipenem or meropenem
<i>Burkholderia mallei</i> (glanders)	Streptomycin + tetracycline ⁴	Chloramphenicol + streptomycin
<i>Salmonella</i> (bacteremia)	Ceftriaxone	A fluoroquinolone ²
<i>Serratia</i>	Carbapenem	TMP-SMZ, ⁵ aminoglycosides, ¹² a fluoroquinolone, ² cefotaxime, ceftriaxone
<i>Shigella</i>	A fluoroquinolone ²	Azithromycin, ampicillin, TMP-SMZ, ⁵ ceftriaxone
<i>Vibrio</i> (cholera, sepsis)	A tetracycline ⁴	TMP-SMZ, ⁵ a fluoroquinolone ²
<i>Yersinia pestis</i> (plague)	Streptomycin ± a tetracycline ⁴	Chloramphenicol, TMP-SMZ ⁵
Gram-positive rods		
<i>Actinomyces</i>	Penicillin ⁶	Tetracycline, ⁴ clindamycin
<i>Bacillus</i> (including anthrax)	Penicillin ⁶ (ciprofloxacin or doxycycline for anthrax; see Table 33-2)	Erythromycin, ³ a fluoroquinolone ²
<i>Clostridium</i> (eg, gas gangrene, tetanus)	Penicillin ⁶	Metronidazole, clindamycin, imipenem or meropenem
<i>Corynebacterium diphtheriae</i>	Erythromycin ³	Penicillin ⁶
<i>Corynebacterium jeikeium</i>	Vancomycin	A fluoroquinolone
<i>Listeria</i>	Ampicillin ± aminoglycoside ¹²	TMP-SMZ ⁵
Acid-fast rods		
<i>Mycobacterium tuberculosis</i> ¹⁴	Isoniazid (INH) + rifampin + pyrazinamide ± ethambutol	Other antituberculous drugs (see Tables 9-17 and 9-18)
<i>Mycobacterium leprae</i>	Dapsone + rifampin ± clofazimine	Minocycline, ofloxacin, clarithromycin
<i>Mycobacterium kansasii</i>	INH + rifampin ± ethambutol	Clarithromycin, azithromycin, ethionamide, cycloserine
<i>Mycobacterium avium complex</i>	Clarithromycin or azithromycin + ethambutol, ± rifabutin	Amikacin, ciprofloxacin
<i>Mycobacterium fortuitum-chelonae</i>	Cefoxitin + clarithromycin	Amikacin, rifampin, sulfonamide, doxycycline, linezolid
<i>Nocardia</i>	TMP-SMZ ⁵	Minocycline, imipenem or meropenem, linezolid
Spirochetes		
<i>Borrelia burgdorferi</i> (Lyme disease)	Doxycycline, amoxicillin, cefuroxime axetil	Ceftriaxone, cefotaxime, penicillin, azithromycin, clarithromycin
<i>Borrelia recurrentis</i> (relapsing fever)	Doxycycline ⁴	Penicillin ⁶
<i>Leptospira</i>	Penicillin ⁶	Doxycycline, ⁴ ceftriaxone
<i>Treponema pallidum</i> (syphilis)	Penicillin ⁶	Doxycycline, ceftriaxone
<i>Treponema pertenue</i> (yaws)	Penicillin ⁶	Doxycycline

(continued)

Table 30–4. Drugs of choice for suspected or proved microbial pathogens, 2012.¹ (continued)

Suspected or Proved Etiologic Agent	Drug(s) of First Choice	Alternative Drug(s)
Mycoplasmas	Clarithromycin or azithromycin or doxycycline	A fluoroquinolone, ² erythromycin ³
Chlamydiae		
<i>C psittaci</i>	Doxycycline	Chloramphenicol
<i>C trachomatis</i> (urethritis or pelvic inflammatory disease)	Doxycycline or azithromycin	Levofloxacin, ofloxacin
<i>C pneumoniae</i>	Doxycycline ⁴	Erythromycin, ³ clarithromycin, azithromycin, a fluoroquinolone ^{2,15}
Rickettsiae	Doxycycline ⁴	Chloramphenicol, a fluoroquinolone ²

¹Adapted, with permission, from Treat Guide Med Lett. 2010 June;6(94):43–52.

²Fluoroquinolones include ciprofloxacin, ofloxacin, levofloxacin, moxifloxacin, and others (see text). Gemifloxacin, levofloxacin, and moxifloxacin have the best activity against gram-positive organisms, including penicillin-resistant *S pneumoniae* and methicillin-sensitive *S aureus*. Activity against enterococci and *S epidermidis* is variable.

³Erythromycin estolate is best absorbed orally but carries the highest risk of hepatitis; erythromycin stearate and erythromycin ethylsuccinate are also available.

⁴All tetracyclines have similar activity against most microorganisms. Minocycline (most likely to have *S aureus* activity), doxycycline, tetracycline have increased activity against *S aureus*.

⁵TMP-SMZ is a mixture of 1 part trimethoprim and 5 parts sulfamethoxazole.

⁶Penicillin G is preferred for parenteral injection; penicillin V for oral administration—to be used only in treating infections due to highly sensitive organisms.

⁷Infections caused by isolates with intermediate resistance may respond to high doses of penicillin, cefotaxime, or ceftriaxone. Infections caused by highly resistant strains should be treated with vancomycin. Many strains of penicillin-resistant pneumococci are resistant to macrolides, cephalosporins, tetracyclines, and TMP-SMZ.

⁸Most intravenous cephalosporins (with the exception of ceftazidime) have good activity against gram-positive cocci.

⁹Parenteral nafcillin or oxacillin; oral dicloxacillin, cloxacillin, or oxacillin.

¹⁰Addition of gentamicin indicated only for severe enterococcal infections (eg, endocarditis, meningitis).

¹¹Linezolid, daptomycin, tigecycline, quinupristin-dalfopristin should be reserved for the treatment of vancomycin resistant isolates or in patients intolerant of vancomycin.

¹²Aminoglycosides—gentamicin, tobramycin, amikacin, netilmicin—should be chosen on the basis of local patterns of susceptibility.

¹³Extended β -lactamase-producing isolates should be treated with a carbapenem.

¹⁴Resistance is common and susceptibility testing should be done.

¹⁵Ciprofloxacin has inferior antichlamydial activity compared with levofloxacin or ofloxacin.

Key: \pm , alone or combined with.

A. Etiologic Diagnosis

Based on the organ system involved, the organism causing infection can often be predicted. See Tables 30–5 and 30–6.

B. “Best Guess”

Select an empiric regimen that is likely to be effective against the suspected pathogens.

C. Laboratory Control

Specimens for laboratory examination should be obtained before institution of therapy to determine susceptibility.

D. Clinical Response

Based on clinical response and other data, the laboratory reports are evaluated and then the desirability of changing the regimen is considered. If the specimen was obtained from a normally sterile site (eg, blood, cerebrospinal fluid, pleural fluid, joint fluid), the recovery of a microorganism in significant amounts is meaningful even if the organism recovered is different from the clinically suspected agent,

and this may force a change in treatment. Isolation of unexpected microorganisms from the respiratory tract, gastrointestinal tract, or surface lesions (sites that have a complex flora) may represent colonization or contamination, and cultures must be critically evaluated before drugs are abandoned that were judiciously selected on a “best guess” basis.

E. Drug Susceptibility Tests

Some microorganisms are predictably inhibited by certain drugs; if such organisms are isolated, they need not be tested for drug susceptibility. For example, all group A hemolytic streptococci are inhibited by penicillin. Other organisms (eg, enteric gram-negative rods) are variably susceptible and generally require susceptibility testing whenever they are isolated. Organisms that once had predictable susceptibility patterns have now become resistant and require testing. Examples include the pneumococci, which may be resistant to multiple drugs (including penicillin, macrolides, and TMP-SMZ); the enterococci, which may be resistant to penicillin, aminoglycosides,

Table 30-5. Examples of initial antimicrobial therapy for acutely ill, hospitalized adults pending identification of causative organism.

Suspected Clinical Diagnosis	Likely Etiologic Diagnosis	Drugs of Choice
Meningitis, bacterial, community-acquired	Pneumococcus, ¹ meningococcus	Cefotaxime, ² 2–3 g intravenously every 6 hours; or ceftriaxone, 2 g intravenously every 12 hours plus vancomycin, 10 mg/kg intravenously every 8 hours
Meningitis, bacterial, age > 50, community-acquired	Pneumococcus, meningococcus, <i>Listeria monocytogenes</i> , ³ gram-negative bacilli	Ampicillin, 2 g intravenously every 4 hours, plus cefotaxime, 2–3 g intravenously every 6 hours; or ceftriaxone, 2 g intravenously every 12 hours plus vancomycin, 10 mg/kg intravenously every 8 hours
Meningitis, postoperative (or posttraumatic)	<i>S aureus</i> , gram-negative bacilli (pneumococcus, in posttraumatic)	Vancomycin, 10 mg/kg intravenously every 8 hours, plus cefepime, 3 g intravenously every 8 hours
Brain abscess	Mixed anaerobes, pneumococci, streptococci	Penicillin G, 4 million units intravenously every 4 hours, plus metronidazole, 500 mg orally every 8 hours; or cefotaxime, 2–3 g intravenously every 6 hours or ceftriaxone, 2 g intravenously every 12 hours plus metronidazole, 500 mg orally every 8 hours
Pneumonia, acute, community-acquired, non-ICU hospital admission	Pneumococci, <i>M pneumoniae</i> , <i>Legionella</i> , <i>C pneumoniae</i>	Cefotaxime, 2 g intravenously every 8 hours (or ceftriaxone, 1 g intravenously every 24 hours or ampicillin 2 g intravenously every 6 hours) plus azithromycin 500 mg intravenously every 24 hours; or a fluoroquinolone ⁵ alone
Pneumonia, postoperative or nosocomial	<i>S aureus</i> , mixed anaerobes, gram-negative bacilli	Cefepime, 1 g intravenously every 8 hours; or ceftazidime, 2 g intravenously every 8 hours; or piperacillin-tazobactam, 4.5 g intravenously every 6 hours; or imipenem, 500 mg intravenously every 6 hours; or meropenem, 1 g intravenously every 8 hours plus tobramycin, 5 mg/kg intravenously every 24 hours; or ciprofloxacin, 400 mg intravenously every 12 hours; or levofloxacin, 500 mg intravenously every 24 hours plus vancomycin, 15 mg/kg intravenously every 12 hours
Endocarditis, acute (including injection drug user)	<i>S aureus</i> , <i>E faecalis</i> , gram-negative aerobic bacteria, viridans streptococci	Vancomycin, 15 mg/kg intravenously every 12 hours, plus gentamicin, 1 mg/kg every 8 hours
Septic thrombophlebitis (eg, IV tubing, IV shunts)	<i>S aureus</i> , gram-negative aerobic bacteria	Vancomycin, 15 mg/kg intravenously every 12 hours plus ceftriaxone, 1 g intravenously every 24 hours
Osteomyelitis	<i>S aureus</i>	Nafcillin, 2 g intravenously every 4 hours; or ceftazolin, 2 g intravenously every 8 hours
Septic arthritis	<i>S aureus</i> , <i>N gonorrhoeae</i>	Ceftriaxone, 1–2 g intravenously every 24 hours
Pyelonephritis with flank pain and fever (recurrent urinary tract infection)	<i>E coli</i> , <i>Klebsiella</i> , <i>Enterobacter</i> , <i>Pseudomonas</i>	Ceftriaxone, 1 g intravenously every 24 hours; or ciprofloxacin, 400 mg intravenously every 12 hours (500 mg orally); or levofloxacin, 500 mg once daily (intravenously/orally)
Fever in neutropenic patient receiving cancer chemotherapy	<i>S aureus</i> , <i>Pseudomonas</i> , <i>Klebsiella</i> , <i>E coli</i>	Ceftazidime, 2 g intravenously every 8 hours; or cefepime, 2 g intravenously every 8 hours
Intra-abdominal sepsis (eg, postoperative, peritonitis, cholecystitis)	Gram-negative bacteria, <i>Bacteroides</i> , anaerobic bacteria, streptococci, clostridia	Piperacillin-tazobactam, 4.5 g intravenously every 6 hours, or ertapenem, 1 g every 24 hours

¹Some strains may be resistant to penicillin.²Most studies on meningitis have been with cefotaxime or ceftriaxone (see text).³TMP-SMZ can be used to treat *Listeria monocytogenes* in patients allergic to penicillin in a dosage of 15–20 mg/kg/d of TMP in three or four divided doses.⁴Depending on local drug susceptibility pattern, use tobramycin, 5 mg/kg/d, or amikacin, 15 mg/kg/d, in place of gentamicin.⁵Levofloxacin 750 mg/d, moxifloxacin 400 mg/d.

Table 30-6. Examples of empiric choices of antimicrobials for adult outpatient infections.

Suspected Clinical Diagnosis	Likely Etiologic Agents	Drugs of Choice	Alternative Drugs
Erysipelas, impetigo, cellulitis, ascending lymphangitis	Group A streptococcus	Phenoxymethyl penicillin, 0.5 g orally four times daily for 7-10 days	Cephalexin, 0.5 g orally four times daily for 7-10 days; or azithromycin, 500 mg on day 1 and 250 mg on days 2-5
Furuncle with surrounding cellulites	<i>Staphylococcus aureus</i>	Dicloxacillin, 0.5 g orally four times daily for 7-10 days (If high-risk for MRSA, clindamycin 0.3 g orally four times daily for 7-10 days)	Cephalexin, 0.5 g orally four times daily for 7-10 days. (If high-risk for MRSA, TMP-SMZ two double strength tablets twice daily for 7-10 days)
Pharyngitis	Group A streptococcus	Phenoxymethyl penicillin, 0.5 g orally four times daily for 10 days	Clindamycin, 300 mg orally four times daily for 10 days; or erythromycin, 0.5 g orally four times daily for 10 days; or azithromycin, 500 mg on day 1 and 250 mg on days 2-5; or clarithromycin, 500 mg twice daily for 10 days
Otitis media	<i>Streptococcus pneumoniae</i> , <i>Haemophilus influenzae</i> , <i>Moraxella catarrhalis</i>	Amoxicillin, 0.5-1 g orally three times daily for 10 days	Augmentin, ² 0.875 g orally twice daily; or cefuroxime, 0.5 g orally twice daily; or cefpodoxime, 0.2-0.4 g daily; or doxycycline, 100 mg twice daily; or TMP-SMZ, ¹ one double-strength tablet twice daily (all regimens for 10 days).
Acute sinusitis	<i>S pneumoniae</i> , <i>H influenzae</i> , <i>M catarrhalis</i>	Amoxicillin, 0.5-1 g orally three times daily; or TMP-SMZ, one double-strength tablet twice daily for 10 days	Augmentin, ² 0.875 g orally twice daily; or cefuroxime, 0.5 g orally twice daily; or cefpodoxime, 0.2-0.4 g daily; or doxycycline, 100 mg twice daily (all regimens for 10 days)
Aspiration pneumonia	Mixed oropharyngeal flora, including anaerobes	Clindamycin, 0.3 g orally four times daily for 10-14 days	Phenoxymethyl penicillin, 0.5 g orally four times daily for 10-14 days
Pneumonia	<i>S pneumoniae</i> , <i>Mycoplasma pneumoniae</i> , <i>Legionella pneumophila</i> , <i>Chlamydia pneumoniae</i>	Doxycycline, 100 mg orally twice daily; or clarithromycin, 0.5 g orally twice daily, for 10-14 days; or azithromycin, 0.5 g orally on day 1 and 0.25 g on days 2-5	Amoxicillin, 0.5-1.0 g orally four times daily; or a fluoroquinolone ⁵ for 10-14 days
Cystitis	<i>Escherichia coli</i> , <i>Klebsiella pneumoniae</i> , <i>Proteus</i> species, <i>Staphylococcus saprophyticus</i>	Fluoroquinolones, ⁴ 3 days for uncomplicated cystitis, nitrofurantoin macrocrystals, 100 mg orally four times daily for 7 days; nitrofurantoin monohydrate macrocrystals, 100 mg twice daily for 7 days	TMP-SMZ, ¹ one double-strength tablet twice daily for 3 days; or cephalexin, 0.5 g orally four times daily for 7 days
Pyelonephritis	<i>E coli</i> , <i>K pneumoniae</i> , <i>Proteus</i> species, <i>S saprophyticus</i>	Fluoroquinolones ⁴ for 7-14 days	TMP-SMZ, ¹ one double-strength tablet twice daily for 7-14 days
Gastroenteritis	<i>Salmonella</i> , <i>Shigella</i> , <i>Campylobacter</i> , <i>Entamoeba histolytica</i>	See Note 3	
Urethritis, epididymitis	<i>Neisseria gonorrhoeae</i> , <i>Chlamydia trachomatis</i>	Ceftriaxone, 250 mg intramuscularly once or cefixime 400 mg orally once or cefpodoxime 200-400 mg orally once, for <i>N gonorrhoeae</i> ; plus doxycycline, 100 mg orally twice daily for 10 days, for <i>C trachomatis</i>	Ciprofloxacin, 500 mg orally once, for <i>N gonorrhoeae</i> ; plus doxycycline, 100 mg orally twice daily for 10 days, or ofloxacin, 300 mg orally twice daily for 10 days

(continued)

Table 30-6. Examples of empiric choices of antimicrobials for adult outpatient infections. (continued)

Suspected Clinical Diagnosis	Likely Etiologic Agents	Drugs of Choice	Alternative Drugs
Pelvic inflammatory disease	<i>N gonorrhoeae</i> , <i>C trachomatis</i> , anaerobes, gram-negative rods	Levofloxacin 500 mg orally daily, or ofloxacin, 400 mg orally twice daily, for 14 days, plus metronidazole, 500 mg orally twice daily, for 14 days	Cefoxitin, 2 g intramuscularly, with probenecid, 1 g orally, followed by doxycycline, 100 mg orally twice daily for 14 days; or ceftriaxone, 250 mg intramuscularly once, followed by doxycycline, 100 mg orally twice daily for 14 days
Syphilis			
Early syphilis (primary, secondary, or latent of < 1 year's duration)	<i>Treponema pallidum</i>	Benzathine penicillin G, 2.4 million units intramuscularly once	Doxycycline, 100 mg orally twice daily for 2 weeks
Latent syphilis of > 1 year's duration or cardiovascular syphilis	<i>T pallidum</i>	Benzathine penicillin G, 2.4 million units intramuscularly once a week for 3 weeks (total: 7.2 million units)	Doxycycline, 100 mg orally twice daily, for 4 weeks
Neurosyphilis	<i>T pallidum</i>	Aqueous penicillin G, 12-24 million units/d intravenously for 10-14 days	

¹TMP-SMZ is a fixed combination of 1 part trimethoprim and 5 parts sulfamethoxazole. Single-strength tablets: 80 mg TMP, 400 mg SMZ; double-strength tablets: 160 mg TMP, 800 mg SMZ.

²Augmentin is a combination of amoxicillin, 250 mg, 500 mg, or 875 mg, plus 125 mg of clavulanic acid. Augmentin XR is a combination of amoxicillin 1 g and clavulanic acid 62.5 mg.

³The diagnosis should be confirmed by culture before therapy. *Salmonella* gastroenteritis does not require therapy. For susceptible *Shigella* isolates, give ciprofloxacin, 0.5 g orally twice daily for 5 days; or TMP-SMZ double-strength tablets twice daily for 5 days; or ampicillin, 0.5 g orally four times daily for 5 days. For *Campylobacter* infection, give azithromycin, 1 g orally times one dose, or ciprofloxacin, 0.5 g orally twice daily for 5 days. For *E histolytica* infection, give metronidazole, 750 mg orally three times daily for 5-10 days, followed by diiodohydroxyquin, 600 mg orally three times daily for 3 weeks.

⁴Fluoroquinolones and dosages include ciprofloxacin, 500 mg orally twice daily; ofloxacin, 400 mg orally twice daily; levofloxacin, 500 mg orally daily.

⁵Fluoroquinolones with activity against *S pneumoniae*, including penicillin-resistant isolates, include levofloxacin (500-750 mg orally once daily) and moxifloxacin (400 mg orally once daily). Use fluoroquinolones as drug of choice if recent antibiotic use within 3 months or comorbidities present.

MRSA, methicillin-resistant *Staphylococcus aureus*; TMP-SMZ, trimethoprim-sulfamethoxazole.

and vancomycin; and extended-spectrum β -lactamase producing-*E coli* resistant to third-generation cephalosporins and fluoroquinolones.

Over the past several years, pharmaceutical companies have shifted away from developing and producing antibacterial medications, particularly those active against gram-negative pathogens. The lack of new drugs and increasing bacterial resistance reinforce the need to use these drugs judiciously. When culture and susceptibility results have been finalized, it is important to utilize the most narrow spectrum agent possible to decrease the selection pressure for antibacterial resistance.

Antimicrobial drug susceptibility tests may be performed on solid media as disk diffusion tests, in broth, in tubes, in wells of microdilution plates, or as E-tests (strips with increasing concentration of antibiotic). The latter three methods yield results expressed as MIC (minimal inhibitory concentration). In most infections, the MIC is the appropriate in vitro test to guide selection of an antibacterial agent. When there appear to be marked discrepancies

between susceptibility testing and clinical response, the following possibilities must be considered:

1. Selection of an inappropriate drug, drug dosage, or route of administration.
2. Failure to drain a collection of pus or to remove a foreign body.
3. Failure of a poorly diffusing drug to reach the site of infection (eg, central nervous system) or to reach intracellular phagocytosed bacteria.
4. Superinfection in the course of prolonged chemotherapy.
5. Emergence of drug-resistant organisms.
6. Participation of two or more microorganisms in the infectious process, of which only one was originally detected and used for drug selection.
7. Inadequate host defenses, including immunodeficiencies and diabetes.
8. Noninfectious causes, including drug fever, malignancy, and autoimmune disease.

F. Promptness of Response

Response depends on a number of factors, including the patient (immunocompromised patients respond slower than immunocompetent patients), the site of infection (deep-seated infections such as osteomyelitis and endocarditis respond more slowly than superficial infections such as cystitis or cellulitis), the pathogen (virulent organisms such as *S aureus* respond more slowly than viridans streptococci; mycobacterial and fungal infections respond slower than bacterial infections), and the duration of illness (in general, the longer the symptoms are present, the longer it takes to respond). Thus, depending on the clinical situation, persistent fever and leukocytosis several days after initiation of therapy may not indicate improper choice of antibiotics but may be due to the natural history of the disease being treated. In most infections, either a bacteriostatic or a bactericidal agent can be used. In some infections (eg, infective endocarditis and meningitis), a bactericidal agent should be used. When potentially toxic drugs (eg, aminoglycosides, flucytosine) are used, serum levels of the drug are measured to minimize toxicity and ensure appropriate dosage. In patients with altered renal or hepatic clearance of drugs, the dosage or frequency of administration must be adjusted; it is best to measure levels in the elderly, morbidly obese patients, or those with altered kidney function when possible and adjust therapy accordingly.

G. Duration of Antimicrobial Therapy

Generally, effective antimicrobial treatment results in reversal of the clinical and laboratory parameters of active infection and marked clinical improvement. However, varying periods of treatment may be required for cure. Key factors include (1) the type of infecting organism (bacterial infections generally can be cured more rapidly than fungal or mycobacterial ones), (2) the location of the process (eg, endocarditis and osteomyelitis require prolonged therapy), and (3) the immunocompetence of the patient. Recommendations about duration of therapy are often given based on clinical experience, not prospective controlled studies of large numbers of patients.

H. Adverse Reactions and Toxicity

These include hypersensitivity reactions, direct toxicity, superinfection by drug-resistant microorganisms, and drug interactions. If the infection is life threatening and treatment cannot be stopped, the reactions are managed symptomatically or another drug is chosen that does not cross-react with the offending one (Table 30–4). If the infection is less serious, it may be possible to stop all antimicrobials and monitor the patient closely.

I. Route of Administration

Intravenous therapy is preferred for acutely ill patients with serious infections (eg, endocarditis, meningitis, sepsis, severe pneumonia) when dependable levels of antibiotics are required for successful therapy. Certain drugs (eg, fluconazole, voriconazole, rifampin, metronidazole,

TMP-SMZ, and fluoroquinolones) are so well absorbed that they generally can be administered orally in seriously ill—but not hemodynamically unstable—patients.

Food does not significantly influence the bioavailability of most oral antimicrobial agents. However, the tetracyclines and the quinolones chelate multivalent cations resulting in decreased antibacterial absorption. Azithromycin capsules are associated with decreased bioavailability when taken with food and should be given 1 hour before or 2 hours after meals. Posaconazole solution should always be administered with food.

A major complication of intravenous antibiotic therapy is catheter infections. Peripheral catheters are changed every 48–72 hours to prevent phlebitis, and antimicrobial-coated central venous catheters (minocycline and rifampin, chlorhexidine and sulfadiazine) have been associated with a decreased incidence of catheter-related infections. Most of these infections present with local signs of infection (erythema, tenderness) at the insertion site. In a patient with fever who is receiving intravenous therapy, the catheter must always be considered a potential source. Small-gauge (20–23F) peripherally inserted silicone or polyurethane catheters (Per Q Cath, A-Cath, Ven-A-Cath, and others) are associated with a low infection rate and can be maintained for 3–6 months without replacement. Such catheters are ideal for long-term outpatient antibiotic therapy.

J. Cost of Antibiotics

The cost of these agents can be substantial. In addition to acquisition cost, monitoring costs, (drug levels, liver function tests, electrolytes, etc), the cost of treating adverse reactions, the cost of treatment failure, and the costs associated with drug administration must be considered.

Boucher HW et al. Bad bugs, no drugs: no ESCAPE! An update from the Infectious Diseases Society of America. *Clin Infect Dis*. 2009 Jan 1;48(1):1–12. [PMID: 19035777]
Drusano GL. Antimicrobial pharmacodynamics: critical interactions of 'bug and drug'. *Nat Rev Microbiol*. 2004 Apr;2(4):289–300. [PMID: 15031728]

HYPERSENSITIVITY TESTS & DESENSITIZATION

▶ Penicillin Allergy

All penicillins are cross-sensitizing and cross-reacting. The responsible antigenic determinants appear to be degradation products of penicillins, particularly penicilloic acid and products of alkaline hydrolysis (minor antigenic determinants) bound to host protein. Skin tests with penicilloyl-polylysine, with minor antigenic determinants, and with degraded penicillin can identify most individuals with IgE-mediated reactions (hives, bronchospasm). Among positive reactors to skin tests, the incidence of subsequent immediate severe penicillin reactions is high. Although IgG antibodies to antigenic determinants of penicillin develop in many persons, the presence of such antibodies is not correlated with allergic reactivity (except for rare instances of

hemolytic anemia), and serologic tests have little predictive value. A history of a penicillin reaction in the past is often not reliable. Only 15–20% of patients with a history of penicillin allergy have an adverse reaction when challenged with the drug. The decision to administer penicillin or related drugs (other β -lactams) to patients with an allergic history depends on the severity of the reported reaction, the severity of the infection being treated, and the availability of alternative drugs. For patients with a history of severe reaction (anaphylaxis), alternative drugs should be used. In the rare situations when there is a strong indication for using penicillin (eg, syphilis in pregnancy) in allergic patients, desensitization can be performed. If the reaction is mild (nonurticarial rash), the patient may be rechallenged with penicillin or may be given another β -lactam antibiotic.

Allergic reactions include anaphylaxis, serum sickness (urticaria, fever, joint swelling, angioedema 7–12 days after exposure), skin rashes, fever, interstitial nephritis, eosinophilia, hemolytic anemia, other hematologic disturbances, and vasculitis. The incidence of hypersensitivity to penicillin is estimated to be 1–5% among adults in the United States. Life-threatening anaphylactic reactions are very rare (0.05%). Ampicillin produces maculopapular skin rashes more frequently than other penicillins, but many ampicillin (and other β -lactam) rashes are not allergic in origin. The non-allergic ampicillin rash usually occurs after 3–4 days of therapy, is maculopapular, is more common in patients with coexisting viral illness (especially Epstein-Barr infection), and resolves with continued therapy. The maculopapular rash may or may not reappear with challenge. Rarely, penicillins can induce nephritis with primary tubular lesions associated with anti-basement membrane antibodies.

If the intradermal test described below is negative, desensitization is not necessary, and a full dose of the material may be given. If the test is positive, alternative drugs should be strongly considered. If that is not feasible, desensitization is necessary.

Patients with a history of allergy to penicillin are also at an increased risk for having a reaction to **cephalosporins** or **carbapenems**. Skin testing with carbapenems has been recommended in patients with confirmed accelerated reaction to penicillins. A common approach to these patients is to assess the severity of the reaction. If an IgE-mediated reaction to penicillin can be excluded by history, a cephalosporin can be administered. When the history justifies concern about an immediate-type reaction, penicillin skin testing should be performed. If the test is negative, the cephalosporin or carbapenem can be given. If the test is positive, there is a 5–10% chance of cross reactivity with cephalosporins, and the decision whether to use cephalosporins depends on the availability of alternative agents and the severity of the infection. While carbapenems historically have been considered highly cross reactive with penicillins, the cross reactivity appears to be minimal (1–5%).

▶ Intradermal Test for Hypersensitivity

Penicillin is the drug that most frequently serves as an indication for sensitivity testing and desensitization. A clinical

history of penicillin allergy has a positive predictive value of only 15%. IgG-mediated delayed reactions such as erythematous or maculopapular skin rash or serum sickness should be distinguished from immediate-type IgE-mediated reactions, such as urticaria, angioedema, and anaphylaxis.

Penicillin skin testing traditionally was used to identify those patients with an accelerated reaction to penicillin. This process involves the introduction of penicillin breakdown products by intradermal or prick application to detect a localized allergic reaction. At the present time, no products are available for penicillin allergy skin testing. In 2004, the only commercially available product (Pre-Pen; HollisterStier Laboratories; Spokane, Washington) was voluntarily withdrawn by the manufacturer from US and Canadian markets due to product irregularities. However, AllerQuest (West Hartford, Connecticut) is pursuing approval from the US Food and Drug Administration to manufacture and market Pre-Pen.

▶ Desensitization

A. Precautions

1. The desensitization procedure is not innocuous—deaths from anaphylaxis have been reported. If extreme hypersensitivity is suspected, it is advisable to use an alternative structurally unrelated drug and to reserve desensitization for situations when treatment cannot be withheld and no alternative drug is available.
2. An antihistaminic drug (25–50 mg of hydroxyzine or diphenhydramine intramuscularly or orally) should be administered before desensitization is begun in order to lessen any reaction that occurs.
3. Desensitization should be conducted in an intensive care unit where cardiac monitoring and emergency endotracheal intubation can be performed.
4. Epinephrine, 1 mL of 1:1000 solution, must be ready for immediate administration.

B. Desensitization Method

Several methods of desensitization have been described for penicillin, including use of both oral and intravenous preparations. All methods start with very small doses of drug and gradually increase the dose until therapeutic doses are achieved. For penicillin, 1 unit of drug is given intravenously and the patient observed for 15–30 minutes. If there is no reaction, some recommend doubling the dose while others recommend increasing it tenfold every 15–30 minutes until a dosage of 2 million units is reached; then give the remainder of the desired dose.

For recommendations on skin testing and desensitization for other preparations (eg, botulism antitoxin and diphtheria antitoxin), the manufacturer's package inserts should be consulted.

▶ Treatment of Reactions

A. Mild Reactions

If a mild reaction occurs, drop back to the next lower dose and continue with desensitization. If a severe reaction

occurs, administer epinephrine (see below) and discontinue the drug unless treatment is urgently needed. If desensitization is imperative, continue slowly, increasing the dosage of the drug more gradually.

B. Severe Reactions

If bronchospasm occurs, epinephrine, 0.3–0.5 mL of 1:1000 dilution, should be given subcutaneously every 10–20 minutes, followed by corticosteroids (250 mg of hydrocortisone or 50 mg of methylprednisolone intravenously every 6 hours for two to four doses), if needed. Hypotension should be treated with intravenous fluids (saline or colloid), epinephrine (1 mL of 1:1000 dilution in 500 mL of D₅W intravenously at a rate of 0.5–5 mcg/min), and antihistamines (25–50 mg of hydroxyzine or diphenhydramine intramuscularly or orally every 6–8 hours as needed). Cutaneous reactions, manifested as urticaria or angioedema, respond to epinephrine subcutaneously and antihistamines in the doses set forth above.

Arroliga ME et al. Penicillin allergy: consider trying penicillin again. *Cleve Clin J Med.* 2003 Apr;70(4):313–4, 317–8, 320–1 passim. [PMID: 12701985]
Gruchalla RS et al. Clinical practice. Antibiotic allergy. *N Engl J Med.* 2006 Feb 9;354(6):601–9. [PMID: 16467547]

IMMUNIZATION AGAINST INFECTIOUS DISEASES

RECOMMENDED IMMUNIZATION OF INFANTS, CHILDREN, & ADOLESCENTS

The recommended schedules and dosages of vaccination change often, so the manufacturer's package inserts should always be consulted.

The schedule for active immunizations in children can be accessed at www.cdc.gov/vaccines/recs/schedules. All adolescents should see a health care provider to ensure vaccination of those who have not received varicella or hepatitis B vaccine, to make certain that a second dose of MMR has been given, to receive a booster of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine (Tdap adolescent preparation), to receive meningococcal vaccine conjugate vaccine, to obtain HPV vaccine if not given previously, and to receive immunizations (influenza and pneumococcal vaccines) that may be indicated for certain high-risk individuals.

RECOMMENDED IMMUNIZATION FOR ADULTS

Immunization is one of the most important tools (along with sanitation) used to prevent morbidity and mortality from infectious diseases. In general, the administration of most vaccinations induces a durable antibody response (active immunity). In contrast, passive immunization occurs when preformed antibodies are given (eg, immune globulin from pooled serum), resulting in temporary protection which is a less durable response. The two variants of active immunization are live attenuated vaccines (which

are believed to result in an immunologic response more like natural infection), and inactivated or killed vaccines.

The schedule of vaccinations varies based on the risk of the disease being prevented by vaccination, whether a vaccine has been given previously, the immune status of the patient (probability of responding to vaccine) and safety of the vaccine (live versus killed product, as well implications for the fetus in pregnant women). Recommendations for healthy adults as well as special populations based on medical conditions are summarized in Table 30–7, which can be accessed online at www.cdc.gov/vaccines/recs/schedules.

1. Healthy Adults

Vaccination recommendations are made by the Advisory Committee on Immunization Practices (ACIP) of the US Centers for Disease Control and Prevention (Table 30–7). In general, all adults should be immune to diphtheria, tetanus, varicella, measles, mumps and rubella, and vaccinated if not immune. Pertussis (via Tdap) boosters should be given once to all adults younger than 65 years, including pregnant women but after the end of the second trimester. A pertussis booster should be administered to persons aged 65 years and older if there is close child contact. The following vaccines are recommended for certain adult subgroups: HPV (women and men up to age 26), herpes zoster (adults aged 60 years and older), hepatitis A (men who have sex with men, injection drug users, patients with chronic liver disease), hepatitis B (sexually active adults, injection drug users, health care workers, patients with chronic kidney and liver disease, and patients with diabetes mellitus under the age of 60 years), and meningococcal vaccination (college freshmen, military recruits, patients with asplenia and terminal complement deficiencies). Pneumococcal polysaccharide vaccination (PPSV23) should be offered to persons 65 years and older, any adult with chronic medical comorbidities, and all cigarette smokers. Influenza vaccination should be offered annually to all persons aged 6 months and older.

2. Pregnant Women

Given the uncertainty of risks to the fetus, vaccination during pregnancy is generally avoided with the following exceptions: tetanus (transfer of maternal antibodies across the placenta important to prevent neonatal tetanus), diphtheria, and influenza. Live vaccines are avoided during pregnancy. If the woman is pregnant and > 10 years has elapsed since tetanus and diphtheria toxoid vaccine (Td), then a Td booster vaccination should be given during the second or third trimester. ACIP also recommends prevention of pertussis in pregnant women (given the repercussions of transmission to the infant) since immunity wanes by adulthood. Women should therefore receive the combined tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine (Tdap) if possible. Tdap can be administered prior to conception, late in second trimester (> 20 weeks gestation), or in the immediate postpartum period if the mother has not previously received Tdap or if she only received Td during pregnancy.

Table 30-7. Recommended adult immunization schedule—United States, 2012.**Recommended Adult Immunization Schedule—United States - 2012**

Note: These recommendations must be read with the footnotes that follow containing number of doses, intervals between doses, and other important information.

Recommended adult immunization schedule, by vaccine and age group¹

VACCINE ▼	AGE GROUP ►	19-21 years	22-26 years	27-49 years	50-59 years	60-64 years	≥ 65 years
Influenza ²		1 dose annually					
Tetanus, diphtheria, pertussis (Td/Tdap) ^{3,*}		Substitute 1-time dose of Tdap for Td booster; then boost with Td every 10 yrs					
Varicella ^{4,*}		2 Doses					
Human papillomavirus (HPV) Female ^{5,*}		3 doses					
Human papillomavirus (HPV) Male ^{5,*}		3 doses					
Zoster ⁶						1 dose	
Measles, mumps, rubella (MMR) ^{7,*}		1 or 2 doses				1 dose	
Pneumococcal (polysaccharide) ^{8,9}		1 or 2 doses					1 dose
Meningococcal ^{10,*}		1 or more doses					
Hepatitis A ^{11,*}		2 doses					
Hepatitis B ^{12,*}		3 doses					

*Covered by the Vaccine Injury Compensation Program



For all persons in this category who meet the age requirements and who lack documentation of vaccination or have no evidence of previous infection



Recommended if some other risk factor is present (e.g., on the basis of medical, occupational, lifestyle, or other indications)



Tdap recommended for ≥65 if contact with <12 month old child. Either Td or Tdap can be used if no infant contact



No recommendation

Report all clinically significant postvaccination reactions to the Vaccine Adverse Event Reporting System (VAERS). Reporting forms and instructions on filing a VAERS report are available at www.vaers.hhs.gov or by telephone, 800-822-7967.

Information on how to file a Vaccine Injury Compensation Program claim is available at www.hrsa.gov/vaccinecompensation or by telephone, 800-338-2382. To file a claim for vaccine injury, contact the U.S. Court of Federal Claims, 717 Madison Place, N.W., Washington, D.C. 20005; telephone, 202-357-6400.

Additional information about the vaccines in this schedule, extent of available data, and contraindications for vaccination is also available at www.cdc.gov/vaccines or from the CDC-INFO Contact Center at 800-CDC-INFO (800-232-4636) in English and Spanish, 8:00 a.m. - 8:00 p.m. Eastern Time, Monday - Friday, excluding holidays.

Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of Health and Human Services.

Vaccines that might be indicated for adults based on medical and other indications¹

VACCINE ▼	INDICATION ►	Pregnancy	Immunocompromising conditions (excluding human immunodeficiency virus [HIV]) ^{4,6,7,14}	HIV infection ^{4,7,13,14} CD4+ T lymphocyte count		Men who have sex with men (MSM)	Heart disease, chronic lung disease, chronic alcoholism	Asplenia ¹³ (including elective splenectomy and persistent complement component deficiencies)	Chronic liver disease	Diabetes, kidney failure, end-stage renal disease, receipt of hemodialysis	Health-care personnel
				<200 cells/ μL	>200 cells/ μL						
Influenza ²		1 dose TIV annually				1 dose TIV or LAIV annually	1 dose TIV annually				1 dose TIV or LAIV annually
Tetanus, diphtheria, pertussis (Td/Tdap) ^{3,*}	Substitute 1-time dose of Tdap for Td booster; then boost with Td every 10 yrs										
Varicella ^{4,*}	Contraindicated	2 doses									
Human papillomavirus (HPV) Female ^{5,*}	3 doses through age 26 yrs				3 doses through age 26 yrs						
Human papillomavirus (HPV) Male ^{5,*}	3 doses through age 26 yrs				3 doses through age 21 yrs						
Zoster ⁶	Contraindicated	1 dose									
Measles, mumps, rubella (MMR) ^{7,*}	Contraindicated	1 or 2 doses									
Pneumococcal (polysaccharide) ^{8,9}	1 or 2 doses										
Meningococcal ^{10,*}	1 or more doses										
Hepatitis A ^{11,*}	2 doses										
Hepatitis B ^{12,*}	3 doses										

*Covered by the Vaccine Injury Compensation Program

The recommendations in this schedule were approved by the Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices (ACIP), the American Academy of Family Physicians (AAFP), the American College of Physicians (ACP), American College of Obstetricians and Gynecologists (ACOG) and American College of Nurse-Midwives (ACNM).

For all persons in this category who meet the age requirements and who lack documentation of vaccination or have no evidence of previous infection
 Recommended if some other risk factor is present (e.g., on the basis of medical, occupational, lifestyle, or other indications)
 Contraindicated
 No recommendation

These schedules indicate the recommended age groups and medical indications for which administration of currently licensed vaccines is commonly indicated for adults ages 19 years and older, as of January 1, 2012. For all vaccines being recommended on the Adult Immunization Schedule: a vaccine series does not need to be restarted, regardless of the time that has elapsed between doses. Licensed combination vaccines may be used whenever any components of the combination are indicated and when the vaccine's other components are not contraindicated. For detailed recommendations on all vaccines, including those used primarily for travelers or that are issued during the year, consult the manufacturers' package inserts and the complete statements from the Advisory Committee on Immunization Practices (www.cdc.gov/vaccines/pubs/acip-list.htm). Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of Health and Human Services.



U.S. Department of Health and Human Services
Centers for Disease Control and Prevention

(continued)

Table 30–7. Recommended adult immunization schedule—United States, 2012. (continued)**Footnotes — Recommended Adult Immunization Schedule—United States - 2012****1. Additional information**

- Advisory Committee on Immunization Practices (ACIP) vaccine recommendations and additional information are available at: <http://www.cdc.gov/vaccines/pubs/acip-list.htm>.
- Information on travel vaccine requirements and recommendations (e.g., for hepatitis A and B, meningococcal, and other vaccines) available at <http://wwwnc.cdc.gov/travel/page/vaccinations.htm>.

2. Influenza vaccination

- Annual vaccination against influenza is recommended for all persons 6 months of age and older.
- Persons 6 months of age and older, including pregnant women, can receive the trivalent inactivated vaccine (TIV).
- Healthy, nonpregnant adults younger than age 50 years without high-risk medical conditions can receive either intranasally administered live, attenuated influenza vaccine (LAIV) (FluMist), or TIV. Health-care personnel who care for severely immunocompromised persons (i.e., those who require care in a protected environment) should receive TIV rather than LAIV. Other persons should receive TIV.
- The intramuscular or intradermal administered TIV are options for adults aged 18–64 years.
- Adults aged 65 years and older can receive the standard dose TIV or the high-dose TIV (Fluzone High-Dose).

3. Tetanus, diphtheria, and acellular pertussis (Td/Tdap) vaccination

- Administer a one-time dose of Tdap to adults younger than age 65 years who have not received Tdap previously or for whom vaccine status is unknown to replace one of the 10-year Td boosters.
- Tdap is specifically recommended for the following persons:
 - pregnant women more than 20 weeks' gestation,
 - adults, regardless of age, who are close contacts of infants younger than age 12 months (e.g., parents, grandparents, or child care providers), and
 - health-care personnel.
- Tdap can be administered regardless of interval since the most recent tetanus or diphtheria-containing vaccine.
- Pregnant women not vaccinated during pregnancy should receive Tdap immediately postpartum.
- Adults 65 years and older may receive Tdap.
- Adults with unknown or incomplete history of completing a 3-dose primary vaccination series with Td-containing vaccines should begin or complete a primary vaccination series. Tdap should be substituted for a single dose of Td in the vaccination series with Tdap preferred as the first dose.
- For unvaccinated adults, administer the first 2 doses at least 4 weeks apart and the third dose 6–12 months after the second.
- If incompletely vaccinated (i.e., less than 3 doses), administer remaining doses.

Refer to the ACIP statement for recommendations for administering Td/Tdap as prophylaxis in wound management (See footnote 1).

4. Varicella vaccination

- All adults without evidence of immunity to varicella (as defined below) should receive 2 doses of single-antigen varicella vaccine or a second dose if they have received only 1 dose.
- Special consideration for vaccination should be given to those who
 - have close contact with persons at high risk for severe disease (e.g., health-care personnel and family contacts of persons with immunocompromising conditions) or
 - are at high risk for exposure or transmission (e.g., teachers; child care employees; residents and staff members of institutional settings, including correctional institutions; college students; military personnel; adolescents and adults living in households with children; nonpregnant women of childbearing age; and international travelers).
- Pregnant women should be assessed for evidence of varicella immunity. Women who do not have evidence of immunity should receive the first dose of varicella vaccine upon completion or termination of pregnancy and before discharge from the health-care facility. The second dose should be administered 4–8 weeks after the first dose.
- Evidence of immunity to varicella in adults includes any of the following:
 - documentation of 2 doses of varicella vaccine at least 4 weeks apart;
 - U.S.-born before 1980 (although for health-care personnel and pregnant women, birth before 1980 should not be considered evidence of immunity);
 - history of varicella based on diagnosis or verification of varicella by a health-care provider (for a patient reporting a history of or having an atypical case, a mild case, or both, health-care providers should seek either an epidemiologic link to a typical varicella case or to a
 - laboratory-confirmed case or evidence of laboratory confirmation, if it was performed at the time of acute disease);
 - history of herpes zoster based on diagnosis or verification of herpes zoster by a health-care provider; or
 - laboratory evidence of immunity or laboratory confirmation of disease.

5. Human papillomavirus (HPV) vaccination

- Two vaccines are licensed for use in females, bivalent HPV vaccine (HPV2) and quadrivalent HPV vaccine (HPV4), and one HPV vaccine for use in males (HPV4).
- For females, either HPV4 or HPV2 is recommended in a 3-dose series for routine vaccination at 11 or 12 years of age, and for those 13 through 26 years of age, if not previously vaccinated.
- For males, HPV4 is recommended in a 3-dose series for routine vaccination at 11 or 12 years of age, and for those 13 through 21 years of age, if not previously vaccinated. Males 22 through 26 years of age may be vaccinated.
- HPV vaccines are not live vaccines and can be administered to persons who are immunocompromised as a result of infection (including HIV infection), disease, or medications. Vaccine is recommended for immunocompromised persons through age 26 years who did not get any or all doses when they were younger. The immune response and vaccine efficacy might be less than that in immunocompetent persons.
- Men who have sex with men (MSM) might especially benefit from vaccination to prevent condyloma and anal cancer. HPV4 is recommended for MSM through age 26 years who did not get any or all doses when they were younger.
- Ideally, vaccine should be administered before potential exposure to HPV through sexual activity; however, persons who are sexually active should still be vaccinated consistent with age-based recommendations. HPV vaccine can be administered to persons with a history of genital warts, abnormal Papanicolaou test, or positive HPV DNA test.
- A complete series for either HPV4 or HPV2 consists of 3 doses. The second dose should be administered 1–2 months after the first dose; the third dose should be administered 6 months after the first dose (at least 24 weeks after the first dose).
- Although HPV vaccination is not specifically recommended for health-care personnel (HCP) based on their occupation, HCP should receive the HPV vaccine if they are in the recommended age group.

6. Zoster vaccination

- A single dose of zoster vaccine is recommended for adults 60 years of age and older regardless of whether they report a prior episode of herpes zoster. Although the vaccine is licensed by the Food and Drug Administration (FDA) for use among and can be administered to persons 50 years and older, ACIP recommends that vaccination begins at 60 years of age.
- Persons with chronic medical conditions may be vaccinated unless their condition constitutes a contraindication, such as pregnancy or severe immunodeficiency.
- Although zoster vaccination is not specifically recommended for health-care personnel (HCP), HCP should receive the vaccine if they are in the recommended age group.

7. Measles, mumps, rubella (MMR) vaccination

- Adults born before 1957 generally are considered immune to measles and mumps. All adults born in 1957 or later should have documentation of 1 or more doses of MMR vaccine unless they have a medical contraindication to the vaccine, laboratory evidence of immunity to each of the three diseases, or documentation of provider-diagnosed measles or mumps disease. For rubella, documentation of provider-diagnosed disease is not considered acceptable evidence of immunity.

Measles component:

- A routine second dose of MMR vaccine, administered a minimum of 28 days after the first dose, is recommended for adults who
 - are students in postsecondary educational institutions;
 - work in a health-care facility; or
 - plan to travel internationally.
- Persons who received inactivated (killed) measles vaccine or measles vaccine of unknown type from 1963 to 1967 should be revaccinated with 2 doses of MMR vaccine.

Mumps component:

- A routine second dose of MMR vaccine, administered a minimum of 28 days after the first dose, is recommended for adults who
 - are students in postsecondary educational institutions;
 - work in a health-care facility; or
 - plan to travel internationally.
- Persons vaccinated before 1979 with either killed mumps vaccine or mumps vaccine of unknown type who are at high risk for mumps infection (e.g., persons who are working in a health-care facility) should be considered for revaccination with 2 doses of MMR vaccine.

Rubella component:

- For women of childbearing age, regardless of birth year, rubella immunity should be determined. If there is no evidence of immunity, women who are not pregnant should be vaccinated. Pregnant women who do not have evidence of immunity should receive MMR vaccine upon completion or termination of pregnancy and before discharge from the health-care facility.

Health-care personnel born before 1957:

- For unvaccinated health-care personnel born before 1957 who lack laboratory evidence of measles, mumps, and/or rubella immunity or laboratory confirmation of disease, health-care facilities should consider routinely vaccinating personnel with 2 doses of MMR vaccine at the appropriate interval for measles and mumps or 1 dose of MMR vaccine for rubella.

(continued)

Table 30–7. Recommended adult immunization schedule—United States, 2012. (continued)**8. Pneumococcal polysaccharide (PPSV) vaccination**

- Vaccinate all persons with the following indications:
 - age 65 years and older without a history of PPSV vaccination;
 - adults younger than 65 years with chronic lung disease (including chronic obstructive pulmonary disease, emphysema, and asthma); chronic cardiovascular diseases; diabetes mellitus; chronic liver disease (including cirrhosis); alcoholism; cochlear implants; cerebrospinal fluid leaks; immunocompromising conditions; and functional or anatomic asplenia (e.g., sickle cell disease and other hemoglobinopathies, congenital or acquired asplenia, splenic dysfunction, or splenectomy [if elective splenectomy is planned, vaccinate at least 2 weeks before surgery]);
 - residents of nursing homes or long-term care facilities; and
 - adults who smoke cigarettes.
- Persons with asymptomatic or symptomatic HIV infection should be vaccinated as soon as possible after their diagnosis.
- When cancer chemotherapy or other immunosuppressive therapy is being considered, the interval between vaccination and initiation of immunosuppressive therapy should be at least 2 weeks. Vaccination during chemotherapy or radiation therapy should be avoided.
- Routine use of PPSV is not recommended for American Indians/Alaska Natives or other persons younger than 65 years of age unless they have underlying medical conditions that are PPSV indications. However, public health authorities may consider recommending PPSV for American Indians/Alaska Natives who are living in areas where the risk for invasive pneumococcal disease is increased.

9. Revaccination with PPSV

- One-time revaccination 5 years after the first dose is recommended for persons 19 through 64 years of age with chronic renal failure or nephrotic syndrome; functional or anatomic asplenia (e.g., sickle cell disease or splenectomy); and for persons with immunocompromising conditions.
- Persons who received PPSV before age 65 years for any indication should receive another dose of the vaccine at age 65 years or later if at least 5 years have passed since their previous dose.
- No further doses are needed for persons vaccinated with PPSV at or after age 65 years.

10. Meningococcal vaccination

- Administer 2 doses of meningococcal conjugate vaccine quadrivalent (MCV4) at least 2 months apart to adults with functional asplenia or persistent complement component deficiencies.
- HIV-infected persons who are vaccinated should also receive 2 doses.
- Administer a single dose of meningococcal vaccine to microbiologists routinely exposed to isolates of *Neisseria meningitidis*, military recruits, and persons who travel to or live in countries in which meningococcal disease is hyperendemic or epidemic.
- First-year college students up through age 21 years who are living in residence halls should be vaccinated if they have not received a dose on or after their 16th birthday.
- MCV4 is preferred for adults with any of the preceding indications who are 55 years old and younger; meningococcal polysaccharide vaccine (MPSV4) is preferred for adults 56 years and older.
- Revaccination with MCV4 every 5 years is recommended for adults previously vaccinated with MCV4 or MPSV4 who remain at increased risk for infection (e.g., adults with anatomic or functional asplenia or persistent complement component deficiencies).

11. Hepatitis A vaccination

- Vaccinate any person seeking protection from hepatitis A virus (HAV) infection and persons with any of the following indications:
 - men who have sex with men and persons who use injection drugs;
 - persons working with HAV-infected primates or with HAV in a research laboratory setting;
 - persons with chronic liver disease and persons who receive clotting factor concentrates;
 - persons traveling to or working in countries that have high or intermediate endemicity of hepatitis A; and
 - unvaccinated persons who anticipate close personal contact (e.g., household or regular babysitting) with an international adoptee during the first 60 days after arrival in the United States from a country with high or intermediate endemicity. (See footnote 1 for more information on travel recommendations). The first dose of the 2-dose hepatitis A vaccine series should be administered as soon as adoption is planned, ideally 2 or more weeks before the arrival of the adoptee.
- Single-antigen vaccine formulations should be administered in a 2-dose schedule at either 0 and 6–12 months (Havrix), or 0 and 6–18 months (Vaqta). If the combined hepatitis A and hepatitis B vaccine (Twinrix) is used, administer 3 doses at 0, 1, and 6 months; alternatively, a 4-dose schedule may be used, administered on days 0, 7, and 21–30 followed by a booster dose at month 12.

12. Hepatitis B vaccination

- Vaccinate persons with any of the following indications and any person seeking protection from hepatitis B virus (HBV) infection:
 - sexually active persons who are not in a long-term, mutually monogamous relationship (e.g., persons with more than one sex partner during the previous 6 months); persons seeking evaluation or treatment for a sexually transmitted disease (STD); current or recent injection-drug users; and men who have sex with men;
 - health-care personnel and public-safety workers who are exposed to blood or other potentially infectious body fluids;
 - persons with diabetes younger than 60 years as soon as feasible after diagnosis; persons with diabetes who are 60 years or older at the discretion of the treating clinician based on increased need for assisted blood glucose monitoring in long-term care facilities, likelihood of acquiring hepatitis B infection, its complications or chronic sequelae, and likelihood of immune response to vaccination;
 - persons with end-stage renal disease, including patients receiving hemodialysis; persons with HIV infection; and persons with chronic liver disease;
 - household contacts and sex partners of persons with chronic HBV infection; clients and staff members of institutions for persons with developmental disabilities; and international travelers to countries with high or intermediate prevalence of chronic HBV infection; and
 - all adults in the following settings: STD treatment facilities; HIV testing and treatment facilities; facilities providing drug-abuse treatment and prevention services; health-care settings targeting services to injection-drug users or men who have sex with men; correctional facilities; end-stage renal disease programs and facilities for chronic hemodialysis patients; and institutions and nonresidential daycare facilities for persons with developmental disabilities.
- Administer missing doses to complete a 3-dose series of hepatitis B vaccine to those persons not vaccinated or not completely vaccinated. The second dose should be administered 1 month after the first dose; the third dose should be given at least 2 months after the second dose (and at least 4 months after the first dose). If the combined hepatitis A and hepatitis B vaccine (Twinrix) is used, give 3 doses at 0, 1, and 6 months; alternatively, a 4-dose Twinrix schedule, administered on days 0, 7, and 21–30 followed by a booster dose at month 12 may be used.
- Adult patients receiving hemodialysis or with other immunocompromising conditions should receive 1 dose of 40 µg/mL (Recombivax HB) administered on a 3-dose schedule or 2 doses of 20 µg/mL (Engerix-B) administered simultaneously on a 4-dose schedule at 0, 1, 2, and 6 months.

13. Selected conditions for which *Haemophilus influenzae* type b (Hib) vaccine may be used

- 1 dose of Hib vaccine should be considered for persons who have sickle cell disease, leukemia, or HIV infection, or who have anatomic or functional asplenia if they have not previously received Hib vaccine.

14. Immunocompromising conditions

- Inactivated vaccines generally are acceptable (e.g., pneumococcal, meningococcal, and influenza [inactivated influenza vaccine]), and live vaccines generally are avoided in persons with immune deficiencies or immunocompromising conditions. Information on specific conditions is available at <http://www.cdc.gov/vaccines/pubs/acip-list.htm>.

Influenza can be a serious infection if acquired in pregnancy, and all pregnant women should be offered influenza (inactivated) vaccination. The live attenuated (intranasal) influenza vaccine is not recommended during pregnancy.

3. HIV-Infected Adults

HIV-infected patients have impaired cellular and B cell responses. Inactivated or killed vaccinations can generally be given without any consequence, but the recipient may not be able to mount an adequate antibody response. Live or attenuated vaccines are generally avoided with some exceptions (ie, in patients with CD4⁺ T lymphocytes > 200 cells/mcL). Guidelines for vaccinating HIV-infected patients have been issued jointly by the Centers for Disease Control and Prevention, the US National Institutes of Health, and the HIV Medical Association of the Infectious Diseases Society of America. The following non-live vaccines are recommended for all HIV-infected patients: tetanus and diphtheria toxoid (Tdap as a booster once, followed by Td boosters every 10 years), HPV (in women and men until age 26), inactivated influenza, pneumococcal polysaccharide (PPSV23), hepatitis A (for HIV-infected men who have sex with men, injection drug users, patients with chronic liver disease), hepatitis B, and meningococcal vaccines (two doses for those at risk). Several live vaccines are now recommended for eligible HIV-infected patients with CD4⁺ T cells > 200 cells/mcL: measles, mumps, and rubella (MMR); varicella; and zoster. Timing of vaccination is important to optimize response. If possible, vaccination should be given early in the course of HIV-disease, or following immune reconstitution.

4. Hematopoietic Cell Transplant Recipients

Hematopoietic cell transplant (HCT) recipients have varying rates of immune reconstitution following transplantation, depending on (1) the type of chemotherapy or radiotherapy used pretransplant (in autologous HCT), (2) the preparative regimen used for the transplant (3) whether graft-versus-host disease is present, and (4) the type of immunosuppression used posttransplantation (in allogeneic HCT). Vaccines may not work immediately in the posttransplant period. B cells may take 3–12 months to return to normal posttransplant, and naïve T cells that can respond to new antigens only appear 6–12 months posttransplant. B cells of posttransplant patients treated with rituximab may take up to 6 months to fully recover after the last dose of the drug. Vaccines are therefore administered 6–12 months following transplantation with a minimum of 1 month between doses to maximize the probability of response. The following vaccines are recommended for HCT recipients: tetanus, diphtheria and pertussis (three doses of Tdap, although full-dose DTaP currently given to children < 7 years may be more immunogenic), inactivated polio (three doses), *H influenzae* (three doses), pneumococcal vaccine (can start at 3 months posttransplant; use three doses of pneumococcal conjugate vaccine [PCV; more immunogenic but covers only 7 strains of pneumococcus], followed by the polysaccharide vaccine [PPSV23, covers 23 strains]), and inactivated influenza (annually). Patients

may receive the live vaccines of MMR and varicella if at least 24 months have passed since the transplant and if they do not have graft-versus-host disease and are not receiving immunosuppressive medications. However, data supporting these recommendations are limited.

5. Solid Organ Transplant Recipients

Solid organ transplant recipients demonstrate a broad spectrum of immunosuppression, depending on the reason for and type of organ transplanted and the nature of the immunosuppression (including T-cell depleting agents during treatment of organ rejection). These factors affect the propensity for infection posttransplantation and the ability to develop antibody responses to vaccination. In many cases, the time between placing a patient on a transplant list and undergoing the transplantation takes months or years. Providers should take this opportunity to ensure that indicated vaccines are given during this pretransplant period to optimize antibody responses. If this is not possible, most experts give vaccines 3–6 months following transplantation. Live vaccines are contraindicated in the posttransplant period. The American Society of Transplantation Infectious Diseases Community of Practice last issued vaccination guidelines in 2009. The following inactivated vaccines are recommended for patients posttransplantation if not given before transplantation: tetanus and diphtheria toxoid (Tdap as a booster once if no tetanus booster in the past 10 years, followed by Td boosters every 10 years), inactivated polio, HPV (until age 26), inactivated influenza, pneumococcal polysaccharide (PPSV23), hepatitis A (for HIV-infected men who have sex with men, injection drug users, patients with chronic liver disease), hepatitis B, and meningococcal vaccines (for those at risk).

RECOMMENDED IMMUNIZATIONS FOR TRAVELERS

Individuals traveling to other countries frequently require immunizations in addition to those routinely recommended and may benefit from chemoprophylaxis against various diseases. Vaccinations against yellow fever and meningococcus are the only ones required by certain countries. These and other travel-specific vaccines are listed <http://wwwnc.cdc.gov/travel/page/vaccinations.htm>.

Various vaccines can be given simultaneously at different sites. Some, such as cholera, plague, and typhoid vaccine, cause significant discomfort and are best given at different times. In general, live attenuated vaccines (measles, mumps, rubella, yellow fever, and oral typhoid vaccine) should not be given to immunosuppressed individuals or household members of immunosuppressed people or to pregnant women. Immunoglobulin should not be given for 3 months before or at least 2 weeks after live virus vaccines, because it may attenuate the antibody response.

Chemoprophylaxis of malaria is discussed in Chapter 35.

► Cholera

Because cholera among travelers is rare and the vaccine marginally effective, the World Health Organization (WHO) does not require immunization for persons traveling

to endemic areas or to areas with recent outbreaks (eg, Haiti). No country requires vaccination for entry, but some local authorities may require documentation for entry. In such cases, a medical waiver will suffice or a single dose of the oral vaccine is usually sufficient.

► Hepatitis B

The risk of hepatitis B infection for most international travelers is low. Hepatitis B vaccination should be considered for those traveling to areas with high ($\geq 8\%$) or intermediate (2–7%) rates of endemic hepatitis B infection if the individual will have contact with blood or secretions, have unprotected sex, or will be using illicit drugs. Examples of high and intermediate risk areas include all of Africa and most of South Asia and the Middle East. Vaccination should begin at least 6 months before travel to allow for completion of the series.

► Hepatitis A

Protection is recommended for susceptible persons traveling to areas where sanitation is poor and the risk of exposure to hepatitis A high because of contaminated food and water supplies and contact with infected persons (eg, anywhere except Canada, western Europe, Japan, Australia, and New Zealand). Either hepatitis A vaccine or immunoglobulin can be used, although vaccination is preferred. The first dose of vaccine should be given as soon as travel is considered. In healthy individuals, a single dose of vaccine administered any time prior to travel will provide adequate protection. In older patients, those who are immunocompromised, and those with chronic liver disease or other chronic medical problems who are planning to travel in 2 weeks or less should receive hepatitis A vaccine and immunoglobulin 0.02 mL/kg simultaneously at different anatomic sites. Those who choose not to receive vaccine should receive immunoglobulin.

► Meningococcal Meningitis

If travel is contemplated to an area where meningococcal meningitis is epidemic (Nepal, sub-Saharan Africa, the “meningitis belt” from Senegal in the west to Ethiopia in the east, northern India) or highly endemic, vaccination with MCV4 is indicated for those 2–55 years of age, otherwise MPSV should be used. (Saudi Arabia requires immunization for pilgrims to Mecca.)

► Plague

The risk of plague is so small to travelers that vaccine is no longer commercially available and vaccination is not required for entry into any country. Travelers at unavoidable high risk of exposure to rodents should consider chemoprophylaxis with doxycycline or TMP-SMZ.

► Poliomyelitis

Polio remains endemic in five countries (Afghanistan, India, Pakistan, Nigeria, and Niger), and sporadic outbreaks from reinfection continues to occur in Somalia, Ethiopia, Angola, and Bangladesh. Adults traveling to

endemic or epidemic areas who have not previously been immunized against poliomyelitis should receive a primary series of three doses of inactivated enhanced-potency poliovaccine (IPV). Travelers who have previously been fully immunized with oral polio vaccine (OPV) or inactivated polio vaccine (IPV) should receive a one-time booster dose with IPV. Live attenuated poliovaccine is no longer recommended because of the risk of vaccine-associated disease and is no longer available in the United States, although it continues to be used in many other countries.

► Rabies

For travelers to areas where rabies is common in domestic animals (eg, India, Asia, Mexico, Africa, areas of Central and South America), with extensive outdoor activities or certain professional activities (veterinarians, animal handlers, field biologists), preexposure prophylaxis with human diploid cell vaccine (HDCV), rabies vaccine adsorbed (RVA), or purified chick embryo cell culture (PCEC) vaccine should be considered. Chloroquine can blunt the immunologic response to rabies vaccine. If malaria prophylaxis with chloroquine (or mefloquine) is required, vaccination should be given intramuscularly (*not* intradermally) to ensure adequate antibody response.

► Typhoid

Typhoid vaccination is recommended for travelers to developing countries (especially the Indian subcontinent, Asia, Africa, Central and South America, and the Caribbean) who will have prolonged exposure to contaminated food and water. Two preparations of approximately equal efficacy (50–75% effective) are available in the United States: (1) an oral live attenuated Ty21a vaccine supplied as enteric-coated capsules, and (2) a Vi capsular polysaccharide (Vi CPS) vaccine for parenteral use. The Ty21a vaccine is given as one capsule every other day for four doses. The capsules must be refrigerated and taken with cool liquids (37°C or less) at least 1 hour before meals. All four doses must be taken for maximum protection and should be completed 1 week before travel. It is not recommended for infants or children younger than 6 years. The Vi CPS vaccine is given as a single intramuscular injection at least 2 weeks prior to travel. It is not recommended for infants younger than 2 years. If continued or repeated exposures are anticipated, boosters are recommended every 2 years for the Vi CPS and every 5 years for the Ty21a. The live attenuated vaccine should not be used in immunosuppressed patients, including those with HIV infection.

► Yellow Fever

The live attenuated yellow fever virus vaccine is administered once subcutaneously. Although the risk of yellow fever is low for most travelers, a number of countries require vaccination for all visitors and others require it for travelers to or from endemic areas (mainly equatorial Africa and parts of South and Central America). The WHO certificate requires registration of the manufacturer and the batch number of the vaccine. Vaccination is available in the United States only at approved centers; the local health

department should be contacted for available resources. Reimmunization is recommended at 10-year intervals if continued risk exists.

Because it is a live attenuated vaccine prepared in embryonated eggs, the yellow fever vaccine should not be given to immunosuppressed individuals or those with a history of anaphylaxis to eggs. Pregnancy is a relative contraindication to vaccination.

Two very severe adverse reactions have been associated with yellow fever vaccination. Viscerotropic disease presents with fever, jaundice, and multiple organ system failure within 30 days of yellow fever vaccination. Clinically and histopathologically, the illness is identical to yellow fever and is associated with a high mortality rate. The other adverse reaction is neurotropic disease and presents as encephalitis, encephalomyelitis, and Guillain-Barré syndrome.

▶ Japanese B Encephalitis

Japanese B encephalitis is a mosquito-borne viral encephalitis that affects primarily children and older adults (65 years and older) and usually occurs from May to September. It is the leading cause of encephalitis in Asia. Because the risk of infection is low and because adverse effects of the vaccine can be serious, not all travelers to Asia

should be vaccinated. Vaccine should be given to travelers to endemic areas who will be staying at least 30 days and who are traveling during the transmission season, particularly if they are visiting rural areas. Travelers who spend < 30 days in the region should be considered for vaccination if they intend to visit areas of epidemic transmission or if extensive outdoor activities are planned in rural rice-growing areas. Of the two vaccines currently available in the United States, only one is for adults (inactivated Vero cell derived vaccine, IXIARO) aged 17 and older. The schedule is 0.5 mL intramuscularly at 0 and 28 days. Only children are eligible to receive the other vaccine (inactivated mouse brain derived vaccine, JE-VAX) given its limited supply in the United States.

VACCINE SAFETY

Most vaccines are safe to administer. In general, it is recommended that the use of live vaccines be avoided in immunocompromised patients, including pregnant women. Vaccines are generally not contraindicated in the following situations: mild, acute illness with low-grade fevers (< 40.5°C); concurrent antibiotic therapy; soreness or redness at the site; family history of adverse reactions to vaccinations. Absolute contraindications to vaccines are rare (Table 30–8).

Table 30–8. Adverse effects and contraindications to vaccinations.

Vaccine	Adverse Effects	Contraindications
Hepatitis A	Minimal Consist mainly of pain at the injection site	
Hepatitis B	Minimal Consist mainly of pain at the injection site	Hypersensitivity to yeast Severe reaction to a previous dose
Human papillomavirus	Minimal Consists mainly of mild to moderate localized pain, erythema, swelling Systemic reactions, mainly fever, seen in 4% of recipients	History of hypersensitivity to yeast or to any vaccine component
Influenza (intramuscular inactivated and intranasal live attenuated vaccines)	Intramuscular, inactivated vaccine: Local reactions (erythema and tenderness) at the site of injection common, but fevers, chills, and malaise (which last in any case only 2–3 days) rare. Either inactivated or live attenuated vaccine: The risk of Guillain-Barré syndrome is not increased following vaccination. Influenza vaccination may be associated with multiple false-positive serologic tests to HIV, HTLV-1, and hepatitis C, but it is self-limited, lasting 2–5 months.	Intranasal, live attenuated vaccine [FluMist] should not be used in: People 50 years of age and over Household members of immunosuppressed individuals Health care workers, or others with close contact with immunosuppressed persons Presence of reactive airway disease; chronic underlying metabolic, pulmonary, or cardiovascular diseases (use intramuscular inactivated vaccine) Long-term aspirin therapy in children or adolescents (because of the risk of Reye syndrome) Pregnancy ¹ Contraindication to both inactivated and live attenuated vaccine: History of Guillain-Barré syndrome, especially within 6 weeks of receiving a previous influenza vaccine History of egg allergy ²

(continued)

Table 30-8. Adverse effects and contraindications to vaccinations. (continued)

Vaccine	Adverse Effects	Contraindications
Measles, mumps, and rubella (MMR) ³	Fever will develop in about 5–15% of unimmunized individuals, and a mild rash will develop in about 5% 5–12 days after vaccination. Fever and rash are self-limiting, lasting only 2–3 days. Local swelling and induration are particularly common in individuals previously vaccinated with inactivated vaccine.	Pregnancy ⁴ Immunosuppressed persons should not be vaccinated (with the exception of asymptomatic HIV-infected individuals whose CD4 count is > 200/mcl). History of anaphylaxis to neomycin or to related agents such as streptomycin
Meningococcal	Minor reactions (fever, redness, swelling, erythema, pain) occur slightly more commonly with MCV4. Major reactions are rare. A potential association between Guillain-Barré syndrome and vaccination with MCV4 has been reported, but current recommendations favor continued use of MCV4, since the benefits of preventing the serious consequences of meningococcal infection outweigh the theoretical risk of Guillain-Barré syndrome.	Persons with history of adverse reaction to diphtheria toxoid should not receive MCV4 since the protein conjugate used in MCV4 is diphtheria toxoid
Pneumococcal (polysaccharide)	Mild local reactions (erythema and tenderness) occur in up to 50% of recipients, but systemic reactions are uncommon. Similarly, revaccination at least 5 years after initial vaccination is associated with mild self-limited local but not systemic reactions.	Revaccination is not recommended for those who had a severe reaction (anaphylaxis or Arthus reaction) to the initial vaccination.
Tetanus, diphtheria, and pertussis	Minimal Consist mainly of pain at the injection site	Any history of anaphylaxis to vaccine components or if there is a history of unexplained encephalitis within 7 days of administration of a pertussis-containing vaccine.
Varicella	Can occur as late as 4–6 weeks after vaccination. Tenderness and erythema at the injection site are seen in 25%, fever in 10–15%, and a localized maculopapular or vesicular rash in 5%; a diffuse rash, usually with five or fewer vesicular lesions, develops in a smaller percentage. Spread of virus from vaccinees to susceptible individuals is possible, but the risk of such transmission even to immunocompromised patients is small and disease, when it develops, is mild and treatable with acyclovir.	Allergy to neomycin Avoid in immunocompromised individuals, including HIV-positive children and adults, or pregnant women. For theoretic reasons, it is recommended that salicylates should be avoided for 6 weeks following vaccination (to prevent Reye syndrome).
Zoster	Mild and limited to local reactions Although it is theoretically possible to transmit the virus to susceptible contacts, no such cases have been reported.	Presence of primary or acquired immunodeficiency state (leukemia, lymphoma, any malignant neoplasm affecting the bone marrow, HIV infection) Therapy with immunosuppressive medications (including high-dose corticosteroids) Pregnancy Persons with an anaphylactic type reaction to gelatin or neomycin should not receive the vaccine.

¹The inactivated influenza vaccine can be given during any trimester.

²The vaccine is prepared using embryonated chicken eggs.

³MMR vaccine can be safely given to patients with a history of egg allergy even when severe.

⁴Although vaccination of pregnant women is *not* recommended, with the currently available RA27/3 vaccine strain the congenital rubella syndrome does not occur in the offspring of those inadvertently vaccinated during pregnancy or within 3 months before conception.

Advisory Committee on Immunization Practices. Recommended adult immunization schedule: United States, 2012. *Ann Intern Med.* 2012 Feb 7;156(3):211–7. [PMID: 22298576]
Centers for Disease Control and Prevention (CDC). Health Information for International Travel 2012. <http://wwwnc.cdc.gov/travel/page/yellowbook-2012-home.htm>

Centers for Disease Control and Prevention (CDC). Vaccine safety. <http://www.cdc.gov/vaccinesafety/>
Danzinger-Isakov L et al; Infectious Diseases Community of Practice. Guidelines for vaccination of solid organ transplant candidates and recipients. *Am J Transplant.* 2009 Dec; 9(Suppl 4): S258–62. [PMID: 20070687]

Deer B. Wakefield's "autistic enterocolitis" under the microscope. *BMJ*. 2010 Apr 15;340:c1127. [PMID: 20395277]

Kaplan JE et al. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. *MMWR Recomm Rep*. 2009 Apr 10;58(RR-4):1–207. [PMID: 19357635]

Palefsky JM et al. HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. *N Engl J Med*. 2011 Oct 27; 365(17):1576–85. [PMID: 22029979]

Shefer A et al. Updated recommendations of the Advisory Committee on Immunization Practices for healthcare personnel vaccination: a necessary foundation for the essential work that remains to build successful programs. *Infect Control Hosp Epidemiol*. 2012 Jan;33(1):71–4. [PMID: 22173525]

Tomblyn M et al. Guidelines for preventing infectious complications among hematopoietic cell transplant recipients: a global perspective. Preface. *Bone Marrow Transplant*. 2009 Oct;44(8):453–5. [PMID: 19861977]

HIV Infection & AIDS

Andrew R. Zolopa, MD
Mitchell H. Katz, MD

31

ESSENTIALS OF DIAGNOSIS

- ▶ Risk factors: sexual contact with an infected person, parenteral exposure to infected blood by transfusion or needle sharing, perinatal exposure.
- ▶ Prominent systemic complaints such as sweats, diarrhea, weight loss, and wasting.
- ▶ Opportunistic infections due to diminished cellular immunity—often life-threatening.
- ▶ Aggressive cancers, particularly Kaposi sarcoma and extranodal lymphoma.
- ▶ Neurologic manifestations, including dementia, aseptic meningitis, and neuropathy.

▶ General Considerations

When AIDS was first recognized in the United States in 1981, cases were identified by finding severe opportunistic infections such as *Pneumocystis* pneumonia that indicated profound defects in cellular immunity in the absence of other causes of immunodeficiency. When HIV was identified as the cause of the syndrome, it became obvious that severe opportunistic infections and unusual neoplasms were at one end of a spectrum of disease, while healthy seropositive individuals were at the other end.

The Centers for Disease Control and Prevention (CDC) AIDS case definition (Table 31–1) includes opportunistic infections and malignancies that rarely occur in the absence of severe immunodeficiency (eg, *Pneumocystis* pneumonia, central nervous system lymphoma). It also classifies persons as having AIDS if they have positive HIV serology and certain infections and malignancies that can occur in immunocompetent hosts but that are more common among persons infected with HIV (pulmonary tuberculosis, invasive cervical cancer). Several nonspecific conditions, including dementia and wasting (documented weight loss)—in the presence of a positive HIV serology—are considered AIDS. The definition includes criteria for both definitive and presumptive diagnoses of certain

infections and malignancies. Finally, persons with positive HIV serology who have ever had a CD4 lymphocyte count below 200 cells/mcL or a CD4 lymphocyte percentage below 14% are considered to have AIDS. Inclusion of persons with low CD4 counts as AIDS cases reflects the recognition that immunodeficiency is the defining characteristic of AIDS. The choice of a cutoff point at 200 cells/mcL is supported by several cohort studies showing that AIDS will develop within 3 years in over 80% of persons with counts below this level in the absence of effective antiretroviral therapy (ART). The 1993 definition was also expanded to include persons with positive HIV serology and pulmonary tuberculosis (see Figure 9–5), recurrent pneumonia, and invasive cervical cancer. The prognosis of persons with HIV/AIDS has dramatically improved due to the introduction of highly active antiretroviral therapy (HAART) in the mid 1990s. One consequence is that fewer persons with HIV ever develop an infection or malignancy or have a low enough CD4 count to classify them as having AIDS, which means that the CDC definition has become a less useful measure of the impact of HIV/AIDS in the United States. Conversely, persons in whom AIDS had been diagnosed based on a serious opportunistic infection, malignancy, or immunodeficiency may now be markedly healthier, with high CD4 counts, due to the use of HAART. Therefore, the Social Security Administration as well as most social service agencies focus on functional assessment for determining eligibility for benefits rather than the simple presence or absence of an AIDS-defined illness.

▶ Epidemiology

The modes of transmission of HIV are similar to those of hepatitis B, in particular with respect to sexual, parenteral, and vertical transmission. Although certain sexual practices (eg, receptive anal intercourse) are significantly riskier than other sexual practices (eg, oral sex), it is difficult to quantify per-contact risks. The reason is that studies of sexual transmission of HIV show that most people at risk for HIV infection engage in a variety of sexual practices and have sex with multiple persons, only some of whom may

Table 31–1. CDC AIDS case definition for surveillance of adults and adolescents.

Definitive AIDS diagnoses (with or without laboratory evidence of HIV infection)
1. Candidiasis of the esophagus, trachea, bronchi, or lungs.
2. Cryptococcosis, extrapulmonary.
3. Cryptosporidiosis with diarrhea persisting > 1 month.
4. Cytomegalovirus disease of an organ other than liver, spleen, or lymph nodes.
5. Herpes simplex virus infection causing a mucocutaneous ulcer that persists longer than 1 month; or bronchitis, pneumonitis, or esophagitis of any duration.
6. Kaposi sarcoma in a patient < 60 years of age.
7. Lymphoma of the brain (primary) in a patient < 60 years of age.
8. <i>Mycobacterium avium</i> complex or <i>Mycobacterium kansasii</i> disease, disseminated (at a site other than or in addition to lungs, skin, or cervical or hilar lymph nodes).
9. <i>Pneumocystis jiroveci</i> pneumonia.
10. Progressive multifocal leukoencephalopathy.
11. Toxoplasmosis of the brain.
Definitive AIDS diagnoses (with laboratory evidence of HIV infection)
1. Coccidioidomycosis, disseminated (at a site other than or in addition to lungs or cervical or hilar lymph nodes).
2. HIV encephalopathy.
3. Histoplasmosis, disseminated (at a site other than or in addition to lungs or cervical or hilar lymph nodes).
4. Isosporiasis with diarrhea persisting > 1 month.
5. Kaposi sarcoma at any age.
6. Lymphoma of the brain (primary) at any age.
7. Other non-Hodgkin lymphoma of B cell or unknown immunologic phenotype.
8. Any mycobacterial disease caused by mycobacteria other than <i>Mycobacterium tuberculosis</i> , disseminated (at a site other than or in addition to lungs, skin, or cervical or hilar lymph nodes).
9. Disease caused by extrapulmonary <i>M tuberculosis</i> .
10. <i>Salmonella</i> (nontyphoid) septicemia, recurrent.
11. HIV wasting syndrome.
12. CD4 lymphocyte count below 200 cells/mcL or a CD4 lymphocyte percentage below 14%.
13. Pulmonary tuberculosis.
14. Recurrent pneumonia.
15. Invasive cervical cancer.
Presumptive AIDS diagnoses (with laboratory evidence of HIV infection)
1. Candidiasis of esophagus: (a) recent onset of retrosternal pain on swallowing; and (b) oral candidiasis.
2. Cytomegalovirus retinitis. A characteristic appearance on serial ophthalmoscopic examinations.
3. Mycobacteriosis. Specimen from stool or normally sterile body fluids or tissue from a site other than lungs, skin, or cervical or hilar lymph nodes, showing acid-fast bacilli of a species not identified by culture.
4. Kaposi sarcoma. Erythematous or violaceous plaque-like lesion on skin or mucous membrane.
5. <i>Pneumocystis jiroveci</i> pneumonia: (a) a history of dyspnea on exertion or nonproductive cough of recent onset (within the past 3 months); and (b) chest x-ray evidence of diffuse bilateral interstitial infiltrates or gallium scan evidence of diffuse bilateral pulmonary disease; and (c) arterial blood gas analysis showing an arterial oxygen partial pressure of < 70 mm Hg or a low respiratory diffusing capacity of < 80% of predicted values or an increase in the alveolar-arterial oxygen tension gradient; and (d) no evidence of a bacterial pneumonia.
6. Toxoplasmosis of the brain: (a) recent onset of a focal neurologic abnormality consistent with intracranial disease or a reduced level of consciousness; and (b) brain imaging evidence of a lesion having a mass effect or the radiographic appearance of which is enhanced by injection of contrast medium; and (c) serum antibody to toxoplasmosis or successful response to therapy for toxoplasmosis.
7. Recurrent pneumonia: (a) more than one episode in a 1-year period; and (b) acute pneumonia (new symptoms, signs, or radiologic evidence not present earlier) diagnosed on clinical or radiologic grounds by the patient's physician.
8. Pulmonary tuberculosis: (a) apical or miliary infiltrates and (b) radiographic and clinical response to antituberculous therapy.

actually be HIV infected. Thus, it is difficult to determine which practice with which person actually resulted in HIV transmission.

Nonetheless, the best available estimates indicate that the risk of HIV transmission with receptive anal intercourse is between 1:100 and 1:30, with insertive anal intercourse 1:1000, with receptive vaginal intercourse 1:1000, with insertive vaginal intercourse 1:10,000, and with receptive fellatio with ejaculation 1:1000. The per-contact risk of HIV transmission with other behaviors, including receptive fellatio without ejaculation, insertive fellatio, and cunnilingus, is not known.

All per-contact risk estimates assume that the source is HIV infected. If the HIV status of the source is unknown, the risk of transmission is the risk of transmission multiplied by the probability that the source is HIV infected. This would vary by risk practices, age, and geographic area. A number of cofactors are known to increase the risk of HIV transmission during a given encounter, including the presence of ulcerative or inflammatory sexually transmitted diseases, trauma, menses, and lack of male circumcision.

The risk of acquiring HIV infection from a needlestick with infected blood is approximately 1:300. Factors known to increase the risk of transmission include depth of penetration, hollow bore needles, visible blood on the needle, and advanced stage of disease in the source. The risk of HIV transmission from a mucosal splash with infected blood is unknown but is assumed to be significantly lower.

The risk of acquiring HIV infection from illicit drug use with sharing of needles from an HIV-infected source is estimated to be 1:150. Use of clean needles markedly decreases the chance of HIV transmission but does not eliminate it if other drug paraphernalia are shared (eg, cookers).

When blood transfusion from an HIV-infected donor occurs, the risk of transmission is 95%. Fortunately, since 1985, blood donor screening using the HIV enzyme-linked immunosorbent assay (ELISA) has been universally practiced in the United States. Also, persons who have recently engaged in unsafe behaviors (eg, sex with a person at risk for HIV, injection drug use) are not allowed to donate. This essentially eliminates donations from persons who are HIV infected but have not yet developed antibodies (ie, persons in the "window" period). In recent years, HIV antigen and viral load testing have been added to the screening of blood to further lower the chance of HIV transmission. With these precautions, the chance of HIV transmission with receipt of blood transfusion is about 1:1,000,000.

In the absence of perinatal HIV prophylaxis, between 13% and 40% of children born to HIV-infected mothers contract HIV infection. The risk is higher with vaginal than with cesarean delivery, higher among mothers with high viral loads, and higher among those who breast-feed their children. The risk can be decreased by administering anti-retroviral treatment to the mother during pregnancy and to the infant immediately after birth (see below).

HIV has not been shown to be transmitted by respiratory droplet spread, by vectors such as mosquitoes, or by casual nonsexual contact.

There are an estimated 1,106,400 Americans infected with HIV, about 51,000 new infections each year and an estimated 468,578 persons in the United States living with AIDS. Of those, 76% are men, of whom 60% were exposed through male-to-male sexual contact, 18% were exposed through injection drug use, 11% were exposed through heterosexual contact, and 8% were exposed through male-to-male sexual contact and injection drug use. Women account for 23% of living persons with HIV infection, of whom 66% were infected through heterosexual contact and 32% were exposed through injection drug use. Children account for < 1% of living cases. African Americans have been disproportionately hard hit by the epidemic. The estimated rate of new AIDS cases in the United States per 100,000 adult/adolescent population is 59.2 among African Americans, 20.4 among Latinos, 8.6 among native Americans and native Alaskans, 6.1 among whites, 4.3 among Asians, and 22.3 among Pacific Islanders.

In general, the progression of HIV-related illness is similar in men and women. However, there are some important differences. Women are at risk for gynecologic complications of HIV, including recurrent candidal vaginitis, pelvic inflammatory disease, and cervical dysplasia. Violence directed against women, pregnancy, and frequent occurrence of drug use and poverty all complicate the treatment of HIV-infected women. Although "safer sex" campaigns dramatically decreased the rates of seroconversions among men who have sex with men (MSM) living in metropolitan areas in the United States by the mid 1980s, relapse to unsafe sexual practices among MSM in several large cities in the United States and in western Europe has been observed. The higher rates of unsafe sex appear to be related to decreased concern about acquiring HIV due to the availability of HAART. Decreased interest in following safer sex recommendations and increasing use of crystal methamphetamine among certain risk groups also appears to be playing a role in the increased unsafe sex rates.

Worldwide there are an estimated 33 million persons infected with HIV, with heterosexual spread being the most common mode of transmission for men and women. In Central and East Africa, in some urban areas, as many as one-third of sexually active adults are infected. The reason for the greater risk for transmission with heterosexual intercourse in Africa and Asia than in the United States may relate to cofactors such as general health status, the presence of genital ulcers, relative lack of male circumcision, the number of sexual partners, and different HIV serotypes.

Centers for Disease Control and Prevention: HIV/AIDS Surveillance Reports. <http://www.cdc.gov/hiv/topics/surveillance/resources/reports/index.htm>.

Hall HI et al; HIV Incidence Surveillance Group. Estimation of HIV incidence in the United States. *JAMA*. 2008 Aug 6;300(5):520-9. [PMID: 18677024]

Public Health Service Task Force recommendations for use of anti-retroviral drugs in pregnant HIV-infected women for maternal health and interventions to reduce perinatal HIV-1 transmission in the United States. April 29, 2009 Guideline. <http://aidsinfo.nih.gov/ContentFiles/PerinatalGL.pdf>

► Etiology

HIV, like other retroviruses, depends on a unique enzyme, reverse transcriptase (RNA-dependent DNA polymerase), to replicate within host cells. The other major pathogenic human retrovirus, human T cell lymphotropic/leukemia virus (HTLV)-I, is associated with lymphoma, while HIV is not known to be directly oncogenic. The HIV genomes contain genes for three basic structural proteins and at least five other regulatory proteins; *gag* codes for group antigen proteins, *pol* codes for polymerase, and *env* codes for the external envelope protein. The greatest variability in strains of HIV occurs in the viral envelope. Since neutralizing activity is found in antibodies directed against the envelope, this variability presents problems for vaccine development.

In addition to the classic AIDS virus (HIV-1), a group of related viruses, HIV-2, has been isolated in West African patients. HIV-2 has the same genetic organization as HIV-1, but there are significant differences in the envelope glycoproteins. Some infected individuals exhibit AIDS-like illnesses, but the rate of progression in individuals infected with HIV-2 appears to be slower than that of HIV-1 infection. HIV-2 remains relatively rare in the United States but has become more common in Western Europe due to immigration from endemic areas. Cases have been documented in which AIDS-like illnesses have occurred in the absence of HIV infection or other known infectious causes of immunodeficiency.

► Pathogenesis

The hallmark of symptomatic HIV infection is immunodeficiency caused by continuing viral replication. The virus can infect all cells expressing the T4 (CD4) antigen, which HIV uses to attach to the cell. Chemokine co-receptors (CCR5 or CXCR4, or both) are required for virus entry, and individuals with CCR5 deletions (ie, “delta 32”) are less likely to become infected and, once infected, the disease is more likely to progress slowly. Once it enters a cell, HIV can replicate and cause cell fusion or death. A latent state is also established, with integration of the HIV genome into the cell’s genome. The cell principally infected is the CD4 (helper-inducer) lymphocyte, which directs many other cells in the immune network. With increasing duration of infection, the number of CD4 lymphocytes falls. Some of the immunologic defects, however, are explained not by *quantitative* abnormalities of lymphocyte subsets but by *qualitative* defects in CD4 responsiveness induced by HIV.

Other cells in the immune network that are infected by HIV include B lymphocytes and macrophages. The defect in B cells is partly due to disordered CD4 lymphocyte function. These direct and indirect effects can lead to generalized hypergammaglobulinemia and can also depress B cell responses to new antigen challenges. Because of these defects, the immunodeficiency of HIV is mixed. Elements of humoral and cellular immunodeficiency are present, especially in children. Macrophages act as a reservoir for HIV and serve to disseminate it to other organ systems (eg, the central nervous system).

Apart from the immunologic effects of HIV, the virus can also directly cause a variety of neurologic effects. Neuropathology largely results from the release of cytokines and other neurotoxins by infected macrophages. Perturbations of excitatory neurotransmitters and calcium flux may contribute to neurologic dysfunction. Direct HIV infection of renal tubular cells and gastrointestinal epithelium may contribute to these organ system manifestations of infection.

► Pathophysiology

Clinically, the syndromes caused by HIV infection are usually explicable by one of three known mechanisms: immunodeficiency, autoimmunity, and allergic and hyper-sensitivity reactions.

A. Immunodeficiency


Immunodeficiency is a direct result of the effects of HIV upon immune cells. A spectrum of infections and neoplasms is seen, as in other congenital or acquired immunodeficiency states. Two remarkable features of HIV immunodeficiency are the low incidence of certain infections such as listeriosis and aspergillosis and the frequent occurrence of certain neoplasms such as lymphoma or Kaposi sarcoma. This latter complication has been seen primarily in MSM or in bisexual men, and its incidence steadily declined through the first 15 years of the epidemic. A herpesvirus (KSHV or HHV-8) is the cause of Kaposi sarcoma.

B. Autoimmunity/Allergic and Hypersensitivity Reactions

Autoimmunity can occur as a result of disordered cellular immune function or B lymphocyte dysfunction. Examples of both lymphocytic infiltration of organs (eg, lymphocytic interstitial pneumonitis) and autoantibody production (eg, immunologic thrombocytopenia) occur. These phenomena may be the only clinically apparent disease or may coexist with obvious immunodeficiency. Moreover, HIV-infected individuals appear to have higher rates of allergic reactions to unknown allergens as seen with eosinophilic pustular folliculitis (“itchy red bump syndrome”) as well as increased rates of hypersensitivity reactions to medications (for example, the fever and sunburn-like rash seen with trimethoprim-sulfamethoxazole reactions).

► Clinical Findings

The complications of HIV-related infections and neoplasms affect virtually every organ. The general approach to the HIV-infected person with symptoms is to evaluate the organ systems involved, aiming to diagnose treatable conditions rapidly. As can be seen in Figure 31–1, the CD4 lymphocyte count provides very important prognostic information. Certain infections may occur at any CD4 count, while others rarely occur unless the CD4 lymphocyte count has dropped below a certain level. For example, a patient with a CD4 count of 600 cells/mL, cough, and



▲ **Figure 31-1.** Relationship of CD4 count to development of opportunistic infections. MAC, *Mycobacterium avium* complex; CMV, cytomegalovirus; CNS, central nervous system.

fever may have a bacterial pneumonia but would be very unlikely to have *Pneumocystis* pneumonia.

A. Symptoms and Signs

Many individuals with HIV infection remain asymptomatic for years even without ART, with a mean time of approximately 10 years between infection and development of AIDS. When symptoms occur, they may be remarkably protean and nonspecific. Since virtually all the findings may be seen with other diseases, a combination of complaints is more suggestive of HIV infection than any one symptom.

Physical examination may be entirely normal. Abnormal findings range from completely nonspecific to highly specific for HIV infection. Those that are specific for HIV infection include hairy leukoplakia of the tongue, disseminated Kaposi sarcoma, and cutaneous bacillary angiomatosis. Generalized lymphadenopathy is common early in infection.

The specific presentations and management of the various complications of HIV infection are discussed under the Complications section below.

B. Laboratory Findings

Specific tests for HIV include antibody and antigen detection (Table 31-2). Conventional HIV antibody testing is done by ELISA. Positive specimens are then confirmed by a different method (eg, Western blot). The sensitivity of screening serologic tests is > 99.9%. The

specificity of positive results by two different techniques approaches 100% even in low-risk populations. False-positive screening tests may occur as normal biologic variants or in association with recent influenza vaccination or other disease states, such as connective tissue disease. These are usually detected by negative confirmatory tests. Molecular biology techniques (PCR) show a small incidence of individuals (< 1%) who are infected with HIV for up to 36 months without generating an antibody response. However, antibodies that are detectable by screening serologic tests will develop in 95% of persons within 6 weeks after infection.

Rapid HIV antibody tests provide results within 10–20 minutes and can be performed in clinician offices, including by personnel without laboratory training and without a Clinical Laboratory Improvement Amendment (CLIA) approved laboratory. Persons who test positive on a rapid test should be told that they may be HIV-infected or their test may be falsely reactive. Standard testing (ELISA with Western blot confirmation) should be performed to distinguish these two possibilities. Rapid testing is particularly helpful in settings where a result is needed immediately (eg, a woman in labor who has not recently been tested for HIV) or when the patient is unlikely to return for a result.

Nonspecific laboratory findings with HIV infection may include anemia, leukopenia (particularly lymphopenia), and thrombocytopenia in any combination, elevation of the erythrocyte sedimentation rate, polyclonal hypergammaglobulinemia, and hypocholesterolemia. Cutaneous anergy is common.

Table 31-2. Laboratory findings with HIV infection.

Test	Significance
HIV enzyme-linked immunosorbent assay (ELISA)	Screening test for HIV infection. Of ELISA tests 50% are positive within 22 days after HIV transmission; 95% are positive within 6 weeks after transmission. Sensitivity > 99.9%; to avoid false-positive results, repeatedly reactive results must be confirmed with Western blot.
Western blot	Confirmatory test for HIV. Specificity when combined with ELISA > 99.99%. Indeterminate results with early HIV infection, HIV-2 infection, autoimmune disease, pregnancy, and recent tetanus toxoid administration.
HIV rapid antibody test	Screening test for HIV. Produces results in 10–20 minutes. Can be performed by personnel with limited training. Positive results must be confirmed with standard HIV test (ELISA and Western blot).
Complete blood count	Anemia, neutropenia, and thrombocytopenia common with advanced HIV infection.
Absolute CD4 lymphocyte count	Most widely used predictor of HIV progression. Risk of progression to an AIDS opportunistic infection or malignancy is high with CD4 < 200 cells/mL in the absence of treatment.
CD4 lymphocyte percentage	Percentage may be more reliable than the CD4 count. Risk of progression to an AIDS opportunistic infection or malignancy is high with percentage < 14% in the absence of treatment.
HIV viral load tests	These tests measure the amount of actively replicating HIV virus. Correlate with disease progression and response to antiretroviral drugs. Best tests available for diagnosis of acute HIV infection (prior to seroconversion); however, caution is warranted when the test result shows low-level viremia (ie, < 500 copies/mL) as this may represent a false-positive test.

Several laboratory markers are available to provide prognostic information and guide therapy decisions (Table 31–2). The most widely used marker is the absolute CD4 lymphocyte count. As counts decrease, the risk of serious opportunistic infection over the subsequent 3–5 years increases (Figure 31–1).

There are many limitations to using the CD4 count, including diurnal variation, depression with intercurrent illness, and intralaboratory and interlaboratory variability. Therefore, the trend is more important than a single determination. The frequency of performance of counts depends on the patient's health status and whether or not they are receiving antiretroviral treatment. Patients not receiving treatment whose CD4 counts are substantially above the threshold for initiation of antiviral therapy (500 cells/mL) should have counts performed every 6 months. Those who have counts near or below 500 cells/mL should have counts performed every 3 months. For patients receiving ART, with undetectable viral loads, and CD4 counts > 350 cells/mL, CD4 counts need only be performed every 3–6 months. In patients who have detectable viral loads, CD4 counts should be performed every 3 months to evaluate the need for a change in therapy or for initiation of *P jiroveci* prophylactic therapy when the CD4 count drops below 200 cells/mL, or initiation of *M avium* prophylaxis when the CD4 count drops below 75–100 cells/mL. Some studies suggest that the percentage of CD4 lymphocytes is a more reliable indicator of prognosis than the absolute counts because the percentage does not depend on calculating a manual differential. While the CD4 count measures immune dysfunction, it does not provide a measure of how actively HIV is replicating in the body. HIV viral load tests (discussed below) assess the level of viral replication and provide useful prognostic information that is independent of the information provided by CD4 counts.

► Differential Diagnosis

HIV infection may mimic a variety of other medical illnesses. Specific differential diagnosis depends on the mode of presentation. In patients presenting with constitutional symptoms such as weight loss and fevers, differential considerations include cancer, chronic infections such as tuberculosis and endocarditis, and endocrinologic diseases such as hyperthyroidism. When pulmonary processes dominate the presentation, acute and chronic lung infections must be considered as well as other causes of diffuse interstitial pulmonary infiltrates. When neurologic disease is the mode of presentation, conditions that cause mental status changes or neuropathy—eg, alcoholism, liver disease, kidney dysfunction, thyroid disease, and vitamin deficiency—should be considered. If a patient presents with headache and a cerebrospinal fluid pleocytosis, other causes of chronic meningitis enter the differential. When diarrhea is a prominent complaint, infectious enterocolitis, antibiotic-associated colitis, inflammatory bowel disease, and malabsorptive symptoms must be considered.

► Complications

A. Systemic Complaints

Fever, night sweats, and weight loss are common symptoms in HIV-infected patients and may occur without a complicating opportunistic infection. Patients with persistent fever and no localizing symptoms should nonetheless be carefully examined, and evaluated with a chest radiograph (*Pneumocystis pneumonia* can present without respiratory symptoms), bacterial blood cultures if the fever is > 38.5 °C, serum cryptococcal antigen, and mycobacterial cultures of the blood. Sinus CT scans or sinus radiographs should be considered to evaluate occult sinusitis. If these studies are

normal, patients should be observed closely. Antipyretics are useful to prevent dehydration.

1. Weight loss—Weight loss is a particularly distressing complication of long-standing HIV infection. Patients typically have disproportionate loss of muscle mass, with maintenance or less substantial loss of fat stores. The mechanism of HIV-related weight loss is not completely understood but appears to be multifactorial.

A. PRESENTATION—AIDS patients frequently suffer from anorexia, nausea, and vomiting, all of which contribute to weight loss by decreasing caloric intake. In some cases, these symptoms are secondary to a specific infection, such as viral hepatitis. In other cases, however, evaluation of the symptoms yields no specific pathogen, and it is assumed to be due to a primary effect of HIV. Malabsorption also plays a role in decreased caloric intake. Patients may suffer diarrhea from infections with bacterial, viral, or parasitic agents.

Exacerbating the decrease in caloric intake, many AIDS patients have an increased metabolic rate. This increased rate has been shown to exist even among asymptomatic HIV-infected persons, but it accelerates with disease progression and secondary infection. AIDS patients with secondary infections also have decreased protein synthesis, which makes maintaining muscle mass difficult.

B. MANAGEMENT—Several strategies have been developed to slow AIDS wasting. Effective fever control decreases the metabolic rate and may slow the pace of weight loss, as does treating the underlying opportunistic infection. Food supplementation with high-calorie drinks may enable patients with not much appetite to maintain their intake. Selected patients with otherwise good functional status and weight loss due to unrelenting nausea, vomiting, or diarrhea may benefit from total parenteral nutrition (TPN). It should be noted, however, that TPN is more likely to increase fat stores than to reverse the muscle wasting process.

Two pharmacologic approaches for increasing appetite and weight gain are the progestational agent megestrol acetate (80 mg orally four times a day) and the antiemetic agent dronabinol (2.5–5 mg orally three times a day). Side effects from megestrol acetate are rare, but thromboembolic phenomena, edema, nausea, vomiting, and rash have been reported. Euphoria, dizziness, paranoia, and somnolence and even nausea and vomiting have been reported in 3–10% of patients using dronabinol. Dronabinol contains only one of the active ingredients in smoked marijuana, and many patients report better relief of nausea and improvement of appetite with smoking marijuana. Thirteen states allow patients to obtain marijuana for medicinal purposes with a letter of recommendation from their doctor. However, the use and sale of marijuana is still illegal under federal law. The Supreme Court has ruled that physicians cannot be prosecuted for recommending marijuana to their patients (it would be an infringement of freedom of speech). Therefore, while a physician's recommendation may not completely protect patients, letters decrease the chance that patients will be prosecuted for use of marijuana. Unfortunately, neither megestrol acetate nor dronabinol increases lean body mass.

Two regimens that have resulted in increases in lean body mass are growth hormone and anabolic steroids. Growth hormone at a dose of 0.1 mg/kg/d (up to 6 mg) subcutaneously for 12 weeks has resulted in modest increases in lean body mass. Treatment with growth hormone can cost as much as \$10,000 per month. Anabolic steroids also increase lean body mass among HIV-infected patients. They seem to work best for patients who are able to do weight training. The most commonly used regimens are testosterone enanthate or testosterone cypionate (100–200 mg intramuscularly every 2–4 weeks). Testosterone transdermal system (apply 5 mg system each evening) and testosterone gel (1%; apply a 5-g packet [50 mg testosterone] to clean, dry skin daily) are also available. The anabolic steroid oxandrolone (20 mg orally in two divided doses) has also been found to increase lean body mass.

2. Nausea—Nausea leading to weight loss is sometimes due to esophageal candidiasis. Patients with oral candidiasis and nausea should be empirically treated with an oral antifungal agent. Patients with weight loss due to nausea of unclear origin may benefit from use of antiemetics prior to meals (prochlorperazine, 10 mg three times daily; metoclopramide, 10 mg three times daily; or ondansetron, 8 mg three times daily). Dronabinol (5 mg three times daily) can also be used to increase appetite. Depression and adrenal insufficiency are two potentially treatable causes of weight loss.

B. Pulmonary Disease

1. *Pneumocystis pneumonia*—(See also discussions in Chapter 36.) *Pneumocystis jiroveci* pneumonia is the most common opportunistic infection associated with AIDS. *Pneumocystis pneumonia* may be difficult to diagnose because the symptoms—fever, cough, and shortness of breath—are nonspecific. Furthermore, the severity of symptoms ranges from fever and no respiratory symptoms through mild cough or dyspnea to frank respiratory distress.

Hypoxemia may be severe, with a $P_{O_2} < 60$ mm Hg. The cornerstone of diagnosis is the chest radiograph. Diffuse or perihilar infiltrates are most characteristic, but only two-thirds of patients with *Pneumocystis pneumonia* have this finding. Normal chest radiographs are seen in 5–10% of patients with *Pneumocystis pneumonia*, while the remainder have atypical infiltrates. Apical infiltrates are commonly seen among patients with *Pneumocystis pneumonia* who have been receiving aerosolized pentamidine prophylaxis. Large pleural effusions are uncommon with *Pneumocystis pneumonia*; their presence suggests bacterial pneumonia, other infections such as tuberculosis, or pleural Kaposi sarcoma.

Definitive diagnosis can be obtained in 50–80% of cases by Wright-Giemsa stain or direct fluorescence antibody (DFA) test of induced sputum. Sputum induction is performed by having patients inhale an aerosolized solution of 3% saline produced by an ultrasonic nebulizer. Patients should not eat for at least 8 hours and should not use toothpaste or mouthwash prior to the procedure since they can interfere with test interpretation. The next step for

patients with negative sputum examinations in whom *Pneumocystis* pneumonia is still suspected should be bronchoalveolar lavage. This technique establishes the diagnosis in over 95% of cases.

In patients with symptoms suggestive of *Pneumocystis* pneumonia but with negative or atypical chest radiographs and negative sputum examinations, other diagnostic tests may provide additional information in deciding whether to proceed to bronchoalveolar lavage. Elevation of serum lactate dehydrogenase occurs in 95% of cases of *Pneumocystis* pneumonia, but the specificity of this finding is at best 75%. A serum β -glucan test is more sensitive and specific test for *Pneumocystis* pneumonia compared with serum lactate dehydrogenase and may avoid more invasive tests when used in the appropriate clinical setting. Either a normal diffusing capacity of carbon monoxide (DL_{CO}) or a high-resolution CT scan of the chest that demonstrates no interstitial lung disease makes the diagnosis of *Pneumocystis* pneumonia very unlikely. In addition, a CD4 count > 250 cells/mcL within 2 months prior to evaluation of respiratory symptoms makes a diagnosis of *Pneumocystis* pneumonia unlikely; only 1–5% of cases occur above this CD4 count level (Figure 31–1). This is true even if the patient previously had a CD4 count lower than 200 cells/mcL but has had an increase with ART. Pneumothoraces can be seen in HIV-infected patients with a history of *Pneumocystis* pneumonia, especially if they have received aerosolized pentamidine treatment.

2. Other infectious pulmonary diseases—

A. PRESENTATION—Other infectious causes of pulmonary disease in AIDS patients include bacterial, mycobacterial, and viral pneumonias. Community-acquired pneumonia is the most common cause of pulmonary disease in HIV-infected persons. An increased incidence of pneumococcal pneumonia with septicemia and *Haemophilus influenzae* pneumonia has been reported. *Pseudomonas aeruginosa* is an important respiratory pathogen in advanced disease and, more rarely, pneumonia from *Rhodococcus equi* infection can occur. The incidence of infection with *Mycobacterium tuberculosis* has markedly increased in metropolitan areas because of HIV infection as well as homelessness. Tuberculosis occurs in an estimated 4% of persons in the United States who have AIDS. Apical infiltrates and disseminated disease occur more commonly than among immunocompetent persons. Although a purified protein derivative (PPD) test should be performed on all HIV-infected persons in whom a diagnosis of tuberculosis is being considered, the lower the CD4 cell count, the greater the likelihood of anergy. Because “anergy” skin test panels do not accurately classify those patients who are infected with tuberculosis but unreactive to the PPD, they are not recommended.

B. MANAGEMENT—Treatment of HIV-infected persons with active tuberculosis is similar to treatment of HIV-uninfected tubercular individuals (see Figure 31–1). However, rifampin should not be given to patients receiving a boosted protease inhibitor (PI)-regimen. In these

cases, rifabutin may be substituted, but it may require dosing modifications depending on the antiretroviral regimen. Multidrug-resistant tuberculosis has been a major problem in several metropolitan areas of the developed world, and reports from South Africa of “extremely resistant” tuberculosis in AIDS patients is a growing global concern. Noncompliance with prescribed antituberculous drugs is a major risk factor. Several of the reported outbreaks appear to implicate nosocomial spread. The emergence of drug resistance makes it essential that antibiotic sensitivities be performed on all positive cultures. Drug therapy should be individualized. Patients with multidrug-resistant *M tuberculosis* infection should receive at least three drugs to which their organism is sensitive. Atypical mycobacteria can cause pulmonary disease in AIDS patients with or without preexisting lung disease and responds variably to treatment. Making a distinction between *M tuberculosis* and atypical mycobacteria requires culture of sputum specimens. If culture of the sputum produces acid-fast bacilli, definitive identification may take several weeks using traditional techniques. DNA probes allow for presumptive identification usually within days of a positive culture. While awaiting definitive diagnosis, clinicians should err on the side of treating patients as if they have *M tuberculosis* infection. In cases in which the risk of atypical mycobacteria is very high (eg, a person without risk for tuberculosis exposure with a CD4 count under 50 cells/mcL—see Figure 31–1), clinicians may wait for definitive diagnosis if the person is smear-negative for acid-fast bacilli, clinically stable, and not living in a communal setting. Isolation of cytomegalovirus (CMV) from bronchoalveolar lavage fluid occurs commonly in AIDS patients but does not establish a definitive diagnosis. Diagnosis of CMV pneumonia requires biopsy; response to treatment is poor. Histoplasmosis, coccidioidomycosis, and cryptococcal disease as well as more common respiratory viral infections should also be considered in the differential diagnosis of unexplained pulmonary infiltrates.

3. Noninfectious pulmonary diseases—

A. PRESENTATION—Noninfectious causes of lung disease include Kaposi sarcoma, non-Hodgkin lymphoma, and interstitial pneumonitis. In patients with known Kaposi sarcoma, pulmonary involvement complicates the course in approximately one-third of cases. However, pulmonary involvement is rarely the presenting manifestation of Kaposi sarcoma. Non-Hodgkin lymphoma may involve the lung as the sole site of disease but more commonly involves other organs as well, especially the brain, liver, and gastrointestinal tract. Both of these processes may show nodular or diffuse parenchymal involvement, pleural effusions, and mediastinal adenopathy on chest radiographs.

Nonspecific interstitial pneumonitis may mimic *Pneumocystis* pneumonia. Lymphocytic interstitial pneumonitis seen in lung biopsies has a variable clinical course. Typically, these patients present with several months of mild cough and dyspnea; chest radiographs show interstitial infiltrates. Many patients with this entity undergo transbronchial biopsies in an attempt to diagnose *Pneumocystis*

pneumonia. Instead, the tissue shows interstitial inflammation ranging from an intense lymphocytic infiltration (consistent with lymphoid interstitial pneumonitis) to a mild mononuclear inflammation.

B. MANAGEMENT—Corticosteroids may be helpful in some cases refractory to ART.

4. Sinusitis—

A. PRESENTATION—Chronic sinusitis can be a frustrating problem for HIV-infected patients even in those on adequate ART. Symptoms include sinus congestion and discharge, headache, and fever. Some patients may have radiographic evidence of sinus disease on sinus CT scan or sinus x-ray in the absence of significant symptoms.

B. MANAGEMENT—Nonsmoking patients with purulent drainage should be treated with amoxicillin (500 mg orally three times a day). Patients who smoke should be treated with amoxicillin-potassium clavulanate (500 mg orally three times a day) to cover *H influenzae*. Prolonged treatment (3–6 weeks) with an antibiotic and guaifenesin (600 mg orally twice daily) to decrease sinus congestion may be required. For patients not responding to amoxicillin-potassium clavulanate, levofloxacin may be tried (400 mg orally daily). In patients with advanced immunodeficiency, *Pseudomonas* infections should be suspected, especially if there is not a response to first-line antibiotics. Some patients may require referral to an otolaryngologist for sinus drainage.

C. Central Nervous System Disease

Central nervous system disease in HIV-infected patients can be divided into intracerebral space-occupying lesions, encephalopathy, meningitis, and spinal cord processes. Many of these complications have declined markedly in prevalence in the era of effective ART. Cognitive declines, however, may be more common in HIV patients, even those who are taking fully suppressive ART.

1. Toxoplasmosis—Toxoplasmosis is the most common space-occupying lesion in HIV-infected patients. Headache, focal neurologic deficits, seizures, or altered mental status may be presenting symptoms. The diagnosis is usually made presumptively based on the characteristic appearance of cerebral imaging studies in an individual known to be seropositive for *Toxoplasma*. Typically, toxoplasmosis appears as multiple contrast-enhancing lesions on CT scan. Lesions tend to be peripheral, with a predilection for the basal ganglia.

Single lesions are atypical of toxoplasmosis. When a single lesion has been detected by CT scanning, MRI scanning may reveal multiple lesions because of its greater sensitivity. If a patient has a single lesion on MRI and is neurologically stable, clinicians may pursue a 2-week empiric trial of toxoplasmosis therapy. A repeat scan should be performed at 2 weeks. If the lesion has not diminished in size, biopsy of the lesion should be performed. Since many HIV-infected patients will have detectable titers, a positive *Toxoplasma* serologic test does not confirm the diagnosis. Conversely, < 3% of patients

with toxoplasmosis have negative titers. Therefore, negative *Toxoplasma* titers in an HIV-infected patient with a space-occupying lesion should be a cause for aggressively pursuing an alternative diagnosis.

2. Central nervous system lymphoma—Primary non-Hodgkin lymphoma is the second most common space-occupying lesion in HIV-infected patients. Symptoms are similar to those with toxoplasmosis. While imaging techniques cannot distinguish these two diseases with certainty, lymphoma more often is solitary. Other less common lesions should be suspected if there is preceding bacteremia, positive tuberculin test, fungemia, or injection drug use. These include bacterial abscesses, cryptococcomas, tuberculomas, and *Nocardia* lesions.

Because techniques for stereotactic brain biopsy have improved, this procedure plays an increasing role in diagnosing cerebral lesions. Biopsy should be strongly considered if lesions are solitary or do not respond to toxoplasmosis treatment, especially if they are easily accessible. Diagnosis of lymphoma is important because many patients benefit from treatment (radiation therapy). Although a positive polymerase chain reaction (PCR) assay of cerebrospinal fluid for Epstein–Barr virus DNA, is consistent with a diagnosis of lymphoma, the sensitive and specificity of the test are not high enough to obviate the need for a brain biopsy.

3. HIV-associated dementia—Patients with HIV-associated dementia typically have difficulty with cognitive tasks (eg, memory, attention), exhibit diminished motor function, and have emotional or behavioral problems. Patients may first notice a deterioration in their handwriting. The manifestations of dementia may wax and wane, with persons exhibiting periods of lucidity and confusion over the course of a day. The diagnosis of HIV-associated dementia is one of exclusion based on a brain imaging study and on spinal fluid analysis that excludes other pathogens. Neuropsychiatric testing is helpful in distinguishing patients with dementia from those with depression. Many patients improve with effective antiretroviral treatment. Metabolic abnormalities may also cause changes in mental status: hypoglycemia, hyponatremia, hypoxia, and drug overdose are important considerations in this population. Other less common infectious causes of encephalopathy include progressive multifocal leukoencephalopathy (discussed below), CMV, syphilis, and herpes simplex encephalitis.

4. Cryptococcal meningitis—Cryptococcal meningitis typically presents with fever and headache. Less than 20% of patients have meningismus. Diagnosis is based on a positive latex agglutination test that detects cryptococcal antigen (or “CRAG”) or positive culture of spinal fluid for *Cryptococcus*. Seventy to 90% of patients with cryptococcal meningitis have a positive serum CRAG. Thus, a negative serum CRAG test makes a diagnosis of cryptococcal meningitis unlikely and can be useful in the initial evaluation of a patient with headache, fever, and normal mental status. HIV meningitis, characterized by lymphocytic pleocytosis of the spinal fluid with negative culture, is common early in HIV infection.

5. HIV myelopathy—Spinal cord function may also be impaired in HIV-infected individuals. HIV myelopathy presents with leg weakness and incontinence. Spastic paraparesis and sensory ataxia are seen on neurologic examination. Myelopathy is usually a late manifestation of HIV disease, and most patients will have concomitant HIV encephalopathy. Pathologic evaluation of the spinal cord reveals vacuolation of white matter. Because HIV myelopathy is a diagnosis of exclusion, symptoms suggestive of myelopathy should be evaluated by lumbar puncture to rule out CMV polyradiculopathy (described below) and an MRI or CT scan to exclude epidural lymphoma.

6. Progressive multifocal leukoencephalopathy (PML)—PML is a viral infection of the white matter of the brain seen in patients with very advanced HIV infection. It typically results in focal neurologic deficits such as aphasia, hemiparesis, and cortical blindness. Imaging studies are strongly suggestive of the diagnosis if they show nonenhancing white matter lesions without mass effect. Extensive lesions may be difficult to differentiate from the changes caused by HIV. Several patients have stabilized or improved after the institution of effective ART or zidovudine, or both.

D. Peripheral Nervous System

A. PRESENTATION—Peripheral nervous system syndromes include inflammatory polyneuropathies, sensory neuropathies, and mononeuropathies.

An inflammatory demyelinating polyneuropathy similar to Guillain-Barré syndrome occurs in HIV-infected patients, usually prior to frank immunodeficiency. The syndrome in many cases improves with plasmapheresis, supporting an autoimmune basis of the disease. CMV can cause an ascending polyradiculopathy characterized by lower extremity weakness and a neutrophilic pleocytosis on spinal fluid analysis with a negative bacterial culture. Transverse myelitis can be seen with herpes zoster or CMV.

Peripheral neuropathy is common among HIV-infected persons. Patients typically complain of numbness, tingling, and pain in the lower extremities. Symptoms are disproportionate to findings on gross sensory and motor evaluation. Beyond HIV infection itself, the most common cause is prior ART with stavudine or didanosine. Although not used commonly in Western countries, stavudine is still being used in resource-limited settings through national ART programs. Caution should be used when administering these agents to patients with a history of peripheral neuropathy. Unfortunately, drug-induced neuropathy is not always reversed when the offending agent is discontinued. Patients with advanced disease may also develop peripheral neuropathy even if they have never taken ART. Evaluation should rule out other causes of sensory neuropathy such as alcoholism, thyroid disease, vitamin B₁₂ deficiency, and syphilis.

B. MANAGEMENT—Treatment of peripheral neuropathy is aimed at symptomatic relief. Patients should be initially treated with gabapentin (start at 300 mg at bedtime and increase to 300–900 mg orally three times a day).

E. Rheumatologic and Bone Manifestations

Arthritis, involving single or multiple joints, with or without effusion, has been commonly noted in HIV-infected patients. Involvement of large joints is most common. Although the cause of HIV-related arthritis is unknown, most patients will respond to nonsteroidal anti-inflammatory drugs. Patients with a sizable effusion, especially if the joint is warm or erythematous, should have the joint aspirated, followed by culture of the fluid to rule out suppurative arthritis as well as fungal and mycobacterial disease.

Several rheumatologic syndromes, including reactive arthritis, psoriatic arthritis, sicca syndrome, and systemic lupus erythematosus, have been reported in HIV-infected patients (see Chapter 20). However, it is unclear if the prevalence is greater than in the general population. Cases of avascular necrosis of the femoral heads have been reported sporadically, generally in the setting of advanced disease with long-standing infection and in patients receiving long-term ART. The etiology is not clear but is probably multifactorial in nature.

Osteoporosis and osteopenia appear to be more common in HIV-infected patients with chronic infection and perhaps associated with long-term use of ART. Vitamin D deficiency appears to be quite common among HIV-infected populations and monitoring vitamin D levels and replacement therapy for detected deficiency is recommended. Bone scans to determine bone density for patients over the age of 50 is also recommended.

F. Myopathy

Myopathies are infrequent in the era of effective ART but can be related to either HIV-infection or ART, particularly with use of zidovudine (azidothymidine [AZT]). Proximal muscle weakness is typical, and patients may have varying degrees of muscle tenderness. A muscle biopsy can distinguish HIV myopathy from zidovudine myopathy and should be considered in patients for whom continuation of zidovudine is essential.

G. Retinitis

Complaints of visual changes must be evaluated immediately in HIV-infected patients. CMV retinitis, characterized by perivascular hemorrhages and white fluffy exudates, is the most common retinal infection in AIDS patients and can be rapidly progressive. In contrast, cotton wool spots, which are also common in HIV-infected people, are benign, remit spontaneously, and appear as small indistinct white spots without exudation or hemorrhage. This distinction may be difficult at times for the nonspecialist, and patients with visual changes should be seen by an ophthalmologist. Other rare retinal processes include other herpesvirus infections or toxoplasmosis.

H. Oral Lesions

A. PRESENTATION—The presence of oral candidiasis or hairy leukoplakia is significant for several reasons. First, these lesions are highly suggestive of HIV infection in patients who have no other obvious cause of immunodeficiency. Second,

several studies have indicated that patients with candidiasis have a high rate of progression to AIDS even with statistical adjustment for CD4 count.

Hairy leukoplakia is caused by the Epstein-Barr virus. The lesion is not usually troubling to patients and sometimes regresses spontaneously. Hairy leukoplakia is commonly seen as a white lesion on the lateral aspect of the tongue. It may be flat or slightly raised, is usually corrugated, and has vertical parallel lines with fine or thick (“hairy”) projections. Oral candidiasis can be bothersome to patients, many of whom report an unpleasant taste or mouth dryness. The two most common forms of oral candidiasis seen are pseudomembranous (removable white plaques) and erythematous (red friable plaques).

B. MANAGEMENT—Treatment is with topical agents such as clotrimazole 10-mg troches (one troche four or five times a day). Patients with candidiasis who do not respond to topical antifungals can be treated with fluconazole (50–100 mg orally once a day for 3–7 days). Angular cheilitis—fissures at the sides of the mouth—is usually due to *Candida* as well and can be treated topically with ketoconazole cream (2%) twice a day.

Gingival disease is common in HIV-infected patients and is thought to be due to an overgrowth of microorganisms. It usually responds to professional dental cleaning and chlorhexidine rinses. A particularly aggressive gingivitis or periodontitis will develop in some HIV-infected patients; these patients should be given antibiotics that cover anaerobic oral flora (eg, metronidazole, 250 mg four times a day for 4 or 5 days) and referred to oral surgeons with experience with these entities.

Aphthous ulcers are painful and may interfere with eating. They can be treated with fluocinonide (0.05% ointment mixed 1:1 with plain Orabase and applied six times a day to the ulcer). For lesions that are difficult to reach, patients should use dexamethasone swishes (0.5 mg in 5 mL elixir three times a day). The pain of the ulcers can be relieved with use of an anesthetic spray (10% lidocaine). Other lesions seen in the mouths of HIV-infected patients include Kaposi sarcoma (usually on the hard palate) and warts.

I. Gastrointestinal Manifestations

1. Candidal esophagitis—(See also discussion in Chapter 15.) Esophageal candidiasis is a common AIDS complication. In a patient with characteristic symptoms, empiric antifungal treatment is begun with fluconazole (200 mg daily for 10–14 days). Further evaluation to identify other causes of esophagitis (herpes simplex, CMV) is reserved for patients who do not improve with antifungal treatment.

2. Hepatic disease

A. PRESENTATION—Autopsy studies have demonstrated that the liver is a frequent site of infections and neoplasms in HIV-infected patients. However, many of these infections are not clinically symptomatic. Clinicians may note elevations of alkaline phosphatase and aminotransferases on routine chemistry panels. Mycobacterial disease, CMV, hepatitis B virus, hepatitis C virus, and lymphoma cause

liver disease and can present with varying degrees of nausea, vomiting, right upper quadrant abdominal pain, and jaundice. Sulfonamides, imidazole drugs, antituberculous medications, pentamidine, clarithromycin, and didanosine have also been associated with hepatitis. HIV-infected patients with chronic hepatitis may have more rapid progression of liver disease because of the concomitant immunodeficiency or hepatotoxicity of ART. Percutaneous liver biopsy may be helpful in diagnosing liver disease, but some common causes of liver disease (eg, *Mycobacterium avium* complex, lymphoma) can be determined by less invasive measures (eg, blood culture, biopsy of a more accessible site).

B. MANAGEMENT—With patients living longer as a result of advances in ART, advanced liver disease and hepatic failure due to chronic active hepatitis B and or C are increasing causes of morbidity and mortality. HIV-infected individuals who are coinfecting with hepatitis B, should be treated with antiretroviral regimens that include drugs with activity against both viruses (eg, lamivudine [3TC], emtricitabine [FTC], tenofovir [TDF]). Treatment of HIV-infected persons with hepatitis C with peginterferon and ribavirin has been shown to be efficacious, although less so than in HIV-uninfected persons. HIV-infected persons are also more likely to have difficulty tolerating treatment with peginterferon than uninfected persons. HIV-infected patients with hepatitis C genotype 1 who received telaprevir therapy for 12 weeks had a better response than those who received only peginterferon and ribavirin. Telaprevir is approved in combination with peginterferon and ribavirin for treatment of hepatitis C in HIV-uninfected persons. Patients with advanced fibrosis or cirrhosis due to chronic hepatitis C infection should be considered for treatment with telaprevir, peginterferon, and ribavirin. However, this treatment regimen is difficult for many patients to tolerate, therefore, coinfecting patients with less advanced liver disease may benefit from waiting until newer direct-acting agents for hepatitis C treatment become available. Liver transplants have been performed successfully in HIV-infected patients. This strategy is most likely to be successful in persons who have CD4 counts > 100 cells/mcL and non-detectable viral loads.

3. Biliary disease—Cholecystitis presents with manifestations similar to those seen in immunocompetent hosts but is more likely to be acalculous. Sclerosing cholangitis and papillary stenosis have also been reported in HIV-infected patients. Typically, the syndrome presents with severe nausea, vomiting, and right upper quadrant pain. Liver function tests generally show alkaline phosphatase elevations disproportionate to elevation of the aminotransferases. Although dilated ducts can be seen on ultrasound, the diagnosis is made by endoscopic retrograde cholangiopancreatography, which reveals intraluminal irregularities of the proximal intrahepatic ducts with “pruning” of the terminal ductal branches. Stenosis of the distal common bile duct at the papilla is commonly seen with this syndrome. CMV, *Cryptosporidium*, and microsporidia are thought to play inciting roles in this syndrome.

4. Enterocolitis—

A. PRESENTATION—Enterocolitis is a common problem in HIV-infected individuals. Organisms known to cause enterocolitis include bacteria (*Campylobacter*, *Salmonella*, *Shigella*), viruses (CMV, adenovirus), and protozoans (*Cryptosporidium*, *Entamoeba histolytica*, *Giardia*, *Isospora*, microsporidia). HIV itself may cause enterocolitis. Several of the organisms causing enterocolitis in HIV-infected individuals also cause diarrhea in immunocompetent persons. However, HIV-infected patients tend to have more severe and more chronic symptoms, including high fevers and severe abdominal pain that can mimic acute abdominal catastrophes. Bacteremia and concomitant biliary involvement are also more common with enterocolitis in HIV-infected patients. Relapses of enterocolitis following adequate therapy have been reported with both *Salmonella* and *Shigella* infections.

Because of the wide range of agents known to cause enterocolitis, a stool culture and multiple stool examinations for ova and parasites (including modified acid-fast staining for *Cryptosporidium*) should be performed. Those patients who have *Cryptosporidium* in one stool with improvement in symptoms in < 1 month should not be considered to have AIDS, as *Cryptosporidium* is a cause of self-limited diarrhea in HIV-negative persons. More commonly, HIV-infected patients with *Cryptosporidium* infection have persistent enterocolitis with profuse watery diarrhea.

B. MANAGEMENT—To date, no consistently effective treatments have been developed for *Cryptosporidium* infection. The most effective treatment of cryptosporidiosis is to improve immune function through the use of effective antiretroviral treatment. The diarrhea can be treated symptomatically with diphenoxylate with atropine (one or two tablets orally three or four times a day). Those who do not respond may be given paregoric with bismuth (5–10 mL orally three or four times a day). Octreotide in escalating doses (starting at 0.05 mg subcutaneously every 8 hours for 48 hours) has been found to ameliorate symptoms in approximately 40% of patients with cryptosporidia or idiopathic HIV-associated diarrhea.

Patients with a negative stool examination and persistent symptoms should be evaluated with colonoscopy and biopsy. Patients whose symptoms last longer than 1 month with no identified cause of diarrhea are considered to have a presumptive diagnosis of AIDS enteropathy. Patients may respond to institution of effective antiretroviral treatment. Upper endoscopy with small bowel biopsy is not recommended as a routine part of the evaluation.

5. Other disorders—Two other important gastrointestinal abnormalities in HIV-infected patients are gastropathy and malabsorption. It has been documented that some HIV-infected patients do not produce normal levels of stomach acid and therefore are unable to absorb drugs that require an acid medium. This decreased acid production may explain, in part, the susceptibility of HIV-infected patients to *Campylobacter*, *Salmonella*, and

Shigella, all of which are sensitive to acid concentration. There is no evidence that *Helicobacter pylori* is more common in HIV-infected persons.

A malabsorption syndrome occurs commonly in AIDS patients. It can be due to infection of the small bowel with *M avium* complex, *Cryptosporidium*, or microsporidia.

J. Endocrinologic Manifestations

Hypogonadism is probably the most common endocrinologic abnormality in HIV-infected men. The adrenal gland is also a commonly afflicted endocrine gland in patients with AIDS. Abnormalities demonstrated on autopsy include infection (especially with CMV and *M avium* complex), infiltration with Kaposi sarcoma, and injury from hemorrhage and presumed autoimmunity. The prevalence of clinically significant adrenal insufficiency is low. Patients with suggestive symptoms should undergo a cosyntropin stimulation test.

Although frank deficiency of cortisol is rare, an isolated defect in mineralocorticoid metabolism may lead to salt-wasting and hyperkalemia. Such patients should be treated with fludrocortisone (0.1–0.2 mg daily).

AIDS patients appear to have abnormalities of thyroid function tests different from those of patients with other chronic diseases. AIDS patients have been shown to have high levels of triiodothyronine (T_3), thyroxine (T_4), and thyroid-binding globulin and low levels of reverse triiodothyronine (rT_3). The causes and clinical significance of these abnormalities are unknown.

K. Skin Manifestations

The skin manifestations that commonly develop in HIV-infected patients can be grouped into viral, bacterial, fungal, neoplastic, and nonspecific dermatitides.

1. Viral dermatitides—

A. HERPES SIMPLEX INFECTIONS—These infections occur more frequently, tend to be more severe, and are more likely to disseminate in AIDS patients than in immunocompetent persons. Because of the risk of progressive local disease, all herpes simplex attacks should be treated with acyclovir (400 mg orally three times a day until healed, usually 7 days), famciclovir (500 mg orally twice daily until healed), or valacyclovir (500 mg orally twice daily until healed). To avoid the complications of attacks, many clinicians recommend suppressive therapy for HIV-infected patients with a history of recurrent herpes. Options for suppressive therapy include acyclovir (400 mg orally twice daily), famciclovir (250 mg orally twice daily), and valacyclovir (500 mg orally daily). A randomized trial of women infected with both herpes simplex and HIV showed that suppressive therapy with valacyclovir at a dose of 500 mg orally twice daily decreased genital and plasma HIV-1 RNA levels, suggesting the possibility that suppressive treatment may reduce HIV transmission. However, a recent large randomized clinical trial failed to show a reduction in HIV transmission with suppressive acyclovir therapy.

B. HERPES ZOSTER—This is a common manifestation of HIV infection. As with herpes simplex infections, patients with zoster should be treated with acyclovir to prevent dissemination (800 mg orally four or five times per day for 7 days). Alternatively, famciclovir (500 mg orally three times a day) or valacyclovir (500 mg three times a day) may be used. Vesicular lesions should be cultured if there is any question about their origin, since herpes simplex responds to much lower doses of acyclovir. Disseminated zoster and cases with ocular involvement should be treated with intravenous (10 mg/kg every 8 hours for 7–10 days) rather than oral acyclovir.

C. MOLLUSCUM CONTAGIOSUM—This infection is caused by a pox virus is seen in HIV-infected patients, as in other immunocompromised patients. The characteristic umbilicated fleshy papular lesions have a propensity for spreading widely over the patient's face and neck and should be treated with topical liquid nitrogen.

2. Bacterial dermatitides—

A. STAPHYLOCOCCAL INFECTION—*Staphylococcus* is the most common bacterial cause of skin disease in HIV-infected patients; it usually presents as **folliculitis**, **superficial abscesses (furuncles)**, or **bullous impetigo**. Because dissemination with sepsis has been reported, attempts should be made to treat these lesions aggressively. Folliculitis is initially treated with topical clindamycin or mupirocin, and patients may benefit from regular washing with an antibacterial soap such as chlorhexidine. Intranasal mupirocin has been used successfully for staphylococcal decolonization in other settings. In HIV-infected patients with recurrent staphylococcal infections, weekly intranasal mupirocin should be considered in addition to topical care and systemic antibiotics. Abscesses often require incision and drainage. Patients may need antistaphylococcal antibiotics as well. Due to high frequency of methicillin-resistant *Staphylococcus aureus* (MRSA) skin infections in HIV-infected populations, lesions should be cultured prior to initiating empiric antistaphylococcal therapy. Although there is limited experience treating MRSA with oral antibiotics, current recommendations for empiric treatment are trimethoprim-sulfamethoxazole (one double-strength tablet orally twice daily) with or without clindamycin (500 mg orally three times daily) or doxycycline (100 mg orally twice daily) with close follow-up.

B. BACILLARY ANGIOMATOSIS—This is a well-described entity in HIV-infected patients. It is caused by two closely related organisms: *Bartonella henselae* and *Bartonella quintana*. The epidemiology of these infections suggests zoonotic transmission from fleas of infected domestic cats. The most common manifestation is raised, reddish, highly vascular skin lesions that can mimic the lesions of Kaposi sarcoma. Fever is a common manifestation of this infection; involvement of bone, lymph nodes, and liver has also been reported. The infection responds to doxycycline, 100 mg orally twice daily, or erythromycin, 250 mg orally four times daily. Therapy is continued for at least 14 days, and patients who are seriously ill with visceral involvement may require months of therapy.

3. Fungal rashes—

A. RASHES DUE TO DERMATOPHYTES AND CANDIDA—The majority of **fungal rashes** afflicting AIDS patients are due to dermatophytes and *Candida*. These are particularly common in the inguinal region but may occur anywhere on the body. Fungal rashes generally respond well to topical clotrimazole (1% twice a day) or ketoconazole (2% twice a day).

B. SEBORRHEIC DERMATITIS—This is more common in HIV-infected patients. Scrapings of seborrhea have revealed *Malassezia furfur* (*Pityrosporum ovale*), implying that the seborrhea is caused by this fungus. Consistent with the isolation of this fungus is the clinical finding that seborrhea responds well to topical clotrimazole (1% cream) as well as hydrocortisone (1% cream).

4. Neoplastic dermatitides—See Chapter 6 and the Kaposi sarcoma section below.

5. Nonspecific dermatitides—

A. XEROSIS—This condition presents in HIV-infected patients with severe pruritus. The patient may have no rash, or nonspecific excoriations from scratching. Treatment is with emollients (eg, absorption base cream) and antipruritic lotions (eg, camphor 9.5% and menthol 0.5%).

B. PSORIASIS—Psoriasis can be very severe in HIV-infected patients. Phototherapy and etretinate (0.25–9.75 mg/kg/d orally in divided doses) may be used for recalcitrant cases in consultation with a dermatologist.

L. HIV-Related Malignancies

Four cancers are currently included in the CDC classification of AIDS: Kaposi sarcoma, non-Hodgkin lymphoma, primary lymphoma of the brain, and invasive cervical carcinoma. Epidemiologic studies have shown that between 1973 and 1987 among single men in San Francisco, the risk of Kaposi sarcoma increased more than 5000-fold and the risk of non-Hodgkin lymphoma more than tenfold. The increase in incidence of malignancies is probably a function of impaired cell-mediated immunity.

1. Kaposi sarcoma—

A. PRESENTATION—Lesions may appear anywhere; careful examination of the eyelids, conjunctiva, pinnae, palate, and toe webs is mandatory to locate potentially occult lesions. In light-skinned individuals, Kaposi lesions usually appear as purplish, nonblanching lesions that can be papular or nodular. In dark-skinned individuals, the lesions may appear more brown. In the mouth, lesions are most often palatal papules, though exophytic lesions of the tongue and gingivae may also be seen. Kaposi lesions may be confused with other vascular lesions such as angiomas and pyogenic granulomas. Visceral disease (eg, gastrointestinal, pulmonary) will develop in about 40% of patients with dermatologic Kaposi sarcoma. Kaposi sarcoma lesions can occur shortly after initiating ART, especially in patients starting ART who have advanced immunodeficiency. In this situation, Kaposi sarcoma is likely to be an immune reconstitution reaction (see below).

B. MANAGEMENT—Rapidly progressive dermatologic or visceral disease is best treated with systemic chemotherapy. Liposomally encapsulated doxorubicin given intravenously every 3 weeks has a response rate of approximately 70%. α -Interferon (10 million units subcutaneously three times a week) also has activity against Kaposi sarcoma. However, symptoms such as malaise and anorexia limit the utility of this therapy. Patients with milder forms of Kaposi sarcoma do not require specific treatment as the lesions usually improve and can completely resolve with ART. However, it should be noted that the lesions may flare when ART is first initiated—probably as a result of an immune reconstitution process (see Inflammatory reactions below).

2. Non-Hodgkin lymphoma—

A. PRESENTATION—Non-Hodgkin lymphoma in HIV-infected persons tends to be very aggressive. The malignancies are usually of B cell origin and characterized as diffuse large-cell tumors. Over 70% of the malignancies are extranodal.

B. MANAGEMENT—The prognosis of patients with systemic non-Hodgkin lymphoma depends primarily on the degree of immunodeficiency at the time of diagnosis. Patients with high CD4 counts do markedly better than those diagnosed at a late stage of illness. Patients with primary central nervous system lymphoma are treated with radiation. Response to treatment is good, but prior to the availability of HAART, most patients died within a few months after diagnosis due to their underlying disease. Systemic disease is treated with chemotherapy. Common regimens are CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) and modified M-BACOD (methotrexate, bleomycin, doxorubicin, cyclophosphamide, vincristine, and dexamethasone). Granulocyte colony-stimulating factor (G-CSF; filgrastim) is used to maintain white blood counts with this latter regimen. Intrathecal chemotherapy is administered to prevent or treat meningeal involvement.

3. Hodgkin disease—Although Hodgkin disease is not included as part of the CDC definition of AIDS, studies have found that HIV infection is associated with a fivefold increase in the incidence of Hodgkin disease. HIV-infected persons with Hodgkin disease are more likely to have mixed cellularity and lymphocyte depletion subtypes of Hodgkin disease and to seek medical attention at an advanced stage of disease.

4. Anal dysplasia and squamous cell carcinoma—These lesions have been strongly correlated with previous infection by human papillomavirus (HPV) and have been noted in HIV-infected men and women. Although many of the infected MSM report a history of anal warts or have visible warts, a significant percentage have silent papillomavirus infection. Cytologic (using Papanicolaou smears) and papillomavirus DNA studies can easily be performed on specimens obtained by anal swab. Because of the risk of progression from dysplasia to cancer in immunocompromised patients, some experts suggest that annual anal swabs for cytologic examination should be done in all

HIV-infected persons. An anal Papanicolaou smear is performed by rotating a moistened Dacron swab about 2 cm into the anal canal. The swab is immediately inserted into a cytology bottle. However, there is no evidence that screening for anal cancer with Papanicolaou smears decreases the incidence of invasive cancer.

HPV also appears to play a causative role in **cervical dysplasia** and **neoplasia**. The incidence and clinical course of cervical disease in HIV-infected women are discussed below.

M. Gynecologic Manifestations

Vaginal candidiasis, cervical dysplasia and neoplasia, and pelvic inflammatory disease are more common in HIV-infected women than in uninfected women. These manifestations also tend to be more severe when they occur in association with HIV infection. Therefore, HIV-infected women need frequent gynecologic care. Vaginal candidiasis may be treated with topical agents (see Chapter 36). However, HIV-infected women with recurrent or severe vaginal candidiasis may need systemic therapy.

The incidence of cervical dysplasia in HIV-infected women is 40%. Because of this finding, HIV-infected women should have Papanicolaou smears every 6 months (as opposed to the Agency for Healthcare Research and Quality [AHRQ] Guideline recommendation for every 12 months). Some clinicians recommend routine colposcopy or cervicography because cervical intraepithelial neoplasia has occurred in women with negative Papanicolaou smears. Cone biopsy is indicated in cases of serious cervical dysplasia. For 1 year following treatment of an abnormal Papanicolaou smear, women should have repeat smears every 3 to 4 months.

Cervical neoplasia appears to be more aggressive among HIV-infected women. Most HIV-infected women with cervical cancer die of that disease rather than of AIDS. Because of its frequency and severity, cervical neoplasia was added to the CDC definition of AIDS in 1993.

While pelvic inflammatory disease appears to be more common in HIV-infected women, the bacteriology of this condition appears to be the same as among HIV-uninfected women. At present, HIV-infected women with pelvic inflammatory disease should be treated with the same regimens as uninfected women (see Chapter 18). However, inpatient therapy is generally recommended.

N. Coronary Artery Disease

HIV-infected persons are at higher risk for coronary artery disease than age- and sex-matched controls. Part of this increase in coronary artery disease is due to changes in lipids caused by antiretroviral agents (see Treatment section on Antiretroviral Therapy below), especially stavudine and several of the PIs. However, some of the risk appears to be due to HIV infection, independent of its therapy. It is important that clinicians pay close attention to this issue because the first presentation of coronary artery disease in HIV-infected persons may be sudden death. HIV-infected patients with symptoms of coronary artery disease such as chest pain or dyspnea should be rapidly evaluated. Clinicians should aggressively treat conditions that result

in increased risk of heart disease, especially smoking, hypertension, hyperlipidemia, obesity, diabetes mellitus, and sedentary lifestyle.

O. Inflammatory Reactions (Immune Reconstitution Syndromes)

With initiation of HAART, some patients experience inflammatory reactions that appear to be associated with immune reconstitution as indicated by a rapid increase in CD4 count. These inflammatory reactions may present with generalized signs of fevers, sweats, and malaise with or without more localized manifestations that usually represent unusual presentations of opportunistic infections. For example, vitreitis has developed in patients with CMV retinitis after they have been treated with HAART.

M avium can present as focal even suppurative lymphadenitis or granulomatous masses in patients receiving HAART. Tuberculosis may paradoxically worsen with new or evolving pulmonary infiltrates and lymphadenopathy. PML and cryptococcal meningitis may also behave atypically. Clinicians should be alert to these syndromes, which are most often seen in patients who have initiated ART in the setting of advanced disease and who show rapid increases in CD4 counts with treatment. The diagnosis of IRIS is one of exclusion and can be made only after recurrence or new opportunistic infection has been ruled out as the cause of the clinical deterioration. Management of IRIS is conservative and supportive with use of corticosteroids only for severe reactions. Most authorities recommend that ART be continued unless the reaction is life-threatening.

► Prevention

A. Primary Prevention

Until vaccination is a reality, prevention of HIV infection will depend on effective precautions regarding sexual practices and injection drug use, use of perinatal HIV prophylaxis, screening of blood products, and infection control practices in the health care setting. Primary care clinicians should routinely obtain a sexual history and provide risk factor assessment of their patients. Because approximately one-fifth of the HIV-infected persons in the United States do not know they are infected, the CDC recommends all adults be tested for HIV as a routine part of medical care. Clinicians should review the risk factors for HIV infection with the patient and discuss safer sex and safer needle use as well as the meaning of a positive test. Although the CDC recommends “opt-out” testing in medical settings, some states require specific written consent. For persons whose test results are positive, referrals for partner-notification services, social services, mental health services, and HIV-prevention services should be provided. Prevention interventions focused on the importance of HIV-infected persons not putting others at risk have been successful. For patients whose test results are negative, clinicians should review safer sex and needle use practices, including counseling not to exchange bodily fluids unless they are in a long-term

mutually monogamous relationship with someone who has tested HIV antibody-negative and has not engaged in unsafe sex, injection drug use, or other HIV risk behaviors for at least 6 months prior to or at any time since the negative test.

Only latex condoms should be used, along with a water-soluble lubricant. Although nonoxynol-9, a spermicide, kills HIV, it is contraindicated because in some patients it may cause genital ulcers that could facilitate HIV transmission. Patients should be counseled that condoms are not 100% effective. They should be made familiar with the use of condoms, including, specifically, the advice that condoms must be used every time, that space should be left at the tip of the condom as a receptacle for semen, that intercourse with a condom should not be attempted if the penis is only partially erect, that men should hold on to the base of the condom when withdrawing the penis to prevent slippage, and that condoms should not be reused. Although anal intercourse remains the sexual practice at highest risk for transmitting HIV, seroconversions have been documented with vaginal and oral intercourse as well. Therefore, condoms should be used when engaging in these activities. Women as well as men should understand how to use condoms so as to be sure that their partners are using them correctly. Several recent randomized trials in Africa demonstrated that male circumcision significantly reduced HIV incidence in men, but there are a number of barriers to performing widespread circumcisions among men in Africa.

Two major studies have demonstrated the proof of concept that HIV transmission can be reduced by drugs that are used to treat HIV infection. In a study from South Africa, women who used a tenofovir-containing vaginal gel reduced their risk of HIV infection by 39% and those who followed the recommended application schedule (use before and after intercourse) had a more than 50% reduction in risk of infection. In a randomized placebo-controlled study of MSM across several different countries, researchers showed that risk of HIV transmission was reduced by 44% in those men receiving daily tenofovir/emtricitabine fixed-dose combination; in those who were over 90% adherent, the risk was reduced more 70%. Although transmission was not universally prevented in either of these studies, they demonstrate that “biological methods” could serve as a useful adjunct to current behavioral approaches in preventing HIV transmission.

In addition, having persons with HIV take effective ART appears to reduce the chance that they can transmit HIV to their partners. An international study showed that among serodiscordant couples, early ART almost completely eliminated the risk of HIV transmission to the uninfected partner. Although HIV-negative persons in stable long-term partnerships with HIV-infected persons represent only one group of at risk persons, theoretically increasing the use of ART among the population of HIV-infected persons could decrease community wide transmission of HIV.

Persons using injection drugs should be cautioned never to exchange needles or other drug paraphernalia. When sterile needles are not available, bleach does appear to inactivate HIV and should be used to clean needles.

Current efforts to screen blood and blood products have lowered the risk of HIV transmission with transfusion of a unit of blood to 1:1,000,000.

In health care settings, universal body fluid precautions should be used, including use of gloves when handling body fluids and the addition of gown, mask, and goggles for procedures that may result in splash or droplet spread, and use of specially designed needles with sheath devices to decrease the risk of needle sticks. Because transmission of tuberculosis may occur in health care settings, all patients with cough should be encouraged to wear masks. Hospitalized HIV-infected patients with cough should be placed in respiratory isolation until tuberculosis can be excluded by chest radiograph and sputum smear examination.

Primate model data have suggested that development of a protective vaccine may be possible, but clinical trials in humans have been disappointing. Only one vaccine trial has shown any degree of efficacy. In this randomized, double-blind, placebo-controlled trial, a recombinant canarypox vector vaccine plus two booster injections of a recombinant gp120 vaccine was moderately efficacious (26–31%) in reducing the risk of HIV among a primarily heterosexual population in Thailand. Current vaccine development efforts are aimed at identifying broadly neutralizing antibodies to the highly conserved regions of the HIV envelope.

B. Secondary Prevention

In the era prior to the development of highly effective antiretroviral treatment, cohort studies of individuals with documented dates of seroconversion demonstrate that AIDS develops within 10 years in approximately 50% of untreated seropositive persons. With currently available treatment, progression of disease has been markedly decreased. In addition to antiretroviral treatment, prophylactic regimens can prevent opportunistic infections and improve survival. Prophylaxis and early intervention prevent several infectious diseases, including tuberculosis and syphilis, which are transmissible to others. Recommendations for screening tests, vaccinations, and prophylaxis are listed in Table 31–3.

1. Tuberculosis—Because of the increased occurrence of tuberculosis among HIV-infected patients, all such individuals should undergo PPD testing. Although anergy is common among AIDS patients, the likelihood of a false-negative result is much lower when the test is done early in infection. Those with positive tests (defined for HIV-infected patients as > 5 mm of induration) need a chest radiograph. Patients with an infiltrate in any location, especially if accompanied by mediastinal adenopathy, should have sputum sent for acid-fast staining. Patients with a positive PPD but negative evaluations for active disease should receive isoniazid (300 mg orally daily) with pyridoxine (50 mg orally daily) for 9 months to a year. A blood test (QuantiFERON Gold test) can also be used to assess prior tuberculosis exposure. Blood samples are mixed with synthetic antigens representing *M tuberculosis*. Patients infected with *M tuberculosis* produce interferon-gamma in response to contact with the antigens. Unlike the PPD, the patient does not have to return for a second

Table 31–3. Health care maintenance of HIV-infected individuals.

For all HIV-infected individuals:

CD4 counts every 3–6 months
Viral load tests every 3–6 months and 1 month following a change in therapy
Cholesterol and triglycerides at baseline, 6–12 months after starting antiretroviral therapy, and annually for everyone over 40 years of age

PPD

INH for those with positive PPD and normal chest radiograph
RPR or VDRL

Toxoplasma IgG serology

Hepatitis serologies: hepatitis A antibody, hepatitis B surface antigen, hepatitis B surface antibody, hepatitis B core antibody, hepatitis C antibody

Pneumococcal vaccine

Inactivated influenza vaccine in season

Hepatitis A vaccine for those without immunity to hepatitis A.

Hepatitis B vaccine for those who are hepatitis B surface antigen and antibody negative. (Use 40 mcg formulation at 0, 1, and 6 months; repeat if no immunity 1 month after three-shot series.)

Combined tetanus, diphtheria, pertussis vaccine

Human papillomavirus vaccine for HIV-infected women age 26 years or less.

Haemophilus influenzae type b vaccination

Bone mineral density monitoring for women and men over 50 years of age

Papanicolaou smears every 6 months for women

Consider anal swabs for cytologic evaluation

For HIV-infected individuals with CD4 < 200 cells/mcL:

Pneumocystis jiroveci prophylaxis (see Prophylaxis of Opportunistic Infections section under Treatment and Table 31–4)

For HIV-infected individuals with CD4 < 75 cells/mcL:

Mycobacterium avium complex prophylaxis (see Prophylaxis of Opportunistic Infections section under Treatment)

For HIV-infected individuals with CD4 < 50 cells/mcL:

Consider CMV prophylaxis

PPD, purified protein derivative; INH, isoniazid; RPR, rapid plasma reagin; VDRL, Venereal Disease Research Laboratories; IgG, immunoglobulin G.

visit. The test is less likely to result in false-positive results than a PPD. Unfortunately, HIV-infected persons may not produce sufficient interferon-gamma, in which case the test may be falsely negative.

2. Syphilis—Because of recent increases in the number of cases of syphilis among MSM, including those who are HIV infected, all such men should be screened for syphilis by rapid plasma reagin (RPR) or Venereal Disease Research Laboratories (VDRL) test every 6 months. Increases of syphilis cases among HIV-infected persons are of particular concern because these individuals are at increased risk for reactivation of syphilis and progression to tertiary syphilis despite standard treatment. Because the only widely available tests for syphilis are serologic and because HIV-infected individuals are known to have

disordered antibody production, there is concern about the interpretation of these titers. This concern has been fueled by a report of an HIV-infected patient with secondary syphilis and negative syphilis serologic testing. Furthermore, HIV-infected individuals may lose fluorescent treponemal antibody absorption (FTA-ABS) reactivity after treatment for syphilis, particularly if they have low CD4 counts. Thus, in this population, a nonreactive treponemal test does not rule out a past history of syphilis. In addition, persistence of treponemes in the spinal fluid after one dose of benzathine penicillin has been demonstrated in HIV-infected patients with primary and secondary syphilis. Therefore, the CDC has recommended an aggressive diagnostic approach to HIV-infected patients with reactive RPR or VDRL tests of > 1 year or unknown duration. All such patients should have a lumbar puncture with cerebrospinal fluid cell count and cerebrospinal fluid VDRL. Those with a normal cerebrospinal fluid evaluation are treated as having late latent syphilis (benzathine penicillin G, 2.4 million units intramuscularly weekly for 3 weeks) with follow-up titers. Those with a pleocytosis or a positive cerebrospinal fluid-VDRL test are treated as having neurosyphilis (aqueous penicillin G, 2–4 million units intravenously every 4 hours, or procaine penicillin G, 2.4 million units intramuscularly daily, with probenecid, 500 mg four times daily, for 10 days). Some clinicians take a less aggressive approach to patients who have low titers (< 1:8), a history of having been treated for syphilis, and a normal neurologic examination. Close follow-up of titers is mandatory if such a course is taken. For a more detailed discussion of this topic, see Chapter 34.

3. Immunizations—HIV-infected individuals should receive the pneumococcal vaccine and the inactivated influenza vaccine. Patients without immunity to hepatitis A should be vaccinated against it. Patients without evidence of hepatitis B surface antigen or surface antibody should receive hepatitis B vaccination, using the 40 mcg formulation; the higher dose is to increase the chance of developing protective immunity. If the patient does not have immunity 1 month after the three-shot series, then the series should be repeated. HIV-infected persons should also receive the standard inactivated vaccines such as tetanus and diphtheria boosters that would be given to uninfected persons. Live vaccines, such as yellow fever vaccine, should be avoided. Measles vaccination, while a live virus vaccine, appears relatively safe when administered to HIV-infected individuals and should be given if the patient has never had measles or been adequately vaccinated. Herpes zoster vaccine is contraindicated in HIV-infected persons with evidence of immune suppression.

4. Other measures—A randomized study found that multivitamin supplementation decreased HIV disease progression and mortality in HIV-infected women in Africa. However, supplementation is unlikely to be as effective in well-nourished populations.

HIV-infected individuals should be counseled with regard to safe sex. Because of the risk of transmission, they should be warned to use condoms with sexual intercourse,

including oral intercourse. Partners of HIV-infected women should use latex barriers such as dental dams (available at dental supply stores) to prevent direct oral contact with vaginal secretions. Substance abuse treatment should be recommended for persons who are using recreational drugs. They should be warned to avoid consuming raw meat or eggs to avoid infections with *Toxoplasma*, *Campylobacter*, and *Salmonella*. HIV-infected patients should wash their hands thoroughly after cleaning cat litter or should forgo this household chore to avoid possible exposure to toxoplasmosis. To reduce the likelihood of infection with *Bartonella* species, patients should avoid activities that might result in cat scratches or bites. Although the data are not conclusive, many clinicians recommend that HIV-infected persons—especially those with low CD4 counts—drink bottled water instead of tap water to prevent cryptosporidia infection.

Because of the emotional impact of HIV infection and subsequent illness, many patients will benefit from supportive counseling.

C. HIV Risk for Health Care Professionals

Epidemiologic studies show that needle sticks occur commonly among health care professionals, especially among surgeons performing invasive procedures, inexperienced hospital house staff, and medical students. Efforts to reduce needle sticks should focus on avoiding recapping needles and use of safety needles whenever doing invasive procedures under controlled circumstances. The risk of HIV transmission from a needle stick with blood from an HIV-infected patient is about 1:300. The risk is higher with deep punctures, large inocula, and source patients with high viral loads. The risk from mucous membrane contact is too low to quantitate.

Health care professionals who sustain needle sticks should be counseled and offered HIV testing as soon as possible. HIV testing is done to establish a negative baseline for worker's compensation claims in case there is a subsequent conversion. Follow-up testing is usually performed at 6 weeks, 3 months, and 6 months.

A case-control study by the CDC indicates that administration of zidovudine following a needle stick decreases the rate of HIV seroconversion by 79%. Therefore, providers should be offered therapy with Combivir (zidovudine 300 mg plus lamivudine 150 mg orally twice daily). Therapy should be started as soon as possible after exposure and continued for 4 weeks. Providers who have exposures to persons who are likely to have antiretroviral drug resistance (eg, persons receiving therapy who have detectable viral loads) should have their therapy individualized, using at least two drugs to which the source is unlikely to be resistant. Some clinicians recommend triple combination regimens, including a PI for all occupational exposures, because of uncertainty about drug resistance. Others save these more aggressive regimens for the higher-risk exposures listed above. Because reports have noted hepatotoxicity due to nevirapine in this setting, this agent should be avoided. Unfortunately, there have been documented cases of seroconversion following potential parenteral exposure to HIV despite prompt use of zidovudine

prophylaxis. Counseling of the provider should include “safer sex” guidelines.

D. Postexposure Prophylaxis for Sexual and Drug Use Exposures to HIV

Following publication of a case-control study indicating that ART decreased the odds of seroconversion among health care workers who had occupational exposure, some experts have recommended offering ART following potential exposure to HIV through sexual activity or drug use. Although there are no efficacy data to support this practice, there are similarities between the immune response following transcutaneous and transmucosal exposures. The goal of postexposure prophylaxis is to reduce or prevent local viral replication prior to dissemination such that the infection can be aborted.

The choice of antiretroviral agents and the duration of treatment are the same as those for exposures that occur through the occupational route (see above). In contrast to those with occupational exposures, some individuals may present very late after exposure. Because the likelihood of success declines with length of time from HIV exposure, it is not recommended that treatment be offered after 72 hours. In addition, because the psychosocial issues involved with postexposure prophylaxis for sexual and drug use exposures are complex, it should be offered only in the context of prevention counseling. Counseling should focus on how to prevent future exposures. Clinicians needing more information on postexposure prophylaxis for occupational or nonoccupational exposures should contact the National Clinician’s Post-exposure Hotline (1-888-448-4911; http://www.nccc.ucsf.edu/about_nccc/pepline/).

E. Preventing Perinatal Transmission of HIV

A multicenter trial showed that when zidovudine is administered to women during pregnancy, labor, and delivery and to their newborns, the rate of HIV transmission is decreased by two-thirds. An observational trial demonstrated that zidovudine treatment is almost as effective when begun during labor or when administered only to the infant, as long as treatment is begun within 48 hours after birth. Nonetheless, treatment begun by at least the second trimester is still recommended. Many women are currently being offered combination antiretroviral treatment to further lower the risk of transmission. The availability of treatment makes it essential that all women who are pregnant or considering pregnancy be offered HIV counseling and testing. Many obstetricians recommend combination antiretroviral treatment, especially if zidovudine resistance is suspected. HIV-infected women receiving ART in whom pregnancy is recognized during the first trimester should be counseled about the benefits and potential risks to the fetus of treatment during the first trimester. Because healthy mothers make healthy babies, continuation of therapy should be strongly considered. Because about half of fetal infections in non-breast-feeding women occur shortly before or during the birth process, ART should be administered whenever a woman initiates perinatal care even if she did not begin therapy in the second trimester. Breast-feeding is

thought to increase the rate of transmission by 10–20% and should be avoided.

- Abdool Karim Q et al; CAPRISA 004 Trial Group. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. *Science*. 2010 Sep 3;329(5996):1168–74. [PMID: 20643915]
- Branson BM et al; Centers for Disease Control and Prevention (CDC). Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. *MMWR Recomm Rep*. 2006 Sep 22;55(RR-14):1–17. [PMID: 16988643]
- Cohen MS et al; HPTN 052 Study Team. Prevention of HIV-1 infection with early antiretroviral therapy. *N Engl J Med*. 2011 Aug 11;365(6):493–505. [PMID: 21767103]
- Grant RM et al; iPrEx Study Team. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. *N Engl J Med*. 2010 Dec 30;363(27):2587–99. [PMID: 21091279]
- Johnston MI et al. HIV vaccine development—improving on natural immunity. *N Engl J Med*. 2011 Sep 8;365(10):873–5. [PMID: 21899447]
- Landovitz RJ et al. Clinical practice. Postexposure prophylaxis for HIV infection. *N Engl J Med*. 2009 Oct 29;361(18):1768–75. [PMID: 19864675]
- Mahajan AP et al. Consistency of state statutes with the Centers for Disease Control and Prevention HIV testing recommendations for health care settings. *Ann Intern Med*. 2009 Feb 17;150(4):263–9. [PMID: 19221378]
- Sax PE et al; AIDS Clinical Trials Group Study A5164 Team. Blood (1→3)-beta-D-glucan as a diagnostic test for HIV *Pneumocystis jirovecii* pneumonia. *Clin Infect Dis*. 2011 Jul 15;53(2):197–202. [PMID: 21690628]

► Treatment

Treatment for HIV infection can be broadly divided into the following categories: (1) prophylaxis for opportunistic infections, malignancies, and other complications of HIV infection; (2) treatment of opportunistic infections, malignancies, and other complications of HIV infection; and (3) treatment of the HIV infection itself with combination ART.

Treatment regimens for HIV infection are constantly changing. Clinicians may obtain up-to-date information on new and experimental treatments by calling the AIDS Clinical Trials Information Service (ACTIS), 800-TRIALS-A (English and Spanish), and the National AIDS Hot Line, 800-342-AIDS (English), 800-344-SIDA (Spanish), and 800-AIDS-TTY (hearing-impaired).

A. Prophylactic Treatment of Complications of HIV Infection

In general, decisions about prophylaxis of opportunistic infections are based on the CD4 count, other evidence of severe immunosuppression (eg, oral candidiasis), and a history of having had the infection in the past. In the era prior to HAART, patients who started taking prophylactic regimens were maintained on them indefinitely. However, studies have shown that in patients with robust improvements in immune function—as measured by increases in CD4 counts above the levels that are used to initiate treatment—prophylactic regimens can safely be discontinued.

Because individuals with advanced HIV infection are susceptible to a number of opportunistic pathogens, the use of agents with activity against more than one pathogen is preferable. It has been shown, for example, that trimethoprim-sulfamethoxazole confers some protection against toxoplasmosis in individuals receiving this drug for *Pneumocystis* prophylaxis.

1. Prophylaxis against *Pneumocystis pneumonia*—

Patients with CD4 counts below 200 cells/mcL, a CD4 lymphocyte percentage below 14%, or weight loss or oral candidiasis should be offered primary prophylaxis for *Pneumocystis pneumonia*. Patients with a history of *Pneumocystis pneumonia* should receive secondary prophylaxis until they have had a durable virologic response to HAART for at least 3–6 months and maintain a CD4 count of > 250 cells/mcL. Regimens for *Pneumocystis* prophylaxis are given in Table 31–4.

2. Prophylaxis against *M avium* complex infection—

Patients whose CD4 counts fall to below 75–100 cells/mcL should be given prophylaxis against *M avium* complex infection. Clarithromycin (500 mg orally twice daily) and azithromycin (1200 mg orally weekly) have both been shown to decrease the incidence of disseminated *M avium* complex infection by approximately 75%, with a low rate of breakthrough of resistant disease. The azithromycin regimen is generally preferred based on high compliance and low cost. Adding rifabutin increases the toxicity of the regimen but does not significantly increase its efficacy and is therefore not recommended. Prophylaxis against *M avium* complex infection may be discontinued in patients whose CD4 counts rise above 100 cells/mcL in response to HAART and whose plasma viral load has been optimally suppressed to < 50–75 copies/mL.

3. Prophylaxis against *M tuberculosis* infection—

Isoniazid, 300 mg orally daily, plus pyridoxine, 50 mg orally daily, for 9–12 months should be given to all HIV-infected patients with positive PPD reactions (defined as > 5 mm of induration for HIV-infected patients).

4. Prophylaxis against toxoplasmosis—Toxoplasmosis prophylaxis is desirable in patients with a positive IgG toxoplasma serology and CD4 counts below 100 cells/mcL. Trimethoprim-sulfamethoxazole (one double-strength tablet daily) offers good protection against toxoplasmosis, as does a combination of pyrimethamine, 25 mg orally once a week, plus dapsone, 50 mg orally daily, plus leucovorin, 25 mg orally once a week. A glucose-6-phosphate dehydrogenase (G6PD) level should be checked prior to dapsone therapy, and a methemoglobin level should be checked at 1 month.

5. Prophylaxis against CMV infection—Oral ganciclovir (1000 mg three times daily with food) is approved for CMV prophylaxis among HIV-infected persons with advanced disease (eg, CD4 counts below 50 cells/mcL). However, because the drug causes neutropenia, it is not widely used. Clinicians should consider performing serum CMV IgG antibody testing prior to starting ganciclovir. Persons who are CMV IgG-negative are not at risk for development of CMV disease, although it is important that such patients receive only CMV-negative blood if they require transfusion. Because over 99% of MSM are positive for CMV IgG, it is appropriate to reserve such testing for heterosexuals with HIV.

6. Prophylaxis against cryptococcosis, candidiasis, and endemic fungal diseases—

One trial showed a decreased incidence of cryptococcal disease with prophylaxis using fluconazole, 200 mg orally daily, but the treated group had no benefit in terms of mortality. Fluconazole (200 mg orally once a week) was found to prevent oral and vaginal candidiasis in women with CD4 counts below 300 cells/mcL. In areas of the world where histoplasmosis and coccidioidomycosis are endemic and are frequent complications of HIV infection, prophylactic use of fluconazole or itraconazole may prove to be useful strategies. However, the problem of identifying individuals at highest risk makes appropriate targeting of prophylaxis difficult.

B. Treatment of Complications of HIV Infection

Treatment of common AIDS-related complications is detailed above and in Table 31–5. In the era prior to the use

Table 31–4. *Pneumocystis jiroveci* prophylaxis in order of preference.

Drug	Dose	Side Effects	Limitations
Trimethoprim-sulfamethoxazole	One double-strength tablet three times a week to one tablet daily	Rash, neutropenia, hepatitis, Stevens-Johnson syndrome	Hypersensitivity reaction is common but, if mild, it may be possible to treat through.
Dapsone	50–100 mg orally daily or 100 mg two or three times per week	Anemia, nausea, methemoglobinemia, hemolytic anemia	Less effective than above. Glucose-6-phosphate dehydrogenase (G6PD) level should be checked prior to therapy. Check methemoglobin level at 1 month.
Atovaquone	1500 mg orally daily with a meal	Rash, diarrhea, nausea	Less effective than suspension trimethoprim-sulfamethoxazole; equal efficacy to dapsone, but more expensive.
Aerosolized pentamidine	300 mg monthly	Bronchospasm (pretreat with bronchodilators); rare reports of pancreatitis	Apical <i>Pneumocystis jiroveci</i> pneumonia, extrapulmonary <i>P jiroveci</i> infections, pneumothorax.

Table 31-5. Treatment of AIDS-related opportunistic infections and malignancies.¹

Infection or Malignancy	Treatment	Complications
<i>Pneumocystis jiroveci</i> infection ²	Trimethoprim-sulfamethoxazole, 15 mg/kg/d (based on trimethoprim component) orally or intravenously for 14-21 days. Pentamidine, 3-4 mg/kg/d intravenously for 14-21 days. Trimethoprim, 15 mg/kg/d orally, with dapsone, 100 mg/d orally, for 14-21 days. ³ Primaquine, 15-30 mg/d orally, and clindamycin, 600 mg every 8 hours orally, for 14-21 days. Atovaquone, 750 mg orally three times daily for 14-21 days. Trimetrexate, 45 mg/m ² intravenously for 21 days (given with leucovorin calcium) if intolerant of all other regimens.	Nausea, neutropenia, anemia, hepatitis, drug rash, Stevens-Johnson syndrome. Hypotension, hypoglycemia, anemia, neutropenia, pancreatitis, hepatitis. Nausea, rash, hemolytic anemia in G6PD ³ -deficient patients. Methemoglobinemia (weekly levels should be < 10% of total hemoglobin). Hemolytic anemia in G6PD-deficient patients. Methemoglobinemia, neutropenia, colitis. Rash, elevated aminotransferases, anemia, neutropenia. Leukopenia, rash, mucositis.
<i>Mycobacterium avium</i> complex infection	Clarithromycin, 500 mg orally twice daily with ethambutol, 15 mg/kg/d orally (maximum, 1 g). May also add: Rifabutin, 300 mg orally daily.	Clarithromycin: hepatitis, nausea, diarrhea; ethambutol: hepatitis, optic neuritis. Rash, hepatitis, uveitis.
Toxoplasmosis	Pyrimethamine, 100-200 mg orally as loading dose, followed by 50-75 mg/d, combined with sulfadiazine, 4-6 g orally daily in four divided doses, and folinic acid, 10 mg orally daily for 4-8 weeks; then pyrimethamine, 25-50 mg/d, with clindamycin, 2-2.7 g/d in three or four divided doses, and folinic acid, 5 mg/d, until clinical and radiographic resolution is achieved.	Leukopenia, rash.
Lymphoma	Combination chemotherapy (eg, modified CHOP, M-BACOD, with or without G-CSF or GM-CSF). Central nervous system disease: radiation treatment with dexamethasone for edema.	Nausea, vomiting, anemia, leukopenia, cardiac toxicity (with doxorubicin).
Cryptococcal meningitis	Amphotericin B, 0.6 mg/kg/d intravenously, with or without flucytosine, 100 mg/kg/d orally in four divided doses for 2 weeks, followed by: Fluconazole, 400 mg orally daily for 6 weeks, then 200 mg orally daily.	Fever, anemia, hypokalemia, azotemia. Hepatitis.
Cytomegalovirus infection	Valganciclovir, 900 mg orally twice a day for 21 days with food (induction), followed by 900 mg daily with food (maintenance). Ganciclovir, 10 mg/kg/d intravenously in two divided doses for 10 days, followed by 6 mg/kg 5 days a week indefinitely. (Decrease dose for kidney disease.) May use ganciclovir as maintenance therapy (1 g orally with fatty foods three times a day). Foscarnet, 60 mg/kg intravenously every 8 hours for 10-14 days (induction), followed by 90 mg/kg once daily. (Adjust for changes in kidney function.)	Neutropenia, anemia, thrombocytopenia. Neutropenia (especially when used concurrently with zidovudine), anemia, thrombocytopenia. Nausea, hypokalemia, hypocalcemia, hyperphosphatemia, azotemia.
Esophageal candidiasis or recurrent vaginal candidiasis	Fluconazole, 100-200 mg orally daily for 10-14 days.	Hepatitis, development of imidazole resistance.
Herpes simplex infection	Acyclovir, 400 mg orally three times daily until healed; or acyclovir, 5 mg/kg intravenously every 8 hours for severe cases. Famciclovir, 500 mg orally twice daily until healed. Valacyclovir, 500 mg orally twice daily until healed. Foscarnet, 40 mg/kg intravenously every 8 hours, for acyclovir-resistant cases. (Adjust for changes in kidney function.)	Resistant herpes simplex with chronic therapy. Nausea. Nausea. See above.

(continued)

Table 31-5. Treatment of AIDS-related opportunistic infections and malignancies.¹ (continued)

Infection or Malignancy	Treatment	Complications	
Herpes zoster	Acyclovir, 800 mg orally four or five times daily for 7 days. Intravenous therapy at 10 mg/kg every 8 hours for ocular involvement, disseminated disease.	See above.	
	Famciclovir, 500 mg orally three times daily for 7 days.	Nausea.	
	Valacyclovir, 500 mg orally three times daily for 7 days.	Nausea.	
	Foscarnet, 40 mg/kg intravenously every 8 hours for acyclovir-resistant cases. (Adjust for changes in kidney function.)	See above.	
Kaposi sarcoma	Limited cutaneous disease	Observation, intralesional vinblastine.	Inflammation, pain at site of injection.
	Extensive or aggressive cutaneous disease	Systemic chemotherapy (eg, liposomal doxorubicin). Interferon- α (for patients with CD4 > 200 cells/mcl and no constitutional symptoms). Radiation (amelioration of edema).	Bone marrow suppression, peripheral neuritis, flulike syndrome.
	Visceral disease (eg, pulmonary)	Combination chemotherapy (eg, daunorubicin, bleomycin, vinblastine).	Bone marrow suppression, cardiac toxicity, fever.

¹For treatment of *M tuberculosis* infection, see Chapter 9.

²For moderate to severe *P jiroveci* infection (oxygen saturation < 90%), corticosteroids should be given with specific treatment. The dose of prednisone is 40 mg orally twice daily for 5 days, then 40 mg daily for 5 days, and then 20 mg daily until therapy is complete.

³When considering use of dapsone, check glucose-6-phosphate dehydrogenase (G6PD) level in black patients and those of Mediterranean origin.

CHOP, cyclophosphamide, doxorubicin (hydroxydaunomycin), vincristine (Oncovin), and prednisone; G-CSF, granulocyte-colony stimulating factor (filgrastim); GM-CSF, granulocyte-macrophage colony-stimulating factor (sargramostim); modified M-BACOD, methotrexate, bleomycin, doxorubicin (Adriamycin), cyclophosphamide, vincristine (Oncovin), and dexamethasone.

of HAART, patients required lifelong treatment for many infections, including CMV retinitis, toxoplasmosis, and cryptococcal meningitis. However, among patients who have a good response to HAART, maintenance therapy for some opportunistic infections can be terminated. For example, in consultation with an ophthalmologist, maintenance treatment for CMV infection can be discontinued when persons receiving HAART have durable suppression of viral load (ie, < 50 copies/mL) and a CD4 count > 100–150 cells/mcL. Similar results have been observed in patients with *M avium* complex bacteremia. Prophylaxis for *P pneumonia* is also commonly discontinued in patients who have achieved and maintained a CD4 > 200 cells/mcL with good virologic control.

Treating patients with repeated episodes of the same opportunistic infection can pose difficult therapeutic challenges. For example, patients with second or third episodes of *P pneumonia* may have developed allergic reactions to standard treatments with a prior episode. Fortunately, there are several alternatives available for the treatment of *Pneumocystis* infection. Trimethoprim with dapsone and primaquine with clindamycin are two combinations that often are tolerated in patients with a prior allergic reaction to trimethoprim-sulfamethoxazole and intravenous pentamidine. On the positive side, patients in whom second episodes of *P pneumonia*

develop while taking prophylaxis tend to have milder courses.

Well-established alternative regimens now also exist for most AIDS-related opportunistic infections: amphotericin B or fluconazole for cryptococcal meningitis; ganciclovir, cidofovir, or foscarnet for CMV infection; and sulfadiazine or clindamycin with pyrimethamine for toxoplasmosis.

Adjunctive Treatments—Although conceptually it would seem that **corticosteroids** should be avoided in HIV-infected patients, corticosteroid therapy has been shown to improve the course of patients with moderate to severe *Pneumocystis jiroveci* pneumonia (oxygen saturation < 90%, P_{O_2} < 65 mm Hg) when administered within 72 hours after diagnosis. The mechanism of action is presumed to be a decrease in alveolar inflammation.

Corticosteroids have also been used to treat immune reconstitution and inflammatory syndromes (IRIS) that can sometimes complicate the early treatment course when ART is initiated in patients with advanced AIDS (see section Inflammatory reactions [immune reconstitution syndromes]).

Epoetin alfa (erythropoietin) is approved for use in HIV-infected patients with anemia, including those with anemia secondary to zidovudine use. It has been shown to decrease the need for blood transfusions. The drug is expensive, and

therefore an erythropoietin level < 500 mU/mL should be demonstrated before starting therapy. The starting dose of epoetin alfa is 8000 units subcutaneously three times a week. The target hematocrit is 35–40%. The dose may be increased by 12,000 units every 4–6 weeks as needed to a maximum dose of 48,000 units per week. Hypertension is the most common side effect.

Human G-CSF (filgrastim) and granulocyte-macrophage colony-stimulating factor (GM-CSF [sargramostim]) have been shown to increase the neutrophil counts of HIV-infected patients. Because of the high cost of this therapy, the dosage should be closely monitored and minimized, aiming for a neutrophil count of 1000/mcL. When the drug is used for indications other than cytotoxic chemotherapy, one or two doses at 5 mcg/kg per week are usually sufficient.

C. Antiretroviral Therapy

The availability of agents that in combination suppress HIV replication (Table 31–6) has had a profound impact on the natural history of HIV infection. Indeed, with the advent of antiretroviral treatment, the life expectancy of HIV-infected persons approaches that of uninfected persons when treatment is initiated early in the course of the disease.

The greater potency and the improved side effect profile have led to recommendations to start treatment earlier in the course of HIV disease. Treatment should be initiated for all symptomatic patients, and for asymptomatic persons who (1) have CD4 cell counts below 500 cells/mcL, (2) have rapidly dropping CD4 counts (> 100 cells/mcL/yr) or very high viral loads (> 100,000/mcL), (3) have active infection with hepatitis B or C (rapid HIV replication is thought to hasten progression of hepatitis B and C), (4) have risk factors for cardiac disease (ongoing HIV replication may increase the risk of cardiac disease), (5) have HIV-related renal impairment, (6) pregnancy, or (7) have risk factors for non-AIDS-related cancers (rapid HIV replication may increase such cancers). Current guidelines suggest that patients who have none of the above conditions but are at high risk for transmitting HIV to another person should be considered for ART. However, for patients with difficulty adhering to therapy, deferring ART until the patient is willing to commit to therapy may be a better strategy. In addition, because 5–20% of patients in developed countries who are treatment-naïve have a virus that is resistant to some drugs, resistance testing is recommended for all patients prior to initiating ART.

Once a decision to initiate therapy has been made, several important principles should guide therapy. First, because drug resistance to antiretroviral agents develops in HIV-infected patients, a primary goal of therapy should be complete suppression of viral replication as measured by the serum viral load. Therapy that achieves a plasma viral load of < 40 or < 50 copies/mL (depending on the test used) has been shown to provide a durable response to the therapy. To achieve this and maintain virologic control over time, combination therapy with at least 3 drugs from at least two different classes is necessary, and partially suppressive combinations such as dual nucleoside therapy

should be avoided. Similarly, if toxicity develops, it is preferable to either interrupt the entire regimen or change the offending drug rather than reduce individual doses.

Two randomized trials compared early initiation of ART (within 2 weeks of starting treatment for an opportunistic infection or tuberculosis) with ART that was deferred until after treatment of the opportunistic infection was completed (6 weeks after its start); results demonstrated that early initiation reduced death or AIDS progression by 50%. The reduced progression rates were related to more rapid improvements in CD4 counts in patients with advanced immunodeficiency. Furthermore, IRIS and other adverse events were no more frequent in the early ART arm. Based on these results, most treatment guidelines recommend that ART be initiated as early as is clinically feasible for patients with an acute AIDS-related opportunistic infection. For hospitalized patients, this recommendation requires close coordination between inpatient and outpatient physicians to ensure that treatment is continued once patients are discharged.

The current standard is to use at least three agents simultaneously from at least two different classes. Because the number of drugs is finite, it is important to avoid drug resistance, which occurs when patients take medications in the setting of ongoing viral replication. Therefore, the best method for avoiding resistance is for the patient to be compliant with an efficacious regimen. Adherence can be promoted through the use of simple regimens (one pill a day combination regimens, and for those patients with more complicated regimens, medication boxes with compartments [eg, Medisets]). Many patients benefit from adherence counseling and some need daily supervision of therapy. Given these options treatment should not be withheld solely on the basis of a patient's circumstances (eg, active drug use or housing status) alone. Often, a trial intervention such as offering *Pneumocystis pneumonia* prophylaxis may be helpful in determining the likelihood of adherence to a more complex antiretroviral regimen.

Monitoring of ART has two goals. Laboratory evaluation for toxicity depends on the specific drugs in the combination but generally should be done approximately every 3–4 months once a patient is on a stable regimen. Patients who are intolerant of their initial regimen (eg, patients who cannot tolerate the neurologic side effects of efavirenz) should be changed to an alternative drug or regimen. The second aspect of monitoring is to regularly measure objective markers of efficacy. The CD4 cell count and HIV viral load should be repeated 1–2 months after the initiation or change of antiretroviral regimen and every 4–6 months thereafter in clinically stable patients (those with higher CD4 counts can have testing every 6 months). In a patient who is adherent to an effective regimen, viral loads should be undetectable within 12–24 weeks. For patients in whom viral loads are not suppressed or who have viral rebound after suppression, the major question facing the clinician is whether the patient is nonadherent or has resistance to the regimen, or both. The issue is complicated because many patients report being more compliant than they really are, not because they wish to be untruthful but because they wish to tell the clinician what

Table 31–6. Antiretroviral therapy.

Drug	Dose	Common Side Effects	Special Monitoring ¹	Cost ²	Cost/Month
Nucleoside reverse transcriptase inhibitors					
Abacavir (Ziagen)	300 mg orally twice daily	Rash, fever—if occur, rechallenge may be fatal	No special monitoring	\$11.17/300 mg	\$670.20
Didanosine (ddI) (Videx)	400 mg orally daily (enteric-coated capsule) for persons \geq 60 kg	Peripheral neuropathy, pancreatitis, dry mouth, hepatitis	Bimonthly neurologic questionnaire for neuropathy, K ⁺ , amylase, bilirubin, triglycerides	\$12.30/400 mg	\$368.72
Emtricitabine (Emtriva)	200 mg orally once daily	Skin discoloration palms/soles (mild)	No special monitoring	\$16.81/200 mg	\$504.30
Lamivudine (3TC) (EpiVir)	150 mg orally twice daily	Rash, peripheral neuropathy	No special monitoring	\$7.16/150 mg	\$429.60
Stavudine (d4T) (Zerit)	40 mg orally twice daily for persons \geq 60 kg	Peripheral neuropathy, hepatitis, pancreatitis	Monthly neurologic questionnaire for neuropathy, amylase	\$6.85/40 mg	\$410.70
Zalcitabine (ddC) (Hivid)	0.375–0.75 mg orally three times daily	Peripheral neuropathy, aphthous ulcers, hepatitis	Monthly neurologic questionnaire for neuropathy	Not available in the US	Not available in the US
Zidovudine (AZT) (Retrovir)	600 mg orally daily in two divided doses	Anemia, neutropenia, nausea, malaise, headache, insomnia, myopathy	No special monitoring	\$6.09/300 mg	\$365.09
Nucleotide reverse transcriptase inhibitors					
Tenofovir (Viread)	300 mg orally once daily	Gastrointestinal distress	Creatinine every 3–4 months, urine analysis every 6–12 months	\$29.11/300 mg	\$873.28
Protease inhibitors (PIs)					
Fosamprenavir (Lexiva)	For PI-experienced patients: 700 mg orally twice daily and 100 mg of ritonavir orally twice daily. For PI-naïve patients: above or 1400 mg orally twice daily or 1400 mg orally once daily and 200 mg of ritonavir orally once daily	Gastrointestinal, rash	No special monitoring	\$15.79/700 mg	\$947.12–\$1894.24 (plus cost of ritonavir for lower dose)
Indinavir (Crixivan)	800 mg orally three times daily	Renal calculi	Bilirubin level	\$3.05/400 mg	\$548.12
Lopinavir/ritonavir (Kaletra)	400 mg/100 mg orally twice daily	Diarrhea	No special monitoring	\$7.26/200 mg (lopinavir)	\$871.36
Nelfinavir (Viracept)	750 mg orally three times daily or 1250 mg twice daily	Diarrhea	No special monitoring	\$3.06/250 mg \$7.66/625 mg	\$826.20 \$919.43
Ritonavir (Norvir)	600 mg orally twice daily or in lower doses (eg, 100 mg orally once or twice daily) for boosting other PIs	Gastrointestinal distress, peripheral paresthesias	No special monitoring	\$10.29/100 mg	\$3703.20 (\$617.20 in lower doses)

(continued)

Table 31-6. Antiretroviral therapy. (continued)

Drug	Dose	Common Side Effects	Special Monitoring ¹	Cost ²	Cost/Month
Saquinavir hard gel (Invirase)	1000 mg orally twice daily with 100 mg ritonavir orally twice daily	Gastrointestinal distress	No special monitoring	\$9.07/500 mg	\$1088.84 (plus cost of ritonavir)
Atazanavir (Reyataz)	400 mg orally once daily or 300 mg atazanavir with 100 mg ritonavir daily.	Hyperbilirubinemia	Bilirubin level	\$19.60/200 mg	\$1176.23 (plus cost of ritonavir)
Darunavir/ritonavir (Prezista/Norvir)	For PI-experienced patients: 600 mg of darunavir and 100 mg of ritonavir orally twice daily. For PI-naïve patients: 800 mg of darunavir and 100 mg of ritonavir orally daily.	Rash	No special monitoring	\$20.50/600 mg (darunavir) \$10.29/100 mg (ritonavir) \$20.50/400 mg (darunavir)	\$1847.40 (for combination) \$1538.80 (for combination)
Tipranavir/ritonavir (Aptivus/Norvir)	500 mg of tipranavir and 200 mg of ritonavir orally twice daily	Gastrointestinal, rash	No special monitoring	\$11.13/250 mg (tipranavir) \$10.29/100 mg (ritonavir)	\$2569.54 (for combination)
Nonnucleoside reverse transcriptase inhibitors (NNRTIs)					
Delavirdine (Rescriptor)	400 mg orally three times daily	Rash	No special monitoring	\$2.12/200 mg	\$381.89
Efavirenz (Sustiva)	600 mg orally daily	Neurologic disturbances, rash	No special monitoring	\$22.98/600 mg	\$689.52
Etravirine (Intelence)	200 mg orally twice daily	Rash, peripheral neuropathy	No special monitoring	\$8.15/100 mg	\$978.64
Nevirapine (Viramune)	200 mg orally daily for 2 weeks, then 200 mg orally twice daily	Rash	No special monitoring	\$12.05/200 mg	\$723.08
Rilpivirine (Edurant)	25 mg daily	Depression, rash	No special monitoring	\$26.81/25 mg	\$804.38
Entry inhibitors					
Enfuvirtide (Fuzeon)	90 mg subcutaneously twice daily	Injection site pain and allergic reaction	No special monitoring	\$54.15/90 mg	\$3248.72
Maraviroc (Selzentry)	150-300 mg orally daily	Cough, fever, rash	No special monitoring	\$20.00/150 mg or 300 mg	\$1199.83
Integrase inhibitor					
Raltegravir (Isentress)	400 mg orally twice daily	Diarrhea, nausea, headache	No special monitoring	\$19.52/400 mg	\$1171.30

¹Standard monitoring is complete blood count (CBC) and differential, serum aminotransferases every 3-4 months, and cholesterol (total, LDL, HDL), and triglycerides 6 months after starting ART and annually among those over age 40 years.

²Average wholesale price (AWP, for AB-rated generic when available) for quantity listed. Source: *Red Book Online, 2012*, Thomson Reuters (Healthcare Inc.). AWP may not accurately represent the actual pharmacy cost because wide contractual variations exist among institutions.

he or she wants to hear. Patients who are having trouble adhering to their treatment should receive counseling on how to better comply to their treatment. In patients who are adherent or who have missed enough doses to make resistance possible, resistance testing should be performed. Based on the results of resistance testing, and assessment of the patient's ability to comply with complicated regimens or to tolerate predictable side effects, the clinician should

prescribe a combination of three medications to which there is no or only minimal resistance. Some patients whose counts rise dramatically on ART and who are fully suppressed (ie, plasma viral load < 50 copies/mL) may be successfully transitioned from a high potency regimen to a lower potency regimen with fewer side effects; however, this "induction-maintenance" strategy is still being evaluated in clinical trials. Stopping therapy in patients with

high CD4 counts will generally result in patients reverting to their pretreatment nadir CD4 count in a matter of months and is therefore not recommended.

Although the ideal combination of drugs has not yet been defined for all possible clinical situations, possible choices can be better understood after a review of the available agents. These drugs can be grouped into five major categories: nucleoside and nucleotide reverse transcriptase inhibitors (NRTI); PI; nonnucleoside reverse transcriptase inhibitors (NNRTI); entry inhibitors, which include a fusion inhibitor and CCR5 antagonists; and integrase inhibitors. Once ART has been initiated in a patient, it is not advisable to stop the therapy unless there is a compelling reason (eg, toxicity, poor adherence, etc). So-called “drug holidays” or “structured treatment interruptions” have been shown to increase risk of AIDS-related complications, increase CD4 declines, and increase morbidity from non-AIDS-related complications (eg, myocardial infarctions and liver failure) and are not recommended.

1. Nucleoside and nucleotide reverse transcriptase inhibitors

There are currently seven nucleoside or nucleotide agents approved for use. The choice of which agent to use depends primarily on the patient's prior treatment experience, results of resistance testing, drug side effects, other underlying conditions, and convenience of formulation. However, most clinicians use fixed-dose combinations of either tenofovir/emtricitabine (TDF/FTC) or abacavir/lamivudine (ABC/3TC), both of which can be given once a day. Zidovudine/lamivudine (AZT/3TC) is usually reserved for second- or third-line regimens because of toxicity and dosing schedule. Recent studies have raised some concerns about the efficacy of ABC/3TC in patients with high viral loads (eg, > 100,000 copies/mL) as well as concerns about increase risks of myocardial infarction with abacavir. Therefore, TDF/FTC is the preferred fixed-dose combination as part of initial treatment regimens.

Of the available agents, zidovudine is the most likely to cause anemia. Zidovudine and didanosine are the most likely to cause neutropenia. Stavudine is the most likely to cause lipotrophy (loss of fat in the face, extremities, and buttocks) followed by zidovudine. Zalcitabine and didanosine are the most likely to cause peripheral neuropathy. Lamivudine, emtricitabine, and tenofovir have activity against hepatitis B. Didanosine, lamivudine, emtricitabine, and tenofovir can be administered daily. Information specific to each drug is given below, and recommendations on how to combine them appear in the Constructing regimens section below.

A. ZIDOVUDINE—Zidovudine was the first approved antiviral drug for HIV infection and remains an important agent. It is administered at a dose of 300 mg orally twice daily. A combination of zidovudine 300 mg and lamivudine 150 mg (Combivir) allows more convenient dosing of medication for individuals taking both of these agents. Side effects seen with zidovudine are listed in Table 31–6. Approximately 40% of patients experience subjective side effects that usually remit within 6 weeks. The common dose-limiting side effects are anemia and neutropenia, which require ongoing laboratory monitoring. Long-term use has been associated with lipotrophy.

B. DIDANOSINE—The most convenient formulation of didanosine (ddI) is the enteric-coated capsule. For adults weighing at least 60 kg, the dose is one 400-mg enteric-coated capsule orally daily; for those 30–59 kg, the dose is one 250-mg enteric-coated capsule orally daily. Didanosine should be taken on an empty stomach.

Didanosine has been associated with pancreatitis. The incidence of pancreatitis with didanosine is 5–10%—of fatal pancreatitis, < 0.4%. Patients with a history of pancreatitis, as well as those taking other medications associated with pancreatitis (including trimethoprim-sulfamethoxazole and intravenous pentamidine) are at higher risk for this complication. Other common side effects with didanosine include a dose-related, reversible, painful peripheral neuropathy, which occurs in about 15% of patients, and dry mouth. Fulminant hepatic failure and electrolyte abnormalities, including hypokalemia, hypocalcemia, and hypomagnesemia, have been reported in patients taking didanosine. Because of the side-effect profile, didanosine is rarely used today.

C. STAVUDINE—Stavudine (d4T) has shown good activity as an antiretroviral drug. The dose is 40 mg orally twice daily for individuals weighing 60 kg or more. However, because of its side effects including lipotrophy, lipodystrophy (see below), peripheral neuropathy and, rarely, lactic acidosis and hepatitis, this drug should no longer be used except when there is no alternative. Patients taking stavudine should be routinely changed to abacavir or tenofovir, both of which are less likely to cause lipotrophy.

D. LAMIVUDINE—Lamivudine (3TC) is a safe and well-tolerated agent. The dosage is 150 mg orally twice daily or 300 mg orally once a day. The dose should be reduced with chronic kidney disease. There are no significant side effects with lamivudine, and it has activity also against hepatitis B.

E. EMTRICITABINE—Emtricitabine is a nucleoside analog that is dosed at 200 mg orally. It was developed primarily as a once a day alternative to lamivudine. However, lamivudine can be dosed daily, eliminating the special indication for emtricitabine. As is true of lamivudine, emtricitabine has activity against hepatitis B and its dosage should be reduced in patients with chronic kidney disease.

F. ABACAVIR—A daily dose of 300 mg orally twice daily results in potent antiretroviral activity. Prior to initiation of abacavir, patients should undergo testing for HLA typing. Those with the B*5701 allele should not be treated with abacavir because the likelihood of a hypersensitivity reaction developing is high; the reaction is characterized by a flu-like syndrome with rash and fever that worsens with successive doses. Unfortunately, the absence of this allele does not guarantee that the patient will avoid the hypersensitivity reaction. Individuals in whom the hypersensitivity reaction develops *should not* be rechallenged with this agent because subsequent hypersensitivity reactions can be fatal. Abacavir has also been shown to be associated with an increased risk of myocardial infarction in some cohort studies. This increased risk is generally seen in patients who have underlying risks of cardiovascular disease. Consequently, abacavir should be avoided in such

patients if effective alternative nucleoside or nucleotide analog agents exist.

Abacavir is formulated with zidovudine and lamivudine in a single pill (Trizivir, one tablet orally twice daily). Trizivir is not recommended as solo treatment for HIV because it is not as efficacious as combining two nucleoside/nucleotide analogs with a PI/ritonavir or an NNRTI; its use as a sole regimen should be reserved only for patients who cannot tolerate a more complicated regimen. Abacavir is also available as a fixed dose combination pill with lamivudine for use as a once daily pill (Epzicom).

G. ZALCITABINE—Zalcitabine (ddC) was one of the least effective antiretroviral agents and is no longer being manufactured.

H. TENOFOVIR—Tenofovir is the only licensed nucleotide analog. It is given as a single daily oral dose of 300 mg and is generally well tolerated. Tenofovir is available in a fixed dose combination pill with emtricitabine (Truvada) for daily dosing and is the only recommended fixed-dose combination for initial regimens. A once-a-day single fixed-dose combination pill that contains efavirenz, emtricitabine, and tenofovir (Atripla) is also available. Tenofovir is active against hepatitis B, including isolates that have resistance to lamivudine.

2. Protease inhibitors—Ten PIs—indinavir, nelfinavir, ritonavir, saquinavir, amprenavir, fosamprenavir, lopinavir (in combination with ritonavir), atazanavir, darunavir, and tipranavir are available. PIs have been shown to potently suppress HIV replication and are administered as part of a combination regimen.

All the PIs—to differing degrees—are metabolized by the cytochrome P450 system, and each can inhibit and induce various P450 isoenzymes. Therefore, drug interactions are common and difficult to predict. Clinicians should consult the product inserts before prescribing PIs with other medications. Drugs such as rifampin that are known to induce the P450 system should be avoided.

The fact that the PIs are dependent on metabolism through the cytochrome P450 system has led to the use of ritonavir to boost the drug levels of saquinavir, lopinavir, indinavir, atazanavir, tipranavir, darunavir and amprenavir, allowing use of lower doses and simpler dosing schedules of these PIs. In fact, current guidelines recommend that all PI-containing regimens use ritonavir boosting if possible. The only PIs that can be safely used without ritonavir boosting are nelfinavir and atazanavir.

When choosing which PI to use, prior patient experience, resistance patterns, side effects, and ease of administration are the major considerations. The first three PIs to be developed—indinavir, saquinavir, and ritonavir (as single agents)—are now rarely used because of the superiority of the second generation of PIs. Amprenavir has been almost entirely replaced by its prodrug, fosamprenavir. Unfortunately, all PIs, with the exception of unboosted atazanavir have been linked to a constellation of metabolic abnormalities, including elevated cholesterol levels, elevated triglyceride levels, insulin resistance, diabetes mellitus, and changes in body fat composition (eg, buffalo hump, abdominal obesity). The lipid abnormalities and body habitus changes are referred to as lipodystrophy. Although

lipodystrophy is commonly associated with PIs, it has been seen also in HIV-infected persons who have never been treated with these agents. In particular, the lipoatrophy effects seen in patients receiving ART appears to be more related to the nucleoside toxicity and in particular to the thymidine analogs (stavudine and zidovudine).

Of the different manifestations of lipodystrophy, the dyslipidemias that occur are of particular concern because of the likelihood that increased levels of cholesterol and triglycerides will result in increased prevalence of heart disease. All patients taking PIs or NRTIs should have fasting serum cholesterol, low-density lipoprotein (LDL) cholesterol, and triglyceride levels performed every 3–6 months. Clinicians should calculate the Framingham 10-year coronary heart disease risk (see Chapter 28) and consider initiating dietary or drug therapy (or both) to achieve target LDL levels depending on the individual's risk factors. Patients who are unable to meet their LDL goal based solely on dietary interventions should be given pravastatin (20 mg daily orally) or atorvastatin (10 mg daily orally). Lovastatin and simvastatin should be avoided because of their interactions with PIs. Fish oil (3000 mg daily) combined with exercise and dietary counseling has been found to decrease triglycerides levels by 25%. Patients with persistently elevated fasting serum triglyceride levels of 500 mg/dL or more who do not respond to dietary intervention should be treated with gemfibrozil (600 mg twice daily prior to the morning and evening meals).

A. INDINAVIR—The standard dose of indinavir is 800 mg orally three times a day, although it is usually dosed twice daily in combination with ritonavir. Nausea and headache are common complaints with this drug. Indinavir crystals are present in the urine in approximately 40% of patients; this results in clinically apparent nephrolithiasis in about 15% of patients receiving indinavir. Lower urinary tract symptoms and acute kidney injury also have been reported. Patients taking this drug should be instructed to drink at least 48 ounces of fluid a day to ensure adequate hydration in an attempt to limit these complications. Mild indirect hyperbilirubinemia is also commonly observed in patients taking indinavir but is not an indication for discontinuation of the drug.

B. SAQUINAVIR—Saquinavir is formulated only as a hard-gel capsule (Invirase). It should only be used with ritonavir (1000 mg of hard-gel saquinavir with 100 mg of ritonavir orally twice daily). The soft-gel capsule (Fortovase) has been removed from the market in the United States. The most common side effects with saquinavir are diarrhea, nausea, dyspepsia, and abdominal pain.

C. RITONAVIR—Use of this potent PI at full dose (600 mg orally twice daily) has been limited by its inhibition of the cytochrome P450 pathway causing a large number of drug–drug interactions and by its frequent side effects of fatigue, nausea, and paresthesias. However, it is widely used in lower dose (eg, 100 mg daily to 100 mg twice daily) as a booster of other PIs.

D. NELFINAVIR—Nelfinavir is the only PI for which ritonavir boosting is not recommended. Unboosted nelfinavir is

generally not as potent as a boosted PI regimen (eg, lopinavir plus ritonavir). The dose of nelfinavir is 1250 mg orally twice daily. Diarrhea is a side effect in 25% of patients taking nelfinavir, but this symptom may be controlled with over-the-counter antidiarrheal agents in most patients.

E. AMPRENAVIR—Amprenavir has efficacy and side effects similar to those of other PIs. Common side effects are nausea, vomiting, diarrhea, rash, and perioral paresthesia. The dose is 1200 mg orally twice daily. The concentration of amprenavir decreases when coadministered with ethinyl estradiol; therefore, amprenavir should be used with circumspection in the treatment of transgender persons requiring high-dose estrogen.

F. FOSAMPRENAVIR—Fosamprenavir is a prodrug of amprenavir. Its major advantage over using amprenavir is a much lower pill burden. For PI-naïve patients, it can be dosed at 1400 mg orally twice daily (four capsules a day) or at 1400 mg orally daily (two capsules) with ritonavir 200 mg orally daily (two capsules) or at 700 mg orally with ritonavir 100 mg orally twice daily. Patients previously treated with PIs should receive 700 mg orally with ritonavir 100 mg orally twice daily. Side effects are similar to those with amprenavir—most commonly gastrointestinal distress and hyperlipidemia. As with amprenavir, the concentration of fosamprenavir decreases when coadministered with ethinyl estradiol; therefore, fosamprenavir should be used with circumspection in the treatment of transgender persons requiring high-dose estrogen.

G. LOPINAVIR/R—Lopinavir/r is lopinavir (200 mg) coformulated with a low dose of ritonavir (50 mg) to maximize the bioavailability of lopinavir. It has been shown to be more effective than nelfinavir when used in combination with stavudine and lamivudine. The usual dose is 400 mg lopinavir with 100 mg of ritonavir (two tablets) orally twice daily with food. When given along with efavirenz or nevirapine, a higher dose (600 mg/150 mg—three tablets) is usually prescribed. The most common side effect is diarrhea, and lipid abnormalities are frequent. Because of these side effects, lopinavir/r has fallen off the list of drugs recommended as part of first-line treatment regimens.

H. ATAZANAVIR—Atazanavir can be dosed as 400 mg (two 200-mg capsules) only daily with food or it can be dosed as 300 mg in combination with 100 mg of ritonavir once daily with food. When used without ritonavir, it has only minimal or no impact on cholesterol and triglyceride levels. The most common side effect is mild hyperbilirubinemia that resolves with discontinuation of the drug. Nephrolithiasis has also been reported with this PI. Both tenofovir and efavirenz lower the serum concentration of atazanavir. Therefore, when either of these two drugs is used with atazanavir, it should be boosted by administering ritonavir. Proton pump inhibitors are contraindicated in patients taking atazanavir because atazanavir requires an acidic pH to remain in solution.

I. TIPRANAVIR—Tipranavir is the only nonpeptidic PI currently approved by the US Food and Drug

Administration (FDA). Because of its unique structure, it is active against some strains of HIV that are resistant to other PIs. It is dosed with ritonavir (two 250 mg capsules of tipranavir with two 100 mg capsules of ritonavir orally twice daily with food). The most common side effects are nausea, vomiting, diarrhea, fatigue, and headache. Tipranavir/ritonavir has been also associated with liver damage and should be used very cautiously in patients with underlying liver disease. Reports of intracranial hemorrhage in patients taking tipranavir-containing regimens have raised additional safety concerns about this potent PI. Because it is a sulfa-containing drug, its use should be closely monitored in patients with sulfa allergy.

J. DARUNAVIR—Darunavir has impressive antiviral activity in the setting of significant PI resistance and in treatment-naïve patients. Darunavir has been added to the list of recommended PIs for initial treatment of HIV at a daily dose of 800 mg with 100 mg of ritonavir. For patients with prior PI treatment experience or PI resistance, darunavir should be dosed at 600 mg orally twice daily, with ritonavir, 100 mg orally twice daily. Once daily dosing can be used in treatment-experienced patients who do not have darunavir-related resistance mutations. Darunavir has a safety profile similar to other PIs, such as lopinavir/ritonavir but is generally better tolerated. Like tipranavir, darunavir is a sulfa-containing drug, and its use should be closely monitored in patients with sulfa allergy.

3. Nonnucleoside reverse transcriptase inhibitors—NNRTIs inhibit reverse transcriptase at a site different from that of the nucleoside and nucleotide agents described above. All five NNRTIs have shown antiviral activity as measured by HIV viral load and CD4 responses. The major advantage of the NNRTIs is that three of them (efavirenz, rilpivirine, and nevirapine) have potencies comparable to that of PIs, at least for patients with viral loads under 100,000 copies/mL—with lower pill burden and fewer side effects. In particular, they do not appear to cause lipodystrophy; patients with cholesterol and triglyceride elevations who are switched from a PI to an NNRTI may have improvement in their lipids. The resistance patterns of the NNRTIs are distinct from those of the PIs, so their use still leaves open the option for future PI use.

The NNRTIs can be used with PIs in patients who are difficult to suppress on simpler regimens or when it is difficult to identify at least two nucleoside/nucleotide agents to which the patient is not resistant. Because these agents may cause alterations in the clearance of PIs, dose modifications may be necessary when these two classes of medications are administered concomitantly. There is a high degree of cross-resistance between the “first generation” NNRTIs, such that resistance to one drug in this class uniformly predicts resistance to other drugs. However, etravirine appears to have consistent antiviral activity in patients with prior exposure and resistance to nevirapine, efavirenz, or delavirdine. In particular, the K103N mutation does not appear to have an impact on etravirine (or rilpivirine). There is no therapeutic reason for using more than one NNRTI at the same time.

A. EFVIRENZ—The major advantages of efavirenz is that it can be given once daily in a single dose (600 mg orally), and it is available in a once-daily fixed-dose combination with tenofovir and emtricitabine in a single pill (Atripla). The combination is probably the best first choice for treatment-naïve patients without resistance to this regimen. The side effects are neurologic, with patients reporting symptoms ranging from lack of concentration and strange dreams to delusions and mania. Although the neurologic side effects of efavirenz subside over time, usually within a month, there are some patients who cannot tolerate these neurologic effects. Administration of efavirenz with food, especially fatty food, may increase its serum levels and consequent neurotoxicity. Due to teratogenicity, efavirenz should be avoided in women who wish to conceive or are already pregnant.

B. RILPIVIRINE—This drug, dosed at 25 mg once daily, is approved for persons initiating ART, and is equal in efficacy to efavirenz in patients with HIV viral loads below 100,000 copies/mL. Those with higher viral loads should be treated with efavirenz or a PI. As is true of efavirenz, rilpivirine is available in a once-daily fixed dose combination with tenofovir and emtricitabine (Complera) to be taken with a fatty meal. Rilpivirine has fewer neurologic side effects than efavirenz, making it a good choice as a first regimen, or an alternative regimen in patients who cannot tolerate the neurologic side effects of efavirenz.

C. NEVIRAPINE—The target dose of nevirapine is 200 mg orally twice daily, but it is initiated at a dose of 200 mg once a day to decrease the incidence of rash, which is as high as 40% when full doses are begun immediately. If rash develops while the patient is taking 200 mg a day, liver enzymes should be checked and the dose should not be increased until the rash resolves. Patients with mild rash and no evidence of hepatotoxicity can continue to be treated with nevirapine. Nevirapine should not be used in treatment-naïve women with high CD4 counts (> 250/mcL). Because of potential fatal hepatotoxicity, nevirapine should only be used in patients who cannot tolerate efavirenz. An extended-release formulation of nevirapine (Viramune XR) allows for once-daily dosing (400 mg daily). In clinical trials, nevirapine XR was not inferior when compared with standard nevirapine (both forms of nevirapine were combined with tenofovir/emtricitabine). This XR formulation potentially provides another once daily NNRTI regimen for first-line ART, although there has yet to be a direct comparison to any of the currently preferred first-line ART regimens (see below).

D. DELAVIRDINE—Of the available NNRTIs, delavirdine is used the least largely because of its less convenient dosing and pill burden compared with the other available NNRTIs. Unlike nevirapine and efavirenz, delavirdine inhibits P450 cytochromes rather than inducing these enzymes. This means that delavirdine can act like ritonavir and boost other antiretrovirals, although delavirdine is not as potent as ritonavir in this capacity. The dosage is 400 mg orally three times a day. The major side effect is rash.

E. ETNAVIRINE—Etravirine is an NNRTI approved for the treatment of patients with prior NNRTI intolerance or resistance. Etravirine has been shown to be effective even when some degree of NNRTI-resistance is present, making it a true “second generation” drug in this class. Etravirine dosage is one 200-mg tablet twice daily. It should be used with a PI and a nucleoside/nucleotide analog and not just with two nucleoside/nucleotide analogs. The most common side effects are nausea and rash; rarely, the rash can be severe (toxic epidermal necrolysis). Patients with signs of severe rash or hypersensitivity reactions should immediately discontinue the drug. Prior rash due to treatment with one of the other NNRTIs does not make rash more likely with etravirine. Etravirine should not be taken by people with severe liver disease or administered with tipranavir/ritonavir, fosamprenavir/ritonavir, atazanavir/ritonavir, full-dose ritonavir, or PIs without low-dose ritonavir.

4. Entry inhibitors

A. ENFUVIRTIDE—Enfuvirtide (Fuzeon) is known as a fusion inhibitor; it blocks the entry of HIV into cells by blocking the fusion of the HIV envelope to the cell membrane. The addition of enfuvirtide to an optimized antiretroviral regimen improved CD4 counts and lowered viral loads in heavily pretreated patients with multidrug-resistant HIV. Unfortunately, resistance develops rapidly in patients receiving nonsuppressive treatment. The dose is 90 mg by subcutaneous injection twice daily; unfortunately, painful injection site reactions develop in most patients, which makes long-term use problematic.

B. MARAVIROC—Maraviroc is a CCR5 co-receptor antagonist. Drugs in this class prevent the virus from entering uninfected cells by blocking the CCR5 co-receptor. Unfortunately, this class of entry inhibitors is only active against “CCR5-tropic virus.” This form of the HIV-1 virus tends to predominate early in infection, while so-called “dual/mixed tropic virus” (which utilizes either R5 or CXCR4 co-receptors) emerges later as infection progresses. Approximately 50–60% of previously treated HIV-infected patients have circulating CCR5-tropic HIV. The drug has been shown to be effective in HIV-infected persons with ongoing viral replication despite being heavily treated and who have CCR5-tropic virus. Tropism testing should be performed before beginning the medication. The dose of maraviroc is 150–300 mg orally twice daily, based on the other drugs the patient is taking at the time. Common side effects are cough, fever, rash, musculoskeletal problems, abdominal pain, and dizziness; however, maraviroc is generally well tolerated with limited impact on serum lipids.

5. Integrase inhibitors

A. RALTEGRAVIR—Raltegravir is an HIV integrase inhibitor. Integrase inhibitors slow HIV replication by blocking the HIV integrase enzyme needed for the virus to multiply. Raltegravir was impressively effective (when combined with other active drugs) in the treatment of HIV-infected patients with documented resistance to at least one drug in each of the three main classes of antiretroviral medications

(nucleoside analogs, PIs, NNRTIs). Clinical trials of integrase inhibitors reveal a consistent pattern of more rapid decline in viral load compared with more standard PI/r or NNRTI-based regimens. The clinical significance of this observation is unclear. Despite the impressive antiviral potency of this new class of antiretroviral drugs, high-level resistance to integrase inhibitors emerges quickly in the setting of virologic failure (much like with the NNRTIs). Therefore, it is critical that raltegravir be used in combination with other active antiretroviral agents.

Studies in treatment-naïve patients have demonstrated that raltegravir in combination with tenofovir/emtricitabine is as effective as the current first-line choice of efavirenz/tenofovir/emtricitabine for daily treatment and has fewer side effects. Furthermore, the CD4 response appeared better in patients treated with the raltegravir combination. Raltegravir is approved by the FDA for treatment-naïve patients. The dose of raltegravir is 400 mg orally twice daily. Common side effects are diarrhea, nausea, and headache.

B. ELVITEGRAVIR—Elvitegravir is another integrase inhibitor that is in late stage development. The dose is 125 mg once daily, given with ritonavir (100 mg) for boosting. Elvitegravir showed impressive short-term virologic responses in phase 2 studies and is expected to be approved in 2012.

6. Constructing regimens—There is now little debate about the necessity for combining drugs to achieve long-term suppression of HIV and its associated clinical benefit. Only combinations of three or more drugs have been able to decrease HIV viral load by 2–3 logs and allow long-term suppression of HIV RNA to below the threshold of detection.

Current evidence supports the use of Truvada (tenofovir and emtricitabine) as the “nucleoside/nucleotide backbone” combined with efavirenz as the initial regimen. This regimen has been shown to be more effective and better tolerated than Combivir (zidovudine and lamivudine) and Epzicom (abacavir/lamivudine). It has the advantages of once daily dosing and is available as a single pill (Atripla and Complera). Because 8–10% of newly infected persons in some urban areas of the United States have NNRTI resistance, resistance testing should be performed before initiating efavirenz in this population. The following medications may also be combined with daily fixed-dose tenofovir/emtricitabine as first-line regimens: darunavir/ritonavir (800 mg/100 mg daily), atazanavir/ritonavir (300 mg/100 mg daily), or raltegravir (400 mg twice daily). Regimens that include only nucleoside and nucleotide analogs without nonnucleoside agents or PIs are clinically inferior and should only be used for patients that cannot adhere to a more complicated regimen.

The most important determinant of treatment efficacy is adherence to the regimen. Therefore, it is vitally important that the regimen chosen be one to which the patient can easily adhere. In general, patients are more compliant with medication regimens that are once or twice a day only, do

not require special timing with regard to meals, can be taken at the same time as other medications, do not require refrigeration or special preparation, and do not have bothersome side effects. Toxicities should ideally be nonoverlapping. An individual's relative contraindications to a given drug or drugs should be considered. The regimen should not include agents that are either virologically antagonistic or incompatible in terms of drug–drug interactions. For example, etravirine should not be used with boosted tipranavir because of drug–drug interactions. Compatible dosing schedules—prescribing medications that can be taken at the same time—improve adherence to treatment. Finally, highly complex therapeutic regimens should be reserved for individuals who are capable of adhering to the rigorous demands of taking multiple medications and having this therapy closely monitored. Conversely, simplified regimens that deliver the lowest number of pills given at the longest possible dosing intervals are desirable for patients who have difficulty taking multiple medications.

Possible ways of incorporating nonnucleoside agents and PIs into combinations are displayed in Figure 31–2.


A number of points about the “nucleoside/nucleotide backbone” of regimens have become clearer. The combination of stavudine plus didanosine should be avoided, since there is increased risk of toxicities, in particular in pregnant women because of the increased risk of lactic acidosis, which can be fatal. Moreover, the nucleoside pair of zidovudine and stavudine should be avoided because of increased toxicity and the potential for antagonism that results from intracellular competition for phosphorylation. Finally, the combination of didanosine with tenofovir should be avoided due to observed declines in CD4 counts.

In designing second-line regimens for patients with resistance to initial therapy, the goal is to identify three drugs from at least two different classes to which the virus is not resistant. This can be quite complicated because of the problem of cross-resistance between drugs within a class. For example, the resistance patterns of lopinavir/ritonavir and indinavir are overlapping, and patients with virus resistant to these agents are unlikely to respond to nelfinavir or saquinavir even though they have never received treatment with these agents. Similarly, the resistance patterns of nevirapine and efavirenz are overlapping. With several new classes of drugs and new generations of existing drug classes now available, the ability to provide fully suppressive regimens even to patients with extensive treatment experience and drug resistance has become more realistic. The goal of therapy, therefore, should be to fully suppress viral loads to < 50 copies/mL even for highly treatment-experienced patients.

In addition to taking a careful history of what antiretroviral agents a patient has taken and for how long, genotypic and phenotypic resistance testing can provide useful information in designing second-line regimens.

Whatever regimen is chosen, patients should be coached in ways to improve adherence. For certain populations (eg, unstably housed individuals), specially tailored programs that include drug dispensing are needed.

Rarely, it is impossible to construct a tolerable regimen that fully suppresses HIV. In such cases, clinicians and



▲ **Figure 31-2.** Approach to initial and subsequent antiretroviral therapy.

patients should consider their goals. Patients maintained on effective antiretroviral agents often benefit from these regimens (eg, higher CD4 counts, fewer opportunistic infections) even if their virus is detectable. In some cases, patients may request a drug holiday during which they are taken off all medications. Patients often immediately feel better because of the absence of drug side effects. Unfortunately, structured treatment interruptions generally result in viral rebound and rapid CD4 decline. Compared with patients who continue their regimens without interruption, those who interrupt their treatment fare poorly, with increased morbidity and mortality from both HIV-related and non-HIV-related causes.

7. The challenge of drug resistance—HIV-1 drug resistance limits the ability to fully control HIV replication and is a leading cause for antiretroviral regimen failure. Resistance has been documented for all currently available antiretrovirals including the newer classes of fusion inhibitor, CCR5 inhibitors, and integrase inhibitors. The problem of drug resistance is widespread in HIV-infected patients undergoing treatment in countries where ART is widely available. However, recent reports suggest that the degree of high level resistance is declining in the past few years, which is likely related to better tolerated, easier to use, and more

efficacious antiretroviral agents. Patients who have taken various antiretroviral regimens and who now have resistant HIV-1 represent a major challenge for the treating clinician. Resistance is now also documented in patients who are ART-naïve, but who have been infected with a drug resistant strain—“primary resistance.” Cohort studies of antiretroviral treatment-naïve patients entering care in North America and Western Europe show that roughly 10–12% (and as high as 25%) of recently infected individuals have been infected with a drug-resistant strain of HIV-1.

Current expert guidelines recommend resistance testing as part of standard baseline testing in all patients. Resistance testing is also recommended for patients who are on an antiretroviral regimen and have suboptimal viral suppression (ie, viral loads > 1000 copies/mL). Both genotypic and phenotypic tests are commercially available and in randomized controlled studies their use has been shown to result in improved short-term virologic outcomes compared to making treatment choices without resistance testing. Furthermore, multiple retrospective studies have conclusively demonstrated that resistance tests provide prognostic information about virologic response to newly initiated therapy that cannot be gleaned from standard clinical information (ie, treatment history, examination, CD4 count, and viral load tests).

Because of the complexity of resistance tests, many clinicians require expert interpretation of results. In the case of genotypic assays, results may show that the mutations that are selected for during ART are drug-specific or contribute to broad cross-resistance to multiple drugs within a therapeutic class. An example of a drug-specific mutation for the reverse transcriptase inhibitors would be the M184V mutation that is selected for by lamivudine or emtricitabine therapy—this mutation causes resistance only to those two drugs. Conversely, the thymidine analog mutations (“TAMs”) of M41L, D67N, K70R, L210W, T215Y/F, and T219Q/K/E are selected for by either zidovudine or stavudine therapy, but cause resistance to all the drugs in the class and often extend to the nucleotide inhibitor tenofovir when three or more of these TAMs are present. Further complicating the interpretation of genotypic tests is the fact that some mutations that cause resistance to one drug can actually make the virus that contains this mutation more sensitive to another drug. The M184V mutation, for example, is associated with increased sensitivity to zidovudine, stavudine, and tenofovir. The most common mutations associated with drug resistance and cross-resistance patterns for NRTIs, NNRTIs, PIs, and integrase inhibitors can be found at <http://hivdb.stanford.edu>. Phenotypic tests also require interpretation in that the distinction between a resistant virus and sensitive one is not fully defined for all available drugs.

Both methods of resistance testing are limited by the fact that they may measure resistance in only some of the viral strains present in an individual. Resistance results may also be misleading if a patient is not taking antiretroviral medications at the time of testing. Thus, resistance results must be viewed cumulatively—ie, if resistance is reported to an agent on one test, it should be presumed to be present thereafter even if subsequent tests do not give the same result.

Despite the prevalence of resistance in patients who have not responded to multiple prior treatment regimens and given the availability of new class drugs and new generation drugs, virtually all patients—no matter how much resistance is present—can be treated with a combination of ART that should be fully suppressive.

► Course & Prognosis

With improvements in therapy, patients are living longer after the diagnosis of AIDS. A population-based study conducted in Denmark found that HIV-infected persons at age 25 years without hepatitis C had a life expectancy of 39 additional years. Unfortunately, not all HIV-infected persons have access to treatment. Studies consistently show less access to treatment for blacks, the homeless, and injection drug users. In addition to access to treatment, sustaining lower mortality will require developing new treatments for patients in whom resistance to existing agents develops. For patients whose disease progresses even though they are receiving appropriate treatment, meticulous palliative care must be provided (see Chapter 5), with attention to pain control, spiritual needs, and family (biologic and chosen) dynamics.

► When to Refer

- Clinicians with limited experience in HIV/AIDS should refer HIV-infected patients to specialists with experience, given the increasing number and complexity of treatment regimens available.
- Extra efforts should be made to obtain specialty consultation for those patients with detectable viral loads on ART; those intolerant of standard medications; those in need of systemic chemotherapy; and those with complicated opportunistic infections, particularly when invasive procedures or experimental therapies are needed.

► When to Admit

Patients with opportunistic infections who are acutely ill (eg, who are febrile, who have had rapid change of mental status, or who are in respiratory distress) or who require intravenous medications.

- Bhaskaran K et al. Changes in the risk of death after HIV seroconversion compared with mortality in the general population. *JAMA*. 2008 Jul 2;300(1):51–9. [PMID: 18594040]
- Cohen CJ et al; THRIVE Study Group. Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naïve adults infected with HIV-1 (Thrive): a phase 3, randomized, non-inferiority trial. *Lancet*. 2011 Jul 16;378(9787):229–37. [PMID: 21763935]
- Lennox JL et al; STARTMRK investigators. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naïve patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. *Lancet*. 2009 Sep 5;374(9692):796–806. [PMID: 19647866]
- Molina JM et al; ECHO Study Group. Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naïve adults infected with HIV-1 (ECHO): a phase 3 randomized double-blind active-controlled trial. *Lancet*. 2011 July 16; 378(9787):238–46. [PMID: 21763936]
- Palella FJ Jr et al; HOPS (HIV Outpatient Study) Investigators. The association of HIV susceptibility testing with survival among HIV-infected patients receiving antiretroviral therapy: a cohort study. *Ann Intern Med*. 2009 Jul 21;151(2):73–84. [PMID: 19620160]
- Sax PE et al; AIDS Clinical Trials Group Study A5202 Team. Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy. *N Engl J Med*. 2009 Dec 3;361(23):2230–40. [PMID: 19952143]
- Thompson MA et al; International AIDS Society-USA. Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. *JAMA*. 2010 Jul 21;304(3):321–33. [PMID: 20639566]
- US Food and Drug Administration. FDA Drug Safety Communication: interactions between certain HIV or hepatitis C drugs and cholesterol-lowering statin drugs can increase the risk of muscle injury. <http://www.fda.gov/Drugs/DrugSafety/ucm293877.htm>
- Wittkop L et al. Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. *Lancet Infect Dis*. 2011 May;11(5):363–71. [PMID: 21354861]
- Zolopa A et al. Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: a multicenter randomized strategy trial. *PLoS One*. 2009;4(5):e5575. [PMID: 19440326]

32

Viral & Rickettsial Infections

Wayne X. Shandera, MD
Ingrid L. Roig, MD

VIRAL DISEASES

HUMAN HERPESVIRUSES

Herpesviruses cause a wide spectrum of human disease. Eight identified human herpesviruses (HHV) include herpes simplex virus (HSV) (type 1), HSV (type 2), varicella zoster virus (VZV) (type 3), Epstein–Barr (EBV) infectious mononucleosis virus (type 4), and cytomegalovirus (CMV) (type 5). A sixth type (HHV-6) is identified as a causative agent of roseola (exanthema subitum), and a seventh (HHV-7) is serologically associated with several syndromes. Finally, human herpesvirus 8 (HHV-8) is linked with Kaposi sarcoma (see Chapter 31) and primary effusion lymphoma.

Subclinical primary infection with the herpesviruses is more common than clinically manifest illness. Each persists in a latent state for the remainder of the person's life. With HSV and VZV, virus remains latent in sensory ganglia. Upon reactivation, lesions appear in the distal sensory nerve distribution. As a result of disease, drug, or radiation-induced immunosuppression, virus reactivation may lead to widespread lesions in affected organs such as the viscera or the central nervous system (CNS). Severe or fatal illness may occur in infants and immunodeficient persons. Herpesviruses can induce cell transformation, hence the association with certain malignancies, such as Burkitt lymphoma and nasopharyngeal carcinoma (with EBV) or primary effusion lymphoma and Kaposi sarcoma (with HHV-8).

1. Herpesviruses 1 & 2

ESSENTIALS OF DIAGNOSIS

- ▶ Spectrum of illness from stomatitis and urogenital lesions to facial nerve paralysis (Bell palsy) and encephalitis.
- ▶ Variable intervals between exposure and clinical disease, since HSV causes both primary (often subclinical) and reactivation disease.
- ▶ Successful management with acyclovir, valacyclovir, or famciclovir.

▶ General Considerations

Herpesviruses 1 and 2 affect primarily the oral and genital areas, respectively. Risk factors for HSV transmission include black race, female gender, a history of sexually transmitted infections, an increased number of partners, contact with commercial sex workers, lower socioeconomic status, young age at onset of sexual activity, and total duration of sexual activity. Therefore, seroprevalence of both viruses increases with age, and the seroprevalence of HSV-2 increases with sexual activity. Currently, 16% of the population in the United States is seropositive for HSV-2; of these, only 10–25% have recognized disease. Asymptomatic shedding of either virus is common, especially following primary infection or symptomatic recurrences, and may be responsible for transmission. Asymptomatic HSV-2–infected individuals shed the virus less frequently than those with symptomatic infection. Disease is typically a manifestation of reactivation. Total and subclinical shedding of HSV-2 virus decrease after the first year of initial infection, although viral shedding continues for years thereafter. Higher than expected rates of HSV-2 lesions occur among women in the postpartum period and also among women who have sex with women.

Although HSV-2 is the most common cause of genital ulcers in the developed world, HSV-1 is increasingly recognized as causing primary urogenital infections. Genital recurrences are much more frequent with HSV-2 and gradually decrease over time, whereas HSV-1 recurrences are rare after the first year. HSV-2 seropositivity increases the risk of HIV acquisition (it is threefold higher among persons who are HSV-seropositive than among those who are HSV-2 seronegative), and reactivates more frequently in advanced HIV infection. HIV replication is increased by interaction with HSV proteins. Suppression of HSV-2 decreases HIV-1 plasma levels and genital tract shedding of HIV, which can contribute to a reduction in sexual transmission of HIV-1.

▶ Clinical Findings

A. Symptoms and Signs

1. Mucocutaneous disease—HSV-1 mucocutaneous disease largely involves the mouth and oral cavity (“herpes



▲ **Figure 32-1.** Herpetic whitlow. (Used, with permission, from Usatine RP, Smith MA, Mayeaux EJ Jr, Chumley H, Tysinger J. *The Color Atlas of Family Medicine*. McGraw-Hill, 2009.)

labialis” or “gingivostomatitis;” the latter largely in children). Digital lesions (**whitlows**) (Figure 32-1) are an occupational hazard in medicine and dentistry. Contact sports (eg, wrestling) are associated with outbreaks of skin infections (“herpes gladiatorum”). Asymptomatic shedding of HSV-1 is frequent, with most infected individuals shedding virus at least once a month.

Vesicles form moist ulcers after several days and epithelialize over 1–2 weeks if untreated. Primary infection is usually more severe than recurrences but may be asymptomatic. Recurrences often involve fewer lesions, tend to be labial, heal faster, and are induced by stress, fever, infection, sunlight, chemotherapy (eg, fludarabine, azathioprine) or other undetermined factors. A specific apolipoprotein E polymorphism correlates with the presence of oral herpetic disease but not with reactivation.

HSV-2 lesions largely involve the genital tract, with the virus remaining latent in the presacral ganglia. Lesions arising on the external genitalia are multiple, painful, small, grouped, and vesicular. Occasionally, lesions arise in the perianal region or on the buttocks and upper thighs. Dysuria, cervicitis, and urinary retention may occur in women. Most HSV-2 infected persons in the United States are unaware that they are infected.

Proctitis and sacral lesions in HIV-infected persons with CD4 cytopenia may present with extensive, ulcerating, weeping lesions. Large ulcerations and atypical lesions suggest drug-resistant isolates (see below).

2. Ocular disease—HSV can cause keratitis, blepharitis, and keratoconjunctivitis. Keratitis is usually unilateral and is often associated with impaired visual acuity. Lesions limited to the epithelium usually heal without affecting vision, whereas stromal involvement can cause uveitis, scarring, and eventually blindness. Recurrences of ocular disease are frequent. HSV is the second most common cause, after VZV, of acute retinal necrosis.

3. Neonatal and congenital infection—Both herpesviruses can infect the fetus and induce congenital

malformations (organomegaly, bleeding, and CNS abnormalities). Maternal infection during the third trimester is associated with the highest risk of neonatal transmission, but about 70% of these infections are asymptomatic or unrecognized. Neonatal transmission during delivery, however, is more common than intrauterine infection. Invasive fetal monitoring and vacuum or forceps delivery can increase the risk of herpesvirus transmission.

4. Central nervous system disease—Herpes simplex encephalitis is predominantly caused by HSV-1 and presents with nonspecific symptoms: a flu-like prodrome, followed by headache, fever, behavioral and speech disturbances, and focal or generalized seizures. The temporal lobe is often involved. Untreated disease and presentation with coma carry a high mortality rate, with many survivors suffering neurologic sequelae. Herpes encephalitis does not occur disproportionately among immunosuppressed persons and a subset of pediatric herpes encephalitis is associated with toll-like receptor 3 deficiencies or abnormalities.

Both HSV-1 and HSV-2 are increasingly recognized as a cause of mild, nonspecific neurologic symptoms and are also associated with benign recurrent lymphocytic (Mollaret) meningitis. Primary HSV-2 infection in women often presents as aseptic meningitis. Recurrent meningitis from HSV-2 occurs in both younger and older individuals. HSV-1 infection may enhance the development of Alzheimer disease by promoting tau phosphorylation.

5. Disseminated infection—Disseminated HSV infection occurs in the setting of immunosuppression, either primary or iatrogenic, or rarely with pregnancy. In disseminated disease, skin lesions are not always present. Disseminated skin lesions are a particular complication in patients with atopic eczema (eczema herpeticum) and burns. Pneumonia can occur in both immunocompetent and immunosuppressed persons.

6. Bell palsy—An association between HSV-1 and Bell palsy is established.

7. Esophagitis and proctitis—HSV-1 can cause esophagitis in immunocompromised patients, particularly those with AIDS. The lesions are smaller and deeper than those observed in patients with CMV esophagitis or with other herpesvirus known to cause esophagitis in immunocompromised hosts. HSV-1 is also postulated to activate mononuclear cells in the pathogenesis of achalasia. Proctitis often occurs mainly in men who have sex with men.

8. Erythema multiforme—Herpes simplex viruses remain, along with certain drugs, a leading cause of erythema multiforme and of the more severe Stevens–Johnson syndrome.

9. Other—HSV is the cause of approximately 1% of cases of acute liver failure, particularly in pregnant women and immunosuppressed patients. When it occurs, the mortality of fulminant hepatitis is nearly 75%. An HSV lower respiratory tract infection of unknown clinical significance is common in mechanically ventilated patients. Evidence suggests that this finding is an indicator of a poor clinical

condition rather than the cause. HSV-1 pneumonia is associated with high morbidity in patients with solid tumors. HSV-1 is reported to be a cause of perinephric abscess, febrile neutropenia, chronic urticaria, and esophagitis and enteritis in systemic lupus erythematosus. HSV is also associated with *Helicobacter pylori*-negative upper gastrointestinal tract ulcers. An association between HSV-1 and endocardial inflammation in the pathogenesis of atrial myxoma is postulated.

B. Laboratory Findings

1. Mucocutaneous disease—Diagnosis is usually made clinically, but viral cultures of vesicular fluid or direct fluorescent antibody staining of scraped lesions remain the standard of diagnosis. Intranuclear inclusion bodies and multinucleated giant cells on a Tzanck preparation or Calcofluor stain are indicative of herpetic infection. Polymerase chain reaction (PCR) is a more sensitive diagnostic assay. A DNA microarray test for simultaneous detection of HSV-1, HSV-2, VZV, CMV, EBV, HHV-6, and adenovirus in immunocompromised patients is found to be sensitive, specific, cost-effective, and time saving. Type-specific serologies are useful for counseling HIV-infected individuals; pregnant women; sexual partners of persons infected with HSV; and those with an uncertain clinical history, high-risk behavior, or increased number of sexual partners.

2. Ocular disease—Herpes keratitis is diagnosed by branching (dendritic) ulcers that stain with fluorescein. The extent of epithelial injury in herpes keratitis correlates well with PCR positivity.

3. Encephalitis and recurrent meningitis—Cerebrospinal fluid pleocytosis is common, with a similar increase in the number of red cells. HSV DNA PCR of the cerebrospinal fluid is a rapid, sensitive, and specific tool for early diagnosis. Antibodies to HSV in cerebrospinal fluid can confirm the diagnosis but appear late in the course of the disease. Viral culture shows a sensitivity of only 10%. MRI scanning is often a useful adjunct showing increased signal in the temporal and frontal lobes. Temporal lobe seizure foci may be shown on electroencephalograms (EEGs).

4. Esophagitis and proctitis—Esophagitis is diagnosed by endoscopic biopsy and cultures. Proctitis may be diagnosed by rectal swab for PCR or culture, or both, although complicated cases may require biopsy.

5. Pneumonia—Pneumonia is diagnosed by clinical, pathologic, and radiographic findings. The CT findings include diffuse or multifocal areas of ground-glass attenuation or consolidative changes or both and are best confirmed using high-resolution CT techniques.

► Treatment & Prophylaxis

Drugs that inhibit replication of HSV-1 and HSV-2 include trifluridine and vidarabine (both for keratitis), acyclovir and related compounds, foscarnet, and cidofovir (Table 32-1).

A. Mucocutaneous Disease

While treatment is often not necessary in immunocompetent patients, it can ameliorate and shorten the duration of symptoms if initiated early. Oral therapy for 7–10 days is the preferred treatment for **primary genital infection** and includes acyclovir (200 mg five times a day or 400 mg three times a day), valacyclovir (1 g twice daily), or famciclovir (250 mg three times daily). **Primary herpes labialis** is most often treated with oral acyclovir (same doses and duration as for genital infection). Intravenous acyclovir (5–10 mg/kg every 8 hours for 7–14 days) should be considered in immunosuppressed patients. Topical 1% hydrocortisone cream in combination with 5% acyclovir cream is also safe and effective in the treatment of recurrent herpes simplex labialis.

For **recurrent genital disease**, acyclovir (800 mg orally three times daily for 2–5 days), valacyclovir (500 mg orally twice daily for 3 days or 1 g once a day for 5 days), or famciclovir (1 g orally twice daily for 1 day or 500 mg initial dose followed by 250 mg twice daily for 2 days) are all acceptable alternatives. Patient-initiated therapy with a short course (1–2 day regimens) of antiviral agents at first symptoms of recurrence or prodrome is a frequently used approach. For the treatment of recurrences of herpes labialis, lesions heal faster with topical penciclovir than with topical acyclovir. Docosanol cream offers modest benefit.

Atypical isolates, large ulcerations, new lesions, or poor response to therapy suggest acyclovir resistance, which often occurs in immunodeficient patients. Alternatives include high dose acyclovir (4–5 g), which is effective in treating proctitis in the HIV-positive population, or foscarnet (40–60 mg/kg intravenously every 8 hours), adjusting the dose interval in patients with kidney dysfunction. Cidofovir is used in rare cases of infection resistant to both acyclovir and foscarnet.

Patients with frequent recurrent genital infections may be given **secondary prophylaxis** with acyclovir, 400 mg twice a day; valacyclovir, 500–1000 mg once daily; or famciclovir, 250 mg twice a day. For herpes labialis, valacyclovir, 500 mg daily, is the best option. Sunscreen may be useful for recurrences associated with sunlight exposure. Advantages of suppressive therapy include a significant reduction in acquisition of disease among the HSV-2 discordant heterosexual partners and a likely reduced transmission in persons with multiple partners, including men who have sex with men and patients with recent HSV-2 infection. AIDS patients with a history of mucocutaneous disease should continue receiving suppressive therapy unless a sustained improvement of immune status occurs. Among the HIV-infected, the use of highly active antiretroviral therapy (HAART) is associated with a shortened duration of HSV-1 or -2 lesions. The CAPRISA study 004 trial recently showed that although topical tenofovir 1% gel was associated with a significant decrease in HSV-2 acquisition, there was no impact in the shedding rates among coinfecting adults.

B. Keratitis

For the treatment of acute epithelial keratitis, topical antiviral agents (ophthalmic trifluridine, vidarabine,

Table 32-1. Agents for viral infections.¹

Drug	Dosing	Spectrum	Renal Clearance/ Hemodialysis	CNS/CSF Penetration	Toxicities
Acyclovir	200-800 mg orally five times daily; 250-500 mg/m ² intravenously every 8 hours for 7 days	HSV, VZV	Yes/Yes	Yes	Neurotoxic reactions, reversible renal dysfunction, local reactions
Adefovir	10 mg daily orally	HBV	Yes/Yes	NA	Gastrointestinal symptoms, transamini- tis, lactic acidosis, nephrotoxicity, rebound hepatitis.
Amantadine	200 mg daily orally, once daily in the elderly	Influenza A (not H1N1)	Yes/Yes	Yes	Confusion
Boceprevir	800 mg three times daily	HCV	NA/NA	NA	Flu like illness, fatigue, nausea, dysgeusia, anemia.
Cidofovir	5 mg/kg intravenously weekly for 2 weeks, then every other week	CMV	Yes/NA	NA	Neutropenia, renal failure, ocular hypotonia
Emtricitabine	200 mg daily orally	HBV, HIV	Yes/Yes	Some	Lactic acidosis, rebound hepatitis.
Entecavir	0.5 mg orally daily, increase to 1 mg orally daily in lamivudine-resistant patients	HBV	Yes/Some	NA	Lactic acidosis, rebound hepatitis.
Famciclovir	500 mg orally three times daily for 7 days for acute VZV; 250 mg three times daily for 7-10 days for genital or cutaneous HSV-1/HSV-2 infection; 125 mg twice daily for 5 days for recurrences (500 mg twice daily for 7 days if HIV-infected)	HSV, VZV	Yes/NA	NA	NA
Fomivirsen	165 mcg by intravitreal injection once weekly for 3 weeks, then every other week	CMV	NA	NA	Ocular inflammation, retinal detachment
Foscarnet	20 mg/kg intravenous bolus, then 120 mg/kg intravenously every 8 hours for 2 weeks; maintain with 60 mg/kg/d intravenously for 5 days each week	CMV, HSV resis- tant to acyclo- vir, VZV, HIV-1	Yes/Yes	Variable	Nephrotoxicity, genital ulcerations, calcium disturbances
Ganciclovir	5 mg/kg intravenous bolus every 12 hours for 14-21 days; maintain with 3.75 mg/kg/d intravenously for 5 days each week	CMV	Yes/Yes	Yes	Neutropenia, thrombocytopenia, CNS side effects
Idoxuridine	Topical, 0.1% every 1-2 hours for 3-5 days	HSV keratitis	NA	NA	Local reactions
Interferon α -2b	3-5 million international units subcuta- neously three times weekly to daily. Intralesionally: 1 million international units per 0.1 mL in up to five warts three times weekly for 3 weeks	HBV, HCV, HPV	Yes/Yes	NA	Influenza-like syndrome, myelosuppression, neurotoxicity
Interferon α -n3	0.05 mL/wart biweekly up to 8 weeks 3 mU intravenously three times per week	HPV HCV	NA/NA NA/NA	NA NA	Local reactions Influenza-like syndrome, myelosuppression, neurotoxicity

(continued)

Table 32-1. Agents for viral infections.¹ (continued)

Drug	Dosing	Spectrum	Renal Clearance/ Hemodialysis	CNS/CSF Penetration	Toxicities
Lamivudine (3TC)	150 mg orally twice daily or 300 mg once daily	HIV, HBV	Yes/NA	Yes	Skin rash, headache, insomnia, rebound hepatitis
Oseltamivir	75 mg orally twice daily for 5 days beginning 48 hours after onset of symptoms	Influenza A and B	Yes/No	NA	Few
Palivizumab	15 mg/kg intramuscularly every month in RSV season	RSV	No/No	No	Upper respiratory infection symptoms
Penciclovir	Topical 1% cream every 2 hours for 4 days	HSV	No/No	No	Local reactions
Peramivir ²	Intravenous, 600 mg daily for 5-10 days	Influenza (H1N1)	Yes/NA	NA	Nausea, vomiting, diarrhea, neutropenia
Ribavirin	Aerosol: 1.1 g/d as 20 mg/mL dilution over 12-18 hours for 3-7 days (See text for Lassa fever doses.)	RSV, severe influenza A or B, Lassa fever	Yes/No	Yes	Wheezing
Rimantadine	100 mg twice daily orally, once daily in the elderly	Influenza A (not H1N1)	No/No	Yes	Confusion
Telaprevir	750 mg three times daily	HCV	NA/NA	NA	Anemia, neutropenia, rash including Stevens-Johnson syndrome
Telbivudine	600 mg once daily orally	HBV	Yes/Yes	NA	Myositis, fatigue, headache, diarrhea, cough, nausea, dizziness, rash, arthralgias, neutropenia; lactic acidosis and rebound hepatitis
Tenofovir	300 mg once daily orally	HBV, HIV	Yes/Some	Some	Rash, neutropenia, lactic acidosis, renal failure (Fanconi syndrome), rebound hepatitis
Trifluridine	Topical, 1% drops every 2 hours to 9 drops/d	HSV keratitis	NA	NA	Local reactions
Valacyclovir	1 g orally three times daily for 7 days for acute VZV; 1 g twice daily for primary genital HSV-1/HSV-2 infection with 500 mg three times daily for recurrences	VZV, HSV	Yes/Poorly	NA	Thrombotic thrombocytopenic purpura or hemolytic-uremic syndrome in AIDS
Valganciclovir	900 mg orally twice daily for 3 weeks; 900 mg daily as maintenance	CMV	Yes/Yes	Yes	See ganciclovir
Vidarabine	15 mg/kg/d intravenously for 10 days	HSV, VZV	Yes/Yes	Yes	Teratogenic, megaloblastosis, neurotoxicity
Zanamivir	2-5 mg inhalations twice daily for 5 days	Influenza A and B	Yes/NA	NA	Few

¹Agents used exclusively in the management of HIV infection and AIDS are found in Chapter 31.²Available through the Centers for Disease Control and Prevention Emergency Use Authorization.

CNS, central nervous system; CSF, cerebrospinal fluid; HSV, herpes simplex virus; VZV, varicella-zoster virus; HBV, hepatitis B virus; CMV, cytomegalovirus; HPV, human papillomavirus; HCV, hepatitis C virus; RSV, respiratory syncytial virus.

acyclovir, and ganciclovir) are all nearly equivalent in efficacy and are recommended. Combination of topical antiviral agents with interferon or debridement (or both) hastens healing. Intravenous acyclovir is used for acute retinal necrosis. Oral famciclovir is a reasonable alternative, especially in patients unable to tolerate intravenous therapy and when acyclovir resistance is present. The use of topical corticosteroids may exacerbate the infection, although systemic corticosteroids may help with selected cases of stromal infection. Long-term treatment (> 1 year) with acyclovir at a dosage of 800 mg/d orally decreases recurrence rates of keratitis, conjunctivitis or blepharitis due to HSV.

C. Neonatal Disease

Intravenous acyclovir (20 mg/kg every 8 hours for 14–21 days) is effective for the treatment of disseminated lesions in neonatal disease. Counseling with serologic screening should be offered to pregnant mothers. The use of maternal antenatal suppressive therapy with acyclovir (typically, 400 mg three times daily) beginning at 36 weeks gestation decreases the presence of detectable HSV, the rates of recurrence at delivery, and the need for cesarean section. Cesarean section is recommended for pregnant women with active genital lesions or typical prodromal symptoms.

D. Encephalitis and CNS Meningitis

Because of the need for rapid treatment to decrease mortality and neurologic sequelae, intravenous acyclovir (10 mg/kg every 8 hours for 10 days or more, adjusting for kidney dysfunction) should be started in those patients with suspected HSV encephalitis, stopping only if another diagnosis is established. If the PCR of cerebrospinal fluid is negative but clinical suspicion remains high, treatment should be continued for 10 days because the false-negative rate for PCR can be as high as 25% (especially in children) and acyclovir is relatively nontoxic. Long-term neurologic sequelae are common and late pediatric relapse is recognized. Acyclovir resistance in a case of herpes simplex encephalitis is reported. Aseptic meningitis may also require a course of intravenous acyclovir or valacyclovir.

E. Disseminated Disease

Disseminated disease responds best to parenteral acyclovir when treatment is initiated early.

F. Bell Palsy

Prednisolone, 25 mg orally twice daily for 10 days started within 72 h of onset, significantly increases the rate of recovery. Data on antiherpes antiviral agents are equivocal; according to one study, valacyclovir (but not acyclovir), 1 g orally daily for 5 days, plus corticosteroid therapy may be beneficial if started within 7 days of symptom onset. In patients with severe or complete facial paralysis, such antiviral therapy is often administered but without a firm proof of efficacy.

G. Esophagitis and Proctitis

Patients with esophagitis should receive either intravenous acyclovir (5–10 mg/kg every 8 hours) or oral acyclovir (400 mg five times daily). Maintenance therapy for AIDS patients is also with acyclovir (400 mg three to five times daily). Proctitis is treated with similar dosages and usually responds within 5 days.

H. Erythema Multiforme

Suppressive therapy with oral acyclovir (400 mg twice a day for 6 months) decreases the recurrence rate of HSV-associated erythema multiforme. Valacyclovir (500 mg twice a day) may be effective in cases unresponsive to acyclovir.

► Prevention

Besides antiviral suppressive therapy, prevention also requires counseling and the use of condom barrier precautions during sexual activity. Disclosure of partner status is associated with about a 50% reduction in the HSV-2 acquisition. Arguments favoring partner testing include confirming exposure, assistance with management, reducing the risk of transmission, and aiding in public health strategies. Male circumcision is associated with a lower incidence of acquiring HSV-2 infection.

Preventing spread to hospital staff and other patients from cases with mucocutaneous, disseminated, or genital disease requires isolation and the usage of hand-washing and gloving–gowning precautions. Staff with active lesions (eg, whitlows) should not have contact with patients. Asymptomatic transmission occurs, especially with HSV-2. Initial success with a glycoprotein vaccine did not persist with studies on a larger scale where the vaccine was found to be ineffective. Current vaccine trials focus on HSV-2 peptides, plasmid expressing peptides (DNA vaccine), viral vectors, and attenuated/replication-defective versions of HSV-2.

Barnabas RV et al; NIAID HIV Vaccine Trials Network. Impact of herpes simplex virus type 2 on HIV-1 acquisition and progression in an HIV vaccine trial (the Step study). *J Acquir Immune Defic Syndr*. 2011 Jul 1;57(3):238–44. [PMID: 21860356]

Cohen J. Immunology: painful failure of promising herpes vaccine. *Science*. 2010 Oct 15;330(6002):304. [PMID: 20947733]

Phipps W et al. Persistent genital herpes simplex virus-2 shedding years following the first clinical episode. *J Infect Dis*. 2011 Jan 15;203(2):180–7. [PMID: 21288817]

Tan DH et al. No impact of oral tenofovir disoproxil fumarate on herpes simplex virus shedding in HIV-infected adults. *AIDS*. 2011 Jan 14;25(2):207–10. [PMID: 21150556]

Tronstein E et al. Genital shedding of herpes simplex virus among symptomatic and asymptomatic persons with HSV-2 infection. *JAMA*. 2011 Apr 13;305(14):1441–9. [PMID: 21486697]

Workowski KA et al; Centers for Disease Control and Prevention (CDC). Sexually transmitted diseases treatment guidelines, 2010. *MMWR Recomm Rep*. 2010 Dec 17;59(RR-12):1–110. Erratum in: *MMWR Recomm Rep*. 2011 Jan 14;60(1):18. [PMID: 21160459]

2. Varicella (Chickenpox) & Herpes Zoster (Shingles)

ESSENTIALS OF DIAGNOSIS

- ▶ Exposure 14–21 days before onset.
- ▶ Fever and malaise just before or with eruption.
- ▶ Rash: pruritic, centrifugal, papular, changing to vesicular (“dewdrops on a rose petal”), pustular, and finally crusting.

▶ General Considerations

Varicella zoster virus (VZV), or HHV-3, disease manifestations include chickenpox (varicella) and shingles (herpes zoster). Chickenpox generally presents during childhood; has an incubation period of 10–20 days (average 2 weeks); and is highly contagious, spreading by inhalation of infective droplets or contact with lesions.

The incidence and severity of herpes zoster (“shingles”), which affects up to 25% of persons during their lifetime, increases with age due to an age-related decline in immunity against VZV. More than half of all patients in whom herpes zoster develops are older than 60 years, and the incidence of herpes zoster reaches 10 cases per 1000 patient-years by age 80 (by which time 50% are infected with VZV). The annual incidence in the United States of 1 million cases is increasing as the population ages. Populations at increased risk for varicella-zoster-related diseases include immunosuppressed persons and persons receiving biologic agents (tumor necrosis factor inhibitors).

▶ Clinical Findings

A. Varicella

1. Symptoms and signs—Fever and malaise are mild in children and more marked in adults. The pruritic rash begins prominently on the face, scalp, and trunk, and later involves the extremities (Table 32–2). Maculopapules

Table 32–2. Diagnostic features of some acute exanthems.

Disease	Prodromal Signs and Symptoms	Nature of Eruption	Other Diagnostic Features	Laboratory Tests
Atypical measles	Same as measles.	Maculopapular centripetal rash, becoming confluent.	History of measles vaccination.	Measles antibody present in past, with titer rise during illness.
Chikungunya fever	2–4 (sometimes 1–12) days, fever, headaches, abdominal complaints, myalgias, arthralgias.	Maculopapular, centrally distributed, pruritic, can be bullous with sloughing in children, occasional facial edema and petechiae.	History of mosquito bites, epidemiologic factors.	ELISA-based immunoglobulin M or IgG (fourfold increase in titers); PCR and cultures are infrequently available.
Eczema herpeticum	None.	Vesiculopustular lesions in area of eczema.		Herpes simplex virus isolated in cell culture. Multinucleate giant cells in smear of lesion.
Ehrlichiosis	Headache, malaise.	Rash in one-third, similar to Rocky Mountain spotted fever.	Pancytopenia, elevated liver function tests.	Polymerase chain reaction, immunofluorescent antibody.
Enterovirus infections	1–2 days of fever, malaise.	Maculopapular rash resembling rubella, rarely papulovesicular or petechial.	Aseptic meningitis.	Virus isolation from stool or cerebrospinal fluid; complement fixation titer rise.
Erythema infectiosum (parvovirus B19)	None. Usually in epidemics.	Red, flushed cheeks; circumoral pallor; maculopapules on extremities.	“Slapped face” appearance.	White blood count normal.
Exanthema subitum (HHV-6, 7; roseola)	3–4 days of high fever.	As fever falls by crisis, pink maculopapules appear on chest and trunk; fade in 1–3 days.		White blood count low.

(continued)

Table 32-2. Diagnostic features of some acute exanthems.(continued)

Disease	Prodromal Signs and Symptoms	Nature of Eruption	Other Diagnostic Features	Laboratory Tests
Infectious mononucleosis (EBV)	Fever, adenopathy, sore throat.	Maculopapular rash resembling rubella, rarely papulovesicular.	Splenomegaly, tonsillar exudate.	Atypical lymphocytes in blood smears; heterophil agglutination (Monospot test).
Kawasaki disease	Fever, adenopathy, conjunctivitis.	Cracked lips, strawberry tongue, maculopapular polymorphous rash, peeling skin on fingers and toes.	Edema of extremities. Angiitis of coronary arteries.	Thrombocytosis, electrocardiographic changes.
Measles (rubeola)	3-4 days of fever, coryza, conjunctivitis, and cough.	Maculopapular, brick-red; begins on head and neck; spreads downward and outward, in 5-6 days rash brownish, desquamating. See Atypical Measles, above.	Koplik spots on buccal mucosa.	White blood count low. Virus isolation in cell culture. Antibody tests by hemagglutination inhibition or neutralization.
Meningococemia	Hours of fever, vomiting.	Maculopapules, petechiae, purpura.	Meningeal signs, toxicity, shock.	Cultures of blood, cerebrospinal fluid. High white blood count.
Rocky Mountain spotted fever	3-4 days of fever, vomiting.	Maculopapules, petechiae, initial distribution centripetal (extremities to trunk, including palms).	History of tick bite.	Indirect fluorescent antibody; complement fixation.
Rubella	Little or no prodrome.	Maculopapular, pink; begins on head and neck, spreads downward, fades in 3 days. No desquamation.	Lymphadenopathy, postauricular or occipital.	White blood count normal or low. Serologic tests for immunity and definitive diagnosis (hemagglutination inhibition).
Scarlet fever	One-half to 2 days of malaise, sore throat, fever, vomiting.	Generalized, punctate, red; prominent on neck, in axillae, groin, skin folds; circumoral pallor; fine desquamation involves hands and feet.	Strawberry tongue, exudative tonsillitis.	Group A β -hemolytic streptococci in cultures from throat; antistreptolysin O titer rise.
Smallpox (based on prior experience)	Fever, malaise, prostration.	Maculopapules to vesicles to pustules to scars (lesions develop at the same pace).	Centrifugal rash; fulminant sepsis in small percentage of patients, gastrointestinal and skin hemorrhages.	Contact CDC ¹ for suspicious rash; EM and gel diffusion assays.
Typhus	3-4 days of fever, chills, severe headaches.	Maculopapules, petechiae, initial distribution centrifugal (trunk to extremities).	Endemic area, lice.	Complement fixation.
Varicella (chickenpox)	0-1 day of fever, anorexia, headache.	Rapid evolution of macules to papules, vesicles, crusts; all stages simultaneously present; lesions superficial, distribution centripetal.	Lesions on scalp and mucous membranes.	Specialized complement fixation and virus neutralization in cell culture. Fluorescent antibody test of smear of lesions.

¹<http://www.bt.cdc.gov/agent/smallpox/response-plan/>.

EBV, Epstein-Barr virus; EM, electron microscopy; HHV, human herpesvirus.


change in a few hours to vesicles that become pustular and eventually form crusts (Figures 32-2 and 32-3). New lesions may erupt for 1-5 days, so that different stages of the eruption are usually present simultaneously. The crusts slough in 7-14 days. The vesicles and pustules are superficial and elliptical, with slightly serrated borders. Pitted scars are frequent. Although the disease is often mild,

complications such as secondary bacterial infection, pneumonia, and encephalitis occur in about 1% of cases and often lead to hospitalization.

After the primary infection, the virus remains dormant in cranial nerves sensory ganglia and spinal dorsal root ganglia. Latent VZV will reactivate as herpes zoster in about 10-30% of persons (see below). Varicella is more



▲ **Figure 32-2.** Primary varicella (chickenpox) skin lesions. (Public Health Image Library, CDC.)



▲ **Figure 32-3.** Chickenpox (varicella) with classic "dew drop on rose petal" appearance. (Courtesy of Richard P. Usatine, MD; used, with permission, from Usatine RP, Smith MA, Mayeaux EJ Jr, Chumley H, Tysinger J. *The Color Atlas of Family Medicine*. McGraw-Hill, 2009.)

severe in older patients and immunocompromised persons. In the latter, atypical presentations, including widespread dissemination in the absence of skin lesions, are often described.

There is a small increased risk of Guillain-Barré syndrome for at least 2 months after an acute herpes zoster attack.

2. Laboratory findings—Diagnosis is usually made clinically, with confirmation by direct immunofluorescent antibody staining or PCR of scrapings from lesions. Multinucleated giant cells are usually apparent on a Tzanck smear or Calcofluor stain of material from the vesicle bases. Leukopenia and subclinical transaminase elevation are often present and thrombocytopenia occasionally occurs.

A varicella skin test and interferon-gamma enzyme-linked immunospot (ELISPOT) can screen for VZV susceptibility.

B. Herpes Zoster

Herpes zoster ("shingles") usually occurs among adults, but cases are reported among infants and children. Skin lesions resemble those of chickenpox. Pain is often severe and commonly precedes the appearance of rash. Lesions follow a dermatomal distribution, with thoracic and lumbar roots being the most common. In most cases, a single unilateral dermatome is involved, but occasionally, neighboring and distant areas are involved. Lesions on the tip of the nose, inner corner of the eye, and root and side of the nose (Hutchinson sign) indicate involvement of the trigeminal nerve (herpes zoster ophthalmicus). Facial palsy, lesions of the external ear with or without tympanic membrane involvement, vertigo and tinnitus, or deafness signify geniculate ganglion involvement (Ramsay Hunt syndrome or herpes zoster oticus). Shingles is a particularly common and serious complication among patients with multiple myeloma who receive bortezomib therapy, and it also occurs among patients with systemic lupus erythematosus receiving corticosteroids and immunomodulators. Contact with patients who have varicella does not appear to be a risk factor for zoster.

► Complications

A. Varicella

Secondary bacterial skin superinfections, particularly with group A β -hemolytic streptococci and *Staphylococcus aureus*, are the most common complications in children. Cellulitis, erysipelas, and scarlet fever are described. Bullous impetigo and necrotizing fasciitis are less often seen. Other associations with varicella include epiglottitis, necrotizing pneumonia, osteomyelitis, septic arthritis, epidural abscess, meningitis, endocarditis, and purpura fulminans. Toxic shock syndrome can also develop.

Interstitial VZV pneumonia is more common in adults (especially smokers, HIV-infected patients, and pregnant women) and may result in acute respiratory distress syndrome (ARDS). After healing, numerous densely calcified lesions are seen throughout the lung fields on chest radiographs.

Historically, neurologic complications developed in about 1 in 2000 children. Currently, cerebellar ataxia occurs at a frequency of 1:4000 in the young. A limited course and complete recovery are the rule. Encephalitis is similarly infrequent, occurs mostly in adults, and is characterized by delirium, seizures, and focal neurologic signs. Both mortality and long-term neurologic sequelae rates are about 10%. Ischemic strokes in the wake of acute VZV infection present a mean of 4 months after rashes and may be due to an associated vasculitis. Multifocal encephalitis, ventriculitis, myeloradiculitis, arterial aneurysm formation, and arteritis are also described in immunosuppressed, especially HIV-infected, patients.

Purpura fulminans is an extremely rare complication of varicella secondary to protein S deficiency resulting in diffuse intravascular coagulation and severe skin defects. VZV reactivation on rare occasions causes a hemophagocytic lymphohistiocytosis syndrome in severely immunocompromised patients.

Clinical hepatitis is uncommon and mostly presents in the immunosuppressed patient but can be fulminant and fatal. Reye syndrome (fatty liver with encephalopathy) also complicates varicella (and other viral infections, especially influenza B), usually in childhood, and is associated with aspirin therapy (see Influenza, below).

When contracted during the first or second trimesters of pregnancy, varicella carries a very small risk of congenital malformations, including cicatricial lesions of an extremity, growth retardation, microphthalmia, cataracts, chorioretinitis, deafness, and cerebrocortical atrophy. If varicella develops around the time of delivery, the newborn is at risk for disseminated disease.

B. Herpes Zoster

Postherpetic neuralgia occurs in 60–70% of patients who have herpes zoster and are older than 60 years. The pain can be prolonged and debilitating. Risk factors for postherpetic neuralgia include advanced age, female sex, the presence of a prodrome, and severity of rash or pain but not family history.

Other complications include the following: (1) bacterial skin superinfections; (2) herpes zoster ophthalmicus, which occurs with involvement of the trigeminal nerve and is a sight-threatening complication (especially when it involves the cornea or the iris), and is a marker for stroke over the ensuing year (Hutchinson sign is a marker of ocular involvement in the HIV-positive population); (3) rarely, unilateral ophthalmoplegia; (4) involvement of the geniculate ganglion of cranial nerve VII as well as cranial nerves V, VIII, IX, and X; (5) aseptic meningitis; (6) peripheral motor neuropathy; (7) transverse myelitis; (8) encephalitis; (9) acute cerebellitis; (10) stroke; (11) vasculopathy; (12) acute retinal necrosis; and (13) progressive outer retinal necrosis (largely among HIV infected persons). VZV is a major cause of Bell palsy in patients who are HSV seronegative. Diagnosis of neurologic complications requires the detection of VZV DNA or anti-VZV IgG in cerebrospinal fluid or the detection of VZV DNA in tissue. *Zoster sine herpette* (pain without rash) can also be associated with most of the above complications. Associations between

recent attacks of zoster and the development of multiple sclerosis and Guillain-Barré syndrome are recognized.

► Treatment

A. General Measures

In general, patients with varicella should be isolated until primary crusts have disappeared and kept at bed rest until afebrile. The skin is kept clean. Pruritus can be relieved with antihistamines, calamine lotion, and colloidal oatmeal baths. As an antipyretic, acetaminophen is used. Fingernails can be closely cropped to avoid skin excoriation and infection.

B. Antiviral Therapy

Acyclovir, 20 mg/kg (up to 800 mg per dose) orally four times daily for 5 days, should be given within the first 24 hours after the onset of varicella rash and should be considered for patients older than 12 years, secondary household contacts (disease tends to be more severe disease in secondary cases), patients with chronic cutaneous and cardiopulmonary diseases, and children receiving long-term therapy with salicylates (to decrease the risk of Reye syndrome). Experience with valacyclovir and famciclovir in these settings is scant.

In immunocompromised patients, in pregnant women during the third trimester, and in patients with extracutaneous disease (encephalitis, pneumonitis), antiviral therapy with high-dose acyclovir (30 mg/kg/d in three divided doses intravenously for at least 7 days) should be started once the diagnosis is suspected. Corticosteroids may be useful in the presence of pneumonia. Prolonged prophylactic acyclovir is important for thorough suppression of VZV reactivation in profoundly immunosuppressed patients.

For uncomplicated herpes zoster, acyclovir (800 mg orally five times daily) or valacyclovir (1 g orally three times daily) for 7 days is recommended. Therapy should start within the first 72 hours of the onset of the lesions. Intravenous acyclovir is used for extradermatomal complications of zoster, although acyclovir is not fully effective in retinal disease. A topical antiviral, sorivudine, appears to be a safe and well-tolerated adjuvant therapy to valacyclovir for treatment of acute herpes zoster. Foscarnet may be used for acyclovir-resistant VZV infections seen in immunosuppressed patients. The Ramsay Hunt syndrome is more resistant to antiviral therapy.

C. Treatment of Complications

Once established, postherpetic neuralgia may respond to gabapentin or lidocaine patches (FDA approved drugs for neuropathic pain). Tricyclic antidepressants, opioids, and capsaicin cream are also widely used and effective. The epidural injection of corticosteroids and local anesthetics appears to modestly reduce herpetic pain at 1 month but is not effective for prevention of long-term postherpetic neuralgia. Secondary bacterial infections are treated with antibiotics providing coverage for staphylococci. The use of antiviral agents for postherpetic neuralgia is under further study.

► Prognosis

The total duration of varicella from onset of symptoms to disappearance of crusts rarely exceeds 2 weeks. Fatalities are rare except in immunosuppressed patients.

Herpes zoster resolves in 2–6 weeks. Antibodies persist longer and at higher levels than with primary varicella. Eye involvement with herpes zoster necessitates periodic future examinations.

► Prevention

Health care workers should be screened for varicella and vaccinated if seronegative. Patients with active varicella or herpes zoster are promptly separated from seronegative patients. For those with varicella, airborne and contact isolation is recommended, whereas for those with zoster, contact precautions are sufficient. For immunosuppressed patients with zoster, precautions should be the same as if the patient had varicella. Exposed serosusceptible patients should be placed in isolation and exposed serosusceptible employees should stay away from work between days 10 and 21 after exposure. Health care workers with zoster should receive antiviral agents during the first 72 hours of disease and withdraw from work until lesions are crusted. Postexposure prophylaxis should be evaluated (see below).

A. Varicella

1. Vaccination—Universal childhood vaccination against varicella is effective. The varicella vaccine (Varilrix) is safe and over 98.1% effective when given after 13 months of age. A single antigen live attenuated vaccine (VARIVAX) or a quadrivalent measles, mumps, rubella, and varicella vaccine (ProQuad) are available. The first dose should be administered at 12–15 months of age and the second at 4–6 years. Aspirin should be avoided for at least 6 weeks because of the risk of Reye syndrome. This vaccine is safe, well tolerated, but the quadrivalent vaccine is associated with a small risk of febrile seizures 5–12 days after vaccination among infants aged 12–23 months. Rashes, when secondary to the varicella vaccine, appear 15–42 days after vaccination. Rare cases of zoster among children who received the varicella vaccine are attributable to delayed vaccination (after age 5), severe asthma, and developmental disorders. Such complications appear to occur less often among American children of African ancestry.

For serosusceptible individuals older than 13 years, two doses of varicella vaccine (single antigen) administered 4–8 weeks apart is recommended. For those who received a single dose in the past, a catch-up second dose is advised, especially in the epidemic setting (where it is effective when it can be given during the first 5 days postexposure). Household contacts of immunocompromised patients should adhere to these recommendations. Susceptible pregnant women need to receive the first dose of vaccine before discharge after delivery and the second dose 4–8 weeks later. The quadrivalent vaccine MMRV can be used for the second doses of MMR and varicella in patients aged 15 months to 12 years and for the first dose in patients aged 48 months or older. (Before this age, the MMR and varicella vaccination can safely be given separately.)

The vaccine, administered 3 months apart, should also be considered for HIV-infected adolescents and adults with CD4 T lymphocyte counts ≥ 200 cells/mL. The vaccine may also be given to patients with impaired humoral immunity, to patients receiving corticosteroids, and to patients with juvenile rheumatoid arthritis who receive methotrexate. Patients receiving high doses of corticosteroids for over 2 weeks may be vaccinated a month after discontinuation of the therapy. Patients with leukemia, lymphoma, or other malignancies whose disease is in remission and who have not undergone chemotherapy for at least 3 months may be vaccinated. Kidney and liver transplant patients should be vaccinated if they are susceptible to varicella.

The incidence of varicella in the United States has been reduced between 67% and 87% as a consequence of the varicella vaccine.

2. Postexposure—Postexposure vaccination is recommended for unvaccinated persons without other evidence of immunity. Varicella-zoster immune globulin (VZIG) (in short supply with production stopped in 2004) or VariZIG (a lyophilized product available under expanded access since December 2007) should be considered for susceptible exposed patients who cannot receive the vaccine, including immunosuppressed patients, neonates from mothers with varicella around the time of delivery, exposed premature infants born from serosusceptible mothers at > 28 weeks of gestation, neonates born at < 28 weeks of gestation regardless of maternal serostatus, and pregnant women. No controlled studies have evaluated the use of acyclovir in this setting. VZIG is given by intramuscular injection in a dosage of 12.5 units/kg up to a maximum of 625 units, with a repeat identical dose in 3 weeks if a high-risk patient remains exposed. VZIG has no place in therapy of established disease.

Further information may be obtained by calling the Centers for Disease Control and Prevention's Immunization Information Hotline (800-232-2522).

B. Herpes Zoster

A live attenuated VZV vaccine (ZOSTAVAX, 19,400 plaque forming units [pfu] of Oka/Merck strain) consists of varicella virus at a concentration at least 14 times that found in VARIVAX (1350 pfu). This vaccine should be offered to persons 60 years and older but cannot be used in children in place of varicella vaccine; if the vaccine is accidentally given to a child, the event should be reported to the CDC. In adults, the vaccine reduces the incidence of postherpetic neuralgia and herpes zoster by 67% and 51%, respectively. Before administration of zoster vaccine, patients do not need to be asked about their history of varicella (chickenpox) or have serologic tests to determine varicella immunity because the vaccine is safe, tolerated, and immunogenic in persons with a history of herpes zoster. A second dose of the zoster vaccine is not recommended because it does not boost VZV specific immunity beyond the levels achieved by the first dose. The attenuated VZV vaccine is safe and modestly immunogenic among HIV-infected persons with a CD4 count of at least 300 cells/mL.

In 2009, the manufacturer advised against concurrent administration with 23-valent pneumococcal polysaccharide vaccine based on a study showing lower VZV titers; however, a subsequent larger study showed equal effectiveness among persons who received the vaccine at the same time when compared to those who received the vaccines 4 weeks apart. Consequently, the CDC continues to recommend the administration of both vaccines at the same visit. If a varicella vaccine is mistakenly administered to an adult instead of a zoster vaccine, the dose should be considered invalid and the patient should be administered a dose of zoster vaccine at the same visit. Prophylaxis with acyclovir, 800 mg orally twice daily, can be considered in patients at high risk for VZV reactivation (eg, allogeneic hematopoietic cell transplant patients).

- Kang JH et al. Increased risk of multiple sclerosis following herpes zoster: a nationwide, population-based study. *J Infect Dis.* 2011 Jul 15;204(2):188–92. [PMID: 21653524]
- Lu PJ et al. Herpes zoster vaccination among adults age 60 years and older, in the U.S., 2008. *Am J Prev Med.* 2011 Feb;40(2):e1–6. [PMID: 21238856]
- Oxman MN. Zoster vaccine: current status and future prospects. *Clin Infect Dis.* 2010 Jul 15;51(2):197–213. [PMID: 20550454]
- Pahud BA et al. Varicella zoster disease of the central nervous system: epidemiological, clinical, and laboratory features 10 years after the introduction of the varicella vaccine. *J Infect Dis.* 2011 Feb 1;203(3):316–23. [PMID: 21177308]
- Tseng HF et al. Herpes zoster vaccine in older adults and the risk of subsequent herpes zoster disease. *JAMA.* 2011 Jan 12;305(2):160–6. [PMID: 21224457]
- Vermeulen JN et al. Safety, tolerability, and immunogenicity after 1 and 2 doses of zoster vaccine in healthy adults \geq 60 years of age. *Vaccine.* 2012 Jan 20;30(5):904–10. [PMID: 22154769]

3. Epstein-Barr Virus & Infectious Mononucleosis



ESSENTIALS OF DIAGNOSIS

- ▶ Malaise, fever, and sore throat, sometimes with exudates.
- ▶ Palatal petechiae, lymphadenopathy, splenomegaly, and, occasionally, a maculopapular rash.
- ▶ Positive heterophil agglutination test (Monospot).
- ▶ Atypical large lymphocytes in blood smear; lymphocytosis.
- ▶ Complications: hepatitis, myocarditis, neuropathy, encephalitis, airway obstruction secondary to lymph node enlargement, hemolytic anemia, thrombocytopenia.

▶ General Considerations

Epstein-Barr virus (EBV, or human herpes virus-4 [HHV-4]) is one of the most ubiquitous human viruses, infecting > 95% of the adult population worldwide and

persisting for the lifetime of the host. Infectious mononucleosis is a common manifestation of EBV and may occur at any age. In the United States, EBV infection usually develops in persons between the ages of 10 and 35 years, sporadically or epidemically. In the developing world, infectious mononucleosis occurs at younger ages and tends to be less symptomatic. Rare cases in the elderly occur usually without the full symptomatology. EBV is largely transmitted by saliva but can also be recovered from genital secretions. Saliva may remain infectious during convalescence, for 6 months or longer after symptom onset. The incubation period lasts several weeks (30–50 days).

▶ Clinical Findings

A. Symptoms and Signs

The protean manifestations of infectious mononucleosis reflect the dissemination of the virus in the oral cavity and through peripheral blood lymphocytes and cell-free plasma. Fever, sore throat, fatigue, malaise, anorexia, and myalgia typically occur in the early phase of the illness. Physical findings include lymphadenopathy (discrete, nonsuppurative, slightly painful, especially along the posterior cervical chain), transient bilateral upper lid edema (Hoagland sign), and splenomegaly (in up to 50% of patients). A maculopapular or occasionally petechial rash occurs in < 15% of patients unless ampicillin is given (in which case rash is seen in > 90%). Conjunctival hemorrhage (Figure 32–4), exudative pharyngitis, uvular edema, tonsillitis, or gingivitis may occur and soft palatal petechiae may be noted.

Other manifestations include hepatitis, cholestasis, gastritis, nervous system involvement in 1–5% (mononeuropathies and occasionally aseptic meningitis, encephalitis, cerebellitis, peripheral and optic neuritis, transverse myelitis, or Guillain-Barré syndrome), kidney disease (mostly interstitial nephritis), pneumonia, pleural involvement, and myocarditis. Vaginal ulcers are rare but may be present. Airway obstruction from lymph node enlargement, pericarditis, life-threatening thrombocytopenia, severe CNS



▲ **Figure 32–4.** Conjunctival hemorrhage of the eye due to infectious mononucleosis. (Courtesy of Dr. Thomas F. Sellers, Emory University, Public Health Image Library, CDC.)

complications, and massive splenomegaly are all considered indications for hospitalization or close observation. Mesenteric adenitis may mimic an acute abdomen.

B. Laboratory Findings

In infectious mononucleosis an initial phase of granulocytopenia is followed within 1 week by lymphocytic leukocytosis (> 50% of all leukocytes) with atypical lymphocytes (larger than normal mature lymphocytes, staining more darkly, and showing vacuolated, foamy cytoplasm and dark nuclear chromatin) comprising >10% of the leukocyte count. Hemolytic anemia, with anti-i antibodies, occurs occasionally as does thrombocytopenia (at times marked).

The diagnosis of infectious mononucleosis is commonly made on the basis of characteristic manifestations and serologic evidence of infection (the heterophil sheep cell agglutination [HA] antibody tests or the correlated mononucleosis spot test [Monospot]). These tests usually become positive within 4 weeks after onset of illness and are specific but often not sensitive in early illness. Heterophil antibodies may be absent in young children and in as many as 20% adults. During acute illness, there is a rise and fall in immunoglobulin M (IgM) antibody to EB virus capsid antigen (VCA) and a rise in IgG antibody to VCA, which persists for life. Antibodies (IgG) to EBV nuclear antigen (EBNA) appear after 4 weeks of onset and also persist. Absence of IgG and IgM VCA or the presence of IgG EBNA should make one reconsider the diagnosis of acute EBV infection.

PCR for EBV DNA is useful in the evaluation of malignancies associated with EBV. For instance, detection of EBV DNA in cerebrospinal fluid shows a sensitivity of 90% and specificity of nearly 100% for the diagnosis of primary CNS lymphoma in patients with AIDS, and monitoring of quantitative EBV DNA levels (a “viral load”) in blood may be useful in early detection of post-transplant lymphoproliferative disorder in high-risk patients. PCR analysis may also be helpful in monitoring disease and treatment response in primary CNS lymphoma and posttransplant lymphoproliferative disorder patients. Antibodies against ZEBRA (a replication protein) are produced in early infection and assays for these antibodies are commercially available.

► Differential Diagnosis

CMV infection, toxoplasmosis, acute HIV infection, secondary syphilis, HHV-6, rubella, and drug hypersensitivity reactions may be indistinguishable from infectious mononucleosis due to EBV, but exudative pharyngitis is usually absent and the heterophil antibody tests are negative. With acute HIV infection, rash and mucocutaneous ulceration are common but atypical lymphocytosis is much less common. Heterophil-negative infectious mononucleosis with nonsignificant lymphocytosis (especially if rash or mucocutaneous ulcers are present) should prompt investigation for acute HIV infection. Heterophil-negative infectious mononucleosis with atypical lymphocytosis can be caused by CMV, toxoplasmosis and, on occasion,

EBV itself. Mycoplasma infection may also present as pharyngitis, though lower respiratory symptoms usually predominate. A hypersensitivity syndrome induced by carbamazepine or phenytoin may mimic infectious mononucleosis.

The differential diagnosis of acute exudative pharyngitis includes diphtheria, gonococcal and streptococcal infections, and infections with adenovirus and herpes simplex. Head and neck soft tissue infections (pharyngeal and tonsillar abscesses) may occasionally be mistaken as the lymphadenopathy of mononucleosis.

► Complications

Secondary bacterial pharyngitis can occur and is often streptococcal. Splenic rupture (0.5–1%) is a rare but dramatic complication, and a history of preceding trauma can be elicited in 50% of the cases. Acalculous cholecystitis, fulminant hepatitis with massive necrosis, pericarditis and myocarditis are also infrequent complications. Neurologic involvement—including transverse myelitis, encephalitis, and Guillain-Barré syndrome—is infrequent.

► Treatment

A. General Measures

Over 95% of patients with acute EBV-associated infectious mononucleosis recover without specific antiviral therapy. Treatment is symptomatic with acetaminophen or other nonsteroidal anti-inflammatory drugs and warm saline throat irrigations or gargles three or four times daily. Acyclovir decreases viral shedding but shows no clinical benefit. Corticosteroid therapy, although widespread, is not recommended in uncomplicated cases; its use is reserved for impending airway obstruction from enlarged lymph nodes, hemolytic anemia, and severe thrombocytopenia. The value of corticosteroid therapy in impending splenic rupture, pericarditis, myocarditis, and nervous system involvement is less well defined. If a throat culture grows β -hemolytic streptococci, a 10-day course of penicillin or erythromycin is indicated. Ampicillin and amoxicillin are avoided because of the frequent association with rash.

B. Treatment of Complications

Hepatitis, myocarditis, and encephalitis are treated symptomatically. Rupture of the spleen requires splenectomy and is most often caused by deep palpation of the spleen or vigorous activity. Patients should avoid contact or collision sports for at least 4 weeks to decrease the risk of splenic rupture (even if splenomegaly is not detected by physical examination which can be insensitive).

► Prognosis

In uncomplicated cases, fever disappears in 10 days and lymphadenopathy and splenomegaly in 4 weeks. The debility sometimes lingers for 2–3 months.

Death is uncommon and is usually due to splenic rupture, hypersplenic phenomena (severe hemolytic anemia, thrombocytopenic purpura), or encephalitis.

4. Other Epstein–Barr Virus Syndromes

EBV viral antigens are found in > 90% of patients with endemic (African) Burkitt lymphoma and nasopharyngeal carcinoma (among whom quantified EBV DNA can be used to follow disease). Risk factors for Burkitt lymphoma include a history of malaria (which may decrease resistance to EBV infection) while risk factors for nasopharyngeal carcinoma include long-term heavy cigarette smoking and seropositive EBV serologies (VCA and deoxyribonuclease [DNase]). VCA-IgA in peripheral blood is a sensitive and specific predictor for nasopharyngeal carcinoma in endemic areas.

Chronic EBV infection is associated with aberrant cellular immunity (a low frequency of EBV-specific CD8 cells), an X-linked lymphoproliferative syndrome (Duncan disease), lymphomatoid granulomatosis, and a fatal T cell lymphoproliferative disorder in children.

EBV is an important cause of hemophagocytic lymphohistiocytosis among immunodeficient patients, B-cell lymphomas (such as primary CNS lymphoma in HIV-infected individuals), and posttransplant lymphoproliferative disorder. In fact, over 70% of posttransplant lymphoproliferative states are associated with EBV. EBV-naïve patients who receive a donor organ from an EBV-infected donor are at the highest-risk for the development of posttransplant lymphoproliferative disorder. Decreasing the iatrogenic immunosuppression, given to reduce graft rejection, is the initial step in managing such patients, while rituximab (CD20 monoclonal antibody) is effective in treating some cases. The efficacy of rituximab therapy can be often assessed by monitoring levels of EBV DNA load in the blood and, if indicated, CNS. Infusion of EBV-specific cytotoxic T cell lymphocytes (adoptive cell therapy) is also used but with a less established role.

Age is a major determinant of the type of tumor associated with EBV. T and NK cell lymphoma caused by chronic active EBV infections are more frequent in childhood while peripheral T cell lymphomas and diffuse large B cell lymphomas are more common in the elderly due to waning immunity. EBV is also associated with leiomyomas in children with AIDS and with nasal T cell lymphomas.

EBV is often implicated in the pathogenesis of a host of disorders from Hodgkin disease and gastric carcinoma to CNS demyelination, multiple sclerosis, Graves disease, histiocytic necrotizing lymphadenitis (Kikuchi-Fujimoto disease), chronic obstructive pulmonary disease (COPD), rheumatic diseases, and dental disorders (pulpitis and apical periodontitis). EBV was previously linked with the chronic fatigue syndrome but there is no persuasive evidence for an association, nor does there appear to be an association between chronic fatigue syndrome and xenotropic murine leukemia virus-related virus. Oral hairy leukoplakia and its association with EBV are discussed in Chapter 8.

► When to Admit

- Acute meningitis, encephalitis, or acute Guillain-Barré syndrome.
- Severe thrombocytopenia.
- Potential splenic rupture.

- Airway obstruction from severe adenitis.
- Significant hemolysis.
- Pericarditis.
- Abdominal findings mimicking an acute abdomen.

Akatori H et al. Graves' disease associated with infectious mononucleosis due to primary Epstein-Barr virus infection: report of 3 cases. *Intern Med.* 2010;49(23):2599–603. [PMID: 21139299]

Hisamatsu A et al. Gastritis associated with Epstein-Barr virus infection. *Intern Med.* 2010;49(19):2101–5. [PMID: 20930436]

Lucas RM et al. Epstein-Barr virus and multiple sclerosis. *J Neurol Neurosurg Psychiatry.* 2011 Oct;82(10):1142–8. [PMID: 21836034]

Luzurriaga K et al. Infectious mononucleosis. *N Engl J Med.* 2010 May 27;362(21):1993–2000. [PMID: 20505178]

Parker A et al; Haemato-oncology Task Force of the British Committee for Standards in Haematology and British Transplantation Society. Diagnosis of post-transplant lymphoproliferative disorder in solid organ transplant recipients—BCSH and BTS Guidelines. *Br J Haematol.* 2010 Jun;149(5):675–92. [PMID: 20408847]

Sárdy M et al. Genital ulcers associated with Epstein-Barr virus infection (ulcus vulvae acutum). *Acta Derm Venereol.* 2011 Jan;91(1):55–9. [PMID: 21031278]

5. Cytomegalovirus Disease



ESSENTIALS OF DIAGNOSIS

- Mononucleosis-like syndrome.
- Frequent pathogen seen in transplant populations.
- Diverse clinical syndromes in HIV (retinitis, esophagitis, pneumonia, encephalitis).
- Major pathogen to consider in neonates in the differential of maternally transmitted agents.

► General Considerations

Most CMV infections are asymptomatic. After primary infection, the virus remains latent in most body cells. Seroprevalence in adults of Western developed countries is about 60–80% but is higher in developing countries. CMV seroprevalence increases with age, number of sexual partners, history of prior sexually transmitted infections, and low socioeconomic status. The virus can be isolated from a variety of tissues under nonpathogenic conditions. Transmission occurs through sexual contact, breastfeeding, blood products, or transplantation; it may also occur person-to-person (eg, day care centers) or be congenital. Serious disease occurs primarily in immunocompromised persons.

There are three recognizable clinical syndromes: (1) perinatal disease and CMV inclusion disease; (2) diseases in immunocompetent persons; and (3) diseases in immunocompromised persons. **Congenital CMV infection** is the most common congenital infection in developed countries (between 0.2% and 2% of all live births, with higher rates in

underdeveloped areas and among lower socioeconomic groups). Transmission is much higher from mothers with primary disease than those with reactivation (40% vs 0.2–1.8%). About 10% of infected newborns will be symptomatic with CMV inclusion disease. In **immunocompetent persons**, acute CMV infection is the most common cause of the mononucleosis-like syndrome with negative heterophil antibodies. CMV appears to play a role in critically ill immunocompetent adults wherein it is reactivated and associated with prolonged hospitalization and death. Other syndromes associated with CMV and whose role in pathogenesis requires further elucidation include inflammatory bowel disease, atherosclerosis, cognitive decline, and breast cancer. In **immunocompromised persons**, tissue and bone marrow transplant patients are mainly at risk for a year after allograft transplantation (but especially during the first 100 days afterward) and in particular when graft-versus-host disease or CMV seropositivity, or both, are present in the donor and recipient. Depending on the serostatus of the donor and recipient, disease may present as primary infection or reactivation. The risk of CMV disease is proportionate to the intensity of immunosuppression. CMV itself is immunosuppressive. CMV may contribute to transplanted organ dysfunction, which often mimics organ rejection. CMV disease in HIV-infected patients (retinitis, serious gastrointestinal disease) occurs most prominently when the CD4 count is < 50 cells/mL. HAART reduces the frequency of retinitis and may reverse active disease. CMV retinitis may also develop after solid organ or bone marrow transplantation. CMV retinitis associated with intravitreal delivery of corticosteroids (injections or implants) or systemic anti-tumor necrosis factor antibodies is also described. Occasionally, CMV retinitis presents in immunocompetent persons. Serious gastrointestinal CMV disease also occurs after organ transplantation, cancer chemotherapy, or corticosteroid therapy. CMV may exist alongside other pathogens, such as *Cryptosporidium*, in up to 15% of patients with AIDS cholangiopathy. CMV pneumonitis occurs in transplant recipients (mainly bone marrow and lung) with a mortality rate up to 60–80%, and less often in AIDS patients. CMV pneumonitis in hematologic malignancies (eg, lymphoma) is increasingly reported. Neurologic CMV in patients with advanced AIDS is usually associated with disseminated CMV infection.

► Clinical Findings

A. Symptoms and Signs

1. Perinatal disease and CMV inclusion disease—

CMV inclusion disease in infected newborns is characterized by jaundice, hepatosplenomegaly, thrombocytopenia, purpura, microcephaly, periventricular CNS calcifications, mental retardation, and motor disability. Hearing loss develops in > 50% of infants who are symptomatic at birth. Most infected neonates are asymptomatic, but neurologic deficits may ensue later in life, including hearing loss in 15% and mental retardation in 10–20%. Perinatal infection acquired through breastfeeding or blood products typically shows a benign clinical course.

2. Disease in immunocompetent persons—Acute acquired CMV infection is characterized by fever, malaise, myalgias, arthralgias, and splenomegaly. Exudative pharyngitis or cervical lymphadenopathies are uncommon, but cutaneous rashes (including the typical maculopapular rash after exposure to ampicillin) are common. The mean duration of symptoms is 7–8 weeks. Complications include mucosal gastrointestinal damage, encephalitis, severe hepatitis, thrombocytopenia (on occasion, refractory), the Guillain-Barré syndrome, pericarditis, and myocarditis. The risk of Guillain-Barre syndrome developing after primary CMV infection is estimated to be 0.6–2.2 cases per 1000 primary infection, similar to that seen with *Campylobacter jejuni* infection. The mononucleosis-like syndrome due to CMV can also occur postsplenectomy, often years later and associated with a protracted fever, marked lymphocytosis, and impaired anti-CMV IgM response.

3. Disease in immunocompromised persons—Distinguishing between CMV infection (with evidence of CMV replication) and CMV disease (evidence for systemic symptoms or organ invasion) is important. In addition to patients infected with HIV, those who have undergone transplantation (solid organ or hematopoietic stem cell) show a wide spectrum of disease including gastrointestinal (including acute cholecystitis), renal, and CNS disease, as outlined above. CMV viral loads correlate with prognosis after transplantation.

A. CMV RETINITIS—A fundoscopic examination reveals neovascular, proliferative lesions (“pizza-pie” retinopathy). Immune restoration with HAART is associated with CMV vitritis and cystoid macular edema. Infants with CMV retinitis tend to have more macular than peripheral disease.

B. GASTROINTESTINAL AND HEPATOBIILIARY CMV—Esophagitis presents with odynophagia. Gastritis can occasionally cause bleeding, and small bowel disease may mimic inflammatory bowel disease or may present as ulceration or perforation. Colonic CMV disease causes diarrhea, hematochezia, abdominal pain, fever, and weight loss and may mimic inflammatory bowel disease. CMV hepatitis commonly complicates liver transplantation and appears to be increased in those with hepatitis B or hepatitis C viral infection.

C. RESPIRATORY CMV—CMV pneumonitis is characterized by cough, dyspnea, and relatively little sputum production.

D. NEUROLOGIC CMV—Neurologic syndromes associated with CMV include polyradiculopathy, transverse myelitis, ventriculoencephalitis (suspected with ependymitis), and focal encephalitis. These manifestations are more prominent in patients with advanced AIDS in whom the encephalitis has a subacute onset.

B. Laboratory Findings

1. Mothers and newborns—Pregnant women should be tested for IgM CMV antibodies every 3 months if an assay during the first trimester is seropositive. Congenital

CMV disease is confirmed by presence of the virus in amniotic fluid or an IgM assay from fetal blood. Amniocentesis is less reliable before 21 weeks of gestation (due to inadequate fetal urinary development and release into the amniotic fluid), but amniocentesis is attendant with greater risk when performed after 21 weeks of gestation. PCR assays of dried blood samples from newborns and micro-enzyme-linked immunosorbent assay (ELISA) on urine, saliva or blood specimens obtained during the first 3 weeks of life are used to diagnose congenital CMV infection.

2. Immunocompetent persons—The acute mononucleosis-like syndrome is characterized by initial leukopenia; within 1 week, it is followed by absolute lymphocytosis with atypical lymphocytes. Abnormal liver function tests are common in the first 2 weeks of the disease (often 2 weeks after the fever). Detection of CMV specific IgM or a four-fold increase of specific IgG levels support the diagnosis of acute infection.

3. Immunocompromised persons—CMV retinitis is diagnosed on the basis of the characteristic ophthalmoscopic findings. In HIV-infected patients, negative CMV serologies lower the possibility of the diagnosis but do not eliminate it. Cultures alone are of little use in diagnosing AIDS-related CMV infections, since viral shedding of CMV is common. PCR analysis should be used to diagnose CNS infection since cultures are insensitive.

Detection of pp65 antigen in blood and determination of quantitative CMV antigenemia (“viral load”) by PCR are increasingly used in posttransplant patients for guidance on both treatment and prevention and should be interpreted in the context of clinical and pathologic findings, although full standardization of CMV viral loads is under development. The PCR is sensitive in predicting clinical disease. Quantitative PCR of bronchoalveolar lavage fluid seems to be useful for diagnosing CMV pneumonia.

Rapid shell-vial cultures for detection of early CMV antigens with fluorescent antibodies have largely replaced the conventional tube culture (for detection of cytopathic changes) since the time to positivity is greatly reduced (24–48 hours compared to weeks). Shell-vial cultures are more useful on bronchoalveolar lavage fluid than in routine blood monitoring.

A variety of false-positive immunologic assays occur in the setting of acute CMV infections, including positive rheumatoid factor, direct Coombs test, cryoglobulins, and speckled antinuclear antibody.

In gastrointestinal disease, CMV antigenemia is more specific than sensitive.

C. Imaging

The chest radiographic findings of CMV pneumonitis are consistent with interstitial pneumonia.

D. Biopsy

Tissue confirmation is especially useful in diagnosing CMV pneumonitis and CMV gastrointestinal disease; the

diagnosis of colonic CMV disease is made by mucosal biopsy showing characteristic CMV histopathologic findings of intranuclear (“owl’s eye”) and intracytoplasmic inclusions.

► Treatment

Sight-threatening CMV retinitis (lesions close to the fovea or optic nerve head) is treated with ganciclovir induction therapy (5 mg/kg intravenously every 12 hours for 14–21 days) followed by maintenance therapy at lower doses (5 mg/kg intravenously daily). Sustained-release ganciclovir intraocular implants (always accompanied by systemic valganciclovir) are another option. In less severe retinal disease, valganciclovir (900 mg orally twice daily for 14–21 days followed by 900 mg/d maintenance) is preferred. Due to potential toxicities, foscarnet, cidofovir, and fomivirsen are usually reserved for CMV infections that are resistant to ganciclovir. Combinations of ganciclovir and foscarnet are shown to be safe and effective in treating clinically resistant CMV retinitis. The role of HAART in reducing the need for CMV antiviral agents is essential. Other forms of CMV disease in AIDS are managed initially with intravenous ganciclovir and subsequently with oral valganciclovir; alternative agents (listed above) are used when resistance evolves.

The treatment of other systemic CMV infection (colitis, encephalitis, pneumonia) involves the use of the main antiviral agents used in CMV retinitis. The length of therapy depends on the state of immunosuppression, and secondary prophylaxis is typically maintained until immune restoration is present for at least 6 months. Prolonged prophylaxis may be necessary in other immunosuppressed patients, such as those receiving tumor necrosis factor (TNF) inhibitors.

For non-severe, posttransplant CMV disease, oral valganciclovir (900 mg twice daily) or intravenous ganciclovir (5 mg/kg every 12 hours) are the recommended first-line agents. Valganciclovir has been shown to be noninferior to intravenous ganciclovir-based therapy in solid organ transplant patients and is associated with less clinical resistance than ganciclovir. **For severe CMV disease**, intravenous ganciclovir remains the treatment of choice. Dosage adjustments of all medications are needed for kidney dysfunction. Reduction of immunosuppression should be attempted when possible (especially for muromonab, azathioprine, or mycophenolate mofetil). Treatment should be continued for at least 2 weeks until viral eradication is achieved. Two consecutive negative samples of CMV quantitative analysis testing or antigenemia based assay ensure viral clearance. Other agents that may be useful in resistant CMV infections include leflunomide, sirolimus-based therapy, and artesunate. Adoptive immunotherapy is also under study.

In pregnant women with primary CMV infection, passive immunization with hyperimmune globulin appears preliminarily to be effective in both treatment and prevention of fetal infection, but controlled clinical trials are lacking. While CMV immunoglobulin is also used in the

treatment of CMV pneumonia in stem cell transplant recipients, its efficacy is not completely established.

► Prevention

A CMV glycoprotein B with MF59 adjuvant vaccine is currently under development. Phase 2 studies show vaccine efficacy of 50% in preventing congenital disease as well as increased antibody titers compared to placebo in seronegative and seropositive transplant recipients and in a population of CMV infected women.

HAART is effective in preventing CMV infections in HIV-infected patients. Use of leukocyte-depleted blood products effectively reduces the incidence of CMV disease in patients who have undergone transplantation. Prophylactic and preemptive strategies (eg, antiviral agents only when antigen detection or PCR assays show evidence of active CMV replication) are effective in preventing disease in the early transplantation period but are associated with a risk of a late-onset form of the disease after the prophylaxis is discontinued. The appropriate management of transplant patients is based on the serostatus of the donor and the recipient. All effective anti-CMV agents can serve as prophylactic agents for CMV-seropositive transplants or for CMV-seronegative recipients of CMV-positive organ transplants. A recent meta-analysis shows that valganciclovir prophylaxis at a lower dose (450 mg orally twice daily vs 900 mg orally twice daily) is equally effective in solid organ transplant patients with less risk of leukopenia and rejection. CMV immune globulin may also be useful in reducing the incidence of bronchiolitis obliterans in the bone marrow transplant population and is used in some centers as part of the prophylaxis in kidney, liver, and lung transplantation patients. CMV immune globulin as prophylaxis is not recommended in hematopoietic stem cell transplant recipients.

Withdrawal of infected children from day care centers, reduction of patient contact by health care workers, screening for women of childbearing age, or restrictions to breastfeeding are not recommended because the virus is ubiquitous.

► When to Refer

- Neonatal infections consistent with CMV inclusion disease.
- AIDS patients with retinitis, esophagitis, colitis, hepatobiliary disease, or encephalitis.
- Organ and hematopoietic stem cell transplants with suspected reactivation CMV.

► When to Admit

- Risk of colonic perforation.
- Evaluation of unexplained, advancing encephalopathy.
- Biopsy of tissues in the differential diagnosis of transplant rejection vs infection.
- Initiation of treatment with intravenous anti-CMV agents.

Cannon MJ et al. Review of cytomegalovirus seroprevalence and demographic characteristics associated with infection. *Rev Med Virol.* 2010 Jul;20(4):202–13. [PMID: 20564615]

Griffiths PD et al. Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial. *Lancet.* 2011 Apr 9;377(9773):1256–63. [PMID: 21481708]

Kalil AC et al. Effectiveness of valganciclovir 900 mg versus 450 mg for cytomegalovirus prophylaxis in transplantation: direct and indirect treatment comparison meta-analysis. *Clin Infect Dis.* 2011 Feb 1;52(3):313–21. [PMID: 21189424]

Kotton CN et al; Transplantation Society International CMV Consensus Group. International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. *Transplantation.* 2010 Apr 15;89(7):779–95. [PMID: 20224515]

Orlikowski D et al. Guillain-Barré syndrome following primary cytomegalovirus infection: a prospective cohort study. *Clin Infect Dis.* 2011 Apr 1;52(7):837–44. [PMID: 21427390]

Sabbaj S et al. Glycoprotein B vaccine is capable of boosting both antibody and CD4 T-cell responses to cytomegalovirus in chronically infected women. *J Infect Dis.* 2011 Jun 1;203(11):1534–41. [PMID: 21592981]

6. Human Herpesviruses 6, 7, & 8

HHV-6 is a B cell lymphotropic virus that is the principal cause of exanthema subitum (roseola infantum, sixth disease). Primary HHV-6 infection occurs most commonly in children under 2 years of age and is a major cause of infantile febrile seizures. HHV-6 is also associated with encephalitis (symptoms may include insomnia, seizures, and hallucinations) and with acute liver failure. Primary infection in immunocompetent adults is rare and can produce a mononucleosis-like illness. Reactivation of HHV-6 in immunocompetent adults is rare and can present as encephalitis. Imaging studies in HHV-6 encephalitis typically show lesions in the hippocampus, amygdala, and limbic structures.

Infection during pregnancy and congenital transmission is recognized. Most cases of reactivation, however, occur in immunocompromised persons. Reactivation is associated with graft rejection, graft-versus-host disease, and bone marrow suppression in transplant patients and with encephalitis and pneumonitis in AIDS patients and in recipients of hematopoietic cell transplants. HHV-6 is on occasion also associated with drug-induced hypersensitivity syndromes that may evolve into diabetes mellitus. The roles of HHV-6 in multiple sclerosis, chronic fatigue syndrome, certain malignancies, myocarditis and progressive multifocal leukoencephalopathy remain unproven. HHV-6 may cause fulminant hepatic failure and acute decompensation of chronic liver disease in children. Purpura fulminans is reported rarely with HHV-6 infection. Recent studies suggest that HHV-6 can cause corneal inflammation.

Two variants (A and B) of HHV-6 have been identified. HHV-6B is the predominant strain found in both normal and immunocompromised persons. Ganciclovir, cidofovir, and foscarnet (but not acyclovir) appear to be clinically active against HHV-6.

HHV-7 is a T cell lymphotropic virus that is associated with roseola (serologically), seizures and, rarely, encephalitis. Pregnant women are often infected. Infection with

HHV-7 is synergistic with CMV in kidney transplant recipients. The membrane glycoprotein CD4 is involved in HHV-7 recognition, but a clinical interaction between HHV-7 and HIV is not established.

HHV-8 is associated with Kaposi sarcoma, multicentric Castleman disease, and primary effusion (body cavity) lymphoma. HHV-8 infection is endemic in Africa; transmission seems to be primarily horizontal in childhood from intrafamilial contacts and continues through adulthood possibly by nonsexual routes. An association between HHV-8 and the development of systemic lupus erythematosus is under study. See Chapter 31 for pathogenesis and management.

Butler LM et al. Human herpesvirus 8 infection in children and adults in a population-based study in rural Uganda. *J Infect Dis.* 2011 Mar 1;203(5):625–34. [PMID: 21273188]

Ogata M. Human herpesvirus 6 in hematological malignancies. *J Clin Exp Hematop.* 2009 Nov;49(2):57–67. [PMID: 19907110]

Okuno T et al. Role of human herpes virus 6 in corneal inflammation alone or with human herpesviruses. *Cornea.* 2011 Feb;30(2):204–7. [PMID: 20847652]

Sun Y et al. Prevalence of human herpesvirus 8 infection in systemic lupus erythematosus. *Virol J.* 2011 May 9;8:210. [PMID: 21549013]

MAJOR VACCINE-PREVENTABLE VIRAL INFECTIONS¹

1. Measles



ESSENTIALS OF DIAGNOSIS

- ▶ Exposure 10–14 days before onset in an unvaccinated patient.
- ▶ Prodrome of fever, coryza, cough, conjunctivitis, malaise, irritability, photophobia, Koplik spots.
- ▶ Rash: brick-red, irregular, maculopapular; onset 3–4 days after onset of prodrome; begins on the face and proceeds “downward and outward,” affecting the palms and soles last.
- ▶ Leukopenia.

▶ General Considerations

Measles is a reportable acute systemic paramyxoviral infection transmitted by inhalation of infective droplets. It is a major worldwide cause of pediatric morbidity and mortality, although vaccination programs successfully reduced this number from nearly 750,000 deaths in 2000 to an estimated 164,000 in 2008. The case numbers increased in 2011 with over 28,000 cases reported in Europe (high risk groups include the Roma, travelers, immigrants, and Orthodox Jews) with the largest number from France. The

214 US measles cases as of October 2011 included 73 (34%) importations (France and India were the leading source countries).

Illness confers permanent immunity. It is highly contagious and communicability is greatest during the preeruptive and catarrhal stages but continues as long as the rash remains. Despite high community vaccination coverage, rising rates of intentional undervaccination lead to sporadic outbreaks among clusters of intentionally undervaccinated children and can undermine measles elimination programs. Therefore, laboratory testing and confirmation of suspected measles infection is especially important in countries that report the elimination of measles. Sporadic outbreaks of the disease in adults, adolescents, and unvaccinated preschool children in dense urban areas, and sporting event participants emphasize the need for specific recommendations concerning prevention (see below).

In the United States, measles was declared eliminated in 2000. The few reported cases since then are largely imported and geographically dispersed, and the associated isolates fail to show a recurrent strain. Immigrants and refugees can show serosusceptibility rates to measles in excess of 35%.

▶ Clinical Findings

A. Symptoms and Signs

Fever is often as high as 40–40.6 °C. It persists through the prodrome and early rash (about 5–7 days) (Table 32–2). Malaise may be marked. Coryza (nasal obstruction, sneezing, and sore throat) resembles that seen with upper respiratory infections. Cough is persistent and nonproductive. Conjunctivitis manifests as redness, swelling, photophobia, and discharge. These symptoms intensify over 2–4 days before onset of the rash and peak on the first day of the rash.

Koplik spots (small, irregular, and red with whitish center on the mucous membranes) are pathognomonic of measles. They appear about 2 days before the rash and last 1–4 days as tiny “table salt crystals” in the buccal mucosa opposite the molars and vaginal membranes. The rash usually appears on the face and behind the ears 4 days after the onset of symptoms. The initial lesions are pinhead-sized papules that coalesce to form a brick-red, irregular, blotchy maculopapular rash. In severe cases, the rash coalesces to form a nearly uniform erythema in some areas. The rash next appears on the trunk, followed by the extremities, including the palms (25–50% of those infected) and soles. The rash lasts for 3–7 days and fades in the same manner it appeared. Hyperpigmentation remains in fair-skinned individuals and severe cases. Slight desquamation may follow.

Other findings in measles include pharyngeal erythema, tonsillar yellowish exudate, coating of the tongue in the center with a red tip and margins, moderate generalized lymphadenopathy and, at times, splenomegaly.

Atypical measles is a syndrome occurring in adults who received inactivated measles vaccine (1963–1968) or who received live measles vaccine before age 12 months and as a result developed hypersensitivity rather than protective immunity. Infection later in life with wild measles

¹A general guide for vaccine preventable diseases is available at www.who.int/vaccines-documents/

virus can lead to a potentially fatal illness with high fever; unusual rashes (papular, hemorrhagic), most prominent on the extremities, without Koplik spots; headache; arthralgias; hepatitis; a high rate of pneumonitis, and sometimes pleural effusions. Atypical measles cases show unusually high hemagglutinin-inhibition titers. Measles may be distinctive in HIV-infected individuals, with higher rates of pneumonitis, higher mortality, prolonged viral shedding, and higher vaccine failure rates. Measles during pregnancy is not known to cause congenital abnormalities of the fetus. It is, however, associated with spontaneous abortion and premature delivery and can cause severe disease in the mother. Although measles does not always develop in the offspring of mothers with the disease, it can be severe when it does. It is recommended that infants born to such mothers be passively immunized with immunoglobulin at birth.

The virologic clearance of measles can take months.

B. Laboratory Findings

Leukopenia is usually present unless secondary bacterial complications exist. A lymphocyte count under 2000/mcL is a poor prognostic sign. Thrombocytopenia is common. Proteinuria is often observed. Although technically difficult, virus can be cultured from nasopharyngeal washings and from blood. Detection of IgM measles antibodies with ELISA or a fourfold rise in serum hemagglutination inhibition antibody supports the diagnosis. Fluorescent antibody staining of respiratory or urinary epithelial cells can also confirm the diagnosis.

IgM assays can be falsely negative the first few days of infection and falsely positive in the presence of rheumatoid factor or with acute rubella, erythrovirus (parvovirus) B19, or HHV-6 infection. White reverse transcriptase-PCR techniques, typically available in research settings, can help establish a diagnosis; the persistence of the virus for months after an acute infection can lead to false positive results.

► Differential Diagnosis

Measles is usually diagnosed clinically but may be mistaken for other exanthematous infections (see Table 32-2). Frequent difficulty in establishing a diagnosis suggests that measles may be more prevalent than is recognized.

► Complications

A. Central Nervous System

Postinfectious encephalomyelitis occurs in about 0.05–0.1% of cases. Higher rates of encephalitis occur in adolescents and adults than in school-aged children. Its onset is usually 3–7 days after the rash. Vomiting, convulsions, coma, and diverse, severe neurologic symptoms and signs may develop. Treatment is symptomatic and supportive. Virus is usually not found in the CNS, though demyelination is prominent. There is an appreciable mortality (10–20%) and morbidity (33% of survivors are left with neurologic deficit).

A similar form, “inclusion body encephalitis,” occurs months after exposure. This complication is reported to

occur after measles vaccination in patients with inadequate cellular immunity but is associated with isolation of the measles virus.

Subacute sclerosing panencephalitis (SSPE) is a very late CNS complication (5–15 years after infection; the measles virus acts as a “slow virus” to produce degenerative CNS disease years after the initial infection. SSPE is rare (1:100,000 cases of measles) and occurs more often when measles develops early in life among males who live in rural environments. SSPE very rarely develops in adults.

Measles virus can opportunistically invade the CNS. An acute progressive encephalitis (subacute measles encephalitis), characterized by seizures, neurologic deficits, and often progressive stupor and death, can occur among immunosuppressed patients. Treatment is supportive, withholding immunosuppressive chemotherapy when feasible. Interferon and ribavirin are variably successful.

B. Respiratory Tract Disease

Early in the course of the disease, bronchopneumonia or bronchiolitis due to the measles virus may occur in up to 5% of patients and result in serious respiratory difficulties. Bronchiectasis may occur in up to a quarter of nonvaccinated children. Pneumonia occurring with or without an evanescent rash is seen in atypical measles.

C. Secondary Bacterial Infections

Immediately following measles, secondary bacterial infection, particularly cervical adenitis, otitis media (the most common complication), and pneumonia, occurs in about 15% of patients.

D. Immune Reactivity

Measles produces temporary anergy to cell-mediated skin tests.

E. Gastroenteritis

Diarrhea and protein-losing enteropathy (prodromal rectal Koplik spots may be seen) are significant complications among malnourished children.

F. Other Complications

Other complications include conjunctivitis, keratitis, and otosclerosis.

► Treatment

A. General Measures

The patient should be isolated for the week following onset of rash and kept at bed rest until afebrile. Treatment is symptomatic including antipyretics and fluids as needed. Vitamin A, 200,000 units/d orally for 2 days (the benefit being maintenance of gastrointestinal and respiratory epithelial mucosa), reduces pediatric morbidity (diarrhea, night blindness, xerophthalmia) and measles-associated mortality for infants between 6 months and 5 years of age,

although high-dose vitamin A exposure increases the severity and risk of antibiotic failure in non-measles pneumonia. Measles virus is susceptible to ribavirin *in vitro* and has been used in selected severe cases of pneumonitis (35 mg/kg/d intravenously in three divided doses for 2 days, followed by 20 mg/kg/d intravenously in three divided doses for 5 days).

B. Treatment of Complications

Secondary bacterial infections, including pneumonia, are treated with appropriate antibacterial antibiotics. Post-measles encephalitis, including SSPE, can be managed only symptomatically.

Repeated studies fail to show an association between vaccination and autism. The prevalence of asthma-like diseases in childhood appears to be reduced among vaccinated children. Some data implicate the measles virus in the pathogenesis of rheumatoid arthritis.

► Prognosis

Between 1999 and 2005, measles mortality rate was reduced an estimated 60%. In the last decade, the case-fatality rate in the United States stayed around 3 per 1000 reported cases, with deaths principally due to encephalitis (15% mortality rate) and secondary bacterial pneumonia. Deaths in the developing world are mainly related to diarrhea and protein-losing enteropathy.

► Prevention

In the United States, children receive their first vaccine dose at 12–15 months and a second at age 4–6 years prior to entry into school. Combination measles-mumps-rubella-varicella vaccines (MMRV) can be used in place of the traditional measles, mumps, and rubella (MMR) vaccine. Recent outbreak data suggest that the efficacy of the vaccine persists longer if the first vaccination is given at a later age (eg, 15 months). The evidence is not convincing that routine anthelmintic treatment affects the immune response to childhood vaccination.

American students beyond high school and medical staff starting employment require documentation of the above vaccination schedule or must show serologic evidence of immunity if they were born after 1956. For individuals born before 1957, herd immunity is assumed. Health care workers, immigrants, and refugees should be screened and vaccinated if necessary regardless of date of birth. International travelers (if immunocompetent and born after 1956) to the developing world and teachers should receive booster doses of vaccination.

At 6 months of age, more than 99% of infants of vaccinated women and 95% of infants of naturally immune women lose maternal antibodies. Therefore, in outbreaks that include infants under 1 year of age, initial vaccination may be given at 6 months, with repeat at 15 months. When outbreaks take place in day care centers, K–12 institutions, or colleges and universities, revaccination is probably indicated for all, in particular for students and their siblings

born after 1956 who do not have documentation of immunity as defined above. Susceptible personnel who were exposed should be isolated from patient contact between the fifth and the twenty-first day after exposure regardless of whether they were vaccinated or given immune globulin. If measles develops in these persons, they should be isolated from patient contact until 7 days after the rash develops.

When susceptible individuals are exposed to measles, live virus vaccine can prevent disease if given within 5 days of exposure. In addition, immune globulin (0.25 mL/kg [0.11 mL/lb] body weight) can be injected intramuscularly for prevention or modification of clinical illness if given within 6 days after exposure. This must be followed by active immunization with live measles vaccine 3 months later. Vaccination of all immunocompetent persons born after 1956 who travel to the developing world is important. In the developing world, the use of a second vaccine dose is an important aspect of achieving control of measles in the community.

Pregnant women and immunosuppressed persons should *not* receive this vaccine. Exception to this contraindication is asymptomatic HIV-infected patients, including children, who have not shown adverse effects from measles vaccination. In asymptomatic HIV-infected children, vaccination improves survival after measles, and HAART therapy is associated with an improved vaccine response. Repeat vaccination may be necessary in HIV-infected children after immune restoration. Immune globulin should be administered within 6 days of exposure for postexposure prophylaxis in any high-risk person exposed to measles. Such high-risk persons include children with malignancy and patients with AIDS who are at risk for developing severe or fatal disease.

Severe allergic reactions including anaphylaxis to the MMR vaccine are rare, though fever and rash appear to occur slightly more often among female recipients. Quadrivalent MMRV vaccine is associated with an increased risk of seizures that appears to be age-related; the risk is highest when MMRV is given to infants under 15 months of age. An aerosolized measles vaccine remains under study. Future vaccines for a variety of infectious agents may utilize measles vectors, thereby augmenting immunity to measles. Rare cases of post-immunization encephalitis represent a form of acute disseminated encephalomyelitis (which can occur after many other vaccines including rabies, DPT, smallpox, and hepatitis B virus vaccinations).

► When to Refer

- Any suspect cases should be reported to public health authorities.
- HIV infection.
- Pregnancy.

► When to Admit

- Meningitis, encephalitis, or myelitis.
- Severe pneumonia.
- Diarrhea that significantly compromises fluid or electrolyte status.

- Leuridan E et al. Early waning of maternal measles antibodies in era of measles elimination: longitudinal study. *BMJ*. 2010 May 18;340:c1626. [PMID: 20483946]
- Mayo-Wilson E et al. Vitamin A supplements for preventing mortality, illness, and blindness in children aged under 5: systematic review and meta-analysis. *BMJ*. 2011 Aug 25;343:d5094. [PMID: 21868478]
- Moss WJ et al. Biological feasibility of measles eradication. *J Infect Dis*. 2011;204(1):S47–53. [PMID: 21666201]
- Omer SB et al. Vaccine refusal, mandatory immunization, and the risks of vaccine-preventable diseases. *N Engl J Med*. 2009 May 7;360(19):1981–8. [PMID: 19420367]
- Sever AE et al. Measles elimination in the Americas: a comparison between countries with a one-dose and two-dose routine vaccination schedule. *J Infect Dis*. 2011 Sep;204(Suppl 2):S748–55. [PMID: 21954277]
- Webb EL et al. Effect of single-dose anthelmintic treatment during pregnancy on an infant's response to immunization and on susceptibility to infectious diseases in infancy: a randomised, double-blind, placebo-controlled trial. *Lancet*. 2011 Jan 1;377(9759):52–62. [PMID: 21176950]

2. Mumps



ESSENTIALS OF DIAGNOSIS

- ▶ Exposure 14–21 days before onset.
- ▶ Painful, swollen salivary glands, usually parotid.
- ▶ Frequent involvement of testes, pancreas, and meninges in unvaccinated individuals.

▶ General Considerations

Mumps is a paramyxoviral disease spread by respiratory droplets. Children are the age group most affected, although in some outbreaks, patients are in the late second or early third decades of life. Mumps can spread rapidly in congregate settings, such as colleges and schools. The incidence is highest in spring. The incubation period is 14–21 days (average, 18 days). Infectivity occurs via saliva and urine and precedes the symptoms by about 1 day and is maximal for 3 days, although it may last a week. Up to one-third of affected individuals have subclinical infection. In 2006, an outbreak of mumps in the United States occurred and involved over 6000 persons; 85% of these cases were reported from eight Midwestern states. More recent mumps outbreak involved 1521 cases at a summer camp in New York (2009) and 134 cases among mostly undervaccinated boys in Ontario (2010). In recent seroprevalence studies of mumps antibody, the highest rates were seen in US-born Americans of African and Hispanic (Mexican-born) ancestry, reflecting perhaps immunity associated with natural infection.

▶ Clinical Findings

A. Symptoms and Signs

Mumps is more serious in adults than in children. Parotid tenderness and overlying facial edema (Figure 32–5) are



▲ **Figure 32–5.** Mumps. (Public Health Image Library, CDC.)

the most common physical findings and typically develop within 48 hours of the prodromal symptoms. Usually, one parotid gland enlarges before the other, but unilateral parotitis alone occurs in 25% of patients. The orifice of Stensen duct may be red and swollen. Trismus may result from parotitis. The parotid glands return to normal within a week. Involvement of other salivary glands (submaxillary and sublingual) occurs in 10% of cases.

Fever and malaise are variable but often minimal in young children. High fever accompanies meningitis or orchitis. Neck stiffness, headache, and lethargy suggest meningitis. Testicular swelling and tenderness (unilateral in 75% of cases) denote orchitis; the testes are the most common extrasalivary site of disease in adults. Orchitis develops 7–10 days after the onset of parotitis in about 25–40% of postpubertal men, but sterility is rare. Acute hormonal disturbances are prevalent, including decreased levels of testosterone and inhibin B with low or normal levels of gonadotropins in up to 35% cases with mumps orchitis. Upper abdominal pain, nausea, and vomiting suggest pancreatitis. Mumps is the leading cause of pancreatitis in children. Lower abdominal pain and ovarian enlargement suggest oophoritis (which occurs in 5% of postpubertal women, usually unilateral); it is a difficult diagnosis to establish.

B. Laboratory Findings

Mild leukopenia with relative lymphocytosis may be present. Serum amylasemia usually reflects salivary gland involvement rather than pancreatitis. Lymphocytic pleocytosis and hypoglycorrhachia of the cerebrospinal fluid in meningitis may be asymptomatic. Mild kidney function abnormalities are found in up to 60% of patients.

Characteristic clinical picture is usually sufficient for diagnosis. An elevated serum IgM is considered diagnostic

and a repeat test 2–3 weeks after the onset of symptoms is recommended if the first assay is negative due to a delay in IgM rise, especially in vaccinated persons. A fourfold rise in complement-fixing antibodies to mumps virus in paired serum IgG also confirms infection. Confirmatory diagnosis of mumps is also made by isolating the virus preferably from a swab of the duct of the parotid or other affected salivary gland. The virus can also be isolated from cerebrospinal fluid early in the course of aseptic meningitis. Isolation from urine is no longer advised. Nucleic acid amplification techniques are more sensitive than viral cultures but their availability is limited.

► Differential Diagnosis

Swelling of the parotid gland may be due to calculi in the parotid ducts, tumors, or cysts, or to a reaction to iodides. Other causes include starch ingestion, sarcoidosis, cirrhosis, diabetes, bulimia, pilocarpine usage, and Sjögren syndrome. Parotitis may be produced by pyogenic organisms (eg, *S aureus*, gram-negative organisms), particularly in debilitated individuals with poor oral intake, drug reaction (phenothiazines, propylthiouracil), and other viruses (influenza A, parainfluenza, EBV infection, coxsackieviruses, adenoviruses, HHV-6). Swelling of the parotid gland must be differentiated from inflammation of the lymph nodes located more posteriorly and inferiorly than the parotid gland.

► Complications

Other manifestations of the disease are less common and usually follow parotitis but may precede it or occur without salivary gland involvement. Such manifestations include meningitis (30%), orchitis (which on rare occasion leads to priapism or testicular infarction), pancreatitis (usually mild), oophoritis, thyroiditis, neuritis, hepatitis, myocarditis, thrombocytopenia, migratory arthralgias (noted infrequently among adults and rarely in children), and nephritis. Mumps has also been associated with cases of endocardial fibroelastosis.

Rare neurologic complications include encephalitis, Guillain-Barré syndrome, cerebellar ataxia, facial palsy, and transverse myelitis. Encephalitis is associated with cerebral edema, serious neurologic manifestations, and sometimes death. Deafness from eighth nerve neuritis develops in about 0.1%; it is typically unilateral, severe, and permanent.

► Treatment

A. General Measures

The patient should be isolated until swelling subsides (about 9 days from onset) and kept on bed rest while febrile. Treatment is symptomatic. Topical compresses may relieve parotid discomfort. Some clinicians advocate intravenous immunoglobulin (IVIG) for complicated disease (eg, thrombocytopenia) although its definitive role is unproven.

B. Management of Complications

1. Aseptic meningitis—The treatment is symptomatic. The management of encephalitis requires attention to cerebral edema, the airway, and vital functions.

2. Epididymo-orchitis—The scrotum should be supported with a suspensor or toweling “bridge” and ice bags applied. Incision of the tunica may be necessary in severe cases. Pain can be relieved with opioids, or by injecting the spermatic cord at the external inguinal ring with 10–20 mL of 1% procaine solution. The merit of hydrocortisone sodium succinate (100 mg intravenously, followed by 20 mg orally every 6 hours for 2 or 3 days) in reducing inflammation is not firmly established. Interferon alfa-2b may be useful in preventing testicular atrophy.

3. Pancreatitis—Symptomatic treatment should be provided, with emphasis on parenteral hydration.

► Prognosis

The entire course of mumps rarely exceeds 2 weeks. Rare fatalities are usually due to encephalitis.

► Prevention

Mumps live virus vaccine is safe and effective (there is some variability among vaccines, the Jeryl Lynn strain being highly effective, the Urabe intermediate, the Rubini less so) with long lasting immunity. It is recommended for routine immunization for children over age 1 year, either alone or in combination with other virus vaccines (eg, in the MMR vaccine or as a quadrivalent vaccine with varicella). A second dose is recommended for children (ages 4–6 years) before starting school. (In recent outbreaks from Canada and Scotland, cases disproportionately included those who received only one dose of the vaccine.) Two doses of the vaccine should also be considered for high-risk individuals (eg, health care workers) born before 1957 and without evidence of immunity. There are no known cases of long-term sequelae associated with mumps vaccination and the currently used mumps strain (Jeryl Lynn) shows the lowest associated incidence of post vaccine aseptic meningitis (from 1 in 150,000 to 1 in 1.8 million). This vaccine is less effective in epidemic settings. Reactions are reviewed in the measles section. It should not be given to pregnant women or to immunocompromised individuals, though the vaccine has been given to asymptomatic HIV-infected individuals without adverse sequelae, especially when the individuals are taking HAART. In the developed world, persons in whom mumps develops are less likely to have received a second vaccine dose. The mumps skin tests are less reliable than serum neutralization titers in determining immunity.

► When to Refer

Any suspect cases should be reported to public health authorities.

► When to Admit

- Trismus.
- Meningitis, encephalitis.
- Severe abdominal pain or vomiting suggesting pancreatitis.
- Severe testicular pain.
- Priapism.
- Severe thrombocytopenia.
- Myocarditis.

Centers for Disease Control and Prevention (CDC). Update: mumps outbreak—New York and New Jersey, June 2009–January 2010. *MMWR Morb Mortal Wkly Rep.* 2010 Feb 12; 59(5):125–9. [PMID: 20150887]

Deeks SL et al. An assessment of mumps vaccine effectiveness by dose during an outbreak in Canada. *CMAJ.* 2011 Jun 14;183(9):1014–20. [PMID: 21576295]

Kutty PK et al. Seroprevalence of antibody to mumps virus in the US population, 1999–2004. *J Infect Dis.* 2010 Sep 1; 202(5): 667–74. [PMID: 20662720]

Smith PJ et al. The association between intentional delay of vaccine administration and timely childhood vaccination coverage. *Public Health Rep.* 2010 Jul–Aug;125(4):534–41. [PMID: 20597453]

3. Poliomyelitis



ESSENTIALS OF DIAGNOSIS

- Incubation period 9–12 days from exposure.
- Muscle weakness, headache, stiff neck, fever, nausea and vomiting, sore throat.
- Lower motor neuron lesion (flaccid paralysis) with decreased deep tendon reflexes and muscle wasting.
- Cerebrospinal fluid shows lymphocytic pleocytosis but rarely > 500/mcL.

► General Considerations

Poliomyelitis virus, an enterovirus, is present in throat washings and stools (excretion may last for weeks after infection). It is highly contagious through fecal–oral route, especially during the first week of infection. By 2005, because of global vaccination efforts, indigenous transmission of wild poliovirus (WPV) types 1 and 3 were eliminated from all but four countries (Afghanistan, India, Nigeria, and Pakistan) and no cases of WPV type 2 were reported since 1999, although a case was reported in 2011 of a woman with combined variable immunodeficiency who acquired type 2 poliomyelitis in Minnesota nearly 12 years after her child was given the oral vaccination. As of October 2011, a total of 467 cases of WPV infection were reported (down from 350,000 in 1988) from 11 countries with 47% of cases in endemic countries of Afghanistan,

India, Nigeria, and Pakistan, with reactivation of the outbreak in the Democratic Republic of the Congo and Chad, and new outbreaks in the Central African Republic, China, Mali, Kenya, Guinea, Cote d'Ivoire, and Nigeria. India is down to a single case this year. The largest number of cases is being reported currently from Pakistan, Chad, and the Democratic Republic of the Congo. The last major outbreak in the Western Hemisphere occurred in Hispaniola (Haiti and the Dominican Republic) from 2000 to 2001. An ongoing outbreak of type 2 VDPV in Nigeria is reportedly the largest to date and is unique in occurring in the presence of extensive transmission of indigenous type 1 and 3 WPV.

► Clinical Findings

A. Symptoms and Signs

At least 95% of infections are asymptomatic, but in those who become ill, manifestations include abortive poliomyelitis (minor illness), nonparalytic poliomyelitis, and paralytic poliomyelitis.

1. Abortive poliomyelitis (minor illness)—Such minor illness occurs in 4–8% of infections and the symptoms are fever, headache, vomiting, diarrhea, constipation, and sore throat lasting 2–3 days. This entity is suspected clinically only during an epidemic.

2. Nonparalytic poliomyelitis—In addition to the above symptoms, signs of meningeal irritation and muscle spasm occur in the absence of frank paralysis. This disease is indistinguishable from aseptic meningitis caused by other viruses.

3. Paralytic poliomyelitis—Paralytic poliomyelitis represents 0.1% of all poliomyelitis cases (the incidence is higher when infections are acquired later in life). Paralysis may occur at any time during the febrile period. Tremors, muscle weakness, constipation, and ileus may appear. Paralytic poliomyelitis is divided into two forms, which may coexist: (1) **spinal poliomyelitis**, with involvement of the muscles innervated by the spinal nerves, and (2) **bulbar poliomyelitis**, with weakness of the muscles supplied by the cranial nerves (especially nerves IX and X) and of the respiratory and vasomotor centers.

In spinal poliomyelitis, paralysis of the shoulder girdle often precedes intercostal and diaphragmatic paralysis, which leads to diminished chest expansion and decreased vital capacity. The paralysis occurs over 2–3 days, is flaccid, has an asymmetric distribution, and affects the proximal muscles of the lower extremities more frequently. Sensory loss is very rare.

In bulbar poliomyelitis, symptoms include diplopia (uncommonly), facial weakness, dysphagia, dysphonia, nasal voice, weakness of the sternocleidomastoid and trapezius muscles, difficulty in chewing, inability to swallow or expel saliva, and regurgitation of fluids through the nose. The most life-threatening aspect of bulbar poliomyelitis is respiratory paralysis. Lethargy or coma may be due to hypoxia, most often from hypoventilation. Vasomotor disturbances in blood pressure and heart rate may occur.

Convulsions are rare. Bulbar poliomyelitis is more common in adults.

B. Laboratory Findings

The peripheral white blood cell count may be normal or mildly elevated. Cerebrospinal fluid pressure and protein are normal or slightly increased. Glucose is not decreased. White blood cells usually number $< 500/\text{mL}$ and are principally lymphocytes after the first 24 hours. Cerebrospinal fluid is normal in 5% of patients. The virus may be recovered from throat washings (early) and stools (early and late). Neutralizing and complement-fixing antibodies appear during the first or second week of illness. Serologic testing cannot distinguish between wild-type and vaccine-related virus infections.

► Differential Diagnosis

Nonparalytic poliomyelitis is similar to other forms of enteroviral meningitis; the distinction is made serologically. Acute flaccid paralysis is the term used in the developing world for the variety of neurologic illnesses that both include and mimic poliomyelitis. Acute flaccid paralysis due to poliomyelitis is distinguished by the greater frequency of fever and asymmetric neurologic signs. Acute inflammatory polyneuritis (Guillain-Barré syndrome), Japanese B virus encephalitis, West Nile virus infection, and tick paralysis may resemble poliomyelitis. In Guillain-Barré syndrome (see Chapter 24), the weakness is more symmetric and ascending in most cases, but the Miller Fisher variant is quite similar to bulbar polio. Paresthesias are uncommon in poliomyelitis but common in Guillain-Barré syndrome. The cerebrospinal fluid usually has high protein content but normal cell count in Guillain-Barré syndrome.

► Complications

Urinary tract infection, atelectasis, pneumonia, myocarditis, paralytic ileus, gastric dilation, and pulmonary edema may occur. Respiratory failure may be a result of paralysis of respiratory muscles, airway obstruction from involvement of cranial nerve nuclei, or lesions of the respiratory center.

► Treatment

In the acute phase of paralytic poliomyelitis patients should be hospitalized. Strict bed rest in the first few days of illness reduces the rate of paralysis. Comfortable but rotating positions should be maintained in a "polio bed": firm mattress, footboard, sponge rubber pads or rolls, sandbags, and light splints. Intensive physiotherapy may help recover some motor function with paralysis. Fecal impaction and urinary retention (especially with paraplegia) are managed appropriately. In cases of respiratory weakness or paralysis, intensive care is needed. Attention to psychological disorders in long-standing disease is also important. The antiviral pleconaril shows no clear benefit in cases of polio meningoencephalitis.

► Prognosis

During the febrile period, paralysis may develop or progress. Mild weakness of small muscles is more likely to regress than severe weakness of large muscles. Bulbar poliomyelitis carries a mortality rate of up to 50%. Long-term sequelae include pain, weakness, fatigue, and obesity, factors often worsened by age and comorbidities. When new muscle weakness and pain develop and progress slowly years after recovery from acute paralytic poliomyelitis, the entity is called **postpoliomyelitis syndrome**. This syndrome presents with signs of chronic and new denervation, is associated with increasing dysfunction of surviving motor neurons, and is not infectious in origin; patients do not shed the virus. Immune modulators, such as prednisone, interferon, and IVIG, do not show any clear benefits in the treatment of post poliomyelitis syndrome.

► Prevention

Given the epidemiologic distribution of poliomyelitis and the continued concern about vaccine-associated disease (estimated in 1:750,000 recipients) with the trivalent oral live poliovirus vaccine (OPV), the inactive (Salk) parenteral vaccination is currently used in the United States for all four recommended doses (at ages 2 months, 4 months, 6–18 months, and at 4–6 years). Inactivated vaccine is also routinely used elsewhere in the developed world. Oral vaccines are limited to usage for outbreak control, travel to endemic areas within the ensuing month, and protection of children whose parents do not comply with the recommended number of immunizations. The advantages of oral vaccination are the ease of administration, low cost, effective local gastrointestinal and circulating immunity, and herd immunity.

Routine immunization of adults in the United States is no longer recommended because of the low incidence of the disease. Exceptions include adults not vaccinated within the prior decade who are exposed to poliomyelitis or who plan to travel to endemic areas (mentioned above). Vaccination should also be considered for adults engaged in high-risk activities (eg, laboratory workers handling stools). Such adults should be given inactivated poliomyelitis vaccine (Salk) as should immunodeficient or immunosuppressed individuals and members of their households.

In the developing world, three doses of OPV seem sufficient for adequate immunization and the interval between doses should probably be > 1 month (because of interference from enteric pathogens). Intramuscular injections should be routinely avoided during the month following oral poliomyelitis vaccination to prevent provocation paralysis. Clinical studies suggest that rotavirus and OPV can be given concomitantly. Ancillary useful control measures ("supplementary immunization activities") in polio-endemic countries include national immunization days (mass campaigns in which all children are vaccinated twice, 4–6 weeks apart, regardless of vaccine history); cross-border vaccination activities; surveillance for acute flaccid paralysis, an indicator for poliomyelitis; and aggressive

outbreak responses as well as intensified immunization activities in countries impacted by armed conflicts.

VDPV cases with the oral Sabin vaccination are due to mutations leading to neurovirulence. Such cases serve as a reminder of the need to maintain high levels of immunization coverage even in the absence of overt disease. An immunogenic monovalent type 1 oral vaccine (several times more effective than the trivalent oral vaccine) is successfully used in India, Egypt, and Nigeria. Cost and administrative considerations along with a need for effective herd immunity remain major reasons the oral Sabin is still administered.

There is no epidemiologic evidence to implicate poliomyelitis vaccination as a cause for recurrent worsening wheezing or eczema in childhood.

► When to Refer

- Neurologic compromise.
- Any suspicious cases should be referred to public health authorities.

DeVries AS et al. Vaccine-derived poliomyelitis 12 years after infection in Minnesota. *N Engl J Med*. 2011 Jun 16;364(24):2316–23. [PMID: 21675890]

Gonzalez H et al. Management of postpolio syndrome. *Lancet Neurol*. 2010 Jun;9(6):634–42. [PMID: 20494327]

Heinsbroek E et al. The global introduction of inactivated polio vaccine can circumvent the oral polio vaccine paradox. *Vaccine*. 2010 May 14;28(22):3778–83. [PMID: 20362626]

Steele AD et al. Comparison of 2 different regimens for reactivity, safety, and immunogenicity of the live attenuated oral rotavirus vaccine RIX4414 coadministered with oral polio vaccine in South African infants. *J Infect Dis*. 2010 Sep 1;202(Suppl):S93–100. [PMID: 20684724]

4. Rubella



ESSENTIALS OF DIAGNOSIS

- Exposure 14–21 days before onset.
- Arthralgia, particularly in young women.
- No prodrome in children, mild prodrome in adults; mild symptoms (fever, malaise, coryza) coinciding with eruption.
- Posterior cervical and postauricular lymphadenopathy 5–10 days before rash.
- Fine maculopapular rash of 3 days duration; face to trunk to extremities.
- Leukopenia, thrombocytopenia.

► General Considerations

Rubella is a systemic disease caused by a togavirus transmitted by inhalation of infective droplets. It is only moderately communicable. One attack usually confers permanent immunity but reinfection is possible, albeit rarely. The incubation period is 14–21 days (average, 16 days). The

disease is transmissible from 1 week before the rash appears until 15 days afterward.

The clinical picture of rubella is difficult to distinguish from other viral illnesses such as infectious mononucleosis, measles, echovirus infections, and coxsackievirus infections; however, arthritis is more prominent in rubella. Surveillance of female military recruits suggests that serologic protection against rubella, measles, and mumps are inadequate. The rubella case load decreased from 670,894 cases in 2000 to 121,344 cases in 2009 with reports of disease from 167 nations. Rubella containing vaccine is available in 130 nations. In the United States, rubella is not endemic since 2001.

The principal importance of rubella lies in its devastating effects on the fetus in utero, producing teratogenic effects and a continuing congenital infection (congenital rubella syndrome). The control of rubella is so successful that the number of cases **worldwide** of reported congenital rubella syndrome in 2008 was only 165 with over one-third of these from the Eastern Mediterranean region. In the United States, congenital rubella syndrome is **eliminated** since 2004. Two reported cases of congenital rubella syndrome between 2005 and 2007 were imported from Nigeria and Cote d'Ivoire.

► Clinical Findings

A. Symptoms and Signs

While fetal rubella can be devastating, postnatally acquired rubella is usually innocuous with up to 50% cases asymptomatic. In the postnatally acquired infection, fever and malaise, usually mild, accompanied by tender suboccipital adenitis, may precede the eruption by 1 week. Mild coryza may be present. Polyarticular arthritis occurs in about 25% of adult cases and involves the fingers, wrists, and knees. Rarely does chronic arthritis develop. The polyarthritides usually subsides within 7 days but may persist for weeks. Early posterior cervical and postauricular lymphadenopathy is very common. Erythema of the palate and throat, sometimes patchy, may be noted.

A fine, pink maculopapular rash appears on the face, trunk, and extremities in rapid progression (2–3 days) and fades quickly, usually lasting 1 day in each area (Table 32–2). Rubella without rash may be at least as common as the exanthematous disease. Diagnosis, when suspected because of disease in the community, requires serologic confirmation.

B. Laboratory Findings

Leukopenia may be present early and may be followed by an increase in plasma cells. The definitive diagnosis of acute rubella infection is based on elevated IgM antibody, fourfold or greater rise in IgG antibody titers, or isolation of the virus. False-positive IgM antibodies, however, are associated with Epstein-Barr virus, cytomegalovirus, erythrovirus (parvovirus), and rheumatoid factor. Detection of antibodies against rubella in other body fluids, such as urine and saliva, are promising diagnostic aids. An interferon-gamma-ELISPOT can provide valuable additional information in seronegative individuals. PCR techniques are also available.

► Complications

A. Exposure During Pregnancy

When a pregnant woman is exposed to a possible case of rubella, an immediate hemagglutination-inhibiting rubella antibody level should be obtained to document immunity, since fetal infection during the first trimester leads to congenital rubella in at least 80% of fetuses.

Positive tests for IgG antibodies alone indicate past infection or vaccination. High-avidity anti-rubella IgG assays may distinguish past infection from vaccination. If no antibodies are found, clinical observation and serologic follow-up are essential. An isolated IgM-positive test needs to be interpreted with caution because it does not necessarily imply acute infection. Confirmation of rubella in the expectant mother raises the question of therapeutic abortion, an alternative to be considered in light of personal, religious, legal, and other factors.

The immune status of the mother needs to be evaluated because titers fall to seronegativity in about 10% by 12 years after vaccination.

B. Congenital Rubella

An infant acquiring the infection in utero may be normal at birth but probably—50% in a series of nearly 70 pregnant women with rubella in Mexico—will have a wide variety of manifestations, including early-onset cataracts and glaucoma, microphthalmia, hearing deficits, psychomotor retardation, congenital heart defects (patent ductus arteriosus, branch pulmonary artery stenosis), organomegaly, and maculopapular rash. In general, the younger the fetus when infected, the more severe the illness. Deafness is the primary complication in the second trimester. Viral excretion in the throat and urine persists for many months despite high antibody levels. A specific test for IgM rubella antibody is useful for diagnosis in the newborn. A confirmatory diagnosis is made by isolation of the virus or PCR detection of viral RNA in tissues. Treatment is directed toward the many anomalies.

C. Postinfectious Encephalopathy

In 1:6000 cases, postinfectious encephalopathy develops 1–6 days after the rash; the virus cannot always be isolated. The mortality rate is 20%, but residual deficits are rare among the recovered. The mechanism is unknown.

Other unusual complications of rubella include hemorrhagic manifestations due to thrombocytopenia and vascular damage, duodenal stenosis, and mild hepatitis.

► Treatment

Acetaminophen provides symptomatic relief for acute rubella. Encephalitis and non-life-threatening thrombocytopenia should be treated symptomatically.

► Prognosis

Rubella is a mild illness and rarely lasts more than 3–4 days. Congenital rubella, on the other hand, has a high mortality rate, and the associated congenital defects are largely permanent.

► Prevention

Live attenuated rubella virus vaccine should be given to all infants and a second dose should be given to children of school age. It is important that girls in particular are immune to rubella prior to the menarche. When women are immunized, they should not be pregnant, and the absence of antibodies should be established. (In the United States, about 80% of 20-year-old women are immune to rubella.) Postpartum administration to susceptible female hospital employees is recommended. It is recommended that women not become pregnant for at least 3 months after vaccine administration. Nonetheless, there are no reports of congenital rubella syndrome after rubella immunization, and inadvertent immunization of a pregnant woman is not considered an indication for therapeutic abortion. Arthritis is more marked after rubella vaccination than in native disease and appears to be immunologically mediated. A flare of juvenile rheumatoid arthritis after rubella vaccination is reported. The association between chronic arthropathies and rubella vaccination is controversial. Anaphylactoid reactions following vaccination are rare, and a self-limited thrombotic thrombocytopenic purpura is a reported but very rare (2.6 per 100,000 doses) complication. The immune response to rubella vaccination is mediated by several polymorphisms in vitamin A receptor and innate immunity genes.

MMR may be given in conjunction with DPT or varicella boosters as adequate serologic responses are documented. The administration of two or more doses appears to overcome an immunogenetic risk for vaccine failure in some vaccinees. Immunogenicity is similar with intramuscular and intracutaneous infection, for MMR and varicella vaccinations. Children with biliary atresia in particular show impaired responses to MMR and varicella vaccinations. Preliminary data suggests that the vaccination of transplant (solid organ, bone marrow, and stem cell) patients on immunosuppressive therapy may be safe.

► When to Refer

- Pregnancy.
- Meningitis/encephalitis.
- Significant vaccination reactions.
- Any suspect cases should be reported to public health authorities.

Abernathy ES et al. Status of global virologic surveillance for rubella viruses. *J Infect Dis.* 2011 Jul;204(Suppl 1):S524–32. [PMID: 21666209]

Klein NP et al; Vaccine Safety Datalink. Measles-mumps-rubella-varicella combination vaccine and the risk of febrile seizures. *Pediatrics.* 2010 Jul;126(1):e1–8. [PMID: 20587679]

Ovsyannikova IG et al. Polymorphisms in the vitamin A receptor and innate immunity genes influence the antibody response to rubella vaccination. *J Infect Dis.* 2010 Jan 15;201(2):207–13. [PMID: 20001730]

Strebel PM et al. Global use of rubella vaccines, 1980–2009. *J Infect Dis.* 2011 Sep 1;204(Suppl 2):S579–84. [PMID: 21954250]

OTHER NEUROTROPIC VIRUSES

1. Rabies

ESSENTIALS OF DIAGNOSIS

- ▶ History of animal bite.
- ▶ Paresthesia, hydrophobia, rage alternating with calm.
- ▶ Convulsions, paralysis, thick tenacious saliva.

▶ General Considerations

Rabies is a viral (rhabdovirus) encephalitis transmitted by infected saliva that gains entry into the body by an animal bite or an open wound. Worldwide, 17.4 million cases of animal bites are reported every year, and more than 50,000 deaths are attributed to rabies. Most of these cases occur in rural areas of Africa and Asia, with India accounting for 36% of the global deaths. In developing countries, more than 90% of human cases are secondary to bites from infected dogs. Rabies among travelers to rabies-endemic areas is usually associated with animal injuries (including dogs in North Africa and India, cats in the Middle East, and non-human primates in sub-Saharan Africa and Asia), with most travel-associated cases occurring within 10 days of arrival. In the United States, domestically acquired rabies cases are rare (approximately 92% of cases are associated with wildlife) but probably underreported. In 2010, 6154 cases of animal rabies and 2 cases of bat-associated human rabies were reported in the United States. Wildlife reservoirs, each species having its own rabies variant(s), follow a unique geographic distribution in the United States: raccoons in the East Coast; skunks in the Midwest, Southwest, and California; and foxes in the Southwest and in Alaska. Hawaii is the only rabies-free state to date. Bats were the third most reported rabid animal after raccoons and skunks during 2010. Coyotes are also common reservoirs. Rodents and lagomorphs (eg, rabbits) are unlikely to spread rabies because they cannot survive the disease long enough to transmit it (woodchucks and groundhogs are exceptions). Wildlife epizootics present a constant public health threat in addition to the danger of reintroducing rabies to domestic animals. Vaccination is the key to rabies in small animals and rabies transmission to human beings.

The virus gains entry into the salivary glands of dogs 5–7 days before their death from rabies, thus limiting their period of infectivity. Less common routes of transmission include contamination of mucous membranes with saliva or brain tissue, aerosol transmission, and corneal transplantation. Transmission through solid organ and vascular segment transplantation from donors with unrecognized infection is also reported.

The incubation period may range from 10 days to many years but is usually 3–7 weeks depending in part on the distance of the wound from the CNS. The virus travels in the nerves to the brain, multiplies there, and then migrates along the efferent nerves to the salivary glands. Rabies virus infection forms cytoplasmic inclusion bodies similar to

Negri bodies. These Negri body-like structures are thought to be the sites of viral transcription and replication.

▶ Clinical Findings

A. Symptoms and Signs

While there is usually a history of animal bite, bat bites may not be recognized. The prodromal syndrome consists of pain at the site of the bite in association with fever, malaise, headache, nausea, and vomiting. The skin is sensitive to changes of temperature, especially air currents (aerophobia). Percussion myoedema can be present and persist throughout the disease. The CNS stage begins about 10 days after the prodrome and may be either encephalitic (“furious”) or paralytic (“dumb”). The encephalitic form (about 80% of the cases) produces the classic rabies manifestations of delirium alternating with periods of calm, extremely painful laryngeal spasms on attempting drinking (hydrophobia), autonomic stimulation (hypersalivation), and seizures. In the less common paralytic form, an acute ascending paralysis resembling Guillain-Barré syndrome predominates with relative sparing of higher cortical functions initially. Both forms progress relentlessly to coma, autonomic nervous system dysfunction, and death.

B. Laboratory Findings

Biting animals that appear well should be quarantined and observed for 10 days. Sick or dead animals should be tested for rabies. A wild animal, if captured, should be sacrificed and the head shipped on ice to the nearest laboratory qualified to examine the brain for evidence of rabies virus. When the animal cannot be examined, raccoons, skunks, bats, and foxes should be presumed to be rabid.

Direct fluorescent antibody testing of skin biopsy material from the posterior neck (where hair follicles are highly innervated) has a sensitivity of 60–80%.

Quantitative reverse transcriptase-PCR, nucleic acid sequence-based amplification, direct rapid immunohistochemical test and viral isolation from the cerebrospinal fluid or saliva are advocated as definitive diagnostic assays. Antibodies can be detected in the serum and the cerebrospinal fluid. Pathologic specimens often demonstrate round or oval eosinophilic inclusion bodies (Negri bodies) in the cytoplasm of neuronal cells, but the finding is neither sensitive nor specific. MRI signs are diffuse and nonspecific.

▶ Treatment & Prognosis

Management requires intensive care with attention to the airway, maintenance of oxygenation, and control of seizures. Universal precautions are essential. The induction of coma by ketamine, midazolam, and supplemental barbiturates along with the use of amantadine and ribavirin (the Milwaukee protocol) was reportedly helpful in one case but has failed to reproduce success in subsequent cases. Corticosteroids are of no use.

If postexposure prophylaxis (discussed below) is given expeditiously, before clinical signs develop, it is nearly

100% successful in prevention of disease. Once the symptoms have appeared, death almost inevitably occurs after 7 days, usually from respiratory failure. Most deaths occur in persons with unrecognized disease who do not seek medical care or in individuals who do not receive postexposure prophylaxis. Up to date, there are only seven cases of rabies that survived to hospital discharge after clinical symptoms started, only one of them did not receive the postexposure prophylaxis (index Milwaukee protocol case) and survived with naturally acquired immunity. Since 2004, the Milwaukee protocol has been applied to 26 additional patients with only one surviving to hospital discharge. The very rare cases in which patients recover without intensive care are referred to as “abortive rabies.”

► Prevention

Immunization of household dogs and cats and active immunization of persons with significant animal exposure (eg, veterinarians) are important. The most important decisions, however, concern animal bites. Animals that are frequent sources of infection to travelers are dogs, cats, and non-human primates.

In the developing world, education, surveillance, and animal (particularly dog) vaccination programs are preferred over mass destruction of dogs, which is followed typically by invasion of susceptible feral animals into urban areas. In some Western European countries, campaigns of oral vaccination of wild animals led to the elimination of rabies in wildlife.

A. Local Treatment of Animal Bites and Scratches

Thorough cleansing, debridement, and repeated flushing of wounds with soap and water are important. Rabies immune globulin or antiserum should be given as stated below. Wounds caused by animal bites should not be sutured.

B. Postexposure Immunization

The decision to treat should be based on the circumstances of the bite, including the extent and location of the wound, the biting animal, the history of prior vaccination, and the local epidemiology of rabies. Any contact or suspect contact with a bat is usually deemed a sufficient indication to warrant prophylaxis. Consultation with state and local health departments is recommended. Postexposure treatment including both immune globulin and vaccination should be administered as promptly as possible when indicated.

The optimal form of passive immunization is human rabies immune globulin (HRIG; 20 international units/kg), administered once. As much as possible of the full dose should be infiltrated around the wound, with any remaining injected intramuscularly at a site distant from the wound. Finger spaces can be safely injected without development of a compartment syndrome. If HRIG is not available, equine rabies antiserum (40 international units/kg) can be used if available after appropriate tests for horse serum

sensitivity. All of the rabies immunoglobulin should be injected at the wound site as much as possible and the remainder injected intramuscularly at a distant site from the vaccine administration.

Two vaccines are licensed and available for use in humans in the United States: a human diploid cell vaccine and a purified chick embryo cell vaccine. The current vaccines may be given as four injections of 1 mL intramuscularly in the deltoid or, in small children, into the anterolateral thigh muscles on days 0, 3, 7, and 14 after exposure. (The fifth dose at 28 days after exposure is no longer recommended except among immunosuppressed patients.) The vaccine should not be given in the gluteal area due to suboptimal response. An alternative vaccination strategy that only takes 1 week, with injections on days 0, 3, and 7 after exposure with a verocell vaccine is under study in Thailand.

Rabies vaccines and HRIG should never be given in the same syringe or at the same site. Allergic reactions to the vaccine are rare, although local reactions (pruritus, erythema, tenderness) occur in about 25% and mild systemic reactions (headaches, myalgias, nausea) in about 20% of recipients. Adverse reactions to HRIG seem to be more frequent in women and rare in young children. The vaccine is commercially available or can be obtained through health departments.

Globally diverse anti-rabies vaccines are used. After Pasteur's research in the 19th century with increasingly virulent strains, the first licensed vaccine (1911) was inactivated and grown on bovine brain tissue. Subsequent vaccines were grown using duck or chick embryo cells but remained allergenic. Increasingly purified vaccines are now grown on verocells, and a sixth-generation verocell rabies vaccine is under development. In some countries, the full spectrum of vaccines, from human diploid rabies to chromatographically purified rabies vaccine are available, whereas in others, the gamut is smaller and intradermal application of smaller vaccine doses at multiple sites and at different times is commonly practiced in an attempt to lower costs, and is deemed safe and effective by the World Health Organization.

In patients with history of past vaccination, the need for HRIG is eliminated (RIG is in short supply worldwide) but postexposure vaccination is still required. The vaccine should be given 1 mL in the deltoid twice (on days 0 and 3). Neither the passive nor the active form of postexposure prophylaxis is associated with fetal abnormalities and thus pregnancy is not considered a contraindication to vaccination.

C. Preexposure Immunization

Preexposure prophylaxis with three injections of human diploid cell vaccine intramuscularly (1 mL on days 0, 7, and 21 or 28) is recommended for persons at high risk for exposure: veterinarians (who should have rabies antibody titers checked every 2 years and be boosted with 1 mL intramuscularly); animal handlers; laboratory workers; Peace Corps workers; and travelers with stays over 1 month to remote areas in endemic countries in Africa, Asia, and Latin America. An intradermal route is also available (0.1 mL on days 0, 7, and 21 over the deltoid) but not in the

United States. Immunosuppressive illnesses and agents including corticosteroids as well as antimalarials—in particular chloroquine—may diminish the antibody response. A single dose booster at 10 years after initial immunization increases the level of antibody titers.

► When to Refer

Suspicion of rabies requires contact with public health personnel to initiate appropriate passive and active prophylaxis and observation of suspect cases.

► When to Admit

- Respiratory, neuromuscular, or CNS dysfunction consistent with rabies.
- Patients with suspect rabies require initiation of therapy until the disease is ruled out in suspect animals, and this requires coordination of care based on likelihood of patient compliance, availability of inpatient and outpatient facilities, and response of local public health teams.

Aramburo A et al. Failure of the Milwaukee protocol in a child with rabies. *Clin Infect Dis*. 2011 Sep;53(6):572–4. [PMID: 21865193]

Blanton JD et al. Rabies surveillance in the United States during 2010. *J Am Vet Med Assoc*. 2011 Sep 15;239(6):773–83. [PMID: 21916759]

Centers for Disease Control and Prevention (CDC). Human rabies from exposure to a vampire bat in Mexico—Louisiana, 2010. *MMWR Morb Mortal Wkly Rep*. 2011 Aug 12;60(31):1050–2. [PMID: 21832976]

Centers for Disease Control and Prevention (CDC). Human rabies—Wisconsin, 2010. *MMWR Morb Mortal Wkly Rep*. 2011 Sep 2;60(34):1164–6. [PMID: 21881547]

2. Arbovirus Encephalitides

ESSENTIALS OF DIAGNOSIS

- Fever, malaise, stiff neck, sore throat, and vomiting, progressing to stupor, coma, and convulsions.
- Upper motor neuron lesion signs: exaggerated deep tendon reflexes, absent superficial reflexes, and spastic paralysis.
- Cerebrospinal fluid opening pressure and protein are often increased, with lymphocytic pleocytosis.

► General Considerations

The arboviruses are arthropod-borne pathogens that produce clinical manifestations in humans. The **mosquito-borne pathogens** that cause encephalitis include three

togaviruses (causing Western, Eastern, and Venezuelan equine encephalitis), five flaviviruses (causing West Nile fever, St. Louis encephalitis, Japanese B encephalitis, dengue, and Murray Valley encephalitis), and bunyaviruses (the California serogroup of viruses, including the Lacrosse agent of California encephalitis). The **tick-borne** causes of encephalitis include the flavivirus of the Powassan encephalitis (northeastern United States and Canada) and tick-borne encephalitis virus of Europe; and the Colorado tick fever reovirus. Tick-borne encephalitis virus, Colorado tick fever, and the arboviruses associated with viral hemorrhagic fever (including dengue) are discussed below, and only those viruses causing primarily encephalitis in the United States will be discussed here, although West Nile agent is being reported in many other areas, especially western Europe with recent cases from Greece, Portugal, and Hungary.

The reported total number of cases in the United States for all but the West Nile virus is low. The 2010 tally of reported patients includes 68 with the La Crosse agent of California encephalitis (22 alone in North Carolina), 10 with Eastern equine encephalitis (4 in Florida), and 8 each with Powassan encephalitis and St Louis encephalitis (5 in Texas and Arkansas). There are no reported patients with Western equine encephalitis since 1999.

Infection with West Nile virus was first identified in the United States in the New York City area in 1999. The virus spread rapidly, and current cases are reported throughout the continental United States. The homeless appear to be at particularly increased risk for infection. In the United States during 2011, 690 cases of West Nile virus disease were reported from all 50 states and the District of Columbia. Among these, there were 216 (31.3%) cases of neuroinvasive disease (0.07 per 100,000), with an increased incidence in the elderly. There were 43 deaths. Among blood donors testing seropositive, an additional 130 presumptively infected patients were identified.

Pathogen-specific reservoirs (typically small mammals or birds) are responsible for maintaining the encephalitis-producing viruses in nature. For the Eastern equine encephalitis virus, cotton rats and house sparrows were recently shown to serve as amplifying reservoirs. Birds are the main reservoir for West Nile virus and substantial avian mortality accompanies West Nile fever outbreaks (chicken surveillance is a recommended and possible mode of disease surveillance). The mosquito species associated with transmission is different in the Western vs Eastern United States (*Culex tarsalis* vs *Culex pipiens*) and consequently the terrain associated with high prevalence areas differs (open grasslands vs urban areas).

Outbreaks tend to occur in late summer and early fall and climatic factors, including elevated mean temperatures and rainfall, are shown to correlate with increased West Nile infection. Only dengue and Venezuelan equine encephalitis viruses produce viremias high enough to allow continued transmission to other mosquitoes and ticks. Human to human transmission of the other arboviruses is usually related to blood (including granulocyte) transfusion or organ transplantation (although most infected donors give a history of clinically significant disease). West

Nile virus perinatal, transplacental, breastfeeding (rarely), laboratory, and possibly aerosol transmission can also occur. Rare case reports of West Nile virus infection follow solid organ transplant. It is estimated that fever develops in 1 of 5 patients infected with West Nile virus, while severe neurologic disease presents in 1 of 150. St. Louis encephalitis and Powassan encephalitis occur among adults; Western equine encephalitis, Venezuelan equine encephalitis, and California encephalitis occur primarily among children, while West Nile fever and Eastern equine encephalitis are diseases of both children and adults.

► Clinical Findings

A. Symptoms and Signs

The human incubation period for arboviral encephalitides is 2–14 days. Symptoms include fever, malaise, sore throat, headache, gastrointestinal upset, lethargy, and stupor progressing to coma. Using blood donor surveys, it is estimated that only about 26% of infections are symptomatic (women and the highly viremic are more symptomatic). A nonpruritic maculopapular rash is variably present. Stiff neck and mental status changes are the most common neurologic signs. About 50% of hospitalized patients with West Nile virus infection in the United States have significant muscle weakness that may be initially confused with the Guillain-Barré syndrome. Acute flaccid (poliomyelitis-like) paralysis is seen in 10% of West Nile virus neuroinvasive disease and less commonly with the other arboviruses. Other signs include tremors, seizures, cranial nerve palsies, and pathologic reflexes. Myocarditis, pancreatitis, and hearing loss are also reported. The disease manifestations associated with West Nile virus infection are strongly age-dependent: the acute febrile syndrome and mild neurologic symptoms (but on occasion meningitis) are more common in the young, aseptic meningitis and poliomyelitis-like syndromes are seen in the middle aged, and frank encephalopathy is seen more often in the elderly. All forms of disease tend to be severe in immunocompromised persons in whom neuroinvasive manifestations and associated high mortality are more apt to develop.

B. Laboratory Findings

The peripheral white blood cell count is variable. Cerebrospinal fluid protein is elevated; cerebrospinal fluid glucose is normal; there is usually a lymphocytic pleocytosis; and polymorphonuclear cells may predominate early. The diagnosis of arboviral encephalitides depends on serologic tests. Antibodies to arboviruses persist for life and the presence of IgG in the absence of a rising titer of IgM may indicate past exposure rather than acute infection. Individuals with chronic symptoms after West Nile virus infection may show persistent renal infection for up to 6 years with West Nile virus RNA present in urine. Documentation of a fourfold increase in acute/convalescence titers IgG or the presence of IgM antibodies is confirmatory. For West Nile virus, an IgM capture ELISA in serum or cerebrospinal fluid is almost always positive

by the time the disease is clinically evident, and the presence of IgM in cerebrospinal fluid indicates neuroinvasive disease. These tests are available commercially but also through local or state health departments. Cross-reactivity exists among the different flaviviruses, so a plaque reduction assay may be needed to definitively distinguish between West Nile fever and St. Louis encephalitis. PCR assays (also available through the CDC) are less sensitive than serologic tests for the diagnosis of acute infections but are the preferred method for screening blood products and may be particularly useful in immunocompromised patients with abnormal antibody responses. CT scans of the brain usually show no acute disease, but MRI may reveal leptomeningeal, basal ganglia, thalamic, or periventricular enhancement.

► Differential Diagnosis

Mild forms of encephalitis must be differentiated from aseptic meningitis, lymphocytic choriomeningitis, and nonparalytic poliomyelitis.

Severe forms of arbovirus encephalitides are to be differentiated from other causes of viral encephalitis (HSV, mumps virus, poliovirus or other enteroviruses, HIV), encephalitis accompanying exanthematous diseases of childhood (measles, varicella, infectious mononucleosis, rubella), encephalitis following vaccination (a demyelinating type following rabies, measles, pertussis), toxic encephalitis (from drugs, poisons, or bacterial toxins such as *Shigella dysenteriae* type 1), Reye syndrome, and severe forms of stroke, brain tumors, brain abscess, autoimmune processes such as lupus cerebritis, and intoxications. In the California Encephalitis Project, the cause for most cases of encephalitis was not identified.

► Complications

Bronchial pneumonia, urinary retention and infection, prolonged weakness, and decubitus ulcers may occur. St. Louis encephalitis is reportedly associated with a postinfectious encephalomyelitis. A chronic syndrome consisting of myalgias, arthralgias, and difficulty with concentration and memory is reported in over half the symptomatic cases.

► Treatment

Although specific antiviral therapy is not available for most causative entities, vigorous supportive measures can be helpful. Such measures include reduction of intracranial pressure (mannitol) and monitoring of intraventricular pressure. The efficacy of corticosteroids in these infections is not established. Preliminary evidence that ribavirin is useful in West Nile virus encephalitis is not substantiated. Other therapeutic options such as IVIG or interferon- α await confirmation of effectiveness. A recent case report suggests that prophylaxis with West Nile virus hyperimmune plasma and gamma globulin may prevent neuroinvasion.

► Prognosis

Although most infections are mild or asymptomatic, the prognosis is always guarded, especially at the extremes of age. Homozygosity for a 32bp deletion in the gene coding for the chemokine receptor CCR5, associated with complete loss of function, predisposes to symptomatic West Nile virus infection. People with this mutation are resistant to acquiring HIV infection. Between January and October 2011, the case fatality rate for West Nile virus disease in the United States was 6.2% (43 of 690). Age older than 50 years is the most important risk factor for severe disease and death. Other risk factors for mortality include black race, chronic kidney disease, hepatitis C virus infection, and immunosuppression. Recovery of persons with severe neurologic compromise may take months. Sequelae of West Nile virus infection include a poliomyelitis-like syndrome, cognitive complaints, movement disorders, epilepsy, and depression; and they may become apparent late in the course of what appears to be a successful recovery.

The long-term prognosis is generally better for Western equine than for Eastern equine or St. Louis encephalitis.

► Prevention

No human vaccine is currently available for the arboviruses prevalent in North America, although yellow fever virus-based chimeric vaccines and recombinant vaccines are under development for West Nile virus. Mosquito control (repellents, protective clothing, and insecticides) is effective in prevention. Since 2003, all blood donations in the United States are screened with nucleic acid amplification tests for West Nile virus. Laboratory precautions are indicated for handling all these pathogens, in particular the West Nile virus.

A vaccine against Japanese B encephalitis is recommended for travelers to rural areas of East Asia, though the risk of disease acquisition among the exposed is estimated at only 1:1,000,000. This vaccination appears to provide some protection against West Nile virus (both agents are related flaviviruses).

Cook RL et al. Demographic and clinical factors associated with persistent symptoms after West Nile virus infection. *Am J Trop Med Hyg.* 2010 Nov;83(5):1133–6. [PMID: 21036852]

Lindsey NP et al; Centers for Disease Control and Prevention (CDC). Surveillance for human West Nile virus disease—United States, 1999–2008. *MMWR Surveill Summ.* 2010 Apr 2;59(2):1–17. [PMID: 20360671]

Morelli MC et al. Absence of neuroinvasive disease in a liver transplant recipient who acquired West Nile virus (WNV) infection from the organ donor and who received WNV antibodies prophylactically. *Clin Infect Dis.* 2010 Aug 15;51(4):e34–7. [PMID: 20597692]

United States Geological Survey. Disease maps 2010: West Nile virus. http://diseasemaps.usgs.gov/wnv_us_human.html

Zeller H et al. West Nile virus: the need to strengthen preparedness in Europe. *Euro Surveill.* 2010 Aug 26;15(34):19647. [PMID: 20807490]

Zou S et al. West Nile fever characteristics among viremic persons identified through blood donor screening. *J Infect Dis.* 2010 Nov 1;202(9):1354–61. [PMID: 20874087]

3. Lymphocytic Choriomeningitis

ESSENTIALS OF DIAGNOSIS

- “Influenza-like” prodrome of fever, chills, and cough, followed by a meningeal phase.
- Aseptic meningitis with stiff neck, headache, nausea, vomiting, and lethargy.
- Cerebrospinal fluid: slight increase of protein, lymphocytic pleocytosis (500–3000/mcl); low glucose in 25% of patients.
- Complement-fixing antibodies within 2 weeks.

► General Considerations

The lymphocytic choriomeningitis virus is an arenavirus (related to the pathogen causing Lassa fever, discussed below) that primarily infects the CNS. Its main reservoir is the house mouse (*Mus musculus*). Other rodents (such as rats, guinea pigs, and even pet hamsters), monkeys, dogs, and swine are also potential reservoirs. Lymphocytic choriomeningitis virus is shed by the infected animal via nasal secretions, urine, and feces; transmission to humans probably occurs through aerosolized particles, direct contact, or animal bites. The disease in humans is underdiagnosed and occurs most often in autumn. The lymphocytic choriomeningitis virus is typically not spread person to person, although vertical transmission is reported, and it is considered as an underrecognized teratogen. Rare cases related to solid organ transplantation and autopsies of infected individuals are also reported. Outbreaks are uncommon, and usually occur in laboratory settings among those workers with significant rodent exposure. Complications of clinical disease are rare.

The ubiquitous nature of its reservoir and the wide distribution of the reported cases suggest a widespread geographic risk for lymphocytic choriomeningitis virus infection. Serologic surveys in the southern and eastern United States suggest past infection in approximately 3–5% of those tested, although more recent data from upstate New York showed < 1% seroprevalence. The risk of infection can be reduced by limiting contact with pet rodents and rodent trappings.

► Clinical Findings

A. Symptoms and Signs

The incubation period is 8–13 days to the appearance of systemic manifestations and 15–21 days to the appearance of meningeal symptoms. Symptoms are biphasic, with a prodromal illness characterized by fever, chills, headache, myalgia, cough, and vomiting, occasionally with lymphadenopathy

and maculopapular rash. After 3–5 days the fever subsides only to return after 2–4 days alongside the meningeal phase, characterized by headache, nausea and vomiting, lethargy, and variably present meningeal signs. Arthralgias can develop late in the course. Transverse myelitis, deafness, Guillain-Barré syndrome and transient and permanent hydrocephalus are reported. As stated above, lymphocytic choriomeningitis virus is a well known, albeit underrecognized, cause of congenital infection frequently complicated with obstructive hydrocephalus and chorioretinitis, leading to an infant mortality of up to 30%. Occasionally, a syndrome resembling the viral hemorrhagic fevers (see below) is described in transplant recipients of infected organs and in patients with lymphoma.

B. Laboratory Findings

Leukocytosis or leukopenia and thrombocytopenia may be initially present. During the meningeal phase, cerebrospinal fluid analysis frequently shows lymphocytic pleocytosis (total count is often 500–3000/mcL) alongside a slight increase in protein, while a low to normal glucose is seen in at least 25%. The virus may be recovered from the blood and cerebrospinal fluid by mouse inoculation. Complement-fixing antibodies appear during or after the second week. Detection of specific IgM by ELISA is becoming widely used. Detection of lymphocytic choriomeningitis virus by PCR is available in research settings.

► Differential Diagnosis

The influenza-like prodrome and latent period may distinguish this from other aseptic meningitides, and bacterial and granulomatous meningitis. A history of exposure to mice or other potential vectors is an important diagnostic clue.

► Treatment

Treatment is supportive. In the survivor of a transplant-associated outbreak, ribavirin (which is effective against other arenaviruses) was used successfully along with decreasing immunosuppression.

► Prognosis

Fatalities are rare. The illness usually lasts 1–2 weeks, though convalescence may be prolonged. Congenital infection is more severe with about 30% mortality rate among infected infants, and more than 90% of survivors suffering long-term neurologic abnormalities.

► Prevention

Pregnant women should be advised of the dangers to their unborn children inherent in exposure to rodents.

Folk S et al. Lymphocytic choriomeningitis with severe manifestations, Missouri, USA. *Emerg Infect Dis.* 2011 Oct;17(10):1973–4. [PMID: 22000392]

Razonable RR. Rare, unusual, and less common viruses after organ transplantation. *Curr Opin Organ Transplant.* 2011 Dec;16(6):580–7. [PMID: 22001713]

4. Prion Diseases

ESSENTIALS OF DIAGNOSIS

- ▶ Rare in humans.
- ▶ Cognitive decline.
- ▶ Myoclonic fasciculations, ataxia, visual disturbances, pyramidal and extrapyramidal symptoms.
- ▶ Variant form presents in younger people with prominent psychiatric or sensory symptoms.
- ▶ Specific EEG patterns.

► General Considerations

Transmissible spongiform encephalopathies is a group of fatal neurodegenerative diseases affecting humans and animals. They are caused by infectious proteins called prions for **proteinaceous infectious particles**. These agents show slow replicative capacity and long latent intervals in the host. They induce the conformational change of a normal brain protein (prion protein; PrP[C]) into an abnormal isoform (PrP[Sc]) that accumulates and causes neuronal vacuolation (spongiosis), reactive proliferation of astrocytes and microglia and, in some cases, the deposition of beta-amyloid oligomeric plaques (PrP[C]).

Prion disease can be hereditary, sporadic, and transmissible in humans. Hereditary disorders are caused by germ line mutations in the PrP[C] gene causing **familial Creutzfeldt–Jakob disease (fCJD)**, **Gerstmann–Sträussler–Scheinker syndrome (GSS)**, and **fatal familial insomnia**. Variations at PrP codons sites, in particular codon 129 but also codons 114, 178, 180, and 232, determine host susceptibility to prion disease and the different phenotypes of the disease.

Sporadic Creutzfeldt–Jakob disease (sCJD) is the most common of the human prion diseases, accounting for approximately 85% of cases; it has no known cause, although a spontaneous misfolding of PrP[C] as well as somatic mutations of PrP[C] or undetectable horizontal transmission are postulated as possible explanations. Transmissible prion disease is only described for kuru and Creutzfeldt–Jakob disease in its iatrogenic (iCJD) and variant (vCJD) form. Iatrogenic transmission of CJD is associated with prion contaminated human corneas, dura mater grafts, growth hormone, gonadotropins, stereotactic electroencephalography, electrodes, and neurosurgical instruments. **Kuru**, once prevalent in central New Guinea, is now rare, a decline in prevalence that started after the abandonment of cannibalism in the late 1950s (a protective allele of the PrP gene is now identified at codon 127).

More than 200 cases of vCJD (bovine spongiform encephalopathy [BSE] or “mad cow disease”) were reported in the United Kingdom since the first documented cases there in the mid-1990s. It is far less common in North America, with only 3 cases reported in the United States (the last 1 in 2006) and 19 in Canada. Of the US reported cases, none acquired the disease locally (2 of them acquired

the infection in the United Kingdom and 1 in Saudi Arabia). This disease is characterized by its bovine-to-human transmission through ingestion of meat from cattle infected with BSE. There is no animal-to-animal spread of BSE, and milk and its derived products are not considered to be infected. Reports of secondary transmission of vCJD due to blood transfusions from asymptomatic donors are reported in the United Kingdom. Although iCJD and vCJD are not associated with a known PrP gene mutation, a polymorphism in codon 129 is prevalent and seems to determine susceptibility and expression of clinical disease. The overall annual incidence of prion disease worldwide is approximately one in 1 million people per year. In the United States, among 2441 cases reported through August 19, 2011 to the US National Prion Disease Pathology Surveillance Center, 2068 (85%) were sporadic, 356 (15%) familial, 5 (0.2%) iatrogenic, and 3 (0.1) vCJD.

► Clinical Findings

A. Symptoms and Signs

Both sCJD and fCJD usually present in the sixth or seventh decade of life, whereas the iCJD form tends to occur in a much younger population. Clinical features of these three forms of disease usually involve mental deterioration (dementia, behavioral changes, loss of cortical function) progressive over several months, as well as myoclonus, extrapyramidal (hypokinesia) and cerebellar manifestations (ataxia, dysarthria). Finally, coma ensues, usually associated with an akinetic state and less commonly decerebrate/decorticate posturing. Like iCJD, vCJD usually affects younger patients (averaging ~28 years), but the duration of disease is longer (about 1 year). The degree of organ involvement is often extensive, and the clinical symptoms are unique, mainly characterized by prominent psychiatric and sensory symptoms. Kuru presents with an early stage of tremors, ataxia, and postural instability followed by a sedentary stage characterized by involuntary movements (myoclonus, fasciculations, and choreoathetosis) and a final stage of dementia. GSS, a rare inherited autosomal dominant (rarely sporadic) disorder that occurs in kindred is rapidly fatal. It typically causes a disruption of the circadian sleep-activity pattern leading to insomnia, hallucinations, behavioral changes, motor disturbance and, rarely, dementia. Fatal familial insomnia is the only prion disease associated with endocrine disorders and dysautonomia.

B. Laboratory Findings

CJD should be considered as a diagnosis in the proper clinical scenario, in the absence of alternative diagnoses after routine investigations. Abnormalities in cerebrospinal fluid are subtle and rarely helpful. The detection of 14-3-3 protein in the cerebrospinal fluid is helpful for the diagnosis of sCJD but not in vCJD and fCJD. Its sensitivity and specificity are widely variable among different studies. Cerebrospinal fluid detection of other proteins like tau, neuron-specific enolase, and S100 protein are reported in smaller studies but do not as yet show clinical utility. More recently, a new blood-based assay and a PCR

in cerebrospinal fluid showed some promising results and are currently under evaluation for clinical use.

In CJD, EEG typically shows a pattern of paroxysms with high voltages and slow waves, while MRI is characteristic for bilateral areas of increased signal intensity, predominantly in the caudate and putamen. In contrast, vCJD shows a diffusely abnormal but nondiagnostic EEG. MRI characteristically reveals hyperintensity of the posterior thalamus (“pulvinar sign”). Positron emission tomography can help distinguish GSS disease. The differentiation and definitive diagnosis of these neurodegenerative diseases are ultimately established by neuropathologic confirmation.

► Treatment & Prevention

There is no specific treatment for CJD. Once symptoms appear, the infection invariably leads to death. Flupirtine (an analgesic drug) is sometimes useful in slowing the associated cognitive decline but does not affect survival.

Iatrogenic CJD can be prevented by limiting patient exposure to potentially infectious sources as mentioned above. Disinfection of equipment requires autoclaving at 15 psi for 1 hour, and disinfection of contaminated surfaces requires 5% hypochlorite or 0.1 N sodium hydroxide solutions. Prevention of vCJD relies on surveillance of potentially infected livestock. The American Red Cross does not accept blood donations from persons with a family history of CJD or with a history of dural grafts or pituitary-derived growth hormone injections.

An international referral and database for CJD is available at: <http://www.cjdsurveillance.com/index.html>.

Atarashi R et al. Ultrasensitive human prion detection in cerebrospinal fluid by real-time quaking-induced conversion. *Nat Med.* 2011 Feb;17(2):175–8. [PMID: 21278748]
 Colby DW et al. Prions. *Cold Spring Harb Perspect Biol.* 2011 Jan 1;3(1):a006833. [PMID: 21421910]
 Edgeworth JA et al. Detection of prion infection in variant Creutzfeldt-Jakob disease: a blood-based assay. *Lancet.* 2011 Feb 5;377(9764):487–93. [PMID: 21295339]
 Norrby E. Prions and protein-folding diseases. *J Inter Med.* 2011 Jul;270(1):1–14. [PMID: 21481020]
 Puopolo M et al. Transmission of sporadic Creutzfeldt-Jakob disease by blood transfusion: risk factor or possible biases. *Transfusion.* 2011 Jul;51(7):1556–66. [PMID: 21214582]

5. Progressive Multifocal Leukoencephalopathy (PML)

PML is a rare demyelinating CNS disorder caused by the reactivation of the JC virus (John Cunningham virus or JCV). This polyomavirus usually causes its primary infection during childhood with > 60% of adults typically being seropositive. The virus remains latent in the kidneys, lymphoid tissues, epithelial cells, peripheral blood leukocytes, bone marrow, and possibly brain until the time reactivation occurs and symptoms become evident (see below). This reactivation is usually seen in adults with impaired cell-mediated immunity, especially AIDS patients (5–10% of whom develop PML), as well as those with idiopathic CD4 lymphopenia syndrome. It is also

reported among those with lymphoproliferative and myeloproliferative disorders; granulomatous, inflammatory, and rheumatic diseases (systemic lupus erythematosus and rheumatoid arthritis in particular); as well as in those who have undergone solid and hematopoietic cell transplantation; and occasionally in those who have other medical states, including cirrhosis and renal failure.

Monoclonal antibody-associated PML is described with the use of natalizumab, rituximab, infliximab, and efalizumab (withdrawn from the market in April 2009). Natalizumab, a monoclonal antibody used in the treatment of multiple sclerosis, is associated with the risk of PML developing in 1.35 cases per 1000 patients treated for more than a year and 1.78 per 1000 for patients treatment > 2 years. Although an immune reconstitution inflammatory state may follow cessation of monoclonal antibody therapy, the JCV presence and the residual neurologic deficits may not clear for years after therapy is stopped. The risk of developing PML associated with rituximab is at least 1 in 25,000 exposed patients with cases reported in various autoimmune conditions (systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis). The mean interval between the use of the drug to the diagnosis of PML is 5.5 months. Only one case of infliximab-associated PML is reported. Smoking is reportedly associated with an increased risk of PML.

► Clinical Findings

A. Symptoms and Signs

JCV causes lytic infection of oligodendrocytes in the white matter and symptoms presenting subacutely reflect the diverse areas of CNS involvement. Symptoms include altered mental status, aphasia, ataxia, hemiparesis or hemiplegia and visual field disturbances. Seizures occur in about 18%. Involvement of cranial nerves and cervical spine is rare.

► B. Laboratory Findings

PCR for JCV in cerebrospinal fluid is used for diagnosis in patients with compatible clinical and radiologic findings. A quantitative PCR is more sensitive. Persistent JC viremia and increasing urinary JCV DNA may be predictive of PML.

MRIs of the brain show multifocal areas of white matter demyelination without mass effect or contrast enhancement.

► Treatment & Prevention

Limiting the immunosuppression state represents the mainstay of therapy for PML. Treatment of HIV with HAART reduces the incidence of PML, improves the clinical symptoms and reverses some of the radiographic abnormalities as well as improves the 1-year mortality rate, regardless of baseline CD4 count. Immune restoration, however, can induce worsening of the clinical picture in a small number of cases. Immune reconstitution syndromes do not alter mortality but are associated with a form of PML called non-determined leukoencephalopathy associated with a distinct chemokine polymorphism. Significant

neurologic sequelae to PML infections are the rule and the deficits associated with monoclonal associated PML may persist for years.

Decreasing immunosuppression in non-AIDS patients with PML (eg, transplant patients) is also typically beneficial. Cidofovir may be beneficial in non-AIDS related cases while corticosteroids may be useful with immune reconstitution. Because the JCV infects cells through serotonin receptors, the use of risperidone and mirtazapine are recommended by some clinicians but the success of these agents remains anecdotal. Future reports will assess the role of small inhibitory RNAs. Plasma exchange, which theoretically reduces the plasma level of agents associated with PML, is used by some for the management of natalizumab-associated PML.

Aly L et al. Central role of JC virus-specific CD4+ lymphocytes in progressive multi-focal leukoencephalopathy-immune reconstitution inflammatory syndrome. *Brain*. 2011 Sep; 134(Pt 9):2687–702. [PMID: 21908874]

Bosch X et al. Monoclonal antibody therapy-associated neurological disorders. *Nat Rev Neurol*. 2011 Mar;7(3):165–72. [PMID: 21263460]

Clifford DB et al. Rituximab-associated progressive multifocal leukoencephalopathy in rheumatoid arthritis. *Arch Neurol*. 2011 Sep;68(9):1156–64. [PMID: 21555606]

Weissert R. Progressive multifocal leukoencephalopathy. *J Neuroimmunol*. 2011 Feb;231(1–2):73–7. [PMID: 20937530]

White MK et al. Pathogenesis of progressive multifocal leukoencephalopathy—revisited. *J Infect Dis*. 2011 Mar 1;203(5): 578–86. [PMID: 21227915]

6. Human T Cell Lymphtropic Virus (HTLV)

HTLV-1 and -2 are retroviruses that infect CD4 and CD8 T cells respectively, where they persist as a lifelong latent infection. HTLV-1 currently infects approximately 20 million individuals worldwide. It is endemic to many regions in the world including southern Japan, the Caribbean, central and south Africa, South America, Eastern Europe, and Oceania. The Caribbean basin and Southwestern Japan show the highest prevalence of infection (4–37%). Conversely, HTLV-2 is mainly found in native populations of South (1–58%), Central (8–10%) and North America (2–13%) as well as African pygmy tribes.

In the United States, studies done in blood donors show a seroprevalence of HTLV-1 of 0.01% and HTLV-2 of 0.02%. The virus is transmitted horizontally (sex), vertically (intrauterine, peripartum, and breastfeeding), and parenterally (injection drug use and blood transfusion). Hence, a higher prevalence is seen among injection drug users.

► Clinical Findings

A. Symptoms and Signs

HTLV-1 infection is associated with HTLV-1 adult T cell lymphoma/leukemia (ATL) and HTLV-1 associated myelopathy/tropical spastic paraparesis (HAM/TSP). In contrast, HTLV-2 is significantly less pathogenic, with few reported cases of HAM/TSP as well as other neurologic

manifestations. The causative association of HTLV-1 with ATL, attributed to the virally encoded oncoprotein *tax*, is well established. The lifetime risk of developing ATL among seropositive persons is estimated to be 3% in women and 7% in men, with an incubation period of at least 15 years. The mean age of diagnosis of ATL is 40–50 years in Central and South America and 60 years in Japan.

ATL clinical syndromes may be classified as chronic, acute (leukemic), smoldering, or lymphomatous. A primary cutaneous tumor is also described and shows a worse prognosis compared with the smoldering type. Clinical features of ATL include diffuse lymphadenopathy, maculopapular skin lesions that may evolve into erythroderma, organomegaly, lytic bone lesions, and hypercalcemia. Opportunistic infections, such as *Pneumocystis jirovecii* pneumonia and cryptococcal meningitis, are common.

HAM/TSP, associated with both HTLV-1 and HTLV-2, develops in 0.3–4% of seropositive individuals and is more common in women. A chronic inflammation of the spinal cord leads to progressive motor weakness and symmetric spastic paraparesis, nociceptive low back pain, and paraplegia with hyperreflexia. Bladder and sexual disorders (eg, dyspareunia), sensory disturbances, erectile dysfunction, and constipation are also common. A progressive cognitive impairment is seen with HAM/TSP in children. Both viruses can also induce motor abnormalities, such as leg weakness, impaired tandem walk, and vibration sense, without overt HTLV-associated myelopathy.

An HTLV-1 provirus load in peripheral blood mononuclear cells and cerebrospinal fluid cells, and an HTLV-1 mRNA load are proposed as markers of HAM risk and progression. HTLV positivity is associated with erythrocytosis, lymphocytosis (HTLV-2) and with thrombocytosis (HTLV-1).

HTLV-1 seropositivity is associated with an increased risk of tuberculosis and *Strongyloides stercoralis* hyperinfection. Crusted scabies and infective dermatitis are also associated. Inflammatory states associated with HTLV-1 infection include arthropathy, polymyositis, uveitis, Sjögren syndrome, vasculitis, cryoglobulinemia, infiltrative pneumonitis, and ichthyosis. An increased risk for bronchioloalveolar carcinoma in the presence of HTLV-1 is recently reported.

HTLV-2 is no longer considered to be associated with hairy cell leukemia. HTLV-2 appears to cause a myelopathy that is milder and slower to progress than HAM. All-cause and cancer mortality is higher among HTLV-2 seropositive patients.

HTLV-1/HIV coinfection is associated both with higher CD4 counts and a higher risk of HAM.

B. Laboratory Findings

The peripheral smear can show atypical lymphoid cells with basophilic cytoplasm and convoluted nuclei (flower cells) but the diagnostic standard is evidence of clonal integration of the proviral DNA genome into tumor cell. The identification of HTLV-1 antibodies supports the diagnosis.

► Treatment & Prevention

Management of ATL consists mainly of chemotherapy, with allogeneic stem cell transplantation and the use of

monoclonal antibodies (anti-CCR4 and anti-CD25). A new chemotherapy regimen in Japan using eight different agents shows a higher response rate than traditional biweekly CHOP (40% vs 25%). Therapy using interferon- α combined with zidovudine is effective in the smoldering type.

HAM is treated with a variety of immune-modulating agents (including corticosteroids) without consistent results. Combination of antiretrovirals does not show benefit. Interferon- α may be of some efficacy. Small uncontrolled studies showed that plasmapheresis appears to result in some improvement in gait and sensory disturbance among PML patients.

Screening of the blood supply for HTLV-1 is required in the United States. There is significant cross-reactivity between HTLV-1 and HTLV-2 by serologic studies, but PCR can distinguish the two. Better assays to screen organ donors for HTLV-1 and -2 infections are needed.

Bittencourt AL et al. Cutaneous manifestations associated with HTLV-1 infection. *Int J Dermatol*. 2010 Oct;49(10):1099–110. [PMID: 20883400]

Matsuoka M et al. Human T-cell leukemia virus type 1 (HTLV-1) and leukemic transformation: viral infectivity, Tax, HBZ and therapy. *Oncogene*. 2011 Mar 24;30(12):1379–89. [PMID: 21119600]

Nomori H et al. Risk of bronchioloalveolar carcinoma in patients with human T-cell lymphotropic virus type 1 (HTLV-1): case-control study results. *Ann Thorac Cardiovasc Surg*. 2011 Feb;17(1):19–23. [PMID: 21587123]

OTHER SYSTEMIC VIRAL DISEASES

1. Hemorrhagic Fevers

This diverse group of illnesses results from infection with one of several single-stranded RNA viruses (members of the families Arenaviridae, Bunyaviridae, Filoviridae, and Flaviviridae). Flaviviruses, such as the pathogens causing dengue and yellow fever (both with occasional hemorrhagic complications), are discussed in separate sections.

Lassa fever (an Old World arenavirus) is rodent associated and transmission usually occurs through aerosolized particles (from rodents or infected individuals). Transmission through direct contact with infected biologic fluids or tissues is also documented and food-borne transmission, while considered, is not definitively proven. Similar modes of transmission are assumed for Junin virus and other members of the New World Arenaviridae (Machupo virus, Sabia virus, Guanarito virus, Whitewater Arroyo virus). Bats (fruit bats for Ebola) are the suspected reservoir for Ebola and Marburg viruses (Filoviridae) but their vectors are unknown. A subtype of Ebola (Bundibugyo) is reported in Uganda (earlier Ebola outbreaks occurred in Democratic Republic of Congo, Sudan, and one case in Côte d'Ivoire). Cases of Marburg hemorrhagic fever are reported in travelers exploring caves and mines inhabited by bats in endemic areas of sub-Saharan Africa. The bunyaviruses include the Crimean-Congo hemorrhagic fever (transmitted by infected animal

exposure or tick bite), the Rift Valley fever (transmitted by exposure to infected animal products or bite of an infected mosquito or flea), and the hantaviruses (associated with rodent exposure and discussed separately below). The geographic distribution of Crimean-Congo hemorrhagic fever, like that of its tick vector, is widespread with cases reported in Asia, the Middle East, and Eastern Europe. In 2002, Turkey experienced the largest reported outbreak with over 2500 cases. Hospital-associated transmission of Crimean-Congo hemorrhagic fever is well documented in Iran. Rift Valley fever causes outbreaks in sub-Saharan and Northern Africa, including a recent 2007 outbreak with 155 deaths in Kenya following heavy rainfalls and associated with three different lineages of the virus. Rift Valley cases are also confirmed outside the African continent, in Saudi Arabia, and Yemen.

A new bunyavirus, a phlebovirus, associated with fever and thrombocytopenia, was identified in 2010 in Central and Northeastern China and is named for its symptoms: the **severe fever with thrombocytopenia syndrome**. Its differential diagnosis includes anaplasmosis, hemorrhagic fever with renal syndrome, or leptospirosis. The current candidate vector is a tick of the Ixodidae family. A mortality of 12% was noted among the first 171 patients.

► Clinical Findings

A. Symptoms and Signs

The incubation period can be as short as 2 days for the Rift Valley fever or as long as 21 days for Lassa fever. The clinical symptoms in the early phase of a viral hemorrhagic fever are very similar, irrespective of the causative virus, and resemble a flu-like illness or gastroenteritis. Hepatitis is common.

The late phase is more specific and is characterized by organ failure, persistent leukopenia, altered mental status, and hemorrhage. Exanthemas and mucosal lesions can occur. The range of pathology described with Crimean-Congo hemorrhagic fever continues to grow and include cardiac failure, bilateral alveolar hemorrhages, and retinal hemorrhages. Rift Valley fever is reportedly associated with encephalitis and also retinitis. Adrenal dysfunction is a common sequela of this class of infections and a cause for the development of the late-stage shock associated with these infections. The case-fatality rate ranges from 5% to 30% and may be as high as 90% in Ebola fever. The convalescence period can be long and complicated. There is no evidence of chronic infection among survivors. Risk factors for complications in patients with Crimean-Congo hemorrhagic fever include advanced age, thrombocytopenia, prolonged clotting factor parameters, and hepatitis; risk factors for mortality include altered sensorium and prolonged international normalized ratio.

B. Laboratory Findings

Laboratory features usually include thrombocytopenia, leukopenia, (although with Lassa fever leukocytosis is

noted), anemia, increased hematocrit, elevated liver function tests, and findings consistent with disseminated intravascular coagulation (although less prominently in Lassa fever). Urinalysis can reveal proteinuria and hematuria.

Special care should be taken for handling clinical specimens of suspected cases. Laboratory personnel should be warned about the diagnostic suspicion and the CDC must be contacted for guidance (Special Pathogens Branch, 404-639-1115). Diagnosis may be made by growing the virus from blood obtained early in the disease, antigen detection (by ELISA), nucleic acid amplification (PCR techniques), or by demonstration of a significant specific fourfold or greater rise in antibody titer. Detection of Ebola virus antigen in oral fluid samples by ELISA and RT-PCR may be possible; sample collection in this manner will be useful since certain ethnic customs prohibit blood collection. These tests are generally available only through the CDC.

► Differential Diagnosis

The differential diagnosis for hemorrhagic fever includes meningococcemia or other septicemias, Rocky Mountain spotted fever, dengue, typhoid fever, and malaria. The likelihood of acquiring hemorrhagic fevers among travelers is low.

► Treatment

Patients should be placed in private rooms with standard contact and droplet precautions. Barrier precautions to prevent contamination of skin or mucous membranes should also be adopted by the caring personnel. Airborne precautions should be considered in patients with significant pulmonary involvement or undergoing procedures that stimulate cough.

Certain arenaviruses (the Lassa pathogen, Junin virus in its viscerotropic phase, Machupo virus) and bunyaviruses (the Congo-Crimean hemorrhagic fever and Rift Valley fever pathogens) respond to oral ribavirin if it is started promptly: 30 mg/kg as loading dose, followed by 16 mg/kg every 6 hours for 4 days and then 8 mg/kg every 8 hours for 3 days. The efficacy for postexposure ribavirin in the management of Lassa fever, other arenaviruses, or hospital-associated Crimean-Congo hemorrhagic fever remains anecdotal. However, if ribavirin is used, it should be given in a high loading dose (35 mg/kg orally followed by 15 mg/kg three times daily for 10 days) and only for high-risk settings (eg, needle stick injury, mucous membrane contamination, emergency resuscitative contact, or prolonged intimate exposure during transport).

The filoviruses and the flaviviruses do not respond to ribavirin. Live attenuated vaccines are available for Junin hemorrhagic fever and the Rift Valley fever, and they are under study for the Crimean-Congo hemorrhagic fever, Ebola, and Marburg viruses. In addition, recombinant vaccines are under development for most of these pathogens (including the Lassa fever virus but not the Junin hemorrhagic fever virus). Therapeutic interventions that target the hematologic system are either ineffective or only marginally effective.

▶ When to Admit

- Persons with symptoms compatible with those of any hemorrhagic fever and who have traveled from a possible endemic area should be isolated for diagnosis and symptomatic treatment.
- Isolation is particularly important because diseases due to some of these agents, such as Ebola virus, are highly transmissible and carry a mortality rate of 50–90%.

Bausch DG. Ebola virus as a foodborne pathogen? Cause for consideration, but not panic. *J Infect Dis.* 2011 Jul 15;204(2):179–81. [PMID: 21571727]

Bausch DG et al. Review of the literature and proposed guidelines for the use of oral ribavirin as postexposure prophylaxis for Lassa fever. *Clin Infect Dis.* 2010 Dec 15;51(12):1435–41. [PMID: 21058912]

Feldmann H et al. Ebola haemorrhagic fever. *Lancet.* 2011 Mar 5;377(9768):849–62. [PMID: 21084112]

Ikegami T et al. Rift valley fever vaccines. *Vaccine.* 2009 Nov 5;27(Suppl 4):D69–72. [PMID: 19837291]

Soares-Weiser K et al. Ribavirin for Crimean-Congo hemorrhagic fever: systematic review and meta-analysis. *BMC Infect Dis.* 2010 Jul 13;10:207. [PMID: 20626907]

Yu XJ et al. Fever with thrombocytopenia associated with a novel bunyavirus in China. *N Engl J Med.* 2011 Apr 21;364(16):1523–32. [PMID: 21410387]

2. Dengue



ESSENTIALS OF DIAGNOSIS

- ▶ Exposure 7–10 days before onset.
- ▶ Sudden onset of high fever, chills, severe myalgias and arthralgias, headache, sore throat, and depression.
- ▶ Biphasic fever curve: initial phase, 3–7 days; remission, few hours to 2 days; second phase, 1–2 days.
- ▶ Biphasic rash: evanescent, then maculopapular, scarlatiniform, morbilliform, or petechial changes from extremities to torso.
- ▶ Leukopenia and thrombocytopenia in the hemorrhagic form.

▶ General Considerations

Dengue is due to a flavivirus transmitted by the bite of the *Aedes* mosquito. It may be caused by one of four serotypes widely distributed globally between the tropics of Capricorn and Cancer. An estimated 50–100 million cases of dengue fever and several hundred thousand cases of dengue hemorrhagic fever occur each year with numbers growing in both dengue fever and dengue hemorrhagic fever as a consequence of climatic factors, travel, and urbanization. It is thus the most common and important vector-borne disease of humans, with 2.5 billion living in dengue-infected regions and major intermittent outbreaks including over 7000 in 2010 in Nepal. The incubation period is 3–15 days

(usually 7–10 days). When the virus is introduced into susceptible populations, usually by viremic travelers, epidemic attack rates range from 50% to 70%. Dengue is endemic in the lower Rio Grande Valley and adjacent border towns, with 40% of Brownsville, Texas residents showing serologic evidence of past infection and the virus being detected in mosquito larvae among 30% of households. The seroprevalence of Haitians by age 3 is over 53%.

Severe epidemics of dengue hemorrhagic fever (serotype 3) occurred over the past 20 years in East Africa, Sri Lanka, and Latin America. Dengue is the second most common cause of fever (after malaria) in travelers returning from developing countries. In one US series based on CDC reports, the highest proportion of laboratory-confirmed and probable cases were among travelers returning from the Dominican Republic (121 cases, 20% of total), Mexico (55 cases, 9% of total) and India (43 cases, 7% of total). In general, the more advanced forms of disease (hemorrhagic fever and shock) occur less often in the Americas than in Asia. Since the 1980s, locally acquired cases of dengue are reported from Texas-Mexico border, and Key West, Florida. Health care-associated transmission (needlestick, mucocutaneous exposure or transplant related) and vertical transmission occur rarely.

▶ Clinical Findings

A. Symptoms and Signs

A history of travel to a dengue-endemic area within 14 days of symptom onset is helpful in establishing a diagnosis of dengue. Dengue infection may range from asymptomatic to severe hemorrhagic fever to fatal shock (**dengue shock syndrome**). Dengue fever is usually a nonspecific, self-limited biphasic febrile illness. More than half of infected children are asymptomatic. The illness is more severe and begins more suddenly in adults. After an incubation period of 4–5 days, there is a sudden onset of high fever, chills, and “break bone” aching of the head, back, and extremities accompanied by sore throat, prostration, and malaise. There may be conjunctival redness. Initially, the skin appears flushed or blotched, but 3–4 days after the lysis of the fever, a maculopapular rash, which spares palms and soles, appears in over 50% of cases. As the rash fades, localized clusters of petechiae on the extensor surface of the limbs become apparent. Up to 25% may manifest signs of cardiac involvement. Hepatitis frequently complicates dengue fever with acute fulminant hepatitis in up to 5%.

Dengue hemorrhagic fever usually affects children living in endemic areas and is most likely to occur in secondary infections and in infections with serotype 2. A few days into the illness, signs of hemorrhage such as ecchymoses, gastrointestinal bleeding, and epistaxis appear. Symptoms found more often among the dengue hemorrhagic fever subset of patients include restlessness, epistaxis, and abdominal pain. Gastroenterologic complications, including hemorrhage, tenderness, and ascites, are more common with dengue hemorrhagic fever and often require intensive care observation.

A subset of patients (more often girls than boys) often with secondary infection, may progress to dengue shock syndrome in which acute fever, hemorrhagic manifestations, and marked capillary leak are prominent; the latter manifests as pleural effusions and ascites, and there is a tendency for shock to develop. In infants, even primary infection can lead to dengue shock syndrome. While the infection is difficult to distinguish from malaria, yellow fever, or influenza, the rash makes dengue far more likely. Continuous abdominal pain with vomiting, bleeding, a decrease in the level of consciousness, rash, conjunctival congestion, and hypothermia should raise concern about dengue shock syndrome. Acute kidney injury in dengue largely occurs with dengue shock syndrome and shows a high mortality. While acute severe hepatitis can occur with dengue, concomitant other hepatotropic agents are usually responsible.

Distinguishing between dengue and other causes of febrile illness in endemic areas is difficult. Fevers due to dengue are more often associated with neutropenia and thrombocytopenia and with myalgias, arthralgias/arthritis, and lethargy among adults.

B. Laboratory Findings

Leukopenia is characteristic, and elevated transaminases are found frequently in dengue fever. Thrombocytopenia, increased fibrinolysis, and hemoconcentration occur more often in the hemorrhagic form of the disease. Liver biochemical test abnormalities are nearly universal. Thrombocytopenia, plasma leakage, and acute hepatitis are identified as predictors of severe manifestations of dengue and higher mortality. The nonspecific nature of the illness mandates laboratory verification for diagnosis, usually with IgM and IgG ELISAs after the febrile phase. Virus may be recovered from the blood during the acute phase. PCR or detection of the specific viral protein NS1 by ELISA may be diagnostic during the first few days of infection and may be appropriate for febrile travelers. Immunohistochemistry for antigen detection in tissue samples can also be used. Because the erythrocyte sedimentation rate is normal in most cases, elevation may help with the differential. Chest radiographs in dengue hemorrhagic fever show infiltrates and effusions, which follow the course of laboratory abnormalities.

► Complications

Usual complications include pneumonia, bone marrow failure, hepatitis, iritis, retinal hemorrhages and maculopathy, orchitis, and oophoritis. Depression and chronic fatigue, occurring more often in older women, are also reported. Neurologic complications (such as encephalitis, Guillain-Barré syndrome, phrenic neuropathy, subdural hematoma, and transverse myelitis) are less common, although encephalitic complications are increasingly recognized. Aplastic anemia and hemophagocytosis syndrome are very rare complications. Dengue is rarely associated with stroke in patients with focal neurologic deficit and encephalopathy. Maternal infection poses a risk for premature birth and hemorrhage in both the mother and the infant if infection occurs near term.

Bacterial superinfection occurs more commonly with advanced age, higher fever, gastrointestinal bleeding, kidney disease, and altered consciousness.

► Treatment

Treatment entails the appropriate use of volume support (with Ringer lactate in moderately severe shock and colloids in more severe cases), blood products, and pressor agents, and acetaminophen rather than nonsteroidal anti-inflammatory drugs for analgesia. Activities are gradually restored during prolonged convalescences. Endoscopic therapy is useful in evaluating and managing gastrointestinal hemorrhage, although injection therapy with sclerosing agents is not beneficial in most dengue hemorrhagic states. Platelet counts do not usefully predict clinically significant bleeding. Platelet transfusions, however, should be considered for severe thrombocytopenia ($< 10,000/\text{mL}$) or when there is evidence of bleeding. Monitoring vital signs and blood volume may help in anticipating the complications of dengue hemorrhagic fever or shock syndrome.

The efficacy of corticosteroids in the management of dengue is not proven. There is anecdotal evidence for the efficacy of intravenous anti-D globulin in the management of dengue hemorrhagic fever.

► Prognosis

Fatalities are rare but do occur (and more often among girls and the very young), especially during epidemic outbreaks, with occasional patients dying of fulminant hepatitis. Renal failure in dengue shock syndrome portends an especially poor prognosis. Convalescence for most patients is slow.

► Prevention

Available prophylactic measures include control of mosquitoes by screening and insect repellents, particularly during early morning and late afternoon exposures. Testing of blood supplies is increasingly necessary especially in endemic areas as dengue spreads.

Two tetravalent live attenuated reverse DNA-based and genetically modified chimeric dengue virus vaccines (one of which uses a yellow fever viral backbone) remain under study and are undergoing clinical trials.

Anders KL et al. Epidemiological factors associated with dengue shock syndrome and mortality in hospitalized dengue patients in Ho Chi Minh City, Vietnam. *Am J Trop Med Hyg.* 2011 Jan; 84(1):127–34. [PMID: 21212214]

Centers for Disease Control and Prevention (CDC). Travel-associated Dengue surveillance—United States, 2006–2008. *MMWR Morb Mortal Wkly Rep.* 2010 Jun 18;59(23):715–9. [PMID: 20559202]

Durbin AP et al. Dengue vaccine candidates in development. *Curr Top Microbiol Immunol.* 2010;338:129–43. [PMID: 19802583]

Durbin AP et al. Heterotypic dengue infection with live attenuated monotypic dengue virus vaccines: implications for

vaccination of populations in areas where dengue is endemic. *J Infect Dis.* 2011 Feb 1;203(3):327–34. [PMID: 21208923]
 Mohammed HP et al. Travel-associated dengue infections in the United States, 1996 to 2005. *J Travel Med.* 2010 Jan–Feb; 17(1):8–14. [PMID: 20074096]
 Thomas SJ. The necessity and quandaries of dengue vaccine development. *J Infect Dis.* 2011 Feb 1;203(3):299–303. [PMID: 21208919]

3. Hantaviruses



ESSENTIALS OF DIAGNOSIS

- ▶ Transmitted by rodents and cause two clinical syndromes.
- ▶ Hemorrhagic fever with renal syndrome (HFRS): mild to severe illness.
- ▶ Hantavirus pulmonary syndrome (HPS): 40% mortality rate.
- ▶ Ribavirin is used with some success in HFRS.

▶ General Considerations

Hantaviruses are enveloped RNA bunyaviruses naturally hosted in rodents, moles, and shrews. Currently, over 21 hantavirus strains are known to cause human disease. These differ in rodent hosts, geographic distribution, and degree of pathogenicity. Two major clinical syndromes are described: **hemorrhagic fever with renal syndrome (HFRS)** and **hantavirus pulmonary syndrome (HPS)**. Each year, over 150,000 cases of these two syndromes occur globally, with HPS being far less common. While they share many clinical features, evidence over the past decade suggest that a specific strain is no longer associated with a specific syndrome, but different degrees of overlap are seen between both syndromes. Usually seen in the southwestern United States, Sin Nombre virus (Muerto Canyon, Four Corners) is the most common hantavirus infection in the United States and is the main North American virus responsible for HPS. Although retrospective diagnostics show that the disease occurred decades earlier, it was not until 1993 when the first outbreak was recognized in the United States. Through 2011, 580 cases were reported in 34 states. Other strains native to North America known to cause HPS include Bayou, Black Creek Canal, New York, and Monongahela viruses. Outbreaks of HPS associated with other hantavirus types are also reported in Central and South America.

Hantaviruses are ubiquitous, with infections described in North and South America (New World hantaviruses) as well as Europe, Africa, and Asia (Old World hantaviruses). The Hantaan viruses cause severe hemorrhagic fever with renal syndrome and are found primarily in Korea, China, and eastern Russia. The Seoul viruses produce a less severe form of disease and are found primarily in Korea and China. Cases of domestically acquired Seoul hantavirus

were recently described in the United States. The Puumala and Dobrava viruses are found in Scandinavia and Europe and are associated with a usually milder form of the syndrome, termed “nephropathia epidemica,” which presents with fever, headache, gastrointestinal symptoms, and impaired kidney function.

Aerosols of virus-contaminated rodent urine and feces are thought to be the main vehicle for transmission to humans. Human to human transmission is rare and confined to one hantavirus, the Andes virus. Occupation is the main risk factor for transmission of all hantavirus, with animal trappers, forestry workers, laboratory personnel, farmers, and military personnel considered to be at highest risk. Climate change appears to be impacting the incidence of hantavirus infection mainly through effects on reservoir ecology.

▶ Clinical Findings

A. Symptoms and Signs

Vascular leakage is the hallmark of the disease for both syndromes, with lungs being the main target on HPS and the kidneys on HFRS.

HPS is a more severe disease than HFRS, with a mortality rate of about 40%. The clinical course of HPS is divided into a febrile prodrome, a cardiopulmonary stage, oliguric and diuretic phase followed by convalescence. A 14- to 17-day incubation period is followed by a prodromal phase, typically lasting 3–6 days, that is associated with myalgia, malaise, a fever of abrupt onset, gastrointestinal disturbance, headache, and chills. An ensuing cardiopulmonary phase is characterized by the acute onset of pulmonary edema. In this stage, cough is generally present, gastrointestinal manifestations may dominate the clinical presentations, and in severe cases, significant myocardial depression occurs. Acute kidney injury and myositis may occur. Sequelae include neuropsychological impairments in some HPS survivors.

HFRS manifests as mild, moderate, or severe illness depending on the causative strain, with a mortality rate of up to 12%. A 2- to 3-week incubation period is followed by a protracted clinical course, typically consisting of five distinct phases: febrile period, hypotension, oliguria, diuresis, and convalescence phase. Various degrees of renal involvement are usually seen, occasionally with frank hemorrhage. Pulmonary edema is not typically seen but when present usually occurs in the final stages of disease (oliguric and diuretic phase). Encephalitis and pituitary involvement are rare findings with hantavirus infection, although a few cases are reported with Puumala virus.

B. Laboratory Findings

Laboratory features include hemoconcentration and elevation in lactate dehydrogenase, serum lactate, and hepatocellular enzymes. Early thrombocytopenia and leukocytosis (as high as 90,000 cells/mcL in HPS) are seen in both HFRS and HPS. In HPS, immunoblasts (activated lymphocytes with plasmacytoid features) can be seen in blood, lungs, kidneys, bone marrow, liver, and spleen. The severity of

“nephropathia epidemica” correlates with plasma interleukin-6 levels.

The viremia of human hantavirus infections is short-term, and therefore, viral RNA cannot be readily detected in the blood or urine of patients. An indirect fluorescent assay and enzyme immunoassay are available for detection of specific IgM or low-avidity IgG virus-specific antibodies. A plaque reduction neutralization test is considered the gold standard serologic assay and distinguishes between the different hantavirus species, although cross reaction between Old World and New World viruses exist. This test needs to be performed in a laboratory with appropriate biosafety (level 3).

► Differential Diagnosis

The differential diagnosis of the acute febrile syndrome seen with HFRS or early HPS includes scrub typhus, leptospirosis, and dengue. HPS requires differentiation from other respiratory infections caused by such pathogens as *Legionella*, *Chlamydia*, and *Mycoplasma*. Coxsackievirus infections should also be considered in the differential diagnosis.

► Treatment

Treatment is mainly supportive. Cardiorespiratory support with vasopressors and sometimes extracorporeal membrane oxygenation are frequently needed in severe cases. Intravenous ribavirin is used in HFRS (Hantaan virus) with some success in decreasing the severity of the kidney injury. Its effectiveness in HPS, however, is not established. The evidence for the use of corticosteroids in the treatment of severe HFRS and HPS is mostly anecdotal.

► Prognosis

The outcome is highly variable depending on severity of disease. In Sin Nombre virus infections, the persistence of elevated IgG titers correlates with a favorable outcome.

► Prevention

Because infection is thought to occur by inhalation of rodent wastes, prevention is aimed at eradication of rodents in houses and avoidance of exposure to rodent excreta in rural settings, including forest service facilities. Vaccine development is underway.

Macneil A et al. Hantavirus pulmonary syndrome. *Virus Res*. 2011 Dec;162(1–2):138–47. [PMID: 21945215]

Rasmuson J et al. Time to revise the paradigm of hantavirus syndromes? Hantavirus pulmonary syndrome caused by European hantavirus. *Eur J Clin Microbiol Infect Dis*. 2011 May;30(5):685–90. [PMID: 21234633]

Roig IL et al. Severe pulmonary involvement in a case attributed to domestically acquired Seoul hantavirus in the United States. *Clin Infect Dis*. 2012 Jan;54(1):91–4. [PMID: 22042876]

4. Yellow Fever



ESSENTIALS OF DIAGNOSIS

- ▶ Endemic area exposure (tropical South and Central America, Africa, but not Asia).
- ▶ Sudden onset of severe headache, aching in legs, and tachycardia.
- ▶ Brief (1 day) remission, followed by bradycardia, hypotension, jaundice, hemorrhagic tendency.
- ▶ Proteinuria, leukopenia, bilirubinemia, bilirubinuria.
- ▶ Rare and potentially fatal reactions to vaccination.

► General Considerations

Yellow fever is a zoonotic flavivirus infection transmitted by *Aedes* and jungle mosquitoes. It occurs in an urban and jungle cycle in Africa and in a jungle cycle in South America (where genetic studies suggest it arose through the slave trade 300–400 years ago). Epidemics have extended far into the temperate zone during warm seasons.

Infection is transmitted by an infected mosquito bite. The incubation period in humans is 3–6 days. Adults and children are equally susceptible, though attack rates are highest among adult males because of their work habits. Between 5% and 50% of infections are asymptomatic.

► Clinical Findings

A. Symptoms and Signs

1. Mild form—Symptoms are malaise, headache, fever, retroorbital pain, nausea, vomiting, and photophobia. Relative bradycardia, conjunctival injection, and facial flushing may be present.

2. Severe form—Severe illness develops in about 15%. Initial symptoms are similar to the mild form, but a brief fever remission lasting hours to a few days is followed by a “period of intoxication” manifested by fever and relative bradycardia (Faget sign), hypotension, jaundice, hemorrhage (gastrointestinal, nasal, oral), and delirium that may progress to coma.

B. Laboratory Findings

Leukopenia occurs, although it may not be present at the onset. Kidney disease with proteinuria is present, sometimes as high as 5–6 g/L, and usually disappears completely with recovery. Levels of liver enzymes and bilirubin can be remarkably abnormal with the levels of aspartate aminotransferase (AST) usually doubling those of alanine aminotransferase (ALT). Prothrombin time may be elevated as well. Serologic diagnosis is made by using capture ELISA to measure IgM during the acute and convalescent phases. Viral culture is used in epidemic settings. Rapid test involving PCR and monoclonal antibodies assays against circulating viral antigens are becoming available.

► Differential Diagnosis

It may be difficult to distinguish yellow fever from hepatitis, malaria, leptospirosis, louse-borne relapsing fever, dengue, and other hemorrhagic fevers on clinical evidence alone. Albuminuria is a constant feature in yellow fever patients and its presence helps differentiate yellow fever from other viral hepatitis. Serologic confirmation is often needed.

► Treatment

No specific antiviral therapy is available. Treatment is directed toward symptomatic relief and management of complications. If not in an endemic area, the patient should be isolated from mosquitoes to prevent transmission, since blood in the acute phase is potentially infectious.

► Prognosis

The mortality rate of the severe form is 20–50%, with death occurring most commonly between the sixth and the tenth days. In survivors, the temperature returns to normal by the seventh or eighth day. The prognosis in any individual case is guarded at the onset, since sudden changes for the worse are common. Intractable hiccups, copious black vomitus, melena, anuria, jaundice, and elevated AST are unfavorable signs. Convalescence is prolonged, including 1–2 weeks of asthenia. Infection confers lifelong immunity to those who recover.

► Prevention

Transmission is prevented through mosquito control. Live virus vaccine is highly effective and should be provided for immunocompetent persons over 9 months of age living in or traveling to endemic areas. Revaccination is recommended every 10 years for persons with continued exposure. Vaccine-induced reactions—including neurotropic (encephalitis-like syndrome) and viscerotropic (resembling yellow fever; with one space-time cluster of viscerotropic disease among five patients with four deaths reported from Ica, Peru in 2007) diseases—are reported particularly among patients aged 60 years or older, patients with immune dysfunction or with multiple sclerosis (whose rate of exacerbation is increased 1–5 weeks after vaccination). The aged should probably not be vaccinated and those with immune dysfunction or multiple sclerosis should not be vaccinated, although HIV-infected persons with high CD4 counts safely receive the vaccine with an adverse event rate of about 3%. The safety of the vaccine in pregnant patients is not verified, and pregnant women should, if possible, defer travel to endemic areas (see Chapter 30). Eradication is difficult because of the sylvatic cycle (mainly maintained by non-human primates). Transmission from mother to infant during breastfeeding is documented.

An inactivated, alum-adjuvant vaccine is under development and in phase I studies appears to be safer than the live vaccine and is immunogenic.

The yellow fever virus vaccine shows genetic homology to a melanoma antigen, and in one retrospective study, patients who were given the vaccine showed a reduced risk of melanoma after 10 years.

Farez MF et al. Yellow fever vaccination and increased relapse rate in travelers with multiple sclerosis. *Arch Neurol*. 2011 Oct;68(10):1267–71. [PMID: 21670384]

Kay A et al. Yellow fever vaccine seroconversion in travelers. *Am J Trop Med Hyg*. 2011 Oct;85(4):748–9. [PMID: 21976582]

Monath TP et al. An inactivated cell-culture vaccine against yellow fever. *N Engl J Med*. 2011 Apr 7;364(14):1326–33. [PMID: 21470010]

Staples JE et al; Centers for Disease Control and Prevention (CDC). Yellow fever vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR Recomm Rep*. 2010 Jul 30;59(RR-7):1–27. [PMID: 20671663]

Whittembury A et al. Viscerotropic disease following yellow fever vaccination in Peru. *Vaccine*. 2009 Oct 9;27(43):5974–81. [PMID: 19679215]

5. Tick-Borne Encephalitis



ESSENTIALS OF DIAGNOSIS

- Flaviviral encephalitis found in Eastern, Central, and occasionally Northern Europe and Asia.
- Transmitted via ticks or ingestion of unpasteurized milk.
- Long-term neurologic sequelae occur in 2–25% of cases.
- Therapy is largely supportive.
- Prevention is based on avoiding tick exposure, pasteurization of milk, and vaccination.

► General Considerations

Tick-borne encephalitis (TBE), flaviviral infection caused by TBE virus is the most common arbovirus infection transmitted by ticks in Europe. This infection is endemic in Russia and in eastern and central Europe, but cases are also well recognized in Western Europe and Japan. A toll-like receptor 3 mutation appears to be a risk factor for TBE. An estimated 10,000 to 12,000 cases occur each year in parts of Europe and the Baltic, with annual increases thought to be a function of increased recognition, climatic changes, and personal or social habits. TBE is endemic in parts of China as well, but information regarding its epidemiology is limited. TBE occurs predominantly in the late spring through fall. It is usually a consequence of exposure to infected ticks, although unpasteurized milk from viremic livestock is also a recognized form of transmission. Surges in cases over the last 20 years are thought to be a consequence of agricultural policies that alter land cover, host prevalence, climatic factors, and human behavior (including pesticide usage). The incubation period is 7–14 days for tick-borne exposures but only 3–4 days for milk ingestion. The principal reservoirs for TBE virus are small rodents; humans are an accidental host. The vectors for most cases are *Ixodes ricinus* (most of Europe, including Turkey, Iran, and the Caucasus) and *Ixodes persulcatus* (in the belt from Eastern Europe to China and Japan).

Related viruses found in Eastern and mid-Western North America are the Powassan agent and the deer tick virus. Increasing prevalence of deer ticks in North America is thought to be responsible for the increased (but still small) number of North American cases of these two serologically indistinguishable viruses.

► Clinical Findings

A. Symptoms and Signs

Most cases are subclinical and many resemble a flu-like syndrome. There are two variants of clinical presentation: the Western subtype occurs mainly in the fall and is most severe among the elderly, and the Eastern subtype is more severe among children.

Western subtype disease is biphasic in which after 2–10 days of fever (usually with malaise, headache, and myalgias), a 1–21 day symptom-free interval leads to a second phase with resumed fevers followed by neurologic symptoms. **Eastern subtype disease** is progressive without an asymptomatic interval. The neurologic manifestations range from febrile headache (accounting for up to 50% of Eastern subtype cases) to aseptic meningitis and encephalitis with or without myelitis (preferentially of the cervical anterior horn) and spinal paralysis (usually flaccid). A myeloradiculitic form can also develop but is less common. Double infection with *Borrelia burgdorferi* (the agent of Lyme disease; transmitted by the same tick vector) may result in a more severe disease. Homozygosity for a 32bp deletion in the gene coding for the chemokine receptor CCR5, producing its complete loss of function, predisposes to severe disease. Mortality in TBE is usually a consequence of brain edema or bulbar involvement.

B. Diagnosis

Leukocytosis and neutrophilia are common. Abnormal cerebrospinal fluid findings include a pleocytosis that may persist for up to 4 months. Neuroimaging shows hyperintense lesions in the thalamus, brainstem, and basal ganglia. TBE virus IgM and IgG are detected by ELISA techniques when neurologic symptoms occur. Cross-reactivity with other flaviviruses or a vaccinated state (see below) may require confirmation by detection of TBE virus-specific antibodies in cerebrospinal fluid. RT-PCR of blood (at earlier stages of the disease) or cerebrospinal fluid can sometimes, if available, assist with the diagnosis. TBE virus can be differentiated from serologically indistinguishable viruses (Powassan agent and deer tick virus) by plaque-reduction neutralization tests.

► Complications

The main sequela of disease is paresis, which occurs in up to 10% of Western and up to 25% of Eastern subtype disease. Other causes of long-term morbidity include protracted cognitive dysfunction and persistent spinal nerve paralysis. The postencephalitic syndrome, characterized by headache, difficulties concentrating, balance disorders, dysphasia, hearing defects, and chronic fatigue, occurs with both subtypes. A progressive motor neuron disease and

partial continuous epilepsy are complications seen with the Eastern subtype.

► Differential Diagnosis

The differential diagnosis includes other causes of aseptic meningitis such as enteroviral infections, herpes simplex encephalitis, and a variety of tick-borne pathogens including tularemia, the rickettsial diseases, babesiosis, Lyme disease, poliomyelitis (no longer reported from Eastern Europe) and other flaviviral infections.

► Treatment

Therapy is largely supportive. Some clinicians believe corticosteroids may be useful, although no controlled clinical trials exist.

► Prevention

There are two inactivated TBE virus vaccines for adults and two vaccines for children licensed in Europe. Their effectiveness is about 99% when properly administered. The initial vaccination schedule requires 1 year with boosters every 3–5 years. There are decreased antibody titers and booster response in recipients of TBE vaccines who are over 50 years of age, indicating the need for a modified immunization strategy in older patients. Neuritis and neuropathies of peripheral nerves (plexus neuropathy—paresis of lower limb muscles, polyradiculopathy) are recognized complications of TBE vaccination. Rare cases of olfactory dysfunction are also reported. Other prevention recommendations include avoidance of tick exposure and pasteurization of milk.

Andersson CR et al. Vaccine failures after active immunisation against tick-borne encephalitis. *Vaccine*. 2010 Apr 1;28(16):2827–31. [PMID: 20167301]

Centers for Disease Control and Prevention (CDC). Tick-borne encephalitis among U.S. travelers to Europe and Asia—2000–2009. *MMWR Morb Mortal Wkly Rep*. 2010 Mar 26;59(11):335–8. [PMID: 20339345]

Kindberg E et al. A functional Toll-like receptor 3 gene (TLR3) may be a risk factor for tick-borne encephalitis virus (TBEV) infection. *J Infect Dis*. 2011 Feb 15;203(4):523–8. [PMID: 21216866]

Weinberger B et al. Decreased antibody titers and booster responses in tick-borne encephalitis vaccinees aged 50–90 years. *Vaccine*. 2010 Apr 30;28(20):3511–5. [PMID: 20332047]

6. Colorado Tick Fever



ESSENTIALS OF DIAGNOSIS

- Onset 1–19 days (average, 4 days) following tick bite.
- Fever, chills, myalgia, headache, prostration.
- Leukopenia, thrombocytopenia.
- Second attack of fever after remission lasting 2–3 days.

► General Considerations

Colorado tick fever is a reportable acute reovirus infection transmitted by *Dermacentor andersoni* tick bite. The disease is limited to the western United States and Canada and is most prevalent during the tick season (March to November). There is a discrete history of tick bite or exposure in 90% of cases. The virus infects the marrow erythrocyte precursors, leading to viremia lasting the life span of the infected red cells. Blood transfusions can be a vehicle of transmission.

► Clinical Findings

A. Symptoms and Signs

The incubation period is 3–6 days. The onset is usually abrupt with fever (to 38.9–40.6 °C), sometimes with chills. Severe myalgia, headache, photophobia, anorexia, nausea and vomiting, and generalized weakness are prominent. Physical findings are limited to an occasional faint rash. The acute symptoms resolve within a week. Remission is followed in 50% of cases by recurrent fever and a full recrudescence lasting 2–4 days. In an occasional case, there may be three bouts of fever.

The differential diagnosis includes influenza, Rocky Mountain spotted fever, numerous other viral infections and, in the right setting, relapsing fevers.

B. Laboratory Findings

Leukopenia (2000–3000/mcL) with a shift to the left and atypical lymphocytes occurs, reaching a nadir 5–6 days after the onset of illness. Thrombocytopenia may occur. Viremia may be demonstrated by inoculation of blood into mice or by fluorescent antibody staining of the patient's red cells (with adsorbed virus). An RT-PCR assay may be used to detect early viremia. Detection of IgM by capture ELISA or plaque reduction neutralization is possible after 2 weeks from symptom onset and is the most frequently used diagnostic tool.

► Complications

Aseptic meningitis (particularly in children), encephalitis, and hemorrhagic fever occur rarely. Malaise may last weeks to months. Fatalities are very rare. There is one reported case of spontaneous abortion and multiple congenital anomalies associated with Colorado tick fever infection during pregnancy.

► Treatment

No specific treatment is available. Ribavirin has shown efficacy in an animal model. Antipyretics are used, although salicylates should be avoided due to potential bleeding with the thrombocytopenia seen in patients with Colorado tick fever. Tick avoidance is the best prevention.

► Prognosis

The disease is usually self-limited and benign.

► Prevention

The essence of prevention is vector (tick) control, particularly from March to November.

Brackney MM et al. Epidemiology of Colorado tick fever in Montana, Utah, and Wyoming, 1995–2003. *Vector Borne Zoonotic Dis.* 2010 May;10(4):381–5. [PMID: 19725767]

7. Chikungunya Fever

Chikungunya (“that which bends up” in Bantu) is a flaviviral infection transmitted to humans by *Aedes aegypti* and *Aedes albopictus* (the “Asian tiger mosquito”) and is considered a classic “arthrogenic” virus. The virus is indigenous to tropical Africa and Asia with recent outbreaks reported from areas that adjoin the Indian Ocean, Southeast Asia and its neighboring islands (2005–2007), South India (2005) a major outbreak in Reunión Island, but also from Europe including an outbreak in Italy (2007). The attack rates are often as high as 50%. The endemicity of *A aegypti* in the Americas and the introduction of *A albopictus* into Europe and the New World raise the concerns of a global extension of the epidemic. The Rh-negative population appears to be immune. There are reports of cases of Chikungunya coinfection with yellow fever, malaria, and dengue fever.

► Clinical Findings

A. Symptoms and Signs

After an incubation period of 1–12 days (average 2–4), there is an abrupt onset of fever; headache; intestinal complaints; myalgias; and arthralgias/arthritis affecting small, large, and axial joints. The simultaneous involvement of more than 10 joints and the presence of tenosynovitis (especially in the wrist) are characteristic. The stooped posture of patients gives the disease its name. Joint symptoms persist for 4 months in 33% and linger for years in about 10%. A centrally distributed pruritic maculopapular rash is reported in 50% of the patients, but it can be bullous with sloughing in children. Mucosal disease occurs in about 15%. Facial edema and localized petechiae are reported. Neurologic complications, including encephalitis, myelopathy, peripheral neuropathy, myeloneuropathy, and myopathy, are usually associated with a good outcome. Rare cases of mother-to-child transmission at birth are reported. The virus has no observable effect on the outcome of pregnancy. In infants, primary manifestations of disease include fever, lethargy, acrocyanosis, and erythema evolving into vesiculobullous lesions. Hemorrhagic fever-like presentations are exceptional. Coinfection with other respiratory viruses, in particular dengue, is common. Death is rare and usually related to underlying comorbidities.

B. Laboratory Findings

Diagnosis is made epidemiologically and clinically. Mild leukopenia occurs as does thrombocytopenia, which is seldom severe. Elevated inflammatory markers do not correlate well with the severity of arthritis. Radiographs of affected joints are normal.

Serologic confirmation requires elevated IgM titers or fourfold increase in convalescent IgG levels using an ELISA. RT-PCR and culture techniques (viral isolation in insect or mammalian cell lines or by inoculation of mosquitoes or mice) are seldom available. Suspected cases in the United States should be promptly reported to public health authorities including the CDC Arboviral Diseases Branch, 970-221-6400. The differential includes other tropical febrile diseases, such as malaria, leishmaniasis, or dengue.

► Treatment & Prevention

Treatment is largely supportive with nonsteroidal anti-inflammatory drugs. Chloroquine may be useful for managing refractory arthritis. No vaccine is available, and prevention relies on avoidance of the mosquito vectors. Vertical transmission is documented, but teratogenicity is not established. Prophylaxis with specific Chikungunya immunoglobulins may be useful for exposed neonates or immunosuppressed persons. Establishing the immunopathologic profile of acute versus chronic cases is an ongoing area of investigation.

Powers AM. Chikungunya. *Clin Lab Med*. 2010 Mar;30(1):209–19. [PMID: 20513548]

Roques P et al. Chikungunya fever: focus on peripheral markers of pathogenesis. *J Infect Dis*. 2011 Jan 15;203(2):141–3. [PMID: 21288810]

COMMON VIRAL RESPIRATORY INFECTIONS

1. Respiratory Syncytial Virus (RSV) & Other Paramyxoviruses



ESSENTIALS OF DIAGNOSIS

- RSV is a major cause of morbidity and mortality at the extremes of age.
- Care for patients with RSV infections is largely supportive.
- A monoclonal antibody against RSV, palivizumab, is good but expensive prophylaxis among patients with certain at-risk cardiopulmonary conditions.
- No active vaccination for RSV is available to date.

► General Considerations

Respiratory syncytial virus (RSV) is a paramyxovirus that causes annual outbreaks during the wintertime with usual onset of pulmonary symptoms between mid October and early January in the United States (excluding Florida). There are two major subtypes, A and B. RSV is the leading cause of hospitalization in US children, with annual hospitalization rates of 17 per 1000 children under 6 months and 3 per 1000 children under 5 years of age. Risk factors for infection in children include prematurity, low birth weight, younger age (especially younger than 6 months), bronchopulmonary dysplasia, congenital heart disease, later

birth order, and day care exposure. RSV infection in children is associated with persistence of airway reactivity later in life.

RSV also causes upper and lower respiratory tract infection in adults with increased severity in the elderly, persons with severe combined immunodeficiency, and following lung or bone marrow transplantation (because CD8 T cells are not available for viral clearance). Recurrent infections occur throughout life. The virus enters through contact with mucosal surfaces. The average incubation period is 5 days.

In immunocompromised patients, such as bone marrow transplant recipients, serious pneumonia can occur and outbreaks with a high mortality rate (> 70%) are reported.

Other paramyxoviruses important in human disease include human metapneumovirus, parainfluenza virus, and Nipah virus.

Human metapneumovirus is less common and less pathogenic than RSV and is mainly a seasonal virus circulating during late winter to early spring. It is divided into subgroups A and B. Clinical presentations include mild upper respiratory tract infections to severe lower respiratory tract infections (eg, bronchiolitis, croup, and pneumonia) among slightly older children and lower respiratory tract (sometimes severe) infections among immunocompromised and elderly adults. In lung transplant recipients, human metapneumovirus is a common cause of respiratory illness and is thought to increase the risk of acute and chronic graft rejection.

Human parainfluenza viruses (HPIVs) are commonly seen in children and are the most common cause of laryngotracheitis (croup). Four different serotypes are described, and they differ in their clinical presentations as well as epidemiology. HPIV-1 and HPIV-2 are responsible for croup. HPIV-3 is associated with bronchiolitis and pneumonia. HPIV-4 is a less frequently reported pathogen. Reinfections are common throughout life. HPIVs can also cause severe disease in the elderly, immunocompromised persons, and those with chronic illnesses.

Nipah virus, is a highly virulent paramyxovirus first described in 1999. Cases are concentrated mainly in Southeast Asia (Malaysia, Singapore, Bangladesh and India). Fruit bats are identified as the natural host of the virus. Direct pig-human, cow-human, human-human, and nosocomial transmission are reported. Nipah virus causes acute encephalitis with a high fatality rate (67–92%), although respiratory symptoms are also described. Cranial nerves palsies, encephalopathy, and dystonia are among neurologic sequelae (15–32%) seen on infected individuals. Relapses occurring weeks and months after initial infection are described (3.4–7.5%).

Bocavirus infections are discussed under Erythrovirus (parvovirus) infections below.

► Clinical Findings

A. Symptoms and Signs

In RSV bronchiolitis, proliferation and necrosis of bronchiolar epithelium develop, producing obstruction from

sloughed epithelium and increased mucus secretion. Signs include low-grade fever, tachypnea, and wheezes. Apnea is a common presenting symptom. Hyperinflated lungs, decreased gas exchange, and increased work of breathing are present. In children, RSV is globally the most common cause of acute lower respiratory infection and also a common cause of acute and recurrent otitis media. In patients with Down syndrome, RSV develops at a later age and is associated with more protracted hospitalizations.

B. Laboratory Findings

A rapid diagnosis of RSV infection is made by viral antigen identification of nasal washings using an ELISA or immunofluorescent assay. Culture of nasopharyngeal or lower respiratory tract secretions remain the standard of diagnosis, although PCR is increasingly used. Coinfection with bacteria is relatively uncommon in industrialized countries. Coinfection with *B pertussis* and other viruses occurs in a subset of patients hospitalized for RSV infection. Detection of parainfluenza virus usually requires culture, but tests for rapid detection of viral antigens with immunofluorescence or ELISA, and PCR techniques are also available. Human metapneumovirus is best diagnosed by PCR. ELISA (serum and cerebrospinal fluid) and PCR (urine, respiratory secretions but not blood) are both used for Nipah virus infection diagnosis.

▶ Treatment & Prevention

Treatment of RSV consists of supportive care, including hydration, humidification of inspired air, and ventilatory support as needed. Neither bronchodilating agents nor corticosteroids have demonstrated efficacy in bronchiolitis although individual patients with significant bronchospasm or history of asthma might respond to them.

The use of nebulized or intravenous ribavirin can be considered in high-risk patients, such as those with a history of bone marrow transplantation, although it is of limited benefit. Pregnant women, including hospital staff, should avoid ribavirin exposure. Therapy with surfactant lacks evidence to make recommendations on its use. In the United States, RSV immunoglobulin G is no longer available and has been replaced with palivizumab, a monoclonal RSV antibody. Prophylactic administration of palivizumab (15 mg/kg intramuscularly monthly during the season of high transmission) is recommended for infants with high-risk factors, such as chronic lung disease of prematurity and congenital heart disease. Future studies may entail the use of small inhibitory RNA molecules and of new monoclonal antibodies under development, such as motavizumab (awaiting FDA approval).

No RSV vaccine is licensed to date; a past formalin-inactivated RSV vaccine was complicated with adverse outcomes and was discontinued. A phase-1 study of a live attenuated RSV given with the parainfluenza virus type 3 vaccine is promising with good seroresponse and safety profile. Other vaccine attempts have included live attenuated vaccines (which failed to show significant clinical protection or immunogenicity), protein subunit vaccines, and live viral vector vaccines (all with limited data). The

use of RNA interference therapy in lung transplant patients may have some beneficial effects.

Prevention in hospitals entails rapid diagnosis, hand-washing, contact isolation, and perhaps passive immunization. The use of conjugated pneumococcal vaccination appears to decrease the incidence of concomitant pneumonia associated with viral infections in children in some countries.

Therapeutic modalities for human metapneumovirus and parainfluenza virus infections under investigation include intravenous ribavirin administration. During the initial Nipah virus outbreak, ribavirin was used empirically, although its efficacy remains questionable. Humanized monoclonal antibodies used in animal models show promising results.

Bernstein DI et al; MI-CP149 Investigators. Phase 1 study of the safety and immunogenicity of a live, attenuated respiratory syncytial virus and parainfluenza virus type 3 vaccine in seronegative children. *Pediatr Infect Dis J*. 2012 Feb;31(2):109–14. [PMID: 21926667]

Centers for Disease Control and Prevention (CDC). Respiratory syncytial virus—United States, July 2007–June 2011. *MMWR Morb Mortal Wkly Rep*. 2011 Sep 9;60(35):1203–6. [PMID: 21900874]

Kroll JL et al. Human metapneumovirus. *Semin Respir Crit Care Med*. 2011 Aug;32(4):447–53. [PMID: 21858749]

Ksiazek TG et al. A review of Nipah and Hendra viruses with an historical aside. *Virus Res*. 2011 Dec;162(1–2):173–83. [PMID: 21963678]

Shadman KA et al. A review of palivizumab and emerging therapies for respiratory syncytial virus. *Expert Opin Biol Ther*. 2011 Nov;11(11):1455–67. [PMID: 21831008]

Zamora MR et al. RNA interference therapy in lung transplant patients infected with respiratory syncytial virus. *Am J Respir Crit Care Med*. 2011 Feb 15;183(4):531–8. [PMID: 20851929]

2. Seasonal Influenza



ESSENTIALS OF DIAGNOSIS

- ▶ Cases usually in epidemic pattern.
- ▶ Abrupt onset with fever, chills, malaise, cough, coryza, and myalgias.
- ▶ Aching, fever, and prostration out of proportion to catarrhal symptoms.
- ▶ Leukopenia.

▶ General Considerations

Influenza (an orthomyxovirus) is a highly contagious disease transmitted by the respiratory route. Transmission occurs primarily by droplet nuclei rather than fomites or direct contact. There are three types of influenza viruses. While type A can infect a variety of mammals (humans, swine, horses, etc) and birds, types B and C almost exclusively infect humans. Type A viruses are further divided into subtypes based on the hemagglutinin (H) and the

neuraminidase (N) expressed in their surface. There are 16 subtypes of hemagglutinin and 9 subtypes of neuraminidase. Annual epidemics usually appear in the fall or winter (although sporadic cases occur as summer outbreaks in northern areas such as Alaska or the southern hemisphere). Epidemics affect 10–20% of the global population on average each year and are typically the result of frequent minor antigenic variations of the virus, or antigenic drift, which are more common in influenza A virus. On the other hand, pandemics—associated with higher mortality—appear at longer and varying intervals (decades) as a consequence of a major genetic reassortment of the virus (antigenic shift) or the mutation of an animal virus that adapts to the human (as with the pandemic virus of 1918 with H1N1 properties).

Currently, the main circulating seasonal influenza viruses are the human-origin A (H3N2) subtype (seasonal H1N1 is no longer widely prevalent), as well as two lineages of type B. A highly pathogenic avian (H5N1) subtype that caused occasional human infections in Asia, Africa (Egypt), and Europe over the last decade is of continued global concern. The novel swine-origin influenza A (pandemic H1N1) virus, which emerged in Mexico in March of 2009 and quickly spread through North America, is of particular concern for pregnant women and immunosuppressed persons. Infections due to avian-origin and the 2009 H1N1 viruses are covered in the next sections.

► Clinical Findings

A. Symptoms and Signs

Seasonal influenza viruses of antigenic types A and B produce clinically indistinguishable infections, whereas type C usually causes a minor illness. The incubation period is 1–4 days. In unvaccinated persons, uncomplicated influenza often begins abruptly. Symptoms include fever, chills, malaise, myalgias, substernal soreness, headache, nasal stuffiness, and occasionally nausea. Fever lasts 1–7 days (usually 3–5). Coryza, nonproductive cough, and sore throat are present. Elderly patients may present with only lassitude and confusion, often without fever or respiratory symptoms. Signs include mild pharyngeal injection, flushed face, and conjunctival redness. Moderate enlargement of the cervical lymph nodes may be observed. The presence of fever (> to 38.2°C) and cough during influenza season is highly predictive of influenza infection in those older than 4 years of age.

B. Laboratory Findings

Leukopenia is common, but leukocytosis can occur. Proteinuria may be present. The virus may be isolated from throat swabs or nasal washings by inoculation of embryonated eggs or cell cultures. Rapid immunofluorescence assays and enzyme immunoassays for detection of influenza antigens from nasal or throat swabs are becoming widely available. The sensitivity of such assays is suboptimal (60–80%) and only a few can distinguish between influenza A and B. More sensitive nucleic acid (PCR) techniques are increasingly accessible. Complement-fixing and

hemagglutination-inhibiting antibodies appear during the second week. Microarrays may be used in the future to monitor the spread of pathogenic viral variants.

► Complications

Influenza causes necrosis of the respiratory epithelium, which predisposes to secondary bacterial infections. In turn, bacterial enzymes (eg, proteases, trypsin-like compounds, and streptokinase) activate influenza viruses. Frequent complications are acute sinusitis, otitis media, purulent bronchitis, and pneumonia. Children under 5 years of age, pregnant women, residents of nursing homes and long-term-care facilities, the elderly (aged 65 years or older), children and teens under 19 years of age who are receiving long-term aspirin therapy, and persons with underlying medical conditions (pulmonary, renal, cardiovascular, hepatic, hematologic, neurologic and neurodevelopmental conditions and immune-deficient conditions such as HIV) are at high risk for complications. Persons who are morbidly obese (body mass index > 40), American Indians, and Alaskan natives are also at high risk for complications.

Primary influenza pneumonia may occur, particularly in young children with cardiovascular disease and pregnant women, and is associated with a high mortality. Secondary bacterial pneumonia due to pneumococci, staphylococci, or *Haemophilus* spp is common. Pericarditis and myocarditis occur rarely. There is an association of acute myocardial infarction with preceding respiratory infection, including influenza; a UK study showed that influenza vaccination is associated with a lower rate of acute myocardial infarction. Rhabdomyolysis is a rare late complication of influenza.

Reye syndrome (fatty liver with encephalopathy) is a rare and severe complication of influenza (usually B type) and other viral diseases (eg, varicella), particularly in young children. It consists of rapidly progressive hepatic failure and encephalopathy, and there is a 30% mortality rate. The pathogenesis is unknown, but the syndrome is associated with aspirin use in the management of viral infections. Hypoglycemia, elevation of serum aminotransferases and blood ammonia, prolonged prothrombin time, and change in mental status all occur within 2–3 weeks after onset of the viral infection. Histologically, the periphery of liver lobules shows striking fatty infiltration and glycogen depletion. Treatment is supportive and directed toward the management of cerebral edema. Other encephalopathic complications of influenza are uncommon and include an acute necrotizing encephalopathy associated with disseminated intravascular coagulation and cytokine storm, with worsening when treated with certain nonsteroidal anti-inflammatory drugs (diclofenac and mefenamic acid), and an acute encephalopathy associated with febrile seizures and the use of theophylline. Influenza infections are an infrequent trigger of Guillain-Barré syndrome.

► Treatment

Many patients with influenza prefer to rest in bed. Analgesics and a cough mixture may be used. Treatment should be considered for those with a suggestive clinical

presentation or with laboratory confirmed influenza and at high risk for developing complications (nursing home residents; patients with chronic pulmonary, cardiovascular, kidney, or liver disease; those with diabetes mellitus, active malignancy, immunosuppression, or impairment for managing respiratory secretions), or living with persons at significant risk for them. Maximum benefit is expected with the earliest initiation of therapy. Although the benefit of antiviral therapy after 48 hours of illness is reduced, it should be considered if the patient is hospitalized.

The neuraminidase inhibitors, either inhaled zanamivir, 10 mg (2 inhalations) twice daily for 5 days, or oral oseltamivir, 75 mg twice daily for 5 days, are equally effective in the treatment of susceptible strains of influenza. Clinical trials show a reduction in the duration of symptoms as well as secondary complications, such as otitis, sinusitis, or pneumonia, but not in the rate of hospitalizations or mortality when using these agents. When administered early, antiviral medications (neuraminidase inhibitors) are most effective. Since high levels of resistance to the adamantanes (amantadine and rimantadine) persist among 2009 influenza A (H1N1) and A (H3N2) viruses and these agents are not effective against influenza B viruses, adamantanes are generally not recommended for treatment. Resistance to neuraminidase inhibitors (oseltamivir and zanamivir) can occur with prolonged use in immunocompromised patients or in avian (H5N1)-infected patients. High rates (approximately 25%) of oseltamivir resistance in influenza A (H1N1) viruses were reported in surveillance data from several areas in Europe and Africa between 2007 and 2009 associated with a genetic mutation (H275Y) in the neuraminidase protein. With the advent of the pandemic H1N1 strain (below) circulating levels of seasonal H1N1 were so low that resistance to oseltamivir was not a significant problem. Oseltamivir-resistant pandemic H1N1 isolates are reported with the same H275Y mutation that shows zanamivir sensitivity. Since December 2010, there is no evidence that significant neuraminidase resistance is occurring among pandemic H1N1 isolates and resistance among current seasonal influenza A (H1N1), influenza A (H3N2), and influenza B isolates is rare. The association of oseltamivir resistance with possible pneumonia is reported but requires further study.

Zanamivir is relatively contraindicated among persons with asthma because of the risk of bronchospasm and is not formulated for use in mechanically ventilated patients. Transient neuropsychiatric events, occasionally resulting in self-injury and death, have been reported post marketing for both neuraminidase inhibitors. Patients receiving these drugs should be closely monitored for any unusual behavior, and healthcare professionals should be notified immediately if such signs occur. Laninamivir is a long-acting neuraminidase inhibitor used for the treatment of seasonal influenza, including infection caused by oseltamivir-resistant virus. It remains under phase III clinical trials in America but is licensed in Japan. Ribavirin (unlabeled usage, 1.1 g/d, diluted to 20 mg/mL, delivered as small particle aerosol with oxygen over 12–18 hours a day for 3–7 days [see Table 32–1]) may be effective in severely ill patients with influenza A or B. In vivo studies often do not mimic efficacy in vitro.

The neuraminidase inhibitor, peramivir, is indicated for intravenous use in patients with 2009 H1N1 (available through the CDC's Emergency Use Authorization).

Antibacterial antibiotics should be reserved for treatment of bacterial complications. Acetaminophen or ibuprofen rather than aspirin should be used for fever in children.

► Prognosis

The duration of the uncomplicated illness is 1–7 days, and the prognosis is excellent in healthy, nonelderly adults. Purulent bronchitis and bronchiectasis may result in chronic pulmonary disease and fibrosis that persist throughout life. Most fatalities are due to bacterial pneumonia although exacerbations of other disease processes, in particular cardiac diseases, occur which contributed to the overall increase in fatalities. Influenza pneumonia has a high mortality rate among pregnant women and persons with a history of rheumatic heart disease. Current mortality is low except in debilitated individuals.

If the fever recurs or persists for more than 4 days with productive cough and white cell count over 10,000/mcL, secondary bacterial infection should be suspected. Pneumococcal pneumonia is the most common secondary infection, and staphylococcal pneumonia is the most serious.

► Prevention

Annual administration of influenza vaccine is the most effective measure for preventing influenza and its complications. Vaccines available for use in the United States are the FDA-approved trivalent inactivated influenza vaccine (TIV) and the trivalent live attenuated influenza vaccine (LAIV). They both contain antigens from 1 strain each of pandemic influenza A (H1N1), influenza A (H3N2), and influenza B. All persons 6 months of age and greater are recommended to receive annual influenza vaccination.

The Centers for Disease Control and Prevention and the American College of Obstetricians and Gynecologists' Committee recommend influenza vaccination for all women who will be pregnant through the influenza season (October through May in the United States) and vaccination early in the season regardless of gestational age. No study to date has shown any adverse consequence of inactivated influenza vaccine in pregnant women or their offspring. The FDA has approved Fluzone High-Dose, a TIV containing four-times more hemagglutinin than standard TIV, for persons age 65 or older as well as Fluzone intradermal trivalent vaccine (15 mcg hemagglutinin per strain) which is now commercially available. The intradermal vaccine is equally immunogenic and safe but more expensive than the traditional intramuscular vaccine.

The LAIV is available for use in healthy individuals between 2 and 49 years of age; it should not be given to adult women who are pregnant. For children, LAIV shows superior efficacy over TIV.

The seasonal influenza vaccines can reduce influenza hospitalizations by an estimated 61%.

All of these vaccines are contraindicated in persons with well-substantiated hypersensitivity to chicken eggs or other components of the vaccine (skin testing can be performed by an allergist), in persons with a history of Guillain-Barré syndrome, or in persons with an acute febrile illness until symptomatic improvement. Concomitant warfarin or corticosteroid therapy is not a contraindication to influenza vaccination. Side effects are infrequent and include tenderness, redness, or induration at the intramuscular site of the TIV and mild upper respiratory symptoms for the LAIV.

Chemoprophylaxis is considered for individuals when vaccination is contraindicated and in those exposed to an infected patient within 2 weeks after vaccination with TIV. It is not necessary and is contraindicated with the LAIV, since this vaccine confers more rapid protection. Other circumstances that warrant consideration of chemoprophylaxis include outbreaks in long-term-care facilities, persons living with or in close contact with high-risk individuals, persons with immune deficiencies who might not respond to vaccination, unvaccinated staff during response to an outbreak in a closed institutional setting with residents at high risk, and first responders to epidemic situations.

Chemoprophylaxis against influenza A and B is traditionally accomplished with a single daily dose of the neuraminidase inhibitors oseltamivir (75 mg/d, oral) or zanamivir (10 mg/d, inhaled). These agents reduce the attack rate among unvaccinated individuals if begun within 48 hours after exposure. The CDC recommends chemoprophylaxis for 7 days after exposure. For outbreak control in long-term-care facilities and hospitals, a minimum of 2 weeks is recommended, including in vaccinated person, and until 1 week after identification of the last known case. Zanamivir should not be given as chemoprophylaxis to asthmatic persons, nursing home residents, or children under 5 years of age. Hand hygiene and surgical facemasks appear to prevent household transmission of influenza virus isolates when implemented within 36 hours of recognition of symptoms in an index patient. Such nonpharmaceutical interventions assist in mitigating the spread of pandemic and inter-pandemic influenza to nonvaccinated persons. Vaccination remains the mainstay of prevention.

▶ When to Admit

- Limited availability of supporting services.
- Pneumonia or decreased oxygen saturation.
- Changes in mental status.
- Consider with pregnancy.

American College of Obstetricians and Gynecologists Committee on Obstetric Practice. ACOG Committee Opinion No. 468: Influenza vaccination during pregnancy. *Obstet Gynecol.* 2010 Oct;116(4):1006–7. [PMID: 20859176]

Centers for Disease Control and Prevention (CDC). FluView: a weekly influenza surveillance report. <http://www.cdc.gov/flu/weekly>

Centers for Disease Control and Prevention (CDC). Licensure of a high-dose inactivated influenza vaccine for persons aged

≥ 65 years (Fluzone High-Dose) and guidance for use—United States, 2010. *MMWR Morb Mortal Wkly Rep.* 2010 Apr 30; 59(16):485–6. [PMID: 20431524]

Fiore AE et al; Centers for Disease Control and Prevention (CDC). Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. *MMWR Recomm Rep.* 2010 Aug 6;59(RR-8):1–62. [PMID: 20689501]

Talbot HK et al. Effectiveness of seasonal vaccine in preventing confirmed influenza-associated hospitalizations in community dwelling older adults. *J Infect Dis.* 2011 Feb 15; 203(4):500–8. [PMID: 21220776]

Thorlund K et al. Systematic review of influenza resistance to the neuraminidase inhibitors. *BMC Infect Dis.* 2011 May 19;11:134. [PMID: 21592407]

3. Avian Influenza (H5N1)



ESSENTIALS OF DIAGNOSIS

- ▶ Cases to date in humans, mostly from Southeast Asia and Egypt.
- ▶ Clinically indistinguishable from influenza.
- ▶ Epidemiologic factors assist in diagnosis.
- ▶ Rapid antigen assays are the means of confirming diagnosis.

▶ General Considerations

The normal hosts for avian influenza viruses are aquatic waterfowl. Although avian influenza was first recognized in Italy in 1878, the current outbreak of highly pathogenic influenza A subtype (H5N1) in poultry was recognized in 1997 in Hong Kong and was followed by the first documented human cases. A massive slaughter of poultry was attempted to contain the disease. Outbreaks of H5N1 influenza in poultry emerged in 2003 and now involve more than 65 countries of East and Southeast Asia, Eurasia, Western and Eastern Europe, Northern Africa, and Haiti. The 562 confirmed human cases as of October 2011 include 332 deaths (79% of cases and 78% of deaths are reported from 3 countries, Egypt, Indonesia, and Vietnam) (details maintained and updated by Global Outbreak Alert and Response Network, World Health Organization).

Although highly contagious among birds, the transmission of this H5N1 strain from human to human is inefficient and not sustained. Evidence from cluster outbreaks suggests that host genetic susceptibility limits human to human transmission. The result is only rare cases of person-to-person infection. Occasional transmission to other mammals, including domestic cats and dogs, is also documented.

Cases of influenza H7N7, transmitted from poultry to persons, especially poultry handlers and their contacts in the Netherlands occurred in 2003.

Rare cases of influenza H9N2, another poultry pathogen, are reported from Bangladesh and human to human transmission of this pathogen is not documented.

Most human cases occur after exposure to infected poultry or surfaces contaminated with poultry droppings. Because infection in humans is associated with a mortality rate > 50% (over 80% [91 of 113] for Indonesian cases) and the avian H5N1 subtype continues to spread among birds (with many parts of Southeast Asia now considered endemic for the virus), there is worldwide concern that the virus may undergo genetic reassortment or mutation (as with the 1918 strain) and develop greater human to human transmissibility with the potential to produce a global pandemic.

► Clinical Findings

A. Symptoms and Signs

Distinguishing avian influenza from regular influenza is difficult. History of exposure to dead or ill poultry in the prior 10 days, recent travel to Southeast Asia or Egypt, or contact with known cases should be investigated. The symptoms and signs include predominantly respiratory symptoms (cough and dyspnea), but a variety of other systems may be involved, producing headaches and gastrointestinal complaints in particular. Subclinical disease is relatively rare. With cytokines responsible for much of the pathology, prolonged febrile states and generalized malaise are common. Children are preferentially impacted. Respiratory failure is the usual cause of death.

B. Laboratory Findings

Current commercial rapid antigen tests are not optimally sensitive or specific for detection of H5N1 influenza but are still first-line diagnostic tests because of their widespread availability. Diagnostic yield can be improved by early collection of samples. More sensitive RT-PCR assays are available through many hospitals and state health departments. An initial negative result in the right clinical setting warrants retesting. Throat or lower respiratory swabs may provide higher yield of detection than nasal swabs. When highly pathogenic strains (eg, H5N1) are suspected, extreme care in the handling of these samples must be observed during preliminary testing. Positive samples must then be forwarded to the appropriate public health authorities for further investigations (eg, culture) in laboratories with the adequate level of biosafety (level 3).

► Treatment

Resistance of avian H5N1 influenza strains to amantadine and rimantadine is present in most geographic areas. The current first-line recommendation is to use the neuraminidase inhibitor oseltamivir, 75 mg orally twice daily for 5 days administered within 48 hours from onset of illness. Overall oseltamivir, by modeling, is associated with a 49% reduction in mortality from H5N1 infections. A higher dose (150 mg twice daily), longer duration (7–10 days), and possible combination therapy with amantadine or rimantadine (in countries where A [H5N1] viruses are likely to be susceptible to adamantanes) may be considered in patients with pneumonia or progressive

disease. Evidence of resistance to oseltamivir is reported. Although inhaled zanamivir is proven effective in treating seasonal influenza, no data of its efficacy against H5N1 strains are available. Therapy should still be considered for patients when severe avian influenza disease persists after several days of onset. Parenteral treatment with unapproved (but under study) parenteral peramivir or zanamivir preparations may be considered.

► Prevention

Postexposure prophylaxis with 75 mg of oseltamivir orally once daily for 7–10 days should be given to household contacts of documented cases. Personnel exposed to patients should be monitored for symptoms. Careful surveillance for human cases and prudent stockpiling of medications with establishment of an infrastructure for dissemination are essential modalities of control. Nonpharmacologic means of control include masks, social distancing, quarantine, travel limitations, and infrastructure development, particularly for emergency departments.

A human vaccine against H5N1 influenza is licensed (but not marketed) in the United States with the government stockpiling supplies in the event of need. This vaccine does not contain adjuvant and as a result, its immunogenicity is only modest. A vaccine with oil-in-water emulsion-based adjuvant is available in Europe. Several other vaccine candidates are undergoing clinical trials. A major concern with H5N1 vaccinology is the evolution of the virus in vaccinated poultry, especially in the endemic nations of Egypt and Indonesia, and the need to maintain current surveillance and update vaccine development should avian influenza become more pathogenic in humans. Seasonal and H5N1 vaccines are given together safely in preliminary studies. Prevention of exposure to avian influenza strains also includes hygienic practices during handling of poultry products, including hand-washing and prevention of cross-contamination, as well as thorough cooking of poultry products (to 70°C). There is no risk of acquiring avian influenza through the consumption of poultry products, although there is a risk associated with handling feathers or birds from endemic areas, and the US government bans the importation of poultry from infected areas.

Adisasmito W et al. Effectiveness of antiviral treatment in human influenza A (H5N1) infections: analysis of a Global Patient Registry. *J Infect Dis.* 2010 Oct 15;202(8):1154–60. [PMID: 20831384]

Aditama TY et al. Risk factors for cluster outbreaks of avian influenza A H5N1 infection, Indonesia. *Clin Infect Dis.* 2011 Dec;53(12):1237–44. [PMID: 22016499]

Couch RB et al. Has oseltamivir been shown to be effective for treatment of H5N1 influenza? *J Infect Dis.* 2010 Oct 15; 202(8):1149–51. [PMID: 20831386]

Reece PA. Treatment options for H5N1: lessons learned from the H1N1 pandemic. *Postgrad Med.* 2010 Sep;122(5):134–41. [PMID: 20861597]

Uyeki TM. Human infection with highly pathogenic avian influenza A (H5N1) virus: review of clinical issues. *Clin Infect Dis.* 2009 Jul 15;49(2):279–90. [PMID: 19522652]

4. 2009 Pandemic H1N1 Influenza (“A(H1N1)pdm09”)

ESSENTIALS OF DIAGNOSIS

- ▶ Influenza-like illness with consistent epidemiologic background.
- ▶ Respiratory swab allows local screen and more specific analysis by state public health laboratories.

▶ General Considerations

An outbreak of swine-origin (H1N1) influenza virus (formerly Swine-Origin Influenza Virus [S-OIV] or H1N1/A/California/04/2009, currently “A(H1N1)pdm09”) emerged in Mexico City in March 2009. After initially spreading in the United States and Canada, the virus spread globally with cases reported from over 40 nations by mid-2009. The World Health Organization declared a pandemic on June 11, 2009 which lasted until August 10, 2010. This was the first pandemic since 1968 with circulation outside the usual influenza season in the Northern Hemisphere. The 2009 H1N1 influenza virus has replaced seasonal A (H1N1) and will presumably continue to spread for years to come, akin to the seasonal influenza virus. This virus originates from triple-reassortment North American swine, human and avian virus lineages and Eurasian swine virus lineages.

▶ Clinical Findings

A. Symptoms and Signs

This pandemic strain of H1N1 causes a broad range of clinical symptoms ranging from typical symptoms (fever, malaise, myalgias, cough, sore throat, rhinorrhea, shortness of breath) commonly accompanied by gastrointestinal manifestations (especially diarrhea) to fulminant viral pneumonia. The principal clinical syndrome leading to hospitalization and ICU admission is diffuse viral pneumonitis with severe hypoxemia and sometimes shock and renal failure. Neurologic complications, including seizures and encephalopathy, and cardiac dysfunction, including myocarditis and pulmonary thromboemboli, have occurred. Cases with pandemic H1N1 associated hemophagocytic syndrome are reported. Most patients with mild disease make full recovery, but 9–31% of hospitalized cases require ICU admission, where the mortality ranges between 14% and 46%. The disease has an incubation period of 1.5 to 7 days.

Attack rates are highest in children and young adults, particularly Hispanics, blacks, and native Americans, with relative sparing of adults older than 60 years of age presumably due to previous exposure with related strains (conferring some degree of cross-protection). High-risk groups include patients with severe obesity, immunosuppression, or neurologic disorders, and especially pregnant and postpartum women. Infection during pregnancy may be associated with severe illness, sepsis, pneumothorax and respiratory failure, spontaneous abortion, preterm labor, and fetal distress. Overall

case fatality rate is < 0.5% with 90% of deaths in those under 65 years of age and higher mortality recognized among men and patients with liver disease or a cancer diagnosis within the last year.

B. Laboratory Findings

Laboratory findings may include normal to low leukocyte counts with lymphocytopenia and elevated aminotransferases. Elevated alkaline phosphatase, creatine kinase, creatinine, thrombocytopenia and metabolic acidosis suggest poor prognosis. A nasopharyngeal swab, nasal aspirate, combined nasopharyngeal swab with oropharyngeal swab, or material from a bronchoalveolar lavage can be tested for 2009 H1N1. Test material can be kept at 4°C up to 4 days (not frozen) and shipped with an ice pack. Chest radiographic findings are most commonly unremarkable or may show exacerbation of bibasilar markings, but rarely show lobar infiltrates. The CDC or many state public health laboratories can then perform a real-time PCR or viral culture. Local laboratories can perform rapid influenza antigen enzyme or direct immunofluorescent assays to distinguish influenza viruses types A and B, but the results of these assays should be interpreted with caution due to a limited sensitivity (11–70%) and inability to differentiate between seasonal and the 2009 H1N1 influenza viruses.

Pathologic findings in pandemic H1N1 influenza show a particular propensity toward diffuse alveolar damage, akin to the damage seen in patients with avian influenza. This explains the increased risk of the development of ARDS with pandemic H1N1.

▶ Treatment

The virus is usually resistant to the adamantanes (amantadine or rimantadine). See the seasonal influenza section for side effects and concerns with these medications.

Treatment entails using neuraminidase inhibitors (oseltamivir or zanamivir; dosages are available in Table 32–1) as early as possible (within 96 hours of onset of symptoms). Early therapy with oseltamivir may reduce duration of hospitalization and progression to severe disease requiring ICU admission or resulting in death. Intravenous formulations of zanamivir and peramivir are available for emergency use in severely ill patients. Oseltamivir-resistant virus is recognized (one cluster of resistant cases is reported from a hospital hematology-oncology ward in North Carolina) and such virus remains sensitive to zanamivir. Person to person transmission with oseltamivir-resistant pandemic H1N1 is documented.

The efficacy of intravenous peramivir is similar to that of oseltamivir but is reduced by a factor of 80 in oseltamivir-resistant 2009 H1N1 viral infection. In such patients, intravenous zanamivir is preferred. While a case of multi-drug-resistant pandemic H1N1 virus with resistance to oseltamivir, zanamivir, and peramivir is reported, this particular isolate is less pathogenic in animal studies than standard H1N1 strains. The use of high frequency oscillatory ventilation and extracorporeal membrane oxygenation can improve oxygenation but the impact on mortality is unknown. Corticosteroids for an associated ARDS are

not useful and may increase the mortality with one exception. The use of corticosteroids are associated with a lower rate of mechanical ventilation if they are used in high doses (1 mg/kg prednisone equivalence orally at the time of diagnosis), in patients with a history of hematologic stem cell transplantation.

Updated advice is available at <http://www.cdc.gov/h1n1flu/recommendations.htm>.

► Prevention

The 2011–2012 seasonal influenza vaccines (discussed above) include the A/California/7/2009 (H1N1)–like viral strain and confer protection against 2009 H1N1 influenza. It is especially important that vaccination includes pregnant and unvaccinated postpartum women, household and caregiver contacts of children under 6 months of age, health care and emergency service personnel, healthy persons between 6 months and 24 years of age, and adults 24–64 with underlying medical complications that predispose to influenza (as listed above).

In other areas of the world, monovalent H1N1 vaccines are used. With respect to such pandemic H1N1 vaccines, postmarketing surveillance in China (where 10 different suppliers are used) fails to show any adverse effects or risk for Guillain-Barré syndrome with the vaccine. In another analysis with a monovalent pandemic H1N1 vaccine, the response in elderly patients with asthma was insufficient at the usual 15 mcg; in this group, it is recommended that the dose be increased to 30 mcg (given twice, 30 days apart).

In general, persons with 2009 H1N1 influenza infection should be considered potentially infectious from 1 day before to about 7 days following illness onset. Children and immunosuppressed persons exhibit prolonged viral shedding and may be infectious longer. Any hospital patient in whom the infection is suspected should be isolated in individual rooms with standard and contact precautions plus eye protection.

The World Health Organization guidelines recommend surgical masks for all patient care with the exception of N95 masks for aerosol generating procedures (eg, bronchoscopy, elective intubation, suctioning, administering nebulized medications). For such procedures, an airborne infection isolation room can be used, with air exhausted directly outside or recirculated after filtration by a high efficiency particulate air (HEPA) filter. Strict adherence to hand hygiene with soap and water or an alcohol-based hand sanitizer and immediate removal of gloves and other equipment after contact with respiratory secretions is essential. Precautions should be maintained until 7 days from symptom onset or until the resolution of symptoms, whichever is longer. Postexposure prophylaxis should be considered for close contacts of patients (confirmed, probable, or suspected) who are at high risk for complications of influenza (see section on seasonal influenza) as well as for healthcare personnel, public health workers, or first responders who have had a recognized, unprotected close contact exposure to a person with novel (H1N1) influenza virus infection (confirmed, probable, or suspected) during that person's infectious period. Despite incomplete data about the safety of neuraminidase inhibitors, the CDC

recommends considering postexposure prophylaxis as well in this population.

The MMWR and World Health Organization website (<http://www.who.int/csr/disease/swineflu/en/>) provide updates about this pandemic.

Brun-Buisson C et al; REVA-SRLF A/H1N1v 2009 Registry Group. Early corticosteroids in severe influenza A/H1N1 pneumonia and acute respiratory distress syndrome. *Am J Respir Crit Care Med*. 2011 May 1;183(9):1200–6. [PMID: 21471082]

Centers for Disease Control and Prevention (CDC). Update: influenza A(H3N2)v transmission and guidelines—five states, 2011. *MMWR Morb Mort Wkly Rep*. 2012 Jan 6;60(51–52):1741–4. [PMID: 22217624]

Chen LF et al. Cluster of oseltamivir-resistant 2009 pandemic influenza A (H1N1) virus infections on a hospital ward among immunocompromised patients—North Carolina, 2009. *J Infect Dis*. 2011 Mar 15;203(6):838–46. [PMID: 21343149]

Cunha BA et al. Swine influenza (H1N1) pneumonia in hospitalized adults: chest film findings. *Heart Lung*. 2011 May–Jun; 40(3):253–6. [PMID: 21545936]

Ellington SR et al. Pandemic 2009 influenza A (H1N1) in 71 critically ill pregnant women in California. *Am J Obstet Gynecol*. 2011 Jun;204(6 Suppl 1):S21–30. [PMID: 21514554]

Liang XF et al. Safety of influenza A (H1N1) vaccine in postmarketing surveillance in China. *N Engl J Med*. 2011 Feb 17; 364(7):638–47. [PMID: 21288090]

5. Severe Acute Respiratory Syndrome (SARS)

ESSENTIALS OF DIAGNOSIS

- Mild, moderate, or severe respiratory illness.
- Travel to endemic area within 10 days before symptom onset, including mainland China, Hong Kong, Singapore, Taiwan, Vietnam, and Toronto.
- Persistent fever; dry cough, dyspnea in most.
- Diagnosis confirmed by antibody testing or isolation of virus.
- No specific treatment; mortality as high as 10% in clinically diagnosed cases.

► General Considerations

SARS is a respiratory syndrome caused by an apparently unique coronavirus, transmitted through direct or indirect contact of mucous membranes with infectious respiratory droplets. The virus is shed in stools but the role of fecal–oral transmission is unknown. The natural reservoir appears to be the horseshoe bat (which eats and drops fruits ingested by civets, the earlier presumed reservoir and a likely amplifying host).

The earliest cases were traced to a health care worker in Guangdong Province in China in late 2002, with rapid spread thereafter throughout Asia and Canada, considered a consequence of spread through travel. The 2003 outbreak involved 8098 probable cases from 29 countries, with

774 fatalities. Nine additional cases associated with a research laboratory were reported in China in 2004 with no further cases reported since then.

► Clinical Findings

A. Symptoms and Signs

SARS is an atypical pneumonia that affects persons in all age groups. Severity ranges from asymptomatic disease to severe respiratory illness. Many subclinical cases probably go undiagnosed. Seasonality, as with influenza, is not established. The incubation period is 2–7 days, and it can be spread to contacts of affected patients for 10 days. The mean time from onset of clinical symptoms to hospital admission is 3–5 days. In all clinical cases, persistent fever is present; chills or rigor (or both), cough, shortness of breath, rales, and rhonchi are the rule. Headache, myalgias, and sore throat are common with watery diarrhea occurring in a subset of patients. Elderly patients may report malaise and delirium, without the typical febrile response.

B. Laboratory Findings and Imaging

Leukopenia (particularly lymphopenia) and low-grade disseminated intravascular coagulation are common. Modest elevations of ALT and creatine kinase are frequently seen. Arterial oxygen saturation < 95% with associated nonspecific pulmonary infiltrates is evident in 80% of affected individuals. A high-resolution CT scan is abnormal in 67% of patients with initially normal chest radiographs.

Serum serologies, including enzyme immunoassays and fluorescent antibody assays, are available through public health departments at the state level, although seroconversion may not occur until 3 weeks after the onset of symptoms. The detection rates for the virus using conventional RT-PCR are generally low in the first week of illness. Urine, nasopharyngeal aspirate, and stool specimens are positive in 42%, 68%, and 97%, respectively, on day 14 of illness. Although viral isolation is possible, it is a technically laborious and time-consuming procedure.

► Complications

ARDS, with extensive bilateral consolidation, occurs in about 16% patients, and about 20–30% of patients require intubation and mechanical ventilation.

► Treatment

Severe cases require intensive supportive management. Different agents including, lopinavir/ritonavir, ribavirin, interferon, IVIG, and systemic corticosteroids were used during the 2003 epidemic, but the treatment efficacy of these agents remains inconclusive. In vitro studies with ribavirin show no activity against the virus, and a retrospective analysis of the epidemic in Toronto suggests worse outcomes in patients who received the drug.

► Prognosis

The overall mortality rate of identified cases is about 14%. Poor prognostic factors include advanced age (mortality

rate > 50% in those over 65 years of age compared to < 1% for those under 2 years of age), chronic hepatitis B infection treated with lamivudine, high initial or high peak lactate dehydrogenase concentration, high neutrophil count on presentation, diabetes mellitus, acute kidney disease, and low counts of CD4 and CD8 on presentation.

► Prevention

Health care workers engaged in procedures that involve contact with respiratory droplets are at risk. Isolation of high-risk patients is essential, and simple hygienic measures may help reduce transmission.

Control measures include quarantining in the home for high-risk exposed persons and the use of facemasks for preventing hospital-acquired infections. The validity of using such masks in the community remains unsubstantiated. Continual reporting of suspected cases is crucial, as is awareness of restrictions on international travel. The most cautious modalities include monitoring for 10 days after the last potential exposure and confinement of recovering patients for a similar interval.

Barnard DL et al. Recent developments in anti-severe acute respiratory syndrome coronavirus chemotherapy. *Future Virol.* 2011 May;6(5):615–31. [PMID: 21765859]
 Cleri DJ et al. Severe acute respiratory syndrome (SARS). *Infect Dis Clin North Am.* 2010 Mar; 24(1):175–202. [PMID: 20171552]
 Raboud J et al. Risk factors for SARS transmission from patients requiring intubation: a multicentre investigation in Toronto, Canada. *PLoS One.* 2010 May 19;5(5):e10717. [PMID: 20502660]

ADENOVIRUS INFECTIONS

► General Considerations

About a half of the existing adenoviruses (there are over 52 serotypes described to date and divided into 7 subgroups A–G) produce a variety of clinical syndromes. Adenoviruses show a worldwide distribution and occur throughout the year. These infections are usually self-limited or clinically inapparent and most common among infants, young children, and military recruits. However, these infections may cause significant morbidity and mortality in immunocompromised persons, such as HIV-infected persons and COPD patients, as well as in patients who have undergone solid organ and hematopoietic stem cell transplantation or cardiac surgery or in those who have received cancer chemotherapy. A few cases of donor-transmitted adenoviral infection are reported in the past years. Adenoviruses, although a common cause of human disease, also receive particular recognition through their role as vectors in gene therapy.

► Clinical Findings

A. Symptoms and Signs

The incubation period is 4–9 days. Clinical syndromes of adenovirus infection, often overlapping, include the following. The **common cold** (see Chapter 8) is characterized by rhinitis, pharyngitis, and mild malaise without fever.

Nonstreptococcal exudative pharyngitis is characterized by fever lasting 2–12 days and accompanied by malaise and myalgia. Conjunctivitis is often present. **Lower respiratory tract infection** may occur, including bronchiolitis, suggested by cough and rales, or pneumonia (types 3, 4, and 7 commonly cause acute respiratory disease and atypical pneumonia). Adenovirus type 14 is increasingly reported as a cause of severe and sometimes fatal pneumonia in those with chronic lung disease, but it is also seen in healthy young adults and military recruit outbreaks. **Pharyngoconjunctival fever** is manifested by fever and malaise, conjunctivitis (often unilateral), mild pharyngitis, and cervical adenitis. **Epidemic keratoconjunctivitis** (transmissible person to person) occurs in adults and is manifested by bilateral conjunctival redness, pain, tearing, and an enlarged preauricular lymph node (multiple types may be involved in a single outbreak). Keratitis may lead to subepithelial opacities (especially with types 8, 19, or 37). **Acute hemorrhagic cystitis** is a disorder of children often associated with adenovirus type 11 and 21. **Sexually transmitted genitourinary ulcers and urethritis** may be caused by types 2, 8, and 37 in particular. Adenoviruses also cause **acute gastroenteritis** (types 40 and 41), **mesenteric adenitis**, **acute appendicitis**, and **intussusception**. Rarely, they are associated with encephalitis, acute flaccid paralysis, and pericarditis. Adenovirus is commonly identified in endomyocardial tissue of patients with **myocarditis** and dilated cardiomyopathy. Risk factors associated with severity of infection include youth, chronic underlying infections, recent transplantation, and serotypes 5 or 21.

Hepatitis (type 5 adenovirus), **pneumonia**, and **hemorrhagic cystitis** (types 11 and 34) tend to develop in infected liver, lung, or kidney transplant recipients, respectively. Syndromes that may develop in hematopoietic stem cell transplant patients include hepatitis, pneumonia, hemorrhagic cystitis, tubulointerstitial nephritis, colitis, and encephalitis.

B. Laboratory Findings

Antigen detection assays including direct fluorescence assay or enzyme immunoassay are rapid and show sensitivity of 40–60% compared with viral culture (considered the standard). Samples with negative rapid assays require PCR assays or viral cultures for diagnosis. Quantitative real-time rapid-cycle PCR is useful in distinguishing disease from colonization, especially in hematologic cell transplant patients.

► Treatment

Treatment is symptomatic. Ribavirin and cidofovir are used in immunocompromised individuals with occasional success, although cidofovir is attendant with significant renal toxicity and reduced immunosuppression is often required. Adoptive immunotherapy with transfusion of adenovirus-specific T cells is currently being investigated. IVIG is used in immunocompromised patients, but data are still limited. Typing of isolates is useful epidemiologically and in distinguishing transmission from endogenous reactivation. Complications of adenovirus pneumonia in children include bronchiolitis obliterans.

Vaccines are not available for general use. Live oral vaccines containing attenuated type 4 and type 7 were used in military personnel, but they have been discontinued.

Castelli JB et al. Fatal adenoviral necrotizing bronchiolitis case in a post-cardiac surgery intensive care unit. *Braz J Infect Dis.* 2011 Jun;15(3):285–7. [PMID: 21670932]
Kozlowski T et al. Donor-transmitted adenovirus infection causing kidney allograft nephritis and graft loss. *Transpl Infect Dis.* 2011 Apr;13(2):168–73. [PMID: 20854282]
Vento TJ et al. Pneumonia in military trainees: a comparison study based on adenovirus serotype 14 infection. *J Infect Dis.* 2011 May 15;203(10):1388–95. [PMID: 21502080]

OTHER EXANTHEMATOUS VIRAL INFECTIONS

1. Erythrovirus (Parvovirus) Infections

Erythrovirus, formerly parvovirus B19, infects human erythroid precursor cells. It is quite widespread (by age 15 years about 50% of children have detectable IgG) and its transmission occurs through respiratory secretions and saliva, through the placenta (vertical transmission with 30–50% of pregnant women nonimmune), and through administration of blood products. The incubation period is 4–14 days. Chronic forms of the infection can occur. Bocavirus, another erythrovirus (parvovirus), is a cause of winter acute respiratory disease in children and adults.

► Clinical Findings

A. Symptoms and Signs

Erythrovirus (parvovirus B19) causes several syndromes and manifests differently in various populations.

1. Children—In children, an exanthematous illness (“fifth disease,” erythema infectiosum) is characterized by a fiery red “slapped cheek” appearance, circumoral pallor, and a subsequent lacy, maculopapular, evanescent rash on the trunk and limbs. Malaise, headache, and pruritus (especially on the palms and soles) occur. Systemic symptoms and fever are mostly abated by the time of rash appearance.

2. Immunocompromised patients—In immunosuppressed patients, including those with HIV infection or transplanted organs, or with hematologic conditions such as sickle cell disease, transient aplastic crisis and pure red blood cell aplasia may occur. Bone marrow aspirates reveal absence of mature erythroid precursors and characteristic giant pronormoblasts.

3. Adults—A limited nonerosive symmetric polyarthritis that mimics lupus erythematosus and rheumatoid arthritis, which may in some cases be a type II mixed cryoglobulinemia, can develop in middle-aged persons (especially women) but can also occur in children. Rashes, especially facial, are less common in adults.

Chloroquine and its derivatives exacerbate erythrovirus (parvovirus)-associated anemia and are linked with significantly lower hematocrit in hospital admissions in malaria

endemic areas. Rare reported presentations include myocarditis with infarction, constrictive pericarditis, chronic dilated cardiomyopathy, hepatitis, pneumonitis, neutropenia, thrombocytopenia, a lupus-like syndrome, glomerulopathy, CNS vasculitis, and a chronic fatigue syndrome. A subclinical infection is documented among patients with sickle cell disease. Other CNS manifestations of erythrovirus (parvovirus) include encephalitis, meningitis, stroke (usually in sickle cell anemia patients with aplastic crises), and peripheral neuropathy (brachial plexitis and carpal tunnel syndrome) with occasional chronic residua.

The symptoms of erythrovirus (parvovirus) infection can mimic those of autoimmune states such as lupus, systemic sclerosis, antiphospholipid syndrome, or vasculitis. The molecular mimicry of erythrovirus (parvovirus) to human cytokeratin and transcription factors engaged in hematopoiesis is the basis for theories that implicate erythrovirus (parvovirus) in the pathogenesis of these autoimmune states.

In pregnancy, premature labor, hydrops fetalis, and fetal loss are reported sequelae. Pregnant women with a recent exposure or with suggestive symptoms should be tested for the disease and carefully monitored if results are positive.

B. Laboratory Findings

The diagnosis is clinical (Table 32–2) but may be confirmed by an elevated titer of IgM anti-erythrovirus (parvovirus) anti-bodies in serum or with PCR in serum or bone marrow. Autoimmune antibodies (antiphospholipid and anti-neutrophil cytoplasmic antibodies) can be present and are thought to be a consequence of molecular mimicry.

► Complications

Uncommon complications include the CNS diseases listed above, chronic hemolytic anemia, thrombotic thrombocytopenic purpuric syndrome, acute postinfectious glomerulonephritis, and hepatitis.

► Treatment

Treatment in healthy persons is symptomatic (nonsteroidal anti-inflammatory drugs are used to treat arthralgias, and transfusions are used to treat transient aplastic crises). In immunosuppressed patients, IVIG can aid in the reduction of anemia. IVIG does not reduce the complications associated with encephalitis related to erythrovirus (parvovirus). Intrauterine blood transfusion can be considered in severe fetal anemia.

► Prevention & Prognosis

Several nosocomial outbreaks are documented. In these cases, standard containment guidelines, including hand-washing after patient exposure and avoiding contact with pregnant women are paramount.

The prognosis is generally excellent in immunocompetent individuals. In immunosuppressed patients,

persistent anemia may require prolonged transfusion dependence. Remission of erythrovirus (parvovirus) infection in AIDS patients may occur with HAART, though the immune restoration syndrome is also reported.

Bock CT et al. Human parvovirus B19-associated myocarditis. *N Engl J Med.* 2010 Apr 1;362(13):1248–9. [PMID: 20357294]
 Bönsch C et al. Chloroquine and its derivatives exacerbate B19V-associated anemia by promoting viral replication. *PLoS Negl Trop Dis.* 2010 Apr 27;4(4):e669. [PMID: 20436917]
 Brown KE. The expanding range of parvoviruses which infect humans. *Rev Med Virol.* 2010 Jul;20(4):231–44. [PMID: 20586082]
 Lamont RF et al. Parvovirus B19 infection in human pregnancy. *BJOG.* 2011 Jan;118(2):175–86. [PMID: 21040396]

2. Poxvirus Infections

Among the nine poxviruses causing disease in humans, the following are the most clinically important: variola/vaccinia, molluscum contagiosum, orf and paravaccinia, and monkeypox.

1. Variola/vaccinia—Smallpox (variola) was a highly contagious disease associated with high mortality and disabling sequelae. Its manifestations include severe headache, acute onset of fever, prostration and a rash characterized by the uniform progression from macules to papules to firm, deep-seated vesicles or pustules. The synchronous progression in smallpox readily differentiates lesions from those of varicella (see also Chapter 6).

Complications of smallpox include bacterial superinfections (cellulitis and pneumonia), encephalitis, and keratitis with corneal ulcerations (risk factor for blindness). Effective vaccination led to its global elimination by 1979 and routine vaccination stopped in 1985. Despite the recommendation of destroying remaining samples of this virus, significant concern exists for the potential misuse of these repositories in military or terrorist activities.

Smallpox should be considered, in concordance with the CDC's Smallpox Response Plan (www.bt.cdc.gov/agent/smallpox/response-plan/index.asp), in any patient with fever and a characteristic rash (see above) for which other etiologies—such as herpes infections, erythema multiforme, drug reactions (eczema herpeticum may be differentiated from suspect smallpox by appropriate serologic stains), or other infections—are unlikely. Rare cases of vaccine-related disease from contact with a smallpox vaccinee, (including sexually transmission) are reported. Two cases of vaccinia infection after contact with oral rabies animal baits (which uses the vaccinia vector) are reported. Patients with suspected infection should be placed in airborne and contact isolation and the official agency contacted (CDC Emergency Preparedness and Response Branch; 770-488-7100). Original smallpox vaccine was crudely manufactured with a significant side-effect profile, including eczema vaccinatum and acute vaccinia syndrome (fatigue, headaches, myalgias, and fever). Subsequent smallpox vaccines had similar side-effect profiles, but myocarditis and pericarditis also developed in

some patients. The most recent vaccine, ACAM2000 (Acambis, Inc) shows similar safety profiles and is currently used by the US military and stockpiled in the event of biologic warfare.

Contraindications to vaccination include immunosuppression, eczema or other dermatitis in the vaccinee or household contacts, allergy to any component of the vaccine, infants younger than 1 year and pregnant or breast-feeding women. According to current recommendation, it is unnecessary for anyone not handling the smallpox vaccine to be vaccinated.

Inoculation of the vaccine in inappropriate sites (eg, eyes) is unfortunately common. Asymptomatic vaccinia viremia can be detected up to 21 days post vaccination and no blood donation should occur during this interval. Cidofovir may be considered for treatment of poxviral conditions and intravenous human vaccinia immunoglobulin may be useful for vaccinia.

2. Molluscum contagiosum—Molluscum contagiosum may be transmitted sexually or by other close contact. It is manifested by pearly, raised, umbilicated skin nodules sparing the palms and soles. Keratoconjunctivitis can occur. There may be an association with atopic dermatitis or eczema. Marked and persistent lesions in AIDS patients respond readily to combination antiretroviral therapy. Treatment options include destructive therapies (curettage, cryotherapy, cantharidin, and keratolytics, among others), immunomodulators (imiquimod, cimetidine, and *Candida* antigen), and antiviral agents (cidofovir). No treatment is uniformly effective and multiple courses of therapy are often needed.

Cryptococcal skin lesions can mimic molluscum contagiosum.

3. Orf and paravaccinia—Orf (contagious pustular dermatitis, or ecthyma contagiosa) and paravaccinia (milker's nodules) are occupational diseases acquired by contact with sheep and cattle, respectively. Orf also occurs among children with ruminant exposures. Orf anecdotally responds to imiquimod.

4. Monkeypox—First identified in 1970, monkeypox is enzootic in the rain forests of equatorial Africa and presents in humans as a syndrome similar to smallpox. The incubation period is about 12 days, and limited person-to-person spread occurs. African mortality rates vary from 3% to 11% depending on the immune status of the patient. Secondary attack rates appear to be about 10%. The first community-acquired outbreak in the United States of monkeypox occurred in 2003 in Wisconsin and other states of the upper Midwest. The source appeared to be imported Gambian giant rats via consequent exposure of prairie dogs. Other susceptible animals include nonhuman primates, rabbits, and rodents. Confusion with smallpox and varicella occurs; however, both lymphadenopathy (seen in up to 90% of unvaccinated persons) and a febrile prodrome are prominent features in monkeypox infection. Distinguishing characteristics of the monkeypox rash are its deep seated and well-circumscribed nature, it appears at the same stage of development (unlike varicella but like

smallpox), and is centrifugal (including the palms and soles). Suspected cases should be placed on standard, contact and droplet precautions; and local and state public health officials, and the CDC should be notified for assistance with confirmation of the diagnosis (electron microscopy, viral culture, ELISA, PCR). Cidofovir is effective against monkeypox, and IVIG can be used in selected cases.

Other general precautions that should be taken are avoidance of contact with prairie dogs and Gambian giant rats (whose illness is manifested by alopecia, rash, and ocular or nasal discharge), appropriate care and isolation of those exposed within 3 prior weeks to such animals, and veterinary examination and investigation of suspect animals through health departments. Vaccinia immunization is effective against monkeypox and is recommended, if no contraindication exists (outlined above), for those involved in the investigation of the outbreak and for healthcare workers caring for those infected with monkeypox. Post exposure vaccination is also advised for documented contacts of infected persons or animals. US federal agencies currently prohibit the importation of African rodents.

Centers for Disease Control and Prevention (CDC). Updated interim CDC guidance for use of smallpox vaccine, cidofovir, and vaccinia immune globulin (VIG) for prevention and treatment in the setting of an outbreak of monkeypox infections. <http://www.cdc.gov/ncidod/monkeypox/treatment-guidelines.htm>

Centers for Disease Control and Prevention (CDC). Vaccinia virus infection after sexual contact with a military smallpox vaccinee—Washington, 2010. *MMWR Morb Mortal Wkly Rep*. 2010 Jul 2;59(25):773–5. [PMID: 20592687]

Essbauer S et al. Zoonotic poxviruses. *Vet Microbiol*. 2010 Jan 27;140(3–4):229–36. [PMID: 19828265]

MacNeil A et al. Monkeypox or varicella? Lessons from an outbreak rash investigation in the Republic of the Congo. *Am J Trop Med Hyg*. 2009 Apr;80(4):503–7. [PMID: 19346366]

Nalca A et al. ACAM2000: the new smallpox vaccine for United States Strategic National Stockpile. *Drug Des Devel Ther*. 2010 May 25;4:71–9. [PMID: 20531961]

VIRUSES & GASTROENTERITIS

Viruses are responsible for at least 30–40% of cases of infectious diarrhea in the United States. These agents include rotaviruses; caliciviruses, including noroviruses such as Norwalk virus; astroviruses; enteric adenoviruses; and, less often, toroviruses, coronaviruses, picornaviruses (including the Aichi virus), and pestiviruses. Rotaviruses and noroviruses are responsible for most of nonbacterial cases of gastroenteritis.

Rotaviruses are the leading worldwide cause of dehydrating gastroenteritis in young children and are associated with significant morbidity and mortality (at least 500,000 children under 5 years of age annually from rotavirus infection). Children aged 6 months to 2 years are the most affected, although adults are affected occasionally as well. By age 5, virtually every child has been infected with this pathogen. The diverse set of rotaviruses

(classified by glycoproteins and protease-sensitive proteins [G-type and P-type antigens] which segregate independently) results in a constellation of phenotypes although only about four of these are responsible for over 90% of disease. Rotavirus infections follow an endemic pattern, especially in the tropics, although they peak during the winter in temperate regions. The virus is transmitted by fecal-oral route and can be shed in feces for up to 3 weeks in severe infections. In outbreak settings (eg, daycare centers), the virus is ubiquitously found in the environment, and secondary attack rates are between 16% and 30% (including household contacts). The disease is usually mild and self-limiting. A 2- to 3-day prodrome of fever and vomiting is followed by nonbloody diarrhea (up to 10–20 bowel movements per day) lasting for 1–4 days. The method of choice for diagnosis is PCR of the stool. It is thought that rarely systemic disease occurs. Treatment is largely symptomatic, with fluid and electrolyte replacement. A trial with nitazoxanide was attendant with moderate success among a small cohort of patients with gastroenteritis from Egypt with efficacy in both the rotavirus and norovirus subgroups. The enkephalinase inhibitor racecadotril (also known as acetorphan, given 1.5 mg/kg every 8 hours orally) is available in many countries (but not the United States), and in a meta-analysis appears to be clinically effective in reducing diarrheal symptoms. Local intestinal immunity gives protection against successive infection.

Two oral rotavirus vaccines are available in the United States: pentavalent human-bovine reassortment rotavirus vaccine (PRV, RotaTeq; to be given at 2, 4, and 6 months of age) and attenuated human rotavirus vaccine (HRV, Rotarix; to be given at 2 and 4 months of age). Contraindications include allergy to any of the vaccine ingredients, previous allergic reaction to the vaccine, and immunodeficiency. The risk of intussusception, which is far lower with this than earlier rotavirus preparations, is small (1:51,000 to 1:68,000 vaccinated infants) and is considered significantly lower than the risk associated with untreated rotavirus gastroenteritis.

Noroviruses, such as Norwalk virus (one of a variety of small round viruses divided into 3 genogroups and at least 25 genotypes), are the major cause of epidemic gastroenteritis. They are responsible for a significant percentage of childhood hospitalizations for gastroenteritis in the developing world (15% in surveys from India, 31% from Peru). They appear to evolve by antigenic drift (similar to influenza). While 90% of young adults show serologic evidence of past infection, no long-lasting protective immunity develops and reinfections are common. In the United States, noroviruses are responsible for over 90% of reported nonbacterial gastroenteritis outbreaks during cold weather intervals (hence the colloquial name “gastric flu”). Outbreak environments include restaurants, long-term care facilities, hospitals, schools, daycare centers, vacation destinations (including cruise ships), and Middle Eastern military bases deployed abroad. Persons at particular risk are the young, the elderly, the institutionalized, and the immunosuppressed. Although transmission is usually fecal-oral, airborne and waterborne transmission

are also documented. A short incubation period (24–48 hours), a short symptomatic illness (12–60 hours, but up to 5 days in hospital-associated cases and in children under 11 years of age), a high frequency (> 50%) of vomiting, and absence of bacterial pathogens in stool samples are highly predictive of norovirus gastroenteritis. RT-PCR of stool samples is used for epidemiologic purposes. Treatment is largely symptomatic.

Outbreak control for both rotavirus and norovirus infections include strict adherence to general hygienic measures. Despite the promise of alcohol-based sanitizers for the control of pathogen transmission, such cleansers may be relatively ineffective against the noroviruses compared with antibacterial soap and water, reinforcing the need for new hygienic agents against this prevalent group of viruses. Cohorting of sick patients, contact precautions for symptomatic hospitalized patients, exclusion from work of symptomatic staff until symptom resolution (or 48–72 h after this for norovirus disease), and proper decontamination procedures are crucial.

The reports of efficacy with nitazoxanide or racecadotril in acute gastroenteritis suggest that new avenues of therapy may become more widely available in the future. Vaccine developments are attendant with the complications associated with the rapid evolution (“antigenic drift”) of noroviruses and the probable need for annual strain selection to match circulating variants.

- Desselberger U et al. Immune responses to rotavirus infection and vaccination and associated correlates of protection. *J Infect Dis.* 2011 Jan 15;203(2):188–95. [PMID: 21288818]
- Glass RI et al. Norovirus gastroenteritis. *N Engl J Med.* 2009 Oct 29;361(18):1776–85. [PMID: 19864676]
- Lehert P et al. Racecadotril for childhood gastroenteritis: an individual patient data meta-analysis. *Dig Liver Dis.* 2011 Sep;43(9):707–13. [PMID: 21514257]
- Liu P et al. Effectiveness of liquid soap and hand sanitizer against Norwalk virus on contaminated hands. *Appl Environ Microbiol.* 2010 Jan;76(2):394–9. [PMID: 19933337]
- Patel MM et al. Intussusception risk and health benefits of rotavirus vaccination in Mexico and Brazil. *N Engl J Med.* 2011 Jun 16;364(24):2283–92. [PMID: 21675888]
- Ward RL. Rotarix: a rotavirus vaccine for the world. *Clin Infect Dis.* 2009 Jan 15;48(2):222–8. [PMID: 19072246]

ENTEROVIRUSES THAT PRODUCE SEVERAL SYNDROMES

The most famous enterovirus, the poliomyelitis virus, is discussed above under Vaccine Preventable Diseases. Other clinically relevant enteroviral infections are discussed in this section.

1. Coxsackievirus Infections

Coxsackievirus infections cause several clinical syndromes. As with other enteroviruses, infections are most common during the summer. Two groups, A and B, are defined either serologically or by mouse bioassay. There are more than 50 serotypes.

► Clinical Findings

A. Symptoms and Signs

The clinical syndromes associated with coxsackievirus infection are summer grippé; herpangina; epidemic pleurodynia; aseptic meningitis and other neurologic syndromes; acute nonspecific pericarditis; myocarditis; hand, foot, and mouth disease; epidemic conjunctivitis; and other syndromes.

1. Summer grippé (A and B)—A febrile illness, principally of children, summer grippé usually lasts 1–4 days. Minor symptoms of upper respiratory tract infection are often present.

2. Herpangina (A2–6, 10: B3)—There is sudden onset of fever, which may be as high as 40.6 °C, sometimes with febrile convulsions. Other symptoms are headache, myalgia, and vomiting. The sore throat is characterized early by petechiae or papules on the soft palate that ulcerate in about 3 days and then heal. An outbreak in Taiwan with A2 was associated with herpangina and coincided with an enterovirus 71 (below) outbreak, characterized by hand, foot, and mouth disease. Treatment is symptomatic.

3. Epidemic pleurodynia (Bornholm disease) (B1–5)—Pleuritic pain is prominent. Tenderness, hyperesthesia, and muscle swelling are present over the area of diaphragmatic attachment. Other findings include headache, sore throat, malaise, nausea, and fever. Orchitis and aseptic meningitis occur in < 10% of patients. Most patients are ill for 4–6 days.

4. Aseptic meningitis (A and B) and other neurologic syndromes—Fever, headache, nausea, vomiting, stiff neck, drowsiness, and cerebrospinal fluid lymphocytosis without chemical abnormalities may occur, and pediatric clusters of group B (especially B5) meningitis are reported. Focal encephalitis and transverse myelitis are reported with coxsackievirus group A. Disseminated encephalitis occurs after group B infection, and acute flaccid paralysis is reported with both coxsackievirus group A and B. An outbreak of aseptic meningitis occurred in central China (Gansu Province) in 2008, with 85 cases reported of coxsackie A9 disease. Severe neonatal illnesses are reported with B1 infections, including encephalomyocarditis and neonatal deaths due to multiorgan failure.

5. Acute nonspecific pericarditis (B types)—Sudden onset of anterior chest pain, often worse with inspiration and in the supine position, is typical. Fever, myalgia, headache, and pericardial friction rub appear early and these symptoms are often transient. Evidence for pericardial effusion on imaging studies is often present, and the occasional patient has a paradoxical pulse. Electrocardiographic evidence of pericarditis is often present. Relapses may occur.

6. Myocarditis (B1–5)—Heart failure in the neonatal period secondary to in utero myocarditis and over 20% of adult cases of myocarditis and dilated cardiomyopathy are associated with group B (especially B3) infections.

7. Hand, foot, and mouth disease (A5, 10, 16)—This disease is sometimes epidemic and is characterized by stomatitis and a vesicular rash on hands and feet. Enterovirus 71 is also a causative agent (see below).

8. Epidemic conjunctivitis—As with enterovirus 70 (see below), the A24 variant of coxsackievirus is associated with acute epidemic hemorrhagic conjunctivitis in tropical areas with outbreaks reported in the last few years in southern China, Pakistan, southern Sudan, and Uganda.

9. Other syndromes associated with coxsackievirus infections—These include rhabdomyolysis, fulminant neonatal hepatitis (occurs rarely), glomerulopathy (group B infections), type 1 diabetes mellitus (mainly group B infections), and thyroid disease (group B4), although definitive causality is not established. A pathogenic role in primary Sjögren syndrome and acute myocardial infarction has also been proposed for group B coxsackievirus infections. A recent report of confirmed infective endocarditis due to coxsackievirus B2 in a patient with a prosthetic cardiac device suggests that viral etiologies of culture-negative infective endocarditis should be considered.

B. Laboratory Findings

Routine laboratory studies show no characteristic abnormalities. Neutralizing antibodies appear during convalescence. The virus may be isolated from throat washings or stools inoculated into suckling mice. Viral culture is expensive, labor demanding, and requires several days for results. A PCR test for enterovirus RNA is available and, although it cannot identify the serotype, it appears to be useful, particularly in cases of meningitis.

► Treatment & Prognosis

Treatment is symptomatic. With the exception of meningitis, myocarditis, pericarditis, perhaps diabetes, and rare illnesses such as pancreatitis or polio-like syndrome, the syndromes caused by coxsackieviruses are benign and self-limited. Two controlled trials showed a potential clinical benefit with pleconaril for patients with enteroviral meningitis although the compassionate use of this drug has stopped. There are anecdotal reports of success with IVIG in severe disease.

Blumental S et al. Enteroviral infection of a cardiac prosthetic device. *Clin Infect Dis*. 2011 Mar 15;52(6):710–6. [PMID: 2136772]

Liapounova NA et al. Acute myocardial infarction spurred by myopericarditis in a young female patient: Coxsackie B2 to blame. *Acta Cardiol*. 2011 Feb;66(1):79–81. [PMID: 21446385]

2. Echovirus Infections

Echoviruses are enteroviruses that produce several clinical syndromes, particularly in children. Infection is most common during summer. Among reported specimens, death ensues in about 3%. Males younger than 20 years are more commonly infected than other persons.

Over 30 serotypes of echoviruses are recognized and the most common serotypes for disease are types 6, 9, 11, and 30. Most can cause aseptic meningitis, which may be associated with a rubelliform rash. Types 30 and 13 (the latter also associated with meningitis) outbreaks are increasingly reported globally, including a Korean outbreak of the former in 2008, Finland in 2009, and five epidemics of the latter in the United States. An echovirus 4 outbreak of aseptic meningitis occurred in Australia in 2007. A type 18 outbreak in Taiwan in 2006 and another in Missouri in 2007 were associated with childcare. Transmission is primarily fecal–oral. Hand-washing is an effective control measure in outbreaks of aseptic meningitis. Outbreaks related to fecal contamination of water sources, including drinking water and swimming and bathing pools, were reported in the past.

Besides meningitis, other conditions associated with echoviruses range from common respiratory diseases (bronchiolitis occurs often in children) and epidemic diarrhea to myocarditis, a hemorrhagic obstetric syndrome, keratoconjunctivitis, hepatitis with coagulopathy, leukocytoclastic vasculitis, and neonatal as well as adult cases of encephalitis and sepsis, interstitial pneumonitis, hemophagocytic syndromes (in children with cancer), sudden deafness, encephalitis, optic neuritis, uveitis, and septic shock. Echoviruses, and enteroviruses in general, are also a common cause of nonspecific exanthems.

Echovirus 1 (EV1) is an oncolytic virus that selectively targets and destroys malignant prostate and ovarian cancer cells *in vivo* and is being studied as a potential adjunctive therapy for the control of the peritoneal dissemination of gastric cancer.

As with other enterovirus infections, diagnosis is best established by correlation of clinical, epidemiologic, and laboratory evidence. Cytopathic effects are produced in tissue culture after recovery of virus from throat washings, blood, or cerebrospinal fluid. An enterovirus PCR of the cerebrospinal fluid can assist in the diagnosis and is associated with a shorter duration of hospitalization in febrile neonates. Fourfold or greater rises in antibody titer signify systemic infection.

Treatment is usually symptomatic, and the prognosis is excellent, though there are reports of mild paralysis after CNS infection. Pleconaril, investigational, appears to be of some use among meningitis patients with more severe disease in shortening the course of illness.

From a public health standpoint, clustered illnesses such as swimming in sewage-infested sea water in travelers suggest point-source exposure. Prevention of fecal–oral contamination and maintenance of pool hygiene through chlorination and pH control are important public health control measures.

Centers for Disease Control and Prevention (CDC). Nonpolio enterovirus and human parechovirus surveillance—United States, 2006–2008. *MMWR Morb Mortal Wkly Rep*. 2010 Dec 10;59(48):1577–80. [PMID: 21150865]

Tsai HP et al. An echovirus 18-associated outbreak of aseptic meningitis in Taiwan: epidemiology and diagnostic and genetic aspects. *J Med Microbiol*. 2011 Sep;60(Pt 9):1360–5. [PMID: 21546563]

3. Enteroviruses 70, 71, & Related Agents

Several distinct clinical syndromes are being described in association with enteroviruses. **Enterovirus 70 (HEV-70)**, a ubiquitous agent first identified in 1969 and responsible for abrupt bilateral eye discharge and subconjunctival hemorrhage with occasional systemic symptoms, is most commonly associated with **acute hemorrhagic conjunctivitis**. Enterovirus infection of the pancreas can trigger cell-mediated autoimmune destruction of beta-cells resulting in diabetes. Enterovirus myocarditis can be a serious infection in neonates, complicated by cardiac dysfunction and arrhythmias. **Enterovirus 71 (HEV-71)** almost always occurs in the Asia-Pacific region and is associated with **hand, foot, and mouth disease (HFMD)**, herpangina as well as a form of **epidemic encephalitis** associated on occasion with pulmonary edema, and **acute flaccid paralysis**. An outbreak of HFMD in Fuyang China in 2008 was caused by a recombinant virus between HEV-71 and coxsackievirus A16.

Human enteroviruses are neurotropic and a potential role for these viruses in amyotrophic lateral sclerosis is the subject of some investigation.

Mortality is especially high in enterovirus 71-associated brainstem encephalitis, which is often complicated by pulmonary edema, particularly when it occurs in children younger than 5 years. A complication is autonomic nervous system dysregulation, which may develop prior to the pulmonary edema. Because of lower herd immunity, HFMD tends to infect the very young (under age 5) in nonendemic areas. Disease is usually more severe and sequelae more common than with other enteroviruses. Some children with enterovirus-associated cardiopulmonary failure require the usage of extracorporeal life support which can improve the outcome. Recognized sequelae include central hypoventilation, dysphagia, and limb weakness.

Diagnosis of both entities is facilitated by the clinical and epidemiologic findings with the isolation of the suspect agent from conjunctival scraping for enterovirus 70 or vesicle swabs, body secretions, or cerebrospinal fluid for enterovirus 71. Serologic methods, including enzyme immunoassays and complement fixation tests, are developed. These assays show good specificity but poor sensitivity (< 80%). RT-PCR may increase the detection rate in enterovirus infections and is useful in the analysis of cerebrospinal fluid samples among patients with meningitis and of blood samples among infants with a sepsis-like illness.

Treatment of both entities remains largely symptomatic, though pleconaril (see above) may be of some use. The role of immunoglobulins is under investigation. Treatment of enterovirus 71 infections with corticosteroids or pyrazolones was associated with a worse prognosis in one study. The major complication associated with enterovirus 70 is the rare development of an acute neurologic illness with motor paralysis akin to poliomyelitis. Attention-deficit with hyperactivity occurs in about 20% with confirmed infection.

Household contacts, especially children under 6 months of age, are at particular risk for enterovirus 71 acquisition. A commercial disinfectant, Virkon S, at 1–2% application, appears to reduce infectivity titers. A stage-based supportive treatment for enterovirus 71 infections, recognizing the potential for late

onset CNS disease and cardiopulmonary failure is important. A human vaccine is needed for enterovirus 71.

Enterovirus 72 (HEV-2) is another term for hepatitis A virus (see Chapter 16). Enterovirus EV-104A is related to rhinoviruses and associated with respiratory illness in reports from Italy and Switzerland.

Enterovirus 68 (HEV-68) is a unique enterovirus that shares epidemiologic characteristics with human rhinovirus and is typically associated with respiratory illness. Several clusters are reported from the Philippines, Japan, Netherlands and the United States. The agent is implicated in a recent, fatal case of meningomyeloencephalitis.

Centers for Disease Control and Prevention (CDC). Clusters of acute respiratory illness associated with human enterovirus 68—Asia, Europe, and United States, 2008–2010. *MMWR Morb Mortal Wkly Rep.* 2011 Sep 30;60(38):1301–4. [PMID: 21956405]

Kreuter JD et al. A fatal central nervous system enterovirus 68 infection. *Arch Pathol Lab Med.* 2011 Jun;135(6):793–6. [PMID: 21631275]

4. Human Parechovirus Infection (HPEV)

HPEV is a member of the Picornaviridae family. The pathogen mainly affects small children although disease can also occur in older adults. Cases are spread worldwide. There were 16 genotypes recognized worldwide by 2011. Clinical presentation is mainly driven by gastrointestinal and respiratory illness, although otitis, neonatal sepsis, flaccid paralysis, aseptic meningitis, and encephalitis are described in the literature.

The added screening with a human parechovirus-specific PCR provides a significant increase in determining the viral cause of neonatal sepsis or CNS symptoms in children younger than 5 years. Human parechoviruses are one of the leading causes of viral sepsis and meningitis in young children. HPEV1 is the most prevalent genotype found among stool and nasopharyngeal samples in children (under 2 years old), whereas HPEV6 affects older individuals (> 20 years old). HPEV3 is responsible for encephalitis, neonatal sepsis, and was recently reported in association with necrotizing enterocolitis and hepatitis. It is the most prevalent picornavirus type found in cerebrospinal fluid samples of CNS-related infections in very young children. Respiratory and gastrointestinal illnesses are seen with types HPEV4–HPEV6. Neonatal deaths are reported with HPEV3 and HPEV6. Treatment is largely supportive and rapid identification of the viral antigen by PCR in stools, respiratory samples, and cerebrospinal fluid may decrease use of unnecessary antibiotics and shorten hospital stay, although current PCR assays are not always sufficiently sensitive to exclude parechoviruses. Reported complications of neonatal cerebral infections include learning disabilities, epilepsy, and cerebral palsy.

Chiochansin T et al. Molecular epidemiology, genome characterization, and recombination event of human parechovirus. *Virology.* 2011 Dec 20;421(2):159–66. [PMID: 22018784]

Harvala H et al. Comparison of human parechovirus and enterovirus detection frequencies in cerebrospinal fluid samples collected over a 5-year period in Edinburgh: HPEV type 3 identified as the most common picornavirus type. *J Med Virol.* 2011 May;83(5):889–96. [PMID: 21412796]

Sainato R et al. Severe human parechovirus sepsis beyond the neonatal period. *J Clin Virol.* 2011 May;51(1):73–4. [PMID: 21388870]

RICKETTSIAL DISEASES

TYPHUS GROUP

1. Epidemic Louse-Borne Typhus



ESSENTIALS OF DIAGNOSIS

- ▶ Prodrome of headache, then chills and fever.
- ▶ Severe, intractable headaches, prostration, persisting high fever.
- ▶ Macular rash appearing on the fourth to seventh days on the trunk and in the axillae, spreading to the rest of the body but sparing the face, palms, and soles.
- ▶ Diagnosis confirmed by specific antibodies using complement fixation, microagglutination, or immunofluorescence.

▶ General Considerations

Epidemic louse-borne typhus is caused by *Rickettsia prowazekii*, an obligate parasite of the body louse *Pediculus humanus corporis* (Table 32–3). Transmission is favored by crowded, unsanitary living conditions, famine, war, or any circumstances that predispose to heavy infestation with lice. After biting a person infected with *R. prowazekii*, the louse becomes infected by the organism, which persists in the louse gut and is excreted in its feces. When the same louse bites an uninfected individual, the feces gain entry into the bloodstream when the person scratches the itching wound. Dry, infectious louse feces may also enter via the respiratory tract. Cases can be acquired by travel to pockets of infection (eg, central and northeastern Africa, Central and South America). In the last few years, outbreaks have been reported from Peru, Burundi, and Russia. Because of aerosol transmissibility, *R. prowazekii* is considered a possible bioterrorism agent.

R. prowazekii can survive in lymphoid tissues after primary infection, and years later, produce recrudescence of disease (Brill-Zinsser disease) without exposure to infected lice. This phenomenon can serve as a point source for future outbreaks.

An extrahuman reservoir of *R. prowazekii* in the United States is flying squirrels, *Glaucomys volans*. Transmission to humans can occur through their ectoparasites, usually causing atypical mild disease. A case of recrudescence (Brill-Zinsser) disease 11 years after the initial flying squirrel-associated disease was reported.

Table 32-3. Rickettsial diseases.

Disease	Rickettsial Pathogen	Geographic Areas of Prevalence	Insect Vector	Mammalian Reservoir	Travel Association
Typhus group					
Epidemic (louse-borne) typhus	<i>Rickettsia prowazekii</i>	South America, Northeastern and Central Africa	Louse	Humans, flying squirrels	Rare
Endemic (murine) typhus	<i>Rickettsia typhi</i>	Worldwide; small foci (United States: southeastern gulf coast)	Flea	Rodents, opossums	Often
Scrub typhus group					
Scrub typhus	<i>Orientia tsutsugamushi</i>	Southeast Asia, Japan, Australia, Western Siberia	Mite ¹	Rodents	Often
Spotted fever group					
Rocky Mountain spotted fever	<i>Rickettsia rickettsii</i>	Western Hemisphere; United States (especially mid-Atlantic coast region)	Tick ¹	Rodents, dogs, porcupines	Rare
California flea rickettsiosis	<i>Rickettsia felis</i>	Worldwide	Flea	Cats, opossums	
Mediterranean spotted fever, Boutonneuse fever, Kenya tick typhus, South African tick fever, Indian tick typhus	<i>Rickettsia conorii</i>	Africa, India, Mediterranean regions	Tick ¹	Rodents, dogs	Often
Queensland tick typhus	<i>Rickettsia australis</i>	Eastern Australia	Tick ¹	Rodents, marsupials	Rare
Siberian Asian tick typhus	<i>Rickettsia sibirica</i>	Siberia, Mongolia	Tick ¹	Rodents	Rare
African tick bite fever	<i>Rickettsia africae</i>	Rural sub-Saharan Africa, Eastern Caribbean	Tick ¹	Cattle	Often
Rickettsialpox	<i>Rickettsia akari</i>	United States, Korea, former USSR	Mite ¹	Mice	
Other					
Ehrlichiosis and anaplasmosis, human Monocytic	<i>Ehrlichia chaffeensis</i> , <i>Anaplasma equi</i> , <i>Ehrlichia canis</i>	Southeastern United States	Tick ¹	Dogs	
Granulocytic	<i>Anaplasma phagocytophilum</i> , <i>Ehrlichia ewingii</i>	Northeastern United States	Tick ¹	Rodents, deer, sheep	
Q fever	<i>Coxiella burnetii</i>	Worldwide	None ²	Cattle, sheep, goats	

¹Also serve as arthropod reservoirs by maintaining rickettsiae through transovarian transmission.

²Human infection results from inhalation of dust.

► Clinical Findings

A. Symptoms and Signs

(Table 32-2). Prodromal malaise, cough, headache, backache, arthralgia, and chest pain begin after an incubation period of 10–14 days, followed by an abrupt onset of chills, high fever, and prostration, with flu-like symptoms progressing to delirium and stupor. The headache is severe and the fever is prolonged.

Other findings consist of conjunctivitis, mild vitritis, retinal lesions, optic neuritis, hearing loss from neuropathy of the eighth cranial nerve, flushed facies, rales at the lung bases, abdominal pain, myalgias, and often splenomegaly.

A macular rash (that may become confluent) appears first in the axillae and then over the trunk, spreading to the extremities but rarely involving the face, palms, or soles. In severely ill patients, the rash becomes hemorrhagic, and hypotension becomes marked. There may be acute kidney injury, stupor, seizures, and delirium. Improvement begins 13–16 days after onset with a rapid drop of fever and typically a spontaneous recovery.

B. Laboratory Findings

The white blood cell count is variable. Thrombocytopenia, elevated liver enzymes, proteinuria and hematuria commonly

occur. Serum obtained 5–12 days after onset of symptoms usually shows specific antibodies for *R prowazekii* antigens as demonstrated by complement fixation, microagglutination, or immunofluorescence. In primary rickettsial infection, early antibodies are IgM; in recrudescence (Brill disease), early antibodies are predominantly IgG. A PCR test exists, but its availability is limited. *R prowazekii* is differentiated into 7 genotypes.

C. Imaging

Radiographs of the chest may show patchy consolidation.

► Differential Diagnosis

The prodromal symptoms and the early febrile stage lack enough specificity to permit diagnosis in nonepidemic situations. The rash is sufficiently distinctive for diagnosis, but it may be absent in up to 50% of cases or may be difficult to observe in dark-skinned persons. A variety of other acute febrile diseases should be considered, including typhoid fever, meningococcemia, and measles.

► Complications

Pneumonia, thromboses, vasculitis with major vessel obstruction and gangrene, circulatory collapse, myocarditis, and uremia may occur.

► Treatment

Treatment consists of either doxycycline (100 mg orally twice daily) or chloramphenicol (50–100 mg/kg/d in four divided doses, orally or intravenously) for 4–10 days. Chloramphenicol is considered less effective than doxycycline, but it is still the drug of choice in pregnancy. In epidemic conditions, a single dose of doxycycline can be effective and is less costly.

► Prognosis

The prognosis depends greatly on the patient's age and immune status. In children under age 10 years, the disease is usually mild. The mortality rate is 10% in the second and third decades but in the past reached 60% in the sixth decade. Brill-Zinsser disease (recrudescence epidemic typhus) has a more gradual onset than primary *R prowazekii* infection, fever and rash are of shorter duration, and the disease is milder and rarely fatal.

► Prevention

Prevention consists of louse control with insecticides, particularly by applying chemicals to clothing or treating it with heat, and frequent bathing. The control of typhus in Finland during World War II is attributed to sauna use.

A deloused and bathed typhus patient is not infectious. The disease is not transmitted from person to person. Patients are infectious for the lice during the febrile period and perhaps 2–3 days after the fever returns to normal. Infected lice pass rickettsiae in their feces within 2–6 days after the blood meal and can be infectious earlier if

crushed. Rickettsiae remain viable in a dead louse for weeks.

No vaccine is currently available for the prevention of *R prowazekii* infection. Past vaccines with crude antigen or inactivated *Rickettsia* provided partial protection but were associated with undesirable toxic reactions and difficulties in standardization. Efforts to identify candidate antigens through DNA technology are underway.

Gross D et al. 100th anniversary of the death of Ricketts: Howard Taylor Ricketts (1871–1910). The namesake of the Rickettsiaceae family. *Microbes Infect.* 2011 Jan;13(1):10–3. [PMID: 20888424]

McQuiston JH et al. Brill-Zinsser disease in a patient following infection with sylvatic epidemic typhus associated with flying squirrels. *Clin Infect Dis.* 2010 Sep 15;51(6):712–5. [PMID: 20687836]

Renvoisé A et al. Widespread use of real-time PCR for rickettsial diagnosis. *FEMS Immunol Med Microbiol.* 2012 Feb;64(1):126–9. [PMID: 22092999]

2. Endemic Flea-Borne Typhus (Murine Typhus)

Rickettsia typhi, a ubiquitous pathogen recognized on all continents, is transmitted from rat to rat through the rat flea (Table 32–3). Serosurveys of animals show high prevalence of antibodies to *R typhi* in opossums, followed by dogs and cats. Humans usually acquire the infection in an urban or suburban setting when bitten by an infected flea, which releases infected feces while sucking blood. Rare human cases in the developed world follow travel, usually to Southeast Asia and the Mediterranean area. In the United States cases are mainly reported from Texas and Southern California. Seroprevalence studies show antibody rates to *R typhi* of 10% among the homeless in Houston and up to 22% in Marseilles, France.

Endemic typhus resembles recrudescence epidemic typhus in that it has a gradual onset, less severe symptoms, and a shorter duration of illness than epidemic typhus (7–10 days versus 14–21 days). The presentation is nonspecific, including fever, headache, and chills. Maculopapular rash occurs in around 50% of cases; it is concentrated on the trunk and fades fairly rapidly. Peripheral facial paralysis and splenic infarction are reported to occur. Severe disease with mental confusion and signs of hepatic, cardiac, renal, and pulmonary involvement may develop. Postinfectious optic neuritis is rare and may occur weeks after successful treatment. Fatalities are uncommon but occur especially in the elderly. Jaundice, bradycardia, and the absence of a headache are correlated with a delayed defervescence (in both epidemic and endemic typhus).

The most common entity in the differential diagnosis is Rocky Mountain spotted fever, usually occurring after a rural exposure and with a different rash (centripetal versus centrifugal for epidemic or endemic typhus). Serologic confirmation may be necessary for differentiation, with complement-fixing or immunofluorescent antibodies detectable within 15 days after onset, with specific *R typhi* antigens. A fourfold rise in serum antibody titers between the acute and the convalescence phase is diagnostic.

Antibiotic treatment is the same as for epidemic typhus (see above). Ciprofloxacin (500–750 mg orally twice a day) and ampicillin (500 mg orally three times a day) are reportedly successful in pregnant women. Mortality is usually low with (1%) or without (4%) appropriate antibiotics. Preventive measures are directed at control of rats and ectoparasites (rat fleas) with insecticides, rat poisons, and rat-proofing of buildings.

Abramowicz KF et al. Urban focus of *Rickettsia typhi* and *Rickettsia felis* in Los Angeles, California. *Vector Borne Zoonotic Dis.* 2011 Jul;11(7):979–84. [PMID: 21142968]

Badiaga S et al. Murine typhus in the homeless. *Comp Immunol Microbiol Infect Dis.* 2012 Jan;35(1):39–43. [PMID: 22093517]

Botelho-Nevers E et al. Host, pathogen and treatment-related prognostic factors in rickettsioses. *Eur J Clin Microbiol Infect Dis.* 2011 Oct;30(10):1139–50. [PMID: 21519943]

Zhang J et al. Postinfectious optic neuropathy in endemic typhus. *J Neuroophthalmol.* 2011 Dec;31(4):342–3. [PMID: 21897295]

3. Scrub Typhus (Tsutsugamushi Fever)



ESSENTIALS OF DIAGNOSIS

- ▶ Exposure to mites in endemic area of Southeast Asia, the western Pacific (including Korea), and Australia.
- ▶ Black eschar at site of the bite, with regional and generalized lymphadenopathy.
- ▶ High fever, headache, myalgia, and a short-lived macular rash.
- ▶ Frequent pneumonitis, encephalitis, and cardiac failure.

▶ General Considerations

Scrub typhus is caused by *Orientia tsutsugamushi*, which is principally a parasite of rodents and is transmitted by larval trombiculid mites (chiggers). The disease is endemic in Korea, China, Taiwan, Japan, Pakistan, India, Thailand, Malaysia and Queensland, Australia (Table 32–3), which form an area known as the “tsutsugamushi triangle”. Transmission is often more common at higher altitudes. The mites live on vegetation but complete their maturation cycle by biting humans who come in contact with infested vegetation. Therefore, the disease is more common in rural areas within these countries. Vertical transmission occurs, and blood transfusions may transmit the pathogen as well. Rare occupational transmission via inhalation is documented among laboratory workers.

▶ Clinical Findings

A. Symptoms and Signs

After a 1- to 3-week incubation period, malaise, chills, severe headache and backache develop. At the site of the

bite, a papule evolves into a flat black eschar, a finding which is usually helpful for diagnosis. The regional lymph nodes are commonly enlarged and tender, and sometimes a more generalized adenopathy occurs. Fever rises gradually and after 1 week, a macular rash appears primarily on the trunk area. This rash can be fleeting or last up to 1 week. The patient may become obtunded. Gastrointestinal symptoms including nausea, vomiting, and diarrhea occur in nearly two-thirds of patients and correspond to the presence of superficial mucosal hemorrhage, multiple erosions, or ulcers in the gastrointestinal tract. Both acalculous cholecystitis and acute abdominal attacks are reported. Severe complications, such as pneumonitis, myocarditis and cardiac failure, encephalitis or meningitis, acute abdominal pain, granulomatous hepatitis, disseminated intravascular coagulation, ARDS, hemophagocytosis, or acute kidney disease may develop during the second or third week. An attack confers prolonged immunity against homologous strains and transient immunity against heterologous strains. Heterologous strains produce mild disease if infection occurs within a year after the first episode.

B. Laboratory Findings

Thrombocytopenia and elevation of liver enzymes, bilirubin, and creatinine are common. Serologic testing with immunofluorescence and immunoperoxidase assays or commercial dot-blot ELISA dipstick assays are convenient diagnostic aids, but a conclusive diagnosis requires documentation of a fourfold increase between acute and convalescence titers of antibodies. An **indirect immunofluorescent assay** is the mainstay of serologic diagnosis. PCR (from the eschar or blood) may be the most sensitive diagnostic test but remains positive even after the initiation of treatment. Culture of the organism (by mouse inoculation) from blood obtained in the first few days of illness is another diagnostic modality but requires a specialized BioSafety Level 3 laboratory. Filter paper immunofluorescent assays are under development, and are as sensitive and specific as paired sera, and may be especially useful in field settings.

▶ Differential Diagnosis

Leptospirosis, typhoid, dengue, malaria, Q fever, hemorrhagic fevers, and other rickettsial infections should be considered. The headache may mimic trigeminal neuralgia. Scrub typhus is a recognized cause of obscure tropical fevers, especially in children.

▶ Treatment & Prognosis

Without treatment, fever subsides spontaneously after 2 weeks, but the mortality rate may be 10–30%. Empiric treatment for 3 days with doxycycline, 100 mg orally twice daily, or with minocycline, 100 mg intravenously twice daily, or for 7 days with chloramphenicol, 25 mg/kg/d orally or intravenously in four divided doses, eliminates most deaths and relapses. Chloramphenicol- and tetracycline-resistant strains have been reported from Southeast Asia, where azithromycin or roxythromycin may become the drug of

choice for children, pregnant women, and patients with refractory disease. Rifampin reduces the duration of fever by 1 day when used with doxycycline.

Poor prognostic factors include requiring care in an ICU, high APACHE-II scores, age over 60 years, absence of an eschar (making the diagnosis difficult) and laboratory findings such as leukocytosis or hypoalbuminemia. HIV infection does not appear to influence the severity of scrub typhus.

► Prevention

Repeated application of long-acting miticides can make endemic areas safe. Insect repellents on clothing and skin as well as protective clothing are effective preventive measures. For short exposure, chemoprophylaxis with doxycycline (200 mg weekly) can prevent the disease but permits infection. No effective vaccines are available.

Jayakrishnan MP et al. Rickettsial infection with hemophagocytosis. *Trop Doct.* 2011 Apr;41(2):111–2. [PMID: 21149571]
 Rajapakse S et al. Drug treatment of scrub typhus. *Trop Doct.* 2011 Jan;41(1):1–4. [PMID: 21172901]
 Shiao CC et al. Eschar: a clue to scrub typhus. *CMAJ.* 2011 Oct 18;183(15):E1152. [PMID: 21911554]

SPOTTED FEVERS

1. Rocky Mountain Spotted Fever



ESSENTIALS OF DIAGNOSIS

- Exposure to tick bite in an endemic area.
- An influenza-like prodrome followed by chills, fever, severe headache, and myalgias; occasionally, delirium and coma.
- Red macular rash appears between the second and sixth days of fever, first on the wrists and ankles and then spreading centrally; it may become petechial.
- Serial serologic examinations by indirect fluorescent antibody confirm the diagnosis retrospectively.

► General Considerations

Despite its name, most cases of Rocky Mountain spotted fever (RMSF) occur outside the Rocky Mountain area. Passive surveillance data from 2002 to 2007 reported cases from 46 states and the District of Columbia. More than half (64%) of these cases were from only five states: North Carolina, Tennessee, Oklahoma, Missouri, and Arkansas. RMSF is endemic in Central and Southern America, with well-documented cases in Mexico, Costa Rica, Panama, Colombia, Brazil, and Argentina. The causative agent, *Rickettsia*, is transmitted to humans by the bite of ticks, including the Rocky Mountain wood tick, *D. andersoni*, in the western United States, and the American dog tick, *Dermacentor variabilis*, in the eastern United States.

Several hours of contact between the tick and the human host are required for transmission. The brown dog tick, *Rhipicephalus sanguineus*, is a vector in eastern Arizona. Other hard ticks transmit the organism in the southern United States and in Central and South America and are responsible for transmitting it among rodents, dogs, porcupines, and other animals. There are 25 genotypes of *R. rickettsii* in four different groups, and potential genomic-clinical correlations are underway.

In the United States, the estimated annual incidence of RMSF is increasing to as high as seven cases per million persons (primarily occurring from April through September), with a higher incidence among children and men. Better diagnostic capacity and improved surveillance are thought responsible for the changing epidemiology.

► Clinical Findings

A. Symptoms and Signs

RMSF can cause severe multiorgan dysfunction and fatality rates of up to 73% if left untreated, making it the most serious rickettsial disease. Two to 14 days (mean, 7 days) after the bite of an infectious tick, symptoms begin with the abrupt onset of high fevers, chills, headache, nausea and vomiting, myalgias, restlessness, insomnia, and irritability. The characteristic rash (faint macules that progress to maculopapules and then petechiae) appears between days 2 and 6 of fever. It initially involves the wrists and ankles, spreading centrally to the arms, legs, and trunk over the next 2–3 days. Involvement of the palms and soles is characteristic. Facial flushing, conjunctival injection, and hard palatal lesions (Figure 32–6) may occur. In about 10% of cases, however, no rash or only a minimal rash is seen. Cough and pneumonitis may develop and delirium, lethargy, seizures, stupor, and coma may also appear in more severe cases. Splenomegaly, hepatomegaly, jaundice, myocarditis (which may mimic an acute coronary syndrome), adrenal hemorrhage, or uremia are occasionally present.



▲ **Figure 32–6.** Hard palate lesion caused by Rocky Mountain spotted fever. (Public Health Image Library, CDC.)

ARDS and necrotizing vasculitis, when present, are of greatest concern.

B. Laboratory Findings

Thrombocytopenia, hyponatremia, elevated aminotransferases, and hyperbilirubinemia are common. Cerebrospinal fluid may show hypoglycorrhachia and mild pleocytosis. Disseminated intravascular coagulation is observed in severe cases. Diagnosis during the acute phase of the illness can be made by immunohistologic (including PCR) demonstration of *R. rickettsiae* in skin biopsy specimens (or cutaneous swabs of eschars or skin lesions), but this must be performed as soon as skin lesions become apparent and before antibiotics are started to achieve maximum sensitivity. Isolation of the organism using the shell-vial technique is available in some laboratories but is hazardous.

Serologic studies confirm the diagnosis, but most patients do not mount an antibody response until the second week of illness. The indirect fluorescent antibody test is most commonly used. No commercial PCR technique is validated for serologic use.

► Differential Diagnosis

The diagnosis is challenging because early symptoms resemble those of many other infections. The classic triad of fever, rash, and tick bite is rarely recognized, with up to 40% of patients not recalling a tick bite. Moreover, the rash may be confused with that of measles, typhoid, and ehrlichiosis, or—most importantly—meningococemia. Blood cultures and examination of cerebrospinal fluid establish the latter. Some spotted fever rickettsioses may also mimic RMSF.

► Treatment & Prognosis

Treatment with doxycycline at similar doses and duration as for epidemic typhus (see above) is recommended. Similarly, chloramphenicol is the preferred alternative during pregnancy. Patients usually defervesce within 48–72 hours and therapy should be maintained for at least 3 days after defervescence occurs. Mild cases in low-risk individuals may be observed without treatment.

The reported mortality rate in the United States is about 3–5%, but it can be as high as 70% in the untreated elderly. Infection in very young children, the presence of atypical clinical features (absence of headache, no history of tick attachment, gastrointestinal symptoms) and underlying chronic diseases, as well as a delay in initiation of appropriate antibiotic therapy are also associated with increased mortality. The usual cause of death is pneumonitis with respiratory or cardiac failure. A fulminant form of RMSF can be seen in patients with glucose-6-phosphate dehydrogenase deficiency. Sequelae, more common than formerly recognized, may include seizures, encephalopathy, peripheral neuropathy, paraparesis, bowel and bladder incontinence, cerebellar and vestibular dysfunction, hearing loss, and motor deficits. These neurologic complications are more common in those patients who require hospitalization for more than 2 weeks.

► Prevention

Protective clothing, tick-repellent chemicals, and the removal of ticks at frequent intervals are helpful measures. Prophylactic therapy after a tick bite is not currently recommended.

- Bechah Y et al. Identification of rickettsial infections by using cutaneous swab specimens and PCR. *Emerg Infect Dis.* 2011 Jan;17(1):83–6. [PMID: 21192860]
- Moncayo AC et al. Absence of *Rickettsia rickettsii* and occurrence of other spotted fever group rickettsiae in ticks from Tennessee. *Am J Trop Med Hyg.* 2010 Sep;83(3):653–7. [PMID: 20810834]
- Oppensaw JJ et al. Rocky Mountain spotted fever in the United States, 2000–2007: interpreting contemporary increase in incidence. *Am J Trop Med Hyg.* 2010 Jul;83(1):174–82. [PMID: 20595498]

2. Rickettsialpox

Rickettsialpox is an acute, self-limiting, febrile illness caused by *Rickettsia akari*, a parasite of mice, transmitted by the mite *Liponyssoides sanguineus* (Table 32–3). Infections are reported globally. Seroprevalence studies done on injection drug users in inner Baltimore showed antibody positivity as high as 16%. Crowded conditions and mouse-infested housing allow transmission of the pathogen to humans. The primary lesion is a painless red papule that vesiculates and forms a black eschar followed by an incubation period of 7–12 days. Onset of symptoms is sudden, with chills, fever, headache, photophobia, and disseminated aches and pains. Two to 4 days later, a widespread papular eruption appears. The rash becomes vesicular and forms crusts that are shed in about 10 days. Early lesions may resemble those of chickenpox (typically vesicular versus papulovesicular in rickettsialpox). Pathologic findings include dermal edema, subepidermal vesicles, and at times a lymphocytic vasculitis.

Transient leukopenia and thrombocytopenia and acute hepatitis can occur. A fourfold rise in serum antibody titers to rickettsial antigen, detected by complement fixation or indirect fluorescent assays, is diagnostic. Conjugated anti-rickettsial globulin can identify antigen in punch biopsies of skin lesions. PCR detection of rickettsial DNA in fresh tissue also appears of value. *R. akari* can reportedly also be isolated from eschar biopsy specimens.

Treatment consists of oral doxycycline (200 mg/d) for 7 days. The disease is usually mild and self-limited without treatment, but occasionally severe symptoms may require hospitalization. Control requires the elimination of mice from human habitations and insecticide applications.

- Bennett SG et al. Serologic evidence of a *Rickettsia akari*-like infection among wild-caught rodents in Orange County and humans in Los Angeles County, California. *J Vector Ecol.* 2007 Dec;32(2):198–201. [PMID: 18260508]
- Brouqui P. Arthropod-borne diseases associated with political and social disorder. *Annu Rev Entomol.* 2011;56:357–74. [PMID: 20822446]

3. Tick Typhus (Rickettsial Fever)

The term “tick typhus” denotes a variety of spotted rickettsial fevers, often named by their geographic location (eg, Mediterranean spotted fever, Queensland tick typhus, Oriental spotted fever, African tick bite fever, Siberian tick typhus, North Asian tick typhus), or by morphology (eg, boutonneuse fever). These illnesses are transmitted by tick vectors of the rickettsial organisms *R africae*, *R australis*, *R conorii*, *R japonica*, *R massiliae*, *R parkeri*, and *R sibirica* (Table 32–3). Dogs and wild animals, usually rodents and even reptiles, may serve as reservoirs. Travel is a risk factor for disease, particularly among elderly ecotourists. In a series of 280 international travelers with rickettsial disease, the most common cause was spotted fever rickettsiosis (231 cases, 82.5% of the total) followed by scrub typhus (16, 5.7%). The pathogens usually produce an eschar or black spot (tâche noire) at the site of the tick bite that may be useful in diagnosis, though spotless boutonneuse fever occurs. Symptoms include fever, headache, myalgias, and rash. Rarely, papulovesicular lesions may resemble rickettsialpox. Endothelial injury produces perivascular edema and dermal necrosis. Regional adenopathy, disseminated lesions, kidney disease, splenic rupture, and focal hepatic necrosis may occur. Neurologic manifestations, including encephalitis, internuclear ophthalmoplegia, coronary involvement, and the hemophagocytic syndrome, are rare. Diabetes, dehydration, and uremia were associated with mortality in one series.

The diagnosis is clinical, with serologic or PCR used for confirmation, and treatment should be started upon clinical suspicion since delayed therapy is the usual cause of increased morbidity. Oral treatment with doxycycline (200 mg/d), chloramphenicol (50–75 mg/kg/d in four divided doses), or ciprofloxacin (500 mg twice daily) for 7–10 days is indicated. Ciprofloxacin is associated with a poor outcome and increases the severity of disease in Mediterranean spotted fever, so the other listed agents are preferred. The combination of erythromycin and rifampin is effective and safe in pregnancy. In one reported case, *R africae* infection was successfully treated with pristinamycin, a streptogramin marketed in Europe. Prevention entails protective clothing, repellents, and inspection for and removal of ticks.

Formerly classified as an endemic or murine typhus, the cat-flea typhus, caused by *Rickettsia felis* is now more properly classified as a spotted fever. The causative agent has been linked to the cat flea and opossum exposure. Most cases in the United States (southern Texas and California, and possibly Hawaii) occur in the spring and summer. Treatment is the same as for other rickettsial fevers.

A rickettsial infection recognized as a cause of eschar-associated illness was recognized in northern California and is referred to as the spotted fever group rickettsia 364D.

Botelho-Nevers E et al. Analysis of risk factors for malignant Mediterranean spotted fever indicates that fluoroquinolone treatment has a deleterious effect. *J Antimicrob Chemother.* 2011 Aug;66(8):1821–30. [PMID: 21642652]

Cascio A et al. Coronary involvement in Mediterranean spotted fever. *New Microbiol.* 2011 Oct;34(4):421–4. [PMID: 22143818]

Shapiro MR et al. Rickettsia 364D: a newly recognized cause of eschar-associated illness in California. *Clin Infect Dis.* 2010 Feb 15;50(4):541–8. [PMID: 20073993]

OTHER RICKETTSIAL & RICKETTSIAL-LIKE DISEASES

1. Ehrlichiosis & Anaplasmosis

ESSENTIALS OF DIAGNOSIS

- ▶ Infection of monocyte or granulocyte by tick-borne gram-negative bacteria.
- ▶ Nine-day incubation period, with variable clinical illness, ranging from asymptomatic to persistent or life-threatening.
- ▶ Common symptoms are malaise, nausea, fever, and headaches.
- ▶ US cases are largely in elderly white men in the summer.
- ▶ Excellent response to therapy with tetracyclines.

▶ General Considerations

Ehrlichiae and anaplasmae are small tick-borne gram-negative obligate intracellular bacteria that infect monocytes or granulocytes. Human monocytic ehrlichiosis is caused by *Ehrlichia chaffeensis* (Table 32–3). Human granulocytic anaplasmosis is caused by *Anaplasma phagocytophilum*. *Ehrlichia ewingii* (infecting primarily dogs) can rarely cause human granulocytic ehrlichiosis similar to human granulocytic anaplasmosis. A third *Ehrlichia* species that infects humans appears to be related to *Ehrlichia muris*. An *Ehrlichia*-like organism, *Neorickettsia sennetsu*, is the etiologic agent of sennetsu fever, which is confined to western Japan.

Human monocytic ehrlichiosis is seen primarily in the South Central states (especially Arkansas, Missouri, and Oklahoma) of the United States, although cases are also recognized in Israel, Japan, Mexico, South America, and Europe. Human granulocytic anaplasmosis is more frequent in the upper Midwestern United States; but infections in Europe and China are also well documented. Human infection with *E ewingii* is limited to Missouri, Oklahoma, and Tennessee and occurs mainly among the immunocompromised. In North America, the major vectors for these pathogens are the Lone Star tick (*Amblyomma americanus* for *E chaffeensis* and *E ewingii*), the western black-legged tick (*Ixodes pacificus*, for *E chaffeensis*), and *Ixodes scapularis* (the same vector for Lyme disease) and babesiosis for *A phagocytophilum*). Reported incidences of both human monocytic and granulocytic ehrlichiosis are increasing and both are now at about 3 per million, respectively, with higher rates in the summer among whites and among men.

The principal reservoirs for human monocytic ehrlichiosis and human granulocytic anaplasmosis are the

white tail deer and the white footed mouse, respectively. Other mammals are implicated as well. A nosocomial outbreak was reported from China. Perinatal transmission of human granulocytic anaplasmosis is also documented.

► Clinical Findings

A. Symptoms and Signs

Clinical disease of human monocytic ehrlichiosis ranges from mild to life threatening. Typically, after about a 9-day incubation period and a prodrome consisting of malaise, rigors, and nausea, worsening fever and headache develop. A pleomorphic rash may occur. Presentation in immunosuppressed patients (including transplant patients) and the elderly tends to be more severe. Serious sequelae include acute respiratory failure and ARDS, encephalopathy, and acute kidney disease, which may mimic thrombotic thrombocytopenic purpura.

The symptoms of human granulocytic ehrlichiosis and *E. ewingii* infection are similar to those seen with human monocytic ehrlichiosis. Rash, however, is infrequent in human granulocytic ehrlichiosis and should prompt the consideration of other infections (eg, Lyme disease). Persistent fever and malaise are reported to occur for 2 or more years. Coinfection with Lyme disease or babesiosis may occur.

B. Laboratory Findings

Diagnosis can be made by the history of tick exposure followed by a characteristic clinical presentation. Leukopenia, absolute lymphopenia, thrombocytopenia, and transaminitis occur often. Thrombocytopenia occurs more often than leukopenia in human granulocytic ehrlichiosis. Examination of peripheral blood with Giemsa stain may reveal characteristic intraleukocytic vacuoles (morulae). An indirect fluorescent antibody assay is available through the CDC and requires acute and convalescent sera. A PCR assay, if available, is a rapid diagnostic tool, especially for early disease.

► Treatment & Prevention

Treatment for all forms of ehrlichiosis is with doxycycline, 100 mg twice daily (orally or intravenously) for at least 10 days or until 3 days of defervescence. Rifampin is an alternative in pregnant women and children. Treatment should not be withheld while awaiting confirmatory serology when suspicion is high. Lack of clinical improvement and defervescence 48 hours after doxycycline initiation suggests an alternate diagnosis. Tick control is the essence of prevention.

Dahlgren FS et al. Increasing incidence of *Ehrlichia chaffeensis* and *Anaplasma phagocytophilum* in the United States, 2000–2007. *Am J Trop Med Hyg*. 2011 Jul;85(1):124–31. [PMID: 21734137]

Ismail N et al. Human ehrlichiosis and anaplasmosis. *Clin Lab Med*. 2010 Mar;30(1):261–92. [PMID: 20513551]

Pritt BS et al. Emergence of a new pathogenic Ehrlichia species, Wisconsin and Minnesota, 2009. *N Engl J Med*. 2011 Aug 4;365(5):422–9. [PMID: 21812671]

2. Q Fever

ESSENTIALS OF DIAGNOSIS

- Exposure to sheep, goats, cattle, or their products; some infections are laboratory acquired.
- An acute or chronic febrile illness with severe headache, cough, prostration, and abdominal pain.
- Extensive pneumonitis, hepatitis, or encephalopathy; less often, endocarditis, vascular infections, or chronic fatigue syndrome.
- A common cause of culture-negative endocarditis.

► General Considerations

Q fever (for “query” in view of its formerly unknown cause), a reportable disease in the United States, is caused by *Coxiella burnetii*, an organism previously classified as a rickettsia but now considered a proteobacteria. Unlike rickettsiae, *C. burnetii* is usually transmitted to humans not by arthropods but by inhalation or ingestion. *Coxiella* infections occur globally, mostly in cattle, sheep, and goats, in which they cause mild or subclinical disease (Table 32–3). In these animals, reactivation of the infection occurs during pregnancy and causes abortions or low birth weight offspring. *Coxiella* is resistant to heat and drying and remains infective in the environment for months.

Humans become infected by inhalation of aerosolized bacteria (in dust or droplets) from feces, urine, milk, or products of conception of infected animals. Ingestion and skin penetration are other recognized routes of transmission. Outbreaks associated with other mammals such as cats and dogs are also described. A major outbreak in Netherlands that began in 2007 was thought to be due to exposure to aborting ruminants. There is a known occupational risk for animal handlers, slaughterhouse workers, veterinarians, laboratory workers, and other workers exposed to animal products. Outbreaks in military personnel returning from Iraq and Afghanistan were described. Transmission through aerosols is possible in that *Coxiella* can be pathogens of other organisms (free living amoebae) which are transmitted through air ducts.

Endocarditis, an uncommon but serious form of *Coxiella* infection, is linked to preexisting valvular conditions, immunocompromised states, urban residence, and raw milk ingestion. Horizontal spread from one human to another does not seem to occur even in the presence of florid pneumonitis, but maternal–fetal infection can occur.

► Clinical Findings

A. Symptoms and Signs

Asymptomatic infection is common. For the remaining cases, a febrile illness develops after an incubation period of 1–3 weeks, usually accompanied by headache, relative bradycardia, prostration, and muscle pains. The clinical course may be acute, chronic (duration ≥ 6 months), or

relapsing. Pneumonia and granulomatous hepatitis are the predominant manifestation in the acute form, whereas other less common manifestations include skin rashes (maculopapular or purpuric), fever of unknown origin, myocarditis, pericarditis, aseptic meningitis, encephalitis, hemolytic anemia, orchitis, acute kidney disease, spondylo-discitis, tenosynovitis, and regional (mediastinal) or diffuse lymphadenopathies. Cases of Q fever mimicking autoimmune and systemic inflammatory disease are reported. The most common presentation of chronic Q fever is culture-negative endocarditis, which occurs in < 1% of infected individuals. It is found mainly in the setting of preexisting valve disease. Vascular infections, particularly of the aorta (causing mycotic aneurysms), are the second most common form of Q fever and are associated with a high mortality (25%). Q fever chronic fatigue syndrome is thought by some experts to involve bacteremic shedding from bone marrow reservoirs and to be immunogenetically determined.

Reactivation of Q fever in pregnant women may cause spontaneous abortions, intrauterine growth retardation, intrauterine fetal death, premature delivery, and oligamnios.

B. Laboratory Findings

Laboratory examination during the acute phase may show elevated liver function tests and occasional leukocytosis. Patients with acute Q fever usually produce antibodies to *C burnetii* phase II antigen. A fourfold rise between acute and convalescent sera by indirect immunofluorescence is diagnostic. Realtime PCR for *C burnetii* DNA is helpful only in early diagnosis of Q fever with *C burnetii* DNA becoming undetectable in serum as serologic responses develop.

While chronic Q fever can be diagnosed on the basis of serologic tests done at 3- and 6-month intervals (with an IgG titer against phase I antigen of 1:1600 or greater), it is now recommended that clinical criteria be used for diagnosis of chronic disease. Diagnosis may be made at the time of valve replacement with PCR of tissue samples. *C burnetii* may also be isolated from affected valves using the shell-vial technique. The organism is highly transmissible to laboratory workers and culture techniques require a biosafety level 3 setting.

C. Imaging

Radiographs of the chest show patchy pulmonary infiltrates, often more prominent than the physical signs suggest.

► Differential Diagnosis

Viral, mycoplasmal, and bacterial pneumonias, viral hepatitis, brucellosis, Legionnaire disease, Kawasaki disease, tuberculosis, psittacosis, and other animal-borne diseases must be considered. Q fever should be considered in cases of unexplained fevers with negative blood cultures in association with embolic or cardiac disease.

► Treatment & Prognosis

For acute infection, treatment with doxycycline (100 mg orally twice daily) for 14 days or at least 3 full days after

defervescence is recommended. Even in untreated patients, the mortality rate is usually low, except when endocarditis develops.

For chronic infection, there is no agreement on the type and duration of antimicrobial therapy. Most experts recommend a combination oral therapy with doxycycline (100 mg twice a day) plus ciprofloxacin (typically 750 mg twice a day) or rifampin (300 mg twice a day) or hydroxychloroquine (200 mg three times a day) for approximately 2 years or more for the treatment of endocarditis. A study reported in 1999 of 35 patients with Q fever endocarditis showed favorable outcomes with oral doxycycline (100 mg twice a day) plus oral hydroxychloroquine (200 mg three times a day) for 18 months for native valves and 24 months for prosthetic valves. Serologic responses can be monitored during and after completion of therapy and treatment extended in the absence of favorable serologic response (considered a titer of 1:1600 or greater to phase I antigen). The general variability of serologic data, however, limits their usefulness and providers usually rely on clinical criteria. Patients should be monitored for at least 5 years due to risk of relapse. Heart valve replacement may be necessary in refractory disease. Given the difficulty in treating endocarditis, transthoracic echocardiography is recommended for all patients with acute Q fever, and the same aforementioned therapy for 1 year should be offered in the presence of valvulopathy.

Because of the many and serious obstetric complications that occur among pregnant women in whom Q fever develops (listed above), a regimen of long-term trimethoprim-sulfamethoxazole (320/1600 mg orally for at least 5 weeks) should be given to all infected, pregnant women.

► Prevention

Prevention is based on detection of the infection in livestock, reduction of contact with infected and, in particular, parturient animals or contaminated dust, special care when working with animal tissues, and effective pasteurization of milk. No vaccine is approved for use in the United States, although a whole-cell Q fever vaccine, with a 5-year efficacy of > 95%, is available in Australia for persons with high-risk exposures.

C burnetii is a category B bioterrorism agent. In the setting of a bioterrorist attack, postexposure prophylaxis with doxycycline (100 mg orally twice daily) for 5 days should be started 8–12 days after exposure. Pregnant women should take trimethoprim-sulfamethoxazole (160 mg/800 mg orally twice daily) for the duration of the pregnancy.

Million M et al. Long-term outcome of Q fever endocarditis: a 26-year personal survey. *Lancet Infect Dis.* 2010 Aug; 10(8):527–35. [PMID: 20637694]

Raoult D. Q fever, free amoeba, and air conditioning. *Clin Infect Dis.* 2010 Oct 1;51(7):869–70. [PMID: 20809841]

van der Hoek W et al. Follow-up of 686 patients with acute Q fever and detection of chronic infection. *Clin Infect Dis.* 2011 Jun 15;52(12):1431–6. [PMID: 21628483]

KAWASAKI DISEASE

ESSENTIALS OF DIAGNOSIS

- ▶ Fever, conjunctivitis, oral mucosal changes, rash, cervical lymphadenopathy, peripheral extremity changes.
- ▶ Elevated erythrocyte sedimentation rate and C-reactive protein levels.

▶ General Considerations

Kawasaki disease is a worldwide multisystemic disease initially described by Tomisaku Kawasaki in 1967. It is also known as the “mucocutaneous lymph node syndrome.” It occurs mainly in children between the ages of 3 months and 5 years but can occur occasionally in adults as well. Kawasaki disease occurs significantly more often in Asians or native Pacific Islanders than in whites. It is an acute, self-limiting, mucocutaneous vasculitis characterized by the infiltration of vessel walls with mononuclear cells and later by IgA secreting plasma cells that can result in the destruction of the tunica media and aneurysm formation. Several infectious agents (New Haven coronavirus, parvovirus, bocavirus, CMV, *Yersinia pseudotuberculosis*, meningococcus), bacterial superantigens, and genetic polymorphisms (confirmed in whole genome analysis) in components of the immune system (interleukin 10 and 18) are currently implicated in its pathogenesis.

▶ Clinical Findings

A clinical diagnosis of “complete” Kawasaki disease requires, in the absence of other processes, explaining the current illness of fever and four of the following criteria for at least 5 days: bilateral nonexudative conjunctivitis, mucous membrane changes of at least one type (injected pharynx, erythema, swelling and fissuring of the lips, strawberry tongue), peripheral extremity changes of at least one type (edema, desquamation, erythema of the palms and soles, induration of the hands and feet, Beau lines [transverse grooves of the nails]), a polymorphous rash, and cervical lymphadenopathy > 1.5 cm. An “incomplete” form is diagnosed when only two criteria are met. The classic syndrome is often preceded by nonspecific symptoms including irritability, vomiting, anorexia, cough, and diarrhea for up to 10 days.

Major complications include arteritis and aneurysms of the coronary vessels, occurring in about 25% of untreated patients, on occasion causing myocardial infarction. The pathogenesis of infarction is often thrombus formation, vasospasm, stenosis, or aneurysm rupture. Coronary complications are more common among patients older than 6 years or younger than 1 year of age. Noninvasive diagnosis of coronary complications can be made with magnetic resonance angiography or transthoracic echocardiography. Other factors associated with the development of coronary artery aneurysms are male sex, relentless fever (even after the

administration of IVIG), high C-reactive protein, urticarial exanthems, anemia, hypoalbuminemia, hyponatremia, and thrombocytopenia. Pericardial effusions, myocarditis, and mitral regurgitation (usually mild) are also common. Coronary artery fistulas occur in up to 5% of patients and diastolic dysfunction is also reported. Arteritis of extremity vessels, peripheral gangrene, syndrome of inappropriate secretion of antidiuretic hormone (SIADH), and the hemophagocytic syndrome are also reported. Cases of pancreatitis and bile duct stenosis due to underlying vasculitis are reported. Cerebrospinal fluid pleocytosis is found in one-third of cases and encephalitis is rarely reported. Other CNS complications include seizures, oculomotor palsies, and sensorineural hearing loss which, when sought, can be found in as many as 55% of cases. Rare case reports of atypical presentations (eg, retropharyngeal abscess) are described.

Differentiation from disseminated adenovirus infection is important and can be performed with rapid adenovirus assays.

▶ Treatment & Prevention

Every patient with a clinical diagnosis of Kawasaki disease (complete or incomplete) should be treated. IVIG (2 g/kg over 10–12 hours) is given within the first 10 days of illness. For those presenting later, but with persistent fever, ongoing systemic inflammation, or aneurysm formation, IVIG should be offered as well. Concomitant aspirin should be started at 80–100 mg/kg/d orally (divided into four doses and not exceeding 4 g/d) until the patient is afebrile for 48 hours and then reduced to 3–5 mg/kg/d until markers of acute inflammation normalize. Aspirin therapy is continued if coronary aneurysm develops. If fevers persist beyond 36 hours after the initial IVIG infusion, a second dose of IVIG at 2 g/kg should be given if no other source of fever is found. Rare cases of aseptic meningitis are reported with IVIG, and this complication may be hard to distinguish from the occasional CNS disease associated with Kawasaki syndrome itself although the time course and the cerebrospinal fluid differential (more polymorphonuclear with IVIG, more lymphocytic with Kawasaki syndrome) may help differentiate the two. Methylprednisolone (30 mg/kg/d intravenously if possible for a maximum of 3 days) followed by tapering dose of corticosteroids should follow if the disease persists after the second IVIG administration. Routine childhood vaccinations should be given and live vaccines (eg, MMR) should be delayed for at least 9 months only if IVIG was administered (because IVIG can block the immune response to live vaccines). If vaccine preventable disease endemicity requires urgent vaccination, it is prudent to revaccinate 11 months after the IVIG and first vaccination were given.

Further options for refractory cases include TNF blockers (infliximab or etanercept), cyclophosphamide, methotrexate, and plasmapheresis. Abciximab therapy may be associated with coronary vessel remodeling in large coronary artery aneurysms. An echocardiogram is essential in the acute phase of illness and 6–8 weeks after onset. Anticoagulation with warfarin or low-molecular-weight heparin (the latter is preferable for children where dosage

adjustments are difficult using warfarin) is indicated along with aspirin, 81 mg orally daily, in patients with aneurysms > 8 mm in diameter. If myocardial infarction occurs, therapy with thrombolytics, percutaneous coronary intervention, coronary artery bypass grafts, and even cardiac transplantation should be considered. Manifestation of coronary artery aneurysms can occur as late as in the third or fourth decade of life. Data are equivocal on the development of accelerated atherosclerosis among those with a history of Kawasaki disease.

While secondary prevention of complications entails the modalities described above, primary prevention is difficult in the absence of a clear explanation for the disease.

► Prognosis

Cases that develop recurrent disease tend to more often show cardiac complications. Patients with a parental history of Kawasaki disease show more recurrent disease and more cardiac complications. The long-term prognosis for adults with a history of Kawasaki disease but without coronary artery aneurysms is excellent. A heart-healthy lifestyle,

however, is essential. The prognosis of patients with a history of cardiac complications requires regular follow-up with risk stratification based on published guidelines and under cardiologic supervision. Children with **Kawasaki disease** appear to have an increased risk for subsequent allergic diseases.

► When to Refer

All cases of Kawasaki disease merit referral to specialists.

Falcini F et al. Kawasaki syndrome: an intriguing disease with numerous unsolved dilemmas. *Pediatr Rheumatol Online J*. 2011 Jul 20;9:17. [PMID: 21774801]

Gomard-Menesson E et al. Kawasaki disease in adults: report of 10 cases. *Medicine (Baltimore)*. 2010 May;89(3):149–58. [PMID: 20453601]

McCandless RT et al. Does abciximab promote coronary artery remodeling in patients with Kawasaki disease? *Am J Cardiol*. 2010 Jun 1;105(11):1625–8. [PMID: 20494673]

Yeung RS. Kawasaki disease: update on pathogenesis. *Curr Opin Rheumatol*. 2010 Sep;22(5):551–60. [PMID: 20616737]

Bacterial & Chlamydial Infections

Brian S. Schwartz, MD

33

INFECTIONS CAUSED BY GRAM-POSITIVE BACTERIA

STREPTOCOCCAL INFECTIONS

1. Pharyngitis



ESSENTIALS OF DIAGNOSIS

- ▶ Abrupt onset of sore throat, fever, malaise, nausea, and headache.
- ▶ Throat red and edematous, with or without exudate; cervical nodes tender.
- ▶ Diagnosis confirmed by culture of throat.

▶ General Considerations

Group A β -hemolytic streptococci (*Streptococcus pyogenes*) are the most common bacterial cause of pharyngitis. Transmission occurs by droplets of infected secretions. Group A streptococci producing erythrogenic toxin may cause scarlet fever in susceptible persons.

▶ Clinical Findings

A. Symptoms and Signs

“Strep throat” is characterized by a sudden onset of fever, sore throat, pain on swallowing, tender cervical adenopathy, malaise, and nausea. The pharynx, soft palate, and tonsils are red and edematous. There may be a purulent exudate. The Centor clinical criteria for the diagnosis of streptococcal pharyngitis are temperature $> 38^{\circ}\text{C}$, tender anterior cervical adenopathy, lack of a cough, and pharyngotonsillar exudate.

The rash of scarlet fever is diffusely erythematous, resembling a sunburn, with superimposed fine red papules, and is most intense in the groin and axillae. It blanches on pressure, may become petechial, and fades in 2–5 days, leaving a fine desquamation. The face is flushed, with circumoral pallor, and the tongue is coated with enlarged red papillae (strawberry tongue).

B. Laboratory Findings

Leukocytosis with neutrophil predominance is common. Throat culture onto a single blood agar plate has a sensitivity of 80–90%. Rapid diagnostic tests based on detection of streptococcal antigen are slightly less sensitive than culture. Clinical criteria, such as the Centor criteria, are useful for identifying patients in whom a rapid antigen test or throat culture is indicated. Patients who meet two or more of these criteria merit further testing. When three of the four are present, laboratory sensitivity of rapid antigen testing exceeds 90%. When only one criterion is present, streptococcal pharyngitis is unlikely. In high-prevalence settings or if clinical suspicion for streptococcal pharyngitis is high, a negative antigen test or culture should be confirmed by a follow-up culture.

▶ Complications

Suppurative complications include sinusitis, otitis media, mastoiditis, peritonsillar abscess, and suppuration of cervical lymph nodes.

Non-suppurative complications are rheumatic fever and glomerulonephritis. Rheumatic fever may follow recurrent episodes of pharyngitis beginning 1–4 weeks after the onset of symptoms. Glomerulonephritis follows a single infection with a nephritogenic strain of streptococcus group A (eg, types 4, 12, 2, 49, and 60), more commonly on the skin than in the throat, and begins 1–3 weeks after the onset of the infection.

▶ Differential Diagnosis

Streptococcal sore throat resembles (and cannot be reliably distinguished clinically from) pharyngitis caused by *Fusobacterium necrophorum*, adenoviruses, Epstein-Barr virus, primary HIV, *Arcanobacterium haemolyticum* (which also may cause a rash), and other agents. Pharyngitis and lymphadenopathy are common findings in primary HIV infection. Generalized lymphadenopathy, splenomegaly, atypical lymphocytosis, and a positive serologic test distinguish mononucleosis from streptococcal pharyngitis. Diphtheria is characterized by a pseudomembrane; candidiasis shows white patches of exudate and less erythema;

and necrotizing ulcerative gingivostomatitis (Vincent fusospirochetal gingivitis or stomatitis) presents with shallow ulcers in the mouth. Retropharyngeal abscess or bacterial epiglottitis should be considered when odynophagia and difficulty in handling secretions are present and when the severity of symptoms is disproportionate to findings on examination of the pharynx. *F necrophorum* causes pharyngitis at a similar rate as group A β -hemolytic streptococci in adolescents and young adults. *F necrophorum* pharyngitis is associated with Lemierre syndrome, suppurative thrombophlebitis of the internal jugular vein, bacteremia, and metastatic infections. Early recognition and treatment of this disease is important.

► Treatment

Antimicrobial therapy has a modest effect on resolution of symptoms and primarily is administered for prevention of complications. Antibiotic therapy can be safely delayed until the diagnosis is established on the basis of a positive antigen test or culture. Empiric therapy usually is not a cost-effective approach to the management of most adults with pharyngitis because the prevalence of streptococcal pharyngitis is likely to be no more than 10–20% in typical clinical settings. The positive predictive value of clinical criteria is low. Since macrolides are not reliable against *F necrophorum* infection, adolescents or young adults with pharyngitis, which is not confirmed to be due to group A β -hemolytic streptococci, should be given penicillin or amoxicillin preferentially at the doses listed below. If the pharyngitis does not resolve quickly, symptoms worsen, or unilateral neck swelling develops, clinicians should consider suppurative complications such as peritonsillar abscess and the Lemierre syndrome.

A. Benzathine Penicillin G

Benzathine penicillin G, 1.2 million units intramuscularly as a single dose, is optimal therapy.

B. Penicillin VK

Penicillin VK, 500 mg orally four times a day (or amoxicillin, 750 mg orally twice daily) for 10 days, is effective, but compliance may be poor after the patient becomes asymptomatic in 2–4 days.

C. Cephalosporins

Cefdinir, 300 mg orally twice daily for 5–10 days or 600 mg orally once daily for 10 days, and cefpodoxime, 100 mg orally twice daily for 5–10 days, are both approved by the US Food and Drug Administration (FDA) for the treatment of streptococcal pharyngitis but should be reserved for penicillin-allergic patients able to tolerate cephalosporins.

D. Macrolides

Erythromycin, 500 mg orally four times a day, or azithromycin, 500 mg orally once daily for 3 days, is an alternative for the penicillin-allergic patient. Macrolides are less effective than penicillins and are considered second-line agents.

Macrolide-resistant strains almost always are susceptible to clindamycin, a suitable alternative to penicillins; a 10-day course of 300 mg orally twice daily is effective.

► Prevention of Recurrent Rheumatic Fever

Effectively controlling rheumatic fever depends on identification and treatment of primary streptococcal infection and secondary prevention of recurrences. Patients who have had rheumatic fever should be treated with a continuous course of antimicrobial prophylaxis for at least 5 years. Effective regimens are erythromycin, 250 mg orally twice daily, or penicillin G, 500 mg orally daily.

Aalbers J et al. Predicting streptococcal pharyngitis in adults in primary care: a systematic review of the diagnostic accuracy of symptoms and signs and validation of the Centor score. *BMC Med.* 2011 Jun 1;9:67. [PMID: 21631919]
 Centor RM. Expand the pharyngitis paradigm for adolescents and young adults. *Ann Intern Med.* 2009 Dec 1;151(11):812–5. [PMID: 19949147]
 van Driel ML et al. Different antibiotic treatments for group A streptococcal pharyngitis. *Cochrane Database Syst Rev.* 2010 Oct 6;(10):CD004406. [PMID: 20927734]

2. Streptococcal Skin Infections

Group A β -hemolytic streptococci are not normal skin flora. Streptococcal skin infections result from colonization of normal skin by contact with other infected individuals or by preceding streptococcal respiratory infection.

► Clinical Findings

A. Symptoms and Signs

Impetigo is a focal, vesicular, pustular lesion with a thick, amber-colored crust with a “stuck-on” appearance (see Chapter 6).

Erysipelas is a painful superficial cellulitis that frequently involves the face. It is well demarcated from the surrounding normal skin. It affects skin with impaired lymphatic drainage, such as edematous lower extremities or wounds.

B. Laboratory Findings

Cultures obtained from a wound or pustule are likely to grow group A streptococci. Blood cultures are occasionally positive.

► Treatment

Parenteral antibiotics are indicated for patients with facial erysipelas or evidence of systemic infection. Penicillin, 2 million units intravenously every 4 hours, is the drug of choice. However, staphylococci infections may at times be difficult to differentiate from streptococcal infections. In practice, initial therapy for patients with risk factors for *Staphylococcus aureus* (eg, injection drug use, diabetes, wound infection) should cover this organism. Nafcillin, 1–2 g every 4–6 hours intravenously, and cefazolin, 1 g intravenously or intramuscularly every 8 hours, are reasonable choices. In the patient at risk for methicillin-resistant

Table 33–1. Empiric treatment of common skin and soft tissue infections (SSTI).

SSTI Type	Pathogens	Treatment
Purulent (abscess, furuncle, carbuncle, cellulitis with purulence)	<i>Staphylococcus aureus</i>	Incision and drainage is the primary treatment Consider the addition of antibiotics in select situations ¹ Oral antibiotic regimens Cephalexin 500 mg four times daily <i>or</i> dicloxacillin 500 mg four times daily Clindamycin 300–450 mg three or four times daily ² <i>or</i> one double-strength tablet of trimethoprim-sulfamethoxazole twice daily ² <i>or</i> doxycycline 100 mg twice daily ² Intravenous antibiotic regimens³ Cefazolin 1 g three times daily <i>or</i> nafcillin 1–2 g four to six times daily Vancomycin 1 g twice daily ² <i>or</i> daptomycin 4 mg/kg once daily ²
Nonpurulent (cellulitis, erysipelas)	β-hemolytic streptococci (<i>S aureus</i> less likely)	Oral antibiotic regimens Cephalexin 500 mg four times daily <i>or</i> dicloxacillin 500 mg four times daily Clindamycin 300–450 mg three or four times daily ² <i>or</i> amoxicillin 875 mg twice daily <i>plus</i> one double-strength tablet of trimethoprim-sulfamethoxazole twice daily ² Intravenous antibiotic regimens³ Cefazolin 1 g three times daily <i>or</i> nafcillin 1–2 g four to six times daily Vancomycin 1 g twice daily ² <i>or</i> daptomycin 4 mg/kg once daily

¹Antibiotic therapy should be given in addition to incision and drainage for purulent SSTI if the patient has any of the following: severe or extensive disease, signs and symptoms of systemic illness, purulent cellulitis/wound infection, comorbidities and extremes of age, abscess in area difficult to drain or face/hand, associated septic phlebitis, or lack of response to incision and drainage alone.

²Regimens with activity against methicillin-resistant *S aureus*.

³Other regimens approved by the FDA for treatment of complicated skin and soft tissue infections include linezolid, 600 mg twice daily (can also be given by mouth); tigecycline, 50 mg twice daily; telavancin, at 10 mg/kg once daily; and ceftaroline, 600 mg twice daily.

S aureus infection or with a serious penicillin allergy (ie, anaphylaxis), vancomycin, 1 g intravenously every 12 hours, or daptomycin 4 mg/kg intravenously daily, should be used (Table 33–1).

Patients who do not require parenteral therapy may be treated with amoxicillin, 875 mg twice daily for 7–10 days. A first-generation oral cephalosporin, eg, cephalexin, 500 mg four times daily, or clindamycin, 300 mg orally three times daily, is an alternative to amoxicillin.

3. Other Group A Streptococcal Infections

Arthritis, pneumonia, empyema, endocarditis, and necrotizing fasciitis are relatively uncommon infections that may be caused by group A streptococci. Toxic shock-like syndrome also occurs.

Arthritis generally occurs in association with cellulitis. In addition to intravenous therapy with penicillin G, 2 million units every 4 hours (or cefazolin or vancomycin in doses recommended above for penicillin-allergic patients), frequent percutaneous needle aspiration should be performed to remove joint effusions. Open surgical drainage may be necessary in many cases.

Pneumonia and **empyema** often are characterized by extensive tissue destruction and an aggressive, rapidly progressive clinical course associated with significant morbidity and mortality. High-dose penicillin and chest tube drainage are indicated for treatment of empyema. Vancomycin is an acceptable substitute in penicillin-allergic patients.

Group A streptococci can cause **endocarditis**. Endocarditis should be treated with 4 million units of penicillin G intravenously every 4 hours for 4–6 weeks.

Vancomycin, 1 g intravenously every 12 hours, is recommended for persons allergic to penicillin.

Necrotizing fasciitis is a rapidly spreading infection involving the fascia of deep muscle. The clinical findings at presentation may be those of severe cellulitis, but the presence of systemic toxicity and severe pain, which may be followed by anesthesia of the involved area due to destruction of nerves as infection advances through the fascial planes, is a clue to the diagnosis. Surgical exploration is mandatory when the diagnosis is suspected. Early and extensive debridement is essential for survival.

Any streptococcal infection—and necrotizing fasciitis in particular—can be associated with **streptococcal toxic shock syndrome**, typified by invasion of skin or soft tissues, acute respiratory distress syndrome, and kidney failure. The very young, the elderly, and those with underlying medical conditions are at particularly high risk for invasive disease. Bacteremia occurs in most cases. Skin rash and desquamation may not be present. Mortality rates can be up to 80%. The syndrome is due to elaboration of pyrogenic erythrotoxin (which also causes **scarlet fever**), a superantigen that stimulates massive release of inflammatory cytokines believed to mediate the shock. A β-lactam, such as penicillin, remains the drug of choice for treatment of serious streptococcal infections, but clindamycin, which is a potent inhibitor of toxin production, should also be administered at a dose of 600 mg every 8 hours intravenously for invasive disease, especially in the presence of shock. Intravenous immune globulin has also been recommended for streptococcal toxic shock syndrome for presumed, although unproven, therapeutic benefit from specific antibody to streptococcal exotoxins in immune

globulin preparations. Two dosage regimens have been used: 450 mg/kg once daily for 5 days or a single dose of 2 g/kg with a repeat dose at 48 hours if the patient remains unstable.

Outbreaks of invasive disease have been associated with colonization by invasive clones that can be transmitted to close contacts who, though asymptomatic, may be a reservoir for disease. Tracing contacts of patients with invasive disease is controversial.

Eisenstein BI. Treatment challenges in the management of complicated skin and soft-tissue infections. *Clin Microbiol Infect.* 2008 Mar;14(Suppl 2):17–25. [PMID: 18226086]

Phan HH et al. Necrotizing soft tissue infections in the intensive care unit. *Crit Care Med.* 2010 Sep;38(9 Suppl):S460–8. [PMID: 20724879]

4. Non-Group A Streptococcal Infections

Non-group A hemolytic streptococci (eg, groups B, C, and G) produce a spectrum of disease similar to that of group A streptococci. The treatment of infections caused by these strains is the same as for group A streptococci.

Group B streptococci are an important cause of sepsis, bacteremia, and meningitis in the neonate. Antepartum screening to identify carriers and peripartum antimicrobial prophylaxis are recommended in pregnancy. This organism, part of the normal vaginal flora, may cause septic abortion, endometritis, or peripartum infections and, less commonly, cellulitis, bacteremia, and endocarditis in adults. Treatment of infections caused by group B streptococci is with either penicillin or vancomycin in doses recommended for group A streptococci. Because of in vitro synergism, some experts recommend the addition of low-dose gentamicin, 1 mg/kg every 8 hours.

Viridans streptococci, which are nonhemolytic or α -hemolytic (ie, producing a green zone of hemolysis on blood agar), are part of the normal oral flora. Although these strains may produce focal pyogenic infection, they are most notable as the leading cause of native valve endocarditis (see below).

Group D streptococci include *Streptococcus bovis* and the enterococci. *S bovis* is a cause of endocarditis in association with bowel neoplasia or cirrhosis and is treated like viridans streptococci.

Deutscher M et al; Active Bacterial Core Surveillance Team. Incidence and severity of invasive *Streptococcus pneumoniae*, group A *Streptococcus*, and group B *Streptococcus* infections among pregnant and postpartum women. *Clin Infect Dis.* 2011 Jul 15;53(2):114–23. [PMID: 21690617]

Jeng A et al. The role of beta-hemolytic streptococci in causing diffuse, nonculturable cellulitis: a prospective investigation. *Medicine (Baltimore).* 2010 Jul;89(4):217–26. [PMID: 20616661]

ENTEROCOCCAL INFECTIONS

Two species, *Enterococcus faecalis* and *Enterococcus faecium*, are responsible for most human enterococcal infections. Enterococci cause wound infections, urinary tract infections, bacteremia, and endocarditis. Infections caused by

penicillin-susceptible strains should be treated with penicillin 3–4 million units every 4 hours; ampicillin 3 g every 6 hours; or if the patient is penicillin-allergic, vancomycin 15 mg/kg every 12 hours intravenously. If the patient has endocarditis or meningitis, gentamicin 1 mg/kg every 8 hours intravenously should be added to the regimen in order to achieve the bactericidal activity that is required to cure these infections.

Resistance to vancomycin, penicillin, and gentamicin is common among enterococcal isolates, especially *E faecium*; it is essential to determine antimicrobial susceptibility of isolates. Infection control measures that may be indicated to limit their spread include isolation, barrier precautions, and avoidance of overuse of vancomycin and gentamicin. Consultation with an infectious diseases specialist is strongly advised when treating infections caused by resistant strains of enterococci. Quinupristin/dalfopristin and linezolid are approved by the FDA for treatment of infections caused by vancomycin-resistant strains of enterococci.

Quinupristin/dalfopristin is not active against strains of *E faecalis* and should be used only for infections caused by *E faecium*. The dose is 7.5 mg/kg intravenously every 8–12 hours. Phlebitis and irritation at the infusion site (often requiring a central line) and an arthralgia-myalgia syndrome are relatively common side effects. Linezolid, an oxazolidinone, is active against both *E faecalis* and *E faecium*. The dose is 600 mg twice daily, and both intravenous and oral preparations are available. Its two principal side effects are thrombocytopenia and bone marrow suppression; however, peripheral neuropathy, optic neuritis, and lactic acidosis have been observed with prolonged use due to mitochondrial toxicity. Emergence of resistance has occurred during therapy with either quinupristin/dalfopristin or linezolid.

Arias CA et al. Management of multidrug-resistant enterococcal infections. *Clin Microbiol Infect.* 2010 Jun;16(6):555–62. [PMID: 20569266]

Huskins WC et al; STAR*ICU Trial Investigators. Intervention to reduce transmission of resistant bacteria in intensive care. *N Engl J Med.* 2011 Apr 14;364(15):1407–18. [PMID: 21488763]

PNEUMOCOCCAL INFECTIONS

1. Pneumococcal Pneumonia



ESSENTIALS OF DIAGNOSIS

- ▶ Productive cough, fever, rigors, dyspnea, early pleuritic chest pain.
- ▶ Consolidating lobar pneumonia on chest radiograph.
- ▶ Gram-positive diplococci on Gram stain of sputum.

▶ General Considerations

The pneumococcus is the most common cause of community-acquired pyogenic bacterial pneumonia. Alcoholism,

asthma, HIV infection, sickle cell disease, splenectomy, and hematologic disorders are predisposing factors. The mortality rate remains high in the setting of advanced age, multilobar disease, severe hypoxemia, extrapulmonary complications, and bacteremia.

► Clinical Findings

A. Symptoms and Signs

Presenting symptoms and signs include high fever, productive cough, occasionally hemoptysis, and pleuritic chest pain. Rigors occur within the first few hours of infection but are uncommon thereafter. Bronchial breath sounds are an early sign.

B. Laboratory Findings

Pneumococcal pneumonia classically is a lobar pneumonia with radiographic findings of consolidation and occasionally effusion. However, differentiating it from other pneumonias is not possible radiographically or clinically because of significant overlap in presentations. Diagnosis requires isolation of the organism in culture, although the Gram stain appearance of sputum can be suggestive. Sputum and blood cultures, positive in 60% and 25% of cases of pneumococcal pneumonia, respectively, should be obtained prior to initiation of antimicrobial therapy in patients who are admitted to the hospital. A good-quality sputum sample (< 10 epithelial cells and > 25 polymorphonuclear leukocytes per high-power field) shows gram-positive diplococci in 80–90% of cases. A rapid urinary antigen test for *S pneumoniae*, with sensitivity of 70–80% and specificity > 95%, can assist with early diagnosis.

► Complications

Parapneumonic (sympathetic) effusion is common and may cause recurrence or persistence of fever. These sterile fluid accumulations need no specific therapy. Empyema occurs in 5% or less of cases and is differentiated from sympathetic effusion by the presence of organisms on Gram-stained fluid or positive pleural fluid cultures.

Pneumococcal pericarditis is a rare complication that can cause tamponade. Pneumococcal arthritis also is uncommon. Pneumococcal endocarditis usually involves the aortic valve and often occurs in association with meningitis and pneumonia (sometimes referred to as Austrian or Osler triad). Early heart failure and multiple embolic events are typical.

► Treatment

A. Specific Measures

Initial antimicrobial therapy for pneumonia is empiric (see Chapter 9 for specific recommendations) pending isolation and identification of the causative agent. Once the pneumonia is determined to be caused by *Streptococcus pneumoniae*, any of several antimicrobial agents may be used depending on the clinical setting, community patterns of penicillin resistance, and susceptibility of the particular isolate. Uncomplicated pneumococcal pneumonia

(ie, arterial PO₂ > 60 mm Hg, no coexisting medical problems, and single-lobe disease without signs of extrapulmonary infection) caused by penicillin-susceptible strains of pneumococcus may be treated on an outpatient basis with amoxicillin, 750 mg orally twice daily for 7–10 days. For penicillin-allergic patients, alternatives are azithromycin, one 500-mg dose orally on the first day and 250 mg for the next 4 days; clarithromycin, 500 mg orally twice daily for 10 days; doxycycline, 100 mg orally twice daily for 10 days; levofloxacin, 750 mg orally for 5 days; or moxifloxacin, 400 mg orally for 7–14 days. Patients should be monitored for clinical response (eg, less cough, defervescence within 2–3 days) because pneumococci have become increasingly resistant to penicillin and the second-line agents.

Parenteral therapy is generally recommended for the hospitalized patient at least until there has been clinical improvement. Aqueous penicillin G, 2 million units intravenously every 4 hours, or ceftriaxone, 1 g intravenously every 24 hours, is effective for strains that are not highly penicillin-resistant (ie, strains for which the minimum inhibitory concentration [MIC] of penicillin is ≤ 1 mcg/mL). For serious penicillin allergy or infection caused by a highly penicillin-resistant strain, vancomycin, 1 g intravenously every 12 hours, is effective. Alternatively, a respiratory fluoroquinolone (eg, levofloxacin, 750 mg) can be used. The total duration of therapy is not well defined but 7–14 days is standard.

B. Treatment of Complications

Pleural effusions developing after initiation of antimicrobial therapy usually are sterile, and thoracentesis need not be performed if the patient is otherwise improving. Thoracentesis is indicated for an effusion present prior to initiation of therapy and in the patient who has not responded to antibiotics after 3–4 days. Chest tube drainage may be required if pneumococci are identified by culture or Gram stain, especially if aspiration of the fluid is difficult.

Echocardiography should be done if pericardial effusion is suspected. Patients with pericardial effusion who are responding to therapy and have no signs of tamponade may be monitored and treated with indomethacin, 50 mg orally three times daily, for pain. In patients with increasing effusion, unsatisfactory clinical response, or evidence of tamponade, pericardiocentesis will determine whether the pericardial space is infected. Infected fluid must be drained either percutaneously (by tube placement or needle aspiration), by placement of a pericardial window, or by pericardiectomy. Pericardiectomy eventually may be required to prevent or treat constrictive pericarditis, a common sequela of bacterial pericarditis.

Endocarditis should be treated for 4 weeks with 3–4 million units of penicillin G every 4 hours intravenously; ceftriaxone, 2 g once daily intravenously; or vancomycin, 15 mg/kg every 12 hours intravenously. Mild heart failure from endocarditis may respond to medical therapy, but moderate to severe heart failure is an indication for prosthetic valve implantation, as are systemic emboli or large friable vegetations as determined by echocardiography.

C. Penicillin-Resistant Pneumococci

Susceptibility breakpoints defining penicillin-resistant pneumococci for isolates causing pneumonia were revised in 2008. Resistance breakpoints for parenterally administered penicillin and high-dose oral amoxicillin (2 g twice daily) are as follows: susceptible, penicillin MIC \leq 2 mcg/mL; intermediate, MIC = 4 mcg/mL; resistant, MIC \geq 8 mcg/mL. This change reflected results from studies demonstrating equivalent cure rates when high doses of parenteral penicillin were used for treatment of pneumococcal pneumonia due to isolates with penicillin MIC \leq 2 mcg/mL. Note, however, that these new breakpoints do not apply to orally administered penicillin, which are the same as for use of penicillin in treatment of meningitis (see below). In cases of pneumococcal pneumonia where the isolate has a penicillin MIC $>$ 2 mcg/mL, cephalosporin cross-resistance is common, and a non- β -lactam antimicrobial, such as vancomycin, 1 g intravenously every 12 hours or a fluoroquinolone with enhanced gram-positive activity (eg, levofloxacin, 750 mg intravenously or orally once daily or moxifloxacin, 400 mg intravenously or orally once daily), is recommended. Penicillin-resistant strains of pneumococci may be resistant to macrolides, trimethoprim-sulfamethoxazole, and chloramphenicol, and susceptibility must be documented prior to their use. All blood and cerebrospinal fluid isolates should still be tested for resistance to penicillin. There has been no change to the penicillin susceptibility breakpoint for pneumococcal isolates causing meningitis, nor any change in treatment recommendations (see below).

Lynch JP 3rd et al. *Streptococcus pneumoniae*: epidemiology and risk factors, evolution of antimicrobial resistance, and impact of vaccines. *Curr Opin Pulm Med*. 2010 May;16(3):217–25. [PMID: 20375783]

Mandell LA et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. *Clin Infect Dis*. 2007 Mar 1;44(Suppl 2):S27–72. [PMID: 17278083]

van der Poll T et al. Pathogenesis, treatment, and prevention of pneumococcal pneumonia. *Lancet*. 2009 Oct 31;374(9700):1543–56. [PMID: 19880020]

Watkins RR et al. Diagnosis and management of community-acquired pneumonia in adults. *Am Fam Physician*. 2011 Jun 1;83(11):1299–306. [PMID: 21661712]

2. Pneumococcal Meningitis



ESSENTIALS OF DIAGNOSIS

- ▶ Fever, headache, altered mental status.
- ▶ Meningismus.
- ▶ Gram-positive diplococci on Gram stain of cerebrospinal fluid.

▶ General Considerations

S pneumoniae is the most common cause of meningitis in adults. Head trauma, with cerebrospinal fluid leaks, sinusitis, and pneumonia may precede it.

▶ Clinical Findings

A. Symptoms and Signs

The onset is rapid, with fever, headache, meningismus, and altered mentation. Pneumonia may be present. Compared with meningitis caused by the meningococcus, pneumococcal meningitis lacks a rash, and focal neurologic deficits, cranial nerve palsies, and obtundation are more prominent features.

B. Laboratory Findings

The cerebrospinal fluid typically has $>$ 1000 white blood cells per microliter, over 60% of which are polymorphonuclear leukocytes; the glucose concentration is $<$ 40 mg/dL, or $<$ 50% of the simultaneous serum concentration; and the protein usually exceeds 150 mg/dL. Not all cases of meningitis will have these typical findings, and alterations in cerebrospinal fluid cell counts and chemistries may be surprisingly minimal, overlapping with those of aseptic meningitis.

Gram stain of cerebrospinal fluid shows gram-positive cocci in 80–90% of cases, and in untreated cases, blood or cerebrospinal fluid cultures are almost always positive.

▶ Treatment

Antibiotics should be given as soon as the diagnosis is suspected. If lumbar puncture must be delayed (eg, while awaiting results of an imaging study to exclude a mass lesion), the patient should be treated empirically for presumed meningitis with intravenous ceftriaxone, 2 g, plus vancomycin, 15 mg/kg, plus dexamethasone, 0.15 mg/kg administered concomitantly after blood cultures (positive in 50% of cases) have been obtained. Once susceptibility to penicillin has been confirmed, penicillin, 24 million units intravenously daily in six divided doses, or ceftriaxone, 2 g every 12 hours intravenously, is continued for 10–14 days in documented cases.

The best therapy for penicillin-resistant strains is not known. Penicillin-resistant strains (MIC $>$ 0.06 mcg/mL) are often cross-resistant to the third-generation cephalosporins as well as other antibiotics. Susceptibility testing is essential to proper management of this infection. If the MIC of ceftriaxone or cefotaxime is \leq 0.5 mcg/mL, single-drug therapy with either of these cephalosporins is likely to be effective; when the MIC is \geq 1 mcg/mL, treatment with a combination of ceftriaxone, 2 g intravenously every 12 hours, plus vancomycin, 30 mg/kg/d intravenously in two or three divided doses, is recommended. If a patient with a penicillin-resistant organism is slow to respond clinically, repeat lumbar puncture may be indicated to assess bacteriologic response.

Dexamethasone administered with antibiotic to adults has been associated with a 60% reduction in mortality and a 50% reduction in unfavorable outcomes. It is recommended that dexamethasone, 10 mg intravenously, be given immediately prior to or concomitantly with the first dose of appropriate antibiotic and continued in those with pneumococcal disease every 6 hours thereafter for a total of 4 days. Patients with pneumococcal meningitis and AIDS

who do not have access to resources may not benefit from dexamethasone. The effect of dexamethasone on outcome of meningitis caused by penicillin-resistant organisms is not known.

Hsu HE et al. Effect of pneumococcal conjugate vaccine on pneumococcal meningitis. *N Engl J Med*. 2009 Jan 15;360(3):244–56. [PMID: 19144940]

Thigpen MC et al; Emerging Infections Programs Network. Bacterial meningitis in the United States, 1998–2007. *N Engl J Med*. 2011 May 26;364(21):2016–25. [PMID: 21612470]

STAPHYLOCOCCUS AUREUS INFECTIONS

1. Skin & Soft Tissue Infections



ESSENTIALS OF DIAGNOSIS

- ▶ Localized erythema with induration and purulent drainage.
- ▶ Abscess formation.
- ▶ Folliculitis commonly observed.
- ▶ Gram stain of pus with gram-positive cocci in clusters; cultures usually positive.

▶ General Considerations

Approximately one-quarter of people are asymptomatic nasal carriers of *S aureus*, which is spread by direct contact. Carriage often precedes infection, which occurs as a consequence of disruption of the cutaneous barrier or impairment of host defenses. *S aureus* tends to cause more localized skin infections than streptococci, and abscess formation is common. The prevalence of methicillin-resistant strains in community settings is increasing, and these strains have been associated with recurrent and severe skin and soft tissue infections, including necrotizing fasciitis.

▶ Clinical Findings

A. Symptoms and Signs

S aureus skin infections may begin around one or more hair follicles, causing folliculitis; may become localized to form boils (or furuncles); or may spread to adjacent skin and deeper subcutaneous tissue (ie, a carbuncle) (Figure 33–1). Deep abscesses involving muscle or fascia may occur, often in association with a deep wound or other inoculation or injection. Necrotizing fasciitis, a rare form of *S aureus* skin and soft tissues infection, has been reported with community strains of methicillin-resistant *S aureus*.

B. Laboratory Findings

Cultures of the wound or abscess material will almost always yield the organism. In patients with systemic signs of infection, blood cultures should be obtained because of potential endocarditis, osteomyelitis, or metastatic seeding of other sites. Patients who are bacteremic should have blood cultures



▲ **Figure 33–1.** Methicillin-resistant *Staphylococcus aureus* (MRSA) abscess of the neck. (Courtesy of Edward Wright, MD; used, with permission, from Usatine RP, Smith MA, Mayeaux EJ Jr, Chumley H, Tysinger J. *The Color Atlas of Family Medicine*. McGraw-Hill, 2009.)

taken early during therapy to exclude persistent bacteremia, an indicator of severe or complicated infection.

▶ Treatment

Proper drainage of abscess fluid or other focal infections is the mainstay of therapy. Incision and drainage alone may be sufficient for cutaneous abscess. For uncomplicated skin infections, oral antimicrobial therapy is satisfactory. Before the emergence of community methicillin-resistant strains of *S aureus*, an oral penicillinase-resistant penicillin or cephalosporin, such as dicloxacillin or cephalexin, 500 mg four times a day for 7–10 days, was the drug of choice for empiric therapy. However, increasing prevalence of methicillin-resistant strains of *S aureus* among community isolates may necessitate use of other oral agents to which the isolate is susceptible in vitro, such as clindamycin, 300 mg three times daily; doxycycline or minocycline, 100 mg twice daily; or trimethoprim-sulfamethoxazole, given in two divided doses based on 5–10 mg/kg/d of the trimethoprim component. Unfortunately, the efficacy of these agents is not well defined and not evidence based. Because of the high prevalence of macrolide resistance among *S aureus* strains, these agents should not be used unless susceptibility is documented (see Table 33–1).

For more complicated infections with extensive cutaneous or deep tissue involvement or fever, parenteral therapy is indicated initially. A penicillinase-resistant penicillin such as nafcillin or oxacillin in a dosage of 1.5 g every 6 hours intravenously or cefazolin 1 g intravenously or intramuscularly is preferred for infections caused by methicillin-susceptible isolates. In patients with a serious allergy to β -lactam antibiotics or if the strain is methicillin-resistant, vancomycin, 1 g intravenously every 12 hours, is a drug of choice. If the local prevalence of methicillin-resistance is high (eg, 10% or more), and particularly if the patient is seriously ill, vancomycin is indicated empirically pending strain isolation and determination of susceptibility.

Linezolid is FDA-approved for treatment of skin and skin-structure infections as well as hospital-acquired pneumonia caused by methicillin-resistant strains of *S aureus* and clinically is as effective as vancomycin. The dose is 600 mg orally (bioavailability of 100%) or intravenously twice a day for 10–14 days. Its considerable cost makes it an unattractive choice for most routine outpatient infections, and its safety in treatment courses lasting longer than 2–3 weeks is not well characterized; nevertheless, it is the only proven effective oral alternative to parenteral vancomycin. Daptomycin, 4 mg/kg once daily (or every other day in the patient with creatinine clearance < 30 mL/min) intravenously for 7–14 days, is also an option for treatment of complicated skin and skin structure infections. Tigecycline (a glycylcycline class antimicrobial), telavancin (a lipoglycopeptide), and ceftaroline (a novel cephalosporin with activity against methicillin-resistant *S aureus*) are all approved by the FDA for treatment of complicated skin and skin structure infections due to methicillin-resistant strains of *S aureus*. The dosage of tigecycline is 100 mg intravenously once followed by 50 mg intravenously twice a day. The dose of telavancin is 10 mg/kg intravenously once daily for 7–14 days. The dosage of ceftaroline is 600 mg twice a day for 7–14 days.

Biek D et al. Ceftaroline fosamil: a novel broad-spectrum cephalosporin with expanded anti-Gram-positive activity. *J Antimicrob Chemother.* 2010 Nov;65(Suppl 4):iv9–16. [PMID: 21115457]

Liu C et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant *Staphylococcus aureus* infections in adults and children. *Clin Infect Dis.* 2011 Feb 1;52(3):e18–55. [PMID: 21208910]

2. Osteomyelitis

S aureus causes approximately 60% of all cases of osteomyelitis. Osteomyelitis may be caused by direct inoculation, eg, from an open fracture or as a result of surgery; by extension from a contiguous focus of infection or open wound; or by hematogenous spread. Long bones and vertebrae are the usual sites. Epidural abscess is a common complication of vertebral osteomyelitis and should be suspected if fever and severe back or neck pain are accompanied by radicular pain or symptoms or signs indicative of spinal cord compression (eg, incontinence, extremity weakness, pathologic reflexes).

► Clinical Findings

A. Symptoms and Signs

The infection may be acute, with abrupt development of local symptoms and systemic toxicity, or indolent, with insidious onset of vague pain over the site of infection, progressing to local tenderness and constitutional symptoms (fever, malaise, anorexia, night sweats). Fever is absent in one-third or more of cases. Back pain is often the only symptom in vertebral osteomyelitis and may be associated with an epidural abscess and spinal cord compression. Draining sinus tracts occur in chronic infections or infections of foreign body implants.

B. Laboratory Findings

The diagnosis is established by isolation of *S aureus* from the blood, bone, or a contiguous focus of a patient with signs and symptoms of focal bone infection. Blood culture will be positive in approximately 60% of untreated cases. Bone biopsy and culture are indicated if blood cultures are sterile.

C. Imaging

Bone scan and gallium scan, each with a sensitivity of approximately 95% and a specificity of 60–70%, are useful in identifying or confirming the site of bone infection. Plain bone films early in the course of infection are often normal but will become abnormal in most cases even with effective therapy. Spinal infection (unlike malignancy) traverses the disk space to involve the contiguous vertebral body. CT is more sensitive than plain films and helps localize associated abscesses. MRI is slightly less sensitive than bone scan but has a specificity of 90%. It is indicated when epidural abscess is suspected in association with vertebral osteomyelitis.

► Treatment

Prolonged therapy is required to cure staphylococcal osteomyelitis. Durations of 4–6 weeks or longer are recommended. In cases of staphylococcal osteomyelitis with associated epidural abscess and spinal cord compression, other abscesses (psoas, paraspinal) or extensive disease, surgical treatment is often indicated. Although oral regimens can be effective, intravenous therapy is preferred, particularly during the acute phase of the infection for patients with systemic toxicity. Nafcillin or oxacillin, 9–12 g/d in six divided doses, is the drug of choice for infection with methicillin-sensitive isolates. Cefazolin, 2 g every 8 hours, also is effective. Patients with infections due to methicillin-resistant strains of *S aureus* or who have severe penicillin allergies should be treated with vancomycin, 30 mg/kg/d intravenously divided in two or three doses. Doses should be adjusted to achieve a vancomycin trough of 15–20 mcg/mL. Oral step-down therapy to a rifampin combination regimen may be effective and in certain cases primary oral therapy may be effective, but consultation with an infectious diseases specialist is recommended. The role of newer agents, such as daptomycin or linezolid, remains to be defined.

Euba G et al. Long-term follow-up trial of oral rifampin-cotrimoxazole combination versus intravenous cloxacillin in treatment of chronic staphylococcal osteomyelitis. *Antimicrob Agents Chemother.* 2009 Jun;53(6):2672–6. [PMID: 19307354]

Hatzenbuehler J et al. Diagnosis and management of osteomyelitis. *Am Fam Physician.* 2011 Nov 1;84(9):1027–33. [PMID: 22046943]

Liu C et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant *Staphylococcus aureus* infections in adults and children. *Clin Infect Dis.* 2011 Feb 1;52(3):e18–55. [PMID: 21208910]

3. Staphylococcal Bacteremia

S aureus readily invades the bloodstream and infects sites distant from the primary site of infection, which may be relatively minor or even inapparent. Whenever *S aureus* is recovered from blood cultures, the possibility of endocarditis, osteomyelitis, or other metastatic deep infection must be considered. Bacteremia that persists for more than 48 to 96 hours after initiation of therapy is strongly predictive of worse outcome and complicated infection. The appropriate duration of therapy for uncomplicated bacteremia arising from a removable source (eg, intravenous device) or drainable focus (eg, skin abscess) has not been well defined, but a 10- to 14-day course of therapy appears to be the minimum. However, 5% or more of patients may relapse, usually with endocarditis or osteomyelitis, even if treated for 2 weeks.

Nafcillin or oxacillin, 2 g intravenously every 4 hours or cefazolin, 2 g every 8 hours is recommended for uncomplicated methicillin-susceptible *S aureus* bacteremia. Vancomycin, 30 mg/kg/d intravenously in two or three divided doses, as definitive therapy should be reserved for patients with serious penicillin allergy or with infections caused by methicillin-resistant strains because it is less active than β -lactam antibiotics and treatment failures are more common than with β -lactams. Maintaining a vancomycin trough concentration of 15–20 mcg/mL may improve outcomes and is recommended. Transesophageal echocardiography (TEE) is a sensitive and cost-effective method for excluding underlying endocarditis. It is considered for patients for whom the pretest probability of endocarditis is 5% or higher—and for all patients with unexplained *S aureus* bacteremia.

Vancomycin treatment failures are relatively common, particularly for complicated bacteremia, in foreign body infection, or when the MIC of the isolate is ≥ 2 mcg/mL. Consultation should be sought with an infectious diseases specialist when vancomycin treatment failure is encountered. Daptomycin, 6 mg/kg intravenously once daily, is approved by the FDA for treatment of *S aureus* bacteremia and is an alternative to vancomycin, especially if a β -lactam cannot be used or if the patient is not responding to vancomycin. Cases of vancomycin treatment failures in which the staphylococcal isolate exhibits a vancomycin MIC ≥ 4 mcg/mL should be reported to the Centers for Disease Control and Prevention (CDC) to help track this potentially serious and emerging problem of vancomycin resistance.

Empiric therapy of suspected staphylococcal infection, whether of community or hospital onset, depends on the severity of the infection and the likelihood that it is caused by methicillin-resistant strains. If the prevalence exceeds 5–10% for more seriously ill patients, initial therapy should include vancomycin, 30 mg/kg/d intravenously divided in two or three doses, until results of susceptibility tests are known. Resistance to vancomycin fortunately remains rare and should not affect the choice of empiric therapy.

Cosgrove SE et al. Management of methicillin-resistant *Staphylococcus aureus* bacteremia. Clin Infect Dis. 2008 Jun 1;46 (Suppl) 5:S386–93. [PMID: 18462094]

Kaasch AJ et al. Use of a simple criteria set for guiding echocardiography in nosocomial *Staphylococcus aureus* bacteremia. Clin Infect Dis. 2011 Jul 1;53(1):1–9. [PMID: 21653295]
Liu C et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant *Staphylococcus aureus* infections in adults and children. Clin Infect Dis. 2011 Feb 1;52(3):e18–55. [PMID: 21208910]

4. Toxic Shock Syndrome

S aureus produces toxins that cause three important entities: “scalded skin syndrome” in children, toxic shock syndrome in adults, and enterotoxin food poisoning. Toxic shock syndrome is characterized by abrupt onset of high fever, vomiting, and watery diarrhea. Sore throat, myalgias, and headache are common. Hypotension with kidney and heart failure is associated with a poor outcome. A diffuse macular erythematous rash (Figure 33–2) and non-purulent conjunctivitis are common, and desquamation, especially of palms and soles, is typical during recovery. Fatality rates may be as high as 15%. Although originally associated with tampon use, any focus (eg, nasopharynx, bone, vagina, rectum, abscess, or wound) harboring a toxin-producing *S aureus* strain can cause toxic shock syndrome and nonmenstrual cases of toxic shock syndrome are common. Classically, blood cultures are negative because symptoms are due to the effects of the toxin and not systemic infection.

Important aspects of treatment include rapid rehydration, antistaphylococcal drugs, management of kidney or heart failure, and addressing sources of toxin, eg, removal of tampon or drainage of abscess.

5. Infections Caused by Coagulase-Negative Staphylococci

Coagulase-negative staphylococci are an important cause of infections of intravascular and prosthetic devices and of wound infection following cardiothoracic surgery.



▲ **Figure 33–2.** Morbilliform rash in toxic shock syndrome caused by *Staphylococcus aureus*. (Public Health Image Library, CDC.)

These organisms infrequently cause infections such as osteomyelitis and endocarditis in the absence of a prosthesis, but rates may be increasing. Most human infections are caused by *Staphylococcus epidermidis*, *S haemolyticus*, *S hominis*, *S warnerii*, *S saprophyticus*, *S saccharolyticus*, and *S cohnii*. These common hospital-acquired pathogens are less virulent than *S aureus*, and infections caused by them tend to be more indolent.

Because coagulase-negative staphylococci are normal inhabitants of human skin, it is difficult to distinguish infection from contamination, the latter perhaps accounting for three-fourths of blood culture isolates. Infection is more likely if the patient has a foreign body (eg, sternal wires, prosthetic joint, prosthetic cardiac valve, pacemaker, intracranial pressure monitor, cerebrospinal fluid shunt, peritoneal dialysis catheter) or an intravascular device in place. Purulent or serosanguineous drainage, erythema, pain, or tenderness at the site of the foreign body or device suggests infection. Instability and pain are signs of prosthetic joint infection. Fever, a new murmur, instability of the prosthesis, or signs of systemic embolization are evidence of prosthetic valve endocarditis. Immunosuppression and recent antimicrobial therapy are risk factors.

Infection is also more likely if the same strain is consistently isolated from two or more blood cultures (particularly if samples were obtained at different times) and from the foreign body site. Contamination is more likely when a single blood culture is positive or if more than one strain is isolated from blood cultures. The antimicrobial susceptibility pattern and speciation are used to determine whether one or more strains have been isolated. More sophisticated typing methods, eg, pulse-field gel electrophoresis of restriction enzyme digested chromosomal DNA, may be required to identify distinct strains.

Whenever possible, the intravascular device or foreign body suspected of being infected by coagulase-negative staphylococci should be removed. However, removal and replacement of some devices (eg, prosthetic joint, prosthetic valve, cerebrospinal fluid shunt) can be a difficult or risky procedure, and it may sometimes be preferable to treat with antibiotics alone with the understanding that the probability of cure is reduced and that surgical management may eventually be necessary.

Coagulase-negative staphylococci are commonly resistant to β -lactams and multiple other antibiotics. For patients with normal kidney function, vancomycin, 1 g intravenously every 12 hours, is the treatment of choice for suspected or confirmed infection caused by these organisms until susceptibility to penicillinase-resistant penicillins or other agents has been confirmed. Duration of therapy has not been established for relatively uncomplicated infections, such as those secondary to intravenous devices, which may be eliminated by simply removing the infected device. Infection involving bone or a prosthetic valve should be treated for 6 weeks. A combination regimen of vancomycin plus rifampin, 300 mg orally twice daily, plus gentamicin, 1 mg/kg intravenously every 8 hours, is recommended for treatment of prosthetic valve endocarditis caused by methicillin-resistant strains.

Raad I et al. Management of the catheter in documented catheter-related coagulase-negative staphylococcal bacteremia: remove or retain? Clin Infect Dis. 2009 Oct 15;49(8):1187–94. [PMID: 19780661]

CLOSTRIDIAL DISEASES

1. Clostridial Myonecrosis (Gas Gangrene)

ESSENTIALS OF DIAGNOSIS

- ▶ Sudden onset of pain and edema in an area of wound contamination.
- ▶ Prostration and systemic toxicity.
- ▶ Brown to blood-tinged watery exudate, with skin discoloration of surrounding area.
- ▶ Gas in the tissue by palpation or radiograph.
- ▶ Gram-positive rods in culture or smear of exudate.

▶ General Considerations

Gas gangrene or clostridial myonecrosis is produced by any one of several clostridia (*Clostridium perfringens*, *C ramosum*, *C bifermentans*, *C histolyticum*, *C novyi*, etc). Trauma and injection drug use are common predisposing conditions. Toxins produced in devitalized tissues under anaerobic conditions result in shock, hemolysis, and myonecrosis.

▶ Clinical Findings

A. Symptoms and Signs

The onset is usually sudden, with rapidly increasing pain in the affected area, hypotension, and tachycardia. Fever is present but is not proportionate to the severity of the infection. In the last stages of the disease, severe prostration, stupor, delirium, and coma occur.

The wound becomes swollen, and the surrounding skin is pale. There is a foul-smelling brown, blood-tinged serous discharge. As the disease advances, the surrounding tissue changes from pale to dusky and finally becomes deeply discolored, with coalescent, red, fluid-filled vesicles. Gas may be palpable in the tissues.

B. Laboratory Findings

Gas gangrene is a clinical diagnosis, and empiric therapy is indicated if the diagnosis is suspected. Radiographic studies may show gas within the soft tissues, but this finding is not specific. The smear shows absence of neutrophils and the presence of gram-positive rods. Anaerobic culture confirms the diagnosis.

▶ Differential Diagnosis

Other bacteria can produce gas in infected tissue, eg, enteric gram-negative organisms, or anaerobes.

► Treatment

Penicillin, 2 million units every 3 hours intravenously, is effective. Clindamycin may decrease the production of bacterial toxin, and some experts recommend the addition of clindamycin, 600–900 mg every 8 hours intravenously, to penicillin. Adequate surgical debridement and exposure of infected areas are essential, with radical surgical excision often necessary. Hyperbaric oxygen therapy has been used empirically but must be used in conjunction with administration of an appropriate antibiotic and surgical debridement.

Bryant AE et al. Clostridial myonecrosis: new insights in pathogenesis and management. *Curr Infect Dis Rep.* 2010 Sep;12(5):383–91. [PMID: 21308521]

2. *Clostridium sordellii* Toxic Shock Syndrome



ESSENTIALS OF DIAGNOSIS

- ▶ Sudden onset after medical abortion.
- ▶ Abdominal pain.
- ▶ Absence of fever.
- ▶ Tachycardia, severe hypotension, capillary leak syndrome with edema.
- ▶ Profound leukocytosis, hemoconcentration.

► General Considerations & Clinical Findings

C sordellii is a rare cause of endometritis and toxic shock syndrome following childbirth. Fatal cases of uterine infection following medically induced abortion with mifepristone have been reported. Onset of illness was within 4–5 days of ingestion of mifepristone and the clinical course fulminant. Infection appeared to be limited to the uterus, which showed necrosis, edema, hemorrhage, and acute inflammatory changes.

► Treatment

Early recognition, aggressive resuscitation from shock, immediate surgical debridement with hysterectomy, and administration of an antimicrobial that is active against *C sordellii* are essential to survival. Based on in vitro susceptibility data, any of several agents should be active, including penicillin, ampicillin, a macrolide, clindamycin, a tetracycline, or metronidazole. Whether a protein synthesis inhibitor to block further toxin production offers any advantage over a β -lactam is unknown.

Ho CS. Undiagnosed cases of fatal *Clostridium*-associated toxic shock in Californian women of childbearing age. *Am J Obstet Gynecol.* 2009 Nov;201(5):459.e1–7. [PMID: 19628200]

3. Tetanus



ESSENTIALS OF DIAGNOSIS

- ▶ History of wound and possible contamination.
- ▶ Jaw stiffness followed by spasms of jaw muscles (trismus).
- ▶ Stiffness of the neck and other muscles, dysphagia, irritability, hyperreflexia.
- ▶ Finally, painful convulsions precipitated by minimal stimuli.

► General Considerations

Tetanus is caused by the neurotoxin tetanospasmin, elaborated by *C tetani*. Spores of this organism are ubiquitous in soil and may germinate when introduced into a wound. The vegetative bacteria produce tetanospasmin, a zinc metalloprotease that cleaves synaptobrevin, a protein essential for neurotransmitter release. Tetanospasmin interferes with neurotransmission at spinal synapses of inhibitory neurons. As a result, minor stimuli result in uncontrolled spasms, and reflexes are exaggerated. The incubation period is 5 days to 15 weeks, with the average being 8–12 days.

Most cases occur in unvaccinated individuals. Persons at risk are the elderly, migrant workers, newborns, and injection drug users. While puncture wounds are particularly prone to causing tetanus, any wound, including bites or decubiti, may become colonized and infected by *C tetani*.

► Clinical Findings

A. Symptoms and Signs

The first symptom may be pain and tingling at the site of inoculation, followed by spasticity of the muscles nearby. Stiffness of the jaw, neck stiffness, dysphagia, and irritability are other early signs. Hyperreflexia develops later, with spasms of the jaw muscles (trismus) or facial muscles and rigidity and spasm of the muscles of the abdomen, neck, and back. Painful tonic convulsions precipitated by minor stimuli are common. Spasms of the glottis and respiratory muscles may cause acute asphyxia. The patient is awake and alert throughout the illness. The sensory examination is normal. The temperature is normal or only slightly elevated.

B. Laboratory Findings

The diagnosis of tetanus is made clinically.

► Differential Diagnosis

Tetanus must be differentiated from various acute central nervous system infections such as meningitis. Trismus may occasionally develop with the use of phenothiazines. Strychnine poisoning should also be considered.

► Complications

Airway obstruction is common. Urinary retention and constipation may result from spasm of the sphincters. Respiratory arrest and cardiac failure are late, life-threatening events.

► Prevention

Tetanus is preventable by active immunization (see Table 30–7). For primary immunization of adults, Td (tetanus and diphtheria toxoids vaccine) is administered as two doses 4–6 weeks apart, with a third dose 6–12 months later. For one of the doses, Tdap (tetanus toxoid, reduced dose diphtheria toxoid, acellular pertussis vaccine) should be substituted for Td. Booster doses are given every 10 years or at the time of major injury if it occurs more than 5 years after a dose. A single dose of Tdap is preferred to Td for wound prophylaxis if the patient has not been previously vaccinated with Tdap.

Passive immunization should be used in nonimmunized individuals and those whose immunization status is uncertain whenever a wound is contaminated or likely to have devitalized tissue. Tetanus immune globulin, 250 units, is given intramuscularly. Active immunization with tetanus toxoid is started concurrently. Table 33–2 provides a guide to prophylactic management.

► Treatment

A. Specific Measures

Human tetanus immune globulin, 500 units, should be administered intramuscularly within the first 24 hours of presentation. Whether intrathecal administration has any additional benefit is controversial. An unblinded, randomized trial comparing intramuscular tetanus immune globulin to intramuscular plus intrathecal tetanus immune globulin found more rapid resolution of spasms, fewer days of ventilatory support, and a shorter hospital stay in the intrathecal group. However, the exact immunoglobulin preparation that was used was not specified and the total dose was 4000 units. Tetanus does not produce natural immunity, and a full course of immunization with tetanus toxoid should be administered once the patient has recovered.

B. General Measures

Minimal stimuli can provoke spasms, so the patient should be placed at bed rest and monitored under the quietest conditions possible. Sedation, paralysis with curare-like agents, and mechanical ventilation are often necessary to control tetanic spasms. Penicillin, 20 million units intravenously daily in divided doses, is given to all patients—even those with mild illness—to eradicate toxin-producing organisms.

► Prognosis

High mortality rates are associated with a short incubation period, early onset of convulsions, and delay in treatment. Contaminated lesions about the head and face are more dangerous than wounds on other parts of the body.

Afshar M et al. Narrative review: tetanus—a health threat after natural disasters in developing countries. *Ann Intern Med.* 2011 Mar 1;154(5):329–35. [PMID: 21357910]
Centers for Disease Control and Prevention (CDC). Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine (Tdap) in pregnant women and persons who have or anticipate having close contact with an infant aged <12 months—Advisory Committee on Immunization Practices (ACIP), 2011. *MMWR Morb Mortal Wkly Rep.* 2011 Oct 21;60(41):1424–6. [PMID: 22012116]

4. Botulism



ESSENTIALS OF DIAGNOSIS

- History of recent ingestion of home-canned or smoked foods or of injection drug use and demonstration of toxin in serum or food.
- Sudden onset of diplopia, dry mouth, dysphagia, dysphonia, and muscle weakness progressing to respiratory paralysis.
- Pupils are fixed and dilated in most cases.

Table 33–2. Guide to tetanus prophylaxis in wound management.

History of Absorbed Tetanus Toxoid	Clean, Minor Wounds		All Other Wounds ¹	
	Tdap or Td ²	TIG ³	Tdap or Td ²	TIG ³
Unknown or < 3 doses	Yes	No	Yes	Yes
3 or more doses	No ⁴	No	No ⁵	No

¹Such as, but not limited to, wounds contaminated with dirt, feces, soil, saliva, etc; puncture wounds; avulsions; and wounds resulting from missiles, crushing, burns, and frostbite.

²Td indicates tetanus toxoid and diphtheria toxoid, adult form. Tdap indicates tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine, which may be substituted as a single dose for Td. Unvaccinated individuals should receive a complete series of three doses, one of which is Tdap.

³Human tetanus immune globulin, 250 units intramuscularly.

⁴Yes if more than 10 years have elapsed since last dose.

⁵Yes if more than 5 years have elapsed since last dose. (More frequent boosters are not needed and can enhance side effects.) Tdap has been safely administered within 2 years of Td vaccination, although local reactions to the vaccine may be increased.

► General Considerations

Botulism is a paralytic disease caused by botulinum toxin, which is produced by *C botulinum*, a ubiquitous, strictly anaerobic, spore-forming bacillus found in soil. Four toxin types—A, B, E, and F—cause human disease. Botulinum toxin is a zinc metalloprotease that cleaves a specific component of the synaptic vesicle membrane docking and fusion complex at the neuromuscular junction blocking release of the neurotransmitter acetylcholine. Botulinum toxin is extremely potent and is classified by the CDC as a high-priority agent because of its potential for use as an agent of bioterrorism. Naturally occurring botulism occurs in one of three forms: food-borne botulism, infant botulism, or wound botulism. Food-borne botulism is caused by ingestion of preformed toxin present in canned, smoked, or vacuum-packed foods such as home-canned vegetables, smoked meats, and vacuum-packed fish. Commercial foods have also been associated with outbreaks of botulism. Infant botulism (associated with ingestion of honey) and wound botulism (which typically occurs in association with injection drug use) result from organisms present in the gut or wound that elaborate toxin in vivo.

► Clinical Findings

A. Symptoms and Signs

Twelve to 36 hours after ingestion of the toxin, visual disturbances appear, particularly diplopia and loss of accommodation. Ptosis, cranial nerve palsies with impairment of extraocular muscles, and fixed dilated pupils are characteristic signs. The sensory examination is normal. Other symptoms are dry mouth, dysphagia, and dysphonia. Nausea and vomiting may be present, particularly with type E toxin. The sensorium remains clear and the temperature normal. Paralysis progressing to respiratory failure and death may occur unless mechanical assistance is provided.

B. Laboratory Findings

Toxin in patients' serum and in suspected foods can be demonstrated by mouse inoculation and identified with specific antiserum.

► Differential Diagnosis

Because the clinical presentation of botulism is so distinctive and the differential diagnosis limited, botulism once considered is not easily confused with other diseases. Cranial nerve involvement may be seen with verte-brobasilar insufficiency, the C. Miller Fisher variant of Guillain-Barré syndrome, myasthenia gravis, or any basilar meningitis (infectious or carcinomatous). Intestinal obstruction or other types of food poisoning are considered when nausea and vomiting are present.

► Treatment

If botulism is suspected, the practitioner should contact the state health authorities or the CDC for advice and help with procurement of equine serum heptavalent botulism

antitoxin and for assistance in obtaining assays for toxin in serum, stool, or food. Skin testing is recommended to exclude hypersensitivity to the antitoxin preparation. Antitoxin should be administered as early as possible, ideally within 24 hours of the onset of symptoms or signs, to arrest progression of disease; its administration should not be delayed for laboratory confirmation of the diagnosis. Respiratory failure is managed with intubation and mechanical ventilation. Parenteral fluids or alimentation should be given while swallowing difficulty persists. The removal of unabsorbed toxin from the gut may be attempted. Any remnants of suspected foods should be assayed for toxin. Persons who might have eaten the suspected food must be located and observed.

Chalk C et al. Medical treatment for botulism. *Cochrane Database Syst Rev*. 2011 Mar 16;(3):CD008123. [PMID: 21412916]

ANTHRAX



ESSENTIALS OF DIAGNOSIS

- Appropriate epidemiologic setting, eg, exposure to animals or animal hides, or potential exposure from an act of bioterrorism.
- A painless cutaneous black eschar on exposed areas of the skin, with marked surrounding edema and vesicles.
- Nonspecific flu-like symptoms that rapidly progress to extreme dyspnea and shock; mediastinal widening and pleural effusions on chest radiograph.

► General Considerations

The death of a Florida photo editor from inhalational anthrax acquired from a letter deliberately contaminated with spores of *Bacillus anthracis* thrust this extremely rare infection into the public awareness. Between September 18 and November 21 of 2001, there were 13 cases of cutaneous anthrax and 11 cases of inhalational anthrax associated with exposure to anthrax spores in contaminated mail.

Naturally occurring anthrax is a disease of sheep, cattle, horses, goats, and swine. *B anthracis* is a gram-positive spore-forming aerobic rod. Spores—not vegetative bacteria—are the infectious form of the organism. These are transmitted to humans from contact with contaminated animals, animal products, or animal hides, or from soil by inoculation of broken skin or mucous membranes; by inhalation of aerosolized spores; or, rarely, by ingestion resulting in cutaneous, inhalational, or gastrointestinal forms of anthrax, respectively. Spores germinate into vegetative bacteria that multiply locally in cutaneous and gastrointestinal anthrax but may also disseminate to cause systemic infection. Inhaled spores are ingested by pulmonary macrophages and carried via lymphatics to regional lymph nodes, where they germinate. The bacteria rapidly

multiply within the lymphatics, causing a hemorrhagic lymphadenitis. Invasion of the bloodstream leads to overwhelming sepsis, killing the host.

► Clinical Findings

A. Symptoms and Signs

1. Cutaneous anthrax—This occurs within 2 weeks after exposure to spores; there is no latency period for cutaneous disease as there is with inhalational anthrax. The initial lesion is an erythematous papule, often on an exposed area of skin that vesiculates and then ulcerates and undergoes necrosis, ultimately progressing to a purple to black eschar. The eschar typically is painless; pain indicates secondary staphylococcal or streptococcal infection. The surrounding area is edematous and vesicular but not purulent. Regional adenopathy, fever, malaise, headache, and nausea and vomiting may be present. The infection is self-limited in most cases, but hematogenous spread with sepsis or meningitis may occur.

2. Inhalational anthrax—Illness occurs in two stages, beginning on average 10 days after exposure, but may have a latent onset 6 weeks after exposure. Nonspecific viral-like symptoms such as fever, malaise, headache, dyspnea, cough, and congestion of the nose, throat, and larynx are characteristic of the initial stage. Anterior chest pain is an early symptom of mediastinitis. Within hours to a few days, progression to the fulminant stage of infection occurs in which symptoms or signs of overwhelming sepsis predominate. Delirium, obtundation, or findings of meningeal irritation suggest an accompanying hemorrhagic meningitis.

3. Gastrointestinal anthrax—This form was recently reported in the United States. Fever, diffuse abdominal pain, rebound abdominal tenderness, vomiting, constipation, and diarrhea occur 2–5 days after ingestion of meat contaminated with anthrax spores. The primary lesion is ulcerative, producing emesis that may be blood-tinged or coffee-ground and stool that may be blood-tinged or melanic. Bowel perforation can occur. The oropharyngeal form of the disease is characterized by local lymphadenopathy, cervical edema, dysphagia, and upper respiratory tract obstruction.

B. Laboratory Findings

Laboratory findings are nonspecific. The white blood cell count initially may be normal or modestly elevated, with polymorphonuclear predominance and an increase in early forms. Pleural fluid from patients with inhalational anthrax is typically hemorrhagic with few white cells. Cerebrospinal fluid from meningitis cases is also hemorrhagic. Gram stain of pleural fluid, cerebrospinal fluid, unspun blood, blood culture, or fluid from a cutaneous lesion may show the characteristic boxcar-shaped encapsulated rods in chains.

The diagnosis is established by isolation of the organism from culture of the skin lesion (or fluid expressed from it), blood, or pleural fluid—or cerebrospinal fluid in cases of meningitis. In the absence of prior antimicrobial therapy, cultures are invariably positive. Cultures obtained after initiation of antimicrobial therapy may be negative. If

anthrax is suspected on clinical or epidemiologic grounds, immunohistochemical tests (eg, to detect capsular antigen), polymerase chain reaction assays, and serologic tests (useful for documenting past cutaneous infection) are available through the CDC and should be used to establish the diagnosis. Any suspected case of anthrax should be immediately reported to the CDC so that a complete investigation can be conducted.

C. Imaging

The chest radiograph is the most sensitive test for inhalational disease, being abnormal (though the findings can be subtle) initially in every case of bioterrorism-associated disease. Mediastinal widening due to hemorrhagic lymphadenitis, a hallmark feature of the disease, has been present in 70% of the bioterrorism-related cases. Pleural effusions were present initially or occurred over the course of illness in all cases, and approximately three-fourths had pulmonary infiltrates or signs of consolidation.

► Differential Diagnosis

Cutaneous anthrax, despite its characteristic appearance, can be confused with a variety of other also uncommon or rare conditions such as ecthyma gangrenosum, rat-bite fever, ulceroglandular tularemia, plague, glanders, rickettsialpox, orf (parapoxvirus infection), or cutaneous mycobacterial infection. Inhalational anthrax must be differentiated from mediastinitis due to other bacterial causes, fibrous mediastinitis due to histoplasmosis, coccidioidomycosis, atypical or viral pneumonia, silicosis, sarcoidosis, and other causes of mediastinal widening (eg, superior vena cava syndrome or aortic aneurysm or dissection). Gastrointestinal anthrax shares clinical features with a variety of common intra-abdominal disorders, including bowel obstruction, perforated viscus, peritonitis, gastroenteritis, and peptic ulcer disease.

► Treatment

Strains of *B anthracis* (including the strain isolated in the bioterrorism cases) are susceptible in vitro to penicillin, amoxicillin, chloramphenicol, clindamycin, imipenem, doxycycline, ciprofloxacin (as well as other fluoroquinolones), macrolides, rifampin, and vancomycin. *B anthracis* may express β -lactamases that confer resistance to cephalosporins and penicillins. For this reason, penicillin or amoxicillin is no longer recommended for use as a single agent in treatment of disseminated disease. Based on results of animal experiments and because of concern for engineered drug resistance in strains of *B anthracis* used in bioterrorism, ciprofloxacin is considered the drug of choice (Table 33–3) for treatment and for prophylaxis following exposure to anthrax spores. Other fluoroquinolones with activity against gram-positive bacteria (eg, levofloxacin, moxifloxacin) are likely to be just as effective as ciprofloxacin. Doxycycline is an alternative first-line agent. Combination therapy with at least one additional agent is recommended for inhalational or disseminated disease and in cutaneous infection involving the face, head, and neck or associated with extensive local edema or systemic signs of

Table 33-3. Antimicrobial agents for treatment of anthrax or for prophylaxis against anthrax.

First-line agents and recommended doses
Ciprofloxacin, 500 mg twice daily orally or 400 mg every 12 hours intravenously
Doxycycline, 100 mg every 12 hours orally or intravenously
Second-line agents and recommended doses
Amoxicillin, 500 mg three times daily orally
Penicillin G, 2-4 million units every 4 hours intravenously
Alternative agents with in vitro activity and suggested doses
Rifampin, 10 mg/kg/d orally or intravenously
Clindamycin, 450-600 mg every 8 hours orally or intravenously
Clarithromycin, 500 mg orally twice daily
Erythromycin, 500 mg every 6 hours intravenously
Vancomycin, 1 g every 12 hours intravenously
Imipenem, 500 mg every 6 hours intravenously

infection, eg, fever, tachycardia and elevated white blood cell count. Single-drug therapy is recommended for prophylaxis following exposure to spores.

The required duration of therapy is poorly defined. In naturally occurring disease, treatment for 7-10 days for cutaneous disease and for at least 2 weeks following clinical response for disseminated, inhalational, or gastrointestinal infection have been standard recommendations. Because of concern about relapse from latent spores acquired by inhalation of aerosol in bioterrorism-associated cases, the initial recommendation was treatment for 60 days.

▶ Prevention

In 2001, the CDC offered one of two options for postal workers receiving prophylaxis for exposure to contaminated mail: (1) antibiotics for 100 days (fearing that even with 60 days of treatment late relapses might occur) or (2) vaccination with an investigational agent (three doses administered over a 1-month period) in conjunction with 40 days of antibiotic administration to cover the time required for a protective antibody response to develop. Insufficient information exists to favor one recommendation over the other.

There is also an FDA-approved vaccine for persons at high risk for exposure to anthrax spores. The vaccine is cell-free antigen prepared from an attenuated strain of *B anthracis*. Multiple injections over 18 months and an annual booster dose are required to achieve and maintain protection. Existing supplies have been reserved for vaccination of military personnel.

▶ Prognosis

The prognosis in cutaneous infection is excellent. Death is unlikely if the infection has remained localized, and lesions heal without complications in most cases. The reported mortality rate for gastrointestinal and inhalational infections is up to 85%. The experience with bioterrorism-associated inhalational cases in which six of eleven victims survived suggests a somewhat better outcome with modern supportive care and antibiotics provided that treatment is initiated before the patient has progressed to the fulminant stage of disease. No cases of

anthrax have occurred among the several thousand individuals receiving antimicrobial prophylaxis following exposure to spores.

Centers for Disease Control and Prevention (CDC). Gastrointestinal anthrax after an animal-hide drumming event—New Hampshire and Massachusetts, 2009. *MMWR Morb Mortal Wkly Rep.* 2010 Jul 23;59(28):872-7. [PMID: 20651643]

Doganay M et al. A review of cutaneous anthrax and its outcome. *J Infect Public Health.* 2010;3(3):98-105. [PMID: 20869669]

DIPHTHERIA



ESSENTIALS OF DIAGNOSIS

- ▶ Tenacious gray membrane at portal of entry in pharynx.
- ▶ Sore throat, nasal discharge, hoarseness, malaise, fever.
- ▶ Myocarditis, neuropathy.
- ▶ Culture confirms the diagnosis.

▶ General Considerations

Diphtheria is an acute infection caused by *Corynebacterium diphtheriae* that usually attacks the respiratory tract but may involve any mucous membrane or skin wound. The organism is spread chiefly by respiratory secretions. Exotoxin produced by the organism is responsible for myocarditis and neuropathy. This exotoxin inhibits elongation factor, which is required for protein synthesis.

▶ Clinical Findings

A. Symptoms and Signs

Nasal, laryngeal, pharyngeal, and cutaneous forms of diphtheria occur. Nasal infection produces few symptoms other than a nasal discharge. Laryngeal infection may lead to upper airway and bronchial obstruction. In pharyngeal diphtheria, the most common form, a tenacious gray membrane covers the tonsils and pharynx. Mild sore throat, fever, and malaise are followed by toxemia and prostration.

Myocarditis and neuropathy are the most common and most serious complications. Myocarditis causes cardiac arrhythmias, heart block, and heart failure. The neuropathy usually involves the cranial nerves first, producing diplopia, slurred speech, and difficulty in swallowing.

B. Laboratory Findings

The diagnosis is made clinically but can be confirmed by culture of the organism.

▶ Differential Diagnosis

Diphtheria must be differentiated from streptococcal pharyngitis, infectious mononucleosis, adenovirus or herpes simplex infection, Vincent angina, pharyngitis due to

Arcanobacterium haemolyticum, and candidiasis. A presumptive diagnosis of diphtheria should be made on clinical grounds without waiting for laboratory verification, since emergency treatment is needed.

► Prevention

Active immunization with diphtheria toxoid is part of routine childhood immunization with appropriate booster injections. The immunization schedule for adults is the same as for tetanus.

Susceptible persons exposed to diphtheria should receive a booster dose of diphtheria toxoid (or a complete series if previously unimmunized), as well as a course of penicillin or erythromycin.

► Treatment

Antitoxin, which is prepared from horse serum, must be given in all cases when diphtheria is suspected. For mild early pharyngeal or laryngeal disease, the dose is 20,000–40,000 units; for moderate nasopharyngeal disease, 40,000–60,000 units; for severe, extensive, or late (3 days or more) disease, 80,000–100,000 units. Diphtheria equine antitoxin can be obtained from the CDC.

Removal of membrane by direct laryngoscopy or bronchoscopy may be necessary to prevent or alleviate airway obstruction.

Either penicillin, 250 mg orally four times daily, or erythromycin, 500 mg orally four times daily, for 14 days is effective therapy, although erythromycin is slightly more effective in eliminating the carrier state. Azithromycin or clarithromycin is probably as effective as erythromycin. The patient should be isolated until three consecutive cultures at the completion of therapy have documented elimination of the organism from the oropharynx. Contacts to a case should receive erythromycin, 500 mg orally four times daily for 7 days, to eradicate carriage.

Centers for Disease Control and Prevention (CDC). Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine (Tdap) in pregnant women and persons who have or anticipate having close contact with an infant aged <12 months—Advisory Committee on Immunization Practices (ACIP), 2011. *MMWR Morb Mortal Wkly Rep.* 2011 Oct 21;60(41):1424–6. [PMID: 22012116]

LISTERIOSIS

ESSENTIALS OF DIAGNOSIS

- Ingestion of contaminated food product leads to primary infection.
- Undifferentiated fever in a pregnant woman in her third trimester.
- Altered mental status and fever in an elderly or immunocompromised patient.
- Obtain blood and cerebral spinal fluid cultures.
- Culture confirms the diagnosis.

► General Considerations

Listeria monocytogenes is a facultative, motile, gram-positive rod that is capable of invading several cell types and causes intracellular infection. Most cases of infection caused by *L. monocytogenes* are sporadic, but outbreaks have been traced to eating contaminated food, including unpasteurized dairy products, hot dogs, and delicatessen meats. In 2011, a multistate outbreak of *Listeria* infection was traced to contaminated cantaloupes. This outbreak resulted in 146 infections, 30 deaths, and 1 miscarriage in a pregnant woman.

► Clinical Findings

Five types of infection are recognized:

(1) **Infection during pregnancy**, usually in the last trimester, is a mild febrile illness without an apparent primary focus. This relatively benign disease for the mother may resolve without specific therapy. However, approximately one in five pregnancies complicated by listeriosis result in spontaneous abortion or stillbirth and surviving infants are at high risk for clinical neonatal listeriosis.

(2) **Granulomatosis infantisepticum** is a neonatal infection acquired in utero, characterized by disseminated abscesses, granulomas, and a high mortality rate.

(3) **Bacteremia** with or without sepsis syndrome is an infection of neonates or immunocompromised adults. The presentation is of a febrile illness without a recognized source.

(4) **Meningitis** caused by *L. monocytogenes* affects infants under 2 months of age as well as older adults, ranking third after meningococcus and pneumococcus as common causes of bacterial meningitis. Cerebrospinal fluid shows a *neutrophilic* pleocytosis. Adults with meningitis are often immunocompromised, and cases have been associated with HIV infection and therapy with tumor necrosis factor (TNF) inhibitors such as infliximab.

(5) Finally, **focal infections**, including adenitis, brain abscess, endocarditis, osteomyelitis, and arthritis, occur rarely.

► Treatment

Ampicillin, 8–12 g/d intravenously in four to six divided doses (the higher dose for meningitis) is considered the treatment of choice. Gentamicin, 5 mg/kg/d intravenously once or in divided doses is synergistic with ampicillin against *Listeria* in vitro and in animal models, and the use of combination therapy may be considered during the first few days of treatment to enhance eradication of organisms. In patients with penicillin allergies, trimethoprim-sulfamethoxazole has excellent intracellular and cerebrospinal fluid penetration and is considered an appropriate alternative. The dose is 10–20 mg/kg/d intravenously of the trimethoprim component. Mortality and morbidity rates still are high. Therapy should be administered for at least 2–3 weeks. Longer durations—between 3 and 6 weeks—have been recommended for treatment of meningitis, especially in immunocompromised persons.

Centers for Disease Control and Prevention (CDC). Multistate outbreak of listeriosis associated with Jensen Farms cantaloupe—United States, August–September 2011. *MMWR Morb Mortal Wkly Rep.* 2011 Oct 7;60(39):1357–8. [PMID: 21976119]

INFECTIVE ENDOCARDITIS

ESSENTIALS OF DIAGNOSIS

- ▶ Fever.
- ▶ Preexisting organic heart lesion.
- ▶ Positive blood cultures.
- ▶ Evidence of vegetation on echocardiography.
- ▶ New or changing heart murmur.
- ▶ Evidence of systemic emboli.

General Considerations

Endocarditis is a bacterial or fungal infection of the valvular or endocardial surface of the heart. The clinical presentation depends on the infecting organism and the valve or valves that are infected. More virulent organisms—*S aureus* in particular—tend to produce a more rapidly progressive and destructive infection. Endocarditis caused by more virulent organisms often presents as an acute febrile illness and is complicated by early embolization, acute valvular regurgitation, and myocardial abscess formation. Viridans strains of streptococci, enterococci, other bacteria, yeasts, and fungi tend to cause a more subacute picture.

Underlying valvular disease, less common than in the past, is present in about 50% of cases. Valvular disease alters blood flow and produces jet effects that disrupt the endothelial surface, providing a nidus for attachment and infection of microorganisms that enter the bloodstream. Predisposing valvular abnormalities include rheumatic involvement of any valve, bicuspid aortic valves, calcific or sclerotic aortic valves, hypertrophic subaortic stenosis, mitral valve prolapse, and a variety of congenital disorders such as ventricular septal defect, tetralogy of Fallot, coarctation of the aorta, or patent ductus arteriosus. Rheumatic disease is no longer the major predisposing factor in developed countries. Regurgitation lesions are more susceptible than stenotic ones.

The initiating event in native valve endocarditis is colonization of the valve by bacteria or yeast that gain access to the bloodstream. Transient bacteremia is common during dental, upper respiratory, urologic, and lower gastrointestinal diagnostic and surgical procedures. It is less common during upper gastrointestinal and gynecologic procedures. Intravascular devices are increasingly implicated as a portal of access of microorganisms into the bloodstream. A large proportion of cases of *S aureus* endocarditis are attributable to healthcare-associated bacteremia.

Native valve endocarditis is usually caused by viridans streptococci, group D streptococci, *S aureus*, enterococci,

or HACEK organisms (an acronym for *Haemophilus aphrophilus* [now *Aggregatibacter aphrophilus*], *Actinobacillus actinomycetemcomitans* [now *Aggregatibacter actinomycetemcomitans*], *Cardiobacterium hominis*, *Eikenella corrodens*, and *Kingella* species). Streptococcal species formerly accounted for the majority of native valve endocarditis cases, but the proportion of cases caused by *S aureus* has been increasing, and this organism is now the leading cause. Gram-negative organisms and fungi account for a small percentage.

In injection drug users, *S aureus* accounts for over 60% of all endocarditis cases and for 80–90% of cases in which the tricuspid valve is infected. Enterococci and streptococci comprise the balance in about equal proportions. Gram-negative aerobic bacilli, fungi, and unusual organisms may cause endocarditis in injection drug users.

The microbiology of prosthetic valve endocarditis also is distinctive. Early infections (ie, those occurring within 2 months after valve implantation) are commonly caused by staphylococci—both coagulase-positive and coagulase-negative—gram-negative organisms, and fungi. In late prosthetic valve endocarditis, streptococci are commonly identified, although coagulase-negative and coagulase-positive staphylococci still cause many cases.

Clinical Findings

A. Symptoms and Signs

Virtually all patients have fever at some point in the illness, although it may be very low grade (< 38°C) in elderly individuals and in patients with heart failure or kidney failure. Rarely, there may be no fever at all.

The duration of illness typically is a few days to a few weeks. Nonspecific symptoms are common. The initial symptoms and signs of endocarditis may be caused by direct arterial, valvular, or cardiac damage. Although a changing regurgitant murmur is significant diagnostically, it is the exception rather than the rule. Symptoms also may occur as a result of embolization, metastatic infection or immunologically mediated phenomena. These include cough; dyspnea; arthralgias or arthritis; diarrhea; and abdominal, back, or flank pain.

The characteristic peripheral lesions—petechiae (on the palate or conjunctiva or beneath the fingernails), subungual (“splinter”) hemorrhages (Figure 33–3), Osler nodes (painful, violaceous raised lesions of the fingers, toes, or feet) (Figure 33–4), Janeway lesions (painless erythematous lesions of the palms or soles), and Roth spots (exudative lesions in the retina)—occur in about 25% of patients. Strokes and major systemic embolic events are present in about 25% of patients, and tend to occur before or within the first week of antimicrobial therapy. Hematuria and proteinuria may result from emboli or immunologically mediated glomerulonephritis, which can cause kidney dysfunction.

B. Imaging

Chest radiograph may show evidence for the underlying cardiac abnormality and, in right-sided endocarditis, pulmonary infiltrates. The electrocardiogram is nondiagnostic,



▲ **Figure 33-3.** Splinter hemorrhages appearing as red lineal streaks under the nail plate and within the nail bed, in endocarditis, psoriasis, and trauma. (Courtesy of Richard P. Usatine, MD; used, with permission, from Usatine RP, Smith MA, Mayeaux EJ Jr, Chumley H, Tysinger J. *The Color Atlas of Family Medicine*. McGraw-Hill, 2009.)

but new conduction abnormalities suggest myocardial abscess formation. Echocardiography is useful in identifying vegetations and other characteristic features suspicious for endocarditis and may provide adjunctive information about the specific valve or valves that are infected. The sensitivity of transthoracic echocardiography is between 55% and 65%; it cannot reliably rule out endocarditis but may confirm a clinical suspicion. TEE is 90% sensitive in detecting vegetations and is particularly useful for identifying valve ring abscesses as well as prosthetic valve endocarditis.

C. Diagnostic Studies

1. Blood cultures—Blood cultures establish the diagnosis. Three sets of blood cultures at least 1 hour apart before starting antibiotics are recommended to maximize the opportunity for a microbiologic diagnosis. Approximately 5% of cases will be culture-negative, usually attributable to administration of antimicrobials prior to obtaining cultures. If antimicrobial therapy has been administered prior to obtaining cultures and the patient is clinically stable, it is reasonable to withhold further antimicrobial therapy for 2–3 days so that appropriate cultures can be obtained. Culture-negative endocarditis may also be due to a fungus, organisms that require special media for growth (eg, *Legionella*, *Bartonella*, *Abiotrophia* species, formerly referred to as nutritionally deficient streptococci), organisms that do not grow on artificial media (*Tropheryma whippelii*, or pathogens of Q fever or psittacosis), or those that are slow-growing and may require prolonged incubation (eg, *Brucella*, anaerobes, HACEK organisms). *Bartonella*



▲ **Figure 33-4.** Osler node causing pain within the pulp of the big toe and multiple painless flat Janeway lesions over the sole of the foot. (Courtesy of David A. Kasper, DO, MBA; used, with permission, from Usatine RP, Smith MA, Mayeaux EJ Jr, Chumley H, Tysinger J. *The Color Atlas of Family Medicine*. McGraw-Hill, 2009.)

quintana has emerged as an important cause of culture-negative endocarditis.

2. Modified Duke Criteria—Clinical criteria, referred to as the Modified Duke criteria, for the diagnosis of endocarditis have been proposed. Major criteria include: (1) two positive blood cultures for a microorganism that typically causes infective endocarditis or persistent bacteremia; (2) evidence of endocardial involvement documented by echocardiography (eg, definite vegetation, myocardial abscess, or new partial dehiscence of a prosthetic valve); or (3) development of a new regurgitant murmur. Minor criteria include the presence of a predisposing condition; fever $\geq 38^{\circ}\text{C}$; vascular phenomena, such as cutaneous hemorrhages, aneurysm, systemic emboli, pulmonary infarction; immunologic phenomena, such as glomerulonephritis, Osler nodes, Roth spots, rheumatoid factor; and positive blood cultures not meeting the major criteria or serologic evidence of an active infection. A definite diagnosis can be made with 80% accuracy if two major criteria, one major

criterion and three minor criteria, or five minor criteria are fulfilled. A possible diagnosis of endocarditis is made if one major and one minor criterion or three minor criteria are met. If fewer criteria are found, or a sound alternative explanation for illness is identified, or the endocarditis syndrome has resolved and the patient has defervesced within 4 days, endocarditis is unlikely.

► **Complications**

The course of infective endocarditis is determined by the degree of damage to the heart, by the site of infection (right-sided versus left-sided, aortic versus mitral valve), by the presence of metastatic foci of infection, by the occurrence of embolization, and by immunologically mediated processes. Destruction of infected heart valves is especially common and precipitous with *S aureus* but can occur with any organism and can progress even after bacteriologic cure. The infection can also extend into the myocardium, resulting in abscesses leading to conduction disturbances, and involving the wall of the aorta, creating sinus of Valsalva aneurysms.

Peripheral embolization to the brain and myocardium may result in infarctions. Embolization to the spleen and kidneys is also common. Peripheral emboli may initiate metastatic infections or may become established in vessel walls, leading to mycotic aneurysms. Right-sided endocarditis, which usually involves the tricuspid valve, causes septic pulmonary emboli, occasionally with infarction and lung abscesses.

► **Prevention**

In 2007, the American Heart Association made major revisions to their recommendation on antibiotic prophylaxis for infective endocarditis. The committee determined that only a few cases of infective endocarditis would be prevented by antibiotic prophylaxis for dental procedures even if the prophylactic therapy were 100% effective. Therefore, they limited their recommendations for prophylaxis to a small group of patients with predisposing congenital or valvular anomalies (Table 33–4) undergoing select dental procedures, operations involving the respiratory tract, or operations of infected skin, skin structure, or musculoskeletal tissue (Table 33–5). Current antimicrobial recommendations are given in Table 33–6.

► **Treatment**

Empiric regimens for endocarditis while culture results are pending should include agents active against staphylococci, streptococci, and enterococci. Vancomycin 1 g every 12 hours intravenously plus ceftriaxone 2 g every 24 hours provides appropriate coverage pending definitive diagnosis.

A. Viridans Streptococci

For penicillin-susceptible viridans streptococcal endocarditis (ie, MIC ≤ 0.1 mcg/mL), penicillin G, 2–3 million units intravenously every 4 hours for 4 weeks, is recommended. The duration of therapy can be shortened to

Table 33–4. Cardiac conditions with high risk of adverse outcomes from endocarditis for which prophylaxis with dental procedures is recommended.^{1,2}

Prosthetic cardiac valve
Previous infective endocarditis
Congenital heart disease (CHD) ³
Unrepaired cyanotic CHD, including palliative shunts and conduits
Completely repaired congenital heart defect with prosthetic material or device, whether placed by surgery or by catheter intervention, during the first 6 months after the procedure ⁴
Repaired CHD with residual defects at the site or adjacent to the site of a prosthetic patch or prosthetic device
Cardiac transplantation recipients in whom cardiac valvulopathy develops

¹Reproduced, with permission, from the American Heart Association. *Circulation*. 2007 Oct 9;116(15):1736–54.

²See Table 33–6 for prophylactic regimens.

³Except for the conditions listed above, antibiotic prophylaxis is no longer recommended for other forms of CHD.

⁴Prophylaxis is recommended because endothelialization of prosthetic material occurs within 6 months after procedure.

2 weeks if gentamicin, 1 mg/kg intravenously every 8 hours, is used with penicillin. Ceftriaxone, 2 g once daily intravenously or intramuscularly for 4 weeks, is also effective therapy for penicillin-susceptible strains and is a convenient regimen for home therapy. For the penicillin-allergic patient, vancomycin, 15 mg/kg intravenously every 12 hours for 4 weeks, is given. The 2-week regimen is not recommended for patients with symptoms of more than 3 months' duration or with complications such as myocardial abscess or extracardiac infection. Prosthetic valve endocarditis is treated with a 6-week course of penicillin with at least 2 weeks of gentamicin.

Viridans streptococci relatively resistant to penicillin (ie, MIC > 0.1 mcg/mL but ≤ 0.5 mcg/mL) should be

Table 33–5. Recommendations for administration of bacterial endocarditis prophylaxis for patients according to type of procedure.¹

Prophylaxis Recommended	Prophylaxis Not Recommended
Dental procedures All dental procedures that involve manipulation of gingival tissue or the periapical region of the teeth or perforation of the oral mucosa	Dental procedures Routine anesthetic injections through noninfected tissue, taking dental radiographs, placement of removable prosthodontic or orthodontic appliances, adjustment of orthodontic appliances, placement of orthodontic brackets, shedding of deciduous teeth, and bleeding from trauma to the lips or oral mucosa
Respiratory tract procedures Only respiratory tract procedures that involve incision of the respiratory mucosa	
Procedures on infected skin, skin structure, or musculoskeletal tissue	Gastrointestinal tract procedures Genitourinary tract procedures

¹Reproduced, with permission, from the American Heart Association. *Circulation*. 2007 Oct 9;116(15):1736–54.

Table 33-6. American Heart Association recommendations for endocarditis prophylaxis for dental procedures for patients with cardiac conditions.¹⁻³

Oral	Amoxicillin	2 g 1 hour before procedure
	Penicillin allergy	
	Clindamycin	600 mg 1 hour before procedure
	or	
	Cephalexin	2 g 1 hour before procedure (contraindicated if there is history of a β -lactam immediate hypersensitivity reaction)
	or	
	Azithromycin or clarithromycin	500 mg 1 hour before procedure
Parenteral	Ampicillin	2 g intramuscularly or intravenously 30 minutes before procedure
Penicillin allergy	Clindamycin	600 mg intravenously 1 hour before procedure
	or	
	Cefazolin	1 g intramuscularly or intravenously 30 minutes before procedure (contraindicated if there is history of a β -lactam immediate hypersensitivity reaction)

¹Data from the American Heart Association. *Circulation*. 2007 Oct 9;116(15):1736-54.

²For patients undergoing respiratory tract procedures involving incision of respiratory tract mucosa to treat an established infection or a procedure on infected skin, skin structure, or musculoskeletal tissue known or suspected to be caused by *S aureus*, the regimen should contain an anti-staphylococcal penicillin or cephalosporin. Vancomycin can be used to treat patients unable to tolerate a β -lactam or if the infection is known or suspected to be caused by a methicillin-resistant strain of *S aureus*.

³See Table 33-4 for list of cardiac conditions.

treated for 4 weeks. Penicillin G, 3 million units intravenously every 4 hours, is combined with gentamicin, 1 mg/kg intravenously every 8 hours for the first 2 weeks. In the patient with IgE-mediated allergy to penicillin, vancomycin alone, 15 mg/kg intravenously every 12 hours for 4 weeks, should be administered.

Endocarditis caused by viridans streptococci with an MIC > 0.5 mcg/mL or by nutritionally deficient streptococci should be treated the same as enterococcal endocarditis (see below).

B. Other Streptococci

Endocarditis caused by *S pneumoniae*, *S pyogenes* (group A streptococcus), or groups B, C, and G streptococci is unusual. *S pneumoniae* sensitive to penicillin (MIC < 0.1 mcg/mL) can be treated with penicillin alone, 2–3 million units intravenously every 4 hours for 4–6 weeks. Vancomycin should be effective for endocarditis caused by strains resistant to penicillin. Group A streptococcal infection can be treated with penicillin, ceftriaxone, or vancomycin for 4–6 weeks. Groups B, C, and G streptococci tend to be more resistant to penicillin than group A streptococci, and some experts have recommended adding gentamicin, 1 mg/kg intravenously every 8 hours, to penicillin for the first 2 weeks of a 4- to 6-week course. Endocarditis caused by *S bovis* is associated with liver disease and gastrointestinal abnormalities, especially colon cancer. Colonoscopy should be performed to exclude the latter.

C. Enterococci

For enterococcal endocarditis, penicillin alone is inadequate; either streptomycin or gentamicin must be included

in the regimen. Because aminoglycoside resistance occurs in enterococci, susceptibility should be documented. Gentamicin is the aminoglycoside of choice, because streptomycin resistance is more common and the nephrotoxicity of gentamicin is generally more easily managed than the vestibular toxicity of streptomycin. Ampicillin, 2 g intravenously every 4 hours, or penicillin G, 3–4 million units intravenously every 4 hours (or, in the penicillin-allergic patient, vancomycin, 15 mg/kg intravenously every 12 hours), plus gentamicin, 1 mg/kg intravenously every 8 hours, are recommended. The recommended duration of combination therapy is 4–6 weeks (the longer duration for patients with symptoms for more than 3 months, relapse, or prosthetic valve endocarditis), although a study from Sweden found that discontinuing the aminoglycoside before 4 weeks did not reduce efficacy. Experience is more extensive with penicillin and ampicillin than with vancomycin for treatment of enterococcal endocarditis, and penicillin and ampicillin are superior to vancomycin in vitro. Thus, whenever possible, either ampicillin or penicillin should be used.

Endocarditis caused by strains resistant to penicillin, vancomycin, or aminoglycosides is particularly difficult to treat. Such cases should be treated according to recent American Heart Association guidelines and managed in consultation with an infectious diseases specialist.

D. Staphylococci

For methicillin-susceptible *S aureus*, nafcillin or oxacillin, 1.5–2 g intravenously every 4 hours for 6 weeks, is the preferred therapy. Uncomplicated tricuspid valve endocarditis probably can be treated for 2 weeks with nafcillin or oxacillin alone. For penicillin-allergic patients, cefazolin, 2 g

intravenously every 8 hours, or vancomycin, 30 mg/kg/d intravenously divided in two or three doses, may be used. For methicillin-resistant strains, vancomycin remains the preferred agent. Aminoglycoside combination regimens are probably of no benefit and in general should be avoided. The effect of rifampin with antistaphylococcal drugs is variable, and its routine use is not recommended.

Because coagulase-negative staphylococci—a common cause of prosthetic valve endocarditis—are routinely resistant to methicillin, β -lactam antibiotics should not be used for this infection unless the isolate is demonstrated to be susceptible. A combination of vancomycin, 30 mg/kg/d intravenously divided in two or three doses for 6 weeks; rifampin, 300 mg every 8 hours for 6 weeks; and gentamicin, 1 mg/kg intravenously every 8 hours for the first 2 weeks is recommended for prosthetic valve infection. If the organism is sensitive to methicillin, either nafcillin or oxacillin or cefazolin can be used in combination with rifampin and gentamicin. Combination therapy with nafcillin or oxacillin (vancomycin for methicillin-resistant strains or patients allergic to β -lactams), rifampin, and gentamicin is also recommended for treatment of *S aureus* prosthetic valve infection.

E. HACEK Organisms

HACEK organisms are slow-growing, fastidious gram-negative coccobacilli or bacilli (*H aphrophilus* [now *A aphrophilus*], *A actinomycetemcomitans* [now *A actinomycetemcomitans*], *C hominis*, *E corrodens*, and *Kingella* species) that are normal oral flora and cause < 5% of all cases of endocarditis. They may produce β -lactamase, and thus the treatment of choice is ceftriaxone (or some other third-generation cephalosporin), 2 g intravenously once daily for 4 weeks. Prosthetic valve endocarditis should be treated for 6 weeks. In the penicillin-allergic patient, experience is limited, but trimethoprim-sulfamethoxazole, quinolones, and aztreonam have in vitro activity and should be considered; desensitization may be preferable.

F. Role of Surgery

While many cases can be successfully treated medically, operative management is frequently required. Acute heart failure unresponsive to medical therapy is an indication for valve replacement even if active infection is present, especially for aortic valve infection. Infections unresponsive to appropriate antimicrobial therapy after 7–10 days (ie, persistent fevers, positive blood cultures despite therapy) are more likely to be eradicated if the valve is replaced. Surgery is nearly always required for cure of fungal endocarditis and is more often necessary with gram-negative bacilli. It is also indicated when the infection involves the sinus of Valsalva or produces septal abscesses. Recurrent infection with the same organism prompts an operative approach, especially with infected prosthetic valves. Continuing embolization presents a difficult problem when the infection is otherwise responding; surgery may be the proper approach. Particularly challenging is a large and fragile vegetation demonstrated by echo in the absence of embolization. Most clinicians favor an operative approach,

vegetectomy with valve repair if the patient is a good candidate. Embolization after bacteriologic cure does not necessarily imply recurrence of endocarditis.

G. Role of Anticoagulation

Anticoagulation is contraindicated in native valve endocarditis because of an increased risk of intracerebral hemorrhage. The role of anticoagulant therapy during active prosthetic valve endocarditis is more controversial. Reversal of anticoagulation may result in thrombosis of the mechanical prosthesis, particularly in the mitral position. On the other hand, anticoagulation during active prosthetic valve endocarditis caused by *S aureus* has been associated with fatal intracerebral hemorrhage. One approach is to discontinue anticoagulation during the septic phase of *S aureus* prosthetic valve endocarditis. In patients with *S aureus* prosthetic valve endocarditis complicated by a central nervous system embolic event, anticoagulation should be discontinued for the first 2 weeks of therapy. Indications for anticoagulation following prosthetic valve implantation for endocarditis are the same as for patients with prosthetic valves without endocarditis (eg, nonporcine mechanical valves and valves in the mitral position).

▶ Response to Therapy

If infection is caused by viridans streptococci, enterococci, or coagulase-negative staphylococci, defervescence occurs in 3–4 days on average; with *S aureus* or *Pseudomonas aeruginosa*, fever commonly persists for 9–12 days. Blood cultures should be obtained to document sterilization of the blood. Other causes of persistent fever are myocardial or metastatic abscess, sterile embolization, superimposed hospital-acquired infection, and drug reaction. Most relapses occur within 1–2 months after completion of therapy. Obtaining one or two blood cultures during this period is prudent.

Baddour LM et al. Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America. *Circulation*. 2005 Jun 14;111(23):e394–434. [PMID: 15956145]

Lalani T et al; International Collaboration on Endocarditis-Prospective Cohort Study (ICE-PCS) Investigators. Analysis of the impact of early surgery on in-hospital mortality of native valve endocarditis: use of propensity score and instrumental variable methods to adjust for treatment-selection bias. *Circulation*. 2010 Mar 2;121(8):1005–13. [PMID: 20159831]

Wilson W et al. Prevention of infective endocarditis: guidelines from the American Heart Association: a guideline from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group. *Circulation*. 2007 Oct 9;116(15):1736–54. [PMID: 17446442]

INFECTIONS CAUSED BY GRAM-NEGATIVE BACTERIA

BORDETELLA PERTUSSIS INFECTION (Whooping Cough)

ESSENTIALS OF DIAGNOSIS

- ▶ Predominantly in infants under age 2 years. Adolescents and adults are an important reservoir of infection.
- ▶ Two-week prodromal catarrhal stage of malaise, cough, coryza, and anorexia.
- ▶ Paroxysmal cough ending in a high-pitched inspiratory “whoop.”
- ▶ Absolute lymphocytosis, often striking; culture confirms diagnosis.

▶ General Considerations

Pertussis is an acute infection of the respiratory tract caused by *B pertussis* that is transmitted by respiratory droplets. The incubation period is 7–17 days. Half of all cases occur before age 2 years. Neither immunization nor disease confers lasting immunity to pertussis. Consequently, adults are an important reservoir of the disease. In the spring of 2010, a large pertussis outbreak that resulted in many infant deaths was identified in California. Following the identification of this epidemic, the California Department of Public Health made changes to their strategy for pertussis prevention and the Advisory Committee on Immunization Practices has made preliminary changes to their recommendations as detailed below.

▶ Clinical Findings

The symptoms of classic pertussis last about 6 weeks and are divided into three consecutive stages. The catarrhal stage is characterized by its insidious onset, with lacrimation, sneezing, and coryza, anorexia and malaise, and a hacking night cough that becomes diurnal. The paroxysmal stage is characterized by bursts of rapid, consecutive coughs followed by a deep, high-pitched inspiration (whoop). The convalescent stage begins 4 weeks after onset of the illness with a decrease in the frequency and severity of paroxysms of cough. The diagnosis often is not considered in adults, who may not have a typical presentation. Cough persisting more than 2 weeks is suggestive. Infection may also be asymptomatic.

The white blood cell count is usually 15,000–20,000/mcL (rarely, as high as 50,000/mcL or more), 60–80% of which are lymphocytes. The diagnosis is established by isolating the organism from nasopharyngeal culture. A special medium (eg, Bordet-Gengou agar) must be requested. Polymerase chain reaction assays for diagnosis of pertussis may be available in some clinical or health department laboratories.

▶ Prevention

Acellular pertussis vaccine is recommended for all infants, combined with diphtheria and tetanus toxoids (DTaP). Infants and susceptible adults with significant exposure should receive prophylaxis with an oral macrolide (see below). In recognition of their importance as a reservoir of disease, vaccination of adolescents and adults against pertussis is recommended (see Table 30–7). The FDA licensed two tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine (Tdap) products (BOOSTRIX, GlaxoSmithKline and ADACEL, Sanofi Pasteur) in 2005. Adolescents aged 11–18 years who have completed the DTP or DTaP vaccination series should receive a single dose of either Tdap product instead of Td (tetanus and diphtheria toxoids vaccine) for booster immunization against tetanus, diphtheria, and pertussis. Either vaccine may be used in place of Td for prophylaxis of tetanus in wound management. The ADACEL vaccine is indicated as a one-time dose for booster immunization for pertussis in persons ages 11 through 64 years. Following the 2010 pertussis outbreak and review of additional data, the Advisory Committee on Immunization Practices changed their recommendations, stating that pregnant women, who had not previously received Tdap should be immunized during pregnancy, preferably during the third or late second trimester (after 20 weeks' gestation). If not administered during pregnancy, Tdap should be administered immediately postpartum. Adults ≤ 64 years who have or who anticipate having close contact with an infant < 2 months (eg, grandparents, child-care providers, and healthcare providers) and who have not previously received Tdap should receive a single dose of Tdap. For adults > 64 years not in close contact with infants, a single dose of Tdap vaccine may be given in place of a tetanus and diphtheria toxoids (Td) vaccine, in persons who have not previously received Tdap. Postpartum women and adults who have not been previously vaccinated with Tdap and who have close contact to an infant younger than 12 months should receive a single dose of Tdap. In addition, the Advisory Committee on Immunization Practices eliminated the recommendation that a 2-year period window is needed between receiving the Td and Tdap vaccines based on data showing that there is not an increased risk of adverse events.

▶ Treatment

Antibiotic treatment should be initiated in all suspected cases. Treatment options include erythromycin, 500 mg four times a day orally for 7 days; azithromycin, 500 mg orally on day 1 and 250 mg for 4 more days; or clarithromycin, 500 mg orally twice daily for 7 days. Trimethoprim-sulfamethoxazole, 160 mg–800 mg orally twice a day for 7 days, also is effective. Treatment shortens the duration of carriage and may diminish the severity of coughing paroxysms. These same regimens are indicated for prophylaxis of contacts to an active case of pertussis that are exposed within 3 weeks of the onset of cough in the index case.

Centers for Disease Control and Prevention (CDC). Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine (Tdap) in pregnant women and persons who have or anticipate having close contact with an infant aged < 12 months—Advisory Committee on Immunization Practices (ACIP), 2011. *MMWR Morb Mortal Wkly Rep*. 2011 Oct 21;60(41):1424–6. [PMID: 22012116]

Cornia PB et al. Does this coughing adolescent or adult patient have pertussis? *JAMA*. 2010 Aug 25;304(8):890–6. [PMID: 20736473]

OTHER *BORDETELLA* INFECTIONS

Bordetella bronchiseptica is a pleomorphic gram-negative coccobacillus causing kennel cough in dogs. On occasion it causes upper and lower respiratory infection in humans, principally HIV-infected patients. Infection has been associated with contact with dogs and cats, suggesting animal-to-human transmission. Treatment of *B bronchiseptica* infection is guided by results of in vitro susceptibility tests.

MENINGOCOCCAL MENINGITIS



ESSENTIALS OF DIAGNOSIS

- ▶ Fever, headache, vomiting, confusion, delirium, convulsions.
- ▶ Petechial rash of skin and mucous membranes in many.
- ▶ Neck and back stiffness with positive Kernig and Brudzinski signs is characteristic.
- ▶ Purulent spinal fluid with gram-negative intracellular and extracellular diplococci.
- ▶ Culture of cerebrospinal fluid, blood, or petechial aspiration confirms the diagnosis.

▶ General Considerations

Meningococcal meningitis is caused by *Neisseria meningitidis* of groups A, B, C, Y, and W-135, among others. Meningitis due to serogroup A is uncommon in the United States. Serogroup B generally causes sporadic cases. The frequency of outbreaks of meningitis caused by group C meningococcus has increased, and this serotype is the most common cause of epidemic disease in the United States. Up to 40% of persons are nasopharyngeal carriers of meningococci, but disease develops in relatively few of these persons. Infection is transmitted by droplets. The clinical illness may take the form of meningococemia (a fulminant form of septicemia without meningitis), meningococemia with meningitis, or meningitis. Recurrent meningococemia with fever, rash, and arthritis is seen rarely in patients with certain terminal complement deficiencies.

▶ Clinical Findings

A. Symptoms and Signs

High fever, chills, and headache; back, abdominal, and extremity pains; and nausea and vomiting are typical. Rapidly developing confusion, delirium, seizures, and coma occur in some. On examination, nuchal and back rigidity are typical. Positive Kernig and Brudzinski signs (Kernig sign is pain in the hamstrings upon extension of the knee with the hip at 90-degree flexion; Brudzinski sign is flexion of the knee in response to flexion of the neck) are specific but not sensitive findings. A petechial rash appearing in the lower extremities and at pressure points is found in most cases. Petechiae may vary in size from pinpoint lesions to large ecchymoses or even skin gangrene that may later slough if the patient survives.

B. Laboratory Findings

Lumbar puncture typically reveals a cloudy or purulent cerebrospinal fluid, with elevated pressure, increased protein, and decreased glucose content. The fluid usually contains > 1000 cells/mcL, with polymorphonuclear cells predominating and containing gram-negative intracellular diplococci. The absence of organisms in a Gram-stained smear of the cerebrospinal fluid sediment does not rule out the diagnosis. The capsular polysaccharide can be demonstrated in cerebrospinal fluid or urine by latex agglutination; this is useful in partially treated patients, though sensitivity is 60–80%. The organism is usually demonstrated by smear and culture of the cerebrospinal fluid, oropharynx, blood, or aspirated petechiae.

Disseminated intravascular coagulation is an important complication of meningococcal infection and is typically present in toxic patients with ecchymotic skin lesions.

▶ Differential Diagnosis

Meningococcal meningitis must be differentiated from other meningitides. In small infants and in the elderly, fever or stiff neck is often missing, and altered mental status may dominate the picture.

Rickettsial, echovirus and, rarely, other bacterial infections (eg, staphylococcal infections, scarlet fever) also cause petechial rash.

▶ Prevention

Two vaccines, meningococcal polysaccharide vaccine (MPSV4, indicated for vaccination of persons over age 55) and a conjugate vaccine (MCV4, indicated for persons aged 2–55 years) are effective for meningococcal groups A, C, Y, and W-135. The Advisory Committee on Immunization Practices recommends immunization with a dose of MCV4 for preadolescents ages 11–12 with a booster at age 16 (see Table 30–7). For ease of program implementation, persons aged 21 years or younger should have documentation of receipt of a dose of MCV4 not more than 5 years before enrollment to college. If the primary dose was administered before the sixteenth birthday,

a booster dose should be administered before enrollment. Vaccine is also recommended as a two-dose primary series administered 2 months apart for persons aged 2 through 54 years with persistent complement deficiency, persons with functional or anatomic asplenia, and for adolescents with HIV infection. All other persons at increased risk for meningococcal disease (eg, military recruits, microbiologists, or travelers to an epidemic or highly endemic country) should receive a single dose.

Eliminating nasopharyngeal carriage of meningococci is an effective prevention strategy in closed populations and to prevent secondary cases in household or otherwise close contacts. Rifampin, 600 mg orally twice a day for 2 days, ciprofloxacin, 500 mg orally once, or one intramuscular 250-mg dose of ceftriaxone is effective. A cluster of cases of fluoroquinolone-resistant meningococcal infections was recently identified in the United States. However, ciprofloxacin remains a recommended empiric agent for eradication of nasopharyngeal carriage. School and work contacts ordinarily need not be treated. Hospital contacts receive therapy only if intense exposure has occurred (eg, mouth-to-mouth resuscitation). Accidentally discovered carriers without known close contact with meningococcal disease do not require prophylactic antimicrobials.

▶ Treatment

Blood cultures must be obtained and intravenous antimicrobial therapy started immediately. This may be done prior to lumbar puncture in patients in whom the diagnosis is not straightforward and for those in whom MR or CT imaging is indicated to exclude mass lesions. Aqueous penicillin G is the antibiotic of choice (24 million units/ 24 h intravenously in divided doses every 4 hours). The prevalence of strains of *N meningitidis* with intermediate resistance to penicillin in vitro (MICs 0.1 to 1 mcg/mL) is increasing, particularly in Europe. At what level of resistance penicillin treatment failure can occur is not known. Penicillin-intermediate strains thus far remain fully susceptible to ceftriaxone and other third-generation cephalosporins used to treat meningitis, and these should be effective alternatives to penicillin. In penicillin-allergic patients or those in whom *Haemophilus influenzae* or gram-negative meningitis is a consideration, ceftriaxone, 2 g intravenously every 12 hours, should be used. Treatment should be continued in full doses by the intravenous route until the patient is afebrile for 5 days. Shorter courses—as few as 4 days if ceftriaxone is used—are also effective.

Centers for Disease Control and Prevention (CDC). Licensure of a meningococcal conjugate vaccine for children aged 2 through 10 years and updated booster dose guidance for adolescents and other persons at increased risk for meningococcal disease—Advisory Committee on Immunization Practices (ACIP), 2011. *MMWR Morb Mortal Wkly Rep.* 2011 Aug 5; 60(30):1018–9. [PMID: 21814165]

Cohn AC et al. Changes in *Neisseria meningitidis* disease epidemiology in the United States, 1998–2007: implications for prevention of meningococcal disease. *Clin Infect Dis.* 2010 Jan 15;50(2):184–91. [PMID: 20001736]

INFECTIONS CAUSED BY HAEMOPHILUS SPECIES

H influenzae and other *Haemophilus* species may cause sinusitis, otitis, bronchitis, epiglottitis, pneumonia, cellulitis, arthritis, meningitis, and endocarditis. Nontypeable strains are responsible for most disease in adults. Alcoholism, smoking, chronic lung disease, advanced age, and HIV infection are risk factors. *Haemophilus* species colonize the upper respiratory tract in patients with chronic obstructive pulmonary disease and frequently cause purulent bronchitis.

β -Lactamase-producing strains are less common in adults than in children. For adults with sinusitis, otitis, or respiratory tract infection, oral amoxicillin, 750 mg twice daily for 10–14 days, is adequate. For β -lactamase-producing strains, use of the oral fixed drug combination of amoxicillin, 875 mg, with clavulanate, 125 mg, is indicated. For the penicillin-allergic patient, oral cefuroxime axetil, 250 mg twice daily; trimethoprim-sulfamethoxazole, 160/800 mg orally twice daily; or a fluoroquinolone (ciprofloxacin, 500 mg orally twice daily; levofloxacin, 500 mg orally once daily; or moxifloxacin, 400 mg orally once daily) for 10 days is effective. Azithromycin and clarithromycin are less effective.

In the more seriously ill patient (eg, the toxic patient with multilobar pneumonia), ceftriaxone, 1 g/d intravenously is recommended pending determination of whether the infecting strain is a β -lactamase producer. Trimethoprim-sulfamethoxazole administered intravenously based on a dose of 10 mg/kg/d of trimethoprim or a fluoroquinolone (see above for dosages) can be used for the penicillin-allergic patient. A 10- to 14-day course of therapy is adequate for most cases.

Epiglottitis is characterized by an abrupt onset of high fever, drooling, and inability to handle secretions. An important clue to the diagnosis is complaint of a severe sore throat despite an unimpressive examination of the pharynx. Stridor and respiratory distress result from laryngeal obstruction. The diagnosis is best made by direct visualization of the cherry-red, swollen epiglottis at laryngoscopy. Because laryngoscopy may provoke laryngospasm and obstruction, especially in children, it should be performed in an intensive care unit or similar setting, and only at a time when intubation can be performed promptly. Ceftriaxone, 1 g intravenously every 24 hours for 7–10 days, is the drug of choice. Trimethoprim-sulfamethoxazole or a fluoroquinolone (see above for dosage) may be used in the patient with serious penicillin allergy.

Meningitis, rare in adults, is a consideration in the patient who has meningitis associated with sinusitis or otitis. Initial therapy for suspected *H influenzae* meningitis should be with ceftriaxone, 4 g/d in two divided doses, until the strain is proved not to produce β -lactamase. Meningitis is treated for 10–14 days. Dexamethasone, 0.15 mg/kg intravenously every 6 hours may reduce the incidence of long-term sequelae, principally hearing loss.

Watt JP et al. Burden of disease caused by *Haemophilus influenzae* type b in children younger than 5 years: global estimates. *Lancet.* 2009 Sep 12;374(9693):903–11. [PMID: 19748399]

INFECTIONS CAUSED BY *MORAXELLA CATARRHALIS*

M catarrhalis is a gram-negative aerobic coccus morphologically and biochemically similar to *Neisseria*. It causes sinusitis, bronchitis, and pneumonia. Bacteremia and meningitis have also been reported in immunocompromised patients. The organism frequently colonizes the respiratory tract, making differentiation of colonization from infection difficult. If *M catarrhalis* is the predominant isolate, therapy is directed against it. *M catarrhalis* typically produces β -lactamase and therefore is usually resistant to ampicillin and amoxicillin. It is susceptible to amoxicillin-clavulanate, ampicillin-sulbactam, trimethoprim-sulfamethoxazole, ciprofloxacin, and second- and third-generation cephalosporins.

Broides A et al. Acute otitis media caused by *Moraxella catarrhalis*: epidemiologic and clinical characteristics. *Clin Infect Dis*. 2009 Dec 1;49(11):1641–7. [PMID: 19886799]

LEGIONNAIRES DISEASE



ESSENTIALS OF DIAGNOSIS

- ▶ Patients are often immunocompromised, smokers, or have chronic lung disease.
- ▶ Scant sputum production, pleuritic chest pain, toxic appearance.
- ▶ Chest radiograph: focal patchy infiltrates or consolidation.
- ▶ Gram stain of sputum: polymorphonuclear leukocytes and no organisms.

▶ General Considerations

Legionella infection ranks among the three or four most common causes of community-acquired pneumonia and is considered whenever the etiology of a pneumonia is in question. Legionnaire disease is more common in immunocompromised persons, in smokers, and in those with chronic lung disease. Outbreaks have been associated with contaminated water sources, such as showerheads and faucets in patient rooms and air conditioning cooling towers.

▶ Clinical Findings

A. Symptoms and Signs

Legionnaire disease is one of the atypical pneumonias, so called because a Gram-stained smear of sputum does not show organisms. However, many features of Legionnaire disease are more like typical pneumonia, with high fevers, a toxic patient, pleurisy, and grossly purulent sputum. Classically, this pneumonia is caused by *Legionella pneumophila*, though other species can cause identical disease.

B. Laboratory Findings

Several laboratory abnormalities can be associated with Legionnaires disease, which include hyponatremia, elevated liver enzymes, and elevated creatine kinase. Culture of *Legionella* species onto charcoal-yeast extract agar or similar enriched medium is the most sensitive method (80–90% sensitivity) for diagnosis and permits identification of infections caused by species and serotypes other than *L pneumophila* serotype 1. Dieterle silver staining of tissue, pleural fluid, or other infected material is also a reliable method for detecting *Legionella* species. Direct fluorescent antibody stains and serologic testing are less sensitive because these will detect only *L pneumophila* serotype 1. In addition, making a serologic diagnosis requires that the host respond with sufficient specific antibody production. Urinary antigen tests, which are targeted for detection of *L pneumophila* serotype 1, are also less sensitive than culture.

▶ Treatment

Azithromycin (500 mg orally once daily), clarithromycin (500 mg orally twice daily), or a fluoroquinolone (eg, levofloxacin 500 mg orally once daily), and not erythromycin, are the drugs of choice for treatment of legionellosis because of their excellent intracellular penetration and in vitro activity, as well as desirable pharmacokinetic properties that permit oral administration and once or twice daily dosing. Duration of therapy is 10–14 days, although a 21-day course of therapy is recommended for immunocompromised patients.

Cunha BA. Legionnaires' disease: clinical differentiation from typical and other atypical pneumonias. *Infect Dis Clin North Am*. 2010 Mar;24(1):73–105. [PMID: 20171547]
Griffin AT et al. Macrolides versus quinolones in *Legionella* pneumonia: results from the Community-Acquired Pneumonia Organization international study. *Int J Tuberc Lung Dis*. 2010 Apr;14(4):495–9. [PMID: 20202309]

GRAM-NEGATIVE BACTEREMIA & SEPSIS

Gram-negative bacteremia can originate in a number of sites, the most common being the genitourinary system, hepatobiliary tract, gastrointestinal tract, and lungs. Less common sources include intravenous lines, infusion fluids, surgical wounds, drains, and decubitus ulcers.

Patients with potentially fatal underlying conditions in the short term such as neutropenia or immunoparesis have a mortality rate of 40–60%; those with serious underlying diseases likely to be fatal in 5 years, such as solid tumors, cirrhosis, and aplastic anemia, die in 15–20% of cases; and individuals with no underlying diseases have a mortality rate of 5% or less.

▶ Clinical Findings

A. Symptoms and Signs

Most patients have fevers and chills, often with abrupt onset. However, 15% of patients are hypothermic

(temperature ≤ 36.4 °C) at presentation, and 5% never develop a temperature above 37.5 °C. Hyperventilation with respiratory alkalosis and changes in mental status are important early manifestations. Hypotension and shock, which occur in 20–50% of patients, are unfavorable prognostic signs.

B. Laboratory Findings

Neutropenia or neutrophilia, often with increased numbers of immature forms of polymorphonuclear leukocytes, is the most common laboratory abnormality in septic patients. Thrombocytopenia occurs in 50% of patients, laboratory evidence of coagulation abnormalities in 10%, and overt disseminated intravascular coagulation in 2–3%. Both clinical manifestations and the laboratory abnormalities are nonspecific and insensitive, which accounts for the relatively low rate of blood culture positivity (approximately 20–40%). If possible, three blood cultures from separate sites should be obtained in rapid succession before starting antimicrobial therapy. The chance of recovering the organism in at least one of the three blood cultures is > 95%. The false-negative rate for a single culture of 5–10 mL of blood is 30%. This may be reduced to 5–10% (albeit with a slight false-positive rate due to isolation of contaminants) if a single volume of 30 mL is inoculated into several blood culture bottles. Because blood cultures may be falsely negative, when a patient with presumed septic shock, negative blood cultures, and inadequate explanation for the clinical course responds to antimicrobials, therapy should be continued for 10–14 days.

► Treatment

Several factors are important in the management of patients with sepsis.

A. Removal of Predisposing Factors

This usually means decreasing or stopping immunosuppressive medications and in certain circumstances (eg, positive blood cultures) giving granulocyte colony-stimulating factor (filgrastim; G-CSF) to the neutropenic patient.

B. Identifying the Source of Bacteremia

By simply finding the source of bacteremia and removing it (central venous catheter) or draining it (abscess), a fatal disease becomes easily treatable.

C. Supportive Measures

The use of fluids and vasopressors for maintaining blood pressure is discussed in Chapter 12; management of disseminated intravascular coagulation is discussed in Chapter 13.

D. Antibiotics

Antibiotics should be given as soon as the diagnosis is suspected, since delays in therapy have been associated with increased mortality rates, particularly once hypotension

develops. In general, bactericidal antibiotics should be used and given intravenously to ensure therapeutic serum levels. Penetration of antibiotics into the site of primary infection is critical for successful therapy—ie, if the infection originates in the central nervous system, antibiotics that penetrate the blood-brain barrier should be used—eg, penicillin, ampicillin, chloramphenicol, and third-generation cephalosporins—but not first-generation cephalosporins or aminoglycosides, which penetrate poorly. Sepsis caused by gram-positive organisms cannot be differentiated on clinical grounds from that due to gram-negative bacteria. Therefore, initial therapy should include antibiotics active against both types of organisms.

The number of antibiotics necessary remains controversial and depends on the cause. Table 30–5 provides a guide for empiric therapy. Although a combination of antibiotics is often recommended for “synergism,” combination therapy has not been shown to be superior to a single-drug regimen with any of several broad-spectrum antibiotics (eg, a third-generation cephalosporin, piperacillin-tazobactam, carbapenem). If multiple drugs are used initially, the regimen should be modified and coverage narrowed based on the results of culture and sensitivity testing.

E. Corticosteroids

The role of corticosteroids in treatment of septic shock is still quite controversial. Clinical data have suggested an association between mortality in patients with septic shock and poor adrenal reserve to cosyntropin (Cortrosyn) stimulation testing. Administration of “stress doses” of hydrocortisone to patients with relative adrenal insufficiency and vasopressor-dependent septic shock was shown to reduce mortality in earlier studies. However, the CORTICUS trial, the largest randomized control trial to evaluate the effect of stress-dose hydrocortisone on mortality in septic shock, refuted these earlier findings. This study failed to demonstrate a survival benefit from the addition of stress-dose hydrocortisone, 50 mg intravenously four times a day for 5 days followed by a 6-day tapering dose regimen, in subjects with or without a normal cosyntropin stimulation test. The use of cosyntropin stimulation testing and use of stress-dose hydrocortisone in patients with septic shock are therefore not considered to be standard care.

F. Adjunctive Therapy

Expanded knowledge of the pathophysiology of sepsis and septic shock and recognition that cytokines play a critical role suggest novel approaches to therapy. Strategies include blocking the effects of endotoxin with anti-endotoxin monoclonal antibodies; blockade of TNF, a potent cytokine mediator of septic shock, with anti-TNF monoclonal antibody or soluble TNF receptor; use of IL-1 receptor antagonists to inhibit the proinflammatory effects of IL-1 binding to its receptor; use of corticosteroids; and blocking platelet or thrombin activation. None of these strategies have been met with improved survival. Recombinant human activated protein C (drotrecogin alfa) was once thought to

reduce mortality of septic patients. However, the PROWESS-SHOCK trial failed to show a survival benefit for patients with severe sepsis and septic shock. In October 2011, the US FDA removed recombinant human activated protein C from the market.

Havel C et al. Vasopressors for hypotensive shock. *Cochrane Database Syst Rev.* 2011 May 11;(5):CD003709. [PMID: 21563137]

Levinson AT et al. Reducing mortality in severe sepsis and septic shock. *Semin Respir Crit Care Med.* 2011 Apr;32(2):195–205. [PMID: 21506056]

SALMONELLOSIS

Salmonellosis includes infection by any of approximately 2000 serotypes of salmonellae. The taxonomy of *Salmonella* species has been confusing. All *Salmonella* serotypes are members of a single species, *Salmonella enterica*. Human infections are caused almost exclusively by *S enterica* subsp *enterica*, of which three serotypes—*typhi*, *typhimurium*, and *choleraesuis*—are predominantly isolated. Three clinical patterns of infection are recognized: (1) enteric fever, the best example of which is typhoid fever, due to serotype *typhi*; (2) acute enterocolitis, caused by serotype *typhimurium*, among others; and (3) the “septicemic” type, characterized by bacteremia and focal lesions, exemplified by infection with serotype *choleraesuis*. All types are transmitted by ingestion of the organism, usually from contaminated food or drink.

1. Enteric Fever (Typhoid Fever)



ESSENTIALS OF DIAGNOSIS

- ▶ Gradual onset of malaise, headache, nausea, vomiting, abdominal pain.
- ▶ Rose spots, relative bradycardia, splenomegaly, and abdominal distention and tenderness.
- ▶ Slow (stepladder) rise of fever to maximum and then slow return to normal.
- ▶ Leukopenia; blood, stool, and urine culture positive for salmonella.

▶ General Considerations

Enteric fever is a clinical syndrome characterized by constitutional and gastrointestinal symptoms and by headache. It can be caused by any *Salmonella* species. The term “typhoid fever” applies when serotype *typhi* is the cause. Infection is transmitted by consumption of contaminated food or drink. The incubation period is 5–14 days. *Salmonella* is an intracellular pathogen. Infection begins when organisms breach the mucosal epithelium of the intestines by transcytosis, an organism-mediated transport process through the cell via an endocytic vesicle. Having crossed the epithelial barrier, organisms invade and replicate in macrophages in

Peyer patches, mesenteric lymph nodes, and the spleen. Serotypes other than *typhi* usually do not cause invasive disease, presumably because they lack the necessary human-specific virulence factors. Bacteremia occurs, and the infection then localizes principally in the lymphoid tissue of the small intestine (particularly within 60 cm of the ileocecal valve). Peyer patches become inflamed and may ulcerate, with involvement greatest during the third week of disease. The organism may disseminate to the lungs, gallbladder, kidneys, or central nervous system.

▶ Clinical Findings

A. Symptoms and Signs

During the prodromal stage, there is increasing malaise, headache, cough, and sore throat, often with abdominal pain and constipation, while the fever ascends in a stepwise fashion. After about 7–10 days, it reaches a plateau and the patient is much more ill, appearing exhausted and often prostrated. There may be marked constipation, especially early, or “pea soup” diarrhea; marked abdominal distention occurs as well. If there are no complications, the patient’s condition will gradually improve over 7–10 days. However, relapse may occur for up to 2 weeks after defervescence.

During the early prodrome, physical findings are few. Later, splenomegaly, abdominal distention and tenderness, relative bradycardia, and occasionally meningismus appear. The rash (rose spots) commonly appears during the second week of disease. The individual spot, found principally on the trunk, is a pink papule 2–3 mm in diameter that fades on pressure. It disappears in 3–4 days.

B. Laboratory Findings

Typhoid fever is best diagnosed by blood culture, which is positive in the first week of illness in 80% of patients who have not taken antimicrobials. The rate of positivity declines thereafter, but one-fourth or more of patients still have positive blood cultures in the third week. Cultures of bone marrow occasionally are positive when blood cultures are not. Stool culture is unreliable because it may be positive in gastroenteritis without typhoid fever. Relative bradycardia and leukopenia are typical.

▶ Differential Diagnosis

Enteric fever must be distinguished from other gastrointestinal illnesses and from other infections that have few localizing findings. Examples include tuberculosis, infective endocarditis, brucellosis, lymphoma, and Q fever. Often there is a history of recent travel to endemic areas, and viral hepatitis, malaria, or amebiasis may be in the differential as well.

▶ Complications

Complications occur in about 30% of untreated cases and account for 75% of deaths. Intestinal hemorrhage, manifested by a sudden drop in temperature and signs of shock followed by dark or fresh blood in the stool, or intestinal

perforation, accompanied by abdominal pain and tenderness, is most likely to occur during the third week. Appearance of leukocytosis and tachycardia should suggest these complications. Urinary retention, pneumonia, thrombophlebitis, myocarditis, psychosis, cholecystitis, nephritis, osteomyelitis, and meningitis are less often observed.

► Prevention

Immunization is not always effective but should be considered for household contacts of a typhoid carrier, for travelers to endemic areas, and during epidemic outbreaks. A multiple-dose oral vaccine and a single-dose parenteral vaccine are available. Their efficacies are similar, but oral vaccine causes fewer side effects. Boosters, when indicated, should be given every 5 years and 2 years for oral and parenteral preparations, respectively.

Adequate waste disposal and protection of food and water supplies from contamination are important public health measures to prevent salmonellosis. Carriers cannot work as food handlers.

► Treatment

A. Specific Measures

Several antibiotics, including ampicillin, azithromycin, chloramphenicol, third-generation cephalosporins, and trimethoprim-sulfamethoxazole all are effective for treatment of enteric fever caused by drug-susceptible strains. These drugs can be given orally or intravenously depending on the patient's condition. Because many salmonella strains are resistant to ampicillin, chloramphenicol, and trimethoprim-sulfamethoxazole, a fluoroquinolone—such as ciprofloxacin 750 mg orally twice daily or levofloxacin 500 mg orally once daily, 5–7 days for uncomplicated enteric fever and 10–14 days for severe infection—is the agent of choice for treatment of salmonella infections. Ceftriaxone, 2 g intravenously for 7 days, is also effective. Although resistance to fluoroquinolones or cephalosporins occurs uncommonly, the prevalence appears to be increasing. When an infection is caused by a multidrug-resistant strain, select an antibiotic to which the isolate is susceptible *in vitro*. Alternatively, increasing the dose of ceftriaxone to 4 g/d and treating for 10–14 days or using azithromycin 500 mg orally for 7 days in uncomplicated cases may be effective.

B. Treatment of Carriers

Chemotherapy often is unsuccessful in eradicating the carrier state. While treatment of carriage with ampicillin, trimethoprim-sulfamethoxazole, or chloramphenicol may be successful, ciprofloxacin, 750 mg orally twice a day for 4 weeks, has proved to be highly effective. Cholecystectomy may also achieve this goal.

► Prognosis

The mortality rate of typhoid fever is about 2% in treated cases. Elderly or debilitated persons are likely to do poorly.

With complications, the prognosis is poor. Relapses occur in up to 15% of cases. A residual carrier state frequently persists in spite of chemotherapy.

Butler T. Treatment of typhoid fever in the 21st century: promises and shortcomings. *Clin Microbiol Infect*. 2011 Jul;17(7):959–63. [PMID: 2172249]

2. *Salmonella* Gastroenteritis

By far the most common form of salmonellosis is acute enterocolitis caused by numerous *Salmonella* serotypes. The incubation period is 8–48 hours after ingestion of contaminated food or liquid.

Symptoms and signs consist of fever (often with chills), nausea and vomiting, cramping abdominal pain, and diarrhea, which may be grossly bloody, lasting 3–5 days. Differentiation must be made from viral gastroenteritis, food poisoning, shigellosis, amebic dysentery, and acute ulcerative colitis. The diagnosis is made by culturing the organism from the stool.

The disease is usually self-limited, but bacteremia with localization in joints or bones may occur, especially in patients with sickle cell disease.

Treatment of uncomplicated enterocolitis is symptomatic only. Malnourished or severely ill patients, those with sickle cell disease, and HIV-positive patients should be treated for 3–5 days with trimethoprim-sulfamethoxazole (one double-strength tablet twice a day), ampicillin (100 mg/kg intravenously or orally), or ciprofloxacin (750 mg orally twice a day).

Maki DG. Coming to grips with foodborne infection—peanut butter, peppers, and nationwide salmonella outbreaks. *N Engl J Med*. 2009 Mar 5;360(10):949–53. [PMID: 19213675]

3. *Salmonella* Bacteremia

Salmonella infection may be manifested by prolonged or recurrent fevers accompanied by bacteremia and local infection in bone, joints, pleura, pericardium, lungs, or other sites. Mycotic abdominal aortic aneurysms may also occur. Serotypes other than *typhi* usually are isolated. This complication tends to occur in immunocompromised persons and is seen in HIV-infected individuals, who typically have bacteremia without an obvious source. Treatment is the same as for typhoid fever, plus drainage of any abscesses. In HIV-infected patients, relapse is common, and lifelong suppressive therapy may be needed. Ciprofloxacin, 750 mg orally twice a day, is effective both for therapy of acute infection and for suppression of recurrence. Incidence of infections caused by drug-resistant strains may be on the rise.

Gordon MA. Invasive nontyphoidal *Salmonella* disease: epidemiology, pathogenesis and diagnosis. *Curr Opin Infect Dis*. 2011 Oct;24(5):484–9. [PMID: 21844803]

SHIGELLOSIS



ESSENTIALS OF DIAGNOSIS

- ▶ Diarrhea, often with blood and mucus.
- ▶ Crampy abdominal pain and systemic toxicity.
- ▶ White blood cells in stools; organism isolated on stool culture.

▶ General Considerations

Shigella dysentery is a common disease, often self-limited and mild but occasionally serious. *S sonnei* is the leading cause in the United States, followed by *S flexneri*. *S dysenteriae* causes the most serious form of the illness. Shigellae are invasive organisms. The infective dose is 10^2 – 10^3 organisms. There has been a rise in strains resistant to multiple antibiotics.

▶ Clinical Findings

A. Symptoms and Signs

The illness usually starts abruptly, with diarrhea, lower abdominal cramps, and tenesmus. The diarrheal stool often is mixed with blood and mucus. Systemic symptoms are fever, chills, anorexia and malaise, and headache. The abdomen is tender. Sigmoidoscopic examination reveals an inflamed, engorged mucosa with punctate and sometimes large areas of ulceration.

B. Laboratory Findings

The stool shows many leukocytes and red cells. Stool culture is positive for shigellae in most cases, but blood cultures grow the organism in < 5% of cases.

▶ Differential Diagnosis

Bacillary dysentery must be distinguished from salmonella enterocolitis and from disease due to enterotoxigenic *Escherichia coli*, *Campylobacter*, and *Yersinia enterocolitica*. Amebic dysentery may be similar clinically and is diagnosed by finding amebas in the fresh stool specimen. Ulcerative colitis is also an important cause of bloody diarrhea.

▶ Complications

Temporary disaccharidase deficiency may follow the diarrhea. Reactive arthritis is an uncommon complication, usually occurring in HLA-B27 individuals infected by *Shigella*. Hemolytic-uremic syndrome occurs rarely.

▶ Treatment

Treatment of dehydration and hypotension is lifesaving in severe cases. The antimicrobial treatments of choice are trimethoprim-sulfamethoxazole, one double-strength tablet twice a day for 7–10 days, or a fluoroquinolone

(ciprofloxacin 750 mg orally twice daily for 7–10 days, or levofloxacin, 500 mg orally once daily) for 3 days. Fluoroquinolones are contraindicated in pregnancy. Shigellae resistant to ampicillin are common, but if the isolate is susceptible, a dose of 500 mg orally four times a day is also effective. Amoxicillin, which is less effective, should not be used.

DuPont HL. Approach to the patient with infectious colitis. *Curr Opin Gastroenterol*. 2012 Jan;28(1):39–46. [PMID: 22080825]

GASTROENTERITIS CAUSED BY *ESCHERICHIA COLI*

E coli causes gastroenteritis by a variety of mechanisms. Enterotoxigenic *E coli* (ETEC) elaborates either a heat-stable or heat-labile toxin that mediates the disease. ETEC is an important cause of traveler's diarrhea. Enteroinvasive *E coli* (EIEC) differs from other *E coli* bowel pathogens in that these strains invade cells, causing bloody diarrhea and dysentery similar to infection with *Shigella* species. EIEC is uncommon in the United States. Neither ETEC nor EIEC strains are routinely isolated and identified from stool cultures because there is no selective medium. Antimicrobial therapy against *Salmonella* and *Shigella*, such as ciprofloxacin 500 mg orally twice daily, shortens the clinical course, but the disease is self-limited.

Shiga-toxin-producing *E coli* (STEC) infection can result in asymptomatic carrier stage, nonbloody diarrhea, hemorrhagic colitis, hemolytic-uremic syndrome, or thrombotic thrombocytopenic purpura. Although *E coli* O157:H7 is responsible for most cases of STEC infection in the United States, other STEC strains (such as *E coli* O145) have been reported to cause severe disease. *E coli* O157:H7 has caused several outbreaks of diarrhea and hemolytic-uremic syndrome related to consumption of undercooked hamburger, unpasteurized apple juice, and spinach, while *E coli* O145 was recently linked to the consumption of contaminated lettuce. Older individuals and young children are most affected, with hemolytic-uremic syndrome being more common in the latter group. STEC identification can be difficult and the CDC now recommends that all stools submitted for routine testing from patients with acute community-acquired diarrhea be simultaneously cultured for *E coli* O157:H7 and tested with an assay that detects Shiga toxins to detect non O157 STEC, such as *E coli* O145. Antimicrobial therapy does not alter the course of the disease and may increase the risk of hemolytic-uremic syndrome. Treatment is primarily supportive. Hemolytic-uremic syndrome or thrombotic thrombocytopenic purpura occurring in association with a diarrheal illness suggests the diagnosis and should prompt evaluation for STEC. Confirmed infections should be reported to public health officials.

Bettelheim KA. Non-O157 Shiga-toxin-producing *Escherichia coli*. *Lancet Infect Dis*. 2012 Jan;12(1):12. [PMID: 22192128]

CHOLERA



ESSENTIALS OF DIAGNOSIS

- ▶ History of travel in endemic area or contact with infected person.
- ▶ Voluminous diarrhea.
- ▶ Stool is liquid, gray, turbid, and without fecal odor, blood, or pus (“rice water stool”).
- ▶ Rapid development of marked dehydration.
- ▶ Positive stool cultures and agglutination of vibrios with specific sera.

▶ General Considerations

Cholera is an acute diarrheal illness caused by certain serotypes of *Vibrio cholerae*. The disease is toxin-mediated, and fever is unusual. The toxin activates adenyl cyclase in intestinal epithelial cells of the small intestines, producing hypersecretion of water and chloride ion and a massive diarrhea of up to 15 L/d. Death results from profound hypovolemia. Cholera occurs in epidemics under conditions of crowding, war, and famine (eg, in refugee camps) and where sanitation is inadequate. Infection is acquired by ingestion of contaminated food or water. For over a century, cholera was rarely seen in the Western Hemisphere until an outbreak occurred in Peru, starting in the early 1990s and ending by 2001; the outbreak resulted in almost 400,000 cholera cases and more than 4000 deaths. Cholera again became a rare disease in the Western Hemisphere until late 2010. A massive earthquake in Haiti in January 2010 crumbled the country’s already fragile infrastructure. Later that fall, a cholera outbreak erupted, resulting in approximately 100,000 cases and over a 1000 deaths as of December 2010.

▶ Clinical Findings

Cholera is characterized by a sudden onset of severe, frequent watery diarrhea (up to 1 L/h). The liquid stool is gray; turbid; and without fecal odor, blood, or pus (“rice water stool”). Dehydration and hypotension develop rapidly. Stool cultures are positive, and agglutination of vibrios with specific sera can be demonstrated.

▶ Prevention

A vaccine is available that confers short-lived, limited protection and may be required for entry into or reentry after travel to some countries. It is administered in two doses 1–4 weeks apart. A booster dose every 6 months is recommended for persons remaining in areas where cholera is a hazard.

Vaccination programs are expensive and not particularly effective in managing outbreaks of cholera. When outbreaks occur, efforts should be directed toward establishing clean water and food sources and proper waste disposal.

▶ Treatment

Treatment is by replacement of fluids. In mild or moderate illness, oral rehydration usually is adequate. A simple oral replacement fluid can be made from 1 teaspoon of table salt and 4 heaping teaspoons of sugar added to 1 L of water. Intravenous fluids are indicated for persons with signs of severe hypovolemia and those who cannot take adequate fluids orally. Lactated Ringer infusion is satisfactory.

Antimicrobial therapy will shorten the course of illness. Several antimicrobials are active against *V cholerae*, including tetracycline, ampicillin, chloramphenicol, trimethoprim-sulfamethoxazole, fluoroquinolones, and azithromycin. Multiple drug-resistant strains are increasingly encountered, so susceptibility testing, if available, is advisable. A single 1 g oral dose of azithromycin is effective for severe cholera caused by strains with reduced susceptibility to fluoroquinolones, but resistance is emerging to this drug as well.

Centers for Disease Control and Prevention (CDC). Update: outbreak of cholera—Haiti, 2010. *MMWR Morb Mortal Wkly Rep.* 2010 Dec 10;59(48):1586–90. [PMID: 21150867]
Harris JB et al. Cholera’s western front. *Lancet.* 2010 Dec 11; 376(9757):1961–5. [PMID: 21112083]

INFECTIONS CAUSED BY OTHER *VIBRIO* SPECIES

Vibrios other than *V cholerae* that cause human disease are *Vibrio parahaemolyticus*, *V vulnificus*, and *V alginolyticus*. All are halophilic marine organisms. Infection is acquired by exposure to organisms in contaminated, undercooked, or raw crustaceans or shellfish and warm (> 20°C) ocean waters and estuaries. Infections are more common during the summer months from regions along the Atlantic coast and the Gulf of Mexico in the United States and from tropical waters around the world. Oysters are implicated in up to 90% of food-related cases. *V parahaemolyticus* causes an acute watery diarrhea with crampy abdominal pain and fever, typically occurring within 24 hours after ingestion of contaminated shellfish. The disease is self-limited, and antimicrobial therapy is usually not necessary. *V parahaemolyticus* may also cause cellulitis and sepsis, though these findings are more characteristic of *V vulnificus* infection.

V vulnificus and *V alginolyticus*—neither of which is associated with diarrheal illness—are important causes of cellulitis and primary bacteremia following ingestion of contaminated shellfish or exposure to sea water. Cellulitis with or without sepsis may be accompanied by bulla formation and necrosis with extensive soft tissue destruction, at times requiring debridement and amputation. The infection can be rapidly progressive and is particularly severe in immunocompromised individuals—especially those with cirrhosis—with death rates as high as 50%. Patients with chronic liver disease and those who are immunocompromised should be cautioned to avoid eating raw oysters.

Tetracycline at a dose of 500 mg orally four times a day for 7–10 days is the drug of choice for treatment of suspected or documented primary bacteremia or cellulitis caused by *Vibrio* species. *V vulnificus* is susceptible in vitro to penicillin, ampicillin, cephalosporins, chloramphenicol, aminoglycosides, and fluoroquinolones, and these agents may also be effective. *V parahaemolyticus* and *V alginolyticus* produce β -lactamase and therefore are resistant to penicillin and ampicillin, but susceptibilities otherwise are similar to those listed for *V vulnificus*.

Bross MH et al. *Vibrio vulnificus* infection: diagnosis and treatment. *Am Fam Physician*. 2007 Aug 15;76(4):539–44. [PMID: 17853628]

INFECTIONS CAUSED BY CAMPYLOBACTER SPECIES

Campylobacter organisms are microaerophilic, motile, gram-negative rods. Two species infect humans: *Campylobacter jejuni*, an important cause of diarrheal disease, and *C fetus* subsp *fetus*, which typically causes systemic infection and not diarrhea. Dairy cattle and poultry are an important reservoir for campylobacters. Outbreaks of enteritis have been associated with consumption of raw milk. *Campylobacter* gastroenteritis is associated with fever, abdominal pain, and diarrhea characterized by loose, watery, or bloody stools. The differential diagnosis includes shigellosis, *Salmonella* gastroenteritis, and enteritis caused by *Y enterocolitica* or invasive *E coli*. The disease is self-limited, but its duration can be shortened with antimicrobial therapy. Either azithromycin, 1 g orally as a single dose, or ciprofloxacin, 500 mg orally twice daily for 3 days, is effective therapy. However, fluoroquinolone resistance among *C jejuni* isolates has been increasing and susceptibility testing should be routinely performed.

C fetus causes systemic infections that can be fatal, including primary bacteremia, endocarditis, meningitis, and focal abscesses. It infrequently causes gastroenteritis. Patients infected with *C fetus* are often older, debilitated, or immunocompromised. Closely related species, collectively termed “campylobacter-like organisms,” cause bacteremia in HIV-infected individuals. Systemic infections respond to therapy with gentamicin, chloramphenicol, ceftriaxone, or ciprofloxacin. Ceftriaxone or chloramphenicol should be used to treat infections of the central nervous system because of their ability to penetrate the blood-brain barrier.

Fernández-Cruz A et al. *Campylobacter* bacteremia: clinical characteristics, incidence, and outcome over 23 years. *Medicine* (Baltimore). 2010 Sep;89(5):319–30. [PMID: 20827109]

Shah N et al. Global etiology of travelers' diarrhea: systematic review from 1973 to the present. *Am J Trop Med Hyg*. 2009 Apr;80(4):609–14. [PMID: 19346386]

BRUCELLOSIS



ESSENTIALS OF DIAGNOSIS

- ▶ History of animal exposure, ingestion of unpasteurized milk or cheese.
- ▶ Insidious onset: easy fatigability, headache, arthralgia, anorexia, sweating, irritability.
- ▶ Intermittent and persistent fever.
- ▶ Cervical and axillary lymphadenopathy; hepatosplenomegaly.
- ▶ Lymphocytosis, positive blood culture, positive serologic test.

▶ General Considerations

The infection is transmitted from animals to humans. *Brucella abortus* (cattle), *B suis* (hogs), and *B melitensis* (goats) are the main agents. Transmission to humans occurs by contact with infected meat (slaughterhouse workers), placentae of infected animals (farmers, veterinarians), or ingestion of infected unpasteurized milk or cheese. The incubation period varies from a few days to several weeks. Brucellosis is a systemic infection that may become chronic. In the United States, brucellosis is very rare. Almost all US cases are imported from countries where brucellosis is endemic (eg, Mexico, Mediterranean Europe, Spain, South American countries).

▶ Clinical Findings

A. Symptoms and Signs

The onset may be acute, with fever, chills, and sweats, but more often is insidious with symptoms of weakness, weight loss, low-grade fevers, sweats, and exhaustion upon minimal activity. Headache, abdominal or back pain with anorexia and constipation, and arthralgias are also common. The chronic form may assume an undulant nature, with periods of normal temperature between acute attacks; symptoms may persist for years, either continuously or intermittently.

Fever, hepatosplenomegaly, and lymphadenopathy are the most common physical findings. Infection may present with or be complicated by specific organ involvement with signs of endocarditis, meningitis, epididymitis, orchitis, arthritis (especially sacroiliitis), spondylitis, or osteomyelitis.

B. Laboratory Findings

The organism can be recovered from cultures of blood, cerebrospinal fluid, urine, bone marrow, or other sites. Modern automated systems have shortened the time to detection of the organism in blood culture. Cultures are more likely to be negative in chronic cases. The diagnosis often is made by serologic testing. Rising serologic titers or an absolute agglutination titer of > 1:160 supports the diagnosis.

► Differential Diagnosis

Brucellosis must be differentiated from any other acute febrile disease, especially influenza, tularemia, Q fever, mononucleosis, and enteric fever. In its chronic form it resembles Hodgkin disease, tuberculosis, HIV infection, malaria, and disseminated fungal infections such as histoplasmosis and coccidioidomycosis.

► Complications

The most frequent complications are bone and joint lesions such as spondylitis and suppurative arthritis (usually of a single joint), endocarditis, and meningoencephalitis. Less common complications are pneumonitis with pleural effusion, hepatitis, and cholecystitis.

► Treatment

Single-drug regimens are not recommended because the relapse rate may be as high as 50%. Combination regimens of two or three drugs are most effective. Regimens of doxycycline (200 mg/d orally for 6 weeks) plus rifampin (600 mg/d orally for 6 weeks) or streptomycin (1 g/d intramuscularly for 2 weeks) or gentamicin (240 mg intramuscularly once daily for 7 days) have the lowest recurrence rates. Longer courses of therapy may be required to prevent relapse of meningitis, osteomyelitis, or endocarditis.

Araj GF. Update on laboratory diagnosis of human brucellosis. *Int J Antimicrob Agents*. 2010 Nov;36(Suppl 1):S12–7. [PMID: 20692128]

Solera J. Update on brucellosis: therapeutic challenges. *Int J Antimicrob Agents*. 2010 Nov;36(Suppl 1):S18–20. [PMID: 20692127]

TULAREMIA

ESSENTIALS OF DIAGNOSIS

- History of contact with rabbits, other rodents, and biting arthropods (eg, ticks in summer) in endemic area.
- Fever, headache, nausea, and prostration.
- Papule progressing to ulcer at site of inoculation.
- Enlarged regional lymph nodes.
- Serologic tests or culture of ulcer, lymph node aspirate, or blood confirm the diagnosis.

► General Considerations

Tularemia is a zoonotic infection of wild rodents and rabbits caused by *Francisella tularensis*. Humans usually acquire the infection by contact with animal tissues (eg, trapping muskrats, skinning rabbits) or from a tick or insect bite. Hamsters and prairie dogs also may carry the organism. An investigation of an outbreak of pneumonic

tularemia on Martha's Vineyard in Massachusetts implicated lawn-mowing and brush-cutting as risk factors for infection, underscoring the potential for probable aerosol transmission of the organism. *F tularensis* has been classified as a high-priority agent for potential bioterrorism use because of its virulence and relative ease of dissemination. Infection in humans often produces a local lesion and widespread organ involvement but may be entirely asymptomatic. The incubation period is 2–10 days.

► Clinical Findings

A. Symptoms and Signs

Fever, headache, and nausea begin suddenly, and a local lesion—a papule at the site of inoculation—develops and soon ulcerates. Regional lymph nodes may become enlarged and tender and may suppurate. The local lesion may be on the skin of an extremity or in the eye. Pneumonia may develop from hematogenous spread of the organism or may be primary after inhalation of infected aerosols, which are responsible for human-to-human transmission. Following ingestion of infected meat or water, an enteric form may be manifested by gastrointestinal symptoms, stupor, and delirium. In any type of involvement, the spleen may be enlarged and tender and there may be non-specific rashes, myalgias, and prostration.

B. Laboratory Findings

Culturing the organism from blood or infected tissue requires special media. For this reason and because cultures of *F tularensis* may be hazardous to laboratory personnel, the diagnosis is usually made serologically. A positive agglutination test (> 1:80) develops in the second week after infection and may persist for several years.

► Differential Diagnosis

Tularemia must be differentiated from rickettsial and meningococcal infections, cat-scratch disease, infectious mononucleosis, and various bacterial and fungal diseases.

► Complications

Hematogenous spread may produce meningitis, peritonitis, pericarditis, pneumonia, and osteomyelitis.

► Treatment

Streptomycin is drug of choice for treatment of tularemia. The recommended dose is 7.5 mg/kg intramuscularly every 12 hours for 7–14 days. Gentamicin, which has good in vitro activity against *F tularensis*, is generally less toxic than streptomycin and probably just as effective. Doxycycline (200 mg/d orally) is also effective but has a higher relapse rate. A variety of other agents (eg, fluoroquinolones) are active in vitro but their clinical effectiveness is less well established.

Aquino LL et al. Cutaneous manifestations of category A bioweapons. *J Am Acad Dermatol*. 2011 Dec;65(6):1213.e1–15. [PMID: 21777993]

Thomas LD et al. Tularemia pneumonia. *Infect Dis Clin North Am.* 2010 Mar;24(1):43–55. [PMID: 20171544]

PLAGUE



ESSENTIALS OF DIAGNOSIS

- ▶ History of exposure to rodents in endemic area.
- ▶ Sudden onset of high fever, malaise, muscular pains, and prostration.
- ▶ Axillary or inguinal lymphadenitis (bubo).
- ▶ Bacteremia, pneumonitis, and meningitis may occur.
- ▶ Positive smear and culture from bubo and positive blood culture.

▶ General Considerations

Plague is an infection of wild rodents with *Yersinia pestis*, a small bipolar-staining gram-negative rod. It is endemic in California, Arizona, Nevada, and New Mexico. It is transmitted among rodents and to humans by the bites of fleas or from contact with infected animals. Following a fleabite, the organisms spread through the lymphatics to the lymph nodes, which become greatly enlarged (bubo). They may then reach the bloodstream to involve all organs. When pneumonia or meningitis develops, the outcome is often fatal. The patient with pneumonia can transmit the infection to other individuals by droplets. The incubation period is 2–10 days. Because of its extreme virulence, its potential for dissemination and person-to-person transmission, and efforts to develop the organism as an agent of biowarfare, plague bacillus is considered a high-priority agent for bioterrorism.

▶ Clinical Findings

A. Symptoms and Signs

The onset is sudden, with high fever, malaise, tachycardia, intense headache, delirium, and severe myalgias. The patient appears profoundly ill. If pneumonia develops, tachypnea, productive cough, blood-tinged sputum, and cyanosis also occur. There may be signs of meningitis. A pustule or ulcer at the site of inoculation and lymphangitis may be observed. Axillary, inguinal, or cervical lymph nodes become enlarged and tender and may suppurate and drain. With hematogenous spread, the patient may rapidly become toxic and comatose, with purpuric spots (black plague) appearing on the skin.

Primary plague pneumonia is a fulminant pneumonitis with bloody, frothy sputum and sepsis. It is usually fatal unless treatment is started within a few hours after onset.

B. Laboratory Findings

The plague bacillus may be found in smears from aspirates of buboes examined with Gram stain. Cultures from bubo

aspirate or pus and blood are positive but may grow slowly. In convalescing patients, an antibody titer rise may be demonstrated by agglutination tests.

▶ Differential Diagnosis

The lymphadenitis of plague is most commonly mistaken for the lymphadenitis accompanying staphylococcal or streptococcal infections of an extremity, sexually transmitted diseases such as lymphogranuloma venereum or syphilis, and tularemia. The systemic manifestations resemble those of enteric or rickettsial fevers, malaria, or influenza. The pneumonia resembles other bacterial pneumonias, and the meningitis is similar to those caused by other bacteria.

▶ Prevention

Avoiding exposure to rodents and fleas in endemic areas is the best prevention strategy. Drug prophylaxis may provide temporary protection for persons exposed to the risk of plague infection, particularly by the respiratory route. Doxycycline, 100 mg twice daily for 7 days, is effective. No vaccine is available at this time.

▶ Treatment

Therapy should be started immediately once plague is suspected. Either streptomycin (the agent with which there is greatest experience), 1 g every 12 hours intravenously, or gentamicin, administered as a 2-mg/kg loading dose, then 1.7 mg/kg every 8 hours intravenously, is effective. Alternatively, doxycycline, 100 mg orally or intravenously, may be used. The duration of therapy is 10 days. Patients with plague pneumonia are placed in strict respiratory isolation, and prophylactic therapy is given to any person who came in contact with the patient.

Butler T. Plague into the 21st century. *Clin Infect Dis.* 2009 Sep 1;49(5):736–42. [PMID: 19606935]

GONOCOCCAL INFECTIONS



ESSENTIALS OF DIAGNOSIS

- ▶ Purulent and profuse urethral discharge, especially in men, with dysuria, yielding positive smear.
- ▶ Men: epididymitis, prostatitis, periurethral inflammation, proctitis.
- ▶ Women: cervicitis with purulent discharge, or asymptomatic, yielding positive culture; vaginitis, salpingitis, proctitis also occur.
- ▶ Fever, rash, tenosynovitis, and arthritis with disseminated disease.
- ▶ Gram-negative intracellular diplococci seen in a smear or cultured from any site, particularly the urethra, cervix, pharynx, and rectum.

► General Considerations

Gonorrhea is caused by *Neisseria gonorrhoeae*, a gram-negative diplococcus typically found inside polymorphonuclear cells. It is transmitted during sexual activity and has its greatest incidence in the 15- to 29-year-old age group. The incubation period is usually 2–8 days.

► Classification

A. Urethritis and Cervicitis

In men, there is initially burning on urination and a serous or milky discharge. One to 3 days later, the urethral pain is more pronounced and the discharge becomes yellow, creamy, and profuse, sometimes blood-tinged. The disorder may regress and become chronic or progress to involve the prostate, epididymis, and periurethral glands with painful inflammation. Chronic infection leads to prostatitis and urethral strictures. Rectal infection is common in homosexual men. Atypical sites of primary infection (eg, the pharynx) must always be considered. Asymptomatic infection is common and occurs in both sexes.

Gonococcal infection in women often becomes symptomatic during menses. Women may have dysuria, urinary frequency, and urgency, with a purulent urethral discharge. Vaginitis and cervicitis with inflammation of Bartholin glands are common. Infection may be asymptomatic, with only slightly increased vaginal discharge and moderate cervicitis on examination. Infection may remain as a chronic cervicitis—an important reservoir of gonococci. It can progress to involve the uterus and tubes with acute and chronic salpingitis, with scarring of tubes and sterility. In pelvic inflammatory disease, anaerobes and chlamydiae often accompany gonococci. Rectal infection may result from spread of the organism from the genital tract or from anal coitus.

Gram stain of urethral discharge in men, especially during the first week after onset, shows gram-negative diplococci in polymorphonuclear leukocytes. Gram stain is less often positive in women. Culture has been the gold standard for diagnosis, particularly when the Gram stain is negative. Nucleic acid amplification tests for *N gonorrhoeae* are FDA approved for the testing of endocervical swabs, vaginal swabs, urethral swabs (men), and urine (from both men and women), and have excellent sensitivity and specificity, and have largely replaced culture. Identification of *N gonorrhoeae* from rectal or pharyngeal sites, blood, and in joint fluid still requires culture.

B. Disseminated Disease

Systemic complications follow the dissemination of gonococci from the primary site via the bloodstream. Two distinct clinical syndromes—either purulent arthritis or the triad of rash, tenosynovitis, and arthralgias—are commonly observed in patients with disseminated gonococcal infection, although overlap can be seen. The skin lesions can range from maculopapular to pustular or hemorrhagic, which tend to be few in number and peripherally located. The tenosynovitis is often found in the hands and wrists and feet and ankles. These unique findings can

help distinguish among other infectious syndromes. The arthritis can occur in one or more joints. Gonococci are isolated by culture from less than half of patients with gonococcal arthritis. Rarely, gonococcal endocarditis or meningitis develops.

C. Conjunctivitis

The most common form of eye involvement is direct inoculation of gonococci into the conjunctival sac. In adults, this occurs by autoinoculation of a person with genital infection. The purulent conjunctivitis may rapidly progress to panophthalmitis and loss of the eye unless treated promptly. A single 1-g dose of ceftriaxone is effective.

► Differential Diagnosis

Gonococcal urethritis or cervicitis must be differentiated from nongonococcal urethritis; cervicitis or vaginitis due to *Chlamydia trachomatis*, *Gardnerella vaginalis*, *Trichomonas*, *Candida*, and many other pathogens associated with sexually transmitted diseases; and pelvic inflammatory disease, arthritis, proctitis, and skin lesions. Often, several such pathogens coexist in a patient. Reactive arthritis (urethritis, conjunctivitis, arthritis) may mimic gonorrhea or coexist with it.

► Prevention

Prevention is based on education and mechanical or chemical prophylaxis. The condom, if properly used, can reduce the risk of infection. Effective drugs taken in therapeutic doses within 24 hours of exposure can abort an infection. Partner notification and referral of contacts for treatment has been the standard method used to control sexually transmitted diseases. Expedited treatment of sex partners by patient-delivered partner therapy is more effective than partner notification in reducing persistence and recurrence rates of gonorrhea and chlamydia. This strategy is being increasingly adopted as a means of disease control.

► Treatment

Therapy typically is administered before antimicrobial susceptibilities are known. The choice of which regimen to use should be based on the national prevalences of antibiotic-resistant organisms. Nationwide, strains of gonococci that are resistant to penicillin, tetracycline, or ciprofloxacin have been increasingly observed. Consequently, these drugs can no longer be considered first-line therapy. All sexual partners should be treated and tested for HIV infection and syphilis, as should the patient.

A. Uncomplicated Gonorrhea

Due to increasing resistance of *N gonorrhoeae* to cephalosporins, the CDC has updated its treatment recommendation for gonorrhea. Treatment for gonorrhea should include a higher dose of intramuscular ceftriaxone in combination with a second drug (azithromycin or doxycycline) regardless of concern for possible secondary infection with chlamydia. For uncomplicated gonococcal infections of the

cervix, urethra, and rectum, the recommended treatment is ceftriaxone (250 mg intramuscularly) plus either azithromycin (1000 mg orally as a single dose) or doxycycline (100 mg twice daily for 7 days). When ceftriaxone is unavailable, cefixime (400 mg orally as a single dose) in combination with either azithromycin or doxycycline as above is an alternative. Fluoroquinolones are no longer recommended because of high rates of resistance. Spectinomycin, 1 g intramuscularly once, may be used for the penicillin-allergic patient but is not currently available in the United States.

Pharyngeal gonorrhea is also treated with ceftriaxone (250 mg intramuscularly) plus either azithromycin (1000 mg orally as a single dose) or doxycycline (100 mg twice daily for 7 days). *All women should have a pregnancy test before a tetracycline (such as doxycycline) is prescribed.*

B. Treatment of Other Infections

Disseminated gonococcal infection should be treated with ceftriaxone, 1 g intravenously daily, until 48 hours after improvement begins, at which time therapy may be switched to cefixime, 400 mg orally daily to complete at least 1 week of antimicrobial therapy. An oral fluoroquinolone (ciprofloxacin, 500 mg twice daily, or levofloxacin, 500 mg once daily) for 7 days also is effective, provided the isolate is susceptible. Endocarditis should be treated with ceftriaxone, 2 g every 24 hours intravenously, for at least 3 weeks. Postgonococcal urethritis and cervicitis, which are usually caused by chlamydia, are treated with a regimen of erythromycin, doxycycline, or azithromycin as described above.

Pelvic inflammatory disease requires cefoxitin, 2 g parenterally every 6 hours, or cefotetan, 2 g intravenously every 12 hours plus doxycycline 100 mg every 12 hours. Clindamycin, 900 mg intravenously every 8 hours, plus gentamicin, administered intravenously as a 2-mg/kg loading dose followed by 1.5 mg/kg every 8 hours, is also effective. Ceftriaxone 250 mg intramuscularly as a single dose (or cefoxitin, 2 g intramuscularly, plus probenecid, 1 g orally as a single dose) plus doxycycline, 100 mg twice a day for 14 days, with or without metronidazole, 500 mg twice daily for 14 days, is an effective outpatient regimen.

Brill JR. Diagnosis and treatment of urethritis in men. *Am Fam Physician*. 2010 Apr 1;81(7):873–8. [PMID: 20353145]

Workowski KA et al; Centers for Disease Control and Prevention (CDC). Sexually transmitted diseases treatment guidelines, 2010. *MMWR Recomm Rep*. 2010 Dec 17;59(RR-12):1–110. Erratum in: *MMWR Recomm Rep*. 2011 Jan 14;60(1):18. [PMID: 21160459]

CHANCROID

Chancroid is a sexually transmitted disease caused by the short gram-negative bacillus *Haemophilus ducreyi*. The incubation period is 3–5 days. At the site of inoculation, a vesicopustule develops that breaks down to form a painful, soft ulcer with a necrotic base, surrounding erythema, and undermined edges. There may be multiple lesions due to autoinoculation. The adenitis is usually unilateral and consists of tender, matted nodes of moderate size with

overlying erythema. These may become fluctuant and rupture spontaneously. With lymph node involvement, fever, chills, and malaise may develop. Balanitis and phimosis are frequent complications in men. Women may have no external signs of infection. The diagnosis is established by culturing a swab of the lesion onto a special medium.

Chancroid must be differentiated from other genital ulcers. The chancre of syphilis is clean and painless, with a hard base. Mixed sexually transmitted disease is very common (including syphilis, herpes simplex, and HIV infection), as is infection of the ulcer with fusiforms, spirochetes, and other organisms.

A single dose of either azithromycin, 1 g orally, or ceftriaxone, 250 mg intramuscularly, is effective treatment. Effective multiple-dose regimens are erythromycin, 500 mg orally four times a day for 7 days, or ciprofloxacin, 500 mg orally twice a day for 3 days.

Workowski KA et al; Centers for Disease Control and Prevention (CDC). Sexually transmitted diseases treatment guidelines, 2010. *MMWR Recomm Rep*. 2010 Dec 17;59(RR-12):1–110. Erratum in: *MMWR Recomm Rep*. 2011 Jan 14;60(1):18. [PMID: 21160459]

GRANULOMA INGUINALE

Granuloma inguinale is a chronic, relapsing granulomatous anogenital infection due to *Calymmatobacterium (Donovania) granulomatis*. The pathognomonic cell, found in tissue scrapings or secretions, is large (25–90 μm) and contains intracytoplasmic cysts filled with bodies (Donovan bodies) that stain deeply with Wright stain.

The incubation period is 8 days to 12 weeks. The onset is insidious. The lesions occur on the skin or mucous membranes of the genitalia or perineal area. They are relatively painless infiltrated nodules that soon slough. A shallow, sharply demarcated ulcer forms, with a beefy-red friable base of granulation tissue. The lesion spreads by contiguity. The advancing border has a characteristic rolled edge of granulation tissue. Large ulcerations may advance onto the lower abdomen and thighs. Scar formation and healing occur along one border while the opposite border advances.

Superinfection with spirochete-fusiform organisms is common. The ulcer then becomes purulent, painful, foul-smelling, and extremely difficult to treat.

Several therapies are available. Because of the indolent nature of the disease, duration of therapy is relatively long. The following recommended regimens should be given for 3 weeks or until all lesions have healed: doxycycline, 100 mg orally twice daily; or azithromycin, 1 g orally once weekly; or ciprofloxacin, 750 mg orally twice daily; or erythromycin, 500 mg orally four times a day.

BARTONELLA SPECIES

Bartonella species are responsible for a wide variety of clinical syndromes. **Bacillary angiomatosis**, an important manifestation of bartonellosis, is discussed in Chapter 31. A variety of atypical infections, including retinitis,

encephalitis, osteomyelitis, and persistent bacteremia and endocarditis have been described.

Trench fever is a self-limited, louse-borne relapsing febrile disease caused by *B quintana*. The disease has occurred epidemically in louse-infested troops and civilians during wars and endemically in residents of scattered geographic areas (eg, Central America). An urban equivalent of trench fever has been described among the homeless. Humans acquire infection when infested lice feces enter sites of skin breakdown. Onset of symptoms is abrupt and fever lasts 3–5 days, with relapses. The patient complains of weakness and severe pain behind the eyes and typically in the back and legs. Lymphadenopathy, splenomegaly, and a transient maculopapular rash may appear. Subclinical infection is frequent, and a carrier state is recognized. The differential diagnosis includes other febrile, self-limited states such as dengue, leptospirosis, malaria, relapsing fever, and typhus. Recovery occurs regularly even in the absence of treatment.

Cat-scratch disease is an acute infection of children and young adults caused by *Bartonella henselae*. It is transmitted from cats to humans as the result of a scratch or bite. Within a few days, a papule or ulcer will develop at the inoculation site in one-third of patients. One to 3 weeks later, fever, headache, and malaise occur. Regional lymph nodes become enlarged, often tender, and may suppurate. Lymphadenopathy from cat scratches resembles that due to neoplasm, tuberculosis, lymphogranuloma venereum, and bacterial lymphadenitis. The diagnosis is usually made clinically. Special cultures for bartonellae, serology, or excisional biopsy, though rarely necessary, confirm the diagnosis. The biopsy reveals necrotizing lymphadenitis and is itself not specific for cat-scratch disease. Cat-scratch disease is usually self-limited, requiring no specific therapy. Encephalitis occurs rarely.

Disseminated forms of the disease—bacillary angiomatosis, peliosis hepatis, and retinitis—occur most commonly in immunocompromised patients such as persons with late stages of HIV or solid organ transplant recipients. The lesions are vasculoproliferative and histopathologically distinct from those of cat-scratch disease. Unexplained fever in patients with late stages of HIV infection is not uncommonly due to bartonellosis. *B quintana*, the agent of trench fever, can also cause bacillary angiomatosis and persistent bacteremia or endocarditis (which will be “culture-negative” unless specifically sought), the latter two entities being associated with homelessness. Due to the fastidious nature of the organism and its special growth requirements, serologic testing (eg, demonstration of a high antibody titer in an indirect immunofluorescence assay) or nucleic acid amplification tests are often required to establish a diagnosis.

The disseminated forms of the disease (bacillary angiomatosis, peliosis hepatis, and retinitis) require a prolonged course of antibiotic therapy often in combination with a second agent. Bacteremia and endocarditis can be effectively treated with a 6-week course of doxycycline (200 mg orally or intravenously in two divided doses per day) plus either gentamicin 3 mg/kg/d intravenously or rifampin 600 mg/d orally in two divided doses. Relapse may occur.

Biswas S et al. Bartonella infection: treatment and drug resistance. *Future Microbiol*. 2010 Nov;5(11):1719–31. [PMID: 21133691]

Klotz SA et al. Cat-scratch disease. *Am Fam Physician*. 2011 Jan 15;83(2):152–5. [PMID: 21243990]

ANAEROBIC INFECTIONS

Anaerobic bacteria comprise the majority of normal human flora. Normal microbial flora of the mouth (anaerobic spirochetes, *Prevotella*, fusobacteria), the skin (anaerobic diphtheroids), the large bowel (bacteroides, anaerobic streptococci, clostridia), and the female genitourinary tract (bacteroides, anaerobic streptococci, fusobacteria) produce disease when displaced from their normal sites into tissues or closed body spaces.

Anaerobic infections tend to be polymicrobial and abscesses are common. Pus and infected tissue often are malodorous. Septic thrombophlebitis and metastatic infection are frequent and may require incision and drainage. Diminished blood supply that favors proliferation of anaerobes because of reduced tissue oxygenation may interfere with the delivery of antimicrobials to the site of anaerobic infection. Cultures, unless carefully collected under anaerobic conditions, may yield negative results.

Important types of infections that are most commonly caused by anaerobic organisms are listed below. Treatment of all these infections consists of surgical exploration and judicious excision in conjunction with administration of antimicrobial drugs.

1. Head & Neck Infections

Prevotella melaninogenica (formerly *Bacteroides melaninogenicus*) and anaerobic spirochetes are commonly involved in periodontal infections. These organisms, fusobacteria, and peptostreptococci may cause chronic sinusitis, peritonsillar abscess, chronic otitis media, and mastoiditis. *F necrophorum* has been recognized as a common cause of pharyngitis in adolescents and young adults. *F necrophorum* infection has been associated with septic internal jugular thrombophlebitis (Lemierre syndrome) and cause septic pulmonary embolization. Hygiene, drainage, and surgical debridement are as important in treatment as antimicrobials. Oral anaerobic organisms have been uniformly susceptible to penicillin, but there has been a recent trend of increasing penicillin resistance, usually due to β -lactamase production. Therefore, ampicillin/sulbactam 1.5–3 g intravenously every 6 hours (if parenteral therapy is required) or amoxicillin/clavulanic acid 875/125 mg orally twice daily, or clindamycin can be used (600 mg intravenously every 8 hours or 300 mg orally every 6 hours). Antimicrobial treatment is continued for a few days after signs and symptoms of infection have resolved. Indolent, established infections (eg, mastoiditis or osteomyelitis) may require prolonged courses of therapy, eg, 4–6 weeks or longer.

Centor RM. Expand the pharyngitis paradigm for adolescents and young adults. *Ann Intern Med*. 2009 Dec 1;151(11):812–5. [PMID: 19949147]

2. Chest Infections

Usually in the setting of poor oral hygiene and periodontal disease, aspiration of saliva (which contains 10^8 anaerobic organisms per milliliter in addition to aerobes) may lead to necrotizing pneumonia, lung abscess, and empyema. Polymicrobial infection is the rule and anaerobes—particularly *P melaninogenica*, fusobacteria, and peptostreptococci—are common etiologic agents. Most pulmonary infections respond to antimicrobial therapy alone. Percutaneous chest tube or surgical drainage is indicated for empyema.

Penicillin-resistant *Bacteroides fragilis* and *P melaninogenica* are commonly isolated and have been associated with clinical failures. Clindamycin, 600 mg intravenously once, followed by 300 mg orally every 6–8 hours, is the treatment of choice for these infections. Metronidazole does not cover facultative streptococci, which often are present, and if used, a second agent that is active against streptococci, such as ceftriaxone 1 g intravenously or intramuscularly daily, should be added. Penicillin, 2 million units intravenously every 4 hours, followed by amoxicillin, 500 mg every 8 hours orally, is an alternative; however, increasing prevalence of β -lactamase producing organisms is a concern. Moxifloxacin, 400 mg orally or intravenously once daily, may be used. Because these infections respond slowly, a prolonged course of therapy (eg, 4–6 weeks) is generally recommended.

Brook I. Antimicrobial treatment of anaerobic infections. Expert Opin Pharmacother. 2011 Aug;12(11):1691–707. [PMID: 21506900]

3. Central Nervous System

Anaerobes are a common cause of brain abscess, subdural empyema, or septic central nervous system thrombophlebitis. The organisms reach the central nervous system by direct extension from sinusitis, otitis, or mastoiditis or by hematogenous spread from chronic lung infections. Antimicrobial therapy—eg, ceftriaxone, 2 g intravenously every 12 hours, plus metronidazole, 500 mg intravenously every 8 hours—is an important adjunct to surgical drainage. Duration of therapy is 6–8 weeks but should be based on follow-up imaging. Some small multiple brain abscesses can be treated with antibiotics alone without surgical drainage.

4. Intra-abdominal Infections

In the colon there are up to 10^{11} anaerobes per gram of content—predominantly *B fragilis*, clostridia, and peptostreptococci. These organisms play a central role in most intra-abdominal abscesses following trauma to the colon, diverticulitis, appendicitis, or perirectal abscess and may also participate in hepatic abscess and cholecystitis, often in association with aerobic coliform bacteria. The bacteriology includes anaerobes as well as enteric gram-negative rods and on occasion enterococci. Therapy should be directed both against anaerobes and gram-negative aerobes. Agents that are active against *B fragilis* include

Table 33–7. Treatment of anaerobic intra-abdominal infections.

Community-onset

Oral therapy

Moxifloxacin 400 mg every 24 hours

Intravenous therapy

Moderate to moderately severe infections:

Ertapenem 1 g every 24 hours

or—

Ceftriaxone 1 g every 24 hours (or ciprofloxacin 400 mg every 12 hours, if penicillin allergic) plus metronidazole 500 mg every 8 hours

or—

Tigecycline 100 mg once followed by 50 mg every 12 hours

or—

Moxifloxacin 400 mg every 24 hours

Severe infections:

Imipenem, 0.5 g every 6–8 hours or meropenem 1 g every 8 hours or doripenem 0.5 g every 8 hours or piperacillin/tazobactam 3.75 g every 6 hours

Health-care-associated

Intravenous therapy

Imipenem, 0.5 g every 6–8 hours or meropenem 1 g every 8 hours or doripenem 0.5 g every 8 hours or piperacillin/tazobactam 4.5 g every 6 hours

or—

Ceftazidime or ceftipime 2 g every 8 hours plus metronidazole 0.5 g every 8 hours

metronidazole, chloramphenicol, moxifloxacin, tigecycline, ertapenem, imipenem, doripenem, ampicillin-sulbactam, ticarcillin-clavulanic acid, and piperacillin-tazobactam. Resistance to cefoxitin, cefotetan, and clindamycin is increasingly encountered. Most third-generation cephalosporins have poor efficacy.

Table 33–7 summarizes the antibiotic regimens for management of moderate to moderately severe infections (eg, patient hemodynamically stable, good surgical drainage possible or established, low APACHE score, no multiple organ failure) and severe infections (eg, major peritoneal soilage, large or multiple abscesses, patient hemodynamically unstable), particularly if drug-resistant organisms are suspected. An effective oral regimen for patients able to take it is presented also.

Löfmark S et al. Metronidazole is still the drug of choice for treatment of anaerobic infections. Clin Infect Dis. 2010 Jan 15;50(Suppl 1):S16–23. [PMID: 20067388]

Solomkin JS et al. Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. Clin Infect Dis. 2010 Jan 15;50(2):133–64. [PMID: 20034345]

5. Female Genital Tract & Pelvic Infections

The normal flora of the vagina and cervix includes several species of bacteroides, peptostreptococci, group B streptococci, lactobacilli, coliform bacteria, and, occasionally, spirochetes and clostridia. These organisms commonly cause genital tract infections and may disseminate from there.

While salpingitis is often caused by gonococci and chlamydiae, tubo-ovarian and pelvic abscesses are associated with anaerobes in most cases. Postpartum infections may be caused by aerobic streptococci or staphylococci, but anaerobes are often found, and the worst cases of postpartum or postabortion sepsis are associated with clostridia and bacteroides. These have a high mortality rate, and treatment requires both antimicrobials directed against anaerobes and coliforms (see above) and abscess drainage or early hysterectomy.

Soper DE. Pelvic inflammatory disease. *Obstet Gynecol.* 2010 Aug;116(2 Pt 1):419–28. [PMID: 20664404]

6. Bacteremia & Endocarditis

Anaerobic bacteremia usually originates from the gastrointestinal tract, the oropharynx, decubitus ulcers, or the female genital tract. Endocarditis due to anaerobic and microaerophilic streptococci and bacteroides originates from the same sites. Most cases of anaerobic or microaerophilic streptococcal endocarditis can be effectively treated with 12–20 million units of penicillin G daily for 4–6 weeks, but optimal therapy of other types of anaerobic bacterial endocarditis must rely on laboratory guidance. Anaerobic corynebacteria (propionibacteria), clostridia, and bacteroides occasionally cause endocarditis.

7. Skin & Soft Tissue Infections

Anaerobic infections in the skin and soft tissue usually follow trauma, inadequate blood supply, or surgery and are most common in areas that are contaminated by oral or fecal flora. These infections also occur in injection drug users and persons sustaining animal to human bites. There may be progressive tissue necrosis (Figure 33–5) and a putrid odor.

Several terms, such as bacterial synergistic gangrene, synergistic necrotizing cellulitis, necrotizing fasciitis, and non-clostridial crepitant cellulitis, have been used to classify these infections. Although there are some differences in microbiology among them, their differentiation on clinical grounds alone is difficult. All are mixed infections caused by aerobic and anaerobic organisms and require aggressive surgical debridement of necrotic tissue for cure. Surgical consultation is obligatory to assist in diagnosis and treatment.

Broad-spectrum antibiotics active against both anaerobes and gram-positive and gram-negative aerobes (eg, vancomycin plus piperacillin-tazobactam) should be instituted empirically and modified by culture results (see Table 30–5). They are given for about a week after progressive tissue destruction has been controlled and the margins of the wound remain free of inflammation.

Ustin JS et al. Necrotizing soft-tissue infections. *Crit Care Med.* 2011 Sep;39(9):2156–62. Erratum in: *Crit Care Med.* 2011 Nov;39(11):2592. [PMID: 21532474]



▲ **Figure 33–5.** Gangrene of the right foot causing necrosis of the toes. (Courtesy of William Archibald, Public Health Image Library, CDC.)

ACTINOMYCOSIS

ESSENTIALS OF DIAGNOSIS

- ▶ History of recent dental infection or abdominal trauma.
- ▶ Chronic pneumonia or indolent intra-abdominal or cervicofacial abscess.
- ▶ Sinus tract formation.

▶ General Considerations

Actinomyces israelii and other species of *Actinomyces* occur in the normal flora of the mouth and tonsillar crypts. They are anaerobic, gram-positive, branching filamentous bacteria (1 μm in diameter) that may fragment into bacillary forms. When introduced into traumatized tissue and associated with other anaerobic bacteria, these actinomycetes become pathogens.

The most common site of infection is the cervicofacial area (about 60% of cases). Infection typically follows extraction of a tooth or other trauma. Lesions may develop in the gastrointestinal tract or lungs following ingestion or aspiration of the organism from its endogenous source in

the mouth. Interestingly, *T whippelii*, the causative agent of Whipple disease, is an actinomycete and therefore is related to the species that cause actinomycosis.

► Clinical Findings

A. Symptoms and Signs

1. Cervicofacial actinomycosis—Cervicofacial actinomycosis develops slowly. The area becomes markedly indurated, and the overlying skin becomes reddish or cyanotic. Abscesses eventually draining to the surface persist for long periods. “Sulfur granules”—masses of filamentous organisms—may be found in the pus. There is usually little pain unless there is secondary infection. Trismus indicates that the muscles of mastication are involved. Radiography may reveal bony involvement.

2. Thoracic actinomycosis—Thoracic involvement begins with fever, cough, and sputum production with night sweats and weight loss. Pleuritic pain may be present. Multiple sinuses may extend through the chest wall, to the heart, or into the abdominal cavity. Ribs may be involved. Radiography shows areas of consolidation and in many cases pleural effusion. Cervicofacial or thoracic disease may occasionally involve the central nervous system, most commonly brain abscess or meningitis.

3. Abdominal actinomycosis—Abdominal actinomycosis usually causes pain in the ileocecal region, spiking fever and chills, vomiting, and weight loss; it may be confused with Crohn disease. Irregular abdominal masses may be palpated. Pelvic inflammatory disease caused by actinomycetes has been associated with prolonged use of an intrauterine contraceptive device. Sinuses draining to the exterior may develop. CT scanning reveals an inflammatory mass extended to involve bone.

B. Laboratory Findings

The anaerobic, gram-positive organism may be demonstrated as a granule or as scattered branching gram-positive filaments in the pus. Anaerobic culture is necessary to distinguish actinomycetes from nocardiae because specific therapy differs for the two infections.

► Treatment

Penicillin G is the drug of choice. Ten to 20 million units are given via a parenteral route for 4–6 weeks, followed by oral penicillin V, 500 mg four times daily. Alternatives include ampicillin, 12 g/d intravenously for 4–6 weeks followed by oral amoxicillin 500 mg three times daily or doxycycline 100 mg twice daily intravenously or orally. Response to therapy is slow. Therapy should be continued for weeks to months after clinical manifestations have disappeared in order to ensure cure. Surgical procedures such as drainage and resection may be beneficial.

With penicillin and surgery, the prognosis is good. The difficulties of diagnosis, however, may permit extensive destruction of tissue before the diagnosis is identified and therapy is started.

Wong VK et al. Actinomycosis. *BMJ*. 2011 Oct 11;343:d6099. [PMID: 21990282]

NOCARDIOSIS

Nocardia asteroides, an aerobic filamentous soil bacterium, causes pulmonary and systemic nocardiosis. Bronchopulmonary abnormalities (eg, alveolar proteinosis) predispose to colonization, but infection is unusual unless the patient is also receiving systemic corticosteroids or is otherwise immunosuppressed.

► Clinical Findings

Pulmonary involvement usually begins with malaise, loss of weight, fever, and night sweats. Cough and production of purulent sputum are the chief complaints. Radiography may show infiltrates accompanied by pleural effusion. The lesions may penetrate to the exterior through the chest wall, invading the ribs.

Dissemination involves any organ. Brain abscesses and subcutaneous nodules are most frequent. This is seen exclusively in immunocompromised patients.

N asteroides is usually found as delicate, branching, gram-positive filaments. It may be weakly acid-fast, occasionally causing diagnostic confusion with tuberculosis. Identification is made by culture.

► Treatment

For cutaneous infections, therapy is initiated with intravenous trimethoprim-sulfamethoxazole administered at a dosage of 5–10 mg/kg/d (based on trimethoprim) and continued with oral trimethoprim-sulfamethoxazole, one double-strength tablet twice a day. Surgical procedures such as drainage and resection may be needed as adjunctive therapy. A higher dose of 15 mg/kg/d (based on trimethoprim) should be used for disseminated or pulmonary infections. Resistance to trimethoprim-sulfamethoxazole may be increasing and initiating treatment with two drugs while awaiting antibiotic susceptibilities is reasonable in cases of disseminated or severe localized disease. Imipenem, 500 mg intravenously every 6 hours, is an alternative. Consultation with an infectious diseases expert should be considered.

Response may be slow, and therapy must be continued for at least 6 months. The prognosis in systemic nocardiosis is poor when diagnosis and therapy are delayed.

Nocardia brasiliensis typically causes a digital lesion—resembling herpetic whitlow—and ascending lymphangitis in normal hosts. Antimicrobial treatment is as for *N asteroides* infection, and the prognosis is excellent.

Uhde KB et al. Antimicrobial-resistant nocardia isolates, United States, 1995–2004. *Clin Infect Dis*. 2010 Dec 15;51(12):1445–8. [PMID: 21058914]

INFECTIONS CAUSED BY MYCOBACTERIA**NONTUBERCULOUS MYCOBACTERIAL DISEASES**

About 10% of mycobacterial infections are caused by nontuberculous mycobacteria. Nontuberculous mycobacterial infections are among the most common opportunistic infections in advanced HIV disease. These organisms have distinctive laboratory characteristics, occur ubiquitously in the environment, are not communicable from person to person, and are often resistant to standard antituberculous drugs.

1. Pulmonary Infections

Mycobacterium avium complex (MAC) causes a chronic, slowly progressive pulmonary infection resembling tuberculosis in immunocompetent patients, who typically have underlying pulmonary disease. Susceptibility testing for macrolide-resistance should be performed on clinical isolates. Treatment of nodular or bronchiectatic pulmonary disease is clarithromycin (1000 mg orally three times per week) or azithromycin (500 mg orally three times per week) plus rifampin (600 mg orally three times per week) or rifabutin (300 mg orally three times per week) plus ethambutol (25 mg/kg orally three times per week). Patients with fibrocavitary lung disease or severe nodular or bronchiectatic disease should receive three-drug therapy with clarithromycin (500–1000 mg orally daily) or azithromycin (250 orally mg daily) plus rifampin (600 mg orally daily) or rifabutin (150–300 mg orally daily) plus ethambutol (15 mg/kg orally daily). Therapy is continued for at least 12 months after sterilization of cultures.

M kansasii can produce clinical disease resembling tuberculosis, but the illness progresses more slowly. Most such infections occur in patients with preexisting lung disease, though 40% of patients have no known pulmonary disease. Microbiologically, *M kansasii* is similar to *M tuberculosis* and is sensitive to the same drugs except pyrazinamide, to which it is resistant. Therapy with isoniazid, ethambutol, and rifampin for 2 years (or 1 year after sputum conversion) has been successful.

Less common causes of pulmonary disease include *M xenopi*, *M szulgai*, and *M goodii*. These organisms have variable sensitivities, and treatment is based on results of sensitivity tests. The rapid growing mycobacteria, *M abscessus*, *M chelonae*, and *M fortuitum* also can cause pneumonia in the occasional patient.

2. Lymphadenitis

Most cases of lymphadenitis (scrofula) in adults are caused by *M tuberculosis* and can be a manifestation of disseminated disease. In children, the majority of cases are due to nontuberculous mycobacterial species, with MAC being the most common followed by *M scrofulaceum* in the United States and *M malmoense* and *M haemophilum* in Northern Europe. *M kansasii*, *M bovis*, *M chelonae*, and *M fortuitum* are less commonly observed. Unlike disease

caused by *M tuberculosis*, which requires systemic therapy for 6 months, infection with nontuberculous mycobacteria can be successfully treated by surgical excision without antituberculous therapy.

3. Skin & Soft Tissue Infections

Skin and soft tissue infections such as abscesses, septic arthritis, and osteomyelitis can result from direct inoculation or hematogenous dissemination or may occur as a complication of surgery.

M abscessus, *M chelonae*, and *M fortuitum* are frequent causes of these types of infections. Most cases occur in the extremities and initially present as nodules. Ulceration with abscess formation often follows. The organisms are resistant to the usual antituberculosis drugs and may have susceptibility to clarithromycin, azithromycin, doxycycline, amikacin, cefoxitin, sulfonamides, imipenem, and ciprofloxacin. Given the multidrug resistant nature of these organisms, obtaining antibiotic susceptibility testing is recommended. Therapy often includes surgical debridement along with at least two active antibiotics. Antibiotic therapy is usually continued for 3 months, although this must be determined based on clinical response.

M marinum infection (“swimming pool granuloma”) presents as a nodular skin lesion following exposure to nonchlorinated water. The lesions respond to therapy with clarithromycin, doxycycline, minocycline, or trimethoprim-sulfamethoxazole.

M ulcerans infection (Buruli ulcer) is seen mainly in Africa and Australia and produces a large ulcerative lesion. Therapy consists of surgical excision and skin grafting.

4. Disseminated Mycobacterium avium Infection

MAC causes disseminated disease in immunocompromised patients, most commonly in patients in the late stages of HIV infection, when the CD4 cell count is < 50/mcL. Persistent fever and weight loss are the most common symptoms. The organism can usually be cultured from multiple sites, including blood, liver, lymph node, or bone marrow. Blood culture is the preferred means of establishing the diagnosis and has a sensitivity of 98%.

▶ Treatment

Agents with proved activity against MAC are rifabutin, azithromycin, clarithromycin, and ethambutol. Amikacin and ciprofloxacin work in vitro, but clinical results are inconsistent. A combination of two or more active agents should be used to prevent rapid emergence of secondary resistance. Clarithromycin, 500 mg orally twice daily, plus ethambutol, 15 mg/kg/d orally as a single dose, with or without rifabutin, 300 mg/d orally, is the treatment of choice. Azithromycin, 500 mg orally once daily, may be used instead of clarithromycin. Insufficient data are available to permit specific recommendations about second-line regimens for patients intolerant of macrolides or those with macrolide-resistant organisms. MAC therapy may be

discontinued in patients who have been treated with 12 months of therapy for disseminated MAC, who have no evidence of active disease, and whose CD4 counts exceed 100 cells/mcL for 6 months while receiving highly active antiretroviral therapy (HAART).

▶ Prevention

Antimicrobial prophylaxis of MAC prevents disseminated disease and prolongs survival. It is the standard of care to offer it to all HIV-infected patients with CD4 counts \leq 50/mcL. In contrast to active infection, single-drug oral regimens of clarithromycin, 500 mg twice daily, azithromycin, 1200 mg once weekly, or rifabutin, 300 mg once daily, are appropriate. Clarithromycin or azithromycin is more effective and better tolerated than rifabutin, and therefore preferred. Primary prophylaxis for MAC infection can be stopped in patients who have responded to antiretroviral combination therapy with elevation of CD4 counts $>$ 100 cells/mcL for 3 months.

Griffith DE et al. ATS Mycobacterial Diseases Subcommittee; American Thoracic Society; Infectious Disease Society of America. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. *Am J Respir Crit Care Med.* 2007 Feb 15;175(4):367–416. [PMID: 17277290]

Kaplan JE et al. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. *MMWR Recomm Rep.* 2009 Apr 10;58(RR-4):1–207. [PMID: 19357635]

Winthrop KL et al. Pulmonary nontuberculous mycobacterial disease prevalence and clinical features: an emerging public health disease. *Am J Respir Crit Care Med.* 2010 Oct 1;182(7):977–82. [PMID: 20508209]

MYCOBACTERIUM TUBERCULOSIS INFECTIONS

Tuberculosis is discussed in Chapter 9. Further information and expert consultation can be obtained from the Francis J. Curry International Tuberculosis Center at the Web site <http://www.currytbcenter.ucsf.edu> or, by phone, 415-502-4600, or fax, 415-502-4620.

TUBERCULOUS MENINGITIS



ESSENTIALS OF DIAGNOSIS

- ▶ Gradual onset of listlessness, irritability, and anorexia.
- ▶ Headache, vomiting, and seizures common.
- ▶ Cranial nerve abnormalities typical.
- ▶ Tuberculosis focus may be evident elsewhere.
- ▶ Cerebrospinal fluid shows several hundred lymphocytes, low glucose, and high protein.

▶ General Considerations

Tuberculous meningitis is caused by rupture of a meningeal tuberculoma resulting from earlier hematogenous seeding of tubercle bacilli from a pulmonary focus, or it may be a consequence of miliary spread.

▶ Clinical Findings

A. Symptoms and Signs

The onset is usually gradual, with listlessness, irritability, anorexia, and fever, followed by headache, vomiting, convulsions, and coma. In older patients, headache and behavioral changes are prominent early symptoms. Nuchal rigidity and cranial nerve palsies occur as the meningitis progresses. Evidence of active tuberculosis elsewhere or a history of prior tuberculosis is present in up to 75% of patients.

B. Laboratory Findings

The spinal fluid is frequently yellowish, with increased pressure, 100–500 cells/mcL (predominantly lymphocytes, though neutrophils may be present early during infection), increased protein, and decreased glucose. Acid-fast stains of cerebrospinal fluid usually are negative, and cultures also may be negative in 15–25% of cases. Nucleic acid amplification tests for rapid diagnosis of tuberculosis have variable sensitivity and specificity and none are FDA-approved for use in meningitis. Chest X-ray often reveals abnormalities compatible with tuberculosis but may be normal.

▶ Differential Diagnosis

Tuberculous meningitis may be confused with any other type of meningitis, but the gradual onset, the predominantly lymphocytic pleocytosis of the spinal fluid, and evidence of tuberculosis elsewhere often point to the diagnosis. The tuberculin skin test is usually (not always) positive. Fungal and other granulomatous meningitides, syphilis, and carcinomatous meningitis are in the differential diagnosis.

▶ Complications

Complications of tuberculous meningitis include seizure disorders, cranial nerve palsies, stroke, and obstructive hydrocephalus with impaired cognitive function. These result from inflammatory exudate primarily involving the basilar meninges and arteries.

▶ Treatment

Presumptive diagnosis followed by early, empiric antituberculous therapy is essential for survival and to minimize sequelae. Even if cultures are not positive, a full course of therapy is warranted if the clinical setting is suggestive of tuberculous meningitis.

Regimens that are effective for pulmonary tuberculosis are effective also for tuberculous meningitis (see Table 9–18). Rifampin, isoniazid, and pyrazinamide all

penetrate into cerebrospinal fluid well. The penetration of ethambutol is more variable, but therapeutic concentrations can be achieved, and the drug has been successfully used for meningitis. Aminoglycosides penetrate less well. Regimens that do not include both isoniazid and rifampin may be effective but are less reliable and generally must be given for longer periods.

Many authorities recommend the addition of corticosteroids for patients with focal deficits or altered mental status. Dexamethasone, 0.15 mg/kg intravenously or orally four times daily for 1–2 weeks, then discontinued in a tapering regimen over 4 weeks, may be used.

Shaw JE et al. Meningeal tuberculosis: high long-term mortality despite standard therapy. *Medicine* (Baltimore). 2010 May; 89(3):189–95. [PMID: 20453606]

LEPROSY (Hansen Disease)



ESSENTIALS OF DIAGNOSIS

- ▶ Pale, anesthetic macular—or nodular and erythematous—skin lesions.
- ▶ Superficial nerve thickening with associated anesthesia.
- ▶ History of residence in endemic area in childhood.
- ▶ Acid-fast bacilli in skin lesions or nasal scrapings, or characteristic histologic nerve changes.

▶ General Considerations

Leprosy (Hansen disease) is a chronic infectious disease caused by the acid-fast rod *M leprae*. The mode of transmission probably is respiratory and involves prolonged exposure in childhood. The disease is endemic in tropical and subtropical Asia, Africa, Central and South America, and the Pacific regions, and rarely seen sporadically in the southern United States.

▶ Clinical Findings

A. Symptoms and Signs

The onset is insidious. The lesions involve the cooler body tissues: skin, superficial nerves, nose, pharynx, larynx, eyes, and testicles. Skin lesions may occur as pale, anesthetic macular lesions 1–10 cm in diameter; discrete erythematous, infiltrated nodules 1–5 cm in diameter; or diffuse skin infiltration. Neurologic disturbances are caused by nerve infiltration and thickening, with resultant anesthesia, and motor abnormalities. Bilateral ulnar neuropathy is highly suggestive. In untreated cases, disfigurement due to the skin infiltration and nerve involvement may be extreme, leading to trophic ulcers, bone resorption, and loss of digits.

The disease is divided clinically and by laboratory tests into two distinct types: lepromatous and tuberculoid. The **lepromatous** type (also referred to as multibacillary

leprosy) occurs in persons with defective cellular immunity. The course is progressive and malignant, with nodular skin lesions; slow, symmetric nerve involvement; abundant acid-fast bacilli in the skin lesions; and a negative lepromin skin test. In the **tuberculoid** type (paucibacillary leprosy), cellular immunity is intact and the course is more benign and less progressive, with macular skin lesions, severe asymmetric nerve involvement of sudden onset with few bacilli present in the lesions, and a positive lepromin skin test. Intermediate (“borderline”) cases are frequent. Eye involvement (keratitis and iridocyclitis), nasal ulcers, epistaxis, anemia, and lymphadenopathy may occur.

B. Laboratory Findings

Laboratory confirmation of leprosy requires the demonstration of acid-fast bacilli in a skin biopsy. Biopsy of skin or of a thickened involved nerve also gives a typical histologic picture. *M leprae* does not grow in artificial media but does grow in the foot pads of armadillos.

▶ Differential Diagnosis

The skin lesions of leprosy often resemble those of lupus erythematosus, sarcoidosis, syphilis, erythema nodosum, erythema multiforme, cutaneous tuberculosis, and vitiligo.

▶ Complications

Kidney failure and hepatomegaly from secondary amyloidosis may occur with long-standing disease.

▶ Treatment

Combination therapy is recommended for treatment of all types of leprosy. Single-drug treatment is accompanied by emergence of resistance, and primary resistance to dapsone also occurs. For borderline and lepromatous cases (ie, multibacillary disease), the World Health Organization recommends a triple oral drug-regimen of rifampin, 600 mg once a month; dapsone, 100 mg daily; and clofazimine, 300 mg once a month and 50 mg daily for 12 months although longer courses may be needed for patients with high burden of disease. For indeterminate and tuberculoid leprosy (paucibacillary disease), the recommendation is rifampin, 600 mg once a month, plus dapsone, 100 mg daily for 6 months.

Two reactional states—erythema nodosum leprosum and reversal reactions—may occur as a consequence of therapy. The reversal reaction, typical of borderline lepromatous leprosy, probably results from enhanced host immunity. Skin lesions and nerves become swollen and tender, but systemic manifestations are not seen. Erythema nodosum leprosum, typical of lepromatous leprosy, is a consequence of immune injury from antigen-antibody complex deposition in skin and other tissues; in addition to skin and nerve manifestations, fever and systemic involvement may be seen. Prednisone, 60 mg/d orally, or thalidomide, 300 mg/d orally (in the nonpregnant patient only), is effective for erythema nodosum leprosum. Improvement is expected within a few days after initiating prednisone, and

thereafter the dose may be tapered over several weeks to avoid recurrence. Thalidomide is also tapered over several weeks to a 100-mg bedtime dose. Erythema nodosum leprosum is usually confined to the first year of therapy, and prednisone or thalidomide can be discontinued. Thalidomide is ineffective for reversal reactions, and prednisone, 60 mg/d, is indicated. Reversal reactions tend to recur, and the dose of prednisone should be slowly tapered over weeks to months. Therapy for leprosy should not be discontinued during treatment of reactional states.

Walsh DS et al. Recent advances in leprosy and Buruli ulcer (*Mycobacterium ulcerans* infection). *Curr Opin Infect Dis*. 2010 Oct;23(5):445–55. [PMID: 20581668]

INFECTIONS CAUSED BY CHLAMYDIAE

Chlamydiae is a family of obligate intracellular parasites closely related to gram-negative bacteria. They include two important genera of human pathogens—*Chlamydia*, which includes the species *C trachomatis*, and *Chlamydophila*, which include the species *C psittaci* (formerly known as *C psittaci*) and *C pneumoniae* (formerly known as *C pneumoniae*). The differentiation of genera is based on differences in intracellular inclusions, sulfonamide susceptibility, antigenic composition, and disease production. *C trachomatis* causes many different human infections involving the eye (trachoma, inclusion conjunctivitis), the genital tract (lymphogranuloma venereum, nongonococcal urethritis, cervicitis, salpingitis), or the respiratory tract in infants (pneumonitis). *C psittaci* causes psittacosis and *C pneumoniae* is a cause of respiratory tract infections.

CHLAMYDIA TRACHOMATIS INFECTIONS

1. Lymphogranuloma Venereum

ESSENTIALS OF DIAGNOSIS

► General Considerations

Lymphogranuloma venereum (LGV) is an acute and chronic sexually transmitted disease caused by *C trachomatis* types L1–L3. The disease is acquired during intercourse or through contact with contaminated exudate from active lesions. The incubation period is 5–21 days. After the genital lesion disappears, the infection spreads to lymph channels and lymph nodes of the genital and rectal areas. Inapparent infections and latent disease are not uncommon.

► Clinical Findings

A. Symptoms and Signs

In men, the initial vesicular or ulcerative lesion (on the external genitalia) is evanescent and often goes unnoticed. Inguinal buboes appear 1–4 weeks after exposure, are often bilateral, and have a tendency to fuse, soften, and break

down to form multiple draining sinuses, with extensive scarring. In women, the genital lymph drainage is to the perirectal glands. Early anorectal manifestations are proctitis with tenesmus and bloody purulent discharge; late manifestations are chronic cicatrizing inflammation of the rectal and perirectal tissue. These changes lead to obstipation and rectal stricture and, occasionally, rectovaginal and perianal fistulas. They are also seen in homosexual men.

B. Laboratory Findings

The complement fixation test may be positive (titers > 1:64), but cross-reaction with other chlamydiae occurs. Although a positive reaction may reflect remote infection, high titers usually indicate active disease. Nucleic acid detection tests are sensitive, but not FDA-approved for rectal specimens and cannot differentiate LGV from non-LGV strains.

► Differential Diagnosis

The early lesion of LGV must be differentiated from the lesions of syphilis, genital herpes, and chancroid; lymph node involvement must be distinguished from that due to tularemia, tuberculosis, plague, neoplasm, or pyogenic infection; and rectal stricture must be distinguished from that due to neoplasm and ulcerative colitis.

► Treatment

If diagnostic testing for LGV is not available, patients with a clinical presentation suggestive of LGV should be treated empirically. The antibiotic of choice is doxycycline (contraindicated in pregnancy), 100 mg orally twice daily for 21 days. Erythromycin, 500 mg orally four times a day for 21 days, is also effective. Azithromycin, 1 g orally once weekly for 3 weeks, may also be effective.

Workowski KA et al; Centers for Disease Control and Prevention (CDC). Sexually transmitted diseases treatment guidelines, 2010. *MMWR Recomm Rep*. 2010 Dec 17;59(RR-12):1–110. Erratum in: *MMWR Recomm Rep*. 2011 Jan 14;60(1):18. [PMID: 21160459]

2. Chlamydial Urethritis & Cervicitis

ESSENTIALS OF DIAGNOSIS

- Chlamydia is a common cause of urethritis, cervicitis, and post-gonococcal urethritis.
- Diagnosis made by nucleic acid amplification of urine or swab specimen.

► General Considerations

C trachomatis immunotypes D–K are isolated in about 50% of cases of nongonococcal urethritis and cervicitis. In other cases, *Ureaplasma urealyticum* or *Mycoplasma genitalium* can be grown as a possible etiologic agent. *C trachomatis* is

an important cause of postgonococcal urethritis. Coinfection with gonococci and chlamydiae is common, and postgonococcal (ie, chlamydial) urethritis may persist after successful treatment of the gonococcal component. Occasionally, epididymitis, prostatitis, or proctitis is caused by chlamydial infection. Chlamydiae are a leading cause of infertility in females in the United States.

► Clinical Findings

A. Symptoms and Signs

Females infected with chlamydiae may be asymptomatic or may have symptoms and signs of cervicitis, salpingitis, or pelvic inflammatory disease. The urethral or cervical discharge due to *C trachomatis* tends to be less painful, less purulent, and watery compared with gonococcal infection.

B. Laboratory Findings

A patient with urethritis or cervicitis and absence of gram-negative diplococci on Gram stain and of *N gonorrhoeae* on culture is assumed to have chlamydial infection until proven otherwise. The diagnosis should be confirmed, whenever possible, by the FDA-approved, highly sensitive nucleic acid amplification tests for use with urine or vaginal swabs. A negative nucleic acid amplification test for chlamydia reliably excludes the diagnosis of chlamydial urethritis or cervicitis and therapy need not be administered.

C. Screening

Active screening for chlamydial infection is recommended in certain settings: pregnant women; all sexually active women 25 years of age and under; older women with risk factors for sexually transmitted diseases; and men with risk factors for sexually transmitted diseases, such as HIV-positive men or men who have sex with men.

► Treatment

Recommended regimens are a single oral 1-g dose of azithromycin (preferred and safe in pregnancy), 100 mg of doxycycline orally for 7 days (contraindicated in pregnancy), or 500 mg of levofloxacin once daily for 7 days (also contraindicated in pregnancy). Presumptively administered therapy still may be indicated for some patients (such as for an individual with gonococcal infection in whom no chlamydial testing was performed or a test other than a nucleic acid amplification test was used to exclude the diagnosis, or an individual for whom a test result is pending but is considered unlikely to follow-up, and for sexual contacts of documented cases). As for all patients in whom sexually transmitted diseases are diagnosed, studies for HIV and syphilis should also be performed.

Workowski KA et al; Centers for Disease Control and Prevention (CDC). Sexually transmitted diseases treatment guidelines, 2010. *MMWR Recomm Rep.* 2010 Dec 17;59(RR-12):1–110. Erratum in: *MMWR Recomm Rep.* 2011 Jan 14;60(1):18. [PMID: 21160459]

CHLAMYDOPHILA PSITTACI & PSITTACOSIS (Ornithosis)



ESSENTIALS OF DIAGNOSIS

- ▶ Fever, chills, and cough; headache common.
- ▶ Atypical pneumonia with slightly delayed appearance of signs of pneumonitis.
- ▶ Contact with infected bird (psittacine, pigeons, many others) 7–15 days previously.
- ▶ Isolation of chlamydiae or rising titer of complement-fixing antibodies.

► General Considerations

Psittacosis is acquired from contact with birds (parrots, parakeets, pigeons, chickens, ducks, and many others), which may or may not be ill. The history may be difficult to obtain if the patient acquired infection from an illegally imported bird.

► Clinical Findings

The onset is usually rapid, with fever, chills, myalgia, dry cough, and headache. Signs include temperature-pulse dissociation, dullness to percussion, and rales. Pulmonary findings may be absent early. Dyspnea and cyanosis may occur later. Endocarditis, which is culture-negative, may occur. The radiographic findings in typical psittacosis are those of atypical pneumonia, which tends to be interstitial and diffuse in appearance, though consolidation can occur. Psittacosis is indistinguishable from other bacterial or viral pneumonias by radiography.

The organism is rarely isolated from cultures. The diagnosis is usually made serologically; antibodies appear during the second week and can be demonstrated by complement fixation or immunofluorescence. Antibody response may be suppressed by early chemotherapy.

► Differential Diagnosis

The illness is indistinguishable from viral, mycoplasmal, or other atypical pneumonias except for the history of contact with birds. Psittacosis is in the differential diagnosis of culture-negative endocarditis.

► Treatment

Treatment consists of giving tetracycline, 0.5 g orally every 6 hours or 0.5 g intravenously every 12 hours, for 14–21 days. Erythromycin, 500 mg orally every 6 hours, may be effective as well.

CHLAMYDOPHILA PNEUMONIAE INFECTION

C pneumoniae causes pneumonia and bronchitis. The clinical presentation of pneumonia is that of an atypical pneumonia. The organism accounts for approximately 10% of community-acquired pneumonias, ranking second

to mycoplasma as an agent of atypical pneumonia. A putative role in coronary artery disease has not held up to close scientific scrutiny.

Like *C psittaci*, strains of *C pneumoniae* are resistant to sulfonamides. Erythromycin or tetracycline, 500 mg orally four times a day for 10–14 days, appears to be effective therapy. Fluoroquinolones, such as levofloxacin (500 mg once daily for 7–14 days) or moxifloxacin (400 mg once daily for 7–14 days), are active in vitro against *C pneumoniae*

and probably are effective. It is unclear if empiric coverage for atypical pathogens in hospitalized patients with community-acquired pneumonia provides a survival benefit or improves clinical outcome.

She RC et al. Limited utility of culture for *Mycoplasma pneumoniae* and *Chlamydia pneumoniae* for diagnosis of respiratory tract infections. *J Clin Microbiol.* 2010 Sep;48(9):3380–2. [PMID: 20610673]

34

Spirochetal Infections

Susan S. Philip, MD, MPH

SYPHILIS

NATURAL HISTORY & PRINCIPLES OF DIAGNOSIS & TREATMENT

Syphilis is a complex infectious disease caused by *Treponema pallidum*, a spirochete capable of infecting almost any organ or tissue in the body and causing protean clinical manifestations (Table 34–1). Transmission occurs most frequently during sexual contact (including oral sex), through minor skin or mucosal lesions; sites of inoculation are usually genital but may be extragenital. The risk of acquiring syphilis after unprotected sex with an individual with infectious syphilis is approximately 30–50%. Rarely, it can also be transmitted through nonsexual contact, blood transfusion, or via the placenta from mother to fetus (congenital syphilis).

The natural history of acquired syphilis is generally divided into two major clinical stages: **early (infectious) syphilis** and **late syphilis**. The two stages are separated by a symptom-free latent phase during the first part of which (early latency) infectious lesions can recur. Infectious syphilis includes the primary lesions (chancre and regional lymphadenopathy), the secondary lesions (commonly involving skin and mucous membranes, occasionally bone, central nervous system, or liver), relapsing lesions during early latency, and congenital lesions. The hallmark of these lesions is an abundance of spirochetes; tissue reaction is usually minimal. Late syphilis consists of so-called benign (gummatous) lesions involving skin, bones, and viscera; cardiovascular disease (principally aortitis); and a variety of central nervous system and ocular syndromes. These forms of syphilis are not contagious. The lesions contain few demonstrable spirochetes, but tissue reactivity (vasculitis, necrosis) is severe and suggestive of hypersensitivity phenomena.

Public health efforts to control syphilis focus on the diagnosis and treatment of early (infectious) cases and their partners.

Most cases of syphilis in the United States continue to occur in men who have sex with men (MSM). From

2009 to 2010, the rates of primary and secondary syphilis increased in white and Hispanic men and decreased in black men and in white, black, and Hispanic women. The highest rates were in black men, however, with 34 cases/100,000 population. In 2010, 46% of the primary and secondary syphilis cases were reported from the South. The rate of congenital syphilis cases decreased between 2009 and 2010 to 9 cases/100,000 live births. Despite the increase in primary and secondary syphilis in MSM in certain urban areas, such as San Francisco, a concomitant increase in the incidence of HIV has not been observed.

COURSE & PROGNOSIS

The lesions associated with primary and secondary syphilis are self-limiting, even without treatment, and resolve with few or no residua. Late syphilis may be highly destructive and permanently disabling and may lead to death. Many experts now believe that while infection is almost never completely eradicated in the absence of treatment, most infections remain latent without sequelae, and only a small number of latent infections progress to further disease.

CLINICAL STAGES OF SYPHILIS

1. Primary Syphilis



ESSENTIALS OF DIAGNOSIS

- ▶ History of sexual contact (may be unreliable).
- ▶ Painless ulcer on genitalia, perianal area, rectum, pharynx, tongue, lip, or elsewhere.
- ▶ Nontender enlargement of regional lymph nodes.
- ▶ Fluid expressed from lesion contains *T pallidum* by immunofluorescence or darkfield microscopy.
- ▶ Serologic nontreponemal and treponemal tests.

Table 34-1. Stages of syphilis and common clinical manifestations.**Primary syphilis**

Genital ulcer: painless ulcer with clean base and firm indurated borders

Regional lymphadenopathy

Secondary syphilis

Skin and mucous membranes

Rash: diffuse (may include palms and soles), macular, papular, pustular, and combinations

Condylomata lata

Mucous patches: painless, silvery ulcerations of mucous membrane with surrounding erythema

Generalized lymphadenopathy

Constitutional symptoms

Fever, usually low-grade

Malaise

Anorexia

Arthralgias and myalgias

Central nervous system

Asymptomatic

Symptomatic

Headache

Meningitis

Cranial neuropathies (II–VIII)

Ocular

Iritis

Iridocyclitis

Other

Renal: glomerulonephritis, nephrotic syndrome

Liver: hepatitis

Bone and joint: arthritis, periostitis

Late syphilis

Late benign (gummatous): granulomatous lesion usually involving skin, mucous membranes and bones, but any organ can be involved

Cardiovascular

Aortic regurgitation

Coronary ostial stenosis

Aortic aneurysm

Neurosyphilis

Asymptomatic

Meningovascular

Seizures

Hemiparesis or hemiplegia

Tabes dorsalis

Impaired proprioception and vibratory sensation

Argyll Robertson pupil

Shooting pains

Ataxia

Romberg sign

Urinary and fecal incontinence

Charcot joint

Cranial neuropathies (II–VIII)

General paresis

Personality changes

Hyperactive reflexes

Argyll Robertson pupil

Decreased memory

Slurred speech

Optic atrophy

Clinical Findings**A. Symptoms and Signs**

This is the stage of invasion and may pass unrecognized. The typical lesion is the chancre at the site or sites of inoculation, most frequently located on the penis (Figure 34-1), labia, cervix, or anorectal region. Anorectal lesions are especially common among MSM. Chancres also occur occasionally in the oropharynx (lip, tongue, or tonsil) and rarely on the breast or finger. An initial small erosion 10–90 days (average, 3–4 weeks) after inoculation appears then rapidly develops into a painless superficial ulcer with a clean base and firm, indurated margins. This is associated with enlargement of regional lymph nodes, which are rubbery, discrete, and nontender. Bacterial infection of the chancre may occur and may lead to pain. Healing occurs without treatment, but a scar may form, especially with secondary bacterial infection. Multiple chancres may be present, particularly in HIV-positive patients. Although the “classic” ulcer of syphilis has been described as nontender, nonpurulent, and indurated, only 31% of patients have this triad.

B. Laboratory Findings

1. Microscopic examination—In early (infectious) syphilis, darkfield microscopic examination by a skilled observer of fresh exudate from lesions or material aspirated from regional lymph nodes is up to 90% sensitive for diagnosis. The darkfield examination requires expertise for proper specimen collection and identification of characteristic features of morphology and motility of pathogenic spirochetes, and repeated examinations may be necessary. Therefore, this testing is usually only available in select sexually transmitted disease clinics. Darkfield examination of oral lesions is not recommended because of the presence of nonpathogenic treponemes in the mouth. Spirochetes usually are not found in late syphilitic lesions by this technique.



▲ **Figure 34-1.** Primary syphilis with a large chancre on the glans of the penis. (Courtesy of Richard P. Usatine, MD; used, with permission, from Usatine RP, Smith MA, Mayeaux EJ Jr, Chumley H, Tysinger J. *The Color Atlas of Family Medicine*. McGraw-Hill, 2009.)

Table 34-2. Percentage of patients with positive serologic tests for syphilis.¹

Test	Stage		
	Primary	Secondary	Tertiary
VDRL or RPR	75-85%	99-100%	40-95%
FTA-ABS, TPPA, or MHA-TP	69-100%	100%	94-98%
IgG EIA	100%	100%	NA
CIA	98	100	100

¹Based on untreated cases.

CIA, chemiluminescence assay; EIA, enzyme immunoassay; FTA-ABS, fluorescent treponemal antibody absorption assay; MHA-TP, microhemagglutination assay for *T pallidum*; RPR, rapid plasma reagin test; TPPA, *T pallidum* particle agglutination; VDRL, Venereal Disease Research Laboratory test.

An immunofluorescent staining technique for demonstrating *T pallidum* in dried smears of fluid taken from early syphilitic lesions is available through some state health department laboratories but is not widely used. Slides are fixed and treated with fluorescein-labeled anti-treponemal antibody that has been preabsorbed with non-pathogenic treponemes. The slides are then examined for fluorescing spirochetes in an ultraviolet microscope. Because of its simplicity, high specificity, and convenience to clinicians (slides can be mailed), this technique has replaced darkfield microscopy in some health departments and medical center laboratories.

2. Serologic tests for syphilis—(Table 34-2.) There are two general categories of serologic tests for syphilis: (1) Nontreponemal tests detect antibodies to lipoidal antigens present in the host after modification by *T pallidum*. (2) Treponemal tests use live or killed *T pallidum* as antigen to detect antibodies specific for pathogenic treponemes.

A. NONTREPONEMAL ANTIGEN TESTS—The most commonly used nontreponemal antigen tests are the Venereal Disease Research Laboratory (VDRL) and rapid plasma reagin (RPR) tests, which measure the ability of heated serum to flocculate a suspension of cardiolipin-cholesterol-lecithin. The flocculation tests are inexpensive, rapid, and easy to perform and have therefore been commonly used for routine screening. A different, enzyme immunoassay (EIA)-based screening algorithm has been recently introduced and is discussed below. Quantitative expression of the reactivity of the serum, based on titration of dilutions of serum, is valuable in establishing the diagnosis and in evaluating the efficacy of treatment, since titers usually correlate with disease activity.

Nontreponemal tests generally become positive 4-6 weeks after infection or 1-3 weeks after the appearance of a primary lesion; they are almost invariably positive in the secondary stage, with titers $\geq 1:16$. In the late

stages, titers tend to be lower ($< 1:4$). These serologic tests are not highly specific and must be closely correlated with other clinical and laboratory findings. The tests are positive in patients with non-sexually transmitted treponematoses (see below). More important, false-positive serologic reactions are frequently encountered in a wide variety of other conditions, including connective tissue diseases, infectious mononucleosis, malaria, febrile diseases, leprosy, injection drug use, infective endocarditis, old age, hepatitis C viral infection, and pregnancy. False-positive reactions are usually of low titer and transient and may be distinguished from true positives by treponemal specific-antibody tests. False-negative results can be seen when very high antibody titers are present (the prozone phenomenon). If syphilis is strongly suspected and the nontreponemal test is negative, the laboratory should be instructed to dilute the specimen to detect a positive reaction. The RPR and VDRL tests are equally reliable, but titers of RPR tend to be higher than the VDRL. Thus, when these tests are used to follow disease activity, the same testing method should be used and preferably should be performed at the same laboratory.

Nontreponemal antibody titers are used to assess adequacy of therapy. The time required for the VDRL or RPR to become negative depends on the stage of the disease, the level of the initial titer, and whether the infection is an initial or repeat episode. In general, persons with repeat infections, higher initial titers, more advanced stages of disease, or those who are HIV positive at the time of treatment have a slower seroconversion rate and are more likely to remain serofast (ie, titers do not become negative). Data based on currently recommended treatment regimens (see below) suggest that in primary and secondary syphilis it may take 6-12 months to see a four-fold decrease in titer.

B. TREPONEMAL ANTIBODY TESTS—These tests measure antibodies capable of reacting with *T pallidum* antigens. The *T pallidum* hemagglutination (TPHA) test and the *T pallidum* particle agglutination (TPPA) test are comparable in specificity and sensitivity to the fluorescent treponemal antibody absorption test (FTA-ABS). The TPPA test, because of ease of performance, has supplanted the FTA-ABS test as the means of confirming the diagnosis of syphilis.

The treponemal tests are of value principally in determining whether a positive nontreponemal antigen test is a false-positive result (see above) or is indicative of syphilis. Because of their great sensitivity, particularly in the late stages of the disease, these tests are also of value when there is clinical evidence of syphilis but the nontreponemal serologic test for syphilis is negative. Treponemal tests are reactive in most patients with primary syphilis and in almost all patients with secondary syphilis. Although a reactive treponemal serologic test remains the same throughout a patient's life in most cases, the treponemal-specific antibody test (like nontreponemal antibody tests) may revert to negative with adequate therapy. Final decisions about the significance of the results of serologic tests for syphilis must be based on a total clinical appraisal.

C. EIA- OR CIA-BASED SCREENING ALGORITHMS—Newer screening algorithms reverse the traditional test order and begin with an automated treponemal antibody test, the EIA or CIA (chemiluminescence assay), and then follow up with a nontreponemal test (RPR or VDRL) if the treponemal test is positive. This algorithm is faster and decreases costs to laboratories when compared with traditional screening. Compared with traditional treponemal-specific tests, the EIAs have sensitivities of 95–99% and specificities of 100%.

The EIA- or CIA-based algorithms can cause challenges in clinical management. A positive EIA with a negative RPR or VDRL should be evaluated with a second treponemal test, but interpretation of discordant results is not yet fully standardized and a clinician may benefit from an expert opinion.

D. RAPID TREPONEMAL TESTS—A single rapid treponemal test was approved by the FDA in 2011 for use in the United States, but is not yet in widespread use. However, such rapid treponemal tests are commonly used worldwide, particularly in limited-resource settings.

3. Polymerase chain reaction—Polymerase chain reaction (PCR) has been increasingly evaluated and utilized worldwide for the diagnosis of genital ulcer disease, including syphilis, but these tests are not yet commercially available in the United States.

4. Cerebrospinal fluid examination—See Neurosyphilis section.

► Differential Diagnosis

The syphilitic chancre may be confused with genital herpes, chancroid (usually painful and uncommon in the United States), lymphogranuloma venereum (also uncommon), or neoplasm. Any genital ulcer should be considered a possible primary syphilitic lesion. Simultaneous evaluation for herpes simplex virus types 1 and 2 using PCR or culture should also be done in these cases.

► Prevention & Screening

Avoidance of sexual contact is the only completely reliable method of prevention but is an impractical public health measure. Latex or polyurethane condoms are effective but protect covered areas only. Screening every 6–12 months for syphilis among MSM has been recommended based on preliminary data suggesting that this may decrease the rate of transmission. High-risk individuals (those who have multiple encounters with anonymous partners or who have sex in conjunction with the use of drugs) should be screened every 3–6 months. Pregnant women should be screened at the first prenatal visit and again in the third trimester if there is a high risk of infection. Indicators of high risk include poverty, sex work, illicit drug use, history of other sexually transmitted diseases, and living in communities with high syphilis morbidity. Patients treated for other sexually transmitted diseases should also be tested for syphilis, and persons who have known or suspected contact with patients who

have syphilis should be evaluated and treated to abort development of infectious syphilis (see Treating Syphilis Contacts below).

► Treatment

A. Antibiotic Therapy

Penicillin remains the preferred treatment for syphilis, since there have been no documented cases of penicillin resistant *T pallidum* (Table 34–3). Although doxycycline is an alternative for some patients, pregnant women must be treated with penicillin (see below).

There are limited data for ceftriaxone, although optimum dose and duration are not well defined. Azithromycin is no longer recommended in many areas due to demonstrated resistance. Patients treated for neurosyphilis should receive at least one dose of long-acting (benzathine) penicillin at the completion of therapy. All patients treated with a non-penicillin regimen must have close clinical and serologic follow up, as noted below.

B. Managing Jarisch–Herxheimer Reaction

The Jarisch–Herxheimer reaction, manifested by fever and aggravation of the existing clinical picture in the hours following treatment, is ascribed to the sudden massive destruction of spirochetes and is not IgE-mediated. It is most common in early syphilis, particularly secondary syphilis where it can occur in 66% of cases. The reaction resolves spontaneously within 24 hours; treatment should not be avoided, but in cases of syphilitic laryngitis, auditory neuritis or labyrinthitis, or involvement of the coronary ostia, patients must be monitored closely for morbidity associated with the reaction. It may also prompt preterm labor in pregnant women so these patients should either be admitted for treatment if they are at high risk for preterm labor, or closely observed with a plan for emergent care if needed.

The reaction may be blunted by simultaneous administration of antipyretics, although no proved method of prevention exists. In cases with increased risk of morbidity due to the Jarisch–Herxheimer reaction, consultation with an infectious disease expert is recommended. Patients should be reminded that the reaction does not signify an allergy to penicillin.

C. Local Measures (Mucocutaneous Lesions)

Local treatment is usually not necessary. No local antiseptics or other chemicals should be applied to a suspected syphilitic lesion until specimens for microscopy have been obtained.

D. Public Health Measures

Patients with infectious syphilis must abstain from sexual activity for 7–10 days after treatment. All cases of syphilis must be reported to the appropriate local public health agency for assistance in identifying and treating sexual contacts. In addition, all patients with syphilis should have an HIV test at the time of diagnosis. In areas of high

Table 34-3. Recommended treatment for syphilis.¹

Stage of Syphilis	Treatment	Alternative ²	Comment
Early			
Primary, secondary, or early latent	Benzathine penicillin G 2.4 million units intramuscularly once	Doxycycline 100 mg orally twice daily for 14 days or Tetracycline 500 mg orally four times daily for 14 days or Ceftriaxone 1 g intramuscularly or intravenously daily for 8-10 days ³	
Late			
Late latent or uncertain duration	Benzathine penicillin G 2.4 million units intramuscularly weekly for 3 weeks	Doxycycline 100 mg orally twice daily for 28 days or Tetracycline 500 mg orally four times a day for 28 days	No routine cerebrospinal fluid evaluation unless neurologic, otologic or ocular abnormalities
Tertiary without neurosyphilis	Benzathine penicillin G 2.4 million units intramuscularly weekly for 3 weeks	Doxycycline 100 mg orally twice daily for 28 days or Tetracycline 500 mg orally four times a day for 28 days	Cerebrospinal fluid evaluation recommended in all patients
Neurosyphilis	Aqueous penicillin G 18-24 million units intravenously daily, given every 3-4 hours or as continuous infusion for 10-14 days	Procaine penicillin, 2.4 million units intramuscularly daily with probenecid 500 mg orally four times a day for 10-14 days or Ceftriaxone 2 g intramuscularly or intravenously daily for 10-14 days	Follow treatment with benzathine penicillin G 2.4 million units intramuscularly weekly for up to 3 weeks

¹Penicillin is the only documented effective treatment in pregnancy, so pregnant patients with true allergy should be desensitized and treated with penicillin according to stage of disease as above.

²Patients treated with alternative therapies require close clinical and serologic monitoring.

³Fewer data for ceftriaxone treatment, optimal dose or duration not known.

HIV prevalence, a repeat HIV test should be performed in 3 months if the initial test result was negative.

E. Treating Syphilis Contacts

Patients who have been sexually exposed to infectious syphilis within the preceding 3 months may be infected but seronegative and thus should be treated as for early syphilis even if serologic tests are negative. Persons exposed more than 3 months previously should be treated based on serologic results. If their partners are unavailable for testing or the patient is unreliable for follow-up, empiric therapy is indicated.

► Follow-Up Care

Because treatment failures and reinfection may occur, patients treated for syphilis should be monitored clinically and serologically at 6 and 12 months. Response to therapy may be difficult to assess, and no definite criteria exist for cure in patients with primary or secondary syphilis. In

primary and secondary syphilis, failure of nontreponemal antibody titers to decrease fourfold by 6 months may identify a group at high risk for treatment failure. Optimal management of these patients is unclear, but at a minimum, close clinical and serologic follow-up is indicated. If titers fail to decrease fourfold by 6-12 months, an HIV test should be repeated (all patients with syphilis should have an HIV test at the time of diagnosis); a lumbar puncture should be considered since unrecognized neurosyphilis can be a cause of treatment failure; and, if careful follow-up cannot be ensured (3-month intervals for HIV-positive individuals and 6-month intervals for HIV-negative patients), treatment should be repeated with 2.4 million units of benzathine penicillin intramuscularly weekly for 3 weeks. If symptoms or signs persist or recur after initial therapy or there is a fourfold or greater increase in nontreponemal titers, therapy has either failed or the patient has been reinfected. In those individuals, an HIV test should be performed, a lumbar puncture done (unless reinfection is a certainty), and re-treatment given as indicated above.

2. Secondary Syphilis




ESSENTIALS OF DIAGNOSIS

- ▶ Generalized maculopapular skin rash.
- ▶ Mucous membrane lesions, including patches and ulcers.
- ▶ Weeping papules (condyloma lata) in moist skin areas.
- ▶ Generalized nontender lymphadenopathy.
- ▶ Fever may be present.
- ▶ Meningitis, hepatitis, osteitis, arthritis, iritis may be present.
- ▶ Many treponemes in moist lesions by immunofluorescence or darkfield microscopy.
- ▶ Serologic tests for syphilis positive.

▶ Clinical Findings

The secondary stage of syphilis usually appears a few weeks (or up to 6 months) after development of the chancre, when dissemination of *T pallidum* produces systemic signs (fever, lymphadenopathy) or infectious lesions at sites distant from the site of inoculation. The most common manifestations are skin and mucosal lesions. The skin lesions are nonpruritic, macular, papular, pustular, or follicular (or combinations of any of these types, but generally *not* vesicular). The skin lesions usually are generalized; involvement of the palms and soles (Figure 34-2) occurs in 80% of cases. Annular lesions simulating ringworm may be observed in dark-skinned individuals. Mucous membrane lesions may include mucous patches (Figure 34-3), which can be found on the lips, mouth, throat, genitalia, and anus. Specific lesions—**condylomata lata** (Figure 34-4)—are fused, weeping papules on the moist areas of the skin and mucous membranes and are sometimes mistaken for genital warts. The mucous membrane lesions are highly infectious.



▲ **Figure 34-2.** Secondary syphilis lesions on the soles of the feet. (Courtesy of Dr. Gavin Hart, Public Health Image Library, CDC.)



▲ **Figure 34-3.** Secondary syphilis mucous patch of the tongue. (Courtesy of Kenneth Katz MD, MSc, MSCE.)

Meningeal (aseptic meningitis or acute basilar meningitis), hepatic, renal, bone, and joint invasion may occur, with resulting cranial nerve palsies, jaundice, nephrotic syndrome, and periostitis. Alopecia (moth-eaten appearance) and uveitis may also occur.

The serologic tests for syphilis are positive in almost all cases (see Primary Syphilis). The moist cutaneous and mucous membrane lesions often show *T pallidum* on darkfield microscopic examination. A transient cerebrospinal fluid (CSF) pleocytosis is seen in 30–70% of patients with secondary syphilis, though only 5% have positive serologic CSF reactions. There may be evidence of hepatitis or nephritis (immune complex type) as circulating immune complexes are deposited in blood vessel walls.

Skin lesions may be confused with the infectious exanthems, pityriasis rosea, and drug eruptions (Figure 34-5). Visceral lesions may suggest nephritis or hepatitis due to other causes. The diffusely red throat may mimic other forms of pharyngitis.



▲ **Figure 34-4.** Secondary syphilis perianal condylomata lata. (Courtesy of Dr. Joseph Engelman, San Francisco City Clinic.)



▲ **Figure 34-5.** Secondary syphilis rash of the buttocks and legs. (Courtesy of J. Pledger, BSS/VD, Public Health Image Library, CDC.)

▶ Treatment

Treatment is as for primary syphilis unless central nervous system or ocular disease is present, in which case a lumbar puncture should be performed and, if positive, treatment for neurosyphilis given (Table 34–3). See Primary Syphilis for follow-up care and treatment of contacts.

3. Latent Syphilis



ESSENTIALS OF DIAGNOSIS

- ▶ Early latent syphilis: infection < 1 year in duration.
- ▶ Late latent syphilis: infection > 1 year in duration.
- ▶ No physical signs.
- ▶ History of syphilis with inadequate treatment.
- ▶ Positive serologic tests for syphilis.

▶ General Considerations

Latent syphilis is the clinically quiescent phase during the interval after the disappearance of secondary lesions. **Early**

latent syphilis is defined as the first year after primary infection and may relapse to secondary syphilis if undiagnosed or inadequately treated (see above). Relapse is almost always accompanied by a rising titer in quantitative serologic tests; indeed, a rising titer may be the first or only evidence of relapse. About 90% of relapses occur during the first year after infection.

Early latent infection can be diagnosed if there was documented seroconversion or a fourfold increase in nontreponemal titers in the past 12 months; the patient can recall symptoms of primary or secondary syphilis; or the patient had a sex partner with documented primary, secondary, or early latent syphilis.

After the first year of latent syphilis, the patient is said to be in the **late latent** (“hidden”) phase and noninfectious to sex partners. Transmission to the fetus, however, can probably occur in any phase. There are (by definition) no clinical manifestations during the latent phase, and the only significant laboratory findings are positive serologic tests. A diagnosis of latent syphilis is justified only when the history and physical examination show no evidence of tertiary disease or neurosyphilis. The latent phase may last from months to a lifetime.

▶ Treatment

Treatment of **early latent syphilis** and follow up is as for primary syphilis unless central nervous system disease is present (Table 34–3). Treatment of **late latent syphilis** is shown in Table 34–3. The treatment of this stage of the disease is intended to prevent late sequelae. If there is evidence of central nervous system involvement, a lumbar puncture should be performed and, if positive, the patient should receive treatment for neurosyphilis. Titers may not decline as rapidly following treatment as in early syphilis. Nontreponemal serologic tests should be repeated at 6, 12, and 24 months. If titers increase fourfold or if initially high titers ($\geq 1:32$) fail to decrease fourfold by 12–24 months or if symptoms or signs consistent with syphilis develop, an HIV test and lumbar puncture should be performed and re-treatment given according to the stage of the disease.

4. Late (Tertiary) Syphilis



ESSENTIALS OF DIAGNOSIS

- ▶ Infiltrative tumors of skin, bones, liver (gummas).
- ▶ Aortitis, aneurysms, aortic regurgitation.
- ▶ Central nervous system disorders, including meningovascular and degenerative changes, paresthesias, shooting pains, abnormal reflexes, dementia, or psychosis.

▶ General Considerations

This stage may occur at any time after secondary syphilis, even after years of latency, and is rarely seen in developed countries in the modern antibiotic era. Late lesions are

thought to represent a delayed hypersensitivity reaction of the tissue to the organism and are usually divided into two types: (1) a localized gummatous reaction, with a relatively rapid onset and generally prompt response to therapy (“benign late syphilis”) and (2) diffuse inflammation of a more insidious onset that characteristically involves the central nervous system and large arteries, is often fatal if untreated, and is at best arrested by treatment. Gummas may involve any area or organ of the body but most often affect the skin or long bones. Cardiovascular disease is usually manifested by aortic aneurysm, aortic regurgitation, or aortitis. Various forms of diffuse or localized central nervous system involvement may occur.

Late syphilis must be differentiated from neoplasms of the skin, liver, lung, stomach, or brain; other forms of meningitis; and primary neurologic lesions.

Although almost any tissue and organ may be involved in late syphilis, the following are the most common types of involvement: skin, mucous membranes, skeletal system, eyes, respiratory system, gastrointestinal system, cardiovascular system, and nervous system.


► Clinical Findings

A. Symptoms and Signs

1. Skin—Cutaneous lesions of late syphilis are of two varieties: (1) multiple nodular lesions that eventually ulcerate (*lues maligna*) or resolve by forming atrophic, pigmented scars and (2) solitary gummas that start as painless subcutaneous nodules, then enlarge, attach to the overlying skin, and eventually ulcerate (Figure 34–6).

2. Mucous membranes—Late lesions of the mucous membranes are nodular gummas or leukoplakia, highly destructive to the involved tissue.

3. Skeletal system—Bone lesions are destructive, causing periostitis, osteitis, and arthritis with little or no associated redness or swelling but often marked myalgia and myositis of the neighboring muscles. The pain is especially severe at night.



▲ **Figure 34-6.** Gumma of the nose due to long-standing tertiary syphilis. (Courtesy of J. Pledger, Public Health Image Library, CDC.)


4. Eyes—Late ocular lesions are gummatous iritis, chorioretinitis, optic atrophy, and cranial nerve palsies, in addition to the lesions of central nervous system syphilis.

5. Respiratory system—Respiratory involvement by late syphilis is caused by gummatous infiltrates into the larynx, trachea, and pulmonary parenchyma, producing discrete pulmonary densities. There may be hoarseness, respiratory distress, and wheezing secondary to the gummatous lesion itself or to subsequent stenosis occurring with healing.

6. Gastrointestinal system—Gummas involving the liver produce the usually benign, asymptomatic *hepar lobatum*. A picture resembling Laennec cirrhosis is occasionally produced by liver involvement. Gastric involvement can consist of diffuse infiltration into the stomach wall or focal lesions that endoscopically and microscopically can be confused with lymphoma or carcinoma. Epigastric pain, early satiety, regurgitation, belching, and weight loss are common symptoms.

7. Cardiovascular system—Cardiovascular lesions (10–15% of late syphilitic lesions) are often progressive, disabling, and life-threatening. Central nervous system lesions are often present concomitantly. Involvement usually starts as an arteritis in the supracardiac portion of the aorta and progresses to one or more of the following: (1) narrowing of the coronary ostia, with resulting decreased coronary circulation, angina, and acute myocardial infarction; (2) scarring of the aortic valves, producing aortic regurgitation, and eventually congestive heart failure; and (3) weakness of the wall of the aorta, with saccular aneurysm formation (Figure 34–7) and associated pressure symptoms of dysphagia, hoarseness, brassy cough, back pain (vertebral erosion), and occasionally rupture of the aneurysm. Recurrent respiratory infections are common as a result of pressure on the trachea and bronchi.

8. Nervous system (neurosyphilis)—See following section.



▲ **Figure 34-7.** Ascending saccular aneurysm of the thoracic aorta in tertiary syphilis. (Public Health Image Library, CDC.)

► Treatment

Treatment of tertiary syphilis (excluding neurosyphilis) is the same as late latent syphilis (Table 34–3). Positive serologic tests do not usually become negative. Viable spirochetes are occasionally found in the eyes, in CSF, and elsewhere in patients with “adequately” treated syphilis, but claims for their capacity to cause progressive disease are speculative.

The pretreatment clinical and laboratory evaluation should include neurologic, ocular, cardiovascular, psychiatric, and CSF examinations. In the presence of definite CSF or neurologic abnormalities, one should treat for neurosyphilis.

5. Neurosyphilis



ESSENTIALS OF DIAGNOSIS

- ▶ Can occur at any stage of disease.
- ▶ Consider both clinical presentation and laboratory data.
- ▶ Carefully evaluate HIV-positive patients and consider CSF evaluation for atypical symptoms or lack of decrease in nontreponemal serology titers.

► General Considerations

Neurosyphilis can occur at any stage of disease and can be a progressive, disabling, and life-threatening complication. CSF pleocytosis has been reported in 10–20% of patients with primary syphilis. Asymptomatic and meningovascular syphilis occur earlier (months to years after infection, sometimes coexisting with primary and secondary syphilis) than tabes dorsalis and general paresis (2–50 years after infection).

► Clinical Findings

A. Classification

1. Asymptomatic neuroinvasion—This form is characterized by spinal fluid abnormalities (positive spinal fluid serology, increased cell count, occasionally increased protein) without symptoms or signs of neurologic involvement. There are no clear data to support that these asymptomatic CSF abnormalities have clinical significance.

2. Meningovascular syphilis—This form is characterized by meningeal involvement or changes in the vascular structures of the brain (or both), producing symptoms of acute or chronic meningitis (headache, irritability); cranial nerve palsies (basilar meningitis); unequal reflexes; irregular pupils with poor light and accommodation reflexes; and when large vessels are involved, cerebrovascular accidents. The CSF shows increased cells (100–1000/mcL), elevated protein, and may have a positive serologic test (CSF VDRL) for syphilis. The symptoms of acute meningitis are rare in late syphilis.

3. Tabes dorsalis—This form is a chronic progressive degeneration of the parenchyma of the posterior columns of the spinal cord and of the posterior sensory ganglia and nerve roots. The symptoms and signs are impairment of proprioception and vibration sense, Argyll Robertson pupils (which react poorly to light but well to accommodation), and muscular hypotonia and hyporeflexia. Impairment of proprioception results in a wide-based gait and inability to walk in the dark. Paresthesias, analgesia, or sharp recurrent pains in the muscles of the leg (“shooting” or “lightning” pains) may occur. Crises are also common in tabes: gastric crises, consisting of sharp abdominal pains with nausea and vomiting (simulating an acute abdomen); laryngeal crises, with paroxysmal cough and dyspnea; urethral crises, with painful bladder spasms; and rectal and anal crises. Crises may begin suddenly, last for hours to days, and cease abruptly. Neurogenic bladder with overflow incontinence is also seen. Painless trophic ulcers may develop over pressure points on the feet. Joint damage may occur as a result of lack of sensory innervation (Charcot joint, Figure 34–8). The CSF may have a normal or increased cell count, elevated protein, and variable results of serologic tests.

4. General paresis—This is generalized involvement of the cerebral cortex with insidious onset of symptoms. There is usually a decrease in concentrating power, memory loss, dysarthria, tremor of the fingers and lips, irritability, and mild headaches. Most striking is the change of personality; the patient may become slovenly, irresponsible, confused, and psychotic. The CSF findings resemble those of tabes dorsalis. Combinations of the various forms of neurosyphilis (especially tabes and paresis) are not uncommon.

B. Laboratory Findings

See Serologic Tests for Syphilis, above; these tests should also be performed in cases of suspected neurosyphilis.

1. Indications for a lumbar puncture—In early syphilis (primary and secondary syphilis and early latent syphilis of < 1 year duration), invasion of the central nervous system



▲ **Figure 34–8.** Neuropathic arthropathy (Charcot joint) from tertiary syphilis. (Courtesy of Susan Lindsley, Public Health Image Library, CDC.)

by *T pallidum* with CSF abnormalities occurs commonly, but clinical neurosyphilis rarely develops in patients who have received the standard therapy outlined above. Thus, unless clinical symptoms and signs of neurosyphilis or ophthalmologic involvement (uveitis, neuroretinitis, optic neuritis, iritis) are present, a lumbar puncture in early syphilis is not recommended as part of the routine evaluation. In latent syphilis, routine lumbar puncture is not indicated since the yield is low and findings rarely influence therapeutic decisions. CSF evaluation is recommended, however, if neurologic or ophthalmologic symptoms and signs are present, if there is evidence of treatment failure (see earlier discussion), or if there is evidence of active tertiary syphilis (eg, aortitis, iritis, optic atrophy, the presence of a gumma).

2. Spinal fluid examination—CSF findings in neurosyphilis are variable. In “classic” cases, there is an elevation of total protein, lymphocytic pleocytosis, and a positive CSF reagin test (VDRL). The serum nontreponemal titers will be reactive in most cases. In later stages of syphilis, normal CSF analysis in the presence of infection can occur, but it is unusual. False-positive reagin tests rarely occur in the CSF; a positive test confirms the presence of neurosyphilis. Because the CSF VDRL may be negative in 30–70% of cases of neurosyphilis, *a negative test does not exclude neurosyphilis*. The CSF FTA-ABS is sometimes used; it is a highly sensitive test but lacks specificity, and a high serum titer of FTA-ABS may result in a positive CSF titer in the absence of neurosyphilis.

▶ Treatment

Current recommendations for the therapy of neurosyphilis include high doses of aqueous penicillin to achieve better penetration and higher levels of drug in the CSF than is possible with benzathine penicillin (Table 34–3). Because of concerns about slowly dividing organisms that may persist after only 10–14 days of therapy, many experts recommend subsequent administration of 2.4 million units of the longer-acting benzathine penicillin intramuscularly once weekly for up to 3 weeks as additional therapy. There are some data for using ceftriaxone to treat neurosyphilis as well, but because this and other regimens have not been adequately studied, patients with a history of an IgE-mediated reaction to penicillin should be skin tested for allergy to penicillin and, if positive, desensitized.

All patients treated for neurosyphilis should have nontreponemal serologic tests done every 3–6 months. Guidelines established by the Centers for Disease Control and Prevention (CDC) recommend spinal fluid examinations at 6-month intervals until the CSF cell count is normal; however, there are data to suggest that in certain patients normalization of serum titers are an acceptable surrogate for CSF response. In general, CSF white blood cell count and CSF VDRL normalize more quickly (usually in 12 months) than CSF protein concentration, which can remain abnormal for extended periods. If the serum nontreponemal titers do not normalize, the CSF analysis should be repeated. A second course of penicillin therapy may be given if the CSF cell count has not decreased at 6 months or is not normal at 2 years.

6. Syphilis in HIV-Infected Patients

Syphilis is common among HIV-infected individuals. Some data suggest that syphilis coinfection is associated with an increase in HIV viral load and a decrease in CD4 count that normalizes with therapy. Researchers from a prospective cohort study of HIV-infected individuals reported that they found no association with HIV disease progression in persons with syphilis coinfection. However, for optimal patient care as well as prevention of transmission to partners, guidelines for the primary care of HIV-infected patients recommend routine syphilis screening.

Interpretation of serologic tests should be the same for HIV-positive and HIV-negative persons. Although unusual serologic responses have been reported in HIV-positive patients, including high titers of nontreponemal tests, delayed appearance of positive titers, and false-negative tests, most HIV-positive patients respond serologically in largely the same way as noninfected patients. All HIV-positive patients in care should be screened at least twice a year to identify latent disease because by establishing a serologic history, unnecessary lumbar punctures and prolonged treatment for latent syphilis of uncertain duration can be avoided. If the diagnosis of syphilis is suggested on clinical grounds but reagin tests are negative, alternative tests should be performed. These tests include darkfield examination of lesions and direct fluorescent antibody staining for *T pallidum* of lesion exudate or biopsy specimens.

Treatment of HIV-positive patients with primary and secondary syphilis is the same as for HIV-negative patients, with careful clinical and serologic follow-up at 3, 6, 9, 12, and 24 months. HIV-infected patients with late latent syphilis, syphilis of uncertain duration, and neurosyphilis should be treated like HIV-negative individuals, with follow-up at 6, 12, 18, and 24 months. A study among HIV-clinic patients in Baltimore found that the use of antiretroviral therapy was associated with reduced serologic failure rates after syphilis treatment.

The diagnosis of neurosyphilis in HIV-infected patients is complicated by the fact that CSF abnormalities are frequently seen if lumbar puncture is performed. The significance of these abnormalities is unknown, and similar abnormalities are frequently seen in non-HIV-infected patients with primary or secondary syphilis. Thus, CSF testing is not recommended in those with early disease and a normal neurologic examination. In contrast, a lumbar puncture should be performed in all patients, regardless of HIV-infection status, if neurologic signs are present or if therapy has failed. Following treatment, CSF white blood cell counts normalize within 12 months regardless of HIV status, while the CSF VDRL is slower to normalize in HIV-infected individuals, especially those with CD4 counts < 200 cells/mL. As discussed above, the same criteria for failure apply to HIV-positive and HIV-negative patients, and re-treatment regimens are the same.

Because clinical experience in treating HIV-infected patients with syphilis is based on penicillin regimens, few options exist for treating the penicillin-allergic patient. Doxycycline or tetracycline regimens can be used for primary, secondary, and early latent syphilis as well as for late

latent syphilis and latent syphilis of unknown duration though with caution and close follow-up (Table 34–3). For neurosyphilis, penicillin regimens are optimal even if this requires skin testing and desensitization; limited data exist for ceftriaxone.

7. Syphilis in Pregnancy

All pregnant women should have a nontreponemal serologic test for syphilis at the time of the first prenatal visit (see Chapter 19). In women who may be at increased risk for syphilis or for populations in which there is a high prevalence of syphilis, additional nontreponemal tests should be performed during the third trimester at 28 weeks and again at delivery. The serologic status of all women who have delivered should be known before discharge from the hospital. Seropositive women should be considered infected and should be treated unless prior treatment with fall in antibody titer is medically documented.

The only acceptable treatment for syphilis in pregnancy is penicillin in dosage schedules appropriate for the stage of disease (see above). Penicillin prevents congenital syphilis in 90% of cases, even when treatment is given late in pregnancy. Tetracycline and doxycycline are contraindicated in pregnancy. Erythromycin should not be used because of failure to eradicate infection in the fetus, and insufficient data are available to justify a recommendation for ceftriaxone or azithromycin. Thus, women with a history of penicillin allergy should be skin tested and desensitized if necessary.

The infant should be evaluated immediately, as noted below, and at 6–8 weeks of age.

8. Congenital Syphilis

Congenital syphilis is a transplacentally transmitted infection that occurs in infants of untreated or inadequately treated mothers. The physical findings at birth are quite variable: The infant may have many or minimal signs or even no signs until 6–8 weeks of life (delayed form). The most common findings are on the mucous membranes and skin—maculopapular rash, condylomas, mucous membrane patches, and serous nasal discharge (snuffles). These lesions are infectious; *T pallidum* can easily be found microscopically, and the infant must be isolated. Other common findings are hepatosplenomegaly, anemia, or osteochondritis. These early active lesions subsequently heal, but if the disease is left untreated it produces the characteristic stigmas of congenital syphilis—interstitial keratitis, Hutchinson teeth, saddle nose, saber shins, deafness, and central nervous system involvement.

The presence of negative serologic tests at birth in both the mother and the infant usually means that the newborn is free of infection. However, recent infection near the time of delivery may result in negative tests because there has been insufficient time to develop a serologic response. Thus, it is necessary to maintain a high index of suspicion in infants born to high-risk mothers (eg, HIV-positive, illicit drug users). All infants born to mothers with positive nontreponemal and treponemal antibody titers should have blood drawn for an RPR or VDRL test and, if positive, be referred to a pediatrician for further evaluation and therapy.

▶ When to Refer

- Consultation with the local public health department may help obtain all prior positive syphilis serologic results and may be helpful in complicated or atypical cases.
- Early (infectious) syphilis cases may be contacted for partner notification and treatment by local public health authorities.

▶ When to Admit

- Pregnant women with syphilis and true penicillin allergy should be admitted for desensitization and treatment.
- Women in late pregnancy treated for early syphilis should have close outpatient monitoring or be admitted because the Jarisch-Herxheimer reaction can induce premature labor.
- Patients with neurosyphilis usually require admission for treatment with aqueous penicillin.

Ghanem KG. Neurosyphilis: a historical perspective and review. *CNS Neurosci Ther.* 2010 Oct;16(5):e157–68. [PMID: 20626434]

Seña AC et al. Novel *Treponema pallidum* serologic tests: a paradigm shift in syphilis screening for the 21st century. *Clin Infect Dis.* 2010 Sep 15;51(6):700–8. [PMID: 20687840]

Tucker JD et al. Accelerating worldwide syphilis screening through rapid testing: a systematic review. *Lancet Infect Dis.* 2010;10:381–6. [PMID: 20510278]

Workowski KA et al; Centers for Disease Control and Prevention (CDC). Sexually transmitted diseases treatment guidelines, 2010. *MMWR Recomm Rep.* 2010 Dec 17;59(RR-12):1–110. Erratum in: *MMWR Recomm Rep.* 2011 Jan 14;60(1):18. [PMID: 21160459]

NON-SEXUALLY TRANSMITTED TREPONEMATOSES

A variety of treponemal diseases other than syphilis occur endemically in many tropical areas of the world. They are distinguished from disease caused by *T pallidum* by their nonsexual transmission, their relatively high incidence in certain geographic areas and among children, and their tendency to produce less severe visceral manifestations. As in syphilis, organisms can be demonstrated in infectious lesions with darkfield microscopy or immunofluorescence but cannot be cultured in artificial media; the serologic tests for syphilis are positive; the diseases have primary, secondary, and sometimes tertiary stages; and penicillin is the drug of choice. There is evidence that infection with these agents may provide partial resistance to syphilis and vice versa. Treatment with penicillin in doses appropriate to primary syphilis (eg, 2.4 million units of benzathine penicillin G intramuscularly) is generally curative in any stage of the non-sexually transmitted treponematoses. In cases of penicillin hypersensitivity, tetracycline, 500 mg orally four times a day for 10–14 days, is usually the recommended alternative.

YAWS (Frambesia)

Yaws is a contagious disease largely limited to tropical regions that is caused by *T pallidum* subspecies *pertenue*. It is characterized by granulomatous lesions of the skin, mucous membranes, and bone. Yaws is rarely fatal, though if untreated it may lead to chronic disability and disfigurement. Yaws is acquired by direct nonsexual contact, usually in childhood, although it may occur at any age. The “mother yaw,” a painless papule that later ulcerates, appears 3–4 weeks after exposure. There is usually associated regional lymphadenopathy. Six to 12 weeks later, secondary lesions that are raised papillomas and papules that weep highly infectious material appear and last for several months or years. Painful ulcerated lesions on the soles are called “crab yaws” because of the resulting gait. Late gummatous lesions may occur, with associated tissue destruction involving large areas of skin and subcutaneous tissues. The late effects of yaws, with bone change, shortening of digits, and contractions, may be confused with similar changes occurring in leprosy. Central nervous system, cardiac, or other visceral involvement is rare. See above for therapy.

PINTA

Pinta is a non-sexually transmitted spirochetal infection caused by *T pallidum* subspecies *carateum*. It occurs endemically in rural areas of Latin America, especially in Mexico, Colombia, and Cuba, and in some areas of the Pacific. A nonulcerative, erythematous primary papule spreads slowly into a papulosquamous plaque showing a variety of color changes (slate, lilac, black). Secondary lesions resemble the primary one and appear within a year after it. These appear successively, new lesions together with older ones; are most common on the extremities; and later show atrophy and depigmentation. Some cases show pigmentary changes and atrophic patches on the soles and palms, with or without hyperkeratosis, that are indistinguishable from “crab yaws.” Very rarely, central nervous system or cardiovascular disease is observed late in the course of infection. See above for therapy.

ENDEMIC SYPHILIS

Endemic syphilis is an acute or chronic infection caused by *T pallidum* subspecies *endemicum*. It has been reported in a number of countries, particularly in the eastern Mediterranean area, often with local names: bejel in Syria, Saudi Arabia, and Iraq, and dichuchwa, njovera, and siti in Africa. It also occurs in Southeast Asia. The local forms have distinctive features. Moist ulcerated lesions of the skin or oral or nasopharyngeal mucosa are the most common manifestations. Generalized lymphadenopathy and secondary and tertiary bone and skin lesions are also common. Deep leg pain points to periostitis or osteomyelitis. In the late stages of disease, destructive gummatous lesions similar to those seen in yaws can develop, resulting in loss of cartilage and saber shin deformity. Cardiovascular and central nervous system involvement are rare. See above for therapy.

Kestelyn P. Venereal and endemic treponematoses in the developing world. *Int Ophthalmol Clin*. 2010 Spring;50(2):41–55. [PMID: 20375861]
Rinaldi A. Yaws: a second (and maybe last?) chance for eradication. *PLoS Negl Trop Dis*. 2008;2(8):e275. [PMID: 18846236]

SELECTED SPIROCHETAL DISEASES

RELAPSING FEVER

The infectious organisms in relapsing fever are spirochetes of the genus *Borrelia*. The infection has two forms: tick-borne and louse-borne. The main reservoir is rodents, which serve as the source of infection for ticks (eg, ornithodoros). Tick-borne relapsing fever may be transmitted transovarially from one generation of ticks to the next. Humans can be infected by tick bites or by rubbing crushed tick tissues or feces into the bite wound. Tick-borne relapsing fever is endemic but is not transmitted from person to person. The distribution and seasonal incidence of the disease are determined by the ecology of the ticks in different areas. Different species (or strain) names have been given to *Borrelia* in different parts of the world where the organisms are transmitted by different ticks. In the United States, infected ticks are found throughout the West, especially in mountainous areas, but clinical cases are uncommon in humans.

The louse-borne form is primarily seen in the developing world. Large epidemics may occur in louse-infested populations, and transmission is favored by crowding, malnutrition, and cold climate.

Clinical Findings

A. Symptoms and Signs

There is an abrupt onset of fever, chills, tachycardia, nausea and vomiting, arthralgia, and severe headache. Hepatomegaly and splenomegaly may develop, as well as various types of rashes (macular, popular, petechial) that usually occur at the end of a febrile episode. Delirium occurs with high fever, and there may be various neurologic and psychic abnormalities. The attack terminates, usually abruptly, after 3–10 days. After an interval of 1–2 weeks, relapse occurs, but often it is somewhat milder. Three to ten relapses may occur before recovery in tick-borne disease, whereas louse-borne disease is associated with only one or two relapses.

B. Laboratory Findings

During episodes of fever, large spirochetes are seen in blood smears stained with Wright or Giemsa stain. The organisms can be cultured in special media but rapidly lose pathogenicity. The spirochetes can multiply in injected rats or mice and can be seen in their blood.

A variety of anti-borrelia antibodies develop during the illness; sometimes the Weil–Felix test for rickettsioses and nontreponemal serologic tests for syphilis may also be falsely positive. Infection with *B recurrentis* can cause

false-positive indirect fluorescent antibody and Western blot tests for *Borrelia burgdorferi*, and some cases may be misdiagnosed as Lyme disease. PCR assays have been developed but are not widely available. CSF abnormalities occur in patients with meningeal involvement. Mild anemia and thrombocytopenia are common, but the white blood cell count tends to be normal.

► Differential Diagnosis

The manifestations of relapsing fever may be confused with malaria, leptospirosis, meningococemia, yellow fever, typhus, or rat-bite fever.

► Prevention

Prevention of tick bites (as described for rickettsial diseases) and delousing procedures applicable to large groups can prevent illness. Arthropod vectors should be controlled if possible.

Postexposure prophylaxis with doxycycline 200 mg orally on day 1 and 100 mg daily for 4 days has been shown to prevent recurrent fever following tick bites in highly endemic areas.

► Treatment

A single dose of tetracycline or erythromycin, 0.5 g orally, or a single dose of procaine penicillin G, 600,000–800,000 units intramuscularly (adults) or 400,000 units intramuscularly (children), probably constitutes adequate treatment for louse-borne relapsing fevers; however, some experts advocate for longer courses of treatment to prevent persistent infection. Because of higher relapse rates, tick-borne disease is routinely treated with 0.5 g of tetracycline or erythromycin given orally four times daily for 10 days. If central nervous system invasion is suspected, penicillin G, 3 million units intravenously every 4 hours, or ceftriaxone, 1 g intravenously daily, should be given for 10–14 days. Jarisch–Herxheimer reactions occur commonly following treatment and may be life-threatening, so patients should be closely monitored (see Syphilis, above). One study in patients with louse-borne relapsing fever showed that administration of anti-TNF antibodies prior to antibiotic therapy can be effective in preventing the reaction.

► Prognosis

The overall mortality rate is usually about 5%. Fatalities are most common in old, debilitated, or very young patients. With treatment, the initial attack is shortened and relapses are largely prevented.

Balicer RD et al. Post exposure prophylaxis of tick-borne relapsing fever. *Eur J Clin Microbiol Infect Dis*. 2010 Mar;29(3):253–8. [PMID: 20012878]

Larsson C et al. Current issues in relapsing fever. *Curr Opin Infect Dis*. 2009 Oct;22(5):443–9. [PMID: 19623064]

RAT-BITE FEVER

Rat-bite fever is an uncommon acute infectious disease caused by the treponeme *Spirillum minus* (Asia), covered in this section, or the bacteria *Streptobacillus moniliformis* (North America). It is transmitted to humans by the bite of a rat. Inhabitants of rat-infested dwellings and laboratory workers are at greatest risk.

► Clinical Findings

A. Symptoms and Signs

In *Spirillum* infections, the original rat bite, unless secondarily infected, heals promptly, but 1 to several weeks later the site becomes swollen, indurated, and painful; assumes a dusky purplish hue; and may ulcerate. Regional lymphangitis and lymphadenitis, fever, chills, malaise, myalgia, arthralgia, and headache are present. Splenomegaly may occur. A sparse, dusky-red maculopapular rash appears on the trunk and extremities in many cases, and there may be frank arthritis.

After a few days, both the local and systemic symptoms subside, only to reappear several days later. This relapsing pattern of fever for 3–4 days alternating with afebrile periods lasting 3–9 days may persist for weeks. The other features, however, usually recur only during the first few relapses. Endocarditis is a rare complication of infection.

B. Laboratory Findings

Leukocytosis is often present, and the nontreponemal test for syphilis is often falsely positive. The organism may be identified in darkfield examination of the ulcer exudate or aspirated lymph node material; more commonly, it is observed after inoculation of a laboratory animal with the patient's exudate or blood. It has not been cultured in artificial media.

► Differential Diagnosis

Rat-bite fever must be distinguished from the rat-bite-induced lymphadenitis and rash of streptobacillary fever. Clinically, the severe arthritis and myalgias seen in streptobacillary disease are rarely seen in disease caused by *S minus*. Reliable differentiation requires an increasing titer of agglutinins against *S moniliformis* or isolation of the causative organism. Other diseases in the differential include tularemia, rickettsial disease, *Pasteurella multocida* infections, and relapsing fever.

► Treatment

Penicillin is given for 10–14 days. During the acute phase of illness, the intravenous route is used (1–2 million units every 4–6 hours) and once improvement has occurred, therapy is completed with oral medication, penicillin V 500 mg four times daily to complete 10–14 days of therapy. For the penicillin-allergic patient, tetracycline 500 mg orally four times daily or doxycycline 100 mg twice a day can be used.

► Prognosis

The reported mortality rate of about 10% should be markedly reduced by prompt diagnosis and antimicrobial treatment.

Dworkin J et al. A case of septic arthritis from rat-bite fever in Hawai'i. *Hawaii Med J.* 2010 Mar;69(3):65–7. [PMID: 20397505]

LEPTOSPIROSIS

ESSENTIALS OF DIAGNOSIS

- ▶ Clinical illness can vary from asymptomatic to fatal liver and kidney disease.
- ▶ Anicteric leptospirosis is the more common and milder form of the disease.
- ▶ Icteric leptospirosis (Weil syndrome) is characterized by impaired kidney and liver function, abnormal mental status, and hemorrhagic pneumonia and has a 5–40% mortality rate.

► General Considerations

Leptospirosis is an acute and often severe treponemal infection that frequently affects the liver or other organs and is caused by the multiple serovars of *Leptospira interrogans*. The disease is worldwide in distribution, and it is among the most common zoonotic diseases. The leptospire are often transmitted to humans by the ingestion of food and drink contaminated by the urine of the reservoir animal. The organism may also enter through minor skin lesions and probably via the conjunctiva. Reports of recreational cases in international travelers have been increasing, following swimming or rafting in contaminated water, and occupational cases occur among sewer workers, rice planters, abattoir workers, and farmers. Sporadic urban cases have been seen in the homeless exposed to rat urine. The incubation period is 2–20 days.

► Clinical Findings

A. Symptoms and Signs

Anicteric leptospirosis, the more common and milder form of the disease, is often biphasic. The initial or “septicemic” phase begins with abrupt fever to 39–40°C, chills, abdominal pain, severe headache, and myalgias, especially of the calf muscles. There may be marked conjunctival suffusion. Leptospire can be isolated from blood, CSF, and tissues. Following a 1- to 3-day period of improvement in symptoms and absence of fever, the second or “immune” phase begins. Leptospire are absent from blood and CSF but are still present in the kidney, and specific antibodies appear. A recurrence of symptoms is seen as in the first phase of disease with the onset of meningitis. Uveitis (which can be unilateral or bilateral and usually involves the entire uveal tract), rash, and adenopathy may occur.

A rare but severe manifestation is hemorrhagic pneumonia. The illness is usually self-limited, lasting 4–30 days, and complete recovery is the rule.

Icteric leptospirosis (Weil syndrome) is the most severe form of the disease, characterized by impaired kidney and liver function, abnormal mental status, hemorrhagic pneumonia, hypotension, and a 5–40% mortality rate. Symptoms and signs often are continuous and not biphasic.

Leptospirosis with jaundice must be distinguished from hepatitis, yellow fever, and relapsing fever.

B. Laboratory Findings

The leukocyte count may be normal or as high as 50,000/mcL (0.05/L), with neutrophils predominating. The urine may contain bile, protein, casts, and red cells. Oliguria is common, and in severe cases uremia may occur. Elevated bilirubin and aminotransferases are seen in 75%, and elevated creatinine (> 1.5 mg/dL) (> 132.6 mcmol/L) is seen in 50% of cases. In cases with meningeal involvement, organisms may be found in the CSF during the first 10 days of illness. Early in the disease, the organism may be identified by darkfield examination of the patient's blood (a test requiring expertise since false-positives are frequent in inexperienced hands) or by culture on a semisolid medium (eg, Fletcher EMJH). Cultures take 1–6 weeks to become positive. The organism may also be grown from the urine from the tenth day to the sixth week. Diagnosis is usually made by means of serologic tests. Agglutination tests (microscopic, using live organisms, and macroscopic, using killed antigen) become positive after 7–10 days of illness, peak at 3–4 weeks, and may persist at high levels for many years. Thus, to make a diagnosis, a fourfold or greater rise in titer must be documented. The agglutination tests are cumbersome to perform and require trained personnel. Indirect hemagglutination and enzyme-linked immunosorbent assay (ELISA) tests are also available. The IgM EIA is particularly useful in making an early diagnosis, since it is positive as early as 2 days into illness, a time when the clinical manifestations may be nonspecific, and it is extremely sensitive and specific (93%). PCR methods (presently investigational) appear to be sensitive, specific, positive early in disease, and able to detect leptospiral DNA in blood, urine, CSF, and aqueous humor. Serum creatine kinase (CK) is usually elevated in persons with leptospirosis and normal in persons with hepatitis.

► Complications

Myocarditis, aseptic meningitis, acute kidney injury, and pulmonary infiltrates with hemorrhage are not common but are the usual causes of death. Iridocyclitis may occur.

► Prevention

The mainstay of prevention is avoidance of potentially contaminated food and water.

Prophylaxis with doxycycline has been effective in trials but is not routinely recommended. Human vaccine is used in some limited settings but is not available in the United States.

► Treatment

Various antimicrobial drugs, including penicillin, ceftriaxone, and tetracyclines, show antileptospiral activity. Penicillin (eg, 1.5 million units every 6 hours intravenously) or ceftriaxone (1 g daily intravenously) is the drug of choice in severe leptospirosis and is especially effective if started within the first 4 days of illness. Jarisch–Herxheimer reactions may occur (see Syphilis, above). Doxycycline, 100 mg orally twice daily for 7 days, is also effective as therapy if started early, but this agent is most often used in mild to moderate disease. Although therapy for mild disease is controversial, most clinicians treat with oral penicillin, 500 mg four times daily, or doxycycline, 100 mg orally twice daily, for 7 days. Azithromycin is also active, but clinical experience is limited.

► Prognosis

Without jaundice, the disease is almost never fatal. With jaundice, the mortality rate is 5% for those under age 30 years and 40% for those over age 60 years.

► When to Admit

Patients with jaundice or other evidence of severe disease should be admitted for close monitoring and may require admission to an intensive care unit.

Lau C et al. Leptospirosis: an emerging disease in travellers. *Travel Med Infect Dis*. 2010 Jan;8(1):33–9. [PMID: 20188303]
Slack A. Leptospirosis. *Aust Fam Physician*. 2010 Jun–Jul;39(6):495–8. [PMID: 20628664]

LYME DISEASE (Lyme Borreliosis)



ESSENTIALS OF DIAGNOSIS

- Erythema migrans, a flat or slightly raised red lesion that expands with central clearing.
- Headache or stiff neck.
- Arthralgias, arthritis, and myalgias; arthritis is often chronic and recurrent.
- Wide geographic distribution, with most United States cases in the Northeast, mid-Atlantic, upper Midwest, and Pacific coastal regions.

► General Considerations

This illness, named after the town of Old Lyme, Connecticut, is the most common tick-borne disease in the United States and Europe and is caused by genospecies of the spirochete *B burgdorferi*. In the United States, the causative genospecies is *B burgdorferi sensu strictu*, whereas in Europe and Asia *B garinii* and *B afzelii* predominate. Most US cases are reported from the mid-Atlantic, northeastern, and north

central regions of the country. The true incidence of Lyme disease is not known for a number of reasons: (1) serologic tests are not standardized (see below); (2) clinical manifestations are nonspecific; and (3) even with reliable testing, serology is insensitive in early disease.

The vector of Lyme disease varies geographically and is *Ixodes scapularis* in the northeastern, north central, and mid-Atlantic regions of the United States; *I pacificus* on the West Coast; *Ixodes r* in Europe; and *I persulcatus* in Asia. The disease also occurs in Australia. Mice and deer make up the major animal reservoir of *B burgdorferi*, but other rodents and birds may also be infected. Domestic animals such as dogs, cattle, and horses can also develop clinical illness, usually manifested as arthritis.

Under experimental conditions, ticks must feed for 24–36 hours or longer to transmit infections. Most cases are reported in the spring and summer months. Human epidemiologic studies have indicated that the incidence of disease is significantly higher when tick attachment is for longer than 72 hours than if it is < 72 hours, though rare cases have been documented with attachment of < 24 hours. In addition, the percentage of ticks infected varies on a regional basis. In the northeastern and midwestern regions, 15–65% of *I scapularis* ticks are infected with the spirochete; in the western United States, only 2% of *I pacificus* are infected. These are important epidemiologic features in assessing the likelihood that tick exposure will result in disease. Exposure to *I pacificus* is unlikely to result in disease, since so few ticks are infected, but this is not true of exposure to *I scapularis*. Eliciting a history of brushing a tick off the skin (ie, the tick was not feeding) or removing a tick on the same day as exposure (ie, the tick did not feed long enough) decreases the likelihood that infection will develop.

Ixodes ticks are smaller than the more common dog ticks (*Dermacentor variabilis*). Larvae are < 1 mm in size, and the adult female is 2–3 mm in size, with a red body and black legs. After a blood meal, ticks can reach two to three times their unengorged size. Because the tick is so small, the bite is usually painless and goes unnoticed. After feeding, the tick drops off in 2–4 days. If a tick is found, it should be removed immediately. The best way to accomplish this is to use a fine-tipped tweezers to pull firmly and repeatedly on the tick's mouth part—not the tick's body—until the tick releases its hold. Saving the tick in a bottle of alcohol for future identification may be useful, especially if symptoms develop.

► Clinical Findings

Prior clinical description of Lyme disease divided the illness into three stages: stage 1, flu-like symptoms and a typical skin rash (**erythema migrans**, see Figure 6–28); stage 2, weeks to months later, facial (cranial nerve VII) palsy or meningitis; and stage 3, months to years later, arthritis. The problem with this simplified scheme is that there is a great deal of overlap, and the skin, central nervous system, and musculoskeletal system can be involved early or late. A more accurate classification divides disease into early and late manifestations and specifies whether disease is localized or disseminated.

A. Symptoms and Signs

1. Stage 1, early localized infection—Stage 1 infection is characterized by erythema migrans. About 1 week after the tick bite (range, 3–30 days; median 7–10 days), a flat or slightly raised red lesion appears at the site, which is commonly seen in areas of tight clothing such as the groin, thigh, or axilla. This lesion expands over several days. Although originally described as a lesion that progresses with central clearing (“bull’s-eye” lesion), often there is a more homogeneous appearance or even central intensification. About 10–20% of patients either do not have typical skin lesions or the lesions go unnoticed. Most patients with erythema migrans will have a concomitant viral-like illness (the “summer flu”) characterized by myalgias, arthralgias, headache, and fatigue. Fever may or may not be present. Even without treatment, the symptoms and signs of erythema migrans resolve in 3–4 weeks. Although the classic lesion of erythema migrans is not difficult to recognize, atypical forms can occur that may lead to misdiagnosis. Vesicular, urticarial, and evanescent erythema migrans have all been reported. Similarly, chemical reactions to tick and spider bites (these usually recede in 24–48 hours whereas erythema migrans increases in size in this time period), drug eruptions, urticaria, and staphylococcal and streptococcal cellulitis have been mistaken for erythema migrans.

Completely asymptomatic disease, without erythema migrans or flu-like symptoms, can occur but is very uncommon in the United States. Serosurveys done as part of vaccination trials found asymptomatic seroconversion in 7% or less of the population.

2. Stage 2, early disseminated infection—Up to 50–60% of patients with erythema migrans are bacteremic. Within days to weeks of the original infection, secondary skin lesions that are not associated with a tick bite develop in about 50% of patients. These lesions are similar in appearance to the primary lesion but are usually smaller. Malaise, fatigue, fever, headache (sometimes severe), neck pain, and generalized aches are common with the skin lesions. Most symptoms are transient, although fatigue may persist for months. After hematogenous spread, the organism may sequester itself in certain areas and produce focal symptoms. Some patients experience cardiac (4–10% of patients) or neurologic (10–15% of patients) manifestations. Cardiac involvement includes myopericarditis, with atrial or ventricular arrhythmias and heart block. Neurologic manifestations include both the central and peripheral nervous systems. The most common central nervous system manifestation is an aseptic meningitis with mild headache and neck stiffness. The most common peripheral manifestation is a cranial neuropathy, ie, facial palsy (usually unilateral but can be bilateral, see Figure 24–2). A sensory or motor radiculopathy and mononeuritis multiplex occur less frequently. Conjunctivitis, keratitis and, rarely, panophthalmitis can also occur.

3. Stage 3, late persistent infection—Stage 3 infection occurs months to years after the initial infection and again primarily manifests itself as musculoskeletal, neurologic, and skin disease. In early reports, musculoskeletal complaints

developed in up to 60% of patients. With early recognition and treatment of disease, joint complaints develop in < 10% of patients. The classic manifestation of late disease is a monoarticular or oligoarticular arthritis most commonly affecting the knee or other large weight bearing joints. While these joints may be quite swollen, these patients generally report less pain compared to patients with bacterial septic arthritis. Even if untreated, the arthritis is self-limited, resolving in a few weeks to months. Multiple recurrences are common but are usually less severe than the original disease. Joint fluid reflects an inflammatory arthritis with a mean white blood cell count of 25,000/mcL (0.025/L) with a predominance of neutrophils. Chronic arthritis develops in about 10% of patients. The pathogenesis of chronic Lyme arthritis may be an immunologic phenomenon rather than persistence of infection.

Rarely, the nervous system (both central and peripheral) can be involved in late Lyme disease. In the United States, a subacute encephalopathy, characterized by memory loss, mood changes, and sleep disturbance, is seen. In Europe, a more severe encephalomyelitis caused by *B garinii* is seen and presents with cognitive dysfunction, spastic paraparesis, ataxia, and bladder dysfunction. Peripheral nervous system involvement includes intermittent paresthesias, often in a stocking glove distribution, or radicular pain.

The cutaneous manifestation of late infection, which can occur up to 10 years after infection, is **acrodermatitis chronicum atrophicans**. It has been described mainly in Europe after infection with *B afzelii*, a genospecies that commonly causes disease in Europe but not the United States. There is usually bluish-red discoloration of a distal extremity with associated swelling. These lesions become atrophic and sclerotic with time and eventually resemble localized scleroderma. Cases of diffuse fasciitis with eosinophilia, an entity that resembles scleroderma, have been rarely associated with infection with *B burgdorferi*.

B. Laboratory Findings

The diagnosis of Lyme disease is based on both clinical manifestations and laboratory findings. The National Surveillance Case Definition specifies a person with exposure to a potential tick habitat (within the 30 days just prior to developing erythema migrans) with (1) erythema migrans diagnosed by a physician or (2) at least one late manifestation of the disease and (3) laboratory confirmation as fulfilling the criteria for Lyme disease.

Nonspecific laboratory abnormalities can be seen, particularly in early disease. The most common are an elevated sedimentation rate of > 20 mm/h seen in 50% of cases, and mildly abnormal liver function tests are present in 30%. The abnormal liver function tests are transient and return to normal within a few weeks of treatment. A mild anemia, leukocytosis (11,000–18,000/mcL) (0.011–0.018/L), and microscopic hematuria have been reported in ≤ 10% of patients.

Laboratory confirmation requires **serologic tests** to detect specific antibodies to *B burgdorferi* in serum, preferably by ELISA and not by indirect immunofluorescence assay (IFA), which is less sensitive and specific and can

lead to diagnostic confusion. A two-test approach is recommended for the diagnosis of active Lyme disease, with all specimens positive or equivocal by ELISA then confirmed with an Western immunoblot assay that can detect both IgM and IgG antibodies. IgM antibody appears first 2–4 weeks after onset of erythema migrans, peaks at 6–8 weeks, and then declines to low levels after 4–6 months of illness. The presence of IgM antibody in patients with prolonged symptoms persisting for several months is likely to be a false-positive result. IgG occurs later (6–8 weeks after onset of disease), peaks at 4–6 months, and may remain elevated at low levels indefinitely despite appropriate therapy and resolution of symptoms. When an Western immunoblot is done during the first 4 weeks of illness, both IgM and IgG should be tested. A positive immunoblot requires that antibodies are detected against two (for IgM) or five (for IgG) specific protein antigens from *B burgdorferi*.

If a patient with suspected early Lyme disease has negative serologic studies, acute and convalescent titers should be obtained since up to 50% of patients with early disease can be antibody negative in the first several weeks of illness. A fourfold rise in antibody titer would be diagnostic of recent infection. In patients with later stages of disease, almost all are antibody positive. False-positive reactions in the ELISA and IFA have been reported in juvenile rheumatoid arthritis, rheumatoid arthritis, systemic lupus erythematosus, infectious mononucleosis, subacute infective endocarditis, syphilis, relapsing fever, leptospirosis, enteroviral and other viral illnesses, and patients with gingival disease (presumably because of cross-reactivity with oral treponemes). False-negative serologic reactions occur early in illness, and antibiotic therapy early in disease can abort subsequent seroconversion.

The diagnosis of late **neuroborreliosis** is often difficult since clinical manifestations, such as subtle memory impairment, may be difficult to document. Most patients with neuroborreliosis have a history of previous erythema migrans or monarticular or polyarticular arthritis, and the vast majority have antibody present in serum. When CSF is sampled from patients with encephalopathy, there may be evidence of inflammation (pleocytosis or elevated protein, or both), and localized antibody production, ie, a ratio of CSF to serum antibody of > 1.0. The role of other tests such as PCR in detection of DNA or ELISA in detecting the presence of outer surface protein A (OspA) antigen is unclear, but in difficult cases these tests can be performed and, if positive, help establish the diagnosis. Patients with late disease and peripheral neuropathy almost always have positive serum antibody tests, usually have abnormal electrophysiology tests, and may have abnormal nerve biopsies showing perivascular collections of lymphocytes. Because disease involves peripheral nerves, the CSF is usually normal and does not demonstrate local antibody production.

Caution should be exercised in interpreting serologic tests because they are not subject to national standards, and inter-laboratory variation is a major problem. In addition, some laboratories perform tests that are entirely

unreliable and should never be used to support the diagnosis of Lyme disease (eg, the Lyme urinary antigen test, immunofluorescent staining for cell wall-deficient forms of *B burgdorferi*, lymphocyte transformation tests, using PCR on inappropriate specimens such as blood or urine). Finally, testing is often done in patients with nonspecific symptoms such as headache, arthralgia, myalgia, fatigue, and palpitations. Even in endemic areas, the pretest probability of having Lyme disease is low in these patients, and the probability of a false-positive test result is greater than that of a true-positive result. For these reasons, the American College of Physicians has established guidelines for laboratory evaluation of patients with suspected Lyme disease:

1. The diagnosis of early Lyme disease is clinical (ie, exposure in an endemic area, with physician-documented erythema migrans), and does *not* require laboratory confirmation. (Tests are often negative at this stage.)
2. Late disease requires objective evidence of clinical manifestations (recurrent brief attacks of monarticular or oligoarticular arthritis of the large joints; lymphocytic meningitis, cranial neuritis [facial palsy], peripheral neuropathy or, rarely, encephalomyelitis—but *not* headache, fatigue, paresthesias, or stiff neck alone; atrioventricular conduction defects with or without myocarditis) and laboratory evidence of disease (two-stage testing with ELISA and Western blot, as described above).
3. Patients with nonspecific symptoms without objective signs of Lyme disease should *not* have serologic testing done. It is in this setting that false-positive tests occur more commonly than true-positive tests.
4. The role of serologic testing in neuroborreliosis is unclear, as sensitivity and specificity of CSF serologic tests have not been determined. However, it is rare for a patient with neuroborreliosis to have positive serologic tests on CSF without positive tests on serum (see below).
5. Other tests such as the T cell proliferative assay and urinary antigen detection have not yet been studied well enough to be routinely used.

Cultures for *B burgdorferi* can be performed but are not routine and are usually reserved for clinical studies. Aspiration of erythema migrans lesions has yielded positive cultures in up to 30% of cases, whereas culture of a 2-mm punch biopsy is positive in 50–70%. PCR of a skin biopsy is even more sensitive, with positivity rates of 80%. In early disease, blood cultures are positive in up to 50% if large volumes (9 mL) are used, but CSF is rarely culture positive. The ability to culture organisms from skin lesions is greatly influenced by antibiotic therapy. Even a brief course of several days will result in negative cultures. Special silver staining of chronically inflamed synovial tissue demonstrates spirochetes in one-third of patients.

PCR is very specific for detecting the presence of *Borrelia* DNA, but sensitivity is variable and depends on which body fluid is tested, the stage of the disease, and collection and testing technique. In general, PCR is more

sensitive than culture, especially in chronic disease. Up to 85% of synovial fluid samples are positive in active arthritis. In contrast, 38% of CSF samples in acute neuroborreliosis are PCR positive, and only 25% are positive in chronic neuroborreliosis. The significance of a positive reaction is unclear. Whether a positive PCR indicates persistence of viable organisms that will respond to further treatment or is a marker for residual DNA (not active infection) has not been clarified. A negative PCR result does not rule out disease.

► Complications

Several observational studies, including serosurveys of over 2000 pregnant women in endemic areas, and case control studies of nearly 800 infants with congenital heart disease have not found any association between seropositivity or tick exposure in prospective mothers and the prevalence of congenital malformations, fetal death, and prematurity. Thus, if *B burgdorferi* causes a congenital syndrome like some other spirochetal illnesses, it must be extremely uncommon.

► Prevention

There is no human vaccine currently available. Simple preventive measures such as avoiding tick-infested areas, covering exposed skin with long-sleeved shirts and wearing long trousers tucked into socks, wearing light-colored clothing, using repellents, and inspecting for ticks after exposure will greatly reduce the number of tick bites. Environmental controls directed at limiting ticks on residential property would be helpful, but trying to limit the deer, tick, or white-footed mouse populations over large areas is not feasible.

Prophylactic antibiotics following tick bites is recommended in certain high risk situations if all of the following criteria are met: (1) a tick identified as an adult or nymphal *I scapularis* has been attached for at least 36 hours; (2) prophylaxis can be started within 72 hours of the time the tick was removed; (3) more than 20% of ticks in the area are known to be infected with *B burgdorferi*; and (4) there is no contraindication to the use of doxycycline (not pregnant, age > 8 years, not allergic). As noted above, *I scapularis* ticks in the northeastern, mid-Atlantic, and upper midwestern states are infected with *B burgdorferi* at a high rate (> 20%) whereas *I pacificus* ticks on the West Coast are not (about 2%). The drug of choice for prophylaxis is a single 200 mg dose of doxycycline. If doxycycline is contraindicated, no prophylaxis should be given, since short course prophylactic therapy with other agents has not been studied and if early disease does develop appropriate therapy is very effective in preventing long-term sequelae. Individuals who have removed ticks (including those who have had prophylaxis) should be monitored carefully for 30 days for possible coinfections.

► Coinfections

Lyme disease, babesiosis (see Chapter 35), and human granulocytic anaplasmosis (formerly human granulocytic

ehrlichiosis) (see Chapter 32) are endemic in similar areas of the country and are transmitted by the same tick, *I scapularis*. Coinfection with two or even all three of these organisms can occur, causing a clinical picture that is not “classic” for any of these diseases. The presence of erythema migrans is highly suggestive of Lyme disease, whereas flu-like symptoms without rash are more suggestive of babesiosis or anaplasmosis. The complete blood count is usually normal in Lyme disease, but in patients with Lyme disease and babesiosis, anemia and thrombocytopenia are more common. Patients with Lyme disease and anaplasmosis are more likely to have leukopenia. Coinfection should be considered and excluded in patients who have persistent high fevers 48 hours after starting appropriate therapy for Lyme disease; in patients with persistent symptoms despite resolution of rash; and in those with anemia, leukopenia, or thrombocytopenia.

Even in patients with documented Lyme disease, immunity is not complete. Reinfection, although uncommon, is predominantly seen in patients successfully treated for early disease (erythema migrans) who do not develop antibody titers. Clinical manifestations and serologic response is similar to an initial infection.

► Treatment

Present recommendations for therapy are outlined in Table 34–4. For erythema migrans, antibiotic therapy shortens the duration of rash and prevents late sequelae. Doxycycline is most commonly used and has the advantage of being active against *Anaplasma phagocytophilum* (formerly *Ehrlichia*). Amoxicillin is also effective and is recommended for pregnant or lactating women and for those who cannot tolerate doxycycline. Cefuroxime axetil, is as effective as doxycycline, but because of its cost it should be considered an alternative choice for those who cannot tolerate doxycycline or amoxicillin or for those in whom the drugs are contraindicated. Erythromycin and azithromycin are less effective, associated with higher rates of relapse, and are not recommended as first-line therapy.

Isolated facial palsy (without meningitis or peripheral neuropathy) can be treated with doxycycline, amoxicillin, or cefuroxime axetil for 2–3 weeks. Although therapy does not affect the rate of resolution of the cranial neuropathy, it does prevent development of late manifestations of disease.

The need for a lumbar puncture in patients with seventh nerve palsy is controversial. Some clinicians perform lumbar puncture on all patients with facial palsy and others only if there are symptoms or signs of meningitis. If meningitis is present, therapy with a parenteral antibiotic is indicated. Ceftriaxone is most commonly used, but penicillin is equally efficacious. In European countries, doxycycline 400 mg/d orally for 14 days is frequently used and is comparable in efficacy to ceftriaxone.

Patients with atrioventricular block or myopericarditis (or both) can be treated with either oral or parenteral agents for 2–3 weeks. Hospitalization and observation is indicated for symptomatic patients, those with second- or third-degree block, and those with first-degree block with

Table 34-4. Treatment of Lyme disease.

Manifestations	Drug and Dosage
Tick bite	No treatment in most circumstances (see text); observe
Erythema migrans	Doxycycline, 100 mg orally twice daily, or amoxicillin, 500 mg orally three times daily, or cefuroxime axetil, 500 mg orally twice daily—all for 2-3 weeks
Neurologic disease	
Facial palsy (without meningitis)	Doxycycline, amoxicillin, or cefuroxime axetil as above for 2-3 weeks
Other central nervous system disease	Ceftriaxone, 2 g intravenously once daily, or penicillin G, 18-24 million units daily intravenously in six divided doses, or cefotaxime, 2 g intravenously every 8 hours—all for 2-4 weeks
Cardiac disease	
Atrioventricular block and myopericarditis ¹	An oral or parenteral (if more severe disease) regimen as described above can be used
Arthritis	
Oral dosage	Doxycycline, amoxicillin, or cefuroxime axetil as above for 28 days (see text)
Parenteral dosage	Ceftriaxone, cefotaxime, or penicillin G as above for 2-4 weeks
Acrodermatitis chroni-cum atrophicans	Doxycycline, amoxicillin, or cefuroxime axetil as above for 3 weeks
“Chronic Lyme disease” or “post-Lyme disease syndrome”	Symptomatic therapy; prolonged antibiotics are not recommended

¹Symptomatic patients, those with second- or third-degree block and those with first-degree block with a PR interval ≥ 300 milliseconds should be hospitalized for observation.

a PR interval ≥ 300 milliseconds. Once stabilized, hospitalized patients can be transitioned to one of the oral regimens to complete therapy.

Therapy of arthritis is difficult because some patients do not respond to any therapy, and those who do respond may do so slowly. Oral agents (doxycycline, amoxicillin, or cefuroxime axetil) are as effective as intravenous regimens (ceftriaxone, cefotaxime, or penicillin). A reasonable approach to the patient with Lyme arthritis is to start with oral therapy for 28 days, and if this fails (persistent or recurrent joint swelling), to re-treat with an oral regimen for 28 days or switch to an intravenous regimen for 2-4 weeks. If some improvement has occurred with initial treatment with an oral regimen, another course of oral therapy is reasonable. If there has been no response or worsening with initial oral therapy, a parenteral regimen

should be used. Re-treatment should be delayed for several months because of the slow resolution of joint symptoms. If arthritis persists after re-treatment, symptomatic therapy with nonsteroidal anti-inflammatory drugs is recommended. For severe refractory pain, synovectomy may be required.

Based on the limited published data, therapy of Lyme disease in pregnancy should be the same as therapy in other patients with the exception that doxycycline should not be used.

Clinicians are often confronted with patients with non-specific symptoms (such as fatigue and myalgias) and positive serologic tests for Lyme disease who request (or demand) therapy for their illness. It is important in managing these patients to remember (1) that the diagnosis of Lyme disease is primarily a clinical one, and nonspecific symptoms alone are not diagnostic; (2) that serologic tests are fraught with difficulty (as noted above), and in areas where disease prevalence is low, false-positive serologic tests are much more common than true-positive tests; and (3) that parenteral therapy with ceftriaxone for 2-4 weeks is costly and has been associated with significant adverse effects, including cholelithiasis and *Clostridium difficile* colitis. Parenteral therapy should be reserved for those most likely to benefit, ie, those with cutaneous, neurologic, cardiac, or rheumatic manifestations that are characteristic of Lyme disease.

► Prognosis

Most patients respond to appropriate therapy with prompt resolution of symptoms within 4 weeks. True treatment failures are thus uncommon, and in most cases re-treatment or prolonged treatment of Lyme disease is instituted because of misdiagnosis or misinterpretation of serologic results (both IgG and IgM antibodies can persist for prolonged periods despite adequate therapy) rather than inadequate therapy or response. Prolonged courses of antibiotic therapy for nonspecific symptoms that persist after completion of appropriate assessment (and treatment, if necessary) for Lyme disease is not recommended.

The long-term outcome of adult patients with Lyme disease is generally favorable, but some patients have chronic complaints. Joint pain, memory impairment, and poor functional status secondary to pain are common subjective complaints in patients with Lyme disease, but physical examination and neurocognitive testing fail to document the presence of these symptoms as objective sequelae. Similarly, in highly endemic areas, patients with a diagnosis of Lyme disease commonly complain of pain, fatigue, and an inability to perform certain physical activities when followed for several years. However, these complaints occur just as commonly in age-matched controls without a history of Lyme disease. Attempts to document chronic cardiac disease in patients treated for Lyme disease also have been unsuccessful. The long-term outcome of treated neuroborreliosis is favorable, with complete recovery in 75% of patients. Of the remaining

individuals, only 12% had sequelae that affected their daily activities.

▶ When to Refer

Consultation with an infectious diseases specialist with experience in diagnosing and treating Lyme disease can be helpful in atypical or prolonged cases.

▶ When to Admit

Admission for parenteral antibiotics is indicated for any patient with symptomatic central nervous system or cardiac disease as well as those with second- or third-degree

atrioventricular block, or first-degree block with a PR interval \geq 300 milliseconds.

- Elamin M et al. The clinical spectrum of Lyme neuroborreliosis. *Ir Med J*. 2010 Feb;103(2):46–9. [PMID: 20666055]
- Murray TS et al. Lyme disease. *Clin Lab Med*. 2010 Mar;30(1):311–28. [PMID: 20513553]
- O'Connell S. Lyme borreliosis: current issues in diagnosis and management. *Curr Opin Infect Dis*. 2010 Jun;23(3):231–5. [PMID: 20407371]
- Stanek G et al. Lyme borreliosis; a European perspective on diagnosis and clinical management. *Curr Opin Infect Dis*. 2009 Oct;22(5):450–4. [PMID: 19571749]

35

Protozoal & Helminthic Infections

Philip J. Rosenthal, MD

PROTOZOAL INFECTIONS

AFRICAN TRYPANOSOMIASIS (Sleeping Sickness)

ESSENTIALS OF DIAGNOSIS

- ▶ Exposure to tsetse flies; chancre at bite site uncommon.
- ▶ **Hemolympathic disease:** Irregular fever, headache, joint pain, rash, edema, lymphadenopathy.
- ▶ **Meningoencephalitic disease:** Somnolence, severe headache, progressing to coma.
- ▶ Trypanosomes in blood or lymph node aspirates; positive serologic tests.
- ▶ Trypanosomes and increased white cells and protein in cerebrospinal fluid.

▶ General Considerations

African trypanosomiasis is caused by the hemoflagellates *Trypanosoma brucei rhodesiense* and *Trypanosoma brucei gambiense*. The organisms are transmitted by bites of tsetse flies (genus *Glossina*), which inhabit shaded areas along streams and rivers. Trypanosomes ingested in a blood meal develop over 18–35 days in the fly; when the fly feeds again on a mammalian host, the infective stage is injected. Human disease occurs in rural areas of sub-Saharan Africa from south of the Sahara to about 15 degrees south latitude. *T b gambiense* causes West African trypanosomiasis, and is transmitted in the moist sub-Saharan savannas and forests of west and central Africa. *T b rhodesiense* causes East African trypanosomiasis, and is transmitted in the savannas of east and southeast Africa.

T b rhodesiense infection is primarily a zoonosis of game animals and cattle; humans are infected sporadically. Humans are the principal mammalian host for *T b gambiense*, but domestic animals can be infected. African trypanosomiasis is an increasing threat, especially where

control has been disrupted by civil strife. The largest number of cases is in the Democratic Republic of the Congo. Annual incidence estimates are about 100,000 cases and 48,000 deaths, mostly due to *T b gambiense*, leading to the loss of 1.5 million disability-adjusted life years. Infections are rare among travelers, including visitors to game parks.

▶ Clinical Findings

A. Symptoms and Signs

1. West African trypanosomiasis—Chancres at the site of the bite are uncommon. After an asymptomatic period that may last for months, **hemolympathic disease** presents with fever, headache, myalgias, arthralgias, weight loss, and lymphadenopathy, with discrete, nontender, rubbery nodes, referred to as Winterbottom sign when in a posterior cervical distribution. Other common signs are mild splenomegaly, transient edema, and a pruritic erythematous rash. Febrile episodes may be broken by afebrile periods of up to several weeks. The hemolympathic stage progresses over months to **meningoencephalitic disease**, with somnolence, irritability, personality changes, severe headache, and parkinsonian symptoms progressing to coma and death.

2. East African trypanosomiasis—Chancres at the bite site are more commonly recognized with *T b rhodesiense* infection, with a painful lesion of 3–10 cm and regional lymphadenopathy that appears about 48 hours after the tsetse fly bite and lasts 2–4 weeks. East African disease follows a much more acute course, with the onset of symptoms usually within a few days of the insect bite. The hemolympathic stage includes intermittent fever and rash, but lymphadenopathy is less common than with West African disease. Myocarditis can cause tachycardia and death due to arrhythmias or heart failure. If untreated, East African trypanosomiasis progresses over weeks to months to meningoencephalitic disease, somnolence, coma, and death.

B. Laboratory Findings

Diagnosis can be difficult, and definitive diagnosis requires identification of trypanosomes. Microscopic examination of fluid expressed from a chancre or lymph node may show

motile trypanosomes or, in fixed specimens, parasites stained with Giemsa. During the **hemolymphatic stage**, detection of parasites in Giemsa-stained blood smears is common in East African disease but difficult in West African disease. Serial specimens should be examined, since parasitemias vary greatly over time. **Meningoencephalitic (or second stage) disease** is defined by the World Health Organization (WHO) as cerebrospinal fluid (CSF) showing at least five mononuclear cells per microliter, elevated protein, or presence of trypanosomes. Concentration techniques can aid identification of parasites in blood or CSF. Serologic tests are also available. The simple card agglutination test for trypanosomes (CATT) has excellent sensitivity and specificity for West African disease and can be performed in the field; however, the diagnosis should be confirmed by identification of the parasites.

► **Treatment**

Detection of trypanosomes is a prerequisite for treatment of African trypanosomiasis because of the significant toxicity of most available therapies. Treatment recommendations depend on the type of trypanosomiasis (Table 35–1), which is determined by geography, and stage of disease, which requires examination of CSF.

A. West African Trypanosomiasis

1. Early stage infection—Pentamidine (4 mg/kg intramuscularly or intravenously every day or every other day for 7 days) is used to treat infection that does not involve the central nervous system (CNS). The side effects of pentamidine include immediate hypotension; tachycardia; gastrointestinal symptoms during administration; sterile abscesses; and pancreatic (hypoglycemia), liver, and kidney abnormalities. An alternate drug is eflornithine (100 mg/kg/d intravenously every 6 hours for 14 days).

2. Late stage infection—Eflornithine is the drug of choice for infection that involves the CNS; the dosage is the same as that used to treat early disease. Eflornithine has less toxicity than older trypanocidal drugs, but it can cause gastrointestinal symptoms and bone marrow suppression

and is limited by lack of availability and the need for infusions four times daily. Alternative therapies are melarsoprol (see below) or nifurtimox (5 mg/kg orally three times per day for 14 days), and drug combinations (eg, oral nifurtimox plus twice-daily eflornithine) may offer improved efficacy over monotherapies, with simplified regimens and decreased toxicity.

B. East African Trypanosomiasis

Pentamidine and eflornithine are not reliably effective, and early disease is treated with suramin. The dosing regimens of suramin vary (eg, 100–200 mg test dose, then 20 mg/kg [maximum 1 g] intravenously on days 1, 3, 7, 14, and 21 or weekly for 5 doses). Suramin toxicities include vomiting and, rarely, seizures and shock during infusions as well as subsequent fever, rash, headache, neuropathy, and kidney and bone marrow dysfunction.

Suramin does not enter the CNS, so East African trypanosomiasis involving the CNS is treated with melarsoprol (three series of 3.6 mg/kg/d intravenously for 3 days, with 7-day breaks between the series or a 10-day intravenous course with 0.6 mg/kg on day 1, 1.2 mg/kg on day 2, and 1.8 mg/kg on days 3–10). Melarsoprol also acts against West African disease, but eflornithine is preferred due to its lower toxicity. Immediate side effects of melarsoprol include fever and gastrointestinal symptoms. The most important side effect is a reactive encephalopathy that can progress to seizures, coma, and death. To help avoid this side effect, corticosteroids are coadministered (recommended regimens include dexamethasone 1 mg/kg/d intravenously for 2–3 days or oral prednisolone 1 mg/kg/d for 5 days, and then 0.5 mg/kg/d until treatment completion). In addition, increasing resistance to melarsoprol is a serious concern. Suramin and melarsoprol are available in the United States from the CDC Drug Service, Centers for Disease Control and Prevention, Atlanta, GA 30333; telephone: 404-639-3670.

► **Prevention & Control**

Individual prevention in endemic areas should include long sleeves and pants, insect repellents, and mosquito nets. Control programs focusing on vector elimination and treatment of infected persons and animals have shown good success in many areas but suffer from limited resources.

Table 35–1. Treatment of African trypanosomiasis.

Disease	Stage	Treatment	
		First Line	Alternative
West African	Early	Pentamidine	Suramin Eflornithine
	CNS involvement	Eflornithine	Melarsoprol Nifurtimox
East African	Early CNS involvement	Suramin Melarsoprol	Pentamidine

CNS, central nervous system.

Brun R et al. Human African trypanosomiasis. *Lancet*. 2010 Jan 9;375(9709):148–59. [PMID: 19833383]
 Checchi F et al. Accuracy of five algorithms to diagnose gambiense human African trypanosomiasis. *PLoS Negl Trop Dis*. 2011 Jul;5(7):e1233. [PMID: 21750745]
 Priotto G et al. Nifurtimox-eflornithine combination therapy for second-stage African *Trypanosoma brucei gambiense* trypanosomiasis: a multicentre, randomised, phase III, non-inferiority trial. *Lancet*. 2009 Jul 4;374(9683):56–64. [PMID: 19559476]
 Wastling SL et al. Diagnosis of human sleeping sickness: sense and sensitivity. *Trends Parasitol*. 2011 Sep;27(9):394–402. [PMID: 21659003]

AMERICAN TRYPANOSOMIASIS (Chagas Disease)



ESSENTIALS OF DIAGNOSIS

Acute stage

- ▶ Inflammatory lesion at inoculation site.
- ▶ Fever.
- ▶ Hepatosplenomegaly.
- ▶ Lymphadenopathy.
- ▶ Myocarditis.
- ▶ Parasites in blood is diagnostic.

Chronic stage

- ▶ Heart failure, cardiac arrhythmias.
- ▶ Thromboembolism.
- ▶ Megaesophagus.
- ▶ Megacolon.
- ▶ Serologic tests are usually diagnostic.

▶ General Considerations

Chagas disease is caused by *Trypanosoma cruzi*, a protozoan parasite found only in the Americas; it infects wild animals and to a lesser extent humans from southern South America to the southern United States. An estimated 10–12 million people are infected, mostly in rural areas. Recent control efforts in endemic countries have decreased disease incidence to about 40,000 new infections and 12,500 deaths per year. The disease is often acquired in childhood. In many countries in South America, Chagas disease is the most important cause of heart disease. In the United States, the vector is found and some animals are infected, but only a few instances of local transmission have been reported.

T. cruzi is transmitted by reduviid (triatomine) bugs infected by ingesting blood from animals or humans who have circulating trypanosomes. Multiplication occurs in the digestive tract of the bug and infective forms are eliminated in feces. Infection in humans occurs when the parasite penetrates the skin through the bite wound, mucous membranes, or the conjunctiva. Transmission can also occur by blood transfusion, organ or bone marrow transplantation, congenital transfer, or ingestion of food contaminated with vector feces. From the bloodstream, *T. cruzi* invades many cell types but has a predilection for myocardium, smooth muscle, and CNS glial cells. Multiplication causes cellular destruction, inflammation, and fibrosis, with progressive disease over decades.

▶ Clinical Findings

A. Symptoms and Signs

As many as 70% of infected persons remain asymptomatic. The **acute stage** is seen principally in children and lasts 1–2 months. The earliest findings are at the site of

inoculation either in the eye—Romaña sign (unilateral edema, conjunctivitis, and lymphadenopathy)—or in the skin—a chagoma (swelling with local lymphadenopathy). Subsequent findings include fever, malaise, headache, mild hepatosplenomegaly, and generalized lymphadenopathy. Acute myocarditis and meningoencephalitis are rare but can be fatal.

An asymptomatic **latent period (indeterminate phase)** may last for life, but symptomatic disease develops in 10–30% of infected individuals, commonly many years after infection.

Chronic Chagas disease generally manifests as abnormalities in cardiac and smooth muscle. Cardiac disease includes arrhythmias, congestive heart failure, and embolic disease. Smooth muscle abnormalities lead to megaesophagus and megacolon, with dysphagia, regurgitation, aspiration, constipation, and abdominal pain. These findings can be complicated by superinfections. In immunosuppressed persons, including AIDS patients and transplant recipients, latent Chagas disease may reactivate; findings have included brain abscesses and meningoencephalitis.

B. Diagnostic Testing

Diagnosis should be considered in persons with suggestive findings who have resided in an endemic area. Transmission by blood transfusion and congenital transmission should also be considered. The diagnosis is made by detecting parasites. With **acute infection**, evaluation of fresh blood or buffy coats may show motile trypanosomes, and fixed preparations may show Giemsa-stained parasites. Trypanosomes may be identified in lymph nodes, bone marrow, or pericardial or spinal fluid. When initial tests are unrevealing in a suspicious case, xenodiagnosis using laboratory vectors, laboratory culture, or animal inoculation may provide a diagnosis, but these methods are expensive and slow.

Chronic Chagas disease is usually diagnosed serologically. Many different serologic assays are available, but sensitivity and specificity are not ideal, so confirmatory assays are advised after an initial positive test, as is standard for blood bank testing in South America. Polymerase chain reaction (PCR) may offer an important new modality for diagnosis, but sensitivity of PCR assays has been disappointing.

▶ Treatment

Treatment is inadequate because the two drugs used, nifurtimox and benznidazole, often cause severe side effects, must be used for long periods, and are ineffective against chronic infection. In acute and congenital infections, the drugs can reduce the duration and severity of infection, but cure is achieved in only about 70% of patients. During the chronic phase of infection, although parasitemia may disappear in up to 70% of patients, treatment does not clearly alter the progression of the disease. Nevertheless, there is general consensus that treatment should be considered in all *T. cruzi*-infected persons regardless of clinical status or time since infection. In particular, treatment is recommended for acute, congenital, and reactivated infections and for children and young adults with chronic disease.

Nifurtimox is given orally in daily doses of 8–10 mg/kg in four divided doses after meals for 90–120 days. Side effects include gastrointestinal (anorexia, vomiting) and neurologic (headaches, ataxia, insomnia, seizures) symptoms, which appear to be reversible and to lessen with dosage reduction. Benznidazole is an alternative therapy that is given orally at a dosage of 5 mg/kg/d in divided doses for 60 days. Its side effects include granulocytopenia, rash, and peripheral neuropathy. In the United States, nifurtimox is available from the CDC Drug Service, Centers for Disease Control and Prevention, Atlanta, GA 30333; telephone: 404-639-3670. Patients with chronic Chagas disease may also benefit from antiarrhythmic therapy, standard therapy for congestive heart failure, and conservative and surgical management of megaesophagus and megacolon.

▶ Prevention & Control

In South America, a major eradication program based on improved housing, use of residual pyrethroid insecticides and pyrethroid-impregnated bed curtains, and screening of blood donors has achieved striking reductions in new infections. In endemic areas and ideally in donors from endemic areas, blood should not be used for transfusion unless at least two serologic tests are negative.

Alarcón de Noya B et al. Large urban outbreak of orally acquired acute Chagas disease at a school in Caracas, Venezuela. *J Infect Dis.* 2010 May 1;201(9):1308–15. [PMID: 20307205]
 Bern C. Antitrypanosomal therapy for chronic Chagas' disease. *N Engl J Med.* 2011 Jun 30;364(26):2527–34. [PMID: 21714649]
 Kirchhoff LV. Epidemiology of American trypanosomiasis (Chagas Disease). *Adv Parasitol.* 2011;75:1–18. [PMID: 21820549]
 Lescuré FX et al. Chagas disease: changes in knowledge and management. *Lancet Infect Dis.* 2010 Aug;10(8):556–70. [PMID: 20670903]
 Rassi A Jr et al. Chagas Disease. *Lancet.* 2010 Apr 17;375(9723):1388–402. [PMID: 20399979]

LEISHMANIASIS



ESSENTIALS OF DIAGNOSIS

- ▶ Sand fly bite in an endemic area.
- ▶ **Visceral leishmaniasis:** irregular fever, progressive hepatosplenomegaly, pancytopenia, wasting.
- ▶ **Cutaneous leishmaniasis:** chronic, painless, moist ulcers or dry nodules.
- ▶ **Mucocutaneous leishmaniasis:** destructive nasopharyngeal lesions.
- ▶ Amastigotes in macrophages in aspirates, touch preparations, or biopsies.
- ▶ Positive culture, serologic tests, PCR, or skin test.

▶ General Considerations

Leishmaniasis is a zoonosis transmitted by bites of sand flies of the genus *Lutzomyia* in the Americas and *Phlebotomus* elsewhere. When sand flies feed on an infected host, the parasitized cells are ingested with the blood meal. Leishmaniasis is caused by about 20 species of *Leishmania*; taxonomy is complex. Clinical syndromes are generally dictated by the infecting species, but some species can cause more than one syndrome.

An estimated 350 million persons are at risk for leishmaniasis. The estimated annual incidence of disease is 1–1.5 million new cases of cutaneous and 500,000 cases of visceral disease, leading to an estimated 50,000–60,000 deaths. The incidence of disease is increasing in many areas.

Visceral leishmaniasis (kala azar) is caused mainly by *Leishmania donovani* in the Indian subcontinent and East Africa; *Leishmania infantum* in the Mediterranean, Middle East, China, parts of Asia, and Horn of Africa; and *Leishmania chagasi* in South and Central America. Other species may occasionally cause visceral disease. Over 90% of cases occur in five countries: India, Bangladesh, Nepal, Sudan, and Brazil. In each locale, the disease has particular clinical and epidemiologic features. The incubation period is usually 4–6 months (range: 10 days to 24 months). Without treatment, the fatality rate reaches 90%. Early diagnosis and treatment reduces mortality to 2–5%.

Old World cutaneous leishmaniasis is caused mainly by *Leishmania tropica*, *Leishmania major*, and *Leishmania aethiopica* in the Mediterranean, Middle East, Africa, Central Asia, and Indian subcontinent. **New World cutaneous leishmaniasis** is caused by *Leishmania mexicana* and *Leishmania amazonensis* in Central and South America. **Mucocutaneous leishmaniasis** (espundia) occurs in lowland forest areas of the Americas and is caused by *Leishmania braziliensis*, *Leishmania panamensis*, and *Leishmania peruviana*.

▶ Clinical Findings

A. Symptoms and Signs

1. Visceral leishmaniasis (kala azar)—Most infections are subclinical, but a small number progress to full-blown disease. A local nonulcerating nodule at the site of the sand fly bite may precede systemic manifestations but usually is inapparent. The onset of illness may be acute, within 2 weeks of infection, or insidious. Symptoms and signs include fever, chills, sweats, weakness, anorexia, weight loss, cough, and diarrhea. The spleen progressively becomes greatly enlarged, firm, and nontender. The liver is somewhat enlarged, and generalized lymphadenopathy may occur. Hyperpigmentation of skin can be seen, leading to the name kala azar (“black fever”). Other signs include skin lesions, petechiae, gingival bleeding, jaundice, edema, and ascites. As the disease progresses, severe wasting and malnutrition are seen; death eventually occurs, often due to secondary infections, within months to a few years. Post-kala azar dermal leishmaniasis may appear after apparent cure in the Indian subcontinent and Sudan. It may simulate leprosy, with hypopigmented macules or nodules



▲ **Figure 35-1.** Skin ulcer due to cutaneous leishmaniasis. (Courtesy of D. S. Martin, Public Health Image Library, CDC.)

developing on preexisting lesions. Viscerotropic leishmaniasis has been reported in small numbers of American military personnel in the Middle East, with mild systemic febrile illnesses after *L tropica* infections.

2. Old World and New World cutaneous leishmaniasis—

Cutaneous swellings appear 2 weeks to several months after sand fly bites and can be single or multiple. Characteristics of lesions and courses of disease vary depending on the leishmanial species and host immune response. Lesions begin as small papules and develop into nonulcerated dry plaques or large encrusted ulcers with well-demarcated raised and indurated margins (Figure 35-1). Satellite lesions may be present. The lesions are painless unless secondarily infected. Local lymph nodes may be enlarged. Systemic symptoms are uncommon, but fever, constitutional symptoms, and regional lymphadenopathy may be seen. For most species, healing occurs spontaneously in months to a few years, but scarring is commonly seen.

Leishmaniasis recidivans is a relapsing form of *L tropica* infection associated with hypersensitivity, in which the primary lesion heals centrally, but spreads laterally, with extensive scarring. **Diffuse cutaneous leishmaniasis** involves spread from a central lesion to local dissemination of nodules and a protracted course. **Disseminated cutaneous leishmaniasis** involves multiple nodular or ulcerated lesions, often with mucosal involvement.

3. Mucocutaneous leishmaniasis (espundia)—In Latin America, mucosal lesions develop in a small percentage of persons infected with *L braziliensis* and some other species, usually months to years after resolution of a cutaneous lesion. Nasal congestion is followed by ulceration of the nasal mucosa and septum, progressing to involvement of the mouth, lips, palate, pharynx, and larynx. Extensive destruction can occur, and secondary bacterial infection is common.

4. Infections in patients with AIDS—Leishmaniasis is an opportunistic infection in persons with AIDS seen in

southern Europe and other areas. Visceral leishmaniasis can present late in the course of HIV infection, with fever, hepatosplenomegaly, and pancytopenia. The gastrointestinal tract, respiratory tract, and skin may also be involved.

B. Laboratory Findings

Identifying parasites in tissue samples or culture material provides a definitive diagnosis. In **visceral leishmaniasis**, fine-needle aspiration of the spleen for culture and tissue evaluation is generally safe, and yields a diagnosis in over 95% of cases. Bone marrow aspiration is less sensitive but safer and diagnostic in most cases. Giemsa-stained buffy coat of peripheral blood may occasionally show organisms. For all tissue biopsies and touch preparations, Giemsa staining will show amastigotes within macrophages. Cultures with media available from the CDC will grow promastigotes within a few days to weeks. PCR can also identify the infection. Inoculation of laboratory animals can also be used but is time consuming. Species are identified by molecular, isoenzyme, and monoclonal antibody methods. Serologic tests may facilitate diagnosis, but none are sufficiently sensitive or specific to be used alone. Antibody levels are typically high with visceral leishmaniasis but not cutaneous disease. For **cutaneous lesions**, biopsies should be taken from the raised border of a skin lesion, with samples for histopathology, touch preparation, and culture. The histopathology shows inflammation with mononuclear cells. Macrophages filled with amastigotes may be present, especially early in infection. An intradermal leishmanin (Montenegro) skin test is positive in most individuals with cutaneous disease but negative in those with progressive visceral or diffuse cutaneous disease; this test is not approved in the United States. In **mucocutaneous leishmaniasis**, diagnosis is established by detecting amastigotes in scrapings, biopsy preparations, or aspirated tissue fluid, but organisms may be rare. Cultures from these samples may grow organisms. Serologic studies are often negative, but the leishmanin skin test is usually positive.

▶ Treatment

A. Visceral Leishmaniasis

The treatment of choice for visceral leishmaniasis is liposomal amphotericin B, which is generally effective and well tolerated but very expensive. Liposomal amphotericin B is approved for this use in the United States. Standard dosing is 3 mg/kg/d intravenously on days 1–5, 14, and 21. Conventional amphotericin B deoxycholate, which is much less expensive, is also highly effective but with more toxicity. It is administered as a slow intravenous infusion of 1 mg/kg/d for 15–20 days or 0.5–1 mg/kg every second day for up to 8 weeks. Infusion-related side effects with conventional or liposomal amphotericin B include gastrointestinal symptoms, fever, chills, dyspnea, hypotension, and hepatic and renal toxicity.

Pentavalent antimonials remain the most commonly used drugs to treat leishmaniasis in most areas. Response rates are good outside India, but in India, resistance is a major problem. Two preparations are available, sodium stibogluconate in the United States and many other

areas and meglumine antimonate in Latin America and francophone countries; the compounds appear to have comparable activities. In the United States, sodium stibogluconate can be obtained from the CDC Drug Service, Centers for Disease Control and Prevention, Atlanta, GA 30333; telephone: 404-639-3670.

Treatment with either antimonial is given once daily at a dose of 20 mg/kg/d intravenously (preferred) or intramuscularly for 20 days for cutaneous leishmaniasis and 28 days for visceral or mucocutaneous disease. Toxicity increases over time, with development of gastrointestinal symptoms, fever, headache, myalgias, arthralgias, pancreatitis, and rash. Intramuscular injections can cause sterile abscesses. Monitoring should include serial ECGs, and changes are indications for discontinuation to avoid progression to serious arrhythmias.

Miltefosine is the first oral drug for the treatment of leishmaniasis, and it provides excellent results in India, where resistance to antimonials is increasing. It can be administered at a daily oral dose of 2.5 mg/kg in two divided doses for 28 days. A 28-day course of miltefosine (2.5 mg/kg/d) is also effective for the treatment of New World cutaneous leishmaniasis. Vomiting, diarrhea, and elevations in transaminases and kidney function studies are common, but generally short-lived, side effects. Miltefosine is registered for the treatment of visceral leishmaniasis in India and may become the standard of care, in particular in combination regimens, in that country.

Pentamidine isethionate is an alternative therapy for visceral leishmaniasis, given daily or on alternate days for 15 doses of 2–4 mg/kg intramuscularly or intravenously. Side effects include immediate hypotension; tachycardia; and gastrointestinal symptoms during administration; sterile abscesses; and pancreatic, liver, and kidney abnormalities.

The aminoglycoside paromomycin (11 mg/kg/d intramuscularly for 21 days) was shown to be similarly efficacious to amphotericin B for the treatment of visceral disease in India. It is much less expensive than liposomal amphotericin B or miltefosine. Of note, paromomycin has shown relatively poor efficacy in studies in Africa. Approval of an intramuscular preparation for visceral leishmaniasis was received in India in 2006. The drug is well tolerated; side effects include ototoxicity and reversible elevations in liver enzymes.

There is increasing interest in combination treatment regimens for visceral leishmaniasis to shorten treatment courses, save costs, and prevent the selection of resistant parasites. Resistance is of particular concern; laboratory studies suggest that resistance to miltefosine and paromomycin may be readily selected by monotherapy regimens. In India, regimens including a 10-day course of miltefosine plus paromomycin or a single dose of liposomal amphotericin B combined with either 7 days of oral miltefosine or 10 days of paromomycin were all noninferior to a 15-dose regimen of conventional amphotericin B. Based on these and other similar results, combination regimens may become the treatments of choice for visceral leishmaniasis in India.

B. Cutaneous Leishmaniasis

In the Old World, cutaneous leishmaniasis is generally self-healing over some months and does not metastasize to the

mucosa, so it may be justified to withhold treatment in regions without mucocutaneous disease if lesions are small and cosmetically unimportant. Lesions on the face or hands are generally treated. New World leishmaniasis has a greater risk of progression to mucocutaneous disease, so treatment is more often warranted. Standard therapy is with pentavalent antimonials for 20 days, as described above. Other treatments include those discussed above for visceral disease, azole antifungals, and allopurinol. In studies in Brazil, a 28-day course of miltefosine was superior to a 20-day course of meglumine antimonate, and oral fluconazole also showed good efficacy. Topical therapy has included intralesional antimony, paromomycin ointment, cryotherapy, local heat, and surgical removal. Diffuse cutaneous leishmaniasis and related chronic skin processes generally respond poorly to therapy.

C. Mucocutaneous Leishmaniasis

Cutaneous infections from regions where parasites include those that cause mucocutaneous disease (eg, *L. braziliensis* in parts of Latin America) should all be treated to help prevent disease progression. Treatment of mucocutaneous disease with antimonials is disappointing, with responses in only about 60% in Brazil. Other therapies listed above for visceral leishmaniasis may also be used, although they have not been well studied for this indication.

► Prevention & Control

Personal protection measures for avoidance of sand fly bites include use of insect repellants, fine-mesh insect netting, long sleeves and pants, and avoidance of warm shaded areas where flies are common. Disease control measures include destruction of animal reservoir hosts, mass treatment of humans in disease-prevalent areas, residual insecticide spraying in dwellings, limiting contact with dogs and other domesticated animals, and use of permethrin-impregnated collars for dogs.

Croft SL et al. Leishmaniasis chemotherapy—challenges and opportunities. *Clin Microbiol Infect.* 2011 Oct;17(10):1478–83. [PMID: 21933306]

Hailu A et al; Leishmaniasis East Africa Platform (LEAP) group. Geographical variation in the response of visceral leishmaniasis to paromomycin in East Africa: a multicentre, open-label, randomized trial. *PLoS Negl Trop Dis.* 2010 Oct 26;4(10):e709. [PMID: 21049059]

Machado PR et al. Miltefosine in the treatment of cutaneous leishmaniasis caused by *Leishmania braziliensis* in Brazil: a randomized and controlled trial. *PLoS Negl Trop Dis.* 2010 Dec 21;4(12):e912. [PMID: 21200420]

Matlashewski G et al. Visceral leishmaniasis: elimination with existing interventions. *Lancet Infect Dis.* 2011 Apr;11(4):322–5. [PMID: 21453873]

Murray HW et al. Advances in leishmaniasis. *Lancet.* 2005 Oct 29–Nov 4;366(9496):1561–77. [PMID: 16257344]

Rahman M et al. Phase IV trial of miltefosine in adults and children for treatment of visceral leishmaniasis (kala-azar) in Bangladesh. *Am J Trop Med Hyg.* 2011 Jul;85(1):66–9. [PMID: 21734127]

Reithinger R et al. Cutaneous leishmaniasis. *Lancet Infect Dis.* 2007 Sep;7(9):581–96. [PMID: 17714672]

Sousa AQ et al. High-dose oral fluconazole therapy effective for cutaneous leishmaniasis due to *Leishmania (Vianna) braziliensis*. *Clin Infect Dis*. 2011 Oct;53(7):693–5. [PMID: 21890773]

Sundar S. Injectable paromomycin for visceral leishmaniasis in India. *N Engl J Med*. 2007 Jun 21;356(25):2571–81. [PMID: 17582067]

Sundar S et al. Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial. *Lancet*. 2011 Feb 5;377(9764):477–86. [PMID: 21255828]

van Griensven J. Combination therapy for visceral leishmaniasis. *Lancet Infect Dis*. 2010 Mar;10(3):184–94. [PMID: 20185097]

MALARIA



ESSENTIALS OF DIAGNOSIS

- ▶ Residence or exposure in a malaria-endemic area.
- ▶ Intermittent attacks of chills, fever, and sweating.
- ▶ Headache, myalgia, vomiting, splenomegaly; anemia, thrombocytopenia.
- ▶ Intraerythrocytic parasites identified in thick or thin blood smears.
- ▶ Complications of falciparum malaria: cerebral malaria, severe anemia, hypotension, noncardiogenic pulmonary edema, acute kidney injury, hypoglycemia, acidosis, and hemolysis.

▶ General Considerations

Malaria is the most important parasitic disease of humans, causing hundreds of millions of illnesses and nearly a million deaths each year. The disease is endemic in most of the tropics, including much of South and Central America, Africa, the Middle East, the Indian subcontinent, Southeast Asia, and Oceania. Transmission, morbidity, and mortality are greatest in Africa, where most deaths from malaria are in young children. Malaria is also common in travelers from nonendemic areas to the tropics.

Four species of the genus *Plasmodium* classically cause human malaria. *Plasmodium falciparum* is responsible for nearly all severe disease. It is endemic in most malarious areas and is by far the predominant species in Africa. *Plasmodium vivax* is about as common as *P falciparum*, except in Africa. *P vivax* uncommonly causes severe disease, although this outcome may be more common than previously appreciated. *Plasmodium ovale* and *Plasmodium malariae* are much less common causes of disease, and generally do not cause severe illness. *Plasmodium knowlesi*, a parasite of macaque monkeys, is now recognized to cause occasional illnesses, including some severe disease, in humans in Southeast Asia.

Malaria is transmitted by the bite of infected female anopheline mosquitoes. During feeding, mosquitoes inject sporozoites, which circulate to the liver, and rapidly infect hepatocytes, causing asymptomatic liver infection. Merozoites are subsequently released from the liver, and

they rapidly infect erythrocytes to begin the asexual erythrocytic stage of infection that is responsible for human disease. Multiple rounds of erythrocytic development, with production of merozoites that invade additional erythrocytes, lead to large numbers of circulating parasites and clinical illness. Some erythrocytic parasites also develop into sexual gametocytes, which are infectious to mosquitoes, allowing completion of the life cycle and infection of others.

Malaria may uncommonly be transmitted from mother-to-infant (congenital malaria), by blood transfusion, and in nonendemic areas by mosquitoes infected after biting infected immigrants or travelers. In *P vivax* and *P ovale*, parasites also form dormant liver hypnozoites, which are not killed by most drugs, allowing subsequent relapses of illness after initial elimination of erythrocytic infections. For all plasmodial species, parasites may recrudescence following initial clinical improvement after suboptimal therapy.

In highly endemic regions, where people are infected repeatedly, antimalarial immunity prevents severe disease in most older children and adults. However, young children, who are relatively nonimmune, are at high risk for severe disease from *P falciparum* infection, and this population is responsible for most deaths from malaria. Pregnant women are also at increased risk for severe falciparum malaria. In areas with lower endemicity, individuals of all ages commonly present with uncomplicated or severe malaria. Travelers, who are generally nonimmune, are at high risk for severe disease from falciparum malaria at any age.

▶ Clinical Findings

A. Symptoms and Signs

An acute attack of malaria typically begins with a prodrome of headache and fatigue, followed by fever. A classic malarial paroxysm includes chills, high fever, and then sweats. Patients may appear to be remarkably well between febrile episodes. Fevers are usually irregular, especially early in the illness, but without therapy may become regular, with 48-hour cycles (*P vivax* and *P ovale*) or 72-hour cycles (*P malariae*), especially with non-falciparum disease. Headache, malaise, myalgias, arthralgias, cough, chest pain, abdominal pain, anorexia, nausea, vomiting, and diarrhea are common. Seizures may represent simple febrile convulsions or evidence of severe neurologic disease. Physical findings may be absent or include signs of anemia, jaundice, splenomegaly, and mild hepatomegaly. Rash and lymphadenopathy are not typical in malaria, and thus suggestive of another cause of fever.

In the developed world, it is imperative that all persons with suggestive symptoms, in particular fever, who have traveled in an endemic area be evaluated for malaria. The risk for falciparum malaria is greatest within 2 months of return from travel; other species may cause disease many months—and occasionally more than a year—after return from an endemic area.

Severe malaria is defined as the presence of signs of severe illness or organ dysfunction or a high parasite load


(peripheral parasitemia > 5% or > 200,000 parasites/mcL). It is principally a result of *P falciparum* infection because this species uniquely infects erythrocytes of all ages and mediates the sequestration of infected erythrocytes in small blood vessels, thereby evading clearance of infected erythrocytes by the spleen.

Severe falciparum malaria can include dysfunction of any organ system, including neurologic abnormalities progressing to alterations in consciousness, repeated seizures, and coma (cerebral malaria); severe anemia; hypotension and shock; noncardiogenic pulmonary edema and the acute respiratory distress syndrome; acute kidney injury due to acute tubular necrosis or, less commonly, severe hemolysis; hypoglycemia; acidosis; hemolysis with jaundice; hepatic dysfunction; retinal hemorrhages and other fundoscopic abnormalities; bleeding abnormalities, including disseminated intravascular coagulation; and secondary bacterial infections, including pneumonia and *Salmonella* bacteremia. In the developing world, severe malaria and deaths from the disease are mostly in young children, in particular from cerebral malaria and severe anemia. Cerebral malaria is a consequence of a single severe infection while severe anemia follows multiple malarial infections, intestinal helminths, and nutritional deficiencies.


Uncommon disorders resulting from immunologic responses to chronic infection are massive splenomegaly and, with *P malariae* infection, immune complex glomerulopathy with nephrotic syndrome. HIV-infected individuals are at increased risk for malaria and for severe disease, in particular with advanced immunodeficiency.

B. Laboratory Findings


Giemsa-stained blood smears remain the mainstay of diagnosis (Figures 35–2 through 35–5), although other routine stains (eg, Wright stain) will also demonstrate parasites. Thick smears provide efficient evaluation of large volumes of blood, but thin smears are simpler for inexperienced personnel and better for discrimination of parasite species. Single smears are usually positive in infected individuals,




▲ **Figure 35-3.** Thin film Giemsa-stained micrograph with *Plasmodium malariae* trophozoite. (Courtesy of Steven Glenn, Laboratory & Consultation Division, Public Health Image Library, CDC.)



▲ **Figure 35-4.** Thin film Giemsa-stained micrograph with *Plasmodium vivax* schizont. (Courtesy of Steven Glenn, Laboratory & Consultation Division, Public Health Image Library, CDC.)



▲ **Figure 35-2.** Thin film Giemsa-stained micrograph with *Plasmodium falciparum* ring forms. (Courtesy of Steven Glenn, Laboratory & Consultation Division, Public Health Image Library, CDC.)



▲ **Figure 35-5.** Thin film Giemsa-stained micrograph with *Plasmodium ovale* trophozoite. (Courtesy of Steven Glenn, Laboratory & Consultation Division, Public Health Image Library, CDC.)

although parasitemias may be very low in nonimmune individuals. If illness is suspected, repeating smears in 8- to 24-hour intervals is appropriate. The severity of malaria correlates only loosely with the quantity of infecting parasites, but high parasitemias (especially > 10–20% of erythrocytes infected or > 200,000–500,000 parasites/mcL) or the presence of malarial pigment (a breakdown product of hemoglobin) in > 5% of neutrophils are associated with a particularly poor prognosis.

A second means of diagnosis is rapid diagnostic tests to identify circulating plasmodial antigens with a simple “dipstick” format. These tests are not well standardized but are increasingly available around the world, including in the United States. At best, they offer sensitivity and specificity near that of high-quality blood smear analysis and are simpler to perform.

Serologic tests indicate history of disease but are not useful for diagnosis of acute infection. PCR is highly sensitive but not available for routine diagnosis. In immune populations, highly sensitive tests, such as PCR, have limited value because subclinical infections, which are of uncertain significance and not routinely treated, are common.

Other diagnostic findings with uncomplicated malaria include thrombocytopenia, anemia, leukocytosis or leukopenia, liver function abnormalities, and hepatosplenomegaly. Severe malaria can present with the laboratory abnormalities expected for the advanced organ dysfunction discussed above.

► Treatment

Malaria is the most common cause of fever in much of the tropics and in travelers seeking medical attention after return from endemic areas. Fevers are often treated presumptively in endemic areas, but ideally, treatment should follow definitive diagnosis, especially in non-immune individuals (see Tables 35–4 and 35–5).

Symptomatic malaria is caused only by the erythrocytic stage of infection. Available antimalarial drugs (Table 35–2) act against this stage, except for primaquine, which acts principally against hepatic parasites.

A. Non-Falciparum Malaria

The first-line drug for non-falciparum malaria from most areas remains chloroquine. Due to increasing resistance of *P vivax* to chloroquine, alternative therapies are recommended when resistance is suspected, particularly for infections acquired in Indonesia, Oceania, and Peru. These infections can be treated with artemisinin-based combination therapies or other first-line regimens for *P falciparum* infections as discussed below. For *P vivax* or *P ovale*, eradication of erythrocytic parasites with chloroquine should be accompanied by treatment with primaquine (after evaluating for glucose-6-phosphate dehydrogenase [G6PD] deficiency; see below) to eradicate dormant liver stages (hypnozoites), which may lead to relapses with recurrent erythrocytic infection and malaria symptoms after weeks

Table 35-2. Major antimalarial drugs.

Drug	Class	Use
Chloroquine	4-Aminoquinoline	Treatment and chemoprophylaxis of infection with sensitive parasites
Amodiaquine ¹	4-Aminoquinoline	Treatment of <i>Plasmodium falciparum</i> , optimally in fixed combination with artesunate
Piperaquine ¹	4-Aminoquinoline	Treatment of <i>P falciparum</i> in fixed combination with dihydroartemisinin
Quinine	Quinoline methanol	Oral and intravenous ¹ (for severe infections) treatment of <i>P falciparum</i>
Quinidine	Quinoline methanol	Intravenous therapy of severe infections with <i>P falciparum</i>
Mefloquine	Quinoline methanol	Chemoprophylaxis and treatment of infections with <i>P falciparum</i>
Primaquine	8-Aminoquinoline	Radical cure and terminal prophylaxis of infections with <i>Plasmodium vivax</i> and <i>Plasmodium ovale</i> ; alternative for malaria chemoprophylaxis
Sulfadoxine-pyrimethamine (Fansidar)	Folate antagonist combination	Treatment of <i>P falciparum</i> , optimally in combination with artesunate; intermittent preventive therapy
Atovaquone-proguanil (Malarone)	Quinone-folate antagonist combination	Treatment and chemoprophylaxis of <i>P falciparum</i> infection
Doxycycline	Tetracycline	Treatment (with quinine) of infections with <i>P falciparum</i> ; chemoprophylaxis
Halofantrine ¹	Phenanthrene methanol	Treatment of infections with some chloroquine-resistant <i>P falciparum</i>
Lumefantrine	Amyl alcohol	Treatment of <i>P falciparum</i> malaria in fixed combination with artemether (Coartem)
Artemisinins (Artesunate, artemether, dihydroartemisinin)	Sesquiterpene lactone endoperoxides	Treatment of <i>P falciparum</i> in oral combination regimens for uncomplicated disease and parenterally for severe malaria

¹Not available in the United States.

Modified, with permission, from Katzung BG. *Basic & Clinical Pharmacology*. 11th edition. McGraw-Hill, 2009.

to months if left untreated. *P malariae* infections need only be treated with chloroquine.

B. Uncomplicated Falciparum Malaria

Decisions about how to treat falciparum malaria are affected by the potential for drug resistance, the high cost and limited availability of newer agents for developing world populations, and potential toxicity. The drug sensitivity of individual strains can be determined, but such testing is slow and not useful clinically. Rather, therapeutic decisions are made based on the infecting species and geography. *P falciparum* is now commonly resistant to chloroquine and sulfadoxine-pyrimethamine in most areas, with the principal exceptions of Central America west of the Panama Canal and Hispaniola. Falciparum malaria from other areas should not be treated with these older drugs, and decisions regarding appropriate chemoprophylaxis should follow the same geographic considerations.

In the developing world, malaria is often treated with suboptimal regimens due to the high cost and limited supplies of newer agents. Chloroquine is still widely used in Africa, and its poor efficacy may be underappreciated due to its antipyretic properties, the ability of some immune individuals to recover from acute malaria without effective therapy, and the fact that recrudescences may not lead to symptoms until weeks after partially effective therapy. Sulfadoxine-pyrimethamine is slower acting than most other agents, and suffers from increasing resistance in most areas. Recommendations for the treatment of uncomplicated falciparum malaria in the developing world have undergone major change in recent years, with artemisinin-based combinations, all including a short-acting artemisinin and longer-acting partner drug, now first-line therapies in nearly all endemic countries. The WHO currently recommends five artemisinin-based combinations to treat falciparum malaria (Table 35-3), but the efficacy of these regimens varies. Other combination therapies are under development. Another drug that remains generally effective for falciparum malaria is quinine, but it must be taken for an extended period to cure disease and is poorly tolerated. Thus, in the developing world, quinine should be reserved for the treatment of severe malaria and for treatment after another regimen has failed (Table 35-4).

In developed countries, malaria is an uncommon but potentially life-threatening infection of travelers and immigrants, many of whom are nonimmune, so they are at risk for rapid progression to severe disease. Nonimmune individuals with falciparum malaria should generally be admitted to the hospital due to risks of rapid progression of disease. Options for the treatment of uncomplicated falciparum malaria in the United States have increased with the approval of artemether-lumefantrine in 2009 (Table 35-4).

C. Severe Malaria

Severe malaria is a medical emergency. Parenteral treatment is indicated for severe malaria, as defined above, and with inability to take oral drugs. With appropriate prompt therapy and supportive care, rapid recoveries may be seen in even very ill individuals.

Table 35-3. WHO recommendations for the treatment of uncomplicated falciparum malaria.

Regimen	Notes
Artemether-lumefantrine (Coartem, Riamet)	Coformulated, first-line therapy in many countries. Approved in the United States.
Artesunate-amodiaquine (ASAQ)	Coformulated, first-line therapy in multiple African countries.
Artesunate-mefloquine	First-line therapy in parts of Southeast Asia and South America.
Artesunate-sulfadoxine-pyrimethamine	First-line in some countries, but efficacy lower than other regimens in most areas.
Dihydroartemisinin-piperaquine	Newer coformulated combination. First-line in some Southeast Asian countries.

World Health Organization: Guidelines for the Treatment of Malaria. World Health Organization. Geneva 2010. ISBN 978 92 4 154792 5.

Standard therapy for severe malaria has been intravenous quinine in most areas and, in the United States, intravenous quinidine, which is equally effective. However, the standard of care is now changing, since intravenous artesunate has shown superiority over quinine.

Patients receiving intravenous quinine or quinidine should receive continuous cardiac monitoring; if QTc prolongation exceeds 25% of baseline, the infusion rate should be reduced. Blood glucose should be monitored every 4-6 hours, and 5-10% dextrose may be coadministered to decrease the likelihood of hypoglycemia. Appropriate care of severe malaria includes maintenance of fluids and electrolytes; respiratory and hemodynamic support; and consideration of blood transfusions, anti-convulsants, antibiotics for bacterial infections, and hemofiltration or hemodialysis. With high parasitemia (> 5-10%), exchange transfusion has been used, but beneficial effects have not clearly been demonstrated, and its role remains uncertain.

Intravenous artesunate has shown superior efficacy and better tolerability than intravenous quinine for severe malaria in large randomized trials in Asian adults and African children. It is the standard of care for severe malaria, although it is not yet available in much of the developing world, where quinine remains standard therapy. In the United States intravenous artesunate is available on an investigational basis through the CDC (for enrollment call 770-488-7788); if approved, the drug is provided emergently from CDC Quarantine Stations. The drug is administered in four doses of 2.4 mg/kg over 3 days, every 12 hours on day 1, and then daily. If artesunate cannot be obtained promptly, severe malaria should be treated with intravenous quinine or quinidine. In endemic regions, if parenteral therapy is not available, intrarectal administration of artemether or artesunate is also effective.

Table 35-4. Treatment of malaria.

Clinical Setting	Drug Therapy ¹	Alternative Drugs
Chloroquine-sensitive <i>Plasmodium falciparum</i> and <i>Plasmodium malariae</i> infections	Chloroquine phosphate, 1 g, followed by 500 mg at 6, 24, and 48 hours or— Chloroquine phosphate, 1 g at 0 and 24 hours, then 0.5 g at 48 hours	
<i>Plasmodium vivax</i> and <i>Plasmodium ovale</i> infections	Chloroquine (as above), then (if G6PD normal) primaquine, 30 mg base daily for 14 days	For infections from Indonesia, Papua New Guinea, and other areas with suspected resistance: therapies listed for uncomplicated chloroquine-resistant <i>P falciparum</i> plus primaquine
Uncomplicated infections with chloroquine-resistant <i>P falciparum</i>	Coartem (artemether 20 mg, lumefantrine 120 mg), four tablets twice daily for 3 days Malarone, four tablets (total of 1 g atovaquone, 400 mg proguanil) daily for 3 days Quinine sulfate, 650 mg three times daily for 3–7 days Plus one of the following (when quinine given for < 7 days) – Doxycycline, 100 mg twice daily for 7 days or— Clindamycin, 600 mg twice daily for 7 days	Mefloquine, 15 mg/kg once or 750 mg, then 500 mg in 6–8 hours or— Dihydroartemisinin-piperaquine ² (dihydroartemisinin 40 mg, piperaquine 320 mg), 4 tablets daily for 3 days or— ASAQ ² (artesunate 100 mg, amodiaquine 270 mg), two tablets daily for 3 days
Severe or complicated infections with <i>P falciparum</i>	Artesunate 2.4 mg/kg intravenously every 12 hours for 1 day, then daily ^{3,6}	Quinidine gluconate, ^{4,6} 10 mg/kg intravenously over 1–2 hours, then 0.02 mg/kg intravenously/min or— Quinidine gluconate, ^{4,6} 15 mg/kg intravenously over 4 hours, then 7.5 mg/kg intravenously over 4 hours every 8 hours or— Quinine dihydrochloride, ^{2,4,6} 20 mg/kg intravenously over 4 hours, then 10 mg/kg intravenously every 8 hours or— Artemether, ^{2,6} 3.2 mg/kg intramuscularly, then 1.6 mg/kg/d intramuscularly

¹All dosages are oral and refer to salts unless otherwise indicated. See text for additional information on all agents, including toxicities and cautions. See Centers for Disease Control and Prevention's guidelines (phone: 877-FYI-TRIP; <http://www.cdc.gov/malaria/>) for additional information and pediatric dosing.

²Not available in the United States.

³Available in the United States only on an investigational basis through the CDC (phone: 770-488-7788).

⁴Cardiac monitoring should be in place during intravenous administration of quinidine or quinine.

⁵Avoid loading doses in persons who have received quinine, quinidine, or mefloquine in the prior 24 hours.

⁶With all parenteral regimens, change to an oral regimen as soon as the patient can tolerate it.

G6PD, glucose-6-phosphate dehydrogenase.

D. Antimalarial Drugs

1. Chloroquine—Chloroquine remains the drug of choice for the treatment of sensitive *P falciparum* and other species of malaria parasites (Table 35-4). Chloroquine is active against erythrocytic parasites of all human malaria species. It does not eradicate hepatic stages, so must be used with primaquine to eradicate *P vivax* and *P ovale* infections. Chloroquine-resistant *P falciparum* is widespread in nearly all areas of the world with falciparum malaria, with the exceptions of Central America west of the Panama Canal, Mexico, and Hispaniola. Chloroquine-resistant *P vivax* has been reported from a number of areas, most notably Southeast Asia and Oceania.

Chloroquine is the drug of choice for the treatment of non-falciparum and sensitive falciparum malaria. It

rapidly terminates fever (in 24–48 hours) and clears parasitemia (in 48–72 hours) caused by sensitive parasites. Chloroquine is also the preferred chemoprophylactic agent in malarious regions without resistant falciparum malaria. Eradication of *P vivax* and *P ovale* requires a course of primaquine.

Chloroquine is usually well tolerated, even with prolonged use. Pruritus is common, primarily in Africans. Nausea, vomiting, abdominal pain, headache, anorexia, malaise, blurring of vision, and urticaria are uncommon. Dosing after meals may reduce some adverse events.

2. Amodiaquine and piperaquine—Amodiaquine is a 4-aminoquinoline that is closely related to chloroquine. Amodiaquine has been widely used to treat malaria because of its low cost, limited toxicity and, in some areas,

effectiveness against chloroquine-resistant strains of *P falciparum*. Use of amodiaquine decreased after recognition of rare but serious side effects, notably agranulocytosis, aplastic anemia, and hepatotoxicity. However, serious side effects are rare with short-term use, and amodiaquine is a component of a new combination therapy (artesunate-amodiaquine) recommended to treat falciparum malaria (Table 35–3). Chemoprophylaxis with amodiaquine is best avoided because of increased toxicity with long-term use.

Piperaquine is another 4-aminoquinoline that was previously heavily used in China and has been coformulated with dihydroartemisinin in an artemisinin-based therapy. Piperaquine appears to be well tolerated, to have minimal problems with resistance (despite prior reports of resistance in China), and in combination with dihydroartemisinin to offer a highly efficacious therapy for falciparum malaria.

3. Mefloquine—Mefloquine is effective therapy for many chloroquine-resistant strains of *P falciparum* and against other malarial species. Although toxicity is a concern, mefloquine is also a recommended chemoprophylactic drug. Resistance to mefloquine has been reported sporadically from many areas, but it appears to be uncommon except in regions of Southeast Asia with high rates of multi-drug resistance (especially border areas of Thailand).

For treatment of uncomplicated malaria, mefloquine is rapidly active and can be administered as a single dose or in two doses over 1 day. It is used in combination with artesunate in Southeast Asia, where resistance to mefloquine has been seen but the combination remains effective in most areas. It should be taken with meals and swallowed with a large amount of water. Mefloquine is recommended by the CDC for chemoprophylaxis in all malarious areas except those with no chloroquine resistance (where chloroquine is preferred) and some rural areas of Southeast Asia with a high prevalence of mefloquine resistance. Eradication of *P vivax* and *P ovale* requires a course of primaquine.

Adverse effects with weekly dosing of mefloquine for chemoprophylaxis include nausea, vomiting, dizziness, sleep and behavioral disturbances, epigastric pain, diarrhea, abdominal pain, headache, rash and, uncommonly, seizures and psychosis. Mefloquine should be avoided in persons with histories of psychiatric disease or seizures.

Adverse effects are more common (up to 50% of treatments) with the higher dosages of mefloquine required for treatment. These effects may be lessened by splitting administration into two doses separated by 6–8 hours. Serious neuropsychiatric toxicities (depression, confusion, acute psychosis, or seizures) have been reported in < 1 in 1000 treatments, but some authorities believe that these are more common. Mefloquine can also alter cardiac conduction, and so it should not be coadministered with quinine, quinidine, or halofantrine, and caution is required if these drugs are used to treat malaria after mefloquine chemoprophylaxis. Mefloquine is generally considered safe in young children and pregnant women.

4. Quinine and quinidine—Quinine dihydrochloride and quinidine gluconate remain first-line therapies for

falciparum malaria, especially severe disease, although toxicity concerns complicate therapy (Table 35–4). Quinine acts rapidly against the four species of human malaria parasites. Quinidine, the dextrorotatory stereoisomer of quinine, is at least as effective as quinine in the treatment of severe falciparum malaria.

Resistance of *P falciparum* to quinine is common in some areas of Southeast Asia, where the drug may fail if used alone to treat falciparum malaria. However, quinine still provides at least a partial therapeutic effect in most patients.

Quinine and quinidine are effective treatments for severe falciparum malaria, although intravenous artesunate is becoming the standard of care (see Artemisinins section below). Quinine can be administered slowly intravenously or, in a dilute solution, intramuscularly, but parenteral quinine is not available in the United States, where quinidine is used. The drugs can be administered in divided doses or by continuous intravenous infusion; treatment should begin with a loading dose to rapidly achieve effective plasma concentrations. Intravenous quinine and quinidine should be administered with cardiac monitoring because of their cardiac toxicity and the relative unpredictability of their pharmacokinetics. Therapy should be changed to oral quinine or another agent as soon as the patient has improved and can tolerate oral medications.

In areas without newer combination regimens, oral quinine sulfate is an alternative first-line therapy for uncomplicated falciparum malaria, although poor tolerance may limit compliance. Quinine is commonly used with a second drug (most often doxycycline) to shorten the duration of use (usually to 3 days) and to limit toxicity. Therapeutic dosages of quinine and quinidine commonly cause tinnitus, headache, nausea, dizziness, flushing, and visual disturbances. Hypersensitivity reactions include rash, urticaria, angioedema, and bronchospasm. Hematologic abnormalities include hemolysis (especially with G6PD deficiency), leukopenia, agranulocytosis, and thrombocytopenia. Therapeutic doses may cause hypoglycemia through stimulation of insulin release; this is a particular problem in severe infections and in pregnant patients, who have increased sensitivity to insulin. Overly rapid infusions can cause severe hypotension. ECG abnormalities (QT prolongation) are fairly common, but dangerous arrhythmias are uncommon when the drugs are administered appropriately. Blackwater fever is a rare severe illness, probably due to hypersensitivity, that includes marked hemolysis and hemoglobinuria in the setting of quinine therapy for malaria. Quinine should not be given concurrently with mefloquine and should be used with caution in a patient who has previously received mefloquine. Absorption may be blocked by aluminum-containing antacids. Quinine can raise plasma levels of warfarin and digoxin. Dosage must be reduced in renal insufficiency.

5. Primaquine—Primaquine phosphate, a synthetic 8-aminoquinoline, is the drug of choice for the eradication of dormant liver forms of *P vivax* and *P ovale* (Table 35–4). It is well absorbed orally, reaching peak plasma levels in 1–2 hours, with a plasma half-life of 3–8 hours. Primaquine is active against hepatic stages of all human malaria

parasites. This action is optimal soon after therapy with chloroquine or quinine. Primaquine also acts against erythrocytic stage parasites, although this activity is too weak for the treatment of active disease, and against gametocytes.

For *P vivax* and *P ovale* infections, chloroquine is used to eradicate erythrocytic forms, and if the G6PD level is normal, a 14-day course of primaquine is initiated to eradicate liver hypnozoites and prevent a subsequent relapse. Some strains of *P vivax*, particularly in New Guinea and Southeast Asia, are relatively resistant to primaquine. For this reason, the CDC doubled the recommended dosage for primaquine to eradicate liver forms (to 52.6 mg primaquine phosphate, or 30 mg base/day) in 2005, but it remains possible that liver forms may not be eradicated by a single treatment.

Standard chemoprophylaxis does not prevent a relapse of *P vivax* or *P ovale* infections, since liver hypnozoites are not eradicated by chloroquine or other standard treatments. To diminish the likelihood of relapse, some authorities advocate the use of a treatment course of primaquine after the completion of travel to an endemic area. Primaquine can also be used for chemoprophylaxis to prevent *P falciparum* and *P vivax* infection in persons with normal levels of G6PD.

Primaquine in recommended doses is generally well tolerated. It infrequently causes nausea, epigastric pain, abdominal cramps, and headache, especially when taken on an empty stomach. Rare adverse effects include leukopenia, agranulocytosis, leukocytosis, and cardiac arrhythmias. Standard doses of primaquine may cause hemolysis or methemoglobinemia (manifested by cyanosis), especially in persons with G6PD deficiency or other hereditary metabolic defects. Patients should be tested for G6PD deficiency before primaquine is prescribed. When a patient is deficient in G6PD, treatment strategies may consist of (1) withholding therapy and treating subsequent relapses, if they occur, with chloroquine; (2) treating patients with standard dosing, paying close attention to their hematologic status; or (3) treating with weekly primaquine (45 mg base) for 8 weeks. G6PD-deficient individuals of Mediterranean and Asian ancestry are most likely to have severe deficiency, while those of African ancestry usually have a milder biochemical defect. This difference can be taken into consideration in choosing a treatment strategy. Primaquine should be discontinued if there is evidence of hemolysis or anemia and should be avoided in pregnancy.

6. Inhibitors of folate synthesis—Inhibitors of two parasite enzymes involved in folate metabolism, dihydrofolate reductase (DHFR) and dihydropteroate synthase (DHPS), are used, generally in combination regimens, for the treatment and prevention of malaria, although the drugs are rather slow acting and now limited by resistance.

Fansidar is a fixed combination of sulfadoxine (500 mg) and pyrimethamine (25 mg). The long half-lives of its components allow weekly dosing for chemoprophylaxis, but due to rare serious side effects with long-term dosing, this drug is no longer recommended for this purpose. Sulfadoxine-pyrimethamine became a common back-up drug after chloroquine in Africa, and replaced chloroquine as the

first-line therapy in a number of countries. Advantages of sulfadoxine-pyrimethamine include ease of administration (a single oral dose) and low cost. However, resistance to sulfadoxine-pyrimethamine, is now a major problem. In addition, it is not reliably effective in *P vivax* infections, and its usefulness against *P ovale* and *P malariae* infections has not been adequately studied, limiting its utility outside of Africa.

Sulfadoxine-pyrimethamine is a component of two combination regimens for uncomplicated malaria recommended by the WHO (Table 35–3). Sulfadoxine-pyrimethamine plus artesunate has shown efficacy in some areas but is best replaced by more effective combination regimens in most areas. Amodiaquine plus sulfadoxine-pyrimethamine has shown surprisingly good efficacy in many parts of Africa, despite increasing resistance to both components, and probably offers the most practical treatment for uncomplicated malaria in many endemic areas without access to artemisinin-based therapies. Another antifolate combination, trimethoprim-sulfamethoxazole, is widely used to prevent coinfections in patients infected with HIV, and it offers partial protection against malaria. Malarone, a combination of proguanil with atovaquone, is discussed below.

7. Artemisinins—Artemisinin (qinghaosu) is a sesquiterpene lactone endoperoxide, the active component of an herbal medicine that has been used for various indications in China for over 2000 years. Analogs have been synthesized to increase solubility and improve antimalarial efficacy. The most important of these analogs are artesunate, artemether, and dihydroartemisinin. The WHO is encouraging availability of oral artemisinins only in coformulated combination regimens.

Artemisinins act very rapidly against all erythrocytic-stage human malaria parasites. Artemisinin resistance is not yet an important clinical problem, but *P falciparum* isolates with diminished in vitro susceptibility to artemether have been described, and delayed clearance of parasites has been seen after treatment with artesunate in parts of Southeast Asia.

Artemisinins are playing an increasing role in the treatment of malaria, including multidrug-resistant *P falciparum* malaria. However, due to their short plasma half-lives, recrudescence rates are unacceptably high after short-course therapy, and they are best used in conjunction with another agent. Also because of their short-half lives, they are not useful in chemoprophylaxis.

Artemisinins should be used for uncomplicated malaria in combination regimens including a longer-acting partner drug, known as artemisinin-based combination therapy. Artesunate plus mefloquine has demonstrated excellent efficacy against multidrug resistant parasites in Thailand, but this regimen is too expensive for widespread use in Africa and other areas. The artemisinin-based combination regimens that are currently most advocated in Africa are artesunate plus amodiaquine (ASAQ) and artemether plus lumefantrine (Coartem), each of which is available as a coformulated product and is the recommended therapy for uncomplicated malaria in a number of countries, although implementation has been slow in some areas. A third available coformulated regimen that has performed well in

clinical trials, and was added to the list of WHO-recommended regimens for uncomplicated falciparum malaria in 2010, is dihydroartemisinin plus piperaquine; this is the first-line regimen in some countries in Southeast Asia.

In studies of severe malaria, intramuscular artemether was at least as effective as intramuscular quinine, and intravenous artesunate was superior to intravenous quinine in terms of efficacy and tolerability. Thus, the standard of care for severe malaria is intravenous artesunate, when it is available, although parenteral quinine and quinidine remain acceptable alternatives. Artesunate and artemether have also been effective in the treatment of severe malaria when administered rectally, offering a valuable treatment modality when parenteral therapy is not available.

Artemisinins are very well tolerated. The most commonly reported adverse effects have been nausea, vomiting, and diarrhea, which may often be due to acute malaria, rather than drug toxicity. Neutropenia, anemia, hemolysis, and elevated levels of liver enzymes have been noted rarely. Artemisinins are teratogenic in animals, and they should be avoided in the first trimester of pregnancy for uncomplicated malaria. However, for severe malaria, for which all available treatments entail some risk, the WHO endorses the use of intravenous artesunate or quinine while additional data are gathered on artesunate safety.

8. Atovaquone plus proguanil (Malarone)—Atovaquone, a hydroxynaphthoquinone, is not effective when used alone, due to rapid development of drug resistance. However, Malarone, a fixed combination of atovaquone (250 mg) and the antifolate proguanil (100 mg), is highly effective for both the treatment and chemoprophylaxis of falciparum malaria, and it is approved for both indications in the United States (Table 35–4). It also appears to be active against other species of malaria parasites. Unlike most other antimalarials, Malarone provides activity against both erythrocytic and hepatic stage parasites.

For treatment, Malarone is given at an adult dose of four tablets daily for 3 days. For chemoprophylaxis, Malarone must be taken daily. It has an advantage over mefloquine and doxycycline in requiring shorter durations of treatment before and after the period at risk for malaria transmission, due to activity against liver-stage parasites. It should be taken with food.

Malarone is generally well tolerated. Adverse effects include abdominal pain, nausea, vomiting, diarrhea, headache, and rash, and these are more common with the higher dose required for treatment. Reversible elevations in liver enzymes have been reported. The safety of atovaquone in pregnancy is unknown.

9. Antibiotics—A number of antibacterials in addition to the folate antagonists and sulfonamides are slow-acting antimalarials. None of the antibiotics should be used as single agents for the treatment of malaria due to their slow rate of action.

Tetracycline and doxycycline are active against asexual erythrocytic forms of all human malaria parasites. Doxycycline is commonly used in the treatment of falciparum malaria in conjunction with quinidine or quinine,

allowing a shorter and better-tolerated course of those drugs (Table 35–4). Doxycycline is also a standard chemoprophylactic drug, especially for use in areas of Southeast Asia with high rates of resistance to other antimalarials, including mefloquine. Doxycycline side effects include gastrointestinal symptoms, candidal vaginitis, and photosensitivity. The drug should be taken while upright with a large amount of water to avoid esophageal irritation. Clindamycin can be used in conjunction with quinine or quinidine in those for whom doxycycline is not recommended, such as children and pregnant women (Table 35–4). The most common toxicities with clindamycin are gastrointestinal. Azithromycin also has antimalarial activity and is now under study for treatment and chemoprophylaxis.

10. Halofantrine and lumefantrine—Halofantrine hydrochloride, a phenanthrene-methanol related to quinine, is effective against erythrocytic stages of all four human malaria species. Because of toxicity concerns, it should not be taken with meals. Halofantrine is rapidly effective against most chloroquine-resistant strains of *P. falciparum*, but its use is limited by irregular absorption and cardiac toxicity. As treatment for falciparum malaria, halofantrine is given orally in three 500-mg doses at 6-hour intervals, and this course is repeated in 1 week for nonimmune individuals. Halofantrine is generally well tolerated. The most common adverse effects are abdominal pain, diarrhea, vomiting, cough, rash, headache, pruritus, and elevated liver enzymes. Of greater concern, the drug alters cardiac conduction, with dose-related prolongation of QT and PR intervals. This effect is worsened by prior mefloquine therapy. Rare instances of dangerous arrhythmias and some deaths have been reported. The drug is contraindicated in patients with cardiac conduction defects and should not be used in those who have recently taken mefloquine. It is also contraindicated in pregnancy.

Lumefantrine, an aryl alcohol related to halofantrine, is available only as a fixed-dose combination with artemether (Coartem or Riamet). As with halofantrine, oral absorption is highly variable. It is improved when the drug is taken with food. Use of Coartem with a fatty meal is recommended. Coartem is highly effective for the treatment of falciparum malaria, but it is fairly expensive and requires twice-daily dosing. Despite these limitations, due to its reliable efficacy against falciparum malaria, Coartem is the first-line therapy for malaria in many malarious countries. Coartem is well tolerated; side effects include headache, dizziness, loss of appetite, gastrointestinal symptoms, and palpitations. Importantly, Coartem does not appear to cause the cardiac toxicity seen with halofantrine.

► Prevention

Malaria is transmitted by night-biting anopheline mosquitoes. Bed nets, in particular nets treated with permethrin insecticides, are heavily promoted as inexpensive means of antimalarial protection, and improvement in mortality rates has been demonstrated. Extensive efforts are also underway to develop a malaria vaccine, and partial

protection of African children has been demonstrated, but a vaccine offering complete protection is not anticipated in the near future. The availability of improved modalities to control mosquito vectors and treat and prevent malaria has heightened enthusiasm for malaria elimination, and there have been important gains in some areas; however, control remains very challenging in highly endemic regions, and elimination is not expected in these areas in the foreseeable future.

When travelers from nonendemic to endemic countries are counseled on the prevention of malaria, it is imperative to emphasize measures to prevent mosquito bites (insect repellents, insecticides, and bed nets), since parasites are increasingly resistant to multiple drugs and no chemoprophylactic regimen is fully protective. Chemoprophylaxis is recommended for all travelers from nonendemic regions to endemic areas, although risks vary greatly for different locations, and some tropical areas entail no risk; specific recommendations for travel to different locales are available from the CDC (www.cdc.gov). Current recommendations from the CDC include the use of chloroquine for chemoprophylaxis in the few areas with only chloroquine-sensitive malaria parasites (principally the Caribbean and Central America west of the Panama Canal), mefloquine or Malarone for most other malarious areas, and doxycycline for areas with a high prevalence of multidrug-resistant *falciparum* malaria (principally of Southeast Asia) (Table 35–5). Recommendations should be checked regularly (Phone: 877-FYI-TRIP; Internet: <http://wwwnc.cdc.gov/travel/>) because they may change in response to changing resistance patterns and increasing experience with new drugs. In some circumstances, it may be appropriate for travelers to not use chemoprophylaxis but to carry supplies of drugs with them in case a febrile illness develops and medical attention is unavailable. Regimens for self-treatment include artemisinin-based

combinations, Malarone, and quinine. Most authorities do not recommend routine terminal chemoprophylaxis with primaquine to eradicate dormant hepatic stages of *P vivax* and *P ovale* after travel, but this may be appropriate in some circumstances, especially for travelers with major exposure to these parasites.

Regular chemoprophylaxis is not a standard management practice in developing world populations due to the expense and potential toxicities of long-term therapy. However, there is increasing interest in intermittent preventive therapy, whereby at-risk populations, in particular pregnant women and children, receive antimalarial therapy at set intervals. This strategy may decrease the incidence of malaria while allowing antimalarial immunity to develop. Intermittent preventive therapy has been best studied with sulfadoxine-pyrimethamine, a long-acting drug that is administered in a single dose. During pregnancy, sulfadoxine-pyrimethamine provided once during both the second and third trimesters has improved pregnancy outcomes. In infants, therapy with sulfadoxine-pyrimethamine following standard immunization schedules has offered benefits. With increasing resistance, it is not clear if sulfadoxine-pyrimethamine will retain prophylactic efficacy or if other drugs with shorter half-lives will be effective.

► Prognosis

When treated appropriately, uncomplicated malaria generally responds well, with resolution of fevers within 1–2 days and a mortality of about 0.1%. Severe malaria can commonly progress to death, but many children respond well to therapy. In the developed world, mortality from malaria is mostly in adults, and often follows extended illnesses and secondary complications long after eradication of the malarial infection. Pregnant women are at particular risk

Table 35–5. Drugs for the prevention of malaria in travelers.¹

Drug	Use ²	Adult Dosage (all oral) ³
Chloroquine	Areas without resistant <i>Plasmodium falciparum</i>	500 mg weekly
Malarone	Areas with multidrug-resistant <i>P falciparum</i>	1 tablet (250 mg atovaquone/100 mg proguanil) daily
Mefloquine	Areas with chloroquine-resistant <i>P falciparum</i>	250 mg weekly
Doxycycline	Areas with multidrug-resistant <i>P falciparum</i>	100 mg daily
Primaquine ⁴	Terminal prophylaxis of <i>Plasmodium vivax</i> and <i>Plasmodium ovale</i> infections; alternative for <i>P falciparum</i> prophylaxis	30 mg base daily for 14 days after travel

¹Recommendations may change, as resistance to all available drugs is increasing. See text for additional information on toxicities and cautions. For additional details and pediatric dosing, see Centers for Disease Control and Prevention's guidelines (phone: 800-CDC-INFO; <http://wwwnc.cdc.gov/travel/>). Travelers to remote areas should consider carrying effective therapy (see text) for use if a febrile illness develops, and they cannot reach medical attention quickly.

²Areas without known chloroquine-resistant *P falciparum* are Central America west of the Panama Canal, Haiti, Dominican Republic, Egypt, and most malarious countries of the Middle East. Malarone or mefloquine is currently recommended for other malarious areas except for border areas of Thailand, where doxycycline is recommended.

³For drugs other than primaquine, begin 1–2 weeks before departure (except 2 days before for doxycycline and Malarone) and continue for 4 weeks after leaving the endemic area (except 1 week for Malarone). All dosages refer to salts unless otherwise indicated.

⁴Screen for glucose-6-phosphate dehydrogenase deficiency before using primaquine.

Reproduced, with permission, from Katzung BG. *Basic & Clinical Pharmacology*. 11th edition. McGraw-Hill, 2009.

during their first pregnancy, probably due to the selection of *P falciparum* strains that preferentially sequester in the placenta; multiparous women are more likely to have antibodies against these strains and thus avoid severe disease. Malaria in pregnancy also increases the likelihood of poor pregnancy outcomes, with increased prematurity, low birth weight, and mortality.

► When to Refer

Referral to an expert on infectious diseases or travel medicine is important with all cases of malaria in the United States, and in particular for falciparum malaria, as management can be complex, but referral should not lead to a delay in initial diagnosis and therapy, since delays in therapy can lead to severe illness or death.

► When to Admit

- Non-falciparum malaria generally does not cause severe disease and responds well to therapy, and so admission is only warranted if a patient presents with specific problems that require hospital management.
- Patients with falciparum malaria are generally admitted because the disease can progress rapidly to severe illness; exceptions may be made with individuals who are from malaria-endemic areas, and thus expected to have a degree of immunity, who are without evidence of severe disease, and who are judged able to return promptly for medical attention if their disease progresses.

Agnandji ST et al. First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children. *N Engl J Med*. 2011 Nov 17;365(20):1863–75. [PMID: 22007715]

Baird JK. Resistance to therapies for infection by *Plasmodium vivax*. *Clin Microbiol Rev*. 2009 Jul;22(3):508–34. [PMID: 19597012]

Dondorp AM et al; AQUAMAT Group. Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trial. *Lancet*. 2010 Nov 13;376(9753):1647–57. [PMID: 21062666]

Dondorp AM et al. Artemisinin resistance in *Plasmodium falciparum* malaria. *N Engl J Med*. 2009 Jul 30;361(5):455–67. [PMID: 19641202]

Freedman DO. Clinical practice. Malaria prevention in short-term travelers. *N Engl J Med*. 2008 Aug 7;359(6):603–12. [PMID: 18687641]

Griffith KS et al. Treatment of malaria in the United States: a systematic review. *JAMA*. 2007 May 23;297(20):2264–77. [PMID: 17519416]

Ngasala BE et al. Efficacy and effectiveness of artemether-lumefantrine after initial and repeated treatment in children < 5 years of age with acute uncomplicated *Plasmodium falciparum* malaria in rural Tanzania: a randomized trial. *Clin Infect Dis*. 2011 Apr 1;52(7):873–82. [PMID: 21427394]

Nosten F et al. Artemisinin-based combination treatment of falciparum malaria. *Am J Trop Med Hyg*. 2007 Dec;77(6 Suppl):181–92. [PMID: 18165491]

O'Meara WP et al. Changes in the burden of malaria in sub-Saharan Africa. *Lancet Infect Dis*. 2010 Aug;10(8):545–55. [PMID: 20637696]

Rosenthal PJ. Artesunate for the treatment of severe falciparum malaria. *N Engl J Med*. 2008 Apr 24;358(17):1829–36. [PMID: 18434652]

World Health Organization. *Guidelines for the treatment of malaria*, 2nd edition. Geneva, Switzerland, 2010. <http://www.who.int/malaria/publications/atoz/9789241547925/en/index.html>

BABESIOSIS



ESSENTIALS OF DIAGNOSIS

- History of tick bite or exposure to ticks.
- Fever, flu-like symptoms, anemia.
- Intraerythrocytic parasites on Giemsa-stained blood smears.
- Positive serologic tests.


► General Considerations

Babesiosis is an uncommon intraerythrocytic infection caused mainly by two *Babesia* species and transmitted by *Ixodes* ticks. In Europe, where only a few dozen cases of babesiosis have been reported, infection is caused by *Babesia divergens*, which also infects cattle. In the United States, hundreds of cases of babesiosis have been reported, and infection is caused by *Babesia microti*, which also infects wild mammals. Most babesiosis in the United States occurs in the coastal northeast, with some cases also in the upper midwest, following the geographic range of the vector *Ixodes scapularis*, and Lyme disease and anaplasmosis, which are spread by the same vector. The incidence of the disease appears to be increasing in some areas. Rare episodes of illnesses caused by *B microti*, *B divergens*, and other *Babesia*-like organisms have been reported from other areas. Babesiosis can also be transmitted by blood transfusion.

► Clinical Findings

A. Symptoms and Signs

With *B microti* infections, symptoms appear 1 to several weeks after a tick bite; parasitemia is evident after 2–4 weeks. Patients usually do not recall the tick bite. The typical flu-like illness develops gradually and is characterized by fever, fatigue, headache, arthralgia, and myalgia. Other findings may include nausea, vomiting, abdominal pain, sore throat, depression, emotional lability, anemia, thrombocytopenia, and splenomegaly. Parasitemia may continue for months to years, with or without symptoms, and the disease is usually self-limited. Severe complications are most likely to occur in older persons or in those who have had splenectomy. Serious complications include respiratory failure, hemolytic anemia, disseminated intravascular coagulation, congestive heart failure, and acute kidney injury. In a study of hospitalized patients, the mortality rate



▲ **Figure 35–6.** Blood smear showing *Babesia* spp. rings with basophilic stippling. (Courtesy of Dr. Mae Melvin, Public Health Image Library, CDC.)

was 6.5%. Most recognized *B divergens* infections in Europe have been in patients who have had splenectomy. These infections progress rapidly with high fever, severe hemolytic anemia, jaundice, hemoglobinuria, and acute kidney injury, with death rates over 40%.

B. Laboratory Findings

Identification of the intraerythrocytic parasite on Giemsa-stained blood smears establishes the diagnosis (Figure 35–6). These can be confused with malaria parasites, but the morphology is distinctive. Repeated smears are often necessary because well under 1% of erythrocytes may be infected, especially early in infection, although parasitemias can exceed 10%. An indirect immunofluorescent antibody test for *B microti* is available from the CDC; antibody is detectable within 2–4 weeks after the onset of symptoms and persists for months. Diagnosis can also be made by PCR or by inoculation of hamsters or gerbils.

▶ Treatment

Most patients have a mild illness and recover without therapy. Standard therapy is a 7-day course of quinine (650 mg orally three times daily) plus clindamycin (600 mg orally three times daily). An alternative is a 7-day course of atovaquone (750 mg orally every 12 hours) plus azithromycin (600 mg orally once daily). Exchange transfusion has been used successfully in severely ill asplenic patients and those with parasitemia > 10%.

Herwaldt BL et al. Transfusion-associated babesiosis in the United States: a description of cases. *Ann Intern Med.* 2011 Oct 18;155(8):509–19. [PMID: 21893613]

Joseph JT et al. Babesiosis in Lower Hudson Valley, New York, USA. *Emerg Infect Dis.* 2011 May;17(5):843–7. [PMID: 21529393]

Vannier E et al. Human babesiosis. *Infect Dis Clin North Am.* 2008 Sep;22(3):469–88. [PMID: 18755385]

TOXOPLASMOSIS



ESSENTIALS OF DIAGNOSIS

- ▶ Infection confirmed by isolation of *Toxoplasma gondii* or identification of tachyzoites in tissue or body fluids.

Primary infection

- ▶ Fever, malaise, headache, sore throat.
- ▶ Lymphadenopathy.
- ▶ Positive IgG and IgM serologic tests.

Congenital infection

- ▶ Follows acute infection of seronegative mothers and leads to CNS abnormalities and retinochoroiditis.

Infection in immunocompromised persons

- ▶ Reactivation leads to encephalitis, retinochoroiditis, pneumonitis, myocarditis.
- ▶ Positive IgG but negative IgM serologic tests.

▶ General Considerations

T gondii, an obligate intracellular protozoan, is found worldwide in humans and in many species of mammals and birds. The definitive hosts are cats. Humans are infected after ingestion of cysts in raw or undercooked meat, ingestion of oocysts in food or water contaminated by cats, transplacental transmission of trophozoites or, rarely, direct inoculation of trophozoites via blood transfusion or organ transplantation. *Toxoplasma* seroprevalence varies widely. It has decreased in the United States to about 20–30%, but it is much higher in other countries in both the developed and developing worlds, where it may exceed 80%.

▶ Clinical Findings

A. Symptoms and Signs

The clinical manifestations of toxoplasmosis may be grouped into four syndromes.

1. Primary infection in the immunocompetent person—

After ingestion, *T gondii* infection progresses from the gastrointestinal tract to lymphatics, and then dissemination. Most acute infections are asymptomatic. About 10–20% are symptomatic after an incubation period of 1–2 weeks. Acute infections in immunocompetent persons typically present as mild, febrile illnesses that resemble infectious mononucleosis. Nontender cervical or diffuse lymphadenopathy may persist for weeks to months. Systemic findings may include fever, malaise, headache, sore throat, rash, myalgias, hepatosplenomegaly, and atypical lymphocytosis. Rare severe manifestations are pneumonitis, meningoencephalitis, hepatitis, myocarditis, polymyositis, and retinochoroiditis. Symptoms may fluctuate, but most patients recover spontaneously within at most a few months.

2. Congenital infection—Congenital transmission occurs as a result of infection, which may be symptomatic or asymptomatic, in a nonimmune woman during pregnancy. Fetal infection follows maternal infection in 30–50% of cases, but this risk varies by trimester: 10–25% during the first, 30–50% during the second, and 60% or higher during the third trimester. In the United States, an estimated 400 to 4000 congenital infections occur yearly. While the risk of fetal infection increases, the risk of severe fetal disease decreases over the course of pregnancy. Early fetal infections commonly lead to spontaneous abortion, stillbirths, or severe neonatal disease, including neurologic manifestations. Neurologic findings can include seizures, psychomotor retardation, deafness, and hydrocephalus. Retinoblastoma and other sight-threatening eye lesions may develop. Systemic findings include fever or hypothermia, jaundice, vomiting, diarrhea, hepatosplenomegaly, pneumonitis, myocarditis, and rash. Infections later in pregnancy less commonly lead to major fetal problems. Most infants appear normal at birth, but they may have subtle abnormalities and progress to symptoms and signs of congenital toxoplasmosis later in life. Hepatosplenomegaly and lymphadenopathy may develop in the first few months of life; CNS and eye disease often present later. The most common late presentation of congenital toxoplasmosis is retinoblastoma.

3. Retinoblastoma—This manifestation of congenital toxoplasmosis presents weeks to years after congenital infection, commonly in teenagers or young adults. Retinoblastoma also is seen in persons who acquire infection early in life, and these patients more often present with unilateral disease. Uveitis is also seen. Disease presents with pain, photophobia, and visual changes, usually without systemic symptoms. Signs and symptoms eventually improve, but visual defects may persist. Rarely, progression may result in glaucoma and blindness.

4. Disease in the immunocompromised person—Reactivated toxoplasmosis occurs in patients with AIDS, cancer, or those given immunosuppressive drugs. In patients with advanced AIDS, the most common manifestation is encephalitis, with multiple necrotizing brain lesions. The encephalitis usually presents subacutely, with fever, headache, altered mental status, focal neurologic findings, and other evidence of brain lesions. Less common manifestations of toxoplasmosis in patients with AIDS are chorioretinitis and pneumonitis. Chorioretinitis presents with ocular pain and alterations in vision. Pneumonitis presents with fever, cough, and dyspnea. Toxoplasmosis can develop in seronegative recipients of solid organ or bone marrow transplants due to reactivation or, more rarely, transmission of infection. Reactivation also can occur in those with hematologic malignancies or treated with immunosuppressive drugs. With primary or reactivated disease in those with immunodeficiency due to malignancy or immunosuppressive drugs, toxoplasmosis is similar to that in individuals with AIDS, but pneumonitis and myocarditis are more common.

B. Diagnostic Testing

1. Identification of parasites—Organisms can be seen in tissue or body fluids, although they may be difficult to identify; special staining techniques can facilitate identification. The demonstration of tachyzoites indicates acute infection; cysts may represent either acute or chronic infection. With lymphadenopathy due to toxoplasmosis, examination of lymph nodes usually does not show organisms. Parasite identification can also be made by inoculation of tissue culture or mice. PCR can be used for sensitive identification of organisms in amniotic fluid, blood, CSF, aqueous humor, and bronchoalveolar lavage fluid.

2. Serologic diagnosis—Multiple serologic methods are used, including the Sabin-Feldman dye test, enzyme-linked immunosorbent assay (ELISA), indirect fluorescent antibody test, and agglutination tests. IgG antibodies are seen within 1–2 weeks of infection, and usually persist for life. IgM antibodies peak earlier than IgG and decline more rapidly, although they may persist for years. In immunocompromised individuals in whom reactivation is suspected, a positive IgG assay indicates distant infection, and thus the potential for reactivated disease; a negative IgG argues strongly against reactivation toxoplasmosis. With reactivation in immunocompromised persons, IgM tests are generally negative.

3. During pregnancy and in newborns—Conversion from a negative to positive serologic test or rising titers are suggestive of acute infection, but tests are not routinely performed during pregnancy. When pregnant women are screened, negative IgG and IgM assays exclude active infection, but indicate the risk of infection during the pregnancy. The pattern of positive IgG with negative IgM is highly suggestive of chronic infection, with no risk of congenital disease unless the mother is severely immunocompromised. A positive IgM test is concerning for new infection because of the risk of congenital disease. Confirmatory testing should be performed before consideration of treatment or possible termination of pregnancy due to the limitations of available tests. Tests of the avidity of anti-IgG antibodies can be helpful, but a battery of tests is needed for confirmation of acute infection during pregnancy. When acute infection during pregnancy is suspected, PCR of amniotic fluid offers a sensitive assessment for congenital disease; this test should optimally be performed at 18 weeks of gestation. In newborns, positive IgM or IgA antibody tests are indicative of congenital infection, although the diagnosis is not ruled out by a negative test. Positive IgG assays may represent transfer of maternal antibodies without infection of the infant. Organisms may be identified by PCR; smears; or culture of blood, CSF, or tissue.

4. In immunocompetent individuals—Individuals with a suggestive clinical syndrome should be tested for IgG and IgM antibodies. Seroconversion, a 16-fold rise in antibody titer, or an IgM titer > 1:64 are suggestive of acute infection, although false-positive results may occur. Acute infection can also be diagnosed by detection of tachyzoites in tissue, culture of organisms, or PCR of blood or body

fluids. Histologic evaluation of lymph nodes can show characteristic morphology, with or without organisms.

5. In immunodeficient individuals—A presentation consistent with toxoplasmic encephalitis warrants imaging of the brain. CT and MRI scans typically show multiple ring-enhancing cerebral lesions, most commonly involving the corticomedullary junction and basal ganglia. MRI is the more sensitive imaging modality. In AIDS patients with a positive IgG serologic test and no recent antitoxoplasma or antiviral therapy, the predictive value of a typical imaging study is about 80%. The other common diagnosis in this setting is CNS lymphoma, which more typically causes a single brain lesion. The differential diagnosis also includes tuberculoma, bacterial brain abscess, fungal abscess, and carcinoma. Diagnosis of CNS toxoplasmosis is most typically made after a therapeutic trial, with clinical and radiologic improvement expected within 2–3 weeks. Definitive diagnosis requires brain biopsy and search for organisms and typical histology. In retinochoroiditis, funduscopic examination shows vitreous inflammatory reaction, white retinal lesions, and pigmented scars. Diagnosis of other clinical entities in immunocompromised individuals is generally based on histology.

► Treatment

A. Approach to Treatment

Therapy is generally not necessary in immunocompetent persons, since primary illness is self-limited. However, for severe, persistent, or visceral disease, treatment for 2–4 weeks may be considered. Treatment is appropriate for primary infection during pregnancy because the risk of fetal transmission or the severity of congenital disease may be reduced. For retinochoroiditis, most episodes are self-limited, and opinions vary on indications for treatment. Treatment is often advocated for episodes with decreases in visual acuity, multiple or large lesions, macular lesions, significant inflammation, or persistence for over a month. Immunocompromised patients with active infection must be treated. For those with transient immunodeficiency, therapy can be continued for 4–6 weeks after cessation of symptoms. For those with persistent immunodeficiency, such as AIDS patients, full therapy for 4–6 weeks is followed by maintenance therapy with lower doses of drugs. Immunodeficient patients who are asymptomatic but have a positive IgG serologic test should receive long-term chemoprophylaxis.

B. Medications

Drugs for toxoplasmosis are active only against tachyzoites, so they do not eradicate infection. Standard therapy is the combination of pyrimethamine (200 mg loading dose, then 50–75 mg [1 mg/kg] orally once daily) plus sulfadiazine (1–1.5 g orally four times daily), with folinic acid (10–20 mg orally once daily) to prevent bone marrow suppression. Patients should be screened for a history of sulfonamide sensitivity (skin rashes, gastrointestinal symptoms, hepatotoxicity). To prevent crystal-induced nephrotoxicity, good urinary output should be maintained. Pyrimethamine side effects include headache and gastrointestinal symptoms. Even with

folinic acid therapy, bone marrow suppression may occur; platelet and white blood cell counts should be monitored at least weekly. A first-line alternative to sulfadiazine is clindamycin (600 mg orally four times daily). Other possible alternatives are trimethoprim-sulfamethoxazole or combining pyrimethamine with atovaquone, clarithromycin, azithromycin, or dapsone. Pyrimethamine is not used during the first trimester of pregnancy due to its teratogenicity. Standard therapy for the treatment of acute toxoplasmosis during pregnancy is with spiramycin (1 g orally three times daily until delivery). This therapy is used only to decrease the risk of fetal infection; it reduces the frequency of transmission to the fetus by about 60%. Spiramycin does not cross the placenta, so when fetal infection is documented or for acute infections late in pregnancy (which commonly lead to fetal transmission) treatment with combination regimens as described above is indicated.

► Prevention

Prevention of primary infection centers on avoidance of undercooked meat or contact with material contaminated by cat feces, particularly for seronegative pregnant women and immunocompromised persons. For meat, irradiation, cooking to 66°C, or freezing to –20°C kills tissue cysts. Thorough cleaning of hands and surfaces is needed after contact with raw meat or areas contaminated by cats. Oocysts passed in cat feces can remain infective for a year or more, but fresh oocysts are not infective for 48 hours. For best protection, litter boxes should be changed daily and soaked in boiling water for 5 minutes. In addition, gloves should be worn when gardening, fruits and vegetables should be thoroughly washed, and ingestion of dried meat should be avoided.

Universal screening of pregnant women for *T gondii* antibodies is conducted in some countries but not the United States. Pregnant women should ideally have their serum examined for IgG and IgM antibody, and those with negative titers should adhere to the prevention measures described above. Seronegative women who continue to have environmental exposure should undergo repeat serologic screening several times during pregnancy.

For immunocompromised individuals, chemoprophylaxis to prevent primary or reactivated infection is warranted. For transplant recipients, pyrimethamine (25 mg daily orally for 6 weeks) has been used. For advanced AIDS patients and others, chemoprophylaxis with trimethoprim-sulfamethoxazole (one double-strength tablet daily or two tablets three times weekly), used primarily for protection against *Pneumocystis*, is also effective against *T gondii*. Alternatives are pyrimethamine plus either sulfadoxine or dapsone (various regimens). In AIDS patients, chemoprophylaxis can be discontinued if antiretroviral therapy leads to immune reconstitution.

Derouin F et al. Prevention of toxoplasmosis in transplant patients. *Clin Microbiol Infect*. 2008 Dec;14(12):1089–101. [PMID: 19018809]

Fernández-Sabé N et al. Risk factors, clinical features, and outcomes of toxoplasmosis in solid-organ transplant recipients: a matched case-control study. *Clin Infect Dis*. 2012 Feb 1;54(3):355–61. [PMID: 22075795]

Montoya JG et al. Management of *Toxoplasma gondii* infection during pregnancy. *Clin Infect Dis*. 2008 Aug 15;47(4):554–66. [PMID: 18624630]
 Montoya JG et al. Toxoplasmosis. *Lancet*. 2004 Jun 12; 363(9425):1965–76. [PMID: 15194258]

AMEBIASIS

ESSENTIALS OF DIAGNOSIS

- ▶ Organisms or antigen present in stools or abscess aspirate.
- ▶ Positive serologic tests with colitis or hepatic abscess, but these may represent prior infections.
- ▶ Mild to moderate colitis with recurrent diarrhea.
- ▶ Severe colitis including bloody diarrhea, fever, and abdominal pain, with potential progression to hemorrhage or perforation.
- ▶ Hepatic abscess with fever, hepatomegaly, and abdominal pain.

▶ General Considerations

The *Entamoeba* complex contains three morphologically identical species: *Entamoeba dispar* and *Entamoeba moshkovskii*, which are avirulent, and *Entamoeba histolytica*, which may be an avirulent intestinal commensal or lead to serious disease. Disease follows penetration of the intestinal wall, resulting in diarrhea, and with severe involvement, dysentery or extraintestinal disease, most commonly liver abscess.

E histolytica infections are present worldwide but are most prevalent in subtropical and tropical areas under conditions of crowding, poor sanitation, and poor nutrition. Of the estimated 500 million persons worldwide infected with *Entamoeba*, most are infected with *E dispar* and an estimated 10% with *E histolytica*. The prevalence of *E moshkovskii* is unknown. Mortality from invasive *E histolytica* infections is estimated at 100,000 per year.

Humans are the only established *E histolytica* host. Transmission occurs through ingestion of cysts from fecally contaminated food or water, facilitated by person-to-person spread, flies and other arthropods as mechanical vectors, and use of human excrement as fertilizer. Urban outbreaks have occurred because of common-source water contamination.

▶ Clinical Findings

A. Symptoms and Signs

1. Intestinal amebiasis—In most infected persons, the organism lives as a commensal, and the carrier is without symptoms. With symptomatic disease, diarrhea may begin within a week of infection, although an incubation period of 2–4 weeks is more common, with gradual onset of abdominal pain and diarrhea. Fever is uncommon. Periods

of remission and recurrence may last days to weeks or longer. Abdominal examination may show distention, tenderness, hyperperistalsis, and hepatomegaly. Microscopic hematochezia is common. More severe presentations include colitis and dysentery, with more extensive diarrhea (10–20 stools per day) and bloody stools. With dysentery, physical findings include high fevers, prostration, vomiting, abdominal pain and tenderness, hepatic enlargement, and hypotension. Severe presentations are more common in young children, pregnant women, those who are malnourished, and those receiving corticosteroids. Thus, in endemic regions, corticosteroids should not be started for presumed inflammatory bowel disease without first ruling out amebiasis. Fulminant amebic colitis can progress to necrotizing colitis, intestinal perforation, mucosal sloughing, and severe hemorrhage, with mortality rates over 40%. More chronic complications of intestinal amebiasis include chronic diarrhea with weight loss, which may last for months to years; bowel ulcerations; and amebic appendicitis. Localized granulomatous lesions (amebomas) can present after either dysentery or chronic intestinal infection. Clinical findings include pain, obstructive symptoms, and hemorrhage and may suggest intestinal carcinoma.

2. Extraintestinal amebiasis—The most common extraintestinal manifestation is amebic liver abscess. This can occur with colitis, but more frequently presents without history of prior intestinal symptoms. Patients present with the acute or gradual onset of abdominal pain, fever, an enlarged and tender liver, anorexia, and weight loss. Diarrhea is present in a small number of patients. Physical examination may show intercostal tenderness. Abscesses are most commonly single and in the right lobe of the liver, and they are much more common in men. Without prompt treatment, amebic abscesses may rupture into the pleural, peritoneal, or pericardial space, which is often fatal. Amebic infections may rarely occur throughout the body, including the lungs, brain, and genitourinary system.


B. Laboratory Findings

Laboratory studies with intestinal amebiasis show leukocytosis and hematochezia, with fecal leukocytes not present in all cases. With extraintestinal amebiasis, leukocytosis and elevated liver function studies are seen.

C. Diagnostic Testing

Diagnosis is by finding *E histolytica* or its antigen or by serologic tests. However, each method has limitations.

1. Intestinal amebiasis—Diagnosis is most commonly made by identifying organisms in the stool. *E histolytica* and *E dispar* cannot be distinguished, but the identification of amebic trophozoites or cysts in a symptomatic patient is highly suggestive of amebiasis. Stool evaluation for organisms is not highly sensitive (~30–50% for amebic colitis), and at least three stool specimens should be evaluated after concentration and staining. Multiple serologic assays are available; these tests are fairly sensitive, although sensitivity is lower (~70% in colitis) early in illness, and they cannot distinguish recent and old disease, as they remain positive



▲ **Figure 35-7.** Gross pathology showing intestinal ulcers due to amebiasis. (Courtesy of Dr. Mae Melvin, Public Health Image Library, CDC.)

for years after infection. A commercially available stool antigen test (TechLab II) offers improved sensitivity (> 90% for colitis); it requires fresh or frozen (not preserved) stool specimens. PCR-based tests are available but not used routinely. Colonoscopy of uncleaned bowel typically shows no specific findings in mild intestinal disease; in severe disease, ulcers may be found with intact intervening friable mucosa, resembling inflammatory bowel disease (Figure 35-7). Examination of fresh ulcer exudate for motile trophozoites and for *E histolytica* antigen may yield a diagnosis.

2. Hepatic abscess—Serologic tests for anti-amebic antibodies are almost always positive, except very early in the infection. Thus, a negative test in a suspicious case should be repeated in about a week. The TechLab II test can also be used to test serum, with good sensitivity if used before the initiation of therapy. Examination of stools for organisms or antigen is frequently negative; the antigen test is positive in ~40% of cases. As imaging studies cannot distinguish amebic and pyogenic abscesses, when a diagnosis is not available from serologic studies, percutaneous aspiration may be indicated, ideally with an image-guided needle. Aspiration typically yields brown or yellow fluid. Detection of organisms in the aspirate is uncommon, but detection of *E histolytica* antigen is very sensitive and diagnostic. The key risk of aspiration is peritoneal spillage leading to peritonitis from amebas or other (pyogenic or echinococcal) organisms.

D. Imaging

Liver abscesses can be identified by ultrasonography, CT, or MRI, typically with round or oval low-density nonhomogeneous lesions, with abrupt transition from normal liver to the lesion, and hypochoic centers. Abscesses are most commonly single, but more than one may be present. The right lobe is usually involved.

► Treatment

Treatment of amebiasis generally entails the use of metronidazole or tinidazole to eradicate tissue trophozoites and a luminal amebicide to eradicate intestinal cysts (Table 35-6).

Asymptomatic infection with *E dispar* does not require therapy. This organism cannot be differentiated morphologically from *E histolytica*, but with negative serology *E dispar* colonization is likely, and treatment is not indicated. Colonization with *E histolytica* is generally treated with a luminal agent. Effective luminal agents are diloxanide furoate (500 mg orally three times daily with meals for 10 days), iodoquinol (diiodohydroxyquin; 650 mg orally three times daily for 21 days), and paromomycin (30 mg/kg base orally, maximum 3 g, in three divided doses after meals daily for 7 days). Side effects associated with luminal agents are flatulence with diloxanide furoate, mild diarrhea with iodoquinol, and gastrointestinal symptoms with paromomycin. Relative contraindications are thyroid disease for iodoquinol and kidney disease for iodoquinol or paromomycin.

Treatment of intestinal amebiasis requires metronidazole (750 mg orally three times daily for 10 days) or tinidazole (2 g orally once daily for 3 days for mild disease and 5 days for serious disease) plus a luminal agent (Table 35-6). Metronidazole has most commonly been used in the United States, but tinidazole offers simpler dosing and less side effects. Metronidazole often induces transient nausea, vomiting, epigastric discomfort, headache, or a metallic taste. A disulfiram-like reaction may occur if alcohol is coingested. Metronidazole should be avoided in pregnant or nursing mothers if possible. The same toxicities and concerns probably apply for tinidazole, although it appears to be better tolerated. Fluid and electrolyte replacement is also important for patients with significant diarrhea. Surgical management of acute complications of intestinal amebiasis is best avoided whenever possible. Successful therapy of severe amebic colitis may be followed by postsymptomatic colitis, with continued diarrhea without persistent infection; this syndrome generally resolves in weeks to months.

Alternatives for the treatment of intestinal amebiasis are tetracycline (250–500 mg orally four times daily for 10 days) plus chloroquine (500 mg orally daily for 7 days). Emetine or dehydroemetine, which are not available in the United States, can be given subcutaneously (preferred) or intravenously in a dose of 1–1.5 mg/kg/d; the maximum daily dose is 90 mg for dehydroemetine and 65 mg for emetine). These agents are effective but cardiotoxic with a narrow therapeutic range and should be used only until severe disease is controlled. They cause nausea, vomiting, and pain at the injection site.

Amebic liver abscess is also treated with metronidazole or tinidazole plus a luminal agent (even if intestinal infection is not documented; Table 35-6). Metronidazole can be used intravenously when necessary. With failure of initial response to metronidazole or tinidazole, chloroquine, emetine or dehydroemetine may be added. Needle aspiration may be helpful for large abscesses (over 5–10 cm), in particular if the diagnosis remains uncertain, if there is an initial lack of response, or if a patient is very ill, suggesting imminent abscess rupture. With successful therapy, abscesses disappear slowly (over months).

► Prevention & Control

Prevention requires safe water supplies; sanitary disposal of human feces; adequate cooking of food; protection of food

Table 35-6. Treatment of amebiasis.¹

Clinical Setting	Drugs of Choice and Adult Dosage	Alternative Drugs and Adult Dosage
Asymptomatic intestinal infection	Luminal agent: Diloxanide furoate, ² 500 mg orally three times daily for 10 days or- Iodoquinol, 650 mg orally three times daily for 21 days or- Paromomycin, 10 mg/kg orally three times daily for 7 days	
Mild to moderate intestinal infection	Metronidazole, 750 mg orally three times daily (or 500 mg intravenously every 6 hours) for 10 days or- Tinidazole, 2 g orally daily for 3 days plus- Luminal agent (see above)	Luminal agent (see above) plus either- Tetracycline, 250 mg orally three times daily for 10 days or- Erythromycin, 500 mg orally four times daily for 10 days
Severe intestinal infection	Metronidazole, 750 mg orally three times daily (or 500 mg intravenously every 6 hours) for 10 days or- Tinidazole, 2 g orally daily for 3 days plus- Luminal agent (see above)	Luminal agent (see above) plus either- Tetracycline, 250 mg orally three times daily for 10 days or- Dehydroemetine ² or emetine, ² 1 mg/kg subcutaneously or intramuscularly for 3-5 days
Hepatic abscess, ameboma, and other extraintestinal disease	Metronidazole, 750 mg orally three times daily (or 500 mg intravenously every 6 hours) for 10 days or- Tinidazole, 2 g orally daily for 3 days plus- Luminal agent (see above)	Dehydroemetine ² or emetine, ² 1 mg/kg subcutaneously or intramuscularly for 8-10 days, followed by (liver abscess only) chloroquine, 500 mg orally twice daily for 2 days, then 500 mg daily for 21 days plus- Luminal agent (see above)

¹See text for additional details and cautions.

²Not available in the United States.

from fly contamination; handwashing; and, in endemic areas, avoidance of fruits and vegetables that cannot be cooked or peeled. Water supplies can be boiled, treated with iodine (0.5 mL tincture of iodine per liter for 20 minutes; cysts are resistant to standard concentrations of chlorine), or filtered.

Bercu TE et al. Amebic colitis: new insights into pathogenesis and treatment. *Curr Gastroenterol Rep.* 2007 Oct;9(5):429-33. [PMID: 17991346]

Fotedar R et al. Laboratory diagnostic techniques for *Entamoeba* species. *Clin Microbiol Rev.* 2007 Jul;20(3):511-32. [PMID: 17630338]

Gonzales ML et al. Antiamoebic drugs for treating amoebic colitis. *Cochrane Database Syst Rev.* 2009 Apr 15;(2):CD006085. [PMID: 19370624]

Pritt BS et al. Amebiasis. *Mayo Clin Proc.* 2008 Oct;83(10):1154-9. [PMID: 18828976]

The free-living amebas that cause disease in humans are of the genera *Acanthamoeba*, *Naegleria*, *Balamuthia*, and *Sappinia*. The organisms are widely distributed in soil and fresh and brackish water. *Acanthamoeba* and *Naegleria* species have been found to harbor *Legionella*, *Vibrio cholerae*, and other endosymbiotic bacteria and may serve as a reservoir for these organisms.

1. Primary Amebic Meningoencephalitis

Primary amebic meningoencephalitis is a fulminating, hemorrhagic, necrotizing meningoencephalitis that occurs in healthy children and young adults and is rapidly fatal. It is caused by free-living amebas, most commonly *Naegleria fowleri*, but also *Balamuthia mandrillaris* and *Acanthamoeba* species. *N fowleri* is a thermophilic organism found in fresh and polluted warm lake water, domestic water supplies, swimming pools, thermal water, and sewers. Most patients give a history of exposure to warm fresh water. The incubation period varies from 2 to 15 days. Early symptoms include headache, fever, stiff neck, and lethargy, often associated with rhinitis and pharyngitis. Vomiting, disorientation, and other signs of meningoencephalitis develop within 1 or 2 days, followed by coma and then death within 7-10 days. No distinctive clinical features distinguish the infection from acute bacterial meningoencephalitis. CSF shows hundreds to thousands of leukocytes and erythrocytes per cubic millimeter. Protein is usually elevated, and

INFECTIONS WITH PATHOGENIC FREE-LIVING AMEBAS



ESSENTIALS OF DIAGNOSIS

- ▶ Acute meningoencephalitis or chronic granulomatous encephalitis after contact with warm fresh water.
- ▶ Keratitis, particularly in contact lens users.

glucose is normal or moderately reduced. A fresh wet mount of the CSF may show motile trophozoites. Staining with Giemsa or Wright stain will identify the trophozoites. Species identification is based on morphology and immunologic methods. Primary amebic meningoencephalitis is nearly always fatal. Amphotericin B appears to be the drug of choice; one survivor was treated with intravenous and intrathecal amphotericin B, intravenous miconazole, and oral rifampin.

2. Granulomatous Amebic Encephalitis

Acanthamoeba species and *B. mandrillaris* can cause an encephalitis that is more chronic in nature than primary amebic meningoencephalitis. One case of encephalitis caused by *Sappinia* has also been described. Neurologic disease may be preceded by skin lesions, including ulcers and nodules. After an uncertain incubation period neurologic symptoms develop slowly, with headache, meningismus, nausea, vomiting, lethargy, and low-grade fevers progressing over weeks to months to focal neurologic findings, mental status abnormalities, and eventually coma and death. CT and MRI show single or multiple nonspecific lesions. Lumbar puncture is dangerous due to increased intracranial pressure. CSF shows a lymphocytic pleocytosis with elevated protein; amebas are not typically seen. Diagnosis can be made by biopsy of skin or brain lesions. Information on the treatment of granulomatous amebic encephalitis is limited. Some patients have been successfully treated with various combinations of flucytosine, pentamidine, fluconazole or itraconazole, sulfadiazine, trimethoprim-sulfamethoxazole, and azithromycin.

3. Acanthamoeba Keratitis

Acanthamoeba keratitis is a painful, sight-threatening corneal infection. It is associated with corneal trauma, most commonly after use of contact lenses and contaminated saline solution. Symptoms include severe eye pain, photophobia, tearing, and blurred vision. The keratitis progresses slowly, with waxing and waning clinical findings over months, and can progress to blindness. Lack of response to antibacterial, antifungal, and antiviral topical treatments and potential use of contaminated contact lens solution are suggestive of the diagnosis. Ocular examination shows corneal ring infiltrates, but these can also be caused by other pathogens. The diagnosis can be made by examination or culture of corneal scrapings. Available diagnostic techniques include examination of a wet preparation for cysts and motile trophozoites, examination of stained specimens, evaluation with immunofluorescent reagents, culture of organisms, and PCR.

Acanthamoeba keratitis can be cured with local therapy. Topical propamidine isethionate (0.1%), chlorhexidine digluconate (0.02%), polyhexamethylene biguanide, neomycin-polymyxin B-gramicidin, miconazole, and combinations of these agents have been used successfully. Oral itraconazole or ketoconazole can be added for deep keratitis. Drug resistance has been reported. Use of corticosteroid therapy is controversial. In some cases, debridement and penetrating keratoplasty have been performed in

addition to medical therapy. Corneal grafting can be done after the amebic infection has been eradicated.

Bravo FG et al. *Balamuthia mandrillaris* is infection of the skin and central nervous system: an emerging disease of concern to many specialties in medicine. *Curr Opin Infect Dis*. 2011 Apr; 24(2):112–7. [PMID: 21192259]

Dart JK et al. *Acanthamoeba* keratitis: diagnosis and treatment update, 2009. *Am J Ophthalmol*. 2009 Oct;148(4):487–499.e2. [PMID: 19660733]

Visvesvara GS et al. Pathogenic and opportunistic free-living amoebae: *Acanthamoeba* spp., *Balamuthia mandrillaris*, *Naegleria fowleri*, and *Sappinia diploidea*. *FEMS Immunol Med Microbiol*. 2007 Jun;50(1):1–26. [PMID: 17428307]

COCCIDIOSIS (Cryptosporidiosis, Isosporiasis, Cyclosporiasis, Sarcocystosis) & MICROSPORIDIOSIS



ESSENTIALS OF DIAGNOSIS

- ▶ Acute diarrhea, especially in children in developing countries.
- ▶ Outbreaks of diarrhea secondary to contaminated water or food.
- ▶ Prolonged diarrhea in immunocompromised persons.
- ▶ Diagnosis mostly by identifying organisms in specially stained stool specimens.

▶ General Considerations

The causes of coccidiosis are *Cryptosporidium* species (*C parvum*, *C hominis*, and others); *Isospora belli*; *Cyclospora cayetanensis*; and *Sarcocystis* species. Microsporidiosis is caused by at least 14 species, most commonly *Enterocytozoon bieneusi* and *Encephalitozoon intestinalis*. These infections occur worldwide, particularly in the tropics and in regions where hygiene is poor. They are causes of endemic childhood gastroenteritis (particularly in malnourished children in developing countries); institutional and community outbreaks of diarrhea; traveler's diarrhea; and acute and chronic diarrhea in immunosuppressed patients, in particular those with AIDS. They are all notable for the potential to cause prolonged diarrhea, often lasting for a number of weeks. Clustering occurs in households, day care centers, and among sexual partners.

The infectious agents are oocysts (coccidiosis) or spores (microsporidiosis) transmitted from person to person or by contaminated drinking or swimming water or food. Ingested oocysts release sporozoites that invade and multiply in enterocytes, primarily in the small bowel. Coccidian oocysts and microsporidian cysts can remain viable in the environment for years.

I belli and *C cayetanensis* appear to infect only humans. *C cayetanensis* has caused a number of food-borne outbreaks in the United States in recent years, most commonly

associated with imported fresh produce. *Sarcocystis* infects many species; humans are intermediate hosts (infected by ingestion of fecal sporocysts) for some species but definitive hosts for *Sarcocystis bovi-hominis* and *Sarcocystis suis-hominis* (infected by ingestion of tissue cysts in undercooked beef and pork, respectively).

Cryptosporidiosis is a zoonosis (*C parvum* principally infects cattle), but most human infections are acquired from humans, in particular with *C hominus*. Cryptosporidia are highly infectious and readily transmitted in day care settings and households. They have caused large community outbreaks due to contaminated water supplies (causing ~400,000 illnesses in Milwaukee in 1993) and are the leading cause of recreational water-associated outbreaks of gastroenteritis. Of note, coccidia and microsporidians will generally be missed on routine evaluations of stool for ova and parasites, as they require special staining techniques for identification.

► Clinical Findings

A. Symptoms and Signs

1. Cryptosporidiosis—The incubation period appears to be about 1–14 days. In developing countries, disease is seen primarily in children under 5 years of age, where cryptosporidiosis causes 5–10% of cases of childhood diarrhea. Presenting symptoms in children include acute watery diarrhea, abdominal pain, and cramps, with rapid resolution in most patients; however, symptoms quite commonly persist for 2 weeks or more. In developed countries, most patients are adults. Diarrhea in immunocompetent individuals typically lasts from 5 to 10 days. It is usually watery, with accompanying abdominal pain and cramps, nausea, vomiting, and fever. Relapses may follow initial resolution of symptoms. Mild illness and asymptomatic infection may also be common.

Cryptosporidiosis is a well-characterized cause of diarrhea in those with AIDS. It was common in this population before the advent of highly active antiretroviral therapy, particularly in those with advanced immunosuppression. Clinical manifestations are variable, but patients commonly have chronic diarrhea with frequent foul smelling stools, malabsorption, and weight loss. Severe, life-threatening watery diarrhea may be seen. Cryptosporidiosis also causes extraintestinal disease with AIDS, including pulmonary infiltrates with dyspnea and biliary tract infection with sclerosing cholangitis and AIDS cholangiopathy.

2. Isosporiasis—The incubation period for *I belli* is about 1 week. In immunocompetent persons, it usually causes a self-limited watery diarrhea lasting 2–3 weeks, with abdominal cramps, anorexia, malaise, and weight loss. Fever is unusual. Chronic symptoms may persist for months in some patients. In immunocompromised patients, isosporiasis more commonly causes severe and chronic diarrhea, with complications including marked dehydration, malnutrition, and hemorrhagic colitis. Extraintestinal disease has been reported rarely.

3. Cyclosporiasis—*C cayetanensis* oocysts must undergo a period of sporulation of 7 days or more after shedding

before they become infectious. Therefore, person-to-person spread is unlikely, and spread has typically been due to contaminated food (especially fresh produce) and water. The incubation period is 1–11 days. Infections can be asymptomatic. Cyclosporiasis causes an illness similar to that described for the other pathogens described in this section, with watery diarrhea, abdominal cramps, nausea, fatigue, and anorexia. Fever is seen in 25% of cases. Symptoms typically continue for 2 weeks or longer and may persist for months. Relapses of diarrhea are common. Diarrhea may be preceded by a flu-like prodrome and followed by persistent fatigue. In immunocompromised patients, cyclosporiasis is typically more severe and prolonged, with chronic fulminant watery diarrhea and weight loss.

4. Sarcocystosis—*Sarcocystis* infection may be common in some developing countries, but it is usually asymptomatic. Infection appears to most commonly follow the ingestion of undercooked beef or pork, leading to the development of cysts in muscle, with myalgias, fever, bronchospasm, pruritic rash, lymphadenopathy, and subcutaneous nodules. Ingestion of fecal sporocysts may lead to gastrointestinal symptoms.

5. Microsporidiosis—Microsporidia are obligate intracellular protozoans that cause a wide spectrum of diseases. Many infections are of zoonotic origin, but human-to-human transmission has been documented. Infection is mainly by ingestion of spores, but also by direct inoculation of the eyes. In immunocompetent hosts, microsporidian infections most commonly present as self-limited diarrhea. Ocular infections have also been described. Disease from microsporidia is seen mainly in immunocompromised persons, particularly those with AIDS. Infections in AIDS patients are most commonly with *E bienersi* and *E intestinalis*. They cause chronic diarrhea, with anorexia, bloating, weight loss, and wasting, especially in those with advanced immunodeficiency. Fever is usually not seen. Other illnesses in immunocompromised persons associated with microsporidians (including the genera *Enterocytozoon*, *Encephalitozoon*, *Brachiola*, *Vittaforma*, *Pleistophora*, *Trachipleistophora*, and *Microsporidium*) include biliary tract disease (AIDS cholangiopathy), genitourinary infection with cystitis, kidney disease, hepatitis, peritonitis, myositis, respiratory infections including sinusitis, central nervous system infections including granulomatous encephalitis, and disseminated infections. Ocular infections with *Encephalitozoon* species cause conjunctivitis and keratitis, presenting as redness, photophobia, and loss of visual acuity.

B. Laboratory Findings

1. Cryptosporidiosis—Typically, stool is without blood or leukocytes. Diagnosis is traditionally made by detecting the organism in stool using a modified acid-fast stain; this technique is relatively insensitive, and multiple specimens should be evaluated before ruling out the diagnosis. Of note, routine evaluation for ova and parasites typically does not include a modified acid-fast stain, so this must be specifically requested in many laboratories. Antigen detection offers improved sensitivity and specificity, both of which are well over 90% with a number of available assays,

and these methods may now be considered the optimal means of diagnosis.

2. Isosporiasis—Diagnosis of isosporiasis is by examination of stool wet mounts or after modified acid-fast staining, in which the organism is clearly distinguishable from other parasites. Other stains also show the organism. Shedding of oocysts may be intermittent, so the sensitivity of stool evaluation is not high, and multiple samples should be examined. The organism may also be identified in duodenal aspirates or small bowel biopsies.

3. Cyclosporiasis—Diagnosis is made by examination of stool wet mounts or after modified acid-fast staining. Multiple specimens may need to be examined to make a diagnosis. The organism can also be identified in small bowel aspirates or biopsy specimens.

4. Sarcocystosis—Eosinophilia and elevated creatine kinase may be seen. Diagnosis is by identification of the acid-fast organisms in stool or by identification of trophozoites or bradyzoites in tissue biopsies.

5. Microsporidiosis—Diagnosis can be made by identification of organisms in specially stained stool, fluid, or tissue specimens, for example with Weber chromotrope-based stain. Electron microscopy is helpful for confirmation of the diagnosis and speciation. PCR and culture techniques are available but not used routinely.

▶ Treatment

Most acute infections with these pathogens in immunocompetent persons are self-limited and do not require treatment. Supportive treatment for severe or chronic diarrhea includes fluid and electrolyte replacement and, in some cases, parenteral nutrition.

1. Cryptosporidiosis—Treatment of cryptosporidiosis is challenging. No agent is clearly effective. Modest benefits have been seen in some (but not other) studies with paromomycin, a non-absorbed aminoglycoside (25–35 mg/kg orally for 14 days has been used), and nitazoxanide (500 mg–1 g orally twice daily for 3 days in nonimmunocompromised and 2–8 weeks in advanced AIDS patients), which is approved in the United States for this indication. It can cause mild gastrointestinal toxicity. Other agents that have been used with mixed success in AIDS patients with cryptosporidiosis include azithromycin, spiramycin, bovine hyperimmune colostrum, and octreotide. Reversing immunodeficiency with effective antiretroviral therapy is of greatest importance.

2. Isosporiasis—Isosporiasis is effectively treated in immunocompetent and immunosuppressed persons with trimethoprim-sulfamethoxazole (160 mg/800 mg orally two to four times daily for 10 days, with the higher dosage for patients with AIDS). An alternative therapy is pyrimethamine (75 mg orally in four divided doses) with folinic acid (10–25 mg/d orally). Maintenance therapy with low-dose trimethoprim-sulfamethoxazole (160 mg/800 mg daily or three times per week) or Fansidar (1 tablet weekly) prevents relapse in those with persistent immunosuppression.

3. Cyclosporiasis—Cyclosporiasis is also treated with trimethoprim-sulfamethoxazole (dosing as for isosporiasis). With AIDS, long-term maintenance therapy (160 mg/800 mg three times weekly) helps prevent relapse. For patients intolerant of trimethoprim-sulfamethoxazole, ciprofloxacin (500 mg orally twice daily for 7 days) showed efficacy, albeit with less ability to clear the organism than trimethoprim-sulfamethoxazole.

4. Sarcocystosis—For sarcocystosis, no specific treatment is established, but sulfadiazine cleared intestinal cysts in one study.

5. Microsporidiosis—Treatment of microsporidiosis is complex. Infections with most species, including those causing gastrointestinal and other manifestations, should be treated with albendazole (400 mg orally twice daily for 2–4 weeks), which has activity against a number of species, but relatively poor efficacy (about 50%) against *E. bienersi*, the most common microsporidial cause of diarrhea in AIDS patients. Fumagillin, which is used to treat honeybees and fish with microsporidian infections, has shown benefit in clinical trials at a dose of 20 mg three times per day for 14 days; treatment was accompanied by reversible thrombocytopenia. As with cryptosporidiosis, the best means of controlling microsporidiosis in AIDS patients is to restore immune function with effective antiretroviral therapy. Ocular microsporidiosis can be treated with fumagillin solution (3 mg/mL); this probably should be given with concurrent systemic therapy with albendazole. Adjunctive management may include corticosteroids to decrease inflammation and keratoplasty.

▶ Prevention

Water purification is important for control of these infections. Chlorine disinfection is not effective against cryptosporidial oocysts, so other purification measures are needed. Immunocompromised patients should boil or filter drinking water and should consider avoidance of lakes and swimming pools. Routine precautions (hand-washing, gloves, disinfection) should prevent institutional patient-to-patient spread. Optimal means of preventing microsporidial infections are not well understood, but water purification as discussed above and body substance precautions for immunocompromised and hospitalized individuals are likely effective.

- Davies AP et al. Cryptosporidiosis. *BMJ*. 2009 Oct 19;339:b4168. [PMID: 19841008]
- Didier ES et al. Microsporidiosis: not just in AIDS patients. *Curr Opin Infect Dis*. 2011 Oct;24(5):490–5. [PMID: 21844802]
- O'Connor RM et al. Cryptosporidiosis in patients with HIV/AIDS. *AIDS*. 2011 Mar 13;25(5):549–60. [PMID: 21160413]
- Ortega YR et al. Update on *Cyclospora cayentanensis*, a food-borne and waterborne parasite. *Clin Microbiol Rev*. 2010 Jan; 23(1):218–34. [PMID: 20065331]
- Pierce KK et al. Update on human infections caused by intestinal protozoa. *Curr Opin Gastroenterol*. 2009 Jan;25(1):12–7. [PMID: 19119509]

GIARDIASIS



ESSENTIALS OF DIAGNOSIS

- ▶ Acute diarrhea; may be profuse and watery.
- ▶ Chronic diarrhea with greasy, malodorous stools.
- ▶ Abdominal cramps, distention, flatulence, and malaise.
- ▶ Cysts or trophozoites in stools.

▶ General Considerations

Giardiasis is a protozoal infection of the upper small intestine caused by the flagellate *Giardia lamblia* (also called *Giardia intestinalis* and *Giardia duodenalis*). The parasite occurs worldwide, most abundantly in areas with poor sanitation. In developing countries, young children are very commonly infected. In the United States and Europe, the infection is the most common intestinal protozoal pathogen; the US estimate is of 100,000 to 2.5 million new infections leading to 5000 hospital admissions yearly. Groups at special risk include travelers to *Giardia*-endemic areas, those who swallow contaminated water during recreation or wilderness travel, men who have sex with men, and persons with impaired immunity. Outbreaks are common in households, children's day care centers, and residential facilities, and may occur as a result of contamination of water supplies.

The organism occurs in feces as a flagellated trophozoite and as a cyst. Only the cyst form is infectious by the oral route; trophozoites are destroyed by gastric acidity. Humans are a reservoir for the pathogen; dogs, cats, beavers, and other mammals have been implicated but not confirmed as reservoirs. Under suitable moist, cool conditions, cysts can survive in the environment for weeks to months. Cysts are transmitted as a result of fecal contamination of water or food, by person-to-person contact, or by anal-oral sexual contact. The infectious dose is low, requiring as few as ten cysts. After the cysts are ingested, trophozoites emerge in the duodenum and jejunum. Epithelial damage and mucosal invasion are uncommon. Hypogammaglobulinemia, low secretory IgA levels in the gut, achlorhydria, and malnutrition favor the development of infection.

▶ Clinical Findings

A. Symptoms and Signs

It is estimated that about 50% of infected persons have no discernable infection, about 10% become asymptomatic cyst passers, and 25–50% develop an acute diarrheal syndrome. Acute diarrhea may clear spontaneously but is commonly followed by chronic diarrhea. The incubation period is usually 1–3 weeks but may be longer. The illness may begin gradually or suddenly. Cysts may not be detected in the stool at the onset of the illness. The acute phase may last days or weeks, and is usually self-limited,

although cyst excretion may be prolonged. The initial illness may include profuse watery diarrhea, and hospitalization may be required due to dehydration, particularly in young children. Typical symptoms of chronic disease are abdominal cramps, bloating, flatulence, nausea, malaise, and anorexia. Fever and vomiting are uncommon. Diarrhea is usually not severe in the chronic stage of infection; stools are greasy or frothy and foul smelling, without blood, pus, or mucus. The diarrhea may be daily or recurrent; intervening periods may include constipation. Symptoms can persist for weeks to months. Weight loss is frequent. Chronic disease can include malabsorption, including fat- and protein-losing enteropathy and vitamin deficiencies.

B. Laboratory Findings

Most patients seek medical attention after having been ill for over a week, commonly with weight loss of 5 kg or more. Stool is generally without blood or leukocytes. Diagnosis is traditionally made by the identification of trophozoites or cysts in stool. A wet mount of liquid stool may identify motile trophozoites. Stained fixed specimens may show cysts or trophozoites. Sensitivity of stool analysis is not ideal, estimated at 50–80% for a single specimen and over 90% for three specimens. Sampling of duodenal contents with a string test or biopsy is no longer generally recommended, but biopsies may be helpful in very ill or immunocompromised patients. When giardiasis is suspected, antigen assays may be simpler and cheaper than repeated stool examinations, but these tests will not identify other stool pathogens. Multiple tests, which identify antigens of trophozoites or cysts, are available. They are generally quite sensitive (85–98%) and specific (90–100%).

▶ Treatment

The treatments of choice for giardiasis are metronidazole (250 mg orally three times daily for 5–7 days) or tinidazole (2 g orally once). The drugs are not universally effective; cure rates for single courses are typically about 80–95%. Toxicities are as described for treatment of amebiasis, but the lower dosages used for giardiasis limit side effects. A meta-analysis showed albendazole (400 mg orally once daily for 5 days) to have equivalent efficacy and fewer side effects compared with metronidazole, and so it may be considered another first-line agent for giardiasis. Nitazoxanide (500 mg orally twice daily for 3 days) is generally well tolerated but may cause mild gastrointestinal side effects. Other drugs with activity against *Giardia* include furazolidone (100 mg orally four times a day for 7 days), which is about as effective as the other named drugs but causes gastrointestinal side effects, and paromomycin (500 mg orally three times a day for 7 days), which appears to have somewhat lower efficacy but unlike metronidazole, tinidazole, and furazolidone is safe in pregnancy. Symptomatic giardiasis should always be treated. Treatment of asymptomatic patients should be considered, since they can transmit the infection to others. With a presumptive diagnosis but negative diagnostic studies, an

empiric course of treatment is sometimes appropriate. Household or day care contacts with an index case should be tested and treated if infected.

▶ Prevention

Community chlorination (0.4 mg/L) of water is relatively ineffective for inactivating cysts, so filtration is required. For wilderness or international travelers, bringing water to a boil for 1 minute or filtration with a pore size < 1 μm are adequate. In day care centers, appropriate disposal of diapers and frequent hand washing are essential.

Rossignol JF. *Cryptosporidium* and *Giardia*: Treatment options and prospects for new drugs. *Exp Parasitol*. 2010 Jan; 124(1):45–53. [PMID: 19632225]
 Solaymani-Mohammadi S et al. A meta-analysis of the effectiveness of albendazole compared with metronidazole as treatments for infections with *Giardia duodenalis*. *PLoS Negl Trop Dis*. 2010 May 11;4(5):e682. [PMID: 20485492]

OTHER INTESTINAL FLAGELLATE INFECTIONS

Balantidium coli is a large ciliated intestinal protozoan found worldwide, but particularly in the tropics. Pigs are the main reservoir. The infection is rare in humans, and results from ingestion of cysts passed in stools of humans or swine. In the new host, the cyst wall dissolves and the trophozoite may invade intestinal mucosa, causing abscesses and ulcerations. Many infections are asymptomatic. Chronic infections may cause recurrent diarrhea or dysentery. Deaths have occurred from intestinal perforation and hemorrhage.

Dientamoeba fragilis is a protozoan that commonly causes infection without symptoms, so its role in human disease remains somewhat controversial. Symptoms attributed to the pathogen include diarrhea, abdominal pain, and anorexia. Other flagellates may infect humans, are generally considered nonpathogens, but may be markers for fecal-oral contamination.

Diagnosis of balantidiasis is established by finding trophozoites or cysts in stool, or in ulcer scrapings of the large bowel. *D fragilis* infection can be hard to diagnose because it only exists in the trophozoite form; the sensitivity of evaluation of three stools is 70–90%. The treatment of choice for balantidiasis is tetracycline, 500 mg orally four times daily for 10 days. The alternative is iodoquinol (diiodohydroxyquin), 650 mg orally three times daily for 21 days, and metronidazole, paromomycin, and nitazoxanide have also been used successfully. *D fragilis* infections have been successfully treated with metronidazole, iodoquinol, paromomycin, and tetracycline, but failures have been reported recently with metronidazole; all the regimens are the same as for balantidiasis.

Schuster FL et al. Current world status of *Balantidium coli*. *Clin Microbiol Rev*. 2008 Oct;21(4):626–38. [PMID: 18854484]
 Stark D et al. A review of the clinical presentation of dientamoebiasis. *Am J Trop Med Hyg*. 2010 Apr;82(4):614–9. [PMID: 20348509]

TRICHOMONIASIS



ESSENTIALS OF DIAGNOSIS

- ▶ Copious vaginal discharge in women.
- ▶ Nongonococcal urethritis in men.
- ▶ Motile trichomonads on wet mounts.

▶ General Considerations

Trichomoniasis is caused by the protozoan *Trichomonas vaginalis* and is among the most common sexually transmitted diseases, causing vaginitis in women and nongonococcal urethritis in men. It can also occasionally be acquired by other means, since it can survive in moist environments for several hours.

▶ Clinical Findings

A. Symptoms and Signs

T vaginalis is often harbored asymptotically. For women with symptomatic disease, after an incubation period of 5 days to 4 weeks, a vaginal discharge develops, often with vulvovaginal discomfort, pruritus, dysuria, dyspareunia, or abdominal pain. Examination shows a copious discharge, which is usually not foul smelling but is often frothy and yellow or green in color. Inflammation of the vaginal walls and cervix with punctate hemorrhages are common. Most men infected with *T vaginalis* are asymptomatic, but it can be isolated from about 10% of men with nongonococcal urethritis. In men with trichomonal urethritis, the urethral discharge is generally more scanty than with other causes of urethritis.

B. Diagnostic Testing

Diagnosis is typically made by identifying the organism in vaginal or urethral secretions. Examination of wet mounts will show motile organisms. Tests for bacterial vaginosis (pH > 4.5, fishy odor after addition of potassium hydroxide) are often positive with trichomoniasis. Rapid antigen and nucleic acid amplification tests that are highly specific and much more sensitive than wet mounts are available but are not yet widely used.

▶ Treatment

The treatment of choice is metronidazole or tinidazole, each as a 2 g single oral dose. Tinidazole may be better tolerated and active against some resistant parasites. Toxicities of these drugs are discussed in the section on amebiasis. If the large single dose cannot be tolerated, an alternative metronidazole dosage is 500 mg orally twice daily for 1 week. All infected persons should be treated, even if asymptomatic, to prevent subsequent symptomatic disease and limit spread. Treatment failure suggests reinfection, but metronidazole-resistant organisms have been reported. These may be treated with tinidazole, longer courses of metronidazole, furazolidone, or other experimental therapies (see Chapter 18).

Bachmann LH et al. *Trichomonas vaginalis* genital infections: progress and challenges. *Clin Infect Dis*. 2011 Dec;53(Suppl 3):S160–72. [PMID: 22080269]
 Wendel KA et al. Trichomoniasis: challenges to appropriate management. *Clin Infect Dis*. 2007 Apr 1;44(Suppl 3):S123–9. [PMID: 17342665]

HELMINTHIC INFECTIONS

TREMATODE (FLUKE) INFECTIONS

SCHISTOSOMIASIS (Bilharziasis)

ESSENTIALS OF DIAGNOSIS

- ▶ History of fresh water exposure in an endemic area.
- ▶ **Acute schistosomiasis:** fever, headache, myalgias, cough, urticaria, diarrhea, and eosinophilia.
- ▶ **Intestinal schistosomiasis:** abdominal pain, diarrhea, and hepatomegaly, progressing to anorexia, weight loss, and features of portal hypertension.
- ▶ **Urinary schistosomiasis:** hematuria and dysuria, progressing to hydronephrosis and urinary infections.
- ▶ Diagnosis based on characteristic eggs in feces or urine; biopsy of rectal or bladder mucosa; positive serology.

General Considerations

Schistosomiasis, which affects more than 200 million persons worldwide, leads to severe consequences in 20 million persons and about 100,000 deaths annually. The disease is caused by five species of trematode blood flukes. Four species cause intestinal schistosomiasis, with infection of mesenteric venules: *Schistosoma mansoni*, which is present in Africa, the Arabian peninsula, South America, and the Caribbean; *Schistosoma japonicum*, which is endemic in China and Southeast Asia; *Schistosoma mekongi*, which is endemic near the Mekong River in Southeast Asia; and *Schistosoma intercalatum*, which occurs in parts of Africa. *Schistosoma haematobium* causes urinary schistosomiasis, with infection of venules of the urinary tract, and is endemic in Africa and the Middle East. Transmission of schistosomiasis is focal, with greatest prevalence in poor rural areas. Control efforts have diminished transmission significantly in many areas, but high level transmission remains common in sub-Saharan Africa and some other areas. Prevalence of infection and illness typically peaks at about 15–20 years of age.

Humans are infected with schistosomes after contact with fresh water containing cercariae released by infected snails. Infection is initiated by penetration of skin or mucous membranes. After penetration, schistosomulae migrate to the portal circulation, where they rapidly mature.

After about 6 weeks, adult worms mate, and migrate to terminal mesenteric or bladder venules, where females deposit their eggs. Some eggs reach the lumen of the bowel or bladder and are passed with feces or urine, while others are retained in the bowel or bladder wall or transported in the circulation to other tissues, in particular the liver. Disease in endemic areas is primarily due to a host response to eggs, with granuloma formation and inflammation, eventually leading to fibrosis. Chronic infection can result in scarring of mesenteric or vesicular blood vessels, leading to portal hypertension and alterations in the urinary tract. In previously uninfected individuals, such as travelers with fresh water contact in endemic regions, acute schistosomiasis may occur, with a febrile illness 2–8 weeks after infection.

Clinical Findings

A. Symptoms and Signs

1. Cercarial dermatitis—Following cercarial penetration, localized erythema develops in some individuals, which can progress to a pruritic maculopapular rash that persists for some days. Dermatitis can be caused by human schistosomes and, in non-tropical areas, by bird schistosomes that cannot complete their life cycle in humans (swimmer's itch).

2. Acute schistosomiasis (Katayama syndrome)

A febrile illness may develop 2–8 weeks after exposure in persons without prior infection, most commonly after heavy infection with *S mansoni* or *S japonicum*. Presenting symptoms and signs include acute onset of fever; headache; myalgias; cough; malaise; urticaria; diarrhea, which may be bloody; hepatosplenomegaly; lymphadenopathy; and pulmonary infiltrates. Localized lesions may occasionally cause severe manifestations, including CNS abnormalities and death. Acute schistosomiasis usually resolves in 2–8 weeks.

3. Chronic schistosomiasis—Many infected persons have light infections and are asymptomatic, but an estimated 50–60% have symptoms and 5–10% have advanced organ damage. Asymptomatic infected children may suffer from anemia and growth retardation. Symptomatic patients with intestinal schistosomiasis typically experience abdominal pain, fatigue, diarrhea, and hepatomegaly. Over years, anorexia, weight loss, weakness, colonic polyps, and features of portal hypertension develop. Late manifestations include hematemesis from esophageal varices, hepatic failure, and pulmonary hypertension. Urinary schistosomiasis may present within months of infection with hematuria and dysuria, most commonly in children and young adults. Fibrotic changes in the urinary tract can lead to hydronephrosis, hydronephrosis, bacterial urinary infections and, ultimately, kidney disease or bladder cancer.

B. Laboratory Findings

Microscopic examination of stool or urine for eggs, evaluation of tissue, or serologic tests establish the diagnosis. Characteristic eggs can be identified on smears of stool or urine, but filtration or concentration techniques can improve yields. Quantitative tests that yield > 400 eggs per

gram of feces or 10 mL of urine are indicative of heavy infections with increased risk of complications. Diagnosis can also be made by biopsy of the rectum, colon, liver, or bladder. Serologic tests include an ELISA available from the CDC that is 99% specific for all species. The test is 99% sensitive for *S mansoni*, 95% sensitive for *S haematobium*, but < 50% sensitive for *S japonicum*. Species-specific immunoblots can increase sensitivity. In acute schistosomiasis, leukocytosis and marked eosinophilia may occur; serologic tests may become positive before eggs are seen in stool or urine. After therapy, eggs may be shed in stool or urine for months, and so the identification of eggs in fluids or tissue or positive serologic tests cannot distinguish past or active disease. Tests for egg viability are available. With a diagnosis of schistosomiasis, evaluation for the extent of disease is warranted, including liver function studies and imaging of the liver with intestinal disease and ultrasound or other imaging studies of the urinary system in urinary disease.

► Treatment

Treatment is indicated for all schistosome infections. In areas where recurrent infection is common, treatment is valuable in reducing worm burdens and limiting clinical complications. The drug of choice for schistosomiasis is praziquantel. The drug is administered for 1 day at an oral dose of 40 mg/kg (in one or two doses) for *S mansoni*, *S haematobium*, and *S intercalatum* infections and a dose of 60 mg/kg (in two or three doses) for *S japonicum* and *S mekongi*. Cure rates are generally > 80% after a single treatment, and those not cured have marked reduction in the intensity of infection. Praziquantel is active against invading cercariae but not developing schistosomulae. Therefore, the drug may not prevent illness when given after exposure and, for recent infections, a repeat course after a few weeks may be appropriate. Praziquantel may be used during pregnancy. Resistance to praziquantel has been reported. Toxicities include abdominal pain, diarrhea, urticaria, headache, nausea, vomiting, and fever, and may be due both to direct effects of the drug and responses to dying worms. Alternative therapies are oxamniquine for *S mansoni* infection and metrifonate for *S haematobium* infection. Both of these drugs currently have limited availability (they are not available in the United States), and resistance may be a problem. No second-line drug is available for *S japonicum* infections. The antimalarial drug artemether has activity against schistosomulae and adult worms and may be effective in chemoprophylaxis; however, it is expensive, and long-term use in malarious areas might select for resistant malaria parasites. With severe disease, use of corticosteroids in conjunction with praziquantel may decrease complications. Treatment should be followed by repeat examinations for eggs about every 3 months for 1 year after therapy, with re-treatment if eggs are seen.

► Prevention

Travelers to endemic areas should avoid fresh water exposure. Vigorous towel drying after exposure may limit cercarial penetration. Chemoprophylaxis with artemether has shown

efficacy but is not standard practice. Community control of schistosomiasis includes improved sanitation and water supplies, elimination of snail habitats, and intermittent administration of treatment to limit worm burdens.

- Gray DJ et al. Diagnosis and management of schistosomiasis. *BMJ*. 2011 May 17;342:d2651. [PMID: 21586478]
- Jauréguiberry S et al. Acute schistosomiasis, a diagnostic and therapeutic challenge. *Clin Microbiol Infect*. 2010 Mar;16(3):225–31. [PMID: 20222897]
- King CH et al. Utility of repeated praziquantel dosing in the treatment of schistosomiasis in high-risk communities in Africa: a systematic review. *PLoS Negl Trop Dis*. 2011 Sep;5(9):e1321. [PMID: 21949893]
- Ross AG et al. Katayama syndrome. *Lancet Infect Dis*. 2007 Mar;7(3):218–24. [PMID: 17317603]
- Wang LD et al. A strategy to control transmission of *Schistosoma japonicum* in China. *N Engl J Med*. 2009 Jan 8;360(2):121–8. [PMID: 19129526]

LIVER, LUNG, AND INTESTINAL FLUKES

FASCIOLIASIS

Infection by *Fasciola hepatica*, the sheep liver fluke, results from ingestion of encysted metacercariae on watercress or other aquatic vegetables. Infection is prevalent in sheep-raising areas in many countries, especially parts of South America, the Middle East, and southern Europe. *Fasciola gigantica* has a more restricted distribution in Asia and Africa and causes similar findings. Eggs are passed from host feces into fresh water, leading to infection of snails, and then deposition of metacercariae on vegetation. In humans, metacercariae excyst, penetrate into the peritoneum, migrate through the liver, and mature in the bile ducts, where they cause local necrosis and abscess formation.

Two clinical syndromes are seen, related to acute migration of worms and chronic infection of the biliary tract. Symptoms related to migration of larvae present 6–12 weeks after ingestion. Typical findings are abdominal pain, fever, malaise, weight loss, urticaria, eosinophilia, and leukocytosis. Tender hepatomegaly and elevated liver function tests may be seen. Rarely, migration to other organs may lead to localized disease. The symptoms of worm migration subside after 2–4 months, followed by asymptomatic infection by adult worms or intermittent symptoms of biliary obstruction, with biliary colic and, at times, findings of cholangitis. Early diagnosis is difficult, as eggs are not found in the feces during the acute migratory phase of infection. Clinical suspicion should be based on clinical findings and marked eosinophilia in at risk individuals. CT and other imaging studies show hypodense migratory lesions of the liver. Serologic assays may be positive about 1 month before eggs are seen in stool, but specificities of available tests are not ideal. Definitive diagnosis is made by the identification of characteristic eggs in stool. Repeated examinations may be necessary. In chronic infection, imaging studies show masses obstructing the extrahepatic biliary tract.

Fascioliasis is unusual among fluke infections, in that it does not respond well to treatment with praziquantel. The

treatment of choice is triclabendazole, which is also used in veterinary medicine, but is not available in the United States. Standard dosing of 10 mg/kg orally in a single dose or two doses over 12 hours achieves a cure rate of about 80%, but repeat dosing is indicated if abnormal radiologic findings or eosinophilia do not resolve. The second-line drug for fascioliasis is bithionol (30–50 mg/kg/d orally in three divided doses on alternate days for 10–15 days); this drug is no longer available in the United States. Treatment with either drug can be accompanied by abdominal pain and other gastrointestinal symptoms. Prevention of fascioliasis involves avoidance of ingestion of raw aquatic plants.

CLONORCHIASIS & OPISTHORCHIASIS

Infection by *Clonorchis sinensis*, the Chinese liver fluke, is endemic in areas of Japan, Korea, China, Taiwan, Southeast Asia, and the far eastern part of Russia. Millions of people are affected and, in some communities, prevalence can reach over 80%. Opisthorchiasis is principally caused by *Opisthorchis felineus* (regions of the former Soviet Union) or *Opisthorchis viverrini* (Thailand, Laos, Vietnam). Clonorchiasis and opisthorchiasis are clinically indistinguishable. Parasite eggs are shed into water in human or animal feces, where they infect snails, which release cercariae, which infect fish. Human infection follows ingestion of raw, undercooked, or pickled freshwater fish containing metacercariae. These parasites encyst in the duodenum and ascend into the biliary tract, where they mature and remain for many years, shedding eggs in the bile.

Most patients harbor few parasites and are asymptomatic. An acute illness can occur 2–3 weeks after initial infection, with fever, abdominal pain, tender hepatomegaly, urticaria, and eosinophilia. The acute syndrome is difficult to diagnose, since ova may not appear in the feces until 3–4 weeks after onset of symptoms. In chronic heavy infections, findings include abdominal pain, anorexia, weight loss, and tender hepatomegaly. More serious findings can include recurrent bacterial cholangitis and sepsis, cholecystitis, liver abscess, and pancreatitis. An increased risk of cholangiocarcinoma has been documented.

Early diagnosis is presumptive, based on clinical findings and epidemiology. Subsequent diagnosis is made by finding characteristic eggs in stool or duodenal or biliary contents. Repeated concentration tests of stool may be necessary. Imaging studies show characteristic biliary tract dilatations with filling defects due to flukes. Serologic tests can be helpful but are limited by suboptimal specificity.

The drug of choice is praziquantel, 25 mg/kg orally three times daily for 2 days, which provides cure rates over 95%. One day of treatment may be sufficient. Re-treatment may be required, especially in some areas with known decreased praziquantel efficacy. The second-line drug is albendazole (400 mg orally twice daily for 7 days), which appears to be somewhat less effective.

PARAGONIMIASIS

Eight species of *Paragonimus* lung flukes cause human disease. The most important is *Paragonimus westermani*.

Paragonimus species are endemic in East Asia, Oceania, West Africa, and South America, where millions of persons are infected. Eggs are released into fresh water, where parasites infect snails, and then cercariae infect crabs and crayfish. Human infection follows consumption of raw, undercooked, or pickled freshwater shellfish. Metacercariae then encyst, penetrate into the peritoneum, and pass into the lungs, where they mature into adult worms over about 2 months.

Most persons have moderate worm burdens and are asymptomatic. In symptomatic cases, abdominal pain and diarrhea develop 2 days to 2 weeks after infection, followed by fever, cough, chest pain, urticaria, and eosinophilia. Acute symptoms may last for several weeks. Chronic infection can cause cough productive of brown sputum, hemoptysis, dyspnea, and chest pain, with progression to chronic bronchitis, bronchiectasis, bronchopneumonia, lung abscess, and pleural disease. Ectopic infections can cause disease in other organs, most commonly the CNS, where disease can present with seizures, headaches, and focal neurologic findings due to parasite meningitis and to intracerebral lesions.

The diagnosis of paragonimiasis is made by identifying characteristic eggs in sputum or stool or identifying worms in biopsied tissue. Multiple examinations and concentration techniques may be needed. Serologic tests may be helpful; an ELISA available from the CDC has sensitivity and specificity > 95%. Chest radiographs may show varied abnormalities of the lungs or pleura, including infiltrates, nodules, cavities, and fibrosis, and the findings can be confused with those of tuberculosis. With CNS disease, skull radiographs can show clusters of calcified cysts, and CT or MRI can show clusters of ring-enhancing lesions.

Treatment is with praziquantel (25 mg/kg orally three times daily for 2 days), which provides efficacy of at least 90%. Alternative therapies are bithionol and triclabendazole. As with cysticercosis, for cerebral paragonimiasis, praziquantel should generally be used with corticosteroids. Chronic infection may lead to permanent lung dysfunction and pleural disease requiring drainage procedures.

INTESTINAL FLUKES

The large intestinal fluke, *Fasciolopsis buski*, is a common parasite of pigs and humans in eastern and southern Asia. Eggs shed in stools hatch in fresh water, followed by infection of snails, and release of cercariae that encyst on aquatic plants. Humans are infected by eating uncooked plants, including water chestnuts, bamboo shoots, and watercress. Adult flukes mature in about 3 months and live in the small intestine attached to the mucosa, leading to local inflammation and ulceration. Other intestinal flukes that cause similar syndromes include *Heterophyes* (North Africa and Turkey) and *Metagonimus* (East Asia) species; these species are transmitted by undercooked freshwater fish.

Infections with intestinal flukes are often asymptomatic, although eosinophilia may be marked. In symptomatic cases, after an incubation period of 1–2 months,

manifestations include epigastric pain and diarrhea. Other gastrointestinal symptoms, ileus, edema, and ascites may be seen uncommonly. Diagnosis is based on identification of characteristic eggs or adult flukes in the stool. In contrast to other fluke infections, illness more than 6 months after travel in an endemic area is unlikely. The drug of choice is praziquantel, 25 mg/kg orally as a single dose. Alternative therapies are triclabendazole and niclosamide (for most species).

Fried B et al. Food-borne trematode infections of humans in the United States of America. *Parasitol Res.* 2010 May;106(6):1263–80. [PMID: 20352454]

Keiser J et al. Food-borne trematodiasis. *Clin Microbiol Rev.* 2009 Jul;22(3):466–83. [PMID: 19597009]

Marcos LA. Update on hepatobiliary flukes: fascioliasis, opisthorchiasis and clonorchiasis. *Curr Opin Infect Dis.* 2008 Oct;21(5):523–30. [PMID: 18725803]

CESTODE INFECTIONS

NONINVASIVE CESTODE INFECTIONS

The four major tapeworms that cause noninvasive infections in humans are the beef tapeworm *Taenia saginata*, the pork tapeworm *Taenia solium*, the fish tapeworm *Diphyllobothrium latum*, each of which can reach many meters in length, and the dwarf tapeworm *Hymenolepis nana*. *Taenia* and *Hymenolepis* species are broadly distributed, especially in the tropics; *D latum* is most prevalent in temperate regions. Other tapeworms that can cause noninvasive human disease include the rodent tapeworm *Hymenolepis diminuta*, the dog tapeworm *Dipylidium caninum*, and other *Taenia* and *Diphyllobothrium* species. Invasive tapeworm infections, including *T solium* (when infective eggs, rather than cysticerci are ingested) and *Echinococcus* species, will be discussed separately.

1. Beef Tapeworm

Infection is most common in cattle breeding areas. Humans are the definitive host. Gravid segments of *T saginata* are passed in human feces to soil, where they are ingested by grazing animals, especially cattle. The eggs then hatch to release embryos that encyst in muscle as cysticerci. Humans are infected by eating raw or undercooked infected beef. Most individuals infected with *T saginata* are asymptomatic, but abdominal pain and other gastrointestinal symptoms may be present. Eosinophilia is common. The most common presenting finding is the passage of proglottids in the stool.

2. Pork Tapeworm

T solium is transmitted to pigs that ingest human feces. Humans can be either the definitive host (after consuming undercooked pork, leading to tapeworm infection) or the intermediate host (after consuming food contaminated with human feces containing *T solium* eggs, leading to cysticercosis, which is discussed under invasive tapeworm

infections). As with the beef tapeworm, infection with *T solium* adult worms is generally asymptomatic, but gastrointestinal symptoms may occur. Infection is generally recognized after passage of proglottids. Autoinfection with eggs can progress to cysticercosis.

3. Fish Tapeworm

Infection with *D latum* follows ingestion of undercooked freshwater fish, most commonly in temperate regions. Eggs from human feces are taken up by crustaceans, these are eaten by fish, which are then infectious to humans. Infection with multiple worms over many years can occur. Infections are most commonly asymptomatic, but nonspecific gastrointestinal symptoms, including diarrhea, may occur. Diagnosis usually follows passage of proglottids. Prolonged heavy infection can lead to megaloblastic anemia and neuropathy from vitamin B₁₂ deficiency, which is due to infection-induced dissociation of the vitamin from intrinsic factor and to utilization of the vitamin by worms.

4. Dwarf Tapeworm

H nana is the only tapeworm that can be transmitted between humans. Infections are common in warm areas, especially with poor hygiene and institutionalized populations. Infection follows ingestion of food contaminated with human feces. Eggs hatch in the intestines, where oncospheres penetrate the mucosa, encyst as cysticercoid larvae, and then rupture after about 4 days to release adult worms. Autoinfection can lead to amplification of infection. Infection with *H nana*, the related rodent tapeworm *H diminuta*, or the dog tapeworm *D caninum* can also follow accidental ingestion of infected insects. *H nana* are dwarf in size relative to other tapeworms but can reach 5 cm in length. Heavy infection is common, especially in children, and can be accompanied by abdominal discomfort, anorexia, and diarrhea.

▶ Laboratory Findings

Diagnosis is usually made based on the identification of characteristic eggs or proglottids in stool. Egg release may be irregular, so examination of multiple specimens or concentration techniques may be needed.

▶ Treatment

The treatment of choice for noninvasive tapeworm infections is praziquantel. A single dose of praziquantel (5–10 mg/kg orally) is highly effective, except for *H nana*, for which the dosage is 25 mg/kg. Treatment of *H nana* is more difficult, as the drug is not effective against maturing cysts. Therefore, with heavy infections with this parasite a repeat treatment after 1 week, and screening after therapy to document cure are appropriate. Therapy can be accompanied by headache, malaise, dizziness, abdominal pain, and nausea.

The alternative therapy for these infections is niclosamide. A single dose of niclosamide (2 g chewed) is effective against *D latum*, *Taenia*, and *D caninum* infections. For *H nana*, therapy is continued daily for 1 week. Niclosamide may cause nausea, malaise, and abdominal pain.

Craig P et al. Intestinal cestodes. *Curr Opin Infect Dis.* 2007 Oct; 20(5):524–32. [PMID: 17762788]

INVASIVE CESTODE INFECTIONS

1. Cysticercosis



ESSENTIALS OF DIAGNOSIS

- ▶ Exposure to *T solium* through fecal contamination of food.
- ▶ Seizures, headache, and other findings of a focal CNS lesion.
- ▶ Brain imaging shows cysts; positive serologic tests.

▶ General Considerations

Cysticercosis is due to tissue infection with cysts of *T solium* that develop after humans ingest food contaminated with eggs from human feces, thus acting as an intermediate host for the parasite. Prevalence is high where the parasite is endemic, in particular Mexico, Central and South America, the Philippines, and Southeast Asia. An estimated 20 million persons are infected with cysticercosis yearly, leading to about 400,000 persons with neurologic symptoms and 50,000 deaths. Antibody prevalence rates up to 10% are recognized in some endemic areas, and the infection is one of the most important causes of seizures in the developing world and in immigrants to the United States from endemic countries.

▶ Clinical Findings

A. Symptoms and Signs

Neurocysticercosis can cause intracerebral, subarachnoid, and spinal cord lesions and intraventricular cysts. Single or multiple lesions may be present. Lesions may persist for years before symptoms develop, generally due to local inflammation or ventricular obstruction. Presenting symptoms include seizures, focal neurologic deficits, altered cognition, and psychiatric disease. Symptoms develop more quickly with intraventricular cysts, with findings of hydrocephalus and meningeal irritation, including severe headache, vomiting, papilledema, and visual loss. A particularly aggressive form of the disease, racemose cysticercosis, involves proliferation of cysts at the base of the brain, leading to alterations of consciousness and death. Spinal cord lesions can present with progressive focal findings.

Cysticercosis of other organ systems is usually clinically benign. Involvement of muscles can uncommonly cause discomfort and is identified by radiographs of muscle showing multiple calcified lesions. Subcutaneous involvement presents with multiple painless palpable skin lesions. Involvement of the eyes can present with ptosis due to extraocular muscle involvement or intraocular abnormalities.

B. Laboratory Findings

CSF examination may show lymphocytic or eosinophilic pleocytosis, decreased glucose, and elevated protein. Serology plays an important role in diagnosis. ELISAs with sensitivity and specificity over 90% are available.

C. Imaging

The diagnosis of neurocysticercosis can be difficult. With neuroimaging by CT or MRI, multiple parenchymal cysts are most typically seen. Parenchymal calcification is also common. Ventricular cysts may be difficult to visualize, with MRI offering better sensitivity than CT.

▶ Treatment

The medical management of neurocysticercosis is controversial, as the benefits of cyst clearance must be weighed against potential harm of an inflammatory response to dying worms. Antihelminthic therapy hastens radiologic improvement in parenchymal cysticercosis. However, some randomized trials have shown that corticosteroids alone are as effective as specific therapy plus corticosteroids for controlling seizures, and some reports have shown exacerbation of disease after antihelminthic therapy. Active lesions with a high likelihood of progression, such as intraventricular cysts, may benefit from therapy. At the other end of the spectrum, inactive calcified lesions probably do not benefit from therapy. Overall, it remains difficult to determine when treatment is indicated. When treatment is deemed appropriate, standard therapy consists of albendazole (10–15 mg/kg/d orally for 8 days) or praziquantel (50 mg/kg/d orally for 15–30 days). Albendazole is probably preferred, since it has shown better efficacy in some comparisons and since corticosteroids appear to lower circulating praziquantel levels but increase albendazole levels. Increasing the dosage of albendazole to 30 mg/kg/d orally may improve outcomes. Corticosteroids are usually administered concurrently, but dosing is not standardized. Patients should be observed for evidence of localized inflammatory responses. Anticonvulsant therapy is provided if needed, and shunting is performed if required for elevated intracranial pressure. Surgical removal of cysts may be helpful for some difficult cases of neurocysticercosis and for symptomatic non-neurologic disease.

Lee YM et al. Serologic diagnosis of human *Taenia solium* cysticercosis by using recombinant and synthetic antigens in QuickELISA™. *Am J Trop Med Hyg.* 2011 Apr;84(4):587–93. [PMID: 21460015]

Matthaiou DK et al. Albendazole versus praziquantel in the treatment of neurocysticercosis: a meta-analysis of comparative trials. *PLoS Negl Trop Dis.* 2008 Mar 12;2(3):e194. [PMID: 18335068]

Nash TE et al. Diagnosis and treatment of neurocysticercosis. *Nat Rev Neurol.* 2011 Sep 13;7(10):584–94. [PMID: 21912406]

Sinha S et al. Neurocysticercosis: a review of current status and management. *J Clin Neurosci.* 2009 Jul;16(7):867–76. [PMID: 19394828]

2. Echinococcosis



ESSENTIALS OF DIAGNOSIS

- ▶ History of exposure to dogs or wild canines in an endemic area.
- ▶ Large cystic lesions, most commonly of the liver or lung.
- ▶ Positive serologic tests.

▶ General Considerations

Echinococcosis occurs when humans are intermediate hosts for canine tapeworms. Infection is acquired by ingesting food contaminated with canine feces containing parasite eggs. The principal species that infect humans are *Echinococcus granulosus*, which causes cystic hydatid disease, and *Echinococcus multilocularis*, which causes alveolar hydatid disease. *E granulosus* is transmitted by domestic dogs in areas with livestock (sheep, goats, camels, and horses) as intermediate hosts, including Africa, the Middle East, southern Europe, South America, Central Asia, Australia, New Zealand, and the southwestern United States. *E multilocularis*, which much less commonly causes human disease, is transmitted by wild canines, and endemic in northern forest areas of the northern hemisphere, including central Europe, Siberia, northern Japan, northwestern Canada, and western Alaska. An increase in the fox population in Europe has been associated with an increase in human cases. The disease range has also extended southward in Central Asia and China. Other species that cause limited disease in humans are endemic in South America and China.

After humans ingest parasite eggs, the eggs hatch in the intestines to form oncospheres, which penetrate the mucosa, enter the circulation, and encyst in specific organs as hydatid cysts. *E granulosus* forms cysts most commonly in the liver (65%) and lungs (25%), but the cysts may develop in any organ, including the brain, bones, skeletal muscles, kidneys, and spleen. Cysts are most commonly single. The cysts can persist and slowly grow for many years.

▶ Clinical Findings

A. Symptoms and Signs

Infections are commonly asymptomatic and may be noted incidentally on imaging studies or present with symptoms caused by an enlarging or superinfected mass. Findings may include abdominal or chest pain, biliary obstruction, cholangitis, portal hypertension, cirrhosis, bronchial obstruction leading to segmental lung collapse, and abscesses. Cyst leakage or rupture may be accompanied by a severe allergic reaction, including fever and hypotension. Seeding of cysts after rupture may extend the infection to new areas.

E multilocularis generally causes a more aggressive disease than *E granulosus*, with initial infection of the liver,

but then local and distant spread commonly suggesting a malignancy. Symptoms based on the areas of involvement gradually worsen over years, with the development of obstructive findings in the liver and elsewhere.

B. Laboratory Findings

Serologic tests, including ELISA and immunoblot, offer sensitivity and specificity over 80% for *E granulosus* liver infections, but lower sensitivity for involvement of other organs. Serologic tests may also distinguish the two major echinococcal infections.

C. Imaging

Diagnosis is usually based on imaging studies, including ultrasonography, CT, and MRI. In *E granulosus* infection, a large cyst containing daughter cysts is highly suggestive of the diagnosis. In *E multilocularis* infection, imaging shows an irregular mass, often with areas of calcification.

▶ Treatment

Treatment of cystic hydatid disease has traditionally involved cautious surgical resection of cysts, with care not to rupture cysts during removal. Injection of a cysticidal agent was used to limit spread in the case of rupture. Newer management algorithms include treatment with albendazole, often in conjunction with surgery. When used alone, as in cases where surgery is not possible, albendazole (10–15 mg/kg/d orally) has demonstrated efficacy, with courses of 3 months or longer duration, in some cases with alternating cycles of treatment and rest. Mebendazole (40–50 mg/kg/d orally) is an alternative drug, and praziquantel may also be effective. In some cases, medical therapy is begun, with surgery performed if disease persists after some months of therapy. Another approach, in particular with inoperable cysts, is percutaneous aspiration, injection, and reaspiration (PAIR). In this approach (which should not be used if cysts communicate with the biliary tract), patients receive antihelminthic therapy, and the cyst is partially aspirated. After diagnostic confirmation by examination for parasite protoscolices, a scolicidal agent (such as 95% ethanol, hypertonic saline, or 0.5% cetrimide) is injected. PAIR includes a small risk of anaphylaxis, which has been reported in about 2% of procedures, but death due to anaphylaxis has been rare. Treatment of alveolar cyst disease is challenging, generally relying on wide surgical resection of lesions. Therapy with albendazole before or during surgery may be beneficial and may also provide improvement or even cure in inoperable cases.

3. Other Invasive Cestode Infections

Ingestion of aquatic copepods infected with larvae of *Spirometra* canine or feline tapeworms can lead to sparganosis, especially in South America and East Asia. Infection can also come from ingestion of undercooked infected meat (including mammals, birds, reptiles, and amphibians) or from use of frog or snake-meat poultices. The worms penetrate the intestinal wall or skin and migrate to various tissues. Inflammatory lesions, most commonly of the skin

or eyes, are typically present. In cerebral sparganosis, an intense inflammatory response to worms can lead to severe neurologic disease. Diagnosis is by biopsy or visualization of the parasite. Treatment consists of surgical resection or local injection of ethanol. Anthelmintics do not appear to be helpful. Other non-human tapeworms can also cause localized and CNS inflammatory lesions. These are also managed with surgical resection.

Brunetti E et al. Cystic echinococcosis: chronic, complex, and still neglected. *PLoS Negl Trop Dis*. 2011 Jul;5(7):e1146. [PMID: 21814584]

Brunetti E et al; Writing Panel for the WHO-IWGE. Expert consensus for the diagnosis and treatment of cystic and alveolar echinococcosis in humans. *Acta Trop*. 2010 Apr;114(1):1–16. [PMID: 19931502]

Junghans T et al. Clinical management of cystic echinococcosis: state of the art, problems, and perspectives. *Am J Trop Med Hyg*. 2008 Sep;79(3):301–11. [PMID: 18784219]

Moro P et al. Echinococcosis: a review. *Int J Infect Dis*. 2009 Mar;13(2):125–33. [PMID: 18938096]

Nasser-Moghaddam S et al. Percutaneous needle aspiration, injection, and re-aspiration with or without benzimidazole coverage for uncomplicated hepatic hydatid cysts. *Cochrane Database Syst Rev*. 2011 Jan 19;(1):CD003623. [PMID: 21249654]

Neumayr A et al. Justified concern or exaggerated fear: the risk of anaphylaxis in percutaneous treatment of cystic echinococcosis—a systematic literature review. *PLoS Negl Trop Dis*. 2011 Jun;5(6):e1154. [PMID: 21695106]

INTESTINAL NEMATODE (ROUNDWORM) INFECTIONS

ASCARIASIS



ESSENTIALS OF DIAGNOSIS

- ▶ Transient cough, urticaria, pulmonary infiltrates, eosinophilia.
- ▶ Nonspecific abdominal symptoms.
- ▶ Eggs in stool; adult worms occasionally passed.

General Considerations

Ascaris lumbricoides is the most common of the intestinal helminths, infecting about a quarter of the world's population, with estimates of over a billion infections, 12 million acute cases, and 10,000 or more deaths annually. Prevalence is high wherever there is poor hygiene and sanitation or where human feces are used as fertilizer. Heavy infections are most common in children.

Infection follows ingestion of eggs in contaminated food. Larvae hatch in the small intestine, penetrate into the bloodstream, migrate to the lungs, and then travel via airways back to the gastrointestinal tract, where they develop to adult worms, which can be up to 40 cm in length, and live for 1–2 years.

Clinical Findings

Most persons with *Ascaris* infection are asymptomatic. In a small proportion of patients, symptoms develop during migration of worms through the lungs, with fever, nonproductive cough, chest pain, dyspnea, and eosinophilia, occasionally with eosinophilic pneumonia. Rarely, larvae lodge ectopically in the brain, kidney, eye, spinal cord, and other sites and may cause local symptoms.

Light intestinal infections usually produce no symptoms. With heavy infection, abdominal discomfort may be seen. Adult worms may also migrate and be coughed up, be vomited, or may emerge through the nose or anus. They may also migrate into the common bile duct, pancreatic duct, appendix, and other sites, which may lead to cholangitis, cholecystitis, pyogenic liver abscess, pancreatitis, obstructive jaundice, or appendicitis. With very heavy infestations, masses of worms may cause intestinal obstruction, volvulus, intussusception, or death. Although severe manifestations of infection are uncommon, the very high prevalence of ascariasis leads to large numbers of individuals, especially children, with important sequelae. Moderate to high worm loads in children are also associated with nutritional abnormalities due to decreased appetite and food intake, and also decreased absorption of nutrients.

The diagnosis of ascariasis is made after adult worms emerge from the mouth, nose, or anus, or by identifying characteristic eggs in the feces. Due to the very high egg burden, concentration techniques are generally not needed. Imaging studies demonstrate worms, with filling defects in contrast studies and at times evidence of intestinal or biliary obstruction. Eosinophilia is marked during worm migration but may be absent during intestinal infection.

Treatment

All infections should ideally be treated. Treatments of choice are albendazole (single 400 mg oral dose), mebendazole (single 500 mg oral dose or 100 mg twice daily for 3 days), or pyrantel pamoate (single 11 mg/kg oral dose, maximum 1 g). These drugs are all well tolerated but may cause mild gastrointestinal toxicity. They are considered safe for children above 1 year of age and in pregnancy, although use in the first trimester is best avoided. Intestinal obstruction usually responds to conservative management and anthelmintic therapy. Surgery may be required for appendicitis and other gastrointestinal complications.

TRICHURIASIS

Trichuris trichiura, the whipworm, infects about a billion persons throughout the world, particularly in humid tropical and subtropical environments. Infection is heaviest and most frequent in children. Infections are acquired by ingestion of eggs. The larvae hatch in the small intestine and mature in the large bowel to adult worms of about 4 cm in length. The worms do not migrate through tissues.

Most infected persons are asymptomatic. Heavy infections may be accompanied by abdominal cramps, tenesmus, diarrhea, distention, nausea, and vomiting. The *Trichuris* dysentery syndrome may develop, particularly in malnourished

young children, with findings resembling inflammatory bowel disease including bloody diarrhea and rectal prolapse. Chronic infections in children can lead to iron deficiency anemia, growth retardation, and clubbing of the fingers.

Trichuriasis is diagnosed by identification of characteristic eggs and sometimes adult worms in stools. Concentration techniques are not needed. Eosinophilia is common. Treatment is with albendazole (400 mg/d orally) or mebendazole (200 mg/d orally), for 1–3 days for light infections or 3–7 days for heavy infections, but cure rates are lower than for ascariasis or hookworm infection. The addition of ivermectin (200 mcg/kg orally daily for 1–2 days) to these drugs improves outcomes.

HOOKWORM DISEASE



ESSENTIALS OF DIAGNOSIS

- ▶ Transient pruritic skin rash and pulmonary symptoms.
- ▶ Anorexia, diarrhea, abdominal discomfort.
- ▶ Iron deficiency anemia.
- ▶ Characteristic eggs and occult blood in the stool.

▶ General Considerations

Infection with the hookworms *Ancylostoma duodenale* and *Necator americanus* is very common, especially in most tropical and subtropical regions. Both worms are broadly distributed. Prevalence is estimated at about 1 billion, causing approximately 65,000 deaths each year. When eggs are deposited on warm moist soil they hatch, releasing larvae that remain infective for up to a week. With contact, the larvae penetrate skin and migrate in the bloodstream to the pulmonary capillaries. In the lungs, the larvae penetrate into alveoli and then are carried by ciliary action upward to the bronchi, trachea, and mouth. After being swallowed, they reach and attach to the mucosa of the upper small bowel, where they mature to adult worms. *Ancylostoma* infection can also be acquired by ingestion of the larvae in food or water. Hookworms attach to the intestinal mucosa and suck blood. Blood loss is proportionate to the worm burden.

▶ Clinical Findings

A. Symptoms and Signs

Most infected persons are asymptomatic. A pruritic maculopapular rash (ground itch) may occur at the site of larval penetration, usually in previously sensitized persons. Pulmonary symptoms may be seen during larval migration through the lungs, with dry cough, wheezing, and low-grade fever, but these symptoms are less common than with ascariasis. About 1 month after infection, as maturing worms attach to the small intestinal mucosa, gastrointestinal symptoms may develop, with epigastric pain, anorexia, and diarrhea, especially in previously unexposed individuals. Persons chronically infected with large worm burdens

may have abdominal pain, anorexia, diarrhea, and findings of marked iron-deficiency anemia and protein malnutrition. Anemia can lead to pallor, weakness, dyspnea, and congestive heart failure, and protein loss can lead to hypoalbuminemia, edema, and ascites. These findings may be accompanied by impairment in growth and cognitive development in children. Infection with the dog hookworm *Ancylostoma caninum* can uncommonly lead to abdominal pain, diarrhea, and eosinophilia, with intestinal ulcerations and regional lymphadenitis.

B. Laboratory Findings

Diagnosis is based on the demonstration of characteristic eggs in feces; concentration techniques are usually not needed. Microcytic anemia, occult blood in the stool, and hypoalbuminemia are common. Eosinophilia is common, especially during worm migration.

▶ Treatment

Treatment is with albendazole (single 400 mg oral dose) or mebendazole (100 mg orally twice daily for 3 days). These drugs are teratogenic, but experience suggests that they are safe in children over 1 year of age and during the second and third trimesters of pregnancy. Occasional adverse effects are diarrhea and abdominal pain. Pyrantel pamoate and levamisole are also effective. Anemia should be managed with iron replacement and, for severe symptomatic anemia, blood transfusion. Mass treatment of children with single doses of albendazole or mebendazole at regular intervals limits worm burdens and the extent of disease and is advocated by the WHO.

STRONGYLOIDIASIS



ESSENTIALS OF DIAGNOSIS

- ▶ Transient pruritic skin rash and pulmonary symptoms.
- ▶ Anorexia, diarrhea, abdominal discomfort.
- ▶ Hyperinfection syndrome in the immunocompromised.
- ▶ Larvae detected in stool.
- ▶ With hyperinfection, larvae detected in sputum or other fluids.
- ▶ Eosinophilia.

▶ General Considerations

Strongyloidiasis is caused by infection with *Strongyloides stercoralis*. Although much less prevalent than ascariasis, trichuriasis, or hookworm infections, strongyloidiasis is nonetheless a significant problem, infecting tens of millions of individuals in tropical and subtropical regions. Infection is also endemic in some temperate regions of North America, Europe, Japan, and Australia. Of particular

importance is the predilection of the parasite to cause severe infections in immunocompromised individuals due to its ability to replicate in humans. A related parasite, *Strongyloides fuelleborni*, infects humans in parts of Africa and New Guinea.

Among nematodes, *S stercoralis* is uniquely capable of maintaining its full life cycle both within the human host and in soil. Infection occurs when filariform larvae in soil penetrate the skin, enter the bloodstream, and are carried to the lungs, where they escape from capillaries into alveoli, ascend the bronchial tree, and are then swallowed and carried to the duodenum and upper jejunum, where maturation to the adult stage takes place. Females live embedded in the mucosa for up to 5 years, releasing eggs that hatch in the intestines as free rhabditiform larvae that pass to the ground via the feces. In moist soil, these larvae metamorphose into infective filariform larvae. Autoinfection can occur in humans, when some rhabditiform larvae develop into filariform larvae that penetrate the intestinal mucosa or perianal skin, and enter the circulation. The most dangerous manifestation of *S stercoralis* infection is the **hyperinfection syndrome**, with dissemination of large numbers of filariform larvae to the lungs and other tissues in immunocompromised individuals. Mortality with this syndrome approaches 100% without treatment and has been about 25% with treatment. The hyperinfection syndrome is seen in patients receiving corticosteroids and other immunosuppressive medications; patients with hematologic malignancies, malnutrition, or alcoholism; or persons with AIDS. The risk seems greatest for those receiving corticosteroids, and considering the large number of at risk individuals, the risk in those with AIDS seems relatively low.

► Clinical Findings

A. Symptoms and Signs

As with other intestinal nematodes, most infected persons are asymptomatic. An acute syndrome can be seen at the time of infection, with a pruritic, erythematous, maculopapular rash, usually of the feet. These symptoms may be followed by pulmonary symptoms (including dry cough, dyspnea, and wheezing) and eosinophilia after a number of days, followed by gastrointestinal symptoms after some weeks, as with hookworm infections. Chronic infection may be accompanied by epigastric pain, nausea, diarrhea, and anemia. Maculopapular or urticarial rashes of the buttocks, perineum, and thighs, due to migrating larvae, may be seen. Large worm burdens can lead to malabsorption or intestinal obstruction. Eosinophilia is common but may fluctuate.

With **hyperinfection** large numbers of larvae can migrate to many tissues, including the lungs, CNS, kidneys, and liver. Gastrointestinal symptoms can include abdominal pain, nausea, vomiting, diarrhea, and more severe findings related to intestinal obstruction, perforation, or hemorrhage. Bacterial sepsis, probably secondary to intestinal ulcerations, is a common presenting finding. Pulmonary findings include pneumonitis, cough, hemoptysis, and respiratory failure. Sputum may contain adult worms, larvae, and eggs. CNS disease includes meningitis

and brain abscesses; the CSF may contain larvae. Various presentations can progress to shock and death.

B. Laboratory Findings

The diagnosis of strongyloidiasis can be difficult, as eggs are seldom found in feces. Diagnosis is usually based on the identification of rhabditiform larvae in the stool or duodenal contents. These larvae must be distinguished from hookworm larvae, which may hatch after stool collection. Repeated examinations of stool or examination of duodenal fluid may be required for diagnosis because the sensitivity of individual tests is only about 30%. Hyperinfection is diagnosed by the identification of large numbers of larvae in stool, sputum, or other body fluids. An ELISA from the CDC offers about 90% sensitivity and specificity, but cross-reactions with other helminths may occur. Eosinophilia and mild anemia are common, but eosinophilia may be absent with hyperinfection. Hyperinfection may include extensive pulmonary infiltrates, hypoproteinemia, and abnormal liver function studies.

C. Screening

It is important to be aware of the possibility of strongyloidiasis in persons with even a distant history of residence in an endemic area, since the infection can be latent for decades. Screening of at-risk individuals for infection is appropriate before institution of immunosuppressive therapy. Screening can consist of serologic tests, with stool examinations in those with positive serologic tests, but consideration of presumptive treatment even if the stool evaluations are negative (see below).

► Treatment

Full eradication of *S stercoralis* is more important than with other intestinal helminths due to the ability of the parasite to replicate in humans. The treatment of choice for routine infection is ivermectin (200 mcg orally daily for 1–2 days). This treatment has replaced thiabendazole (25 mg/kg orally twice daily for 3 days), which is relatively poorly tolerated, and albendazole (400 mg orally twice daily for 3 days), which is less effective. For hyperinfection, ivermectin should be administered daily until the clinical syndrome has resolved and larvae have not been identified for at least 2 weeks. Follow-up examinations for larvae in stool or sputum are necessary, with repeat dosing if the infection persists. With continued immunosuppression, eradication may be difficult, and regular repeated doses of antihelminthic therapy (eg, monthly ivermectin) may be required.

ENTEROBIOSIS



ESSENTIALS OF DIAGNOSIS

- Nocturnal perianal pruritus.
- Identification of eggs or adult worms on perianal skin or in stool.

► General Considerations

Enterobius vermicularis, the pinworm, is a common cause of intestinal infections worldwide, with maximal prevalence in school-age children. Enterobiasis is transmitted person-to-person via ingestion of eggs after contact with the hands or perianal region of an infected individual, food or fomites that have been contaminated by an infected individual, or infected bedding or clothing. Autoinfection also occurs. Eggs hatch in the duodenum and larvae migrate to the cecum. Females mature in about a month, and remain viable for about another month. During this time they migrate through the anus to deposit large numbers of eggs on the perianal skin. Due to the relatively short lifespan of these helminths, continuous reinfection, as in institutional settings, is required, for long-standing infection.

► Clinical Findings

A. Symptoms and Signs

Most individuals with pinworm infection are asymptomatic. The most common symptom is perianal pruritus, particularly at night, due to the presence of the female worms or deposited eggs. Insomnia, restlessness, and enuresis are common in children. Perianal scratching may result in excoriation and impetigo. Many mild gastrointestinal symptoms have also been attributed to enterobiasis, but associations are not proven. Serious sequelae are uncommon. Rarely, worm migration results in inflammation or granulomatous reactions of the gastrointestinal or genitourinary tracts. Colonic ulceration and eosinophilic colitis have been reported.

B. Laboratory Findings

Pinworm eggs are usually not found in stool. Diagnosis is made by finding adult worms or eggs on the perianal skin. A common test is to apply clear cellophane tape to the perianal skin, ideally in the early morning, followed by microscopic examination for eggs. The sensitivity of the tape test is reported to be about 50% for a single test and 90% for three tests. Nocturnal examination of the perianal area or gross examination of stools may reveal adult worms, which are about 1 cm in length. Eosinophilia is rare.

► Treatment

Treatment is with single oral doses of albendazole (400 mg), mebendazole (100 mg) or pyrantel pamoate (11 mg/kg, to a maximum of 1 g). The dose is repeated in 2 weeks due to frequent reinfection. Other infected family members should be treated concurrently, and treatment of all close contacts may be appropriate when rates of reinfection are high in family, school, or institutional settings. Standard handwashing and hygiene practices are helpful in limiting spread. Perianal scratching should be discouraged. Washing of clothes and bedding should kill pinworm eggs.

Bisoffi Z et al. Randomized clinical trial on ivermectin versus thiabendazole for the treatment of strongyloidiasis. *PLoS Negl Trop Dis*. 2011 Jul;5(7):e1254. [PMID: 21814588]

Hotez PJ et al. Neglected tropical diseases in sub-Saharan Africa: review of their prevalence, distribution, and disease burden. *PLoS Negl Trop Dis*. 2009 Aug 25;3(8):e412. [PMID: 19707588]

Keiser J et al. Efficacy of current drugs against soil-transmitted helminth infections: systematic review and meta-analysis. *JAMA*. 2008 Apr 23;299(16):1937–48. [PMID: 18430913]

Knopp S et al. Albendazole and mebendazole administered alone or in combination with ivermectin against *Trichuris trichiura*: a randomized controlled trial. *Clin Infect Dis*. 2010 Dec 15; 51(12):1420–8. [PMID: 21062129]

Marcos LA et al. Update on strongyloidiasis in the immunocompromised host. *Curr Infect Dis Rep*. 2011 Feb;13(1):35–46. [PMID: 21308453]

Steinmann P et al. Efficacy of single-dose and triple-dose albendazole and mebendazole against soil-transmitted helminths and *Taenia* spp.: a randomized controlled trial. *PLoS One*. 2011;6(9):e25003. [PMID: 21980373]

Vercruyse J et al. Assessment of the anthelmintic efficacy of albendazole in school children in seven countries where soil-transmitted helminths are endemic. *PLoS Negl Trop Dis*. 2011 Mar 29;5(3):e948. [PMID: 21468309]

INVASIVE NEMATODE (ROUNDWORM) INFECTIONS

DRACUNCULIASIS



ESSENTIALS OF DIAGNOSIS

- Tender cutaneous ulcer and worm protruding from the skin of an individual who has ingested untreated water in rural Africa.

► General Considerations

Dracunculiasis is caused by the nematode *Dracunculus medinensis*, or Guinea worm. It causes chronic cutaneous ulcers with protruding worms in rural Africa. It occurs only in humans and is a major cause of disability, although recent control efforts have been remarkably successful, with decreased annual incidence from about 3.5 million cases in the late 1980s to 1793 reported cases in 2010. Dracunculiasis has been eradicated from Asia, but remains endemic in a few countries in West and Northeast Africa, with > 90% of cases in South Sudan. The disease occurs almost exclusively in isolated rural areas; all ages are affected, and prevalence may reach 60%.

Infection occurs after swallowing water containing the infected intermediate host, the crustacean *Cyclops* (known as copepods or water fleas). In the stomach, larvae escape from the copepods and migrate through the intestinal mucosa to the retroperitoneum, where mating occurs. Females then migrate to subcutaneous tissue, usually of the legs, over about a year. A subcutaneous ulcer then forms. Upon contact with water, the parasite discharges large

numbers of larvae, which are ingested by copepods. Adult worms, which can be up to a meter in length, are gradually extruded. Worm death and disintegration in tissue may provoke a severe inflammatory reaction.

► Clinical Findings

Patients are usually asymptomatic until the time of worm extrusion. At that time a painful papule develops, with erythema, pruritus, and burning, usually on the lower leg. Multiple lesions may be present. At this time, some patients may also develop a short-lived systemic reaction, which may include fever, urticaria, nausea, vomiting, diarrhea, and dyspnea. The skin lesion vesiculates over a few days, followed by ulceration. The ulcer is tender, often with a visible worm. The worm is then extruded or absorbed over a few weeks, followed by ulcer healing. Secondary infections, including infectious arthritis and tetanus, are common. The disease causes significant disability; lesions commonly prevent walking for a month or more.

Diagnosis follows identification of a typical skin ulcer with a protruding worm. When the worm is not visible, larvae may be identified on smears or seen after immersion in cold water. Eosinophilia is usually present.

► Treatment

No drug cures the infection, but metronidazole and mebendazole are sometimes used to limit inflammation and facilitate worm removal. Wet compresses may relieve discomfort. Occlusive dressings improve hygiene and limit shedding of infectious larvae. Worms are typically removed by sequentially rolling them out over a small stick. When available, simple surgical procedures can be used to remove worms. Corticosteroid ointments may hasten healing. Topical antibiotics may limit bacterial superinfection.

► Prevention

Dracunculiasis has proven to be easier to control than most parasitic infections. The disease is prevented by avoidance of contaminated drinking water. This can be accomplished by boiling, chlorination, or filtration through finely woven cloth. A WHO dracunculiasis eradication program, initiated in 1986, has been highly successful.

Barry M. The tail end of guinea worm—global eradication without a drug or a vaccine. *N Engl J Med*. 2007 Jun 21;356(25):2561–4. [PMID: 17582064]

Centers for Disease Control and Prevention (CDC). Progress toward global eradication of dracunculiasis, January 2010–June 2011. *MMWR Morb Mortal Wkly Rep*. 2011 Oct 28;60(42):1450–3. [PMID: 22031217]

Hopkins DR et al. Dracunculiasis eradication: neglected no longer. *Am J Trop Med Hyg*. 2008 Oct;79(4):474–9. [PMID: 18840732]

TRICHINOSIS



ESSENTIALS OF DIAGNOSIS

- Ingestion of inadequately cooked pork or game.
- Transient intestinal symptoms followed by fever, myalgias, and periorbital edema.
- Eosinophilia and elevated serum muscle enzymes.

► General Considerations

Trichinosis (or trichinellosis) is caused worldwide by *Trichinella spiralis* and related *Trichinella* species. The disease is spread by ingestion of undercooked meat, most commonly pork in areas where pigs feed on garbage. When infected raw meat is ingested, *Trichinella* larvae are freed from cyst walls by gastric acid and pass into the small intestine. The larvae then invade intestinal epithelial cells, develop into adults, and the adults release infective larvae. These parasites travel to skeletal muscle via the bloodstream. They invade muscle cells, enlarge, and form cysts. These larvae may be viable for years. Pigs and other animals become infected by eating infected uncooked food scraps or other animals, such as rats.

The worldwide incidence of trichinosis has decreased, but human infections continue to occur sporadically or in outbreaks. In addition to undercooked pork, infections have been transmitted by ingestion of game and other animals, including bear and walrus in North America and wild boar and horse in Europe. In the United States, about 100 infections are reported annually, about three-fourths from pork and the remainder from game animals.

► Clinical Findings

A. Symptoms and Signs

Most infections are asymptomatic. In symptomatic cases, gastrointestinal symptoms, including diarrhea, vomiting, and abdominal pain, develop within the week after ingestion of contaminated meat. These symptoms usually last for less than a week but can occasionally persist for much longer. During the following week, symptoms and signs related to migrating larvae are seen. These findings include, most notably, fever, myalgias, periorbital edema, and eosinophilia. Additional findings may include headache, cough, dyspnea, hoarseness, dysphagia, macular or petechial rash, and subconjunctival and retinal hemorrhages. Systemic symptoms usually peak within 2–3 weeks, and commonly persist for about 2 months. In severe cases, generally with large parasite burdens, muscle involvement can be pronounced, with severe muscle pain, edema, and weakness, especially in the head and neck. Muscle pain may persist for months. Uncommon severe findings include myocarditis, pneumonitis, and meningoencephalitis, sometimes leading to death.

B. Laboratory Findings

The clinical diagnosis is supported by findings of elevated serum muscle enzymes (creatinine kinase, lactate dehydrogenase, aspartate aminotransferase). Serologic tests become positive 3 or more weeks after infection; a variety of techniques are used, including ELISA, immunofluorescence, indirect hemagglutinin, precipitin, and bentonite flocculation assays. Rising antibody titers are highly suggestive of the diagnosis. Muscle biopsy can usually be avoided, but if the diagnosis is uncertain, biopsy of a tender, swollen muscle may identify *Trichinella* larvae. For maximal yield, biopsy material should be examined histologically, and a portion should be enzymatically digested to release larvae, but evaluation before about 3 weeks after infection may not show muscle larvae.

► Treatment

No effective specific therapy for full-blown trichinosis has been identified. However, if infection is suspected early in the course of illness, treatment with mebendazole (2.5 mg/kg orally twice daily) or albendazole (5–7.5 mg/kg orally twice daily) will kill intestinal worms and may limit progression to tissue invasion. Supportive therapy for systemic disease consists of analgesics, antipyretics, bed rest and, in severe illness, corticosteroids. Infection is prevented by cooking to a temperature of at least 71°C for at least 1 minute. Irradiation of meat is also effective in eliminating *Trichinella* larvae, but freezing is not fully reliable.

Gottstein B et al. Epidemiology, diagnosis, treatment, and control of trichinellosis. *Clin Microbiol Rev.* 2009 Jan;22(1):127–45. [PMID: 19136437]

ANGIOSTRONGYLIASIS

Nematodes of rats of the genus *Angiostrongylus* cause two distinct syndromes in humans. *Angiostrongylus cantonensis*, the rat lungworm, causes eosinophilic meningoencephalitis, primarily in Southeast Asia and some Pacific islands. *Angiostrongylus costaricensis* causes gastrointestinal inflammation. In both diseases, human infection follows ingestion of larvae within slugs or snails (and also crabs or prawns for *A cantonensis*) or on material contaminated by these organisms. Since the parasites are not in their natural hosts, they cannot complete their life cycles, but they can cause disease after migrating to the brain or gastrointestinal tract.

► Clinical Findings

A. *A cantonensis* Infection

The disease appears to be caused primarily by worm larvae migrating through the CNS and an inflammatory response to dying worms. After an incubation period of 1 day to 2 weeks, presenting symptoms and signs include headache, stiff neck, nausea, vomiting, cranial nerve abnormalities, and paresthesias. Most cases resolve spontaneously after

2–8 weeks, but serious sequelae and death have been reported. The diagnosis is strongly suggested by the finding of eosinophilic CSF pleocytosis (leukocytosis with over 10% eosinophils) in a patient with a history of travel to an endemic area. Peripheral eosinophilia may not be present. *A cantonensis* larvae have rarely been recovered from the CSF and the eyes.

B. *A costaricensis* Infection

Parasites penetrate ileocecal vasculature and develop into adults, which lay eggs, but do not complete their life cycle. Disease is due to an inflammatory response to dying worms in the intestinal tract, with an eosinophilic granulomatous response, at times including vasculitis and ischemic necrosis. Common findings are abdominal pain, vomiting, and fever. Pain is most commonly localized to the right lower quadrant, and a mass may be appreciated, all mimicking appendicitis. Symptoms may recur over months. Uncommon findings are intestinal perforation or obstruction, or disease due to migration of worms to other sites. Many cases are managed surgically, usually for suspected appendicitis. Biopsy of inflamed intestinal tissue may show worms localized to mesenteric arteries and eosinophilic granulomas.

► Treatment

Anthelmintic therapy may be harmful for *A cantonensis* infection, since responses to dying worms may worsen with therapy. If anthelmintic treatment is to be used, albendazole is probably the best choice. Corticosteroids have been used in severe cases, and these are probably appropriate if anthelmintics are provided. It is not known if anthelmintic therapy is helpful for *A costaricensis* infection.

Ramirez-Avila L et al. Eosinophilic meningitis due to *Angiostrongylus* and *Gnathostoma* species. *Clin Infect Dis.* 2009 Feb 1;48(3):322–7. [PMID: 19123863]

Wang QP et al. Human angiostrongyliasis. *Lancet Infect Dis.* 2008 Oct;8(10):621–30. [PMID: 18922484]

GNATHOSTOMIASIS

A number of species of *Gnathostoma*, which are parasites of carnivores, can occasionally infect humans. Most cases have been seen in Southeast Asia, but the disease has also been described in many other areas. Eggs shed in the feces of mammals are ingested by marine crustaceans, which are then ingested by fish, frogs, snakes, or mammals. Larvae then encyst in muscles. Human infection follows eating undercooked fish, shellfish, chicken, or pork and can also be transmitted by ingesting copepods in contaminated water. After ingestion, larvae cannot complete development in humans, but rather migrate through tissues.

Acute gastrointestinal symptoms, including nausea, vomiting, abdominal pain, and fever, may develop soon after infection and persist for 2–3 weeks. The disease may then progress

to findings consistent with cutaneous or visceral larva migrans. Migratory subcutaneous erythematous swellings may be painful or pruritic. Migrating larvae may also invade other tissues, leading to findings in the eyes, lungs, intestines, and elsewhere. The most serious complications are due to invasion of the CNS, leading to eosinophilic meningoencephalitis and other serious findings. Although a less common cause of eosinophilic meningitis than *A cantonensis* infection, gnathostomiasis tends to be more severe. Severe pain due to migration through spinal roots and focal neurologic findings may be seen. Symptoms are highly variable over time. CSF eosinophilic pleocytosis and peripheral eosinophilia are seen.

The diagnosis of gnathostomiasis is suggested by the history of intermittent subcutaneous swellings and typical CNS findings and established by identification of worms in tissues. Worms can occasionally be identified in skin lesions. Serologic tests may be helpful in establishing a diagnosis. Treatment is with ivermectin (200 mcg/kg orally single dose) or albendazole (400 mg/kg/d orally for 21 days). However, indications for treatment are uncertain with CNS disease, as inflammatory responses to dying worms might worsen outcomes, and corticosteroids may be indicated with antihelminthics in these cases.

Graeff-Teixeira C et al. Update on eosinophilic meningoencephalitis and its clinical relevance. *Clin Microbiol Rev.* 2009 Apr;22(2):322–48. [PMID: 19366917]

Herman JS et al. Gnathostomiasis, another emerging imported disease. *Clin Microbiol Rev.* 2009 Jul;22(3):484–92. [PMID: 19597010]

TOXOCARIASIS

► General Considerations

The dog roundworm *Toxocara canis*, the cat roundworm *Toxocara cati*, and less commonly other helminths may cause visceral larva migrans. *T canis* is highly prevalent in dogs. Humans are infected after ingestion of eggs in material contaminated by dog or other feces. With *T canis*, infection is spread principally by puppies and lactating females, and the eggs must be on the ground for several weeks before they are infectious. After ingestion by humans, larvae migrate to various tissues but cannot complete their life cycle.

► Clinical Findings

Visceral larva migrans is seen principally in young children. Most infections are asymptomatic. The most commonly involved organs are the liver and lungs. Presentations include cough, fever, wheezing, hepatomegaly, splenomegaly, lymphadenopathy, pulmonary infiltrates, and eosinophilia. Involvement of the CNS can occur rarely, leading to eosinophilic meningitis and other abnormalities. Ocular larva migrans is a distinct syndrome, usually in children older than is typical for visceral larva migrans. Children present with visual deficits, pain, and a retinal mass, which can be confused with retinoblastoma. *Baylisascaris procyonis*, a roundworm of raccoons, can rarely cause visceral larva migrans in humans, with typically more severe

manifestations than those with *T canis*, including eosinophilic meningitis and eye disease.

The diagnosis of visceral larva migrans is suggested by the finding of eosinophilia in a child with hepatomegaly or other signs of the disease, especially with a history of exposure to puppies. The diagnosis is confirmed by the identification of larvae in a biopsy of infected tissue, usually performed when other diseases are suspected. Serologic tests may be helpful; an available ELISA was estimated to have 78% sensitivity and 92% specificity. Most patients recover without specific therapy, although symptoms may persist for months.

► Treatment

Treatment with antihelminthics or corticosteroids may be considered in severe cases. No drugs have been proven to be effective, but albendazole (400 mg orally twice daily for 5 days), mebendazole, thiabendazole, diethylcarbamazine, and ivermectin have been used, and albendazole has been recommended as the treatment of choice.

Rubinsky-Elefant G et al. Human toxocariasis: diagnosis, worldwide seroprevalences and clinical expression of the systemic and ocular forms. *Ann Trop Med Parasitol.* 2010 Jan;104(1):3–23. [PMID: 20149289]

CUTANEOUS LARVA MIGRANS (Creeping Eruption)

Cutaneous larva migrans is caused principally by larvae of the dog and cat hookworms, *Ancylostoma braziliense* and *A caninum*. Other animal hookworms, gnathostomiasis, and strongyloidiasis may also cause this syndrome. Infections are common in warm areas, including the southeastern United States. They are most common in children. The disease is caused by the migration of worms through skin; the non-human parasites cannot complete their life cycles, so only cause cutaneous disease.

► Clinical Findings

Intensely pruritic erythematous papules develop, usually on the feet or hands, followed within a few days by serpiginous tracks marking the course of the parasite, which may travel several millimeters per day (Figure 35–8). Several tracks may be present. The process may continue for weeks, with lesions becoming vesiculated, encrusted, or secondarily infected. Systemic symptoms or eosinophilia are uncommon.

The diagnosis is based on the characteristic appearance of the lesions. Biopsy is usually not indicated.

► Treatment

Without treatment, the larvae eventually die and are absorbed. Mild cases do not require treatment. Thiabendazole (10% aqueous suspension) can be applied topically three times daily for 5 or more days. Systemic therapy with albendazole (400 mg orally once or twice daily for 3–5 days) or ivermectin (200 mcg/kg orally single dose) is highly effective.



▲ **Figure 35-8.** Cutaneous larva migrans on the foot. (Courtesy of Richard P. Usatine, MD from Usatine RP: A rash on the feet and buttocks. *Western Journal of Medicine* 1999;170(6):344; used, with permission, from Usatine RP, Smith MA, Mayeux EJ Jr, Chumley H, Tysinger J. *The Color Atlas of Family Medicine*. McGraw-Hill, 2009.)

Heukelbach J et al. Epidemiological and clinical characteristics of hookworm-related cutaneous larva migrans. *Lancet Infect Dis.* 2008 May;8(5):302–9. [PMID: 18471775]

ANISAKIASIS

Anisakiasis is caused by infection with larvae of parasites of saltwater fish and squid. Multiple species of the family *Anisakidae* may occasionally infect humans. Definitive hosts for these parasites are marine mammals. Eggs are passed in the feces and ingested by crustaceans, which are then eaten by fish and squid. When ingested by humans in undercooked seafood, larvae penetrate the stomach or intestinal wall but cannot complete their life cycle. The disease is most common in Japan.

► Clinical Findings

Clinical manifestations of anisakiasis follow burrowing of worms into the stomach or intestinal wall, leading to localized ulceration, edema, and eosinophilic granuloma formation. Symptoms usually occur within 2 days of parasite ingestion and include severe epigastric or abdominal pain, nausea, and vomiting. Intestinal involvement can mimic appendicitis. Allergic symptoms, including urticaria, angioedema, and anaphylaxis, have also been attributed to acute infection. Acute symptoms generally resolve within 2 weeks, but chronic symptoms may also be seen, suggesting chronic intestinal diseases such as inflammatory bowel disease, diverticulitis, or carcinoma. Rarely, worms may migrate to other sites or be coughed up. Eosinophilia is usually not seen.

The diagnosis of anisakiasis is suggested in those with acute abdominal symptoms after ingestion of raw fish. Radiographic studies may identify stomach or intestinal lesions, and endoscopy may allow visualization and removal of the worm. When surgery is performed due to

consideration of other diagnoses, eosinophilic inflammatory lesions and the invading worms are found.

► Treatment

Specific therapy is not indicated, but endoscopic worm removal hastens recovery. The parasites are killed by cooking or deep freezing fish.

Hochberg NS et al. Anisakidosis: perils of the deep. *Clin Infect Dis.* 2010 Oct 1;51(7):806–12. [PMID: 20804423]

Yasunaga H et al. Clinical features of bowel anisakiasis in Japan. *Am J Trop Med Hyg.* 2010 Jul;83(1):104–5. [PMID: 20595486]

FILARIASIS

LYMPHATIC FILARIASIS

ESSENTIALS OF DIAGNOSIS

- ▶ Episodic attacks of lymphangitis, lymphadenitis, and fever.
- ▶ Chronic progressive swelling of extremities and genitals; hydrocele; chyluria; lymphedema.
- ▶ Microfilariae in blood, chyluria, or hydrocele fluid; positive serologic tests.

Lymphatic filariasis is caused by three filarial nematodes: *Wuchereria bancrofti*, *Brugia malayi*, and *Brugia timori*, and is among the most important parasitic diseases of man. Approximately 120 million people are infected with these organisms in tropical and subtropical countries, about a third of these suffer clinical consequences of the infections, and many are seriously disfigured. *W bancrofti* causes about 90% of episodes of lymphatic filariasis. It is transmitted by *Culex*, *Aedes*, and *Anopheles* mosquitoes and is widely distributed in the tropics and subtropics, including subsaharan Africa, Southeast Asia, the western Pacific, India, South America, and the Caribbean. *B malayi* is transmitted by *Mansonia* and *Anopheles* mosquitoes and is endemic in parts of China, India, Southeast Asia, and the Pacific. *B timori* is found only in islands of southeastern Indonesia. *Mansonella* are filarial worms transmitted by midges and other insects in Africa and South America.

Humans are infected by the bites of infected mosquitoes. Larvae then move to the lymphatics and lymph nodes, where they mature over months to thread-like adult worms, and then can persist for many years. The adult worms produce large numbers of microfilariae, which are released into the circulation, and infective to mosquitoes, particularly at night (except for the South Pacific, where microfilaremia peaks during daylight hours).

► Clinical Findings

A. Symptoms and Signs

Many infections remain asymptomatic despite circulating microfilariae. Clinical consequences of filarial infection are principally due to inflammatory responses to developing, mature, and dying worms. The initial manifestation of infection is often acute lymphangitis, with fever, painful lymph nodes, edema, and inflammation spreading peripherally from involved lymph nodes (in contrast to bacterial lymphangitis, which spreads centrally). Lymphangitis and lymphadenitis of the upper and lower extremities is common (Figure 35–9); genital involvement, including epididymitis and orchitis, with scrotal pain and tenderness, occurs principally only with *W bancrofti* infection. Acute attacks of lymphangitis last for a few days to a week and may recur a few times per year. Filarial fevers may also occur without lymphatic inflammation.

The most common chronic manifestation of lymphatic filariasis is swelling of the extremities or genitals due to chronic lymphatic inflammation and obstruction. Extremities become increasingly swollen, with a progression over time from pitting edema, to nonpitting edema, to sclerotic changes of the skin that are referred to as elephantiasis. Genital involvement, particularly with *W bancrofti*, occurs more commonly in men, progressing from painful epididymitis to hydroceles that are usually painless but can become very large, with inguinal lymphadenopathy, thickening of the spermatic cord, scrotal lymphedema, thickening and fissuring of the scrotal skin, and occasionally chyluria. Lymphedema of the female genitalia and breasts may also occur.

Tropical pulmonary eosinophilia is a distinct syndrome principally affecting young adult males with either *W bancrofti* or *B malayi* infection but typically without microfilaremia. This syndrome is characterized by asthma-like symptoms, with cough, wheezing, dyspnea, and low-grade

fevers, usually at night. Without treatment, tropical pulmonary eosinophilia can progress to interstitial fibrosis and chronic restrictive lung disease. *Mansonella* can inhabit serous cavities, the retroperitoneum, the eye, or the skin, and cause abnormalities related to inflammation at these sites.

B. Laboratory Findings

The diagnosis of lymphatic filariasis is strongly suggested by characteristic findings of lymphangitis or lymphatic obstruction in persons with risk factors for the disease. The diagnosis is confirmed by finding microfilariae, usually in blood, but this may be difficult. In addition, microfilariae may be absent, especially early in the disease progression (first 2–3 years) or with chronic obstructive disease. To increase yields, blood samples are obtained at about midnight in most areas, but not in the South Pacific, where microfilaremia is diurnal. Smears are evaluated by wet mount to identify motile parasites and by Giemsa staining; these examinations can be delayed until the following morning, with storage of samples at room temperature. Of note, the periodicity of microfilaremia is variable, and daytime samples may yield positive results. Microfilariae may also be identified in hydrocele fluid or chylous urine. Eosinophilia is usually absent, except during acute inflammatory syndromes. Available serologic tests, including bentonite flocculation, indirect hemagglutination, ELISA, and indirect fluorescent antibody tests, may be helpful but cannot distinguish between past and active infections. Rapid antigen tests with sensitivity and specificity over 90% are available, and these are increasingly used to guide control programs. Adult worms may also be found in lymph node biopsy specimens (although biopsy is not usually clinically indicated) or by ultrasound of a scrotal hydrocele or lymphedematous breast. When microfilaremia is lacking, especially if sophisticated techniques are not available, diagnoses may need to be made on clinical grounds alone.

► Treatment & Control

A. Drug Treatment

Treatment is somewhat controversial, as no drug can fully control or reverse the disease, and treatment may cause serious acute inflammatory symptoms. Diethylcarbamazine is the drug of choice, but it cannot cure infections due to its limited action against adult worms. Asymptomatic infection and acute lymphangitis are treated with this drug (2 mg/kg orally three times daily) for 10–14 days, leading to a marked decrease in microfilaremia. Therapy may be accompanied by allergic symptoms, including fever, headache, malaise, hypotension, and bronchospasm, probably due to release of antigens from dying worms. For this reason, treatment courses may begin with a lower dosage, with escalation over the first 4 days of treatment. Single annual doses of diethylcarbamazine (6 mg/kg orally), alone or with ivermectin (400 mcg/kg orally) or albendazole (400 mg orally) may be as effective as longer courses of diethylcarbamazine. When onchocerciasis or loiasis is suspected, it may be appropriate to withhold diethylcarbamazine to avoid severe reactions to dying microfilariae; rather, ivermectin plus albendazole may



▲ **Figure 35–9.** Elephantiasis of legs due to filariasis. (Public Health Image Library, CDC.)

be given, although these drugs are less active than diethylcarbamazine against adult worms. Appropriate management of advanced obstructive disease is uncertain. Drainage of hydroceles provides symptomatic relief, although they will recur. Therapy with diethylcarbamazine cannot reverse chronic lymphatic changes but is typically provided to lower worm burdens. An interesting approach under study is to treat with doxycycline (100–200 mg/d orally for 4–6 weeks), which kills obligate intracellular *Wolbachia* bacteria, leading to death of adult filarial worms. Doxycycline was also effective at controlling *Mansonella perstans* infection, which does not respond well to standard antifilarial drugs. Secondary bacterial infections must be treated. Surgical correction may be helpful in some cases.

B. Disease Control

Avoidance of mosquitoes is a key measure; preventive measures include the use of screens, bed nets (ideally treated with insecticide), and insect repellents. Community-based treatment with single annual doses of effective drugs offers a highly effective means of control. The current WHO strategy for control includes mass treatment of at risk communities with single annual doses of diethylcarbamazine plus albendazole or, for areas with onchocerciasis, albendazole plus ivermectin; in some circumstances, more frequent dosing offers improved control.

Coulbaly YI et al. A randomized trial of doxycycline for *Mansonella perstans* infection. *N Engl J Med*. 2009 Oct 8;361(15):1448–58. [PMID: 19812401]

Hoerauf A et al. Filariasis in Africa—treatment challenges and prospects. *Clin Microbiol Infect*. 2011 Jul;17(7):977–85. [PMID: 21722251]

Ottesen EA et al. The global programme to eliminate lymphatic filariasis: health impact after 8 years. *PLoS Negl Trop Dis*. 2008 Oct 8;2(10):e317. [PMID: 18841205]

Rosenblatt JE. Laboratory diagnosis of infections due to blood and tissue parasites. *Clin Infect Dis*. 2009 Oct 1;49(7):1103–8. [PMID: 19691431]

Supali T et al. Doxycycline treatment of *Brugia malayi*-infected persons reduces microfilaremia and adverse reactions after diethylcarbamazine and albendazole treatment. *Clin Infect Dis*. 2008 May 1;46(9):1385–93. [PMID: 18419441]

Taylor MJ et al. Lymphatic filariasis and onchocerciasis. *Lancet*. 2010 Oct 2;376(9747):1175–85. [PMID: 20739055]

Tisch DJ et al. Reduction in acute filariasis morbidity during a mass drug administration trial to eliminate lymphatic filariasis in Papua New Guinea. *PLoS Negl Trop Dis*. 2011 Jul; 5(7):e1241. [PMID: 21765964]

ONCHOCERCIASIS



ESSENTIALS OF DIAGNOSIS

- ▶ Severe pruritus; skin excoriations, thickening, and depigmentation; and subcutaneous nodules.
- ▶ Conjunctivitis progressing to blindness.
- ▶ Microfilariae in skin snips and on slit-lamp examination; adult worms in subcutaneous nodules.

▶ General Considerations

Onchocerciasis, or river blindness is caused by *Onchocerca volvulus*. An estimated 18 million persons are infected, of whom 3–4 million have skin disease, 500,000 have severe visual impairment, and 300,000 are blinded. Over 99% of infections are in subsaharan Africa, especially the West African savanna, with about half of cases in Nigeria and Congo. In some hyperendemic African villages, close to 100% of individuals are infected, and 10% or more of the population is blind. The disease is also prevalent in the southwestern Arabian peninsula and Latin America, including southern Mexico, Guatemala, Venezuela, Colombia, Ecuador, and northwestern Brazil. Onchocerciasis is transmitted by simulium flies (blackflies). These insects breed in fast-flowing streams and bite during the day.

After the bite of an infected blackfly, larvae are deposited in the skin, where adults develop over 6–12 months. Adult worms live in subcutaneous connective tissue or muscle nodules for a decade or more. Microfilariae are released from the nodules and migrate through subcutaneous and ocular tissues. Disease is due to responses to worms and to intracellular *Wolbachia* bacteria.

▶ Clinical Findings

A. Symptoms and Signs

After an incubation period of up to 1–3 years, the disease typically produces an erythematous, papular, pruritic rash, which may progress to chronic skin thickening and depigmentation. Itching may be severe and unresponsive to medications, such that more disability-adjusted life years are lost to onchocercal skin problems than to blindness. Numerous firm, nontender, movable subcutaneous nodules of about 0.5–3 cm, which contain adult worms, may be present. Due to differences in vector habits, these nodules are more commonly on the lower body in Africa but on the head and upper body in Latin America. Inguinal and femoral lymphadenopathy is common, at times resulting in a “hanging groin,” with lymph nodes hanging within a sling of atrophic skin. Patients may also have systemic symptoms, with weight loss and musculoskeletal pain.

The most serious manifestations of onchocerciasis involve the eyes. Microfilariae migrating through the eyes elicit host responses that lead to pathology. Findings include punctate keratitis and corneal opacities, progressing to sclerosing keratitis and blindness. Iridocyclitis, glaucoma, choroiditis, and optic atrophy may also lead to vision loss. The likelihood of blindness after infection varies greatly based on geography, with the risk greatest in savanna regions of West Africa.

B. Diagnostic Testing

The diagnosis is made by identifying microfilariae in skin snips, by visualizing microfilariae in the cornea or anterior chamber by slit-lamp examination, by identification of adult worms in a biopsy or aspirate of a nodule or, uncommonly, by identification of microfilariae in urine. Skin snips from the iliac crest (Africa) or scapula (Americas) are allowed to stand in saline for 2–4 hours or longer, and then examined microscopically for microfilariae. Deep punch

biopsies are not needed, and if suspicion persists after a skin snip is negative, the procedure should be repeated. Ultrasound may identify characteristic findings suggestive of adult worms in skin nodules. When the diagnosis remains difficult, the Mazzotti test can be used. In this test, a 50-mg dose of diethylcarbamazine is given. A positive test, with exacerbation of skin rash and pruritus, usually within 3 hours, is highly suggestive of the diagnosis. This test should only be used in suspected lightly infected patients (after other tests are negative), as this treatment can elicit severe skin and eye reactions in heavily infected individuals. A related and safer test using topical diethylcarbamazine is available in some areas. Eosinophilia is a common, but inconsistent finding. Serologic tests are poorly standardized, nonspecific, and generally unhelpful, as in endemic areas positivity is not indicative of acute disease.

▶ Treatment & Control

The treatment of choice is ivermectin, which has replaced diethylcarbamazine due to a much lower risk of severe reactions to therapy. Ivermectin kills microfilariae, but not adult worms, so disease control requires repeat administrations. Treatment is with a single oral dose of 150 mcg/mL, but schedules for re-treatment have not been standardized. One regimen is to treat every 3 months for 1 year, followed by treatment every 6–12 months for the suspected lifespan of adult worms (about 15 years). Treatment results in marked reduction in numbers of microfilariae in the skin and eyes, although its impact on the progression of visual loss remains uncertain. Toxicities of ivermectin are generally mild; fever, pruritus, urticaria, myalgias, edema, hypotension, and tender lymphadenopathy may be seen, presumably due to reactions to dying worms. Ivermectin should be used with caution in patients also at risk for loiasis, since it can elicit severe reactions including encephalopathy. In patients with severe skin findings not controlled by ivermectin, therapy with suramin may be considered. This is the only drug known to kill adult worms, but it is very toxic. As with other filarial infections, doxycycline acts against *O. volvulus* by killing intracellular *Wolbachia* bacteria. A course of 100 mg/day for 6 weeks kills the bacteria and prevents parasite embryogenesis for at least 18 months. Doxycycline is under study for onchocerciasis control but has no clear role in treatment of individual affected patients.

Protection against onchocerciasis includes avoidance of biting flies. Major efforts are underway to control insect vectors in Africa. In addition, mass distribution of ivermectin for intermittent administration at the community level is ongoing, and the prevalence of severe skin and eye disease is decreasing.

Basáñez MG et al. Effect of single-dose ivermectin on *Onchocerca volvulus*: a systematic review and meta-analysis. *Lancet Infect Dis*. 2008 May;8(5):310–22. [PMID: 18471776]

Diawara L et al. Feasibility of onchocerciasis elimination with ivermectin treatment in endemic foci in Africa: first evidence from studies in Mali and Senegal. *PLoS Negl Trop Dis*. 2009 Jul 21;3(7):e497. [PMID: 19621091]

Udall DN. Recent updates on onchocerciasis: diagnosis and treatment. *Clin Infect Dis*. 2007 Jan 1;44(1):53–60. [PMID: 17143815]

LOIASIS



ESSENTIALS OF DIAGNOSIS

- ▶ Subcutaneous swellings; adult worms migrating across the eye.
- ▶ Encephalitis, which may be brought on by treatment.
- ▶ Microfilariae in the blood.

▶ General Considerations

Loiasis is a chronic filarial disease caused by infection with *Loa loa*. The infection occurs in humans and monkeys in rainforest areas of West and central Africa. An estimated 3–13 million persons are infected. The disease is transmitted by chrysops flies, which bite during the day. Over 6–12 months after infection, larvae develop into adult worms, which migrate through subcutaneous tissues, including the subconjunctiva (leading to the term “eye worm”). Adults can live for up to 17 years.

▶ Clinical Findings

A. Symptoms and Signs

Many infected persons are asymptomatic, although they may have high levels of microfilaremia and eosinophilia. Transient subcutaneous swellings (Calabar swellings) develop in symptomatic persons. The swellings are non-erythematous, up to 20 cm in diameter, and may be preceded by local pain or pruritus. They usually resolve after 2–4 days but occasionally persist for several weeks. Calabar swellings are commonly seen around joints and may recur at the same or different sites. Visitors from nonendemic areas are more likely to have allergic-type reactions, including pruritus, urticaria, and angioedema. Adult worms may be seen to migrate across the eye, with either no symptoms or conjunctivitis, with pain and edema. The most serious complication of loiasis is encephalitis, which is most common in those with high level microfilaremia and microfilariae in the CSF. Symptoms may range from headache and insomnia to coma and death. Encephalitis may be brought on by treatment with diethylcarbamazine or ivermectin. Other complications of loiasis include kidney disease, with hematuria and proteinuria; endomyocardial fibrosis; and peripheral neuropathy.

B. Laboratory Findings

The diagnosis is established by identifying microfilariae in blood. Blood is evaluated as for lymphatic filariasis, but for loiasis blood should be obtained during the day. The failure to find microfilariae does not rule out the diagnosis. Identification of a migrating eye worm is also diagnostic. Serologic tests may be helpful in persons from nonendemic areas who may be acutely ill without detectable microfilaremia, but such tests have limited utility for residents of endemic areas because most of them will have positive test results. PCR methods have been described to

rule out loiasis before administration of ivermectin for the control of other filarial infections.

▶ Treatment

The treatment of choice is diethylcarbamazine, which eliminates microfilariae and has some activity against adult worms. Treatment with 8–10 mg/kg/d orally for 21 days is curative in about 50% of amicrofilaremic patients, and repeat courses increase efficacy. Mild side effects are common with therapy, including fever, pruritus, arthralgias, nausea, diarrhea, and Calabar swellings. These symptoms may be lessened by administration of antihistamines or corticosteroids. Patients with large worm burdens are at greater risk for serious complications of therapy, including kidney injury, shock, encephalitis, coma, and death. Treatment with ivermectin, which is highly active against microfilariae, but not adult worms, also entails a high risk of severe reactions. To attempt to avoid these sequelae,

pretreatment with corticosteroids and antihistamines, and escalating dosage of diethylcarbamazine have been used, but this strategy does not prevent encephalitis. The circulating parasite load that indicates particular risk for severe complications with therapy has been estimated at 2500/mL or greater. Strategies to treat patients with high parasite loads include (1) no treatment; (2) apheresis, if available, to remove microfilariae prior to therapy with diethylcarbamazine; or (3) therapy with albendazole, which appears to be well tolerated due to its slow antiparasitic effects, prior to therapy with diethylcarbamazine or ivermectin.

Fink DL et al. Rapid molecular assays for specific detection and quantitation of *Loa loa* microfilaremia. *PLoS Negl Trop Dis*. 2011 Aug;5(8):e1299. [PMID: 21912716]
Padgett JJ et al. Loiasis: African eye worm. *Trans R Soc Trop Med Hyg*. 2008 Oct;102(10):983–9. [PMID: 18466939]

Mycotic Infections

Samuel A. Shelburne, MD, PhD
Richard J. Hamill, MD

36

Fungal infections have assumed an increasingly important role as use of broad-spectrum antimicrobial agents has increased and the number of immunodeficient patients has grown. Some pathogens (eg, *Cryptococcus*, *Candida*, *Pneumocystis*, *Fusarium*) rarely cause serious disease in normal hosts. Other endemic fungi (eg, *Histoplasma*, *Coccidioides*, *Paracoccidioides*) commonly cause disease in normal hosts but tend to be more aggressive in immunocompromised ones. Superficial mycoses are discussed in Chapter 6.

Successful management of most systemic fungal infections requires knowledge of the natural history of these diseases as well as familiarity with the unique pharmacokinetics, adverse effects, and drug interactions of the various therapeutic agents. Furthermore, most affected individuals usually have significant underlying illnesses. Consequently, clinicians with extensive experience in the management of these disorders should be routinely consulted.

CANDIDIASIS



ESSENTIALS OF DIAGNOSIS

- ▶ Common normal flora but opportunistic pathogen.
- ▶ Gastrointestinal mucosal disease, particularly esophagitis, most common.
- ▶ Intravenous catheter-associated fungemia occurs in patients who have sustained cutaneous or mucosal injury, undergone instrumentation, or received broad-spectrum antibiotics.

▶ General Considerations

Candida albicans can be cultured from the mouth, vagina, and feces of most people. Cutaneous and oral lesions are discussed in Chapters 6 and 8, respectively. The risk factors for invasive candidiasis include prolonged neutropenia, recent abdominal surgery, broad-spectrum antibiotic therapy, advanced chronic kidney disease, and the presence of

intravascular catheters (especially when providing total parenteral nutrition). Cellular immunodeficiency predisposes to mucocutaneous disease. When no other underlying cause is found, persistent oral or vaginal candidiasis should arouse a suspicion of HIV infection.

▶ Clinical Findings

A. Mucosal Candidiasis

Esophageal involvement is the most frequent type of significant mucosal disease. Presenting symptoms include substernal odynophagia, gastroesophageal reflux, or nausea without substernal pain. Oral candidiasis, though often associated, is not invariably present. Diagnosis is best confirmed by endoscopy with biopsy and culture.

Vulvovaginal candidiasis occurs in an estimated 75% of women during their lifetime. Risk factors include pregnancy, uncontrolled diabetes mellitus, broad-spectrum antimicrobial treatment, corticosteroid use, and HIV infection. Symptoms include acute vulvar pruritus, burning vaginal discharge, and dyspareunia.

B. Candidal Funguria

Most cases of candidal funguria are asymptomatic and represent specimen contamination or bladder colonization. However, signs and symptoms of true *Candida* urinary tract infections are indistinguishable from bacterial urinary tract infections and can include urgency, hesitancy, fever, chills, or flank pain.

C. Disseminated Candidiasis

The diagnosis of disseminated *Candida* infection is problematic because *Candida* species are often isolated from mucosal sites in the absence of invasive disease while blood cultures are positive only 50% of the time in disseminated infection. Serologic tests have not proved useful for distinguishing colonization from invasive disease. Isolation of *Candida* species from blood cultures may represent a benign, self-limited process, but until proven otherwise it should be considered a sign of serious, complicated disease.

Another form of invasive disease is hepatosplenic candidiasis. This results from aggressive chemotherapy and prolonged neutropenia in patients with underlying hematologic cancers. Typically, fever and variable abdominal pain present weeks after chemotherapy, when neutrophil counts have recovered. Blood cultures are generally negative. Hepatic enzymes reveal an alkaline phosphatase elevation that may be marked.

D. Candidal Endocarditis

Candidal endocarditis is a rare infection that is most frequently associated with exposure to a healthcare setting. Candidal endocarditis occurs with increased frequency on prosthetic valves in the first few months following surgery. The diagnosis is established definitively by culturing *Candida* from emboli or from vegetations at the time of valve replacement.

► Treatment

A. Mucosal Candidiasis

Therapy of **esophageal candidiasis** depends on the severity of disease. If patients are able to swallow and take adequate amounts of fluid orally, fluconazole, 100 mg/d (or itraconazole solution, 10 mg/mL, 200 mg/d), for 10–14 days usually suffices. In the individual who is more ill or in whom esophagitis has developed while taking fluconazole, options include oral or intravenous voriconazole, 200 mg twice daily; intravenous amphotericin B, 0.3 mg/kg/d; intravenous caspofungin, 50 mg/d; intravenous anidulafungin, 100 mg on day 1, then 50 mg/d; or intravenous micafungin, 150 mg/d. Relapse is common with all agents when there is underlying HIV infection without adequate immune reconstitution.

Various topical azole preparations (eg, clotrimazole, 100 mg vaginal tablet for 7 days, or miconazole, 200 mg vaginal suppository for 3 days) are effective against **vulvovaginal candidiasis**. One 150 mg oral dose of fluconazole has been shown to have equivalent efficacy with better patient acceptance. Disease recurrence is common but can be decreased with weekly fluconazole therapy (150 mg weekly).

B. Candidal Funguria

Candidal funguria frequently resolves with discontinuance of antibiotics or removal of bladder catheters. Clinical benefit from treatment of asymptomatic candiduria has not been demonstrated, but persistent funguria should raise the suspicion of disseminated infection. When symptomatic funguria persists, oral fluconazole, 200 mg/d for 7–14 days, can be used. Newer generation azoles (eg, voriconazole) and echinocandins are not considered standard therapy for candidal urinary tract infections due to low levels of active drug in the urine.

C. Disseminated Candidiasis

The decision to treat for disseminated *Candida* when organisms are isolated from urine or sputum (or both) needs to be individualized for each patient. A randomized

trial of empiric fluconazole for patients at high risk for, but not proven to have, disseminated candidiasis showed no clinical benefit compared with placebo.

The 2009 guidelines for treatment of invasive candidiasis recommend fluconazole (loading dose of 800 mg [12 mg/kg] intravenously, then 400 mg [6 mg/kg] intravenously daily) for less critically ill patients who have had no recent azole exposure. For patients with moderately severe to severe illness or for patients who have had recent azole exposure, an echinocandin such as caspofungin (loading dose of 70 mg intravenously once, then 50 mg intravenously daily), micafungin (100 mg intravenously daily), anidulafungin (loading dose of 200 mg intravenously once, then 100 mg intravenously daily) is favored. Therapy for candidemia should be continued for 2 weeks after the last positive blood culture and resolution of symptoms and signs of infection. A dilated fundoscopic examination is recommended for all patients with candidemia to exclude endophthalmitis and repeat blood cultures should be drawn to demonstrate organism clearance. Once patients have become clinically stable, parenteral therapy can be discontinued and oral fluconazole, 200–800 mg orally given as one or two doses daily, is used to complete treatment for isolates known to be or likely to be susceptible to fluconazole. Removal or exchange of intravascular catheters is generally recommended for non-neutropenic patients, since this may decrease the duration of candidemia and overall mortality, which approaches 30%.

Non-*albicans* species of *Candida* account for over 50% of clinical bloodstream isolates and often have resistance patterns that are different from *C. albicans*. An echinocandin is recommended for treatment of *Candida glabrata* infection with a transition to oral fluconazole or voriconazole reserved for patients whose isolates are known to be susceptible to these agents. Similarly, *Candida krusei* is generally fluconazole-resistant and so should be treated with an alternative agent, such as echinocandin or voriconazole. Fluconazole is the treatment of choice for *Candida parapsilosis* due to possible echinocandin resistance in such isolates.

Treatment for hepatosplenic candidiasis is with fluconazole, 400 mg orally daily, or a lipid formulation of amphotericin B should be given until clinical and radiographic improvement occurs.

D. Candidal Endocarditis

Amphotericin, either in a lipid or standard formulation, has long been considered the optimal therapy for candidal endocarditis, given in a dosage of 0.5–1 mg/kg/d intravenously, and can be given along with 5-flucytosine (25 mg/kg four times daily). Alternatively, fluconazole can be added to amphotericin B at dosages greater than 400 mg/d, followed by long-term oral suppressive therapy. Aggressive surgical intervention appears to be beneficial. There are now more data regarding the usefulness of echinocandins in this setting.

In high-risk patients undergoing induction chemotherapy, bone marrow transplantation, or liver transplantation, prophylaxis with antifungal agents has been shown to prevent invasive fungal infections although the effect on mortality and the preferred agent remain debated.

Oude Lashof AM et al. Ocular manifestations of candidemia. *Clin Infect Dis*. 2011 Aug 1;53(3):262–8. [PMID: 21765074]

Reboli AC et al. Anidulafungin compared with fluconazole for treatment of candidemia and other forms of invasive candidiasis caused by *Candida albicans*: a multivariate analysis of factors associated with improved outcomes. *BMC Infect Dis*. 2011 Sep 30;11:261. [PMID: 21961941]

Smego RA Jr et al. The role of fluconazole in the treatment of *Candida* endocarditis: a meta-analysis. *Medicine (Baltimore)*. 2011 July;90(4):237–49. [PMID: 21694646]

HISTOPLASMOSIS

ESSENTIALS OF DIAGNOSIS

- ▶ Epidemiologically linked to bird droppings and bat exposure; common along river valleys (especially the Ohio River and the Mississippi River valleys).
- ▶ Most patients asymptomatic; respiratory illness most common clinical problem.
- ▶ Widespread disease especially common in AIDS or other immunosuppressed states, with poor prognosis.
- ▶ Biopsy of affected organs with culture or urinary polysaccharide antigen most useful in disseminated disease.

▶ General Considerations

Histoplasmosis is caused by *Histoplasma capsulatum*, a dimorphic fungus that has been isolated from soil contaminated with bird or bat droppings in endemic areas (central and eastern United States, eastern Canada, Mexico, Central America, South America, Africa, and southeast Asia). Infection presumably takes place by inhalation of conidia. These convert into small budding cells that are engulfed by phagocytes in the lungs. The organism proliferates and undergoes lymphohematogenous spread to other organs.

▶ Clinical Findings

A. Symptoms and Signs

Most cases of histoplasmosis are asymptomatic or mild and thus go unrecognized. Past infection is recognized by pulmonary and splenic calcification noted on incidental radiographs. Symptomatic infection may present with mild influenza-like illness, often lasting 1–4 days. Moderately severe infections are frequently diagnosed as atypical pneumonia. These patients have fever, cough, and mild central chest pain lasting 5–15 days.

Clinically evident infections occur in several forms: (1) **Acute histoplasmosis** frequently occurs in epidemics, often when soil containing infected bird or bat droppings is disturbed. It is a relatively severe disease manifested by marked prostration, fever, and comparatively few pulmonary complaints even when radiographs show diffuse

pneumonia. The illness may last from 1 week to 6 months but is almost never fatal. (2) **Progressive disseminated histoplasmosis** is commonly seen in patients with underlying HIV infection (with CD4 cell counts usually < 100 cells/mcL) or other conditions causing immunosuppression. Disseminated histoplasmosis has been more frequently reported in patients from endemic areas taking tumor necrosis factor (TNF)-blocking agents. It is characterized by fever and multiple organ system involvement. Chest radiographs may show a miliary pattern. Presentation may be fulminant, simulating septic shock, with death ensuing rapidly unless treatment is provided. Symptoms usually consist of fever, dyspnea, cough, loss of weight, and prostration. Ulcers of the mucous membranes of the oropharynx may be present. The liver and spleen are nearly always enlarged, and all the organs of the body are involved, particularly the adrenal glands, though this infrequently results in adrenal insufficiency. Gastrointestinal involvement may mimic inflammatory bowel disease. (3) **Subacute/chronic progressive pulmonary histoplasmosis** is usually seen in older patients with various lesions including apical cavities, infiltrates, and nodules found on radiographs. (4) **Chronic progressive disseminated histoplasmosis** usually occurs in middle-aged to elderly men with no known condition causing immunosuppression. Presentation is similar to acute disseminated histoplasmosis except for the chronicity of symptoms; it can result in death if not treated. (5) **Complications of pulmonary histoplasmosis** include granulomatous mediastinitis characterized by persistently enlarged mediastinal lymph nodes and fibrosing mediastinitis in which an excessive fibrotic response to *Histoplasma* infection results in compromise of the great vessels.

B. Laboratory Findings

Most patients with progressive pulmonary disease show anemia of chronic disease. Bone marrow involvement may be prominent in disseminated forms with occurrence of pancytopenia. Alkaline phosphatase and marked lactate dehydrogenase (LDH) and ferritin elevations are also common as are mild elevations of serum aspartate aminotransferase, although alanine aminotransferase is often normal.

With pulmonary involvement, sputum culture is rarely positive except in chronic disease; antigen testing of bronchoalveolar lavage fluid may be helpful in acute disease. The combination of a urine and serum antigen assay has an 83% sensitivity for the diagnosis of acute pulmonary histoplasmosis. Blood or bone marrow cultures from immunocompromised patients with acute disseminated disease are positive more than 80% of the time but may take several weeks for growth. The urine antigen assay has a sensitivity of > 90% for disseminated disease in immunocompromised patients and a declining titer can be used to follow response to therapy.

▶ Treatment

For progressive localized disease and for mild to moderately severe nonmeningeal disseminated disease in immunocompetent or immunocompromised patients,

itraconazole, 200–400 mg/d orally divided into two doses, is the treatment of choice with an overall response rate of approximately 80%. The oral solution is better absorbed than the capsule formulation, which requires gastric acid for absorption. Duration of therapy ranges from weeks to several months depending on the severity of illness. Intravenous amphotericin B formulations are used in patients with more severe illness such as meningitis, with guidelines favoring the use of liposomal or lipid complex amphotericin formulations at a dose of 3 mg/kg/d over amphotericin B deoxycholate. Patients with AIDS-related histoplasmosis require lifelong suppressive therapy with itraconazole, 200–400 mg/d orally, although secondary prophylaxis may be discontinued if immune reconstitution occurs in response to antiretroviral therapy. There is no clear evidence that antifungal or anti-inflammatory agents are of benefit for patients with granulomatous mediastinitis or fibrosing mediastinitis although oral itraconazole is often used. Reported outcomes in patients with fibrosing mediastinitis treated with either surgical procedures or nonsurgical intravascular interventions appear to be relatively good.

Hage CA et al. A multicenter evaluation of tests for diagnosis of histoplasmosis. *Clin Infect Dis*. 2011 Sep;53(5):448–54. [PMID: 21810734]

Knox KS et al. Histoplasmosis. *Proc Am Thorac Soc*. 2010 May; 7(3):169–72. [PMID: 20463244]

Peikert T et al. Fibrosing mediastinitis: clinical presentation, therapeutic outcomes, and adaptive immune response. *Medicine (Baltimore)*. 2011 Nov;90(6):412–23. [PMID: 22033450]

COCCIDIOIDOMYCOSIS



ESSENTIALS OF DIAGNOSIS

- ▶ Influenza-like illness with malaise, fever, backache, headache, and cough.
- ▶ Erythema nodosum common with acute infection.
- ▶ Dissemination may result in meningitis, bony lesions, or skin and soft tissue abscesses.
- ▶ Chest radiograph findings vary from pneumonitis to cavitation.
- ▶ Serologic tests useful; spherules containing endospores demonstrable in sputum or tissues.

▶ General Considerations

Coccidioidomycosis should be considered in the diagnosis of any obscure illness in a patient who has lived in or visited an endemic area.

Infection results from the inhalation of arthroconidia of *Coccidioides immitis* or *C. posadasii*; both organisms are molds that grow in soil in certain arid regions of the southwestern United States, in Mexico, and in Central and South America.

Less than 1% of immunocompetent persons show dissemination, but among these patients, the mortality rate is high.

In HIV-infected people in endemic areas, coccidioidomycosis is a common opportunistic infection. In these patients, disease manifestations range from focal pulmonary infiltrates to widespread miliary disease with multiple organ involvement and meningitis; severity is inversely related to the extent of control of the HIV infection.

▶ Clinical Findings

A. Symptoms and Signs

Symptoms of **primary coccidioidomycosis** occur in about 40% of infections. Symptom onset (after an incubation period of 10–30 days) is usually that of a respiratory tract illness with fever and occasionally chills. Coccidioidomycosis is a common, frequently unrecognized, etiology of community-acquired pneumonia in endemic areas.

Arthralgia accompanied by periarticular swelling, often of the knees and ankles, is common. Erythema nodosum may appear 2–20 days after onset of symptoms. Persistent pulmonary lesions, varying from cavities and abscesses to parenchymal nodular densities or bronchiectasis, occur in about 5% of diagnosed cases.

Disseminated disease occurs in about 0.1% of white and 1% of nonwhite patients. Filipinos and blacks are especially susceptible, as are pregnant women of all races. Any organ may be involved. Pulmonary findings usually become more pronounced, with mediastinal lymph node enlargement, cough, and increased sputum production. Lung abscesses may rupture into the pleural space, producing an empyema. These may also extend to bones and skin, and pericardial and myocardial involvement has been occasionally observed. Fungemia may occur and is characterized clinically by a diffuse miliary pattern on chest radiograph and by early death. The course may be particularly rapid in immunosuppressed patients. Clinicians caring for immunosuppressed patients in endemic areas need to consider that patients may be latently infected.

Meningitis occurs in 30–50% of cases of dissemination. Subcutaneous abscesses and verrucous skin lesions are especially common in fulminating cases. Lymphadenitis may occur and may progress to suppuration. HIV-infected persons with disseminated disease have a higher incidence of miliary infiltrates, lymphadenopathy, and meningitis, but skin lesions are uncommon.

B. Laboratory Findings

In **primary coccidioidomycosis**, there may be moderate leukocytosis and eosinophilia. Serologic testing is useful for both diagnosis and prognosis. The immunodiffusion tube precipitin test and enzyme-linked immunosorbent assay (ELISA) detect IgM antibodies and are both useful for diagnosis early in the disease process. Historically, a persistent rising IgG complement fixation titer ($\geq 1:16$) has been considered suggestive of disseminated disease; in addition, complement fixation titers can be used to assess the adequacy of therapy. Serum complement fixation titer may be

low when there is meningitis but no other disseminated disease. In patients with HIV-related coccidioidomycosis, the false-negative rate may be as high as 30%.

Demonstrable complement-fixing antibodies in spinal fluid are diagnostic of coccidioidal meningitis. These are found in over 90% of cases. Spinal fluid findings include increased cell count with lymphocytosis and reduced glucose. Spinal fluid culture is positive in approximately 30% of meningitis cases. Spherules filled with endospores may be found in biopsy specimens of soft tissues and bone; though they are not infectious, they convert to the highly contagious arthroconidia when grown in culture media. Blood cultures are rarely positive.

C. Imaging

Radiographic findings vary, but patchy, nodular pulmonary infiltrates and thin-walled cavities are most common. Hilar lymphadenopathy may be visible and is seen in localized disease; mediastinal lymphadenopathy suggests dissemination. There may be pleural effusions and lytic lesions in bone with accompanying complicated soft-tissue collections.

► Treatment

General symptomatic therapy is given as needed for disease limited to the chest with no evidence of progression. For progressive pulmonary or extrapulmonary disease, amphotericin B intravenously is used although oral azoles may be used for mild cases (see Chapter 30). Duration of therapy is determined by a declining complement fixation titer and a favorable clinical response. For meningitis, treatment usually is with high-dose oral fluconazole (400–800 mg/d, or higher) although lumbar or cisternal intrathecal administration of amphotericin B daily in increasing doses up to 1–1.5 mg/d is used initially by some physicians or in cases refractory to fluconazole. Systemic therapy with amphotericin B, 0.6 mg/kg/d intravenously, is generally given concurrently with intrathecal therapy but is not sufficient alone for the treatment of meningeal disease. Voriconazole or posaconazole may be alternatives to intrathecal amphotericin B in patients who do not respond to fluconazole. Once the patient is clinically stable, oral therapy with an azole, usually with fluconazole (400 mg daily) and given lifelong, is the recommended alternative to intrathecal amphotericin B therapy.

Itraconazole, 400 mg orally daily divided into two doses, or fluconazole, 200–400 mg, or higher, orally once or twice daily should be given for disease in the chest, bones, and soft tissues; however, therapy must be continued for 6 months or longer after the disease is inactive to prevent relapse. In some patients with disease refractory to itraconazole or fluconazole, voriconazole or posaconazole may be beneficial. Response to therapy should be monitored by following the clinical response and progressive decrease in serum complement fixation titers.

Surgical drainage is necessary for management of soft tissue abscesses, necrotic bone and complicated pulmonary disease (eg, rupture of coccidioidal cavity).

► Prognosis

The prognosis for patients with limited disease is good, but persistent pulmonary cavities may cause complications such as hemoptysis or rupture producing pyopneumothorax. Nodules, cavities, and fibrotic residuals may rarely progress after long periods of stability or regression. Serial complement fixation titers should be performed after therapy for patients with coccidioidomycosis; rising titers warrant reinstitution of therapy because relapse is likely. Late central nervous system complications of adequately treated meningitis include cerebral vasculitis and hydrocephalus that may require shunting. Disseminated and meningeal forms still have mortality rates exceeding 50% in the absence of therapy.

Bercovitch RS et al. Coccidioidomycosis during pregnancy: a review and recommendations for management. *Clin Infect Dis.* 2011 Aug 15;53(4):363–8. [PMID: 21810749]

Kim MM et al. Treatment of refractory coccidioidomycosis with voriconazole or posaconazole. *Clin Infect Dis.* 2011 Dec; 53(11):1060–6. [PMID: 22045955]

Ruddy BE et al. Coccidioidomycosis in African Americans. *Mayo Clin Proc.* 2011 Jan;86(1):63–9. [PMID: 21193657]

Taljanovic MS et al. Musculoskeletal coccidioidomycosis. *Semin Musculoskelet Radiol.* 2011 Nov;15(5):511–26. [PMID: 22081286]

PNEUMOCYSTOSIS (*Pneumocystis jiroveci* Pneumonia)



ESSENTIALS OF DIAGNOSIS

- Fever, dyspnea, nonproductive cough.
- Bilateral diffuse interstitial disease without hilar adenopathy by chest radiograph.
- Bibasilar crackles on auscultation in many cases; others have no findings.
- Reduced partial pressure of oxygen.
- *P jiroveci* in sputum, bronchoalveolar lavage fluid, or lung tissue.

► General Considerations

Pneumocystis jiroveci, the *Pneumocystis* species that affects humans, is distributed worldwide. Although symptomatic *P jiroveci* disease is rare in the general population, serologic evidence indicates that asymptomatic infections have occurred in most persons by a young age. The overt infection is an acute interstitial plasma cell pneumonia that occurs with high frequency among two groups: (1) as epidemics of primary infections among premature or debilitated or marasmic infants on hospital wards in underdeveloped parts of the world, and (2) as sporadic cases among older children and adults who have an abnormal or altered cellular immunity. Cases occur most commonly in patients with cancer or severe malnutrition and

debility, in patients treated with immunosuppressive or cytotoxic drugs or irradiation for the management of organ transplants and cancer and, most frequently, in patients with AIDS (see Chapter 31).

The mode of transmission in primary infection is unknown, but the evidence suggests airborne transmission. Following asymptomatic primary infection, latent and presumably inactive organisms are sparsely distributed in the alveoli. Whether acute disease in older children and adults results from *de novo* infection or from reactivation of latent infection is not entirely clear, although both mechanisms probably contribute.

Pneumocystis pneumonia occurs in up to 80% of AIDS patients not receiving prophylaxis and is a major cause of death. Its incidence increases in direct proportion to the fall in CD4 cells, with most cases occurring at CD4 cell counts < 200/mcL. In non-AIDS patients receiving immunosuppressive therapy, symptoms frequently begin after corticosteroids have been tapered or discontinued.

► Clinical Findings

A. Symptoms and Signs

Findings are usually limited to the pulmonary parenchyma; extrapulmonary disease is reported rarely. In the sporadic form of the disease associated with deficient cell-mediated immunity, the onset is typically abrupt, with fever, tachypnea, shortness of breath, and usually nonproductive cough. Pulmonary physical findings may be slight and disproportionate to the degree of illness and the radiologic findings; many patients have bibasilar crackles, but others do not. Without treatment, the course is usually one of rapid deterioration and death. Adult patients may present with spontaneous pneumothorax, usually in patients with previous episodes or those receiving aerosolized pentamidine prophylaxis. Patients with AIDS will usually have other evidence of HIV-associated disease, including fever, fatigue, and weight loss, for weeks or months preceding the illness.

B. Laboratory Findings

Chest radiographs most often show diffuse “interstitial” infiltration, which may be heterogeneous, miliary, or patchy early in infection. There may also be diffuse or focal consolidation, cystic changes, nodules, or cavitation within nodules. Pleural effusions are not seen. About 5–10% of patients with *Pneumocystis* pneumonia have normal chest films. High-resolution chest CT scans may be quite suggestive of *P jiroveci* pneumonia, helping distinguish it from other causes of pneumonia.

Arterial blood gas determinations usually show hypoxemia with hypocapnia but may be normal; however, rapid desaturation occurs if patients are exercised before samples are drawn. Isolated elevation or rising levels of serum LDH are very sensitive but not specific findings for *P jiroveci*. Serologic tests are not helpful in diagnosis, but several studies have suggested that elevated (1→3)- β -D-glucan levels have reasonably good sensitivity and specificity for the diagnosis of *Pneumocystis* pneumonia. Specific

diagnosis depends on morphologic demonstration of the organisms in clinical specimens using specific stains. The organism cannot be cultured. Adequate specimens can sometimes be obtained with induced sputum by having patients inhale an aerosol of hypertonic saline (3%) produced by an ultrasonic nebulizer. Specimens are then stained with Giemsa stain or methenamine silver, either of which allows detection of cysts. The use of monoclonal antibody with immunofluorescence has increased the sensitivity of diagnosis. Alternative techniques for obtaining specimens include bronchoalveolar lavage (sensitivity 86–97%) followed by transbronchial lung biopsy (85–97%), if necessary. Open lung biopsy and needle lung biopsy are infrequently done but may need to be performed to diagnose a granulomatous form of *Pneumocystis* pneumonia.

► Treatment

See Table 31–5. It is appropriate to start empiric therapy for *P jiroveci* pneumonia if the disease is suspected clinically; however, in both AIDS patients and non-AIDS patients with mild to moderately severe disease, continued treatment should be based on a proved diagnosis because of clinical overlap with other infections, the toxicity of therapy, and the possible coexistence of other infectious organisms. Oral trimethoprim-sulfamethoxazole (TMP-SMZ) is the preferred agent because of its low cost and excellent bioavailability in both AIDS patients and non-AIDS patients with mild to moderately severe disease. Patients suffering from nausea and vomiting or intractable diarrhea should be given intravenous TMP-SMZ until they can tolerate the oral formulation. The impact of resistance of *Pneumocystis* to TMP-SMZ is unclear, although increasing rates of mutations in the *DHFR* gene that mediate TMP-SMZ resistance have been reported. The best-studied second-line option is a combination of primaquine and clindamycin, although dapsone/trimethoprim, pentamidine, and atovaquone have also been used. Therapy should be continued with the selected drug for at least 5–10 days before considering changing agents, as fever, tachypnea, and pulmonary infiltrates persist for 4–6 days after starting treatment. Some patients have a transient worsening of their disease during the first 3–5 days, which may be related to an inflammatory response secondary to the presence of dead or dying organisms. Early addition of corticosteroids may attenuate this response (see Chapter 31). Some clinicians prefer to treat episodes of AIDS-associated *Pneumocystis* pneumonia for 21 days rather than the usual 14 days recommended for non-AIDS cases.

A. Trimethoprim-Sulfamethoxazole

The dosage of TMP/SMZ is 15–20 mg/kg/d (based on trimethoprim component) given orally or intravenously daily in three or four divided doses for 14–21 days. Patients with AIDS have a high frequency of hypersensitivity reactions (approaching 50%), which may include fever, rashes (sometimes severe), malaise, neutropenia, hepatitis, nephritis, thrombocytopenia, hyperkalemia, and hyperbilirubinemia.

B. Primaquine/Clindamycin

Although there are strong data indicating that trimethoprim-sulfamethoxazole is optimal first-line therapy for *Pneumocystis* pneumonia, the data on alternative agents is less clear. A meta-analysis suggested that primaquine, 15–30 mg/d, plus clindamycin, 600 mg three times daily, is the best second-line therapy with superior results when compared with pentamidine. Primaquine may cause hemolytic anemia in patients with glucose-6-phosphate dehydrogenase (G6PD)-deficiency.

C. Pentamidine Isethionate

The use of pentamidine has decreased as alternative agents have been studied. This drug is administered intravenously (preferred) or intramuscularly as a single dose of 3–4 mg (salt)/kg/d for 14–21 days. Pentamidine causes side effects in nearly 50% of patients. Hypoglycemia (often clinically inapparent), hyperglycemia, hyponatremia, and delayed nephrotoxicity with azotemia may occur. Rarely, a variety of other severe adverse reactions may occur, including anemia, thrombocytopenia, ventricular arrhythmias, and fatal pancreatitis. Blood glucose levels should be monitored. Inadvertent rapid intravenous infusion may cause precipitous hypotension.

D. Atovaquone

Atovaquone is approved by the US Food and Drug Administration (FDA) for patients with mild to moderate disease who cannot tolerate TMP-SMZ or pentamidine, but failure is reported in 15–30% of cases. Mild side effects are common, but no serious reactions have been reported. The dosage is 750 mg three times daily for 21 days. Atovaquone should be administered with a fatty meal.

E. Other Drugs

Trimethoprim, 15 mg/kg/d in three divided doses daily, plus dapsone, 100 mg/d, is an alternative oral regimen for mild to moderate disease or for continuation of therapy after intravenous therapy is no longer needed.

F. Prednisone

Based on studies done in patients with AIDS, prednisone is given for moderate to severe pneumonia (when PaO₂ on admission is < 70 mm Hg or oxygen saturation is < 90%) in conjunction with antimicrobials. The dosage of prednisone is 40 mg twice daily orally for 5 days, then 40 mg daily for 5 days, and then 20 mg daily until therapy is completed. The role of prednisone in non-AIDS patients is unclear, especially in patients in whom symptoms developed following tapering doses of corticosteroids.

G. Supportive Care

Oxygen therapy is indicated to maintain the oxygen saturation over 90% by pulse oximetry.

► Prevention

Primary prophylaxis for *Pneumocystis* pneumonia in HIV-infected patients should be given to persons with CD4 counts < 200 cells/mL, a CD4 percentage below 14%, or weight loss or oral candidiasis (see Table 31–4). Primary prophylaxis is often used in patients with hematologic malignancy and transplant recipients, although the clinical characteristics of persons with these conditions who would benefit from *Pneumocystis* prophylaxis have not been clearly defined. Patients with a history of *Pneumocystis* pneumonia should receive secondary prophylaxis until they have had a durable virologic response to antiretroviral therapy for at least 3–6 months and maintain a CD4 count of > 200 cells/mL.

► Prognosis

In the absence of early and adequate treatment, the fatality rate for the endemic infantile form of *Pneumocystis* pneumonia is 20–50%; for the sporadic form in immunodeficient persons, the fatality rate is nearly 100%. Early treatment reduces the mortality rate to about 3% in the former and 10–20% in AIDS patients. The mortality rate in other immunodeficient patients is still 30–50%, probably because of failure to make a timely diagnosis. In immunodeficient patients who do not receive prophylaxis, recurrences are common (30% in AIDS).

Huang L et al; International HIV-associated Opportunistic Pneumonias (IHOP) Study; Lung HIV Study. HIV-associated *Pneumocystis* pneumonia. *Proc Am Thorac Soc*. 2011 Jun; 8(3):294–300. [PMID: 21653531]

Sax PE et al; AIDS Clinical Trials Group Study A5164 Team. Blood (1→3)-β-D-glucan as a diagnostic test for HIV-related *Pneumocystis jirovecii* pneumonia. *Clin Infect Dis*. 2011 Jul 15;53(2):197–202. [PMID: 21690628]

CRYPTOCOCCOSIS



ESSENTIALS OF DIAGNOSIS

- Most common cause of fungal meningitis.
- Predisposing factors: Hematologic cancer chemotherapy, Hodgkin disease, corticosteroid therapy, transplant recipients, TNF inhibitor therapy, HIV infection.
- Symptoms of headache, abnormal mental status; meningismus seen occasionally, though rarely in HIV-infected patients.
- Demonstration of capsular polysaccharide antigen in cerebrospinal fluid is diagnostic; 95% of HIV-infected and solid-organ transplant patients also have a positive serum antigen.

► General Considerations

Cryptococcosis is mainly caused by *Cryptococcus neoformans*, an encapsulated budding yeast that has been found worldwide in soil and on dried pigeon dung. *C gattii* is a closely related species that also causes disease in humans although *C gattii* may affect more immunocompetent persons. It has been emerging as a major cause of cryptococcosis in the Pacific Northwestern region of the United States and may result in more severe disease than *C neoformans*.

Infections are acquired by inhalation. In the lung, the infection may remain localized, heal, or disseminate. Clinically apparent cryptococcal pneumonia rarely develops in immunocompetent persons, except in those individuals infected by *C gattii*. Progressive lung disease and dissemination most often occur in the setting of cellular immunodeficiency, including underlying hematologic cancer under treatment, Hodgkin disease, long-term corticosteroid therapy, solid-organ transplant, TNF-inhibitor therapy, or HIV infection.

► Clinical Findings

A. Symptoms and Signs

Pulmonary disease ranges from simple nodules to widespread infiltrates leading to respiratory failure. Disseminated disease may involve any organ, but central nervous system disease predominates. Headache is usually the first symptom of meningitis. Confusion and other mental status changes as well as cranial nerve abnormalities, nausea, and vomiting may be seen as the disease progresses. Nuchal rigidity and meningeal signs occur about 50% of the time but are uncommon in HIV-infected patients. Communicating hydrocephalus may complicate the course. *C gattii* infection frequently presents with neurologic signs caused by space-occupying lesions. Primary *C neoformans* infection of the skin may mimic bacterial cellulitis, especially in immunocompromised persons. Clinical worsening associated with improved immunologic status has been reported in HIV-positive and transplant patients with cryptococcosis; this entity has been labeled the immune reconstitution inflammatory syndrome (IRIS).

B. Laboratory Findings

Respiratory tract disease is diagnosed by culture of respiratory secretions or pleural fluid. For suspected meningeal disease, lumbar puncture is the preferred diagnostic procedure. Spinal fluid findings include increased opening pressure, variable pleocytosis, increased protein, and decreased glucose, though as many as 50% of AIDS patients have no pleocytosis. Gram stain of the cerebrospinal fluid usually reveals budding, encapsulated fungal cells. Cryptococcal capsular antigen in cerebrospinal fluid and culture together establish the diagnosis over 90% of the time. Patients with AIDS often have the antigen in both cerebrospinal fluid and serum, and extrameningeal disease (lungs, blood, urinary tract) is common. In patients with AIDS, the serum

cryptococcal antigen is also a sensitive screening test for meningitis, being positive in over 95% of cases. MRI is more sensitive than CT in finding central nervous system abnormalities such as cryptococcomas.

► Treatment

Because of decreased efficacy, initial therapy with an azole alone is not recommended for treatment of acute cryptococcal meningitis. Consequently, amphotericin B, 0.7–1 mg/kg/d intravenously is used for 14 days, followed by an additional 8 weeks of fluconazole, 400 mg/d orally. This regimen has been quite effective, achieving clinical responses and cerebrospinal fluid sterilization in about 70% of patients. Lipid amphotericin B preparations (eg, liposomal amphotericin B, 3–4 mg/kg/d) have equivalent efficacy to conventional amphotericin B with reduced nephrotoxicity. The addition of flucytosine has been associated with improved survival, but toxicity is common. Flucytosine is administered orally at a dose of 100 mg/kg/d divided into four equal doses and given every 6 hours. Hematologic parameters should be closely monitored during flucytosine therapy, and it is important to adjust the dose for any decreases in renal function. Fluconazole (800–1200 mg orally daily) may be given with amphotericin B when flucytosine is not available or patients cannot tolerate it. Frequent, repeated lumbar punctures or ventricular shunting should be performed to relieve high cerebrospinal fluid pressures or if hydrocephalus is a complication. Failure to adequately relieve raised intracranial pressure is a major cause of morbidity and mortality. The end points for amphotericin B therapy and for switching to oral fluconazole are a favorable clinical response (decrease in temperature; improvement in headache, nausea, vomiting, and mini-mental status scores), improvement in cerebrospinal fluid biochemical parameters and, most importantly, conversion of cerebrospinal fluid culture to negative.

A similar approach is reasonable for patients with cryptococcal meningitis in the absence of AIDS, though the mortality rate is considerably higher. Therapy is generally continued until cerebrospinal fluid cultures become negative. Maintenance antifungal therapy is important after treatment of an acute episode in HIV-related cases, since otherwise the rate of relapse is > 50%. Fluconazole, 200 mg/d orally, is the maintenance therapy of choice, decreasing the relapse rate approximately tenfold compared with placebo and threefold compared with weekly amphotericin B in patients whose cerebrospinal fluid has been sterilized by the induction therapy. After successful therapy of cryptococcal meningitis, it is possible to discontinue secondary prophylaxis with fluconazole in individuals with AIDS who have had a satisfactory response to antiretroviral therapy (eg, CD4 cell count > 100–200 cells/mL for at least 6 months). Among practitioners treating patients without AIDS, there has been a trend in recent years to prescribe a course (eg, 6–12 months) of fluconazole as maintenance therapy following successful treatment of the acute illness; recently published guidelines suggest this as an option.

► Prognosis

Factors that indicate a poor prognosis include the activity of the predisposing conditions, older age, organ failure, lack of spinal fluid pleocytosis, high initial antigen titer in either serum or cerebrospinal fluid, decreased mental status, increased intracranial pressure, and the presence of disease outside the nervous system.

Harris JR. *Cryptococcus gattii* in the United States: clinical aspects of infection with an emerging pathogen. *Clin Infect Dis*. 2011 Dec;53(12):1188–95. [PMID: 22016503]

Loyse A et al. Comparisons of the early fungicidal activity of high-dose fluconazole, voriconazole and flucytosine as second line drugs given in combination with amphotericin B for the treatment of HIV-associated cryptococcal meningitis. *Clin Infect Dis*. 2012 Jan;54(1):121–8. [PMID: 22052885]

Perfect JR et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America. *Clin Infect Dis*. 2010 Feb 15;50(3):291–322. [PMID: 20047480]

ASPERGILLOSIS



ESSENTIALS OF DIAGNOSIS

- ▶ Most common cause of non-candidal invasive fungal infection in stem cell or organ transplant patients.
- ▶ Predisposing factors: leukemia, bone marrow or organ transplant, late HIV infection.
- ▶ Pulmonary, sinus, and CNS are most common disease sites.
- ▶ Demonstration of galactomannan or β -D-glucan in serum or other body fluid samples is useful for early diagnosis and treatment.

► General Considerations

Aspergillus fumigatus is the usual cause of aspergillosis, though many species of *Aspergillus* may cause a wide spectrum of disease. The lungs, sinuses, and brain are the organs most often involved. Clinical illness results either from an aberrant immunologic response or tissue invasion.

► Clinical Findings

A. Allergic Bronchopulmonary Aspergillosis

This form of aspergillosis occurs in patients with preexisting asthma who develop worsening bronchospasm and fleeting pulmonary infiltrates accompanied by eosinophilia, high levels of IgE, and IgG *Aspergillus* precipitins in the blood. It also may complicate cystic fibrosis.

B. Invasive Aspergillosis

Invasive manifestations may be seen in immunocompetent or only mildly immunocompromised adults. These include

chronic **sinusitis**, colonization of preexisting pulmonary cavities (**aspergilloma**), and chronic necrotizing pulmonary aspergillosis.

1. Sinusitis—Sinus involvement is usually diagnosed histologically after patients with chronic sinus disease undergo surgery.

2. Aspergillomas—Aspergillomas of the lung occur when preexisting lung cavities become secondarily colonized with *Aspergillus* species. These may be found by incidental radiographic studies but may also present with significant hemoptysis.

3. Chronic necrotizing aspergillosis—This invasive manifestation is a relatively rare disease seen in patients with some degree of immunocompromise and presents with a protracted course compared with the more common acute invasive form of the disease. Fibrosis and cavity formation may be prominent.

4. Life-threatening invasive aspergillosis—Severe invasive aspergillosis most commonly occurs in profoundly immunodeficient patients, particularly in patients who have undergone hematopoietic stem cell transplants; in those with prolonged, severe neutropenia; and in patients with chronic granulomatous disease. Specific risk factors in patients who have undergone a hematopoietic stem cell transplant include cytopenias, corticosteroid use, iron overload, cytomegalovirus disease, and graft-versus-host disease. Pulmonary disease is most common, with patchy infiltration leading to a severe necrotizing pneumonia. Invasive sinus disease also occurs. There is often tissue infarction as the organism grows into blood vessels; clues to this are the development of pleuritic chest pain and elevation of serum LDH. At any time, there may be hematogenous dissemination to the central nervous system, skin, and other organs. Early diagnosis and reversal of any correctable immunosuppression are essential. Blood cultures have very low yield. Detection of galactomannan by ELISA or β -D-glucan, or both, has been used for the early diagnosis of invasive disease, though multiple determinations should be done. Higher galactomannan levels are correlated with increased mortality. False-positive galactomannan tests have been reported in patients receiving β -lactam antibiotics. Isolation of *Aspergillus* from pulmonary secretions does not necessarily imply invasive disease, although its positive predictive value increases with more advanced immunosuppression. Therefore, a definitive diagnosis requires demonstration of *Aspergillus* in tissue or culture from a sterile site. CT scan of the chest may show characteristics quite suggestive of invasive aspergillosis (eg, “halo sign”).

► Prevention

The high mortality rate and difficulty in diagnosis of invasive aspergillosis often leads clinicians to institute prophylactic therapy for patients with profound immunosuppression. The best-studied agents include fluconazole, itraconazole, voriconazole, and posaconazole, although patient and agent selection criteria remain undefined. Widespread use of broad-spectrum azoles raises concern for development of invasive disease by highly resistant fungi.

► Treatment

A. Allergic Bronchopulmonary Aspergillosis

For acute exacerbations, oral prednisone is begun at a dose of 1 mg/kg/d and then tapered slowly over several months. Itraconazole at a dose of 200 mg daily for 16 weeks appears to improve pulmonary function and decrease corticosteroid requirements in these patients, although voriconazole may become the preferred oral agent. Some patients treated with the anti-IgE monoclonal antibody omalizumab have shown improvement in respiratory symptoms and lung function.

B. Invasive Aspergillosis

1. Sinusitis—These patients may require protracted courses of antifungals (itraconazole, 200 mg twice daily, for weeks to months) in addition to the surgical debridement.

2. Aspergilloma—The most effective therapy for symptomatic aspergilloma remains surgical resection.

3. Chronic necrotizing aspergillosis—Guidelines suggest some benefits from prolonged oral voriconazole (200 mg twice daily) or itraconazole (200 mg twice daily) therapy.

4. Life-threatening invasive aspergillosis—When severe invasive aspergillosis is considered clinically likely or is demonstrable by laboratory testing, rapid institution of voriconazole, high doses of liposomal amphotericin B (3–5 mg/kg/d), or caspofungin may be life-saving. Voriconazole (6 mg/kg intravenously twice on day 1, then 4 mg/kg/d thereafter) has been shown to be more effective, improve survival, and be associated with fewer severe side effects than conventional amphotericin B when used as initial therapy in invasive aspergillosis. Oral dosing of voriconazole at 4 mg/kg twice daily can be used for less serious infections or as a step-down strategy after intravenous therapy.

Caspofungin (70 mg intravenously on day 1, then 50 mg/d thereafter) is approved for the treatment of invasive aspergillosis in patients who do not respond to or are intolerant of other treatments. Other options include micafungin (100–150 mg/d intravenously) and posaconazole (200 mg orally four times daily). In critically ill patients who are not responding to conventional antifungal treatment, there may be a role for the addition of caspofungin to liposomal amphotericin B or voriconazole therapy, although randomized trials are lacking. Surgical debridement is generally done for sinusitis, and there is increasing data regarding resection of focal pulmonary lesions, especially for treatment of life-threatening hemoptysis. The mortality rate of pulmonary or disseminated disease in the immunocompromised patient remains well above 50%, particularly in patients with refractory neutropenia.

Knutsen AP et al. Allergic bronchopulmonary aspergillosis in asthma and cystic fibrosis. *Clin Dev Immunol.* 2011;2011:843763. [PMID: 21603163]

Kousha M et al. Pulmonary aspergillosis: a clinical review. *Eur Respir Rev.* 2011 Sep 1;20(121):156–74. [PMID: 21881144]

Traunmüller F et al. Efficacy and safety of current drug therapies for invasive aspergillosis. *Pharmacology.* 2011;88(3–4):213–24. [PMID: 21986253]

MUCORMYCOSIS

The term “mucormycosis” (zygomycosis, phycomycosis) is applied to opportunistic infections caused by members of the genera *Rhizopus*, *Mucor*, *Absidia*, and *Cunninghamella*. Predisposing conditions include hematologic malignancy, stem cell transplantation, solid organ transplantation, diabetic ketoacidosis, chronic kidney disease, desferoxamine therapy, and treatment with corticosteroids or cytotoxic drugs. These organisms appear in tissues as broad, branching nonseptate hyphae. Biopsy with histologic examination is almost always required for diagnosis; cultures are frequently negative. Invasive disease of the sinuses, orbits, and the lungs may occur. Widely disseminated disease is seen in patients who have received aggressive chemotherapy and broad-spectrum antifungal prophylaxis. A prolonged course of a lipid preparation of amphotericin B should be started early. Based on in vitro susceptibility and reports of successful salvage therapy, there may be a role for posaconazole in the treatment of these infections following control of acute infection by amphotericin. Other azoles are not effective. There are limited data suggesting beneficial synergistic activity when amphotericin and caspofungin are used in combination for mucormycosis. Despite favorable animal studies, a recent pilot study in humans incorporating adjunctive iron chelation therapy with deferasirox demonstrated a higher mortality rate than antifungal therapy alone. Control of diabetes and other underlying conditions, along with extensive repeated surgical removal of necrotic, nonperfused tissue, is essential. Even when these measures are introduced in a timely fashion, the prognosis is poor, with a 30–50% mortality rate for localized disease and higher rates in disseminated cases.

Kontoyiannis DP et al. How I treat mucormycosis. *Blood.* 2011 Aug;118(5):1216–24. [PMID: 21622653]

Spellberg B et al. The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) study: a randomized, double-blinded, placebo-controlled trial. *J Antimicrob Chemother.* 2012 Mar;67(3):715–22. [PMID: 21937481]

Sun HY. Mucormycosis: its contemporary face and management strategies. *Lancet Infect Dis.* 2011 Apr;11(4):301–11. [PMID: 21453871]

BLASTOMYCOSIS

Blastomycosis occurs most often in men infected during occupational or recreational activities out of doors and in a geographically limited area of the south central and midwestern United States and Canada. Disease usually occurs in immunocompetent individuals.

Chronic pulmonary infection is most common and may be asymptomatic. When dissemination takes place, lesions are most frequently seen in the skin, bones, and urogenital system.

Cough, moderate fever, dyspnea, and chest pain are common. These may resolve or progress, with purulent sputum production, pleurisy, fever, chills, loss of weight, and prostration. Radiologic studies, either chest radiographs or CT scans, usually reveal airspace consolidation or masses.

Raised, verrucous cutaneous lesions are commonly present in disseminated blastomycosis. Bones—often the ribs and vertebrae—are frequently involved. Epididymitis, prostatitis, and other involvement of the male urogenital system may occur. Although they do not appear to be at greater risk for acquisition of disease, infection in HIV-infected persons may progress rapidly, with dissemination common.

Laboratory findings usually include leukocytosis and anemia, though these are not specific. The organism is found in clinical specimens, such as expectorated sputum or tissue biopsies, as a thick-walled cell 5–20 μm in diameter that may have a single broad-based bud. It grows readily on culture. Serologic tests are not well standardized. A urinary antigen test is available, but it has considerable cross reactivity with *Histoplasma*; consequently, its usefulness in diagnosis and in assessing response to therapy is unclear.

Itraconazole, 200–400 mg/d orally for at least 2–3 months, is the therapy of choice for nonmeningeal disease, with a response rate of over 80%. Amphotericin B, 0.7–1.0 mg/kg/d intravenously (or lipid formulation amphotericin B), is given for severe disease, treatment failures, or central nervous system involvement.

Clinical follow-up for relapse should be made regularly for several years so that therapy may be resumed or another drug instituted.

Bariola JR et al. Detection of *Blastomyces dermatitidis* antigen in patients with newly diagnosed blastomycosis. *Diagn Microbiol Infect Dis*. 2011 Feb;69(2):187–91. [PMID: 21251563]
Saccante M et al. Clinical and laboratory update on blastomycosis. *Clin Microbiol Rev*. 2010 Apr;23(2):367–81. [PMID: 20375357]

PARACOCIDIOIDOMYCOSIS (South American Blastomycosis)

Paracoccidioides brasiliensis infections have been found only in patients who have resided in South or Central America or Mexico. Long asymptomatic periods enable patients to travel far from the endemic areas before developing clinical problems. Weight loss, pulmonary complaints, or mucosal ulcerations are the most common symptoms. Cutaneous papules may ulcerate and enlarge both peripherally and deeper into the subcutaneous tissue. Differential diagnosis includes mucocutaneous leishmaniasis and syphilis. Extensive coalescent ulcerations may eventually result in destruction of the epiglottis, vocal cords, and uvula. Extension to the lips and face may occur. Eating and drinking are extremely painful. Skin lesions may occur, usually on the face. Variable in appearance, they may have a necrotic central crater with a hard hyperkeratotic border. Lymph node enlargement may follow mucocutaneous lesions, eventually ulcerating and forming draining sinuses; in some patients, it is the presenting symptom. Hepatosplenomegaly may be present as well. HIV-infected patients with paracoccidioidomycosis are more likely to have extra-pulmonary dissemination and a more rapid clinical disease course.

Laboratory findings are nonspecific. Serology by immunodiffusion is positive in 98% of cases. Complement fixation titers correlate with progressive disease and fall with effective therapy. The fungus is found in clinical specimens as a spherical cell that may have many buds arising from it. If direct examination of secretions does not reveal the organism, biopsy with Gomori staining may be helpful.

Itraconazole, 100 mg twice daily orally, is the treatment of choice and generally results in a clinical response within 1 month and effective control after 2–6 months. Voriconazole, 200 mg twice daily orally, appears to be as effective as itraconazole. Amphotericin B intravenously is the drug of choice for severe and life-threatening infection.

Ameen M et al. Advances in paracoccidioidomycosis. *Clin Exp Dermatol*. 2010 Aug;35(6):576–80. [PMID: 19874328]
Bellissimo-Rodrigues F et al. Paracoccidioidomycosis epidemiological features of a 1,000-cases series from a hyperendemic area on the southeast of Brazil. *Am J Trop Med Hyg*. 2011 Sep;85(3):546–50. [PMID: 21896820]

SPOROTRICHOSIS

Sporotrichosis is a chronic fungal infection caused by *Sporothrix schenckii*. It is worldwide in distribution; most patients have had contact with soil, sphagnum moss, or decaying wood. Transmission from animals to humans has also been reported. Infection takes place when the organism is inoculated into the skin—usually on the hand, arm, or foot, especially during gardening.

The most common form of sporotrichosis begins with a hard, nontender subcutaneous nodule. This later becomes adherent to the overlying skin and ulcerates. Within a few days to weeks, similar nodules develop along the lymphatics draining this area, and these may ulcerate as well.

Disseminated sporotrichosis is rare in the immunocompetent person but may present with widespread cutaneous, lung, bone, joint, and central nervous system involvement in immunocompromised patients, especially those with AIDS and alcohol abuse.

Cultures are needed to establish diagnosis. Antibody tests may be useful for diagnosis of disseminated disease, especially meningitis.

Itraconazole, 200–400 mg orally daily for several months, is the treatment of choice for localized disease and some milder cases of disseminated disease. Terbinafine, 500 mg orally twice daily, also appears to have good efficacy in lymphocutaneous disease. Amphotericin B intravenously, 1–2 g, is used for severe systemic infection. Surgery is usually contraindicated except for simple aspiration of secondary nodules. Joint involvement may require arthrodesis.

The prognosis is good for lymphocutaneous sporotrichosis; pulmonary, joint, and disseminated disease respond less favorably.

de Lima Barros MB et al. *Sporothrix schenckii* and sporotrichosis. *Clin Microbiol Rev*. 2011 Oct;24(4):633–54. [PMID: 21976602]
de Lima Barros MB et al. Treatment of cutaneous sporotrichosis with itraconazole—study of 645 patients. *Clin Infect Dis*. 2011 Jun 15;52(12):e200–6. [PMID: 21628477]

PENICILLIUM MARNEFFI INFECTIONS

Penicillium marneffi is a dimorphic fungus, endemic in southeast Asia, that causes systemic infection in both healthy and immunocompromised hosts. There have been reports of travelers with advanced AIDS returning from southeast Asia with disseminated infection. Clinical manifestations include fever, generalized umbilicated papular rash, lymphadenopathy, cough, and diarrhea. Central nervous system infection has been reported. Diagnosis is made by identification of the organism on smears or histopathologic specimens or by culture, where the fungus produces a characteristic red pigment. The best sites for isolation of the fungus include the skin, blood, bone marrow, respiratory tract, and lymph nodes. Antigen and antibody tests have been developed in endemic regions. Patients with mild to moderate infection can be treated with itraconazole, 400 mg divided into two doses daily by mouth for 8 weeks. Amphotericin B, 0.5–0.7 mg/kg/d intravenously, is the drug of choice for severe disease and should be continued until patients have had a satisfactory clinical response, at which time they can be switched to itraconazole. Because the relapse rate after successful treatment is 30%, maintenance therapy with itraconazole, 200–400 mg daily orally, is indicated indefinitely, or until immune reconstitution occurs.

Wong SY et al. *Penicillium marneffi* infection in AIDS. *Patholog Res Int.* 2011 Feb 10;2011:764293. [PMID: 21331327]

CHROMOBLASTOMYCOSIS (Chromomycosis)

Chromoblastomycosis is a chronic, principally tropical cutaneous infection usually affecting young men who are agricultural workers and caused by several species of closely related black molds; *Cladophialophora carrionii* and *Fonsecaea pedrosoi* are the most common etiologic agents.

Lesions usually follow puncture wounds and are slowly progressive, occurring most frequently on a lower extremity. The lesion begins as a papule or ulcer. Over months to years, papules enlarge to become vegetating, papillomatous, verrucous elevated nodules. Satellite lesions may appear along the lymphatics. There may be secondary bacterial infection. Elephantiasis may result.

The fungus is seen as brown, thick-walled, spherical, sometimes septate cells in potassium hydroxide preparations of pus or skin scrapings, which are quite sensitive for diagnosis. The type of reproduction found in culture determines the species.

Itraconazole, 200–400 mg/d orally for 6–18 months, achieves a response rate of 65%. Terbinafine at 500–1000 mg/d orally may have similar efficacy to itraconazole and may be useful in combination, especially in difficult to treat cases. Cryosurgery alone for smaller lesions or combined with itraconazole for larger lesions is beneficial.

Ameen M. Managing chromoblastomycosis. *Trop Doct.* 2010 Apr;40(2):65–7. [PMID: 20305094]

Queiroz-Telles F et al. Chromoblastomycosis: an overview of clinical manifestations, diagnosis and treatment. *Med Mycol.* 2009 Feb;47(1):3–15. [PMID: 19085206]

MYCETOMA (Maduromycosis & Actinomycetoma)

Mycetoma is a chronic local, slowly progressive destructive infection, usually involving the foot, that begins in subcutaneous tissues, frequently after localized trauma, and then spreads to contiguous structures. Maduromycosis (also known as eumycetoma) is the term used to describe mycetoma caused by the true fungi and by phylogenetically diverse organisms. Actinomycetoma is caused by *Nocardia* and *Actinomadura* species. The disease begins as a papule, nodule, or abscess that over months to years progresses slowly to form multiple abscesses and sinus tracts ramifying deep into the tissue. Secondary bacterial infection may result in large open ulcers. Radiographs may show destructive changes in the underlying bone. Tissue Gram stain reveals fine branching hyphae with actinomycetoma. Larger hyphae are seen with fungal mycetoma; the causative species can often be identified by the color of the characteristic grains within the infected tissues.

The prognosis is good for patients with actinomycetoma, since they usually respond well to sulfonamides and sulfones, especially if treated early. TMP-SMZ, 160/800 mg orally twice a day, or dapsone, 100 mg twice daily after meals, has been reported to be effective. Streptomycin, 14 mg/kg/d intramuscularly, may be useful during the first month of therapy. All oral medications must be taken for months and continued for several months after clinical cure to prevent relapse. Debridement assists healing.

The prognosis for maduromycosis is poor, though surgical debridement along with prolonged itraconazole therapy may result in a response rate of 70%. The various etiologic agents may respond differently to antifungal agents, so culture results are invaluable. Amputation is necessary in far advanced cases.

Garnica M et al. Difficult mycoses of the skin: advances in the epidemiology and management of eumycetoma, phaeohyphomycosis and chromoblastomycosis. *Curr Opin Infect Dis.* 2009 Dec;22(6):559–63. [PMID: 19773651]

OTHER OPPORTUNISTIC MOLD INFECTIONS

Fungi previously considered to be harmless colonizers, including *Pseudallescheria boydii* (*Scedosporium apiospermum*), *Scedosporium prolificans*, *Fusarium*, *Paecilomyces*, *Trichoderma longibrachiatum*, and *Trichosporon*, are emerging as significant pathogens in immunocompromised patients. This occurs most often in patients being treated for hematopoietic malignancies and in those receiving broad-spectrum antifungal prophylaxis. Infection may be localized in the skin, lungs, or sinuses, or widespread disease may appear with lesions in multiple organs. Fusariosis should be suspected in severely immunosuppressed persons in whom multiple, painful skin lesions develop; blood cultures are often positive. Sinus infection may cause bony erosion. Infection in subcutaneous tissues following traumatic implantation may develop as a well-circumscribed cyst or as an ulcer.

Nonpigmented septate hyphae are seen in tissue and are indistinguishable from those of *Aspergillus* when infections

are due to *S apiospermum* or species of *Fusarium*, *Paecilomyces*, *Penicillium*, or other hyaline molds. Spores or mycetoma-like granules are rarely present in tissue. The differentiation of *S apiospermum* and *Aspergillus* is particularly important, since the former is uniformly resistant to amphotericin B but may be sensitive to azole antifungals (eg, voriconazole). Infection by any of a number of black molds is designated as phaeohyphomycosis. These black molds (eg, *Exophiala*, *Bipolaris*, *Cladophialophora*, *Curvularia*, *Alternaria*) are common in the environment, especially on decaying vegetation. Human disease due to these agents is rarely encountered but may result in soft tissue abscesses due to traumatic inoculation or may occur as a sequela of chronic sinusitis or profound immunosuppression. In tissues of patients with phaeohyphomycosis, the mold is seen as black or faintly brown hyphae, yeast cells, or both. Culture on appropriate medium is needed to identify the agent. Histologic demonstration of these organisms is definitive evidence of invasive infection; positive cultures must be interpreted cautiously and not

assumed to be contaminants in immunocompromised hosts. Some isolates are sensitive to antifungal agents.

Ben-Ami R et al. Phaeohyphomycosis in a tertiary care center. *Clin Infect Dis*. 2009 Apr 15;48(8):1033–41. [PMID: 19267655]

Campo M et al. Invasive fusariosis in patients with hematologic malignancies at a cancer center: 1998–2009. *J Infect*. 2010 May;60(5):331–7. [PMID: 20138081]

Revankar SG et al. Melanized fungi in human disease. *Clin Microbiol Rev*. 2010 Oct;23(4):884–928. [PMID: 20930077]

ANTIFUNGAL THERAPY

Table 36–1 summarizes the major properties of currently available antifungal agents. Two different lipid-based amphotericin B formulations are used to treat systemic candidiasis, invasive aspergillosis and other disseminated mold infections, disseminated histoplasmosis, and

Table 36–1. Agents for systemic mycoses.

Drug	Dosing	Renal Clearance?	CSF Penetration?	Toxicities	Spectrum of Activity
Amphotericin B	0.3–1.5 mg/kg/d intravenously	No	Poor	Rigors, fever, azotemia, hypokalemia, hypomagnesemia, renal tubular acidosis, anemia	All major pathogens except <i>Scedosporium</i>
Amphotericin B lipid complex	5 mg/kg/d intravenously	No	Poor	Fever, rigors, nausea, hypotension, anemia, azotemia, tachypnea	Same as amphotericin B, above
Amphotericin B, liposomal	3–6 mg/kg/d intravenously	No	Poor	Fever, rigors, nausea, hypotension, azotemia, anemia, tachypnea, chest tightness	Same as amphotericin B, above
Anidulafungin	100 mg intravenous loading dose, followed by 50 mg/d intravenously in one dose	< 1%	Poor	Diarrhea, hepatic enzyme elevations, histamine-mediated reactions	Mucosal and invasive candidiasis
Caspofungin acetate	70 mg intravenous loading dose, followed by 50 mg/d intravenously in one dose	< 50% ¹	Poor	Transient neutropenia; hepatic enzyme elevations when used with cyclosporine	Aspergillosis, mucosal and invasive candidiasis, empiric antifungal therapy in febrile neutropenia
Fluconazole	100–800 mg/d in one or two doses intravenously or orally	Yes	Yes	Nausea, rash, alopecia, headache, hepatic enzyme elevations	Mucosal candidiasis (including urinary tract), cryptococcosis, histoplasmosis, coccidioidomycosis
Flucytosine (5-FC)	100–150 mg/kg/d orally in four divided doses	Yes	Yes	Leukopenia, ² rash, diarrhea, hepatitis, nausea, vomiting	Cryptococcosis, ³ candidiasis, ³ chromomycosis
Itraconazole	100–400 mg/d orally in one or two doses with a meal or carbonated beverage	No	Variable	Nausea, hypokalemia, edema, hypertension, peripheral neuropathy	Histoplasmosis, coccidioidomycosis, blastomycosis, paracoccidioidomycosis, mucosal candidiasis (except urinary), sporotrichosis, aspergillosis, chromomycosis

(continued)

Table 36-1. Agents for systemic mycoses. (continued)

Drug	Dosing	Renal Clearance?	CSF Penetration?	Toxicities	Spectrum of Activity
Ketoconazole	200-800 mg/d orally in one or two doses with a meal or carbonated beverage	No	Poor	Anorexia, nausea, suppression of testosterone and cortisol, rash, headache, hepatic enzyme elevations, hepatic failure	Nonmeningeal histoplasmosis and coccidioidomycosis, blastomycosis, paracoccidioidomycosis, mucosal candidiasis (except urinary)
Micafungin sodium	150 mg intravenously in one dose (treatment) 50 mg (prophylaxis)	No	Poor	Rash, rigors, headache, phlebitis	Mucosal and invasive candidiasis, prophylaxis in hematopoietic stem cell transplantation
Posaconazole	400-800 mg/d orally in one or two doses ⁵	No	Yes	Nausea, vomiting, abdominal pain, diarrhea, and headache	Broad range of activity including zygomycosis
Terbinafine	250 mg/d orally in one dose	Yes	Poor	Nausea, abdominal pain, taste disturbance, rash, diarrhea, and hepatic enzyme elevations	Dermatophytes, sporotrichosis
Voriconazole	200-400 mg/d orally in two doses or 12 mg/kg intravenously as loading dose for 2 days followed by 6 mg/kg/d intravenously in two doses ⁵	Yes	Yes	Transient visual disturbances, rash, photosensitivity, fluoride excess with periostitis, peripheral neuropathy, hepatic enzyme elevations ⁴	All major pathogens except zygomycetes and sporotrichosis

¹No dosage adjustment required for chronic kidney disease; dosage adjustment necessary with moderate to severe hepatic dysfunction.

²Use should be monitored with blood levels to prevent this or the dose adjusted according to creatinine clearance.

³In combination with amphotericin B.

⁴Administration with drugs that are metabolized by the cytochrome P450 system is contraindicated or requires careful monitoring.

⁵Some authorities advocate therapeutic drug monitoring in patients who are not responding to therapy.

cryptococcal meningitis. Their principal advantage appears to be substantially reduced nephrotoxicity, allowing administration of much higher doses. Three agents of the echinocandin class, caspofungin acetate, anidulafungin, and micafungin sodium, are currently approved. The echinocandins have relatively few adverse effects and are useful for the treatment of invasive *Candida* infections. Caspofungin acetate is also approved for use in refractory cases of invasive aspergillosis. Voriconazole has excellent activity against a broad range of fungal pathogens and has been FDA approved for use in invasive *Aspergillus* cases, *Fusarium* and *Scedosporium* infections, *Candida* esophagitis, deep *Candida* infections, and candidemia. Posaconazole has good activity against a broad range of filamentous fungi, including the zygomycetes. Some experts now recommend therapeutic drug monitoring in individuals with severe invasive fungal infections receiving these newer azoles because of unreliable serum levels due to either metabolic alterations as a result of

genetic polymorphisms (voriconazole) or erratic absorption (posaconazole). As a result of their more frequent and sometimes extended use, newly recognized adverse drug effects are being recognized with the azoles, including peripheral neuropathy (itraconazole and voriconazole) and fluoride excess resulting in periostitis and alkaline phosphatase elevations (voriconazole).

Baxter CG et al. Peripheral neuropathy in patients on long-term triazole antifungal therapy. *J Antimicrob Chemother.* 2011 Sep;66(9):2136-9. [PMID: 21685202]

Lass-Flörl C. Triazole antifungal agents in invasive fungal infections: a comparative review. *Drugs.* 2011 Dec 24;71(18):2405-19. [PMID: 22141384]

Lewis RE. Current concepts in antifungal pharmacology. *Mayo Clin Proc.* 2011 Aug;86(8):805-17. [PMID: 21803962]

Wermers RA et al. Fluoride excess and periostitis in transplant patients receiving long-term voriconazole therapy. *Clin Infect Dis.* 2011 Mar;52(5):604-11. [PMID: 21239842]

Disorders Related to Environmental Factors

Jacqueline A. Nemer, MD, FACEP

37

COLD & HEAT

The human body maintains a steady temperature through the balance of internal heat production and environmental heat loss. Heat exchange between the body and environment occurs via four common processes: radiation, evaporation, conduction, and convection. In extreme temperatures, the body's thermoregulation may fail. This results in the body's internal temperature moving toward the temperature of the external environment.

Temperature-related conditions may arise in any individual, regardless of sex, race, age, or underlying health status. Cold and heat exposure may cause a wide spectrum of conditions; the severity varies considerably among individuals. The likelihood and severity of extreme temperature-related conditions depends on physiologic and environmental factors. Physiologic risk factors include underlying medical conditions (cardiopulmonary, vascular, neurologic, psychiatric, musculoskeletal, immunologic, hematologic, endocrine [hypothyroidism, adrenal insufficiency, hypopituitarism], renal, hepatic, and infectious diseases); extremes of age; cognitive impairment; poor physical conditioning/sedentary lifestyle; poor acclimatization; concurrent injury; inadequate thermoregulation; prior temperature-related injury; and pharmacologic effects (ie, medications, recreational drugs, tobacco, and alcohol). Environmental risk factors include inadequate clothing, inadequate housing, occupational or recreational exposure.

ACCIDENTAL SYSTEMIC HYPOTHERMIA

ESSENTIALS OF DIAGNOSIS

- ▶ Hypothermia is a reduction of core body temperature below 35°C.
- ▶ To accurately measure hypothermia, an intravascular, esophageal, rectal, or bladder probe that measures temperatures as low as 25°C is required; oral, axillary, and otic temperatures are inaccurate and unreliable.

- ▶ Rewarming is the initial, imperative treatment. Refreezing must be avoided to reduce further damage.
- ▶ The core temperature must be over 32°C before terminating resuscitation efforts.

General Considerations

Systemic hypothermia is defined as core body temperature < 35°C. This may be primary (from exposure to prolonged ambient extremely low temperature) or secondary (due to thermoregulatory dysfunction). Primary and secondary hypothermia may also be present at the same time. Hypothermia risk factors include prior cold weather injury as well as those factors listed in the Cold & Heat section. Heat loss occurs more rapidly with high wind velocity ("windchill factor"), water exposure (including wet clothing), or direct contact with a cold surface.

The human body generates internal heat through muscle activity (ie, shivering or increased physical exertion) and preserves heat loss via peripheral vasoconstriction. In prolonged or repetitive cold exposure, these thermoregulatory responses can become impaired; hypothermia ensues. Hypothermia diagnosis can be easily overlooked and delayed in a critically ill or injured patient. Hypothermia should be considered in any patient with prolonged exposure to ambient or cold environment, trauma, inadequate clothing, or altered mental status.

Systemic hypothermia depresses physiologic function, resulting in decreased respiratory drive, oxygen consumption, central and peripheral nerve conduction, gastrointestinal motility, myocardial repolarization, and coagulation cascade.

Accidental hypothermia may occur iatrogenically in the hospital setting. This section does not cover induced hypothermia post-resuscitation by critical care specialists.

Clinical Findings

Symptoms and signs of hypothermia are typically non-specific and markedly variable based on the patient's



▲ **Figure 37-1.** Electrocardiogram shows leads II and V5 in a patient whose body temperature is 24°C. Note the bradycardia and Osborn waves. These findings become more prominent as the body temperature lowers, and gradually resolve with rewarming. Osborn waves have an extra positive deflection in the terminal portion of the QRS complex and are best seen in the inferior and lateral precordial leads (most notably in leads II, V₅, and V₆).

underlying health and circumstances of hypothermia. At body core temperature between 32°C and 35°C, symptoms include tachypnea, tachycardia, hypertension, shivering, impaired coordination, poor judgment, and apathy. At body core temperature between 32°C and 28°C, the body slows down. Shivering stops; bradycardia, dilated pupils, slowed reflexes, cold diuresis, and confusion and lethargy ensue. The electrocardiogram (ECG) may reveal a J wave or Osborn wave (positive deflection in the terminal portion of the QRS complex, most notable in leads II, V₅, and V₆) (Figure 37-1). In extreme hypothermia (body core temperature below 28°C), the skin may appear blue or puffy; coma, apnea, loss of reflexes, asystole, or ventricular fibrillation may lead the clinician to assume that patient is dead. Prolonged hypothermia may lead to dysrhythmias and conduction abnormalities, acidemia, hyperkalemia, rhabdomyolysis, pulmonary edema, kidney disease, pneumonia, pancreatitis, hypoglycemia or hyperglycemia, and coagulopathy. Death from systemic hypothermia is usually due to ventricular fibrillation, asystole, or kidney disease.

► Treatment

Resuscitation begins with rapid assessment and support of airway, breathing and circulation, initiation of rewarming, and prevention of further heat loss. Rewarming is the initial, imperative treatment. All cold, wet clothing must be removed and replaced with warm, dry clothing. To accurately measure hypothermia, an intravascular, esophageal, rectal or bladder probe that measures temperatures as low as 25°C is required; oral, axillary, and otic temperatures are inaccurate and unreliable. The patient should be evaluated for associated conditions of hypoglycemia, trauma, overdose and peripheral cold injury. Rewarming methods are

determined by the degree of hypothermia and the resources available.

During rewarming, continuous monitoring of temperature and other vital signs, cardiac rhythm, and blood sugar must be done. Common complications of rewarming occur as colder peripheral blood returns to central circulation. This may result in core temperature afterdrop, rewarming acidosis from shunting lactate into the circulation, rewarming shock from peripheral vasodilation and hypovolemia, ventricular fibrillation and other cardiac arrhythmias. Extreme caution must be taken when handling the hypothermic patient to avoid triggering arrhythmias. During the rewarming process, essential testing includes ECG, chest radiograph, arterial blood gases, and bedside glucose. Laboratory evaluation should assess for potential complications of lactic acidosis; rhabdomyolysis; electrolyte abnormalities; infection; and dysfunction of the pancreas, liver, kidneys, and coagulation. False laboratory values will occur if the blood sample is warmed to 37°C for the testing. Antibiotics are not routinely given. Comatose patients have a high risk of aspiration pneumonia.

A. Passive and Active External Rewarming Methods

Patients with mild hypothermia (rectal temperature > 33°C) who have been otherwise healthy usually respond well to passive and active external warming. **Passive external rewarming** involves removal of cold wet clothing, then drying and covering the patient with blankets to prevent further heat loss. The patient will rewarm due to the body's internal heat production through shivering and increased metabolism. **Active external rewarming** is highly effective and safe for mild hypothermia. This is a noninvasive method of applying external heat to the patient's skin. Examples include warm bedding, heated blankets, heat packs, and immersion into a 40°C bath. Afterdrop can be lessened by active external rewarming of the trunk but not the extremities and by avoiding any muscle movement by the patient.

B. Active Internal (Core) Rewarming Methods

Active internal core rewarming methods are required for patients with core temperatures of < 33°C. Patients with milder degrees of hypothermia may also benefit from these methods. Warm humidified oxygen (43–46°C) is an easy, safe, and highly effective method. Warmed intravenous saline infusions (43°C) should be used instead of lactated Ringer solution. Volume resuscitation is needed to prevent shock as vasodilation occurs during rewarming. Other rewarming methods are based on the availability of equipment and skilled personnel (ie, warm solution lavage; esophageal rewarming tubes; endovascular warming devices; and hemodialysis).

For patients with core temperature < 30°C, initial treatment includes active rewarming, cardiopulmonary resuscitation (CPR), one shock attempt for dysrhythmia, and withholding of intravenous medications. Once the core temperature reaches 30°C, cardiac medications can be given but at intervals longer than standard intervals because metabolism is slowed and there is a risk of toxic

accumulation as circulation is restored. Defibrillation may be performed as needed. Resuscitative efforts should be continued until the patient's core temperature increases to at least 32°C.

► Prognosis

Prognosis is directly related to the patient's underlying health and comorbidities, circumstances surrounding the hypothermia (duration, extent, and the severity of associated conditions), and degree of metabolic acidosis. Prognosis is poor with low pH (≤ 6.6), elevated potassium (≥ 4.0 mEq/L or ≥ 4.0 mmol/L), serious underlying condition, or treatment delay. If treated early, most otherwise healthy patients may survive moderate or severe hypothermia.

► When to Admit

- Hypothermia patients must undergo close monitoring for potential complications. This is typically done during an inpatient admission or prolonged emergency department observation depending on the comorbidities and home care situation.
- Monitoring includes vital signs, temperature, cardiac rhythm, oximetry, serial examinations (including extremity cold-induced injuries), and serial laboratory studies (electrolyte abnormalities, renal or hepatic dysfunction, cardiac ischemia, and infection).

HYPOTHERMIA OF THE EXTREMITIES

ESSENTIALS OF DIAGNOSIS

- Extremities suffering cold-induced injuries should not be exercised, rubbed, or massaged during rewarming.
- Rewarming of extremities affected by cold-induced injuries must be performed as soon as possible after there is no risk of refreezing.

► Clinical Findings

Cold-induced injuries to the extremities (ie, frostnip, chilblain, trench foot, and frostbite) range from mild to severe. Cold exposure of the extremities produces immediate localized vasoconstriction followed by generalized vasoconstriction. When the skin temperature falls to 25°C, tissue demand for oxygen is greater than what is supplied by the slowed circulation: the area becomes cyanotic. At 15°C, tissue damage occurs due to marked reduction in tissue metabolism and oxyhemoglobin dissociation. This gives a deceptive pink, well-oxygenated appearance to the skin. Tissue damage may result from ischemia and intravascular thromboses, endothelial damage, or by actual freezing. Freezing (frostbite) may occur when the skin temperature drops below -4 to -10°C or at higher

temperatures in the presence of wind, water, immobility, malnutrition, or vascular disease.

► Prevention

"Keep warm, keep dry, and keep moving." Individuals should wear warm, dry clothing, preferably several layers, with a windproof outer garment. Arms, legs, fingers, and toes should be exercised to maintain circulation. Wet clothing, socks, and shoes should be replaced with dry ones. Extra socks, mittens, and insoles should always be carried in a pack during travel in cold or icy areas. Caution must be taken to avoid cramped positions; constrictive clothing; prolonged dependency of the feet; use of tobacco, alcohol, and sedative medications; and exposure to wet muddy ground and windy conditions.

FROSTNIP & CHILBLAIN (Erythema Pernio)

Frostnip is a mild temporary form of cold-induced injury. The involved area has local paresthesias that completely resolve with passive external rewarming. Rewarming can be done by placing cold fingers in the armpits and, in the case of the toes or heels, by removing footwear, drying feet, rewarming, and covering with adequate dry socks or other protective footwear.

Chilblains or **erythema pernio** are inflammatory skin changes caused by exposure to cold without actual freezing of the tissues. These skin lesions may be red or purple papular lesions, which are painful or pruritic, with burning or paresthesias. They may be associated with edema or blistering and aggravated by warmth. With continued exposure, ulcerative or hemorrhagic lesions may appear and progress to scarring, fibrosis, and atrophy. This may resemble vasculitis or peripheral thromboemboli. A detailed history of cold exposure will differentiate chilblains from these other conditions, thereby avoiding unnecessary diagnostic testing.

Treatment consists of elevating and passively externally rewarming the affected part. Caution must be taken to avoid rubbing or massaging injured tissues and to avoid applying ice or heat. The area must be protected from trauma, secondary infection, and further cold exposure.

IMMERSION FOOT OR TRENCH FOOT

Immersion foot (or hand) is caused by prolonged immersion in cool or cold water or mud, usually $< 10^{\circ}\text{C}$. **Prehyperemic stage** is marked by early symptoms, which include cold and anesthesia of the affected area. **Hyperemic stage** follows with hot sensation, intense burning, and shooting pains. With ongoing cold exposure, the affected part becomes pale or cyanotic with diminished pulsations due to vasospasm (**posthyperemic stage**). This may result in blistering, swelling, redness, ecchymoses, hemorrhage, necrosis, peripheral nerve injury, or gangrene and secondary complications such as lymphangitis, cellulitis, and thrombophlebitis.

Treatment is best instituted during the hyperemic stage. Treatment consists of air drying, protecting the extremities from trauma and secondary infection, and

gradual rewarming by exposure to air at room temperature (not ice or heat). Caution must be taken to avoid massaging or moistening the skin and to avoid further water immersion. Bed rest is required until all ulcers have healed. Affected parts are elevated to aid in removal of edema fluid. Pressure sites (ie, heels) are protected with pillows. Prevention involves properly fitting footwear, improved foot hygiene, and sock changes to keep feet clean and dry.

FROSTBITE

Frostbite is injury from tissue freezing and formation of ice crystals in the tissue. Most tissue destruction follows the reperfusion of the frozen tissues, with damaged endothelial cells and progressive microvascular thrombosis resulting in further tissue damage. In mild cases, only the skin and subcutaneous tissues are involved; the symptoms are numbness, prickling, itching, and pallor. With increasing severity, deep frostbite involves deeper structures. The skin appears white or yellow, loses its elasticity, and becomes immobile. Edema, hemorrhagic blisters, necrosis, and gangrene may appear. This may cause paresthesias and stiffness.

► Treatment

A. Immediate Treatment

Evaluate and treat the patient for associated systemic hypothermia and injury. Avoid secondary exposure to cold. Early use of systemic analgesics is recommended for nonfrozen injuries. Fluids and electrolytes should be monitored.

1. Rewarming—Rapid rewarming at temperatures slightly above body heat may significantly decrease tissue necrosis and reverse the tissue crystallization. If there is any possibility of refreezing, the frostbitten part should not be thawed, even if this might mean prolonged walking on frozen feet. Refreezing results in increased tissue necrosis. Rewarming is best accomplished by warm bath immersion. The frozen extremity is immersed for several minutes in a moving water bath heated to 40–42°C until the distal tip of the part being thawed flushes. Dry heat (ie, stove or open fire) is more difficult to regulate, increases likelihood of accidental burns and is not recommended. Thawing may cause tenderness and burning pain. Once the frozen part has thawed and returned to normal temperature (usually in about 30 minutes), discontinue external heat. *In the early stage, rewarming by exercise, rubbing, or friction is contraindicated.* The patient must be kept at bed rest with the affected parts elevated and uncovered at room temperature. Casts, occlusive dressings, or bandages are not applied. Blisters should be left intact unless signs of infection supervene.

2. Anti-infective measures and wound care—Frostbite increases susceptibility to tetanus and infection. Tetanus prophylaxis must be considered. Infection risk may be reduced by aseptic wound care and protection of skin blebs

from physical contact. Wounds should be kept open and allowed to dry before applying dressings. Nonadherent sterile gauze and fluffy dressing should be loosely applied to wounds and cushions used for all areas of pressure. Antibiotics should not be administered empirically. Systemic antibiotics are reserved for deep infections not responding to local wound care.

B. Medical and Surgical Treatment Options

With the availability of telemedicine, specialists are able to provide advice on early field treatment of cold-injured patients in remote areas, thereby improving outcome. Eschar formation without evidence of infection may be conservatively treated. The underlying skin may heal spontaneously with the eschar acting as a biologic dressing. Intra-arterial thrombolytic administration within 24 hours of exposure has resulted in improved tissue perfusion and has reduced amputation.

C. Follow-Up Care

Gentle, progressive physical therapy to promote circulation should be instituted as tolerated. Debridement and amputation should be considered only after it is established that the tissues are necrotic.

► Prognosis

Recovery from frostbite depends on the underlying comorbidities, the extent of initial tissue damage, the rewarming reperfusion injury, and the late sequelae. The involved extremity may be at increased susceptibility for discomfort and injury upon reexposure to cold. Neuropathic sequelae such as pain, numbness, tingling, hyperhidrosis, and cold sensitivity of the extremities, and nerve conduction abnormalities may persist for many years after the cold injury.

► When to Admit

- Patients with local cold-induced injury may require admission for management of tissue damage, comorbidities, associated injuries, or an inadequate living situation, which could compromise patient safety or recovery.

Grieve AW et al. A clinical review of the management of frostbite. *J R Army Med Corps.* 2011 Mar;157(1):73–8. [PMID: 21465915]

Imray C et al. Cold damage to the extremities: frostbite and non-freezing cold injuries. *Postgrad Med J.* 2009 Sep; 85(1007): 481–8. [PMID: 19734516]

Mohr WJ et al. Cold injury. *Hand Clin.* 2009 Nov;25(4):481–96. [PMID: 19801122]

Prakash S et al. Idiopathic chilblains. *Am J Med.* 2009 Dec; 122(12):1152–5. [PMID: 19958897]

DISORDERS DUE TO HEAT



ESSENTIALS OF DIAGNOSIS

- ▶ There is a spectrum of preventable heat-related illnesses: heat cramps, heat exhaustion, heat syncope, and heat stroke.
- ▶ Pre-event planning and adequate preparation are the best preventive measures. Salt tablets are not recommended without medical supervision.
- ▶ The hallmarks of heat stroke are hyperthermia with cerebral dysfunction in a patient with heat exposure.
- ▶ The best outcome is related to early recognition, initiation of rapid cooling, and avoidance of shivering during cooling.
- ▶ The best choice of cooling method depends on which can be instituted the fastest with the least compromise to the overall care of the patient. Delays in cooling result in higher morbidity and mortality in heat stroke victims.

▶ General Considerations

Hyperthermia results from the body's inability to maintain normal internal temperature through heat loss. The body's heat source is a result of internal metabolic function and environmental conditions (temperature, humidity). Heat loss occurs through sweating and peripheral vasodilation.

There is a spectrum of preventable heat-related illnesses related to environmental exposure, ranging from mild forms, such as heat cramps and heat exhaustion, to severe forms, such as heat syncope and heat stroke. The common comorbidities and risk factors leading to heat-related conditions are listed in the chapter's introduction "Cold & Heat" section. Additional risk factors include duration of exertion, hot environment, physical inactivity, and insufficient acclimatization, skin disorders or other medical conditions that inhibit sweat production or evaporation, obesity, dehydration, prolonged seizures, hypotension, reduced cutaneous blood flow, reduced cardiac output, the use of drugs that increase metabolism or muscle activity or impair sweating, and withdrawal syndromes. Nonexertional heat-related illness can also occur in a hot relaxing environment (ie, hot bath, steam room, or sauna).

▶ Prevention

Public education is necessary to improve prevention and early recognition of heat-related disorders. Individuals should take steps to reduce personal risk factors and to acclimatize to the hot environment. Acclimatization is achieved by scheduled regulated exposure to hot environments and by gradually increasing the duration of exposure and the workload until the body adjusts. Proper acclimatization must be achieved before heavy physical exertion is performed in hot environments. Heat-related

illnesses are the leading cause of morbidity and mortality in high school sports in the United States. All children's athletic programs must set heat-acclimatization guidelines. Parents, coaches, athletic trainers and athletes must be educated about heat-related illness, specifically about prevention, risks, signs and symptoms, and treatment.

Medical evaluation and monitoring should be used to identify the individuals and the weather conditions that increase risk of heat-related disorders. Athletic events should be organized with attention to thermoregulation. Guidance regarding heat hazard is found in the National Weather Service's Heat Index, which rates weather conditions based on humidity and temperature measurements (<http://www.nws.noaa.gov/os/heat/index.shtml>).

Those who are physically active in a hot environment should increase fluid consumption before, during, and after physical activities. Fluid consumption should include balanced electrolyte fluids and water. Water consumption alone may lead to electrolyte imbalance, particularly hyponatremia. *It is not recommended to have salt tablets available for use without medical supervision.* Close monitoring of fluid and electrolyte intake and early intervention are recommended in situations necessitating exertion or activity in hot environments. Exertional heat-related disorders are common in unconditioned participants in strenuous activities in hot humid conditions. Classic (non-exertional) heat-related disorders occur when extreme environmental conditions (heat, humidity) affect patients who are not physically active, in the extremes of ages, or with chronic medical or psychiatric illnesses.

SPECIFIC SYNDROMES DUE TO HEAT EXPOSURE

1. Heat Syncope or Collapse

Heat syncope or sudden collapse may result in unconsciousness from volume depletion and cutaneous vasodilation with consequent systemic and cerebral hypotension. Exercise-associated postural hypotension is usually the cause of this: it may occur during or immediately following exercise. There is usually a history of prolonged vigorous physical activity or prolonged standing in a hot humid environment. Typically, the skin is cool and moist, the pulse is weak, and the systolic blood pressure is low.

Treatment consists of rest and recumbency in a cool place and fluid and electrolyte rehydration by mouth (or intravenously if necessary).

2. Heat Cramps

Fluid and electrolyte depletion may result in slow, painful skeletal muscle contractions ("cramps") and severe muscle spasms lasting 1–3 minutes, usually of the muscles most heavily used. The skin is moist and cool. The muscles are tender, hard and lumpy, and muscle twitching may be present. The patient is alert, with stable vital signs, and may be agitated and complaining of focal pain. The body temperature may be normal or slightly increased. There is almost always a history of vigorous activity just preceding the onset of symptoms.

The patient should be moved to a cool environment and given oral saline solution (4 tsp of salt per gallon of water) to replace both salt and water. *Oral salt tablets are not recommended.* The patient may have to rest for 1–3 days with continued dietary supplementation before returning to work or resuming strenuous activity in the heat.

3. Heat Exhaustion

Heat exhaustion results from prolonged strenuous activity with inadequate water or salt intake in a hot environment. It is characterized by dehydration, sodium depletion, or isotonic fluid loss with accompanying cardiovascular changes.

The diagnosis is based on symptoms and clinical findings of a rectal temperature over 37.8°C, increased pulse, and moist skin. Symptoms are similar to those associated with heat syncope and heat cramps. Additional symptoms include nausea, vomiting, malaise, myalgias, hyperventilation, thirst, and weakness. Central nervous system symptoms include headache, dizziness, fatigue, anxiety, paresthesias, hysteria, impaired judgment, and occasionally psychosis. Heat exhaustion may progress to heat stroke if sweating ceases and mental status declines.

Treatment consists of moving patient to a shaded, cool environment, providing adequate hydration (1–2 L over 2–4 hours), oral salt replenishment, and active cooling (ie, fans, cool packs) if necessary. Physiologic saline or isotonic glucose solution should be administered intravenously when oral administration is not appropriate. At least 24 hours of rest and rehydration are recommended.

4. Heat Stroke

Heat stroke is a life-threatening medical emergency. *The hallmarks of heat stroke are cerebral dysfunction with core temperature over 40°C.* It presents in one of two forms: classic and exertional. **Classic heat stroke** occurs in patients with impaired thermoregulatory mechanisms; **exertional heat stroke** occurs in healthy persons undergoing strenuous exertion in a hot or humid environment. Persons at greatest risk are those who are at the extremes of age, chronically debilitated, and taking medications that interfere with heat-dissipating mechanisms (ie, anticholinergics, antihistamines, phenothiazines).

Heat stroke is associated with high morbidity and mortality from cerebral, cardiovascular, liver, or kidney damage. Increased mortality rates are associated with a high Simplified Acute Physiology Score II, high body temperature, prolonged prothrombin time, use of vasoactive drugs within the first day in the intensive care unit (ICU), and an ICU without air conditioning.

► Clinical Findings

A. Symptoms and Signs

Heat stroke must be considered in any patient with hyperthermia and cerebral dysfunction. Presenting symptoms include all those seen in heat exhaustion with additional symptoms of dizziness, weakness, emotional lability, confusion, delirium, blurred vision, convulsions, collapse, and

unconsciousness. Physical examination findings include core temperature usually over 40°C, hot skin, initially covered with perspiration, then later it dries; strong pulse initially; widened pulse pressure; blood pressure is slightly elevated at first, but hypotension develops later; tachycardia; and hyperventilation. Exertional heat stroke may present with sudden collapse and loss of consciousness followed by irrational behavior. Sweating may not be present. Multiorgan dysfunction or failure is a common and serious complication.

B. Laboratory Findings

Laboratory evaluation may reveal dehydration; leukocytosis; elevated blood urea nitrogen (BUN); hyperuricemia; hemoconcentration; acid-base abnormalities (lactic acidosis, respiratory alkalosis); decreased serum glucose, sodium, calcium, and phosphorus; thrombocytopenia, fibrinolysis, and coagulopathy; elevated creatine kinase (CK); elevated aminotransferase levels and liver dysfunction; and elevated cardiac markers. Urine is concentrated, with proteinuria, hematuria, tubular casts, and myoglobinuria. Potassium may be high or low. ECG findings may include ST–T changes consistent with myocardial ischemia. PCO₂ may be < 20 mm Hg.

► Treatment

Treatment is aimed at rapidly reducing the core temperature (within 1 hour) while supporting circulatory and organ system function to prevent irreversible tissue damage and death. Clinicians must assess for possibility of concurrent conditions (infection, trauma, and drug effects, including adverse side effects, withdrawal, or overdose). Circulatory failure in heat-related illness is mostly due to shock from relative or absolute hypovolemia. Intravascular volume status should be assessed and managed early to reduce the risk of hypovolemic shock. Central venous monitoring is useful to guide volume status. Oral or intravenous fluid administration must be provided to ensure adequate urinary output. Fluid output should be monitored through the use of an indwelling urinary catheter.

Cooling methods are evaporative and conductive-based. Systemic review of the research found that there are comparable effects of these cooling methods whether used singly or in combination. No single cooling method is found to be superior. Choice of cooling method depends on which can be instituted the fastest with the least compromise to the overall care of the patient.

Evaporative cooling is a noninvasive, effective, quick and easy way to reduce temperature. Large fans circulate the room air while the entire undressed body is sprayed with lukewarm water (20°C). Inhalation of cool air or oxygen is also effective.

Conductive-based cooling involves cool fluid infusion, lavage, ice packs, and immersion into ice water or cool water. Intravascular heat exchange catheter systems as well as hemodialysis using cold dialysate (30–35°C) have been successful in reducing core temperature. Research suggests that brain cooling may lessen cerebrovascular injury from heat stroke.

Shivering must be avoided because it inhibits the effectiveness of cooling by increasing internal heat production. Medications that can be used to suppress shivering include magnesium, quick-acting opioid analgesics, benzodiazepines, and quick-acting anesthetic agents. Skin massage is recommended to prevent cutaneous vasoconstriction. *Antipyretics (aspirin, acetaminophen) have no effect on environmentally induced hyperthermia and are contraindicated.* Treatment should be continued until the rectal temperature drops to 39°C.

► Prognosis

Multiorgan dysfunction is the usual cause of heat stroke-related death, and it can be predicted by elevated creatine kinase, metabolic acidosis, coagulopathy and elevated liver enzymes. Multiorgan dysfunction, rhabdomyolysis, acute respiratory distress syndrome (ARDS), and inflammation may continue after temperature is normalized. Following heat stroke, immediate reexposure should be avoided. Sensitivity to high environmental temperature may persist for prolonged periods.

► When to Admit

- All patients with suspected heat stroke must be admitted to the hospital for close monitoring.
- Monitoring includes vital signs, temperature, and cardiac rhythm, and observation for potential complications of metabolic abnormalities, cardiac arrhythmias, coagulopathy, ARDS, hypoglycemia, seizures, organ dysfunction, and infection.

Becker JA et al. Heat-related illness. *Am Fam Physician.* 2011 Jun 1;83(11):1325–30. [PMID: 21661715]

Centers for Disease Control and Prevention (CDC). Heat illness among high school athletes—United States, 2005–2009. *MMWR Morb Mortal Wkly Rep.* 2010 Aug 20;59(32):1009–13. [PMID: 20724966]

Marom T et al. Acute care for exercise-induced hyperthermia to avoid adverse outcome from exertional heat stroke. *J Sport Rehabil.* 2011 May;20(2):219–27. [PMID: 21576713]

O'Connor FG et al. American College of Sports Medicine Roundtable on exertional heat stroke—return to duty/return to play: conference proceedings. *Curr Sports Med Rep.* 2010 Sep–Oct;9(5):314–21. [PMID: 20827100]

Zeller L et al. Exertional heatstroke: clinical characteristics, diagnostic and therapeutic considerations. *Eur J Intern Med.* 2011 Jun;22(3):296–9. [PMID: 21570651]

THERMAL BURNS

ESSENTIALS OF DIAGNOSIS

- Estimates of the burn location, size and depth greatly determine treatment plan.
- The first 48 hours of burn care offers the greatest impact on morbidity and mortality of a burn victim.

Epidemiologic data on thermal burn injury show that the incidence and severity have been declining over recent years. Scald, direct thermal, and flame burns account for the majority of such injuries. Over three-fourths of burns involve < 10% of total body surface area. Related injuries include smoke inhalation, fractures, and blast injuries. Subsequent problems include bacterial superinfection, sepsis, respiratory damage, and multiorgan failure.


Telemedicine evaluation of acute burns offers accurate, cost-effective access to a burn specialist during the crucial 48 hours after the burn injury. The first 48 hours after the burn injury offer the greatest opportunity to impact the survival of the patient. Early surgical intervention, wound care, enteral feeding, glucose control and metabolic management, infection control, and prevention of hypothermia and compartment syndrome have contributed to significantly lower mortality rates and shorter hospitalizations.

► General Considerations

A. Classification

Burns are classified by extent, depth, patient age, and associated illness or injury. Accurate estimation of burn size and depth is important since this figure will quantify the parameters of resuscitation.

1. Extent—In adults, the “rule of nines” (Figure 37–2) is useful for rapidly assessing the extent of a burn. It is important to view the entire patient to make an accurate assessment of skin findings on initially and on subsequent examinations. One rule of thumb is that the palm of an open hand constitutes 1% total body surface area in adults. Only second- and third-degree burns are included



▲ **Figure 37–2.** Estimation of body surface area in burns.

in calculating the total burn surface area, since first-degree burns usually do not represent significant injury in terms of prognosis or fluid and electrolyte management. However, first- or second-degree burns may convert to deeper burns, especially if treatment is delayed or bacterial colonization or superinfection occurs.

2. Depth—Judgment of depth of injury is difficult. The **first-degree burn** may be red or gray but will demonstrate excellent capillary refill. First-degree burns are not blistered initially. If the wound is blistered, this represents a partial-thickness injury to the dermis, which is referred to as a **second-degree burn**. As the degree of burn is progressively deeper, there is a progressive loss of adnexal structures, referred to as a **third-degree burn**. Hairs can be easily extracted or are absent, sweat glands become less visible, and the skin appears smoother.

Deep second- and third-degree burns are treated in a similar fashion. Neither will heal appropriately without early debridement and grafting; the resultant skin is thin and scarred.

B. Survival after Burn Injury

The **Prognostic Burn Index** is the sum of the patient's age and percentage of full thickness or deep partial thickness burn. An additional 20% mortality is added if inhalation injury is present. The Prognostic Burn Index is most useful at the extremes of age. Transfer to a burn unit is indicated for large burn size, circumferential burn, or burn involving a joint or high-risk body part, and patients with comorbidities. Mortality rates have been significantly reduced due to treatment advances including improvements in wound care, treatment of infection, early burn excision, skin substitute usage, and early nutritional support through parenteral or enteral feeding. Telemedicine consultation with a burn center is an alternative, cost-effective way to access burn specialists when there are barriers that prevent transfer (distance, bed unavailability, travel risks, etc).

C. Associated Injuries or Illnesses

Smoke inhalation, associated trauma, and electrical injuries are commonly associated with burns. Smoke inhalation (see Chapter 9) must be suspected when a burn victim is found in an enclosed space, or in close proximity to the fire. Electrical injury (see following section of this chapter) may cause deep tissue burns without significant superficial skin findings and may also produce cardiac arrhythmias that require immediate attention. Severe burns from any source may cause gastrointestinal complications including pancreatitis and stress ulcers.

D. Systemic Reactions to Burn Injury

The actual burn injury is only the incipient event leading to cascade of deleterious local tissue and systemic inflammatory reactions causing multisystem organ failure in the severely burned patient. When burns greater than approximately 20% of total body surface area are present, systemic metabolic alterations occur and require intensive support. The inflammatory cascade can result in shock.

► Treatment

A. Initial Resuscitation

1. Primary survey—The clinician must proceed with a full trauma assessment, starting with “ABCDE” (airway, breathing, circulation, disability, exposure). **Airway** assessment and management is the first priority. A patient with an inhalation injury needs to be intubated early to maintain airway patency even though he or she may appear to be breathing normally. To assess and support **breathing and circulation**, the clinician should administer supplemental oxygen and obtain vascular access for fluid resuscitation simultaneously with initial resuscitation. **Disability** assessment is next followed by complete patient **exposure** and thorough examination to assess the extent of burn and associated injuries. Serial assessments of airway and breathing are necessary since endotracheal intubation or tracheotomy may be needed for major burn victims, particularly those with possible inhalation injury. Generalized edema develops during fluid resuscitation, including edema of the soft tissues of the upper airway and perhaps the lungs as well. Chest radiographs are typically normal initially but may develop an ARDS picture in 24–48 hours with severe inhalation injury. The use of corticosteroids or routine use of antibiotic therapy is not indicated.

A. AIRWAY CONTROL—Early intubation is recommended before airway edema occurs in cases of smoke inhalation or direct thermal injury to the upper airway (look for singed eyebrows or facial hair, carbonaceous sputum).

B. VASCULAR ACCESS—Large bore peripheral venous catheter access should be established. Femoral lines provide good temporary access during resuscitation if central venous access is needed. Intraosseous access can be obtained if venous access is unsuccessful or contraindicated. *Venous access catheters placed in the emergency department should be changed within 24 hours because of the high risk of non-sterile placement.* An arterial line is useful for monitoring mean arterial pressure and for drawing serial blood gases and other laboratory tests in critically ill patients.

C. FLUID RESUSCITATION—Generalized capillary leak results from burn injury over more than 20% of total body surface area. This often necessitates replacement with large volumes of crystalloid. There are many guidelines for fluid resuscitation. The **Parkland formula** relies on the use of lactated Ringer injection. The fluid requirement in the first 24 hours is estimated as 4 mL/kg body weight per percent of body surface area burned. Half the calculated fluid is given in the first 8-hour period. The remaining fluid, divided into two equal parts, is delivered over the next 16 hours. An extremely large volume of fluid may be required. For example, an injury over 40% of the total body surface area in a 70-kg victim may require 11.2 L in the first 24 hours [$4 \text{ mL} \times 40(\%) \times 70 \text{ (kg)} = 11,200 \text{ mL}$]. The first 8-hour period is measured from the hour of injury. These guidelines may be inadequate, since crystalloid solutions alone may be insufficient to restore cardiac preload during the period of burn shock. Deep electrical burns and inhalation injury increase the fluid requirement.

Adequacy of resuscitation is determined by clinical parameters, including urinary output and specific gravity, blood pressure, pulse, temperature, and central venous pressure. Overly aggressive crystalloid administration must be avoided in patients with pulmonary injury or cardiac dysfunction, since significant pulmonary edema can develop in patients with normal pulmonary capillary wedge and central venous pressures. A Foley catheter is essential for monitoring urinary output. Diuretics have no role in this phase of patient management unless fluid overload has occurred.

The need for fluid replacement of more than 150% of calculated values indicates possible unrecognized injury, possible comorbidities, and a worse prognosis.

B. Management

1. Chemoprophylaxis—

A. TETANUS IMMUNIZATION—For all burns deeper than superficial thickness, tetanus immunization must be updated. Tetanus toxoid-containing vaccine should be given intramuscularly to all patients with wounds regardless of how recently the patient received tetanus immunization. In addition, if a patient has not completed the recommended three doses of primary immunization or this is unknown, then tetanus immunoglobulin should also be administered intramuscularly in a different site than the tetanus toxoid. (See Chapter 33)

B. ANTIBIOTICS—All nonsuperficial depth wounds should be covered with topical antibiotics. Prophylaxis with systemic antibiotics is not indicated.

2. Surgical management—

A. ABDOMINAL COMPARTMENT SYNDROME—Abdominal compartment syndrome is emerging as a potentially lethal condition in severely burned patients, even if abdominal decompression is performed. Markedly increased intra-abdominal pressures can cause pulmonary damage and multisystem organ failure. Only 40% of patients with this complication survive. Bladder pressures over 30 mm Hg establish the diagnosis in at-risk patients. Surgical abdominal decompression may be indicated to improve ventilation and oxygen delivery, but even after this surgery, survival remains low.

B. ESCHAROTOMY—As edema fluid accumulates, ischemia may develop under any constricting eschar of an extremity, neck, chest, or trunk if the full-thickness burn is circumferential. Escharotomy incisions through the anesthetic eschar can save life and limb and can be performed in the emergency department or operating room.

C. FASCIOTOMY—Similar to escharotomy, fasciotomy is indicated to prevent further soft tissue, vascular, and nerve damage when soft tissue edema produces high pressures in the deep tissue compartments in the arms and legs since these compartments are divided by unyielding fascia.

D. DEBRIDEMENT, DRESSINGS, AND TOPICAL AND SYSTEMIC ANTIBIOTIC THERAPY—Minor burn wounds should be debrided at the bedside to determine the depth of the

burn and then thoroughly cleansed. Thereafter, the wound should be debrided daily and dressed with a topical antibiotic and a wound dressing. Patient compliance and adequate pain treatment is essential for successful outpatient treatment. The wound should be reevaluated by the treating clinician within 24–72 hours to evaluate for signs of infection.

The goal of burn wound management is to protect the wound from desiccation and avoid further injury or infection. Regular and thorough cleansing of burned areas is a critically important intervention in burn units. Minor burn wounds (first- and superficial second-degree types, partial thickness) will spontaneously reepithelialize in 7–10 days. Topical wound agents should be applied. Topical antibiotic wound agents are painless, easy to apply, and effective against most skin pathogens.

For severely burned patients, early excision and grafting of burned areas may be performed as soon as 24 hours after burn injury or when the patient can hemodynamically tolerate the excision and grafting procedure. Meticulous prevention of infections, seromas, hypergranulation tissue formation, and malnutrition all decrease the time to complete wound healing in skin-grafted patients. Skin autograft is the most definitive treatment. Prevention of autograft infection is paramount since autograft loss is most commonly due to autograft infection.

Systemic infection remains a leading cause of morbidity among patients with major burn injuries, with nearly all severely burned patients having one or more septicemic episodes during the hospital course. Healthcare-associated infections are increasingly common. Routine use of blood culture in the severely burned population is indicated to elucidate systemic blood infections that do not manifest these clinical predictors of sepsis.

E. WOUND CLOSURE—The goal of therapy after fluid resuscitation is rapid and stable closure of the wound. Wounds that will not heal spontaneously in 7–10 days (ie, deep second-degree or third-degree burns) are best treated by excision and autograft.

With severe burns, skin substitution with cultured grafts can be lifesaving. However, although the replaced dermis does have nearly normal histologic dermal elements, there are no adnexal structures present and very few, if any, elastic fibers. Wound infection is the top cause of skin graft rejection and failure.

C. Patient Support

Burn patients require extensive supportive care, both physiologically and psychologically. It is important to maintain normal core body temperature and avoid hypothermia (by maintaining environmental temperature at or above 30°C) in patients with burns over more than 20% of total body surface area. Respiratory injury, sepsis, and multiorgan failure are common. Burn patients require careful assessment and provision of optimal nutritional needs since their metabolism is higher and they require more energy, nutrients, and antioxidants for wound healing. Enteral feedings may be started once the ileus of the resuscitation period has resolved, usually the day after the

injury. There is often a markedly increased metabolic rate after burn injury, due in large part to whole body synthesis and increased fatty acid substrate cycles. Early aggressive nutrition (by parenteral or enteral routes) reduces infections, recovery time, noninfectious complications, length of hospital stay, long-term sequelae, and mortality.

Careful control of the postinjury blood glucose has been associated with improved hepatic function and better survival after severe burns. Occasionally, ARDS or respiratory failure unresponsive to maximal ventilatory support may develop in burn patients. In addition, the incidence of venous thromboembolism is high among burn patients.

Prevention of long-term scars remains a formidable problem in seriously burned patients. Long-term sequelae can be reduced by burn specialist consultation either directly or via telemedicine, prevention of infection, early nutrition, early aggressive rehabilitation, compressive garments, and early and continual psychological support.

► Prognosis

Prognosis depends on the extent and location of the burn tissue damage, associated injuries, comorbidities, and complications. Hyperglycemia from poor glucose control is a predictor of worse outcomes. Psychiatric support may be necessary following burn injury.

► When to Admit

- All burn patients require extensive supportive care, both physiologically and psychologically.
- Patients with significant burns (based on location and extent), comorbidities, and suboptimal home situations must be admitted to the hospital for close monitoring. Burn center consultation can advise which patients require transfer and which can be managed via telemedicine/telephone consultation.
- Monitoring includes vital signs, wound care, and observation for potential complications of electrolyte abnormalities, acute kidney injury, hepatic failure, cardiopulmonary compromise, hypoglycemia, and infection.

Advisory Committee on Immunization Practices. Recommended adult immunization schedule: United States, 2011. *Ann Intern Med.* 2011 Feb 1;154(3):168–73. [PMID: 21282696]

Avni T et al. Prophylactic antibiotics for burns patients: systematic review and meta-analysis. *BMJ.* 2010 Feb 15;340:c241. [PMID: 20156911]

Jeschke MG et al. Glucose control in severely thermally injured pediatric patients: what glucose range should be the target? *Ann Surg.* 2010 Sep;252(3):521–8. [PMID: 20739853]

Latenser BA. Critical care of the burn patient: the first 48 hours. *Crit Care Med.* 2009 Oct;37(10):2819–26. [PMID: 19707133]

Saffle JR et al. Telemedicine evaluation of acute burns is accurate and cost-effective. *J Trauma.* 2009 Aug;67(2):358–65. [PMID: 19667890]

Williams FN et al. What, how, and how much should patients with burns be fed? *Surg Clin North Am.* 2011 Jun;91(3):609–29. [PMID: 21621699]

ELECTRICAL INJURY

ESSENTIALS OF DIAGNOSIS

- Extent of injury is determined by the type, amount, duration, and pathway of electrical current.
- Resuscitation must be attempted before assuming the electrical injury victim is dead; clinical findings are unreliable.
- Skin findings may be misleading and are not indicative of the degree of deeper tissue injury.

► General Considerations

Electricity-induced injuries are common and most are preventable. These inquiries occur by exposure to electrical current of low voltage, high voltage, or lightning. Electrical current type is either alternating current (AC) or direct current (DC). Electricity causes acute damage by direct tissue damage, muscle tetany, direct thermal injury and coagulation necrosis, and associated trauma.

Alternating current (AC) is bidirectional electrical flow that reverses direction in a sine wave pattern. This may cause muscle tetany, which prolongs the duration and amount of current exposure. AC current can be low voltage or high voltage. **Low voltage** (< 1000 V) is typically household AC current that ranges in severity from minor injury to significant damage and death. **High voltage** (> 1000 V) is most often related to occupational exposure and is associated with deep tissue damage and higher morbidity and mortality. **Direct current (DC)** is unidirectional electrical flow (eg, that associated with lightning, batteries, and automotive electrical systems). It is more likely to cause a single intense muscle contraction and asystole. **Lightning** differs from other high-voltage electrical shock in that lightning is massive DC current of millions of volts lasting a very brief duration (a small fraction of a second).

The extent of damage depends on the following factors: voltage (high or low, whether greater or lesser than 1000 volts), current type, tissue resistance, moisture, pathway; duration of exposure; associated trauma and comorbidities. Current is the most important determinant of tissue damage. Current passes through the tissues of least resistance, and this energy produces heat causing direct thermal injury. Tissue resistance varies throughout the body. Nerve cells are the most vulnerable, and bone is the most resistant to electrical current. Skin resistance depends on thickness and condition of the skin. The entrance and exit points are the most damaged. Current passing through skeletal muscle can cause muscle necrosis and contractions severe enough to result in bone fracture.

► Clinical Findings

Electrical burns are of three distinct types: flash (arcing) burns, flame (clothing) burns, and the direct heating effect of tissues by the electrical current. The latter lesions are usually sharply demarcated, round or oval, painless yellow-brown areas (Joule burn) with inflammatory reaction.

Skin damage does not correlate with the degree of injury. Significant subcutaneous damage can be accompanied by little skin injury, particularly with larger skin surface area electrical contact. Symptoms and signs may range from tingling, superficial skin burns, and myalgias to coma, paralysis, massive tissue damage, or death. Not all electrical injuries cause skin damage; only very minor skin damage may be present with massive internal injuries. The presence of entrance and exit burns signifies an increased risk of deep tissue damage.

Resuscitation must be initiated on all victims of electrical injury since clinical findings are deceptive and unreliable. A victim of electrical current injury may appear dead due to dysrhythmia, respiratory arrest, or autonomic dysfunction resulting in pupils that are fixed, dilated, or asymmetric.

► Complications

Complications include dysrhythmias, altered mental status, seizures, paralysis, headache, pneumothorax, vascular injury, tissue edema and necrosis, compartment syndrome, associated traumatic injuries, rhabdomyolysis, acute kidney injury, hypovolemia from third spacing, infections, and acute or delayed cataract formation.

► Treatment

A. Emergency Measures

The patient must be assessed and treated as a trauma victim since associated traumatic injuries are common. The victim must be safely separated from the electrical current prior to initiation of CPR or other treatment. The rescuer must be protected. Separate the victim using nonconductive implements, such as dry clothing. Resuscitation must then be initiated since clinical findings of death are unreliable.

B. Hospital Measures

The initial assessment involves airway, breathing, and circulation followed by a full trauma protocol. Fluid resuscitation is important to maintain adequate urinary output. Initial evaluation includes cardiac monitoring and ECG, complete blood count, electrolytes, renal function tests, liver biochemical tests, urinalysis, urine myoglobin, serum creatine kinase, and cardiac enzymes. ECG does not show typical patterns of ischemia since the electrical damage is epicardial. Victims must be evaluated for hidden injury.

Electrical burn injury remains the most underrecognized and devastating burn injury, sometimes leading to amputations (often because of unrecognized compartment syndromes) and acute kidney injury, resulting in part from rhabdomyolysis (see Chapter 22).

Superficial skin may appear deceptively benign, leading to a delayed or completely overlooked diagnosis of deep tissue injury. When electrical injury occurs, extensive deep tissue necrosis should be suspected. Deep tissue necrosis leads to profound tissue swelling and this in turn results in the high risk of a compartment syndrome. Early debridement of devitalized tissues and tetanus prophylaxis may reduce the risks of infection. In pregnant patients exposed to electrical injury, the fetus may sustain intrauterine growth retardation, fetal distress, and fetal demise. Fetal monitoring is recommended.

Pain management is important before, during, and after initial treatment and rehabilitation. Multimodal approach to pain is the most effective. Interventions include medications (opioids, acetaminophen, nonsteroidal anti-inflammatory drugs), heat therapy, massage, and cognitive-behavioral therapy.

► Prognosis

Prognosis depends on the degree and location of electrical injury, initial tissue damage, associated injuries, comorbidities, and complications. Psychiatric support may be necessary following lightning or severe electroshock exposures.

► When to Refer

Surgical specialists may be needed to perform fasciotomy for compartment syndrome or devitalized tissue debridement or microvascular reconstruction.

► When to Admit

Indications for hospitalization include high voltage exposure; dysrhythmia or ECG changes; large burn; neurologic, pulmonary, or cardiac symptoms; suspicion of significant deep tissue or organ damage; transthoracic current pathway; history of cardiac disease or other significant comorbidities or injuries; and need for surgery.

- Li AL et al. Effectiveness of pain management following electrical injury. *J Burn Care Res.* 2010 Jan–Feb;31(1):73–82. [PMID: 20061840]
- Primavesi R. A shocking episode: care of electrical injuries. *Can Fam Physician.* 2009 Jul;55(7):707–9. [PMID: 19602655]
- Schneider JC et al. Neurologic and musculoskeletal complications of burn injuries. *Phys Med Rehabil Clin N Am.* 2011 May;22(2):261–75. [PMID: 21624720]
- Vierhapper MF et al. Electrical injury: a long-term analysis with review of regional differences. *Ann Plast Surg.* 2011 Jan; 66(1):43–6. [PMID: 21102303]

▼ RADIATION EXPOSURE

ESSENTIALS OF DIAGNOSIS

- Damage from radiation is determined by the source, type, quantity, duration, bodily location, and susceptibility and accumulation of exposures of the person.
- Radiation exposure from medical diagnostic imaging has dramatically risen over the past few decades; medical imaging radiation dosing needs to be standardized and regulated in order to minimize necessary radiation exposure.
- Clinicians and patients should be educated regarding the risks of medical diagnostic radiation. These radiation risks must be weighed against the benefits of the medical imaging needed.
- All patients should keep records of their medical imaging radiation exposures, and copies of the medical images and interpretations.

Exposure to radiation may occur from environmental, occupational, medical care, accidental, or intentional (ie, terrorism) exposure. With advancements in nuclear technology in the fields of medicine, energy, and industry, there is a growing risk of radiation exposure to patients, occupational workers, and the public. The extent of damage due to radiation exposure depends on the type, quantity, and duration of radiation exposure; the organs exposed; the degree of disruption to DNA; metabolic and cellular function; and the age, underlying condition, susceptibility, and accumulative exposures of the victim.

Professionals who work with radiation or its victims must have a basic understanding of radiation physics in order to identify risk, manage exposure, and minimize preventable spread of exposure. Radiation is energy waves or particles that travel through space. These energetic waves or particles radiate (move outward in all directions) from the source. Radiation occurs from both nonionizing and ionizing radiation sources. **Nonionizing radiation** is low energy, resulting in injuries related to local thermal damage (ie, microwave, ultraviolet, visible light and radio-wave). **Ionizing radiation** is high energy, causing bodily damage in several ways (ie, cellular disruption, DNA damage, and mutations). Ionizing radiation is either electromagnetic (ie, x-rays and gamma rays) or particulate (ie, alpha or beta particles, neutrons, and protons). Exposure may be external, internal, or both.

In **acute radiation exposure**, medical care includes close monitoring of the gastrointestinal, cutaneous, hematologic, and cerebrovascular symptoms and signs from initial exposure and over time.

Radiation exposure results in early and delayed effects. Early effects involve damage of the rapidly dividing cells (ie, the mucosa, skin, and bone marrow). This may be manifested as nausea, vomiting, and decreased lymphocyte count over hours to days after exposure. Delayed effects include malignancy, reproduction abnormalities, liver, kidney, and central nervous system and immune system dysfunction.

ACUTE & DELAYED EFFECTS OF RADIATION EXPOSURE ON NORMAL TISSUES

► Clinical Findings

A. Injury to Superficial Structures

Acute radiation exposure to the skin and mucous membranes may cause erythema, epilation, destruction of fingernails, or epidermolysis, and burns that appear similar to thermal burns but usually have a slower onset and course. Chronic damage includes skin scarring, atrophy, telangiectasis, and xerostomia. Radiation effects on the eyes include cataracts, dry eye syndrome, and retinopathy.

B. Injury to Deep Structures

Hematopoietic system radiation exposure causes injury to the bone marrow that may vary from transient decreases to complete destruction of blood elements. Lymphocytes are most sensitive, followed by polymorphonuclear leukocytes; erythrocytes are the least sensitive. Hematopoietic effects consisting of anemia, thrombocytopenia, and bone marrow suppression can occur 1–3 weeks after radiation

exposures. Bone marrow failure is the main cause of death within the first few months following exposure.

Nervous system structures are sensitive to radiation. The brain and spinal cord are much more sensitive than the peripheral nerves to the acute and delayed effects of radiation.

Cardiovascular system effects of ionizing radiation result in damage to the heart and coronary arteries. Smaller vessels (the capillaries and arterioles) are more susceptible to damage than larger blood vessels. Delayed effects from radiation include obliterative endarteritis; coronary artery disease; pericarditis with effusion; or constrictive pericarditis, which may occur months or years later. Myocarditis is less common.

Pulmonary system radiation with high or repeated moderate doses of radiation may cause pneumonitis or pulmonary fibrosis, which is often delayed for weeks or months.

Gastrointestinal system radiation results in mucositis and mucosal edema within hours or days after exposure. Symptoms include odynophagia, anorexia, nausea, vomiting, dehydration, and weakness. High doses of radiation inhibit gastric secretion and cause inflammation and ulceration of the bowels. Delayed effects include hepatitis, liver dysfunction, and intestinal stenosis. The stomach and colon are the gastrointestinal organs most at risk for cancer induction due to internal radiation.

Urogenital system radiation effects are dose-dependent, varying from transient decrease in fertility to permanent sterility, chromosomal aberrations, fetal damage, or demise. Moderate to heavy irradiation of the embryo results in injury to the fetus or in embryonic death and spontaneous abortion. Microcephaly and other congenital abnormalities may occur in children exposed in utero, especially if the fetus was exposed during early pregnancy. Nephritis and kidney dysfunction may occur as immediate or delayed effects.

Endocrine system organs are relatively resistant to low or moderate doses of radiation. The thyroid gland is the endocrine gland at highest risk for cancer induction from internal radiation exposure. Delayed effects of radiation include thyroid dysfunction (hypothyroidism).

C. Systemic Reaction (Acute Radiation Syndrome)

Clinicians must be educated to recognize and treat acute radiation sickness also referred to as **acute radiation syndrome**. Acute radiation syndrome is due to an exposure to high doses of ionizing radiation over a brief time course. The symptom onset is within hours to days depending on the dose. Symptoms include anorexia, nausea, vomiting, weakness, exhaustion, lassitude and, in some cases, prostration; these symptoms may occur singly or in combination. Dehydration, anemia, and infection may follow. The Centers for Disease Control and Prevention offers web-based information for clinicians regarding acute radiation syndrome (<http://emergency.cdc.gov/radiation/arsphysicianfactsheet.asp>).

► Therapeutic Radiation Exposure

Radiation therapy has been a successful component to treating many malignancies. This growing population of

cancer survivors treated with radiation therapy is an important resource to review and quantify associations between radiation therapy and risk of long-term adverse health and quality of life outcomes. These radiation-treated cancer survivors have a higher risk of development of a second malignancy; obesity; and pulmonary, cardiac and thyroid dysfunction as well as an increased overall risk for chronic health conditions and mortality. Ongoing study of childhood cancer survivors is needed to establish long-term risks and to evaluate the impact of newer techniques such as conformal radiation therapy or proton-beam therapy.

▶ Medical Imaging Radiation Exposure

Medical imaging with ionizing radiation exposure (eg, computed tomography [CT] and nuclear medicine studies) has dramatically increased over the past two decades. In addition, researchers have found that the radiation dose for the same study varies significantly among different machines and different clinicians, within and across institutions, with radiation doses varying by as much as a factor of 10. This finding highlights the urgent safety need for standardization and regulation of radiation dosing for medical diagnostics.

Clinicians and patients must be aware of the dangers of radiation when deciding on an imaging test. The risks and benefits must be carefully weighed. All patients should keep records of their cumulative medical imaging radiation exposures, as well as copies of the medical images and their interpretations. The American College of Radiology website offers additional safety information (<http://www.radiologyinfo.org/en/safety/>).

▶ Occupational and Environmental Radiation Exposure

Prevention of occupational radiation exposure involves adequate training of all persons handling radiation as well as creating safety policies and procedures. This will reduce occupational risk of radiation exposure and improve the emergency response to accidental exposure. Prehospital and hospital disaster plans are required for optimal management of radiation exposure. The Radiation Assistance Center (1-865-576-1005) provides 24-hour access to expert information. The Centers for Disease Control and Prevention "Radiation Emergency" website (<http://emergency.cdc.gov/radiation>) is a useful resource for professionals.

▶ Treatment

Treatment is focused on decontamination, symptomatic relief, supportive care, and psychosocial support. Specific treatments focus on the dose, route, and effects of exposure.

▶ Prognosis

Prognosis is determined by the radiation dose, duration, and frequency as well as by the underlying condition of the victim. Approximate dose of exposure correlates with the early onset and severity of symptoms (ie, nausea, vomiting, anorexia, abdominal pain, bloody diarrhea, weight loss)

and laboratory findings, particularly the decline in lymphocyte count on the complete blood count. Death is usually due to hematopoietic failure (ie, hemorrhage, anemia, and immunosuppression), gastrointestinal mucosal damage, central nervous system damage, widespread vascular injury, or secondary infection.

Carcinogenesis is related to the total dose, duration, accumulation of exposure, and to the susceptibility of the victim. The younger the victim's age at the time of exposure, the greater the risk of acute and long-term damage from radiation. Radiation-related cancer risks persist throughout the exposed person's lifespan. Cancer risk is particularly increased for persons exposed to nuclear radiation (eg, those exposed at Chernobyl, Hiroshima, Nagasaki, and Marshall Island nuclear test detonations). X-rays are classified as carcinogens since exposure causes leukemia and cancers of the thyroid, breast, and lung.

With the increased use of ionizing radiation for medical diagnostics and treatments, there is a growing concern for the iatrogenic increase in radiation-induced cancer risks, especially in children. There are age-related sensitivities to radiation; prenatal and younger age victims are more susceptible to carcinogenesis.

▶ When to Admit

Most patients with significant ionizing radiation exposure require admission for close monitoring and supportive treatment.

Armstrong GT et al. Long-term effects of radiation exposure among adult survivors of childhood cancer: results from the childhood cancer survivor study. *Radiat Res.* 2010 Dec; 174(6):840–50. [PMID: 21128808]

Christodouleas JP et al. Short-term and long-term health risks of nuclear-power-plant accidents. *N Engl J Med.* 2011 Jun 16; 364(24):2334–41. [PMID: 21506737]

Donnelly EH et al. Acute radiation syndrome: assessment and management. *South Med J.* 2010 Jun;103(6):541–6. [PMID: 20710137]

Little MP. Cancer and non-cancer effects in Japanese atomic bomb survivors. *J Radiol Prot.* 2009 Jun;29(2A):A43–59. [PMID: 19454804]

Nguyen PK et al. Radiation exposure from imaging tests: is there an increased cancer risk? *Expert Rev Cardiovasc Ther.* 2011 Feb;9(2):177–83. [PMID: 21453214]

Smith-Bindman R. Is computed tomography safe? *N Engl J Med.* 2010 Jul 1;363(1):1–4. [PMID: 20573919]

NEAR DROWNING

ESSENTIALS OF DIAGNOSIS

- ▶ The first requirement of rescue is immediate basic life support and CPR.
- ▶ Patient must also be assessed for hypothermia, hypoglycemia, concurrent injuries, and medical conditions.
- ▶ Clinical manifestations are hypoxemia, pulmonary edema, and hypoventilation.

► General Considerations

Near drowning describes a submersion event leading to injury. Submersion injury may result in aspiration, laryngospasm, hypoxemia, and acidemia. **Drowning** describes submersion resulting in death. “Wet” drowning is due to aspiration of fluid or foreign material. “Dry” drowning is due to laryngospasm or airway obstruction. The primary effect is hypoxemia due to perfusion of poorly ventilated alveoli, intrapulmonary shunting, and decreased compliance. A patient may be deceptively asymptomatic during the initial recovery period only to deteriorate or die as a result of acute respiratory failure within the following 12–24 hours.

Preventative measures should be taken to reduce morbidity and mortality from drowning. Conditions that increase risk of submersion injury include the following: (1) use of alcohol or other drugs, (2) extreme fatigue from inadequate water safety skills, (3) poor physical health, (4) hyperventilation, (5) sudden acute illness (eg, hypoglycemia, seizure, dysrhythmia, myocardial infarction, asthma flare), (6) acute trauma (particularly brain or spinal cord injury, or both), (7) venomous stings or bites, (8) decompression sickness, (9) dangerous water conditions (temperature and turbulence), and (10) carbon monoxide exposure from boat motors.

► Clinical Findings

A. Symptoms and Signs

The patient’s appearance may vary from asymptomatic, to abnormal vital signs, anxiety, dyspnea, cough, wheezing, trismus, cyanosis, chest pain, dysrhythmia, hypotension, vomiting, diarrhea, headache, altered level of consciousness, neurologic deficit, and apnea. Hypothermia is highly likely with cold water or prolonged submersion.

B. Laboratory Findings

Arterial blood gas results are helpful in determining the degree of injury since initial clinical findings may appear benign. PaO_2 is usually decreased; PaCO_2 may be increased or decreased; pH is decreased. Bedside blood sugar must be checked rapidly. Other testing is based on clinical scenario and may include kidney function, electrolytes, urinalysis, blood count, lactate, cardiac markers, coagulation studies, and alcohol and toxicology levels. Metabolic acidosis is common.

► Prevention

Prevention is multi-faceted. Physical barriers (ie, fences) should be placed around pools and other accessible bodies of water. Safety flotation devices and rescue supplies must be immediately available. Use of alcohol or sedative drugs must be avoided during swimming, boating, or other water-based activities. There must be close supervision of those who cannot swim, and personal flotation devices must be worn when boating or water skiing. Swimming lessons, water and boat safety, and basic life support (BLS) education is necessary for anyone involved in water-based activities.

► Treatment

A. First Aid

The first requirement of rescue is immediate BLS treatment and CPR. At the scene, immediate measures to combat hypoxemia are critical to improve outcome. BLS care includes sustained ventilation, oxygenation, and circulatory support. Hypothermia and associated trauma, especially brain and cervical spine injury, should always be suspected.

1. Standard BLS is initiated. CPR is provided if pulse and respirations are absent.
2. Patient must be assessed for hypothermia, hypoglycemia, trauma, and concurrent medical conditions.
3. Rescuer should not attempt to drain water from the victim’s lungs. The Heimlich maneuver (subdiaphragmatic pressure) should be used only if foreign material airway obstruction is suspected.
4. Resuscitation and BLS efforts must be continued until core temperature reaches 32°C even for seemingly “hopeless” patients. Complete recovery has been reported after prolonged resuscitation of hypothermic patients.

B. Subsequent Management

1. Ensure optimal ventilation and oxygenation—The onset of hypoxemia exists even in the alert, conscious patient who appears to be breathing normally. Oxygen should be administered immediately at the highest available concentration. Oxygen saturation should be maintained at 90% or higher. Endotracheal intubation and mechanical ventilation are necessary for patients unable to maintain an open airway, adequate oxygenation, or ventilation. Continuous positive airway pressure (CPAP) is an effective noninvasive way of reversing hypoxia and hypercarbia in patients with spontaneous respirations and a patent airway. Positive end-expiratory pressure (PEEP) is also effective for treating respiratory insufficiency. Serial physical examinations and chest radiographs should be carried out to detect possible pneumonitis, atelectasis, and pulmonary edema. Bronchodilators may be used to treat wheezing and bronchospasms due to aspiration. Nasogastric suctioning can decompress the stomach, aid in removal of swallowed water, and reduce the risk of aspiration. Antibiotics are reserved for clinical evidence of infection and should not be given prophylactically.

2. Cardiovascular support—Intravascular volume status must be monitored to determine whether vascular fluid replacement and vasopressors or diuretics are needed. Standard therapy for hypotension and pulmonary edema is administered.

3. Correction of blood pH and electrolyte abnormalities—Metabolic acidosis is present in 70% of near-drowning victims, but it is usually corrected through adequate ventilation and oxygenation. Glycemic control improves outcome.

4. Cerebral and spinal cord injury—Central nervous system damage may progress despite apparently adequate treatment of hypoxia and shock. Standard treatment for brain and spinal cord injury must be followed.

5. Hypothermia—Core temperature should be measured and managed as appropriate (see Systemic Hypothermia, above).

► Course & Prognosis

Respiratory damage is often severe in the minutes to hours following a near drowning. With respiratory supportive treatment, improvements typically occur quickly over the first few days following the near drowning. Long-term complications of near drowning may include neurologic impairment, seizure disorder, and pulmonary or cardiac damage. There is a direct correlation between prognosis and the patient's age, submersion time, rapid prehospital resuscitation and rapid transport to a medical facility, clinical status at time of arrival to hospital, Glasgow Coma Scale score, pupillary reactivity, and overall health assessment (APACHE II score).

► When to Admit

Most patients with significant near drowning or concurrent medical or traumatic conditions require inpatient monitoring for 24 hours following near drowning. This includes continuous monitoring of cardiorespiratory, neurologic, renal and metabolic function. Pulmonary edema may not appear for 24 hours.

- Ballesteros MA et al. Prognostic factors and outcome after drowning in an adult population. *Acta Anaesthesiol Scand*. 2009 Aug;53(7):935–40. [PMID: 19496759]
- Gregorakos L et al. Near-drowning: clinical course of lung injury in adults. *Lung*. 2009 Mar–Apr;187(2):93–7. [PMID: 19132444]
- Nasrullah M et al. Drowning mortality in the United States, 1999–2006. *J Community Health*. 2011 Feb;36(1):69–75. [PMID: 20532599]
- Schilling UM et al. Drowning. *Minerva Anesthesiol*. 2011 May 30. 2012 Jan; 78(1): 69-77. [PMID: 21623341]
- Youn CS et al. Out-of-hospital cardiac arrest due to drowning: an Utstein Style report of 10 years of experience from St. Mary's Hospital. *Resuscitation*. 2009 Jul;80(7):778–83. [PMID: 19443097]

ENVIRONMENTAL DISORDERS RELATED TO ALTITUDE

DYSBARISM & DECOMPRESSION SICKNESS

ESSENTIALS OF DIAGNOSIS

- Symptoms temporally related to recent altitude or pressure changes (ie, scuba diving).
- Early recognition and prompt treatment of decompression sickness are extremely important.
- Patient must also be assessed for hypothermia, hypoglycemia, concurrent injuries, and medical conditions.
- Consultation with diving medicine or hyperbaric oxygen specialist is indicated.

► General Considerations

Dysbarism and decompression sickness are physiologic problems that result from altitude changes and the environmental pressure effects on gases in the body during underwater descent and ascent, particularly when scuba diving is followed closely by air travel or hiking to high altitudes.

Physics laws describe the mechanisms involved in dysbarism and decompression sickness. As a diver descends, the gases in the body compress; gases dissolve in blood and tissues. During the ascent, gases in the body expand. **Dysbarism** results from gas compression or expansion in parts of the body that are noncompressible or have limited compliance. Lung barotrauma results in pneumomediastinum, pneumothorax, and rupture of the pulmonary vein causing arterial gas embolism. Overpressurization of the bowels may occur, especially if there is underlying pathology. This can result in gastric rupture, bowel obstruction or perforation, or pneumoperitoneum. Less serious conditions can also occur such as mask squeeze, ear squeeze, sinus squeeze, headache, tooth squeeze.

Decompression sickness occurs when the ascent is too rapid and gas bubbles form and cause damage depending on their location (eg, coronary, pulmonary, spinal or cerebral blood vessels, joints, soft tissue). Decompression sickness symptoms depends on the size and number and location of gas bubbles released (notably nitrogen). Risk of decompression sickness depends on the dive details (depth, duration, number of dives, and interval surface time between dives, water conditions) as well as the diver's age, weight, physical condition, physical exertion, the rate of ascent, and the length of time between the low altitude (scuba dive) and high altitude (air travel or ground ascent). Predisposing factors for decompression sickness include obesity, injury, hypoxia, lung or cardiac disease, right to left cardiac shunt, diver's overall health, dehydration, alcohol and medication effects, and panic attacks. Decompression sickness also occurs in those who take hot showers after cold dives. Conservative recommendation is to avoid high altitudes (air travel or ground ascent) for at least 24 hours after surfacing from the dive.

► Clinical Findings

The range of clinical manifestations varies depending on the location of the gas bubble formation or the compressibility of gases in the body. Symptom onset may be immediate, within minutes or hours (in the majority), or present up to 36 hours later. Decompression sickness symptoms include pain in the joints (“the bends”); skin pruritus or burning (skin bends); rashes; spinal cord or cerebral symptoms (“dissociation” symptoms that do not follow typical distribution patterns); labyrinthine decompression sickness (“the staggers,” central vertigo); pulmonary decompression sickness (“the chokes,” inspiratory pain, cough, and respiratory distress); arterial gas embolism (cerebral, pulmonary); barotrauma of the lungs, ear and sinus; dysbaric osteonecrosis; and coma.

The clinician must assess for associated conditions of hypothermia, hypoglycemia, near drowning, trauma, envenomations, or concurrent medical conditions.

► Treatment

Early recognition and prompt treatment are extremely important. Decompression sickness must be considered if symptoms are temporally related to recent diving or altitude or pressure changes within the past 48 hours. Immediate consultation with a diving medicine or hyperbaric oxygen specialist is indicated even if mild symptoms resolved, since relapses with worse outcomes have occurred. Continuous administration of 100% oxygen is indicated and beneficial for all patients. Aspirin may be given for pain. Opioids should be used very cautiously, since these may obscure the response to recompression.

► When to Admit

Rapid transportation to a hyperbaric treatment facility for recompression is imperative for decompression sickness. If air transportation is chosen, the aircraft must maintain pressurization near sea level to avoid worsening decompression sickness. The Divers Alert Network is an excellent worldwide resource for emergency advice 24 hours daily for the management of diving-related conditions (www.diversalertnetwork.org). For diving emergencies, call local emergency responder first, then the Divers Alert Network.

Vann RD et al. Decompression illness. *Lancet*. 2011 Jan 8; 377(9760):153–64. [PMID: 21215883]

Webb JT et al. Fifty years of decompression sickness research at Brooks AFB, TX: 1960–2010. *Aviat Space Environ Med*. 2011 May;82(5 Suppl):A1–25. [PMID: 21614886]

HIGH-ALTITUDE ILLNESS



ESSENTIALS OF DIAGNOSIS

- ▶ The severity of the high-altitude illness correlates with the rate and height of ascent, and the individual's susceptibility.
- ▶ Prompt recognition and medical attention of early symptoms of high-altitude illness should prevent progression.
- ▶ Immediate descent is the definitive treatment for high-altitude cerebral edema and high-altitude pulmonary edema.

► General Considerations

As altitude increases, hypobaric hypoxia results due to a decrease in both barometric pressure and oxygen partial pressure. High-altitude medical problems are due to hypobaric hypoxia at high altitudes (usually > 2000 meters or 6560 feet). Acclimatization occurs as a physiologic response to the rise in altitude and increasing hypobaric hypoxia. Physiologic changes include increases in alveolar ventilation and oxygen extraction by the tissues and increased hemoglobin level and oxygen binding.

High-altitude illness results when the hypoxic stress is greater than the individual's ability to acclimatize. Risk factors for high-altitude illness include increased physical activity with insufficient acclimatization, inadequate education and preparation, and individual susceptibility (pre-existing medical conditions and medication use), and previous high-altitude illness. The key determinants of high-altitude illness risk and severity include both individual susceptibility factors and altitudinal factors (rapid rate and height of ascent and total change in altitude). Presentations may be acute, subacute, or chronic disturbances that result from hypobaric hypoxia. Acclimatization to altitudes above 5500 m (18,045 ft) is incomplete or physiologically impossible, although individual differences in tolerance to hypoxia exist.

Individual susceptibility factors include underlying conditions such as cardiac and pulmonary dysfunction, patent foramen ovale, blood disorders (ie, sickle cell disease), pregnancy, neurologic condition, recent surgery, and many other chronic medical conditions. Those with symptomatic cardiac or pulmonary disease should avoid high altitudes.

High-altitude illness comprises a spectrum of conditions based on end-organ effects, mostly cerebral and pulmonary. This is a result of fluid shifts from intravascular to extravascular spaces, especially in the brain and lungs. Manifestations of altitude illness include acute and long-term disorders. Acute high-altitude disorders are high-altitude neurologic conditions (acute mountain sickness and high-altitude cerebral edema) and high-altitude pulmonary edema. Long-term exposure to high altitude over months or years with inadequate acclimatization can result in subacute mountain sickness and chronic mountain sickness (Monge disease). (While subacute mountain sickness and Monge disease are mentioned briefly below, a more detailed discussion can be found in the online version of *Current Medical Diagnosis & Treatment*.)

1. High-Altitude–Associated Neurologic Conditions (Acute Mountain Sickness & High-Altitude Cerebral Edema)

There is a spectrum of neurologic conditions caused by high altitude, ranging from acute mountain sickness to a more serious form, high altitude cerebral edema.

Acute mountain sickness includes both neurologic and pulmonary symptoms, such as headache (most severe and persistent symptom), lassitude, drowsiness, dizziness, chilliness, nausea and vomiting, facial pallor, dyspnea, and cyanosis. Later symptoms include facial flushing, irritability, difficulty concentrating, vertigo, tinnitus, visual and auditory disturbances, anorexia, insomnia, increased dyspnea and weakness on exertion, increased headaches (due to cerebral edema), palpitations, tachycardia, Cheyne-Stokes breathing, and weight loss. More severe manifestations include cerebral and pulmonary edema (high-altitude cerebral edema and high-altitude pulmonary edema; see below).

High-altitude cerebral edema appears to be an extension of the central nervous system symptoms of acute mountain sickness and results from cerebral vasogenic

edema and cerebral cellular hypoxia. It usually occurs at elevations above 2500 meters (8250 feet) and is more common in unacclimatized individuals. Hallmarks are altered consciousness and ataxic gait. Severe headaches, confusion, truncal ataxia, urinary retention or incontinence, focal deficits, papilledema, nausea, vomiting, and seizures may also occur. Symptoms may progress to obtundation and coma.

► Treatment

Initial treatment involves oxygen administration by mask. Voluntary periodic hyperventilation will often relieve acute symptoms. Definitive treatment is immediate descent. Descent should be at least 610 meters (2000 feet) and should continue until symptoms improve. Descent is essential if the symptoms are persistent, severe, or worsening or if high-altitude pulmonary edema or high-altitude cerebral edema are present. If immediate descent is not possible, portable hyperbaric chambers can provide symptomatic relief.

Acetazolamide (125–250 mg orally every 8–12 hours, conflicting data as to the optimal dose) remains the most effective medication for treatment of acute mountain sickness and for more severe forms of altitude-related conditions. Adverse reactions include peripheral paresthesias, altered taste of carbonated beverages, polyuria, nausea, drowsiness, erectile dysfunction, and myopia. This is a sulfonamide drug and should be used with caution or avoided in persons with past reactions to this class of drug.

Dexamethasone (dose varies depending on the activity level of the individual, ranging from 2 to 4 mg orally every 6 hours) is effective for treatment of acute mountain sickness and acute cerebral edema; this medication should not be used for prophylaxis and should not be continued beyond 7 days. These medications can be continued for as long as symptoms persist and may be used together in severe cases. In most individuals, symptoms clear within 24–48 hours.

2. Acute High-Altitude Pulmonary Edema

High-altitude pulmonary edema is a serious complication of hypoxia induced pulmonary hypertension. It is the leading cause of death from high altitude illness. The hallmark is markedly elevated pulmonary artery pressure followed by pulmonary edema. It usually occurs at levels above 3000 meters (9840 feet). High altitude increases pulmonary arterial pressure and decreases the oxygen uptake and saturation and alters oxygen kinetics. Early symptoms may appear within 6–36 hours after arrival at a high-altitude area. These include incessant dry cough, shortness of breath disproportionate to exertion, headache, decreased exercise performance, fatigue, dyspnea at rest, and chest tightness. Recognition of the early symptoms may enable the patient to descend before incapacitating pulmonary edema develops. Strenuous exertion should be avoided. An early descent of even 500 or 1000 meters may result in improvement of symptoms. Later, wheezing, orthopnea, and hemoptysis may occur as pulmonary edema worsens. Physical findings include tachycardia, mild fever, tachypnea, cyanosis, prolonged respiration, and rales and rhonchi.

The clinical picture may resemble severe pneumonia. The patient may become confused or comatose. Diagnosis is usually clinical; ancillary tests are nonspecific or unavailable on site. Prompt recognition and medical attention of early symptoms prevent progression.

► Treatment

Treatment must often be initiated under field conditions. The patient must rest in the semi-Fowler position (head raised), and 100% oxygen must be administered. *Immediate descent (at least 610 meters [2000 feet]) is essential.* Recompression in a portable hyperbaric bag will temporarily reduce symptoms if rapid or immediate descent is not possible. To conserve oxygen, lower flow rates (2–4 L/min) may be used until the victim recovers or is evacuated to a lower altitude and $\text{SaO}_2 \geq 90\%$. Treatment for ARDS (see Chapter 9) may be required for some patients. Calcium channel blockers and selective phosphodiesterase type 5 (PDE5) inhibitors are effective for symptomatic relief: nifedipine (30 mg slow-release tablets every 12 hours), tadalafil (10 mg by mouth every 12 hours), and sildenafil (50 mg by mouth every 8 hours) are alternatives.

3. Subacute Mountain Sickness

This occurs most frequently in unacclimatized individuals and at high altitudes for a prolonged period of time. The hypobaric hypoxia results in pulmonary hypertension.

4. Chronic Mountain Sickness (Monge Disease)

This uncommon condition is seen in residents of high-altitude communities who have lost their acclimatization to such a hypobaric hypoxic environment. It is difficult to differentiate from chronic pulmonary disease.

► Prevention of High-Altitude Disorders

Pre-trip preventive measures include participant education, medical prescreening, pre-trip planning, optimal physical conditioning before travel, and adequate rest and sleep the day before travel. Preventive efforts during ascent include reduced food intake; avoidance of alcohol, tobacco, and unnecessary physical activity during travel; slow ascent to allow acclimatization (300 meters per day); and a period of rest and inactivity for 1–2 days after arrival at high altitudes. Mountaineering parties at altitudes of ≥ 3000 meters or higher should carry a supply of oxygen and medical equipment sufficient for several days. Prophylactic medications may be prescribed if no contraindications exist. Prophylactic low-dose acetazolamide (250–500 mg every 12 hours orally or 500 mg extended-release once to twice daily orally) has been shown to reduce the incidence and severity of acute mountain sickness when started 3 days prior to ascent and continued for 48–72 hours at high altitude. Dexamethasone (4 mg every 12 hours orally beginning on the day of ascent, continuing for 3 days at the higher altitude, and then tapering over 5 days) is an alternative prophylactic medication.

▶ When to Admit

- All patients with high-altitude pulmonary edema or high-altitude cerebral edema must be hospitalized for further observation.
- Hospitalization must also be considered for any patient who remains symptomatic after treatment and descent. Pulmonary symptoms and hypoxia may be worsened by pulmonary embolism, bacterial pneumonia, or bronchitis.

Butler GJ et al. Altitude mountain sickness among tourist populations: a review and pathophysiology supporting management with hyperbaric oxygen. *J Med Eng Technol.* 2011 Apr–May;35(3–4):197–207. [PMID: 20836748]

Imray C et al. Acute mountain sickness: pathophysiology, prevention, and treatment. *Prog Cardiovasc Dis.* 2010 May–Jun;52(6):467–84. [PMID: 20417340]

Maggiolini M. Prevention and treatment of high-altitude pulmonary edema. *Prog Cardiovasc Dis.* 2010 May–Jun;52(6):500–6. [PMID: 20417343]

Murdoch D. Altitude sickness. *Clin Evid (Online).* 2010 Mar 18;2010. pii:1209. [PMID: 21718562]

Palmer BF. Physiology and pathophysiology with ascent to altitude. *Am J Med Sci.* 2010 Jul;340(1):69–77. [PMID: 20442648]

Vann RD et al. Decompression illness. *Lancet.* 2011 Jan 8; 377(9760):153–64. [PMID: 21215883]

SAFETY OF AIR TRAVEL & SELECTION OF PATIENTS FOR AIR TRAVEL

The medical safety of air travel depends on the nature and severity of the traveler's preflight condition and factors such as travel duration, frequency and use of in-flight exercise, cabin pressurization, availability of medical supplies, and presence of health care professionals on board. In-flight medical emergencies are increasing because there are an increasing number of travelers with preexisting medical conditions. Air travel passengers are susceptible to a wide range of flight-related problems: pulmonary (eg, hypoxia, gas expansion), vascular (venous thromboembolism, VTE), infectious, cardiovascular, gastrointestinal, ocular, immunologic, syncope, neuropsychiatric, metabolic, trauma, and substance-related. These air-travel risks are higher for those air travelers with preexisting medical conditions: cardiovascular disease, thromboembolic disease, asthma, chronic obstructive pulmonary disease, epilepsy, stroke, recent surgery or trauma, diabetes mellitus, infectious disease, mental illness, and substance dependence. Occupational and frequent flyers are at risk for these as well as accumulative radiation exposure, cabin air quality, circadian disturbance, and pressurization problems.

Hypobaric hypoxia is the underlying etiology of most serious medical emergencies in flight. Despite commercial aircraft pressurization requirements, there is significant hypoxemia, dyspnea, gas expansion, and stress in travelers with underlying serious cardiopulmonary and other conditions. Patients with underlying respiratory or cardiac conditions are at highest risk for problems stemming from hypobaric hypoxia.

Research also demonstrates an association between VTE and air travel. Air travel has a threefold higher risk of VTE, especially severe pulmonary embolism. The VTE risk increases proportionally with the flight duration. Higher risk of VTE is seen in travelers with thrombophilia, those receiving hormonal therapy, and pregnant travelers.

Air travel is not advised for anyone who is incapacitated, or who has an active pneumothorax, class III and IV pulmonary hypertension, acute worsening of an underlying lung disease, or any unstable conditions. The Air Transport Association of America defines an **incapacitated passenger** as “one who is suffering from a physical or mental disability and who, because of such disability or the effect of the flight on the disability, is incapable of self-care; would endanger the health or safety of such person or other passengers or airline employees; or would cause discomfort or annoyance of other passengers.” **Unstable conditions** include poorly controlled hypertension, dysrhythmias, angina, valvular disease, congestive heart failure, or psychiatric condition; severe anemia or sickle cell disease; recent myocardial infarction, cerebrovascular accident, or deep venous thrombosis; postsurgery, especially heart surgery (unless approved by surgeon); and any active communicable disease (influenza, tuberculosis, measles, chickenpox, or other communicable virulent infections). Risk of transmission increases when there is close contact to infected passengers.

Pregnancy and Infancy

Pregnancy is a hypercoagulable state with fivefold to tenfold increase in VTE risk. Air travel increases this risk of VTE. Pregnant women may be permitted to fly during the first 8 months of pregnancy unless there is a history of pregnancy complications or premature birth. Infants younger than 1 week old should not be flown at high altitudes or for long distances. There is a higher risk of transmission of infection in-flight for pregnant women and infants due to their weaker immune response. Estimates of air travel radiation exposure are available through the Federal Aviation Administration and vary based on frequency and duration of flights.

▶ Prevention

Air travel complications may be reduced by the following preventive measures: passenger education, passenger prescreening, and in-flight positioning and activity. Prescreening is especially important for those who have had recent surgery or an emergency condition, and those with chronic serious medical conditions. Travelers with pulmonary disease must have preflight medical assessment to determine whether supplemental oxygen is required. Travelers can reduce VTE risk by avoiding constrictive clothing, wearing support hose, changing position frequently, avoiding leg crossing, engaging in frequent in-flight leg exercises, and walking. Low-molecular-weight heparin may be prescribed in travelers at high risk for VTE.

ACOG Committee on Obstetric Practice. ACOG Committee Opinion No. 443: Air travel during pregnancy. *Obstet Gynecol.* 2009 Oct;114(4):954–5. [PMID: 19888065]

Akerø A et al. COPD and air travel: oxygen equipment and pre-flight titration of supplemental oxygen. *Chest.* 2011 Jul; 140(1):84–90. [PMID: 21071527]

Bartholomew JR et al. Air travel and venous thromboembolism: minimizing the risk. *Cleve Clin J Med.* 2011 Feb;78(2):111–20. [PMID: 21285343]

Brenner B. Prophylaxis of travel-related thrombosis in women. *Thromb Res.* 2009;123(Suppl 3):S26–9. [PMID: 19203643]

Chandra D et al. Meta-analysis: travel and risk for venous thromboembolism. *Ann Intern Med.* 2009 Aug 4;151(3): 180–90. [PMID: 19581633]

Shrikrishna D et al; Air Travel Working Party of the British Thoracic Society Standards of Care Committee. Managing passengers with stable respiratory disease planning air travel: British Thoracic Society recommendations. *Thorax.* 2011 Sep; 66(9):831–3. [PMID: 21807654]

Silverman D et al. Medical issues associated with commercial flights. *Lancet.* 2009 Jun 13;373(9680):2067–77. [PMID: 19232708]

38

Poisoning

Kent R. Olson, MD

INITIAL EVALUATION: POISONING OR OVERDOSE

Patients with drug overdoses or poisoning may initially have no symptoms or they may have varying degrees of overt intoxication. The asymptomatic patient may have been exposed to or may have ingested a lethal dose but not yet exhibit any manifestations of toxicity. It is important to: (1) quickly assess the potential danger, (2) consider gut decontamination to prevent absorption, (3) treat complications if they occur, and (4) observe the asymptomatic patient for an appropriate interval.

▶ Assess the Danger

If the drug or poison is known, its danger can be assessed by consulting a text or computerized information resource or by calling a regional poison control center. (In the United States, dialing 1-800-222-1222 will direct the call to the regional poison control center.) Assessment will usually take into account the dose ingested; the time since ingestion; the presence of any symptoms or clinical signs; pre-existing cardiac, respiratory, kidney, or liver disease; and, occasionally, specific serum drug or toxin levels. Be aware that the history given by the patient or family may be incomplete or unreliable.

IMMEDIATE 24-HOUR TOXICOLOGY CONSULTATION

Call your regional poison control center
U.S. toll-free 1-800-222-1222

▶ Observation of the Patient

Asymptomatic or mildly symptomatic patients should be observed for at least 4–6 hours. Longer observation is indicated if the ingested substance is a sustained-release preparation or is known to slow gastrointestinal motility or may cause a delayed onset of symptoms (such as acetaminophen, colchicine, or hepatotoxic mushrooms). After that time, the patient may be discharged if no symptoms

have developed. Before discharge, psychiatric evaluation should be performed to assess suicide risk. Intentional ingestions in adolescents should raise the possibility of unwanted pregnancy or sexual abuse.

THE SYMPTOMATIC PATIENT

In symptomatic patients, treatment of life-threatening complications takes precedence over in-depth diagnostic evaluation. Patients with mild symptoms may deteriorate rapidly, which is why all potentially significant exposures should be observed in an acute care facility. The following complications may occur, depending on the type of poisoning.

COMA

▶ Assessment & Complications

Coma is commonly associated with ingestion of large doses of antihistamines (eg, diphenhydramine), benzodiazepines and other sedative-hypnotic drugs, ethanol, opioids, antipsychotic drugs, or antidepressants. The most common cause of death in comatose patients is respiratory failure, which may occur abruptly. Pulmonary aspiration of gastric contents may also occur, especially in victims who are deeply obtunded or convulsing. Hypoxia and hypoventilation may cause or aggravate hypotension, arrhythmias, and seizures. Thus, protection of the airway and assisted ventilation are the most important treatment measures for any poisoned patient.

▶ Treatment

A. Emergency Management

The initial emergency management of coma can be remembered by the mnemonic *ABCD*, for *Airway*, *Breathing*, *Circulation*, and *Drugs* (dextrose, thiamine, and naloxone or flumazenil), respectively.

1. Airway—Establish a patent airway by positioning, suction, or insertion of an artificial nasal or oropharyngeal airway. If the patient is deeply comatose or if airway

reflexes are depressed, perform endotracheal intubation. These airway interventions may not be necessary if the patient is intoxicated by an opioid or a benzodiazepine and responds to intravenous naloxone or flumazenil (see below).

2. Breathing—Clinically assess the quality and depth of respiration, and provide assistance if necessary with a bag-valve-mask device or mechanical ventilator. Administer supplemental oxygen, if needed. The arterial blood CO₂ tension is useful in determining the adequacy of ventilation. The arterial blood PO₂ determination may reveal hypoxemia, which may be caused by respiratory arrest, bronchospasm, pulmonary aspiration, or noncardiogenic pulmonary edema. Pulse oximetry provides an assessment of oxygenation but is not reliable in patients with methemoglobinemia or carbon monoxide poisoning, unless a newer pulse oximetry device capable of detecting these forms of hemoglobin is used (eg, the Masimo pulse CO-oximeter).

3. Circulation—Measure the pulse and blood pressure and estimate tissue perfusion (eg, by measurement of urinary output, skin signs, arterial blood pH). Place the patient on continuous ECG monitoring. Insert an intravenous line, and draw blood for glucose, electrolytes, serum creatinine and liver tests, and possible quantitative toxicologic testing.

4. Drugs

A. DEXTROSE AND THIAMINE—Unless promptly treated, severe hypoglycemia can cause irreversible brain damage. Therefore, in all obtunded, comatose or convulsing patients, give 50% dextrose, 50–100 mL by intravenous bolus, unless a rapid bedside blood sugar test is available and rules out hypoglycemia. In alcoholic or very malnourished patients who may have marginal thiamine stores, give thiamine, 100 mg intramuscularly or in the intravenous fluids.

B. OPIOID ANTAGONISTS—Naloxone, 0.4–2 mg intravenously, may reverse opioid-induced respiratory depression and coma. It is often given empirically to any comatose patient with depressed respirations. If opioid overdose is strongly suspected, give additional doses of naloxone (up to 5–10 mg may be required to reverse the effects of potent opioids). **Note:** Naloxone has a shorter duration of action (2–3 hours) than most common opioids; repeated doses may be required, and continuous observation for at least 3–4 hours after the last dose is mandatory. Nalmefene, a newer opioid antagonist, has a duration of effect longer than that of naloxone but still shorter than that of the opioid methadone.

C. FLUMAZENIL—Flumazenil, 0.2–0.5 mg intravenously, repeated as needed up to a maximum of 3 mg, may reverse benzodiazepine-induced coma. **Caution:** Flumazenil should **not** be given if the patient has coingested a tricyclic antidepressant or other potential convulsant, is a user of high-dose benzodiazepines, or has a seizure disorder because its use in these circumstances may precipitate seizures. *In most circumstances, use of flumazenil is not advised as the potential risks outweigh its benefits.* **Note:** Flumazenil has a short duration of effect (2–3 hours), and resedation requiring additional doses may occur.

HYPOTHERMIA

▶ Assessment & Complications

Hypothermia commonly accompanies coma due to opioids, ethanol, hypoglycemic agents, phenothiazines, barbiturates, benzodiazepines, and other sedative-hypnotics and central nervous system depressants. Hypothermic patients may have a barely perceptible pulse and blood pressure. Hypothermia may cause or aggravate hypotension, which will not reverse until the temperature is normalized.

▶ Treatment

Treatment of hypothermia is discussed in Chapter 37. Gradual rewarming is preferred unless the patient is in cardiac arrest.

HYPOTENSION

▶ Assessment & Complications

Hypotension may be due to poisoning by many different drugs and poisons, including antihypertensive drugs, β -blockers, calcium channel blockers, disulfiram (ethanol interaction), iron, trazodone, quetiapine, and other antipsychotic agents and antidepressants. Poisons causing hypotension include cyanide, carbon monoxide, hydrogen sulfide, aluminum phosphide, arsenic, and certain mushrooms.

Hypotension in the poisoned or drug-overdosed patient may be caused by venous or arteriolar vasodilation, hypovolemia, depressed cardiac contractility, or a combination of these effects.

▶ Treatment

Most hypotensive patients respond to empiric treatment with repeated 200 mL intravenous boluses of 0.9% saline or other isotonic crystalloid up to a total of 1–2 L; much larger amounts may be needed if the victim is profoundly volume depleted (eg, as with *Amanita phalloides* mushroom poisoning). Monitoring the central venous pressure (CVP) can help determine whether further fluid therapy is needed. If fluid therapy is not successful, give dopamine or norepinephrine by intravenous infusion. Consider bedside cardiac ultrasound or pulmonary artery catheterization (or both) if hypotension persists.

Hypotension caused by certain toxins may respond to specific treatment. For hypotension caused by overdoses of tricyclic antidepressants or other sodium channel blockers, administer sodium bicarbonate, 50–100 mEq by intravenous bolus injection. Norepinephrine 4–8 mcg/min by intravenous infusion is more effective than dopamine in some patients with overdoses of tricyclic antidepressants or of drugs with predominantly vasodilating effects. For β -blocker overdose, glucagon (5–10 mg intravenously) may be of value. For calcium channel blocker overdose, administer calcium chloride, 1–2 g intravenously (repeated doses may be necessary; doses of 5–10 g and more have been given in some cases). High-dose insulin (0.5–1 units/kg/h intravenously) euglycemic therapy may also be used (see the sections on β -Adrenergic Blockers and Calcium Channel Blockers, below). Intralipid 20% lipid emulsion

has been reported to improve hemodynamics in human case reports or animal studies of intoxication by highly lipid-soluble drugs such as bupivacaine, bupropion, clomipramine, and verapamil.

Jamaty C et al. Lipid emulsions in the treatment of acute poisoning: a systematic review of human and animal studies. *Clin Toxicol (Phila)*. 2010 Jan;48(1):1–27. [PMID: 20095812]

HYPERTENSION

► Assessment & Complications

Hypertension may be due to poisoning with amphetamines, anticholinergics, cocaine, performance-enhancing products (containing caffeine, phenylephrine, ephedrine, or yohimbine), monoamine oxidase (MAO) inhibitors, and other drugs.

Severe hypertension (eg, diastolic blood pressure > 105–110 mm Hg in a person who does not have chronic hypertension) can result in acute intracranial hemorrhage, myocardial infarction, or aortic dissection.

► Treatment

Treat hypertension if the patient is symptomatic or if the diastolic pressure is > 105–110 mm Hg—especially if there is no prior history of hypertension.

Hypertensive patients who are agitated or anxious may benefit from a sedative such as lorazepam, 2–3 mg intravenously. For persistent hypertension, administer phenolamine, 2–5 mg intravenously, or nitroprusside sodium, 0.25–8 mcg/kg/min intravenously. If excessive tachycardia is present, add propranolol, 1–5 mg intravenously, or esmolol, 25–100 mcg/kg/min intravenously, or labetalol 0.2–0.3 mg/kg intravenously. **Caution:** Do not give β -blockers alone, since doing so may paradoxically worsen hypertension as a result of unopposed α -adrenergic stimulation.

Wang NE et al. Hypertensive crisis and NSTEMI after accidental overdose of sustained release pseudoephedrine: a case report. *Clin Toxicol (Phila)*. 2008 Nov;46(9):922–3. [PMID: 18608273]

ARRHYTHMIAS

► Assessment & Complications

Arrhythmias may occur with a variety of drugs or toxins (Table 38–1). They may also occur as a result of hypoxia, metabolic acidosis, or electrolyte imbalance (eg, hyperkalemia, hypokalemia, hypomagnesemia or hypocalcemia), or following exposure to chlorinated solvents or chloral hydrate overdose. Atypical ventricular tachycardia (torsades de pointes) is often associated with drugs that prolong the QT interval.

► Treatment

Arrhythmias may be caused by hypoxia or electrolyte imbalance, and these conditions should be sought and treated. If

Table 38–1. Common toxins or drugs causing arrhythmias.¹

Arrhythmia	Common Causes
Sinus bradycardia	β -Blockers, calcium channel blockers, clonidine, digitalis glycosides, organophosphates
Atrioventricular block	β -Blockers, calcium channel blockers, class Ia antiarrhythmics (including quinidine), carbamazepine, clonidine, digitalis glycosides, lithium
Sinus tachycardia	β -Agonists (eg, albuterol), amphetamines, anticholinergics, antihistamines, caffeine, cocaine, pseudoephedrine, tricyclic and other antidepressants
Wide QRS complex	Class Ia and class Ic antiarrhythmics, phenothiazines (eg, thioridazine), potassium (hyperkalemia), propranolol, tricyclic antidepressants, bupropion, lamotrigine, diphenhydramine (severe overdose)
QT interval prolongation and torsades de pointes	Arsenic, class Ia and class III antiarrhythmics, citalopram, droperidol, lithium, methadone, pentamidine, sertraline, sotalol, thioridazine, and many other drugs ²
Ventricular premature beats and ventricular tachycardia	Amphetamines, cocaine, ephedrine, caffeine, chlorinated or fluorinated hydrocarbons, digoxin, aconite (found in some Chinese herbal preparations), fluoride, theophylline. QT prolongation can lead to atypical ventricular tachycardia (torsades de pointes)

¹Arrhythmias may also occur as a result of hypoxia, metabolic acidosis, or electrolyte imbalance (eg, hyperkalemia or hypokalemia, hypocalcemia, hypomagnesemia).

²<http://www.azcert.org/medical-pros/drug-lists/drug-lists.cfm>

ventricular arrhythmias persist, administer lidocaine or amiodarone at usual antiarrhythmic doses. **Note:** Wide QRS complex tachycardia in the setting of tricyclic antidepressant overdose (or diphenhydramine or class Ia antiarrhythmic drugs) should be treated with sodium bicarbonate, 50–100 mEq intravenously by bolus injection. (See discussion of tricyclic antidepressant poisoning.) **Caution:** Avoid class Ia antiarrhythmic agents (eg, procainamide, disopyramide), which may aggravate arrhythmias caused by tricyclic antidepressants. Torsades de pointes associated with prolonged QT interval may respond to intravenous magnesium (2 g intravenously over 2 minutes) or overdrive pacing. Treat digitalis-induced arrhythmias with digoxin-specific antibodies (see discussion of cardiac glycoside poisoning).

For tachyarrhythmias induced by chlorinated solvents, chloral hydrate, Freons, or sympathomimetic agents, use propranolol or esmolol (see doses given above in Hypertension section).

Barnes BJ et al. Drug-induced arrhythmias. *Crit Care Med*. 2010 Jun;38(6 Suppl):S188–97. [PMID: 20502173]

SEIZURES

► Assessment & Complications

Seizures may be due to poisoning with many poisons and drugs, including amphetamines, antidepressants (especially tricyclic antidepressants, bupropion, and venlafaxine), antihistamines (especially diphenhydramine), antipsychotics, camphor, cocaine, isoniazid (INH), chlorinated insecticides, and theophylline. Massive overdose with acetaminophen has caused seizures. The onset of seizures may be delayed for up to 22 hours after sustained-released bupropion overdose.

Seizures may also be caused by hypoxia, hypoglycemia, hypocalcemia, hyponatremia, withdrawal from alcohol or sedative-hypnotics, head trauma, central nervous system infection, or idiopathic epilepsy.

Prolonged or repeated seizures may lead to hypoxia, metabolic acidosis, hyperthermia, and rhabdomyolysis.

► Treatment

Administer lorazepam, 2–3 mg, or diazepam, 5–10 mg, intravenously over 1–2 minutes, or—if intravenous access is not immediately available—midazolam, 5–10 mg intramuscularly. If convulsions continue, administer phenobarbital, 15–20 mg/kg slowly intravenously over no less than 30 minutes. (For drug-induced seizures, phenobarbital is preferred over phenytoin.) Propofol infusion has also been reported effective for some resistant drug-induced seizures.

Seizures due to a few drugs and toxins may require antidotes or other specific therapies (as listed in Table 38–2).

Table 38–2. Seizures related to toxins or drugs requiring special consideration.¹

Toxin or Drug	Comments
Methylenedioxymethamphetamine (MDMA; “Ecstasy”)	Seizures may also be due to hyponatremia or hyperthermia.
Isoniazid	Administer pyridoxine.
Lithium	May indicate need for hemodialysis.
Organophosphates	Administer pralidoxime (2-PAM) and atropine in addition to usual anticonvulsants.
Strychnine	“Seizures” are actually spinally mediated muscle spasms and usually require neuromuscular paralysis and mechanical ventilation.
Theophylline	Seizures indicate need for hemodialysis.
Tricyclic antidepressants	Hyperthermia and cardiotoxicity are common complications of repeated seizures; paralyze early with neuromuscular blockers to reduce muscular hyperactivity.

¹See text for dosages.

Heard K et al. Massive acetylcysteine overdose associated with cerebral edema and seizures. *Clin Toxicol (Phila)*. 2011 Jun; 49(5):423–5. [PMID: 21740141]
 Young AC et al. Late-onset seizures associated with quetiapine poisoning. *J Med Toxicol*. 2009 Mar;5(1):24–6. [PMID: 19191211]

HYPERTHERMIA

► Assessment & Complications

Hyperthermia may be associated with poisoning by amphetamines (especially methylenedioxymethamphetamine [MDMA; “Ecstasy”]), atropine and other anti-cholinergic drugs, cocaine, salicylates, strychnine, tricyclic antidepressants, and various other medications. Overdoses of serotonin reuptake inhibitors (eg, fluoxetine, paroxetine, sertraline) or their use in a patient taking an MAO inhibitor may cause agitation, hyperactivity, myoclonus, and hyperthermia (“serotonin syndrome”). Antipsychotic agents can cause rigidity and hyperthermia (neuroleptic malignant syndrome [NMS]). (See section on schizophrenia and other psychotic disorders in Chapter 25.) Malignant hyperthermia is a rare disorder associated with general anesthetic agents.

Hyperthermia is a rapidly life-threatening complication. Severe hyperthermia (temperature > 40–41°C) can rapidly cause brain damage and multiorgan failure, including rhabdomyolysis, acute renal failure, and coagulopathy (see Chapter 37).

► Treatment

Treat hyperthermia aggressively by removing the patient’s clothing, spraying the skin with tepid water, and fanning. If this is not rapidly effective, as shown by a normal rectal temperature within 30–60 minutes, or if there is significant muscle rigidity or hyperactivity, induce neuromuscular paralysis with a nondepolarizing neuromuscular blocker (eg, rocuronium, vecuronium). Once paralyzed, the patient must be intubated and mechanically ventilated and sedated. While the patient is paralyzed, the absence of visible muscular convulsive movements may give the false impression that brain seizure activity has ceased; bedside electroencephalography may be useful in recognizing continued nonconvulsive seizures.

Dantrolene (2–5 mg/kg intravenously) may be effective for hyperthermia associated with muscle rigidity that does not respond to neuromuscular blockade (ie, malignant hyperthermia). Bromocriptine, 2.5–7.5 mg orally daily, has been recommended for neuroleptic malignant syndrome. Cyproheptadine, 4 mg orally every hour for three or four doses, or chlorpromazine, 25 mg intravenously or 50 mg intramuscularly, has been used to treat serotonin syndrome.

Ables AZ et al. Prevention, recognition, and management of serotonin syndrome. *Am Fam Physician*. 2010 May 1;81(9): 1139–42. [PMID: 20433130]
 Gallelli L et al. A case of neuroleptic malignant syndrome induced by risperidone in a schizophrenic woman. *Curr Drug Saf*. 2009 May;4(2):119–20. [PMID: 19442104]

ANTIDOTES & OTHER TREATMENT

ANTIDOTES

Give an antidote (if available) when there is reasonable certainty of a specific diagnosis (Table 38–3). Be aware that some antidotes themselves may have serious side effects. The indications and dosages for specific antidotes are discussed in the respective sections for specific toxins.

Dart RC et al; Antidote Summit Authorship Group. Expert consensus guidelines for stocking of antidotes in hospitals that provide emergency care. *Ann Emerg Med.* 2009;54(3):386–94. [PMID: 19406507]

DECONTAMINATION OF THE SKIN

Corrosive agents rapidly injure the skin and eyes and must be removed immediately. In addition, many toxins are readily absorbed through the skin, and systemic absorption can be prevented only by rapid action.

Wash the affected areas with copious quantities of lukewarm water or saline. Wash carefully behind the ears, under the nails, and in skin folds. For oily substances (eg, pesticides), wash the skin at least twice with plain soap and shampoo the hair. Specific decontaminating solutions or

solvents (eg, alcohol) are rarely indicated and in some cases may paradoxically enhance absorption. For exposure to chemical warfare poisons such as nerve agents or vesicants, some authorities recommend use of a dilute hypochlorite solution (household bleach diluted 1:10 with water), but not in the eyes.

DECONTAMINATION OF THE EYES

Act quickly to prevent serious damage. Flush the eyes with copious amounts of saline or water. (If available, instill local anesthetic drops in the eye before beginning irrigation.) Remove contact lenses if present. Direct the irrigating stream so that it will flow across the eyes after running off the nasal bridge. Lift the tarsal conjunctiva to look for undissolved particles and to facilitate irrigation. Continue irrigation for 15 minutes or until each eye has been irrigated with at least 1 L of solution. If the toxin is an acid or a base, check the pH of the tears after irrigation, and continue irrigation until the pH is between 6 and 8. Special amphoteric solutions (Diphoterine, Previn) have been introduced in Europe for treatment of alkali injuries to the eye.

After irrigation is complete, perform a careful examination of the eye, using fluorescein and a slit lamp or Wood lamp to identify areas of corneal injury. Patients with serious conjunctival or corneal injury should be immediately referred to an ophthalmologist.

Table 38–3. Some toxic agents for which there are specific antidotes.¹

Toxic Agent	Specific Antidote
Acetaminophen	<i>N</i> -Acetylcysteine
Anticholinergics (eg, atropine)	Physostigmine
Anticholinesterases (eg, organophosphate pesticides)	Atropine and pralidoxime (2-PAM)
Benzodiazepines	Flumazenil (rarely used; see warning in text)
Carbon monoxide	Oxygen (hyperbaric oxygen of uncertain benefit)
Cyanide	Sodium nitrite, sodium thiosulfate, hydroxocobalamin
Digitalis glycosides	Digoxin-specific Fab antibodies
Heavy metals (eg, lead, mercury, iron) and arsenic	Specific chelating agents
Isoniazid	Pyridoxine (vitamin B ₆)
Methanol, ethylene glycol	Ethanol (ethyl alcohol) or fomepizole (4-methylpyrazole)
Opioids	Naloxone, nalmefene
Snake venom	Specific antivenin
Sulfonylurea oral hypoglycemic drugs	Glucose, octreotide

¹See text for indications and dosages.

GASTROINTESTINAL DECONTAMINATION

Removal of ingested poisons was a routine part of emergency treatment for decades. However, prospective randomized studies have failed to demonstrate improved clinical outcome after gastric emptying. For small or moderate ingestions of most substances, toxicologists generally recommend oral activated charcoal alone without prior gastric emptying; in some cases, when the interval after ingestion has been more than 1–2 hours and the ingested is non–life-threatening, even charcoal is withheld. Exceptions are large ingestions of anticholinergic compounds and salicylates, which often delay gastric emptying, and ingestion of sustained-release or enteric-coated tablets, which may remain intact for several hours.

Gastric emptying is not generally used for ingestion of corrosive agents or petroleum distillates, because further esophageal injury or pulmonary aspiration may result. However, in certain cases, removal of the toxin may be more important than concern over possible complications. Consult a medical toxicologist or regional poison control center (1-800-222-1222) for advice.

A. Emesis

Emesis using syrup of ipecac can partially evacuate gastric contents if given very soon after ingestion (eg, at work or at home). However, it may increase the risk of pulmonary aspiration and delay or prevent the use of oral activated charcoal. Therefore, it is no longer used in the routine management of ingestions.

B. Gastric Lavage

Gastric lavage is more effective for liquid poisons or small pill fragments than for intact tablets or pieces of mushroom. It is most useful when started within 60 minutes after ingestion. However, the lavage procedure may delay administration of activated charcoal and may stimulate vomiting and pulmonary aspiration in an obtunded patient.

1. Indications—Gastric lavage is sometimes used after very large ingestions (eg, massive aspirin overdose), for collection and examination of gastric contents for identification of the poison, and make it easier to administer charcoal and oral antidotes.

2. Contraindications—Do *not* use lavage for stuporous or comatose patients with depressed airway protective reflexes unless they are endotracheally intubated beforehand. Some authorities advise against lavage when caustic material has been ingested; others regard it as essential to remove liquid corrosives from the stomach.

3. Technique—In obtunded or comatose patients, the danger of aspiration pneumonia is reduced by performing endotracheal intubation with a cuffed tube before the procedure. Gently insert a lubricated, soft but noncollapsible stomach tube (at least 37–40 F) through the mouth or nose into the stomach. Aspirate and save the contents, and then lavage repeatedly with 50- to 100-mL aliquots of fluid until the return fluid is clear. Use lukewarm tap water or saline.

C. Activated Charcoal

Activated charcoal effectively adsorbs almost all drugs and poisons. Poorly adsorbed substances include iron, lithium, potassium, sodium, mineral acids, and alcohols.

1. Indications—Activated charcoal can be used for prompt adsorption of drugs or toxins in the stomach and intestine. Studies in volunteers show that activated charcoal given alone may be as effective as, or more effective, than ipecac-induced emesis or gastric lavage. However, evidence of benefit in clinical studies is lacking. Administration of charcoal, especially if mixed with sorbitol, can provoke vomiting, which could lead to pulmonary aspiration in an obtunded patient.

2. Contraindications—Activated charcoal should not be used for comatose or convulsing patients unless it can be given by gastric tube and the airway is first protected by a cuffed endotracheal tube. It is also contraindicated for patients with ileus or intestinal obstruction or those who have ingested corrosives for whom endoscopy is planned.

3. Technique—Administer activated charcoal, 60–100 g orally or via gastric tube, mixed in aqueous slurry. Repeated doses may be given to ensure gastrointestinal adsorption or to enhance elimination of some drugs (see below).

D. Catharsis

1. Indications—Cathartics are used by some toxicologists for stimulation of peristalsis to hasten the elimination of unabsorbed drugs and poisons and the activated charcoal

slurry. There is no clinical evidence to support their use, and some agents (eg, sorbitol) can provoke vomiting, increasing the risk of pulmonary aspiration.

2. Contraindications and cautions—Do not give a cathartic to patients with suspected intestinal obstruction. Avoid sodium-based cathartics in patients with hypertension, advanced chronic kidney disease, and congestive heart failure and avoid magnesium-based cathartics in patients with advanced chronic kidney disease. Sorbitol (an osmotic cathartic found in some prepackaged activated charcoal slurry products) can cause hypotension and dehydration due to third-spacing and also causes intestinal cramping and vomiting.

E. Whole Bowel Irrigation

Whole bowel irrigation uses large volumes of a balanced polyethylene glycol-electrolyte solution to mechanically cleanse the entire intestinal tract. Because of the composition of the irrigating solution, there is no significant gain or loss of systemic fluids or electrolytes.

1. Indications—Whole bowel irrigation is particularly effective for massive iron ingestion in which intact tablets are visible on abdominal radiographs. It has also been used for ingestions of lithium, sustained-release and enteric-coated tablets, and swallowed drug-filled packets.

2. Contraindications—Do not use in patients with suspected intestinal obstruction. Use with caution in patients who are obtunded or have depressed airway protective reflexes.

3. Technique—Administer a balanced polyethylene glycol-electrolyte solution (CoLyte, GoLYTELY) into the stomach via gastric tube at a rate of 1–2 L/h until the rectal effluent is clear. This may take several hours. It is most effective when patients are able to sit on a commode to pass the intestinal contents.

F. Increased Drug Removal

1. Urinary manipulation—Forced diuresis is hazardous; the risk of complications (pulmonary edema, electrolyte imbalance) usually outweighs its benefits. Acidic drugs (eg, salicylates, phenobarbital) are more rapidly excreted with an alkaline urine. Acidification (sometimes promoted for amphetamines, phencyclidine) is *not* very effective and is contraindicated in the presence of rhabdomyolysis or myoglobinuria.

2. Hemodialysis—The indications for dialysis are as follows: (1) Known or suspected potentially lethal amounts of a dialyzable drug (Table 38–4); (2) Poisoning with deep coma, apnea, severe hypotension, fluid and electrolyte or acid-base disturbance, or extreme body temperature changes that cannot be corrected by conventional measures; or (3) Poisoning in patients with severe kidney, cardiac, pulmonary, or hepatic disease who will not be able to eliminate toxin by the usual mechanisms.

Continuous renal replacement therapy (also known as continuous venovenous hemodiafiltration or venovenous hemodiafiltration) is of uncertain benefit for elimination

Table 38-4. Recommended use of hemodialysis in poisoning.

Poison	Common Indications ¹
Carbamazepine	Seizures, severe cardiotoxicity; serum level > 60 mg/L
Ethylene glycol	Acidosis, serum level > 50 mg/dL
Lithium	Severe symptoms; level > 4 mEq/L more than 12 hours after last dose. Note: dialysis of uncertain value; CVVHD may be preferable; consult with medical toxicologist.
Methanol	Acidosis, serum level > 50 mg/dL
Phenobarbital	Intractable hypotension, acidosis despite maximal supportive care
Salicylate	Severe acidosis, CNS symptoms, level > 100 mg/dL (acute overdose) or > 60 mg/dL (chronic intoxication)
Theophylline	Serum level > 90–100 mg/L (acute) or seizures and serum level > 40–60 mg/L (chronic)
Valproic acid	Serum level > 900–1000 mg/L or deep coma, severe acidosis

¹See text for further discussion of indications.

CNS, central nervous system; CVVHD, continuous venovenous hemodialysis.

of most poisons but has the advantage of slow removal of the toxin and any accompanying acidosis, and its use has been reported in the management of lithium intoxication.

3. Repeat-dose charcoal—Repeated doses of activated charcoal, 20–30 g orally or via gastric tube every 3–4 hours, may hasten elimination of some drugs (eg, phenytoin, carbamazepine, dapsone) by absorbing drugs excreted into the gut lumen (“gut dialysis”). However, clinical studies have failed to prove better outcome using multiple-dose charcoal. Sorbitol or other cathartics should *not* be used with each dose, or resulting large stool volumes may lead to dehydration or hypernatremia.

Dohlman CH et al. Chemical burns to the eye: paradigm shifts in treatment. *Cornea*. 2011 Jun;30(6):613–4. [PMID: 21242777]

Kumar VV et al. The effect of decontamination procedures on the pharmacokinetics of venlafaxine in overdose. *Clin Pharmacol Ther*. 2009 Oct;86(4):403–10. [PMID: 19606091]

Olson KR. Activated charcoal for acute poisoning: one toxicologist's journey. *J Med Toxicol*. 2010 Jun;6(2):190–8. [PMID: 20490748]

Thanacoody RH. Extracorporeal elimination in acute valproic acid poisoning. *Clin Toxicol (Phila)*. 2009 Aug;47(7):609–16. [PMID: 19656009]

DIAGNOSIS OF POISONING

The identity of the ingested substance or substances is usually known, but occasionally a comatose patient is found with an unlabeled container or the patient is unable or unwilling to give a coherent history. By performing a

directed physical examination and ordering common clinical laboratory tests, the clinician can often make a tentative diagnosis that may allow empiric interventions or may suggest specific toxicologic tests.

► Physical Examination

Important diagnostic variables in the physical examination include blood pressure, pulse rate, temperature, pupil size, sweating, and the presence or absence of peristaltic activity. Poisonings may present with one or more of the following common syndromes.

A. Sympathomimetic Syndrome

The blood pressure and pulse rate are elevated, though with severe hypertension reflex bradycardia may occur. The temperature is often elevated, pupils are dilated, and the skin is sweaty, though mucous membranes are dry. Patients are usually agitated, anxious, or frankly psychotic.

Examples: Amphetamines, cocaine, ephedrine and pseudoephedrine.

B. Sympatholytic Syndrome

The blood pressure and pulse rate are decreased and body temperature is low. The pupils are small or even pinpoint. Patients are usually obtunded or comatose.

Examples: Barbiturates, benzodiazepines and other sedative hypnotics, γ -hydroxybutyrate (GHB), clonidine and related antihypertensives, ethanol, opioids.

C. Cholinergic Syndrome

Stimulation of muscarinic receptors causes bradycardia, miosis, sweating, and hyperperistalsis as well as bronchorrhea, wheezing, excessive salivation, and urinary incontinence. Nicotinic receptor stimulation may produce initial hypertension and tachycardia as well as fasciculations and muscle weakness. Patients are usually agitated and anxious.

Examples: Carbamates, nicotine, organophosphates (including nerve agents), physostigmine.

D. Anticholinergic Syndrome

Tachycardia with mild hypertension is common, and the body temperature is often elevated. Pupils are widely dilated. The skin is flushed, hot, and dry. Peristalsis is decreased, and urinary retention is common. Patients may have myoclonic jerking or choreoathetoid movements. Agitated delirium is frequently seen, and severe hyperthermia may occur.

Examples: Atropine, scopolamine, other naturally occurring and pharmaceutical anticholinergics, antihistamines, tricyclic antidepressants.

► Laboratory Tests

The following clinical laboratory tests are recommended for screening of the overdosed patient: measured serum osmolality and osmol gap, electrolytes and anion gap, glucose, creatinine, blood urea nitrogen (BUN), urinalysis (eg, oxalate crystals with ethylene glycol poisoning,

myoglobinuria with rhabdomyolysis), and electrocardiography. Serum acetaminophen and ethanol quantitative levels should be determined in all patients with drug overdoses.

A. Osmol Gap

The osmol gap (see Table 38–5) is increased in the presence of large quantities of low-molecular-weight substances, most commonly ethanol. Common poisons associated with increased osmol gap are acetone, ethanol, ethylene glycol, isopropyl alcohol, methanol, and propylene glycol. **Note:** Severe alcoholic ketoacidosis and diabetic ketoacidosis can also cause an elevated osmol gap resulting from the production of ketones and other low-molecular-weight substances.

B. Anion Gap

Metabolic acidosis associated with an elevated anion gap is usually due to an accumulation of lactic acid or other acids (see Chapter 21). Common causes of elevated anion gap in poisoning include carbon monoxide, cyanide, ethylene glycol, medicinal iron, INH, methanol, metformin, ibuprofen and salicylates. Massive acetaminophen overdose can cause early-onset anion gap metabolic acidosis.

Table 38–5. Use of the osmol gap in toxicology.

The osmol gap (Δosm) is determined by subtracting the calculated serum osmolality from the measured serum osmolality.			
$\text{Calculated osmolality (osm)} = 2[\text{Na}^+ \text{ (mEq/L)}] + \frac{\text{Glucose (mg/dL)}}{18} + \frac{\text{BUN (mg/dL)}}{2.8}$			
$\Delta\text{osm} = \text{Measured osmolality} - \text{Calculated osmolality}$			
Serum osmolality may be increased by contributions of circulating alcohols and other low-molecular-weight substances. Since these substances are not included in the calculated osmolality, there will be a gap proportionate to their serum concentration and inversely proportionate to their molecular weight:			
$\text{Serum concentration (mg/dL)} = \Delta\text{osm} \times \frac{\text{Molecular weight}}{10}$			
	Molecular Weight	Toxic Concentration	Approximate Corresponding Δosm (mosm/L)
Ethanol	46	300	65
Methanol	32	50	16
Ethylene glycol	60	100	16
Isopropanol	60	150	25

Note: The normal osmol gap may vary by as much as ± 10 mosm/L; thus, small osmol gaps may be unreliable in the diagnosis of poisoning.

Adapted, with permission, from Stone CK, Humphries RL (editors): *Current Emergency Diagnosis & Treatment*, 5th ed. McGraw-Hill, 2004.

The osmol gap should also be checked; combined elevated anion and osmol gaps suggests poisoning by methanol or ethylene glycol, though this may also occur in patients with diabetic ketoacidosis and alcoholic ketoacidosis.

C. Toxicology Laboratory Testing

A comprehensive toxicology screen is of little value in the initial care of the poisoned patient because results do not return in time to influence clinical management. Specific quantitative levels of certain drugs may be extremely helpful (Table 38–6) however, especially if specific antidotes or interventions (eg, dialysis) would be indicated based on the results.

If a toxicology screen is required, urine is the best specimen. Many hospitals can perform a quick but limited screen for “drugs of abuse” (typically these screens include

Table 38–6. Specific quantitative levels and potential therapeutic interventions.¹

Drug or Toxin	Treatment
Acetaminophen	Specific antidote (<i>N</i> -acetylcysteine) based on serum level
Carbon monoxide	High carboxyhemoglobin level indicates need for 100% oxygen, consideration of hyperbaric oxygen
Carbamazepine	High level may indicate need for hemodialysis
Digoxin	On basis of serum digoxin level and severity of clinical presentation, treatment with Fab antibody fragments (eg, Digifab) may be indicated
Ethanol	Low serum level may suggest nonalcoholic cause of coma (eg, trauma, other drugs, other alcohols). Serum ethanol may also be useful in monitoring ethanol therapy for methanol or ethylene glycol poisoning.
Iron	Level may indicate need for chelation with deferoxamine
Lithium	Serum levels can guide decision to institute hemodialysis
Methanol, ethylene glycol	Acidosis, high levels indicate need for hemodialysis, therapy with ethanol or fomepizole
Methemoglobin	Methemoglobinemia can be treated with methylene blue intravenously
Salicylates	High level may indicate need for hemodialysis, alkaline diuresis
Theophylline	Immediate hemodialysis or hemoperfusion may be indicated based on serum level
Valproic acid	Elevated levels may indicate need to consider hemodialysis or L-carnitine therapy, or both

¹Some drugs or toxins may have profound and irreversible toxicity unless rapid and specific management is provided outside of routine supportive care. For these agents, laboratory testing may provide the serum level or other evidence required for administering a specific antidote or arranging for hemodialysis.

only opiates, amphetamines, and cocaine, and some add benzodiazepines, barbiturates, methadone, and tetrahydrocannabinol [marijuana]). There are numerous false-positive and false-negative results. For example, synthetic opioids, such as fentanyl, oxycodone, and methadone are usually not detected by routine opiate screening. Blood samples may be saved for possible quantitative testing, but blood is not generally used for screening purposes since it is relatively insensitive for many common drugs, including psychotropic agents, opioids, and stimulants.

▶ Abdominal Radiographs

A plain film of the abdomen may reveal radiopaque iron tablets, drug-filled condoms, or other toxic material. Studies suggest that few tablets are predictably visible (eg, ferrous sulfate, sodium chloride, calcium carbonate, and potassium chloride). Thus, the radiograph is useful only if abnormal.

▶ When to Refer

Consultation with a regional poison control center (1-800-222-1222) or a medical toxicologist is recommended when the diagnosis is uncertain; there are questions about what laboratory tests to order; when dialysis is being considered to remove the drug or poison; or when advice is needed regarding the indications, dose, and side effects of antidotes.

▶ When to Admit

- The patient has symptoms and signs of intoxication that are not expected to clear within a 6–8 hour observation period.
- Delayed absorption of the drug might be predicted to cause a later onset of serious symptoms (eg, after ingestion of a sustained-release product).
- Continued administration of an antidote is required (eg, *N*-acetylcysteine for acetaminophen overdose).
- Psychiatric or social services evaluation is needed for suicide attempt or suspected drug abuse.

Goldfrank LR (editor). *Goldfrank's Toxicologic Emergencies*, 9th ed. McGraw-Hill, 2010.

Olson KR (editor). *Poisoning & Drug Overdose*, 6th ed. McGraw-Hill, 2011.

SELECTED POISONINGS

ACETAMINOPHEN


Acetaminophen (paracetamol in the United Kingdom, Europe) is a common analgesic found in many nonprescription and prescription products. After absorption, it is metabolized mainly by glucuronidation and sulfation, with a small fraction metabolized via the P450 mixed-function oxidase system (2E1) to a highly toxic reactive intermediate. This toxic intermediate is normally detoxified by cellular glutathione. With acute acetaminophen overdose (> 150–200 mg/kg, or 8–10 g in an average adult), hepatocellular glutathione is depleted and the reactive

intermediate attacks other cell proteins, causing necrosis. Patients with enhanced P450 2E1 activity, such as chronic alcoholics and patients taking INH, are at increased risk of developing hepatotoxicity. Hepatic toxicity may also occur after long-term overuse of acetaminophen—eg, as a result of taking two or three acetaminophen-containing products concurrently or exceeding the recommended maximum dose of 4 g/d for several days.

▶ Clinical Findings

Shortly after ingestion, patients may have nausea or vomiting, but there are usually no other signs of toxicity until 24–48 hours after ingestion, when hepatic aminotransferase levels begin to increase. With severe poisoning, fulminant hepatic necrosis may occur, resulting in jaundice, hepatic encephalopathy, advanced chronic kidney disease, and death. Rarely, massive ingestion (eg, serum levels > 500–1000 mg/L [33–66 mmol/L]) can cause early onset of acute coma, seizures, hypotension, and metabolic acidosis unrelated to hepatic injury.

The diagnosis after acute overdose is based on measurement of the serum acetaminophen level. Plot the serum level versus the time since ingestion on the acetaminophen nomogram shown in Figure 38–1. Ingestion of sustained-release products or coingestion of an anticholinergic agent,



▲ **Figure 38–1.** Nomogram for prediction of acetaminophen hepatotoxicity following acute overdosage. The upper line defines serum acetaminophen concentrations associated with a risk of hepatotoxicity; the lower line defines serum levels 25% below those expected to cause hepatotoxicity. In uncomplicated cases, the upper line can be used as an indication for therapy with *N*-acetylcysteine. However, to provide a margin for error in the estimation of the time of ingestion and for patients at higher risk for hepatotoxicity, the lower line is usually used as a guide to treatment. (Adapted, with permission, from Rumack BH et al. Acetaminophen poisoning and toxicity. *Pediatrics*. 1975 Jun;55(6):871–6.)

salicylate, or opioid drug may cause delayed elevation of serum levels and may render the nomogram useless. The nomogram is also not useful after chronic overdose.

► Treatment

A. Emergency and Supportive Measures

Administer activated charcoal (see p 1567) if it can be given within 1–2 hours of the ingestion. Although charcoal may interfere with absorption of the oral antidote acetylcysteine, this is not considered clinically significant.

B. Specific Treatment

Although the risk is greatest if the serum acetaminophen level is above the upper line on the nomogram (Figure 38–1), many clinicians and published guidelines prefer to use the lower line as a guide to treatment, as it provides an added safety margin. If the precise time of ingestion is unknown or if the patient is at higher risk for hepatotoxicity (eg, alcoholic, liver disease, long-term use of P450-inducing drugs), then some clinicians use a lower threshold for initiation of *N*-acetylcysteine (in some case reports, a level of 100 mg/L [66 mmol/L] at 4 hours was suggested in very high-risk patients).

The antidote *N*-acetylcysteine can be given orally or intravenously. Oral treatment begins with a loading dose of *N*-acetylcysteine, 140 mg/kg, followed by 70 mg/kg every 4 hours. Dilute the solution to about 5% with water, juice, or soda. If vomiting interferes with oral *N*-acetylcysteine administration, consider giving the antidote intravenously (see below). The conventional oral *N*-acetylcysteine protocol in the United States calls for 72 hours of treatment. However, other regimens have demonstrated equivalent success with 20–48 hours of treatment.

The FDA-approved 21-hour intravenous regimen of acetylcysteine (Acetadote) calls for a loading dose of 150 mg/kg given intravenously over 60 minutes, followed by a 4-hour infusion of 50 mg/kg, and a 16-hour infusion of 100 mg/kg. (If Acetadote is not available, the conventional oral formulation may also be given intravenously using a micropore filter and a slow rate of infusion. Call a regional poison control center or medical toxicologist for assistance.)

Treatment with *N*-acetylcysteine is most effective if it is started within 8–10 hours after ingestion.

Alhelail MA et al. Clinical course of repeated supratherapeutic ingestion of acetaminophen. *Clin Toxicol (Phila)*. 2011 Feb;49(2):108–12. [PMID: 21370947]

Chomchai S et al. Acetaminophen psi parameter: a useful tool to quantify hepatotoxicity risk in acute acetaminophen overdose. *Clin Toxicol (Phila)*. 2011 Aug;49(7):664–7. [PMID: 21819286]

Chun LJ et al. Acetaminophen hepatotoxicity and acute liver failure. *J Clin Gastroenterol*. 2009 Apr;43(4):342–9. [PMID: 19169150]

ACIDS, CORROSIVE

The strong mineral acids exert primarily a local corrosive effect on the skin and mucous membranes. Symptoms include severe pain in the throat and upper gastrointestinal

tract; bloody vomitus; difficulty in swallowing, breathing, and speaking; discoloration and destruction of skin and mucous membranes in and around the mouth; and shock. Severe systemic metabolic acidosis may occur both as a result of cellular injury and from systemic absorption of the acid.

Severe deep destructive tissue damage may occur after exposure to hydrofluoric acid because of the penetrating and highly toxic fluoride ion. Systemic hypocalcemia and hyperkalemia may also occur after fluoride absorption, even following skin exposure.

Inhalation of volatile acids, fumes, or gases such as chlorine, fluorine, bromine, or iodine causes severe irritation of the throat and larynx and may cause upper airway obstruction and noncardiogenic pulmonary edema.

► Treatment

A. Ingestion

Dilute immediately by giving a glass (4–8 oz) of water to drink. Do *not* give bicarbonate or other neutralizing agents, and do *not* induce vomiting. Some experts recommend immediate cautious placement of a small flexible gastric tube and removal of stomach contents followed by lavage, particularly if the corrosive is a liquid or has important systemic toxicity.

In symptomatic patients, perform flexible endoscopic esophagoscopy to determine the presence and extent of injury. CT scan or plain radiographs of the chest and abdomen may also reveal the extent of injury. Perforation, peritonitis, and major bleeding are indications for surgery.

B. Skin Contact

Flood with water for 15 minutes. Use no chemical antidotes; the heat of the reaction may cause additional injury.

For hydrofluoric acid burns, soak the affected area in benzalkonium chloride solution or apply 2.5% calcium gluconate gel (prepared by adding 3.5 g calcium gluconate to 5 oz of water-soluble surgical lubricant, eg, K-Y Jelly); then arrange immediate consultation with a plastic surgeon or other specialist. Binding of the fluoride ion may be achieved by injecting 0.5 mL of 5% calcium gluconate per square centimeter under the burned area. (**Caution:** Do *not* use calcium chloride.) Use of a Bier-block technique or intra-arterial infusion of calcium is sometimes required for extensive burns or those involving the nail bed; consult with a hand surgeon or poison control center (1-800-222-1222).

C. Eye Contact

Anesthetize the conjunctiva and corneal surfaces with topical local anesthetic drops (eg, proparacaine). Flood with water for 15 minutes, holding the eyelids open. Check pH with pH 6.0–8.0 test paper, and repeat irrigation, using 0.9% saline, until pH is near 7.0. Check for corneal damage with fluorescein and slit lamp examination; consult an ophthalmologist about further treatment.

D. Inhalation

Remove from further exposure to fumes or gas. Check skin and clothing. Treat pulmonary edema.

Rauber-Lüthy C et al. Household chemicals: management of intoxication and antidotes. *EXS*. 2010;100:339–63. [PMID: 20358689]

Vohra R et al. Recurrent life-threatening ventricular dysrhythmias associated with acute hydrofluoric acid ingestion: observations in one case and implications for mechanism of toxicity. *Clin Toxicol (Phila)*. 2008 Jan;46(1):79–84. [PMID: 17906993]

Donoghue AM. Diphoterine for alkali chemical splashes to the skin at alumina refineries. *Int J Dermatol*. 2010 Aug;49(8):894–900. [PMID: 21174372]

Pace F et al. What is new in esophageal injury (infection, drug-induced, caustic, stricture, perforation)? *Curr Opin Gastroenterol*. 2009 Jul;25(4):372–9. [PMID: 19530274]

Schmidt SM et al. Corneal injury due to a calcium hydroxide containing food preparation product (“cal”). *Pediatr Emerg Care*. 2008 Jul;24(7):468–70. [PMID: 18633308]

ALKALIES

The strong alkalis are common ingredients of some household cleaning compounds and may be suspected by their “soapy” texture. Those with alkalinity above pH 12.0 are particularly corrosive. Disk (or “button”) batteries are also a source. Alkalis cause liquefactive necrosis, which is deeply penetrating. Symptoms include burning pain in the upper gastrointestinal tract, nausea, vomiting, and difficulty in swallowing and breathing. Examination reveals destruction and edema of the affected skin and mucous membranes and bloody vomitus and stools. Radiographs may reveal evidence of perforation or the presence of radiopaque disk batteries in the esophagus or lower gastrointestinal tract.

► Treatment

A. Ingestion

Dilute immediately with a glass of water. Do *not* induce emesis. Some gastroenterologists recommend immediate cautious placement of a small flexible gastric tube and removal of stomach contents followed by gastric lavage after ingestion of liquid caustic substances to remove residual material.

Prompt endoscopy is recommended in symptomatic patients to evaluate the extent of damage; CT scanning may also aid in assessment. If a radiograph reveals the location of ingested disk batteries in the esophagus, immediate endoscopic removal is mandatory.

The use of corticosteroids to prevent stricture formation is of no proved benefit and is definitely contraindicated if there is evidence of esophageal perforation.

B. Skin Contact

Wash with running water until the skin no longer feels soapy. Relieve pain and treat shock.

C. Eye Contact

Anesthetize the conjunctival and corneal surfaces with topical anesthetic (eg, proparacaine). Irrigate with water or saline continuously for 20–30 minutes, holding the lids open. Amphoteric solutions may be more effective than water or saline and some are available in Europe (Diphoterine, Previn). Check pH with pH test paper, and repeat irrigation for additional 30-minute periods until the pH is near 7.0. Check for corneal damage with fluorescein and slit lamp examination; consult an ophthalmologist for further treatment.

AMPHETAMINES & COCAINE

Amphetamines and cocaine are widely abused for their euphorogenic and stimulant properties. Both drugs may be smoked, snorted, ingested, or injected. Amphetamines and cocaine produce central nervous system stimulation and a generalized increase in central and peripheral sympathetic activity. The toxic dose of each drug is highly variable and depends on the route of administration and individual tolerance. The onset of effects is most rapid after intravenous injection or smoking. Amphetamine derivatives and related drugs include methamphetamine (“crystal meth,” “crank”), MDMA (“Ecstasy”), ephedrine (“herbal ecstasy”), and methcathinone (“cat” or “khat”). Methcathinone derivatives and related synthetic chemicals such as methylenedioxypropylamphetamine (MDPV) have become popular drugs of abuse and are often sold as purported “bath salts.” Amphetamine-like reactions have also been reported after use of synthetic cannabinoids (eg, “Spice” and “K2”). Nonprescription medications and nutritional supplements may contain stimulant or sympathomimetic drugs such as ephedrine, yohimbine, or caffeine (see also Theophylline section).

► Clinical Findings

Presenting symptoms may include anxiety, tremulousness, tachycardia, hypertension, diaphoresis, dilated pupils, agitation, muscular hyperactivity, and psychosis. Muscle hyperactivity may lead to metabolic acidosis and rhabdomyolysis. In severe intoxication, seizures and hyperthermia may occur. Sustained or severe hypertension may result in intracranial hemorrhage, aortic dissection, or myocardial infarction. Ischemic colitis has been reported. Hyponatremia has been reported after MDMA use; the mechanism is not known but may involve excessive water intake, syndrome of inappropriate antidiuretic hormone (SIADH), or both.

The diagnosis is supported by finding amphetamines or the cocaine metabolite benzoylecgonine in the urine. Note that many drugs can give a false-positive result on the immunoassay for amphetamines.

► Treatment

A. Emergency and Supportive Measures

Maintain a patent airway and assist ventilation, if necessary. Treat seizures as described at the beginning of this chapter (see p 1565). Rapidly lower the body temperature (see hyperthermia, p 1565) in patients who are hyperthermic (temperature > 39–40°C).

B. Specific Treatment

Treat agitation, psychosis, or seizures with a benzodiazepine such as diazepam, 5–10 mg, or lorazepam, 2–3 mg intravenously. Add phenobarbital 15 mg/kg intravenously for persistent seizures. Treat hypertension with a vasodilator drug such as phentolamine (1–5 mg intravenously) or a combined α - and β -adrenergic blocker such as labetalol (10–20 mg intravenously). Do *not* administer a pure β -blocker such as propranolol alone, as this may result in paradoxical worsening of the hypertension as a result of unopposed α -adrenergic effects.

Treat tachycardia or tachyarrhythmias with a short-acting β -blocker such as esmolol (25–100 mcg/kg/min by intravenous infusion). Treat hyperthermia as described above (see p 1565). Treat hyponatremia as outlined in Chapter 21.

Holubar SD et al. Methamphetamine colitis: a rare case of ischemic colitis in a young patient. *Arch Surg*. 2009 Aug;144(8):780–2. [PMID: 19687384]

Kiely E et al. A fatality from an oral ingestion of methamphetamine. *J Anal Toxicol*. 2009 Oct;33(8):557–60. [PMID: 19874669]

Ross EA et al. “Bath salts” intoxication. *N Engl J Med*. 2011 Sep 8;365(10):967–8. [PMID: 21899474]

Spiller HA et al. Clinical experience with and analytical confirmation of “bath salts” and “legal highs” (synthetic cathinones) in the United States. *Clin Toxicol (Phila)*. 2011 Jul;49(6):499–505. [PMID: 21824061]

ANTICOAGULANTS

Warfarin and related compounds (including ingredients of many commercial rodenticides) inhibit the clotting mechanism by blocking hepatic synthesis of vitamin K-dependent clotting factors.

Anticoagulants may cause hemoptysis, gross hematuria, bloody stools, hemorrhages into organs, widespread bruising, and bleeding into joint spaces. The prothrombin time is increased within 12–24 hours (peak 36–48 hours) after a single overdose. After ingestion of brodifacoum, difenacoum, and related rodenticides (so-called “superwarfarins”), inhibition of clotting factor synthesis may persist for several weeks or even months after a single dose.

► Treatment

A. Emergency and Supportive Measures

Discontinue the drug at the first sign of gross bleeding, and determine the prothrombin time (international normalized ratio, INR). If the patient has ingested an acute overdose, administer activated charcoal (see p 1567).

B. Specific Treatment

Do *not* treat prophylactically with vitamin K—wait for evidence of anticoagulation (elevated prothrombin time). If the INR is elevated, give phytonadione (vitamin K₁), 10–25 mg orally, and increase the dose as needed to restore the prothrombin time to normal. Doses as high as 200 mg/d have been required after ingestion of “superwarfarins.” Give

fresh-frozen plasma, prothrombin complex concentrate, or activated Factor VII as needed to rapidly correct the coagulation factor deficit if there is serious bleeding. If the patient is chronically anticoagulated and has strong medical indications for being maintained in that status (eg, prosthetic heart valve), give much smaller doses of vitamin K (1 mg orally) and fresh-frozen plasma (or both) to titrate to the desired prothrombin time.

If the patient has ingested brodifacoum or a related superwarfarin, prolonged observation (over weeks) and repeated administration of large doses of vitamin K may be required.

Gunja N et al. Management of intentional superwarfarin poisoning with long-term vitamin K and brodifacoum levels. *Clin Toxicol (Phila)*. 2011 Jun;49(5):385–90. [PMID: 21740137]
Wiedermann CJ et al. Warfarin-induced bleeding complications—clinical presentation and therapeutic options. *Thromb Res*. 2008;122(Suppl 2):S13–8. [PMID: 18549907]

ANTICONSULSANTS

Anticonvulsants (carbamazepine, phenytoin, valproic acid, and many newer agents) are widely used in the management of seizure disorders and some are also used for treatment of mood disorders or pain.

Phenytoin can be given orally or intravenously. Rapid intravenous injection of phenytoin can cause acute myocardial depression and cardiac arrest owing to the solvent propylene glycol (fosphenytoin does not contain this diluent). Chronic phenytoin intoxication can occur following only slightly increased doses because of zero-order kinetics and a small toxic-therapeutic window. Phenytoin intoxication can also occur following acute intentional or accidental overdose. The overdose syndrome is usually mild even with high serum levels. The most common manifestations are ataxia, nystagmus, and drowsiness. Choreoathetoid movements have been described.

Carbamazepine is used for treatment of trigeminal neuralgia, temporal lobe epilepsy, and other seizure disorders. Intoxication causes drowsiness, stupor and, with high levels, atrioventricular block, coma, and seizures. Dilated pupils and tachycardia are common. Toxicity may be seen with serum levels > 20 mg/L (85 mcmol/L), though severe poisoning is usually associated with concentrations > 30–40 mg/L (127–169 mcmol/L). Because of erratic and slow absorption, intoxication may progress over several hours to days.

Valproic acid intoxication produces a unique syndrome consisting of hypernatremia (from the sodium component of the salt), metabolic acidosis, hypocalcemia, elevated serum ammonia, and mild liver aminotransferase elevation. Hypoglycemia may occur as a result of hepatic metabolic dysfunction. Coma with small pupils may be seen and can mimic opioid poisoning. Encephalopathy and cerebral edema can occur.

The newer anticonvulsants **gabapentin**, **levetiracetam**, **vigabatrin**, and **zonisamide** generally cause somnolence, confusion and dizziness; **felbamate** can cause crystalluria

and kidney dysfunction after overdose, and may cause idiosyncratic aplastic anemia with therapeutic use; **lamotrigine**, **topiramate**, and **tiagabine** have been reported to cause seizures after overdose.

► Treatment

A. Emergency and Supportive Measures

For recent ingestions, give activated charcoal orally or by gastric tube (see p 1567). For large ingestions of carbamazepine or valproic acid—especially of sustained-release formulations—consider whole bowel irrigation (see p 1567). Multiple-dose activated charcoal and whole-bowel irrigation may be beneficial in ensuring gut decontamination for selected large ingestions.

B. Specific Treatment

There are no specific antidotes. Naloxone was reported to have reversed valproic acid overdose in one anecdotal case. Carnitine may be useful in patients with valproic acid-induced hyperammonemia. Consider hemodialysis for massive intoxication with valproic acid or carbamazepine (eg, carbamazepine levels > 60 mg/L [254 μmol/L] or valproic acid levels > 800 mg/L [5544 μmol/L]).

French LK et al. Complete heart block and death following lamotrigine overdose. *Clin Toxicol (Phila)*. 2011 Apr;49(4):330–3. [PMID: 21563910]

Thanacoody RH. Extracorporeal elimination in acute valproic acid poisoning. *Clin Toxicol (Phila)*. 2009 Aug;47(7):609–16. [PMID: 19656009]

Wade JF et al. Emergent complications of the newer anticonvulsants. *J Emerg Med*. 2010 Feb;38(2):231–7. [PMID: 18762404]

ANTIPSYCHOTIC DRUGS

Promethazine, prochlorperazine, chlorpromazine, haloperidol, droperidol, risperidone, olanzapine, ziprasidone, quetiapine, and aripiprazole are used as antipsychotic agents, and sometimes as antiemetics and potentiators of analgesic and hypnotic drugs.

Phenothiazines (particularly chlorpromazine) induce drowsiness and mild orthostatic hypotension in as many as 50% of patients. Larger doses can cause obtundation, miosis, severe hypotension, tachycardia, convulsions, and coma. Abnormal cardiac conduction may occur, resulting in prolongation of QRS or QT intervals (or both) and ventricular arrhythmias. Among the newer agents, quetiapine is more likely to cause coma and hypotension.

With therapeutic or toxic doses, an acute extrapyramidal dystonic reaction may develop in some patients, with spasmodic contractions of the face and neck muscles, extensor rigidity of the back muscles, carpopedal spasm, and motor restlessness. This reaction is more common with haloperidol and other butyrophenones and less common with newer atypical antipsychotics such as ziprasidone, olanzapine, aripiprazole, and quetiapine. Severe rigidity accompanied by hyperthermia and metabolic acidosis (“neuroleptic malignant syndrome”) may occasionally occur and is life-threatening (see Chapter 25).

► Treatment

A. Emergency and Supportive Measures

Administer activated charcoal (see p 1567) for large or recent ingestions. For severe hypotension, treatment with intravenous fluids and vasopressor agents may be necessary. Treat hyperthermia as outlined on p 1565. Maintain cardiac monitoring.

B. Specific Treatment

Hypotension and cardiac arrhythmias associated with widened QRS intervals on the ECG in a patient with thioridazine poisoning may respond to intravenous sodium bicarbonate as used for tricyclic antidepressants. Prolongation of the QT interval and torsades de pointes is usually treated with intravenous magnesium or overdrive pacing.

For extrapyramidal signs, give diphenhydramine, 0.5–1 mg/kg intravenously, or benztropine mesylate, 0.01–0.02 mg/kg intramuscularly. Treatment with oral doses of these agents should be continued for 24–48 hours.

Bromocriptine (2.5–7.5 mg orally daily) may be effective for mild or moderate neuroleptic malignant syndrome. Dantrolene (2–5 mg/kg intravenously) has also been used for muscle rigidity but is not a true antidote. For severe hyperthermia, rapid neuromuscular paralysis (see p 1565) is preferred.

Caroff SN et al. Movement disorders induced by antipsychotic drugs: implications of the CATIE schizophrenia trial. *Neurol Clin*. 2011 Feb;29(1):127–48. [PMID: 21172575]

Morris E et al. Neuroleptic malignant syndrome developing after acute overdose with olanzapine and chlorpromazine. *J Med Toxicol*. 2009 Mar;5(1):27–31. [PMID: 19191213]

Page CB et al. Promethazine overdose: clinical effects, predicting delirium and the effect of charcoal. *QJM*. 2009 Feb;102(2):123–31. [PMID: 19042969]

ARSENIC

Arsenic is found in some pesticides and industrial chemicals, and arsenic trioxide has recently been reintroduced as a chemotherapeutic agent. A massive epidemic of chronic arsenic poisoning has occurred in Bangladesh due to naturally occurring arsenic in deep aquifers used for drinking water. Symptoms of acute poisoning usually appear within 1 hour after ingestion but may be delayed as long as 12 hours. They include abdominal pain, vomiting, watery diarrhea, and skeletal muscle cramps. Profound dehydration and shock may occur. In chronic poisoning, symptoms can be vague but often include pancytopenia, painful peripheral sensory neuropathy, and skin changes including melanosis, keratosis, and desquamating rash. Urinary arsenic levels may be falsely elevated after certain meals (eg, seafood) that contain large quantities of a nontoxic form of organic arsenic.

► Treatment

A. Emergency Measures

After recent ingestion (within 1–2 hours), perform gastric lavage. Activated charcoal is of uncertain benefit because it

binds arsenic poorly. Administer intravenous fluids to replace losses due to vomiting and diarrhea.

B. Antidote

For patients with severe acute intoxication, give dimercaprol injection (British anti-Lewisite, BAL), 10% solution in oil, 3–5 mg/kg intramuscularly every 4–6 hours for 2 days. The side effects include nausea, vomiting, headache, and hypertension. Follow dimercaprol with oral succimer (dimercaptosuccinic acid, DMSA), 10 mg/kg every 8 hours, for 1 week. Consult a medical toxicologist or regional poison control center (1-800-222-1222) for advice regarding chelation.

Balakumar P et al. Arsenic exposure and cardiovascular disorders: an overview. *Cardiovasc Toxicol.* 2009 Dec;9(4):169–76. [PMID: 19787300]

Pimparkar BD et al. Arsenicosis: review of recent advances. *J Assoc Physicians India.* 2010 Oct;58:617–9. [PMID: 21510113]

Rahman MM et al. Chronic exposure of arsenic via drinking water and its adverse health impacts on humans. *Environ Geochem Health.* 2009 Apr;31(Suppl 1):189–200. [PMID: 19190988]

ATROPINE & ANTICHOLINERGICS

Atropine, scopolamine, belladonna, diphenoxylate with atropine, *Datura stramonium*, *Hyoscyamus niger*, some mushrooms, tricyclic antidepressants, and antihistamines are antimuscarinic agents with variable central nervous system effects. The patient complains of dryness of the mouth, thirst, difficulty in swallowing, and blurring of vision. The physical signs include dilated pupils, flushed skin, tachycardia, fever, delirium, myoclonus, ileus, and flushed appearance. Antidepressants and antihistamines may induce convulsions.

Antihistamines are commonly available with or without prescription. Diphenhydramine commonly causes delirium, tachycardia, and seizures. Massive overdose may mimic tricyclic antidepressant poisoning.

► Treatment

A. Emergency and Supportive Measures

Administer activated charcoal (see p 1567). Tepid sponge baths and sedation, or neuromuscular paralysis in rare cases, are indicated to control high temperatures (see p 1565).

B. Specific Treatment

For severe anticholinergic syndrome (eg, agitated delirium), give physostigmine salicylate, 0.5–1 mg slowly intravenously over 5 minutes, with ECG monitoring; repeat as needed to a total dose of no more than 2 mg. **Caution:** Bradycardias and convulsions are a hazard with physostigmine administration, and the drug should be avoided in patients with cardiotoxic effects from tricyclic antidepressants or other sodium channel blockers.

Irioka T et al. Opsoclonus caused by diphenhydramine self-poisoning. *J Neuroophthalmol.* 2009 Mar;29(1):72–3. [PMID: 19458581]

Mateo Montoya A et al. Acute anticholinergic syndrome from *Atropa belladonna* mistaken for blueberries. *Eur J Ophthalmol.* 2009 Jan–Feb;19(1):170–2. [PMID: 19123171]

β-ADRENERGIC BLOCKERS

There are a wide variety of β-adrenergic blocking drugs, with varying pharmacologic and pharmacokinetic properties (see Table 11–7). The most toxic β-blocker is propranolol. Propranolol competitively blocks β₁ and β₂ adrenoceptors and also has direct membrane-depressant and central nervous system effects.

► Clinical Findings

The most common findings with mild or moderate intoxication are hypotension and bradycardia. Cardiac depression from more severe poisoning is often unresponsive to conventional therapy with β-adrenergic stimulants such as dopamine and norepinephrine. In addition, with propranolol and other lipid-soluble drugs, seizures and coma may occur. Propranolol, oxprenolol, acebutolol, and alprenolol also have membrane-depressant effects and can cause conduction disturbance (wide QRS interval) similar to tricyclic antidepressant overdose.

The diagnosis is based on typical clinical findings. Routine toxicology screening does not usually include β-blockers.

► Treatment

A. Emergency and Supportive Measures

Attempts to treat bradycardia or heart block with atropine (0.5–2 mg intravenously), isoproterenol (2–20 mcg/min by intravenous infusion, titrated to the desired heart rate), or an external transcutaneous cardiac pacemaker are often ineffective, and specific antidotal treatment may be necessary (see below).

For drugs ingested within an hour of presentation (or longer after ingestion of an extended-release formulation), administer activated charcoal (see p 1567).

B. Specific Treatment

For persistent bradycardia and hypotension, give glucagon, 5–10 mg intravenously, followed by an infusion of 1–5 mg/h. Glucagon is an inotropic agent that acts at a different receptor site and is therefore not affected by β-blockade. High-dose insulin (0.5–1 units/kg/h intravenously) along with glucose supplementation has been used to reverse severe cardiotoxicity. Membrane-depressant effects (wide QRS interval) may respond to boluses of sodium bicarbonate (50–100 mEq intravenously) as for tricyclic antidepressant poisoning. Intravenous lipid emulsion (Intralipid 20%, 1.5 mL/kg) has been used successfully in severe propranolol overdose.

Jovic-Stosic J et al. Severe propranolol and ethanol overdose with wide complex tachycardia treated with intravenous lipid emulsion: a case report. *Clin Toxicol (Phila)*. 2011 Jun; 49(5):426–30. [PMID: 21740142]

Page C et al. The use of high-dose insulin-glucose euglycemia in beta-blocker overdose: a case report. *J Med Toxicol*. 2009 Sep; 5(3):139–43. [PMID: 19655287]

CALCIUM CHANNEL BLOCKERS

Calcium channel blockers are used to treat angina pectoris, hypertension, supraventricular tachycardia, migraine, and other disorders. In therapeutic doses, nifedipine, nicaldipine, amlodipine, felodipine, isradipine, nisoldipine, and nimodipine act mainly on blood vessels, while verapamil and diltiazem act mainly on cardiac contractility and conduction. However, these selective effects can be lost after acute overdose. Patients may present with bradycardia, atrioventricular (AV) nodal block, hypotension, or a combination of these effects. Hyperglycemia is common due to blockade of insulin release. With severe poisoning, cardiac arrest may occur.

► Treatment

A. Emergency and Supportive Measures

For ingested drugs, administer activated charcoal (see p 1567). In addition, whole bowel irrigation (see p 1567) should be initiated as soon as possible if the patient has ingested a sustained-release product.

B. Specific Treatment

If bradycardia and hypotension are not reversed with atropine (0.5–2 mg intravenously), isoproterenol (2–20 mcg/min by intravenous infusion), or a transcutaneous cardiac pacemaker, administer calcium intravenously. Start with calcium chloride 10%, 10 mL, or calcium gluconate 10%, 20 mL. Repeat the dose every 3–5 minutes. The optimum (or maximum) dose has not been established, but many toxicologists recommend raising the ionized serum calcium level to as much as twice the normal level. Calcium is most useful in reversing negative inotropic effects and is less effective for AV nodal blockade and bradycardia. Epinephrine infusion (1–4 mcg/min initially) and glucagon (5–10 mg intravenously) have also been recommended. In addition, high doses of insulin (0.5–1 units/kg intravenous bolus followed by 0.5–1 units/kg/h infusion) along with sufficient dextrose to maintain euglycemia have been reported to be beneficial but there are no controlled studies. Infusion of Intralipid 20% lipid emulsion has been reported to improve hemodynamics in animal models and case reports of calcium channel blocker poisoning.

Abeyinghe N et al. Diltiazem overdose: a role for high-dose insulin. *Emerg Med J*. 2010 Oct;27(10):802–3. [PMID: 20660906]

Cave G et al. Intravenous lipid emulsion as antidote: a summary of published human experience. *Emerg Med Australas*. 2011 Apr;23(2):123–41. [PMID: 21489160]

Engelbreten KM et al. High-dose insulin therapy in beta-blocker and calcium channel-blocker poisoning. *Clin Toxicol (Phila)*. 2011 Apr;49(4):277–83. [PMID: 21563902]

CARBON MONOXIDE

Carbon monoxide is a colorless, odorless gas produced by the combustion of carbon-containing materials. Poisoning may occur as a result of suicidal or accidental exposure to automobile exhaust, smoke inhalation in a fire, or accidental exposure to an improperly vented gas heater, generator, or other appliance. Carbon monoxide avidly binds to hemoglobin, with an affinity approximately 250 times that of oxygen. This results in reduced oxygen-carrying capacity and altered delivery of oxygen to cells (see also Smoke Inhalation in Chapter 9).

► Clinical Findings

At low carbon monoxide levels (carboxyhemoglobin saturation 10–20%), victims may have headache, dizziness, abdominal pain, and nausea. With higher levels, confusion, dyspnea, and syncope may occur. Hypotension, coma, and seizures are common with levels > 50–60%. Survivors of acute severe poisoning may develop permanent obvious or subtle neurologic and neuropsychiatric deficits. The fetus and newborn may be more susceptible because of high carbon monoxide affinity for fetal hemoglobin.

Carbon monoxide poisoning should be suspected in any person with severe headache or acutely altered mental status, especially during cold weather, when improperly vented heating systems may have been used. Diagnosis depends on specific measurement of the arterial or venous carboxyhemoglobin saturation, although the level may have declined if high-flow oxygen therapy has already been administered, and levels do not always correlate with clinical symptoms. Routine arterial blood gas testing and pulse oximetry are not useful because they give falsely normal PaO₂ and oxyhemoglobin saturation determinations, respectively. (A specialized pulse oximetry device, the Masimo pulse CO-oximeter, is capable of distinguishing oxyhemoglobin from carboxyhemoglobin.)

► Treatment

A. Emergency and Supportive Measures

Maintain a patent airway and assist ventilation, if necessary. Remove the victim from exposure. Treat patients with coma, hypotension, or seizures as described at the beginning of this chapter (see pp 1562, 1563, 1565).

B. Specific Treatment

The half-life of the carboxyhemoglobin (CoHb) complex is about 4–5 hours in room air but is reduced dramatically by high concentrations of oxygen. Administer 100% oxygen by tight-fitting high-flow reservoir face mask or endotracheal tube. Hyperbaric oxygen (HBO) can provide 100% oxygen under higher than atmospheric pressures, further shortening the half-life; it may also reduce the incidence of subtle neuropsychiatric sequelae. Randomized controlled studies disagree about the benefit of HBO, but commonly recommended indications for HBO in patients with carbon monoxide poisoning include a history of loss of

consciousness, CoHb > 25%, metabolic acidosis, age over 50 years, and cerebellar findings on neurologic examination.

Annane D et al. Hyperbaric oxygen therapy for acute domestic carbon monoxide poisoning: two randomized controlled trials. *Intensive Care Med.* 2010 Mar;37(3):486–9. [PMID: 21125215]

Buckley NA et al. Hyperbaric oxygen for carbon monoxide poisoning. *Cochrane Database Syst Rev.* 2011 Apr 13;(4):CD002041. [PMID: 21491385]

CLONIDINE & OTHER SYMPATHOLYTIC ANTIHYPERTENSIVES

Overdosage with these agents (clonidine, guanabenz, guanfacine, methyl dopa) causes bradycardia, hypotension, miosis, respiratory depression, and coma. (Transient hypertension occasionally occurs after acute overdosage, a result of peripheral α -adrenergic effects in high doses.) Symptoms are usually resolved in < 24 hours, and deaths are rare. Similar symptoms may occur after ingestion of topical nasal decongestants chemically similar to clonidine (oxymetazoline, tetrahydrozoline, naphazoline). Brimonidine and apraclonidine are used as ophthalmic preparations for glaucoma. Tizanidine is a centrally acting muscle relaxant structurally related to clonidine; it produces similar toxicity in overdose.

► Treatment

A. Emergency and Supportive Measures

Give activated charcoal (see p 1567). Maintain the airway and support respiration if necessary. Symptomatic treatment is usually sufficient even in massive overdose. Maintain blood pressure with intravenous fluids. Dopamine can also be used. Atropine is usually effective for bradycardia.

B. Specific Treatment

There is no specific antidote. Although tolazoline has been recommended for clonidine overdose, its effects are unpredictable and it should not be used. Naloxone has been reported to be successful in a few anecdotal and poorly substantiated cases.

Farooqi M et al. Toxicity from a clonidine suspension. *J Med Toxicol.* 2009 Sep;5(3):130–3. [PMID: 19655285]

Fernandez MA et al. Pediatric systemic poisoning resulting from brimonidine ophthalmic drops. *Pediatr Emerg Care.* 2009 Jan; 25(1):59. [PMID: 19148021]

COCAINE

See Amphetamines & Cocaine.

CYANIDE

Cyanide is a highly toxic chemical used widely in research and commercial laboratories and many industries. Its gaseous form, hydrogen cyanide, is an important component of smoke in fires. Cyanide-generating glycosides are also found in the pits of apricots and other related plants.

Cyanide is generated by the breakdown of nitroprusside, and poisoning can result from rapid high-dose infusions. Cyanide is also formed by metabolism of acetonitrile, a solvent found in some over-the-counter fingernail glue removers. Cyanide is rapidly absorbed by inhalation, skin absorption, or ingestion. It disrupts cellular function by inhibiting cytochrome oxidase and preventing cellular oxygen utilization.

► Clinical Findings

The onset of toxicity is nearly instantaneous after inhalation of hydrogen cyanide gas but may be delayed for minutes to hours after ingestion of cyanide salts or cyanogenic plants or chemicals. Effects include headache, dizziness, nausea, abdominal pain, and anxiety, followed by confusion, syncope, shock, seizures, coma, and death. The odor of “bitter almonds” may be detected on the victim’s breath or in vomitus, though this is not a reliable finding. The venous oxygen saturation may be elevated (> 90%) in severe poisonings because tissues have failed to take up arterial oxygen.

► Treatment

A. Emergency and Supportive Measures

Remove the victim from exposure, taking care to avoid exposure to rescuers. For suspected cyanide poisoning due to nitroprusside infusion, stop or slow the rate of infusion. (Metabolic acidosis and other signs of cyanide poisoning usually clear rapidly.)

For cyanide ingestion, administer activated charcoal (see p 1567). Although charcoal has a low affinity for cyanide, the usual doses of 60–100 g are adequate to bind typically ingested lethal doses (100–200 mg).

B. Specific Treatment

In the United States, there are two available cyanide antidote regimens. The conventional cyanide antidote package (Taylor Pharmaceuticals) (Table 38–7) contains nitrites (to induce methemoglobinemia, which binds free cyanide) and thiosulfate (to promote conversion of cyanide to the less toxic thiocyanate). Administer amyl nitrite by crushing an ampule under the victim’s nose or at the end of the endotracheal tube, and administer 3% sodium nitrite solution, 10 mL intravenously. **Caution:** Nitrites may induce hypotension and dangerous levels of methemoglobin. Also administer 25% sodium thiosulfate solution, 50 mL intravenously (12.5 g).

The other approved cyanide treatment in the United States is hydroxocobalamin (Cyanokit, EMD Pharmaceuticals), a newer and potentially safer antidote. The adult dose of hydroxocobalamin is 5 g intravenously (children’s dose is, 70 mg/kg).

Barillo DJ. Diagnosis and treatment of cyanide toxicity. *J Burn Care Res.* 2009 Jan–Feb;30(1):148–52. [PMID: 19060738]

Cigolini D et al. Hydroxocobalamin treatment of acute cyanide poisoning from apricot kernels. *Emerg Med J.* 2011 Sep;28(9):804–5. [PMID: 21856998]

Lawson-Smith P et al. Cyanide intoxication as part of smoke inhalation—a review on diagnosis and treatment from the emergency perspective. *Scand J Trauma Resusc Emerg Med.* 2011 Mar 3;19:14. [PMID: 21371322]

Table 38-7. Currently available cyanide (CN) antidote kits.

Antidote	Contents	Action
Conventional cyanide antidote kit ¹	Amyl nitrite, 0.3 mL aspirol for inhalation; sodium nitrite 300 mg in a 10-mL vial; sodium thiosulfate 12.5 g in a 50-mL vial	Nitrites induce methemoglobinemia, which binds CN; thio-sulfate hastens CN conversion to less toxic thiocyanate
Cyanokit ²	Hydroxocobalamin 5 g in two 2.5-g vials	Converts CN to cyanocobalamin (vitamin B ₁₂)

¹In the United States, manufactured by Taylor Pharmaceuticals.

²Manufactured by EMD Pharmaceuticals.

DIETARY SUPPLEMENTS & HERBAL PRODUCTS

Following passage of the Dietary Supplement Health and Education Act (DSHEA) in 1994, there has been an increase in the use of dietary supplements and herbal medicines in the United States. Unlike prescription and over-the-counter pharmaceuticals, dietary supplements do not require FDA approval, do not undergo the same pre-marketing evaluation of safety and efficacy as drugs, and purveyors may or may not adhere to good manufacturing practices and quality control standards. Supplements may cause illness as a result of intrinsic toxicity, misidentification or mislabeling, drug-herb reactions, or adulteration with pharmaceuticals. If you suspect a dietary supplement or herbal product may be the cause of an otherwise unexplained illness, contact the FDA (1-888-463-6332) or the regional poison control center (1-800-222-1222), or consult one of the following online databases: <http://www.naturaldatabase.therapeuticresearch.com> and, <http://www.fda.gov/food/dietarysupplements/default.htm>.

Table 38-8 lists selected examples of clinical toxicity from some of these products.

Ashar BH. The Dietary Supplement Health and Education Act: time for a reassessment: comment on "acute selenium toxicity associated with a dietary supplement". *Arch Intern Med.* 2010 Feb 8;170(3):261-3. [PMID: 20142571]
 Shaw D. Toxicological risks of Chinese herbs. *Planta Med.* 2010 Dec;76(17):2012-8. [PMID: 21077025]

DIGITALIS & OTHER CARDIAC GLYCOSIDES

Cardiac glycosides are derived from a variety of plants and are widely used to treat heart failure and supraventricular arrhythmias. These drugs paralyze the Na⁺-K⁺-ATPase pump and have potent vagotonic effects. Intracellular effects include enhancement of calcium-dependent contractility and shortening of the action potential duration. A number of plants (eg, oleander, foxglove, lily-of-the-valley)

Table 38-8. Examples of potential toxicity associated with some dietary supplements and herbal medicines.

Product	Common Use	Possible Toxicity
Azarcon (Greta)	Mexican folk remedy for abdominal pain, colic	Contains lead (see p 1581)
Comfrey	Gastric upset, diarrhea	Contains pyrrolizidine alkaloids, can cause hepatic veno-occlusive disease
Creatine	Athletic performance enhancement	Nausea, diarrhea, abdominal cramps; elevated serum creatinine
Ginkgo	Memory improvement, tinnitus	Antiplatelet effects, hemorrhage; abdominal pain, diarrhea
Ginseng	Immune system; stress	Decreased glucose; increased cortisol
Guarana	Athletic performance enhancement, appetite suppression	Contains caffeine: can cause tremor, tachycardia, vomiting
Kava	Anxiety, insomnia	Drowsiness, hepatitis, skin rash
Ma huang	Stimulant; athletic performance enhancement	Contains ephedrine: anxiety, insomnia, hypertension, tachycardia, seizures
Spirulina	Body building	Niacin-like flushing reaction
Yohimbine	Sexual enhancement	Hallucinations, hypertension, tachycardia
Zinc	Cold/flu symptoms	Nausea, oral irritation, anosmia

Adapted, with permission, from Table II-30 by Haller C in "Herbal and Alternative Products," In: Olson KR (ed.) *Poisoning & Drug Overdose*, 5th edition, McGraw Hill, 2007.

contain cardiac glycosides. Bufotenin, a cardiotoxic steroid found in certain toad secretions and used as an herbal medicine and a purported aphrodisiac, has pharmacologic properties similar to cardiac glycosides.

► Clinical Findings

Intoxication may result from acute single exposure or chronic accidental overmedication. After acute overdosage, nausea and vomiting, bradycardia, hyperkalemia, and AV block frequently occur. Patients in whom toxicity develops gradually during long-term therapy may be hypokalemic and hypomagnesemic owing to concurrent diuretic treatment and more commonly present with ventricular arrhythmias (eg, ectopy, bidirectional ventricular tachycardia, or ventricular fibrillation). Digoxin levels may be only slightly elevated in patients with intoxication from cardiac glycosides other than digoxin because of limited cross-reactivity of immunologic tests.

► Treatment

A. Emergency and Supportive Measures

After acute ingestion, administer activated charcoal (see p 1567). Monitor potassium levels and cardiac rhythm closely. Treat bradycardia initially with atropine (0.5–2 mg intravenously) or a transcutaneous external cardiac pacemaker.

B. Specific Treatment

For patients with significant intoxication, administer digoxin-specific antibodies (digoxin immune Fab [ovine]; Digibind or DigiFab). Estimation of the Digibind dose is based on the body burden of digoxin calculated from the ingested dose or the steady-state serum digoxin concentration, as described below. More effective binding of digoxin may be achieved if the dose is given partly as a bolus and the remainder as an infusion over a few hours.

1. From the ingested dose—Number of vials = approximately $1.5\text{--}2 \times$ ingested dose (mg).

2. From the serum concentration—Number of vials = serum digoxin (ng/mL) \times body weight (kg) $\times 10^{-2}$. **Note:** This is based on the equilibrium digoxin level; after acute overdose, serum levels may be falsely high before tissue distribution is complete, and overestimation of the Digibind or DigiFab dose is likely.

3. Empiric dosing—Empiric titration of Digibind or DigiFab may be used if the patient's condition is relatively stable and an underlying condition (eg, atrial fibrillation) favors retaining a residual level of digitalis activity. Start with one or two vials and reassess the patient's clinical condition after 20–30 minutes. For cardiac glycosides other than digoxin or digitoxin, there is no formula for estimation of vials needed and treatment is entirely based on response to empiric dosing.

Note: After administration of digoxin-specific Fab antibody fragments, serum digoxin levels may be falsely elevated depending on the assay technique.

Bandara V et al. A review of the natural history, toxicology, diagnosis and clinical management of *Nerium oleander* (common oleander) and *Thevetia peruviana* (yellow oleander) poisoning. *Toxicon*. 2010 Sep 1;56(3):273–81. [PMID: 20438743]

Eyer F et al. Free and total digoxin in serum during treatment of acute digoxin poisoning with Fab fragments: case study. *Am J Crit Care*. 2010 Jul;19(4):391–87. [PMID: 19875723]

Rajapakse S. Management of yellow oleander poisoning. *Clin Toxicol (Phila)*. 2009 Mar;47(3):206–12. [PMID: 19306191]

ETHANOL, BENZODIAZEPINES, & OTHER SEDATIVE-HYPNOTIC AGENTS

The group of agents known as sedative-hypnotic drugs includes a variety of products used for the treatment of anxiety, depression, insomnia, and epilepsy. Besides common benzodiazepines, such as lorazepam, alprazolam, clonazepam, diazepam, oxazepam, chlordiazepoxide, and triazolam, this group includes the newer benzodiazepine-like hypnotics zolpidem and zaleplon, and the muscle relaxant carisoprodol. Ethanol and other selected agents are also popular recreational drugs. All of these drugs depress the central nervous system reticular activating system, cerebral cortex, and cerebellum.

► Clinical Findings

Mild intoxication produces euphoria, slurred speech, and ataxia. Ethanol intoxication may produce hypoglycemia, even at relatively low concentrations, in children and in fasting adults. With more severe intoxication, stupor, coma, and respiratory arrest may occur. Carisoprodol (Soma) commonly causes muscle jerking or myoclonus. Death or serious morbidity is usually the result of pulmonary aspiration of gastric contents. Bradycardia, hypotension, and hypothermia are common. Patients with massive intoxication may appear to be dead, with no reflex responses and even absent electroencephalographic activity. Diagnosis and assessment of severity of intoxication are usually based on clinical findings. Ethanol serum levels > 300 mg/dL (0.3 g/dL; 65 mmol/L) can produce coma in persons who are not chronically abusing the drug, but regular users may remain awake at much higher levels.

► Treatment

A. Emergency and Supportive Measures

Administer activated charcoal if the patient has ingested a massive dose and the airway is protected (see p 1567). Repeat-dose charcoal may enhance elimination of phenobarbital, but it has not been proved to improve clinical outcome. Hemodialysis may be necessary for patients with severe phenobarbital intoxication.

B. Specific Treatment

Flumazenil is a benzodiazepine receptor-specific antagonist; it has no effect on ethanol, barbiturates, or other sedative-hypnotic agents. If used, flumazenil is given slowly intravenously, 0.2 mg over 30–60 seconds, and repeated in

0.2-0.5 mg increments as needed up to a total dose of 3–5 mg. **Caution:** Flumazenil may induce seizures in patients with preexisting seizure disorder, benzodiazepine addiction, or concomitant tricyclic antidepressant or other convulsant overdose. If seizures occur, diazepam and other benzodiazepine anticonvulsants will not be effective. As with naloxone, the duration of action of flumazenil is short (2–3 hours) and resedation may occur, requiring repeated doses.

Cantrell FL et al. Death on the doorstep of a border community—intentional self-poisoning with veterinary pentobarbital. *Clin Toxicol (Phila)*. 2010 Oct;48(8):849–50. [PMID: 20738183]
 Kuzniar TJ et al. Coma with absent brainstem reflexes resulting from zolpidem overdose. *Am J Ther*. 2010 Sep–Oct;17(5):e172–4. [PMID: 20862780]
 Lakhal K et al. Protracted deep coma after bromazepam poisoning. *Int J Clin Pharmacol Ther*. 2010 Jan;48(1):79–83. [PMID: 20040343]

γ-HYDROXYBUTYRATE (GHB)

GHB has become a popular drug of abuse. It originated as a short-acting general anesthetic and is occasionally used in the treatment of narcolepsy. It gained popularity among bodybuilders for its alleged growth hormone stimulation and found its way into social settings, where it is consumed as a liquid. It has been used to facilitate sexual assault (“date-rape” drug). Symptoms after ingestion include drowsiness and lethargy followed by coma with respiratory depression. Muscle twitching and seizures are sometimes observed. Recovery is usually rapid, with patients awakening within a few hours. Other related chemicals with similar effects include butanediol and γ-butyrolactone (GBL). A prolonged withdrawal syndrome has been described in some heavy users.

▶ Treatment

Monitor the airway and assist breathing if needed. There is no specific treatment. Most patients recover rapidly with supportive care. GHB withdrawal syndrome may require very large doses of benzodiazepines.

Galicia M. Liquid ecstasy intoxication: clinical features of 505 consecutive emergency department patients. *Emerg Med J*. 2011 Jun;28(6):462–6. [PMID: 21602168]
 Zvosec DL et al. Case series of 226 γ-hydroxybutyrate-associated deaths: lethal toxicity and trauma. *Am J Emerg Med*. 2011 Mar;29(3):319–32. [PMID: 20825811]

HYPOGLYCEMIC DRUGS

Medications used for diabetes mellitus include insulin, sulfonylureas and other insulin secretagogues, α-glucosidase inhibitors (acarbose, miglitol), biguanides (metformin), thiazolidinediones (pioglitazone, rosiglitazone), and newer peptide analogs (pramlintide, exenatide) or enhancers (sitagliptin) (see Chapter 27). Of these, insulin and the insulin secretagogues are the most likely to cause hypoglycemia. Metformin can cause lactic acidosis, especially in

patients with renal insufficiency or after intentional drug overdose. Table 27–7 lists the duration of hypoglycemic effect of oral hypoglycemic agents and Figure 27–3 the extent and duration of various types of insulins.

▶ Clinical Findings

Hypoglycemia may occur quickly after injection of short-acting insulins or may be delayed and prolonged, especially if a large amount has been injected into a single area, creating a “depot” effect. Hypoglycemia after sulfonylurea ingestion is usually apparent within a few hours but may be delayed several hours, especially if food or glucose-containing fluids have been given.

▶ Treatment

Give sugar and carbohydrate-containing food or liquids by mouth, or intravenous dextrose if the patient is unable to swallow safely. For severe hypoglycemia, start with D50W, 50 mL intravenously (25 g dextrose); repeat, if needed. Follow up with dextrose-containing intravenous fluids (D5W or D10W) to maintain a blood glucose > 70–80 mg/dL.

For hypoglycemia caused by sulfonylureas and related insulin secretagogues, consider use of octreotide, a synthetic somatostatin analog that blocks pancreatic insulin release. A dose of 50–100 mcg octreotide subcutaneously every 6–12 hours can reduce the need for exogenous dextrose and prevent rebound hypoglycemia from excessive dextrose dosing.

Admit all patients with symptomatic hypoglycemia after sulfonylurea overdose. Observe asymptomatic overdose patients for at least 12 hours.

Dougherty PP et al. Octreotide’s role in the management of sulfonylurea-induced hypoglycemia. *J Med Toxicol*. 2010 Jun; 6(2):199–206. [PMID: 20352540]
 Fasano CJ et al. Quantitative insulin and C-peptide levels among ED patients with sulfonylurea-induced hypoglycemia—a prospective case series. *Am J Emerg Med*. 2010 Oct;28(8):952–5. [PMID: 20887914]

IRON

Iron is widely used therapeutically for the treatment of anemia and as a daily supplement in multiple vitamin preparations. Most children’s preparations contain about 12–15 mg of elemental iron (as sulfate, gluconate, or fumarate salt) per dose, compared with 60–90 mg in most adult-strength preparations. Iron is corrosive to the gastrointestinal tract and, once absorbed, has depressant effects on the myocardium and on peripheral vascular resistance. Intracellular toxic effects of iron include disruption of Krebs cycle enzymes.

▶ Clinical Findings

Ingestion of < 30 mg/kg of elemental iron usually produces only mild gastrointestinal upset. Ingestion of > 40–60 mg/kg

may cause vomiting (sometimes with hematemesis), diarrhea, hypotension, and acidosis. Death may occur as a result of profound hypotension due to massive fluid losses and bleeding, metabolic acidosis, peritonitis from intestinal perforation, or sepsis. Fulminant hepatic failure may occur. Survivors of the acute ingestion may suffer permanent gastrointestinal scarring.

Serum iron levels > 350–500 mcg/dL are considered potentially toxic, and levels > 1000 mcg/dL are usually associated with severe poisoning. A plain abdominal radiograph may reveal radiopaque tablets.

▶ Treatment

A. Emergency and Supportive Measures

Treat hypotension aggressively with intravenous crystalloid solutions (0.9% saline or lactated Ringer solution). Fluid losses may be massive owing to vomiting and diarrhea as well as third-spacing into injured intestine.

Perform whole bowel irrigation to remove unabsorbed pills from the intestinal tract (see p 1567). Activated charcoal is not effective but may be appropriate if other ingestants are suspected.

B. Specific Treatment

Deferoxamine is a selective iron chelator. It is not useful as an oral binding agent. For patients with established manifestations of toxicity—and particularly those with markedly elevated serum iron levels (eg, > 800–1000 mcg/dL)—administer 10–15 mg/kg/h by constant intravenous infusion; higher doses (up to 40–50 mg/kg/h) have been used in massive poisonings. Hypotension may occur. The presence of an iron-deferoxamine complex in the urine may give it a “vin rosé” appearance. Deferoxamine is safe for use in pregnant women with acute iron overdose. **Caution:** Prolonged infusion of deferoxamine (> 36–48 hours) has been associated with development of acute respiratory distress syndrome (ARDS)—the mechanism is not known.

Chang TP et al. Iron poisoning: a literature-based review of epidemiology, diagnosis, and management. *Pediatr Emerg Care.* 2011 Oct;27(10):978–85. [PMID: 21975503]

Ng HW et al. Endoscopic removal of iron bezoar following acute overdose. *Clin Toxicol (Phila).* 2008 Nov;46(9):913–5. [PMID: 18608283]

ISONIAZID

INH is an antibacterial drug used mainly in the treatment and prevention of tuberculosis. It may cause hepatitis with long-term use, especially in alcoholic patients and elderly persons. It produces acute toxic effects by competing with pyridoxal 5-phosphate, resulting in lowered brain γ -aminobutyric acid (GABA) levels. Acute ingestion of as little as 1.5–2 g of INH can cause toxicity, and severe poisoning is likely to occur after ingestion of more than 80–100 mg/kg.

▶ Clinical Findings

Confusion, slurred speech, and seizures may occur abruptly after acute overdose. Severe lactic acidosis—out of proportion to the severity of seizures—is probably due to inhibited metabolism of lactate. Peripheral neuropathy and acute hepatitis may occur with long-term use.

Diagnosis is based on a history of ingestion and the presence of severe acidosis associated with seizures. INH is not usually included in routine toxicologic screening, and serum levels are not readily available.

▶ Treatment

A. Emergency and Supportive Measures

Seizures may require higher than usual doses of benzodiazepines (eg, lorazepam, 3–5 mg intravenously) or administration of pyridoxine as an antidote (see below).

Administer activated charcoal (see p 1567) after large recent ingestion, but with caution because of the risk of abrupt onset of seizures.

B. Specific Treatment

Pyridoxine (vitamin B₆) is a specific antagonist of the acute toxic effects of INH and is usually successful in controlling convulsions that do not respond to benzodiazepines. Give 5 g intravenously over 1–2 minutes or, if the amount ingested is known, give a gram-for-gram equivalent amount of pyridoxine. Patients taking INH are usually given 25–50 mg of pyridoxine orally daily to help prevent neuropathy.

Gokhale YA et al. Isoniazid toxicity presenting as status epilepticus and severe metabolic acidosis. *J Assoc Physicians India.* 2009 Jan;57:70–1. [PMID: 19753763]

Metushi IG et al. A fresh look at the mechanism of isoniazid-induced hepatotoxicity. *Clin Pharmacol Ther.* 2011 Jun;89(6):911–4. [PMID: 21412230]

LEAD

Lead is used in a variety of industrial and commercial products, such as storage batteries, solders, paints, pottery, plumbing, and gasoline and is found in some traditional Hispanic and Ayurvedic ethnic medicines. Lead toxicity usually results from chronic repeated exposure and is rare after a single ingestion. Lead produces a variety of adverse effects on cellular function and primarily affects the nervous system, gastrointestinal tract, and hematopoietic system.

▶ Clinical Findings

Lead poisoning often goes undiagnosed initially because presenting symptoms and signs are nonspecific and exposure is not suspected. Common symptoms include colicky abdominal pain, constipation, headache, and irritability. Severe poisoning may cause coma and convulsions. Chronic intoxication can cause learning disorders (in children) and motor neuropathy (eg, wrist drop). Lead-containing bullet fragments in or near joint spaces can result in chronic lead toxicity.

Diagnosis is based on measurement of the blood lead level. Whole blood lead levels < 10 mcg/dL are usually considered nontoxic. Levels between 10 and 25 mcg/dL have been associated with impaired neurobehavioral development in children. Levels of 25–50 mcg/dL may be associated with headache, irritability, and subclinical neuropathy. Levels of 50–70 mcg/dL are associated with moderate toxicity, and levels > 70–100 mcg/dL are often associated with severe poisoning. Other laboratory findings of lead poisoning include microcytic anemia with basophilic stippling and elevated free erythrocyte protoporphyrin.

▶ Treatment

A. Emergency and Supportive Measures

For patients with encephalopathy, maintain a patent airway and treat coma and convulsions as described at the beginning of this chapter.

For recent acute ingestion, if a large lead-containing object (eg, fishing weight) is still visible in the stomach on abdominal radiograph, whole bowel irrigation (see p 1567), endoscopy, or even surgical removal may be necessary to prevent subacute lead poisoning. (The acidic gastric contents may corrode the metal surface, enhancing lead absorption. Once the object passes into the small intestine, the risk of toxicity declines.)

Conduct an investigation into the source of the lead exposure.

Workers with a single lead level > 60 mcg/dL (or three successive monthly levels > 50 mcg/dL) or construction workers with any single blood lead level > 50 mcg/dL must by federal law be removed from the site of exposure. Contact the regional office of the United States Occupational Safety and Health Administration (OSHA) for more information. Several states mandate reporting of cases of confirmed lead poisoning.

B. Specific Treatment

The indications for chelation depend on the blood lead level and the patient's clinical state. A medical toxicologist or regional poison control center (1-800-222-1222) should be consulted for advice about selection and use of these antidotes.

Note: It is impermissible under the law to treat asymptomatic workers with elevated blood lead levels in order to keep their levels < 50 mcg/dL rather than remove them from the exposure.

1. Severe toxicity—Patients with severe intoxication (encephalopathy or levels > 70–100 mcg/dL) should receive edetate calcium disodium (ethylenediaminetetraacetic acid, EDTA), 1500 mg/m²/kg/d (approximately 50 mg/kg/d) in four to six divided doses or as a continuous intravenous infusion. Most clinicians also add dimercaprol (BAL), 4–5 mg/kg intramuscularly every 4 hours for 5 days, for patients with encephalopathy.

2. Less severe toxicity—Patients with less severe symptoms and asymptomatic patients with blood lead levels between 55 and 69 mcg/dL may be treated with edetate calcium disodium alone in dosages as above. An oral chelator,

succimer (DMSA), is available for use in patients with mild to moderate intoxication. The usual dose is 10 mg/kg orally every 8 hours for 5 days, then every 12 hours for 2 weeks.

Bradberry S et al. Dimercaptosuccinic acid (succimer; DMSA) in inorganic lead poisoning. *Clin Toxicol (Phila)*. 2009 Aug; 47(7):617–31. [PMID: 19663612]

Rehani B et al. Lead poisoning from a gunshot wound. *South Med J*. 2011 Jan;104(1):57–8. [PMID: 21079537]

Saper RB et al. Lead, mercury, and arsenic in US- and Indian-manufactured Ayurvedic medicines sold via the Internet. *JAMA*. 2008 Aug 27;300(8):915–23. [PMID: 18728265]

LITHIUM

Lithium is widely used for the treatment of bipolar depression and other psychiatric disorders. The only normal route of lithium elimination is via the kidney, so patients with chronic kidney disease are at risk for accumulation of lithium resulting in gradual onset (chronic) toxicity. Intoxication resulting from chronic accidental overmedication or renal impairment is more common and usually more severe than that seen after acute oral overdose.

▶ Clinical Findings

Mild to moderate toxicity causes lethargy, confusion, tremor, ataxia, and slurred speech. This may progress to myoclonic jerking, delirium, coma, and convulsions. Recovery may be slow and incomplete following severe intoxication. Laboratory studies in patients with chronic intoxication often reveal an elevated serum creatinine and an elevated BUN/creatinine ratio due to underlying volume contraction. The white blood cell count is often elevated. ECG findings include T-wave flattening or inversion, and sometimes bradycardia or sinus node arrest. Nephrogenic diabetes insipidus can occur with overdose or with therapeutic doses. Lithium levels may be difficult to interpret. Lithium has a low toxic:therapeutic ratio and chronic intoxication can be seen with levels only slightly above the therapeutic range (0.8–1.2 mEq/L). In contrast, patients with acute ingestion may have transiently very high levels (up to 10 mEq/L reported) without any symptoms before the lithium fully distributes into tissues. **Note:** Falsely high lithium levels (as high as 6–8 mEq/L) can be measured if a green-top blood specimen tube (containing lithium heparin) is used instead of a red- or marbled-top tube.

▶ Treatment

After acute oral overdose, consider gastric lavage (see p 1567) or whole bowel irrigation (see p 1567) to prevent systemic absorption (lithium is not adsorbed by activated charcoal). In all patients, evaluate renal function and volume status, and give intravenous saline-containing fluids as needed. Monitor serum lithium levels, and seek assistance with their interpretation and the need for dialysis from a medical toxicologist or regional poison control center (1-800-222-1222). Consider hemodialysis if the patient is markedly symptomatic or if the serum level

exceeds 10 mEq/L after an acute overdose. Continuous renal replacement hemofiltration may be an effective alternative to hemodialysis.

Bailey AR et al. Comparison of intermittent haemodialysis, prolonged intermittent renal replacement therapy and continuous renal replacement haemofiltration for lithium toxicity: a case report. *Crit Care Resusc.* 2011 Jun;13(2):120–2. [PMID: 21627581]

LSD & OTHER HALLUCINOGENS

A variety of substances—ranging from naturally occurring plants and mushrooms to synthetic substances such as phencyclidine (PCP), toluene and other solvents, dextromethorphan, and lysergic acid diethylamide (LSD)—are abused for their hallucinogenic properties. The mechanism of toxicity and the clinical effects vary for each substance.

Many hallucinogenic plants and mushrooms produce anticholinergic delirium, characterized by flushed skin, dry mucous membranes, dilated pupils, tachycardia, and urinary retention. Other plants and mushrooms may contain hallucinogenic indoles such as mescaline and LSD, which typically cause marked visual hallucinations and perceptual distortion, widely dilated pupils, and mild tachycardia. PCP, a dissociative anesthetic agent similar to ketamine, can produce fluctuating delirium and coma, often associated with vertical and horizontal nystagmus. Toluene and other hydrocarbon solvents (butane, trichloroethylene, “chemo,” etc) cause euphoria and delirium and may sensitize the myocardium to the effects of catecholamines, leading to fatal dysrhythmias. Newer drugs used for their psychostimulant effects include synthetic cannabinoid receptor agonists (street names include “spice” and “K2”), *Salvia divinorum*, and mephedrone. See www.erowid.org for very thorough descriptions of a variety of hallucinogenic substances.

► Treatment

A. Emergency and Supportive Measures

Maintain a patent airway and assist respirations if necessary. Treat coma, hyperthermia, hypertension, and seizures as outlined at the beginning of this chapter. For recent large ingestions, consider giving activated charcoal orally or by gastric tube (see p 1567).

B. Specific Treatment

Patients with anticholinergic delirium may benefit from a dose of physostigmine, 0.5–1 mg intravenously, not to exceed 1 mg/min. Dysphoria, agitation, and psychosis associated with LSD or mescaline intoxication may respond to benzodiazepines (eg, lorazepam, 1–2 mg orally or intravenously) or haloperidol (2–5 mg intramuscularly or intravenously) or another antipsychotic drug (eg, olanzapine or ziprasidone). Monitor patients who have sniffed solvents for cardiac dysrhythmias (most commonly premature ventricular contractions, ventricular tachycardia, ventricular fibrillation); treatment with β -blockers such as propranolol (1–5 mg intravenously) or esmolol (250–500 mcg/kg intravenously,

then 50 mcg/kg/min by infusion) may be more effective than lidocaine or amiodarone.

Atwood BK et al. JWH018, a common constituent of ‘Spice’ herbal blends, is a potent and efficacious cannabinoid CB receptor agonist. *Br J Pharmacol.* 2010 Jun;160(3):585–93. [PMID: 20100276]

Björnstad K et al. Bioanalytical and clinical evaluation of 103 suspected cases of intoxications with psychoactive plant materials. *Clin Toxicol (Phila).* 2009 Jul;47(6):566–72. [PMID: 19586355]

Jamison SC et al. A 60-year-old woman with agitation and psychosis following ingestion of dextromethorphan and opioid analgesics. *J Psychopharmacol.* 2009 Nov;23(8):989–91. [PMID: 18583439]

MERCURY

Acute mercury poisoning usually occurs by ingestion of inorganic mercuric salts or inhalation of metallic mercury vapor. Ingestion of the mercuric salts causes a burning sensation in the throat, discoloration and edema of oral mucous membranes, abdominal pain, vomiting, bloody diarrhea, and shock. Direct nephrotoxicity causes acute kidney injury. Inhalation of high concentrations of metallic mercury vapor may cause acute fulminant chemical pneumonia. Chronic mercury poisoning causes weakness, ataxia, intention tremors, irritability, and depression. Exposure to alkyl (organic) mercury derivatives from highly contaminated fish or fungicides used on seeds has caused ataxia, tremors, convulsions, and catastrophic birth defects. Nearly all fish have some traces of mercury contamination; the US Environmental Protection Agency (EPA) advises consumers to avoid swordfish, shark, king mackerel, and tilefish because they contain higher levels. Fish that are generally low in mercury content include shrimp, canned light tuna (not albacore “white” tuna), salmon, pollock, and catfish. Dental fillings composed of mercury amalgam pose a very small risk of chronic mercury poisoning and their removal is rarely justified.

► Treatment

A. Acute Poisoning

There is no effective specific treatment for mercury vapor pneumonitis. Remove ingested mercuric salts by lavage, and administer activated charcoal (see p 1567). For acute ingestion of mercuric salts, give dimercaprol (BAL) at once, as for arsenic poisoning. Unless the patient has severe gastroenteritis, consider succimer (DMSA), 10 mg/kg orally every 8 hours for 5 days and then every 12 hours for 2 weeks. Unithiol (DMPS) is a chelator that can be given orally or parenterally, but is not commonly available in the United States. Maintain urinary output. Treat oliguria and anuria if they occur.

B. Chronic Poisoning

Remove from exposure. Neurologic toxicity is not considered reversible with chelation, although some authors recommend a trial of succimer or unithiol (contact a regional poison center or medical toxicologist for advice).

Alhamad T et al. Lessons learned from a fatal case of mercury intoxication. *Int Urol Nephrol*. 2012 Apr; 44(2):647-51 [PMID: 21234679]

Vearrier D et al. Care of patients who are worried about mercury poisoning from dental fillings. *J Am Board Fam Med*. 2010 Nov-Dec;23(6):797-8. [PMID: 21057078]

METHANOL & ETHYLENE GLYCOL

Methanol (wood alcohol) is commonly found in a variety of products, including solvents, duplicating fluids, record cleaning solutions, and paint removers. It is sometimes ingested intentionally by alcoholic patients as a substitute for ethanol and may also be found as a contaminant in bootleg whiskey. Ethylene glycol is the major constituent in most antifreeze compounds. The toxicity of both agents is caused by metabolism to highly toxic organic acids—methanol to formic acid; ethylene glycol to glycolic and oxalic acids. Diethylene glycol is a nephrotoxic solvent that has been improperly substituted for glycerine in various liquid medications (cough syrup, teething medicine, acetaminophen) causing numerous deaths in Haiti, Panama, and Nigeria.

► Clinical Findings

Shortly after ingestion of methanol or ethylene glycol, patients usually appear “drunk.” The serum osmolality (measured with the freezing point device) is usually increased, but acidosis is often absent early. After several hours, metabolism to toxic organic acids leads to a severe anion gap metabolic acidosis, tachypnea, confusion, convulsions, and coma. Methanol intoxication frequently causes visual disturbances, while ethylene glycol often produces oxalate crystalluria and acute renal failure.

► Treatment

A. Emergency and Supportive Measures

For patients presenting within 30–60 minutes after ingestion, empty the stomach by aspiration through a nasogastric tube (see p 1567). Charcoal is not very effective but should be administered if other poisons or drugs have also been ingested.

B. Specific Treatment

Patients with significant toxicity (manifested by severe metabolic acidosis, altered mental status, and markedly elevated osmol gap) should undergo hemodialysis as soon as possible to remove the parent compound and the toxic metabolites. Treatment with folic acid, thiamine, and pyridoxine may enhance the breakdown of toxic metabolites.

Ethanol blocks metabolism of the parent compounds by competing for the enzyme alcohol dehydrogenase. Fomepizole (4-methylpyrazole; Antizol) blocks alcohol dehydrogenase and is much easier to use than ethanol. If started before onset of acidosis, fomepizole may be used as the sole treatment for ethylene glycol ingestion in some cases. A regional poison control center (1-800-222-1222) should be contacted for indications and dosing.

Brent J. Fomepizole for ethylene glycol and methanol poisoning. *N Engl J Med*. 2009 May 21;360(21):2216–23. [PMID: 19458366]

Buller GK et al. When is it appropriate to treat ethylene glycol intoxication with fomepizole alone without hemodialysis? *Semin Dial*. 2011 Jul–Aug;24(4):441–2. [PMID: 21801226]

Caravati EM et al. Breath alcohol analyzer mistakes methanol poisoning for alcohol intoxication. *Ann Emerg Med*. 2010 Feb;55(2):198–200. [PMID: 19833410]

Sanaei-Zadeh H et al. Hyperglycemia is a strong prognostic factor of lethality in methanol poisoning. *J Med Toxicol*. 2011 Sep;7(3):189–94. [PMID: 21336799]

METHEMOGLOBINEMIA-INDUCING AGENTS

A large number of chemical agents are capable of oxidizing ferrous hemoglobin to its ferric state (methemoglobin), a form that cannot carry oxygen. Drugs and chemicals known to cause methemoglobinemia include benzocaine (a local anesthetic found in some topical anesthetic sprays and a variety of nonprescription products), aniline, propanil (an herbicide), nitrites, nitrogen oxide gases, nitrobenzene, dapsone, phenazopyridine (Pyridium), and many others. Dapsone has a long elimination half-life and may produce prolonged or recurrent methemoglobinemia.

► Clinical Findings

Methemoglobinemia reduces oxygen-carrying capacity and may cause dizziness, nausea, headache, dyspnea, confusion, seizures, and coma. The severity of symptoms depends on the percentage of hemoglobin oxidized to methemoglobin; severe poisoning is usually present when methemoglobin fractions are > 40–50%. Even at low levels (15–20%), victims appear cyanotic because of the “chocolate brown” color of methemoglobin, but they have normal PO_2 results on arterial blood gas determinations. Conventional pulse oximetry gives inaccurate oxygen saturation measurements; the reading is often between 85% and 90%. (A newer pulse oximetry device [Masimo Pulse CO-oximeter] is capable of estimating the methemoglobin level.) Severe metabolic acidosis may be present. Hemolysis may occur, especially in patients susceptible to oxidant stress (ie, those with glucose-6-phosphate dehydrogenase deficiency).

► Treatment

A. Emergency and Supportive Measures

Administer high-flow oxygen. If the causative agent was recently ingested, administer activated charcoal (see p 1567). Repeat-dose activated charcoal may enhance dapsone elimination (see p 1568).

B. Specific Treatment

Methylene blue enhances the conversion of methemoglobin to hemoglobin by increasing the activity of the enzyme methemoglobin reductase. For symptomatic patients, administer 1–2 mg/kg (0.1–0.2 mL/kg of 1% solution)

intravenously. The dose may be repeated once in 15–20 minutes if necessary. Patients with hereditary methemoglobin reductase deficiency or glucose-6-phosphate dehydrogenase deficiency may not respond to methylene blue treatment. In severe cases where methylene blue is not available or is not effective, exchange blood transfusion may be necessary.

Barclay J et al. Dapsone-induced methemoglobinemia: a primer for clinicians. *Ann Pharmacother*. 2011 Sep;45(9):1103–15. [PMID: 21852596]

Harvey M et al. Fatal methaemoglobinaemia induced by self-poisoning with sodium nitrite. *Emerg Med Australas*. 2010 Oct;22(5):463–5. [PMID: 21040485]

MONOAMINE OXIDASE INHIBITORS

Overdoses of MAO inhibitors (isocarboxazid, phenelzine, selegiline, moclobemide) cause ataxia, excitement, hypertension, and tachycardia, followed several hours later by hypotension, convulsions, and hyperthermia.

Ingestion of tyramine-containing foods may cause a severe hypertensive reaction in patients taking MAO inhibitors. Foods containing tyramine include aged cheese and red wines. Hypertensive reactions may also occur with any sympathomimetic drug. Severe or fatal hyperthermia (serotonin syndrome) may occur if patients receiving MAO inhibitors are given meperidine, fluoxetine, paroxetine, fluvoxamine, venlafaxine, tryptophan, dextromethorphan, tramadol, or other serotonin-enhancing drugs. This reaction can also occur with the newer selective MAO inhibitor moclobemide, and the antibiotic linezolid, which has MAO-inhibiting properties. The serotonin syndrome has also been reported in patients taking selective serotonin reuptake inhibitors (SSRIs) in large doses or in combination with other SSRIs, even in the absence of an MAO inhibitor or meperidine. It is characterized by fever, agitation, delirium, diaphoresis, hyperreflexia, and clonus (spontaneous, inducible, or ocular). Hyperthermia can be life-threatening.

▶ Treatment

Administer activated charcoal (see p 1567). Treat severe hypertension with nitroprusside, phentolamine, or other rapid-acting vasodilators (see p 1564). Treat hypotension with fluids and positioning, but avoid use of pressor agents if possible. Observe patients for at least 24 hours, since hyperthermic reactions may be delayed. Treat hyperthermia with aggressive cooling; neuromuscular paralysis may be required (see p 1565). Cyproheptadine, 4 mg orally (or by gastric tube) every hour for three or four doses, or chlorpromazine, 25 mg intravenously, has been reported to be effective against serotonin syndrome.

Sun-Edelstein C et al. Drug-induced serotonin syndrome. *Expert Opin Drug Saf*. 2008 Sep;7(5):587–96. [PMID: 18759711]

Wu ML et al. Serotonin toxicity caused by moclobemide too soon after paroxetine-selegiline. *J Chin Med Assoc*. 2009 Aug;72(8):446–9. [PMID: 19687003]

MUSHROOMS

There are thousands of mushroom species that cause a variety of toxic effects. The most dangerous species of mushrooms are *A phalloides*, *Amanita ocreata*, *Amanita verna*, *Amanita virosa*, *Gyromitra esculenta*, and the *Galerina* species, all of which contain potent cytotoxins (amatoxins). Ingestion of even a portion of one mushroom of a dangerous species may be sufficient to cause death.

The characteristic pathologic finding in fatalities from amatoxin-containing mushroom poisoning is acute massive necrosis of the liver.

▶ Clinical Findings (Table 38–9)

A. Symptoms and Signs

Amatoxin-containing mushrooms typically cause a delayed onset (8–12 hours after ingestion) of severe abdominal cramps, vomiting and profuse diarrhea, followed by hepatic necrosis, hepatic encephalopathy, and frequently acute kidney injury in 1–2 days. Cooking the mushrooms does not prevent poisoning.

Monomethylhydrazine poisoning (*Gyromitra* and *Helvella* species) is more common following ingestion of uncooked mushrooms, as the toxin is water-soluble. Vomiting, diarrhea, hepatic necrosis, convulsions, coma, and hemolysis may occur after a latent period of 8–12 hours.

The clinical effects of these and other mushrooms are described in Table 38–9.

▶ Treatment

A. Emergency Measures

After the onset of symptoms, efforts to remove the toxic agent are probably useless, especially in cases of amatoxin or gyromitrin poisoning, where there is usually a delay of 12 hours or more before symptoms occur and patients seek medical attention. However, induction of vomiting or administration of activated charcoal is recommended for any recent ingestion of an unidentified or potentially toxic mushroom (see p 1567).

B. Specific Treatment

A variety of purported antidotes (eg, thiocetic acid, penicillin, corticosteroids) have been suggested for amatoxin-type mushroom poisoning, but controlled studies are lacking and experimental data in animals are equivocal. Aggressive fluid replacement for diarrhea and intensive supportive care for hepatic failure are the mainstays of treatment. Silymarin (silibinin), a derivative of milk thistle, is commonly used in Europe but is currently only commercially available in the United States as a nutritional supplement given orally. The European intravenous product (Legalon-SIL) can be obtained in the United States under an emergency IND provided by the FDA. Contact the regional poison control center (1-800-222-1222) for more information.

Interruption of enterohepatic circulation of the amatoxin by the administration of activated charcoal or by cannulation and drainage of the bile duct may be of value

Table 38-9. Poisonous mushrooms.

Toxin	Genus	Symptoms and Signs	Onset	Treatment
Amanitin	<i>Amanita (A phalloides, A verna, A virosa)</i>	Severe gastroenteritis followed by delayed hepatic failure and acute kidney injury after 48–72 hours	6–24 hours	Supportive. Correct dehydration. Give repeated doses of activated charcoal orally. Consider intravenous silibinin (Legalon-SIL) (see text).
Muscarine	<i>Inocybe, Clitocybe</i>	Muscarinic (salivation, miosis, bradycardia, diarrhea)	30–60 minutes	Supportive. Give atropine, 0.5–2 mg intravenously, for severe cholinergic symptoms and signs.
Ibotenic acid, muscimol	<i>Amanita muscaria</i> (“fly agaric”)	Anticholinergic (mydriasis, tachycardia, hyperpyrexia, delirium)	30–60 minutes	Supportive. Give physostigmine, 0.5–2 mg intravenously, for severe anticholinergic symptoms and signs.
Coprine	<i>Coprinus</i>	Disulfiram-like effect occurs with ingestion of ethanol	30–60 minutes	Supportive. Abstain from ethanol for 3–4 days.
Monomethylhydrazine	<i>Gyromitra</i>	Gastroenteritis; occasionally seizures, hemolysis, hepatic failure, and acute kidney injury	6–12 hours	Supportive. Correct dehydration. Pyridoxine, 2.5 mg/kg intravenously, may be helpful for seizures.
Orellanine	<i>Cortinarius</i>	Nausea, vomiting; acute kidney injury after 1–3 weeks	2–14 days	Supportive.
Psilocybin	<i>Psilocybe</i>	Hallucinations	15–30 minutes	Supportive.
Gastrointestinal irritants	Many species	Nausea and vomiting, diarrhea	1/2–2 hours	Supportive. Correct dehydration.

in removing some of the toxin, based on animal studies and isolated case reports.

Liver transplant may be the only hope for survival in gravely ill patients—contact a liver transplant center early.

Garrouste C et al. *Amanita phalloides* poisoning-induced end-stage renal failure. *Clin Nephrol.* 2009 May;71(5):571–4. [PMID: 19473620]

Trabulus S et al. Clinical features and outcome of patients with amatoxin-containing mushroom poisoning. *Clin Toxicol (Phila).* 2011 Apr;49(4):303–10. [PMID: 21563906]

West PL et al. *Amanita smithiana* mushroom ingestion: a case of delayed renal failure and literature review. *J Med Toxicol.* 2009 Mar;5(1):32–8. [PMID: 19191214]

OPIATES & OPIOIDS

Prescription and illicit opiates and opioids (morphine, heroin, codeine, oxycodone, fentanyl, hydromorphone, etc) are popular drugs of misuse and abuse and the cause of frequent hospitalizations for overdose. These drugs have widely varying potencies and durations of action; for example, some of the illicit fentanyl derivatives are up to 2000 times more potent than morphine. All of these agents decrease central nervous system activity and sympathetic outflow by acting on opiate receptors in the brain. Tramadol is an analgesic that is unrelated chemically to the opioids but acts on opioid receptors. Buprenorphine is a partial agonist-antagonist opioid used for the outpatient treatment of opioid addiction.

► Clinical Findings

Mild intoxication is characterized by euphoria, drowsiness, and constricted pupils. More severe intoxication may cause

hypotension, bradycardia, hypothermia, coma, and respiratory arrest. Pulmonary edema may occur. Death is usually due to apnea or pulmonary aspiration of gastric contents. Methadone has been associated with QT interval prolongation and torsades de pointes. Tramadol, dextromethorphan, and meperidine also occasionally cause seizures. With meperidine, the metabolite normeperidine is probably the cause of seizures and is most likely to accumulate with repeated dosing in patients with chronic kidney disease. While the duration of effect for heroin is usually 3–5 hours, methadone intoxication may last for 48–72 hours or longer. Propoxyphene may cause seizures and prolongs the QRS interval; it has now been removed from the US market by the FDA. Many opioids, including fentanyl, tramadol, oxycodone, and methadone, are not detected on routine urine toxicology “opiate” screening. Wound botulism has been associated with skin-popping, especially involving “black tar” heroin. Buprenorphine added to an opioid regimen may produce acute narcotic withdrawal symptoms.

► Treatment

A. Emergency and Supportive Measures

Protect the airway and assist ventilation. Administer activated charcoal (see p 1567) for recent large ingestions.

B. Specific Treatment

Naloxone is a specific opioid antagonist that can rapidly reverse signs of narcotic intoxication. Although it is structurally related to the opioids, it has no agonist effects of its own. Administer 0.2–2 mg intravenously, and repeat as needed to awaken the patient and maintain airway protective

reflexes and spontaneous breathing. Very large doses (10–20 mg) may be required for patients intoxicated by some opioids (eg, codeine, fentanyl derivatives). **Caution:** The duration of effect of naloxone is only about 2–3 hours; repeated doses may be necessary for patients intoxicated by long-acting drugs such as methadone. Continuous observation for at least 3 hours after the last naloxone dose is mandatory.

Bohnert AS et al. Association between opioid prescribing patterns and opioid overdose-related deaths. *JAMA*. 2011 Apr 6; 305(13):1315–21. [PMID: 21467284]

Okie S. A flood of opioids, a rising tide of deaths. *N Engl J Med*. 2010 Nov 18;363(21):1981–5. [PMID: 21083382]

Taghaddosinejad F et al. Factors related to seizure in tramadol poisoning and its blood concentration. *J Med Toxicol*. 2011 Sep;7(3):183–8. [PMID: 21735309]

PESTICIDES: CHOLINESTERASE INHIBITORS

Organophosphorus and carbamate insecticides (organophosphates: parathion, malathion, etc; carbamates: carbaryl, aldicarb, etc) are widely used in commercial agriculture and home gardening and have largely replaced older, more environmentally persistent organochlorine compounds such as DDT and chlordane. The organophosphates and carbamates—also called anticholinesterases because they inhibit the enzyme acetylcholinesterase—cause an increase in acetylcholine activity at nicotinic and muscarinic receptors and in the central nervous system. There are a variety of chemical agents in this group, with widely varying potencies. Most of them are poorly water-soluble, are often formulated with an aromatic hydrocarbon solvent such as xylene, and are well absorbed through intact skin. Most chemical warfare “nerve agents” (such as GA [tabun], GB [sarin], GD [soman] and VX) are organophosphates.

► Clinical Findings

Inhibition of cholinesterase results in abdominal cramps, diarrhea, vomiting, excessive salivation, sweating, lacrimation, miosis (constricted pupils), wheezing and bronchospasm, seizures, and skeletal muscle weakness. Initial tachycardia is usually followed by bradycardia. Profound skeletal muscle weakness, aggravated by excessive bronchial secretions and wheezing, may result in respiratory arrest and death. Symptoms and signs of poisoning may persist or recur over several days, especially with highly lipid-soluble agents such as fenthion or dimethoate.

The diagnosis should be suspected in patients who present with miosis, sweating, and hyperperistalsis. Serum and red blood cell cholinesterase activity is usually depressed at least 50% below baseline in those victims who have severe intoxication.

► Treatment

A. Emergency and Supportive Measures

If the agent was recently ingested, consider gut decontamination by aspiration of the liquid using a nasogastric tube

followed by administration of activated charcoal (see p 1567). If the agent is on the victim's skin or hair, wash repeatedly with soap or shampoo and water. Providers should take care to avoid skin exposure by wearing gloves and waterproof aprons. Dilute hypochlorite solution (eg, household bleach diluted 1:10) is reported to help break down organophosphate pesticides and nerve agents on equipment or clothing.

B. Specific Treatment

Atropine reverses excessive muscarinic stimulation and is effective for treatment of salivation, bronchial hypersecretion, wheezing, abdominal cramping, and sweating. However, it does not interact with nicotinic receptors at autonomic ganglia and at the neuromuscular junction and has no direct effect on muscle weakness. Administer 2 mg intravenously, and if there is no response after 5 minutes, give repeated boluses in rapidly escalating doses (eg, doubling the dose each time) as needed to dry bronchial secretions and decrease wheezing; as much as several hundred milligrams of atropine has been given to treat severe poisoning.

Pralidoxime (2-PAM, Protopam) is a specific antidote that reverses organophosphate binding to the cholinesterase enzyme; therefore, it should be effective at the neuromuscular junction as well as other nicotinic and muscarinic sites. It is most likely to be clinically effective if started very soon after poisoning, to prevent permanent binding of the organophosphate to cholinesterase. However, clinical studies have yielded conflicting results regarding the effectiveness of pralidoxime in reducing mortality. Administer 1–2 g intravenously as a loading dose, and begin a continuous infusion (200–500 mg/h, titrated to clinical response). Continue to give pralidoxime as long as there is any evidence of acetylcholine excess. Pralidoxime is of questionable benefit for carbamate poisoning, because carbamates have only a transitory effect on the cholinesterase enzyme. Other, unproven therapies for organophosphate poisoning include magnesium, sodium bicarbonate, clonidine, and extracorporeal removal.

Blain PG. Organophosphorus poisoning (acute). *Clin Evid* (Online). 2011 May 17;2011. pii2102. [PMID: 21575287]

Peter JV et al. Clinical profile and outcome of patients hospitalized with dimethyl and diethyl organophosphate poisoning. *Clin Toxicol* (Phila). 2010 Nov;48(9):916–23. [PMID: 21171848]

Thiermann H et al. Atropine maintenance dosage in patients with severe organophosphate pesticide poisoning. *Toxicol Lett*. 2011 Sep 25;206(1):77–83. [PMID: 21771644]

PETROLEUM DISTILLATES & SOLVENTS

Petroleum distillate toxicity may occur from inhalation of the vapor or as a result of pulmonary aspiration of the liquid during or after ingestion. Acute manifestations of aspiration pneumonitis are vomiting, coughing, and bronchopneumonia. Some hydrocarbons—ie, those with aromatic or halogenated subunits—can also cause severe systemic poisoning after oral ingestion. Hydrocarbons can also cause systemic intoxication by inhalation. Vertigo,

muscular incoordination, irregular pulse, myoclonus, and seizures occur with serious poisoning and may be due to hypoxemia or the systemic effects of the agents. Chlorinated and fluorinated hydrocarbons (trichloroethylene, Freons, etc) and many other hydrocarbons can cause ventricular arrhythmias due to increased sensitivity of the myocardium to the effects of endogenous catecholamines.

► Treatment

Remove the patient to fresh air. For simple aliphatic hydrocarbon ingestion, gastric emptying and activated charcoal are not recommended, but these procedures may be indicated if the preparation contains toxic solutes (eg, an insecticide) or is an aromatic or halogenated product. Observe the victim for 6–8 hours for signs of aspiration pneumonitis (cough, localized crackles or rhonchi, tachypnea, and infiltrates on chest radiograph). Corticosteroids are not recommended. If fever occurs, give a specific antibiotic only after identification of bacterial pathogens by laboratory studies. Because of the risk of arrhythmias, use bronchodilators with caution in patients with chlorinated or fluorinated solvent intoxication. If tachyarrhythmias occur, use esmolol intravenously 25–100 mcg/kg/min.

Amiri AH et al. Clinical finding and outcome in suicidal attempt due to intravenous injection of kerosene. *Pak J Biol Sci.* 2009 Mar 1;12(5):439–42. [PMID: 19579984]

Argo A et al. A fatal case of a paint thinner ingestion: comparison between toxicological and histological findings. *Am J Forensic Med Pathol.* 2010 June;31(2):186–91. [PMID: 20010286]

QUINIDINE & RELATED ANTIARRHYTHMICS

Quinidine, procainamide, and disopyramide are class Ia antiarrhythmic agents, and flecainide and propafenone are class Ic agents. These drugs have membrane-depressant effects on the sodium-dependent channel responsible for cardiac cell depolarization. Manifestations of cardiotoxicity include arrhythmias, syncope, hypotension, and widening of the QRS complex on the ECG (> 100–120 ms). With type Ia drugs, a lengthened QT interval and atypical or polymorphous ventricular tachycardia (torsades de pointes) may occur. The antimalarials chloroquine and hydroxychloroquine, and the tricyclic antidepressants, have similar cardiotoxic effects in overdose.

► Treatment

A. Emergency and Supportive Measures

Administer activated charcoal (see p 1567); consider gastric lavage (see p 1567) after large recent overdose. Assist ventilation if needed. Perform continuous cardiac monitoring.

B. Specific Treatment

Treat cardiotoxicity (hypotension, QRS interval widening) with intravenous boluses of sodium bicarbonate, 50–100 mEq. Torsades de pointes may be treated with intravenous magnesium or overdrive pacing.

Gunja N et al. Survival after massive hydroxychloroquine overdose. *Anaesth Intensive Care.* 2009 Jan;37(1):130–3. [PMID: 19157361]

SALICYLATES

Salicylates (aspirin, methyl salicylate, etc) are found in a variety of over-the-counter and prescription medications. Salicylates uncouple cellular oxidative phosphorylation, resulting in anaerobic metabolism and excessive production of lactic acid and heat, and they also interfere with several Krebs cycle enzymes. A single ingestion of more than 200 mg/kg of salicylate is likely to produce significant acute intoxication. Poisoning may also occur as a result of chronic excessive dosing over several days. Although the half-life of salicylate is 2–3 hours after small doses, it may increase to 20 hours or more in patients with intoxication.

► Clinical Findings

Acute ingestion often causes nausea and vomiting, occasionally with gastritis. Moderate intoxication is characterized by hyperpnea (deep and rapid breathing), tachycardia, tinnitus, and elevated anion gap metabolic acidosis. Serious intoxication may result in agitation, confusion, coma, seizures, cardiovascular collapse, pulmonary edema, hyperthermia, and death. The prothrombin time is often elevated owing to salicylate-induced hypoprothrombinemia. Central nervous system intracellular glucose depletion can occur despite normal measured serum glucose levels.

Diagnosis of salicylate poisoning is suspected in any patient with metabolic acidosis and is confirmed by measuring the serum salicylate level. Patients with levels > 100 mg/dL (1000 mg/L or 7.2 mmol/L) after an acute overdose are more likely to have severe poisoning. On the other hand, patients with subacute or chronic intoxication may suffer severe symptoms with levels of only 60–70 mg/dL (4.3–5 mmol/L). The arterial blood gas typically reveals a respiratory alkalosis with an underlying metabolic acidosis.

► Treatment

A. Emergency and Supportive Measures

Administer activated charcoal orally (see p 1567). Gastric lavage followed by administration of extra doses of activated charcoal may be needed in patients who ingest more than 10 g of aspirin (see p 1567). The desired ratio of charcoal to aspirin is about 10:1 by weight; while this cannot always be given as a single dose, it may be administered over the first 24 hours in divided doses every 2–4 hours along with whole bowel irrigation (see p 1567). Give glucose-containing fluids to reduce the risk of cerebral hypoglycemia. Treat metabolic acidosis with intravenous sodium bicarbonate. This is critical because acidosis (especially acidemia, pH < 7.40) promotes greater entry of salicylate into cells, worsening toxicity. **Warning:** Sudden and severe deterioration can occur after rapid sequence intubation and controlled ventilation if the pH is allowed to fall during the apneic period.

B. Specific Treatment

Alkalinization of the urine enhances renal salicylate excretion by trapping the salicylate anion in the urine. Add 100 mEq (two ampules) of sodium bicarbonate to 1 L of 5% dextrose in 0.2% saline, and infuse this solution intravenously at a rate of about 150–200 mL/h. Unless the patient is oliguric or hyperkalemic, add 20–30 mEq of potassium chloride to each liter of intravenous fluid. Patients who are volume-depleted often fail to produce an alkaline urine (paradoxical aciduria) unless potassium is given.

Hemodialysis may be lifesaving and is indicated for patients with severe metabolic acidosis, markedly altered mental status, or significantly elevated salicylate levels (eg, > 100–120 mg/dL [1000–1200 mg/L or 7.2–8.6 mmol/L] after acute overdose or > 60–70 mg/dL [600–700 mg/L or 4.3–5 mmol/L] with subacute or chronic intoxication).

Herres J et al. Delayed salicylate toxicity with undetectable initial levels after large-dose aspirin ingestion. *Am J Emerg Med.* 2009 Nov;27(9):1173.e1–3. [PMID: 19931787]

Jacob J et al. Falsely normal anion gap in severe salicylate poisoning caused by laboratory interference. *Ann Emerg Med.* 2011 Sep;58(3):280–1. [PMID: 21492961]

Minns AB et al. Death due to acute salicylate intoxication despite dialysis. *J Emerg Med.* 2011 May;40(5):515–7. [PMID: 20347249]

SEAFOOD POISONINGS

A variety of intoxications may occur after eating certain types of fish or other seafood. These include scombroid, ciguatera, paralytic shellfish, and puffer fish poisoning. The mechanisms of toxicity and clinical presentations are described in Table 38–10. In the majority of cases, the seafood has a normal appearance and taste (scombroid may have a peppery taste).

► Treatment

A. Emergency and Supportive Measures

Caution: Abrupt respiratory arrest may occur in patients with acute paralytic shellfish and puffer fish poisoning. Observe patients for at least 4–6 hours. Replace fluid and electrolyte losses from gastroenteritis with intravenous saline or other crystalloid solution.

For recent ingestions, it may be possible to adsorb residual toxin in the gut with activated charcoal, 50–60 g orally (see p 1567).

B. Specific Treatment

There is no specific antidote for paralytic shellfish or puffer fish poisoning.

1. Ciguatera—There are anecdotal reports of successful treatment of acute neurologic symptoms with mannitol, 1 g/kg intravenously, but this approach is not widely accepted.

2. Scombroid—Antihistamines such as diphenhydramine, 25–50 mg intravenously, and the H₂-blocker cimetidine, 300 mg intravenously, are usually effective. For severe reactions, give also epinephrine, 0.3–0.5 mL of a 1:1000 solution subcutaneously.

Hungerford JM. Scombroid poisoning: a review. *Toxicol.* 2010 Aug 15;56(2):231–43. [PMID: 20152850]

Stewart I et al. Emerging tropical diseases in Australia. Part 2. Ciguatera fish poisoning. *Ann Trop Med Parasitol.* 2010 Oct;104(7):557–71. [PMID: 21092393]

SEAFOOD POISONINGS

The venom of poisonous snakes and lizards may be predominantly neurotoxic (coral snake) or predominantly cytolytic (rattlesnakes, other pit vipers). Neurotoxins

Table 38–10. Common seafood poisonings.

Type of Poisoning	Mechanism	Clinical Presentation
Ciguatera	Reef fish ingest toxic dinoflagellates, whose toxins accumulate in fish meat. Commonly implicated fish in the United States are barracuda, jack, snapper, and grouper.	1–6 hours after ingestion, victims develop abdominal pain, vomiting, and diarrhea accompanied by a variety of neurologic symptoms, including paresthesias, reversal of hot and cold sensation, vertigo, headache, and intense itching. Autonomic disturbances, including hypotension and bradycardia, may occur.
Scombroid	Improper preservation of large fish results in bacterial degradation of histidine to histamine. Commonly implicated fish include tuna, mahimahi, bonita, mackerel, and kingfish.	Allergic-like (anaphylactoid) symptoms are due to histamine, usually begin within 15–90 minutes, and include skin flushing, itching, urticaria, angioedema, bronchospasm, and hypotension as well as abdominal pain, vomiting, and diarrhea.
Paralytic shellfish poisoning	Dinoflagellates produce saxitoxin, which is concentrated by filter-feeding mussels and clams. Saxitoxin blocks sodium conductance and neuronal transmission in skeletal muscles.	Onset is usually within 30–60 minutes. Initial symptoms include perioral and intraoral paresthesias. Other symptoms include nausea and vomiting, headache, dizziness, dysphagia, dysarthria, ataxia, and rapidly progressive muscle weakness that may result in respiratory arrest.
Puffer fish poisoning	Tetrodotoxin is concentrated in liver, gonads, intestine, and skin. Toxic effects are similar to those of saxitoxin. Tetrodotoxin is also found in some North American newts and Central American frogs.	Onset is usually within 30–40 minutes but may be as short as 10 minutes. Initial perioral paresthesias are followed by headache, diaphoresis, nausea, vomiting, ataxia, and rapidly progressive muscle weakness that may result in respiratory arrest.

cause respiratory paralysis; cytolytic venoms cause tissue destruction by digestion and hemorrhage due to hemolysis and destruction of the endothelial lining of the blood vessels. The manifestations of rattlesnake envenomation are mostly local pain, redness, swelling, and extravasation of blood. Perioral tingling, metallic taste, nausea and vomiting, hypotension, and coagulopathy may also occur. Thrombocytopenia can persist for several days after a rattlesnake bite. Neurotoxic envenomation may cause ptosis, dysphagia, diplopia, and respiratory arrest.

▶ Treatment

A. Emergency Measures

Immobilize the patient and the bitten part in a neutral position. Avoid manipulation of the bitten area. Transport the patient to a medical facility for definitive treatment. Do *not* give alcoholic beverages or stimulants; do *not* apply ice; do *not* apply a tourniquet. The potential trauma to underlying tissues resulting from incision and suction performed by unskilled people is probably not justified in view of the small amount of venom that can be recovered.

B. Specific Antidote and General Measures

1. Pit viper (eg, rattlesnake) envenomation—For local signs such as swelling, pain, and ecchymosis but no systemic symptoms, give 4–6 vials of crotalid antivenin (CroFab) by slow intravenous drip in 250–500 mL saline. Repeated doses of 2 vials every 6 hours for up to 18 hours has been recommended. For more serious envenomation with marked local effects and systemic toxicity (eg, hypotension, coagulopathy), higher doses and additional vials may be required. Monitor vital signs and the blood coagulation profile. Type and cross-match blood. The adequacy of venom neutralization is indicated by improvement in symptoms and signs, and the rate that swelling slows. Prophylactic antibiotics are not indicated after a rattlesnake bite.

2. Elapid (coral snake) envenomation—Give 1–2 vials of specific antivenom as soon as possible. To locate antisera for exotic snakes, call a regional poison control center (1-800-222-1222).

Cruz LS et al. Snakebite envenomation and death in the developing world. *Ethn Dis*. 2009 Spring;19(1 Suppl 1):S1–42–6. [PMID: 19484874]

Lavonas EJ et al. Crotaline Fab antivenom appears to be effective in cases of severe North American pit viper envenomation: an integrative review. *BMC Emerg Med*. 2009 Jun 22;9:13. [PMID: 19545426]

Lavonas EJ et al; Rocky Mountain Poison and Drug Center, Denver Health and Hospital Authority. Unified treatment algorithm for the management of crotaline snakebite in the United States: results of an evidence-informed consensus workshop. *BMC Emerg Med*. 2011 Feb 3;11:2. [PMID: 21291549]

SPIDER BITES & SCORPION STINGS

The toxin of most species of spiders in the United States causes only local pain, redness, and swelling. That of the more venomous black widow spiders (*Latrodectus mactans*)

causes generalized muscular pains, muscle spasms, and rigidity. The brown recluse spider (*Loxosceles reclusa*) causes progressive local necrosis as well as hemolytic reactions (rare).

Stings by most scorpions in the United States cause only local pain. Stings by the more toxic *Centruroides* species (found in the southwestern United States) may cause muscle cramps, twitching and jerking, and occasionally hypertension, convulsions, and pulmonary edema. Stings by scorpions from other parts of the world are not discussed here.

▶ Treatment

A. Black Widow Spider Bites

Pain may be relieved with parenteral opioids or muscle relaxants (eg, methocarbamol, 15 mg/kg). Calcium gluconate 10%, 0.1–0.2 mL/kg intravenously, may transiently relieve muscle rigidity, though its effectiveness is unproven. *Latrodectus* antivenom is very effective, but because of concerns about acute hypersensitivity reactions (horse serum-derived), it is often reserved for very young or elderly patients or those who do not respond promptly to the above measures. Horse serum sensitivity testing is required. (Instruction and testing materials are included in the antivenin kit.)

B. Brown Recluse Spider Bites

Because bites occasionally progress to extensive local necrosis, some authorities recommend early excision of the bite site, whereas others use oral corticosteroids. Anecdotal reports have claimed success with dapsone and colchicine. All of these treatments remain of unproved value.

C. Scorpion Stings

No specific treatment other than analgesics is required for envenomations by most scorpions found in the United States. For *Centruroides* stings, a specific antivenom developed in Arizona was proved effective and was granted FDA approval in 2011.

Bawaskar HS et al. Efficacy and safety of scorpion antivenom plus prazosin compared with prazosin alone for venomous scorpion (*Mesobuthus tamulus*) sting: randomised open label clinical trial. *BMJ*. 2011 Jan 5;342:c7136. [PMID: 21209062]

Boyer LV et al. Antivenom for critically ill children with neurotoxicity from scorpion stings. *N Engl J Med*. 2009 May 14;360(20):2090–8. [PMID: 19439743]

Khattabi A et al; Scorpion Consensus Expert Group. Classification of clinical consequences of scorpion stings: consensus development. *Trans R Soc Trop Med Hyg*. 2011 Jul;105(7):364–9. [PMID: 21601228]

Isbister GK et al. Spider bite. *Lancet*. 2011 Dec 10;378(9808):2039–s47. [PMID: 21762981]

Tuuri RE et al. Scorpion envenomation and antivenom therapy. *Pediatr Emerg Care*. 2011 Jul;27(7):667–72. [PMID: 21730810]

THEOPHYLLINE & CAFFEINE

Theophylline may cause intoxication after an acute single overdose, or intoxication may occur as a result of chronic

accidental repeated overmedication or reduced elimination resulting from hepatic dysfunction or interacting drug (eg, cimetidine, erythromycin). The usual serum half-life of theophylline is 4–6 hours, but this may increase to more than 20 hours after overdose. Caffeine and caffeine-containing herbal products can produce similar toxicity.

► Clinical Findings

Mild intoxication causes nausea, vomiting, tachycardia, and tremulousness. Severe intoxication is characterized by ventricular and supraventricular tachyarrhythmias, hypotension, and seizures. Status epilepticus is common and often intractable to the usual anticonvulsants. After acute overdose (but not chronic intoxication), hypokalemia, hyperglycemia, and metabolic acidosis are common. Seizures and other manifestations of toxicity may be delayed for several hours after acute ingestion, especially if a sustained-release preparation such as Theo-Dur was taken.

Diagnosis is based on measurement of the serum theophylline concentration. Seizures and hypotension are likely to develop in acute overdose patients with serum levels > 100 mg/L (555 μmol/L). Serious toxicity may develop at lower levels (ie, 40–60 mg/L [222–333 μmol/L]) in patients with chronic intoxication.

► Treatment

A. Emergency and Supportive Measures

After acute ingestion, administer activated charcoal (see p 1567). Repeated doses of activated charcoal may enhance theophylline elimination by “gut dialysis.” Addition of whole bowel irrigation should be considered for large ingestions involving sustained-release preparations (see p 1567).

Hemodialysis is effective in removing theophylline and is indicated for patients with status epilepticus or markedly elevated serum theophylline levels (eg, > 100 mg/L [555 μmol/L] after acute overdose or > 60 mg/L [333 μmol/L] with chronic intoxication).

B. Specific Treatment

Treat seizures with benzodiazepines (lorazepam, 2–3 mg intravenously, or diazepam, 5–10 mg intravenously) or phenobarbital (10–15 mg/kg intravenously). Phenytoin is not effective. Hypotension and tachycardia—which are mediated through excessive β-adrenergic stimulation—may respond to β-blocker therapy even in low doses. Administer esmolol, 25–50 mcg/kg/min by intravenous infusion, or propranolol, 0.5–1 mg intravenously.

Rudolph T et al. A case of fatal caffeine poisoning. *Acta Anaesthesiol Scand*. 2010 Apr;54(4):521–3. [PMID: 20096021]
 Trabulo D et al. Caffeinated energy drink intoxication. *Emerg Med J*. 2011 Aug;28(8):712–4. [PMID: 21788240]

TRICYCLIC & OTHER ANTIDEPRESSANTS

Tricyclic and related cyclic antidepressants are among the most dangerous drugs involved in suicidal overdose. These


drugs have anticholinergic and cardiac depressant properties (“quinidine-like” sodium channel blockade). Tricyclic antidepressants produce more marked membrane-depressant cardiotoxic effects than the phenothiazines.

Newer antidepressants such as trazodone, fluoxetine, citalopram, paroxetine, sertraline, bupropion, venlafaxine, and fluvoxamine are not chemically related to the tricyclic antidepressant agents and do not generally produce quinidine-like cardiotoxic effects. However, they may cause seizures in overdoses and they may cause serotonin syndrome (see Monoamine Oxidase Inhibitors section).

► Clinical Findings

Signs of severe intoxication may occur abruptly and without warning within 30–60 minutes after acute tricyclic overdose. Anticholinergic effects include dilated pupils, tachycardia, dry mouth, flushed skin, muscle twitching, and decreased peristalsis. Quinidine-like cardiotoxic effects include QRS interval widening (> 0.12 s; Figure 38–2), ventricular arrhythmias, AV block, and hypotension. Rightward-axis deviation of the terminal 40 ms of the QRS has also been described. Prolongation of the QT interval and torsades de pointes have been reported with several of the newer antidepressants. Seizures and coma are common with severe intoxication. Life-threatening hyperthermia may result from status epilepticus and anticholinergic-induced impairment of sweating. Among newer agents, bupropion and venlafaxine have been associated with a greater risk of seizures.

The diagnosis should be suspected in any overdose patient with anticholinergic side effects, especially if there is widening of the QRS interval or seizures. For



▲ **Figure 38-2.** Cardiac arrhythmias resulting from tricyclic antidepressant overdose. **A:** Delayed intraventricular conduction results in prolonged QRS interval (0.18 s). **B** and **C:** Supraventricular tachycardia with progressive widening of QRS complexes mimics ventricular tachycardia. (Reproduced, with permission, from Benowitz NL, Goldschlager N. Cardiac disturbances in the toxicologic patient. In: Haddad LM, Winchester JF [editors], *Clinical Management of Poisoning and Drug Overdose*, 3rd edition. Saunders/Elsevier, 1998.)

intoxication by most tricyclic antidepressants, the QRS interval correlates with the severity of intoxication more reliably than the serum drug level.

Serotonin syndrome should be suspected if agitation, delirium, diaphoresis, tremor, hyperreflexia, clonus (spontaneous, inducible, or ocular), and fever develop in a patient taking serotonin reuptake inhibitors.

► Treatment

A. Emergency and Supportive Measures

Observe patients for at least 6 hours, and admit all patients with evidence of anticholinergic effects (eg, delirium, dilated pupils, tachycardia) or signs of cardiotoxicity (see above).

Administer activated charcoal (see p 1567) and consider gastric lavage (see p 1567) after recent large ingestions. All of these drugs are highly tissue-bound and are not effectively removed by hemodialysis procedures.

B. Specific Treatment

Cardiotoxic sodium channel-depressant effects of tricyclic antidepressants may respond to boluses of sodium bicarbonate (50–100 mEq intravenously). Sodium bicarbonate provides a large sodium load that alleviates depression of the sodium-dependent channel. Reversal of acidosis may

also have beneficial effects at this site. Maintain the pH between 7.45 and 7.50. Alkalinization does not promote excretion of tricyclic antidepressants. Prolongation of the QT interval or torsades de pointes is usually treated with intravenous magnesium or overdrive pacing. Severe cardiotoxicity in patients with overdoses of lipid-soluble drugs (eg, amitriptyline, bupropion) has responded to intravenous lipid emulsion (Intralipid).

Mild serotonin syndrome may be treated with benzodiazepines and withdrawal of the antidepressant. Moderate cases may respond to cyproheptadine (4 mg orally or via gastric tube hourly for three or four doses) or chlorpromazine (25 mg intravenously). Severe hyperthermia should be treated with neuromuscular paralysis and endotracheal intubation in addition to external cooling measures.

Body R et al. Guidelines in Emergency Medicine Network (GEMNet): guideline for the management of tricyclic antidepressant overdose. *Emerg Med J*. 2011 Apr;28(4):347–68. [PMID: 21436332]

Boegevig S et al. Successful reversal of life threatening cardiac effect following dosulepin overdose using intravenous lipid emulsion. *Clin Toxicol (Phila)*. 2011 Apr;49(4):337–9. [PMID: 21563912]

Engels PT et al. Intravenous fat emulsion to reverse haemodynamic instability from intentional amitriptyline overdose. *Resuscitation*. 2010 Aug;81(8):1037–9. [PMID: 20605670]

Cancer

Patricia A. Cornett, MD
Tiffany O. Dea, PharmD

39

The major features of this chapter are the clinical aspects of cancer, including etiology and prevention; staging; diagnosis and treatment of common cancers; and recognition and management of complications from cancer. Additional information may be obtained from the National Cancer Institute (NCI) website at www.cancer.gov/cancer topics, the American Society of Clinical Oncology website at www.asco.org, and the National Comprehensive Cancer Network (NCCN) website at www.nccn.org. The NCCN website provides detailed, evidence-based recommendations for management of specific cancers as well as guidelines for cancer screening and for supportive care. General reviews in oncology can be obtained from Medscape Hematology/Oncology (www.medscape.com).

► Etiology

Cancer is the second most common cause of death in the United States. In 2011 an estimated 1,596,670 cases of cancer were diagnosed, and 571,950 persons died as a result of cancer. Based on cancer rates determined in 2003–2005, more than 40% of people born today will have cancer diagnosed at some point in their lifetime. Table 39–1 lists the 10 leading cancer types in men and women by site.

However, the incidence of cancer in both men and women is decreasing. In 2008, the American Cancer Society, NCI, and the Centers for Disease Control and Prevention reported that the incidence of all cancers for both sexes decreased 0.8% per year from 1999 through 2005. As the incidence of cancer is decreasing, the survival rate is increasing. In 2010, using information from the Surveillance Epidemiology and End Results (SEER) database, the NCI reported a survival rate of 68% for individuals in whom cancer was diagnosed between 1999 and 2006 compared to 50% for those in whom cancer was diagnosed between 1975 and 1977.

Reductions in cancer incidence and mortality reflect a successful implementation of a broad strategy of prevention, detection, and treatment.

► Modifiable Risk Factors

Tobacco is the most common preventable cause of cancer death; it is estimated that at least 30% of all cancer deaths

in the United States are directly linked to tobacco. A total of 171,000 cancer deaths in the United States and 1.42 million cancer deaths worldwide can be directly attributed to tobacco abuse. Clear evidence links at least 15 cancers to tobacco use. The most dramatic link is with lung cancer, the most common non-dermatologic malignancy; 87% of lung cancer cases occur in smokers. Any strategy for cancer control must include the goal of markedly reducing if not eliminating tobacco use.

Strategies for tobacco control should involve a focus on the individual as well as society as a whole. Tobacco cessation directed toward the individual should start with the clinician providing counseling. Simple, concise advice from a clinician can yield cessation rates of 10–20%. Additive strategies include more intensive counseling; nicotine replacement therapy with patches, gum, or lozenges; and prescription medication with bupropion or varenicline. Perhaps a more intriguing phenomenon, with potential for significant impact on cessation rates, is the influence of social contact behavior on an individual smoker's abstinence decision. For instance, analysis of the Framingham Heart Study demonstrated that smoking cessation by a spouse resulted in a 67% decrease in the subject's likelihood of continuing to smoke, and smoking cessation by a friend resulted in a 36% decrease in the subject's likelihood of smoking.

On a societal level, many initiatives have been put into place to actively discourage tobacco use. State or local laws regulating tobacco use in restaurants, the workplace, and other public places have resulted in declines in tobacco use. Countermarketing with aggressive anti-tobacco advertisements has also contributed to tobacco cessation and abstinence. The key recipients of these messages are children; 80% of smokers will start by age 18. Preventing the start of addiction in this vulnerable population should be a top priority (see Chapter 1).

There are encouraging signs of success with tobacco control. The prevalence of smoking for United States adults based on the 2011 National Health Interview Survey is 19.4%, which is a remarkable reduction from the 1955 peak of 57% for males and the 1965 peak of 34% for females but still falls short of the Healthy People 2010 goal of < 12%. See Chapter 1 for additional material on smoking cessation techniques.

Table 39-1. Estimated 10 most common cancer cases in the United States in males and females (all races).

Rank	Males	Females
	Total Cases = 822,300 (percent)	Total Cases = 774,370 (percent)
1	Prostate (29)	Breast (30)
2	Lung and bronchus (14)	Lung and bronchus (14)
3	Colon and rectum (9)	Colon and rectum (9)
4	Urinary bladder (6)	Uterine corpus (6)
5	Lymphoma (5)	Thyroid (5)
6	Melanoma (5)	Lymphoma (4)
7	Kidney and renal pelvis (5)	Melanoma (4)
8	Oral cavity and pharynx (3)	Kidney and renal pelvis (3)
9	Leukemia (3)	Ovary (3)
10	Pancreas (3)	Pancreas (3)
	Other sites (18)	Other sites (19)

Data from the American Cancer Society, 2011.

For those Americans who do not use tobacco, the most modifiable risk factors would be nutrition and physical activity. Epidemiologic studies suggest that fruit- and vegetable-rich diets lower risks of several gastrointestinal malignancies, including esophageal, stomach, and colon cancers. Excessive consumption of alcohol is linked to increased risks of head and neck cancers as well as cancers of the esophagus and liver. Lastly, being overweight is linked to several malignancies, including breast and uterine cancers in women and colorectal, esophageal, and kidney cancers in both men and women. More importantly, weight reduction can decrease the risks of these cancers.

Another modifiable risk factor is radiation from radiographic studies. A 2009 study reported that the use of computed tomography (CT) in diagnostic algorithms exposes individuals to significant radiation doses that may increase the lifetime risk of developing cancer. Both standardization of CT radiation doses and limiting testing will be important steps in minimizing this risk.

Smith-Bindman R et al. Radiation dose associated with common computed tomography examinations and the associated lifetime attributable risk of cancer. *Arch Intern Med.* 2009 Dec 14;169(22):2078–86. [PMID: 20008690]

► Staging

The most commonly used staging system at the time of diagnosis is the TNM (Tumor, Nodes, Metastasis) system (see www.cancerstaging.org). Rules for staging for individual cancers are established and published by the American

Joint Committee on Cancer (AJCC). Elements used for staging include tumor location, size and level of tumor invasion (T), absence or presence and extent of nodal metastases (N), and presence or absence of systemic metastases (M). Once the TNM designations have been determined, an overall stage is assigned, stage I, II, III, or IV. Clinical staging utilizes physical examination, laboratory and imaging tests as well as results from biopsies; pathologic staging relies on the results from surgery. In some instances, other classifications may be used for certain cancers such as the Ann Arbor staging system for lymphomas.

Other characteristics of cancers, not reflected in the TNM stage, may be used as another indicator of prognosis. Pathologic features seen on routine histologic examination for some cancers are very important; examples include the Gleason score for prostate cancer and the grade of sarcomas. Cancer specimens may also be sent for targeted molecular diagnostic testing; results are used to determine prognosis as well as treatment. Examples include testing for *HER-2/neu* in breast and gastric cancers, *KRAS* and *BRAF* mutations in colorectal cancers, and *EGFR* and *KRAS* mutations in lung cancer. In the future, as the pathways for oncogenesis and relationships of mutations to treatment and prognosis are better delineated, analysis for detection of chromosomal alterations and oncogene products will continue to be increasingly incorporated into routine practice.

THE PARANEOPLASTIC SYNDROMES

The clinical manifestations of cancer are usually due to pressure effects of local tumor growth, infiltration or metastatic deposition of tumor cells in a variety of organs in the body, or certain systemic symptoms. General problems observed in many patients with advanced or widespread metastatic cancer include anorexia, malaise, weight loss, and sometimes fever. These characteristics must be considered when evaluating a patient with an undiagnosed illness. Except in the case of functioning tumors such as those of the endocrine glands, systemic symptoms of cancer usually are not specific, often consisting of weakness, anorexia, and weight loss. The term “paraneoplastic” refers to features of disease considered to be due to the remote effects of a cancer. These features cannot be attributed either to a cancer’s direct invasive or metastatic properties and are often considered to be due to aberrant hormonal or metabolic effects not observed in a cancer’s normal tissue equivalent. In the paraneoplastic syndromes, clinical findings may resemble those of primary endocrine, metabolic, hematologic, or neuromuscular disorders. At present, the mechanisms for such remote effects can be classified into three groups: (1) effects initiated by a tumor product (eg, carcinoid syndrome, ectopic hormone production), (2) effects of destruction of normal tissues by tumor (eg, hypercalcemia with osteolytic skeletal metastases), and (3) effects due to unknown mechanisms. In paraneoplastic syndromes associated with ectopic hormone production, tumor tissue itself secretes the hormone that produces the syndrome. Ectopic hormones secreted by neoplasms are often pro-hormones of higher molecular weight than those

secreted by the more differentiated normal endocrine cell. Such ectopic hormone production by cancer cells is believed to result from activation of genes in the malignant cells that are suppressed in the normal tissue equivalent and in most somatic cells. Autocrine growth factors secreted by neoplastic cells may also result in paraneoplastic syndromes. Small cell lung cancer is the one type of cancer most likely to be associated with paraneoplastic syndromes.

The paraneoplastic syndromes are clinically important for the following reasons:

(1) They sometimes accompany relatively limited neoplastic growth and may provide the clinician with an early clue to the presence of certain types of cancer.

(2) The metabolic or toxic effects of the syndrome may constitute a more urgent hazard to the patient's life than the underlying cancer (eg, hypercalcemia, hyponatremia).

(3) Effective treatment of the tumor should be accompanied by resolution of the paraneoplastic syndrome and, conversely, recurrence of the cancer may be heralded by return of the systemic symptoms. In some instances, rapid response to cytotoxic chemotherapy may briefly increase the severity of the paraneoplastic syndrome in association with tumor lysis (eg, hyponatremia with inappropriate antidiuretic hormone excretion). In some instances the identical symptom complex (eg, hypercalcemia) may be induced by entirely different mechanisms. A single syndrome such as hypercalcemia may be due to any one of a variety of humoral factors, such as secretion of parathyroid hormone precursors or homologs or 1,25 dihydroxyvitamin D. Effective antitumor treatment usually results in return of serum calcium to normal.

Common paraneoplastic syndromes and endocrine secretions associated with functional cancers are summarized in Table 39–2.

TYPES OF CANCER

LUNG CANCER

Sunny Wang, MD

BRONCHOGENIC CARCINOMA

ESSENTIALS OF DIAGNOSIS

- ▶ New cough, or change in chronic cough.
- ▶ Dyspnea, hemoptysis, anorexia, weight loss.
- ▶ Enlarging nodule or mass; persistent opacity, atelectasis, or pleural effusion on chest radiograph or CT scan.
- ▶ Cytologic or histologic findings of lung cancer in sputum, pleural fluid, or biopsy specimen.

General Considerations

Lung cancer is the leading cause of cancer deaths in both men and women. The American Cancer Society estimates

226,160 new diagnoses and 160,340 deaths from lung cancer in the United States in 2012, accounting for approximately 14% of new cancer diagnoses and 28% of all cancer deaths. More Americans die of lung cancer than of colorectal, breast, and prostate cancers combined.

Cigarette smoking causes 85–90% of cases of lung cancer. Lung cancer was a previously reportable disease until the widespread use of manufactured cigarettes in the 20th century. The causal connection between cigarettes and lung cancer is established not only epidemiologically but also through identification of carcinogens in tobacco smoke and analysis of the effect of these carcinogens on specific oncogenes expressed in lung cancer.

Since the early 1990s, mortality from lung cancer fell among men while it increased among women and is only now peaking among women, reflecting changing patterns of tobacco use over the past 30 years (see Chapter 1). Other environmental risk factors for the development of lung cancer include exposure to environmental tobacco smoke, radon gas (among uranium miners and in areas where radium in the soil causes significant indoor air contamination), asbestos (60- to 100-fold increased risk in smokers with asbestos exposure), metals (arsenic, chromium, nickel, iron oxide), and industrial carcinogens (bis-chloromethyl ether). A familial predisposition to lung cancer is recognized. Certain diseases are associated with an increased risk of lung cancer, including pulmonary fibrosis, chronic obstructive pulmonary disease, and sarcoidosis. Second primary lung cancers are more frequent in patients who survive their initial lung cancer.

The median age at diagnosis of lung cancer in the United States is 71; it is unusual under the age of 40. After the diagnosis of lung cancer is made, approximately 41% of patients survive 1 year. The combined relative 5-year survival rate for all stages of lung cancer is currently 16%, slightly improved from 13% for lung cancers diagnosed in the 1970–80s.

Five histologic categories of bronchogenic carcinoma account for more than 90% of cases of primary lung cancer. **Squamous cell carcinoma** (20% of cases) arises from the bronchial epithelium, typically as a centrally located, intraluminal sessile or polypoid mass. Squamous cell tumors are more likely to present with hemoptysis and more frequently diagnosed by sputum cytology. They spread locally and may be associated with hilar adenopathy and mediastinal widening on chest radiography. **Adenocarcinoma** (35–40% of cases) arises from mucus glands or, in the case of **bronchioloalveolar cell carcinoma** (2% of cases), from any epithelial cell within or distal to the terminal bronchioles. Adenocarcinomas usually present as peripheral nodules or masses. Bronchioloalveolar cell carcinoma, now known as **adenocarcinoma in situ**, spreads along preexisting alveolar structures (lepidic growth) without evidence of invasion. **Large cell carcinoma** (3–5% of cases) is a heterogeneous group of relatively undifferentiated tumors that share large cells and do not fit into other categories. Large cell carcinomas typically have rapid doubling times and an aggressive clinical course. They present as central or peripheral masses. Tumors that are not better differentiated on pathologic review other than carcinoma

Table 39-2. Paraneoplastic syndromes associated with cancer.

Hormone Excess or Syndrome	Non-Small Cell Lung Cancer	Small Cell Lung Cancer	Breast Cancer	Renal Cell Carcinoma	Adrenal Cancer	Hepato-cellular Carcinoma	Gastro-intestinal Cancers	Multiple Myeloma	Lymphoma	Thymoma	Prostatic Cancer	Ovarian Cancer	Chorio-carcinoma	Germ Cell Cancers
Endocrine														
Hypercalcemia	++		++	++	++			++	+		++			
Cushing syndrome	+	++		+	++					++	+			
SIADH	++	++												
Hypoglycemia					+	++	+							
Gonadotropin secretion	+	++		+	+	+	+						++	++
Hyperthyroidism													++	+
Hematologic														
Erythrocytosis				++	+	++								
Pure red cell aplasia									+	++				
Coagulopathy			++				++				++	+		
Thrombophlebitis			+				++				++	+		
Neurologic														
Lambert-Eaton myasthenia syndromes	+	++	+				+		+	+		+		
Subacute cerebellar syndrome		++	+				+		+			+		
Sensory motor peripheral neuropathy		++												
Stiff man syndrome			+											
Dermatologic														
Dermatomyositis	++	++	+				+					+		
Acanthosis nigricans	+		+				++				+			
Fever														
Hypertrophic osteoarthropathy	++													

+, reported associated; ++, strong association.

SIADH, syndrome of inappropriate antidiuretic hormone.

unspecified make up about 20–25% of cases. **Small cell carcinoma** (10–15% of cases) is a tumor of bronchial origin that typically begins centrally, infiltrating submucosally to cause narrowing or obstruction of the bronchus without a discrete luminal mass. Hilar and mediastinal abnormalities are common on chest radiography.

For purposes of staging and treatment, bronchogenic carcinoma is divided into small cell lung cancer (SCLC) and the other four types, conveniently labeled non–small cell lung cancer (NSCLC). This practical classification reflects different natural histories and different treatment. SCLC is prone to early hematogenous spread. It is rarely amenable to surgical resection and has a very aggressive course with a median survival (untreated) of 6–18 weeks. The four histologic categories comprising NSCLC spread more slowly. They may be cured in the early stages following resection, and for advanced disease, chemotherapy is tailored to specific histologies and molecular mutations found within NSCLC.

► Clinical Findings

Lung cancer is symptomatic at diagnosis in 75–90% of patients. The clinical presentation depends on the type and location of the primary tumor, the extent of local spread, and the presence of distant metastases and any paraneoplastic syndromes.

A. Symptoms and Signs

Anorexia, weight loss, or asthenia occurs in 55–90% of patients presenting with a new diagnosis of lung cancer. Up to 60% of patients have a new cough or a change in a chronic cough; 6–31% have hemoptysis; and 25–40% complain of pain, either nonspecific chest pain or pain from bony metastases to the vertebrae, ribs, or pelvis. Local spread may cause endobronchial obstruction with atelectasis and postobstructive pneumonia, pleural effusion (12–33%), change in voice (compromise of the recurrent laryngeal nerve), superior vena cava syndrome (obstruction of the superior vena cava with supraclavicular venous engorgement), and Horner syndrome (ipsilateral ptosis, miosis, and anhidrosis from involvement of the inferior cervical ganglion and the paravertebral sympathetic chain). Distant metastases to the liver are associated with asthenia and weight loss. Brain metastases (10% in NSCLC, more common in adenocarcinoma, and 20–30% in SCLC) may present with headache, nausea, vomiting, seizures, dizziness, or altered mental status.

Paraneoplastic syndromes are incompletely understood patterns of organ dysfunction related to immune-mediated or secretory effects of neoplasms. These syndromes occur in 10–20% of lung cancer patients. They may precede, accompany, or follow the diagnosis of lung cancer and do not necessarily indicate metastatic disease. In patients with small cell carcinoma, the syndrome of inappropriate antidiuretic hormone (SIADH) can develop in 10–15%; in those with squamous cell carcinoma, hypercalcemia can develop in 10% (Table 39–2). Digital clubbing is seen in up to 20% of patients at diagnosis (see Figure 6–41). Other common paraneoplastic syndromes include

increased ACTH production, anemia, hypercoagulability, peripheral neuropathy, and the Eaton-Lambert myasthenia syndrome. Their recognition is important because treatment of the primary tumor may improve or resolve symptoms even when the cancer is not curable.

B. Laboratory Findings

The diagnosis of lung cancer rests on examination of a tissue or cytology specimen. Sputum cytology is highly specific but insensitive; the yield is highest when there are lesions in the central airways. Thoracentesis (sensitivity 50–65%) can be used to establish a diagnosis of lung cancer in patients with malignant pleural effusions. If cytologic examination of an adequate sample (50–100 mL) of pleural fluid is nondiagnostic, the procedure should be repeated; approximately 30% of second samples are positive when the first sample is negative. If results remain negative, thoracoscopy is preferred to blind pleural biopsy. Fine-needle aspiration (FNA) of palpable supraclavicular or cervical lymph nodes is frequently diagnostic. Serum tumor markers are neither sensitive nor specific enough to aid in diagnosis.

Fiberoptic bronchoscopy allows visualization of the major airways, cytology brushing of visible lesions or lavage of lung segments with cytologic evaluation of specimens, direct biopsy of endobronchial abnormalities, blind transbronchial biopsy of the pulmonary parenchyma or peripheral nodules, and FNA biopsy of mediastinal lymph nodes. Diagnostic yield varies widely (10–90%) depending on the size of the lesion and its location. The use of fluorescence bronchoscopy improves the ability to identify early endobronchial lesions, while endobronchial and transesophageal endoscopic ultrasound enhance the direction and yield of FNA of mediastinal nodes. Transthoracic needle aspiration (TTNA) has a sensitivity between 50% and 97%. Mediastinoscopy, video-assisted thoracoscopic surgery (VATS), and thoracotomy are necessary in cases where less invasive techniques fail to yield a diagnosis.

C. Imaging

Nearly all patients with lung cancer have abnormal findings on chest radiography or CT scan. These findings are rarely specific for a particular diagnosis. Interpretation of characteristic findings in isolated nodules is described in Chapter 9.

D. Special Examinations

1. Staging—Accurate staging is crucial (1) to provide the clinician with information to guide treatment, (2) to provide the patient with accurate information regarding prognosis, and (3) to standardize entry criteria for clinical trials to allow interpretation of results.

There are two essential principles of staging NSCLC. First, the more extensive the disease, the worse the prognosis; second, surgical resection offers the best chance for cure. Staging of NSCLC uses two integrated systems. The **TNM international staging system** attempts a physical description of the neoplasm: T describes the size and location of the primary tumor; N describes the presence and location of nodal metastases; and M refers to the presence

Table 39-3. Approximate survival rates following treatment for lung cancer.

Non-Small Cell Lung Cancer: Mean 5-Year Survival Following Resection		
Stage	Clinical Staging	Surgical Staging
IA (T1N0M0)	60%	74%
IB (T2N0M0)	38%	61%
IIA (T1N1M0)	34%	55%
IIB (T2N1M0, T3N0M0)	23%	39%
IIIA	9–13%	22%
IIIB ¹	3–12%	
IV ¹	4%	
Small Cell Lung Cancer: Survival Following Chemotherapy		
Stage	Mean 2-Year Survival	Median Survival
Limited	15–20%	14–20 months
Extensive	< 3%	8–13 months

¹Independent of therapy, generally not surgical patients. Data from multiple sources. Modified and reproduced, with permission, from Reif MS et al. Evidence-based medicine in the treatment of non-small cell cancer. Clin Chest Med. 2000;21:107.

or absence of distant metastases. These TNM stages are grouped into prognostic categories (stages I–IV) using the results of clinical trials. This classification is used to guide therapy. Many patients with stage I and stage II disease are cured through surgery. Patients with stage IIIB and stage IV disease do not benefit from surgery (Table 39–3). Patients with stage IIIA disease have locally invasive disease that may benefit from surgery in certain circumstances.

SCLC is not staged using the TNM system because micrometastases are assumed to be present on diagnosis. SCLC is divided into two categories: **limited disease** (30%), when the tumor is limited to the unilateral hemithorax (including contralateral mediastinal nodes); or **extensive disease** (70%), when the tumor extends beyond the hemithorax (including pleural effusion). For both SCLC and NSCLC, staging begins with a thorough history and physical examination. A complete examination is essential to exclude obvious metastatic disease to lymph nodes, skin, and bone. A detailed history is essential because the patient's performance status is a powerful predictor of disease course. All patients should have measurement of a complete blood count, electrolytes including calcium, creatinine, liver tests, lactate dehydrogenase, albumin, and a chest radiograph. Further evaluation will follow the results of these tests.

NSCLC patients being considered for surgery require meticulous evaluation to identify those with resectable disease. CT imaging is the most important modality for staging candidates for resection. A chest CT scan precisely defines the size of parenchymal lesions and identifies atelectatic lung or pleural effusions. However, CT imaging is less accurate at determining invasion of the chest wall

(sensitivity 62%) or mediastinum (sensitivity 60–75%). The sensitivity and specificity of CT imaging for identifying lung cancer metastatic to the mediastinal lymph nodes are 57% (49–66%) and 82% (77–86%), respectively. Therefore, chest CT imaging does not provide definitive information on staging. CT imaging does help in making the decision about whether to proceed to resection of the primary tumor and sample the mediastinum at thoracotomy (common if there are no lymph nodes > 1 cm) or to use TTNA, mediastinoscopy, esophageal ultrasound with transesophageal needle aspiration, or limited thoracotomy to biopsy suspected metastatic disease (common where there are lymph nodes > 1–2 cm).

Positron emission tomography (PET) using 2-[¹⁸F] fluoro-2-deoxyglucose (FDG) is an important modality for identifying metastatic foci in the mediastinum or distant sites. The sensitivity and specificity of PET for detecting mediastinal spread of primary lung cancer depend on the size of mediastinal nodes or masses. When only normalized (< 1 cm) mediastinal lymph nodes are present, the sensitivity and specificity of PET for tumor involvement of nodes are 74% and 96%, respectively. When CT shows enlarged (> 1 cm) lymph nodes, the sensitivity and specificity are 95% and 76%, respectively.

The combined modalities of PET and CT imaging have improved preoperative staging compared with CT or PET alone. Many lung cancer specialists find whole body fusion PET-CT imaging most useful to confirm lack of metastatic disease in NSCLC patients who are candidates for surgical resection. There is evidence that PET-CT imaging reduces futile thoracotomies by identifying mediastinal and distant metastases in patients with NSCLC. Disadvantages of PET imaging include limited resolution below 1 cm; the expense of FDG; limited availability; and false-positive scans due to sarcoidosis, tuberculosis, or fungal infections. PET-CT scans are also inadequate for evaluating brain metastases due to the high FDG uptake there. Obtaining an MRI of the brain is important to rule out brain metastases in patients with at least stage II disease.

2. Preoperative assessment—See Chapter 3.

3. Pulmonary function testing—

Many patients with NSCLC have moderate to severe chronic lung disease that increases the risk of perioperative complications as well as long-term pulmonary insufficiency following lung resection. All patients considered for surgery require spirometry. In the absence of other comorbidities, patients with good lung function (preoperative FEV₁ ≥ 2 L) are at low risk for complications from lobectomy or pneumonectomy. If the FEV₁ is < 2 L, then an estimated postoperative FEV₁ should be calculated. The postresection FEV₁ may be estimated from considering preoperative spirometry and the amount of lung to be resected; in severe obstructive disease, a quantitative lung perfusion scan may improve the estimate. A predicted post-lung resection FEV₁ > 800 mL (or > 40% of predicted FEV₁) is associated with a low incidence of perioperative complications. High-risk patients include those with a predicted postoperative FEV₁ < 700 mL (or < 40% of predicted FEV₁). In these patients and in those with borderline spirometry, cardiopulmonary

exercise testing may be helpful. A maximal oxygen uptake ($\dot{V}O_2$) of > 15 mL/kg/min identifies patients with an acceptable incidence of complications and mortality. Patients with a $\dot{V}O_2$ of < 10 mL/kg/min have a very high mortality rate at thoracotomy. Hypoxemia and hypercapnia are not independent predictors of outcome.

4. Screening—Prior data showed that chest radiographs and analysis of expectorated sputum as lung cancer screening modalities did not improve survival. The National Lung Screening Trial, a multicenter randomized national trial involving over 53,000 current and former heavy smokers, published results showing a 20% reduction in lung cancer deaths. It compared low-dose helical CT with standard chest radiographs as screening modalities for lung cancer. Given these findings, clinical guidelines and policy recommendations on lung cancer screening are currently being discussed. Risk-benefit and cost-effective analyses are underway. The implications of widespread screening of smokers raise issues of false positives (96% in this study), surgical and medical complications from additional testing, risks of cumulative exposure to radiation, and risks of increasing patient anxiety and stress on an already limited pool of resources.

► Treatment

A. Non-Small Cell Carcinoma

Cure of NSCLC is unlikely without resection. Therefore, the initial approach to the patient is determined by the answers to two questions: (1) Is complete surgical resection technically feasible? (2) If yes, is the patient able to tolerate the surgery with acceptable morbidity and mortality? Clinical features that preclude complete resection include extrathoracic metastases or a malignant pleural effusion; or tumor involving the heart, pericardium, great vessels, esophagus, recurrent laryngeal or phrenic nerves, trachea, main carina, or contralateral mediastinal lymph nodes. Accordingly, stage I and stage II patients are treated with surgical resection where possible. Stage II, and possibly a subset of stage IB, are additionally recommended to receive adjuvant chemotherapy. Stage IIIA patients have poor outcomes when treated with resection alone. They should be referred to multimodality protocols, including chemotherapy or radiotherapy, or both. Stage IIIB patients treated with concurrent chemotherapy and radiation therapy have improved survival. Stage IV patients are treated with chemotherapy or symptom-based palliative therapy, or both (see below).

Surgical approach affects outcome. The North American Lung Cancer Study Group conducted a prospective trial of stage IA patients randomized to lobectomy versus limited resection. They reported a threefold increased rate of local recurrence in the limited resection group ($P = 0.008$) and a trend toward an increase in overall death rate (increase of 30%, $P = 0.08$) and increase in death rate due to cancer (increase of 50%, $P = 0.09$), compared with patients receiving lobectomy. There are inadequate outcome data on which to base a comparison of VATS with standard thoracotomy. Radiation therapy following surgery improves local control but does not improve survival.

Patients with small early-stage primary lung cancers who are not candidates for surgery because of significant comorbidity or other surgical contraindication may be candidates for stereotactic body radiotherapy. Stereotactic body radiotherapy (cyberknife), which is composed of multiple non-parallel radiation beams that converge, allows the delivery of a relatively large dose of radiation to a small, well-defined target. For small, early-stage cancers, 3-year local control rates with cyberknife exceed 90%, and 3-year survival is estimated at over 55%. Patients with locally advanced disease (stages IIIA and IIIB) who are not surgical candidates have improved survival when treated with concurrent chemotherapy and radiation therapy compared with no therapy, radiation alone, or even sequential chemotherapy and radiation.

Neoadjuvant chemotherapy consists of giving anti-neoplastic drugs in advance of surgery or radiation therapy. There is no consensus on the impact of neoadjuvant therapy on survival in stage I and stage II NSCLC. Such therapy is not recommended outside of ongoing clinical trials. Neoadjuvant therapy is more widely used in selected patients with stage IIIA or stage IIIB disease. Some studies suggest a survival advantage. This remains an area of active research.

Adjuvant chemotherapy consists of administering antineoplastic drugs following surgery or radiation therapy. Cisplatin-containing regimens have been shown to confer an overall survival benefit in at least stage II disease and possibly a subset of stage IB disease. The Lung Adjuvant Cisplatin Evaluation Collaborative Group published a meta-analysis of the five largest cisplatin-based adjuvant trials. They reported a 5% absolute benefit in 5-year overall survival with a cisplatin-containing doublet regimen following surgery ($P = 0.005$) in patients with at least stage II disease. For patients with poor performance status (Eastern Cooperative Oncology Group Score ≤ 2), there is no evidence of survival benefit for adjuvant chemotherapy; rather, it may be detrimental. Novel targeted agents with less toxicity are in clinical trials, and gene expression profiling has shown promise in defining a subset of patients who may benefit from adjuvant therapy.

Although not curative, chemotherapy has been shown in multiple clinical trials to provide a modest increase in overall survival and performance status in patients with stage IIIB and stage IV NSCLC compared with supportive care alone, with median survival increased from 5 months to a range of 7–11 months. Palliative chemotherapy also leads to improved quality of life and symptom control, with first-line therapy involving a platinum-based regimen. Platinum-based doublet regimens consist of cisplatin or carboplatin (agents that bind DNA to form adducts that inhibit their synthesis and function) combined with another agent, such as gemcitabine, taxane, vinorelbine, or pemetrexed. When compared in phase III trials for advanced NSCLC, these doublet regimens have shown comparable efficacy with varying toxicity profiles. Investigators have shown that the choice of chemotherapeutic agent can be tailored to histologic subtype in NSCLC. For nonsquamous histologies, patients have modestly improved overall survival when treated with a platinum agent plus pemetrexed

(an inhibitor of folate-dependent enzymes important in purine and pyrimidine synthesis). Patients with squamous cell lung carcinomas have modestly improved overall survival when a platinum agent is combined with gemcitabine (a deoxycytidine analog that inhibits DNA synthesis). For good performance status patients with nonsquamous histologies, bevacizumab (a monoclonal antibody to vascular endothelial growth factor [VEGF]) can be added to a traditional platinum doublet regimen with further modest increase in survival benefit. Cetuximab (a monoclonal antibody to the epidermal growth factor receptor [EGFR]) added to a platinum doublet regimen for all histologies of NSCLC has also shown a small survival benefit.

With the advent of molecular profiling, targeted therapy has played a significant role in NSCLC. For the subgroup of patients with EGFR mutations, an EGFR inhibitor (erlotinib and gefitinib) rather than platinum-based chemotherapy is the first-line treatment. Response rates with EGFR inhibitors in patients with EGFR mutation are at least 60%, and median overall survival is estimated at 27–30 months. EGFR mutations are found in approximated 10–15% of the white population and 30–40% in the Asian population and are usually found among nonsmokers to light-smokers, females, and adenocarcinoma histology. Approximately 5% of all patients with NSCLC carry a different mutation, the EML4-ALK fusion gene product. This is found in a comparatively younger population, with adenocarcinoma histology, and nonsmoking to light-smoking history. Based on early single-arm trials showing 60% response rates, crizotinib, an ALK and MET inhibitor, was approved by the US Food and Drug Administration (FDA) to treat EML4-ALK-positive NSCLCs. Finally, KRAS mutations are found among 25% of patients with adenocarcinomas, are associated with smoking, indicate a poor prognosis, and typically do not respond to EGFR inhibition. These three mutations are mutually exclusive. Ongoing research seeks to define the role of these targeted agents in early stage and locally advanced lung cancers, and identification of new novel mutations.

B. Small Cell Carcinoma

Response rates of SCLC to cisplatin and etoposide are excellent with 80–90% response in limited-stage disease (50–60% complete response), and 60–80% response in extensive stage disease (15–20% complete response). However, remissions tend to be short-lived with a median duration of 6–8 months. Once the disease has recurred, median survival is 3–4 months. Overall 2-year survival is 20–40% in limited-stage disease and < 5% in extensive-stage disease. Thoracic radiation therapy improves survival in patients with limited SCLC and is given concurrently with chemotherapy. Thoracic radiation therapy is not beneficial for patients with extensive disease, and they should receive chemotherapy alone. There is a high rate of brain metastasis in patients with SCLC, even following a good response to chemotherapy, because chemotherapy does not adequately penetrate the blood-brain barrier. Prophylactic cranial irradiation has been shown to decrease the incidence of central nervous system disease and improve survival in patients with limited stage disease who respond to chemotherapy and a subset of

patients with extensive stage disease who have had an excellent response to chemotherapy.

Occasionally, a patient may have a peripheral nodule resected that turns out to be SCLC. Five-year survival following resection of the equivalent of stage I and stage II SCLC is higher than in patients treated with chemotherapy.

C. Palliative Therapy

Photoresection with the Nd:YAG laser is sometimes performed on central tumors to relieve endobronchial obstruction, improve dyspnea, and control hemoptysis. External beam radiation therapy is also used to control dyspnea, hemoptysis, endobronchial obstruction, pain from bony metastases, obstruction from superior vena cava syndrome, and symptomatic brain metastases. Resection of a *solitary* brain metastasis improves quality of life when combined with radiation therapy, and if there is no evidence of other metastatic disease, it may improve survival. Intraluminal radiation (brachytherapy) is an alternative approach to endobronchial disease. Pain syndromes are very common in advanced disease. As patients approach the end of life, meticulous efforts at pain control are essential (see Chapter 5). In addition to standard oncologic care, early consultation with—or referral to—a palliative care specialist is recommended in advanced disease to aid in symptom management; it may even modestly improve survival.

► Prognosis

The overall 5-year survival rate for lung cancer is approximately 15%. Predictors of survival include the type of tumor (SCLC versus NSCLC), molecular typing, the stage of the tumor, the patient's performance status, and weight loss in the past 6 months. Patients with EGFR mutation have better overall survival when compared with those without EGFR mutation, even when receiving similar cytotoxic chemotherapy.

- Anantham D et al. Endobronchial ultrasound. *Respir Med*. 2009 Oct;103(10):1406–14. [PMID: 19447014]
- Fischer B et al. Preoperative staging of lung cancer with combined PET-CT. *N Engl J Med*. 2009 July 2;361(1):32–39. [PMID: 19571281]
- Goldstraw P et al. Non-small-cell lung cancer. *Lancet*. 2011 Nov 12;378(9804):1727–40. [PMID: 21565398]
- Kwak EK et al. Anaplastic lymphoma kinase inhibition in non-small cell lung cancer. *N Engl J Med*. 2010 Oct 28;363(18):1693–703. [PMID: 20979469]
- Maemondo M et al; North-East Japan Study Group. Gefitinib or chemotherapy for non-small cell lung cancer with mutated EGFR. *N Engl J Med*. 2010 Jun 24;362(25):2380–8. [PMID: 20573926]
- Mok TS et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. *N Engl J Med*. 2009 Sept 3;361(10):947–57. [PMID: 19692680]
- National Lung Screening Trial Research Team; Aberle DR et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. *N Engl J Med*. 2011 Aug 4;365(5):395–409. [PMID: 21714641]
- Ries LAG et al (eds). SEER Cancer Statistics Review, 1975–2005, National Cancer Institute, Bethesda, MD, http://seer.cancer.gov/csr/1975_2005/, based on November 2007 SEER data submission, posted to the SEER web site, 2008.

Sangha R et al. Adjuvant therapy in non-small cell lung cancer: current and future directions. *Oncologist*. 2010;15(8):862–72. [PMID: 20682608]

Siegel R et al. Cancer Statistics, 2012. *CA Cancer J Clin*. 2012 Jan–Feb;62(1):10–29. [PMID: 22237781]

Silvestri GA. Screening for lung cancer: it works, but does it really work? *Ann Intern Med*. 2011 Oct 18;155(8):537–9. [PMID: 21893614]

Temel JS et al. Early palliative care for patients with metastatic non-small cell lung cancer. *N Engl J Med*. 2010 Aug 19;363(8):733–42. [PMID: 20818875]

Timmerman R et al. Stereotactic body radiation therapy for inoperable early stage lung cancer. *JAMA*. 2010 Mar 17;303(11):1070–6. [PMID: 20233825]

PULMONARY METASTASES

Pulmonary metastasis results from the spread of an extrapulmonary malignant tumor through vascular or lymphatic channels or by direct extension. Almost any cancer can metastasize to the lung, including primary lung carcinomas. Metastases usually occur via the pulmonary artery and typically present as multiple nodules or masses on chest radiography. The radiographic differential diagnosis of multiple pulmonary nodules also includes pulmonary arteriovenous malformation, pulmonary abscesses, granulomatous infection, sarcoidosis, rheumatoid nodules, and granulomatosis with polyangiitis (formerly Wegener granulomatosis). Metastases to the lungs are found in 20–55% of patients dying of various malignancies. Most are intraparenchymal. Endobronchial metastases occur in < 5% of patients dying of nonpulmonary cancer. Carcinoma of the kidney, breast, rectum, colon, and cervix and malignant melanoma are the most likely primary tumors. Head and neck cancers with extensive or lower cervical nodal involvement have a 30% risk for distant metastasis; half of these metastases present in the lungs.

Lymphangitic carcinomatosis denotes diffuse involvement of the pulmonary lymphatic network by primary or metastatic lung cancer, probably a result of extension of tumor from lung capillaries to the lymphatics. **Tumor embolization** from extrapulmonary cancer (renal cell carcinoma, hepatocellular carcinoma, choriocarcinoma) is an uncommon route for tumor spread to the lungs. Metastatic cancer may also present as a malignant pleural effusion.

► Clinical Findings

A. Symptoms and Signs

Symptoms are uncommon but include cough, hemoptysis and, in advanced cases, dyspnea and hypoxemia. Symptoms are more often referable to the site of the primary tumor.

B. Laboratory Findings

The diagnosis of metastatic cancer involving the lungs is usually established by identifying a primary tumor. Appropriate studies should be ordered if there is a suspicion of any primary cancer, such as breast, thyroid, testis, colorectal, or prostate, for which specific treatment is available.

For example, an elevated prostate-specific antigen (PSA) may indicate prostate cancer, carcinoembryonic antigen (CEA) tests for colorectal cancer, and β -human chorionic gonadotropin (β HCG) and α -fetoprotein test for germ cell tumors. Based on the clinical setting, imaging studies should be ordered (see below). If the history, physical examination, and initial studies fail to reveal the site of the primary tumor, attention is better focused on the lung, where tissue samples obtained by bronchoscopy, percutaneous needle biopsy, VATS, or thoracotomy may establish the histologic diagnosis and suggest the most likely primary cancer. Occasionally, cytologic studies of pleural fluid or pleural biopsy reveal the diagnosis. Sputum cytology is rarely helpful.

If the initial histologic review does not reveal a primary diagnosis, immunohistochemical staining should be done on the biopsy specimen. For example, PSA and thyroglobulin staining are highly specific for prostate and thyroid cancer, respectively. Thyroid transcription factor-1 (TTF-1) is relatively specific for primary lung adenocarcinoma, while also positive for SCLC and thyroid carcinoma. An adenocarcinoma that demonstrates negative TTF-1 staining strongly suggests a nonpulmonary primary cancer. Positive estrogen receptor (ER) and progesterone receptor (PR) stains suggest primary breast cancer.

C. Imaging

Chest radiographs usually show multiple spherical densities with sharp margins. The size of metastatic lesions varies from a few millimeters (miliary densities) to large masses. Nearly all are < 5 cm in diameter. The lesions are usually bilateral, pleural or subpleural in location, and more common in lower lung zones. Cavitation suggests squamous cell tumor; calcification suggests osteosarcoma. Lymphangitic spread and solitary pulmonary nodule are less common radiographic presentations of pulmonary metastasis. Conventional chest radiography is less sensitive than CT scan in detecting pulmonary metastases. Mammography should be considered in women to search for possible primary breast cancer. CT imaging of the chest, abdomen, and pelvis may reveal the site of a primary tumor and will help determine feasibility of surgical resection of the metastatic lung tumors. PET-CT scan may also help in identifying the site of a primary cancer or identifying other areas of extrathoracic metastasis.

► Treatment

Once the diagnosis has been established, management consists of treatment of the primary neoplasm and any pulmonary complications. Surgical resection of a *solitary* pulmonary nodule is often prudent in the patient with known current or previous extrapulmonary cancer. Local resection of one or more pulmonary metastases is feasible in a few carefully selected patients with various sarcomas and carcinomas (breast, testis, colon, and kidney). Surgical resection should be considered only if the primary tumor is under control, if the patient is a good surgical risk, if all of the metastatic tumor can be resected, if effective non-surgical approaches are not available, and if there are no

metastases elsewhere in the body. Relative contraindications to resection of pulmonary metastases include (1) malignant melanoma primary, (2) requirement for pneumonectomy, and (3) pleural involvement. Data from the International Registry of Lung Metastases report an overall 5-year survival rate of 36% and 10-year survival rate of 26% after complete resection of pulmonary metastases. Patients who are not surgical candidates but have solitary or limited metastatic disease to the lungs may be candidates for stereotactic radiosurgery, radioablation, or cryotherapy. For patients with progressive disease, diligent attention to palliative care is essential (see Chapter 5).

Kaifi JT et al. Indications and approach to surgical resection of lung metastases. *J Surg Oncol.* 2010 Aug 1;102(2):187–95. [PMID: 20648593]

Mitry E et al. Epidemiology, management and prognosis of colorectal cancer with lung metastases: a 30-year population-based study. *Gut.* 2010 Oct;59(10):1383–8. [PMID: 20732912]

Oliaro A et al. Pulmonary metastasectomy for melanoma. *J Thorac Oncol.* 2010 Jun;5(6 Suppl 2):S187–91. [PMID: 20502260]

Pfannschmidt J. Reported outcome factors for pulmonary resection of metastatic colorectal cancer. *J Thorac Oncol.* 2010 Jun;5(6 Suppl 2):S172–8. [PMID: 20502257]

Pfannschmidt J. Thoracic metastasectomy for non-seminomatous germ cell tumors. *J Thorac Oncol.* 2010 Jun;5(6 Suppl 2):S182–6. [PMID: 20502259]

Rusch VW. Pulmonary metastasectomy: a moving target. *J Thorac Oncol.* 2010 Jun;5(6 Suppl 2):S130–1. [PMID: 20502246]

Treasure T et al. Pulmonary metastasectomy in colorectal cancer: the PulMiCC Trial. *J Thorac Oncol.* 2010 Jun;5(6 Suppl 2):S203–6. [PMID: 20502265]

MESOTHELIOMA



ESSENTIALS OF DIAGNOSIS

- ▶ Unilateral, nonpleuritic chest pain and dyspnea.
- ▶ Distant (> 20 years earlier) history of exposure to asbestos.
- ▶ Pleural effusion or pleural thickening or both on chest radiographs.
- ▶ Malignant cells in pleural fluid or tissue biopsy.

▶ General Considerations

Mesotheliomas are primary tumors arising from the surface lining of the pleura (80% of cases) or peritoneum (20% of cases). About three-fourths of pleural mesotheliomas are diffuse (usually malignant) tumors, and the remaining one-fourth are localized (usually benign). Men outnumber women by a 3:1 ratio. Numerous studies have confirmed the association of **malignant pleural mesothelioma** with exposure to asbestos (particularly the crocidolite form). The lifetime risk to asbestos workers of developing malignant pleural mesothelioma is as high as 10%. Sixty to 80 percent of patients with malignant mesothelioma report

a history of asbestos exposure. The latent period between exposure and onset of symptoms ranges from 20 to 40 years. The clinician should inquire about asbestos exposure through mining, milling, manufacturing, shipyard work, insulation, brake linings, building construction and demolition, roofing materials, and a variety of asbestos products (pipe, textiles, paint, tile, gaskets, panels). Although cigarette smoking significantly increases the risk of bronchogenic carcinoma in asbestos workers and aggravates asbestosis, there is no association between smoking and mesothelioma.

▶ Clinical Findings

A. Symptoms and Signs

The average interval between onset of symptoms and diagnosis is 2–3 months; the median age at diagnosis is 69 years in Western countries. Symptoms include the insidious onset of shortness of breath, nonpleuritic chest pain, and weight loss. Physical findings include dullness to percussion, diminished breath sounds and, in some cases, digital clubbing.

B. Laboratory Findings

Pleural fluid is exudative and often hemorrhagic. Cytologic tests of pleural fluid are often negative. VATS biopsy is usually necessary to obtain an adequate specimen for histologic diagnosis. The histologic variants of malignant pleural mesothelioma are epithelial (50–60%), sarcomatoid (10%), and biphasic (30–40%). Since distinction from benign inflammatory conditions and metastatic adenocarcinoma may be difficult, immunohistochemical stains are important to confirm the diagnosis. Epithelial mesothelioma stains are positive for pankeratin, calretinin, keratin 5/6, and WT1 and are negative for epithelial markers, such as CEA, MOC-31, TTF-1, CD15, and B72.3 (usually three needed). Soluble mesothelin-related peptide also may be found in serum or pleural fluid (or both) of patients with mesothelioma, epithelioid type.

C. Imaging

Radiographic abnormalities consist of nodular, irregular, unilateral pleural thickening and varying degrees of unilateral pleural effusion. Sixty percent of patients have right-sided disease, while only 5% have bilateral involvement. CT scans demonstrate the extent of pleural involvement. PET-CT is increasingly used to help differentiate benign from malignant pleural disease, improve staging accuracy, and identify candidates for aggressive surgical approaches.

▶ Complications

Malignant pleural mesothelioma progresses rapidly as the tumor spreads along the pleural surface to involve the pericardium, mediastinum, and contralateral pleura. The tumor may eventually extend beyond the thorax to involve abdominal lymph nodes and organs. Progressive pain and dyspnea are characteristic. Local invasion of thoracic

structures may cause superior vena cava syndrome, hoarseness, Horner syndrome, arrhythmias, and dysphagia. Paraneoplastic syndromes associated with mesothelioma include thrombocytosis, hemolytic anemia, disseminated intravascular coagulopathy, hypercalcemia, and migratory thrombophlebitis.

► Treatment

Chemotherapy is the mainstay of treatment, unless there is localized disease that can be surgically resected. Surgery, radiotherapy, chemotherapy, or a combination of modalities may be attempted, but treatments are generally unsuccessful. For localized disease, pleurectomy and decortication (surgical stripping of the pleura and pericardium from apex of the lung to diaphragm) is one surgical approach and can be effective in controlling malignant pleural effusion. Previously, some thoracic surgeons favored a trimodality approach for localized disease with extrapleural pneumonectomy, adjuvant radiation, and chemotherapy, based on limited retrospective data that it prolongs survival in highly selected patients. Extrapleural pneumonectomy is a radical surgical procedure involving removal of the ipsilateral lung, parietal and visceral pleura, pericardium, and most of the hemidiaphragm. However, the Mesothelioma and Radical Surgery (MARS) trial, a small randomized study comparing extrapleural pneumonectomy with no extrapleural pneumonectomy after induction chemotherapy in 50 patients, showed that extrapleural pneumonectomy offered no survival benefit and may have caused more harm. In advanced unresectable cases, palliative chemotherapy with cisplatin and pemetrexed can extend survival as well as improve quality of life. Other alternative chemotherapy regimens include gemcitabine, anthracyclines, or vinorelbine. Drainage of pleural effusions, pleurodesis, radiation therapy, and even surgical resection may offer palliative benefit in some patients.

► Prognosis

Most patients die of respiratory failure and complications of local extension. Median survival time from onset of symptoms ranges from 4 months in extensive disease to 16 months in localized disease. Five-year survival is < 5%. Tumors that are predominantly sarcomatoid are more resistant to therapy and have a worse prognosis, with median survivals < 1 year. Poor prognostic features include poor performance status, non-epithelioid histology, male gender, nodal involvement, elevated lactate dehydrogenase, high white blood cell count, low hemoglobin, and high platelet count.

Nowak AK et al. Imaging in pleural mesothelioma: a review of imaging research presented at the 9th International Meeting of the International Mesothelioma Interest Group. *Lung Cancer*. 2010 Oct;70(1):1–6. [PMID: 20541834]

Stahel RA et al. Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol*. 2010 May;21(suppl 5):v126–8. [PMID: 20555061]

Treasure T et al. Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomized feasibility study. *Lancet Oncol*. 2011 Aug;12(8):763–72. [PMID: 21723781]

Van Meerbeeck JP et al. Malignant pleural mesothelioma: the standard of care and challenges for future management. *Crit Rev Oncol Hematol*. 2011 May;78(2):92–111. [PMID: 20466560]

Weder W. Mesothelioma. *Ann Oncol*. 2010 Oct;21(Suppl 7):vii326–33. [PMID: 20943637]

Wheatley-Price P. Soluble mesothelin-related peptide and osteopontin as markers of response in malignant mesothelioma. *J Clin Oncol*. 2010 Jul 10;28(20):3316–22. [PMID: 20498407]

HEPATOBIILIARY CANCERS

Lawrence S. Friedman, MD

HEPATOCELLULAR CARCINOMA



ESSENTIALS OF DIAGNOSIS

- In Western countries, usually a complication of cirrhosis.
- Characteristic CT and MRI features and elevated serum α -fetoprotein may obviate the need for a confirmatory biopsy.

► General Considerations

Malignant neoplasms of the liver that arise from parenchymal cells are called hepatocellular carcinomas; those that originate in the ductular cells are called cholangiocarcinomas.

Hepatocellular carcinomas are associated with cirrhosis in 80% of cases. Incidence rates are rising rapidly (twofold since 1978) in the United States and other Western countries, presumably because of the increasing prevalence of cirrhosis caused by chronic hepatitis C infection and non-alcoholic fatty liver disease. In Western countries, risk factors for hepatocellular carcinoma in patients known to have cirrhosis are male gender, age > 55 years (although there has been an increase in the number of younger cases), Asian or Hispanic ethnicity, family history in a first-degree relative, overweight, obesity, alcohol use (especially in combination with obesity), diabetes mellitus, hypothyroidism (in women), HCV infection, HBsAg and anti-HBc positivity, a prolonged prothrombin time, a low platelet count, and an elevated serum transferrin saturation. In Africa and most of Asia, hepatitis B is of major etiologic significance, whereas in Western countries and Japan, hepatitis C (particularly genotype 1b and sometimes in combination with “occult” HBV infection) and alcoholic cirrhosis are the most common risk factors. Other associations include high levels of HBV replication, HBV genotype C, hepatitis D coinfection, hemochromatosis (and possibly the C282Y carrier state), aflatoxin exposure (associated with mutation of the *TP53* gene),

α_1 -antiprotease (α_1 -antitrypsin) deficiency, tyrosinemia, and radiation exposure. In patients with the metabolic syndrome, hepatocellular carcinoma may arise from a hepatocellular adenoma in the absence of cirrhosis. Evidence for an association with long-term use of oral contraceptives is inconclusive. Coffee consumption and, in diabetic patients, the use of statins appear to be protective. The fibrolamellar variant of hepatocellular carcinoma occurs in young women and is characterized by a distinctive histologic picture, absence of risk factors, and indolent course. Vinyl chloride exposure is associated with angiosarcoma of the liver.

► Clinical Findings

A. Symptoms and Signs

The presence of a hepatocellular carcinoma may be unsuspected until there is deterioration in the condition of a cirrhotic patient who was formerly stable. Cachexia, weakness, and weight loss are associated symptoms. The sudden appearance of ascites, which may be bloody, suggests portal or hepatic vein thrombosis by tumor or bleeding from a necrotic tumor.

Physical examination may show tender enlargement of the liver, occasionally with a palpable mass. In Africa, the typical presentation in young patients is a rapidly expanding abdominal mass. Auscultation may reveal a bruit over the tumor or a friction rub when the tumor has extended to the surface of the liver.

B. Laboratory Findings

Laboratory tests may reveal leukocytosis, as opposed to the leukopenia that is frequently encountered in cirrhotic patients. Anemia is common, but a normal or elevated hematocrit value may be found in up to one-third of patients owing to elaboration of erythropoietin by the tumor. Sudden and sustained elevation of the serum alkaline phosphatase in a patient who was formerly stable is a common finding. HBsAg is present in a majority of cases in endemic areas, whereas in the United States anti-HCV is found in up to 40% of cases. α -Fetoprotein levels are elevated in up to 70% of patients with hepatocellular carcinoma in Western countries (although the sensitivity is lower in blacks and levels are not elevated in patients with fibrolamellar hepatocellular carcinoma); however, mild elevations (10–200 ng/mL [10–200 mcg/L]) are also often seen in patients with chronic hepatitis. Serum levels of des-gamma-carboxy prothrombin are elevated in up to 90% of patients with hepatocellular carcinoma, but they may also be elevated in patients with vitamin K deficiency, chronic hepatitis, and metastatic cancer. The L3 glycoform of α -fetoprotein (AFP-L3) is under study and may not be sensitive for early hepatocellular carcinoma. Cytologic study of ascitic fluid rarely reveals malignant cells.

C. Imaging

Multiphasic helical CT and MRI with contrast enhancement are the preferred imaging studies for determining the location and vascularity of the tumor. Lesions smaller than

1 cm may be difficult to characterize. Arterial phase enhancement of the lesion followed by delayed hypointensity (“washout”) is most specific for hepatocellular carcinoma. Ultrasonography is less sensitive and operator dependent but is used to screen for hepatic nodules in high-risk patients. Contrast-enhanced ultrasonography has a sensitivity and specificity approaching those of arterial phase helical CT but, unlike CT and MRI, cannot image the entire liver during the short duration of the arterial phase and is associated with false-positive results. In selected cases, endoscopic ultrasonography may be useful. PET is under study.

D. Liver Biopsy and Staging

Liver biopsy is diagnostic, although seeding of the needle tract by tumor is a potential risk (1–3%). For lesions < 1 cm, ultrasonography may be repeated every 3 months followed by further investigation of enlarging lesions. For lesions \geq 1 cm, biopsy can be deferred when characteristic arterial hypervascularity and delayed washout are demonstrated on either multiphasic helical CT or MRI with contrast enhancement (or both) or if surgical resection is planned. Staging in the TNM classification includes the following definitions: T0: no evidence of primary tumor; T1: solitary tumor without vascular invasion; T2: solitary tumor with vascular invasion or multiple tumors none more than 5 cm; T3: multiple tumors more than 5 cm (3a) or tumor involving a major branch of the portal or hepatic vein (3b); and T4: tumor(s) with direct invasion of adjacent organs other than the gallbladder or with perforation of the visceral peritoneum; N1, regional lymph node metastasis; M1, distant metastasis; F0, no to moderate hepatic fibrosis; F1, severe hepatic fibrosis to cirrhosis. The Barcelona Clinic Liver Cancer (BCLC) staging system is preferred and includes the Child-Turcotte-Pugh stage, tumor stage, and liver function and has the advantage of linking overall stage with preferred treatment modalities and with an estimation of life expectancy.

► Screening & Prevention

In the patient with chronic hepatitis B (beginning as early as age 20 in Africans and age 40 in Asians or those with a family history of hepatocellular carcinoma) or cirrhosis caused by HCV, HBV, or alcohol, surveillance for the development of hepatocellular carcinoma is recommended. Although the standard approach is α -fetoprotein testing and ultrasonography every 6 months, the value of α -fetoprotein screening has been questioned because of its low sensitivity. CT and MRI are considered too expensive for screening, but the sensitivity of ultrasonography for detecting early hepatocellular carcinoma is only 63%. The risk of hepatocellular carcinoma in a patient with cirrhosis is 3–5% a year, and patients with tumors detected by surveillance have a less advanced stage on average and greater likelihood that treatment will prolong survival than those not undergoing surveillance. In a population of patients with cirrhosis, over 60% of nodules < 2 cm in diameter detected on a screening ultrasonography prove to be hepatocellular carcinoma. Mass vaccination programs against

HBV in developing countries are leading to reduced rates of hepatocellular carcinoma. Successful treatment of hepatitis B and of hepatitis C in patients with cirrhosis also reduces the subsequent risk of hepatocellular carcinoma.

▶ Treatment

Surgical resection of a solitary hepatocellular carcinoma may result in cure if liver function is preserved (Child class A or possibly B) and portal vein thrombosis is not present. Laparoscopic liver resection has been performed in selected cases. Treatment of underlying chronic viral hepatitis, adjuvant chemotherapy, and adaptive immunotherapy may lower postsurgical recurrence rates. Liver transplantation may be appropriate for small unresectable tumors in a patient with advanced cirrhosis, with reported 5-year survival rates of up to 75%. The recurrence-free survival may be better for liver transplantation than for resection in patients with well-compensated cirrhosis and small tumors (one tumor < 5 cm or three or fewer tumors each < 3 cm in diameter [Milan criteria]) and in those with expanded (University of California, San Francisco) criteria of one tumor ≤ 6.5 cm or three or fewer tumors ≤ 4.5 cm. Patients with stage 2 hepatocellular carcinoma receive an additional 22 points on their Model for End-Stage Liver Disease (MELD) score (see Chapter 16), markedly increasing their chances of undergoing transplantation. However, liver transplantation is often impractical because of the donor organ shortage, and living donor liver transplantation may be considered in these cases. Patients with larger tumors (3–5 cm), a serum α -fetoprotein level ≥ 455 ng/mL (455 mcg/L), or a MELD score ≥ 20 have poor posttransplantation survival. Chemotherapy, hormonal therapy with tamoxifen, and long-acting octreotide have not been shown to prolong life, but transarterial chemoembolization (TACE), transarterial chemoinfusion (TACI), and transarterial radioembolization (TARE) via the hepatic artery are palliative and may prolong survival in patients with a large or multifocal tumor in the absence of extrahepatic spread. TACI and TARE are suitable for patients with portal vein thrombosis. Injection of absolute ethanol into, radiofrequency ablation of, cryotherapy of, or microwave ablation of small tumors (< 2 cm) may prolong survival in patients who are not candidates for resection; these interventions may provide a “bridge” to liver transplantation. Radiofrequency ablation is superior to ethanol injection for tumors > 2 cm in diameter and can be performed after TACE in select cases. Sorafenib (an oral multikinase inhibitor of Raf kinase, the VEGF receptor, and the platelet-derived growth factor receptor [and others]), prolongs median survival as well as the time to radiologic progression by 3 months in patients with advanced hepatocellular carcinoma; sorafenib is the standard of care in these patients. New chemotherapy and radiation therapy techniques (eg, radioembolization with yttrium-90 microspheres), novel biologic approaches (eg, bortezomib, a proteasome inhibitor; antiangiogenesis agents; other inhibitors of growth-factor signaling; and gene therapy), and multimodal approaches are under study. For patients whose disease progresses despite treatment or who present with advanced tumors, vascular invasion, or extrahepatic

spread, meticulous efforts at palliative care are essential (see Chapter 5). Severe pain may develop in such patients due to expansion of the liver capsule by the tumor and requires concerted efforts at pain management, including the use of opioids (see Chapter 5).

▶ Prognosis

In the United States, overall 1- and 5-year survival rates for patients with hepatocellular carcinoma are 23% and 5%, respectively. Five-year survival rates rise to 56% for patients with localized resectable disease (T1, T2, selected T3 and T4; N0; M0) but are virtually nil for those with locally unresectable or advanced disease. In patients with HCV-related hepatocellular carcinoma, the serum α -fetoprotein level at the time of diagnosis of cancer has been reported to be an independent predictor of mortality. Contrary to traditional opinion, the fibrolamellar variant does not have a better prognosis than conventional hepatocellular carcinoma without cirrhosis.

▶ When to Refer

All patients with hepatocellular carcinoma should be referred to a specialist.

▶ When to Admit

- Complications of cirrhosis.
- Severe pain.
- For surgery and other interventions.

Bruix J et al. Management of hepatocellular carcinoma: an update. *Hepatology*. 2011 Mar;53(3):1020–2. [PMID: 21374666]
 El-Serag HB. Hepatocellular carcinoma. *N Engl J Med*. 2011 Sep 22;365(12):1118–27. [PMID: 21992124]
 Villanueva A et al. Targeted therapies for hepatocellular carcinoma. *Gastroenterology*. 2011 May;140(5):1410–26. [PMID: 21406195]

CARCINOMA OF THE BILIARY TRACT



ESSENTIALS OF DIAGNOSIS

- ▶ Presents with obstructive jaundice, usually painless, often with dilated biliary tree.
- ▶ Pain is more common in gallbladder carcinoma than cholangiocarcinoma.
- ▶ A Courvoisier (dilated) gallbladder may be detected.
- ▶ Diagnosis by cholangiography with biopsy and brushings for cytology.

▶ General Considerations

Carcinoma of the gallbladder occurs in approximately 2% of all people operated on for biliary tract disease. It is

notoriously insidious, and the diagnosis is often made unexpectedly at surgery. Cholelithiasis (often large, symptomatic stones) is usually present. Other risk factors are chronic infection of the gallbladder with *Salmonella typhi*, gallbladder polyps over 1 cm in diameter, mucosal calcification of the gallbladder (porcelain gallbladder), and anomalous pancreaticobiliary ductal junction. Genetic factors include *K-ras* and *TP53* mutations. Spread of the cancer—by direct extension into the liver or to the peritoneal surface—may be the initial manifestation. The TNM classification includes the following stages: Tis, carcinoma in situ; T1a, tumor invades lamina propria, and T1b, tumor invades muscle layer; T2, tumor invades perimuscular connective tissue, no extension beyond serosa (visceral peritoneum) or into liver; T3, tumor perforates the serosa or directly invades the liver or adjacent organ or structure; T4, tumor invades the main portal vein or hepatic artery or invades multiple extrahepatic organs or structures; N1, regional lymph node metastasis; and M1, distant metastasis.

Carcinoma of the bile ducts (cholangiocarcinoma) accounts for 10–25% of all hepatobiliary malignancies and 3% of all cancer deaths in the United States. It is more prevalent in persons aged 50–70, with a slight male predominance, and more common in Asia. Two-thirds arise at the confluence of the hepatic ducts (Klatskin tumors), and one-fourth arise in the distal extrahepatic bile duct; the remainder are intrahepatic (peripheral), the incidence of which has risen dramatically since the 1970s. Staging for extrahepatic cholangiocarcinoma is as follows: T1, tumor is confined to bile duct; T2, tumor spreads beyond the wall of the bile duct (2a) or to the adjacent liver (2b); T3, tumor spreads to unilateral branches of the portal vein or hepatic artery; T4, tumor spreads to main portal vein or its branches bilaterally, common hepatic artery, second-order biliary radicals bilaterally, or various combinations; N1, regional lymph node metastasis; M1, distant metastasis. Staging for intrahepatic cholangiocarcinoma is as follows: T1, solitary tumor without vascular invasion; T2, solitary tumor with vascular invasion or multiple tumors ≤ 5 cm; T3, multiple tumors > 5 cm or involving major branch of portal or hepatic veins; T4, tumor invades adjacent organ (except gallbladder) or perforation of visceral peritoneum; N1, regional lymph node metastasis; and M1, distant metastasis. Other staging systems consider tumor extent and form, vascular encasement, hepatic lobe atrophy, and underlying liver disease. The frequency of carcinoma in persons with choledochal cysts has been reported to be over 14% at 20 years, and surgical excision is recommended. There is an increased incidence in patients with bile duct adenoma; biliary papillomatosis; Caroli disease; a biliary-enteric anastomosis; ulcerative colitis, especially those with primary sclerosing cholangitis; biliary cirrhosis; diabetes mellitus; hyperthyroidism; chronic pancreatitis; heavy alcohol consumption; and past exposure to thorotrast, a contrast agent. In Southeast Asia, hepatolithiasis and infection of the bile ducts with helminths (*Clonorchis sinensis*, *Opisthorchis viverrini*) are associated with chronic cholangitis and an increased risk of cholangiocarcinoma. Hepatitis C virus infection, cirrhosis, HIV infection,

nonalcoholic fatty liver disease, diabetes mellitus, obesity, and tobacco smoking are additional risk factors for intrahepatic cholangiocarcinoma.

► Clinical Findings

A. Symptoms and Signs

Progressive jaundice is the most common and usually the first sign of obstruction of the extrahepatic biliary system. Pain in the right upper abdomen with radiation into the back is usually present early in the course of gallbladder carcinoma but occurs later in the course of bile duct carcinoma. Anorexia and weight loss are common and may be associated with fever and chills due to cholangitis. Rarely, hematemesis or melena results from erosion of tumor into a blood vessel (hemobilia). Fistula formation between the biliary system and adjacent organs may also occur. The course is usually one of rapid deterioration, with death occurring within a few months.

Physical examination reveals profound jaundice. Pruritus and skin excoriations are common. A palpable gallbladder with obstructive jaundice usually is said to signify malignant disease (Courvoisier law); however, this clinical generalization has been proved to be accurate only about 50% of the time. Hepatomegaly due to hypertrophy of the unobstructed liver lobe is usually present and is associated with liver tenderness. Ascites may occur with peritoneal implants.

B. Laboratory Findings

With biliary obstruction, laboratory examination reveals predominantly conjugated hyperbilirubinemia, with total serum bilirubin values ranging from 5 to 30 mg/dL. There is usually concomitant elevation of the alkaline phosphatase and serum cholesterol. AST is normal or minimally elevated. An elevated CA 19-9 level may help distinguish cholangiocarcinoma from a benign biliary stricture (in the absence of cholangitis).

C. Imaging

Ultrasonography and contrast-enhanced, triple-phase, helical CT may show a gallbladder mass in gallbladder carcinoma and intrahepatic mass or biliary dilatation in carcinoma of the bile ducts. CT may also show involved regional lymph nodes and atrophy of a hepatic lobe because of vascular encasement with compensatory hypertrophy of the unaffected lobe. MRI with magnetic resonance cholangiopancreatography (MRCP) and gadolinium enhancement permits visualization of the entire biliary tree and detection of vascular invasion and obviates the need for angiography and, in some cases, direct cholangiography; it is the imaging procedure of choice but may understage malignant hilar strictures. The sensitivity and image quality can be increased with use of ferumoxime enhancement. The features of intrahepatic cholangiocarcinoma on MRI appear to differ from those of hepatocellular carcinoma, with contrast washout in the latter but not the former. In indeterminate cases, PET can detect cholangiocarcinomas as small as 1 cm and lymph node and

distant metastases, but false-positive results occur. The most helpful diagnostic studies before surgery are either percutaneous transhepatic or endoscopic retrograde cholangiography with biopsy and cytologic specimens, although false-negative biopsy and cytology results are common. Digital image analysis and fluorescent in situ hybridization of cytologic specimens improve sensitivity. Endoscopic ultrasonography with FNA of tumors, choledochoscopy, and intraductal ultrasonography may confirm a diagnosis of cholangiocarcinoma in a patient with bile duct stricture and an otherwise indeterminate evaluation.

▶ Treatment

In young and fit patients, curative surgery may be attempted if the tumor is well localized. The 5-year survival rate for carcinoma of the gallbladder invading the lamina propria or muscularis (stage 1, T1a or 1b, N0, M0) is as high as 85% with laparoscopic cholecystectomy but drops to 60%, even with a more extended open resection, if there is perimuscular invasion (T2). The role of radical surgery for T3 and T4 tumors is debatable. If the tumor is unresectable at laparotomy, biliary-enteric bypass (eg, Roux-en-Y hepaticojejunostomy) can be performed. Carcinoma of the bile ducts is curable by surgery in < 10% of cases. If resection margins are negative, the 5-year survival rate may be as high as 47% for intrahepatic cholangiocarcinomas, 41% for hilar cholangiocarcinoma, and 37% for distal cholangiocarcinomas, but the perioperative mortality rate may be as high as 10%. Palliation can be achieved by placement of a self-expandable metal stent via an endoscopic or percutaneous transhepatic route. Covered metal stents may be more cost-effective than uncovered metal stents because of a longer duration of patency, but they are associated with a higher rate of stent migration and cholecystitis due to occlusion of the cystic duct and are not associated with longer survival. For hilar tumors, there is controversy as to whether unilateral or bilateral stents should be inserted. Plastic stents are less expensive but more prone to occlude than metal ones; they are suitable for patients expected to survive only a few months. Photodynamic therapy in combination with stent placement has been demonstrated to prolong survival when compared with stent placement alone in patients with nonresectable cholangiocarcinoma. Radiotherapy may relieve pain and contribute to biliary decompression. There is limited response to chemotherapy with gemcitabine alone, but the combination of cisplatin and gemcitabine prolongs survival by about 3 months in patients with locally advanced or metastatic cholangiocarcinoma. Few patients survive for more than 24 months. Although cholangiocarcinoma is generally considered to be a contraindication to liver transplantation because of rapid tumor recurrence, a 75% 5-year survival rate has been reported in patients with stage I and II cholangiocarcinoma undergoing chemoradiation and exploratory laparotomy followed by liver transplantation.

For those patients whose disease progresses despite treatment, meticulous efforts at palliative care are essential (see Chapter 5).

▶ When to Refer

All patients with carcinoma of the biliary tract should be referred to a specialist.

▶ When to Admit

- Biliary obstruction.
- Cholangitis.

DeOliveira ML et al. New staging system and a registry for perihilar cholangiocarcinoma. *Hepatology*. 2011 Apr;53(4):1363–71. [PMID: 21480336]

Saleem A et al. Meta-analysis of randomized trials comparing the patency of covered and uncovered self-expandable metal stents for palliation of distal malignant bile duct obstruction. *Gastrointest Endosc*. 2011 Aug;74(2):321–7. [PMID: 21683354]

Tyson GL et al. Risk factors for cholangiocarcinoma. *Hepatology*. 2011 Jul;54(1):173–84. [PMID: 21488076]

CARCINOMA OF THE PANCREAS & THE PERIAMPULLARY AREA



ESSENTIALS OF DIAGNOSIS

- ▶ Obstructive jaundice (may be painless).
- ▶ Enlarged gallbladder (may be painful).
- ▶ Upper abdominal pain with radiation to back, weight loss, and thrombophlebitis are usually late manifestations.

▶ General Considerations

Carcinomas involving the head of the pancreas, ampulla of Vater, distal bile duct, and duodenum are considered together because they are usually indistinguishable clinically; of these, carcinomas of the pancreas constitute over 90%. Carcinoma is the most common neoplasm of the pancreas. About 75% are in the head and 25% in the body and tail of the organ. They comprise 2% of all cancers and 5% of cancer deaths. Risk factors include age, tobacco use (which is thought to cause 20–25% of cases), heavy alcohol use, obesity, chronic pancreatitis, prior abdominal radiation, family history, and possibly gastric ulcer. New-onset diabetes mellitus after age 45 years occasionally heralds the onset of pancreatic cancer. In diabetic patients, preliminary data suggest that metformin use reduces the risk but insulin use and glucagon-like peptide-1-based therapy (eg, sitagliptin) increase the risk of pancreatic cancer. About 7% of patients with pancreatic cancer have a family history of pancreatic cancer in a first-degree relative, compared with 0.6% of control subjects. Point mutations in codon 12 of the *K-ras* oncogene are found in 70–100% of pancreatic cancers; inactivation of the tumor suppressor genes *INK4A* on chromosome 9, *TP53* on chromosome 17, and *MADH4* on chromosome 18 is found in 95%, 75%, and 55% of pancreatic cancers,

respectively; and mutation of the palladin gene is reported to be common. In 5–10% of cases, pancreatic cancer occurs as part of several hereditary syndromes, including familial breast cancer (carriers of *BRCA-2* have a 7% lifetime risk of pancreatic cancer), hereditary pancreatitis (*PSS1* mutation), familial atypical multiple mole melanoma (*p16/CDKN2A* mutation), Peutz-Jeghers syndrome (*STK11/LKB1* mutation), ataxia-telangiectasia, and hereditary nonpolyposis colorectal cancer. Polymorphisms of the genes for methylene tetrahydrofolate reductase and thymidylate synthase have been reported to be associated with pancreatic cancer. Neuroendocrine tumors account for 1–2% of pancreatic neoplasms and may be functional (producing gastrin, insulin, glucagon, vasoactive intestinal peptide, somatostatin, growth hormone–releasing hormone, adrenocorticotrophic hormone, and others) or non-functional. Plasma chromogranin A levels are elevated in 88–100% of affected patients. Cystic neoplasms account for only 1% of pancreatic cancers, but they are important because they are often mistaken for pseudocysts. A cystic neoplasm should be suspected when a cystic lesion in the pancreas is found in the absence of a history of pancreatitis. At least 15% of all pancreatic cysts are neoplasms. Whereas serous cystadenomas (which account for 32–39% of cystic pancreatic neoplasms and also occur in patients with von Hippel-Lindau disease) are benign, mucinous cystic neoplasms (defined by the presence of ovarian stroma) (10–45%), intraductal papillary mucinous neoplasms (21–33%), solid pseudopapillary tumors (< 5%), and cystic islet cell tumors (3–5%) may be malignant, although their prognoses are better than the prognosis of adenocarcinoma of the pancreas, unless the neoplasm is locally advanced.

► Clinical Findings

A. Symptoms and Signs

Pain is present in over 70% of cases and is often vague, diffuse, and located in the epigastrium or left upper quadrant when the lesion is in the tail. Radiation of pain into the back is common and sometimes predominates. Sitting up and leaning forward may afford some relief, and this usually indicates that the lesion has spread beyond the pancreas and is inoperable. Diarrhea, perhaps due to maldigestion, is an occasional early symptom. Migratory thrombophlebitis is a rare sign. Weight loss is a common but late finding and may be associated with depression. Occasionally a patient presents with acute pancreatitis in the absence of an alternative cause. Jaundice is usually due to biliary obstruction by a cancer in the pancreatic head. A palpable gallbladder is also indicative of obstruction by neoplasm (Courvoisier law), but there are frequent exceptions. A hard, fixed, occasionally tender mass may be present. In advanced cases, a hard periumbilical (Sister Joseph's) nodule may be palpable.

B. Laboratory Findings

There may be mild anemia. Glycosuria, hyperglycemia, and impaired glucose tolerance or true diabetes mellitus are found in 10–20% of cases. The serum amylase or lipase

level is occasionally elevated. Liver biochemical tests may suggest obstructive jaundice. Steatorrhea in the absence of jaundice is uncommon. Occult blood in the stool is suggestive of carcinoma of the ampulla of Vater (the combination of biliary obstruction and bleeding may give the stools a distinctive silver appearance). CA 19-9, with a sensitivity of 70% and a specificity of 87%, has not proved sensitive enough for early detection of pancreatic cancer; increased values are also found in acute and chronic pancreatitis and cholangitis.

C. Imaging

Multiphase thin-cut helical CT is generally the initial diagnostic procedure and detects a mass in over 80% of cases. CT identifies metastases, delineates the extent of the tumor, and allows for percutaneous FNA for cytologic studies and tumor markers. MRI is an alternative to CT. Ultrasonography is not reliable because of interference by intestinal gas. PET is a sensitive technique for detecting pancreatic cancer and metastases, but PET-CT is not a routine staging procedure. Selective celiac and superior mesenteric arteriography may demonstrate vessel invasion by tumor, a finding that would preclude attempts at surgical resection, but it is less widely used since the advent of multiphase helical CT. Endoscopic ultrasonography is more sensitive than CT for detecting pancreatic cancer and equivalent to CT for determining nodal involvement and resectability. A normal endoscopic ultrasonogram excludes pancreatic cancer. Endoscopic ultrasonography may also be used to guide FNA for tissue diagnosis, tumor markers, and DNA analysis. Endoscopic retrograde cholangiopancreatography (ERCP) may clarify an ambiguous CT scan or MRI study by delineating the pancreatic duct system or confirming an ampullary or biliary neoplasm. MRCP appears to be at least as sensitive as ERCP in diagnosing pancreatic cancer. In some centers, pancreatoscopy or intraductal ultrasonography can be used to evaluate filling defects in the pancreatic duct and assess resectability of intraductal papillary mucinous tumors. With obstruction of the splenic vein, splenomegaly or gastric varices are present, the latter delineated by endoscopy, endoscopic ultrasonography, or angiography.

Cystic neoplasms can be distinguished by their appearance on CT, endoscopic ultrasonography, and ERCP and features of the cyst fluid on gross and cytologic analysis. For example, serous cystadenomas may have a central scar or honeycomb appearance; mucinous cystadenomas are unilocular or multilocular and contain mucin-rich fluid with high carcinoembryonic antigen levels (> 200 ng/mL) (200 mcg/L); and intraductal papillary mucinous neoplasms are associated with a dilated pancreatic duct and extrusion of gelatinous material from the ampulla.

► Staging

Staging of pancreatic cancer by the TNM classification includes the following definitions: Tis: carcinoma in situ; T1: tumor limited to the pancreas, 2 cm or less in greatest dimension; T2: tumor limited to the pancreas, more than

2 cm in greatest dimension; T3: tumor extends beyond the pancreas but without involvement of the celiac axis or the superior mesenteric artery; T4, tumor involves the celiac axis or the superior mesenteric artery (unresectable primary tumor); N1, regional lymph node metastasis; M1, distant metastasis.

► Treatment

Abdominal exploration is usually necessary when cytologic diagnosis cannot be made or if resection is to be attempted, which includes about 30% of patients. In a patient with a localized mass in the head of the pancreas and without jaundice, laparoscopy may detect tiny peritoneal or liver metastases and thereby avoid resection in 4–13% of patients. Radical pancreaticoduodenal (Whipple) resection is indicated for lesions strictly limited to the head of the pancreas, periampullary area, and duodenum (T1, N0, M0). Five-year survival rates are 20–25% in this group and as high as 40% in those with negative resection margins and without lymph node involvement. Preoperative endoscopic decompression of an obstructed bile duct is often achieved with a plastic stent or short metal stent but does not reduce operative mortality and is associated with complications. The best surgical results are achieved at centers that specialize in the multidisciplinary treatment of pancreatic cancer. Adjuvant or neoadjuvant chemotherapy with gemcitabine or fluorouracil (or both), possibly combined with irradiation, is of benefit (Table 39–4). Chemoradiotherapy downstages about 30% of patients with locally advanced disease to allow resection. When resection is not feasible, endoscopic stenting of the bile duct is performed to relieve jaundice. A plastic stent is generally placed if the patient's anticipated survival is < 6 months (or surgery is planned). A metal stent is preferred when anticipated survival is 6 months or greater. Whether covered metal stents designed to prevent tumor ingrowth offer an advantage over uncovered stents is uncertain because covered stents are associated with higher rates of migration and acute cholecystitis due to occlusion of the cystic duct. Surgical biliary bypass may be considered in patients expected to survive at least 6 months. Surgical duodenal bypass may be considered in patients in whom duodenal obstruction is expected to develop later; alternatively, endoscopic placement of a self-expandable duodenal stent may be feasible. Chemoradiation may be used for palliation of unresectable cancer confined to the pancreas. Chemotherapy has been disappointing in metastatic pancreatic cancer, although improved response rates have been reported with the combination of oxaliplatin, irinotecan, fluorouracil, and leucovorin (FOLFIRINOX). The addition of erlotinib (an inhibitor of the EGFR receptor), capecitabine (an oral fluoropyrimidine), or a platinum agent may improve survival but also increases toxicity. The high rate of *K-ras* mutations in pancreatic cancer limits the benefit of erlotinib. Nucleoside cytidine analogues and topoisomerase inhibitors are under study. Celiac plexus nerve block (under CT or endoscopic ultrasound guidance) or thoracoscopic splanchnicectomy may improve pain control. Photodynamic therapy is under study.

Surgical resection is the treatment of choice for neuroendocrine tumors, when feasible. Metastatic disease may be controlled with long-acting somatostatin analogs, interferon, peptide-receptor radionuclide therapy, and chemoembolization. There is a growing consensus that asymptomatic incidental pancreatic cysts ≤ 2 cm are at low risk for harboring invasive carcinoma. The cysts may be monitored by imaging tests at 6- to 12-month intervals and every 3–6 months in those > 2 cm, with surgery or possibly endoscopic ultrasound-guided cyst ablation performed if a cyst enlarges or exceeds 2.5 cm.

Surgical resection is indicated for mucinous cystic neoplasms, symptomatic serous cystadenomas, solid pseudopapillary tumors (which have a 15% risk of malignant transformation), and cystic tumors > 2 cm in diameter that remain undefined after helical CT, endoscopic ultrasonography, and diagnostic aspiration. All intraductal papillary mucinous neoplasms of the main pancreatic duct should be resected, but those of branch ducts may be followed with serial imaging if they are asymptomatic and exhibit benign features (eg, diameter < 3 cm [some authorities recommend a diameter ≤ 1.5 cm], absence of nodules or a thick wall); most of the latter remain stable on follow-up, but the risk of pancreatic ductal carcinoma and of nonpancreatic cancers may also be increased in this group of patients. In the absence of locally advanced disease, survival is higher for malignant cystic neoplasms than for adenocarcinoma. Endoscopic resection or ablation, with temporary placement of a pancreatic duct stent, may be feasible for ampullary adenomas, but patients must be followed for recurrence.

► Prognosis

Carcinoma of the pancreas, especially in the body or tail, has a poor prognosis; 80–85% of patients present with advanced unresectable disease, and reported 5-year survival rates range from 2% to 5%. Lesions of the ampulla have a better prognosis, with reported 5-year survival rates of 20–40% after resection; jaundice and lymph node involvement are adverse prognostic factors. In carefully selected patients, resection of cancer of the pancreatic head is feasible and results in reasonable survival. In persons with a family history of pancreatic cancer in at least two first-degree relatives, screening with endoscopic ultrasonography and helical CT or MRI/MRCP should be considered beginning at age 40–45 or 10 years before the age at which pancreatic cancer was diagnosed in a family member.

For those patients whose disease progresses despite treatment, meticulous efforts at palliative care are essential (see Chapter 5).

► When to Refer

All patients with carcinoma involving the pancreas and the periampullary area should be referred to a specialist.

► When to Admit

Patients who require surgery and other interventions should be hospitalized.

Table 39-4. Treatment choices for cancers responsive to systemic agents.

Diagnosis	Current Treatment of Choice	Other Treatments
Acute lymphoblastic leukemia (ALL)	Induction combination chemotherapy: Vincristine, prednisone, daunorubicin, asparaginase, intrathecal methotrexate Consolidation combination chemotherapy: Cyclophosphamide, vincristine, doxorubicin, dexamethasone (hyper-CVAD) alternated with cytarabine, methotrexate Maintenance chemotherapy: Methotrexate, 6-mercaptopurine	Imatinib mesylate (Ph positive ALL), autologous or allogeneic transplantation for high risk or at relapse
Acute myeloid leukemia (AML)	Combination chemotherapy: Cytarabine, daunorubicin or Cytarabine, idarubicin	Mitozantrone, doxorubicin, cladribine, fludarabine, prednisone
Chronic myeloid leukemia (CML)	Imatinib mesylate or nilotinib or dasatinib	Dasatinib, nilotinib, allogeneic bone marrow transplantation, hydroxyurea, interferon- α , cytarabine, busulfan
Chronic lymphocytic leukemia (CLL)	Combination chemotherapy: Fludarabine, cyclophosphamide, rituximab (FCR); or Fludarabine, or Bendamustine or Chlorambucil	Alemtuzumab, bendamustine, pentostatin, cladribine, cyclophosphamide, vincristine, doxorubicin, prednisone
Hairy cell leukemia	Cladribine (2-chlorodeoxyadenosine)	Pentostatin, rituximab, interferon- α
Hodgkin disease (stages III and IV)	Combination chemotherapy: Doxorubicin, bleomycin, vinblastine, dacarbazine (ABVD) or Doxorubicin, vinblastine, mechlorethamine, etoposide, vincristine, bleomycin, prednisone (Stanford V)	Gemcitabine, vinorelbine, ifosfamide, cyclophosphamide, procarbazine, transplantation for relapse
Non-Hodgkin lymphoma (intermediate and high grade)	Combination chemotherapy: Cyclophosphamide, doxorubicin, vincristine, prednisone, rituximab (CHOP-R)	Combination chemotherapy second line: Dexamethasone, cisplatin, cytarabine (DHAP) or Etoposide, methylprednisolone, cytarabine, cisplatin (ESHAP) or Ifosfamide, carboplatin, etoposide (ICE) or Mesna, ifosfamide, mitoxantrone, etoposide (MINE); transplantation for high risk or first relapse
Non-Hodgkin lymphoma (low grade)	Combination chemotherapy: Fludarabine, cyclophosphamide, rituximab (FCR) or Fludarabine, rituximab (FR) or Bendamustine, rituximab or Cyclophosphamide, vincristine, doxorubicin, prednisone, rituximab (CHOP-R), or Cyclophosphamide, vincristine, prednisone, rituximab (CVP-R) or Chlorambucil	^{131}I tositumomab, ^{90}Y ibritumomab tiuxetan, bendamustine, autologous or allogeneic transplantation
Multiple myeloma	Combination chemotherapy (transplant candidates): Bortezomib, dexamethasone, thalidomide or Bortezomib, dexamethasone, lenalidomide or Dexamethasone, thalidomide or Dexamethasone, lenalidomide Followed by autologous or miniallogeneic stem cell transplantation Combination chemotherapy (non-transplant candidates): Melphalan, prednisone, bortezomib, or Melphalan, prednisone, lenalidomide, or Melphalan, prednisone, thalidomide, or Melphalan, prednisone	Bortezomib, lenalidomide, thalidomide, dexamethasone, cyclophosphamide, liposomal doxorubicin
Waldenstrom macroglobulinemia	Plasmapheresis alone or followed by combination chemotherapy: Bortezomib with or without rituximab or, cyclophosphamide, prednisone or thalidomide with or without rituximab	Cladribine, thalidomide, bortezomib, chlorambucil, bendamustine, autologous bone marrow transplantation, prednisone
Polycythemia vera	Phlebotomy, hydroxyurea	Anagrelide, radiophosphorus ^{32}P , interferon- α , busulfan, chlorambucil, cyclophosphamide
Non-small cell lung cancer	Combination chemotherapy: Cisplatin, vinorelbine or Cisplatin, etoposide or Paclitaxel, carboplatin or Cisplatin, gemcitabine (squamous histology) Cisplatin, pemetrexed (nonsquamous histology) All regimens with or without bevacizumab Erlotinib (EGFR mutation positive) Crizotinib (ALK mutation positive)	Docetaxel, vinorelbine, erlotinib, cetuximab

(continued)

Table 39-4. Treatment choices for cancers responsive to systemic agents. (continued)

Diagnosis	Current Treatment of Choice	Other Treatments
Small cell lung cancer	Combination chemotherapy: Cisplatin, etoposide	Irinotecan, cyclophosphamide, doxorubicin, vincristine, topotecan, gemcitabine, paclitaxel
Mesothelioma	Combination chemotherapy: Cisplatin, pemetrexed or Carboplatin, pemetrexed or Gemcitabine, cisplatin	Doxorubicin, vinorelbine
Head and neck cancer	Combination chemotherapy: Cisplatin, fluorouracil or Paclitaxel, carboplatin or Docetaxel, cisplatin, fluorouracil or Cisplatin or cetuximab with radiation therapy	Hydroxyurea, bleomycin, methotrexate, cetuximab
Esophageal cancer	Combination chemotherapy: Cisplatin, fluorouracil or Paclitaxel, carboplatin	Paclitaxel, irinotecan, oxaliplatin, capecitabine, docetaxel, epirubicin
Uterine cancer	Progestins, tamoxifen, aromatase inhibitors or Combination chemotherapy: Cisplatin, doxorubicin, or Paclitaxel or Cisplatin, doxorubicin or Carboplatin, paclitaxel	Fluorouracil, docetaxel, liposomal doxorubicin
Ovarian cancer	Combination chemotherapy: Paclitaxel, carboplatin or Intraperitoneal cisplatin, paclitaxel or Docetaxel, carboplatin or Paclitaxel, cisplatin	Gemcitabine, liposomal doxorubicin, topotecan, cyclophosphamide, etoposide, docetaxel
Cervical cancer	With radiation: Cisplatin Combination chemotherapy: Cisplatin, paclitaxel or Cisplatin, topotecan or Carboplatin, paclitaxel or Cisplatin, gemcitabine	Docetaxel, ifosfamide, vinorelbine, irinotecan, epirubicin, mitomycin, fluorouracil
Breast cancer	Adjuvant endocrine therapy: <i>Premenopausal:</i> Tamoxifen <i>Postmenopausal:</i> Aromatase inhibitors (anastrozole, letrozol, exemestane) Adjuvant chemotherapy (without trastuzumab): Doxorubicin, cyclophosphamide, docetaxel or Doxorubicin, cyclophosphamide, paclitaxel or Docetaxel, cyclophosphamide or Doxorubicin, cyclophosphamide Adjuvant chemotherapy (with trastuzumab): Doxorubicin, cyclophosphamide, paclitaxel, trastuzumab or Docetaxel, carboplatin, trastuzumab	Megestrol, aminoglutethimide, capecitabine, mitoxantrone, cisplatin, etoposide, vinblastine, fluorouracil, ixabepilone, gemcitabine
Choriocarcinoma (trophoblastic neoplasms)	Single agents: Methotrexate or dactinomycin for low risk disease Combination chemotherapy: Etoposide/methotrexate, dactinomycin, cyclophosphamide, vincristine (EMA-CO) for high-risk disease	Vinblastine, cisplatin, mercaptopurine, chlorambucil, doxorubicin
Testicular cancer	Combination chemotherapy: Bleomycin, etoposide, cisplatin (BEP) or Cisplatin, etoposide (EP) or Etoposide, mesna, ifosfamide, cisplatin (VIP)	Vinblastine, ifosfamide, paclitaxel, gemcitabine, oxaliplatin
Kidney cancer	Sunitinib or temsirolimus or bevacizumab or sorafenib, or pazopanib or interleukin-2	Interferon- α , vinblastine, capecitabine, fluorouracil
Bladder cancer	Combination chemotherapy: Gemcitabine, cisplatin or Methotrexate, vinblastine, doxorubicin, cisplatin (MVAC)	Carboplatin, paclitaxel, docetaxel, fluorouracil, pemetrexed, methotrexate
Prostate cancer	Luteinizing hormone-releasing agonist (leuprolide, goserelin, triptorelin, degarelix) plus an antiandrogen (flutamide, bicalutamide, nilutamide)	Ketoconazole, docetaxel, abiraterone, mitoxantrone, cabazitaxel, sipuleucel-T, estramustine, prednisone
Brain cancer (anaplastic astrocytoma and glioblastoma multiforme)	Temozolomide	Bevacizumab, irinotecan, procarbazine, carmustine, lomustine

(continued)

Table 39-4. Treatment choices for cancers responsive to systemic agents. (continued)

Diagnosis	Current Treatment of Choice	Other Treatments
Neuroblastoma	Combination chemotherapy: Cyclophosphamide, doxorubicin, cisplatin, etoposide	Vincristine, topotecan, irinotecan, ifosfamide, carboplatin, 13-cis-retinoic acid, ¹³¹ I-MIBG, autologous or allogeneic transplantation
Thyroid cancer	Radioiodine (¹³¹ I) or sorafenib or vandetanib (medullary thyroid cancer)	Doxorubicin, dacarbazine
Adrenal cancer	Mitotane	Doxorubicin, etoposide, cisplatin
Stomach cancer	Combination chemotherapy: Epirubicin, cisplatin, fluorouracil or Docetaxel, cisplatin, fluorouracil or Fluorouracil, leucovorin, oxaliplatin Trastuzumab added for Her2-neu overexpressing adenocarcinomas	Capecitabine, sorafenib, trastuzumab, irinotecan
Pancreatic cancer	Combination chemotherapy: Gemcitabine, cisplatin or Gemcitabine, erlotinib or Fluorouracil, leucovorin, irinotecan, oxaliplatin (FOLFIRINOX) Gemcitabine	Capecitabine
Colon cancer	Combination chemotherapy: Fluorouracil, leucovorin, oxaliplatin (FOLFOX6) or Capecitabine, oxaliplatin (CapeOx) or Fluorouracil, leucovorin, irinotecan (FOLFIRI) each regimen with or without bevacizumab	Cetuximab, irinotecan, panitumumab
Rectal cancer	Chemotherapy with radiation: Fluorouracil; For advanced disease same regimens used with colon cancer	Cetuximab, irinotecan, panitumumab
Anal cancer	Combination chemotherapy with radiation: Fluorouracil, mitomycin	Cisplatin
Carcinoid	Combination chemotherapy: Streptozocin, fluorouracil or Bevacizumab or sorafenib or sunitinib	Doxorubicin, dacarbazine, octreotide, interferon- α
Insulinoma	Interferon or streptozocin	Doxorubicin, fluorouracil, mitomycin
Osteogenic sarcoma	Combination chemotherapy with two of these agents: Doxorubicin, cisplatin, ifosfamide, high-dose methotrexate	Cyclophosphamide, dacarbazine
Soft tissue sarcomas	Combination chemotherapy: Doxorubicin, dacarbazine (AD) or Doxorubicin, ifosfamide, mesna (AIM) or Mesna, doxorubicin, ifosfamide, dacarbazine (MAID) Imatinib or Sunitinib (Gastrointestinal Stromal Tumors)	Liposomal doxorubicin, methotrexate, gemcitabine, docetaxel, temozolomide
Melanoma	Ipilimumab or vemurafenib or dacarbazine or Temozolomide or high-dose interleukin-2	Paclitaxel, cisplatin, carboplatin, interferon- α , vinblastine
Hepatocellular cancer	Sorafenib	Doxorubicin
Kaposi sarcoma	Liposomal doxorubicin or liposomal daunorubicin	Paclitaxel, vinblastine, vincristine, etoposide, doxorubicin

Al-Haddad M et al. Diagnosis and treatment of cystic pancreatic tumors. *Clin Gastroenterol Hepatol.* 2011 Aug;9(8):635–48. [PMID: 21397725]

Butte JM et al. Solid pseudopapillary tumors of the pancreas. Clinical features, surgical outcomes, and long-term survival in 45 consecutive patients from a single center. *J Gastrointest Surg.* 2011 Feb;15(2):350–7. [PMID: 20824369]

Conroy T et al; PRODIGE Intergroup. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. *N Engl J Med.* 2011 May 12;364(19):1817–25. [PMID: 21561347]

Hidalgo M. Pancreatic cancer. *N Engl J Med.* 2010 Apr 29;362(17): 1605–17. [PMID: 20427809]

Kang MJ et al. Cyst growth rate predicts malignancy in patients with branch duct intraductal papillary mucinous neoplasms. *Clin Gastroenterol Hepatol.* 2011 Jan;9(1):87–93. [PMID: 20851216]

Vincent A et al. Pancreatic cancer. *Lancet.* 2011 Aug 13;378(9791): 607–20. [PMID: 21620466]

ALIMENTARY TRACT CANCERS

Kenneth R. McQuaid, MD

Robin K. Kelley, MD

ESOPHAGEAL CANCER



ESSENTIALS OF DIAGNOSIS

- ▶ Progressive solid food dysphagia.
- ▶ Weight loss common.
- ▶ Endoscopy with biopsy establishes diagnosis.

► General Considerations

Esophageal cancer usually develops in persons between 50 and 70 years of age. The overall ratio of men to women is 3:1. There are two histologic types: squamous cell carcinoma and adenocarcinoma. In the United States, **squamous cell cancer** is much more common in blacks than in whites. Squamous cell cancer has a high incidence in certain regions of China and Southeast Asia. Half of all cases occur in the distal third of the esophagus. Chronic alcohol and tobacco use are strongly associated with an increased risk of squamous cell carcinoma. The risk of squamous cell cancer is also increased in patients with tylosis, achalasia, caustic-induced esophageal stricture, and other head and neck cancers. **Adenocarcinoma** is more common in whites. It is increasing dramatically in incidence and now is as common as squamous carcinoma. The majority of adenocarcinomas develop as a complication of Barrett metaplasia due to chronic gastroesophageal reflux. Thus, most adenocarcinomas arise in the distal third of the esophagus. Obesity also is strongly associated with adenocarcinoma, even after controlling for gastroesophageal reflux; however, no causal relationship has been convincingly shown.

► Clinical Findings

A. Symptoms and Signs

Most patients with esophageal cancer present with advanced, incurable disease. Over 90% have solid food dysphagia, which progresses over weeks to months. Odynophagia is sometimes present. Significant weight loss is common. Local tumor extension into the tracheobronchial tree may result in a tracheoesophageal fistula, characterized by coughing on swallowing or pneumonia. Chest or back pain suggests mediastinal extension. Recurrent laryngeal involvement may produce hoarseness. Physical examination is often unrevealing. The presence of supraclavicular or cervical lymphadenopathy or of hepatomegaly implies metastatic disease.

B. Laboratory Findings

Laboratory findings are nonspecific. Anemia related to chronic disease or occult blood loss is common. Elevated aminotransferase or alkaline phosphatase concentrations suggest hepatic or bony metastases. Hypoalbuminemia may result from malnutrition.

C. Imaging

A barium esophagogram may be the first study obtained to evaluate dysphagia. The appearance of a polypoid, obstructive, or ulcerative lesion is suggestive of carcinoma and requires endoscopic evaluation. However, even lesions believed to be benign by radiography warrant endoscopic evaluation. Chest radiographs may show adenopathy, a widened mediastinum, pulmonary or bony metastases, or signs of tracheoesophageal fistula such as pneumonia.

D. Upper Endoscopy

Endoscopy with biopsy establishes the diagnosis of esophageal carcinoma with a high degree of reliability. In some cases, significant submucosal spread of the tumor may yield nondiagnostic mucosal biopsies. Repeated biopsy may be necessary.

► Staging

After confirmation of the diagnosis of esophageal carcinoma, the stage of the disease should be determined since doing so influences the choice of therapy. Patients should undergo evaluation with CT of the chest and abdomen to look for evidence of pulmonary or hepatic metastases, lymphadenopathy, and local tumor extension. If there is no evidence of distant metastases or extensive local spread on CT, endoscopic ultrasonography with guided FNA biopsy of lymph nodes should be performed, which is superior to CT in demonstrating the level of local mediastinal extension and local lymph node involvement. PET with fluorodeoxyglucose or integrated PET-CT imaging is indicated to look for regional or distant spread in patients thought to have localized disease after other diagnostic studies. Bronchoscopy is sometimes required in esophageal cancers above the carina to exclude tracheobronchial extension. Laparoscopy to exclude occult peritoneal carcinomatosis should be considered in tumors at gastroesophageal junction.

► Differential Diagnosis

Esophageal carcinoma must be distinguished from other causes of progressive dysphagia, including peptic stricture, achalasia, and adenocarcinoma of the gastric cardia with esophageal involvement. Benign-appearing peptic strictures should be biopsied at presentation to exclude occult malignancy.

► Treatment

The approach to esophageal cancer depends on the tumor stage, patient preference and functional status, and the expertise of the surgeons, oncologists, gastroenterologists, and radiotherapists. There is no consensus about the optimal treatment approach. It is helpful, however, to classify patients into two general categories.

A. Therapy for “Curable” Disease

Superficial esophageal cancers confined to the epithelium (high-grade dysplasia or carcinoma in situ [Tis]), lamina propria (T1a), or submucosal (T1b) are increasingly recognized in endoscopic screening and surveillance programs. Esophagectomy achieves high cure rates for superficial tumors but is associated with mortality (2%) and morbidity. If performed by experienced physicians, endoscopic mucosal resection of superficial cancers (especially Tis and T1a) achieves equivalent long-term survival with less morbidity. For a full discussion of management options in superficial adenocarcinoma, see the section on Barrett Esophagus in Chapter 15.

1. Surgery with or without neoadjuvant chemoradiation therapy

—There is debate over the optimal surgical approach for invasive (non-superficial) but potentially “curable” esophageal cancers (stage I, II, or IIIA). The procedure with the lowest morbidity is transhiatal esophagectomy with anastomosis of the stomach to the cervical esophagus; however, this approach does not involve sampling or removal of mediastinal lymph nodes. Alternatively, surgeons may perform en bloc transthoracic excision of the esophagus with extended dissection of lymph nodes in the mediastinum and upper abdomen. In a randomized controlled trial comparing these two approaches, en bloc resection was associated with higher perioperative morbidity but a nonsignificant trend toward improved 5-year survival (39% vs 27%). Transhiatal resection may be more appropriate for patients who are elderly or have comorbid illness, and en bloc resection more appropriate in younger or healthier patients with a better prognosis.

Patients with stage I tumors have high cure rates with surgery alone and do not require radiation or chemotherapy. If regional lymph node metastases have occurred (stages IIB and III), the rate of cure with surgery alone is reduced to <20%. Meta-analysis of trials comparing neoadjuvant (preoperative) therapy followed by surgery with surgery alone suggests a 13% absolute improvement in 2-year survival with combined therapy. A 2008 randomized phase III trial of surgery alone versus a combined modality approach with neoadjuvant chemoradiation followed by surgery also demonstrated a significant survival benefit, with 5-year survival of 39% in the combined modality group versus 16% for surgery alone. Therefore, preoperative (neoadjuvant) chemoradiation therapy is recommended for stage IIA, IIB, and III tumors in fit patients. The chemotherapy regimens used with radiation include weekly carboplatin plus paclitaxel or two cycles of cisplatin plus 5-fluorouracil, based on the randomized phase III CROSS trial and CALGB 9781, respectively. Perioperative chemotherapy without radiation is also appropriate for tumors of the gastroesophageal junction based on the randomized, multicenter, phase III MAGIC trial.

2. Chemotherapy plus radiation therapy without surgery

—Combined treatment with chemotherapy and radiation therapy is superior to radiation therapy alone and has achieved long-term survival rates in up to 25% of patients. Chemoradiation therapy alone should be considered in patients with localized disease (stage II or IIIA) who are poor surgical candidates due to serious medical illness or poor functional status (Eastern Cooperative Oncology Group score > 2). Chemoradiation alone as definitive, non-surgical therapy is more likely to achieve long-term disease-free survival in patients with squamous cell carcinoma than in patients with adenocarcinoma.

B. Therapy for Incurable Disease

More than half of patients have either locally extensive tumor spread (T4) that is unresectable or distant metastases (M1) ie, stage IIIB and stage IV tumors. Surgery is not warranted in these patients. Since prolonged survival can be achieved in few patients, the primary goal is to provide

relief from dysphagia and pain, optimize quality of life, and minimize treatment side effects. The optimal palliative approach depends on the presence or absence of metastatic disease, expected survival, patient preference, and local institutional experience. Many patients with advanced disease may prefer concerted efforts at pain relief and care directed at symptom management (see Chapter 5).

1. Radiation therapy, chemotherapy, and combined therapy

—Combined radiation therapy and chemotherapy may achieve palliation in two-thirds of patients but is associated with significant side effects. It should be considered for patients with locally advanced tumors without distant metastases (stage IIIB) who have good functional status and no significant medical problems, in whom prolonged survival may be achieved. Improvement in dysphagia occurs within 2–4 weeks in almost 90% of patients.

Combination chemotherapy may be considered in patients with metastatic disease who still have good functional status and expected survival of several months. Although there is no consensus on optimal therapy, three drug combinations are commonly used: (1) epirubicin or a taxane (docetaxel or paclitaxel), (2) cisplatin or oxaliplatin, and (3) a fluoropyrimidine (5-FU or capecitabine). For patients with poor functional status, single-agent therapy with a fluoropyrimidine, a taxane, or irinotecan may be used. In patients with metastatic distal esophageal and gastroesophageal junction adenocarcinomas positive for amplification of the *HER-2* gene (approximately 15% of cases), addition of the monoclonal antibody trastuzumab to chemotherapy is associated with prolonged survival.

Radiation therapy alone may afford short-term relief of pain and dysphagia and may be suitable for patients with poor functional status or underlying medical problems. This can generally be performed in a short course over a few weeks or less, but may be complicated by temporary worsening of dysphagia and odynophagia. For patients with frank obstruction or near obstruction, local anti-tumor therapies may be preferred.

2. Local therapy—Patients with advanced esophageal cancer often have a poor functional and nutritional status with an average survival of < 12 weeks from diagnosis. In patients with poor performance status, chemoradiation or radiation may be associated with greater toxicity than potential for long-term benefit. Rapid palliation of dysphagia may be achieved by peroral placement of permanent expandable wire stents, application of endoscopic laser therapy, or photodynamic therapy. Palliative feeding tube placement may be considered for hydration and nutrition in selected cases if the obstruction is not amenable or if it is refractory to stenting, radiation, or other local therapies. Although dysphagia and quality of life are improved significantly, patients can seldom eat normally. Stents are most commonly used because of their relative ease of placement, although the choice of treatment depends on available expertise and equipment. Complications of stents occur in 20–40% and include perforation, migration, and tumor ingrowth.

► Prognosis

The overall 5-year survival rate of esophageal carcinoma is < 20%. Apart from distant metastasis (M1b), the two most important predictors of poor survival are adjacent mediastinal spread (T4) and lymph node involvement. Whereas cure may be achieved in patients with regional lymph node involvement (stages IIB and III), involvement of nodes outside the chest (M1a) is indicative of metastatic disease (stage IV) that is incurable. For those patients whose disease progresses despite chemotherapy, meticulous efforts at palliative care are essential (see Chapter 5).

► When to Refer

- Patients should be referred to gastroenterologist for evaluation and staging (endoscopy with biopsy, endoscopic ultrasonography) and palliative endoscopic antitumor therapy (stent).
- Patients with metastatic disease and obstructive tumors not amenable or refractory to palliative radiation or stenting may require referral to an interventional radiologist, gastroenterologist, or surgeon for feeding tube placement.
- Patients with curable and resectable disease (stage IIB or IIIA) and those with locally advanced or metastatic disease should be referred to an oncologist for consideration of neoadjuvant chemoradiotherapy or palliative chemotherapy, respectively.

► When to Admit

Patients with high-grade esophageal obstruction with inability to manage oral secretions or maintain hydration should be admitted.

Bang Y et al; ToGA Trial Investigators. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. *Lancet*. 2010 Aug 28;376(9742):687–97. [PMID: 20728210]

Bedenne L et al. Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFOCD 9102. *J Clin Oncol*. 2007 Apr 1;25(10):1160–8. [PMID: 17401004]

Courrech Staal EF et al. Systematic review of the benefits and risks of neoadjuvant chemoradiation for oesophageal cancer. *Br J Surg*. 2010 Oct;97(10):1482–96. [PMID: 20645400]

Cunningham D et al; Upper Gastrointestinal Clinical Studies Group of the National Cancer Research Institute of the United Kingdom. Capecitabine and oxaliplatin for advanced esophagogastric cancer. *N Engl J Med*. 2008 Jan 3;358(1):36–46. [PMID: 18172173]

Krasna MJ. Multimodality therapy for esophageal cancer. *Oncology (Williston Park)*. 2010 Nov 15;24(12):1134–8. [PMID: 21141694]

Schuchert MJ et al. Management of esophageal cancer. *Curr Probl Surg*. 2010 Nov;47(11):845–946. [PMID: 20937424]

Sharma P et al. Role of esophageal stents in benign and malignant diseases. *Am J Gastroenterol*. 2010 Feb;105(2):258–73. [PMID: 20029413]

Stahl M et al; ESMO Guidelines Working Group. Esophageal cancer: clinical practice guidelines for diagnosis, treatment and follow-up. *Ann Oncol*. 2010 May;21(Suppl 5):v46–9. [PMID: 20555101]

Tepper J et al. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. *J Clin Oncol*. 2008 Mar 1;26(7):1086–92. [PMID: 18309943]

Umar SB et al. Esophageal cancer: epidemiology, pathogenesis and prevention. *Nat Clin Pract Gastroenterol Hepatol*. 2008 Sep;5(9):517–26. [PMID: 18679388]

Zingg U et al. Minimally invasive versus open esophagectomy for patients with esophageal cancer. *Ann Thorac Surg*. 2009 Mar;87(3):911–9. [PMID: 19231418]

GASTRIC ADENOCARCINOMA



ESSENTIALS OF DIAGNOSIS

- Dyspeptic symptoms with weight loss in patients over age 40 years.
- Iron deficiency anemia: occult blood in stools.
- Abnormality detected on upper gastrointestinal series or endoscopy.

► General Considerations

Gastric adenocarcinoma remains the second most common cause of cancer death worldwide. However, its incidence has declined rapidly over the last 70 years, especially in western countries, which may be attributable to changes in diet (more fruits and vegetables), food refrigeration (allowing more fresh foods and reduced salted, smoked, and preserved foods), reduced toxic environmental exposures, and a decline in *Helicobacter pylori*. The incidence of gastric cancer remains high (70/100,000) in Japan and many developing regions, including eastern Asia, Eastern Europe, Chile, Colombia, and Central America. In the United States, there are an estimated 21,500 new cases and 10,800 deaths/year. The incidence is higher in Latinos, African Americans, and Asian Americans.

There are two main histologic variants of gastric cancer: “intestinal-type” (which resembles intestinal cancers in forming glandular structures) and “diffuse” (which is poorly differentiated, has signet-ring cells, and lacks glandular formation). Although both types are declining in incidence, intestinal-type has had the most dramatic reduction. **Intestinal-type** is still more common (70–80%), occurs twice as often in men as women, primarily affects older people (mean age 63 years), and is more strongly associated with environmental factors. It is believed to arise through a gradual, multi-step progression from inflammation (most commonly due to *H pylori*), to atrophic gastritis, to intestinal metaplasia, and finally dysplasia or cancer. Chronic *H pylori* gastritis is the strong risk factor for gastric carcinoma, increasing the relative risk 3.5- to 20-fold. It is estimated that 60–90% of cases of gastric carcinomas may be attributable to *H pylori*. Other risk factors for

intestinal-type gastric cancer include pernicious anemia, a history of partial gastric resection more than 15 years previously, smoking, and diets that are high in nitrates or salt and low in vitamin C.

Diffuse gastric cancer accounts for 20–30% of gastric cancer. In contrast to intestinal-type cancer, it affects men and women equally, occurs more commonly in young people, is not as strongly related to *H pylori* infection, has a worse prognosis, and has not declined in incidence. Most diffuse gastric cancers are attributable to acquired or hereditary mutations in the genes regulating the E-cadherin cell adhesion protein. Familial diffuse gastric cancer accounts for 1–3% of gastric cancers. The cancer may arise at a young age, is often multifocal and infiltrating with signet ring cell histology, and confers poor prognosis. Many of these families have a germline mutation of E-cadherin *CDH1*, which is inherited in an autosomal dominant pattern and carries a > 60% lifetime risk of gastric cancer. Prophylactic gastrectomy should be considered in patients known to carry this mutation.

Most gastric cancers arise in the body and antrum. These may occur in a variety of morphologic types: (1) polypoid or fungating intraluminal masses; (2) ulcerating masses; (3) diffusely spreading (linitis plastica), in which the tumor spreads through the submucosa, resulting in a rigid, atonic stomach with thickened folds (prognosis dismal); and (4) superficially spreading or “early” gastric cancer—confined to the mucosa or submucosa (with or without lymph node metastases) and associated with a favorable prognosis.

In contrast to the dramatic decline in cancers of the distal stomach, a rise in incidence of tumors of the gastric cardia has been noted. These tumors have demographic and pathologic features that resemble Barrett-associated esophageal adenocarcinomas (see Esophageal Cancer).

▶ Clinical Findings

A. Symptoms and Signs

Gastric carcinoma is generally asymptomatic until the disease is quite advanced. Symptoms are nonspecific and are determined in part by the location of the tumor. Dyspepsia, vague epigastric pain, anorexia, early satiety, and weight loss are the presenting symptoms in most patients. Patients may derive initial symptomatic relief from over-the-counter remedies, further delaying diagnosis. Ulcerating lesions can lead to acute gastrointestinal bleeding with hematemesis or melena. Pyloric obstruction results in postprandial vomiting. Lower esophageal obstruction causes progressive dysphagia. Physical examination is rarely helpful. A gastric mass is palpated in < 20% of patients. Signs of metastatic spread include a left supraclavicular lymph node (Virchow node), an umbilical nodule (Sister Mary Joseph nodule), a rigid rectal shelf (Blumer shelf), and ovarian metastases (Krukenberg tumor). Guaiac-positive stools may be detectable.

B. Laboratory Findings

Iron deficiency anemia due to chronic blood loss or anemia of chronic disease is common. Liver function test

abnormalities, particularly elevation of alkaline phosphatase, may be present if there is metastatic liver spread. Other tumor markers are of no value.

C. Endoscopy

Upper endoscopy should be obtained in all patients over age 55 years with new onset of epigastric symptoms (dyspepsia) and in anyone with dyspepsia that is persistent or fails to respond to a short trial of antisecretory therapy. Endoscopy with biopsies of suspicious lesions is highly sensitive for detecting gastric carcinoma. It can be difficult to obtain adequate biopsy specimens in linitis plastica lesions.

D. Imaging

A barium upper gastrointestinal series is an acceptable alternative when endoscopy is not readily available but may not detect small or superficial lesions and cannot reliably distinguish benign from malignant ulcerations. Any abnormalities detected with this procedure require endoscopic confirmation.

Once a gastric cancer is diagnosed, preoperative evaluation with CT of chest and abdomen (including pelvis in females) and endoscopic ultrasonography is indicated to delineate the local extent of the primary tumor as well as nodal or distant metastases. PET or combined PET-CT imaging may be more sensitive than CT for detection of distant metastasis. Endoscopic ultrasonography is superior to CT in determining the depth of tumor penetration and is useful for evaluation of early gastric cancers that may be removed by endoscopic mucosal resection.

▶ Screening

Because of its unproven efficacy and cost-effectiveness, screening for *H pylori* infection and treating it to prevent gastric cancer is not recommended for asymptomatic adults in the general population but may be considered in patients who have immigrated from regions with a high incidence of gastric cancer or who have a family history of gastric cancer. Because of the high incidence of gastric carcinoma in Japan, screening upper endoscopy is performed to detect early gastric carcinoma. Approximately 40% of tumors detected by screening are early, with a 5-year survival rate of almost 90%. Screening programs are not recommended in the United States.

▶ Staging

Staging is defined according to the TNM system, in which T1 tumors invade the lamina propria (T1a) or submucosa (T1b), T2 invade the muscularis propria, T3 penetrate the serosa, and T4 invade adjacent structures. Lymph nodes are graded as N0 if there is no involvement, and N1, N2, or N3 if there are is involvement of 1–6, 7–15, or more than 15 regional nodes. M1 signifies the presence of metastatic disease.

▶ Differential Diagnosis

Ulcerating gastric adenocarcinomas are distinguished from benign gastric ulcers by biopsies. Approximately 3% of

gastric ulcers initially believed to be benign later prove to be malignant. To exclude malignancy, all gastric ulcers identified at endoscopy should be biopsied. Ulcers that are suspicious for malignancy to the endoscopist or that have atypia or dysplasia on histologic examination warrant repeat endoscopy in 2–3 months to verify healing and exclude malignancy. Nonhealing ulcers should be considered for resection. Infiltrative carcinoma with thickened gastric folds must be distinguished from lymphoma and other hypertrophic gastropathies.

► Treatment

A. Curative Surgical Resection

Surgical resection is the only therapy with curative potential. After preoperative staging, about two-thirds of patients will be found to have localized disease (ie, stages I–III). In Japan and in specialized centers in the United States, endoscopic mucosal resection is performed in selected patients with small (< 1–2 cm), early (intramucosal or T1aN0) gastric cancers after careful staging with endoscopic ultrasonography. Approximately 25% of patients undergoing surgery will be found to have locally unresectable tumors or peritoneal, hepatic, or distant lymph node metastases that are incurable. The remaining patients with confirmed localized disease should undergo radical surgical resection with curative intent. For adenocarcinoma localized to the distal two-thirds of the stomach, a subtotal distal gastrectomy should be performed. For proximal gastric cancer or diffusely infiltrating disease, total gastrectomy is necessary. Vitamin B₁₂ supplementation is required postgastrectomy. Although lymph node dissection should be performed for curative resections, there has been ongoing debate about whether an extended (perigastric; D1), regional (D2), or distant (porta hepatic and periaortic; D3) lymph node dissection is needed. A 2008 large Japanese trial found no difference in survival between patients treated with D2 and D3 (para-aortic) lymphadenectomy. Current NCCN treatment guidelines recommend regional (D2) node resection with 15 or more lymph nodes sampled. The role of preoperative (neoadjuvant) or postoperative (adjuvant) chemotherapy or radiochemotherapy after curative resection is controversial. Recommended options include either adjuvant chemoradiotherapy (commonly 5-FU and leucovorin) or a perioperative chemotherapy regimen of epirubicin, 5-FU, and cisplatin (ECF) without radiation. Treatment of tumors arising in the gastroesophageal junction may be treated following algorithms for either gastric or esophageal primary tumors; multidisciplinary treatment decision-making involving the surgeon, radiation oncologist, and medical oncologist is imperative.

B. Palliative Modalities

Many patients will be found either preoperatively or at the time of surgical exploration to have advanced disease that is not amenable to “curative” surgery due to peritoneal or distant metastases or local invasion of other organs. In some of these cases, palliative resection of the tumor

nonetheless may be indicated to alleviate pain, bleeding, or obstruction. For patients with unresectable disease, gastrojejunostomy may be indicated to prevent obstruction. Alternatively, unresected tumors may be treated with endoscopic laser or stent therapy, radiation therapy, or angiographic embolization to relieve bleeding or obstruction. Chemotherapy may be considered in patients with metastatic disease who still have good functional status and expected survival of several months. Multiple chemotherapy regimens have demonstrated activity in metastatic gastric adenocarcinoma. A combination of epirubicin, cisplatin, and 5-FU or a modification thereof is commonly used in first-line treatment for fit patients. A 2009 randomized, phase III study showed that addition of the biologic agent trastuzumab to standard chemotherapy prolonged survival in the subset (approximately 15%) of patients with advanced gastric adenocarcinomas harboring amplification of the EGFR-2 (HER-2). Trastuzumab is not recommended for combination with anthracyclines such as epirubicin, however, due to risk for cardiotoxicity.

► Prognosis

The long-term survival of gastric carcinoma is < 15%. However, 5-year survival in patients who undergo successful curative resection is over 45%. Survival is related to tumor stage, location, and histologic features. Stage I and stage II tumors resected for cure have a > 50% long-term survival. Patients with stage III tumors have a poor prognosis (< 20% long-term survival) and should be considered for enrollment in clinical trials. Tumors of the diffuse type have a worse prognosis than the intestinal type. Tumors of the proximal stomach (fundus and cardia) carry a far worse prognosis than distal lesions. Even with apparently localized disease, proximal tumors have a 5-year survival of < 15%. For those whose disease progresses despite therapy, meticulous efforts at palliative care are essential (see Chapter 5).

► When to Refer

- Patients with dysphagia, weight loss, protracted vomiting, iron-deficiency anemia, or new-onset of dyspepsia (especially if age 55 years or older or associated with other alarm symptoms) in whom gastric cancer is suspected should be referred to a gastroenterologist for endoscopic screening.
- Patients should be referred to a surgeon for attempt at curative resection in stage I, II, or III cancer as well as to an oncologist to evaluate for adjuvant or neoadjuvant chemotherapy (or both) or chemoradiotherapy.
- Patients who have undergone gastrectomy require consultation with a nutritionist due to propensity for malnutrition and complications, such as dumping syndrome, postoperatively.
- Patients with unresectable or metastatic disease should be referred to an oncologist for consideration of adjuvant chemotherapy or chemoradiotherapy after curative resection or palliative therapy.

▶ When to Admit

Patients with protracted vomiting, inability to maintain oral intake, or acute bleeding.

- Ajani JA et al; NCCN Gastric Cancer Panel. Gastric cancer. J Natl Compr Canc Netw. 2010 Apr;8(4):378–409. [PMID: 20410333]
- Bang Y et al; ToGA Trial Investigators. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010 Aug 28;376(9742):687–97. [PMID: 20728210]
- Cunningham D et al; MAGIC Trial Participants. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006 Jul 6;355(1):11–20. [PMID: 16822992]
- Cunningham D et al; Upper Gastrointestinal Clinical Studies Group of the National Cancer Research Institute of the United Kingdom. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med. 2008 Jan 3;358(1):36–46. [PMID: 18172173]
- de Bree E et al. The extent of lymph node dissection for gastric cancer: a critical appraisal. J Surg Oncol. 2010 Nov 1;102(6):552–62. [PMID: 20976727]
- De Vita F et al. Human epidermal growth factor receptor 2 (HER2) in gastric cancer: a new therapeutic target. Cancer Treat Rev. 2010 Nov;36(Suppl 3):S11–5. [PMID: 21129604]
- Ohtani H et al. A meta-analysis of randomized controlled trials that compared laparoscopy-assisted and open distal gastrectomy for early gastric cancer. J Gastrointest Surg. 2010 Jun;14(6):958–64. [PMID: 20354807]
- Okines A et al. Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010 May;21(Suppl 5):v50–4. [PMID 20555102]
- Polk DB et al. *Helicobacter pylori*: gastric cancer and beyond. Nat Rev Cancer. 2010 Jun;10(6):403–14. [PMID: 20495574]
- Rogers WM et al. Risk-reducing total gastrectomy for germline mutations in E-cadherin (CDH1): pathologic findings with clinical implications. Am J Surg Pathol. 2008 Jun;32(6):799–809. [PMID: 18391748]
- Sasako M et al; Japan Clinical Oncology Group. D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer. N Engl J Med. 2008 Jul 31;359(5):453–62. [PMID: 18669424]
- Schrader K et al. Hereditary diffuse gastric cancer. Cancer Treat Res. 2010;155:33–63. [PMID: 20517687]
- Shi Y et al. The role of surgery in the treatment of gastric cancer. J Surg Oncol. 2010 Jun 15;101(8):687–92. [PMID: 20512944]
- Wagner AD et al. Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev. 2010 Mar 17;(3):CD004064. [PMID: 20238327]

GASTRIC LYMPHOMA

ESSENTIALS OF DIAGNOSIS

- ▶ Symptoms of dyspepsia, weight loss, or anemia.
- ▶ Variable abnormalities on upper gastrointestinal series or endoscopy including thickened folds, ulcer, mass or infiltrating lesions; diagnosis established by endoscopic biopsy.
- ▶ Abdominal CT and endoscopic ultrasonography required for staging.

▶ General Considerations

Gastric lymphomas may be primary (arising from the gastric mucosa) or may represent a site of secondary involvement in patients with nodal lymphomas. Distinguishing advanced primary gastric lymphoma with adjacent nodal spread from advanced nodal lymphoma with secondary gastric spread can be problematic. Because the prognosis and treatment of primary and secondary gastric lymphomas are entirely different, the distinction is important. Primary lymphoma is the second most common gastric malignancy, accounting for 3% of cancers. More than 95% of these are non-Hodgkin B cell lymphomas. Most primary gastric lymphomas are believed to arise from mucosa-associated lymphoid tissue (MALT). Primary gastric lymphomas comprise two main types: 60% are diffuse large B-cell lymphomas (previously called “high-grade” MALT lymphomas) and 40% are marginal zone B-cell lymphomas of the MALT-type (previously called “low-grade” MALT lymphoma).

Infection with *H pylori* is an important risk factor for the development of primary gastric lymphoma. Chronic infection with *H pylori* causes an intense lymphocytic inflammatory response that may lead to the development of lymphoid follicles. Over 90% of low-grade primary gastric MALT-type lymphomas are associated with *H pylori* infection. It is hypothesized that chronic antigenic stimulation may result in a monoclonal lymphoproliferation that may culminate in low-grade or high-grade lymphoma.

▶ Clinical Findings

The clinical presentation and endoscopic appearance of gastric lymphoma are similar to those of adenocarcinoma. Most patients have abdominal pain, weight loss, or bleeding. Patients with diffuse large B-cell lymphoma are more likely to have systemic symptoms and advanced tumor stage. At endoscopy, lymphoma may appear as an ulcer, mass, or diffusely infiltrating lesion. The diagnosis is established with endoscopic biopsy. All patients should undergo staging with abdominal and chest CT. Endoscopic ultrasonography is the most sensitive test for determining the level of invasion and presence of perigastric lymphadenopathy.

▶ Treatment

Nodal lymphomas with secondary gastrointestinal involvement usually present at an advanced stage with widely disseminated disease and are seldom curable. Their treatment is addressed in Chapter 13. Treatment of primary gastric lymphomas depends on the tumor histology, grade, and stage. Marginal B-cell lymphomas of the MALT type that are low-grade and localized to the stomach wall (stage IE) or perigastric lymph nodes (stage IIE₁) have an excellent prognosis. Endoscopic ultrasonography should be performed to accurately determine tumor stage. Patients with primary gastric MALT-lymphoma should be tested for *H pylori* infection and treated if positive. Complete lymphoma regression after successful *H pylori* eradication occurs in 75% of cases of stage IE and 55% with stage II₁ low-grade lymphoma. Remission may take as long as a year, and relapse occurs in 2% of

cases per year. Endoscopic surveillance after *H pylori* eradication is recommended every 6 months for 2 years to look for recurrence. Remission rates (22%) are much lower in patients whose tumors have an API2-MALT1 gene translocation. Patients with localized marginal zone MALT-type lymphomas who either are not infected with *H pylori* or do not respond to eradication therapy may be treated with radiation therapy or rituximab, if not a candidate for radiation. Data from a 2010 study, however, suggest that many patients with minimal disease after successful *H pylori* eradication may be observed closely without further therapy. The long-term survival of low-grade MALT lymphoma for stage I is over 90% and for stage II is 35–65%. Patients with diffuse large cell (high-grade) lymphomas or disseminated MALT-type lymphomas should be treated with combination chemotherapy (eg, CHOP with rituximab). Because of a low risk of perforation with either radiation therapy or chemotherapy, surgical resection is no longer recommended.

Sagaert X et al. Gastric MALT lymphoma: a model of chronic inflammation-induced tumor development. *Nat Rev Gastroenterol Hepatol*. 2010 Jun;7(6):336–46. [PMID: 20440281]

Zullo A et al. Effects of *Helicobacter pylori* eradication on early stage gastric mucosa-associated lymphoid tissue lymphoma. *Clin Gastroenterol Hepatol*. 2010 Feb;8(2):105–10. [PMID: 19631287]

GASTRIC CARCINOID TUMORS

Gastric carcinoids are rare neuroendocrine tumors that make up < 1% of gastric neoplasms. They may occur sporadically or secondary to chronic hypergastrinemia that results in hyperplasia and transformation of enterochromaffin cells in the gastric fundus. Sporadic carcinoids account for 20% of gastric carcinoids. Most are solitary, over 2 cm in size, and have a strong propensity for metastatic spread. Most sporadic carcinoids already have carcinoid syndrome and hepatic or pulmonary metastatic involvement at initial presentation. Localized sporadic carcinoids should be treated with radical gastrectomy.

The majority of carcinoids caused by hypergastrinemia occur in association with either pernicious anemia (75%) or Zollinger-Ellison syndrome (5%). Carcinoids associated with Zollinger-Ellison syndrome occur almost exclusively in patients with MEN 1, in which loss of 11q13 has been reported. Carcinoids caused by hypergastrinemia tend to be multicentric, < 1 cm in size, and have a low potential for metastatic spread or development of carcinoid syndrome. Small lesions may be successfully treated with endoscopic resection followed by periodic endoscopic surveillance. Antrectomy reduces serum gastrin levels and may lead to regression of small tumors. Patients with large or multiple carcinoids should undergo surgical tumor resection (see Carcinoid Tumors section).

Landry CS et al. A proposed staging system for gastric carcinoid tumors based on an analysis of 1,543 patients. *Ann Surg Oncol*. 2009 Jan;16(1):51–60. [PMID: 18953609]

GASTROINTESTINAL MESENCHYMAL TUMORS

Gastrointestinal mesenchymal tumors occur throughout the gastrointestinal tract, but approximately two-thirds occur in the stomach. These tumors (which include stromal tumors, leiomyomas, and schwannomas) derive from mesenchymal stem cells and have an epithelioid or spindle cell histologic pattern, resembling smooth muscle. The most common stromal tumors are gastrointestinal stromal tumors (“GISTs”), which appear to originate from interstitial cells of Cajal. GISTs occur throughout the gastrointestinal tract but most commonly in the stomach (50%) and small intestine (30%). About 85–90% of GISTs have mutations in KIT, a receptor tyrosine kinase that binds stem cell factor, or a homologous tyrosine kinase, platelet-derived growth factor alpha that lead to constitutive activation. Approximately 90% of stromal tumors stain positively for CD117 (part of the KIT protein). Other mesenchymal tumors such as leiomyomas, which derive from smooth muscle cells, stain negative for CD117. Mesenchymal tumors may be discovered incidentally on imaging studies or endoscopy or may cause symptoms, mainly obstruction by large tumors or acute or chronic bleeding due to central ulceration within the tumor. At endoscopy, they appear as a submucosal mass that may have central umbilication or ulceration. Endoscopic ultrasonography (possibly with guided FNA biopsy) is the optimal study for diagnosing mesenchymal tumors and distinguishing them from other submucosal lesions. While almost all GISTs have malignant potential, the risk of developing metastasis is related to the tumor size (> 2 cm), location (small bowel is highest risk), and mitotic index (> 5 mitoses per high-powered field); however, mitotic index can only be assessed after resection. It is difficult to distinguish with certainty benign from malignant (sarcoma) tumors before resection by endoscopic ultrasonographic appearance or FNA. In general, lesions that are smaller than 2 cm, have a smooth border, and have a homogeneous echo pattern on endoscopic ultrasonogram are more likely benign.

Surgery is recommended for all patients with tumors that are symptomatic, ≥ 2 cm, are increasing in size, or have an endoscopic ultrasonographic appearance suspicious for malignancy. PET-CT scan should be obtained prior to surgery to look for metastatic disease. The management of asymptomatic benign-appearing lesions ≤ 2 cm in size is problematic. Because of a low risk of malignancy, surgical resection should be considered in younger, otherwise healthy patients; however, other patients may be followed up with serial endoscopic ultrasonographic examinations or, in selected cases, endoscopic resections. (GIST tumors with high-risk features have a 50% 5-year survival rate after complete surgical resection.) Adjuvant therapy with the tyrosine kinase inhibitor imatinib delays recurrence and prolongs survival in patients with high-risk tumors. Three years of adjuvant imatinib is superior to 1 year, although optimal duration remains unknown. Metastatic tumors are aggressive and carry a poor prognosis. Imatinib induces disease control in up to 85% of patients with metastatic disease with a progression free-survival of 20–24 months and median overall survival of almost 5 years. Patients whose

tumors harbor exon 11 mutations in the KIT gene (approximately 70%) are more likely to respond to imatinib than those with exon 9 mutations in the KIT gene (approximately 12%), platelet-derived growth factor receptor alpha (PDGFRA) mutations (5–8%), or wild-type tumors (10–15%). Resistant tumors may respond to high-dose imatinib or to sunitinib, another tyrosine kinase inhibitor that is approved as second-line therapy for metastatic GIST. Clinical trials of potent new KIT inhibitors and other multikinase inhibitors are underway.

Chen P et al. Efficacy evaluation of imatinib treatment in patients with gastrointestinal stromal tumors: a meta-analysis. *World J Gastroenterol.* 2010 Sep 7;16(33):4227–32. [PMID: 20806443]

Dematteo RP et al; American College of Surgeons Oncology Group (ACOSOG) Intergroup Adjuvant GIST Study Team. Adjuvant imatinib mesylate after resection of localized, primary gastrointestinal stromal tumor: a randomised, double-blind, placebo-controlled trial. *Lancet.* 2009 March 28;373(9669):1097–104. [PMID: 19303137]

Dematteo RP et al. Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST). *Cancer.* 2008 Feb 1;112(3):608–15. [PMID: 18076015]

Demetri GD et al. Imatinib plasma levels are correlated with clinical benefit in patients with unresectable/metastatic gastrointestinal stromal tumors. *J Clin Oncol.* 2009 Jul 1;27(19):3141–7. [PMID: 19451435]

Demetri GD et al. NCCN Task Force Report: update on the management of patients with gastrointestinal stromal tumors. *J Natl Compr Canc Netw.* 2010 Apr;8(Suppl 2):S1–41. [PMID: 20457867]

Joensuu H et al. Twelve vs. 36 months of adjuvant imatinib as treatment of operable GIST with high risk of recurrence: final results of a randomized trial (SSGXVIII/AIO). Presented at American Society of Clinical Oncology Annual Meeting, 2011, Chicago, IL.

Reichardt P. Optimal use of targeted agents for advanced gastrointestinal stromal tumors. *Oncology.* 2010;78(2):130–40. [PMID: 20389135]

MALIGNANCIES OF THE SMALL INTESTINE

1. Adenocarcinoma

These are aggressive tumors that occur most commonly in the duodenum or proximal jejunum. The ampulla of Vater is the most common site of small bowel carcinoma, and the incidence of ampullary carcinoma is increased more than 200-fold in patients with familial adenomatous polyposis. Ampullary carcinoma may present with jaundice due to bile duct obstruction or bleeding. Surgical resection of early lesions is curative in up to 40% of patients. Periodic endoscopic surveillance to detect early ampullary neoplasms therefore is recommended in patients with this disorder. Nonampullary adenocarcinoma of the small intestine accounts for < 3% of all gastrointestinal cancers but one-third of small bowel cancers. Peak incidence is in the sixth decade. Most cases present with symptoms of obstruction, acute or chronic bleeding, or weight loss. The majority of small bowel cancers have already metastasized at the time of diagnosis. Resection is recommended for control of symptoms. The role of adjuvant therapy is unclear but is generally administered using chemotherapy agents active

in colorectal cancer. The prognosis is poor with a 5-year overall survival of 20–30%. Patients with Crohn disease have an increased risk of small intestine adenocarcinoma, most commonly in the ileum, which may be difficult to distinguish from disease-related fibrous strictures. Small bowel adenocarcinoma in young patients or those with a family history of gastrointestinal adenocarcinomas should prompt screening for the Lynch syndrome.

2. Lymphoma

Gastrointestinal lymphomas may arise in the gastrointestinal tract or involve it secondarily with disseminated disease. In Western countries, primary gastrointestinal lymphomas account for 5% of lymphomas and 20% of small bowel malignancies. They occur most commonly in the distal small intestine. The majority are non-Hodgkin high-grade marginal zone B cell lymphomas. There is an increased incidence of small intestinal lymphomas in patients with AIDS, immunosuppressive therapy, and Crohn disease. T cell lymphomas may arise in patients with celiac sprue. In the Middle East, lymphomas may arise in the setting of immunoproliferative small intestinal disease. In this condition, there is diffuse lymphoplasmacytic infiltration with IgA-secreting B lymphocytes of the mucosa and submucosa that results in weight loss, diarrhea, and malabsorption, which may lead to lymphomatous transformation. A characteristic feature of the disease is the presence of α heavy chains in the serum in 70% produced by clones of IgA plasma cells. Other types of intestinal lymphomas include mantle cell and Burkitt.

Presenting symptoms or signs of primary lymphoma include abdominal pain, weight loss, nausea and vomiting, distention, anemia, and occult blood in the stool. Fevers are unusual. Protein-losing enteropathy may result in hypoalbuminemia, but other signs of malabsorption are unusual. Barium radiography or CT enterography helps localize the site of the lesion. The diagnosis requires endoscopic, percutaneous, or laparoscopic biopsy. Imaging and bone marrow biopsy are required to determine stage.

Treatment depends on the tumor histologic grade and stage of disease. Resection of primary intestinal lymphoma, if feasible, is usually recommended. Even in cases of stage III or stage IV disease, surgical debulking may improve survival. In patients with limited disease (stage IE) in whom resection is performed, the role of adjuvant chemotherapy is unclear. Most patients with more extensive disease are treated with combination chemotherapy (eg, CHOP with rituximab) with or without radiation therapy.

3. Carcinoid Tumors

ESSENTIALS OF DIAGNOSIS

- ▶ Majority are asymptomatic and discovered incidentally at endoscopy or surgery.
- ▶ Carcinoid syndrome occurs in < 10%; hepatic metastases are generally present.
- ▶ Risk of metastasis related to tumor size and location.

► General Considerations

Gastrointestinal carcinoids are slow growing neuroendocrine tumors that may arise anywhere in the gastrointestinal tract but most commonly occur in the small intestine (30%), rectum (12%), colon (8%), appendix (8%), and stomach (10–30%; see above). Carcinoids may contain a variety of hormones, including serotonin, somatostatin, gastrin, and substance P that may or may not be secreted, and usually display immunoreactivity to chromogranin A. Although many carcinoids behave in an indolent fashion, the overall 5-year survival rate for patients with carcinoids is 50%, suggesting that most are malignant. The risk of metastatic spread is closely related to tumor size and tumor location. Many small carcinoids are detected incidentally at endoscopy or autopsy. It is not possible by histologic examination to distinguish benign from malignant disease. The best indicator of prognosis is evidence of invasive growth and the presence of regional or distant metastasis.

Carcinoids account for one-third of small intestinal tumors. Small intestinal carcinoids most commonly arise in the ileum. Up to one-third are multicentric. Although 60% are < 2 cm in size, even these small carcinoids may metastasize. Almost all small intestinal carcinoids over 2 cm are associated with metastasis.

Appendiceal carcinoids are identified in 0.3% of appendectomies, usually as an incidental finding. Almost 80% of these tumors are < 1 cm in size, and 90% are < 2 cm. Rectal carcinoids are usually detected incidentally as submucosal nodules during proctoscopic examination. Rectal carcinoids < 1 cm and localized appendiceal carcinoids < 2 cm virtually never metastasize and are treated effectively with local excision or simple appendectomy. Tumors larger than 2 cm are associated with the development of metastasis in over 20% of appendiceal carcinoids and 10% of rectal carcinoids. Hence, in younger patients who are good candidates for surgery, a more extensive cancer resection operation is warranted.

► Clinical Findings

A. Symptoms and Signs

Most smaller lesions (< 1–2 cm) are asymptomatic and difficult to detect by endoscopy or imaging studies. Through local extension or metastasis to mesenteric lymph nodes, carcinoids engender a fibroblastic reaction with contraction and kinking of the bowel or encasement of mesenteric vessels. Small intestinal carcinoids may present with abdominal pain, bowel obstruction, bleeding, or bowel infarction. Appendiceal and rectal carcinoids usually are small and asymptomatic but large lesions can cause bleeding, obstruction, or altered bowel habits. **Carcinoid syndrome** occurs in < 10% of patients. More than 90% of patients with carcinoid syndrome have hepatic metastases, usually from carcinoids of small bowel origin. About 10% of patients with carcinoid syndrome have primary bronchial or ovarian tumors without hepatic metastases. Carcinoid syndrome is caused by tumor secretion of hormonal mediators. The manifestations include facial flushing, edema of the head and neck (especially

with bronchial carcinoid), abdominal cramps and diarrhea, bronchospasm, cardiac lesions (pulmonary or tricuspid stenosis or regurgitation in 10–30%), and telangiectases.

B. Laboratory Findings

Serum chromogranin A (CgA) is elevated in the majority of neuroendocrine tumors, although its sensitivity for small, localized carcinoid tumors is unknown. CgA is elevated in almost 90% of patients with advanced small bowel carcinoid. Urinary 5-hydroxyindoleacetic acid (5-HIAA) and platelet serotonin levels are also elevated in patients with metastatic carcinoid; however, these tests are less sensitive than CgA. There is increased urinary 5-HIAA in carcinoid syndrome; symptomatic patients usually excrete more than 25 mg of 5-HIAA per day in the urine. Ideally, all drugs should be withheld for several days prior to a 24-hour urine collection.

C. Imaging

Abdominal CT may demonstrate a mesenteric mass with tethering of the bowel, lymphadenopathy, and hepatic metastasis. Abdominal CT or enterography may reveal kinking of the bowel, but because the lesion is extraluminal, the diagnosis may be overlooked for several years. Somatostatin receptor scintigraphy, which is positive in up to 90% of patients with metastatic carcinoid, is routinely used in staging. Most patients with carcinoid syndrome have liver metastasis on abdominal imaging.

► Treatment

Small intestinal carcinoids are extremely indolent tumors with slow spread. Patients with disease confined to the small intestine should be treated with surgical excision, for which the cure rate exceeds 85%. In patients with resectable disease who have lymph node involvement, the 5-year disease-free survival is 80%; however, by 25 years, < 25% remain disease free. Even patients with hepatic metastases may have an indolent course with a median survival of 3 years. In patients with advanced disease, therapy historically has been deferred until the patient is symptomatic, although a 2009 phase III, randomized, placebo-controlled trial demonstrated that early initiation of somatostatin analog therapy delayed time to progression of hepatic metastases. Surgery should be directed toward palliation of obstructive symptoms.

In patients with carcinoid syndrome, resection of hepatic metastases may provide dramatic improvement. The somatostatin analog octreotide, 100–500 mcg subcutaneously three times daily or administered as a long-acting intramuscular depot formulation, inhibits hormone secretion from the carcinoid tumor. This results in dramatic relief of symptoms of carcinoid syndrome, including diarrhea or flushing, in 90% of patients for a median period of 1 year. Thereafter, many patients stop responding to octreotide. Hepatic artery occlusion, liver-directed debulking procedures, and chemotherapy may provide symptomatic improvement in some patients with hepatic metastases.

4. Small Intestine Sarcoma

Most small intestine sarcomas arise from stromal tumors (GISTs) that stain positive for CD117; a minority arise from smooth muscle tumors (leiomyosarcomas) (see Gastrointestinal Mesenchymal Tumors above).

Kaposi sarcoma was at one time a common complication in AIDS, but the incidence is declining with highly active antiretroviral therapy (HAART). It is strongly associated with infection with human herpesvirus 8. Lesions may be present anywhere in the intestinal tract. Visceral involvement usually is associated with cutaneous disease. Most lesions are clinically silent; however, large lesions may be symptomatic. Interferon- α induces regression in up to one-third of patients who have a CD4 cell count of > 200 /mL. Widespread involvement may be best treated by systemic chemotherapy using combinations of vincristine, bleomycin, or doxorubicin, to which the tumor is very responsive.

Bilimoria KY et al. Small bowel cancer in the United States: changes in epidemiology, treatment, and survival over the last 20 years. *Ann Surg*. 2009 Jan;249(1):63–71. [PMID: 19106677]

Chambers AJ et al. The palliative benefit of aggressive surgical intervention for both hepatic and mesenteric metastases from neuroendocrine tumors. *Surgery*. 2008 Oct;144(4):645–51. [PMID: 18847650]

Ellis L et al. Carcinoid tumors of the gastrointestinal tract: trends in incidence in England since 1971. *Am J Gastroenterol*. 2010 Dec;105(12):2563–9. [PMID: 20823835]

Massironi S et al. Plasma chromogranin A response to octreotide test: prognostic value for clinical outcome in endocrine digestive tumors. *Am J Gastroenterol*. 2010 Sep;105(9):2072–8. [PMID: 20372113]

Pasieka JL. Carcinoid tumors. *Surg Clin North Am*. 2009 Oct;89(5):1123–37. [PMID: 19836488]

Rinke A et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. *J Clin Oncol*. 2009 Oct 1;27(28):4656–63. [PMID: 19704057]

Yamagami H et al. Usefulness of double-balloon endoscopy in the diagnosis of malignant small-bowel tumors. *Clin Gastroenterol Hepatol*. 2008 Nov;6(11):1202–5. [PMID: 18799359]

COLORECTAL CANCER



ESSENTIALS OF DIAGNOSIS

- ▶ Personal or family history of adenomatous polyps or colorectal cancer are important risk factors.
- ▶ Symptoms or signs depend on tumor location.
- ▶ Proximal colon: fecal occult blood, anemia.
- ▶ Distal colon: change in bowel habits, hematochezia.
- ▶ Diagnosis established with colonoscopy.

▶ General Considerations

Colorectal cancer is the second leading cause of death due to malignancy in the United States. Colorectal cancer will develop in approximately 6% of Americans and 40% of those will die of the disease. In 2010, there were an estimated 142,570 new cases and 51,370 deaths from colorectal cancer in the United States. Colorectal cancers are almost all adenocarcinomas, which tend to form bulky exophytic masses or annular constricting lesions. Slightly $< 50\%$ of cancers are located distal to the splenic flexure (within the descending colon or rectosigmoid region).

The current belief is that the majority of colorectal cancers arise from malignant transformation of an adenomatous polyp (tubular, tubulovillous, or villous adenoma) or serrated polyp (hyperplastic polyp, traditional serrated adenoma, or sessile serrated adenoma). Polyps that are “advanced” (ie, polyps at least 1 cm in size, adenomas with villous features, or adenomas with high-grade dysplasia) are associated with a greater risk of cancer. Approximately 85% of sporadic colorectal cancers arise from adenomatous polyps and have loss of function of one or more tumor suppressor genes (eg, *p53*, *APC*, or *DCC*) due to a combination of spontaneous mutation of one allele combined with chromosomal instability and aneuploidy (abnormal DNA content) that leads to deletion and loss of heterozygosity of the other allele (eg, 5q, 17q, or 18p deletion). Activation of oncogenes such as *K-ras* and *B-raf* is present in a subset of colorectal cancers with prognostic and therapeutic implications discussed further below.

Approximately 10–20% of colorectal cancers arise from serrated polyps, most of which have hypermethylation of CpG-rich promoter regions that leads to inactivation of the DNA mismatch repair gene *MLH1*, resulting in microsatellite instability, and activation of mutations of the *BRAF* gene. Serrated colon cancers have distinct clinical and pathologic characteristics, including diploid DNA content, predominance in the proximal colon, poor differentiation, and more favorable prognosis.

Up to 5% of colorectal cancers are caused by inherited germline mutations resulting in polyposis syndromes (eg, familial adenomatous polyposis) or hereditary nonpolyposis colorectal cancer (HNPCC or Lynch syndrome). These conditions are discussed further in Chapter 15.

▶ Risk Factors

A number of factors increase the risk of developing colorectal cancer. Recognition of these has impact on screening strategies. However, 75% of all cases occur in people with no known predisposing factors.

A. Age

The incidence of colorectal cancer rises sharply after age 45 years, and 90% of cases occur in persons over the age of 50 years.

B. Family History of Neoplasia

A family history of colorectal cancer is present in 20% of patients with colon cancer. Hereditary factors are believed

to contribute to 20–30% of colorectal cancers; however, the genes responsible for most of these cases have not yet been identified. (See Chapter 15 for discussion of inherited polyposis syndromes.) Approximately 6% of the Ashkenazic Jewish population has a missense mutation in the *APC* gene (*APC I1307K*) that confers a modestly increased lifetime risk of developing colorectal cancer (OR 1.4–1.9) but phenotypically resembles sporadic colorectal cancer rather than familial adenomatous polyposis. Genetic screening is available, and patients harboring the mutation merit intensive screening.

A family history of colorectal cancer or adenomatous polyps is one of the most important risk factors for colorectal cancer. The risk of colon cancer is proportionate to the number and age of affected first-degree family members with colon neoplasia. People with one first-degree family member with colorectal cancer have an increased risk approximately two times that of the general population; however, the risk is almost four times if the family member's cancer was diagnosed at < 45 years of age. Patients with two first-degree relatives have a fourfold, or 25–30% lifetime, risk of developing colon cancer. First-degree relatives of patients with adenomatous polyps also have a twofold increased risk for colorectal neoplasia, especially if the polyp was large (≥ 10 mm) or detected before age 60 years.

C. Inflammatory Bowel Disease

The risk of adenocarcinoma of the colon begins to rise 7–10 years after disease onset in patients with ulcerative colitis and Crohn colitis. The cumulative risk approaches 5–10% after 20 years and 20% after 30 years. Chronic treatment with 5-ASA agents and folate is associated with a lower risk of cancer in patients with ulcerative colitis.

D. Dietary Factors and Chemoprevention

In epidemiologic studies, diets rich in fats and red meat are associated with an increased risk of colorectal adenomas and cancer, whereas diets high in fruits, vegetables, and fiber are associated with a decreased risk. However, prospective, randomized controlled trials failed to demonstrate a risk reduction in the recurrence of adenomatous polyps after treatment with a diet low in fat and high in fiber, fruits, and vegetables, or with fiber supplementation. Calcium carbonate (3 g/d) has been shown in large cohort studies as well as small prospective trials to yield a modest reduction in the relative risk of developing colorectal neoplasia; however, a prospective study of 36,000 women did not show a protective benefit of calcium (500 mg) and vitamin D (200 international units twice daily) in preventing colon cancer. Similarly, the risk of colon cancer is not decreased in persons taking folic acid supplements. The antioxidant vitamins A, C, E, and beta carotene also have not been shown to be of benefit in prospective controlled studies.

A US Preventive Services Task Force meta-analysis of cohort and case-control studies suggest that prolonged (> 6 years) regular use of aspirin (at least 325 mg twice weekly) or NSAIDs is associated with a 22–33% relative risk reduction in the incidence of colorectal cancer. Two

prospective, blinded clinical trials have shown that daily low-dose aspirin (80–325 mg) reduces the number of recurrent adenomas at 1–3 years in patients with a history of colorectal adenomas or cancer; however, two large randomized controlled trials in the United States did not demonstrate a reduction in colorectal cancer incidence in patients taking low-dose aspirin over a 5–10 years. Because long-term aspirin use is associated with a low incidence of serious complications (gastrointestinal hemorrhage, stroke), the US Preventive Services Task Force concluded that it should not be prescribed as a chemopreventive agent in people without polyps or with small adenomas unless there are other medical indications. Long-term administration of low-dose aspirin may be considered in patients with a personal or family history of colorectal cancer or advanced adenomas; however, they do not obviate the need for colonoscopy screening and surveillance.

E. Other Factors

The incidence of colon adenocarcinoma is higher in blacks than in whites. It is unclear whether this is due to genetic or socioeconomic factors (eg, diet or reduced access to screening). Diabetes, metabolic syndrome, obesity, and cigarette smoking are associated with a modest increase in cancer risk.


► Clinical Findings

A. Symptoms and Signs

Adenocarcinomas grow slowly and may be present for several years before symptoms appear. However, some asymptomatic tumors may be detected by the presence of fecal occult blood (see Colorectal Cancer Screening, below). Symptoms depend on the location of the carcinoma. Chronic blood loss from right-sided colonic cancers may cause iron deficiency anemia, manifested by fatigue and weakness. Obstruction, however, is uncommon because of the large diameter of the right colon and the liquid consistency of the fecal material. Lesions of the left colon often involve the bowel circumferentially. Because the left colon has a smaller diameter and the fecal matter is solid, obstructive symptoms may develop with colicky abdominal pain and a change in bowel habits. Constipation may alternate with periods of increased frequency and loose stools. The stool may be streaked with blood, though marked bleeding is unusual. With rectal cancers, patients note tenesmus, urgency, and recurrent hematochezia. Weight loss is uncommon. Physical examination is usually normal except in advanced disease. A mass may be palpable in the abdomen. The liver should be examined for hepatomegaly, suggesting metastatic spread. For cancers of the distal rectum, digital examination is necessary to determine whether there is extension into the anal sphincter or fixation, suggesting extension to the pelvic floor.

B. Laboratory Findings

A complete blood count is obtained to look for evidence of anemia. Elevated liver function tests, particularly the



▲ **Figure 39-1.** Cecal adenocarcinoma on colonoscopy. (Courtesy of Marvin Derezin, MD; used, with permission, from Usatine RP, Smith MA, Mayeaux EJ Jr, Chumley H, Tysinger J. *The Color Atlas of Family Medicine*. McGraw-Hill, 2009.)

alkaline phosphatase, are suspicious for metastatic disease. Carcinoembryonic antigen (CEA) should be measured in all patients with proved colorectal cancer. A preoperative CEA level > 5 ng/mL is a poor prognostic indicator. After complete surgical resection, CEA levels should normalize; persistently elevated levels suggest the presence of persistent disease and warrant further evaluation.

C. Colonoscopy

Colonoscopy is the diagnostic procedure of choice in patients with a clinical history suggestive of colon cancer or in patients with an abnormality suspicious for cancer detected on radiographic imaging. Colonoscopy permits biopsy for pathologic confirmation of malignancy (Figure 39-1). In patients in whom the colonoscope is unable to reach the cecum ($< 5\%$ of cases) or when a nearly obstructing tumor precludes passage of the colonoscope, barium enema or CT colonography examination should be performed.

D. Imaging

Chest, abdominal, and pelvic CT scans are required for preoperative staging. CT scans may demonstrate distal metastases but are less accurate in the determination of the level of local tumor extension (T stage) or lymphatic spread (N stage). Intraoperative assessment of the liver by direct palpation and ultrasonography is more accurate than CT scanning for the detection of hepatic metastases. For rectal cancer, pelvic MRI or endorectal ultrasonography identifies the depth of penetration of the cancer through the rectal wall (T stage) and perirectal lymph nodes, informing decisions about preoperative (neoadjuvant) chemoradiotherapy and operative management. PET is not routinely used for staging or surveillance in colorectal cancers.

► Staging

The TNM system is the commonly used classification to stage colorectal cancer. Staging is important not only because it correlates with the patient's long-term survival but also because it is used to determine which patients should receive adjuvant therapy.

► Differential Diagnosis

The nonspecific symptoms of colon cancer may be confused with those of irritable bowel syndrome, diverticular disease, ischemic colitis, inflammatory bowel disease, infectious colitis, and hemorrhoids. Neoplasm must be excluded in any patient over age 40 years who reports a change in bowel habits or hematochezia or who has an unexplained iron deficiency anemia or occult blood in stool samples.

► Treatment

A. Surgery

Resection of the primary colonic or rectal cancer is the treatment of choice for almost all patients who have resectable lesions and can tolerate general anesthesia. For colon cancer, multiple studies demonstrate that minimally invasive, laparoscopically assisted colectomy results in similar outcomes and rates of recurrence to open colectomy. Regional dissection of at least 12 lymph nodes should be performed to determine staging, which guides decisions about adjuvant therapy.

For rectal carcinoma, preoperative (neoadjuvant) chemoradiation with 5-FU is recommended in all node-positive tumors, and in T3 and greater tumors, due to increased risk of local recurrence. Neoadjuvant chemoradiation is discussed further below. After neoadjuvant therapy, the operative approach depends on the level of the tumor above the anal verge, the size and depth of penetration, and the patient's overall condition. Clinical staging by endorectal ultrasound or MRI with endorectal coil is important in guiding the clinical approach. In carefully selected patients with small, mobile (< 4 cm), well-differentiated T1 or T2 rectal tumors that are < 8 cm from the anal verge and that appear on endosonography to be localized to the rectal wall, transanal excision may be performed. This approach avoids laparotomy and spares the rectum and anal sphincter, preserving normal bowel continence. All other patients will require either a low anterior resection with a colorectal anastomosis or an abdominoperineal resection with a colostomy, depending on how far above the anal verge the tumor is located and the extent of local tumor spread. Careful dissection of the entire mesorectum at the time of surgery has been shown to reduce local recurrence to 8%. With improvements in surgical stapling techniques, it is possible to perform low anterior resection provided there is a margin of at least 2 cm of normal tissue below the tumor. Although low anterior resections obviate a colostomy, they are associated with increased immediate postsurgical complications (leak, dehiscence, stricture) and defecatory complaints (increased stool frequency, defecatory problems, and incontinence).

With unresectable rectal cancer, the patient may be palliated with a diverting colostomy, laser fulguration, or placement of an expandable wire stent.

B. Systemic Chemotherapy for Colon Cancer

Chemotherapy and radiotherapy have been demonstrated to improve overall and tumor-free survival in selected patients with colorectal cancers depending on stage.

1. Stage I—Because of the excellent 5-year survival rate (90–100%), no adjuvant therapy is recommended.

2. Stage II (node-negative disease)—The expected 5-year survival rate is 80%. A survival benefit from adjuvant chemotherapy has not been demonstrated in most controlled trials for stage II colon cancer (see discussion for stage III disease). However, otherwise healthy patients with stage II disease that is at higher risk for recurrence (perforation, obstruction, T4 tumors, or fewer than 12 lymph nodes sampled) may benefit from adjuvant chemotherapy.

3. Stage III (node-positive disease)—With surgical resection alone, the expected 5-year survival rate is 30–50%. Postoperative adjuvant chemotherapy significantly increases disease-free survival as well as overall survival by up to 30% and is recommended for all fit patients. Large, well-designed studies of adjuvant therapy for stage III colon cancer reported a higher rate of disease-free survival at 5 years for patients treated with a combination of oxaliplatin, 5-FU, and leucovorin (FOLFOX) (73.3%) than with 5-FU and leucovorin (FL) alone (67.4%). The addition of oxaliplatin is associated with an increased incidence of diarrhea, myelosuppression, and peripheral sensory neuropathy, all of which generally are reversible. Based on these studies, FOLFOX currently is the preferred adjuvant therapy for most patients with stage III disease (see Table 39–11). The addition of a biologic agent (bevacizumab or cetuximab) to FOLFOX does not improve outcomes in the adjuvant setting.

4. Stage IV (metastatic disease)—Approximately 20% of patients have metastatic disease at the time of initial diagnosis, and another 30% eventually develop metastasis. A subset of these patients has limited disease that is potentially curable with surgical resection. Resection of isolated liver or lung metastases may result in long-term (over 5 years) survival in 35–55% of cases. For those with unresectable hepatic metastases, local ablative techniques (cryosurgery, radio-frequency or microwave coagulation, embolization, hepatic intra-arterial chemotherapy) may provide long-term tumor control. The majority of patients with metastatic disease do not have resectable (curable) disease. In the absence of other treatment, the median survival is only 6 months. The goals of therapy are to slow tumor progression while maintaining a reasonable quality of life for as long as possible. Currently, either FOLFOX (the addition of oxaliplatin to 5-FU and folinic acid) or FOLFIRI (the addition of irinotecan to 5-FU and folinic acid) is the preferred first-line treatment regimens for most patients with metastatic colorectal cancer, increasing median survival to 15–20 months. For convenience, oral capecitabine (instead of intravenous 5-FU and leucovorin) can be used in combination with

oxaliplatin; however, combination with irinotecan should not be used due to increased toxicity (diarrhea). Addition of a biologic agent to combination chemotherapy improves response rates and overall survival and is recommended in the first-line of treatment in suitable patients. Bevacizumab is a monoclonal antibody targeting VEGF. Combination therapy with bevacizumab and FOLFOX or FOLFIRI prolongs mean survival 2–5 months compared with either regimen alone (see Table 39–11). Cetuximab and panitumumab are monoclonal antibodies targeting EGFR. Activating codon 12 and 13 *K-ras* gene mutations downstream of EGFR are present in approximately 35% of patients with metastatic colorectal cancer and are a biomarker for nonresponse to cetuximab and panitumumab, for which reason the use of these agents is restricted to patients with tumors wild-type for *K-ras*. In stage 4 patients with *K-ras* wild-type tumors, the addition of panitumumab or cetuximab to FOLFOX or FOLFIRI prolongs survival by approximately 4 months. Bevacizumab may cause serious side effects, including arterial thromboembolic events, bowel perforation, or serious bleeding, in up to 5% of patients. EGFR-targeted agents cause an acneiform rash in the majority of patients. Cetuximab is associated with anaphylaxis in a small subset.

When disease progresses with FOLFOX or FOLFIRI (often in conjunction with bevacizumab or an EGFR-targeted antibody), therapy is switched to the alternative regimen. Patients progressing with one regimen may respond to the alternative regimen, prolonging mean survival to > 20 months. A phase III study randomizing patients to receive either cetuximab or bevacizumab in addition to standard first-line chemotherapy (FOLFIRI or FOLFOX) is ongoing to determine whether one biologic agent is superior. The simultaneous combination of both classes of biologic agents (anti-EGFR and anti-VEGF) with chemotherapy has been associated with worse outcomes in multiple studies. This is a sobering finding that demonstrates the complexity of the signaling pathways involved. Single-agent, palliative therapy with cetuximab or panitumumab can benefit patients with *K-ras* wild-type tumors whose disease has progressed after first-line and second-line chemotherapies. Clinical trial participation should be considered for eligible patients whose tumors have progressed despite standard treatment, including 5-FU, oxaliplatin, irinotecan, an EGFR-inhibitor (if *K-ras* gene is wild-type), and bevacizumab.

Patients with metastatic colorectal cancer whose tumors harbor a mutation in the *B-raf* oncogene (approximately 8% in metastatic disease) have a significantly worse prognosis than patients whose tumors are wild-type for *B-raf*. Unlike activating *K-ras* mutations, randomized phase 3 data suggest potential benefit from cetuximab or panitumumab in combination with chemotherapy in patients whose tumors harbor an activating *B-raf* mutation (which almost never coexist with *K-ras* mutations).

C. Adjuvant Therapy for Rectal Cancer

Compared with colon cancer, rectal cancer has lower long-term survival rates and significantly higher rates of local

tumor recurrence (25%) due to the difficulty of achieving adequate surgical resection margins. When initial imaging studies suggest stage I disease, surgery may be performed first. Combination therapy with 5-FU (as a radiation sensitizing agent) and radiation has been shown to improve the disease-free survival rate and to decrease pelvic recurrence and is recommended for all patients with stage II and stage III rectal cancers (see Table 39–11). Preoperative chemoradiation has been shown to be superior to postoperative chemoradiation and is recommended for patients with distal rectal cancers that are determined to be stage II or III by endorectal ultrasound or MRI. Following surgical resection with total mesorectal excision, 5-FU–based therapy (generally with the FOLFOX regimen extrapolating from its benefit in patients with similarly-staged colon cancers) may be administered for an additional 4 months.

► Follow-Up after Surgery

Patients who have undergone resections for cure are followed closely to look for evidence of symptomatic or asymptomatic tumor recurrence that may be amenable to curative resection in a small number of patients. The optimal cost-effective strategy is not clear. Two randomized trials reported that intense follow-up with yearly colonoscopy, abdominal CT, and chest radiography did not improve overall outcome compared with most standard follow-up protocols. Patients should be evaluated every 3–6 months for 3–5 years with history, physical examination, and CEA determinations. The NCCN recommends surveillance CT scans of chest, abdomen, and pelvis annually for the first 3 years post-resection in high-risk patients. Patients who had a complete preoperative colonoscopy should undergo another colonoscopy 1 year after surgical resection. Patients who did not undergo full colonoscopy preoperatively also should undergo colonoscopy within 3–6 months postoperatively to exclude other synchronous colorectal neoplasms. If a colonoscopy does not detect new adenomatous polyps 1 year postoperatively, surveillance colonoscopy should be performed every 3–5 years thereafter to look for metachronous polyps or cancer. Because of the high incidence of local tumor recurrence in patients with rectal cancer, proctoscopy surveillance of the low anterior resection anastomotic site may also be performed periodically. New onset of symptoms or a rising CEA warrants investigation with chest, abdominal, and pelvic CT to look for recurrent or metastatic disease that may be amenable to therapy. For patients with a rising CEA with unrevealing CT imaging, a PET scan is more sensitive for the detection of occult metastatic disease.

► Prognosis

The stage of disease at presentation is the most important determinant of long-term survival: stage I, > 90%; stage II, 70–85%; stage III with fewer than four positive lymph nodes, 67%; stage III with more than four positive lymph nodes, 33%; and stage IV, 5–7%. For each stage, rectal cancers have a worse prognosis. For those patients whose disease progresses despite therapy, meticulous efforts at palliative care are essential (see Chapter 5).

► Screening for Colorectal Neoplasms

Colorectal cancer is ideal for screening because it is a common disease that is fatal in almost 50% of cases yet is curable if detected at an earlier stage. Furthermore, most cases arise from benign adenomatous or serrated polyps that progress over many years to cancer, and removal of these polyps has been shown to prevent the majority of cancers. Colorectal cancer screening is endorsed by the US Preventive Services Task Force, the Agency for Health Care Policy and Research, the American Cancer Society, and every professional gastroenterology and colorectal surgery society. Although there is continued debate about the optimal cost-effective means of providing population screening, there is unanimous consent that screening of *some kind* should be offered to every patient over the age of 50 years. Several analyses suggest that screening is cost effective.

It is important for primary care providers to understand the relative merits of various options and to discuss them with their patients. Despite growing awareness of the importance of screening on the part of medical professionals and the public, < 50% of patients have undergone screening of any kind. Discussion and encouragement by the primary care provider are the most important factors in achieving patient compliance with screening programs.

Recommendations for screening from the US Multi-Society Task Force are listed in Table 39–5. Screening is recommended for all men and women ages 50 through 75 years of age who are at average risk for cancer. Some

Table 39–5. Recommendations for colorectal cancer screening.¹

Average-risk individuals ≥ 50 years old²
Annual fecal occult blood testing using higher sensitivity tests (Hemeoccult SENSAs)
Annual fecal immunochemical test (FIT)
Fecal DNA test (interval uncertain)
Flexible sigmoidoscopy every 5 years
Colonoscopy every 10 years
CT colonography every 5 years
Individuals with a family history of a first-degree member with colorectal neoplasia³
Single first-degree relative with colorectal cancer diagnosed at age ≥ 60 years: Begin screening at age 40. Screening guidelines same as average-risk individual; however, preferred method is colonoscopy every 10 years.
Single first-degree relative with colorectal cancer or advanced adenoma diagnosed at age < 60 years, or two first-degree relatives: Begin screening at age 40 or at age 10 years younger than age at diagnosis of the youngest affected relative, whichever is first in time. Recommended screening: colonoscopy every 5 years.

¹For recommendations for families with inherited polyposis syndromes or hereditary nonpolyposis colon cancer, see Chapter 19.

²Joint Guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. *Gastroenterology* 2008 May; 134(5):1570.

³American College of Gastroenterology. Guidelines for Colorectal Cancer Screening. *Am J Gastroenterol*. 2009 Mar;104(3):739.

guidelines recommend screening for African Americans beginning at age 45. The potential for harm from screening must be weighed against the likelihood of benefit, especially in elderly patients with comorbid illnesses and shorter life expectancy. Although routine screening is not recommended in adults above age 75, it may be considered on a case-by-case basis in adults age 76 through 85 years who have excellent health and functional status. Patients with first-degree relatives with colorectal neoplasms (cancer or adenomatous polyps) are at increased risk; earlier and more frequent screening is recommended (preferably with colonoscopy) for these individuals. Recommendations for screening in families with inherited cancer syndromes or inflammatory bowel disease are provided in Chapter 15. For patients at average risk for colorectal cancer, the recommendations of the Task Force are discussed below. Screening tests may be classified into two broad categories: stool-based tests and exams that visualize the structure of the colon by direct endoscopic inspection or radiographic imaging.

A. Stool-based Tests

1. Fecal occult blood test—Most colorectal cancers and some large adenomas result in increased chronic blood loss. A variety of tests for fecal occult blood are commercially available that have varying sensitivities and specificities for colorectal neoplasia. These include guaiac-based tests (Hemoccult I and II and Hemeoccult SENSAs) that detect the pseudoperoxidase activity of heme or hemoglobin and fecal immunochemical tests (FITs) that detect human globin.

Guaiac-based tests have undergone the most extensive testing and currently have the greatest clinical use. For optimal detection, one specimen card must be prepared from three consecutive bowel movements. To reduce the likelihood of false-positive tests, patients should abstain from aspirin (in doses > 325 mg/d), NSAIDs, red meat, poultry, fish, and vegetables with peroxide activity (turnips, horseradish) for 72 hours. Vitamin C may cause a false-negative test. Slides should be developed within 7 days after preparation. The reported sensitivities of a single guaiac-based test for detection of colorectal cancer vary widely, but are lower for Hemeoccult II (35%) than Hemeoccult SENSAs (65%). When fecal occult blood test is administered to the general population as part of a screening program, 2–6% of tests are positive. Of those with positive tests, 5–18% have colorectal cancer that is more likely to be at an earlier stage (stage I or II).

Several FITs are commercially available. These tests are highly specific for detecting human globin and therefore eliminate the need for pretest dietary restrictions. As with guaiac-based tests, sampling of three consecutive bowel movements is recommended. In clinical trials that compare FIT with guaiac-based tests, FIT had at least comparable sensitivity to Hemeoccult SENSAs for detection of cancers (60–85%) with higher specificity. Because FITs are not affected by diet or medications and have superior accuracy, they are increasingly being substituted for guaiac-based tests despite a higher cost per test (\$10–20).

The US Multi-Society Task Force emphasizes that colon cancer prevention should be the primary goal of screening. For that reason, the lower sensitivity of fecal occult blood tests for advanced neoplasia (cancer and advanced adenomatous polyps) makes them a less attractive choice for population-based screening than endoscopic or radiographic tests. Currently, fecal occult blood tests are most suitable in settings where health care resources are limited or in patients who desire a noninvasive method of screening. The Task Force recommends that tests with higher sensitivity for colorectal cancer (Hemeoccult SENSAs or FIT) be used rather than less sensitive tests (Hemeoccult II). Regardless of which stool-based test is used, patients should understand that annual testing is required to achieve the maximum screening benefit and that a positive test will require evaluation by colonoscopy accompanied by removal of any polyps identified. If colonoscopy reveals no colorectal neoplasm, further screening for colorectal cancer can be deferred for 10 years. In a meta-analysis of four large, prospective, longitudinal studies, annual or biennial screening with Hemeoccult or Hemeoccult II reduced mortality from colorectal cancer by 25% among those who were compliant with regular testing. Long-term studies with more sensitive stool tests (Heme SENSAs or FIT) have not been performed.

2. Multitarget DNA assay—A fecal DNA assay (Pre-Gen Plus) is available for screening for colorectal neoplasia. The test analyzes fecal DNA for 22 gene mutations and DNA integrity. The commercially available first-generation fecal DNA panel detected only one-half of cancers; however, a second-generation assay detected almost 90%. Although the Multi-Society Task Force concluded that fecal DNA is an acceptable option for colorectal cancer screening, this test is not yet practical for population-based screening due to its high cost and cumbersome requirements for stool collection and mailing.

B. Endoscopic Examinations of the Colon

1. Flexible sigmoidoscopy—Use of a 60-cm flexible sigmoidoscope permits visualization of the rectosigmoid and descending colon. It requires no sedation and in many centers is performed by a nurse specialist or physician's assistant. Adenomatous polyps are identified in 10–20% and colorectal cancers in 1% of patients. Case-control studies suggest that screening sigmoidoscopy programs lead to a 60% reduction in colorectal cancer mortality. A 2010 randomized controlled trial in 170,000 participants in the United Kingdom comparing a one-time flexible sigmoidoscopy screening to usual care confirmed a 50% reduction in distal colorectal cancer incidence and 43% reduction in mortality after a median follow-up of 11 years. The risk of serious complications (perforation) associated with flexible sigmoidoscopy is < 1:10,000 patients.

The chief disadvantage of screening with flexible sigmoidoscopy is that it does not examine the proximal colon. The prevalence of proximal versus distal neoplasia is higher in people over age 65 years of age, African Americans, and women. In men, approximately 50%

of advanced neoplasms (cancer, adenomas ≥ 1 cm in size, polyps with villous histology, or high-grade dysplasia) are located in the proximal colon, compared with 60–70% in women. The finding at sigmoidoscopy of an adenomatous polyp in the distal colon increases the likelihood at least twofold that an advanced neoplasm is present in the proximal colon. Therefore, patients found on screening sigmoidoscopy to have an adenomatous polyp of any size should subsequently undergo colonoscopy to evaluate the proximal colon. Using this strategy in men, it is estimated that screening sigmoidoscopy programs will detect approximately 65% of advanced colonic neoplasms. In women, however, sigmoidoscopy screening programs may fail to detect up to 65% of advanced neoplasia.

2. Colonoscopy—Colonoscopy permits examination of the entire colon. In addition to detecting early cancers, colonoscopy allows removal of adenomatous polyps by biopsy or polypectomy, which is believed to reduce the risk of subsequent cancer. Over the past decade, there has been a dramatic increase in screening colonoscopy and a similar decrease in screening sigmoidoscopy due to poor reimbursement and the perceived inferiority of sigmoidoscopy compared with colonoscopy. Colonoscopy requires aggressive bowel cleansing prior to the examination. To alleviate discomfort, intravenous sedation is used for most patients. The incidence of serious complications after colonoscopy (perforation, bleeding, cardiopulmonary events) is 0.1%. In asymptomatic individuals between 50 and 75 years of age undergoing screening colonoscopy, the prevalence of advanced neoplasia is 4–11% and of cancer is 0.1–1%.

Although colonoscopy is believed to be the most sensitive test for detecting adenomas and cancer, it is not infallible. In several studies, the rate of colorectal cancer within 3 years of a screening colonoscopy was 0.7–0.9%, ie, approximately 1 in 110 patients. This may be attributable to adenomatous polyps and early cancers that were overlooked during colonoscopy. Studies of back-to-back colonoscopies confirm that endoscopists overlook 6–12% of polyps > 1 cm and up to 25% of smaller adenomas. Polyps that are small, flat, or located behind folds are easily missed, especially if the bowel preparation is poor. Population-based case-control and cohort studies suggest that colonoscopy is associated with greater reduction in colorectal cancer incidence and mortality in the distal colon than the proximal colon. This may be attributable to incomplete examination of the proximal colon, and differences between the proximal and distal colon that include worse bowel preparation, suboptimal colonoscopic technique, and a higher prevalence of serrated polyps and flat adenomas. The latter are more common than previously recognized, are more likely to contain advanced pathology, and are more difficult to identify than raised (sessile or pedunculated) polyps. To optimize diagnostic accuracy as well as patient safety and comfort, colonoscopy should be performed after optimal bowel preparation by a well-trained endoscopist who spends sufficient time (at least 7 minutes) carefully examining the colon (especially the proximal colon) while withdrawing the endoscope.

C. Radiographic Examinations of the Colon

1. CT colonography—Using helical CT with computer-assisted image reconstruction, two- and three-dimensional views can be generated of the colon lumen that simulate the view of colonoscopy (virtual colonoscopy). CT colonography requires a similar bowel cleansing regimen as colonoscopy as well as insufflation of air into the colon through a rectal tube, which may be associated with discomfort. Nonetheless, this examination is performed rapidly and requires no sedation or intravenous contrast. It has minimal acute risk although there is controversy about potential long-term risks related to radiation exposure from CT examinations. Several large studies have compared the accuracy of virtual colonoscopy with colonoscopy for colorectal screening. Using current imaging software with multidetector helical scanners, the sensitivity is $> 95\%$ for the detection of cancer and $> 84\text{--}92\%$ for the detection of polyps ≥ 10 mm in size. The sensitivity for polyps 6–9 mm in size ranges from 57% to 84%; for polyps 5 mm or less, the sensitivity is extremely poor.

Patients undergoing screening with CT colonography should be managed appropriately. If no polyps are found, the interval for repeat screening examination is uncertain; however, 5 years may be reasonable. All patients with polyps ≥ 10 mm in size should be referred for colonoscopy with polypectomy because of the high prevalence (30%) of advanced pathology (cancer, high-grade dysplasia, or villous features) within these polyps. The optimal management of patients with polyps < 10 mm in size is controversial. The likelihood of advanced pathology in polyps 6–9 mm in size is 4–7% and in polyps 1–5 mm is $< 2\%$. The US Multi-Society Task Force currently recommends that colonoscopy with polypectomy be offered to patients with one or more 6–9 mm polyps. Patients who refuse or who have increased risk of carcinoma should undergo surveillance CT colonography in 3–5 years. At the present time, there is no consensus on the management of patients with polyps < 6 mm; however, some radiologists choose not even to report these findings.

2. Barium enema—Double-contrast barium enema was previously used as a screening technique because it was widely available, relatively inexpensive, and safe. However, compared to CT colonography, it is more time consuming and difficult to perform, less comfortable, and less accurate. Although it continues to be included among recommended screening options, it has been supplanted by CT colonography, where available. A multicenter trial demonstrated that the sensitivity of barium enema is only 50% for polyps ≥ 1 cm and 55–85% for early-stage cancers when compared with colonoscopy. At present, barium enema may be recommended when screening of the entire colon is desired but expertise in CT colonography is unavailable and the patient is unable or unwilling to undergo colonoscopy.

▶ When to Refer

- Patients with symptoms (change in bowel habits, hematochezia), signs (mass on abdominal examination or digital rectal examination [DRE]), or laboratory tests

(iron deficiency anemia) suggestive of colorectal neoplasia should be referred for colonoscopy.

- Patients with suspected cancer or adenomatous polyps of any size should be referred for colonoscopy.
- Virtually all patients with proven colorectal cancer should be referred to a surgeon for resection. Patients with clinical stage T3 or node-positive rectal tumors (or both) also should be referred to an oncologist preoperatively for neoadjuvant therapy. Patients with stage III or IV colorectal tumors should be referred to an oncologist.

▶ When to Admit

- Patients with complications of colorectal cancer (obstruction, acute bleeding) requiring urgent evaluation and intervention.
- Patients with severe complications of chemotherapy.
- Patients with advanced metastatic disease requiring palliative care.

Ahnen DJ. The American College of Gastroenterology Emily Couric lecture—the adenoma-carcinoma sequence revisited: has the era of genetic tailoring finally arrived? *Am J Gastroenterol.* 2011 Feb;106(2):190–8. [PMID: 21266962]

Allison JE. FIT: a valuable but underutilized screening test for colorectal cancer—it's time for a change. *Am J Gastroenterol.* 2010 Sep;105(9):2026–8. [PMID: 20818351]

André T et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. *N Engl J Med.* 2009 Jul 1;27(19):3109–16. [PMID: 19451431]

Atkin WS et al; UK Flexible Sigmoidoscopy Trial Investigators. Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial. *Lancet.* 2010 May 8;375(9726):1624–33. [PMID: 20430429]

Baxter NN et al. Analysis of administrative data finds endoscopist quality measures associated with postcolonoscopy colorectal cancer. *Gastroenterology.* 2011 Jan;140(1):65–72. [PMID: 20854818]

Bokemeyer C et al. Cetuximab with chemotherapy (CT) as first-line treatment for metastatic colorectal cancer (mCRC): analysis of the CRYSTAL and OPUS studies according to KRAS and BRAF mutation status. Presented at American Society of Clinical Oncology Annual Meeting, 2010. Chicago, IL.

Brenner H et al. Protection from colorectal cancer after colonoscopy: a population-based, case-control study. *Ann Intern Med.* 2011 Jan 4;154(1):22–30. [PMID: 21200035]

Day LW et al. Colorectal cancer screening and surveillance in the elderly patient. *Am J Gastroenterol.* 2011 Jul;106(7):1197–206. [PMID: 21519362]

Douillard JY et al. Final results from PRIME: randomized phase 3 study of panitumumab (pmab) with FOLFOX4 for 1st-line metastatic colorectal cancer (mCRC). Presented at American Society of Clinical Oncology Annual Meeting, 2011. Chicago, IL.

Hecht JR et al. A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. *J Clin Oncol.* 2009 Feb 10;27(5):672–80. [PMID: 19114685]

Jemal A et al. Cancer statistics, 2010. *CA Cancer J Clin.* 2010 Sep–Oct;60(5):277–300. [PMID: 20610543]

Kaminski MF et al. Quality indicators for colonoscopy and the risk of interval cancer. *N Engl J Med.* 2010 May 13;362(19):1795–803. [PMID: 20463339]

Karpets CS et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. *N Engl J Med.* 2008 Oct 23;359(17):1757–65. [PMID: 18946061]

Lakoff J et al. Risk of developing a proximal versus distal colorectal cancer after a negative colonoscopy: a population-based study. *Clin Gastroenterol Hepatol.* 2008 Oct;6(10):1117–21. [PMID: 18691942]

Levin B et al. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. *Gastroenterology.* 2008 May;134(5):1570–95. [PMID: 18384785]

Lieberman DA. Clinical Practice. Screening for colorectal cancer. *N Engl J Med.* 2009 Sep 17;361(12):1179–87. [PMID: 19759380]

Pohl H et al. Colorectal cancers detected after colonoscopy frequently result from missed lesions. *Clin Gastroenterol Hepatol.* 2010 Oct;8(10):858–64. [PMID: 20655393]

Regge D et al. Diagnostic accuracy of computed tomographic colonography for the detection of advanced neoplasia in individuals at increased risk of colorectal cancer. *JAMA.* 2009 Jun 17;301(23):2453–61. [PMID: 19531785]

Rex D et al. American College of Gastroenterology Guidelines for colorectal cancer screening 2009. *Am J Gastroenterol.* 2009 Mar;104(3):739–50. [PMID: 19240699]

Singh H et al. The reduction in colorectal cancer mortality after colonoscopy varies by site of cancer. *Gastroenterology.* 2010 Oct;139(4):1128–37. [PMID: 20600026]

Singh H et al. Rate and predictors of early/missed colorectal cancers after colonoscopy in Manitoba: a population-based study. *Am J Gastroenterol.* 2010 Dec;105(12):2588–96. [PMID: 20877348]

Soetikno RM et al. Prevalence of nonpolypoid (flat and depressed) colorectal neoplasms in asymptomatic and symptomatic adults. *JAMA.* 2008 Mar 5;299(9):1027–35. [PMID: 18319413]

Terdiman JP et al. Surveillance guidelines should be updated to recognize the importance of serrated polyps. *Gastroenterology.* 2010 Nov;139(5):1444–7. [PMID: 20875785]

Tol J et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. *N Engl J Med.* 2009 Feb 5;360(6):563–72. [PMID: 19196673]

Van Cutsem E et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. *N Engl J Med.* 2009 Apr 2;360(14):1408–17. [PMID: 19339720]

Van Rossum LG et al. Random comparison of guaiac and immunochemical fecal occult blood tests for colorectal cancer in a screening population. *Gastroenterology.* 2008 Jul;135(1):82–90. [PMID: 18482589]

CARCINOMA OF THE ANUS

The anal canal is lined from its proximal to distal extent by columnar, transitional and non-keratinized squamous epithelium, which merges at the anal verge with the keratinized perianal skin. Tumors arising from the mucosa of the anal canal are relatively rare, comprising only 1–2% of all cancers of the anus and large intestine. Squamous cancers make up the majority of anal cancers. Anal cancer is increased among people practicing receptive anal intercourse and those with a history of anorectal warts. In over 80% of cases, HPV may be detected, suggesting that this virus is a major causal factor. Women with anal cancer are at increased risk for cervical cancer, which may be due to a field effect of oncogenic HPV infection, and require gynecologic screening and surveillance. Anal cancer is increased in HIV-infected individuals, possibly due to interaction

with HPV. Bleeding, pain, and local tumor are the most common symptoms. The lesion is often confused with hemorrhoids or other common anal disorders. These tumors tend to become annular, invade the sphincter, and spread upward via the lymphatics into the perirectal mesenteric lymphatic nodes. CT or MRI scans of the abdomen and pelvis are required to identify regional lymphadenopathy or metastatic disease at diagnosis. PET imaging may be used in conjunction.

Treatment depends on the tumor location and histologic stage. Small (< 3 cm) superficial lesions of the perianal skin may be treated with wide local excision. Adenocarcinoma of the anal canal is treated in similar fashion to rectal cancer (see above), commonly by abdominoperineal resection with neoadjuvant chemoradiotherapy and adjuvant chemotherapy. Squamous cancer of the anal canal and large perianal tumors invading the sphincter or rectum are treated with combined-modality therapy that includes external radiation with simultaneous chemotherapy (5-FU and mitomycin). Local control is achieved in approximately 80% of patients. Radical surgery (abdominoperineal resection) is reserved for patients who fail chemotherapy and radiation therapy. Metastatic disease is generally treated with 5-FU in combination with cisplatin. The 5-year survival rate is 60–70% for localized tumors and over 25% for metastatic (stage IV) disease.

Ajani JA et al. Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial. *JAMA*. 2008 Apr 23;299(16):1914–21. [PMID: 18430910]

Glynn-Jones R et al. Anal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol*. 2010 May;21(Suppl 5):v87–92. [PMID: 20551110]

National Cancer Institute. Anal Cancer Treatment (PDQ). <http://www.cancer.gov/cancertopics/pdq/treatment/anal/HealthProfessional>

Shia J. An update on tumors of the anal canal. *Arch Pathol Lab Med*. 2010 Nov;134(11):1601–11. [PMID: 21043813]

Zeller JL et al. JAMA patient page. Anal cancer. *JAMA*. 2008 Apr 23;299(16):1980. [PMID: 18430917]

CANCERS OF THE GENITOURINARY TRACT

Maxwell V. Meng, MD, FACS

PROSTATE CANCER



ESSENTIALS OF DIAGNOSIS

- ▶ Prostatic induration on DRE or elevation of PSA.
- ▶ Most often asymptomatic.
- ▶ Rarely: systemic symptoms (weight loss, bone pain).

▶ General Considerations

Prostatic cancer is the most common noncutaneous cancer detected in American men and the second leading

cause of cancer-related death. In the United States, over 241,000 new cases of prostate cancer are diagnosed annually, and about 28,000 deaths result. However, the clinical incidence of the disease does not match the prevalence noted at autopsy, where more than 40% of men over 50 years of age are found to have prostatic carcinoma. Most such occult cancers are small and contained within the prostate gland; few are associated with regional or distant disease. The incidence of prostatic cancer increases with age. Whereas 30% of men aged 60–69 years will have the disease, autopsy incidence increases to 67% in men aged 80–89 years. Although the global prevalence of prostatic cancer at autopsy is relatively consistent, the clinical incidence varies considerably (high in North America and European countries, intermediate in South America, and low in the Far East), suggesting that environmental or dietary differences among populations may be important for prostatic cancer growth. A 50-year-old American man has a lifetime risk of 40% for latent cancer, 16% for developing clinically apparent cancer, and a 2.9% risk of death due to prostatic cancer. Blacks, men with a family history of prostatic cancer, and those with a history of high dietary fat intake are at increased risk for developing prostate cancer.

▶ Clinical Findings

A. Symptoms and Signs

Prostate cancer may manifest as focal nodules or areas of induration within the prostate at the time of DRE. However, currently most prostate cancers are associated with palpably normal prostates and are detected solely on the basis of elevations in serum PSA.

Patients rarely present with signs of urinary retention or neurologic symptoms as a result of epidural metastases and cord compression. Obstructive voiding symptoms are most often due to benign prostatic hyperplasia, which occurs in the same age group. Nevertheless, large or locally extensive prostatic cancers can cause obstructive voiding symptoms while lymph node metastases can lead to lower extremity lymphedema. As the axial skeleton is the most common site of metastases, patients may present with back pain or pathologic fractures.

B. Laboratory Findings

1. Serum tumor markers—PSA is a glycoprotein produced only by cells, either benign or malignant, of the prostate gland. The serum level is typically low and correlates with the volume of both benign and malignant prostate tissue. Measurement of serum PSA is useful in detecting and staging prostate cancer, monitoring response to treatment, and detecting recurrence before it becomes clinically evident. As a screening test, PSA will be elevated in 10–15% of men. Approximately 18–30% of men with intermediate degrees of elevation (4.1–10 ng/mL) will be found to have prostate cancer. Between 50% and 70% of those with elevations >10 ng/mL will have prostate cancer. Patients with intermediate levels of PSA usually have localized and therefore potentially curable cancers. It should be remembered that approximately 20% of patients

who undergo radical prostatectomy for localized prostate cancer have normal levels of PSA.

In untreated patients with prostate cancer, the level of PSA correlates with the volume and stage of the disease. Whereas most organ-confined cancers are associated with PSA levels <10 ng/mL, advanced disease (seminal vesicle invasion, lymph node involvement, or occult distant metastases) is more common in patients with PSA levels in excess of 40 ng/mL. Approximately 98% of patients with metastatic prostate cancer will have elevated PSA. However, there are rare cancers that are localized despite substantial elevations in PSA. Therefore, initial treatment decisions cannot be made on the basis of PSA testing alone. A rising PSA after therapy is usually consistent with progressive disease, either locally recurrent or metastatic.

2. Miscellaneous laboratory testing—Patients in urinary retention or those with ureteral obstruction due to loco-regionally advanced prostate cancers may present with elevations in blood urea nitrogen or creatinine. Patients with bony metastases may have elevations in alkaline phosphatase or hypercalcemia. Laboratory and clinical evidence of disseminated intravascular coagulation can occur in patients with advanced prostate cancers.

3. Prostate biopsy—Transrectal ultrasound-guided biopsy is the standard method for detection of prostate cancer. The use of a spring-loaded, 18-gauge biopsy needle has allowed transrectal biopsy to be performed with minimal patient discomfort and morbidity. Local anesthesia is routinely used and increases the tolerability of the procedure. The specimen preserves glandular architecture and permits accurate grading. Prostate biopsy specimens are taken from the apex, mid-portion, and base in men who have an abnormal DRE or an elevated serum PSA, or both. Extended-pattern biopsies, including a total of at least ten biopsies, are associated with improved cancer detection and risk stratification of patients with newly diagnosed disease. Patients with abnormalities of the seminal vesicles can have these structures specifically biopsied to identify local tumor invasion.

C. Imaging

Transrectal ultrasonography has primarily been used for the staging of prostate carcinomas, where tumors typically appear as hypoechoic areas. In addition, transrectal ultrasound-guided, rather than digitally-guided, biopsy of the prostate is a more accurate way to evaluate suspicious lesions. Use of imaging should be tailored to the likelihood of advanced disease in newly diagnosed cases. Asymptomatic patients with well-differentiated to moderately differentiated cancers, thought to be localized to the prostate on DRE and transurethral ultrasound and associated with modest elevations of PSA (ie, < 10 ng/mL), need no further imaging.

MRI allows for evaluation of the prostate as well as regional lymph nodes. The positive predictive value for detection of both capsular penetration and seminal vesicle invasion is similar for transrectal ultrasound and MRI. CT

plays little role because of its inability to accurately identify or stage prostate cancers, but it can be used to detect regional lymphatic metastases and intra-abdominal metastases.

Radionuclide bone scan is superior to conventional plain skeletal radiographs in detecting bony metastases. Most prostate cancer metastases are multiple and most commonly localized to the axial skeleton. Men with more advanced local lesions, symptoms of metastases (eg, bone pain), high-grade disease, or elevations in PSA > 20 ng/mL should undergo radionuclide bone scan. Because of the high frequency of abnormal scans in patients in this age group resulting from degenerative joint disease, plain films are often necessary in evaluating patients with indeterminate findings on bone scan. Cross-sectional imaging either by CT or MRI is usually indicated only in those patients in the latter group who have negative bone scans in an attempt to detect lymph node metastases. Patients found to have enlarged pelvic lymph nodes are candidates for FNA.

Intravenous urography and cystoscopy are not routinely needed to evaluate patients with prostate cancer.

Despite application of modern, sophisticated techniques, understaging of prostate cancer occurs in at least 20% of patients.

► Screening for Prostate Cancer

Whether screening for prostate cancer results in a decrease in mortality rates due to the disease is the subject of much debate. The screening tests currently available include DRE, PSA testing, and transrectal ultrasound. Depending on the patient population being evaluated, detection rates using DRE alone vary from 1.5% to 7%. Unfortunately, most cancers detected in this manner are advanced (stage T3 or greater). Transrectal ultrasound should not be used as a first-line screening tool because of its expense, low specificity (and therefore high biopsy rate), and minimal improvement in detection rate when compared with the combined use of DRE and PSA testing.

PSA testing increases the detection rate of prostate cancers compared with DRE. Approximately 2–2.5% of men older than 50 years of age will be found to have prostate cancer using PSA testing compared with a rate of approximately 1.5% using DRE alone. PSA is not specific for cancer, and there is considerable overlap of values between men with benign prostate hyperplasia and those with prostate cancers. The sensitivity, specificity, and positive predictive value of PSA and DRE are listed in Table 39–6. PSA-detected cancers are more likely to be localized compared with those detected by DRE alone. The Prostate Cancer Prevention Trial provided data demonstrating a significant risk of prostate cancer even in men with PSA less than 4.0 ng/mL (Table 39–7) and a web-based calculator has been developed to estimate the risk of harboring both cancer and high-grade prostate cancer (<http://deb.uthscsa.edu/URORiskCalc/Pages/uroriskcalc.jsp>).

To improve the performance of PSA as a screening test, several investigators have developed alternative methods for its use. These include establishment of age- and race-specific reference ranges, measurement of free serum and protein-bound levels of PSA (percent free

Table 39-6. Screening for prostatic cancer: Test performance.

Test	Sensitivity	Specificity	Positive Predictive Value
Abnormal PSA (> 4 ng/mL)	0.67	0.97	0.43
Abnormal DRE	0.50	0.94	0.24
Abnormal PSA or DRE	0.84	0.92	0.28
Abnormal PSA and DRE	0.34	0.995	0.49

DRE, digital rectal examination; PSA, prostate-specific antigen. Modified, with permission, from Kramer BS et al. Prostate cancer screening: what we know and what we need to know. *Ann Intern Med.* 1993 Nov 1;119(9):914-23.

PSA), and calculation of changes in PSA over time (PSA velocity). Generally, men with PSA free fractions exceeding 25% are unlikely to have prostate cancer, whereas those with free fractions < 10% have an approximately 50% chance of having prostate cancer. The frequency of PSA testing remains a matter of some debate. The traditional yearly screening approach may not be the most efficient, rather, earlier PSA testing at younger age may allow less frequent testing as well as provide information regarding PSA velocity. Studies from the Baltimore Longitudinal Study of Aging suggest that men with PSA above the age-based median when tested between 40 and 60 years are at significantly increased risk for subsequent cancer detection over 25 years. Therefore, men with lower PSA (0.6 ng/mL ages 40–50 and 0.71 ages 50–60) may require less frequent PSA tests. In addition, men with PSA velocity greater than 0.35 ng/mL per year measured 10–15 years before diagnosis had significantly worse cancer-specific survival compared with those with lower PSA velocity. The current NCCN guidelines (http://www.nccn.org/professionals/physician_gls/f_guidelines.asp) for prostate cancer early detection incorporate many of these factors (Figure 39–2).

Table 39-7. Risk of prostate cancer in men with PSA ≤ 4.0 ng/mL.

PSA Level (ng/mL)	Percentage with prostate cancer	Percentage with high-grade prostate cancer
≤ 0.5	6.6	12.5
0.6-1.0	10.1	10.0
1.1-2.0	17.0	11.8
2.1-3.0	23.9	19.1
3.1-4.0	26.9	25.0

Data from Thompson IM et al. Prevalence of prostate cancer among men with a prostate-specific antigen level ≤4.0 ng per milliliter. *N Engl J Med.* 2004 May 27;350(22):2239-46. [PMID: 15163773]

High-grade cancer was defined as Gleason score ≥ 7.

Two large, randomized trials question the benefit of screening men for prostate cancer. In the US Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial, no mortality benefit was observed after combined screening with PSA testing and digital rectal examination during follow-up of 13 years. Although screening resulted in a 12% increase in prostate cancer detection, the cancer-specific mortality rate was similar in the screening and control arms (3.7 and 3.4 deaths per 10,000 person-years, respectively). Similarly in the European Randomized Study of Screening for Prostate Cancer (ERSPC) trial, the benefit of PSA screening was minimal with a 20% relative reduction in death rate from prostate at follow-up of 9 years, with an absolute reduction of 7 prostate cancer deaths per 10,000 men screened. A subset of these patients from Göteborg, Sweden, in an independently designed and initiated population-based screening trial, was analyzed separately. During a median follow-up of 14 years, the absolute risk reduction of death from prostate cancer in the screening group was 40% and the relative risk of prostate-cancer death in the attendees of screening was 0.44. Based on these data, the US Preventive Services Task Force recommended against PSA-based screening for prostate cancer in asymptomatic men (grade D recommendation). Criticisms of the negative PLCO study include use of a relatively high PSA threshold (4 ng/mL), significant screening of men in the 3 years prior to enrolling in the trial (44%), and significant number of men in the control arm undergoing screening during the trial (> 50%).


► Staging

The majority of prostate cancers are adenocarcinomas. Most arise in the periphery of the prostate (peripheral zone), though a small percentage arise in the central (5–10%) and transition zones (20%) of the gland. Pathologists utilize the Gleason grading system whereby a “primary” grade is applied to the architectural pattern of malignant glands occupying the largest area of the specimen and a “secondary” pattern is assigned to the next largest area of cancer. Grading is based on architectural rather than histologic criteria, and five “grades” are possible (Figure 39–3). Adding the score of the primary and secondary patterns (grades) gives a Gleason score. Grade correlates with tumor volume, pathologic stage, and prognosis (Figure 39–4).

► Treatment

A. Localized Disease

The optimal treatment for patients with clinically localized prostate cancers remains controversial. Patients need to be advised of all treatment options, including active surveillance, with the specific benefits, risks, and limitations. Currently, treatment decisions are made based on tumor grade and stage as well as the age and health of the patient. Although selected patients may be candidates for surveillance based on age or health and evidence of small-volume or well-differentiated cancers, most men with an anticipated life expectancy in excess of 10 years should be




¹NCCN guidelines utilize PSA threshold of 1.0 ng/mL in men < 50 years, the 75th percentile range for this age group; the median PSA value for men 40–49 years is 0.6 ng/mL.

▲ Figure 39–2. An algorithm for prostate cancer early detection. DRE, digital rectal examination; 5-ARI, 5 α -reductase inhibitor; PSAV, PSA velocity (ng/mL/year) calculated on at least three consecutive values over at least an 18–24 month period. (Based on NCCN guidelines, data from the Baltimore Longitudinal Study on Aging, and Prostate Cancer Prevention Trial.)

considered for treatment. Both radiation therapy and radical prostatectomy result in acceptable levels of local control. A large, prospective, randomized trial compared surveillance with radical prostatectomy in 695 men with clinically localized and well- differentiated to moderately differentiated tumors for a median of 12.8 years. Radical prostatectomy significantly reduced disease-specific mortality, overall mortality, and risks of metastasis and local progression. The relative reduction in the risk of death at

15 years was 0.62 in the prostatectomy group, with the number needed to treat to avert one death of 15; the benefit was confined to men younger than 65 years of age. This trial accrued patients in Sweden between 1989 and 1999, thus likely including patients with greater cancer burden compared with that in patients currently diagnosed using PSA screening. Nevertheless, the survival benefit in the trials was still observed in men with low-risk prostate cancer.




▲ **Figure 39-3.** Patterns of prostate cancer according to the 2005 International Society of Urological Pathology modified Gleason system. (Adapted with permission from Epstein JI et al. The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. *Am J Surg Pathol.* 2005;29(9):1228-1242.)

B. Radical Prostatectomy

During radical prostatectomy, the seminal vesicles, prostate, and ampullae of the vas deferens are removed. Refinements in technique have allowed preservation of urinary continence in most patients and erectile function

in selected patients. Radical prostatectomy can be performed via open retropubic, transperineal, or laparoscopic (with or without robotic assistance) surgery. Local recurrence is uncommon after radical prostatectomy, and the incidence is related to pathologic stage. Organ-confined



▲ **Figure 39-4.** Prostate cancer mortality as a factor of Gleason grade and age at diagnosis in men managed conservatively. (Adapted, with permission, from Albertsen PC et al. 20-year outcomes following conservative management of clinically localized prostate cancer. *JAMA*. 2005 May 4;293(17):2095-101.)

cancers rarely recur; however, cancers with adverse pathologic features (capsular penetration, seminal vesicle invasion) are associated with higher local (10–25%) and distant (20–50%) relapse rates.

Ideal candidates for prostatectomy include healthy patients with stages T1 and T2 prostate cancers. Patients with advanced local tumors (T4) or lymph node metastases are rarely candidates for prostatectomy alone, although surgery is sometimes used in combination with hormonal therapy and postoperative radiation therapy for select high-risk patients.

Patients with advanced pathologic stage or positive surgical margins are at an increased risk for local and distant tumor relapse. Such patients are candidates for adjuvant therapy (radiation for positive margins or androgen deprivation for lymph node metastases). Two randomized clinical trials (EORTC 22911 and SWOG 8794) have demonstrated improved progression-free and metastasis-free survival with early radiotherapy in these men, and subsequent analysis of SWOG 8794 showed improved overall survival in men receiving adjuvant radiation therapy. Evidence suggests that salvage radiotherapy after radical prostatectomy, within 2 years of PSA relapse, increases prostate cancer-specific survival in men with shorter PSA doubling time (< 6 months).

C. Radiation Therapy

Radiation can be delivered by a variety of techniques including use of external beam radiotherapy and transperineal implantation of radioisotopes. Morbidity is limited, and the survival of patients with localized cancers (T1, T2, and selected T3) approaches 65% at 10 years. As with surgery, the likelihood of local failure correlates with technique and tumor characteristics. The likelihood of a positive prostate biopsy more than 18 months after radiation varies between 20% and 60%. Patients with local recurrence are at an increased risk of cancer progression and cancer death compared with those who have negative biopsies. Ambiguous target definitions, inadequate radiation doses, and understaging of the tumor may be responsible for the failure noted in some series. Newer techniques of radiation (implantation, conformal therapy using three-dimensional reconstruction of CT-based tumor volumes, heavy particle, charged particle, and heavy charged particle) may improve local control rates. Three-dimensional conformal radiation delivers a higher dose because of improved targeting and appears to be associated with greater efficacy as well as lower likelihood of adverse side effects compared with previous techniques. As a result of improvements in imaging, most

notably transrectal ultrasound, there has been a resurgence of interest in brachytherapy—the implantation of permanent or temporary radioactive sources (palladium, iodine, or iridium) into the prostate. Brachytherapy can be combined with external beam radiation in patients with higher-grade or higher-volume disease or as monotherapy in those with low-grade or low-volume malignancies. The PSA may rise after brachytherapy because of prostate inflammation and necrosis. This transient elevation (PSA bounce) should not be mistaken for recurrence and may occur up to 20 months after treatment.

D. Surveillance

A beneficial impact of treating localized prostate cancer with respect to survival has not been conclusively demonstrated. Therefore, surveillance alone may be an appropriate form of management for selected patients with prostate cancer. Patients included in observational series are typically older with small volume, well-differentiated cancers. Many men with prostate cancer may be candidates for surveillance due to the significant migration to lower stage as well as lower grade, resulting from screening for prostate cancer using PSA testing. Depending on the age and health of the patient, some of these very low-volume, low-grade cancers may never become clinically relevant and can be monitored with serial PSA levels, rectal examinations, and periodic prostate biopsies to assess grade and extent of tumor. The goal of surveillance is to avoid treatment in men who never experience disease progression while recognizing and effectively treating men with evidence of progression. End points for intervention in patients on surveillance, particularly PSA changes, have not been clearly defined and surveillance regimens remain investigational.

E. Cryosurgery

Cryosurgery is a technique whereby liquid nitrogen is circulated through small hollow-core needles inserted into the prostate under ultrasound guidance. The freezing process results in tissue destruction. There has been a resurgence of interest in less invasive forms of therapy for localized prostate cancer as well as several recent technical innovations, including improved percutaneous techniques, expertise in transrectal ultrasound, improved cryotechnology, and better understanding of cryobiology. The positive biopsy rate after cryoablation ranges between 7% and 23%.

F. Locally and Regionally Advanced Disease

Prostate cancers associated with minimal degrees of capsular penetration are candidates for standard irradiation or surgery. Those with locally extensive cancers, including those with seminal vesicle and bladder neck invasion, are at increased risk for both local and distant relapse despite conventional therapy. Currently, a variety of investigational regimens are being tested in an effort to improve

cancer outcomes in such patients. Combination therapy (androgen deprivation combined with surgery or irradiation), newer forms of irradiation, and hormonal therapy alone are being tested, as is neoadjuvant and adjuvant chemotherapy. Neoadjuvant and adjuvant androgen deprivation therapy combined with external beam radiation therapy have demonstrated improved survival compared with external beam radiation therapy alone.

G. Metastatic Disease

Since death due to prostate carcinoma is almost invariably the result of failure to control metastatic disease, research has emphasized efforts to improve control of distant disease. It is well known that most prostate carcinomas are hormone dependent and approximately 70–80% of men with metastatic prostate carcinoma will respond to various forms of androgen deprivation. Androgen deprivation may be affected at several levels along the pituitary–gonadal axis using a variety of methods or agents (Table 39–8). Use of luteinizing hormone-releasing hormone (LHRH) agonists (leuprolide, goserelin) achieves androgen deprivation without orchiectomy or administration of diethylstilbestrol and is currently the most common method of reducing testosterone levels. A single LHRH antagonist (degarelix) is FDA approved and has no short-term testosterone “flare” associated with LHRH agonists. Because of its rapid onset of action, ketoconazole should be considered in patients with advanced prostate cancer who present with spinal cord compression, bilateral ureteral obstruction, or disseminated intravascular coagulation. Although testosterone is the major circulating androgen, the adrenal gland secretes the androgens dehydroepiandrosterone, dehydroepiandrosterone sulfate, and androstenedione. Some investigators believe that suppressing both testicular and adrenal androgens allows for a better initial and longer response than methods that only inhibit production of testicular androgens. Complete androgen blockade can be achieved by combining an antiandrogen with use of an LHRH agonist/antagonist or orchiectomy. Nonsteroidal antiandrogen agents appear to act by competitively binding the receptor for dihydrotestosterone, the intracellular androgen responsible for prostate cell growth and development. A meta-analysis of trials comparing the use of either an LHRH agonist or orchiectomy alone with the use of either in combination with an antiandrogen agent shows little benefit of combination therapy. However, patients at risk for disease-related symptoms (bone pain, obstructive voiding symptoms) due to the initial elevation of serum testosterone that accompanies the use of an LHRH agonist should receive antiandrogens initially. Bisphosphonates can prevent osteoporosis associated with androgen deprivation, decrease bone pain from metastases, and reduce skeletal related events. Denosumab, a RANK ligand inhibitor, is approved for the prevention of skeletal-related events in patients with bone metastases from prostate cancer and also appears to delay the development of these metastases.

Docetaxel is the first cytotoxic chemotherapy agent to improve survival in patients with hormone-refractory

Table 39-8. Androgen deprivation for prostatic cancer.

Level	Agent	Dose	Sequelae
Pituitary, hypothalamus	Diethylstilbestrol	1-3 mg orally daily	Gynecomastia, hot flushes, thromboembolic disease, erectile dysfunction
	LHRH agonists Leuprolide Goserelin	Monthly or 3-monthly depot injection	Erectile dysfunction, hot flushes, gynecomastia, rarely anemia
	LHRH antagonist Degarelix	240 mg subcutaneously initial dose, then 80 mg subcutaneously monthly	Hot flushes, weight gain, erectile dysfunction, increased liver function tests
Adrenal	Ketoconazole	400 mg three times orally daily	Adrenal insufficiency, nausea, rash, ataxia
	Aminoglutethimide	250 mg four times orally daily	Adrenal insufficiency, nausea, rash, ataxia
	Corticosteroids Prednisone	20-40 mg orally daily	Gastrointestinal bleeding, fluid retention
	CYP17a1 inhibitor Abiraterone	500 mg orally daily	Weight gain, fluid retention, hypokalemia, hypertension
Testis	Orchiectomy		Gynecomastia, hot flushes, erectile dysfunction
Prostate cell	Antiandrogens Flutamide Bicalutamide	250 mg three times orally daily 50 mg orally daily	No erectile dysfunction when used alone; nausea, diarrhea

LHRH, luteinizing-hormone-releasing hormone.

prostate cancer. Current research is underway combining docetaxel with androgen deprivation therapy, radiation therapy, and surgery to determine whether combinations are effective in patients with high-risk prostate cancer. Immune therapies are also under investigation and have shown promise for patients with advanced prostate cancer. Sipuleucel-T, an autologous cellular immunotherapy, is FDA approved in asymptomatic or minimally symptomatic men with metastatic hormone-refractory prostate cancer. Other agents—cabazitaxel and abiraterone—are also approved for advanced prostate cancer after clinical trials have demonstrated improvements in survival in men having received prior docetaxel, and it is expected that MDV3100, cabozantinib, and alpharadin will be approved shortly.

► Prognosis

The likelihood of success of surveillance or treatment can be predicted using risk assessment tools that usually combine stage, grade, PSA level, and number and extent of positive prostate biopsies. Several tools are available on the Internet (eg, <http://mskcc.org/mskcc/html/5794.cfm>). One of the most widely used is the Kattan nomogram; it incorporates tumor stage, grade, and PSA level to predict the likelihood that a patient will be disease-free after radical prostatectomy or radiation therapy.

The University of California San Francisco CAPRA nomogram uses serum PSA, Gleason grade, clinical stage, percent positive biopsies, and patient age in a point system to risk stratify and predict the likelihood of PSA

recurrence 3 and 5 years after radical prostatectomy (Tables 39-9 and 39-10). The CAPRA has been validated on large multicenter and international radical prostatectomy cohorts.

Table 39-9. The UCSF Cancer of the Prostate Risk Assessment (CAPRA).

Variable	Level	Points
PSA (ng/mL)	0-6	0
	6.1-10	1
	10.1-20	2
	20.1-30	3
	> 30	4
Gleason grade	1-3/1-3	0
	1-3/4-5	1
	4-5/1-5	3
T-stage	T1 or T2	0
	T3a	1
% positive biopsies (biopsy cores positive divided by the number of biopsies obtained)	< 34%	0
	> 34%	1
Age	< 50 years	0
	> 50 years	1

Table 39-10. CAPRA: Probability of freedom from PSA recurrence after radical prostatectomy by CAPRA point total.

CAPRA Score	3-Year Recurrence Free Survival (%) (95% CI)	5-Year Recurrence Free Survival (%) (95% CI)
0-1	91 (85-95)	85 (73-92)
2	89 (83-94)	81 (69-89)
3	81 (73-87)	66 (54-76)
4	81 (69-89)	59 (40-74)
5	69 (51-82)	60 (37-77)
6	54 (27-75)	34 (12-57)
7+	24 (9-43)	8 (0-28)

PSA, prostate-specific antigen.

The patterns of prostate cancer progression have been well defined. Small and well-differentiated cancers (Gleason grades 1 and 2) are usually confined within the prostate, whereas large-volume (> 4 mL) or poorly differentiated (Gleason grades 4 and 5) cancers are more often locally extensive or metastatic to regional lymph nodes or bone. Penetration of the prostate capsule by cancer is common and occurs along perineural spaces. Seminal vesicle invasion is associated with a high likelihood of regional or distant disease, and disease recurrence. Lymphatic metastases can be identified in the obturator and internal iliac lymph node chains. The axial skeleton, as mentioned previously, is the most common site of distant metastases.

▶ When to Refer

- All patients should be referred to an urologist. PSA remains integral in prostate cancer diagnosis. Low-risk disease may be managed by active surveillance, surgery, or radiation therapy.
- High-risk disease often requires multimodal treatment strategies.

Albertsen PC et al. 20-year outcomes following conservative management of clinically localized prostate cancer. *JAMA*. 2005 May 4;293(17):2095–101. [PMID: 15870412]

Andriole GL et al; PLCO Project Team. Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. *J Natl Cancer Inst*. 2012 Jan 18;104(2):125–32. [PMID: 22228146]

Andriole GL et al; REDUCE Study Group. Effect of dutasteride on the risk of prostate cancer. *N Engl J Med*. 2010 Apr 1;362(13):1192–202. [PMID: 20357281]

Bill-Axelsson A et al; Scandinavian Prostate Cancer Study Group No. 4. Radical prostatectomy versus watchful waiting in early prostate cancer. *N Engl J Med*. 2005 May 12;352(19):1977–84. [PMID: 15888698]

Dall'Era MA et al. Active surveillance for the management of prostate cancer in a contemporary cohort. *Cancer*. 2008 Jun 15;112(12):2664–70. [PMID: 18433013]

Freedland SJ et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. *JAMA*. 2005 Jul 27;294(4):433–9. [PMID: 16046649]

Hugosson J et al. Mortality results from the Göteborg randomized population-based prostate-cancer screening trial. *Lancet Oncol*. 2010 Aug 11(8):725–32. [PMID: 20598634]

Meng MV et al. Treatment of patients with high risk localized prostate cancer: results from cancer of the prostate strategic urological research endeavor (CaPSURE). *J Urol*. 2005 May; 173(5):1557–61. [PMID: 15821485]

Schröder FH et al; ECRSPC Investigators. Screening and prostate-cancer mortality in a randomized European study. *N Engl J Med*. 2009 Mar;360(13):1320–8. [PMID: 19297566]

Thompson IM et al. Prediction of prostate cancer for patients receiving finasteride: results from the Prostate Cancer Prevention Trial. *J Clin Oncol*. 2007 Jul 20;25(21):3076–81. [PMID: 17634486]

Trock BJ et al. Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy. *JAMA*. 2008 Jun 18;299(23):2760–9. [PMID: 18560003]

Walsh PC et al. Clinical practice. Localized prostate cancer. *N Engl J Med*. 2007 Dec 27;357(26):2696–705. [PMID: 18160689]

Zeller JL et al. JAMA patient page. Prostate cancer. *JAMA*. 2008 Jul 9;300(2):236. [PMID: 18612121]

BLADDER CANCER



ESSENTIALS OF DIAGNOSIS

- ▶ Gross or microscopic hematuria.
- ▶ Irritative voiding symptoms.
- ▶ Positive urinary cytology in most patients.
- ▶ Filling defect within bladder noted on imaging.

▶ General Considerations

Bladder cancer is the second most common urologic cancer; it occurs more commonly in men than women (3.1:1), and the mean age of patients at diagnosis is 73 years. Cigarette smoking and exposure to industrial dyes or solvents are risk factors for the disease and account for approximately 60% and 15% of new cases, respectively. Ninety-eight percent of primary bladder cancers are epithelial malignancies, with the majority being urothelial cell carcinomas (90%). Adenocarcinomas and squamous cell cancers account for approximately 2% and 7%, respectively, of all bladder cancers detected in the United States. The latter is often associated with schistosomiasis, vesical calculi, or prolonged catheter use.

▶ Clinical Findings

A. Symptoms and Signs

Hematuria—gross or microscopic, chronic or intermittent—is the presenting symptom in 85–90% of patients with bladder cancer (also see the section on Hematuria, in

Chapter 23). Irritative voiding symptoms (urinary frequency and urgency) occur in a small percentage of patients as a result of the location or size of the cancer. Most patients with bladder cancer do not have signs of the disease because of its superficial nature. Abdominal masses detected on bimanual examination may be present in patients with large-volume or deeply infiltrating cancers. Hepatomegaly or palpable lymphadenopathy may be present in patients with metastatic disease, and lymphedema of the lower extremities may be present as a result of locally advanced cancers or metastases to pelvic lymph nodes.

B. Laboratory Findings

Urinalysis reveals microscopic or gross hematuria in the majority of cases. On occasion, hematuria may be accompanied by pyuria. Azotemia may be present in a small number of cases associated with ureteral obstruction. Anemia may occasionally be due to chronic blood loss or to bone marrow metastases. Exfoliated cells from normal and abnormal urothelium can be readily detected in voided urine specimens. Cytology can be useful in detecting the disease at the time of initial presentation or to detect recurrence. Cytology is sensitive in detecting cancers of higher grade and stage (80–90%) but less so in detecting superficial or well-differentiated lesions (50%). There are numerous urinary tumor markers under investigation for screening, assessing recurrence, progression, prognosis or response to therapy; the NMP22 point-of-care assay for a specific urinary protein has shown utility in detecting recurrent tumors.

C. Imaging

Bladder cancers may be identified using ultrasound, CT, or MRI where masses within the bladder are noted. However, the presence of cancer is confirmed by cystoscopy and biopsy, with imaging primarily used to evaluate the upper urinary tract and stage more advanced lesions.

D. Cystourethroscopy and Biopsy

The diagnosis and staging of bladder cancers are made by cystoscopy and transurethral resection. If cystoscopy—performed usually under local anesthesia—confirms the presence of bladder cancer, the patient is scheduled for transurethral resection under general or regional anesthesia. Random bladder and, on occasion, prostate urethral biopsies are performed to detect occult disease elsewhere in the bladder and potentially identify patients at greater risk for tumor recurrence and progression.

► Pathology & Staging

Grading is based on cellular features: size, pleomorphism, mitotic rate, and hyperchromatism. Bladder cancer staging is based on the extent of bladder wall penetration and the presence of regional or distant metastases.

The natural history of bladder cancer is based on two separate but related processes: tumor recurrence within the bladder and progression to higher-stage disease. Both are correlated with tumor grade and stage.

► Treatment

Patients with superficial cancers (Ta, T1) are treated with complete transurethral resection and selective use of intravesical chemotherapy. In the subset of patients with large, high-grade, recurrent Ta lesions or T1 cancers and those with carcinoma *in situ* are good candidates for adjuvant intravesical therapy.

Patients with invasive (T2, T3) but still localized cancers are at risk for both nodal metastases and progression and require radical cystectomy, irradiation, or the combination of chemotherapy and selective surgery or irradiation due to the much higher risk of progression compared with patients with lower-stage lesions.

For patients with muscle invasive (T2 or greater) transitional cell carcinoma, neoadjuvant systemic chemotherapy prior to radical cystectomy is superior to radical cystectomy alone. This is particularly important for higher stage or bulky tumors in order to improve their surgical resectability.

A. Intravesical Chemotherapy

Immunotherapeutic or chemotherapeutic agents delivered directly into the bladder via a urethral catheter can reduce the likelihood of recurrence in those who have undergone complete transurethral resection. Most agents are administered weekly for 6–12 weeks. Efficacy may be increased by prolonging contact time to 2 hours. The use of maintenance therapy after the initial induction regimen is beneficial. Common agents include thiotepa, mitomycin, doxorubicin, and BCG, the last being the most effective agent when compared with the others with respect to reducing disease progression. Side effects of intravesical chemotherapy include irritative voiding symptoms and hemorrhagic cystitis. Patients in whom symptoms or infection develop from BCG may require antituberculous therapy.

B. Surgical Treatment

Although transurethral resection is the initial form of treatment for all bladder tumors since it is diagnostic, allows for proper staging, and controls superficial cancers, muscle-infiltrating cancers require more aggressive treatment. Partial cystectomy is indicated in selected patients with solitary lesions or those with cancers in a bladder diverticulum. Radical cystectomy entails removal of the bladder, prostate, seminal vesicles, and surrounding fat and peritoneal attachments in men and the uterus, cervix, urethra, anterior vaginal vault, and usually the ovaries in women. Bilateral pelvic lymph node dissection is performed in all patients.

Urinary diversion can be performed using a conduit of small or large bowel. However, continent forms of diversion have been developed that avoid the necessity of an external appliance and can be considered in a significant number of patients.

C. Radiotherapy

External beam radiotherapy delivered in fractions over a 6- to 8-week period is generally well tolerated, but approximately 10–15% of patients will develop bladder,

bowel, or rectal complications. Local recurrence is common after radiotherapy alone (30–70%) and is therefore combined with systemic chemotherapy in an effort to reduce the need for radical cystectomy or to treat patients who are poor candidates for radical cystectomy.

D. Chemotherapy

Metastatic disease is present in 15% of patients with newly diagnosed bladder cancer, and metastases develop within 2 years in up to 40% of patients who were believed to have localized disease at the time of cystectomy or definitive radiotherapy. Cisplatin-based combination chemotherapy results in partial or complete responses in 15–45% of patients (see Table 39–4).

Combination chemotherapy has been integrated into trials of surgery and radiotherapy. It has been used to decrease recurrence rates with both modalities and to attempt bladder preservation in those treated with radiation. Chemotherapy should be considered before surgery in those with bulky lesions or those suspected of having regional disease, and recent evidence suggests that neoadjuvant chemotherapy may benefit all patients with muscle-invasive disease prior to planned cystectomy. Chemoradiation is best suited for those with T2 or limited T3 disease without ureteral obstruction. Alternatively, chemotherapy has been used after cystectomy in patients at high risk for recurrence, such as those who have lymph node involvement or local invasion.

► Prognosis

The frequency of recurrence and progression are correlated with grade. Whereas progression may be noted in few grade I cancers (19–37%), it is common with poorly differentiated lesions (33–67%). Carcinoma in situ is most often found in association with papillary bladder cancers. Its presence identifies patients at increased risk for recurrence and progression.

At initial presentation, approximately 50–80% of bladder cancers are superficial: stage Ta, Tis, or T1. When properly treated, lymph node metastases and progression are uncommon in this population and survival is excellent at 81%. Five-year survival of patients with T2 and T3 disease ranges from 50% to 75% after radical cystectomy. Long-term survival for patients with metastatic disease at presentation is rare.

► When to Refer

- All patients should be referred to an urologist. Hematuria often deserves evaluation with upper urinary tract imaging and cystoscopy, particularly in a high-risk group (ie, older men).
- Histologic diagnosis and staging require endoscopic resection of tumor.

Grossman HB et al. Surveillance for recurrent bladder cancer using a point-of-care proteomic assay. *JAMA*. 2006 Jan 18; 295(3):299–305. [PMID: 16418465]

International Collaboration of Trialists et al. International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. *J Clin Oncol*. 2011 Jun 1;29(16):2171–7. [PMID: 21502557]

Parikh DJ et al. Superficial and muscle-invasive bladder cancer: principles of management for outcomes assessments. *J Clin Oncol*. 2006 Dec 10;24(35):5519–27. [PMID: 17158537]

Stenzl A et al. Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines. *Eur Urol*. 2011 Jun;59(6):1009–18. [PMID: 21454009]

Yafi FA et al. Contemporary outcomes of 2287 patients with bladder cancer who were treated with radical cystectomy: a Canadian multicentre experience. *BJU Int*. 2011 Aug;108(4): 539–45. [PMID: 21166753]

CANCERS OF THE URETER & RENAL PELVIS

Cancers of the renal pelvis and ureter are rare and occur more commonly in patients with bladder cancer, smokers, those with Balkan nephropathy, those exposed to Thorotrast (a contrast agent with radioactive thorium in use until the 1960s), or those with a long history of analgesic abuse. The majority are urothelial cell carcinomas. Gross or microscopic hematuria is present in most patients, and flank pain secondary to bleeding and obstruction occurs less commonly. Like primary bladder tumors, urinary cytology is often positive. The most common signs identified at the time of intravenous urography or CT include an intraluminal filling defect, unilateral nonvisualization of the collecting system, and hydronephrosis. Ureteral and renal pelvic tumors must be differentiated from calculi, blood clots, papillary necrosis, or inflammatory and infectious lesions. On occasion, upper urinary tract lesions are accessible for biopsy, fulguration, or resection using a ureteroscope. Treatment is based on the site, size, grade, depth of penetration, and number of tumors present. Most are excised with laparoscopic or open nephroureterectomy (renal pelvic and upper ureteral lesions) or segmental excision of the ureter (distal ureteral lesions). Endoscopic resection may be indicated in patients with limited renal function or focal, low-grade, cancers.

RENAL CELL CARCINOMA



ESSENTIALS OF DIAGNOSIS

- Gross or microscopic hematuria.
- Flank pain or mass in some patients.
- Systemic symptoms such as fever, weight loss may be prominent.
- Solid renal mass on imaging.

► General Considerations

Renal cell carcinoma accounts for 2.6% of all adult cancers. In the United States, approximately 60,000 cases of renal cell carcinoma are diagnosed and 12,500 deaths result

annually. Renal cell carcinoma has a peak incidence in the sixth decade of life and a male-to-female ratio of 2:1. It may be associated with a number of paraneoplastic syndromes (see below and Table 39–2).

The cause is unknown. Cigarette smoking is the only significant environmental risk factor that has been identified. Familial settings for renal cell carcinoma have been identified (von Hippel–Lindau syndrome, hereditary papillary renal cell carcinoma, hereditary leiomyoma-renal cell carcinoma, Birt-Hogg-Dube syndrome) as well as an association with dialysis-related acquired cystic disease and specific genetic aberrations (eg, Xp11.2 translocation), but sporadic tumors are far more common.

Renal cell carcinoma originates from the proximal tubule cells. Various histologic cell types are recognized (clear cell, papillary, chromophobe, collecting duct and sarcomatoid).

► Clinical Findings

A. Symptoms and Signs

Historically, 60% of patients presented with gross or microscopic hematuria. Flank pain or an abdominal mass was detected in approximately 30% of cases. The triad of flank pain, hematuria, and mass was found in only 10–15% of patients and is often a sign of advanced disease. Fever may be present as a paraneoplastic symptom (see Table 39–2). Symptoms of metastatic disease (cough, bone pain) occur in 20–30% of patients at presentation. Because of the widespread use of ultrasound and CT scanning, renal tumors are frequently detected incidentally in individuals with no urologic symptoms. There has been profound stage migration toward lower stages of disease over the past 10 years, likely due to the increased use of abdominal imaging. However, population mortality rates remain stable.

B. Laboratory Findings

Hematuria is present in 60% of patients. Erythrocytosis from increased erythropoietin production occurs in 5%, though anemia is more common; hypercalcemia may be present in up to 10% of patients. **Stauffer syndrome** is a reversible syndrome of hepatic dysfunction (with elevated liver function tests) in the absence of metastatic disease.

C. Imaging

Solid renal masses are often first identified by abdominal ultrasonography or CT. CT and MRI scanning are the most valuable imaging tests for renal cell carcinoma. It confirms the character of the mass and further stages the lesion with respect to regional lymph nodes, renal vein, or hepatic involvement. CT and MRI also provide valuable information regarding the contralateral kidney (function, bilaterality of neoplasm). Chest radiographs exclude pulmonary metastases, and bone scans should be performed for large tumors and in patients with bone pain or elevated alkaline phosphatase levels. MRI and duplex Doppler ultrasonography are excellent methods of assessing for the presence and extent of tumor thrombus within the renal vein or vena cava.

► Differential Diagnosis

Solid lesions of the kidney are renal cell carcinoma until proved otherwise. Other solid masses include angiomyolipomas (fat density usually visible by CT), urothelial cell cancers of the renal pelvis (more centrally located, involvement of the collecting system, positive urinary cytologic tests), adrenal tumors (superoanterior to the kidney) and oncocytomas (indistinguishable from renal cell carcinoma preoperatively), and renal abscesses.

► Treatment

Surgical resection is the primary treatment for localized renal cell carcinoma. Patients with a single kidney, bilateral lesions, or significant medical renal disease should be considered for partial nephrectomy. Patients with a normal contralateral kidney and good renal function but a small cancer are also candidates for partial nephrectomy, while radical nephrectomy is indicated in cases of larger tumors (> 7 cm) and those where partial nephrectomy is not technically feasible. The use of radiofrequency or cryosurgical ablation is being studied and likely yield equivalent short-term oncologic outcomes with reduced morbidity.

No effective chemotherapy is available for metastatic renal cell carcinoma. Vinblastine is the single most efficacious agent, with short-term partial response rates of 15%. Bevacizumab can prolong time to progression in those with metastatic disease (see Table 39–4). Biologic response modifiers have received much attention, including interferon- α and interleukin-2. Partial response rates of 15–20% and 15–35%, respectively, have been reported. Responders tend to have lower tumor burdens, metastatic disease confined to the lung, and a high performance status. Patients with metastatic kidney cancer and good performance status who have resectable primary tumors should undergo cytoreductive nephrectomy. Two randomized trials have shown a survival benefit of surgery followed by the use of systemic therapy—specifically, biologic response modifiers—compared with the use of systemic therapy alone.

Several targeted drugs, specifically VEGF, Raf-kinase, and mTOR inhibitors, are effective (40% response rates) in patients with advanced kidney cancer. The drugs are oral agents, well tolerated, and particularly active for clear cell carcinoma. The appropriate timing and combination of these agents, with and without surgery and cytokine therapy, remains to be determined.

► Prognosis

After radical or partial nephrectomy, tumors confined to the renal capsule (T1–T2) demonstrate 5-year disease-free survivals of 90–100%. Tumors extending beyond the renal capsule (T3 or T4) and node-positive tumors have 50–60% and 0–15% 5-year disease-free survival, respectively. One subgroup of patients with nonlocalized disease has reasonable long-term survival, namely, those with solitary resectable metastases. In this setting, radical nephrectomy with resection of the metastasis results in 5-year disease-free survival rates of 15–30%.

▶ When to Refer

- Patients with solid renal masses or complex cysts require further evaluation and should be referred to an urologist.
- Surgical excision of renal cell carcinoma remains the gold standard.
- Patients with metastatic disease should be referred to an oncologist.

Antonelli A et al. Elective partial nephrectomy is equivalent to radical nephrectomy in patients with clinical T1 renal cell carcinoma: results of a retrospective, comparative, multi-institutional study. *BJU Int.* 2012 Apr;109(7):1013–8. [PMID: 21883829]

Escudier B et al. Sunitinib in advanced clear-cell renal-cell carcinoma. *N Engl J Med.* 2007 Jan 11;356(2):125–34. [PMID: 17215530]

Flanigan RC et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. *N Engl J Med.* 2001 Dec 6;345(23):1655–9. [PMID: 11759643]

Heng DY et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. *J Clin Oncol.* 2009 Dec 1;27(34): 5794–9. [PMID: 19826129]

Hudes G et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. *N Engl J Med.* 2007 May 31;356(22):2271–81. [PMID: 17538086]

Motzer RJ et al. Sunitinib in patients with metastatic renal cell carcinoma. *JAMA.* 2006 Jun 7;295(21):2516–24. [PMID: 15479931]

Rini BI et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomized phase 3 trial. *Lancet.* 2011 Dec 3;378(9807):1931–9. [PMID: 22056247]

OTHER PRIMARY TUMORS OF THE KIDNEY

Oncocytomas account for 3–5% of renal tumors, are usually benign, and are indistinguishable from renal cell carcinoma on preoperative imaging. These tumors are seen in other organs, including the adrenals, salivary glands, and thyroid and parathyroid glands.

Angiomyolipomas are rare benign tumors composed of fat, smooth muscle, and blood vessels. They are most commonly seen in patients with tuberous sclerosis (often multiple and bilateral) or in young to middle-aged women. CT scanning may identify the fat component, which is diagnostic for angiomyolipoma. Asymptomatic lesions < 5 cm in diameter usually do not require intervention; large lesions can spontaneously bleed. Acute bleeding can be treated by angiographic embolization or, in rare cases, nephrectomy. Lesions over 5 cm are often prophylactically treated with angioembolization to reduce the risk of bleeding.

SECONDARY TUMORS OF THE KIDNEY

The kidney is not an infrequent site for metastatic disease. Of the solid tumors, lung cancer is the most common (20%), followed by breast (10%), stomach (10%), and the contralateral kidney (10%). Lymphoma, both Hodgkin and non-Hodgkin, may also involve the kidney, although

it tends to appear as a diffusely infiltrative process resulting in renal enlargement rather than a discrete mass.

PRIMARY TUMORS OF THE TESTIS



ESSENTIALS OF DIAGNOSIS

- ▶ Most common neoplasm in men aged 20–35 years.
- ▶ Patient typically discovers a painless nodule.
- ▶ Orchiectomy necessary for diagnosis.

▶ General Considerations

Malignant tumors of the testis are rare, with approximately five to six cases per 100,000 males reported in the United States each year. Ninety to 95 percent of all primary testicular tumors are germ cell tumors and can be divided into two major categories: **nonseminomas**, including embryonal cell carcinoma (20%), teratoma (5%), choriocarcinoma (< 1%), and mixed cell types (40%); and **seminomas** (35%). The remainder of primary testicular tumors are nongerminal neoplasms (Leydig cell, Sertoli cell, gonadoblastoma). The lifetime probability of developing testicular cancer is 0.3% for an American male. For the purposes of this review, only germ cell tumors will be considered.

Approximately 5% of testicular tumors develop in a patient with a history of cryptorchidism, with seminoma being the most common. However, 5–10% of these tumors occur in the contralateral, normally descended testis. The relative risk of development of malignancy is highest for the intra-abdominal testis (1:20) and lower for the inguinal testis (1:80). Placement of the cryptorchid testis into the scrotum (orchidopexy) does not alter the malignant potential of the cryptorchid testis but does facilitate routine examination and tumor detection.

Testicular cancer is slightly more common on the right than the left, paralleling the increased incidence of cryptorchidism on the right side. One to 2 percent of primary testicular tumors are bilateral and up to 50% of these men have a history of unilateral or bilateral cryptorchidism. Primary bilateral testicular tumors may occur synchronously or asynchronously but tend to be of the same histology. Seminoma is the most common histologic finding in bilateral *primary* testicular tumors, while malignant lymphoma is the most common bilateral testicular tumor overall.

In animal models, exogenous estrogen administration during pregnancy has been associated with an increased development of testicular tumors with relative risk ranging from 2.8 to 5.3. Other acquired factors such as trauma and infection-related testicular atrophy have been associated with testicular tumors; however, a causal relationship has not been established.

▶ Clinical Findings

A. Symptoms and Signs

The most common symptom of testicular cancer is painless enlargement of the testis. Sensations of heaviness are

not unusual. Patients are usually the first to recognize an abnormality, yet the typical delay in seeking medical attention ranges from 3 to 6 months. Acute testicular pain resulting from intratesticular hemorrhage occurs in approximately 10% of cases. Ten percent of patients are asymptomatic at presentation, and 10% manifest symptoms relating to metastatic disease such as back pain (retroperitoneal metastases), cough (pulmonary metastases), or lower extremity edema (vena cava obstruction).

A discrete mass or diffuse testicular enlargement is noted in most cases. Secondary hydroceles may be present in 5–10% of cases. In advanced disease, supraclavicular adenopathy may be present, and abdominal examination may reveal a mass. Gynecomastia is seen in 5% of germ cell tumors.

B. Laboratory Findings

Several serum markers are important in the diagnosis and monitoring of testicular carcinoma, including human chorionic gonadotropin (hCG), α -fetoprotein, and lactate dehydrogenase. α -Fetoprotein is never elevated with pure seminomas, and while hCG is occasionally elevated in seminomas, levels tend to be lower than those seen with nonseminomas. Lactate dehydrogenase may be elevated with either type of tumor. Liver function tests may be elevated in the presence of hepatic metastases, and anemia may be present in advanced disease.

C. Imaging

Scrotal ultrasound can readily determine whether a mass is intratesticular or extratesticular. Once the diagnosis of testicular cancer has been established by inguinal orchiectomy, clinical staging of the disease is accomplished by chest, abdominal, and pelvic CT scanning.

► Staging

In a commonly used staging system for nonseminoma germ cell tumors, a stage A lesion is confined to the testis; stage B demonstrates regional lymph node involvement in the retroperitoneum; and stage C indicates distant metastasis. For seminoma, the M.D. Anderson system is commonly used. In this system, a stage I lesion is confined to the testis, a stage II lesion has spread to the retroperitoneal lymph nodes, and a stage III lesion has supradiaphragmatic nodal or visceral involvement.

► Differential Diagnosis

An incorrect diagnosis is made at the initial examination in up to 25% of patients with testicular tumors. Scrotal ultrasonography should be performed if any uncertainty exists with respect to the diagnosis. Although most intratesticular masses are malignant, a benign lesion—epidermoid cyst—may rarely be seen. Epidermoid cysts are usually very small benign nodules located just underneath the tunica albuginea; occasionally, however, they can be large.

► Treatment

Inguinal exploration with early vascular control of the spermatic cord structures is the initial intervention. If cancer

cannot be excluded by examination of the testis, radical orchiectomy is warranted. Scrotal approaches and open testicular biopsies should be avoided. Further therapy depends on the histology of the tumor as well as the clinical stage.

Up to 75% of clinical stage I **nonseminomas** are cured by orchiectomy alone. Selected patients who meet specific criteria may be offered surveillance after orchiectomy. These criteria are as follows: (1) tumor is confined within the tunica albuginea; (2) tumor does not demonstrate vascular invasion; (3) tumor markers normalize after orchiectomy; (4) radiographic imaging of the chest and abdomen shows no evidence of disease; and (5) the patient is reliable. Patients most likely to experience relapse on a surveillance regimen include those with predominantly embryonal cancer and those with vascular or lymphatic invasion identified in the orchiectomy specimen.

Stage I and IIa/b **seminomas** (retroperitoneal disease < 2 cm/2–5 cm in diameter) are treated by radical orchiectomy and retroperitoneal irradiation. Patients with clinical stage I disease may be candidates for surveillance or single-agent carboplatin. Seminomas of stage IIc (> 5 cm retroperitoneal involvement) and stage III receive primary chemotherapy (etoposide and cisplatin or cisplatin, etoposide, and bleomycin) (Table 39–4). Surgical resection of residual retroperitoneal masses is warranted if the mass is > 3 cm in diameter, under which circumstances 40% will harbor residual carcinoma.

Surveillance needs to be considered an active process both by the clinician and by the patient. Patients are followed monthly for the first 2 years and bimonthly in the third year. Tumor markers are obtained at each visit, and chest radiographs and CT scans are obtained every 3 months. Follow-up continues beyond the initial 3 years; however, 80% of relapses will occur within the first 2 years. With rare exceptions, patients who relapse can be cured by chemotherapy or surgery. Alternatives to surveillance for clinical stage I nonseminoma include adjuvant chemotherapy (bleomycin, etoposide, cisplatin) (see Table 39–4) or retroperitoneal lymph nodes dissection.

Patients with bulky retroperitoneal disease (> 5 cm nodes) or metastatic nonseminomas are treated with primary cisplatin-based combination chemotherapy following orchiectomy (etoposide and cisplatin or cisplatin, etoposide, and bleomycin). If tumor markers normalize and a residual mass > 1 cm persists on imaging studies, the mass is resected because 15–20% of the time it will harbor viable cancer and 40% of the time it will harbor teratoma. Even if patients have a complete response to chemotherapy, some clinicians advocate retroperitoneal lymphadenectomy since 10% of patients may harbor residual carcinoma and 10% may have teratoma in the retroperitoneum. If tumor markers fail to normalize following primary chemotherapy, salvage chemotherapy is required (cisplatin, etoposide, ifosfamide).

► Prognosis

The 5-year disease-free survival rate for patients with stage A **nonseminomas** (includes all treatments) ranges from 96% to 100%. For low-volume stage B disease, 90% 5-year

disease-free survival is expected. The 5-year disease-free survival rates for stage I and IIa **seminomas** (retroperitoneal disease < 10 cm in diameter) treated by radical orchiectomy and retroperitoneal irradiation are 98% and 92–94%, respectively. Ninety-five percent of patients with stage III disease attain a complete response following orchiectomy and chemotherapy. Patients with bulky retroperitoneal or disseminated disease treated with primary chemotherapy followed by surgery have a 5-year disease-free survival rate of 55–80%.

▶ When to Refer

Patients with solid masses of the testis should be referred to a urologist.

Albers P et al. Randomized phase III trial comparing retroperitoneal lymph node dissection with one course of bleomycin and etoposide plus cisplatin chemotherapy in the adjuvant treatment of clinical stage I nonseminomatous testicular germ cell tumors: AUO trial AH 01/94 by the German Testicular Cancer Study Group. *J Clin Oncol.* 2008 Jun 20;26(18):2966–72. [PMID: 18458040]

Albers P et al; European Association of Urology. EAU guidelines on testicular cancer: 2011 update. *Eur Urol.* 2011 Aug;60(2):304–19. [PMID: 21632173]

Aparicio J et al. Risk-adapted treatment in clinical stage I testicular seminoma: the third Spanish Germ Cell Cancer Study Group. *J Clin Oncol.* 2011 Dec 10;29(35):4677–81. [PMID: 22042940]

Einhorn LH et al. High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors. *N Engl J Med.* 2007 Jul 26;357(4):340–8. [PMID: 17652649]

Oliver RT et al. Randomized trial of carboplatin versus radiotherapy for stage I seminoma: mature results on relapse and contralateral testis cancer rates in MRC TE19/EORTC 30982 study (ISRCTN27163214). *J Clin Oncol.* 2011 Mar 10;29(8):957–62. [PMID: 21282539]

Pettersson A et al. Age at surgery for undescended testis and risk of testicular cancer. *N Engl J Med.* 2007 May 3;356(18):1835–41. [PMID: 17476009]

Tandstad T et al. Risk-adapted treatment in clinical stage I nonseminomatous germ cell testicular cancer: the SWENOTECA management program. *J Clin Oncol.* 2009 May 1;27(13):2122–8. [PMID: 19307506]

Torpy JM et al. JAMA patient page. Testicular cancer. *JAMA.* 2008 Feb 13;299(6):718. [PMID: 18270362]

SECONDARY TUMORS OF THE TESTIS

Secondary tumors of the testis are rare. In men over the age of 50 years, lymphoma is the most common testis tumor, and overall it is the most common secondary neoplasm of the testis, accounting for 5% of all testicular tumors. It may be seen in three clinical settings: (1) late manifestation of widespread lymphoma, (2) the initial presentation of clinically occult disease, and (3) primary extranodal disease. Radical orchiectomy is indicated to make the diagnosis. Prognosis is related to the stage of disease.

Metastasis to the testis is rare. The most common primary site of origin is the prostate, followed by the lung, gastrointestinal tract, melanoma, and kidney.

CANCER COMPLICATIONS & EMERGENCIES

SPINAL CORD COMPRESSION

ESSENTIALS OF DIAGNOSIS

- ▶ Complication of metastatic solid tumor, lymphoma, or multiple myeloma.
- ▶ Back pain is most common presenting symptom.
- ▶ Prompt diagnosis is essential because once a severe neurologic deficit develops, it is often irreversible.
- ▶ Emergent treatment may prevent or potentially reverse paresis and urinary and bowel incontinence.

▶ General Considerations

Cancers that cause spinal cord compression most commonly metastasize to the vertebral bodies, resulting in physical damage to the spinal cord from edema, hemorrhage, and pressure-induced ischemia to the vasculature of the spinal cord. Persistent compression can result in irreversible changes to the myelin sheaths resulting in permanent neurologic impairment.

Prompt diagnosis and therapeutic intervention are essential, since the probability of reversing neurologic symptoms largely depends on the duration of symptoms. Patients who are treated promptly after symptoms appear may have partial or complete return of function and, depending on tumor sensitivity to specific treatment, may respond favorably to subsequent anticancer therapy.

▶ Clinical Findings

A. Symptoms and Signs

Back pain at the level of the tumor mass occurs in over 80% of cases and may be aggravated by lying down, weight bearing, sneezing, or coughing; it usually precedes the development of neurologic symptoms or signs. Since involvement is usually epidural, a mixture of nerve root and spinal cord symptoms often develops. Progressive weakness and sensory changes commonly occur. Bowel and bladder symptoms progressing to incontinence are late findings.

The initial findings of impending cord compression may be quite subtle, and there should be a high index of suspicion when back pain or weakness of the lower extremities develops in cancer patients.

B. Imaging

MRI is usually the initial imaging procedure of choice in a cancer patient with new-onset back pain. When there are neurologic findings suggesting spinal cord compression, an emergent MRI should be obtained; the MRI should include a survey of the entire spine in order to define all areas of tumor involvement for treatment planning purposes.

Bone radiographs, if done, may show evidence of vertebral body or pedicle destruction by the cancer. However, bone radiographs are neither sensitive nor specific and therefore are not helpful in diagnosis or treatment planning. If the back pain symptoms are nonspecific, bone scan imaging may be useful as a screening procedure.

► Treatment

Patients found to have epidural impingement of the spinal cord should be given corticosteroids immediately. The initial dexamethasone dose is 10–100 mg intravenously followed by 4–6 mg every 6 hours intravenously or orally. Patients without a known diagnosis of cancer should have emergent surgery to relieve the impingement and obtain a pathologic specimen. Patients with a single area of compression due to solid tumors are best treated with surgical decompression followed by radiation therapy. A randomized trial comparing surgery followed by radiation therapy with radiation therapy alone showed better outcomes (ie, improved ability to ambulate and improved bladder and bowel functions) in persons who had surgery followed by radiation therapy. If multiple vertebral body levels are involved with cancer, radiation therapy is the preferred treatment option. Corticosteroids are generally tapered toward the end of radiation therapy.

George R et al. Interventions for the treatment of metastatic extracranial spinal cord compression in adults. *Cochrane Database Syst Rev.* 2008 Oct 8;(4):CD006716. [PMID: 18843728]

Walji N et al. Common acute oncological emergencies: diagnosis, investigation and management. *Postgrad Med J.* 2008 Aug;84(994):418–27. [PMID: 18832403]

White BD et al. Diagnosis and management of patients at risk of or with metastatic spinal cord compression: summary of NICE guidance. *BMJ.* 2008 Nov 27;337:a2538. [PMID: 19039017]

MALIGNANT EFFUSIONS



ESSENTIALS OF DIAGNOSIS

- Occur in pleural, pericardial, and peritoneal spaces.
- Caused by direct neoplastic involvement of serous surface or obstruction of lymphatic drainage.
- Half of undiagnosed effusions in patients not known to have cancer are malignant.

► General Considerations

The development of an effusion in the pleural, pericardial, or peritoneal space may be the initial finding in a patient with cancer, or an effusion may appear during the course of disease progression. Direct involvement of the serous surface with tumor is the most frequent initiating cause of the accumulation of fluid. The most common malignancies

causing pleural and pericardial effusions are lung and breast cancers; the most common malignancies associated with malignant ascites are ovarian, colorectal, stomach, and pancreatic cancers.

► Clinical Findings

A. Symptoms and Signs

Patients with pleural and pericardial effusions complain of shortness of breath and orthopnea. Patients with ascites complain of abdominal distention and discomfort. Cardiac tamponade causing pressure equalization in the chambers impairing both filling and cardiac output can be a life-threatening event. Signs of tamponade include tachycardia, pulsus paradoxus, and hypotension. Signs of pleural effusions include decreased breath sounds, egophony, and percussion dullness.

B. Laboratory Findings

Malignancy is confirmed as the cause of an effusion when analysis of the fluid specimen shows malignant cells in either the cytology or cell block specimen.

C. Imaging

The presence of effusions can be confirmed with radiographic studies or ultrasonography.

► Differential Diagnosis

The differential diagnosis of a malignant exudative pleural or pericardial effusion includes nonmalignant processes, such as infection, pulmonary embolism, congestive heart failure, and trauma. Malignant effusions are rarely transudative.

The differential diagnosis of malignant ascites includes similar benign processes, such as congestive heart failure and infections; cirrhosis and pancreatic disease also cause ascites.

Bloody effusions are usually due to cancer, but a bloody pleural effusion can also be due to pulmonary embolism, trauma and, occasionally, infection. Chylous pleural or ascitic fluid is generally associated with obstruction of lymphatic drainage as might occur in lymphomas.

► Treatment

In some cases, treatment of the underlying cancer with chemotherapy can cause regression of the effusions; however, not uncommonly, the presence of an effusion is an end-stage manifestation of the disease. In this situation, decisions regarding management are in large part dictated by the patient's symptoms and goals of care.

A. Pleural Effusion

A pleural effusion that is symptomatic may be managed initially with a **large volume thoracentesis**. With some patients, the effusion slowly reaccumulates, which allows

for periodic thoracentesis when the patient becomes symptomatic. However, in many patients, the effusion reaccumulates quickly, causing rapid return of symptoms of shortness of breath. For those patients, several options exist for management. **Chest tube drainage followed by pleurodesis** is the preferred option for patients with a reasonable life expectancy. The procedure involves placement of a chest tube that is connected to closed water seal drainage. After lung expansion is confirmed on a chest radiograph, a sclerosing agent (such as talc slurry or doxycycline) is injected into the catheter. Patients should be premedicated with analgesics and placed in a variety of positions in order to distribute the drug through the pleural spaces. Previously, injection of the sclerosing agent was done only after drainage had decreased to < 100 mL/d; but it is now clear that effective sclerosis can be achieved after 24 hours of drainage regardless of the amount of the residual fluid. Pleurodesis will not be successful if the lung cannot be reexpanded; these patients may be treated with the placement of a shunt or an indwelling catheter. Placement of an indwelling catheter that can be drained by a family member or a visiting nurse may also be preferable for patients with short life expectancies or for those who do not respond to pleurodesis.

B. Pericardial Effusion

Fluid may be removed by a needle aspiration or by placement of a catheter for more thorough drainage. As with pleural effusions, most pericardial effusions will reaccumulate. Management options for recurrent, symptomatic effusions include catheter drainage followed by sclerosis with such agents as doxycycline or bleomycin or by pericardiectomy.

C. Malignant Ascites

Patients with malignant ascites not responsive to chemotherapy are generally treated with repeated large volume paracenteses. As the frequency of drainage to maintain comfort can compromise the patient's quality of life, other alternatives include placement of a catheter or port so that the patient, family member, or visiting nurse can drain fluid as needed at home. Another option is placement of a peritoneovenous shunt; this can be considered for a select group of patients with life expectancy > 3 months and fluid that is nonviscous, nonbloody, and nonoculated.

Becker G et al. Malignant ascites: systematic review and guideline for treatment. *Eur J Cancer*. 2006 Mar;42(5):589–97. [PMID: 16434188]

Maisch B et al; Task Force on the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology. Guidelines on the diagnosis and management of pericardial diseases executive summary. *Eur Heart J*. 2004 Apr;25(7):587–610. [PMID: 15120056]

Roberts ME et al. Management of a malignant pleural effusion: British Thoracic Society Pleural Disease Guideline, 2010. *Thorax*. 2010 Aug;65(Suppl 2):ii32–40. [PMID: 20696691]

HYPERCALCEMIA



ESSENTIALS OF DIAGNOSIS

- ▶ Usually symptomatic and severe (≥ 15 mg/dL [> 3.75 mmol/L]).
- ▶ Most common paraneoplastic endocrine syndrome; accounts for most inpatients with hypercalcemia.
- ▶ The neoplasm is clinically apparent in nearly all cases when hypercalcemia is detected.

▶ General Considerations

Hypercalcemia affects 20–30% of cancer patients at some point during their illness. The most common cancers causing hypercalcemia are myeloma, breast carcinoma, and non–small cell lung cancer. The presence of bone metastases is not an essential feature of the syndrome, since hypercalcemia can be caused by systemic effects of tumor-released proteins (see The Paraneoplastic Syndromes above).

▶ Clinical Findings

A. Symptoms and Signs

Symptoms and signs of hypercalcemia can be subtle; more severe symptoms occur with higher levels of hypercalcemia and with a rapid rate at which the calcium level rises. Early symptoms typically include anorexia, nausea, fatigue, constipation, and polyuria; later findings may include muscular weakness and hyporeflexia, confusion, psychosis, tremor, and lethargy.

B. Laboratory Findings

Symptoms and signs are caused by free calcium; as calcium is bound by protein in the serum, the measured serum calcium will underestimate the free or ionized calcium in patients with low albumin levels. In the setting of hypoalbuminemia, the corrected serum calcium should be calculated by one of several available formulas (eg, corrected calcium = measured calcium – measured albumin + 4). Alternatively, the free calcium can be measured. When the corrected serum calcium rises above 12 mg/dL (3 mmol/L), sudden death due to cardiac arrhythmia or asystole may occur. The presence of hypercalcemia does not invariably indicate a dismal prognosis, especially in patients with breast cancer, myeloma, or lymphoma.

In the absence of signs or symptoms of hypercalcemia, a laboratory finding of elevated serum calcium should be retested immediately to exclude the possibility of error.

C. ECG

Electrocardiography often shows a shortening of the QT interval.

▶ Treatment

Emergency management should begin with the initiation of intravenous fluids with 0.9% saline at 100–200 mL/h to

ensure rehydration with brisk urinary output of the often volume-depleted patient. If kidney function is normal or only marginally impaired, a bisphosphonate should be given. Choices include pamidronate, 60–90 mg intravenously over 2–4 hours, or zoledronic acid, 4 mg intravenously over several minutes. Zoledronic acid is more potent than pamidronate and has the advantage of a shorter administration time as well as a longer duration of effect but is more associated with the uncommon but serious side effect of osteonecrosis of the jaw. Once hypercalcemia is controlled, treatment directed at the cancer should be initiated if possible. Commonly, though, hypercalcemia occurs in patients with cancers that are unresponsive to treatment. In the event that the hypercalcemia becomes refractory to repeated doses of bisphosphonates, other agents that can help control hypercalcemia (at least temporarily) include gallium nitrate, calcitonin, and mithramycin; corticosteroids can be useful in patients with myeloma and lymphoma. Salmon calcitonin, 4–8 international units/kg given subcutaneously or intramuscularly every 12 hours, can be useful in patients with kidney disease; its onset of action is within hours but its hypocalcemic effect will wane in 2–3 days.

Drake MT et al. Bisphosphonates: mechanism of action and role in clinical practice. *Mayo Clin Proc.* 2008 Sep;83(9):1032–45. [PMID: 18775204]

Mundy GR et al. PTH-related peptide (PTHrP) in hypercalcemia. *J Am Soc Nephrol.* 2008 Apr;19(4):672–5. [PMID: 18256357]

Pelosof LC et al. Paraneoplastic syndromes: an approach to diagnosis and treatment. *Mayo Clin Proc.* 2010 Sep;85(9):838–54. [PMID: 20810794]

Walji N et al. Common acute oncological emergencies: diagnosis, investigation and management. *Postgrad Med J.* 2008 Aug;84(994):418–27. [PMID: 18832403]

HYPERURICEMIA & TUMOR LYSIS SYNDROME



ESSENTIALS OF DIAGNOSIS

- ▶ Complication of treatment-associated tumor lysis of hematologic and rapidly proliferating malignancies.
- ▶ May be worsened by thiazide diuretics.
- ▶ Rapid increase in serum uric acid can cause acute urate nephropathy from uric acid crystallization.
- ▶ Reducing pre-chemotherapy serum uric acid is fundamental to preventing urate nephropathy.

▶ General Considerations

Tumor lysis syndrome (TLS) is seen most commonly following treatment of hematologic malignancies, such as acute lymphoblastic leukemia and Burkitt lymphoma. However, TLS can develop from any tumor highly sensitive to chemotherapy. TLS is caused by the massive release

of cellular material including nucleic acids, proteins, phosphorus, and potassium. If both the metabolism and excretion of these breakdown products are impaired, hyperuricemia, hyperphosphatemia, and hyperkalemia will develop abruptly. Acute kidney injury may then develop from the crystallization and deposition of uric acid and calcium phosphate within the renal tubules further exacerbating the hyperphosphatemia and hyperkalemia.

▶ Clinical Findings

Symptoms of hyperphosphatemia include nausea and vomiting as well as seizures. Also, with high levels of phosphorus, co-precipitation with calcium can cause renal tubule blockage further exacerbating the kidney injury. Hyperkalemia, due to release of intracellular potassium and impaired kidney excretion, can cause arrhythmias and sudden death.

▶ Treatment

Prevention is the most important factor in the management of TLS. Published guidelines for TLS management include aggressive hydration prior to initiation of chemotherapy as well as during and after completion of the chemotherapy. Administration of fluid helps keep urine flowing and facilitates excretion of uric acid and phosphorus. For the patients with moderate risk of developing TLS, for instance, those with intermediate grade lymphomas and acute leukemias, allopurinol (which blocks the enzyme xanthine oxidase and therefore the formation of uric acid from purine breakdown) should be given before starting chemotherapy at an oral dose of 100 mg/m² every 8 hours (maximum 800 mg/d) with dose reductions for impaired kidney function. For patients at high risk for developing TLS, for instance, patients with high-grade lymphomas or patients with acute leukemias and markedly elevated white blood cell counts (with acute myeloid leukemia, white blood cell count > 50,000/mcL [$> 50,000/10^9/L$]; with acute lymphoblastic leukemia, white blood cell count > 100,000/mcL [$> 100,000/10^9/L$]) or in whom hyperuricemia develops despite treatment with allopurinol, rasburicase 0.1–0.2 mg/kg/d is given intravenously for 1–7 days. Rasburicase is a recombinant urate oxidase that converts uric acid into the more soluble form resulting in rapid decline in uric acid levels. Rasburicase cannot be given to patients with known glucose 6-phosphate dehydrogenase (G6PD) deficiency nor can it be given to pregnant or lactating women. One of the mainstays of TLS management, systemic bicarbonate infusions to alkalinize the urine, is no longer routinely recommended. Laboratory values should be monitored following initiation of chemotherapy; elevated potassium or phosphorus levels need to be promptly managed.

▶ When to Refer

Should urinary output drop, creatinine level rise, or hyperphosphatemia persist, a nephrologist should be immediately consulted to evaluate the need for dialysis.

Cairo MS et al. Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus. *Br J Haematol*. 2010 May;149(4):578–86. [PMID: 20331465]

Howard SC et al. The tumor lysis syndrome. *N Engl J Med*. 2011 May 12;364(19):1844–54. [PMID: 21561350]

INFECTIONS

Chapter 30 provides a more detailed discussion of infections in the immunocompromised patient.



ESSENTIALS OF DIAGNOSIS

- ▶ In patients with neutropenia, infection is a medical emergency.
- ▶ The presence of fever, although sometimes attributable to other causes, must be assumed to be due to an infection.

▶ General Considerations

Many patients with disseminated neoplasms have increased susceptibility to infection. In some patients, this results from impaired defense mechanisms (eg, acute leukemia, Hodgkin disease, multiple myeloma, chronic lymphocytic leukemia); in others, it results from the myelosuppressive and immunosuppressive effects of cancer chemotherapy or a combination of these factors. Complicating impaired defense mechanisms are the frequent presence of indwelling catheters, impaired mucosal surfaces, and colonization with more virulent hospital-acquired pathogens.

The source of a neutropenic febrile episode is determined in about 30% of cases through blood, urine, or sputum cultures. The bacterial organisms accounting for the majority of infections in cancer patients include gram-negative bacteria (*Escherichia coli*, *Klebsiella*, *Pseudomonas*, *Enterobacter*) and gram-positive bacteria (coagulase-negative *Staphylococcus*, *Staphylococcus aureus*, *Streptococcus pneumoniae*, *Corynebacterium*, and streptococci). There has been a trend over the last few decades of an increasing percentage of gram-positive organisms. The risk of bacterial infections rises when the neutrophil count is below 1000/mcL ($1.0 \times 10^9/L$); the risk dramatically increases when the count falls below 100/mcL ($0.1 \times 10^9/L$).

▶ Clinical Findings

A thorough physical examination should be performed. Routine DREs are generally avoided unless symptoms suggest a rectal abscess or prostatitis. If a rectal examination is necessary, antibiotics should be administered first. Appropriate cultures (eg, blood, sputum, urine and, if indicated, cerebrospinal fluid) should always be obtained before starting therapy. Two sets of blood cultures should be drawn; if the patient has an indwelling catheter, one of the cultures should be drawn from the line. A chest radiograph should also be obtained.

▶ Treatment

Empiric antibiotic therapy needs to be initiated immediately in the febrile, neutropenic patient. The choice of antibiotics depends on a number of different factors including the patient's clinical status and any localizing source of infection. If the patient is clinically well, monotherapy with an intravenous β -lactam with anti-*Pseudomonas* activity (cefepime, ceftazidime, imipenem/cilastatin, piperacillin/tazobactam) should be started (see Infections in the Immunocompromised Patient, Chapter 30). If the patient is clinically ill with hypotension or hypoxia, an aminoglycoside or fluoroquinolone should be added for “double” gram-negative bacteria coverage. If there is a strong suspicion of a gram-positive organism, such as from *S aureus* catheter infection, vancomycin can be given empirically. In some instances, patients may be treated with oral antibiotics and potentially in the outpatient setting. The Infectious Disease Society of America (IDSA) has published recommendations for antibiotic use in these low-risk patients. These patients must have an expected neutropenic timeframe of 7 days or less and not have comorbidities or signs of hemodynamic instability, gastrointestinal symptoms, altered mental status, pulmonary issues (an infiltrate, hypoxia, or underlying chronic obstructive pulmonary disease) and their liver and kidney function must not be impaired. If a patient is to be treated as an outpatient, he or she must also have good support at home and easy access to returning to the hospital if the clinical status worsens.

Antibiotics should be continued until the neutrophil count is rising and $> 500/mcL$ ($> 0.5 \times 10^9/L$) for at least 1 day and the patient has been afebrile for 2 days. If an organism is identified through the cultures, the antibiotics should be adjusted to the antibiotic sensitivities of the isolate; treatment should be continued for the appropriate period of time and at least until the neutrophil count recovers.

For the neutropenic patient who is persistently febrile despite broad-spectrum antibiotics, an empiric antifungal drug should be added (amphotericin B, caspofungin, itraconazole, voriconazole, or liposomal amphotericin B).

Freifeld AG et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 Update by the Infectious Diseases Society of America. *Clin Infect Dis*. 2011 Feb 15;52(4):427–31. [PMID: 21205990]

PRIMARY CANCER TREATMENT

SYSTEMIC CANCER THERAPY

Detailed guidelines from the NCCN for cancer treatment can be found at www.nccn.org.

Use of cytotoxic drugs, hormones, antihormones, and biologic agents has become a highly specialized and increasingly effective means of treating cancer, with therapy usually administered by a medical oncologist. Selection of specific drugs or protocols for various types of cancer has traditionally been based on results of prior clinical trials; however, many patients have drug-resistant

tumors. Molecular mechanisms of drug resistance continue to be the subject of intense study. Described mechanisms of drug resistance include impaired membrane transport of drugs, enhanced drug metabolism, mutated target proteins, and blockage of apoptosis due to mutations in cell cycle -proteins. Cancer cells may initially be resistant to chemotherapy or acquire resistance when exposed to drugs.

TOXICITY & DOSE MODIFICATION OF CHEMOTHERAPEUTIC AGENTS

Use of chemotherapy to treat cancer is generally guided by results from clinical trials in individual tumor types. The complexity of treating cancer has increased over the last decade as more drugs, including those with novel mechanisms of action, have been approved by the Food and Drug Administration and introduced into general practice. Drug side effects and toxicities must be anticipated and carefully monitored. The short- and long-term toxicities of individual drugs are listed in Tables 39–11 and 39–12. Decisions on dose modifications for toxicities should be guided by the intent of therapy. In the palliative setting where the aim of therapy is to improve symptoms and quality of life, lowering doses to minimize toxicity is commonly done. However, when the goal of treatment is cure, dosing frequency and intensity should be maintained whenever possible. Cancer chemotherapy should be given and monitored by a medical oncologist or hematologist.

A complete blood count consisting of a differential count with particular attention to the absolute neutrophil count and platelet count as well as tests of liver and kidney function should be obtained before the initiation of chemotherapy. In patients with normal blood counts as well as normal liver and kidney function, drugs are started at their full dose. When the intent of chemotherapy is cure, including treatment in the adjuvant setting, every attempt should be made to schedule chemotherapy on time and at full dose. A complete blood count with differential should be checked at mid cycle to determine the nadir of the absolute neutrophil and platelet counts as well as immediately before the next cycle of chemotherapy is due.

Dose reductions may be necessary for patients with impaired kidney or liver function depending on the clearance mechanism of the drug. For patients receiving chemotherapy for palliation, bone marrow toxicity can be managed with dose reductions or delaying the next treatment cycle. A schema for dose modification is shown in Table 39–13.

1. Bone Marrow Toxicity

A. Neutropenia

Granulocyte colony-stimulating factor (G-CSF), given as either daily subcutaneous injections (filgrastim, 300 mcg or 480 mcg) or as a one-time dose (pegfilgrastim, 6 mg) beginning 24–72 hours after cytotoxic chemotherapy is completed, has been shown to reduce the duration and severity of granulocytopenia following cytotoxic chemotherapy

(Table 39–12). The American Society of Clinical Oncology and NCCN guidelines recommend primary prophylaxis with a G-CSF when there is 20% risk of febrile neutropenia or when the patient's age, medical history, and disease characteristics make the patient at high risk for complications related to myelosuppression.

B. Anemia

Erythropoiesis-stimulating agents (ESAs) ameliorate the anemia and associated symptoms caused by cancer chemotherapy but these drugs have untoward effects, including an increased risk of thromboembolism, and even more concerning, potentially decreased survival due to cancer-related deaths. These findings have prompted the US Food and Drug Administration and other organizations (American Society of Hematology, American Society of Clinical Oncology, and NCCN) to issue advisories and guidelines limiting their use. The NCCN recommendation that these drugs should not be used when the intent of chemotherapy is curative is based on evidence that survival can be affected by the administration of ESAs. Studies done in patients with potentially curable head and neck, breast, and cervical cancers have shown inferior outcomes when ESAs were used. It is important to point out that the target hemoglobin used in these studies was higher than is currently recommended. Nonetheless, ESAs cannot be currently recommended when the intent of therapy is cure. The alternative to managing symptomatic anemia in these patients receiving curative chemotherapy is administration of red blood cell transfusions.

When using ESAs, treatment should not be initiated until the hemoglobin is < 10 g/dL (< 100 g/L) with the medication held when the hemoglobin is > 12 g/dL (> 120 g/L). Epoetin alfa can be given subcutaneously as a weekly dose of 30,000–40,000 units with a target hemoglobin of 11–12 g/dL (110–120 g/L) (see Table 39–12). Darbepoetin alfa is given subcutaneously every 2–3 weeks at a dose of 200–300 mcg with the same target hemoglobin. Patients need to be iron replete to have maximum therapeutic effect. Uncontrolled hypertension is a contraindication to the use of ESAs; blood pressure must be controlled prior to initiation of this therapy. The FDA mandates that prescribing clinicians receive specific education on use of ESAs, and patients receiving ESAs must be provided written material describing the risks and benefits of the drug.

C. Thrombocytopenia

Drug management of chemotherapy-induced thrombocytopenia is more limited. The only available drug, oprelvekin or recombinant interleukin-11, has modest activity in improving thrombocytopenia associated with chemotherapy; however, the side effects of fluid retention, congestive heart failure, and arrhythmias have limited its use. Thrombopoietin, the protein that stimulates megakaryopoiesis in vivo, was isolated in 1994. Despite much work attempting to produce a clinically effective thrombopoietin agent for therapeutic use, no such drug is commercially available for this indication. Two drugs that activate the thrombopoietin receptor and are approved for use in

Table 39-11. Chemotherapeutic agents: Dosage and toxicity.

Chemotherapeutic Agent	Usual Adult Dosage	Acute Toxicity	Delayed Toxicity
Alkylating Agents—Nitrogen Mustards			
Bendamustine (Treanda)	100–120 mg/m ² intravenously every 3–4 weeks	Hypersensitivity reaction, nausea, vomiting, skin reaction	Myelosuppression, pyrexia, fatigue
Cyclophosphamide (Cytoxan)	500–1000 mg/m ² intravenously every 3 weeks; 100 mg/m ² /d orally for 14 days every 4 weeks	Nausea and vomiting	Myelosuppression, hemorrhagic cystitis, alopecia, cardiotoxicity with high-dose therapy, SIADH
Estramustine (Emcyt)	14 mg/kg/d orally in three or four divided doses	Nausea, vomiting, diarrhea	Gynecomastia, thromboembolism, edema
Ifosfamide (Ifex)	1200 mg/m ² daily for 5 days intravenously every 3 weeks	Nausea and vomiting	Myelosuppression, hemorrhagic cystitis, neurotoxicity, alopecia, SIADH
Mechlorethamine (nitrogen mustard, Mustargen)	0.4 mg/kg intravenously every 3–6 weeks; or 6 mg/m ² intravenously on days 1 and 8 every 4 weeks	Severe nausea and vomiting, severe vesicant	Myelosuppression, increased risk of secondary malignancies
Melphalan (Alkeran)	0.25 mg/kg/d or 8–10 mg/m ² /d orally for 4 days every 4–6 weeks; 16 mg/m ² intravenously every 2–4 weeks; 200 mg/m ² intravenously for bone marrow transplant	Nausea, vomiting, diarrhea, hypersensitivity (IV), mucositis (IV)	Myelosuppression, increased risk of secondary malignancies
Alkylating Agents—Platinum Analogs			
Carboplatin (Paraplatin)	Area under the curve (AUC)-based dosing use Calvert equation [Dose (mg) = AUC × (GFR + 25)] AUC = 2–7 mg/mL/min every 2–4 weeks; or 200–400 mg/m ² intravenously every 4 weeks	Nausea, vomiting, hypersensitivity reaction	Myelosuppression, electrolyte disturbances, peripheral neuropathy, nephrotoxicity (less common than with cisplatin)
Cisplatin (Platinol)	50–100 mg/m ² intravenously every 3–4 weeks; 20 mg/m ² /d intravenously for 5 days every 3 weeks	Severe nausea and vomiting	Nephrotoxicity, ototoxicity, peripheral neuropathy, myelosuppression, electrolyte disturbances
Oxaliplatin (Eloxatin)	85–130 mg/m ² intravenously every 2–3 weeks	Peripheral neuropathy triggered or exacerbated by cold, nausea, vomiting, diarrhea, rare anaphylactic reactions	Peripheral neuropathy, myelosuppression
Alkylating Agents—Triazines			
Dacarbazine (DTIC-Dome)	375 mg/m ² intravenously on day 1 and 15 every 4 weeks, 250 mg/m ² intravenously for 5 days	Severe nausea and vomiting, anorexia	Myelosuppression, photosensitivity, hepatotoxicity, flu-like syndrome
Procarbazine (Matulane)	60–100 mg/m ² orally for 14 days every 4 weeks	Nausea and vomiting	Myelosuppression; disulfiram-like reaction with alcohol; caution with tyramine-containing foods, tricyclic antidepressants, and sympathomimetic agents – MAO inhibition; increased risk of secondary malignancies
Temozolomide (Temodar)	75 mg/m ² orally daily during radiation for 42 days 150–200 mg/m ² orally for 5 days every 4 weeks	Nausea, vomiting, headache, constipation	Myelosuppression
Alkylating Agents—Miscellaneous			
Busulfan (Myleran)	1–8 mg daily orally	Nausea and vomiting	Myelosuppression, mucositis, hyper-pigmentation of skin, rare pulmonary fibrosis, hepatic veno-occlusive disease with high doses (> 16 mg/d in transplant patients)

(continued)

Table 39–11. Chemotherapeutic agents: Dosage and toxicity. (continued)

Chemotherapeutic Agent	Usual Adult Dosage	Acute Toxicity	Delayed Toxicity
Chlorambucil (Leukeran)	0.1–0.2 mg/kg/d orally for 3–6 weeks; or 0.4 mg/kg pulse every 4 weeks	None	Myelosuppression, rare pulmonary toxicity, skin reaction, increased risk of secondary malignancies with prolonged use
Lomustine (CCNU)	100–130 mg/m ² orally every 6 weeks	Nausea and vomiting	Myelosuppression, pulmonary toxicity
Antimetabolites—Folate Antagonists			
Methotrexate (MTX; Trexall)	Intrathecal: 12 mg High dose: 1000–12,000 mg/m ² intravenously every 2–3 weeks	Nausea, vomiting, mucositis	Myelosuppression, nephrotoxicity, hepatotoxicity, neurotoxicity (with intrathecal administration and high-dose therapy), photosensitivity, pulmonary toxicity, caution multiple drug interactions which may enhance toxicities (avoid aspirin, penicillins, NSAIDs, omeprazole, TMP-SMZ)
Pemetrexed (Alimta)	500 mg/m ² intravenously every 3 weeks	Fatigue, nausea, vomiting, diarrhea, rash	Myelosuppression, mucositis Avoid NSAIDs which may decrease pemetrexed clearance and enhance toxicities
Pralatrexate (Folotylin)	30 mg/m ² intravenous bolus once weekly for 6 weeks in 7-week cycle	Nausea, mucositis	Myelosuppression, edema, fever, fatigue, liver function test abnormalities, renal impairment
Antimetabolites—Purine Analogs			
Cladribine (Leustatin)	0.14 mg/kg/d intravenously or subcutaneously daily for 5 days or 0.09 mg/kg/d intravenously via continuous infusion for 7 days	Mild nausea, fatigue, injection site reaction, rash	Myelosuppression, immunosuppression, fever
Clofarabine (Clolar)	52 mg/m ² intravenously daily for 5 days every 2–6 weeks (for patients < 21 years of age)	Nausea, vomiting, diarrhea, dermatitis, pruritus, headache, rigor	Myelosuppression, hepatotoxicity, nephrotoxicity, capillary leak syndrome, immunosuppression
Fludarabine (Fludara)	25 mg/m ² intravenously for 5 days every 4 weeks	Asthenia, fever, myalgias, rare hypersensitivity reaction	Myelosuppression, immunosuppression, neurotoxicity, visual disturbances
Mercaptopurine (6-MP; Purinethol)	Induction: 2.5–5 mg/kg/d orally Maintenance: 1.5–2.5 mg/kg/d orally	Diarrhea, hyperpigmentation of skin, rash	Myelosuppression, immunosuppression, hepatotoxicity, mucositis
Pentostatin (Nipent)	4 mg/m ² intravenously every other week	Nausea, vomiting, rash	Myelosuppression, immunosuppression, hepatotoxicity
Antimetabolites—Pyrimidine Analogs			
Azacitidine (Vidaza)	75 mg/m ² subcutaneously or intravenously for 7 days every 4 weeks, may increase to 100 mg/m ² after two cycles if no response	Injection site reaction, nausea, constipation, fever	Myelosuppression, hepatotoxicity, and nephrotoxicity (rare)
Capecitabine (Xeloda)	625–1250 mg/m ² orally twice a day for 14 days every 3 weeks	Nausea, vomiting, diarrhea	Hand-foot syndrome, mucositis, hyperbilirubinemia, myelosuppression
Cytarabine (Ara-C, Cytosar U)	Standard dose: 100 mg/m ² /d intravenously via continuous infusion for 7 days High dose: 1000–3000 mg/m ² intravenously every 12 hours on days 1, 3, 5	Nausea, vomiting, rash, flu-like syndrome	Myelosuppression High-dose therapy: neurotoxicity (cerebellar ataxia, lethargy, confusion), ocular toxicities (conjunctivitis and keratitis), hepatotoxicity, pancreatitis, pulmonary toxicity
Cytarabine Liposome (DepoCyt)	50 mg intrathecally every 14 or 28 days		Chemical arachnoiditis

(continued)

Table 39–11. Chemotherapeutic agents: Dosage and toxicity. (continued)

Chemotherapeutic Agent	Usual Adult Dosage	Acute Toxicity	Delayed Toxicity
Decitabine (Dacogen)	15 mg/m ² intravenously every 8 hours for 3 days, repeat every 8 weeks	Nausea, fatigue, hyperglycemia	Myelosuppression
Fluorouracil (5-FU; Adrucil)	500–600 mg/m ² intravenous bolus weekly for 6 weeks, repeat every 8 weeks; in combination with oxaliplatin: 400 mg/m ² intravenous bolus followed immediately by 600 mg/m ² intravenously over 22 hours on days 1 and 2 or 400 mg/m ² intravenous bolus followed immediately by 2400 mg/m ² intravenously over 46 hours; 1000 mg/m ² intravenously via continuous infusion for 4–5 days every 3–4 weeks	Nausea, diarrhea	Myelosuppression (intravenous bolus), hand-foot syndrome, mucositis, neurotoxicity, ocular toxicity, photosensitivity, cardiotoxicity (rare)
Gemcitabine (Gemzar)	1000–1250 mg/m ² intravenously on days 1, 8, 15 every 4 weeks	Nausea, rash, flu-like symptoms, fever, diarrhea	Myelosuppression, edema, hepatotoxicity (rare), hemolytic uremic syndrome (rare), pulmonary toxicity (rare)
Antimicrotubules—Vinca Alkaloids			
Vinblastine (Velban)	6 mg/m ² intravenously on days 1 and 15 every 4 weeks; 0.11 mg/kg on days 1 and 2	Vesicant, bronchospasm and dyspnea (rare)	Myelosuppression, peripheral neuropathy, constipation, mucositis, alopecia, SIADH (rare)
Vincristine (Oncovin)	0.5–1.4 mg/m ² intravenously every 3 weeks; 0.4 mg/m ² intravenously via continuous infusion for 4 days; maximum single dose usually limited to 2 mg	Vesicant	Peripheral neuropathy, constipation, alopecia, SIADH (rare)
Vinorelbine (Navelbine)	30 mg/m ² intravenously on days 1 and 8 every 3 weeks	Vesicant, nausea, vomiting, bronchospasm and dyspnea (rare)	Myelosuppression, peripheral neuropathy, constipation, alopecia, SIADH (rare)
Antimicrotubules—Taxanes			
Cabazitaxel (Jevtana)	25 mg/m ² intravenously every 3 weeks	Hypersensitivity reaction, nausea, vomiting	Myelosuppression, peripheral neuropathy, fatigue, diarrhea, renal failure
Docetaxel (Taxotere)	60–100 mg/m ² intravenously every 3 weeks; 35–40 mg/m ² intravenously weekly for 3 weeks with 1 week rest	Hypersensitivity reaction, nausea, vomiting	Myelosuppression, peripheral neuropathy, alopecia, edema, fatigue, mucositis, diarrhea
Paclitaxel (Taxol)	135–175 mg/m ² intravenously every 3 weeks; 50–80 mg/m ² intravenously weekly	Hypersensitivity reaction, nausea, vomiting, bradycardia and hypotension during infusion	Myelosuppression, peripheral neuropathy, alopecia, mucositis, diarrhea, arthralgias/myalgias
Paclitaxel protein-bound (Abraxane)	260 mg/m ² intravenously every 3 weeks	Nausea, vomiting, diarrhea, hypersensitivity reaction (less than paclitaxel)	Myelosuppression, peripheral neuropathy, alopecia, mucositis, arthralgias/myalgias
Antimicrotubules—Epothilone			
Ixabepilone (Ixempra)	40 mg/m ² intravenously every 3 weeks	Hypersensitivity reaction, nausea, vomiting	Peripheral neuropathy, myelosuppression, alopecia, fatigue, mucositis, diarrhea, arthralgias/myalgias

(continued)

Table 39–11. Chemotherapeutic agents: Dosage and toxicity. (continued)

Chemotherapeutic Agent	Usual Adult Dosage	Acute Toxicity	Delayed Toxicity
Enzyme Inhibitors—Anthracyclines			
Daunorubicin (Cerubidine)	30–60 mg/m ² intravenously for 3 days	Nausea, vomiting, mucositis, diarrhea, red/orange discoloration of urine, cardiotoxicity (ECG changes). All anthracyclines except for liposomal doxorubicin are potent vesicants.	Myelosuppression, cardiotoxicity (cardiomyopathy with congestive heart failure–dose related), alopecia. Liposomal Doxorubicin can also cause hand-foot syndrome
Liposomal Daunorubicin (Daunoxome)	40 mg/m ² intravenously every 2 weeks		
Doxorubicin (Adriamycin)	15–20 mg/m ² intravenously weekly; 45–60 mg/m ² intravenously every 3 weeks		
Liposomal Doxorubicin (Doxil)	20–50 mg/m ² intravenously every 3–4 weeks		
Epirubicin (Ellence)	35 mg/m ² intravenously every 2 weeks; 60–120 mg/m ² intravenously every 3–4 weeks	Liposomal daunorubicin and liposomal doxorubicin may cause infusion-related reactions	
Idarubicin (Idamycin)	12 mg/m ² intravenously for 3 days		
Enzyme Inhibitors—Topoisomerase Inhibitors			
Etoposide (Vepesid)	50–100 mg/m ² intravenously for 3–5 days every 3 weeks, oral dose is twice the intravenous dose	Nausea, vomiting, hypersensitivity reaction, fever, hypotension	Myelosuppression, alopecia, fatigue
Etoposide Phosphate (Etopophos)	100 mg/m ² intravenously for 3–5 days every 3 weeks		
Irinotecan (Camptosar)	60 mg/m ² intravenously on days 1, 8, and 15 every 4 weeks; 125 mg/m ² intravenously weekly for 4 weeks every 6 weeks; 180 mg/m ² intravenously every other week; 350 mg/m ² intravenously every 3 weeks	Diarrhea and cholinergic syndrome, nausea, vomiting	Myelosuppression, alopecia
Topotecan (Hycamtin)	1.5 mg/m ² intravenously for 5 days every 3 weeks; 2.3 mg/m ² orally for 5 days every 3 weeks	Nausea, vomiting, diarrhea	Myelosuppression, alopecia, asthenia
Targeted Therapy—Monoclonal Antibodies			
Alemtuzumab (Campath)	30 mg/m ² intravenously three times weekly	Infusion-related reaction, nausea, vomiting, hypotension	Myelosuppression, immunosuppression
Bevacizumab (Avastin)	5–15 mg/kg intravenously every 2–3 weeks	Infusion-related reaction	Arterial thromboembolism, wound healing complications, gastro-intestinal perforation or fistula, hemorrhage, hypertension, proteinuria
Brentuximab Vedotin (Adcetris)	1.8 mg/kg intravenously every 3 weeks	Infusion-related reaction, nausea, vomiting, diarrhea	Myelosuppression, peripheral neuropathy, tumor lysis syndrome, fatigue, rash
Cetuximab (Erbix)	Loading dose 400 mg/m ² intravenously followed by maintenance dose 250 mg/m ² intravenously weekly	Infusion-related reaction	Acneiform skin rash, hypomagnesemia, asthenia, paronychia inflammation, pulmonary toxicity (rare)
Ibritumomab tiuxetan (Zevalin)	0.4 mCi/kg intravenously on day 8	Infusion-related reaction	Myelosuppression, asthenia, infections, increased risk of secondary malignancies

(continued)

Table 39-11. Chemotherapeutic agents: Dosage and toxicity. (continued)

Chemotherapeutic Agent	Usual Adult Dosage	Acute Toxicity	Delayed Toxicity
Ipilimumab (Yervoy)	3 mg/kg intravenously every 3 weeks for a total of four doses	Infusion-related reaction	Fatigue, diarrhea, colitis, pruritus, rash, hepatotoxicity, neuropathy, endocrinopathy
¹³¹ I Tositumomab (Bexxar)	450 mg intravenously	Infusion-related reaction	Myelosuppression, asthenia, infections, hypothyroidism, increased risk of secondary malignancies
Ofatumumab (Arzerra)	300 mg initial dose (Dose 1), followed 1 week later by 2000 mg weekly for 7 doses (Doses 2 through 8), followed 4 weeks later by 2000 mg every 4 weeks for 4 doses (Doses 9 through 12)	Infusion-related reaction, diarrhea, nausea	Neutropenia, infections, pyrexia, rash, fatigue
Panitumumab (Vectibix)	6 mg/kg intravenously every 2 weeks	Infusion-related reaction	Acneiform skin rash, hypomagnesemia, asthenia, paronychia inflammation, pulmonary toxicity (rare)
Rituximab (Rituxan)	375 mg/m ² intravenously weekly for 4 weeks, or every 3 weeks	Infusion-related reaction	Rare reactions: Hepatitis B reactivation, pulmonary toxicity, tumor lysis syndrome, Stevens-Johnson syndrome, progressive multifocal leukoencephalopathy, cardiac arrhythmias, bowel obstruction
Trastuzumab (Herceptin)	Loading dose 4 mg/kg intravenously followed by 2 mg/kg intravenously weekly; or loading dose 8 mg/kg followed by 6 mg/kg intravenously every 3 weeks	Infusion-related reaction, headache, diarrhea	Cardiotoxicity, pulmonary toxicity, myelosuppression in combination with chemotherapy
Targeted Therapy—mTOR Inhibitors			
Everolimus (Afinitor)	10 mg orally once daily	Mucositis, diarrhea, cough	Myelosuppression, fatigue, edema, hypercholesterolemia, hypertriglyceridemia, hyperglycemia, hypophosphatemia, immunosuppression, pneumonitis (rare)
Temsirolimus (Torisel)	25 mg intravenously weekly	Hypersensitivity reaction, rash, mucositis	Myelosuppression, edema, fatigue, mucositis, hyperglycemia, hyperlipemia, immunosuppression, nephrotoxicity, interstitial lung disease (rare), bowel perforation (rare), abnormal wound healing
Targeted Therapy—Tyrosine Kinase Inhibitors			
Crizotinib (Xalkori)	250 mg orally twice daily	Nausea, vomiting, diarrhea, constipation	Edema, pneumonitis, vision disorder, liver function test abnormalities, prolonged QT interval
Dasatinib (Sprycel)	70 mg orally twice daily; 100-140 mg orally once daily	Diarrhea, nausea, vomiting	Myelosuppression, fluid retention, fatigue, musculoskeletal pain, rash, cardiac dysfunction/congestive heart failure (rare), hemorrhage (rare)
Erlotinib (Tarceva)	100-150 mg orally once daily	Diarrhea	Acneiform skin rash, fatigue, anorexia, conjunctivitis, gastrointestinal hemorrhage (rare), pulmonary toxicity (rare)
Gefitinib (Iressa)	250 mg orally once daily	Diarrhea	Acneiform skin rash, asthenia, ocular toxicity, myelosuppression, hepatotoxicity (rare), pulmonary toxicity (rare)
Imatinib (Gleevec)	100-800 mg orally once daily	Nausea, vomiting, diarrhea	Myelosuppression, edema, myalgias, rash, congestive heart failure, left ventricular dysfunction (rare), hemorrhage (rare), hepatotoxicity (rare)

(continued)

Table 39-11. Chemotherapeutic agents: Dosage and toxicity. (continued)

Chemotherapeutic Agent	Usual Adult Dosage	Acute Toxicity	Delayed Toxicity
Lapatinib (Tykerb)	1250 mg orally once daily in combination with capecitabine	Diarrhea, nausea, vomiting	Hand-foot syndrome, fatigue, hepatotoxicity (rare), left ventricular dysfunction (rare), prolonged QT interval (rare), interstitial lung disease (rare)
Nilotinib (Tasigna)	400 mg orally twice daily	Nausea, vomiting, headache, diarrhea	Edema, rash, arthralgia, fatigue, myelosuppression, electrolyte abnormalities, elevated serum lipase (rare), hepatotoxicity (rare), prolonged QT interval (rare)
Pazopanib (Votrient)	800 mg orally once daily	Nausea, vomiting, diarrhea	Hypertension, hair color changes, hepatotoxicity, hemorrhagic events, hypothyroidism
Sorafenib (Nexavar)	400 mg orally twice daily	Diarrhea and nausea	Hypertension, hand-foot syndrome, rash, fatigue, gastrointestinal perforation (rare), hemorrhage (rare), cardiac ischemia/infarction (rare)
Sunitinib (Sutent)	50 mg orally once daily for 4 weeks followed by 2 weeks rest.	Diarrhea and nausea	Hypertension, hand-foot syndrome, rash, yellow discoloration of skin, fatigue, hypothyroidism, mucositis, myelosuppression, left ventricular dysfunction (rare), prolonged QT interval (rare), hemorrhage (rare)
Vandetanib (Caprelsa)	300 mg orally once daily	Nausea and diarrhea	Acneiform skin rash, hypertension, fatigue, anorexia, abdominal pain, prolonged QT interval, interstitial lung disease (rare)
Vemurafenib (Zelboraf)	960 mg orally twice daily	Nausea, hypersensitivity reaction (rare)	Photosensitivity, rash, arthralgia, alopecia, fatigue, prolonged QT interval, cutaneous squamous cell carcinoma
Miscellaneous Agents			
Altretamine (Hexalen)	260 mg/m ² orally in 4 divided doses for 14-21 days every 4 weeks	Nausea, vomiting, diarrhea	Neurotoxicity, myelosuppression, flu-like syndrome
Arsenic Trioxide (Trisenox)	0.15 mg/kg intravenously daily	Nausea, dizziness	Edema, acute promyelocytic leukemia differentiation syndrome (fever, dyspnea, skin rash, fluid retention, pleural effusions), prolonged QT interval and complete atrioventricular block
Asparaginase (Elspar)	6000-10,000 units/m ² intravenously daily on days 17-28; 6000-10,000 units/m ² intramuscularly every 3 days for a total of 9 doses	Hypersensitivity reaction (requires test dose), nausea, vomiting	Coagulation abnormalities (hemorrhagic and/or thrombotic events), hepatotoxicity, pancreatitis, neurotoxicity
Bleomycin (Blenoxane)	10 units/m ² intravenously on days 1 and 15 every 4 weeks; 30 units on day 2, 9, and 16 every 3 weeks	Hypersensitivity reaction	Skin reaction (rash, hyperpigmentation of skin, striae), pulmonary fibrosis
Bortezomib (Velcade)	1.3 mg/m ² intravenous bolus on days 1, 4, 8, 11 followed by a 10 day rest every 3 weeks	Orthostatic hypotension, fever	Peripheral neuropathy, fatigue, myelosuppression, hemorrhage (rare), left ventricular dysfunction (rare), pulmonary toxicity (rare), reversible posterior leukoencephalopathy syndrome (rare), hepatotoxicity (rare)
Dactinomycin (Cosmegen)	15 mcg/kg intravenously daily for 5 days; 12 mcg/kg intravenously daily for 5 days; 1000 mcg/m ² intravenously	Vesicant, nausea, vomiting	Myelosuppression, mucositis, diarrhea, alopecia, hyperpigmentation of skin, hepatotoxicity, hepato-veno-occlusive disease (rare)
Denileukin diftitox (Ontak)	9 or 18 mcg/kg intravenously daily for 5 days every 3 weeks	Flu-like syndrome, hypersensitivity reaction, nausea, vomiting	Diarrhea, decreased visual acuity, fever, increased risk for infection, hypoalbuminemia, capillary leak syndrome (rare)
Hydroxyurea (Hydrea)	20-30 mg/kg orally once daily	Nausea	Myelosuppression, dermatopathy

(continued)

Table 39-11. Chemotherapeutic agents: Dosage and toxicity. (continued)

Chemotherapeutic Agent	Usual Adult Dosage	Acute Toxicity	Delayed Toxicity
Lenalidomide (Revlimid)	5-25 mg orally once daily for 21 days every 4 weeks	Diarrhea, itching, rash	Myelosuppression, potential for birth defects, thromboembolic events, fatigue
Mitomycin (Mutamycin)	20 mg/m ² intravenously every 6-8 weeks; 20-40 mg intravesically weekly	Vesicant, local irritation (cystitis when given intravesically)	Myelosuppression, mucositis, hemolytic uremic syndrome (rare), pulmonary toxicity (rare)
Mitoxantrone (Novantrone)	12-14 mg/m ² intravenously every 3 weeks; induction chemotherapy for leukemia 12 mg/m ² intravenously for 2-3 days	Blue-green discoloration of urine, nausea, vomiting, diarrhea, intravenous irritant	Myelosuppression, cardiotoxicity, alopecia, mucositis, increased risk of secondary malignancies (rare)
Romidepsin (Istodax)	14 mg/m ² intravenously on days 1, 8, 15 of a 28-day cycle	Nausea, vomiting	Myelosuppression, fatigue, anorexia, ECG changes, QT prolongation
Sipuleucel-T (Provenge)	One dose (minimum of 50 million autologous CD54+ cells) intravenously every 2 weeks for three doses	Infusion-related reaction, nausea, vomiting	Fatigue, back pain, joint ache, headache, stroke
Thalidomide (Thalomid)	50-800 mg orally once daily	Sedation, constipation, fatigue	Potential for birth defects, thromboembolic events, peripheral neuropathy, edema
Tretinoin (All-Trans-Retinoic Acid, ATRA, Vesanoid)	45 mg/m ² orally divided twice daily for 45-90 days or 30 days past complete remission		Headache, vitamin A toxicity, retinoic acid-acute promyelocytic leukemia syndrome, ototoxicity
Antiandrogens			
Bicalutamide (Casodex)	50 mg orally once daily	None	Hot flashes, decreased libido, erectile dysfunction, gynecomastia, breast tenderness, fatigue
Flutamide (Eulexin)	250 mg orally every 8 hours	Diarrhea, yellow-green discoloration of urine	Hot flashes, decreased libido, erectile dysfunction, gynecomastia, breast tenderness, hepatotoxicity (rare)
Nilutamide (Nilandron)	300 mg orally for 30 days then 150 mg orally once daily	Nausea	Visual disturbances (impaired adaptation to dark), hot flashes, decreased libido, erectile dysfunction, gynecomastia, breast tenderness, disulfiram reaction with alcohol, interstitial pneumonitis (rare), hepatotoxicity (rare)
Selective Estrogen Receptor Modulators			
Tamoxifen (Nolvadex)	20-40 mg orally once daily	None	Hot flashes, vaginal discharge or bleeding, menstrual irregularities, thromboembolic events (rare), endometrial hyperplasia, cataracts, hepatotoxicity, tumor flare
Toremifene (Fareston)	60 mg orally once daily	Nausea	Hot flashes, vaginal discharge, thromboembolic events (rare), tumor flare, endometrial hyperplasia, cataracts, hepatotoxicity
Aromatase Inhibitors			
Anastrozole (Arimidex)	1 mg orally once daily	Nausea	Hot flashes, peripheral edema, hypercholesterolemia, arthralgia/myalgia, headache, osteoporosis
Exemestane (Aromasin)	25 mg orally once daily		
Letrozole (Femara)	2.5 mg orally once daily		

(continued)

Table 39–11. Chemotherapeutic agents: Dosage and toxicity. (continued)

Chemotherapeutic Agent	Usual Adult Dosage	Acute Toxicity	Delayed Toxicity
Pure Estrogen Receptor Antagonist			
Fulvestrant (Faslodex)	250 mg intramuscularly once a month	Injection site reactions, nausea, diarrhea, constipation	Hot flashes, backache, headache
Progestins			
Megestrol acetate (Megace)	40–320 mg orally once daily or in divided doses (four times a day)	Nausea	Hot flashes, tumor flare, weight gain, hyperglycemia, thrombotic events (rare), adrenal insufficiency (rare)
LHRH Analogs			
Goserelin acetate (Zoladex)	3.6 mg subcutaneously once every month; 10.8 mg subcutaneously once every 3 months	Injection site discomfort	Hot flashes, tumor flare, decreased libido, erectile dysfunction, vaginal bleeding, thromboembolic events (rare), osteoporosis (rare)
Leuprolide (Lupron)	7.5 mg intramuscularly once every month; 22.5 mg intramuscularly once every 3 months; 30 mg intramuscularly once every 4 months	Injection site reaction	Hot flashes, tumor flare, edema, erectile dysfunction thromboembolic events (rare), osteoporosis
Triptorelin pamoate (Trelstar)	3.75 mg intramuscularly once every month; 11.25 mg intramuscularly once every 3 months	None	Hot flashes, tumor flare, skeletal pain, erectile dysfunction
LHRH Antagonist			
Degarelix (Firmagon)	Initial: 240 mg subcutaneously Maintenance: 80 mg subcutaneously every 28 days	Injection site reaction	Hot flashes, weight gain, LFT elevation
Adrenocorticosteroids			
Abiraterone (Zytiga)	1000 mg orally once daily	Diarrhea, edema	Adrenocortical insufficiency, hepatotoxicity, joint swelling, hypokalemia, hot flashes
Dexamethasone	40 mg orally once weekly or 40 mg orally on days 1–4, 9–12, 17–20	None	Hyperglycemia, weight gain, fluid retention, psychiatric symptoms
Ketoconazole	400 mg orally three times daily	Nausea and vomiting	Hepatotoxicity (rare)
Prednisone	5 mg orally twice a day; 100 mg orally daily for 5 days	None	Hyperglycemia, weight gain, gastritis, fluid retention, psychiatric symptoms
Biologic Response Modifiers			
Aldesleukin (IL-2, Proleukin)	600,000 international units/kg intravenously every 8 hours for 14 doses, repeat after 9 days rest	Hypotension, nausea, vomiting, diarrhea	Capillary leak syndrome (rare), impaired neutrophil function and increased risk of infection, lethargy or somnolence that may result in coma if therapy is not held
Interferon- α -2b (Intron A)	5 million international units subcutaneously 3 times a week; 2 million international units/m ² intramuscularly/subcutaneously three times a week; 20 million international units/m ² 5 days a week for 4 weeks then 10 million international units/m ² three times a week	Hypersensitivity reaction, injection site reaction, flu-like syndrome, nausea, vomiting, diarrhea	Myelosuppression, fatigue, anorexia, alopecia, depression, hyperthyroidism or hypothyroidism (rare), hepatotoxicity (rare), visual disturbances

GFR, glomerular filtration rate; LFT, liver function tests; LHRH, luteinizing hormone–releasing hormone; MAO, monoamine oxidase; NSAIDs, nonsteroidal anti-inflammatory drugs; SIADH, syndrome of inappropriate antidiuretic hormone; TMP-SMZ, trimethoprim-sulfamethoxazole.

Table 39–12. Supportive care agents: Dosage and toxicity.

Agent	Indication	Usual Dose	Acute Toxicity	Delayed Toxicity
Allopurinol (Xyloprim)	Prevent hyperuricemia from tumor lysis syndrome	300 mg orally once daily	None	Rash, Stevens-Johnson syndrome (rare), myelosuppression (rare)
Rasburicase (Elitek)	Prevent hyperuricemia from tumor lysis syndrome	0.1–0.2 mg/kg intravenously for pediatric patients; 3–6 mg intravenously once	Hypersensitivity reaction in patients with G6PD deficiency, nausea, vomiting, diarrhea, fever, headache	Rash
Mesna (Mesnex)	Prevent ifosfamide-induced hemorrhagic cystitis	20% of ifosfamide dose intravenously immediately before ifosfamide and at 4 hours and 8 hours after (total dose is 60% of ifosfamide dose); 100% of ifosfamide dose mixed with ifosfamide in same intravenous bag	Nausea and vomiting	Fatigue, hypotension
Leucovorin	Rescue after high-dose methotrexate; in combination with fluorouracil for colon cancer	10 mg/m ² intravenously or orally every 6 hours until serum methotrexate level is below 0.01 micromolar; 20 mg/m ² or 200–500 mg/m ² intravenously before fluorouracil	Nausea	None
Levoleucovorin (Fusilev)	Rescue after high-dose methotrexate in osteosarcoma	7.5 mg intravenously every 6 hours for 10 doses (to start 24 hours after the beginning of methotrexate infusion)	Nausea, vomiting	Stomatitis
Amifostine (Ethylol)	Prevent cisplatin nephropathy; prevent radiation-induced xerostomia	910 mg/m ² intravenously before cisplatin; 200 mg/m ² intravenously before radiation	Nausea, vomiting, hypotension, infusion-related reaction	Hypocalcemia
Dexrazoxane (ZIncard)	Prevent cardiomyopathy secondary to doxorubicin; anthracycline-induced injection site extravasation	10 times the doxorubicin dose intravenously before doxorubicin	Nausea	Myelosuppression
Palifermin (Kepivance)	Prevent mucositis following chemotherapy	60 mcg/kg/d intravenously for 3 days before and 3 days after chemotherapy	None	Edema, rash, pruritus, erythema, fever, enlargement or discoloration of tongue, altered taste sensation
Pilocarpine (Salagen)	Radiation-induced xerostomia	5 mg orally 1 hour before chemotherapy, then 5 mg once daily for 7 days; 5–10 mg orally three times a day	Flushing, sweating, nausea, dizziness, increased urinary frequency, rhinitis	None
Samarium (Quadramet)	Pain from bone metastasis	1 milliCurie/kg intravenously	Pain flare, diarrhea, hematuria	Myelosuppression, spinal cord compression
Strontium (Metastron)	Pain from bone metastasis	148 megabecquerels (4 milliCuries) intravenously; or 1.5–2.2 megabecquerels/kg (40–60 microcuries/kg)	Flushing, pain flare	Myelosuppression
Bone-Modifying Agents				
Denosumab (Xgeva)	Osteolytic bone metastasis	120 mg subcutaneously every 4 weeks	None	Hypocalcemia, hypophosphatemia, fatigue, nausea, osteonecrosis of the jaw

(continued)

Table 39-12. Supportive care agents: Dosage and toxicity. (continued)

Agent	Indication	Usual Dose	Acute Toxicity	Delayed Toxicity
Pamidronate (Aredia)	Osteolytic bone metastasis, hypercalcemia of malignancy	90 mg intravenously every 3-4 weeks; 60-90 mg intravenously, may repeat after 7 days	Injection site reaction	Electrolyte disturbances (hypocalcemia), anemia, arthralgia, bone pain, osteonecrosis of the jaw, nephrotoxicity
Zoledronic acid (Zometa)	Osteolytic bone metastasis, hypercalcemia of malignancy	4 mg intravenously every 3-4 weeks	Injection site reaction	Electrolyte disturbances (hypocalcemia), anemia, arthralgia, bone pain, osteonecrosis of the jaw, nephrotoxicity
Growth Factors				
Epoetin alfa (Epoen, Procrit)	Chemotherapy-induced anemia	40,000 units subcutaneously once weekly; 150 units/kg subcutaneously 3 times a week	Injection site reaction	Hypertension, thrombotic events, increased risk of tumor progression or recurrence, seizures, rash
Darbepoetin alfa (Aranesp)	Chemotherapy-induced anemia	2.25 mcg/kg subcutaneously weekly; 500 mcg subcutaneously every 3 weeks Alternative dosing: 200 mcg subcutaneously every 2 weeks or 300 mcg subcutaneously every 3 weeks	Injection site reaction	Hypertension, thrombotic events, increased risk of tumor progression or recurrence, seizures, rash
Filgrastim (Neupogen)	Febrile neutropenia prophylaxis	5-10 mcg/kg/d subcutaneously or intravenously once daily, treat past nadir	Injection site reaction	Bone pain, enlarged spleen, leukocytosis
Pegfilgrastim (Neulasta)	Febrile neutropenia prophylaxis	6 mg subcutaneously once per chemotherapy cycle	Injection site reaction	Bone pain, enlarged spleen, leukocytosis
Sargramostim (Leukine)	Myeloid reconstitution following bone marrow transplant, febrile neutropenia prophylaxis	250 mcg/m ² intravenously daily until the absolute neutrophil count is > 1500 cells/mcL for 3 consecutive days	Rash, pruritus, injection site reaction, dyspnea, fever	Bone pain, myalgia, fluid retention, supraventricular tachycardia, capillary leak syndrome (rare)
Oprelvekin (Neumega)	Chemotherapy-induced thrombocytopenia	50 mcg/kg subcutaneously every day for 14-21 days or until post-nadir platelet count is > 50,000/mcL	Nausea, vomiting, headache, dizziness, blurred vision, dyspnea, injection site reaction	Candidiasis, rash, fluid retention, arrhythmias, febrile neutropenia

G6PD, glucose 6-phosphate dehydrogenase.

Table 39-13. A common scheme for dose modification of cancer chemotherapeutic agents.

Granulocyte Count (cells/mcL)	Platelet Count (/mcL)	Suggested Drug Dosage (% of Full Dose)
> 2000	> 100,000	100%
1000-2000	75,000-100,000	50%
< 2000	< 50,000	0%

idiopathic thrombocytopenia, romiplostim and eltrombopag, may also benefit patients with chemotherapy-associated thrombocytopenia, although larger trials are needed to establish their use in this setting.

2. Chemotherapy-Induced Nausea & Vomiting

A number of cytotoxic anticancer drugs can induce nausea and vomiting, which can be the most anticipated and stressful side effects for patients. Chemotherapy-induced

nausea and vomiting is mediated in part by the stimulation of at least two central nervous system receptors, 5-hydroxytryptamine subtype 3 (5HT₃) and neurokinin subtype 1 (NK₁). Chemotherapy-induced nausea and vomiting can be acute, occurring within minutes to hours of chemotherapy administration, or delayed until the second day and lasting up to 7 days. Anticipatory nausea and vomiting may even occur before the administration of chemotherapy. Chemotherapy drugs or drug regimens are classified into high, moderate, low, and minimal likelihoods of causing emesis (90%, 30–90%, 10–30%, < 10%, respectively). Highly emetogenic chemotherapy drugs include cisplatin, carmustine, cyclophosphamide at doses over 1.5 g/m², dacarbazine, mechlorethamine, and streptozocin. Chemotherapy drugs that are moderately emetogenic include doxorubicin, daunomycin, idarubicin, epirubicin, cyclophosphamide, irinotecan, oxaliplatin, ifosfamide, cytarabine, and carboplatin. Drugs with low emetic potential include bortezomib, docetaxel, etoposide, fluorouracil, gemcitabine, methotrexate, mitomycin, mitoxantrone, paclitaxel, pemetrexed, temsirolimus, and topotecan. Drugs with minimal risk of emesis include bevacizumab, bleomycin, cladribine, fludarabine, vinblastine, vincristine, and vinorelbine.

By understanding the physiology of chemotherapy-induced nausea and vomiting, major advances have occurred with the development of highly effective antiemetic drugs. Antagonists to the 5HT₃-receptor include ondansetron, granisetron, dolasetron, tropisetron, and palonosetron. Each of these drugs has similar efficacy. Ondansetron can be given either intravenously (8 mg or 0.15 mg/kg) or orally (24 mg for highly emetogenic chemotherapy, 8 mg twice daily for moderately emetogenic chemotherapy). Doses of 8 mg can be repeated parenterally or orally every 8 hours. Dosing of granisetron is 1 mg or 0.01 mg/kg intravenously or 1–2 mg orally. Dolasetron is given 1.8 mg/kg or a fixed dose of 100 mg intravenously or 100 mg can be given orally. Tropisetron is given at a dose of 5 mg either orally or intravenously. Palonosetron, a long-acting 5HT₃ with high affinity for the 5HT₃-receptor given at a dose of 0.25 mg intravenously, is effective for not only acute but also delayed emesis. The efficacy of the 5HT₃-blockers is improved by adding 6–10 mg of either oral or intravenous dexamethasone.

Aprepitant is an antagonist to the NK₁ receptor. When given as a 125-mg oral dose followed by 80 mg on the second and third day with a 5HT₃-receptor antagonist (such as ondansetron or granisetron), the immediate and delayed protective effect for highly emetogenic chemotherapy is increased.

Standard therapy for highly emetogenic chemotherapy includes a 5HT₃-antagonist given on the first day and both dexamethasone and aprepitant given on the first day as well as the second and third days. Moderately emetogenic chemotherapy regimens are best managed with a two-drug regimen of a 5HT₃-antagonist and dexamethasone. Doses of the 5HT₃ may be given on days 2 and 3 to prevent delayed emesis.

Other adjunctive medications that may be helpful include lorazepam, 0.5–1.0 mg given orally every 6–8 hours,

and prochlorperazine, 5–10 mg orally or intravenously every 8 hours. Lorazepam, in addition to antianxiety effects, has an antiemetic effect. Prochlorperazine is generally sufficient to treat patients receiving low emetogenic chemotherapy. A suppository form of prochlorperazine, 25 mg, may be used for patients who are unable to swallow oral medications.

The importance of treating chemotherapy-induced nausea and vomiting expectantly and aggressively beginning with the first course of chemotherapy cannot be overemphasized. Patients being treated in the clinic setting should always be given antiemetics for home use with written instructions as well as contact numbers to call for advice.

3. Gastrointestinal Toxicity

Untoward effects of cancer chemotherapy include damage to the more rapidly growing cells of the body such as the mucosal lining from the mouth through the gastrointestinal tract. Oral symptoms range from mild mouth soreness to frank ulcerations in the mouth. Not uncommonly, mouth ulcerations will have superimposed candida or herpes simplex infections. In addition to receiving cytotoxic chemotherapy, a significant risk factor for development of oral mucositis is poor oral hygiene and existing caries or periodontal disease. Toxicity in the gastrointestinal tract usually manifests as diarrhea. Gastrointestinal symptoms can range from mild symptoms of loose stools to life-threatening diarrhea due to dehydration and electrolyte imbalances. Drugs most commonly associated with causing mucositis in the mouth and the gastrointestinal tract are cytarabine, 5-FU, and methotrexate.

Patients undergoing treatment for head and neck cancer with concurrent chemotherapy and radiation therapy have a very high risk of developing severe mucositis.

Preventive strategies for managing oral mucositis includes a pretreatment dental examination, particularly for all head and neck cancer patients and any cancer patient with poor dental hygiene who will be receiving chemotherapy. For patients receiving fluorouracil, simple measures such as ice chips in the mouth for 30 minutes during infusion can reduce the incidence and severity of mucositis. Once mucositis is encountered, superimposed fungal infections should be treated with topical anti-fungal medications (oral nystatin mouth suspensions, or clotrimazole troches) or systemic therapy (fluconazole 100–400 mg orally daily). Suspected herpetic infections can be treated with acyclovir (up to 800 mg orally five times daily) or valacyclovir (1 g orally twice daily). Mucositis may also be managed with mouthwashes; it is also important to provide adequate pain medication.

Newer strategies for prevention of oral mucositis include the recombinant keratinocyte growth factor inhibitor palifermin. Practice guidelines recommend prophylaxis with intravenous palifermin (60 mcg/kg/d) for patients receiving high-dose chemotherapy in order to reduce the incidence and duration of mucositis.

Diarrhea is most associated with fluorouracil, capecitabine, and irinotecan as well as the tyrosine kinase inhibitors

(sorafenib, sunitinib, imatinib, dasatinib) and epithelial growth factor inhibitors (cetuximab, panitumumab, and erlotinib). Mild to moderate diarrhea can be managed with oral antidiarrheal medication (loperamide, 4 mg initially followed by 2 mg every 2–4 hours until bowel movements are formed). Occasionally, the diarrhea will be overwhelming causing dehydration, electrolyte imbalances, and acute kidney injury. These patients require inpatient management with aggressive intravenous hydration and replacement of electrolytes.

4. Skin Toxicity

Dermatologic complications from cancer chemotherapy can include hyperpigmentation (liposomal doxorubicin, busulfan, hydroxyurea) alopecia, photosensitivity, nail changes, acral erythema, and generalized rashes. Acral erythema, otherwise known as hand-foot syndrome and most commonly associated with administration of fluorouracil, capecitabine, and liposomal doxorubicin, manifests as painful palms or soles accompanied by erythema, progressing to blistering desquamation and ulceration in its worst forms. Management can include attempts at prevention with oral pyridoxine, 200 mg daily, and applying cold packs to the extremities while the chemotherapy is being administered. Agents targeting the epidermal growth factor pathway can cause an acne like rash; interestingly, the development of the rash may identify those who will respond to the drug. Inhibitors of the tyrosine kinase pathway are also associated with a high incidence of dermatologic complications, such as rash and acral erythema.

5. Miscellaneous Drug-Specific Toxicities

The toxicities of individual drugs have been summarized in Tables 39–11 and 39–12; however, several of these warrant additional mention, since they occur with frequently administered agents, and special measures are often indicated.

A. Hemorrhagic Cystitis Induced by Cyclophosphamide or Ifosfamide

Metabolic products of cyclophosphamide that retain cytotoxic activity are excreted into the urine. Some patients appear to metabolize more of the drug to these active excretory products; if their urine is concentrated, severe bladder damage may result. Patients receiving cyclophosphamide must maintain a high fluid intake prior to and following the administration of the drug and be counseled to empty their bladders frequently. Early symptoms suggesting bladder toxicity include dysuria and increased frequency or urination. Should microscopic hematuria develop, it is advisable to stop the drug temporarily or switch to a different alkylating agent, to increase fluid intake, and to administer a urinary analgesic such as phenazopyridine. With severe cystitis, large segments of bladder mucosa may be shed, resulting in prolonged gross hematuria. Such patients should be observed for signs of urinary obstruction and may require cystoscopy for removal of obstructing blood clots. The cyclophosphamide analog ifosfamide can cause severe

hemorrhagic cystitis when used alone. However, when its use is followed by a series of doses of the neutralizing agent mesna, bladder toxicity can be prevented. Mesna can also be used for patients taking cyclophosphamide in whom cystitis develops.

B. Neuropathy Due to Vinca Alkaloids and Other Chemotherapy Drugs

Neuropathy is caused by a number of different chemotherapy drugs, the most common being vincristine. The peripheral neuropathy can be sensory, motor, autonomic, or a combination of these effects. In its mildest form, it consists of paresthesias of the fingers and toes. Occasionally, acute jaw or throat pain can develop after vincristine therapy. This may be a form of trigeminal neuralgia. With continued vincristine therapy, the paresthesias extend to the proximal interphalangeal joints, hyporeflexia appears in the lower extremities, and significant weakness can develop. Other drugs in the vinca alkaloid class as well as the taxane drugs (paclitaxel and docetaxel) and agents to treat myeloma (thalidomide and bortezomib) cause similar toxicity. The presence of neurologic symptoms is not in itself a reason to stop therapy; the severity of the symptoms must be balanced against the goals of therapy. Usually though, the presence of moderate to severe paresthesias or the detection of motor impairment would result in the decision to discontinue the drug.

Constipation is the most common symptom of autonomic neuropathy associated with the vinca alkaloids. Patients receiving these drugs should be started on stool softeners and mild cathartics when therapy is begun; otherwise, severe impaction may result from an atonic bowel.

More serious autonomic involvement can lead to acute intestinal obstruction with signs indistinguishable from those of an acute abdomen. Bladder neuropathies are uncommon but may be severe. These two complications are absolute contraindications to continued vincristine therapy.

C. Methotrexate Toxicity

Methotrexate, a folate antagonist, is a commonly used drug and a key component of regimens to treat patients with leptomeningeal disease, acute lymphoblastic leukemia, and sarcomas. The dose used in intrathecal therapy is 12 mg. Methotrexate is almost entirely eliminated by the kidney. The methotrexate toxicity affects cells with rapid turnover, including the bone marrow and mucosa resulting in myelosuppression and mucositis. Methotrexate can also damage the liver and kidney manifesting as elevated liver enzymes and creatinine. High-dose methotrexate, usually defined as a dose of 500 mg/m² or more given over 4–36 hours, would be lethal without “rescue” of the normal tissues. Leucovorin, a form of folate, will reverse the toxic effects of methotrexate and is given until serum methotrexate levels are in the safe range (< 0.05 mmol/L). It is crucial that high-dose methotrexate and leucovorin are given precisely according to protocol as deviations of the timing of methotrexate delivery or delay in rescue can result in patient death. Lower doses of methotrexate can be problematic in patients with kidney disease who cannot

clear the drug normally or with patients who have effusions. In the latter instance, methotrexate distributes itself in effusions and will leak out continuously, exposing normal tissue to small but cumulatively toxic amounts of the drug. If methotrexate is given to a patient who either has or develops kidney disease or to a patient with an effusion, prolonged rescue with leucovorin will be necessary.

Vigorous hydration and bicarbonate loading also appear to be important in preventing crystallization of high-dose methotrexate in the renal tubular epithelium and minimizing the possibility of nephrotoxicity. Daily monitoring of the serum creatinine is mandatory. Drugs impairing methotrexate excretion include aspirin, nonsteroidal anti-inflammatory drugs, amiodarone, omeprazole, penicillin, phenytoin, and sulfa compounds; these drugs should be stopped if possible before methotrexate administration.

D. Anthracycline Cardiotoxicity

A number of cancer chemotherapy drugs can cause cardiotoxicity. The most common class of drugs associated with cardiotoxicity is the anthracycline antibiotics, including doxorubicin, daunomycin, idarubicin, and epirubicin. They can produce acute (during administration), subacute (days to months following administration), and delayed (years following administration) cardiac toxicity. The most feared complication is the delayed development of congestive heart failure. Risk factors for this debilitating toxicity include the anthracycline cumulative dose, age over 70, previous or concurrent irradiation of the chest, preexisting cardiac disease, and concurrent administration of chemotherapy drugs such as trastuzumab. The problem is greatest with doxorubicin because this drug is the most commonly administered anthracycline due to its major role in the treatment of lymphomas, sarcomas, breast cancer, and certain other solid tumors. Patients receiving anthracyclines should have a baseline multiple-gated radio-nuclide cardiac scan (MUGA) to calculate the left ventricular ejection fraction (LVEF). If the LVEF is $> 50\%$, anthracyclines can be administered; if the LVEF is $< 30\%$, these drugs should not be given. For patients with intermediate cardiac function, anthracycline dosing, if necessary, should be cautiously done with LVEF monitoring between doses. Studies of left ventricular function and endomyocardial biopsies indicate that some changes in cardiac dynamics occur in most patients by the time they have received 300 mg/m^2 of doxorubicin. In general, patients should not receive a total dose of doxorubicin in excess of 450 mg/m^2 ; the dose should be lower if prior chest radiotherapy has been given. The appearance of a high resting pulse may herald the appearance of overt cardiac toxicity. Unfortunately, toxicity may be irreversible and frequently fatal at dosage levels above 550 mg/m^2 . At lower doses (eg, 350 mg/m^2 of doxorubicin), the symptoms and signs of cardiac failure generally respond well to medical therapy as well as the discontinuation of anthracycline. Laboratory studies suggest that cardiac toxicity may be due to a mechanism involving the formation of intracellular free radicals in cardiac muscle. The iron chelator dexrazoxane has been approved for use as a cardioprotectant for

patients receiving anthracyclines; however, some evidence suggests that the anthracycline anticancer effect may be compromised by the coadministration of dexrazoxane. In general, dexrazoxane should not be used when the goal of chemotherapy is for curative intent either in the settings of adjuvant or definitive treatment. Doxorubicin and daunomycin have been formulated as liposomal products; these drugs, approved for use in patients with Kaposi sarcoma and sometimes used in certain cancers as a substitute for conventional anthracyclines, appear to have minimal potential for cardiac toxicity.

E. Cisplatin Nephrotoxicity and Neurotoxicity

Cisplatin is effective in treating a wide range of malignancies, including testicular, bladder, lung, and ovarian cancers. Although nausea and vomiting are the side effects most commonly associated with cisplatin, the more serious side effects of nephrotoxicity and neurotoxicity must also be anticipated and aggressively managed. Patients must be vigorously hydrated prior, during, and after cisplatin administration. Both kidney function and electrolytes must be monitored. Low magnesium and potassium levels as well as hyponatremia can develop. The neurotoxicity is usually manifested as a peripheral neuropathy of mixed sensorimotor type and may be associated with painful paresthesias. Development of neuropathy typically occurs after cumulative doses of 300 mg/m^2 . Ototoxicity is a potentially serious manifestation of neurotoxicity and can progress to deafness. Amifostine, developed initially as a radioprotective agent and given intravenously at a dose of 910 mg/m^2 over 15 minutes prior to cisplatin, is used to protect against nephrotoxicity and neuropathy. Use of amifostine does not appear to compromise the antineoplastic effect of cisplatin. The second-generation platinum analog carboplatin is non-nephrotoxic, although it is myelosuppressive. In the setting of preexisting kidney disease or neuropathy, carboplatin is occasionally substituted for cisplatin.

F. Bleomycin Toxicity

Bleomycin is used for the treatment of testicular cancer, Hodgkin disease, and non-Hodgkin lymphoma. Bleomycin produces edema of the interphalangeal joints and hardening of the palmar and plantar skin. The more serious toxicities include an anaphylactic or serum sickness-like reaction and a serious or fatal pulmonary fibrotic reaction (seen especially in elderly patients receiving a total dose of over 300 units). If nonproductive cough, dyspnea, and pulmonary infiltrates develop, the drug is discontinued, and high-dose corticosteroids are instituted as well as empiric antibiotics pending cultures. Fever alone or with chills is an occasional complication of bleomycin treatment and is not an absolute contraindication to continued treatment. The fever may be avoided by intravenous premedication with hydrocortisone administration. Moreover, fever alone is not predictive of pulmonary toxicity. About 1% of patients (especially those with lymphoma) may have a severe or even fatal hypotensive reaction after the initial dose of bleomycin. In order to identify such patients, a test dose of 5 units of bleomycin is administered first with

adequate monitoring and emergency facilities available should they be needed. Patients exhibiting a hypotensive reaction should not receive further bleomycin therapy.

PROGNOSIS

A valuable sign of clinical improvement is the general well-being of the patient. Although this finding is a combination of subjective and objective factors and may be partly a placebo effect, it nonetheless serves as a sign of clinical improvement in assessing some of the objective observations listed above. Factors included in the

assessment of general well-being are improved appetite and weight gain and increased “performance status” (eg, ambulatory versus bedridden). Evaluation of factors such as activity status enables the clinician to judge whether the net effect of chemotherapy is worthwhile palliation (see Chapter 5).

Basch E et al. Antiemetics: American Society of Clinical Oncology clinical practice guideline update. 2011 Nov 1;29(31):4189–98. [PMID: 21947834]

Zeller JL et al. JAMA patient page. Cancer chemotherapy. JAMA. 2008 Jun 11;299(22):2706. [PMID: 18544731]

40

Clinical Genetic Disorders

Reed E. Pyeritz, MD, PhD

ACUTE INTERMITTENT PORPHYRIA



ESSENTIALS OF DIAGNOSIS

- ▶ Unexplained abdominal crisis, generally in young women.
- ▶ Acute peripheral or central nervous system dysfunction.
- ▶ Recurrent psychiatric illnesses.
- ▶ Hyponatremia.
- ▶ Porphobilinogen in the urine during an attack.

▶ General Considerations

Though there are several different types of porphyrias, the one with the most serious consequences and the one that usually presents in adulthood is acute intermittent porphyria (AIP), which is inherited as an autosomal dominant, though it remains clinically silent in most patients who carry a mutation in *HMBS*. Clinical illness usually develops in women. Symptoms begin in the teens or 20s, but onset can begin after menopause in rare cases. The disorder is caused by partial deficiency of porphobilinogen deaminase activity, leading to increased excretion of aminolevulinic acid and porphobilinogen in the urine. The diagnosis may be elusive if not specifically considered. The characteristic abdominal pain may be due to abnormalities in autonomic innervation in the gut. In contrast to other forms of porphyria, cutaneous photosensitivity is absent in AIP. Attacks are precipitated by numerous factors, including drugs and intercurrent infections. Harmful and relatively safe drugs for use in treatment are listed in Table 40–1. Hyponatremia may be seen, due in part to inappropriate release of antidiuretic hormone, although gastrointestinal loss of sodium in some patients may be a contributing factor.

▶ Clinical Findings

A. Symptoms and Signs

Patients show intermittent abdominal pain of varying severity, and in some instances it may so simulate acute

abdomen as to lead to exploratory laparotomy. Because the origin of the abdominal pain is neurologic, there is an absence of fever and leukocytosis. Complete recovery between attacks is usual. Any part of the nervous system may be involved, with evidence for autonomic and peripheral neuropathy. Peripheral neuropathy may be symmetric or asymmetric and mild or profound; in the latter instance, it can even lead to quadriplegia with respiratory paralysis. Other central nervous system manifestations include seizures, psychosis, and abnormalities of the basal ganglia. Hyponatremia may further cause or exacerbate central nervous system manifestations.

B. Laboratory Findings

Often there is profound hyponatremia. The diagnosis can be confirmed by demonstrating an increased amount of porphobilinogen in the urine during an acute attack. Freshly voided urine is of normal color but may turn dark upon standing in light and air.

Most families have a different mutation in the porphobilinogen deaminase gene causing AIP. Mutations can be detected and used for presymptomatic and prenatal diagnosis.

▶ Prevention

Avoidance of factors known to precipitate attacks of AIP—especially drugs—can reduce morbidity. Sulfonamides and barbiturates are the most common culprits; others are listed in Table 40–1 and on the Internet (www.drugs-porphyria.org). Starvation diets or prolonged fasting also cause attacks and so must be avoided. Hormonal changes during pregnancy can precipitate crises.

▶ Treatment

Treatment with a high-carbohydrate diet diminishes the number of attacks in some patients and is a reasonable empiric gesture considering its benignity. Acute attacks may be life-threatening and require prompt diagnosis, withdrawal of the inciting agent (if possible), and treatment with analgesics and intravenous glucose and hemeatin. A minimum of 300 g of carbohydrate per day should be provided orally or intravenously. Electrolyte balance

Table 40-1. Some of the “unsafe” and “probably safe” drugs used in the treatment of acute porphyrias.

Unsafe	Probably Safe
Alcohol	Acetaminophen
Alkylating agents	β-Adrenergic blockers
Barbiturates	Amitriptyline
Carbamazepine	Aspirin
Chloroquine	Atropine
Chlorpropamide	Chloral hydrate
Clonidine	Chlordiazepoxide
Dapsone	Corticosteroids
Ergots	Diazepam
Erythromycin	Digoxin
Estrogens, synthetic	Diphenhydramine
Food additives	Guanethidine
Glutethimide	Hyoscyne
Griseofulvin	Ibuprofen
Hydralazine	Imipramine
Ketamine	Insulin
Meprobamate	Lithium
Methyldopa	Naproxen
Metoclopramide	Nitrofurantoin
Nortriptyline	Opioid analgesics
Pentazocine	Penicillamine
Phenytoin	Penicillin and derivatives
Progestins	Phenothiazines
Pyrazinamide	Procaine
Rifampin	Streptomycin
Spironolactone	Succinylcholine
Succinimides	Tetracycline
Sulfonamides	Thiouracil
Theophylline	
Tolazamide	
Tolbutamide	
Valproic acid	

requires close attention. Hematin therapy should be undertaken with full recognition of adverse consequences, especially phlebitis and coagulopathy. The intravenous dosage is up to 4 mg/kg once or twice daily. Liver transplantation may provide an option for patients with disease poorly controlled by medical therapy.

► When to Refer

- For management of severe abdominal pain, seizures, or psychosis.
- For preventive management when a patient with porphyria contemplates pregnancy.
- For genetic counseling and molecular diagnosis.

► When to Admit

The patient should be hospitalized when he or she has an acute attack accompanied by mental status changes, seizure, or hyponatremia.

Dar FS et al. Liver transplantation for acute intermittent porphyria: a viable treatment? *Hepatobiliary Pancreat Dis Int.* 2010 Feb;9(1):93–6. [PMID: 20133237]

Pischik E et al. Neurological manifestations of acute intermittent porphyria. *Cell Mol Biol (Noisy-le-Grand).* 2009 Feb 16;55(1):72–83. [PMID: 19268005]

ALKAPTONURIA



ESSENTIALS OF DIAGNOSIS

- Ochronosis (gray-black discoloration of connective tissue, including the sclerae, ears, and cartilage).
- Characteristic radiologic changes in the spine, with radiodense intervertebral discs.
- Arthropathy.
- Urine darkens on standing.

► Clinical Findings

A. Symptoms and Signs

Alkaptonuria is caused by a recessively inherited deficiency of the enzyme homogentisic acid oxidase. This acid derives from metabolism of both phenylalanine and tyrosine and is present in large amounts in the urine throughout the patient's life. An oxidation product accumulates slowly in cartilage throughout the body, leading to degenerative joint disease of the spine and peripheral joints. Indeed, examination of patients in the third and fourth decades shows a slight darkish blue color below the skin in areas overlying cartilage, such as in the ears, a phenomenon called **ochronosis**. In some patients, a more severe hyperpigmentation can be seen in the sclera, conjunctiva, and cornea. Accumulation of metabolites in heart valves can lead to aortic or mitral stenosis. A predisposition to coronary artery disease may also be present. Although the syndrome causes considerable morbidity, life expectancy is reduced only modestly. Symptoms are more often attributable to spondylitis with back pain, leading to a clinical picture difficult to distinguish from that of ankylosing spondylitis, though on radiographic assessment the sacroiliac joints are not fused in alkaptonuria.

B. Laboratory Findings

The diagnosis is established by demonstrating homogentisic acid in the urine, which turns black spontaneously on exposure to the air; this reaction is particularly noteworthy if the urine is alkaline or when alkali is added to a specimen. Molecular analysis of the homogentisic acid oxidase gene (*HGD*) is available but not necessary for diagnosis.

► Prevention

Carrier screening and prenatal diagnosis are possible by testing for genetic mutations.

► Treatment

Treatment of the arthritis is similar to that for other arthropathies. Though, in theory, rigid dietary restriction might reduce accumulation of the pigment, this has not proved to be of practical benefit.

Al-Mahfoudh R et al. Alkaptonuria presenting with ochronotic spondyloarthropathy. *Br J Neurosurg.* 2008 Dec;22(6):805–7. [PMID: 19085367]

Vilboux T et al. Mutation spectrum of homogentisic acid oxidase (HGD) in alkaptonuria. *Hum Mutat.* 2009 Dec;30(12):1611–9. [PMID: 19862842]

DOWN SYNDROME



ESSENTIALS OF DIAGNOSIS

- ▶ Typical craniofacial features (flat occiput, epicanthal folds, large tongue).
- ▶ Mental retardation.
- ▶ Congenital heart disease (eg, atrioventricular canal defects) in 50% of patients.
- ▶ Three copies of chromosome 21 (trisomy 21) or a chromosome rearrangement that results in three copies of a region of the long arm of chromosome 21.

► Clinical Findings

A. Symptoms and Signs

Down syndrome is usually diagnosed at birth on the basis of the typical craniofacial features, hypotonia, and single palmar crease. Several serious problems that may be evident at birth or may develop early in childhood include duodenal atresia, congenital heart disease (especially atrioventricular canal defects), and hematologic malignancy. The intestinal and cardiac anomalies usually respond to surgery. A transient neonatal leukemia generally responds to conservative management. The incidences of both acute lymphoblastic and myeloid leukemias are increased in childhood. Intelligence varies across a wide spectrum. Many people with Down syndrome do well in sheltered workshops and group homes, but few achieve full independence in adulthood. Other frequent complications include atlanto-axial instability, celiac disease, and hypothyroidism. An Alzheimer-like dementia usually becomes evident in the fourth or fifth decade. Patients with Down syndrome who survive childhood and who develop dementia have a reduced life expectancy; on average, they live to about age 55 years.

B. Laboratory Findings

Cytogenomic analysis should always be performed—even though most patients will have simple trisomy for chromosome 21—to detect unbalanced translocations; such patients may have a parent with a balanced translocation, and there

will be a substantial recurrence risk of Down syndrome in future offspring of that parent and potentially that parent's relatives.

► Prevention

Nearly 0.5% of all human conceptions are trisomic for chromosome 21. Because of increased fetal mortality, birth incidence of Down syndrome is 1 per 700 but varies from 1 per 1000 in young mothers to more than three times as frequent in women of advanced maternal age. The presence of a fetus with Down syndrome can be detected in many pregnancies in the first or early second trimester through screening maternal serum for α -fetoprotein and other biomarkers (“multiple marker screening”) and by detecting increased nuchal thickness and underdevelopment of the nasal bone on fetal ultrasound. The risk of bearing a child with Down syndrome increases exponentially with the age of the mother at conception and begins a marked rise after age 35. By age 45 years, the odds of having an affected child are as high as 1 in 40. The risk of other conditions associated with trisomy also increases, because of the predisposition of older oocytes to nondisjunction during meiosis. There is little risk of trisomy associated with increased paternal age. However, older men do have an increased risk of fathering a child with a new autosomal dominant condition. Because there are so many distinct conditions, though, the chance of fathering an offspring with any given one is extremely small.

► Treatment

Duodenal atresia should be treated surgically. Congenital heart disease should be treated as in any other patient. No medical treatment has been proven to affect the intellectual capacity.

► When to Refer

- For comprehensive evaluation of infants to investigate congenital heart disease, hematologic malignancy, and duodenal atresia.
- For genetic counseling of the parents.
- For signs of dementia in an adult patient.

► When to Admit

An affected young patient should be hospitalized when he or she has failure to thrive, regurgitation, breathlessness, or easy bruising.

Andriolo RB et al. Aerobic exercise training programmes for improving physical and psychosocial health in adults with Down syndrome. *Cochrane Database Syst Rev.* 2010 May 12;5:CD005176. [PMID: 20464738]

Driscoll DA et al; Professional Practice and Guidelines Committee. First trimester diagnosis and screening for fetal aneuploidy. *Genet Med.* 2008 Jan;10(1):73–4. [PMID: 18197059]

Lott IT et al. Cognitive deficits and associated neurological complications in individuals with Down's syndrome. *Lancet Neurol.* 2010 Jun;9(6):623–33. [PMID: 20494326]

Mégarbané A et al. The 50th anniversary of the discovery of trisomy 21: the past, present, and future of research and

treatment of Down syndrome. *Genet Med.* 2009 Sept;11(9):611–16. [PMID: 19636252]

Wiseman FK et al. Down syndrome—recent progress and future prospects. *Hum Molec Genet.* 2009 Apr 15;18(R1):R75–83. [PMID: 19297404]

FRAGILE X MENTAL RETARDATION



ESSENTIALS OF DIAGNOSIS

- ▶ Expanded trinucleotide repeat in the *FMR1* gene.
- ▶ Mental retardation and autism in males.
- ▶ Large testes after puberty.
- ▶ Learning disabilities or mental retardation in females.
- ▶ Premature ovarian failure.
- ▶ Late-onset tremor and ataxia in males and females with moderate trinucleotide repeat expansion (premutation carriers).

▶ Clinical Findings

A. Symptoms and Signs

This X-linked condition accounts for more cases of mental retardation in males than any condition except Down syndrome; about 1 in 5000 males is affected. The condition also affects intellectual function in females, although less severely and about 50% less frequently than in males. Affected (heterozygous) young women show no physical signs other than early menopause, but they may have learning difficulties or frank retardation. Affected males show macro-orchidism (enlarged testes) after puberty, large ears and a prominent jaw, a high-pitched voice, autistic characteristics, and mental retardation. Some males show evidence of a mild connective tissue defect, with joint hypermobility and mitral valve prolapse.

Women who are premutation carriers (55–200 CGG repeats) are at increased risk for premature ovarian failure and mild cognitive abnormalities. Male and female premutation carriers are at risk for mood and anxiety disorders and the development of tremor and ataxia beyond middle age (fragile-X tremor-ataxia syndrome, FXTAS). Changes in the cerebellar white matter may be evident on MRI before symptoms appear. Because of the relatively high prevalence of premutation carriers in the general population, older people in whom any of these behavioral or neurologic problems develop should undergo testing of the *FMR1* locus.

B. Laboratory Findings

The first marker for this condition was a small gap, or fragile site, evident near the tip of the long arm of the X chromosome. Subsequently, the condition was found to be due to expansion of a trinucleotide repeat (CGG) near a gene called *FMR1*. All individuals have some CGG repeats in

this location, but as the number increases beyond 52, the chances of further expansion during spermatogenesis or oogenesis increase.

Being born with one *FMR1* allele with 200 or more repeats results in mental retardation in most men, and in about 60% of women. The more repeats, the greater the likelihood that further expansion will occur during gameto-genesis; this results in anticipation, in which the disorder can worsen from one generation to the next.

▶ Prevention

DNA diagnosis for the number of repeats has supplanted cytogenetic analysis for both clinical and prenatal diagnosis. This should be done on any male or female who has unexplained mental retardation. Newborn screening based on hypermethylation of the *FMR1* gene is being considered as a means of early detection and intervention.

▶ Treatment

No specific treatments have been developed but several based on the mouse model are in development. Valproic acid may reduce symptoms of hyperactivity and attention deficit, but standard therapies should be tried first.

▶ When to Refer

- For otherwise unexplained mental retardation or learning difficulties in boys and girls.
- For otherwise unexplained tremor or ataxia in middle-aged individuals.
- For premature ovarian failure.
- For genetic counseling.

Bourgeois JA et al. A review of fragile X premutation disorders: expanding the psychiatric perspective. *J Clin Psychiatry.* 2009 Jun;70(6):852–62. [PMID: 19422761]

Coffee B et al. Incidence of fragile X syndrome by newborn screening for methylated *FMR1* DNA. *Am J Hum Genet.* 2009 Oct;85(4):503–14. [PMID: 19804849]

Martin JR et al. Fragile X and reproduction. *Curr Opin Obstet Gynecol.* 2008 Jun;20(3):216–20. [PMID: 18460934]

Sutherland GR et al. Fragile X syndrome and other causes of X-linked mental handicap. In: Rimoin DL et al (editors). *Emery and Rimoin's Principles and Practice of Medical Genetics*, 5th ed. Philadelphia: Churchill Livingstone, 2007.

Torrioli M et al. Treatment with valproic acid ameliorates ADHD symptoms in fragile X syndrome boys. *Am J Med Genet A.* 2010 Jun;152A(6):1420–7. [PMID: 20503316]

GAUCHER DISEASE



ESSENTIALS OF DIAGNOSIS

- ▶ Deficiency of β -glucocerebrosidase.
- ▶ Anemia and thrombocytopenia.
- ▶ Hypersplenism.
- ▶ Pathologic fractures.

► Clinical Findings

A. Symptoms and Signs

Gaucher disease has an autosomal recessive pattern of inheritance. A deficiency of β -glucocerebrosidase causes an accumulation of sphingolipid within phagocytic cells throughout the body. Anemia and thrombocytopenia are common and may be symptomatic; both are due primarily to hypersplenism, but marrow infiltration with Gaucher cells may be a contributing factor. Cortical erosions of bones, especially the vertebrae and femur, are due to local infarctions, but the mechanism is unclear. Episodes of bone pain (termed “crises”) are reminiscent of those in sickle cell disease. A hip fracture in a patient with a palpable spleen—especially in a Jewish person of Eastern European origin—suggests the possibility of Gaucher disease.

Two uncommon forms of Gaucher disease, called type II and type III, involve neurologic accumulation of sphingolipid and a variety of neurologic problems. Type II is of infantile onset and has a poor prognosis. Heterozygotes for Gaucher disease are at increased risk for developing Parkinson disease.

B. Laboratory Findings

Bone marrow aspirates reveal typical Gaucher cells, which have an eccentric nucleus and periodic acid–Schiff (PAS)-positive inclusions, along with wrinkled cytoplasm and inclusion bodies of a fibrillar type. In addition, the serum acid phosphatase is elevated. Definitive diagnosis requires the demonstration of deficient glucocerebrosidase activity in leukocytes. Hundreds of mutations have been found to cause Gaucher disease and some are highly predictive of the neuronopathic forms. Thus, mutation detection, especially in a young person, is of potential value. Only four mutations in glucocerebrosidase account for more than 90% of the disease among Ashkenazi Jews, in whom the carrier frequency is 1:15.

► Prevention

Most clinical complications can be prevented by early institution of enzyme replacement therapy. Carrier screening, especially among Ashkenazi Jews, detects those couples at 25% risk of having an affected child. Prenatal diagnosis through mutation analysis is feasible.

► Treatment

For many years, treatment was supportive and included splenectomy for thrombocytopenia secondary to platelet sequestration. A recombinant form of the enzyme glucocerebrosidase (imiglucerase) for intravenous administration on a regular basis now permits a reduction in total body stores of glycolipid and improvement in orthopedic and hematologic manifestations. Unfortunately, the neurologic manifestations of types II and III have not improved with enzyme replacement therapy. The major drawback is the exceptional cost of imiglucerase, which can exceed \$100,000

per year for a severely affected patient. Early treatment of affected children normalizes growth and bone mineral density and improves liver and spleen size, anemia, and thrombocytopenia. Alternative or complementary therapies, including methods to reduce substrate and to provide a chaperone for a defective enzyme, are being developed. One approved medication, miglustat, does reduce the production of glucocerebrosidase in some patients, but can be poorly tolerated because of adverse effects.

Andersson H et al. Eight-year clinical outcomes of long-term enzyme replacement therapy for 884 children with Gaucher disease type I. *Pediatrics*. 2008 Dec;122(6):1182–90. [PMID: 19047232]

Cox TM et al. Management of non-neuronopathic Gaucher disease with special reference to pregnancy, splenectomy, bisphosphonate therapy, use of biomarkers and bone disease monitoring. *J Inherit Metab Dis*. 2008 Jun;31(3):319–36. [PMID: 18509745]

Piran S et al. Gaucher disease: a systematic review and meta-analysis of bone complications and their response to treatment. *J Inherit Metab Dis*. 2010 Jun;33(3):271–9. [PMID: 20336376]

Sidransky E et al. Multicenter analysis of glucocerebrosidase mutation in Parkinson's disease. *N Engl J Med*. 2009 Oct 22;361(17):1651–61. [PMID: 19846850]

Zimran A et al. Phase 1/2 and extension study of velaglucerase alfa replacement therapy in adults with type 1 Gaucher disease: 48-month experience. *Blood*. 2010 Jun 10;115(23):4651–6. [PMID: 20299511]

DISORDERS OF HOMOCYSTEINE METABOLISM



ESSENTIALS OF DIAGNOSIS

- For homocystinuria, dislocated ocular lenses.
- Elevated homocysteine in the urine or plasma.

► General Considerations

Considerable evidence has accumulated to support the observation that patients with clinical and angiographic evidence of coronary artery disease tend to have higher levels of plasma homocysteine than persons without coronary artery disease. The relationship has been extended to cerebrovascular and peripheral vascular diseases. Although this effect was initially thought to be due at least in part to heterozygotes for cystathionine β -synthase deficiency (see below), there is little supporting evidence. Rather, an important factor leading to hyperhomocysteinemia is folate deficiency. Pyridoxine (vitamin B₆) and vitamin B₁₂ are also important in the metabolism of methionine, and deficiency of any of these vitamins can lead to accumulation of homocysteine. A number of genes influence utilization of these vitamins and can predispose to deficiency. For example, having one—and especially two—copies of an allele that causes thermolability of methylene tetrahydrofolate

reductase predisposes people to elevated fasting homocysteine levels. Both nutritional and most genetic deficiencies of these vitamins can be corrected by dietary supplementation of folic acid and, if serum levels are low, vitamins B₆ and B₁₂. In the United States, cereal grains are fortified with folic acid. However, therapy with B vitamins and folate lowers homocysteine levels significantly but does not reduce the risk of either venous thromboembolism or complications of coronary artery disease. The role of lowering homocysteine as primary prevention for sequelae of atherosclerosis has received little direct support in clinical trials. Hyperhomocysteinemia occurs with end-stage chronic kidney disease.

► Clinical Findings

A. Symptoms and Signs

Homocystinuria in its classic form is caused by cystathionine β-synthase deficiency and exhibits an autosomal recessive pattern of inheritance. This results in extreme elevations of plasma and urinary homocystine levels, a basis for diagnosis of this disorder. Homocystinuria is similar in certain superficial aspects to Marfan syndrome, since patients may have a similar body habitus and ectopia lentis is almost always present. However, mental retardation is often present in homocystinuria, and the cardiovascular events are those of repeated venous and arterial thromboses whose precise cause remains obscure. Life expectancy is reduced, especially in untreated and pyridoxine-unresponsive patients; myocardial infarction, stroke, and pulmonary embolism are the most common causes of death. This condition is diagnosed by newborn screening for hypermethioninemia; however, pyridoxine-responsive infants may not be detected. The diagnosis should be suspected in patients in the second and third decades of life who have arterial or venous thromboses without other risk factors.

B. Laboratory Findings

Although many mutations have been identified in the cystathionine β-synthase gene (*CBC*), amino acid analysis of plasma remains the most appropriate diagnostic test. Patients should be studied after they have been off folate or pyridoxine supplementation for at least 1 week. Relatively few laboratories currently provide highly reliable assays for homocysteine. Processing of the specimen is crucial to obtain accurate results. The plasma must be separated within 30 minutes; otherwise, blood cells release the amino acid and the measurement will then be artificially elevated.

► Prevention

About 50% of patients have a form of cystathionine β-synthase deficiency that improves biochemically and clinically through pharmacologic doses of pyridoxine (50–500 mg/d) and folate (5–10 mg/d). For these patients, treatment from infancy can prevent retardation and the other clinical problems. Patients who are pyridoxine non-responders must be treated with a dietary reduction in

methionine and supplementation of cysteine, also from infancy. The vitamin betaine is also useful in reducing plasma methionine levels by facilitating a metabolic pathway that bypasses the defective enzyme.

► Treatment

Patients with classic homocystinuria who have suffered venous thrombosis receive anticoagulation therapy, but there are no studies to support prophylactic use of warfarin or antiplatelet agents.

Lee M et al. Efficacy of homocysteine-lowering therapy with folic acid in stroke prevention: a meta-analysis. *Stroke*. 2010 Jun;41(6):1205–12. [PMID: 20413740]

Miller ER 3rd et al. Meta-analysis of folic acid supplementation trials on risk of cardiovascular disease and risk interaction with baseline homocysteine levels. *Am J Cardiol*. 2010 Aug 15;106(4):517–27. [PMID: 20691310]

Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH) Collaborative Group et al. Effects of homocysteine-lowering with folic acid plus vitamin B₁₂ vs placebo on mortality and major morbidity in myocardial infarction survivors: a randomized trial. *JAMA*. 2010 Jun 23;303(24):2486–94. [PMID: 20571015]

Varela-Moreiras G et al. Cobalamin, folic acid and homocysteine. *Nutr Rev*. 2009 May;67(Suppl 1):S69–72. [PMID: 19453682]

KLINFELTER SYNDROME



ESSENTIALS OF DIAGNOSIS

- Males with hypogonadism and small testes.
- 47,XXY karyotype.

► Clinical Findings

A. Symptoms and Signs

Boys with an extra X chromosome are normal in appearance before puberty; thereafter, they have disproportionately long legs and arms, a female escutcheon, gynecomastia, and small testes. Infertility is due to azoospermia; the seminiferous tubules are hyalinized. The diagnosis is often not made until a couple is evaluated for inability to conceive. Mental retardation is somewhat more common than in the general population. Many men with Klinefelter syndrome have learning problems. However, their intelligence usually tests within the broad range of normal. As adults, detailed psychometric testing may reveal a deficiency in executive skills. The risk of breast cancer and diabetes mellitus is much higher in men with Klinefelter syndrome than in 46,XY men.

B. Laboratory Findings

Low serum testosterone is common. The karyotype is typically 47,XXY.

▶ Prevention

Screening for cancer, especially of the breast, and for glucose intolerance are indicated.

▶ Treatment

Treatment with testosterone after puberty is advisable but will not restore fertility. However, men with Klinefelter syndrome have had mature sperm aspirated from their testes and injected into oocytes, resulting in fertilization. After the blastocysts have been implanted into the uterus of a partner, conception has resulted. However, men with Klinefelter syndrome do have an increased risk for aneuploidy in sperm, and therefore genomic analysis of a blastocyst should be considered before implantation.

Gravholt CH. Sex chromosome abnormalities. In: Rimoin DL et al (editors). *Emery and Rimoin's Principles and Practice of Medical Genetics*, 6th ed. Philadelphia: Churchill Livingstone, 2012.

Radicioni AF et al. Strategies and advantages of early diagnosis in Klinefelter's syndrome. *Mol Hum Reprod*. 2010 Jun; 16(6):434–40. [PMID: 20392711]

Ramasamy R et al. Successful fertility treatment for Klinefelter's syndrome. *J Urol*. 2009 Sept;182(3):1108–13. [PMID: 19616796]

Turriff A et al. Prevalence and psychosocial correlates of depressive symptoms among adolescents and adults with Klinefelter syndrome. *Genet Med*. 2011 Nov;13(11):966–72. [PMID: 21799429]

Vignozzi L et al. Clinical and therapeutic aspects of Klinefelter's syndrome: sexual function. *Mol Hum Reprod*. 2010 Jun;16(6):418–24. [PMID: 20348547]

MARFAN SYNDROME



ESSENTIALS OF DIAGNOSIS

- ▶ Disproportionately tall stature, thoracic deformity, and joint laxity or contractures.
- ▶ Ectopia lentis and myopia.
- ▶ Aortic dilation and dissection.
- ▶ Mitral valve prolapse.

▶ General Considerations

Marfan syndrome, a systemic connective tissue disease, has an autosomal dominant pattern of inheritance. It is characterized by abnormalities of the skeletal, ocular, and cardiovascular systems; spontaneous pneumothorax; dural ectasia; and striae atrophicae. Of most concern is disease of the ascending aorta, which begins as a dilated aortic root. Histology of the aorta shows diffuse medial degeneration. Mitral valve leaflets are also abnormal and mitral prolapse and regurgitation may be present, often

with elongated chordae tendineae, which on occasion may rupture.

▶ Clinical Findings

A. Symptoms and Signs

Affected patients are typically tall, with particularly long arms, legs, and digits (arachnodactyly). However, there can be wide variability in the clinical presentation. Commonly, scoliosis and anterior chest deformity, such as pectus excavatum, are found. Ectopia lentis is present in about half of patients; severe myopia is common and retinal detachment can occur. Mitral valve prolapse is seen in about 85% of patients. Aortic root dilation is common and leads to aortic regurgitation or dissection with rupture. To diagnose Marfan syndrome, people with an affected relative need features in at least two systems. People with no family history need features in the skeletal system, two other systems, and one of the major criteria of ectopia lentis, dilation of the aortic root, or aortic dissection. Patients with homocystinuria due to cystathionine synthase deficiency also have dislocated lenses; tall, disproportionate stature; and thoracic deformity. They tend to have below normal intelligence, stiff joints, and a predisposition to arterial and venous occlusive disease. Males with Klinefelter syndrome do not show the typical ocular or cardiovascular features of Marfan syndrome and are generally sporadic occurrences in the family.

B. Laboratory Findings

Mutations in the fibrillin gene (*FBN1*) on chromosome 15 cause Marfan syndrome. Nonetheless, no simple laboratory test is available to support the diagnosis in questionable cases because related conditions may also be due to defects in fibrillin. The nature of the *FBN1* mutation has little predictive value in terms of prognosis. The pathogenesis of Marfan syndrome involves aberrant regulation of transforming growth factor (TGF) β activity. Mutations in either of two receptors for TGF β (TGFBR1 and TGFBR2) can cause conditions that resemble Marfan syndrome in terms of aortic aneurysm and dissection and autosomal dominant inheritance.

▶ Prevention

There is prenatal and presymptomatic diagnosis for patients in whom the molecular defect in fibrillin has been found.

▶ Treatment

Children with Marfan syndrome require regular ophthalmologic surveillance to correct visual acuity and thus prevent amblyopia, and annual orthopedic consultation for diagnosis of scoliosis at an early enough stage so that bracing might delay progression. Patients of all ages require echocardiography at least annually to monitor aortic diameter and mitral valve function. Long-term

β -adrenergic blockade, titrated to individual tolerance but enough to produce a negative inotropic effect (atenolol, 1–2 mg/kg orally daily) retards the rate of aortic dilation. Several clinical trials comparing the effectiveness of atenolol and losartan, a drug that reduces activity of TGF β , are underway. Restriction from vigorous physical exertion protects from aortic dissection. Prophylactic replacement of the aortic root with a composite graft when the diameter reaches 45–50 mm in an adult (normal: < 40 mm) prolongs life. A procedure to reimplant the patient's native aortic valve and replace just the aneurysmal sinuses of Valsalva avoids the need for lifelong anticoagulation.

► Prognosis

People with Marfan syndrome who are untreated commonly die in the fourth or fifth decade from aortic dissection or congestive heart failure secondary to aortic regurgitation. However, because of earlier diagnosis, lifestyle modifications, β -adrenergic blockade, and prophylactic aortic surgery, life expectancy has increased by several decades in the past 25 years.

► When to Refer

- For detailed ophthalmologic examination.
- For at least annual cardiologic evaluation.
- For moderate scoliosis.
- For pregnancy in a woman with Marfan syndrome.
- For genetic counseling.

► When to Admit

Any patient with Marfan syndrome in whom severe or unusual chest pain develops should be hospitalized to exclude pneumothorax and aortic dissection.

Brooke BS et al. Angiotensin II blockade and aortic-root dilation in Marfan's syndrome. *N Engl J Med*. 2008 Jun 26;358(26):2787–95. [PMID: 18579813]

Keane M et al. Medical management of Marfan syndrome. *Circulation*. 2008 May 27;117(21):2802–13. [PMID: 18506019]

Loeys BL et al. The revised Ghent nosology for the Marfan syndrome. *J Med Genet*. 2010 Jul;47(7):476–85. [PMID: 20591885]

Pyeritz RE. Evaluation of the adolescent or adult with some features of Marfan syndrome. *Genet Med*. 2012 Jan;14(1):171–7. [PMID: 22237449]

Pyeritz RE. Marfan syndrome and related disorders. In: Rimoin DL et al (editors). *Emery and Rimoin's Principles and Practice of Medical Genetics*, 6th ed. Philadelphia: Churchill Livingstone, 2012.

Volguina IV et al; Aortic Valve Operative Outcomes in Marfan Patients Study Group. Valve-sparing and valve-replacing techniques for aortic root replacement in patients with Marfan syndrome: analysis of early outcome. *J Thorac Cardiovasc Surg*. 2009 May;137(5):1124–31. [PMID: 19379977]

HEREDITARY HEMORRHAGIC TELANGIECTASIA



ESSENTIALS OF DIAGNOSIS

- Recurrent epistaxis.
- Mucocutaneous telangiectases.
- Visceral arteriovenous malformations (especially lung, liver, brain, bowel).

► Clinical Findings

A. Symptoms and Signs

Hereditary hemorrhagic telangiectasia (HHT), formerly termed “Osler-Weber-Rendu syndrome,” is an autosomal dominant disorder of development of the vasculature. Epistaxis may begin in childhood or later in adolescence. Punctate telangiectases of the lips, tongue, fingers, and skin generally appear in later childhood and adolescence. Arteriovenous malformations (AVMs) can occur at any age in the brain, lungs, and liver. Bleeding from the gastrointestinal tract is due to mucosal vascular malformations and usually is not a problem until mid-adult years or later. Pulmonary AVMs can cause hypoxemia (with peripheral cyanosis, dyspnea, and clubbing) and right-to-left shunting (with embolic stroke or brain abscess). The criteria for diagnosis require presence of three of the following four features: (1) recurrent epistaxis, (2) visceral AVMs, (3) mucocutaneous telangiectases, and (4) being the near relative of a clearly affected individual. Mutation analysis can be used for presymptomatic diagnosis or exclusion of the worry of HHT.

B. Laboratory Findings

MR or CT arteriography detects AVMs. Mutations in at least five genes can cause HHT. Three have been identified and molecular analysis to identify them is available; these mutations in *ENG*, *ALK1*, and *SMAD4* account for about 87% of families with HHT. When the familial mutation is known, molecular testing is far more cost effective than repeated screening of relatives who are at risk.

► Prevention

Embolization of pulmonary AVMs with wire coils or other occlusive devices reduces the risk of stroke and brain abscess. Treatment of brain AVMs reduces the risk of hemorrhagic stroke. All patients with HHT with evidence of a pulmonary shunt should practice routine endocarditis prophylaxis (see Table 33–6). All intravenous lines (except those for transfusion of red blood cells and radiographic contrast) should have an air-filter to prevent embolization of an air bubble. Prenatal diagnosis through mutation detection is possible.

▶ Treatment

All patients in whom the diagnosis of HHT is considered should have an MRI of the brain with contrast. A contrast echocardiogram will detect most pulmonary AVMs when “bubbles” appear on the left side of the heart after 3–6 cardiac cycles. A positive contrast echocardiogram should be followed by a high-resolution CT angiogram for localization of pulmonary AVMs. Patients who have AVMs with a feeding artery of 1–2 mm diameter or greater should undergo embolization. After successful embolization of all treatable pulmonary AVMs, the CT angiogram should be repeated in 3 years. A person with a negative contrast echocardiogram should have the test repeated every 5 years.

Bernhardt BA et al. Cost savings through molecular diagnosis for hereditary hemorrhagic telangiectasia. *Genet Med.* 2012 Jan 26. [Epub ahead of print] [PMID: 22281938]

Faughnan ME et al; HHT Guidelines Working Group. International guidelines for the diagnosis and management of hereditary haemorrhagic telangiectasia. *J Med Genet.* 2011 Feb;48(2):73–87. [PMID: 19553198]

Guttmacher AE et al. Hereditary hemorrhagic telangiectasia. In: Rimoin DL et al (editors). *Emery and Rimoin's Principles and Practice of Medical Genetics*, 6th ed. Philadelphia: Churchill Livingstone, 2012.

McDonald J et al. Hereditary hemorrhagic telangiectasia: an overview of diagnosis, management, and pathogenesis. *Genet Med.* 2011 Jul;13(7):607–16. [PMID: 21546842]

Trerotola SO, Pyeritz RE. PAVM embolization: an update. *AJR Am J Roentgenol.* 2010 Oct;195(4):837–45. [PMID: 20858807]

Sports Medicine & Outpatient Orthopedics

Anthony Luke, MD, MPH, & C. Benjamin Ma, MD

41

GENERAL APPROACH TO MUSCULOSKELETAL INJURIES



ESSENTIALS OF DIAGNOSIS

- ▶ History is most important in diagnosing musculoskeletal problems.
- ▶ The mechanism of injury can explain the pathology and symptoms.
- ▶ Determine whether the injury is traumatic or atraumatic, acute or chronic, high or low velocity (greater velocity suggests more structural damage), or whether any movement aggravates or relieves pain associated with the injury.

▶ General Considerations

Musculoskeletal problems account for about 10–20% of outpatient primary care clinical visits. Orthopedic problems can be classified as traumatic (ie, injury-related) or atraumatic (ie, degenerative or overuse syndromes) as well as acute or chronic. The mechanism of injury is usually the most helpful part of the history in determining the diagnosis.

The onset of symptoms should be elicited. With acute traumatic injuries, patients typically seek medical attention within 1–6 weeks of onset. The patient should describe the exact location of symptoms, which helps determine anatomic structures that may be damaged. If the patient is vague, the clinician can ask the patient to point with one finger only to the point of maximal tenderness.

▶ Clinical Findings

A. Symptoms and Signs

The chief musculoskeletal complaints are typically pain (most common), instability or dysfunction around the joints. Since symptoms and signs are often nonspecific, recognizing the expected combination of symptoms and

physical examination signs can help facilitate the clinical diagnosis. Patients may describe symptoms of “locking” or “catching,” suggesting internal derangement in joints. Symptoms of “instability” or “giving way” suggest ligamentous injury; however, these symptoms may also be due to pain causing muscular inhibition. Constitutional symptoms of fever or weight loss, swelling with no injury, or systemic illness suggest medical conditions (such as infection, cancer, or rheumatologic disease).

Initial evaluation should follow routine trauma guidelines to rule out serious joint injury. However, typical evaluations in the clinic follow the traditional components of the physical examination and should include inspection, palpation, and assessment of range of motion and neurovascular status.

Inspection includes observation of swelling, erythema, atrophy, deformity, and (surgical) scars (remembered by the mnemonic, “SEADS”). The patient should be asked to move joints of concern (see Table 41–1). If motion is asymmetric, the clinician should assess the passive range of motion for any physical limitation.

There are special tests to assess each joint. Typically, **provocative tests** recreate the mechanism of injury with the goal to reproduce the patient’s pain. **Stress tests** apply load to ligaments of concern. Typically, 10 to 15 pounds of force should be applied when performing stress tests. **Functional testing**, including simple tasks performed during activities of daily living, is useful to assess injury severity.

B. Imaging

Bony pathology can be assessed using standard radiographs, although there also may be characteristic soft tissue findings. However, CT scans are the most effective method for visualizing any bony pathology, including morphology of fractures. Nuclear bone scans are now less commonly used but are still valuable for identifying stress injuries, infection, malignancy, or multisite pathology. Positron emission tomography (PET) scans are useful in identifying metastatic malignant lesions. MRI provides excellent visualization of ligaments, cartilage, and soft tissues. Gadolinium contrast can be injected as an MRI arthrogram to increase sensitivity

of detecting certain internal derangements in joints such as labral injuries. Musculoskeletal ultrasound, where available, can be useful for identifying superficial tissue problems, including tendinopathies and synovial problems.

C. Special Tests

Arthrocentesis must be performed promptly to rule out an infection when acute knee pain with effusion and inflammation are present and the patient is unable to actively flex the joint. The joint fluid should be sent for cell count, crystal analysis, and culture. Arthrocentesis and joint fluid analysis demonstrating crystals can lead to the diagnosis of gout (negatively birefringent, needle-shaped crystals) or pseudogout (positively birefringent, rectangular-shaped crystals). In large, uncomfortable knee joint effusions, removal of excessive joint fluid may improve joint range of motion (flexion) and patient comfort. To avoid infecting the joint, arthrocentesis should not be performed when there is an active cellulitis or abscess overlying the joint. It is also contraindicated if there is a significant coagulopathy (INR > 3.0). Markers of inflammation such as complete blood cell count, erythrocyte sedimentation rate, and C-reactive protein, and rheumatologic tests are useful in evaluating for infectious, oncologic, or rheumatologic processes. Electrodiagnostic studies such as electromyography and nerve conduction studies are useful when there are neurologic concerns; they can also help with prognostication in chronic conditions.

► Treatment

While most outpatient musculoskeletal problems are best treated conservatively, the first consideration is whether there is an immediate surgical need. Surgical treatment is chosen when the outcome promises better health, restoration of function, and improved quality of life. During surgery, the musculoskeletal problem is usually repaired, removed, realigned, reconstructed, or replaced (eg, joint replacement).

If surgery is not immediately indicated, conservative treatment in the outpatient setting usually includes modification of activities, ice, compression, and elevation (remembered by the mnemonic, “MICE”). Controlling pain is an early concern for most patients. Commonly prescribed medications are analgesics (nonsteroidal anti-inflammatory drugs [NSAIDs], acetaminophen, or opioids). Other medications that may also be prescribed, albeit less commonly, are muscle relaxants or co-analgesics for neuropathic pain (which include the calcium channel α_2 - δ ligands [eg, gabapentin] or tricyclic antidepressants). Topical medications, such as capsaicin cream or patch, lidocaine patches, and NSAID patches, can help provide superficial local pain relief.

Immobilization by casting, slings, and braces is helpful to protect an injured limb. Crutches are useful to reduce weight bearing. Rehabilitation and physical therapy are frequently needed. Other modalities commonly used by patients include chiropractic manipulation, massage therapy, acupuncture, and osteopathy.

► When to Refer

Indications for *emergency* referral (immediate)

- Neurovascular injury.
- Fractures (open, unstable).
- Unreduced joint dislocation.
- Septic arthritis.

Indications for *urgent* referral (within 7 days)

- Fractures (closed, stable).
- Reduced joint dislocation.
- “Locked” joint (inability to fully extend a joint due to mechanical derangement, usually a loose body or torn cartilage).
- Tumor.

Indications for *early* orthopedic assessment (2–4 weeks)

- Motor weakness (neurologic).
- Constitutional symptoms (eg, fever not due to septic arthritis, weight loss).
- Multiple joint involvement.

Indications for *routine* orthopedic assessment (for further management)

- Failure of conservative treatment (persistent symptoms > 3 months).
- Persistent numbness and tingling in an extremity.

Ma L et al. Acute monoarthritis: what is the cause of my patient's painful swollen joint? CMAJ. 2009 Jan 6;180(1):59–65. [PMID: 19124791]

SHOULDER

1. Subacromial Impingement Syndrome



ESSENTIALS OF DIAGNOSIS

- Shoulder pain with overhead motion.
- Night pain with sleeping on shoulder.
- Pain with internal rotation.
- Numbness and pain radiation below the elbow are usually due to cervical spine disease.

► General Considerations

The chief complaints for shoulder problems are usually pain, instability, weakness, or loss of range of motion. With any shoulder problem, it is important to establish the patient's hand dominance, occupation, and recreational activities because shoulder injuries may present differently depending on the demands placed on the shoulder joint.

For example, baseball pitchers with impingement syndrome may complain of pain while throwing. Alternatively, elders with even full thickness rotator cuff tears may not complain of any pain because the demands on the joint are low.

The subacromial impingement syndrome describes a collection of diagnoses that cause mechanical inflammation in the subacromial space. Causes of impingement syndrome can be related to muscle strength imbalances, poor scapula control, rotator cuff tears, and subacromial bone spurs.

▶ Clinical Findings

A. Symptoms and Signs

Shoulder problems classically present with one or more of the following: pain with overhead activities, nocturnal pain with sleeping on the shoulder, or pain on internal rotation (eg, putting on a jacket or bra). On inspection, there may be appreciable atrophy in the supraspinatus or infraspinatus fossa. The patient with impingement syndrome can have mild scapula winging or “dyskinesis.” The patient often has a rolled-forward shoulder posture or head-forward posture. On palpation, the patient can have tenderness over the anterolateral shoulder at the edge of the greater tuberosity. The patient may lack full active range of motion (Table 41–1) but should have preserved passive range of motion. Impingement symptoms can be elicited with the Neer and Hawkins impingement signs (Table 41–1).

B. Imaging

The following four radiographic views should be ordered to evaluate subacromial impingement syndrome: the anteroposterior scapula, the anteroposterior acromioclavicular joint, the lateral scapula (scapular Y), and the axillary lateral. The anteroposterior scapula view can rule out glenohumeral joint arthritis. The anteroposterior acromioclavicular view evaluates the acromioclavicular joint for inferior spurs. The scapula Y view evaluates the acromial shape, and the axillary lateral view visualizes the glenohumeral joint as well and for the presence of os acromiale.

MRI of the shoulder may demonstrate full or partial thickness tears or tendinosis. Ultrasound evaluation may demonstrate thickening of the rotator cuff tendons and tendinosis. Tears may also be visualized, although it is more difficult to identify partial tears from small full thickness on ultrasound than on MRI.

▶ Treatment

A. Conservative

The first-line treatment for impingement syndrome is usually a conservative approach with education, activity modification, and physical therapy exercises. Impingement syndrome can be caused by muscle weakness or tear. Rotator cuff muscle strengthening can alleviate weakness or pain, unless the tendons are seriously compromised, which may cause more symptoms. Physical therapy is directed at rotator cuff muscle strengthening, scapula stabilization, and postural exercises. There is no strong

evidence supporting the effectiveness of ice and NSAID therapy. In a 2004 Cochrane review, corticosteroid injections produced slightly better relief of symptoms in the short-term when compared with placebo. Most patients respond well to conservative treatment.

B. Surgical

Procedures include arthroscopic acromioplasty with coracoacromial ligament release, bursectomy, or debridement or repair of rotator cuff tears.

▶ When to Refer

- Failure of conservative treatment over 3 months.
- Young and active patients with impingement due to full thickness rotator cuff tears.

Hegedus EJ et al. Physical examination tests of the shoulder: a systematic review with meta-analysis of individual tests. *Br J Sports Med.* 2008 Feb;42(2):80–92. [PMID: 17720798]
Kuhn JE. Exercise in the treatment of rotator cuff impingement: a systematic review and a synthesized evidence-based rehabilitation protocol. *J Shoulder Elbow Surg.* 2009 Jan–Feb; 18(1):138–60. [PMID: 18835532]

2. Rotator Cuff Tears



ESSENTIALS OF DIAGNOSIS

- ▶ A common cause of shoulder impingement syndrome after age 40.
- ▶ Difficulty lifting the arm with limited active range of motion.
- ▶ Weakness with resisted strength testing suggests full thickness tears.

▶ General Considerations



Rotator cuff tears can be caused by acute injuries related to falls on an outstretched arm or to pulling on the shoulder. It can also be related to chronic repetitive injuries with overhead movement and lifting. Partial rotator cuff tears are one of the major reasons for impingement syndrome. Full thickness rotator cuff tears are usually more symptomatic and may require surgical treatment. The most commonly torn tendon is the supraspinatus.

▶ Clinical Findings

A. Symptoms and Signs




Most patients complain of weakness or pain with overhead movement. Night pain is also a common complaint. The clinical findings with rotator cuff tears include those of the impingement syndrome except that with full-thickness rotator cuff tears there may be more obvious weakness noted with light resistance testing of specific rotator cuff muscles. Supraspinatus tendon strength is tested with

Table 41-1. Shoulder examination.

Maneuver	Description
Inspection	Check the patient's posture and "SEADS" (swelling, erythema, atrophy, deformity, surgical scars).
Palpation	Include important landmarks: acromioclavicular (AC) joint, long head of biceps tendon, coracoid, and greater tuberosity (supraspinatus insertion).
Range of motion testing	Check range of motion actively (patient performs) and passively (clinician performs).
Flexion  <p>A line drawing of a person's upper body from the side, performing shoulder flexion. A vertical dashed line represents the midline. The arm is raised forward and upward. An arc indicates a 180-degree angle from the vertical to the arm's position. Another arc indicates a 150-degree angle from the vertical to the arm's position.</p>	Move the arm forward as high as possible in the sagittal plane .
External rotation  <p>A line drawing of a person's upper body from the front, performing shoulder external rotation. The arm is raised forward. A dashed line represents the midline. An arc indicates a 50-degree angle of external rotation. Another arc indicates a 70-degree angle from the midline to the arm's position.</p>	Check the patient's elbow touching their body so that external rotation occurs predominantly at the glenohumeral joint.




(continued)

Table 41-1. Shoulder examination. (continued)

Maneuver	Description
<p>Internal rotation</p> 	<p>The patient is asked to reach the thumbs as high as possible behind the spine on each side. The clinician can record the highest spinous process that the individual can reach on each side (iliac crest = L4, inferior angle of scapula = T8).</p>
<p>Rotator cuff strength testing</p> <p>Supraspinatus (open can) test</p> 	<p>Perform resisted shoulder abduction at 90 degrees with slight forward flexion to around 45 degrees to test for supraspinatus tendon strength ("open can" test), or with shoulder abduction at 30 degrees and flexion to 30 degrees ("empty can" test).</p>
<p>External rotation</p> 	<p>The patient resists by externally rotating the arms with elbows at his or her side.</p>




(continued)

Table 41-1. Shoulder examination. (continued)

Maneuver	Description
<p data-bbox="107 290 348 316">Internal rotation (lift off test)</p> 	<p data-bbox="820 290 1249 445">A positive “lift-off” test is the inability of the patient to hold his or her hand away from the body when reaching toward the small of the back. The clinician pushes the patient’s hand toward the back while the patient resists. A positive lift-off indicates subscapularis tendon insufficiency.</p>
<p data-bbox="107 733 248 788">Internal rotation (belly press test)</p> 	<p data-bbox="820 733 1259 838">A positive “belly-press” test is the inability to hold the elbow in front of the trunk while pressing down with the hand on the belly. A positive belly press test indicates subscapularis tendon insufficiency.</p>
Impingement tests	
<p data-bbox="107 1237 300 1264">Neer impingement sign</p> 	<p data-bbox="820 1237 1236 1366">Perform by having the clinician flex the shoulder maximally in an overhead position. The test is positive when pain is reproduced with full passive shoulder flexion. Sensitivity is 79%; specificity is 53%.</p>


(continued)

Table 41-1. Shoulder examination. (continued)

Maneuver	Description
<p>Hawkins impingement sign</p> 	<p>Perform with the shoulder forward flexed 90 degrees and the elbow flexed at 90 degrees. The shoulder is then maximally internally rotated to impinge the greater tuberosity on the undersurface of the acromion. The test is considered positive when the patient's pain is reproduced by this maneuver. Sensitivity is 79%; specificity is 59%.</p>
Stability tests	
<p>Apprehension test</p> 	<p>With persistent anterior instability or a recent dislocation, the patient feels pain or guards when the shoulder is abducted and externally rotated at 90 degrees. With posterior instability, the patient is apprehensive with the shoulder forward flexed and internally rotated to 90 degrees with a posteriorly directed force.</p>
<p>Load and shift test</p> 	<p>Perform to determine shoulder instability by manually translating the humeral head anteriorly and posteriorly in relation to the glenoid. However, this test can be difficult to perform when the patient is not relaxed.</p>

(continued)

Table 41-1. Shoulder examination. (continued)

Maneuver	Description
<p>O'Brien test</p> 	<p>Performed to rule out labral cartilage tears that often occur following a shoulder subluxation or dislocation. The test involves flexing the patient's arm to 90 degrees, fully internally rotating the arm so the thumb is facing down (palm down) and adducting the arm to 10 degrees. Once positioned properly, the clinician applies downward force and asks the patient to resist. The test is then repeated in the same position except that the patient has his arm fully supinated (palm up). A positive O'Brien test for labral tear is pain deep in the shoulder with palm down more than the palm up.</p> <p>The O'Brien test can also be used to identify AC joint pathology. The patient would typically complain equally of pain directly over the AC joint with the palm down or up.</p>

resisted shoulder abduction at 90 degrees with slight forward flexion to around 45 degrees ("open can" test) (Table 41-1). Infraspinatus/teres minor strength is tested with resisted shoulder external rotation with shoulder at 0 degrees abduction, elbow by side (Table 41-1). Subscapularis strength is tested with the "lift-off" or "belly-press" tests (Table 41-1). The affected patient usually also has positive Neer and Hawkins impingement tests.

B. Imaging

Recommended radiographs are very similar to impingement syndrome: anteroposterior scapula (glenohumeral), axillary lateral, supraspinatus outlet, and anteroposterior acromioclavicular joint views. The anteroposterior scapula view is useful in visualizing rotator cuff tears because degenerative changes can appear between the acromion and greater tuberosity of the shoulder. Axillary lateral views show superior elevation of the humeral head in relation to the center of the glenoid. Supraspinatus outlet views allow evaluation of the shape of the acromion. High-grade acromial spurs are associated with a higher incidence of rotator cuff tears. The anteroposterior acromioclavicular joint view evaluates for the presence of acromioclavicular

joint arthritis, which can mimic rotator cuff tears, and for spurs that can cause rotator cuff injuries.

MRI is the best method for visualizing rotator cuff tears. The MR arthrogram can show partial or small (< 1 cm) rotator cuff tears. For patients who cannot undergo MRI testing or when postoperative artifacts limit MRI evaluations, ultrasonography can be helpful.

► Treatment

Partial rotator cuff tears may heal with scarring. Most partial rotator cuff tears can be treated with physical therapy and scapular and rotator cuff muscle strengthening. Physical therapy can strengthen the remaining muscles to compensate for loss of strength. Physical therapy is also an option for older sedentary patients. On the contrary, **full-thickness rotator cuff tears** do not heal well and have a tendency to progress with time. Most young active patients with acute, full-thickness tears should be treated with operative fixation.

Subscapularis tendon injuries warrant different treatment. Full-thickness subscapularis tendon tears should undergo surgical repair as they usually lead to premature osteoarthritis of the shoulder.

▶ When to Refer

- Young and active patients with full thickness rotator cuff tears.
- Partial tears with > 50% involvement and with significant pain.
- Older and sedentary patients with full-thickness rotator cuff tears who have not responded to nonoperative treatment.
- Full thickness subscapularis tears.

Kim HM et al. Shoulder strength in asymptomatic individuals with intact compared with torn rotator cuffs. *J Bone Joint Surg Am.* 2009 Feb;91(2):289–96. [PMID: 19181972]

Mall NA et al. Symptomatic progression of asymptomatic rotator cuff tears: a prospective study of clinical and sonographic variables. *J Bone Joint Surg Am.* 2010 Nov;92(16):2623–33. [PMID: 21084574]

Pedowitz RA et al; American Academy of Orthopaedic Surgeons. Optimizing the management of rotator cuff problems. *J Am Acad Orthop Surg.* 2011 Jun;19(6):368–79. [PMID: 21628648]

Yadav H et al. Rotator cuff tears: pathology and repair. *Knee Surg Sports Traumatol Arthrosc.* 2009 Apr;17(4):409–21. [PMID: 19104772]

3. Shoulder Dislocation & Instability



ESSENTIALS OF DIAGNOSIS

- ▶ Most dislocations (95%) are in the anterior direction.
- ▶ Pain and apprehension with an unstable shoulder that is abducted and externally rotated.
- ▶ Acute shoulder dislocations should be reduced as quickly as possible, using manual relocation techniques if necessary.

▶ General Considerations

The shoulder is a ball and socket joint, similar to the hip. However, the bony contours of the shoulder bones are much different than the hip. Overall, the joint has much less stability than the hip, allowing greater movement and action. Stabilizing the shoulder joint relies heavily on rotator cuff muscle strength and also scapular control. Ninety five percent of the shoulder dislocations/instability occur in the anterior direction. Dislocations usually are caused by a fall on an outstretched and abducted arm. Patients complain of pain and feeling of instability when the arm is in the abducted and externally rotated position. Posterior dislocations are usually caused by falls from a height, epileptic seizures, or electric shocks. Traumatic shoulder dislocation can lead to instability. The rate of repeated dislocation is directly related to the patient's age: patients age 21 years or younger have a 70–90% risk of redislocation, whereas patients age 40 years or older have a much lower rate (20–30%). Ninety percent of young active individuals who had traumatic shoulder dislocation have labral injuries often described as Bankart lesions when the anterior inferior labrum is torn,

which can lead to continued instability. Older patients (over age 55 years) are more likely to have rotator cuff tears or fractures following dislocation. Atraumatic shoulder dislocations are usually caused by intrinsic ligament laxity or repetitive microtrauma leading to joint instability. This is often seen in swimmers, gymnasts, and pitchers as well as other athletes involved in overhead and throwing sports.

▶ Clinical Findings

A. Symptoms and Signs

For acute traumatic dislocations, patients usually have an obvious deformity with the humeral head dislocated anteriorly. The patient holds the shoulder and arm in an externally rotated position. The patient complains of acute pain and deformity that are improved with manual relocation of the shoulder. Reductions are usually performed in the emergency department. Even after reduction, the patient will continue to have limited range of motion and pain especially following a first-time shoulder dislocation.

Patients with recurrent dislocations can have less pain with subsequent dislocations. Posterior dislocations can be easily missed because the patient usually holds the shoulder and arm in an internally rotated position, which makes the shoulder deformity less obvious. Patients complain of difficulty pushing open a door.

Atraumatic shoulder instability is usually well tolerated with activities of daily living. Patients usually complain of a “sliding” sensation during exercises or strenuous activities such as throwing. Such dislocations may be less symptomatic and can often undergo spontaneous reduction of the shoulder with pain resolving within days after onset. The clinical examination for shoulder instability includes the apprehension test (Table 41–1), the load and shift test (Table 41–1) and the O'Brien test (Table 41–1). Most patients with persistent shoulder instability have preserved range of motion.

B. Imaging

Radiographs for acute dislocations should include a standard trauma series of anteroposterior and axillary lateral scapula (glenohumeral) views to determine the relationship of the humerus and the glenoid and to rule out fractures. Orthogonal views are used to identify a posterior shoulder dislocation, which can be missed easily with one anteroposterior view of the shoulder. An axillary lateral view of the shoulder can be safely performed even in the acute setting of a patient with a painful shoulder dislocation. For chronic injuries or symptomatic instability, these recommended radiographic views are helpful to identify bony injuries and Hill-Sachs lesions (indented compression fractures at the posterior-superior part of the humeral head associated with anterior shoulder dislocation). MRI is commonly used to show soft tissue injuries to the labrum and to visualize associated rotator cuff tears. MRI arthrograms better identify labral tears and ligamentous structures.

▶ Treatment

For **acute dislocations**, the shoulder should be reduced as soon as possible. The Stimson procedure is the least

traumatic method and is quite effective. The patient lies prone with the dislocated arm hanging off the examination table with a weight applied to the wrist to provide traction for 20–30 minutes. Afterward, gentle medial mobilization can be applied manually to assist the reduction. The shoulder can also be reduced with axial “traction” on the arm with “counter-traction” along the trunk. The patient should be sedated and relaxed. The shoulder can then be gently internally and externally rotated to guide it back into the socket.

Initial treatment of acute shoulder dislocations should include sling immobilization for 2–4 weeks along with pendulum exercises. Early physical therapy can be used to maintain range of motion and strengthening of rotator cuff muscles. Patients can also modify their activities to avoid active and risky sports. For patients with a traumatic incident and unilateral shoulder dislocation, a Bankart lesion is commonly present (remembered by the mnemonic, “TUBS”) and surgical treatment is often required.

The treatment of **atraumatic shoulder instability** is different than traumatic shoulder instability. Patients with chronic, recurrent shoulder dislocations should be managed with physical therapy and a regular maintenance program, consisting of scapular stabilization and postural and rotator cuff strengthening exercises. Activities may need to be modified. In patients with an atraumatic, multidirectional, bilateral shoulder instability, rehabilitation is the mainstay for treatment; inferior capsular shift surgery is rarely required (remembered by the mnemonic, “AMBRI”).

▶ When to Refer

- Patients who are at risk for second dislocation, such as young patients, certain jobholders (eg, police officers, fire fighters, and rock climbers) to avoid recurrent dislocation or dislocation while at work.
- Patients who have not responded to conservative approach or who have chronic instability.

Hovelius L et al. Nonoperative treatment of primary anterior shoulder dislocation in patients forty years of age and younger: a prospective twenty-five-year follow-up. *J Bone Joint Surg Am.* 2008 May;90(5):945–52. [PMID: 18451384]

Johnson SM et al. Shoulder instability in patients with joint hyperlaxity. *J Bone Joint Surg Am.* 2010 Jun;92(6):1545–57. [PMID: 20516333]

Voos JE et al. Prospective evaluation of arthroscopic Bankart repairs for anterior instability. *Am J Sports Med.* 2010 Feb; 38(2):302–7. [PMID: 20028847]

4. Adhesive Capsulitis (“Frozen Shoulder”)



ESSENTIALS OF DIAGNOSIS

- ▶ Very painful shoulder triggered by minimal or no trauma.
- ▶ Pain out of proportion to clinical findings during the inflammatory phase.
- ▶ Stiffness during the “freezing” phase and resolution during the “thawing” phase.

▶ General Considerations

Adhesive capsulitis (“frozen shoulder”) is seen commonly in patients 40- to 65-years-old. It is more commonly seen in women than men, especially in perimenopausal women or in patients with endocrine disorders, such as diabetes mellitus or thyroid disease. Adhesive capsulitis is a self-limiting but very debilitating disease.

▶ Clinical Findings

A. Symptoms and Signs

Patients usually present with a painful shoulder that has a limited range of motion with both passive and active movements. A useful clinical sign is limitation of movement of external rotation with the elbow by the side of the trunk (Table 41–1). Strength is usually normal but it can appear diminished when the patient is in pain.

There are three phases: the inflammatory phase, the “freezing” phase, and the “thawing” phase. During the **inflammatory phase**, which usually lasts 4–6 months, patients complain of a very painful shoulder without obvious clinical findings to suggest trauma, fracture, or rotator cuff tear. During the **“freezing” phase**, which also usually lasts 4–6 months, the shoulder becomes stiffer and stiffer even though the pain is improving. The **“thawing” phase** can take up to a year as the shoulder slowly regains its motion. The total duration of an idiopathic frozen shoulder is usually about 24 months; it can be much longer for patients who have trauma or an endocrinopathy.

B. Imaging

Standard anteroposterior, axillary, and lateral glenohumeral radiographs are useful to rule out glenohumeral arthritis, which can also present with limited active and passive range of motion. However, adhesive capsulitis is usually a clinical diagnosis, and it does not need an extensive diagnostic work-up.

▶ Treatment

Adhesive capsulitis is caused by acute inflammation of the capsule followed by scarring and remodeling. During the acute “freezing” phase, NSAIDs and physical therapy are recommended to maintain motion. There is also evidence of short-term benefit from intra-articular corticosteroid injection or oral prednisone. One study demonstrated improvement at 6 weeks but not 12 weeks following 30 mg of daily prednisone for 3 weeks. During the “freezing” phase, the shoulder is less painful but remains stiff. Anti-inflammatory medication is not as helpful during the “thawing” phase as it is during the “freezing” phase, and the shoulder symptoms usually resolve with time. Surgical treatments include manipulation under anesthesia and arthroscopic release.

▶ When to Refer

- When the patient does not respond after more than 6 months of conservative treatment.
- When there is no progress or worsening range of motion over 3 months.

Neviaser AS et al. Adhesive capsulitis: a review of current treatment. *Am J Sports Med.* 2010 Nov;38(11):2346–56. [PMID: 20110457]

Rill BK et al. Predictors of outcome after nonoperative and operative treatment of adhesive capsulitis. *Am J Sports Med.* 2011 Mar;39(3):567–74. [PMID: 21160014]

SPINE PROBLEMS

1. Low Back Pain



ESSENTIALS OF DIAGNOSIS

- ▶ The cause of back pain may be categorized by pain on flexion versus pain on extension.
- ▶ Nerve root impingement is suspected when pain is leg-dominant rather than back-dominant.
- ▶ Alarming signs for serious spinal disease include unexplained weight loss, failure to improve with treatment, severe pain for more than 6 weeks, and night or rest pain.
- ▶ The cauda equina syndrome often presents with bowel or bladder symptoms (or both) and is an emergency.

▶ General Considerations

Low back pain is the most common cause of disability for patients under the age of 45 and is the second most common cause for primary care visits. The annual prevalence of low back pain is 15–45%, and the annual cost in the United States is over \$50 billion. Approximately 80% of episodes of low back pain resolve within 2 weeks and 90% resolve within 6 weeks. The exact cause of the low back pain is often difficult to diagnose; its cause is often multifactorial, although there are usually degenerative changes in the lumbar spine.

Alarming symptoms for back pain caused by cancer include unexplained weight loss, failure to improve with treatment, pain for more than 6 weeks, and pain at night or rest. History of cancer and age > 50 years are other risk factors for malignancy. Alarming symptoms for infection include fever, rest pain, recent infection (urinary tract infection, cellulitis, pneumonia), or history of immunocompromise or injection drug use. The **cauda equina syndrome** is suggested by urinary retention or incontinence, saddle anesthesia, decreased anal sphincter tone or fecal incontinence, bilateral lower extremity weakness, and progressive neurologic deficits. Risk factors for back pain due to vertebral fracture include use of corticosteroids, age > 70 years, history of osteoporosis, recent significant trauma, or very severe focal pain. Back pain may also be the presenting symptom in other serious medical problems, including abdominal aortic aneurysm, peptic ulcer disease, kidney stones, and pancreatitis.

▶ Clinical Findings

A. Symptoms and Signs

The physical examination is best done with the patient in the standing, sitting, supine, and then prone positions to avoid frequent repositioning of the patient. In the standing position, the patient's posture can be observed. Commonly encountered spinal asymmetries include scoliosis, thoracic kyphosis, and lumbar hyperlordosis. The active range of motion of the lumbar spine can be assessed. The common directions include flexion, rotation, and extension. The one-leg standing extension test assesses for pain as the patient stands on one leg while extending the spine. A positive test can be caused by pars interarticularis fractures (spondylolysis or spondylolisthesis) or facet joint arthritis, although sensitivity and specificity of the test is limited.

In the sitting position, the major muscles in the lower extremities are assessed for weakness by eliciting a resisted isometric contraction for approximately 5 seconds. It is important to compare the strength bilaterally to detect subtle muscle weakness, including hip flexors (L1–2 nerve roots), knee extensors or quadriceps (L3), ankle dorsiflexors (L4–L5), first toe extensor or extensor hallucis longus (L5), knee flexors or hamstrings (S1), ankle plantar-flexors or calf muscles (S1), and hip extensors (S1). Sensory testing to light touch is done next for the following areas: groin (L1 nerve root), thigh (L2), knee (L3), lateral shin and medial ankle (L4), first dorsal web space of the foot between first and second toes (L5), lateral foot (S1), back of the thigh (S2), and perianal area (S3, S4, S5). Knee (femoral nerve L2–4), ankle (deep peroneal nerve L4–L5), and Babinski (sciatic nerve L5–S1) reflexes can be checked with the patient sitting.

In the supine position, the hip should be evaluated for range of motion, focusing on internal rotation. The straight leg raise test puts traction and compression forces on the lower lumbar nerve roots (Table 41–2).

Finally, in the prone position, the clinician can carefully palpate each level of the spine and sacroiliac joints for tenderness. A rectal examination is required if the cauda equina syndrome is suspected. Superficial skin tenderness to a light touch over the lumbar spine, overreaction to maneuvers in the regular back examination, low back pain on axial loading of spine in standing, inconsistency in the straight leg raise test or on the neurologic examination suggest nonorthopedic causes for the pain or malingering.

B. Imaging

In the absence of alarming “red flag” symptoms suggesting infection, malignancy, or cauda equina syndrome, diagnostic imaging, including radiographs, is not typically recommended in the first 6 weeks. If done, radiographs of the lumbar spine should include anteroposterior and lateral views. Oblique views can be useful if the neuroforamina or lesions need to be visualized. MRI is the method of choice in the evaluation of symptoms not responding to conservative treatment or in the presence of red flags of serious conditions.

Table 41-2. Spine: back examination.

Maneuver	Description
Inspection	Check the patient's posture in the standing position. Assess for hyperlordosis, kyphosis, and scoliosis.
Palpation	Include important landmarks: spinous process, facet joints, paravertebral muscles, sacroiliac joints, and sacrum.
Range of motion testing	Check range of motion actively (patient performs) and passively (clinician performs) especially with flexion and extension of the spine. Rotation and lateral bending are also helpful to assess symmetric motion or any restrictions.
Neurologic examination	Check motor strength, reflexes and dermatomal sensation in the lower extremities.
Straight leg raise test	The patient lies supine and the clinician elevates the patient's leg. A positive test for sciatica pain is classically described as "electric shock"-like pain radiating down the posterior aspect of the leg from the low back. This can occur in the setting of a disk herniation or degenerative conditions causing neural foraminal stenosis. Cross-over pain, where sciatica symptoms occur down the opposite leg during a straight leg raise, usually indicates a large disk herniation.
Indirect straight leg raise test	The patient sits on the side of the exam table with the knees bent. The clinician extends the knee fully. A positive test for sciatica pain is classically described as "electric shock"-like pain radiating down the posterior aspect of the leg from the low back. Cross-over pain, where sciatica symptoms occur down the opposite leg during a straight leg raise, usually indicates a large disk herniation.

C. Special Tests

Electromyography or nerve conduction studies may be useful in assessing patients with possible nerve root symptoms lasting longer than 6 weeks; back pain may or may not also be present. These tests are usually not necessary if the diagnosis of radiculopathy is clear.

► Treatment

A. Conservative

Nonpharmacologic treatments are key in the management of low back pain. Education alone improves patient satisfaction with recovery and recurrence. Patients require information and reassurance when diagnostic procedures are not necessary. Discussion must include reviewing safe and effective methods of symptom control as well as how to decrease the risk of recurrence with proper lifting techniques, abdominal wall/core strengthening, weight loss, and smoking cessation. Strengthening and stabilization effectively reduce pain and functional limitation compared with usual care.

Physical therapy exercise programs can be tailored to the patient's symptoms and pathology. Spinal manipulation has short-term benefits if therapy is started within 6 weeks of onset of low back pain without radiculopathy. Heat and cold treatments have not shown any long-term benefits but may be used for symptomatic treatment. The efficacy of transcutaneous electrical nerve stimulation (TENS), back braces, physical agents, and acupuncture is unproven. Improvements in posture, core stability strengthening, physical conditioning, and modifications of activities to decrease physical strain are keys for ongoing management.

NSAIDs are effective in the early treatment of low back pain (see Chapter 20). There is limited evidence that muscle

relaxants can provide short-term relief; since these medications have addictive potential, they should be used with care. Muscle relaxants are best used if there is true muscle spasm that is painful rather than simply a protective response. Opioids may be necessary to alleviate pain immediately. Treatment of more chronic neuropathic pain with gabapentin and tricyclic antidepressants may be helpful.

B. Surgical

Surgical indications for back surgery include cauda equina syndrome, ongoing morbidity with no response to > 6 months of conservative treatment, cancer, infection, or severe spinal deformity. Prognosis is improved when there is an anatomic lesion that can be corrected and symptoms are neurologic. Spinal surgery has limitations. Patient selection is very important and the specific surgery recommended should have very clear indications. Patients should understand that surgery can improve their pain but is unlikely to cure it. Surgery is not generally indicated for radiographic abnormalities alone when the patient is asymptomatic. Depending on the surgery performed, possible complications include persistent pain; surgical site pain, especially if bone grafting is needed; infection; neurologic damage; non-union; cutaneous nerve damage; implant failure; deep venous thrombosis; and death.

► When to Refer

- Patients with the cauda equina syndrome.
- Patients with cancer, infection, or severe spinal deformity.
- Patients who have not responded to conservative treatment.

- Chou R et al. Surgery for low back pain: a review of the evidence for an American Pain Society Clinical Practice Guideline. *Spine (Phila Pa 1976)*. 2009 May 1;34(10):1094–109. [PMID: 19363455]
- Chou R et al. Will this patient develop persistent disabling low back pain? *JAMA*. 2010 Apr 7;303(13):1295–302. [PMID: 20371789]
- Lin CW et al. Cost-effectiveness of guideline-endorsed treatments for low back pain: a systematic review. *Eur Spine J*. 2011 Jul;20(7):1024–38. [PMID: 21229367]

2. Spinal Stenosis



ESSENTIALS OF DIAGNOSIS

- ▶ Pain is usually worse with back extension and relieved by sitting.
- ▶ Occurs in older patients.
- ▶ May present with neurogenic claudication symptoms with walking.

▶ General Considerations

Osteoarthritis in the lumbar spine can cause narrowing of the spinal canal. A large disk herniation can also cause stenosis and compression of neural structures or the spinal artery resulting in “claudication” symptoms with ambulation. The condition usually affects patients aged 50 years or older.

▶ Clinical Findings

Patients report pain that worsens with extension. They describe reproducible single or bilateral leg symptoms that are worse after walking several minutes and that are relieved by sitting (termed “neurogenic claudication”). On examination, patients often exhibit limited extension of the lumbar spine, which may reproduce the symptoms radiating down the legs. A thorough neurovascular examination is recommended.

▶ Treatment

Flexion-based exercises as demonstrated by a physical therapist can help relieve symptoms. Spinal or facet joint corticosteroid injections can also reduce pain symptoms. Spinal decompression (widening the spinal canal or laminectomy), nerve root decompression (freeing a single nerve), and spinal fusion (joining the vertebra to eliminate motion and diminish pain from the arthritic joints) have not been shown to be superior to natural history, placebo treatment, or conservative management of degenerative lumbar disk disease (spondylosis). Some evidence suggests that instrumentation (adding surgical hardware to a spinal fusion) leads to a higher fusion rate, but there is no evidence that it makes any difference to clinical outcomes.

▶ When to Refer

- If a patient exhibits radicular or claudication symptoms > 12 weeks.
- MRI or CT confirmation of significant spinal stenosis.

- Ammendolia C et al. Non-Operative Treatment for Lumbar Spinal Stenosis with Neurogenic Claudication: A Systematic Review. *Spine (Phila Pa 1976)*. 2012 May 1;37(10):E 609–E616.
- Genevay S et al. Lumbar spinal stenosis. *Best Pract Res Clin Rheumatol*. 2010 Apr;24(2):253–65. [PMID: 20227646]
- Weinstein JN et al. Surgical versus nonsurgical treatment for lumbar degenerative spondylolisthesis. *N Engl J Med*. 2007 May 31;356(22):2257–70. [PMID: 17538085]

3. Lumbar Disk Herniation



ESSENTIALS OF DIAGNOSIS

- ▶ Pain with back flexion or prolonged sitting.
- ▶ Radicular pain with compression of neural structures.
- ▶ Lower extremity numbness.
- ▶ Lower extremity weakness.

▶ General Considerations

Lumbar disk herniation is usually due to bending or heavy loading (eg, lifting) with the back in flexion, causing herniation or extrusion of disk contents (nucleus pulposus) into the spinal cord area. However, there may not be an inciting incident. Disk herniations usually occur from degenerative disk disease (dissociation of the annulus fibrosus) in patients between 30- and 50-years-old. The L5–S1 disk is affected in 90% of cases. Compression of neural structures, such as the sciatic nerve, causes radicular pain. Severe compression of the spinal cord can cause the cauda equina syndrome, a surgical emergency (see above).

▶ Clinical Findings

A. Symptoms and Signs

Discogenic pain typically is localized in the low back at the level of the affected disk and is worse with activity. “Sciatica” causes electric shock-like pain radiating down the posterior aspect of the leg often to below the knee. Symptoms usually worsen with back flexion such as bending or sitting for long periods (eg, driving). A significant disk herniation can cause numbness and weakness, including weakness with plantar flexion of the foot (L5/S1) or dorsiflexion of the toes (L4/L5). The cauda equina syndrome should be ruled out if the patient complains of perianal numbness or bowel or bladder incontinence.

B. Imaging

Plain radiographs are helpful to assess spinal alignment (scoliosis, lordosis), disk space narrowing, and osteoarthritis

changes. MRI is the best method to assess the level and morphology of the herniation and is recommended if surgery is planned.

► Treatment

For an acute exacerbation of pain symptoms, bed rest is appropriate for up to 48 hours. Otherwise, first-line treatments include modified activities; NSAIDs and other analgesics; and physical therapy, including core stabilization and McKenzie exercises. Epidural and transforaminal corticosteroid injections can be beneficial, especially in relieving acute radicular pain, although the benefit tends to last only 3 months. These injections may be effective in delaying surgery for chronic low back pain. Oral prednisone can reduce inflammation and is useful in reducing symptoms of acute sciatica; the initial dose is approximately 1 mg/kg once daily with tapering doses over 10 days. Co-analgesics for neuropathic pain, such as the calcium channel α_2 - δ ligands (ie, gabapentin, pregabalin) or tricyclic antidepressants, may be helpful (see Chapter 5).

A large, ongoing trial has shown that patients who underwent surgery for a lumbar disk herniation achieved greater improvement than conservatively treated patients in all primary and secondary outcomes except return to work status after 4 year follow-up.

► When to Refer

- Cauda equina syndrome.
- Progressive worsening of neurologic symptoms.
- Loss of motor function (sensory losses can be followed in the outpatient clinic).

Hadjipavlou AG et al. The pathophysiology of disc degeneration: a critical review. *J Bone Joint Surg Br.* 2008 Oct;90(10):1261–70. [PMID: 18827232]

Rihn JA et al. Duration of symptoms resulting from lumbar disc herniation: effect on treatment outcomes: analysis of the Spine Patient Outcomes Research Trial (SPORT). *J Bone Joint Surg Am.* 2011 Oct 19;93(20):1906–14. [PMID: 22012528]

Weinstein JN et al. Surgical versus nonoperative treatment for lumbar disc herniation: four-year results for the Spine Patient Outcomes Research Trial (SPORT). *Spine (Phila Pa 1976).* 2008 Dec 1;33(25):2789–800. [PMID: 19018250]

4. Neck Pain



ESSENTIALS OF DIAGNOSIS

- Poor posture is often a factor for persistent neck pain.
- Degenerative disk disease is a typical underlying cause for neck pain.
- Cervical radiculopathy symptoms can be referred to the shoulder, arm, or upper back.
- Pain is usually worse with back extension and relieved by sitting.

► General Considerations

Most neck pain, especially in older patients, is due to mechanical degeneration involving the cervical disks, facet joints, and ligamentous structures and may occur in the setting of degenerative changes at other sites as well. Pain can also come from the supporting neck musculature, which often acts to protect the underlying neck structures. Posture is a very important factor, especially in younger patients. Many work-related neck symptoms are due to poor posture and repetitive motions over time. Acute injuries can also occur secondary to trauma. For example, whiplash occurs in 15–40% of motor vehicle accidents, with chronic pain developing in 5–7%. Neck fractures are serious traumatic injuries acutely and can lead to osteoarthritis in the long term. Ultimately, many degenerative conditions of the neck result in cervical canal stenosis or neural foraminal stenosis, sometimes affecting underlying neural structures. Cervical radiculopathy can cause neurologic symptoms in the upper extremities usually deriving from disease of the C5–C7 disks. Patients with neck pain may report associated headaches and shoulder pain. Thoracic outlet syndrome, in which there is mechanical compression of the brachial plexus and neurovascular structures with overhead positioning of the arm, should be considered in the differential diagnosis of neck pain.

► Clinical Findings

A. Symptoms and Signs

The patient's posture should be assessed, checking for shoulder rolled forward or head forward posture as well as scoliosis in the thoracolumbar spine. Patients with discogenic neck pain often complain of pain with flexion, which causes cervical disks to herniate posteriorly. Extension of the neck usually affects the neural foraminal and facet joints of the neck. Rotation and lateral flexion of the cervical spine should be measured both to the left and the right. A detailed neurovascular examination of the upper extremities should be performed, including sensory input to light touch and temperature; motor strength testing, especially the hand intrinsic muscles (thumb extension strength [C6], opponens strength (thumb to pinky) [C7], and finger abductors and adductors strength [C8–T1]); and upper extremity reflexes (biceps, triceps, brachioradialis). True cervical radiculopathy symptoms should match an expected dermatomal or myotomal distribution. The **Spurling test** involves asking the patient to rotate and extend the neck to one side (Table 41–3). The clinician can apply a gentle axial load to the neck. Reproduction of the cervical radiculopathy symptoms is a positive sign of nerve root compression. Palpation of the neck is best performed with the patient in the supine position where the clinician can palpate each level of the cervical spine with the muscles of the neck relaxed.

B. Imaging

Radiographs of the cervical spine can assist in determining the area of degenerative changes. Useful views include the anteroposterior and lateral view of the cervical spine. The

Table 41-3. Spine: neck examination.

Maneuver	Description
Inspection	Check the patient's posture in the standing position. Assess for cervical hyperlordosis, head forward posture, kyphosis, scoliosis, torticollis.
Palpation	Include important landmarks: spinous process, facet joints, paracervical muscles (sternocleidomastoid, scalene muscles).
Range of motion testing	Check range of motion in the cervical spine, especially with flexion and extension. Rotation and lateral bending are also helpful to assess symmetric motion or any restrictions. Pain and radicular symptoms can be exacerbated by range of motion testing.
Neurologic examination	Check motor strength, reflexes and dermatomal sensation in the upper (and lower if necessary) extremities.
Spurling test	Involves asking the patient to rotate and extend the neck to one side. The clinician can apply a gentle axial load to the neck. Reproduction of the cervical radiculopathy symptoms is a positive sign of nerve root compression.

odontoid view is usually added to rule out traumatic fractures and congenital abnormalities. Oblique views of the cervical spine can provide further information about arthritis changes and assess the neural foramina for narrowing.

CT scanning is the most useful method if bony abnormalities, such as fractures, are suspected. MRI is the best method to assess the cervical spine since the soft tissue structures (such as the disks, spinal cord, and nerve roots) can be evaluated. If the patient has signs of cervical radiculopathy with motor weakness, these more sensitive imaging modalities should be obtained urgently.

▶ Treatment

A course of neck stretching, strengthening and postural exercises in physical therapy have demonstrated benefit in relieving symptoms. Chiropractic manual manipulation and mobilization can provide short-term benefit for mechanical neck pain. Although the rate of complications is low (5–10/million manipulations), care should be taken whenever there are neurologic symptoms present. Specific patients may respond to use of home cervical traction. A soft cervical collar can be useful for short-term use (up to 1–2 weeks) in acute neck injuries. NSAIDs are commonly used and opioids may be needed in cases of severe neck pain. Muscle relaxants (eg, cyclobenzaprine 5–10 mg orally three times daily) can be used short-term if there is muscle spasm or as a sedative to aid in sleeping. Acute radicular symptoms can be treated with neuropathic medications (eg, gabapentin 300–1200 mg orally three times daily), and a short course of oral prednisone (5–10 days) can be considered (starting at 1 mg/kg). Cervical foraminal or

facet joint injections can also reduce symptoms. Surgeries are successful in reducing neurologic symptoms in 80–90% of cases but are still considered as treatments of last resort.

▶ When to Refer

- Patients with severe symptoms with motor weakness.
- Surgical decompression surgery if the symptoms are severe and there is identifiable, correctable pathology.

Carette S et al. Clinical practice. Cervical radiculopathy. *N Engl J Med.* 2005 Jul 28;353(4):392–9. [PMID: 16049211]
 Eubanks JD. Cervical radiculopathy: nonoperative management of neck pain and radicular symptoms. *Am Fam Physician.* 2010 Jan 1;81(1):33–40. [PMID: 20052961]
 Kelly JC et al. The natural history and clinical syndromes of degenerative cervical spondylosis. *Adv Orthop.* 2012;2012:393642. [PMID: 22162812]

UPPER EXTREMITY

1. Lateral & Medial Epicondylitis



ESSENTIALS OF DIAGNOSIS

- ▶ Tenderness over the lateral or medial epicondyle.
- ▶ Diagnosis of tendinopathy is confirmed by pain with resisted strength testing and passive stretching of the affected tendon and muscle unit.
- ▶ Physical therapy and activity modification are more successful than anti-inflammatory treatments.

▶ General Considerations

Tendinopathy involving the wrist extensors, flexors, and pronators are very common complaints. The underlying mechanism is chronic repetitive overuse causing microtrauma at the tendon insertion, although acute injuries can occur as well if the tendon is strained due to excessive loading. The traditional term “epicondylitis” is a misnomer because histologically tendinosis or degeneration in the tendon is seen rather than acute inflammation. Therefore, these entities should be referred to as “tendinopathy” or “tendinosis.” Lateral epicondylitis involves the wrist extensors, especially the extensor carpi radialis brevis. This is usually caused by lifting with the wrist and the elbow extended. Medial epicondylitis involves the wrist flexors and most commonly the pronator teres tendon. Ulnar neuropathy and cervical radiculopathy should be considered in the differential diagnosis.

▶ Clinical Findings

A. Symptoms and Signs

For lateral epicondylitis, the patient describes pain with the arm and wrist extended. For example, common complaints include pain while shaking hands, lifting

objects, using a computer mouse, or hitting a backhand in tennis (“tennis elbow”). Medial epicondylitis presents with pain during motions in which the arm is repetitively pronated or the wrist is flexed. This is also known as “golfer’s elbow” due to the motion of turning the hands over during the golf swing. On examination, tenderness directly over the epicondyle is present, especially over the posterior aspect where the tendon insertion occurs. The proximal tendon and musculotendinous junction can also be sore. To confirm that the pain is due to tendinopathy, pain can be reproduced over the epicondyle with resisted wrist extension and third digit extension for lateral epicondylitis and resisted wrist pronation and wrist flexion for medial epicondylitis. The pain is also often reproduced with passive stretching of the affected muscle groups, which can be performed with the arm in extension. It is useful to check the ulnar nerve (located in a groove at the posteromedial elbow) for tenderness as well as to perform a Spurling test for cervical radiculopathy.

B. Imaging

Radiographs are often normal, although a small traction spur may be present in chronic cases (enthesopathy). Diagnostic investigations are usually unnecessary, unless the patient does not improve after up to 3 months of conservative treatment. At that point, a patient who demonstrates significant disability due to the pain should be assessed with an MRI or ultrasound. Ultrasound and MRI can visualize the tendon and confirm tendinosis or tears.

► Treatment

Treatment is usually conservative, including patient education regarding activity modification and management of symptoms. Ice and NSAIDs can help with pain. The most important steps are to begin a good stretching program followed by strengthening exercises. Counterforce elbow braces might provide some symptomatic relief, although there is no published evidence to support their use. If the patient has severe or long-standing symptoms, a course of physical therapy should be performed. Corticosteroid injection offers some short-term improvement. However, physical therapy and rehabilitative exercises are still the mainstays of treatment. Treatments such as extracorporeal shock wave therapy and injectable medications other than corticosteroids have not shown clear long-term benefit.

► When to Refer

Patients not responding to 6 months of conservative treatment should be referred for surgical debridement or repair of the tendon.

Bisset L et al. Mobilisation with movement and exercise, corticosteroid injection, or wait and see for tennis elbow: randomised trial. *BMJ*. 2006 Nov 4;333(7575):939. [PMID: 17012266]

Calfee RP et al. Management of lateral epicondylitis: current concepts. *J Am Acad Orthop Surg*. 2008 Jan;16(1):19–29. [PMID: 18180389]

2. Carpal Tunnel Syndrome



ESSENTIALS OF DIAGNOSIS

- Pain, burning, and tingling in the distribution of the median nerve.
- Initially, most bothersome during sleep.
- Late weakness or atrophy, especially of the thenar eminence.
- Can be caused by repetitive activities using the wrist.
- Commonly seen during pregnancy and in patients with diabetes mellitus or rheumatoid arthritis.

► General Considerations

An entrapment neuropathy, carpal tunnel syndrome is a painful disorder caused by compression of the median nerve between the carpal ligament and other structures within the carpal tunnel. The contents of the tunnel can be compressed by synovitis of the tendon sheaths or carpal joints, recent or malhealed fractures, tumors, tissue infiltration, and occasionally congenital syndromes (eg, mucopolysaccharidoses). Even though no anatomic lesion is apparent, flattening or even circumferential constriction of the median nerve may be observed during operative section of the overlying carpal ligament. The disorder may occur in fluid retention of pregnancy, in individuals with a history of repetitive use of the hands, or following injuries of the wrists. There is a familial type of carpal tunnel syndrome in which no etiologic factor can be identified. Carpal tunnel syndrome can also be a feature of many systemic diseases, such as rheumatoid arthritis and other rheumatic disorders (inflammatory tenosynovitis), myxedema, amyloidosis, sarcoidosis, leukemia, acromegaly, and hyperparathyroidism.

► Clinical Findings

A. Symptoms and Signs

The initial symptoms are pain, burning, and tingling in the distribution of the median nerve (the palmar surfaces of the thumb, the index and long fingers, and the radial half of the ring finger). Aching pain may radiate proximally into the forearm and occasionally proximally to the shoulder and over the neck and chest. Pain is exacerbated by manual activity, particularly by extremes of volar flexion or dorsiflexion of the wrist. It is most bothersome at night. Impairment of sensation in the median nerve distribution may or may not be demonstrable. Subtle disparity between the affected and opposite sides can be shown by testing for two-point discrimination or by requiring the patient to identify different textures of cloth by rubbing them between the tips of the thumb and the index finger. A Tinel or Phalen sign may be positive. A **Tinel sign** is tingling or shock-like pain on volar wrist percussion (Table 41–4). The **Phalen sign** is pain or paresthesia in the distribution of the

Table 41-4. Wrist examination.

Maneuver	Description
Inspection	Examine for the alignment of the wrist and fingers SEADS
Palpation	Include important landmarks: scaphoid "snuff box," distal radius, scapholunate ligament, hook of hamate, ulnar joint line, distal radioulnar joint
Range of motion testing	Check range of motion actively (patient performs) and passively (clinician performs) especially with flexion and extension of the wrist. Ulnar and radial deviation and circumduction of the wrist can be screened.
Neurovascular examination	Check motor strength and dermatomal sensation in the fingers in the radial (thumb), median (3rd finger) and ulnar distribution (5th finger). Check capillary refill to digits as well as radial pulse.
Tinel sign	Tingling or shock-like pain on volar wrist percussion. The carpal compression test, in which numbness and tingling are induced by the direct application of pressure over the carpal tunnel, may be more sensitive and specific than the Tinel and Phalen tests.
Phalen sign	Pain or paresthesia in the distribution of the median nerve when the patient flexes both wrists to 90 degrees for 60 seconds.
Carpel compression test	Performed by applying direct application of pressure over the carpal tunnel.

SEADS, swelling, erythema, atrophy, deformity, and (surgical) scars.

median nerve when the patient flexes both wrists to 90 degrees for 60 seconds (Table 41-4). The **carpal compression test**, in which numbness and tingling are induced by the direct application of pressure over the carpal tunnel, may be more sensitive and specific than the Tinel and Phalen tests (Table 41-4). Muscle weakness or atrophy, especially of the thenar eminence, can appear later than sensory disturbances as compression of the nerve worsens.

B. Imaging

Ultrasound can demonstrate flattening of the median nerve beneath the flexor retinaculum. Sensitivity of ultrasound for carpal tunnel syndrome is variable but estimated between 54% and 98%.

C. Special Tests

Electromyography and nerve conduction studies show evidence of sensory conduction delay before motor delay, which can occur in severe cases. This syndrome should be differentiated from other cervicobrachial pain syndromes,

from compression syndromes of the median nerve in the forearm or arm, and from mononeuritis multiplex. When left-sided, it may be confused with angina pectoris.

► Treatment

Treatment is directed toward relief of pressure on the median nerve. When a causative lesion is discovered, it should be treated appropriately. Otherwise, patients in whom carpal tunnel syndrome is suspected should modify their hand activities and have the affected wrist splinted in the neutral position for up to 3 months. Oral corticosteroids or NSAIDs can also be tried. Carpal tunnel release surgery can be beneficial if the patient has a positive electrodiagnostic test, at least moderate symptoms, high clinical probability, unsuccessful nonoperative treatment, and symptoms lasting longer than 12 months.

► When to Refer

- If symptoms persist > 3 months despite conservative treatment, including the use of a wrist splint.
- If thenar muscle (eg, abductor pollicis brevis) weakness or atrophy develops.

Bickel KD. Carpal tunnel syndrome. *J Hand Surg Am.* 2010 Jan;35(1):147–52. [PMID: 20117319]
 Jarvik JG et al. Surgery versus non-surgical therapy for carpal tunnel syndrome: a randomised parallel-group trial. *Lancet.* 2009 Sep 26;374(9695):1074–81. [PMID: 19782873]
 Keith MW et al. Treatment of carpal tunnel syndrome. *J Am Acad Orthop Surg.* 2009 Jun;17(6):397–405. [PMID: 19474449]

HIP

1. Hip Fractures



ESSENTIALS OF DIAGNOSIS

- Internal rotation of the hip is the best provocative diagnostic maneuver.
- Hip fractures should be surgically repaired as soon as possible (within 24 hours).
- Delayed treatment of hip fractures in the elderly leads to increased complications and mortality.

► General Considerations

Approximately 4% of the 7.9 million fractures that occur each year in the United States are hip fractures. There is a high mortality rate among elderly patients following hip fracture, with death occurring in 8–9% within 30 days and in approximately 25–30% within 1 year. Osteoporosis, female sex, height > 5-foot 8-inches, and age over 50 years are risk factors for hip fracture. Hip fractures usually occur after a fall. High velocity trauma is needed in younger patients. Stress fractures can occur in athletes or individuals with

poor bone mineral density following repetitive loading activities.

► Clinical Findings

A. Symptoms and Signs

Patients typically report pain in the groin, though pain radiating to the lateral hip, buttock, or knee can also commonly occur. If a displaced fracture is present, the patient will not be able to bear weight and the leg may be externally rotated. Gentle logrolling of the leg with the patient supine helps rule out a fracture. Examination of the hip demonstrates pain with deep palpation in the area of the femoral triangle (similar to palpating the femoral artery). Provided the patient can tolerate it, the clinician can, with the patient supine, flex the hip to 90 degrees with the knee flexed to 90 degrees. The leg can then be internally and externally rotated to assess the range of motion on both sides. Pain with internal rotation of the hip is the most sensitive test to identify intra-articular hip pathology. Hip flexion, extension, abduction, and adduction strength can be tested.

Patients with hip stress fractures have less pain on physical examination than described previously but typically have pain with weight bearing. The Trendelenburg test can be performed to examine for weakness or instability of the hip abductors, primarily the gluteus medius muscle (Table 41–5). Another functional test is asking the patient to hop or jump during the examination. If the patient has a compatible clinical history of pain and is unable or unwilling to hop, then a stress fracture should be ruled out. The back should be carefully examined in

patients with hip complaints, including examining for signs for sciatica.

Following displaced hip fractures, a thorough medical evaluation and treatment should be pursued to maximize the patients' ability to undergo operative intervention. Patients who are unable to get up by themselves may have been immobile for hours or even days following their falls. Thus, clinicians must exclude rhabdomyolysis, hypothermia, deep venous thrombosis, pulmonary embolism, and other conditions that can occur with prolonged immobilization. Delay of operative intervention leads to an increased risk of perioperative morbidity and mortality.

B. Imaging

Useful radiographic views of the hip include anteroposterior views of the pelvis and bilateral hips and frog-leg lateral views of the painful hip. A CT scan or MRI may be necessary to identify the hip fracture pattern or to evaluate non-displaced fractures. Hip fractures are generally described by location, including femoral neck, intertrochanteric, or subtrochanteric.

► Treatment

Almost all patients with a hip fracture will require surgery and may need to be admitted to hospital for pain control while they await surgery. Surgery is recommended within the first 24 hours because studies have shown that delaying surgery 48 hours results in at least twice the rate of major and minor medical complications, including pneumonia, decubitus ulcers, and deep venous thrombosis.

Stress fractures in active patients require a period of protected weight-bearing and a gradual return to activities, although it may take 4–6 months before a return to normal activities. Femoral neck fractures are commonly treated with hemiarthroplasty or total hip replacement. This allows the patient to begin weight-bearing immediately postoperatively. Peritrochanteric hip fractures are treated with open reduction internal fixation, where plate and screw construct or intramedullary devices are used. The choice of implant will depend on the fracture pattern. Since fracture fixation requires the fracture to proceed to union, the patient may need to have protected weight-bearing during the early postoperative period. Dislocation, periprosthetic fracture, and avascular necrosis of the hip are common complications after surgery.

Patients should be mobilized as soon as possible postoperatively to avoid pulmonary complications and decubitus ulcers. Supervised physical therapy and rehabilitation is important for the patient to regain as much function as possible. Unfortunately, most patients following hip fractures will lose some degree of independence.

► Prevention

Bone density screening can identify patients at risk for osteopenia or osteoporosis, and treatment can be planned accordingly. Nutrition (calcium and vitamin D intake) and bone health (bone densitometry, serum calcium and 25-OH vitamin D levels) should be reviewed with the

Table 41–5. Hip examination.

Maneuver	Description
Inspection	Examine for the alignment of the lower extremity, consider lumbar spine exam
Palpation	Include important landmarks: ASIS and AIIIS (proximal quadriceps muscle insertions), greater trochanter (gluteal tendon insertions and bursa), anterior femoral triangle (hip joint and hip flexion insertion), ischial tuberosity (hamstring tendon insertion), sacroiliac joints
Range of motion testing	Check range of motion passively (clinician performs) especially internal and external rotation of the hip
Hip strength testing	Test resisted hip flexion, extension, abduction and adduction strength manually
Trendelenburg test	The patient balances first on one leg, raising the non-standing knee toward the chest. The clinician can stand behind the patient and observe for dropping of the pelvis and buttock on the non-stance side.

AIIIS, anterior inferior iliac spine; ASIS, anterior superior iliac spine.

patient (see Chapter 26). For patients with decreased mobility, systemic anticoagulation with low-molecular-weight heparin or warfarin should be considered to avoid deep venous thrombosis (see Table 14–13). Fall prevention exercise programs are available for elderly patients at risk for falls and hip fractures. Hip protectors are uncomfortable and have less use in preventing fractures.

► When to Refer

All patients in whom hip fracture is suspected.

Forte ML et al. Ninety-day mortality after intertrochanteric hip fracture: does provider volume matter? *J Bone Joint Surg Am.* 2010 Apr;92(4):799–806. [PMID: 20360501]

Lowe JA et al. Optimal treatment of femoral neck fractures according to patient's physiologic age: an evidence-based review. *Orthop Clin North Am.* 2010 Apr;41(2):157–66. [PMID: 20399355]

2. Osteoarthritis



ESSENTIALS OF DIAGNOSIS

- Pain deep in the groin on the affected side.
- Swelling.
- Degeneration of joint cartilage.
- Loss of active and passive range of motion in severe osteoarthritis.

► General Considerations

In the United States, the prevalence of osteoarthritis will grow as the number of persons over age 65 years doubles to more than 70 million by 2030. Cartilage loss and osteoarthritis symptoms are preceded by damage to the collagen-proteoglycan matrix. The etiology of osteoarthritis is often multifactorial, including previous trauma, prior high-impact activities, genetic factors, obesity, and rheumatologic or metabolic conditions.

► Clinical Findings

A. Symptoms and Signs

Osteoarthritis usually causes pain in the affected joint with loading of the joint or at the extremes of motion. Mechanical symptoms—such as swelling, grinding, catching, and locking—suggest internal derangement, which is indicated by damaged cartilage or bone fragments that affect the smooth range of motion expected at an articular joint. Pain can also produce the sensation of “buckling” or “giving way” due to muscle inhibition. As the joint degeneration becomes more advanced, the patient loses active range of motion and may lose passive range of motion as well.

Patients complain of pain deep in the groin on the affected side and have problems with weight-bearing activities such as walking, climbing stairs, and getting up

from a chair. They may limp and develop a lurch during their gait, leaning toward the affected side as the walk to reduce pressure on the hip.

B. Imaging

Weight-bearing radiographs of the affected hip are preferred for evaluation of hip osteoarthritis. To reduce radiation exposure, obtain an anteroposterior weight-bearing radiograph of the pelvis with a lateral view of the symptomatic hip. Joint space narrowing and sclerosis suggest early osteoarthritis, while osteophytes near the femoral head or acetabulum and subchondral bone cysts are more advanced changes.

► Treatment

A. Conservative

Changes in the articular cartilage are irreversible. Therefore, a cure for the diseased joint is not possible, although symptoms or structural issues can be addressed to try to maintain activity level. Conservative treatment for patients with osteoarthritis includes activity modification, therapeutic exercises, weight loss, and use of assistive devices (such as a cane). Lifestyle modifications also include proper footwear and avoidance of high impact activities.

Analgesics may be effective in some cases. Corticosteroid injections can be considered for short-term relief of pain; however, hip injections are best performed under fluoroscopic, ultrasound, or CT guidance to ensure accurate injection in the joint. Use of viscosupplementation in the hip has been studied with modest improvements; however, it remains an off-label use at this time.

B. Surgical

Two published randomized trials demonstrate that arthroscopy does not improve outcomes at 1 year over placebo or routine conservative treatment of osteoarthritis. Arthroscopic surgery is indicated in patients with osteoarthritis if, rather than pain, they have mechanical symptoms and internal derangement symptoms that can be removed as the main complaint. Such surgical treatments are useful to restore range of motion by removing osteophytes, cartilage fragments, or loose bodies.

Joint replacement surgeries are effective and cost-effective for patients with significant symptoms and functional limitations, providing improvements in pain, function, and quality of life. Minimally invasive surgeries and computer-assisted navigation during operation are being investigated as methods to improve techniques (eg, accurate placement of the hardware implant) and to reduce complication rates.

Hip resurfacing surgery is a newer joint replacement technique. Rather than use a traditional artificial joint implant of the whole neck and femur, only the femoral head is removed and replaced. Concerns following resurfacing surgery include the risk of femoral neck fracture and collapse of the head. The cumulative survival rate of this implant at 10 years from recent studies is estimated to be 94%. Evidence so far suggests that hip resurfacing is

comparable to total hip replacement and is a viable alternative for younger patients.

► When to Refer

Patients with sufficient disability, limited benefit from conservative therapy, and evidence of severe osteoarthritis can be referred for joint replacement surgery.

Lee YH et al. Effect of glucosamine or chondroitin sulfate on the osteoarthritis progression: a meta-analysis. *Rheumatol Int.* 2010 Jan;30(3):357–63. [PMID: 19544061]

Zhang W et al. OARSI recommendations for the management of hip and knee osteoarthritis: part III: changes in evidence following systematic cumulative update of research published through January 2009. *Osteoarthritis Cartilage.* 2010 Apr; 18(4):476–99. [PMID: 20170770]

KNEE

1. Knee Pain



ESSENTIALS OF DIAGNOSIS

- Effusion can occur with intra-articular pathology, such as osteoarthritis, and meniscus and cruciate ligament tears.
- Acute knee swelling (hemarthrosis) within 2 hours may indicate ligament injuries or patellar dislocation or fracture.

► General Considerations

The knee is the largest joint in the body and is susceptible to injury from trauma, inflammation, infection, and degenerative changes. The knee is a hinge joint. The joint line exists between the femoral condyles and tibial plateaus. Separating and cushioning these bony surfaces is the lateral and medial meniscal cartilage, which functions as a shock absorber during weight bearing, protecting the articular cartilage. The patella is a large sesamoid bone anterior to the joint. It is embedded in the quadriceps tendon, and it articulates with the trochlear groove of the femur. Poor patellar tracking in the trochlear groove is a common source of knee pain especially when the cause is atraumatic in nature. The knee is stabilized by the collateral ligaments against varus (lateral collateral ligament) and valgus (medial collateral ligament) stresses. The tibia is limited in its anterior movement by the anterior cruciate ligament (ACL) and in its posterior movement by the posterior cruciate ligament (PCL). The bursae of the knee are located between the skin and bony prominences. They are sac-like structures with a synovial lining. They act to decrease friction of tendons and muscles as they move over adjacent bony structures. Excessive external pressure or friction can lead to swelling and pain of the bursae. The prepatellar bursae (located between the skin and patella), and the pes

anserine bursa (which is medial and inferior to the patella, just below the tibial plateau) are most commonly affected. Joint fluid, when excessive due to synovitis or trauma, can track posteriorly through a potential space, resulting in a popliteal cyst (also called a Baker cyst). Other structures that are susceptible to overuse injury and may cause knee pain following repetitive activity include the patellofemoral joint and the iliotibial band. Osteoarthritis of the knees is common after 50 years of age and can develop due to previous trauma, aging, activities, alignment issues, and genetic predisposition.

► Clinical Findings

A. Symptoms and Signs

Evaluation of knee pain should begin with general questions regarding duration and rapidity of symptom onset and the mechanism of injury or aggravating symptoms. Overuse or degenerative problems can occur with stress or compression from sports, hobbies, or occupation. A history of trauma, previous orthopedic problems with, or surgery to, the affected knee should also be specifically queried. Symptoms of infection (fever, recent bacterial infections, risk factors for sexually transmitted infections [such as gonorrhea] or other bacterial infections [such as staphylococcal infection]) should always be elicited.

Common symptom complaints include the following:

1. Presence of grinding, clicking, or popping with bending, may be indicative of osteoarthritis or the patellofemoral syndrome.
2. “Locking” or “catching” when walking suggests an internal derangement, such as meniscal injury or a loose body in the knee.
3. Intra-articular swelling of the knee or an effusion indicates an internal derangement or a synovial pathology. Large swelling may cause a popliteal (Baker) cyst. Acute swelling within minutes to hours suggests a hemarthrosis, most likely due to an ACL injury, fracture or patellar dislocation, especially if trauma is involved.
4. Lateral “snapping” with flexion and extension of the knee may indicate inflammation of the iliotibial band.
5. Pain that is worsened with bending and walking downstairs suggests issues with the patellofemoral joint, usually degenerative such as chondromalacia of the patella or osteoarthritis.
6. Pain that occurs when rising after prolonged sitting suggests a problem with tracking of the patella.

A careful history, coupled with a physical examination that includes observation, palpation and range of motion testing, as well as specific tests for particular anatomic structures is frequently sufficient to establish a diagnosis. When there is a knee joint effusion caused by increased fluid in the intra-articular space, physical examination will demonstrate swelling in the hollow or dimple around the patella and distention of the suprapatellar space.

Table 41–6 shows the differential diagnosis of knee pain, and Table 41–7 outlines possible diagnoses based on the location of pain.

Table 41-6. Differential diagnosis of knee pain.

Mechanical dysfunction or disruption
Internal derangement of the knee: injury to the menisci or ligaments
Degenerative changes caused by osteoarthritis
Dynamic dysfunction or misalignment of the patella
Fracture as a result of trauma
Intra-articular inflammation or increased pressure
Internal derangement of the knee: injury to the menisci or ligaments
Inflammation or infection of the knee joint
Ruptured popliteal (Baker) cyst
Peri-articular inflammation
Internal derangement of the knee: injury to the menisci or ligaments
Prepatellar or anserine bursitis
Ligamentous sprain

B. Laboratory Findings

Laboratory testing of aspirated joint fluid, when indicated, can lead to a definitive diagnosis in most patients.

C. Imaging

Knee pain is evaluated with plain (weight-bearing) radiographs and MRI most commonly, but CT and ultrasound are sometimes useful.

An acute hemarthrosis represents bloody swelling that usually occurs within the first 1–2 hours following trauma. In situations where the trauma may be activity-related and

not a result of a fall or collision, the differential diagnosis most commonly includes ACL tear (responsible for almost 50% of hemarthrosis in children and > 70% in adults), fracture (patella, tibial plateau, femoral supracondylar, growth plate [physeal]), and patellar dislocation. Meniscal tears are unlikely to cause large hemarthrosis.

2. Anterior Cruciate Ligament Injury



ESSENTIALS OF DIAGNOSIS

- ▶ An injury involving an audible pop when the knee buckles.
- ▶ Acute swelling immediately (or within 4 hours).
- ▶ Instability occurs with lateral movement activities and going down stairs.

▶ General Considerations

The anterior cruciate ligament (ACL) connects the posterior aspect of the lateral femoral condyle to the anterior aspect of the tibia. Its main function is to control anterior translation of the tibia on the femur. It also provides rotational stability of the tibia on the femur. ACL tears are common with sporting injuries. They can result from both contact (valgus blow to the knee) and non-contact (jumping, pivoting, and deceleration) activities. The patient usually falls down following the injury, has acute swelling and difficulty with weight-bearing, and complains of instability. ACL injuries are common in skiing, soccer, football, and basketball among young adolescents and middle-age patients. Pre-pubertal and older patients usually sustain fractures instead of ligamentous injuries.

▶ Clinical Findings




A. Symptoms and Signs

Acute ACL injuries usually lead to acute swelling of the knee, causing difficulty with motion. After the swelling has resolved, the patient can walk with a “stiff-knee” gait or quadriceps avoidance gait because of the instability. More importantly, patients describe symptoms of instability while performing side-to-side maneuvers or descending stairs. Stability tests assess the amount of laxity of the knee while performing side-to-side maneuvers or descending stairs. The **Lachman test** (84–87% sensitivity and 93% specificity) is performed with the patient lying supine and the knee flexed to 20–30 degrees (Table 41-8). The clinician grasps the distal femur from the lateral side and the proximal tibia with the other hand on the medial side. With the knee in neutral position, stabilize the femur, and pull the tibia anteriorly using a similar force to lifting a 10- to 15-pound weight. Excessive anterior translation of the tibia compared with the other side indicates injury to the ACL. The **anterior drawer test** (48% sensitivity and 87% specificity) is performed with the patient lying supine and the knee flexed to 90 degrees (Table 41-8). The clinician

Table 41-7. Location of common causes of knee pain.



Medial knee pain
Medial compartment osteoarthritis
Medial collateral ligament strain
Medial meniscal injury
Anserine bursitis (pain over the proximal medial tibial plateau)
Anterior knee pain
Patellofemoral syndrome (often bilateral)
Osteoarthritis
Prepatellar bursitis (associated with swelling anterior to the patella)
“Jumper’s knee” (pain at the inferior pole of the patella)
Septic arthritis
Gout or other inflammatory disorder
Lateral knee pain
Lateral meniscal injury
Iliotibial band syndrome (pain superficially along the distal iliotibial band near lateral femoral condyle or lateral tibial insertion)
Lateral collateral ligament sprain (rare)
Posterior knee pain
Popliteal (Baker) cyst
Osteoarthritis
Meniscal tears
Hamstring or calf tendinopathy

Table 41-8. Knee examination.

Maneuver	Description
Inspection	Examine for the alignment of the lower extremities (varus, valgus, knee recurvatum), ankle eversion and foot pronation, gait, SEADS.
Palpation	Include important landmarks: patellofemoral joint, medial and lateral joint lines (especially posterior aspects), pes anserine bursa, distal iliotibial band and Gerdy tubercle (iliotibial band insertion).
Range of motion testing 	Check range of motion actively (patient performs) and passively (clinician performs), especially with flexion and extension of the knee normally 0–10 degrees of extension and 120–150 degrees of flexion.
Knee strength testing	Test resisted knee extension and knee flexion strength manually.
Ligament stress tests	
Lachman test 	Performed with the patient lying supine, and the knee flexed to 20–30 degrees. The examiner grasps the distal femur from the lateral side, and the proximal tibia with the other hand on the medial side. With the knee in neutral position, stabilize the femur, and pull the tibia anteriorly using a similar force to lifting a 10–15 pound weight. Excessive anterior translation of the tibia compared with the other side indicates injury to the anterior cruciate ligament.
Anterior drawer 	Performed with the patient lying supine and the knee flexed to 90 degrees. The clinician stabilizes the patient's foot by sitting on it and grasps the proximal tibia with both hands around the calf and pulls anteriorly. A positive test finds anterior cruciate ligament laxity compared with the unaffected side.


(continued)

Table 41-8. Knee examination. (continued)

Maneuver	Description
<p data-bbox="107 290 193 314">Pivot shift</p> 	<p data-bbox="834 290 1266 469">Used to determine the amount of rotational laxity of the knee. The patient is examined while lying supine with the knee in full extension. It is then slowly flexed while applying internal rotation and a valgus stress. The clinician feels for a subluxation at 20-40 degrees of knee flexion. The patient must remain very relaxed to have a positive test.</p>
<p data-bbox="107 1157 214 1181">Valgus stress</p>  <p data-bbox="334 1770 408 1794">Fix ankle</p>	<p data-bbox="834 1157 1256 1387">Performed with the patient supine. The clinician should stand on the outside of the patient's knee. With one hand, the clinician should hold the ankle while the other hand is supporting the leg at the level of the knee joint. A valgus stress is applied at the ankle to determine pain and laxity of the medial collateral ligament. The test should be performed at both 30 degrees and at 0 degrees of knee extension.</p>



(continued)

Table 41-8. Knee examination. (continued)

Maneuver	Description
<p>Varus stress</p> 	<p>The patient is again placed supine. For the right knee, the clinician should be standing on the right side of the patient. The left hand of the examiner should be holding the ankle while the right hand is supporting the lateral thigh. A varus stress is applied at the ankle to determine pain and laxity of the lateral collateral ligament. The test should be performed at both 30 degrees and at 0 degrees of knee flexion.</p>
<p>The sag sign</p>	<p>The patient is placed supine and both hips and knees are flexed up to 90 degrees. Because of gravity, the posterior cruciate ligament-injured knee will have an obvious set-off at the anterior tibia which is "sagging" posteriorly.</p>
<p>Posterior drawer</p>	<p>The patient is placed supine with the knee flexed at 90 degrees (see Anterior drawer figure above). In a normal knee, the anterior tibia should be positioned about 10 mm anterior to the femoral condyle. The clinician can grasp the proximal tibia with both hands and push the tibia posteriorly. The movement, indicating laxity and possible tear of the posterior cruciate ligament, is compared with the uninjured knee.</p>
<p>Meniscal signs</p>	
<p>McMurray test</p>	<p>Performed with the patient lying in supine. The clinician flexes the knee until the patient reports pain. For this test to be valid, it must be flexed pain-free beyond 90 degrees. The clinician externally rotates the patient's foot and then extends the knee while palpating the medial knee for "click" in the medial compartment of the knee or pain reproducing pain from a meniscus injury. To test the lateral meniscus, the same maneuver is repeated while rotating the foot internally (53% sensitivity and 59-97% specificity).</p>

(continued)

Table 41-8. Knee examination. (continued)

Maneuver	Description
<p>Modified McMurray</p> 	<p>Performed with the hip flexed to 90 degrees. The knee is then flexed maximally with internally or externally rotation of the lower leg. The knee can then be rotated with the lower leg in internal or external rotation to capture the torn meniscus underneath the condyles. A positive test is pain over the joint line while the knee is being flexed and internally or externally rotated.</p>
<p>Thessaly test</p> 	<p>Performed with the patient standing on one leg with knee slightly flexed. The patient is asked to twist the knee while standing on one leg. Pain can be elicited during twisting motion.</p>
<p>Patellofemoral joint test</p> <p>Apprehension sign</p>	<p>Suggests instability of the patellofemoral joint and is positive when the patient becomes apprehensive when the patella is deviated laterally.</p>

SEADS, swelling, erythema, atrophy, deformity, and (surgical) scars.

stabilizes the patient's foot by sitting on it and grasps the proximal tibia with both hands around the calf and pulls anteriorly. A positive test finds ACL laxity compared with the unaffected side. The **pivot shift** test is used to determine the amount of rotational laxity of the knee (Table 41–8). The patient is examined while lying supine with the knee in full extension. It is then slowly flexed while applying internal rotation and a valgus stress. The clinician feels for a subluxation at 20–40 degrees of knee flexion. The patient must remain very relaxed to have a positive test.

B. Imaging

Plain radiographs are usually negative in ACL tears but are useful to rule out fractures. A small avulsion injury can sometimes be seen over the lateral compartment of the knee. This is called a “segond” fracture and is pathognomonic of an ACL injury. MRI is the best method to diagnose ACL tears. It has > 95% sensitivity and specificity for ACL tears. MRI also allows evaluation of other associated structures, such as menisci and cartilages.

► Treatment

Most young and active patients will require surgical reconstruction of the ACL. Common surgical techniques use the patient's own tissues, usually the patellar or hamstring tendons (autograft) or a cadaver graft (allograft) to arthroscopically reconstruct the torn ACL. Different patients groups experienced improved results with specific surgical graft choices. Recovery from surgery usually requires 6 months.

Nonoperative treatments are usually reserved for older patients or those with a very sedentary lifestyle. Physical therapy can focus on hamstring strengthening and core stability. An ACL brace can help stability. Longitudinal studies have demonstrated that nonoperative management of an ACL tear can lead to a higher incidence of meniscus tears.

► When to Refer

- Almost all ACL tears should be referred to an orthopedic surgeon for evaluation.
- Individuals with instability in the setting of a chronic ACL tear (> 6 months) should be considered for surgical reconstruction.
- Patients with an ACL tear and associated meniscus or articular injuries may benefit from surgery to address the other injuries.

Barrett GR et al. Allograft anterior cruciate ligament reconstruction in the young, active patient: Tegner activity level and failure rate. *Arthroscopy*. 2010 Dec;26(12):1593–601. [PMID: 20952145]

Delincé P et al. Anterior cruciate ligament tears: conservative or surgical treatment? A critical review of the literature. *Knee Surg Sports Traumatol Arthrosc*. 2012 Jan;20(1):48–61. [PMID: 21773828]

Peeler J et al. Accuracy and reliability of anterior cruciate ligament clinical examination in a multidisciplinary sports medicine setting. *Clin J Sport Med*. 2010 Mar;20(2):80–5. [PMID: 20215888]

3. Collateral Ligament Injury



ESSENTIALS OF DIAGNOSIS

- Caused by a valgus or varus blow or stress to the knee.
- Pain and instability in the affected area.
- Limited range of motion.

► General Considerations

The medial collateral ligament (MCL) is the most commonly injured ligament in the knee. It is usually injured with a valgus stress to the partially flexed knee. It can also occur with a blow to the lateral leg. The MCL is commonly injured with acute ACL injuries. The lateral collateral ligament (LCL) is less commonly injured, but this can occur with a medial blow to the knee. Since both collateral ligaments are extra-articular, injuries to these ligaments may not lead to any intra-articular effusion. Affected patients may have difficulty walking initially, but this can improve when the swelling decreases.

► Clinical Findings

A. Symptoms and Signs

The main clinical findings for patients with collateral ligament injuries are pain along the course of the ligaments. The patient may have limited range of motion due to pain, especially during the first 2 weeks following the injury. The best tests to assess the collateral ligaments are the varus and valgus stress tests. The sensitivity of the tests is as high as 86–96%.

The **valgus stress test** is performed with the patient supine (Table 41–8). The clinician should stand on the outside of the patient's knee. With one hand, the clinician should hold the ankle while the other hand is supporting the leg at the level of the knee joint. A valgus stress is applied at the ankle to determine pain and laxity of the MCL. The test should be performed at both 30 degrees and at 0 degrees of knee extension.

For the **varus stress test**, the patient is again placed supine (Table 41–8). For the right knee, the clinician should be standing on the right side of the patient. The clinician's left hand should be holding the ankle while the right hand is supporting the lateral thigh. A varus stress is applied at the ankle to determine pain and laxity of the LCL. The test should be performed at both 30 degrees and at 0 degrees of knee flexion.

The test results can be graded from 1–3. Grade 1 is when the patient has pain with varus/valgus stress test but no instability. With grade 2 injuries, the patient has pain, and the knee shows instability at 30 degrees of knee flexion. In grade 3 injuries, the patient has marked instability but not much pain. The knee is often unstable at both 30 degrees and 0 degrees of knee flexion.

B. Imaging

Radiographs are usually nondiagnostic except for avulsion injuries. However, radiographs should be used to rule out fractures that can occur with collateral ligament injuries. Isolated MCL injuries usually do not require evaluation by MRI, but MRI should be used to evaluate possible associated cruciate ligament injuries. LCL or posterolateral corner injuries should have MRI evaluation to exclude associated injuries and to determine their significance.

► Treatment

The majority of MCL injuries can be treated with protected weight-bearing and physical therapy. For grade 1 and 2 injuries, the patient can usually bear weight as tolerated with full range of motion. A hinged knee brace can be given to patients with grade 2 MCL tears to provide stability. Early physical therapy is recommended to protect range of motion and muscle strength. Grade 3 MCL injuries require long leg braces to provide stability. Patients can weight-bear but only with the knee locked in extension with a brace. The motion can then be increased with the brace unlocked. Grade 3 injuries can take up to 6–8 weeks to heal. MCL injuries rarely need surgery. LCL injuries usually require surgical repair or reconstruction.


► When to Refer

- Symptomatic instability with chronic MCL tears or acute MCL tears with other ligamentous injuries.
- LCL or posterolateral corner injuries require urgent surgical repair or reconstruction (within 1 week).

Pacheco RJ et al. Posterolateral corner injuries of the knee: a serious injury commonly missed. *J Bone Joint Surg Br.* 2011 Feb;93(2):194–7. [PMID: 21282758]

Phisitkul P et al. MCL injuries of the knee: current concepts review. *Iowa Orthop J.* 2006;26:77–90. [PMID: 16789454]

4. Posterior Cruciate Ligament Injury


ESSENTIALS OF DIAGNOSIS

- ▶ Usually follows an anterior trauma to the tibia, such as a dashboard injury during a motor vehicle accident.
- ▶ The knee may freely dislocate and reduce.
- ▶ One-third of multi-ligament injuries involving the PCL have neurovascular injuries.

► General Considerations

The posterior cruciate ligament (PCL) is the strongest ligament in the knee. PCL injuries usually represent significant trauma and are highly associated with multi-ligament injuries and knee dislocations. More than 70–90% of PCL

injuries have associated injuries to the posterolateral corner, MCL, and ACL. There should be high suspicion for neurovascular injuries and a thorough neurovascular examination of the limb should be performed.

► Clinical Findings

A. Symptoms and Signs

Most patients with acute injuries have difficulty with ambulation. Patients with chronic PCL injuries can ambulate without gross instability but may complain of subjective “looseness” and often report pain and dysfunction, especially with bending. Clinical examinations of PCL injuries include the “**sag sign**” (Table 41–8). The patient is placed supine and both hips and knees are flexed up to 90 degrees. Because of gravity, the PCL-injured knee will have an obvious set-off at the anterior tibia which is “sagging” posteriorly. The PCL ligament can also be examined using the **posterior drawer test** (90% sensitivity and 99% specificity) (Table 41–8). The patient is placed supine with the knee flexed at 90 degrees. In a normal knee, the anterior tibia should be positioned about 10 mm anterior to the femoral condyle. The clinician can grasp the proximal tibia with both hands and push the tibia posteriorly. The movement, indicating laxity and possible tear of the PCL, is compared with the uninjured knee. A PCL injury is sometimes mistaken for an ACL injury during the anterior drawer test since the tibia is subluxed posteriorly in a sagged position and can be abnormally translated forward, yielding a false-positive test for an ACL injury. Pain, swelling, pallor, and numbness in the affected extremity may suggest a knee dislocation with possible injury to the popliteal artery.

B. Imaging

Radiographs are often nondiagnostic but are required to diagnose any fractures. MRI is used to diagnose PCL and other associated injuries.

► Treatment

Isolated PCL injuries can be treated nonoperatively. Acute injuries are usually immobilized using a knee brace with the knee extension; the patient uses crutches for ambulation. Physical therapy can help achieve increased range of motion and improved ambulation. Many PCL injuries are associated with other injuries and may require operative reconstruction. Neurovascular injuries occur in up to one-third of all knee dislocations or PCL injuries.

► When to Refer

- The patient should be seen urgently within 1–2 weeks.
- If the lateral knee is also unstable with varus stress testing, the patient should be assessed for a posterolateral corner injury, which may require an urgent surgical reconstruction.
- Isolated PCL tears may require surgery if the tear is complete (grade 3) and the patient is symptomatic.

Hammoud S et al. Outcomes of posterior cruciate ligament treatment: a review of the evidence. *Sports Med Arthrosc.* 2010 Dec;18(4):280–91. [PMID: 21079509]

5. Meniscus Injuries



ESSENTIALS OF DIAGNOSIS

- ▶ Patient may or may not report an injury.
- ▶ Joint line pain and pain with deep squatting are the most sensitive signs.
- ▶ Difficulty with knee extension suggests an internal derangement that should be evaluated urgently with MRI.

▶ General Considerations

The menisci act as shock absorbers within the knee. Injuries to a meniscus can lead to pain, clicking, and locking sensation. Most meniscus injuries occur with acute injuries (usually in younger patients) or repeated microtrauma, such as squatting or twisting (usually in older patients).

▶ Clinical Findings

A. Symptoms and Signs

The patient may have an antalgic (painful) gait and difficulty with squatting. He or she may complain of catching or locking of the meniscal fragment. Physical findings can include effusion or joint line tenderness. Patients can usually point out the area of maximal tenderness along the joint line. Swelling usually occurs during the first 24 hours after the injury or later. Meniscus tears rarely lead to the immediate swelling that is commonly seen with fractures and ligament tears. Meniscus tears are commonly seen in arthritic knees. However, it is often unclear whether the pain is coming from the meniscus tear or the arthritis.

Provocative tests, including the **McMurray test**, the **modified McMurray test**, and the **Thessaly test**, can be performed to confirm the diagnosis (Table 41–8). Most symptomatic meniscus tears cause pain with deep squatting and when waddling (performing a “duck walk”).

B. Imaging

Radiographs are usually normal but may show joint space narrowing, early osteoarthritis changes, or loose bodies. MRI of the knee is the best diagnostic tool for meniscal injuries (93% sensitivity and 95% specificity). High signal through the meniscus (bright on T2 images) represents a meniscal tear.

▶ Treatment

Conservative treatment can be used for degenerative tears in older patients. The treatment is similar for patients with

mild knee osteoarthritis, including analgesics and physical therapy for strengthening and core stability. Acute tears in young and active patients can be best treated arthroscopically with meniscus repair or debridement. Recent randomized controlled studies have demonstrated no benefit with arthroscopic meniscectomy in patients with advanced osteoarthritis.

▶ When to Refer

- If the patient has symptoms of internal derangement suspected as meniscus injury. The patient should receive an MRI to confirm the injury.
- If the patient cannot extend the knee due to a mechanical block, the patient should be evaluated as soon as possible. Certain shaped tears on MRI, such as bucket handle tears, are amenable to meniscal repair surgery.

Konan S et al. Do physical diagnostic tests accurately detect meniscal tears? *Knee Surg Sports Traumatol Arthrosc.* 2009 Jul;17(7):806–11. [PMID: 19399477]

McDermott I. Meniscal tears, repairs and replacement: their relevance to osteoarthritis of the knee. *Br J Sports Med.* 2011 Apr;45(4):292–7. [PMID: 21297172]

6. Patellofemoral Pain



ESSENTIALS OF DIAGNOSIS

- ▶ Pain experienced with bending activities (kneeling, squatting, climbing stairs).
- ▶ Lateral deviation or tilting of the patella in relation to the femoral groove.

▶ General Considerations

Patellofemoral pain, also known as anterior knee pain or “runner’s knee,” describes any pain involving the patellofemoral joint. The pain affects any or all of the anterior knee structures, including the medial and lateral aspects of the patella as well as the quadriceps and patellar tendon insertions. The patella engages the femoral trochlear groove with approximately 30 degrees of knee flexion. Forces on the patellofemoral joint increase up to three times body weight as the knee flexes to 90 degrees (eg, climbing stairs), and five times body weight when going into full knee flexion (eg, squatting). Abnormal patellar tracking during flexion can lead to abnormal articular cartilage wear and pain. When the patient has ligamentous hyperlaxity, the patella can sublux out of the groove, usually laterally. Patellofemoral pain is also associated with muscle strength and flexibility imbalances as well as altered hip and ankle biomechanics.

▶ Clinical Findings

A. Symptoms and Signs

Patients usually complain of pain in the anterior knee with bending movements and less commonly in full extension.

Pain from this condition is localized under the kneecap but can sometimes be referred to the posterior knee or over the medial or lateral inferior patella. Symptoms may begin after a trauma or after repetitive physical activity, such as running and jumping. When maltracking, palpable and sometimes audible crepitus can occur.

Intra-articular swelling usually does not occur unless there are articular cartilage defects or if osteoarthritis changes develop. On physical examination, it is important to palpate the articular surfaces of the patella. For example, the clinician can use one hand to move the patella laterally, and use the fingertips of the other hand to palpate the lateral undersurface of patella. Patellar mobility can be assessed by medially and laterally deviating the patella (deviation by one-quarter of the diameter of the kneecap is consider normal; greater than one-half the diameter suggests excessive mobility). The **apprehension sign** suggests instability of the patellofemoral joint and is positive when the patient becomes apprehensive when the patella is deviated laterally (Table 41–8). The **patellar grind test** is performed by grasping the knee superior to the patella and pushing it downward with the patient supine and the knee extended, pushing the patella inferiorly. The patient is asked to contract the quadriceps muscle to oppose this downward translation, with reproduction of pain or grinding being the positive sign for chondromalacia of the patella. There are two common presentations: (1) Patients whose ligaments and patella are too loose (hypermobility); (2) and patients who have soft tissues that are too tight leading to excessive pressure on the joint.

Evaluation of the quadriceps strength and hip stabilizers can be accomplished by having the patient perform a one-leg squat without support. Patients who are weak may display poor balance, with dropping of the pelvis (similar to a positive hip Trendelenburg sign) or excessive internal rotation of the knee medially. Normally, with a one-leg squat, the knee should align over the second metatarsal ray of the foot.

B. Imaging

Diagnostic imaging has limited use in younger patients and is more helpful in older patients to assess for osteoarthritis or to evaluate patients who do not respond to conservative treatment. Radiographs may show lateral deviation or tilting of the patella in relation to the femoral groove. MRI may show thinning of the articular cartilage but is not clinically necessary, except prior to surgery or to exclude other pathology.

► Treatment

A. Conservative

For symptomatic relief, use of local modalities such as ice and anti-inflammatory medications can be beneficial. If the patient has signs of patellar hypermobility, physical therapy exercises are useful to strengthen the quadriceps (especially the vastus medialis obliquus muscle) to help stabilize the patella and improve tracking. Support for the patellofemoral joint can be provided by use of a patellar

stabilizer brace or special taping techniques (McConnell taping). Correcting lower extremity alignment (with appropriate footwear or over-the-counter orthotics) can help improve symptoms, especially if the patient has pronation or high arched feet. If the patient demonstrates tight peripatellar soft tissues, special focus should be put on stretching the hamstrings, iliotibial band, quadriceps, calves and hip flexors. Strengthening exercises should include the quadriceps and hip abductors.

B. Surgical

Surgery is rarely needed and is considered a last resort for patellofemoral pain. Procedures performed include lateral release or patellar realignment surgery.

► When to Refer

Patients with persistent symptoms.

Collado H et al. Patellofemoral pain syndrome. *Clin Sports Med.* 2010 Jul;29(3):379–98. [PMID: 20610028]
van Linschoten R et al. Supervised exercise therapy versus usual care for patellofemoral pain syndrome: an open label randomised controlled trial. *BMJ.* 2009 Oct 20;339:b4074. [PMID: 19843565]

7. Osteoarthritis



ESSENTIALS OF DIAGNOSIS

- Degeneration of joint cartilage.
- Pain with bending or twisting activities.
- Swelling.
- Loss of active and passive range of motion in severe osteoarthritis.

► General Considerations

In the United States, the prevalence of osteoarthritis will grow as the number of persons over age 65 years doubles to more than 70 million by 2030. The incidence of knee osteoarthritis in the United States is 240 per 100,000 person-years.

Cartilage loss and osteoarthritis symptoms are preceded by damage to the collagen-proteoglycan matrix. The etiology of osteoarthritis is often multifactorial including previous trauma, prior high-impact activities, genetic factors, obesity, and rheumatologic or metabolic conditions.

► Clinical Findings

A. Symptoms and Signs

Osteoarthritis usually causes pain in the affected joint with loading of the joint or at the extremes of motion.

Mechanical symptoms—such as swelling, grinding, catching, and locking—suggest internal derangement, which is indicated by damaged cartilage or bone fragments that affect the smooth range of motion expected at an articular joint. Pain can also produce the sensation of “buckling” or “giving way” due to muscle inhibition. As the joint degeneration becomes more advanced, the patient loses active range of motion and may lose passive range of motion as well.

As the condition worsens, patients with knee osteoarthritis have an increasingly limited ability to walk. Symptoms include pain with bending or twisting activities, and going up and down stairs. Swelling, limping, and pain while sleeping are common complaints with osteoarthritis, especially as it progresses.

B. Imaging

The most commonly recommended radiographs include bilateral weight-bearing 45-degree bent knee posteroanterior, lateral, and patellofemoral joint views (Merchant view). Radiographic findings include diminished width of the articular cartilage causing joint space narrowing, subchondral sclerosis, presence of osteophytes, and cystic changes in the subchondral bone. MRI of the knee is most likely unnecessary unless other pathology is suspected, including ischemic osteonecrosis of the knee.

► Treatment

A. Conservative

Changes in the articular cartilage are irreversible. Therefore, a cure for the diseased joint is not possible, although symptoms or structural issues can be addressed to try to maintain activity level. Conservative treatment for all patients with osteoarthritis includes activity modification, therapeutic exercises, and weight loss. Lifestyle modifications also include proper footwear and avoidance of high impact activities.

Use of a cane in the hand opposite to the affected side is mechanically advantageous. Knee sleeves or braces provide some improvement in subjective pain symptoms most likely due to improvements in neuromuscular function. If patients have unicompartamental osteoarthritis in the medial or lateral compartment, joint unloader braces are available to offload the degenerative compartment. Cushioning footwear and appropriate orthotics or shoe adjustments are useful for reducing impact to the lower extremities.

The initial drugs of choice for the treatment of pain in knee osteoarthritis are oral acetaminophen and topical capsaicin. If a traditional NSAID is indicated, the choice should be based on cost, side-effect profile, and compliance. The cyclooxygenase (COX)-2 inhibitor, celecoxib, is no more effective than traditional NSAIDs; it may offer short-term, but probably not long-term, advantage in preventing gastrointestinal complications. Due to its cost and potential cardiovascular risk, celecoxib should be reserved for carefully selected patients. The role of topical NSAIDs are being considered in the

osteoarthritis treatment algorithm, as they do avoid many of the traditional NSAID complications. Opioids can be used appropriately in patients with severe osteoarthritis (see Chapter 5). Glucosamine and chondroitin sulfate are supplements that have been widely used and marketed for osteoarthritis. Evidence for their effectiveness in slowing or reversing cartilage loss is limited and any effect present appears to be small. Despite some initial promise, the best-controlled studies indicate these supplements are ineffective as analgesics in osteoarthritis. However, they have minimal side effects and may be appropriate if the patient experiences subjective benefit.

Knee joint corticosteroid injections are options to help reduce pain and inflammation and can provide short-term pain relief, usually lasting about 6–12 weeks. Viscosupplementation by injections of hyaluronic acid-based products improves synovial fluid viscosity by increasing the molecular weight and quantity of hyaluronic acid beyond that naturally synthesized by the synovium. Laboratory studies also demonstrate that hyaluronic acid injections decrease inflammatory cytokines and free radicals. A review of five meta-analysis studies of viscosupplementation demonstrates a modest benefit. Studies also demonstrate more prolonged effects of viscosupplementation products compared with corticosteroid injection with symptom improvement for > 6 months in some patients with mild knee osteoarthritis.

B. Surgical

Two published randomized trials demonstrate that arthroscopy does not improve outcomes at 1 year over placebo or routine conservative treatment of osteoarthritis. Arthroscopic surgery is indicated in patients with osteoarthritis if, rather than pain, they have mechanical symptoms and internal derangement symptoms. Such surgical treatments are useful to restore range of motion by removing osteophytes, cartilage fragments, or loose bodies.

Joint replacement surgeries are effective and cost-effective for patients with significant symptoms or functional limitations, providing improvements in pain, function, and quality of life. Minimally invasive surgeries and computer-assisted navigation during operation are being investigated as methods to improve techniques (eg, accurate placement of the hardware implant) and to reduce complication rates.

Knee realignment surgery, such as high tibial osteotomy or partial knee replacement surgery, is indicated in patients younger than age 60 with unicompartamental osteoarthritis, who would benefit from delaying total knee replacement. Knee joint replacement surgery has been very successful in improving outcomes for patient with end-stage osteoarthritis. Recent long-term series describe > 95% survival rate of the implant at 15 years.

► When to Refer

Patients with sufficient disability, limited benefit from conservative therapy, and evidence of severe osteoarthritis can be referred for joint replacement surgery.

- Altman RD. New guidelines for topical NSAIDs in the osteoarthritis treatment paradigm. *Curr Med Res Opin.* 2010 Dec;26(12):2871–6. [PMID: 21070097]
- Bellamy N et al. Viscosupplementation for the treatment of osteoarthritis of the knee. *Cochrane Database Syst Rev.* 2006 Apr 19;(2):CD005321. [PMID: 16625635]
- Lee YH et al. Effect of glucosamine or chondroitin sulfate on the osteoarthritis progression: a meta-analysis. *Rheumatol Int.* 2010 Jan;30(3):357–63. [PMID: 19544061]
- Zhang W et al. OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. *Osteoarthritis Cartilage.* 2008 Feb;16(2):137–62. [PMID: 18279766]

ANKLE INJURIES

1. Inversion Ankle Sprains

ESSENTIALS OF DIAGNOSIS

- ▶ Localized pain and swelling.
- ▶ The majority of ankle injuries involve inversion injuries affecting the lateral ligaments.
- ▶ Consider chronic ankle instability or associated injuries if pain persists for > 3 months following an ankle sprain.

▶ General Considerations

Ankle sprains are the most common sports injuries seen in outpatient clinics. Patients usually report “turning the ankle” during a fall or after landing on an irregular surface such as a hole or an opponent’s foot. The most common mechanism of injury is an inversion and plantarflexion sprain, which injures the anterior talofibular ligament (ATF) ligament rather than the calcaneofibular ligament (CF) ligament. Other injuries that can occur with inversion ankle injuries are listed in (Table 41–9).

▶ Clinical Findings

A. Symptoms and Signs

The usual symptoms following a sprain include localized pain and swelling over the lateral aspect of the ankle, difficulty weight bearing, and limping. The patient’s ankle may feel unstable. On examination, there may be swelling or bruising over the lateral aspect of the ankle. The anterior, inferior aspect below the lateral malleolus is most often the point of maximal tenderness consistent with ATF and CF ligament injuries. The swelling may limit motion of the ankle. Special stress tests for the ankle include the **anterior drawer test** (Table 41–10) and **subtalar tilt test** (Table 41–10). In order to grade the severity of ankle sprains, no laxity on stress tests is considered a grade 1 injury, laxity of the ATF ligament on anterior drawer testing but a negative tilt test is a grade 2 injury, and both positive drawer and tilt tests signify a grade 3 injury.

Table 41–9. Injuries associated with ankle sprains.

Ligaments
Subtalar joint sprain
Sinus tarsi syndrome
Syndesmotic sprain
Deltoid sprain
Lisfranc injury
Tendons
Posterior tibial tendon strain
Peroneal tendon subluxation
Bones
Osteochondral talus injury
Lateral talar process fracture
Posterior impingement (os trigonum)
Fracture at the base of the fifth metatarsal
Jones fracture
Salter fracture (fibula)
Ankle fractures

B. Imaging

Routine ankle radiographic views include the anteroposterior, lateral, and oblique (mortise) views. Less common views requested include the calcaneal view and subtalar view. Ottawa Ankle Rules are clinical prediction rules to the need for radiographs and have a 97% sensitivity and 99% negative predictive value. If the patient is unable to bear weight immediately in the office setting or emergency department for four steps, then the clinician should check for (1) bony tenderness at the posterior edge of the medial or lateral malleolus and (2) bony tenderness over the navicular (medial midfoot) or at the base of the fifth metatarsal. If either malleoli demonstrates pain or deformity, then ankle radiographs should be obtained. If the foot has bony tenderness, obtain foot radiographs. An MRI is helpful when considering the associated injuries.

▶ Treatment

Immediate treatment of an ankle sprain follows the MICE mnemonic: *modified activities, ice, compression, and elevation*. Subsequent treatment involves protected weight bearing with crutches and use of an ankle stabilizer brace, especially for grade 2 and 3 injuries. Early motion is essential, and patients should be encouraged to do home exercises or physical therapy. Proprioception and balance exercises (eg, “wobble board”) are useful to restore function to the ankle and prevent future ankle sprains. Regular use of an ankle support with activities can reduce the risk of lateral ankle sprains. Chronic instability can develop after acute ankle sprain in 10–20% of people and may require surgical stabilization with ligament reconstruction surgery.

▶ When to Refer

- Ankle fractures.
- Recurrent ankle sprains or signs of chronic ligamentous ankle instability.

Table 41–10. Ankle examination.

Maneuver	Description
Inspection	Examine for the alignment of the ankle. (SEADS)
Palpation	Include important landmarks: Ottawa Ankle Rules (medial and lateral malleolus, base of fifth metatarsal and navicular area), anterior tibiofibular ligament, posterior talus; tendons (Achilles, peroneals, posterior tibialis, flexor hallucis longus).
Range of motion testing	Check range of motion actively (patient performs) and passively (clinician performs), especially with flexion and extension of the spine. Rotation and lateral bending are also helpful to assess symmetric motion or any restrictions.
Ankle strength testing	Test resisted ankle dorsiflexion, plantarflexion, inversion and eversion strength manually.
Ankle anterior drawer	The clinician keeps the foot and ankle in the neutral position with the patient sitting, then uses one hand to fix the tibia and the other to hold the patient's heel and draw the ankle forward. Normally, there may be approximately 3 mm of translation until an endpoint is felt. A positive test includes increased translation of one foot compared to the other with loss of the endpoint of the anterior talofibular ligament.
Subtalar tilt test	Performed with the foot in the neutral position with the patient sitting. The clinician uses one hand to fix the tibia and the other to hold and invert the calcaneus. Normal inversion at the subtalar joint is approximately 30 degrees. A positive test consists of increased subtalar joint inversion greater than 10 degrees on the affected side with loss of endpoint for the calcaneofibular ligament.
External rotation stress test	Performed when the clinician fixes the tibia with one hand and grasps the foot in the other with the ankle in the neutral position and then dorsiflexes and externally rotates the ankle, reproducing the patient's pain.

SEADS, swelling, erythema, atrophy, deformity, and (surgical) scars.

- No response after more than 3 months of conservative treatment.
- Suspicion of associated injuries.

de Vries JS et al. Interventions for treating chronic ankle instability. *Cochrane Database Syst Rev.* 2011 Aug;(8):CD004124. [PMID: 21833947]

Lamb SE et al. Mechanical supports for acute, severe ankle sprain: a pragmatic, multicentre, randomised controlled trial. *Lancet.* 2009 Feb 14;373(9663):575–81. [PMID: 19217992]

2. Eversion (“High”) Ankle Sprains



ESSENTIALS OF DIAGNOSIS

- ▶ Severe and prolonged pain.
- ▶ Limited range of motion.
- ▶ Mild swelling.
- ▶ Difficulty with weight bearing.

▶ General Considerations

A syndesmotic injury or “high ankle” sprain involves the anterior *tibio*fibular ligament in the anterolateral aspect of the ankle, superior to the anterior *talof*ibular (ATF) ligament. The injury mechanism often involves the foot being turned out or externally rotated and everted (eg, when being tackled). This injury is commonly missed or misdiagnosed as an ATF ligament sprain on initial visit.

▶ Clinical Findings

A. Symptoms and Signs

Symptoms of a high ankle sprain include severe and prolonged pain over the anterior ankle at the anterior tibiofibular ligament, worse with weight bearing. This is often more painful than the typical ankle sprain. The point of maximal tenderness involves the anterior tibiofibular ligament, which is higher than the ATF ligament. It is also important to palpate the proximal fibula to rule out any proximal syndesmotic ligament injury and associated fracture known as a “maisonneuve fracture.” There is often some mild swelling in this area, and the patient may or may not have an ankle effusion. The patient usually has limited range of motion in all directions. The **external rotation stress test** reproduces the mechanism of injury (Table 41–10). (**Note:** The patient's foot should have an intact neurovascular examination before undertaking this test.)

B. Imaging

Radiographs of the ankle should include the anteroposterior, mortise, and lateral views. The mortise view may demonstrate loss of the normal overlap between the tibia and fibula, which should be at least 1–2 mm. Asymmetry in the joint space around the tibiotalar joint suggests disruption of the syndesmotic ligaments. If there is proximal tenderness in the lower leg especially around the fibula, an anteroposterior and lateral view of the tibia and fibula should be obtained to rule out a proximal fibula fracture. MRI is the best method to visualize injury to the tibiofibular ligament and to assess status of the other ligaments and the articular cartilage.

► Treatment

Whereas most ankle sprains are treated with early motion and weight bearing, treatment for a high ankle sprain should be conservative with a cast or walking boot for 4–6 weeks. Thereafter, protected weight bearing with crutches is recommended until the patient can walk pain-free. Physical therapy can start early to regain range of motion and maintain strength with limited weight-bearing initially.

► When to Refer

If there is widening of the joint space and asymmetry at the tibiotalar joint, the patient should be referred urgently to a

foot and ankle surgeon. Severe or prolonged persistent cases that do not heal may require internal fixation to avoid chronic instability at the tibiofibular joint.

Press CM et al. Management of ankle syndesmosis injuries in the athlete. *Curr Sports Med Rep.* 2009 Sep–Oct;8(5):228–33. [PMID: 19741349]

Scheyerer MJ et al. Diagnostics in suspicion of ankle syndesmotomic injury. *Am J Orthop (Belle Mead NJ).* 2011 Apr;40(4):192–7. [PMID: 21731928]

42

Women's Health Issues

Megan McNamara, MD, MSc, &
Judith Walsh, MD, MPH

The field of women's health encompasses more than the reproductive health issues commonly addressed by obstetricians and gynecologists; it evaluates diseases and conditions only seen or experienced in women or experienced by women in ways different than men, as well as the evidence-based prevention and treatment of risk factors and diseases in women. Hence, all primary care providers, including internists and family physicians, should be well versed in women's health issues.

PREVENTIVE HEALTH CARE

Prevention of disease can be **primary** (preventing disease before it happens as well as identifying and modifying risk factors), **secondary** (identifying early disease), or **tertiary** (treating complications of the disease or limiting the impact of established disease). Important areas for primary prevention include encouraging women to exercise regularly to reduce the risk of coronary heart disease (CHD) and breast cancer as well as counseling women to discontinue smoking to reduce the risk of cardiac and lung diseases. Cancer screening in women focuses on secondary prevention, so that disease is detected early when prompt treatment improves outcome.

CARDIOVASCULAR DISEASE PREVENTION

Although cardiovascular disease is the leading cause of death in women, they are often more concerned about developing breast cancer (see below) than about developing heart disease. While some heart disease risk factors such as age and family history are not modifiable, as with men, other risk factors such as hypertension, hyperlipidemia, smoking, obesity, and diabetes are potentially modifiable. The Framingham risk calculator (<http://hp2010.nhlbihin.net/atp/iii/calculator.asp?usertype=prof>) can be used to estimate a woman's 10-year risk of CHD based on her age, smoking status, blood pressure, and cholesterol levels.

▶ Modifiable Risk Factors

A. Hypertension

Hypertension is a risk factor for CHD and stroke in both men and women. Approximately 70–80% of women over age 70 have hypertension. A woman with high blood pressure is at lower risk for CHD than a similar aged man. For many young and otherwise healthy women, drug treatment can be deferred, since their absolute risk of CHD in the next 10 years is likely to be low. When pharmacotherapy is started, the choice of medication is similar to those used in men (see Chapter 11).

B. Hyperlipidemia

Hyperlipidemia is a CHD risk factor in both men and women, but low levels of high-density lipoprotein (HDL) is more predictive of CHD risk in women. Elevated cholesterol is defined as a total cholesterol > 240 mg/dL (> 7.2 mmol/L) or low-density lipoprotein (LDL) cholesterol > 160 mg/dL (> 4.8 mmol/L). Borderline cholesterol is defined as a total cholesterol between 200 mg/dL and 240 mg/dL (6 mmol/L and 7.2 mmol/L) or an LDL cholesterol of 130–159 mg/dL (3.9–4.77 mmol/L). Ideal cholesterol is defined as a total cholesterol < 200 mg/dL (< 6 mmol/L) or an LDL < 130 mg/dL (< 3.9 mmol/L) and an HDL cholesterol > 50 mg/dL (> 1.5 mmol/L).

The US Preventive Services Task Force (USPSTF) recommends screening all women aged 45 and older for hyperlipidemia, whereas the National Cholesterol Education Program (NCEP) recommends screening all individuals aged 20 and over. Before screening a woman for hyperlipidemia, an important consideration is whether or not treatment recommendations will change based on the results. Since therapeutic lifestyle changes are recommended for all women, the question is at what point should medication treatment be considered.

There is clear evidence that medication treatment of hyperlipidemia reduces CHD events in women who already have CHD, but when lipid-lowering medications are used

in women who do not already have CHD, the evidence of benefit is less clear. Decisions about when to initiate medication treatment should include an assessment of an individual's absolute risk of CHD in the next 10 years. Medication treatment should be targeted toward women with CHD and high-risk women who are most likely to benefit. The NCEP recommends different thresholds at which to initiate medication therapy based on individual CHD risk. For example, for a woman with known CHD, lipid-lowering medication is initiated at an LDL cholesterol of > 130 mg/dL, whereas for a woman with 0–1 risk factor, medication therapy is not initiated until the LDL cholesterol measures > 190 mg/dL.

C. Diabetes

Diabetes is a CHD risk factor in both men and women. Studies have reached conflicting conclusions about the effect of tight control of diabetes on CHD outcomes in both men and women, although lipid lowering is clearly associated with a reduction in CHD events in diabetic women. All women should focus on primary prevention of diabetes with avoidance of obesity and maintenance of regular exercise.

D. Obesity

Obesity has been established as an independent risk factor for CHD in women. It is not known whether or not weight loss will decrease CHD risk. Since most obese women who lose weight gain it back, the overall goal should be ongoing avoidance of weight gain above normal weight.

E. Predictive Biomarkers and Clinical Tests

The use of high-sensitivity C-reactive protein (hsCRP) has increased in recent years. CRP is an inflammatory biomarker that has been shown to predict cardiovascular events. However, there is currently no evidence that screening for hsCRP improves cardiac outcomes. It has been suggested that measuring hsCRP may be useful in women for whom it would change treatment outcomes, but there is currently no evidence to support this. The USPSTF recently published guidelines outlining the use of nontraditional risk factors in the evaluation of CHD. The risk factors included in the recommendation were hsCRP, ankle-brachial index, leukocyte count, fasting blood glucose, periodontal disease, carotid intima media thickness, coronary artery calcification score, electron beam CT, homocysteine, and lipoprotein (a). The USPSTF concluded that there is insufficient evidence to balance the benefits and harms of screening asymptomatic men and women with no history of CHD to predict CHD events and did not recommend routine screening.

▶ Therapeutic Options for Reducing Risk Factors

A. Aspirin

Aspirin is clearly useful for secondary prevention of CHD in women. Among women who do not have CHD,

aspirin reduces the risk of stroke, whereas in men, it reduces the risk of CHD. Before starting an aspirin regimen to reduce the risk of the stroke, women should be assessed for their risk of gastrointestinal bleeding, which is the most common adverse side effect of aspirin use. The USPSTF recommends aspirin in women aged 55–79 years when the potential benefit of a reduction in ischemic strokes outweighs the potential harms of a gastrointestinal hemorrhage. For healthy or at-risk women, 81 mg/d or 100 mg every other day is the suggested dose. For high-risk women, a dose of 75–325 mg/d is recommended.

B. Exercise

Exercise has been associated with a reduction in all causes of cardiovascular mortality. Women often want to know how much exercise is necessary for health benefits. Studies have shown that walking 2.5–3 hours a week is associated with a reduction in cardiovascular disease. The Centers for Disease Control and Prevention and the American College of Sports Medicine recommend that all women accumulate at least 30 minutes a day of moderate intensity physical activity on most if not all days of the week. The Institute of Medicine recommends an hour a day for the goal of maintaining health and ideal body weight.

Berg AO et al. U.S. Preventive Services Task Force: screening for lipid disorders in adults: recommendations and rationale. *Am J Nurs*. 2002 Jun;102(6): 91,93,95. [PMID: 12394084]

Centers for Disease Control and Prevention. National Center for Health Statistics, Health Data Interactive. Mortality by underlying cause, ages 18+: US/State, 1999–2007. <http://205.207.175.93/HDI/TableView/tableView.aspx?ReportId=673>.

Mosca L et al. Effectiveness-based guidelines for the prevention of cardiovascular disease in women—2011 update: a guideline from the American Heart Association. *Circulation*. 2011 Mar 22;123(11):1243–62. [PMID: 21325087]

National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. *Circulation*. 2002 Dec 17;106(25):3143–421. [PMID: 12485966]

U.S. Preventive Services Task Force. Aspirin for the prevention of cardiovascular disease: U.S. Preventive Services Task Force Recommendation Statement. *Ann Intern Med*. 2009 Mar 17;150(6):396–404. [PMID: 19293072]

U.S. Preventive Services Task Force. Screening for Lipid Disorders in Adults: U.S. Preventive Services Task Force recommendation statement. <http://www.uspreventiveservicestaskforce.org/uspstf08/lipid/lipids.htm>

U.S. Preventive Services Task Force. Using nontraditional risk factors in coronary heart disease risk assessment: U.S. Preventive Services Task Force recommendation statement. *Ann Intern Med*. 2009 Oct 6;151(7):474–82. [PMID: 19805770]

CANCER PREVENTION

1. Breast Cancer

► Risk Factors & Risk Assessment

Breast cancer is the most commonly detected cancer in women and the second leading cause of cancer death. Breast cancer risk is increased with age and with a family history of breast cancer. Women who drink more than two alcoholic drinks per day are at increased risk for breast cancer, and exercise is associated with a decreased risk of breast cancer. Dietary intake has not been conclusively associated with breast cancer risk.

Various models have been used to predict a woman's risk for breast cancer. The National Cancer Institute has developed the Breast Cancer Risk Assessment Tool, which is based on the Gail Model, and calculates the woman's risk of developing breast cancer in the next 5 years by considering the following factors: (1) the woman's age, (2) age at which she had her first menstrual period, (3) age at delivery of first live child, (3) number of first-degree relatives with breast cancer, (4) history of any breast biopsies, and (5) history of atypical hyperplasia. The model has been validated in white women and has been evaluated in black women and found to be relatively accurate, although it may underestimate the risk in black women with a history of previous breast biopsies. It has yet to be validated in women of other ethnicities.

► Primary Prevention

In addition to lifestyle modifications, such as exercise and moderation of alcohol intake, chemoprevention of breast cancer is an option for some women. The selective estrogen receptor modifiers (SERMS) tamoxifen and raloxifene have both been shown to reduce invasive breast cancer in high-risk women. However, there are risks associated with SERM treatment. Tamoxifen is associated with an increased risk of endometrial cancer and deep venous thrombosis (DVT). Although raloxifene is not associated with an increased risk of endometrial cancer, the risk of DVT remains. The USPSTF recommends that clinicians discuss chemoprevention with women at high risk for breast cancer and at low risk for the adverse effects of chemoprevention. Clinicians should inform patients of the potential benefits and harms of chemoprevention. Breast cancer risk increases with age, but the risk of adverse effects does as well. Since the clinical trials of tamoxifen and raloxifene for breast cancer prevention used a 1.66% 5-year risk, this risk level is often used as a guide for treatment.

► Breast Cancer Screening

Traditional breast cancer screening modalities include screening mammography, clinical breast examination, and breast self-examination. Teaching women to do routine breast self-examination has not been shown to reduce breast cancer mortality. The USPSTF recommends against teaching women to do breast self-examination. The American Cancer Society states that it is acceptable not to do it, but that if women are performing

breast self-examination, it is important to ensure that they are doing it correctly. The combination of breast examination done by a clinician and mammography is associated with a decrease in breast cancer mortality, but there is insufficient evidence to recommend clinical breast examination alone.

Mammography reduces breast cancer mortality in women aged 50–74 years and routine mammographic screening is recommended for women in this age group. For women aged 40–49 years, screening has been more controversial. Recent guidelines published by the USPSTF recommend that clinicians not routinely order mammography among 40- to 49-year-old women but rather that they individualize the decision to begin screening, since the number needed to invite to screen to prevent one breast cancer death is much higher in younger women and the number of false-positive and false-negative test results are much higher. Since women over age 75 have not been included in clinical trials and since the likelihood of comorbid diseases limiting life expectancy increases, routine screening of women in this age group is not recommended, but rather the decision making should be individualized.

Hubbard et al. Cumulative probability of false-positive recall or biopsy recommendation after 10 years of screening mammography: a cohort study. *Ann Intern Med.* 2011 Oct 18; 155(8):481–92. [PMID: 22007042]

National Cancer Institute. Breast Cancer Risk Assessment Tool. <http://www.cancer.gov/bcrisktool>

U.S. Preventive Services Task Force. Screening for breast cancer: U.S. Preventive Services Task Force recommendation statement. *Ann Intern Med.* 2009 Nov 17;151(10):716–26. [PMID: 19920272]

2. Colorectal Cancer

Colorectal cancer is the third leading cause of cancer death in both men and women. In 2010, an estimated 9% of cancer deaths in women were caused by colorectal cancer. Since the risk of colorectal cancer increases with age, all women should be screened for colorectal cancer starting at the age of 50. The USPSTF recommends routine screening in men and women age 50–75, individualized decision making about screening in individuals aged 76–85, and no screening after the age of 85. Details of the screening options and suggested screening intervals are described in Chapter 1.

Holden DJ et al. Enhancing the use and quality of colorectal cancer screening. *Evid Rep Technol Assess (Full Rep).* 2010 Feb;(190):1–195. [PMID: 20726624]

Levin B et al. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-society Task Force on Colorectal Cancer, and the American College of Radiology. *Gastroenterology.* 2008 May;134(5): 1570–95. [PMID: 18384785]

U.S. Preventive Services Task Force. Screening for Colorectal Cancer: U.S. Preventive Services Task Force recommendation statement. *Ann Intern Med.* 2008 Nov 4;149(9):627–37. [PMID: 18838716]

3. Cervical Cancer

In contrast to most other cancers for which routine screening is recommended, the incidence of cervical cancer is higher in younger women and decreases with age. The major risk factor for cervical cancer is exposure to the human papillomavirus (HPV). Primary prevention of cervical cancer includes avoidance of smoking, postponing sexual debut, and limiting the number of sexual partners. Condom use may also be protective.

► Primary Prevention

A quadrivalent HPV vaccine that includes capsid proteins against four HPV types (6, 11, 16, and 18) has been approved for use in girls and women aged 9–26 years to prevent disease associated with these HPV types. A bivalent vaccine (Cervarix) is also available. The published studies, which are based on interim results, show a high degree of efficacy of prevention of vaccine-associated genital warts, persistent infections, and cervical intraepithelial neoplasia. Protection has not been shown against strains that are not in the vaccine or strains that were present before vaccination. The Advisory Committee on Immunization Practices (ACIP) recommends routine vaccination for girls aged 11 or 12 up to age 26, whereas the American Cancer Society recommends the vaccine for girls aged 11–18 but states that there is insufficient evidence to recommend for or against routine vaccination for women aged 19–26. The ACIP also recommends that all 11- and 12-year-old boys get vaccinated against HPV. Unanswered questions about the vaccine include the long-term effects and the length of protection. Receipt of vaccine should not change cervical cancer screening intervals in women.

► Secondary Prevention

An important focus of cervical cancer prevention is screening using the Papanicolaou smear. Cervical cancer screening is the biggest success in the history of cancer screening. Cervical cancer mortality has been reduced by about 70% with routine cervical cancer screening. One of the reasons that screening has been so successful is that there is a long preclinical phase where early changes can be detected and treated so as to avoid the development of cancer. In a 2012 update, the US Preventive Services Task Force (USPSTF) recommends screening for cervical cancer in women age 21 to 65 years with cytology (Papanicolaou smear) every 3 years or, for women age 30 to 65 years who want to lengthen the screening interval, screening with a combination of cytology and HPV testing every 5 years. Screening may be done with either liquid-based or conventional cytology. The USPSTF recommends against screening for cervical cancer with HPV testing, alone or in combination with cytology, in women younger than age 30 years. The USPSTF recommends against screening for cervical cancer in women older than age 65 years who have had adequate prior screening and are not otherwise at high risk for cervical cancer. Women with risk factors that place them at higher risk for cervical intraepithelial neoplasia may require more frequent screening. Guidelines from the American

College of Obstetricians and Gynecologists (ACOG) state screening should start at age 21 regardless of the onset of sexual activity. ACOG recommends screening every 2 years in women aged 21–29 and every 3 years in women aged 30 and older who have had at least three normal smears. All organizations agree that older women (over age 65 or 70) can stop screening.

Testing for high-risk HPV types is routinely used for the evaluation of abnormal Papanicolaou smears, but their use in routine screening is controversial. Since the prevalence of exposure to high risk HPV types is very high, the potential utility of HPV testing would be finding no evidence of HPV. ACOG and the American Cancer Society recommend co-testing with high risk HPV types as an option, and then rescreening in 3 years if the HPV testing is negative. The USPSTF concludes that the evidence is insufficient to assess the balance of benefits and harms of HPV testing, alone or in combination with cytology for screening for cervical cancer in women aged 30 and older. Given that women with a normal Papanicolaou smear can be rescreened in 3 years, it is not clear what high risk HPV testing for primary screening adds. However, given that the vast majority of cervical cancers occur in women who have never been screened, or who have not been screened in the past 5 years, efforts for cervical cancer prevention should primarily focus on those women.

American College of Obstetricians and Gynecologists. ACOG Practice Bulletin no. 109: Cervical cytology screening. *Obstet Gynecol.* 2009 Dec;114(6):1409–20. [PMID: 20134296]
U.S. Preventive Services Task Force. Screening for cervical cancer. <http://www.uspreventiveservicestaskforce.org/uspstf/uspsscerv.htm>
U.S. Preventive Services Task Force. Screening for cervical cancer: U.S. Preventive Services Task Force recommendation statement. <http://www.uspreventiveservicestaskforce.org/uspstf11/cervcancer/cervcancers.htm>

4. Lung Cancer

Although lung cancer is not typically considered a “women’s cancer,” it is the leading cause of cancer mortality in both men and women. Primary prevention of lung cancer should be a high priority with encouragement of tobacco cessation among women who smoke. The use of chest radiographs and sputum cytology for cancer screening have not been shown to reduce lung cancer mortality. The National Lung Screening Trial (NLST) compared screening with low-dose CT to screening with chest radiography. High-risk participants (either current or former smokers) received either annual CT or chest radiography for 3 years and were then monitored for 6.5 years. There was a significant reduction in both lung cancer mortality and total mortality with CT screening. However, there were a very large number of false-positive test results, many of which led to additional testing. The USPSTF does not currently recommend any of these modalities for lung cancer screening, although many organizations are in the midst of reassessing their recommendations for lung cancer screening based on the results of the NLST.

National Lung Screening Trial Research Team; Aberle DR et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. *N Engl Med*. 2011 Aug 4;365(5):395–409. [PMID: 21714641]

U.S. Preventive Services Task Force. Lung cancer screening: recommendation statement. *Ann Intern Med*. 2004 May 4;140(9):738–9. [PMID: 15126258]

5. Ovarian Cancer

Ovarian cancer is a relatively rare but dreaded cancer, with a lifetime incidence of about 1.2% in women with no family history of ovarian cancer. Because it is often detected late, treatment options may be limited.

Many of the risk factors for ovarian cancer such as age and family history are not modifiable, but there are protective factors, including having more than one full-term pregnancy, breast-feeding, and oral contraceptive use. Women at high-risk for ovarian cancer should consider the use of oral contraceptives for as long as it is feasible.

Although screening for ovarian cancer with either the serum marker CA-125 or with transvaginal ultrasound is theoretically appealing, the rarity of the disease limits their use and leads to many false-positive test results. The Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial, where women were screened for ovarian cancer with annual CA-125 and transvaginal ultrasound and monitored for 12.4 years, resulted in no reduction in ovarian cancer mortality. In addition, there were a large number of false-positive test results, some leading to surgical follow-up and resultant surgical complications. The USPSTF does not recommend screening for ovarian cancer.

Buys SS et al. Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. *JAMA*. 2011 Jun 8;305(22):2295–303. [PMID: 21642681]

U.S. Preventive Services Task Force. Screening for ovarian cancer: recommendation statement. *Am Fam Physician*. 2005 Feb 15;71(4):759–62. [PMID: 15756773]

OSTEOPOROSIS PREVENTION

Osteoporotic fractures are increasing as the population ages. Age and female sex are major risk factors for osteoporotic fractures. Hip and vertebral fractures are associated with premature mortality. Osteoporosis risk can be assessed by measuring bone mineral density (BMD). Normal BMD is no lower than 1.0 standard deviation below the mean for young adult women (t score). Osteopenia is defined as BMD between 1.0 and 2.5 standard deviations below the mean for young adults (t score of –1.0 to –2.5) and osteoporosis is defined as a BMD more than 2.5 standard deviations below the young adult mean (t score < –2.5).

The World Health Organization has developed a fracture risk assessment tool (FRAX, available at <http://www.shef.ac.uk/FRAX/index.jsp>) that can predict a woman's 10-year risk of having any osteoporotic fracture and the 10-year risk of hip fracture. Risk factors used in the FRAX tool include age, gender, personal history of fracture,

parental history of hip fracture, low body mass index, use of oral corticosteroids, secondary osteoporosis, current smoking, and alcohol intake of three or more drinks per day. It can be used with or without BMD. The FRAX tool is particularly helpful in determining which women with osteopenia are most likely to benefit from treatment. Based on the World Health Organization algorithm adopted for the United States, treatment is recommended when there is a 10-year risk of hip fracture $\geq 3\%$ or a 10-year risk of a major osteoporotic fracture $\geq 20\%$.

► Primary Prevention

Although calcium supplementation is routinely recommended, evidence from the Women's Health Initiative showed that calcium supplementation did not reduce fracture risk in healthy postmenopausal women. Calcium appears to be necessary but not sufficient for fracture prevention. Recommended calcium intake for women younger than 50 years is 1000 mg/day and for women aged 51 and over, it is 1200 mg/day. Calcium can be given as either calcium citrate or calcium carbonate and should be given with vitamin D. Regular weight bearing exercise has also been associated with an increase in bone density although the effect is lost when the exercise is not continued.

Increasing evidence suggests that vitamin D supplementation is associated with a reduction in fracture risk. Vitamin D can be given as either D₂ or D₃ formulations. Recommendations are that women aged 70 and younger should consume 600 international units of vitamin D per day, whereas women aged 71 and older should consume 800 international units per day. Individuals with vitamin D deficiency (25-OH vitamin D < 20 mg/mL) may require higher doses, although most recommendations for vitamin D supplementation are based on achieving a serum 25-OH vitamin D concentration of a particular level, rather than on a clinical outcome. Whether or not women should be routinely screened for vitamin D deficiency remains an ongoing question. However, given the association of vitamin D and fractures, checking a 25-OH vitamin D level in women with osteoporosis is reasonable.

► Bone Mineral Density Screening

The biggest risk factor for developing osteoporosis is increasing age. Although many women expect to be screened around the time of menopause, routine BMD screening is not recommended until the age of 65. The National Osteoporosis Foundation recommends screening all women age 65 and older and screening younger postmenopausal women if there is a concern based on their risk-factor profile, if they have had a fracture, or if they are discontinuing hormone therapy. The USPSTF recommends screening women aged 65 and older and only screening women aged 60–64 who are at increased risk.

Treatment is generally recommended in women who have a t score < –2.5, who have already had a fracture or who have a t score in the osteopenic range but are at high risk for fracture. Treatment options for osteoporosis are described in Chapter 26.

Bischoff-Ferrari HA et al. Prevention of nonvertebral fractures with oral vitamin D and dose dependency: meta-analysis of randomized controlled trials. *Arch Intern Med.* 2009 Mar 23;169(6):551–6. [PMID: 19307517]

World Health Organization Collaborating Centre for Metabolic Bone Diseases. Fracture Risk Assessment Tool (FRAX). <http://www.shef.ac.uk/FRAX/index.jsp>

Institute of Medicine (IOM). Dietary reference intakes for calcium and vitamin D. <http://www.iom.edu/Reports/2010/Dietary-Reference-Intakes-for-Calcium-and-Vitamin-D.aspx>.

U.S. Preventive Services Task Force. Screening for osteoporosis: U.S. Preventive Services Task Force recommendation statement. *Ann Intern Med.* 2011 Mar 1;154(5):356–64. [PMID: 21242341]

Watts NB et al; AACE Osteoporosis Task Force. American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of postmenopausal osteoporosis. *Endocr Pract.* 2010 Nov–Dec; 16(Suppl 3):1–37. [PMID: 21224201]

PREVENTION OF SEXUALLY TRANSMITTED INFECTIONS

Many sexually transmitted infections are asymptomatic in women and some can lead to significant consequences. Primary prevention of sexually transmitted infections includes postponing sexual debut, limiting number of sexual partners, and regular condom use.

The USPSTF and the Centers for Disease Control and Prevention recommend annual screening for *Chlamydia trachomatis* and gonorrhea in sexually active women age 25 and younger. Screening should continue in women over age 25 and in women who have high-risk sexual behaviors. The Centers for Disease Control and Prevention recommends screening all women for HIV, whereas the USPSTF recommends focusing screening efforts on high-risk individuals. All patients who have a sexually transmitted infection or who seek testing for a sexually transmitted infection should be offered HIV testing.

Meyers D et al. U.S. Preventive Services Task Force recommendations for STI screening. *Am Fam Physician.* 2008 Mar 15; 77(6):819–24. [PMID: 18386598]

DEPRESSION SCREENING

Since depression is approximately two times more common in women than in men, clinicians should be alert to symptoms suggesting depression in women. Symptoms include depressed mood, loss of interest in activities, sleep disturbance, change in appetite or weight, psychomotor retardation, difficulty concentrating, feelings of worthlessness, and thoughts of suicide. Low energy or fatigue is a particularly common symptom in women.

There are several clinical surveys for depression screening. The two question screen appears to be effective. Patients are asked “Over the past 2 weeks, have you felt down, depressed or hopeless?” and “Over the past 2 weeks, have you felt little interest or pleasure in doing things?”

There is no evidence to suggest that any particular screening tool is superior. A positive screening test should lead to more extensive evaluation.

The USPSTF recommends screening for depression if staff-assisted depression care supports are in place to ensure accurate diagnosis, effective treatment, and follow-up. If these supports are not in place, screening is not recommended.

Phelan E et al. A study of the diagnostic accuracy of the PHQ-9 in primary care elderly. *BMC Fam Pract.* 2010 Sept 1;11:63. [PMID: 20807445]

U.S. Preventive Services Task Force. Screening for depression in adults: U.S. Preventive Services Task Force recommendation statement. *Ann Intern Med.* 2009 Dec 1;151(11):784–92. [PMID: 19949144]

Zuithoff NP et al. The Patient Health Questionnaire-9 for detection of major depressive disorder in primary care: consequences of current thresholds in a cross-sectional study. *BMC Fam Pract.* 2010 Dec 13;11:98. [PMID: 21144018]

SPECIFIC ISSUES & CONDITIONS

INTIMATE PARTNER VIOLENCE

Intimate partner violence (IPV) is a pattern of abusive behavior by a person who is in some type of intimate relationship with the victim. The abuse can be physical, sexual, or emotional and can include economic deprivation. Although anyone can be a victim of IPV, women are much more likely than men to be victims. Regardless of the type of abuse, the goal of the abuser is to gain control over the victim. IPV is common but is often not diagnosed, in part because patients try to hide the abuse.

The prevalence estimate of IPV varies depending on the setting. Rates are higher when measured in emergency departments than when measured in the general population. In a randomized controlled trial of IPV screening in emergency departments, the prevalence over 12-months ranged from 4% to 18%.

Risk factors for abuse include being young (under age 35 years); being pregnant; being single, divorced, or separated; alcohol or drug abuse in the victim or the partner; smoking; and being poor.

Evaluation

Since patients often do not volunteer that they have been abused, clinicians must be alert to clues that suggest abuse, including an explanation of the injuries that do not fit with what is being seen; frequent visits to the emergency department; and somatic complaint such as chronic headache, abdominal pain, and fatigue. The patient may be vague about some of her symptoms and may avoid eye contact. If the abusing partner is present, he or she may answer all the questions or may decline to leave the room. It is critical that the patient have the opportunity to speak with the clinician alone. The patient's description of the events should be carefully detailed in case there are any subsequent legal issues.

Physical examination often reveals injuries in the central area of the body. There may be injuries on the forearms as well if the patient tried to defend herself. As with any situation of expected abuse, bruises that are in various stages of healing may be an important clue. All physical examination findings should be well documented.

In addition to the physical consequences, abuse can have psychological consequences. Posttraumatic stress disorder, depression, anxiety, and alcohol or other substance abuse can develop in victims. Somatization is also very common among victims.

Several instruments have been developed to screen for IPV. These include the HITS (Hurt, Insult, Threaten, Screamed at) tool, the Women Abuse Screening tool (WAST), the Partner Violence Screen (PVS), the Abuse Assessment Screen (AAS), and the Women's Experience with Battering (WEB) scale. A systematic review of these screening tools showed that most tools only had been evaluated in a relatively small number of studies and the sensitivities and specificities varied widely within and between the tools.

Inclusion of one question in the context of the medical history, "Have you ever been hit, kicked, punched or otherwise hurt by someone within the past year? If so, by whom?" has been shown to increase identification of IPV.

Many studies have addressed how the questions about IPV are asked. In one randomized trial, women preferred written questionnaires over face to face interviewing.

Screening for IPV (in contrast to asking questions when IPV is suspected) has been advocated by many experts, although there is currently no evidence that it improves outcomes. In a randomized controlled trial conducted in emergency departments and other clinical sites, women in the screened group were assessed for IPV and if the screen was positive, the information was given to the clinician before the visit. At 18-month follow-up, there was no difference in recurrence of IPV among women in the screened compared with the non-screened groups. There were also no differences in quality of life, although there were no adverse effects of screening.

The USPSTF has concluded that there is insufficient evidence to recommend for or against universal screening for IPV, since there is currently no evidence that screening improves outcomes. However, clinicians should remain on high alert for clues to IPV among patients.

▶ Interventions for IPV

Interventions can include encouraging the woman to leave the abusive situation, ensuring that she has a safe place to go, and counseling so that she can adequately assess her risk of danger and create a plan for safety. There is no evidence that treatment of the abuser changes abuser behavior.

▶ When to Refer

- Victims should be referred to social services so that they can provide information on local resources. There is a national domestic violence hotline (1-800-799-SAFE) that can provide information on local resources.
- In general, mandatory reporting of IPV or suspicion of it in adult women who are competent is not required in

most states. However, mandatory reporting by physicians is required in California, Colorado, Kentucky, Mississippi, Ohio and Rhode Island.

Ahmad F et al. Computer-assisted screening for intimate partner violence and control: a randomized trial. *Ann Intern Med.* 2009 Jul 21;151(2):93–102. [PMID: 19487706]

MacMillan HL et al; McMaster Violence Against Women Research Group. Screening for intimate partner violence in health care settings: a randomized trial. *JAMA.* 2009 Aug 5;302(5):493–501. [PMID: 19654384]

Rabin RF et al. Intimate partner violence screening tools: a systematic review. *Am J Prev Med.* 2009 May;36(5):439–45. [PMID: 19362697]

EATING DISORDERS

Eating disorders are common in women. Anorexia nervosa and bulimia nervosa are described in detail in Chapter 29. The female athlete triad, disordered eating in diabetics, and binge eating disorders are other eating disorders that should be considered in appropriate women.

1. Female Athlete Triad



ESSENTIALS OF DIAGNOSIS

- ▶ Disordered eating.
- ▶ Menstrual disorders.
- ▶ Low BMD.

▶ General Considerations

Female athletes who participate in sports and activities valuing thinness are at increased risk for developing the female athlete triad. The definition of the triad includes disordered eating (a spectrum of abnormal patterns of eating, including bingeing; purging; food restriction; prolonged fasting; and the use of diet pills, diuretics, or laxatives), menstrual disorders, and low BMD. Half of all athletes with amenorrhea have bone density at least 1.0 standard deviation below the mean. The bone density is decreased even in those areas subjected to stress during exercise. The diagnosis is made when the individual meets the three criteria of the triad.

▶ Clinical Findings

A. Symptoms and Signs

Individuals with the female athlete triad display some pattern of disordered eating and have some menstrual irregularities. Many women have amenorrhea but others have irregular menses. Typically, the patient has concerns about weight and body image. A history of stress fractures should also raise the clinician's concern.

B. Laboratory Findings

Depending on the severity of the symptoms and whether or not the patient is bingeing and purging, the laboratory

abnormalities can be similar to those seen in anorexia nervosa or bulimia nervosa. BMD, if measured, is decreased.

► Differential Diagnosis

The main differential diagnoses include anorexia nervosa, bulimia nervosa as well as endocrine disorders such as hyperthyroidism and diabetes mellitus.


► Treatment

Little evidence is currently available about treatment of the female athlete triad. Strategies such as counseling, cognitive behavior therapy, and possibly exercise restriction may be helpful. A multidisciplinary approach, including consultation with a nutritionist and communication with the coach and trainers, may enable common goal setting. The desire to participate in sports and the lure of a performance enhancing diet may motivate some patients to pursue treatment.

Bonci CM et al. National Athletic Trainers' Association position statement: preventing, detecting and managing disordered eating in athletes. *J Athl Train.* 2008 Jan-Mar;43(1):80-108. [PMID: 18335017]

Nattiv A et al. American College of Sports Medicine position stand. The female athlete triad. *Med Sci Sports Exerc.* 2007 Oct;39(10):1867-82. [PMID: 17909417]

2. Disordered Eating in Diabetics



ESSENTIALS OF DIAGNOSIS

- Binge eating.
- Purging with laxatives or vomiting.
- Insulin omission.
- Taking less insulin than prescribed to lose weight.

► General Considerations

Eating disturbances have been estimated to be present in up to one-third of young women with diabetes. Eating disorders are more common in adolescents with diabetes than in their non-diabetic peers. Mortality is particularly high in individuals with both diabetes and eating disorders.

For diabetes, the dietary regimen emphasizes intense meal timing and consistency. In addition, the hunger associated with hypoglycemia encourages binge eating. Finally, weight gain is often associated with good glycemic control. Diabetics with disordered eating have been shown to have an increased risk of retinopathy. Given the emphasis that young women often place on body weight, maintaining optimal diabetes control is a particular challenge. The diagnosis is typically made in a diabetic who has worsening diabetic control, when other causes of worsening control have been ruled out.

► Clinical Findings

A. Symptoms and Signs

Diabetics may report polydipsia, polyuria, or weight loss. In addition, upon questioning, they may report disturbed

eating patterns. Other symptoms associated with eating disorders, such as disturbance of body image and menstrual irregularities, may also be present.

B. Laboratory Findings

The main laboratory finding will be a trend of increasing levels of hemoglobin A_{1c}.

► Differential Diagnosis

The main differential diagnosis includes looking for other causes of worsening glycemic control such as underlying infection or metabolic disease such as hyperthyroidism.


► Treatment

There is currently no evidence to support any particular strategies for the treatment of disordered eating in diabetic patients. Proposed strategies for at risk diabetic patients include nutritional counseling to promote healthy eating instead of dietary restraint, regular (instead of fixed) meal and snack times, less intensive insulin therapy to reduce weight gain, and family counseling to improve communication.

No studies have evaluated the optimal treatment of diabetic patients with established eating disorders. Presumably, strategies that are effective for patients without diabetes, such as cognitive behavioral therapy and medications, will be effective. In addition, diabetic management strategies that do not require the patient to constantly think about food may be beneficial.

Gobel-Fabbri AE et al. Disturbed eating behaviors and eating disorders in type 1 diabetes: clinical significance and treatment recommendations. *Curr Diab Rep.* 2009 Apr;9(2):133-9. [PMID: 19323958]

3. Binge Eating Disorder



ESSENTIALS OF DIAGNOSIS

- Binge eating disorder consists of episodes of eating a large amount of food in a discreet period of time with a sense of lack of control.
- Binge episodes characterized by at least three of the following:
 - Eating large amounts of food when not feeling hungry.
 - Eating more rapidly than normal.
 - Eating until feeling uncomfortably full.
 - Eating alone because of embarrassment about the amount of food consumed.
 - Feeling disgusted, depressed, or guilty after eating.
- Episodes occur at least two times a week for at least 6 months.
- No compensatory behavior (purging, fasting, or excessive exercise) after eating.

► General Considerations

Binge eating disorder is more common than either anorexia nervosa or bulimia nervosa, but it is currently not recognized as a psychiatric diagnosis. Currently, the *Diagnostic and Statistical Manual of Mental Disorders*, fourth edition (DSM-IV) has criteria that are considered research criteria. Individuals who meet these criteria are defined as having eating disorder, not otherwise specified.

Binge eating disorder is much more common in women and is associated with obesity, although not all individuals with binge eating disorder are obese. Obesity-related complications are likely to occur, and the disorder may be more common in weight cycling patients.

► Clinical Findings

The patient may present with weight gain or may describe disordered eating patterns and binge eating episodes. There are no specific laboratory findings for binge eating disorder.

► Differential Diagnosis

The main differential diagnosis includes other psychiatric and eating disorders. Other diagnostic possibilities include hypothyroidism and Prader-Willi syndrome.

► Treatment

Treatment goals focus on decreasing the patient's binge eating episodes and may include weight loss and treatment of other psychiatric comorbidities. As in bulimia nervosa, cognitive behavioral therapy is the mainstay of treatment. Interpersonal therapy has also been shown to be effective. Pharmacotherapy with selective serotonin reuptake inhibitors is also helpful, but does not appear to be better than cognitive behavioral therapy.

National Institute for Health and Clinical Excellence. Eating disorders: core interventions in the treatment and management of anorexia nervosa, bulimia nervosa and related eating disorders. <http://www.nice.org.uk/CG009>

Vocks S et al. Meta-analysis of the effectiveness of psychological and pharmacological treatments for binge eating disorder. *Int J Eat Disord.* 2010 Apr;43(3):205–17. [PMID: 19402028]

Wilson GT et al. Psychological treatments of binge eating disorder. *Arch Gen Psychiatry.* 2010 Jan;67(1):94–101. [PMID: 20048227]

SEXUALITY & SEXUAL HEALTH

Sexual health is defined by the World Health Organization as a state of physical, emotional, mental, and social well-being in relation to sexuality. Healthy sexual functioning therefore depends on a complex interplay of physical, psychological, and societal factors. In the United States, sexual dysfunction is common, with more than 44% of surveyed women reporting a sexual problem and 12% experiencing distress from the problem. Six female sexual disorders have been identified in the DSM-IV and include hypoactive sexual desire disorder (HSDD), sexual aversion disorder, female sexual arousal disorder, female orgasmic

disorder, dyspareunia, and vaginismus; these are discussed in detail in Chapters 18 and 25. Notably, HSDD is most prevalent in middle-aged women. Several psychological and biological risk factors can contribute to female sexual dysfunction, including poor mental health, relationship difficulties, and hormonal changes that are associated with aging. In contrast, positive feelings about the partner and the relationship can be “protective.” Physicians should routinely assess patients' sexual health during office visits; even a brief assessment provides patients with reassurance that this is an important topic. Providers can broach the subject using a broad question, such as “What concerns or questions do you have about your sexual functioning?” and then follow-up with more specific questions, including “Do you have difficulty with desire, arousal, or orgasm?” and “If you are not currently sexual, are there any particular problems that are contributing to your lack of sexual behavior?” Patient concerns can then be delineated more fully during the complete sexual assessment, which encompasses details about medical, surgical, and psychiatric problems, as well as medications and reproductive history. Treatment options depend on the diagnosed disorder and can include psychosexual and hormonal therapy (see Chapter 18).

Kingsberg S et al. Evaluation and treatment of female sexual disorders. *Int Urogynecol J Pelvic Floor Dysfunct.* 2009 May; 20(Suppl 1):S33–43. [PMID: 19440781]

World Health Organization. Measuring sexual health: conception and practical considerations and related indicators. World Health Organization, 2010, Geneva, Switzerland. http://www.who.int/reproductivehealth/publications/monitoring/who_rhr_10.12/en/index.html

CHRONIC PELVIC PAIN



ESSENTIALS OF DIAGNOSIS

- Noncyclic pain.
- Duration of 6 months or more.
- Localized to anatomic pelvis, anterior abdominal wall at or below the umbilicus, the lumbosacral back, or buttocks.
- Associated with functional disability.

► General Considerations

Chronic pelvic pain is defined as noncyclic pain lasting at least 6 months that localizes to one of the following areas: the anatomic pelvis, the anterior abdominal wall at or below the umbilicus, the lumbosacral back, or the buttocks. It must be of sufficient severity to cause functional disability or necessitate medical care. Endometriosis is diagnosed in up to two-thirds of women with chronic pelvic pain; other common etiologies include postoperative pelvic adhesions, pelvic varices, interstitial cystitis (IC), and

irritable bowel syndrome (IBS). Musculoskeletal disorders such as fibromyalgia and levator ani syndrome have also been linked to chronic pelvic pain. Women with a history of physical and sexual abuse, pelvic inflammatory disease, abdominopelvic surgery, or difficult obstetric deliveries are at increased risk for developing chronic pelvic pain.

► Clinical Findings

A. Symptoms and Signs

Certain features of the history and physical examination can provide clues to the underlying diagnosis. Patients should be asked about the location, quality, and intensity of their pain as well as the relationship with the menstrual cycle, sexual activity, urination, and defecation. Endometriosis, IC, and IBS may all worsen with hormonal changes, resulting in more pain during menses. Dysmenorrhea and dyspareunia are often experienced by patients with endometriosis, whereas dysuria, urgency, and frequency in association with pelvic pain are characteristic of IC. Pain related to pelvic varices is usually postural, worsening with prolonged standing and improving with leg elevation. Patients with IBS often report abdominal pain, distention, and diarrhea or constipation. The physical examination, including the pelvic examination, is usually quite painful in the patient with chronic pelvic pain and should be done carefully. A single-digit internal vaginal examination should be done to localize the exact area of pain and to assess for trigger points along the pelvic floor muscles, which may indicate a musculoskeletal etiology for the pain. Tenderness with palpation of the anterior vaginal wall is consistent with IC, whereas discomfort with palpation of the cervix is suggestive of endometriosis or chronic pelvic infection. Women with pelvic congestion related to varices may have significant uterine tenderness. The external genitalia should also be examined carefully to identify areas of vulvar discomfort because vulvodynia often coexists in patients with chronic pelvic pain. Notably, the absence of physical examination findings does not rule out significant pathology.

B. Laboratory Findings

Laboratory studies are useful if the history and physical examination do not identify an underlying cause for the pelvic pain. Laboratory tests can include a complete blood count, serum chemistry, erythrocyte sedimentation rate, urine microscopy and culture, and vaginal swabs for detecting chlamydia and gonorrhea.

C. Diagnostic Testing and Imaging

Pelvic ultrasonography is useful for investigating any abnormalities detected on physical examination, for screening patients in whom pelvic varices are suspected, and for providing reassurance to the patient if the ultrasound is normal. Additional testing may be done to confirm a suspected diagnosis. Patients with IC often have a positive intravesical potassium chloride test or abnormalities detected on cystoscopy. Laparoscopy may be helpful for diagnosing endometriosis or pelvic adhesions, although

40% of diagnostic laparoscopies are normal in patients with chronic pelvic pain.

► Differential Diagnosis

Chronic pelvic pain is frequently a manifestation of another disease, as noted above. The history, physical examination, and diagnostic testing should be directed toward identifying patients with the most common “benign” underlying conditions, including endometriosis, pelvic adhesions, pelvic varices, IC, and IBS. Clinicians should be aware that patients frequently have more than one diagnosis contributing to the chronic pelvic pain syndrome. Less common but serious causes of chronic pelvic pain should also be considered in the differential diagnosis, including bladder malignancy, colon cancer, endometrial cancer, and inflammatory bowel disease. Accordingly, symptoms such as unexplained weight loss, hematochezia, and abnormal vaginal bleeding should be investigated thoroughly. Many patients have no clear pathologic basis for their symptoms, and are thus diagnosed with idiopathic chronic pelvic pain.

► Treatment

A. Medical Treatment

Medical treatment may focus on managing the chronic pain, the underlying condition, or both. Analgesics are commonly used, and nonsteroidal anti-inflammatory drugs (NSAIDs), such as diclofenac and naproxen, are typically helpful. However, patients and clinicians should be cautious about long-term use of these medications because long-term NSAID therapy can be associated with significant gastric toxicity. Antidepressants (eg, amitriptyline) and antiseizure medications (eg, gabapentin) (see Table 5–5), which have demonstrated efficacy in the treatment of other pain syndromes, may also be useful for chronic pelvic pain. Opioid therapy improves pain but not functional or psychological outcomes and should generally be avoided.

Hormonal therapies are used primarily for treating gynecologic sources of chronic pelvic pain. Women with endometriosis often benefit from treatment with combined oral contraceptive pills, which suppress ovulation and reduce dysmenorrhea. Gonadotropin-releasing hormone (GnRH) agonists and progestins improve pain associated with endometriosis and pelvic varices. The decrease in BMD associated with GnRH agonist treatment can be mitigated with estrogen or progesterone add-back therapy. Patients in whom endometriosis is suspected may also be treated with GnRH agonist therapy; improvement in symptoms may allow such patients to avoid laparoscopy.

Medical therapies directed at the treatment of nongynecologic sources of chronic pelvic pain, including IC and IBS, are discussed in Chapters 15 and 23. Notably, pelvic pain associated with IC and IBS frequently varies with the menstrual cycle, and GnRH agonist therapy may be helpful for treatment in these disorders as well.

Physical therapy and injection of identified trigger points provide significant pain relief in patients with musculoskeletal sources of pain. Sacral nerve stimulation has been used in patients with IC but may also be effective in up to 60% of women with chronic pelvic pain but without urinary symptoms. Psychological evaluation and treatment should also be strongly considered in all patients, both to improve treatment outcomes (particularly in patients with pelvic varices) as well as to address a history of sexual or physical abuse.

B. Surgical Treatment

Surgical treatment of chronic pelvic pain requires referral to a gynecologist. Surgical therapies that treat the pain itself include presacral neurectomy and laparoscopic uterosacral nerve ablation. These denervating interventions are typically used in the treatment of patients with severe dysmenorrhea. Condition-specific surgical treatments include adhesiolysis in patients with pelvic adhesions and laparoscopic surgical destruction of implants in patients with endometriosis. Importantly, the efficacy of adhesiolysis in the treatment of chronic pelvic pain is controversial. Hysterectomy can be effective for relieving chronic pelvic pain and may also result in improved psychological and sexual outcomes.

► Prognosis

Cohort studies provide some information on the prognosis of women who undergo hysterectomy as definitive treatment for chronic pelvic pain. In a comparative study of women with chronic pelvic pain, abnormal uterine bleeding, or leiomyomas, women who had a hysterectomy experienced significant improvement in symptoms compared with those treated medically after 1 year. However, among younger patients with chronic pelvic pain who do not have obvious anatomic pathology, the benefits of surgery are less clear, and up to 40% of patients may still have persistent pain after hysterectomy.

► When to Refer

Patients should be referred to a gynecologist for diagnostic or therapeutic surgical procedures, if the underlying diagnosis is unclear, or if the provider feels uncomfortable managing side effects associated with medical treatments (ie, GnRH agonist therapy).

American College of Obstetricians and Gynecologists (ACOG). ACOG Practice Bulletin No. 51. Chronic pelvic pain. *Obstet Gynecol.* 2004 Mar;103(3):589–605. [PMID: 14990428]
 Daniels JP et al. Chronic pelvic pain in women. *BMJ.* 2010 Oct 5;341:c4834. [PMID: 20923840]
 Vercellini P et al. Chronic pelvic pain in women: etiology, pathogenesis, and diagnostic approach. *Gynecol Endocrinol.* 2009 Mar;25(3):149–58. [PMID: 19347704]
 Vercellini P et al. Medical, surgical, and alternative treatments for chronic pelvic pain in women: a descriptive review. *Gynecol Endocrinol.* 2009 Apr;25(4):208–21. [PMID: 19296329]

MASTALGIA



ESSENTIALS OF DIAGNOSIS

- ▶ Infection, malignancy, and extramammary conditions can cause breast pain.
- ▶ Benign mastalgia is diagnosed once other causes of breast pain have been excluded and is characterized as cyclical or noncyclical.
- ▶ Abnormal physical examination findings, such as a breast mass or skin abnormalities, should prompt radiographic imaging.

► General Considerations

Breast pain, or mastalgia, is categorized as cyclical, noncyclical, or extramammary. Although minor breast discomfort is commonly associated with the normal menstrual cycle, women with cyclical mastalgia typically have moderate to severe pain that can last more than 5 days. Cyclical mastalgia can be diagnosed only in reproductive-age women who experience breast pain as a result of the hormonally-mediated proliferation in breast tissue that occurs with ovulation. In contrast, noncyclical mastalgia has no relationship to the menstrual cycle and can occur in premenopausal or postmenopausal women. Causes of noncyclical mastalgia include large breast size (with stretching of Cooper ligaments), medications, pregnancy, thrombophlebitis, or inflammatory breast cancer. Extramammary mastalgia is caused by pain that is referred from other anatomic locations, including the chest wall, heart, gallbladder, or spine. Trauma or previous surgery may also produce extramammary pain.

► Clinical Findings

A. Symptoms and Signs

Cyclical mastalgia is often described as a deep, heavy, aching pain, which is typically diffuse and bilateral and is clearly associated with the menstrual cycle. Conversely, noncyclical pain, which may be constant or intermittent, is often well localized and can involve one or both breasts. Chest wall pain, a frequent cause of extramammary mastalgia, typically causes unilateral, burning pain that may be either localized or diffuse. Malignancy-associated mastalgia is often severe, progressive, and unilateral.

Breast cancer may be associated with mastalgia, and thus a careful physical examination is essential in all women who report breast pain. Large, pendulous breasts may be observed in women who have noncyclical pain caused by stretching of Cooper ligaments. Chest wall pain is usually related to inflammation or injury to the pectoralis major muscle; it may be reproduced by palpation or by having the patient place her hand on her hip and push inward. Any palpable breast mass must be evaluated further with radiologic imaging.

B. Imaging

An ultrasound or mammogram or both should be obtained in women who have a palpable breast mass. Clinicians should also ensure that patients with mastalgia are up to date on routine screening mammography, as appropriate for their age and personal risk factors.

► Differential Diagnosis

Malignancy must be ruled out in all patients with mastalgia, and this is usually accomplished through a careful history, physical examination, and diagnostic imaging in patients with clinical abnormalities, such as a palpable breast mass. Extramammary causes of breast pain include chest wall pain, spinal or gallbladder disease, and myocardial ischemia. Cyclical and noncyclical mastalgia are easily differentiated by assessing the temporal relationship between the patient's pain and her menstrual cycle.

► Treatment

Women with cyclical mastalgia who have a normal physical examination and are up to date on routine mammographic screening should be reassured about the benign nature of their symptoms and monitored closely. Cyclical and noncyclical mastalgia often improve with use of a supportive bra. Although there is conflicting evidence regarding the benefit of vitamin E, some experts advocate its use (at a dose of 2000–3000 mg daily) for women with cyclical breast pain. Topical NSAIDs, such as diclofenac gel, improve localized breast pain.

Women who experience severe and persistent cyclical mastalgia despite adherence to conservative measures may be offered hormonal treatment. Commonly used hormonal therapies for cyclical mastalgia include danazol, bromocriptine, and tamoxifen. Danazol, a synthetic androgen that inhibits ovulation, is the only medication that has been approved by the Food and Drug Administration (FDA) for the treatment of cyclical mastalgia. However, side effects associated with treatment are common and include weight gain, menstrual irregularities, voice deepening, and hot flashes. Similarly, in a study of patients with cyclical mastalgia who were treated with bromocriptine, 40% of patients experienced adverse reactions, including nausea, dizziness, and headache. Tamoxifen therapy is tolerated well by most women, and many experts recommend it as first-line therapy for the treatment of cyclical mastalgia. Patients treated with tamoxifen should be counseled about the possibility of hot flashes and menstrual irregularities (experienced by up to 10% of women), as well as the risk for more serious adverse events, such as thromboembolic disease and endometrial cancer.

► Prognosis

Symptoms of cyclical and noncyclical mastalgia improve without pharmacologic treatment in most women. In addition, most women with cyclical mastalgia have resolution of their pain with menopause. Observational studies examining the association between cyclical mastalgia

and the subsequent development of breast cancer have produced conflicting results. Two case-control studies suggested an increased risk of breast cancer, while a third observational study suggested a decreased risk. Based on this evidence, guidelines indicate that all women with mastalgia should have an individual assessment of their breast cancer risk, and that this should guide subsequent management.

Women in whom mastalgia develops while receiving hormone replacement therapy may have an increased risk of breast cancer. In a recent analysis of data from the Women's Health Initiative, women in whom new-onset breast tenderness developed after initiating treatment with conjugated equine estrogen plus medroxyprogesterone had a 48% higher risk of developing breast cancer compared with those who did not experience breast pain. Thus, women in whom mastalgia develops in the setting of hormone-replacement therapy should have a thorough discussion with their clinician regarding the risks and benefits of continued treatment as well as screening and preventative strategies for breast cancer.

► When to Refer

Patients with mastalgia and a palpable breast mass should be referred to a breast surgeon, even if the results of diagnostic imaging are normal.

Crandall CJ et al. New-onset breast tenderness after initiation of estrogen plus progestin therapy and breast cancer risk. *Arch Intern Med.* 2009 Oct 12;169(18):1684–91. [PMID: 19822825]

Rosolowich V et al; Society of Obstetricians and Gynecologists of Canada (SOGC). Mastalgia. *J Obstet Gynaecol Can.* 2006 Jan;28(1):49–60. [PMID: 16533457]

Rungruang B et al. Benign breast diseases: epidemiology, evaluation, and management. *Clin Obstet Gynecol.* 2011 Mar;54(1):110–24. [PMID: 21278510]

THE PALPABLE BREAST MASS



ESSENTIALS OF DIAGNOSIS

- Diagnostic imaging is essential for any women with a palpable dominant breast mass, regardless of her age.
- Ultrasound is the initial test of choice for women under the age of 30; diagnostic mammography with or without ultrasonography is performed initially in women over the age of 30.

► General Considerations

Palpable breast masses may be detected by a patient on a breast self-examination, or may be identified by the provider during a routine physical examination. Approximately 10% of breast masses are malignant, and thus a thorough work-up of any palpable breast mass is essential, regardless of age and personal risk factors for breast cancer.

Common benign causes of palpable breast masses include fibrocystic condition, cysts, and fibroadenomas (see also Chapter 17).

► Clinical Findings

A. Symptoms and Signs

Clinicians should ask patients about temporal changes in the mass shape and size, as well as associated symptoms, including pain, skin thickening, and nipple discharge. A patient's personal risk for breast cancer should be assessed, including age, previous breast biopsies, family history, and age at menarche and first pregnancy.

The location of the mass should be described using the clock-face position and distance from the nipple, as this aids the radiologist in the diagnostic evaluation. Examiners should also note the size, site, mobility, and texture of the mass, as well as areas of skin dimpling, retraction, or erythema. Benign masses are typically mobile with well-defined margins; conversely, malignant lesions may be fixed and have indistinct borders. Some women may have areas of indeterminate thickening in the absence of a discrete and well-defined palpable mass; if this finding is asymmetric it should be evaluated further with diagnostic imaging.

B. Diagnostic Tests and Imaging

As noted above, all women with a dominant palpable breast mass require diagnostic imaging. Approved imaging techniques include diagnostic mammography and ultrasonography. Diagnostic mammography consists of the standard views that are used in screening mammography, plus additional views, such as spot-compression and magnification, to better delineate the area of concern. The breast ultrasound is the most sensitive test for distinguishing a cystic from a solid lesion, and also provides detailed information regarding the shape, borders, and acoustic properties of an identified mass. In addition, ultrasonography can be used to guide the biopsy of suspicious lesions.

Women over the age of 30 with a palpable breast mass should initially be evaluated with diagnostic mammography. Features of a benign lesion include a round shape with well-circumscribed borders; a suspicious finding may have an irregular shape with spiculated margins. Ultrasonography may be coupled with diagnostic mammography if the mass is mammographically occult or has concerning mammographic features. For women under the age of 30, ultrasonography is the initial diagnostic test of choice because the dense breast tissue found in younger women limits the sensitivity of mammography. Abnormal findings on ultrasound include posterior acoustic shadowing, microlobulations, and a spiculated margin. A mass which has a thin, echogenic capsule, an ellipsoid shape, and homogenous echogenicity is more likely to be benign.

In women who are pregnant, ultrasonography is the initial diagnostic test of choice; the sensitivity of mammography is limited by the loss of contrasting fatty tissue in the breast during pregnancy. Fine-needle aspiration (FNA) biopsy does not have the same accuracy in pregnant women as a result of the increased cellularity of the breast tissue, and breast biopsy may be technically difficult

because of increased breast vascularity. Surgical consultation should be obtained to evaluate persistent areas of concern that are identified on clinical breast examination and ultrasound.

► Differential Diagnosis

The differential diagnosis of palpable masses includes benign etiologies, such as cysts, fibroadenomas, fibrocystic condition, lymph nodes, galactoceles, lipomas, and hematomas. Breast cancer, including ductal carcinoma in situ, invasive lobular carcinoma, and invasive ductal carcinoma, can also initially present with a palpable breast mass. Certain history and physical examination features may be suggestive of a particular diagnosis. Cysts are fluid-filled structures that are commonly found in women aged 35–50 years; acute enlargement of the cysts may cause abrupt and severe pain. Fibroadenomas are typically diagnosed in reproductive age women between the ages of 15 and 35 years and present as firm, nontender, and mobile masses on physical examination. Fibrocystic condition describes a pathologic diagnosis that may be accompanied by clinical symptoms and signs, including cyclical pain that is bilateral and poorly localized as well as tender, multifocal nodules. These fibrocystic changes, which include macrocysts, microcysts, fibrosis, and ductal hyperplasia, are most common among premenopausal women.

► Treatment

Management of the palpable breast mass depends on the results of diagnostic imaging. If ultrasonography or mammography suggests that the mass is related to a simple cyst, fine-needle aspiration (FNA) may be offered to symptomatic women to relieve associated pain. Characteristics of the aspirated fluid guides further work-up. If benign fluid, which is typically yellow, straw-colored, green, or brown, is aspirated and the mass resolves, the patient can be monitored expectantly. Conversely, if bloody fluid is aspirated, or if the mass persists after aspiration, further intervention with either core biopsy or excision may be indicated. A complex cyst should always be aspirated because there is a small chance (0.4%) that it may be malignant.

Core-needle biopsy, which provides a sample of tissue for histologic diagnosis, is typically used to evaluate breast masses that have a *suspicious* appearance on diagnostic imaging. Ultrasonography, mammography, or MRI may be used to guide the biopsy, thereby resulting in few complications and minimal trauma to the breast tissue. Excisional biopsy may be necessary if the mass is not amenable to core-needle biopsy (because of location or imaging characteristics) or if additional tissue is needed to confirm a benign diagnosis.

Women who have palpable masses that are associated with *normal* ultrasound or mammographic imaging should be referred to a breast surgeon, with consideration given to performing a diagnostic core-needle biopsy. Benign biopsy results are reassuring but require close clinical follow-up for at least 1–2 years.

The radiologist may categorize certain breast masses as *probably benign* after review of ultrasound or mammographic

images. In rare cases, these masses may be associated with malignancy, and so two diagnostic options may be considered. The patient may opt to forgo biopsy at that time and have imaging performed again in 6 months. Alternatively, diagnostic core excisional biopsy may be performed immediately (after consultation with a breast surgeon) if there are worrisome findings on physical examination or if there is a high clinical suspicion for malignancy. All masses categorized as probably benign require follow-up imaging at 6-month intervals for at least 2 years.

The “triple test,” which is composed of the findings on physical examination, the results of diagnostic imaging, and the pathologic diagnosis obtained from FNA or core-needle biopsy, helps clinicians determine the likelihood that a palpable breast mass is malignant. In all cases, the results of each of these tests should be concordant. For example, the diagnostic imaging should identify the palpable area of concern, and if benign features are noted, the results of the FNA biopsy or core-needle biopsy should confirm a benign diagnosis, such as a fibroadenoma. If the results of any of the tests are discordant, further evaluation is warranted. Thus, if the results of FNA biopsy or core-needle biopsy suggest a benign diagnosis, but the radiographic imaging indicates a suspicious lesion, it may be appropriate to repeat the biopsy or perform an excisional biopsy. Similarly, if there is a palpable breast mass that is not identified on radiographic imaging, referral to a breast surgeon is necessary to document resolution or persistence of the mass. If the mass is persistent, the surgeon may elect to perform a biopsy to obtain a definitive diagnosis.

► Prognosis

In general, the benign causes of a palpable breast mass have a favorable prognosis. Many women with breast pain and palpable masses due to fibrocystic condition have spontaneous resolution or have improvement in their symptoms with menopause. Benign simple cysts that are asymptomatic may be followed clinically, and symptomatic cysts should resolve with aspiration.

Certain pathologic diagnoses increase the risk of breast cancer, including papillary lesions, radial scars, atypical ductal or lobular hyperplasia, and lobular carcinoma in situ. FNA biopsy or core-needle biopsy results that indicate one of these diagnoses necessitate referral to a breast surgeon for further evaluation and management.

► When to Refer

- Women with a palpable breast mass should be referred to a breast surgeon in the following situations:
 - If diagnostic imaging indicates that the mass has *suspicious* features.
 - If the mass persists and diagnostic imaging is *normal*.
 - If the mass is categorized as *probably benign* on diagnostic imaging, but there are worrisome features on physical examination or there is a high clinical suspicion for malignancy.
 - If diagnostic imaging demonstrates a complex cyst, or aspiration of a simple cyst reveals a bloody aspirate.

- If the biopsy demonstrates a lesion with an increased risk of breast cancer (papillary lesions, radial scars, atypical hyperplasia, lobular carcinoma in situ).
- If the biopsy results are discordant with the physical examination and radiographic findings.
- It may also be prudent to refer pregnant women with a palpable breast mass to a breast surgeon, because of the limitations noted above with radiographic imaging and biopsy.

Pearlman MD et al. Benign breast disease. *Obstet Gynecol.* 2010 Sep;116(3):747–58. [PMID: 20733462]

Rungruang B et al. Benign breast diseases: epidemiology, evaluation, and management. *Clin Obstet Gynecol.* 2011 Mar;54(1):110–24. [PMID: 21278510]

Stein L et al. The radiologic workup of a palpable breast mass. *Cleve Clin J Med.* 2009 Mar;76(3):175–80. [PMID: 19258464]

NIPPLE DISCHARGE

Nipple discharge is a common breast complaint but is rarely indicative of malignancy. In one retrospective study, invasive breast cancer was subsequently diagnosed in only 5% of women in whom nipple discharge was the presenting symptom. Nipple discharge that comes from multiple ducts, is bilateral, and is produced only with squeezing is considered physiologic, and no further work-up is necessary. Milky discharge that is bilateral and spontaneous is consistent with galactorrhea caused by an elevated prolactin level. Investigation should focus on identifying the underlying causes of the hyperprolactinemia, including pregnancy, pituitary tumors, and certain medications. Women who have bloody discharge or persistent spontaneous unilateral discharge from a single duct, should be referred for mammography and surgical consultation. These features are suggestive of a pathologic diagnosis, such as papilloma, duct ectasia, or malignancy. In addition, the presence of a palpable breast mass in association with the nipple discharge significantly increases the likelihood of underlying malignancy. Surgical excision of the involved duct is the gold standard for diagnosis. See also Chapter 17.

Dolan RT et al. Nipple discharge and the efficacy of duct cytology in establishing breast cancer risk. *Surgeon.* 2010 Oct;8(5):252–8. [PMID: 20709281]

Rungruang B et al. Benign breast diseases: epidemiology, evaluation, and management. *Clin Obstet Gynecol.* 2011 Mar;54(1):110–24. [PMID: 21278510]

FEMALE PATTERN HAIR LOSS

Androgenetic alopecia, also known as female pattern hair loss, is the most common cause of alopecia in women; up to 50% of females will be affected in their lifetime. This type of alopecia is mediated by the effects of androgen on the hair follicle and is characterized by shortening of the anagen (growth) phase and follicle miniaturization. Clinically, presenting signs include diffuse thinning over the central scalp and a prominent midline part; the frontal

hairline is typically preserved. Although serum androgen levels are typically normal, androgen excess disorders can present with female pattern hair loss. If irregular menses, hirsutism, or acne accompany the female pattern hair loss, the patient should be evaluated for an underlying hyperandrogenic condition with measurements of total and free testosterone, prolactin, and dehydroepiandrosterone.

Topical minoxidil is currently the only medication that has been approved by the FDA for the treatment of female pattern hair loss. Randomized trials have confirmed the efficacy of this therapy, compared with placebo, for inducing minimal to moderate hair regrowth in the majority of treated women (NNT = 8). In patients with suspected female pattern hair loss, minoxidil 2% is applied directly onto the scalp twice daily while symptoms persist. The most common side effect of minoxidil is facial hypertrichosis, which can affect 3–5% of women, but this typically resolves after 1 year of treatment. In women who have excess androgen levels, the addition of spironolactone (an anti-androgen) to minoxidil treatment may result in additional clinical benefit. Similarly, an oral contraceptive pill containing drospirone, which is a spironolactone analogue, is an appropriate choice in women desiring hormonal contraception.

Harrison S et al. Diffuse hair loss: its triggers and management. *Cleve Clin J Med.* 2009 Jun;76(6):361–7. [PMID: 19487557]
Mounsey AL et al. Diagnosing and treating hair loss. *Am Fam Physician.* 2009 Aug 15;80(4):356–62, 373–4. [PMID: 19678603]

TREATMENT OF VARICOSE VEINS

Varicose veins result from weakness in the vein wall and may involve obstruction to, or reversal of, normal blood flow. Approximately 30–40% of women are affected, and the clinical presentation ranges from asymptomatic to severe, with lower extremity pain, swelling, and nocturnal cramps. Medical complications can include venous ulceration, abnormal skin pigmentation, and eczema.

Treatment may be considered to relieve symptoms or for cosmetic purposes. Conservative therapy is generally recommended for asymptomatic patients or those who experience only mild to moderate discomfort. The principle behind conservative therapy is to limit disease progression: weight loss and physical exercise will improve circulation, and avoidance of prolonged standing will reduce the pressure on affected valves. Compression stockings improve venous hemodynamics and reduce symptoms of pain and swelling.

Invasive therapy may be indicated to treat patients with more severe symptoms, or those who desire significant cosmetic results. The gold standard for treating varicose veins is surgical ligation and vein stripping. If the greater saphenous vein is involved, both ligation and stripping are typically performed; smaller saphenous veins may be treated only with ligation. Surgical techniques are effective in the short-term, but recurrence is common, ranging from 30% to 50% after 5 years. Moreover, patients who receive surgical therapy are exposed to the risks of general

or epidural anesthesia and may experience postoperative pain and neurologic damage.

Minimally invasive techniques for treating varicose veins have been increasing in popularity and are often associated with faster recovery times and fewer complications when compared with surgical treatment. Currently available therapies include ultrasound-guided foam sclerotherapy (UGFS), radiofrequency ablation (RFA), and endovenous laser ablation (EVLA). Sclerotherapy is usually done in the ambulatory setting and involves injecting a chemical through a catheter into the abnormal vein to induce scarring and collapse. UGFS mixes air or gas with the sclerosing substance to produce foam, which allows for coverage of a larger surface area. Injection sclerotherapy is most beneficial for small and medium-size veins; rare complications include embolization of foam to the brain or retina. RFA and EVLA both use the principles of thermolysis to selectively induce vessel-wall damage and collapse. Laser (EVLA) or radiofrequency (RFA) energy is used to generate a heated fiber, which is inserted into the abnormal vein and slowly advanced along its length. Endothelial and vessel wall damage results, with contraction of the vein wall and ultimate collapse of the entire vessel. A minority of patients may experience local bruising, tenderness, or paresthesias as a result of these procedures.

Meta-analysis evaluating the efficacy of each of these techniques compared with surgical intervention demonstrated that success rates, as measured by complete obliteration of the vessel at 5 years, were highest for EVLA and RFA (95.4% and 79.9%, respectively) and were similar for UGFS and surgery (73.5% and 75.7% respectively). Moreover, the efficacy of RFA, UGFS, and surgery declined substantially over time, but remained relatively constant for EVLA. The authors of this study concluded that EVLA was the most effective of the minimally invasive techniques and was associated with fewer side effects and faster improvement in health-related quality of life when compared with surgical therapy. However, more studies that directly compare these methods to each other are needed.

Leopardi D et al. Systematic review of treatments for varicose veins. *Ann Vasc Surg.* 2009 Mar;23(2):264–76. [PMID: 19059756]

Raju S et al. Clinical practice. Chronic venous insufficiency and varicose veins. *N Engl J Med.* 2009 May 28;360(22):2319–27. [PMID: 19474429]

Van den Bos R et al. Endovenous therapies of lower extremity varicosities: a meta-analysis. *J Vasc Surg.* 2009 Jan;49(1):230–9. [PMID: 18692348]

AGE-RELATED FACIAL CHANGES

Minimally invasive aesthetic procedures are now commonly used to treat mild to moderate age-related changes in the face. These procedures are generally safe and are associated with high rates of patient satisfaction. In 2008, more than 80% of aesthetic plastic surgery treatments involved minimally invasive techniques. Thus, primary care clinicians should be familiar with the efficacy and safety of these treatment modalities in order to best counsel their patients.

Visible signs of aging in the face result from loss of subcutaneous fat, gravitational changes, and alterations in skin elasticity. Various areas of the face respond differently to each of these changes and at different times. In the upper one-third of the face, hyperdynamic wrinkles, manifested as frown lines, crow's feet, and horizontal forehead lines, typically develop as a result of repetitive muscle contraction. Conversely, volume changes are more prominent in the mid-face, as gravitational descent of the malar fat pad and volume loss leads to deepening of the nasolabial folds. Changes in the lower one-third of the face are characterized both by hyperdynamic changes resulting in deep furrows and lines, as well as flattening and loss of fullness in the lips.

Clostridium botulinum is an organism that produces potent neurotoxins with various serotypes, ranging from A to G. These serotypes vary in both their mechanism of action and clinical use, and only serotype A is used for cosmetic purposes. Botox and Dysport are two formulations of botulinum serotype A that the FDA has approved for treating hyperactivity of the glabellar muscles, which produces frown lines. Both of these products work by inhibiting the release of acetylcholine at the neuromuscular junction, thereby resulting in a chemical denervation and an overall relaxation of hyperdynamic facial muscles. Botox and Dysport are also commonly used off-label to treat horizontal frown lines and crow's feet, as the restriction of muscular movement in these areas also reduces the appearance of fine wrinkles. The onset of action of these treatments is immediate, and results typically last 3–4 months. In one study, only 5% of studied patients who had been treated with Botox experienced adverse effects, the most common of which was local bruising.

Whereas Botox and Dysport are the treatments of choice in the upper one-third of the face to treat fine wrinkles, dermal fillers are commonly used in the mid- and lower face to restore volume and fullness. Several filler substances are currently used, including collagen, hydroxylapatite,

hyaluronic acid, and injectable poly-L-lactic acid. Among these, hyaluronic acid fillers have become increasingly popular and have been approved by the FDA for treatment of nasolabial folds. They are also frequently used off-label to volumize and shape the lips. Several formulations are currently available, and they differ in their degree of cross-linking, gel hardness, and ability to resist dilution. Clinically, these differences result in various degrees of longevity, with the effects of Restylane and Perlane lasting approximately 6 months, and the effects of Juvederm Ultra and Juvederm Ultra Plus lasting approximately 12 months. The effects of injection are immediately apparent, and complications are typically mild and local, including bruising, redness, and swelling. If necessary, the injection of hyaluronidase can reverse any significant adverse effects. Notably, the clinical improvement associated with hyaluronic acid injections seems to be closely associated with the expertise of the practitioner.

Combination therapy with botulinum toxin and hyaluronic acid is now commonly being used to achieve more satisfying cosmetic results. However, serious complications can result from the injection of hyaluronic acids in the upper face, including skin necrosis, which occurs when the injection inadvertently involves a blood vessel. A thorough knowledge of the anatomy in this area is essential for avoiding this adverse event. Similarly, only experienced practitioners should use botulinum toxin in the lower face, to avoid the drooling, speech problems, and mouth incompetence that result from over-injection or misplaced treatment.

Berbos ZJ et al. Update on botulinum toxin and dermal fillers. *Curr Opin Ophthalmol.* 2010 Sep;21(5):387–95. [PMID: 20703120]

Small R. Aesthetic procedures in office practice. *Am Fam Physician.* 2009 Dec 1;80(11):1231–7. [PMID: 19961136]

Wollina U et al. Aging well—the role of minimally invasive aesthetic dermatological procedures in women over 65. *J Cosmet Dermatol.* 2010 Mar;9(1):50–8. [PMID: 20367673]

Appendix: Therapeutic Drug Monitoring, Pharmacogenetic Testing, & Laboratory Reference Intervals

C. Diana Nicoll, MD, PhD, MPA
 Chuanyi Mark Lu, MD, PhD

Table 1. Therapeutic drug monitoring.¹

Drug	Effective Concentrations	Half-Life (hours)	Dosage Adjustments	Comments
Amikacin	Conventional dosing: Peak: 20-30 mg/L; trough: < 10 mg/L High dose once daily: Peak: 60 mg/L; trough: undetectable	2-3; ↑ in uremia	↓ in renal dysfunction	Concomitant kanamycin or tobramycin therapy may give falsely elevated amikacin results by immunoassay.
Amitriptyline	95-250 ng/mL	9-25		Drug is highly protein-bound. Patient-specific decrease in protein binding may invalidate quoted therapeutic reference interval for effective concentration.
Carbamazepine	4-12 mg/L	10-15		Induces its own metabolism. Metabolite 10,11-epoxide exhibits 13% cross-reactivity by immunoassay. Adverse reactions: skin reactions, myelosuppression.
Cyclosporine	100-300 mcg/L (ng/mL) whole blood	6-12	↓ in renal dysfunction, liver disease	Cyclosporine is lipid-soluble (20% bound to leukocytes; 40% to erythrocytes; 40% in plasma, highly bound to lipoproteins); the binding is temperature-dependent in vitro and concentration-dependent in vivo. HPLC and LC-tandem mass spectrometry methods are highly specific for parent drug and considered as the gold standard assays. Monoclonal fluorescence polarization immunoassay (FPIA) and monoclonal chemiluminescence immunoassay also measure cyclosporine reliably; polyclonal immunoassays are less specific due to cross-reaction with drug metabolites. Anticonvulsants and rifampin increase metabolism. Erythromycin, ketoconazole, and calcium channel blockers decrease metabolism. The main adverse reaction is concentration-related nephrotoxicity.
Desipramine	100-250 ng/mL	13-23		Drug is highly protein-bound. Patient-specific decrease in protein binding may invalidate quoted therapeutic reference interval for effective concentration.

(continued)

Table 1. Therapeutic drug monitoring.¹ (continued)

Drug	Effective Concentrations	Half-Life (hours)	Dosage Adjustments	Comments
Digoxin	CHF: 0.5-0.9 ng/mL Atrial fibrillation: 0.5-2 ng/mL	42; ↑ in uremia, CHF	↓ in renal dysfunction, CHF, hypothyroidism ↑ in hyperthyroidism	Bioavailability of digoxin tablets is 50-90%. Specimen must not be drawn within 4 hours of an intravenous dose or 6 hours of an oral dose. Dialysis does not remove a significant amount. Hypokalemia potentiates toxicity. Digitalis toxicity is a clinical and <i>not</i> a laboratory diagnosis. Digibind (digoxin-specific antibody) therapy of digoxin overdose can interfere with measurement of digoxin levels depending on the digoxin assay. Elimination reduced by amiodarone, quinidine, and verapamil.
Ethosuximide	40-100 mg/L	Child: 30 Adult: 50		Levels used primarily to assess clinical response and compli- ance. Toxicity is rare and does not correlate well with plasma concentrations.
Gentamicin	Conventional dosing: Peak: 4-8 mg/L; trough: < 2 mg/L High dose once daily: Peak: 20 mg/L; trough: undetectable	2-3; ↑ in uremia (7.3 during dialysis)	↓ in renal dysfunction	Draw peak specimen (conventional dosing) 30 minutes after end of 30- to 60-min infusion. Draw trough just before next dose. In uremic patients, some penicillins (eg, carbenicillin, ticarcillin, piperacillin) may decrease gentamicin half-life from 46 hours to 22 hours, posing a risk of reduced antibacterial efficacy. The main adverse reactions are CNS, otic, and renal toxicities.
Imipramine	180-350 ng/mL	10-16		Drug is highly protein-bound. Patient-specific decrease in protein binding may invalidate quoted therapeutic reference interval for effective concentration.
Lidocaine	1-5 mg/L	1.8; × in uremia, CHF; ↑ in cirrhosis	↓ in CHF, liver disease	Levels increased with cimetidine therapy. CNS toxicity common in the elderly.
Lithium	0.5-1.5 mmol/L	22; ↑ in uremia	↓ in renal dysfunction	Thiazides and loop diuretics may increase serum lithium levels.
Methotrexate		3-10 low dose; 8-15 high dose; ↑ in uremia	↓ in renal dysfunction	Therapeutic concentrations depend on the treatment protocol (low versus high dose) and time of specimen collection. 7-Hydroxymethotrexate cross-reacts 1.5% in immunoassay. To minimize toxicity, leucovorin or glucarpidase should be continued if methotrexate level is > 0.1 mcmol/L at 48 hours after start of therapy. Methotrexate > 1 mcmol/L at > 48 hours requires an increase in rescue therapy.
Nortriptyline	50-140 ng/mL	18-44		Drug is highly protein-bound. Patient-specific decrease in protein binding may invalidate quoted therapeutic reference interval for effective concentration.
Phenobarbital	10-40 mg/L	Child: 37-73 Adult: 53-140; ↑ in cirrhosis	↓ in liver disease	Metabolized primarily by the hepatic microsomal enzyme system. Many drug-drug interactions.
Phenytoin	10-20 mg/L; 5-10 mg/L in uremia and severe hypoalbuminemia	Dose/concentration- dependent		Drug metabolite cross-reacts in immunoassays; the cross- reactivity may be of significance only in the presence of advanced chronic kidney disease. Metabolism is capacity-limited. Increase dose cautiously when level approaches therapeutic reference interval, since new steady-state level may be disproportionately higher. Drug is very highly protein-bound; protein binding is decreased in uremia and hypoalbuminemia. Free drug level (pharmacologically active fraction) may be indicated in certain clinical circumstances.

(continued)

Table 1. Therapeutic drug monitoring.¹ (continued)

Drug	Effective Concentrations	Half-Life (hours)	Dosage Adjustments	Comments
Sirolimus	Trough: 4–12 ng/mL when used in combination with cyclosporine A; 12–20 ng/mL if used alone	62	↓ in liver dysfunction and with drugs inhibiting CYP3A4 activity	Sirolimus is an immunosuppressant used in combination with cyclosporine and corticosteroids for prophylaxis of organ rejection after kidney transplantation. It has also been used in liver and heart transplantation. When used in combination with cyclosporine, careful monitoring of kidney function is required. Once the initial dose titration is complete, monitoring sirolimus trough concentrations weekly for the first month and every 2 weeks for the second month appears to be appropriate. The optimal time for specimen collection is 24 h after the previous dose or 0.5 to 1 h prior to the next dose (trough level).
Tacrolimus	Trough: 8–12 ng/mL	8.7–11.3	↓ in liver dysfunction and with drugs inhibiting CYP3A4 activity	Tacrolimus is used for prophylaxis of organ rejection in adult patients undergoing liver or kidney transplantation and in pediatric patients undergoing liver transplantation. It has also been used to prevent rejection in heart, small bowel, and allogeneic bone marrow transplant patients and to treat autoimmune diseases. Antacid or sucralfate administration should be separated from tacrolimus by at least 2 h. The optimal time for specimen collection is 12 h after the previous dose or 0.5 to 1 h prior to the next dose (trough level).
Theophylline	5–15 mg/L	9	↓ in CHF, cirrhosis, and with cimetidine	Caffeine cross-reacts 10%. Elimination is increased 1.5–2 times in smokers. 1,3-Dimethyl uric acid metabolite increased in uremia and, because of cross-reactivity, may cause an apparent slight increase in serum theophylline.
Tobramycin	Conventional dosing: Peak: 5–10 mg/L; trough: < 2 mg/L High dose once daily: Peak: 20 mg/L; trough: undetectable	2–3; ↑ in uremia	↓ in renal dysfunction	Tobramycin, kanamycin, and amikacin may cross-react in immunoassay. Some antibiotics may decrease tobramycin half-life in uremic patients, causing reduced antibacterial efficacy.
Valproic acid	50–100 mg/L	Child: 6–8 Adult: 10–12		Significant fraction of the drug is protein-bound in vivo (concentration-dependent). Decreased binding in uremia and cirrhosis.
Vancomycin	Trough: 10–20 mg/L	6; ↑ in uremia	↓ in renal dysfunction	Ototoxicity in uremic patients may lead to irreversible deafness. Keep peak level < 40–50 mg/L to avoid severe toxicity.

¹Serum from a plain red-top tube is typically used for therapeutic drug monitoring except for cyclosporine, which requires whole blood sample in a lavender (EDTA) tube. In general, the specimen should be drawn just before the next dose (trough).

↑, increased; ↓, decreased; CYP, cytochrome P450; HPLC, high performance liquid chromatography; CHF, congestive heart failure; CNS, central nervous system.

Modified, with permission, from Nicoll D et al. *Pocket Guide to Diagnostic Tests*, 6th ed. McGraw-Hill, 2012.

Table 2. Selected pharmacogenetic tests: clinical relevance.¹

Pharmacogenetic Biomarker	Selected Variants (mutant allele, enzyme activity)	Allele Frequency	Drugs	Clinical Relevance
Cytochrome P450 (CYP) 2C9 variants	2C9*2 (430C>T, ↓) 2C9*3 (1075A>C, ↓↓)	2C9*2 and 2C9*3 are present in 9–20% of whites, 1–3% of blacks, and < 1% of Asians	Warfarin (Coumadin)	Hepatic CYP2C9 is responsible for the metabolic inactivation and clearance of the anticoagulant warfarin. Patients carrying 2C9*2 or 2C9*3 (or both) (heterozygote, homozygote or compound heterozygote) require reduced maintenance dose to reach a therapeutic INR. While INR remains the standard for monitoring warfarin therapy, CYP2C9 genotyping can be an important aid to dosing strategy for warfarin-naïve patients, particularly whites.
CYP 2C19 variants	2C19*2(681G>A, none) 2C19*3(636G>A, none) 2C19*4(1A>G, none) 2C19*5(1297C>T, none)	The mutant variants are present in 12–25% of Asians, and 2–7% of whites and blacks	Clopidogrel (Plavix)	Clopidogrel, an antiplatelet drug, must be metabolized in the liver by CYP isoenzymes, principally CYP 2C19, to become active. When treated with clopidogrel at recommended dosages, patients with CYP 2C19 variants have more cardiovascular events than do patients with normal CYP 2C19 function. Alternative drug or intervention strategies should be considered for patients with 2C19 variants. CYP 2C19*17 carrier status (25% of whites) is associated with increased enzyme activity and an increased risk of bleeding.
HLA-B*1502 allele	HLA-B*1502	10–15% of Asians; 1–2% of whites	Carbamazepine (Tegretol, Eptol)	Carbamazepine is associated with serious or even fatal idiosyncratic skin reactions, eg, Stevens-Johnson syndrome and toxic epidermal necrolysis. The reactions are significantly more common in patients who carry the HLA-B*1502 allele. This allele occurs almost exclusively in patients with ancestry across broad areas of Asia, including South Asian Indians. HLA-B*1502 genotyping may be useful for risk stratification in patients of Asian descent. Patients carrying the HLA-B*1502 allele should not be given carbamazepine unless the expected benefit clearly outweighs the increased risk of serious skin reactions.
HLA-B*5701 allele	HLA-B*5701	6–8% of whites and selected Indians; 1–2% of blacks and Asians	Abacavir (Ziagen)	Abacavir is a nucleoside analog reverse transcriptase inhibitor used for HIV treatment. The major treatment-limiting toxicity for abacavir use is drug hypersensitivity, occurring in 5–8% of recipients within 6 weeks of commencing therapy. There is an established association between carriage of the HLA-B*5701 allele and abacavir hypersensitivity reactions. HLA-B*5701-positive patients should not be prescribed abacavir or an abacavir-containing regimen.

(continued)

Table 2. Selected pharmacogenetic tests: clinical relevance.¹ (continued)

Pharmacogenetic Biomarker	Selected Variants (mutant allele, enzyme activity)	Allele Frequency	Drugs	Clinical Relevance
Thiopurine methyltransferase (TPMT) variants	TPMT*2 (238G>C, ↓) TPMT*3A (460G>A and 719A>G, ↓↓) TPMT*3B (460G>A, ↓) TPMT*3C (719A>G, ↓)	About 10–12% of whites and blacks have reduced enzyme activity because they are heterozygous for one of the mutant alleles. About 1 in 300 whites is homozygous for a mutant allele.	Azathioprine (AZA), 6-mercaptopurine (6-MP)	AZA is a prodrug that is metabolized to 6-MP, which is then further metabolized to active 6-thioguanine (6-TG) and inactive 6-methylmercaptopurine (6-MMP) through hypoxanthine phosphoribosyltransferase and TPMT, respectively. Variation in the TPMT gene can result in functional inactivation of the enzyme and an increased risk of life-threatening, 6-TG associated myelosuppression. TPMT genotyping before instituting AZA or 6-MP can help prevent toxicity by identifying individuals with low or absent TPMT enzyme activity. Patients with homozygous or compound heterozygous mutant alleles (“poor metabolizers”) should not be given AZA or 6-MP, while heterozygotes with a single mutant allele should be treated with lower doses.
Uridine diphosphoglucuronosyltransferase 1A1 (UGT 1A1) variants	UGT1A1*28 (7 TA repeats in promoter, ↓)	Homozygosity in 9–23% of whites, blacks and Indians, and in 1–2% of eastern Asians.	Irinotecan (Camptosar)	Irinotecan is used in the treatment of metastatic colorectal cancer. It is metabolized to active SN-38, a topoisomerase I inhibitor. SN-38 is further glucuronidated to inactive SN-38G by UGT1A1 and excreted. Heterozygous and homozygous UGT1A1*28 genotypes show a 25% and 70% decrease in enzyme activity, respectively. The presence of the UGT1A1*28 allele is a risk factor for the development of adverse drug reactions (eg, neutropenia, severe diarrhea). Testing for the allele can prevent drug toxicity at high doses of irinotecan.
Vitamin K epoxide reductase complex (VKORC1) variants	VKORC1 (–1639G>A)	The homozygous (–1639G>A) allele (–1639AA genotype) is present in approximately 15% of whites and 80% of Chinese.	Warfarin (Coumadin)	The primary therapeutic target of the anticoagulant warfarin is VKOR. Polymorphisms in the VKOR encoding gene (VKORC1) explain about 30% of the phenotypic variability in drug effect. Patients carrying the VKORC1 (–1639G>A) allele require a lower warfarin maintenance dose to reach a therapeutic INR.
<i>BRAF</i> gene	<i>BRAF</i> V600E mutation	40–60% of advanced melanomas	Vemurafenib (Zelboraf)	Activating mutations in <i>BRAF</i> (a serine-threonine protein kinase) are present in 40–60% of advanced melanomas. Most, with (80–90%) of the mutations are the substitution of glutamic acid for valine at amino acid 600 (V600E mutation), and this is associated with a more aggressive clinical course. Vemurafenib, a potent inhibitor of the mutant <i>BRAF</i> , has a high level of therapeutic activity against advanced melanomas containing the V600E mutation.

¹Testing of these genetic biomarkers prior to instituting drug therapy is now recommended per US Food and Drug Administration-approved drug labels. Note, however, that these tests are not yet mandated as standard practice.

↓, decreased; ↓↓, markedly decreased; >, single wild-type to variant nucleotide switch at the specific gene location; CYP, cytochrome P450 oxidase.

Table 3. Reference intervals for commonly used tests.^{1,2}

Current metric units × Conversion factor = SI units SI units ÷ Conversion factor = Current metric units					
Test	Specimen	Conventional Units	Conversion Factor	SI Units ²	Collection ³
Acetaminophen	Serum	10–20 mcg/mL Panic: > 50 mcg/mL	6.616	66–132 mcmol/L	Serum separator tube (SST)
Acetoacetate	Serum or urine	Negative (0 mg/dL)	0.098	Negative (0 mmol/L)	SST or urine container
Activated clotting time (ACT)	Whole blood	70–180 seconds (method-specific)			Collect in a plastic syringe without anticoagulant
Adrenocorticotrophic hormone (ACTH)	Plasma	9–52 pg/mL (laboratory-specific)	0.22	2–11 pmol/L	Siliconized glass or plastic lavender
Alanine aminotransferase (ALT, SGPT, GPT)	Serum or plasma	0–35 units/L (laboratory-specific)	0.02	0–0.7 mckat/L (laboratory-specific)	SST, plasma preparation tube (PPT) (green)
Albumin	Serum or plasma	3.4–4.7 g/dL	10.00	34–47 g/L	SST, PPT (green)
Aldosterone	Serum	Salt-loaded (120 mEq Na ⁺ /d for 3–4 days): Supine: 3–10 ng/dL Upright: 5–30 ng/dL Salt-depleted (20 mEq Na ⁺ /d for 3–4 days): Supine: 12–36 ng/dL Upright: 17–137 ng/dL	27.74	83–277 pmol/L 139–831 pmol/L 332–997 pmol/L 471–3795 pmol/L	SST
	Urine	Salt-loaded (120 mEq Na ⁺ /d for 3–4 days): 1.5–12.5 mcg/24 h Salt-depleted (20 mEq Na ⁺ /d for 3–4 days): 18–85 mcg/24 h	2.77	4.2–34.6 nmol/d 49.9–235.5 nmol/d	Urine bottle containing boric acid
Alkaline phosphatase	Serum or plasma	41–133 units/L (method- and age-dependent)	0.02	0.7–2.2 mckat/L (method- and age-dependent)	SST, PPT (green)
Ammonia (NH ₃)	Plasma	18–60 mcg/dL	0.587	11–35 mcmol/L	Green (iced)
Amylase	Serum or plasma	20–110 units/L (laboratory-specific)	0.02	0.33–1.83 mckat/L (laboratory-specific)	SST, PPT (green)
Angiotensin-converting enzyme (ACE)	Serum	12–35 units/L (method-dependent)	16.67	200–583 nkat/L (method-dependent)	SST
Antithrombin (AT)	Plasma	84–123% (qualitative/activity) 80–130% (quantitative/antigen)			Blue
α ₁ -Antitrypsin, α ₁ -Antiprotease	Serum or plasma	110–270 mg/dL	0.01	1.1–2.7 g/L	SST, PPT (green)
Aspartate aminotransferase (AST, SGOT, GOT)	Serum or plasma	0–35 units/L (laboratory-specific)	0.02	0–0.58 mckat/L (laboratory-specific)	SST, PPT (green)
Basophil count	Whole blood	0.01–0.12 × 10 ³ /mCL	1.00	0.01–0.12 × 10 ⁹ /L	Lavender
<i>bcr/abl</i> , t (9;22) translocation by reverse-transcriptase polymerase chain reaction (RT-PCR), qualitative	Whole blood	Negative (Positive: chronic myeloid leukemia, some acute B-lymphoblastic leukemia)			Lavender
β ₂ microglobulin	Serum or plasma	< 0.2 mg/dL	10	< 2 mg/L	SST, PPT (green)

(continued)

Table 3. Reference intervals for commonly used tests.^{1,2} (continued)

Current metric units × Conversion factor = SI units SI units ÷ Conversion factor = Current metric units					
Test	Specimen	Conventional Units	Conversion Factor	SI Units ²	Collection ³
Bilirubin	Serum or plasma	Total: 0.1–1.2 mg/dL	17.10	2–21 mcmol/L	SST, PPT (green)
		Direct (conjugated to glucuronide): 0.1–0.5 mg/dL		< 8 mcmol/L	
		Indirect (unconjugated): 0.1–0.7 mg/dL		< 12 mcmol/L	
Blood urea nitrogen (BUN)	Serum or plasma	8–20 mg/dL	0.357	2.9–7.1 mmol/L	SST, PPT (green)
B-type natriuretic peptide (BNP)	Plasma	< 100 pg/mL	1.0	< 100 ng/L	Lavender
C-peptide	Serum or plasma	0.8–4.0 ng/mL	0.333	0.27–1.33 nmol/L	SST or green/iced (fasting)
C-reactive protein, high sensitivity (hs-CRP)	Serum or plasma	< 1.0 mg/dL	10.00	< 10 mg/L	SST, PPT (green)
C-telopeptide, beta-cross-linked (CTX)	Serum	Male: 60–850 pg/mL Female: premenopausal 60–650 pg/mL, postmenopausal 100–1000 pg/mL (age- and laboratory-specific)	1.00	Male: 60–850 ng/L Female: premenopausal 60–650 ng/L, postmenopausal 100–1000 ng/L (age- and laboratory-specific)	Red, SST
Calcitonin	Plasma or serum	Male: 0–11.5 pg/mL Female: 0–4.6 pg/mL	1.00	Male: 0–11.5 ng/L Female: 0–4.6 ng/L	Green, SST
Calcium (Ca ²⁺)	Serum or plasma	8.5–10.5 mg/dL Panic: < 6.5 or > 13.5 mg/dL	0.25	2.1–2.6 mmol/L	SST, PPT (green)
Calcium (ionized)	Serum or whole blood	4.6–5.3 mg/dL	0.25	1.15–1.32 mmol/L	SST, PPT (green) (anaerobic)
Calcium (U _{Ca})	Urine	100–300 mg/24 h	0.025	2.5–7.5 mmol/24 h	Urine bottle containing hydrochloric acid
Carbon dioxide, partial pressure (Pco ₂)	Whole blood	32–48 mm Hg	0.13	4.26–6.38 kPa	Heparinized syringe (iced)
Carbon dioxide (CO ₂), total (bicarbonate)	Serum or plasma	22–32 mEq/L Panic: < 15 or > 40 mEq/L	1.00	22–32 mmol/L Panic: < 15 or > 40 mmol/L	SST, PPT (green)
Carboxyhemoglobin (HbCO)	Whole blood	< 9% of total hemoglobin (Hb)	0.01	< 0.09 fraction of total hemoglobin	Heparinized syringe or Green
Carcinoembryonic antigen (CEA)	Serum	0–5 ng/mL	1.00	0–5 mcg/L	SST
Catecholamines	Urine	Norepinephrine: 15–80 mcg/24 h	5.91	89–473 nmol/24 h	Urine container with hydrochloride acid
		Epinephrine: 0–20 mcg/24 h	5.46	0–109 nmol/24 h	
		Dopamine: 65–400 mcg/24 h	6.53	425–2610 nmol/24 h	
CD4 T cell count	Whole blood	0.36–1.73 × 10 ³ /mCL	1.00	0.36–1.73 × 10 ⁶ /L	Lavender (order T-cell subsets and a CBC with differential)

(continued)

Table 3. Reference intervals for commonly used tests.^{1,2} (continued)

Current metric units × Conversion factor = SI units SI units ÷ Conversion factor = Current metric units					
Test	Specimen	Conventional Units	Conversion Factor	SI Units ²	Collection ³
Ceruloplasmin	Serum or plasma	20–60 mg/dL (laboratory-specific)	10.00	200–600 mg/L	SST, PPT (green)
Chloride (Cl ⁻)	Serum or plasma	101–112 mEq/L	1.00	101–112 mmol/L	SST, PPT (green)
Cholesterol	Serum or plasma	Desirable: < 200 mg/dL Borderline: 200–240 mg/dL High risk: > 240 mg/dL	0.0259	Desirable: < 6.0 mmol/L Borderline: 6.0–7.2 mmol/L High risk: > 7.2 mmol/L	SST, PPT (green)
Chorionic gonadotropin, β-subunit (β-hCG), quantitative	Serum	Males and nonpregnant females: undetectable or < 5 mU/mL	1.00	Males and nonpregnant females: undetectable or < 5 units/L	SST
Complement C3	Serum	64–166 mg/dL	10.00	640–1660 mg/L	SST
Complement C4	Serum	15–45 mg/dL	10.00	150–450 mg/L	SST
Complement CH50	Serum	(Laboratory-specific)			Red
Cortisol	Serum or plasma	8:00 AM: 5–20 mcg/dL	27.59	140–550 nmol/L	SST, PPT (green)
Cortisol (urinary free)	Urine	10–110 mcg/24 h	2.76	27.6–303.6 nmol/24 h	Urine bottle containing boric acid
Creatine kinase (CK)	Serum or plasma	32–267 units/L (method-dependent)	0.02	0.53–4.45 mckat/L (method-dependent)	SST, PPT (green)
Creatine kinase MB (CKMB)	Serum or plasma	< 16 units/L or < 4% of total CK (laboratory-specific) Mass units: 0–7 mcg/L	0.04	< 0.27 mckat/L	SST, PPT (green)
Creatinine (Cr)	Serum or plasma	0.6–1.2 mg/dL	88.4	50–100 μmol/L	SST, PPT (green)
Creatinine clearance (Cl _{Cr})	See Collection column	Adults: 90–140 mL/min/1.73 m ² body surface area (BSA)	0.0167	1.5–2.3 mL/s/1.73 m ² BSA	Carefully timed 24-hour urine and simultaneous serum or plasma creatinine sample
Cryoglobulins	Serum	Negative			Red (transported at 37 °C)
D-dimer, quantitative	Plasma	< 500 ng/mL	1.00	< 500 mcg/L	Blue
Dehydroepiandrosterone sulfate (DHEA-S)	Serum or plasma	Male: 40–500 mcg/dL Female: 20–320 mcg/dL	10.00	Male: 400–5000 mcg/L Female: 200–3200 mcg/L	SST, PPT (green)
Eosinophil count	Whole blood	0.04–0.5 × 10 ³ /mCL	1.00	0.04–0.5 × 10 ⁹ /L	Lavender
Erythrocyte count (RBC count)	Whole blood	4.7–6.1 × 10 ⁶ /mCL	1.00	4.7–6.1 × 10 ¹² /L	Lavender
Erythrocyte sedimentation rate	Whole blood	Male: < 10 mm/h Female: < 15 mm/h (laboratory-specific)		Same	Lavender (test must be run within 2 h)
Erythropoietin (EPO)	Serum	5–30 mU/mL	1.00	5–30 units/L	SST
Estradiol	Serum	Early follicular: 30–100 pg/mL Late follicular: 100–400 pg/mL Luteal: 50–150 pg/mL Postmenopausal: 2–21 pg/mL	3.671	110–367 pmol/L 367–1468 pmol/L 183–550 pmol/L 7–77 pmol/L	SST

(continued)

Table 3. Reference intervals for commonly used tests.^{1,2} (continued)

Current metric units × Conversion factor = SI units SI units ÷ Conversion factor = Current metric units					
Test	Specimen	Conventional Units	Conversion Factor	SI Units ²	Collection ³
Estrogens, total	Serum	Follicular: 60–200 pg/mL Luteal: 160–400 pg/mL Postmenopausal: < 130 pg/mL	1.00	60–200 ng/L 160–400 ng/L < 130 ng/L	SST
Ethanol	Serum or plasma	0 mg/dL Legal “driving under the influence” in many states is defined as > 80 mg/dL (> 17 mmol/L) blood alcohol level; serum alcohol levels are 10–35% higher than whole blood alcohol levels	0.217	0 mmol/L	SST, PPT
Factor VIII assay	Plasma	50–150% of normal (varies with age)			Blue (iced)
Fecal fat	Stool	Random: < 60 droplets of fat per high-power field 72-hour: < 7 g/24 h			Qualitative: Random stool sample Quantitative: 72-hour collection following 2-day dietary fat regimen
Ferritin	Serum or plasma	Male: 16–300 ng/mL Female: 4–161 ng/mL	2.247	Male: 36–674 pmol/L Female: 9–362 pmol/L	SST, PPT (green)
α-Fetoprotein (AFP)	Serum	0–15 ng/mL	1.00	0–15 mcg/L	SST
Fibrinogen (functional)	Plasma	175–433 mg/dL Panic: < 75 mg/dL	0.0294	5.15–12.73 mcg/mL Panic: < 2.2 mcg/mL	Blue
Follicle-stimulating hormone (FSH)	Serum or plasma	Female: Follicular phase 4–13 mU/mL Luteal phase 2–13 mU/mL Midcycle 5–22 mU/mL Postmenopausal 30–138 mU/mL Male: 1–10 mU/mL (laboratory-specific)	1.00	Female: 4–13 units/L 2–13 units/L 5–22 units/L 30–138 units/L Male: 1–10 units/L (laboratory-specific)	SST, PPT (green)
Free erythrocyte protoporphyrin (FEP)	Whole blood	< 35 mcg/dL (method-dependent)			Lavender
Fructosamine	Serum or plasma	190–270 mcg/mol/L	1.0	190–270 mcg/mol/L	SST, PPT (green)
γ-Glutamyl transpeptidase (GGT)	Serum or plasma	9–85 units/L (laboratory-specific)	0.02	0.15–1.42 mU/L (laboratory-specific)	SST, PPT (green)
Gastrin	Serum	< 100 pg/mL (laboratory-specific)	1.00	< 100 ng/L	SST
Glomerular filtration rate, estimated (eGFR)	Serum or plasma	> 60 mL/min/1.73 m ² (calculated based on creatinine level)			SST, PPT (green)
Glucagon	Plasma	20–100 pg/mL	1.00	20–100 ng/L	Lavender
Glucose	Serum or plasma	60–110 mg/dL Panic: < 40 or > 500 mg/dL	0.0555	3.33–6.11 mmol/L Panic: < 2.22 or > 27.75 mmol/L	(Fasting) SST, PPT, gray
Glucose-6-phosphate dehydrogenase (G6PD) screen	Whole blood	5–14 units/g Hb	0.02	0.1–0.28 mU/L	Lavender
Glutamine	Cerebrospinal fluid (CSF)	6–15 mg/dL Panic: > 40 mg/dL	68.42	411–1028 mcg/mol/L	Collect CSF in a plastic tube

(continued)

Table 3. Reference intervals for commonly used tests.^{1,2} (continued)

Current metric units × Conversion factor = SI units SI units ÷ Conversion factor = Current metric units					
Test	Specimen	Conventional Units	Conversion Factor	SI Units ²	Collection ³
Glycated (glycosylated) hemoglobin (HbA _{1c})	Whole blood	3.9–5.6% (method-dependent)			Lavender, pink
Growth hormone (GH)	Serum or plasma	0–5 ng/mL	1.00	0–5 mcg/L	SST, PPT (green)
Haptoglobin	Serum or plasma	46–316 mg/dL	0.01	0.5–3.2 g/L	SST, PPT (green)
HDL cholesterol	Serum or plasma	Male: 27–67 mg/dL Female: 34–88 mg/dL (HDL cholesterol > 60 mg/dL is thought to lower risk of coronary heart disease)	0.0259	0.7–1.73 mmol/L 0.88–2.28 mmol/L	SST, PPT (green)
Hematocrit (Hct)	Whole blood	Male: 39–49% Female: 35–45% (age-dependent)	0.01	Male: 0.39–0.49 Female: 0.35–0.45	Lavender, Pink
Hemoglobin A _{1c} (See Glycated Hemoglobin)	Whole blood	3.9–5.6% (method-dependent)			
Hemoglobin A ₂ (HbA ₂)	Whole blood	1.5–3.5% of total hemoglobin	0.01	0.015–0.035	Lavender
Hemoglobin electrophoresis	Whole blood	HbA: > 95% HbA ₂ : 1.5–3.5% HbF: < 2% (age-dependent)			Lavender
Hemoglobin, total (Hb)	Whole blood	Male: 13.6–17.5 g/dL Female: 12.0–15.5 g/dL (age dependent) Panic: ≤ 7 g/dL	10.00	Male: 136–175 g/L Female: 120–155 g/L	Lavender
Heparin-associated antibody (heparin-induced thrombocytopenia)	Serum	Negative			SST
HIV antibody	Serum or plasma	EIA: Negative Western blot: Nonreactive			SST, PPT
HIV RNA, quantitative (viral load)	Plasma	Negative (or < 75 copies/mL, assay-specific)			Lavender, PPT (white)
Homocysteine	Serum or plasma	4.5–12 mg/dL (method- and age-dependent)	7.397	33.29–88.76 mcmol/L	SST, PPT
5-Hydroxyindoleacetic acid (5-HIAA)	Urine	2–8 mg/24 h	5.23	10–40 mcmol/d	Urine bottle containing hydrochloric acid
IgG index	Serum and CSF	0.29–0.59 ratio (CSF: serum ratio)			SST (for serum) and plastic tube (for CSF)
Immunoglobulins (Ig)	Serum	IgA: 78–367 mg/dL IgG: 583–1761 mg/dL IgM: 52–335 mg/dL	0.01	IgA: 0.78–3.67 g/L IgG: 5.83–17.6 g/L IgM: 0.52–3.35 g/L	SST
Insulin, immunoreactive	Serum or plasma	6–35 mU/mL	6.945	42–243 pmol/L	SST, PPT
Insulin-like growth factor-1	Plasma	123–463 ng/mL (age- and sex-dependent)	1.0	123–463 mcg/L	Lavender
Iron (Fe)	Serum or plasma	50–175 mcg/dL	0.179	9–31 mcmol/L	SST, PPT (green)
Iron-binding capacity, total (TIBC)	Serum or plasma	250–460 mcg/dL	0.179	45–82 mcmol/L	SST, PPT (green)

(continued)

Table 3. Reference intervals for commonly used tests.^{1,2} (continued)

Current metric units × Conversion factor = SI units SI units ÷ Conversion factor = Current metric units					
Test	Specimen	Conventional Units	Conversion Factor	SI Units ²	Collection ³
JAK2 mutations (V617F or exon 12/13 mutation), qualitative	Whole blood	Negative (Positive: myeloproliferative neoplasms, ie, polycythemia vera, essential thrombocythemia, and primary myelofibrosis)			Lavender
Kappa and lambda free light chains, quantitative	Serum	Free kappa: 0.57-2.63 mg/dL Free lambda: 0.33-1.94 mg/dL Free kappa/lambda ratio: 0.26-1.65	0.01	5.7-26.3 × 10 ⁻³ g/L 3.3-19.4 × 10 ⁻³ g/L	SST, red
Ketone bodies	Serum or plasma	Qualitative: Negative Quantitative: <10 mg/dL	10.0	< 100 mg/L	SST, PPT (green)
Lactate dehydrogenase (LDH)	Serum or plasma	88-230 units/L (laboratory-specific)	0.02	1.46-3.82 mckat/L (laboratory-specific)	SST, PPT (green)
Lactic acid (lactate)	Venous blood	0.5-2.0 mEq/L	1.00	0.5-2.0 mmol/L	Gray (iced)
LDL cholesterol (calculated or direct)	Serum or plasma	Desirable: < 130 mg/dL (< 99 mg/dL for patients with CHD); Borderline: 130-159 mg/dL; High risk: ≥ 160 mg/dL	0.0259	< 3.37 mmol/L (< 2.57 mmol/L); 3.38-4.13 mmol/L; > 4.16 mmol/L	SST, PPT (green)
Lead (Pb)	Whole blood	Child: < 25 mcg/dL Adult: < 40 mcg/dL	0.0483	Child: < 1.21 mcmol/L Adult: < 1.93 mcmol/L	Dark blue (trace metal free)
Leukocyte (white blood cell) count, total (WBC count)	Whole blood	4.8-10.8 × 10 ³ /mcl Panic: < 1.5 × 10 ³ /mcl	1.00	4.8-10.8 × 10 ⁹ /L	Lavender
Lipase	Serum	0-160 units/L (laboratory-specific)	0.02	0-2.66 mckat/L (laboratory-specific)	SST
Luteinizing hormone (LH)	Serum or plasma	Female: Follicular phase 1-18 mU/mL Luteal phase 0.4-20 mU/mL Midcycle 24-105 mU/mL Postmenopausal 15-62 mU/mL Male: 1-10 mU/mL (laboratory-specific)	1.00	Female: 1-18 units/L 0.4-20 units/L 24-105 units/L 15-62 units/L Male: 1-10 units/L (laboratory-specific)	SST, PPT
Lymphocyte count	Whole blood	0.8-3.5 × 10 ³ /mcl	1.00	0.8-3.5 × 10 ⁹ /L	Lavender
Magnesium (Mg ²⁺)	Serum or plasma	1.8-3.0 mg/dL Panic: < 0.5 or > 4.5 mg/dL	0.411	0.75-1.25 mmol/L	SST, PPT (green)
Mean corpuscular hemoglobin (MCH)	Whole blood	27-34 pg			Lavender
Mean corpuscular hemoglobin concentration (MCHC)	Whole blood	31-36 g/dL	10.00	310-360 g/L	Lavender
Mean corpuscular volume (MCV)	Whole blood	80-100 fL			Lavender
Metanephrines, free	Plasma	Normetanephrine: < 0.9 nmol/L Metanephrine: < 0.5 nmol/L			Lavender

(continued)

Table 3. Reference intervals for commonly used tests.^{1,2} (continued)

Current metric units × Conversion factor = SI units SI units ÷ Conversion factor = Current metric units					
Test	Specimen	Conventional Units	Conversion Factor	SI Units ²	Collection ³
Metanephrines	Urine	0.3–0.9 mg/24 h	5.46	1.6–4.9 mcmol/24 h	Urine bottle containing hydrochloric acid
Methemoglobin (MetHb)	Whole blood	< 1% of total hemoglobin	0.01	< 0.01 fraction of total hemoglobin	Blood gas syringe, lavender, or green
Methylmalonic acid	Serum or plasma	0–0.05 mg/L	8.475	0–0.4 mcmol/L	SST, PPT (green)
Monocyte count	Whole blood	0.2–0.8 × 10 ³ /mCL	1.00	0.2–0.8 × 10 ⁹ /L	Lavender
Neutrophil count	Whole blood	2.2–8.6 × 10 ³ /mCL	1.00	2.2–8.6 × 10 ⁹ /L	Lavender
Osmolality	Serum or plasma	275–293 mosm/kg H ₂ O Panic: < 240 or > 320 mosm/kg H ₂ O	1.00	275–293 mmol/kg H ₂ O	SST, PPT
	Urine	Random: 100–900 mosm/kg H ₂ O	1.00	Random: 100–900 mmol/kg H ₂ O	Urine container
Osteocalcin	Serum or plasma	Child or adolescent (age 7–17 years): 25–300 ng/mL	1.00	Child or adolescent (age 7–17 years): 25–300 mcg/L Adult: 10–15 mcg/L	SST, PPT (green)
		Adult: 10–15 ng/mL			
Oxygen, partial pressure (P _{O₂})	Whole blood	83–108 mm Hg	0.13	11.04–14.36 kPa	Heparinized syringe (iced)
Pancreatic elastase, fecal	Formed stool	> 200 mcg/g			Leak-proof container (freeze immediately)
Parathyroid hormone (PTH), intact	Serum or plasma	Intact PTH: 11–54 pg/mL (laboratory-specific)	0.11	Intact PTH: 1.2–5.7 pmol/L (laboratory-specific)	Red, SST, PPT
Partial thromboplastin time, activated (PTT)	Plasma	25–35 seconds (reference interval varies) Panic: ≥ 60 seconds			Blue
pH	Whole blood	Arterial: 7.35–7.45 Venous: 7.31–7.41			Heparinized syringe (iced)
Phosphorus	Serum or plasma	2.5–4.5 mg/dL Panic: < 1.0 mg/dL	0.323	0.8–1.45 mmol/L	SST, PPT (green)
Plasminogen	Plasma	70–113% (activity)	1.00	70–113%	Blue
Platelet count (Plt)	Whole blood	150–450 × 10 ³ /mCL Panic: < 25 × 10 ³ /mCL	1.0	150–450 × 10 ⁹ /L Panic: < 25 × 10 ⁹ /L	Lavender
Platelet-associated IgG	Plasma or serum	Negative			Lavender, PPT, SST
Platelet function test (PFA-100 closure time) (CEPI: collagen/epinephrine cartridge; CADP: collagen/ADP cartridge)	Whole blood	CEPI: 70–170 seconds (laboratory-specific) CADP: 50–110 seconds (laboratory-specific)	1.0	CEPI: 70–170 seconds CADP: 50–110 seconds	Blue
Porphobilinogen (PBG)	Urine	Negative			Protect from light

(continued)

Table 3. Reference intervals for commonly used tests.^{1,2} (continued)

Current metric units × Conversion factor = SI units SI units ÷ Conversion factor = Current metric units					
Test	Specimen	Conventional Units	Conversion Factor	SI Units ²	Collection ³
Potassium (K ⁺)	Serum or plasma	3.5–5.0 mEq/L Panic: < 3.0 or > 6.0 mEq/L	1.00	3.5–5.0 mmol/L	SST, PPT (green)
Procalcitonin	Serum or plasma	< 0.10 ng/mL	1.00	< 0.10 mcg/L	SST, PPT (green)
Prolactin (PRL)	Serum or plasma	< 20 ng/mL	1.00	< 20 mcg/L	SST, PPT (green)
Prostate-specific antigen (PSA)	Serum or plasma	0–4 ng/mL	1.00	0–4 mcg/L	SST, PPT
Protein C	Plasma	71–176% (functional) 60–150% (antigenic)			Blue
Protein electrophoresis	Serum	Adult: Albumin: 3.3–4.7 g/dL α_1 : 0.1–0.4 g/dL α_2 : 0.3–0.9 g/dL β_2 : 0.7–1.5 g/dL γ : 0.5–1.4 g/dL (polyclonal)	10.00	33–47 g/L 1–4 g/L 3–9 g/L 7–15 g/L 5–14 g/L (polyclonal)	SST, red
Protein S (antigen)	Plasma	76–178%			Blue
Protein, total	Serum or plasma	6.0–8.0 g/dL	10.00	60–80 g/L	SST, PPT (green)
Prothrombin time (PT)	Plasma	11–15 seconds Panic: ≥ 30 seconds (laboratory-specific)			Blue
Red blood cell count	Whole blood	4.7–6.1 × 10 ⁶ /mL (male) 3.5–5.5 × 10 ⁶ /mL (female)	1.00	4.7–6.1 × 10 ¹² /L 3.5–5.5 × 10 ¹² /L	Lavender
Renin activity	Plasma	High-sodium diet (75–150 mEq Na ⁺ /d): Supine: 0.2–2.3 ng/mL/h Standing: 1.3–4.0 ng/mL/h Low-sodium diet (30–75 mEq Na ⁺ /d): Standing: 4.0–7.7 ng/mL/h			Lavender
Reticulocyte count	Whole blood	33–137 × 10 ³ /mL	1.00	33–137 × 10 ⁹ /L	Lavender
Russell viper venom clotting time (dilute) (RVVT)	Plasma	24–37 seconds			Blue
Salicylate (aspirin)	Serum	200–300 mg/L Panic: > 350 mg/L	0.00724	1.45–2.17 mmol/L Panic: > 2.53 mmol/L	Red
Sodium (Na ⁺)	Serum or plasma	135–145 mEq/L Panic: < 125 or > 155 mEq/L	1.00	135–145 mmol/L Panic: < 125 or > 155 mmol/L	SST, PPT (green)
Somatostatin	Plasma	< 25 pg/mL (laboratory-specific)	0.611	< 15.28 pmol/L (laboratory-specific)	Lavender, PPT (white)
Testosterone	Serum or plasma	Male: 175–781 ng/dL Female: 10–75 ng/dL	0.0347	Male: 6–27 nmol/L Female: 0.3–2.6 nmol/L	SST, PPT (green)
Thyroglobulin	Serum or plasma	3–42 ng/mL	1.00	3–42 mcg/L	SST, PPT (green)
Thyroid-stimulating hormone (TSH)	Serum or plasma	0.4–4 mIU/mL	1.00	0.4–4 mU/L	SST, PPT (green)

(continued)

Table 3. Reference intervals for commonly used tests.^{1,2} (continued)

Current metric units × Conversion factor = SI units SI units ÷ Conversion factor = Current metric units					
Test	Specimen	Conventional Units	Conversion Factor	SI Units ²	Collection ³
Thyroid-stimulating antibody, Thyroid stimulating hormone receptor antibody (TSH-R Ab [stim])	Serum	< 130% of basal activity; based on cAMP generation in thyroid cell tissue culture			
Thyroxine, free (FT ₄)	Serum or plasma	0.7-1.86 ng/dL	12.87	9-24 pmol/L (varies with method)	SST, PPT (green)
Thyroxine (T ₄), total	Serum or plasma	5-11 mcg/dL	12.87	64-142 nmol/L	SST, PPT (green)
Transferrin	Serum or plasma	190-375 mg/dL	0.01	1.9-3.75 g/L	SST, PPT (green)
Transferrin receptor, soluble (sTfR)	Serum or plasma	2.2-5 mg/L (male) 1.9-4.4 mg/L (female) (laboratory-specific)			SST, PPT (green)
Triglycerides	Serum or plasma	< 165 mg/dL	0.0113	< 1.8 mmol/L	SST, PPT (green) (fasting)
Triiodothyronine (T ₃), total	Serum	95-190 ng/dL	0.0154	1.5-2.9 nmol/L	Red
Troponin-I (cTnI)	Plasma	< 0.1 ng/mL (method-dependent)	1.0	< 0.1 mcg/L (method-dependent)	Lavender
Uric acid	Serum or plasma	Male: 2.4-7.4 mg/dL Female: 1.4-5.8 mg/dL	59.48	Male: 140-440 mcmol/L Female: 80-350 mcmol/L	SST, PPT (green)
Vanillylmandelic acid (VMA)	Urine	2-7 mg/24 h	5.05	10-35 mcmol/d	Urine bottle containing hydrochloric acid
Vitamin B ₁₂	Serum or plasma	170-820 pg/mL	0.738	125-600 pmol/L	SST, PPT (green)
Vitamin D, 25-hydroxy (25[OH]D)	Serum or plasma	20-50 ng/mL	2.496	50-125 nmol/L	SST, PPT (green)
Vitamin D, 1,25-dihydroxy (1,25[OH] ₂ D)	Serum or plasma	20-76 pg/mL	2.6	48-182 pmol/L	SST, PPT (green)
von Willebrand factor (vWF)	Plasma	50-180% (activity and antigen)			Blue
White blood cell count	Whole blood	4.8-10.8 × 10 ³ /mCL	1.00	4.8-10.8 × 10 ⁹ /L	Lavender

¹The reference intervals given here in conventional units and in SI units are from several large medical centers. Always use the reference intervals provided by your clinical laboratory, since intervals may be method-dependent.

²References: Young DS. Implementation of SI units for clinical laboratory data. *Ann Intern Med.* 1987 Jan;106(1):114-29. [PMID: 3789557]; Systeme Internationale (SI) conversion factors for selected laboratory components. *JAMA Author Instructions.* 2001 Sep 28. http://jama.ama-assn.org/site/misc/auinst_si.xhtml; and Stein K. Journal adopts use of conventional and SI units. *J Am Diet Assoc.* 2005 Aug;105(8):1186-7. [PMID: 16182628]

³See Table 4 for commonly used blood specimen collection tubes.

Table 4. Commonly used blood specimen collection tubes.

Tube	Tube Contents	Typical Use
Lavender or Pink	K ₂ EDTA	Complete blood count; blood banking (plasma); molecular testing
Gold SST	Clot activator and gel for serum separation	Serum chemistry tests
White PPT	K ₂ EDTA and gel for plasma separation	Molecular testing (plasma-based)
Red	None	Blood banking (serum); therapeutic drug monitoring
Blue	Na citrate	Coagulation studies
Gray	Inhibitor of glycolysis (sodium fluoride)	Lactic acid; glucose
Green PPT, light green PPT	Sodium heparin or lithium heparin (green PPT, without gel; light green PPT, with gel for plasma separation)	Plasma chemistry tests (light green PPT); chromosome analysis (sodium heparin) (green PPT)
Yellow	Acid citrate dextrose (ACD) Sodium polyanethol sulfonate (SPS)	ACD: HLA typing; blood banking (plasma); flow cytometry immunophenotyping SPS: blood culture (microbiology)
Dark Blue	Clot activator (trace metal free)	Trace metals (eg, lead, mercury, arsenic)
Orange RST	Thrombin and gel for serum separation	Serum chemistry tests

EDTA, ethylenediamine tetraacetic acid; PPT, plasma preparation tube; RST, rapid serum tube; SST, serum separator tube.

Index

NOTE: Page numbers in **boldface** type indicate a major discussion. A *t* following a page number indicates tabular material, and *f* following a page number indicates a figure. Drugs are listed under their generic names. When a drug trade name is listed, the reader is referred to the generic name.

- A3243G mutation, in diabetes mellitus, 1195
- A antigen, in compatibility testing, 534
- A-C ventilation. *See* Assist-control (A-C) ventilation
- A cells, pancreatic, 1171
- a* wave
- in AV junctional rhythm, 390
 - in cardiomyopathy, 414
 - palpitations and, 31
 - in pulmonary stenosis, 325
 - in tetralogy of Fallot, 331
 - in tricuspid stenosis, 346
- AA (Alcoholics Anonymous), 1082
- AA (secondary) amyloidosis, 531, 920*t*, 930. *See also* Amyloidosis
- A-a DO₂ (alveolar-arterial oxygen difference)
- in asthma, 246
 - in COPD, 261
 - in pulmonary embolism, 298
- AAA. *See* Abdominal aortic aneurysm
- AAAS gene, in triple A (Allgrove) syndrome, 1156
- AAS (Abuse Assessment Screen), 1712
- Abacavir, 1341*t*, 1343, 1343–1344, 1348*f*.
See also Antiretroviral therapy/HAART
- with lamivudine, 1343, 1344, 1347, 1348*f*
 - with zidovudine and lamivudine, 1344, 1348*f*
- Abatacept, for rheumatoid arthritis, 830
- ABCB4 gene, in idiopathic adulthood ductopenia, 710
- ABCD/ABCDE rule/features, in melanoma, 102, 102*f*
- ABCD rule, for hypertension management, 457, 457*f*
- ABCD score, in transient ischemic attacks, 978
- Abciximab. *See also* Glycoprotein IIb/IIIa receptors, drugs blocking
- for acute coronary syndromes, 362*t*, 363
 - for myocardial infarction, 362*t*, 368 PCI and, 362*t*, 368
 - platelet function affected by, 549*t*
- Abdominal abscess/infection, 1302*t*
- actinomycosis, 1457
 - anaerobic, 1302*t*, 1455, 1455*t*
 - in Crohn disease, 641, 642
 - in diverticulitis, 651, 652
 - secondary peritonitis and, 589–590
- Abdominal aortic aneurysm, 472–474
- screening for, 6, 7*t*, 473
 - smoking and, 6, 473
- Abdominal compartment syndrome, in burn patient, 1551
- Abdominal distention
- in acute colonic pseudo-obstruction (Ogilvie syndrome), 628
 - in acute paralytic ileus, 627
 - in chronic intestinal pseudo-obstruction/gastroparesis, 629
 - gastrointestinal gas causing, 573
- Abdominal fistulas, in Crohn disease, 642
- Abdominal pain/tenderness, 564–566. *See also* Dyspepsia
- in actinomycosis, 1457
 - in acute colonic pseudo-obstruction (Ogilvie syndrome), 628
 - in acute paralytic ileus, 627
 - in aortic aneurysm, 472, 473
 - in appendicitis, 630
 - in ascites, 587
 - in biliary tract carcinoma, 1606
 - in cholecystitis, 703*t*, 704
 - in choledocholithiasis/cholangitis, 703*t*, 706
 - in cholelithiasis/gallstones, 703, 703*t*
 - in cirrhosis, 686
 - in Crohn disease, 641
 - in diverticulitis, 651
 - in ectopic pregnancy, 790
 - in erosive/hemorrhagic gastritis (gastropathy), 607
 - in familial Mediterranean fever, 591
 - in GI disorders, 564–566
 - in Henoch-Schönlein purpura, 852, 923
 - in hepatitis, 666
 - in intestinal ischemia, 471
 - in irritable bowel syndrome, 632, 633
 - in mesenteric vascular insufficiency, 470, 471
 - in mesenteric vein occlusion (acute), 471
 - in pancreatic/periampullary carcinoma, 1608
 - in pancreatitis, 711, 713, 715–716, 716
 - in peptic ulcer disease, 564, 565, 612
 - perforation and, 618
 - in PID, 763
 - in polyarteritis nodosa, 847
 - in polycystic kidney disease, 934, 935
 - in porphyria, 1664
 - in preeclampsia-eclampsia, 793–794
 - in spontaneous bacterial peritonitis, 589, 689
 - in ulcerative colitis, 646
 - in visceral artery insufficiency/intestinal angina, 470, 471
- Abdominal paracentesis. *See* Paracentesis
- Abdominal radiographs, in poisoning/drug overdose, 1570
- Abelcet. *See* Amphotericin B lipid complex
- Abetalipoproteinemia, vitamin E deficiency and, 1012, 1267
- Aβ₂M (renal failure type) amyloidosis, 531
- ABI/ABPI. *See* Ankle-brachial index
- ABIC score, in alcoholic liver disease, 682
- Abilify. *See* Aripiprazole
- Abiraterone, 1657*t*
- for prostate cancer, 1174, 1637, 1637*t*
- abl* gene, in chronic myeloid leukemia, 515, 516–517
- ABL. *See* Amphotericin B lipid complex
- Abnormal illness behaviors, 1045–1047
- Abnormal movements. *See* Movement disorders
- ABO system
- compatibility testing for transfusion and, 534
 - hemolytic transfusion reactions and, 534
- Abortion
- elective/induced, 776–777
 - breast cancer during pregnancy and, 745, 807–808
 - clostridial infection after, 777, 1429
 - gestational trophoblastic disease and, 792
 - heart disease during pregnancy and, 802
 - hypertension during pregnancy and, 802
 - rubella infection and, 1375
 - toxoplasmosis testing and, 1501
- infection after, 777
- anaerobic, 1456
 - IUD insertion after, 774
 - recurrent (habitual), 789–790
 - spontaneous. *See* Spontaneous abortion
- Abortive poliomyelitis, 1372
- ABPA. *See* Allergic bronchopulmonary mycosis/aspergillosis
- ABPI. *See* Ankle-brachial index
- Abraxane. *See* Paclitaxel, protein-bound
- Abruptio placentae, third-trimester bleeding and, 797
- Abscesses, 151–152, 1421*t*. *See also specific type and organ or structure affected*
- in actinomycetoma, 1540
 - in actinomycosis, 1457
 - anaerobic, 1454
 - abdominal, 1302*t*, 1455, 1455*t*
 - brain, 1302*t*, 1455
 - of lung, 278–279, 1455
 - anorectal, 642–643
 - in bacterial rhinosinusitis, 216
 - brain, 993–994, 1287, 1288, 1302*t*
 - in strongyloidiasis, 1519

- Abscesses (*Cont.*):
 in Crohn disease, 641, 642, 642–643
 deep neck, 230, 231
 in drug users, 1292
 in HIV infection/AIDS, 1331
 intravascular (septic superficial thrombophlebitis), 480. *See also* Septic thrombophlebitis
- liver
 amebic, 1503, 1504, 1505*t*
 pyogenic, **700–701**
- lung, 1532
 in coccidioidomycosis, 1532
 mycobacteria causing, 1458
 occult, fever/FUO and, 1277
 perforated appendicitis and, 631
 perianal, 661
 peritonsillar, **229–230**, 1420
 retropharyngeal, 1420
 staphylococcal, 1421*t*, 1425, 1425*f*
- Absence (petit mal) seizures, 970, 970*t*.
See also Seizures
 drug therapy for, 973*t*
- Absidia* infection, 217, 1538
- Absorption (digestion), disorders of. *See* Malabsorption
- Absorptive hypercalciuria, 947*t*, 948
- Abulia, in stroke, 982
- Abuse
 aggression/violence/impulse control disorders and, 1078, 1079
 child. *See* Child abuse
 drug/alcohol. *See* Alcohol use/dependency/abuse; Substance use disorders
 elder, 17, **72–73**, 73*t*
 partner/spousal (domestic violence), 17, 1078, 1079, **1711–1712**
 prevention of, 17, 1712
 PTSD and, 1039, 1712
- Abuse Assessment Screen (AAS), 1712
- ABVD regimen, for Hodgkin lymphoma, 527
- AC regimen, for breast cancer, 736, 737
- AC-T regimen, for breast cancer, 737
- AC-TH regimen, for breast cancer, 737
- Acamprosate, for alcohol use/abuse, 18, 1082
- Acanthamoeba* (acanthamoeba infections), 1505
 encephalitis/meningoencephalitis, 1287, 1505–1506, 1506
 keratitis, **174, 1506**
- Acanthosis nigricans*
 cancer-related, 1596*t*
 insulin resistance/diabetes and, 1195, 1195*f*, 1196, 1197
- Acarbose, 1206*t*, 1210, 1210–1211
 overdose/toxicity of, 1211, 1580
- Accelerated idioventricular rhythm, **393**
 in myocardial infarction, 373, 393
- Acceptance and commitment therapy
 for anxiety disorders, 1044
 for schizophrenia/psychotic disorders, 1062
- Accessory atrioventricular pathways, supraventricular tachycardia caused by, 381, **383–384**
- Accessory muscles of respiration, in asthma, 247*t*
- Accidental injury. *See* Trauma
- Acclimatization
 heat-related disorders and, 1547
 high-altitude illness and, 1558
- Accommodation, aging affecting (presbyopia), 162
- ACCORD study, 356, 1204
- Accupril. *See* Quinapril
- Accuretic. *See* Quinapril, with hydrochlorothiazide
- Accutane. *See* Isotretinoin
- ACE. *See* Angiotensin converting enzyme
- ACE inhibitors. *See* Angiotensin converting enzyme (ACE) inhibitors
- Acebutolol, 447*t*
 overdose/toxicity of, 1575
- Acellular pertussis vaccine, with tetanus-diphtheria toxoid (DTaP/Tdap vaccines), 3, 1308*t*, 1309*t*, 1310*t*, 1314, 1430, 1430*t*, 1434, 1440
 adverse effects/contraindications and, 1317*t*
 booster and, 1307, 1430, 1430*t*, 1434, 1440
 burn injury and, 1551
 in immunocompromised host/HIV infection/AIDS, 1309*t*, 1314, 1335
 pregnancy and, 787, 1307, 1309*t*, 1440
- Aceon. *See* Perindopril
- Acesulfame potassium, for diabetics, 1205
- Acetadote. *See* Acetylcysteine
- Acetaldehyde, in alcoholic liver disease, 680–681
- Acetaminophen, **76, 77*t***
 in analgesic nephropathy, 932–933
 with codeine, 79, 83*t*
 for fever, 36
 for osteoarthritis, 811
 overdose/toxicity of, 1566*t*, 1569*t*, **1570–1571**, 1570*f*
 anion gap acidosis and, 1569
 hepatotoxicity/liver failure and, 76, 672–673, 1570–1571, 1570*f*
 with oxycodone, 83*t*
 for pain management, **76, 77*t***
 reference values for, 1727*t*
- Acetazolamide
 adverse ophthalmic effects of, 196*t*
 for glaucoma/ocular hypertension, 174, 177
 in head injury, 1016
 for high-altitude illness, 1559
 prophylactic, 1559
 for pseudotumor cerebri, 995
 renal tubular acidosis caused by, 892
- Acetoacetate
 in alcoholic ketoacidosis, 891
 in diabetic ketoacidosis, 891, 1233
 reference values for, 1727*t*
- Acetohexamide, 1206*t*, 1207
- Acetone, in diabetic coma/ketoacidosis, 1197, 1232*t*, 1233
- Acetone breath odor, in diabetic ketoacidosis, 1197, 1232
- Acetonitrile, cyanide formed by metabolism of, 1577
- Acetorphan, for rotavirus gastroenteritis, 1405
- Acetylcholine
 aminoglycosides affecting, 1034
 in botulism, 1033, 1431
 in Huntington disease, 1002
 in myasthenic (Lambert-Eaton) syndrome, 1033
- Acetylcholine receptor antibodies
 in cancer-related neuropathy, 975, 1024
 in myasthenia gravis, 1032
- Acetylcholinesterase inhibitors. *See* Anticholinesterases
- Acetylcysteine
 for acetaminophen overdose/toxicity, 673, 1566*t*, 1571
 contrast media nephrotoxicity mediated by, 904–905
- Achalasia, 592*t*, **604–605**
 herpes simplex infection and, 1351
- Achlorhydria
 in bacterial overgrowth, 624
 in pernicious anemia gastritis, 610
- Achromycin. *See* Tetracycline
- Acid, caustic/corrosive, **1571–1572**
 esophageal injury caused by, 599, 1571
 eye injury caused by, 194, 1571
 ingestion of, 1566, 1567, 1571, 1572
- Acid-antisecretory agents. *See also* Antacids; H₂ receptor blocking drugs; Proton pump inhibitors
 for dyspepsia, 565, 566
 for GI bleeding, 582–583, 618
 for peptic ulcer disease, 613
 bleeding control and, 582–583, 618
- Acid-base disorders, **888–897**, 889*t*. *See also* Acidosis; Alkalosis
 genetic, 878*t*
 in heat exposure syndromes, 1548
 in hypothermia, 1544, 1545
 in kidney disease/renal failure, 892, 892*t*, 893, 893–894, 914
 mixed, **889–890**
 in near drowning, 1556
- Acid-fast bacilli, identification of in tuberculosis, 280, 281, 281*t*
- Acid-fast rods, treatment of infections caused by, 1300*t*
- Acid refluxate. *See* Gastric acid refluxate
- Acidosis, 889, 889*t*. *See also* Ketoacidosis
 anion gap. *See* Anion gap/anion gap acidosis
 dilutional, 893
 dyspnea and, 24, 25
 in heat exposure syndromes, 1548
 hyperkalemia and, 879, 892, 892*t*, 894
 hypokalemia and, 878, 892, 892*t*, 894
 hyporeninemic hypoaldosteronemic, 892, 892*t*, 894, 933, 1157
 in hypothermia, 1544, 1545
 in kidney disease/renal failure, 892, 892*t*, 893, 893–894, 911*f*, 914
 lactic, 890–891, 1232*t*, 1237–1238. *See also* Lactic acidosis
 metabolic, 889, 889*t*, **890–894**, 890*t*, 892*t*. *See also* Metabolic acidosis
 in near drowning, 1556
 nephrolithiasis and, 892

- normal anion gap, 890, 890t, **891–893**, 892t, 893–894. *See also* Normal anion gap acidosis
- parenteral nutritional support and, 893, 1274t
- in poisoning/drug overdose, 891, 1569
- with methanol or ethylene glycol, 877, 891, 1584
- with salicylates, 891, 1588
- posthypocapnia, 893, 897
- renal tubular, 892, 892t, 893, 893–894. *See also* Renal tubular acidosis
- in tubulointerstitial disease, 933
- respiratory, 889, 889t, **895–896**. *See also* Respiratory acidosis
- in respiratory failure, 320, 896
- rewarming, 1544
- step-by-step analysis and, 889
- uremic, 890, 891, 902
- Aciduria, paradoxical
- in metabolic alkalosis, 895
- in salicylate overdose/toxicity, 1589
- Acinetobacter* infections, 1299t
- Acitretin
- adverse ophthalmic effects of, 197t
- for psoriasis, 107
- teratogenicity of, 107
- ACL. *See* Anterior cruciate ligament
- Aclovate. *See* Alclometasone
- Acne, **125–128**, 126f
- antibiotics for, 97t, 127
- folliculitis and, 126, 129
- hyperandrogenism and, 125
- inversa (hidradenitis suppurativa), 151
- oral contraceptive use and, 127, 770
- rosacea, 126
- steroid (steroid folliculitis), 126, 129
- testosterone replacement therapy and, 1177, 1185
- vulgaris, **125–128**, 126f
- Acoustic neuroma/neurinoma (vestibular schwannoma/eighth nerve tumors), 210t, **212–213**, 990t, 991
- hearing loss and, 210t, 212, 990t
- in neurofibromatosis, 212, 996
- Acoustic trauma. *See* Noise trauma
- Acquired immunodeficiency syndrome (AIDS). *See* HIV infection/AIDS
- Acral erythema (hand-foot syndrome), chemotherapy-induced, 1661
- Acral-lentiginous melanoma, 102
- Acrocyanosis, 837
- Acrodermatitis chronica atrophicans, 1479, 1482t
- Acromegaly, **1100–1102**
- Acromioclavicular joint
- in impingement syndrome, 1675
- in rotator cuff disorders, 1680
- Acropachy, thyroid, 1113
- ACS. *See* Acute coronary syndromes
- ACT. *See* Activated clotting time
- ACTH. *See* Adrenocorticotropic hormone
- Actin, in hereditary spherocytosis, 501
- Actinic (ultraviolet) keratitis, **194**
- Actinic keratoses, **117**
- squamous cell carcinoma arising from, 117, 143
- Actinobacillus/Aggregatibacter actinomycetemcomitans*. *See* HACEK organisms
- Actinomadura* species, actinomycotic mycetoma caused by, 1540
- Actinomyces/Actinomyces israelii* (actinomycosis), 1300t, **1456–1457**
- Actinomycetoma, **1540**
- Actinomycotic mycetoma, 1540
- Actiq. *See* Fentanyl
- Activated charcoal, for poisoning/drug overdose, 1567
- repeat-dose, 1568
- Activated clotting time (ACT), reference values for, 1727t
- Activated partial thromboplastin time. *See* Partial thromboplastin time
- Activated protein C. *See* Protein C, activated
- Activella, 1184
- Activin-like kinase-type (*ALK-1*) gene
- in hereditary hemorrhagic telangiectasia, 1671
- in pulmonary hypertension, 423–424
- Activities of daily living—instrumental activities of daily living (ADL–IADL), assessment of ability to perform, 58, 59, 1006
- Activity. *See* Exercise/activity
- ACTOplus Met. *See* Pioglitazone, with metformin
- Actos. *See* Pioglitazone
- Acuity, visual. *See* Visual acuity
- Acular. *See* Ketorolac
- Acupuncture, for migraine prophylaxis, 965
- Acute angle-closure glaucoma. *See* Angle-closure glaucoma
- Acute coronary syndromes
- chest pain/discomfort in, 28, 29
- in pheochromocytoma/paraganglioma, 1167
- preoperative risk assessment/perioperative management and, 46, 47–49, 47t, 48f, 48t
- without ST segment elevation, **360–365**, 362t, 364t
- angiography/revascularization in, 364, 364t. *See also* Revascularization procedures
- medical management of, 361–364, 362t
- postinfarction ischemia and, 372
- thrombolysis contraindicated in, 363, 367
- ST segment elevation (STEMI), 360, 364t, **365–376**, 367t, 369t. *See also* Myocardial infarction
- Acute fatty liver of pregnancy, **795**
- Acute flaccid paralysis (AFP)
- coxsackievirus causing, 1406
- enterovirus 71 causing, 1407
- poliomyelitis and, 1372, 1373
- Acute idiopathic polyneuropathy. *See* Guillain-Barré syndrome
- Acute intermittent porphyria, 1022, **1664–1665**, 1665t
- Acute interstitial pneumonia (AIP), 294t
- Acute kidney injury (acute renal failure), 898, **901–908**, 902t. *See also* Kidney disease
- ACE inhibitor use and, 449, 902–903
- acute tubular necrosis causing, 902t, **904–906**
- cardiorenal syndrome and, **908**
- cirrhosis and (hepatorenal syndrome), 689
- glomerulonephritis causing, 902t, 903, **907–908**
- in hyperglycemic hyperosmolar state, 1236
- interstitial nephritis causing, 902t, **906–907**
- intrinsic disorders causing, 902t, 903
- postoperative, 55, 55t
- postrenal causes of, 902t, 903
- prerenal causes of, 902–903, 904
- in tumor lysis syndrome, 1647
- Acute leukemia, **519–521**. *See also specific type and* Leukemias
- bone marrow/stem cell transplantation for, 520–521, 533
- chemotherapy choices for, 1610t
- Acute lymphoblastic/lymphocytic leukemia (ALL), 519, 520, 521, 1610t
- Acute motor axonal neuropathy (AMAN), 1024–1025
- Acute motor and sensory axonal neuropathy (AMSAN), 1024
- Acute mountain sickness, 1558–1559
- Acute myeloid leukemia (AML), 519, 520, 520–521, 521, 1610t
- bone marrow/stem cell transplantation for, 520–521, 532
- Acute paralytic (adynamic) ileus, **627–628**
- Acute-phase response, bisphosphonates causing, 1147
- Acute Physiology and Chronic Health Evaluation score. *See* APACHE system
- Acute promyelocytic leukemia (APL), 519, 520
- DIC associated with, 519, 546
- Acute radiation syndrome, 1554
- Acute renal failure. *See* Acute kidney injury
- Acute respiratory distress syndrome (ARDS), **322–323**, 322t. *See also* Respiratory failure
- acute gastric aspiration and, 308
- in burn injury, 1550, 1552
- influenza A/H1N1 and, 214, 1399
- in pancreatitis, 713
- in SARS, 1401
- smoke inhalation and, 307
- Acute respiratory failure, **319–322**, 320t. *See also* Acute respiratory distress syndrome; Respiratory failure
- Acute retinal necrosis, 178
- Acute tubular necrosis. *See* Tubular necrosis
- Acute vaccinia syndrome, 1403

- Acylovir, 1353*t*
for herpes simplex infections, 118–119, 598, 1280, 1330, 1338*t*, 1352, 1353*t*, 1355
keratitis, 168*t*, 173, 1355
for herpes zoster, 120, 173, 1331, 1339*t*, 1353*t*, 1359, 1361
nephrotoxicity of, 904, 1353*t*
during pregnancy, 806, 1355
prophylactic/suppressive, 118, 1280, 1352, 1353*t*, 1355, 1361
resistance to, 1352
for varicella, 1353*t*, 1359
- AD. *See* Alzheimer disease
- ADA diet recommendations for diabetes, 1204–1205
- ADACEL. *See* Tdap vaccine
- Adalat. *See* Nifedipine
- Adalimumab. *See also* Anti-TNF agents
for inflammatory bowel disease, 640
Crohn disease, 644–645
ulcerative colitis, 648
for psoriasis, 108
for rheumatoid arthritis, 830
- Adamantanes (amantadine and rimantadine), influenza/
influenza resistance and, 23, 1354*t*, 1396, 1398, 1399
- ADAMTS-13 (von Willebrand factor cleaving protease), in thrombotic microangiopathies, 542
- Adapalene, for acne, 127
with benzoyl peroxide, 127
- Adcetris. *See* Brentuximab vedotin
- Addiction (drug), 1079. *See also*
Poisoning/drug overdose;
Substance use disorders
pain management in terminally ill/
dying patient and, 76
- Addison disease (adrenocortical insufficiency), **1155–1158**
acute adrenal crisis and, 1154, 1158
hypercalcemia and, 1142, 1156
hyperkalemia and, 879, 1155, 1157
hyperpigmentation and, 155, 1156
hypoglycemia and, 1156, 1222
hyponatremia and, 871*f*, 872, 1156
- Adefovir, for hepatitis B, 675, 676, 1353*t*
- Adenitis. *See also* Lymphadenitis
mesenteric, adenoviruses causing, 1402
- Adenocarcinoma. *See specific type and*
Cancer
- Adenoid cystic carcinoma, salivary, 233
- Adenoma sebaceum, 996
- Adenomas. *See specific type or structure or*
organ affected
- Adenomatous polyposis coli gene. *See*
APC gene
- Adenomatous polyps, 652, 653
colonoscopy/sigmoidoscopy in
identification/treatment of,
653, 653–654, 1627–1628, 1628
colorectal cancer and, 653, 654, 655, 1622, 1623, 1626, 1628
familial, **654–655**, 1622. *See also*
Familial adenomatous
polyposis
FOBT in patients with, 653
- gastric, 620–621, 655
nonfamilial, **653–654**
- Adenomyomatosis
biliary tract/gallbladder, 703*t*, 705
endometrial, 758
- Adenomyosis, uterine, 750
- Adenopathy. *See* Lymphadenopathy
- Adenosine, 377
for paroxysmal supraventricular
tachycardia, 379*t*, 382
- Adenosine deaminase
ascitic fluid, in tuberculous peritonitis,
588
pleural fluid, in tuberculosis, 282, 315
- Adenosine triphosphatase, copper-
transporting (*ATP7B*), in
Wilson disease, 696, 697
- Adenosylcobalamin, 497. *See also*
Vitamin B₁₂
- Adenovirus infections, **1401–1403**
bronchiolitis, 269, 1402
conjunctivitis/keratoconjunctivitis,
164–165, 1402
diarrhea/gastroenteritis, 1293, 1330, 1402, 1404–1405
- ADH. *See* Antidiuretic hormone
- Adherence/nonadherence, patient, **1–2**
antipsychotic drugs and, 1056, 1059
antiretroviral therapy and, 1, 1340, 1340–1342, 1347
diabetic ketoacidosis and, 1232, 1235
in elderly
hearing amplification and, 72
medication regimen and, 71–72
lifestyle changes and, 1
lithium therapy and, 1074
refractory ulcers and, 617
status epilepticus and, 974
tuberculosis therapy and, 283–284, 1326
- Adhesion molecules, autoantibodies to, in pemphigus, 138
- Adhesive capsulitis (frozen shoulder), **1682–1683**
in diabetes, 1228
- ADHH. *See* Autosomal dominant
hypocalcemia with
hypercalciuria
- Adiana, for tubal interruption, 777
- Adipokines, insulin action in obesity and, 1194
- Adiponectin, insulin action in obesity and, 1194
- Adipose tissue. *See* Body fat
- Adjustment (situational) disorders, **1038–1039**
with depressed mood, 1063
posthospital, 1090–1091
suicide risk and, 1064
- Adjuvant chemotherapy. *See also*
Chemotherapy
for bladder cancer, 1639, 1640
for breast cancer, 735, 736–737, 1611*t*
in older women, 738
for colorectal cancer, 1624, 1625, 1625–1626
for gastric adenocarcinoma, 1617
for lung cancer, 1599–1600
for prostate cancer, 1635
for renal cell carcinoma, 1641
- Adjuvant pain medications/treatments, **85**
- ADL–IADL. *See* Activities of daily living–
instrumental activities of
daily living
- Adnexal masses. *See* Ovarian cancer/
tumors
- Adnexectomy, for tubo-ovarian abscess, 764
- Adolescents, immunization
recommendations for, **1307**
- ADPKD1/ADPKD2* genes, 934
- Adrenal cortex
diseases of, **1154–1166**. *See also specific*
disorder
in hypopituitarism, 1093, 1094, 1095
in HIV infection/AIDS, 1157, 1330
hyperplasia of
aldosteronism caused by, 438, 1164, 1165, 1166
congenital, 1156, 1163
Cushing syndrome caused by, 1158
hirsutism/virilization and, 1163
in MEN, 1189
hypoplasia of, congenital, 1093, 1094, 1156, 1175
tumors of. *See* Adrenal tumors
- Adrenal crisis, **1154–1155**
- Adrenal hemorrhage, 1155
- Adrenal insufficiency. *See* Adrenocortical
insufficiency
- Adrenal tumors
amenorrhea caused by, 1179
cancer, 1158, 1159, 1160, 1161, 1162, 1189, 1596*t*, 1612*t*
cortical, 1158
aldosterone-secreting, 438, 1164, 1165, 1166
androgen-secreting, 1162
cortisol-secreting, 1158, 1159, 1161
medullary. *See* Pheochromocytoma
in MEN, 1188*t*, 1189
paraneoplastic syndromes associated
with, 1596*t*
- Adrenal vein sampling, in aldosteronism, 1165
- Adrenalectomy/medical adrenalectomy
adrenal crisis and, 1154
for aldosteronism, 1165, 1166
for breast cancer, 740
in male, 746
for congenital adrenal hyperplasia, 1163
for Conn syndrome, 1166
for Cushing syndrome, 1160, 1161
Nelson syndrome after, 1160
- Adrenergic drugs. *See* Alpha-adrenergic
agonists; Alpha-adrenergic
blocking drugs; Beta-
adrenergic agonists; Beta-
adrenergic blocking drugs
- Adrenocortical insufficiency, 1093, 1094, 1095, 1096
acute, **1154–1155**
chronic, **1155–1158**. *See also* Addison
disease
congenital, 1155
corticosteroids causing, 1093, 1096, 1154
in HIV infection/AIDS, 1157, 1330

- hypercalcemia and, 1142, 1154, 1156
 hyperkalemia and, 879, 1154, 1157
 hyponatremia and, 871*f*, 872, 1154, 1156
 perioperative corticosteroid replacement and, 54
- Adrenocorticosteroids. *See* Corticosteroids
- Adrenocorticotrophic hormone (ACTH)
 deficiency of, 1093, 1094, 1095, 1156.
See also Adrenocortical insufficiency
 ectopic/hypersecretion of, 1158, 1159, 1160, 1161, 1172
 in hypertension, 437
 petrosal sinus levels of, in Cushing syndrome, 1159
 pituitary adenoma secreting, 1158, 1189
 plasma levels of
 in acute adrenal insufficiency, 1154
 in Addison disease, 1156
 in hypercortisolism/Cushing syndrome, 1159
 reference values for, 1727*t*
- Adrenoleukodystrophy, 1155–1156, 1156, 1157, 1157–1158
- Adriamycin. *See* Doxorubicin
- Adrucil. *See* Fluorouracil
- Adson test, 1031
- Adult respiratory distress syndrome. *See* Acute respiratory distress syndrome
- Adult Still disease, 831
- Adult T cell lymphoma/leukemia (ATL), 1383–1384. *See also* Human T cell lymphotropic/leukemia virus
- Advance care planning/advance directives, 89
- ADVANCE study, 356, 1204
- Advil. *See* Ibuprofen
- Adynamic bone disease, 912
- Adynamic (paralytic) ileus, 627–628
- Aedes* mosquitoes. *See* Mosquitoes
- Aeroallergens. *See also* Allergens
 in allergic rhinitis, 218, 219
 asthma caused by, 243, 248, 249*f*
 atopy and, 866
 avoidance therapy and, 219
 desensitization therapy/
 immunotherapy and, 249*f*, 252*t*, 253
- AeroBid. *See* Flunisolide
- Aerodigestive tract. *See also specific structure*
 foreign bodies in, 238–239, 308
- Aeromonas*, diarrhea caused by, 574*t*, 576, 578, 1298
- Aerophobia, 573
- Aerophobia, in rabies, 1376
- Aerosols, sniffing, 1086
- Aesthetic plastic surgery, 1720–1721. *See also* Reconstructive surgery
- Affect, in schizophrenia/psychotic disorders, 1053, 1054
- Afibrinogenemia, congenital, 552
- Afinitor. *See* Everolimus
- Aflatoxin exposure, hepatocellular carcinoma and, 1603
- AFP. *See* Acute flaccid paralysis; Alpha-fetoprotein
- AFP-L3, in hepatocellular carcinoma, 1604
- African American patients. *See* Black patients
- African tick bite fever, 1414
- African trypanosomiasis, 1484–1485, 1485*t*
- Age/aging. *See also* Older adults
 accommodative loss and (presbyopia), 162
 arthritis and, 810
 atrial fibrillation and, 385, 385*t*, 386
 benign prostatic hyperplasia and, 956
 breast cancer risk and, 722, 723*t*, 1708
 burn injury survival and, 1550
 colorectal cancer risk and, 1622
 dementia and, 59–63, 1005–1010, 1008*t*
 facial changes related to, 1720–1721
 fever/FUO and, 1276
 foreign body aspiration and, 238–239
 gynecomastia and, 1178
 hearing loss and (presbycusis), 72, 198, 206
 hypertension/hypertension management and, 433, 435, 436, 437, 458*t*, 459
 luteinizing hormone affected by, 1173
 maternal, Down syndrome and, 1666
 paternal, mutations and, 1666
 postoperative delirium and, 53, 53*t*
 postoperative pulmonary complications and, 50
 prostate cancer and, 1630, 1631, 1632, 1635*f*, 1637, 1637*t*
 PSA reference ranges and, 1631–1632
 radiation-related carcinogenesis and, 1555
 sleep changes and, 1075
 testosterone deficiency/hypogonadism and, 1096, 1173, 1175
 in women, 1185
 vision impairment and, 72
 weight loss and, 37, 37*t*, 69–70
- Age-Related Eye Disease Study (AREDS), 181
- Age-related macular degeneration, 180–181
- Age-related maculopathy, 181
- Agenerase. *See* Amprenavir
- Agglutinins
 cold, 507
 febrile, 1277
- Aggregatibacter actinomycetemcomitans*. *See* HACEK organisms
- Aggregatibacter aphrophilus*. *See* HACEK organisms
- Aggression, 1078–1079. *See also* Violence
 alcohol use/abuse and, 1078, 1080
 anabolic steroid use and, 1078, 1086
 in dementia, 1089
 phencyclidine use/abuse and, 1055, 1078, 1084
 suicide and, 1064
- Aggestat. *See* Tirofiban
- Aging. *See* Age/aging
- Agitation
 in dementia patients, treatment of, 61–62, 1009, 1089
 palliation of in terminally ill/dying patient, 86–87
- Agnogenic myeloid metaplasia (primary myelofibrosis), 511*t*, 514–515
- Agnosia
 in dementia, 59
 intracranial tumors causing, 991
- Agoraphobia, 1041
- Agranulocytosis. *See also* Neutropenia
 drug-induced, 510
 clozapine causing, 1000, 1056, 1059
 mirtazapine causing, 1068
 thiourea therapy causing, 1114–1115
- “A(H1N1)pdm09” (swine-origin) influenza, 23, 214, 1395, 1396, 1399–1400. *See also* Influenza
 drug resistance and, 1396, 1399
 prevention of, 1400. *See also* H1N1 influenza vaccine
- AI. *See* Aromatase inhibitors
- Aichi virus, gastroenteritis caused by, 1404–1405
- Aid to Capacity Evaluation, evaluation of decision-making ability and, 73
- AIDS. *See* HIV infection/AIDS
- AIDS cholangiopathy, 1364, 1507
- AIDS enteropathy, 1330
- AIDS wasting syndrome, 1325
- AIP. *See* Acute intermittent porphyria; Acute interstitial pneumonia
- Air bronchogram
 in ARDS, 322
 in bronchial obstruction, 243
- Air travel
 compression stocking use during, 34
 dysbarism/decompression sickness and, 1557, 1558
 eustachian tube dysfunction/barotrauma and, 202
 lower extremity edema and, 33, 34
 medical safety/patient selection and, 1560–1561
 during pregnancy, 786, 1560
 retinal detachment and, 180
 SARS transmission and, 1400, 1401
 venous thromboembolism and, 34, 1560
- AIRE gene, in type 1 diabetes, 1193
- Airway disorders, 242–270. *See also specific type*
 allergic bronchopulmonary mycosis, 266–267, 1537, 1538
 asthma, 243–259
 bronchiectasis, 265–266
 bronchiolitis, 269–270
 chronic obstructive pulmonary disease (COPD), 259–265, 260*t*
 cystic fibrosis, 267–268
 glaucoma treatment and, 176
 lower airway, 242–243
 obstruction
 in diphtheria, 1433, 1434
 drowning/near drowning and, 1556
 dyspnea and, 24, 25
 by food (café coronary), 308

- Airway disorders, obstruction (*Cont.*):
 foreign body causing, 238–239, 308
 in hypoparathyroidism, 1136, 1137
 of lower airways, 242–243
 occupational disorders and, **310–311**
 in recurrent respiratory
 papillomatosis, 234
 during sleep (obstructive sleep
 apnea), 231, 318, **318–319**
 tracheostomy and cricothyrotomy
 for, **238**
 of upper airways, 242
 respiratory failure caused by, 320*t*
 stridor and, 233
 thermal injury, smoke inhalation and,
 307, 1550
 upper airway, **242**
- Airway management. *See also* Intubation
 burn injury and, 1550
 for coma, 1014, 1562–1563
 in hypoparathyroidism, 1137
 tracheostomy and cricothyrotomy
 in, **238**
- Akathisia, 1004
 antipsychotic drugs causing, 1060
 SSRIs causing, 1067
- AKIN criteria, in acute kidney injury, 901
- Akinesia, in Huntington disease, 1001
- Akinetic mutism (persistent vegetative
 state), **1016**
- Akineton. *See* Biperiden
- AL (primary) amyloidosis, **530–532**, 920*t*,
 930. *See also* Amyloidosis
- Al-Anon, 1079, 1082
- Ala-Ala. *See* Teplizumab
- Alanine aminotransferase (ALT), 664,
 664*t*. *See also*
 Aminotransferase levels
 in acute fatty liver of pregnancy, 795
 in alcoholic liver disease, 681
 in liver disease/jaundice, 664, 664*t*
 monitoring, in tuberculosis therapy, 4
 in nonalcoholic fatty liver disease, 684,
 685
 olanzapine affecting, 1057
 reference/normal values for, 664*t*,
 1727*t*
 in viral hepatitis, 666, 666*f*, 668*f*, 671*f*,
 675
- Alarm response, 1041
- Albendazole
 for ascariasis, 1517
 for clonorchiasis/opisthorchiasis,
 1513
 for cutaneous larva migrans, 1523
 for cysticercosis, 1515
 for enterobiasis/pinworms, 1520
 for filariasis, 1525–1526
 for giardiasis, 1509
 for gnathostomiasis, 1523
 for hookworm disease, 1518
 for hydatid disease, 1516
 for microsporidiosis, 1508
 for strongyloidiasis, 1519
 for trichinosis, 1522
 for trichuriasis/whipworm, 1518
- Albinism, 155
- Albinism-associated storage pool disease,
 548
- Albright hereditary osteodystrophy, 1137
- Albumin
 ascitic fluid, 588. *See also* Serum-ascites
 albumin gradient
 in cirrhosis, 686, 688, 692*t*
 serum levels of
 anion gap and, 890
 calcium levels and, 882, 883, 1136,
 1646
 in liver disease/jaundice, 664*t*
 in myeloma staging, 529
 in nephrotic syndrome, 927
 postoperative pulmonary
 complications and, 51
 in protein-losing enteropathy, 631,
 632
 reference/normal values for, 664*t*,
 1727*t*
 urinary. *See* Albuminuria
- Albuminuria, 899. *See also* Proteinuria
 in diabetes/diabetic nephropathy, 931,
 1224
 glycemic control and, 931, 1201, 1224
- Albuterol
 for asthma, 254*t*, 255
 with ipratropium, 254*t*
 for cystic fibrosis, 268
 for hyperkalemia, 881*t*
- Alcimetasonone, 95*t*
- Alcohol addiction, 1080. *See also* Alcohol
 use/dependency/abuse
- Alcohol use/dependency/abuse
 (alcoholism), **18–20**,
1080–1083
 acute intoxication/poisoning, 1080,
 1569*t*, **1579–1580**
 metabolic acidosis/osmolar gap and,
 877, 1081, 1569, 1569*t*
 aggressive/violent behavior and, 1078,
 1080
 amnestic syndrome and, 1088
 anxiety self-treatment and, 1043
 atrial fibrillation and, 384
 cancer and, 1594
 breast cancer, 722, 1708
 esophageal cancer, 1613
 liver cancer, 682, 685, 687, 1603,
 1604
 oral cancer, 224
 in cardiomyopathy, 411, 412
 cirrhosis and, 680, 681, 682, 686, 687
 hepatocellular carcinoma and, 682,
 685, 687, 1603, 1604, 1605
 coma in diabetic patient and, 1232*t*
 complications associated with, 1081
 Cushing syndrome/hypercortisolism
 and, 1160
 delirium caused by, 1080, 1087*t*
 depression and, 1064, 1072, 1080
 differential diagnosis of, 1081
 drug therapy for, 1082
 Dupuytren contracture and, 686, 824
 fatty liver and, 681, 684, 685
 folic acid deficiency and, 499
 gastritis/dyspepsia and, 565, 607, 608
 gout/hyperuricemia and, 812, 813, 814
 hepatitis and, 680–682
 hyperosmolality caused by, 877
 hypertension and, 436, 441, 441*t*
 hypoglycemia associated with, 1083,
 1222, 1238, 1238*t*
- hypophosphatemia and, 885
 immunization recommendations in,
 1309*t*
 ketoacidosis and, 891, 893
 lipid abnormalities and, 1247, 1248*t*
 liver disease associated with, **680–682**,
 1081, 1083
 Mallory-Weiss syndrome/tears and,
 581, 582, 599
 management of, 1081–1083
 methotrexate toxicity and, 829
 myopathy associated with, 1036
 neuropathy associated with, 1023
 in pancreatitis, 711, 712, 715, 716
 in panic disorder, 1041
 platelet function affected by, 549*t*
 porphyria cutanea tarda and, 122
 pregnancy and, 783, 1081
 preventable disease/deaths and, 3*t*
 prevention of injury related to, 17
 prevention of/screening tests for,
18–20, 19*t*, 20*t*
 psychotic behavior associated with
 (alcoholic hallucinosis),
 1081, 1082, 1088
 PTSD and, 1039, 1040, 1079
 rhabdomyolysis and, 844
 sleep disorders and, 318, 319, 1076
 suicide and, 1064, 1080
 thiamine deficiency/supplement and,
 681, 891, 893, 1083, 1264
 trauma outcome/incidence affected
 by, 17
 Wernicke encephalopathy/Wernicke-
 Korsakoff syndrome and,
 681, 893, 1013, 1081, 1083,
 1264
 withdrawal and, 1080–1081,
 1082–1083
 delirium caused by, 1080
 differential diagnosis of, 1081
 drug therapy for, 18, 1082–1083
 seizures caused by, 969, 974, 1080,
 1083
- Alcohol Use Disorder Identification Test
 (AUDIT), 18, 19*t*
- Alcoholic brain syndromes, chronic,
 1081, 1083
- Alcoholic cardiomyopathy, 411, 412
- Alcoholic (organic) hallucinosis, 1081,
 1082, 1088
- Alcoholic hepatitis, 680–682
 postoperative complications associated
 with, 51
- Alcoholic hyaline, 681
- Alcoholic ketoacidosis, 891, 893
- Alcoholics Anonymous, 1082
- Aldactazide. *See* Spironolactone, for
 hypertension, with
 hydrochlorothiazide
- Aldactone. *See* Spironolactone
- Aldehyde dehydrogenase deficiency,
 alcohol use/abuse and,
 1080
- Aldesleukin. *See also* Interleukin-2
 for cancer chemotherapy, 1657*t*
- Aldicarb poisoning, 1587
- Aldolase, in polymyositis/
 dermatomyositis, 841
- Aldomet. *See* Methyldopa

- Aldosterone. *See also* Aldosteronism; Hypoaldosteronism
 adrenal adenoma/hyperplasia secreting, 438, 1164, 1165, 1166
 drugs blocking receptors for. *See also* Spironolactone
 for heart failure, 402
 for hypertension, 437, 438, 442*t*, 445*t*, 449–453
 for myocardial infarction, 371
 in hypertension, 437, 438, 440, 453, 1164, 1165
 resistant disease and, 438, 453, 460, 1164, 1165
 potassium balance and, 402, 878, 879, 1164
 in renal tubular acidosis, 892, 892*t*, 933
 serum/urine levels of
 in primary aldosteronism, 438, 1165
 reference values for, 1727*t*
 in steroidogenic enzyme defects, 1166
- Aldosterone:renin ratio, 438, 1164, 1165
- Aldosteronism (hyperaldosteronism), 437–438, **1164–1166**
 glucocorticoid-remediable, 437, 878*t*, 1164, 1166
 hypertension and, 437, 437–438, 440, 453, 1164, 1165
 hypokalemia and, 878, 1164
 primary, 437–438, **1164–1166**
 saline-unresponsive metabolic alkalosis and, 895, 1164
- Alefacept. *See also* Anti-TNF agents
 for psoriasis, 108
- Alemtuzumab, 1653*t*
 for aplastic anemia, 509
 for chronic lymphocytic leukemia, 522
- Alendronate, 1146. *See also* Bisphosphonates
 adverse ophthalmic effects of, 197*t*
 in hyperparathyroidism, 1143
 for osteoporosis prevention/management, 1146
 corticosteroid use and, 1191
 for Paget disease of bone, 1153
- Aleukemic leukemia, 520
- Aleve. *See* Naproxen
- Alfieri procedure, 341
- Alfuzosin, for benign prostatic hyperplasia, 959, 959*t*
 adverse ophthalmic effects of, 196*t*
- Alimentary hypoglycemia, functional, **1242–1243**
- Alimentary tract cancers, **1612–1630**. *See also specific type or structure affected*
- Alimta. *See* Pemetrexed
- Aliskiren, 449
 with hydrochlorothiazide, 450*t*
 with valsartan, 452*t*
- ALK inhibitors, for lung cancer, 1600
- ALK-1 (activin-like kinase-type) gene
 in hereditary hemorrhagic telangiectasia, 1671
 in pulmonary hypertension, 423–424
- Alkali administration. *See* Bicarbonate
- Alkalies, caustic/corrosive, 1572
 esophageal injury caused by, 599, 1572
 eye injury caused by, 194, 1572
 ingestion of, 1566, 1567, 1571, 1572
- Alkaline phosphatase
 in alcoholic liver disease, 681
 in biliary cirrhosis, 693
 in cholecystitis, 704
 in choledocholithiasis/cholangitis, 707
 in cirrhosis, 686
 in hemochromatosis, 695
 in hepatitis A, 666
 in hepatocellular carcinoma, 1604
 in hypophosphatasia, 1150
 in liver disease/jaundice, 664, 664*t*
 in osteomalacia, 1150, 1151
 in Paget disease of bone, 1152
 in primary sclerosing cholangitis, 709
 reference/normal values for, 664*t*, 1727*t*
- Alkalinization, urine. *See* Urine, alkalinization of
- Alkalosis, 889, 889*t*
 contraction, 895
 in heat exposure syndromes, 1548
 metabolic, 889, 889*t*, **894–895**, 894*t*.
 See also Metabolic alkalosis
 posthypercapnia, 895, 896
 respiratory, 889, 889*t*, **896–897**, 896*t*.
 See also Respiratory alkalosis
 salicylate overdose/toxicity causing, 1588
 saline-responsive, 894, 894–895, 894*t*, 895
 saline-unresponsive, 894, 894*t*, 895
- Alkaptonuria, **1665–1666**
- Alkeran. *See* Melphalan
- Alkylating agents, 1650–1651*t*
 breastfeeding and, 782*t*
- ALL. *See* Acute lymphoblastic/lymphocytic leukemia
- All-Trans-Retinoic Acid. *See* Tretinoin
- Allergens. *See also* Allergies/allergic reactions
 anaphylaxis/urticaria/angioedema caused by, 132, 133, 866
 asthma caused by, 243, 248
 desensitization therapy/
 immunotherapy for, 249*f*, 252*t*, 253
 avoidance of
 for allergic contact dermatitis, 124–125
 for allergic rhinitis, 219
- Allergic alveolitis, extrinsic (hypersensitivity pneumonitis), **310**, 310*t*
- Allergic angitis and granulomatosis (Churg-Strauss syndrome), 306
 leukotriene modifiers for asthma and, 253
 pulmonary involvement in, 306
 renal involvement in, 919*t*, 921*f*, 924
- Allergic bronchopulmonary mycosis/aspergillosis, **266–267**, 1537, 1538
- Allergic conjunctivitis, 167
- Allergic contact dermatitis, **124–125**, 124*f*, 866
 impetigo differentiated from, 123, 124
 topical medications causing, 100, 124
 urticaria in, 133
- Allergic eye disease, **166–167**
- Allergic rhinitis (hay fever), **218–219**
 conjunctivitis and, 167
 nasal polyps and, 218, 222
- Allergic vasculitis, drugs causing, 159*t*
- Allergies/allergic reactions, **865–866**
 anaphylactic, 866
 angioedema and, 132, 133, 866
 antibody-mediated (cytotoxic), 866
 asthma and, 243, 248
 desensitization therapy/
 immunotherapy for, 249*f*, 252*t*, 253
 atopic, 866. *See also under Atopic*
 to drugs. *See* Drug allergy
 eosinophilic esophagitis and, 600
 in HIV infection/AIDS, 1322
 IgE-mediated (immediate), 866
 immune complex-mediated, 866
 serum sickness and, 866, **867**
 to insulin, 1222
 Kawasaki disease affecting risk of, 1418
 pseudoallergic (anaphylactoid), **867**
 radiocontrast media causing, 867
 T-cell mediated (delayed/cell-mediated), 866
 in topical dermatologic therapy, 100
 in topical ophthalmic therapy, 166, 195
 urticaria caused by, 132, 133, 866
- Allergy testing, 866
 in asthma, 248
- Allgrove (triple A) syndrome, 1156, 1157, 1157–1158
- Allogeneic stem cell transplantation, **532–534**. *See also* Bone marrow/stem cell transplantation
- Alloimmunization
 platelet transfusion and, 536
 stem cell transplantation and, 533
- Allopurinol
 drug interactions of, 816
 for hyperuricemia/gout, 815–816, 816
 in cancer patients, 1647, 1658*t*
 in polycythemia, 513
 in transplant patients, 816
 urinary stones and, 949
 for tumor lysis syndrome, 1647, 1658*t*
- Almonds (bitter), odor of in cyanide poisoning, 1577
- Almotriptan, for migraine headache, 964
- Alocril. *See* Nedocromil
- Alomide. *See* Lodoxamide
- Alopecia, **156–157**
 androgenetic (pattern), 156
 in women, 156, 1719–1720
 areata, 157
 chemotherapy-induced, 1661
 nonscarring, 156–157
 scarring (cicatricial), 156
 in SLE, 833
 in syphilis, 1469
 totalis, 157
 universalis, 157
 in women, 156, **1719–1720**
- Alora, 1183
- Alosetron, for irritable bowel syndrome, 635

- Alpha-adrenergic agonists
for glaucoma/ocular hypertension, 176–177
for retrograde ejaculation, 955
for Tourette syndrome, 1005
- Alpha-adrenergic blocking drugs, 456*t*
adverse ophthalmic effects of, 179, 195*t*, 196*t*, 959
for benign prostatic hyperplasia, 958*t*, 959, 959*t*
for hypertension, 453, 456*t*, 458*t*
in urgencies/emergencies, 462*t*
pheochromocytoma/
pheochromocytoma surgery
and, 1170
phosphodiesterase inhibitor
interaction and, 952
ureteral stone expulsion and, 950
for urinary incontinence, 69
- Alpha₂-antiplasmin deficiency, 552
- Alpha₁-antiprotease/antitrypsin
in COPD/emphysema, 260, 261
replacement therapy and, 264
hepatocellular carcinoma and, 1604
in protein-losing enteropathy, 631, 632
reference values for, 1727*t*
- Alpha-delta storage pool disease, 548
- Alpha-fetoprotein
in Down syndrome, 783, 1666
in hepatocellular carcinoma, 1604, 1605
prenatal testing for, 783
reference values for, 1730*t*
testicular tumors producing, 1177, 1643
- Alpha-globin gene, 494
in alpha thalassemia syndromes, 494, 495
in beta thalassemia syndromes, 495*t*
- Alpha-glucosidase inhibitors
for diabetes mellitus, 1206*t*, 1210–1211, 1220
overdose/toxicity of, 1211, 1220, 1580
- Alpha interferon. *See* Interferon- α
- 5-Alpha-reductase, deficiency of, 1162
- 5-Alpha-reductase inhibitors. *See also* Finasteride
for benign prostatic hyperplasia, 959–960
- Alpha-synuclein gene/inclusions, in parkinsonism/Lewy body dementia, 998, 1008*t*
- Alpha thalassemia syndromes, 494, 494*t*, 495, 496
sickle cell disease and, 505, 505*t*
- Alpha thalassemia trait, 494*t*, 495, 495–496, 496
- Alphagan. *See* Brimonidine
- Alpharadin, for prostate cancer, 1637
- ALPL gene, in hypophosphatasia, 1150
- Alprazolam, 1042*t*, 1043
overdose/toxicity of, 1579–1580
for panic attacks, 1043, 1044
- Alprenolol, overdose/toxicity of, 1575
- Alprostadil, for erectile dysfunction, 953, 1226–1227
- ALT. *See* Alanine aminotransferase
- Altace. *See* Ramipril
- Alteplase (tissue plasminogen activator/t-PA), 369*t*. *See also* Thrombolytic therapy
for acute arterial occlusion of limb, 468
for myocardial infarction, 368–369, 369*t*
pleural instillation of, 316
for pulmonary embolism, 303, 562*t*, 563
for retinal vein occlusion, 182
for stroke, 982
- Altered mental status. *See* Mental status, altered
- Alternaria*, phaeohyphomycosis caused by, 1541
- Alternating current (AC) electrical injury, 1552
- Altitude-related illness. *See* Decompression sickness; High-altitude illness
- Altretamine, 1655*t*
- Aluminum preparations
for hyperphosphatemia, 886
metabolic bone disorders/
osteomalacia and, 912, 913, 1150
osteomalacia caused by, 912, 913, 1150
- Alveolar-arterial oxygen difference (A–a DO₂)
in asthma, 246
in COPD, 261
in pulmonary embolism, 298
- Alveolar hemorrhage syndromes, 26, 306–307
- Alveolar hydatid disease, 1516
- Alveolar hyperventilation, 318
- Alveolar hypoventilation
central, 318
obesity and (Pickwickian syndrome), 318
primary (Ondine curse), 317–318
- Alveolar proteinosis, 296
- Alveolitis, 292
extrinsic allergic (hypersensitivity pneumonitis), 310, 310*t*
- Alvimopan, for acute paralytic ileus, 627–628
- Alzheimer disease, 59, 1007, 1008*t*.
See also Dementia
clinical features of, 60, 1008*t*
hypertension and, 439
prognosis for, 62
seizures in, 969
treatment of, 61–62, 1008, 1009, 1089
- Alzheimer's Association/Alzheimer's Disease and Related Disorders Association, 61, 1089
- Amalgams, metal-containing, allergy to, lichen planus-like lesions and, 144
- AMAN. *See* Acute motor axonal neuropathy
- Amanita* mushroom poisoning, 1585–1586, 1586*t*
- Amanitin toxin (amatoxin), poisoning with mushrooms containing, 1585–1586, 1586*t*
- Amantadine, 1353*t*. *See also* Antiparkinsonism drugs
for extrapyramidal side effects of antipsychotics, 1060
for Huntington disease, 1002
influenza/influenza resistance and, 23, 1353*t*, 1396, 1398, 1399
for neuroleptic malignant syndrome, 1060
for parkinsonism, 999
- Amaryl. *See* Glimepiride
- Amatoxin (amanitin toxin), poisoning with mushrooms containing, 1585–1586, 1586*t*
- Amaurosis fugax, 184, 469, 981
- Ambien. *See* Zolpidem
- Ambiguous genitalia, in steroidogenic enzyme defects, 1156, 1162
- AmBisome. *See* Liposomal amphotericin B
- Amblyomma* ticks. *See* Ticks
- Ambulatory blood pressure monitoring, 433
- Ambulatory electrocardiographic monitoring
in angina, 354
in atrial fibrillation, 388
in palpitation evaluation, 31, 32
in seizure evaluation, 971
in syncope evaluation, 397
- Ambulatory esophageal pH monitoring. *See* Esophageal pH monitoring
- Ambulatory peritoneal dialysis, continuous, 916
- Amcinonide, 96*t*
- Amebas, pathogenic free-living, 1505–1506
encephalitis/meningoencephalitis caused by, 1287, 1505–1506, 1506
- Amebiasis (entamoeba infection), 1503–1505, 1504*f*, 1505*t*
extraintestinal/hepatic, 1503, 1504, 1505*t*
intestinal, 574*t*, 575, 576, 578, 1293, 1298, 1303*t*, 1330, 1503, 1503–1504, 1504, 1504*f*, 1505*t*
- Amebic encephalitis/
meningoencephalitis, 1287, 1505–1506, 1506
- Amebic liver abscess (hepatic amebiasis), 1503, 1504, 1505*t*
- Amebic ulcers, 1504, 1504*f*
- Amebicides, 1504, 1505*t*
adverse ophthalmic effects of, 197*t*
- Ameboma, 1503
- Amegakaryocytic thrombocytopenia, 538, 539
- Amen. *See* Progesterone
- Amenorrhea, 1179–1188
in anorexia nervosa, 1262
in female athlete triad, 1712
in hyperprolactinemia, 1102, 1103, 1180, 1181
oral contraceptive use and, 770
in polycystic ovary syndrome, 765, 1162, 1179, 1180
pregnancy/lactation causing, 781, 786, 1180, 1181
primary, 1179–1180
secondary, 1180–1186. *See also* Menopause; Pregnancy
in Turner syndrome, 1179, 1180, 1186, 1187

- American Diabetes Association diet recommendations, 1204–1205
- American trypanosomiasis (Chagas disease), **1486–1487**
 achalasia and, 605
- Amevive. *See* Alefacept
- Amicar. *See* ϵ -Aminocaproic acid
- Amifostine, for chemotherapy/radiation-induced toxicity, 1658*t*
 cisplatin therapy and, 1658*t*, 1662
- Amikacin, 1722*t*
 for pneumonia, 273*t*, 277*t*
- Amikin. *See* Amikacin
- Amiloride
 for heart failure, 401
 hyperkalemia caused by, 401, 879
 for hypertension, 445*t*
 with hydrochlorothiazide, 445*t*
 lithium interactions and, 1074, 1074*t*
- ϵ -Aminocaproic acid (EACA), for bleeding disorders, 550*t*
- Aminoglutethimide, for prostate cancer, 1637*t*
- Aminoglycosides
 contraindications to in myasthenia gravis, 1032, 1034
 nephrotoxicity/acute kidney injury and, 904
 neuromuscular transmission affected by, **1034**
 ototoxicity of, 207
 for pneumonia, 273*t*
- Aminolevulinic acid, urinary, in porphyria, 1664
- Aminophylline
 for asthma, 255
 lithium interactions and, 1074*t*
 for lithium overdose/toxicity, 1073
- 5-Aminosalicylic acid, for inflammatory bowel disease, 638–639
- colorectal cancer risk and, 1623
- Crohn disease, 644
- ulcerative colitis, 647, 647–648
- Aminotransferase levels, 664*t*. *See also*
 Alanine aminotransferase;
 Aspartate aminotransferase
- in acetaminophen toxicity, 1570, 1570*f*
 in acute fatty liver of pregnancy, 795
 in alcoholic liver disease, 681
 in autoimmune hepatitis, 679
 in cholecystitis, 704
 in choledocholithiasis/cholangitis, 707
 in liver disease/jaundice, 664*t*
 in liver failure, 673
 in nonalcoholic fatty liver disease, 684, 685
- postoperative, 51
 in shock liver, 699
 in viral hepatitis, 666, 666*f*, 668, 668*f*, 670, 671*f*, 674, 675, 676
- zileuton affecting, 253
- Amiodarone
 adverse ophthalmic effects of, 196*t*
 for arrhythmias, 377, 378*t*
 atrial fibrillation, 372, 378*t*, 386, 387, 388
 atrial flutter, 389
 in heart failure, 405
 infarct-related, 372, 373, 376
- supraventricular tachycardia, 378*t*, 382
- ventricular tachycardia, 378*t*, 391, 392
- epididymitis and, 944
- hyperthyroidism/Graves disease caused by, 1110, 1112, 1113–1114, 1114, 1117
- hyponatremia caused by, 872
- hypothyroidism caused by, 1106
- levothyroxine therapy affected by, 1109
- Amitriptyline, 1068, 1070*t*, 1722*t*. *See also*
 Antidepressants
- for interstitial cystitis, 946
- for migraine prophylaxis, 964*t*
- for neuropathic pain/painful diabetic neuropathy, 84, 1021, 1225
- for postherpetic neuralgia, 121, 968
- AML. *See* Acute myeloid leukemia
- Amlodipine, 454*t*. *See also* Calcium channel blocking drugs
- for angina, 356
- for heart failure, 405
- for hypertension, 453, 454*t*
 with atorvastatin, 454*t*
 with benazepril, 450*t*
 with hydrochlorothiazide and valsartan, 452*t*
 with olmesartan, 451*t*
 with telmisartan, 452*t*
 with valsartan, 452*t*
- lower extremity edema caused by, 33
- overdose/toxicity of, 454*t*, 1576
- Ammonia
 in hepatic encephalopathy, 690
 in liver failure, 673
 in normal anion gap/renal tubular acidosis, 892, 892*f*, 893, 933
- reference values for, 1727*t*
- Ammonium tetrathiomolybdate, for Wilson disease, 697
- Amnesia
 in delirium, 1088
- dissociative, 1041
- in head injury, 1016
- Amnesic syndrome, 1088
- Amniocentesis, 783, 784
- CMV infection and, 1365
- Amodiaquine, 1492*t*, 1494–1495
- with artesunate (ASAQ), 1493*t*, 1494*t*, 1495, 1496
- with sulfadoxine-pyrimethamine, 1496
- Amoxapine, 1068, 1070*t*
- Amoxicillin/amoxicillin-clavulanate
 for anaerobic pleuropulmonary infection, 279, 1455
- for anthrax, 1432, 1433*t*
- for bacterial rhinosinusitis, 215, 216*t*
- for endocarditis, 1438*t*
- in *H pylori* eradication therapy, 613, 614*t*
- for Lyme disease, 1481, 1482
- for pneumonia, 273, 273*t*, 279, 1423
- resistance to, pneumococcal pneumonia and, 273, 1424
- for rosacea, 129
- “AMP” (marijuana soaked in formaldehyde), 1085
- Amphetamines
 abuse/overdose of, **1085–1086**, **1572–1573**
- psychotic behavior caused by, 1085, 1086
- adverse ophthalmic effects of, 196*t*
 during pregnancy, 783
- Amphotericin B, 1541–1542, 1541*t*
 for aspergillosis, 1538
- for blastomycosis, 1539
- for candidiasis, 598, 1530
- for coccidioidomycosis, 1533
- for cryptococcal meningitis, 993, 1338*t*, 1536
- for histoplasmosis, 1532
- for leishmaniasis, 1488
- lipid-based preparations of, 1541–1542, 1541*t*. *See also* Lipid-based amphotericin B
- for mucormycosis, 217, 1538
- nephrotoxicity/acute kidney injury and, 904
- for ophthalmic disorders, 168*t*
- for *P marneffei* infection, 1540
- for paracoccidioidomycosis, 1539
- prophylactic, 1281
- for sporotrichosis, 1539
- Amphotericin B lipid complex, 1541–1542, 1541*t*. *See also*
 Lipid-based amphotericin B
- Ampicillin
 allopurinol interactions and, 816
- for endocarditis, 1438*t*
- for pneumonia, 273*t*
- rash caused by, 1306
- in mononucleosis, 228, 1361, 1362
- for urinary tract infection, 940*t*
- Ampicillin-sulbactam, for pneumonia, 273*t*, 277*t*
- Amprenavir, 1344, 1345, 1348*f*. *See also*
 Antiretroviral therapy/
 HAART
- Ampulla of Vater, carcinoma of (ampullary/periampullary carcinoma), **1607–1612**, 1620
- Amputation
 in acute arterial limb occlusion, 469
- in electrical burns, 1553
- in lower leg/foot occlusive disease, 467
- AMSAN. *See* Acute motor and sensory axonal neuropathy
- Amyl nitrite
 abuse of, 1086
- for cyanide poisoning, 1577, 1578*t*
- Amylase
 ascitic fluid, 588
- in pancreatitis, 588, 591, 711, 713
- pleural fluid, 314
- serum levels of
- in diabetic ketoacidosis, 1233
- in liver failure, 673
- in mumps, 1370
- in pancreatitis, 711, 713, 716
- reference values for, 1727*t*
- Amyloid angiopathy, cerebral, 983, 984
- Amyloid protein, 531, 930. *See also*
 Amyloidosis
- in dementia, 1007
- Amyloidosis, **530–532**, 920*t*, **930**
 cardiac, 531
- cardiomyopathy and, 415, 416–417, 417, 427, 531

- Amyloidosis (*Cont.*):
 familial Mediterranean fever and, 591
 hereditary (transthyretin/TTR), 531
 localized, 531
 myeloma and, 528, 531, 930, 936
 nephrotic spectrum disorders and, 920*t*, **930**
 neuropathy and, 531, 1023
 primary (AL), **530–532**, 930
 renal failure type (β_2 -microglobulin), 531
 secondary (AA), 531, 930
 senile (atrial natriuretic peptide), 531
 systemic, 531
- Amyotrophic lateral sclerosis, 1019, 1020
 enterovirus infection and, 1407
- Amyotrophy
 diabetic, 1022, 1225
 neuralgic (idiopathic brachial plexus neuropathy), 1029–1030
- ANA. *See* Antinuclear antibody
- Anabolic steroids
 abuse of, 18, 1086
 aggression/violence and, 1078, 1086
 gynecomastia and, 1178
 for AIDS wasting, 1325
- Anacetrapib, 1252
- Anaerobic infections, **1454–1456**, 1455*t*, 1456*f*
 pleuropulmonary (pneumonia/lung abscess), **278–279**, 1302*t*, 1303*t*, 1455
- Anafranil. *See* Clomipramine
- Anagrelide
 for essential thrombocytosis, 514
 for polycythemia, 512
- Anakinra
 for gout, 814
 for Still disease, 831
- Anal dysplasia/cancer, 1612*t*, **1629–1630**
 in HIV infection/AIDS, 1332, 1629
- Anal fissures, 660–661
 in Crohn disease, 641, 642
- Anal fistulas, 661
- Anal gonorrhea, 658. *See also* Anorectal disorders, gonococcal
- Anal sphincter, disorders of
 constipation and, 570
 fecal incontinence and, 659, 660
- Anal syphilis, 658–659, 1465, 1469, 1469*f*
- Analgesia/analgesics. *See also specific type or disorder and* Pain management
 breastfeeding and, 782*t*
 caffeine-containing, 1086
 for migraine headache, 964
 for chronic pain/chronic pain disorders, 1048–1049
 in end-of-life care, 75–76
 for osteoarthritis, 811–812
 patient-controlled, 1091
 thrombocytopenia caused by, 547*t*
 tubulointerstitial disease caused by, 932–933, 933
- Analgesic nephropathy, 932–933, 933
 ureteral/renal pelvis cancer and, 1640
- Analgesic rebound headache, **966**
- Anaphylactoid (pseudoallergic) reactions, **867**
- Anaphylaxis/anaphylactic shock, 866
- insect stings causing, 866
 insulin allergy causing, 1222
 penicillin allergy causing, 1306
 transfusion causing, 535
- Anaplasma* (anaplasmosis), 1409*t*, **1414–1415**
 babesiosis coinfection and, 1415, 1499
equi, 1409*t*
 Lyme disease coinfection and, 1415, 1481
phagocytophilum, 1409*t*, 1414
- Anaprox. *See* Naproxen
- Anasarca, 588
- Anastrozole, 1656*t*
 for breast cancer, 740*t*
 for endometriosis, 761
 for gynecomastia, 1179
- ANCA. *See* Antineutrophil cytoplasmic antibody
- Ancef. *See* Cefazolin
- Ancobon. *See* Flucytosine
- Ancylostoma*
braziliense, 1523
caninum, 1518, 1523
 cutaneous larva migrans caused by, 1523
duodenale, 1518
- Andes virus, 1388
- Androderm, 1176. *See also* Testosterone replacement therapy
- Androgel, 1176. *See also* Testosterone replacement therapy
- Androgen deprivation, for prostate cancer, 1635, 1636, 1637*t*
- Androgen insensitivity/resistance
 gynecomastia in, 1178
 male hypogonadism caused by, 1094, 1175
 pseudohermaphroditism/amenorrhea in, 1179
- Androgenetic (pattern) baldness, 156
 in women, 156, 1719–1720
- Androgens. *See also* Antiandrogens; Testosterone
 for aplastic anemia, 509
 deficiency of, 1173–1177, 1173*t*. *See also* Hypogonadism
 pseudohermaphroditism/amenorrhea and, 1179
 in women, 1185
 replacement therapy and, 780, 1181, 1185
 excess of. *See* Hyperandrogenism
 oral, replacement therapy with, 1176. *See also* Testosterone replacement therapy
- Androstenedione
 in hirsutism/virilization, 1163
 prostate cancer and, 1636
- Anejaculation, 951, 1050. *See also* Erectile dysfunction/impotence
- Anemias, **490–509**, 491*t*. *See also specific cause or type*
 antiretroviral therapy and, 1343
 in cancer chemotherapy, 1649
 supportive care agents for, 1649, 1659*t*
 in celiac disease, 622
 of chronic disease, 492, **493–494**
 in cirrhosis, 686
- classification of, 490, 491*t*
 in colorectal cancer, 1623
 in erythrovirus (parvovirus) infection, 1402, 1403
 fish tapeworm infection and, 1514
 in gastric adenocarcinoma, 1616
 in hairy cell leukemia, 523
 hemolytic. *See* Hemolytic anemias/hemolysis
 in hookworm disease, 1518
 in kidney disease, 493, 898, 902, 911*f*, 913
 macrocytic, 490, 491*t*
 malabsorption and, 621*t*
 in malaria, 1491
 microcytic, 490, 491*t*
 in myelodysplastic syndromes, 517, 518
 in myeloma, 528
 during pregnancy, 784, **798–799**
 preoperative evaluation/perioperative management and, 52
 in primary myelofibrosis, 514
 pulmonary hypertension in, 424
 refractory, 517
 retinal disease associated with, 186–187
 in SLE, 834*t*
 thalassemias causing, 492, **494–496**, 494*t*, 495*t*
 thiazolidinediones causing, 1210
 in Waldenström macroglobulinemia, 530
- Anergy, skin test. *See* Skin test anergy
- Anesthesia/anesthetics
 liver function affected by, 51
 local, for eye disorders, precautions for use of, **194**
- Aneuploidy screening, in prenatal testing, 783, 784
- Aneurysms, **472–478**. *See also specific type and artery involved*
 aortic
 abdominal, **472–474**
 thoracic, **474–475**
 mycotic
 drug use and, 1292
 intracranial, 986
 peripheral arterial, **475–476**
 stroke and, 984
- Angiitis
 allergic, granulomatosis and. *See* Allergic angiitis and granulomatosis
 with granulomatosis (Wegener granulomatosis). *See* Granulomatosis, with polyangiitis
 primary, of central nervous system, **854**
- Angina
 intestinal (visceral artery insufficiency), **470–471**
 Ludwig, 230, 230–231
 pectoris, **351–359**, 358*t*. *See also* Coronary heart disease
 alteration in before myocardial infarction, 365
 aortic regurgitation and, 344
 aortic stenosis and, 342
 in apathetic hyperthyroidism, 1114, 1118

- chest pain/discomfort in, 28, 29, 351–352
 change in before myocardial infarction, 365
 chronic stable, 351–359, 358t
 coronary vasospasm and, 351, 360
 diagnosis/differential diagnosis of, 351–355
 jaw pain and, 968
 with normal arteriogram, 359–360
 postinfarction, 372
 preoperative risk assessment/
 perioperative management
 and, 46, 47–49, 47t, 48f, 48t
 prevention of further attacks and,
 355–358
 trial results in, 358
 Prinzmetal (variant), 360
 prognosis for, 358, 358t
 in pulmonary embolism, 298t
 risk reduction and, 356
 thiazolidinedione use and, 1210
 treatment of, 355
 unstable. *See* Acute coronary
 syndromes; Unstable angina
- Vincent (necrotizing ulcerative
 gingivitis), 226
- Angiodysplasias, GI bleeding and, 581,
 584, 586, 587
- Angioectasias, GI bleeding and, 581, 584,
 586, 587
- Angioedema, 132–134, 866
 ACE inhibitor/angiotensin II receptor
 antagonist therapy and, 132,
 449
 in drug desensitization, 1307
- Angiofibroma
 juvenile, 222
 in MEN, 1188t, 1189
- Angiogenesis, drugs targeting, in breast
 cancer therapy, 741
- Angiography/arteriography. *See also*
specific disorder
 in aortoiliac occlusive disease, 464
 cardiac/coronary. *See also* Cardiac
 catheterization
 in acute coronary syndromes, 364
 in angina, 354–355
 normal findings and, 359–360
 in chest pain evaluation, 29, 354–355
 in myocardial infarction, 364t, 371
 cerebral. *See* Cerebral angiography/
 arteriography; Neuroimaging
 CT. *See* Computed tomography;
 Helical (spiral) CT
 in GI bleeding
 diagnostic, 585
 therapeutic, 583, 585, 586
 in insulinoma diagnosis, 1240–1241
 interventional. *See* Embolization
 left ventricular, in angina, 355
 magnetic resonance. *See* Magnetic
 resonance angiography
 in polyarteritis nodosa, 848
 pulmonary, in pulmonary embolism, 300
 chest pain evaluation and, 29
 helical CT, 299, 300, 301f
 radionuclide
 in angina, 353
 in cardiomyopathy, 412
 in heart failure, 400
 in postinfarct pseudoaneurysm, 375
 in renal artery stenosis/renal vascular
 hypertension, 437, 917
- Angiomas/angiomatosis
 bacillary, 1323, 1331, 1453–1454, 1454
 spider, in cirrhosis, 686
 in Sturge-Weber syndrome, 997
- Angiomyolipomas, of kidney, 1641, 1642
- Angioplasty. *See also* Endovascular
 surgery/prostheses
 for aortoiliac occlusive disease, 465
 carotid, 470
 coronary
 for angina, 357–358
 angiography before, 354
 for myocardial infarction, 371
 for femoral/popliteal occlusive disease,
 466
 for hepatic vein obstruction (Budd-
 Chiari syndrome), 698
 for renal artery stenosis/renal vascular
 hypertension, 437, 917, 918
 for superior vena caval obstruction, 482
 for visceral artery insufficiency/
 intestinal angina, 471
- Angiosarcoma, of liver, 1604
- Angiostrongylus cantonensis/costaricensis*
 (angiostrongyliasis), 1522
- Angiotensin II receptor blocking agents,
 451–452t
 angioedema/urticaria and, 132, 449
 for aortic regurgitation, 345
 for chronic kidney disease, 908
 for diabetic nephropathy, 449, 928, 931
 for heart failure, 402, 449
 chronic kidney disease and, 912
 infarct-related, 371, 376
 hyperkalemia caused by, 449, 879, 928
 for hypertension, 442t, 449, 451–452t,
 457–458, 457f, 458t
 in chronic kidney disease/renal failure,
 442t, 449, 458–459, 911
 in combination regimen, 457–458,
 457f, 458t
 contraindications to during
 pregnancy, 802
 in diabetics, 442t, 449, 458, 1203
 for myocardial infarction, 371, 376
 for nephrotic syndrome/nephrotic
 spectrum disorders, 928
 preoperative discontinuation of, 49, 55
- Angiotensin-converting enzyme (ACE)
 in hypertension, 436
 reference values for, 1727t
 in sarcoidosis, 295
- Angiotensin-converting enzyme (ACE)
 inhibitors, 450–451t
 for acute coronary syndromes, 362t
 acute kidney injury/renal failure and,
 449, 902–903
 angioedema/urticaria and, 132, 449
 breastfeeding and, 782t
 for chronic kidney disease, 908
 cough and, 402, 449
 for diabetic nephropathy, 928, 931, 1224
 for heart failure, 401, 401–402, 449
 chronic kidney disease and, 402, 912
 infarct-associated, 370–371, 376
 hyperkalemia caused by, 449, 879, 928
 for hypertension, 442t, 449, 450–451t,
 457–458, 457f, 458t
 in chronic kidney disease, 442t, 449,
 458–459, 911
 in combination regimen, 449,
 457–458, 457f, 458t
 contraindications to in pregnancy,
 449, 802
 in diabetics, 442t, 449, 457–458, 458,
 1202, 1203, 1227
 in urgencies/emergencies, 462t
 hypoglycemia caused by, 1244
 hyponatremia caused by, 871f, 872
 lithium interactions and, 1074, 1074t
 for myocardial infarction, 362t,
 370–371, 376
 for nephrotic syndrome/nephrotic
 spectrum disorders, 928
 pregnancy and, 449, 802
 preoperative discontinuation of, 55
 for renal artery stenosis/renal vascular
 hypertension, 437
- Angiotensinogen/angiotensin, in
 hypertension, 436, 437, 449
- Angle closure, pupillary dilation and, 174,
 194–195
- Angle-closure glaucoma
 acute, 165t, 174–175
 antipsychotics precipitating, 1059
 pupillary dilation precipitating, 174,
 194–195
 chronic, 174
- Angular cheilitis
 candidiasis and, 225, 226f, 1329
 in HIV infection/AIDS, 226f, 1329
- Anhedonia, 1063. *See also* Depression
- Anhidrosis and asthenia (tropical), 131
- Anicteric leptospirosis, 1477
- Anidulafungin, 1541t, 1542
 for candidiasis, 1530
- Aniline, methemoglobinemia caused by,
 1584
- Animal bites, 1288–1290. *See also* Insect
 bites/stings
 anaerobic skin infections and, 1289,
 1456
 poisonous snake, 1566t, 1589–1590
 rabies and, 1289, 1290, 1376
- Anion gap/anion gap acidosis, 889–890,
 890, 890t. *See also* Urinary
 anion gap
 alcoholic ketoacidosis and, 891, 893
 decreased, 890, 890t
 diabetic ketoacidosis and, 891,
 1234–1235
 increased, 890, 890–891, 890t, 893
 in kidney disease, 892, 892t, 893,
 893–894, 902
 lactic acidosis and, 890–891, 1237–1238
 normal, 890, 890t, 891–893, 892t,
 893–894. *See also* Normal
 anion gap acidosis
 with osmolar gap, 877, 1569
 in poisoning/drug overdose, 891, 1569
 with methanol or ethylene glycol,
 877, 891, 1569, 1584
 with salicylates, 891, 1588
 in renal failure (uremic), 890, 891, 902
 in renal tubular acidosis, 892, 892t,
 893, 893–894, 933

- Anisakiasis (*Anisakis marina*), 1524
gastritis caused by, 610
- Anismus (pelvic floor dyssynergia), 570, 570t, 571
- Ankle
examination of, 1703, 1704, 1704t
injuries/sprains of, 1703–1705, 1703t, 1704t
 eversion (high), 1704–1705, 1704t
 inversion, 1703–1704, 1703t, 1704t
 range of motion and, 1704, 1704t
 strength testing and, 1704t
- Ankle-brachial index (ABI/ABPI)
in aortoiliac occlusive disease, 464
in femoral/popliteal occlusive disease, 466
in lower leg/foot occlusive disease, 467
in venous insufficiency, 34
 leg ulcers and, 154
- Ankylosing spondylitis, 820, 854–856
arthritis and, 855, 857
back pain caused by, 820, 855
inflammatory bowel disease and, 855, 858
- ANNA-1. *See* Antineuronal nuclear antibodies
- Annuloplasty, for tricuspid regurgitation, 347
- Anocutaneous reflex, fecal continence and, 660
- Anogenital/perianal pruritus, 14f, 146–147, 661
in enterobiasis/pinworms, 146, 1520
- Anogenital warts. *See* Venereal (genital) warts
- Anopheles* mosquitoes. *See* Mosquitoes
- Anorectal disorders, 657–661. *See also* Genital ulcers
anal cancer, 1612t, 1629–1630
bleeding in, 583, 584. *See also* Rectal bleeding
candidal infection, 131, 132
chlamydial, 659, 1461
constipation and, 570, 570–571, 570t
in Crohn disease, 641, 642, 642–643
fecal incontinence and, 659–660
fissures/abscesses/fistula, 660–661
 in inflammatory bowel disease, 641, 642, 642–643, 661
gonococcal, 658, 1452
in granuloma inguinale, 1453
hemorrhoids, 657–658
in herpes simplex infection, 659
infections, 658–659
in lymphogranuloma venereum, 659, 1461
in syphilis, 658–659, 1465, 1469, 1469f
in ulcerative colitis, 646
venereal warts, 139, 140, 140f, 659
- Anorexia
in cirrhosis, 686
folic acid deficiency and, 499
in HIV infection/AIDS, 1325
nervosa, 1262–1263
 bulimia and, 1263
 Cushing syndrome and, 1160
- Anorexia-cachexia syndrome, in terminally ill/dying patient, 90
- Anorgasmia. *See* Orgasm, loss of
- Anoscopy
in GI bleeding, 584
in hemorrhoids/fecal incontinence, 657, 660
- Anosmia, 220, 989
in Kallmann syndrome, 1094
- Anosognosia, intracranial tumors causing, 991
- Anovulation, 747
differential diagnosis of, 765
dysfunctional uterine bleeding and, 747
infertility and, 768
 ovulation induction and, 769, 1097
in polycystic ovary syndrome, 765, 766, 1162
- Ansaid. *See* Flurbiprofen
- Anserine (pes anserine) bursa/bursitis, 1692
- Antacids. *See also* Acid-antisecretory agents
antidepressant drug interactions and, 1071t
benzodiazepine interactions and, 1043t
diarrhea caused by, 578
for GERD, 596
hypermagnesemia and, 888, 906
metabolic alkalosis and, 895
for peptic ulcer disease, 613
- Anterior blepharitis, 163, 163–164
- Anterior chest wall syndrome, 355
- Anterior communicating artery, occlusion of in stroke, 981
- Anterior cruciate ligament (ACL), 1692, 1693
assessment of, 1693–1698, 1694–1695t
injury of, 1693–1698, 1694–1695t
- Anterior drawer sign/test
ankle sprain and, 1703, 1704t
knee stability/ACL injury and, 1693–1698, 1694t
- Anterior hypopituitarism, 1093–1098
- Anterior interosseous syndrome, 1026
- Anterior ischemic optic neuropathy, 188
in giant cell arteritis, 188, 845–846
- Anterior talofibular ligament, in ankle sprains, 1703, 1704
- Anterior tibiofibular ligament, in ankle sprains, 1704
- Anterior uveitis, 165t, 173, 177, 177–178, 178. *See also* Uveitis
- Anthracyclines, 1653t
for acute myeloid leukemia, 520
for breast cancer, 736–737
toxicity of, 1653t, 1662
 cardiac, 411, 1662
 dexrazoxane for, 1658t, 1662
- Anthrax, 1300t, 1431–1433, 1433t
- Anthrax vaccine, 1433
- Anti-Xa
 heparin affecting, 555, 558
 rivaroxaban affecting, 555, 558
- Anti-155/140, in polymyositis/dermatomyositis, 841
- Anti-AMPA receptor antibody, in autoimmune paraneoplastic disorders, 995
- Anti-amphiphysin antibody, in autoimmune paraneoplastic disorders, 995
- Antiandrogens
for cancer chemotherapy, 1656t
for hirsutism/virilization, 1163, 1164
pregnancy and, 1164
for prostate cancer, 1636, 1637t
- Antianginal drugs, 355–356
preoperative management for patient taking, 47
- Anti-angiogenesis agents, for breast cancer, 741
- Antianxiety drugs, 1042–1044, 1042t, 1043t. *See also* specific type
- Antiarrhythmic drugs, 377, 378–379t. *See also* specific agent and specific arrhythmia
for arrhythmias in poisoning/drug overdose, 1564
in heart failure, 405
for infarct-associated arrhythmias, 372–373
 prophylaxis/postinfarction management and, 371, 376
overdose/toxicity of, 377, 1564, 1588
perioperative risk and, 49
- Antibacterial agents. *See also* Antibiotics; Antimicrobial therapy
adverse ophthalmic effects of, 197t
ophthalmic, 168t
- Antibiotic-associated *C difficile* colitis/diarrhea, 575, 576, 636–638, 1293, 1294t
- Antibiotics, 1298–1307, 1299–1301t, 1302t, 1303–1304t. *See also* specific type or disorder and Antimicrobial therapy
for acid-fast rod infections, 1300t
for acne, 97t, 127
adverse reactions/toxicity and, 1305
 dermatitis medicamentosa, 160
 ophthalmic, 197t
for asthma, 256
for bacterial overgrowth, 625
for bacterial rhinosinusitis, 215–216, 216t, 1303t
for bite wounds, 1289–1290
for brain abscess, 994, 1288, 1302t
breastfeeding and, 782t
for bronchiectasis, 266
in burn care, 1551
C difficile colitis/diarrhea and, 575, 576, 636–638, 1293, 1294t
for chlamydial infections, 1301t, 1461, 1462
clinical response to, 1301
 promptness of, 1305
colitis associated with use of. *See* Antibiotic-associated *C difficile* colitis/diarrhea
for COPD, 263–264, 264
cost of, 1305
for Crohn disease, 642, 644
for cystic fibrosis, 268
for diarrhea, 577, 1296, 1298
diarrhea caused by. *See* Antibiotic-associated *C difficile* colitis/diarrhea
for diverticulitis, 652
duration of treatment and, 1305
in fever management, 36, 1278

- for gram-negative infections, 1299t, 1299–1300t, 1444
- for gram-positive infections, 1299t, 1300t
- in *H pylori* eradication therapy, 609, 613–615, 614t, 615
- for hepatic encephalopathy, 690
- hypersensitivity tests/desensitization and, **1305–1307**
- in immunocompromised host, 1281–1282, 1648
- for impetigo, 97t, 123, 1303t
- infection in cancer patient and, 1648
- intravenous administration of, 1305
- for irritable bowel syndrome, 635
- for liver abscess, 701
- for malaria, 1497
- for meningitis, 1286t, 1288, 1424–1425
- partial treatment and, 1286–1287
- for mycoplasma infection, 1301t
- in neutropenic patient, 36, 510, 1281, 1281–1282, 1648
- ophthalmic, 168t
- oral contraceptive failure and, 127
- perioperative
- pulmonary complications and, 51
 - for surgical site infections, **55–56**
- for pharyngitis, 228, 229, 1303t, 1420
- for PID, 763, 1304t
- platelet function affected by, 549t
- for pneumonia
- anaerobic, 278–279, 1302t, 1303t, 1455
 - in community-acquired disease, 270, 271, 272–274, 273t, 274, 1302t
 - nosocomial, 277, 277t, 1302t
 - pneumococcal, 1423
- principles of use of, **1298–1305**, 1299–1301t, 1302t, 1303–1304t
- prophylactic. *See* Antimicrobial chemoprophylaxis
- resistance to. *See* Drug resistance
- for rickettsial infections, 1301t
- routes of administration for, 1305
- for shock, 489
- for skin and soft tissue infections, 1420–1421, 1421t
- for spirochetal infections, 1300t
- for spontaneous bacterial peritonitis, 589, 590, 689
- for syphilis, 1467, 1468t
- thrombocytopenia caused by, 547t
- topical
- for acne, 97t, 127
 - for impetigo, 97t, 123
- tubulointerstitial nephritis caused by, 932t
- for urinary tract infections, 940t, 1303t
- Antibodies.** *See also* Immunoglobulins
- infections associated with defects in, 1279
- Antibody-mediated (cytotoxic/type II) hypersensitivity, 866
- Anticancer drugs. *See* Chemotherapy
- Anticardiolipin antibodies
- in antiphospholipid antibody syndrome, 799, 834, 836
 - pregnancy loss and, 789
 - in SLE, 834, 834t
- Anti-CCP antibodies, in rheumatoid arthritis, 827
- Anti-CD3 antibodies, in new-onset type 1 diabetes, 1202
- Anticentromere antibody, 833t
- in CREST syndrome/scleroderma, 833t, 839
- Anticholinergic agents
- for allergic disorders/rhinitis, 219
 - antidepressant drug interactions and, 1071t
 - for asthma
 - long-acting, 252, 252t
 - short-acting, 254t, 255
 - breastfeeding and, 782t
 - for COPD, 262
 - for irritable bowel syndrome, 634–635
 - for nausea and vomiting, 86, 569
 - overdose/toxicity of, 999, 1566t, **1575**, 1583
 - ophthalmic effects and, 195t, 196t
 - for parkinsonism, 998, 999, 999t
- Anticholinergic delirium, 1568, 1575, 1583
- Anticholinergic syndrome/effects, 1568, 1575, 1583
- antidepressants causing, 1068–1069, 1070t, 1575, 1591
 - antipsychotic drugs causing, 1055, 1057t, 1059
 - hallucinogens causing, 1583
- Anticholinergic-type mushroom poisoning, 1575, 1583
- Anticholinesterases/acetylcholinesterase inhibitors
- for Alzheimer disease/dementia, 61, 1008–1009
 - for myasthenia gravis, 1032–1033
 - overdose/toxicity/poisoning with, 1566t, **1587**
 - for parkinsonism, 1000
- Anticipatory anxiety, in panic disorders, 1041
- Anticoagulants, lupus. *See* Lupus anticoagulant
- Anticoagulation therapy, 554–555, 556–562, 557t, 558t, 559t, 560t, 561t, 562t
- for acute arterial occlusion of limb, 468
 - for acute coronary syndromes, 361–363, 362t
 - for antiphospholipid antibody syndrome, 799, 836
 - in pregnancy, 799, 836
 - in SLE, 834
 - for atrial fibrillation, 385t, 386–387, 388
 - in hyperthyroidism, 1118
 - in mitral stenosis, 338
 - for atrial flutter, 389
 - bleeding and, 302–303
 - after cardiac valve replacement, 343, 349
 - endocarditis and, 1439
 - pregnancy and, 349
 - drug interactions and, 560t
 - antidepressants, 1071t
 - for DVT/PE (venous thromboembolic disease)
 - drug selection and, 556–562, 559t, 560t, 561t, 562t
 - duration of, 301–302, 558–560, 562t
 - patient selection and, 560t
 - prevention and, 301, 555–556, 555t, 556t, 557t, 558t
 - treatment and, 301–303, 556–562, 559t, 560t, 561t, 562t
 - in endocarditis, 1439
 - epistaxis and, 220
 - for heart failure, 405
 - hematuria and, 938
 - heparin-induced thrombocytopenia and, 544–545, 544t, 554
 - for hepatic vein obstruction (Budd-Chiari syndrome), 698
 - for intracranial venous thrombosis, 988
 - investigational agents in, 558
 - for myocardial infarction, 362t, 367, 371, 376
 - after thrombolytic therapy, 369–370
 - for nephrotic syndrome/nephrotic spectrum disorders, 928
 - overdose/toxicity and, **1573**
 - peptic ulcer disease and, 616
 - perioperative management of, 52, 53t
 - for pulmonary hypertension, 305, 424, 425f
 - for septic superficial thrombophlebitis, 480
 - for stroke, 982
 - thrombocytopenia caused by, 547t
 - for transient ischemic attacks, 978–979
- Anticochlear antibodies, autoimmune audiovestibular dysfunction and, 208
- Anticonstipation agents. *See* Fiber, dietary; Fiber laxatives; Laxatives
- Anticonvulsant therapy, 972, 973t
- breastfeeding and, 782t
 - corticosteroid interactions and, 1190
 - discontinuing, 972
 - drug selection and, 972, 973t
 - for glossopharyngeal neuralgia, 968
 - for migraine prophylaxis, 964t
 - monitoring serum levels during, 972
 - for myoclonus, 1004
 - overdose/toxicity and, 972, **1573–1574**
 - for postherpetic neuralgia, 968
 - during pregnancy, 803, 972
 - for PTSD, 1040
 - for status epilepticus, 974
 - thyroid testing affected by, 1108
 - for trigeminal neuralgia, 967
 - vitamin D affected by, 1149
- Anti-CV2/CRMP5 antibody, in autoimmune paraneoplastic disorders, 995
- Anti-D, for immune thrombocytopenia, 541, 541f, 542
- Anti-D antibodies, transfusion producing, 534
- Antidepressants, 1065–1069, 1066f, 1069t, 1070t, 1071t. *See also specific type and agent*
- with antipsychotic agents, 1058, 1065–1066, 1069
 - for anxiety, 1042, 1043–1044
 - aripiprazole with, 1058, 1069
 - atypical, 1067–1068

- Antidepressants (*Cont.*):
 breastfeeding and, 782t
 buspirone as augmenting agent for, 1065, 1069
 combination therapy and, 1069
 in dementia, 61, 1009
 dispensing, 1065, 1067
 dose tapering and, 1069
 drug interactions of, 1071t
 for dyspepsia, 566
 in elderly, 63, 71
 for irritable bowel syndrome, 635
 lithium augmentation/interaction and, 1065, 1069, 1073
 maintenance therapy with, 1069
 mania caused by, 1063
 for migraine prophylaxis, 964t
 monoamine oxidase inhibitors (MAOIs), 1069, 1069t, 1070t. *See also* Monoamine oxidase inhibitors
 for neuropathic pain/painful diabetic neuropathy, 84, 84t, 1021, 1049, 1225
 for OCD, 1044, 1067, 1068
 overdose/toxicity of, 1070t, 1591–1592
 arrhythmias and, 1068, 1564, 1588, 1591, 1591f
 hypotension caused by, 1068, 1069, 1563
 seizures and, 1068–1069, 1565t, 1591
 suicide and, 1065, 1067, 1591
 in pain management, 84, 84t, 1021, 1049
 for panic attacks, 1044
 for personality disorder, 1053
 for phobic disorder, 1044
 during pregnancy, 1067–1068
 for psychotic depression, 1058, 1065–1066, 1068
 for PTSD, 1040
 selection of, 1065
 sexual dysfunction caused by, 1051, 1067, 1069
 SSRIs, 1067–1068, 1070t. *See also* Serotonin-selective reuptake inhibitors
 switching agents and, 1069
 thyroid medication/liothyronine as augmenting agent for, 1065, 1069
 tricyclic, 1068–1069, 1070t. *See also* Tricyclic antidepressants
- Antidiabetic agents, 1205–1213, 1206–1207t, 1220–1221. *See also specific type and agent and* Insulin therapy
 adverse ophthalmic effects of, 197t
 combination regimens and, 1213
 with insulin therapy, 1221
 intensive therapy with, 1201, 1202, 1203, 1204
 intraoperative requirements/
 administration of, 54, 54t, 1229, 1229t
 MAOI interactions and, 1071t
 overdose/toxicity of, 1566t, 1580
 during pregnancy, 801, 1230
 in prevention/delay of diabetes, 1201, 1201–1202, 1202
- Antidiarrheal agents, 577, 580, 1296
 for Crohn disease, 643–645
 for fecal incontinence, 660
 for irritable bowel syndrome, 635
 for microscopic colitis, 650
 for short bowel, 626
 for traveler's diarrhea, 1298
 for ulcerative colitis, 647
- Antidiuretic hormone (ADH). *See also* Vasopressin
 antipsychotic drugs affecting, 1059
 in diabetes insipidus/hyponatremia, 876
 in hyponatremia, 871, 871f, 872, 873
 inappropriate secretion of (SIADH). *See* Syndrome of inappropriate ADH secretion
 volume overload and, 877
- Anti-DNase B, in rheumatic fever/heart disease, 418
- Antidotes, 1566, 1566t. *See also specific agent*
- Anti-double-stranded (anti-ds)-DNA
 in hyperthyroidism, 1113
 in lupus/SLE, 114, 833, 833t
- Antidromic reentrant tachycardia, 383
- Anti-EGFR therapy. *See* EGFR (epidermal growth factor) mutations/inhibitors
- Antiemetics, 568–569, 568–569t
 for chemotherapy-induced nausea and vomiting, 568–569, 1660
 for hyperemesis gravidarum, 787
 for opioid-induced nausea and vomiting, 84
- Antiendomyosial antibodies, in celiac disease, 622
- Antiepilepsy drugs. *See* Anticonvulsant therapy
- Antifolates
 in cancer chemotherapy, 1651t
 for malaria, 1497, 1498
- Antifreeze. *See* Ethylene glycol poisoning
- Antifungal agents, 97–98t, 1541–1542, 1541–1542t. *See also specific agent or disorder*
 for candidiasis, 1530, 1541–1542
 invasive disease, 1530, 1541, 1542
 oral disease, 226, 1329
 for dermatologic disorders, 97–98t
 for invasive sinusitis, 217
 in neutropenia, 510, 1281
 for ophthalmic disorders, 168t
 prophylactic, 1281, 1530
 for systemic disorders, 1541–1542, 1541–1542t
- Anti-GABA_B receptor antibody, in autoimmune paraneoplastic disorders, 995
- Anti-GalNAC-CD1a antibodies, in Guillain-Barré syndrome, 1025
- Anti-GBM antibodies. *See* Anti-glomerular basement membrane antibodies
- Anti-GD1a/GD1b antibodies, in Guillain-Barré syndrome, 1025
- Antigen-antibody complexes, 866. *See also* Immune complex-mediated hypersensitivity
- in glomerulonephritis, 907, 921f
 membranous nephropathy and, 929
 serum sickness and, 866, 867
 in SLE, 832
- Antigenic drift/shift
 influenza epidemics/pandemics and, 1395
 norovirus and, 1405
- Antiglaucoma agents, 170–172t, 176–177
- Antigliadin antibody, in celiac disease, 622
- Antiglobulin test. *See* Coombs test
- Anti-glomerular basement membrane antibodies, in glomerulonephritis/Goodpasture syndrome, 306, 907, 919t, 921f, 924–925
- Anti-GM1/GM1b antibodies, in Guillain-Barré syndrome, 1025
- Anti-GQ1b antibodies, in Guillain-Barré syndrome, 1025
- Anti-HAV, 666
- Anti-HBc, 668f, 668t, 669, 674
 hepatocellular carcinoma and, 1603
 screening blood for, 535–536, 669
- Anti-HBe, 668f, 668t, 669, 674
- Anti-HBs, 668–669, 668f, 668t
- Anti-HCV, 671, 671f, 676
 in hepatocellular carcinoma, 1604
 screening blood for, 536, 671
- Anti-HDV, 672, 675
- Antihistamines, 99
 abuse/overdose/toxicity of, 1575
 for allergic eye disease, 167, 169t
 for allergic rhinitis, 218–219
 for atopic dermatitis, 104
 breastfeeding and, 782t
 for desensitization reactions, 1306, 1307
 for insomnia, 1076
 MAOI interactions and, 1071t
 for nausea and vomiting, 86, 569
 nefazodone interactions and, 1068
 for ophthalmic disorders, 167, 168t
 in OTC medications, 1086
 for pruritus, 99
 for scombroid poisoning, 1589
 for urticaria, 99, 133
- Anti-Hu antibody
 achalasia and, 605
 in autoimmune paraneoplastic disorders, 995
 in cancer-related neuropathy, 1024
- Antihypertensive drug therapy, 434t, 441–444, 442t, 443f, 444–459, 444t, 457f, 458t. *See also specific class or agent*
 age and, 458t, 459
 aldosterone receptor antagonists in, 437, 438, 442t, 445t, 449–453
 α-adrenoceptor antagonists in, 453, 456t
 angiotensin II receptor blocking agents in, 442t, 449, 451–452t, 457–458, 457f, 458t
 contraindications to during pregnancy, 802
 angiotensin-converting enzyme (ACE) inhibitors in, 442t, 449, 450–451t, 457–458, 457f, 458t

- contraindications to in pregnancy, 449, 802
 in diabetics, 442t, 449, 457–458, 458, 1202, 1203, 1224, 1227
 for urgencies/emergencies, 462t
 in aortic dissection, 461t, 477
 arteriolar dilators in, 453, 456t
 for urgencies/emergencies, 462t
 β -adrenergic blocking agents in, 442t, 446–449, 447–448t, 457, 457f, 458t
 during pregnancy, 802
 for urgencies/emergencies, 462t
 in black patients, 446, 449, 453, 457f, 458t, 459
 breastfeeding and, 782t
 calcium channel blocking drugs in, 442t, 453, 454–455t, 457–458, 457f, 458t
 during pregnancy, 802
 for urgencies/emergencies, 462t
 combination regimens and, 457–458, 457f, 458t
 in congestive heart failure, 439, 442t, 457
 depression caused by, 456t, 457, 1064
 developing regimen for, 457–458, 457f, 458t
 in diabetes mellitus, 442t, 443, 457–458, 458, 1202, 1203, 1227
 complication rate/diabetic nephropathy and, 931, 1202, 1203, 1224, 1227
 diuretics in, 434t, 444–446, 445t, 457–458, 457f, 458t
 in combination products, 445t, 450t, 451t, 452t
 in combination regimens, 457–458, 457f, 458t
 during pregnancy, 802
 for urgencies/emergencies, 462t, 463
 follow-up and, 459
 goals of, 442–444
 heart disease prevention and, 10–11, 439, 441–442, 442–444, 442t, 443f, 444t, 457
 in women, 1706
 patient selection for, 441–444, 442t, 443f, 444t
 peripheral sympathetic inhibitors in, 453–457, 456t
 pheochromocytoma surgery and, 1170
 for preeclampsia/eclampsia, 795
 during pregnancy, 795, 802
 in hypertensive emergency, 461t
 for prehypertension, 434t, 441–442, 443
 preoperative/perioperative, 49
 in renal disease/failure, 439, 442t, 458–459, 911
 renin inhibitors in, 449, 450t
 stroke/stroke prevention and, 442t, 457
 in urgencies/emergencies, 460–461, 461t
 sympatholytics in, 453, 456t
 overdose/toxicity of, 456t, 1577
 in urgencies/emergencies, 462t
 for urgencies/emergencies, 460–463, 461t, 462t
 vasodilators in, 453, 456t
 for urgencies/emergencies, 462t
 Anti-IgA antibodies, 868
 Anti-inflammatory drugs. *See also* Corticosteroids; Nonsteroidal anti-inflammatory drugs
 for asthma, 250
 ophthalmic, 169–170t
 for osteoarthritis, 811–812
 Anti-insulin antibodies
 in autoimmune/immunopathologic hypoglycemia, 1238, 1238t, 1243
 in factitious hypoglycemia, 1243
 in immune insulin resistance, 1222
 insulin therapy causing, 1222–1223
 in type 1 diabetes, 1193, 1193t
 Anti-insulin receptor antibodies, in hypoglycemia, 1243
 Anti-integrins, in inflammatory bowel disease, 640
 Anti-intrinsic factor antibodies, in pernicious anemia gastritis, 610
 Anti-Itch lotion. *See* Pramoxine
 Anti-Jo-1 antibody, in polymyositis/dermatomyositis, 833t, 841
 Antileukocyte antibodies, transfusion-related acute lung injury caused by, 536
 Antileukotriene agents
 for allergic rhinitis, 219
 for asthma, 249f, 252t, 253
 Anti-liver cytosol type 1, in autoimmune hepatitis, 679
 Anti-LKM1, in autoimmune hepatitis, 679
 Anti-Ma2 antibody, in autoimmune paraneoplastic disorders, 995
 Anti-MAG antibodies, in cancer-related neuropathy, 1024
 Antimalarial agents, 1492t, 1493t, 1494–1497, 1494t
 adverse ophthalmic effects of, 197t
 for lupus/SLE, 115, 834
 for malaria, 1492–1498, 1492t, 1493t, 1494t
 chemoprophylaxis, 1498, 1498t
 non-falciparum, 1492–1493
 nonimmune populations, 1493
 self-treatment, 1498
 severe disease, 1493, 1494t, 1497
 treatment, 1492–1497, 1492t, 1493t, 1494t
 uncomplicated falciparum, 1493, 1493t, 1494t
 for porphyria cutanea tarda, 122
 rabies vaccination and, 1315, 1378
 resistance to, 1492, 1493, 1494, 1494t, 1495, 1496, 1497, 1498, 1498t
 for rheumatoid arthritis, 830
 Antimania therapy, 1072–1075, 1074t
 Antimetabolites, in cancer chemotherapy, 1651–1652t
 breastfeeding and, 782t
 Anti-Mi-2 antibody, in polymyositis/dermatomyositis, 841
 Antimicrobial chemoprophylaxis. *See also* specific agent and Antimicrobial therapy
 for anthrax, 1433
 for aspergillosis, 1537
 for bite wounds, 1289
 in bronchiectasis, 266
 in burn injury, 1551
 for candidiasis, 1337, 1530
 for CMV infection, 1280–1281, 1337, 1339, 1366
 in COPD, 263
 for cryptococcosis, 1337, 1536
 in cystic fibrosis, 268
 for cystitis, 939
 for endocarditis, 1437, 1437t, 1438t
 in hereditary hemorrhagic telangiectasia, 1671
 during pregnancy, 431, 803
 for esophageal varices, 602
 for filariasis, 1526
 for group B streptococcal infection, in pregnancy, 784–785, 804
 for herpes simplex infection, 1280, 1330, 1352, 1352–1355, 1353–1354t
 in HIV infection/AIDS/
 immunocompromised host, 1280–1281, 1334–1335, 1334t, 1336–1337, 1337t
 for influenza, 1397
 for Lyme disease, 1481
 for MAC infections, 1337, 1339, 1459
 for malaria, 1498, 1498t. *See also* Antimalarial agents
 rabies vaccination and, 1315, 1378
 for meningococcal meningitis, 1442
 in neutropenia, 1281
 for opportunistic infections, 1280–1281, 1334–1335, 1334t, 1336–1337, 1337t
 for *P jiroveci* infection, 1280, 1337, 1337t, 1339, 1535
 for *P marneffeii* infection, 1540
 for peritonitis, 590, 689
 for pertussis, 1440
 for plague, 1315, 1451
 for *Pneumocystis* infection, 1280, 1337, 1337t, 1339, 1535
 in rape/sexual assault, 778, 1291
 for relapsing fever, 1476
 for rheumatic fever, 418
 for spontaneous bacterial peritonitis, 590, 689
 for surgical site infections, 55–56
 for toxoplasmosis, 1337, 1502
 for traveler's diarrhea, 1298
 for tuberculosis, 280
 in HIV infection/AIDS, 4, 1334, 1337
 Antimicrobial therapy, 1298–1307, 1299–1301t, 1302t, 1303–1304t. *See also* specific type or disorder and Antimicrobial chemoprophylaxis
 adverse reactions/toxicity and, 1305
 for asthma, 256
 breastfeeding and, 782t
 in burn care, 1551
 clinical response to, 1301
 promptness of, 1305
 cost of agents and, 1305
 duration of, 1305

- Antimicrobial therapy (*Cont.*):
 empiric, 1301, 1302*t*, 1303–1304*t*
 for brain abscess, 994, 1288, 1302*t*
 for diarrhea, 577
 in fever management, 36, 1278
 in drug user, 1292–1293
 in immunocompromised host,
 1281–1282
 for pneumonia
 community-acquired, 270, 271,
 272, 273*t*, 1302*t*
 in immunocompromised host,
 279
 nosocomial, 275, 277, 277*t*, 1302*t*
 for urinary tract infections, 940*t*,
 1303*t*
 in fever management, 36, 1278
 hypersensitivity tests/desensitization
 and, **1305–1307**
 for meningitis, 1286*t*, 1288, 1424–1425
 in neutropenic patient, 36, 510,
 1281–1282
 for opportunistic infection, 1281–1282
 principles of, **1298–1305**, 1299–1301*t*,
 1302*t*, 1303–1304*t*
 resistance to. *See* Drug resistance
 routes of administration for, 1305
 for shock, 489
 for skin and soft tissue infections,
 1420–1421, 1421*t*
 susceptibility testing and, 1301–1304
 thrombocytopenia caused by, 547*t*
- Antimicrotubule agents, in cancer
 chemotherapy, 1652*t*
- Antimigrainous agents, 963–965, 965*t*
- Antimitochondrial antibodies, in biliary
 cirrhosis, 693
- Antimitochondrial antibody-negative
 primary biliary cirrhosis, 693
- Antimonials, pentavalent, for
 leishmaniasis, 1488–1489
- Antimony. *See* Stibogluconate
- Antimotility drugs. *See* Antidiarrheal
 agents
- Anti-nAChR, in cancer-related
 neuropathy, 1024
- Anti-native DNA antibody, 833*t*, 834*t*
- Antineoplastic agents. *See* Chemotherapy
- Antineuronal nuclear antibodies
 (ANNA-1), neurologic
 paraneoplastic syndromes/
 achalasia and, 605
- Antineutrophil cytoplasmic antibody
 (ANCA), 833*t*
 in autoimmune hepatitis, 679
 in Churg-Strauss syndrome, 921*f*, 924
 in Crohn disease, 642
 in glomerulonephritis (pauci-
 immune), 849, 907, 919*t*,
 921*f*, **924**
 in granulomatosis with polyangiitis,
 833*t*, 848, 849, 924
 in microscopic polyangiitis, 851, 921*f*,
 924
 in primary sclerosing cholangitis, 709
- Anti-NMDA receptor-associated
 encephalitis, 995
- Antinuclear antibody (ANA), 833*t*
 in autoimmune hepatitis, 679
 in biliary cirrhosis, 693
 in granulomatosis with polyangiitis,
 833*t*
 in hyperthyroidism/Graves disease,
 1110, 1113
 in lupus/SLE, 114, 832, 833, 833*t*, 834*t*
 in mixed connective tissue disease/
 overlap syndrome, 842
 in nonalcoholic fatty liver disease, 684
 in polymyositis/dermatomyositis, 833*t*,
 841
 in rheumatoid arthritis, 827, 833*t*
 in scleroderma/CREST syndrome,
 833*t*, 839
 in Sjögren syndrome, 833*t*, 843
- Antioxidants. *See also* Vitamin C;
 Vitamin E
 for age-related macular degeneration,
 181
 in chemoprevention, 11
 lipid-lowering and, 1252
- Antiparkinsonism drugs, 999–1001, 999*t*
 for antipsychotic-induced side effects/
 parkinsonism, 1061
- Antiphlebotic stockings. *See* Compression
 stockings
- Antiphospholipid antibody syndrome/
 antiphospholipid antibodies,
799–800, 835–836
 cardiac involvement in, 428
 factor II antibodies and, 553
 false-positive syphilis tests and, 836
 livedo reticularis in, 836, 854
 pregnancy loss and, 789, 799, 834, 836
 in SLE, 833–834, 834, 834*t*
- α_2 -Antiplasmin deficiency, 552
- Antiplatelet antibody
 heparin-associated, 544
 reference values for, 1731*t*
 in immune thrombocytopenia, 540
 in posttransfusion purpura, 546
- Antiplatelet therapy. *See also* Aspirin
 for acute coronary syndromes,
 361–363, 362*t*
 for angina, 356
 for myocardial infarction, 362*t*, 367,
 371, 376
 peptic ulcer disease and, 615, 616
 perioperative discontinuation of, 49,
 52, 53*t*, 363
 for stroke, 982, 983
 thrombocytopenia caused by, 547*t*
 for transient ischemic attacks, 979
- α_1 -Antiprotease/antitrypsin
 in COPD/emphysema, 260, 261
 replacement therapy and, 264
 hepatocellular carcinoma and, 1604
 in protein-losing enteropathy, 631, 632
 reference values for, 1727*t*
- Antiproteinase-3 ANCA. *See* Proteinase-3
 ANCA
- Antipruritic agents
 systemic, 99
 topical, 94, 98*t*
- Antipsychotic drugs (neuroleptics),
 1055–1061, 1056*t*, 1057*t*,
 1060*t*. *See also specific type*
and agent
 abnormal movements caused by, 998,
 1004, 1060–1061
 adherence/nonadherence and, 1056, 1059
 for aggressive/violent behavior, 1078
 for alcoholic hallucinosis, 1082
 with antidepressants, 1058, 1065–1066,
 1069
 atypical. *See* Atypical antipsychotics
 for bipolar disease/mania, 1072
 breast cancer and, 1059
 clinical indications for, 1058
 for delirium, 64, 86, 1089
 postoperative, 53
 for dementia-associated behavior
 problems, 61–62, 1009, 1089
 for depression, 1058, 1069
 dosage forms and patterns of,
 1058–1059
 in elderly, 1058
 for hallucinogen overdose/toxicity,
 1583
 for Huntington disease, 1002
 lactation and, 1059
 for mania, 1072
 neuroleptic malignant syndrome
 caused by, 1060, 1565, 1574
 for OCD, 1044
 overdose/toxicity/side effects of, 1057*t*,
 1059–1061, 1060*t*, **1574**
 for parkinsonism, 1000
 parkinsonism (reversible) caused by,
 998, 1061
 for personality disorders, 1052–1053
 in pregnancy, 1060
 for psychedelic abuse/overdose, 1084
 for psychotic depression, 1058,
 1065–1066
 relative potency of, 1057*t*
 seizure threshold affected by, 1060
 for Tourette syndrome, 1005
- Antipyretic drugs, 36
 contraindications to in heat stroke,
 1549
- Antireflux surgery. *See* Fundoplication
- Antiretroviral therapy/HAART, 4, 1319,
 1340–1349, 1341–1342*t*,
 1348*f*. *See also specific agent*
- adherence and, 1, 1340, 1340–1342,
 1347
- antituberculous drug interactions and,
 285, 1326, 1344
- CMV disease control and, 187, 598,
 1364, 1365, 1366
- combinations/regimens for, 1340, 1342,
 1343, 1347–1348, 1348*f*
 fixed-dose preparations and, 1343,
 1347, 1348*f*
- drug holidays/structured treatment
 interruptions and, 1343,
 1348
- drug resistance and, 675–676, 1340,
 1342, 1347, 1348–1349, 1348*f*
- gynecomastia and, 1178
 for hepatitis B, 675–676, 1343
 HIV transmission affected by, 1333,
 1340
- immune reconstitution disease and,
 1333
 corticosteroids in management of,
 1339
 Kaposi sarcoma flare and, 1331,
 1332
 Kaposi sarcoma flare and, 1331, 1332

- lipid abnormalities/lipodystrophy/
lipatrophy and, 1036, 1160,
1332, 1343, 1344
- myopathy caused by, 1036, 1328
- neuropathy caused by, 1328, 1343
- opportunistic infection/malignancies
and, 1339
- oral contraceptive drug interaction
and, 770
- postexposure, 4, 1336
after needle stick, 1335–1336
after sexual assault/rape, 1291
after sexual/drug use exposure, 1336
- preexposure/prophylactic, 4, 1291
- pregnancy/newborn and, 805, 1321, 1336
after rape/sexual assault, 1291
- Anti-Rh₀ (D) antibody
in hemolytic disease of newborn, 785–
786
prenatal screening for, 783, 784, 786
- Anti-ribonuclear protein (anti-RNP)
antibody, 842
- Anti-RNA polymerase III antibody, in
scleroderma, 839
- Anti-SCL-70 antibody, 833*t*
- Antisecretory agents. *See* Acid-
antisecretory agents
- Antiseizure therapy. *See* Anticonvulsant
therapy
- Anti-signal recognition particle (anti-
SRP) antibody, in
polymyositis/
dermatomyositis, 841
- Anti-SLA, in autoimmune hepatitis, 679
- Anti-Smith (anti-Sm) antibody, in lupus/
SLE, 114, 833, 833*t*, 834*t*
- Anti-smooth muscle antibodies
in autoimmune hepatitis, 679
in nonalcoholic fatty liver disease, 684
- Antisocial personality disorder, 1051,
1052*t*, 1053
- Antispasmodic agents, for irritable bowel
syndrome, 634–635
- Anti-SRP antibody, in polymyositis/
dermatomyositis, 841
- Anti-SS-A/Ro antibody, 833*t*
in lupus/SLE, 114, 833*t*
in Sjögren syndrome, 833*t*, 843
- Anti-SS-B/La antibody, 833*t*
in lupus/SLE, 114, 833*t*
in Sjögren syndrome, 833*t*, 843
- Antistreptolysin O (ASO) titers
in postinfectious glomerulonephritis,
922
in rheumatic fever, 418
- Antisynthetase syndrome, 841
- Antithrombin, reference values for, 1727*t*
- Antithrombotic therapy, 554–563. *See*
also Anticoagulation therapy;
Antiplatelet therapy;
Thrombolytic therapy
for immobilized patient, 65
for myocardial infarction, 363, 371
PCI and, 357
- Antithymocyte globulin
for aplastic anemia, 509
for myelodysplastic syndromes, 518
- Antithyroid (antithyroglobulin/
antithyropoxidase)
antibodies, 1105*t*
in hepatitis C, 1106
in hyperthyroidism/Graves disease,
1105*t*, 1110, 1113
thiourea treatment and, 1114
in hypothyroidism, 1105*t*, 1107
in thyroid nodules, 1123
in thyroiditis
Hashimoto, 1117, 1119–1120, 1121,
1122
postpartum, 1120
- Anti-TNF agents. *See also specific agent*
adverse effects of, 640, 830
for ankylosing spondylitis, 855
antibodies to, 640
for gram-negative bacteremia/sepsis,
1444–1445
for inflammatory bowel disease, 640
Crohn disease, 642, 644–645
ulcerative colitis, 648
for psoriasis/psoriatic arthritis, 108,
856
for rheumatoid arthritis, 830
in combination regimen, 830, 831
tuberculosis reactivation and, 640, 830,
1281
- Antitoxin
botulinus, 1034, 1431
diphtheria, 1434
- Anti-Tr antibody, in autoimmune
paraneoplastic disorders, 994
- α_1 -Antitrypsin/antiprotease
in COPD/emphysema, 260, 261
replacement therapy and, 264
hepatocellular carcinoma and, 1604
in protein-losing enteropathy, 631, 632
reference values for, 1727*t*
- Anti-tTG (transglutaminase/tissue
transglutaminase) antibody,
in celiac disease/dermatitis
herpetiformis, 123, 622
- Antituberculous drugs, 4, 283–287, 284*t*,
289*t*
antiretroviral drug interactions and,
285, 1326, 1344
directly observed therapy (DOT) and,
284, 285, 286
drug-resistant disease and, 280, 281,
281*t*, 285, 286
tests in identification of, 281, 281*t*,
285
treatment of contacts and, 286
for extrapulmonary disease, 285
in fixed dose combinations, 285
hepatotoxicity of, 4
in HIV-negative persons, 284–285, 289*t*
in HIV-positive persons, 4, 285, 1326
drug-resistant disease and, 280, 281,
281*t*, 1326
prophylactic, 4, 1334, 1337
in latent disease/chemoprophylactic,
280, 286–287
for meningitis, 1459–1460
monitoring therapy with, 286
during pregnancy/lactation, 285–286,
287, 805
for tuberculous pericarditis, 420
- Anti-VEGF therapy. *See also specific agent*
for age-related macular degeneration,
181
for breast cancer, 741
for colorectal cancer, 1625
for diabetic retinopathy, 185, 1223
in lung cancer, 1600
for renal cell carcinoma, 1641
for retinal vein occlusion, 182
- Antivenin
for black widow spider bites, 1590
for scorpion stings, 1590
for snake bites, 1566*t*, 1590
- Antiviral agents, 1353–1354*t*. *See also*
specific agent or infection
for ophthalmic disorders, 168–169*t*
- Anti-voltage-gated calcium channel
antibody, in autoimmune
paraneoplastic disorders, 994
- Anti-voltage-gated potassium channel
antibody, in autoimmune
paraneoplastic disorders, 995
- Anti-Yo antibody, in autoimmune
paraneoplastic disorders, 994
- Anti-Zic antibody, in autoimmune
paraneoplastic disorders, 994
- Antizol. *See* Fomepizole
- Anton syndrome, 991
- Anus. *See also under Anal*
carcinoma of, 1612*t*, 1629–1630
in HIV infection/AIDS, 1332, 1629
rectum protruding through (rectal
prolapse), 657
- Anxiety/anxiety disorders, 1040–1045,
1042*t*, 1043*t*
anticipatory, 1041
chronic pain and, 1047
drugs for management of, 1042–1044,
1042*t*, 1043*t*
generalized, 1041, 1042–1044, 1042*t*,
1043*t*
hospitalization/illness and, 1089, 1090,
1091
hyperventilation/respiratory alkalosis
and, 318, 896, 896–897
palpitations in, 31, 32
panic disorders and, 1041
personality disorder and, 1051
in pheochromocytoma, 1167
pre- and postsurgical, 1090, 1091
in schizophrenia/psychotic disorders,
1054
- Anxiolytic drugs. *See also specific type*
- Aorta. *See also under Aortic*
atherosclerotic/occlusive disease of,
464–465
coarctation of. *See* Coarctation of aorta
in Marfan syndrome, 428, 431, 1670, 1671
traumatic injury to, 428, 431
- Aortic aneurysms
abdominal, 472–474
screening for, 6, 7*t*, 473
smoking and, 6, 473
abdominal pain caused by, 472, 473
atherosclerosis and, 472, 473, 474
back pain caused by, 472, 474, 820
inflammatory, 472, 473
in Marfan syndrome, 428, 474, 1670,
1671
ruptured, 473, 474
smoking and, 6, 473
in syphilis, 474, 1471, 1471*f*
thoracic, 474–475
giant cell arteritis and, 846, 847

- Aortic arch
 abnormalities of in tetralogy of Fallot, 331
 aneurysm of, 475
 superior vena caval obstruction and, 482
 narrowing of in coarctation of aorta, 326
- Aortic dissection, **476–478**
 aortic regurgitation and, 345
 chest pain/discomfort in, 29, 355, 477
 hypertension and, 439, 477
 management of, 461*f*, 477
 in Marfan syndrome, 428, 1670, 1671
 in pregnancy, 431
 in Turner syndrome, 1187
- Aortic regurgitation, 334–336*t*, **344–346**
 in Marfan syndrome, 345, 428, 1670
 preoperative evaluation/perioperative management and, 49
- Aortic root dilation
 aortic regurgitation and, 345
 aortic stenosis and, 342, 343
 in Marfan syndrome, 1670, 1671
 mitral valve prolapse and, 340
- Aortic sclerosis, 333, 342
- Aortic stenosis, 334–336*t*, **342–344**
 atherosclerosis and, 333, 342
 calcific/degenerative, 333, 342, 343
 interventions affecting murmur in, 337*t*
 preoperative evaluation/perioperative management and, 49
 syncope and, 342, 396
- Aortic valve, in rheumatic fever/heart disease, 417
- Aortic valve repair, 349
- Aortic valve replacement, 343–344, 345, 349. *See also* Valve replacement
- Aortic valve rupture, 428
- Aortitis, in rheumatoid arthritis, 827
- Aortoenteric fistula, GI bleeding and, 581
- Aorto-femoral bypass, for aortoiliac occlusive disease, 465
- Aortoiliac occlusive disease, **464–465**
- Aorto-visceral bypass, for visceral ischemia, 471
- APACHE system
 in pancreatitis, 712
 prognosis at end of life and, 87
 septic shock and, 489
- Apallic state (persistent vegetative state), **1016**
- Apathetic hyperthyroidism, 1114, 1118
- Apathy, in dementia, 1006, 1009
- APC gene, 653, 655, 1622, 1623
 screening for, 655, 1623
- APECED. *See* Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy
- Aphasia
 dementia and, 59
 intracranial tumors causing, 989, 990
 progressive nonfluent, 1008*t*
 stroke causing, 981
- Aphonia, in conversion disorder, 1045
- Aphthous ulcer, **227, 227*f***
 in Behçet syndrome, 853
- in Crohn disease, 641
 in HIV infection/AIDS, 1329
- API2-MALT1* gene translocation, in gastric lymphoma, 1619
- Apical ballooning syndrome. *See* Tako-Tsubo (stress/catecholamine-induced) cardiomyopathy
- Apical impulse
 in aortic regurgitation, 345
 in cardiomyopathy, 414
- Apicitis, petrous, 204–205
- Apidra. *See* Insulin glulisine
- Apixaban, for atrial fibrillation, 387
- APL. *See* Acute promyelocytic leukemia
- Aplastic anemia, **508–509**, 508*t*
 stem cell transplantation for, 509, 533, 539–540
 thrombocytopenia in, 508, 538, 539–540
- Aplastic crises
 in erythrovirus (parvovirus) infection, 1402, 1403
 in hereditary spherocytosis, 501
 in sickle cell disease, 503, 504
 in thalassemia, 495
- Apnea, sleep. *See* Sleep apnea
- Apnea test, 1015
- Apneustic breathing, in coma or stupor, 1014
- ApoE genotyping, in Alzheimer disease, 1007
- APOL-1* gene, in chronic kidney disease, 439, 908
- Apparent mineralocorticoid excess
 genetic mutation in, 437, 878*t*
 hypertension and, 437
- Appearance, in schizophrenia/psychotic disorders, 1054
- Appendectomy, 631
 carcinoid tumors and, 1621
 during pregnancy, 807
 ulcerative colitis risk and, 646
- Appendiceal carcinoids, 1621
- Appendicitis, **630–631**
 adenoviruses causing, 1402
 amebic, 1503
 in pregnancy, 630, **807**
- Appetite, genes affecting control of, 1259
- Apprehension test
 for knee, 1697*t*, 1701
 for shoulder, 1679*t*, 1681
- Apraclonidine
 for glaucoma/ocular hypertension, 170*t*, 177
 overdose/toxicity of, 1577
- Apraxia
 in dementia, 59, 1006
 intracranial tumors causing, 991
- Aprepitant, 569, 569*t*, 1660
- Apresoline. *See* Hydralazine
- Apriso. *See* Mesalamine
- APS. *See* Antiphospholipid antibody syndrome
- Aptivus/Norvir. *See* Tipranavir, with ritonavir
- aPTT. *See* Partial thromboplastin time
- Aqua glycolic, 98*t*
- Aquaphor, 94, 98*t*
- Aquaporin-4, in neuromyelitis optica, 1012
- Aqueous tear deficiency, 166
- Aquinil. *See* Hydrocortisone
- Ara-C. *See* Cytarabine
- Arachnodactyly, in Marfan syndrome, 1670
- Aranesp. *See* Darbepoetin alfa
- Arbovirus encephalitides, **1378–1380**
- ARBs. *See* Angiotensin II receptor blocking agents
- Arcanobacterium haemolyticum*, 1419
- Arch aneurysms, 475
 superior vena caval obstruction and, 482
- Arcing (flash) burns, 1552
- ARDS. *See* Acute respiratory distress syndrome
- Aredia. *See* Pamidronate
- AREDS (Age-Related Eye Disease Study), 181
- Arenaviruses, hemorrhagic fever caused by, 1384, 1385
- Arg133Trp* (*PAX-4*) mutation, in idiopathic type 1 diabetes mellitus, 1194
- Argatroban, for heparin-induced thrombocytopenia, 544, 544*t*
- Arginine/GHRH stimulation testing, 1095
- Arginine vasopressin, in diabetes insipidus, 1098
- Argyll Robertson pupils, in tabes dorsalis, 1472
- Arimidex. *See* Anastrozole
- Aripiprazole, 1055, 1056*t*, 1057*t*, 1058
 for bipolar disease/mania, 1072
 for depression, 1058, 1069
 overdose/toxicity of, 1057*t*, 1058, 1060*t*, 1574
- Arm edema, in breast cancer/postmastectomy, 727, 744
- Armadillos, in leprosy testing, 1460
- Armour thyroid, for hypothyroidism, 1108
- Arnold-Chiari malformation
 cough headache and, 966
 syringomyelia and, 1018, 1019
- Aromasin. *See* Exemestane
- Aromatase inhibitors/inactivators, 1656*t*
 adverse effects of, 740, 1656*t*
 for breast cancer treatment/prevention, 723, 738, 739, 740
 in male, 746
 in neoadjuvant therapy, 738
 for endometriosis, 761
 for gynecomastia, 1179
- Arousal (excitement) stage of sexual activity, 1049
- disorders related to, 1049–1050, 1050–1051. *See also* Sexual dysfunction
 in female, 766, 767, 1714
- Arrhythmias, **376–393**. *See also specific type and* Electrocardiogram
 in angina, 352
 antidepressants causing, 1068, 1564, 1591, 1591*f*
 in atrial septal defect, 328
 in cardiomyopathy, 411, 414
 in COPD, 261, 264
 in cor pulmonale, 426

- in electrical injury, 1553
 in heart failure, 400, 405
 in hypocalcemia, 882
 in hypothermia, 1544, 1544f
 in infectious myocarditis, 409, 410
 myocardial infarction and, 365, 372–373
 antiarrhythmic prophylaxis/
 treatment and, 371, 372–373, 376
 palpitations and, 30–32, 32t
 in pheochromocytoma, 1167, 1169
 in poisoning/drug overdose, **1564**, 1564t. *See also specific agent*
 with antiarrhythmic drugs, 1564, 1588
 with antidepressants, 1068, 1564, 1591, 1591f
 with antipsychotic drugs, 1059, 1574
 with digitalis glycosides, 404, 1564
 with phenothiazines, 1574
 with solvents, 1583, 1588
 with theophylline, 1591
 preoperative evaluation/perioperative management of, 46, 49
 seizures differentiated from cerebral hypoperfusion caused by, 971
 sinus, **380–381**
 in sleep apnea, 319
 syncope caused by, 396, 397
 in tetralogy of Fallot, 332
 treatment of
 catheter ablation for, 380
 pharmacologic, 377, 378–379t. *See also Antiarrhythmic drugs*
 in valvular heart disease, 334t
 ARS. *See* Acute radiation syndrome
 Arsenic poisoning, 1566t, **1574–1575**
 Arsenic trioxide, 1574, 1655t
 toxicity of, 1575, 1655t
 Arsenical melanosis, 155, 1574
 ART. *See* Antiretroviral therapy/HAART;
 Assisted reproductive technologies
 Artane. *See* Trihexyphenidyl
 Artemether
 for malaria, 1492t, 1494t, 1496–1497
 with lumefantrine (Coartem/
 Riamet), 1492t, 1493t, 1494t, 1496, 1497
 for schistosomiasis, 1512
 Artemisinins (qinghaosu)/artemisinin derivatives/combinations, 1492, 1492t, 1493, 1493t, 1496–1497
 self-treatment and, 1498
 teratogenicity of, 1497
 Arterial aneurysms. *See specific type and*
 Aneurysms
 Arterial blood gases
 in acid-base disorders, 888–889
 in asthma/asthma exacerbation, 246, 247t
 in COPD, 260t, 261
 in cystic fibrosis, 267
 in dyspnea, 25
 home oxygen therapy and, 262, 262t
 in near drowning, 1556
 in *Pneumocystis pneumonia*, 1534
 preoperative, 51
 in pulmonary embolism, 298
 in respiratory failure, 319–320
 ventilatory control and, 317
 Arterial embolism. *See* Embolism;
 Thromboembolism;
 Thrombosis
 Arterial graft/prosthesis. *See* Bypass grafting
 Arterial lines
 in burn care, 1550
 health care-associated infection and, 1284
 in shock management, 486
 Arterial occlusion
 acute, **468–469**. *See also* Arterial thrombosis
 atherosclerotic, **464–471**. *See also*
 Atherosclerosis
 peripheral artery aneurysms and, 476
 Arterial thrombosis. *See also* Thrombosis
 acute occlusion of limb caused by, 468
 in antiphospholipid antibody syndrome, 835
 in homocystinuria and, 1669
 Arteriography. *See specific type and*
 Angiography
 Arteriolar dilators. *See also* Vasodilator therapy
 for hypertension, 453, 456t
 Arteriopathy, plexogenic pulmonary (idiopathic/primary pulmonary hypertension), 304, 423, 424, 425
 Arteriovenous fistulae, spinal dural, 989
 Arteriovenous malformations
 gastrointestinal (angioectasias), bleeding from, 581, 584, 586, 587
 in hereditary hemorrhagic telangiectasia, 1671, 1672
 intracranial, 980t, **987–988**. *See also*
 Stroke
 aneurysms and, 985, 987
 intracerebral/subarachnoid hemorrhage and, 984, 985, 987
 pulmonary, 1671, 1672
 spinal cord, 990
 Arteriovenous sheathotomy, for retinal vein occlusion, 182
 Arteritis. *See also* Polyarteritis
 coronary artery, 428
 in Kawasaki disease, 428, 1417
 giant cell. *See* Giant cell (temporal/cranial) arteritis
 glomerulonephritis in, 919t
 in thromboangiitis obliterans (Buerger disease), 472
 Artesunate, 1492t, 1493, 1494t, 1496–1497
 with amodiaquine (ASAQ), 1493t, 1494t, 1495, 1496
 with mefloquine, 1493t, 1495, 1496
 for severe malaria, 1493, 1494t, 1497
 with sulfadoxine-pyrimethamine, 1493t, 1496
 Arthritis/arthralgia
 in alkaptonuria, 1665
 in ankylosing spondylitis, 855, 857
 arthroplasty/joint replacement for, 812, 1690, 1691–1692, 1702
 coagulase-negative staphylococcal infection and, 1428
 DVT/PE (venous thromboembolic disease) prevention and, 555t
 osteomyelitis and, 862
 back pain caused by, 819
 in Behçet syndrome, 853
 bursitis differentiated from, 825
 cancer-associated, 864
 in Chikungunya fever, 1392, 1393
 chondroitin/glucosamine for, 812, 1702
 in coccidioidomycosis, 863, 1532
 in Crohn disease, 641, 858
 crystal deposition, **812–817**, 813f, 813t, 815t
 degenerative, **809–812**, 811f. *See also*
 Osteoarthritis
 diagnosis and evaluation of, 809, 810t, 811t
 in erythrovirus (parvovirus) infection, 861, 1402
 rheumatoid arthritis differentiated from, 828, 861
 exercise/activity in management of, 12–13, 811
 extra-articular manifestations and, 809
 glucosamine/chondroitin for, 812, 1702
 gonococcal, **860**, 1302t, 1452
 gouty. *See* Gout/gouty arthritis
 in granulomatosis with polyangiitis, 849
 in hemophilia, 549–550, 550
 in Henoch-Schönlein purpura, 852, 923
 in hepatitis, 861
 rheumatoid arthritis differentiated from, 828, 861
 of hip, **1691–1692**
 in HIV infection/AIDS, 861, 1328
 infectious, **858–861**
 in drug users, 859, 1292
 inflammatory intestinal diseases and, 641, **858**
 joint involvement pattern and, 809, 810t
 leukemic, 864
 Lyme, 1479, 1482, 1482t
 rheumatoid arthritis differentiated from, 828
 mutilans, 856
 neck pain caused by, 818, 1029, 1686
 nongonococcal bacterial (septic), **858–859**, 1302t
 in drug users, 859, 1292
 rheumatoid arthritis and, 827, 859
 pneumococcal, 1423
 pseudoseptic, 859
 psoriatic, 106, **856–857**
 reactive. *See* Reactive arthritis
 in rheumatic fever, 418
 rheumatoid arthritis differentiated from, 828
 rheumatoid. *See* Rheumatoid arthritis
 rubella/rubella vaccination and, 861, 1374, 1375
 in sarcoidosis, **864**
 septic. *See* Arthritis/arthralgia, nongonococcal bacterial

- Arthritis/arthralgia (*Cont.*):
 in SLE, 833
 rheumatoid arthritis differentiated
 from, 828
 in Still disease, 831
 streptococcal, 1421
 surgery for, 812, 1690, 1691–1692, 1702
 tophaceous, 812, 813, 813f, 816
 rheumatoid arthritis differentiated
 from, 814
 tuberculous, **864**
 in ulcerative colitis, 858
 viral, **861**
 in Whipple disease, 623, 858
- Arthrocentesis, 809, 810t, 811t, 1674. *See also* Synovial fluid examination
- Arthropathy, neurogenic. *See* Neurogenic arthropathy
- Arthroplasty. *See* Joints, replacement of
- Arthropods
 in encephalitis, **1378–1380**
 skin lesions caused by, **148–150**. *See also specific cause*
- Arthroscopy
 for ACL repair, 1698
 for meniscal injury, 1700
 in osteoarthritis, 812, 1702
- Artificial insemination, 769
- Artificial nutrition. *See* Nutritional support
- Artificial sweeteners, for diabetics, 1205
- Artificial tears, for dry eye, 166, 843
- Aryepiglottic folds, cancer of, 236, 237
- Arytenoid cartilage, contact ulcers/
 granulomas of, 235
- Arzerra. *See* Ofatumumab
- 5-ASA. *See* 5-Aminosalicylic acid
- Asacol. *See* Mesalamine
- ASAQ (artesunate-amodiaquine), 1493t, 1494t, 1495, 1496
- Asbestosis (asbestos exposure), **309, 309t**
 lung cancer and, 309, 311, 1595, 1602
 mesothelioma and, 311, 591, 1602
 pleural effusion and, 311
 smoking and, 309, 311
- ASC-US. *See* Atypical squamous cells of unknown significance
- ASCA. *See* *Saccharomyces cerevisiae* antibodies
- Ascaris lumbricoides* (ascariasis), **1517**
 eosinophilic pulmonary syndromes and, 296, 1517
- Ascites, **587–589, 587t**. *See also specific causative disorder*
 bile, 591
 chylous, 588, 591, 1645
 in cirrhosis, 686, 687–689, 692t
 in constrictive pericarditis, 422
 in heart failure, 699
 malignant, 588, **590–591**, 1645, 1646
 neutrocytic, 588, 589, 590
 in noncirrhotic portal hypertension, 700
 pancreatic, 588, 591, 711, 713, 717
 perioperative complications and, 52
 spontaneous bacterial peritonitis and, 588, **589–590**, 689
- Ascites albumin gradient, serum (SAAG). *See* Serum-ascites albumin gradient
- Ascitic fluid analysis/examination, 588.
See also Paracentesis
 in ascites, 588
 in bacterial peritonitis, 588, 589, 590, 689
 in bile ascites, 591
 in chylous ascites, 588, 591
 in cirrhosis, 588, 687–688
 culture/Gram stain, 588, 589
 in malignant ascites, 590
 in mesothelioma, 591
 in pancreatic ascites, 588, 591, 711, 713
 in peritoneal carcinomatosis, 588, 590
 in tuberculous peritonitis, 588
- Ascorbic acid. *See* Vitamin C
- ASD. *See* Atrial septal defect
- Asenapine, 1056t, 1058, 1060t
- Asendin. *See* Amoxapine
- Aseptic meningitis, 1286, 1286t. *See also* Meningitis
 coxsackieviruses causing, 1286, 1406
 echoviruses causing, 1286, 1407
 herpes simplex causing, 1286, 1351, 1352, 1355
 leptospiral, 1286, 1478
 in Lyme disease, 1023, 1286, 1479, 1481
 mumps/mumps vaccine and, 1286, 1370, 1371
 in syphilis, 1286, 1469, 1472
 in tick-borne encephalitis, 1391
- Ash leaf spots (hypopigmentation), in
 tuberous sclerosis, 996
- Asherman syndrome, 1181
- ASO titers. *See* Antistreptolysin O (ASO) titers
- Asparaginase, 1655t
- Aspartame, for diabetics, 1205
- Aspartate aminotransferase (AST), 664, 664t. *See also*
 Aminotransferase levels
 in acute fatty liver of pregnancy, 795
 in alcoholic liver disease, 681
 in cirrhosis, 686
 in hemochromatosis, 695
 in liver disease/jaundice, 664, 664t
 in nonalcoholic fatty liver disease, 684, 685
 reference/normal values for, 664t, 1727t
 in viral hepatitis, 666
- Aspergilloma, 1537, 1538
- Aspergillus/Aspergillus fumigatus* (aspergillosis), **1537–1538**
 allergic bronchopulmonary, **266–267**, 1537, 1538
 chronic necrotizing, 1537, 1538
 in immunocompromised host/HIV infection/AIDS, 213, 1537
 invasive, 217, 1537, 1538, 1542
 opportunistic mold infection differentiated from, 1540–1541
 prevention of, 1537
 sinusitis and, 217, 1537, 1538
- Asphyxia
 aspiration of inert material causing, 308
 in severe asthma exacerbation, 256
- Aspiration, **307–308**
 caustic esophageal injury and, 599
 in drowning/near drowning, 1556
 enteral nutritional support and, 1273
 of food (café coronary), **308**
 foreign body, 238–239
 retention of, **308**
 of gastric contents
 acute (Mendelson syndrome), **308**, 1283
 chronic, **308**
 in comatose patient, 1562
 in pneumonia. *See* Pneumonia, aspiration
 of inert material, **308**
 of toxic material, **308**
 petroleum distillates, 308, 1587–1588
- Aspirin, 76, 77t. *See also* Antiplatelet therapy; Salicylates
 for acute coronary syndromes, 361, 362t
 in analgesic nephropathy, 932–933
 for angina, 356
 for atrial fibrillation, 386
 bleeding caused by, 76, 583, 612, 616
 breastfeeding and, 782t
 after cardiac valve replacement surgery, 349
 for chemoprevention, 7t, 11
 atherosclerosis/cardiovascular/heart disease prevention and, 7t, 11, 1253
 in diabetics, 1203, 1227
 in women, 1707
 in colorectal cancer, 1623
 with codeine, 83t
 COX-1/COX-2 affected by, 611
 coxib/NSAID coadministration and, 612, 616
 for essential thrombocytosis, 513, 514
 for fever, 36
 GI/diverticular bleeding associated with, 76, 583, 612, 616
 iron deficiency and, 491
 for myocardial infarction, 362t, 367, 371, 376
 after thrombolytic therapy, 369
 nasal polyps and asthma as
 contraindication to, 222
 overdose/toxicity of, 76, 1588–1589
 for pain management, 76, 77t
 in peptic ulcer disease, 611, 612, 615, 616. *See also* Peptic ulcer disease, NSAID-induced
 for pericarditis, 420
 platelet function affected by, 549, 549t
 for polycythemia, 512–513
 reference values for, 1734t
 Reye syndrome and, 76, 1359, 1360, 1395
 for rheumatic fever, 418
 for stroke/stroke prevention, 7t, 11, 982
 for transient ischemic attacks, 979
 for transient monocular blindness, 184
 uricosuric drugs and, 815
- Asplenia
 fever management and, 36
 immunization recommendations in, 1309t
- Assist-control (A-C) ventilation, for
 respiratory failure, 321

- Assisted reproductive technologies, 769, 956
- Assistive devices
fall prevention and, 66
hearing rehabilitation and, 199
stroke rehabilitation and, 983
- AST. *See* Aspartate aminotransferase
- Astemizole, antidepressant drug
interactions and, 1068, 1071*t*
- Astereognosis, intracranial tumors
causing, 991
- Asthma, 243–259
allergic, 243, 248
desensitization therapy/
immunotherapy for, 249*f*,
252*t*, 253
allergic bronchopulmonary mycosis/
aspergillosis and, 266, 1537
aspirin triggering (triad asthma), 222,
243
β-adrenergic agents for
long-acting, 249*f*, 250–252, 251*t*, 253
short-acting, 244*f*, 245*t*, 249*f*, 254*t*,
255, 256, 257*f*, 258*f*, 259
bronchial provocation testing in,
246–247
cardiac, 243
catamenial, 243
classification/diagnosis of, 243–248,
244*f*, 245*t*, 246*t*, 247*t*,
248–250, 249*f*
comorbid conditions and, 248, 249*f*
complications of, 248
controller medications for, 249*f*, 250
COPD differentiated from, 248, 261
cough and, 21, 22, 22*t*, 244
differential diagnosis of, 248
drugs causing, 243, 312*t*
dyspnea in, 24, 246*t*
estrogen replacement therapy and,
1183
exacerbations of
classification of severity of, 243–248,
244*f*, 245*t*, 246*t*, 247*t*, 248
treatment of, 244*f*, 245*t*, 246*t*,
253–256, 254–255*t*, 256–259,
257*f*, 258*f*
exercise-induced, 243, 247
GERD and, 594, 596
hypophosphatemia and, 885
incidence/prevalence of, 243
mediator inhibitors for, 250, 251*t*
NAEPP 3 diagnosis/management
guidelines for, 244*f*, 245*t*,
246*t*, 248–250, 249*f*
occupational, 243, 310
perioperative pulmonary
complications and, 50, 51
during pregnancy, 803
pulmonary function testing in, 244*f*,
245*t*, 246–247, 246*t*, 247*t*,
256, 257
reliever medications for, 249–250, 249*f*,
253–256, 254–255*t*
severity/control of, assessing/
monitoring, 243–248, 244*f*,
245*t*, 246*t*, 247*t*, 248
treatment of, 244*f*, 245*t*, 246*t*, 248–250,
249*f*, 250–256, 251–252*t*,
253*t*, 254–255*t*
desensitization/immunotherapy in,
249*f*, 252*t*, 253
for exacerbations, 244*f*, 245*t*, 246*t*,
253–256, 254–255*t*, 256–259,
257*f*, 258*f*
inhalation therapy, 250, 253*t*, 254*t*,
255, 256, 257*f*
long-term control medications for,
249*f*, 250, 250–253, 251–252*t*,
253*t*
NAEPP 3 guidelines for, 244*f*, 245*t*,
246*t*, 248–250, 249*f*
pharmacologic, 244*f*, 245*t*, 248–250,
249*f*, 250–256, 251–252*t*,
253*t*, 254–255*t*, 256–259,
257*f*, 258*f*
in pregnant patient, 803
quick relief medications for, 249–
250, 249*f*, 253–256, 254–255*t*
stepwise approach to, 244*f*, 245*t*, 249*f*
triad, 222
vaccinations for patients with, 253
vocal fold disorders differentiated
from, 242, 248
Asthma action plan, 248, 256
Astigmatism, 162
Astrocytoma, 990*t*, 1611*t*
Astroviruses, diarrhea/gastroenteritis
caused by, 1293, 1404–1405
Asymmetric septal hypertrophy, 414
At-risk (problem) drinking, 18, 1080. *See*
also Alcohol use/dependency/
abuse
differential diagnosis of, 1081
treatment of, 1081–1082
Atabrine. *See* Quinacrine
Atacand/Atacand HCT. *See* Candesartan
Atactic breathing, in coma or stupor,
1014
Ataxia
in acute high-altitude cerebral edema,
1559
fragile-X tremor-ataxia syndrome and,
1667
Friedreich, 1022
intracranial tumors causing, 991
in varicella, 1359
Ataxia-telangiectasia mutation
breast cancer risk and, 722
pancreatic/periampullary carcinoma
and, 1608
Atazanavir, 1342*t*, 1344, 1345, 1348*f*. *See*
also Antiretroviral therapy/
HAART
with ritonavir, 1345, 1347
Atelectasis
in bronchial obstruction, 243
mechanical ventilation and, 321
pleural effusion and, 313
in right middle lobe syndrome, 291
Atenolol, 447*t*
for alcohol withdrawal, 1083
for hypertension, 447*t*, 449
in diabetics, 1202
for Marfan syndrome, 1671
perioperative, 47
ATF ligament. *See* Anterior talofibular
ligament
ATG. *See* Antithymocyte globulin
Atherogenesis. *See also* Atherosclerosis
Atherosclerosis, 464–471. *See also specific*
artery affected and
Cardiovascular disorders;
Vascular disorders
acute limb occlusion and, 468–469
aneurysms and, 472, 473, 474
aortic valvular disease and, 333
aortoiliac disease and, 464–465
cerebrovascular occlusive disease and,
469–470. *See also* Stroke
cholesterol/lipoproteins in, 350,
1245–1246, 1246
screening tests and, 1248–1252,
1249–1250*t*, 1251*t*
in women, 7*t*, 1248, 1251, 1706
coronary artery disease and. *See*
Coronary heart disease
in diabetes mellitus, 1227–1228
femoral/popliteal disease and, 465–466
homocysteine/hyperhomocysteinemia
and, 1668–1669
hypertension and, 439
lipid-lowering therapy and, 1246–1247,
1252–1255, 1255*t*. *See also*
Lipid-lowering therapy
in women, 1706–1707
lower leg/foot disease and, 466–468
myocardial infarction and, 365
renal artery stenosis/renal vascular
hypertension and, 437, 917
in SLE, 835
transient ischemic attacks and, 977, 978
visceral artery insufficiency and,
470–471
Atherosclerotic plaques. *See*
Atherosclerosis
Athletes
cardiovascular screening of, 431–432
female, eating disorders in (female
athlete triad), 1712–1713
heat exposure syndromes and, 1547,
1548
sports medicine injuries and,
1673–1705
sudden death of, 431–432
cardiomyopathy causing, 414, 431, 432
Athlete's foot, 111*f*, 112–113, 113*f*
cellulitis and, 112, 137
Ativan. *See* Lorazepam
ATL. *See* Adult T cell lymphoma/
leukemia
Atlantoaxial subluxation, neck pain
caused by, 818, 1029
ATM mutations, in chronic lymphocytic
leukemia, 522
ATN1 gene, in dentatorubral-
pallidoluyian atrophy, 1002
Atonic seizures (epileptic drop attacks),
970. *See also* Seizures
Atopic dermatitis, 103–105, 866
herpes simplex infection (eczema
herpeticum) and, 104, 1351,
1356*t*
photosensitivity and, 152
smallpox vaccination (eczema
vaccinatum) and, 104, 1403,
1404
vesiculobullous hand (pompholyx),
121–122, 121*f*
tinea differentiated from, 113

- Atopic disease (atopy), 866, **866–867**. *See also specific disorder and*
Allergies/allergic reactions
allergic bronchopulmonary mycosis/
aspergillosis and, 266, 1537,
1538
asthma and, 243
COPD and, 260
eosinophilic esophagitis and, 600
eye disease and, 166–167
- Atopic keratoconjunctivitis, 167
- Atopic-like dermatitis, 103
- Atorvastatin, 1253–1254, 1255*t*. *See also*
Statin drugs
with amlodipine, 454*t*
in HIV infection/AIDS, 1344
- Atovaquone
for malaria, with proguanil (Malarone),
1492*t*, 1494*t*, 1497
chemoprophylaxis and, 1497, 1498,
1498*t*
self-treatment and, 1498
for *P firoveci* infection, 1337*t*, 1338*t*,
1534, 1535
- ATPIA2* gene, in familial hemiplegic
migraine, 963
- ATP7B* in Wilson disease, 696, 697
- ATRA. *See* Tretinoin
- Atrial fibrillation, **384–388**, 385*t*
arterial emboli and, 384–385, 385*t*
anticoagulation in prevention/
management of, 385*t*, 386–
387, 388
limb occlusion and, 468
retinal artery occlusion and, 183
stroke and, 385, 385*t*, 386–387, 469,
982
transient ischemic attacks and, 385*t*,
469, 977, 978–979
in atrial septal defect, 328
in cardiomyopathy, 412, 414
catheter ablation of, 380, 388
in constrictive pericarditis, 422
in COPD, 261
in hyperthyroidism/thyrotoxicosis, 384,
1112, 1114, 1118
in mitral regurgitation, 339
in mitral stenosis, 338
in myocardial infarction, 372
palpitations and, 31
in preexcitation syndromes, 383, 384
preoperative evaluation/perioperative
management of, 49
recurrent paroxysmal, 388
refractory, 388
treatment of, 378–379*t*, 385–388
- Atrial flutter, **389**
in COPD, 261, 264, 389
reentry/preexcitation and, 383, 384, 389
- Atrial gallop. *See* Heart sounds
- Atrial myxoma, 426–427
fever/FUO and, 1277
herpes simplex virus and, 1352
- Atrial natriuretic peptide, in senile
amyloidosis, 531
- Atrial (supraventricular) premature beats
(atrial extrasystoles), **381**
in myocardial infarction, 372
- Atrial septal aneurysm, 328
- Atrial septal defect, **327–329**
- Atrial septal lipoma, 427
- Atrial tachycardia, multifocal, **389**
- Atrioventricular (heart) block, 373,
394–395
in atrial septal defect, 328
intra-ventricular conduction defects
and, 395–396
lithium use and, 1073
in Lyme disease, 1479, 1481–1482, 1482*t*
in myocardial infarction, 373
palpitations in, 31
in poisoning/drug overdose, 1564*t*
with antidepressants, 1068, 1591
- Atrioventricular canal defect, 329
- Atrioventricular dissociation, **395**
- Atrioventricular junctional rhythm, **390**
- Atrioventricular nodal reentry
tachycardia (AVNRT), 381
palpitations in, 31
- Atrioventricular pathways, accessory,
supraventricular tachycardia
caused by, 381, **383–384**
- Atrioventricular reentrant tachycardia
(AVRT), 381, 383
- Atripla. *See* Efavirenz, with tenofovir and
emtricitabine
- Atrophic age-related macular
degeneration, 181
- Atrophic gastritis
H pylori infection and, 610
in pernicious anemia, 497, 610
- Atrophic urethritis, urinary incontinence
and, 67
- Atrophic vaginitis
in menopause, 779, 780
urinary incontinence and, 67
- Atrophie blanche, 34
- Atropine
breastfeeding and, 782*t*
for cholinesterase inhibitor
(anticholinesterase)
poisoning, 1566*t*, 1587
with diphenoxylate. *See* Diphenoxylate
with atropine
for infarct-related heart block, 373
overdose/toxicity of, 1566*t*, **1575**
in terminally ill/dying patient, 91
- Atypical absence seizures, 970, 970*t*
- Atypical antidepressants, 1067–1068. *See*
also Antidepressants
- Atypical antipsychotics, 1055, 1056,
1056–1058, 1058, 1060*t*. *See*
also Antipsychotic drugs
for bipolar disease/mania, 1072
for dementia/dementia-associated
behavior problems, 61–62,
1009, 1089
for depression, 1058, 1069
in elderly, 1058
for Huntington disease, 1002
overdose/toxicity/side effects of, 1056–
1058, 1057*t*, 1059–1061, 1060*t*
for parkinsonism, 1000
for Tourette syndrome, 1005
- Atypical facial pain, **967–968**
- Atypical measles, 1356*t*, 1367–1368
- Atypical mycobacteria. *See*
Nontuberculous atypical
mycobacteria
- Atypical nevi/mole, **100–101**, 100*f*
- Atypical psychoses, 1054
- Atypical squamous cells of unknown
significance (ASC-US),
754*t*, 755
- Audiology, 198–199
- Audiovestibular disorders, 208, 209*t*, 210*t*,
212–213. *See also* Vestibular
disorders
autoimmune pattern of, 208, 210*t*
- AUDIT (Alcohol Use Disorder
Identification Test), 18, 19*t*
- Auditory adaptation, 212
- Auditory canal. *See* Ear canal
- Auditory hallucinations. *See also*
Hallucinations
intracranial tumors causing, 991
in schizophrenia/psychotic disorders, 1054
- Auer rods, in acute leukemia, 520
- Augmentation mammoplasty. *See* Breast
implants
- Augmentin. *See* Amoxicillin/amoxicillin-
clavulanate
- Aura
migraine headache, 964
pre-seizure, 971
- Auricle, **199**
- Austin Flint murmur, 345
- Austrian triad, 1423
- Autism, vaccines and, 1369
- Autoimmune cholangitis, 693
- Autoimmune disorders, **826–844**. *See also*
specific disease
cognitive disorders/delirium caused by,
1087*t*
common variable immunodeficiency
and, 868
diabetes and, 1192, 1193
fever/FUO and, 1276, 1277
hearing loss in, 208, 210*t*
in HIV infection/AIDS, 1322
myocarditis, 409, 409*t*, 410
silicone gel breast implants and, 721
- Autoimmune hemolytic anemia, **506–507**
with thrombocytopenia (Evans
syndrome), 506
- Autoimmune hepatitis, **678–680**
- Autoimmune (immunopathologic)
hypoglycemia, 1238, 1238*t*,
1243
- Autoimmune hypoparathyroidism, 1135
- Autoimmune neutropenia, 510
- Autoimmune pancreatitis, 715
- Autoimmune paraneoplastic disorders, 994
- Autoimmune polyendocrinopathy-
candidiasis-ectodermal
dystrophy, 1135, 1155. *See*
also Polyglandular
autoimmune syndrome
- Autoimmune regulatory gene, in type 1
diabetes, 1193
- Autoimmune retinal vasculitis, 178.
See also Uveitis
- Autoimmune thyroiditis. *See* Hashimoto
(chronic lymphocytic/
autoimmune) thyroiditis;
Transient autoimmune
thyroiditis
- Autoinflation, for eustachian tube
dysfunction/barotrauma,
201, 202

- Autologous packed red blood cells, transfusion of, 534. *See also* Transfusion
- Autologous serum eye drops, 166
- Autologous stem cell transplantation, 532. *See also* Bone marrow/stem cell transplantation
- Autologous tissue flaps, for breast reconstruction, 745
- Automatism, postepileptic, 970
- focal seizures and, 969
- Automobile accidents
- cardiac trauma and, 428
- prevention of injury caused by, 17
- Automobile driving
- by patients with dementia, 62, 1010
- by patients with syncope/ventricular tachycardia/aborted sudden death, 397–398
- by suicidal patients, 1065
- Autonomic dysfunction (dysautonomia), 975–976
- in diabetes, 1022, 1226–1227
- in focal seizures, 969
- in Guillain-Barré syndrome, 975, 1024
- in polyneuropathies, 975, 976, 1021
- prenatal screening for, 783
- Autonomic failure, pure, 975
- Autonomic neuropathy
- cancer-related, 1024
- chemotherapy-induced, 1661
- in diabetes, 1022, 1226–1227
- hypoglycemia and, 1222
- dysautonomia and, 975, 976, 1021
- in porphyria, 1022, 1664
- Autonomic testing
- in dysautonomia, 976
- in syncope, 397
- Autophony, patulous eustachian tube and, 202
- Autopsy, 93
- Autosomal dominant hypocalcemia with hypercalciuria (ADHH), 1136, 1137
- Autosomal dominant polycystic kidney disease, 934–935, 934*t*
- intracranial aneurysms and, 935, 986
- Autosomal recessive syndromes, diabetes mellitus in, 1195–1196
- AV block. *See* Atrioventricular (heart) block
- AV dissociation, 395
- AV junctional rhythm, 390
- AV nodal reentry tachycardia (AVNRT), 381
- palpitations in, 31
- AV reentrant tachycardia (AVRT), 381, 383
- Avalide. *See* Irbesartan/irbesartan with hydrochlorothiazide
- Avandamet. *See* Rosiglitazone, with metformin
- Avandaryl. *See* Rosiglitazone, with glimepiride
- Avandia. *See* Rosiglitazone
- Avapro. *See* Irbesartan
- Avascular necrosis of bone (osteonecrosis), 865
- corticosteroid use and, 865, 1190–1191
- dysbaric, 865
- of jaw, bisphosphonate use and, 11, 738, 865, 1147
- in sickle cell anemia, 503, 865
- Avastin. *See* Bevacizumab
- Aveno, 98*t*
- Aveno Anti-Itch lotion. *See* Pramoxine
- Avelox. *See* Moxifloxacin
- Aventis. *See* Insulin glargine
- Aventyl. *See* Nortriptyline
- Aversive conditioning. *See* Behavior modification
- Avian influenza (H5N1), 1395, 1396, 1397–1398. *See also* Influenza
- Avinza. *See* Morphine
- Avita. *See* Tretinoin
- AVM. *See* Arteriovenous malformations
- AVNRT (AV nodal reentry tachycardia), 381
- palpitations in, 31
- Avoidance therapy
- for allergic contact dermatitis, 124–125
- for allergic rhinitis, 219
- for rosacea, 128
- Avoidant personality disorder, 1051, 1052*t*
- AVR. *See* Aortic valve replacement
- AVRT (AV reentrant tachycardia), 381, 383
- Axilla, radial nerve lesions in, 1027
- Axillary lymph nodes, in breast cancer, 726, 727
- adjuvant/neoadjuvant therapy and, 736, 738–739
- dissection of, 735, 735*f*
- arm edema and, 744
- in breast-conserving therapy, 735
- irradiation of, 736, 739
- palpation for evaluation of, 726, 726*f*, 727
- prognosis and, 736, 736*t*, 743, 743*t*
- recurrence and, 744
- sentinel node biopsy and, 735, 735*f*
- arm edema avoidance and, 744
- Axillary vessels, compression of in thoracic outlet/cervical rib syndromes, 818
- Axillo-femoral bypass, for aortoiliac occlusive disease, 465
- Axiron, 1176. *See also* Testosterone replacement therapy
- Axonal injury, diffuse, 1017*t*
- Axonal neuropathies, 1020, 1024–1025. *See also specific type and* Guillain-Barré syndrome; Neuropathies
- in critically ill patient, 1024
- myeloma/paraproteinemias and, 1023
- toxic, 1024
- Aygestin. *See* Norethindrone
- Azacididine, 1651*t*
- for myelodysplastic syndromes, 518
- Azactam. *See* Aztreonam
- Azarcon, toxicity of, 1578*t*
- Azarga. *See* Brinzolamide/timolol
- Azathioprine
- for autoimmune hepatitis, 679–680
- for granulomatosis with polyangiitis, 850
- for inflammatory bowel disease, 639
- Crohn disease, 644
- with anti-TNF agents, 645
- ulcerative colitis, 649
- for microscopic polyangiitis, 851
- for pemphigus, 139
- Azelastine
- for allergic eye disease, 167, 169*t*
- for allergic/perennial rhinitis, 219
- Azidothymidine. *See* Zidovudine
- Azithromycin. *See also* Macrolides
- for endocarditis, 1438*t*
- for MAC prophylaxis/treatment, 1337, 1458, 1459
- for malaria, 1497
- for pharyngitis, 229, 1420
- for pneumonia, 273, 273*t*
- for syphilis, 1467
- Azo compounds, for inflammatory bowel disease, 638–639
- Azoospermia, 954*f*, 955
- artificial insemination for infertility caused by, 769, 956
- in cystic fibrosis, 267
- in Klinefelter syndrome, 1174
- Azopt. *See* Brinzolamide
- Azor (olmesartan with amlodipine). *See* Olmesartan/olmesartan HCTZ, with amlodipine
- Azotemia, 898, 902*t*. *See also* Kidney disease/injury
- heart failure and, 400
- in hepatorenal syndrome, 689
- in hyperglycemic hyperosmolar state, 1236
- hyperparathyroidism associated with, 1143–1144
- in obstructive uropathy, 932
- pancreatitis and, 713
- parenteral nutritional support and, 1274*t*
- postrenal, 902*t*, 903
- prerenal, 902–903, 902*t*, 904
- AZT. *See* Zidovudine
- Aztreonam, for pneumonia, 273*t*, 277*t*
- B19 parvovirus infection. *See* Erythrovirus (parvovirus B19) infection
- B antigen, in compatibility testing, 534
- B cell lymphoma, 524, 524*t*, 525. *See also* Non-Hodgkin lymphoma
- gastric, 1618–1619
- in HIV infection/AIDS, 1332, 1338*t*
- methotrexate causing, 829
- small intestine, 1620
- stem cell transplantation for, 532
- of thyroid, 1128, 1131, 1134
- B cells, pancreatic, 1171
- in diabetes mellitus, 1193, 1193*t*, 1194
- latent autoimmune diabetes of adulthood, 1193
- hypoglycemia caused by tumors of, 1172, 1189, 1238–1241, 1239*t*, 1240*t*. *See also* Insulinomas; Islet cell tumors
- B lymphocytes
- clonal malignancy of (chronic lymphocytic leukemia), 521–523

- B lymphocytes (*Cont.*):
 in common variable
 immunodeficiency, 869
 in HIV infection/AIDS, 1322
 in Waldenström macroglobulinemia, 529, 530
- B-raf/BRAF* gene/mutations
 clinical relevance of testing for, 1726*t*
 colorectal cancer/HNPCC and, 653, 656, 657, 1622, 1625
 papillary thyroid carcinoma and, 1126
- “B” symptoms, 525
- B-type natriuretic peptide (BNP/beta)
 in aortic regurgitation, 345
 in aortic stenosis, 343, 344
 in cardiomyopathy of pregnancy, 429
 in cor pulmonale, 426
 in dyspnea, 25
 heart failure and, 400
 in mitral regurgitation, 339
 recombinant. *See* Nesiritide
 reference values for, 1728*t*
- Babesia divergens/microti* (babesiosis), 1499–1500, 1500*f*
 anaplasmosis/ehrlichiosis and, 1415, 1499
 Lyme disease coinfection and, 1481, 1499
- Bacillary angiomatosis, 1323, 1331, 1453–1454, 1454
- Bacillary dysentery (shigella dysentery/gastroenteritis), 574*t*, 575, 1293, 1295*t*, 1296, 1297, 1298, 1303*t*, 1330, 1447
- Bacillus*, 1300*t*
anthracis, 1300*t*, 1431. *See also* Anthrax
cereus, diarrhea/food poisoning/gastroenteritis caused by, 574*t*, 575, 1293, 1294*t*
- Bacillus Calmette-Guérin* (BCG), for bladder cancer, 1639
- Bacillus Calmette-Guérin* (BCG) vaccine, 287
 tuberculin skin test affected by, 282, 287
 tuberculosis blood tests/interferon gamma release assays and, 4, 282–283
- Bacitracin, for ophthalmic disorders, 168*t*
- Back manipulation, 818, 1684
- Back pain, 818–821, 820*t*, 821*t*, 1683–1685, 1684*t*
 in alkaptouria, 1665
 in ankylosing spondylitis, 820, 855
 in aortic aneurysm, 472, 474, 820
 in aortic dissection, 477
 diagnosis/evaluation of, 819–821, 820*t*, 821*t*, 1683–1684, 1684*t*
 disk-related, 819, 819–820, 820*t*, 1685–1686
 epidural/subdural hemorrhage causing, 989
 management of, 821, 1684
 in osteoporosis, 1145
 in prostatitis, 942, 943
 spinal cord lesions/tumors/
 compression causing, 819, 993, 1644, 1683, 1684
 in spinal dural arteriovenous fistulae, 989
 spinal stenosis causing, 822, 1685
 spinal tuberculosis causing, 863
 vertebral fractures causing, 819, 1683
- Background retinopathy, 185, 1223
- Baclofen, for spasticity, 1012
- Bacteremia. *See also* Sepsis/septic shock
 anaerobic, 1456
 campylobacter causing, 1449
 endocarditis and, 1435
 gram-negative, 1443–1445
 health care-associated, 1284, 1285
 in listeriosis, 1434
 in Lyme disease, 1479
 in neutropenic patient, 510, 1281
 osteomyelitis from, 861–862
 salmonella, 1296, 1300*t*, 1445, 1446
 staphylococcal, 1427
 in streptococcal toxic shock syndrome, 1421
 transfusion of contaminated blood causing, 535
 vibrios causing, 1300*t*, 1448–1449
- Bacterial infections, 1419–1461. *See also* specific type
 actinomycosis, 1456–1457
 anaerobic, 1454–1456, 1455*t*, 1456*f*
 conjunctivitis, 165–166
 diarrhea in, 574*t*, 575. *See also* Diarrhea, infectious
 drugs for. *See* Antibiotics;
 Antimicrobial therapy
 endocarditis, 1302*t*, 1435–1439
 gram-negative, 1299–1300*t*, 1440–1456
 gram-positive, 1299*t*, 1300*t*, 1419–1435
 keratitis, 172
 after measles, 1368, 1369
 meningitis, 1285, 1286–1287, 1286*t*, 1288, 1302*t*
 mycobacterial, 1458–1461
 myocarditis in, 409*t*
 nocardiosis, 1457
 pericarditis, 419, 420
 peritonitis, 589–590, 689
 rhinosinusitis (sinusitis), 214–217, 216*t*, 1303*t*
 shock and. *See* Sepsis/septic shock
 vaginosis, 751–752, 752*f*, 753
 rape/sexual assault in transmission of, 1291
- Bacterial overgrowth, 624–625
 diarrhea and, 579*f*, 580, 624
 irritable bowel syndrome and, 633
 tests for, 580, 625
 vitamin B₁₂ deficiency and, 497, 624, 625
- Bacterial synergistic gangrene, 1456
- Bacteriuria
 catheter-associated, 1284
 in cystitis, 939
 during pregnancy, 804
- Bacteroides*
fragilis, 1455
 gastrointestinal strains of, 1299*t*
melaninogenicus. *See* *Prevotella*,
 melaninogenica
- Bactrim. *See* Trimethoprim-sulfamethoxazole
- Bactroban. *See* Mupirocin
- Baden-Walker system, 762
- Bagassosis, 310*t*
- Baker (popliteal) cyst, 825, 826, 1692
- BAL. *See* Dimercaprol
- Balamuthia mandrillaris*, 1287, 1505, 1506
- Balance. *See* Dysequilibrium; Falls;
 Vestibular disorders
- Balanitis
 candidal, 132
 in chancroid, 1453
 in reactive arthritis, 857, 857*f*
- Balanoposthitis, in diabetes, 1197
- Balantidium coli* (balantidiasis), 1510
- Baldness, 156–157. *See also* Alopecia
 androgenetic, 156
 in women, 156, 1719–1720
- Balint syndrome, 991
- Balkan nephropathy, ureteral/renal pelvis cancer and, 1640
- Balloon angioplasty, coronary. *See* Angioplasty, coronary;
 Percutaneous coronary intervention
- Balloon tube tamponade, for esophageal varices, 603
- Balloon valvuloplasty. *See* Valvuloplasty
- Balsalazide, for inflammatory bowel disease, 638
 ulcerative colitis, 647–648
- Bamboo spine, 855
- Band keratopathy, in hypercalcemia/hyperparathyroidism, 1139
- Banding, gastric, for obesity, 14, 1261
 in type 2 diabetes, 1220
- Banding (band/variceal ligation)
 for esophageal varices, 582, 602, 602–603
 in noncirrhotic portal hypertension, 700
 prevention of first bleeding episode and, 604
 prevention of rebleeding and, 603
 for hemorrhoids, 658
- Bankart lesion, 1681
- Barakat syndrome, 1136
- Barbiturates. *See* Opioids/opioid analgesics; Sedative-hypnotics
- Barcelona Clinic Liver Cancer (BCLC) staging system, 1604
- BARD score, in nonalcoholic fatty liver disease, 685
- Bariatric surgery, for obesity, 14, 1261
 hypoglycemia after, 1242
 in type 2 diabetes, 1220
- Baritosis, 309*t*
- Barium enema
 in cancer screening and evaluation/
 polyp identification, 653, 1624, 1628
 in diverticular disease, 651
- Barium esophagography, 592–593
 in achalasia, 605
 in esophageal cancer, 1613
 in esophageal webs and rings, 600
 in GERD, 594
 in motility disorders, 606
- Barium upper gastrointestinal series. *See* Upper gastrointestinal series
- Baroreceptors, in volume overload, 877

- Barotrauma, 202–203, 205
 dysbarism/decompression sickness
 and, 202, 1557
 mechanical ventilation and, 321
 Barrett esophagus, 594–595
 esophageal carcinoma and, 595
 Bartholin duct cyst/abscess, 753–754,
 754f
Bartonella henselae/quintana
 (bartonellosis), 1453–1454
 bacillary angiomatosis caused by, 1331,
 1453–1454, 1454
 endocarditis caused by, 1436, 1454
 in HIV infection/AIDS, 1323, 1331,
 1454
 prevention and, 1335
 Bart's hemoglobin, 495
 Bartter syndrome, 878t
 Basal body temperature charting, in
 contraception, 775
 symptothermal natural family
 planning and, 775
 Basal cell carcinoma
 of skin, 142, 142f
 eyelid involvement and, 164
 of vulva, 760
 Basal energy expenditure (BEE)
 exercise and, 1260
 nutritional support and, 1271
 Basedow disease, 1110–1111. *See also*
 Graves disease;
 Hyperthyroidism
 Basic life support, in near drowning, 1556
 Basilar artery migraine, 963
 Basilar artery occlusion, stroke caused by,
 981
 Basilar meningitis, in syphilis, 1469, 1472
 Basilar skull fracture, 1016
 vertigo caused by, 211
 Basophil count, 1727t
 “Bath salts,” 1572
 Bathing
 atopic dermatitis and, 103
 in dermatologic therapy, 94
 preoperative, surgical site infections
 and, 56
 Bats
 hemorrhagic fevers and, 1384
 histoplasmosis and, 1531
 rabies and, 1376
 Battered elderly, 17
 Battered woman, 17, 1078, 1079, 1711–1712
 prevention of abuse and, 17, 1712
 Batteries (disk/button), ingested, alkali
 injuries caused by, 1572
 Battle sign, 1016
Baylisascaris procyonis, visceral larva
 migrans caused by, 1523
 Bayou virus, 1388
 BCG, for bladder cancer, 1639
 BCG vaccine, 287
 tuberculin skin test affected by, 282, 287
 tuberculosis blood tests/interferon
 gamma release assays and, 4,
 282–283
bcl-2 expression, in non-Hodgkin
 lymphoma, 524
 BCLC (Barcelona Clinic Liver Cancer)
 staging system, 1604
bcr/abl fusion gene, 515
 in acute lymphoblastic leukemia, 521
 in chronic myeloid leukemia, 515, 516
 reference values for, 1727t
 BEACOPP regimen, for Hodgkin
 lymphoma, 527
 Beano, for gastrointestinal gas, 573
 Beau lines, 157
 in Kawasaki disease, 1417
 Becaplermin, for leg/foot ulcers, 154,
 1225
 Becker muscular dystrophy, 1034, 1035t
 Beclomethasone
 for allergic rhinitis, 218
 for asthma, 253t
 Bed rest. *See also* Immobility
 back pain and, 821, 1686
 hazards of, 65
 DVT/PE (venous thromboembolic
 disease) and, 297, 301t
 hypercalcemia and, 1142
 for preeclampsia-eclampsia, 794
 for preterm labor prevention, 796
 for third-trimester bleeding, 797
 Bedbugs, skin lesions caused by, 149
 Bedside Index for Severity in Acute
 Pancreatitis (BISAP), 712
 Bedside tracheotomy, 238
 Bedsores. *See* Pressure ulcers
 BEE. *See* Basal energy expenditure
 Beef. *See* Meat
 Beef tapeworm (*T saginata*), 1514
 Beer consumption, gout/hyperuricemia
 and, 813, 814
 Beer potomania, hyponatremia caused by,
 871f, 873
 Beger procedure, for pancreatitis, 717
 Behavior
 abnormal
 illness, 1045–1047
 during sleep (parasomnias),
 1077–1078
 in dementia patients, 6–12, 1009, 1089
 insulin-induced hypoglycemia and, 1222
 in schizophrenia/psychotic disorders,
 1054
 Behavior modification. *See also* Cognitive
 behavior therapy
 for alcohol use/abuse, 1082
 for anxiety disorders, 1044
 for chronic fatigue syndrome, 40
 in chronic pain disorders, 1048
 for dementia/Alzheimer disease, 61,
 1009, 1089
 for depression, 1072
 exercise/activity and, 13
 for obesity management, 14, 1260
 for paraphilias and gender identity
 disorders, 1051
 for personality disorders, 1052
 for psychiatric problems associated
 with hospitalization/illness
 and, 1091
 for psychosexual dysfunction, 1051
 for schizophrenia/psychotic disorders,
 1062
 for Tourette syndrome, 1005
 for urinary incontinence management,
 68, 69
 Behavioral-variant frontotemporal
 dementia, 1008t
 Behçet syndrome, 853
 uveitis in, 178, 853
 Bejel (endemic syphilis), 1475
 Belching (eructation), 573
 Belimumab, for SLE, 834
 Bell palsy, 1028. *See also* Facial paralysis/
 palsy
 herpes simplex/varicella zoster
 infection and, 1028, 1351,
 1355, 1359
 Belladonna
 MAOI interactions and, 1071t
 overdose/toxicity of, 1575
 Belly press test, 1678t, 1680
 Benazepril/benazepril with
 hydrochlorothiazide/
 benazepril with amlodipine,
 450t
 Bence Jones proteinuria (light chain in
 urine), 905
 in myeloma, 528, 936
 renal toxicity and, 905, 936
 Bendamustine, 1650t
 for chronic lymphocytic leukemia, 522
 Bends, 1557
 Benicar/Benicar HCT. *See* Olmesartan/
 olmesartan HCTZ
 Benign essential (familial) tremor, 997
 parkinsonism differentiated from, 998
 Benign mole, 100, 100f
 Benign paroxysmal positioning vertigo
 (BPPV), 210t, 211
 Benign prostatic hyperplasia, 956–961,
 957t, 958f, 958t, 959t
 hematuria in, 938
 phytotherapy/saw palmetto for, 960
 postrenal acute kidney injury and, 903
 testosterone replacement therapy and,
 1176, 1177
 tubulointerstitial disease caused by, 932
 urinary incontinence and, 68, 69, 958t,
 960
 Bentall procedure, 343, 346
 for aortic regurgitation, 346
 for aortic stenosis, 343
 BenzaClin. *See* Clindamycin, with benzoyl
 peroxide
 Benzalkonium, for hydrofluoric acid
 burns, 1571
 Benzamycin. *See* Erythromycin, with
 benzoyl peroxide
 Benzisoxazoles, 1055. *See also*
 Antipsychotic drugs
 Benznidazole, for Chagas disease,
 1486, 1487
 Benzocaine, methemoglobinemia caused
 by, 1584
 Benzodiazepines, 1042–1043, 1042t,
 1043t. *See also* specific agent
 for aggressive/violent patient, 1078
 for alcohol detoxification/withdrawal,
 18, 974, 1043, 1082, 1083
 with antipsychotic agents, 1058
 for anxiety, 1042–1043, 1042t, 1043t
 for delirium, 1089
 in dementia, 1009
 drug interactions of, 1043, 1043t
 for hallucinogen overdose/toxicity,
 1583
 for nausea and vomiting, 86, 569, 569t

- Benzodiazepines (*Cont.*):
 in older adult, 1043
 overdose/toxicity of, 1043, 1563, 1566*t*,
 1579–1580. *See also*
 Flumazenil
 for panic attacks, 1044
 for PTSD, 1040
 for serotonin syndrome, 36, 1592
 for sleep disorders/insomnia, 1042*t*,
 1043, 1076, 1078
 withdrawal from, 1043
 sleep disorders and, 1043, 1076
- Benzoyl peroxide
 for acne, 97*t*, 127
 with adapalene, 127
 with clindamycin, 97*t*, 127
 with erythromycin, 97*t*, 127
 for rosacea, 129
- Benzoyllecgonine, in cocaine abuse, 1572
- Benzotropine, for parkinsonism, 999*t*. *See also*
 Antiparkinsonism drugs
- Bepotastine, for allergic eye disease, 167,
 169*t*
- Bepreve. *See* Bepotastine
- Beraprost, for pulmonary hypertension,
 305
- Berger disease (IgA nephropathy), 919*t*,
 921*f*, 922–923
- Beriberi, 1264. *See also* Thiamine
 (vitamin B₁), deficiency of
 neuropathy associated with, 1023, 1264
- Bernard-Soulier syndrome, 548
- Berry aneurysms, 984, 986. *See also*
 Intracranial aneurysm
- Berylliosis, 311
- Beta-adrenergic agonists
 for asthma
 exacerbation management and, 244*f*,
 245*t*, 249*f*, 254*t*, 255, 256, 259
 long-acting, 249*f*, 250–252, 251*t*, 253
 in pregnant patient, 803
 short-acting, 244*f*, 245*t*, 249*f*, 254*t*,
 255, 256, 257*f*, 258*f*, 259
 for COPD, 262
 for hyperkalemia, 880
 hypokalemia caused by, 878
 for preterm labor prevention, 796
- Beta-adrenergic blocking drugs
 for acute coronary syndromes, 362*t*, 363
 for angina, 355–356
 for anxiety/stress disorders, 1040, 1043
 for aortic dissection, 477
 for aortic regurgitation, 345
 for arrhythmias, 377, 378*t*
 atrial fibrillation, 386
 in hyperthyroidism, 1118
 infarct-related, 372, 386
 in heart failure, 405
 supraventricular tachycardia, 378*t*,
 382
 ventricular tachycardia, 391, 392
 for cardiomyopathy, 415
 cardioselectivity of, 446, 447–448*t*
 depression caused by, 1064
 for esophageal varices
 prevention of first bleeding episode
 and, 604
 prevention of rebleeding and, 603
 for glaucoma/ocular hypertension,
 171*t*, 176
- in heart failure, 402–403, 446
 infarct-related, 370
 for hypertension, 442*t*, 446–449,
 447–448*t*, 457, 457*f*, 458*t*
 in aortic dissection, 477
 in combination regimen, 457, 457*f*,
 458*t*
 in diabetics, 442*t*, 446, 1202, 1203
 pregnancy and, 802
 in urgencies/emergencies, 462*t*
 hypoglycemia caused by, 1244
 lipid abnormalities associated with use
 of, 1248*t*
 for Marfan syndrome, 1671
 for mitral valve prolapse, 341
 for myocardial infarction, 362*t*, 370,
 375–376
 overdose/toxicity of, 1563, 1575–1576
 for panic attacks, 1044
 perioperative, 47, 48*t*
 in cardiac patients, 47, 48*t*
 pheochromocytoma and, 446, 1170
 for phobic disorder, 1044
- Beta-carotene
 in chemoprevention, 11
 excess intake of, 1267
- Beta-catenin, hepatocellular adenoma
 and, 702
- Beta-cross linked C-telopeptide, reference
 values for, 1728*t*
- β-D-glucan levels
 in aspergillosis, 1537
 in *Pneumocystis* pneumonia, 1326,
 1534
- Beta-globin gene, 494
 in beta thalassemia syndromes, 494,
 494–495
 in sickle cell syndromes, 503
- Beta-glucocerebrosidase, in Gaucher
 disease, 1668
- Beta-hemolytic streptococci. *See specific
 type under Group*
- Beta-hydroxybutyrate/hydroxybutyric
 acid
 in alcoholic ketoacidosis, 891
 in diabetes mellitus, 1198
 in diabetic ketoacidosis, 891, 1233
- Beta interferon. *See* Interferon-β
- Beta-lactam antibiotics, for pneumonia,
 273*t*
- Beta₂-microglobulin
 in amyloidosis, 531
 in myeloma staging, 529
 reference values for, 1727*t*
- Beta-natriuretic peptide. *See* B-type
 natriuretic peptide
- Beta thalassemia syndromes, 494–495,
 495, 495*t*, 496
 sickle cell disease and, 505, 505*t*
- Betagan. *See* Levobunolol
- Betaine, for homocystinuria, 1669
- Betamethasone/betamethasone valerate,
 1190*t*
 for fetal lung maturity, 794, 796
 topical, 96*t*
- Betaxolol
 for glaucoma/ocular hypertension,
 171*t*, 176
 for systemic hypertension, 447*t*
- Bethesda assay, 550, 553
- Bethesda criteria, for HNPCC, 656
- Bethesda System, for Pap smear
 classification, 754*t*, 755
- Betimol. *See* Timolol
- Betoptoc S. *See* Betaxolol
- Bevacizumab, 1653*t*
 for breast cancer, 737, 741
 for colorectal cancer, 1625
 for lung cancer, 1600
 for renal cell carcinoma, 1641
 for retinal vein occlusion, 182
 for vestibular schwannoma (acoustic
 neuroma), 212–213
- Bexarotene, TSH affected by, 1094, 1096
- Bexxar. *See* Tositumomab
- Bezafibrate, 1254
- Bezold-Jarisch reflex, in angina, 352
- Biaxin. *See* Clarithromycin
- Bicalutamide, 1656*t*
 for prostate cancer, 1637*t*
- Bicarbonate
 for acidosis
 alcoholic ketoacidosis, 891, 893
 in chronic kidney disease, 914
 diabetic ketoacidosis, 1234
 increased anion gap acidosis, 893
 lactic acidosis, 1238
 normal anion gap/renal tubular
 acidosis, 892*t*, 893–894
 arterial, 888–889
 in chronic kidney disease, alkalosis
 and, 895
 contrast media nephrotoxicity
 mediated by, 905
 in fluid management, 897*t*
 gastrointestinal loss of, acidosis caused
 by, 892, 892*t*
 urinary anion gap and, 892*t*, 893
 for hyperkalemia, 879, 880, 881*t*
 lithium interactions and, 1074*t*
 plasma/serum levels of
 in acid-base disorders, 888–889, 889,
 889*t*, 890
 in alcoholic ketoacidosis, 891
 in diabetic ketoacidosis, 1232, 1232*t*
 in lactic acidosis, 1232*t*, 1237
 in metabolic acidosis, 889, 889*t*, 890
 in metabolic alkalosis, 889, 889*t*,
 890, 894, 894*t*, 895
 in normal anion gap/renal tubular
 acidosis, 890, 892
 in respiratory acidosis, 889*t*, 896
 in respiratory alkalosis, 889*t*, 896
 reference values for, 1728*t*
 for salicylate poisoning, 893, 1588, 1589
 for shock, 489
 for tricyclic antidepressant overdose,
 1563, 1564, 1592
 venous, 889
- Bicarbonaturia, in normal anion gap/
 renal tubular acidosis, 892
- Bicuspid aortic valve, 341–342, 343
 in Turner syndrome, 1186, 1187
- Bicycle riding, injury prevention and, 17
- Bier block, for hydrofluoric acid burns,
 1571
- Bifascicular block, 395, 396
- Bifidobacterium infantis* probiotic, for
 irritable bowel syndrome,
 635–636

- “Big gastrin,” gastrinoma secreting, 1172
 “Big IGF-2,” nonislet cell tumor
 hypoglycemia and, 1241–1242
 “Big prolactin,” 1103
 Bigeminy, 390
 Biguanides
 for diabetes mellitus, 1206*t*
 overdose/toxicity of, 1580
 Bilateral fold paralysis, 238
 Bile acid-binding resins, for lipid modification, 1253
 Bile ascites, 591
 Bile ducts. *See also under Biliary*
 carcinoma of. *See* Cholangiocarcinoma;
 Periapillary/ampullary carcinoma
 common, stones in. *See* Cholelithiasis
 Bile salts, malabsorption of
 in Crohn disease, 641, 643
 in short bowel syndrome, 625
 BiLE score, in liver failure, 674
 Bilharziasis, 1511–1512. *See also* *Schistosoma*
 Biliary cirrhosis, 687, 692–694
 Biliary colic. *See* Abdominal pain/
 tenderness
 Biliary-enteric bypass, for gallbladder cancer, 1607
 Biliary obstruction, 662–663, 663*t*
 biliary tract carcinoma causing, 1606
 in choledocholithiasis/cholangitis, 707
 jaundice caused by, 662–663, 663*t*, 664*t*, 707, 709
 Biliary pain. *See* Abdominal pain/
 tenderness
 Biliary pancreatitis, 711
 Biliary sludge (microlithiasis), 703
 pancreatitis and, 711
 Biliary stricture, 708–709
 cholangitis and, 708
 Biliary tract disease, 702–710, 703*t*. *See also specific disease*
 carcinoma, 1605–1607
 cholecystitis, 703*t*, 704–705
 choledocholithiasis/cholangitis, 703*t*, 706–708
 cholelithiasis (gallstones), 702–704, 703*t*
 CMV infection and, 1364
 dyspepsia and, 565
 in fascioliasis, 1512
 in HIV infection/AIDS, 1329
 inflammation. *See* Cholangitis
 pancreatitis and, 711
 pre- and postcholecystectomy syndromes, 705–706
 during pregnancy, 807
 primary sclerosing cholangitis, 709–710
 strictures, 708–709
 Biliopancreatic diversion/duodenal switch, for obesity, in type 2 diabetes, 1220
 Bilirubin levels, 662, 664*t*. *See also* Hyperbilirubinemia
 in alcoholic liver disease, 681, 682
 ascitic fluid, 591
 in autoimmune hepatitis, 679
 in biliary tract carcinoma, 1606
 in cholecystitis, 704
 in choledocholithiasis/cholangitis, 707
 in cirrhosis, 686, 692*t*
 in G6PD deficiency, 503
 in hemolytic anemia, 500, 505
 in liver disease/jaundice, 662, 663*t*, 664*t*
 in passive congestion of liver, 699
 reference/normal values for, 662, 664*t*, 1728*t*
 urine, 664*t*
 in viral hepatitis, 666
 in vitamin B₁₂ deficiency, 498
 Bilirubinate, calcium, in gallstones, 703
 Bilivist. *See* Iodate sodium
 Billowing mitral valve. *See* Mitral valve prolapse
 Biloma, 708
 Bimatoprost, for glaucoma/ocular hypertension, 171*t*, 176
 Bimatoprost/timolol, for glaucoma/ocular hypertension, 172*t*, 176
 Binge eating, 1713–1714
 bulimia nervosa and, 1263
 in diabetes, 1713
 Binge eating disorder, 1713–1714
 Biofeedback
 for chronic pain, 1048
 in factitious disorders, 1046
 for fecal incontinence, 660
 for somatoform disorders, 1046–1047
 for urinary incontinence, 68, 69
 Biologic response modifiers, 1657*t*. *See also specific agent*
 for renal cell carcinoma, 1641
 Biologic therapies, for inflammatory bowel disease, 639–640
 Biomarkers
 in breast cancer, 728, 733–734. *See also* Hormone receptor sites
 prognosis and, 734, 736, 736*t*, 743
 treatment and, 734
 cardiac, 360, 366. *See also* Cardiac biomarkers/enzymes
 in women, 1707
 pregnancy and, 781
 Bioprostheses, for cardiac valve replacement, 338, 343, 346, 347, 348, 349. *See also* Valve replacement
 Bioterrorism
 anthrax and, 1432, 1433
 botulinum toxin and, 1431
 chemical warfare agents and nerve agents, 1587
 skin decontamination for, 1566, 1587
 Coxiella burnetii and, 1416
 plague and, 1451
 smallpox/smallpox vaccination and, 1403
 tularemia (*Francisella tularensis*) and, 1450
 Biperiden, for parkinsonism, 999*t*. *See also* Antiparkinsonism drugs
 Bipolar disorders, 1063–1064. *See also* Depression; Mania
 drug therapy for, 1072–1075, 1074*t*
 lithium, 1072–1074, 1074*t*
 suicide risk and, 1064
Bipolaris, phaeohyphomycosis caused by, 1541
 Bird-fancier’s lung (pigeon-breeder’s disease), 310*t*
 Bird mites. *See* Mites
 Birds
 avian influenza and, 1397, 1398
 histoplasmosis and, 1531
 hypersensitivity pneumonitis and, 310*t*
 psittacosis (ornithosis) and, 1462
 West Nile virus in, 1378
 Birt-Hogg-Dube syndrome, renal cell carcinoma and, 1641
 Birth classes, 784
 Birth control pills. *See* Oral contraceptives
 Bisacodyl, 571, 572*t*
 BISAP score, in pancreatitis, 712
 Bisferiens pulse, in cardiomyopathy, 414
 Bismuth compounds
 for diarrhea, 577, 1298
 pregnancy and, 787
 in *H pylori* eradication therapy, 613, 614*t*
 for peptic ulcer disease, 613
 Bisoprolol
 for heart failure, 403
 with hydrochlorothiazide, for hypertension, 447*t*
 perioperative, 47
 Bisphosphonates, 1146–1147. *See also specific agent*
 adverse ophthalmic effects of, 197*t*
 in breast cancer management, 738, 739
 hypercalcemia associated with use of, 1142, 1147
 for hypercalcemia/
 hyperparathyroidism, 884, 1143, 1647
 hypocalcemia associated with use of, 1147
 metabolic bone disorders/renal osteodystrophy and, 912
 for myeloma-related bone disease, 529
 osteonecrosis of jaw and, 11, 738, 865, 1147
 for osteoporosis, 11, 780, 1146–1147, 1181
 androgen deprivation therapy and, 1636
 chronic corticosteroid treatment and, 1146, 1191
 for Paget disease of bone, 1153
 Bite cells, in G6PD deficiency, 503
 Bites. *See* Animal bites; Human bite wounds; Insect bites
 Bithionol, for fascioliasis, 1513
 Bitolterol, for asthma, 255
 Bitot spots, in vitamin A deficiency, 1266
 Bitter almonds, odor of in cyanide poisoning, 1577
 Bivalirudin
 for acute coronary syndromes, 361, 362*t*
 for heparin-induced
 thrombocytopenia, 544*t*
 for myocardial infarction, 362*t*, 368
 Biventricular pacing (resynchronization) for cardiomyopathy, 412, 415
 for heart failure, 405–406

- Black cohosh, for menopausal symptoms, 1181
- Black Creek Canal virus, 1388
- Black eye, 192
- in nasal trauma, 221
- Black fever. *See* Visceral leishmaniasis
- Black molds
- chromoblastomycosis caused by, 1540
 - phaeohyphomycosis caused by, 1541
- Black patients. *See also* Racial/ethnic background
- atopic dermatitis in, 103
 - cardiomyopathy in, 411
 - colorectal cancer risk in, 1623
 - diuretics in, 446
 - G6PD deficiency in, 502
 - glaucoma in, 175
 - HIV-associated nephropathy in, 931
 - hypertension in, 433, 435, 439, 459
 - management and, 446, 449, 453, 457f, 458t, 459
 - Kaposi sarcoma in, 145, 1331
 - sarcoidosis in, 295
 - sickle cell anemia/syndromes in, 503
 - thalassemia in, 495
- Black plague, 1451
- Black widow spider bite, 149, 1590
- Blackwater fever, in malaria, 1495
- Bladder
- biopsy of, in bladder cancer, 1639
 - cancer of, 1611t, **1638–1640**
 - hematuria in, 938, 1638, 1639
 - incidence/risk/mortality of, 1594t, 1638
 - schistosomiasis and, 1511, 1638
 - thiazolidinedione use and, 1210
 - disorders/dysfunction of. *See also specific type and* Urinary incontinence
 - postrenal acute kidney injury and, 903
 - spinal trauma causing, 1018
 - infection of. *See* Cystitis
 - neuropathic
 - chemotherapy-induced, 1661
 - in diabetes, 1226
 - painful. *See* Interstitial cystitis
 - paraganglioma of, 1167
- Bladder catheterization
- intermittent, for incontinence management, 69
 - urinary tract infection and, 939, 1282, 1284
- Bladder toxicity
- cyclophosphamide/ifosfamide causing, 1661
 - mesna for, 1658t, 1661
 - neuropathies, chemotherapy-induced, 1661
- Bladder training, for urinary incontinence, 68
- Blalock/Blalock-Taussig shunt, for tetralogy of Fallot, 331
- Blast cells
- in acute leukemia, 520
 - in chronic myeloid leukemia, 516
 - in myelodysplastic syndromes, 517, 518
 - refractory anemia with (RAEB), 517
- Blastomycosis, **1538–1539**
- South American (paracoccidiodomycosis), **1539**
- Bleach. *See* Hypochlorite
- Bleeding/blood loss. *See also specific cause or structure affected and* Thrombocytopenia
- in acute leukemia, 519
 - anticoagulation/anticoagulant overdose and, 302–303, 1573
 - in chronic kidney disease, 913
 - in cirrhosis, 581, 601, 602, 687
 - coagulation disorders causing, **549–554**
 - acquired, **553–554**
 - congenital, **549–553**, 550t, 552t
 - in DIC, 545–546, 554
 - in essential thrombocytosis, 513
 - evaluation of, 438, 539t
 - gastrointestinal. *See* Gastrointestinal bleeding
 - iron deficiency and, 490, 490–491, 586–587
 - in liver disease, **553–554**
 - malabsorption and, 621t
 - miscellaneous causes of, **554**
 - ovulation, 747
 - perioperative risk evaluation/management and, 46, 47t, **52**, 53t
 - platelet count and, 536, 538, 539t
 - platelet disorders causing, **538–549**, 539t
 - acquired, **548–549**, 549t
 - congenital, **548**
 - qualitative, **548–549**, 549t
 - thrombocytopenia, **538–548**, 539t, 541f, 543t, 544t, 546t, 547t
 - in polycythemia, 512
 - during pregnancy
 - ectopic pregnancy and, 790
 - in gestational trophoblastic disease, 791
 - third-trimester, **797**
 - premenopausal/postmenopausal. *See* Vaginal bleeding
 - rectal. *See* Rectal bleeding
 - retinal disorders and, **186–187**
 - thrombolytic therapy for myocardial infarction and, 368
 - vaginal. *See* Menstruation; Vaginal bleeding
- Bleeding history, directed, preoperative, 46, 47t, 52
- Blenoxane. *See* Bleomycin
- Bleomycin, 1655t, 1662
- Raynaud phenomenon caused by, 837
 - for testicular cancer, 1643
 - toxicity of, 1655t, 1662–1663
 - for wart removal, 141
- Blepharitis, 110, **163–164**
- Blepharospasm, 1003
- Blind loop syndrome
- bacterial overgrowth and, 497
 - vitamin B₁₂ deficiency in, 497
- Blind spot, enlargement of in papilledema, 189, 189f
- Blindness. *See also disorders causing and* Visual impairment/loss
- age-related macular degeneration causing, 181
 - in basilar artery migraine, 963
 - cataract causing, 179
 - cortical, occipital lobe lesions causing, 991
 - diabetic eye disease and, 185, 1223
 - fleeting (amaurosis fugax), 184, 469, 981
 - in giant cell arteritis, 845, 845–846, 846
 - glaucoma causing, 177
 - river (onchocerciasis), **1526–1527**
 - snow, 194
 - trachoma causing, 165–166
 - transient monocular, **184**, 469
 - vitamin A deficiency and, 1266
- Blister, burn, 1550
- Blister cells, in G6PD deficiency, 503
- Blistering (bullous) skin disorders, 95t, **138–139**. *See also specific type*
- Blocadren. *See* Timolol
- Blood. *See also* Bleeding/blood loss
- contaminated, transfusion of, 535
 - disorders of, **490–537**. *See also Hematologic disorders*
 - screening, 535–536
 - for cytomegalovirus, 536
 - for drugs/toxins, 1570
 - for hepatitis, 535–536, 667, 669
 - for HIV, 536, 1321, 1334
 - for HTLV, 536, 1383, 1384
 - for West Nile virus, 536, 1379, 1380
 - stem cells in, for transplantation, 532, 533
 - in stool. *See* Diarrhea, bloody; Dysentery; Fecal occult blood testing
 - for toxicology testing, 1570
 - transfusion of. *See* Transfusion
 - in urine. *See* Hematuria; Hemoglobinuria
- Blood alcohol level
- in acute intoxication/poisoning, 1080, 1579
 - reference values for, 1730t
- Blood culture
- central venous catheter sepsis and, 1284
 - in disseminated candidiasis, 1529
 - in endocarditis, 1436
 - in fever/FUO, 1277
 - in gram-negative bacteremia/sepsis, 1444
 - in health care-associated infection, 1283–1284
 - in Lyme disease, 1480
 - in nongonococcal acute bacterial (septic) arthritis, 859
 - in pneumonia, 271, 272t, 276
 - in staphylococcal infection, 1427
 - osteomyelitis, 1426, 1427
 - in tuberculosis, 281
 - in typhoid fever, 1445
- Blood dyscrasias. *See also* Bleeding
- retinal disorders associated with, **186–187**
- Blood flukes, schistosomiasis caused by, **1511–1512**
- Blood gases. *See* Arterial blood gases; Venous blood gases
- Blood glucose levels. *See* Glucose, blood levels of

- Blood glucose meters, 1200
- Blood loss. *See* Bleeding
- Blood pressure, 433, 434*t*, 435*f*. *See also* Hypertension; Hypotension cardiovascular/heart disease and, 10–11, 433, 434, 1249*t*, 1250 classification/management and, 433, 434*t*, 435*f* exercise/activity affecting, 12–13 in GI bleeding, 581 in hypertension, 433, 434*t*, 435*f*, 440 in poisoning/drug overdose, 1564 treatment goals and, 443 in chronic kidney disease/diabetic nephropathy, 459, 911, 931, 1224 in diabetes, 1227 in hypertensive urgencies/emergencies, 433, 460 in hypotension, 434*t* measurement of, **433–434** orthostatic changes in. *See* Orthostatic (postural) hypotension in preeclampsia-eclampsia, 793, 793*t*, 795 in prehypertension, 434, 434*t*, 441 in shock, 485, 486 in valvular heart disease, 334*t*
- Blood pressure screening, in cardiovascular/heart disease prevention, 7*t*, 11
- Blood smear for babesiosis diagnosis, 1499, 1500*f* for filariasis diagnosis, 1525 for loiasis diagnosis, 1527 for malaria diagnosis, 1491–1492, 1491*f*
- Blood specimen, tubes for collection of, 1736*t*
- Blood transfusion. *See* Transfusion
- Blood (compatibility) typing, for transfusions, 534
- Blood urea nitrogen (BUN), 900, 900*f* in acute kidney injury, 902, 902*t* in diabetic ketoacidosis, 1232, 1233 in hyperglycemia hyperosmolar state, in hyperglycemic hyperosmolar state, 1236 in pancreatitis, 711 preoperative levels of, postoperative pulmonary complications and, 51 reference values for, 1728*t* in SIADH, 874
- Blood urea nitrogen:creatinine ratio, 900 in acute kidney injury/tubular necrosis, 902*t*, 903, 905 in glomerulonephritis, 907
- Blood vessels. *See specific type and under Vascular*
- Blowout fracture, of orbital floor, 192
- Blue bloaters, 260, 260*t*
- Blue nevi, **101**, 101*f* melanoma and, 101
- Blue sclera, in osteogenesis imperfecta, 1145
- Blue and dark blue top tubes, 1736*t*
- Blumer shelf, 1616
- Blunt trauma, cardiac, 428–429
- Blurred vision. *See* Visual impairment/loss
- BMI. *See* Body mass index
- BMPRIA* gene, in familial juvenile polyposis, 655
- BMPR2* gene, in pulmonary hypertension, 423
- BNP. *See* B-type natriuretic peptide
- Bocavirus, 1402
- Boceprevir, 1353*t* for hepatitis C, 677
- BODE index, 265
- Body cavity (primary effusion) lymphoma, 1367
- Body dysmorphic disorder, 1090
- Body fat. *See also* Obesity distribution of in obesity, 1259 diabetes and, 1194, 1197, 1220
- Body fluid precautions (universal). *See* Body substance isolation
- Body image disturbances in anorexia nervosa, 1262 in female athlete triad, 1712 postsurgical anxiety states and, 1090 surgery proneness and, 1090
- Body lice, 148. *See also* Lice
- Body mass index, 13, 1259 coronary heart disease risk and, 350 genetic factors affecting, 1259 preventable disease/deaths and, 3*t*
- Body ringworm, **110–111**, 111*f*
- Body substance isolation/universal precautions, 1284 in H1N1 influenza, 1400 in hemorrhagic fevers, 1385 in herpes simplex prevention, 1355 HIV infection/AIDS prevention and, 1334 in monkeypox, 1404 in SARS, 1401 in smallpox/variola, 1403
- Body surface area, in burns, estimating, 1549–1550, 1549*f*
- Body temperature antipsychotic drug use affecting, 1059 basal. *See* Basal body temperature elevated. *See also* Fever; Hyperthermia cholinergic urticaria caused by, 133 in hyperthermia/heat exposure syndromes, 35, 1548, 1565 in hypothermia, 1543, 1544 in near drowning, resuscitation efforts and, 1556 normal, 35 circadian variations in, 1277 in pulmonary embolism, 298 regulation of, 1543. *See also* Thermoregulation
- Body water, 870, 871*t* fluid management and, 897, 897*t* water deficit calculation and, 876 weight changes and, 870, 897
- Body weight. *See* Weight
- Boerhaave syndrome, 568
- Boils (furunculosis), **151–152**, 1303*t*, 1421*t*, 1425, 1425*f* in HIV infection/AIDS, 1331
- Bone adynamic disease of, 912 avascular necrosis of (osteonecrosis), **865** corticosteroid use and, 865, 1190–1191 dysbaric, 865 of jaw, bisphosphonate use and, 11, 738, 865, 1147 in sickle cell anemia, 503, 865 blastomycosis involving, 1539 coccidioidomycosis involving, **863**, 1532 defective mineralization of, in osteomalacia, 912, 1148–1149, 1149, 1150 in diabetes, 1228 in histoplasmosis, **863** in HIV infection/AIDS, 1328 in hypercalcemia/hyperparathyroidism, 884, 1139 infections of, **861–864**. *See also* Osteomyelitis metabolic disease of, **1144–1153**. *See also specific disorder* in chronic kidney disease (renal osteodystrophy), 912–913, 912*f*, 1139, 1141, 1144 mycotic infection of, **862–863** myeloma involving, 527, 528 Paget disease of, **1152–1153** in syphilis, 1471 tuberculosis of, 285, **863–864**
- Bone density/bone density measurements/bone densitometry in diabetes, 1228 in female athlete triad, 1712 in HIV infection/AIDS, 1328 in hyperparathyroidism, 1139, 1140, 1141 levothyroxine treatment and, 1125, 1130 in male hypogonadism, 1175 normal, 1710 in osteomalacia, 1150, 1151 in osteoporosis, 1145–1146, 1710. *See also* Osteoporosis prevention and, 11, 1145, 1710
- Bone marrow depression/failure of antipsychotic drug use and, 1059 in aplastic anemia, 508 in cancer chemotherapy, **1649–1659** infections and, 1279, 1648 in chronic lymphocytic leukemia, 521 methotrexate causing, 829 in myelodysplastic syndromes, 517 in myeloma, 527, 528 in neutropenia, 510, 510*t* in primary myelofibrosis, 514 radiation exposure and, 1554 thrombocytopenia caused by, **538–540** examination/morphology of in acute leukemia, 520 in anemia evaluation, 490 in aplastic anemia, 508 in chronic lymphocytic leukemia, 522 in chronic myeloid leukemia, 515, 516 in essential thrombocytosis, 513 in Gaucher disease, 1668

- Bone marrow, examination/morphology of (*Cont.*):
- in hairy cell leukemia, 523
 - in leishmaniasis, 1488
 - in myelodysplastic syndromes, 518
 - in myeloma, 528
 - in neutropenia, 510
 - in non-Hodgkin lymphoma, 525
 - in polycythemia, 512
 - in primary myelofibrosis, 514
 - in sideroblastic anemia, 497
 - in vitamin B₁₂ deficiency, 497, 498
 - in Waldenström macroglobulinemia, 530
- infiltration of, thrombocytopenia caused by, 540
- stem cells in, for transplantation, 532, 533
- Bone marrow/stem cell transplantation, 532–534
- for acute leukemia, 520–521, 533
 - adenovirus infection and, 1401
 - allogeneic, 532–534
 - for amyloidosis, 531, 930
 - for aplastic anemia, 509, 533, 539–540
 - aspergillosis after, 1537
 - autologous, 532
 - for breast cancer, 742
 - for cancer, 532–534
 - chemotherapy and, 532, 533
 - for chronic lymphocytic leukemia, 523, 533
 - for chronic myeloid leukemia, 517, 533
 - CMV infection and, 1280, 1364
 - for Hodgkin lymphoma, 527, 532
 - immunizations and, 5, 1314
 - infection and, 1279, 1280–1281
 - for lymphoma, 525, 526, 532, 533
 - for mantle cell lymphoma, 525, 532
 - for myelodysplastic syndromes, 518, 533
 - for myeloma, 529, 532
 - for paroxysmal nocturnal hemoglobinuria, 502
 - for primary myelofibrosis, 515
 - for sickle cell anemia/syndromes, 504
 - for thalassemia, 496
- Bone-modifying agents, for chemotherapy-induced toxicity, 1658–1659t
- Bone morphogenetic receptor protein 1A (*BMPRIA*) gene, in familial juvenile polyposis, 655
- Bone morphogenetic receptor protein 2 (*BMPR2*) gene, in pulmonary hypertension, 423
- Bone pain
- adjuvant modalities for, 85, 1658–1659t
 - bisphosphonates causing, 1153
 - in Gaucher disease, 1668
 - in hyperparathyroidism, 1139
 - malabsorption and, 621t
 - in metabolic bone disorders/renal osteodystrophy, 912
 - in myeloma, 528, 529
 - in osteomalacia, 1150
 - in Paget disease, 1152
- Bone scanning
- for breast cancer metastases, 727
 - in musculoskeletal evaluation, 1673
 - in Paget disease, 1152
 - for prostate cancer metastases, 1631
- BOOP (bronchiolitis obliterans with organizing pneumonia). *See* Cryptogenic organizing pneumonia/pneumonitis
- BOOSTRIX. *See* Tdap vaccine
- Borderline personality disorder, 1051, 1052, 1052t, 1053
- Bordetella* infection
- bronchiseptica*, 1441
 - pertussis* (whooping cough), 1440–1441
 - cough in, 21, 22, 23, 1440
 - prevention/immunization and, 3, 1307, 1440. *See also* Pertussis vaccine
- Boredom, in schizophrenia/psychotic disorders, 1054
- Bornholm disease (epidemic pleurodynia), 1406
- Borrelia* (borreliosis)
- afzelii*, 1478, 1479
 - burgdorferi*, 240, 1300t, 1478, 1479. *See also* Lyme disease
 - myopericarditis caused by, 419, 1479
 - senu strictu*, 1478
 - garinii*, 1478, 1479
 - loneastari*, 136
 - recurrentis*, 1300t, 1475
 - relapsing fever caused by, 1300t, 1475
 - tick-borne encephalitis coinfection and, 1391
- Bortezomib, 1655t
- for myeloma, 529
 - neuropathy caused by, 529, 1661
- Bosentan, for pulmonary hypertension, 305
- Botanical (herbal) medicines, toxicity of, 1578, 1578t
- Botox. *See* Botulinum toxin therapy
- Botulinum toxin, 1033, 1431
- Botulinum toxin therapy
- for achalasia, 605
 - for age-related facial changes, 1721
 - for diabetic autonomic neuropathy, 1226
 - for focal torsion dystonias, 1003
 - for migraine prophylaxis, 964t, 965
 - for spasticity, 1012
 - for Tourette syndrome, 1005
- Botulinus antitoxin, 1034, 1431
- Botulism, 1033–1034, 1294t, 1430–1431
- Bouchard nodes, 810, 811f
- Bougie dilators. *See* Esophageal dilation
- Boutonneuse fever, 1409t, 1414
- Boutonnière deformity, 831
- Bouveret syndrome, 703
- Bovine spongiform encephalopathy (vCJD/mad cow disease), 1381–1382, 1382
- Bowel function/dysfunction, in spinal injury, 1018
- Bowel irrigation, for poisoning/drug overdose, 1567
- Bowen disease, 117
- BPH. *See* Benign prostatic hyperplasia
- BPPV. *See* Benign paroxysmal positioning vertigo
- Brachial plexus
- lesions of, 1029–1032
 - in thoracic outlet/cervical rib syndromes, 818, 1031–1032
- Brachial plexus neuropathy, 1029–1030
- Brachytherapy. *See also* Radiation therapy
- for breast cancer, 736
 - for lung cancer, 1600
 - for prostate cancer, 1636
- Braden scale, for pressure ulcers, 70
- Bradycardia/bradyarrhythmias, 380, 394–397
- in myocardial infarction, 365, 372
 - palpitations and, 31, 32
 - persistent (sick sinus syndrome), 394
 - in poisoning/drug overdose, 1564t
 - sinus. *See* Sinus bradycardia in sleep apnea, 319
- Bradykinesia, in parkinsonism, 998, 999
- B-raf/BRAF* gene/mutations
- clinical relevance of testing for, 1726t
 - colorectal cancer/HNPCC and, 653, 656, 657, 1622, 1625
 - papillary thyroid carcinoma and, 1126
- Brain, vasculitis of (primary angitis of central nervous system), 854
- Brain abscess, 993–994, 1287, 1288, 1302t
- anaerobes causing, 1302t, 1455
 - bacterial rhinosinusitis and, 216
 - cancer-related, 994
 - in nocardiosis, 1457
 - otitis media and, 205
 - seizures and, 969, 994
 - in strongyloidiasis, 1519
- Brain biopsy
- in abscesses, 994
 - in CNS lymphoma in HIV infection/AIDS, 1327
 - in primary angitis of central nervous system, 854
 - in toxoplasmosis, 1502
- Brain cancer, 990t, 1611t. *See also* Intracranial masses/tumors
- metastatic, 992
 - primary, 989–992, 990t
- Brain death, 1015
- organ donation and, 93
- Brain edema. *See* Cerebral edema
- Brain imaging. *See* Neuroimaging
- Brain natriuretic peptide. *See* B-type natriuretic peptide
- Brain stimulation
- for idiopathic torsion dystonia, 1003
 - for parkinsonism, 1001
 - for Tourette syndrome, 1005
- Brain tumors, 989–993, 990t, 1612t. *See also* Brain cancer; Intracranial masses/tumors
- Brainstem
- arteriovenous malformations in, 987
 - ischemia of, seizures differentiated from, 971
 - lesions/tumors/infarction of, 991
 - coma or stupor caused by, 1014, 1015
 - gliomas, 990t, 991
 - vertigo caused by, 212
- Bran, dietary (bran powder), 572t, 1269. *See also* Fiber, dietary
- Branch retinal artery occlusion, 183–184
- Branch retinal vein occlusion, 181–182
- Branchial cleft cysts, 239
- deep neck infections and, 230
- Brandt-Daroff exercises, 211
- BRCA1/BRCA2* genes
- breast cancer and, 722, 723, 723t

- in male, 746
 - ovarian cancer and, 764
 - pancreatic/periampullary carcinoma and, 1608
 - Breast, 718–746**
 - abscess of, 721, 721f
 - nipple discharge caused by, 720
 - puerperal mastitis and, 721, 797–798
 - augmented, 721. *See also* Breast implants
 - disorders of, 721
 - benign disorders of, 718–721
 - biopsy of
 - in breast mass evaluation, 718, 727–729, 728f, 729f, 1718, 1719
 - during pregnancy, 807
 - in fat necrosis, 721
 - in fibroadenoma, 719
 - in fibrocystic condition, 718
 - mammographic localization, 729
 - stereotactic, 729
 - cancer of. *See* Breast cancer
 - cysts (simple) of, 1718, 1719. *See also* Breast, fibrocystic condition and
 - examination of
 - in cancer follow-up, 743
 - in cancer screening/early detection/mass evaluation, 15t, 724, 726–727, 726f, 727f, 1708, 1718
 - in gynecmastia, 1178
 - fat necrosis of, 720–721
 - fibroadenoma of, 719–720, 1718
 - fibrocystic condition and, 718–719, 1718, 1719
 - breast cancer risk and, 718, 719, 722, 723t
 - nipple discharge in, 718, 720, 720t
 - male, disorders of. *See* Breast cancer, in male; Gynecmastia
 - mass/lump in. *See* Breast cancer; Lump (breast)
 - nipple discharge and, 720, 720t, 730, 1719
 - phyllodes tumor of, 719
 - pregnancy affecting, 781
 - reconstruction of after mastectomy, 736, 744–745
 - local recurrence and, 721, 745
 - self-examination of, in cancer screening, 15t, 724, 1708
 - Breast cancer, 722–746, 1611t**
 - anatomic locations of, 726, 726f
 - antipsychotic drug use and, 1059
 - arm edema and, 727, 744
 - bilateral, 733
 - biomarkers/gene expression profiling and, 728, 733–734
 - prognosis and, 734, 736, 736t, 743
 - treatment and, 734
 - biopsy in diagnosis of, 718, 727–729, 728f, 729f, 1719
 - during pregnancy, 807
 - breast pain (mastalgia) and, 726, 730, 1716, 1717
 - breast reconstruction/implants and, 721, 736, 744–745
 - clinical examination in detection/evaluation of, 15t, 724, 726–727, 726f, 727f, 1718
 - clinical findings in early detection of, 726–730, 726f, 727f, 728f, 729f, 1718
 - cytology in evaluation of, 730
 - diet and, 722
 - differential diagnosis of, 730
 - ductal
 - in situ, 733, 733t
 - invasive/infiltrating, 733t
 - early detection/screening for, 15t, 724–725, 1708
 - clinical findings and, 726–730, 726f, 727f, 728f, 729f, 1718
 - genetic testing and, 722, 723
 - pregnancy and, 730, 807
 - endometrial cancer and, 722, 723t, 759
 - estrogen replacement therapy and, 722, 743–744, 780, 1182, 1183
 - exercise affecting risk of, 12, 15, 722, 1708
 - fibrocystic condition and, 718, 719, 722, 723t
 - genetic mutations associated with, 722, 723. *See also* BRCA1/BRCA2 genes
 - HER-2/*neu* oncogene overexpression
 - in, 733–734, 737
 - prognosis and, 734, 736, 736t, 737, 743
 - therapy and, 736, 737, 738, 741
 - incidence/risk/mortality of, 722–723, 723t, 1594t, 1708
 - in male, 745–746
 - inflammatory, 721, 730
 - in situ, 730, 733, 733t
 - lactation and, 730
 - lobular
 - in situ, 733, 733t
 - invasive, 733t
 - in male, 745–746
 - in Klinefelter syndrome, 1174, 1669
 - mammography in detection/evaluation of, 15t, 16, 718, 724, 724–725, 727, 728f, 729, 1708
 - biopsy and, 729
 - breast implants and, 721
 - pregnancy and, 730, 807, 1718
 - metastatic**
 - lymph node assessment and, 726, 726f, 727
 - prognosis and, 736, 736t, 743
 - treatment of, 734, 739–743, 740t
 - nipple discharge in, 720, 720t, 730, 1719
 - noninvasive, 730, 733, 733t
 - oral contraceptive use and, 722, 772
 - Paget, 117, 117f, 726, 730
 - nipple involvement and, 117, 117f, 726, 730
 - pancreatic/periampullary carcinoma and, 1608
 - paraneoplastic syndromes associated with, 1596t
 - pathologic types of, 730, 733t
 - prognosis and, 736t
 - pleural effusion in, 315
 - pregnancy affecting risk of, 722, 723t, 743, 1708
 - pregnancy and, 730, 743, 745, 807–808
 - prevention of, 723, 1708
 - chemoprevention and, 15, 723, 733, 736, 1708
 - genetic risk factors and, 723
 - prognosis for, 736, 736t, 743, 743t
 - adjuvant systemic therapy and, 736, 736t
 - biomarkers and, 734, 736, 736t, 743
 - in male, 746
 - recurrence of, 744
 - adjuvant systemic therapy and, 736, 736t
 - biomarkers/gene expression profiling and, 727, 734
 - breast reconstruction/implants and, 721, 745
 - Oncotype Dx assay in assessment of, 734
 - self-examination in prevention/screening of, 15t, 724, 1708
 - smoking/passive smoking and, 6
 - staging of, 730, 731–732t
 - prognosis and, 736t, 743, 743t
 - treatment choice and, 734–735
 - survivorship issues and, 744–745
 - treatment of, 734–743, 1611t
 - adjuvant systemic, 735, 736–738, 736t, 1611t
 - in older women, 738
 - biomarkers/hormone receptor status and, 734, 736, 736t, 738, 739
 - breast-conserving, 735
 - chemotherapy in, 735, 736–737, 738, 740, 741–742, 1611t
 - adjuvant/neoadjuvant, 735, 736–737, 738, 1611t
 - palliative, 740, 741–742
 - pregnancy and, 730, 745, 808
 - choice/timing of primary therapy and, 734–735
 - curative, 734–739, 735f, 736t
 - endocrine therapy in, 736, 738, 739–741, 740t. *See also* Hormone therapy, for breast cancer
 - adjuvant/neoadjuvant, 736, 738, 1611t
 - follow-up, 743–745
 - genetic markers for cancer and, 723
 - in male, 746
 - neoadjuvant, 735, 738
 - palliative, 734, 739–743, 740t
 - during pregnancy/lactation, 730, 745, 807–808
 - radiation therapy in, 735, 736, 739, 744
 - surgical resection, 735, 735–736, 735f. *See also* Lumpectomy; Mastectomy
 - targeted therapy in, 737–738, 739–741, 740t
 - “triple-negative,” 734, 741
 - ultrasonography in evaluation of, 718, 727, 728f, 729
- Breast Cancer Risk Assessment Tool, 1708**
- Breast-conserving therapy, for breast cancer, 735**
 - local recurrence and, 744
 - during pregnancy/lactation, 730
- Breast implants, 721**
 - breast cancer in patient with, 721
 - for breast reconstruction, 721, 745
 - disorders associated with, 721
 - rupture of, 721

- Breast milk. *See* Lactation
- Breast pain (mastalgia), **1716–1717**
 in cancer, 726, 730, 1716, 1717
 in fibrocystic condition, 718, 719, 1718, 1719
- Breast surgery, 735–736, 735*f*. *See also* Lumpectomy; Mastectomy
 during pregnancy, 807
- Breastfeeding. *See* Lactation
- Breath odor
 in cyanide poisoning, 1577
 in diabetic ketoacidosis, 1197, 1232
 in uremia, 909*t*, 910
- Breath sounds
 in asthma, 246
 in bronchial obstruction, 243
 in heart failure, 399
 in pneumonia, 271
- Breath tests
 in bacterial overgrowth, 580, 625
 in *H pylori* infection, 565, 609, 613
 in lactose intolerance, 573, 626
 in nausea and vomiting, 568
- Breathing. *See also under Respiratory*
 abnormalities of in coma or stupor, 1014, 1563
 assessment/support of
 in burn injury, 1550
 in coma, 1014, 1563
 impaired control of, pulmonary hypertension and, 424
 muscles/accessory muscles of
 in asthma exacerbation, 247*t*
 in myasthenia gravis, 1032
 sleep-related disorders of, **318–319**. *See also* Sleep apnea
- Breathing exercises
 for COPD, 264
 for cystic fibrosis, 268
 prevention of postoperative pulmonary complications and, 51
- Brentuximab vedotin, 1653*t*
 for Hodgkin lymphoma, 527
- Brevibloc. *See* Esmolol
- Brief psychotic disorders, 1054
- Brill-Zinsser disease, 1408
- Brimonidine
 for glaucoma/ocular hypertension, 171*t*, 176
 overdose/toxicity of, 1577
- Brimonidine/timolol, for glaucoma/ocular hypertension, 171*t*, 176
- Brinzolamide, for glaucoma/ocular hypertension, 171*t*, 176
- Brinzolamide/timolol, for glaucoma/ocular hypertension, 171*t*, 176
- Briquet syndrome, 1045–1046
- British anti-Lewisite (BAL). *See* Dimercaprol
- Brodifacoum poisoning, 1573
- “Broken heart syndrome.” 413. *See also* Tako-Tsubo (stress/catecholamine-induced) cardiomyopathy
- Bromfenac, for ophthalmic disorders, 169*t*
- Bromocriptine. *See also* Dopamine agonists
 for cocaine withdrawal, 1085
- for hyperprolactinemia, 1104
 lactation suppression and, 786
 for mastalgia, 1717
 for neuroleptic malignant syndrome, 36, 1060, 1565, 1574
 for ovulation induction, 769
 for parkinsonism, 1000
- Brompheniramine, for allergic/perennial rhinitis, 218–219
- Bronchi, foreign body in, **238–239**, 308
- Bronchial carcinoid tumors (bronchial adenomas), **291**
- Bronchial gland carcinoma, 291
- Bronchial obstruction, 243
- Bronchial provocation testing, in asthma, 246–247
- Bronchiectasis, **265–266**
 COPD differentiated from, 261
 cystic fibrosis and, 266, 267
 in measles, 1368
 nontuberculous mycobacterial infection and, 266, 288
- Bronchiolitis, **269–270**
 acute, 269
 adenoviruses causing, 269, 1402
 constrictive (obliterative/bronchiolitis obliterans), 269, 270
 with organizing pneumonia (BOOP/cryptogenic organizing pneumonia/pneumonitis/COP), 269, 294*t*, 295
 silo-filler’s disease and, 311
 follicular, 269
 measles causing, 1368
 proliferative, 269, 270
 respiratory, 269
 interstitial lung disease associated with (RB-ILD), 269, 294*t*, 295
 RSV, 269, 1393–1394, 1394
- Bronchioloalveolar cell carcinoma, 1595. *See also* Lung cancer
- Bronchitis
 chlamydial, 1462
 chronic, 259, 260*t*. *See also* Chronic obstructive pulmonary disease
 imaging findings in, 261
 industrial, **311**
 management of, 264
 cough in, 23, 260*t*
 dyspnea in, 24, 260*t*
- Bronchoalveolar lavage, for respiratory secretion analysis
 in eosinophilic pneumonia, 297
 in immunocompromised host, 279
 in interstitial (diffuse parenchymal) lung disease, 293
 in *Pneumocystis* pneumonia, 279, 1326, 1534
 in pneumonia, 277, 279
 in pulmonary alveolar proteinosis, 296
 in sarcoidosis, 296
 in tuberculosis, 280
- Bronchoconstriction. *See* Asthma; Bronchospasm
- Bronchodilators
 adverse ophthalmic effects of, 195*t*
 for asthma
- exacerbation management and, 244*f*, 245*t*, 249*f*, 254–255*t*, 255, 256
 long-acting, 249*f*, 250–252
 short-acting, 244*f*, 245*t*, 249*f*, 254–255*t*, 255, 256, 257*f*, 258*f*
- for COPD, 262–263
 for cystic fibrosis, 268
 perioperative, 51
 response to, in asthma diagnosis, 246
- Bronchogenic carcinoma, **1595–1601**, 1598*t*. *See also* Lung cancer
- Bronchopneumonia, in measles, 1368
- Bronchoprovocation testing. *See* Bronchial provocation testing
- Bronchopulmonary mycosis/aspergillosis, allergic, **266–267**, 1537, 1538
- Bronchoscopy. *See also* Bronchoalveolar lavage
 in bronchial carcinoid tumors, 291
 in bronchial obstruction, 243
 in hemoptysis, 27
 in interstitial (diffuse parenchymal) lung disease, 293
 in lung cancer, 1597
 in pneumonia, 272
 in solitary pulmonary nodule, 290
 in tuberculosis, 280–281
- Bronchospasm/bronchoconstriction. *See also* Asthma
 adenosine causing, 382
 in COPD, 260
 in desensitization therapy, 1307
 exercise-induced, 243
 perioperative, 50
 in pulmonary edema, 408
 transfusion causing, 535
- Broth technique, for drug susceptibility testing, 1304
- Brown recluse spider bites, 149, 1590
- Brown-Séquard syndrome, 1018
- Brown tumors of bone, in hyperparathyroidism, 1139
- Bruce protocol, for exercise testing, 352
- Brucella abortus/melitensis/suis* (brucellosis), 1299*t*, **1449–1450**
- Bruzdzinski sign, 41, 1441
- Brugada syndrome, 432
- Brugia*
malayi, 1524
 eosinophilic pulmonary syndromes and, 296, 1525
timori, 1524
- Bruits
 in aortoiliac occlusive disease, 464
 carotid, 469
 in cerebral arteriovenous malformation, 987
 in occlusive cerebrovascular disease, 469
- Bruxism, earache and, 206
- BSE. *See* Bovine spongiform encephalopathy; Breast, self-examination of
- BSS. *See* Bernard-Soulier syndrome
- Buboes
 in lymphogranuloma venereum, 659, 1461
 in plague, 1451

- Budd-Chiari syndrome (hepatic vein obstruction), 697–699
- Budesonide
for allergic rhinitis, 218
for asthma, 253*t*
with formoterol, 251*t*, 252
in pregnant patient, 803
for autoimmune hepatitis, 679
for inflammatory bowel disease, 639
Crohn disease, 644
microscopic colitis, 650
- Buergler disease (thromboangiitis obliterans), 471–472
Raynaud disease/phenomenon and, 472, 837
- Bufotenin, toxicity of, 1579
- Bulbar palsy
progressive, 1019, 1020
in syringomyelia, 1019
- Bulbar poliomyelitis, 1372–1373
- Bulbospinal neuronopathy, X-linked, 1020
- Bulimia nervosa, 1263
with anorexia nervosa, 1263
- Bullectomy, for emphysema, 265
- Bullous impetigo, 123*f*
in HIV infection/AIDS, 1331
- Bullous pemphigoid, 139
- Bullous (blistering) skin disorders, 95*t*, 138–139. *See also specific type*
- Bumetanide
for heart failure, 401
infarct-related, 373
for hypertension, 445*t*
in urgencies/emergencies, 463
lithium use and, 1074
for pulmonary edema, 408
- Bumex. *See* Bumetanide
- BUN. *See* Blood urea nitrogen
- Bundibugyo virus, 1384
- Bundle branch block, 395–396
in atrial septal defect, 328
in myocardial infarction, 366, 373
preoperative evaluation/perioperative management and, 49
in tetralogy of Fallot, 331
- Bunyaviruses
encephalitis caused by, 1378–1380
hantaviruses as, 1388
hemorrhagic fever caused by, 1384–1385, 1385
- Buprenorphine, 80*t*
for heroin/opioid addiction/
withdrawal, 18–20, 1084
overdose/toxicity of, 1586–1587
- Bupropion, 1067, 1070*t*
for drug-induced erectile dysfunction, 1067
for obesity, 1261
overdose/toxicity of, 1070*t*, 1591–1592
for smoking cessation, 8, 261, 1593
- Burin variant MEN 1, 1189
- Burkholderia*
mallei (glanders), 1300*t*
pseudomallei (melioidosis), 1300*t*
- Burkitt lymphoma, 524, 525
Epstein-Barr virus in, 1363
- Burkitt type ALL, 520
- Burn blister, 1550
- Burn dressings, 1551
- Burn surface area, estimating, 1549–1550, 1549*f*
- Burning mouth syndrome, 226
- Burns, 1549–1552, 1549*f*
abdominal compartment syndrome and, 1551
chemical. *See* Chemical injury
classification of, 1549–1550, 1549*f*
depth of, 1550
electric, 1550, 1552–1553
extent of, 1549–1550, 1549*f*
fasciotomy in, 1551
flame (clothing), 1552
flash (arcing), 1552
infection and, 1551
injuries/illnesses associated with, 1550
Joule, 1552
patient assessment and, 1549–1550, 1549*f*, 1550
radiation, 1554
smoke inhalation and, 307, 1550
survival and, 1550
survival after, 1550
systemic reactions to, 1550
tetanus immunization and, 1551
treatment of, 1550–1552
chemoprophylaxis for, 1551
initial resuscitation, 1550–1551
patient support and, 1551–1552
Stevens Johnson syndrome/toxic epidermal necrolysis treatment and, 135
surgical management in, 1551
- Bursa/bursitis, 825–826, 825*f*. *See also specific type or joint affected*
in diabetes, 1228
- Buruli ulcer, 1458
- “Bush teas,” sinusoidal obstruction syndrome caused by, 698
- Buspar. *See* Buspirone
- Buspirone, 1042*t*
for aggressive/violent behavior, 1079
antidepressant drug augmentation and, 1065, 1069
for anxiety, 1042*t*, 1043
for OCD, 1044
- Busulfan, 1650*t*
- Butane, toxicity of, 1583
- Butanediol, overdose/toxicity of, 1580
- Butenafine, 98*t*
for tinea corporis, 111
- Butoconazole, for vulvovaginal candidiasis, 752
- Butterfly rash, in SLE, 833
- Button batteries, ingested, alkali injuries caused by, 1572
- γ -Butyrolactone, overdose/toxicity of, 1580
- Butyrophenones, 1055, 1056. *See also* Antipsychotic drugs; Haloperidol
overdose/toxicity of, 1574
- Bydureon. *See* Exenatide
- Byetta/Byetta LAR. *See* Exenatide
- Bypass grafting
for aortic dissection, 477
for aortoiliac occlusive disease, 465
coronary artery. *See* Coronary artery bypass grafting
for erectile dysfunction, 953
for femoral/popliteal occlusive disease, 466
for lower leg/foot occlusive disease, 467
for superior vena caval syndrome, 482
for visceral artery insufficiency/intestinal angina, 471
- Bypass surgery, for obesity, 14, 1261
hypoglycemia after, 1242
in type 2 diabetes, 1220
- Byssinosis, 311
- Bystolic. *See* Nebivolol
- C3
in bullous pemphigoid, 139
in focal segmental glomerulosclerosis, 930
in IgA nephropathy, 923
in membranous nephropathy, 929
in nonalcoholic fatty liver disease, 684
in postinfectious glomerulonephritis, 922
reference values for, 1729*t*
- C3b
in autoimmune hemolytic anemia, 506
in cold agglutinin disease, 507
- C3 nephritic factor, in
membranoproliferative glomerulonephropathy, 921*f*, 925
- C4, reference values for, 1729*t*
- C5A, in familial Mediterranean fever, 591
- C282Y mutation, in hemochromatosis, 694, 695
hepatocellular carcinoma and, 682, 1603
- C_{cr}. *See* Creatinine clearance
- c-erbB-2. *See* HER-2/*neu* overexpression
- c-myc gene, in Burkitt lymphoma, 524
- 13C-octanoic acid breath test, in nausea and vomiting, 568
- C-peptide
in factitious hypoglycemia, 1239, 1243
insulinoma secreting, 1172, 1239
reference values for, 1728*t*
- C-reactive protein
coronary heart disease and, 350–351, 1250
in women, 1707
in Crohn disease, 642
reference values for, 1728*t*
in rheumatoid arthritis, 827
- C-telopeptide
beta-cross-linked, reference values for, 1728*t*
in Paget disease of bone, 1152
- C-urea breath testing. *See* Urea breath testing
- c-v wave
in pulmonary stenosis, 325
in tetralogy of Fallot, 331
- ¹⁴C-xylose test, in bacterial overgrowth, 580
- Ca. *See* Calcium
- CA 15-3, in breast cancer, 727
- CA 19-9
in cholangiocarcinoma, 710, 1606
in pancreatic/periampullary carcinoma, 1608
- CA 27-29, in breast cancer, 727
- CA 125, in ovarian tumors, 764, 765
screening for, 16, 764, 1710

- CA-MRSA. *See* Community-associated methicillin-resistant *S aureus*
- Cabazitaxel, 1652*t*
for prostate cancer, 1637
- Cabergoline
for Cushing disease, 1160
for GH-secreting tumors, 1101
for hyperprolactinemia, 1104
- CABG. *See* Coronary artery bypass grafting
- Cabozantinib, for prostate cancer, 1637
- Cachectin. *See* Tumor necrosis factor
- Cachexia
diabetic neuropathic, 1226
in protein-energy malnutrition, 1258
in terminally ill/dying patient, 90
- CACNA1 gene, in familial hemiplegic migraine, 963
- CACNA1S gene, in periodic paralysis, 1036
- CACNLIA3 gene, in periodic paralysis, 1036
- CAD (coronary artery disease). *See* Coronary heart disease
- Cadherin cell adhesion protein, gastric cancer and, 1616
- Cadmium, tubulointerstitial disease caused by, 933
- CADP test, 1733*t*
- Caduet. *See* Atorvastatin, with amlodipine
- Café au lait spots, 996
- Café coronary, 308
- Cafergot, for migraine headache, 963
- Caffeine, 1086
fibrocystic breast condition and, 719
for migraine headache, 963
overdose/toxicity of, 1086, 1590–1591
during pregnancy, 783
- Caffeinism, 1086
- cagA gene, in *H pylori* gastritis, 609
- CAGE screening test, 18, 19*t*
- Cajal, interstitial cells of, gastrointestinal stromal tumors and, 1619
- Calabar swellings, 1527, 1528
- Calan. *See* Verapamil
- Calcaneofibular ligament, ankle sprains and, 1703
- Calcifediol (25-hydroxyvitamin D₃), 1149
for hypoparathyroidism/tetany, 1137
reference values for, 1735*t*
serum levels of in osteoporosis, 1145
for vitamin D deficiency/osteomalacia, 1151
- Calciferol. *See* Ergocalciferol
- Calcific (degenerative) aortic stenosis, 333, 342, 343
- Calcimar. *See* Calcitonin
- Calcimimetic agents. *See* Cinacalcet
- Calcinosis
cardiac, 427
in cor pulmonale, 426
tumoral, 912
- Calciphylaxis, 1139, 1141
- Calcipotriene, for psoriasis, 107
- Calcitonin
reference values for, 1728*t*
in thyroid cancer, 1128, 1189
- Calcitonin/nasal calcitonin-salmon
for hypercalcemia, 884, 1647
for osteoporosis, 1148
for Paget disease of bone, 1153
- Calcitriol (1,25-dihydroxycholecalciferol)
for hypocalcemia/hypoparathyroidism/tetany, 1137, 1137*t*, 1138
for metabolic bone disorders/renal osteodystrophy, 913
for osteomalacia/rickets, 1151
for parathyroid hyperplasia, 1143
reference values for, 1735*t*
- Calcitriol ointment, for psoriasis, 107
- Calcium
coronary, tomographic assessment of, in chest pain evaluation, 29
dietary/supplementary, 1146, 1269–1270
for calcium channel blocker overdose, 1563, 1576
in colorectal cancer prevention, 1269–1270, 1623
deficiency of in osteomalacia/rickets, 1149–1150
high-calcium diet and, 1269–1270
hypercalcemia caused by, 883, 1141
hypercalciuria and, 948
for hyperkalemia, 880, 881*t*
for hypermagnesemia, 888
for hyperoxaluric calcium nephrolithiasis, 949
for hyperphosphatemia, 886, 913
for hypertension, 441, 1269–1270
for hypocalcemia/
hypoparathyroidism/tetany, 882, 1137, 1138
for metabolic bone disorders/renal osteodystrophy, 913
milk-alkali syndrome and, 883, 884
for osteomalacia, 1151
for osteoporosis prevention/
management, 11, 780, 1146, 1269–1270, 1710
after parathyroidectomy, 1143
during pregnancy/lactation, 785, 786
requirements for in nutritional support, 1272
urinary stone formation and, 948, 1146
disorders of concentration/metabolism of, 881–884, 882*t*, 883*t*. *See also* Hypercalcemia;
Hypocalcemia
in chronic kidney disease/renal osteodystrophy, 882, 912, 912*f*
genetic disorders associated with, 878*t*
intracellular, in hypertension, 436
reference/normal values for, 881, 1728*t*
serum levels of
albumin levels and, 882, 883, 1136, 1646
in hypercalcemia/
hyperparathyroidism, 883, 884, 1139, 1140*f*, 1646
in hypercalciuria, 947, 947*t*
in hypocalcemia/
hypoparathyroidism, 882, 1136, 1138
magnesium serum levels and, 882, 883, 887
in Paget disease of bone, 1152
parathyroid hormone affecting, 882, 883, 884, 1135, 1138, 1140*f*
phosphorus/phosphate metabolism and, 885
reference/normal values for, 881, 1728*t*
urinary excretion of, 947*t*, 948. *See also* Hypercalciuria
in hypercalcemia, 884, 947*t*
in hypocalcemia, 882–883
reference value for, 1728*t*
in urinary stones, 946, 947, 948–949, 1146. *See also* Calcium nephrolithiasis;
Hypercalciuria
- Calcium acetate. *See* Calcium, dietary/supplementary
- Calcium bilirubinate, in gallstones, 703
- Calcium carbonate. *See* Calcium, dietary/supplementary
- Calcium channel α_2 - δ ligands, for neuropathic pain, 84–85, 84*t*
- Calcium channel blocking drugs,
454–455*t*
for acute coronary syndromes, 363
for angina, 356
for arrhythmias, 377, 379*t*
atrial fibrillation, 386
supraventricular tachycardia, 379*t*, 382
for cardiomyopathy, 415
in heart failure, 405, 453
for hypertension, 442*t*, 453, 454–455*t*, 457–458, 457*f*, 458*t*
in combination regimen, 457–458, 457*f*, 458*t*
in diabetes, 442*t*, 458, 1203
during pregnancy, 802
in urgencies/emergencies, 462*t*
lower extremity edema caused by, 33, 34
for myocardial infarction, 371, 376
overdose/toxicity of, 453, 454*t*, 1563, 1576
pheochromocytoma/
pheochromocytoma surgery and, 1170
for pulmonary hypertension, 305, 424, 425*f*
for Raynaud phenomenon, 837, 839
for subarachnoid hemorrhage, 985
- Calcium chloride. *See* Calcium, dietary/supplementary
- Calcium citrate. *See* Calcium, dietary/supplementary
- Calcium disodium edetate (EDTA), for lead poisoning, 933, 1582
- Calcium gluconate. *See also* Calcium, dietary/supplementary
for calcium channel blocker overdose, 1576
for hydrofluoric acid burns, 1571
for hypocalcemia/hypoparathyroidism/tetany, 882, 1137
- Calcium nephrolithiasis, 946, 947, 948–949
hypercalcemia/hypercalciuria/
hyperparathyroidism and, 947*t*, 948, 1139, 1141
hypercitraturia and, 949

- hyperoxaluria and, 949
hyperuricosuria and, 948–949
in polycystic kidney disease, 935
Calcium polycarbophil, 572*t*. *See also*
Fiber, dietary
Calcium pyrophosphate dihydrate
deposition disease
(pseudogout), 809, 814,
816–817
rheumatoid arthritis differentiated
from, 828
Calcium-sensing receptor, 881
mutations in gene for, 878*t*, 881
in hypercalcemia, 878*t*, 1142
in hypocalcemia, 878*t*, 882
in hypoparathyroidism, 882, 1136
Calcium-stimulated angiography, in
insulinoma diagnosis,
1240–1241
Calculus formation. *See specific type or*
structure or organ affected
Calderol. *See* Calcifediol
Calendar method of contraception, 775
Caliciviruses, gastroenteritis caused by,
1295*t*, 1404–1405
California encephalitis, 1378–1380
California flea rickettsiosis, 1409*t*
Callosities of feet or toes, **141**
in diabetes/vascular disorders, 141,
1224
Caloric testing
in coma or stupor, 1014, 1015
in Ménière syndrome, 210
Calorie requirements, in nutritional
support, 1271–1272
Calorie restriction, in obesity
management, 14, 1260
Calorimetry, for energy expenditure
measurement, 1272
Calprotectin, in Crohn disease, 642
Calretinin, in mesothelioma, 1602
Calymmatobacterium (Donovania)
granulomatis, 1453
CAM. *See* Confusion assessment method
Cameron erosions/lesions, 586, 617
Campath. *See* Alemtuzumab
Camphor/menthol preparations, 94, 98*t*
Camptosar. *See* Irinotecan
Campylobacter, 1299*t*, **1449**
diarrhea/gastroenteritis caused by,
574*t*, 575, 1293, 1295*t*, 1296,
1297, 1298, 1303*t*, 1330, 1449
Guillain-Barré syndrome and, 1024
fetus subsp *fetus*, 1449
jejuni, 1295*t*, 1297, 1299*t*, 1449
Campylobacter-like organisms, 1449
Canalicular plugs, for dry eye, 166
Canasa. *See* Mesalamine
Canavan disease, prenatal testing for, 783
Cancer, **1593–1663**. *See also specific type*
and under Malignant
back pain in, 1683
cognitive disorders/delirium and, 1087*t*
complications of, **1644–1648**
DIC in, 545, 546
early detection/screening tests for,
15–16, 15*t*
effusions associated with, **1645–1646**
emergencies associated with,
1644–1648
Epstein-Barr virus infection and, 1363
etiology of, 1593, 1594*t*
exfoliative dermatitis/erythroderma
and, 116
fever/FUO and, 1276, 1277, 1596*t*
HIV infection/AIDS and, 1319, 1320*t*,
1322, 1331–1332
hypercalcemia associated with, 883,
884, 1141, 1596*t*, **1646–1647**.
See also Hypercalcemia
hyperuricemia associated with, **1647–**
1648
allopurinol for, 1647, 1658*t*
rasburicase for, 1647, 1658*t*
incidence/risk/mortality of, 1593–1594,
1594*t*
obesity and, 13, 1259, 1594
infectious complications of, 994, 1279,
1648
lipid abnormalities associated with,
1248*t*
neuropathies associated with, **1024**,
1596*t*
nonmetastatic neurologic
complications of, **994–995**,
1024
oral contraceptive use and, 722, 770,
772
paraneoplastic syndromes and,
1594–1595, 1596*t*
pericarditis associated with, 419, 420
pleural effusions in (malignant pleural
effusions), 314, 314*t*, 315,
1645, 1645–1646
polymyositis/dermatomyositis and,
840, 841, 864, 1596*t*
prevention of, **15–17**, 15*t*. *See also*
Cancer, early detection/
screening tests for
chemoprevention and, 11, 15
in women, **1708–1710**
prognosis for, **1663**
radiation exposure and, 1555, 1594
rheumatic manifestations of, **864–865**
SIADH and, 873, 873*t*, 1596*t*
smoking/smoking cessation and, 6, 15,
1593
spinal cord compression and, 993,
1644–1645
staging of, 1594
stem cell transplants for, 532–534
treatment of, **1648–1663**. *See also*
Chemotherapy; Radiation
therapy
tumor lysis syndrome and, **1647–1648**
venous thrombosis/pulmonary
embolism and, 301*t*, 1596*t*
Candidas. *See* Caspofungin
Cancuas. *See* Caspofungin
Candesartan, 451*t*
for heart failure, 402
for hypertension, 451*t*
with hydrochlorothiazide, 451*t*
for migraine prophylaxis, 964*t*
Candida (candidiasis), **1529–1531**
albicans, 225, 1529
in diabetes, 1228
disseminated, 132, 1529–1530, 1530
endocarditis in, 1530
esophageal, 598, 1529, 1530, 1542
in HIV infection/AIDS, 598, 1325,
1329, 1338*t*, 1530
glabrata, 1530
hepatic, 701
hepatosplenic, 1530
in HIV infection/AIDS, 131, 132, 225–
226, 226, 226*f*, 598, 1325,
1331, 1337, 1338*t*, 1529
invasive, 132, 1529–1530, 1541, 1542
krusei, 1530
mucocutaneous/mucosal, **131–132**,
131*f*, 1529, 1530
nail infection and, 131, 131*f*, 132, 157
non-albicans, 132, 752, 1530
oral (thrush), 131, 131*f*, **225–226**, 226*f*
esophagitis and, 598, 1529
in HIV infection/AIDS, 131,
225–226, 226, 226*f*, 1325,
1328–1329, 1337
osteomyelitis caused by, **862–863**
parapsilosis, 1292, 1530
pharyngeal, 1419–1420
prevention of, 1337
resistant strains of, 1530
tinea cruris differentiated from, 112
in urine, 1529, 1530
vulvovaginal, 132, 751, 751*f*, 752–753,
1529, 1530
in diabetes, 1197, 1197*t*, 1228
in HIV infection/AIDS, 1332, 1337,
1338*t*
rape/sexual assault and, 1291
Candida antigen, for wart removal, 141
Candidal funguria (candiduria), 1529,
1530
Candidemia, 132, 1530, 1542
Canker sore (aphthous ulcer), **227**, 227*f*
in Behçet syndrome, 853
in Crohn disease, 641
in HIV infection/AIDS, 1329
Cannabinoids
for nausea and vomiting, 86, 569. *See*
also Dronabinol
in pain management, 85
synthetic, amphetamine-like reactions
and, 1572
Cannabis sativa, **1084–1085**. *See also*
Marijuana
Cannon A waves
in AV junctional rhythm, 390
palpitations and, 31
CAP. *See* Community-acquired
pneumonia
CAPD. *See* Continuous ambulatory
peritoneal dialysis
Capecitabine, 1651*t*
for breast cancer, 738, 741
for colorectal cancer, 1625
for pancreatic/periampullary
carcinoma, 1609
Capillariasis, 578
Capillary angiomas, in Sturge-Weber
syndrome, 997
Caplan syndrome, 309
Capoten. *See* Captopril
Capozide. *See* Captopril, for
hypertension, with
hydrochlorothiazide
CAPRA nomogram, for prostate cancer
assessment, 1637, 1637*t*, 1638*t*

- Caprelsa. *See* Vandetanib
- Capsaicin
for anogenital pruritus, 146–147
for neuropathic itch, 94
for osteoarthritis, 812
for painful diabetic neuropathy, 1225
for postherpetic neuralgia, 120, 968, 1359
- Capsule imaging/endoscopy
in colon polyp identification, 653
in Crohn disease, 642
in GI bleeding, 585
obscure bleeding and, 586
- Captopril, 450*t*
for heart failure, 402
for hypertension, 449, 450*t*
in diabetics, 1202, 1224
with hydrochlorothiazide, 450*t*
in urgencies/emergencies, 462*t*, 463
for myocardial infarction, 371
- Car accidents. *See* Automobile accidents
- Car driving
by patients with dementia, 62, 1010
by patients with syncope/ventricular tachycardia/aborted sudden death, **397–398**
by suicidal patients, 1065
- Carac. *See* Fluorouracil
- Carbamate poisoning, 1587
- Carbamazepine, 972, 973*t*, 1074–1075, 1722*t*. *See also*
Anticonvulsant therapy
for aggressive/violent patient, 1078
for alcohol withdrawal, 1083
for bipolar disease/mania, 1074–1075
breastfeeding and, 782*t*
for dementia-associated behavior problems, 1089
for neuropathic pain, 1021
overdose/toxicity of, 973*t*, 1074–1075, 1569*t*, 1573
hemodialysis for, 1568*t*, 1574
for personality disorder, 1053
during pregnancy and, 803, 1075
for seizures, 972, 973*t*
- Carbapenems, allergy to, penicillin allergy cross-reactivity and, 1306
- Carbaryl poisoning, 1587
- Carbidopa, 999
- Carbidopa/levodopa, 999
with entacapone, 999, 1000
- Carbimazole, for hyperthyroidism/Graves disease, 1114
- Carbohydrate deficient transferrin, alcohol use/abuse and, 1081
- Carbohydrates, dietary. *See also* High-carbohydrate diet; Low-carbohydrate diets
in diabetic diet, 1204, 1205
glycemic index of, 1205
for hypoglycemia, 1222
for islet cell tumors/insulinomas, 1241
malabsorption of
diarrhea and, 578
flatus and, 573
in porphyria, 1022, 1664
- Carbon dioxide
increased production of, respiratory failure and, 320*t*
partial pressure of. *See* PaCO₂; PCO₂
reference values for, 1728*t*
venous, 889. *See also* Bicarbonate
- Carbon dioxide laser therapy
for CIN, 756
for wart removal/condylomata acuminata, 140, 753
- Carbon monoxide, diffusing capacity for (Dl_{CO}). *See* Diffusing capacity for carbon monoxide
- Carbon monoxide poisoning, 307, 1566*t*, 1569*t*, **1576–1577**
dyspnea in, 25, 1576
headache in, 41, 1576
- Carbonic anhydrase inhibitors
adverse ophthalmic effects of, 196*t*
for glaucoma/ocular hypertension, 171*t*, 177
renal tubular acidosis caused by, 892
- Carboplatin, 1650*t*
as cisplatin substitute, 1662
for lung cancer, 1599
for testicular cancer, 1643
toxicity of, 1650*t*
- Carboxyhemoglobin levels
in carbon monoxide poisoning, 307, 1576
reference values for, 1728*t*
- Carbuncles, **151–152**, 1421*t*, 1425, 1425*f*
- Carcinoembryonic antigen (CEA)
in breast cancer, 727
in colorectal cancer, 1624, 1626
reference values for, 1728*t*
in thyroid cancer, 1128
- Carcinoid heart disease, 428
pulmonary valve regurgitation and, 348
tricuspid stenosis and, 346
- Carcinoid syndrome, 291, 1172, 1621
- Carcinoid tumors, 1612*t*
bronchial, **291**
gastric, **1619**, 1621
intestinal, **1620–1621**
in MEN, 1188*t*, 1619
pancreatic, 1172
pernicious anemia gastritis and, 610, 1619
- Carcinoma in situ
of breast, 730, 733, 733*t*
of cervix, 756, 757
of vulva, 760
- Carcinomatosis
lymphangitic, 1601
peritoneal, 588, 590
- Carcinomatous meningitis
(leptomeningeal metastases), 922, 1287
- Card agglutination test (CATT), in African trypanosomiasis, 1485
- Cardene/Cardene SR. *See* Nicardipine
- Cardiac amyloidosis, 531. *See also* Cardiomyopathy, amyloid
- Cardiac angiography. *See* Angiography/arteriography, cardiac/coronary
- Cardiac arrhythmias. *See* Arrhythmias
- Cardiac asthma, 243
- Cardiac biomarkers/enzymes
in acute MI (STEMI), 360, 366
in infectious myocarditis, 410
in non-ST elevation acute coronary syndromes, 360, 361
in women, 1707
- Cardiac calcinosis, 427
in cor pulmonale, 426
- Cardiac catheterization
in acute coronary syndromes, 364, 364*t*
in aortic stenosis, 342
in atrial septal defect/patent foramen ovale, 328
in cardiomyopathy, 412*t*, 414
in constrictive pericarditis, 422
in coronary artery disease, 354
in heart failure, 400
in myocardial infarction, 364*t*, 371
in patent ductus arteriosus, 333
in pulmonary stenosis, 326
in Tako-Tsubo cardiomyopathy, 413
in tetralogy of Fallot, 331
in ventricular septal defect, 330
- Cardiac cirrhosis, 687
- Cardiac dysrhythmias. *See* Arrhythmias
- Cardiac failure
acute, 399, **407–409**
congestive, **398–409**, 399*f*. *See also* Congestive heart (cardiac) failure
- Cardiac friction rub. *See also* Pericardial friction rub
in chest pain evaluation, 29
- Cardiac glycosides. *See* Digitalis/digitalis glycosides
- Cardiac index
in myocardial infarction, 367*t*
in shock, 367*t*, 487
- Cardiac magnetic resonance imaging. *See* Magnetic resonance imaging (MRI), cardiac
- Cardiac murmurs. *See* Heart murmurs
- Cardiac output
acute kidney injury and, 903
in aortic stenosis, 342
in pregnancy, 802
in shock liver, 699
- Cardiac risk assessment
in postinfarction management, 375
preoperative, **46–50**, 47*t*, 48*f*, 48*t*
- Cardiac Risk Index, Revised, 46, 47*t*
- Cardiac rupture, 428
- Cardiac-specific markers (cardiac enzymes). *See* Cardiac biomarkers
- Cardiac tamponade. *See* Tamponade
- Cardiac transplantation, for heart failure, 406
- Cardiac trauma, **428–429**
sudden death of athlete and, 431
- Cardiac tumors, **426–427**
- Cardiac valves. *See also* Prosthetic heart valves; Valve replacement; Valvular heart disease
endocarditis affecting, 338, 1435, 1437. *See also* Endocarditis
in systemic disease, 427, 428
- Cardiobacterium hominis*. *See* HACEK organisms
- Cardioembolism
stroke and, 982
transient ischemic attacks and, 977, 978–979
- Cardiogenic pulmonary edema, 399, **407–409**
perioperative, 49

- Cardiogenic shock, 367*t*, 368, 374, 485, 485*t*, 486, 487, 487–488, 489
 in infectious myocarditis, 410
- Cardiogenic syncope, 396
- Cardiomegaly
 in heart failure, 400
 in hypothyroidism (myxedema heart), 1106
- Cardiomyopathy, **411–417**, 412*t*, 416*f*
 adenovirus infection and, 1402
 amyloid, 415, 416–417, 417, 427, 531
 catecholamine-induced. *See* Cardiomyopathy, Tako-Tsubo
 cirrhotic, 687
 coxsackieviruses causing, 1406
 in diabetes, 1227
 dilated, **411–413**, 412*t*
 genetic factors in, 411, 414
 heart failure and, 398, 411, 411–412, 412–413
 heart murmurs in, 337*t*, 411–412, 414
 in hyperthyroidism, 1112, 1118
 hypertrophic/hypertrophic obstructive, 412*t*, **414–415**, 416*f*
 sudden death and, 414, 415
 of athlete, 414, 431, 432
 infectious myocarditis and, 410, 411
 infiltrative, 427
 ischemic, 398
 mitral regurgitation and, 339, 340, 412, 415
 palpitations and, 31
 in pregnancy
 dilated (peripartum
 cardiomyopathy/heart failure), **429–430**, 802, 803
 hypertrophic constrictive, 415
 prolactin causing, 429, 1103
 restrictive, 412*t*, **415–417**
 constrictive pericarditis
 differentiated from, 416, 422
- Tako-Tsubo (stress/catecholamine-induced), 411, **413**
 myocardial infarction mimicked by, 365
 pheochromocytoma and, 1169, 1170
 trastuzumab causing, 737
 ventricular arrhythmias in, 391, 411, 412, 414
- Cardiomyoplasty, for heart failure, 406
- Cardiomyotomy, Heller, for achalasia, 605
- Cardiopulmonary resuscitation
 in electrical injury, 1553
 for hypothermia, 1544
 in near drowning, 1556
 orders regarding in end-of-life care, **89–90**
- Cardiorenal syndrome, **908**
- Cardiotoxicity
 anthracycline, 411, 1662
 dexrazoxane for, 1658*t*, 1662
 antiarrhythmics causing, 1588
 antidepressants causing, 1591
- Cardiovascular disorders. *See also under* *Cardiac*; *Coronary*; *Myocardial and Heart disease*; *Stroke*
 adverse ophthalmic effects of drugs used in, 195–196*t*
 in athletes, screening for, **431–432**
 in Chagas disease, 1486
 chemoprevention in, **7*t*, 11**
 chronic kidney disease/uremia and, 908, 909*t*, 910, 911–912, 911*f*
 cocaine abuse and, 360, 365, 1085
 cognitive disorders/delirium caused by, 1087*t*
 coxibs (COX-2 inhibitors) and, 76, 608
 in diabetes mellitus, 356, 1197, 1227–1228
 glycemic control and, 203, 356, 1201, 1202, 1203, 1204
 hypertension control and, 356, 443, 457–458, 458, 1202, 1203, 1227
 in women, 1707
 estrogen replacement therapy and, 780, 1182
 homocysteine/hyperhomocysteinemia/homocystinuria and, 1668–1669
 in hypercalcemia, 1139
 hypertension/hypertension control and, **10–11**, 433, 434, 439, 441–442, 442–444, 442*t*, 443*f*, 444*t*, 457
 in women, 1706
 in hyperthyroidism, 1112, 1114, 1118–1119
 in hypothyroidism, 1108
 immobility/bed rest and, 65
 lipid disorders and, **8–10**
 in Lyme disease, 419, 1479, 1481–1482, 1482*t*
 in pheochromocytoma/paraganglioma, 1167, 1168*t*, 1169, 1170
 pregnancy and, **429–431**, **802–803**
 preoperative evaluation/perioperative management and, **46–50**, 47*t*, 48*f*, 48*t*
 prevention of, **5–11**, 7*t*
 abdominal aortic aneurysm
 screening in, **6**, 7*t*, 473
 chemoprevention/aspirin use and, 7*t*, 11, 1253
 in women, 1707
 cholesterol screening and, 7*t*, 8–10, **1248–1252**, 1249–1250*t*, 1251*t*
 in women, 7*t*, 1248, 1251, 1706
 exercise/activity and, 7*t*, 12–13
 hypertension prevention/
 management and, 7*t*, **10–11**, 439, 441–442, 442–444, 442*t*, 443*f*, 444*t*, 457
 in women, 1706
 lipid disorder prevention/
 management and, 7*t*, **8–10**, 1246–1247, 1252–1255, 1255*t*. *See also* Lipid-lowering therapy
 smoking/smoking cessation and, **6–8**, 7*t*, 9–10*t*, 10*t*
 in women, 1249*t*, 1251, **1706–1707**
 radiation causing, 1554
 syphilis and, 1304*t*, 1464, 1471, 1471*f*
 in Turner syndrome, 1186, 1187, 1187*t*
- Cardiovascular system
 abnormal development of,
 hypertension and, 435–436
 thiamine deficiency affecting, 1264
- Cardioversion
 electrical
 for atrial fibrillation, 385, 386, 387
 in hyperthyroidism, 1118
 infarct-related, 372
 rate control compared with, 387–388
 for atrial flutter, 389
 in hypothermia, 1454
 for supraventricular tachycardia, 382
 for ventricular arrhythmias/
 tachycardia/fibrillation, 391
 infarct-related, 373
 pharmacologic
 for atrial fibrillation, 387–388
 for atrial flutter, 389
 transesophageal echocardiography-guided, for atrial fibrillation, 386
- Cardioverter defibrillator, implantable. *See* Implantable cardioverter defibrillator
- Carditis, rheumatic, 417, 417–418, 418
- Cardizem. *See* Diltiazem
- Cardura/Cardura XL. *See* Doxazosin
- Caregiver issues
 in care of elderly, 58–59
 terminally ill/dying patient and, 88, 88*t*
- Carey-Coombs murmur, in rheumatic carditis, 417
- Carisoprodol, overdose/toxicity of, 1579–1580
- Carmol, 98*t*
- Carney complex/syndrome, 426, 1190
 acromegaly and, 1100
 Cushing syndrome and, 1158
 thyroid cancer and, 1123
- β-Carotene/carotenoids
 in chemoprevention, 11
 excess intake of, 1267
- Carotid angioplasty, 470
- Carotid artery dissection
 headache and, 41, 966
 retinal artery occlusion and, 183
- Carotid artery occlusive disease (carotid stenosis/insufficiency), 469–470
 headache associated with, 966
 recurrent, 470
 retinal artery occlusion and, 183, 469
 stroke/transient ischemic attacks
 caused by, 469–470, 977, 978, 980*t*, 981
 postoperative stroke and, 54
 transient monocular blindness and, 184, 469, 981
- Carotid bruits, 469
 postoperative stroke and, 54
- Carotid endarterectomy/
 thromboendarterectomy, 470
 prophylactic, 469
 preoperative, 54
 transient monocular blindness and, 184
 stroke as complication of, 469–470
 for transient ischemic attacks and
 stroke, 469, 470, 978
- Carotid insufficiency. *See* Carotid artery occlusive disease
- Carotid pulse
 in cardiomyopathy, 414
 in heart failure, 399

- Carotid sinus hypersensitivity, syncope in, 397
- Carotid sinus massage/pressure for paroxysmal supraventricular tachycardia, 382
in syncope evaluation, 397
- Carotid stenosis. *See* Carotid artery occlusive disease
- Carotid stenting, 470
- Carpal compression test, 824, 1689, 1689t
- Carpal spasm. *See* Trousseau sign
- Carpal tunnel syndrome, **823–824**, **1688–1689**, 1689t
in acromegaly/gigantism, 1101
Raynaud phenomenon and, 837
- Carrier (genetic)
for acute intermittent porphyria, 1664
for alkaptonuria, 1665
for cystic fibrosis, 267
for fragile X mental retardation, 1667
for G6PD deficiency, 502
for Gaucher disease, 1668
for hemophilia, 549
for hypophosphatasia, 1150
for sickle cell disease, **504**, 505t, 799
for thalassemia, 494t, 495
- Carrier state (infection)
in amebiasis, 1503
in furunculosis, 151
in giardiasis, 1509
in group B streptococcal infection, 784–785, 804
in hepatitis B, 674
maternal, 667, 669, **806**
in hepatitis C, 670, 677
maternal, 783, **806**
in meningococcal meningitis, 1442
staphylococcal, 1425
in HIV infection/AIDS, 1331
impetigo and, 123
nasal vestibulitis and, **217**
surgical site infection associated with, 55–56, 1284
in trench fever, 1454
in trichomoniasis, 1510
in typhoid fever, 1446
- Carteolol, for glaucoma/ocular hypertension, 171t, 176
- Cartia. *See* Diltiazem
- Carvedilol, 447t
for esophageal varices, prevention of first bleeding episode and, 604
for heart failure, 403
for hypertension, 446, 447t
for myocardial infarction, 370, 376
- Cascara, 571, 572t
- Case management, in heart failure, 406
- Casodex. *See* Bicalutamide
- Caspofungin, 1541t, 1542
for aspergillosis, 1538
for candidiasis, 598, 1530
for mucormycosis, 1538
- CaSR. *See* Calcium-sensing receptor
- Castleman disease, 1277, 1367
- Castration, for breast cancer in male, 746
- Casts, urinary. *See* Urinary casts
- Cat bites, 1288–1290
cat-scratch disease and, 1454
rabies and, 1376
- Cat exposure/feces
bacillary angiomatosis and, 1331
tinea corporis/circinata and, 110
toxoplasmosis and, 1334, 1500, 1502
- Cat-flea typhus, 1414
- Cat fleas. *See* Fleas
- Cat hookworm, cutaneous larva migrans caused by, 1523
- Cat roundworm (*T. cati*), 1523
- Cat-scratch disease, 1454
in HIV infection/AIDS, 1335
lymphadenitis/lymphadenopathy in, 483, 1454
- Cataflam. *See* Diclofenac
- Catamenial asthma, 243
- Catamenial pneumothorax, 316
- Cataplexy, 1077
- Catapres/Catapres TTS. *See* Clonidine
- Cataract, **179**
diabetic, 1223
hypoparathyroidism and, 1136
quetiapine use and, 1057
- Cataract surgery, 179
 α -blocker use and, 179, 959
for angle-closure glaucoma, 175
- Catastrophic antiphospholipid syndrome, 835, 836
- Catatonic schizophrenia, 1053, 1058
- Catatonic syndrome (catatonia), 1055, 1058
neuroleptic-induced, 1055, 1061
- Catcher's mitt hand, 825
- Catecholamine-O-methyltransferase (COMT) inhibitors, for parkinsonism, 1000
- Catecholamine myocarditis, pheochromocytoma and, 1169, 1170
- Catecholamines
factors affecting assays for, 1167, 1169t
reference values for, 1728t
Tako-Tsubo cardiomyopathy and, 413
tumors secreting
diabetes and, 1196
pheochromocytoma/paraganglioma, 438, 1166, 1167
- β -Catenin, hepatocellular adenoma and, 702
- Caterpillars, skin lesions caused by, 149
- Cathartics
abuse of in bulimia nervosa, 1263
for poisoning/drug overdose, 1567
- Cathepsin-D cleavage product, in cardiomyopathy of pregnancy, 429
- Catheter ablation techniques, for arrhythmias, 380
- Cathartics
accessory pathway/preexcitation syndromes, 380, 383–384
atrial fibrillation, 380, 388
atrial flutter, 380, 389
supraventricular tachycardia, 380, 382–383, 383–384
ventricular premature beats, 380, 390
ventricular tachycardia, 380, 391
- Catheterization
bladder/urinary. *See* Bladder catheterization
cardiac. *See* Cardiac catheterization
- Catheters/intravenous lines
in burn care, 1550
candidiasis and, 1529, 1530
coagulase-negative staphylococcal infection and, 1427–1428
GI bleeding and, 581
health care-associated infection and, 1282, 1283, 1284, 1284–1285, 1305
for parenteral nutritional support, 1271
complications and, 1274
thrombophlebitis/septic phlebitis and, 480, 1302t
- CATT (card agglutination test), in African trypanosomiasis, 1485
- Cauda equina syndrome/tumor, back pain caused by, 819, 820, 1683, 1684
- Cauliflower ear (auricular hematoma), 199
- Caustic/corrosive agents
acids, **1571–1572**
alkalies, **1572**
esophageal injury caused by, **599**, 1566, 1571, 1572
eye injury caused by, 194, 1566, 1571, 1572
skin injury caused by, 1566, 1571, 1572
- Cauterization, for CIN, 756
- Cavernoma, portal, 699, 700
- Cavernous hemangioma, of liver, 701
- Cavernous sinus thrombosis, bacterial rhinosinusitis and, 216
- Cbir 1 antibodies, in Crohn disease, 642
- CCFA (Crohn's and Colitis Foundation of America), 641
- CCLE. *See* Chronic cutaneous lupus erythematosus
- CCNU. *See* Lomustine
- CCP antibodies, in rheumatoid arthritis, 827
- CCPD. *See* Continuous cyclic peritoneal dialysis
- C_{cr}. *See* Creatinine clearance
- CCR5 co-receptor
in HIV infection/AIDS, 1322
in tick-borne encephalitis, 1391
in West Nile virus, 1380
- CCR5 co-receptor antagonist, for HIV infection/AIDS, 1346
- CD markers. *See also specific marker*
in hematologic neoplasia
acute leukemia, 520
chronic lymphocytic leukemia, 522
hairy cell leukemia, 523
- CD2, in acute lymphoblastic leukemia, 520
- CD3 antibodies, in new-onset type 1 diabetes, 1202
- CD4/CD8 cell ratio, in sarcoidosis, 296
- CD4 lymphopenia syndrome, idiopathic, 1382
- CD4 T cells
in HIV infection/AIDS, 1319, 1322, 1322–1323, 1323f, 1324, 1324t
absolute count, 1319, 1323f, 1324, 1324t
antiretroviral therapy initiation/monitoring and, 1324, 1340
CMV infection and, 187, 1364

- immune reconstitution and, 1333
 MAC infections and, 1337, 1458, 1459
 opportunistic infection/course of disease and, 1322–1323, 1323f, 1324, 1334t, 1336, 1339, 1349
 percentage of, 1319, 1324, 1324t
Pneumocystis pneumonia and, 1322–1323, 1323f, 1324, 1326, 1337, 1339, 1534, 1535
 syphilis and, 1473
 HTLV infection of, 1383
 reference values for, 1728t
- CD5
 in acute lymphoblastic leukemia, 520
 in chronic lymphocytic leukemia/
 mantle cell lymphoma, 522
- CD7, in acute lymphoblastic leukemia, 520
- CD8 cells, HTLV infection of, 1383
- CD10, in acute lymphoblastic leukemia, 520
- CD11c, in hairy cell leukemia, 523
- CD13, in acute myeloid leukemia, 520
- CD19
 in acute lymphoblastic leukemia, 520
 in chronic lymphocytic leukemia/
 mantle cell lymphoma, 522
- CD20
 in acute lymphoblastic leukemia, 520
 in hairy cell leukemia, 523
 in mantle cell lymphoma, 522
- CD22, in hairy cell leukemia, 523
- CD23, in mantle cell lymphoma, 522
- CD25, in hairy cell leukemia, 523
- CD33, in acute myeloid leukemia, 520
- CD34, in nephrogenic systemic fibrosis, 937
- CD38, in chronic lymphocytic leukemia, 522
- CD55 deficiency, in paroxysmal nocturnal hemoglobinuria, 501, 502
- CD56, in nasal/paranasal lymphoma, 223
- CD59 deficiency, in paroxysmal nocturnal hemoglobinuria, 501, 502
- CD103, in hairy cell leukemia, 523
- CD117, in gastrointestinal stromal tumors, 1619, 1622
- CD123, in hairy cell leukemia, 523
- CdA. *See* Cladribine
- CDH-1* mutation, gastric cancer and, 1616
- CDKAL1* gene, in type 2 diabetes, 1194
- CDKN2A* gene
 pancreatic/periapillary carcinoma and, 1608
 in type 2 diabetes, 1194
- CDKN2B* gene, in type 2 diabetes, 1194
- CEA. *See* Carcinoembryonic antigen
- Cecostomy, for acute colonic pseudo-obstruction (Ogilvie syndrome), 629
- Cecum, dilation of, in colonic pseudo-obstruction (Ogilvie syndrome), 628
- CEE. *See* Conjugated equine estrogens
- Cefazolin
 for endocarditis, 1438–1439, 1438t
 for ophthalmic disorders, 168t
- Cefdinir, for pharyngitis, 1420
- Cefepime
 for anaerobic abdominal infections, 1455t
 for pneumonia, 273t, 277t
- Cefotaxime
 for Lyme disease, 1482
 for pneumonia, 273t
- Cefpodoxime
 for pharyngitis, 1420
 for pneumonia, 273t
- Ceftaroline, for staphylococcal skin infections, 1426
- Ceftazidime
 for anaerobic abdominal infections, 1455t
 for pneumonia, 264, 277t
- Ceftin. *See* Cefuroxime
- Ceftriaxone
 for anaerobic infections, 1455, 1455t
 for endocarditis, 1437, 1438, 1439
 for Lyme disease, 1481, 1482
 for pneumonia, 273t, 277t
 for syphilis, 1467, 1468t
 for urinary tract infection, 940t
- Cefuroxime/cefuroxime axetil
 for Lyme disease, 1481, 1482
 for pharyngitis, 229
 for pneumonia, 273t
- Ceiroarthropathy/cheiroopathy, diabetic, 839, 1228
- Celebrex. *See* Celecoxib
- Celecoxib, 76, 77t, 611. *See also* Coxibs
 cardiovascular complications and, 76, 608, 612
 for familial adenomatous polyposis, 655
 gastritis and, 608
 for gout, 814
 for osteoarthritis of knee, 1702
 for pain management, 76, 77t
 peptic ulcers/peptic ulcer prevention and, 611–612
 for rheumatoid arthritis, 828
- Celexa. *See* Citalopram
- Celiac disease/sprue (gluten enteropathy), 621–623
 dermatitis herpetiformis and, 123, 622
 hypothyroidism/Hashimoto's thyroiditis and, 1106, 1120, 1121
 microscopic colitis and, 650
 osteoporosis and, 622, 1145
 pancreatitis and, 711
- Celiac plexus block, for pain management, 85
- Cell-mediated (delayed/type IV) hypersensitivity, 866
- Cell-mediated (cellular) immunity
 infections associated with defects in, 1279
 Epstein-Barr virus, 1363
- Cell surface antigens, immune cell. *See under* CD
- Cellophane tape test, in enterobiasis/
 pinworms, 1520
- Cellulitis, 136–138, 137f, 1303t, 1421t
 anaerobic, 1456
 of auricle, 199
 in chronic venous insufficiency, 137, 481
- deep vein thrombosis differentiated from, 137
 in drug users, 1292
 leg ulcers and, 137, 154
 lymphangitis/lymphadenitis and, 483, 1303t
 lymphedema and, 484
 necrotizing fasciitis differentiated from, 137
 non-cholesteric, 1456
 orbital, 191–192
 in bacterial rhinosinusitis, 191, 216
 peritonsillar, 229–230
 sublingual/submaxillary space (Ludwig angina), 230, 230–231
 superficial (erysipelas), 136, 137f, 1303t, 1420–1421, 1421t
 synergistic necrotizing, 1456
 tinea pedis and, 112, 137
 vibrios causing, 1448–1449
- Cellulose phosphate, for absorptive hypercalciuria, 948
- Cenesthetic hallucinations. *See also* Hallucinations
 in schizophrenia/psychotic disorders, 1054
- Cenestin, 1184
- Centor criteria, for streptococcal pharyngitis, 228, 229, 1419
- Central alveolar hypoventilation, 318
- Central cord syndrome, 989, 1018
- Central nervous system disorders. *See also* Neurologic disorders
 adverse ophthalmic effects of drugs used in, 196t
 infections, 1285–1288, 1286t. *See also* Encephalitis; Meningitis
 anaerobic, 1455
 otitis media and, 205
 primary angitis, 854
- Central nervous system lymphoma, primary, 525
- Central neurogenic hyperventilation, in coma or stupor, 318, 1014
- Central pontine myelinolysis, hyponatremia treatment and, 874
- Central retinal artery occlusion, 183–184
- Central retinal vein occlusion, 181–182
- Central sleep apnea, 318
- Central vein nutritional support (total parenteral nutrition/hyperalimentation), 1271, 1271f
 acidosis caused by, 893, 1274t
 in burn injury, 1552
 catheter-associated complications and, 1274
 complications of, 1274–1275, 1274t
 in Crohn disease, 642, 643
 diabetic patient and, 1229
 in HIV infection/AIDS, 1325
 patient monitoring during, 1275
 in short bowel syndrome, 626
 solutions for, 1273, 1273t, 1274
 for ulcerative colitis, 648
- Central venous catheters
 infection/infection prevention and, 1274, 1284, 1285
 in shock management, 486–487
 superficial thrombophlebitis and, 480

- Central venous pressure, in shock, 486, 486–487
- Centruroides* (scorpion) stings, 1590
- Cephalixin
for endocarditis, 1438*t*
for impetigo, 123
for urinary tract infection, 939, 940*t*
- Cephalosporins
allergy to, penicillin allergy cross-reactivity and, 1306
nephrotoxicity of, 904
for pharyngitis, 229, 1420
- Cephalothin, platelet function affected by, 549*t*
- CEPI test, 1733*t*
- Ceratopic, 99*t*
- Cercariae/metacercariae
in clonorchiasis/opisthorchiasis, 1513
in fascioliasis, 1512
in fasciolopsiasis, 1513
in paragonimiasis, 1513
in schistosomiasis, 1511
- Cercarial dermatitis, in schistosomiasis, 1511
- Cerclage
for incompetent cervix, 789
for preterm birth prevention, 796
- Cerebellar arteriovenous malformations, 987
- Cerebellar artery obstruction, in stroke, 981, 981–982
- Cerebellar degeneration
paraneoplastic, 994, 1596*t*
vertigo in, 210*t*, 212
- Cerebellar hemorrhage, stroke and, 984
- Cerebellar tonsils, herniation of, intracranial tumors causing, 989
- Cerebellar tumors, 991
hemangioblastoma, 990*t*, 991
- Cerebral amyloid angiopathy, 983, 984
- Cerebral aneurysm. *See* Intracranial aneurysm
- Cerebral angiography/arteriography. *See also* Neuroimaging
in arteriovenous malformations, 987
in brain death determination, 1015
in carotid occlusive disease, 469
in headache evaluation, 42
in intracranial aneurysm, 985, 986
in intracranial mass lesions, 991
in primary angitis of central nervous system, 854
in subarachnoid hemorrhage, 985
- Cerebral arteriovenous malformations, 987, 987–988
- Cerebral artery occlusion, in stroke, 981
- Cerebral contusions/lacerations, 1017*t*
- Cerebral edema
in hepatic encephalopathy, 690
high-altitude, 1558–1559
hyponatremia treatment and, 876
in liver failure, 673
in stroke, 982
- Cerebral hemorrhage. *See* Intracerebral hemorrhage
- Cerebral hypoperfusion, arrhythmias causing, seizures differentiated from, 971
- Cerebral infarction/ischemia, 980*t*, 981–983. *See also* Stroke
coma or stupor caused by, 982, 1015
- Cerebral injury, 1016, 1017*t*
in near drowning, 1556
- Cerebral ischemia. *See* Cerebral infarction; Transient ischemic attacks
- Cerebral lymphoma, 990*t*
in HIV infection/AIDS, 990*t*, 992–993, 1327, 1332, 1338*t*
- Cerebral malaria, 1491
- Cerebral metastases, 992
- Cerebral salt wasting, 871*f*, 872, 874
- Cerebral sparganosis, 1517
- Cerebral toxoplasmosis, in HIV infection/AIDS, 993, 1327, 1501, 1502. *See also* *Toxoplasma*
- Cerebritis, lupus, 834
- Cerebrospinal fluid analysis
in African trypanosomiasis, 1485
in amebic encephalitis/meningoencephalitis, 1505–1506, 1506
in angiostrongyliasis, 1522
in anthrax, 1432
in arbovirus encephalitis, 1379
in CNS infections, 1286*f*, 1287
in CNS lymphoma, 1327
in Creutzfeldt-Jakob disease, 1382
in cryptococcosis, 1536
in cysticercosis, 1515
in eosinophilic meningoencephalitis (angiostrongyliasis), 1522
in gnathostomiasis, 1523
in Guillain-Barré syndrome, 1025
in headache evaluation, 42
in herpes simplex encephalitis/meningitis, 1352, 1355
in leptomeningeal metastases (carcinomatous meningitis), 992
in listeriosis, 1434
in lymphocytic choriomeningitis, 1381
in meningitis, 1286*f*, 1287
in meningococcal meningitis, 1441
in multiple sclerosis, 1011
in neuroborreliosis, 1480, 1481
normal, 1286*t*
in pneumococcal meningitis, 1424
in poliomyelitis, 1373
in purulent/bacterial meningitis, 1286–1287, 1286*t*
in rabies, 1376
in spinal tumors, 993
in subarachnoid hemorrhage, 985
in syphilis, 1469, 1472, 1472–1473, 1473
in HIV infection/AIDS, 1335, 1468, 1473
indications for, 1472–1473
treatment failure and, 1468, 1473
in tick-borne encephalitis, 1391
in tuberculous meningitis, 1459
- Cerebrospinal fluid leakage, in head injury, 1016
- Cerebrovascular accident. *See* Stroke
- Cerebrovascular disorders
cancer-related, 994–995
headache in, 41, 966
hypertensive, 439, 440, 443
occlusive, 469–470. *See also* Stroke;
Transient ischemic attacks
homocysteine/
hyperhomocysteinemia in, 1668–1669
oral contraceptive use and, 770
- Certolizumab, 830
for inflammatory bowel disease, 640
Crohn disease, 644–645
for rheumatoid arthritis, 830
- Cerubidine. *See* Daunorubicin
- Ceruloplasmin
reference values for, 1729*t*
in Wilson disease, 697
- Cerumen impaction, 198, 200
- Ceruminous gland adenoma, 201
- Cervarix. *See* Human papillomavirus (HPV) vaccine
- Cervical band, 1031, 1032
- Cervical canal stenosis, 1686
- Cervical cap, 775
- Cervical carcinoma. *See* Cervix (uterine), cancer of
- Cervical collar, for neck pain, 818, 1029, 1687
- Cervical intraepithelial neoplasia (CIN/dysplasia of cervix), 754–756, 754*f*, 754*t*
carcinoma of cervix and, 754, 755, 756
cytologic (Pap smear) testing for, 754*t*, 755
in HIV infection/AIDS, 1332
HPV tests in screening for, 755, 1332
HPV vaccination in prevention of, 4, 755–756
oral contraceptive use and, 772
- Cervical lymphadenopathy, reactive, 240
- Cervical mucus/secretions, evaluation of
in symptothermal natural family planning, 775
in TwoDay method of contraception, 776
- Cervical musculotendinous strain, acute, 817–818
- Cervical radiculopathy, 1686
- Cervical rib syndrome, 818, 819, 1031–1032
- Cervical spine/disk disease, 818, 1029, 1030–1031*f*, 1686–1687, 1687*t*. *See also* Spine
arthritic/degenerative, 818, 1686
chest pain/discomfort in, 355
herniation/protrusion, 818, 1029, 1030–1031*f*, 1686
neck pain in, 818, 1029, 1030–1031*f*, 1686–1687, 1687*t*
vertigo and, 211–212
- Cervical spondylosis, 818, 1029
- Cervical vertigo, 211–212
- Cervical warts, 752. *See also* Venereal (genital) warts
- Cervicitis
chlamydial, 1461–1462
gonococcal, 1452
postgonococcal, 1453
- Cervicocolpopexy, for pelvic organ prolapse, 762
- Cervicofacial actinomycosis, 1456, 1457

- Cervix (uterine)
 anaerobic flora/infection of, 1455–1456
 biopsy of
 in abnormal premenopausal bleeding, 747
 in CIN/cervical cancer, 754, 755, 757
 cancer of, **756–757**, 1611*t*
 HIV infection/AIDS and, 1332
 HPV infection and, 755, 1332, 1709
 screening tests for, 755, 1332, 1709
 vaccine in prevention of, 4, 755–756, 757, 1709
 invasive, 754*t*, 757
 oral contraceptive use and, 772
 preinvasive (carcinoma in situ/CIN), 754, 755, 756, 757
 prevention of/screening for, 15*t*, 16, 754*t*, 755, 1332, 1709
 cauterization of, for CIN, 756
 conization of, for CIN/cervical cancer, 756, 757
 dysplasia (CIN) of, **754–756**, 754*f*, 754*t*. *See also* Cervical intraepithelial neoplasia
 incompetent, 788
 cerclage/activity restriction for, 789
 polyps of, **753**
 stenosis of, pain and, 750
- Cesarean delivery
 for cardiac patient, 431, 803
 placenta previa and, 797
 for prevention of disease transmission to fetus/newborn
 herpes genitalis, 806, 1355
 HIV, 805, 1321
- Cestode infections, **1514–1517**. *See also specific type*
 invasive, **1515–1517**
 noninvasive, **1514–1515**
- Cetilistat, for obesity, 1261
- Cetirizine, 99
 for allergic/perennial rhinitis, 218, 219
 breastfeeding and, 782*t*
 for urticaria, 133
- Cetuximab, 1653*t*
 for colorectal cancer, 1625
 for laryngeal cancer, 237
 for lung cancer, 1600
 for Ménétrier disease (hypertrophic gastropathy), 610
- CFTR. *See* Cystic fibrosis transmembrane conductance regulator (CFTR) protein
- CgA. *See* Chromogranin A
- CH50 (complement)
 in gonococcal arthritis, 860
 reference values for, 1729*t*
- CHADS₂ Risk Score, 385*t*, 386
- CHADS-VASC score, 386
- Chagas disease (American trypanosomiasis), **1486–1487**
 achalasia and, 605
- Chagoma, 1486
- Chalazion, **163**, 163*f*
- Chalkstick fractures, bisphosphonates causing, 1147
- Chancre
 differential diagnosis of, 1467
 syphilitic, 1464, 1465, 1465*f*
 anal/anorectal, 658, 658–659, 1465
 trypanosomal, 1484
- Chancroid, **1453**
- Channelopathies, periodic paralysis, 1036
- Charcoal, activated, for poisoning/drug overdose, 1567
 repeat-dose, 1568
- Charcot joint (neurogenic arthropathy), **865**
 in diabetes mellitus, 865, 1224–1225
 in tabes dorsalis, 865, 1472, 1472*f*
- Charcot-Marie-Tooth disease, 1021–1022
- Charcot triad, 706
- CHD. *See* Coronary heart disease
- Cheese. *See* Dairy products
- Cheilitis, angular
 candidiasis and, 225, 226*f*, 1329
 in HIV infection/AIDS, 226*f*, 1329
- Chelation therapy. *See also specific type*
 adverse ophthalmic effects of, 197*t*
 for arsenic poisoning, 1575
 for heavy metal poisoning, 1566*t*
 for hemochromatosis/iron poisoning/overload, 696, 1581
 for lead poisoning, 933, 1582
 for mercury poisoning, 1583
 for Wilson disease, 697
- Chemical injury
 acids causing, **1571–1572**
 alkalis causing, **1572**
 of esophagus, **599**, 1571, 1572
 of eye (conjunctivitis/keratitis), **194**, 1571, 1572
 of lung, 311, 1571
 aspiration and, 308
 smoke inhalation and, 307
- Chemical warfare agents. *See also* Bioterrorism
 nerve agents, 1587
 skin decontamination and, 1566, 1587
- Chemiluminescence (CIA) assay, in syphilis, 1466*t*, 1467
- Chemo brain, 744
- Chemoembolization, transarterial, for hepatocellular carcinoma, 1605
- Chemoinfusion, transarterial, for hepatocellular carcinoma, 1605
- Chemokine co-receptors, in HIV infection/AIDS, 1322
- Chemoprevention/chemoprophylaxis, **11**. *See also specific agent*
 antibiotic/antimicrobial. *See* Antimicrobial chemoprophylaxis
 for cancer, 11, 15
 breast cancer and, 15, 723, 733, 736, 1708
 colorectal cancer and, 11, 1623
 prostate cancer and, 959–960
 for cardiovascular disease, 7*t*, **11**
 in women, 1707
 for cluster headache, 965
 for migraine headache, 964–965, 964*t*
 for stress gastritis, 608
 for venous thromboembolic disease, 301, 555–556, 556*t*, 557*t*, 558*t*
- Chemoprotection, ototoxic, 207
- Chemoradiation therapy
 for bladder cancer, 1639, 1640
 for breast cancer, 739
 for colorectal cancer, 1624, 1625, 1626
 for esophageal cancer, 1614
 for gastric adenocarcinoma, 1617
 for laryngeal cancer, 237
- Chemoreceptor trigger zone, 566, 567*t*
- Chemosclerosis, for malignant effusions, 1646
- Chemosis
 in allergic eye disease, 167
 in dysthyroid eye disease, 191, 1112
- Chemotherapy (cancer), 1610–1612*t*, **1648–1663**, 1650–1657*t*, 1658–1659*t*, 1659*t*. *See also specific agent and cancer type*
 adverse ophthalmic effects of, 197*t*
 bone marrow/stem cell transplantation after, 532, 533
 cancers responsive to, 1610–1612*t*
 dosages/modifications of agents used in, **1649–1663**, 1650–1657*t*, 1659*t*
 fever and, 1302*t*
 hyperuricemia/tumor lysis syndrome and, 1647
 leukemia caused by, 519
 myocarditis and, 411
 nausea and vomiting caused by, 567*t*, **1659–1660**
 neurologic disorders associated with, 994–995, 1661, 1662
 neutropenia caused by, 510, 1302*t*, 1649
 infections and, 1279, 1302*t*, 1648
 ototoxicity and, 207
 with radiation therapy. *See* Chemoradiation therapy
 supportive agents/care and, 1658–1659*t*
 thrombocytopenia and, **540**, 547*t*, 1649–1659
 toxicity of agents used in, **1649–1663**, 1650–1657*t*, 1658–1659*t*
 ophthalmic effects and, 197*t*
- Chen sign, 325
- Chenodeoxycholic acid, for cholelithiasis/gallstones, 704
- Chest pain/discomfort, **28–30**, 28*t*, 360–361, **606–607**
 in acute coronary syndromes, 28, 29, 360
 in angina, 28, 29, 351–352
 alteration in before myocardial infarction, 365
 coronary vasospasm causing, 351, 360
 Prinzmetal (variant), 360
 in aortic dissection, 29, 355, 477
 in aortic stenosis/regurgitation, 28, 344
 cardiac trauma and, 428
 in cardiomyopathy, 414
 in cervical/thoracic spine disease, 355
 in chronic kidney disease/uremia, 909*t*, 910
 dyspnea and, 24, 29, 355
 in esophageal disorders, 29, 355, 594, 598, 605, 606
 achalasia, 605
 GERD, 355, 594, 606
 infectious esophagitis, 598
 motility disorders, 355, 606
 pill-induced esophagitis, 598

- Chest pain/discomfort (Cont.):
 ischemic, 28. *See also* Acute coronary syndromes; Angina
 in myocardial infarction, 28, 28t, 29, 365
 reperfusion assessment and, 370
 in myocarditis, 409, 410
 noncardiac, 30, 355, 594, 605, 606, **606–607**. *See also* Chest pain/discomfort, in esophageal disorders
 palpitations and, 31
 in panic disorders, 30, 1041
 in pericarditis, 28, 29, 419
 pleuritic (pleuritis), 28–29, 28t, **313**
 in epidemic pleurodynia (Bornholm disease), 1406
 in pericarditis, 419
 in thoracic actinomycosis, 1457
 in pneumothorax, 316, 355
 psychologic causes of, 30, 607
 in pulmonary embolism, 28, 29, 29–30, 298, 298t, 355
 in pulmonary hypertension, 305
 in thoracic outlet syndrome, 355
 visceral sensitivity causing, 606–607
- Chest pain observation units, 361
- Chest percussion
 in bronchiectasis, 266
 in chronic bronchitis, 264
 in cystic fibrosis, 268
- Chest tube drainage (tube thoracostomy)
 for empyema, 279
 for hemothorax, 316
 for malignant effusions, 1646
 for parapneumonic effusion, 315–316
 for pneumothorax, 317
- Chest wall
 breast cancer recurrence in, 744
 disorders of, chest pain/discomfort in, 29, 606
 anterior chest wall/Tietze syndrome, 355
 respiratory failure caused by disorders of, 320t
- Cheyne-Stokes respiration, in coma or stupor, 1014, 1015
- CHF. *See* Congestive heart (cardiac) failure
- Chibroxin. *See* Norfloxacin
- Chickenpox. *See* Varicella
- Chiggers
 scrub typhus transmitted by, 1411
 skin lesions caused by, 149
- Chikungunya fever, 1356t, **1392–1393**
- Chilblain (erythema pernio), **1545**
- Child abuse
 aggression/violence/impulse control disorders and, 1078
 incest, 1050
 Munchausen by proxy and, 1046
 pedophilia, 1049–1050
 PTSD and, 1039
- Child-Turcotte-Pugh classification for cirrhosis, 691, 692t
- hepatocellular carcinoma and, 1604
 postoperative complications and, 52
 variceal hemorrhage and, 602, 604
- Childbirth preparation classes, 784
- Children
 antidepressant use/suicidality and, 1067
 fever/FUO in, 1276
 immunization recommendations for, **1307**
 injury prevention and, 17
 pheochromocytomas/paragangliomas in, 1168t
 seizures in, 969
- Chimera, allogeneic stem cell transplantation producing, 533
- Chinese liver fluke infection, **1513**
- Chiropractic manipulation
 for back pain, 818, 1684
 for neck pain, 1687
- Chlamydia* (chlamydial infections), 1301t, **1461–1463**. *See also* *Chlamydomphila*
 cough in, 23
 diarrhea caused by, 574t
 dysuria in, 43
 gonococcal coinfection and, 1453, 1462
 inclusion conjunctivitis, 166
 keratoconjunctivitis, 165–166
 screening for, 1462
 in STD patients, 1291
 in women, 1711
 trachoma, 165–166
trachomatis, 1301t, 1461, **1461–1462**
 anorectal involvement and, 659, 1461
 epididymitis, 944, 945, 1303t, 1462
 lymphogranuloma venereum, 659, **1461**
 pelvic infection/PID, 763, 1301t, 1304t, 1461–1462
 pregnancy and, 784, **806**, 1462
 rape/sexual assault in transmission of, 778, 1291
 urethritis and cervicitis, 1301t, 1303t, **1461–1462**
- Chlamydomphila pneumoniae*, 1301t, 1461, **1462–1463**
 pneumonia caused by, 1303t, 1462–1463
psittaci, 1301t, 1461, **1462**
- Chloasma (melasma), 155, 156
 oral contraceptive use and, 155, 773
- Chloral hydrate, 1042t
- Chlorambucil, 1651t
 adverse ophthalmic effects of, 197t
 for chronic lymphocytic leukemia, 522
- Chloramphenicol
 adverse ophthalmic effects of, 197t
 for ophthalmic disorders, 168t
- Chlordane poisoning, 1587
- Chlordiazepoxide, 1042t
 overdose/toxicity of, 1579–1580
- Chlorguanide. *See* Proguanil
- Chloride
 in fluid management, 897t
 reference values for, 1729t
 requirements for in nutritional support, 1272
 serum levels of, in hypercalcemia/hyperparathyroidism, 884
 transport of, defects of in cystic fibrosis, 267
 urinary, in metabolic alkalosis, 894
- 2-Chlorodeoxyadenosine. *See* Cladribine
- Chloromethyl methyl ether, lung cancer caused by, 311, 1595
- Chlorophenothane (DDT) poisoning, 1587
- Chloroquine, 1492t, 1494, 1494t
 adverse ophthalmic effects of, 197t
 for amebiasis, 1504, 1505t
 arrhythmias caused by, 1588
 erythrovirus (parvovirus)-associated anemia and, 1402–1403
 for lupus, 115
 for malaria, 1492t, 1494, 1494t
 for chemoprophylaxis, 1494, 1498, 1498t
 for non-falciparum malaria, 1492, 1494, 1494t
 in pregnancy, 787
 resistance to, 1492, 1493, 1494, 1494t
 for uncomplicated falciparum malaria, 1493, 1494, 1494t
 rabies vaccination affected by, 1315, 1378
- Chlorpheniramine, for allergic/perennial rhinitis, 218–219
- Chlorpromazine, 1055, 1056t, 1057t. *See also* Antipsychotic drugs
 overdose/toxicity of, 1057t, 1574
 for serotonin syndrome, 1565, 1585, 1592
- Chlorpropamide, 1206t, 1207
 adverse ophthalmic effects of, 197t
 intensive therapy with, 1203
- Chlorthalidone
 for heart failure, 401
 for hypertension, 445t, 446
 with clonidine, 456t
 in diabetes, 1227
- Chokes, 1557
- Cholangiocarcinoma, 1603, 1606, 1607
 in clonorchiasis/opisthorchiasis, 1513, 1606
 in primary sclerosing cholangitis, 710
- Cholangiography. *See* Endoscopic retrograde cholangiopancreatography; Percutaneous transhepatic cholangiography
- Cholangiopancreatography. *See* Endoscopic retrograde cholangiopancreatography; Magnetic resonance cholangiopancreatography
- Cholangiopathy, AIDS, 1364, 1507
- Cholangitis
 autoimmune, 693
 biliary stricture and, 708
 choledocholithiasis and, **706–708**
 drugs/toxins causing, 683
 liver abscess and, 700
 during pregnancy, 807
 primary sclerosing, **709–710**
 cholangiocarcinoma and, 710
 in HIV infection/AIDS, 1329
 pyogenic, 707
- Cholecalciferol (vitamin D₃), 1149. *See also* Vitamin D
 in hypercalcemia, 883, 884, 1141–1142, 1151
 for hypoparathyroidism, 1137t
 for vitamin D deficiency/osteomalacia, 1151

- Cholecystectomy
 for cholecystitis, 704, 705
 for choledocholithiasis/cholangitis, 707, 708
 for cholelithiasis/gallstones, 703–704
 cirrhosis and, 702
 for gallbladder cancer, 1607
 pancreatitis and, 714
 for precholecystectomy syndrome, 706
 pregnancy and, 704, 807
 symptom persistence after (postcholecystectomy syndrome), **706**
- Cholecystitis, 703*t*, **704–705**, 1302*t*
 acalculous, 704
 in HIV infection/AIDS, 1329
 parenteral nutritional support and, 1274*t*
 acute, 703*t*, **704–705**
 cholelithiasis/gallstones and, 703, 704, 705
 chronic, 703*t*, 705
 in HIV infection/AIDS, 1329
 during pregnancy, **807**
 xanthogranulomatous, 705
- Cholecystostomy, 705
 pancreatitis and, 714
- Choledocholithiasis, 703*t*, **706–708**
 pancreatitis and, 703*t*, 707
 during pregnancy, 807
- Cholelithiasis (gallstones), **702–704**, 703*t*
 cholecystitis and, 703, 704, 705
 choledocholithiasis (bile duct stones) and, 706
 in Crohn disease, 641
 gallbladder cancer and, 1606
 in hereditary spherocytosis, 501
 pancreatitis and, 711
 during pregnancy, 703, 704, **807**
 in short bowel syndrome, 625
 in sickle cell anemia, 503, 702
- Cholera, 1300*t*, **1448**
 prevention/immunization and, 1314–1315, 1448
- Cholestasis, 662
 in biliary cirrhosis, 693
 drugs/toxins causing, 683
 in hepatitis, 666
 hereditary/intrahepatic, 662, 663*t*
 of pregnancy, 663*t*, **807**
- Cholestatic jaundice, 662, 663*t*
 antipsychotic drugs causing, 1059
- Cholesteatoma, 204, 204*f*
- Cholesterol, 1246. *See also specific lipoprotein and Lipoproteins*
 in atherogenesis/cardiovascular/
 coronary heart disease, 350,
 1245–1246, 1246
 in diabetes mellitus, 1200–1201, 1205,
 1227
 dietary, 1269
 elevated levels of. *See also*
 Hypercholesterolemia; Lipid
 disorders
 isotretinoin use and, 127
 screening tests for, **1248–1252**,
 1249–1250*t*, 1251*t*
 cardiovascular disease prevention
 and, 7*t*, 1248–1252,
 1249–1250*t*, 1251*t*
 in older adults, 1251–1252
 in women, 7*t*, 1248, 1251, 1706
 estrogen replacement affecting, 1182
 in gallstones, 702, 703
 lowering levels of. *See* Lipid-lowering
 therapy
 protease inhibitors affecting, 1344
 reference values for, 1246, 1729*t*
 thiazolidinedione therapy and,
 1209–1210
- Cholesterol-lowering diet, 1250, 1252,
 1269
 in diabetes, 1205
 in nephrotic syndrome, 928
- Cholesterosis of gallbladder, 703*t*, 705
- Cholestyramine
 for diarrhea, 580
 in Crohn disease, 643
 in short bowel syndrome, 625
 for intrahepatic cholestasis of
 pregnancy, 807
 for lipid modification, 1253, 1255*t*
 vitamin D affected by, 1149
- Choline magnesium salicylate, 77*t*
- Cholinergic rebound, 1069
- Cholinergic syndrome, 1568
- Cholinergic urticaria, 133
- Cholinesterase inhibitors. *See*
 Anticholinesterases
- Chondritis, 199. *See also* Polychondritis
- Chondrocalcinosis, **816–817**
- Chondroitin/chondroitin plus
 glucosamine sulfate, in
 osteoarthritis, 812, 1702
- Chordae tendineae
 in Marfan syndrome, 1670
 in mitral regurgitation, 339
 in mitral stenosis, 337
 in mitral valve prolapse, 340, 341
 rupture of, 339, 340, 1670
- Chorea, 1002
 drug-induced, 1004
 in Huntington disease, 1001, 1002
 Sydenham, 418, 1002
- Chorioamnionitis, **798**
- Choriocarcinoma, **791–792**, 1611*t*. *See*
also Gestational trophoblastic
 disease
 hyperthyroidism and, 791, 1112, 1596*t*
 paraneoplastic syndrome associated
 with, 1596*t*
 testicular, 1642
- Choriomeningitis, lymphocytic,
1380–1381
- Chorionic gonadotropin. *See* Human
 chorionic gonadotropin
- Chorionic villus sampling, 783, 784
- Chorioretinitis, toxoplasmic, in HIV
 infection/AIDS, 1501
- Choroidal angioma, in Sturge-Weber
 syndrome, 997
- Choroidal circulation, hypertension
 affecting (hypertensive
 retinochoroidopathy), **186**,
 440, 440*f*
- Choroidal neovascularization, in age-
 related macular
 degeneration, 181
- Chromoblastomycosis (chromomycosis),
1540
- Chromoendoscopy, in ulcerative colitis,
 649
- Chromogranin A (CgA)
 in carcinoid tumors, 1621
 in pancreatic/periampullary
 carcinoma, 1608
 in pheochromocytomas, 1167
- Chronic bronchitis. *See* Bronchitis
- Chronic cluster headache, 965
- Chronic cutaneous lupus erythematosus,
114–115
- Chronic disease
 anemia of, 492, **493–494**
 mood disorders and, 1064
- Chronic fatigue syndrome, **38–40**, 39*f*
 fibromyalgia and, 822–823
 Q fever, 1416
- Chronic inflammatory polyneuropathy,
1025–1026
- Chronic kidney disease (CKD), 898, **908–**
918, 909*t*, 910*f*, 910*t*, 911*f*,
 912*f*. *See also* Renal failure
 acid-base disorders and, 892, 892*t*, 893,
 893–894, 914
 alkalosis in alkali administration and,
 895
 anemia in, 493, 898, 911*f*, 913
 cardiorenal syndrome and, **908**
 cardiovascular disorders and, 908, 909*t*,
 911–912, 911*f*
 coagulopathy of, 913
 complications of, 911–914, 911*f*, 912*f*
 congestive heart failure and, 400, 910*t*,
 912
 diabetes and, 908, 910, 914, 927, **931**,
 1223–1224. *See also* Diabetic
 nephropathy
 dietary management in, 914–915
 drug/medication use and, 915
 endocrine disorders and, 914
 gout and, 812, 813, 816, **936–937**
 hematologic complications and, 913
 hepatitis C infection and, 671, 926
 hypercalcemia/hyperparathyroidism
 and, 883, 910*t*, 912, 912*f*,
 1139, 1141, 1143–1144
 hyperkalemia and, 879, 911, 911*f*,
 913–914
 hypermagnesemia and, 888
 hyperphosphatemia in, 886, 902, 905,
 911*f*, 912, 912–913, 912*f*
 hypertension/hypertension
 management and, 433, 439,
 442*t*, 458–459, 908, 910, 910*t*,
 911, 911*f*
 hypocalcemia and, 882, 912, 912*f*
 hypoglycemia and, 910, 914, 1222
 hypomagnesemia treatment and, 888
 hyponatremia in, 874
 immunization recommendations in,
 1309*t*
 lipid abnormalities and, 1248*t*
 metabolic bone disorders of (renal
 osteodystrophy), 912–913,
 912*f*, 1139, 1141, 1144
 in nephrogenic systemic fibrosis, **937**
 neurologic complications of, 909*t*, 910,
 914
 neuropathy associated with, 909*t*, 914,
 1022–1023

- Chronic kidney disease (CKD) (*Cont.*):
 pericarditis and (uremic pericarditis),
 419, 420, 910, 912
 protein-restricted diet for, 914–915,
 1269
 reversible causes of, 910, 910t
 in SLE, 833, 834, 835, 919t, 921f,
 926–927
 slowing progression of, 914
 stages of, 908, 909t
 urinalysis in, 910
- Chronic lymphocytic leukemia (CLL),
 521–523, 1610t
 stem cell transplantation for, 523, 533
- Chronic lymphocytic thyroiditis. *See*
 Hashimoto (chronic
 lymphocytic/autoimmune)
 thyroiditis
- Chronic mountain sickness (Monge
 disease), 1559
- Chronic myeloid leukemia (CML), 511t,
 515–517, 1610t
 bone marrow/stem cell transplantation
 for, 517, 533
- Chronic myelomonocytic leukemia
 (CMML), 517
- Chronic obstructive pulmonary disease
 (COPD), 259–265, 260t
 acidosis in, 261, 264, 896
 atrial flutter in, 261, 264, 389
 cor pulmonale and, 261, 264, 426
 cough in, 21, 22, 23, 260, 260t
 dyspnea in, 24, 24t, 25, 26, 260, 260t,
 264, 265
 hypophosphatemia and, 885
 immunization recommendations in,
 261, 1309t
 postoperative pulmonary
 complications and, 50, 51
 pulmonary function tests in, 260–261,
 260t
 pulmonary hypertension and, 305, 424
 respiratory failure in, 261, 264
 smoking and, 6, 259, 261
 surgery for, 264–265
- Chronic pain disorders, 1047–1049,
 1048f. *See also* Pain
 opioids in management of, 79, 1049
- Chronic pelvic pain
 in female, 1714–1716
 in male (nonbacterial prostatitis), 942t,
 943–944
- Chronic polymorphocytic leukemia, 522
- Chronic renal failure, 898, 908–918, 909t,
 910f, 910t, 911f, 912f. *See also*
 Chronic kidney disease
- Chronic venous insufficiency. *See* Venous
 insufficiency/stasis
- Churg-Strauss syndrome (allergic angitis
 and granulomatosis), 306
 leukotriene modifiers for asthma and,
 253
 pulmonary involvement in, 306
 renal involvement in, 919t, 921f, 924
- Chvostek sign
 in hypocalcemia/hypoparathyroidism,
 882, 1136
 malabsorption and, 621t
- Chylomicronemia. *See*
 Hyperchylomicronemia
- Chylous ascites, 588, 591, 1645
- Chylous pleural effusion, 314, 1645
- CIA assay, in syphilis, 1466t, 1467
- Cialis. *See* Tadalafil
- Cicatrical alopecia, 156
- Ciclopirox, 98t
- Cidofovir, 1353t
 for CMV infection, 187, 1353t, 1365
 for herpes simplex infection, 1352
 for recurrent respiratory
 papillomatosis, 234
- Cigarette/cigar smoking. *See* Smoking
- Ciguatera poisoning, 1589, 1589t
- Cilostazol, for transient ischemic attacks,
 979
- Ciloxan. *See* Ciprofloxacin
- Cimetidine, 613. *See also* H₂ receptor
 blocking drugs
 antidepressant drug interactions and,
 1071t
 benzodiazepine interactions and, 1043t
 for scombroid poisoning, 1589
- Cimex lectularius* bites, 149
- CIN. *See* Cervical intraepithelial neoplasia
- Cinacalcet
 for hypercalcemia/
 hyperparathyroidism, 884,
 1143, 1144
 for metabolic bone disorders/renal
 osteodystrophy, 913
 for parathyroid carcinoma, 1143, 1144
 for parathyroid hyperplasia, 1143
- Cingulotomy, for OCD, 1044
- Cipro. *See* Ciprofloxacin
- Ciprofibrate, 1254
- Ciprofloxacin. *See also* Fluoroquinolones
 for anthrax, 1432, 1433t
 breastfeeding and, 782t
 for Crohn disease, 642, 644
 for cyclosporiasis, 1508
 for folliculitis, 130
 for ophthalmic disorders, 168t
 for pneumonia, 273, 273t, 277t
 for urinary tract infection, 940t
- Circadian rhythm
 asthma symptoms and, 246
 sleep and, 1075
- Circadian rhythm dysfunction, in
 seasonal affective disorder,
 1063
- Circulation assessment/support
 in burn injury, 1550
 in comatose patient, 1563
- Circumcision, HIV infection risk and,
 1333
- Cirrhosis, 686–692, 692t
 alcoholic liver disease/hepatitis and,
 680, 681, 682, 687
 autoimmune hepatitis and, 679
 biliary, 687, 692–694
 cardiac, 687
 cholecystectomy and, 702
 coagulopathy and, 553
 drugs/toxins causing, 683
 Dupuytren contracture and, 686, 824
 esophageal varices in, 581, 601, 602,
 604, 687. *See also* Esophageal
 varices
 prevention of first bleeding episode
 and, 604
- GI bleeding in, 581, 601, 602, 687
 hemochromatosis and, 687, 695
 hyponatremia in, 873
 Laennec, 686
 lipid abnormalities and, 1248t
 liver cancer and, 682, 685, 687, 1603,
 1604, 1605
 lower extremity edema and, 33–34
 methotrexate toxicity and, 829
 nonalcoholic fatty liver disease and,
 684, 685, 687
 hepatocellular carcinoma and, 685,
 1603
 portal hypertension and, 601, 688
 postoperative complications and, 52
 spontaneous bacterial peritonitis and,
 589, 689
 viral hepatitis and, 668, 670, 671, 672,
 674, 675, 676, 678, 687
- Cirrhotic cardiomyopathy, 687
- CIS. *See* Clinically isolated syndrome
- Cisapride, antidepressant drug
 interactions and, 1068, 1071t
- Cisplatin, 1650t, 1662
 for bladder cancer, 1640
 for gastric adenocarcinoma, 1617
 for laryngeal cancer, 237
 for lung cancer, 1599, 1600
 for testicular cancer, 1643
 toxicity of, 1650t, 1662
 amifostine for, 1658t, 1662
 ophthalmic, 197t
 ototoxicity, 207, 1662
- Citalopram, 1067, 1070t
 in elderly, 63
 overdose toxicity of, 1067, 1070t,
 1591–1592
 during pregnancy, 1067–1068
- Citracal (calcium citrate). *See* Calcium,
 dietary/supplementary
- Citrate, in hypocitraturic calcium
 nephrolithiasis, 949
- Civamide, for cluster headache
 prophylaxis, 965
- CJD. *See* Creutzfeldt-Jakob disease
- CK. *See* Conductive keratoplasty;
 Creatine kinase
- CK-MB. *See* Creatine kinase-MB
- CKD. *See* Chronic kidney disease
- CKD-EPI formula, for GFR estimation,
 901
- Cl⁻. *See* Chloride
- Cladophialophora/Cladophialophora*
carrionii
 chromoblastomycosis caused by, 1540
 phaeohiphomyces caused by, 1541
- Cladribine (2-chlorodeoxyadenosine),
 1651t
 for hairy cell leukemia, 524
- Clarithromycin. *See also* Macrolides
 for anthrax, 1433t
 for endocarditis, 1438t
 in *H pylori* eradication therapy, 613,
 614, 614t
 for MAC treatment/prophylaxis, 1337,
 1338t, 1458, 1459
 for pneumonia, 273, 273t
- Claudication
 acute arterial limb occlusion and, 468
 in aortoiliac occlusive disease, 464

- in femoral/popliteal occlusive disease, 465, 466
- jaw (masticatory), in giant cell arteritis, 846
- neurogenic, in spinal stenosis, 822, 1685
- peripheral artery aneurysms and, 476
- spinal stenosis/disk herniation and, 822, 1685
- Cl_{cr}. *See* Creatinine clearance
- Clean-catch urine specimen, for dysuria evaluation, 43
- Cleaning agents, poisoning caused by. *See* Caustic/corrosive agents
- Clear liquid diet, 1268
- Clemastine, for allergic/perennial rhinitis, 219
- Cleocin T. *See* Clindamycin
- Clevidipine, for hypertensive urgencies/emergencies, 462t, 463
- Cleviprex. *See* Clevidipine
- Clicks. *See also* Heart murmurs
- in aortic stenosis, 342
- in mitral valve prolapse, 340, 341
- in pulmonary stenosis, 325
- in pulmonary valve regurgitation, 348
- Climacteric, 1181. *See also* Menopause
- Climara/Climara Pro, 1183, 1184
- Clindamycin
- for acne, 97t, 127
- for anaerobic pleuropulmonary infection, 278–279, 1455
- for anthrax, 1433t
- for bacterial vaginosis, 753
- with benzoyl peroxide, 97t
- for endocarditis, 1438t
- for malaria, 1494t, 1497
- for *Pneumocystis pneumonia*, 1534, 1535
- for rosacea, 129
- for toxoplasmosis, 1338t, 1502
- Clinically isolated syndrome (CIS), multiple sclerosis and, 1011
- Clinician–patient relationship. *See* Doctor–patient relationship
- Clinoril. *See* Sulindac
- Clitocybe* (muscarine) mushroom poisoning, 1586t
- CLL. *See* Chronic lymphocytic leukemia
- Clobetasol, 96t
- Clock draw, in dementia screening, 60, 1007
- Clocortolone, 96t
- Cloderm. *See* Clocortolone
- Clofarabine, 1651t
- Clofazimine, for leprosy, 1460
- Clolar. *See* Clofarabine
- Clomiphene
- for male infertility, 1097
- for ovulation induction, 769, 1097, 1163
- Clomipramine, 1068, 1070t. *See also* Antidepressants
- for OCD, 1044, 1068
- Clonazepam, 973t, 1042t, 1043. *See also* Benzodiazepines
- for bipolar disease/mania, 1072
- for burning mouth syndrome, 226
- for panic attacks, 1043, 1044
- for seizures, 973t
- for sleep disorders, 1077
- Clonic seizures, 970. *See also* Seizures
- Clonidine, 456t
- for alcohol withdrawal, 1082–1083
- antidepressant drug interactions and, 1071t
- for diarrhea, 580
- in diabetic autonomic neuropathy, 1226
- for heroin/opioid withdrawal, 1084
- for hypertension, 453, 456t
- with chlorthalidone, 456t
- in urgencies/emergencies, 462t, 463
- for menopausal symptoms, 780
- overdose/toxicity of, 456t, 462t, 1577
- for Tourette syndrome, 1005
- Clonorchis sinensis* (clonorchiasis), 1513
- cholangiocarcinoma and, 1513, 1606
- Clopidogrel
- for acute coronary syndromes, 361, 361–363, 362t
- for angina, 356
- for atrial fibrillation, 386
- for myocardial infarction, 362t, 367, 371, 376
- peptic ulcer disease and, 615, 616
- platelet function affected by, 549t
- proton pump inhibitor interaction/coadministration and, 370, 616
- for transient ischemic attacks, 979
- Clorazepate, 1042, 1042t
- Clorpres. *See* Clonidine, for hypertension, with chlorthalidone
- Clostridium* (clostridial infections), 1300t, 1428–1431
- bifermentans*, 1428
- botulinum* (botulism), 1033–1034, 1294t, 1430–1431
- difficile*, colitis/diarrhea caused by, 574t, 575, 576, 636–638, 1293, 1294t
- histolyticum*, 1428
- myonecrosis/gas gangrene, 1300t, 1428–1429
- novyi*, 1428
- perfringens*, 1428
- diarrhea/food poisoning/gastroenteritis caused by, 574t, 575, 1293, 1294t
- postabortion endometritis caused by, 777, 1429
- ramosum*, 1428
- sordellii*/endometritis/toxic shock, 777, 1429
- tetani*, 1300t, 1429. *See also* Tetanus
- Clothing (flame) burns, electrical, 1552
- Clotrimazole, 97t
- for oral candidiasis, 226, 1329
- for vulvovaginal candidiasis, 752, 752–753, 1530
- Clotting factors. *See* Coagulation factors
- Clotting time, activated (ACT), reference values for, 1727t
- Clozapine, 1055, 1056, 1056t, 1057t, 1060t. *See also* Antipsychotic drugs
- agranulocytosis caused by, 1000, 1056, 1059
- diabetes and, 1057, 1059, 1060t
- neuroleptic malignant syndrome and, 1060
- overdose/toxicity of, 1000, 1056, 1057, 1057t, 1059, 1059–1060, 1060t
- in parkinsonism, 1000
- Clozaril. *See* Clozapine
- Clubbed fingers (digital clubbing), 157, 158f
- in bronchiectasis, 266
- in lung cancer, 1597
- Clue cells, in bacterial vaginosis, 752, 752f
- Cluster headache, 962, 965
- Clusters of differentiation. *See* CD markers
- CMF regimen, for breast cancer, 736–737
- CML. *See* Chronic myeloid leukemia
- CMML. *See* Chronic myelomonocytic leukemia
- CMV. *See* Controlled mechanical ventilation
- CMV disease. *See* Cytomegalovirus (CMV) disease
- CMV immune globulin, 1365–1366
- CMV inclusion disease, 1364
- CO₂ laser therapy. *See* Carbon dioxide laser therapy
- Coagulase-negative staphylococci, 1427–1428
- endocarditis caused by, 1428, 1435, 1439
- Coagulation disorders, 549–554. *See also* Bleeding; Coagulopathy; Disseminated intravascular coagulation
- Coagulation factors. *See also specific type under Factor*
- for anticoagulant overdose, 1573
- deficiencies/defects of
- in acquired coagulation disorders, 553, 554
- in congenital coagulation disorders, 549, 550, 551, 552
- in liver disease, 553
- transfusion and, 537
- Coagulative necrosis techniques, for benign prostatic hyperplasia, 961
- Coagulopathy, 549–554. *See also specific type and Bleeding*
- acquired disorders causing, 553–554
- cancer-related, 1596t
- of chronic kidney disease, 913
- congenital disorders causing, 549–553, 550t, 552t
- consumptive (DIC), 545–546, 546t, 554. *See also* Disseminated intravascular coagulation
- in gram-negative bacteremia/sepsis, 1444
- of liver disease, 553–554
- in cirrhosis, 553, 690–691
- liver failure and, 672
- variceal hemorrhage and. *See* Esophageal varices
- preoperative evaluation/perioperative management and, 46, 47t, 52, 53t
- Coal worker's pneumoconiosis, 309, 309t
- Coapsys system, for mitral valve prolapse, 341

- Coarctation of aorta, 326–327
hypertension and, 326, 327, 438
in Turner syndrome, 1186
- Coartem (artemether-lumefantrine/
Riamet), 1492*t*, 1493*t*, 1494*t*,
1496, 1497
- Cobalamin. *See* Vitamin B₁₂
- Cocaine. *See also* Cocaine abuse
toxicity and, 1085, 1572–1573
cardiac, 360, 365, 410–411, 1085
- Cocaine abuse, 18, 1085–1086,
1572–1573
desipramine for, 1068
epistaxis and, 220, 1085
heroin abuse and, 1083
in hypertensive emergency, 461*t*
myocardial ischemia/infarction/
myocarditis and, 360, 365,
410–411, 1085
during pregnancy, 783
psychotic behavior caused by, 1055,
1085, 1086
pulmonary disorders caused by, 311
rhabdomyolysis and, 844
- Coccidioides immitis/posadasii*
(coccidioidomycosis),
1532–1533
bone and joint infection in, 863, 1532
in HIV infection/AIDS, prophylaxis of,
1337, 1532, 1533
- Coccidiosis, 1505–1508. *See also specific*
causative organism
- Cochlea
hearing loss caused by disorders of,
198, 199, 206–208. *See also*
Sensory hearing loss
noise trauma affecting, 207
recruitment/hyperacusis caused by
disorders of, 208
tinnitus caused by disorders of, 208
- Cochlear implants, 199
- Cochlear otosclerosis, 205
- Cockcroft-Gault formula, 900
- Codeine, 79
with aspirin or acetaminophen, 79, 83*t*
for diarrhea, 580
overdose/toxicity of, 1586–1587
in pain management, 79, 83*t*
- Coffee grounds emesis/aspirate
in erosive/hemorrhagic gastritis
(gastropathy), 607
in GI bleeding, 580, 581, 584, 617
in peptic ulcer disease, 617
- Cogan syndrome, 208
- Cogentin. *See* Benztropine
- Cognitive ability
estrogen replacement therapy and, 780,
1182, 1183
impairment in. *See* Cognitive disorders
- Cognitive behavior therapy. *See also*
Behavior modification
for anxiety disorders, 1044
for chronic fatigue syndrome, 40
for depression, 1072
in elderly, 63
for insomnia, 1076
for irritable bowel syndrome, 636
for schizophrenia/psychotic disorders,
1062
for Tourette syndrome, 1005
- Cognitive disorders, 59–63, 1005–1010,
1008*t*, 1087–1089, 1087*t*. *See*
also specific type and
Delirium; Dementia
assessment of, 60, 1006–1007, 1087–1088
breast cancer treatment and, 744
decision-making capacity and, 60
delirium and, 59–60, 61, 64, 1006,
1087–1089, 1087*t*
in elderly, 59–63, 1005–1010, 1008*t*
hypertension and, 439
in intracranial mass lesions, 989
in migraine headache, 963
mild impairment, 60–61, 1005
postoperative, 53, 53*t*
psychiatric disorders and, 1006
screening for, 1006–1007
seizures and, 969, 1088–1089
treatment of, 61, 1008–1009
- Cognitive remediation therapy, for
schizophrenia/psychotic
disorders, 1062
- Coin lesion. *See* Solitary pulmonary nodule
- Coitus. *See* Sexual intercourse
- Colchicine
for familial Mediterranean fever, 591
for gout, 814, 815
neuropathy/myopathy caused by, 815,
841–842
for pericarditis, 420
- Cold (common cold/viral rhinosinusitis),
213–214, 1401
bacterial rhinosinusitis and, 213, 214
cough in, 21
- Cold agglutinin disease, 507
Waldenström macroglobulinemia and,
507, 530
- Cold exposure, 1543, 1543–1546, 1544*f*
hypothermia caused by
extremities, 1545–1546
rhabdomyolysis and, 844
systemic, 1543–1545, 1544*f*
Raynaud phenomenon and, 836, 837,
838
- Cold/fever sore (herpes simplex),
118–119, 118*f*, 1350–1351,
1352. *See also* Herpes
simplex infection
- Cold urticaria, 133
- Colectomy
for colorectal cancer, 1624
in familial adenomatous polyposis, 655
for GI bleeding, 585
for HNPCC, 657
prophylactic, 655
in ulcerative colitis, 649
- Colesevelam
for diarrhea in Crohn disease, 643
for lipid modification, 1253, 1255*t*
- Colectid. *See* Colestipol
- Colestipol
for diarrhea in Crohn disease, 643
for lipid modification, 1253, 1255*t*
- Colic. *See* Abdominal pain/tenderness;
Renal colic
- Colitis. *See also* Diarrhea
amebic (intestinal amebiasis), 574*t*,
575, 576, 578, 1293, 1298,
1303*t*, 1330, 1503, 1503–
1504, 1504, 1504*f*, 1505*t*
postdysenteric, 1504
severe (dysentery), 575, 1503, 1505*t*.
See also Dysentery
antibiotic-associated/*C difficile*, 575,
576, 636–638, 1293, 1294*t*
collagenous, 650
Crohn, 641. *See also* Crohn disease
ischemic, 470–471, 471
lymphocytic, 650
microscopic, 574*t*, 578, 650
postdysenteric, 1504
pseudomembranous, 637. *See also*
Colitis, antibiotic-associated
ulcerative. *See* Ulcerative colitis
- Collagen
in nephrogenic systemic fibrosis, 937
type I, gene mutations in osteogenesis
imperfecta and, 1145
- Collagen/ADP cartridge test, 1733*t*
- Collagen/epinephrine cartridge test, 1733*t*
- Collagen injections, for age-related facial
changes, 1721
- Collagenomas, in MEN, 1188*t*, 1189
- Collagenous colitis, 650
- Collateral ligaments of knee, 1692
injury of, 1695–1696*t*, 1698–1699
- Colloids, for fluid management/volume
replacement in shock, 487
- Colography, CT (virtual colonoscopy).
See Colonoscopy, virtual
- Colon
anaerobic flora of, 1456
biopsy of, in diarrhea, 579
cancer of, 1612*t*. *See also* Colorectal
cancer
adjuvant therapy for, 1625
exercise affecting risk of, 12, 15
GI bleeding and, 584
surgical excision and, 1624
carcinoid tumors of, 1621
dilation of. *See also* Megacolon
in acute colonic pseudo-obstruction
(Ogilvie syndrome), 628
disorders of, 632–657. *See also specific*
disorder
constipation and. *See* Constipation
diverticular, 651–652. *See also*
Diverticulitis; Diverticulosis
fecal impaction and, 572
GI bleeding and, 584
polyps of, 652–657
- Colon cutoff sign, in pancreatitis, 712
- Colonic inertia (slow colonic transit),
constipation and, 570, 570*t*,
571
- Colonic pseudo-obstruction
acute (Ogilvie syndrome), 628–629
chronic, 629–630
- Colonic transit time, 570, 571
- Colonography, CT (virtual colonoscopy).
See Colonoscopy, virtual
- Colonoscopy
in amebiasis, 1504
for colon decompression in acute
colonic pseudo-obstruction
(Ogilvie syndrome), 629
in colorectal cancer screening/
evaluation, 15*t*, 16, 1624,
1624*f*, 1626*t*, 1628
after surgery, 1626

- in Crohn disease, 642
 in diarrhea, 579
 in diverticular disease, 651
 in GI bleeding
 diagnostic, 585
 obscure bleeding and, 586
 occult bleeding and, 586
 therapeutic, 585
 in HNPCC, 657
 hyponatremia after, 872
 in irritable bowel syndrome, 634
 in ischemic colitis, 471
 in polyp identification/removal, 653, 653–654
 bleeding after, 584, 654
 surveillance, 649, 654
 in ulcerative colitis, 647, 649
 virtual
 in colorectal cancer screening and evaluation/polyp identification, 16, 653, 1626*t*, 1628
 in diverticular disease, 651, 652
- Color flow Doppler ultrasound. *See* Echocardiography; Ultrasonography
- Color perception, loss of
 in intracranial tumors, 991
 in optic neuritis, 188
- Colorado tick fever, **1391–1392**
- Colorectal cancer, 1612*t*, **1622–1629**
 adjuvant/neoadjuvant therapy for, 1624, 1625, 1625–1626
 aspirin/NSAIDs in prevention of, 11, 1623
 calcium supplements in prevention of, 1269–1270, 1623
 chemoprevention and, 11, 1623
 chemotherapy for, 1612*t*, 1625, 1625–1626
 constipation and, 570, 571, 1623
 Crohn disease and, 643, 1623
 diet and, 1269, 1594, 1623
 familial adenomatous polyposis/family history and, 654, 655, 1622, 1622–1623
 genetic mutations associated with, 654, 655, 1622
 fecal DNA assay in identification of, 653, 1626*t*, 1627
 GI bleeding and, 584, 1623
 hamartomatous polyposis syndromes and, 655
 hereditary, **654–657**, 1622–1623
 hereditary nonpolyposis (HNPCC), **656–657**, 1622
 endometrial carcinoma and, 656, 657, 759
 pancreatic/periampullary carcinoma and, 1608
 small intestine adenocarcinoma in, 1620
 incidence/risk/mortality of, 1594*t*, 1622, 1622–1623
 inflammatory bowel disease and, 643, 1623
 nonfamilial adenomatous polyps and, 653
 pancreatic/periampullary carcinoma and, 1608
- polyps/polyposis and, 653, 654, 655, 1622, 1623, 1626, 1628
 prevention of/screening for, 15*t*, 16, 1626–1628, 1626*t*
 chemoprevention and, 11, 1623
 in women, 1708
 primary sclerosing cholangitis and, 710
 prognosis for, 1626
 staging of, 1624
 surgery for, 1624–1625
 follow-up after, 1626
 ulcerative colitis and, 649, 1623
 in women, 1708
- Colorectal surgery, 1624–1625
 adjuvant therapy and, 1624, 1625, 1625–1626
 follow-up after, 1626
- Colostomy
 after colorectal surgery, 1624
 diverting, for rectal cancer, 1625
- Colostrum, 786
- Colpocleisis, for pelvic organ prolapse, 762
- Colpopexy, for pelvic organ prolapse, 762
- Colposcopy, 748*t*
 in CIN, 755, 756
- Columbia-Suicide Severity Risk Scale, 1065
- CoLYTE. *See* Polyethylene glycol
- Coma, **1013–1016**
 assessment/emergency management of, 1013–1014, 1562–1563
 diabetic/hyperglycemic, 1197, **1231–1235**, 1232*t*. *See also specific cause*
 diabetic ketoacidosis and, 1197, 1231, 1232, 1232*t*, 1233
 hyperglycemic hyperosmolar state and, 1197, 1231, 1232*t*, 1236, 1237
 lactic acidosis and, 1231, 1232*t*
 hypoglycemic, 1231, 1232*t*
 in poisoning/drug overdose, 1232*t*, 1563
 hypopituitarism associated with, 1093
 hypothermia and, 1014, 1015, 1544
 metabolic disturbances causing, 1014, **1015**. *See also* Metabolic encephalopathy
 myxedema, 1108
 in poisoning/drug overdose, 1015, 1232*t*, **1562–1563**
 reversible, brain death differentiated from, 1015
 in stroke, 981, 982, 1014, 1232*t*
 structural lesions causing, **1014–1015**
 in subarachnoid hemorrhage, 984, 1014
- Coma vigil (persistent vegetative state), **1016**
- Combigan. *See* Brimonidine/timolol
- Combination antiretroviral therapy, 1340, 1342, 1343, 1347–1348, 1348*f*
 fixed-dose preparations and, 1343, 1347, 1348*f*
- Combined pituitary hormone deficiency, 1094–1095
- Combipatch, 1184
- Combivir. *See* Zidovudine (AZT), with lamivudine
- Comedones, in acne, 125–126, 126–127
- Comfrey
 sinusoidal obstruction syndrome caused by, 698
 toxicity of, 1578*t*
- Commissurotomy
 mitral, 338
 for pulmonary stenosis, 326
- Common ALL antigen, 520
- Common cold. *See* Cold (common cold/viral rhinosinusitis)
- Common duct stones. *See* Cholelithiasis
- Common femoral artery, atherosclerotic/occlusive disease of, **465–466**
- Common peroneal (fibular) nerve palsy, **1027**
- Common variable immunodeficiency, **868–869**
- Commotio cordis, 431
- Communicating artery
 anterior, occlusion of in stroke, 981
 posterior, disorders of in third nerve paralysis, 190
- Community-acquired pneumonia, **270–275**, 270*t*, 272*t*, 273*t*, 1302*t*. *See also* Pneumonia
 chlamydial, 1302*t*, 1462–1463
 in coccidioidomycosis, 1532
 cough in, 22, 22*f*, 271
 in HIV infection/AIDS, 1326
 nosocomial pneumonia differentiated from, 275
- Community-associated methicillin-resistant *S aureus* (CA-MRSA), 5
 cellulitis caused by, 137
 impetigo/ecthyma caused by, 123
 pneumonia caused by, 273, 273*t*
- Compartment syndrome
 abdominal, in burn patient, 1551
 in electrical burns, 1553
- Compatibility testing, for transfusion, 534
- Complement. *See also specific component*
 in antibody-mediated/cytotoxic hypersensitivity, 866
 in autoimmune hemolytic anemia, 506
 in cold agglutinin disease, 507
 in familial Mediterranean fever, 591
 in glomerulonephritis, 908
 in gonococcal arthritis, 860
 in immune complex-mediated hypersensitivity, 866
 immunization recommendations in deficiencies and, 1309*t*
 in paroxysmal nocturnal hemoglobinuria, 501, 502
 reference values for, 1729*t*
 in SLE, 833, 834*t*
 in urticaria, 132
- Complement fixation tests, in coccidioidomycosis, 1532–1533
- Complera. *See* Rilpivirine, with tenofovir and emtricitabine
- Complete abortion, 788
- Complete mole, 791. *See also* Gestational trophoblastic disease
- Complete (third-degree) heart block, 394, 395
 in atrial septal defect, 328
 in myocardial infarction, 373

- Complex 15, 98t
 Complex drug eruptions, 160–161
 Complex partial seizures, 969. *See also* Seizures
 schizophrenia differentiated from, 1055
 Complex regional pain syndrome (reflex sympathetic dystrophy), 824–825
 Compliance. *See* Adherence/
 nonadherence
 Compound nevi, 100, 100f
 Compression chambers/centers. *See* Hyperbaric oxygen therapy;
 Recompression
 Compression fractures. *See* Vertebral/
 compression fracture
 Compression neuropathy. *See* Entrapment/compression
 neuropathy; Neuropathies
 Compression sclerotherapy, for varicose
 veins, 479
 Compression stockings/therapy
 for lymphedema, 484
 for varicose veins, 479, 1720
 for venous insufficiency/leg ulcers, 34,
 154, 154–155, 481
 for venous thromboembolic disease,
 555–556, 563
 Compromised host. *See* Immunocompromised host
 Compulsions, 1041. *See also* Obsessive-
 compulsive disorder
 Compulsive water drinking. *See* Psychogenic polydipsia
 Computed tomography (CT scans). *See also specific disorder and*
 Neuroimaging
 in abdominal aortic aneurysms, 473
 in angina, 353–354
 in aortic dissection, 477
 in aortoiliac occlusive disease, 464
 in appendicitis, 630
 in breast cancer, 727
 cardiac, in constrictive pericarditis, 422
 in carotid occlusive disease, 469
 in chest pain evaluation, 29, 29–30
 in colorectal cancer evaluation/
 screening, 16
 in constrictive pericarditis, 422
 in dysuria evaluation, 43–44
 electron beam (EBCT)
 in angina, 354
 in heart disease screening, 1250
 in headache, 42
 in hemoptysis, 27
 in liver disease/jaundice, 665
 in lung cancer screening, 16, 289, 1599
 in women, 1709
 in lung cancer staging, 1598
 in musculoskeletal evaluation, 1673
 in pancreatic/periapillary
 carcinoma, 1608
 in pancreatitis, 712, 712t, 713
 in peripheral artery aneurysms, 476
 in pheochromocytoma/paraganglioma,
 1168
 in pulmonary embolism, 299, 300, 301f
 in pulmonary hypertension, 305
 radiation exposure/cancer risk and,
 1594
 in renal artery stenosis/renal vascular
 hypertension, 437, 917
 in renal cell carcinoma, 1641
 in seizure evaluation, 971
 in solitary pulmonary nodule, 290
 in thoracic aortic aneurysm, 475
 in thyroid cancer, 1129
 in urinary stone disease, 947–948
 in visceral artery insufficiency, 471
 Computed tomography colography/
 colonography (virtual
 colonoscopy)
 in colorectal cancer screening and
 evaluation/polyp
 identification, 16, 653, 1624,
 1626t, 1628
 in diverticular disease, 651, 652
 Computerized stereotactic guided core
 needle breast biopsy, 729
 COMT (catecholamine-O-
 methyltransferase) inhibitors,
 for parkinsonism, 1000
 Concussion, 1017t
 hearing loss and, 207
 labyrinthine, vertigo caused by, 210t,
 211
 Condoms, 775, 1291
 condylomata acuminata and, 753
 for contraception, 775
 genital herpes prevention and, 119,
 1355
 for gonorrhea prevention, 1452
 for HIV infection/AIDS prevention, 4,
 1333, 1335
 for STD prevention, 1291
 in women, 1711
 for syphilis prevention, 1467
 Conduction disturbances, 394–397. *See also specific type and*
 Arrhythmias
 chest pain/discomfort and, 28t
 in endocarditis, 1436, 1437
 in hyperkalemia, 880
 intraventricular, 395–396
 in myocardial infarction, 373
 in restrictive cardiomyopathy, 416
 Conduction velocity studies
 in back pain evaluation, 1684
 in carpal tunnel syndrome, 824, 1689
 in motor neuron diseases, 1020
 in neuropathies, 1020, 1021, 1022
 Conductive-based cooling, for heat
 stroke, 1548
 Conductive hearing loss, 198, 199. *See also* Hearing loss
 in chronic otitis media/cholesteatoma,
 204
 ossicular disruption causing, 198
 in otosclerosis, 205
 after trauma, 205
 Conductive keratoplasty, 163
 Condylomas (condylomata)
 acuminata (venereal/genital warts),
 139, 140, 140f, 141, 752, 753
 anorectal involvement and, 139, 140,
 140f, 659
 cervical/vaginal/vulvar, 752, 753
 HPV vaccination in prevention of, 4,
 140, 659, 1709
 imiquimod for removal of, 140, 753
 podophyllum resin for removal of,
 140, 753
 lata, 140, 1469, 1469f
 anorectal involvement and, 658–659
 Conformal radiation therapy, three-
 dimensional, for prostate
 cancer, 1635
 Confusion, 64, 1088. *See also* Cognitive
 disorders; Delirium
 ECT causing, 1071
 Confusion assessment method, 64
 Congenital adrenal hyperplasia, 1156,
 1157, 1163
 Congenital adrenal hypoplasia, 1093,
 1094, 1156, 1175
 Congenital afibrinogenemia, 552
 Congenital heart disease, 324–333. *See also specific disorder*
 pregnancy and, 431, 802–803
 Congenital isolated hypogonadotropic
 hypogonadism, 1093
 Congenital rubella syndrome, 1374, 1375
 Congestive heart (cardiac) failure (CHF),
 398–409, 399f
 acute failure and, 399, 407–409
 angiotensin-converting enzyme (ACE)
 inhibitors for, 401, 401–402,
 449
 angiotensin II receptor blockers for,
 402, 449
 antiarrhythmic therapy in, 405
 anticoagulation therapy for, 405
 in aortic regurgitation, 344, 345
 in aortic stenosis, 342, 343
 arrhythmias in, 400, 405
 asthma/wheezing caused by (cardiac
 asthma), 243
 atrial fibrillation and, 385, 385t, 386
 in atrial septal defect, 328
 β -blocker therapy in, 402–403, 446
 biventricular pacing
 (resynchronization) for,
 405–406
 calcium channel blockers for, 405
 cardiac transplantation for, 406
 cardiomyopathy and, 398, 411,
 411–412, 412–413
 cardiorenal syndrome and, 908
 case management in, 406
 chemotherapy-induced, 1662
 chronic kidney disease and, 400, 910t,
 912
 cirrhosis and, 687
 classification of, 324, 398, 399, 399f
 in coarctation of aorta, 326, 327
 combination therapies in management
 of, 405
 in cor pulmonale, 425–426
 in coronary heart disease syndromes,
 360, 398, 406
 coronary revascularization for, 406
 cough in, 22, 398
 in coxsackievirus myocarditis, 1406
 diet in management of, 406
 digitalis glycosides for, 403–404, 405
 diuretic therapy for, 401
 chronic kidney disease and, 912
 drug management of, 401–405
 dyspnea in, 25, 398, 399
 edema in, 398–399, 401

- evolution/prevention/treatment of, 398, 399f
 exercise/activity in management of, 12–13, 406
 hypertension/hypertension management and, 10–11, 398, 433, 439, 442t, 457
 in hyperthyroidism, 399, 400, 1112, 1118
 hyponatremia in, 873
 in hypothyroidism/myxedema, 399, 400, 1108
 implantable cardioverter defibrillators for, 405
 in infectious myocarditis, 409, 410
 liver in, 400, 699
 management of, 401–406
 myocardial infarction and, 365, 366, 367t, 370, 373–374, 376, 407
 nonpharmacologic management of, 405–406
 palliative care in, 406
 in patent ductus arteriosus, 333
 pleural effusion in, 314, 399
 in pneumococcal pneumonia, 1423
 positive inotropic agents for, 405
 postoperative pulmonary complications and, 50
 in pregnancy/postpartum period (peripartum cardiomyopathy), 429, 802, 803
 preoperative evaluation/perioperative management and, 46, 49
 prognosis for, 406–407
 pulmonary edema in, 399, 407–409
 in pulmonary heart disease, 425–426
 pulmonary hypertension and, 304, 400, 424, 425
 in pulmonary stenosis, 326
 refeeding in protein–energy malnutrition and, 1258
 reversible causes of, correction of, 401
 rheumatic fever and, 417
 shock and. *See* Cardiogenic shock
 in SLE, 833
 spironolactone for, 401, 402
 statin therapy in, 405
 surgical interventions in, 406
 thiamine deficiency and, 1264
 thiazolidinedione use and, 1210
 in toxic myocarditis, 411
 in tricuspid regurgitation, 347
 in tricuspid stenosis, 346
 vasodilator therapy for, 404
 in ventricular septal defect, 330
 Congo-Crimean hemorrhagic fever, 1384–1385, 1385
 Conivaptan, for hyponatremia/SIADH, 875
 Conization of cervix, for CIN/cervical cancer, 756, 757
 Conjugated equine estrogens, 1182, 1184
 Conjunctiva
 foreign body of, 192
 lacerations of, 193
 Conjunctival hemorrhage, in
 mononucleosis, 1361, 1361f
 Conjunctivitis, 164–167, 165t. *See also* Keratoconjunctivitis
 adenovirus, 164–165, 1402
 allergic, 166–167
 bacterial, 165–166
 chemical, 194
 chlamydial, 165–166
 coxsackievirus infection and, 1406
 differential diagnosis of, 165t
 dry eyes and, 166
 enterovirus 70 causing, 1407
 gonococcal, 165, 1452
 herpes simplex, 165
 inclusion, 166, 806
 in Kawasaki disease, 1417
 in thyroid eye disease, 1112
 viral, 164–165
 Conn syndrome, 1164, 1166
 Connective tissue disorders. *See also specific disorder*
 cardiac/pericardial involvement in, 427
 cognitive disorders/delirium caused by, 1087t
 interstitial (diffuse parenchymal) lung disease and, 293
 mixed/overlap syndrome, 842
 pulmonary hypertension and, 424
 Connexin-26 mutation, hearing loss and, 207
 Consciousness
 in absence seizures, 970, 970t
 in focal seizures, 969, 970t
 inconsistent evidence of, in minimally conscious state, 1016
 level of, in head injury, 1016
 in psychogenic nonepileptic/pseudoepileptic seizure, 972, 1045
 in tonic-clonic (“grand mal”) seizures, 970, 970t
 Constipation, 86, 570–573, 570t, 572t
 alarm symptoms in, 570
 anogenital pruritus and, 146
 in chemotherapy-induced neuropathy, 1661
 colorectal cancer and, 570, 571, 1623
 in diabetic autonomic neuropathy, 1226
 in enteric (typhoid) fever, 1445
 fecal impaction and, 572–573
 in irritable bowel syndrome, 633, 635
 opioids causing, 79, 84, 86, 571–572
 overflow incontinence and, 660
 palliation of, 86
 in terminally ill/dying patient, 86
 Constitutional delay in growth and puberty, 1096, 1173, 1179
 Constrictive bronchiolitis, 269, 270. *See also* Bronchiolitis
 Constrictive pericarditis, 422–423
 cirrhosis and, 687
 restrictive cardiomyopathy differentiated from, 416, 422
 superior vena caval obstruction and, 482
 Contact dermatitis
 allergic, 124–125, 124f, 866
 impetigo differentiated from, 123, 124
 topical medications causing, 100, 124
 urticaria in, 133
 irritant, 124, 125
 photodermatitis differentiated from, 153
 tinea differentiated from, 113
 Contact lens cleaning solutions, toxic/hypersensitivity reactions to, 195
 Contact lenses, 162
 corneal infections/ulcers/
 acanthamoeba keratitis and, 162, 172, 173, 174, 1506
 for orthokeratology, 163
 Contact photosensitivity, 152. *See also* Photodermatitis/ photosensitivity
 Contact ulcers, of arytenoid cartilage, 235
 Contagious pustular dermatitis (orf), 1404
 Continuous ambulatory peritoneal dialysis, 916
 Continuous cyclic peritoneal dialysis, 916
 Continuous positive airway pressure (CPAP)
 nasal
 for sleep apnea, 319
 for snoring, 231
 for near drowning, 1556
 prevention of postoperative pulmonary complications and, 51
 for respiratory failure, 321
 Continuous renal replacement therapy (continuous venovenous/venovenous hemodiafiltration), for poisoning/drug overdose, 1567–1568
 Continuous subcutaneous insulin infusion (CSII), 1217, 1219.
 See also Insulin infusion pumps
 Contraception, 770–777, 771–772t, 772t, 774t. *See also specific method*
 antibiotic use affecting efficacy of, 127
 emergency/postcoital, 776
 IUD for, 774, 776
 fertility awareness and, 775–776
 after gestational trophoblastic disease, 792
 sickle cell disease and, 799
 sterilization for, 777
 Contraceptive foam/cream/film/sponge/jelly/suppository, 775
 Contraceptive injections/implants, 773
 Contraceptive-related hypertension, 438, 772
 Contraceptive transdermal patch, 773
 Contraceptive vaginal ring, 773
 Contraction alkalosis, 895
 Contrast media
 iodinated, for hyperthyroidism/Graves disease, 1115
 subacute (de Quervain) thyroiditis and, 1117, 1122
 nephrotoxicity/acute kidney injury and, 904–905
 reactions to, 867
 Contrast nephropathy, 904–905
 Contrast venography, in DVT/PE (venous thromboembolic disease), 300
 Controlled mechanical ventilation (CMV), for respiratory failure, 321

- Contusions
 cerebral, 1017t
 of eye, 192–193, 193f
 myocardial, 428
- Conversion disorder (hysterical conversion), 1045, 1046
 psychogenic nonepileptic/pseudoepileptic seizure and, 971–972, 1045
- Convulsions. *See* Seizures
- Cooling, for hyperthermia
 in heat exposure syndromes, 1547, 1548, 1548–1549
 in poisoning/drug overdose, 1565, 1585
- Coombs test/micro-Coombs test
 in autoimmune hemolytic anemia, 506
 in cold agglutinin disease, 507
 in SLE, 834t
 in Waldenström macroglobulinemia, 530
- CO-oximetry. *See* Pulse oximetry/
 CO-oximetry
- COP. *See* Cryptogenic organizing pneumonia/pneumonitis
- COPD. *See* Chronic obstructive pulmonary disease
- Copepods
 in dracunculiasis, 1520–1521
 in gnathostomiasis, 1522
 in sparganosis, 1516
- Copper
 accumulation of in Wilson disease, 696, 697
 parenteral nutritional support and, 1272, 1274t
- Copper TCu380A IUD, 773–774
 for emergency/postcoital contraception, 774, 776
- Coprine (*Coprinus*) mushroom poisoning, 1586t
- Coprolalia, in Tourette syndrome, 1005
- Coproporphyrins, in porphyria cutanea tarda, 122
- Cor pulmonale, 425–426
 in COPD, 261, 264, 426
 in pulmonary hypertension, 305, 425, 426
- Coral snake envenomation, 1589–1590
- Cord blood, stem cells in, for transplantation, 533
- Cord cavitation (syringomyelia), 1018–1019
- Corditis, polypoid, 235
- Cordran. *See* Flurandrenolide
- Core-binding factor leukemias, 519
- Core needle (large-needle) biopsy, for breast lump evaluation, 718, 728, 728f, 729f, 1718, 1719.
See also Breast, biopsy of stereotactic guided, 729
- Core rewarming, for systemic hypothermia, 1544–1545
- Core temperature
 in burn injury, maintaining, 1551
 in hyperthermia/heat exposure syndromes, 35, 1548
 in hypothermia, 1543, 1544
 in near drowning, resuscitation efforts and, 1556
 normal, 35
- Coreg. *See* Carvedilol
- CoreValve prosthetic valve, 343
- Corgard. *See* Nadolol
- Corlopan. *See* Fenoldopam
- Cornea
 calcium precipitation in, 1139
 exposure of, in dysthyroid eye disease, 191, 1112
 foreign body of, 192
 infection of. *See* Keratitis;
 Keratoconjunctivitis
 trauma to, 165t
 abrasions, 192
 keratitis and, 172
 lacerations, 193, 193f
 ulcers of, 167–174. *See also* Keratitis
 contact lens wear and, 162, 172, 173, 174
 ultraviolet burns of (ultraviolet/actinic keratitis), 194
- Corneal transplantation
 Creutzfeldt-Jakob disease transmission and, 1381
 rabies transmission and, 1376
- Corns, of feet or toes, 141. *See also* Callosities
- Coronary angiography. *See* Angiography/
 arteriography, cardiac/
 coronary
- Coronary angioplasty
 for angina, 357–358
 for myocardial infarction, 371
- Coronary arteries
 disorders of. *See also* Coronary heart disease
 in Kawasaki syndrome, 428, 1417
 in pregnancy, 431
 radiation exposure causing, 1554
 revascularization indications and, 356–357
 sudden death and, 392
 of athlete, 431, 432
 systemic disease and, 427, 428
 in tetralogy of Fallot, 332
 traumatic injury to, 428
- Coronary artery aneurysm, in Kawasaki disease, 428, 1417
- Coronary artery bypass grafting (CABG), 357
 PCI compared with, 358
 platelet function affected by, 549t
 postoperative stroke and, 53
 prophylactic/preoperative, 48–49
 for traumatic injuries, 428
- Coronary artery disease (CAD). *See* Coronary heart disease
- Coronary artery revascularization procedures. *See specific type and* Revascularization procedures
- Coronary heart disease, 350–376. *See also* Acute coronary syndromes; Angina; Myocardial infarction
 acute coronary syndromes without ST segment elevation and, 360–365, 362t, 364t
 acute myocardial infarction with ST segment elevation (STEMI) and, 360, 364t, 365–376, 367t, 369t. *See also* Myocardial infarction
- angina pectoris (chronic stable) and, 351–359, 358t
 antihypertensive drug therapy and, 433, 441–442, 442–444, 442t, 443f, 444t, 457
 aortic stenosis and, 342, 343
 cholesterol/lipoproteins in, 8, 350, 1245, 1246
 screening tests for levels of, 7t, 8–10, 1248–1252, 1249–1250t, 1251t
 in women, 7t, 1248, 1251, 1706
 chronic kidney disease and, 909t, 911
 in diabetes mellitus, 356, 1227
 in women, 1707
 heart failure and, 360, 398, 406
 in HIV infection/AIDS, 1332–1333, 1344
 homocysteine/hyperhomocysteinemia in, 1668–1669
 hypertension/hypertension prevention/management and, 7t, 10–11, 433, 441–442, 442–444, 442t, 443f, 444t, 457, 1249t, 1250
 in women, 1706
 hypertriglyceridemia and, 1256
 lipid disorders and, 8–10, 350, 1245–1246, 1246
 in women, 1251, 1706–1707
 metabolic syndrome (syndrome X) and, 350, 351, 360
 myocardial hibernation/stunning and, 351
 in pregnancy, 431
 preoperative evaluation/perioperative management and, 46, 47–49, 47t, 48f, 48t
 prevention of, 5–11, 7t
 chemoprevention/aspirin use and, 7t, 11, 1253
 in women, 1707
 cholesterol screening and, 7t, 8–10, 1248–1252, 1249–1250t, 1251t
 in women, 7t, 1248, 1251, 1706
 exercise/activity in, 7t, 12–13
 hypertension prevention/management and, 7t, 10–11, 433, 434, 439, 441–442, 442–444, 442t, 443f, 444t, 457
 in women, 1706
 lipid disorder prevention/management and, 7t, 8–10, 1246–1247, 1252–1255, 1255t. *See also* Lipid-lowering therapy
 in women, 1251, 1706–1707
 smoking/smoking cessation and, 6–8, 7t, 9–10t, 10t, 350
 in women, 1249t, 1251, 1706–1707
 revascularization procedures for, 356–358, 376. *See also* Revascularization procedures
 risk factors for, 5–6, 350–351
 lipoproteins/lipid fractions and, 350, 1245, 1246, 1248–1252, 1249–1250t, 1251t
 in women, 7t, 1248, 1251, 1706
 modification/risk reduction and, 356
 sudden death and, 392

- in athletes, 431, 432
vasospasm and, 359–360
- Coronary reperfusion. *See* Reperfusion therapy
- Coronary sinus atrial septal defect, 327–328
- Coronary stents, 357–358, 367–368. *See also* Percutaneous coronary intervention
subsequent perioperative risks/
management and, 48–49
- Coronary vasospasm, 359–360
- Coronaviruses
diarrhea caused by, 1404, 1404–1405
SARS caused by, 1400
- Corpus luteum cyst, 808
- Corrigan pulse, 344
- Corrosive agents. *See* Caustic/corrosive agents
- Corti, organ of, hearing loss caused by disorders of, 198
- Cortical blindness, occipital lobe lesions causing, 991
- Corticobasal degeneration, parkinsonism and, 998
- Corticospinal lesions, coma or stupor caused by, 1015
- Corticosteroids, 1190–1191, 1190*t*, 1191*t*.
See also specific agent and disease
acne/folliculitis caused by, 126, 129
for ACTH deficiency, 1096
acute, 1154, 1154–1155
Addison disease, 1157, 1158
for adhesive capsulitis (frozen shoulder), 1682
adrenocortical insufficiency caused by, 1093, 1096, 1154
adverse effects of, 639, 1190–1191
ophthalmic, 196*t*
for alcoholic liver disease, 681
for allergic eye disease, 167, 170*t*
for allergic rhinitis, 218
for alopecia, 157
amebiasis in patients taking, 1503
for ARDS, 323, 1399–1400
for asthma, 244*f*, 245*t*, 249*f*, 250, 251*t*, 253*t*, 254–255*t*, 255, 256, 257*f*, 258*f*
exacerbation management and, 244*f*, 245*t*, 250, 255, 256, 257*f*, 258*f*
inhaled, 249*f*, 250, 253*t*
systemic, 244*f*, 245*t*, 249*f*, 250, 251*t*, 254–255*t*, 255, 256, 257*f*
for atopic dermatitis, 104
for back pain, 821, 1686
for Bell palsy, 1028, 1355
for bronchiolitis, 270
in cancer chemotherapy, 1657*t*
for cancer-related hypercalcemia, 1647
for chronic inflammatory polyneuropathy, 1025
clinical use of, 1190–1191, 1190*t*, 1191*t*
for contact dermatitis, 125
for COPD, 263
Cushing syndrome caused by, 1096, 1158
for cysticercosis, 1515
depression associated with use of, 1064
for dysthyroid eye disease, 191
in erythema multiforme, 135
for exfoliative dermatitis/
erythroderma, 116
for fetal lung maturity, 794, 796
for giant cell arteritis, 183, 846, 847
for gout, 814
in transplant patient, 816
for gram-negative bacteremia/sepsis, 1444
for herpes zoster, 120
in HIV infection/AIDS, 1339
for hypopituitarism, 1096
for immune thrombocytopenia, 541, 541*f*
infection and, 1279
for inflammatory bowel disease, 639
Crohn disease, 644
ulcerative colitis, 647, 648
in interstitial lung disease, 295
intra-articular, for osteoarthritis, 812, 1702
intranasal, 218
for lateral and medial epicondylitis, 1688
for lichen planus, 144, 224
for lichen simplex chronicus, 105
lipid abnormalities associated with use of, 1248*t*
for lumbar disk herniation, 1686
for lupus/SLE, 114–115, 834, 835
management of patient receiving, 1191*t*
mechanisms of action of, 1190
for minimal change disease, 928, 929
for multiple sclerosis, 1011
for myasthenia gravis, 1033
for nausea and vomiting, 86, 568*t*, 569
for ophthalmic disorders, 167, 170*t*
precautions for use of, 195
osteoporosis/osteoporosis prevention and, 639, 1146, 1190, 1191
in pain management, 85
for pemphigus, 139
for pericarditis, 420
perioperative, 54, 1096
insulin requirements and, 54
for polyarteritis nodosa, 848
for polymyositis/dermatomyositis, 842
for pompholyx, 121–122
for prostate cancer, 1637*t*
psoriasis flares and, 107, 856
for psoriasis/psoriatic arthritis, 107, 856
relative potencies of, 1190, 1190*t*
for rheumatic fever/heart disease, 418
for rheumatoid arthritis, 829
rosacea exacerbated by, 100, 128
for shock, 488, 1444
for skin disorders, 94, 95–96*t*
overuse and, 100
for smoke inhalation, 307
for spinal stenosis, 822, 1685
for spinal trauma/compression, 993, 1018, 1645
strongyloidiasis in patients taking, 1519
for sudden sensory hearing loss, 207
surgery in patients taking
insulin requirements and, 54, 122
perioperative replacement and, 54
topical, 94, 95–96*t*
ophthalmic, 167, 170*t*
overuse and, 100
for urticaria, 133–134
- CORTICUS trial, in shock management, 488
- Cortinarius* mushroom poisoning, 1586*t*
- Cortisol, 1190. *See also* Corticosteroids
excess of, 1158–1161. *See also* Cushing syndrome
familial resistance to, 1160, 1166
in hypertension, 437
insufficiency of, 1094. *See also* Adrenocortical insufficiency
acute, 1154–1155
chronic, 1155–1158. *See also* Addison disease
in HIV infection/AIDS, 1157
mechanism of action of, 1190
salivary, in Cushing syndrome, 1159
serum levels of
in ACTH deficiency, 1095
in acute adrenal insufficiency, 1154
in Addison disease, 1156
in Cushing syndrome, 1159
reference values for, 1729*t*
tumor secreting, 1158, 1160, 1161
urine free
in Cushing syndrome, 1159
reference values for, 1729*t*
- Cortisol withdrawal syndrome, 1160
- Cortisone, 1190
- Corynebacterium diphtheriae*, 1300*t*, 1433. *See also* Diphtheria
jeikeium, 1300*t*
- Cosmegen. *See* Dactinomycin
- Cosmetic surgery, 1720–1721. *See also* Reconstructive surgery
- Cosopt. *See* Dorzolamide/timolol
- Cosyntropin test
in adrenal insufficiency/Addison disease, 1095, 1154, 1156
adrenal vein sampling in, in aldosteronism, 1165
corticosteroid therapy in shock and, 1444
in hirsutism/virilization, 1163
- Cotton dust, byssinosis caused by inhalation of, 311
- Cotton wool spots
in retinal artery occlusion, 183
in retinal vein occlusion, 182
in SLE, 833
- Cough, 21–23, 22*f*, 22*t*
angiotensin-converting enzyme (ACE) inhibitors causing, 402, 449
in asthma, 21, 22, 22*t*, 244
blood production and (hemoptysis), 26–27
in *Bordetella pertussis* infection (whooping cough), 21, 22, 23, 1440
in bronchiectasis, 266
in COPD, 21, 22, 23, 260, 260*t*
drugs causing, 312*t*
dyspnea and, 21, 22, 24
in GERD, 22, 22*t*, 23, 234, 594
headache associated with, 962, 966
in heart failure, 22, 398

- Cough (*Cont.*):
 in lung cancer, 21–22, 1597
 in pneumonia, 22, 22f
 anaerobic pneumonia/lung abscess, 278
 community-acquired, 22, 22f, 271
 postnasal drip causing, 21, 22, 22t, 23
 in pulmonary embolism, 298t
 in tuberculosis, 280
- Counterpulsation, extracorporeal, for angina, 358
- COURAGE trial, 357, 358
- Courvoisier law/sign, 663, 1606, 1608
- Covera. *See* Verapamil
- Cowden syndrome/disease, 655, 1190
 thyroid disease and, 1123, 1190
- COX-1/COX-2, aspirin/NSAIDs affecting, 611
 peptic ulcer disease and, 611–612, 828
- COX-2 inhibitors. *See* Coxibs
- Coxibs (COX-2 inhibitors), 76, 77t, 611
 aspirin coadministration and, 612, 616
 cardiovascular complications associated with, 76, 608, 612, 615, 829
 for familial adenomatous polyposis, 655
 gastritis and, 608
 for gout, 814
 lithium interactions and, 1074t
 in pain management, 76, 77t
 peptic ulcers/peptic ulcer prevention and, 611–612, 616
 for rheumatoid arthritis, 828, 829
- Coxiella burnetii*, 1409t, 1415, 1416
- Coxsackievirus infections, **1405–1406**
 herpetic stomatitis differentiated from, 227
 myocarditis, 1406
 pericarditis, 419, 1406
- Cozaar. *See* Losartan
- CPAP. *See* Continuous positive airway pressure
- CPPD. *See* Calcium pyrophosphate dihydrate deposition disease
- CPR. *See* Cardiopulmonary resuscitation
- Cr. *See* Creatinine
- “Crab yaws,” 1475
- Crabs (pubic lice), 148. *See also* Lice
- Crack cocaine. *See* Cocaine abuse
- Crackles (rales)
 in heart failure, 399
 in interstitial (diffuse parenchymal) lung disease, 292
 in pulmonary embolism, 298t
- CRAG (cryptococcal antigen) test, 1327, 1536
- Cramps. *See* Dysmenorrhea; Muscle cramps
- Cranial arteritis. *See* Giant cell (temporal/cranial) arteritis
- Cranial nerve VIII (acoustic nerve) lesions. *See* Schwannoma, vestibular
- Cranial nerve palsies. *See also specific type*
 brainstem lesions causing, 190, 991
 in diabetes, 1225
 in head injury, 1016
 in malignant external otitis, 200
 ocular motor palsies and, 190
 in Paget disease of bone, 1152
 in sarcoidosis, 1024
 in stroke, 981
 in syphilis, 1469, 1471, 1472
- Craniectomy, decompressive
 for Arnold–Chiari malformation/syringomyelia, 1019
 in coma or stupor, 1015
 in stroke, 982
- Craniopharyngioma, 990t, 1096
- Creatine
 serum, in acute coronary syndromes/STEMI, 361
 toxicity of, 1578t
- Creatine kinase
 in acute coronary syndromes/STEMI, 361
 in polymyositis/dermatomyositis, 840, 841
 in psychogenic nonepileptic/pseudoepileptic seizure identification, 972
 reference values for, 1729t
 in rhabdomyolysis, 844, 905
- Creatine kinase-MB (CK-MB)
 in acute coronary syndromes/STEMI, 361, 366
 in infectious myocarditis, 410
 reference values for, 1729t
- Creatinine, 900, 900t, 901
 ascitic fluid, 588
 serum levels of
 in acute kidney injury, 901, 902
 in chronic kidney disease, 908, 910, 910f, 911
 conditions affecting, 900, 900t
 in diabetic ketoacidosis, 1232, 1233
 in glomerulonephritis, 907, 918
 in hepatorenal syndrome, 689
 monitoring in methotrexate therapy, 829, 1662
 in nephrotic syndrome, 927
 reference values for, 1729t
- urinary
 in pheochromocytoma, 1167
 ratio of to urinary protein, 899. *See also* Proteinuria
 in glomerulonephritis, 908
 in nephrotic syndrome, 927
- Creatinine:blood urea nitrogen ratio. *See* Blood urea nitrogen:creatinine ratio
- Creatinine clearance, 900, 900t
 GFR measurement and, 900, 900t
 in glomerulonephritis, 908
 in hepatorenal syndrome, 689
 reference/normal values for, 900, 1729t
- Creeping eruption, **1523–1524**, 1524f
- Crepitus, 810
- Crescentic glomerulonephritis, 907, 919t, 924
- CREST syndrome, 838, 839. *See also* Scleroderma
 autoantibodies in, 833t, 839
 GI bleeding and, 581, 839
 Raynaud phenomenon and, 837
- Crestor. *See* Rosuvastatin
- Cretinism, 1106, 1134. *See also* Hypothyroidism
- Creutzfeldt–Jakob disease, 1009, 1381–1382
 myoclonus in, 1004
 parkinsonism and, 998
- Cricothyrotomy, **238**
 for aerodigestive foreign body, 239
- Crigler–Najjar syndrome, 662
- Crimean–Congo hemorrhagic fever, 1384–1385, 1385
- Critical illness
 acute kidney injury and, 901–902
 asthma exacerbation management and, 257–259
 diabetes management and, 1229, 1230
 fever/health care-associated infection and, 1283, 1284
 hypercalcemia and, 1142
 neuropathy associated with, **1024**
 pneumonia, 270t, 274, 274–275
 psychosis associated with, 1090
 stress gastritis associated with, 607, 608
 thyroid function affected in, 1096, 1107–1108
- Crixivan. *See* Indinavir
- Crizotinib, 1654t
 for lung cancer, 1600
- CroFab, for snake bites, 1590
- Crohn disease, 638, **641–646**. *See also* Inflammatory bowel disease
 arthritis in, 641, 858
 cholelithiasis/gallstones and, 641
 colorectal cancer and, 643, 1623
 diarrhea in, 574t, 578, 641, 643
 drug therapy for, 643–645
 extraintestinal manifestations of, 641
 primary sclerosing cholangitis and, 709
 small intestine adenocarcinoma and, 643, 1620
 social support and, 641
- Crohn’s and Colitis Foundation of America (CCFA), 641
- Crolom. *See* Cromolyn
- Cromolyn
 for allergic eye disease, 167, 169t
 for allergic rhinitis, 219
 for asthma, 249f, 250, 251t
- Cross-dressing, 1049
- Cross-reactivity, in drug allergies, 1306
- Cross-resistance, in antiretroviral therapy, 1345, 1347
- Crossed straight leg sign, 820
- Crossmatching, in blood compatibility testing, 534
 for platelet transfusion, 536
- Crotalid antivenin (CroFab), 1590
- Croup, human parainfluenza virus causing, 1393
- CRP. *See* C-reactive protein
- CRT. *See* Conformal radiation therapy
- Cruciate ligaments of knee, 1692
 injury of
 anterior cruciate (ACL), **1693–1698**, 1694–1695t
 posterior cruciate (PCL), 1696t, **1699–1700**
- Crush injuries, rhabdomyolysis/renal failure and, 844
- Crusted/weeping skin lesions, 95t, **123–125**. *See also specific type*
 drying agents for, 94
- Cryoglobulins/cryoglobulinemia, **851–852**

- glomerulonephritis and, 851, 919*t*, 921*f*, **925**
- in hepatitis C, 671, 677, 851, 852, 925, 926
- neuropathies and, 851, 1023
- Raynaud phenomenon and, 837
- reference values for, 1729*t*
- Cryoprecipitate, 537
- for DIC, 537, 545, 546*t*
- Cryotherapy/cryosurgery. *See also* Liquid nitrogen
- for chromoblastomycosis, 1540
- for CIN/cervical cancer, 756
- for fibroadenoma of breast, 719
- for prostate cancer, 1636
- for renal cell carcinoma, 1641
- for retinal detachment, 180
- for tetralogy of Fallot, 332
- for wart removal/condylomata acuminata, 140, 753
- Cryptococcal antigen (CRAG) test, 1327, 1536
- Cryptococcomas, 1536
- Cryptococcus gattii/neoformans* (cryptococcosis), **1536–1537**
- in HIV infection/AIDS, 993, 1327, 1338*t*, 1536
- prophylaxis of, 1337, 1536
- meningitis caused by, 993, 1327, 1338*t*, 1536
- Cryptogenic organizing pneumonia/pneumonitis (COP/idiopathic bronchiolitis obliterans with organizing pneumonia/BOOP), 269, 294*t*, 295
- Cryptogenic stroke. *See* Stroke
- Cryptorchism, **1177–1178**
- pseudohermaphroditism and, 1179
- testicular cancer and, 1175, 1178, 1642
- Cryptosporidium hominis/parvum* (cryptosporidiosis), 574*t*, 575, 576, 579, 1293, 1330, **1505–1508**
- Crystal deposition arthritis, **812–817**, 813*f*, 813*t*, 815*t*
- Crystalloids, for fluid management/volume replacement
- in burn injuries, 1550–1551
- in shock, 487
- CSF analysis. *See* Cerebrospinal fluid analysis
- CSF FTA-ABS test, 1473
- CSF-VDRL test, 1473
- in HIV infection/AIDS, 1335
- CSII. *See* Continuous subcutaneous insulin infusion
- CT angiography. *See* Computed tomography; Helical (spiral) CT
- CT scans. *See* Computed tomography
- CTCL. *See* Cutaneous T cell lymphoma
- Ctx. *See* C-telopeptide, beta-cross-linked
- Cubicin. *See* Daptomycin
- Cubital tunnel, ulnar nerve lesions and, 1026
- Culdocentesis
- in ectopic pregnancy, 790
- in PID, 763
- Culex* mosquitoes. *See* Mosquitoes
- Cultural issues, in end-of-life care, **90**
- Culture-negative endocarditis, 1436
- Cultured grafts
- for burn wound closure, 1551
- for leg ulcers, 154
- Cunninghamella* infection, 1538
- Cup-disk ratio
- in chronic glaucoma, 175–176, 176*f*
- normal, 176*f*
- Cupping, optic disk, in chronic glaucoma, 175, 175–176, 176*f*
- Cupulolithiasis, vertigo associated with, 210*t*, 211
- Curative efforts, withdrawal of, in terminally ill/dying patient, **91, 91*t***
- advance directives and, 89
- CURB-65, 274
- Curetage. *See* D&C; Endocervical curettage; Endometrial biopsy
- Curetage and electrodesiccation
- for basal cell carcinoma, 142
- for squamous cell carcinoma, 143
- Curvularia*, phaeoophomycosis caused by, 1541
- Cushing disease, 1158, 1159, 1160, 1161. *See also* Cushing syndrome
- Cushing syndrome (hypercortisolism), **1158–1161**, 1172
- amenorrhea in, 1181
- cancer-related, 1158, 1159, 1160, 1596*t*
- thyroid cancer and, 1128
- corticosteroid-induced, 1096, 1158
- hypertension and, 438
- lipid abnormalities associated with, 1248*t*
- in MEN, 1189
- muscle weakness and, 841, 1158
- obesity in, 1158, 1160
- Cutaneous anthrax, 1431, 1432, 1433
- Cutaneous candidiasis, 132
- in HIV infection/AIDS, 1331
- Cutaneous drug reactions, **158–161**, 159–160*t*
- Cutaneous larva migrans, **1523–1524**, 1524*f*
- Cutaneous leishmaniasis, 1487, 1488, 1488*f*, 1489
- post-kala azar, 1487–1488
- Cutaneous lupus erythematosus, discoid/subacute/chronic, **114–115**
- Cutaneous T cell lymphoma (mycosis fungoides), **115–116**
- exfoliative dermatitis/erythroderma and, 116
- Cutaneous tests. *See specific type and* Skin tests
- Cutting (self-mutilation), 1065
- c-v wave
- in pulmonary stenosis, 325
- in tetralogy of Fallot, 331
- CVP. *See* Central venous pressure
- CXCR4 co-receptor, in HIV infection/AIDS, 1322, 1346
- Cyanide antidotes, 1566*t*, 1577, 1578*t*
- Cyanide poisoning, 1566*t*, 1577, 1578*t*
- dyspnea in, 25
- Cyanocobalamin. *See* Vitamin B₁₂
- Cyanokit, 1577, 1578*t*
- Cyanosis
- in atrial septal defect/patent foramen ovale, 328, 329
- digital, in Raynaud phenomenon, 836
- in pulmonary embolism, 298*t*
- in ventricular septal defect, 330
- Cyberknife radiosurgery
- for lung cancer, 1599
- for pituitary adenoma, 1102, 1104, 1160
- Cyclic citrullinated peptide (CCP)
- antibody, in rheumatoid arthritis, 827
- Cyclic thrombocytopenia, **540**
- Cyclical mastalgia, 1716
- Cyclin D1, in mantle cell lymphoma, 522
- Cycling, in bipolar disorder, 1064
- lithium use and, 1072
- Cyclocort. *See* Amcinonide
- Cyclooxygenase-1 and 2 (COX-1/COX-2), aspirin/NSAIDs affecting, 611
- peptic ulcer disease and, 611–612, 828
- Cyclooxygenase-2 (COX-2) inhibitors. *See* Coxibs
- Cyclophosphamide, 1650*t*. *See also* Immunosuppressive therapy
- for breast cancer, 736
- breastfeeding and, 782*t*
- for chronic lymphocytic leukemia, 522
- for granulomatosis with polyangiitis, 306, 850
- hemorrhagic cystitis caused by, 1661
- for lupus nephritis, 834, 926
- for microscopic polyangiitis, 851
- Cycloserine (DCS), for phobic disorder, 1044
- Cyclospora cayetanensis* (cyclosporiasis), 574*t*, 575, 576, 578, 579, 1293, **1506–1508**
- Cyclosporine, 1722*t*
- adverse ophthalmic effects of, 196*t*
- for aplastic anemia, 509
- hyperkalemia caused by, 879–880
- nefazodone interaction and, 1068
- nephrotoxicity/acute kidney injury/graft rejection caused by, 905
- for ophthalmic disorders, 166, 170*t*, 173
- for psoriasis, 107–108
- for ulcerative colitis, 648–649
- Cyclothymic disorders, 1064
- Cyclin. *See* Progesterone
- Cymbalta. *See* Duloxetine
- CYP. *See* Cytochrome P450 (CYP) system
- CYP17 deficiency, 1157, 1174
- CYP17 inhibition, 1174
- CYP17a1 inhibition, for prostate cancer, 1637*t*
- Cyproheptadine
- for drug-induced anorgasmia, 1067
- for serotonin syndrome, 1565, 1585, 1592
- for urticaria, 133
- Cyproterone, for hirsutism/virilization, 1163
- Cystadenocarcinoma, of liver, 702
- Cystadenoma
- of liver, 702
- pancreatic, 1608, 1609

- Cystathionine β -synthase deficiency, in hyperhomocysteinemia/homocystinuria and, 1668, 1669
- Cystatin C
in acute tubular necrosis, 904
in GFR estimation, 901
- Cystectomy, for bladder cancer, 1639
- Cysteine, supplementary, for homocystinuria, 1669
- Cystic fibrosis, 267–268
bronchiectasis and, 266, 267
COPD differentiated from, 261
genetic/prenatal testing for, 267, 268, 783
vas deferens absence and, 267, 955
- Cystic fibrosis transmembrane conductance regulator (CFTR) corrector therapy, 268
- Cystic fibrosis transmembrane conductance regulator (CFTR) protein, 267
genetic/prenatal testing for mutations of, 267, 268
in pancreatitis, 711, 715, 716
- Cystic hydatid disease, 1516
- Cystic inflammatory acne, 127–128
- Cystic medial necrosis, sudden death in athlete and, 431
- Cysticercosis, 1514, 1515
- Cystine urinary stones, 946, 947, 949
- Cystinuria, 946
- Cystitis, 43–45, 44f, 939–940, 940t, 1303t
in epididymitis, 944
in female, 43–45, 44f, 939, 940
hemorrhagic. *See* Hemorrhagic cystitis
interstitial, 45, 945–946
pelvic pain and, 1715, 1716
in male, 939
- Cystocele, 762
- Cystometrogram, in benign prostatic hyperplasia, 957
- Cystoscopy, 938
in benign prostatic hyperplasia, 957
in bladder cancer, 1639
in interstitial cystitis, 945–946
- Cystourethroscopy, in bladder cancer, 1639
- Cytadren. *See* Aminoglutethimide
- Cytarabine, 1651t
for acute myeloid leukemia, 520
- Cytarabine liposome, 1651t
- Cytochrome P450 (CYP) system
antibodies to, in autoimmune hepatitis, 679
fentanyl and, 79
hepatotoxicity and, 683
nefazodone affecting, 1068
protease inhibitors affecting, 1344
testing for biomarker variants in, 1725t
- Cytochrome P450 (CYP) 2C9 variants, testing for, 1725t
- Cytochrome P450 (CYP) 2C19 variants, testing for, 1725t
- Cytokeratin 8 gene, cirrhosis and, 687
- Cytokines
in ARDS, 322
in fever, 35
- Cytolytic snake venom, 1589, 1590
- Cytomegalovirus (CMV) disease, 1363–1366
esophageal, 598, 1364
gastritis/diarrhea, 574t, 575, 610, 1330, 1364
in immunocompetent host, 1364, 1365
in immunocompromised host/HIV infection/AIDS, 598, 1326, 1328, 1338t, 1364, 1365
prophylaxis of, 1280–1281, 1337, 1339, 1366
mononucleosis, 1362, 1364, 1365
perinatal/congenital, 1363–1364, 1364, 1364–1365
posttransplant, 1280–1281, 1364, 1365, 1366
prevention of, 1280–1281, 1337, 1339, 1366
retinitis, 187, 187f, 1328, 1364, 1365
screening blood for, 536
- Cytomegalovirus (CMV) immune globulin, 1365–1366
- Cytomegalovirus (CMV) inclusion disease, 1364
- Cytomel. *See* Triiodothyronine
- Cytopenia, methotrexate causing, 829
- Cytosar U. *See* Cytarabine
- Cytotoxic drugs. *See specific agent and* Chemotherapy
- Cytotoxic (antibody-mediated/type II) hypersensitivity, 866
- Cytotoxicity assay, in antibiotic-associated colitis, 637
- Cytovene. *See* Ganciclovir
- Cytoxan. *See* Cyclophosphamide
- d4T. *See* Stavudine
- D antigen, in compatibility testing, 534
- D&C, 748t
for abnormal premenopausal bleeding, 748
for postmenopausal bleeding, 749
- D cells, pancreatic, 1171
- D-cycloserine (DCS), for phobic disorder, 1044
- D-dimer fibrin
anticoagulation duration and, 559
in DIC, 545
in DVT/PE (venous thromboembolic disease), 34, 299, 300, 301f
chest pain evaluation and, 29
reference values for, 1729t
- D state sleep, 1075
- Dabigatran, 555, 558
for atrial fibrillation, 386–387
after cardiac valve replacement surgery, 350
for transient ischemic attacks, 979
- Dacarbazine, 1650t
- Dacogen. *See* Decitabine
- Dacryocystitis, 164
- Dacryocystorhinostomy, 164
- Dactinomycin, 1655t
- Dairy products
intolerance to. *See* Lactose (milk)
intolerance
raw
brucellosis and, 1449
campylobacter infection and, 1449
tick-borne encephalitis and, 1390
- Dalfampridine, for multiple sclerosis, 1011
- Dalfopristin/quinupristin. *See* Quinupristin/dalfopristin
- Dalmane. *See* Flurazepam
- Dalrymple sign, 1112
- Dalteparin, 557t, 559t
- Danazol
for abnormal premenopausal bleeding, 748
for autoimmune hemolytic anemia, 506
breastfeeding and, 782t
for endometriosis, 761
for fibrocystic condition, 719
for mastalgia, 1717
for SLE, 834
- Dandruff, 109
- Dantrolene
for neuroleptic malignant syndrome/malignant hyperthermia, 36, 1060, 1283, 1565, 1574
for spasticity, 1012
- Dapsone
for actinomycetoma, 1540
for dermatitis herpetiformis, 123
G6PD deficiency and, 503
for leprosy, 1460
methemoglobinemia caused by, 1584
for *P jiroveci* infection, 1280, 1337t, 1339, 1534, 1535
prophylactic, 1337t
for toxoplasma prophylaxis, 1337, 1502
- Daptomycin
for staphylococcal bacteremia, 1427
for staphylococcal skin infections, 1426
- Darbepoetin alfa
for anemia of chronic disease/chronic kidney disease, 493, 913
for aplastic anemia, 509
for chemotherapy-induced anemia, 1649, 1659t
- Darifenacin, for urinary incontinence, 68
- Dark blue top tubes, 1736t
- Darkfield microscopic examination
in leptospirosis, 1477
in non-sexually transmitted treponematoses, 1474
in syphilis, 1465
- Darunavir, 1344, 1345, 1348f
with ritonavir, 1342t, 1345, 1347
- Dasatinib, 1654t
for acute lymphoblastic leukemia, 521
for chronic myeloid leukemia, 516
- DASH diet, in hypertension/hypertension prevention, 441, 441t
- “Date-rape” drug (γ -hydroxybutyrate/GHB), 1580
Cushing syndrome and, 1158, 1160
- Datril. *See* Acetaminophen
- Datura stramonium*, toxicity of, 1575
- Daunorubicin/daunomycin, 1653t
liposomal, 1653t, 1662
toxicity of, 1653t, 1662
- Daunoxome. *See* Liposomal daunorubicin
- Dawn phenomenon, 1219, 1219t
- DAX-1 gene mutation, in congenital adrenal hypoplasia/hypogonadism/azoospermia, 1093, 1094, 1175

- Daypro. *See* Oxaprozin
- Daytime somnolence. *See* Somnolence
- DBE (deep breathing exercises). *See* Breathing exercises
- DC cardioversion. *See* Cardioversion, electrical
- DCC gene, in colorectal cancer, 1622
- DCCT (Diabetes Control and Complications Trial), 1201
- DCIS. *See* Ductal carcinoma in situ
- DCS. *See* D-cycloserine; Decompression sickness
- DDAVP. *See* Desmopressin
- ddC. *See* Zalcitabine
- ddI. *See* Didanosine
- DDT (chlorophenothane) poisoning, 1587
- de Morsier syndrome (septo-optic dysplasia), 1093
- De Quervain (subacute) thyroiditis, 1111, 1113, 1114, 1117, 1120, 1121, 1122
- hypothyroid phase in, 1106, 1111, 1121
- “Deadly quartet.” *See* Metabolic syndrome
- Deafness. *See* Hearing loss
- Death. *See also* End of life; Sudden death
- Kübler-Ross’ stages of, 91
- leading causes of, 2t, 3t
- patient expectations about, **87–88**
- preventable causes of, 3t. *See also* Preventive care
- tasks after, **92–93**
- Death certificate, **93**
- Debridement, in burn care, 1551
- Decerebrate posturing, 1014, 1015
- Decision making, medical
- advance directives and, 88
- determination of older patient’s capacity for, 60
- self neglect and, 73
- at end of life, **89**
- Decitabine, 1652t
- for myelodysplastic syndromes, 518
- Decompression sickness, **1557–1558**
- barotrauma and, 202, 1557
- Decompressive craniectomy/
 hemicraniectomy
- for Arnold-Chiari malformation/
 syringomyelia, 1019
- in coma or stupor, 1015
- in stroke, 982
- Decompressive laminectomy
- for Arnold-Chiari malformation/
 syringomyelia, 1019
- for spinal stenosis, 1685
- for spinal trauma, 1018
- for spinal tumors/cord compression, 993, 1645
- Decongestants
- for bacterial rhinosinusitis, 215
- overdose/toxicity of, 1577
- ophthalmic effects and, 195t
- for viral rhinosinusitis (common cold), 214
- Decontamination
- eye, 194, **1566**
- for caustic/corrosive burns, 194, 1566, 1571, 1572
- gastrointestinal, **1566–1568**, 1568t
- caustic/corrosive agent ingestion and, 1566, 1567, 1571, 1572
- skin, **1566**
- for caustic/corrosive burns, 1566, 1571, 1572
- chemical warfare agents and, 1566, 1587
- Decorticate posturing, 1014, 1015
- Decubitus ulcers. *See* Pressure ulcers
- De-efferented state (locked-in syndrome), **1016**
- Deep brain stimulation
- for idiopathic torsion dystonia, 1003
- for parkinsonism, 1001
- for Tourette syndrome, 1005
- Deep breathing exercises. *See* Breathing exercises
- Deep neck infections, **230–231**
- Deep sulcus sign, in pneumothorax, 317
- Deep venous thrombosis, 33, 33t. *See also* Venous thromboembolic disease
- in antiphospholipid antibody syndrome, 835
- Baker cyst differentiated from, 826
- cellulitis differentiated from, 137
- detection of, 33, 33t, 300
- pulmonary embolism diagnosis and, 300, 301t
- estrogen replacement therapy and, 780, 1183
- in granulomatosis with polyangiitis, 849
- hip/knee replacement and, 555, 557t
- hypercoagulability and, 297
- lower extremity edema and, 33, 33t, 34
- prevention of, 301, 555–556, 556t, 557t, 558t
- pulmonary embolism and, 297, 300, 301, 301t. *See also* Pulmonary venous thromboembolism
- risk/risk stratification for, 33, 33t, 297, 297–301, 298t, 301f, 301t, 302t, 555–556, 556, 556t
- superficial thrombophlebitis and, 480
- superior vena caval obstruction and, 482
- treatment of
- anticoagulation, 301–303, 556–562, 559t, 560t, 561t, 562t
- nonpharmacologic, 563
- venous insufficiency/stasis and, 33, 33t, 34, 297, 480, 481
- Deer tick virus, 1391
- Deer ticks. *See* Ticks
- Defecation, dyssynergic (pelvic floor dyssynergia), 570, 570t, 571
- Deferasirox, for hemochromatosis/iron toxicity, 696
- Deferoxamine
- adverse ophthalmic effects of, 197t
- for hemochromatosis/iron toxicity, 696, 1581
- Defibrillation. *See* Cardioversion, electrical
- Defibrillator cardioverter, implantable. *See* Implantable cardioverter defibrillator
- Defibrotide, for sinusoidal obstruction syndrome, 698
- Deflazacort, 1190, 1190t. *See also* Corticosteroids
- Degarelix, 1657t
- for prostate cancer, 1636, 1637t
- Degenerative (calcific) aortic stenosis, 333, 342, 343
- Degenerative joint disease/arthritis, **809–812**, 811f. *See also* Osteoarthritis
- in alkalptonuria, 1665
- Dehydration
- calculating water deficit in, 876
- in cholera, 1448
- in diabetes insipidus, 1098, 1099
- in diabetic ketoacidosis, 1232, 1233
- diarrhea and, 576
- chemotherapy-induced, 1660, 1661
- in heat exposure syndromes, 1547, 1548
- in hyperglycemic hyperosmolar state, 1236, 1237
- hyponatremia and, 875, 876
- enteral nutritional support and, 1273
- hyperosmolar nonketotic, parenteral nutritional support and, 1274t
- kidney injury and, 902, 910t, 933
- management of. *See* Fluid management/hydration
- metabolic alkalosis and, 895
- vomiting and, 568
- Dehydroemetine, for amebiasis, 1504, 1505t
- Dehydroepiandrosterone/
 dehydroepiandrosterone sulfate (DHEA/DHEAS)
- for adrenal insufficiency/Addison disease, 1157
- for hypopituitarism and hypogonadism, 1097
- prostate cancer and, 1636
- serum levels of
- in adrenal deficiency/Addison disease, 1095, 1156
- hirsutism/virilization and, 1163
- reference values for, 1729t
- for SLE, 834
- Déjà vu
- in focal seizures, 969
- intracranial tumors causing, 990
- Dejerine-Sottas disease, 1022
- Delavirdine, 1342t, 1346, 1348f. *See also* Antiretroviral therapy/HAART
- Delayed adolescence/puberty. *See* Puberty
- Delayed (T-cell mediated/type IV) hypersensitivity, 866
- Delirium, **64, 86–87**, 1006, **1087–1089**, 1087t
- alcohol use/abuse/withdrawal and, 1080, 1087t
- anticholinergic, 1568, 1575, 1583. *See also* Anticholinergic syndrome/effects
- antipsychotics causing, 1059
- clinical findings in, 64, 1088
- dementia and, 59–60, 61, 64, 1087t
- in elderly, **64**
- dementia and, 59–60, 61, 64, 1006
- at end of life, 86–87
- postoperative, 53, 53t
- urinary incontinence and, 67

- Delirium (*Cont.*):
 hospitalization/illness and, 1089, 1091
 lithium-induced, 1073
 palliation of, **86–87**
 postoperative, 53, 53*t*
 in terminally ill/dying patient, **86–87**, 1088
 treatment of, 64, 1088–1089
- Delirium tremens, 1080
- Delivery. *See* Labor and delivery
- “Delta 32” deletion, HIV infection/AIDS and, 1322
- Delta agent (hepatitis D virus/HDV), 670, **672**, 675, 676. *See also* Hepatitis D
- Delta sleep, 1075
- Delta wave, in preexcitation syndromes, 383
- Delusional disorders, 1053–1054
- Delusions, in schizophrenia/psychotic disorders, 1053, 1053–1054, 1054
- Demadex. *See* Torsemide
- Demeclocycline, for hyponatremia, 875
- Dementia, **59–63**, **1005–1010**, 1008*t*, 1088. *See also* Alzheimer disease
 assessment of/screening for, 60, 1006–1007
 automobile driving and, 62, 1010
 behavior-variant frontotemporal, 1008*t*
 behavioral problems and, 6–12, 1009, 1089
 clinical findings in, 60, 1006, 1088
 cognitive impairment assessment/treatment and, 60, 61, 1006–1007, 1008–1009, 1087–1089
 decision-making capacity and, 60
 delirium and, 59–60, 61, 64, 1006, 1087*t*
 depression and (pseudodementia), 59–60, 1006, 1088
 differential diagnosis of, 60–61, 1007, 1008*t*
 in Down syndrome, 1666
 in elderly, **59–63**
 estrogen replacement therapy and, 1182
 frontotemporal, 1008–1009, 1008*t*
 in HIV infection/AIDS, 1327
 in Huntington disease, 1001
 hypertension and, 439
 in Jakob-Creutzfeldt disease, 1009, 1382
 with Lewy bodies, 59, 1008, 1008*t*
 mood disorders and, 1006, 1009
 in niacin deficiency, 1265
 nonpharmacologic approaches to management of, 1008–1009
 psychiatric disorders and, 1006
 rapidly progressive, 1009
 semantic, 1008*t*
 treatment of, 61–62, 1007–1009, 1089
 vascular, 59, 1008*t*
 vitamin B₁₂ deficiency and, 60, 498, 1007
- Demerol. *See* Meperidine
- Demyelinating neuropathies/
 polyneuropathies, 1020. *See also specific type and* Neuropathies
 chronic inflammatory, **1025–1026**
 Guillain-Barré syndrome and, 1025
 in HIV infection/AIDS, 1023, 1328
 myeloma/paraproteinemias and, 1023
 optic neuritis and, 188–189
- Demyelination. *See also* Demyelinating neuropathies/
 polyneuropathies
 in Guillain-Barré syndrome, 1025
 hyponatremia and, 875
 hyponatremia complications/treatment and, 874
 in multiple sclerosis, 1010
 in progressive multifocal leukoencephalopathy, 1382, 1383
- Dengue/dengue hemorrhagic fever, 1378, **1386–1388**
- Dengue shock syndrome, 1386, 1387
- Denial, at-risk drinking and, 1081
- Denial of illness, 1090, 1091
- Denileukin diftitox, 1655*t*
- Denosumab
 for breast cancer, 739
 for chemotherapy-induced toxicity, 1658*t*
 for osteoporosis, 1148
 for prostate cancer, 1636
- Dental disorders
 actinomycosis and, 1456
 anaerobic pleuropulmonary infections and, 278
 bacterial rhinosinusitis and, 215
 bisphosphonate use and, 11
 deep neck infections and, 230
 earache and, 206
 facial pain caused by, 968
 in Sjögren syndrome, 843
- Dental procedures, endocarditis prophylaxis and, 1437, 1437*t*, 1438*t*
- Dentatorubral-pallidolusian atrophy, 1002
- Dentition, poor. *See* Dental disorders
- Dentures, foreign body aspiration and, 238–239, 308
- Deoxyribonuclease, human (rhDNase)
 for cystic fibrosis, 268
 pleural instillation of, 316
- Dependency (drug), **18–20**, **1079–1086**. *See also specific drug and* Substance use disorders
 in opioid therapy, 76, 1083–1084
 physiologic, 1079
 psychologic, 1079
- Dependent personality disorder, 1052*t*
- Depersonalization, 1041
 intracranial tumors causing, 990
 in schizophrenia/psychotic disorders, 1054
- Depigmentation disorders, 155–156, 155*f*. *See also* Hypopigmentation
- DepoCyt. *See* Cytarabine liposome
- DepoEstradiol, 1184
- Depression, **1062–1072**
 adjustment disorder with, 1063
 alcohol dependency and, 1064, 1072, 1080
 with atypical features, 1063, 1066
 bipolar disorder and, 1063–1064
 chronic pain and, 1047
 complications of, 1064–1065
 in cyclothymic disorders, 1064
 dementia and (pseudodementia), 59–60, 1006, 1088
 differential diagnosis of, 1064
 dispensing medications and, 1065, 1067
 drug-induced, 63, 1064
 drug therapy for, 63, 1065–1069, 1066*f*, 1069*t*, 1070*t*, 1071*t*. *See also* Antidepressants
 dysthymia, 1063
 ECT for, 1069–1071
 in elderly, **63**
 caregiver issues and, 58
 stimulants for, 1066–1067
 urinary incontinence and, 67
 experimental treatments for, 1071
 hospitalization/illness and, 1064, 1090, 1091
 hypercortisolism and, 1160
 lithium for, 1065, 1072
 major depressive disorder, 1063
 OCD and, 1041
 oral contraceptive use and, 772, 1064
 panic disorder and, 1041
 parkinsonism differentiated from, 998
 perimenopausal, 1181
 estrogen replacement therapy and, 1182
 personality disorder and, 1051
 phototherapy for, 1071
 with postpartum onset, 1063
 in premenstrual dysphoric disorder, 749, 1063
 PTSD and, 1039, 1040
 reserpine causing, 456*t*, 457
 schizophrenic/psychotic disorders/ideation and, 1054, 1055, 1058, 1065–1066, 1068
 screening for
 in elderly, 63
 in women, **1711**
 with seasonal onset, 1063, 1066, 1071
 sleep disorders and, 1076
 somatization disorder and, 1045
 suicide and, 1064–1065
 in terminally ill/dying patient, 91
 treatment of, 1065–1072, 1066*f*, 1069*t*, 1070*t*, 1071*t*. *See also* Antidepressants
- Dermabrasion, for acne scars, 128
- DermaCenter ticks. *See* Ticks
- Dermal fillers, for age-related facial changes, 1721
- Dermatitis. *See also* Skin disorders
 atopic. *See* Atopic dermatitis
 bacterial, in HIV infection/AIDS, 1331
 cercarial, in schistosomiasis, 1511
 contact
 allergic, **124–125**, 124*f*, 866
 impetigo differentiated from, 123, 124
 topical medications causing, 100, 124
 urticaria in, 133
 irritant, 124, 125
 photodermatitis differentiated from, 153
 tinea differentiated from, 113
 contagious pustular (orf), 1404

- drugs causing, 158–161, 159–160t
exfoliative (exfoliative erythroderma), 116–117
 drugs causing, 116, 159t
 psoriatic, 106, 116. *See also* Psoriasis
fungal, in HIV infection/AIDS, 1331
hand, vesiculobullous (pompholyx), 121–122, 121f
 tinea differentiated from, 113
herpetiformis, 122–123
 celiac disease/gluten sensitivity and, 123, 622
in HIV infection/AIDS, 1330–1331
medicamentosa (drug eruption), 158–161, 159–160t
in niacin deficiency, 1265
seborrheic. *See* Seborrheic dermatitis
stasis, 34, 478. *See also* Venous insufficiency/stasis
 leg ulcers and, 153
 viral, in HIV infection/AIDS, 1330–1331
- Dermatographism, 133
- Dermatologic disorders. *See* Skin disorders
- Dermatologic therapy, 94–100, 95–99t
 adverse ophthalmic effects of, 197t
 complications of, 99–100
- Dermatomal herpes zoster, 119, 120f, 1358
- Dermatomyositis, 840–842, 840f
 autoantibodies in, 833t, 841
 cancer-related, 840, 841, 864, 995, 1596t
 sine myositis, 840
- Dermatop. *See* Prednicarbate
- Dermatopathic lymphadenopathy, 115
- Dermatophytosis, 111f, 112–113, 113f.
 See also Tinea
 drugs for treatment of, 110
 furunculosis differentiated from, 151
 in HIV infection/AIDS, 1331
 nail changes in, 157, 158
- Dermopathy
 in Graves disease (pretibial myxedema), 1110, 1113
 nephrogenic fibrosing, 839
- DES. *See* Diethylstilbestrol
- Des-gamma-carboxy prothrombin, in hepatocellular carcinoma, 1604
- Desensitization techniques
 for phobic disorder, 1044
 for psychiatric problems associated with hospitalization/illness, 1091
 for PTSD, 1040
- Desensitization therapy. *See also* Immunotherapy
 for asthma, 249f, 253
 for drug/penicillin allergies, 1305–1307
- Designer drugs, 18, 1086
- Desipramine, 1065, 1068, 1070t, 1722t.
 See also Antidepressants
 for neuropathic pain/painful diabetic neuropathy, 84, 84t, 1225
- Desloratadine, for allergic/perennial rhinitis, 219
- Desmoid tumors, in familial adenomatous polyposis, 655
- Desmopressin (DDAVP)
 for bleeding in chronic kidney disease/uremia, 582, 913
 in diabetes insipidus diagnosis, 1099
 in diabetes insipidus treatment, 1099
 for enuresis, 1078
 for hemophilia, 550, 550t
 for von Willebrand disease, 550t, 551
- Desogestrel, in oral contraceptives, 770, 771t
 for hirsutism/virilization, 1163
 thromboembolism and, 770
- Desonide, 95t
- Desquamative interstitial pneumonia (DIP), 269, 294t
- Desvenlafaxine, 1068, 1070t
- Desynchronization sleep disorder, 1075
- Desyrel. *See* Trazodone
- Detergent worker's lung, 310t
- Detrusor muscle disorders, urinary
 incontinence and, 68, 68–69.
 See also Overflow incontinence; Urge incontinence
- DeVega annuloplasty, 347
- Devic disease/syndrome (neuromyelitis optica), 1012
 optic neuritis in, 188, 1012
- Dexamethasone, 1190, 1190t. *See also* Corticosteroids
 in cancer chemotherapy, 1657t
 for fetal lung maturity, 794, 796
 for high-altitude illness, 1559
 for nausea and vomiting, 568t, 569, 1660
 for ophthalmic disorders, 170t
 in pain management, 85
 for pneumococcal meningitis, 1288, 1424–1425
 prophylactic, 1559
 for spinal tumors/cord compression, 993, 1645
- Dexamethasone suppression test, in Cushing syndrome diagnosis, 1159
- Dexlansoprazole, 613. *See also* Proton pump inhibitors
- Dexrazoxane, for chemotherapy-induced cardiac toxicity, 1658t, 1662
- Dextroamphetamine
 abuse/overdose of, 1085
 for depression, 1066–1067
 for narcolepsy, 1077
 for opioid-induced sedation, 79
- Dextromethorphan
 for cough, 23
 MAOI interactions and, 1071t, 1585
 overdose/toxicity of, 1583, 1586–1587
- Dextrose
 for coma, 1014, 1563
 in diabetes management of hospitalized patient, 1229
 for drug-induced hypoglycemia, 1580
 in fluid management, 897, 897t
 for hypernatremia, 876
 for hyperglycemia hyperosmolar state, 1236
 for shock, 486
 for status epilepticus, 974
- DHEA/DHEAS. *See* Dehydroepiandrosterone/dehydroepiandrosterone sulfate
- DHFR gene, TMP-SMZ resistance and, 1534
- DiaBeta. *See* Glyburide
- Diabetes Control and Complications Trial (DCCT), 1201
- Diabetes insipidus, 1098–1100
 craniopharyngioma and, 1096
 hypernatremia in, 876, 1098, 1099
 nephrogenic, 878t, 1098, 1099
 hypercalcemia/hyperparathyroidism and, 883, 884, 1139
 lithium causing, 1073, 1582
 after pituitary microsurgery, 1099, 1101
 in Wolfram syndrome, 1098, 1195
- Diabetes mellitus, 1192–1238, 1193t. *See also* under *Diabetic*
 antipsychotic drug use and, 1057, 1059, 1060t
 aspirin in chemoprevention and, 1203, 1227
 atrial fibrillation and, 385, 385t
 β-blocker use in, 442t, 446
 blood glucose levels in diagnosis of, 1198, 1198t, 1218
 blood glucose self-monitoring in, 1200
 in pregnant patient, 801
 blood-testing procedures in, 1198–1200, 1198t, 1199t
 cardiovascular complications of, 356, 1197, 1227–1228
 glycemic control and, 356, 1201, 1202, 1203, 1204
 hypertension control and, 433, 442t, 443, 444, 449, 457–458, 458, 1202, 1203, 1227
 in women, 1707
 chronic kidney disease and, 908, 910, 914, 927, 931, 1223–1224. *See also* Diabetic nephropathy
 cirrhosis and, 687
 classification and pathogenesis of, 1192–1196, 1193t
 clinical findings in, 1196–1197, 1197t
 clinical trials in, 1201–1204
 coma in patient with, 1197, 1231–1235, 1232t
 complications of, 1223–1228
 clinical studies of glycemic control and, 1201–1202, 1202–1204
 hypoglycemia and, 1222
 insulin therapy causing, 1221–1223
 continuous glucose monitoring systems in, 1200
 diagnostic examination in, 1217–1218
 disordered eating in women and, 1713
 emphysematous pyelonephritis in, 941
 enterovirus infection and, 1407
 epidemiologic considerations in, 1192, 1193t
 erectile dysfunction in, 1226–1227
 estrogen replacement affecting, 1182
 exercise and, 12–13, 1202, 1203, 1220
 insulin requirements and, 12, 1218
 foot disorders/foot care in, 154, 467, 1224–1225, 1225f, 1227–1228
 callosities and corns, 141, 1224
 cellulitis, 137
 gastroparesis in, 629
 hypoglycemia and, 1222
 gestational, 784, 800–801, 801t

- Diabetes mellitus (*Cont.*):
- glaucoma in, 175, 1223
 - glucose tolerance test in, 1198, 1198t
 - glucosuria/glycosuria in, 1197–1198
 - glycated hemoglobin (hemoglobin A_{1c}) measurements in, 1198–1199, 1198t, 1199t, 1201, 1202
 - glycemic control in
 - acceptable levels of, 1221
 - blood glucose self-monitoring in, 1200
 - clinical studies in evaluation of, 1201–1202, 1202–1204
 - glycated hemoglobin (hemoglobin A_{1c}) measurements in evaluation of, 1198–1199, 1199t, 1201, 1202, 1203
 - intensive insulin therapy for. *See* Insulin therapy, intensive
 - pregnancy and, 801, 1230
 - surgery and, 54, 54t, 1229, 1229t
 - heart disease in, 356, 1227
 - in women, 1707
 - HLA in, 1192
 - in hospitalized patient, 1228–1230, 1229t
 - hypernatremia and, 876
 - hypertension/hypertension
 - management in, 433, 442t, 443, 444, 449, 457–458, 458, 1197, 1202, 1203, 1227
 - angiotensin-converting enzyme (ACE) inhibitors for, 442t, 449, 457–458, 458, 1202, 1203, 1227
 - antihypertensive therapy regimens for, 442t, 457–458, 458
 - benefits of control and, 1202, 1203, 1224, 1227
 - calcium channel blocking agents for, 442t, 458, 1203
 - immunization recommendations in, 1309t
 - insulin resistance and, 1194, 1196. *See also* Insulin resistance/insulin insensitivity; Insulin resistance syndrome
 - ketonuria in, 1198, 1218
 - laboratory findings in, 1197–1201, 1198t, 1199t
 - latent autoimmune of adulthood (LADA), 1193, 1220
 - lipid/lipoprotein abnormalities in, 1197, 1200–1201, 1247, 1248t
 - lipotrophic, 1193t
 - maturity-onset of young (MODY), 1193t, 1194–1195
 - hepatocellular adenoma and, 702
 - mitochondrial DNA mutations and, 1195
 - mucormycosis in, 217–218, 1538
 - mutant insulin receptors causing, 1195, 1195f
 - mutant insulins causing, 1195
 - nephrotic syndrome and, 931, 1224. *See also* Diabetic nephropathy
 - neurogenic arthropathy (Charcot joint) in, 865, 1224–1225
 - neuropathy and, 1022, 1197, 1197t, 1224–1227, 1225f. *See also* Diabetic neuropathy
 - nonalcoholic fatty liver disease and, 684, 685
 - occult, 1243
 - ocular complications of, 185–186, 185f, 1197t, 1201, 1223. *See also* Diabetic retinopathy
 - ocular examinations in, 185, 1223
 - osteomyelitis in, 862
 - pancreatic/periampullary carcinoma and, 1607, 1608
 - patient education (self-management training) in, 1218
 - polycystic ovary syndrome and, 765, 1162
 - prebreakfast hyperglycemia in, 1219–1220, 1219t
 - during pregnancy, 784, 800–801, 801t, 1230
 - continuous glucose monitoring and, 1200
 - preoperative evaluation/perioperative management and, 46, 54, 54t, 1229, 1229t
 - prevention/delay of
 - clinical trials studying, 1201, 1201–1202, 1202
 - exercise and, 12–13, 1202, 1203
 - immune intervention therapy and, 1201–1202
 - prognosis for, 1231
 - screening for
 - cardiovascular disease prevention and, 7t
 - pregnancy and, 784
 - secondary, 1196, 1196t
 - self-monitoring of blood glucose and, 1200
 - in pregnant patient, 801
 - serum fructosamine levels in, 1199
 - skin/mucous membrane disorders and, 1197, 1228
 - surgery in patients with, 54, 54t, 1229, 1229t
 - tibial atherosclerosis and, 467
 - treatment of, 1204–1217, 1217–1223
 - clinical studies in evaluation of, 1201–1204
 - combination regimens and, 1213
 - diet in. *See also* Diet
 - drugs in, 1205–1213, 1206–1207t. *See also* Antidiabetic agents
 - for hospitalized patient, 1228–1230, 1229t
 - insulin in, 1213–1217, 1213t, 1214f, 1214t, 1218–1220, 1219t. *See also* Insulin therapy
 - in pregnant patient, 1230
 - principles of, 1218–1221, 1219t
 - steps in, 1217–1223
 - transplantation in, 1217
 - type 1, 1192, 1192–1194, 1218–1220
 - clinical trials in, 1201–1202
 - HLA in, 1192
 - idiopathic (type 1B), 1192, 1194
 - immune-mediated (type 1A), 1192, 1192–1194
 - insulin therapy for, 1213–1217, 1213t, 1214f, 1214t, 1218–1220, 1219t
 - prognosis for, 1231
 - surgery in patient with, 54, 1229, 1229t
 - symptoms/signs of, 1197, 1197t
 - type 2, 1192, 1194, 1220–1221
 - clinical trials in, 1202–1204
 - drugs for management of, 1205–1213, 1206–1207t, 1220–1221. *See also* Antidiabetic agents
 - hepatitis C and, 671
 - insulin therapy for, 1202, 1221
 - in nonobese patients, 1220
 - in obese patients, 13, 1194, 1197, 1202, 1203, 1220
 - prognosis for, 1231
 - surgery in patient with, 54, 54t, 1229, 1229t
 - symptoms/signs of, 1197, 1197t
 - urinalysis findings in, 1197–1198
 - vascular disorders in, 356, 1197, 1227–1228
 - glycemic control and, 356, 1201, 1202, 1203, 1204
 - hypertension control and, 433, 442t, 443, 457–458, 458, 1202, 1203, 1227
 - weight loss (unintended) in, 1197, 1197t
 - diabetic neuropathic cachexia and, 1226
 - in Wolfram syndrome, 1098, 1195
- Diabetes Prevention Program (DPP), 1202
- Diabetes Prevention Trial-1 (DPT-1), 1201
- Diabetic amyotrophy, 1022, 1225
- Diabetic cataracts, 1223
- Diabetic cheiroarthropathy/cheiropathy, 839, 1228
- Diabetic coma, 1197, 1231–1235, 1232t. *See also specific cause*
- diabetic ketoacidosis and, 1197, 1231, 1232, 1232t, 1233
 - hyperglycemic hyperosmolar state and, 1197, 1231, 1232t, 1236
 - lactic acidosis and, 1231, 1232t
- Diabetic diarrhea, 1226
- Diabetic dyslipidemia, 1197, 1200–1201, 1247, 1248t
- Diabetic ketoacidosis, 891, 1197, 1231–1235, 1232t
- coma caused by, 1197, 1231, 1232, 1232t, 1233
 - hypophosphatemia in, 886, 1234
 - increased anion gap acidosis and, 891
 - insulin infusion pump use and, 1217, 1232
 - insulin needs during surgery and, 1229
 - normal anion gap acidosis and, 891, 1234–1235
- Diabetic maculopathy/macular edema, 185, 185f, 1223
- Diabetic nephropathy, 920t, 928, 931, 1223–1224
- dialysis for, 1224
 - glycemic control and, 931, 1201, 1203, 1224
 - hypertension/hypertension control and, 458, 931, 1203, 1224

- Diabetic neuropathic cachexia, 1226
- Diabetic neuropathy, 1022, 1197, 1197t, 1224–1227, 1225f
- foot disorders/ulcers/gangrene and, 467, 1224–1225, 1225f, 1227
 - glycemic control and, 1201, 1203
 - neurogenic arthropathy (Charcot joint) and, 865, 1224–1225
- Diabetic retinopathy, 185–186, 185f, 1223
- glycemic control and, 185, 1201, 1203
- Diabetic shin spots, 1228
- Diabinese. *See* Chlorpropamide
- Diacetyl, bronchiolitis obliterans caused by inhalation of, 311
- Diagnostic/laboratory tests. *See also specific disorder*
- in poisoning/drug overdose, 1569–1570, 1569t
 - in prenatal care, 783, 784–785. *See also* Prenatal testing
 - in primary prevention, 2
 - reference values for, 1727–1735t
 - tubes for specimen collection and, 1736t
- Dialectical behavioral therapy, for personality disorders, 1052
- Dialysis, 915–916
- for bleeding in chronic kidney disease, 913
 - “gut” (repeat-dose charcoal), 1568
 - for heat stroke, 1548
 - for hypercalcemia, 884
 - hypercalcemia/hyperphosphatemia associated with, 884
 - for hyperkalemia, 880, 881t
 - for hypermagnesemia, 888
 - for hypernatremia, 876
 - for hyperphosphatemia, 886
 - hypocalcemia/hyperphosphatemia associated with, 884
 - for hyponatremia, 874
 - for kidney disease/injury
 - acute injury/acute tubular necrosis, 906
 - chronic, 910, 915–916
 - coagulopathy and, 913
 - in diabetic, 1224
 - perioperative, 55
 - neuropathies in chronic kidney disease and, 914, 1022
 - for poisoning/drug overdose, 1567–1568, 1568t
 - with carbamazepine, 1568t, 1574
 - with lithium, 1073, 1568t, 1582–1583
 - with methanol or ethylene glycol, 1568t, 1584
 - with phenobarbital, 1568t
 - with salicylates, 1568t, 1589
 - with theophylline, 1568t
 - with valproic acid, 1568t, 1574
 - prognosis for patient undergoing, 916
 - pruritus associated with, 145
 - renal cysts and, 934
 - renal cell carcinoma and, 1641
 - skin lesions and (porphyria cutanea tarda-like), 122
 - surgery in patient receiving, 55
 - for uremic pericarditis, 420, 912
 - uremic pericarditis in patients receiving, 419
- Diaphragm, respiratory failure caused by disorders of, 320t
- Diaphragm (contraceptive), 774–775
- DIAPPERS mnemonic, 67
- Diarrhea, 574–580, 574t, 576f, 579f, 1293–1296, 1294–1295t. *See also specific cause and* Colitis; Gastroenteritis
- acidosis associated with, 892, 892t, 893
 - acute, 574t, 575–577, 576f, 1293–1296, 1294–1295t
 - adenoviruses causing, 1293, 1330, 1402, 1404–1405
 - antibiotic-associated, 575, 576, 636
 - antibiotics for, 577, 1296, 1298
 - Bacillus cereus* causing, 574t, 575, 1293, 1294t
 - in bacterial overgrowth, 579f, 580, 624
 - bloody, 575, 576, 584, 1293, 1298. *See also* Dysentery
 - C difficile* causing, 574t, 575, 576, 636, 1293, 1294t
 - campylobacter causing, 574t, 575, 1293, 1295t, 1296, 1297, 1298, 1303t, 1330, 1449
 - Guillain-Barré syndrome and, 1024
 - in celiac disease, 622, 623
 - chemotherapy/radiation-induced, 1660, 1660–1661
 - in cholera, 1448
 - chronic, 574t, 577–580, 579f
 - clostridial, 574t, 575, 576, 636–638, 1293, 1294t
 - occidial and microsporidial, 1330, 1506–1508
 - in Crohn disease, 574t, 578, 641, 643
 - in cryptosporidiosis, 574t, 575, 576, 579, 1293, 1330, 1507
 - in cyclosporiasis, 574t, 575, 576, 578, 579, 1293, 1507
 - cytomegalovirus causing, 574t, 575, 1330
 - in diabetic autonomic neuropathy, 1226
 - diet in management of, 576
 - drugs in management of, 577, 580. *See also* Antidiarrheal agents
 - E coli* causing, 574t, 575, 576, 1293, 1294t, 1296, 1297, 1298, 1447
 - endoscopy/mucosal biopsy in, 579
 - enteral nutritional support and, 1273
 - factitious, 574t, 579f
 - fecal impaction and, 572
 - fluid management in, 576, 897t, 1296
 - in giardiasis, 574t, 575, 576, 578, 579, 1293, 1298, 1330, 1509
 - in hyperoxaluric calcium nephrolithiasis, 949
 - in hypocitricuric calcium nephrolithiasis, 949
 - hypokalemia caused by, 878
 - in immunocompromised host/HIV infection/AIDS, 575, 578, 1325, 1330, 1506, 1507
 - infectious
 - acute, 574t, 575, 1293–1296, 1294–1295t
 - chronic, 574t, 578
 - inflammatory. *See also* Dysentery
 - acute, 574t, 575, 1293
 - chronic, 574t, 578, 579f
 - in intestinal amebiasis, 574t, 575, 576, 578, 1293, 1298, 1303t, 1330, 1503
 - in irritable bowel syndrome, 578, 579f, 633, 634, 635
 - in isosporiasis, 1293, 1330, 1507
 - in lactase deficiency/lactose (milk) intolerance, 578, 579f, 621t, 626
 - in malabsorption, 574t, 578, 579, 579f, 580, 621t
 - in measles, 1368
 - in microscopic colitis, 574t, 578, 650
 - motility disorders and, 574t, 578
 - in niacin deficiency, 1265
 - noninflammatory, 574t, 575, 1293
 - noroviruses/Norwalk virus causing, 574t, 1293, 1295t, 1404–1405
 - osmotic, 574t, 577–578
 - rotaviruses causing, 574t, 1293, 1295t, 1404–1405
 - salmonella causing, 574t, 575, 1293, 1295t, 1296, 1298, 1303t, 1330, 1446
 - secretory, 574t, 578, 579f
 - shigella causing, 574t, 575, 1293, 1295t, 1296, 1297, 1298, 1303t, 1330, 1447
 - in short bowel syndrome, 625, 626
 - staphylococcal, 574t, 575
 - stool analysis in, 575, 576, 576f, 578, 579f
 - toxins causing, 574t, 575, 1293, 1294t
 - traveler's, 575, 576, 1297, 1297–1298. *See also* Traveler's diarrhea
 - in typhoid fever, 1445
 - in ulcerative colitis, 574t, 578, 646, 647
 - in vibrio infection, 574t, 576, 1293, 1294t, 1298, 1448
 - VIP/VIPoma causing, 580, 1172, 1189
 - viral, 574t, 575, 1293, 1330, 1404–1405. *See also specific virus*
 - in Zollinger-Ellison syndrome (gastrinoma), 619, 1172, 1189
- Diastolic blood pressure, 434t. *See also* Blood pressure
- in congestive heart failure, 398
 - in hypertension, 433, 434t, 435f
 - in poisoning/drug overdose, 1564
 - treatment goals and, 443
 - in hypertensive urgencies/emergencies, 433, 460
 - in preeclampsia-eclampsia, 793, 793t, 795
 - in prehypertension, 434, 434t, 441
- Diastolic dysfunction/heart failure, 398. *See also* Congestive heart (cardiac) failure
- Diastolic murmurs. *See* Heart murmurs
- Diazepam, 1042, 1042t, 1043. *See also* Benzodiazepines
- adverse ophthalmic effects of, 196t
 - for aggressive/violent patient, 1078
 - for alcohol withdrawal, 974, 1082
 - for anxiety, 1042, 1042t, 1043
 - breastfeeding and, 782t
 - for nausea and vomiting, 569t
 - overdose/toxicity of, 1579–1580
 - for seizures, 1565
 - status epilepticus and, 974
 - for spasticity, 1012

- Diazoxide, for islet cell tumors/
insulinomas, 1241
- Dibenzodiazepines, 1055. *See also*
Antipsychotic drugs
- DIC. *See* Disseminated intravascular
coagulation
- Dichuchwa (endemic syphilis), 1475
- Diclofenac, 77t
for arthritis, 811, 812
for ophthalmic disorders, 169t
topical, 76, 811, 812
- Didanosine (ddI), 1341t, 1343, 1347,
1348f. *See also* Antiretroviral
therapy/HAART
neuropathy caused by, 1328, 1343
- DIDMOAD (Wolfram syndrome), 1098,
1195
- Dienestrol, 1184
- Dientamoeba fragilis*, 1510
- Diet. *See also* Nutrition
acne and, 126
for alcohol use/abuse patient, 1083
breast cancer risk and, 722, 1708
cancer prevention and, 1269, 1594
cardiovascular disease prevention and, 7t
cholelithiasis/gallstones and, 703
cholesterol/lipid-lowering, 1250, 1252,
1269
in diabetes, 1205
in nephrotic syndrome/nephrotic
spectrum disorders, 928
in chronic kidney disease, 914–915
in cirrhosis, 687
colorectal cancer and, 1269, 1594, 1623
consistency alterations and, **1268**
constipation and, 571
coronary heart disease and, 350
in Crohn disease, 643
in diabetes mellitus, 1204–1205
for obese type 2 diabetic, 1202, 1205,
1220
pregnancy and, 801
prevention/complications and, 1202,
1203
in diarrhea control, 576
in diverticular disease, 651, 652
in fibrocystic condition, 719
flatus and, 573
gastric adenocarcinoma and, 1615
in GERD management, 596
gluten-free, for celiac disease/
dermatitis herpetiformis,
123, 622–623
in gout, 814, 815t
in heart failure management, 406
in hemochromatosis, 695
in hypertension/hypertension
prevention, 11, 441, 441t
in hypertriglyceridemia, 1255
in irritable bowel syndrome, 634
for islet cell tumors/insulinomas, 1241
lactation and, 786
lactose-free, 626, 627
MAOI interactions and, 1000
Mediterranean, 14, 1252
in nephrotic syndrome, 928
nutrient-restricting, **1268–1269**. *See also*
specific type
nutrient-supplementing, **1269–1270**
obesity management/prevention and,
13, 14, 1260
in osteoporosis, 1146
in pancreatitis, 713–714, 716
in porphyria, 1022, 1664
during pregnancy, 783, 785
diabetes mellitus and, 801
preventable disease/deaths and, 3t, 7t
therapeutic, **1268–1270**
in ulcerative colitis, 647
urinary stone formation and, 946, 947,
948
in Wilson disease, 697
- Diet therapy, **1268–1270**. *See also* Diet;
Nutrition
- Dietary supplements
oral nutritional supplements, 1270
in HIV infection/AIDS, 1325
for undernourished elderly, 70
toxicity of, **1578**, 1578t
- Diethylcarbamazine
for filariasis, 1525, 1526
for loiasis, 1528
- Diethylene glycol, toxicity of, 1584
- Diethylpropion, for obesity, 1260
- Diethylstilbestrol (DES), 740t
for breast cancer, 740t
in male, 746
for prostate cancer, 1636, 1637t
- Dieulafoy lesion, 581, 586
- Difenacoum poisoning, 1573
- Diffuse axonal injury, 1017t
- Diffuse cutaneous leishmaniasis, 1488
- Diffuse esophageal spasm, 592t, 606
- Diffuse gastric cancer, 1616
- Diffuse idiopathic skeletal hyperostosis
(DISH), 855, 1228
- Diffuse panbronchiolitis, 269, 269–270
- Diffuse parenchymal lung disease,
292–297, 292t, 294t. *See also*
specific disorder and
Interstitial lung disease
- Diffusing capacity for carbon monoxide
(DL_{CO})
in *Pneumocystis* pneumonia, 1326
in pulmonary hypertension, 305, 424
- Diflorasone, 96t
- Diflucan. *See* Fluconazole
- Diffunisal, 77t
- DiGeorge syndrome, hypoparathyroidism
in, 1136
- Digestion, disorders of. *See*
Malabsorption
- Digibind. *See* Digoxin-specific Fab
antibody
- DigiFab. *See* Digoxin-specific Fab
antibody
- Digital clubbing, 157, 158f
in bronchiectasis, 266
in lung cancer, 1597
- Digital cyanosis, in Raynaud
phenomenon, 836
- Digital gangrene, in polyarteritis nodosa,
847
- Digital ischemia
in Raynaud phenomenon, 836
in scleroderma, 838
- Digital lesion, in nocardiosis, 1457
- Digital mammography, 16, 725
- Digital rectal examination. *See* Rectal
examination
- Digitalis/digitalis glycosides. *See also*
Digoxin
antidepressant drug interactions and,
1071t
for heart failure, 403–404, 405
overdose/toxicity of, 403–404, 1564,
1566t, **1578–1579**
hypokalemia and, 878
ophthalmic effects and, 196t
- Digoxin, 377, 403–404, 1723t. *See also*
Digitalis/digitalis glycosides
for arrhythmias, 377, 379t
atrial fibrillation, 386
in hyperthyroidism, 1118
in myocardial infarction, 372
benzodiazepine interactions and, 1043t
for cardiomyopathy, 412, 417
for heart failure, 403–404
overdose/toxicity of, 379t, 403–404,
1564, 1566t, 1569t, 1578–
1579
chronic kidney disease and, 912
perioperative management for patient
taking, 49
- Digoxin-specific Fab antibody (digoxin
immune Fab), for digitalis
toxicity, 404, 1564, 1566t,
1579
- Dihydroartemisinin, 1492t, 1496–1497
with piperazine, 1493t, 1494t, 1495,
1497
- Dihydroergotamine
for cluster headache, 965
for migraine headache, 963
- Dihydrofolate reductase, antimalarial
drugs affecting, 1496
- Dihydroindolones, 1055. *See also*
Antipsychotic drugs
- Dihydropteroate synthase, antimalarial
drugs affecting, 1496
- 1,25-Dihydroxycholecalciferol. *See*
Calcitriol
- Diiodohydroxyquin. *See* Iodoquinol
- Dilacor. *See* Diltiazem
- Dilated cardiomyopathy. *See*
Cardiomyopathy
- Dilation and curettage. *See* D&C
- Dilaudid. *See* Hydromorphone
- Diloxanide, for amebiasis, 1504, 1505t
- Diltiazem, 454t. *See also* Calcium channel
blocking drugs
for acute coronary syndromes, 363
for angina, 356
for arrhythmias, 379t
atrial fibrillation, 372, 386
infarct-related, 372
supraventricular tachycardia, 379t, 382
for hypertension, 453, 454t
overdose/toxicity of, 379t, 454t, 1576
- Dilutional acidosis, 893
- Dimenhydrinate, 569
- Dimercaprol (BAL)
for arsenic poisoning, 1575
for lead poisoning, 1582
for mercury poisoning, 1583
- Dimercaptosuccinic acid (DMSA). *See*
Succimer
- 1,1-Dimethylbiguanide hydrochloride.
See Metformin
- Dimethyltryptamine, 1084
- Diovan/Diovan HCT. *See* Valsartan
- DIP. *See* Desquamative interstitial
pneumonia

- Dipeptidyl peptidase 4 (DPP-4), 1211
 Dipeptidyl peptidase 4 (DPP 4)
 inhibitors, 1207t, 1212–1213, 1221
- Diphenhydramine. *See also*
 Antihistamines
 breastfeeding and, 782t
 for insomnia, 1076
 for nausea and vomiting, 86
 overdose/toxicity of, 1564, 1575
 for scombroid poisoning, 1589
- Diphenoxylate with atropine, 580. *See also* Antidiarrheal agents
 overdose/toxicity of, 1575
 for ulcerative colitis, 647
- Diphtheria, **1433–1434**
 neuropathy in, 1024, 1433
 pharyngitis in, 228, 1419, 1433
 prevention/immunization and, 1434.
 See also Diphtheria and tetanus toxoids and pertussis vaccine
- Diphtheria antitoxin, 1434
- Diphtheria-tetanus toxoid. *See* Tetanus-diphtheria toxoid
- Diphtheria and tetanus toxoids and pertussis vaccine (DTaP/Tdap vaccines), 3, 1308t, 1309t, 1310t, 1314, 1430, 1430t, 1434, 1440
 adverse effects/contraindications and, 1317t
 booster and, 1307, 1430, 1430t, 1434, 1440
 burn injury and, 1551
 in immunocompromised host/HIV infection/AIDS, 1309t, 1314, 1335
 pregnancy and, 787, 1307, 1309t, 1440
- Diphtheria toxoid, 1434. *See also* Tetanus-diphtheria toxoid
- Diphyllobothrium latum* (fish tapeworm), **1514**
 vitamin B₁₂ deficiency and, 497, 1514
- Dipivefrin, for glaucoma/ocular hypertension, 177
- Diplopia
 in dysthyroid eye/Graves disease, 191, 1112
 in ocular motor palsies, 190
 in ocular myasthenia gravis, 1113
 vertigo and, 210
- Diprolene. *See* Betamethasone
- Dipstick urinalysis, 898. *See also specific disorder*
 in dysuria evaluation, 43
 in hematuria evaluation, 899, 938
 in proteinuria evaluation, 899
 in urinary stone disease, 947
- Dipylidium caninum* (dog tapeworm), 1514
 echinococcosis and, 1516
- Dipyridamole
 platelet function affected by, 549t
 for transient ischemic attacks, 979
- Dipyridamole-thallium scintigraphy. *See* Myocardial perfusion scintigraphy
- Direct current (DC) electrical injury, 1552
- Direct thrombin inhibitors
 for heparin-induced thrombocytopenia, 544, 544t
 for venous thromboembolism, 558
- Directed bleeding history, preoperative, 46, 47t, 52
- Directly observed therapy (DOT), for tuberculosis, 284, 285, 286
 in drug-resistant tuberculosis, 284, 285, 286
 in HIV-positive persons, 285
- Disability assessment, in burn injury, 1550
- Discogenic disease. *See* Cervical spine/disk disease; Lumbar spine/disk disease; Sacral spine/disk disease; Thoracic spine/disk disease
- Discoid lupus erythematosus, **114–115**
- Disease-modifying antirheumatic drugs (DMARDs), 828, 829–831
 biologic, 830–831
 combination regimens for, 831
 synthetic, 829–830
- Disease prevention. *See* Preventive care
- DISH. *See* Diffuse idiopathic skeletal hyperostosis
- Disipal. *See* Orphenadrine
- Disk batteries, ingested, alkali injuries caused by, 1572
- Disk diffusion tests, drug susceptibility, 1304
- Disk disease. *See* Cervical spine/disk disease; Lumbar spine/disk disease; Sacral spine/disk disease; Thoracic spine/disk disease
- Dislocated shoulder, 1679–1680t, **1681–1682**
- Disopyramide, 377, 378t
 for cardiomyopathy, 415
 overdose/toxicity of, 378t, 1588
- Disorganized (hebephrenic) schizophrenia, 1053
- Dissection. *See* Aortic dissection
- Disseminated cutaneous leishmaniasis, 1488
- Disseminated intravascular coagulation (DIC), **545–546**, 546t, **554**
 in acute leukemia, 519, 520, 546
 in cancer, 545, 546, 994
 in gram-negative bacteremia/sepsis, 545, 1444
 in meningococcal meningitis, 1441
- Dissociated sensory loss, 976
 in spinal cord infarction, 989
- Dissociative disorder, 1041
- Dissociative identity disorder (multiple personality disorder), 1041
- Distal muscular dystrophy, 1035t
- Distal renal tubular acidosis, 892, 892t, 894. *See also* Renal tubular acidosis
 genetic defects associated with, 878t
 nephrolithiasis/urinary stone formation and, 892, 946–947
 hypocitraturic calcium nephrolithiasis and, 949
 in tubulointerstitial disease, 933
- Distal symmetric polyneuropathy, diabetic, 1224–1225, 1225f
- Distributive shock, 485, 485t, 488
- Disulfiram
 for alcohol use/abuse, 18, 1082
 antidepressant drug interactions and, 1071t
 benzodiazepine interactions and, 1043t
- Diulo. *See* Metolazone
- Diuresis. *See also* Urine output forced
 in poisoning/drug overdose, 1567
 urinary stones and, 950
- Diuretics. *See also specific agent*
 abuse of in bulimia nervosa, 1263
 for acute tubular necrosis, 905–906
 adverse effects of, 445t, 446
 ophthalmic, 196t
 for cardiomyopathy, 415, 417
 in chronic venous insufficiency, 34
 for cirrhotic ascites, 688
 for constrictive pericarditis, 422
 contraction alkalosis and, 895
 for diabetes insipidus, 1099
 gout/hyperuricemia and, 814–815
 for heart failure, 401
 chronic kidney disease and, 912
 left ventricular (infarct-related), 373
 hypercalcemia and, 884, 1142
 for hypercalciuria, 948
 for hyperkalemia, 879, 881t, 914
 for hypernatremia, 876
 for hypertension, 434t, 442t, 444–446, 445t, 457–458, 457f, 458t
 in chronic kidney disease, 459, 911
 in combination products, 445t, 450t, 451t, 452t
 in combination regimen, 457–458, 457f, 458t
 during pregnancy, 802
 in urgencies/emergencies, 462t, 463
 hypocalcemia/hypoparathyroidism and, 1138
 hypokalemia and, 401, 446, 878, 879
 for hyponatremia, 874
 hyponatremia caused by, 871f, 872
 lipid abnormalities associated with use of, 1248t
 lithium interactions and, 1074, 1074t
 for nephrotic syndrome/nephrotic spectrum disorders, 928
 ototoxicity of, 207
 perioperative management for patient taking, 49
 for pulmonary edema, 408
 tubulointerstitial nephritis caused by, 932t
- Divalproex. *See* Valproic acid/valproate
- Diverticula
 colonic, **651–652**
 esophageal/Zenker, **601**
- Diverticular bleeding, 583, 584, 585, **652**
- Diverticulectomy, for Zenker diverticulum, 601
- Diverticulitis, **651–652**
- Diverticulosis, **651**
 GI bleeding in, 583, 584, 585, **652**
 infection and (diverticulitis), **651–652**
- Divigel, 1184
- Diving (underwater). *See* Scuba/deep sea diving
- Dix-Hallpike testing, 209
- Dizziness. *See also* Dysequilibrium (imbalance); Vertigo; Vestibular disorders
 falls/gait abnormalities in elderly and, 65, 67t

- DJ1* gene, in parkinsonism, 998
 DKA. *See* Diabetic ketoacidosis
 DL_{CO} (diffusing capacity for carbon monoxide)
 in *Pneumocystis* pneumonia, 1326
 in pulmonary hypertension, 305, 424
 DLE. *See* Discoid lupus erythematosus
 DMARDs. *See* Disease-modifying antirheumatic drugs
 DML, 98*t*
 DMP1 mutations, in osteomalacia/rickets, 1150
 DMPA. *See* Medroxyprogesterone
 DMPS. *See* Unithiol
 DMSA. *See* Succimer
 DNA
 double-stranded, antibodies to. *See* Anti-double-stranded (antids)-DNA
 hepatitis B virus, 668*f*, 669, 674, 675
 native, antibodies to, 833*t*, 834*t*
 DNA amplification tests, in tuberculosis, 281, 281*t*
 DNA analysis/diagnosis/probes. *See also* Genetic testing
 in colorectal cancer screening/polyp identification, 653, 1626*t*, 1627
 in muscular dystrophy, 1034
 in tuberculosis, 281*t*
 Do not attempt resuscitation (DNAR) orders, 89–90
 Dobrava virus, 1388
 Dobutamine
 for cardiogenic shock, 374, 487–488
 for heart failure, 405
 left ventricular (infarct-related), 373–374
 Dobutamine stress echocardiography. *See* Echocardiography
 Docetaxel, 1652*t*
 for breast cancer, 737, 741
 neuropathy caused by, 1661
 for prostate cancer, 1636–1637
 Docosanol cream, for herpes simplex infection, 1352
 Doctor-patient communication, in end-of-life care, 88, 88*t*
 Doctor-patient relationship
 adherence and, 2
 chronic pain disorders and, 1047
 depression and, 1062
 obesity management and, 1260
 psychiatric problems associated with hospitalization/illness and, 1091
 smoking cessation and, 8, 9–10*t*, 10*t*, 1593
 somatoform disorders and, 1046
 Docusate sodium, 572*t*
 Dofetilide, 377, 379*t*
 for atrial fibrillation, 378*t*, 387, 388
 for atrial flutter, 378*t*, 389
 Dog bites, 1288–1290
 rabies and, 1289, 1290, 1376
 Dog feces
 echinococcosis and, 1516
 toxocariasis/visceral larva migrans and, 1523
 Dog fleas. *See* Fleas
 Dog hookworm, 1518
 cutaneous larva migrans caused by, 1523
 Dog roundworm (*T canis*), 1523
 Dog tapeworm (*D caninum*), 1514
 echinococcosis and, 1516
 Dog ticks. *See* Ticks
 Dolasetron, 568, 568*t*, 1660. *See also* Antiemetics
 Doll's-head eye response, in coma or stupor, 1014, 1015
 Dolobid. *See* Diflunisal
 Dolophine. *See* Methadone
 Domestic violence, 17, 1078, 1079
 elder abuse and, 17
 intimate partner, 17, 1078, 1079, 1711–1712
 prevention of, 17, 1712
 Domperidone, for gastroparesis, 629
 Donepezil, for dementia, 61, 1008
 Donovan bodies, 1453
 Dopamine
 depletion of in parkinsonism, 998
 in Huntington disease, 1002
 for hypotension/shock, 488
 cardiogenic, 374, 488
 in poisoning/drug overdose, 1563
 for left ventricular (infarct-related) failure, 374
 positive and negative schizophrenic symptoms and, 1053
 receptors for, in nausea and vomiting, 566
 Dopamine agonists
 for acromegaly/gigantism, 1101
 for cocaine withdrawal, 1085
 for hyperprolactinemia, 1103, 1104
 for neuroleptic malignant syndrome, 1060
 for parkinsonism, 999–1000
 for restless legs syndrome, 1004
 Dopamine antagonists. *See also* Antipsychotic drugs
 for nausea and vomiting, 568*t*, 569
 Doppler ultrasound. *See* Echocardiography; Ultrasonography
 Dor procedure, 340
 Doral. *See* Quazepam
 Doripenem, for abdominal infections, 1455, 1455*t*
 Dornase alpha (rhDNase)
 for cystic fibrosis, 268
 pleural instillation of, 316
 Dorzolamide, for glaucoma/ocular hypertension, 171*t*, 176
 Dorzolamide/timolol, for glaucoma/ocular hypertension, 171*t*, 176
 DOT. *See* Directly observed therapy
 Double-stranded DNA antibodies
 in hyperthyroidism, 1113
 in lupus/SLE, 114, 833, 833*t*
 Double vision. *See* Diplopia
 Down syndrome (trisomy 21), 1666–1667
 prenatal screening for, 783, 1666
 Doxazosin, 456*t*
 adverse ophthalmic effects of, 195*t*, 196*t*
 for benign prostatic hyperplasia, 959, 959*t*, 960
 for hypertension, 453, 456*t*
 Doxepin, 1070*t*. *See also* Antidepressants
 for anogenital itching, 146
 topical, 94, 98*t*
 for urticaria, 133
 Doxercalciferol, for hyperparathyroidism, 1143–1144
 Doxil. *See* Liposomal doxorubicin
 Doxorubicin, 1653*t*
 for bladder cancer, 1639
 for breast cancer, 736
 liposomal, 1653*t*, 1662
 for Kaposi sarcoma, 145, 1332, 1339*t*
 toxicity of, 1653*t*, 1662
 Doxycycline
 for acne, 127
 adverse ophthalmic effects of, 197*t*
 for anthrax, 1432, 1433*t*
 for bacterial rhinosinusitis, 216*t*
 for impetigo, 123
 for Lyme disease, 1481, 1482
 for malaria, 1492*t*, 1494*t*, 1497
 for chemoprophylaxis, 1497, 1498, 1498*t*
 for malignant pleural effusion, 1646
 for pneumonia, 273*t*
 for rosacea, 129
 for syphilis, 1468*t*
 for urinary tract infection, 940*t*
 for *Wolbachia* eradication in filariasis, 1526
 in onchocerciasis, 1527
 DPI. *See* Dry powder inhalers
 DPOA-HC. *See* Durable Power of Attorney for Health Care
 DPOAF. *See* Durable power of attorney for finance matters
 DPP-4, 1211
 DPP-4 inhibitors, 1207*t*, 1212–1213, 1221
 DPP (Diabetes Prevention Program), 1202
 DPT-1 (Diabetes Prevention Trial-1), 1201
Dracunculus medinensis (dracunculiasis), 1520–1521
 Drawer sign/test
 anterior
 ankle sprain and, 1703, 1704*t*
 knee stability/ACL injury and, 1693–1698, 1694*t*
 posterior, 1696*t*, 1699
 DRE (digital rectal examination). *See* Rectal examination
 Dream sleep, 1075
 DRESS mnemonic, 160–161
 Dressler syndrome (postmyocardial infarction/postcardiotomy pericarditis), 375, 419, 419–420, 420
 Drinking. *See also* Alcohol use/dependency/abuse
 at-risk/problem, 18, 1080
 differential diagnosis of, 1081
 treatment of, 1081–1082
 Driving (automobile)
 by patients with dementia, 62, 1010
 by patients with syncope/ventricular tachycardia/aborted sudden death, 397–398
 by suicidal patients, 1065
 Dronabinol (Δ^9 -tetrahydrocannabinol) for AIDS wasting, 1325

- for nausea and vomiting, 86, 569
 - in HIV infection/AIDS, 1325
- Dronedarone, 377, 379t, 387
- Drooling, in esophageal foreign body, 239
- Drop attacks, epileptic (atonic seizures), 970. *See also* Seizures
- Droperidol
 - for migraine headache, 964
 - for nausea and vomiting, 569
 - overdose/toxicity of, 569, 1574
 - torsades de pointes caused by, 569
- Drospirenone, in oral contraceptives, 770, 771t
 - for hirsutism/virilization, 1163
 - hyperkalemia caused by, 1157
- Drotrecogin alfa (activated protein C)
 - for bacteremia/sepsis/shock, 488–489, 1444–1445
 - removal of from market, 489, 1445
- Drowning, 1556
 - near drowning and, 1555–1557
- Drug abuse, 18–20, 1079–1086. *See also* Substance use disorders
- Drug addiction, 1079. *See also* Substance use disorders
 - pain management in terminally ill/dying patient and, 76
- Drug allergy. *See also specific agent*
 - anaphylaxis and, 866
 - cross-reactivity and, 1306
 - desensitization therapy for, 1305–1307
 - in HIV infection/AIDS, 1322
 - testing for, 1305, 1306
 - in topical dermatologic therapy, 100, 158–160
- Drug dependency, 18–20, 1079–1086. *See also specific drug and* Substance use disorders
 - in opioid therapy, 76, 1083–1084
 - physiologic, 1079
 - psychologic, 1079
- Drug-eluting stents, 357, 358, 368
- Drug eruptions, 158–161, 159–160t
 - complex, 160–161
 - fixed, 159t
 - simple, 160
- Drug-induced disorders/side effects
 - abnormal movements, 1004
 - acute tubular necrosis, 904–905
 - adrenal insufficiency, 1156
 - agranulocytosis, 510
 - allergic reactions. *See* Drug allergy
 - anion gap acidosis, 891
 - aseptic meningitis, 1286
 - asthma, 243, 312t
 - cholestasis, 683
 - cognitive disorders/delirium, 64, 1087t
 - constipation, 570, 570t
 - depression, 63, 1064
 - dermatitis (dermatitis medicamentosa), 158–161, 159–160t
 - diarrhea, 574t, 577
 - dyspepsia, 564, 565
 - dysthyroid eye disease, 1117
 - dystonia, 1004, 1060–1061
 - in elderly, 71–72
 - depression, 63
 - falls, 65, 67t
 - incontinence, 67
 - eosinophilic pulmonary syndromes, 296
 - erectile/sexual dysfunction, 952, 1051, 1067
 - erythema multiforme, 134, 135
 - erythema nodosum, 150, 159t
 - exfoliative dermatitis/erythroderma, 116, 159t
 - fatty liver disease (hepatic steatosis), 683
 - fetotoxicity, 782, 782t
 - fever, 1283
 - G6PD deficiency, 503
 - gastritis/gastropathy, 607
 - goiter, 1106
 - gout/hyperuricemia, 814–815
 - gynecomastia, 1174t, 1178
 - hallucinations/hallucinoses, 1088
 - Hashimoto thyroiditis, 1120
 - headache (analgesic rebound/medication overuse headache), 966
 - heart failure, 401
 - hepatitis, 161, 683
 - hirsutism, 1162, 1164
 - hyperglycemia, 1193t, 1196
 - hyperkalemia, 879–880, 928
 - hyperpigmentation, 155, 160t
 - nail, 157, 160t
 - hyperthermia, 35, 36
 - hypoglycemia, 1238t, 1243–1244, 1580
 - hyponatremia, 871f, 872, 874
 - hypothyroidism, 1106, 1109
 - interstitial lung disease, 292t, 312t
 - interstitial nephritis, 906–907
 - lichenoid/lichen planus-like, 144, 159t
 - liver disease/failure, 672–673, 682–684
 - long QT syndrome, 393
 - lower extremity edema, 33
 - lung disease, 292t, 311, 312t
 - lupus/SLE, 114, 159t, 312t, 832, 832t
 - male infertility, 954, 955
 - meningeal irritation, 1287
 - microscopic colitis, 650
 - microscopic polyangiitis, 851
 - myocarditis, 409t, 410–411
 - myopathy, 1036
 - myotonia, 1036
 - nail hyperpigmentation, 157, 160t
 - nausea and vomiting, 567t
 - neutropenia, 510
 - nipple discharge, 720
 - olfactory disorders, 220
 - ototoxicity, 207, 210t
 - overdoses. *See* Poisoning/drug overdose
 - palpitations, 31, 32
 - pancreatitis, 711
 - parkinsonism, 998, 1004, 1061
 - pemphigus, 138
 - pheochromocytoma attacks/paroxysms and, 1167, 1169
 - photosensitivity/photodermatitis, 95t, 152–153, 159t
 - pigmentary changes, 155, 160t
 - pityriasis rosea-like eruption, 109, 160t
 - platelet dysfunction, 548–549, 549t
 - pompholyx-like eruption, 121
 - porphyria, 1664, 1665t
 - cutanea tarda, 122
 - psoriasis/psoriasiform, 107, 160t
 - psychotic behavior, 1055
 - pulmonary disorders, 292t, 311, 312t
 - pulmonary hypertension, 424
 - pure red cell aplasia, 500
 - Raynaud phenomenon, 837
 - rhabdomyolysis/myopathy/myositis, 842, 844
 - rhinitis (rhinitis medicamentosa), 214
 - SIADH, 873, 873t
 - sick sinus syndrome, 394
 - Stevens-Johnson syndrome, 134, 135, 159t, 161
 - teratogenicity, 782, 782t
 - thrombocytopenia, 546, 547t
 - torsades de pointes, 393, 1564, 1564t
 - toxic epidermal necrolysis, 134, 135, 159t, 161
 - tubulointerstitial nephritis, 932–933, 932t, 933
 - urticaria, 133, 159t

Drug-induced hypersensitivity syndromes (complex drug eruptions), 160–161

Drug monitoring (therapeutic), 1722–1724t. *See also specific agent* in elderly, 72

Drug overdose. *See* Poisoning/drug overdose

Drug resistance. *See also specific agent* in anaerobic infections, 1454, 1455 in anthrax, 1432 in antiretroviral therapy, 675–676, 1340, 1342, 1347, 1348–1349, 1348f in bacterial rhinosinusitis, 215–216 in breast cancer therapy, 740–741 in cryptococcosis, 1536 in enterococcal infections, 1422 in gonococcal infection, 860, 1452, 1452–1453 in *H pylori* infection, 613 health care-associated infections and, 1282–1283 in HIV infection/AIDS, 675–676, 1340, 1342, 1347, 1348–1349, 1348f in influenza, 1396, 1399 in leishmaniasis, 1488, 1489 in leprosy, 1460 in malaria, 1492, 1493, 1494, 1494t, 1495, 1496, 1497, 1498, 1498t in meningococcal infection, 1442 pharyngitis treatment and, 228, 229, 1420 in pneumococcal infections, 228, 273, 273–274, 1423, 1424 in *Pneumocystis jiroveci* pneumonia, 1534 *Salmonella* infection and, 1446 in staphylococcal infections, 1425. *See also Staphylococcus* (staphylococcal infections), *aureus*, methicillin-resistant susceptibility testing and, 1301–1304 in HIV infection/AIDS, 1347, 1348–1349, 1348f in nontuberculous mycobacterial infection, 288, 1458 in tuberculosis, 281, 281t, 285 in syphilis, 1467 in tuberculosis, 280, 285, 286 directly observed therapy (DOT) and, 284, 285, 286 treatment of contacts and, 286

- Drug susceptibility testing, 1301–1304.
See also Drug resistance
 in HIV infection/AIDS, 1347, 1348–1349, 1348f
 in nontuberculous mycobacterial infection, 288
 in tuberculosis, 281, 281t, 285
- Drug tolerance, 1079. *See also* Substance use disorders
 in opioid therapy, 76, 79
 in stimulant abuse, 1085
- “Drugs of abuse” toxicology screen, 1569–1570
- Drusen
 in age-related macular degeneration/maculopathy, 181
 optic disk, 189–190
- Dry eye (keratoconjunctivitis sicca), **166**
 in Sjögren syndrome, 843
- Dry mouth
 antipsychotics causing, 1059
 in Sjögren syndrome, 843
- Dry powder inhalers, for asthma therapy, 250
- Dry skin
 atopic dermatitis and, 103
 emollients for, 94, 98–99t
- Drying agents, for weepy dermatoses, 94
- DTaP vaccines. *See* Diphtheria and tetanus toxoids and pertussis vaccine
- DTI. *See* Direct thrombin inhibitors
- DTIC-Dome. *See* Dacarbazine
- Dual-chamber pacing, 395
 for cardiomyopathy, 415
 for heart block, 395
 for sick sinus syndrome, 394
- Dual energy x-ray absorptiometry, in osteoporosis, 622, 1141, 1145–1146
- Dubin-Johnson syndrome, 662, 663t
- Duchenne muscular dystrophy, 1034, 1035t
 cardiomyopathy in, 427
- Duct occluder devices, for patent ductus arteriosus, 333
- Ductal carcinoma in situ, 733, 733t
 Paget carcinoma and, 730
- Ductal lavage, in breast mass evaluation, 730
- Ductography, in nipple discharge/breast cancer, 720, 729, 730
- Ductopenia, idiopathic adulthood, 710
- Ductoscopy, in nipple discharge/breast cancer, 720, 729
- Ductus arteriosus, patent, **332–333**, 333t
- Duetact. *See* Pioglitazone, with glimepiride
- Duke criteria (modified), for endocarditis, 1436–1437
- Duke Treadmill Score, 358, 358t
- Duloxetine, 1067, 1068, 1070t
 for anxiety, 1043
 for neuropathic pain/diabetic neuropathy, 84t, 85, 1021, 1067, 1225
 overdose/toxicity of, 1068, 1070t
 for postherpetic neuralgia, 121
 for urinary incontinence, 69
- Dumping syndrome, after gastric surgery, 1220
 hypoglycemia and, 1242
- Duncan disease, 1363
- Duodenal neuroendocrine tumors, **1171–1173**
- Duodenal ulcers, 611, 612, 613, 614t, 615, 616, 619. *See also* Peptic ulcer disease
- Duodenotomy, for Zollinger-Ellison syndrome (gastrinoma), 620
- Duodenum. *See also* Small intestine disorders of, **607–621**
 adenoma/carcinoma, 655, 1607–1612, 1620
- DuoTrav. *See* Travoprost/timolol
- Duplex ultrasonography. *See* Ultrasonography
- Dupuytren contracture, **824**
 in cirrhosis, 686, 824
- Durable power of attorney for finance matters (DPOAF), for dementia patients, 62
- Durable Power of Attorney for Health Care (DPOA-HC), 89
- Duroziez sign, 344
- Dust mites, atopic dermatitis caused by, 103, 866
- Dutasteride, for benign prostatic hyperplasia, 959–960
- DVT. *See* Deep venous thrombosis
- Dwarf tapeworm (*H nana*), **1514**
- Dwarfism, in GH deficiency, 1094
- DXA. *See* Dual energy x-ray absorptiometry
- Dyazide. *See* Triamterene, with hydrochlorothiazide
- Dying patient, care of. *See* End of life, provision of care at
- Dymelor. *See* Acetohexamide
- DynaCirc/DynaCirc CR. *See* Isradipine
- Dysarthria, in motor neuron disease, 1019
- Dysautonomia (autonomic dysfunction), **975–976**
 in diabetes, 1022, 1226–1227
 in focal seizures, 969
 in Guillain-Barré syndrome, 975, 1024
 in polyneuropathies, 975, 976, 1021
 prenatal screening for, 783
- Dysbarism, **1557–1558**
- Dysbetalipoproteinemia, 1245
- Dysentery, 575
 amebic, 575, 1503, 1505t
 colitis after (postdysenteric colitis), 1504
 bacillary (*Shigella*). *See* Bacillary dysentery
 enteroinvasive *E coli* causing, 574t, 575, 1293, 1447
 reactive arthritis and, 857
 in trichuriasis/whipworm, 1517–1518
Trichuris, 1517–1518
- Dysequilibrium (imbalance). *See also* Vertigo
 falls/gait disorders in elderly and, 65, 67t
 in multiple sclerosis, 213, 1010
 posttraumatic headache and, 965
 in vestibular schwannoma (acoustic neuroma), 212
- Dysesthesias, 976
- Dysfunctional uterine bleeding, 747, 748
 estrogen replacement therapy and, 748, 1183, 1185
- Dysgeusia, **226**
- Dyshidrosis/dyshidrotic eczema. *See* Vesiculobullous hand eczema
- Dyskinesia
 in Huntington disease, 1001, 1002
 levodopa-induced, 999
 tardive, 1004, 1061
 metoclopramide causing, 566, 629
- Dyslipidemia. *See also* Hyperlipidemia
 antiretroviral therapy and, 1332, 1344
 in diabetes mellitus, 1197, 1200–1201, 1247, 1248t
 exercise affecting, 12–13
- Dysmenorrhea, **750–751**, 1715, 1716
 endometriosis and, 750, 761, 1715
 IUD use and, 750, 774
 oral contraceptive use and, 750, 770
- Dysmetabolic iron overload syndrome, 684
- Dysmotility. *See* Motility disorders
- Dysnomia, intracranial tumors causing, 990
- Dysorgasmia. *See* Orgasm, loss of
- Dyspareunia (painful intercourse), 767, 1715
- Dyspepsia, **564–566**. *See also* Abdominal pain/tenderness
 alarm symptoms in, 565
 functional, 564, 565, 566
 in gastric cancer, 564, 1616
 GERD and, 564, 594
 in NSAID gastritis, 608
 in peptic ulcer disease, 564, 565, 612, 613
- Dysphagia, 592, 592–593, 592t
 in achalasia, 592t, 604
 barium esophagography in, 592–593
 chemoradiation-associated, 237
 in eosinophilic esophagitis, 592t, 600
 in esophageal cancer, 592t, 1613, 1614
 in esophageal stricture, 592t, 595
 in esophageal webs and rings, 491, 592t, 600
 in GERD, 594
 in infectious esophagitis, 598
 in motility disorders, 592, 592t, 605–606
 in motor neuron disease, 1019, 1020
 in pill-induced esophagitis, 598, 599
 in polymyositis/dermatomyositis, 840
 in scleroderma, 592t, 838, 839
 in Zenker diverticulum, 601
- Dysphasia, in stroke, 981
- Dysphonia, **233**
 in laryngopharyngeal reflux, 234
 in vocal fold lesions, 235
 in vocal fold paralysis, 237
- Dysphoric disorder, premenstrual, 749, 1063
- Dysplastic nevi. *See* Atypical nevi/mole
- Dyspnea, **24–26**, 24t, 25t, **85–86**
 in aortic regurgitation, 344
 in ARDS, 322
 in asthma/asthma exacerbations, 24, 246t, 247t
 in cardiomyopathy, 414
 in COPD, 24, 24t, 25, 26, 260, 260t, 264, 265

- cough and, 21, 22, 24
 in heart failure, 25, 398, 399
 in hepatopulmonary syndrome, 691
 in interstitial (diffuse parenchymal) lung disease, 292
 in malignant pleural effusion, 1645, 1646
 palliation of, 26, **85–86**, 265
 in pneumothorax, 24, 316
 psychogenic, 24, 25
 in pulmonary alveolar proteinosis, 296
 in pulmonary edema, 407–408
 in pulmonary embolism, 24, 25, 298, 298t
 in pulmonary hypertension, 305
 in respiratory failure, 320
 in terminally ill/dying patient, 26, **85–86**, 265
 in vocal fold dysfunction, 25, 242
- Dysport. *See* Botulinum toxin therapy
- Dysrhythmias. *See* Arrhythmias
- Dyssomnias, **1075–1077**. *See also* Insomnia
- Dyssynergia, pelvic floor (dyssynergic defecation), 570, 570t, 571
- Dysthymia, 1063, 1065. *See also* Depression
- Dysthyroid eye disease, **191**, 1110, 1112–1113, 1117–1118
 RAI treatment for hyperthyroidism and, 1115–1116, 1117–1118
- Dystocia, maternal diabetes and, 800
- Dystonia
 drug-induced, 1004
 antipsychotics, 1060–1061, 1574
 SSRIs, 1067
 oromandibular, 1003
 torsion
 focal, **1003**
 idiopathic, **1002–1003**
- Dystrophin, in muscular dystrophy, 1034, 1035t
- Dysuria (painful voiding), **43–45**, 44f. *See also* Irritative voiding symptoms
- DYT1* gene, in idiopathic torsion dystonia, 1002
- DYT6/DYT7* genes, in focal torsion dystonia, 1003
- E-cadherin cell adhesion protein, gastric cancer and, 1616
- E coli*. *See* *Escherichia coli*
- E-tests, drug susceptibility, 1304
- EACA. *See* ϵ -Aminocaproic acid
- Ear, **198–213**. *See also under* Hearing barotrauma affecting, **202–203**
 cauliflower, 199
 in HIV infection/AIDS, **213**
 inner, **206–212**
 middle, **203–206**
 painful. *See* Earache
- Ear canal, **200–201**
 bony overgrowths (exostoses/osteomas) of, **201**
 foreign body in, **200**
 neoplasia of, **201**
 pruritus of, **201**
- Ear drops
 for cerumen removal, 200
 for external otitis, 200
 ototoxic, avoidance of with perforated tympanic membrane, 207
- Earache (otalgia), **206**
 in acute otitis media, 203, 206
 barotrauma and, 202
 in external otitis/malignant external otitis, 200, 206
- East African trypanosomiasis, 1484, 1485, 1485t
- Eastern (equine) encephalitis, 1378–1380
- Eastern subtype tick-borne encephalitis, 1391
- Eating disorders, **1262–1263**. *See also* specific type
 OCD and, 1041
 in women, **1712–1714**
 in diabetes, **1713**
- Eaton-Lambert syndrome. *See* Lambert-Eaton (myasthenic) syndrome
- Ebastine, for allergic/perennial rhinitis, 219
- EBCT. *See* Electron beam CT
- Ebola virus/hemorrhagic fever, 1384, 1385
- Ebstein anomaly, 347
 lithium use during pregnancy and, 1073
- EBV. *See* Epstein-Barr virus
- EC regimen, for breast cancer, 736
- Ecchymosis
 of eye (black eye), 192
 in nasal trauma, 221
 malabsorption and, 621t
- ECG. *See* Electrocardiogram
- Echinacea purpurea*
 for benign prostatic hyperplasia, 960
 for cough prevention, 23
- Echinocandins, 1530, 1542. *See also* specific agent
- Echinococcus granulosus/multilocularis* (echinococcosis), **1516**
- Echocardiography. *See also* Ultrasonography
 in angina, 353
 in aortic dissection, 477
 in aortic regurgitation, 336t, 345
 in aortic stenosis, 336t, 342, 344
 in atrial septal defect/patent foramen ovale, 328
 in cardiac tumors, 427
 in cardiomyopathy, 412, 412t, 414, 416
 cardioversion for atrial fibrillation and, 386
 in coarctation of aorta, 327
 in constrictive pericarditis, 422
 in cor pulmonale, 426
 in Dressler syndrome, 419–420
 in endocarditis, 1436
 in heart failure, 400
 in hypertension, 440
 in infectious myocarditis, 410
 in mitral regurgitation, 336t, 339
 in mitral stenosis, 336t, 338
 in mitral valve prolapse, 340, 341
 in myocardial infarction, 366
 in patent ductus arteriosus, 333
 in pericardial effusion/tamponade, 421
 in pulmonary edema, 408
 in pulmonary hypertension, 305, 424
 in pulmonary stenosis, 325, 326
 in pulmonary valve regurgitation, 348
 in shock, 486, 487
 stress/dobutamine stress
 in angina, 353
 in heart failure, 400
 preoperative, 46–47, 48f
- in Tako-Tsubo cardiomyopathy, 413
 in tetralogy of Fallot, 331
 in tricuspid regurgitation, 336t, 347
 in tricuspid stenosis, 336t, 346
 in valvular heart disease, 336t
 in ventricular septal defect, 330
- Echolalia
 in schizophrenia/psychotic disorders, 1054
 in Tourette syndrome, 1005
- Echopraxia, in Tourette syndrome, 1005
- Echovirus 1, in cancer treatment, 1407
- Echovirus infections, **1406–1407**
 pericarditis, 419
- Eclampsia, 793, 794, 794–795. *See also* Preeclampsia-eclampsia
 hypermagnesemia associated with treatment of, 794, 888
- Econazole, 97t
- ECP. *See* Extracorporeal counterpulsation
- “Ecstasy,” 1086, 1572
 “herbal” (ephedrine), 1572
 hyponatremia caused by, 872
 seizures caused by, 1565t
- ECT. *See* Electroconvulsive therapy
- Ectasias, GI bleeding in, 581, 584, 586, 587
- Ecthyma, 123
 contagiosa (orf), 1404
- Ectopia lentis
 in homocystinuria, 1669
 in Marfan syndrome, 1670
- Ectopic pregnancy, **790–791**
 elective abortion and, 776
 hCG levels in, 781, 790
 IUDs and, 774
 minipill use and, 773
 PID and, 763
 ruptured, appendicitis differentiated from, 631, 790
- Ectropion, **164**
- Eculizumab
 for atypical hemolytic-uremic syndrome, 543
 for paroxysmal nocturnal hemoglobinuria, 502
- Eczema. *See also* Atopic dermatitis
 dyshidrotic. *See* Eczema, vesiculobullous hand
 herpeticum, 104, 1351, 1356t
 vaccinatum, 104, 1403, 1404
 vesiculobullous hand (pompholyx), **121–122**, 121f
 tinea differentiated from, 113
- Edecrin. *See* Ethacrynic acid
- Edema
 arm, in breast cancer/postmastectomy, 727, 744
 in burn injury, 1550
 in cirrhosis, 33, 687–689
 in filariasis, 1525, 1525f
 in glomerulonephritis, 907, 918, 920
 in heart failure, 398–399, 401
 hyponatremia and, 873
 lower extremity, **33–34**, 33t. *See also* Lower extremity edema

- Edema (*Cont.*):
 malabsorption and, 621t
 in nephrotic syndrome, 33, 34, 927, 928
 optic disk. *See* Optic disk, swelling of
 in preeclampsia-eclampsia, 792, 793
 refeeding, 1258
 Reinke, 235
 in superior vena caval obstruction, 482
 thiazolidinediones causing, 1210
 in venous insufficiency, 33, 34, 481
 leg ulcers and, 33, 34, 153, 481
 volume overload and, 877
- Edetate calcium disodium (EDTA), for
 lead poisoning, 933, 1582
- EDIC (Epidemiology of Diabetes
 Interventions and
 Complications) study, 1201
- EDTA. *See* Edetate calcium disodium
- Efalizumab, progressive multifocal
 leukoencephalopathy caused
 by, 1383
- Efavirenz, 1342t, 1345, 1346, 1347, 1348f.
See also Antiretroviral
 therapy/HAART
 fetal anomalies caused by, 805, 1346
 with tenofovir and emtricitabine, 1344,
 1346, 1347, 1348f
- Effexor. *See* Venlafaxine
- Effusions. *See* Malignant effusions;
 Pericardial effusions; Pleural
 effusions
- Effusive-constrictive pericarditis, 422
- Eflornithine
 for African trypanosomiasis, 1485,
 1485t
 for hirsutism/virilization, 1163
- Egatin. *See* Triclabendazole
- eGFR. *See* Estimated glomerular filtration
 rate
- EGFR (epidermal growth factor)
 mutations/inhibitors
 in colorectal cancer, 1625
 in gastric carcinoma, 1617
 in lung cancer, 1600
 in pancreatic/periapillary
 carcinoma, 1609
- EGWs. *See* External genital warts
- EHEC. *See* *Escherichia coli*,
 enterohemorrhagic
- Ehlers-Danlos syndrome
 aortic disorders/aneurysm in, 428, 474
 pregnancy and, 431
 mitral valve prolapse in, 340
- Ehrlichia canis/chaffeensis/ewingii/muris*
 (ehrlichiosis), 1356t, 1409t,
 1414-1415
 babesiosis coinfection and, 1415
 Lyme disease coinfection and, 1415,
 1481
- EIA. *See* Enzyme immunoassay
- EIC. *See* Epidermal inclusion cysts
- EIEC. *See* *Escherichia coli*, enteroinvasive
EIF2AK3 gene, in diabetes, 1196
- Eighth nerve lesions. *See* Schwannoma,
 vestibular
- Eikenella corrodens*. *See* HACEK
 organisms
- Eisenmenger physiology
 in atrial septal defect, 328
 in patent ductus arteriosus, 332, 333
 pulmonary hypertension and, 424
 in ventricular septal defect, 329, 330
- Ejaculate, for semen analysis. *See* Semen
 analysis
- Ejaculation disturbances, 951, 1050. *See*
also Erectile dysfunction/
 impotence
 antidepressants causing, 1067, 1069
 antipsychotics causing, 1059
 after benign prostatic hyperplasia
 treatment, 958t, 960
 in infertility, 955
- Ejaculatory ducts, obstruction of, in
 infertility, 955-956
- Ejection clicks. *See* Clicks
- Ektacytometry, in hereditary
 spherocytosis, 501
- ELA-2/ELANE* gene defect, in
 neutropenia, 510
- Elapid (coral snake) envenomation,
 1589-1590
- Elastase, fecal
 in diarrhea, 580
 reference values for, 1733t
- Elastic compression stockings. *See*
 Compression stockings
- Elastography, in liver disease/cirrhosis,
 687
- Elavil. *See* Amitriptyline
- Elbow
 bursitis of, 825, 825f, 826
 tennis or golf, 1688
 ulnar nerve lesions at, 1026
- Elder mistreatment, 17, 72-73, 73t
- Elderly patients. *See* Geriatric medicine;
 Older adults
- Electric burns, 1550, 1552-1553
- Electrical alternans, in pericardial
 effusion, 421
- Electrical cardioversion. *See*
 Cardioversion, electrical
- Electrical injury, 1550, 1552-1553
- Electrocardiogram (ECG). *See also specific
 disorder*
 in acute coronary syndromes, 361
 in acute kidney injury, 902
 ambulatory monitoring of
 in angina, 354
 in atrial fibrillation, 388
 in seizure evaluation, 971
 in syncope evaluation, 397
 in ventricular premature beats, 390
 in angina, 352
 antidepressants affecting, 1068, 1591,
 1591f
 antipsychotic drugs affecting, 1057,
 1057-1058, 1058, 1059
 in aortic dissection, 477
 in aortic regurgitation, 335t, 345
 in aortic stenosis, 335t, 342
 in atrial fibrillation, 384, 385
 in atrial flutter, 389
 in atrial septal defect/patent foramen
 ovale, 328
 in cardiac tumors, 427
 in cardiomyopathy, 412, 412t, 414, 416
 in chest pain evaluation, 28t, 29
 in coarctation of aorta, 327
 in COPD, 261
 in cor pulmonale, 426
 exercise/stress
 in angina, 352-353
 before exercise program initiation,
 12
 in heart failure, 400
 in hyperkalemia, 880
 in hypertension, 440
 in hypokalemia, 879
 in hypothermia, 1544, 1544f
 in infectious myocarditis, 410
 lithium affecting, 1073
 in mitral regurgitation, 335t
 in mitral stenosis, 335t
 in myocardial infarction, 366
 in palpitations, 31, 32, 32t
 in paroxysmal supraventricular
 tachycardia, 382
 in patent ductus arteriosus, 332
 in pericardial effusion, 421
 in pericarditis, 420
 uremic, 912
 preoperative, 46
 in pulmonary embolism, 298
 in pulmonary hypertension, 305, 424
 in pulmonary stenosis, 325
 in syncope, 397
 in tetralogy of Fallot, 331
 in tricuspid regurgitation, 335t, 347
 in tricuspid stenosis, 335t, 346
 in valvular heart disease, 335t
 in ventricular premature beats, 390
 in ventricular septal defect, 330
- Electrocautery, radiofrequency wave
 ablation (HALO), for Barrett
 esophagus, 595
- Electroconvulsive therapy (ECT), 1065,
 1069-1071
 for catatonia, 1058
 for neuroleptic malignant syndrome,
 1060
- Electrodesiccation and curettage
 for basal cell carcinoma, 142
 for squamous cell carcinoma, 143
- Electroencephalogram (EEG)
 in Creutzfeldt-Jakob disease, 1382
 in epilepsy partialis continua, 1004
 in epilepsy, 971
 absence (petit mal) seizures and,
 970, 971
 focal seizures and, 971
 nonconvulsive status epilepticus
 and, 975
 solitary seizure and, 974
 in intracranial tumors, 991
 isoelectric, in brain death
 determination, 1015
 in psychogenic nonepileptic/
 pseudoepileptic seizure
 identification, 972, 1045
 in sleep, 1075
- Electrolytes. *See also specific type
 disorders of concentration of, 870-888.*
*See also specific electrolyte
 and Fluid and electrolyte
 disorders*
 genetic disorders and, 878t
 replacement guidelines for, 897t
 requirements for in nutritional
 support, 897t, 1272

- Electromyography
 in back pain evaluation, 1684
 in carpal tunnel syndrome, 824, 1689
 in motor neuron disease, 1019–1020
 in muscular dystrophy, 1034
 in myasthenia gravis, 1032
 in myotonic dystrophy, 1034
 in polymyositis/dermatomyositis, 841
- Electron beam CT (EBCT)
 in angina, 354
 for heart disease screening, 1250
- Electrostygmography (ENG), in
 vertigo, 210, 212
- Electrophoresis. *See* Hemoglobin
 electrophoresis;
 Immunofixation
 electrophoresis; Serum
 protein electrophoresis
- Electrophysiologic testing
 in multiple sclerosis, 1011
 in myasthenia gravis, 1032
 in syncope evaluation, 397
- Electrovaporization of prostate,
 transurethral, for benign
 prostatic hyperplasia, 961
- Elemental nutritional support solutions,
 1273
- Elephantiasis
 in chromoblastomycosis, 1540
 in filariasis, 1525, 1525*f*
- Elestat. *See* Epinastine
- Elestrin, 1184
- Eletriptan, for migraine headache, 964
- Elevated intraocular pressure
 in acute angle closure glaucoma, 174
 in chronic glaucoma, 176
- Elidel. *See* Pimecrolimus
- ELISA. *See* Enzyme-linked
 immunosorbent assay
- Elitek. *See* Rasburicase
- Ellence. *See* Epirubicin
- Elmiron. *See* Pentosan
- Elocon. *See* Mometasone
- Elongation factor, diphtheria and, 1433
- Eloxatin. *See* Oxaliplatin
- Elspar. *See* Asparaginase
- Eltrombopag
 for myelodysplastic syndromes, 518,
 540
 for thrombocytopenia
 chemotherapy-induced, 540, 1659
 immune, 542
- Elvitegravir, 1347. *See also* Antiretroviral
 therapy/HAART
- Emadine. *See* Emedastine
- Embolectomy
 in acute arterial limb occlusion, 468
 pulmonary, 303
- Embolism. *See also* Thromboembolism;
 Venous thromboembolic
 disease
 acute arterial limb occlusion caused by,
 468
 in atrial fibrillation, 384–385, 385*t*
 in atrial flutter, 389
 in atrial septal defect/patent foramen
 ovale, 328, 329
 carotid sources of, 469
 cerebrovascular occlusion and, 469–
 470, 982. *See also* Stroke
 in endocarditis, 1435, 1437, 1439
 gas, in decompression sickness, 1557
 in heart failure, 297, 405
 mesenteric, 470, 471
 in mitral stenosis, 338
 in myocardial infarction, 375
 paradoxical. *See* Paradoxical embolism
 peripheral arterial aneurysms and,
 475–476
 during pregnancy, 431
 pulmonary. *See* Pulmonary venous
 thromboembolism
 in retinal artery occlusion, 183
 in transient ischemic attacks, 469, 977,
 978–979
 in transient monocular blindness, 184,
 469, 981
- Embolization
 for GI bleeding, 583, 585, 618
 for hemoptysis, 27
 for pulmonary AVMs in hereditary
 hemorrhagic telangiectasia,
 1672
- Embryo. *See* Fetus
- Embryonal cell carcinoma, of testis, 1642
- Emcyt. *See* Estramustine
- Emedastine, for allergic eye disease, 167,
 169*t*
- Emergencies
 hypertensive. *See* Hypertensive
 emergencies
 in-flight (air travel), 1560
- Emergency/postcoital contraception, 776
 IUD for, 774, 776
- Emery-Dreifuss muscular dystrophy,
 1035*t*
- Emesis. *See also* Nausea and vomiting
 for poisoning/drug overdose, 1566
- Emetine, for amebiasis, 1504, 1505*t*
- Emission, loss of (anejaculation), 951,
 1050. *See also* Erectile
 dysfunction/impotence
- EML4-ALK fusion gene product, in lung
 cancer, 1600
- Emmetropia, 162
- Emollients, 94, 98–99*t*
 for atopic dermatitis, 103
- Emotional challenges, for terminally ill/
 dying patient, 91–92, 92*t*
- Emotional laryngeal wheezing, 248
- Emotive imagery, in anxiety disorders,
 1044
- Emphysema, 259, 260*t*. *See also* Chronic
 obstructive pulmonary
 disease
 α_1 -antiprotease/antitrypsin deficiency
 in, 260
 replacement therapy and, 264
 bullectomy for, 265
 complications of, 261
 imaging findings in, 261
 lung volume reduction surgery for, 265
 panacinar bibasilar, 261
- Emphysematous pyelonephritis, 941
- Empty can test, 1677*t*
- Empyema
 anaerobes causing, 278, 279, 1455
 group A streptococci causing, 1421
 middle ear, 203. *See also* Otitis, media
 pleural, 278, 279, 313, 314*t*, 315
 in pneumococcal pneumonia, 1423
 subdural, 1455
- Emsam. *See* Selegiline, transdermal
- Emtansine, for breast cancer, 741
- Emtricitabine, 1341*t*, 1343, 1348*f*, 1353*t*.
See also Antiretroviral
 therapy/HAART
 for hepatitis B, 676, 1329, 1343, 1353*t*
 resistance to, 1349
 with tenofovir, 1343, 1344, 1347, 1348*f*
 prophylactic, 1291, 1333
 with tenofovir and efavirenz, 1344,
 1346, 1347, 1348*f*
 with tenofovir and rilpivirine, 1346,
 1347
- Emtriva. *See* Emtricitabine
- Enalapril, 450*t*
 for heart failure, 402
 for hypertension, 450*t*
 with hydrochlorothiazide, 450*t*
- Enalaprilat, for hypertensive urgencies/
 emergencies, 462*t*, 463
- Enbrel. *See* Etanercept
- Encainide, toxicity of, 377
- Encephalitis, 1286. *See also*
 Meningoencephalitis
 acanthamoeba, 1287, 1505–1506, 1506
 amebic, 1287, 1506
 anti-NMDA receptor-associated, 995
 arbovirus, 1378–1380
 CMV, 1364
 in coxsackievirus infection, 1406
 enterovirus 71 causing, 1407
 herpes simplex, 1351, 1352, 1355
 HHV-6 causing, 1366
 inclusion body, 1368
 Japanese B, 1378–1380
 immunization against, 1316, 1380
 limbic, 994–995
 in loiasis, 1527, 1528
 measles/measles vaccination and, 1368,
 1369
 mumps, 1371
 neuronal cell antibodies and, 995
 Nipah virus, 1393
 parechovirus infection causing, 1408
 parkinsonism after, 998
 rabies, 1376
 tick-borne, 1378, 1390–1391
 toxoplasma, 1501, 1502
 in varicella, 1359
 West Nile, 1378–1380
 yellow fever vaccine-associated, 1316,
 1390
- Encephalitozoon/Encephalitozoon
intestinalis, 1506, 1507
- Encephalomyelitis
 cancer-related, 995
 in Lyme disease, 1479
 measles/measles vaccine and, 1368, 1369
 optic neuritis and, 188
 yellow fever vaccine-associated, 1316,
 1390
- Encephalomyocarditis, neonatal,
 coxsackieviruses causing,
 1406
- Encephalopathy
 alcohol use/abuse and (chronic
 alcoholic brain syndromes),
 1081, 1083

- Encephalopathy (*Cont.*):
 bovine spongiform (vCJD/mad cow disease), 1381–1382, 1382
 in cancer, 994
 hepatic. *See* Hepatic encephalopathy
 hypertensive, 440, 460
 hyponatremic, 874
 in hypophosphatemia, 885
 in influenza, 1395
 lead, 1582
 gasoline sniffing and, 1086
 lithium causing, 1073
 in Lyme disease, 1479, 1480
 melarsoprol causing, 1485
 metabolic. *See* Metabolic encephalopathy
 in Reye syndrome. *See* Reye syndrome
 in rubella, 1375
 spongiform, **1381–1382**
 uremic, 914
 Wernicke, 893, **1013**, 1081, 1264
- End of life
 Kübler-Ross' stages of, 91
 patient expectations about, 87–88
 prognosis at, 87
 provision of care at, 87–93. *See also*
 Palliative care
 advance care planning/advance directives and, 89
 care of family and, 88–89, 88*t*
 clinician self-care and, 89
 communicating with patient and, 88, 88*t*
 cultural issues in, 90
 decision-making and, 89
 DNAR orders and, 89–90
 in hospice/palliative care program, 90
 nutrition/hydration needs and, 90–91
 pain management, **75–76**
 patient's wishes regarding, 89
 psychologic/social/spiritual issues and, 91–92, 92*t*
 tasks after death and, **92–93**
 withdrawal/withholding curative efforts and, 91, 91*t*
 advance directives and, 89
- End-stage renal disease (ESRD), 908, 909*t*, 915–916. *See also*
 Chronic kidney disease;
 Renal failure
 diabetic nephropathy and, 931, 1224
 GFR calculation in, 900
 hepatitis C infection and, 926
 immunization recommendations in, 1309*t*
 kidney function decline and, 910, 910*f*
 kidney transplantation for. *See* Kidney transplantation
 medical management of, 916
 pregnancy and, 914
 prognosis in, 916
 SLE and, 927
- Endarterectomy
 carotid. *See* Carotid endarterectomy/
 thromboendarterectomy
 visceral artery, for visceral ischemia, 471
- Endemic flea-borne (murine) typhus, 1409*t*, **1410–1411**
- Endemic goiter, **1134–1135**
- Endemic syphilis, **1475**
- Endocarditis
 infective, 1302*t*, **1435–1439**, 1436*f*, 1437*t*, 1438*t*
 anaerobic, **1456**
 anticoagulation and, 1439
 antimicrobial chemoprophylaxis and, 1437, 1437*t*, 1438*t*
 in hereditary hemorrhagic telangiectasia, 1671
 during pregnancy, **431**, 803
 aortic regurgitation and, 345
 back pain in, 819
 in bartonellosis, 1436, 1454
C psittaci causing, 1462
 candidal, 1530
Coxiella/Q fever, 1415, 1416
 in drug user, 1292, 1302*t*
 fever/FUO in, 1277
 gonococcal, 1452, 1453
 HACEK organisms causing, 1435, 1436, 1439
 in mitral regurgitation, 339
 native valve, 1435, 1437
 anticoagulation and, 1439
 pneumococcal, 1423
 prosthetic valve, 338, 1435, 1437, 1439
 anticoagulation and, 1439
 staphylococcal, 1302*t*, 1435, 1438–1439
 coagulase-negative organisms causing, 1428, 1435, 1439
 streptococcal, 1421, 1435, 1438
 viridans streptococci causing, 1302*t*, 1422, 1435, 1437–1438
 surgical management of, 1439
 tricuspid regurgitation and, 347
 valve replacement for, 349, 1439
 in ventricular septal defect, 330
 Libman-Sacks, 428
 in SLE, 833
- Endocervical curettage, 748*t*
 in abnormal premenopausal bleeding, 747
 in CIN/cervical cancer, 755, 757
 in endometrial carcinoma, 759
- Endoclips, for GI bleeding, 582, 585
 for Mallory-Weiss syndrome/tears, 582, 600
 in peptic ulcer disease, 618
- Endocrine disorders, **1093–1191**. *See also*
specific gland and specific disorder
 antipsychotic drug use and, 1059
 cancer-related, 1596*t*
 in chronic kidney disease, 914
 cognitive disorders/delirium caused by, 1087*t*
 in HIV infection/AIDS, 1330
 in MEN, **1188–1190**, 1188*t*. *See also*
 Multiple endocrine neoplasia
 preoperative evaluation/perioperative management and, **54–55**, 54*t*
 radiation exposure and, 1554
- Endocrine therapy. *See* Hormone therapy
- Endogenous unipolar disorder, 1063. *See also*
 Depression
- Endoglin (*ENG*) gene
 in hereditary hemorrhagic telangiectasia, 1671
 in pulmonary hypertension, 424
- Endoleaks, after abdominal aneurysm repair, 474
- Endolymphatic hydrops (Ménière syndrome), 210, 210*t*
 hearing loss and, 208, 210, 210*t*
- Endometrial ablation, for abnormal premenopausal bleeding, 748
- Endometrial biopsy, 748*t*
 in abnormal premenopausal bleeding, 747, 748
 in endometrial carcinoma, 759
 in postmenopausal bleeding, 749
- Endometrial carcinoma/cancer of uterus, **759**, 1611*t*
 breast cancer and, 722, 723*t*, 759
 estrogen replacement therapy and, 759, 779, 1183, 1185
 HNPCC and, 656, 657, 759
 incidence/mortality/risk of, 1594*t*
 oral contraceptive use and, 770, 772
 polycystic ovary syndrome and, 765, 1162
 postmenopausal bleeding and, 749, 759
- Endometrial curettage. *See* Endometrial biopsy
- Endometrial hyperplasia
 estrogen replacement therapy and, 1183, 1184, 1185
 postmenopausal bleeding caused by, 749
- Endometriosis, **760–762**
 dysmenorrhea and, 750, 761, 1715
 infertility and, 760
 pelvic pain and, 760, 761, 1714, 1715
- Endometritis, **762–764**, 798. *See also*
 Pelvic inflammatory disease
 amenorrhea and, 1180–1181
 clostridial, 777, 1429
 postabortion, 777
 postpartum, **798**
 clostridial, 1429
 streptococcal, 804
- Endomyocardial biopsy, in infectious myocarditis, 410
- Endomyocardial fibrosis, cardiomyopathy in, 415
- Endomyometritis, 798. *See also*
 Endometritis
- Endomysial antibodies, in celiac disease, 622
- Endophthalmitis, globe injuries causing, 193
- Endoscopic retrograde cholangiopancreatography (ERCP), 665
 in biliary stricture, 708
 in choledocholithiasis/cholangitis, 707, 708
 in liver disease/jaundice, 665
 in pancreatic/periampullary carcinoma, 1608
 in pancreatitis, 714, 716
 pancreatitis after, 714
 during pregnancy, 807
 in primary sclerosing cholangitis, 709, 1329
- Endoscopic ultrasonography. *See also*
 Ultrasonography
 in gastric adenocarcinoma, 1616, 1617
 in gastric lymphoma, 1618
 in gastrointestinal mesenchymal tumors, 1619

- in insulinoma detection, 1172, 1240
 in liver disease/jaundice, 665
 in pancreatic/periampullary carcinoma, 1608
 in pancreatitis, 713, 716, 717
 in Zollinger-Ellison syndrome/gastrinoma, 620
- Endoscopy**
 in achalasia, 605
 in celiac disease, 622
 in colorectal cancer screening/polyp identification/removal, 653, 653–654, 1626*t*, 1627–1628. *See also* Colonoscopy; Sigmoidoscopy
 in Crohn disease, 642
 in diarrhea, 579
 in dyspepsia, 565
 in erosive/hemorrhagic gastritis (gastropathy), 607, 608
 in esophageal disorders, 592
 Barrett esophagus, 595
 benign neoplasms, 601
 bleeding varices, 602–603
 prevention of first bleeding episode and, 604
 cancer, 1613
 caustic injury, 599, 1571, 1572
 eosinophilic esophagitis, 600
 GERD, 594, 597
 infectious esophagitis, 598
 motility disorders, 606
 pill-induced esophagitis, 598
 stricture, 595
 in gastric adenocarcinoma, 1616, 1617
 in gastric lymphoma, 1618
 in gastric outlet obstruction, 619
 in gastrointestinal mesenchymal tumors, 1619
 in GI bleeding, 582, 584, 618
 obscure bleeding and, 586
 occult bleeding and, 586
 in peptic ulcer disease, 612, 618
 in *H pylori* detection/assessment, 609–610
 in Mallory-Weiss syndrome/tears, 582, 599, 600
 in pancreatitis, 717
 in peptic ulcer disease, 612
 bleeding management and, 618
 in pernicious anemia gastritis, 610
 in polyp identification, 653
 in ulcerative colitis, 647
 in Whipple disease, 624
- Endothelial erectile dysfunction**, 951–952
- Endothelin receptor blockers (ERB)**, for pulmonary hypertension, 305, 424, 425*f*
- Endotracheal aspiration cultures**, in pneumonia, 277
- Endotracheal intubation**. *See* Intubation
- Endovaginal ultrasound**. *See* Ultrasonography
- Endovascular surgery/prostheses**. *See also* Angioplasty; Stents/stent grafts
 for abdominal aortic aneurysm, 473, 474
 for acute arterial limb occlusion, 468
 for aortoiliac occlusive disease, 465
 for carotid occlusive disease, 470
 for femoral/popliteal occlusive disease, 466
 for intracranial aneurysms, 986
 for intracranial venous thrombosis, 988
 for lower leg/foot occlusive disease, 467
 for renal artery stenosis/renal vascular hypertension, 437, 917–918
 for subarachnoid hemorrhage, 985
 for thoracic aortic aneurysm, 475
 for visceral artery insufficiency/intestinal angina, 471
- Endovascular warming**, for hypothermia, 1544
- Endovenous ablation**, for varicose veins, 479, 1720
- Endurance exercise**. *See also* Exercise/activity
 hyponatremia after, 871*f*, 873
- Endurant**. *See* Rilpivirine
- Enemas**
 barium. *See* Barium enema
 for constipation, 572*t*
- Energy deficiency (protein–energy malnutrition)**, 1257–1258
- Energy requirements**, in nutritional support, 1271–1272
- Enfuvirtide**, 1342*t*, 1346, 1348*f*. *See also* Antiretroviral therapy/HAART
- ENG**. *See* Electronystagmography
- ENG (endoglin) gene**
 in hereditary hemorrhagic telangiectasia, 1671
 in pulmonary hypertension, 424
- Engerix B**. *See* Hepatitis B vaccine
- Enolase**, neuron-specific, in pheochromocytoma, 1167
- Enoxaparin**, 557*t*, 559*t*
 for acute coronary syndromes, 361
 after thrombolytic therapy for myocardial infarction, 370
 for venous thromboembolic disease prevention/treatment, 557*t*, 559*t*
- Entacapone**, with levodopa and carbidopa, 999, 1000
- Entamoeba**, 1503. *See also* Amebiasis
dispar, 1503
histolytica, 574*t*, 576, 578, 579, 1293, 1298, 1303*t*, 1503
 stool antigen tests for, 576, 579, 1504
moshkovskii, 1503
- Entecavir**, for hepatitis B, 675, 1353*t*
- Enteral nutritional support (tube feedings)**, 1270, 1270–1271, 1271*f*. *See also* Nutritional support
 in burn injury, 1551–1552
 complications of, 1273
 for Crohn disease, 643
 for elderly, 70
 in pancreatitis, 714
 patient monitoring during, 1275
 for protein–energy malnutrition, 1258
 solutions for, 1272–1273, 1272*t*
 for terminally ill/dying patient, 90–91
- Enteric (typhoid) fever**, 1445, 1445–1446
 prevention/immunization and, 1315, 1446
- Enteric infection**. *See also* Gastroenteritis
 irritable bowel syndrome after, 633
- Enteritis**. *See* Gastroenteritis
- Enterobacter infections**, 1299*t*
- Enterobius vermicularis (enterobiasis/pinworms)**, 1519–1520
- Enterocoele**, 762
- Enterococcus faecalis/faecium (enterococcal infection)**, 1299*t*, 1422
 endocarditis, 1302*t*, 1422, 1435, 1438
- Enterocolitis**. *See also* Diarrhea; Gastroenteritis
 in HIV infection/AIDS, 575, 578, 1325, 1330
 salmonella, 574*t*, 575, 1330, 1445, 1446
- Enterocytozoon/Enterocytozoon bienersi**, 1506, 1507
- Enteropancreatic tumors**, in MEN, 1171, 1172, 1188*t*, 1189
- Enteropathy**
 AIDS, 1330
 gluten-sensitive. *See* Celiac disease
 protein-losing. *See* Protein-losing enteropathy
- Enteroscopy**, in GI bleeding, 585, 586
- Enterostomies**, tube, 1271, 1271*f*. *See also* Enteral nutritional support
- Enterovirus infections**, 1356*t*, 1405–1408. *See also* specific virus
- Enterovirus 68**, 1408
- Enterovirus 70/enterovirus 71**, 1407–1408
- Enterovirus 72**. *See* Hepatitis A virus
- Enterovirus 104A**, 1408
- Enthesopathy/enthesis**
 in ankylosing spondylitis, 855
 in lateral/medial epicondylitis, 1688
 in psoriatic arthritis, 856
 in reactive arthritis, 857
- Entocort**. *See* Budesonide
- Entrapment/compression neuropathy**, 1026–1028. *See also* Neuropathies
 in amyloidosis, 1023
 common peroneal (fibular) nerve, 1027
 femoral nerve, 1027
 lateral femoral cutaneous nerve (meralgia paresthetica), 1027
 median nerve (carpal tunnel syndrome), 823–824, 1688–1689, 1689*t*
 pronator teres or anterior interosseous nerve, 1026
 radial nerve/Saturday night palsy, 1026, 1027
 in rheumatoid arthritis, 827, 1024
 sciatic nerve, 1027
 tibial nerve (tarsal tunnel syndrome), 1027
 ulnar nerve, 1026–1027
- Entropion**, 164
 in trachoma, 166
- Entry inhibitors**, for HIV infection/AIDS, 1342*t*, 1346, 1348*f*. *See also* Antiretroviral therapy/HAART
- Enuresis**, 1077–1078, 1078
 in diabetes insipidus, 1098
 in diabetes mellitus, 1197*t*
 imipramine for, 1068, 1078

- Environmental factors. *See also* Home environment
- in asthma, 243, 248, 310
 - control of, 248, 249f
 - in diabetes mellitus, 1193, 1193–1194, 1194
 - disorders caused by, **1543–1561**
 - burn injury, **1549–1552**, 1549f
 - cold causing, **1543–1546**
 - dysbarism/decompression sickness, **1557–1558**
 - electrical injury, **1552–1553**
 - heat (hot environment) causing, **1547–1549**
 - high-altitude illness, **1558–1560**
 - lung disease, 292t, **307–312**
 - near drowning, **1555–1557**
 - radiation exposure causing, **1553–1555**
 - in obesity, 1259
- Environmental lung disorders, 292t, **307–312**. *See also* specific disorder
- Environmental tobacco smoke. *See* Passive smoking
- Enzyme immunoassay (EIA)
- in antibiotic-associated colitis, 637
 - in leptospirosis, 1477
 - in syphilis, 1466t, 1467
- Enzyme inhibitors, in cancer
 - chemotherapy, 1653t
- Enzyme-linked immunosorbent assay (ELISA). *See also* specific disorder
- in coccidioidomycosis, 1532
 - in HIV infection/AIDS, 1323, 1324t
 - blood screening and, 1321
 - in Lyme disease, 1479, 1480
- Eosinophil count, 1729t
- in asthma, 248
- Eosinophilia
- in allergic angitis and granulomatosis (Churg-Strauss syndrome), 306
 - in filariasis, 1525
 - in interstitial nephritis, 907
 - in pulmonary disorders. *See* Eosinophilic pulmonary syndromes
 - sputum, in asthma, 248
 - in toxocariasis/visceral larva migrans, 1523
- Eosinophilic esophagitis, 592t, **600**
- Eosinophilic fasciitis, 839
- Eosinophilic folliculitis, 129, 130, 1322
- Eosinophilic gastritis, 610
- Eosinophilic meningitis/meningoencephalitis
- in angiostrongyliasis, 1522
 - in gnathostomiasis, 1523
 - in toxocariasis, 1523
- Eosinophilic pneumonia, 297. *See also* Löffler syndrome
- Eosinophilic pulmonary syndromes, **296–297**
- ascariasis causing, 296, 1517
 - drugs causing, 296
 - filariasis and, 296, 1525
- Eosinophiluria, 898
- in interstitial nephritis, 907
- Ependymoma, 990t, 993
- Ephedra (ma huang), toxicity of, 1578t
- Ephedrine (“herbal ecstasy”), 1572
- Ephelides (freckles), **101**, 155, 156
- Epicondylitis (epicondylitis), lateral and medial, **1687–1688**
- Epidemic encephalitis, enterovirus 71 causing, 1407
- Epidemic keratoconjunctivitis
- adenovirus, 165, 1402
 - coxsackievirus, 1406
- Epidemic louse-borne typhus, **1408–1410**, 1409t
- Epidemic pleurodynia, 1406
- Epidemiology of Diabetes Interventions and Complications (EDIC) study, 1201
- Epidermal growth factor (EGFR) mutations/inhibitors
- in colorectal cancer, 1625
 - in gastric carcinoma, 1617
 - in lung cancer, 1600
 - in pancreatic/periampullary carcinoma, 1609
- Epidermal inclusion cysts (EIC), **152**
- furuncles differentiated from, 151
- Epidermoid cyst, testicular, 1643
- Epididymitis, 940t, **944–945**, 1303t
- chlamydial, 944, 945, 1303t, 1462
 - in filariasis, 1525
 - gonococcal, 944, 945, 1303t, 1452
- Epididymo-orchitis, in mumps, 1370, 1371
- Epidural abscess
- bacterial rhinosinusitis and, 216
 - otitis media and, 205
 - vertebral osteomyelitis and, 861–862, 862, 1426
- Epidural hemorrhage
- cerebral, 1017t
 - spinal, 989
- Epifrin. *See* Epinephrine
- Epigastric pain. *See* Abdominal pain/tenderness; Dyspepsia
- Epiglottis, cancer of, 236
- Epiglottis thumb sign, 235
- Epiglottitis (supraglottitis), **235**, 1420
- Haemophilus* causing, 235, 1442
- Epi-LASIK, 162
- Epilepsia partialis continua, 1004
- Epilepsy, **968–975**, 970t, 973t. *See also* Seizures
- drug therapy for, 972, 973t. *See also* Anticonvulsant therapy
 - genetic, 969
 - myoclonic ragged red fiber (MERRF), 1036
 - myoclonus/myoclonic jerks and, 1004
 - photosensitive, 971
 - posttraumatic, 969
 - pregnancy and, 803, 972
 - seizure classification in, 969–970, 970t
 - solitary seizure and, 974
 - structural/metabolic, 969
 - surgical management of, 974
 - vagal nerve stimulation in
 - management of, 974
- Epileptic drop attacks (atonic seizures), 970. *See also* Seizures
- Epinastine, for allergic eye disease, 167, 169t
- Epinephrine
- deficiency of, 1095
 - in Addison disease, 1156, 1158
 - for desensitization reactions, 1306, 1307
- endoscopic injection of
 - for GI bleeding/peptic ulcer, 582, 585, 618
 - for Mallory-Weiss syndrome/tears, 582, 600
 - for glaucoma/ocular hypertension, 177
 - in pheochromocytoma, 1166, 1167
 - for scombroid poisoning, 1589
 - for shock, 488
- Epi-pen. *See* Epinephrine
- Epirubicin, 1653t
- for breast cancer, 736
 - for gastric adenocarcinoma, 1617
 - toxicity of, 1653t, 1662
- Episodic dyspnea, 25
- Episodic laryngeal dyskinesia, 248
- Epistaxis, **220–221**
- cocaine abuse and, 220, 1085
 - in hereditary hemorrhagic telangiectasia, 220, 1671
 - juvenile angiofibroma and, 222
 - malabsorption and, 621t
 - nasal trauma and, 220, 221
 - in polycythemia, 511
- Epithelial cells/renal tubular casts, 898, 899t
- Epithelial LASIK (epi-LASIK), 162
- Epiriv. *See* Lamivudine
- Eplerenone
- for adrenal hyperplasia/Conn syndrome, 1166
 - for heart failure, 402
 - for hypertension, 445t, 449–453
 - for myocardial infarction, 371
- Epley maneuver, 211
- EPO. *See* Erythropoietin
- Epoetin alfa. *See* Erythropoietin
- Epogen. *See* Erythropoietin
- Epoprostenol, for pulmonary hypertension, 305, 424, 425, 425f
- Epothilones, in cancer chemotherapy, 1652t
- Eprosartan/eprosartan with hydrochlorothiazide, 451t
- Epsom salts. *See* Magnesium sulfate
- Epstein-Barr virus, **1361–1363**
- Burkitt lymphoma and, 1363
 - hairy leukoplakia caused by, 1329
 - mononucleosis caused by, 228, 1357t, **1361–1362**, 1361f
 - nasopharyngeal carcinoma and, 223, 1363
- Epstein-Barr virus DNA
- in Burkitt lymphoma/nasopharyngeal carcinoma, 1363
 - in CNS lymphoma, 1327, 1362, 1363
- Eptifibatide
- for acute coronary syndromes, 362t, 363
 - for myocardial infarction, 362t
 - platelet function affected by, 549t
- Epzicom. *See* Abacavir, with lamivudine
- Equianalgesic dosing, 79, 80–83t
- Equine encephalitis, 1378–1380
- Equine rabies antiserum, 1377
- ERB. *See* Endothelin receptor blockers
- Erb (limb-girdle) muscular dystrophy, 1034, 1035t

- Erbix. *See* Cetuximab
- ERCP. *See* Endoscopic retrograde cholangiopancreatography
- Erec-Aid System. *See* Vacuum erection device
- Erectile dysfunction/impotence, **951–953**, 1050, 1051. *See also* Sexual dysfunction
- after benign prostatic hyperplasia treatment, 958*t*, 960
- in chronic kidney disease, 909*t*, 914
- in diabetes mellitus, 1226–1227
- drugs causing, 952
- antidepressants, 1051, 1067, 1069
- antipsychotics, 1059
- lithium, 1073
- endocrine causes/hypogonadism and, 952, 1094, 1175
- phosphodiesterase inhibitors/sildenafil for, 952, 1051, 1067, 1226
- prostatectomy and, 1634
- psychological/psychogenic, 951, 952, 1050, 1051
- vascular disease and, 464, 951, 952
- Erections
- loss of, 951. *See also* Erectile dysfunction/impotence
- prolonged painful. *See* Priapism
- Ergocalciferol (vitamin D₂), 1149. *See also* Vitamin D
- for hypoparathyroidism, 1137*t*, 1138
- for vitamin D deficiency/osteomalacia, 1151
- Ergosterol. *See* Ergocalciferol
- Ergotamine
- for migraine headache, 963
- Raynaud phenomenon and, 837
- Eribulin, for breast cancer, 742
- Erlotinib, 1654*t*
- for lung cancer, 1600
- for pancreatic/periampullary carcinoma, 1609
- Erosive esophagitis. *See* Esophagitis
- Erosive gastritis. *See* Gastritis
- Erosive skin disorders, 95*t*
- Ertaczo. *See* Sertaconazole
- Ertapenem
- for anaerobic infections, 1455, 1455*t*
- for pneumonia, 277*t*
- Eructation (belching), 573
- Eruptive psoriasis, 106. *See also* Psoriasis
- Eruptive xanthoma, 1247, 1248*f*
- in diabetes, 1197, 1228, 1248*f*
- Erysipelas, **136**, 137*f*, 1303*t*, 1420–1421, 1421*t*
- Erysipeloid, 136
- Erythemas, 95*t*, **132–138**. *See also specific type*
- acral (hand-foot syndrome), chemotherapy-induced, 1661
- in dermatomyositis, 840
- figurate (shaped), 95*t*
- induratum, 150
- infectiosum, 1356*t*, 1402
- infectious, **136–138**
- marginatum, in rheumatic fever, 418
- migrans, **135–136**, 135*f*, 1478, 1479, 1481, 1482*t*. *See also* Lyme disease
- multiforme, **134–135**, 134*f*
- drugs causing, 134, 135
- herpes-associated, 134, 134*f*, 135, 1351, 1355
- major. *See* Stevens-Johnson syndrome; Toxic epidermal necrolysis
- nodosum, **150–151**, 150*f*
- in coccidioidomycosis, 1532
- drugs causing, 150, 159*t*
- leprosum, 1460–1461
- in sarcoidosis, 150, 296
- palmar
- in cirrhosis, 686
- in rheumatoid arthritis, 827
- pernio (chilblain), **1545**
- reactive, **132–136**
- in rosacea, 128, 129*f*
- toxic, drugs causing, 159*t*
- Erythrasma, 112, 146, 146*f*
- Erythroblastosis fetalis, prevention of, 785–786
- Erythrocyte count
- in pleural fluid, 314, 314*t*
- reference values for, 1729*t*, 1734*t*
- Erythrocyte sedimentation rate, 1729*t*
- Erythrocytes. *See also under Red cell*
- in anemia, 490, 491*t*
- in myeloproliferative neoplasms, 511*t*
- in pleural fluid, 314, 314*t*
- in polycythemia, 511, 511*t*
- preparation of for transfusion, 534
- in thalassemias, 492, 494
- in urine. *See* Hematuria; Red cell casts
- Erythrocytosis, 511
- cancer-related, 1596*t*
- in polycythemia, 511
- testosterone replacement therapy and, 1177
- Erythroderma, exfoliative, **116–117**
- drugs causing, 116, 159*t*
- psoriatic, 106, 116. *See also* Psoriasis
- Erythrotoxic toxin (pyrogenic erythrotoxin), 1419, 1421
- Erythromelalgia, 837, 865
- in essential thrombocytosis, 513, 514
- Erythromycin. *See also* Macrolides
- for acne, 97*t*, 127
- for amebiasis, 1505*t*
- for anthrax, 1433*t*
- with benzoyl peroxide, 97*t*
- for diabetic autonomic neuropathy, 1226
- for ophthalmic disorders, 168*t*
- for pharyngitis, 229, 1420
- resistance and, 229
- Erythroplakia, **224**
- Erythropoiesis-stimulating agents, for chemotherapy-associated anemia, 1649
- Erythropoietin (EPO)
- in anemia of chronic disease, 493
- in polycythemia, 511, 512
- reference values for, 1729*t*
- Erythropoietin (epoetin alfa)
- for anemia of chronic disease, 493
- for anemia of chronic kidney disease, 493, 913
- for aplastic anemia, 509
- for chemotherapy-induced anemia, 1649, 1659*t*
- for HIV infection/AIDS, 1339–1340
- for myelodysplastic syndromes, 518
- for primary myelofibrosis, 515
- Erythrotoxin, pyrogenic (erythrotoxic toxin), 1419, 1421
- Erythrovirus (parvovirus B19) infection, **1402–1403**
- arthritis in, 861, 1402
- rheumatoid arthritis differentiated from, 828, 861
- erythema infectiosum and, 1356*t*, 1402
- ESAs. *See* Erythropoiesis-stimulating agents
- Eschar formation
- in anthrax, 1432
- in burn injury, 1551
- in frostbite, 1546
- in tick typhus, 1414
- Escharotomy, in burn care, 1551
- Escherichia coli*, 1299*t*, 1447
- antibodies to, in Crohn disease, 642
- diarrhea/gastroenteritis/food poisoning caused by, 574*t*, 575, 1293, 1294*t*, 1296, 1297, 1298, **1447**
- enterohemorrhagic (EHEC), 574*t*, 575, 1294*t*
- enteroinvasive (EIEC), 574*t*, 1293, 1447
- enterotoxigenic (ETEC), 574*t*, 575, 1293, 1294*t*, 1297, 1298, 1447
- Escherichia coli* O104:H4, 575
- Escherichia coli* O145, 1447
- Escherichia coli* O157:H7, 574*t*, 575, 1447
- diarrhea caused by, 574*t*, 575, 1293, 1294*t*, 1447
- antibiotics contraindicated in, 1296, 1447
- hemolytic-uremic syndrome caused by, 542, 543, 543*t*, 575, 1296, 1447
- Escin, for venous insufficiency, 34
- Escitalopram, 1067, 1070*t*
- Escim, 1183
- Esidrix. *See* Hydrochlorothiazide
- Esmolol
- for arrhythmias, 378*t*
- atrial fibrillation, 372, 386
- infarct-related, 372
- supraventricular tachycardia, 378*t*, 382
- for hypertension
- in aortic dissection, 477
- in urgencies/emergencies, 462*t*, 463
- Esomeprazole, 613. *See also* Proton pump inhibitors
- Esophageal clearance, abnormal, in GERD, 594
- Esophageal dilation
- for achalasia, 605
- for esophageal webs and rings, 600–601
- for stricture, 595, 599
- Esophageal diverticula, **601**
- Esophageal dysphagia, 592, 592*t*. *See also* Dysphagia
- Esophageal manometry. *See* Manometry
- Esophageal motility disorders, **604–606**
- chest pain/discomfort in, 355, 606
- dysphagia in, 592, 592*t*, 605–606
- in scleroderma, 838, 839
- Esophageal pH monitoring, 593
- in gastroesophageal/laryngopharyngeal reflux, 234, 593, 594, 596–597

- Esophageal (Schatzki) rings, 592*t*, 600–601
- Esophageal spasm, diffuse, 592*t*, 606
- Esophageal sphincter, lower
in achalasia, 604, 605
chronic aspiration of gastric contents
and, 308
in GERD, 593
- Esophageal varices, 601–604
cirrhosis and, 581, 601, 602, 604, 687
GI bleeding from, 581, 601–604
portal hypertension and, 581, 601
noncirrhotic portal hypertension and,
700
prevention of first bleeding episode
and, 604
prevention of rebleeding from, 603–604
- Esophageal webs, 600–601
iron deficiency anemia and (Plummer-
Vinson syndrome), 491, 600
- Esophagectomy
for Barrett esophagus, 595
for caustic esophageal injury, 599
for esophageal cancer, 1613–1614
- Esophagitis
bisphosphonates and, 1146
candidal, 598, 1529, 1530, 1542
in HIV infection/AIDS, 598, 1325,
1329, 1338*t*, 1530
chest pain/discomfort in, 355, 598
CMV, 598, 1364
eosinophilic, 592*t*, 600
erosive/reflux. *See also*
Gastroesophageal reflux
disease
chest pain/discomfort in, 355
GERD and, 593, 594, 596, 597
GI bleeding and, 581
refractory, 597
strictures and, 595
herpetic, 598, 1351, 1352, 1355
in HIV infection/AIDS, 598, 1325, 1329
infectious, 598
pill-induced, 598–599
- Esophagogastroduodenoscopy, in
cirrhosis, 687
- Esophagography, barium. *See* Barium
esophagography
- Esophagus
Barrett, 594–595
esophageal carcinoma and, 595
benign tumors of, 601
cancer of, 1611*t*, 1612–1615
adenocarcinoma, 1613
Barrett esophagus and, 595
bisphosphonate use and, 1147
dysphagia in, 592*t*, 1613, 1614
squamous cell, 1613
disorders of, 591–607, 592*t*. *See also*
under Esophageal and
Esophagitis
benign, 599–604
caustic injury, 599, 1571, 1572
chest pain/discomfort in, 29, 355,
594, 598, 605, 606
dysphagia in, 592, 592–593, 592*t*,
598, 599
GERD, 593–597
motility and, 604–606. *See also*
Esophageal motility
disorders
in scleroderma, 592*t*, 838, 839
foreign body in, 239
nutcracker, 606
resection of, for cancer, 1613, 1614
rupture of
pleural effusion in, 314*t*
vomiting and (Boerhaave
syndrome), 568
sigmoid, 605
strictures of
caustic injury causing, 599
dysphagia in, 592*t*, 595
peptic, 592*t*, 595
Espundia (mucocutaneous
leishmaniasis), 1487, 1488,
1489
ESRD. *See* End-stage renal disease
Essential fatty acids, in nutritional
support, 1272
Essential hypertension, 435–436. *See also*
Hypertension
in pregnancy, 438, 802
Essential thrombocytosis, 511*t*, 513–514
Essure, for tubal interruption, 777
Estazolam, 1042*t*
Estimated glomerular filtration rate, 899–
901, 900*t*. *See also*
Glomerular filtration rate
reference/normal value for, 899, 1730*t*
Estrace, 1184
Estraderm, 1184
Estradiol. *See also* Ethinyl estradiol
for breast cancer, 740
in estrogen replacement therapy, 779,
780, 1182, 1183–1184, 1184
transdermal, 779, 1182, 1183–1184,
1184, 1184–1185
serum levels of
in menopause, 1181
reference values for, 1729*t*
Estradiol intramuscular, 1184–1185
Estradiol transdermal systems (skin
patches), 1183–1184
Estradiol vaginal ring
contraceptive, 773
in estrogen replacement therapy, 780,
1184
with progestin, 1184
Estradiol vaginal tablets, 1184
Estramustine, 1650*t*
Estrasorb, 1184
Estratab, 1184
Estratest, 1185
Estring, 1184
EstroGel, 1184
Estrogen-progesterone therapy. *See*
Estrogen (hormone)
replacement therapy
Estrogen receptor modulators, selective
(SERMs). *See* Selective
estrogen receptor modulators
Estrogen (hormone) replacement therapy,
779–780, 1182–1185. *See also*
Estrogens; Selective estrogen
receptor modulators
adverse ophthalmic effects of, 196*t*
agents used in, 779–780, 1183–1185
for atrophic urethritis/vaginitis, 780,
1184
benefits of, 1182
breast cancer/breast cancer risk and, 722,
743–744, 780, 1182, 1183
cholelithiasis/gallstones and, 703, 780,
1183
endometrial hyperplasia/carcinoma
and, 759, 779, 1183, 1184,
1185
growth hormone replacement and,
1097
hypercalcemia/hyperparathyroidism
affected by, 1144
intramuscular, 1184
lipid modification/heart disease and,
780, 1182, 1183
mastalgia in patient receiving, 1717
nipple discharge caused by, 720
oral, 1184
for osteoporosis prevention/
management, 1147
ovarian cancer risk and, 1183
without progestins, 1182, 1182–1183,
1184
with progestins, 779–780, 1182, 1183,
1184
risks of, 780, 1182–1183
after surgical menopause, 780
transdermal, 1183–1184
in Turner syndrome, 1186–1187
vaginal, 780, 1184
for vasomotor symptoms of
menopause, 779–780, 1182
in XY gonadal dysgenesis, 1175
Estrogen vaginal creams, 780, 1184
Estrogens. *See also* Estrogen (hormone)
replacement therapy
for abnormal premenopausal bleeding,
748
adverse ophthalmic effects of, 196*t*
amprenavir/fosamprenavir therapy
and, 1345
for bleeding in chronic kidney disease,
913
for breast cancer, 740
in male, 746
in fibrocystic breast condition, 718, 719
hypertension and, 438
in menopause, 779
with methyltestosterone, 1185
oral, 1184
in oral contraceptives, 770, 771–772*t*
plant-derived, 1185
without progestins, 779, 1182, 1182–
1183, 1184
with progestins, 779–780, 1182, 1183,
1184
receptors for
antagonists of, in cancer
chemotherapy, 739, 740,
1657*t*
in breast cancer, 733–734
in male, 746
prognosis and, 734, 736, 736*t*, 743
therapy and, 736, 738, 739
reference values for, 1730*t*
testicular tumors producing, 1177
transdermal, 779, 1183–1184
in utero exposure to, testicular cancer
and, 1642
vaginal, 780, 1184
Estrone
in estrogen replacement therapy, 779
serum levels of, in menopause, 1181
Estropipate, 1184

- Eszopiclone, 1042*t*, 1076
- Etanercept. *See also* Anti-TNF agents
for psoriasis, 108
for rheumatoid arthritis, 830
- ETEC. *See Escherichia coli*,
enterotoxigenic
- Ethacrynic acid, 445*t*
lithium use and, 1074
- Ethambutol, 284*t*, 289*t*
adverse ophthalmic effects of, 197*t*,
284*t*
for MAC infections, 1338*t*, 1458
for tuberculosis, 284–285, 284*t*, 285,
289*t*
in pregnancy, 285, 805
- Ethanol (ethyl alcohol). *See also* Alcohol
use/dependency/abuse
blood levels of
in acute intoxication/poisoning,
1080, 1579
reference values for, 1730*t*
for methanol or ethylene glycol
poisoning, 1566*t*, 1584
for thyroid nodules, 1125
- Ethanol-associated hypoglycemia, 1083,
1222, 1238, 1238*t*, 1579
- Ethanol intoxication/poisoning, 1080,
1569*t*, 1579–1580. *See also*
Alcohol use/dependency/
abuse
metabolic acidosis/osmolar gap and,
877, 1081, 1569, 1569*t*
- Ethics, principles of care and, 2
- Ethinyl estradiol. *See also* Estradiol;
Estrogens
amprenavir/fosamprenavir therapy
and, 1345
for emergency/postcoital
contraception, 776
in estrogen replacement therapy, 1184
in oral contraceptives, 770, 771–772*t*
in transdermal contraceptive patch, 773
in vaginal contraceptive ring, 773
- Ethmoiditis/ethmoid sinusitis, 215, 216
- Ethnicity. *See* Racial/ethnic background
- Ethosuximide, 973*t*, 1723*t*
- Ethyl alcohol. *See* Alcohol use/
dependency/abuse; Ethanol
- Ethylene glycol poisoning, 1566*t*, 1569*t*,
1584
anion gap/osmolar gap in, 877, 891,
1569, 1569*t*, 1584
hemodialysis for, 1568*t*, 1584
- Ethylenediaminetetraacetic acid (EDTA),
for lead poisoning, 933, 1582
- Ethinodiol diacetate, in oral
contraceptives, 771*t*
- Ethylol. *See* Amifostine
- Etodolac, 77*t*
- Etonogestrel
in contraceptive implant, 773
in contraceptive vaginal ring, 773
- Etopophos. *See* Etoposide
- Etoposide/etoposide phosphate, 1653*t*
for lung cancer, 1600
for testicular cancer, 1643
- Etravirine, 1342*t*, 1345, 1346, 1347, 1348*f*.
See also Antiretroviral
therapy/HAART
- Etreinate, adverse ophthalmic effects of,
197*t*
- Eucerin, 94, 98*t*
- Eulexin. *See* Flutamide
- Eumycetoma (maduromycosis), 1540
- Euphoria
marijuana-induced, 1085
opioid-induced, 79
- EUS. *See* Endoscopic ultrasonography
- Eustachian tube, 201
dysfunction of, 201–202
barotrauma and, 202
cholesteatoma and, 204, 204*f*
hearing loss and, 198, 201
in HIV infection/AIDS, 213
serous otitis media development
and, 202
patulous, 202
- Euthyroid sick syndrome, 1107
- Euvolemic hypernatremia, 876
- Euvolemic hypotonic hyponatremia, 871*f*,
872–873, 874
- Evamist, 1184
- Evans syndrome, 506
- Evaporative cooling, for heat stroke, 1548
- Event recording
in atrial fibrillation, 388
in palpitation evaluation, 31
in seizure evaluation, 971
in syncope evaluation, 397
- Everolimus, 1654*t*
for breast cancer, 741
- Eversion (high) ankle sprain, 1704–1705,
1704*t*
- Evista. *See* Raloxifene
- Exanthea subitum (roseola infantum),
1350, 1356*t*, 1366
- Exanthems. *See also* Rashes
ricketsial, 1356–1357*t*
in simple drug eruption, 160
viral, 1356–1357*t*, 1402–1404
- Exchange lists, diabetic diet, 1205
- Exchange transfusion. *See also*
Transfusion
for malaria, 1493
for sickle cell crises, 504
for thrombotic microangiopathies, 543
- Excitement (arousal) stage of sexual
activity, 1049
disorders related to, 1049–1050,
1050–1051. *See also* Sexual
dysfunction
in female, 766, 767, 1714
- Exclamation hairs, in alopecia areata, 157
- Executive function, impaired, dementia
causing, 59, 1006
- Exelderm. *See* Sulconazole
- Exemestane, 1656*t*
for breast cancer prevention/treatment,
723, 740*t*, 741
- Exenatide, 1206*t*, 1211, 1211–1212,
1220–1221
for obesity, 1261
overdose/toxicity of, 1211–1212,
1220–1221, 1580
- Exendin 4. *See* Exenatide
- Exercise/activity
angina precipitated by, 351
asthma/bronchoconstriction
precipitated by, 243, 247. *See
also* Asthma
back pain and, 821, 1684, 1686
in cancer prevention, 12–13, 15, 1594
cardiovascular/heart disease prevention
and, 7*t*, 12–13, 1252
in women, 1707
in constipation management, 571
for COPD, 264
in dementia management, 1007, 1008
in diabetes
insulin requirements and, 12, 1218
prevention/management and, 12–13,
1202, 1203, 1220
in fall prevention/management, 66, 67*t*
for fatigue/chronic fatigue syndrome,
40
in health maintenance, 12–13
in heart failure management, 12–13,
406
heart murmurs affected by, 337*t*
heat exposure syndromes and, 1547,
1548
hypertension/hypertension
management and, 11, 12–13,
436, 441, 441*t*
hyponatremia and, 871*f*, 873
in obesity management/prevention,
12–13, 13, 14, 1260
for osteoarthritis, 12–13, 811
for osteoporosis prevention/
management, 11, 12–13, 780,
1146, 1710
for polycystic ovary syndrome, 766
during pregnancy, 784
prescription for, 13
reduced. *See* Bed rest; Immobility
ventricular premature beats and, 390
- Exercise challenge (bronchial
provocation) testing, in
asthma, 247
- Exercise-induced asthma, 243, 247. *See
also* Asthma
- Exercise-induced hypoglycemia, 12, 1222
- Exercise testing. *See also* Stress testing
in asthma, 247
in chest pain/angina, 29, 352–353
echocardiography, 46, 353, 400
electrocardiography, 12, 352–353
before exercise program
initiation, 12
perfusion scintigraphy, 353
postinfarction, 375
preoperative, 46–47, 48*f*
radionuclide angiography, 353
in syncope evaluation, 397
- Exertional headache, primary, 966
- Exertional heat-related disorders/stroke,
1547, 1548
- Exfoliative dermatitis/erythroderma,
116–117
drugs causing, 116, 159*t*
psoriatic, 106, 116. *See also* Psoriasis
- Exforge. *See* Valsartan, for hypertension,
with amlodipine
- Exforge HCT. *See* Valsartan, for
hypertension, with
amlodipine and
hydrochlorothiazide
- Exhibitionism, 1049
- Existential challenges, for terminally ill/
dying patient, 92, 92*t*
- Exon 12/13 mutation, 511, 1732*t*
- Exophiala, phaeocephalomyces caused by,
1541

- Exophthalmos (proptosis), in dysthyroid eye/Graves disease, 191, 1110, 1112–1113, 1117–1118
RAI treatment for hyperthyroidism and, 1115–1116, 1117–1118
- Exostoses, ear canal, **201**
- Exposure (cold). *See* Cold exposure
- Exposure keratitis, 167
- Extensively drug-resistant tuberculosis, 280, 285
- External auditory canal. *See* Ear canal
- External genital warts, 140. *See also* Venereal (genital) warts
- External hordeolum (sty), 163, 163f
- External otitis/malignant external otitis, **200–201**
earache in, 200, 206
- External rotation, assessment of
in ankle, 1704, 1704t
in shoulder, 1676t
adhesive capsulitis (frozen shoulder) and, 1682
rotator cuff strength and, 1677t, 1680
- External rotation stress test, in ankle sprain, 1704, 1704t
- Extinction (behavior), personality disorders and, 1052
- Extracorporeal counterpulsation, for angina, 358
- Extracorporeal shock wave lithotripsy
for renal stones, 950
for salivary stones, 232
for ureteral stones, 950
- Extramammary Paget disease, 117
- Extraocular movements. *See* Eye (extraocular) movements
- Extrapyramidal disorders/effects
antipsychotic drugs and, 1055, 1057t, 1060, 1061, 1574
lithium and, 1073
SSRIs and, 1067
- Extrasystoles. *See* Atrial (supraventricular) premature beats; Ventricular premature beats
- Extruterine pregnancy. *See* Ectopic pregnancy
- Extremities. *See also* Lower extremity; Upper extremity
hypothermia of, **1545–1546**
swelling of, in filariasis, 1525, 1525f
traumatic injury to, complex regional pain syndrome and, **824–825**
- Extrinsic allergic alveolitis (hypersensitivity pneumonitis), **310, 310t**
- Exubera, 1217
- Exudates
pharyngotonsillar, 228, 228f
pleural fluid, 313, 313t, 314, 314t, 315
- Eye, **162–195, 195–197t**. *See also under Ocular; Optic; Visual*
chemical burns involving, **194, 1571, 1572**
in chronic kidney disease/uremia, 909t
decontamination of, 194, **1566**
disorders of, **162–195**. *See also specific type and* Visual impairment/loss
allergic, **166–167**
in Behçet syndrome, 178, 853
bisphosphonates causing, 1147
in blood dyscrasias, **186–187**
chlamydial, 165–166
diabetes and, **185–186, 185f, 1197t, 1201, 1223**. *See also* Diabetic retinopathy
drugs (systemic) causing, **195, 195–197t**
dysthyroid, **191, 1110, 1112–1113, 1117–1118**
RAI treatment for hyperthyroidism and, 1115–1116, 1117–1118
gonococcal, 165, 1452
in granulomatosis with polyangiitis, 849, 849f
headache and, 41–42, 962
herpes simplex infection, 1351
herpes zoster infection, 120, 173, 1331
in HIV infection/AIDS, **187, 187f**
hypertension and, **186, 440, 440f**
inflammation, 165t, 177–178. *See also* Conjunctivitis; Uveitis
in leptospirosis, 1477
in loiasis, 1527
management of
ophthalmic agents in, 168–172t
precautions in, **194–195**
in microsporidiosis, 1507
in onchocerciasis, 1526–1527
refractive errors, **162–163**
in rheumatoid arthritis, 827
in SLE, 833
in syphilis, 1471
systemic disease associations and, **185–187**
in toxocariasis/visceral larva migrans, 1523
traumatic, **192–194, 193f**
in vitamin A deficiency, 1266, 1267
dry (keratoconjunctivitis sicca), **166**
in Sjögren syndrome, 843
examination of
in coma or stupor, 1014
after decontamination, 1566
in diabetes patients, 185, 1223
in glaucoma prevention, 176
in Marfan syndrome, 1670
foreign body in
conjunctival/corneal, **192**
intraocular, **192**
painful. *See* Ocular/orbital pain
systemic drugs affecting, **195, 195–197t**
- Eye drops. *See also* Ophthalmic medications
allergic/toxic reaction to, 166, 195
autologous serum, 166
contaminated, 195
systemic effects associated with use of, 195
- Eye movement desensitization reprocessing, for PTSD, 1040
- Eye (extraocular) movements
in coma or stupor, 1014
disorders of
in myasthenia gravis, 1032
in ocular motor palsies, 190
“Eye worm” (*Loa loa*), 1527
- Eyelids
blepharitis affecting margins of, 110, **163–164**
disorders of, **163–164, 163f**
in dysthyroid eye disease, 191, 1112
lacerations of, 193
seborrheic dermatitis affecting margins of, 110
tumors of, **164**
- Ezetimibe, 1254, 1255t
- Ezogabine, 972, 973t
- F cells, pancreatic, 1171
- Face. *See also under Facial*
age-related changes in, aesthetic procedures for, **1720–1721**
herpes zoster affecting, 119, 213, 1358. *See also* Ramsay Hunt syndrome
seborrheic dermatitis affecting, 109
Facial neuropathy, **1027, 1028, 1028f**. *See also* Bell palsy
- Facial pain, **967–968**
atypical, **967–968**
in bacterial rhinosinusitis, 216, 968
in glaucoma, 968
in rhinocerebral mucormycosis, 217
- Facial paralysis/palsy, **1027, 1028, 1028f**. *See also* Bell palsy
in herpes zoster infection (Ramsay Hunt syndrome), 213, 1358, 1359
Lyme disease and, 1028f, 1479, 1481, 1482t
otitis media and, 205
in sarcoidosis, 1024
- Facioscapulohumeral muscular dystrophy, 1035t
- Factitious disorders, 1046
diarrhea, 574t, 579f
fever, 1277
hypoglycemia, 1239, **1243**
thyrotoxicosis, 1111, 1113
- Factiv. *See* Gemifloxacin
- Factor II antibodies, **553**
- Factor II deficiency, 552
- Factor V antibodies, **553**
- Factor V deficiency, 552
- Factor V Leiden, DVT/PE (venous thromboembolic disease) and, 297
- Factor VII deficiency, 552
- Factor VIII
acquired antibodies to, **552**
deficiency of
in hemophilia, 550
in von Willebrand disease, 551
inhibitors of in hemophilia, 549, 550, 550–551
reference values for, 1730t
- Factor VIII concentrate
for hemophilia, 550, 550t
vWF-containing, for von Willebrand disease, 550t, 552
- Factor IX
deficiency of in hemophilia, 550
inhibitors of in hemophilia, 549, 550, 550–551
- Factor IX concentrate, for hemophilia, 550, 550t
- Factor X deficiency, 552
- Factor Xa, fondaparinux affecting, 558

- Factor Xa inhibitors, for stroke prevention in atrial fibrillation, 387
- Factor XI deficiency, 550*t*, 552
- Factor XII deficiency, 552
- Factor XIII deficiency, 552
- Factor concentrates, for hemophilia, 550
- Factor inhibitors, in hemophilia, 549, 550, 550–551
- Faget sign, 1389
- Failure to thrive (unintended weight loss), in elderly, 37, 37*t*, 69–70
- Fainting, 396. *See also* Syncope
- Fallot
 pentalogy of, 331
 tetralogy of, 331–332
 pulmonary valve regurgitation and, 332, 348
- Falls, in elderly, 65–66, 66*t*, 67*t*
 fear of, 66
 prevention/injury prevention and, 17, 66, 67*t*
- False vocal folds, cancer of, 236, 237
- Famciclovir, 1353*t*
 for herpes simplex infections, 118–119, 598, 1330, 1338*t*, 1352, 1353*t*
 for herpes zoster, 120, 173, 1331, 1339*t*, 1353*t*
 prophylactic/suppressive, 118, 119
- Familial adenomatous polyposis, 654–655, 1622
 colorectal cancer and, 654, 655, 1622, 1623
 genetic mutations associated with, 655, 1622
 small intestinal adenocarcinoma and, 655, 1620
- Familial (benign essential) tremor, 997
 parkinsonism differentiated from, 998
- Familial combined hyperlipidemia, 1245
- Familial Creutzfeldt-Jakob disease, 1381, 1382. *See also* Creutzfeldt-Jakob disease
- Familial dysautonomia, prenatal testing for, 783
- Familial hemiplegic migraine, 963
- Familial hypercholesterolemia, 1245
- Familial hyperchylomicronemia, 1245
- Familial hypocalcemia, 878*t*
- Familial hypocalciuric hypercalcemia, 878*t*, 884, 1142
- Familial juvenile polyposis, 655
- Familial Mediterranean fever, 591
- Familial melanoma, 101
- Familial paraganglioma, 1167
- Familial partial lipodystrophy type I, 1160
- Familial renal glycosuria, 1198
- Family/significant others, of patient at end of life
 caring for, 88–89, 88*t*
 follow-up/grieving and, 93
- Family counseling
 for anxiety disorders, 1044
 chronic pain disorders and, 1049
 cognitive disorders and, 1089
 in depression, 1072
 for paraphilias and gender identity disorders, 1051
 psychiatric problems associated with hospitalization/illness and, 1091
- for schizophrenia/psychotic disorders, 1062
 for somatoform disorders, 1047
- Family planning. *See also* Contraception
- symptothermal natural, 775
- Famotidine, 613. *See also* H₂ receptor blocking drugs
- Famvir. *See* Famciclovir
- Fanapt. *See* Iloperidone
- Fanconi anemia/syndrome, 538, 886, 892, 936
- Fansidar (pyrimethamine-sulfadoxine), 1492*t*, 1493, 1496
 with amodiaquine, 1496
 with artesunate, 1493*t*, 1496
 for isosporiasis, 1508
 for prophylaxis in pregnancy/infants, 1498
 resistance to, 1493, 1496
- FAP. *See* Familial adenomatous polyposis
- Fareston. *See* Toremifene
- Farmer's lung, 310*t*
- Farsightedness (hyperopia), 162
- Fasciitis
 eosinophilic, 839
 necrotizing, 1421, 1425, 1456
 cellulitis differentiated from, 137
 palmar
 cancer and, 864
 rheumatoid arthritis differentiated from, 828
 in Dupuytren contracture, 824
- Fasciola hepatica/gigantica* (fascioliasis), 1512–1513
- Fasciolopsis buski* (fasciolopsiasis), 1513
- Fasciotomy, in burn care, 1551
- Faslodex. *See* Fulvestrant
- Fasting
 cholelithiasis/gallstones and, 703
 in insulinoma diagnosis, 1240, 1240*t*
- Fasting hypoglycemia, 1238, 1238*t*. *See also* Hypoglycemia
- Fasting plasma glucose, in diabetes, 1198, 1198*t*, 1218
 pregnancy and, 784, 800, 801
- Fat. *See also* Lipid disorders/lipids
 body. *See* Body fat; Obesity
 dietary, 1269. *See also* Lipid disorders/lipids
 colorectal cancer and, 1269, 1623
 in diabetic diet, 1204
 gastrointestinal gas and, 573
 lowering. *See* Lipid-lowering therapy
- fecal. *See* Fecal fat
- intravenous, in nutritional support, 1272, 1274
- Fat necrosis of breast, 720–721
- Fat-restricted diet, 1269. *See also* Low-fat diet
 for pancreatitis, 714, 716
- Fatal familial insomnia, 1381, 1382
- Fatigue, 38–40, 39*f*, 86
 in Addison disease, 1157, 1158
 in diabetes mellitus, 1197*t*
 palliation of, 86
 Q fever causing, 1416
 sleep disorders and, 38, 40, 319
- Fatty acids
 in nutritional support, 1272
 omega-3. *See* Omega-3 fatty acids
 trans, preventable disease/deaths associated with high intake of, 3*t*
- Fatty liver (hepatic steatosis)
 alcoholic, 681
 drugs/toxins causing, 683
 hepatitis C and, 671
 liver failure and, 673
 nonalcoholic, 684–685
 of pregnancy, 673, 795
 in Reye syndrome. *See* Reye syndrome
- FBN1* gene mutation, in Marfan syndrome, 1670
- 5-FC. *See* Flucytosine
- fCJD. *See* Familial Creutzfeldt-Jakob disease
- FE. *See* Fractional excretion
- Febrile agglutinins, 1277
- Febuxostat, for hyperuricemia/gout, 816
 in transplant patients, 816
- Fecal antigen assay, in *H pylori* infection, 565, 609, 613
- Fecal DNA tests, in colorectal cancer screening/polyp identification, 653, 1626*t*, 1627
- Fecal elastase
 in diarrhea, 580
 reference values for, 1733*t*
- Fecal examination. *See* Stool analysis
- Fecal fat
 in bacterial overgrowth, 625
 in diarrhea, 579, 579*f*, 580
 reference values for, 1730*t*
- Fecal immunochemical test (FIT). *See also* Fecal occult blood testing
 in colorectal cancer screening/polyp identification, 16, 653, 1626*t*, 1627
- constipation and, 570, 571
 in GI bleeding, 586
 in peptic ulcer disease, 612
- Fecal impaction, 572–573
 “overflow” fecal incontinence/diarrhea and, 572, 660
 urinary incontinence and, 68
- Fecal incontinence, 659–660
 fecal impaction and, 572, 660
- Fecal leukocytes, in diarrhea, 575, 576*f*, 579, 579*f*, 1293
- Fecal occult blood testing
 in cancer screening/polyp identification, 15*t*, 16, 653, 1623, 1626*t*, 1627
 in constipation, 570, 571
 in gastric cancer, 1616
 in GI bleeding, 586
 in Kaposi sarcoma, 145
 in pancreatic/periampullary carcinoma, 1608
 in peptic ulcer disease, 612
- Fecal osmolality, diarrhea and, 577–578
- Fecal transplant, for antibiotic-associated colitis relapse, 638
- Feces. *See* Stool analysis
- Feeding tubes, 1270–1271, 1271*f*. *See also* Enteral nutritional support
- Fest
 atherosclerotic/occlusive disease and, 466–468
 callosities and corns of, 141
 in diabetes/vascular disorders, 141, 1224

- Feet (*Cont.*):
 in diabetes mellitus, 141, 1224–1225, 1227–1228
 immersion/trench, **1545–1546**
 mycetoma affecting, 1540
 peripheral artery aneurysms affecting, 476
 tinea of, 111*f*, 112–113, 113*f*
 cellulitis and, 112, 137
 vesiculobullous dermatitis of (pompholyx), 121–122
 tinea differentiated from, 113
- Felbamate, 972, 973*t*
 overdose/toxicity of, 973*t*, 1573–1574
- Feldene. *See* Piroxicam
- Felodipine, 454*t*
 for angina, 356
 for hypertension, 453, 454*t*
 lower extremity edema caused by, 33
 overdose/toxicity of, 454*t*, 1576
- Fely syndrome, 510, 827
- Fem-fem bypass, for aortoiliac occlusive disease, 465
- Female athlete triad, **1712–1713**
- Female condom, 775
- Female health issues. *See* Women's health issues
- Female infertility. *See* Infertility
- Female pattern hair loss, 156, **1719–1720**
- Female sex hormones. *See* Estrogens
- Female sexual dysfunction, **766–767**, **1714**
- Femara. *See* Letrozole
- Femhrt, 1184
- Femoral arteries
 aneurysms of, 476
 atherosclerotic/occlusive disease of, **465–466**
 compression of, in DVT detection, 300
- Femoral cutaneous nerve, lateral, lesions of (meralgia paresthetica), **1027**
- Femoral neck fracture. *See* Hip fracture
- Femoral neuropathy/femoral nerve palsy, **1027**
- Femoral-popliteal bypass, 466
- Femoral pulses, in aortoiliac occlusive disease, 464
- FemPatch, 1183–1184
- Femring, 1184
- Femtosecond laser assisted LASIK (IntraLASIK), 162
- Femtrace, 1184
- Fenofibrate, 1254, 1255*t*
- Fenofibric acid, 1255*t*
- Fenoldopam, for hypertensive urgencies/emergencies, 462*t*, 463
- Fenopropfen, 77*t*
- Fentanyl/fentanyl oral transmucosal and buccal/fentanyl transdermal, 79, 80–81*t*
 methyl analogues of, abuse of, 1086, 1586–1587
 overdose/toxicity of, 1586–1587
- Fentora. *See* Fentanyl
- FEP. *See* Free erythrocyte protoporphyrin
- Ferric gluconate. *See* Iron, supplementary
- Ferriman-Gallwey scale, 1161
- Ferritin, 490, 492
 in anemia of chronic disease, 492
 in anemia of chronic kidney disease, 493, 913
 in hemochromatosis, 695
 in iron deficiency anemia, 492
 in nonalcoholic fatty liver disease, 684
 reference values for, 1730*t*
 in Still disease, 831
- Ferroportin, 490
 in hemochromatosis, 695
- Ferrous sulfate. *See* Iron, supplementary
- Fertility awareness, contraception based on, **775–776**
- Fertility disorders. *See* Infertility
- Fertilization, in vitro, 768, 769, 956
- Fesoterodine, for urinary incontinence, 68
- Fetal alcohol syndrome, 783, 1081
- Fetal fibronectin, preterm labor and, 796
- Fetal hemoglobin. *See* Hemoglobin F
- Fetal lung maturity
 delivery in preeclampsia/eclampsia and, 794
 preterm labor and, 796
- Fetal monitoring
 in diabetes, 801
 in HIV infection/AIDS, 805
 in preeclampsia-eclampsia, 794, 795
 in third-trimester bleeding, 797
- Fetal-placental unit, in preeclampsia-eclampsia, 793, 793*t*, 794, 795
- Fetal testing. *See* Prenatal testing/diagnosis
- Fetal varicella infection, 804
- α -Fetoprotein. *See* Alpha-fetoprotein
- Fetotoxic drugs, 782, 782*t*
- Fetus. *See also* Pregnancy
 electrical injury during pregnancy and, 1553
 hepatitis transmission to, 667, 783, 806
 herpes simplex transmission to, 806, 1351, 1355
 HIV transmission to, 805–806, 1321, 1336
 Lyme disease transmission to, 1481, 1482
 malaria transmission to, 1490
 radiation affecting, 1554
 rubella affecting, 1374, 1375
 syphilis transmission to, 806, 1464, 1474
 thyroid disease affecting, 800, 1106, 1117
 toxoplasmosis transmission to, 1501, 1502
- FEV₁ (forced expiratory volume in first second)
 in asthma, 244*f*, 245*t*, 246, 246*t*, 256, 257, 258*f*
 bronchial provocation testing and, 246
 exacerbation classification/management and, 246*t*, 256, 257, 258*f*
 in COPD, 260, 265
 corticosteroid treatment and, 263
 lung cancer surgery and, 1598–1599
- FEV₁/FVC ratio
 in asthma, 244*f*, 246
 in COPD, 260
- Fever, **35–36**, 36*t*
 in acute bacterial diarrhea/food poisoning, 575
 cancer-related, 1276, 1277, 1596*t*
 in cirrhosis, 686
 in critically ill patient, 1283, 1284
 drug user presenting with, 1292–1293
 factitious (self-induced), 1277
 giant cell arteritis and, 846, 1277
 health care-associated, 1276, 1283, 1284
 in HIV infection/AIDS, 36, 1276, 1277, 1324–1325
 in malaria, 1490
 medications causing, 1283
 in neutropenic patient, 36, 510, 1276, 1277
 antimicrobial therapy and, 36, 510, 1281–1282, 1302*t*, 1648
 postoperative, 1283
 in pulmonary embolism, 298*t*
 in serous sickness, 867
 severe, with thrombocytopenia, 1385
 in spontaneous bacterial peritonitis, 589
 in Still disease, 831, 1277
 in thrombotic microangiopathies, 543, 543*t*
 travel and, 1296, 1297
 of unknown/undetermined origin (FUO), **35–36**, **1276–1278**
 in giant cell arteritis, 846, 1277
 in Whipple disease, 623
- Fever/cold sore (herpes simplex), **118–119**, 118*f*, 1350–1351, 1352. *See also* Herpes simplex infection
- Fexofenadine, 99
 for allergic/perennial rhinitis, 219
 for urticaria, 133
- FFI. *See* Fatal familial insomnia
- FGF23. *See* Fibroblast growth factor-23
- FHM. *See* Familial hemiplegic migraine
- Fiber, dietary, 571, 572*t*, 1269
 for anal fissures, 660
 in colorectal cancer prevention, 1269, 1623
 constipation and, 571
 in diabetes mellitus, 1205, 1269
 diverticular disease and, 651, 652, 1269
 for hemorrhoids, 658
 for irritable bowel syndrome, 634, 1269
 lipid-modifying effects of, 1252
 for urinary stone disease, 948
- Fiber laxatives, 571, 572*t*
- Fibric acid derivatives (fibrates), for lipid modification, 1254
- Fibrillation. *See* Atrial fibrillation; Ventricular fibrillation
- Fibrillin gene mutation, in Marfan syndrome, 1670
- Fibrin D-dimer
 anticoagulation duration and, 559
 in DIC, 545
 in DVT/PE (venous thromboembolic disease), 34, 299, 300, 301*f*
 chest pain evaluation and, 29
 reference values for, 1729*t*
- Fibrinogen
 deficiency of in liver disease, 553

- in DIC, 545
reference values for, 1730t
replacement. *See* Cryoprecipitate
- Fibroadenoma of breast, 719–720, 1718
- Fibroblast growth factor-23
(phosphatonin), 884, 1150
in metabolic bone disease/renal osteodystrophy/osteomalacia/rickets, 912, 1150
- Fibrocystic breast condition, 718–719, 1718, 1719
breast cancer risk and, 718, 719, 722, 723t
nipple discharge in, 718, 720, 720t
- Fibroelastoma, valvular papillary, 427
- Fibrogenesis imperfecta ossium, 1150, 1152
- Fibroid tumor of uterus, 757–759
- Fibromuscular dysplasia/hyperplasia
renal artery stenosis/renal vascular hypertension and, 437, 917, 918
transient ischemic attacks and, 977
- Fibromyalgia, 822–823
- Fibronectin, fetal, preterm labor and, 796
- Fibrosing cholestatic hepatitis, 675
- FibroSure score, in cirrhosis, 687
- Fibular (peroneal) nerve, common, injury to, 1027
- Fidaxomicin, for antibiotic-associated colitis, 637, 638
- Field defects/loss. *See* Visual field defects/loss; Visual impairment/loss
- Fifth disease (erythema infectiosum), 1356t, 1402
- Figurate (“shaped”) erythema, 95t. *See also specific type and Erythemas*
- Filariasis, 1524–1528
eosinophilic pulmonary syndromes and, 296, 1525
loiasis, 1527–1528
lymphatic, 1524–1525, 1525f
onchocerciasis, 1526–1527
- Filgrastim (G-CSF)
for chemotherapy-induced toxicity, 1649, 1659t
for HIV infection/AIDS, 1340
for myelodysplastic syndromes, 518
for neutropenia, 510, 1649
for stem cell mobilization, 532, 533
- Filoviruses, hemorrhagic fevers caused by, 1384, 1385
- Financial abuse, of elderly, 72
- Financial planning, advance, for dementia patients, 62
- Finasteride (5-alpha-reductase inhibitor), 1163
for androgenetic (pattern) baldness, 156
for benign prostatic hyperplasia, 958t, 959–960, 960
for hirsutism/virilization, 1163
for urinary incontinence, 69
- Fine-needle aspiration biopsy/cytology
for breast lump evaluation/
management, 718, 719, 727–728, 728f, 729f, 1718, 1719.
See also Breast, biopsy of
- in lung cancer, 1597
for metastatic neck disease, 240
in mycobacterial lymphadenitis, 240
for parotid tumors, 233
thyroid, 1105t, 1124–1125, 1124t
in thyroid nodules/cancer, 1105t, 1124–1125, 1124t
in thyroiditis, 1121
in visceral leishmaniasis, 1488
- Fingernails, disorders of. *See* Nail disorders
- Fingers
in nocardiosis, 1457
in polyarteritis nodosa, 847
in pompholyx (vesiculobullous hand eczema), 121, 121f
in Raynaud phenomenon, 836, 837
in rheumatoid arthritis, 826, 826f, 831
in scleroderma, 838
thromboangiitis obliterans (Buerger disease) involving, 472
- Fingolimod, for multiple sclerosis, 1011
- Firearms, prevention of injury caused by, 17
- Firmagon. *See* Degarelix
- First aid. *See also* Cardiopulmonary resuscitation
in near drowning, 1556
- First-degree burn, 1550
- First-degree heart block, 394, 394–395
in myocardial infarction, 373
- First heart sound (S₁). *See* Heart sounds
- Fish. *See also* Shellfish
anisakiasis and, 610, 1524
clonorchiasis/opisthorchiasis and, 1513
gnathostomiasis and, 1522
intestinal flukes and, 1513
mercury contamination and, 1583
poisoning caused by, 1589, 1589t
tapeworm infection and, 1514
- FISH. *See* Fluorescent in situ hybridization
- Fish oil/omega-3 fatty acids
platelet function affected by, 549t
preventable disease/deaths associated with low intake of, 3t
- Fish tapeworm (*D latum*), 1514
vitamin B₁₂ deficiency and, 497, 1514
- Fistula in ano, 661
- Fistulas
bacterial overgrowth and, 625
in Crohn disease, 641, 642, 661
in diverticulitis, 652
perianal, 661
perilymphatic, 210t, 211
- FIT. *See* Fecal immunochemical test
- Fitness. *See also* Exercise/activity functional, 13
- Fitz-Hugh and Curtis syndrome, 763
- 5q- syndrome, 517, 518
- Fixed drug eruptions, 159t
- FLAER (fluorescein-labeled proacrolysin variant) assay, in paroxysmal nocturnal hemoglobinuria, 502
- Flagellates, intestinal, 1510. *See also specific type*
- Flagyl. *See* Metronidazole
- Flail leaflet, 340
- Flame (clothing) burns, electrical, 1552
- Flank pain
in polycystic kidney disease, 934, 935
in pyelonephritis, 941
in renal cell carcinoma, 1641
in urinary stone disease, 947, 947–948
- Flash (arcing) burns, 1552
- Flashbacks, psychedelic drug use and, 1084
- Flashing lights (photopsia), in migraine headache, 963
- Flatus, 573
in lactase deficiency, 573, 626
- Flaviviruses
Chikungunya fever caused by, 1392
dengue caused by, 1386
encephalitis caused by, 1378–1380, 1390
hemorrhagic fevers caused by, 1384, 1385
yellow fever caused by, 1389
- Fleas
in bacillary angiomatosis, 1331
in California rickettsiosis, 1409t
in endemic typhus, 1409t, 1410–1411
in plague transmission, 1451
skin lesions caused by, 149
in tick typhus transmission, 1414
- Flecainide, 377, 378t
for atrial fibrillation, 387
overdose/toxicity of, 377, 378t, 1588
- “Fleeting blindness” (amaurosis fugax), 184, 469, 981
- FleetsPhospho-soda. *See* Sodium phosphate
- Flexible sigmoidoscopy. *See* Sigmoidoscopy
- Flexion, assessment of, in shoulder, 1676t
- Fliers. *See* Air travel
- Flies
in African trypanosomiasis, 1484, 1485
in amebiasis, 1503, 1504–1505
in leishmaniasis, 1487, 1489
in loiasis, 1527
in onchocerciasis, 1526, 1527
- Floater, in vitreous hemorrhage, 180
- Flofan. *See* Epoprostenol
- Floppy iris/eye syndrome, 179, 959
- Floppy mitral valve. *See* Mitral valve prolapse
- Flower cells, in adult T cell lymphoma/leukemia, 1384
- Floxin. *See* Ofloxacin
- FLT3 gene, in acute leukemia, 519
- Flu. *See* Influenza
- Flu shots. *See* Influenza virus vaccine
- Fluconazole, 110, 1541t
for candidiasis, 110, 1530
disseminated disease, 1530
endocarditis, 1530
esophageal, 598, 1338t, 1530
funguria, 1530
mastitis, 132
oral, 226, 1329
prophylactic, 1337
vulvovaginal, 132, 752, 1338t, 1530
for coccidioidomycosis, 1337, 1533
for cryptococcal meningitis, 993, 1337, 1338t, 1536
for onychomycosis, 158
prophylactic, 1281
for tinea versicolor, 114

- Flucytosine, 1541*t*
for cryptococcal meningitis, 1338*t*, 1536
- Fludara. *See* Fludarabine
- Fludarabine, 1651*t*
for chronic lymphocytic leukemia, 522
- Fludrocortisone
for Addison disease, 1157
for autonomic dysfunction/diabetic neuropathy, 1021, 1226
for renal tubular acidosis, 892*t*, 894
- Fluid and electrolyte disorders, **870–888**.
See also specific electrolyte
assessment of, **870**, 871*t*
in diabetic ketoacidosis, 1232, 1233
management/replacement guidelines and, **897**, 897*t*
- Fluid management/hydration, **897**, 897*t*.
See also Water/fluid intake
in ARDS, 323
in burns, 1550–1551
chemotherapy-induced hemorrhagic cystitis and, 1661
in cholera, 1448
cisplatin therapy and, 1662
contrast media nephrotoxicity mediated by, 904
in diabetes insipidus, 1098, 1099
for diabetic ketoacidosis, 1233
for diarrhea/gastroenteritis, 576, 897*t*, 1296
in GI bleeding/variceal hemorrhage, 581, 602
gout and, 814, 815
heat exposure syndromes and, 1547, 1548
for hypercalcemia, 884, 1143, 1646–1647
for hyperemesis gravidarum, 787
for hyperglycemic hyperosmolar state, 1236
for hyponatremia, 876
for hyponatremia, 874–875
hypotension in poisoning/drug overdose and, 1563
with hypotonic fluids, hyponatremia and, 872
lactation and, 786
for metabolic alkalosis, 895
methotrexate therapy and, 1662
in nausea and vomiting, 568
nutritional support and, 897, 1271
for pancreatitis, 713, 714
in protein–energy malnutrition, 1258
for rhabdomyolysis, 844, 905
in shock, 486, 487
cardiogenic, 374, 487
for terminally ill/dying patient, **90–91**
for tumor lysis syndrome/
hyperuricemia, 1647
in urinary stone disease, 947, 948, 949
water deficit calculation and, 876
- Fluid volume alterations. *See also*
Dehydration
hyperosmolality with and without, **877**
metabolic alkalosis and, 894–895
overload, **877**
- Flukes, infections caused by, **1511–1514**.
See also specific type
blood flukes (schistosomiasis), **1511–1512**
liver/lung/intestinal flukes, **1512–1514**
- Flumazenil, for benzodiazepine overdose/coma, 1043, 1563, 1566*t*, 1579–1580
- FluMist. *See* Influenza virus vaccine
- Flunisolide
for allergic rhinitis, 218
for asthma, 253*t*
- Fluocinolone, 96*t*, 1190*t*
- Fluocinonide, 96*t*
- Fluorescein-labeled proacrolysin variant (FLAER) assay, in
paroxysmal nocturnal hemoglobinuria, 502
- Fluorescent in situ hybridization (FISH),
for HER-2/*neu* assessment in breast cancer, 734
- Fluorescent treponemal antibody absorption (FTA-ABS) test.
See FTA-ABS test
- Fluorometholone, for ophthalmic disorders, 170*t*
- Fluoroquinolones
adverse ophthalmic effects of, 197*t*
for bacterial rhinosinusitis, 215–216
for diarrhea, 577
hypo- and hyperglycemia caused by, 1244
for pneumonia, 273, 273*t*
- Fluorouracil, 1652*t*
for actinic keratoses, 117
adverse ophthalmic effects of, 197*t*
for colorectal cancer, 1625, 1626
for gastric adenocarcinoma, 1617
- Fluoxetine, 1067, 1070*t*. *See also*
Serotonin-selective reuptake inhibitors
breastfeeding and, 782*t*
in elderly, 63
lithium interactions and, 1074*t*
MAOI interactions and, 1585
for OCD, 1044
overdose/toxicity of, 1070*t*, 1591–1592
during pregnancy, 1067–1068
for psychosexual disorders, 1051
- Fluoxymesterone, 1176
for aplastic anemia, 509
- Fluphenazine, 1056, 1056*t*, 1057*t*. *See also*
Antipsychotic drugs
enanthate or decanoate forms of, 1059
for Tourette syndrome, 1005
- Flurandrenolide, 96*t*, 1190*t*
- Flurazepam, 1042*t*, 1043, 1076
- Flurbiprofen, 77*t*
for ophthalmic disorders, 169*t*
- Flutamide, 1163, 1656*t*
for hirsutism/virilization, 1163
for prostate cancer, 1637*t*
- Fluticasone
for allergic rhinitis, 218
for asthma, 251*t*, 253*t*
for COPD, 263
with salmeterol, 251*t*, 263
- Flutter valve breathing devices
for bronchiectasis, 266
for chronic bronchitis, 264
for cystic fibrosis, 268
- Fluvastatin, 1253–1254, 1255*t*. *See also*
Statin drugs
- Fluvoxamine, 1067. *See also* Serotonin-selective reuptake inhibitors
- MAOI interactions and, 1585
overdose/toxicity of, 1591–1592
during pregnancy, 1067–1068
- Fluzone High-Dose. *See* Influenza virus vaccine, high-dose
- Flying. *See* Air travel
- Flying squirrels, in epidemic louse-borne typhus, 1408
- FML/FML Forte/FML S.O.P. *See* Fluorometholone
- FMRI* gene, in fragile X mental retardation, 1667
- FNA cytology. *See* Fine-needle aspiration biopsy/cytology
- Foam sclerotherapy, for varicose veins, 479
- FOBT. *See* Fecal occult blood testing
- Focal nodular hyperplasia of liver, 701, 702
telangiectatic, 702
- Focal segmental glomerulosclerosis, 920*t*, **930**
in HIV-associated nephropathy, 931
- Focal (partial) seizures, 969, 970*t*. *See also* Seizures
differential diagnosis of, 971
drug therapy for, 972, 973*t*
intracranial tumors causing, 969, 989
schizophrenia differentiated from, 1055
transient ischemic attack differentiated from, 971, 978
- Focal torsion dystonia, **1003**
- Folate. *See* Folic acid
- Foley catheter
fluid resuscitation in burn care and, 1551
health care (hospital)-associated urinary tract infection and, 1282, 1284
in shock management, 486
- FOLFIRI regimen, 1625
- FOLFIRINOX regimen, 1609
- FOLFOX regimen, 1625, 1626
- Folic acid (folate), 499
antagonists/inhibition of synthesis of.
See also Methotrexate
in cancer chemotherapy, 1651*t*
for malaria, 1497, 1498
deficiency of, 490, **499**, 499*t*
hereditary spherocytosis and, 501
in homocystinuria/
hyperhomocysteinemia, 1668
in pregnancy, 499, 799
thrombocytopenia and, 540
vitamin B₁₂ deficiency and, 498, 499
supplementary, 499
for hemoglobin H disease, 496
for hereditary spherocytosis, 501
for homocystinuria/
hyperhomocysteinemia, 1669
with methotrexate, 829, 1658*t*, 1661, 1662
in pregnancy, 499, 783, 785, 799
seizure disorders and, 803
- Folinic acid (leucovorin) rescue
with 5-fluorouracil, 1625, 1658*t*
with methotrexate, 829, 1658*t*, 1661, 1662
- Follicle-stimulating hormone (FSH)
in amenorrhea, 1163, 1179, 1180, 1180–1181, 1181

- deficiency of, 1093, 1094. *See also* Hypogonadism
 in hirsutism/virilization, 1163
 in hypogonadism, 1093, 1094, 1097, 1173, 1175
 in infertility workup, 768, 955
 for male infertility, 955, 1097
 in menopause, 779, 1181
 in polycystic ovary syndrome, 765, 1162, 1163
 recombinant, for ovulation induction, 769
 reference values for, 1730*t*
 in testicular cancer, 1177
- Follicular bronchiolitis, 269
 Follicular lymphoma, 524, 525
 stem cell transplantation for, 533
- Folliculitis, 129–130, 130*f*, 1425
 acne and, 126, 129
 eosinophilic, 129, 130, 1322
 in HIV infection/AIDS, 129, 130, 1322, 1331
 nasal vestibulitis and, 130, 217
 steroid (steroid acne), 126, 129
- Follitropins, for infertility, 1097
- Folotyn. *See* Pralatrexate
- Fomepizole, for methanol or ethylene glycol poisoning, 1566*t*, 1584
- Fomivirsen, 1353*t*, 1365
- Fondaparinux, 555, 557*t*, 558, 559*t*
 for acute coronary syndromes, 361, 362*t*
 coagulopathy caused by, 554
 for myocardial infarction, 362*t*
 after thrombolytic therapy, 370
 for venous thromboembolic disease prevention/treatment, 557*t*, 558, 559*t*
- Fonsecaea pedrosoi*, chromoblastomycosis caused by, 1540
- Food
 allergy/intolerance to
 anaphylaxis caused by, 866
 atopic dermatitis and, 103
 dyspepsia caused by, 564
 aspiration of (café coronary), 308
 contaminated. *See specific disease and*
 Food poisoning
 esophageal foreign body, 239
 goitrogenic, 1134
 inadequate, in protein–energy malnutrition, 1257
 MAOI interactions and, 1000, 1585
 oral antimicrobial administration and, 1305
 supplementing oral intake and, 1270–1271, 1271*f*. *See also* Nutritional support
 withholding, in terminally ill/dying patient, 90–91
- Food poisoning, 575, 1293, 1294–1295*t*. *See also* Gastroenteritis
 botulism, 1033–1034, 1294*t*, 1431
Cyclospora causing, 574*t*, 575, 576, 578, 1293, 1506–1507, 1507
 seafood contamination/toxicity and, 1589, 1589*t*
 vibrios causing, 574*t*, 576, 1293, 1294*t*, 1298, 1448
- Foot. *See* Feet
- Foramen ovale, patent, 327–329
- Forced diuresis
 in poisoning/drug overdose, 1567
 urinary stones and, 950
- Forced expiratory volume in one second. *See* FEV₁
- Forced expiratory volume in one second/forced vital capacity ratio.
See FEV₁/FVC ratio
- Forced vital capacity. *See* FVC
- Foreign body
 aspiration of, 238–239. *See also*
 Aspiration
 retention and, 308
 conjunctival/corneal, 192
 in ear canal, 200
 esophageal, 239
 intraocular, 192
 in trachea and bronchi, 238–239, 308
 in upper aerodigestive tract, 238–239, 308
- Formaldehyde, marijuana soaked in (“AMP”), 1085
- Formication, stimulant abuse and, 1055
- Formoterol, for asthma, 250–252, 251*t*
 with budesonide, 251*t*, 252
- Fortaz. *See* Ceftazidime
- Forteo. *See* Teriparatide
- Fortesta, 1176. *See also* Testosterone replacement therapy
- Fortovase. *See* Saquinavir
- Fosamprenavir, 1341*t*, 1344, 1345, 1348*f*.
See also Antiretroviral therapy/HAART
 with ritonavir, 1345
- Fosaprepitant, 569, 569*t*
- Foscarnet, 1353*t*
 for CMV infection, 187, 598, 1338*t*, 1353*t*, 1365
 for herpes simplex infections, 1338*t*, 1352, 1353*t*
 for herpes zoster, 120, 1339*t*, 1353*t*, 1359
- Foscavir. *See* Foscarnet
- Fosinopril/fosinopril with hydrochlorothiazide, 450*t*
- Fosphenytoin, 974
- Fourth heart sound (S₄/atrial gallop). *See* Heart sounds
- Fourth nerve paralysis, 190
- Foxglove, toxicity of, 1578–1579
- FOXP3 gene, in type 1 diabetes, 1193
- FPN1 gene, in hemochromatosis, 695
- Fractional excretion, 870
 of magnesium, in hypomagnesemia, 888
 of nitric oxide, in asthma, 248
 of phosphate, 886
 of sodium
 in acute kidney injury/tubular necrosis, 902*t*, 903, 905
 in glomerulonephritis, 908
- Fractional flow reserve, in angina, 354
- Fracture-dislocation, spinal, 1018
- Fractures. *See also specific type and under*
 Bone
 atypical, bisphosphonates causing, 1147
 in diabetes, 1228
 in elderly, falls and, 65
- estrogen replacement therapy affecting risk of, 1182
- in hypercalcemia/hyperparathyroidism, 1139, 1141
- in metabolic bone disorders/renal osteodystrophy, 912
- in osteomalacia, 1150, 1151
- in osteoporosis, 11, 1144, 1710
 prevention of, 11, 1710–1711
 in Paget disease of bone, 1152, 1153
 pathologic. *See* Pathologic fractures risk assessment tool and, 1710
 thiazolidinedione use and, 1210
- Fragile X mental retardation, 1667
- Fragile-X tremor-ataxia syndrome, 1667
- Fragility fractures. *See* Pathologic fractures
- Frailty, in elderly, 69–70
- Frambesia (yaws), 1300*t*, 1475
- Framingham score/projections, 1249–1250*t*, 1250
 in HIV infection/AIDS, 1344
 obesity and, 14
 for women, 1249–1250*t*, 1250, 1706
- Francisella tularensis* (tularemia), 1450–1451
- Frataxin gene, in Friedreich ataxia, 1022
- FRAX tool, 1710
- Freckles (ephelides), 101, 155, 156
- Free erythrocyte protoporphyrin, 1730*t*
- Free-living amebas. *See* Amebas
- Free thyroxine assay (FT₄), 1105, 1105*t*.
See also Thyroxine
 in euthyroid sick syndrome, 1107
 in hyperthyroidism, 1113
 amiodarone-induced, 1113
 during pregnancy, 800, 1113
 thyroiditis and, 1121
 after treatment, 1115, 1116
 in hypopituitarism, 1095
 in hypothyroidism, 1107
 levothyroxine treatment and, 1096, 1107, 1108
 reference values for, 1735*t*
 thyroid cancer surveillance and, 1132
- Free thyroxine index (FT₄I)
 in euthyroid sick syndrome, 1107
 in hyperthyroidism, 1113
 hypothyroidism in pregnancy and, 1109
- Free triiodothyronine (FT₃), 1105, 1105*t*
 in hyperthyroidism, 1105*t*, 1113
- Frenzel goggles, in vertigo evaluation, 210
- Freons, toxicity of, 1588
- Frequency, urinary. *See* Irritative voiding symptoms
- Fresh-frozen plasma, transfusion of, 537.
See also Transfusion
 for anticoagulant overdose, 1573
 for bleeding disorders, 537, 550*t*
 for cirrhosis-related bleeding, 690–691
 for DIC, 545, 546*t*
 for GI bleeding/variceal hemorrhage, 582
 for thrombotic microangiopathies, 543
- Fresh whole blood, transfusion of, 534.
See also Transfusion
- Frey procedure, for pancreatitis, 717
- Friction rubs. *See* Pericardial friction rub; Pleural friction rub; Tendon friction rub

- Fried rice, *Bacillus cereus* contamination of, 1293, 1294t
- Friedreich ataxia, 1022
- Frigidity, 1050
- Frontal lobe lesions, 989
- Frontal sinusitis, 215, 216
- Frontotemporal dementias, 1008–1009, 1008t
- Frostbite, 1545, **1546**
Raynaud phenomenon and, 837
- Frostnip, **1545**
- Frovatriptan, for migraine headache, 964
- Frozen packed red blood cells, transfusion of, 534. *See also* Transfusion
- Frozen shoulder, **1682–1683**
in diabetes, 1228
- Fructosamine, serum levels of
in diabetes mellitus, 1199
reference/normal values for, 1199, 1730t
- Fructose
for diabetics, 1205
diarrhea caused by, 578
flatus caused by, 573
- FSH. *See* Follicle-stimulating hormone
- FT₃. *See* Free triiodothyronine
- FT₄. *See* Free thyroxine assay
- FT₄I. *See* Free thyroxine index
- FTA-ABS test, 1466, 1466t
on cerebrospinal fluid (CSF FTA-ABS), 1473
in HIV infection/AIDS, 1335
- FTO gene, in type 2 diabetes, 1194
- FU. *See* Fluorouracil
- Fuchthalmic. *See* Fusidic acid
- Fugue, 1041
- Fukuda test, 210
- Full liquid diet, 1268
- Full-thickness burn, survival and, 1550
- Fulminant ulcerative colitis, 646, 649
- Fulvestrant, 740, 740t, 1657t
- Fumagillin, for microsporidiosis, 1508
- Functional alimentary hypoglycemia, **1242–1243**
- Functional asthma, 248
- Functional capacity/status, assessment of/
screening for
cancer evaluation and, 1663
in elderly, 57–58, 59
- Functional dyspepsia, 564, 565, 566
- Functional fitness, 13
- Functional hyperventilation. *See* Hyperventilation
- Functional proteinuria, 898–899
- Functional testing, in musculoskeletal evaluation, 1673
- Fundoplication
for erosive esophagitis/GERD, 597
with myotomy, for achalasia, 605
- Fungal infections, **1529–1542**. *See also* specific type
of bones and joints, **862–863**
drugs for, 97–98t, **1541–1542**, 1541–1542t. *See also* Antifungal agents
in HIV infection/AIDS
otologic, 213
prevention of, 1337
rashes, 1331
keratitis, 173–174
myocarditis in, 409t
of nails, 157, 158
opportunistic, 1280–1281
superficial, **110–114**, 110f, 111f, 113f.
See also Tinea
in HIV infection/AIDS, 1331
systemic/invasive, **1529–1542**
sinusitis, **217–218**
- Fungemia
in candidiasis, 132, 1530, 1542
in coccidioidomycosis, 1532
- Funguria, candidal (candiduria), 1529, 1530
- FUO. *See* Fever, of unknown/
undetermined origin
- Furazolidone, for giardiasis, 1509
- Furosemide. *See also* Diuretics; Loop diuretics
in acute tubular necrosis, 905–906
for cirrhotic ascites, 688
for heart failure, 401
infarct-related, 373
for hypercalcemia, 884
for hypertension, 445t, 446
in urgencies/emergencies, 462t, 463
hypocalcemia/hypoparathyroidism and, 1138
hypokalemia and, 878
lithium use and, 1074
for pulmonary edema, 408
- Furuncles/furunculosis, **151–152**, 1303t, 1421t, 1425, 1425f
in HIV infection/AIDS, 1331
- Fusarium*, in opportunistic infection, 1540–1541, 1542
- Fusidic acid, for ophthalmic disorders, 168t
- Fusilev. *See* Levoleucovorin
- Fusion inhibitors. *See* Entry inhibitors
- Fusobacteria/*Fusobacterium necrophorum*, 1419, 1420, 1454
- Fuzeon. *See* Enfuvirtide
- FVC (forced vital capacity)
in asthma, 244t, 246
in COPD, 260
in cystic fibrosis, 267
ratio of to forced expiratory volume in one second. *See* FEV₁/FVC ratio
- FXTAS (fragile-X tremor-ataxia syndrome), 1667
- G6PD deficiency. *See* Glucose-6-phosphate dehydrogenase (G6PD) deficiency
- G20210A prothrombin mutation
in hepatic vein obstruction (Budd-Chiari syndrome), 698
in noncirrhotic portal hypertension, 700
- GA (tabun) poisoning, 1587
- GABA. *See* Gamma-aminobutyric acid
- Gabapentin, 972, 973t. *See also* Anticonvulsant therapy
for menopausal symptoms, 780, 1181, 1186
for neuropathic pain/painful diabetic neuropathy, 84–85, 84t, 1021, 1049, 1225
overdose/toxicity of, 973t, 1573
for phobic disorder, 1044
for postherpetic neuralgia, 121, 968, 1359
for restless legs syndrome, 1004
for seizures, 972, 973t
- GABHS. *See* Group A β -hemolytic streptococcal infection
- GAD65 antibodies, in type 1 diabetes, 1193, 1193t
- Gadolinium, nephrogenic systemic fibrosis caused by, 437, 917, 937
- Gait/gait disorders. *See also* Falls
in ACL injury, 1693
in elderly, **65–66**, 66t, 67t
hip osteoarthritis and, 1691
in meniscal injuries of knee, 1700
in normal-pressure hydrocephalus, 1007
in parkinsonism, 998
in spinal stenosis, 822
in tabes dorsalis, 1472
- Galactomannan, in invasive aspergillosis, 1537
- Galactorrhea, 1102, 1103
- α -D-Galactosidase enzyme (Beano), for gastrointestinal gas, 573
- Galantamine, for dementia, 61, 1008
- Galerina* (amatoxin/aminitin toxin)
mushroom poisoning, 1585–1586
- Gallaverdin phenomenon, 342
- Gallbladder
carcinoma of, 1605–1606, 1606, 1607
cholesterolosis of, 703t, 705
gangrene of, 705
hydrops of, 705
porcelain, 703t, 705, 1606
during pregnancy, 703, 704, 807
removal of. *See* Cholecystectomy
stones in. *See* Cholelithiasis
strawberry, 705
- Gallium nitrate, for cancer-related hypercalcemia/toxicity/bone pain, 1647
- Gallstone ileus, 703
- Gallstones. *See* Cholelithiasis
- Galvus. *See* Vildagliptin
- Gamete intrafallopian transfer (GIFT), 769
- Gamma-aminobutyric acid (GABA), in Huntington disease, 1002
- Gamma-butyrolactone, overdose/toxicity of, 1580
- Gamma-globin, in sickle cell syndromes, 503
- Gamma globulin
intravenous. *See* Intravenous immune globulin
serum
in autoimmune hepatitis, 679
in cirrhosis, 687
- Gamma-glutamyl transpeptidase (GGTP) levels
alcohol use/abuse and, 1081
in liver disease/jaundice, 664
reference values for, 1730t
- Gamma-hydroxybutyrate, overdose/toxicity of, **1580**
Cushing syndrome and, 1158, 1160
- Gamma interferon. *See* Interferon- γ
- Gamma knife radiation/gamma radiosurgery

- for intracranial arteriovenous malformations, 988
for pituitary adenoma, 1102, 1104, 1160
for thyroid cancer brain metastases, 1131
for trigeminal neuralgia, 967
- Gammopathy, monoclonal. *See* Monoclonal gammopathy
- Gamolenic acid, for fibrocystic condition, 719
- Ganciclovir, 1353*t*
for CMV infection, 187, 598, 1280, 1337, 1338*t*, 1353*t*, 1365
for ophthalmic disorders, 168*t*, 187, 1365
- Ganfort. *See* Bimatoprost/timolol
- Ganglioneuromas, in MEN, 1188*t*, 1190
- Gangrene
anaerobic infection and, 1456
bacterial synergistic, 1456
digital, in polyarteritis nodosa, 847
of feet, in diabetes mellitus, 1227–1228
of gallbladder, 705
gas, 1300*t*, **1428–1429**
- Gardasil. *See* Human papillomavirus (HPV) vaccine
- Gardner syndrome, epidermal inclusion cysts in, 152
- Gardnerella infection* (bacterial vaginosis), 751–752, 752*f*, 753
rape/sexual assault in transmission of, 1291
- Gas, gastrointestinal, **573–574**
- Gas gangrene, 1300*t*, **1428–1429**
- Gasoline, sniffing, 1086
- Gastrectomy
for carcinoids, 1619
for gastric cancer, 1617
prophylactic, 1616
hypoglycemia after, 1242
vitamin B₁₂ deficiency and, 497
- Gastric acid/gastric contents
aspiration of. *See also* Aspiration
acute (Mendelson syndrome), **308**, 1283
anaerobic pneumonia/lung abscess and, 278, 1303*t*
chemical pneumonitis and, 308
chronic, **308**
in comatose patient, 1562
nosocomial pneumonia and, 275
hypersecretion of, in Zollinger-Ellison syndrome/gastrinoma, 619, 620, 1172, 1189
inhibition of secretion of. *See* Acid-antisecretory agents; Antacids; H₂ receptor blocking drugs; Proton pump inhibitors
radiation affecting secretion of, 1554
reflux of. *See* Gastric acid refluxate; Gastroesophageal reflux disease
- Gastric acid refluxate. *See also* Gastroesophageal reflux disease
abnormal clearance of, 594
irritant effects of, 593–594
- Gastric banding surgery, for obesity, 14, 1261
in type 2 diabetes, 1220
- Gastric bypass, for obesity, 14, 1261
hypoglycemia after, 1242
in type 2 diabetes, 1220
- Gastric cancer, 1612*t*
adenocarcinoma, **1615–1618**
H pylori infection and, 609, 1615, 1616
pernicious anemia gastritis and, 610
carcinoid tumors, **1619**, 1621
dyspepsia in, 564, 1616
GI bleeding and, 581, 1616
H pylori gastritis and, 609, 1615, 1616
lymphoma, **1618–1619**
H pylori infection and, 525, 609, 1618, 1618–1619
mesenchymal tumors, **1619–1620**
peptic ulcer disease and, 609, 617, 1616–1617
pernicious anemia gastritis and, 610
- Gastric emptying
delayed
antipsychotics causing, 1059
in GERD, 594
in scleroderma, 839
in poisoning/drug overdose, 1566, 1567
- Gastric lavage, for poisoning/drug overdose, 1567
- Gastric mucosal biopsy, in gastric adenocarcinoma, 1616, 1617
- Gastric neoplasms
benign, **620–621**
malignant. *See* Gastric cancer
- Gastric outlet obstruction
in peptic ulcer disease, **619**
vomiting and, 567*t*, 568, 619
- Gastric pH
nosocomial pneumonia and, 276
in Zollinger-Ellison syndrome/gastrinoma, 619–620
- Gastric polyps, 620–621
- Gastric ulcers, 611, 612, 613, 614*t*, 615, 616. *See also* Peptic ulcer disease
gastric cancer and, 609, 617, 1616–1617
H pylori gastritis and, 609
refractory, 617, 1617
- Gastric varices, GI bleeding from, in portal hypertension, 581, 601
- Gastrin
D cells secreting, 1171
hypersecretion of
carcinoid tumors and, 1619
in pernicious anemia gastritis, 610
in Zollinger-Ellison syndrome/gastrinoma, 619, 620, 1172, 1189
proton pump inhibitors affecting, 613, 620
reference values for, 1730*t*
- Gastrinoma (Zollinger-Ellison syndrome), **619–620**, 1172, 1189
carcinoid tumors and, 1619
GERD and, 597, 619
in MEN, 619, 620, 1172, 1189
peptic ulcer disease and, 617, 619–620, 1172, 1189
- Gastritis, **607–610**. *See also* Gastropathy
alarm symptoms in, 608
alcoholic, 607, 608
in anisakiasis, 610, 1524
atrophic
H pylori infection and, 610
in pernicious anemia, 497, 610
CMV, 610, 1364
eosinophilic, 610
erosive/hemorrhagic, **607–609**
GI bleeding and, 581, 607
H pylori, 564, 609–610
gastric cancer and, 609, 1615, 1616
nonerosive/nonspecific, **609–610**
NSAID, 607, 608, 828–829
in pernicious anemia, 497, 610
phlegmonous/necrotizing, 610
stress, 321, 607, 608
- Gastroenteritis, 1303*t*. *See also* Diarrhea
adenoviruses causing, 1293, 1330, 1402, 1404–1405
amebic (intestinal amebiasis), 574*t*, 575, 576, 578, 1293, 1298, 1303*t*, 1330, 1503, 1503–1504, 1504*f*, 1505*t*
appendicitis differentiated from, 631
Bacillus cereus causing, 574*t*, 1293, 1294*t*
campylobacter, 574*t*, 575, 1293, 1295*t*, 1296, 1297, 1298, 1303*t*, 1330, 1449
Guillain-Barré syndrome and, 1024
clostridial, 574*t*, 575, 576, 636–638, 1293, 1294*t*
coccidial and microsporidial, 1330, 1506–1508
E coli causing, 574*t*, 575, 576, 1293, 1294*t*, 1296, **1447**
food-borne. *See* Food poisoning
hypokalemia and, 878
in immunocompromised host/HIV infection/AIDS, 575, 578, 1325, 1330
irritable bowel syndrome and, 633
in measles, 1368
nausea/vomiting in, 575
noroviruses/Norwalk virus causing, 574*t*, 1293, 1295*t*, 1404–1405
reactive arthritis and, 857
rotaviruses causing, 574*t*, 1293, 1295*t*, 1404–1405
salmonella causing, 574*t*, 575, 1293, 1295*t*, 1296, 1298, 1303*t*, 1330, **1446**
shigella causing (shigellosis), 574*t*, 575, 1293, 1295*t*, 1296, 1297, 1298, 1303*t*, 1330, **1447**
staphylococcal, 574*t*, 575, 1293, 1294*t*
in vibrio infection, 574*t*, 576, 1293, 1294*t*, 1298, 1448
viral, 574*t*, 575, 1293, 1330, **1404–1405**. *See also* specific virus
Yersinia enterocolitica causing, 574*t*, 575, 576, 1293, 1295*t*
- Gastroesophageal junction mucosal laceration of. *See* Mallory-Weiss syndrome/tears
stricture at. *See* Esophagus, strictures of
- Gastroesophageal reflux disease (GERD), **593–597**
alarm features/troublesome symptoms and, 594, 596
antipsychotics causing, 1059
Barrett esophagus and, 594–595

- Gastroesophageal reflux disease (GERD)
(*Cont.*):
chest pain/discomfort in, 355, 594, 606
chronic gastric aspiration and, 308
cough and, 22, 22*t*, 23, 234, 594
dyspepsia in, 564, 594
erosive (reflux) esophagitis/GI bleeding
and, 581, 593, 594, 597
esophageal webs and rings and, 600
extraesophageal manifestations of, 594,
596–597
gastrinoma (Zollinger-Ellison
syndrome) and, 597, 619
heartburn in, 592, 593, 594
laryngopharyngeal reflux and, 234
peptic stricture and, 595
in scleroderma, 838, 839
- Gastrointestinal adenocarcinoma
gastric, **1615–1618**
H pylori infection and, 609, 1615,
1616
pernicious anemia gastritis and, 610
small intestine, **1620**
Crohn disease and, 643, 1620
- Gastrointestinal bleeding, **580–587**.
See also specific cause
abdominal aortic aneurysm repair and,
474
acute
lower, **583–585**
upper, **580–583**
from angioectasias, 581, 584, 586, 587
anorectal disease causing, 583, 584
aspirin and, 76, 583, 612
in cirrhosis, 581, 601, 602, 687
colorectal cancer and, 584, 1623
diverticular, 583, 584, 585, **652**
in erosive/hemorrhagic gastritis
(gastropathy), 581, 607
gastric cancer and, 581, 1616
from gastrointestinal/esophageal
varices, 581, 601–604
hemorrhoids causing, 584, 657, 658
in Henoch-Schönlein purpura, 852, 923
hepatic encephalopathy and, 602, 690
in hereditary hemorrhagic
telangiectasia, 581, 584, 1671
iron deficiency and, 491, 586–587
Kaposi sarcoma causing, 145
Mallory-Weiss syndrome/tears and,
581, 582, 599–600
noncirrhotic portal hypertension and,
700
NSAIDs and, 76, 583, 607, 615,
615–616, 828–829
obscure, **585–586**, 587
occult, **586–587**. *See also* Fecal occult
blood testing
in peptic ulcer disease, 581, **617–618**
in polycythemia, 512
in portal hypertension/portal
hypertensive gastropathy,
581, 601, 608
rebleeding and, 582, 602, 618, 828
in stress gastritis, 608
tumors causing, 581, 584
in typhoid fever, 1445–1446
- Gastrointestinal carcinoids
gastric, **1619**, 1621
small intestine, **1620–1621**
- Gastrointestinal fluid losses, replacement
guidelines for, 897*t*
- Gastrointestinal gas, **573–574**
- Gastrointestinal irritant-type mushroom
poisoning, 1586*t*
- Gastrointestinal lymphoma
gastric, **1618–1619**
H pylori infection and, 525, 609,
1618, 1618–1619
small intestine, **1620**
- Gastrointestinal mesenchymal tumors,
1619–1620
small intestinal sarcoma and, **1622**
- Gastrointestinal stromal tumors (GISTs),
1619–1620, 1622
- Gastrointestinal system, **564–661**. *See also
specific structure or organ and
under Intestinal*
anaerobic flora of, 1456
decontamination of, in poisoning/drug
overdose, **1566–1568**, 1568*t*
caustic/corrosive agent ingestion
and, 1566, 1567, 1571, 1572
disorders of, **564–661**
adverse ocular effects of drugs
used in, 196*t*
Angiostrongylus causing, 1522
in anisakiasis, 610, 1524
in anthrax, 1431, 1432, 1433
in ascariasis, 1517
bleeding. *See* Gastrointestinal
bleeding
cancer, **1612–1630**
paraneoplastic syndromes
associated with, 1596*t*
chemotherapy-induced, **1660–1661**
in chronic kidney disease/uremia,
909*t*, 910
CMV infection and, 1364
in common variable
immunodeficiency, 868
constipation and, **570–573**, 570*t*,
572*t*
in diabetic autonomic neuropathy,
1226
diarrhea and, **574–580**, 574*t*, 576*f*,
579*f*
dyspepsia in, **564–566**
in enterobiasis/pinworm infection,
1520
exenatide use and, 1211, 1211–1212
flukes causing, **1513–1514**
functional
dyspepsia, 564, 565, 566
irritable bowel syndrome, **632–
636**
gastrointestinal gas and, **573–574**
in gnathostomiasis, 1522
hiccups and, **569–570**
in HIV infection/AIDS, 1329–1330
in hookworm disease, 1518
in hypercalcemia/
hyperparathyroidism, 1139
in hyperoxaluric calcium
nephrolithiasis, 949
liraglutide use and, 1212
luminal gastrointestinal tract
dysfunction, 564
mesenchymal tumors, **1619–1620**
motility. *See* Motility disorders
- mushroom poisoning causing, 1585,
1586*t*
nausea and vomiting in, **566–569**,
567*t*
noncardiac chest pain/discomfort
and, **606–607**
in pheochromocytoma/
paraganglioma, 1168*t*
radiation causing, 1554
in schistosomiasis, 1511
in scleroderma, 838, 839
in strongyloidiasis, 578, 1519
in syphilis, 1471
in trichinosis, 1521
in trichuriasis/whipworm, 1517–
1518
in Turner syndrome, 1187*t*
Kaposi sarcoma involving, 145, 1331,
1339*t*, 1622
obstruction of. *See* Intestinal
obstruction
- Gastrojejunostomy, for gastric cancer,
1617
- Gastroparesis, 568, **629–630**
in diabetics, 629, 1226
hypoglycemia and, 1222
vomiting and, 568, 629
- Gastropathy, **607–610**. *See also* Gastritis
erosive/hemorrhagic, **607–609**
GI bleeding and, 581, 607
in HIV infection/AIDS, 1330
hypertrophic (Ménétrier disease), 610
portal hypertensive, 581, 607, 608–609.
See also Portal hypertension
- Gastroplasty, for obesity, 14
- Gastrostomies, 1271
- GATA3 gene mutations, HDR/Barakat
syndrome caused by, 1136
- Gatifloxacin
hypo- and hyperglycemia caused by,
1244
for ophthalmic disorders, 168*t*
- Gaucher cells, 1668
- Gaucher disease, **1667–1668**
- GB (sarin) poisoning, 1587
- GB surgery. *See* Gastric banding surgery
- GBL (γ -butyrolactone), overdose/toxicity
of, 1580
- GBM antibodies. *See* Anti-glomerular
basement membrane
antibodies
- GBP. *See* Gastric bypass
- G-CSF (granulocyte colony-stimulating
factor). *See* Filgrastim
- GD (soman) poisoning, 1587
- Gefitinib, 1654*t*
for lung cancer, 1600
- Gelatinase-associated lipocalin,
neutrophil, in acute tubular
necrosis, 904
- Gemcitabine, 1652*t*
- Gemfibrozil, 1254, 1255*t*
in HIV infection/AIDS, 1344
- Gemifloxacin, for pneumonia, 273*t*, 277*t*
- Gemzar. *See* Gemcitabine
- Gender identity disorder/gender
dysphoria, 1050, 1050–1051
- Gene expression profiling, in breast
cancer, 733–734
- Gene therapy

- for hemophilia, 550
for parkinsonism, 1001
- Generalized anxiety disorder, 1041, 1042–1044, 1042*t*, 1043*t*
- Generalized seizures, 969–970, 970*t*. *See also* Seizures
differential diagnosis of, 971–972
drug therapy for, 972, 973*t*
- Genetic disorders, **1664–1672**. *See also* *specific type*
electrolyte metabolism disturbances and, 878*t*
- Genetic instability
in colorectal cancer, 653, 656, 1622
in HNPCC, 656, 657
- Genetic testing/counseling. *See also* *specific disorder and* Prenatal testing
for cancer susceptibility genes/cancer screening
APC gene mutation, 655
breast cancer and, 722, 723
colorectal cancer and, 654, 655, 656
HNPCC and, 656, 656–657
MYH gene mutation, 655
ovarian cancer and, 764
ret mutation, 1189, 1190
clinical relevance and, 1725–1726*t*
for diabetes genes, 1193
for Duchenne muscular dystrophy, 1034
for familial Mediterranean fever, 591
for hemochromatosis, 695
for Huntington disease, 1002
in hypertrophic obstructive cardiomyopathy, 415
in male infertility, 955
for MEN, 1188, 1189
for pancreatitis, 716
for pheochromocytoma/paraganglioma, 1168
prenatal, 783
in sickle cell syndromes, 503, 504, 783, 799
- Genital herpes, **118–119**, 1350, 1351, 1352, 1355. *See also* Herpes simplex infection
anorectal involvement and, 659
during pregnancy/neonatal/congenital infection, **806**, 1351, 1355
- Genital reconstruction surgery, for transsexuals, 1050, 1051
- Genital ulcers, 1290
adenoviruses causing, 1402
in Behçet syndrome, 853
in chancroid, 1453
in granuloma inguinale, 1453
herpetic. *See* Genital herpes
in lymphogranuloma venereum, 659, 1461
STDs causing, 1290
in syphilis (chancr), 658, 1464, 1465, 1465*f*
- Genital warts. *See* Venereal (genital) warts
- Genitalia, ambiguous, in steroidogenic enzyme defects, 1156, 1162
- Genitourinary system. *See also* *specific organ or structure*
anaerobic flora of, 1456
disorders of, **938–961**. *See also* *specific type*
benign prostatic hyperplasia, **956–961**, 957*t*, 958*f*, 958*t*, 959*t*
in blastomycosis, 1539
cancer, **1630–1644**
in chronic kidney disease/uremia, 909*t*, 910
hematuria in, **938–939**
infections, **939–945**, 940*t*
anaerobic, in women, **1455–1456**
interstitial cystitis, 45, **945–946**
male erectile/sexual dysfunction, **951–953**
male infertility, **953–956**, 954*f*
radiation exposure causing, 1554
ulcers. *See* Genital ulcers
urinary incontinence, **67–69**
urinary stone disease, **946–950**, 947*t*
- Genotypic resistance testing, in antiretroviral therapy, 1347, 1348, 1349
- Gentamicin, 1723*t*. *See also* Aminoglycosides
for endocarditis, 1437, 1438, 1439
for ophthalmic disorders, 168*t*
for pneumonia, 273*t*, 277*t*
resistance to, 1422
for urinary tract infection, 940*t*
- Geodon. *See* Ziprasidone
- GERD. *See* Gastroesophageal reflux disease
- Geriatric medicine/disorders, **57–73**. *See also* Age/aging; Older adults
assessment of older adult and, **57–59**, 58*f*, 58*t*, 59*t*
management of common problems and, **59–73**
principles of care and, **57**
- Germ cell tumors
paraneoplastic syndrome associated with, 1596*t*
testicular, 1177, 1642–1644
bone marrow/stem cell transplantation for, 532
gynecomastia and, 1178, 1643
- Germline mutations/testing
in breast cancer, 722, 723*t*
in colorectal cancer, 1622
in gastric cancer, 1616
in HNPCC, 656, 1622
in MEN 1, 1188
- Gerstmann syndrome, 991
- Gerstmann-Sträussler-Scheinker syndrome (GSS), 1381, 1382
- Gestational diabetes, 784, 800–801, 801*t*. *See also* Diabetes mellitus
- Gestational hyperthyroidism. *See* Hyperthyroidism (thyrotoxicosis), during pregnancy
- Gestational thrombocytopenia, **547**
- Gestational trophoblastic disease, **791–792**, 1611*t*
hCG levels in, 781, 791, 792
hyperthyroidism in, 791, 1112
- Gestodene, in oral contraceptives, thromboembolism and, 770
- GFR. *See* Glomerular filtration rate
- GGTP levels. *See* Gamma-glutamyl transpeptidase (GGTP) levels
- GH. *See* Growth hormone
- GHB (γ -hydroxybutyrate), overdose/toxicity of, **1580**
Cushing syndrome and, 1158, 1160
- Ghon complex, in tuberculosis, 282
- GHRH. *See* Growth hormone-releasing hormone
- GHRH/arginine stimulation testing, 1095
- Giant cell (temporal/cranial) arteritis, **845–847**
headache in, 41, 845, **966**
ischemic optic neuropathy in, 188, 845–846
retinal artery occlusion and, 183
- Giant cell myocarditis, 409, 410
- Giant cell thyroiditis. *See* Subacute (de Quervain) thyroiditis
- Giardia antigen assay, stool, 576, 579, 1509
- Giardia lamblia/intestinalis/duodenalis* (giardiasis), 574*t*, 575, 576, 578, 579, 1293, 1298, 1330, **1509–1510**
- Gibbus deformity, in spinal tuberculosis, 863
- GIFT. *See* Gamete intrafallopian transfer
- Gigantism, **1100–1102**
- Gilbert syndrome, 662, 663*t*
- Gilles de la Tourette syndrome, **1004–1005**
OCD and, 1005, 1041
- Gingivitis
in HIV infection/AIDS, 1329
necrotizing ulcerative, **226**
- Gingivostomatitis. *See also* Gingivitis; Stomatitis
herpetic, 118, **227**, 1351
- Ginkgo, toxicity of, 1578*t*
- Ginseng, toxicity of, 1578*t*
- GIP1. *See* Glucose-dependent insulinotropic polypeptide
- GISTs. *See* Gastrointestinal stromal tumors
- Gitelman syndrome, 878*t*
- GLIS3 mutation, in diabetes, 1195, 1195–1196
- Glanders, 1300*t*
- Glanzmann thrombasthenia, 548
- Glasgow alcoholic hepatitis score, 682
- Glatiramer, for multiple sclerosis, 1011
- Glaucoma
acute angle-closure, 165*t*, **174–175**
antipsychotics precipitating, 1059
pupillary dilation precipitating, 174, **194–195**
chronic, **175–177**, 176*f*
angle-closure, 174
in diabetes mellitus, 176, 1223
facial pain caused by, 968
neovascular (rubeotic), retinal vein occlusion and, 182
normal-tension, 175
treatment of, 170–172*t*, 176–177
- Gleason grading system/score, for prostate cancer, 1632, 1634*f*, 1635*f*, 1638
CAPRA assessment tool and, 1637, 1637*t*
- Gleevec. *See* Imatinib
- GLI-similar 3 mutation, in diabetes, 1195, 1195–1196

- Gliclazide, 1206t, 1208
- Glimepiride, 1206t, 1208
with pioglitazone, 1213
with rosiglitazone, 1213
- Glioblastoma multiforme, 990t, 1611t
- Gliomas, 989, 991
brainstem, 990t, 991
spinal, 993
- Gliososis, in multiple sclerosis, 1010
- Glipizide, 1206t, 1208
with metformin, 1213
- Globin chain synthesis, in thalassemias, 494
- α -Globin gene, 494
in alpha thalassemia syndromes, 494, 494t, 495
in beta thalassemia syndromes, 495t
- β -Globin gene, 494
in beta thalassemia syndromes, 494, 494–495
- β -Globin synthesis, in sickle cell syndromes, 503
- γ -Globin, in sickle cell syndromes, 503
- Glomerular diseases, 909t, **918–928**, 918f, 919t, 920t, 921f
nephritic spectrum, 918f, 919, 919t, **920–927**, 921f. *See also specific type and Glomerulonephritis*
nephrotic spectrum, 918–919, 918f, 920t, **927–928**. *See also specific type and Nephrotic syndrome*
- Glomerular filtration rate (GFR), 899–901, 900t
acute kidney injury/tubular necrosis and, 902, 903, 904
alkalosis in alkali administration and, 895
chronic kidney disease and, 909, 910, 911f
dialysis indications and, 915
estimated, 899–901, 900t
reference/normal value for, 899, 1730t
uremic acidosis and, 891
- Glomerular proteinuria, 899
- Glomerulonephritis, 902t, **907–908**, 918f, 919t, 920–927, 920t, 921f
acute kidney injury caused by, 902t, 903, **907–908**
anti-glomerular basement membrane (anti-GBM), 306, 907, 919t, 921f, **924–925**
cryoglobulin-associated, 851, 919t, 921f, **925**
in Goodpasture syndrome, 306, 907, 919t, 921f, **924–925**
in granulomatosis with polyangiitis, 306, 849, 907, 919t, 921f, 924
in Henoch-Schönlein purpura, 852, 919t, **923**
IgA nephropathy, 919t, 921f, **922–923**
immune-complex, 907, 921f
in lupus/SLE, 833, 834, 835, 919t, 921f, **926–927**
membranoproliferative, 919t, 921f, **925**
hepatitis C infection and, 671, 919t, 926
idiopathic, 919t, 925
in microscopic polyangiitis, 851, 907, 921f, 924
nephritic presentation of, 918f, 919, 919t, 920–927, 921f
nephrotic spectrum presentation of, 918–919, 918f, 920t, **927–931**
pauci-immune (ANCA-associated), 849, 907, 919t, 921f, **924**
peri-infectious, 921f
postinfectious, 919t, 921f, **922**, 1419
rapidly progressive, 918, 918f
serologic testing in, 922
in syphilis, 1469
urinalysis in, 898, 902t, 907–908, 922
- Glomerulonephropathies, 909t. *See also Glomerulonephritis; Nephropathy*
membranoproliferative, 919t, 920t, 921f, **925**
hepatitis C infection and, 671, 926
- Glomerulopathy, sickle cell, 936
- Glomerulosclerosis
in diabetic nephropathy, 931
focal segmental, 920t, **930**
in HIV-associated nephropathy, 931
- Glomus tumors (tympanicum/jugulare), 206
tinnitus and, 206, 208
- Glossitis, **226**
- Glossodynia, **226**
- Glossopharyngeal neuralgia, **968**
earache in, 206
headache in, 962
- Glottic (true vocal fold) cancer, 236, 237
- GLP-1. *See* Glucagon-like peptide 1
- Glucagon
A cells secreting, 1171
for β -blocker overdose/toxicity, 1563, 1575
contraindications to use of in pheochromocytoma, 1168
for hypoglycemia, 1222
impaired response to, hypoglycemia and, 1222
in insulinoma diagnosis, 1240
reference values for, 1730t
tumors secreting, 1172, 1189
diabetes and, 1196
- Glucagon emergency kit, 1222
- Glucagon-like peptide 1 (GLP-1), 1211
- Glucagon-like peptide 1 (GLP-1) receptor agonists, for diabetes, 1206t, 1211–1212, 1220–1221, 1221
pancreatic/periapillary carcinoma and, 1607
- Glucagonomas, 1172, 1189
- β -D-Glucan levels
in aspergillosis, 1537
in *Pneumocystis* pneumonia, 1326, 1534
- β -Glucocerebrosidase, in Gaucher disease, 1668
- Glucocorticoid deficiency. *See also Adrenocortical insufficiency*
familial, 1156
- Glucocorticoid-remediable hyperaldosteronism, 437, 878t, 1164, 1166. *See also Aldosteronism*
- Glucocorticoid-secreting tumors, diabetes and, 1196
- Glucokinase gene defect, in MODY, 1194, 1195
- Glucometers, 1200
- Glucophage/Glucophage XR. *See* Metformin
- Glucosamine/glucosamine sulfate plus chondroitin, in osteoarthritis, 812, 1702
- Glucose. *See also* Glucose tolerance/intolerance
ascitic fluid, 588
bacterial peritonitis and, 588, 589
blood levels of. *See also* Hyperglycemia; Hypoglycemia
in alcoholic ketoacidosis, 891
in burn injury, 1552
in diabetes mellitus, 1198, 1198t, 1218
acceptable, 1221
coma and, 1232t
continuous monitoring of, 1200
control of. *See* Glycemic control
in diabetes
pregnancy and, 784, 800, 800–801, 801t, 1230
self-monitoring of, 1200
in pregnant patient, 801
surgery and, 54, 54t, 1229, 1229t
in diabetic ketoacidosis, 1232, 1232t
hemoglobin A_{1c} levels and, 1198–1199, 1198t, 1199t, 1201, 1202, 1203, 1204
in hyperglycemic hyperosmolar state, 1232f, 1236
in insulinoma, 1172, 1239–1240, 1240, 1241
monitoring/management of during surgery, 54, 54t, 1229, 1229t
near drowning and, 1556
prebreakfast hyperglycemia and, 1219, 1219t
reference/normal values for, 1198, 1198t, 1730t
testing, 1198, 1198t, 1218
in pregnancy, 784, 800, 800–801, 801t
- cerebrospinal fluid, in CNS infection, 1286t
- in diabetic ketoacidosis management, 1233
- drugs affecting absorption of, for diabetes mellitus, 1210–1211
- drugs affecting liver/muscle/adipose tissue, for diabetes mellitus, 1208–1210
- fatal hypophosphatemia and, 885
hyperosmolality caused by, 877
for hypoglycemia, 1222
hyponatremia and, 871f, 872, 874
pleural fluid, 314, 314t
in parapneumonic effusion, 314t, 315
for porphyria, 1022, 1664
in urine. *See* Glycosuria
- Glucose breath test, in bacterial overgrowth, 580, 625
- Glucose-dependent insulinotropic polypeptide (GIP1), 1211
- Glucose-6-phosphate dehydrogenase (G6PD) deficiency, **502–503**
dapsones therapy and, 503, 1280, 1337
primaquine therapy and, 1496
sulfasalazine therapy and, 830

- Glucose-6-phosphate dehydrogenase (G6PD) screen, 1730t
- Glucose tolerance/intolerance, 1198, 1198t. *See also* Diabetes mellitus
- in chronic kidney disease/uremia, 910
 - in Cushing syndrome, 1159
 - in diabetes mellitus, 1198, 1198t
 - functional alimentary hypoglycemia and, 1242–1243
 - impaired, 1198, 1198t, 1202
 - lithium affecting, 1073
 - prediabetes and, 1202
 - in pregnancy, 800, 800–801, 801t
 - reference/normal values for, 1198, 1198t
 - secondary conditions affecting, 1196, 1196t
 - testing, 1198t
 - in pregnancy, 784, 800, 800–801, 801t
- Glucose transporters, thiazolidinediones affecting expression of, 1209
- α -Glucosidase inhibitors
- for diabetes mellitus, 1206t, 1210–1211, 1220
 - overdose/toxicity of, 1211, 1220, 1580
- Glucosuria. *See* Glycosuria
- Glucotrol/Glucotrol XL. *See* Glipizide
- Glucovance. *See* Glyburide, with metformin
- GLUT 1/GLUT 4. *See* Glucose transporters
- Glutamate dehydrogenase assay, in antibiotic-associated colitis, 637
- Glutamic acid decarboxylase, in gene therapy for parkinsonism, 1001
- Glutamic acid decarboxylase 65 antibodies, in type 1 diabetes, 1193, 1193t
- Glutaminase gene, kidney-type, in hepatic encephalopathy, 690
- Glutamine, reference values for, 1730t
- γ -Glutamyl transpeptidase (GGTP) levels
- alcohol use/abuse and, 1081
 - in liver disease/jaundice, 664
 - reference values for, 1730t
- Glutathione reductase, in riboflavin deficiency, 1264
- Gluten
- in celiac disease/sprue, 621
 - in dermatitis herpetiformis, 123
- Gluten enteropathy. *See* Celiac disease
- Gluten-free diet, for celiac disease/dermatitis herpetiformis, 123, 622–623
- Glyburide, 1206t, 1207, 1207–1208
- with metformin, 1213
 - during pregnancy, 801, 1230
- Glycated (glycosylated) hemoglobin. *See* Hemoglobin A_{1c}/A_{1a}/A_{1b}/A_{1c}
- Glycemic control in diabetes
- acceptable/target levels of, 1221
 - complications rate and clinical studies of, 1201–1202, 1202–1204
 - in women, 1707
 - continuous glucose monitoring systems and, 1200
 - disordered eating in women and, 1713
 - estrogen replacement therapy affecting, 1182
 - exercise/activity and, 12, 1202, 1203
 - glycated hemoglobin (hemoglobin A_{1c}) measurements and, 1198–1199, 1199t, 1201, 1202, 1203
 - insulin injection sites and, 1216
 - nephropathy development/progression and, 931, 1201, 1203, 1224
 - pregnancy and, 801, 1230
 - retinopathy development/progression and, 185, 1201, 1203
 - self-monitoring of blood glucose and, 1200
 - in pregnant patient, 801
 - surgery and, 54, 54t, 1229, 1229t
 - vascular disorders and, 356, 1201, 1202, 1203, 1204
- Glycemic index, 1205
- Glycohemoglobins. *See* Hemoglobin A_{1c}/A_{1a}/A_{1b}/A_{1c}
- Glycoprotein Ib/IX, in Bernard-Soulier syndrome, 548
- Glycoprotein IIb/IIIa receptors
- drugs blocking
 - for acute coronary syndromes, 361, 362t, 363
 - for myocardial infarction, 362t, 368
 - PCI and, 357, 362t, 368
 - platelet function affected by, 549t
 - Glanzmann thrombasthenia and, 548
- Glycoprotein B vaccine, for CMV infection, 1366
- Glycoprotein-D vaccine, for HSV-2
- Glycopyrrrolate, in terminally ill/dying patient, 91
- Glycosuria/glycosuria
- in diabetes mellitus, 1197–1198
 - coma and, 1232t
 - hyperglycemic hyperosmolar state and, 1232t, 1236
 - ketoacidosis and, 235, 1232t
 - hypernatremia and, 876
 - nondiabetic (renal), 1198
 - in pregnancy, 1198
- Glycosylated (glycated) hemoglobin (hemoglobin A_{1c}). *See* Hemoglobin A_{1c}/A_{1a}/A_{1b}/A_{1c}
- Glycosylphosphatidylinositol (GPI) anchor deficiency, in paroxysmal nocturnal hemoglobinuria, 501
- Glycyrrheticin/glycyrrhizinic acid, hypertension/hypokalemia and, 437, 1166
- Glynase. *See* Glyburide
- Glyset. *See* Miglitol
- GM-CSF (granulocyte macrophage colony-stimulating factor). *See* Sargramostim
- GN. *See* Glomerulonephritis
- Gnathostoma* (gnathostomiasis), 1522–1523
- GnRH analogs. *See* Gonadotropin-releasing hormone (GnRH) analogs
- Goeckerman regimen, for psoriasis, 107
- Goiter
- endemic, 1134–1135
 - fetal, 1117
 - hyperthyroidism and, 1111
 - hypothyroidism/cretinism and, 1106, 1107, 1134
 - lithium causing, 1073
 - multinodular (nodular), 1123–1126, 1124t, 1134, 1135
 - toxic, 1111, 1114, 1116
 - substernal/retrosternal, 1134
 - thyroid surgery for, 1116, 1135
- Gold salts, adverse ophthalmic effects of, 197t
- Gold top SST, 1736t
- Golfer's elbow, 1688
- Golimumab, for rheumatoid arthritis, 830
- GoLYTELY. *See* Polyethylene glycol
- Gonadal dysgenesis. *See* Turner syndrome
- Gonadoblastoma, testicular, 1642
- Gonadotropin-releasing hormone (GnRH), deficiency/low pulse frequency of
- in amenorrhea, 1179, 1180
 - in hypogonadism, 1093
- Gonadotropin-releasing hormone (GnRH) analogs. *See also* Luteinizing hormone-releasing hormone (LHRH) analogs
- for abnormal premenopausal bleeding, 748
 - for breast cancer, 740
 - for chronic pelvic pain, 1715
 - for endometriosis, 761, 1715
 - hypogonadism caused by, 1096
- Gonadotropins
- cancer-related production of, 1596t
 - deficiency of, 1093, 1094. *See also* Hypogonadism
 - in amenorrhea, 1179, 1180
 - human chorionic (hCG). *See* Human chorionic gonadotropin
 - human menopausal (hMG), for ovulation induction, 769
- Gonococcal infections/gonorrhea, 1299t, 1451–1453
- anorectal involvement and, 658, 1452
 - arthritis and, 860, 1302t, 1452
 - chlamydial coinfection and, 1453, 1462
 - conjunctivitis, 165, 1452
 - diarrhea and, 574t
 - disseminated disease and, 1452, 1453
 - drug resistant, 860, 1452–1453
 - epididymitis in, 944, 945, 1303t, 1452
 - pelvic infection/PID, 763, 1304t, 1452, 1453
 - pharyngitis in, 1452, 1453
 - during pregnancy, 784, 806
 - prevention and, 1452
 - rape/sexual assault in transmission of, 778, 1291
 - screening for
 - in STD patients, 1291
 - in women, 1711
 - urethritis and, 1303t, 1452
- Goodpasture syndrome, 306–307, 924–925
- alveolar hemorrhage in, 306–307, 924, 925
 - glomerulonephritis in, 306, 907, 919t, 921f, 924–925
 - hemoptysis in, 27, 924

- Gordon syndrome, 878t
- Goserelin, 1657t. *See also* Luteinizing hormone-releasing hormone (LHRH) analogs
for breast cancer, 738, 740t
for prostate cancer, 1636, 1637t
- GOT. *See* Aspartate aminotransferase
- Gottron sign, 840
- Gout/gouty arthritis, **812–816**, 813f, 813t, 815t, 1674
kidney disease and, 812, 813, 816, **936–937**
rheumatoid arthritis differentiated from, 814, 828
saturnine, in lead poisoning, 814
in transplant patient, 816
- gp120, HIV vaccine development and, 1334
- GPI (glycosylphosphatidylinositol)
anchor deficiency, in paroxysmal nocturnal hemoglobinuria, 501
- GPT. *See* Alanine aminotransferase
- GRACE Risk Score, 364, 375
- Gradenigo syndrome, 204
- Graft-versus-host disease, transfusion-associated, 536
granulocyte transfusions and, 537
- Graft-versus-host reaction, 533
- Graft-versus-malignancy effect, 533
- Graham–Steel murmur, 348
- Gram-negative infections, 1299t, 1299–1300t, **1440–1456**. *See also specific causative agent*
bacteremia and sepsis, **1443–1445**
in cancer patient, 1279, 1648
folliculitis, 129
acne and, 126, 129
- Gram-positive infections, 1299t, 1300t, **1419–1435**. *See also specific causative agent*
in cancer patient, 1648
- Gram stain
ascitic fluid, 588, 589
in pneumonia diagnosis
in community-acquired disease, 270, 271
in nosocomial disease, 277
synovial fluid, 809
in gonococcal arthritis, 860
in nongonococcal acute bacterial (septic) arthritis, 859
- Grand mal (tonic-clonic) seizures, 970, 970t. *See also* Seizures
- Grand mal (tonic-clonic) status epilepticus, 970, 974
- Granisetron, 568, 568t, 1660. *See also* Antiemetics
- Granular urinary casts, 898, 899t
- Granulocyte colony-stimulating factor (G-CSF). *See* Filgrastim
- Granulocyte count
chemotherapy dosage modification and, 1659t
infections and, 1279
- Granulocyte macrophage colony-stimulating factor (GM-CSF). *See* Sargramostim
- Granulocyte transfusion, **536–537**. *See also* Transfusion
- Granulocytic anaplasmosis/ehrlichiosis, 1409t, 1414–1415
Lyme disease coinfection and, 1415, 1481
- Granulocytopenia. *See also* Neutropenia
in cancer chemotherapy, 1649
infections and, 1279, 1648
- Granuloma. *See also* Granulomatosis; Granulomatous disorders
arytenoid cartilage, 235
in Crohn disease, 642
hepatic, drugs/toxins causing, 683
inguinal, **1453**
lethal midline, 223
pulmonary, 290
in granulomatosis with polyangiitis, 306, 849
in sarcoidosis, 295, 296
swimming pool, 1458
- Granulomatosis
allergic angiitis and. *See* Allergic angiitis and granulomatosis
infantisepticum, 1434
lymphomatoid, 1363
with polyangiitis (Wegener granulomatosis), 306, **848–850**, 849f
alveolar hemorrhage and, 306
autoantibodies/ANCA in, 833t, 848, 849, 921f, 924
microscopic polyangiitis
differentiated from, 850, 851
nose and paranasal sinus
involvement in, **223**, 849
pulmonary involvement in, 306, 848–849
renal involvement in, 306, 849, 850, 907, 919t, 921f, 924
- Granulomatous disorders. *See also specific type and* Granuloma; Granulomatosis
amebic encephalitis, 1287, **1506**
aspergillosis in patients with, 1537
fever/FUO and, 1276
hypercalcemia in, 883, 884, 1141
meningitis, 1286t
neck masses, 240
of nose and paranasal sinuses, **222–223**
- Granulomatous thyroiditis. *See* Subacute (de Quervain) thyroiditis
- Graves dermatopathy (pretibial myxedema), 1110, 1113
- Graves disease, **1110–1111**, 1113, 1119. *See also* Hyperthyroidism
eye disease and, 191, 1110, 1112–1113, 1117–1118
RAI treatment for hyperthyroidism and, 1115–1116, 1117–1118
in pregnancy, 1111, 1113
RAI scan in, 1114
thyroid antibodies/TSH receptor antibody in, 1105t, 1113
treatment of, 1114–1116
- Graves ophthalmopathy/exophthalmos, 191, 1110, 1112–1113, 1117–1118
RAI treatment for hyperthyroidism and, 1115–1116, 1117–1118
- Gray platelet syndrome, 548
- Gray top tubes, 1736t
- Great toe, in gout, 813
- Green top PPT, 1736t
- Greta. *See* Azarcon
- Grief reaction/grieving, 93, 1062, 1063
- Grind (patellar) test, 1701
- Grip (handgrip), heart murmurs affected by, 337t
- Grippe, summer, 1406
- Griseofulvin, 110
for onychomycosis, 158
for tinea infection, 111, 112, 113
- Ground itch, 1518
- Group A β -hemolytic streptococcal infection, 1299t, **1421–1422**
cellulitis, 136–138, 1303t, 1421t
endocarditis, 1421, 1438
erysipelas, **136**, 137f, 1303t, 1420–1421, 1421t
glomerulonephritis and, 922, 1419
pharyngitis, 228–229, 228f, 1303t, 1419–1420. *See also* Pharyngitis, streptococcal
rapid antigen tests for, 228, 1419
rheumatic fever and, 229, 417, 418
scarlet fever, 1419, 1421
skin infections, **1420–1422**, 1421t
- Group B streptococcal infection, 1299t, 1422
arthritis, 858, 859
endocarditis, 1435, 1438
in pregnancy/neonate, 784–785, **804**
- Group C streptococcal infection, 1299t, 1422
endocarditis, 1438
- Group D streptococcal infection, 1422
endocarditis, 1435
- Group G streptococcal infection, 1299t, 1422
endocarditis, 1438
- Group therapy. *See also* Support groups
for anxiety disorders, 1044
for chronic pain disorders, 1049
for personality disorders, 1052
for smoking cessation, 8
for somatoform disorders, 1046
- Growth factors. *See also* Filgrastim; Sargramostim
for chemotherapy-induced toxicity, 1659t
for neutropenia, 510
platelet-derived, in primary myelofibrosis, 514
for stem cell mobilization, 532, 533
- Growth hormone (GH)
deficiency of, 1093, 1094, 1095, 1096, 1097
excess of, acromegaly and gigantism caused by, 1100
replacement therapy with, 1095, 1097
for AIDS wasting, 1325
during pregnancy, 1097
for Turner syndrome, 1186
serum levels of, 1095
in acromegaly/gigantism, 1100, 1101
reference values for, 1731t
tumors secreting, 1093, 1100, 1189
diabetes and, 1196
prolactin cosecretion and, 1093, 1103, 1189
- Growth hormone-releasing hormone (GHRH)

- ectopic secretion of, in acromegaly, 1100
 in GH stimulation tests, 1095
 Growth hormone stimulation tests, 1095
 GSS. *See* Gerstmann-Sträussler-Scheinker syndrome
 GTP cyclohydrolase I gene, in idiopathic torsion dystonia, 1003
 Guaiac testing. *See* Fecal occult blood testing
 Guanabenz, 453, 456*t*
 overdose/toxicity of, 453, 456*t*, 1577
 Guanadrel, for hypertension, 457
 Guanarito virus, 1384
 Guanethidine
 antidepressant drug interactions and, 1071*t*
 for hypertension, 457
 MAOI interactions and, 1071*t*
 Guanfacine, 453, 456*t*
 overdose/toxicity of, 453, 456*t*, 1577
 for Tourette syndrome, 1005
 Guarana, toxicity of, 1578*t*
 Guargum, 572*t*. *See also* Fiber, dietary
 Guillain-Barré syndrome (acute idiopathic polyneuropathy), 1024–1025
 dysautonomia in, 975, 1024
 herpes zoster and, 1358
 influenza/influenza vaccination and, 1397
 poliomyelitis differentiated from, 1373
 yellow fever vaccination and, 1316
 Guinea worm infection (dracunculiasis), 1520–1521
 Gum disease. *See* Gingivitis
 Gummas, in syphilis, 1464, 1471, 1471*f*
 Guns. *See* Firearms
 Gut. *See* Gastrointestinal system
 Gut dialysis, (repeat-dose charcoal), 1568
 Guttate psoriasis, 106. *See also* Psoriasis
 Guyton hypothesis, salt-sensitive hypertension and, 436
 GVH. *See* Graft-versus-host reaction
 GVHD. *See* Graft-versus-host disease
 GVM. *See* Graft-versus-malignancy effect
 Gynecologic disorders, 747–780. *See also* specific disorder and Women's health issues
 appendicitis differentiated from, 631
 diagnostic procedures used in, 748*t*
 in HIV infection/AIDS, 1332
 Gynecomastia, 1174*t*, 1178–1179
 carcinoma of male breast and, 746
 in hyperprolactinemia, 1102, 1178
 in hypogonadism, 1174*t*, 1178
 in Klinefelter syndrome, 1174, 1178, 1669
 testicular tumors causing, 1178, 1643
 testosterone replacement therapy and, 1177, 1179
 Gypsy moths, skin lesions caused by, 149
Gyromitra (monomethylhydrazine)
 mushroom poisoning, 1585–1586, 1586*t*
 H₁ receptor blocking drugs. *See* Antihistamines
 H₂ receptor blocking drugs
 for GERD, 596
 for laryngopharyngeal reflux, 234
 for peptic ulcer disease, 613, 615, 616
 for stress gastritis, 321, 608
 H1N1 influenza/2009 pandemic
 H1N1/“A(H1N1)pdm09”/
 swine-origin influenza, 23, 214, 1395, 1396, 1399–1400.
See also Influenza
 drug resistance and, 1396, 1399
 prevention of, 1400. *See also* H1N1 influenza vaccine
 H1N1 influenza vaccine, 1396, 1400. *See also* Influenza virus vaccine
 in asthma patients, 253, 1400
 in COPD, 261
 pregnancy and, 1400
 H3N2 influenza, 1395
 drug resistance and, 1396
 vaccine against, 1396. *See also* Influenza virus vaccine
 H5N1 avian influenza, 1395, 1396, 1397–1398. *See also* Influenza
 H7N7 avian influenza, 1397
 H9N2 avian influenza, 1397
 H63D mutation, in hemochromatosis, 694–695
 H1069Q mutation, in Wilson disease, 696
H pylori infection. *See Helicobacter pylori* infection
 HAART regimens (highly active antiretroviral therapy). *See* Antiretroviral therapy/HAART
 Habitual (recurrent) abortion, 789–790
 Habituation techniques
 for benign paroxysmal positioning vertigo, 211
 for hyperacusis, 208
 for tinnitus, 208
 HACEK organisms, endocarditis caused by, 1435, 1436, 1439
 HAEM. *See* Herpes-associated erythema multiforme
Haemophilus, 1299*t*, 1442
aphrophilus (*Aggregatibacter aphrophilus*). *See* HACEK organisms
ducreyi, 1453
influenzae, 1442
 bronchiectasis caused by, 266
 in HIV infection/AIDS, 1326
 immunization in
 immunocompromised host and, 1314
Haemophilus influenzae type b (Hib)
 vaccine, 1313*t*
 Hair
 excess of. *See* Hirsutism
 exclamation, in alopecia areata, 157
 loss of, 156–157. *See also* Alopecia chemotherapy-induced, 1661
 in women, 156, 1719–1720
 removal of, preoperative, 56
 Hair analysis, for drug detection, 1079
 Hair cells, hearing loss and, 198
 Hairy cell leukemia, 523–524, 1610*t*
 aplastic anemia differentiated from, 509
 rheumatic manifestations of, 864
 Hairy leukoplakia, 224, 225*f*, 1323, 1329
 Halcion. *See* Triazolam
 Haldol. *See* Haloperidol
 Hallucinations/hallucinoses
 alcoholic (organic), 1081, 1082, 1088
 in delirium tremens, 1080
 in focal seizures, 969
 intracranial tumors causing, 989–990, 991
 luminous, in migraine headache, 963
 in narcolepsy, 1077
 psychedelic drug use and, 1084
 in schizophrenia/psychotic disorders, 1053, 1054
 substance-induced, 1088, 1583
 Hallucinogenic mushroom poisoning, 1583, 1586*t*
 Hallucinogens, 1583
 Hallucinoses. *See* Hallucinations/hallucinoses
 HALO (radiofrequency wave ablation electrocautery), for Barrett esophagus, 595
 Halo sign, in invasive aspergillosis, 1537
 Halobetasol, 96*t*
 Halofantrine, 1492*t*, 1497
 Haloperidol, 1056, 1056*t*, 1057*t*, 1058. *See also* Antipsychotic drugs
 for aggressive/violent behavior, 1078
 for alcoholic hallucinosis, 1082
 antidepressant drug interactions and, 1071*t*
 for bipolar disease/mania, 1072
 decanoate form of, 1059
 for delirium, 64, 86, 1089
 postoperative, 53
 for dementia-associated behavior problems, 62
 in elderly, 1058
 for hallucinogen overdose/toxicity, 1583
 for Huntington disease, 1002
 intravenous, 1059
 for opioid-induced nausea and vomiting, 84, 86
 overdose/toxicity of, 1055, 1057*t*, 1059, 1574
 ophthalmic effects and, 196*t*
 for personality disorder, 1052
 for psychedelic abuse/overdose, 1084
 for Tourette syndrome, 1005
 HAM. *See* Human T cell lymphotropic/leukemia virus (HTLV), myelopathy caused by
 Hamartin gene, in tuberous sclerosis, 996
 Hamartoma, as solitary pulmonary nodule, 290
 Hamartomatous polyposis syndromes, 655
 Hamburger. *See* Meat
 Hamilton scale, assessment of suicidal intent and, 1065
 Hamman-Rich syndrome (acute interstitial pneumonia/AIP), 294*t*
 HAMP gene, in hemochromatosis, 695
 Hampton hump, in pulmonary embolism, 299

- Hand
 in complex regional pain syndrome, 825
 in immersion syndrome, 1545
 in osteoarthritis, 809, 810, 811, 811f
 in porphyria cutanea tarda, 122, 122f
 in Raynaud phenomenon, 836, 838
 in rheumatoid arthritis, 826, 826f, 831
 ulnar nerve lesions at, 1027
- Hand disinfection/washing, in infection control, 1280, 1284
- Hand eczema, vesiculobullous (pompholyx), 121–122, 121f
 tinea differentiated from, 113
- Hand-foot-mouth disease
 coxsackieviruses causing, 1406
 herpetic stomatitis differentiated from, 227
 enterovirus 71 causing, 1407
- Hand-foot syndrome (acral erythema), chemotherapy-induced, 1661
- Handgrip, heart murmurs affected by, 337t
- Hansen disease (leprosy), 1460–1461
 neuropathy associated with, 1023, 1460
- Hantaan viruses, 1388, 1389
- Hantavirus pulmonary syndrome, 1388–1389
- Hantaviruses, 1388–1389
- HAP. *See* Hospital-acquired pneumonia
- HAPS (harmless acute pancreatitis score), 712
- Haptoglobin
 in hemolytic anemia, 500
 reference values for, 1731t
- Harmless acute pancreatitis score (HAPS), 712
- Harris-Benedict equation, 1271
- Hartley-Dunhill operation, 1116
- Hashimoto (chronic lymphocytic/autoimmune) thyroiditis, 1106, 1111, 1117, 1119–1120, 1120, 1121, 1122
 hepatitis C and, 1120
 hyperthyroidism and, 1111, 1117, 1121
 hypothyroidism and, 1106, 1120, 1121, 1122
 thyroid antibodies in, 1117, 1119–1120, 1121
- Hashitoxicosis (painless sporadic thyroiditis), 1117, 1120, 1121. *See also* Hashimoto (chronic lymphocytic/autoimmune) thyroiditis
- HAV. *See* Hepatitis A virus
- Havrix. *See* Hepatitis A vaccine
- Hawkins impingement sign, 1675, 1679t, 1680
- Hay fever. *See* Allergic rhinitis
- Hb. *See* Hemoglobin
- HbA_{1c}. *See* Hemoglobin A_{1c}/A_{1a}/A_{1b}/A_{1c}
- HbA₂. *See* Hemoglobin A₂
- HbC_{Ag}, 667
 antibody to (anti-HBc), 668f, 668t, 669, 674
 screening blood for, 535–536, 669
- HbCO. *See* Carboxyhemoglobin levels
- HBeAg, 668f, 668t, 669, 674, 675
 antibody to (anti-HBe), 668f, 668t, 669, 674
 transmission to newborn and, 806
- HBeAg-negative chronic hepatitis B, 674–675, 675
- HbF. *See* Hemoglobin F
- HBIG. *See* Hepatitis B immune globulin
- HBsAg, 667, 668, 668t
 antibody to (anti-HBs), 668–669, 668f, 668t
 hepatitis D and, 672
 in hepatocellular carcinoma, 1603, 1604
 inactive carrier state, 674
 maternal carrier state/transmission to newborn and, 667, 783, 806
 vaccination recommendations and, 669, 806
 screening blood for, 535, 669
- HBV. *See* Hepatitis B virus
- HCAP. *See* Health care-associated pneumonia
- HCC. *See* Hepatocellular carcinoma
- hCG. *See* Human chorionic gonadotropin
- HCO₃⁻. *See* Bicarbonate
- HCOM (hypertrophic obstructive cardiomyopathy). *See* Cardiomyopathy
- Hct. *See* Hematocrit
- HCTZ. *See* Hydrochlorothiazide
- HCV. *See* Hepatitis C virus
- HDag, 672, 675
 antibody to (anti-HDV), 672, 675
- HDCV (human diploid cell) rabies vaccine, 1315, 1377, 1377–1378
- HDL. *See* High-density lipoproteins/cholesterol
- HDL disorders. *See* Huntington disease-like (HDL) disorders
- HDL1/HDL2/HDL3* genes, in Huntington disease-like disorders, 1002
- HDR syndrome, 1136
- HDV. *See* Hepatitis D virus
- Head injury, 1016–1018, 1017t
 acute cerebral/subdural/subarachnoid hemorrhage and, 984, 1014, 1017t
 chronic subdural hemorrhage and, 1017
 coma in diabetic patient and, 1232t
 headache associated with, 965
 hearing loss associated with, 207
 hypopituitarism associated with, 1093
 olfactory dysfunction and, 220
 seizures associated with, 969
 vertigo associated with, 211
- Head lice, 148. *See also* Lice
- Head and neck cancer, 1611t
 lymphoma, 240–241
 metastatic, 240
 squamous cell carcinoma of larynx, 236–237
- Head and neck infections
 actinomycosis, 1456, 1457
 anaerobic, 1454
 deep neck infections and, 230–231
 masses caused by, 240
- Head-up tilt table testing, in syncope, 397
- Headache, 40–42, 41t, 962–967. *See also* specific type and Migraine headache
 acupuncture for, 965
 acute, 40–42, 41t
- bacterial rhinosinusitis and, 215, 962
 brain tumors causing, 41, 962, 966
 in carbon monoxide poisoning, 41, 1576
 cerebral arteriovenous malformations causing, 987
 chronic, 962–967
 ECT causing, 1071
 in giant cell arteritis, 41, 845, 966
 in high-altitude illness, 1558, 1559
 hypertension and, 41, 439
 in intracerebral/subarachnoid hemorrhage, 41, 42, 962, 966, 983, 984
 from intracranial aneurysm leak, 984
 oral contraceptive use and, 772
 in patent foramen ovale, 329
 in pheochromocytoma, 41, 1167
 in preeclampsia-eclampsia, 41, 793
 in pseudotumor cerebri, 966, 995
- Health care (hospital)-associated infections, 1282–1285
 bacterial rhinosinusitis, 215, 216
 burn injury and, 1551
 coagulase-negative staphylococci causing, 1427–1428
 erythrovirus (parvovirus), 1403
 fever/FUO and, 1276, 1283
 hepatitis C, 670
 meningitis, 1287, 1288, 1302t
 pneumonia, 275–278, 276t, 277t, 1302t. *See also* Pneumonia scabies, 147
 in transplant recipient, 1279
- Health care providers
 H1N1 influenza transmission prevention and, 1400
 hemorrhagic fever prevention and, 1385
 HIV transmission risk and, 1335–1336
 HSV transmission prevention and, 1355
 immunization recommendations for, 1309t
 radiation safety and, 1555
 relationship of with patient. *See* Doctor–patient relationship
 SARS transmission prevention and, 1401
- Health care proxy. *See* Advance care planning/advance directives
- Health literacy, adherence and, 1
- Health maintenance/disease prevention, 2–20. *See also* specific disease adherence and, 1–2
 approach to patient and, 1–2
 immunization and, 3–5, 1307–1318, 1308–1313t, 1316–1317t
 principles of care and, 2
 in women, 1706–1711
- Hearing aids/hearing amplification, 72, 199
 adherence and, 72
 in recruitment, 208
- Hearing evaluation, 198–199
 in elderly, 72
- Hearing loss, 198–199, 199t. *See also* specific type
 aminoglycosides causing, 207
 autoimmune, 208, 210t
 barotrauma and, 202

- cisplatin causing, 207, 1662
classification/epidemiology of, 199, 199t
conductive, 198, 199
diabetes and (maternally inherited diabetes and deafness), 1195
in elderly (presbycusis), 72, 198, 206
in endolymphatic hydrops (Ménière syndrome), 208, 210, 210t
eustachian tube dysfunction causing, 198, 201
glomus tumors causing, 206
head injury causing, 207
hereditary, 207–208
in HIV infection/AIDS, 213
in labyrinthitis, 210t, 211
long QT syndrome and, 393
in multiple sclerosis, 213
mumps causing, 1371
neural, 198
noise trauma causing, 207
ossicular chain disruption causing, 198
in otitis media, 204
in otosclerosis, 205
ototoxicity and, 207, 210t. *See also* Ototoxicity
physical trauma causing, 207
recruitment and, 208
sensorineural, 198, 199
sensory, 198, **206–208**
sudden, 207
tinnitus and, **208**
vertigo and, 209, 210, 210t, 211, 212
in vestibular disorders, 209, 210, 210t, 212–213
vestibular schwannoma (acoustic neuroma) causing, 210t, 212
- Hearing rehabilitation, 199. *See also* Hearing aids/hearing amplification
- Heart, **324–432**. *See also under Cardiac; Coronary; Myocardial and Cardiovascular disorders; Heart disease*
examination of
in cardiovascular screening of athletes, 431
in myocardial infarction, 366
holiday, 384
in hypertension, 435–436, 439, 440
myxedema, 1106
radiation injury and, 1554
sarcoidosis involving, 296
systemic diseases affecting, **427–428**
traumatic injury of, **428–429**
sudden death of athlete and, 431
tumors of, **426–427**
- Heart block. *See* Atrioventricular (heart) block
- Heart disease, **324–432**. *See also specific disorder*
acute heart failure/pulmonary edema, 399, **407–409**
amyloidosis and, 531. *See also* Cardiomyopathy, amyloid
anthracycline-induced, 411, 1662
dexrazoxane for, 1658t, 1662
in athletes, screening for, **431–432**
bradycardias, 380, **394–397**
carcinoid, 346, 348, 428
cardiomyopathies, **411–417**, 412t, 416f
peripartum, **429–430**
cardiorenal syndrome and, **908**
in Chagas disease, 1486
chest pain/discomfort in, 28, 28t, 29
cholesterol/lipoproteins in, 8, 350, 1245, 1246
screening tests for levels of, 7t, 8–10, 1248–1252, 1249–1250t, 1251t
in women, 7t, 1248, 1251, 1706
conduction disturbances, **394–398**
congenital, **324–333**
pregnancy and, 431, 802–803
pulmonary hypertension in, 424
congestive heart failure, **398–409**, 399f. *See also* Congestive heart (cardiac) failure
coronary (atherosclerotic CAD/ischemic), **350–376**. *See also* Coronary heart disease
in diabetes mellitus, 356, 1227
in women, 1707
dyspnea in, 24, 25
endocarditis prophylaxis and, 1437, 1437t, 1438t
during pregnancy, **431**, 803
functional classification of, **324**
pregnancy and, 802
in HIV infection/AIDS, 1332–1333, 1344
homocysteine/hyperhomocysteinemia and, 1668–1669
hypertension/hypertension management and, 10–11, 433, 434, 439, 440, 441–442, 442–444, 442t, 443f, 444t, 457, 1249t, 1250
in women, 1706
in hyperthyroidism, 1112, 1114, 1118–1119
hypertriglyceridemia and, 1256
in hypothyroidism, 399, 400, 1106
immunization recommendations in, 1309t
lipid disorders and, 8–10, 350
in women, 1251, 1706–1707
in Lyme disease, 419, 1479, 1481–1482, 1482t
in Marfan syndrome, 345, 428, 431, 1670, 1671
metabolic syndrome (syndrome X) and, 350, 351, 360
myocarditis, **409–411**, 409t
neoplastic, **426–427**
pericardial disorders and, **419–423**
in pheochromocytoma/paraganglioma, 1167, 1168t, 1169, 1170
in polyarteritis nodosa, 847
pregnancy and, **429–431**, **802–803**
preoperative evaluation/perioperative management and, 46, 47–49, 47t, 48f, 48t
prevention of
chemoprevention/aspirin in, 7t, 11, 1253
in women, 1707
cholesterol screening and, 7t, 8–10, 1248–1252, 1249–1250t, 1251t
in women, 7t, 1248, 1251, 1706
exercise/activity and, 7t, 12–13
hypertension prevention/management and, 7t, 10–11, 434, 439, 441–442, 442–444, 442t, 443f, 444t, 457
in women, 1706
lipid disorder prevention/management and, 7t, 8–10, 1246–1247, 1252–1255, 1255t. *See also* Lipid-lowering therapy
in women, 1251, 1706–1707
smoking/smoking cessation and, 6–8, 7t, 9–10t, 10t, 350
in women, 1249t, 1251, **1706–1707**
pulmonary (cor pulmonale), **425–426**. *See also* Pulmonary heart disease
pulmonary hypertension and, 304, 400, **423–425**, 423t, 425f
rate and rhythm disturbances, **376–393**, 378–379t. *See also* Arrhythmias
rheumatic/rheumatic fever and, **417–419**
risk factors for, 5–6, 350–351
lipoproteins/lipid fractions and, 350, 1245, **1246**, 1248–1252, 1249–1250t, 1251t
in women, 7t, 1248, 1251, 1706–1707
modification/risk reduction and, 356
in scleroderma, 838
in SLE, 427, 833, 835
spondylitic, 855
surgery in patient with, **429**, 430f
preoperative evaluation/perioperative management and, 46, 47–49, 47t, 48f, 48t
systemic disorders and, **427–428**
thiazolidinedione use and, 1210
traumatic, **428–429**
sudden death of athlete and, 431
in Turner syndrome, 1186, 1187, 1187t
valvular, **333–350**, 334–336t, 337t. *See also* Valvular heart disease
- Heart failure
acute, 399, **407–409**
congestive, **398–409**, 399f. *See also* Congestive heart (cardiac) failure
- Heart-lung transplant, for cystic fibrosis, 268
- Heart murmurs, 334–335t
in angina, 352
in aortic regurgitation, 334–335t, 344, 345
in aortic stenosis, 334–335t, 337t, 342
atrial myxoma causing, 427
in atrial septal defect/patent foramen ovale, 328
bedside maneuvers/interventions affecting, 337t
in cardiomyopathy, 337t, 411–412, 414
in coarctation of aorta, 326–327
in endocarditis, 1435, 1436
in heart failure, 400
in mitral regurgitation, 334–335t, 337t, 339
in mitral stenosis, 334–335t, 337
in mitral valve prolapse, 337t, 341
in myocardial infarction, 366

- Heart murmurs (*Cont.*):
 in patent ductus arteriosus, 332
 in pulmonary stenosis, 325
 in pulmonary valve regurgitation, 348
 in rheumatic carditis, 417
 in tetralogy of Fallot, 331
 in tricuspid regurgitation, 334–335t, 347
 in tricuspid stenosis, 334–335t, 346
 in ventricular septal defect, 329, 330
- Heart rate
 in asthma exacerbation, 247t
 in atrial fibrillation, 384
 disturbances of, 376–393, 378–379t.
See also Arrhythmias
 in mitral stenosis, 338
 in GI bleeding, 581
 in paroxysmal supraventricular tachycardia, 382
 in pulmonary embolism, 298t, 301t
 in ventricular tachycardia, 390
- Heart rhythm, disturbances of, 376–393, 378–379t. *See also* Arrhythmias
- Heart sounds
 in aortic regurgitation, 334t, 345
 in aortic stenosis, 334t, 342
 in atrial myxoma, 427
 in atrial septal defect, 328
 in cardiomyopathy, 411, 414
 in heart failure, 400
 in hypertension, 440
 in mitral regurgitation, 334t, 339
 in mitral stenosis, 334t, 337
 in myocardial infarction, 366
 in patent ductus arteriosus, 332
 in pulmonary embolism, 298t
 in pulmonary hypertension, 305
 in pulmonary stenosis, 325
 in pulmonary valve regurgitation, 348
 in tetralogy of Fallot, 331
 in tricuspid regurgitation, 334t, 347
 in tricuspid stenosis, 334t
 in valvular heart disease, 334t
- Heart transplantation, for heart failure, 406
- Heart valves. *See also* Prosthetic heart valves; Valve replacement; Valvular heart disease
 in alkaptonuria, 1665
 endocarditis affecting, 338, 1435, 1437, 1439. *See also* Endocarditis
- Heartburn (pyrosis), 592, 593, 594
- Heat
 disorders caused by exposure to, 1543, 1547–1549. *See also* Burns; Hyperthermia
 cholinergic urticaria, 133
 miliaria (heat rash), 130–131
 prevention of, 1547
 reduction/removal of, 36, 1543
 for heat exposure syndromes, 1547, 1548, 1548–1549
- Heat cramps, 1547–1548
- Heat exhaustion, 1548
- Heat rash, 130–131
- Heat stroke, 1548–1549
- Heat syncope/collapse, 1547
- Heavy metals. *See also specific type*
 overdose/poisoning and, 1566t
 tubulointerstitial disease caused by, 933
- Hebephrenic (disorganized) schizophrenia, 1053
- Heberden nodes, 810, 811f
- Hectorol. *See* Doxercalciferol
- Heel, plantar hyperkeratosis of, 141
- Hegar dilators, for vaginismus, 1051
- Heimlich maneuver
 for foreign body removal, 239, 308
 in near drowning, 1556
- Heinz bodies
 in G6PD deficiency, 502, 503
 unstable hemoglobins and, 505
- Helical (spiral) CT. *See also* Computed tomography
 in chest pain evaluation, 29, 29–30
 in colorectal cancer screening. *See* Virtual colonoscopy
 in dysuria evaluation, 43–44
 in lung cancer screening, 16, 289, 1599
 in women, 1709
 in pancreatic/periampullary carcinoma, 1608
 in pulmonary embolism, 299, 300, 301f
 in renal artery stenosis, 917
 in urinary stone disease, 947–948
- Helicobacter pylori* infection, 609–610, 1299t
 dyspepsia and, 564, 565, 609
 eradication therapy for, 609, 613–615, 614t, 615
 dyspepsia management and, 565–566, 566, 609
 gastric cancer/MALT lymphoma and, 525, 609, 1618–1619
 gastritis management and, 609
 peptic ulcer management and, 611, 613–615, 614t, 615
 NSAID-induced ulcers and, 614t, 615
 rebleeding prevention and, 618
 recurrence prevention and, 614t, 615
 gastric cancer/MALT lymphoma and, 525, 609, 1615, 1616, 1618, 1618–1619
 gastritis, 564, 609–610
 gastric cancer and, 609, 1615, 1616
 peptic ulcer disease and, 609, 611, 612–613, 613–615, 614t, 615
 refractory, 617
 testing for, 609–610, 612–613, 615
 in dyspepsia, 565, 609
- Heliotrope rash, in dermatomyositis, 840
- Helium-oxygen mixture (Heliox), for smoke inhalation, 307
- Heller cardiomyotomy, for achalasia, 605
- HELLP syndrome, 545, 546, 794
- Helmet cells, in microangiopathic hemolytic anemia, 508
- Helminthic infections, 1511–1528. *See also specific type*
 cestodes causing, 1514–1517
 eosinophilic pulmonary syndromes caused by, 296, 1525
 myocarditis in, 409t
 nematodes causing
 filariasis, 1524–1528
 intestinal, 578, 1517–1520
 invasive, 1520–1524
 trematodes (flukes) causing, 1511–1514
- Helper-inducer T cells. *See* CD4 T cells
- Helvella* (monomethylhydrazine) mushroom poisoning, 1585–1586
- Hemangioblastoma, cerebellar, 990t, 991
- Hemangioma, cavernous, of liver, 701
- Hemarthroses
 in hemophilia, 550
 of knee, 1693
- Hematemesis, 580
 in cirrhosis, 686
 in erosive/hemorrhagic gastritis (gastropathy), 607
 in GI bleeding, 580, 617
 in Mallory-Weiss syndrome/tears, 599
 in peptic ulcer disease, 617
- Hematin, for porphyria, 1022, 1664, 1665
- Hematochezia, 580, 584
 in lower GI bleeding, 583, 584
 in peptic ulcer disease, 617
 in upper GI bleeding, 580, 584, 617
- Hematocrit. *See also specific disorder*
 in anemia, 490
 blood glucose self-measurement and, 1200
 in myeloproliferative neoplasms, 511t
 in polycythemia, 511t, 512
 reference values for, 1731t
- Hematogenous osteomyelitis, 861–862
- Hematologic disorders, 490–537. *See also specific type and* Hemostasis disorders
 anemias, 490–509
 blood transfusions and, 534–537
 cancer-related, 1596t
 in chronic kidney disease, 913
 leukemias/myeloproliferative neoplasms, 511–524, 511t
 lymphomas, 524–532, 524t
 neutropenia, 509–511, 510t
 in preeclampsia-eclampsia, 793t
 preoperative evaluation/perioperative management and, 46, 47t, 52, 53t
 radiation exposure and, 1554
 stem cell transplantation and, 532–534
- Hematoma
 auricular (cauliflower ear), 199
 myocardial, 428
 perianal, thrombosed hemorrhoid causing, 658
 septal, in nasal trauma, 221
 subdural. *See* Subdural hemorrhage/hematoma
- Hematometra, in endometrial carcinoma, 759
- Hematopoiesis, extramedullary, in primary myelofibrosis, 514
- Hematopoietic progenitor cell transplantation. *See* Bone marrow/stem cell transplantation
- Hematopoietic stimulating factors. *See* Filgrastim; Growth factors; Sargramostim
- Hematuria, 898, 899, 918, 918f, 938–939
 asymptomatic, 918f
 in bladder cancer, 938, 1638, 1639
 in cystitis, 43, 939
 in dysuria, 43

- in glomerulonephritis/nephritic spectrum disorders, 898, 899, 907, 918, 918f, 920
- hemoptysis and, 27
- in hemorrhagic cystitis, 43, 166f
- in Henoch-Schönlein purpura, 852, 923
- in IgA nephropathy, 923
- in polycystic kidney disease, 934, 935
- in renal cell carcinoma, 938, 164f
- in sickle cell disease, 503, 936
- in SLE, 834t, 926
- sympathetic, 922
- in tuberculosis, 936
- in ureteral/renal pelvis cancer, 938, 1640
- in urinary stone disease, 938, 947
- in urologic disorders, **938–939**
- Hemeocult tests. *See* Fecal occult blood testing
- Hemianopia. *See* Visual field defects
- Hemicrania continua, 965
- Hemicraniectomy. *See also* Craniectomy decompressive, for stroke, 982
- Hemiplegia, in stroke, 981, 983, 985
- Hemiplegic migraine, familial/sporadic, 963
- Hemobilia, 581, 1606
- Hemochromatosis, **694–696**
- Addison disease and, 1157
- cirrhosis and, 687, 695
- hepatocellular carcinoma and, 682, 695, 1603
- hypopituitarism caused by, 1095
- nonalcoholic fatty liver disease and, 684, 695
- Hemodiafiltration, continuous
- venovenous/venovenous, for poisoning/drug overdose, 1567–1568
- Hemodialysis, 915. *See also* Dialysis
- for chronic kidney disease, 915
- for heat stroke, 1548
- for hyperkalemia, 880, 881t
- for hypermagnesemia, 888
- for hypernatremia, 876
- immunization recommendations for patient receiving, 1309t
- for poisoning/drug overdose, 1567–1568, 1568t
- with carbamazepine, 1568t, 1574
- with lithium, 1073, 1568t, 1582–1583
- with methanol or ethylene glycol, 1568t, 1584
- with phenobarbital, 1568t
- with salicylates, 1568t, 1589
- with theophylline, 1568t
- with valproic acid, 1568t, 1574
- pruritus associated with, 145
- surgery in patient receiving, 55
- for uremic pericarditis, 420, 912
- uremic pericarditis in patients receiving, 419
- Hemodynamic status
- in ARDS, monitoring, 323
- in atrial fibrillation, management and, 385–386
- in COPD, 260t
- GI bleeding and, 581
- in myocardial infarction, 366, 367t
- Hemoglobin, 494
- in anemia, 490
- Bart's, 495
- glycated/glycosylated. *See* Hemoglobin A_{1c}/A_{1a}/A_{1b}/A_{1c}
- nephrotoxicity/acute tubular necrosis and, 905
- reference values for, 1731t
- in sickle cell syndromes, 503, 504, 505t. *See also* Sickle cell anemia/syndromes
- in thalassemias, 494, 495, 495t, 496
- total, 1731t
- unstable, **505**
- Hemoglobin A, 494
- in beta thalassemia syndromes, 494, 495, 495t, 496
- reference values for, 1731t
- in sickle cell syndromes, 504, 505t
- Hemoglobin A_{1c}/A_{1a}/A_{1b}/A_{1c} (glycated/glycosylated hemoglobin)
- in diabetes mellitus, 1198–1199, 1199t, 1201, 1202, 1203, 1204
- acceptable levels of, 1221
- diagnosis and, 1198–1199, 1198t, 1199t
- disordered eating in women and, 1713
- postoperative complications and, 54
- pregnancy and, 801, 1230
- reference/normal values for, 1198t, 1731t
- Hemoglobin A₂, 494
- in beta thalassemia syndromes, 494, 495, 495t, 496
- reference values for, 1731t
- in sickle cell syndromes, 505t
- Hemoglobin AS genotype (sickle cell trait), **504**, 505t
- pregnancy and, 799
- Hemoglobin C disorders, **505**
- Hemoglobin electrophoresis
- in hemoglobin C disorders, 505
- in hemoglobin H disease, 496
- in prenatal care, 783
- reference values for, 1731t
- in sickle cell syndromes, 504, 505t
- in thalassemias, 494, 494–495, 496
- Hemoglobin F (fetal hemoglobin), 494
- in beta thalassemia syndromes, 494, 495, 495t, 496
- glycated hemoglobin values and, 1199
- reference values for, 1731t
- in sickle cell syndromes, 503, 504, 505t
- Hemoglobin H/hemoglobin H disease, 494, 494t, 495, 496
- Hemoglobin S, 503, 504, 505t
- in hemoglobin C disorders, 505
- in pregnancy, 799
- Hemoglobin saturation. *See* SaO₂
- Hemoglobin SC disease, 505
- in pregnancy, 799
- retinopathy in, 187, 505
- Hemoglobinemia, in hemolytic anemia, 500
- Hemoglobinuria
- in hemolytic anemia, 500
- iron deficiency and, 491
- paroxysmal nocturnal, **501–502**
- Hemojuvelin, in hemochromatosis, 695
- Hemolymphatic disease, in African trypanosomiasis, 1484, 1485
- Hemolytic anemias/hemolysis, **500**, 500t. *See also specific type or cause*
- autoimmune, **506–507**
- in cold agglutinin disease, 507
- in G6PD deficiency, 502, 503
- in hemoglobin C disorders, 505
- in hereditary spherocytosis, 501
- microangiopathic, **508**
- thrombotic microangiopathies and, 508, 542, 543, 543t
- pulmonary hypertension in, 424
- in sickle cell syndromes, 503, 504
- unstable hemoglobins and, 505
- Hemolytic crises, in sickle cell disease, 503
- Hemolytic disease of newborn, prevention of, 785–786
- Hemolytic streptococcus. *See specific type under Group*
- Hemolytic transfusion reactions, 534–535
- Hemolytic-uremic syndrome, 542–544, 543t, 575, 1447
- atypical, 542, 543
- E coli* causing, 542, 543, 543t, 575, 1447
- Hemopericardium, 428
- Hemophagocytosis, 547
- in H1N1 influenza, 1399
- Hemophilia A and B, **549–551**, 550t
- Hemophilia C (factor XI deficiency), 550t, **552**
- Hemoptysis, **26–27**
- in bronchiectasis, 266
- in Goodpasture syndrome, 27, 924
- in lung cancer, 26, 27, 1597
- in pulmonary embolism, 298t, 301t
- in tuberculosis, 280
- Hemorrhage. *See specific type or structure affected and* Bleeding
- Hemorrhagic conjunctivitis
- acute, enterovirus 70 causing, 1407
- coxsackievirus infection and, 1406
- Hemorrhagic cystitis, 43, 166f
- adenoviruses causing, 1402
- chemotherapy-induced, 1661
- mesna for, 1658t, 1661
- Hemorrhagic effusion, pleural, 314. *See also* Hemothorax
- Hemorrhagic fever with renal syndrome (HFRS), 1388–1389
- Hemorrhagic fevers, **1384–1386**
- dengue, 1386–1388
- hantaviruses causing, 1388–1389
- Hemorrhagic (erosive) gastritis. *See* Gastritis
- Hemorrhagic shock, 485, 485t, 487. *See also* Hypovolemic shock
- Hemorrhoidectomy, 658
- Hemorrhoids, **657–658**
- bleeding and, 584, 657, 658
- fecal soiling/incontinence and, 657, 659
- pruritus ani caused by, 146
- thrombosed, 658
- Hemosiderin, 490
- accumulation of. *See also* Hemochromatosis
- urine
- in hemolytic anemia, 500
- in paroxysmal nocturnal hemoglobinuria, 502

- Hemosiderosis
 idiopathic pulmonary, 307
 transfusional, in thalassemia, 495, 496
- Hemostasis disorders, **538–563**, 539*t*. *See also specific type and Bleeding*
 antithrombotic therapy and, 536–545
 in cirrhosis, 690–691
 coagulation disorders, **549–554**
 platelet disorders, **538–549**, 539*t*
 preoperative evaluation/perioperative management and, 46, 47*t*, 52, 53*t*
- Hemosuccus pancreaticus, 581
- Hemothorax, 313, 314, 316
- Hemotympanum, 205
- Henderson-Hasselbalch equation, 889
- Henoch-Schönlein purpura, **852**, 852*f*, 919*t*, **923**
- HepA. *See* Hepatitis A vaccine
- HepB. *See* Hepatitis B vaccine
- Hepacare. *See* Hepatitis B vaccine
- Hepar lobatum, 1471
- Heparin/low-molecular weight heparin, 554–555, 557–558, 557*t*, 559*t*
 for acute arterial limb occlusion, 468
 for acute coronary syndromes, 361, 362*t*
 for antiphospholipid antibody syndrome, pregnancy and, 789, 799, 834, 836
 after cardiac valve replacement surgery, 349
 coagulopathy caused by, **554**
 for DIC, 546, 546*t*
 for DVT/PE (venous thromboembolic disease)
 prevention and, 557*t*
 treatment and, 301, 557–558, 559*t*
 for hepatic vein obstruction (Budd-Chiari syndrome), 698
 hyperkalemia and, 879
 for intracranial venous thrombosis, 988
 for myocardial infarction, 362*t*, 375
 after thrombolytic therapy, 369, 370
 perioperative, 52, 53*t*, 349
 for septic superficial thrombophlebitis, 480
 thrombocytopenia caused by, **544–545**, 544*t*, 554
 reference values in, 1731*t*
- Heparin-associated antibody
 in heparin-induced thrombocytopenia, 544
 reference values for, 1731*t*
- Heparin-induced thrombocytopenia, **544–545**, 544*t*, 554
 reference values in, 1731*t*
- Heparin-platelet factor 4 antibody
 in heparin-induced thrombocytopenia, 544
 reference values for, 1731*t*
- Hepatic abscess
 amebic, 1503, 1504, 1505*t*
 pyogenic, **700–701**
- Hepatic adenoma. *See* Hepatocellular adenoma
- Hepatic biopsy. *See* Liver, biopsy of
- Hepatic candidiasis, 701
- Hepatic coagulopathy, **553–554**
 in cirrhosis, 553
 liver failure and, 672
- Hepatic cysts, hydatid, 1516
- Hepatic disease. *See* Liver, disorders of
- Hepatic encephalopathy, 690
 in acute fatty liver of pregnancy, 795
 in acute liver failure, 672, 673, 674
 in cirrhosis, 686, 690, 692*t*
 GI bleeding/esophageal varices and, 602, 690
 perioperative complications and, 52
 protein-restricted diet for, 687, 690, 1269
- Hepatic failure. *See* Liver (hepatic) failure
- Hepatic fibrosis
 in cirrhosis, 687
 drugs/toxins causing, 683
 methotrexate toxicity and, 829
 in nonalcoholic fatty liver disease, 684, 685
 in primary sclerosing cholangitis, 709
- Hepatic hydrothorax, 688, 689
- Hepatic iminodiacetic acid (HIDA) scan, in cholecystitis, 704
- Hepatic steatosis. *See* Fatty liver
- Hepatic vein obstruction (Budd-Chiari syndrome), **697–699**
- Hepaticojejunostomy, for gallbladder cancer, 1607
- Hepatitis
 alcoholic, 680–682
 postoperative complications associated with, 51
 autoimmune, **678–680**
 CMV, 1364
 drugs/toxins causing, 161, 683
 fibrosing cholestatic, 675
 hypoxic, 699
 ischemic, 699
 isoniazid causing, 1581
 postoperative complications associated with, 51–52
 in Q fever, 1416
 in syphilis, 1469
 in varicella, 1359
 viral. *See also* Hepatitis A; Hepatitis B; Hepatitis C; Hepatitis D; Hepatitis E; Hepatitis G
 arthritis in, 861
 rheumatoid arthritis differentiated from, 828, 861
 chronic, 668, 670, 671, **674–678**
 postoperative complications associated with, 51–52
 cirrhosis and, 668, 670, 671, 672, 674, 675, 676, 678, 687
 in drug users, 667, 670, 672, 1292
 in HIV infection/AIDS, 667, 670, 676, 1329
 HSV causing, 1351
 liver cancer and, 668, 670, 672, 674, 676, 678, 1603, 1604
 liver failure and, 673
 in liver transplant patients, adenoviruses causing, 1402
 postoperative complications associated with, 51–52
 prevention of, 3, 666–667
 transfusion-associated, 535–536
- Hepatitis A, **665–667**, 666*f*
 prevention/immunization and, 3, 665, 666–667. *See also* Hepatitis A vaccine
 screening for, in STD patients, 1291
- Hepatitis A and B vaccine, 667
- Hepatitis A immune globulin, 3, 667
 during pregnancy/for newborn, 787
- Hepatitis A vaccine, 3, 665, 666–667, 1308*t*, 1309*t*, 1312*t*
 adverse effects/contraindications and, 1316*t*
 in immunocompromised host/HIV infection/AIDS, 667, 1309*t*, 1314, 1335
 during pregnancy, 787, 1309*t*
 in STD patients, 1291
 for travelers, 667, 1315
- Hepatitis A virus (HAV), 665, 666*f*, 1408
 antibody to, 666, 666*f*
- Hepatitis B, **667–670**, 668*f*, 668*t*
 acute, **667–670**, 668*f*, 668*t*
 antiretroviral agents for, 675–676, 1343, 1353*t*
 arthritis in, 861
 cancer associated with, 668, 670, 674, 676, 1603, 1604
 chronic, 668, 670, 672, **674–676**
 cirrhosis and, 668, 670, 674, 675, 676, 687
 delta agent (hepatitis D) and, 672, 675
 HIV infection/AIDS and, 667, 676, 1329
 inactive carrier state, 674
 maternal carrier state/transmission to newborn and, 667, 783, **806**
 vaccination/vaccination recommendations and, 669, 806, 1309*t*
 polyarteritis nodosa and, 847, 848
 prevention/immunization/screening and, 669. *See also* Hepatitis B vaccine
 in STD patients, 1291
 sexual assault/rape in transmission of, 1291
 transfusion in transmission of/
 screening blood for, 535–536, 667, 669
- Hepatitis B core antigen (HBcAg), 667
 antibody to (anti-HBc), 668*f*, 668*t*, 669, 674
 screening blood for, 535–536, 669
- Hepatitis B e antigen (HBeAg), 668*f*, 668*t*, 669, 674, 675
 antibody to (anti-HBe), 668*f*, 668*t*, 669, 674
 transmission to newborn and, 806
- Hepatitis B e antigen (HBeAg)-negative chronic hepatitis B, 674–675, 675
- Hepatitis B immune globulin, 669
 during pregnancy/for newborn, 669, 806
- Hepatitis B surface antigen (HBsAg), 667, 668, 668*t*
 antibody to (anti-HBs), 668–669, 668*f*, 668*t*
 hepatitis D and, 672
 in hepatocellular carcinoma, 1603, 1604
 inactive carrier state, 674
 maternal carrier state/transmission to newborn and, 667, 783, 806
 vaccination recommendations and, 669, 806
 screening blood for, 535, 669

- Hepatitis B vaccine, 669, 1308*t*, 1309*t*, 1313*t*
 adverse effects/contraindications and, 1316*t*
 in cancer prevention, 15, 1604–1605
 in immunocompromised host/HIV infection/AIDS, 669, 1309*t*, 1314, 1335
 for newborn/pregnant patient, 669, 786, 806, 1309*t*
 after rape/sexual assault, 778, 1291
 in STD patients, 1291
 for travelers, 1315
- Hepatitis B virus (HBV), 667
- Hepatitis B virus DNA, 668*f*, 669, 674, 675
- Hepatitis C, **670–671**, 671*f*, **676–678**
 acute, **670–671**, 671*f*
 arthritis in, 861
 rheumatoid arthritis differentiated from, 828, 861
 cancer associated with, 678, 1603, 1604
 chronic, 671, **676–678**
 cirrhosis and, 670, 671, 676, 678, 687
 cryoglobulinemia in, 671, 677, 851, 852, 925, 926
 HIV infection/AIDS and, 670, 676, 1329
 immune thrombocytopenia in, 540, 541, 542
 lichen planus and, 144
 in pregnancy, 670, 671, **806**
 testing for, 783
 renal disease and, 671, **926**
 thyroiditis/hypothyroidism and, 1106
 transfusion in transmission of/
 screening blood for, 536, 670, 671
- Hepatitis C virus (HCV), 670
 antibodies to (anti-HCV), 671, 671*f*, 676
 screening blood for, 536, 671
- Hepatitis C virus RNA, 671, 671*f*, 676, 677
- Hepatitis D, 670, **672**, 675, 676
 acute, 670, **672**
 chronic, **674–676**
 hepatitis B and, 672, 675
 hepatocellular carcinoma and, 1603
- Hepatitis D antigen (HDAg), 672, 675
 antibody to (anti-HDV), 672, 675
- Hepatitis D virus (HDV/delta agent), 670, 672, 675
- Hepatitis D virus RNA, 672, 675
- Hepatitis E, 670, **672**
 prevention/immunization and, 3, 672
- Hepatitis E vaccine, 3, 672
- Hepatitis E virus (HEV), 670, 672
- Hepatitis G, 670, **672**
- Hepatitis G virus (HGV), 670, 672
- Hepatobiliary cancers, **1603–1612**. *See also specific type*
- Hepatobiliary CMV, 1364
- Hepatocellular adenoma, 701–702, 702
 hepatocellular carcinoma arising from, 1604
 oral contraceptive use and, 702, 772
- Hepatocellular carcinoma, **1603–1605**, 1612*t*
 cirrhosis and, 682, 685, 687, 1603, 1604, 1605
 hemochromatosis and, 682, 695, 1603
 hepatitis and, 668, 670, 672, 674, 676, 678, 679, 1603, 1604
 hepatitis B vaccine in prevention of, 15, 1604–1605
 incidence/risk/mortality of, 1603
 paraneoplastic syndromes associated with, 1596*t*
 pyogenic abscess and, 701
- Hepatocellular disease. *See also Cirrhosis*;
 Liver, disorders of
 jaundice in, 662, 663*t*, 664*t*
- Hepatocyte nuclear factor (HNF)
 hepatocellular adenomas and, 702
 in MODY, 1194–1195
- Hepatojugular reflux, in heart failure, 400, 699
- Hepatolenticular degeneration. *See*
 Wilson disease
- Hepatomegaly
 in biliary tract carcinoma, 1606
 in choledocholithiasis/choolangitis, 706
 in chronic lymphocytic leukemia, 522
 in cirrhosis, 686
 in fatty liver, 684
 in hairy cell leukemia, 523
 in hepatitis, 666
 in hepatocellular carcinoma, 1604
- Hepatopathy, ischemic, 699
- Hepatopulmonary syndrome, 691
- Hepatorenal syndrome, 689–690
- Hepatosplenic candidiasis, 1530
- Hepatotoxicity, 672–673, **682–684**
 of acetaminophen, 76, 672–673, 1570–1571, 1570*f*
 of anesthetics, 51
 of methotrexate, 829, 1661
 of nevirapine, 1346
 of thiazolidinediones, 1209, 1210
 of tuberculosis therapy, 4
- Hepcidin
 in anemia of chronic kidney disease, 913
 in anemia of inflammation, 493
 in hemochromatosis, 694
 in iron deficiency anemia, 490
- HER-2/*neu* overexpression, in breast cancer, 733–734, 737
 in male, 746
 prognosis and, 734, 736, 736*t*, 737, 743
 therapy and, 736, 737, 738, 741
- Herald patch, in pityriasis rosea, 108
- “Herbal ecstasy” (ephedrine), 1572
- Herbal products
 for dyspepsia, 566
 toxicity of, **1578**, 1578*t*
- Herbicide poisoning (cholinesterase inhibitors), 1566*t*, **1587**
- Herceptin. *See* Trastuzumab
- Hereditary angioedema, 133
- Hereditary cholestatic syndromes, 662, 663*t*
- Hereditary colorectal cancer/polyposis syndromes, **654–657**, 1622–1623. *See also specific disorder*
- Hereditary hearing loss, 207–208
- Hereditary hemorrhagic telangiectasia, **1671–1672**
 epistaxis in, 220, 1671
 GI bleeding in, 581, 584, 1671
- Hereditary leiomyoma-renal cell carcinoma, 1641
- Hereditary motor and sensory neuropathy (HMSN), types I to IV, 1021–1022
- Hereditary nonpolyposis colorectal cancer (HNPCC), **656–657**, 1622
 endometrial carcinoma and, 656, 657, 759
 pancreatic/periampullary carcinoma and, 1608
 small intestine adenocarcinoma in, 1620
- Hereditary papillary renal cell carcinoma, 1641
- Hereditary spherocytosis, **500–501**
- Heritable pulmonary hypertension, 423–424
- Hernias
 hiatal
 esophageal webs and rings and, 600
 gastric ulcers and, 617
 GERD and, 593
 vaginal (pelvic organ prolapse), **762**
- Herniated nucleus pulposus. *See* Nucleus pulposus, herniation of
- Herniation syndromes
 intracranial tumors causing, 989, 992
 lumbar puncture and, 982, 984, 991, 1015
 in stroke, 982, 984
- Heroin abuse, 1083–1084, 1586–1587
- Herpangina
 coxsackievirus, 1406
 enterovirus, 1407
- Herpes-associated erythema multiforme, 134, 134*f*, 135, 1351, 1355
- Herpes genitalis. *See* Genital herpes
- Herpes labialis (cold/fever sore), **118–119**, 118*f*, 1350–1351, 1352. *See also* Herpes simplex infection
- Herpes simplex infection, **118–119**, 118*f*, **1350–1355**, 1351*f*
 acyclovir prophylaxis/treatment and, 118–119, 1280, 1330, 1338*t*, 1352, 1353*t*, 1355
 anorectal involvement and, 659
 Bell palsy and, 1028, 1351, 1355
 chemoprophylaxis for, 118, 119, 1280, 1330, 1352, 1352–1355, 1353–1354*t*
 disseminated/generalized, 1351, 1355
 dermatitis in (eczema herpeticum), 104, 1351, 1356*t*
 encephalitis, 1351, 1352, 1355
 erythema multiforme associated with, 134, 134*f*, 135, 1351, 1355
 esophagitis in, 598, 1351, 1352, 1355
 gladiatorum, 1351
 in HIV infection/AIDS, 118, 1330, 1338*t*, 1350, 1351
 esophageal, 598, 1351, 1355
 keratitis, **173**, 1351, 1352, 1352–1355
 during pregnancy/neonatal/congenital infection, **806**, 1351, 1355
 stomatitis/gingivostomatitis in, 118, **227**, 1351
 treatment/prevention of, 118–119, 1280, 1352–1355, 1353–1354*t*
 type 1, 118, 118*f*, 1350
 type 2, 118, 1350
 vaccine development and, 1355

- Herpes zoster (shingles), 5, **119–121**, 120*f*, **1356–1361**
 earache in, 206, 1358
 eye involvement and, 120, 173, 1331
 facial involvement/Ramsay Hunt syndrome and, 119, 213, 1358, 1359
 in immunocompromised host/HIV infection/AIDS, 119, 120, 1331, 1339*t*
 neuralgia after, 5, 120, 120–121, **968**, 1359
 pregnancy and, 804
 prevention and, 5, 120, 1360–1361. *See also* Herpes zoster vaccine
- Herpes zoster ophthalmicus, 120, **173**, 1331, 1358, 1359
- Herpes zoster oticus, 206, 1358
- Herpes zoster vaccine, 5, 120, 1308*t*, 1309*t*, 1311*t*, 1360–1361
 adverse effects/contraindications and, 1317*t*
 immunocompromised host/HIV infection/AIDS and, 5, 1309*t*, 1314, 1335, 1360
 neuralgia prevention and, 5, 120, 968, 1360
- Herpesviruses, **1350–1367**. *See also specific type under Human herpesvirus*
- Herpetic stomatitis/gingivostomatitis, 118, **227**, 1351
- Herpetic whitlow, 1351, 1351*f*
- Herplex. *See* Idoxuridine
- Heterophil antibody tests, in mononucleosis, 1362
- Heterophyes* species, 1513
- Heterotopic pregnancy, 790. *See also* Ectopic pregnancy
- HEV. *See* Hepatitis E virus
- HEV-70/HEV-71. *See* Enterovirus 70/enterovirus 71
- Hexalen. *See* Altretamine
- Hexosaminidase deficiency, in juvenile spinal muscular atrophy, 1020
- HFE* gene, in hemochromatosis, 694
- HFRS. *See* Hemorrhagic fever with renal syndrome
- HGD* gene, in alkaptonuria, 1665
- hGH. *See* Human growth hormone
- HGV. *See* Hepatitis G virus
- HHEX-IDE* gene, in type 2 diabetes, 1194
- HHT. *See* Hereditary hemorrhagic telangiectasia
- HHV. *See* Human herpesviruses
- 5-HIAA. *See* 5-Hydroxyindoleacetic acid
- Hiatal hernia
 esophageal webs and rings and, 600
 gastric ulcers and, 617
 GERD and, 593
- Hibernation, myocardial, 351
- Hiccups, **569–570**
- HIDA scan, in cholecystitis, 704
- Hidradenitis suppurativa (acne inversa), 151
- High-altitude cerebral edema, 1558–1559
- High-altitude illness, **1558–1560**
 acute mountain sickness, 1558–1559
 cerebral edema, 1558–1559
 chronic mountain sickness (Monge disease), 1559
 neurologic conditions, **1558–1559**
 prevention of, 1559
 pulmonary edema, **1559**
 pulmonary hypertension, 424, 1559
 subacute mountain sickness, 1559
- High-altitude pulmonary edema, **1559**
- High (eversion) ankle sprain, **1704–1705**, 1704*t*
- High blood pressure. *See* Hypertension
- High-calcium diet, 1269–1270
- High-carbohydrate diet
 cholesterol lowering and, 1252
 in porphyria, 1022, 1664
- High-density lipoproteins/cholesterol, 1246
 atherogenesis/cardiovascular/coronary heart disease and, 8, 350, 1245, 1246, 1249*t*, 1250
 in women, 1249*t*, 1251
 cholesterol-lowering diets and, 1252
 in diabetes mellitus, 1200
 estrogen replacement affecting, 1182
 isotretinoin affecting, 127
 raising levels of, 8, 1252, 1255*t*
 fibric acid derivatives for, 1254, 1255*t*
 niacin for, 1253, 1255*t*, 1265
 reference values for, 1731*t*
 screening tests for levels of, 1248–1252, 1249–1250*t*, 1251*t*
 in women, 1251, 1706
 tendinous xanthomas and, 1247–1248
 testosterone replacement affecting, 1177, 1185
 thiazolidinedione therapy and, 1210
- High dose chemotherapy, with bone marrow/stem cell transplantation, 532, 533. *See also* Bone marrow/stem cell transplantation; Chemotherapy
- High-fiber diet. *See* Fiber, dietary
- High molecular-weight kininogen deficiency, 552
- High-potassium diet, 1269
- High-sensitivity troponin assays. *See also* Troponins
 in acute coronary syndromes/STEMI, 366
- High tibial osteotomy, for osteoarthritis of knee, 1702
- Highly active antiretroviral therapy (HAART). *See* Antiretroviral therapy/HAART
- Hill sign, 345
- Hip, **1689–1692**, 1690*t*
 arthritis of, **1691–1692**
 back pain and, 820
 nongonococcal acute bacterial (septic), 859
 bursitis affecting, 825
 examination of, 820, 1690, 1690*t*
 osteonecrosis of, 865
 range of motion of, 1690*t*
 in back pain, 1683, 1684*t*
 in hip fracture, 1690, 1690*t*
 strength testing and, 1690*t*
- Hip fracture, **1689–1690**, 1690*t*
 atypical, bisphosphonate use and, 1147
 estrogen replacement therapy affecting risk of, 1182
 falls in elderly and, 65, 66, 1690, 1691
 osteoporosis and, 1144, 1147, 1689, 1690, 1710
 postoperative delirium and, 52, 64
 Hip protectors, fracture prevention and, 1691
- Hip replacement
 for arthritis, 812, 1691
 DVT/PE (venous thromboembolic disease) prevention and, 555*t*
 for fracture, 1690
- Hip resurfacing surgery, 1691–1692
- Hirschsprung disease, in MEN, 1189
- Hirsutism, **1161–1164**
 in congenital adrenal hyperplasia, 1156, 1163
 in polycystic ovary syndrome, 765, 1162
 testosterone replacement therapy in women and, 1185
- His-ventricular interval, long, 395
- Histamine
 in bronchial provocation testing for asthma, 246–247
 drugs blocking receptors for. *See* Antihistamines; H₂ receptor blocking drugs
- Histidine decarboxylase gene mutation, in Tourette syndrome, 1005
- Histiocytic necrotizing lymphadenitis (Kikuchi/Kikuchi-Fujimoto disease), 240
- Histiocytosis, Langerhans cell, 1097, 1099
- Histoplasma capsulatum* (histoplasmosis), **1531–1532**
 bone and joint involvement in, **863**
 in HIV infection/AIDS, 1337, 1531, 1532
- Histrionic (hysterical) personality disorder, 1052*t*
- HIT. *See* Heparin-induced thrombocytopenia
- HITS (Hurt, Insult, Threaten, Screamed at) tool, 1712
- HIV/HIV-1, 1322. *See also* HIV infection/AIDS
 direct toxicity of, 1322
 drug resistance and, 675–676, 1340, 1342, 1347, 1348–1349, 1348*f*
 drugs blocking entry of into cells (entry inhibitors), 1342*t*, 1346, 1348*f*
 screening blood for antibody to, 536, 1321, 1334
 serologic tests in identification of. *See* HIV testing
- HIV-2, 1322. *See also* HIV infection/AIDS
- HIV-associated dementia, 1327
- HIV-associated nephropathy, 920*t*, **931**
- HIV infection/AIDS, 4, **1319–1349**. *See also* Immunocompromised host
 adenovirus infection and, 1401
 adherence to therapy and, 1
 allergic reactions in, 1322
 anal dysplasia/cancer and, 1332, 1629
 arthritis in, 861, 1328
 autoimmunity in, 1322
 bacillary angiomatosis/bartonellosis in, 1323, 1331, 1335, 1454

- biliary disease in, 1329
 blastomycosis in, 1539
 breastfeeding in transmission of, 1321, 1336
 campylobacter/campylobacter-like organisms causing disease in, 1330, 1449
 cancer associated with, 1319, 1320*t*, 1322, 1331–1332
 candidiasis in, 131, 132, 225–226, 226, 226*f*, 1325, 1331, 1337, 1338*t*, 1529
 esophageal, 598, 1325, 1329, 1338*t*, 1530
 oral (thrush), 131, 225–226, 226, 226*f*, 1325, 1328–1329, 1337
 vulvovaginal, 1332, 1337, 1338*t*
 CD4 T cells in. *See* CD4 T cells
 CDC definitions and, 1319, 1320*t*
 cerebral lymphoma in, 990*t*, 992–993, 1327, 1332, 1338*t*
 Chagas disease and, 1486
 cholecystitis in, 1329
 CIN/cervical cancer in, 1332
 clinical findings in, 1322–1324, 1323*f*
 CMV infections in, 598, 1326, 1328, 1338*t*, 1364
 prophylaxis of, 1280–1281, 1337, 1339, 1366
 retinitis, 187, 187*f*, 1328, 1364, 1365
 coccidial and microsporidial infection in, 1330, 1506–1508
 coccidioidomycosis in, 1337, 1532
 complications of, 1324–1333
 treatment of, 1337–1340, 1338–1339*t*
 adjunctive, 1339–1340
 prophylactic, 1336–1337, 1337*t*
 condylomata acuminata/venereal warts and, 659
 coronary heart disease in, 1332–1333, 1344
 cortisol resistance/adrenal insufficiency and, 1157, 1330
 counseling and, 1333, 1335
 postexposure prophylaxis and, 1336
 cryptococcosis/cryptococcal meningitis in, 993, 1327, 1338*t*, 1536
 prevention/prophylaxis and, 1337, 1536
 cryptosporidiosis in, 1330, 1506, 1507, 1508
 dementia associated with, 1327
 diarrhea/enterocolitis in, 575, 578, 1325, 1330, 1506, 1507
 differential diagnosis of, 1324
 drug use and, 1292, 1321
 prevention/postexposure prophylaxis and, 1333, 1335, 1336
 endocrinologic manifestations of, 1330
 epidemiology of. *See* HIV infection/AIDS, transmission of
 erythrovirus (parvovirus) infection in, 1402, 1403
 esophagitis in, 598, 1329
 etiology of, 1322
 extrapyramidal effects in patients with, 1061
 fever/FUO and, 36, 1276, 1277, 1324–1325
 folliculitis and, 129, 130, 1322, 1331
 fungal rashes in, 1331
 gastrointestinal manifestations of, 1329–1330
 gastropathy in, 1330
 gynecologic manifestations of, 1332
 gynecomastia and, 1178
 hairy leukoplakia in, 224, 225*f*, 1323, 1329
 headache in, 41, 42
 health care maintenance for patients with, 1334–1335, 1334*t*
 hepatic disease/hepatitis in, 667, 670, 672, 676, 1329
 hepatitis A vaccine in, 667, 1309*t*, 1314, 1335
 hepatitis B vaccine in, 1309*t*, 1314, 1335
 herpes simplex infection in, 118, 1330, 1338*t*, 1350, 1351
 acyclovir treatment/prophylaxis and, 1330, 1338*t*, 1352
 esophagitis, 598, 1351, 1355
 herpes zoster and, 119, 120, 1331, 1339*t*
 histoplasmosis in, 1337, 1531, 1532
 Hodgkin disease in, 1332
 hyperkalemia in, 880
 hypersensitivity reactions and, 1322
 hyponatremia in, 872
 immune thrombocytopenia in, 540, 541, 542
 immunization recommendations in, 1309*t*, 1313*t*, 1314, 1335
 incidence/prevalence of, 4, 1321
 infections in, 1319, 1320*t*. *See also specific type and*
 Opportunistic infections
 CD4 T cell levels and, 1322–1323, 1323*f*, 1324, 1334*t*, 1336, 1339
 prevention of, 1334–1335, 1334*t*, 1336–1337, 1337*t*
 treatment of, 1337–1340, 1338–1339*t*
 adjunctive, 1339–1340
 inflammatory reactions (immune reconstitution syndromes) in, 1333
 corticosteroids in management of, 1339
 Kaposi sarcoma flare and, 1331, 1332
 influenza vaccination and, 5, 1309*t*, 1314, 1335
 intracranial tumors in, 992–993, 1327
 Kaposi sarcoma in, 145, 213, 1322, 1323, 1331–1332, 1339*t*, 1622
 kidney disease in, 931
 laboratory findings in, 1323–1324, 1324*t*
 leishmaniasis and, 1488
 lymphadenopathy in, 239, 241, 1323
 eustachian tube dysfunction/serous otitis media and, 213
 lymphoma in, 241, 990*t*, 992–993, 1322, 1327, 1332, 1338*t*
 MAC infections in, 288, 1324, 1338*t*, 1458–1459
 prevention of, 1324, 1337, 1339, 1459
 malabsorption in, 1325, 1330
 malaria in, 1491
 measles/measles (MMR) vaccine in, 4, 5, 1309*t*, 1314, 1335, 1368, 1369
 mental status/cognitive changes in, 1327
 molluscum contagiosum in, 141, 142, 1331, 1404
 mucormycosis in, 217, 218
 myelopathies in, 1328
 myopathy in, 861, 1036, 1328
 needle-stick injury and, 1321, 1335
 nephropathy in, 920*t*, 931
 neurologic manifestations of, 1288
 central, 1327–1328
 peripheral/neuropathy, 1023, 1328
 non-Hodgkin lymphoma in, 241, 1326, 1327, 1332, 1338*t*
 nontuberculous mycobacterial infection in, 1326, 1458, 1458–1459
 ophthalmic manifestations of, 187, 187*f*
 oral lesions in, 1328–1329
 otitis media and, 213
 otologic manifestations of, 213
P. marneffei infection in, 1540
 pathogenesis of, 1322
 pathophysiology of, 1322
 perinatal transmission of, 805–806, 1321, 1336
 breastfeeding and, 1321, 1336
 pneumonia in, 279, 1325–1326, 1533–1535. *See also Pneumocystis jirovecii* pneumonia
 CD4 T cell count and, 1322–1323, 1323*f*, 1324, 1326, 1339, 1534, 1535
 immunization against. *See* Pneumococcal vaccine
 pneumonitis in, nonspecific interstitial, 1326–1327
 postexposure prophylaxis and, 4, 1335–1336, 1336
 in pregnancy, 783, 784, 805–806, 1321, 1336
 prevention of. *See* HIV infection/AIDS, transmission of, prevention of
 prognosis of, 1319, 1324, 1349
 progressive multifocal leukoencephalopathy in, 1328, 1382, 1383
 psoriasis/psoriatic arthritis in, 106, 861, 1328, 1331
 pulmonary hypertension in, 424
 pulmonary manifestations of, 279, 1325–1327. *See also* HIV infection/AIDS, pneumonia in
 reactive arthritis and, 858, 861, 1328
 retinitis in, 187, 187*f*, 1328
 rheumatic manifestations of, 861, 1328
Salmonella infection in
 bacteremia, 1296, 1446
 enterocolitis, 1296, 1446
 scabies in, 147
 sclerosing cholangitis in, 1329
 screening for. *See* HIV testing
 seborrheic dermatitis in, 109, 1331

- HIV infection/AIDS (*Cont.*):
 seizures in, 969
 sinusitis in, 217, 1327
 skin disorders in, 1330–1331
 spermicides/nonoxynol 9 and, 775, 1333
 sporotrichosis in, 1539
 staphylococcal skin infections in, 1331
 strongyloidiasis in, 1519
 syphilis and, 1334–1335, 1465, 1467–1468, 1468, **1473–1474**
 syphilis tests affected by, 1334–1335, 1473
 systemic complaints associated with, 1324–1325
- T cells in. *See* CD4 T cells
- toxoplasmosis in, 993, 1327, 1338*t*, 1501, 1502
 prevention/chemoprophylaxis and, 1335, 1337, 1502
- transient ischemic attacks and, 977
- transmission of, 1319–1321
 bites in, 1289
 to fetus/newborn, 805–806, 1321, 1336
 health care providers and, 1335–1336
 prevention of, 4–5, 1333–1336
 blood screening/blood treatment and, 536, 1321, 1334
 condoms for, 4, 1333, 1335
 postexposure prophylaxis and, 4, 1335–1336, 1336
 rape/sexual assault and, 778, 1291
 sexual behavior and, 4, 1319–1321, 1333
 transfusions and, 536, 1321, 1334
- treatment of, 1336–1349, 1337*t*, 1338–1339*t*, 1341–1342*t*, 1348*f*
 antiretroviral therapy/HAART in, 4, 1319, 1340–1349, 1341–1342*t*, 1348*f*. *See also* Antiretroviral therapy/HAART
- opportunistic infections/
 malignancies and, 1337–1340, 1338–1339*t*
 prophylaxis and, 1334–1335, 1334*t*, 1336–1337, 1337*t*
 in pregnancy, 805–806, 1321, 1336
 tuberculosis and, 285, 1326
- tuberculin skin test in, 283*t*, 1326, 1334, 1337
- tuberculosis in, 4, 280, 281, 1326
 chemoprophylaxis/prevention and, 4, 1334, 1337
 drug-resistant disease and, 280, 281, 281*t*, 1326
 drug use and, 1292
 intestinal involvement in, 631
 treatment of, 4, 285, 1326
- vaccine development and, 1334
- varicella zoster virus infection/varicella vaccine and, 5, 120, 1309*t*, 1314, 1335, 1359, 1360
- VDRL test in, 1334, 1335
- weight loss in, 1325
- Wernicke encephalopathy in, 1013
 in women, 783, 784, 805–806, 1321, 1332, 1336, 1711. *See also* HIV infection/AIDS, perinatal transmission of
- xerosis in, 1331
- HIV integrase inhibitors, 1342*t*, 1346–1347, 1348*f*
 resistance to, 1349
- HIV myelopathy, 1328
- HIV painful articular syndrome, 861
- HIV rapid antibody tests, 1290, 1323, 1324*t*
- HIV RNA tests, reference values for, 1731*t*
- HIV testing, 4, 1323–1324, 1324*t*
 in blood screening, 536, 1321, 1334
 influenza vaccine affecting results in, 1323
 after needle-stick, 1335
 in pregnancy, 783, 784, 805, 1336
 after rape/sexual assault, 778, 1291
 reference values for, 1731*t*
 in STD patients, 1290, 1291, 1711
 in syphilis patients, 1467–1468, 1468
 transmission prevention and, 1333
 in women, 1711
- HIV viral load tests, 1324, 1324*t*
 antiretroviral therapy initiation/monitoring and, 1340
 blood screening and, 1321
 reference values for, 1731*t*
- Hives. *See* Urticaria
- Hivid. *See* Zalcitabine
- HJV gene, in hemochromatosis, 695
- HLA. *See* Human leukocyte antigen
- HMBS gene mutation, in acute intermittent porphyria, 1664
- hMG. *See* Human menopausal gonadotropins
- HMG-CoA reductase inhibitors. *See* Statin drugs
- HMSN. *See* Hereditary motor and sensory neuropathy
- HNF
 hepatocellular adenomas and, 702
 in MODY, 1194–1195
- HNPPC. *See* Hereditary nonpolyposis colorectal cancer
- Hoagland sign, 1361
- Hoarseness, **233**
 contact ulcers/granulomas causing, 235
 GERD and, 234, 594
 laryngeal leukoplakia causing, 236
 laryngitis causing, 233
 laryngopharyngeal reflux causing, 234
 in lung cancer, 234, 1597
 in recurrent respiratory papillomatosis, 234
 vocal folds/vocal fold lesions and, 233, 235
- HOCM (hypertrophic obstructive cardiomyopathy). *See* Cardiomyopathy
- Hodgkin lymphoma, **526–527**, 1610*t*
 bone marrow/stem cell transplantation for, 527, 532
 fever/FUO and, 1277
 in HIV infection/AIDS, 1332
 motor neuronopathy in, 1020
- Holiday heart, 384
- Holosystolic murmurs. *See* Heart murmurs
- Holter monitoring. *See* Ambulatory electrocardiographic monitoring
- Homans sign, in DVT/PE (venous thromboembolic disease), 298*t*
- Home environment, of elderly patients, falls and, 65, 67*t*
- Home hemodialysis, 915
- Home oxygen therapy, 262, 262*t*
- Homeostenosis. *See* Age/aging
- Homocysteine
 disorders of metabolism of, **1668–1669**
 reference values for, 1731*t*
- Homocystinuria, 1669
- Homogentisic acid oxidase deficiency, in alkaptonuria, 1665
- Homonymous field defects. *See* Visual field defects
- Homosexuality
 hepatitis transmission and, 667, 670
 HIV infection/AIDS transmission risk and, 1321, 1333
 immunization recommendations and, 1309*t*, 1314
 STD prevention/screening and, 1291
 syphilis and, 1334, 1464, 1465, 1467
- Honey, infant botulism and, 1431
- Hookworm disease, **1518**
 cutaneous larva migrans, 1523
 pulmonary disease and, 296, 1518
- Hordeolum, **163**, 163*f*
- Hormone receptor sites, in breast cancer, 733–734
 in male, 746
 prognosis and, 734, 736, 736*t*, 743
 treatment and, 734, 736, 738, 739
- Hormone replacement therapy (HRT). *See* Estrogen (hormone) replacement therapy
- Hormone therapy. *See also* Estrogen (hormone) replacement therapy; Testosterone replacement therapy
 adverse ophthalmic effects of, 196*t*
 for breast cancer, 736, 738, 739–741, 740*t*
 adjuvant/neoadjuvant, 736, 738, 1611*t*
 hormone receptor sites and, 734, 736, 738, 739
 in male, 746
 for metastatic disease (palliative), 739–741, 740*t*
 breastfeeding and, 782*t*
 in contraception, **773**
 injections/implants, **773**
 oral contraceptives, **770–773**, 771–772*t*, 772*t*
 for dysfunctional uterine bleeding, 748
 for endometriosis, 761
 for erectile dysfunction, 952
 for hypogonadism, 1096–1097, 1146–1147
 for infertility, 769, 1097
 in male, 955, 1097
 for lactation suppression, 786
 for osteoporosis prevention/management, 1147
 for prostate cancer, 1635, 1636, 1637*t*
- Hormones, ectopic production of
 by islet cell tumors, 1172, 1189
 in paraneoplastic syndromes, 1594–1595, 1596*t*

- Horner syndrome (oculosympathetic paralysis)
in coma or stupor, 1014
headache and, 42, 965
in lung cancer, 1597
- Horse chestnut seed extract, for venous insufficiency, 34
- Hospice care, **90**. *See also* End of life, provision of care at
- Hospital-acquired pneumonia, **275–278**, 277t
- Hospital-associated infections. *See* Health care (hospital)-associated infections
- Hospitalization
for alcohol use/abuse/withdrawal, 1082
for asthma/asthma exacerbation, 243, 246t, 256–259, 258f
for atrial fibrillation, 385
in community-acquired pneumonia, 270, 274, 274–275
for COPD, 264
for depression, 1064–1065
diabetes management during, 1228–1230, 1229t
for hyperemesis gravidarum, 787
infections acquired during, **1282–1285**. *See also* Health care (hospital)-associated infections
for personality disorders, 1052–1053
for preeclampsia/eclampsia, 794 prolonged, 1090
psychiatric problems associated with, **1089–1092**
for schizophrenia/psychotic disorders, 1055
for suicidal patient, 1064–1065
for third-trimester bleeding, 797
for thyroid surgery, 1129–1130
for tuberculosis, 284
- Host defenses, impairment of. *See* Immunocompromised host
- Hot environments, disorders caused by exposure to, 1543, **1547–1549**. *See also under* Heat
- Hot flushes, in menopause, 779, 779–780, 1181, 1186
estrogen replacement therapy for, 779–780, 1182
topical progesterone for, 1185
- Hot soaks, for wart removal, 141
- Hot tub (*Pseudomonas*) folliculitis, 129, 130
- Hounsfield units, urinary stone density measured with, 948
- Household cleaning agents, poisoning caused by. *See* Caustic/corrosive agents
- Howell-Jolly bodies, in sickle cell anemia, 504
- HPC (hematopoietic progenitor cell transplantation). *See* Bone marrow/stem cell transplantation
- HPeV. *See* Human parechovirus infection
- HPIVs. *See* Human parainfluenza viruses
- HPMPC. *See* Cidofovir
- HPS. *See* Hantavirus pulmonary syndrome
- HPV. *See* Human papillomavirus
- HPV vaccine, 4, 140, 659, 755–756, 757, 1308t, 1309t, 1311t, 1709
adverse effects/contraindications and, 1316t
in immunocompromised host/HIV infection/AIDS, 1309t, 1314
recurrent respiratory papillomatosis prevention and, 234
in STD prevention, 1291
- HPV (16/18) and HPV (6/11/16/18) L1 virus-like particle vaccine, 4, 755, 757, 1709. *See also* HPV vaccine
- HRIG. *See* Human rabies immune globulin
- HRT (hormone replacement therapy). *See* Estrogen (hormone) replacement therapy
- HRV. *See* Rotavirus vaccine
- HSDD. *See* Hypoactive sexual desire disorder
- HSH (hydrogenated starch hydrolases), 1205
- HSV-1. *See* Herpes simplex infection, type 1
- HSV-2. *See* Herpes simplex infection, type 2
- 5-HT₃ receptor antagonists. *See* Serotonin 5-HT₃-receptor-blocking agents
- HTLV. *See* Human T cell lymphotropic/leukemia virus
- Humalog. *See* Insulin lispro
- Human bite wounds, **1288–1290**
- Human chorionic gonadotropin (hCG)
in amenorrhea, pregnancy and, 1180, 1181
for cryptorchism, 1178
in ectopic pregnancy, 781, 790
in gestational trophoblastic disease, 781, 791, 792
hyperthyroidism and, 791, 1112
gynecomastia and, 1178
hyperthyroidism during pregnancy and, 791, 1111, 1112
for infertility, 955, 1097
pregnancy tests and, 781
reference values for, 1729t
spontaneous abortion and, 788
testicular tumors producing, 1177, 1643
- Human deoxyribonuclease (rhDNase)
for cystic fibrosis, 268
pleural instillation of, 316
- Human diploid cell (HDCV) rabies vaccine, 1315, 1377, 1377–1378
- Human granulocytic anaplasmosis/ehrlichiosis, 1409t, 1414–1415
Lyme disease coinfection and, 1415, 1481
- Human growth hormone, 1097. *See also* Growth hormone
- Human herpesvirus 1 and 2. *See* Herpes simplex infection
- Human herpesvirus 3. *See* Varicella zoster virus
- Human herpesvirus 4. *See* Epstein-Barr virus
- Human herpesvirus 6, 1350, 1356t, **1366**
aphthous ulcers and, 227
- Human herpesvirus 7, 1356t, **1366–1367**
- Human herpesvirus 8 (Kaposi sarcoma-associated herpes virus), 145, 1322, 1350, **1367**, 1622
- Human herpesviruses, **1350–1367**. *See also specific type*
- Human immunodeficiency virus. *See* HIV/HIV-1; HIV-2
- Human insulin, 1213, 1213t, 1214. *See also* Insulin therapy
- Human interferons. *See specific type under Interferon*
- Human leukocyte antigen (HLA)
clinical relevance of testing for, 1725t
in diabetes, 1192
- Human leukocyte antigen (HLA) typing
for granulocyte transfusions, 537
for platelet transfusions, 536
for stem cell transplant, 533
- Human menopausal gonadotropins (hMG), for ovulation induction, 769
- Human metapneumovirus, 1393, 1394
- Human monocytic ehrlichiosis, 1409t, 1414–1415
- Human papillomavirus (HPV)
in anal cancer, 1332, 1629
in CIN/cervical cancer, 755, 756, 1332, 1709
screening for, 755, 1332, 1709
genital types of. *See* Venereal (genital) warts
in laryngeal cancer, 236
nasal tumors (inverted papillomas) caused by, 222
recurrent respiratory (laryngeal) papillomas caused by, 234
vaccine for. *See* Human papillomavirus (HPV) vaccine
in vulvar carcinoma, 760
warts caused by, 139–141, 139f, 752. *See also* Venereal (genital) warts
- Human papillomavirus (HPV) vaccine, 4, 140, 659, 755–756, 757, 1308t, 1309t, 1311t, 1709
adverse effects/contraindications and, 1316t
in immunocompromised host/HIV infection/AIDS, 1309t, 1314
recurrent respiratory papillomatosis prevention and, 234
in STD prevention, 1291
- Human papillomavirus (HPV) virus-like particle (VLP) vaccine, 4, 755, 757, 1709. *See also* Human papillomavirus (HPV) vaccine
- Human parainfluenza viruses, 1393, 1394
- Human parechovirus infection, **1408**
- Human parvovirus B19 infection. *See* Erythrovirus (parvovirus B19) infection
- Human rabies immune globulin, 1377
- Human T cell lymphotropic/leukemia virus (HTLV), 1013, 1322, **1383–1384**
myelopathy caused by, **1013**, 1383–1384
transfusion in transmission of/
screening blood for, 536, 1383, 1384

- Humidifier lung, 310t
 Humira. *See* Adalimumab
 Humoral immunity. *See also* B lymphocytes; Immunoglobulins
 infections associated with defects in, 1279
 Humulin, 1213, 1214. *See also* Insulin therapy
 Hungry bone syndrome, 1135, 1143
 Hunter canal, femoral artery disease and, 465
 Huntingtin gene, 1001
 Huntington disease, **1001–1002**
 parkinsonism differentiated from, 998
 Huntington disease-like (HDL) disorders, 1002
 Hurt, Insult, Threaten, Screamed at (HITS) tool, 1712
 Hürthle cell thyroid carcinoma, 1124, 1127, 1133
 HUS. *See* Hemolytic-uremic syndrome
 Hutchinson sign, 1358, 1359
 Hyaline, alcoholic, 681
 Hyaline casts, 899t
 Hyaluronic acid fillers, for age-related facial changes, 1721
 Hyaluronic acid injections, for osteoarthritis of knee, 1702
 Hybridization, in situ, for HER-2/*neu* assessment in breast cancer, 734
 Hycamtin. *See* Topotecan
 Hydatid disease/cysts, 1516
 Hydatidiform mole, **791–792**. *See also* Gestational trophoblastic disease
 hCG levels in, 781, 791, 792
 hyperthyroidism in, 791, 1112
 Hydralazine, 456t
 for heart failure, 404
 for hypertension, 453, 456t
 eclampsia and, 795
 in urgencies/emergencies, 462t, 463
 Hydration. *See* Fluid management/hydration
 Hydronephrosis. *See* Hydroxyurea
 Hydrocarbon toxicity/abuse, 1086, 1583, 1587–1588
 pneumonitis and, 308, 1587–1588
 Hydrocele
 in filariasis, 1525, 1526
 in testicular cancer, 1643
 Hydrocephalus
 arteriovenous malformations causing, 987
 intracranial tumor causing, 991
 normal-pressure, 1007, 1017
 in subarachnoid hemorrhage, 985
 Hydrochlorothiazide, 445t. *See also* Diuretics; Thiazide diuretics
 in combination products, 445t, 450t, 451t, 452t
 for diabetes insipidus, 1099
 for islet cell tumors/insulinomas, 1241
 lithium interactions and, 1074
 Hydrocodone, 79
 in combination agents, 79, 83t
 Hydrocortisone, 1190, 1190t. *See also* Corticosteroids
 for ACTH deficiency, 1096
 acute adrenal insufficiency, 1154, 1154–1155
 Addison disease, 1157
 in antipruritics, 94
 hypercortisolism/Cushing syndrome treatment and, 1160, 1161
 for hypopituitarism, 1096
 for inflammatory bowel disease/ulcerative colitis, 639, 647, 648
 perioperative, 54
 topical, 94, 95t
 Hydrodistention, in interstitial cystitis, 946
 Hydro-Diuril. *See* Hydrochlorothiazide
 Hydrofluoric acid burns, 1571
 Hydrogen breath test
 in bacterial overgrowth, 625
 in lactose intolerance, 573, 626
 Hydrogen cyanide gas, poisoning caused by, 1577
 Hydrogenated starch hydrolases, 1205
 Hydromorphone, 79, 81t
 overdose/toxicity of, 1586–1587
 Hydronephrosis
 dysuria and, 43
 postrenal acute kidney injury and, 903
 in tubulointerstitial disease, 932
 Hydrophobia, in rabies, 1376
 Hydrops
 endolymphatic. *See* Endolymphatic hydrops
 fetalis, 494t, 495
 of gallbladder, 705
 Hydroquinone, for hyperpigmentation, 156
 Hydrothorax, hepatic, 688, 689
 Hydroureter
 postrenal acute kidney injury and, 903
 in tubulointerstitial disease, 932
 Hydroxocobalamin, for cyanide poisoning, 1566t, 1577, 1578t
 β -Hydroxybutyrate/hydroxybutyric acid
 in alcoholic ketoacidosis, 891
 in diabetes mellitus, 1198
 in diabetic ketoacidosis, 891, 1233
 γ -Hydroxybutyrate, overdose/toxicity of, **1580**
 Cushing syndrome and, 1158, 1160
 Hydroxychloroquine
 adverse ophthalmic effects of, 197t, 830
 arrhythmias caused by, 1588
 for lichen planus, 144
 for lupus/SLE, 115, 834
 for porphyria cutanea tarda, 122
 for rheumatoid arthritis, 830
 18-Hydroxycorticosterone, in aldosteronism, 1165
 5-Hydroxyindoleacetic acid (5-HIAA)
 carcinoids secreting, 1621
 reference values for, 1731t
 Hydroxylapatite, for age-related facial changes, 1721
 1- α -Hydroxylase, vitamin D-dependent rickets and, 1149
 11-Hydroxylase/P450c11 deficiency, 1162, 1166, 1179
 17-Hydroxylase/P450c17 deficiency, 1156, 1166, 1179
 21-Hydroxylase/P450c21 deficiency, 1156, 1162, 1163, 1179
 Hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors. *See* Statin drugs
 17-Hydroxyprogesterone
 in amenorrhea, 1179
 in congenital adrenal hyperplasia, 1156, 1163
 in hirsutism/virilization, 1163
 Hydroxyproline, in Paget disease of bone, 1152
 11 β -Hydroxysteroid dehydrogenase
 in hypertension, 437
 in licorice-induced hypokalemia, 1166
 3 β -Hydroxysteroid dehydrogenase
 deficiency, amenorrhea in, 1179
 17 β -Hydroxysteroid dehydrogenase-3
 deficiency, 1162
 5-Hydroxytryptamine-3 receptor antagonists. *See* Serotonin 5-HT₃-receptor-blocking agents
 Hydroxyurea
 in cancer chemotherapy, 1655t
 for essential thrombocytosis, 513–514
 for polycythemia, 512
 for sickle cell disease, 504
 25-Hydroxyvitamin D₃. *See* Calcifediol
 Hydroxyzine, 99, 1042t. *See also* Antihistamines
 for insomnia, 1042t, 1076
 for pruritus, 99
 for urticaria, 133
 Hygiene hypothesis, for diabetes mellitus, 1194
 Hydroton. *See* Chlorthalidone
 Hymen, imperforate, absent menses and, 1179
 Hymenolepis
 diminuta (rodent tapeworm), 1514
 nana (dwarf tapeworm), **1514**
Hyoscyamus niger, toxicity of, 1575
 Hyper-IgE syndrome, atopic-like dermatitis in, 103
 Hyperacusis, **208**
 Hyperadrenergic syndrome
 in hypertensive emergency, 461t
 mitral valve prolapse and, 340, 341
 Hyperaldosteronism. *See* Aldosteronism
 Hyperalimentation. *See* Central vein nutritional support
 Hyperandrogenism, 1162–1163, 1163–1164
 acne and, 125
 adrenal tumors causing, 1162
 amenorrhea caused by, 1179, 1180
 female pattern hair loss and, 1720
 in hirsutism/virilization, 1161, 1162
 in polycystic ovary syndrome, 765, 1162
 Hyperbaric oxygen therapy
 for carbon monoxide poisoning, 1566t, 1576–1577
 for clostridial myonecrosis, 1429
 for dysbarism/decompression sickness, 1558
 for high-altitude illness, 1559
 Hyperbilirubinemia, 662, 663t. *See also* Bilirubin levels; Jaundice

- in biliary tract carcinoma, 1606
 in choledocholithiasis/choolangitis, 707
- Hypercalcemia**, 883–884, 883*t*, 1138, 1139, 1140, 1140*f*. *See also* Hyperparathyroidism
- adrenocortical insufficiency/Addison disease and, 1142, 1154, 1156
- artifact causing, 1141
- bisphosphonate use causing, 1142, 1147
- bisphosphonates for, 884
- calcium ingestion causing, 883, 1141
- cancer-related, 883, 884, 1141, 1596*t*, 1646–1647
- lung cancer and, 1597
- pamidronate/zoledronic acid for, 1647, 1659*t*
- familial hypocalciuric, 878*t*, 884, 1142
- hypercalciuria and, 884, 947*t*, 948
- hyperparathyroidism and, 883, 884, 1138, 1139, 1140, 1140*f*
- in hyperthyroidism, 1142
- hypocalciuria and, 878*t*, 884, 1142
- hypoparathyroidism/hypocalcemia treatment and, 1138
- immobilization, 1142
- in kidney injury/renal failure/dialysis patients, 883, 884, 910*t*, 1139
- lithium use and, 1073, 1142
- in MEN, 1188, 1189
- in myeloma, 527, 528, 529, 936, 1141
- pancreatitis and, 1139, 1141, 1144
- parathyroid tumors and, 1139, 1143
- in sarcoidosis, 295, 883, 1141
- vitamin D ingestion and, 107, 884, 1141–1142, 1151
- Hypercalciuria**, 947*t*, 948. *See also* Calcium nephrolithiasis
- hypercalcemia/hyperparathyroidism and, 884, 947*t*, 948, 1139, 1140
- hypocalcemia/hypoparathyroidism and, 882–883, 1136, 1137
- hypomagnesemia and, 878*t*, 948
- in sarcoidosis, 295, 883
- Hypercapnia**. *See* Permissive hypercapnia; Respiratory acidosis
- Hypercarotenosis**, 1267
- Hyperchloremic normal anion gap acidosis**, 890, 890*t*, 891–893, 892*t*, 893–894. *See also* Normal anion gap acidosis
- Hypercholesterolemia**. *See also* Cholesterol; Lipid disorders
- antiretroviral therapy and, 1344
- clinical presentations in, 1247–1248, 1248*f*
- familial, 1245
- heart disease risk and, 350, 1245, 1246, 1248–1252, 1249–1250*t*, 1251*t*
- in women, 1251, 1706
- isotretinoin causing, 127
- management of. *See* Lipid-lowering therapy
- in nephrotic syndrome, 927, 928
- preventable disease/deaths and, 3*t*, 8–10
- screening for, 1248–1252, 1249–1250*t*, 1251*t*
- in cardiovascular disease prevention, 7*t*, 8–10, 1248–1252, 1249–1250*t*, 1251*t*
- in women, 7*t*, 1248, 1251, 1706
- in older adults, 1251–1252
- in women, 7*t*, 1248, 1251, 1706
- Hyperchylomicronemia**
- clinical presentations in, 1247–1248, 1248*f*
- in diabetes, 1197
- familial, 1245
- Hypercoagulability**
- in acute mesenteric vein occlusion, 471
- in antiphospholipid antibody syndrome, 799, 835
- in Behçet syndrome, 853
- DVT/PE (venous thromboembolic disease) and, 297
- in hepatic vein obstruction (Budd-Chiari syndrome), 698
- in membranous nephropathy, 929
- in nephrotic syndrome/nephrotic spectrum disorders, 928
- in noncirrhotic portal hypertension, 700
- pulmonary hypertension and, 424
- superficial thrombophlebitis and, 480
- Hypercortisolism**, 1158–1161. *See also* Cushing syndrome
- Hyperdynamic state**, in myocardial infarction, 367*t*
- Hyperemesis gravidarum**, 787–788
- thyroid disorders and, 787, 1111
- Wernicke encephalopathy and, 1013
- Hyper eosinophilic syndromes**, cardiac involvement in, 428
- Hypergammaglobulinemia**
- bronchiectasis and, 266
- chronic pancreatitis and, 715
- in HIV infection/AIDS, 1322
- in Waldenström macroglobulinemia, 529
- Hypergastrinemia**
- carcinoid tumors and, 1619
- in pernicious anemia gastritis, 610
- Zollinger-Ellison syndrome (gastrinoma) and, 619, 620, 1172, 1189
- Hyperglycemia**, 1192. *See also* Diabetes mellitus
- in alcoholic ketoacidosis, 891
- antipsychotic drug use and, 1057, 1059, 1060*t*
- in burn injury, 1552
- coma caused by. *See* Diabetic coma
- control of. *See* Glycemic control in diabetes
- in diabetic ketoacidosis, 891, 1232, 1232*t*
- drugs causing, 1244
- drugs for treatment of, 1205–1213, 1206–1207*t*. *See also* Antidiabetic agents; Insulin therapy
- in hyperglycemic hyperosmolar state, 877, 1232*t*, 1235, 1236
- hypertremia and, 876
- hyponatremia and, 871*f*, 872
- insulin resistance and, 1194, 1196, 1196*t*
- pancreatitis/pancreatectomy and, 1196
- parenteral nutritional support and, 1274*t*
- pentamidine-induced, 1244, 1535
- in pheochromocytoma, 1168
- prebreakfast, 1219–1220, 1219*t*
- in pregnancy, 800–801
- congenital anomalies caused by, 801
- preventable disease/deaths and, 3*t*
- secondary, 1196, 1196*t*
- surgery and, prevention of, 54, 54*t*, 1229, 1229*t*
- Hyperglycemic coma**. *See* Diabetic coma
- Hyperglycemic hyperosmolar state**, 877, 1232*t*, 1235–1237
- Hyperhomocysteinemia**, in coronary heart disease/occlusive arterial disease, 1668–1669
- Hyperinfection syndrome**, in strongyloidiasis, 1519
- Hyperinsulinemia**
- acne and, 126
- factitious, 1239
- hypoglycemic
- insulinoma causing, 1189, 1239
- islet cell hyperplasia causing, 1242
- in insulin resistance syndrome, 1196
- in polycystic ovary syndrome, 765, 1162
- Hyperkalemia**, 879–880, 880*t*, 881*t*
- adrenocortical insufficiency/Addison disease and, 879, 1154, 1157
- angiotensin-converting enzyme (ACE) inhibitors/angiotensin blockers causing, 449, 879, 928
- in diabetic ketoacidosis, 1232, 1234
- genetic disorders and, 878*t*, 879
- in HIV infection/AIDS, 880
- in hyperglycemic hyperosmolar state, 1236
- in hyporeninemic hypoaldosteronism, 892, 892*t*, 894, 933, 1157
- in metabolic acidosis, 879, 892, 892*t*, 914
- postoperative, 55
- renal disorders/failure and, 879, 902, 905, 913–914, 928
- spurious/phlebotomy technique and, 1164
- in tubulointerstitial disease, 933
- in tumor lysis syndrome, 1647
- Hyperkalemic periodic paralysis**, 878*t*, 1036–1037
- Hyperkeratosis**, plantar, of heels, 141
- Hyperketonemia**
- in diabetic ketoacidosis, 1232, 1233
- at end of life, 90
- Hyperleukocytosis**, in acute leukemia, 520
- Hyperlipidemia**. *See also* Lipid disorders
- antipsychotic drugs and, 1059, 1060*t*
- antiretroviral therapy causing, 1332, 1344
- in diabetes mellitus, 1197, 1200–1201, 1247, 1248*t*
- familial combined, 1245
- hyponatremia and, 871*f*, 872
- in nephrotic syndrome/nephrotic spectrum disorders, 918, 927, 928, 1248*t*
- treatment of. *See* Lipid-lowering therapy

- Hypermagnesemia, **888**
 in acute tubular necrosis/kidney injury, 906
 hypomagnesemia treatment and, **888**
 hypoparathyroidism and, **887, 1136**
- Hypermetabolism
 in burn injury, **1552**
 in chronic myeloid leukemia, **516**
 in HIV infection/AIDS, **1325**
- Hypermethioninemia, newborn screening for, **1669**
- Hyponatremia, **875–876**
 in diabetes insipidus, **876, 1098, 1099**
 in diabetes mellitus/glycosuria, **876**
 enteral nutritional support and, **1273**
- Hyperopia, **162**
- Hyperosmolality (hyperosmolar disorders), **877**
 hyperglycemia and (hyperglycemic hyperosmolar state), **877, 1232t, 1235–1237**
 hyponatremia and, **875**
- Hyperosmolar nonketotic dehydration, parenteral nutritional support and, **1274t**
- Hyperostosis, diffuse idiopathic skeletal (DISH), **855, 1228**
- Hyperoxaluric calcium nephrolithiasis, **949**
- Hyperparathyroidism, **1138–1144, 1140f**.
 See also Hypercalcemia
 bisphosphonate use and, **1142, 1147**
 bone changes and, **1139, 1141**
 chronic kidney disease and, **911f, 912, 912f, 1139, 1141, 1143–1144**
 hypercalcemia and, **883, 884, 1138, 1139, 1140, 1140f**
 hypercalciuria and, **884, 947t, 948, 1139**
 hypophosphatemia and, **885, 1139, 1140**
 lithium use and, **1073**
 in MEN, **1138–1139, 1141, 1144, 1188–1189, 1189**
 pancreatitis and, **1139, 1141, 1144**
 after parathyroidectomy, **1143**
 parathyroidectomy for, **1142–1144**
 during pregnancy, **1139**
- Hyperparathyroidism–jaw tumor syndrome, **1139**
- Hyperpathia
 intracranial mass lesions causing, **991**
 neuropathy causing, **1021**
 stroke causing, **981**
- Hyperphosphatemia, **886–887, 886t**
 in diabetic ketoacidosis, **1232**
 hypercalcemia and, **884**
 in kidney disease, **886, 902, 911f**
 acute tubular necrosis, **905**
 bone disorders and, **912, 912–913, 912f, 1139**
 hyperparathyroidism and, **912, 912f, 1139**
 hypocalcemia/hypoparathyroidism and, **882, 912, 912f**
 in lactic acidosis, **1237**
 parenteral nutritional support and, **1274t**
 in tumor lysis syndrome, **1647**
- Hyperpigmentation, **155–156**. *See also* Pigmented skin lesions
 in Addison disease, **155, 1156**
 in alkaptonuria, **1665**
 antipsychotic drugs causing, **1060**
 chemotherapy-induced, **1661**
 drugs causing, **155, 160t**
 in hemochromatosis, **695**
 nail, drugs causing, **157, 160t**
 in porphyria cutanea tarda, **122**
 postinflammatory, **155, 156**
 in varicose veins, **478, 479**
 in venous insufficiency/leg ulcers, **34, 153, 481**
 in visceral leishmaniasis, **1487**
- Hyperplastic polyps, **652, 653, 653–654**
- Hyperprolactinemia, **1102–1105, 1103t**
 amenorrhea and, **1102, 1103, 1180, 1181**
 asenapine causing, **1058**
 gynecomastia and, **1102, 1178**
 hypogonadotropic hypogonadism and, **1096, 1102, 1103**
 hypothyroidism and, **1103, 1107**
 infertility and, **768, 769, 955, 1102, 1103, 1104**
 nipple discharge in, **720, 1103, 1719**
 risperidone-induced, **1057**
- Hyperproteinemia, hyponatremia and, **871f, 872, 874**
- Hyperreactio luteinalis, **1162**
- Hyperreflexia, in tetanus, **1429**
- Hyperreninemic hypoadosteronism, **1157**
- Hypersensitivity
 to ultraviolet radiation. *See* Photodermatitis/ photosensitivity
 visceral
 chest pain/discomfort and, **606–607**
 irritable bowel syndrome and, **633**
- Hypersensitivity pneumonitis, **310, 310t**
- Hypersensitivity reactions, **865–866**. *See also* Allergies/allergic reactions
 to antimicrobials, **1305–1307**
 in HIV infection/AIDS, **1322**
 myocarditis caused by, **409t, 410**
 to ophthalmic medications, **166, 195**
 to transfusion, **535**
- Hypersensitivity syndromes, drug-induced (complex drug eruptions), **160–161**
- Hypersomnias, **1077**
- Hypertension, **10–11, 433–463**
 aldosteronism and, **437, 437–438, 440, 453, 1164, 1165**
 aortic dissection and, **439, 461t, 477**
 assessment/diagnosis of, **433–434, 434t, 435f, 439–440**
 atherosclerosis and, **439**
 atrial fibrillation and, **385, 385t, 386**
 cardiovascular disease/risk factors/ prevention and, **7t, 10–11, 433, 434, 439, 441–442, 442–444, 442t, 443f, 444t, 457, 1249t, 1250**
 in women, **1706**
 cerebrovascular disease and, **439, 440, 443**
 chronic kidney disease/renal failure and, **433, 439, 442t, 458–459, 908, 910, 910t, 911, 911f**
 classification of, **433, 434t, 435–439, 436t**
 in coarctation of aorta, **326, 327, 438**
 complications of untreated disease and, **439**
 in Cushing syndrome, **438**
 dementia and, **439**
 in diabetes mellitus/diabetic nephropathy, **433, 442t, 443, 444, 457–458, 458, 931, 1197, 1224, 1227**
 angiotensin-converting enzyme (ACE) inhibitors for, **442t, 449, 457–458, 458, 931, 1202, 1203, 1224, 1227**
 antihypertensive therapy regimens for, **442t, 457–458, 458, 931**
 benefits of control of, **1202, 1203, 1224, 1227**
 calcium channel blocking agents and, **442t, 458, 1203**
 in elderly, **433, 435, 436, 437, 458t, 459**
 epistaxis and, **220**
 essential, **435–436**
 estrogen use and, **438**
 fibromuscular dysplasia/renal artery stenosis and, **437, 917, 918**
 genetic factors in, **437**
 headache and, **41, 439**
 in heart disease/failure, **10–11, 398, 433, 434, 439, 442t, 457**
 insulin resistance syndrome and, **436, 1196**
 intracerebral hemorrhage and, **434, 461t, 983**
 intracranial. *See* Intracranial hypertension
 malignant, **460**
 headache and, **41**
 management of, **434t**
 in blacks, **436, 449, 453, 457f, 458t, 459**
 cardiovascular/heart disease prevention and, **10–11, 434, 439, 441–442, 442–444, 442t, 443f, 444t, 457**
 in women, **1706**
 congestive heart failure and, **10–11, 439, 442t, 457**
 in diabetic patients, **442t, 443, 444, 457–458, 458, 1202, 1203, 1227**
 exercise/activity and, **12–13, 436, 441, 441t**
 kidney disease/renal failure and, **439, 442t, 458–459, 911**
 in hypertensive emergency, **461t**
 lifestyle modifications/ nonpharmacologic therapy and, **434t, 441, 441t**
 pharmacologic, **434t, 441–444, 442t, 443f, 444–459, 444t, 445t, 447–448t, 450–452t, 454–455t, 456t, 457f, 458t**. *See also* Antihypertensive drug therapy
 in urgencies and emergencies, **461–463, 462t**
 preoperative, **49–50**
 for urgencies/emergencies, **461–463, 462t**

- metabolic syndrome (syndrome X)
and, 436, 1196
in nephritic syndrome, 920
ocular. *See* Ocular hypertension
oral contraceptive use and, 438, 772
in pheochromocytoma, 438, 440, 1166,
1166–1167, 1167, 1168*t*, 1169
in poisoning/drug overdose, **1564**
in polyarteritis nodosa, 847
in polycystic kidney disease, 935
portal. *See* Portal hypertension
portopulmonary, 691
during pregnancy, 437, 438, 461*t*, **793–**
795, 793*t*, **802**. *See also*
Preeclampsia-eclampsia
preoperative evaluation/perioperative
management and, 49–50
preventable disease/deaths and, 3*t*,
10–11
prevention of, **10–11**
exercise/activity in, 11, 12–13, 436
primary essential, 435–436
pulmonary. *See* Pulmonary
hypertension
renal disease and, 437, 442*t*, 458–459
renal vascular, 437
resistant, 438, 459–460, 460*t*
retinchoroidopathy/retinopathy in,
186, 440, 440*f*
salt-sensitive, 436
screening for, 7*t*, 10–11
secondary, 436–437, 436*t*
sleep apnea and, 319, 436
sodium restriction and, 436
stroke/stroke prevention and, 10–11,
433, 439, 440, 442*t*, 457
in emergencies/urgencies, 460–461,
461*t*
Hypertension exacerbated in pregnancy,
437
Hypertensive emergencies, 433, **460–463**,
461*t*, 462*t*
MAOIs causing, 1069
in pheochromocytoma, 438, 1167,
1169
in scleroderma, 839
Hypertensive encephalopathy, 440, 460
Hypertensive nephropathy, 460
Hypertensive urgencies, 433, **460–463**,
461*t*, 462*t*. *See also*
Hypertensive emergencies
Hyperthecosis. *See* Polycystic ovary
syndrome
Hyperthermia, **35–36**, 36*t*, **1547–1549**.
See also Fever; Heat;
Serotonin syndrome
antipsychotic drugs causing. *See*
Neuroleptic malignant
syndrome
heat exposure syndromes and,
1547–1549
malignant, 35, 1283, 1565
in poisoning/drug overdose, **1565**. *See*
also Serotonin syndrome
with antidepressants, 1591, 1592
prevention of, 1547
Hyperthermia therapy, for benign
prostatic hyperplasia, 961
Hyperthyroidism (thyrotoxicosis), 1105*t*,
1110–1119, 1111*t*
amiodarone-induced, 1110, 1112,
1113–1114, 1114, 1117
apathetic, 1114, 1118
atrial fibrillation in, 384, 1112, 1114,
1118
cancer-related, 1112, 1127, 1128, 1596*t*
cardiac disorders/failure and, 399, 400,
1112, 1114, 1118
eye disease associated with, **191**, 1110,
1112–1113, 1117–1118
RAI treatment for hyperthyroidism
and, 1115–1116, 1117–1118
factitious, 1111, 1113
fetal, 800
in gestational trophoblastic disease,
791, 1112
goiter/thyroid nodules and, 1111, 1114,
1123, 1125, 1134
in Graves disease, 1110–1111
Hashimoto thyroiditis and, 1111, 1117,
1121
hypercalcemia and, 1142
hypothyroidism after treatment for,
1115, 1116, 1119
iodine-induced (Jod-Basedow disease/
phenomenon), 1110, 1111,
1112, 1113, 1114
lactation and, 1115, 1117
levothyroxine causing, 1125
lipid abnormalities and, 1248*t*
lithium causing, 1111
muscle weakness and, 841
osteoporosis and, 1145
palpitations and, 31
after parathyroidectomy, 1143
periodic paralysis and, 1036, 1113,
1119
pituitary tumor/hyperplasia causing,
1111, 1117
postpartum, 1111, 1119, 1121
during pregnancy, 800, 1111, 1111–
1112, 1113, 1117, 1121
preoperative evaluation/perioperative
management and, 55
struma ovarii and, 1111, 1114
subacute (de Quervain) thyroiditis
and, 1111, 1113, 1114, 1117,
1121, 1122
subclinical, 1113, 1119
thyroid carcinoma and, 1112
thyroid testing in, 1105*t*, 1113–1114
toxic adenoma/solitary nodule causing,
1111, 1116
TSH levels in, 1105*t*, 1110, 1113
Hypertonic hyponatremia, 871–872, 871*f*
Hypertonic saline
for cystic fibrosis, 268
for hyponatremia, 874–875
Hypertrichosis
lanuginosa, 1162
minoxidil therapy and, 1164, 1720
in porphyria cutanea tarda, 122
Hypertriglyceridemia, **1255–1256**. *See*
also Lipid disorders
alcohol use/abuse and, 1247, 1248*t*
cholelithiasis/gallstones and, 702
clinical presentations in, 1247–1248,
1248*f*
HIV infection/antiretroviral therapy
and, 1344
hyponatremia and, 871*f*, 872, 874
insulin resistance syndrome/diabetes
mellitus and, 1197, 1228
isotretinoin causing, 127
management of, 1253, 1254, 1255–
1256, 1255*t*
in nephrotic syndrome, 927, 928
nonalcoholic fatty liver disease and,
684
pancreatitis and, 711, 714, 1255
Hypertrophic/hypertrophic obstructive
cardiomyopathy. *See*
Cardiomyopathy
Hypertrophic gastropathy (Ménétrier
disease), 610
Hypertrophic osteoarthropathy/
hypertrophic pulmonary
osteoarthropathy, 864, 1596*t*
rheumatoid arthritis differentiated
from, 828
Hyperuricemia, 812, 813*t*, 814
acute tubular necrosis/kidney injury
and, 905
asymptomatic, 814
cancer-related/chemotherapy-induced,
1647–1648
allopurinol for, 1647, 1658*t*
rasburicase for, 1647, 1658*t*
in diabetes insipidus, 1098, 1099
in diabetes mellitus, 1228
drugs causing, 814–815
drugs in management of, 815–816
in gout, 812, 812–813, 813*t*, 814,
936–937
kidney disease and, 812, 813, 816, 905,
910*t*, 936–937, 1647
in myeloma, 528, 529, 936
in polycythemia, 512
in preeclampsia-eclampsia, 794
in transplant patient, 816
urinary stone formation and, 813,
936–937, 949. *See also* Uric
acid urinary stones
Hyperuricosuric calcium nephrolithiasis,
948–949
Hyperventilation, **318**
for high-altitude illness, 1559
lactic acidosis and, 1237
in metabolic acidosis, 893
neurogenic, in coma or stupor, 318,
1014
respiratory alkalosis (hypocapnia) and,
318, 896, 896–897
Hyperviscosity
DVT/PE (venous thromboembolic
disease) and, 297
myeloma and, 527, 528
Waldenström macroglobulinemia and,
530
Hypervitaminosis A, **1267**
Hypervolemia, acute kidney injury and,
902
Hypervolemic hyponatremia,
875, 876
Hypervolemic hypotonic hyponatremia,
871*f*, 873–874, 874
Hyphema, 192, 193, 193*f*
Hypnagogic hallucinations. *See also*
Hallucinations
in narcolepsy, 1077

- Hypnosis/hypnotherapy
 for chronic pain, 1048
 for conversion disorders, 1046
 for dyspepsia, 566
 for irritable bowel syndrome, 636
- Hypnotic drugs. *See* Sedative-hypnotics
- Hypoactive sexual desire disorder (HSDD), 1181, 1185, 1714
- Hypoadrenalism. *See* Adrenocortical insufficiency
- Hypoalbuminemia
 anion gap affected in, 890
 ascites and, 587*t*
 calcium levels and, 882, 883, 1136, 1646
 in nephrotic syndrome, 918, 927
 in protein-losing enteropathy, 631, 632
- Hypoadosteronism, 1157
 Addison disease and, 1155, 1157
 after adrenalectomy, 1166
 hyperreninemic, 1157
 hyporeninemic/in renal tubular acidosis, 892, 892*t*, 894, 933, 1157
- Hypobaric hypoxia, 1558, 1559. *See also* High-altitude illness
 air travel emergencies and, 1560
- Hypocalcemia, **882–883**, 882*t*, 1136, 1137, 1137–1138
 bisphosphonate use and, 1147
 familial, 878*t*
 with hypercalciuria, 882–883, 1136, 1137
 hyperphosphatemia and, 882
 hypomagnesemia and, 882, 883, 887, 888
 hypoparathyroidism and, 882, 1136, 1137, 1137–1138. *See also* Hypoparathyroidism
 in kidney disease, 882, 910*t*
 acute tubular necrosis/
 rhabdomyolysis, 905, 906
 bone disorders and, 912, 912*f*
 muscle cramps caused by, 882
 pancreatitis and, 714, 882, 1137
 after parathyroidectomy, 1143
 in pseudohypoparathyroidism, 1137
 tetany and, 882, 1136, 1137, 1137*t*
- Hypocalciuria, hypercalcemia and (hypocalciuric hypercalcemia), 878*t*, 884, 1142
- Hypocapnia. *See* Respiratory alkalosis
- Hypochloremia
 in normal anion gap acidosis, 892. *See also* Hyperchloremic normal anion gap acidosis
 in respiratory acidosis, 896
- Hypochlorite, for skin/clothing decontamination, 1566, 1587
- Hypocholesterolemia drugs. *See* Lipid-lowering therapy
- Hypochondriasis, 1041, 1046
- Hypocitraturic calcium nephrolithiasis, 949
- Hypocomplementemia
 in hepatitis C-related renal disease, 926
 in SLE, 834*t*
- Hypogammaglobulinemia
 in bronchiectasis, 266
 in chronic lymphocytic leukemia, 522
- in common variable immunodeficiency, 868–869
- infection and, 1279
- Hypoglycemia, 1221–1222, **1238–1244**
 adrenocortical insufficiency and, 1154, 1156
 alcohol-related, 1083, 1222, 1238, 1238*t*
 in alcoholic ketoacidosis, 891
 altered awareness of, 1222, 1239
 autoimmune/immunopathologic, 1238, 1238*t*, **1243**
 cancer-related, 1596*t*
 chronic kidney disease/uremia and, 910, 914, 1222
 coma caused by, 1231, 1232*t*
 in poisoning/drug overdose, 1232*t*, 1563
 diabetes treatment and, 1221–1222. *See also* Hypoglycemia, insulin-induced
 disordered eating in women and, 1713
 drug-induced, 1238*t*, **1243–1244**, 1580
 exercise-induced, 12, 1222
 factitious, 1239, **1243**
 fasting, 1238, 1238*t*
 functional alimentary, **1242–1243**
 after gastric surgery, 1242
 in GH deficiency, 1094
 glucagon response to, impaired, 1222
 hyperinsulinemic
 insulinoma causing, 1189, 1239
 islet cell hyperplasia causing, 1242
 hypophosphatemia associated with treatment of, 885
 insulin-induced/intensive glycemic control and, 1201, 1221–1222, 1580
 in hospitalized patient, 1230
 insulin receptor antibodies causing, **1243**
 near drowning and, 1556
 noninsulinoma pancreatogenous hypoglycemia syndrome (islet cell hyperplasia) causing, 1238, 1241, **1242**
 nonislet cell tumors causing, **1241–1242**
 occult diabetes and, **1243**
 pancreatic B cell tumors/insulinoma causing, 1172, 1189, **1238–1241**, 1239*t*, 1240*t*
 patient education and, 1218
 pentamidine-induced, 1244, 1535
 postprandial (reactive), 1238, 1238*t*, **1242–1243**
 pramlintide use and, 1213
 status epilepticus caused by, 974
 surgery and, prevention of, 54, 54*t*, 1229
- Hypoglycemic drugs, 1205–1213, 1206–1207*t*. *See also* Antidiabetic agents; Insulin therapy
 overdose/toxicity of, 1566*t*, **1580**
- Hypoglycemic unawareness, 1222, 1239
- Hypogonadism
 Addison disease and, 1155, 1156, 1157
 androgen insensitivity causing, 1094, 1175
 female
 amenorrhea in, 1094, 1179, 1181
 hormone replacement therapy for, 1096–1097
 premature (premature menopause/ovarian failure), 779, 1181
 in Turner syndrome, 1186
- GH-secreting pituitary tumor causing, 1100
- in HIV infection/AIDS, 1330
- hypergonadotropic, 955, 1173, 1173*t*, 1174–1175, 1175
- hyperprolactinemia and, 1096, 1102, 1103
- hypogonadotropic, 955, 1093, 1094, 1096, 1097, 1173, 1173*t*, 1175
 isolated/congenital, 1093, 1173
- in hypopituitarism, 1093, 1094, 1096, 1097
- male, 1093, 1094, 1173*t*, **1174–1177**
 gynecomastia and, 1174*t*, 1178
 hormone replacement therapy for, 1096–1097, 1176–1177
 infertility and, 954, 955, 1094, 1175
 sexual dysfunction and, 1094, 1175
 osteoporosis and, 1145
- Hypokalemia, **877–879**, 877*t*, 878*t*
 aldosteronism and, 878, 1164
 differential diagnosis and, 1165–1166
 diabetic ketoacidosis treatment and, 1234
 diuretic use and, 401, 446, 878, 879
 genetic disorders and, 878, 878*t*
 hypomagnesemia and, 878, 879, 887, 888
 kidney injury/renal disorders and, 879, 892*t*, 910*t*
 in metabolic acidosis, 878, 892, 892*t*, 894
 in metabolic alkalosis, 894–895, 895
 parenteral nutritional support and, 1274*t*
 VIPomas and, 1172, 1189
 vitamin B₁₂ replacement therapy and, 498
- Hypokalemic periodic paralysis, 878*t*, 1036
 in hyperthyroidism, 1036, 1113, 1119
- Hypomagnesemia, **887–888**, 887*t*
 hypercalciuria and, 878*t*, 948
 hypocalcemia/hypoparathyroidism and, 882, 883, 887, 888, 1135–1136, 1136, 1137
 hypokalemia and, 878, 879, 887, 888
 parenteral nutritional support and, 1274*t*
 proton pump inhibitors causing, 887–888
- Hypomagnesemia-hypercalciuria syndrome, 878*t*
- Hypomania, 1063. *See also* Mania
 in cyclothymic disorders, 1064
 drug therapy for, 1072–1075, 1074*t*
- Hyponatremia, **871–875**, 871*f*, 873*t*
 adrenocortical insufficiency/Addison disease and, 871*f*, 872, 1154, 1156
 in diabetic ketoacidosis, 1232
 drugs causing, 871*f*, 872, 874
 endurance exercise causing, 871*f*, 873
 in HIV infection/AIDS, 872
 hormone abnormalities causing, 872
 in hyperglycemic hyperosmolar state, 1236

- in hypopituitarism, 1095, 1096
 in hypothyroidism/myxedema, 871f, 872, 1106
 MDMA causing, 872, 1572
 nausea/pain/surgery/procedures causing, 871f, 872
 after pituitary surgery, 1096, 1104
 in porphyria, 1664
 psychogenic polydipsia/beer
 potomania causing, 871f, 873, 1055
 reset osmostat causing, 873, 874
 in schizophrenia/psychotic disorders, 873, 1055
 in SIADH, 871f, 873, 874, 875
 in subarachnoid hemorrhage, 985–986
 Hypoparathyroidism, **1135–1138**, 1137t
 congenital, 1136
 fetal, maternal hyperparathyroidism and, 1136
 hyper-/hypomagnesemia and, 882, 887, 1135–1136, 1136, 1137
 hypercalcemia and, 884
 hypercalciuria and, 882–883, 1136, 1137, 1138
 hypocalcemia and, 882, 1136, 1137, 1137–1138, 1140f
 after parathyroid surgery, 1135, 1143, 1189
 tetany and, 1136, 1137, 1137t
 after thyroidectomy, 1116, 1119, 1129, 1135
 Hypophosphatase, 1150, 1151
 Hypophosphatemia, **885–886**, 885t, 1150, 1151
 in diabetic ketoacidosis, 886, 1234
 hypercalciuria and, 947t, 948
 in hyperglycemic hyperosmolar state, 1236–1237
 hyperparathyroidism and, 885, 1139, 1140
 hypocalcemia and, 882
 osteomalacia/rickets and, 878t, 1150, 1151
 Hypophosphatemic rickets/osteomalacia, 878t, 1150, 1151
 Hypophysectomy, for breast cancer, 740
 Hypopigmentation, 155–156, 155f
 in atopic dermatitis, 103
 in tinea (pityriasis) versicolor, 113
 in tuberous sclerosis, 996
 Hypopituitarism, **1093–1098**
 after acromegaly/gigantism treatment, 1102
 amenorrhea and, 1179, 1181
 hypogonadism and, 1093, 1094, 1096, 1097, 1173
 Hypopnea, sleep, 318. *See also* Sleep apnea
 Hypoproteinemia, in nephrotic syndrome, 927
 Hypoprothrombinemia
 in cirrhosis, 690–691
 factor II antibodies and, 553
 salicylate-induced, 1588
 Hypopyon
 in anterior uveitis, 178
 in bacterial keratitis, 172
 in Behçet syndrome, 853
 Hyporeninemic hypoaldosteronism, 1157
 in renal tubular acidosis, 892, 892t, 894, 933, 1157
 Hyposmia, 220
 in Kallmann syndrome, 1094
 Hypotension
 ACE inhibitors causing, 402, 449
 in Addison disease, 1156, 1157
 antipsychotics causing, 1059, 1574
 in cholera, 1448
 in desensitization therapy, 1307
 in diabetes, 1197, 1226
 dysautonomia (autonomic dysfunction) and, 975, 976, 1021
 myocardial infarction and, 374
 orthostatic (postural). *See* Orthostatic (postural) hypotension
 palpitations and, 31
 pheochromocytoma/
 pheochromocytoma removal and, 1169, 1170
 in poisoning/drug overdose, **1563–1564**
 right ventricular infarction and, 374
 in shock, 485, 486
 syncope and, 396
 transient ischemic attacks and, 977
 Hypotensive agents. *See* Antihypertensive drug therapy
 Hypothalamic disorders, **1093–1105**
 amenorrhea caused by, 1179, 1180
 Hypothermia
 coma and, 1014, 1015, 1544
 of extremities, **1545–1546**
 near drowning and, 1556, 1557
 in poisoning/drug overdose, **1563**
 prevention of, 1545
 rhabdomyolysis and, 844
 systemic (accidental), **1543–1545**, 1544f
 Hypothyroidism, 1094, **1105–1110**, 1105t, 1107t
 Addison disease and (Schmidt syndrome), 1155
 amiodarone-induced, 1106
 cardiac disorders/failure and, 399, 400, 1108
 congenital/fetal, 800, 1117
 maternal hyperthyroidism and, 800, 1106, 1117
 cretinism and, 1106, 1134
 dementia and, 60
 goiter/thyroid nodules and, 1106, 1123, 1125, 1134
 Hashimoto thyroiditis and, 1106, 1120, 1121, 1122
 hepatitis C and, 1106
 hyperprolactinemia and, 1103, 1107
 after hyperthyroidism treatment, 1115, 1116, 1119
 hyponatremia in, 871f, 872, 1106
 iodine deficiency and, 1134
 lipid abnormalities in, 1248t
 lithium causing, 1073
 mania/bipolar disease and, 1064
 muscle weakness and, 841
 pericardial effusions and, 420, 1106
 during pregnancy, 800, 1106, 1108, 1109
 preoperative evaluation/perioperative management and, 55
 after radioiodine therapy, 1116, 1119
 in subacute (de Quervain) thyroiditis, 1106, 1111, 1121
 subclinical, 800, 1107
 thiourea treatment and, 1115
 thyroid testing in, 1105t, 1107, 1107t
 after thyroidectomy, 1119, 1129
 TSH deficiency/levels in, 1094, 1096, 1105t, 1106, 1107
 Hypotonic fluid administration,
 hyponatremia and, 872
 Hypotonic hyponatremia, 871f, 872–874
 Hypouricemia, in SIADH, 874
 Hypoventilation
 alveolar
 central, 318
 primary (Ondine curse), **317–318**
 obesity and (Pickwickian syndrome), **318**
 respiratory acidosis and, 895–896
 Hypovolemia
 kidney injury and, 902, 910t
 in myocardial infarction, 367t
 rhabdomyolysis and, 844
 Hypovolemic hypernatremia, 875, 876
 Hypovolemic hypotonic hyponatremia, 871f, 872, 874
 Hypovolemic shock, 485, 485t, 486, 487
 in heat stroke, 1548
 in myocardial infarction, 367t, 374
 Hypoxemia
 in ARDS, 322, 323
 in asthma/asthma exacerbations, 246, 256
 in COPD, 261, 264
 oxygen therapy and, 261–262, 264
 in cystic fibrosis, 267
 dyspnea and, 25, 26, 86
 near drowning and, 1556
 in patent foramen ovale, 329
 in pulmonary embolism, 297, 299
 in respiratory failure, 320
 in sleep apnea, 318
 Hypoxia
 hypobaric, 1558, 1559. *See also* High-altitude illness
 air travel emergencies and, 1560
 lactic acidosis and, 891
 near drowning and, 1556
 in pulmonary embolism, 298
 Hypoxic hepatitis, 699
Hypoxis rooperi, for benign prostatic hyperplasia, 960
 Hysterectomy. *See also* Menopause/
 menopausal syndrome,
 surgical
 for abnormal premenopausal bleeding, 748
 for cervical cancer, 757
 for chronic pelvic pain, 1716
 for dysmenorrhea, 750–751, 1716
 for endometrial carcinoma, 759
 for endometriosis, 761
 estrogen replacement therapy and, 779
 for gestational trophoblastic disease, 792
 for ovarian cancer, 765
 for pelvic organ prolapse, 762
 for PID, 764
 for postmenopausal bleeding, 749
 premature menopause/ovarian failure and, 779, 780, 1181
 prophylactic, in HNPCC, 657
 for uterine leiomyoma, 758

- Hysteria (somatization disorder), 1045–1046
- Hysterical conversion. *See* Conversion disorder
- Hysterical (histrionic) personality disorder, 1052*t*
- Hysterosalpingography, 748*t*
in infertility workup, 768
- Hysteroscopy, 748*t*
in abnormal premenopausal bleeding, 747, 748
in endometrial carcinoma, 759
in postmenopausal bleeding, 749
tubal ligation and, 777
- Hytrin. *See* Terazosin
- Hyzaar. *See* Losartan, for hypertension, with hydrochlorothiazide
- ¹²³I. *See also* Radioactive iodine
for thyroid scanning, 1105*t*, 1124*t*, 1127*t*. *See also* Radioiodine thyroid scans and uptake
for whole body scanning, in thyroid cancer surveillance, 1128–1129, 1132–1133
- ¹²³I-MIBG scanning, in pheochromocytoma/paraganglioma, 1169, 1170, 1171
- ¹³¹I. *See also* Radioactive iodine
for goiter, 1135
for hyperthyroidism/Graves disease, 1115–1116
amiodarone-induced, 1117
hypothyroidism after, 1116, 1119
ophthalmopathy flares and, 1115–1116
thiourea treatment and, 1115
toxic multinodular goiter, 1116
toxic solitary thyroid nodule and, 1116
for thyroid cancer treatment/surveillance, 1130–1131, 1132–1133
for thyroid nodules, 1125–1126
for whole body scanning, in thyroid cancer surveillance, 1128–1129, 1132–1133
- ¹³¹I-MIBG therapy, in pheochromocytoma/paraganglioma, 1171
- ¹³¹I tositumomab, 1654*t*
for non-Hodgkin lymphoma, 525
- IA-2 antibodies, in type 1 diabetes, 1193, 1193*t*
- IAA. *See* Insulin, antibodies to
- IADL. *See* Instrumental activities of daily living
- Iatrogenic Creutzfeldt-Jakob disease, 1381, 1382
- Iatrogenic pneumothorax, 316
- Ibandronate, 1146. *See also* Bisphosphonates
- Ibotenic acid, poisoning with mushrooms containing, 1586*t*
- Ibritumomab tiuxetan, 1653*t*
for non-Hodgkin lymphoma, 525
- Ibuprofen, 77*t*
lithium interactions and, 1074*t*
platelet function affected by, 549*t*
- Ibutilide, 377, 379*t*
for atrial fibrillation, 378*t*, 385, 387
for atrial flutter, 378*t*, 389
- ICA. *See* Islet cell antibodies
- ICD. *See* Implantable cardioverter defibrillator
- Ice pack, as topical antipruritic, 94
- iCJD. *See* Iatrogenic Creutzfeldt-Jakob disease
- ICSI. *See* Intracytoplasmic sperm injection
- Icteric leptospirosis (Weil syndrome), 1477
- Icterus. *See* Jaundice
- Idamycin. *See* Idarubicin
- Idarubicin, 1653*t*
toxicity of, 1653*t*, 1662
- Idiogenic osmoles, hyponatremia treatment and, 876
- Idiopathic adulthood ductopenia, 710
- Idiopathic brachial plexus neuropathy (neuralgic amyotrophy), 1029–1030
- Idiopathic bronchiolitis obliterans with organizing pneumonia. *See* Cryptogenic organizing pneumonia/pneumonitis
- Idiopathic CD4 lymphopenia syndrome, 1382
- Idiopathic crescentic glomerulonephritis, 919*t*, 924
- Idiopathic interstitial pneumonias, 293–295, 294*t*
- Idiopathic intracranial hypertension, 995
- Idiopathic membranoproliferative glomerulonephritis, 919*t*, 925. *See also* Membranoproliferative glomerulonephritis
- Idiopathic midline destructive disease, 223
- Idiopathic polyneuropathy, acute. *See* Guillain-Barré syndrome
- Idiopathic pulmonary hemosiderosis, 307
- Idiopathic (primary) pulmonary hypertension, 304, 423, 424, 425
- Idiopathic skeletal hyperostosis, diffuse (DISH), 855, 1228
- Idiopathic torsion dystonia, 1002–1003
- Idiosyncratic drug reactions, liver disease caused by, 683
- Idioventricular rhythm, accelerated, 393
in myocardial infarction, 373, 393
- Idoxuridine, 1353*t*
- IEP. *See* Immunofixation electrophoresis
- IFA. *See* Immunofluorescence assay
- Ifex. *See* Ifosfamide
- Ifosfamide, 1650*t*
hemorrhagic cystitis caused by, 1661
mesna for, 1658*t*, 1661
- IgA
in celiac disease/dermatitis herpetiformis, 123, 622, 868
in common variable immunodeficiency, 868–869
in myeloma, 527
reference values for, 1731*t*
selective deficiency of, 868
anaphylactic transfusion reactions and, 535, 868
serum levels of, in IgA nephropathy, 923
in toxoplasmosis, 1501
- IgA nephropathy (Berger disease), 919*t*, 921*f*, 922–923
- IgA vasculitis, 919*t*
- IgE. *See also* Allergies/allergic reactions
in anaphylaxis/urticaria/angioedema, 132, 866
atopy/atopic disease and, 103, 866
tests for, 866
- IgE-mediated (immediate/type I) hypersensitivity, 865–866. *See also* Allergies/allergic reactions
- IGF-1. *See* Insulin-like growth factor-1
- IGF-2. *See* Insulin-like growth factor-2
- IGF2BP2 gene, in type 2 diabetes, 1194
- IgG
in antibody-mediated/cytotoxic hypersensitivity, 866
in autoimmune hemolytic anemia, 506
in bullous pemphigoid, 139
in common variable immunodeficiency, 868–869
deficiency of, with IgA deficiency, 868
in *H pylori* infection, 565
in hepatitis A, 666, 666*f*
in hepatitis B, 668*f*, 668*t*, 669
in immune complex hypersensitivity, 866
intravenous. *See* Intravenous immune globulin
in Lyme disease, 1480
in membranous nephropathy, 929
in mononucleosis, 1362
in multiple sclerosis, 1011
in myeloma, 527
in neuromyelitis optica, 1012
in pancreatitis, 715, 716
platelet-associated, 1733*t*
in postinfectious glomerulonephritis, 922
reference values for, 1731*t*
in rubella, 1374, 1375
in toxoplasmosis, 1501, 1502
- IgG index, 1731*t*
- IgG₄-associated cholangitis, 709–710
- IgG₄-associated pancreatitis, 715, 716
- IGIV. *See* Intravenous immune globulin
- IgM
in antibody-mediated/cytotoxic hypersensitivity, 866
in biliary cirrhosis, 693
in cold agglutinin disease, 507
in common variable immunodeficiency, 868–869
in focal segmental glomerulosclerosis, 930
in hepatitis A, 666, 666*f*
in hepatitis B, 668*f*, 668*t*, 669, 674
in immune complex hypersensitivity, 866
in Lyme disease, 1480
in mononucleosis, 1362
reference values for, 1731*t*
in rubella, 1374, 1375
in toxoplasmosis, 1501, 1502
in Waldenström macroglobulinemia, 529, 530

- IL. *See under Interleukin*
- IL2RA/IL7RA* genes, in multiple sclerosis, 1010
- IL12A/IL12RB2* genes, in biliary cirrhosis, 693
- IL28B* gene, in hepatitis C, 670–671, 677
- Ileitis/ileocolitis, in Crohn disease, 641
- Ileum. *See also* Small intestine resection of
 short bowel syndrome and, 625
 vitamin B₁₂ deficiency and, 497
- Ileus
 antipsychotics causing, 1059
 gallstone, 703
 in pancreatitis, 711, 713, 714, 716
 paralytic (acute/adynamic), 627–628
- Iliac arteries, atherosclerotic/occlusive disease of, 464–465
- Illicit drug use. *See* Substance use disorders
- Illness behaviors, abnormal, 1045–1047
- Illusions
 in focal seizures, 969
 intracranial tumors causing, 990
 psychedelic drug use and, 1084
 in schizophrenia/psychotic disorders, 1054
- Iloperidone, 1055, 1056t, 1057t, 1058
- Iloprost, for pulmonary hypertension, 305, 424, 425f
- Imagery (emotive imagery), in anxiety disorders, 1044
- Imaging, radiation exposure and, 1554, 1555
 cancer risk and, 1555, 1594
- Imatinib, 1654t
 for chronic myeloid leukemia, 516
 for gastrointestinal mesenchymal tumors, 1619–1620
- Imbalance. *See* Dysequilibrium; Falls; Vertigo; Vestibular disorders
- Imidazoles, topical, 97t. *See also specific agent*
- Imiglucerase, for Gaucher disease, 1668
- Imipenem
 for anaerobic abdominal infections, 1455, 1455t
 for anthrax, 1433t
 for pneumonia, 273t, 277t
- Imipramine, 1068, 1070t, 1723t. *See also* Antidepressants
 for cataplexy, 1077
 for enuresis, 1068, 1078
- Imiquimod
 for actinic keratoses, 117
 for genital warts, 140, 753
- Immediate (IgE-mediated/type I) hypersensitivity, 865–866. *See also* Allergies/allergic reactions
- Immersion (trench) foot/hand, 1545–1546
- Immobility
 DVT/PE (venous thromboembolic disease) and, 297, 301t
 in elderly, 65
 hypercalcemia and, 1142
 pressure ulcers and, 65, 70
 rhabdomyolysis and, 844
 urinary incontinence and, 68
- Immobilization
 for dislocated shoulder, 1682
 in musculoskeletal injury management, 1674
- Immune alveolar hemorrhage, 306
- Immune clearance hepatitis B, 674
- Immune complex-mediated hypersensitivity (type III), 866
 glomerulonephritis and, 907, 921f
 membranous nephropathy and, 929
 serum sickness and, 866, 867
- Immune globulin. *See specific type and* Intravenous immune globulin
- Immune insulin resistance, 1222
- Immune intervention therapy, for diabetes prevention/delay, 1201–1202
- Immune reconstitution inflammatory syndromes (IRIS), 187, 1333
 corticosteroids in management of, 1339
 in cryptococcosis, 1536
 Kaposi sarcoma flare and, 1331, 1332
 progressive multifocal leukoencephalopathy and, 1383
- Immune recovery uveitis, 187
- Immune thrombocytopenia, 540–542, 541f. *See also* Thrombocytopenia
- Immune tolerant hepatitis B, 674
- Immunity/immune response disorders. *See* Allergies/allergic reactions; Atopic disease; Autoimmune disorders; Immunodeficiency
- Immunizations (vaccines), 3–5, 1307–1318, 1308–1313t, 1316–1317t. *See also specific type* recommended types/schedules for
 for adults, 1307–1314, 1308–1313t
 in immunocompromised host/HIV infection/AIDS, 1309t, 1313t, 1314, 1335
 for infants/children/adolescents, 1307
 during pregnancy, 786–787, 1307–1314, 1309t
 for travelers, 4, 1314–1316
 safety (adverse effects/contraindications) and, 1316–1318, 1316–1317t
- Immunocompromised host. *See also* HIV infection/AIDS; Immunodeficiency
 adenovirus infection in, 1401
 aspergillosis in, 213, 1537
 bronchiectasis in, 266
 cancer-related infection and, 994, 1648
 CMV infection in, 1280–1281, 1364, 1365, 1366
 coccidial and microsporidial infection in, 1330, 1506–1508
 cognitive disorders/delirium and, 1087t
 diarrhea in, 575, 578
 erythrovirus (parvovirus) infection in, 1402, 1403
 fever/FUO and, 36, 510, 1276, 1277
 antimicrobial therapy and, 36, 510
- gram-negative bacteremia/sepsis in, 1443
- herpes zoster/herpes zoster vaccination in, 5, 120, 1309t, 1314, 1360
- herpetic stomatitis in, 227
- histoplasmosis in, 1337, 1531, 1532
- immunizations in, 4–5, 1309t, 1313t, 1314
 influenza virus vaccine, 3, 4, 1309t, 1314
 MMR vaccine, 4, 5, 1309t, 1314, 1369
 pneumococcal vaccine, 1309t, 1314
- infections in, 1278–1282. *See also* Opportunistic infections
 infectious esophagitis in, 598
 mucormycosis in, 217, 1538
 nocardiosis in, 1457
Pneumocystis infections in, 279, 1280, 1533–1535
- progressive multifocal leukoencephalopathy in, 1382, 1383
- pulmonary infiltrates/pneumonia in, 279, 1533–1535
- scabies in, 147, 147–148
- squamous cell carcinoma in, 143
- strongyloidiasis in, 1519
- toxoplasmosis in, 993, 1327, 1335, 1337, 1338t, 1501, 1502
- varicella/varicella vaccine and, 5, 120, 1309t, 1314, 1356, 1358, 1359, 1360
- Immunodeficiency. *See also* Immunocompromised host
 acquired, in HIV infection/AIDS. *See also* HIV infection/AIDS
 in chronic lymphocytic leukemia, 521
 common variable, 868–869
 in Epstein-Barr virus infection, 1363
 infections associated with, 1278–1282. *See also* Opportunistic infections
 primary, 868–869
 selective IgA, 868
 anaphylactic transfusion reactions and, 535, 868
- Immunofixation electrophoresis
 in amyloidosis, 531
 in myeloma, 528
- Immunofluorescence assay
 in Lyme disease, 1479
 in scrub typhus, 1411
- Immunofluorescent staining technique
 in non-sexually transmitted treponematoses, 1474
 in syphilis, 1466
- Immunoglobulins. *See also specific type under Ig and Antibodies*
 in colostrum/breast milk, 786
 reference values for, 1731t
- Immunologic disorders. *See* Allergies/allergic reactions; Atopic disease; Autoimmune disorders; Immunodeficiency
- Immunomodulating therapy. *See also* Immunotherapy
 adverse ophthalmic effects of, 196t
 for asthma, 249f, 252t, 253

- Immunomodulating therapy (*Cont.*):
 for inflammatory bowel disease, 639
 Crohn disease, 642, 644
 with anti-TNF agents, 645
 ulcerative colitis, 648
 for myeloma, 529
 for ophthalmic disorders, 170*t*
 thrombocytopenia caused by, 547*t*
- Immunopathologic (autoimmune)
 hypoglycemia, 1238, 1238*t*,
 1243
- Immunosuppressive therapy. *See also*
 Immunocompromised host;
 Immunomodulating therapy
 for aplastic anemia, 509
 for autoimmune hemolytic anemia,
 506
 fever/FUO and, 36, 1277
 hyperkalemia caused by, 879–880
 infections and, 994, 1279. *See also*
 Opportunistic infections
 Kaposi sarcoma complicating, 145
 for multiple sclerosis, 1011
 for myelodysplastic syndromes, 518
 neurologic disorders associated with,
 994
 for pericarditis, 420
 for polyarteritis nodosa, 848
 for pure red cell aplasia, 500
 skin cancer and, 143
 for SLE, 834
 thrombocytopenia caused by, 547*t*
 after transplant
 immunization recommendations
 and, 1314
 infections and, 1279, 1279–1280,
 1314
 kidney transplant and, 916
 squamous cell carcinoma and, 143
 stem cell transplantation and, 533
- Immunotherapy. *See also*
 Immunomodulating therapy
 for allergic rhinitis, 219
 for asthma, 249*f*, 252*t*, 253
 intravesical, for bladder cancer, 1639
 for venomous stings, 149
 in wart removal, 141
- Impedance plethysmography/testing
 in esophageal disorders, 593, 594,
 596–597
 in venous thrombosis/pulmonary
 embolism, 300
- Imperforate hymen, absent menses and,
 1179
- Impetiginization, in allergic contact
 dermatitis, 124
- Impetigo, 123, 123*f*, 1303*t*, 1420
 allergic contact dermatitis
 differentiated from, 123, 124
 antibiotics for, 97*t*, 123, 1303*t*
 glomerulonephritis after, 922
 in HIV infection/AIDS, 1331
- Impingement syndrome (subacromial),
 1674–1675, 1678–1679*t*
- Implanon, 773
- Implantable cardioverter defibrillator
 for cardiomyopathy, 405, 412, 415
 for heart failure, 405
 for long QT syndrome, 393
 postinfarction, 376
- preoperative evaluation/perioperative
 management and, 49
 for ventricular fibrillation/sudden
 death, 392
 for ventricular tachycardia, 391
- Impotence. *See* Erectile dysfunction/
 impotence
- Impulse conduction, disturbances of. *See*
 Conduction disturbances
- Impulse control disorders
 aggressive/violent behavior and, 1078
 in dementia, 1088
- In vitro fertilization, 768, 769, 956
- Inactivated enhanced-potency
 poliovaccine (IPV/Salk
 vaccine), 1373
 pregnancy and, 786
 for travelers, 1315
- Inactive HBsAg carrier state, 674
- Inactivity, physical
 lipid abnormalities and, 1248*t*
 preventable disease/deaths and, 3*t*, 7*t*,
 12–13
 prevention of, 12–13
- Incentive spirometry, prevention of
 postoperative pulmonary
 complications and, 51
- Incest, 1050
- Incidentalomas (incidentally discovered
 thyroid nodules), 1121, 1123,
 1124
- Inclusion body encephalitis, measles and,
 1368
- Inclusion body myositis, 841, 1036
- Inclusion conjunctivitis, 166
 in newborn, 806
- Inclusion cysts, epidermal (EIC), 152
 furuncles differentiated from, 151
- Inclusion disease, CMV, in newborn, 1364
- Incompetent cervix, 788
 cerclage/activity restriction for, 789
- Incomplete abortion, 788, 789
- Incontinence. *See* Fecal incontinence;
 Urinary incontinence
- Increased intracranial pressure. *See*
 Intracranial hypertension
- Incretins
 for diabetes mellitus, 1211–1213
 for obesity, 1261
- Indapamide, 445*t*
- Inderal. *See* Propranolol
- Indian tick typhus, 1409*t*
- Indigestion. *See* Dyspepsia
- Indinavir, 1341*t*, 1344, 1347, 1348*f*. *See also*
 Antiretroviral therapy/
 HAART
 with ritonavir, 1344
- Indirect straight leg raise test, 1684*t*
- Indocin. *See* Indomethacin
- Indolent lymphoma, 525
- Indometh. *See* Indomethacin
- Indomethacin, 77*t*
 adverse ophthalmic effects of, 197*t*
 for gout, 814
 lithium interactions and, 1074*t*
 in pain management, 77*t*
 for patent ductus arteriosus, 332
 for preterm labor prevention, 796
 “Induction-maintenance” strategy, for
 antiretroviral therapy, 1342
- Industrial bronchitis, 311
- Inevitable abortion, 788, 789
- Infant. *See* Newborn
- Infant botulism, 1431
- Infarcts. *See specific type*
- Infection/infectious diseases, 1276–1298.
*See also specific type or organ
 system affected*
 in acute leukemia, 519–520
 adrenal crisis caused by, 1154, 1155
 adrenal hemorrhage and, 1155
 arthritis and, 858–861
 bacterial, 1419–1461
 bite wounds and, 1288–1290
 of bone, 861–864. *See also*
 Osteomyelitis
 burn injury and, 1551
 in cancer patients, 1279, 1648. *See also*
 Opportunistic infections
 catheter-associated, 939, 1282, 1283,
 1284, 1284–1285
 chlamydial, 1301*t*, 1461–1462
 cognitive disorders/delirium caused by,
 1087*t*
 diarrhea in, 574*t*, 575
 in drug users, 1292–1293. *See also*
 Injection drug use, infections
 and
 dysphagia in, 592*t*
 esophagitis caused by, 598
 fever/FUO and, 36, 1276, 1277
 after frostbite, prevention of, 1546
 gastritis caused by, 610
 glomerulonephritis and, 919*t*, 921*f*,
 922, 1419
 headache and, 41
 health care-associated, 1282–1285
 helminthic, 1511–1528
 immunization against, 3–5, 1307–1318,
 1308–1313*t*, 1316–1317*t*. *See also*
 Immunizations
 in immunocompromised host, 1278–
 1282. *See also* HIV infection/
 AIDS; Opportunistic
 infections
 immunization recommendations
 and, 4–5, 1309*t*, 1313*t*, 1314
 insulin requirements and, 1218
 interstitial nephritis and, 907
 mycotic, 1529–1542
 of bones and joints, 862–863
 superficial, 110–114, 110*f*, 111*f*, 113*f*.
See also Tinea
 in HIV infection/AIDS, 1331
 in myeloma, 528
 myocarditis and, 409–410, 409*t*
 neuropathies associated with, 1023–1024
 neutropenia and, 120–121, 509–510,
 1279, 1281, 1281–1282, 1302*t*
 opportunistic. *See* Opportunistic
 infections
 during pregnancy, 803–806
 prevention of, 3–5. *See also*
 Immunizations
 in cancer patient/
 immunocompromised host,
 1280–1281, 1334–1335,
 1334*t*, 1336–1337, 1337*t*,
 1648. *See also* HIV infection/
 AIDS

- protozoal, **1484–1511**
 reactive arthritis and, 857
 rickettsial, 1301*t*, **1408–1416**
 seizures and, 969
 sexually transmitted, **1290–1292**
 shock associated with. *See* Sepsis/septic shock
- spirochetal, 1300*t*, **1464–1483**
 surgical site, 55
 antibiotic prophylaxis for, **55–56**
 in diabetic patients, 54
 thrombocytopenia and, **547**
 transfusion in transmission of, 535–536
- travel and, **1296–1297**
 tubulointerstitial nephritis and, 932*t*
 vaccine-preventable, 3, **1367–1375**
 viral, **1350–1408**
- Infection control
 handwashing and, 1280, 1284
 health care-associated infection prevention and, 1284
- Infection (struvite) urinary stones, 946, 947, 949
- Infectious diseases. *See* Infection
- Infectious mononucleosis. *See* Mononucleosis
- Infective endocarditis. *See* Endocarditis, infective
- Inferior vena cava filters/interruption, for pulmonary embolism, 303, 563
- Infertility, 768, 954, 954*f*
 chronic kidney disease and, 914
 female, **768–770**, 954
 endometriosis and, 760
 in polycystic ovary syndrome, 765, 766, 768
 hyperprolactinemia and, 768, 769, 955, 1102, 1103, 1104
 in hypopituitarism, 1094, 1097. *See also* Hypogonadism
 male, 768, 769, **953–956**, 954*f*, 1097
 cryptorchism and, 1177
 in cystic fibrosis, 267, 955
 hormone treatment in, 955, 1097
 hypogonadism and, 954, 955, 1094, 1175
 in Klinefelter syndrome, 955, 1174, 1669, 1670
 marijuana use and, 1085
 radiation exposure causing, 1554
- Inflammasomes, NALP-3, in gout, 812
- Inflammation. *See also specific type and structure/systems affected*
 anemia of, 493
 coronary heart disease and, 350–351
 in HIV infection/AIDS, 1333
- Inflammatory adenoma of liver, 702
- Inflammatory aneurysm, 472, 473
- Inflammatory bowel disease, **638–650**.
See also Crohn disease;
 Ulcerative colitis
 acne treatment and, 127–128
 arthritis and, 641, **858**
 colorectal cancer and, 643, 1623
 diarrhea in, 574*t*, 578, 579*f*, 641, 643, 646
 drug therapy for, 638–641
 GI bleeding and, 584
 hyperoxaluric calcium nephrolithiasis and, 949
 primary sclerosing cholangitis and, 709, 710
 social support for patient with, 641
- Inflammatory breast carcinoma, 721, 730.
See also Breast cancer
- Inflammatory eye disease, 165*t*, 177–178.
See also Conjunctivitis; Uveitis
- Inflammatory myopathy, 1036
 idiopathic, **840–842**, 840*f*
- Inflammatory pericarditis, acute, **419–420**. *See also specific cause and* Pericarditis
- Inflammatory polyneuropathy, chronic, **1025–1026**
- Inflammatory skin nodules, **150–152**. *See also specific type*
- Infliximab. *See also* Anti-TNF agents
 for inflammatory bowel disease, 640
 Crohn disease, 644–645
 ulcerative colitis, 648, 649
 progressive multifocal leukoencephalopathy caused by, 1383
 for psoriasis, 108
 for rheumatoid arthritis, 830
- Influenza
 cough in, 22, 23, 1395
 drug resistance and, 1396, 1399
 H1N1/2009 pandemic
 H1N1/“A(H1N1)pdm09”/swine-origin), 23, 214, 1395, 1396, **1399–1400**
 drug resistance and, 1396, 1399
 prevention of, 1400. *See also* H1N1 influenza vaccine
 H5N1 (avian), 1395, 1396, **1397–1398**
 neuraminidase inhibitors (oseltamivir/zanamivir) for, 23, 1354*t*, 1395, 1396, 1398, 1399
 prophylactic, 1397
 resistance to, 1396, 1399
 pneumonia and, 271, 1395, 1396
 prevention of, 3, 1396–1397. *See also* Influenza virus vaccine
 seasonal, **1394–1397**
- Influenza A/California/04/2009. *See* “A(H1N1)pdm09” (swine-origin) influenza
- Influenza virus vaccine, 3, 1308*t*, 1309*t*, 1310*t*, 1396–1397
 adverse effects/contraindications and, 1316*t*
 in asthma patients, 253
 avian (H5N1) influenza and, 1398
 in COPD, 261
 for cystic fibrosis patients, 268
 H1N1 influenza and, 1396, 1400
 in asthma patients, 253, 1400
 high-dose, 3, 1396
 HIV screening tests affected by, 1323
 in immunocompromised host/HIV infection/AIDS, 3, 4, 5, 1309*t*, 1314, 1335
 pneumonia prevention and, 274
 pregnancy and, 3, 787, 1307, 1309*t*, 1396, 1400
 seasonal influenza, 3, 1396–1397
- Infraspinatus tendon, evaluation of, 1680
- Infratentorial arteriovenous malformations, 987
- Infundibular stenosis, 325–326
 in tetralogy of Fallot, 331, 332
- Infusion pumps
 for enteral nutritional support, 1273
 insulin. *See* Insulin infusion pumps
- Ingrown hairs, pseudofolliculitis caused by, 129
- Ingrown nails, 157–158
- INH. *See* Isoniazid
- Inhalation injury/smoke inhalation, **307**, 1550
 burn survival and, 1550
 corrosive acids and, 1571
 cyanide poisoning and, 1577
- Inhalational anthrax, 1431, 1432, 1433
- Inhaled insulin, 1217
- Inhalers
 for asthma therapy, 250, 254*t*, 255, 256, 257*f*
 for COPD therapy, 262, 264
- Inhibin A, prenatal screening for, 783
- Inhibitor tolerance induction, in hemophilia management, 551
- Injection drug use. *See also* Substance use disorders
 febrile patient and, 1292–1293
 infections and, 1292–1293
 clostridial infection/wound botulism and, 1428, 1431, 1586
 endocarditis, 1292, 1302*t*, 1435
 hepatitis, 667, 670, 672, 1292
 HIV infection/AIDS, 1292, 1321
 prevention/postexposure prophylaxis and, 1333, 1335, 1336
 osteomyelitis, 861–862, 1292
 skin infections, 1292
- Injury. *See* Trauma
- INK4A gene, pancreatic/periampullary carcinoma and, 1607
- Inkspot lentiginos, 101
- Inner ear, **206–212**
- Inner ear antigens, autoimmune audiovestibular dysfunction and, 208
- Innocent murmurs. *See* Heart murmurs
- Inocybe (muscarine) mushroom poisoning, 1586*t*
- Inotropic agents. *See also* Digitalis/digitalis glycosides
 for heart failure, 405
 left ventricular (infarct-related), 373–374
 for shock, 487
- Insect bites/stings. *See also specific type of insect*
 anaphylaxis caused by, 866
 scorpion stings, **1590**
 spider bites, 149, **1590**
 urticaria caused by, 133
- Insecticide poisoning (cholinesterase inhibitors), 1566*t*, **1587**
- Insemination, artificial, 769
- Insomnia, **1075–1077**
 in dementia, 1009
 drug therapy for, 1042*t*, 1043, 1076–1077

- Insomnia (*Cont.*):
 fatal familial, 1381, 1382
 in older patients, 1075, 1076
 psychological strategies for, 1076
 Inspira. *See* Eplerenone
- Instability. *See also* Falls; Gait/gait disorders; Genetic instability
 knee, 1693, 1694–1696*t*, 1698, 1701
 shoulder, 1679–1680*t*, **1681–1682**
- Instrumental activities of daily living (IADL), assessment of ability to perform, 58, 59, 1006
- Insulin. *See also* Insulin therapy
 adipokines affecting action of in obesity, 1194
 antibodies to
 in autoimmune/immunopathologic hypoglycemia, 1238, 1238*t*, 1243
 in factitious hypoglycemia, 1243
 in immune insulin resistance, 1222
 insulin therapy causing, 1222–1223
 in type 1 diabetes, 1193, 1193*t*
 B cell tumors/insulinomas secreting, 1172, 1189, 1238–1241, 1239*t*, 1240*t*
 B cells secreting, 1171
 blood levels of
 chronic kidney disease and, 914
 in insulinoma diagnosis, 1239, 1239*t*
 prebreakfast hyperglycemia and, 1219, 1219–1220, 1219*t*
 drugs affecting secretion of, 1205–1208, 1206*t*
 factitious hypoglycemia caused by administration of, 1239, 1243
 immunoreactive, reference values for, 1731*t*
 insensitivity to. *See* Insulin resistance/insulin insensitivity
 mutant, in diabetes mellitus, 1195
 oral, diabetes prevention/delay and, 1201
 receptors for. *See* Insulin receptors
 resistance to. *See* Insulin resistance/insulin insensitivity
- Insulin aspart, 1213, 1213*t*, 1214, 1214*f*, 1214*t*, 1215. *See also* Insulin therapy
 in mixtures/combination therapy, 1214*t*, 1216
 in pregnancy, 1230
- Insulin detemir, 1213, 1213*t*, 1214, 1214*f*, 1214*t*, 1216, 1219, 1219*t*, 1221. *See also* Insulin therapy
- Insulin gene, in diabetes mellitus, 1193
- Insulin glargine, 1213, 1213*t*, 1214, 1214*f*, 1214*t*, 1215–1216, 1219, 1219*t*, 1221. *See also* Insulin therapy
 in pregnancy, 1230
- Insulin glulisine, 1213, 1213*t*, 1214*t*, 1215. *See also* Insulin therapy
- Insulin hypoglycemia test, in GH deficiency, 1095
- Insulin infusion pumps, 1216–1217, 1219
 clinical studies of complications and, 1201
 continuous glucose monitoring and, 1200, 1217
 ketoacidosis and, 1217, 1232
 during pregnancy, 801, 1230
 rapidly acting analogs used in, 1215, 1219
 surgery and, 1229, 1229*t*
- Insulin-like growth factor-1 (IGF-1)
 deficiency of, 1094
 in GH deficiency/rhGH therapy, 1095, 1097
 in GH excess, 1100
 reference values for, 1731*t*
- Insulin-like growth factor-2 (IGF-2), nonislet cell tumor hypoglycemia and, 1241
- Insulin lispro, 1213, 1213*t*, 1214*t*, 1215, 1218. *See also* Insulin therapy
 in mixtures/combination therapy, 1214*t*, 1216
 in pregnancy, 1230
- Insulin pens, 1216
- Insulin receptors
 antibodies to, hypoglycemia caused by, **1243**
 mutant, diabetes caused by, 1195, 1195*f*
- Insulin resistance/insulin insensitivity. *See also* Insulin resistance syndrome
 acanthosis nigricans and, 1195, 1195*f*, 1196, 1197
 acne and, 126
 cholelithiasis/gallstones and, 703
 in Cushing syndrome, 1159
 in diabetes, 1193*t*, 1194, 1196, 1196*t*
 diabetic ketoacidosis and, 1231, 1235
 hepatitis C and, 671
 hyperglycemia and, 1194, 1196, 1196*t*
 immune, 1222
 in polycystic ovary syndrome, 765, 1162
 during pregnancy, 800
- Insulin resistance syndrome (metabolic syndrome/syndrome X), 13–14, 350, 1196
 acne and, 126
 cholelithiasis/gallstones and, 703
 coronary heart disease/angina and, 350, 351, 360
 diabetes and, 1196
 dyslipidemia in, 1196, 1200–1201
 fatty liver and, 684
 hepatocellular carcinoma and, 1604
 hypertension and, 436, 1196
 hypophosphatemia and, 885
 obesity and, 13, 350, 1259
 psoriasis and, 108
- Insulin syringes and needles, 1216
- Insulin therapy, 1213–1217, 1213*t*, 1214*f*, 1214*t*, 1218–1220, 1219*t*
 administration methods/regimens for, 1216–1217
 allergy to, 1222
 antidepressant drug interactions and, 1071*t*
 anti-insulin antibodies and, 1222–1223
 for β -blocker overdose/toxicity, 1575
 bioavailability of preparations and, 1213*t*
 for calcium channel blocker overdose/toxicity, 1563, 1576
 complications of, 1221–1223
 concentrations of insulin and, 1213–1214
 continuous subcutaneous infusion (CSII), 1217, 1219. *See also* Insulin infusion pumps
 for diabetic ketoacidosis, 1215, 1233–1234
 transition to subcutaneous regimen and, 1235
 exercise affecting, 12, 1218
 factitious hypoglycemia and, 1239, 1243
 for hospitalized patient, 1228–1230, 1229*t*
 for hyperglycemic hyperosmolar state, 1236
 for hyperkalemia, 880, 881*t*
 hypoglycemia and, 1201, 1221–1222, 1230, 1580
 immunopathology of, 1222–1223
 inhalation for administration of, 1217
 injection sites for, 1216, 1223
 intensive, 1218–1220, 1219*t*
 acceptable levels of glycemic control and, 1221
 clinical studies of, 1201–1202, 1202–1204
 diabetic nephropathy development/progression and, 1201, 1224
 diabetic retinopathy development/progression and, 1201, 1203
 hypoglycemia and, 1201, 1221–1222, 1230, 1580
 during pregnancy, 801, 1230
 self-monitoring of blood glucose and, 1200
 in pregnant patient, 801
 surgery and, 1229, 1229*t*
 in type 2 diabetics, 1202, 1221
 intraoperative requirements/administration of, 54, 1215, 1229, 1229*t*
 lipodystrophy/lipoatrophy/lipohypertrophy and, 1222–1223
 MAOI interactions and, 1071*t*
 mixtures/combination therapy and, 1214*t*, 1216
 with oral antidiabetic agents, for type 2 diabetes, 1221
 pancreatic/periampullary carcinoma and, 1607
 patient education/self-management and, 1218
 during pregnancy, 801, 1230
 preparation types available, 1214–1216
 in prevention/delay of diabetes, 1201
 purified insulin and, 1213
 self-monitoring of blood glucose and, 1200
 in pregnant patient, 801
 species of insulin and, 1213
 surgery and, 54, 1215, 1229, 1229*t*
 thiazolidinediones with, 1209
 for type 1 diabetics, 1213–1217, 1213*t*, 1214*f*, 1214*t*, 1218–1220, 1219*t*
 for type 2 diabetics, 1202, 1221
- Insulinomas, 1172, 1189, 1238–1241, 1239*t*, 1240*t*, 1612*t*. *See also* Islet cell tumors
 localization of, 1172, 1240–1241
 in MEN, 1172, 1189, 1239, 1241

- INTACS (intraströmial corneal ring segments), 163
- Intal. *See* Cromolyn
- Integrase inhibitors, for HIV infection/AIDS, 1342*t*, 1348*f*
resistance to, 1349
- Integritin. *See* Eptifibatide
- Intelligence. *See* Etravirine
- Intensive care unit, patient in. *See* Critical illness
- Intensive care unit psychosis, 1090
- Intercostal neuritis, 355
- Intercourse, sexual. *See* Sexual intercourse
- Interdigital (toe web) tinea pedis, 112, 113*f*
cellulitis and, 112, 137
- Interferon- α /interferon alfa, 1353*t*. *See* also Peginterferon
for cancer chemotherapy, 1657*t*
for essential thrombosis, 514
for Kaposi sarcoma, 1332, 1339*t*, 1622
for renal cell carcinoma, 1641
thyroid dysfunction caused by, 1106, 1110, 1111
toxicity of, 1353*t*
ophthalmic effects and, 196*t*
- Interferon- β
for multiple sclerosis, 1011
thyroid dysfunction caused by, 1106, 1111
- Interferon- γ
assays for
spinal, 863
in tuberculosis, 282, 282–283, 286, 315, 1334
in fever, 35
- Interleukin-1 (IL-1), in fever, 35
- Interleukin-2 (IL-2)
in cancer chemotherapy, 1657*t*
for renal cell carcinoma, 1641
thyroid dysfunction caused by, 1106, 1111
- Interleukin-2 receptor α gene, in multiple sclerosis, 1010
- Interleukin-6 (IL-6)
in Addison disease, 1156
in amiodarone-induced hyperthyroidism, 1114
in fever, 35
- Interleukin-7 receptor α gene, in multiple sclerosis, 1010
- Interleukin-8 (IL-8), in familial Mediterranean fever, 591
- Interleukin-11 (neumega/IL-11), recombinant (oprelvekin), for chemotherapy-induced thrombocytopenia, 1649, 1659*t*
- Interleukin-12/23 (IL-12/23) monoclonal antibodies, for psoriasis, 108
- Intermediate-acting insulin, 1214*f*, 1214*t*. *See also* Insulin therapy; NPH insulin
mixed insulin preparations and, 1214*t*, 1216
- Intermediate uveitis (pars planitis), 178. *See also* Uveitis
- Intermittent claudication. *See* Claudication
- Intermittent mandatory ventilation, synchronized (SIMV), for respiratory failure, 321
- Intermittent positive-pressure breathing (IPPB), prevention of postoperative pulmonary complications and, 51
- Internal hordeolum, 163
- Internal rotation, assessment of
in hip, 1690
in shoulder, 1677*t*
rotator cuff strength and, 1678*f*
- Interosseous nerve, anterior, lesion of, 1026
- Interpersonal relationships
in schizophrenia/psychotic disorders, 1054
social issues for terminally ill/dying patient and, 91–92, 92*t*
- Interstitial cystitis, 45, 945–946
- Interstitial lung disease, 292–297, 292*t*, 294*t*. *See also* specific disorder
acute pneumonia (AIP), 294*t*
cryptogenic organizing pneumonia/pneumonitis (COP)/bronchiolitis obliterans organizing pneumonia (BOOP), 269, 294*t*, 295
desquamative pneumonia (DIP), 269, 294*t*
drug-related, 292*t*, 312*t*
eosinophilic, 296–297
idiopathic pneumonias, 293–295, 294*t*
methotrexate causing, 829
nonspecific pneumonia (NSIP), 294*t*, 295
in HIV infection/AIDS, 1326–1327
pulmonary alveolar proteinosis, 296
respiratory bronchiolitis-associated (RB-ILD), 269, 294*t*, 295
respiratory failure caused by, 320*t*
in rheumatoid arthritis, 827
sarcoidosis, 295–296
usual pneumonia (UIP), 293, 294*t*, 295
- Interstitial nephritis, 902*t*
in SLE, 833
urinalysis in, 898, 902*t*, 907
- Intertriginous area
miliaria affecting, 130–131
seborrhea of, 109
- Intertrigo, 117
tinea differentiated from, 112
- Interventricular septum
hypertrophy of, in cardiomyopathy, 414, 416
rupture of, in myocardial infarction, 374
- Intervertebral disk disorders. *See* Cervical spine/disk disease; Lumbar spine/disk disease; Sacral spine/disk disease; Thoracic spine/disk disease
- Interview (medical), 1
- Intestinal adenocarcinoma, 1620
- Intestinal amebiasis, 574*t*, 575, 576, 578, 1293, 1298, 1303*t*, 1330, 1503, 1503–1504, 1504, 1504*f*, 1505*t*
- Intestinal angina (visceral artery insufficiency), 470–471
- Intestinal bacterial overgrowth. *See* Bacterial overgrowth
- Intestinal carcinoids, 1620–1621
- Intestinal disorders. *See* Gastrointestinal system, disorders of
- Intestinal flagellate infections, 1510. *See also* specific type
- Intestinal flukes, 1513–1514
- Intestinal ischemia, 470–471
GI bleeding and, 584
- Intestinal lymphoma, 1620
- Intestinal motility disorders. *See* Motility disorders
- Intestinal nematode (roundworm) infections, 578, 1517–1520
- Intestinal obstruction. *See also* Motility disorders
in acute colonic pseudo-obstruction (Ogilvie syndrome), 628–629
chemotherapy-induced neuropathy causing, 1661
in chronic intestinal pseudo-obstruction, 629–630
in Crohn disease, 641, 642
gallstones causing, 703
in gastroparesis, 629–630
tumors causing
colorectal cancer, 1623
gastric carcinoma, 1616, 1617
small intestinal carcinoids, 1621
vomiting and, 567*t*, 568
- Intestinal sarcoma, 1622
- Intestinal transplantation, for short bowel syndrome, 626
- Intestinal tuberculosis, 631
- Intestinal-type gastric cancer, 1615–1616
- Intimate partner (domestic) violence, 17, 1078, 1079, 1711–1712
prevention of, 17, 1712
- Intoxication. *See also* specific substance causing
acute alcohol, 1080, 1579–1580
metabolic acidosis/osmolar gap and, 877, 1081, 1569, 1569*t*
cognitive disorders/delirium caused by, 1087*t*
pathologic, 1078
- Intra-arterial embolization. *See* Embolization
- Intracerebral hemorrhage, 980*t*, 983–984. *See also* Stroke
arteriovenous malformations causing, 987
in coarctation of aorta, 326, 327
head injury causing, 1017*t*
headache in, 41, 42, 962, 966, 983
hypertension and, 434, 461*t*
thrombolytic therapy for myocardial infarction and, 368
thrombolytic therapy for pulmonary embolism and, 303
- Intracoronary stents, 357–358, 367–368. *See also* Percutaneous coronary intervention
subsequent perioperative risks/management and, 48–49
- Intracranial abscess. *See* Brain abscess
- Intracranial aneurysm, 980*t*, 986. *See also* Stroke
arteriovenous malformations and, 985, 987
in polycystic kidney disease, 935, 986
subarachnoid hemorrhage and, 984, 985, 986

- Intracranial bleeding. *See* Intracerebral hemorrhage; Subarachnoid hemorrhage
- Intracranial hypertension
in arteriovenous malformations, 987, 988
benign (pseudotumor cerebri), 995–996
headache and, 966, 995
brain abscess/infection causing, 994
cerebral injury and, 1016
ECT contraindicated in, 1071
headache and, 41, 42
idiopathic, 995
in liver failure, 673
in meningitis, 1288
optic disk swelling and (papilledema), 189, 189f, 995
headache and, 42
in stroke, 982, 984, 985
in subarachnoid hemorrhage, 985
tumors causing, 989, 991. *See also* Intracranial masses/tumors
vomiting caused by, 567t
- Intracranial masses/tumors, 989–993, 990t, 1611t
abscess causing, 993–994, 1287, 1288. *See also* Brain abscess
coma or stupor caused by, 1014, 1014–1015
false localizing signs and, 991
headache caused by, 41, 962, 966
cough headache and, 966
in HIV infection/AIDS, 992–993, 1327
metastatic, 992
nonmetastatic neurologic complications and, 994–995, 1024
ocular motor palsies and, 190
primary, 989–992, 990t
seizures caused by, 969, 989
vocal fold paralysis caused by, 238
- Intracranial venous thrombosis, 988. *See also* Stroke
- Intracytoplasmic sperm injection (ICSI), 768, 769, 956
- Intraepidermal squamous cell carcinoma (Bowen disease), 117
- Intrahepatic cholestasis, 662, 663t
of pregnancy, 663t, 807
- Intrahepatic portosystemic shunts. *See* Transvenous (transjugular) intrahepatic portosystemic shunts
- IntraLASIK (femtosecond laser assisted LASIK), 162
- Intralesional triamcinolone, for acne, 128
- Intralipid. *See* Intravenous fat
- Intraocular foreign body, 192
- Intraocular hypertension. *See* Ocular hypertension
- Intraocular inflammation, 165t, 177–178. *See also* Uveitis
- Intraocular lenses
after cataract removal, 179
for refractive errors, 163
- Intraocular pressure
elevated. *See* Elevated intraocular pressure
normal, 176
- Intraperitoneal chemotherapy
for malignant ascites/peritoneal carcinomatosis, 590
for mesothelioma, 591
- Intrastromal corneal ring segments (INTACS), 163
- Intrathecal pumps, for pain medications, 75
- Intrauterine devices (IUDs), 773–774, 774t
dysmenorrhea and, 750, 774
for emergency/postcoital contraception, 774, 776
levonorgestrel-releasing, 773–774
for abnormal premenopausal bleeding, 748, 774
for dysmenorrhea, 750, 774
for endometriosis, 761
for postmenopausal bleeding, 749
pelvic infection/PID and, 763, 774
progesterin-releasing, 1185
- Intrauterine insemination, 956
- Intravascular abscesses (septic superficial thrombophlebitis), 480. *See also* Septic thrombophlebitis
- Intravascular heat exchange systems, for heat stroke, 1548
- Intravascular ultrasound, in angina, 354–355
- Intravenous catheters. *See* Catheters/intravenous lines
- Intravenous drug use. *See* Injection drug use
- Intravenous fat
for calcium channel blocker overdose, 1576
for hypotension in poisoning/overdose, 1563–1564
in nutritional support, 1272, 1274
- Intravenous fluids. *See* Fluid management/hydration
- Intravenous gamma globulin. *See* Intravenous immune globulin
- Intravenous immune globulin
for autoimmune hemolytic anemia, 506–507
for cold agglutinin disease, 507
for common variable immunodeficiency, 869
for Guillain-Barré syndrome, 1025
for immune thrombocytopenia, 541, 541f, 542
for multiple sclerosis, 1011
for pemphigus, 139
for posttransfusion purpura, 546
for pure red cell aplasia, 500
for toxic epidermal necrolysis, 135
- Intravenous lines. *See* Catheters/intravenous lines
- Intraventricular conduction defects, 395–396
- Intraventricular cysts, in cysticercosis (neurocysticercosis), 1515
- Intravesical chemotherapy, for bladder cancer, 1639
- Intrinsic acute kidney injury, 902t, 903. *See also specific cause*
- Intrinsic factor, in pernicious anemia/gastritis, 497, 610
- Intron A. *See* Interferon- α /interferon alfa
- Intubation. *See also* Airway management; Mechanical ventilation
in ARDS, 323
in asthma, 259
for burn injuries, 1550
in comatose patient, 1563
conversion to tracheotomy and, 238
in epiglottitis, 235
for near drowning, 1556
pneumonia (ventilator-associated) and, 275–278, 277t
for respiratory failure, 320, 321
for smoke inhalation, 307
- Intussusception, adenoviruses causing, 1402
- Invalidism. *See* Sick role
- Invasive fibrous/invasive (Riedel) thyroiditis, 1120, 1121, 1122
- Invasive fungal sinusitis, 217–218
- Invasive mole, 791. *See also* Gestational trophoblastic disease
- Invasive nematode (roundworm) infections, 1520–1524
- Invega. *See* Paliperidone
- Inverse pityriasis rosea, 108
- Inverse psoriasis, tinea differentiated from, 112
- Inversion ankle sprains, 1703–1704, 1703t, 1704t
- Inverted papilloma, 222
- Invirase. *See* Saquinavir
- Iodinated contrast agents, for hyperthyroidism/Graves disease, 1115
subacute (de Quervain) thyroiditis and, 1117, 1122
- Iodine
in amiodarone-induced thyroid disease
hyperthyroidism, 1112
hypothyroidism, 1106
deficiency of, 1134–1135
goiter and, 1112, 1123, 1126, 1134–1135
thyroid nodules caused by, 1112, 1123, 1125
dietary/supplementary
in goiter prevention/treatment, 1135
Graves disease triggered by, 1110
restriction for thyroid nodules/cancer/goiter, 1125, 1126
Jod-Basedow disease/phenomenon and, 1110, 1111
radioactive. *See* Radioactive iodine; Radioiodine thyroid scans and uptake
- Iodine-131 tositumomab, 1654t
for non-Hodgkin lymphoma, 525
- Iodized salt, goiter prevention/treatment and, 1135
- ¹²³meta-Iodobenzylguanidine (¹²³I-MIBG) scanning, in pheochromocytoma/paraganglioma, 1169, 1170, 1171
- ¹³¹meta-Iodobenzylguanidine (¹³¹I-MIBG) therapy, in pheochromocytoma/paraganglioma, 1171
- Iodochlorhydroxyquin, adverse ophthalmic effects of, 197t

- Iodoquinol, for amebiasis, 1504, 1505t
- Ionizing radiation, 1554. *See also under Radiation*
- from medical imaging, 1554, 1555
 - cancer risk and, 1555, 1594
- Iontophoresis sweat test, in cystic fibrosis, 267–268
- Iopanoic acid, for hyperthyroidism/Graves disease, 1115
- subacute (de Quervain) thyroiditis and, 1117, 1122
- Iopidine. *See* Apraclonidine
- Ipecac, for poisoning/drug overdose, 1566
- Ipilimumab, 1654t
- iPledge, 127
- Iodate sodium, for hyperthyroidism/Graves disease, 1115
- subacute (de Quervain) thyroiditis and, 1117, 1122
 - thyroid crisis/storm and, 1118
- IPPB. *See* Intermittent positive-pressure breathing
- Ipratropium
- for allergic rhinitis, 219
 - for asthma, 254t, 255
 - with albuterol, 254t
 - for COPD, 262, 264
- IPV. *See* Intimate partner (domestic) violence
- IPV (inactivated poliovaccine/Salk vaccine), 1373
- pregnancy and, 786
 - for travelers, 1315
- Iquix. *See* Levofloxacin
- Irbesartan/irbesartan with hydrochlorothiazide, 451t
- Iressa. *See* Gefitinib
- IRF5-TNPO3 gene, in biliary cirrhosis, 693
- Iridodialysis, 192
- Iridoplasty/iridotomy/iridectomy, for angle-closure glaucoma, 175, 177
- Irinotecan, 1653t
- for colorectal cancer, 1625
- IRIS (immune reconstitution inflammatory syndromes), 187, 1333
- corticosteroids in management of, 1339
 - in cryptococcosis, 1536
 - Kaposi sarcoma flare and, 1331, 1332
 - progressive multifocal leukoencephalopathy and, 1383
- Iris nodules, in uveitis, 178
- Iritis, 165t
- Iron
- accumulation of
 - in hemochromatosis, 695
 - in sideroblastic anemia, 497
 - deficiency of/iron deficiency anemia, 490, **490–493**, 491t
 - anemia of inflammation and, 493
 - celiac disease and, 622
 - in chronic kidney disease, 913
 - in colorectal cancer, 1623
 - esophageal webs and (Plummer-Vinson syndrome), 491, 600
 - GI bleeding and, 491, 586–587
 - in idiopathic pulmonary hemosiderosis, 307
 - in paroxysmal nocturnal hemoglobinuria, 491, 502
 - in polycythemia, 512
 - during pregnancy, 491, 798
 - thrombocytopenia and, 540
 - dietary, 490
 - nutritional support requirements and, 1272
 - overdose/toxicity of, 1566t, 1569t, **1580–1581**. *See also* Hemosiderosis
 - serum levels of
 - in anemia of chronic disease, 492, 493
 - in iron deficiency anemia, 492
 - in overdose, 1581
 - reference values for, 1731t
 - in sideroblastic anemia, 497
 - supplementary
 - in chronic kidney disease, 913
 - for iron deficiency anemia, 492
 - for paroxysmal nocturnal hemoglobinuria, 502
 - in pregnancy, 491, 783, 785, 798
 - total body, 492
- Iron-binding capacity, total (TIBC), 492, 1731t
- in anemia of chronic disease, 492
- Iron deficiency anemia. *See* Iron, deficiency of
- Iron overload. *See* Hemochromatosis; Hemosiderosis
- Irritable bowel syndrome, 578, **632–636**
- alarm symptoms in, 633
 - diarrhea in, 578, 579f, 633, 634, 635
 - pelvic pain and, 1715
 - psychological therapies for, 636
- Irritant contact dermatitis, 124, 125
- Irritative voiding symptoms
- in benign prostatic hyperplasia, 956, 957t
 - in bladder cancer, 1639
 - in cystitis, 43, 939
 - in epididymitis, 944
 - in interstitial cystitis, 945
 - in prostatitis, 942, 943
 - in pyelonephritis, 941
 - in urinary stone disease, 947
- IS. *See* Incentive spirometry
- Ischemia
- acute kidney injury/tubular necrosis caused by, 902, 904
 - brainstem, seizures differentiated from, 971
 - digital
 - in Raynaud phenomenon, 836
 - in scleroderma, 838
 - intestinal, 470–471
 - GI bleeding and, 584
 - mesenteric, **470–471**
 - myocardial. *See* Angina, pectoris; Coronary heart disease; Myocardial ischemia
 - peripheral artery aneurysms causing, 476
 - visceral, 470–471
- Ischemia testing, noninvasive, preoperative, 46–47, 47t, 48f
- Ischemic cardiomyopathy, 398
- Ischemic chest pain, 28, 28t, 29. *See also* Angina
- Ischemic colitis, 470–471, 471, 584
- Ischemic heart disease. *See* Angina, pectoris; Coronary heart disease; Myocardial ischemia
- Ischemic hepatitis/hepatopathy, 699
- Ischemic optic neuropathy, **187–188**
- in giant cell arteritis, 188, 845–846
- Ischemic rest pain. *See* Rest pain
- Isentress. *See* Raltegravir
- Islet cell antibodies, in diabetes mellitus, 1193
- Islet cell tumors, **1171–1173**
- hypoglycemia caused by, 1172, 1189, **1238–1241**, 1239t, 1240t
 - in MEN, 1171, 1172, 1189, 1239, 1241
- Islet cells, pancreatic. *See also* B cells
- hyperplasia of (noninsulinoma pancreatogenous hypoglycemia syndrome), 1238, 1241, **1242**
 - transplantation of, for diabetes, 1217
- Ismelin. *See* Guanethidine
- Isoagglutinins
- compatibility testing and, 534
 - hemolytic transfusion reactions and, 534
- Isocarboxazid, overdose/toxicity of, 1585
- Isolated hypogonadotropic hypogonadism, 1093, 1173. *See also* Hypogonadism
- congenital, 1093
- Isomalt, 1205
- Isoniazid, 284t, 289t
- benzodiazepine interactions and, 1043t
 - overdose/toxicity of, 284t, 1566t, **1581**
 - ophthalmic effects and, 197t
 - pyridoxine (vitamin B₆) for, 285, 285–286, 286, 805, 1566t, 1581
 - seizures and, 1565t, 1581
 - for tuberculosis, 284–285, 284t, 289t
 - in latent disease/prophylactic, 286, 287, 1334, 1337
 - in pregnancy, 285–286, 287, 805
 - resistance and, 280, 281t, 285
- Isoniazid/rifampin, for tuberculosis, 285
- Isoniazid/rifampin/pyrazinamide, for tuberculosis, 285
- Isophane (NPH) insulin. *See* Insulin therapy; NPH insulin
- Isopropanol, overdose/toxicity of, osmolar gap in, 891, 1569, 1569t
- Isoptin. *See* Verapamil
- Isosorbide. *See also* Nitrates
- for angina, 355
 - for heart failure, 404
 - left ventricular (infarct-related), 373
 - for pulmonary edema, 408
- Isospora belli* (isosporiasis), 1293, 1330, **1506–1508**
- Isosthenuria
- in chronic kidney disease, 910
 - in sickle cell disease, 936
- Isotonic hyponatremia, 871–872, 871f

- Isotretinoin
for acne, 127–128
adverse ophthalmic effects of, 197t
breastfeeding and, 782t
for lupus, 115
for rosacea, 129
teratogenicity of, 115, 127
- Isradipine, 454t
for angina, 356
for hypertension, 453, 454t
overdose/toxicity of, 454t, 1576
- Istodax. *See* Romidepsin
- Itch-scratch cycle. *See also* Pruritus
in lichen simplex chronicus, 105
- Itch-X-Gel. *See* Pramoxine
- Itching. *See* Pruritus
- Itchy red bump syndrome (eosinophilic folliculitis), 129, 130, 132z
- Itopride, for functional dyspepsia, 566
- ITP. *See* Immune thrombocytopenia
- Itraconazole, 110, 1541t
for aspergillosis, 1538
for blastomycosis, 1539
for candidiasis, 132, 598, 1530
for chromoblastomycosis, 1540
for coccidioidomycosis, 1337, 1533
for histoplasmosis, 1337, 1532
for maduromycosis, 1540
for onychomycosis, 158
for *P. marneffei* infection, 1540
for paracoccidioidomycosis, 1539
for sporotrichosis, 1539
for tinea infection, 112, 113
- IUDs. *See* Intrauterine devices
- Ivacaftor, for cystic fibrosis, 268
- IVC filters. *See* Inferior vena cava filters/
interruption
- Ivermectin
for cutaneous larva migrans, 1523
for filariasis, 1525, 1525–1526
for gnathostomiasis, 1523
for loiasis, 1528
for onchocerciasis, 1527
for scabies, 147–148
for strongyloidiasis, 1519
for trichuriasis, 1518
- IVF. *See* In vitro fertilization
- IVIG. *See* Intravenous immune globulin
- IVUS. *See* Intravascular ultrasound
- Ixabepilone, 1652t
- Ixempra. *See* Ixabepilone
- Ixodes* ticks. *See* Ticks
- J stents, ureteral, after shock wave lithotripsy, 950
- J wave, in hypothermia, 1544, 1544f
- JAK2/JAK2 mutation, 1732t
in essential thrombocytosis, 513
in hepatic vein obstruction (Budd-Chiari syndrome), 698
in noncirrhotic portal hypertension, 700
in polycythemia, 511, 512, 513
in primary myelofibrosis, 514
- JAK2 inhibitors, for primary myelofibrosis, 515
- Jakob-Creutzfeldt disease, 1009, 1381–1382
myoclonus in, 1004
parkinsonism and, 998
- Jamais vu
in focal seizures, 969
intracranial tumors causing, 990
- Janeway lesions, in endocarditis, 1435
- Janumet. *See* Sitagliptin, with metformin
- Januvia. *See* Sitagliptin
- Japanese B encephalitis, 1378–1380
immunization against, 1315, 1380
- Jarisch-Herxheimer reaction
in leptospirosis, 1478
in relapsing fever, 1476
in syphilis, 1467
- Jaundice (icterus), 662–665, 663t, 664t
in acute fatty liver of pregnancy, 795
biliary stricture causing, 708
in biliary tract carcinoma, 1606
in cholecystitis, 704
in choledocholithiasis/cholangitis, 703t, 707
cholestatic, 662, 663t
antipsychotic drugs causing, 1059
in cirrhosis, 686
in hepatitis, 666, 666f, 668, 668f, 671f
in intrahepatic cholestasis of pregnancy, 663t
in leptospirosis, 1477
liver failure and, 673
obstructive, 662–663, 663t
choledocholithiasis/cholangitis causing, 707
in primary sclerosing cholangitis, 709
in primary sclerosing cholangitis, 709
in sickle cell syndromes, 503, 504
travel and, 1297
- Jaw
osteonecrosis of, bisphosphonate use and, 11, 738, 865, 1147
tumors of, hyperparathyroidism and, 1139
- Jaw claudication, in giant cell arteritis, 846
- Jaw pain, in acute coronary syndromes/angina, 968
- JC virus (John Cunningham virus/JCV), progressive multifocal leukoencephalopathy caused by, 1382, 1383
natalizumab and, 640, 1011, 1383
- Jejunostomies, 1271
- Jentadueto. *See* Linagliptin, with metformin
- Jervell-Lange-Nielsen syndrome, 393
- Jevtana. *See* Cabazitaxel
- Jo-1 antibody, in polymyositis/dermatomyositis, 833t, 841
- Jock itch, 111–112
- Jod-Basedow disease/phenomenon (iodine-induced hyperthyroidism), 1110, 1111, 1112, 1113, 1114. *See also* Graves disease; Hyperthyroidism
- John Cunningham virus. *See* JC virus
- Joint fluid examination. *See* Synovial fluid examination
- Joints
bleeding into, in hemophilia, 550
Charcot. *See* Charcot joint
coccidioidomycosis involving, 863, 1532
in decompression sickness, 1557
disorders/inflammation of
in Chikungunya fever, 1392, 1393
- degenerative, 809–812, 811f. *See also* Arthritis; Osteoarthritis
in alkaptonuria, 1665
diagnosis and evaluation of, 809, 810t, 811t
in HIV infection/AIDS, 861
palindromic, 865
pattern of, 809, 810t
in rheumatoid arthritis, 826–827, 826f
- histoplasmosis involving, 863
- mycotic infections of, 862–863
- replacement of, 812, 1690, 1691–1692, 1702
coagulase-negative staphylococcal infection and, 1428
DVT/PE (venous thromboembolic disease) prevention and, 555, 555t
osteomyelitis and, 862
in sarcoidosis, 864
tuberculosis of, 285, 864
- Jones criteria, for rheumatic fever, 417–418
- Joule burn, 1552
- Jugular venous pulsations
in cardiomyopathy, 411, 414
in constrictive pericarditis, 422
in heart failure, 399, 400
in myocardial infarction, 366
in pericardial effusion/tamponade, 421
in tetralogy of Fallot, 331
in tricuspid regurgitation, 347
in tricuspid stenosis, 346
- “Jump rope septum,” 328
- Junctional nevi, 100
- Junctional rhythm, atrioventricular, 390
- Junctophilin-3* gene, in Huntington disease-like disorders, 1002
- Junin virus, 1384, 1385
- JUPITER trial, 10
- Juvederm. *See* Hyaluronic acid fillers
- Juvenile angiofibroma, 222
- Juvenile polyposis, familial, 655
- Juvenile spinal muscular atrophy, 1020
- JVP. *See* Jugular venous pulsations
- K⁺. *See* Potassium
- K103N mutation, antiretroviral drug resistance and, 1345
- K-ras/KRAS* gene/mutations
colorectal cancer and, 653, 1622, 1625
gallbladder cancer and, 1606
lung cancer and, 1600
pancreatic/periapillary carcinoma and, 1607, 1609
- Kadian. *See* Morphine
- Kal 1-6* genes, in Kallmann syndrome, 1094
- Kala azar. *See* Visceral leishmaniasis
- Kaletra. *See* Lopinavir/r
- Kallmann syndrome, 1094, 1173, 1179, 1180
- Kaolin pneumoconiosis, 309t
- Kaposi sarcoma, 145, 1322, 1323, 1331–1332, 1339t, 1612t
chemotherapy for, 145, 1332, 1339t, 1612t
cutaneous, 1331, 1339t
ear involvement in, 213
in HIV infection/AIDS, 145, 213, 1322, 1323, 1331–1332, 1339t, 1622

- intestinal/visceral, 145, 1331, 1339*t*, 1622
- oral, 1329, 1331
- pulmonary, 145, 1326, 1331, 1339*t*
- virus causing, 145, 1322, 1350, 1367, 1622
- Kaposi sarcoma-associated herpes virus (human herpesvirus 8), 145, 1322, 1350, **1367**, 1622
- Kappa amyloid, 531
- Kappa free light chains, reference values for, 1732*t*
- Karyotyping
- in Klinefelter syndrome, 1174, 1669
 - in male infertility, 955
 - in Turner syndrome, 1186, 1187
- Kasabach-Merritt syndrome, 701
- Katayama syndrome, 1511
- Kattan nomogram, for prostate cancer assessment, 1637
- Kava, toxicity of, 1578*t*
- Kawasaki disease, 428, 1357*t*, **1417–1418**
- Kayexalate. *See* Sodium polystyrene sulfonate
- Kayser-Fleischer ring, in Wilson disease, 696, 697*f*
- KCNE3 gene, in periodic paralysis, 1036
- KCNJ2 gene, in periodic paralysis, 1036
- KCNJ11 gene, in type 2 diabetes, 1194
- Kearns-Sayre syndrome, hypoparathyroidism in, 1136
- Kefir, for flatus, 573
- Keflex. *See* Cephalexin
- Kegel (pelvic muscle) exercises
- for fecal incontinence, 659, 660
 - for pelvic organ prolapse, 762
 - for urinary incontinence, 68, 69
- Kemadrin. *See* Procyclidine
- Kennedy syndrome, 1020
- Kenny-Caffey syndrome, 1136
- Kent bundles, in preexcitation syndromes, 383
- Kenya tick typhus, 1409*t*
- Kepivance. *See* Palifermin
- Keratotomy, photorefractive (PRK), 162
- Keratic precipitates, 178
- Keratin 5/6, in mesothelioma, 1602
- Keratitis, 165*t*, 167–174
- acanthamoeba, **174**, **1506**
 - adenovirus, 1402
 - bacterial, **172**
 - chemical, **194**
 - contact lens wear and, 162, 172, 173, 174, 1506
 - exposure, 167
 - fungal, **173–174**
 - herpes simplex, **173**, 1351, 1352, 1352–1355
 - herpes zoster ophthalmicus, **173**
 - neurotrophic, 167
 - ultraviolet (actinic), **194**
- Keratoconjunctivitis. *See also* Conjunctivitis
- adenovirus, 164–165, 1402
 - atopic, 167
 - chlamydial, 165–166
 - epidemic
 - adenovirus, 165, 1402
 - coxsackievirus, 1406
 - herpes simplex, 165, 1351
 - sicca (dry eye), **166**
 - in Sjögren syndrome, 843
 - vernal, 167
- Keratoderma blennorrhagicum, in reactive arthritis, 857, 857*f*
- Keratolytic agents, for wart removal, 140
- Keratomalacia, in vitamin A deficiency, 1266
- Keratomileusis
- laser assisted in situ (LASIK), 162
 - laser epithelial (LASEK), 162
- Keratopathy, band, in hypercalcemia/hyperparathyroidism, 1139
- Keratoplasty, conductive, 163
- Keratoses
- actinic, **117**
 - squamous cell carcinoma arising from, 117, 143
 - seborrhagic, **101–102**, 101*f*
- Kerlone. *See* Betaxolol
- Kernig sign, 41, 1441
- Ketamine, in pain management, 85
- Ketoacidemia, in diabetic ketoacidosis, 1233
- Ketoacidosis
- alcoholic, 891, 893
 - diabetic, 891, 1197, **1231–1235**, 1232*t*. *See also* Diabetic ketoacidosis
- Ketoconazole, 97*t*, 110, 1542*t*
- for ACTH-secreting adrenal tumor/adrenocortical carcinoma, 1160
- in cancer chemotherapy, 1657*t*
 - for candidiasis, 226
 - for prostate cancer, 1636, 1637*t*
 - for tinea versicolor, 114
 - topical, 97*t*
- Ketonemia
- in diabetic ketoacidosis, 1232, 1233
 - at end of life, 90
- Ketones/ketone bodies
- serum, reference values for, 1732*t*
 - in urine. *See* Ketonuria
- Ketonuria
- in diabetes mellitus, 1198, 1218
 - in diabetic ketoacidosis, 891, 1232, 1235
- Ketoprofen, 77*t*
- Ketorolac, 78*t*
- for ophthalmic disorders, 167, 169*t*
- Ketosis, in diabetes mellitus, 1192. *See also* Diabetic ketoacidosis
- 17-Ketosteroid reductase deficiency, in hypogonadotropic hypogonadism, 1175
- Ketotifen, for allergic eye disease, 167, 169*t*
- Ki-67 stain, breast cancer division rate and, 733–734
- Kidney. *See also under Renal and Kidney disease/injury*
- abnormal development of, hypertension and, 436
 - acute injury of (acute renal failure), 898, **901–908**, 902*t*. *See also* Acute kidney injury; Renal failure
 - biopsy of. *See* Renal biopsy
 - calculus formation in. *See* Nephrolithiasis; Urinary stone disease
 - cancer of, 1611*t*, **1640–1642**
 - incidence/risk/mortality of, 1594*t*, 1640–1641
 - paraneoplastic syndromes associated with, 1596*t*, 1641
 - chronic disease of, 898, **908–918**, 909*t*, 910*f*, 910*t*, 911*f*, 912*f*. *See also* Chronic kidney disease
 - cystic diseases of. *See* Renal cysts
 - disorders of, **898–937**. *See also* Kidney disease/injury
 - in gout, 812, 813, 816, **936–937**
 - medullary cystic, 934*t*
 - medullary sponge, 934*t*, **935–936**
 - metastatic disease of, **1642**
 - methotrexate eliminated by, 1661, 1662
 - in myeloma, 527, 528, **936**
 - NSAIDs affecting, 829
 - in phosphate regulation, 884
 - polycystic, **934–935**, 934*t*
 - intracranial aneurysms and, 935, 986
 - in preclampsia-eclampsia, 793*t*
 - in SLE, 833, 834, 835, 919*t*, 921*f*, **926–927**
 - systemic fibrosis and, **937**
 - toxic drug effects on. *See* Nephrotoxicity
 - transplantation of. *See* Kidney transplantation
 - tumors of, 1612*t*
- Kidney disease/injury, **898–937**. *See also under Renal and Nephritis; Nephropathy; Nephrotoxicity*
- ACE inhibitor use and, 442*t*, 449
 - acid-base disorders in, 892, 892*t*, 893, 893–894, 911*f*, 914. *See also* Renal tubular acidosis
 - acute, 898, **901–908**, 902*t*
 - postoperative, 55, 55*t*
 - aminoglycosides and, 904
 - in amyloidosis, 531, **930**
 - anion gap acidosis and, 892, 892*t*, 893, 893–894, 902
 - assessment of, **898–901**, 899*t*, 900*t*
 - cardiorenal syndrome and, **908**
 - cardiovascular disorders and, 908, 909*t*, 911–912, 911*f*
 - chronic, 898, **908–918**, 909*t*, 910*f*, 910*t*, 911*f*, 912*f*. *See also* Chronic kidney disease
 - cystic, **933–936**, 934*t*. *See also* Renal cysts
 - in diabetes, 908, 910, 914, 927, **931**, 1223–1224. *See also* Diabetic nephropathy
 - duration in evaluation of, 898
 - exenatide use and, 1211
 - GFR in, 899–910, 900*t*, 902, 903, 904, 909, 910
 - glomerular, 909*t*, **918–928**, 918*f*, 919*t*, 920*t*, 921*f*
 - nephritic spectrum, 918*f*, 919, 919*t*, **920–927**, 921*f*
 - nephrotic spectrum, 918–919, 918*f*, 920*t*, **927–928**
 - in gout, 812, 813, 816, **936–937**
 - in granulomatosis with polyangiitis, 849, 850
 - hantaviruses causing (hemorrhagic fever with renal syndrome), 1388–1389
 - heart failure and, 400, 910*t*

- Kidney disease/injury (*Cont.*):
 hematuria in, 898, 899, 907, 918, 918f, 938
 Henoch-Schönlein purpura and, 852, 919f, **923**
 hepatitis C infection and, 671, **926**
 in HIV infection/AIDS, **931**
 hypercalcemia/hyperparathyroidism and, 883, 910t, 912, 912f, 1139, 1141, 1143–1144
 in hyperglycemic hyperosmolar state, 1236
 hyperkalemia and, 879, 905, 911, 911f, 913–914, 928
 hypermagnesemia and, 888
 hypernatremia and, 876
 hyperphosphatemia in, 886, 902, 905, 911f, 912, 912–913, 912f
 hypertension and, 433, 436, 439, 442t, 908, 910, 910t, 911, 911f
 treatment of, 439, 442t, 458–459, 911
 in hypertensive emergency, 461t
 hypocalcemia and, 882, 905, 906, 910t, 912, 912f
 hypokalemia and, 879, 892, 892t, 910t
 hypomagnesemia treatment and, 888
 hyponatremia in, 874
 intrinsic, 902t, 903
 lithium associated with, 1073
 lower extremity edema and, 33, 34
 mercury causing, 1583
 methotrexate and, 1661, 1662
 in microscopic polyangiitis, 851, 907, 921f, 924
 multisystem diseases and, **936–937**
 in myeloma, 527, 528, **936**
 myoglobinuria/rhabdomyolysis and, 844, 905
 nephritic spectrum, 918f, 919, 919t, **920–927**, 921f. *See also* Nephritic syndrome
 nephrotic spectrum, 918–919, 918f, 920t, **927–931**. *See also* Nephrotic syndrome
 glomerular, 918–919, 918f, 920t, **927–928**
 in primary renal disorders, 920t, **928–930**
 from systemic disorders, 920t, **930–931**
 neurologic disorders and, 909t, 910, 914
 neuropathy associated with, 909t, 914, 1022–1023
 NSAIDs causing, 829
 in pheochromocytoma/paraganglioma, 1168t
 in polyarteritis nodosa, 847, 848
 in preeclampsia-eclampsia, 793t
 preoperative evaluation/perioperative management and, 55, 55t
 proteinuria in, 898, 898–899, 908, 910
 pruritus associated with, 145, 909t
 radiation exposure causing, 1554
 renal biopsy in, **901**
 in scleroderma, 838, 839
 sickle cell syndromes and, 503, **936**
 in SLE, 833, 834, 835, 919t, 921f, **926–927**
 in spontaneous bacterial peritonitis, 590
 in systemic fibrosis, **937**
 in thrombotic microangiopathies, 543, 543t
 toxic drug effects and. *See* Nephrotoxicity
 in tuberculosis, **936**
 tubulointerstitial, **932–933**, 932t
 in tumor lysis syndrome, 1647
 in Turner syndrome, 1186, 1187, 1187t
 urinalysis in, 898–899, 899t
- Kidney stones. *See* Nephrolithiasis;
 Urinary stone disease
- Kidney transplantation, 916
 adenovirus infection and, 1402
 for diabetic nephropathy, 1224
 hyperkalemia and, 879–880
 for IgA nephropathy, 923
 neuropathies and, 1022
 pancreas transplantation and, for diabetes, 1217
 in SLE patient, 927
- Kidney-type glutaminase gene, in hepatic encephalopathy, 690
- Kiesselbach plexus, epistaxis and, 220
- Kikuchi/Kikuchi-Fujimoto disease, 240
- Killer cell immunoglobulin-like receptors (KIR), in hepatitis C, 671
- Killip classification, 366
- Kimmelstiel-Wilson nodules, 931
- Kindling, in substance abuse disorders, 1079, 1085
- Kingella* species. *See* HACEK organisms
- Kininogen, high molecular-weight, deficiency of, 552
- KIR (killer cell immunoglobulin-like receptors), in hepatitis C, 671
- KIT protein, in gastrointestinal stromal tumors, 1619, 1620
- Klatskin tumors, 1606
- Klebsiella/Klebsiella pneumoniae*, 1299t
- Kleine-Levin syndrome, 1077
- Klinefelter syndrome, 1174, **1669–1670**
 gynecomastia in, 1174, 1178, 1669
 infertility and, 955, 1174, 1669, 1670
- Klonopin. *See* Clonazepam
- Knee, **1692–1703**, 1693t, 1694–1697t
 arthritis of, 1692, **1701–1703**
 meniscal injuries and, 1700
 nongonococcal acute bacterial (septic), 859
 arthrocentesis in evaluation of, 1674
 bursitis of, 825
 complex regional pain syndrome and, 825
 examination of, 1692–1693, 1694–1697t
 meniscal injuries and, 1696–1697t, **1700**
 range of motion of, 1694t
 arthritis and, 1702
 strength testing and, 1694t
- Knee pain, **1692–1693**, 1693t, 1694–1697t
 anterior (patellofemoral pain), 1692, 1697t, **1700–1701**
 osteoarthritis and, 1692, 1702
- Knee realignment surgery, 1702
- Knee replacement
 for arthritis, 812, 1702
 DVT/PE (venous thromboembolic disease) prevention and, 555, 555t
- Kocher sign, 1112
- Koebner phenomenon
 in lichen planus, 144
 in psoriasis, 106
- KOH preparation, 110, 110f
- Kombiglyze XR. *See* Saxagliptin, with metformin
- Koplik spots, 1367
- Korsakoff psychosis/syndrome, 1013, 1081, 1264
- KPs. *See* Keratic precipitates
- K-ras/KRAS* gene/mutations
 colorectal cancer and, 653, 1622, 1625
 gallbladder cancer and, 1606
 lung cancer and, 1600
 pancreatic/periampullary carcinoma and, 1607, 1609
- Krukenberg tumor, 1616
- KSHV. *See* Kaposi sarcoma-associated herpes virus
- Kübler-Ross, stages of dying described by, 91
- Kugelberg-Welander syndrome, 1020
- Kumamoto study, 1202
- Kupffer cells
 in autoimmune hemolytic anemia, 506
 in cirrhosis, 687
 in cold agglutinin disease, 507
- Kuru, 1381, 1382
- Kussmaul respirations, in metabolic acidosis, 24, 893
- Kussmaul sign
 in constrictive pericarditis, 422
 in myocardial infarction, 366
- Kwashiorkor/kwashiorkor-like secondary protein-energy malnutrition, 1257–1258
- Kyphoscoliosis, in syringomyelia, 1018
- L-AmB. *See* Liposomal amphotericin B
- La belle indifférence, 1045
- La/SSB antibody, 833t
 in lupus/SLE, 114, 833t
 in Sjögren syndrome, 833t, 843
- Labetalol, for hypertension, 447t
 in aortic dissection, 477
 eclampsia and, 795
 pheochromocytoma and, 1170
 in urgencies/emergencies, 461–463, 462t
- Labor and delivery
 acute fatty liver of pregnancy and, 795
 for cardiac patient, 431, 802–803
 endocarditis prophylaxis and, **431**, 803
 for diabetic patient, 801, 1230
 herpes simplex transmission during, 806, 1355
 for HIV-positive patient, 1321
 induction of, after 41 weeks, 785
 preeclampsia/eclampsia and, 793, 794, 795
 preterm, **796–797**
 varicella transmission and, 1359
- Laboratory tests. *See* Diagnostic/laboratory tests
- Labyrinthine concussion, vertigo caused by, 210t, 211
- Labyrinthitis, 210–211, 210t
- Lacerations
 cerebral, 1017t

- ocular, 193–194, 193f
scalp, 1016
- Lachman test, 1693, 1694t
- Lac-Hydrin-Five, 99t
- Lacosamide, 973t
- Lacrimal apparatus, disorders of, 163–164, 163f
- Lacrimal punctal occlusion, for dry eye, 166
- Lacrimal sac, infection of (dacryocystitis), 164
- LaCrosse agent, California encephalitis caused by, 1378
- β -Lactam antibiotics. *See* Beta-lactam antibiotics
- Lactase deficiency, 626–627. *See also* Lactose (milk) intolerance
- Lactase enzyme replacement, 627
- Lactate. *See* Lactic acid
- Lactate dehydrogenase (LD/LDH)
ascitic fluid, 588
bacterial peritonitis and, 588, 589
in hemolytic anemia, 500
in non-Hodgkin lymphoma, 525, 526
in paroxysmal nocturnal hemoglobinuria, 502
pleural fluid, 314
in parapneumonic effusion, 315
in *Pneumocystis pneumonia*, 1326, 1534
reference values for, 1732t
in testicular cancer, 1643
in vitamin B₁₂ deficiency, 498
- Lactated Ringer solution. *See* Fluid management/hydration
- Lactation/breastfeeding, 786
antituberculosis drug therapy during, 286, 805
breast abscess and, 721
breast cancer and, 730
CMV transmission and, 1364
drug/medication use/avoidance during, 782t, 786. *See also specific agent*
HIV infection/AIDS transmission and, 1321, 1336
iron requirements/supplementation during, 491
mastitis and, 721, 797–798
candidal, 132
oral contraceptive use and, 772
progestin minipill and, 773
suppression of, 786
thyroid medication during, 1115, 1117
- Lactic acid (lactate), 890–891, 1237
in alcoholic ketoacidosis, 891
in lactic acidosis, 890–891
reference/normal values for, 891
- Lactic acidosis, 890–891, 1232t, 1237–1238
alcoholic ketoacidosis and, 891
in heat exposure syndromes, 1548
metformin causing, 914, 1209, 1237, 1580
- Lactitol, 1205
- Lactobacillus* probiotic, for antibiotic-associated colitis prevention, 636
- Lactoferrin, fecal
in Crohn disease, 642
in diarrhea, 575, 579, 1293
- Lactose-free diet, 626, 627
- Lactose (milk) intolerance, 621t, 626–627
diarrhea caused by, 578, 579f, 621t, 626
flatus caused by, 573, 626
- Lactulose
for constipation, 571, 572t
diarrhea caused by, 579f
in GI bleeding, 602
for hepatic encephalopathy, 602, 673, 690
- Lactulose breath test, in bacterial overgrowth, 580, 625
- Lacunar infarction, 979–981, 980t. *See also* Stroke
- LADA. *See* Latent autoimmune diabetes mellitus of adulthood
- Laennec cirrhosis, 686
- LAIV influenza vaccine, 1396. *See also* Influenza virus vaccine
- Lambda amyloid, 531
- Lambda free light chains, reference values for, 1732t
- Lambert-Eaton (myasthenic) syndrome, 1033
in cancer, 995, 1033, 1596t
- Laminectomy, decompressive
for Arnold-Chiari malformation/syringomyelia, 1019
for spinal stenosis, 1685
for spinal trauma, 1018
for spinal tumors/cord compression, 993, 1645
- Lamisil. *See* Terbinafine
- Lamivudine (3TC), 1341t, 1343, 1348f, 1354t. *See also* Antiretroviral therapy/HAART
with abacavir, 1343, 1344, 1347, 1348f
for hepatitis B, 675, 676, 1329, 1343, 1354t
during pregnancy, 806
resistance to, 675, 1349
with zidovudine, 1343, 1347, 1348f
postexposure/after needle stick, 1335
with zidovudine and abacavir, 1344, 1348f
- Lamotrigine, 972, 973t, 1075
for bipolar disease/mania, 1075
overdose/toxicity of, 973t, 1075, 1574
for seizures, 972, 973t
pregnancy and, 803
- Langerhans cell histiocytosis, 1097, 1099
- Language. *See* Speech/language
- Janinamivir, 1396
- Janreotide, for acromegaly/gigantism, 1101
- Lansoprazole, 613. *See also* Proton pump inhibitors
- Lanthanum, for hyperphosphatemia, 886
in metabolic bone disorders/renal osteodystrophy, 913
- Lantus. *See* Insulin glargine
- Laparoscopy
in ascites, 589
in ectopic pregnancy, 790, 790–791
in gynecologic disorders, 748t
in PID, 763
pulmonary complication rate and, 50
for tubal ligation, 777
- Lapatinib, 741, 1655t
- Large cell carcinoma of lung, 1595–1597. *See also* Lung cancer
- Large-needle (core needle) biopsy, for breast lump evaluation, 718, 728, 728f, 729f, 1718, 1719. *See also* Breast, biopsy of
stereotactic guided, 729
- Large-volume paracentesis. *See* Paracentesis
- Large-volume thoracentesis. *See* Thoracentesis
- Laron syndrome/dwarfism, 1094
- Larva migrans
cutaneous, 1523–1524, 1524f
ocular, 1523
visceral, 1523
- Laryngeal carcinoma, 236–237
hoarseness and, 233
leukoplakia and, 236
- Laryngeal leukoplakia, 236
- Laryngeal nerve, recurrent
damage to during thyroid surgery, 237, 238, 1116, 1119, 1129
vocal fold paralysis caused by damage/lesions of, 237–238
- Laryngeal papillomas, 234–235
- Laryngectomy, for laryngeal cancer, 237
- Laryngitis, 233. *See also* Hoarseness
- Laryngopharyngeal reflux, 234. *See also* Gastroesophageal reflux disease
- Laryngospasm
in drowning, 1556
in hypocalcemia, 882
- Laryngotracheitis, human parainfluenza virus causing, 1393
- Larynx, 233–238. *See also under Laryngeal*
masses of, 235–237
papillomas of, 234–235
stenosis of, 242
- LASEK (laser epithelial keratomileusis), 162
- Laser assisted in situ keratomileusis (LASIK), 162–163
- Laser epithelial keratomileusis (LASEK), 162
- Laser-induced prostatectomy, transurethral (TULIP), for benign prostatic hyperplasia, 961
- Laser therapy
for acne scars, 128
for age-related macular degeneration, 181
for benign prostatic hyperplasia, 961
for CIN/cervical cancer, 756
for diabetic retinopathy, 185, 1223
endovenous, for varicose veins, 479, 1720
for esophageal cancer palliation, 1614
for glaucoma, 175, 177
for hirsutism, 1163–1164
for hyperpigmentation, 156
for lung cancer palliation, 1600
for pseudofolliculitis, 129
for refractive errors, 162–163
for retinal detachment, 180
for retinal vein occlusion, 182
for sickle cell retinopathy, 187
for wart removal/condylomata acuminata, 140–141, 753
- LASIK (laser assisted in situ keratomileusis), 162

- Lasix. *See* Furosemide
- Lasmiditan, for migraine headache, 964
- Lassa fever, 1384, 1385
- Latanoprost, for glaucoma/ocular hypertension, 171*t*, 176
- Latanoprost/timolol, for glaucoma/ocular hypertension, 172*t*, 176
- Late life psychosis, 1054
- Latent autoimmune diabetes mellitus of adulthood (LADA), 1193, 1220
- Lateral collateral ligament, 1692
injury of, 1695–1696*t*, 1698–1699
- Lateral epicondylitis, 1687–1688
- Lateral femoral cutaneous nerve lesions (meralgia paresthetica), 1027
- Lateral meniscus, 1692. *See also* Meniscal cartilage, of knee
- Lateral sclerosis
amyotrophic, 1019, 1020
enterovirus infection and, 1407
primary, 1019
- Latex allergy, anaphylaxis and, 866
- Latissimus dorsi flap, for breast reconstruction, 745
- Latrodectus mactans* (black widow spider), 149, 1590
- Latuda. *See* Lurasidone
- Lavage
bronchoalveolar. *See* Bronchoalveolar lavage
gastric, for poisoning/drug overdose, 1567
- Lavender top tubes, 1736*t*
- Laxative abuse, 1086
diarrhea caused by, 578, 579*f*
- Laxatives, 571–572, 572*t*
hypermagnesemia and, 888
for irritable bowel syndrome, 635
for opioid-induced constipation, 86, 571–572
- LCHAD deficiency, acute fatty liver of pregnancy and, 795
- LCIS. *See* Lobular carcinoma in situ
- LCL. *See* Lateral collateral ligament
- LCM. *See* Lymphocytic choriomeningitis
- LD. *See* Lactate dehydrogenase
- LDCT. *See* Low-dose helical computed tomography
- LDH. *See* Lactate dehydrogenase
- LDL. *See* Low-density lipoproteins/cholesterol
- Lead, reference values for, 1732*t*
- Lead encephalopathy, 1582
gasoline sniffing and, 1086
- Lead nephropathy, 933, 1581, 1582
- Lead poisoning, 1566*t*, 1581–1582
gasoline sniffing and, 1086
gout and, 814
tubulointerstitial disease caused by, 933
- Leflunomide, for rheumatoid arthritis, 830
- Left-to-right shunts. *See* Shunts
- Left ventricular aneurysm
coronary artery trauma and, 428
myocardial infarction and, 375
- Left ventricular angiography, in angina, 355
- Left ventricular (LV) apical ballooning syndrome. *See* Tako-Tsubo (stress/catecholamine-induced) cardiomyopathy
- Left ventricular assist devices, 406
for cardiomyopathy, 413
for infectious myocarditis, 410
- Left ventricular end-diastolic pressure, increased, in dyspnea, 25, 25*t*
- Left ventricular (left heart) failure/dysfunction, 367*t*, 398, 399.
See also Congestive heart (cardiac) failure
in hypertensive emergency, 461*t*
myocardial infarction and, 366, 367*t*, 373–374, 376
preoperative evaluation/perioperative management and, 49
pulmonary hypertension and, 423*t*, 424
- Left ventricular hypertrophy in aortic dissection, 477
in aortic regurgitation, 345
in aortic stenosis, 342
in cardiomyopathy, 414. *See also* Cardiomyopathy
in coarctation of aorta, 327
in congestive heart failure, 398, 400
hypertensive, 439, 440
sudden death of athlete and, 431, 432
- Leg. *See also* under Lower extremity
acute arterial occlusion of, 468–469
peripheral artery aneurysms and, 476
appearance of
in acute arterial occlusion, 468
in femoral/popliteal occlusive disease, 465
in lower leg/foot occlusive disease, 467
in varicose veins, 478, 479
in venous insufficiency, 33, 34, 481
peripheral artery aneurysms affecting, 476
- Leg elevation
for lymphedema, 484
for varicose veins, 479
for venous insufficiency, 34, 481
- Leg pain. *See also* Claudication
in acute arterial occlusion, 468
in aortoiliac occlusive disease, 464
in femoral/popliteal occlusive disease, 465
peripheral artery aneurysms and, 476
in pulmonary embolism, 298*t*, 301*t*
in spinal dural arteriovenous fistulae, 989
in spinal stenosis, 822, 1685
- Leg ulcers
in polyarteritis nodosa, 847
in sickle cell syndromes, 503, 504
in venous insufficiency/varicose veins/
lower extremity occlusive disease, 33, 34, 153–155, 154*f*, 467, 479, 481
osteomyelitis and, 154, 862
- Legal blindness. *See also* Blindness
age-related macular degeneration causing, 181
- Legalon-SIL. *See* Silymarin
- Legionella*/*Legionella pneumophila*, 1299*t*, 1302*t*, 1303*t*, 1443
- Legionnaires disease (legionella pneumonia/legionellosis), 271, 272*t*, 1299*t*, 1302*t*, 1303*t*, 1443
- Leiden mutation, DVT/PE (venous thromboembolic disease) and, 297
- Leiomyoma-renal cell carcinoma, 1641
- Leiomyomas
esophageal, 601
gastrointestinal, 1619
of uterus (fibroid tumor), 757–759
- Leiomyosarcoma
gastrointestinal, 1622. *See also* Gastrointestinal stromal tumor
of uterus, 758
- Leishmania* (leishmaniasis), 1487–1490, 1488*f*
cutaneous, 1487, 1488, 1488*f*, 1489
post-kala azar, 1487–1488
mucocutaneous (espundia), 1487, 1488, 1489
post-kala azar dermal, 1487–1488
recidivans, 1488
visceral (kala azar), 1487, 1487–1488, 1488, 1488–1489
- Leishmanin skin test, 1488
- Lemierre syndrome, 230, 231, 1420, 1454
- Lenalidomide, 1656*t*
for chronic lymphocytic leukemia, 522
for myelodysplastic syndromes, 518, 540
for myeloma, 529
for primary myelofibrosis, 515
- Lennox-Gastaut syndrome, 972
- Lens opacity. *See* Cataract
- Lentiginos, 101, 155
solar (liver spots), 101, 155, 156
- Lentigo maligna melanoma, 102
- Lepirudin, for heparin-induced thrombocytopenia, 544, 544*t*
- Leprechaunism, 1193*t*, 1195
- Lepromatous leprosy, 1460. *See also* Leprosy
- Lepromin skin test, 1460
- Leprosy (Hansen disease), 1460–1461
neuropathy associated with, 1023, 1460
- Leptin/leptin receptor, in obesity, 1259
insulin action and, 1194
- Leptomeningeal metastases (carcinomatous meningitis), 992, 1287
- Leptospira*/*Leptospira interrogans* (leptospirosis), 1300*t*, 1477–1478
- Lescol. *See* Fluvastatin
- Lethal midline granuloma, 223
- Letrozole, 1656*t*
for breast cancer, 740*t*
for endometriosis, 761
for gynecocoma, 1179
for ovulation induction, 769
- Leucine, in insulinoma diagnosis, 1240
- Leucovorin (folinic acid) rescue with 5-fluorouracil, 1625, 1658*t*
with methotrexate, 829, 1658*t*, 1661, 1662
- Leukapheresis
for acute leukemia, 520
for chronic myeloid dysplasia, 516
- Leukemias, 511–524, 1610*t*
acute, 519–521, 1610*t*. *See also* specific type

- infection and, 519–520, 1279
 lymphoblastic/lymphocytic (ALL), 519, 520, 521, 1610t
 myeloid (AML), 519, 520, 520–521, 521, 1610t
 promyelocytic (APL), 519, 520
 DIC associated with, 519, 546
 adult T cell (ATL), 1383–1384. *See also* Human T cell lymphotropic/leukemia virus
- aleukemic, 520
 chronic, 1610t
 lymphocytic (CLL), 521–523, 1610t
 myeloid (CML), 511t, 515–517, 1610t
 myelomonocytic (CMML), 517
 prolymphocytic, 522
 exfoliative dermatitis/erythroderma and, 116
 fever/FUO and, 1277
 hairy cell, 523–524, 1610t
 incidence/mortality/risk of, 1594t
 meningeal, 520
 neutropenia and, 510, 520
 plasma cell, 528
 rheumatic manifestations of, 864
 secondary to chemotherapy or radiation therapy, 519
 stem cell transplants for, 517, 520–521, 533
- Leukemic arthritis, 864
 Leukeran. *See* Chlorambucil
 Leukine. *See* Sargramostim
 Leukoagglutinin transfusion reactions, 535
 leukocyte-poor blood in prevention of, 534, 535
- Leukocidin, Panton-Valentine, 273
 Leukocyte casts, 898, 899t
 in interstitial nephritis, 898, 907
 Leukocyte count. *See* White blood cell count
 Leukocyte-poor blood, transfusion of, 534, 535. *See also* Transfusion
- Leukocytes
 fecal, in diarrhea, 575, 576f, 1293
 pleural fluid, 314, 314t
 Leukocytosis
 in acute leukemia, 520
 in cellulitis, 137
 in lymphangitis/lymphadenitis, 483
 in Still disease, 831
 Leukoderma, 155–156
 Leukoencephalopathy, progressive multifocal (PML), 1328, 1382–1383
 natalizumab and, 640, 1011, 1383
 Leukopenia, in SLE, 834t
 Leukoplakia
 hairy, 224, 225f, 1323, 1329
 laryngeal, 236
 oral, 224–225, 224f, 225f, 1323, 1329
 Leukoreduced blood, transfusion of, 534, 535
- Leukotriene modifiers
 for allergic rhinitis, 219
 for asthma, 249f, 252t, 253
- Leuprolide, 1657t. *See also* Luteinizing hormone-releasing hormone (LHRH) analogs
 for abnormal premenopausal bleeding, 748
 for endometriosis, 761
 hypogonadism caused by, 1096
 for male infertility, 1097
 for prostate cancer, 1636, 1637t
- Leustatin. *See* Cladribine
 Levalbuterol, for asthma, 254t, 255
 Levaquin. *See* Levofloxacin
 Levatol. *See* Penbutolol
 Levemir. *See* Insulin detemir
 Levetiracetam, 972, 973t
 overdose/toxicity of, 973t, 1573
 for seizures, 972, 973t
 pregnancy and, 803
- Levitra. *See* Vardenafil
 Levo-Dromoran. *See* Levorphanol
 Levobunolol, for glaucoma/ocular hypertension, 171t, 176
 Levocabastine, for allergic eye disease, 167, 169t
- Levodopa
 benzodiazepine interactions and, 1043t
 for idiopathic torsion dystonia, 1003
 MAOI interactions and, 999, 1071t
 for neuroleptic malignant syndrome, 36
 for parkinsonism, 998, 999
 with carbidopa, 999
 with carbidopa and entacapone, 999, 1000
- Levofloxacin. *See also* Fluoroquinolones
 for bacterial rhinosinusitis, 216t
 for ophthalmic disorders, 168t
 for pneumonia, 273, 273t, 277t
- Levoleucovorin rescue, with methotrexate, 829, 1658t
- Levonorgestrel
 for emergency/postcoital contraception, 776
 for menopausal symptoms, 779
 in Mirena IUD, 773, 774, 1185
 in oral contraceptives, 771t
 with transdermal estradiol, 1183
- Levonorgestrel-releasing IUD, 773–774
 for abnormal premenopausal bleeding, 748, 774
 for dysmenorrhea, 750, 774
 for endometriosis, 761
 for postmenopausal bleeding, 749
- Levorphanol, 81t
 Levothyroxine (thyroxine)
 hyperthyroidism caused by, 1125
 for hypothyroidism/myxedema, 1096, 1107, 1108–1110
 in Hashimoto thyroiditis, 1122
 during pregnancy, 800, 1108, 1109
 for thyroid cancer, 1125, 1129, 1130
 surveillance and, 1132
 withdrawal stimulated RAI therapy and, 1131
 thyroid nodule evaluation/treatment and, 1124t, 1125
 after thyroidectomy, 1129, 1130
- Levulose, for porphyria, 1022
 Lewy bodies, dementia with, 59, 1008, 1008t
- Lexapro. *See* Escitalopram
 Lexiva. *See* Fosamprenavir
 Leydig cell tumors/hyperplasia, 1177, 1642
 hypogonadism and, 1175
- LGV. *See* Lymphogranuloma venereum
 Lhermitte sign, 818
 LHRH analogs. *See* Luteinizing hormone-releasing hormone (LHRH) analogs
 LHRH antagonist. *See* Luteinizing hormone-releasing hormone (LHRH) antagonist
- Lialda. *See* Mesalamine
 Libido
 loss of, 951, 1050. *See also* Sexual dysfunction
 in chronic kidney disease, 914
 postmenopausal changes and, 1050
- Libman-Sacks endocarditis, 428
 in SLE, 833
- Librium. *See* Chlordiazepoxide
 Lice, 148
 in epidemic typhus, 1408–1410, 1409t
 in relapsing fever, 1475, 1476
 in trench fever, 1454
- Lichen planus, 143–145, 144f
 drugs causing eruptions similar to, 144, 159t
 oral, 144, 224
- Lichen planus-like drug eruptions, 144, 159t
- Lichen sclerosis
 anogenital pruritus and, 146
 vulvar, 760
- Lichen simplex chronicus (circumscribed neurodermatitis), 105, 105f
- Lichenoid eruptions, drugs causing, 159t
- Licorice, hypertension/hypokalemia and, 437, 1165–1166
- Lid. *See* Eyelids
 Lid retraction/lid lag, in dysthyroid eye disease, 191, 1112
- Liddle syndrome, 437, 878t, 1166
- Lidex. *See* Fluocinonide
 Lidocaine, 377, 378t, 1723t. *See also* Lidocaine patch
 for arrhythmias, 377, 378t
 infarct-related, 371, 372, 373
 ventricular tachycardia, 378t, 391
 for cluster headache, 965
- Lidocaine patch
 for painful diabetic neuropathy, 1225–1226
 for postherpetic neuralgia/neuropathic pain, 84t, 85, 120, 968, 1359
- Lidoderm. *See* Lidocaine patch
- Life expectancy
 after Alzheimer's disease diagnosis, 62
 assessment/prognosis of older adult and, 57, 58f
 obesity affecting, 14, 1259
 prognosis at end of life and, 87
- Life support
 basic, in near drowning, 1556
 withdrawal/withholding, in end-of-life care, 91, 91t
 advance directives and, 89
- Lifestyle
 modifications of
 adherence and, 1
 in constipation management, 571
 in GERD management, 596
 in hypertension management/prevention, 434t, 441, 441t

- Lifestyle, modifications of (*Cont.*):
 lipid-lowering and, 1250, 1251*t*
 menopausal hot flush management and, 1186
 in obesity management, 14, 1260
 in urinary incontinence management, 68, 69
- sedentary
 lipid abnormalities and, 1248*t*
 preventable disease/deaths and, 3*t*, 7*t*, 12–13
 prevention of, 12–13
- Lift off test, 1678*t*, 1680
- Light, pupillary reaction to. *See* Pupillary reactions
- Light chains
 in amyloidosis, 531, 930
 in myeloma, 527, 527–528, 528, 936
 reference values for, 1732*t*
 in urine. *See* Bence Jones proteinuria
- Light eruption, polymorphous (PMLE), 153
- Light green top PPT, 1736*t*
- Light therapy. *See* Phototherapy
- Light visors, for depression with seasonal onset, 1071
- Lightning injuries, 1552
- Ligneous (Riedel) thyroiditis, 1120, 1121, 1122
- Lille model, in alcoholic liver disease, 682
- Lily-of-the-valley, toxicity of, 1578–1579
- Limb-girdle (Erb) muscular dystrophy, 1034, 1035*t*
- Limb loss. *See* Amputation
- Limbic encephalitis, 994–995
- Linagliptin, 1207*t*, 1212–1213
 with metformin, 1213
- Linear scleroderma, 839
- Linezolid
 adverse ophthalmic effects of, 197*t*
 for enterococcal infection, 1422
 for pneumonia, 273, 277*t*
 serotonin syndrome caused by, 1585
 for staphylococcal skin infection, 1426
- Linitis plastica, 1616
- Linoleic acid, in nutritional support, 1272
- Liothyronine. *See also* Thyroid hormone
 antidepressant drug augmentation and, 1065, 1069
 for myxedema coma, 1108
- Lipase
 lipoprotein, abnormality of, 1245
 in pancreatic enzyme supplements, 716
 serum levels of
 in pancreatitis, 711, 716
 reference values for, 1732*t*
- Lipedema, chronic venous insufficiency differentiated from, 481
- Lipemia retinalis, 1248
 in diabetes mellitus, 1197
- Lipid-based amphotericin B, 1541–1542, 1541*t*
 for aspergillosis, 1538
 for cryptococcal meningitis, 1536
 for mucormycosis, 217, 1538
- Lipid disorders/lipids, 1245–1256. *See also* Fat; Lipoproteins
 antiretroviral therapy and, 1036, 1160, 1332, 1344
- atherogenesis/cardiovascular/coronary heart disease and, 7*t*, 8–10, 350, 1245–1246, 1246
 in women, 1251, 1706–1707
- cholesterol lowering and, 8–10, 1246–1247, 1252–1255, 1255*t*
 in women, 1706–1707
- clinical presentations in, 1247–1248, 1248*f*
- in diabetes mellitus, 1197, 1200–1201, 1247, 1248*t*
- in nephrotic syndrome/nephrotic spectrum disorders, 898, 918, 927, 928, 1248*t*
- pharmacologic therapy affecting. *See* Lipid-lowering therapy
- screening for, 1248–1252, 1249–1250*t*, 1251*t*
 cardiovascular disease prevention and, 7*t*, 8–10, 1248–1252, 1249–1250*t*, 1251*t*
 in women, 7*t*, 1248, 1251, 1706
- secondary conditions and, 1247, 1248*t*
- thiazolidinediones affecting, 1209–1210
- triglycerides and, 1255–1256
- Lipid fractions, coronary heart disease risk and, 350, 1245, 1246, 1248–1252, 1249–1250*t*, 1251*t*. *See also* Lipoproteins
 in women, 1251, 1706
- Lipid-lowering therapy, 1246–1247, 1251*t*, 1252–1255, 1255*t*
 acute coronary syndromes and, 362*t*, 364
 in aortic stenosis, 343
 for cardiovascular/heart disease prevention, 8–10, 1246–1247, 1252–1255, 1255*t*
 in women, 1251, 1706–1707
- cholesterol screening and, 8–10, 1248–1252, 1249–1250*t*, 1251*t*
 in older patients, 1251–1252
 in women, 1251, 1706
- combination therapy and, 1254
 in diabetes, 1227
- diet and, 1250
- exercise/activity and, 12–13, 1252
- goals of, 1248, 1251*t*, 1253
- high LDL cholesterol and, 1252–1255, 1255*t*
- high triglycerides and, 1255–1256, 1255*t*
- in HIV infection/AIDS, 1344
- in hypertension, 443–444
- in nephrotic syndrome, 928
- pharmacologic, 1250, 1251*t*, 1253–1255, 1255*t*. *See also specific type of therapy and* Statin drugs
 rhabdomyolysis/myopathy/myositis and, 842, 844, 1254
- selection of agents for, 1254, 1255*t*
- therapeutic effects of, 1246–1247
- Lipid-modifying diet, 1250, 1252
 in diabetes, 1205
 in nephrotic syndrome, 928
- Lipiduria, 898
- Lipitor. *See* Atorvastatin
- Lipoatrophic diabetes, 1193*t*
- Lipoatrophy
 antiretroviral therapy and, 1343, 1344
 at insulin injection sites, 1222–1223
- Lipocalin, neutrophil gelatinase-associated, in acute tubular necrosis, 904
- Lipodermatosclerosis, 34
- Lipodystrophy
 Cushing syndrome differentiated from, 1160
 familial partial, type I, 1160
 HIV infection/antiretroviral therapy and, 1036, 1160, 1332, 1344
 at insulin injection sites, 1222–1223
- Lipohypertrophy, at insulin injection sites, 1216, 1223
- Lipoid nephrosis (minimal change disease), 920*t*, 928–929
- Lipoid pneumonia, 308
- Lipomas
 atrial septal, 427
 epidermal inclusion cysts differentiated from, 152
 intestinal, 638
 in MEN, 1188*t*, 1189
- Liponyssoides sanguineus* mites. *See* Mites
- Lipoprotein lipase, abnormality of, 1245
- Lipoproteins. *See also specific type and* Cholesterol
 atherogenesis/cardiovascular/coronary heart disease and, 350, 1245–1246, 1246, 1248–1252, 1249–1250*t*, 1251*t*
 in diabetes mellitus, 1200–1201
 estrogen replacement affecting, 1182
 lowering. *See* Lipid-lowering therapy
- screening tests for levels of, 7*t*, 1248–1252, 1249–1250*t*, 1251*t*
 in women, 7*t*, 1248, 1251, 1706
- testosterone replacement affecting, 1177, 1185
- thiazolidinediones affecting, 1209–1210
- Liposomal amphotericin B, 1541*t*. *See also* Lipid-based amphotericin B
 for histoplasmosis, 1532
 for leishmaniasis, 1488
- Liposomal daunorubicin, 1653*t*, 1662
- Liposomal doxorubicin, 1653*t*, 1662
 for Kaposi sarcoma, 145, 1332, 1339*t*
- 5-Lipoxygenase inhibitor, for asthma, 252*t*, 253
- Liquid diets, 1268
- Liquid nitrogen. *See also* Cryotherapy
 for actinic keratoses, 117
 hypopigmentation/depigmentation and, 155–156
 for wart removal/condylomata acuminata, 140, 753
- Liquid oxygen systems, for home oxygen therapy, 262
- Liraglutide, 1206*t*, 1212, 1220–1221
- Lisinopril, 450*t*
 breastfeeding and, 782*t*
 for heart failure, 402
 for hypertension, 450*t*
 with hydrochlorothiazide, 450*t*
- Lispro insulin. *See* Insulin lispro

- Listeria monocytogenes* (listeriosis), 574t, 1300t, **1434–1435**
 meningitis caused by, 1302t, 1434
- Literacy (health), adherence and, 1
- LITH* gene, in cholelithiasis/gallstones, 702
- Lithium, 1072–1074, 1074t, 1723t
 for aggressive/violent patient, 1078–1079
 antidepressant drug augmentation/interaction and, 1065, 1069, 1071t, 1073
 breastfeeding and, 782t, 1073
 dosage recommendations for, 1073
 drug interactions of, 1071t, 1074, 1074t
 ECT-associated memory loss and, 1071
 hypercalcemia and, 1073, 1142
 hyperthyroidism/thyrotoxicosis/thyroiditis and, 1111
 hypothyroidism and, 1073
 monitoring levels of, 1073, 1723t
 overdose/toxicity of, 1073–1074, 1569t, **1582–1583**
 hemodialysis for, 1073, 1568t, 1582–1583
 ophthalmic effects and, 196t
 seizures and, 1073, 1565t
 pregnancy/breastfeeding and, 1073
 for unipolar depression, 1072
- Lithotripsy
 for choledocholithiasis/choolangitis, 707
 for cholelithiasis/gallstones, 704
 for pancreatic duct stones, 717
 for renal stones, 950
 for sialolithiasis, 232
 for ureteral stones, 950
- Livalo. *See* Pitavastatin
- Livedo reticularis, **854**
 antiphospholipid antibody syndrome and, 836, 854
 in polyarteritis nodosa, 847, 854
- Liver
 abscesses of
 amebic, 1503, 1504, 1505t
 pyogenic, **700–701**
 anesthesia/surgery affecting function of, 51
 biopsy of, 665
 in alcoholic liver disease, 681
 in cirrhosis, 687
 in hemochromatosis, 695
 in hepatic vein obstruction (Budd-Chiari syndrome), 698
 in hepatocellular carcinoma, 1604
 in nonalcoholic fatty liver disease, 685
 in noncirrhotic portal hypertension, 700
 in primary sclerosing cholangitis, 709
 cancer of, **1603–1605**, 1612t
 cirrhosis and, 682, 685, 687, 1603, 1604, 1605
 hemochromatosis and, 682, 695, 1603
 hepatitis and, 668, 670, 672, 674, 676, 678, 679, 1603, 1604
 hepatitis B vaccine in prevention of, 15, 1604–1605
 incidence/mortality/risk of, 1603
 paraneoplastic syndromes associated with, 1596t
 pyogenic abscess and, 701
 carcinoid metastases involving, 1621
 cavernous hemangioma of, 701
 disorders of, **665–702**. *See also specific disorder and under Hepatic*
 acute liver failure, **672–674**
 alcoholic, **680–682**, 1081, 1083
 ascites in, 587, 587–588, 587t
 spontaneous bacterial peritonitis and, 588, 589, 689
 biliary cirrhosis, **692–694**
 bleeding associated with, **553–554**
 cholelithiasis/gallstones and, **702–704**, 703t
 cirrhosis, **686–692**, 692t
 coagulopathy, **553–554**
 diagnosis of, 663t, 664–665, 664t
 drug- and toxin-induced, **682–684**. *See also Hepatotoxicity*
 esophageal varices in, 581, 601, 602, 604
 in fascioliasis, 1512
 hemochromatosis, **694–696**
 hepatic vein obstruction (Budd-Chiari syndrome), **697–699**
 hepatitis. *See* Hepatitis
 in HIV infection/AIDS, 1329
 hyponatremia in, 873
 immunization recommendations in, 1309t
 jaundice in, 662, 663t
 lipid abnormalities and, 1248t
 neoplastic. *See also* Liver, cancer of
 benign tumors, **701–702**
 drugs/toxins causing, 683
 oral contraceptive use and, 701, 702, 772
 nonalcoholic fatty liver disease, **684–685**. *See also* Fatty liver
 noncirrhotic portal hypertension, **699–700**
 NSAIDs causing, 829
 parenteral nutritional support and, 1274t
 in preeclampsia-eclampsia, 793t
 preoperative evaluation/
 perioperative management and, **51–52**
 pruritus associated with, 145
 in syphilis, 1471
 Wilson disease, **696–697**, 697f
 enlarged. *See* Hepatomegaly
 fatty. *See* Fatty liver
 fibrosis of. *See* Hepatic fibrosis
 focal nodular hyperplasia of, 701, 702
 telangiectatic, 702
 in heart failure, 400, **699**
 in HIV infection/AIDS, 1329
 hydatid cyst of, 1516
 nodular regenerative hyperplasia of, noncirrhotic portal hypertension and, 699
 passive congestion of, 699
 resection of, for hepatocellular carcinoma, 1605
 shock, 699
 transplantation of, 691
 for acute liver failure, 673
 adenovirus infection and, 1402
 alcoholic liver disease and, 682
 for autoimmune hepatitis, 680
 for biliary cirrhosis, 694
 biliary stricture and, 709
 for cholangiocarcinoma, 1607
 for cirrhosis, 685, 687, 689, 691
 CMV infection and, 1364
 esophageal varices and, 604
 for hepatic coagulopathy, 553
 for hepatic vein obstruction (Budd-Chiari syndrome), 698
 for hepatocellular carcinoma, 1605
 for hepatopulmonary syndrome/portopulmonary hypertension, 691
 for hepatorenal syndrome, 689
 in HIV infection/AIDS, 691, 1329
 for mushroom poisoning, 674, 1586
 for nonalcoholic fatty liver disease, 685
 for Wilson disease, 697
- Liver biochemical tests. *See also specific test*
 evaluation of, 663t, **664–665**, 664t
- Liver cell adenoma. *See* Hepatocellular adenoma
- Liver (hepatic) failure, **672–674**
 acetaminophen causing, 76, 672–673, 1570
 acute, **672–674**
 fatty liver of pregnancy and, 673, 795
 anemia in, 493
 in cirrhosis, 687
 drugs/toxins causing, 672–673, 682–684
 herpetic, 1351
 in HIV infection/AIDS, 1329
 in mushroom poisoning, 673, 674, 1585
 nefazodone causing, 1068
- Liver flukes, **1512–1513**
 Chinese, **1513**
 sheep, **1512–1513**
- Liver-kidney microsomes, antibody to, in autoimmune hepatitis, 679
- Liver-kidney transplantation, 691
- Liver spots (solar lentigines), 101, 155, 156
- Liver stiffness, in hepatic fibrosis, 685
- Livial. *See* Tibolone
- Livostin. *See* Levocabastine
- Lixivaptan, for hyponatremia/SIADH, 875
- LKB1/STK11* mutation, pancreatic/periampullary carcinoma and, 1608
- LMWH (low-molecular-weight heparin). *See* Heparin
- Loa loa* (loiasis), **1527–1528**
- Load and shift test, 1679t, 1681
- Lobectomy
 pulmonary, for lung cancer, 1599.
See also Lung resection
 thyroid, for thyroid carcinoma, 1129
- Lobular carcinoma in situ, 733, 733t
- Local anesthetics, for eye disorders, precautions for use of, **194**
- Locasamide, 972

- Locked-in syndrome (de-efferented state), **1016**
- Lodine. *See* Etodolac
- Lodoxamide, for allergic eye disease, 167, 169t
- Loeys-Dietz syndrome, aortic disorders/aneurysm in, 428
- pregnancy and, 431
- Löffler syndrome, 296
- cardiomyopathy in, 415–416
- Loiasis, **1527–1528**
- Lomustine (CCNU), 1651t
- “Lone atrial fibrillation,” 387
- Lone Star tick. *See* Ticks
- Long-acting insulin, 1213, 1214, 1214f, 1214t, 1215–1216, 1218, 1219t. *See also* Insulin therapy
- in pregnancy, 1230
- in type 2 diabetes, 1221
- Long-chain acyl coenzyme A
- dehydrogenase (LCHAD)
- deficiency, acute fatty liver of pregnancy and, 795
- Long His-ventricular interval, 395
- Long QT syndrome, **393**. *See also* QT interval, long
- palpitations and, 31
- Long-term care facility, caregiver issues related to placement in, 58–59
- Loniten. *See* Minoxidil
- Loop diuretics. *See also* Diuretics; Furosemide
- for acute tubular necrosis, 905–906
- for cirrhotic ascites, 688
- for heart failure, 401
- chronic kidney disease and, 912
- for hyperkalemia, 879, 881t, 914
- for hypernatremia, 876
- for hypertension, 445t, 446
- in chronic kidney disease, 446, 459
- in urgencies/emergencies, 463
- hypokalemia and, 401, 446, 878
- for hyponatremia, 874
- hyponatremia caused by, 872
- lithium use and, 1074
- for nephrotic syndrome/nephrotic spectrum disorders, 928
- ototoxicity of, 207
- Loop excision, for CIN, 756
- Loperamide, 577, 580, 1298. *See also* Antidiarrheal agents
- for fecal incontinence, 659–660
- for irritable bowel syndrome, 635
- microscopic colitis, 650
- ulcerative colitis, 647
- Lopid. *See* Gemfibrozil
- Lopinavir/r (lopinavir/ritonavir), 1341t, 1344, 1345, 1347, 1348f. *See also* Antiretroviral therapy/HAART
- Lopressor. *See* Metoprolol
- Loprox. *See* Ciclopirox
- Loratadine, 99
- for allergic eye disease, 167
- for allergic/perennial rhinitis, 218, 219
- for urticaria, 133
- Lorazepam, 1042, 1042t, 1043. *See also* Benzodiazepines
- for alcohol withdrawal, 974
- with antipsychotics, 1058
- for anxiety/stress disorders, 1039, 1042, 1042t, 1043
- for delirium, 1089
- for insomnia, 1043, 1076
- for nausea and vomiting, 569t, 1660
- overdose/toxicity of, 1579–1580
- for psychedelic abuse/overdose, 1084
- for seizures, 1565
- in eclampsia, 794
- status epilepticus and, 974
- Lorazepam interview, in conversion disorder, 1046
- Lorcaserin, for obesity, 14, 1261
- Lorcet. *See* Hydrocodone
- Lortab. *See* Hydrocodone
- Losartan, 451t
- for hypertension, 449, 451t
- with hydrochlorothiazide, 451t
- for Marfan syndrome, 1671
- Lotemax. *See* Loteprednol
- Lotensin/Lotensin HCT. *See* Benazepril
- Loteprednol, for ophthalmic disorders, 170t
- Lotrel. *See* Benazepril
- Louse. *See* Lice
- Lovastatin, 1246, 1253–1254, 1255t. *See also* Statin drugs
- protease inhibitor interactions and, 1344
- for thyroid cancer, 1131
- Lovenox. *See* Enoxaparin
- Low back pain, **818–821**, 820t, 821t, **1683–1685**, 1684t. *See also* Back pain
- Low birth weight infants, hypertension risk and, 436
- Low-calorie diets, in obesity management, 14, 1260
- Low-carbohydrate diets, in obesity management, 14, 1260
- Low-cholesterol diet, 1250, 1252, 1269
- in diabetes, 1205
- in nephrotic syndrome, 928
- Low-density lipoproteins/cholesterol, 1246
- atherogenesis/cardiovascular/coronary heart disease and, 8, 350, 1245, 1246, 1248, 1250
- in older patients, 1251–1252
- in women, 1251
- in diabetes mellitus, 1200, 1205, 1227
- diet affecting, 1252
- in familial hypercholesterolemia, 1245
- lowering levels of, 8–10, 1246–1247, **1252–1255**, 1255t. *See also* Lipid-lowering therapy
- target values and, 1248, 1251t, 1253
- reference values for, 1246, 1732t
- screening tests for levels of, 1248–1252, 1249–1250t, 1251t
- in women, 1251, 1706
- thiazolidinedione therapy and, 1209, 1210
- Low-dose helical computed tomography (LDCT), in lung cancer screening, 16, 289, 1599
- in women, 1709
- Low-fat diet, 1252, 1269
- in diabetes, 1202, 1203, 1204–1205
- in obesity management, 14, 1260
- for pancreatitis, 714, 716
- Low-molecular-weight heparin. *See* Heparin
- Low-protein diet. *See* Protein-restricted diet
- Low-salt diet. *See* Sodium-restricted diet
- Low-saturated-fat diet, 1252, 1269
- Low-sodium diet. *See* Sodium-restricted diet
- Low vision. *See* Visual impairment/loss
- Lower airway/respiratory tract disorders, 242–243. *See also* Pneumonia
- asthma differentiated from, 248
- Lower esophageal sphincter. *See* Esophageal sphincter, lower
- Lower extremity edema, **33–34**, 33t
- in chronic venous insufficiency, 33, 34, 481
- leg ulcers and, 33, 34, 153, 481
- Lower gastrointestinal bleeding, **583–585**. *See also* Gastrointestinal bleeding
- Lower leg/foot arteries
- aneurysm of, 475–476
- atherosclerotic/occlusive disease of, **466–468**
- leg ulcers and, 153–155, 154f, 467
- osteomyelitis and, 154, 862
- Lower motor neuron lesions. *See also* Motor neuron diseases
- weakness in, 977
- LOX. *See* Liquid oxygen systems
- Loxapine, 1056, 1056t, 1057t
- Loxitane. *See* Loxapine
- Loxosceles laeta/reclusa* (brown recluse spider), 149, 1590
- Loxoscelism, 149
- Lozol. *See* Indapamide
- LRRK2 gene, in parkinsonism, 998
- LSD, 1084, **1583**
- Lubiprostone, 571, 572t
- for irritable bowel syndrome, 635
- LubriDerm, 99t
- Ludomil. *See* Maprotiline
- Ludwig angina, 230, 230–231
- Lues maligna, 1471
- Lumbar motion, Schober test of, 820
- Lumbar puncture. *See also* Cerebrospinal fluid analysis
- in CNS infections, 1287–1288
- headache after, 966
- in headache evaluation, 42
- herniation syndromes and, 982, 984, 991, 1015, 1287
- in intracranial tumors, 991
- in Lyme disease, 1481
- for pseudotumor cerebri, 995
- in syphilis, indications for, 1472–1473
- Lumbar spine/disk disease. *See also* Spine back pain and, 820, 820t, 1685–1686
- herniated disk, 820, 820t, **1685–1686**
- stenosis, **822**, **1685**
- tuberculosis (Pott disease), 863
- Lumbosacral plexus lesions, **1032**
- Lumefantrine-artemether (Coartem/Riamet), 1492t, 1493t, 1494t, 1496, 1497
- Lumigan. *See* Bimatoprost

- Luminal gastrointestinal tract dysfunction, 564
- Luminous hallucinations. *See also* Hallucinations
in migraine headache, 963
- Lump (breast), 726–727, 726f, 727f, 1717–1719. *See also* Breast cancer
detection/evaluation of, 15t, 718, 721, 724–725, 1708, 1718–1719
biopsy in, 718, 721, 727–729, 728f, 729f, 1718, 1719
pregnancy and, 807
clinical examination in, 15t, 724, 726–727, 726f, 727f, 1718
cytology in, 730
mammography in, 15t, 16, 718, 724, 724–725, 727, 728f, 729, 1708, 1718, 1718–1719
biopsy and, 729
pregnancy and, 730, 807, 1718
in pregnant patient, 730, 807, 1718
self-examination in, 15t, 724
ultrasonography in, 718, 727, 728f, 729, 1718
differential diagnosis of, 1718
fat necrosis causing, 720–721
fibroadenoma, 719–720, 1718
in fibrocystic condition, 718–719, 1718, 1719
in male, 746
removal of. *See* Lumpectomy
- Lumpectomy, 735
genetic mutations for breast cancer and, 723
local recurrence and, 744
for noninvasive (ductal/lobular) carcinoma, 733
for phyllodes tumor, 719
- Lunesta. *See* Eszopiclone
- Lung. *See also under* Pulmonary and Respiratory
abscess of, 278–279
in coccidioidomycosis, 1532
aspergilloma of, 1537
cancer of. *See* Lung cancer
in chronic kidney disease/uremia, 909t, 910
collapse of. *See* Atelectasis
fibrosis of. *See* Pulmonary fibrosis
hydatid cyst of, 1516
radiation injury of, 311–312
toxic/chemical injury of, 311
aspiration and, 308
smoke inhalation and, 307
- Lung biopsy
in granulomatosis with polyangiitis, 849
hemoptysis caused by, 27
in interstitial (diffuse parenchymal) lung disease, 293, 293–295
in lung cancer, 1597
in mesothelioma, 1602
in *Pneumocystis pneumonia*, 279, 1534
in pulmonary alveolar proteinosis, 296
in pulmonary infiltrates in immunocompromised host, 279
in sarcoidosis, 296
in solitary pulmonary nodule, 290
in tuberculosis, 281
- Lung cancer, 1595–1603, 1598t, 1610t
adenocarcinoma, 1595
in situ (bronchioloalveolar cell), 1595
asbestosis and, 309, 311, 1595, 1602
bronchioloalveolar cell (adenocarcinoma in situ), 1595
bronchogenic carcinoma, 1595–1601, 1598t
chemical carcinogens and, 311, 1595
cough in, 21–22, 1597
granulomatosis with polyangiitis differentiated from, 850, 1601
hemoptysis in, 26, 27, 1597
hoarseness and, 233, 1597
incidence/risk/mortality of, 1594t, 1595, 1597, 1598t
large cell, 1595–1597
mesothelioma, 311, 1602–1603
metastatic, 1601–1602
myasthenic syndrome in, 1596t
non–small cell, 1596t, 1597, 1610t
occupational exposures and, 311
palliative therapy for, 1599, 1600
paraneoplastic syndromes associated with, 994, 995, 1596t, 1597
pleural effusion in, 314t, 315, 1597
prevention of/screening for, 16, 289–290, 1599
in women, 1709–1710
prognosis for, 1600
pulmonary function testing in, 1598–1599
small cell, 1596t, 1597, 1611t
smoking/smoking cessation and, 6, 1593, 1595
as co-carcinogen, 311
screening and, 289, 1599
in women, 1709
- solitary pulmonary nodule and, 290–291, 1601
squamous cell carcinoma, 1595
staging of, 1597–1598, 1598t
superior vena caval obstruction in, 482, 1597
survival rates for, 1595, 1597, 1598t
treatment of, 1599–1601, 1610t
- Lung capacity, total (TLC). *See also* Pulmonary function tests
in COPD, 261
in cystic fibrosis, 267
- Lung flukes (*Paragonimus*), 1513
- Lung injury, acute, transfusion-related, 536
- Lung resection, for lung cancer, 1599
metastatic disease and, 1601–1602
pulmonary function testing and, 1598–1599
staging and, 1597, 1598, 1599
- Lung scanning
in cor pulmonale, 426
in pulmonary embolism, 299–300, 300, 302t
chest pain evaluation and, 29
in pulmonary hypertension, 305, 424
- Lung sounds. *See* Breath sounds
- Lung transplantation
adenovirus infection and, 1402
CMV infection and, 1364
for COPD, 264–265
for cystic fibrosis, 268
for pulmonary hypertension, 306, 425
- Lung volume reduction surgery (LVRS), for COPD, 265
- Lung volumes. *See also* Pulmonary function tests
in COPD, 260–261
- Lungworm, rat (*A cantonensis*), 1522
- Lupron. *See* Leuprolide
- Lupus anticoagulant, 554, 833–834
in antiphospholipid antibody syndrome, 799, 836
pregnancy loss and, 789, 799
in SLE, 833–834, 834t
- Lupus cerebritis, 834
- Lupus erythematosus
autoantibodies in, 114
discoid/subacute (chronic cutaneous), 114–115
drug-related, 114, 159t, 312t, 832, 832t
photosensitivity and, 114, 153
systemic, 831–835, 832t, 833t, 834t. *See also* Systemic lupus erythematosus
- Lupus nephritis, 833, 834, 835, 919t, 921f, 926–927
- Lupus panniculitis, 150
- Lupus pernio, 295, 295f
- Lurasidone, 1055, 1056t, 1057t, 1058, 1060t
- Luteinizing hormone (LH)
in amenorrhea, 1163, 1180, 1181
deficiency of, 1093, 1094, 1173–1174. *See also* Hypogonadism
gynecomastia and, 1178
in hirsutism/virilization, 1163
in hypogonadism, 1093, 1094, 1173–1175, 1173t, 1175
in infertility workup, 768, 955
in menopause, 779
in polycystic ovary syndrome, 765, 1162, 1163
reference values for, 1732t
- Luteinizing hormone-releasing hormone (LHRH) analogs
in cancer chemotherapy, 1657t
for prostate cancer, 1636, 1637t
- Luteinizing hormone-releasing hormone (LHRH) antagonist, 1657t
for prostate cancer, 1636, 1637t
- Luteoma of pregnancy, 1162
- Luvox. *See* Fluvoxamine
- IVEDP. *See* Left ventricular end-diastolic pressure
- IVRS. *See* Lung volume reduction surgery
- Lyme disease (Lyme borreliosis), 240, 1300t, 1478–1483, 1482t
anaplasmosis/ehrlichiosis and, 1415
arthritis in, 1479, 1482, 1482t
rheumatoid arthritis differentiated from, 828
babesiosis and, 1481, 1499
chronic (post-Lyme disease syndrome), 1482t
coinfections and, 1415, 1481
congenital, 1481

- Lyme disease (*Cont.*):
 diagnosis/overdiagnosis of, 1479–1481, 1482
 erythema migrans in, 135–136, 135f, 1478, 1479, 1481, 1482t
 facial palsy and, 1028f, 1479, 1481, 1482t
 head and neck symptoms in, 240
 myopericarditis in, 419, 1479, 1481–1482, 1482t
 neuropathy associated with, 1023, 1479
 during pregnancy, 1481, 1482
 prevention of, 1481
 prognosis for, 1482
 serologic testing in, 1479–1480
 treatment of, 1481–1482, 1482t
- Lyme urinary antigen test, 1480
- Lymph nodes. *See also specific nodes and*
 Lymphadenitis;
 Lymphadenopathy
 in filariasis, 1524, 1525
 in Hodgkin lymphoma, 526
 in neck, normal, 240
- Lymphadenectomy
 selective (sentinel lymph node biopsy)
 in breast cancer, 735, 735f
 arm edema avoidance and, 744
 neoadjuvant therapy and, 738–739
 in melanoma, 102
 in testicular cancer, 1643
- Lymphadenitis, 483–484
 in cat-scratch disease, 483, 1454
 in chancroid, 1453
 in coccidioidomycosis, 1532
 in filariasis, 1525, 1525f
 histiocytic necrotizing (Kikuchi/
 Kikuchi-Fujimoto disease), 240
 mycobacterial (tuberculous and nontuberculous), 240, 1458
 in plague, 1451
- Lymphadenopathy
 in African trypanosomiasis, 1484
 in American trypanosomiasis/Chagas disease, 1487
 in cat-scratch disease, 483, 1454
 in chronic lymphocytic leukemia, 522
 in cutaneous T cell lymphoma (mycosis fungoides), 115
 dermatopathic, 115
 in exfoliative dermatitis/erythroderma, 116
 HIV, 239, 241, 1323
 eustachian tube dysfunction/serous otitis media and, 213
 in Kawasaki disease, 1417
 in leishmaniasis, 1487, 1488
 in lymphogranuloma venereum (buboes), 659, 1461
 in mononucleosis, 1361
 in non-Hodgkin lymphoma, 524, 525
 in onchocerciasis, 1526
 in pharyngitis, 228, 1420
 in plague, 1451
 reactive cervical, 240
 in syphilis, 658, 1464
 in toxoplasmosis, 1500, 1501
 in Whipple disease, 623
- Lymphangitic carcinomatosis, 1601
- Lymphangitis, 483–484, 1303t
 in filariasis, 1525
- Lymphatic channel diseases, 483–484
 in filariasis, 1525, 1525f
- Lymphatic filariasis, 1524–1525, 1525f
- Lymphedema, 484
 chronic venous insufficiency
 differentiated from, 481
 in filariasis, 1525, 1525f
 in myxedema, 1106
- Lymphoblastic lymphoma, 525
- Lymphocyte count, 1732t
- Lymphocyte transformation tests,
 autoimmune audiovestibular dysfunction and, 208
- Lymphocyte-white blood cell count ratio,
 differentiation of tonsillitis
 from mononucleosis and, 228
- Lymphocytic choriomeningitis, 1380–1381
- Lymphocytic colitis, 650
- Lymphocytic meningitis, benign
 recurrent (Mollaret meningitis), 1351
- Lymphocytosis, in chronic lymphocytic leukemia, 521, 522
- Lymphoepithelioma, nasopharyngeal, 223
- Lymphogranuloma venereum, 659, 1461
- Lymphohistiocytosis, hemophagocytic, 1359, 1363
- Lymphoma, 524–532, 524t, 1610t. *See also* Burkitt lymphoma;
 Hodgkin lymphoma; Non-Hodgkin lymphoma
 B cell. *See* B cell lymphoma
 in celiac disease/dermatitis herpetiformis, 123, 623
 cerebral, 990t
 in HIV infection/AIDS, 990t, 992–993, 1327, 1332, 1338t
 classification of, 524, 524t
 cutaneous T cell (mycosis fungoides), 115–116
 exfoliative dermatitis/erythroderma and, 116
 fever/FUO and, 1277, 1596t
 follicular, 524, 525
 stem cell transplantation for, 533
 gastric, 1618–1619
H pylori infection and, 525, 609, 1618, 1618–1619
 head and neck, 240–241
 high-grade, 525
 in HIV infection/AIDS, 241, 990t, 992–993, 1322, 1326, 1327, 1332, 1338t
 incidence/risk/mortality of, 1594t
 of kidney, 1642
 large cell (Richter syndrome), 522
 lymphoblastic, 525
 mantle cell, 522, 525
 marginal zone, 525, 1618, 1619
 methotrexate causing, 829
 mucosa-associated lymphoid tissue (MALToma)
 Crohn disease and, 643
 gastric, 525, 1618–1619
H pylori infection and, 525, 609, 1618, 1618–1619
 of thyroid, 1128, 1131, 1134
 nose and paranasal sinus involvement and, 223
 paraneoplastic syndromes associated with, 1596t
 pemphigus and, 138
 primary central nervous system, 525
 primary effusion (body cavity), 1367
 in Sjögren syndrome, 843
 small intestine, 1620
 stem cell transplantation for, 525, 526, 532
- T cell. *See* Human T cell lymphotropic/leukemia virus; T cell lymphoma
 testicular, 1642
 of thyroid, 1128, 1131, 1134
- Lymphopenia, idiopathic, 1382
- Lymphoproliferative disorder,
 posttransplant, 1277, 1362, 1363
- Lynch syndrome (hereditary nonpolyposis colon cancer/HNPCC), 656–657, 1622
 endometrial carcinoma and, 656, 657, 759
 pancreatic/periampullary carcinoma and, 1608
 small intestine adenocarcinoma in, 1620
- Lysergic acid diethylamide (LSD)LSD, 1084, 1583
- M2 inhibitors (amantadine/rimantadine),
 influenza/influenza resistance and, 23, 1354t, 1396, 1398, 1399
- M184V mutation, antiretroviral drug resistance and, 1349
- M918T gene mutation, medullary thyroid carcinoma and, 1133
- M-protein, 528
- Ma huang (ephedra), toxicity of, 1578t
- MAC (*Mycobacterium avium* complex) infections. *See* *Mycobacterium* (mycobacterial infections), *avium* complex
- Machupo virus, 1384, 1385
- Macroglobulinemia
 neuropathy associated with, 1023
 Waldenström. *See* Waldenström macroglobulinemia
- Macrolides. *See also specific agent and*
 Erythromycin
 for pharyngitis, 229, 1420
 for pneumonia, 273, 273t
 resistance to, 274
- Macrophages, in HIV infection/AIDS, 1322
- Macroprolactin/macroprolactinemia/macroprolactinoma, 1102, 1103, 1103–1104, 1104
- Macropsia, intracranial tumors causing, 990
- Macular degeneration, age-related, 180–181
- Maculopathy/macular edema
 age-related, 181
 diabetic, 185, 185f, 1223
 retinal vein occlusion causing, 182
 thiazolidinedione use and, 1210

- Mad cow disease (vCJD/bovine spongiform encephalopathy), 1381–1382, 1382
- Maddrey discriminant function index, in alcoholic liver disease, 681
- MADH4* gene
in familial juvenile polyposis, 655
pancreatic/periampullary carcinoma and, 1607
- Maduromycosis, **1540**
- Magnesium
dietary/supplementary
for hypocalcemia, 883
for hypomagnesemia, 888
for hypoparathyroidism/tetany, 1135–1136, 1137
requirements for in nutritional support, 1272
restriction of in chronic kidney disease, 888
in ventricular tachycardia, 391, 1564
disorders of concentration of, **887–888**, 887*t*. *See also* Hypermagnesemia; Hypomagnesemia
genetic disorders and, 878*t*
in hypocalcemia, 882, 883, 887
potassium balance/hypokalemia and, 878, 879, 887, 888
serum/plasma levels of
calcium serum levels and, 882, 883, 887
reference/normal values for, 887, 1732*t*
urinary excretion of, in hypomagnesemia, 888
- Magnesium-ammonium-phosphate (struvite) urinary stones, 946, 947, 949
- Magnesium chloride. *See* Magnesium, dietary/supplementary
- Magnesium citrate, for constipation/bowel cleansing, 571, 572*t*
- Magnesium hydroxide, 571, 572*t*
- Magnesium oxide. *See* Magnesium, dietary/supplementary
- Magnesium salicylate, 78*t*
choline, 77*t*
- Magnesium sulfate
for asthma, 256
for eclampsia, 794, 795
hypermagnesemia and, 794, 888
for hypomagnesemia, 888
for hypoparathyroidism/tetany, 1137
for preterm labor prevention, 796
- Magnetic resonance angiography (MRA)
in aortoiliac occlusive disease, 464
in carotid occlusive disease, 469
in peripheral artery aneurysms, 476
in renal artery stenosis/renal vascular hypertension, 437, 917
in visceral artery insufficiency, 471
- Magnetic resonance
cholangiopancreatography (MRCP), 665
in biliary stricture, 708
in biliary tract carcinoma, 1606
in liver disease/jaundice, 665
in pancreatic/periampullary carcinoma, 1608
in pancreatitis, 714, 716
in primary sclerosing cholangitis, 709
- Magnetic resonance elastography, in liver disease/cirrhosis, 687
- Magnetic resonance imaging (MRI). *See also specific disorder and Neuroimaging*
in ACL injury, 1698
for breast cancer evaluation/screening, 16, 727, 729–730, 743
in cancer-related spinal cord compression, 1644
cardiac
in angina, 354
in cardiomyopathy, 412, 412*t*, 414, 416
in constrictive pericarditis, 422
in infective myocarditis, 410
in myocardial infarction, 366
in DVT/PE (venous thromboembolic disease), 300
in liver disease/jaundice, 664, 665
in meniscal injuries, 1700
in musculoskeletal evaluation, 1673–1674
in pancreatic/periampullary carcinoma, 1608
in pancreatitis, 712–713
in pheochromocytoma/paraganglioma, 1168
in prostate cancer, 1631
in renal cell carcinoma, 1641
for rotator cuff evaluation, 1680
in seizure evaluation, 971
in thyroid cancer evaluation/surveillance, 1129
- Mahaim fibers, in preexcitation syndromes, 383
- Maisonneuve fracture, 1704
- Major depressive disorder, 1063. *See also* Depression
- Malabsorption, **621–627**, 621*t*. *See also specific disorder or cause*
bacterial overgrowth causing, **624–625**
in celiac disease, **621–623**
in Crohn disease, 643
diarrhea caused by, 574*t*, 578, 579, 579*f*, 580, 621*t*
flatus and, 573
HIV infection/AIDS, 1325, 1330
hyperoxaluric calcium nephrolithiasis and, 949
in lactase deficiency, **626–627**
in protein-losing enteropathy, 632
in scleroderma, 839
in short bowel syndrome, **625–626**
vitamin D deficiency and, 1012, 1149
in Whipple disease, **623–624**
- Malar rash
in dermatomyositis, 840, 840*f*
in SLE, 833
- Malaria, **1490–1499**
cerebral, 1491
congenital, 1490
drug resistance in, 1492, 1493, 1494, 1494*t*, 1495, 1496, 1497, 1498, 1498*t*
laboratory findings in, 1491–1492, 1491*f*
during pregnancy, 1490
treatment/chemoprophylaxis and, 787, 1498
prevention of, 1497–1498, 1498*t*. *See also* Antimalarial agents
self-treatment and, 1498
severe, 1490, 1490–1491, 1493, 1494*t*, 1497
treatment of, 1492–1497, 1492*t*, 1493*t*, 1494*t*. *See also* Antimalarial agents
nonimmune populations and, 1493
vaccine development and, 1497–1498
- Malarone (atovaquone plus proguanil), 1492*t*, 1494*t*, 1497
for chemoprophylaxis, 1497, 1498, 1498*t*
self treatment and, 1498
- Malassezia furfur*
seborrheic dermatitis in HIV caused by, 1331
tinea versicolor caused by, 113
- Malathion lotion, for pediculosis, 148
- Malathion poisoning, 1587
- Male breast
carcinoma of, **745–746**
enlargement of. *See* Gynecomastia
- Male erectile dysfunction. *See* Erectile dysfunction/impotence
- Male infertility. *See* Infertility
- Malignancy-related DIC, 545, 546
- Malignant ascites, 588, **590–591**, 1645, 1646
- Malignant effusions, **1645–1646**. *See also specific type*
- Malignant external otitis, 200–201
earache in, 200, 206
- Malignant hypertension, 460
headache in, 41
- Malignant hypertensive retinopathy, 186
- Malignant hyperthermia, 35, 1283, 1565
- Malignant melanoma. *See* Melanoma
- Malignant neoplastic disease. *See* Cancer
- Malignant pleural mesothelioma, 1602–1603
- Malingering, psychogenic nonepileptic/pseudoepileptic seizure and, 971–972
- Mallory bodies, in alcoholic liver disease, 681
- Mallory-Denk bodies, in alcoholic liver disease, 681
- Mallory-Weiss syndrome/tears, 568, 581, 582, **599–600**
- Malnutrition. *See also* Nutritional disorders
alcoholic liver disease/cirrhosis and, 680, 681, 687
in anorexia nervosa, 1262
in elderly, **69–70**
neuropathy associated with, 1023
protein–energy, **1257–1258**
- Malocclusion (dental)
earache and, 206
facial pain and, 968
- MALT lymphoma (MALToma)
Crohn disease and, 643
gastric, 525, 1618–1619
H pylori infection and, 525, 609, 1618, 1618–1619
thyroid, 1128, 1131, 1134

- Maltese crosses, 927
 Maltitol, 1205
 Mammalian target of rapamycin (mTOR) expression, in tuberous sclerosis, 996
 Mammaprint, breast cancer prognosis and, 734, 736
 Mammographic localization biopsy, 729
 Mammography, 15t, 16, 724, 724–725, 729, 1708
 breast implants and, 721
 in breast lump evaluation, 15t, 16, 718, 724, 724–725, 727, 728f, 729, 1708, 1718, 1718–1719
 computerized stereotactic guided core needle biopsy and, 729
 digital, 16, 725
 estrogen replacement therapy and, 1183
 localization biopsy and, 729
 mastalgia evaluation and, 1717
 pregnancy and, 730, 807, 1718
 Mammoplasty, augmentation. *See* Breast implants
 Mandibular advancement appliances, for snoring, 231
 Mania/manic episodes, 1062, 1063–1064, 1072–1075
 drug therapy for, 1072–1075, 1074t
 ECT for, 1071
 schizophrenia differentiated from, 1055
 sleep disorders and, 1076
 Mannitol
 for ciguatera poisoning, 1589
 hyponatremia caused by, 871f, 872, 874
 lithium interactions and, 1074t
 for liver failure, 673
 as sweetening agent, 1205
 Manometry
 anal, 660
 esophageal, 593
 in achalasia, 605
 in motility disorders, 606
Mansonella/Mansonella perstans, filariasis caused by, 1525, 1526
 Mantle cell lymphoma, 522, 525
 bone marrow/stem cell transplantation for, 525, 532
 Mantoux test, 282, 283t. *See also* Tuberculin skin test
 MAO inhibitors (MAOIs). *See* Monoamine oxidase inhibitors
 Maple bark stripper's disease, 310t
 Maprotiline, 1070t
 Marasmus/marasmus-like secondary protein–energy malnutrition, 1257–1258
 Maraviroc, 1342t, 1346, 1348f. *See also* Antiretroviral therapy/HAART
 Marburg virus/hemorrhagic fever, 1384, 1385
 Marfan syndrome, 1670–1671
 aortic disorders (dissection/aneurysm/regurgitation) in, 345, 428, 431, 474, 1670, 1671
 pregnancy and, 431
 sudden death and, 431
 mitral valve prolapse and, 340, 1670
 Marginal blepharitis, 110, 163–164
 Marginal zone lymphoma, 525, 1618, 1619, 1620
 Marijuana, 1084–1085
 for AIDS wasting, 1325
 legal issues in use of, 1325
 for nausea and vomiting, 86, 569. *See also* Dronabinol
 in pain management, 85
 MARS. *See* Molecular adsorbent recirculating system
 Mask of pregnancy, 155, 156
 Masochism, sexual, 1050
 Mast cell stabilizers/mediator inhibitors. *See also* Cromolyn; Nedocromil
 for allergic eye disease, 167, 169t
 for allergic rhinitis, 219
 for asthma, 250, 251t
 Mastalgia (breast pain), 1716–1717
 in cancer, 726, 730, 1716, 1717
 in fibrocystic condition, 718, 719, 1718, 1719
 Mastectomy, 735–736
 arm edema after, 744
 breast reconstruction/implants after, 721, 736, 744–745
 recurrence and, 721, 744
 for inflammatory carcinoma, 730
 local recurrence after, 744
 in male, 746
 for noninvasive (ductal/lobular) carcinoma, 733
 for phyllodes tumor of breast, 719
 prophylactic, 723
 Masticatory (jaw) claudication, in giant cell arteritis, 846
 Mastitis, puerperal, 721, 797–798
 candidal, 132
 Mastoideotomy, 204
 Mastoiditis, 203, 204
 Match test, in cough evaluation, 22
 Maternal age, Down syndrome and, 1666
 Maternally inherited diabetes and deafness (MIDD), 1195
 Matulane. *See* Procarbazine
 Maturity-onset diabetes of young (MODY), 1193t, 1194–1195
 hepatocellular adenoma and, 702
 Mavik. *See* Trandolapril
 Maxillary sinusitis, 215
 Maximal oxygen uptake, lung cancer surgery and, 1599
 Maxipime. *See* Cefepime
 Maxzide. *See* Triamterene, with hydrochlorothiazide
 Maze procedure, 338
 Mazindol, for obesity, 1260
 Mazzotti test, for onchocerciasis, 1527
 MC2R, familial glucocorticoid deficiency and, 1156
MC4R gene, in type 2 diabetes, 1194
 McCune-Albright syndrome, 1100, 1190
 MCH. *See* Mean corpuscular hemoglobin
 MCHC. *See* Mean corpuscular hemoglobin concentration
MCKD1/MCKD2 genes, in medullary sponge kidney, 935
 MCL. *See* Medial collateral ligament
 McMurray test, 1696t, 1700
 MCTD. *See* Mixed connective tissue disease
 MCV. *See* Mean cell/corpuscular volume
 MCV/MCV4 vaccine. *See* Meningococcal vaccine
 MDIs. *See* Metered-dose inhalers
 MDMA (methylenedioxy-methamphetamine), 1086, 1572
 hyponatremia caused by, 872, 1572
 seizures caused by, 1565t
 MDPV (methylenedioxypyrovalerone), 1572
 MDR. *See* Multidrug resistance
 MDRD (Modification of Diet and Renal Disease) equation, for GFR estimation, 901
 MDRTB. *See* Multidrug resistance, in tuberculosis
 MDS. *See* Myelodysplastic syndromes
 MDV3100, for prostate cancer, 1637
 Meal replacement diets, 1260
 “Meals on Wheels” mnemonic, 37, 37t
 Mean cell/corpuscular volume (MCV), 1732t
 alcohol use/abuse and, 1081
 in anemia classification, 490, 491t. *See also specific disorder*
 Mean corpuscular hemoglobin (MCH), 1732t
 Mean corpuscular hemoglobin concentration (MCHC), 1732t
 Measles (rubeola), 1357t, 1367–1370
 atypical, 1356t, 1367–1368
 prevention/immunization and, 1367, 1369. *See also* MMR (measles-mumps-rubella) vaccine
 Measles encephalitis, 1368, 1369
 Measles immune globulin, 1369
 Measles-mumps-rubella vaccine. *See* MMR (measles-mumps-rubella) vaccine
 Measles-mumps-rubella-varicella vaccine (MMRV), 1360, 1369, 1371
 Measles vaccine, 1367, 1369. *See also* MMR (measles-mumps-rubella) vaccine
 Meat
 bovine spongiform encephalopathy/variant Creutzfeldt-Jakob disease and, 1382
 brucellosis and, 1449
 contaminated, in sarcocystosis, 1507
 E coli gastroenteritis and, 1293, 1447
 gnathostomiasis and, 1522
 sparganosis and, 1516
 tapeworm infection and, 1514
 toxoplasmosis and, 1500, 1502
 trichinosis and, 1521, 1522
 Mebendazole
 for ascariasis, 1517
 for enterobiasis/pinworms, 1520
 for hookworm disease, 1518
 for hydatid disease, 1516
 for trichinosis, 1522
 for trichuriasis/whipworm, 1518
 Mecasermin, for Laron syndrome, 1097
 Mechanical ventilation
 for ARDS, 323
 for asthma, 258f, 259
 complications of, 321

- for COPD, 264
for near drowning, 1556
pneumonia and, 275–278, 277t, 321
for respiratory failure, 320, 321
for shock, 486
tracheotomy for, 238
withdrawal of, in end-of-life care, 91, 91t
- Mechanic's hands, 841
- Mechlorethamine, 1650t
- Meclozine, 569
- Meclofenamate, 78t
- Meclomen. *See* Meclofenamate
- Medial collateral ligament, 1692
injury of, 1695–1696t, 1698–1699
- Medial epicondylitis, 1687–1688
- Medial meniscus, 1692. *See also* Meniscal cartilage, of knee
- Median nerve compression, in carpal tunnel syndrome, 823, 1688
- Mediastinal lymph node biopsy, in lung cancer, 1597
- Mediastinal masses, 291–292
superior vena caval obstruction and, 482
- Mediastinal widening, drug-induced, 312t
- Mediastinitis
in histoplasmosis, 1532
superior vena caval obstruction and, 482
- Mediator inhibitors. *See also* Cromolyn; Nedocromil
for asthma, 250, 251t
- Medical imaging. *See also specific disorder and under* Radiation
radiation exposure and, 1554, 1555
cancer risk and, 1555, 1594
- Medical interview, 1
- Medical marijuana. *See* Marijuana
- Medication overuse headache, 966
- Medications. *See also under* Drug
adherence to regimen for, 1–2. *See also* Adherence/nonadherence
- Medicinal herbs. *See* Botanical (herbal) medicines
- Mediterranean diet, 14, 1252
- Mediterranean fever, familial, 591
- Mediterranean spotted fever, 1409t, 1414
- Medrol Dosepak. *See* Methylprednisolone
- Medroxyprogesterone
for abnormal premenopausal bleeding, 748
for contraceptive injection, 773
for endometriosis, 761
in hormone replacement therapy, 779, 1182, 1183, 1184, 1185
for postmenopausal bleeding, 749
for psychosexual disorders, 1051
- Medullary cystic kidney, 934t
- Medullary sponge kidney, 934t, 935–936
- Medulloblastoma, 990t
- Mefenamic acid, 78t
- Mefloquine, 1492t, 1494t, 1495
with artesunate, 1493t, 1495, 1496
for chemoprophylaxis, 1495, 1498, 1498t
rabies vaccination and, 1315
- MEFV gene, 591
- Megace. *See* Megestrol
- Megacolon
in Chagas disease, 1487
- toxic
acute colonic pseudo-obstruction (Ogilvie syndrome)
differentiated from, 628
in ulcerative colitis, 649
- Megaesophagus, in Chagas disease, 1487
- Megakaryocytes
in essential thrombocytosis, 513
in myelodysplastic syndromes, 518
- Megaloblastic anemia, 490, 491t
in celiac disease, 622
folic acid deficiency causing, 499, 799
subacute combined degeneration of spinal cord and, 1013
vitamin B₁₂ deficiency causing, 498
fish tapeworm infection and, 1514
- Megestrol
for AIDS wasting, 1325
for breast cancer, 740t
in cancer chemotherapy, 1657t
corticosteroid activity of, 1190
for elderly, 70
- Meglitinide analogs, for diabetes mellitus, 1206t, 1208
- Meglumine antimonate, for leishmaniasis, 1489
- Meibomian gland
abscess of (internal hordeolum), 163
inflammation of
blepharitis and, 163, 164
chalazion and, 163, 163f
- Melancholia, 1063. *See also* Depression
- Melanocortin 2 receptor (MC2R), familial glucocorticoid deficiency and, 1156
- Melanocytic nevi (normal moles), 100, 100f
- Melanoma, 102–103, 102f, 1612t
atypical nevi and, 100–101
blue nevi and, 101
familial, 101
incidence/risk/mortality of, 1594t
intraoral, 224
in MEN, 1189
pancreatic/perianipillary carcinoma and, 1608
yellow fever virus vaccine and, 1390
- Melanosis, arsenical, 155, 1575
- Melarsoprol, for African trypanosomiasis, 1485, 1485t
- MELAS syndrome, 1036
hypoparathyroidism in, 1136
- Melasma (chloasma), 155, 156
oral contraceptive use and, 155, 773
- MELD (Model for End-Stage Liver Disease) score, 691–692, 692t
in alcoholic liver disease/cirrhosis, 682, 691–692, 692t
hepatocellular carcinoma and, 1605
in liver failure, 673
postoperative complications and, 52
- Melena, 580, 584
in erosive/hemorrhagic gastritis (gastropathy), 607
in GI bleeding, 580, 584, 617
in peptic ulcer disease, 617
- Melioidosis, 1300t
- Mellaril. *See* Thioridazine
- Melody percutaneous pulmonary valve, 350
- Melphalan, 1650t
- Memantine, for dementia, 61, 1009
- Membranoproliferative
glomerulonephritis/
glomerulonephropathy, 919t, 920t, 921f, 925
hepatitis C infection and, 671, 919t, 926
idiopathic, 919t, 925
- Membranous nephropathy, 920t, 929–930
hepatitis C infection and, 671, 926
- Memory impairment. *See also* Amnesia
in dementia/delirium, 59, 60–61, 1006, 1088
ECT causing, 1071
head injury and, 1016
in mild cognitive impairment, 60–61
- MEN. *See* Multiple endocrine neoplasia
- MEN1 gene mutation, 1188
thyroid tumors and, 1127, 1189, 1190
- Menarche, 1179
age at, 1179
breast cancer risk and, 722, 723t, 1708
failure of. *See* Amenorrhea
- Mendelson syndrome, 308, 1283
- Menest, 1184
- Ménétrier disease (hypertrophic gastropathy), 610
- Ménière syndrome (endolymphatic hydrops), 208, 210, 210t
hearing loss and, 208, 210, 210t
- menin gene, in MEN 1, 1188
- Meningeal irritation, noninfectious, 1287
- Meningeal leukemia, 520
- Meningiomas, 989, 990t, 991
- Meningismus, 1287. *See also specific infection*
- Meningitis, 1302t. *See also* Meningoencephalitis
in anthrax, 1432
aseptic/viral, 1286, 1286t. *See also specific causative agent and* Aseptic meningitis
bacterial rhinosinusitis and, 216, 1442
benign recurrent lymphocytic (Mollaret), 1351
carcinomatous (leptomeningeal metastases), 992, 1287
chronic, 1285
in coccidioidomycosis, 1532, 1533
coxsackieviruses causing, 1286, 1406
cryptococcal, 993, 1327, 1338t, 1536
prophylaxis of, 1536
CSF analysis in, 1286t, 1287
echoviruses causing, 1286, 1407
in gnathostomiasis, 1523
H influenzae causing, 1442
headache in, 41, 42, 962, 966
health care-associated, 1287, 1288, 1302t
herpes simplex, 1286, 1351, 1352, 1355
in HIV infection/AIDS (cryptococcal), 993, 1327, 1338t, 1536
prophylaxis of, 1536
leptospirosis, 1286, 1477
in listeriosis, 1302t, 1434
in Lyme disease, 1023, 1286, 1479, 1481
meningococcal, 1302t, 1441–1442
prevention/immunization and, 1315, 1441–1442. *See also* Meningococcal vaccine

- Meningitis, (*Cont.*):
 in mumps, 1286, 1370, 1371
 otogenic, 205
 in paragonimiasis, 1513
 parechovirus infection causing, 1408
 in plague, 1451
 pneumococcal, 1302*t*, **1424–1425**
 prevention of. *See* Pneumococcal vaccine
 in poliomyelitis (nonparalytic), 1372, 1373
 purulent/bacterial, 1285, 1286*t*, 1288, 1302*t*
 partially treated, 1286–1287
 in strongyloidiasis, 1519
 in syphilis, 1286, 1469, 1472
 in tick-borne encephalitis, 1391
 in toxocariasis, 1523
 tuberculous, **1459–1460**
 viral. *See* Meningitis, aseptic
- Meningococcal (*Neisseria meningitidis*) infections, 1299*t*
 drug resistance and, 1442
 meningitis, 1302*t*, **1441–1442**
 prevention/immunization and. *See* Meningococcal vaccine
- Meningococcal vaccine, 1308*t*, 1309*t*, 1312*t*, 1441–1442
 adverse effects/contraindications and, 1317*t*
 in immunocompromised host/HIV infection/AIDS, 1309*t*, 1314, 1442
 pregnancy and, 1309*t*
 for travelers, 1315
- Meningococcemia, 1357*t*, 1441
 adrenal crisis and (Waterhouse-Friderichsen syndrome), 1154
- Meningoencephalitis, 1286*t*. *See also* Encephalitis; Meningitis
 acanthamoeba, 1287, 1505–1506, 1506
 in African trypanosomiasis, 1484, 1485
 amebic, 1287, **1505–1506**
 in American trypanosomiasis/Chagas disease, 1486
 in angiostrongyliasis, 1522
 in gnathostomiasis, 1523
 travel and, 1297
- Meningomyeloencephalitis, enterovirus 68 causing, 1408
- Meningovascular syphilis, 1472. *See also* Neurosyphilis
- Meniscal cartilage, of knee, 1692, 1700
 injuries/tears of, 1696–1697*t*, **1700**
- Menopause/menopausal syndrome, **779–780, 1180–1186**
 age at
 average, 779, 1181
 breast cancer risk and, 722, 723*t*
 amenorrhea in, 1180, 1181
 early, 1181
 estrogen replacement therapy for. *See* Estrogen (hormone) replacement therapy
 libido and, 1050
 osteoporosis and, 779, 780, 1145, 1145*t*, 1146, 1147, 1181, 1710
 premature, 779, 1181. *See also* Ovarian failure
- surgical, 779, 780, 1181
 vaginal bleeding after. *See* Postmenopausal vaginal bleeding
- Menorrhagia, 747, 748
 iron deficiency anemia and, 490–491, 747
 IUD use and, 774
- Menostar, 1184
- Menstruation/menstrual cycle, 747. *See also* Vaginal bleeding
 abnormalities of, in polycystic ovary syndrome, 765, 766, 1162
 age of onset of, breast cancer risk and, 722, 723*t*, 1708
 asthma associated with (catamenial asthma), 243
 breast pain and, 1716
 cessation of, 779. *See also* Amenorrhea; Menopause
 depression associated with, 749, 1063
 failure to appear. *See* Amenorrhea
 in female athlete triad, 1712
 iron deficiency anemia and, 490–491, 747
 pain associated with. *See* Dysmenorrhea
 pneumothorax associated with (catamenial pneumothorax), 316
- Mental retardation
 in Down syndrome, 1666
 fragile X, **1667**
 in homocystinuria, 1669
 in Klinefelter syndrome, 1174, 1669
 in tuberous sclerosis, 996
- Mental status, altered. *See also* Cognitive disorders
 in chronic kidney disease/uremia, 910
 head injury and, 1016, 1017
 headache and, 42, 963
- Mentax. *See* Butenafine
- Mepacrine. *See* Quinacrine
- Meperidine, 81*t*
 MAOI interactions and, 1071*t*, 1585
 overdose/toxicity of, 1586–1587
- Mephedrone, toxicity of, 1583
- Meralgia paresthetica, **1027**
- Mercaptopurine, 1651*t*
 for inflammatory bowel disease, 639
 Crohn disease, 644
 ulcerative colitis, 649
- Mercury, allergy to, lichen planus-like lesions and, 144
- Mercury poisoning, 1566*t*, **1583–1584**
 marijuana use and, 1085
- Merlin gene, in neurofibromatosis, 996
- Meropenem
 for anaerobic abdominal infections, 1455*t*
 for pneumonia, 273*t*
- Merrem. *See* Meropenem
- MERRF syndrome, 1036
- Mesalamine, for inflammatory bowel disease, 638, 639
 Crohn disease, 642, 644
 ulcerative colitis, 647, 647–648, 649
- Mescaline, 1084, 1583
- Mesenchymal tumors
 gastrointestinal, **1619–1620**
 small intestine and, 1622
 osteomalacia/rickets and, 1150
- Mesenteric adenitis, adenoviruses causing, 1402
- Mesenteric ischemia/mesenteric artery occlusive disease, **470–471**
- Mesenteric vascular insufficiency, nonocclusive, 470
- Mesenteric vasculitis, 847
- Mesenteric vein occlusion, 471
- Mesna, for hemorrhagic cystitis, 1658*t*, 1661
 Mesnex. *See* Mesna
- Mesothelin-related peptide, in mesothelioma, 1602
- Mesothelioma, 311, **591, 1602–1603, 1611*t***
 asbestos exposure and, 311, 591, 1602
- Metabolic acidosis, 889, 889*t*, **890–894, 890*t*, 892*t***. *See also* specific type
 anion gap. *See* Anion gap/anion gap acidosis
 dyspnea and, 24
 in hypothermia, 1544, 1545
 in kidney disease/renal failure, 892, 892*t*, 893, 893–894, 914
 in near drowning, 1556
 nephrolithiasis and, 892
 hypocitratric calcium
 nephrolithiasis, 949
 parenteral nutritional support and, 893, 1274*t*
 in poisoning/drug overdose, 891, 1569
 with methanol or ethylene glycol, 877, 891, 1584
 with salicylates, 891, 1588
 posthypocapnia, 893, 897
- Metabolic alkalosis, 889, 889*t*, **894–895, 894*t***
 alcoholic ketoacidosis and, 891, 893
 posthypercapnia, 895, 896
 saline-responsive, 894, 894–895, 894*t*
 saline-unresponsive, 894, 894*t*, 895
- Metabolic bone disease, **1144–1153**. *See also* specific disorder
 in chronic kidney disease (renal osteodystrophy), 912–913, 912*f*, 1139, 1141, 1144
- Metabolic disturbances
 antipsychotic drug use and, 1059
 cognitive disorders/delirium caused by, 1087*t*
 coma or stupor caused by, 1014, **1015**
 dysphagia in, 592*t*
 neuropathies associated with, **1022–1023**
 nutritional support and, 893, 1273, 1274–1275, 1274*t*
 in pheochromocytoma/paraganglioma, 1168*t*
 seizures caused by, 969
- Metabolic encephalopathy
 cancer-related, 994
 coma or stupor caused by, 1015
- Metabolic syndrome (syndrome X/insulin resistance syndrome), 13–14, 350, 1196
- acne and, 126
 cholelithiasis/gallstones and, 703

- coronary heart disease/angina and, 350, 351, 360
- diabetes and, 1196
- dyslipidemia in, 1196, 1200–1201
- fatty liver and, 684
- hepatocellular carcinoma and, 1604
- hypertension and, 436, 1196
- hypophosphatemia and, 885
- obesity and, 13, 350, 1259
- psoriasis and, 108
- Metacercariae. *See* Cercariae/metacercariae
- Metaglip. *See* Glipizide, with metformin
- Metagonimus* species, 1513
- Metal amalgams, allergy to, lichen planus-like lesions and, 144
- Metanephries
- in pheochromocytoma/paraganglioma, 1167, 1170
 - reference values for, 1732t, 1733t
- Metapneumovirus, human, 1393, 1394
- Metastrom. *See* Strontium
- Metered-dose inhalers
- for asthma therapy, 250, 254t, 255, 256, 257f
 - for COPD therapy, 262, 264
- Metformin
- antipsychotic drug-related weight gain and, 1059
 - for diabetes mellitus, 1202, 1203, 1206t, 1208–1209, 1220
 - in combination preparations/regimens, 1209, 1213
 - with insulin, 1221
 - intensive therapy with, 1202, 1203
 - pancreatic/periampullary carcinoma and, 1607
 - in pregnancy, 801
 - prevention and, 1202
 - for hirsutism/virilization, 1163
 - lactic acidosis caused by, 914, 1209, 1237, 1580
 - overdose/toxicity of, 1209, 1580
- Methacholine bronchial provocation testing, in asthma, 246–247
- Metadone, 79, 81t, 1083–1084
- for heroin withdrawal/maintenance, 1083–1084, 1084
 - hypogonadism caused by, 1096
 - overdose/toxicity of, 1586–1587
 - for pain management, 79, 81t
- Methamphetamine, 18, 1085, 1572
- Methanol poisoning, 1566t, 1569t, 1584
- anion gap/osmolar gap in, 877, 891, 1569, 1569t, 1584
 - ethanol for, 1566t, 1584
 - hemodialysis for, 1568t, 1584
- Methcathinone, 1572
- Methemalbuminemia, in hemolytic anemia, 500
- Methemoglobinemia, 1569t, 1584–1585
- reference values in, 1733t
- Methicillin-resistant *S aureus* (MRSA) infections, 5, 1299t. *See also* Community-associated methicillin-resistant *S aureus*
- arthritis, 858, 859
 - cellulitis, 137
 - community-acquired pneumonia, 273, 273t
 - endocarditis and, 1439
 - furunculosis, 151
 - in HIV infection/AIDS, 1331
 - impetigo, 123
 - in mastitis, 798
 - skin/soft tissue infections, 1425, 1425f, 1426
 - surgical site infection, 56
- Methimazole
- autoimmune hypoglycemia and, 1243
 - for hyperthyroidism/Graves disease, 1114–1115, 1115
 - amiodarone-induced, 1117
 - during pregnancy/lactation, 800, 1117
 - RAI therapy and, 1115
 - thyroid crisis/storm and, 1118
 - toxic multinodular goiter and, 1116
 - toxic solitary thyroid nodule and, 1116
- Methionine, in homocystinuria/ hyperhomocysteinemia, 1668, 1669
- Methotrexate, 1651t, 1661–1662, 1723t
- breastfeeding and, 782t
 - for ectopic pregnancy, 790
 - for elective abortion, 776
 - with folinic acid/leucovorin rescue, 829, 1658t, 1661, 1662
 - for gestational trophoblastic disease, 792
 - for granulomatosis with polyangiitis, 850
 - for inflammatory bowel disease, 639
 - Crohn disease, 639, 644
 - for psoriasis/psoriatic arthritis, 107, 856
 - for rheumatoid arthritis, 829
 - in combination regimen, 831
 - toxicity of, 829, 1651t, 1661–1662
- Methyl alcohol. *See* Methanol
- Methyl salicylate. *See also* Salicylates
- overdose/toxicity of, 1588–1589
- Methylcellulose, 572t. *See also* Fiber, dietary
- Methylcobalamin, 497. *See also* Vitamin B₁₂
- Methyldopa, 456t
- antidepressant drug interactions and, 1071t
 - breastfeeding and, 782t
 - for hypertension, 453, 456t
 - during pregnancy, 453, 802
 - lithium interactions and, 1074t
 - MAOI interactions and, 1071t
 - overdose/toxicity of, 453, 456t, 1577
- Methylene blue, for methemoglobinemia, 1584–1585
- Methylene tetrahydrofolate reductase homocysteine levels and, 1668–1669
- pancreatic/periampullary carcinoma and, 1608
- Methylenedioxymethamphetamine. *See* MDMA
- Methylenedioxypyrovalerone (MDPV), 1572
- Methylmalonic acid
- reference values for, 1733t
 - in vitamin B₁₂ deficiency, 498
- Methylnaltrexone, for opioid-induced constipation, 86, 572
- Methylphenidate
- abuse/overdose of, 1085
 - for depression, 1066–1067
 - for fatigue, 40, 86
 - for opioid-induced sedation, 79
- 1-Methyl-4-phenyl-1,2,5,6-tetrahydropyridine, parkinsonism caused by, 998
- Methylprednisolone, 1190t. *See also* Corticosteroids
- for alcoholic liver disease, 681
 - for allergic contact dermatitis, inappropriateness of, 125
 - for asthma, 251t, 254t, 255, 255t
 - for inflammatory bowel disease, 639
 - Crohn disease, 644
 - ulcerative colitis, 648
 - for nausea and vomiting, 568t
- 4-Methylpyrazole. *See* Fomepizole
- Methyltestosterone, 1176, 1185
- Methylxanthines, for asthma, 252t, 255
- Metipranolol, for glaucoma/ocular hypertension, 171t, 176
- Metoclopramide
- for diabetic autonomic neuropathy, 1226
 - for dyspepsia, 566
 - for gastroparesis, 629
 - for migraine headache, 964
 - for nausea and vomiting, 84, 86, 568t
 - tardive dyskinesia and, 566, 629
- Metolazone
- for acute tubular necrosis, 906
 - for heart failure, 401
 - for hypertension, 445t
- Metoprolol, 447t
- for acute coronary syndromes, 363
 - for arrhythmias, 378t
 - atrial fibrillation, 372, 386
 - infarct-related, 372
 - supraventricular tachycardia, 378t, 382
 - for heart failure, 403
 - for hypertension, 447t
 - for myocardial infarction, 370
 - perioperative, 47
 - for pheochromocytoma, 1170
- Metritis, 798, 804. *See also* Endometritis
- Metronidazole
- for amebiasis, 1504, 1505t
 - for anaerobic abdominal infections, 1455, 1455t
 - for anaerobic pneumonia/lung abscess, 279, 1455
 - for antibiotic-associated colitis, 637
 - for bacterial vaginosis, 753
 - for Crohn disease, 642, 644
 - for giardiasis, 1509
 - in *H pylori* eradication therapy, 613, 614t
 - for hepatic encephalopathy, 690
 - for leg ulcers, 154
 - for rosacea, 128–129
 - for trichomoniasis, 753, 1510
- Metyrapone, for ACTH-secreting adrenal tumor/adrenocortical carcinoma, 1160
- Metyrosine, for pheochromocytoma/paraganglioma, 1171
- Mevacor. *See* Lovastatin

- Mexiletine, 377, 378t
 MF59, in CMV vaccine, 1366
 Mg. *See* Magnesium
 MGUS. *See* Monoclonal gammopathy, of unknown significance
 MHA-TP test, 1466, 1466t
 MI. *See* Myocardial infarction
 Mi-2 antibody, in polymyositis/dermatomyositis, 841
 Miacalcin. *See* Calcitonin
 MIC (minimal inhibitory concentration), 1301t
 Micafungin, 1542, 1542t
 for aspergillosis, 1538
 for candidiasis, 1530
 Micardis/Micardis HCT. *See* Telmisartan
 Mice
 lymphocytic choriomeningitis transmission and, 1380
 rickettsialpox transmission and, 1413
 MICE mnemonic, in musculoskeletal injuries, 1674
 ankle sprains, 1703
 Miconazole, 97t
 for vulvovaginal candidiasis, 752, 1530
 Micro-Coombs test. *See* Coombs test
 Microalbuminuria, in diabetes/diabetic nephropathy, 931, 1224
 glycemic control and, 931, 1201, 1224
 Microangiopathic hemolytic anemias, **508**
 thrombotic microangiopathies and, 508, 542, 543, 543t
 Microangiopathy
 in diabetes mellitus, 1227
 thrombotic, **542–544**, 543t
 Microbes. *See* Infection/infectious diseases
 Microchimerism, in painless postpartum thyroiditis, 1120
 Microdilution plates, for drug susceptibility testing, 1304
 β_2 -Microglobulin
 in amyloidosis, 531
 in myeloma staging, 529
 reference values for, 1727t
 Microide. *See* Hydrochlorothiazide
 Microlithiasis (biliary sludge), 703
 pancreatitis and, 711
 Micronase. *See* Glyburide
 Micronor. *See* Norethindrone
 Microprolactinoma, 1102, 1103, 1104
 Micropsia, intracranial tumors causing, 990
 Microsatellite instability
 in colorectal cancer, 653, 656, 1622
 in HNPCC, 656, 657
 Microscopic colitis, 574t, 578, **650**
 Microscopic polyangiitis, **850–851**
 autoantibodies in, 851
 glomerulonephritis and, 851, 907, 921f, 924
 granulomatosis with polyangiitis differentiated from, 850, 851
 Microscopic urinalysis, 898
 Microsporidiosis, 1330, **1506–1508**. *See also specific causative organism*
Microsporium infection, tinea corporis/circinata caused by, 110, 111
 Microwave hyperthermia, for benign prostatic hyperplasia, 961
 Micturition. *See* Voiding
 Midamor. *See* Amiloride
 Midazolam, 1042t, 1043
 for delirium, 86
 for seizures, 1565
 status epilepticus and, 974
 MIDD. *See* Maternally inherited diabetes and deafness
 Middle cerebral artery occlusion, in stroke, 981
 Middle ear, **203–206**
 infection of. *See* Otitis, media
 neoplasia of, **206**
 trauma to, **205**, 206f
 Midline malignant reticulosis, 223
 Midodrine, for autonomic dysfunction/diabetic neuropathy, 1021, 1226
 Mifepristone (RU 486)
 for elective abortion, 776
 clostridial infection after, 777, 1429
 for psychotic depression, 1066
 Miglitol, 1206t, 1210, 1211
 overdose/toxicity of, 1211, 1580
 Miglustat, for Gaucher disease, 1668
 Migraine equivalent, 963
 Migraine headache, 41, 41t, 42, 962, **962–966**, 965t
 acupuncture for, 965
 nausea and vomiting in, 41, 41t, 567t, 962
 oral contraceptive use and, 772
 in patent foramen ovale, 329
 prophylactic treatment of, 964–965, 964t
 transient ischemic attacks differentiated from, 978
 vertigo/dizziness and, 210t, 212
 Migrainous vertigo, 210t, 212
 Milan criteria, 1605
 Mild cognitive impairment, 60–61, 1005, 1006
 Miliaria, **130–131**
 crystallina/pustulosa/rubra, 131
 Milk-alkali syndrome, 883, 884, 895
 Milk intolerance. *See* Lactose (milk) intolerance
 Milk thistle (silymarin), for mushroom poisoning, 673, 1585
 Milker's nodules (paravaccinia), 1404
 Miller Fisher syndrome, 1025
 poliomyelitis and, 1373
 Millitary tuberculosis, 282
 Milrinone, for heart failure, 405
 Miltefosine, for leishmaniasis, 1489
 Milwaukee protocol, 1376, 1377
 Mineral oil
 for constipation, 572t
 as skin emollient, 94
 Mineral oil enema, 572t
 Mineralocorticoids. *See also* Aldosterone
 apparent excess of
 genetic mutation and, 437, 878t
 hypertension and, 437
 deficiency of. *See also* Adrenocortical insufficiency
 hyperkalemia and, 879
 steroidogenic enzyme defects and, 1156, 1162
 in metabolic alkalosis, 895
 Minerals
 chronic kidney disease/renal osteodystrophy and, 912–913, 912f
 requirements for in nutritional support, 1272
 “Mini-cog” screening, in dementia, 60
 Mini-Mental State Examination, in dementia, 1006, 1088
 self neglect and, 73
 Minilaparotomy, for tubal ligation, 777
 Minimal change disease, 920t, **928–929**
 Minimal inhibitory concentration (MIC), 1301t
 Minimally conscious state, **1016**
 Minimally invasive prostate surgery, for benign prostatic hyperplasia, 961
 Minipill (progestin), 772t, 773
 Minipress. *See* Prazosin
 Minnesota tube, for esophageal varices, 603
 Minocycline
 for acne, 127
 adverse ophthalmic effects of, 197t
 for rheumatoid arthritis, 830
 for rosacea, 129
 Minoxidil, 456t
 for androgenetic (pattern) baldness, 156, 1164
 in women, 156, 1720
 for hypertension, 453, 456t
 hypertrichosis caused by, 1164, 1720
 lower extremity edema caused by, 33
 Miotics, for glaucoma/ocular hypertension, 171t
 Miralax. *See* Polyethylene glycol
 Mirena IUD, 773–774, 1185
 Mirizzi syndrome, 705
 Mirtazapine, 1067, 1068, 1070t
 in elderly, 63
 Miscarriage. *See* Abortion
 Mismatch repair gene defects, in colorectal cancer/HNPCC, 653, 656
 Misolastine, for allergic/perennial rhinitis, 219
 Misoprostol
 for elective abortion, 776
 for IUD insertion, 774
 for missed abortion, 789
 for peptic ulcer disease/NSAID toxicity mitigation, 613, 616, 828–829
 Missed abortion, 788, 788–789
 Mistreatment (elder), 17, **72–73**, 73t
 Mitchell-Riley syndrome, 1195
 Mites
 atopic dermatitis and, 103
 bird and rodent, 149
 rickettsialpox and, 1409t, 1413
 scrub typhus and, 1409t, 1411
 skin lesions and, 149
 in stored products, 149
 trombiculid, 149
 Mithramycin, for cancer-related hypercalcemia, 1647
 Mitiglinide, 1206t, 1208
 Mitochondrial DNA mutations
 in diabetes mellitus, 1195
 hearing loss and, 207, 1195

- hypoparathyroidism and, 1136
myopathies associated with, **1036**
- Mitomycin, 1656*t*
for bladder cancer, 1639
- Mitotane
for ACTH-secreting adrenal tumor/
adrenocortical carcinoma,
1160, 1161
hypothyroidism caused by, 1093
- Mitoxantrone, 1656*t*
- Mitral clips, for mitral valve prolapse, 341
- Mitral regurgitation/insufficiency, 333,
334–336*t*, **339–340**, 349
interventions affecting murmur in,
337*t*
in Kawasaki syndrome, 1417
mitral valve prolapse and, 339, 340–341
in myocardial infarction, 339, 340, 366
preoperative evaluation/perioperative
management and, 49
secondary, 340
- Mitral stenosis, 333, 334–336*t*, **337–338**
pregnancy and, 338
preoperative evaluation/perioperative
management and, 49
- Mitral valve
parachute, 337
repair of, 349
replacement of, 338, 340, 349. *See also*
Valve replacement
in rheumatic fever/heart disease, 337,
417
- Mitral valve prolapse (“floppy”/
myxomatous mitral valve),
333, **340–341**, 349
interventions affecting murmur in,
337*t*, 341
in Marfan syndrome, 340, 1670
mitral regurgitation and, 339, 340–341
panic disorder and, 1041
in polycystic kidney disease, 935
- Mitral valve rupture, 428
- Mittelschmerz
appendicitis differentiated from, 631
in symptothermal natural family
planning, 775
- Mixed acid-base disorders, **889–890**
alcoholic ketoacidosis and, 891
step-by-step analysis and, 889
- Mixed connective tissue disease, **842**
- Mixed sleep apnea, 318
- MLH1* gene, in colorectal cancer/
HNPCC, 653, 656, 1622
- MLL* gene, in acute lymphoblastic
leukemia, 519
- MMR (measles-mumps-rubella) vaccine,
1308*t*, 1309*t*, 1311*t*, 1369,
1371, 1375
adverse effects/contraindications and,
1317*t*, 1369, 1375
arthritis and, 861, 1375
encephalitis and, 1368
in immunocompromised host/HIV
infection/AIDS, 4, 5, 1309*t*,
1314, 1335, 1369
pregnancy and, 1309*t*, 1369, 1375
- MMRV (measles-mumps-rubella-
varicella) vaccine, 1360,
1369, 1371
- MMSE. *See* Mini-Mental State
Examination
- Moban. *See* Molindone
- Mobility, reduced. *See* Immobility
- Mobitz type I (Wenckebach)
atrioventricular block, 394,
394–395
in myocardial infarction, 373
- Mobitz type II atrioventricular block,
394, 395
in myocardial infarction, 373
- MoCA®
in dementia screening, 60
self neglect and, 73
- Moclobemide, overdose/toxicity of, 1585
- Modafinil
for cognitive decline in cancer
survivors, 744
for fatigue, 86
in multiple sclerosis, 1011
for sleep disorders, 1077
- Model for End-Stage Liver Disease
(MELD) score, 691–692, 692*t*
in alcoholic liver disease/cirrhosis, 682,
691–692, 692*t*
hepatocellular carcinoma and, 1605
in liver failure, 673
postoperative complications and, 52
- Modification of Diet and Renal Disease
(MDRD) equation, for GFR
estimation, 901
- Modified Duke criteria, for endocarditis,
1436–1437
- Modified McMurray test, 1697*t*, 1700
- Moduretic. *See* Amiloride, for
hypertension, with
hydrochlorothiazide
- MODY. *See* Maturity-onset diabetes of
young
- Moexipril, 450*t*
with hydrochlorothiazide, 450*t*
- Mohs surgery
for basal cell carcinoma, 142
for eyelid tumors, 164
for squamous cell carcinoma, 143
- Moisturizers (skin)/emollients, 94, 98–99*t*
- Molar pregnancy. *See* Hydatidiform mole
- Molds, opportunistic infections caused
by, 1281, **1540–1541**
- Mole, hydatidiform. *See* Hydatidiform
mole
- Mole (skin). *See also* Nevi
atypical (atypical nevus), **100–101**, 100*f*
benign, 100, 100*f*
changes in, melanoma and, 102
normal, **100**, 100*f*
- Molecular adsorbent recirculating system
(MARS)
for hepatorenal syndrome, 689
for liver failure, 673
for Wilson disease, 697
- Molindone, 1056
- Mollaret meningitis, 1351
- Molluscum contagiosum, **141–142**, 141*f*,
1404
in HIV infection/AIDS, 141, 142, 1331,
1404
- Mometasone
inhaled, for asthma, 253*t*
intranasal, for allergic rhinitis, 218
topical, for dermatologic disorders, 96*t*
- Monge disease, 1559
- Monkeypox, 1404
- Monoamine oxidase inhibitors (MAOIs),
1069, 1069*t*, 1070*t*
drug/food interactions of, 1000, 1069,
1069*t*, 1071*t*, 1585
serotonin syndrome and, 1067, 1565,
1585
overdose/toxicity of, 1069, 1070*t*, **1585**
ophthalmic effects and, 196*t*
for parkinsonism, 1000
for phobic disorder, 1044
- Monoclonal antibodies
in cancer chemotherapy, 1653–1654*t*
in new-onset type 1 diabetes, 1202
in progressive multifocal
leukoencephalopathy, 1383
for psoriasis, 108
- Monoclonal gammopathy
motor syndromes in, 1020
of unknown significance (MGUS), 528,
529
amyloidosis and, 531
- Monoclonal protein. *See also* Paraproteins
in myeloma, 527–528, 528, 936
in Waldenström macroglobulinemia,
529, 530
- Monocular blindness, transient, **184**, 469
- Monocyte count, 1733*t*
- Monocytic ehrlichiosis, 1409*t*, 1414–1415
- Monomethylhydrazine mushroom
poisoning, 1585–1586, 1586*t*
- Mononeuritis multiplex, **1021–1026**. *See also*
Neuropathies
in diabetes mellitus, 1225
in HIV infection/AIDS, 1023
in Lyme disease, 1479
microscopic polyangitis and, 851
polyarteritis nodosa and, 847, 1024
- Mononeuropathies, 1020, **1026–1029**. *See also*
Mononeuritis multiplex;
Neuropathies
in diabetes, 1022, 1225
in HIV infection/AIDS, 1023, 1328
in sarcoidosis, 1024
- Monongahela virus, 1388
- Mononucleosis
CMV, 1362, 1364
drugs causing illness similar to, 161
Epstein-Barr virus, 228, 1357*t*,
1361–1362, 1361*f*
meningitis in, 1286
pharyngitis in, 228, 1361, 1362, 1419
- Mononucleosis spot (Monospot) test,
1362
- Monopril/Monopril HCT. *See* Fosinopril
- Montelukast
for allergic rhinitis, 219
for asthma, 252*t*, 253
- Montenegro (leishmanin) skin test, 1488
- Montgomery-Asberg rating scale,
assessment of suicidal intent
and, 1065
- Montreal Cognitive Assessment
(MoCA®), in dementia
screening, 60, 1006
self neglect and, 73
- Mood disorders, **1062–1075**. *See also*
Depression; Mania
dementia and, 1006, 1009
- Moraxella/Moraxella catarrhalis*
infections, 1299*t*, **1443**
keratitis, 172

- Morbilloform skin disorders, 95t
Morganella, 1300t
 Moricizine, toxicity of, 377
 Morning sickness. *See* Vomiting, of pregnancy
- Morphaea, 839
 Morphine, 79, 82t
 for dyspnea, 86, 264
 for myocardial infarction, 370
 overdose/toxicity of, 1586–1587
 ophthalmic effects and, 196t
 for pulmonary edema, 408
 left ventricular/infarct-related, 373
- de Morsier syndrome (septo-optic dysplasia), 1093
- Mosaicism
 Klinefelter syndrome and, 1174
 Turner syndrome and, 1186, 1187
- Mosquitoes/mosquito control
 chikungunya fever and, 1392, 1393
 dengue and, 1386, 1387
 encephalitis and, 1378
 filariasis and, 1524, 1526
 malaria and, 1490, 1497, 1498
 yellow fever and, 1389, 1390
- Moths, skin lesions caused by, 149
- Motility disorders. *See also specific disorder*
 colonic, constipation and, 570, 570t
 esophageal, **604–606**
 chest pain/discomfort in, 355, 606
 dysphagia in, 592, 592t, 605–606
 intestinal, **627–630**. *See also* Intestinal obstruction
 diarrhea and, 574t, 578
 in irritable bowel syndrome, 633
 in scleroderma, 838
 vomiting and, 567t, 568
- Motivational interview, at-risk drinking and, 1081
- Motor activity, in schizophrenia/psychotic disorders, 1054
- Motor conduction velocity studies. *See* Conduction velocity studies
- Motor neuron diseases, 977, **1019–1020**
 spasticity caused by, 977, 1012, 1019, 1020
 spinal trauma and, 1018
 weakness/paralysis caused by, 977, 1019, 1020
- Motor palsies, ocular, **190–191**
 in myasthenia gravis, 1032
- Motor tics, in Tourette syndrome, 1004–1005
- Motor vehicle accidents. *See* Automobile accidents
- Motrin. *See* Ibuprofen
- Mountain sickness
 acute, 1558–1559
 chronic (Monge disease), 1559
 subacute, 1559
- Mouth. *See* Oral cavity
- Movement disorders, **997–1005**. *See also specific type*
 drug-induced, **1004**
 in Wilson disease, 696, **1004**
- Moviprep. *See* Polyethylene glycol
- Moxalactam, platelet function affected by, 549t
- Moxifloxacin
 for anaerobic infections, 1455, 1455t
 for bacterial rhinosinusitis, 216t
 for ophthalmic disorders, 168t
 for pneumonia, 273t, 277t, 1455
- 6-MP. *See* Mercaptopurine
- MPGN. *See* Membranoproliferative glomerulonephritis
- MPL mutation, in primary myelofibrosis, 514
- MPO-ANCA. *See* Antineutrophil cytoplasmic antibody; Myeloperoxidase ANCA
- M-protein, 528
- MPSV4 vaccine. *See* Meningococcal vaccine
- MPTP, parkinsonism caused by, 998
- MRA. *See* Magnetic resonance angiography
- MRCP. *See* Magnetic resonance cholangiopancreatography
- MRI. *See* Magnetic resonance imaging
- MRSA infections. *See* Methicillin-resistant *S aureus* (MRSA) infections
- MS Contin. *See* Morphine
- MSH2/MSH6* genes, in HNPCC, 656
- MSI. *See* Microsatellite instability
- mTOR expression, in tuberous sclerosis, 996
- mTOR inhibitors, 1654t
 for breast cancer, 741
 for renal cell carcinoma, 1641
- MTX. *See* Methotrexate
- Mucin tear deficiency, 166
- Mucocutaneous (mucosal) candidiasis, **131–132**, 131f, 1529, 1530
- Mucocutaneous herpes simplex, 1350–1351, 1351f, 1352
- Mucocutaneous leishmaniasis (espundia), 1487, 1488, 1489
- Mucocutaneous lymph node syndrome (Kawasaki disease), 428, 1357t, **1417–1418**
- Mucor* infection, 217, 1538
- Mucormycosis, **1538**
 rhinocerebral, 217
- Mucosa-associated lymphoid tissue lymphoma. *See* MALT lymphoma
- Mucosal associated lymphoid tumors. *See* MALT lymphoma
- Mucosal biopsy
 in celiac disease, 622
 in diarrhea, 579
 in gastric adenocarcinoma, 1616, 1617
 in Whipple disease, 624
- Mucosal protective agents, for peptic ulcer disease, 613
- Mucositis, oral, chemotherapy/radiation causing, 1554, 1660
- Mucous membranes
 radiation exposure affecting, 1554
 in syphilis, 1467, 1469, 1469f, 1471
- Multibacillary (lepromatous) leprosy, 1460. *See also* Leprosy
- Multidetector CT
 in chest pain/discomfort, 29–30
 in DVT/PE (venous thromboembolic disease), 299
 in polyp/cancer detection, 653, 1628
- Multidrug resistance. *See also* Drug resistance
 health care-associated infections and, 1283
 in tuberculosis, 280, 285
- Multifocal atrial tachycardia, **389**
- Multinodular (nodular) goiter, **1123–1126**, 1124t, 1134, 1135. *See also* Goiter
 toxic, 1111, 1114, 1116
- Multiple endocrine neoplasia (MEN), **1188–1190**, 1188t
 type 1 (Wermer syndrome), **1188–1189**, 1188t
 follicular thyroid carcinoma and, 1127
 gastric carcinoids in, 1619
 gastrinomas in, 619, 620, 1172, 1189
 insulinoma in, 1172, 1189, 1239, 1241
 islet cell tumors in, 1171, 1172, 1189, 1239, 1241
 neuroendocrine tumors in, 1171, 1172, 1189
 parathyroid adenoma/hyperplasia in, 1138, 1141, 1144, 1188–1189, 1188t, 1189
 pituitary adenomas in, 1093, 1100, 1188t, 1189
 prolactinomas in, 1102, 1189
 type 2A (Sipple syndrome), 1188t, **1189**
 medullary thyroid carcinoma in, 1123, 1127, 1131, 1133, 1188t, 1189
 parathyroid adenoma/hyperplasia in, 1138–1139, 1188t, 1189
 pheochromocytoma in, 1167, 1188t, 1189
 type 2B, 1188t, **1189–1190**
 medullary thyroid carcinoma in, 1123, 1127, 1131, 1133, 1188t, 1189–1190
 parathyroid adenoma/hyperplasia in, 1138, 1188t
 pheochromocytoma in, 1167, 1188t, 1189
- Multiple marker screening, in Down syndrome, 1666
- Multiple myeloma. *See* Myeloma
- Multiple personality disorder (dissociative identity disorder), 1041
- Multiple sclerosis, **213**, **1010–1012**
 glossopharyngeal neuralgia and, 968
 optic neuritis and, 188, 189
 trigeminal neuralgia and, 967
 vertigo/hearing loss in, 210t, 213
- Multisystem atrophy (Shy-Drager syndrome)
 dysautonomia and, 975
 parkinsonism and, 998
- Multitarget DNA tests, in colorectal cancer screening/polyp detection, 653, 1626t, 1627
- Mumps, **1370–1372**, 1370f
 prevention/immunization and, 1371.
 See also MMR (measles-mumps-rubella) vaccine

- Mumps vaccine, 1371. *See also* MMR (measles-mumps-rubella) vaccine
- Munchausen by proxy, 1046
- Munchausen syndrome, 1046
- Mupirocin, 97t, 123, 130, 217
- Mural thrombus, myocardial infarction and, 375
- Murine (flea-borne) typhus, 1409t, **1410–1411**
- Murmurs. *See* Heart murmurs
- Murphy sign, in cholecystitis, 703t, 704
- Murray Valley encephalitis, 1378
- Mus musculus*, lymphocytic choriomeningitis transmission and, 1380
- Muscarine, poisoning with mushrooms containing, 1586t
- Muscimol, poisoning with mushrooms containing, 1586t
- Muscle biopsy
in motor neuron diseases, 1020
in muscular dystrophy, 1034
in polyarteritis nodosa, 848
in polymyositis/dermatomyositis, 841
in trichinosis, 1522
- Muscle cramps. *See also* Tetany
heat exposure causing, **1547–1548**
in hypocalcemia, 882
- Muscle cysticercosis, 1515
- Muscle necrosis, in rhabdomyolysis, 844
- Muscle-specific tyrosine kinase (MuSK) antibodies, in myasthenia gravis, 1032
- Muscle wasting. *See also* Weakness
in HIV infection/AIDS, 1325
in malabsorption, 621t
in motor neuron disease, 977, 1019, 1020
in muscular dystrophy, 1034
- Muscle weakness. *See* Myopathies; Weakness
- Muscular dystrophies, **1034**, 1035t
cardiomyopathy in, 427
- Musculoskeletal disorders, **809–844**, **1673–1705**. *See also* specific type
ankle injuries and, **1703–1705**, 1703t, 1704t
arthritis
crystal deposition-induced, **812–817**, 813f, 813t, 815t
degenerative, **809–812**, 811f
infectious, **858–861**
rheumatoid, **826–831**, 826f, 827f
autoimmune, **826–844**
bone infections, **861–864**
chest pain/discomfort and, 29
chronic pelvic pain and, 1715, 1716
diagnosis and evaluation of, 809, 810t, 811t
dysphagia in, 592t
general approach to, **1673–1674**
hip problems, **1689–1692**, 1690t
knee problems, **1692–1703**, 1693t, 1694–1697t
in Lyme disease, 1479
pain/pain syndromes and, **817–826**, 1673, 1674
seronegative spondyloarthropathies, **854–858**
shoulder problems, **1674–1683**, 1676–1680t
spine problems, **1683–1687**, 1684t, 1687t
sports injuries and, **1673–1705**
surgery for, 1674
in syphilis, 1471
treatment of, 1674
in trichinosis, 1521
in tuberculosis, 285, **863–864**
upper extremity problems, **1687–1689**, 1689t
- Musculotendinous strain, cervical, acute, 817–818
- Mushroom picker's disease, 310t
- Mushroom poisoning, **1585–1586**, 1586t
anticholinergic-type mushrooms and, 1575, 1583
hallucinogenic mushrooms and, 1583, 1586t
liver failure and, 673, 674, 1585
- MuSK antibodies, in myasthenia gravis, 1032
- Musset sign, 344
- Mustargen. *See* Mechlorethamine
- Mutamycin. *See* Mitomycin
- Mutations. *See also* specific type and specific disorder
- Mutism
akineti (persistent vegetative state), **1016**
in schizophrenia/psychotic disorders, 1053, 1054
- Myasthenia gravis, **1032–1033**
aminoglycosides contraindicated in, 1032, 1034
in Graves disease, 1113
ocular, 1113
- Myasthenic crisis, 1032
- Myasthenic (Lambert-Eaton) syndrome, **1033**
in cancer, 995, 1033, 1596t
- Mycamine. *See* Micafungin
- Mycetoma, **1540**
- Mycobacterium* (mycobacterial infections), 1300t, **1458–1461**
abscessus, 288, 1458
avium complex (MAC), 287, 1300t, 1338t
disseminated disease caused by, **1458–1459**
in HIV infection/AIDS, 288, 1324, 1338t, 1458–1459
prophylaxis and, 1324, 1337, 1339, 1459
lymphadenitis caused by, 1458
pulmonary disease caused by, 287, 1458
- bovis*
BCG vaccine made from, 287
intestinal disease caused by, 631
lymphadenitis caused by, 1458
chelonae/chelonaei, 288, 1300t, 1458
fortuitum, 288, 1300t, 1458
gordonae, 1458
haemophilum, 1458
kansasii, 287, 288, 1300t, 1458
leprae, 1300t, 1460
lymphadenitis, **240**, **1458**
malmoense, 288, 1458
marinum, 1458
meningitis, 1286t
nontuberculous atypical, 287, **1458–1459**. *See also* Nontuberculous atypical mycobacteria
lymphadenitis caused by, **240**, **1458**
pulmonary disease caused by, **287–289**, 289t, **1458**
skin and soft tissue infections caused by, **1458**
- scrofulaceum*, 1458
szulgai, 1458
tuberculosis, **279–287**, 1300t, **1459–1460**. *See also* Tuberculosis
bone and joint disease caused by, 285, **863–864**
detection of, 280–282, 281t
intestinal disease caused by, 631
lymphadenitis caused by, **240**, 1458
meningitis caused by, **1459–1460**
pulmonary disease caused by, **279–287**, 281t, 282f, 283t, 284t, 289t
resistant strains of, 280, 281, 281t, 285, 286
ulcerans, 1458
xenopi, 288, 1458
- Mycophenolate mofetil
for autoimmune hepatitis, 680
lupus nephritis, 834, 926
for pemphigus, 139
- Mycoplasma*, 1301t
cough caused by, 23
genitalium, 1461
pneumoniae, 1302t, 1303t
Stevens-Johnson syndrome caused by, 134
- Mycosis fungoides (cutaneous T cell lymphoma), **115–116**
exfoliative dermatitis/erythroderma and, 116
- Mycotic aneurysms
drug use and, 1292
intracranial, 986
- Mycotic infections (mycoses), **1529–1542**. *See also* Fungal infections
allergic bronchopulmonary, **266–267**, 1537, 1538
of bones and joints, **862–863**
drugs for management of, 97–98t, **1541–1542**, 1541–1542t. *See also* Antifungal agents
superficial, **110–114**, 110f, 111f, 113f. *See also* Tinea
in HIV infection/AIDS, 1331
- Myelinolysis, central pontine, hyponatremia treatment and, 874
- Myelitis
in CMV infection, 1364
in coxsackievirus infection, 1406
in neuromyelitis optica, 1012
in tick-borne encephalitis, 1391
- Myelodysplastic syndromes, **517–519**
aplastic anemia differentiated from, 508–509
platelets affected in, 518, 549t
rheumatic manifestations of, 864–865

- Myelodysplastic syndromes (*Cont.*):
sideroblasts/sideroblastic anemia and, 496, 497, 517, 518
stem cell transplantation for, 518, 533
thrombocytopenia and, 538–539, 540
- Myelofibrosis (primary/idiopathic), 511*t*, 514–515
- Myelography
in spinal dural arteriovenous fistulae, 989
in spinal tumors, 993
- Myeloid growth factors. *See* Filgrastim; Growth factors; Sargramostim
- Myeloid leukemia. *See* Acute myeloid leukemia; Chronic myeloid leukemia
- Myeloma, 527–529, 1610*t*
amyloidosis and, 528, 531, 930, 936
hypercalcemia in, 527, 528, 529, 936, 1141, 1596*t*
kidney involvement in, 527, 528, 936
neuropathy associated with, 528, 1023
nonsecretory, 528
paraneoplastic syndromes associated with, 1596*t*
proteinuria in, 528, 936
stem cell transplantation for, 529, 532
Myeloma kidney, 527, 528, 936
- Myelopathy. *See also specific cause*
epidural/subdural hemorrhage causing, 989
HIV, 1328
human T cell leukemia virus (HTLV), 1013, 1383–1384
in multiple sclerosis, 1010
neck pain/cervical spondylosis and, 818, 1029
in subacute combined degeneration of spinal cord, 1013
- Myeloperoxidase ANCA (MPO-ANCA). *See also* Antineutrophil cytoplasmic antibody
in granulomatosis with polyangiitis, 306, 849, 924
in microscopic polyangiitis, 851, 924
- Myeloproliferative neoplasms, 511–524, 511*t*. *See also* Leukemias
in hepatic vein obstruction (Budd-Chiari syndrome), 698
platelet function affected in, 549*t*
rheumatic manifestations of, 864
- Myeloradiculopathy, in spinal dural arteriovenous fistulae, 989
- Myelosuppressive therapy
bone marrow/stem cell transplantation and, 532, 533
infection and, 1279
for polycythemia, 512–513
- Myerson sign, 998
- MYH gene mutations
in familial adenomatous polyposis, 655
screening for, 655
- Mykrox. *See* Metolazone
- Myleran. *See* Busulfan
- Myocardial contusions/hematomas, 428
- Myocardial dysfunction. *See also* Congestive heart (cardiac) failure
myocardial infarction and, 373–374
- Myocardial failure. *See* Congestive heart (cardiac) failure
- Myocardial hibernation, 351
- Myocardial hypertrophy. *See* Cardiomyopathy
- Myocardial infarction/ST-segment elevation myocardial infarction (STEMI), 360, 364*t*, 365–376, 367*t*, 369*t*. *See also* Coronary heart disease
abacavir and, 1343, 1343–1344
abdominal aortic aneurysm repair and, 474
accelerated idioventricular rhythm in, 373, 393
angiography/catheterization in, 364*t*, 371
antihypertensive therapy and, 442*t*, 457
in hypertensive emergency, 461*t*
arrhythmias associated with, 365, 372–373
antiarrhythmic prophylaxis/treatment and, 371, 372–373, 376
aspirin for, 362*t*, 367, 371, 376
atrial fibrillation in, 372
biomarkers in, 360, 366
bradycardia/sinus bradycardia in, 365, 372
chest pain/discomfort in, 28, 28*t*, 29, 365
cocaine abuse and, 360, 365, 1085
complications of, 371–375
conduction disturbances associated with, 373
coronary artery trauma and, 428
coronary vasospasm causing, 360
coxibs (COX-2 inhibitors) associated with, 612
definition of, 360
in diabetes mellitus, 1227
glycemic/hypertension control and, 1203, 1227
Dressler syndrome after, 375
dyspnea in, 24
estrogen replacement therapy and, 1183
heart failure and, 365, 366, 367*t*, 370, 373–374, 376, 407
hemodynamic status and, 366, 367*t*
hypotension and, 374
interventricular septum rupture and, 374
ischemia after, 372
in Kawasaki disease, 1417
left ventricular aneurysm and, 375
left ventricular failure and, 366, 367*t*, 373–374, 376
mechanical defects associated with, 374
mitral regurgitation and, 339, 340, 366
mural thrombus and, 375
myocardial dysfunction and, 373–374
myocardial rupture and, 374–375
oral contraceptive use and, 770
painless, 365
papillary muscle dysfunction/rupture and, 374
pericarditis after, 375, 419, 419–420
perioperative, preoperative risk assessment/management and, 46, 47–49, 47*t*
- postinfarction risk stratification/ modification and, 375
during pregnancy, 431
prevention and, 375–376, 1246–1247
Q waves and, 366. *See also* Non-Q wave (non-ST elevation) infarction
reperfusion therapy for, 364*t*, 367–370
revascularization procedures and, 364*t*
postinfarction, 376
prophylactic/preoperative, 48–49
right ventricular infarction and, 366, 374
rosiglitazone use and, 1210
shock and, 367*t*, 368, 374
in SLE, 835
sudden death and, 365, 392
supraventricular tachyarrhythmias in, 372, 376, 391
- Tako-Tsubo cardiomyopathy
mimicking, 365
thiazolidinedione use and, 1210
thrombolytic therapy for, 368–370, 369*t*
PCI and, 357, 368
treatment of, 362*t*, 364*t*, 367–371, 367*t*, 369*t*
postinfarction management and, 375–376
ventricular arrhythmias in, 365, 372–373
antiarrhythmic prophylaxis/ treatment and, 371, 372–373
- Myocardial ischemia. *See also* Angina; Coronary heart disease; Myocardial infarction
in acute coronary syndromes, 360
chest pain/discomfort in, 28, 28*t*, 29, 360. *See also* Angina; Myocardial infarction
cocaine abuse and, 360, 365, 1085
coronary vasospasm causing, 360
dyspnea in, 24, 25
mitral regurgitation and, 339, 340
postinfarction, 372
- Myocardial perfusion scintigraphy
in angina, 353
in cardiomyopathy, 412, 412*t*, 414
in myocardial infarction, 366
preoperative, 46–47
- Myocardial rupture, 374–375, 428
- Myocardial sarcoidosis, 296
- Myocardial stress imaging, in angina, 353
- Myocardial stunning, 351
- Myocarditis, 409–411, 409*t*
adenovirus infection and, 1402
in African trypanosomiasis, 1484
in American trypanosomiasis/Chagas disease, 1486
autoimmune/giant cell, 409, 410
clozapine causing, 1056, 1059–1060
coxsackievirus infection and, 1406
in diphtheria, 1433
drug-induced/toxic, 409*t*, 410–411
enterovirus, 1407
infectious, 409–410, 409*t*
cardiomyopathy and, 410, 411
in Kawasaki syndrome, 1417
pheochromocytoma and, 1169, 1170
- Myoclonic epilepsy, ragged red fiber (MERRF) syndrome, 1036

- Myoclonic seizures, 970, 970*t*, 1004.
See also Seizures
 drug therapy for, 973*t*
- Myoclonus, **1003–1004**
 nocturnal, 1077
 opioid-induced, 79
 with opsoclonus, 995
 palatal, tinnitus and, 208
- Myoglobinuria, 905
 acute tubular necrosis/rhabdomyolysis
 and, 844, 905
- Myolysis, 758
- Myomas (leiomyomas/fibroid tumors), of
 uterus, 757–759
- Myomectomy, 758
- Myonecrosis, clostridial, 1300*t*, **1428–1429**
- Myopathies (myopathic disorders), 977,
1034–1036, 1035*t*
 HIV, 861, 1036, 1328
 inflammatory, 1036
 idiopathic, **840–842**, 840*f*
 lipid-lowering therapy/statin drugs
 causing, 842
 miscellaneous causes of, **1036**
 mitochondrial, **1036**
 zidovudine causing, 1036, 1343
- Myopericarditis. *See also* Pericarditis
Borrelia burgdorferi/Lyme disease
 causing, 419, 1479,
 1481–1482, 1482*t*
- Myopia, 162
 in Marfan syndrome, 1670
 surgical correction of, 162–163
- Myositis. *See also* Dermatomyositis;
 Polymyositis
 HMG-CoA reductase inhibitors (statin
 drugs) causing, 842, 1254
 inclusion body, 841, **1036**
- Myotomy
 for achalasia, 605
 for Zenker diverticulum, 601
- Myotomy–myomectomy, for
 cardiomyopathy, 415
- Myotonia/myotonic dystrophy,
1034–1035, 1035*t*
 cardiomyopathy in, 427
 congenita, **1035–1036**
- Myringotomy
 for barotrauma, 202
 for mastoiditis, 204
 for otitis media, 203
- Myxedema, **1105–1110**. *See also*
 Hypothyroidism
 pretibial (Graves dermopathy), 1110,
 1113
- Myxedema coma, 1108
- Myxedema crisis, 1108
- Myxedema heart, 1106
- Myxedema madness, 1106, 1108
- Myxedema pericardial effusion, 420, 1106
- Myxoma, atrial, 426–427
 fever/FUO and, 1277
 herpes simplex virus and, 1352
- Myxomatous mitral valve. *See* Mitral
 valve prolapse
- Na⁺. *See* Sodium
- NAAT. *See* Nucleic acid amplification
 tests
- Nabumetone, 78*t*
- Nadolol, 448*t*
 for esophageal varices, prevention of
 rebleeding and, 603
- Naegleria fowleri*, 1287, 1505
- NAEPP. *See* National Asthma Education
 and Prevention Program
- Nafarelin
 for abnormal premenopausal bleeding,
 748
 for endometriosis, 761
- Nafcillin
 for endocarditis, 1438, 1439
 platelet function affected by, 549*t*
- NAFLD. *See* Nonalcoholic fatty liver
 disease
- Naftifine, 98*t*
- Naftin. *See* Naftifine
- Nail atrophy, 157
- Nail disorders, **157–158**, 158*f*. *See also*
 Digital clubbing
 candidal infection, 131, 131*f*, 132, 157
 chemotherapy-induced, 1661
 hyperpigmentation, drugs causing,
 157, 160*t*
 in Kawasaki disease, 1417
 pitting/stippling, 157
 in psoriasis, 106, 106*f*, 856
 in reactive arthritis, 857
 in Raynaud phenomenon, 837
 tinea unguium (onychomycosis), 157,
158
- Nalfon. *See* Fenoprofen
- Nalmefene, for coma/opioid overdose,
 1563, 1566*t*
- Naloxone, 1083
 for heroin/opioid overdose/withdrawal,
 1083, 1563, 1566*t*, 1586–1587
- NALP-3 inflammasomes, in gout, 812
- Naltrexone
 for alcohol use/abuse, 18, 1082
 for heroin/opioid withdrawal, 1084
 for obesity, 1261
- Naphazoline, overdose/toxicity of, 1577
- Naprosyn. *See* Naproxen
- Naproxen, 78*t*
 cardiovascular risk and, 608, 612, 615,
 616
- Naratriptan, for migraine headache, 964
- Narcissistic personality disorder, 1052*t*
- Narcolepsy, 1077
- Narcotic (opioid) antagonists. *See also*
 Naloxone
 for constipation, 86, 571–572
 for heroin/opioid overdose/withdrawal,
 20, 1083, 1084, 1563, 1566*t*,
 1586–1587
- Narcotics. *See also* Opioids/opioid
 analgesics
 abuse of, 18–20, **1083–1084**,
 1586–1587
 narcotic antagonists/naloxone for,
 20, 1084, 1563, 1566*t*,
 1586–1587
- Nardil. *See* Phenelzine
- Narrowband UVB (NB-UVB) therapy.
See also Phototherapy
 for lichen planus, 144
 for psoriasis, 107
- Nasal biopsy, in granulomatosis with
 polyangiitis, 223, 849
- Nasal bleeding. *See* Epistaxis
- Nasal CPAP
 for sleep apnea, 319
 for snoring, 231
- Nasal polyps, 222
 allergic rhinitis and, 218, 222
- Nasal pyramid, fracture of, 221
- Nasal septoplasty, for sleep apnea, 319
- Nasal sinuses. *See* Paranasal sinuses
- Nasal trauma, **221–222**
 epistaxis and, 220, 221
- Nasal tumors, **222–223**
 benign, **222**
 malignant, **223**
- Nasal vestibulitis, **217**
- NASH. *See* Nonalcoholic steatohepatitis
- Nasoduodenal feeding tube, 1270, 1271*f*
- Nasoenteric feeding tube, 1271*f*
 for caustic esophageal injury, 599
- Nasogastric intubation
 for acute colonic pseudo-obstruction
 (Ogilvie syndrome), 628
 for acute paralytic ileus, 627
 for caustic/corrosive ingestions, 1571,
 1572
 for esophageal varices, 603
 for feeding tube, 1270, 1271, 1271*f*,
 1273
 for gastric outlet obstruction, 619
 for GI bleeding, 581, 584
 hospital-acquired bacterial
 rhinosinusitis and, 215, 216
 in near drowning, 1556
 for vomiting, 86, 568
- Nasolacrimal duct, obstruction of,
 dacryocystitis and, 164
- Nasopharynx
 juvenile angiofibroma arising in, 222
 malignant tumors of, **223**
 Epstein-Barr virus and, 223, 1363
 serous otitis media and, 202, 223
- Natacyn. *See* Natamycin
- Natalizumab
 for inflammatory bowel disease, 640
 for multiple sclerosis, 1011
 progressive multifocal
 leukoencephalopathy caused
 by, 640, 1011, 1383
- Natamycin, for ophthalmic disorders,
 168*t*
- Nateglinide, 1206*t*, 1208
 hypoglycemia caused by, 1221–1222
- National Asthma Education and
 Prevention Program
 (NAEPP), asthma diagnosis/
 management guidelines of,
 244*f*, 245*t*, 246*t*, 248–250,
 249*f*
- National Comprehensive Cancer Network
 (NCNN) website, 1593, 1648,
 1649. *See also specific type of*
cancer
- Native DNA, antibodies to, 833*t*, 834*t*
- Natriuresis defects, in hypertension, 436
- Natriuretic peptide
 atrial, in senile amyloidosis, 531
 B-type (BNP/beta)
 in aortic regurgitation, 345
 in aortic stenosis, 343, 344
 in cardiomyopathy of pregnancy, 429

- Natriuretic peptide, B-type (BNP/beta) (*Cont.*):
 in cor pulmonale, 426
 in dyspnea, 25
 heart failure and, 400
 in mitral regurgitation, 339
 recombinant. *See* Nesiritide
 reference values for, 1728t
- Natural orifice transluminal endoscopic surgery (NOTES),
 cholecystectomy via, 704
- Nausea and vomiting, **86, 566–569, 567t**
 in appendicitis, 630
 chemotherapy-induced, 567t,
1659–1660
 with diarrhea/food poisoning/
 gastroenteritis, 575, 1293,
 1294–1295t
 drugs for management of. *See also*
 Antiemetics
 exenatide use and, 1211
 in HIV infection/AIDS, 1325
 hyponatremia caused by, 871f, 872
 in intestinal obstruction, 567t, 568
 in intracerebral hemorrhage, 983, 984
 liraglutide use and, 1212
 in migraine headache, 41, 41t, 567t,
 962
 opioids causing, 84
 palliation of, **86**
 in pancreatitis, 567t, 711
 in polyarteritis nodosa, 847
 pramlintide use and, 1213
 in pregnancy, 781, **787–788**
 in gestational trophoblastic disease,
 791
 in subarachnoid hemorrhage, 984
 in terminally ill/dying patient, **86**
- Navane. *See* Thiothixene
- Navelbine. *See* Vinorelbine
- NB-UVB therapy. *See* Narrowband UVB
 (NB-UVB) therapy
- NCCN (National Comprehensive Cancer
 Network) website, 1593,
 1648, 1649. *See also specific*
type of cancer
- Nd:YAG laser photoresection. *See also*
 Laser therapy
 for lung cancer palliation, 1600
- Near drowning, **1555–1557**
- Nearsightedness (myopia), 162
 surgical correction of, 162–163
- Nebido. *See* Testosterone undecanoate
- Nebivolol, 448t
 for heart failure, 403
 for hypertension, 446, 448t
- Nebulizer therapy
 for asthma, 254t, 255, 256, 257f
 for COPD, 262, 264
- Necator americanus*, 1518
- Neck
 infections of
 anaerobic, **1454**
 deep, **230–231**
 masses caused by, **240**
 masses in, **239–241**. *See also* Head and
 neck cancer
 congenital lesions in adults, **239**
 in Hodgkin lymphoma, 526
 infectious and inflammatory, **240**
 lymphoma, **240–241**
 metastatic, **240**
 thyroid cancer. *See* Thyroid cancer
- Neck dissection
 for laryngeal cancer, 237
 for thyroid cancer, 1129
 vocal fold paralysis caused by, 237
- Neck fractures, 1686
- Neck injury, cervical vertigo and, 211
- Neck manipulation, 1687
- Neck pain, **817–818, 1029, 1030–1031f,**
1686–1687, 1687t
 disk-related, **818, 1029, 1030–1031f,**
 1686
- Necrobiosis lipoidica diabetorum, 1228
- Necrolysis, toxic epidermal, 134, 135
 drugs causing, 134, 135, 159t, 161
- Necrosectomy, for necrotizing
 pancreatitis, 714
- Necrotizing cellulitis, synergistic, 1456
- Necrotizing fasciitis, 1421, 1425, 1456
 cellulitis differentiated from, 137
- Necrotizing (phlegmonous) gastritis, 610
- Necrotizing lymphadenitis, histiocytic
 (Kikuchi/Kikuchi-Fujimoto
 disease), 240
- Necrotizing pancreatitis, 713, 714
- Necrotizing pneumonia, 278
- Necrotizing ulcerative gingivitis, **226**
- Nedocromil
 for allergic eye disease, 167, 169t
 for allergic rhinitis, 219
 for asthma, 249f, 250, 251t
- Needle ablation of prostate, transurethral
 (TUNA), for benign prostatic
 hyperplasia, 961
- Needle-stick injury, HIV infection/AIDS
 transmission risk and, 1321,
 1335
- Neer impingement sign, 1675, 1678t,
 1680
- Nefazodone, 1067, 1068
- Neglect/abuse, of elderly, 17, **72–73, 73t**
- Negri/Negri-like bodies, in rabies, 1376
- Neighborhood reaction, 1286t, 1287
- Neisseria*
gonorrhoeae, 1299t, 1452. *See also*
 Gonococcal infections
 resistant strains of, 860, 1452–1453
meningitidis, 1299t, 1441. *See also*
 Meningococcal (*Neisseria*
meningitidis) infections
 resistant strains of, 1442
- Nelfinavir, 1341t, 1344, 1344–1345, 1347,
 1348f. *See also* Antiretroviral
 therapy/HAART
- Nelson syndrome, 1160
- Nematode infections. *See also specific type*
filiariasis, 1524–1528
 intestinal, 578, **1517–1520**
 invasive, **1520–1524**
- Neoadjuvant chemotherapy. *See also*
 Chemotherapy
 for bladder cancer, 1639, 1640
 for breast cancer, 735, 738, 1611t
 for esophageal cancer, 1614
 for gastric adenocarcinoma, 1617
 for lung cancer, 1599
 for rectal cancer, 1624, 1626
 for renal cell carcinoma, 1641
- Neodymium:yttrium-aluminum-garnet
 laser photoresection. *See*
 Nd:YAG laser photoresection
- Neologisms, in schizophrenia/psychotic
 disorders, 1054
- Neonate. *See* Newborn
- Neoplasia. *See* Cancer
- Neoplastic pericarditis, 419, 420
- Neorickettsia sennetsu*, 1414
- Neostigmine
 for acute colonic pseudo-obstruction
 (Ogilvie syndrome), 629
 adverse ophthalmic effects of, 196t
 for myasthenia gravis, 1033
- Neovascular age-related macular
 degeneration, 181
- Neovascular (rubeotic) glaucoma, retinal
 vein occlusion and, 182
- Neovascularization
 in age-related macular degeneration, 181
 in diabetic retinopathy, 185, 1223
 in retinal vein occlusion, 182
- Nepafenac, for ophthalmic disorders, 170t
- Nephrectomy, for renal cell carcinoma,
 1641
- Nephritic spectrum glomerular diseases,
 918f, 919, 919t, **920–927,**
 921f. *See also*
 Glomerulonephritis
- Nephritic syndrome, 918, 918f, 919t,
 920–922. *See also*
 Glomerulonephritis
- in IgA nephropathy, 923
- in membranoproliferative
 glomerulonephritis, 925
- in postinfectious glomerulonephritis,
 922
- Nephritis. *See also* Glomerulonephritis
 interstitial, 902t, **906–907**
 in SLE, 833
 urinalysis in, 898, 902t
 lupus, 833, 834, 835, 919t, 921f, **926–**
927
 radiation exposure and, 1554
 in syphilis, 1469
 tubulointerstitial, 909t, 932–933, 932t
- Nephrocalcinosis
 in hypercalcemia/hyperparathyroidism,
 1139
- in renal tubular acidosis, 892
- Nephrogenic diabetes insipidus. *See*
 Diabetes insipidus,
 nephrogenic
- Nephrogenic fibrosing dermopathy, 839
- Nephrogenic systemic fibrosis (NSF), **937**
- Nephrolithiasis (kidney stones). *See also*
 Urinary stone disease
 calcium, 946, 947, 948–949, 1139, 1141,
 1146
 in Crohn disease, 641
 cystine, 946, 947, 949
 dysuria and, 43–44
 hyperparathyroidism and, 947t, 948,
 1139, 1141
 in polycystic kidney disease, 935
 in renal tubular acidosis, 892, 946–947
 in short bowel syndrome, 625
 struvite, 946, 947, 949
 uric acid, 813, 936–937, 946, 947, 948,
 949

- Nephrolithotomy, 949, 950
 Nephropathia epidemica, 1388, 1389
 Nephropathy
 analgesic, 932–933, 933
 Balkan, ureteral/renal pelvis cancer and, 1640
 contrast, 904–905
 diabetic. *See* Diabetic nephropathy
 HIV-associated, 920*t*, **931**
 hypertensive, 460
 IgA (Berger disease), 919*t*, 921*f*, **922–923**
 lead, 933
 membranous. *See* Membranous nephropathy
 obstructive, 909*t*
 reflux, 932
 urate/uric acid, 813, 936–937
 Nephrosclerosis, hypertension causing, 439
 Nephrosis, lipid (minimal change disease), 920*t*
 Nephrostomy, for pyelonephritis, 941
 Nephrotic spectrum diseases, 918–919, 918*f*, 920*t*, **927–931**
 glomerular, 918–919, 918*f*, 920*t*, **927–928**. *See also* Nephrotic syndrome
 in primary renal disorders, 920*t*, **928–930**
 from systemic disorders, 920*t*, **930–931**
 Nephrotic syndrome, 898, 918–919, 918*f*, 920*t*, 927–928. *See also* *specific disease*
 in diabetes mellitus, 931, 1224. *See also* Diabetic nephropathy
 in focal segmental glomerulosclerosis, 930
 in Henoch-Schönlein purpura, 923
 hepatitis C and, 926
 in HIV infection/AIDS, 931
 hyponatremia in, 873–874
 in IgA nephropathy, 923
 lipid abnormalities and, 898, 918, 927, 928, 1248*t*
 lithium causing, 1073, 1582
 lower extremity edema and, 33, 34, 927, 928
 in membranoproliferative glomerulonephritis, 925
 in membranous nephropathy, 929
 in minimal change disease, 928, 929
 in primary renal disorders, 920*t*, **928–930**
 proteinuria in, 898, 918, 918*f*, 927
 from systemic disorders, 920*t*, **930–931**
 urinalysis in, 898, 927
 vitamin D deficiency and, 1149
 Nephrotoxicity. *See also* *specific agent*
 acute kidney injury and, 902–903
 acute tubular necrosis, 904–905
 interstitial nephritis, 906–907
 of aminoglycosides, 904
 of cisplatin, 1662
 of cyclosporine, 905
 endogenous substances causing, 905
 exogenous agents causing, 904–905
 of mercury, 1583
 of methotrexate, 1661, 1662
 of NSAIDs, 829, 902
 of radiographic contrast media, 904–905
 reversible kidney injury and, 910*t*
 Nephroureterectomy, 1640
 Nerve agents, for chemical warfare, 1587
 skin decontamination and, 1566, 1587
 Nerve biopsy
 in polyarteritis nodosa, 848
 in polyneuropathies, 1021
 Nerve block, for pain management, 85
 in herpes zoster/postherpetic neuralgia, 120, 120–121
 Nerve conduction velocity studies. *See* Conduction velocity studies
 Nervous system. *See under Neurologic*
 Nesiritide
 for heart failure, 404
 for pulmonary edema, 408
 Neulasta. *See* Pegfilgrastim
 Neumega. *See* Oprelvekin
 Neupogen. *See* Filgrastim
 Neural hearing loss, 198, 212. *See also* Hearing loss
 Neural tube defects, folic acid in prevention of, 785, 799
 Neuralgia
 glossopharyngeal. *See* Glossopharyngeal neuralgia
 postherpetic, 120, 120–121, **968**, 1359
 varicella vaccine in prevention of, 120, 968, 1360
 trigeminal. *See* Trigeminal neuralgia
 Neuralgic amyotrophy (idiopathic brachial plexus neuropathy), 1029–1030
 Neuraminidase inhibitors (oseltamivir/zanamivir), for influenza, 23, 1354*t*, 1395, 1396, 1398, 1399
 prophylactic, 1397
 resistance to, 1396, 1399
 Neuritis
 intercostal, 355
 optic, **188–189**
 in neuromyelitis optica, 188, 1012
 Neuroblastoma, 1612*t*
 Neuroborreliosis, 1480, 1481, 1482, 1482*t*. *See also* Lyme disease
 Neuroclaudication (neurogenic claudication), in spinal stenosis, 822, 1685
 Neurocutaneous diseases, **996–997**, 996*f*
 Neurocysticercosis, 1515
 Neurodermatitis, circumscribed (lichen simplex chronicus), **105**, 105*f*
 Neuroendocrine tumors, **1171–1173**. *See also* Carcinoid tumors; Islet cell tumors
 diarrhea and, 578, 580
 gastrinoma differential diagnosis and, 620
 in MEN, 1171, 1172, 1189
 pancreatic, **1171–1173**, 1189, 1608, 1609
 Neurofibromas, 996, 996*f*
 Neurofibromatosis, **996**, 996*f*
 neuroendocrine tumors in, 1172
 pheochromocytoma/paraganglioma in, 1167
 vestibular schwannoma (eight nerve tumors/acoustic neuroma) and, 212, 996
NEUROG3 mutation, in diabetes, 1195
 Neurogenic arthropathy (Charcot joint), **865**
 in diabetes mellitus, 865, 1224–1225
 in tabes dorsalis, 865, 1472, 1472*f*
 Neurogenic claudication (neuroclaudication), in spinal stenosis, 822, 1685
 Neurogenic hyperventilation, in coma or stupor, 318, 1014
 Neurogenic shock, 485–486, 486
 Neuroimaging
 in bacterial rhinosinusitis, 215, 216
 in brain abscess, 994
 in cerebral infarction, 982
 in cerebrovascular occlusive disease, 469
 in CNS infections, 1287–1288
 in comatose patient, 1014
 in Cushing syndrome, 1159
 in cysticercosis, 1515
 in dementia, 60, 1007
 in head injury, 1016
 in headache, 41, 41*t*, 42
 in Huntington disease, 1001–1002
 in intracerebral hemorrhage, 984
 in intracranial aneurysm, 985, 986
 in intracranial arteriovenous malformations, 987
 in intracranial tumors, 991
 in lacunar infarcts, 981
 in multiple sclerosis, 1010–1011
 in pituitary tumors, 1095
 in schizophrenia/psychotic disorders, 1055
 in seizure evaluation, 971
 in stroke, 981, 982, 984, 985, 986, 987
 in subarachnoid hemorrhage, 985
 in transient ischemic attacks, 978
 in vestibular disorders/vertigo, 210
 Neurokinin receptor antagonists, for nausea and vomiting, 569, 569*t*, 1660
 Neurokinin receptors, in nausea and vomiting, 566, 1660
 Neuroleptic malignant syndrome, 35, 36, 1060, 1565, 1574
 Neuroleptics. *See* Antipsychotic drugs
 Neurologic deficits
 arteriovenous malformations causing, 987
 back pain and, 819–820, 821
 in brain abscess, 994
 in cerebral infarction, 981
 in cysticercosis, 1515
 in head injury, 1017
 in intracerebral hemorrhage, 983, 984
 in intracranial aneurysms, 985, 986
 intracranial tumors causing, 989, 990*t*
 false localizing signs and, 991
 in lacunar infarct, 979, 981
 in leprosy, 1023, 1460
 migraine headache and, 963
 neck pain and, 817, 1029, 1686
 spinal cord tumors/compression causing, 993, 1645
 spinal trauma causing, 1018
 in stroke, 979, 981, 983
 in subarachnoid hemorrhage, 985
 in thrombotic microangiopathy, 543, 543*t*
 in transient ischemic attacks, 977

- Neurologic disorders, **962–1037**. *See also specific type and* Neurologic deficits; Neuropathies
- adverse ophthalmic effects of drugs used in, *196t*
 - in African trypanosomiasis, 1484, 1485, 1485*t*
 - in American trypanosomiasis/Chagas disease, 1486
 - Angiostrongylus* causing, 1522
 - in Behçet syndrome, 853
 - cancer-related, 1596*t*
 - in chronic kidney disease/uremia, 909*t*, 910, 914
 - CMV causing, 1364
 - coxsackieviruses causing, 1286, 1406
 - in cryptococcosis, 993, 1327, 1338*t*, 1536
 - in cysticercosis, 1515
 - dysphagia in, 592*t*
 - in Gaucher disease, 1668
 - in gnathostomiasis, 1523
 - herpes simplex infection, 1351, 1355
 - in high-altitude illness, **1558–1559**
 - in HIV infection/AIDS, 1023, 1288, 1327–1328
 - in hypercalcemia, 883–884, 1139
 - hyponatremia treatment and, 876
 - hyponatremia treatment and, 871
 - infection, **1285–1288**, 1286*t*. *See also* Encephalitis; Meningitis
 - anaerobic, **1455**
 - in leprosy, 1023, 1460
 - in loiasis, 1527, 1528
 - in Lyme disease, 1479
 - in malaria, 1491
 - measles/measles vaccination causing, 1368
 - nausea and vomiting and, 567*t*
 - in near drowning, 1556
 - nonmetastatic complications of cancer, **994–995**, 1024
 - in paragonimiasis, 1513
 - in pheochromocytoma/paraganglioma, 1168*t*
 - in porphyria, 1022, 1664
 - postoperative, **53–54**, 53*t*
 - in preeclampsia-eclampsia, 793*t*
 - primary angiitis and, **854**
 - radiation exposure and, 1554
 - respiratory failure caused by, 320*t*
 - SIADH caused by, 873, 873*t*
 - in SLE, 833, 834, 835
 - in sparganosis, 1517
 - in strongyloidiasis, 1519
 - in syphilis, 1304*t*, 1464, **1472–1473**, 1472*f*. *See also* Neurosyphilis
 - thiamine deficiency causing, 1023, 1264
 - in varicella, 1359
 - vertigo and, 209*t*, 210, 210*t*, 212, 212–213
 - vitamin B₁₂ deficiency causing, 498
 - vitamin E deficiency causing, **1012**
 - in Whipple disease, 623, 624
 - in Wilson disease, 696, 1004
- Neurologic evaluation
- in back pain, 820, 820*t*, 1683, 1684*t*
 - in carpal tunnel syndrome, 824, 1688–1689, 1689*t*
 - in dementia, 60, 1006–1007
 - in headache, 41, 41*t*, 42
 - in neck pain, 1686, 1687*t*
 - preoperative, **53–54**, 53*t*
- Neuroma/neurinoma. *See also* Neurofibromatosis
- acoustic. *See* Acoustic neuroma/neurinoma
 - mucosal, in MEN, 1189
 - plexiform, 996
- Neuromodulation, for angina, 358
- Neuromuscular/neuromuscular transmission disorders, **1032–1034**
- in chronic kidney disease/uremia, 909*t*
 - dysphagia in, 592*t*
 - in hypercalcemia, 1139
 - respiratory failure caused by, 320*t*
 - weakness in, 977
- Neuromyelitis optica (Devic disease/syndrome), **1012**
- optic neuritis in, 188, 1012
- Neuron-specific enolase, in pheochromocytoma, 1167
- Neuronal neuropathies. *See also specific type and* Neuropathies
- Neuronal nicotinic acetylcholine receptor antibodies, in cancer-related neuropathy, 975, 1024
- Neuronitis, vestibular, 210*t*, 211
- Neuronopathy
- bulbospinal X-linked, 1020
 - cancer-related, 995
- Neuropathic bladder
- chemotherapy-induced, 1661
 - in diabetes, 1226
- Neuropathic pain, **84–85**, 84*t*, 1021. *See also* Neuropathies
- Neuropathies, **1020–1029**
- acute motor axonal/acute motor and sensory axonal (AMAN/AMSAN), 1024–1025. *See also* Guillain-Barré syndrome
 - alcoholism and nutritional deficiency and, 1023
 - in amyloidosis, 531, 1023
 - antiretroviral agents causing, 1328, 1343
 - autonomic. *See* Autonomic neuropathy
 - bortezomib causing, 529
 - brachial plexus, **1029–1032**
 - cancer-related, **1024**, 1596*t*
 - chemotherapy-induced, 1661, 1662
 - in chronic kidney disease/uremia, 909*t*, 914, 1022–1023
 - cisplatin-induced, 1662
 - compression. *See* Entrapment/compression neuropathy
 - in critically ill patient, **1024**
 - in cryoglobulinemia, 851, 1023
 - diabetic, 1022, 1197, 1197*t*, 1224–1227, 1225*f*
 - foot disorders/ulcers/gangrene and, 467, 1224–1225, 1225*f*, 1227
 - glycemic control and, 1201, 1203
 - neurogenic arthropathy (Charcot joint) and, 865, 1224–1225
 - didanosine therapy and, 1328, 1343
 - diphtheritic, 1024, 1433
 - dyssautonomia and, 975, 976, 1021
 - entrapment. *See* Entrapment/compression neuropathy
 - facial, **1027**, 1028, 1028*f*. *See also* Bell palsy
 - hereditary motor and sensory (HMSN), types I to IV, 1021–1022
 - in HIV infection/AIDS, 1023, 1328
 - infectious/inflammatory disease and, **1023–1024**
 - inherited, **1021–1022**
 - in leprosy, 1023, 1460
 - in Lyme disease, 1023, 1479
 - metabolic/systemic disease and, **1022–1023**
 - in microscopic polyangiitis, 851
 - in myeloma, 528, 1023
 - nutritional, 1023. *See also specific nutrient*
 - optic
 - inflammatory (optic neuritis), **188–189**
 - in neuromyelitis optica, 188, 1012
 - ischemic, **187–188**
 - giant cell arteritis and, 188, 845–846
 - in paraproteinemias, 1023
 - peripheral, **1020–1029**. *See also specific type*
 - in polyarteritis nodosa, 847, 1024
 - in porphyria, 1022, 1664
 - in rheumatoid arthritis, 827, 1024
 - in sarcoidosis, 1024
 - stavudine therapy and, 1328, 1343
 - in thiamine deficiency, 1023, 1264
 - toxic, **1024**
 - vincristine-induced, 1661
 - vitamin B₆ causing, 1266
 - in vitamin B₁₂ deficiency, 498, 1023
- Neuropeptide Y, in pheochromocytoma, 1166
- Neuropsychological assessment, in dementia, 1006–1007
- Neuroses, Sunday, 1040
- Neurosyphilis, 1304*t*, 1464, **1472–1473**, 1472*f*
- cerebrospinal fluid examination in, 1472, 1472–1473, 1473
 - indications for, 1472–1473
 - drug therapy for, 1304*t*, 1467, 1468*t*, 1473
 - in HIV infection/AIDS, 1335, 1468, 1473
 - treatment failures and, 1468, 1473
- Neurotomy, radial optic, for retinal vein occlusion, 182
- Neurotoxicity. *See also* Neurologic disorders
- of cisplatin, 1662
 - opioid-induced, 79
 - of snake venom, 1589, 1589–1590
- Neurotransmitters. *See specific type*
- Neutrotrophic keratitis, 167
- Neutrotropic disease
- viral, **1376–1384**. *See also specific disorder*
 - yellow fever vaccine-associated, 1316, 1390
- Neutral protamine Hagedorn (NPH) insulin. *See* Insulin therapy; NPH insulin

- Neutral protamine lispro (NPL) insulin.
See Insulin therapy; NPL insulin
- Neurocytic ascites, 588, 589, 590
- Neutrogena, 99*t*
- Neutropenia, **509–511**, 510*t*
antibiotic prophylaxis/therapy in, 36, 510, 1281, 1281–1282, 1648
antiretroviral therapy and, 1343
in aplastic anemia, 509, 510
aspergillosis and, 1537, 1538
autoimmune, 510
cancer chemotherapy causing, 510, 1302*t*, 1649
fever/FUO and, 36, 510, 1276, 1277
antimicrobial therapy and, 36, 510, 1281–1282, 1302*t*, 1648
gram-negative bacteremia/sepsis and, 510, 1443, 1444
granulocyte transfusion for, 536–537
infections and, 509–510, 1279, 1281, 1281–1282
in cancer patients, 1279, 1302*t*, 1648
prevention/treatment and, 510, 1280–1281, 1281–1282, 1302*t*
in leukemia, 510, 520, 523
- Neutrophil count. See also Neutropenia; Neutrophilia
ascitic, 588
in bacterial peritonitis, 588, 589, 590, 689
joint fluid, 810*t*
reference values for, 1733*t*
- Neutrophil elastase gene mutations, in neutropenia, 510
- Neutrophil gelatinase-associated lipocalin, in acute tubular necrosis, 904
- Neutrophilia
in cellulitis, 137
in gram-negative bacteremia/sepsis, 1444
- Nevanac. See Nefafenac
- Nevi. See also Mole (skin)
atypical (dysplastic), **100–101**, 100*f*
blue, **101**, 101*f*
compound, 100, 100*f*
junctional, 100
melanocytic, **100**, 100*f*
pigmented, 95*t*
- Nevirapine, 1342*t*, 1345, 1346, 1347, 1348*f*. See also Antiretroviral therapy/HAART
- Nevus. See Nevi
- New World cutaneous leishmaniasis, 1487, 1488, 1489
- New World hantaviruses, 1388, 1389
- New York Heart Association, heart disease classification and, 324
- New York virus, 1388
- Newborn/infant
air travel and, 1560
antiretroviral/zidovudine therapy for, 805, 1321, 1336
chlamydial infection in, 806
CMV infection/inclusion disease in, 1363–1364, 1364, 1364–1365
coxsackievirus infection in, 1406
gonococcal infection in, 806
group B streptococcal infection in, 784–785, 804
hemolytic disease of, prevention of, 785–786
hepatitis B transmission/vaccine and, 667, 806
hepatitis C transmission and, 670, 806
herpes simplex infection and, **806**, 1351, 1355
HIV transmission to, 805, 1321, 1336
listeriosis in (granulomatosis infantisepticum), 1434
maternal thyroid disease and, 800, 1106, 1111, 1113, 1115
parechovirus infection in, 1408
pneumocystosis in, 1533, 1535
rubella infection and, 1374, 1375
seizures presenting in, 970
syphilis in (congenital syphilis), 806, 1464, **1474**
penicillin treatment in maternal disease and, 1474
toxoplasmosis during pregnancy and, 1501, 1502
varicella in, 1359
- Nexavar. See Sorafenib
- NF-κB, in myeloma, 527
- NF1/NF2 genes, in neurofibromatosis, 996
- NH₃. See Ammonia
- NHERF1 mutation, in osteomalacia/rickets, 1150
- Niacin (vitamin B₃)
deficiency of, **1265**
for lipid modification, 1253, 1255*t*, 1265
side effects/toxicity of, 1253, **1265**
- Niacinamide, 1265. See also Niacin
- Niaspan. See Niacin
- Nicardipine, 455*t*
for angina, 356
for hypertension, 453, 455*t*
pheochromocytoma/
pheochromocytoma surgery and, 1170
in urgencies/emergencies, 462*t*, 463
overdose/toxicity of, 454*t*, 462*t*, 1576
- Nicosamide, for tapeworm infection, 1514
- Nicotinamide. See also Niacin
for niacin deficiency, 1265
- Nicotine, 6. See also Smoking
for replacement therapy, 8, 1593
- Nicotinic acid. See Niacin
- Nifedipine, 455*t*. See also Calcium channel blocking drugs
for angina, 356
for hypertension, 453, 455*t*
in urgencies/emergencies, 462*t*, 463
MAOI-induced, 1069
overdose/toxicity of, 454*t*, 462*t*, 1576
pheochromocytoma/
pheochromocytoma surgery and, 1170
for preterm labor prevention, 796
- Nifurtimox
for African trypanosomiasis, 1485, 1485*t*
for American trypanosomiasis/Chagas disease, 1486, 1487
- Night blindness, in vitamin A deficiency, 1266, 1267
- Nightmares, 1077
- Nikolsky sign, 138
- Nil disease (minimal change disease), 920*t*, **928–929**
- Nilandron. See Nilutamide
- Nilotinib, 1655*t*
for chronic myeloid leukemia, 516
- Nilutamide, 1656*t*
- Nimodipine. See also Calcium channel blocking drugs
overdose/toxicity of, 1576
- Nipah virus, 1393, 1394
- NIPD. See Nocturnal intermittent peritoneal dialysis
- Nipent. See Pentostatin
- NIPHS. See Noninsulinoma pancreatogenous hypoglycemia syndrome
- Nipple, Paget disease of, 117, 117*f*, 726, 730
- Nipple discharge, **720**, 720*t*, **1719**
in breast cancer, 720, 720*t*, 730, 1719
cytologic evaluation of, 730
in fibrocystic breast condition, 718, 720, 720*t*
in hyperprolactinemia, 720, 1103, 1719
in male, 746
- Nipride. See Nitroprussside
- Nisoldipine, 455*t*
for angina, 356
for hypertension, 453, 455*t*
overdose/toxicity of, 454*t*, 1576
- Nitazoxanide
for cryptosporidiosis, 1508
for giardiasis, 1509
for rotavirus gastroenteritis, 1405
- Nitrates. See also Nitroglycerin
for acute coronary syndromes, 363
for angina
for acute attack, 355
prophylactic administration of, 355
for heart failure, 404
left ventricular (infarct-related), 373
for myocardial infarction, 370
phosphodiesterase inhibitor/sildenafil
contraindications and, 370, 952, 1051, 1226
for pulmonary edema, 408
- Nitric oxide
in erection, 951, 952
in exhaled breath, in asthma, 248
in shock, 488
- Nitrites
for cyanide poisoning, 1566*t*, 1577, 1578*t*
methemoglobinemia caused by, 1584
- Nitrobenzene, methemoglobinemia caused by, 1584
- Nitrofurantoin
breastfeeding and, 782*t*
for urinary tract infection, 939, 940, 940*t*
- Nitrogen, liquid. See Liquid nitrogen
- Nitrogen balance, nutritional support and, 1272
- Nitrogen mustards, in cancer chemotherapy, 1650*t*

- Nitrogen oxide gases,
methemoglobinemia caused
by, 1584
- Nitroglycerin. *See also* Nitrates
for acute coronary syndromes, 363
for angina
for acute attack, 355
in diagnosis, 352
prophylactic administration of, 355
for heart failure, 404
left ventricular (infarct-related), 373
for hypertensive urgencies/
emergencies, 461, 462*t*
for myocardial infarction, 370
phosphodiesterase inhibitor/sildenafil
contraindications and, 370,
1051, 1226
for pulmonary edema, 408
- Nitropruss. *See* Nitroprusside
- Nitroprusside
for cardiogenic shock, 374
cyanide poisoning caused by, 1577
for heart failure, 404
infarct-related, 373
for hypertension
in aortic dissection, 477
pheochromocytoma surgery and,
1170
in urgencies/emergencies, 461, 462*t*
- Nix. *See* Permethrin
- Nizatidine, 613. *See also* H₂ receptor
blocking drugs
- Nizoral. *See* Ketoconazole
- Njovera (endemic syphilis), 1475
- NK cell lymphoma, 524, 524*t*
Epstein-Barr virus and, 1363
nose and paranasal sinus involvement
and, 223
- NK₁ receptor antagonists, for nausea and
vomiting, 569, 569*t*, 1660
- NK₁ receptors, in nausea and vomiting,
566, 1660
- NMO-IgG, in neuromyelitis optica, 1012
- NMP22 assay, in bladder cancer, 1639
- NMS. *See* Neuroleptic malignant
syndrome
- NNRTIs. *See* Nonnucleoside reverse
transcriptase inhibitors
- Nocardia asteroides/brasiliensis*
(nocardiosis), 1300*t*, 1457
actinomycotic mycetoma and, 1540
- Noctec. *See* Chloral hydrate
- Nocturia, in heart failure, 398
- Nocturnal hemodialysis, 915
- Nocturnal intermittent peritoneal
dialysis, 916
- Nocturnal myoclonus, 1077
- Nocturnal penile tumescence testing, 952,
1050
- Nodular glomerulosclerosis, in diabetic
nephropathy, 931
- Nodular goiter. *See* Multinodular
(nodular) goiter
- Nodular malignant melanoma, 102
- Nodular regenerative hyperplasia,
noncirrhotic portal
hypertension and, 699
- Nodules
milker's (paravaccinia), 1404
pulmonary, solitary. *See* Solitary
pulmonary nodule
- rheumatoid, 827, 827*f*
in coal workers (Caplan syndrome),
309
gouty tophi differentiated from, 814,
828
- skin, 95*t*. *See also specific type*
inflammatory, 150–152
violaceous to purple, 143–145
subcutaneous. *See* Subcutaneous
nodules
- thyroid, 1105*t*, 1123–1126, 1124*t*. *See
also* Goiter; Thyroid cancer;
Thyroid nodules
- vocal fold, 235
- Noise trauma
hearing loss caused by, 207
tympanic membrane perforation and,
205, 206*f*
- Nolvadex. *See* Tamoxifen
- Non-ABCDE hepatitis, transfusion-
associated, 670
- Nonadherence. *See* Adherence/
nonadherence
- Nonalcoholic fatty liver disease (NAFLD),
684–685. *See also* Fatty liver
cirrhosis and, 684, 685, 687
hepatocellular carcinoma and, 685,
1603
- Nonalcoholic steatohepatitis (NASH),
684, 685
- Nonbacterial prostatitis, 942*t*, 943–944
- Noncirrhotic portal hypertension,
699–700
- Non-clostridial crepitant cellulitis, 1456
- Noncompliance. *See* Adherence/
nonadherence
- Nonconvulsive status epilepticus, 975
- Non-determined leukoencephalopathy,
1383
- Nondiabetic (renal) glucosuria, 1198
- Nonepileptic seizure, psychogenic
(PNES), 971–972, 1045
- Nonerosive/nonspecific gastritis, 609–610
- Nonfamilial adenomatous polyps, 653–
654
- Nongonococcal acute bacterial (septic)
arthritis, 858–859, 1302*t*
in drug users, 859, 1292
rheumatoid arthritis and, 827, 859
- Non-group A streptococcal infections, 1422
- Non-Hodgkin lymphoma, 524–526, 524*t*,
1610*t*. *See also* Lymphoma
fever/FUO and, 1277
gastric, 525, 1618–1619
hepatitis C and, 671
in HIV infection/AIDS, 241, 1326,
1327, 1332, 1338*t*
nose and paranasal sinus involvement
and, 223
pemphigus and, 138
small intestine, 1620
thyroid, 1128, 1131, 1134
- Noninsulinoma pancreatogenous
hypoglycemia syndrome
(islet cell hyperplasia), 1238,
1241, 1242
- Noninsulinomas, localization of, 1172
- Noninvasive ischemia testing,
preoperative, 46–47, 47*t*, 48*f*
- Noninvasive positive-pressure ventilation
(NPPV)
for COPD, 264
for obesity-hypoventilation
(Pickwickian) syndrome, 318
for respiratory failure, 320
- Nonionizing radiation, 1554
- Nonislet cell tumor hypoglycemia, 1241–
1242
- Nonketotic hyperglycemic hyperosmolar
coma. *See* Hyperglycemic
hyperosmolar state
- Nonmyeloablative allogeneic transplant.
See Bone marrow/stem cell
transplantation; Reduced-
intensity allogeneic stem cell
transplantation
- Nonnucleoside reverse transcriptase
inhibitors (NNRTIs), 1342*t*,
1345–1346, 1348*f*. *See also*
Antiretroviral therapy/
HAART
antituberculous drug interactions and,
285
in combinations, 1345, 1348*f*
resistance to, 1347, 1349
- Nonocclusive mesenteric vascular
insufficiency, 470
- Nonoxynol 9, 775
HIV infection/AIDS and, 775, 1333
- Nonparalytic poliomyelitis, 1372, 1373
- Nonparoxysmal junctional tachycardia,
390
- Nonproliferative retinopathy, 185, 1223
- Non-Q wave (non-ST elevation)
infarction, 360, 366. *See also*
Acute coronary syndromes;
Myocardial infarction
- Non-rapid eye movement (non-REM)
sleep, 1075
- Nonscarring alopecia, 156–157
- Nonsecretory myeloma, 528
- Nonseminomas, 1177, 1642, 1643,
1643–1644
- Non-sexually transmitted epididymitis,
940*t*, 944, 945
- Non-sexually transmitted
treponematoses, 1474–1475
- Non-small cell lung cancer, 1597, 1610*t*.
See also Lung cancer
paraneoplastic syndromes associated
with, 1596*t*
staging of, 1597–1598, 1598*t*
survival rates for, 1597, 1598*t*
treatment of, 1599–1600, 1610*t*
- Nonspecific interstitial pneumonia
(NSIP), 294*t*, 295
in HIV infection/AIDS, 1326–1327
- Non-ST elevation acute coronary
syndromes. *See also* Acute
coronary syndromes
- Nonsteroidal anti-inflammatory drugs
(NSAIDs), 76, 77–78*t*. *See
also specific agent*
for abnormal premenopausal bleeding,
748
for acute coronary syndromes, 362*t*
acute kidney injury and, 829, 902
in analgesic nephropathy, 932–933
for ankylosing spondylitis, 855
aspirin coadministration and, 612, 616
cardiovascular complications and, 608,
612, 615

- in colorectal cancer prevention, 11, 1623
 COX-1/COX-2 affected by, 611
 for endometriosis, 761
 gastritis/gastropathy caused by, 607, 608, 828–829
 gastrointestinal side effects/bleeding and, 76, 583, 607, 615, 615–616, 828–829
 for gout, 814
 for headache, 42
 hypertension and, 436
 hyponatremia caused by, 872
 myocardial infarction and, 362f, 370
 nonselective, 608, 611, 615, 616. *See also* Coxibs
 for ophthalmic disorders, 169–170t
 for osteoarthritis, 811–812, 1702
 for pain management, 76, 77–78t, 1049
 with opioid analgesics, 79, 83t
 in peptic ulcer disease, 611, 611–612, 614t, 615–616, 828–829
H pylori eradication therapy and, 614t, 615
 misoprostol coadministration and, 616
 prevention and, 615–616
 proton pump inhibitors for, 613, 615, 615–616, 828–829
 risk reduction and, 616
 for pericarditis, 420
 platelet function affected by, 549t, 611, 829
 pompholyx-like eruption caused by, 121
 for psoriatic arthritis, 856
 renal toxicity of, 829
 for rheumatoid arthritis, 828–829
 selective. *See* Coxibs
 topical, 76, 97t, 811–812
 tubulointerstitial nephritis caused by, 932t
- Nonsustained ventricular tachycardia, 391–392
- Nontreponemal antigen tests, for syphilis, 1466, 1466t
- Nontuberculous atypical mycobacteria (NTM), 287, **1458–1459**
 adenitis/lymphadenitis caused by, **240, 1458**
 MAC infections. *See Mycobacterium* (mycobacterial infections), *avium* complex
 pulmonary disease caused by, **287–289, 289t, 1458**
 in HIV infection/AIDS, 1326
 skin and soft tissue infections caused by, **1458**
- Noonan syndrome, 325
- Nor-QD. *See* Norethindrone
- Norelgestromin, in transdermal contraceptive patch, 773
- Norepinephrine
 for hypotension/shock, 488
 cardiogenic, 374, 487
 in tricyclic antidepressant overdose, 1563
 in pheochromocytoma/paraganglioma, 1166, 1167
- Norethindrone
 for abnormal premenopausal bleeding, 748
 for endometriosis, 761
 in hormone replacement therapy, 779, 1183, 1184, 1185
 in oral contraceptives, 771t, 772t
 for postmenopausal bleeding, 749
 in progestin minipill, 772t, 773
 with transdermal estradiol, 1183
- Norflex. *See* Orphenadrine
- Norfloxacin. *See also* Fluoroquinolones
 for ophthalmic disorders, 168t
 for urinary tract infection, 940t
- Norgestimate
 in estrogen replacement therapy, 1184
 in oral contraceptives, 770, 771t
 for hirsutism/virilization, 1163
- Norgestrel, in oral contraceptives, 771t
- Normal anion gap acidosis, 890, 890t, **891–893, 892t, 893–894**
 alcoholic ketoacidosis and, 891
 diabetic ketoacidosis and, 891, 1234–1235
 dilutional, 893
 gastrointestinal bicarbonate loss and, 892, 892t, 893
 parenteral nutritional support and, 893, 1274t
 posthypocapnia, 893, 897
 renal disease/renal tubular acidosis and, 892, 892t, 893, 893–894, 902
 tubulointerstitial disease and, 933
 urinary anion gap in assessment of, 892t, 893
- Normal flora
 anaerobic infections caused by, 1454–1456
 coagulase-negative staphylococci as, 1428
 opportunistic infections caused by, 1279
- Normal-pressure hydrocephalus, 1007, 1017
- Normal ranges, for diagnostic/laboratory tests, 1727–1735t. *See also specific test*
- Normal-tension glaucoma, 175
- Normetanephrine, in pheochromocytoma, 1167
- Normochloremic metabolic (increased anion gap) acidosis, 890, **890–891, 890t, 893**
- Normodyne. *See* Labetalol
- Normokalemic periodic paralysis, 1037
- Noroviruses, acute diarrhea/food poisoning caused by, 574t, 1293, 1295t, 1404–1405
- Norplant system, 773
- Norpramin. *See* Desipramine
- Norprolac. *See* Quinagolide
- Nor-QD. *See* Norethindrone
- North Asian tick typhus, 1414
- Norton score, for pressure ulcers, 70
- Nortriptyline, 1068, 1070t, 1723t. *See also* Antidepressants
 for neuropathic pain/diabetic neuropathy, 84, 84t, 1225
- Norvasc. *See* Amlodipine
- Norvir. *See* Ritonavir
- Norwalk virus, gastroenteritis caused by, 1404–1405. *See also* Noroviruses
- Nose, **213–223**. *See also under* Nasal
 in granulomatosis with polyangiitis, **223, 849**
 infections of, **213–218**. *See also* Rhinosinusitis; Sinusitis
 inflammatory disease of, **223**
 in sarcoidosis, 223, 295f
 traumatic injury of, **221–222**
 tumors/granulomatous disease of, **222–223**
- Nosebleed. *See* Epistaxis
- Nosocomial infections. *See* Health care (hospital)-associated infections
- Nosocomial pneumonia, **275–278, 276t, 277t, 1302t**
- Notch 1, in aortic stenosis, 342
- NOTES (natural orifice transluminal endoscopic surgery), cholecystectomy via, 704
- Novantrone. *See* Mitoxantrone
- Novolin, 1213. *See also* Insulin therapy
- Novolog. *See* Insulin aspart
- NPH insulin, 1213, 1213t, 1214, 1214f, 1214t, 1215, 1219, 1221. *See also* Insulin therapy
 in mixtures/composition therapy, 1214t, 1216, 1219, 1221
 in pregnancy, 801, 1230
- NPL insulin, 1216. *See also* Insulin therapy
 in mixtures/composition therapy, 1214t, 1216
- NPM1, in acute leukemia, 519
- NPPV. *See* Noninvasive positive-pressure ventilation
- NPT2a/NPT2c mutations, in osteomalacia/rickets, 1150
- NREM sleep, 1075
- NRTIs. *See* Nucleoside reverse transcriptase inhibitors
- NSAIDs. *See* Nonsteroidal anti-inflammatory drugs
- NSCLC. *See* Non-small cell lung cancer
- NSF. *See* Nephrogenic systemic fibrosis
- NSIP. *See* Nonspecific interstitial pneumonia
- nsNSAID. *See* Nonsteroidal anti-inflammatory drugs
- NSVT. *See* Nonsustained ventricular tachycardia
- NTM. *See* Nontuberculous atypical mycobacteria
- NTZ. *See* Nitazoxanide
- Nuclear bleeding scans, in GI bleeding, 585
- Nuclear bone scanning. *See* Bone scanning
- Nuclear radiation, carcinogenesis and, 1555
- Nuclear transcription factor mutations, in MODY, 1194–1195
- Nucleic acid amplification tests
 in chlamydial infection, 1461
 in gonococcal infection, 1452
 in STD screening, 1290, 1291
 in tuberculosis, 281, 281t
- Nucleophosmin 1 (NPM1), in acute leukemia, 519
- Nucleoside/nucleotide backbone, for antiretroviral regimens, 1347, 1348f

- Nucleoside reverse transcriptase inhibitors (NRTIs), 1341*t*, 1343–1344, 1348*f*. *See also* Antiretroviral therapy/HAART
- in combinations, 1343, 1348*f*
- for hepatitis B, 675–676
- lactic acidosis caused by, 891, 1347
- myopathy associated with use of, 861
- resistance to, 675, 676, 1349
- Nucleotide reverse transcriptase inhibitor, 1341*t*, 1344, 1348*f*. *See also* Antiretroviral therapy/HAART
- for hepatitis B, 675–677
- resistance to, 675, 676
- Nucleus pulposus, herniation of
- cervical (neck pain), 818, **1029**, 1030–1031*f*, 1686
- lumbar/sacral (back pain), 819, 819–820, 820, 820*t*, 1685–1686
- NuLYTE. *See* Polyethylene glycol
- Nursing (breastfeeding). *See* Lactation
- Nursing homes
- caregiver issues related to placement in, 58–59
- scabies outbreaks and, 147
- Nutcracker esophagus, 606
- NutraSweet. *See* Aspartame
- Nutrients. *See also* Diet; Nutritional disorders; Nutritional support
- diets restricting, **1268–1269**
- diets supplementing, **1269–1270**
- requirements for in nutritional support, **1271–1272**
- Nutrition. *See also* Diet; Nutrients; Nutritional disorders; Nutritional support
- in Crohn disease, 642, 643
- in pregnancy, **785**
- preventable disease/deaths and, *3t*, *7t*
- for terminally ill/dying patient, **90–91**
- Nutritional disorders, **1257–1275**. *See also* Eating disorders; Malnutrition; Nutritional support; Obesity
- alcoholic ketoacidosis and, 891, 893
- alcoholic liver disease/cirrhosis and, 680, 681
- cognitive disorders/delirium caused by, 1087*t*
- diet therapy for, **1268–1270**
- neuropathy associated with, 1023. *See also specific type*
- thrombocytopenia associated with, **540**
- Nutritional support, **1270–1275**, 1271*f*, 1272*t*, 1273*t*, 1274*t*. *See also* Central vein nutritional support; Enteral nutritional support; Parenteral nutritional support
- in alcoholic liver disease/cirrhosis, 681
- in anorexia nervosa, 1262–1263
- in burn injury, 1551–1552
- in caustic esophageal injury, 599
- complications of, **1273**, **1274–1275**, 1274*t*
- in Crohn disease, 642, 643
- in elderly, 70
- in HIV infection/AIDS, 1325
- indications for, **1270**
- for involuntary weight loss, 38
- methods for, **1270–1271**, 1271*f*
- nutritional requirements and, **1271–1272**
- in pancreatitis, 714
- for protein–energy malnutrition, 1258
- in respiratory failure, 321
- in short bowel syndrome, 626
- for terminally ill/dying patient, 90–91
- in ulcerative colitis, 648
- Nutropin Depot. *See* Recombinant human growth hormone
- NuvaRing, 1184
- Nystagmus
- in coma or stupor, 1014
- intracranial tumors causing, 991
- in vertigo, 209, 210, 212
- in vestibular neuronitis, 211
- Nystatin, for candidiasis
- oral, 226
- vulvovaginal, 752
- Obesity, 13–15, **1258–1261**
- arthritis and, 810
- asthma risk and, 243
- binge eating disorder and, 1714
- cancer risk and, 13, 1259, 1594
- cholelithiasis/gallstones and, 702
- coronary heart disease and, 13, 350
- in women, 1707
- in Cushing syndrome, 1158, 1160
- definition of/measurements in, 13, 1259
- in diabetes mellitus, 13, 1194, 1197, 1220
- diet and, 1202, 1205, 1220
- metformin treatment and, 1202, 1203, 1209, 1220
- diet/eating behavior changes and, 13, 14, 1260
- exercise/activity and, 12–13, 13, 14, 1260
- genetic factors in, 1259
- health consequences of, 13–14, 1259
- in hypertension, 13, 436
- hypogonadism in, 1173
- hypoventilation and (Pickwickian syndrome), **318**
- lipid abnormalities in, 1248*t*
- medical conditions/evaluation and, 1259–1260
- medications in management of, 14, 1260–1261
- nonalcoholic fatty liver disease and, 684, 685
- in polycystic ovary syndrome, 765, 766, 1162
- postoperative pulmonary complications and, 50
- prevalence of, 13, 1259
- preventable disease/deaths and, *3t*, 13–15, 1259
- prevention of, **13–15**
- psoriasis and, 106
- treatment of, 14, 1260–1261. *See also* Bariatric surgery
- weight gain in pregnancy and, 783, 785
- Obesity-hypoventilation syndrome (Pickwickian syndrome), **318**
- Obliterative bronchiolitis, 269, 270. *See also* Bronchiolitis
- O'Brien test, 1680*t*, 1681
- Obscure gastrointestinal bleeding, **585–586**, 587
- Obscure-occult bleeding, 586, 587
- Obscure-overt bleeding, 585–586
- Obsessions, 1041. *See also* Obsessive-compulsive disorder
- Obsessive-compulsive disorder, 1041, 1044
- drug therapy for, 1044, 1067, 1068
- panic disorder and, 1041
- Tourette syndrome and, 1005, 1041
- Obsessive-compulsive personality disorder, 1052*t*
- Obsessive-compulsive spectrum, 1041
- Obstetrics/obstetric disorders, **781–808**. *See also* Pregnancy
- adverse ophthalmic effects of drugs used in, 196*t*
- Obstructive jaundice, 662–663, 663*t*
- choledocholithiasis/cholangitis causing, 707
- in primary sclerosing cholangitis, 709
- Obstructive lung disease. *See* Airway disorders, obstruction; Chronic obstructive pulmonary disease
- Obstructive shock, 485, 485*t*, 486
- Obstructive sleep apnea, 231, 318, **318–319**
- obesity-hypoventilation syndrome and, 318
- postoperative pulmonary complications and, 50
- Obstructive uropathy
- postrenal, 903
- tubulointerstitial disease caused by, 932
- Obstructive voiding symptoms
- in benign prostatic hyperplasia, 956, 957*t*
- in prostate cancer, 1630
- in prostatitis, 942
- Obturator sign, in appendicitis, 630
- Occipital lobe lesions, 991
- Occluder devices, for patent ductus arteriosus, 333
- Occlusive dressings, 94
- in exfoliative dermatitis/erythroderma, 116
- for leg ulcers, 154
- for psoriasis, 107
- for wart removal, 140
- Occult diabetes, **1243**
- Occult gastrointestinal bleeding, **586–587**. *See also* Gastrointestinal bleeding
- stool test for. *See* Fecal occult blood testing
- Occupational asthma, 243, **310**
- Occupational pulmonary diseases, 292*t*, **308–311**, 309*t*, 310*t*. *See also specific disorder*
- Occupational radiation exposure, 1555
- Occupational therapy, for stroke patient, 983
- OCD. *See* Obsessive-compulsive disorder
- OCD spectrum, 1041
- Ochronosis, 1665

- ¹³C-Octanoic acid breath test, in nausea and vomiting, 568
- Octreotide
for acromegaly/gigantism, 1101
for ACTH-secreting tumor identification/treatment, 1159, 1160
for carcinoid syndrome, 1621
for diarrhea, 580
for drug-induced hypoglycemia, 1566t, 1580
for GH-secreting tumor, 1096, 1101
for GI bleeding/esophageal varices, 583, 602
for islet cell tumors/insulinomas, 1172, 1241
for pheochromocytoma/paraganglioma identification, 1169
- Ocu-chlor. *See* Chloramphenicol
- Ocuflox. *See* Ofloxacin
- Ocular contusions, 192–193, 193f
- Ocular disease. *See* Eye, disorders of
- Ocular examination. *See* Eye, examination of
- Ocular hemorrhages
eye injuries and, 192, 193, 193f
vitreous, 180
- Ocular hypertension, 176. *See also* Glaucoma
treatment of, 170–172t
- Ocular lacerations, 193–194, 193f
- Ocular larva migrans, 1523
- Ocular medications. *See* Ophthalmic medications
- Ocular melanoma, 102
- Ocular motor palsies, 190–191
in myasthenia gravis, 1032
- Ocular movements. *See* Eye (extraocular) movements
- Ocular muscular dystrophy, 1035t
- Ocular myasthenia gravis, 1113
- Ocular/orbital pain
in acute angle-closure glaucoma, 174
in corneal abrasion, 192
headache and, 962
in ultraviolet (actinic) keratitis, 194
in uveitis, 178
- Ocular trauma, 192–194, 193f
- Oculocephalic reflex, in coma or stupor, 1014
- Oculomotor response, in coma or stupor, 1014
- Oculopharyngeal muscular dystrophy, 1035t
- Oculosympathetic paralysis. *See* Horner syndrome
- Oculovestibular reflex, in coma or stupor, 1014, 1015
- Ocu-Pred. *See* Prednisolone
- Ocusert. *See* Pilocarpine
- Oddi, sphincter of. *See* Sphincter of Oddi
- Odontogenic infections. *See also* Dental disorders
deep neck infections and, 230
- Odor, breath
in cyanide poisoning, 1577
in diabetic ketoacidosis, 1197, 1232
in uremia, 909t, 910
- Odor identification/discrimination/
threshold, disorders of, 219–220
- Odynophagia, 592
in epiglottitis (supraglottitis), 235, 1420
in esophageal cancer, 1613
in infectious esophagitis, 592, 598
in pharyngitis, 228, 1420
in pill-induced esophagitis, 598
- Odynophonia, laryngeal contact ulcers/
granulomas causing, 235
- OEP. *See* Oil of evening primrose
- Ofatumumab, 1654t
- Ofloxacin. *See also* Fluoroquinolones
for ophthalmic disorders, 168t
for urinary tract infection, 940t
- Ogen, 1184
- Ogilvie syndrome, 628–629
- Oil of evening primrose (OEP), for fibrocystic condition, 719
- Oka/Merck VZV vaccine. *See* Herpes zoster vaccine
- Olanzapine, 1055, 1056, 1056t, 1057, 1057t, 1058, 1060t. *See also* Antipsychotic drugs
for bipolar disease/mania, 1072
for depression, 1065, 1069
diabetes and, 1057, 1059, 1060t
in elderly, 1057, 1058
overdose/toxicity of, 1057, 1057t, 1059, 1060t, 1574
for personality disorder, 1052
for psychedelic abuse/overdose, 1084
- Old World cutaneous leishmaniasis, 1487, 1488, 1489
- Old World hantaviruses, 1388, 1389
- Older adults, 57–73. *See also specific disorder affecting*
abuse/mistreatment/neglect and, 17, 72–73, 73t
advance directives and, 89
anemia in, 493
antipsychotic therapy in, 1058
appendicitis in, 630
assessment of, 57–59, 58f, 58t, 59t
benzodiazepine use in, 1043
caregiver issues and, 58–59
cholesterol screening in, 1251–1252
delirium in, 64
at end of life, 86–87, 1088
postoperative, 53, 53t
dementia in, 59–63, 1005–1010, 1008t
assessment of/screening for, 60, 1006–1007
decision-making capacity and, 60
depressed, 63. *See also* Depression
drug use (pharmacotherapy/
polypharmacy) and, 71–72
falls and, 65, 67t
urinary incontinence and, 67
falls and, 65–66, 66t, 67t
fecal incontinence and, 660
fever/FUO in, 35
frailty and, 69–70
functional assessment/screening for, 57–58, 59
gait disorders in, 65–66, 66t, 67t
hearing impairment in, 72
hypertension/hypertension management and, 433, 435, 436, 437, 458t, 459
immobility and, 65
- influenza vaccine for, 3
injury prevention and, 17
insomnia/insomnia management in, 1075, 1076
malnourished, 69–70
management of common problems in, 59–73
pressure ulcers in, 70–71, 71f
principles of care of, 57
prognosis/life expectancy and, 57, 58f, 58t, 59t
psychosis in (late life psychosis), 1054
suicide in, 63
undernutrition and, 69–70
urinary incontinence and, 67–69
values/preferences and, 57
vision impairment in, 72
weight loss in, 37, 37t, 69–70
- Oleander, toxicity of, 1578–1579
- Olecranon bursitis, 825, 825f, 826
- Olestra, diarrhea caused by, 578
- Olfactory dysfunction, 219–220
- Oligoclonal bands, in multiple sclerosis, 1011
- Oligodendroglioma, 990t
- Oligozoospermia, 954f, 955
- Oliguria, 898, 903
in acute tubular necrosis, 905, 906
in obstructive uropathy, 932
- Olmesartan/olmesartan HCTZ, 451t
with amlodipine, 451t
- Olopatadine, for allergic eye disease, 167, 169t
- Olsalazine, for inflammatory bowel disease, 638
- Omalizumab, for asthma, 249f, 252t, 253
- Omega-3 fatty acids/fish oil
platelet function affected by, 549t
preventable disease/deaths associated with low intake of, 3t
- Omeprazole, 613. *See also* Proton pump inhibitors
clopidogrel interaction/
coadministration and, 616
- On-off phenomenon, 999
- On-X prosthetic valves, 343, 349
- Onchocerca volvulus* (onchocerciasis/river blindness), 1526–1527
- Oncocytoma, of kidney, 1641, 1642
- Oncotype Dx assay, 734, 736, 743
- Oncovin. *See* Vincristine
- Ondansetron, 84, 568, 568t, 1660. *See also* Antiemetics
- Ondine curse (primary alveolar hypoventilation), 317–318
- One-leg standing extension test, in back pain, 1683
- Onglyza. *See* Saxagliptin
- Ontak. *See* Denileukin diftitox
- Onycholysis, 157
- Onychomycosis (tinea unguium), 157, 158
- Onychophagia, 1041
- Oophorectomy (salpingo-oophorectomy)/ovarian ablation
in breast cancer prevention/treatment, 723, 738, 739, 739–740
for endometrial carcinoma, 759
for endometriosis, 761

- Oophorectomy (salpingo-oophorectomy)/ovarian ablation (*Cont.*):
 estrogen replacement therapy after, 780
 for hirsutism/virilization, 1163
 in ovarian cancer prevention/treatment, 764, 765
 HNPCC and, 657
 for PID, 764
 surgical menopause and, 779, 780, 1181
 testosterone levels after, 1185
- Oophoritis, in mumps, 1370, 1371
- Opana/Opana ER. *See* Oxycodone
- Open-angle glaucoma, chronic, 175–177, 176f
- Open biopsy, for breast lump evaluation, 729, 1718. *See also* Breast, biopsy of
- Open can test, 1677t, 1680
- Opening snap, in mitral stenosis, 337
- Operant conditioning. *See* Behavior modification
- Ophthalmia neonatorum, 806
- Ophthalmic artery, obstruction of, 981
- Ophthalmic medications, 168–172t
 contaminated, 195
 systemic effects of, 195
 toxic and hypersensitivity reactions to, 166, 195
- Ophthalmopathy, Graves, 191, 1110, 1112–1113, 1117–1118
 RAI treatment for hyperthyroidism and, 1115–1116, 1117–1118
- Ophthalmoplegia
 episodic vertigo in, 210
 headache and, 41–42, 963
- Ophthalmoplegic migraine, 963
- Opioid-receptor antagonist laxatives, 86, 571–572
- Opioids/opioid analgesics, 79–83, 80–83t.
See also specific agent
 addiction and, 76, 1083–1084
 allergic reaction to, 84
 for chronic pain, 79, 1049
 constipation caused by, 79, 84, 86, 571–572
 for COPD, 264
 dependency and, 76, 1083–1084
 for diarrhea, 577
 for dyspnea, 26, 86, 264
 in end-of-life care, 76
 hypogonadism caused by, 1096
 long-acting, 79
 for migraine headache, 964
 for myocardial infarction, 370
 nausea and vomiting caused by, 84
 for neuropathic pain, 79, 1021
 with NSAIDs/acetaminophen, 79, 83t
 overdose/abuse of, 18–20, 1083–1084, 1566t, 1586–1587
 management of, 18–20, 1563, 1586–1587
 narcotic antagonists/naloxone for, 20, 1084, 1563, 1566t, 1586–1587
 during pregnancy, 783
 pseudo-addiction and, 76
 short-acting, 79
 tolerance and, 76, 79
 withdrawal and, 1083–1084
- Opisthorchis felineus/viverrini* (opisthorchiasis), 1513
 cholangiocarcinoma and, 1513, 1606
- Opium, tincture of. *See* Tincture of opium
- Opportunistic infections, 1278–1282. *See also specific type*
 in cancer patients, 1648
 fungi/molds causing, 1280–1281, 1540–1541
 in HIV infection/AIDS, 1319, 1320t
 CD4 T cell counts and, 1322–1323, 1323f, 1324, 1334t, 1336, 1339
 prevention of, 1334–1335, 1334t, 1336–1337, 1337t
 treatment of, 1337–1340, 1338–1339t
 adjunctive, 1339–1340
 immunization recommendations and, 4–5, 1309t, 1313t, 1314
 prevention of, 1280–1281, 1334–1335, 1334t, 1336–1337, 1337t
 in transplant recipients, 1279, 1279–1280, 1280–1281
 treatment of, 1281–1282, 1337–1340, 1338–1339t
- Oprelvekin, for chemotherapy-induced thrombocytopenia, 1649, 1659t
- Opsoclonus/myoclonus, 995
- Optic atrophy
 in optic neuritis, 188
 in pseudotumor cerebri, 995
- Optic disk
 crowded, 189–190
 ischemic optic neuropathy and, 188
 cupping of, in chronic glaucoma, 175, 175–176, 176f
 drusen of, 189–190
 swelling of, 189–190
 in ischemic optic neuropathy and, 188
 in optic neuritis, 188
- Optic nerve
 compression of, in dysthyroid eye disease, 191, 1112
 damage to in glaucoma, 175, 175–176, 176f
- Optic neuritis, 188–189
 in neuromyelitis optica, 188, 1012
- Optic neuropathy
 inflammatory (optic neuritis), 188–189
 in neuromyelitis optica, 188, 1012
 ischemic, 187–188
 in giant cell arteritis, 188, 845–846
- Optic neurotomy, radial, for retinal vein occlusion, 182
- Optipranolol. *See* Metipranolol
- Optivar. *See* Azelastine
- OPV (oral/Sabin polio vaccine), 1373, 1373–1374
 IPV booster and, 1315
 VDPV and, 1372, 1374
- Oragrafin. *See* Ipodate sodium
- Oral cavity, 224–232
 anaerobic flora of, 1455
 pneumonia/lung abscess and, 278, 1455
 bullous pemphigoid involving, 139
 cancer of, 224–225, 225f
 incidence/risk/mortality of, 1594t
 candidiasis involving (thrush), 131, 131f, 225–226, 226f
 esophagitis and, 598, 1529
 in HIV infection/AIDS, 131, 225–226, 226, 226f, 1325, 1328–1329, 1337
 erythema multiforme involving, 134, 135
 erythroplakia involving, 224
 in HIV infection/AIDS, 1325, 1328–1329
 leukoplakia involving, 224–225, 224f, 225f, 1323, 1329
 lichen planus involving, 144, 224
 mucositis of, chemotherapy/radiation causing, 1554, 1660
 pemphigus involving, 138
 ulcerative lesions of, 226–227, 227f
 in Behçet syndrome, 853
 chemotherapy-induced, 1660
 herpes simplex esophagitis and, 598
 in HIV infection/AIDS, 1329
- Oral contraceptives, 770–773, 771–772t, 772t
 for abnormal premenopausal bleeding, 748
 antibiotics affecting efficacy of, 127
 benefits of, 770
 benzodiazepine interactions and, 1043t
 breast cancer risk and, 722, 772
 cervical dysplasia/cancer and, 772
 combined, 770–773, 771–772t, 772t
 contraindications/adverse effects of, 770–773, 772t
 depression associated with use of, 772, 1064
 drug interactions and, 770
 efficacy/methods of use and, 770
 for emergency/postcoital contraception, 776
 endometrial hyperplasia/carcinoma and, 770, 772
 for endometriosis, 761, 1715
 after gestational trophoblastic disease, 792
 hepatocellular adenoma/liver tumors associated with, 701, 702, 772, 1604
 for hirsutism/virilization, 1163
 for hormone replacement therapy, 1184
 hypertension and, 438, 772
 lactation/breastfeeding and, 772
 lipid abnormalities associated with use of, 1248t
 melasma (chloasma) caused by, 155, 773
 nipple discharge caused by, 720
 ovarian cancer prevention and, 770, 772, 1710
 selection of, 770
 thromboembolic disease and, 770
- Oral glucose tolerance test. *See* Glucose tolerance/intolerance
- Oral hypoglycemic agents. *See* Antidiabetic agents
- Oral nutritional supplements, 1270
 in HIV infection/AIDS, 1325
 for undernourished elderly, 70

- Oral polio vaccine (OPV/Sabin vaccine), 1373
 IPV booster and, 1315
 VDPV and, 1372, 1374
 Oramorph. *See* Morphine
 Orange top RST, 1736t
 Orbital cellulitis/abscess, **191–192**
 bacterial rhinosinusitis and, 191, 216
 Orbital floor, blowout fracture of, 192
 Orchiectomy
 hypergonadotropic hypogonadism and, 1174
 for intra-abdominal testes, 1178
 for prostate cancer, 1636, 1637t
 for testicular cancer, 1147, 1643, 1644
 Orchiopexy/orchidopexy, infertility/
 testicular cancer risk and,
 1178, 1642
 Orchitis
 in filariasis, 1525
 mumps, 1370, 1371
 Orellanine, *Cortinarius* mushroom
 poisoning and, 1586t
 Orf, 1404
 Organ of Corti, hearing loss caused by
 disorders of, 198
 Organ donation, **93**. *See also*
 Transplantation
 Organ failure, anemia of, 493
 Organ transplantation. *See specific type*
and Transplantation
 Organic brain syndrome. *See* Cognitive
 disorders; Delirium;
 Dementia
 Organic (alcoholic) hallucinosis, 1081,
 1082, 1088
 Organic personality syndrome, 1088
 Organophosphate poisoning, 1566t, 1587
 seizures caused by, 1565t
 Orgasm, 1049
 loss of/orgasmic dysfunction. *See also*
 Sexual dysfunction
 antidepressants causing, 1067, 1069
 antipsychotics causing, 1059
 in female, 767, 1050
 in male, 951
 Oriental spotted fever, 1414
Orientia tsutsugamushi, 1409t, 1411
 Orinase. *See* Tolbutamide
 Orlistat
 for obesity, 1260–1261
 in type 2 diabetes, 1220
 vitamin D affected by, 1149
 Ornithosis (psittacosis), **1462**
 Oromandibular dystonia, 1003
 Oropharyngeal anthrax, 1432
 Oropharyngeal dysphagia, 592, 592t. *See*
also Dysphagia
 Oropharyngeal secretions, aspiration of,
 anaerobic pleuropulmonary
 infection and, 278, 1455
 Orphenadrine, for parkinsonism, 999t.
See also Antiparkinsonism
 drugs
 Ortho Dienestrol, 1184
 Orthodeoxia
 in hepatopulmonary syndrome, 691
 in patent foramen ovale, 329
 Orthodromic reentrant tachycardia, 383
 Orthokeratology, 163
 Orthomyxovirus, influenza virus as, 1394
 Orthopedics, **1673–1705**. *See also*
 Musculoskeletal disorders
 ankle injuries, **1703–1705**, 1703t, 1704t
 general approach to musculoskeletal
 injuries and, **1673–1674**
 hip problems, **1689–1692**, 1690t
 knee problems, **1692–1703**, 1693t,
 1694–1697t
 shoulder problems, **1674–1683**, 1676–
 1680t
 spine problems, **1683–1687**, 1684t, 1687t
 upper extremity problems, **1687–1689**,
 1689t
 Orthophosphates, for hypercalciuria, 948
 Orthostatic (postural) hypotension
 antipsychotics causing, 1059
 in diabetes, 1197, 1226
 dysautonomia (autonomic dysfunction)
 and, 975, 976, 1021
 falls in elderly and, 65, 67t
 heat syncope/collapse and, 1547
 MAOIs causing, 1069
 pheochromocytoma/paraganglioma
 and, 440
 syncope and, 396
 tricyclic antidepressants causing, 1068
 Orthostatic proteinuria, 899
 Orudis. *See* Ketoprofen
 Oruvail. *See* Ketoprofen
 Osborn wave, in hypothermia, 1544,
 1544f
 OsCal (calcium carbonate). *See* Calcium,
 dietary/supplementary
 Oseltamivir, for influenza, 23, 1354t,
 1395, 1396, 1398, 1399
 prophylactic, 1397
 resistance to, 1396, 1398, 1399
 Osler nodes, in endocarditis, 1435, 1436f
 Osler sign, 440
 Osler triad, 1423
 Osler-Weber-Rendu syndrome. *See*
 Hereditary hemorrhagic
 telangiectasia
 Osmolality
 fecal/stool, diarrhea and, 577–578, 579f
 serum, 870
 in diabetic ketoacidosis, 1232–1233
 in hyperglycemic hyperosmolar
 state, 1236
 in hyponatremia, 875
 in hyponatremia, 871, 871f
 in methanol/ethylene glycol
 poisoning, 1584
 reference values for, 1733t
 urine
 in acute kidney injury, 902t, 903
 in hyponatremia, 875–876
 in hyponatremia, 873
 reference values for, 1733t
 Osmolar/osmol gap, **870, 877**
 calculation of, 1569t
 in poisoning/drug overdose, 1569,
 1569t
 alcohol toxicity and, 877, 1081, 1569,
 1569t
 isopropanol toxicity and, 891, 1569,
 1569t
 methanol or ethylene glycol toxicity
 and, 877, 1569, 1569t, 1584
 Osmolarity, 870
 Osmophobia, in migraine headache, 963
 OsmoPrep. *See* Sodium phosphate
 Osmostat, reset, hyponatremia caused by,
 873, 874
 Osmotic diarrhea, 574t, 577–578. *See also*
 Diarrhea
 Osmotic diuretics
 for angle-closure glaucoma, 174
 lithium interactions and, 1074t
 Osmotic fragility test, in hereditary
 spherocytosis, 501
 Osmotic gap, stool, 577–578, 579, 579f
 Osmotic laxatives, 571, 572t
 OspA, in Lyme disease, 1480
 Ossicular disruption, hearing loss and,
 198, 204, 205
 Osteitis condensans ilii, 855
 Osteitis deformans (Paget disease of
 bone), **1152–1153**
 Osteitis fibrosa cystica, 912, 1139
 Osteoarthritis, **809–812**, 811f. *See also*
 Arthritis
 arthroplasty/joint replacement for, 812,
 1690, 1691–1692, 1702
 coagulase-negative staphylococcal
 infection and, 1428
 DVT/PE (venous thromboembolic
 disease) prevention and, 555,
 555t
 osteomyelitis and, 862
 of cervical spine, 818, 1686
 exercise/activity in prevention/
 management of, 12–13, 811
 glucosamine/chondroitin for, 812, 1702
 of hip, **1691–1692**
 of knee, 1692, **1701–1703**
 meniscal injuries and, 1700
 prevention of, 811
 rheumatoid arthritis differentiated
 from, 811, 828
 spinal stenosis and, 1685
 Osteoarthropathy, hypertrophic
 pulmonary. *See* Hypertrophic
 osteoarthropathy
 Osteocalcin, reference values for,
 1733t
 Osteodystrophy
 Albright hereditary, 1137
 renal, 912–913, 912f, 1139, 1141,
 1144
 Osteogenesis imperfecta, 1145
 Osteogenic sarcoma. *See* Osteosarcoma
 Osteoma, ear canal, **201**
 Osteomalacia, 912, **1148–1151**, 1149t
 in celiac disease, 622
 in chronic kidney disease, 912
 hypophosphatemic, 878t, 1150, 1151
 osteoporosis with, 1146, 1151
 Osteomyelitis, **861–864**, 1302t
 acute pyogenic, **861–862**
 bacterial rhinosinusitis and, 216
 candidal, **862–863**
 in coccidioidomycosis, 863
 in drug users, 861–862, 1292
 hematogenous, 861–862
 in histoplasmosis, 863
 leg ulcers and, 154, 862
 mycotic, **862–863**
 in sickle cell syndromes, 503, 861

- Osteomyelitis (*Cont.*):
of skull base (malignant external otitis), 200–201
earache in, 200, 206
staphylococcal, 862, 1302*t*, 1426
vertebral, 861–862, 862, 1426
back pain and, 819, 820, 1426
epidural abscess and, 861–862, 862, 1426
- Osteonecrosis, **865**
corticosteroid use and, 865, 1190–1191
dysbaric, 865
of jaw, bisphosphonate use and, 11, 738, 865, 1147
in sickle cell anemia, 503, 865
- Osteopenia, 1145, 1710. *See also* Osteoporosis
in complex regional pain syndrome, 825
in HIV infection/AIDS, 1328
- Osteophytes
in diffuse idiopathic skeletal hyperostosis, 855
neck pain/cervical spondylosis and, 818, 1029
in osteoarthritis, 811
in spinal stenosis, 822
- Osteoporosis, 779, 780, **1144–1148**, 1145*t*, 1710
androgen deprivation and, 1636
in celiac disease, 622, 1145
circumscripta, 1152
in cirrhosis, 687
corticosteroid therapy and, 639, 1146, 1190, 1191
in Cushing syndrome, 1161
fractures/bone pain and, 11, 1144, 1710
risk assessment tool and, 1710
hip fractures and, 1144, 1147, 1689, 1690, 1710
in HIV infection/AIDS, 1328
in hyperthyroidism, 1145
hypogonadism and, 1145
levothyroxine treatment and, 1125, 1130
in men, 1147, 1148, 1175
in myeloma, 528
osteomalacia with, 1146, 1151
postmenopausal, 779, 780, 1145, 1145*t*, 1146, 1147, 1181, 1710
prevention/treatment of, **11–12**, 780, 1146–1148, **1710–1711**
bisphosphonates in, 11, 780
calcium in, 11, 780, 1146, 1710
milk-alkali syndrome and, 883, 884
chronic corticosteroid treatment and, 639, 1146, 1190, 1191
estrogen replacement therapy in, 1147
exercise/activity and, 11, 12–13, 780, 1146, 1710
selective estrogen receptor modulators in, 1147, 1185
vitamin D in, 11, 66, 67*t*, 780, 1146, 1710
thiazolidinedione use and, 1210
- Osteoprotegerin
in juvenile Paget disease, 1152
in myeloma, 527
- Osteosarcoma (osteogenic sarcoma), 1612*t*
Paget disease of bone and, 1153
- Osteosclerosis, in renal osteodystrophy, 1141
- Osteotomy, high tibial, for osteoarthritis of knee, 1702
- Ostium primum atrial septal defect, 327
- Ostium secundum atrial septal defect, 327, 328, 329
- Otalgia. *See* Earache
- Otelixizumab, for new-onset type 1 diabetes, 1202
- Otic barotrauma. *See* Barotrauma
- Otic drops
for cerumen removal, 200
for external otitis, 200
ototoxic, avoidance of with perforated tympanic membrane, 207
- Otitis
external/malignant external, **200–201**
earache in, 200, 206
facial pain and, 968
media, 1303*t*
acute, **203**
cholesteatoma and, 204, 204*f*
chronic, **203–205**, 204*f*
complications of, 204–205
earache in, 203, 206
in HIV infection/AIDS, 213
RSV causing, 1394
serous, **202**
nasopharyngeal carcinoma and, 202, 223
- Otoconia, vertigo associated with, 211
- Otogenic meningitis, 205
- Otorrhea, in acute otitis, 203
- Otosclerosis, 205
- Ototoxic chemoprotection, 207
- Ototoxicity
of aminoglycosides, 207
of cisplatin, 207, 1662
hearing loss and, 207, 210*t*
- Ottawa Ankle Rules, 1703
- Outer surface protein A (OspA), in Lyme disease, 1480
- Ovarian ablation. *See* Oophorectomy
- Ovarian cancer/tumors, **764–765**, 1611*t*, 1710
dermatomyositis and, 841, 1596*t*
estrogen replacement therapy and, 1183
genetic mutations associated with, 764. *See also* BRCA1/BRCA2 genes
HNPCC and, 657
hirsutism/virilization caused by, 1162, 1163
incidence/mortality/risk of, 1594*t*, 1710
malignant ascites and, 591
palmar fasciitis and, 864
paraneoplastic syndromes associated with, 1596*t*
during pregnancy, **808**
prevention of, **1710**
genetic risk factors and, 764
oral contraceptive use and, 770, 772, 1710
screening and, 16, 764, 1710
thyroid hormone secreted by, 1111
- Ovarian cyst, 765
appendicitis differentiated from, 631
in gestational trophoblastic disease, 791, 792
- Ovarian failure, 779, 780, 1179, 1181. *See also* Amenorrhea
in Turner syndrome, 1179, 1186, 1187
- Ovarian tumor antigen. *See* CA 125
- Ovaries, polycystic. *See* Polycystic ovary syndrome
- Over-the-counter drugs, use/abuse of, **1086**
stimulants and, 1086, 1572
- Overflow incontinence
fecal, 572, 660
urinary, 68, 69
- Overlap syndrome, **842**
- Overload proteinuria, 899
- Overweight. *See also* Obesity
definition of, 13
preventable disease/deaths and, 3*t*, 13–15
prevention of, **13–15**
- Ovide. *See* Malathion
- Ovulation
awareness of
contraception based on, **775–776**
infertility workup and, 768
cyclical mastalgia and, 1716
induction of for infertility, 769, 1097
in polycystic ovary syndrome, 766
- Ovulation bleeding, 747
- Owl's eye inclusions, in CMV infection, 1365
- Oxacillin, for endocarditis, 1438, 1439
- Oxalate, in urinary stones, 946, 948, 949. *See also* Calcium nephrolithiasis
- Oxaliplatin, 1650*t*
for colorectal cancer, 1625
- Oxandrolone, for AIDS wasting, 1325
- Oxapropin, 78*t*
- Oxazepam, 1042*t*
overdose/toxicity of, 1579–1580
- Oxcarbazepine, 972, 973*t*. *See also* Anticonvulsant therapy
for bipolar disease/mania, 1075
for seizures, 972, 973*t*
pregnancy and, 803
- Oxiconazole, 97*t*
- Oximetry. *See* Pulse oximetry/
CO-oximetry
- Oxistat. *See* Oxiconazole
- Oxitriptan, for myoclonus, 1004
- Oxprenolol, overdose/toxicity of, 1575
- Oxybate. *See* Gamma-hydroxybutyrate
- Oxybutynin, for urinary incontinence, 68
- Oxycodone, 79, 82*t*
in combination preparations, 83*t*
overdose/toxicity of, 1586–1587
- Oxycontin. *See* Oxycodone
- Oxygen, partial pressure of. *See* PaO₂; PO₂
- Oxygen concentrators, for home oxygen therapy, 262
- Oxygen saturation. *See* SaO₂
- Oxygen tension. *See* PO₂
- Oxygen therapy
adverse ophthalmic effects of, 195*t*
for ARDS, 323
for asthma exacerbation, 256, 258*f*

- for burn injury, 1550
for carbon monoxide poisoning, 307, 1566t, 1576–1577
for cluster headache, 965
for COPD, 261–262, 262t, 264
for dysbarism/decompression sickness, 1558
for dyspnea, 26, 86
for heart failure, left ventricular (infarct-related), 373
for high-altitude illness, 1559
home, 262, 262t
hyperbaric. *See* Hyperbaric oxygen therapy
for hypothermia, 1544
for methemoglobinemia, 1584
for near drowning, 1556
perioperative, surgical site infection and, 56
for *Pneumocystis* pneumonia, 1535
for pulmonary edema, 408
for pulmonary hypertension, 305, 424
for respiratory failure, 320
for sleep apnea, 319
for smoke inhalation, 307
transtracheal, 262
- Oxygen uptake, maximal, lung cancer surgery and, 1599
- Oxyhemoglobin saturation. *See* SaO₂
- OxyIR. *See* Oxycodone
- Oxymetazoline, overdose/toxicity of, 1577
- Oxymorphone, 82t
- Oxyuriasis (pinworms), 1519–1520
- Oysters, contaminated, vibrio infection caused by, 1448
- 3P tumor suppressor gene, in thyroid cancer, 1127
- P2Y₁₂ inhibitor
for acute coronary syndromes/STEMI, 361, 363, 367, 368
perioperative discontinuation of, 363
- P16/CDKN2A gene mutations, pancreatic/periapillary carcinoma and, 1608
- p24 antigen assay, in blood screening, 536
- P53 gene mutations. *See also* TP53 gene mutations
in breast cancer, 722
in colorectal cancer, 1622
smoking and, 6
in thyroid cancer, 1127, 1128
- P450 aromatase (P450arom) deficiency, amenorrhea in, 1179
- P450 (CYP) 2C9 variants, testing for, 1725t
- P450 (CYP) system/cytochrome P450 antibodies to, in autoimmune hepatitis, 679
fentanyl and, 79
hepatotoxicity and, 683
nefazodone affecting, 1068
protease inhibitors affecting, 1344
testing for biomarker variants in, 1725t
- P450c11 deficiency, 1162, 1166, 1179
- P450c17 deficiency, 1156, 1166, 1179
- P450c21 deficiency, 1156, 1162, 1163, 1179
- 3P tumor suppressor gene, in thyroid cancer, 1127
- P wave
in atrial premature beats, 381
in atrial septal defect/patent foramen ovale, 328
in cor pulmonale, 426
in differentiation of aberrantly conducted supraventricular beats from ventricular beats, 381, 391
in multifocal atrial tachycardia, 389
in paroxysmal supraventricular tachycardia, 382
in pulmonary stenosis, 325
- Pacemaker
for intraventricular conduction defects, 396
overdrive, for ventricular tachycardia, 391, 1564
permanent, 395
for atrioventricular block, 395
infarct-related, 373
biventricular (resynchronization) for cardiomyopathy, 412, 415
for heart failure, 405–406
for cardiomyopathy, 415
preoperative placement of, 49
for refractory atrial fibrillation, 388
for sick sinus syndrome, 394
temporary
for infarct-associated conduction disturbances, 373
perioperative placement of, 49
- Pacemaker syndrome, 394
- Packed red blood cells, transfusion of, 534. *See also* Transfusion
autologous, 534
for DIC, 546t
frozen, 534
for GI bleeding, 582
- Paclitaxel, 1652t
for breast cancer, 737, 741
neuropathy caused by, 1661
protein-bound, 1652t
- PaCO₂. *See also* PCO₂
in asthma, exacerbation severity/management and, 246, 247t, 258f
in near drowning, 1556
- Paecilomyces*, in opportunistic infection, 1540–1541
- Paget carcinoma of breast, 117, 117f, 726, 730
nipple involvement and, 117, 117f, 726, 730
- Paget disease
of bone, 1152–1153
extramammary, 117
mammary. *See* Paget carcinoma of breast
- PAI-I. *See* Plasminogen activator I
- Pain. *See also specific type and* Pain disorders; Pain management; Pain syndromes
assessment scales for, 74, 75t
chronic, 1047–1049, 1048f
opioids in management of, 79, 1049
in complex regional pain syndrome, 824, 825
drug therapy for. *See* Pain management, pharmacologic at end of life, 75–76
hypersensitivity to, in diabetes, 1225
hyponatremia caused by, 872
ischemic. *See* Rest pain
in musculoskeletal disorders, 817–826, 1673, 1674
neuropathic, 84–85, 84t, 1021. *See also* Neuropathies
nonpharmacologic interventions in, 85
ocular. *See* Ocular/orbital pain
otic. *See* Earache
psychologic factors and (somatoform pain disorder), 1046
response to, in coma or stupor, 1014, 1015
rest. *See* Rest pain
in sickle cell anemia, 503, 504
- Pain disorders, 817–826. *See also* Pain chronic, 1047–1049, 1048f
with psychologic factors (somatoform pain disorder), 1046
- Pain management, 74–85. *See also specific disorder and* Analgesia/analgesics
assessment scales and, 74, 75t
back pain and, 821
barriers to good care and, 76
for chronic pain/chronic pain disorders, 79, 1048–1049
at end of life, 75–76
musculoskeletal disorders and, 1674
nonpharmacologic, 85
in osteoarthritis, 811–812
pharmacologic, 76–85
acetaminophen/NSAIDs/coxibs (COX-2 inhibitors), 76, 77–78t
adjuvant, 85
for neuropathic pain, 84–85, 84t, 1021
opioids, 79–83, 80–83t, 1049
principles of, 74–75, 75t
in terminally ill/dying patient, 75–76
- Pain syndromes, 817–826. *See also specific type and* Pain
- Painful bladder syndrome. *See* Interstitial cystitis
- Painful diabetic neuropathy, 1225–1226
- Painful intercourse. *See* Dyspareunia
- Painless myocardial infarction, 365
- Painless postpartum thyroiditis, 1120, 1121. *See also* Postpartum thyroiditis
- Painless sporadic thyroiditis, 1120, 1121
- PAIR (percutaneous aspiration/injection/reaspiration), for hydatid cysts, 1516
- Palatal myoclonus, tinnitus and, 208
- Palifermin, for chemotherapy-induced mucositis, 1658t, 1660
- Palilalia, in Tourette syndrome, 1005
- Palindromic rheumatism, 865
- Paliperidone, 1055, 1056t, 1058, 1060t
- Palivizumab, 1354t, 1394
- Palladin gene, pancreatic/periapillary carcinoma and, 1608
- Palladone. *See* Hydromorphone
- Palliative care, 74–93
definition and scope of, 74

- Palliative care (*Cont.*):
 at end of life, 74. *See also* End of life, provision of care at
 pain management, 75–76
 for gastric cancer, 1617
 for heart failure, 406
 for lung cancer, 1600
 symptom management and
 constipation, 86
 delirium and agitation, 86–87
 dyspnea, 26, 85–86, 265
 fatigue, 86
 nausea and vomiting, 86
 pain, 74–85
- Palliative care institutions, 90. *See also* End of life, provision of care at
- Palliative Performance Scale, prognosis at end of life and, 87
- Pallidotomy, for parkinsonism, 1001
- Pallor, in Raynaud phenomenon, 836
- Palmar erythema
 in cirrhosis, 686
 in rheumatoid arthritis, 827
- Palmar fasciitis
 cancer and, 864
 rheumatoid arthritis differentiated from, 828
- in Dupuytren contracture, 824
- Palms
 tinea of, 112–113
 ulnar lesions at, 1027
 vesiculobullous dermatitis of (pompholyx), 121–122, 121f
 tinea differentiated from, 113
- Palonosetron, 568, 568t, 1660. *See also* Antiemetics
- Palpitations, 30–32, 32t
 in pheochromocytoma, 1167
 in pulmonary embolism, 298t
 somatoform, 1045
- Palsies. *See specific type and* Paralysis/palsies
- Paludrine. *See* Proguanil
- 2-PAM. *See* Pralidoxime
- Pamelor. *See* Nortriptyline
- Pamidronate, 1146–1147, 1147. *See also* Bisphosphonates
 adverse ophthalmic effects of, 197t
 for chemotherapy-induced toxicity/bone pain, 1659t
 for hypercalcemia/
 hyperparathyroidism, 1143, 1647
 for osteoporosis prevention/
 management, 1146–1147, 1147
 corticosteroid use and, 1191
 for Paget disease of bone, 1153
- Panacinar bibasilar emphysema, 261. *See also* Emphysema
- Panbronchiolitis, diffuse, 269, 269–270
- Pancreas
 cancer of, 1607–1612, 1612t
 GI bleeding and, 581
 incidence/mortality/risk of, 1594t, 1607
 pancreatitis and, 1608
 diseases of, 711–717. *See also specific type and* Diabetes mellitus; Pancreatitis
 diabetes/hyperglycemia and, 1196
 dyspepsia and, 564
 vomiting and, 567t, 711
 divisum, 711, 714
 functioning/neuroendocrine tumors of, 1171–1173, 1608, 1609
 hypoglycemia caused by, 1172, 1189, 1238–1241, 1239t, 1240t
 in MEN, 1171, 1172, 1188t, 1189, 1239
 pseudocysts of, 713, 717
 ascites and, 591
 cystic carcinoma differentiated from, 1608
 infected (pancreatic abscess), 713, 714
 transplantation of, for diabetes mellitus, 1217
- Pancreatectomy, 717
 diabetes/hyperglycemia and, 1196
 for insulinoma, 1172, 1241
 for noninsulinoma pancreatogenous hypoglycemia syndrome (islet cell hyperplasia), 1242
- Pancreatic abscess, 713, 714
- Pancreatic ascites, 588, 591, 717
- Pancreatic duct
 ascites caused by disruption of, 591
 calculus formation in (pancreaticolithiasis), 616, 717
- Pancreatic duodenal homeobox gene, in MODY, 1195
- Pancreatic elastase, fecal
 in diarrhea, 580
 reference values for, 1733t
- Pancreatic enzyme supplements, 716
- Pancreatic islets, 1171. *See also* B cells, pancreatic
 hyperplasia of (noninsulinoma pancreatogenous hypoglycemia syndrome), 1238, 1241, 1242
 transplantation of, for diabetes, 1217
 tumors of. *See* Islet cell tumors
- Pancreatic polypeptide, F cells secreting, 1171
- Pancreatic pseudocysts, 713, 717
 ascites and, 591
 cystic carcinoma differentiated from, 1608
 infected (pancreatic abscess), 713, 714
- Pancreatic secretory trypsin inhibitory (PSTI) gene, in pancreatitis, 715, 716
- Pancreatic transcription factor mutations, in diabetes, 1195
- Pancreaticocholangitis, sclerosing, 709–710
- Pancreaticoduodenal resection, for pancreatic/periampullary carcinoma, 1609
- Pancreaticojejunostomy, for pancreatitis, 717
- Pancreaticolithiasis, 716, 717
- Pancreatitis
 acute, 711–715, 712t
 ascites in, 588, 591, 711, 713, 717
 autoimmune, 715
 biliary, 711
 biliary stricture and, 708–709
 cholelithiasis and, 703t, 707
 cholelithiasis/cholecystitis and, 714
 chronic, 715–717
 tumefactive, 716
 cystic fibrosis and, 711, 715, 716
 diabetes/hyperglycemia and, 1196, 1228
 diarrhea in, 579f, 580
 didanosine therapy and, 1343
 exenatide use and, 1211
 hereditary, 715, 716
 hypercalcemia/hyperparathyroidism and, 1139, 1141, 1144
 hypertriglyceridemia and, 711, 714, 1255
 hypocalcemia/hypoparathyroidism and, 714, 882, 1137
 liraglutide use and, 1212
 in mumps, 1370, 1371
 necrotizing, 713, 714
 pancreatic/periampullary carcinoma and, 1608
 pleural effusion in, 314, 314t
 sitagliptin use and, 1212, 1221
 sphincter of Oddi dysfunction and, 706, 711, 713
 tropical, 715
- Pancytopenia, 508, 508t, 509
 in acute leukemia, 520
 in aplastic anemia, 508, 508t
 in hairy cell leukemia, 523
 methotrexate causing, 829
 stem cell transplantation and, 532
- Panencephalitis, subacute sclerosing, 1368
 myoclonus in, 1004
- Panhypergammaglobulinemia. *See* Hypergammaglobulinemia
- Panhypogammaglobulinemia. *See* Hypogammaglobulinemia
- Panhypopituitarism, 1094–1095. *See also* Hypopituitarism
- Panic disorders/panic attacks, 1041, 1044
 chest pain/discomfort in, 30, 1041
 drug therapy in, 1043, 1044, 1067
 hypochondriasis and, 1041, 1046
 OCD and, 1041
 palpitations in, 31, 32
 PTSD and, 1039, 1040
 seizures differentiated from, 971
 sleep, 1041
- Panitumumab, 1654t
 for colorectal cancer, 1625
- Pankeratin, in mesothelioma, 1602
- Panniculitis
 lupus, 150
 sclerosing, 137
- Pannus
 in rheumatoid arthritis, 826
 in trachoma, 166
- Pansinusitis, 215
- Panton-Valentine leukocidin, 273
- Pantoprazole, 613. *See also* Proton pump inhibitors
- Panuveitis, 177. *See also* Uveitis
- PaO₂. *See also* PO₂
 in ARDS, 322, 323
 in asthma, exacerbation severity/management and, 247t
 in carbon monoxide poisoning, 307, 1576
 COPD/home oxygen therapy and, 262, 262t
 in near drowning, 1556

- Papanicolaou smear (Pap smear), 15*t*, 16, 754*t*, 755, 1709
 anal, in HIV infection/AIDS, 1332
 in cancer screening, 15*t*, 16, 754*t*, 755, 1332, 1709
 in CIN, 754*t*, 755
 in endometrial carcinoma, 759
 in HIV infection/AIDS, 1332
 for HPV screening, 755, 1332, 1709
 for rape victim, 778
 in STD patient, 1291
- Papillary muscles
 dysfunction/rupture of
 mitral regurgitation and, 339, 340
 in myocardial infarction, 374
 mitral stenosis and, 337
- Papilledema, 189, 189*f*, 995
 headache and, 41
- Papillitis. *See also* Optic disk, swelling of
 in optic neuritis, 188
- Papillomas
 intractable, nipple discharge and, 720, 720*t*
 inverted, 222
 recurrent respiratory (laryngeal), 234–235
- Papillomaviruses. *See* Human papillomavirus
- PAPP-A. *See* Pregnancy-associated plasma protein-A
- Papular acne, 127–128
- Papular urticaria, 133
 bedbugs causing, 149
- Papules, 95*t*, 139–143
 violaceous to purple, 143–145
- Paracentesis
 in ascites, 588. *See also* Ascitic fluid analysis/examination
 in cirrhosis, 588, 687–688
 large-volume
 for cirrhotic ascites, 688
 for malignant ascites, 590, 1646
 in peritoneal carcinomatosis, 588, 590
 in spontaneous bacterial peritonitis, 588, 589, 590
- Paracetamol, 1570. *See also* Acetaminophen
 in analgesic nephropathy, 932–933
- Parachute mitral valve, 337
- Paracoccidioides brasiliensis*
 (paracoccidioidomycosis), 1539
- Paradoxic aciduria
 in metabolic alkalosis, 895
 in salicylate overdose/toxicity, 1589
- Paradoxic embolism
 in atrial septal defect/patent foramen ovale, 328, 329
 in pregnancy, 431
 in transient ischemic attacks, 977
- Paradoxic pulse. *See* Pulsus paradoxus
- Paradoxical sleep, 1075
- Paraganglioma, 1166–1171, 1168*t*, 1169*t*
 familial, 1167
 metastatic, 1170–1171
- Paragonimus westermani*
 (paragonimiasis), 1513
- Parainfluenza viruses, 1393, 1394
- Paralysis/palsies, 977. *See also specific type or structure affected*
 acute flaccid
 coxsackievirus causing, 1406
 enterovirus 71 causing, 1407
 poliomyelitis and, 1372, 1373
 in botulism, 1034, 1431
 in conversion disorder, 1045
 facial/Bell palsy, 1027, 1028, 1028*f*
 herpes simplex/varicella zoster infection and, 1028, 1351, 1355, 1359
 in motor neuron diseases, 977, 1019, 1020
 ocular motor, 190–191
 in myasthenia gravis, 1032
 periodic. *See* Periodic paralysis
 in poliomyelitis, 1372–1373, 1373
 progressive supranuclear, parkinsonism differentiated from, 998
 in rabies, 1376
 sleep, in narcolepsy, 1077
 spinal cord infarction causing, 988–989
 spinal trauma causing, 1018
 in stroke, 981, 982
 after thoracic aneurysm repair, 475
 in tick-borne encephalitis, 1391
 vocal fold, 237–238
 thyroid surgery and, 237, 238, 1116, 1119, 1129
- Paralytic (adynamic) ileus, 627–628
- Paralytic shellfish poisoning, 1589, 1589*t*
- Paramalignant pleural effusion, 315
- Paramedian artery occlusion, in stroke, 982
- Paramyxovirus respiratory infections, 1392–1394
- Paranasal sinuses, 213–223
 in granulomatosis with polyangiitis, 223, 849
 granulomatous disease of, 222
 infections of, 213–218, 1303*t*. *See also* Rhinosinusitis; Sinusitis
 inflammatory disease of, 223
 malignant tumors of, 223
 in sarcoidosis, 223
- Paraneoplastic cerebellar degeneration, 994, 1596*t*
- Paraneoplastic pemphigus, 138
- Paraneoplastic syndromes, 1594–1595, 1596*t*
 achalasia and, 605
 autoimmune, 994–995
 hypercalcemia and. *See* Hypercalcemia, cancer-related
 in lung cancer, 994, 995, 1596*t*, 1597
 neurologic disorders and, 994–995
 neuropathies, 975, 1024
 rheumatoid arthritis differentiated from, 828
- Paranoid delusion, 1054
- Paranoid personality disorder, 1052*t*
- Paranoid schizophrenia, 1053
 delusions and, 1053, 1054
- Paraparesis, tropical spastic, 1383–1384
- Paraphilias (sexual arousal disorders), 1049–1050, 1050–1051
 in female, 766, 767, 1714
- Paraplatin. *See* Carboplatin
- Paraplegia. *See also* Paralysis
 spinal cord infarction causing, 988–989
 spinal trauma causing, 1018
 after thoracic aneurysm repair, 475
- Parapneumonic pleural effusion, 313, 314, 314*f*, 315–316
 in community-acquired disease, 272
 in pneumococcal pneumonia, 1423
- Paraproteins
 in monoclonal gammopathy of unknown significance, 528
 in myeloma, 527–528, 528, 936
 neuropathy associated with, 1023
 in Waldenström macroglobulinemia, 529, 530
- Parasitic infections
 diarrhea in, 574*t*, 578
 stool analysis for, 576
 myocarditis in, 409*t*
- Parasomnias, 1077–1078
- Parasternal lift
 in heart failure, 400
 in pulmonary stenosis, 325
- Parathar. *See* Teriparatide
- Parathion poisoning, 1587
- Parathyroid gland
 disorders of, 1135–1144, 1137*f*, 1140*f*.
See also
 Hyperparathyroidism;
 Hypoparathyroidism
 adenoma/hyperplasia, 1138, 1139, 1140, 1141, 1143, 1144
 in hypercalciuria, 948
 in MEN, 1138–1139, 1141, 1144, 1188–1189, 1188*t*, 1189
 carcinoma, 1138, 1139, 1143, 1144
 resection of (parathyroidectomy), 1142–1144
 thyroid surgery affecting, 1116, 1119, 1129, 1135
 transplantation of tissue from, for hypoparathyroidism/tetany, 1137
- Parathyroid hormone (PTH), 1135. *See also* Hyperparathyroidism; Hypoparathyroidism
 bisphosphonates affecting, 1142, 1147
 calcium balance/imbalance and, 882, 883, 884, 1135, 1138, 1140*f*
 in hypercalciuria, 947, 947*t*, 948
 in hypophosphatemia, 885, 1139, 1140
 magnesium imbalances and, 882, 887, 1135–1136, 1136
 in metabolic bone disorders/renal osteodystrophy, 912, 912*f*, 913, 1139
 after parathyroidectomy, 1143
 phosphate balance/imbalance and, 884, 885, 886, 1139, 1140
 recombinant human. *See* Teriparatide
 reference values for, 1733*t*
 resistance to, in pseudohypoparathyroidism, 1137
- Parathyroid hormone-related protein (PTHrP)
 in cancer-related hypercalcemia, 883, 884, 1141
 in hypophosphatemia, 886
- Parathyroidectomy, 1142–1144
 hypoparathyroidism after, 1135, 1143, 1189
 in MEN 1, 1144, 1188–1189
- Paravaccinia, 1404
- Paravertebral abscess, in spinal tuberculosis, 863
- Parechovirus infection, 1408

- Parenchymal lung disease
diffuse, **292–297**, 292*t*, 294*t*. *See also*
specific disorder and
Interstitial lung disease
pulmonary hypertension and, 423*t*, 424
respiratory failure caused by, 320*t*
- Parenteral fluids. *See* Fluid management/
hydration
- Parenteral nutritional support, 897, 1271,
1271*f*. *See also* Nutritional
support
acidosis and, 893, 1274*t*
in burn injury, 1552
complications of, **1274–1275**, 1274*t*
for Crohn disease, 642, 643
in pancreatitis, 714
patient monitoring during, **1275**
for protein–energy malnutrition, 1258
in short bowel syndrome, 626
solutions for, 1273–1274, 1273*t*
- Paresis (general). *See also* Weakness
in syphilis, 1472
- Paresthesias, 976
chemotherapy-induced, 1661
in diabetes mellitus, 1197
malabsorption and, 621*t*
in thoracic outlet syndrome, 819
- Paricalcitol, for hyperparathyroidism, 1143
- Parietal lobe lesions, 991
- Parkin gene, in parkinsonism, 998
- Parkinsonism, **997–1001**, 999*t*
drug-induced, 998, 1004, 1061
antipsychotic agents and, 998, 1061
- Parkland formula, for fluid resuscitation
in burns, 1550
- Parnate. *See* Tranlycypromine
- Paromomycin
for amebiasis, 1504, 1505*t*
for cryptosporidiosis, 1508
for giardiasis, 1509
for leishmaniasis, 1489
- Paronychia, 151
candidal, 131, 131*f*, 132, 151
staphylococcal, 151, 152
- Parotid glands. *See also* Salivary glands
chronic inflammatory/infiltrative
disorders affecting, 232
in mumps, 1370, 1370*f*, 1371
sialadenitis affecting, 232
in Sjögren syndrome, 843
tumors of, 232–233
- Parotidectomy, 233
- Parotitis, 1370, 1370*f*, 1371
- Paroxetine, 1067. *See also* Serotonin-
selective reuptake inhibitors
MAOI interactions and, 1585
overdose/toxicity of, 1591–1592
ophthalmic effects and, 196*t*
during pregnancy, 1067–1068
- Paroxysmal atrial fibrillation, recurrent, 388
- Paroxysmal nocturnal hemoglobinuria,
501–502
- Paroxysmal supraventricular tachycardia,
381–383
- PARP-inhibitors. *See* Poly-ADP ribose-
polymerase inhibitors
- Pars plana vitrectomy, for retinal
detachment, 180
- Pars planitis (intermediate uveitis), 178.
See also Uveitis
- Partial mole, 791. *See also* Gestational
trophoblastic disease
- Partial pressure of carbon dioxide. *See*
PaCO₂; PCO₂
- Partial pressure of oxygen. *See* PaO₂; PO₂
- Partial seizures. *See* Focal (partial)
seizures
- Partial-thickness burn, 1550
survival and, 1550
- Partial thromboplastin time/activated
partial thromboplastin time
(PTT/aPTT)
prolonged
acquired factor VIII antibodies
causing, 553
in congenital coagulation disorders/
hemophilia, 550
in DIC, 545, 554
in hepatic coagulopathy, 553
lupus anticoagulant causing, 554,
834, 836
in vitamin K deficiency, 553
reference values for, 1733*t*
- Partner abuse (domestic violence), 17,
1078, 1079, **1711–1712**
prevention of, 17, 1712
- Partner Violence Screen (PVS), 1712
- Parvovirus B19 infection. *See*
Erythrovirus (parvovirus
B19) infection
- PAS. *See* Aminosalicic acid
- Pasireotide, for Cushing disease, 1160
- Passive smoking (environmental tobacco
smoke), health hazards of, 6
asthma, 243
cancer, 6, 1595
COPD, 6, 259
during pregnancy, 783
- Pasteurella* species, in animal bite
infections, 1289
- Patanol. *See* Olopatadine
- Patatin-like phospholipase domain
containing 3 (*PNPLA3*) gene,
in nonalcoholic fatty liver
disease, 684
- Patella, 1692
- Patellar apprehension test, 1697*t*, 1701
- Patellar grind test, 1701
- Patellofemoral joint, assessment of, 1697*t*,
1700–1701
- Patellofemoral pain/syndrome, 1692,
1697*t*, **1700–1701**
- Patent ductus arteriosus, **332–333**, 333*t*
- Patent foramen ovale, **327–329**
- Paternal age, mutations and, 1666
- Pathergy phenomenon, in Behçet
syndrome, 853
- Pathologic fractures. *See also* Fractures
of hip, 1689–1690, 1690
in hypercalcemia/hyperparathyroidism,
1139, 1141
malabsorption and, 621*t*
in myeloma, 528, 529
in osteomalacia, 1150
in osteoporosis, 1145
- Patient adherence/nonadherence
(compliance/
noncompliance). *See*
Adherence/nonadherence
- Patient-controlled analgesia, 1091
- Patient-delivered therapy, for STDs, 1291
- Patient–doctor relationship. *See* Doctor–
patient relationship
- Patient education
acne and, 126
adherence and, 1–2
asthma management and, 248, 249*f*,
256, 258*f*
diabetes/insulin therapy and, 1218
fibromyalgia and, 823
heat-related disorders and, 1547
HIV infection/AIDS and, 1333, 1335
postexposure prophylaxis and, 1336
infertility and, 768, 955
psychiatric problems associated with
hospitalization/illness and,
1091
in SLE, 834
sleep disorders and, 1076
- Patient Health Questionnaire-9,
assessment of suicidal intent
and, 1065
- Patient surrogate, Durable Power of
Attorney for Health Care, 89
- Patient values/preferences, assessing in
older adult, 57
- Pattern baldness (androgenetic alopecia),
156
in women, 156, 1719–1720
- Patulous eustachian tube, 202
- Paucibacillary (tuberculoid) leprosy,
1460. *See also* Leprosy
- Pauci-immune (ANCA-associated)
glomerulonephritis, 849, 907,
919*t*, 921*f*, **924**
- Pavor nocturnus (sleep terror), 1077,
1078
- PAX-4* (*Arg133Trp*) mutation, in
idiopathic type 1 diabetes
mellitus, 1194
- Paxil. *See* Paroxetine
- Pazopanib, 1655*t*
- Pb. *See* Lead
- PBG. *See* Porphobilinogen
- PCA. *See* Patient-controlled analgesia
- PCEC (purified chick embryo cell culture)
rabies vaccine, 1315, 1377
- PCI. *See* Percutaneous coronary
intervention
- PCI-02765, for chronic lymphocytic
leukemia, 522
- PCL. *See* Posterior cruciate ligament
- PCO₂. *See also* PaCO₂
in acid-base disorders, 888–889, 889,
889*t*
arterial, 888–889
in diabetic ketoacidosis, 1232
in metabolic acidosis, 889*t*
in metabolic alkalosis, 889*t*, 894, 895
reference values for, 1728*t*
in respiratory acidosis, 889, 889*t*, 896
in respiratory alkalosis, 889, 889*t*, 896
in respiratory failure, 320
venous, 889
- PCOS. *See* Polycystic ovary syndrome
- PCP. *See* Phencyclidine
- PCR. *See* Polymerase chain reaction
- PCV. *See* Pressure control ventilation
- PCV (pneumococcal conjugate vaccine).
See Pneumococcal vaccine

- PCWP. *See* Pulmonary capillary wedge pressure
- PDA. *See* Patent ductus arteriosus
- PDGF. *See* Platelet-derived growth factor
- PDGFRA (platelet-derived growth factor receptor alpha) mutation, in gastrointestinal stromal tumors, 1619, 1620
- PDT. *See* Photodynamic therapy
- PDX1, in MODY, 1195
- PE (pulmonary embolism). *See* Pulmonary venous thromboembolism
- Pea soup diarrhea, in enteric (typhoid) fever, 1445
- Peak expiratory flow (PEF)
 - in asthma, 245*t*, 246*t*, 247
 - exacerbation classification/management and, 246*t*, 247*t*, 256, 257, 257*f*, 258*f*
 - in cough evaluation, 22
- Pedal pulses
 - absence of in lower leg/foot disease, 467
 - in spinal stenosis, 822
- Pediculosis (capitis/corporis/pubis), **148**. *See also* Lice
- Pediculus humanus*
 - var *capitis*, 148
 - var *corporis*, 148, 1408
- Pedophilia, 1049–1050
 - intrafamilial (incest), 1050
- PEEP. *See* Positive end-expiratory pressure
- Peer support groups. *See* Support groups
- PEF. *See* Peak expiratory flow
- PEG. *See* Polyethylene glycol
- Pegasys. *See* Peginterferon
- Pegfilgrastim, for chemotherapy-induced toxicity, 1649, 1659*t*
- Peginterferon. *See also* Interferon- α /interferon alfa
 - for essential thrombocytosis, 514
 - for hepatitis B, 675, 675–678, 676
 - for hepatitis C, 671, 676–677, 676–678
 - in HIV infection/AIDS, 1329
 - for hepatitis D, 676
 - for polycythemia, 513
 - toxicity of, 677–678
- Pegintron. *See* Peginterferon
- Pegloticase, for hyperuricemia/gout, 816
- Pegvisomant, for acromegaly/gigantism, 1101
- Pelger-Huet abnormality, 518
- Peliosis hepatis
 - in bartonellosis, 1454
 - drugs/toxins causing, 683
- Pellagra, 1265
- Pelvic abscess, anaerobic, 1456
- Pelvic adhesions, chronic pain and, 1715, 1716
- Pelvic appendicitis, 630
- Pelvic examination, in rape victim, 778
- Pelvic floor dyssynergia, 570, 570*t*, 571
- Pelvic inflammatory disease (PID)/pelvic infection, **762–764**, 1304*t*. *See also* Endometritis; Salpingitis
 - in actinomycosis, 1457
 - anaerobic, 1304*t*, 1456
 - appendicitis differentiated from, 631, 763
 - chlamydial, 763, 1301*t*, 1304*t*, 1461–1462
 - dysmenorrhea and, 750
 - gonococcal, 763, 1304*t*, 1452, 1453
 - in HIV infection/AIDS, 1332
 - IUDs and, 763, 774
- Pelvic muscle (Kegel) exercises
 - for fecal incontinence, 659, 660
 - for pelvic organ prolapse, 762
 - for urinary incontinence, 68, 69
- Pelvic organ prolapse, **762**
- Pelvic pain
 - chronic
 - in female, **1714–1716**
 - in male (nonbacterial prostatitis), 942*t*, **943–944**
 - in dysmenorrhea, 750, 1715
 - in ectopic pregnancy, 790
 - in endometriosis, 760, 761, 1714, 1715
 - in PID, 763
- Pelvic varices, pelvic pain and, 1715
- Pemberton sign, 1123
- Pemetrexed, 1651*t*
- Pemphigoid, bullous, **139**
- Pemphigus, **138–139**, 138*f*
 - foliaceus/erythematosus, 138
 - paraneoplastic, 138
 - vulgaris/vegetans, 138
- Pen injectors, for insulin administration, 1216
- Penbutolol, 448*t*
- Penciclovir, 119, 1354*t*. *See also* Famciclovir
- Penicillamine
 - adverse ophthalmic effects of, 197*t*
 - for Wilson disease, 697
- Penicillin. *See also specific disorder used in*
 - allergy to, 1305–1306
 - for anaerobic pneumonia/lung abscess, 279, 1455
 - for anthrax, 1432, 1433*t*
 - for bacterial rhinosinusitis, 215
 - for endocarditis, 1421, 1437, 1438
 - for group B streptococcal infection
 - prophylaxis in pregnancy, 784–785
 - for Lyme disease, 1481, 1482
 - for non-sexually transmitted treponematoses, 1474
 - for pharyngitis, 229, 1420
 - platelet function affected by, 549*t*
 - resistance to
 - in enterococcal infections, 1422
 - in pneumococcal infections, 1423, 1424
 - for rheumatic fever, 418
 - for syphilis. *See* Syphilis
- Penicillin skin testing, 1305, 1306
- Penicillium marneffei* infections, **1540**
- Penile discharge. *See* Urethral discharge
- Penile prostheses, 953, 1227
- Penile tumescence testing, nocturnal, 952, 1050
- Penlac. *See* Ciclopirox
- Pentalogy of Fallot, 331
- Pentamidine
 - for African trypanosomiasis, 1485, 1485*t*
 - blood glucose levels affected by (hyper-/hypoglycemia), 1244, 1535
 - for leishmaniasis, 1489
 - for *P. jiroveci* infection, 1325, 1337*t*, 1338*t*, 1534, 1535
 - pneumothorax and, 316
- Pentasa. *See* Mesalamine
- Pentavalent antimonials, for leishmaniasis, 1488–1489
- Pentosan, for interstitial cystitis, 946
- Pentostam. *See* Stibogluconate
- Pentostatin, 1651*t*
 - for hairy cell leukemia, 524
- Pentoxifylline
 - for alcoholic liver disease, 681
 - for leg ulcers, 154
- PEP. *See* Positive expiratory pressure (PEP) therapy; Protein electrophoresis
- Peptic stricture of esophagus, 592*t*, 595. *See also* Esophagus, strictures of
- Peptic ulcer disease, **611–619**
 - complications of, **617–619**
 - dyspepsia in, 564, 565, 612
 - gastric cancer and, 609, 617, 1616–1617
 - gastric outlet obstruction and, **619**
 - GI bleeding in, 581, **617–618**
 - H. pylori*-associated, 609, 611, 612–613, 613–615, 614*t*, 615
 - gastritis and, 609
 - HSV infection and, 1352
 - NSAID-induced, 611, 611–612, 614*t*, 615–616, 828–829
 - pharmacologic/medical management of, 613–615, 614*t*, 615–616
 - refractory, 617
 - silent, 612
 - smoking and, 6, 611
 - ulcer perforation and, **618–619**
 - Zollinger-Ellison syndrome (gastrinoma) and, **619–620**, 1172, 1189
- Pepto-Bismol. *See* Bismuth compounds
- Peptostreptococci, 1454
- Paramivir, 1354*t*, 1396, 1398, 1399
- Perceptual distortions
 - psychedelic drug use and, 1084
 - in schizophrenia/psychotic disorders, 1054
- Percocet. *See* Oxycodone
- Percodan. *See* Oxycodone
- Percussion. *See* Chest percussion
- Percutaneous aspiration/injection/reaspiration (PAIR), for hydatid cysts, 1516
- Percutaneous coronary intervention (PCI), 357–358, 364*t*, 367–368
 - for acute coronary syndromes, 364, 364*t*
 - for angina, 357, 357–358
 - angiography before, 354
 - CABG compared with, 358
 - for myocardial infarction, 364*t*, 367–368
 - prophylactic/preoperative, 48–49
 - for traumatic injuries, 428
- Percutaneous dilatational tracheotomy, 238

- Percutaneous transhepatic cholangiography (PTC)
 in biliary stricture, 708
 in choledocholithiasis/choolangitis, 707
 in liver disease/jaundice, 665
- Percutaneous transluminal coronary angioplasty (PTCA). *See* Angioplasty, coronary; Percutaneous coronary intervention
- Percutaneous valvuloplasty. *See* Valvuloplasty
- Perennial rhinitis, 218
- Perforation
 in appendicitis, 631
 pregnancy and, 807
 of colonic diverticula (diverticulitis), 651–652
 ulcer, 618–619
- Performance anxiety, 1041
- Perfusion scans
 lung. *See* Ventilation-perfusion scans
 myocardial. *See* Myocardial perfusion scintigraphy
- Pergolide
 for pituitary adenoma, 1101, 1104
 withdrawal of from market, 1000
- Periapillary adenomas, 655
- Periapillary/ampullary carcinoma, 1607–1612, 1620
- Perianal cellophane tape test, in enterobiasis/pinworms, 1520
- Perianal disease. *See also* Anorectal disorders
 abscesses and fistulas, 661
 anal cancer, 1612f, 1629–1630
 in Crohn disease, 641, 642, 642–643
 hematoma, thrombosed hemorrhoid causing, 658
 in ulcerative colitis, 646
 warts, 139, 140, 140f, 659, 752. *See also* Venereal (genital) warts
- Perianal pruritus. *See* Anogenital/perianal pruritus
- Pericardial disease, 419–423
 in SLE, 833
- Pericardial effusions, 420–421
 in Kawasaki syndrome, 1417
 malignant, 420, 1645, 1646
 myxedema, 420, 1106
 in pericarditis, 419, 420. *See also* Pericarditis
 in pneumococcal pneumonia, 1423
- Pericardial friction rub
 in myocardial infarction, 366, 375
 in pericardial effusion, 421
 in pericarditis, 419
- Pericardial tamponade. *See* Tamponade
- Pericardiectomy/pericardial window
 for constrictive pericarditis, 423
 for pericardial effusion/tamponade, 421
 for pericarditis, 420
 in pneumococcal pneumonia, 1423
- Pericardiocentesis
 in inflammatory pericarditis, 420
 for pericardial effusion/tamponade, 421, 428
- Pericarditis
 acute inflammatory, 419–420
- bacterial, 419, 420
 chest pain/discomfort in, 28, 29, 419
 constrictive, 422–423
 cirrhosis and, 687
 restrictive cardiomyopathy
 differentiated from, 416, 422
 superior vena caval obstruction and, 482
 coxsackieviruses causing, 419, 1406
 effusive-constrictive, 422
 myocardial infarction and, 375, 419, 419–420
 neoplastic, 419, 420
 pneumococcal, 419, 1423
 postmyocardial infarction/
 postcardiotomy (Dressler syndrome), 375, 419, 419–420, 420
 radiation, 419, 420, 1554
 tuberculous, 419, 420
 uremic, 419, 420, 910, 912
 viral, 419, 420
- Perichondritis, 199
- Perihepatitis, Fitz-Hugh and Curtis syndrome and, 763
- Peri-infectious glomerulonephritis, 921f
- Perilymphatic fistula, 210t, 211
- Perindopril, 450t
- Perinephric abscess, dysuria and, 43
- Periocular pain. *See* Ocular/orbital pain
- Periodic limb movement disorder (nocturnal myoclonus), 1077
- Periodic paralysis, 1036–1037
 hyperkalemic, 878t, 1036–1037
 hypokalemic, 878t, 1036
 in hyperthyroidism, 1036, 1113, 1119
 normokalemic, 1037
- Periodontal disease
 anaerobic, 1454, 1455
 pneumonia and, 278, 1455
 in HIV infection/AIDS, 1329
- Perioperative management. *See* Preoperative evaluation/perioperative management
- Periorbital pain. *See* Ocular/orbital pain
- Peripartum cardiomyopathy, 429–430
- Peripheral artery aneurysms, 475–476
- Peripheral intravenous lines, infection/
 infection prevention and, 1284, 1305
- Peripheral nerve tumors,
 mononeuropathy caused by, 1020, 1026
- Peripheral neuropathies, 1020–1029. *See also* specific type and Neuropathies
 in diabetes, 1022, 1224–1226, 1225f
- Peripheral pulses. *See* Pulses
- Peripheral stem cells, for transplantation, 532, 533
- Peripheral vascular disease. *See* Vascular disorders
- Peripheral vein nutritional support, 1271, 1271f. *See also* Nutritional support
 solutions for, 1271, 1274
- Peripherally inserted central catheter (PICC), superficial thrombophlebitis and, 480
- Peristalsis, disorders of. *See* Motility disorders
- Peritoneal carcinomatosis, 588, 590
- Peritoneal dialysis, 915–916. *See also* Dialysis
 for chronic kidney disease, 915–916
 for hyperkalemia, 881t
 for hypermagnesemia, 888
- Peritoneal effusions, malignant, 1645
- Peritoneovenous shunts, for ascites, 689
- Peritoneum
 diseases of, 587–591, 587t. *See also* specific type and Ascites; Peritonitis
 nausea and vomiting in, 567t
 mesothelioma arising in, 591, 1602
- Peritonitis, 1302t
 ascitic fluid analysis in, 588, 589, 590, 689
 dialysis and, 916
 diverticulitis and, 651, 652
 in familial Mediterranean fever, 591
 peptic ulcer perforation and, 618
 perforated appendicitis and, 631
 pregnancy and, 807
 secondary, 589–590
 spontaneous bacterial, 589–590, 689
 in cirrhosis, 589, 689
 tuberculous, 588, 590
- Peritonsillar abscess/cellulitis, 229–230, 1420
- Periungual warts, 139, 140
- PERK gene mutation, in diabetes, 1196
- Perlane. *See* Hyaluronic acid fillers
- Permethrin
 for pediculosis, 148
 for scabies, 147
- Permissive hypercapnia, 321
 for asthma, 259
- Permitil. *See* Fluphenazine
- Permixon. *See* Saw palmetto
- Pernicious anemia, 497, 498
 carcinoid tumors and, 610, 1619
 gastritis and, 497, 610
 subacute combined degeneration of
 spinal cord and, 1013
- Pernicious vomiting of pregnancy, 787–788
- Peroneal (fibular) nerve, common, injury to, 1027
- Peroxisome proliferator-activated receptor alpha (PPAR- α), fibrates affecting, 1254
- Peroxisome proliferator-activated receptor gamma (PPAR- γ)
 thiazolidinediones affecting, 1209
 thyroid cancer and, 1127
- Peroxisome proliferator-activated receptor gamma (PPAR- γ)
 tumor suppressor gene,
 thyroid cancer and, 1127
- Perphenazine, 1056, 1056t, 1057t
 in elderly, 1058
- Persistent anovulation. *See* Polycystic ovary syndrome
- Persistent vegetative state, 1016
- Personal relationships, social issues for terminally ill/dying patient and, 91–92, 92t

- Personality changes
 due to general medical condition, 1088
 in neurosyphilis, 1472
- Personality disorders, **1051–1053**, 1052*t*
- Perspiration. *See* Sweating
- Pertussis (whooping cough), **1440–1441**
 cough in, 21, 22, 23, 1440
 prevention/immunization and, 3, 1307, 1440. *See also* Pertussis vaccine
- Pertussis vaccine, with diphtheria and tetanus toxoids (DTaP/Tdap vaccines), 3, 1308*t*, 1309*t*, 1310*t*, 1314, 1430, 1430*t*, 1434, 1440
 adverse effects/contraindications and, 1317*t*
 booster and, 1307, 1430, 1430*t*, 1434, 1440
 burn injury and, 1551
 in immunocompromised host/HIV infection/AIDS, 1309*t*, 1314, 1335
 pregnancy and, 787, 1307, 1309*t*, 1440
 Pertuzumab, for breast cancer, 741
- Pes anserine bursa/bursitis, 1692
- PESI. *See* Pulmonary embolism severity index
- Pessary
 for pelvic organ prolapse, 762
 for urinary incontinence, 69
- Pesticide poisoning (cholinesterase inhibitors), 1566*t*, **1587**
- Pestiviruses, gastroenteritis caused by, 1404–1405
- PET. *See* Positron emission tomography
- Petit mal (absence) seizures, 970, 970*t*.
See also Seizures
 drug therapy for, 973*t*
- Petrolatum, as skin emollient, 94
- Petroleum products, toxicity/abuse of, 1086, **1587–1588**
 aspiration and, 308, 1587–1588
- Petrosal sinus sampling, in hypercortisolism/Cushing syndrome, 1159
- Petrous apicitis, 204–205
- Peutz-Jeghers syndrome, 655
 pancreatic/periampullary carcinoma and, 1608
- Peyronie disease, 951, 952, 953
 Dupuytren contracture and, 824
- PF4 heparin antibody. *See* Heparin-platelet factor 4 antibody
- PFA-100 closure time, reference values for, 1733*t*
- PFO. *See* Patent foramen ovale
- PFT. *See* Pulmonary function tests
- PGA. *See* Polyglandular autoimmune syndrome
- PGI₂. *See* Prostacyclin
- pH
 in acid-base disorders, 888–889, 889, 892*t*. *See also specific type*
 in acidosis, 889, 890
 in alcoholic ketoacidosis, 891
 in alkalosis, 889, 895
 arterial blood, 888–889
 in diabetic ketoacidosis, 891, 1232, 1233
 esophageal, monitoring, 593
 in gastroesophageal/laryngopharyngeal reflux, 234, 593, 594, 596–597
- gastric
 nosocomial pneumonia and, 276
 in Zollinger-Ellison syndrome/gastrinoma, 619–620
- in lactic acidosis, 1237
 in metabolic acidosis, 889, 890
 in metabolic alkalosis, 889, 895
 in near drowning, 1556
- pharyngeal, monitoring, in gastroesophageal/laryngopharyngeal reflux, 234
- pleural fluid, 314
 in parapneumonic effusion, 314, 315
 reference values for, 1733*t*
 in respiratory acidosis, 889, 896
 in respiratory alkalosis, 889, 896
- urine
 calcium stones and, 947, 949
 cystine calculi and, 947, 949
 manipulation of in poisoning/drug overdose, 1567
 in metabolic alkalosis, 895
 in normal anion gap/renal tubular acidosis, 892, 892*t*, 893
 stone disease and, 947
 struvite calculi and, 947, 949
 uric acid calculi and, 947, 949
- vaginal, 751
 venous blood, 889
- Phacoemulsification, for cataract removal, 179
- Phaeohyphomycosis, 1541
- Phakic intraocular lenses, 163
- Phalen sign, in carpal tunnel syndrome, 824, 1688–1689, 1689*t*
- Pharmaceuticals. *See under Drug*
- Pharmacogenetic tests. *See also* Genetic testing/counseling
 clinical relevance of, 1725–1726*t*
- Pharyngeal dysphagia, 592. *See also* Dysphagia
- Pharyngeal pH monitoring, in gastroesophageal/laryngopharyngeal reflux, 234
- Pharyngitis, **227–229**, 228*f*, 1303*t*
 antibiotics for, 228, 229, 1303*t*, 1420
 in diphtheria, 228, 1419, 1433
Fusobacterium necrophorum, 1419, 1420, 1454
 gonococcal, 1452, 1453
 in mononucleosis, 228, 1361, 1362, 1419
 nonstreptococcal exudative (adenovirus), 1402
 in peritonsillar abscess and cellulitis, 229, 1420
 in Still disease, 831
 streptococcal, 228–229, 228*f*, 1303*t*, **1419–1420**
 eruptive (guttate) psoriasis after, 1606
 glomerulonephritis and, 922, 1419
 rheumatic fever and, 229, 417, 418, 1419, 1420
- Pharyngoconjunctival fever, 165, 1402
- Pharynx, **224–232**
- Phenacetin, in analgesic nephropathy, 932–933
- Phenazopyridine
 methemoglobinemia caused by, 1584
 for urinary tract infection, 45, 940
- Phencyclidine, **1084**, 1583
 aggressive/violent/psychotic behavior caused by, 1055, 1078, 1084
- Phenelzine, 1070*t*
 overdose/toxicity of, 1070*t*, 1585
- Phenobarbital, 972, 973*t*, 1042*t*, 1723*t*
 for anxiety, 1042*t*, 1044
 overdose/toxicity of, 973*t*
 hemodialysis for, 1568*t*
 for seizures, 972, 973*t*, 1565
 status epilepticus and, 974
- Phenothiazines, 1055, 1056. *See also* Antipsychotic drugs
 hypocalcemia/hypoparathyroidism and, 1138
 overdose/toxicity of, 1574
 ophthalmic effects and, 196*t*
- Phenotypic resistance testing, in antiretroviral therapy, 1347, 1348, 1349
- Phenoxybenzamine
 for benign prostatic hyperplasia, 959*t*
 pheochromocytoma surgery and, 1170
- Phentermine, for obesity, 1260, 1261
- D-Phenylalanine derivative, for diabetes mellitus, 1206*t*, 1208
- Phenylbutazone
 adverse ophthalmic effects of, 197*t*
 lithium interactions and, 1074*t*
- Phenylpropranolamine, in OTC medications, 1086
- Phenytoin, 972, 973*t*, 1723*t*
 antidepressant drug interactions and, 1071*t*
 for arrhythmias, 377
 overdose/toxicity of, 973*t*, 974, 1573
 ophthalmic effects and, 196*t*
 for seizures, 972, 973*t*
 pregnancy and, 803
 status epilepticus and, 974
 vitamin D deficiency/supplementation and, 1149, 1151
- Pheochromocytoma, 438, **1166–1171**, 1168*t*, 1169*t*
 β-blocker use in, 446, 1170
 headache in, 41, 1167
 hypertension in, 438, 440, 1166–1167, 1167, 1168*t*, 1169
 in MEN, 1167, 1188*t*, 1189
 metastatic, 1170–1171
- PHEX endopeptidase mutation, in osteomalacia/rickets, 1150
- Philadelphia chromosome, 510, 515
 in acute lymphoblastic leukemia, 519, 521
 in chronic myeloid leukemia, 510, 515, 516
- Phimosis
 in balanitis, 132
 in chancroid, 1453
- Phlebectomy, 479
- Phlebitis. *See* Thrombophlebitis
- Phlebotomy
 for hemochromatosis, 695
 for polycythemia, 512
 for polycythemia-related pulmonary hypertension, 305
 for porphyria cutanea tarda, 122

- Phlebovirus, hemorrhagic fever caused by, 1385
- Phlegmon
in Crohn disease, 641
in neck infection, 230
- Phlegmonous (necrotizing) gastritis, 610
- Phobic disorder, 1041, 1044
- Phonic tics, in Tourette syndrome, 1005
- Phonophobia, in migraine headache, 41, 41*t*, 962, 963
- Phosphate. *See* Phosphorus/phosphate
- Phosphate enema, 572*t*
- Phosphatidylinositol class A (PIG-A) gene defect, in paroxysmal nocturnal hemoglobinuria, 501
- Phosphatonin (fibroblast growth factor-23), 884, 1150
in metabolic bone disease/renal osteodystrophy/osteomalacia/rickets, 912, 1150
- Phosphaturia
hyperparathyroidism and, 1140
hyperphosphatemia and, 886
hypophosphatemia and, 886
osteomalacia and, 1150, 1151
- Phosphodiesterase inhibitors
adverse ophthalmic effects of, 196*t*, 1226
for asthma, 252, 255
for benign prostatic hyperplasia, 960
for erectile dysfunction, 952, 1051, 1067
antidepressant-induced, 1051, 1067
in diabetes, 1226
nitrate/nitroglycerin contraindications and, 370, 952, 1226
for pulmonary hypertension, 305, 424, 425*f*
- Phospholipase A2 receptor, in membranous nephropathy, 929
- Phosphorus/phosphate
calcium metabolism affected by, 885
in calcium nephrolithiasis/hypercalciuria, 947*t*, 948
deficiency of, 1150. *See also* Hypophosphatemia
in osteomalacia/rickets, 878*t*, 1150, 1151
dietary/supplementary
for diabetic ketoacidosis, 1234
for hyperglycemic hyperosmolar state, 1236–1237
for hypophosphatemia, 886
for osteomalacia, 1151
requirements for in nutritional support, 897, 1272
restriction of in chronic kidney disease, 912–913, 915
disorders of concentration/metabolism of, **884–887**, 885*t*, 886*t*. *See also* Hyperphosphatemia; Hypophosphatemia
in chronic kidney disease/renal osteodystrophy, 912, 912*f*, 1144
genetic disorders and, 878*t*, 1150
in hypercalcemia, 884
in hypocalcemia/hypoparathyroidism, 882, 1136
parathyroid hormone affecting, 884, 885, 886, 1139, 1140
reference values for, 1733*t*
urinary excretion of. *See* Phosphaturia
- Photoallergy, 152. *See also* Photodermatitis/photosensitivity
- Photocoagulation
for age-related macular degeneration, 181
for diabetic retinopathy, 185, 1223
for retinal detachment, 180
for retinal vein occlusion, 182
for sickle cell retinopathy, 187
- Photodermatitis/photosensitivity, 95*t*, **152–153**
acne treatment and, 127
antipsychotic drugs causing, 1060
chemotherapy-induced, 1661
drugs causing, 95*t*, 152–153, 159*t*
in SLE, 834
- Photodynamic therapy
for actinic keratoses, 117
for cholangiocarcinoma, 1607
for esophageal cancer palliation, 1614
- Photoepilation, 1163–1164
- Photophobia
in corneal abrasion, 192
in migraine headache, 41, 41*t*, 962, 963
in ultraviolet (actinic) keratitis, 194
- Photopsia (flashing lights), in migraine headache, 963
- Photorefractive keratectomy (PRK), 162
- Photoresection, Nd:YAG laser, for lung cancer palliation, 1600
- Photosensitive epilepsy, 971
- Photosensitivity. *See* Photodermatitis/photosensitivity
- Phototherapy
for atopic dermatitis, 104
for lichen planus, 144
for major depression with seasonal onset, 1071
for psoriasis, 107
- Phototoxicity, 152. *See also* Photodermatitis/photosensitivity
- Photovaporization of prostate (PVP), for benign prostatic hyperplasia, 961
- Phrenic nerve, hiccups caused by irritation of, 569
- Phthirus pubis*, 148
- Phycomycosis (mucormycosis), **1538**
rhinocerebral, 217
- Phylloides tumor of breast, 719
- Physical abuse. *See* Abuse
- Physical activity. *See* Exercise/activity
- Physical inactivity. *See* Inactivity
- Physical instability. *See* Falls; Gait/gait disorders; Instability
- Physical therapy
for complex regional pain syndrome, 825
after fall, 66, 67*t*
for stroke patient, 982–983
- Physician, relationship of with patient. *See* Doctor–patient relationship
- Physician Orders for Life-Sustaining Treatment (POLST) forms, 89
- Physiologic drug dependence, 1079
- Physostigmine, for atropine/anticholinergic overdose/delirium, 1566*t*, 1575, 1583
- Phytanic acid metabolism, in Refsum disease, 1022
- Phytoestrogens (plant-derived estrogens), 1185
- Phytonadione
for anticoagulant overdose, 1573
for hypoprothrombinemia, in cirrhosis, 690
for vitamin K deficiency, 553
- Phytotherapy, for benign prostatic hyperplasia, 960
- PI. *See* Protease inhibitors
- Pica, in iron deficiency anemia, 491
- PICC. *See* Peripherally inserted central catheter
- Pickwickian syndrome (obesity-hypoventilation syndrome), **318**
- Picornaviruses, gastroenteritis caused by, 1404–1405
- PID. *See* Pelvic inflammatory disease
- Piebaldism, 155
- PIG-A gene defect, in paroxysmal nocturnal hemoglobinuria, 501
- Pigeon-breeder's disease (bird-fancier's lung), 310*t*
- Pigmentary skin disorders, **155–156**. *See also* Hyperpigmentation; Hypopigmentation; Pigmented skin lesions
drugs causing, 155, 160*t*
in hypercarotenosis, 1267
- Pigmented basal cell carcinoma, 142
- Pigmented skin lesions, 95*t*, **100–103**. *See also specific type*
- Pill-induced esophagitis, **598–599**
- Pilocarpine
for chemotherapy/radiation-induced toxicity, 1658*t*
for glaucoma/ocular hypertension, 171*t*, 175, 177
- Pilocarpine iontophoresis sweat test, in cystic fibrosis, 267–268
- Pilopine. *See* Pilocarpine
- Pimecrolimus, 97*t*
for atopic dermatitis, 97*t*, 104
T cell lymphoma and, 104
- Pimozide, for Tourette syndrome, 1005
- Pindolol, 448*t*
for aggressive/violent behavior, 1078
for angina, 355–356
for hypertension, 448*t*
- Pineal tumor, 990*t*
- Pinguecula, 167
- Pingueculitis, 167
- Pink puffers, 260, 260*t*
- Pink top tubes, 1736*t*
- PINK1 gene, in parkinsonism, 998
- Pinta, **1475**
- Pinworm infection, **1519–1520**
anogenital pruritus and, 146, 1520
- Pioglitazone, 1206*t*, 1220, 1221

- with glimepiride, 1213
with insulin, 1221
with metformin, 1213
overdose/toxicity of, 1210, 1220, 1580
- Piperacillin-tazobactam
for anaerobic abdominal infections, 1455, 1455t
for pneumonia, 273t, 277t
- Piperazine, 1492t, 1495
with dihydroartemisinin, 1493t, 1494t, 1495, 1497
- Piperazines, 1056. *See also* Antipsychotic drugs
- Pipracil. *See* Piperacillin
- Piracetam, for myoclonus, 1004
- Pirbuterol, for asthma, 254t, 255
- Piroxicam, 78t
- Pit viper envenomation, 1589–1590
- Pitavastatin, 1253–1254, 1255t
- Pitting (nail), 157
in psoriasis, 106, 106f, 856
in reactive arthritis, 857
- Pituitary adenoma, 1093
ACTH-secreting, 1158, 1159, 1160, 1161, 1189
GH-secreting, 1100, 1189
hypopituitarism caused by, 1093
in MEN, 1093, 1100, 1188t, 1189
Nelson syndrome and, 1160
prolactin-secreting, 1093, 1095, 1102, 1103, 1104, 1189
surgical resection/removal of, 1096, 1097, 1101, 1104, 1160
thyrotrophe (TSH-secreting), 1111, 1117
- Pituitary apoplexy, 1096
- Pituitary gland
destruction/necrosis of, adrenal crisis caused by, 1154
disorders of, **1093–1105**
acromegaly/gigantism, **1100–1102**
amenorrhea caused by, 1179, 1180, 1181
anterior hypopituitarism, **1093–1098**
diabetes insipidus, **1098–1100**. *See also* Diabetes insipidus
diabetes mellitus. *See also* Diabetes mellitus
hyperprolactinemia, **1102–1105**, 1103t
hormones produced by, 1094t
absence of (panhypopituitarism), 1094–1095
combined deficiency of, 1094–1095
hyperplasia of, thyrotrophe, 1106, 1107, 1111, 1117
in hypothyroidism, 1106, 1107, 1108
tumors of. *See also* Pituitary adenoma
amenorrhea caused by, 1179, 1180
- Pituitary microsurgery, 1101
- Pityriasis
alba, in atopic dermatitis, 103
rosea, **108–109**, 108f
drugs causing eruptions similar to, 109, 160t
rubra pilaris, 116
versicolor (tinea versicolor), **113–114**
- Pityrosporum ovale*. *See Malassezia furfur*
- Pivot shift test, knee stability/ACL injury and, 1695t, 1698
- “Pizza-pie” retinopathy, in CMV infection, 1364
- PKD1/PKD2* gene mutations, 934
- PKR-like ER kinase gene, in diabetes, 1196
- PLA₂R (phospholipase A2 receptor), in membranous nephropathy, 929
- Placenta previa, third-trimester bleeding caused by, 797
- Placental abruption, third-trimester bleeding caused by, 797
- Plague, 1300t, **1451**
chemoprophylaxis for, 1315, 1451
- Plan B, for emergency/postcoital contraception, 776
- Plantar fibromatosis, Dupuytren contracture and, 824
- Plantar hyperkeratosis of heels, 141
- Plantar nerves, compressive lesions of, 1027
- Plantar warts, 139, 140
- Plaque psoriasis, 106. *See also* Psoriasis
- Plasma cell leukemia, 528
- Plasma cells
in monoclonal gammopathy of unknown significance, 528
in myeloma, 527, 528
- Plasma chromogranin A (CgA) screening test. *See* Chromogranin A
- Plasma fractions/components, transfusion of, **537**. *See also* Fresh-frozen plasma; Transfusion
for thrombotic microangiopathies, 543
- Plasma glucose, in diabetes, 1198, 1198t
- Plasma preparation tubes (PPT), white/green/light green, 1736t
- Plasma renin activity
in Addison disease, 1156
in aldosteronism, 438, 1164, 1165
in hypertension, 436, 438
reference/normal values for, 1734t
- Plasma renin concentration, in aldosteronism, 1165
- Plasma ultrafiltration, for acute tubular necrosis, 906
- Plasmacytomas, 527. *See also* Myeloma
- Plasmapheresis
for autoimmune hemolytic anemia, 506
for Guillain-Barré syndrome, 1025
for multiple sclerosis, 1011
for myeloma, 936
for Waldenström macroglobulinemia, 530
- Plasminogen, reference values for, 1733t
- Plasminogen activator I, congenital deficiency of, 552
- Plasmodium*, 1490–1499. *See also* Malaria
falciparum, 1490–1499, 1491f
resistant strains of, 1493, 1494, 1494t, 1495, 1496, 1497, 1498, 1498t
severe infection caused by, 1490, 1490–1491, 1493, 1494t
uncomplicated infection caused by, 1493, 1493t, 1494t
knowlesi, 1490
malariae, 1490–1499, 1491f
ovale, 1490–1499, 1491f
vivax, 1490–1499, 1491f
resistant strains of, 1492, 1494, 1496
- Plastic surgery, aesthetic, 1720–1721. *See also* Reconstructive surgery
- Platelet-associated IgG, 1733t
- Platelet count, 539t
bleeding/platelet transfusion and, 536, 538, 539t
chemotherapy dosage modification and, 1659t
in chronic myeloid leukemia, 511t, 516
cyclic oscillations of (cyclic thrombocytopenia), **540**
in essential thrombocytosis, 511t, 513
in myeloproliferative neoplasms, 511t
in polycythemia, 511t, 512
in preeclampsia-eclampsia, 793, 793t
in pregnancy, 547
reference/desired values for, 539t, 1733t
- Platelet-derived growth factor
for chemotherapy-induced thrombocytopenia, 540
for diabetic foot ulcers, 1225
in primary myelofibrosis, 514
- Platelet-derived growth factor receptor alpha (PDGFRA) mutation, in gastrointestinal stromal tumors, 1619, 1620
- Platelet disorders, **538–549**, 539t
acquired, **548–549**, 549t
congenital, **548**
qualitative, **548–549**, 549t
thrombocytopenia, **538–548**, 539t, 541f, 543t, 544t, 546t, 547t. *See also* Thrombocytopenia
- Platelet function test, reference values for, 1733t
- Platelet glycoprotein IIb/IIIa receptors. *See* Glycoprotein IIb/IIIa receptors
- Platelet-inhibiting agents. *See* Antiplatelet therapy
- Platelet transfusion, **536**. *See also* Transfusion
contraindications to in thrombotic microangiopathy, 543
for DIC, 545, 546t
for GI bleeding/variceal hemorrhage, 582
in myelodysplastic syndrome, 540
- Platelets. *See also* Platelet disorders
aspirin/NSAIDs affecting function of, 549t, 611, 829
autoantibodies against. *See* Antiplatelet antibody
in Bernard-Soulier syndrome, 548
in chronic kidney disease/uremia, 549t
drugs inhibiting. *See* Antiplatelet therapy
in essential thrombocytosis, 513
in Glanzmann thrombasthenia, 548
in myeloproliferative neoplasms, 549t
in polycythemia, 512
in primary myelofibrosis, 514
sequestration of in spleen, 539t, **547**, 547t
in storage pool disease, 548
in von Willebrand disease, 551, 552t

- Platinol. *See* Cisplatin
- Platinum analogs/platinum-based chemotherapy, 1650*t*. *See also* Cisplatin
- for lung cancer, 1599–1600
- Platypnea
- in hepatopulmonary syndrome, 691
- orthodeoxia, in patent foramen ovale, 329
- Pleconaril
- in enterovirus infection, 1407
- in poliomyelitis, 1373
- Plendil. *See* Felodipine
- Plerixafor, for stem cell mobilization, 532
- Plesiomonas*, diarrhea caused by, 574*t*, 578
- Plethysmography, impedance, in venous thrombosis/pulmonary embolism, 300
- Pleural biopsy
- in lung cancer, 1597
- in tuberculosis, 281–282, 314–315
- Pleural diseases, **313–317**, 313*t*, 314*t*. *See also* Pulmonary disorders
- occupational, **308–311**
- respiratory failure caused by, 320*t*
- Pleural effusions, **313–316**, 313*t*, 314*t*
- in asbestosis, 311
- drug-induced, 312*t*
- exudative, 313, 313*f*, 314, 314*t*, 315
- in heart disease/failure, 314, 399
- in lung cancer, 314*t*, 315, 1597
- malignant, 315, 1645, 1645–1646
- in mesothelioma, 1602, 1603
- paramalignant, 315
- parapneumonic, 313, 314, 314*t*, 315–316
- in community-acquired disease, 272
- in pneumococcal pneumonia, 1423
- rheumatoid, 314*t*
- transudative, 313, 313*t*, 314, 315
- tuberculous, 282, 314–315, 314*t*
- Pleural fluid analysis, 313–314
- in anthrax, 1432
- in lung cancer, 314*t*, 315, 1597
- in malignant effusion, 315
- in mesothelioma, 1602
- in pneumonia, 272
- in tuberculosis, 281–282, 281*t*, 314–315, 314*t*
- Pleural friction rub, 313
- in pulmonary embolism, 298*t*
- Pleural mesothelioma/malignant pleural mesothelioma, 1602–1603
- Pleurectomy, for mesothelioma, 1603
- Pleuritis/pleuritic chest pain, 28–29, 28*t*, **313**
- in epidemic pleurodynia (Bornholm disease), 1406
- in pericarditis, 419
- in thoracic actinomycosis, 1457
- Pleurodesis, for malignant pleural effusion, 1646
- Pleurodynia, epidemic, 1406
- Plexiform neuroma, 996
- Plexogenic pulmonary arteriopathy (idiopathic/primary pulmonary hypertension), 304, 423, 424, 425
- Plexopathy (diabetic amyotrophy), 1022, 1225
- Plummer disease (toxic adenoma of thyroid), 1111, 1116
- in MEN, 1188*t*
- Plummer-Vinson syndrome, 491, 600
- PMDD. *See* Premenstrual dysphoric disorder
- PML. *See* Progressive multifocal leukoencephalopathy
- PML-RAR α* fusion gene, 519
- PMLE. *See* Polymorphous light eruption
- PMS. *See* Premenstrual syndrome/tension
- PMS2* genes, in HNPCC, 656
- PNES. *See* Psychogenic nonepileptic seizure
- Pneumatic compression devices
- for lymphedema, 484
- for venous insufficiency/leg ulcers, 154, 481
- for venous thromboembolic disease, 555–556
- Pneumatic dilation. *See also* Esophageal dilation
- for achalasia, 605
- Pneumatic retinopathy, for retinal detachment, 180
- Pneumococcal (*Streptococcus pneumoniae*) infections, 1299*t*, 1302*t*, **1422–1425**
- drug resistance and, 228, 273, 273–274, 1423, 1424
- endocarditis, 1423, 1438
- immunization against. *See* Pneumococcal vaccine
- keratitis, 172
- meningitis, 1302*t*, **1424–1425**
- pericarditis, 419, 1423
- pneumonia, 271, 272–273, 274, 276, 1302*t*, 1303*t*, 1421, **1422–1424**
- in HIV infection/AIDS, 1326
- Pneumococcal vaccine, 1308*t*, 1309*t*, 1312*t*
- adverse effects/contraindications and, 1317*t*
- for asthma patients, 253
- for cystic fibrosis patients, 268
- herpes zoster vaccine and, 1361
- in immunocompromised host/HIV infection/AIDS, 1309*t*, 1314, 1335
- in pneumonia prevention, 274
- revaccination and, 1312*t*
- Pneumoconioses, **309**, 309*t*
- Pneumocystis carinii*. *See* *Pneumocystis jiroveci* infection;
- Pneumocystis jiroveci* pneumonia
- Pneumocystis jiroveci* infection, 1338*t*
- otitis, 213
- pentamidine treatment/chemoprophylaxis and, 1325, 1337*t*, 1338*t*, 1534, 1535
- pneumonia. *See* *Pneumocystis jiroveci* pneumonia
- prevention of, 1280, 1337, 1337*t*, 1339, 1535
- Pneumocystis jiroveci* pneumonia (pneumocystosis), 279, 1325–1326, 1338*t*, **1533–1535**
- CD4 T cell count and, 1322–1323, 1323*f*, 1324, 1326, 1337, 1339, 1534, 1535
- dyspnea and, 25
- pentamidine treatment/chemoprophylaxis and, 1325, 1337*t*, 1338*t*, 1534, 1535
- pneumothorax and, 316, 317, 1534
- prophylaxis of, 1280, 1337, 1337*t*, 1339, 1535
- Pneumocystosis. *See* *Pneumocystis jiroveci* pneumonia
- Pneumomediastinum, pneumothorax and, 317
- Pneumectomy, extrapleural, for mesothelioma, 1603
- Pneumonia, **270–279**, 1303*t*. *See also* specific causative agent and Pneumonitis
- adenoviruses causing, 1402
- anaerobic, **278–279**, 1302*t*, 1303*t*, 1455
- in aspergillosis, 1537
- aspiration, 1303*t*. *See also* Aspiration in anaerobic infections, 278, 1303*t*, 1455
- in community-acquired disease, 270–271, 274
- drug use and, 1292
- gastric contents causing, 308
- nosocomial disease and, 275
- toxic materials and, 308
- bronchial obstruction and, 243
- bronchiolitis obliterans and (BOOP/cryptogenic organizing pneumonia/pneumonitis/COP), 269, 294*t*, 295
- chlamydial
- C pneumoniae* causing, 1302*t*, 1303*t*, 1462–1463
- in psittacosis, 1462
- CMV, 1364
- in coccidioidomycosis, 1532
- community-acquired, **270–275**, 270*t*, 272*t*, 273*t*, 1302*t*
- cough and, 22, 22*f*
- cryptococcal, 1536
- desquamate interstitial (DIP), 269, 294*t*
- dyspnea in, 25, 271
- eosinophilic, 297. *See also* Löffler syndrome
- in H1N1 influenza, 1399
- Haemophilus* causing, 1442
- health-care associated, **275–278**, 276*t*, 277*t*, 1302*t*
- herpes simplex, 1351–1352, 1352
- in histoplasmosis, 1531
- hospital-acquired, **275–278**, 277*t*
- hospitalization of patient with, 270, 274, 274–275
- idiopathic interstitial, **293–295**, 294*t*
- in immunocompromised host/HIV infection/AIDS, 279, 1325–1326, 1533–1535. *See also* *Pneumocystis jiroveci* pneumonia
- CD4 T cell count and, 1322–1323, 1323*f*, 1324, 1326, 1339
- influenza and, 271, 1395, 1396

- Legionnaires, 271, 272*t*, 1299*t*, 1302*t*, 1303*t*, **1443**
 in leptospirosis, 1477
 lipoid, 308
 in measles, 1368, 1369
 mercury vapor, 1583
 mycobacterial (NTM), 287–289, 1458
 necrotizing, 278
 nonspecific interstitial (NSIP), 294*t*, 295
 in HIV infection/AIDS, 1326–1327
 nosocomial, **275–278**, 276*t*, 277*t*, 1302*t*
 plague, 1451
 pleural effusion in (parapneumonic pleural effusion), 313, 314, 314*t*, 315–316
 in community-acquired disease, 272
 pneumococcal, 1423
 pneumococcal/streptococcal, 271, 272–273, 274, 276, 1302*t*, 1303*t*, 1421, **1422–1424**
 immunization against. *See* Pneumococcal vaccine
Pneumocystis. *See* *Pneumocystis jiroveci* pneumonia
 postoperative, 50–51, 50*t*
 prevention of, 274
 in Q fever, 1416
 RSV, 1393
 in SARS, 1401
 treatment of, 1303*t*
 anaerobic infection, 278–279, 1302*t*, 1303*t*, 1455
 community-acquired disease, 272–274, 273*f*, 1302*t*
 hospitalized patient and, 274
 nosocomial disease, 277, 277*t*, 1302*t*
 in tularemia, 1450
 usual interstitial (UIP), 293, 294*t*, 295
 varicella zoster virus, 1358
 during pregnancy, 804
 ventilator-associated, **275–278**, 277*t*, 321, 1283
 viral, 271
 Pneumonia Severity Index (PSI), 274
 Pneumonitis. *See also* Pneumonia
 acute gastric aspiration causing, 308
 CMV, 1364
 cryptogenic organizing (COP/
 idiopathic bronchiolitis
 obliterans with organizing
 pneumonia/BOOP), 269,
 294*t*, 295
 in H1N1 influenza, 1399
 hydrocarbon/petroleum distillates/
 solvents causing, 308, 1587–
 1588
 hypersensitivity, **310**, 310*t*
 interstitial, drug-induced, 312*t*
 mercury vapor, 1583
 methotrexate causing, 829
 radiation, **312**, 1554
 toxoplasmic, in HIV infection/AIDS,
 1501
 Pneumoplasty, reduction, for COPD, 265
 Pneumothorax, **316–317**
 catamenial, 316
 chest pain/discomfort in, 316, 355
 in COPD, 261, 316
 dyspnea in, 24, 316
 iatrogenic, 316
 P jiroveci pneumonia/pentamidine
 prophylaxis and, 316, 317,
 1534
 spontaneous, **316–317**
 tension, 316, 317
 traumatic, 316
 Pneumovax. *See* Pneumococcal vaccine
 PNH. *See* Paroxysmal nocturnal
 hemoglobinuria
 PNPLA3 (patatin-like phospholipase
 domain containing 3) gene,
 in nonalcoholic fatty liver
 disease, 684
 PO₂. *See also* PaO₂
 in dyspnea evaluation, 25
 in pulmonary embolism, 298
 reference values for, 1733*t*
 in respiratory failure, 320
 Podagra, 813
 Podophyllum resin (podophyllin/
 podoflox), for genital warts,
 140, 753
 Poison control centers, 1562, 1570
 Poison ivy/oak/sumac, 124, 124*f*, 866. *See also* Allergic contact
 dermatitis
 Poisoning/drug overdose, **1562–1592**. *See also specific drug or agent*
 abdominal radiographs in, 1570
 anion gap in, 891, 1569. *See also* Anion
 gap/anion gap acidosis
 antidotes for, **1566**, 1566*t*
 arrhythmias in, **1564**, 1564*t*
 coma caused by, 1015, 1232*t*, **1562–1563**
 diagnosis of, **1568–1570**, 1569*t*
 eye decontamination in, **1566**
 gastrointestinal decontamination in,
 1566–1568, 1568*t*
 hypertension in, **1564**
 hyperthermia in, **1565**
 hypotension in, **1563–1564**
 hypothermia in, **1563**
 initial evaluation in, **1562**
 laboratory tests in, 1568–1570, 1569*t*
 osmol gap in, 877, 1569, 1569*t*
 patient observation and, 1562
 physical examination in, 1568
 seizures in, **1565**, 1565*t*
 skin decontamination in, **1566**
 toxicology screen in, 1569–1570, 1569*t*
 Poisonous mushrooms, **1585–1586**, 1586*t*
 anticholinergic-type, 1575, 1583
 hallucinogenic mushrooms and, 1583,
 1586*t*
 liver failure and, 673, 674, 1585
 Poisonous snakes, 1566*t*, **1589–1590**
 Poliomyelitis, **1372–1374**
 prevention/immunization and, 1372,
 1373–1374. *See also*
 Poliovirus vaccine
 vaccine-associated/VDPV and, 1372,
 1374
 Poliovirus vaccine, 1372, 1373–1374
 in immunocompromised host/HIV
 infection/AIDS, 5, 1314
 pregnancy and, 786
 for travelers, 1315
 vaccine-derived virus (VDPV) and,
 1372, 1374
 POLST forms, 89
 Poly-ADP ribose-polymerase inhibitors,
 for breast cancer, 741
 Polyalcohols (polyols), for diabetics, 1205
 Polyangiitis, microscopic. *See* Microscopic
 polyangiitis
 Polyarteritis. *See also* Arteritis
 glomerulonephritis in, 919*t*
 neuropathy associated with, 847, 1024
 nodosa, 150, **847–848**
 Polyarthralgia/polyarthritis. *See* Arthritis/
 arthralgia
 Polycarbophil. *See* Fiber, dietary
 Polychondritis, relapsing, 199, **852–853**
 Polycystic kidney disease, **934–935**, 934*t*
 intracranial aneurysms and, 935, 986
 Polycystic ovary syndrome, **765–766**, 1162
 acne in, 125
 amenorrhea in, 765, 1162, 1179, 1180
 hirsutism/virilization in, 765, 1162
 infertility and, 765, 766, 768
 obesity in, 765, 766, 1162
 Polycythemia, **511–513**, 511*t*, 512*t*, 1610*t*
 in cor pulmonale, 426
 hypertension and, 436
 pulmonary hypertension and, 305
 spurious, 511, 512
 vera, **511–513**, 511*t*, 512*t*, 1610*t*
 hepatic vein obstruction (Budd-
 Chiari syndrome) and, 698
 Polydipsia/thirst, 1055
 in diabetes insipidus, 1098, 1099
 in diabetes mellitus, 1197, 1197*t*
 in hypercalcemia/hyperparathyroidism,
 1139
 hyponatremia caused by, 871*f*, 872, 873
 lithium causing, 1073
 psychogenic, 1055, 1099
 hyponatremia caused by, 871*f*, 873,
 1055
 in schizophrenia/psychotic disorders,
 1055
 Polyendocrinopathy-candidiasis-
 ectodermal dystrophy,
 autoimmune, 1135, 1155. *See also* Polyglandular
 autoimmune syndrome
 Polyethylene glycol/PEG 3350
 for constipation/preoperative bowel
 cleansing, 571, 572*t*, 585
 for whole bowel irrigation, 1567
 Polyglandular autoimmune syndrome,
 1135, 1155
 Addison disease in, 1155
 Hashimoto thyroiditis in, 1120
 type 1, 1135, 1155
 autoimmune hepatitis in, 679
 type 2, 1120, 1155
 Poly-L-lactic acid, for age-related facial
 changes, 1721
 Polymerase chain reaction (PCR) testing
 in Lyme disease, 1480, 1480–1481
 in malaria, 1492
 in meningitis, 1287
 in syphilis, 1467
 Polymorphic reticulosis, 223
 Polymorphonuclear neutrophil count. *See*
 Neutrophil count
 Polymorphous light eruption (PMLE),
 153

- Polymyalgia rheumatica, **845–847**
 fibromyalgia differentiated from, 823
 polymyositis differentiated from, 841
 rheumatoid arthritis differentiated from, 828
- Polymyositis, **840–842**
 autoantibodies in, 833t, 841
 cancer-related, 840, 841
- Polymyxin B/trimethoprim sulfate, for ophthalmic disorders, 168t
- Polyneuropathies, 1020–1021, **1021–1026**.
See also specific type and Neuropathies
 acute idiopathic. *See* Guillain-Barré syndrome
 cancer-related, 976, 1024
 chronic inflammatory, **1025–1026**
 in critically ill patients, 1024
 in diabetes mellitus, 1022, 1224–1225, 1225f
 in HIV infection/AIDS, 1023, 1328
 in Lyme disease, 1023, 1479
 in polyarteritis nodosa, 847, 1024
 in rheumatoid arthritis, 1024
 in sarcoidosis, 1024
 toxic, 1024
- Polyols (polyalcohols), for diabetics, 1205
- Polypectomy
 cervical, 753
 colonoscopic, 653–654, 1628
 GI bleeding after, 584, 654
 colorectal cancer and, 654, 1626, 1628
- Polyphagia with weight loss, in diabetes mellitus, 1197, 1197t
- Polypharmacy, in elderly, **71–72**
 falls and, 65, 67t
 urinary incontinence and, 67
- Polypoid corditis, 235
- Polyps/polyposis
 adenomatous, 652, 653. *See also* Adenomatous polyps
 familial, **654–655**, 1622. *See also* Familial adenomatous polyposis
 nonfamilial, **653–654**
 cervical, 753
 of colon, **652–657**
 colorectal cancer and, 653, 654, 655, 1622, 1623, 1626, 1628
 GI bleeding and, 584
 screening for, 15t, 16, 1624, 1624f, 1626–1628, 1626t
 esophageal, 601
 gastric, 620–621
 hamartomatous, **655**
 in HNPCC, 656–657
 hyperplastic/serrated, 652, 653, **653–654**
 juvenile familial, 655
 malignant, 654
 nasal, 222
 allergic rhinitis and, 218, 222
 nonneoplastic, 652
 submucosal, 652
 vocal fold, 235
- Polyradiculoneuropathy/
 polyradiculopathy
 in CMV infection, 1364
 in Guillain-Barré syndrome, 1024
 in HIV infection/AIDS, 1023, 1328
 in Lyme disease, 1023, 1479
- Polysomnography
 preoperative, 51
 in sleep apnea, 319
 in snoring, 231
- Polystyrene sulfonate, for hyperkalemia, 881t, 914
- Polysurgery (surgery proneness), 1090
 somatization disorder and, 1045
- Polytrim. *See* Polymyxin B/trimethoprim sulfate
- Polyuria
 in Cushing syndrome, 1158, 1159
 in diabetes insipidus, 1098, 1099
 in diabetes mellitus, 1197, 1197t
 in hypercalcemia/hyperparathyroidism, 883, 1139
 lithium causing, 1073
 in obstructive uropathy/
 tubulointerstitial disease, 932, 933
- Pomalidomide, for primary myelofibrosis, 515
- Pomeroy tubal resection, 777
- Pompholyx (vesiculobullous hand eczema), **121–122**, 121f
 tinea differentiated from, 113
- Ponatinib, for chronic myeloid leukemia, 517
- Ponstel. *See* Mefenamic acid
- Pool (swimming pool) granuloma, 1458
- Pool (swimming pool) safety, 1556
- Popliteal arteries
 acute occlusion of, 468
 aneurysms of, 475–476
 atherosclerotic/occlusive disease of, **465–466**
 compression of, in DVT detection, 300
- Popliteal (Baker) cyst, 825, 826, 1692
- Porcelain gallbladder, 703t, 705, 1606
- Pork. *See also* Meat
 in gnathostomiasis, 1522
 in trichinosis, 1521, 1522
- Pork tapeworm (*T solium*), **1514**
 cysticercosis and, 1514, 1515
- Porphobilinogen, urinary
 in porphyria, 1664
 reference values for, 1733t
- Porphobilinogen deaminase, deficiency of
 in porphyria, 1664
- Porphyria
 acute intermittent, 1022, **1664–1665**, 1665t
 cutanea tarda, **122**, 122f
 hemochromatosis and, 695
 photosensitivity and, 153
 peripheral nerve involvement in, 1022, 1664
 variegata, 1022
- Porphyryns, urine, in porphyria cutanea tarda, 122
- Portal cavernoma, 699, 700
- Portal decompression, for esophageal varices, 603
- Portal hypertension
 ascites in, 587, 587–588, 587t
 cirrhosis and, 688
 malignant, 590
 cirrhosis and, 601, 688
 esophageal varices and, 581, 601
 GI bleeding in, 581, 601
 noncirrhotic, **699–700**
 in primary myelofibrosis, 514
 pulmonary hypertension in, 424
- Portal hypertensive gastropathy, 581, 607, 608–609. *See also* Portal hypertension
- Portal vein thrombosis, noncirrhotic
 portal hypertension caused by, 699, 700
- Portopulmonary hypertension, 691
- Portosystemic shunts
 emergency/surgical, for esophageal varices, 603
 rebleeding prevention and, 603–604
 transvenous (transjugular). *See* Transvenous (transjugular) intrahepatic portosystemic shunts
- Posaconazole, 1542, 1542t
 for aspergillosis, 1538
 for mucormycosis, 1538
 prophylactic, 1281
- Positioning vertigo, benign paroxysmal (BPPV), 210t, 211
- Positive end-expiratory pressure (PEEP)
 for ARDS, 321, 322, 323
 for near drowning, 1556
 for smoke inhalation, 307
- Positive expiratory pressure (PEP)
 therapy, in cystic fibrosis, 268
- Positive inotropic agents. *See* Inotropic agents
- Positive-pressure breathing
 for COPD, 264
 intermittent (IPPB), prevention of
 postoperative pulmonary complications and, 51
- Positive-pressure ventilation
 for ARDS, 323
 for COPD, 264
 for respiratory failure, 321
- Positron emission tomography (PET)
 in angina, 353
 in biliary tract carcinoma, 1606–1607
 for breast cancer evaluation, 727
 in dementia, 1007
 in liver disease/jaundice, 665
 for lung cancer staging, 1598
 in musculoskeletal evaluation, 1673
 in pancreatic/periampullary carcinoma, 1608
 in pheochromocytoma/paraganglioma, 1169
 in solitary pulmonary nodule, 290–291
 in thyroid cancer evaluation/
 surveillance, 1129, 1131, 1133
 in thyroid nodule/goiter, 1121, 1123, 1124
 in thyroiditis, 1121
- Postcapillary pulmonary hypertension, 304
- Postcardiotomy/postmyocardial infarction pericarditis (Dressler syndrome), 375, 419, 419–420, 420
- Postcholecystectomy syndrome, **706**
- Postcoital/emergency contraception, **776**
 IUD for, 774, 776
- Postdysenteric colitis, 1504

- Postencephalitic parkinsonism, 998
- Postepileptic automatism, 970
focal seizures and, 969
- Posterior blepharitis, 163, 164
- Posterior cerebral artery occlusion, in stroke, 981
- Posterior communicating artery, disorders of in third nerve paralysis, 190
- Posterior cruciate ligament (PCL), 1692, 1699
assessment of, 1696*t*, 1699
injury of, 1696*t*, **1699–1700**
- Posterior drawer sign/test, 1696*t*, 1699
- Posterior inferior cerebellar artery obstruction, in stroke, 981
- Posterior ischemic optic neuropathy, 188
- Posterior nasal cavity, epistaxis originating in, 221
- Posterior synechiae, in uveitis, 178
- Posterior uveitis, 177, 178. *See also* Uveitis
- Postgonococcal urethritis/cervicitis, 1453, 1462
- Postherpetic neuralgia, 120, 120–121, **968**, 1359
varicella vaccine in prevention of, 120, 968, 1360
- Posthypercapnia alkalosis, 895, 896
- Posthypocapnia acidosis, 893, 897
- Postictal period, psychogenic nonepileptic/pseudoepileptic seizure and, 972, 1045
- Postinfarction ischemia/angina, 372
- Postinfectious glomerulonephritis, 919*t*, 921*f*, **922**, 1419
- Postinfectious irritable bowel syndrome, 633
- Postinflammatory hyperpigmentation, 155, 156
- Post-kala azar dermal leishmaniasis, 1487–1488
- Post-Lyme disease syndrome, 1482*t*
- Postmenopausal osteoporosis. *See* Osteoporosis
- Postmenopausal vaginal bleeding, **749**
endometrial carcinoma and, 749, 759
- Postmyocardial infarction/
postcardiotomy pericarditis (Dressler syndrome), 375, 419, 419–420, 420
- Postnasal drip, cough caused by, 21, 22, 22*t*, 23
- Postoperative cognitive dysfunction, 53, 53*t*
- Postoperative fever, 1283
- Postoperative hyponatremia, 872
- Postoperative ileus, 627
- Postpartum depression, 1063
- Postpartum infection
anaerobic, 1456
C sordellii causing, 1429
mastitis, 721, **797–798**
candidal, 132
streptococcal, 804
- Postpartum psychosis, 1063
- Postpartum thyroiditis, 800, 1111, 1120, 1121
- Postphlebotic syndrome, 33, 479
- Postpoliomyelitis syndrome, 1373
- Postpolypectomy hemorrhage, 584, 654
- Postpolypectomy surveillance, 654
- Postprandial (reactive) hypoglycemia, 1238, 1238*t*, **1242–1243**. *See also* Hypoglycemia
- Postrenal acute kidney injury/azotemia, 902*t*, 903. *See also* Acute kidney injury
- Postsurgical anxiety states, 1090, 1091
- Post-thrombotic syndrome, 481
compression stockings in prevention of, 563
- Posttransfusion purpura (PTP), **546**
- Posttransplant lymphoproliferative disorder, 1277, 1362, 1363
- Posttraumatic epilepsy/seizure disorder, 969
- Posttraumatic headache, **965**
- Posttraumatic stress disorder, **1039–1040**
abuse victims and, 1039, 1712
rape and, 778
- Posttraumatic syringomyelia, 1019
- Posttraumatic vertigo, 211
- Postural drainage
in bronchiectasis, 266
in chronic bronchitis, 264
in cystic fibrosis, 268
- Postural hypotension. *See* Orthostatic (postural) hypotension
- Postural instability. *See* Falls; Gait/gait disorders; Instability
- Postural tremor, drug-induced, 1004
- Posture
in impingement syndrome, 1675
neck pain and, 1686
- Posture stimulation test, in aldosteronism, 1165
- Potassium
dietary/replacement, 1269
for diabetic ketoacidosis, 1234
in fluid management, 897, 897*t*
for hyperglycemic hyperosmolar state, 1236
hypertension and, 11, 436, 441
for hypokalemia, 879
in renal tubular acidosis, 894
requirements for in nutritional support, 1272
restriction of, in chronic kidney disease, 915
for thyroid nodules, 1125
disorders of concentration of, **877–880**, 877*t*, 878*t*, 880*t*, 881*t*. *See also* Hyperkalemia; Hypokalemia
in acidosis, 879, 892, 892*t*
genetic disorders and, 878*t*
periodic paralysis and, 878*t*, 1036–1037
serum/plasma levels of
aldosterone/aldosteronism and, 402, 878, 1164
in hyperkalemia, 879, 880
phlebotomy technique and, 1164
reference values for, 1734*t*
urinary levels of, in hypokalemia, 878
- Potassium channel blocking drugs, for arrhythmias, 377, 378–379*t*
- Potassium chloride. *See* Potassium, dietary/replacement
- Potassium citrate
for hypocitraturic calcium nephrolithiasis, 949
for uric acid calculi, 949
- Potassium concentration gradient, transtubular (TTKG), 878
- Potassium iodide
in table salt, goiter prevention/treatment and, 1135
for thyroid nodules, 1125
- Potassium-sparing diuretics, 446
for heart failure, 401
lithium interactions and, 1074, 1074*t*
- Potomania, beer, hyponatremia caused by, 871*f*, 873
- Pott disease (spinal tuberculosis), **863–864**
- Pott puffy tumor, 216
- Potts shunt, for tetralogy of Fallot, 331
- Pouchitis, 649
- Poultry
avian influenza and, 1397, 1398
in gnathostomiasis, 1522
psittacosis and, 1462
- Powassan encephalitis/agent, 1378–1380, 1391
- Power of attorney, durable, for health care, 89
- Poxvirus infections, **1403–1404**. *See also* specific type
in HIV infection/AIDS, 1331
- pp65 antigen, in CMV infection, 1365
- PPAR- α . *See* Peroxisome proliferator-activated receptor alpha
- PPAR- γ . *See* Peroxisome proliferator-activated receptor gamma
- PPARG gene. *See also* Peroxisome proliferator-activated receptor gamma
in insulin resistance, 1194
- PPD (purified protein derivative) test, 282, 283*t*. *See also* Tuberculin skin test
- PPSV/PPSV23. *See* Pneumococcal vaccine
- PPT (plasma preparation tubes), white/green/light green, 1736*t*
- PPV (pneumococcal polysaccharide vaccine). *See* Pneumococcal vaccine
- PR3-ANCA. *See* Antineutrophil cytoplasmic antibody; Proteinase-3 ANCA
- PRA. *See* Plasma renin activity
- Prader-Willi syndrome, 1093–1094, 1094
- Pralatrexate, 1651*t*
- Pralidoxime, for cholinesterase inhibitor (anticholinesterase) poisoning, 1566*t*, 1587
- PrameGel. *See* Pramoxine
- Pramipexole, for parkinsonism, 1000
- Pramlintide, 1207*t*, 1213
- overdose/toxicity of, 1213, 1580
- Pramosone. *See* Hydrocortisone; Pramoxine
- Pramoxine, 94, 98*t*, 146
- Prandi-Met. *See* Repaglinide, with metformin
- Prandin. *See* Repaglinide
- Prasugrel
for acute coronary syndromes, 361, 362*t*, 363
for myocardial infarction, 362*t*, 367, 371, 376
PCI and, 362*t*

- Pravachol. *See* Pravastatin
- Pravastatin, 1246, 1247, 1253–1254, 1255*t*. *See also* Statin drugs
in HIV infection/AIDS, 1344
in older patients, 1251
- Prax. *See* Pramoxine
- Praziquantel
for clonorchiasis/opisthorchiasis, 1513
for cysticercosis, 1515
for intestinal flukes, 1514
for paragonimiasis, 1513
for schistosomiasis, 1512
for tapeworm infections, 1514
- Prazosin, 456*t*
for benign prostatic hyperplasia, 959, 959*t*
for hypertension, 453, 456*t*
for urinary incontinence, 69
- Pre-Gen Plus. *See* Multitarget DNA tests
- Prebreakfast hyperglycemia, 1219–1220, 1219*t*
- Precholecystectomy syndrome, 705–706
- Precose. *See* Acarbose
- Prediabetes, 1202
- PredMild. *See* Prednisolone
- Prednicarbate, 96*t*
- Prednisolone
for asthma, 251*t*, 254*t*
for Bell palsy, 1028, 1355
for ophthalmic disorders, 170*t*
- Prednisone, 1190, 1190*t*. *See also specific disease and* Corticosteroids
for Addison disease, 1157
for adhesive capsulitis (frozen shoulder), 1682
for allergic contact dermatitis, 125
for asthma, 251*t*, 254*t*, 255
for autoimmune hemolytic anemia, 506
for autoimmune hepatitis, 679–680
for back pain, 1686
for Bell palsy, 1028
in cancer chemotherapy, 1657*t*
for chronic inflammatory polyneuropathy, 1025
for erythema nodosum leprosum, 1460–1461
for giant cell arteritis, 845, 846, 847
for granulomatosis with polyangiitis, 306, 850
for herpes zoster, 120
for inflammatory bowel disease, 639
 Crohn disease, 644
 ulcerative colitis, 647, 648
for microscopic polyangiitis, 851
for minimal change disease, 929
in pain management, 85
perioperative, 54
for *Pneumocystis* infection, 1535
for polymyalgia rheumatica, 845, 846
for prostate cancer, 1637*t*
- Preeclampsia-eclampsia, 438, 792–795, 793*t*, 802
antihypertensive therapy in, 795
 in hypertensive emergency, 461*t*
in gestational trophoblastic disease, 791
headache and, 41, 793
hypermagnesemia associated with
 treatment of, 794, 888
late-onset (postpartum), 795
 continuous glucose monitoring
 systems and, 1200
diagnosis/differential diagnosis of, 781
drug/medication use/avoidance during,
 782*t*, 783. *See also specific agent*
- ECT during, 1071
- ectopic, 790–791
 elective abortion and, 776
 hCG levels in, 781, 790
 IUDs and, 774
 minipill use and, 773
 PID and, 763
 ruptured, appendicitis differentiated
 from, 631, 790
- electrical burns during, 1553
- endocarditis prophylaxis and, 431, 803
- erythrovirus (parvovirus) infection in,
 1402, 1403
- fatty liver of, 673, 795
- folic acid deficiency/supplementation
 during, 499, 783, 785, 799
- gallbladder disease/surgery during,
 703, 704, 807
- genital warts/wart removal and, 140, 753
- glucosuria and, 1198
- gonorrhea and, 784, 806
- group B streptococcal infection and,
 784–785, 804
- growth hormone replacement during,
 1097
- headache during, preeclampsia and, 41, 793
- heart disease and, 429–431, 802–803
- hepatitis B and, 667, 783, 806
 vaccination/vaccination
 recommendations and, 669,
 786, 806, 1309*t*
- hepatitis C and, 670, 671, 806
 testing for, 783
- hepatitis E and, 672
- herpes infection during, 806, 1351, 1355, 1366
- HIV infection/AIDS in, 783, 784, 805–806, 1321, 1336
- hypercortisolism and, 1160
- hyperparathyroidism during, 1139
- hypertension and, 437, 438, 461*t*, 793–795, 793*t*, 802. *See also* Preeclampsia-eclampsia
- hyperthyroidism/Graves disease
 during, 800, 1111–1112, 1113, 1117, 1121
 methimazole for, 800, 1117
 propylthiouracil for, 800, 1115, 1117
 thyroidectomy for, 1116, 1117
- hyposmolality of, reset osmostat and,
 873
- hypothyroidism/hypothyroidism
 treatment during, 800, 1106, 1108, 1109
- immune thrombocytopenia associated
 with, 542
- immunizations during, 786–787, 1307–1314, 1309*t*
- influenza/H1N1 influenza vaccination
 and, 3, 787, 1307, 1309*t*, 1395, 1396, 1399, 1400
- iodine deficiency and, 1123, 1134
- Preexcitation syndromes, 383–384
 atrial flutter and, 383, 384, 389
 palpitations in, 31
- Prefest, 1184
- Pregabalin
for neuropathic pain/diabetic
 neuropathy, 84–85, 84*t*, 1021, 1225
for restless legs syndrome, 1004
for seizures, 973*t*
- Pregnancy, 781–808
 acne treatment and, 127
 adverse ophthalmic effects of drugs
 used in, 196*t*
 air travel during, 786
 alcohol use during, 783, 1081
 amenorrhea (primary/secondary)
 caused by, 781, 786, 1180, 1181
 anemia during, 784, 798–799
 antidepressant use during, 1067–1068
 antiphospholipid antibody syndrome
 and, 799–800, 834, 836
 antipsychotic drug use during, 1060
 appendicitis during, 630, 807
 asthma during, 803
 bleeding during
 ectopic pregnancy and, 790
 in gestational trophoblastic disease,
 791
 third-trimester, 797
 breast cancer and, 730, 743, 745, 807–808
 breast cancer risk and, 722, 723*t*, 743, 1708
 cardiac disease and, 429–431, 802–803
 cardiomyopathy and
 dilated (peripartum
 cardiomyopathy), 429–430
 hypertrophic constrictive, 415
 Chlamydia trachomatis infection and,
 784, 806, 1462
 choledocholithiasis during, 807
 cholelithiasis/cholecystitis during, 703, 704, 807
 cholestasis of, 663*t*, 807
 chorioamnionitis and, 798
 in chronic kidney disease, 914
 CMV infection during, 1363–1364, 1364, 1364–1365, 1365
 complications of
 cardiovascular, 429–431, 802–803
 during first and second trimesters,
 787–792
 infectious conditions, 803–806
 medical conditions, 798–803
 peripartum, 797–798
 during second and third trimesters,
 792–797, 793*t*
 surgical, 807–808
 coxsackievirus infection during,
 neonatal myocarditis and,
 1406
 dengue and, 1387
 depression during, 1067–1068
 depression after (postpartum
 depression), 1063
 diabetes insipidus and, 1098, 1099
 diabetes mellitus and, 784, 800–801, 801*t*, 1230

- iron requirements/deficiency anemia during, 491, 783, 785, 798
- IUDs and, 774
- lactation and, **786**
- listeriosis during, 1434
- luteoma of, 1162
- Lyme disease and, 1481, 1482
- lymphocytic choriomeningitis and, 1381
- malaria/malaria treatment/chemoprophylaxis during, 787, 1490, 1495, 1497, 1498
- manifestations of, 781
- Marfan syndrome and, 431
- mask of (melasma/chloasma), 155, 156
- measles/measles vaccine during, 1309*t*, 1368
- mitral stenosis and, 338
- MMR vaccination and, 1309*t*, 1369
- molar (hydatidiform mole), **791–792**. *See also* Gestational trophoblastic disease
- hCG levels in, 781, 791, 792
- hyperthyroidism in, 791, 1112
- myomectomy and, 758
- nutrition in, **785**
- ovarian tumors during, **808**
- parathyroidectomy during, 1142
- pheochromocytoma/paraganglioma and, 1168*t*
- preeclampsia-eclampsia in, **792–795**, 793*t*
- hypermagnesemia associated with treatment of, 794, 888
- prenatal care and, **782–785**, 782*t*
- preterm labor/birth and, **796–797**
- prevention of hemolytic disease of newborn and, 785–786
- prolactinoma in, 1102–1103, 1103, 1103–1104
- prosthetic heart valves and, 338, 349, 431, 803
- pulmonary hypertension as contraindication to, 425
- Q fever during, 1416
- rabies vaccination during, 1377
- radiation exposure during, 783–784, 1554
- radioactive iodine contraindicated in, 800, 1114, 1115, 1131
- respiratory alkalosis in, 896
- Rhesus alloimmunization (Rh incompatibility) and, 534, 783, 784, **785–786**. *See also* Rh₀ (D) immune globulin
- rubella exposure/rubella vaccination and, 1309*t*, 1374, 1375
- scabies/scabies treatment and, 147
- screening tests in. *See* Prenatal testing
- seizures/seizure treatment and, 803, 972
- in eclampsia, 794, 795
- sexually transmitted disorders and, **806**
- sickle cell anemia and, 799
- smoking during, 783
- streptococcal infection and, 784–785, 804
- syphilis/syphilis testing and, 784, **806**, 1467, **1474**
- termination of
- by delivery
- in acute fatty liver of pregnancy, 795
- in diabetic patient, 801, 1230
- in preeclampsia-eclampsia, 793, 794, 795
- by elective abortion. *See* Abortion, elective/induced
- by recurrent (habitual) abortion, **789–790**
- by spontaneous abortion, **788–789**
- thrombocytopenia during, 547
- thrombotic microangiopathies during, 542
- thyroid disease during, **800**, 1106, 1108, 1109, 1111, 1111–1112, 1113, 1117, 1119, 1120, 1121
- hyperemesis gravidarum and, 787, 1111
- hyperthyroidism, 800, 1111, 1111–1112, 1113, 1117, 1121
- hypothyroidism, 800, 1106, 1108, 1109
- surgery for, 1116, 1117
- thyroid cancer treatment and, 1130
- thyroiditis, 800, 1111, 1119, 1120, 1121
- toxoplasmosis during, 1501, 1502
- travel and, **786–787**
- traveler's diarrhea during, 787, 1298
- trophoblastic disease and, **791–792**, 1612*t*. *See also* Gestational trophoblastic disease
- tuberculosis/tuberculosis treatment during, 285–286, 287, **805**
- ultrasonography during, 781, 783, 784
- ectopic pregnancy and, 790
- of unknown location, 781
- urinary tract infection during, **803–804**
- varicella (chickenpox)/varicella vaccine during, 786, **804–805**, 1309*t*, 1359, 1360
- virilization during, 1162
- vomiting of, 781, **787–788**
- gestational trophoblastic disease and, 791
- Wernicke encephalopathy and, 1013
- in von Willebrand patients, 552
- weight gain in, 783, 785
- yellow fever vaccination and, 1316, 1390
- Pregnancy-associated plasma protein-A (PAPP-A), testing for, 783
- Pregnancy tests, 781. *See also* Human chorionic gonadotropin
- in amenorrhea, 1180, 1181
- in ectopic pregnancy, 781, 790
- for rape victim, 778
- in spontaneous abortion, 788
- Prehn sign, 945
- Prehypertension, **434**, 434*t*
- treatment of, 434*t*, 441–442, 443
- Prekallikrein deficiency, 552
- Preleukemia, 517. *See also* Myelodysplastic syndromes
- Premarin cream, 1184
- Premature beats. *See* Atrial (supraventricular) premature beats; Ventricular premature beats
- Premature ejaculation, 951, 1050. *See also* Erectile dysfunction/impotence
- Premature menopause/ovarian failure, 779, 1181
- in Turner syndrome, 1179, 1186, 1187
- Premature rupture of membranes, 796
- Premature ventricular contractions. *See* Ventricular premature beats
- Premenopausal bleeding
- abnormal, **747–749**
- in polycystic ovary syndrome, 765, 1162
- normal menstrual. *See also* Menstruation; Vaginal bleeding
- Premenstrual dysphoric disorder, 749, 1063
- Premenstrual syndrome/tension, **749–750**
- Premphase, 1184
- Prempro, 1184
- Prenatal care, **782–785**, 782*t*
- Prenatal testing/diagnosis, 783, 784–785. *See also* Genetic testing
- for Down syndrome, 783, 1666
- for Gaucher disease, 1668
- for muscular dystrophy, 1034
- for sickle cell disease, 503, 504, 783, 799
- for syphilis, 784, 806, 1467, 1474
- for toxoplasmosis, 1501, 1502
- Prenatal vitamins, 783, 785
- Preoperative evaluation/perioperative management, **46–56**. *See also specific type of disorder*
- adverse ophthalmic effects of agents used in, 196*t*
- antibiotic prophylaxis and, **55–56**
- asymptomatic patient and, **46**
- cardiovascular disorders and, **46–50**, 47*t*, 48*f*, 48*t*
- endocrine disorders and, **54–55**, 54*t*
- hematologic disorders and, 46, 47*t*, **52**, 53*t*
- kidney disease and, **55**, 55*t*
- liver disease and, **51–52**
- neurologic disorders and, **53–54**, 53*t*
- pulmonary disorders and, for non-lung resection surgery, **50–51**, 50*t*
- Prepatellar bursae/bursitis, 825, 1692
- Pre-proliferative retinopathy, 186
- Prerenal acute kidney injury/azotemia, 902–903, 902*t*, 904. *See also* Acute kidney injury
- Presbycusis (hearing impairment in elderly), **72**, 198, 206
- Presbyopia, 162
- Presenilin gene, 1007
- Preservative-free eye medications, contamination and, 195
- Preservatives, ocular, toxic/hypersensitivity reactions to, 166, 195
- Pressure control ventilation, for respiratory failure, 321
- Pressure support ventilation, for respiratory failure, 321
- Pressure ulcers, **70–71**, 71*f*
- bed rest/immobility and, 65, 70
- Presurgical anxiety states, 1090

- Preterm birth, 796
 Preterm labor, **796–797**
 Pretibial myxedema (Graves dermopathy), 1110, 1113
 Preventive care, **1–20**. *See also specific disease*
 adherence and, **1–2**
 approach to patient and, **1–2**
 immunization and, **3–5**, **1307–1318**, 1308–1313*t*, 1316–1317*t*
 principles of care and, **2**
 in women, **1706–1711**
Prevotella, 1299*t*
 melaninogenica, 1454, 1455
 Prezista/Norvir. *See* Darunavir, with ritonavir
 Priapism (prolonged painful erection), 951, 953
 erectile dysfunction therapy causing, 951, 952, 953, 1226
 trazodone causing, 1069, 1076–1077
 Primaquine
 for malaria, 1492–1493, 1492*t*, 1494, 1494*t*, 1495–1496
 chemoprophylaxis, 1496, 1498, 1498*t*
 for *P jiroveci* infection, 1338*t*, 1339, 1534, 1535
 Primary angitis of central nervous system, **854**
 Primary central nervous system lymphoma, 525
 Primary effusion (body cavity) lymphoma, 1367
 Primary exertional headache, 966
 Primary headache associated with sexual activity, 966
 Primary lateral sclerosis, 1019
 Primary sclerosing cholangitis, **709–710**
 cholangiocarcinoma and, 710
 in HIV infection/AIDS, 1329
 Primaxin. *See* Imipenem
 Primidone, 972, 973*t*
 Primrose oil (oil of evening primrose/OEP), for fibrocystic condition, 719
 Prinivil. *See* Lisinopril
 Prinzide. *See* Lisinopril, for hypertension, with hydrochlorothiazide
 Prinzmetal (variant) angina, 360
 Prion diseases, **1381–1382**
 Creutzfeldt-Jakob disease (familial/variant) and, 1009, 1381–1382
 Huntington disease-like disorders and, 1002
 Prion protein, 1381, 1382
 Pristiq. *See* Desvenlafaxine
 PRK. *See* Photorefractive keratectomy
 PRNP gene
 in Huntington disease-like disorders, 1002
 in Jakob-Creutzfeldt disease, 1009
 Pro-IGF-2, nonislet cell tumor hypoglycemia and, 1241–1242
 Probenecid
 allopurinol interactions and, 816
 for gout, 815
 Probiotics
 for antibiotic-associated colitis, 636, 638
 for flatus, 573
 for irritable bowel syndrome, 635–636
 ulcerative colitis, 648
 for pouchitis, 649–650
 Problem drinking. *See* Alcohol use/dependency/abuse; At-risk (problem) drinking
 Procainamide, 377, 378*t*
 antidepressant drug interactions and, 1071*t*
 for arrhythmias, 377, 378*t*
 infarct-related, 373
 supraventricular tachycardia, 378*t*, 382
 ventricular tachycardia, 378*t*, 391
 overdose/toxicity of, 378*t*, 1588
 Procalcitonin assay
 in pneumonia diagnosis, 272
 reference values for, 1734*t*
 Procarbazine, 1650*t*
 antidepressant drug interactions and, 1071*t*
 Procardia. *See* Nifedipine
 Prochlorperazine. *See also* Antiemetics
 for migraine headache, 963, 964
 for nausea and vomiting, 84, 568*t*, 1660
 overdose/toxicity of, 1574
 Procollagen, in nephrogenic systemic fibrosis, 937
 Procrit (epoetin alfa). *See* Erythropoietin
 Proctitis, 658
 chlamydial, 659, 1462
 diarrhea and, 575
 herpes simplex, 1351, 1352, 1355
 radiation, 584, 585
 in syphilis, 658
 in ulcerative colitis, 647
 Proctocolectomy
 for familial adenomatous polyposis, 655
 for ulcerative colitis, 649
 Proctoscopy, for rectal cancer follow-up, 1626
 Proctosigmoiditis, in ulcerative colitis, 646, 647
 Proctosigmoidoscopy. *See* Sigmoidoscopy
 Procyclidine, for parkinsonism, 999*t*. *See also* Antiparkinsonism drugs
 Prodromal schizophrenia, 1054
 Profunda femoris artery, atherosclerotic/occlusive disease of, 465
 Progesterone. *See also* Progestins
 in estrogen replacement therapy, 1185
 for preterm labor prevention, 796
 receptors for, in breast cancer, 733–734
 prognosis and, 734, 736, 736*t*, 743
 therapy and, 734, 736, 738
 serum levels of
 in infertility workup, 768
 for pregnancy testing, 781
 ectopic pregnancy and, 781, 790
 topical, 1185
 Progestin minipill, 772*t*, 773
 Progestins
 for abnormal premenopausal bleeding, 748
 in amenorrhea evaluation, 1181
 in cancer chemotherapy, 1657*t*
 for chronic pelvic pain, 1715
 for endometriosis, 761, 1715
 in estrogen replacement therapy, 779–780, 1182, 1183, 1184, 1185
 IUDs releasing, 1185
 long-acting (contraceptive injections/implants), 773
 oral, 1185
 in oral contraceptives, 770, 771–772*t*
 for postmenopausal bleeding, 749
 Prognosis
 assessment of in older adult, 57, 58*t*, 59*t*
 at end of life, **87**
 Prognostic Burn Index, 1550
 Progressive bulbar palsy, 1019, 1020
 Progressive massive pulmonary fibrosis, 309
 Progressive multifocal leukoencephalopathy, 1328, **1382–1383**
 natalizumab and, 640, 1011, 1383
 Progressive nonfluent aphasia, 1008*t*
 Progressive spinal muscular atrophy, 1019, 1020
 Progressive supranuclear palsy, parkinsonism differentiated from, 998
 Proguanil
 with atovaquone (Malarone), 1492*t*, 1494*t*, 1497
 for chemoprophylaxis, 1497, 1498, 1498*t*
 self-treatment and, 1498
 during pregnancy, 787
 Proinsulin
 in factitious hypoglycemia, 1239
 in insulinoma, 1172, 1239
 PROKR2 gene mutation, hypogonadism and, 1173
 Prolactin (PRL)
 in cardiomyopathy of pregnancy, 429, 1103, 1103–1104
 deficiency of, 1093
 gynecomastia and, 1102, 1178
 hypogonadotropic hypogonadism and, 1096, 1102, 1103, 1175
 serum levels of
 in amenorrhea, 1103, 1180, 1181
 elevations in, **1102–1105**, 1103*t*. *See also* Hyperprolactinemia
 infertility and, 768, 769, 955, 1102, 1103, 1104
 in psychogenic nonepileptic/pseudoepileptic seizure identification, 972, 1045
 reference values for, 1734*t*
 tumors secreting, 1093, 1095, 1102, 1103, 1189
 GH cosecretion and, 1093, 1103, 1189
 Prolactinoma, 1093, 1095, 1102, 1103, 1189
 GH cosecretion and, 1093, 1103, 1189
 in MEN, 1102, 1189
 Proleukin. *See* Aldesleukin
 Proliferative bronchiolitis, 269, 270. *See also* Bronchiolitis
 Proliferative retinopathy, 185, 185–186, 1223
 Prolixin. *See* Fluphenazine
 Promethazine, 568*t*. *See also* Antiemetics
 overdose/toxicity of, 1574

- Prometrium. *See* Progesterone
- Pronator teres syndrome, **1026**
- Pronouncement (death), **93**
- PROPI* gene mutation, in
hypopituitarism, 1093, 1094
- Propafenone, 377, 378*t*
for atrial fibrillation, 387
overdose/toxicity of, 378*t*, 1588
- Propanil, methemoglobinemia caused by,
1584
- Propecia. *See* Finasteride
- Prophylactic antibiotics. *See*
Antimicrobial
chemoprophylaxis
- Propine. *See* Dipivefrin
- Propionibacterium acnes*, 125. *See also*
Acne
- Propofol
for drug-induced seizures, 1565
for migraine headache, 964
for status epilepticus, 974
- Propoxyphene
benzodiazepine interactions and, 1043*t*
overdose/toxicity of, 1586–1587
removal of from market, 1586
- Propranolol, 448*t*. *See also* Beta-
adrenergic blocking drugs
for aggressive/violent behavior, 1078
antidepressant drug interactions and,
1071*t*
for arrhythmias, 378*t*
for esophageal varices, prevention of
rebleeding and, 603
for hypertension, 448*t*
for hyperthyroidism/Graves disease,
1114, 1115
for migraine prophylaxis, 964*t*
overdose/toxicity of, 378*t*, 1575
for panic attacks, 1044
- Proprioceptive disorders, in tabes
dorsalis, 1472
- Proptosis (exophthalmos), in dysthyroid
eye/Graves disease, 191,
1110, 1112–1113, 1117–1118
RAI treatment for hyperthyroidism
and, 1115–1116, 1117–1118
- Propylene glycol, lactic acidosis and, 891
- Propylthiouracil, for hyperthyroidism/
Graves disease, 1114–1115,
1115
during pregnancy/lactation, 800, 1115,
1117
RAI therapy and, 1115
thyroid crisis/storm and, 1118
toxic solitary thyroid nodule and, 1116
- ProQuad. *See* MMRV (measles-mumps-
rubella-varicella) vaccine
- Prosom. *See* Estazolam
- Prosopagnosia, intracranial tumors
causing, 991
- Prostacyclin/prostacyclin analogs, for
pulmonary hypertension,
305, 425
- Prostaglandin analogs. *See also specific*
agent
for glaucoma/ocular hypertension,
171*t*, 176
- Prostaglandins
in erectile dysfunction, 952–953
vascular evaluation and, 952
- hyponatremia caused by, 872
NSAIDs affecting, 611
- Prostate cancer, 1611*t*, **1630–1638**, 1632*t*,
1633*f*, 1634*f*, 1635*f*, 1637*t*,
1638*t*
chemoprevention and, 959–960
hormone therapy for, 1635, 1636, 1637*t*
incidence/risk/mortality of, 1594*t*,
1630, 1632, 1632*t*, 1637,
1637*t*
localized, 1632–1633
locally/regionally advanced, 1636
metastatic, 1636–1637
paraneoplastic syndromes and, 1596*t*
pathology/staging of, 1632, 1634*f*,
1635*f*
imaging in, 1631
screening for, 15*t*, 16, 1630–1631,
1631–1632, 1632*t*
testosterone replacement therapy and,
1176, 1177
- Prostate gland
benign hyperplasia of, **956–961**, 957*t*,
958*f*, 958*t*, 959*t*. *See also*
Benign prostatic hyperplasia
biopsy of, 1631, 1633*f*
cancer of. *See* Prostate cancer
electrovaporization of, 961
inflammation/infection of. *See*
Prostatitis
minimally invasive surgery on, 961
photovaporization of (PVP), 961
transurethral incision of (TUIP), 958*t*,
960
transurethral needle ablation of
(TUNA), 961
transurethral resection of (TURP),
958*t*, 960
- Prostate-specific antigen (PSA), 1630–
1631
in benign prostatic hyperplasia, 956–
957
in prostate cancer, 1630, 1631, 1632*t*,
1633*f*
after brachytherapy, 1636
in CAPRA assessment tool, 1637,
1637*t*
screening and, 16, 1630–1631, 1631–
1632, 1632*t*, 1633*f*
reference values for, 1632, 1734*t*
- Prostate-specific antigen (PSA) velocity,
in cancer screening, 1632,
1633*f*
- Prostatectomy, 1634–1635
open, for benign prostatic hyperplasia,
958*t*, 960
radical, for prostate cancer, 1633,
1634–1635, 1637, 1638*t*
transurethral laser-induced (TULIP),
for benign prostatic
hyperplasia, 961
transurethral (TURP), for benign
prostatic hyperplasia, 958*t*,
960
urinary incontinence after, 958*t*, 960,
1634
- Prostatic pain, in acute bacterial
prostatitis, 943
- Prostatitis
acute bacterial, 940*t*, **942**, 942*t*
chronic bacterial, 940*t*, **942–943**, 942*t*
dysuria in, 43, 942, 943
gonococcal, 1452
nonbacterial, 942*t*, **943–944**
Prostatodynia, 942*t*, **944**
- Prostheses
arterial/endovascular. *See* Bypass
grafting
for joint replacement
coagulase-negative staphylococcal
infection and, 1428
DVT/PE (venous thromboembolic
disease) prevention and, 555,
555*t*
osteomyelitis and, 862
perioperative antibiotic prophylaxis
for patients with, 56
penile, 953
- Prosthetic heart valves, **349–350**. *See also*
Valve replacement
anticoagulant therapy and, 343, 349
pregnancy and, 349
coagulase-negative staphylococcal
infection and, 1428
endocarditis and, 338, 1435, 1437, 1439
anticoagulation and, 1439
pregnant patient and, 338, 349, 431,
803
- Protamine, for heparin neutralization,
554
- Protease inhibitors, 1341–1342*t*, 1344–
1345, 1348*f*. *See also*
Antiretroviral therapy/
HAART
antituberculous drug interactions and,
285, 1326
for hepatitis C, 677
lipid abnormalities caused by, 1344
resistance to, 1349
ritonavir boosting and, 1344
- Protein
ascitic fluid, 588
bacterial peritonitis and, 588, 589,
689
pancreatic ascites and, 591, 713
peritoneal carcinomatosis and,
590
cerebrospinal fluid, in CNS infection,
1286*t*
dietary, 1269
deficiency of (protein–energy
malnutrition), **1257–1258**
in diabetic diet, 1204, 1205, 1224
lactation and, 786
nephrotic syndrome/nephrotic
spectrum disorders and, 928
requirements for in nutritional
support, 1272
restriction of. *See* Protein-restricted
diet
urinary stone formation and, 946,
947, 948
- pleural fluid, 314
serum
in nephrotic syndrome, 927
reference values for, 1734*t*
urinary, 898, 898–899. *See also*
Proteinuria
ratio of to urinary creatinine, 899
in glomerulonephritis, 908

- Protein C
activated
 human recombinant
 for bacteremia/sepsis/shock, 488–489, 1444–1445
 removal of from market, 489, 1445
 resistance to, hypercoagulability and, 297
 reference values for, 1734t
- Protein-calorie undernutrition (protein-energy malnutrition), 1257–1258
- Protein/creatinine urinary concentration, 899. *See also* Proteinuria
 in glomerulonephritis, 908
- Protein electrophoresis
 in amyloidosis, 531
 in myeloma, 528
 in protein-losing enteropathy, 632
 reference values for, 1734t
 urinary
 in myeloma, 528
 in overload proteinuria, 899
 in Waldenström macroglobulinemia, 530
- Protein-energy malnutrition, 1257–1258
- Protein kinase gene, in myotonic dystrophy, 1034, 1035t
- Protein-losing enteropathy, 631–632
 GI lymphoma and, 1650
 in measles, 1368
 in Whipple disease, 623
- Protein malnutrition, in nephrotic syndrome/nephrotic spectrum disorders, 928
- Protein-restricted diet, 1269
 in acute tubular necrosis, 906
 for chronic kidney disease, 914–915, 1269
 for diabetes mellitus/diabetic nephropathy, 1205, 1224
 for hepatic encephalopathy, 687, 690, 1269
 for nephrotic syndrome/nephrotic spectrum disorders, 928
 for urinary stones, 947, 948
- Protein S
 deficiency of, purpura fulminans and, 1359
 reference values for, 1734t
- Proteinaceous infectious particles, 1381.
 See also Prion diseases
- Proteinase-3 ANCA (PR3-ANCA). *See also* Antineutrophil cytoplasmic antibody
 in granulomatosis with polyangiitis, 849, 924
- Proteinosis, pulmonary alveolar, 296
- Proteinuria, 898, 898–899
 asymptomatic, 918f
 Bence Jones. *See* Bence Jones proteinuria
 in chronic kidney disease, 908, 910
 in diabetes mellitus/diabetic nephropathy, 931, 1224
 by dipstick, 899
 in glomerulonephritis/nephritic spectrum disorders, 907, 908, 918
 in IgA nephropathy, 923
 in interstitial nephritis, 907
 in membranous nephropathy, 929
 in minimal change disease, 928, 929
 in myeloma, 528, 936
 in nephrotic syndrome/nephrotic spectrum disorders, 898, 918, 918f, 927, 928
 in preeclampsia-eclampsia, 792, 793t, 794
 in sickle cell disease/glomerulopathy, 936
 in SLE, 834, 834t, 926
 in tubulointerstitial disease, 932, 933
- Proteus*
 mirabilis, 1300t
 vulgaris, 1300t
- Prothrombin (factor II)
 acquired antibodies to, 553
 deficiency of, 552
 des-gamma-carboxy, in hepatocellular carcinoma, 1604
- Prothrombin time
 in alcoholic liver disease, 681, 682
 in anticoagulant overdose/toxicity, 1573
 in liver disease/jaundice, 553, 664t
 prolonged
 in cirrhosis, 553, 686, 690, 692t
 in DIC, 545, 554
 in vitamin K deficiency, 553
 reference/normal values for, 664t, 1734t
- Proton pump inhibitors
 adverse effects of, 596, 613
 atazanavir and, 1345
 for Barrett esophagus, 595
 chest pain/discomfort in esophageal disorders and, 606
 clopidogrel interaction/
 coadministration and, 370, 616
 for dyspepsia, 565, 566
 for dysphagia, 606
 for eosinophilic esophagitis, 600
 for esophageal motility disorders, 606
 gastrin levels affected by, 613
 for GERD/esophagitis, 594, 596, 597
 in *H pylori* eradication therapy, 613, 614, 614t, 615
 H pylori test results affected by, 609, 613
 hypomagnesemia and, 887–888
 for laryngopharyngeal reflux, 234
 for NSAID gastritis/ulcers/toxicity mitigation, 76, 608, 615, 615–616, 616, 828–829
 for peptic stricture, 595
 for peptic ulcer disease, 613, 614, 614t, 615, 616
 bleeding management and, 582–583, 618
 prevention and, 615–616
 refractory ulcers and, 617
 for stress gastritis, 321, 608
 for Zollinger-Ellison syndrome/
 gastrinoma, 620, 1172, 1189
- Protopam. *See* Pralidoxime
- Protopic. *See* Tacrolimus, topical
- Protoporphyria
- free erythrocyte, 1730t
 in sideroblastic anemia, 496
- Protozoal infections, 1484–1511. *See also specific type and organism*
 diarrhea in, 574t, 578, 1330
 myocarditis in, 409t
- Protriptyline, 1070t
- Provenge. *See* Sipuleucel-T
- Provera. *See* Progesterone
- Providencia, 1300t
- Provocation testing. *See also specific test*
- Provocative tests, in musculoskeletal evaluation, 1673
- Proximal renal tubular acidosis, 892, 892t, 894. *See also* Renal tubular acidosis
 genetic defects associated with, 878t
 tubulointerstitial disease and, 933
- Prozac. *See* Fluoxetine
- Prozone phenomenon, 1466
- PrP^C/PrP^{Sc}, in prion disease, 1381, 1382
- PRSS1 gene, in chronic pancreatitis, 715
- Pruritus (itching), 95t, 145–150. *See also specific cause*
 ani, 146
 tinea infection causing, 112
 anogenital. *See* Anogenital/perianal pruritus
 arthropod bites causing, 148–150
 in chronic kidney disease/uremia, 145, 909t, 910
 in cutaneous larva migrans, 1523
 in decompression sickness (skin bends), 1557
 in diabetes, 1197, 1197t
 drugs for
 systemic, 99
 topical, 94, 98t
 of ear canal, 201
 in hypercalcemia/hyperparathyroidism, 1139
 in lichen simplex chronicus, 105
 in polycythemia, 511, 512
 in renal failure/uremia, 145, 909t, 910
 vulvae, 146
- PRV. *See* Rotavirus vaccine
- PSA. *See* Prostate-specific antigen
- Pseudallescheria boydii*, in opportunistic infection, 1540–1541
- Pseudoachalasia, 605
- Pseudo-addiction, pain management in terminally ill/dying patient and, 76
- Pseudoallergic (anaphylactoid) reactions, 867
- Pseudoaneurysm
 femoral artery, 476
 GI bleeding and, 581
 myocardial rupture and, 374–375
- Pseudobacteremia, 1284
- Pseudobulbar palsy, 1019
- Pseudoclaudication, of spinal stenosis, 822
- Pseudocysts
 pancreatic, 713, 717
 ascites and, 591
 cystic carcinoma differentiated from, 1608
 infected (pancreatic abscess), 713, 714
 vocal fold, 235

- Pseudodementia (depression and dementia), 59–60, 1006, 1088
- Pseudoephedrine, MAOI interactions and, 1071*t*
- Pseudoepileptic seizures. *See* Psychogenic nonepileptic seizure
- Pseudofolliculitis, 129
- Pseudofractures, in osteomalacia, 1150, 1151
- Pseudogout, 809, 814, **816–817**, 1674
- Pseudogynecomastia, 1178
- Pseudohermaphroditism, 1179
- Pseudohypoadosteronism
type I, 878*t*
type II, 878*t*
- Pseudohyponatremia, 872, 874
- Pseudohypoparathyroidism, **1135–1138**, 1140*f*. *See also* Hypoparathyroidism
- Pseudomembrane, in diphtheria, 1419, 1433, 1434
- Pseudomembranous colitis, 637. *See also* Colitis, antibiotic-associated
- Pseudomonas aeruginosa*, 1300*t*
bronchiectasis caused by, 266
eye medications contaminated by, 195
hot tub folliculitis caused by, 129, 130
keratitis caused by, 172
malignant external otitis caused by, 200
pneumonia caused by, 273*t*, 274, 276
in HIV infection/AIDS, 1326
- Pseudomonic acid. *See* Mupirocin
- Pseudo-obstruction, intestinal
acute (Ogilvie syndrome), **628–629**
chronic, **629–630**
- Pseudopapilledema, 190
- Pseudoporphyria, 122
- Pseudoprecocious puberty, testicular tumors causing, 1177
- Pseudopseudohypoparathyroidism, 1137
- Pseudoseizures. *See* Psychogenic nonepileptic seizure
- Pseudo-septic arthritis, 859. *See also* Septic (nongonococcal acute bacterial) arthritis
- Pseudothrombocytopenia, **548**
- Pseudotumor
cerebri, **995–996**
headache and, 966, 995
lithium use and, 1073
pleural fluid, 315
- PSI (Pneumonia Severity Index), 274
- Psilocybin, 1084
Psilocybe mushroom poisoning and, 1586*t*
- Psittacosis (ornithosis), **1462**
- Psoas sign, in appendicitis, 630
- Psoralen plus ultraviolet A (PUVA) therapy. *See also* Phototherapy
for atopic dermatitis, 104
for lichen planus, 144
for psoriasis, 107
- Psoriasiform eruptions, drugs causing, 107, 160*t*
- Psoriasis, **106–108**, 106*f*
arthritis and, 106, **856–857**
drugs causing, 107, 160*t*
exfoliative dermatitis and (erythrodermic psoriasis), 106, 116
in HIV infection/AIDS, 106, 1331
lithium use and, 1073
nonalcoholic fatty liver disease and, 684
tinea differentiated from, 112
- Psoriatic arthritis, 106, **856–857**
in HIV infection/AIDS, 106, 861, 1328, 1331
- Psoriatic erythroderma, 106
- Psoriatic spondylitis, 856
- PSS1 mutation, pancreatic/periampullary carcinoma and, 1608
- PSTI gene, in chronic pancreatitis, 715, 716
- PSV. *See* Pressure support ventilation
- Psychedelic drug abuse, **1084**
- Psychiatric/psychologic disorders. *See also* specific type
asthma differentiated from, 248
chest pain/discomfort and, 30, 607
cognitive disorders and, 1006, **1087–1089**, 1087*t*. *See also* specific type
in elderly, urinary incontinence and, 67
fatigue/chronic fatigue syndrome and, 38, 40
hospitalization and illness and, **1089–1092**
hyponatremia and, 871*f*, 873
irritable bowel syndrome and, 633, 635, 636
in pheochromocytoma/paraganglioma, 1168*t*
vomiting and, 567*t*
in Wilson disease, 696, 1004
- Psychogenic dyspnea, 24, 25
- Psychogenic nonepileptic seizure (PNES/pseudoepileptic seizure), 971–972, 1045
- Psychogenic polydipsia, 1055, 1099
hyponatremia caused by, 871*f*, 873, 1055
- Psychologic challenges, for terminally ill/dying patient, 91
- Psychologic disorders. *See* Psychiatric/psychologic disorders
- Psychologic drug dependence, 1079
- Psychopathic (antisocial) personality disorder, 1051, 1052*t*, 1053
- Psychosexual disorders, **1049–1051**
sexual dysfunction and, 1050, 1051. *See also* Sexual dysfunction
- Psychosurgery, for OCD, 1044
- Psychotic depression, 1054, 1055, 1058, 1065–1066, 1068
- Psychotic disorders (psychoses), **1053–1062**, 1056*t*, 1057*t*, 1060*t*. *See also* Schizophrenia
alcohol withdrawal and (delirium tremens), 1080
alcoholic (organic) hallucinosis, 1081, 1082
atypical, 1054
brief, 1054
classification of, 1053–1054
delusions and, 1053–1054
depression and, 1054, 1055, 1058, 1065–1066, 1068
differential diagnosis of, 1055
drug-induced/toxic, 1055
drug therapy for, 1055–1061, 1056*t*, 1057*t*, 1060*t*. *See also* Antipsychotic drugs
ECT for, 1058, 1060, 1071
in hypothyroidism (myxedema madness), 1106, 1108
intensive care unit, 1090
Korsakoff, 1013, 1081, 1264
late life (in elderly), 1054
mania differentiated from, 1055
personality disorders and, 1052, 1052–1053
postpartum, 1063
stimulant/cocaine abuse and, 1055, 1085, 1086
suicide risk and, 1054, 1056, 1060, 1064
Psychotic resolution, 1054
Psychotropic agents. *See also* Antianxiety drugs; Antidepressants; Antipsychotic drugs
breastfeeding and, 782*t*
hyponatremia and, 873
for irritable bowel syndrome, 635
thrombocytopenia caused by, 547*t*
- Psyllium fiber, 572*t*, 1269. *See also* Fiber, dietary
- PT. *See* Prothrombin time
- PTC. *See* Percutaneous transhepatic cholangiography
- PTCA (percutaneous transluminal coronary angioplasty). *See* Angioplasty, coronary; Percutaneous coronary intervention
- PTEN multiple hamartoma syndrome (Cowden disease), 655, 1190
thyroid disease and, 1123, 1190
- Pteroylmonoglutamic acid. *See* Folic acid
- Pterygium, **167**, 172*f*
- PTF1A mutation, in diabetes, 1195
- PTH. *See* Parathyroid hormone
- PTHrP. *See* Parathyroid hormone-related protein
- Ptosis
in myasthenia gravis, 1032
in third nerve paralysis, 190
- PTP. *See* Posttransfusion purpura
- PTSD. *See* Posttraumatic stress disorder
- PTT. *See* Partial thromboplastin time
- Puberty
delayed/failure to enter, 1096, 1173, 1175, 1179
adrenal hyperplasia and, 1157
male hypogonadism and, 1094, 1173, 1175
Turner syndrome and, 1186
gynecomastia during, 1178
- Pubic lice, 148. *See also* Lice
- Puerperal mastitis, 721, **797–798**
candidal, 132
- Puestow procedure, modified, for pancreatitis, 717
- Puffer fish poisoning, 1589, 1589*t*
- Puffy tumor, Pott, 216
- Pulmonary alveolar proteinosis, **296**
- Pulmonary angiography, in pulmonary embolism, 300
chest pain evaluation and, 29
helical CT, 299, 300, 301*f*

- Pulmonary arteriopathy, plexogenic (idiopathic/primary pulmonary hypertension), 304, 423, 424, 425
- Pulmonary arteriovenous malformations, in hereditary hemorrhagic telangiectasia, 1671, 1672
- Pulmonary artery catheter, in shock management, 486–487
- Pulmonary aspiration syndromes, **307–308**. *See also* Aspiration
- Pulmonary capillary wedge pressure (PCWP)
in ARDS, 322
in myocardial infarction, 367*t*
in shock, 367*t*, 486, 487
- Pulmonary circulation disorders, **297–307**
alveolar hemorrhage syndromes, **306–307**
pulmonary hypertension, **304–306**, 304*t*, **423–425**, 423*t*, 425*f*
respiratory failure caused by, 320*t*
thromboembolism, **297–303**, 298*t*, 301*f*, 301*t*, 302*t*. *See also* Pulmonary venous thromboembolism
vasculitis, **306**
- Pulmonary cysts, hydatid, 1516
- Pulmonary diffusing capacity. *See* Diffusing capacity
- Pulmonary disorders, **242–323**. *See also specific disorder and under Respiratory*
acute respiratory distress syndrome (ARDS), **322–323**, 322*t*
acute respiratory failure, **319–322**, 320*t*
adverse ophthalmic effects of drugs used in, 195*t*
air travel and, 1560
airway disorders, **242–270**
in anthrax, 1431, 1432
in ascariasis, 1517
in aspergillosis, 266–267, 1537, 1538
in blastomycosis, 1538
chronic. *See specific disorder and* Chronic obstructive pulmonary disease
in chronic kidney disease/uremia, 909*t*, 910
circulatory, **297–307**
in coccidioidomycosis, 1532, 1533
cognitive disorders/delirium caused by, 1087*t*
cryptococcal, 1536
in decompression sickness, 1557
drug-induced, 292*t*, **311**, 312*t*
enterovirus 68 causing, 1408
environmental, 292*t*, **307–312**
eosinophilic, **296–297**
in filariasis, 296, 1525
in granulomatosis with polyangiitis, 306, 848–849
hantaviruses causing, 1388–1389
in histoplasmosis, 1531
in HIV infection/AIDS, 279, 1325–1327. *See also* Pneumonia; Tuberculosis
in hookworm disease, 296, 1518
HSV causing, 1351–1352, 1352
immunization recommendations in, 1309*t*
infections, **270–289**. *See also* Pneumonia; Tuberculosis
adenovirus, 1402
anaerobic, **278–279**
Bordetella bronchiseptica causing, 1441
CMV, 1364
hemoptysis in, 26, 27
herpes simplex, 1351–1352, 1352
interstitial, 292*t*
mycobacterial
nontuberculous, **287–289**, 289*t*, **1458**
tuberculous, **279–287**, 281*t*, 282*f*, 283*t*, 284*t*, 289*t*. *See also* Tuberculosis
viral, **1393–1401**
interstitial (diffuse parenchymal), **292–297**, 292*t*, 294
Kaposi sarcoma, 145, 1326, 1331
in measles, 1368
metastatic, **1601–1602**
in microscopic polyangiitis, 851
neoplastic, **289–292**. *See also* Lung cancer
in nocardiosis, 1457
occupational, 292*t*, **308–311**, 309*t*, 310*t*
in paragonimiasis, 1513
in pheochromocytoma/paraganglioma, 1168*t*
pleural diseases and, **313–317**, 313*t*, 314*t*
postoperative, risk factors for, **50–51**, 50*t*
preoperative evaluation/perioperative management of, **50–51**, 50*t*
radiation causing, **311–312**, 1554
respiratory failure, **319–322**, 320*t*
in scleroderma, 838, 839
SIADH caused by, 873, 873*t*
in SLE, 833
in strongyloidiasis, 1519
in syphilis, 1471
toxic, **311**. *See also* Toxic lung injury
transfusion-related, 536
travel and, 1297
tropical pulmonary eosinophilia, 296, 1525
ventilation control disorders and, **317–319**
- Pulmonary edema, **407–409**
in aortic regurgitation, 345
cardiac tumors causing, 427
drug-induced, 312*t*
fluid resuscitation in burns and, 1551
in heart failure (cardiogenic), 399, **407–409**
perioperative, 49
high-altitude, **1559**
in hypertensive emergency, treatment of, 461*t*
in mitral regurgitation, 339, 340
in near drowning, 1556
noncardiac causes of, 408
respiratory failure caused by, 320*t*
in silo-filler's disease, 311
transfusion-related (transfusion-related acute lung injury), 536
- Pulmonary embolectomy, 303
- Pulmonary embolism. *See* Pulmonary venous thromboembolism
- Pulmonary embolism severity index (PESI), 557, 560*t*
- Pulmonary fibrosis
cor pulmonale caused by, 426
in interstitial (diffuse parenchymal) diseases, 292, 293
drug-induced, 312*t*
in pneumoconioses, 309
progressive massive, 309
radiation causing, **312**, 1554
- Pulmonary function tests. *See also* Spirometry
in asthma/asthma exacerbation, 244*f*, 245*t*, 246–247, 246*t*, 247*t*, 256, 257
in COPD, 260–261, 260*t*
in cor pulmonale, 426
in cystic fibrosis, 267
in lung cancer, 1598–1599
preoperative, 50–51
- Pulmonary heart disease (cor pulmonale), **425–426**
in COPD, 261, 264, 426
in pulmonary hypertension, 305, 425, 426
- Pulmonary hemosiderosis, idiopathic, 307
- Pulmonary hypertension, **304–306**, 304*t*, **423–425**, 423*t*, 425*f*
in atrial septal defect, 328
in cirrhosis, 691
classification of, 423, 423*t*
in COPD, 261, 305
cor pulmonale in, 305, 425, 426
drug and toxin, 424
heart failure and, 400, 424, 425
heritable, 423–424
in high-altitude illness, 424, 1559
in hyperthyroidism, 1112
idiopathic (primary), 304, 423, 424, 425
in mitral stenosis, 337, 338
in patent ductus arteriosus, 332
pulmonary valve regurgitation and, 348, 424
in scleroderma, 424, 838
secondary, 304–306, 304*t*
in ventricular septal defect, 330
- Pulmonary infarction, pleural effusion in, 314*t*
- Pulmonary infiltrates. *See also* Pneumonia
in ARDS, 322
drugs causing, 312*t*
in granulomatosis with polyangiitis, 306
in immunocompromised host/HIV infection/AIDS, **279**, 1325
in nontuberculous mycobacterial infection, 288
travel and, 1297
- Pulmonary nodules
in metastatic disease, 1601
solitary, **290–291**
- Pulmonary osteoarthropathy, hypertrophic. *See* Hypertrophic osteoarthropathy
- Pulmonary radiation fibrosis, **312**, 1554
- Pulmonary regurgitation. *See* Pulmonary valve regurgitation

- Pulmonary rehabilitation, for COPD, 264
- Pulmonary stenosis, **325–326**, 349
in tetralogy of Fallot, 331, 332
- Pulmonary thromboembolism. *See* Pulmonary venous thromboembolism
- Pulmonary thromboendarterectomy, 305–306
- Pulmonary tuberculosis, **279–287**, 281*t*, 282*f*, 283*t*, 284*t*, 289*t*. *See also* Tuberculosis
- Pulmonary valve
replacement of, 326, 348, 349. *See also* Valve replacement
in rheumatic fever/heart disease, 417
- Pulmonary valve regurgitation, **348–349**, 349
in tetralogy of Fallot, 332, 348
- Pulmonary vasculitis, **306**
asthma differentiated from, 248
- Pulmonary veno-occlusive disease, pulmonary hypertension and, 304–305, 423*t*, 424
- Pulmonary venous thromboembolism, **297–303**, 298*t*, 301*f*, 301*t*, 302*t*
air travel and, 1560
assessment/diagnosis of, 297–301, 298*t*, 301*f*, 301*t*, 302*t*
chest pain/discomfort in, 28, 29, 29–30, 298, 298*t*, 355
dyspnea in, 24, 25, 298, 298*t*
in granulomatosis with polyangiitis, 849
immobility and, 297, 301*t*
prevention of, 301, 555–556, 556*t*, 557*t*, 558*t*
pulmonary hypertension and, 304, 305, 424
risk/risk assessment/stratification and, 297, 297–301, 298*t*, 301*f*, 301*t*, 302*t*, 555–556, 556–557, 556*t*, 560*t*
septic, in drug users, 1292
treatment of, 301–303, 556–563
anticoagulation in, 301–303, 556–562, 559*t*, 560*t*, 561*t*, 562*t*
nonpharmacologic therapy in, 563
thrombolytic therapy in, 303, 556, 562–563, 562*t*
venous thrombosis and, 297, 300, 301, 301*t*, 555. *See also* Deep venous thrombosis; Venous thromboembolic disease
- Pulmonary ventilation-perfusion scans. *See* Ventilation-perfusion scans
- Pulmonic regurgitation. *See* Pulmonary valve regurgitation
- Pulmonic stenosis. *See* Pulmonary stenosis
- Pulsatile tinnitus, 208
- Pulse deficit, in atrial fibrillation, 385
- Pulse generators, pacemaker, 395
- Pulse oximetry/CO-oximetry
in carbon monoxide poisoning, 1576
in coma patient evaluation, 1563
in cough evaluation, 22
in dyspnea evaluation, 25
in hepatopulmonary syndrome, 691
in methemoglobinemia, 1584
- Pulse rate. *See* Heart rate
- Pulses
absence/weakness of
in acute arterial limb occlusion, 468
in aortoiliac occlusive disease, 464
in lower leg/foot occlusive disease, 467
in aortic regurgitation, 344–345
in hypertension, 440
- Pulsus paradoxus, 421
asthma exacerbation and, 247*t*
in pericardial effusion/tamponade/pericarditis, 29, 421, 912
- Pulvinar sign, 1382
- Punctal occlusion, for dry eye, 166
- Pupillary dilation, acute angle-closure glaucoma and, 174, **194–195**
- Pupillary reactions
in coma or stupor, 1014, 1015
in third nerve paralysis, 190
- Pure autonomic failure, 975
- Pure red cell aplasia, **499–500**
cancer-related, 1596*t*
- Pure white cell aplasia, 510
- Purgatives, for constipation/preoperative bowel cleansing, 571, 585
- Purified chick embryo cell culture (PCEC) rabies vaccine, 1315, 1377
- Purified insulin, 1213. *See also* Insulin therapy
- Purified protein derivative (PPD) test, 282, 283*t*. *See also* Tuberculin skin test
- Purine analogs, in cancer chemotherapy, 1651*t*
- Purines, dietary, 814, 815*t*
in hyperuricemia/gout, 814, 815*t*
in urinary stone formation, 948, 948–949
- Purinethol. *See* Mercaptopurine
- Purpura
cancer-related, 864
in cryoglobulinemia, 851, 925
fulminans, 545, 1359
Henoch-Schönlein, **852**, 852*f*, 919*t*, **923**
in microscopic polyangiitis, 851
posttransfusion, **546**
thrombotic thrombocytopenic, 542–544, 543*t*. *See also* Thrombocytopenia
diarrhea and, 543, 1447
microangiopathic hemolytic anemias and, 508, 542, 543, 543*t*
- Pursed lip breathing
for COPD, 264
prevention of postoperative pulmonary complications and, 51
- Push enteroscopy, in GI bleeding, 585
- Pustular skin disorders, 95*t*, **125–132**. *See also specific type*
- Puumala viruses, 1388
- PUVA therapy. *See also* Phototherapy
for atopic dermatitis, 104
for lichen planus, 144
for psoriasis, 107
- PVCs (premature ventricular contractions). *See* Ventricular premature beats
- PVS (Partner Violence Screen), 1712
- Pyelonephritis, 940*t*, **941**, 1302*t*, 1303*t*
dysuria and, 43, 941
emphysematous, 941
during pregnancy, 804
urinalysis in, 898, 941
- Pygeum africanum*, for benign prostatic hyperplasia, 960
- Pylephlebitis
noncirrhotic portal hypertension and, 699
perforated appendicitis and, 631
- Pyoderma
miliaria and, 131
in pediculosis, 148
in scabies, 148
- Pyogenic arthritis. *See* Nongonococcal acute bacterial (septic) arthritis
- Pyogenic hepatic abscess, **700–701**
- Pyogenic osteomyelitis, **861–862**
- Pyometra, in endometrial carcinoma, 759
- Pyrantel pamoate
for ascariasis, 1517
for enterobiasis/pinworms, 1520
- Pyrazinamide, for tuberculosis, 284–285, 284*t*, 285, 289*t*
in latent disease/prophylactic, 286, 287
pregnancy and, 285
- Pyrazinamide/isoniazid/rifampin, for tuberculosis, 285
- Pyridium. *See* Phenazopyridine
- Pyridostigmine, for myasthenia gravis, 1033
- Pyridoxine (vitamin B₆)
deficiency of, **1265–1266**
homocystinuria/
hyperhomocysteinemia and, 1668, 1669
for isoniazid overdose/toxicity, 285, 285–286, 286, 805, 1566*t*, 1581
toxicity of, **1266**
- Pyrimethamine
for isosporiasis, 1508
for malaria
with sulfadoxine (Fansidar), 1492*t*, 1493, 1496
with amodiaquine, 1496
with artesunate, 1493*t*, 1496
isosporiasis and, 1508
for prophylaxis in pregnancy/infants, 1498
resistance to, 1493, 1496
for toxoplasmosis, 1337, 1338*t*, 1502
- Pyrimidine analogs, in cancer chemotherapy, 1651–1652*t*
- Pyrogenic erythrotoxin (erythrogenic toxin), 1419, 1421
- Pyrophosphate (technetium-99m) scintigraphy, in myocardial infarction, 366
- Pyrosis (heartburn), 592, 593, 594
- Pyuria, 898
in cystitis, 939
sterile, in tuberculosis, 936
- Q fever, 1409*t*, **1415–1416**
- Q waves
in cardiomyopathy, 414
in cor pulmonale, 426
in infectious myocarditis, 410

- Q waves (*Cont.*):
 in myocardial infarction, 360, 366. *See also* Myocardial infarction; Non-Q wave (non-ST elevation) infarction
 chest pain/discomfort and, 28*t*
- Qinghaosu/qinghaosu derivatives. *See* Artemisinin
- QRS complex. *See also* Electrocardiogram
 in atrial fibrillation, 385
 in nonparoxysmal junctional tachycardia, 390
 in preexcitation syndromes, 383
 in tetralogy of Fallot, 331
 wide
 in atrial premature beats, 381
 differentiation of aberrantly conducted supraventricular beats from ventricular beats and, 381, 391
 in poisoning/drug overdose, 1564, 1564*t*
 with antiarrhythmics, 1564, 1588
 with antidepressants, 1564, 1591, 1591*f*, 1592
 with opiates/opioids, 1586
 with phenothiazines, 1574
 in tetralogy of Fallot, 331
 in ventricular premature beats, 390
- QT interval. *See also* Electrocardiogram
 long, 393
 in hypocalcemia, 882
 in hypomagnesemia, 888
 palpitations and, 31
 in poisoning/drug toxicity, 393, 1564, 1564*t*
 antiarrhythmic agents in, 393, 1588
 antidepressants in, 1067, 1068, 1591
 antipsychotics in, 1057, 1057–1058, 1058, 1059, 1060*t*, 1574
 droperidol in, 569
 opioids in, 1586
 phenothiazines in, 1574
 quinine/quinidine in, 1493, 1495
 ranolazine in, 356
 short, in hypercalcemia, 884, 1646
- Quad screen, in prenatal testing, 783, 784
- Quadramet. *See* Samarium
- Quadrantanopia. *See* Visual field defects
- Quadriceps, assessment of strength of, 1701
- Quadriceps avoidance gait, in ACL injury, 1693
- Quadriplegia. *See also* Paralysis
 spinal trauma causing, 1018
 in stroke, 981
- Quality of life
 assessment of for older adult, 57–58
 decision-making at end of life and, 89
 palliative care for improvement of, 74
- Quazepam, 1042*t*
- Quebec platelet disorder, 548
- Queensland tick typhus, 1409*t*, 1414
- Questran. *See* Cholestyramine
- Quetiapine, 1055, 1056*t*, 1057, 1057*t*, 1060*t*. *See also* Antipsychotic drugs
 for delirium, 64
 overdose/toxicity of, 1057, 1057*t*, 1060*t*, 1574
 “Quickening,” 781
 Quinacrine, for lupus, 115
 Quinagolide, for hyperprolactinemia, 1104
- Quinapril, 450*t*
 with hydrochlorothiazide, 451*t*
- Quincke pulses, 344
- Quinidine, 377, 378*t*
 antidepressant drug interactions and, 1071*t*
 for arrhythmias, 377, 378*t*
 for malaria, 1492*t*, 1493, 1494*t*, 1495
 overdose/toxicity of, 378*t*, 1493, 1588
- Quinine, for malaria, 1492*t*, 1493, 1494*t*, 1495
 adverse ophthalmic effects of, 197*t*
 pregnancy and, 1495
 self-treatment and, 1498
 severe disease and, 1493, 1494*t*, 1495
- Quinsy (peritonsillar abscess), 229–230, 1420
- Quinsy tonsillectomy, 229–230
- Quinupristin/dalfopristin, for *E faecium* infection, 1422
- “Quitlines,” for smoking cessation counseling, 8
- Quixin. *See* Levofloxacin
- R5 co-receptor, in HIV infection/AIDS, 1346
- R-CHOP regimen, 525
- R-CVP regimen, 525
- Rabeprazole, 613. *See also* Proton pump inhibitors
- Rabies, 1376–1378
 bite injuries and, 1289, 1290, 1376
 prevention/immunization and, 1315, 1376–1377, 1377–1378. *See also* Rabies vaccine
- Rabies antiserum, 1377
- Rabies immune globulin, 1377
- Rabies vaccine, 1315, 1376–1377, 1377–1378
 adsorbed, 1315
 antimalarial drugs/chloroquine and, 1315, 1378
 postexposure, 1376–1377, 1377
 preexposure, 1315, 1377–1378
- Rabson-Mendenhall syndrome, 1193*t*
- Raccoon roundworm (*Baylisascaris procyonis*), visceral larva migrans caused by, 1523
- Raccoon sign, 1016
- Racecadotril, for rotavirus gastroenteritis, 1405
- Racemose cysticercosis, 1515
- Racial/ethnic background
 alcoholism and, 1080
 antipsychotic drug dosing and, 1059
 breast cancer risk and, 722, 723*t*, 1708
 cardiomyopathy and, 411
 cholelithiasis/gallstones and, 702
 cirrhosis and, 686
 colorectal cancer incidence and, 1623
 diabetes mellitus and, 1192–1193, 1193–1194, 1194
 esophageal cancer and, 1613
 G6PD deficiency and, 502
- gastric adenocarcinoma and, 1615
 gestational trophoblastic disease and, 791
 goiter and, 1134
 gout and, 812
 hemochromatosis and, 694
 hepatitis C and, 676
 hepatocellular carcinoma and, 1603
 hirsutism and, 1161
 HIV infection/AIDS and, 1321
 hypertension and, 433, 435, 439
 management of, 446, 449
 lactase deficiency and, 626
 melanoma and, 102
 multiple sclerosis and, 1010
 obesity rates and, 13, 1259
 Paget disease of bone and, 1152
 periodic paralysis and, 1036, 1119
 sarcoidosis and, 295
 sickle cell anemia and, 503
 SLE and, 832
 thalassemia and, 495
- Radial nerve lesions, 1027
- Radial optic neurotomy, for retinal vein occlusion, 182
- Radiation burns, 1554
- Radiation exposure/reactions, 1553–1555. *See also* Radiation therapy
 acute, 1554
 cancer risk and, 1555, 1594
 chronic, 1554
 Hashimoto’s thyroiditis risk and, 1120
 lung injury caused by, 311–312
 from medical imaging, 1554, 1555
 cancer risk and, 1555, 1594
 occupational/environmental, 1555
 during pregnancy, 783–784, 1554
 thyroid cancer risk and, 1123, 1126, 1554
 vomiting, 567*t*
- Radiation fibrosis, pulmonary, 312, 1554
- Radiation pericarditis, 419, 420, 1554
- Radiation pneumonitis, 312, 1554
- Radiation proctitis, 584, 585
- Radiation syndrome, acute (radiation sickness), 1554
- Radiation therapy. *See also* Radiation exposure/reactions
 for acromegaly/gigantism, 1102
 for basal cell carcinoma, 142
 for bladder cancer, 1639–1640
 for breast cancer, 735, 736, 739, 744
 arm edema and, 744
 breast implants and, 721
 cancer risks and, 1555, 1594
 with chemotherapy. *See* Chemoradiation therapy
 for cutaneous squamous cell carcinoma, 143
 for esophageal cancer, 1614
 for Graves ophthalmopathy, 1118
 in gynecostasia, 1179
 health risks and, 1554, 1554–1555
 for hepatocellular carcinoma, 1605
 for Hodgkin lymphoma, 526–527
 for intracranial tumors, 991–992
 for laryngeal cancer, 237
 leukemia and, 519
 for lung cancer, 1599, 1600
 lung injury and, 311–312

- for myeloma-related bone disease, 529
pericarditis caused by, 419, 420, 1554
for pituitary adenoma, 1102, 1104, 1160
pneumonitis and, 312, 1554
for prolactinoma, 1104
for prostate cancer, 1633, 1635, 1635–1636
pulmonary fibrosis and, 312, 1554
for rectal cancer, 1626
for spinal tumors/cord compression, 993, 1645
for testicular cancer, 1643
thrombocytopenia and, 540
for thyroid cancer, 1131
thyroid cancer risk and, 1123, 1126, 1554
toxicity of. *See* Radiation exposure/reactions
- Radiculomyelopathy, in HIV infection/AIDS, 1023
- Radiculopathy, cervical, 1686
- Radioactive iodine
breastfeeding and, 782*t*
for goiter, 1135
for hyperthyroidism/Graves disease, 1115–1116
amiodarone-induced, 1117
hypothyroidism after, 1116, 1119
ophthalmopathy flares and, 1115–1116
thiourea treatment and, 1115
toxic multinodular goiter, 1116
toxic solitary thyroid nodule and, 1116
side effects/contraindications to, 1131
pregnancy and, 800, 1114, 1115, 1131
for thyroid cancer treatment/surveillance, 1130–1131, 1132–1133
for thyroid nodules, 1125–1126
for thyroid scanning. *See* Radioiodine thyroid scans and uptake
- Radioactive materials for testing, breastfeeding and, 782*t*
- Radiocontrast media
iodinated, for hyperthyroidism/Graves disease, 1115
subacute (de Quervain) thyroiditis and, 1117, 1122
nephrotoxicity/acute kidney injury and, 904–905
reactions to, 867
- Radioembolization
for islet cell tumors, 1172
transarterial (TARE), for hepatocellular carcinoma, 1605
- Radiofrequency ablation techniques
for arrhythmias. *See* Catheter ablation techniques
for benign prostatic hyperplasia (TUNA), 961
for hepatocellular carcinoma, 1605
for renal cell carcinoma, 1641
for trigeminal neuralgia, 967
for varicose veins, 1720
- Radiofrequency wave ablation
electrocautery (HALO), for Barrett esophagus, 595
- Radioiodine. *See* Radioactive iodine
- Radioiodine thyroid scans and uptake
contraindications to in pregnancy, 1114
in goiter, 1124*t*, 1134
in hyperthyroidism/Graves disease, 1105*t*, 1114
amiodarone-induced disease and, 1112, 1114
in nodule evaluation, 1105*t*, 1123, 1124, 1124*t*
in thyroid cancer, 1124*t*, 1127, 1127*t*, 1128
false positive/false negative, 1129
postoperative/surveillance, 1131, 1132–1133
in thyroiditis, 1121, 1122
- Radionuclide angiography
in angina, 353
in cardiomyopathy, 412
in heart failure, 400
in postinfarct pseudoaneurysm, 375
- Radionuclide scanning. *See specific type*
- Radiosurgery. *See* Cyberknife
radiosurgery; Gamma knife radiation/gamma radiosurgery
- Radiotherapy. *See* Radiation therapy
- Radon, lung cancer associated with exposure to, 1595
- RADT. *See* Rapid antigen/rapid antigen detection testing
- RAEB. *See* Refractory anemia with excess blasts
- Raf-kinase inhibitors, for renal cell carcinoma, 1641
- Rage attacks, seizures differentiated from, 971
- Ragged red fibers, in mitochondrial myopathies, 1036
- Rai classification, for chronic lymphocytic leukemia, 522
- RAI scans, thyroid. *See* Radioiodine thyroid scans and uptake
- Rales. *See* Crackles
- Raloxifene, 1147, 1708
breast cancer prevention and, 723, 1708
for gynecmastia, 1179
hypercalcemia/hyperparathyroidism and, 1144
for osteoporosis, 1147, 1181, 1185
- Raltegravir, 1342*t*, 1346–1347, 1347, 1348*f*. *See also* Antiretroviral therapy/HAART
- Ramelteon, 1042*t*, 1077
- Ramipril, for hypertension, 451*t*
diabetes and, 1227
- Ramsay Hunt syndrome, 213, 1358, 1359
myoclonus in, 1004
- Range of motion testing, in musculoskeletal disorders, 1673
ankle injuries and, 1704, 1704*t*
back pain and, 1683, 1684*t*
hip fractures and, 1690, 1690*t*
knee pain/injury and, 1692, 1694*t*, 1698, 1702
neck pain and, 1686, 1687*t*
shoulder disorders and, 1675, 1676–1677*t*, 1682
wrist disorders and, 1689*t*
- Ranitidine, 613. *See also* H₂ receptor blocking drugs
- RANK/RANKL, in myeloma, 527
- Ranke complex, in tuberculosis, 282
- Ranolazine, for angina, 356
- Ranson criteria, 712, 712*t*
- Rapamycin, for breast cancer, 741
- Rape, 777–778, 1078
γ-hydroxybutyrate (“date rape” drug) use and, 1580
sexually transmitted diseases and, 778, 1291
statutory, 777
- Rape trauma syndrome, 778
- Rapid antigen/rapid antigen detection testing
in filariasis, 1525
in malaria, 1492
in pharyngitis (RADT), 228, 1419
in pneumonia, 271, 272*t*, 1423
- Rapid cyclers, in bipolar disorder, 1064
lithium use and, 1072
- Rapid detoxification, for heroin/opioid withdrawal, 20, 1084
- Rapid eye movement (REM) sleep, 1075
- Rapid eye movement (REM) sleep behavior disorder, 1077
- Rapid HIV antibody tests, 1290, 1323, 1324*t*
- Rapid plasma reagin (RPR) test. *See* RPR test
- Rapid serum tube (RST), orange top, 1736*t*
- Rapid treponemal tests, 1467
- Rapidly acting insulin analogs, 1213, 1214, 1214*f*, 1214*t*, 1215, 1218, 1219*t*. *See also* Insulin therapy
for diabetic ketoacidosis, 1235
in mixtures/combination therapy, 1214*t*, 1216, 1218
in pregnancy, 1230
in pumps, 1215, 1219
- Rapidly progressive acute glomerulonephritis, 918, 918*f*
- ras oncogene, thyroid tumors and, 1126, 1127
- Rasagiline, for parkinsonism, 1000
- Rasburicase, for tumor lysis syndrome/hyperuricemia, 1647, 1658*t*
- Rashes. *See also specific type or cause and* Skin disorders
acute exanthems
rickettsial, 1356–1357*t*
viral, 1356–1357*t*, 1402–1404
antipsychotic drugs causing, 1060
chemotherapy-induced, 1661
in dermatomyositis, 840, 840*f*, 842
drugs causing (dermatitis medicamentosa), 158–161, 159–160*t*
fungal, in HIV infection/AIDS, 1331
heat causing (miliaria), 130–131
in Kawasaki disease, 1417
in Lyme disease, 135–136, 135*f*
in meningococcal meningitis, 1441
in mononucleosis, 1357*t*, 1361, 1362
in pharyngitis, 228, 1419
photodistributed (photodermatitis), 95*t*, 152–153. *See also* Photodermatitis/ photosensitivity

- Rashes (*Cont.*):
 in scarlet fever, 1419
 in SLE, 833
 in Still disease, 831
 in strongyloidiasis, 1519
 in syphilis, 1469, 1470*f*
 travel and, 1297
 in typhoid fever, 1445
- Rat-bite fever, **1476–1477**
- Rat fleas. *See* Fleas
- Rat lungworm (*A cantonensis*), 1522
- Rat poison, anticoagulant toxicity and, 1573
- Rate control
 for atrial fibrillation, 385–386, 387
 in cardiomyopathy, 412
 cardioversion compared with, 387–388
 for atrial flutter, 389
- Rattlesnake envenomation, 1589–1590
- Rauwolfia derivatives, antidepressant drug interactions and, 1071*t*
- Raynaud disease, 836, 837, 838
- Raynaud phenomenon, **836–838**, 837*t*
 scleroderma and, 837, 838, 839
 in SLE, 833, 838
- RB-ILD. *See* Respiratory bronchiolitis-associated interstitial lung disease
- RBC. *See* Erythrocyte count
- Reactivated chronic hepatitis B, 674–675
- Reactive arthritis (Reiter syndrome), **857–858**, 857*f*
 HIV infection/AIDS and, 858, 861, 1328
- Reactive cervical lymphadenopathy, **240**
- Reactive erythemas, **132–136**
- Reactive (postprandial) hypoglycemia, 1238, 1238*t*, **1242–1243**. *See also* Hypoglycemia
- Reactive thrombocytosis, 513
- Rebiana, for diabetics, 1205
- Rebound headache, analgesic overuse and, **966**
- Rebound tenderness, in appendicitis, 630
- Recall. *See* Memory
- Recklinghausen disease, **996**, 996*f*
 pheochromocytoma/paraganglioma in, 1167
- Recombinant follicle-stimulating hormone (FSH), for ovulation induction, 769
- Recombinant growth factors. *See* Growth factors
- Recombinant human deoxyribonuclease (rhDNase)
 for cystic fibrosis, 268
 pleural instillation of, 316
- Recombinant human growth hormone (rhGH), 1097
- Recombinant human thyroid-stimulating hormone (rhTSH), RAI therapy/surveillance for thyroid cancer and, 1131, 1132–1133
 hyperthyroidism and, 1112
- Recombinant immunoblot assay (RIBA), in hepatitis C, 671
- Recombinant tissue plasminogen activator. *See* Alteplase
- Recombivax-HB. *See* Hepatitis B vaccine
- Recompression. *See also* Hyperbaric oxygen therapy
 for dysbarism/decompression sickness, 1558
 for high-altitude illness, 1559
- Reconstructive surgery
 genital, for transsexuals, 1050, 1051
 after mastectomy, 721, 736, 744–745
 local recurrence and, 721, 745
 vascular. *See* Bypass grafting
- Recrudescence epidemic typhus (Brill-Zinsser disease), 1408
- Recruitment, in cochlear dysfunction, 208
- Rectal bleeding, 583, 584. *See also* Gastrointestinal bleeding
 hemorrhoids causing, 584, 657, 658
 in ulcerative colitis, 646
- Rectal carcinoids, 1621
- Rectal examination
 in acute bacterial prostatitis, 942
 in benign prostatic hyperplasia, 956
 in constipation, 571
 in prostate cancer screening/diagnosis, 16, 1630, 1631, 1632*t*, 1633*f*
- Rectal prolapse, 657
- Rectal (Blumer) shelf, 1616
- Rectal temperature. *See* Core temperature
- Rectal ulcer, GI bleeding caused by, 584
- Rectocele, 762
- Rectovaginal fistulas, in Crohn disease, 641, 642
- Rectum. *See also under* Rectal cancer of, 1612*t*, 1623, 1625–1626. *See also* Colorectal cancer
 adjuvant therapy for, 1625–1626
 neoadjuvant therapy for, 1624, 1626
 surgical excision and, 1624–1625, 1626
 disorders of, **632–657**. *See also* Anorectal disorders
 gonococcal infection, 658, 1452
 ulcerative colitis involving, 646, 647
- Recurrent (habitual) abortion, **789–790**
- Recurrent laryngeal nerve
 damage to during thyroid surgery, 237, 238, 1116, 1119, 1129
 vocal fold paralysis caused by damage/lesions of, 237–238
- Recurrent paroxysmal atrial fibrillation, 388
- Recurrent respiratory papillomatosis, **234–235**
- Red blood cells. *See under* Red cell and Erythrocytes
- Red bugs, skin lesions caused by, 149
- Red cell aplasia, pure, **499–500**
 cancer-related, 1596*t*
- Red cell casts, 898, 899*t*
 in glomerulonephritis/nephritic spectrum disorders, 898, 907–908
 in interstitial nephritis, 907
- Red cell count
 in pleural fluid, 314, 314*t*
 reference values for, 1729*t*, 1734*t*
- Red cell mass, in polycythemia, 512
- Red cell transfusions, **534**. *See also specific type and* Transfusion
 for DIC, 546*t*
- Red man syndrome, 867
- Red top tubes, 1736*t*
- Reduced-intensity allogeneic stem cell transplantation, 533
- 5 α -Reductase deficiency, 1162
- 5 α -Reductase inhibitors. *See also* Finasteride
 for benign prostatic hyperplasia, 959–960
- Reduction pneumoplasty, for COPD, 265
- Reduviid bugs, in Chagas disease, 1486
- Reed-Sternberg cells, 526
- Reentry
 atrial flutter and, 383
 in supraventricular tachycardia, 381, 383–384
 in ventricular premature beats, 390
 in ventricular tachycardia, 391
- Refeeding
 fatal hypophosphatemia and, 885
 for protein-energy malnutrition, 1258
- Refeeding edema, 1258
- Reference ranges, for diagnostic/laboratory tests, 1727–1735*t*. *See also specific test*
- Reflex sympathetic dystrophy (complex regional pain syndrome), **824–825**
- Reflux
 gastroesophageal. *See* Gastroesophageal reflux disease
 hepatojugular, 400, 699
 laryngopharyngeal, **234**
 vesicoureteral, tubulointerstitial disease caused by, 932
- Reflux esophagitis. *See* Esophagitis
- Reflux nephropathy, 932
- Reflux (venous)
 in chronic venous insufficiency, 480, 481
 in varicose veins, 478, 479
- Refractive errors, **162–163**
- Refractive surgery, **162–163**
- Refractory anemia, 517
- Refractory anemia with excess blasts (RAEB), 517
- Refractory atrial fibrillation, 388
- Refractory ulcers, 617
 gastric cancer and, 617, 1617
 Zollinger-Ellison syndrome (gastrinoma) and, 617
- Refsum disease, 1022
- Regional hyperthermia, for benign prostatic hyperplasia, 961
- Regional poison control centers, 1562, 1570
- Regranex. *See* Becaplermin; Platelet-derived growth factor
- Regular insulin, 1213, 1213*t*, 1214, 1214*f*, 1214*t*, 1215, 1218, 1221. *See also* Insulin therapy
 for diabetic ketoacidosis, 1215, 1233–1234
 in mixtures/combination therapy, 1214*t*, 1216, 1221
- Regurgitation, 566
 in achalasia, 605
 in GERD, 594
 in Zenker diverticulum, 601
- Rehydration. *See* Fluid management/hydration
- Reinke edema, 235
- Reiter syndrome. *See* Reactive arthritis

- Relafen. *See* Nabumetone
- Relapsing fever, 1300*t*, 1475–1476
- Relapsing polychondritis, 199, 852–853
- Relapsing-remitting multiple sclerosis, 1010
- Relaxation techniques
for anxiety disorders, 1044
for insomnia, 1076
for irritable bowel syndrome, 636
for psychiatric problems associated with hospitalization/illness, 1091
for tension headache, 965
- REM sleep, 1075
- REM sleep behavior disorder, 1077
- Remediation therapy, for schizophrenia/psychotic disorders, 1062
- Remeron. *See* Mirtazapine
- Remicade. *See* Infliximab
- Remitting seronegative synovitis with non-pitting edema, 864
- Renal angiography/arteriography, in renal artery stenosis/renal vascular hypertension, 437, 917
- Renal artery stenosis, 437, 917–918
hypertension caused by, 437, 917
renal insufficiency/acute kidney injury and, 903
- Renal biopsy, 901
in analgesic nephropathy, 933
in focal segmental glomerulosclerosis, 930
in granulomatosis with polyangiitis, 849
in HIV-associated nephropathy, 931
in IgA nephropathy, 923
in membranoproliferative glomerulonephritis, 925
in membranous nephropathy, 929
in minimal change disease, 928, 929
in nephritic spectrum disorders, 922
in nephrotic syndrome/nephrotic spectrum disorders, 927
in SLE, 926
- Renal calculi, 950. *See also* Nephrolithiasis; Urinary stone disease
- Renal cell carcinoma, 1611*t*, 1640–1642
cystic, 934
incidence/risk/mortality of, 1594*t*, 1640–1641
paraneoplastic syndromes associated with, 1596*t*, 1641
- Renal colic/pain, urinary stones causing, 947
- Renal cysts, 909*t*, 933–936, 934*t*
acquired, 934*t*
in autosomal dominant polycystic kidney disease, 934–935, 934*t*
complex, 934
infected, 935
in medullary cystic kidney, 934*t*
in medullary sponge kidney, 934*t*, 935–936
simple/solitary, 934, 934*t*
- Renal disorders. *See* Kidney disease/injury
- Renal failure. *See also* Acute kidney injury; Chronic kidney disease; Kidney disease/urinary; Uremia
acute, 898, 901–908, 902*t*. *See also* Acute kidney injury
chronic, 898, 908–918, 909*t*, 910*f*, 910*t*, 911*f*, 912*f*. *See also* Chronic kidney disease
dialysis for. *See* Dialysis
exenatide use and, 1211
immunization recommendations in, 1309*t*
intrinsic, 902*t*
lower extremity edema and, 33, 34
in myeloma, 527, 528
myoglobinuria/rhabdomyolysis and, 844, 905
neuropathy associated with, 909*t*, 914, 1022–1023
postoperative, 55, 55*t*
transplantation for. *See* Kidney transplantation
- Renal failure type (β_2 -microglobulin) amyloidosis, 531
- Renal (nondiabetic) glucosuria, 1198
- Renal hypercalciuria, 947*t*, 948
- Renal imaging
in chronic kidney disease, 910, 911
in dysuria evaluation, 43–44
- Renal osteodystrophy, 912–913, 912*f*, 1139, 1141, 1144
- Renal pain. *See* Renal colic
- Renal pelvis
cancer of, 1640
incidence/risk/mortality of, 1594*t*, 1640
obstruction of, postrenal acute kidney injury and, 903
- Renal salt wasting
in hyponatremia, 871*f*, 872
in renal tubular acidosis, 892
in subarachnoid hemorrhage, 985
- Renal transplantation. *See* Kidney transplantation
- Renal tubular cell casts, 899*t*
- Renal tubular necrosis, acute, 902*t*, 904–906
in pancreatitis, 713
rhabdomyolysis and, 844, 905
urinalysis in, 898, 902*t*, 905
- Renal vascular hypertension, 437. *See also* Hypertension
- Renin activity (plasma). *See* Plasma renin activity
- Renin-angiotensin-aldosterone system. *See also* Aldosterone
in hypertension, 436, 437, 438, 449, 1164
inhibitors of. *See* Angiotensin II receptor blocking agents; Angiotensin-converting enzyme (ACE) inhibitors; Renin inhibitors
- Renin inhibitors, 450*t*. *See also* Angiotensin II receptor blocking agents; Angiotensin-converting enzyme (ACE) inhibitors
for heart failure, 401–402
for hypertension, 449, 450*t*
in chronic kidney disease/renal failure, 458–459
in combination regimen, 450*t*
in diabetes, 458
- Renova. *See* Tretinoin
- Reoviruses, Colorado tick fever caused by, 1392
- Repaglinide, 1206*t*, 1208
hypoglycemia caused by, 1221–1222
with metformin, 1213
- Repeat-dose charcoal, 1568
- Reperfusion therapy. *See also* Revascularization procedures
for myocardial infarction, 364*t*, 367–370
assessment of, 370
percutaneous coronary intervention (PCI), 364*t*, 367–368
thrombolytic therapy, 364*t*, 368–370, 369*t*
- Rescriptor. *See* Delavirdine
- Rescue angioplasty, for myocardial infarction, 371
- Rescula. *See* Unoprostone
- Reserpine, 456*t*
depression caused by, 456*t*, 457, 1064
for Huntington disease, 1002
for hypertension, 453–457, 456*t*
MAOI interactions and, 1071*t*
- Reset osmostat, hyponatremia caused by, 873, 874
- Residential facilities
for cognitive disorders/dementia, 1089
for personality disorders, 1052
for schizophrenia/psychotic disorders, 1061
- Residual schizophrenia, 1053
- Residual volume (RV), in COPD, 261
- Resin T₃/T₄ uptake
in euthyroid sick syndrome, 1107
in hyperthyroidism, 1113
pregnancy and, 1113
- Resistance, microbial. *See* Drug resistance
- Resistant hypertension, 438, 459–460, 460*t*
- Resistin, insulin action in obesity and, 1194
- Resolution, psychotic, 1054
- Resolution stage of sexual activity, 1049
- Resorptive hypercalciuria, 947*t*, 948
- Resource allocation, principles of care and, 2
- Respiration. *See* Breathing; Ventilation
- Respiratory acidosis (hypercapnia), 889, 889*t*, 895–896
in asthma, 246, 247*t*
in COPD, 261, 896
in cystic fibrosis, 267
dyspnea and, 25
metabolic alkalosis and, 895, 896
permissive, 321
for asthma, 259
respiratory failure and, 320, 896

- Reynolds pentad, 706
 Reynolds Risk Score, 351
 Rezulin. *See* Troglitazone
 RF. *See* Rheumatoid factor
 RFX6 mutation, in diabetes, 1195
 Rh₀ (D) immune globulin, 785–786
 after delivery, 785–786
 after ectopic pregnancy, 785–786, 791
 after elective abortion, 776, 785–786
 prenatal administration of, 786
 prenatal screening for antibody to, 783, 784, 786
 after spontaneous abortion, 785–786, 788
 Rh incompatibility, **785–786**. *See also* Rh₀ (D) immune globulin
 hemolytic disease of newborn caused by, 785–786
 testing for, 534, 783, 784, 786
 Rh typing
 during pregnancy, 783, 784, 786
 for transfusions, 534
 Rhabdomyolysis, **844, 905**
 acute tubular necrosis and, 844, 905
 in electric burns/crush injuries, 844, 1553
 in hypophosphatemia, 885
 statin drugs causing, 842, 844, 1254
 Rhabdomyoma, cardiac, 427
 rhDNase
 for cystic fibrosis, 268
 pleural instillation of, 316
 Rhegmatogenous retinal detachment, 179, 180
 Rhesus alloimmunization (Rh incompatibility), **785–786**. *See also* Rh₀ (D) immune globulin
 hemolytic disease of newborn caused by, 785–786
 testing for, 534, 783, 784, 786
 Rheumatic carditis/rheumatic valvulitis, 417, 418–419
 endocarditis and, 1435
 Rheumatic diseases. *See also specific disease and* Musculoskeletal disorders
 adverse ophthalmic effects of drugs used in, 197t
 cancer and, **864–865**
 HIV infection/AIDS and, **861, 1328**
 Raynaud phenomenon and, 836, 837t
 Rheumatic fever, **417–419**
 arthritis in, 418
 rheumatoid arthritis differentiated from, 828
 prevention and, 418, 1420
 streptococcal pharyngitis and, 229, 417, 418, 1419, 1420
 Rheumatic heart disease, 417–419
 valvular involvement and, 333, 337, 417, 418–419
 Rheumatism, palindromic, **865**
 Rheumatoid arthritis, **826–831, 826f, 827f**
 autoantibodies in, 827, 833t
 differential diagnosis of, 827–828
 ankylosing spondylitis and, 855
 gouty/tophaceous arthritis and, 814, 828
 granulomatosis with polyangiitis and, 850
 osteoarthritis and, 811, 828
 neuropathies associated with, 827, 1024
 septic arthritis and, 827, 859
 Rheumatoid factor, 827, 833t
 in cryoglobulinemia, 851
 in polymyositis/dermatomyositis, 833t, 841
 in rheumatoid arthritis, 827, 833t
 in Sjögren syndrome, 833t, 843
 Rheumatoid nodules, 827, 827f
 in coal workers (Caplan syndrome), 309
 gouty tophi differentiated from, 814, 828
 Rheumatoid pleural effusion, 314t
 rhGH. *See* Recombinant human growth hormone
 Rhinitis
 allergic (hay fever), **218–219**
 conjunctivitis and, 167
 nasal polyps and, 218, 222
 medicamentosa, 214
 nasopharyngeal/paranasal sinus cancer and, 223
 perennial, 218
 vasomotor, 218, 219
 Rhinocerebral mucormycosis, 217
 Rhinosinusitis
 acute bacterial, **214–217, 216t, 1303t**. *See also* Sinusitis
 facial pain associated with, 216, 968
 Haemophilus causing, 1442
 headache and, 215, 962
 in HIV infection/AIDS, 1327
 hospital-associated, 215, 216
 nasopharyngeal/paranasal sinus cancer and, 223
 orbital cellulitis and, 191, 216
 acute viral (common cold), **213–214, 1401**
 bacterial rhinosinusitis and, 213, 214
 cough in, 21
 Rhipicephalus sanguineus ticks. *See* Ticks
 Rhizopus infection, 217, 1538
 Rhizotomy, for trigeminal neuralgia, 967
 Rhodococcus equi, pneumonia in HIV infection/AIDS caused by, 1326
 rhTSH. *See* Recombinant human thyroid-stimulating hormone
 Rhus (poison ivy/oak) contact dermatitis, 124, 124f, 866. *See also* Allergic contact dermatitis
 Riamet (artemether-lumefantrine/Coartem), 1492t, 1493t, 1494t, 1496, 1497
 RIBA. *See* Recombinant immunoblot assay
 Ribavirin, 1354t
 in hantavirus infection, 1389
 for hemorrhagic fevers, 1385
 for hepatitis C, 671, 676–678
 in HIV infection/AIDS, 1329
 for influenza, 1354t, 1396
 for RSV infection, 1354t, 1394
 teratogenicity of, 1394
 Riboflavin (vitamin B₂), deficiency of, **1264–1265**
 Ribonuclear protein (RNP) antibody, 842
 Rice, *Bacillus cereus* contamination of, 1293, 1294t
 Rice water stool, in cholera, 1448
 Richter syndrome, 522
 Ricketts, 1148, 1149, 1149–1150, 1151
 hypophosphatemic (vitamin D-resistant), 878t, 1150, 1151
 vitamin D-dependent, 1149
Rickettsia (rickettsial diseases), 1301t, **1408–1416**
 africae, 1409t, 1414
 akari, 1409t, 1413
 australis, 1409t, 1414
 conorii, 1409t, 1414
 felis, 1409t, 1414
 japonica, 1414
 massiliae, 1414
 myocarditis in, 409t
 parkeri, 1414
 prowazekii, 1408, 1409t
 rickettsii, 1409t, 1412
 sibirica, 1409t, 1414
 typhi, 1409t, 1410
 Rickettsial fever (tick typhus), 1409t, **1414**
 Rickettsialpox, 1409t, **1413**
 Rickettsiosis
 California flea, 1409t
 spotted fever, 1414
 Riedel thyroiditis/struma, 1120, 1121, 1122
 Rifabutin
 antiretroviral agent interactions and, 285, 1326
 for MAC prophylaxis/treatment, 1337, 1338t, 1458, 1459
 Rifamate. *See* Isoniazid/rifampin
 Rifampin, 284t, 289t
 for anthrax, 1433t
 antiretroviral agent interactions and, 285, 1326, 1344
 benzodiazepine interactions and, 1043t
 for endocarditis, 1439
 for leprosy, 1460
 for staphylococcal carriage, 123, 130
 for tuberculosis, 284–285, 284t, 285, 289t
 in latent disease/prophylactic, 286, 287
 in pregnancy, 285, 805
 resistance and, 280, 281t, 285
 Rifampin/isoniazid, for tuberculosis, 285
 Rifampin/isoniazid/pyrazinamide, for tuberculosis, 285
 Rifater. *See* Isoniazid/rifampin/pyrazinamide
 Rifaximin
 for bacterial overgrowth, 625
 for Crohn disease, 644
 for flatus, 573
 for hepatic encephalopathy, 690
 for irritable bowel syndrome, 635
 for rosacea, 129
 for traveler's diarrhea, 577, 1298
 RIFLE criteria, in acute kidney injury, 901
 Rift Valley fever, 1385
 Right middle lobe syndrome, **291**
 Right-to-left shunts. *See* Shunts

- Right ventricular (right heart) failure, 398, 398–399. *See also* Congestive heart (cardiac) failure
liver in, 400, 699
- Right ventricular hypertrophy
in atrial septal defect/patent foramen ovale, 328
in pulmonary stenosis, 325
in tetralogy of Fallot, 331
- Right ventricular infarction, 366, 374
- Rigidity
in Huntington disease, 1001
lithium use and, 1073
in neuroleptic malignant syndrome, 1060, 1565, 1574
in parkinsonism, 998
- Rilpivirine, 1342*t*, 1345, 1346. *See also* Antiretroviral therapy/HAART
with tenofovir and emtricitabine, 1346, 1347
- Riluzole, for amyotrophic lateral sclerosis, 1020
- Rimantadine, influenza/influenza resistance and, 23, 1354*t*, 1396, 1398
- Rimexolone, for ophthalmic disorders, 170*t*
- Ring shadow sign, 933
- Ring X chromosome, in Turner syndrome, 1186
- Ringer lactate. *See* Fluid management/hydration
- Ringworm. *See* Tinea
- Rinne test, 199
- RIPA. *See* Ristocetin-induced platelet aggregation
- Risedronate, 1146. *See also* Bisphosphonates
for osteoporosis prevention/management, 1146
for Paget disease of bone, 1153
- Risperdal. *See* Risperidone
- Risperidone, 1055, 1056–1057, 1056*t*, 1057*t*, 1058, 1060*t*. *See also* Antipsychotic drugs
for aggressive/violent behavior, 1078
for bipolar disease/mania, 1072
for delirium, 86
postoperative, 53
for dementia-associated behavior problems, 62
for depression, 1069
long-acting form of, 1057, 1059
overdose/toxicity of, 1056, 1057, 1057*t*, 1060*t*, 1574
ophthalmic effects and, 179, 196*t*
for personality disorder, 1052
for psychedelic abuse/overdose, 1084
- Ristocetin co-factor assay, in von Willebrand disease, 551, 552*t*
- Ristocetin-induced platelet aggregation, in von Willebrand disease, 551, 552*t*
- Ritonavir, 1341*t*, 1344, 1348*f*. *See also* Antiretroviral therapy/HAART
with atazanavir, 1345, 1347
with darunavir, 1342*t*, 1345, 1347
with fosamprenavir, 1345
with lopinavir (lopinavir/r), 1341*t*, 1344, 1345, 1347
for protease inhibitor boosting, 1344
with tipranavir, 1342*t*, 1345, 1347
- Rituxan. *See* Rituximab
- Rituximab, 1654*t*
for autoimmune hemolytic anemia, 506
for chronic lymphocytic leukemia, 522
for cold agglutinin disease, 507
for granulomatosis with polyangiitis, 850
for hairy cell leukemia, 524
for immune thrombocytopenia, 541, 541*f*
for non-Hodgkin lymphoma, 525
for pemphigus, 139
for posttransplant lymphoproliferative disorder, 1363
progressive multifocal leukoencephalopathy caused by, 1383
for pure red cell aplasia, 500
for rheumatoid arthritis, 830
for SLE, 834
for Waldenström macroglobulinemia, 530
- Rivaroxaban, 555, 557*t*, 558
for atrial fibrillation, 387
- Rivastigmine
for dementia, 61, 1008
for parkinsonism, 1000
- River blindness (onchocerciasis), 1526–1527
- Rizatriptan, for migraine headache, 964
- RMSF. *See* Rocky Mountain spotted fever RNA
hepatitis C virus, 671, 671*f*, 676, 677
hepatitis D virus, 672, 675
HIV, reference values for, 1731*t*
- RNA amplification tests, in tuberculosis, 281, 281*t*
- RNA-dependent DNA-polymerase. *See* Reverse transcriptase
- RNP. *See* Ribonuclear protein (RNP) antibody
- Ro/SSA antibody, 833*t*
in lupus/SLE, 114, 833*t*
in Sjögren syndrome, 833*t*, 843
- Rocaltrol. *See* Calcitriol
- Rocephin. *See* Ceftriaxone
- Rocky Mountain spotted fever, 1357*t*, 1409*t*, 1412–1413, 1412*f*
- Rodent excreta/rodents
endemic flea-borne typhus transmission and, 1410
hantavirus transmission and, 1388
hemorrhagic fever transmission and, 1384
lymphocytic choriomeningitis transmission and, 1380
rat-bite fever transmission and, 1476
relapsing fever transmission and, 1475, 1476
tick-borne encephalitis transmission and, 1390
- Rodent fleas. *See* Fleas
- Rodent mites. *See* Mites
- Rodent tapeworm (*H. diminuta*), 1514
- Rodent ticks. *See* Ticks
- Rodenticide poisoning, anticoagulant toxicity and, 1573
- Rogaine. *See* Minoxidil
- Romaña sign, 1486
- Romano-Ward syndrome, 393
- Romberg testing, 209
- Romidepsin, 1656*t*
- Romiplostim
for myelodysplastic syndromes, 518, 540
for thrombocytopenia chemotherapy-induced, 540, 1659
immune, 541–542
- Ropinirole, for parkinsonism, 1000
- Rosacea, 128–129, 129*f*
acne, 126
steroid, 100, 128
- Rose spots, in enteric (typhoid) fever, 1445
- Rosemont criteria, for chronic pancreatitis, 716
- Roseola infantum (exanthema subitum), 1350, 1356*t*, 1366
- Rosiglitazone, 1206*t*, 1209–1210
with glimepiride, 1213
with metformin, 1213
overdose/toxicity of, 1209, 1210, 1580
- Ross procedure, 325, 343, 346, 349
for aortic regurgitation, 346
for aortic stenosis, 343
postoperative pulmonary stenosis and, 325
- Rosuvastatin, 1253–1254, 1255*t*. *See also* Statin drugs
- RotaTaq. *See* Rotavirus vaccine
- Rotation
external, assessment of
in ankle, 1704, 1704*t*
in shoulder, 1676*t*
adhesive capsulitis (frozen shoulder) and, 1682
rotator cuff strength and, 1677*t*, 1680
internal, assessment of
in hip, 1690
in shoulder, 1677*t*
rotator cuff strength and, 1678*t*
- Rotator cuff tears, 1675–1681, 1677–1678*t*
impingement syndrome and, 1675
strength testing and, 1675–1680, 1677–1678*t*
- Rotatrix. *See* Rotavirus vaccine
- Rotavirus vaccine, 1405
- Rotaviruses, diarrhea/gastroenteritis caused by, 574*t*, 1293, 1295*t*, 1404–1405
- Roth spots, in endocarditis, 1435
- Rotor syndrome, 663*t*
- Rotterdam score, in hepatic vein obstruction (Budd-Chiari syndrome), 699
- Rouleaux formation
in myeloma, 528
in Waldenström macroglobulinemia, 530
- Roundworm infections. *See also specific type*
filariasis, 1524–1528

- intestinal, 578, **1517–1520**
invasive, **1520–1524**
visceral larva migrans caused by, 1523
Roux-en-Y gastric bypass, for obesity, 14, 1261
hypoglycemia after, 1242
in type 2 diabetes, 1220
Roux-en-Y hepaticojejunostomy, for gallbladder cancer, 1607
Rowasa. *See* Mesalamine
Roxanol. *See* Morphine
Roxicodone. *See* Oxycodone
Rozerem. *See* Ramelteon
RP. *See* Raynaud phenomenon
RPR test, 659, 1466, 1466t
in antiphospholipid antibody syndrome, 836
in HIV infection/AIDS, 1334, 1335
pityriasis rosea differential diagnosis and, 109
RRP. *See* Recurrent respiratory papillomatosis
RS3PE (remitting seronegative synovitis with non-pitting edema), 864
RST (rapid serum tube), orange top, 1736t
RSV. *See* Respiratory syncytial virus
RSVIG. *See* Respiratory syncytial virus immune globulin
rt-PA. *See* Tissue plasminogen activator
RT₃U. *See* Resin T₃/T₄ uptake
RTA. *See* Renal tubular acidosis
rtPA (recombinant tissue plasminogen activator). *See* Alteplase
RU 486. *See* Mifepristone
Rubber band ligation. *See* Banding
Rubella, 1357t, **1374–1375**
arthritis associated with, 861, 1374, 1375
during pregnancy/congenital, 1374, 1375
prevention/immunization and, 1374, 1375. *See also* MMR (measles-mumps-rubella) vaccine
arthritis and, 861, 1375
pregnancy and, 1309t, 1375
Rubella virus vaccine, 1374, 1375. *See also* MMR (measles-mumps-rubella) vaccine
Rubeola. *See* Measles
Rubeotic (neovascular) glaucoma, retinal vein occlusion and, 182
Rufen. *See* Ibuprofen
Rufinamide, 972
Rugger jersey spine, 1141
Rule of nines, 1549–1550, 1549f
for topical corticosteroid calculation, 94
Rumination, 566
Runner's knee (patellofemoral pain), 1692, 1697t, **1700–1701**
Russell viper venom time/Russell viper venom clotting time
for lupus anticoagulant detection, 554, 834, 836
reference values for, 1734t
Ruxolitinib, for primary myelofibrosis, 515
RV (residual volume), in COPD, 261
RVA (rabies vaccine adsorbed), 1315
RVD regimen, for myeloma, 529
RVV/RVVT. *See* Russell viper venom time/Russell viper venom clotting time
RYGB. *See* Roux-en-Y gastric bypass
S-OIV (Swine-Origin Influenza Virus). *See* "A(H1N1)pdm09" (swine-origin) influenza
S stage sleep, 1075
SAAG. *See* Serum-ascites albumin gradient
Sabia virus, 1384
Sabin-Feldman dye test, in toxoplasmosis, 1501
Sabin vaccine (oral/OPV poliovaccine), 1373
IPV booster and, 1315
VDPV and, 1372, 1374
Saccharin, for diabetics, 1205
Saccharomyces boulardii probiotic, for antibiotic-associated colitis relapse, 638
Saccharomyces cerevisiae antibodies, in Crohn disease, 642
Saccular (berry) aneurysm, 984, 986. *See also* Intracranial aneurysm
Sacral spine/disk disease. *See also* Spine back pain and, 820, 820t
Sacral zoster, 119
Sacroiliac joint/sacroiliitis
in ankylosing spondylitis, 855
in psoriatic arthritis, 856
reactive arthritis and, 857
SAD. *See* Seasonal affective disorder
Saddle nose deformity
in granulomatosis with polyangiitis, 849
in nasal trauma, 221
Sadism, sexual, 1050
Safer sex
in hepatitis prevention, 669, 671
in herpes simplex infection prevention, 1355
in HIV infection/AIDS prevention, 4, 1321, 1333, 1335
in syphilis prevention, 1467
Sag sign, 1696t, 1699
Sagittal sinus thrombosis, in pseudotumor cerebri, 995
Salagen. *See* Pilocarpine
Salicylates. *See also* Aspirin
overdose/toxicity of, 1569t, **1588–1589**
alkali therapy for, 893, 1589
anion gap/osmolar gap in, 891, 1588
hemodialysis for, 1568t, 1589
ophthalmic effects and, 197t
platelet function affected by, 549t
reference values for, 1734t
for rheumatic fever/heart disease, 418
Salicylic acid preparations, for wart removal, 140
Saline, 897, 897t. *See also* Fluid management/hydration
contrast media nephrotoxicity mediated by, 904
for core rewarming, 1544
for cystic fibrosis, 268
for diabetic ketoacidosis, 891, 1233
dilutional acidosis and, 893
for eye decontamination, 194, 1566
for heat exposure syndromes, 1548
for hypercalcemia, 884, 1646–1647
for hyperglycemic hyperosmolar state, 1236
for hypernatremia, 876
for hyponatremia, 874–875
hypotension in poisoning/drug overdose and, 1563
for liver failure, 673
for metabolic alkalosis, 895
Saline breast prosthesis. *See* Breast implants
Saline infusion sonohysterography, 748t
in abnormal postmenopausal bleeding, 749
in abnormal premenopausal bleeding, 747, 748
Saline purgatives. *See* Purgatives
Saline-responsive metabolic alkalosis, 894, 894–895, 894t, 895
Saline-unresponsive metabolic alkalosis, 894, 894t, 895
Salivary glands, **232–233**
infiltrative disorders of, **232**
inflammatory disorders of
acute, **232**
chronic, **232**
in mumps, 1370, 1370f, 1371
tumors of, **232–233**
Salivary stones (sialolithiasis), **232**
Salk vaccine (inactivated/IPV poliovaccine), 1373
pregnancy and, 786
for travelers, 1315
Salmeterol
for asthma, 250–252, 251t
for COPD, 263
with fluticasone, 251t, 263
Salmon calcitonin. *See* Calcitonin
Salmonella enterica subsp *enterica* (salmonellosis), 1300t, **1445–1446**
bacteremia caused by, 1296, 1300t, 1445, **1446**
choleraesuis, 1445
diarrhea/enterocolitis/gastroenteritis caused by, 574t, 575, 1293, 1295t, 1296, 1298, 1303t, 1330, 1446
drug resistance and, 1446
typhi, 1445
typhimurium, 1445
Salpingectomy, for ectopic pregnancy, 791
Salpingitis, **762–764**. *See also* Pelvic inflammatory disease
appendicitis differentiated from, 631
chlamydial, 1462
gonococcal, 1452
tuberculous, 763
Salpingo-oophorectomy. *See* Oophorectomy
Salpingostomy, for ectopic pregnancy, 791
Salt restriction. *See* Sodium-restricted diet
Salt-sensitive hypertension, 436
Salt tablets, heat exposure syndromes and, 1547, 1548

- Salt wasting. *See* Renal salt wasting
- Salvia divinorum*, toxicity of, 1583
- Samarium, for bone pain, 1658t
- Sambuca, hypertension and hypokalemia caused by, 1165–1166
- Samter triad, 222
- Sand flies. *See* Flies
- Sandostatin. *See* Octreotide
- Sanjad-Sakati syndrome, 1136
- SaO₂ (oxygen saturation)
- in ARDS, 323
 - in asthma, exacerbation severity/management and, 247t, 256, 258f
 - in carbon monoxide poisoning, 307, 1576
 - in cor pulmonale, 426
 - in dyspnea evaluation, 25
 - home oxygen therapy and, 262t
 - in near drowning, 1556
 - Pneumocystis pneumonia* treatment and, 1535
 - in respiratory failure, 320
 - in sleep apnea, 318, 319
- SAPE (sentinel acute pancreatitis event), 715
- Saphenous vein
- superficial thrombophlebitis of, 480
 - varicose, 478, 479, 1720
- Saphris. *See* Asenapine
- SAPIEN prosthetic valve, 343
- Sappinia*, 1505, 1506
- Saquinavir, 1342t, 1344, 1347, 1348f. *See also* Antiretroviral therapy/HAART
- with ritonavir, 1344
- Sarafem. *See* Fluoxetine
- Sarcocystis bovis/hominis/sui/hominis* (sarcocystosis), 1506–1508
- Sarcoidosis, 223, 295–296, 295f
- arthritis in, 864
 - erythema nodosum and, 150
 - hypercalcemia/hypercalciuria in, 296, 883, 1141
 - neuropathy associated with, 1024
 - nose and paranasal sinus involvement and, 223, 295f
 - optic neuritis in, 188
 - pulmonary involvement and, 295–296
- Sarcoma. *See also specific type*
- soft tissue, 1612t
- Sarcoptes scabiei* infection (scabies), 147–148, 147f
- Sargramostim (GM-CSF)
- for chemotherapy-induced toxicity, 1659t
 - for HIV infection/AIDS, 1340
 - for neutropenia, 510
- Sarin (GB) poisoning, 1587
- Sarna. *See* Camphor/menthol preparations
- SARS. *See* Severe acute respiratory syndrome
- Satavaptan, for hyponatremia/SIADH, 875
- Saturday night palsy, 1026, 1027
- Saturnine gout, in lead poisoning, 814
- Saw palmetto, for benign prostatic hyperplasia, 960
- Saxagliptin, 1207t, 1212, 1221
- with metformin, 1213
- Saxitoxin, paralytic shellfish poisoning caused by, 1589t
- Sb. *See* Stibogluconate
- Scabies, 147–148, 147f
- tinea differentiated from, 113
- Scaling skin disorders, 95t, 103–117. *See also specific type*
- Scalp
- allergic contact dermatitis involving, 124
 - injuries of, 1016–1017
 - in pediculosis, 148
 - pemphigus involving, 138
 - psoriasis of, 107
 - seborrhea of, 109
- Scalpicin. *See* Hydrocortisone
- Scapula winging/“dyskinesia,” in impingement syndrome, 1675
- Scarlet fever, 1357t, 1419, 1421
- Scarring, prevention of in burn injury, 1552
- Scarring (cicatricial) alopecias, 156
- SCC. *See* Squamous cell carcinoma
- SCDs (sequential compression devices). *See* Pneumatic compression devices
- Scedosporium apiospermum/prolificans*, in opportunistic infections, 1540–1541, 1542
- Schatzki rings, 592t, 600–601
- Schiller test, in CIN, 755
- Schilling test, short bowel syndrome/ileal resection and, 625
- Schirmer test, 166
- in Sjögren syndrome diagnosis, 843
- Schistocytes
- in DIC, 545
 - in microangiopathic hemolytic anemia, 508
- Schistosoma haematobium/intercalatum/japonicum/mansoni/mekongi* (schistosomiasis), 1511–1512
- bladder cancer and, 1511, 1638
 - pulmonary hypertension in, 424, 1511
- Schizoaffective disorders, 1054
- Schizoid personality disorder, 1051, 1052t
- Schizophrenia/schizophrenic disorders, 1053–1062, 1056t, 1057t, 1060t. *See also* Psychotic disorders
- classification of, 1053–1054
 - depression and, 1054, 1055, 1058, 1065–1066, 1068
 - differential diagnosis of, 1055
 - drug-induced/toxic, 1055
 - drug therapy for, 1055–1061, 1056t, 1057t, 1060t. *See also* Antipsychotic drugs
 - mania differentiated from, 1055
 - positive and negative symptoms in, 1053
 - antipsychotic drugs affecting, 1057, 1058
 - prodromal, 1054
 - suicide risk and, 1054, 1056, 1060
- Schizophreniform disorders, 1054
- Schizotypal personality disorder, 1051, 1052t
- Schmidt syndrome, 1155
- Schneiderian papillomas, 222
- Schober test of lumbar motion, 820
- Schwannoma
- gastrointestinal, 1619
 - vestibular (acoustic neuroma/nerinoma/eighth nerve tumor), 210t, 212–213, 990t, 991
 - hearing loss and, 210t, 212
 - in neurofibromatosis, 212, 996
- Sciatic nerve palsy, 1027
- Sciatica, 819, 820, 821, 1685, 1686. *See also* Back pain
- Scintigraphy. *See specific type*
- sCJD. *See* Sporadic Creutzfeldt-Jakob disease
- SCL-70 (scleroderma) antibody, 833t, 839
- SCLC. *See* Small cell carcinoma of lung
- SACLE. *See* Subacute cutaneous lupus erythematosus
- Sclera
- blue, in osteogenesis imperfecta, 1145
 - lacerations of, 193
- Sclerectomy, for glaucoma, 177
- Scleritis, in granulomatosis with polyangiitis, 849, 849f
- Scleroderma (systemic sclerosis), 838–840
- autoantibodies in, 833t, 839
 - dysphagia in, 592t, 838, 839
 - limited. *See* CREST syndrome
 - linear, 839
 - pulmonary hypertension in, 424, 838
 - Raynaud phenomenon and, 837, 838, 839
- Scleroderma (anti-SCL-70) antibody, 833t, 839
- Scleroderma renal crisis, 838, 839
- Scleromyxedema, 839
- Sclerosis. *See* Sclerotherapy
- Sclerotherapy
- for esophageal varices, 602, 603
 - in noncirrhotic portal hypertension, 700
 - for hemorrhoids, 658
 - for malignant effusions, 1646
 - for varicose veins, 479, 1720
- SCN1A gene, in familial hemiplegic migraine, 963
- SCN4A gene, in periodic paralysis, 1036
- Scoliosis
- back pain and, 820
 - in Marfan syndrome, 1670
 - in syringomyelia, 1018
- Scombroid poisoning, 1589, 1589t
- Scopolamine
- for nausea and vomiting, 86, 569
 - overdose/toxicity of, 1575
 - in terminally ill/dying patient, 91
- Scorpion stings, 1590
- Scotch tape test, in enterobiasis/pinworms, 1520
- Scotomas. *See also* Visual field defects/loss in migraine headache, 963
- in optic neuritis, 188
- Scratch-itch cycle. *See also* Pruritus in lichen simplex chronicus, 105
- Screamer’s nodules, 235
- Screening tests. *See specific type and disorder and* Diagnostic/laboratory tests; Genetic testing; Prenatal testing

- Scrofula, 1458
- Scrotal mass. *See* Testes, masses/tumors of
- Scrotal pain. *See also* Testicular pain in epididymitis, 944
- Scrotal pruritus, 146
- Scrotal swelling, in filariasis, 1525
- Scrub typhus, 1409*t*, 1411–1412
- Scuba/deep sea diving
- dysbarism/decompression sickness and, 202, 1557–1558
 - eustachian tube dysfunction/otic barotrauma and, 202, 202–203
- Scurvy, 1266
- SDH (succinate dehydrogenase) gene mutations, in
- pheochromocytoma/paraganglioma, 1167, 1168, 1171
- SDHB mutation, in pheochromocytoma/paraganglioma, 1168, 1171
- SDHD mutation, in pheochromocytoma/paraganglioma, 1168
- “SEADS” mnemonic, in musculoskeletal injury evaluation, 1673
- Seafood poisonings, 1589, 1589*t*. *See also* Fish; Shellfish
- Seasonal affective disorder, 1063, 1066, 1071
- Seasonal influenza, 1394–1397. *See also* Influenza
- Seborrheic dermatitis, 109–110, 109*f*
- atopic dermatitis differentiated from, 103
 - in HIV infection/AIDS, 109, 1331
 - pityriasis rosea differentiated from, 109
 - tinea differentiated from, 112
- Seborrheic keratoses, 101–102, 101*f*
- Sebum, in acne, 125
- Seclusion rooms, for aggressive/violent patient, 1079
- Second-degree burn, 1550
- Second-degree heart block, 394
- in myocardial infarction, 373
- Second-hand smoke. *See* Passive smoking
- Second heart sound (S₂). *See* Heart sounds
- Secretin stimulation test
- in pancreatitis, 716
 - in Zollinger-Ellison syndrome/gastrinoma, 620
- Secretory diarrhea, 574*t*, 578, 579*f*. *See also* Diarrhea
- Sectral. *See* Acebutolol
- Sedation
- antidepressants causing, 1067, 1068, 1070*t*
 - opioids causing, 79
- Sedative-hypnotics, 1042*t*
- for alcohol withdrawal, 1082
 - antidepressant drug interactions and, 1071*t*
 - for anxiety/stress disorders, 1039, 1042*t*
 - in COPD management, 264
 - for delirium, 86
 - for insomnia, 1042*t*, 1076
 - for nausea and vomiting, 569, 569*t*
 - overdose/toxicity of, 1579–1580
 - sleep affected by, 1076
- Sedentary lifestyle. *See* Lifestyle, sedentary
- Segmental myoclonus, 1004
- Segond fracture, 1698
- Seizures, 968–975, 970*t*, 973*t*. *See also* specific type and Epilepsy; Status epilepticus
- absence (petit mal), 970, 970*t*, 973*t*
 - alcohol withdrawal, 969, 974, 1080, 1083
 - antidepressant use and, 1068–1069, 1565*t*, 1591
 - antipsychotic drug use and, 1060
 - atonic, 970
 - brain abscess and, 969, 994
 - cerebral arteriovenous malformations causing, 987, 987–988
 - classification of, 969–970, 970*t*
 - clonic, 970
 - cognitive disorders/delirium and, 969, 1087*t*
 - in cysticercosis, 1515
 - degenerative disorders and, 969
 - differential diagnosis of, 971–972
 - drug therapy for, 972, 973*t*. *See also* Anticonvulsant therapy
 - flumazenil causing, 1563, 1580
 - focal, 969, 970*t*, 973*t*
 - generalized, 969–970, 970*t*, 973*t*
 - in hypocalcemia, 882
 - hysterical, 971–972
 - infection/infectious diseases and, 969
 - intracranial tumors causing, 969, 989, 991
 - isoniazid causing, 1565*t*, 1581
 - in malaria, 1490, 1491
 - myoclonic, 970, 970*t*, 973*t*, 1004
 - panic disorder differentiated from, 971
 - in poisoning/drug overdose, 1565, 1565*t*
 - posttraumatic, 969
 - during pregnancy, 803
 - eclampsia and, 794, 795
 - psychogenic nonepileptic (pseudoepileptic), 971–972, 1045
 - schizophrenia differentiated from, 1055
 - serial, 970
 - solitary, 974
 - in Sturge-Weber syndrome, 997
 - surgical management of, 974
 - in tetanus, 1429
 - theophylline use and, 1565*t*, 1591
 - tonic, 970
 - tonic-clonic (grand mal), 970, 970*t*
 - transient ischemic attacks differentiated from, 971, 978
 - in tuberous sclerosis, 996
 - vagal nerve stimulation for, 974
 - vascular disorders and, 969
- Selective estrogen receptor modulators (SERMs), 1656*t*. *See also* Tamoxifen
- in breast cancer prevention/treatment, 723, 1708
 - in cancer chemotherapy, 1656*t*
 - for gynecomasia, 1179
 - for osteoporosis, 1147, 1185
- Selective immunoglobulin A deficiency, 868
- anaphylactic transfusion reactions and, 535
- Selective serotonin reuptake inhibitors. *See* Serotonin-selective reuptake inhibitors
- Selegiline
- overdose/toxicity of, 1070*t*, 1585
 - for parkinsonism, 1000
 - transdermal, 1069, 1070*t*
- Selenium
- for Hashimoto thyroiditis, 1122
 - for tinea versicolor, 114
- Self-care
- assessment of ability to manage, 58, 59, 1006
 - asthma management and, 248, 249*f*, 256, 258*f*
 - clinician, providing end-of-life care and, 89
 - diabetes management and, 1218
- Self-examination, breast, in cancer screening, 15*t*, 724, 1708
- Self-help groups. *See* Support groups
- Self-hypnosis, for factitious disorders, 1046
- Self-monitoring of blood glucose, in diabetes mellitus, 1200
- in pregnant patient, 801
- Self-mutilation, 1065
- Self-neglect, in elderly, 72–73
- Self-treatment, malaria prophylaxis and, 1498
- Selzentry. *See* Maraviroc
- Semantic dementia, 1008*t*
- Semen analysis
- in infertility workup, 768, 954, 954*f*, 955
 - in Klinefelter syndrome, 1174
- Semicircular canal dehiscence, vertigo and, 212
- Seminal emission, loss of (anejaculation), 951, 1050. *See also* Erectile dysfunction/impotence
- Seminiferous tubule dysgenesis. *See* Klinefelter syndrome
- Seminomas, 1177, 1642, 1643, 1644
- SEN-V virus, 670
- Sengstaken-Blakemore tube, for esophageal varices, 603
- Senile (atrial natriuretic peptide) amyloid, 531
- Senile cataract, 179
- Senile freckles. *See* Lentiginos
- Senna, 571, 572*t*
- Sennetsu fever, 1414
- SENSA tests. *See* Fecal occult blood testing
- Sensorimotor peripheral neuropathy. *See* Neuropathies
- Sensorineural hearing loss, 198, 199. *See also* Hearing loss
- in HIV infection/AIDS, 213
 - in Ménière syndrome (endolymphatic hydrops), 210, 210*t*
- Sensory conduction velocity studies. *See* Conduction velocity studies
- Sensory disturbances/loss, 976. *See also* Neuropathies
- dementia evaluation and, 60, 61
 - in diabetic neuropathy, 1022, 1224
 - dissociated, 976
 - in focal seizures, 969, 976, 991

- Sensory disturbances/loss (*Cont.*):
 in intracerebral hemorrhage, 983
 in intracranial tumors, 991
 in leprosy, 1023, 1460
 in restless legs syndrome, 1004
 in spinal cord infarction, 989
 in spinal lesions/tumors, 976
 in spinal trauma, 1018
 in stroke, 981
 in syringomyelia, 1018
- Sensory hearing loss, 198, **206–208**.
See also Hearing loss
 autoimmune, 208, 210*t*
 in cochlear otosclerosis, 205
 hereditary, 207–208
 sudden, 207
 tinnitus and, 208
- Sensory neuropathy, cancer-related,
 995, 1024, 1596*t*
- Sentinel acute pancreatitis event (SAPE),
 715
- Sentinel loop, in pancreatitis, 712
- Sentinel lymph node biopsy
 in breast cancer, 735, 735*f*
 arm edema avoidance and, 744
 neoadjuvant therapy and, 738–739
 in melanoma, 102–103
- Sentinel pile, 660
- Seoul viruses, 1388
- Sepsis/septic shock, 485, 486, 487, 488,
 488–489, 489. *See also*
 Bacteremia; Infection/
 infectious diseases
- ARDS and, 322, 323
 burn injury and, 1551
 catheter-related, 1282, 1283, 1284
 corticosteroids for, 488, 1444
 DIC and, 545, 1444
E coli causing, 1299*t*
 goal directed therapy of, 487
 gram-negative, **1443–1445**
 in listeriosis, 1434
 in liver failure, 673
 postabortion, 777
 anaerobic, 1456
 in pyelonephritis, 941
 in strongyloidiasis, 1519
 thrombocytopenia and, **547**, 1444
 vibrios causing, 1300*t*, 1448–1449
- Septal ablation, for cardiomyopathy,
 415
- Septal hematoma, in nasal trauma, 221
- Septal hypertrophy, in cardiomyopathy,
 414, 416
- Septata species. *See* *Encephalitozoon*
- Septic (nongonococcal acute bacterial)
 arthritis, **858–859**, 1302*t*
 in drug users, 859, 1292
 rheumatoid arthritis and, 827, 859
- Septic bursitis, 825
- Septic thrombophlebitis, 480, 1302*t*
 anaerobic infections and, 1454, 1455
 catheter-associated infection and, 480,
 1302*t*
 in drug user, 1292
 perforated appendicitis and, 631
 portal vein, noncirrhotic portal
 hypertension and, 699
 sigmoid sinus, otitis media and, 205
- Septic transfusion reaction, 535
- Septo-optic dysplasia (de Morsier
 syndrome), 1093
- Septoplasty, nasal, for sleep apnea, 319
- Septra. *See* Trimethoprim-
 sulfamethoxazole
- Sequential compression devices. *See*
 Pneumatic compression
 devices
- Sequential organ failure assessment
 (SOFA) score
 in liver failure, 673
 in pancreatitis, 712
- Sequoiosis, 310*t*
- Serax. *See* Oxazepam
- Serial seizures, 970. *See also* Seizures
- Serine protease 1 (*PRSSI*) gene, in
 chronic pancreatitis, 715
- Serine protease inhibitor (*SPINK1*) gene,
 in chronic pancreatitis, 715
- Serine threonine kinase gene, in Peutz-
 Jeghers syndrome, 655
- SERMs. *See* Selective estrogen receptor
 modulators
- Seronegative spondyloarthropathies,
854–858. *See also* *specific type*
 back pain in, 820
 rheumatoid arthritis differentiated
 from, 828
- Seronegative synovitis, remitting, with
 non-pitting edema, 864
- Seroquel. *See* Quetiapine
- Serotonin, carcinoids secreting, 1172,
 1621
- Serotonin receptor agonists, for irritable
 bowel syndrome, 635
- Serotonin 5-HT₃ receptors, in nausea and
 vomiting, 566, 1660
- Serotonin 5-HT₃-receptor-blocking
 agents. *See also* Serotonin-
 selective reuptake inhibitors
 for irritable bowel syndrome, 635
 for migraine headache, 963–964
 for nausea and vomiting, 568–569,
 568*t*
- Serotonin-selective norepinephrine
 reuptake inhibitors (SSNRIs),
 for neuropathic pain, 84*t*, 85
- Serotonin-selective reuptake inhibitors
 (SSRIs), 1067–1068, 1070*t*
 for aggressive/violent patient,
 1078–1079
 for anxiety/stress disorders, 1043
 for dementia, 1009
 for depression, 1067–1068
 hyponatremia caused by, 872
 for irritable bowel syndrome, 635
 MAOI interaction and, 1067
 for menopausal vasomotor symptoms,
 780
 for OCD, 1044, 1067
 overdose/toxicity of, 1067–1068, 1070*t*,
 1565, 1585
 suicidal, 1065
 for panic attacks, 1044, 1067
 for personality disorders, 1053
 for phobic disorder, 1044
 platelet function affected by, 549*t*, 1067
 during pregnancy, 1067–1068
 for psychosexual disorders, 1051
 for PTSD, 1040
- serotonin syndrome caused by, 1067,
 1565, 1585, 1592
 sexual side effects of, 1051, 1067
 withdrawal from, 1067
- Serotonin syndrome, 35, 36, 1067, 1565,
 1585, 1592
- Serous otitis media, **202**
 in HIV infection/AIDS, 213
 nasopharyngeal carcinoma and, 202, 223
- Serous retinal detachment, 180
- Serpalan. *See* Reserpine
- Serpasil. *See* Reserpine
- Serrated adenomas, 652, 653, 1622
- Serrated polyps, 652, 653, **653–654**
- Serratia*, 1300*t*
- Sertaconazole, 97*t*
- Sertoli cell tumors, 1177, 1642
 gynecomastia and, 1178
- Sertraline, 1065, 1067, 1070*t*. *See also*
 Serotonin-selective reuptake
 inhibitors
 breastfeeding and, 782*t*
 in elderly, 63
 overdose/toxicity of, 1070*t*, 1591–1592
 for panic attacks, 1044
 during pregnancy, 1067–1068
- Serum-ascites albumin gradient (SAAG),
 587*t*, 588
 in cirrhosis, 588, 688
 in mesothelioma, 591
 in pancreatic ascites, 591
 in peritoneal carcinomatosis, 590
 in portal hypertension, 587*t*, 588
- Serum eye drops, for dry eye, 166
- Serum glucose, in diabetes, 1198
- Serum osmolality. *See* Osmolality
- Serum protein electrophoresis
 in amyloidosis, 531
 in myeloma, 528
 in protein-losing enteropathy, 632
 reference values for, 1734*t*
 in Waldenström macroglobulinemia,
 530
- Serum separator tubes (SST), gold top,
 1736*t*
- Serum sickness, 866, **867**. *See also*
 Immune complex-mediated
 hypersensitivity
 in hepatitis B, 668
 urticarial vasculitis in, 133
- Serzone. *See* Nefazodone
- Sessile serrated adenoma, 652, 653
- Sestamibi (technetium-99m)
 scintigraphy, in angina, 353
- Sevelamer, for hyperphosphatemia, 886
 in metabolic bone disorders/renal
 osteodystrophy, 913
- Severe acute respiratory syndrome
 (SARS), **1400–1401**
- Severe fever with thrombocytopenia
 syndrome, 1385
- Sex change surgery, for transsexuals,
 1050, 1051
- Sex chromosomes. *See* X chromosome; Y
 chromosome
- Sex steroid replacement therapy. *See also*
 Estrogen (hormone)
 replacement therapy;
 Testosterone replacement
 therapy

- for hypogonadism, 1096–1097, 1176–1177
- Sexual abuse
incest, 1050
pedophilia, 1049–1050
victims of, 1078
- Sexual arousal disorders, 1049–1050, 1050–1051. *See also* Sexual dysfunction
- in female, 766, 767, 1714
- Sexual assault. *See* Rape
- Sexual behavior
hepatitis/hepatitis vaccination and, 667, 669, 670, 671
herpes simplex infections and, 1350
HIV infection/AIDS and, 4, 1319–1321, 1333
postexposure prophylaxis and, 4, 1336
prevention and, 4
STDs and, 1291
syphilis and, 1464, 1467
- Sexual desire disorders, 1050
in female, 766, 767, 1714
- Sexual dysfunction
in chronic kidney disease/uremia, 909t, 910, 914
drugs causing, 952, 1051, 1067
antidepressants, 1051, 1067, 1069
antipsychotics, antipsychotics causing, 1059
lithium, 1073
endocrine causes of, 952
in female, **766–767, 1714**
in male, **951–953**. *See also* Erectile dysfunction/impotence
hypogonadism and, 952, 1094, 1175
psychosexual, 1050, 1051
- Sexual identity, disorders of, 1050, 1050–1051
- Sexual intercourse
cystitis associated with, 43
headache associated with, 966
HIV infection/AIDS transmission and, 4, 1319–1321, 1333
postexposure prophylaxis and, 4, 1336
painful. *See* Dyspareunia
unlawful (statutory rape), 777
unprotected, emergency/postcoital contraception and, **776**
IUD for, 774, 776
- Sexual masochism, 1050
- Sexual pain disorders, in female, 767
- Sexual sadism, 1050
- Sexuality/sexual health, in women, **1714**
- Sexually transmitted diseases, **1290–1292**. *See also specific disease*
condoms in prevention of, 4, 1291, 1711. *See also* Condoms
drug use and, 1292
epididymitis, 940t, 944, 945
HIV testing in patients with, 1290, 1291, 1711
IUD use and, 774
during pregnancy, **806**
prevention of, 4, 1290–1291
in women, **1711**
rape/sexual assault and, 778, 1291
reactive arthritis and, 857
syphilis testing and, 1291, 1467
- Sézary cells, in cutaneous T cell lymphoma (mycosis fungoides), 115
- Sézary syndrome, exfoliative dermatitis/erythroderma and, 116
- SFA. *See* Superficial femoral artery
- SGLT2* gene, in nondiabetic (renal) glycosuria, 1198
- SGOT. *See* Aspartate aminotransferase
- SGPT. *See* Alanine aminotransferase
- Shagreen patches, in tuberous sclerosis, 996
- Shared epitope, in rheumatoid arthritis, 826
- Shaver disease, 309t
- Shaving
preoperative, surgical site infection and, 56
pseudofolliculitis and, 129
- Shawl sign, 840
- Sheathotomy, arteriovenous, for retinal vein occlusion, 182
- Sheep cell agglutination tests, in mononucleosis, 1362
- Sheep liver fluke infection, **1512–1513**
- Shellfish
in angiostrongyliasis, 1522
in gnathostomiasis, 1522
in paragonimiasis, 1513
poisoning by, 1589, 1589t
in vibrio infection, 1448
- Shift work sleep disorder, 1077
- Shiga-toxin–producing *E coli*, 575, 576, 1293, 1294t, 1447. *See also* *Escherichia coli* O157:H7
- Shigella dysenteriae/flexneri/sonnei* (shigellosis/bacillary dysentery), 574t, 575, 1293, 1295t, 1296, 1297, 1298, 1300t, 1303t, 1330, **1447**
- Shin spots, diabetic, 1228
- Shingles. *See* Herpes zoster
- Shiny corner sign, 855
- Shock, **485–489, 485t**
anaphylactic. *See* Anaphylaxis/
anaphylactic shock
cardiogenic, 367t, 368, 374, 485, 485t, 486, 487, 487–488, 489
dengue, 1386, 1387
distributive, 485, 485t, 488
in heat stroke, 1548
hypovolemic, 485, 485t, 486, 487
in infectious myocarditis, 410
in myocardial infarction, 367t, 368, 374
neurogenic, 485–486, 486
obstructive, 485, 485t, 486
in pancreatitis, 711, 713, 714
pheochromocytoma/
pheochromocytoma removal and, 1169, 1170
rewarming, 1544
septic. *See* Sepsis/septic shock
vasodilatory (distributive), 485, 485t, 488
- Shock liver, 699
- Shock wave lithotripsy. *See also* Lithotripsy
for renal stones, 950
for salivary stones, 232
for ureteral stones, 950
- Short-acting insulin, 1214, 1214f, 1214t, 1215. *See also* Insulin therapy
in diabetic ketoacidosis, 1215
- Short bowel syndrome, **625–626**
lactic acidosis and, 891
- Short stature
in GH deficiency, 1094
in Turner syndrome, 1186, 1187, 1187t
- Shortness of breath. *See* Dyspnea
- Shoulder, **1674–1683, 1676–1680t**
dislocated/unstable, 1679–1680t, **1681–1682**
examination of, 1676–1680t
frozen (adhesive capsulitis), **1682–1683**
in diabetes, 1228
rotator cuff tears and, **1675–1681, 1677–1678t**
subacromial impingement syndrome and, **1674–1675, 1678–1679t**
- Shoulder apprehension test, 1679t, 1681
- Shoulder-hand syndrome, 825
- Shoulder pain
in adhesive capsulitis (frozen shoulder), 1682
in brachial plexus neuropathy, 1029
dislocation/instability and, 1681
in impingement syndrome/rotator cuff disorders, 1675
in polymyalgia rheumatica, 845
- Shoulder stability/instability, 1679–1680t, **1681–1682**
- SHOX* gene, in Turner syndrome, 1187
- Shunt procedures
for hydrocephalus in intracranial tumors, 991
portosystemic. *See* Portosystemic shunts
for pseudotumor cerebri, 995–996
for tetralogy of Fallot, 331
- Shunts
in atrial septal defect/patent foramen ovale, 327–328, 328, 329
in patent ductus arteriosus, 332, 333
in ventricular septal defect, 329, 330
- Shy-Drager syndrome (multisystem atrophy)
dysautonomia and, 975
parkinsonism and, 998
- SIADH. *See* Syndrome of inappropriate ADH secretion
- Sialadenitis, **232**
- Sialoendoscopy, for sialolithiasis, 232
- Sialolithiasis, **232**
- Siberian Asian tick typhus, 1409t, 1414
- Sibutramine, for obesity, 1260
in type 2 diabetes, 1220
- Sick role (invalidism)
chronic pain disorders and, 1047
psychiatric problems associated with hospitalization/illness and, 1091
- Sick sinus syndrome, **394**
- Sickle cell anemia/syndromes, **503–505, 505t**
acute chest syndrome in, 28
cholelithiasis/gallstones and, 503, 702
contraceptive counseling and, 799
genetic/prenatal/screening testing for, 503, 504, 783, 799
osteomyelitis and, 503, 861

- Sickle cell anemia/syndromes (*Cont.*):
 in pregnancy, 799
 renal dysfunction associated with, 503, 936
- Sickle cell glomerulopathy, 936
- Sickle cell retinopathy, 187, 503
- Sickle cell trait, 504, 505*t*
 pregnancy and, 799
- Sickle thalassemia, 505, 505*t*
- Sideroblastic anemia/sideroblasts, 496–497
 myelodysplastic syndromes and, 496, 497, 517, 518
- Siderosis, 309*t*
- Sigmoid esophagus, 605
- Sigmoid sinus thrombosis, otitis media and, 205
- Sigmoidoscopy
 in antibiotic-associated colitis, 637
 in cancer screening/polyp identification, 16, 653, 1626*t*, 1627–1628
 in fecal incontinence, 660
 in GI bleeding, 584
 in irritable bowel syndrome, 634
 in ulcerative colitis, 647
- Signal recognition particle (SRP)
 antibody, in polymyositis/dermatomyositis, 841
- Significant others. *See* Family/significant others
- SIL. *See* Squamous intraepithelial lesions
- Sildenafil
 adverse ophthalmic effects of, 196*t*, 1226
 for erectile dysfunction, 952, 1051
 antidepressant-induced, 1051, 1067
 in diabetes, 1226
 nitrate/nitroglycerin contraindications and, 370, 952, 1051, 1226
 for pulmonary hypertension, 305, 424
 in women, 767
- Silent myocardial infarction. *See also* Myocardial infarction
 dyspnea in, 24
- Silent thyroiditis, 1111, 1121. *See also* Subacute (de Quervain) thyroiditis
- Silent ulcers, 612
- Silibinin/silymarin, for mushroom poisoning, 673, 1585
- Silicone gel breast implants. *See* Breast implants
- Silicosis, 309, 309*t*
- Silo-filler's disease, 311
- Silodosin, for benign prostatic hyperplasia, 959*t*
- Silymarin/silibinin, for mushroom poisoning, 673, 1585
- Simple drug eruptions, 160
- Simple partial seizures, 969. *See also* Seizures
- Simple/solitary renal cysts, 934, 934*t*
- Simultagnosia, intracranial tumors causing, 991
- SIMV. *See* Synchronized intermittent mandatory ventilation
- Simvastatin, 1253–1254, 1255*t*. *See also* Statin drugs
 for Hashimoto thyroiditis, 1122
 for polycystic ovary syndrome, 1163
 protease inhibitor interactions and, 1344
- Sin Nombre virus, 1388
- Sinemet. *See* Carbidopa/levodopa
- Sinequan. *See* Doxepin
- Singer's nodules, 235
- Single photon emission computed tomography (SPECT)
 in angina, 353
 in thyroid cancer surveillance, 1132
 in Zollinger-Ellison syndrome/gastrinoma, 620
- Singultus (hiccups), 569–570
- Sinoatrial exit block (sick sinus syndrome), 394
- Sinonasal inflammatory disease, 223
- Sinus arrest (sick sinus syndrome), 394
- Sinus arrhythmia, 380–381
- Sinus bradycardia, 380. *See also* Bradycardia/bradyarrhythmias
 in myocardial infarction, 365, 372
 persistent (sick sinus syndrome), 394
 in poisoning/drug overdose, 1564*t*
 in sleep apnea, 319
- Sinus tachycardia, 380–381. *See also* Tachycardia/tachyarrhythmia
 in hyperthyroidism, 1112, 1118
 in myocardial infarction, 372
 in poisoning/drug overdose, 1564*t*
- Sinus venosus atrial septal defect, 327, 328
- Sinuses. *See* Paranasal sinuses
- Sinusitis, 214–217, 216*t*, 1303*t*
 in aspergillosis, 217, 1537, 1538
 facial pain in, 216, 968
Haemophilus causing, 1442
 headache in, 215, 962
 in HIV infection/AIDS, 217, 1327
 hospital-associated, 215, 216
 invasive fungal, 217–218
 nasopharyngeal/paranasal sinus cancer and, 223
 orbital cellulitis and, 191, 216
- Sinusoidal obstruction syndrome, 698
 drugs/toxins causing, 683
- Siipple syndrome. *See* Multiple endocrine neoplasia (MEN), type 2A
- Sipuleucel-T, 1656*t*
 for prostate cancer, 1637
- Sirolimus, 1724*t*
- SIRS. *See* Systemic inflammatory response syndrome
- Sister Joseph's nodule, 1608
- Sister Mary Joseph nodule, 1616
- Sitagliptin, 1207*t*, 1212, 1221
 with metformin, 1213
 with metformin and pioglitazone, 1212
 overdose/toxicity of, 1212, 1221, 1580
 pancreatic/periampullary carcinoma and, 1607
- Siti (endemic syphilis), 1475
- Situational (stress and adjustment) disorders, 1038–1039. *See also* Adjustment (situational) disorders
- Sixth disease (exanthema subitum), 1350, 1356*t*, 1366
- Sixth nerve paralysis, 190
- Sjögren syndrome, 842–844
 autoantibodies in, 833*t*, 843
- SJS. *See* Stevens-Johnson syndrome
- SJS/TEN overlap. *See* Stevens-Johnson syndrome/toxic epidermal necrolysis overlap
- Skeletal hyperostosis, diffuse idiopathic (DISH), 855, 1228
- Skeletal system disorders. *See* Bone; Musculoskeletal disorders
- Skin, 94–161
 anaerobic flora of, 1454
 atrophy of, atopic dermatitis treatment and, 104
 biopsy of
 in basal cell carcinoma, 142
 in cellulitis, 137
 in cutaneous leishmaniasis, 1488
 in cutaneous T cell lymphoma (mycosis fungoides), 115
 in exfoliative dermatitis/erythroderma, 116
 in leprosy, 1460
 in Lyme disease, 1480
 in onchocerciasis, 1526–1527
 in polyarteritis nodosa, 848
 in rabies, 1376
 in Rocky Mountain spotted fever, 1412
 in stasis ulcer, 154
 caustic/corrosive injuries of, 1566, 1571, 1572
 changes in, in chronic venous insufficiency, 33, 34, 481
 decontamination of, 1566
 for caustic/corrosive burns, 1566, 1571, 1572
 chemical warfare agents and, 1566, 1587
 disorders of. *See specific type and* Skin cancer; Skin disorders
 dry
 atopic dermatitis and, 103
 emollients for, 94, 98–99*t*
 hardening of. *See* Scleroderma
 Skin bends, 1557
- Skin cancer. *See also specific type*
 basal cell carcinoma, 142, 142*f*
 ear involved in, 199
 eyelid involvement and, 164
 melanoma, 102–103, 102*f*
 PUVA therapy and, 107
 squamous cell carcinoma, 143, 143*f*
 sun avoidance in prevention of, 15, 99
 in transplant recipients, 143
- Skin disorders, 94–161, 95*t*. *See also specific type and* Dermatitis
 anaerobic infections, 1456, 1456*f*
 anthrax, 1431, 1432, 1433
 antipsychotic drugs causing, 1060
 arthropod infestations, 148–150
 in blastomycosis, 1539
 blistering (bullous), 95*t*, 138–139
 cancer. *See* Skin cancer
 cancer-related, 1596*t*
 candidal infection, 132
 in HIV infection/AIDS, 1331
 in Chagas disease (chagoma), 1486
 chemotherapy causing, 1661
 chilblain (erythema pernio), 1545

- in chromoblastomycosis, 1540
 in chronic kidney disease/uremia, 909t, 910
 in coccidioidomycosis, 1532
 cryptococcal, 1536
 in cutaneous larva migrans, 1523, 1524f
 in cutaneous leishmaniasis, 1488, 1488f, 1489
 cystic, 95t
 in decompression sickness, 1557
 in diabetes mellitus, 1197, 1228
 in dracunculiasis, 1520, 1521
 in drug users, 1292
 drugs causing (dermatitis medicamentosa/drug eruption), 158–161, 159–160t
 in electrical burns, 1550, 1552, 1553
 epidermal inclusion cysts, 152
 erosive, 95t
 erythemas, 95t, 132–138
 frostbite, 1546
 fungal infections, 110–114, 110f, 111f, 113f. *See also* Tinea
 in HIV infection/AIDS, 1331
 in gnathostomiasis, 1523
 in gonococcal arthritis, 860, 1452
 in Graves disease (dermatopathy/pretibial myxedema), 1110, 1113
 in Henoch-Schönlein purpura, 852, 919t, 923
 in HIV infection/AIDS, 1330–1331
 in hookworm disease, 1518, 1523
 in leprosy, 1460
 in Lyme disease, 135–136, 135f, 1478, 1479
 morbilliform, 95t
 morphologic categorization of, 95t
 in mycetoma, 1540
 mycobacterial infections, 1458
 in nephrogenic systemic fibrosis, 937
 in niacin deficiency, 1265
 in nocardiosis, 1457
 nodules, 95t
 inflammatory, 150–152
 violaceous to purple, 143–145
 in onchocerciasis, 1526
 papules, 95t, 139–143
 violaceous to purple, 143–145
 in paracoccidioidomycosis (South American blastomycosis), 1539
 in pheochromocytoma/paraganglioma, 1168t
 photodermatitis, 95t, 152–153. *See also* Photodermatitis/ photosensitivity
 pigmentary, 155–156. *See also* Hyperpigmentation; Hypopigmentation
 drugs causing, 155, 160t
 in hypercarotenosis, 1267
 pigmented lesions, 95t, 100–103
 in polyarteritis nodosa, 150, 847
 pruritus (itching) and, 95t, 145–150.
 See also specific cause
 pustular, 95t, 125–132
 radiation causing, 1554
 in sarcoidosis, 295, 295f
 scaling, 95t, 103–117
 in schistosomiasis, 1511
 in sporotrichosis, 1539
 staphylococcal infections, 1421t, 1425–1426, 1425f
 in HIV infection/AIDS, 1331
 streptococcal infections, 1420–1422, 1421t
 in strongyloidiasis, 1519
 in syphilis, 1464, 1469, 1469f, 1470f, 1471. *See also* Chancre; Gummas
 treatment of, 94–100, 95–99t
 adverse ophthalmic effects of drugs in, 197t
 complications of, 99–100
 in tuberculous sclerosis, 996
 in tularemia, 1450
 ulcers, 95t, 153–155
 in diabetics, 153–155, 1224–1225, 1225f, 1228
 in dracunculiasis, 1520, 1521
 in mycetoma, 1540
 osteomyelitis and, 154, 862
 in paracoccidioidomycosis, 1539
 in polyarteritis, 847
 pressure, 70–71, 71f
 bed rest/immobility and, 65, 70
 in sickle cell syndromes, 503, 504
 in sporotrichosis, 1539
 venous insufficiency/varicose veins/
 lower extremity occlusive
 disease and, 33, 34, 153–155,
 154f, 467, 479, 481
 venous insufficiency/varicose veins
 and. *See* Skin disorders,
 ulcers; Stasis dermatitis;
 Venous insufficiency/stasis
 vesicular, 95t, 118–123
 weeping/crusted, 95t, 123–125
 drying agents for, 94
 Skin grafts
 in burn care, 1550, 1551
 for leg ulcers, 154
 Skin test anergy
 in HIV infection/AIDS, 1323, 1326, 1334
 measles causing, 1368
 in sarcoidosis, 295
 tuberculin skin test and, 282
 Skin tests. *See also specific type*
 allergy, 866, 1306
 in asthma, 248
 in penicillin allergy, 1305, 1306
 tuberculin, 4, 282, 283t, 286. *See also*
 Tuberculin skin test
 latent disease treatment and, 286,
 286–287
 Skull base tumors, vocal fold paralysis
 caused by, 238
 Skull fractures, 1016, 1016–1017. *See also*
 Head injury
 hearing loss and, 207
 vertigo caused by, 211
 SLC30A8 gene/antibodies, in type 2
 diabetes, 1194
 SLE. *See* Systemic lupus erythematosus
 Sleep
 abnormal behaviors during
 (parasomnias), 1077–1078
 age-related changes in, 1075
 breathing disorders and, 231–232,
 318–319. *See also* Sleep
 apnea
 disorders of, 1075–1078
 fatigue/chronic fatigue and, 38, 40
 drugs for problems with, 1042t, 1043,
 1076–1077
 stages of, 1075
 Sleep apnea, 318, 1077
 central, 318
 fatigue/chronic fatigue and, 38, 40, 319
 hypertension and, 319, 436
 mixed, 318
 in obesity-hypoventilation syndrome,
 318
 obstructive, 231, 318, 318–319
 postoperative pulmonary
 complications and, 50
 pulmonary hypertension and, 424
 testosterone replacement therapy and,
 1177
 Sleep attacks, in narcolepsy, 1077
 Sleep hygiene, 1076
 Sleep panic attacks, 1041
 Sleep paralysis, in narcolepsy, 1077
 Sleep terror (pavor nocturnus), 1077,
 1078
 Sleepiness. *See* Somnolence
 Sleeping sickness, 1484–1485, 1485t
 Sleepwalking (somnambulism), 1041,
 1077, 1078
 Slow colonic transit, constipation and,
 570, 570t, 571
 Sm antibody, in lupus/SLE, 114, 833,
 833t, 834t
 SMA. *See* Spinal muscular atrophy
 SMAD4 gene mutation, in hereditary
 hemorrhagic telangiectasia,
 1671
 Small cell carcinoma of lung, 1597, 1611t.
 See also Lung cancer
 myasthenic syndrome and, 1596t
 paraneoplastic syndromes associated
 with, 1596t, 1597
 staging of, 1598, 1598t
 survival rates for, 1597, 1598t
 treatment of, 1600, 1611t
 Small intestine. *See also under* Intestinal
 adenocarcinomas in, 1620
 Crohn disease and, 643, 1620
 bacterial overgrowth in, 624–625. *See*
 also Bacterial overgrowth
 biopsy of
 in celiac disease, 622
 in Whipple disease, 624
 carcinoid tumors in, 1620–1621
 disorders of, 621–632, 621t
 appendicitis and, 630–631
 malabsorption and, 621–627, 621t
 malignant tumors, 1620–1622
 motility disorders, 627–630. *See also*
 Intestinal obstruction
 protein-losing enteropathy and,
 631–632
 tuberculosis, 631
 lymphomas in, 1620
 resection of, short bowel syndrome
 and, 625–626
 sarcomas in, 1622

- Small intestine push enteroscopy, in GI bleeding, 585
- Small intestine transplantation, for short bowel syndrome, 626
- Smallpox (variola), 1357*t*, 1403–1404
- Smallpox (variola) vaccination, 1403–1404
- atopic dermatitis/eczema and, 104, 1403, 1404
- Smell, disorders of sensation of, **219–220**
- Smith antibody, in lupus/SLE, 114, 833, 833*t*, 834*t*
- SMN (survival motor neuron) gene, in spinal muscular atrophies, 1020
- Smoke inhalation, **307**, 1550
- burn survival and, 1550
- cyanide poisoning and, 1577
- Smoking, **6–8**
- aortic aneurysms and, 6, 473
- asbestosis and, 309, 311
- atherosclerotic disease and, 6, 464–465
- bladder cancer and, 6, 1638
- cancer and, 6, 15, 1593
- cataract development and, 179
- cessation of, 6–8, 7*t*, 9–10*t*, 10*t*, 1593
- acute coronary syndromes and, 362*t*
- atherosclerotic disease and, 464–465, 1252
- bupropion for, 8, 261, 1593
- in cancer prevention, 15, 1593
- in cardiovascular/cerebrovascular disease prevention, 6–8, 7*t*, 9–10*t*, 10*t*, 1252
- clinician's role in, 8, 9–10*t*, 10*t*
- in COPD prevention/management, 6, 261
- for hypertension, 441
- nicotine replacement therapy for, 8, 1593
- postoperative pulmonary complications reduced by, 51
- for thromboangiitis obliterans (Buerger disease), 472
- in COPD, 6, 259, 261
- coronary heart disease and, **6–8**, 7*t*, 9–10*t*, 10*t*, 350, 1249*t*, 1250
- Crohn disease and, 641
- environmental exposure and. *See* Passive smoking
- esophageal cancer and, 1613
- Graves ophthalmopathy and, 1115, 1116, 1117
- health hazards of, 6
- hemoptysis and, 27
- hypertension and, 436
- incidence/prevalence of, 6–8
- laryngeal cancer and, 236
- laryngeal leukoplakia and, 236
- lung cancer and, 6, 1593, 1595
- as co-carcinogen, 311
- screening for, 289, 1599
- in women, 1709
- in women, 1709
- oral cancer and, 224
- pancreatic/periampullary carcinoma and, 1607
- pancreatitis and, 711, 715
- pneumothorax and, 317
- postoperative pulmonary complications and, 51
- during pregnancy, 783
- preventable disease/deaths and, 3*t*, 6–8, 7*t*
- in renal cell carcinoma, 1641
- respiratory bronchiolitis and, 269
- sleep disorders and, 1076
- thromboangiitis obliterans (Buerger disease) and, 472
- ulcerative colitis and, 646
- ureteral/renal pelvis cancer and, 1640
- vocal fold changes and, 235
- Smoldering multiple myeloma, 528, 529
- Smooth muscle antibodies
- in autoimmune hepatitis, 679
- in nonalcoholic fatty liver disease, 684
- Snails, in disease transmission. *See* Cercariae/metacercariae
- Snake bites, 1566*t*, **1589–1590**
- Snare resection, for Barrett esophagus, 595
- Sneddon syndrome, 854
- Sniffing (solvents/gases), 1086, 1583, 1587–1588
- Snip biopsy, for wart removal, 140
- Snoreplasty, 231
- Snoring, **231–232**
- in sleep apnea, 231, 319
- Snow blindness, 194
- Social challenges, for terminally ill/dying patient, 91–92, 92*t*
- Social phobias, 1041, 1044
- Social support. *See* Support groups
- Sodium
- dietary, 1268
- hypertension and, 436, 441*t*, 1268
- during pregnancy, 785
- preventable disease/deaths
- associated with high intake of, 3*t*
- requirements for in nutritional support, 1272
- restriction of. *See* Sodium-restricted diet
- urinary stone formation and, 946, 947, 948
- disorders of concentration of, **871–877**, 871*f*, 873*t*. *See also* Hyponatremia; Hypnatremia
- in fluid management, 897*t*. *See also* Saline
- fractional excretion of, in acute kidney injury, 902*t*, 903
- hyperosmolality caused by, 877
- intracellular, in hypertension, 436
- retention of in volume overload, 877
- serum
- in hyponatremia, 875
- in hyponatremia, 871, 874
- reference values for, 1734*t*
- urine
- in acute kidney injury/tubular necrosis, 902*t*, 903, 905
- in glomerulonephritis, 908
- in SIADH, 874
- Sodium bicarbonate. *See* Bicarbonate
- Sodium channel blocking drugs, for arrhythmias, 377, 378*t*
- Sodium deficit, calculation of, 874–875
- Sodium-glucose transporter 2 gene, in nondiabetic (renal) glycosuria, 1198
- Sodium ipodate. *See* Ipodate sodium
- Sodium nitrite, for cyanide poisoning, 1566*t*, 1577, 1578*t*
- Sodium nitroprusside. *See* Nitroprusside
- Sodium oxybate. *See* Gamma-hydroxybutyrate
- Sodium phosphate, for constipation/bowel cleansing, 571, 572*t*
- Sodium-phosphate cotransporters, in osteomalacia/rickets, 1150
- Sodium phosphate enema, 572*t*
- Sodium polystyrene sulfonate, for hyperkalemia, 881*t*, 914
- Sodium-restricted diet, 1268
- for chronic kidney disease, 911, 915, 1268
- in cirrhosis, 687, 688, 1268
- for heart failure, 406, 1268
- in cardiomyopathy, 412
- for hypertension, 436, 441*t*, 1268
- for nephrotic syndrome/nephrotic spectrum disorders, 928
- pregnancy and, 785
- for urinary stones, 947, 948
- Sodium salicylate, in pain management, 78*t*
- Sodium stibogluconate (antimony), for leishmaniasis, 1488–1489
- Sodium sulfacetamide. *See* Sulfacetamide
- Sodium thiosulfate, for cyanide poisoning, 1566*t*, 1577, 1578*t*
- SOFA score
- in liver failure, 673
- in pancreatitis, 712
- Soft diet, 1268
- Soft tissue infections, 1421*t*
- anaerobic, **1456**, 1456*f*
- mycobacterial, **1458**
- staphylococcal, 1421*t*, **1425–1426**, 1425*f*
- Soft tissue sarcoma, 1612*t*
- Solar lentiginos (liver spots), 101, 155, 156
- Soles of feet
- tinea of, 111*f*, **112–113**
- vesiculobullous dermatitis of (pompholyx), 121–122
- tinea differentiated from, 113
- Solifenacin, for urinary incontinence, 68
- Solitary pulmonary nodule, **290–291**
- metastatic disease and, 1601
- Solitary/simple renal cysts, **934**, 934*t*
- Solitary seizures, 974
- Solitary thyroid nodule, 1123
- toxic (thyroid adenoma), 1111, 1116
- in MEN, 1188*t*
- Soluble liver antigen antibodies, in autoimmune hepatitis, 679
- Soluble transferrin receptor, 493, 1735*t*
- Solvents
- bladder cancer caused by exposure to, 1638
- toxicity/abuse of, **1086**, 1583, **1587–1588**
- Soma. *See* Carisoprodol
- Soman (GD) poisoning, 1587
- Somatization disorder (Briquet syndrome/hysteria), 1045–1046
- Somatiform disorders, **1045–1047**
- Somatiform pain disorder, 1046

- Somatostatin/somatostatin analogs. *See* *also* Octreotide
- D cells secreting, 1171
 - for esophageal varices, 602
 - reference values for, 1734*t*
 - tumors secreting, 1172, 1189
 - diabetes and, 1196
- Somatostatin receptor scintigraphy
- for ACTH-secreting tumor identification, 1159
 - in carcinoids, 1621
 - in islet cell tumors, 1172
 - for pheochromocytoma/paraganglioma identification, 1169
 - in Zollinger-Ellison syndrome/gastrinoma, 620
- Somatostatinomas, 1172, 1189
- Somatuline. *See* Lanreotide
- Somnambulism (sleepwalking), 1041, 1077, 1078
- Somnolence, excessive, **1077**
- restless legs syndrome causing, 1004
 - in sleep apnea, 319, 1077
- Somogyi effect, 1219, 1219*t*
- Sonata. *See* Zaleplon
- SONIC staging system, in hepatic encephalopathy, 690
- Sonography. *See* Ultrasonography
- Sonohysterography, saline infusion, 748*t*
- in abnormal postmenopausal bleeding, 749
 - in abnormal premenopausal bleeding, 747, 748
- Sorafenib, 1655*t*
- for hepatocellular carcinoma, 1605
 - for thyroid carcinoma, 1130
- Sorbitol, 1205
- for constipation, 571, 572*t*
 - diarrhea caused by, 578, 579*f*
- Sore throat. *See* Pharyngitis
- Sorivudine, for herpes zoster, 1359
- Sotalol, 377, 379*t*
- for atrial fibrillation, 378*t*, 387
 - toxicity of, 377, 379*t*, 387
 - for ventricular tachycardia, 391
- South African tick fever, 1409*t*
- South American blastomycosis, **1539**
- Southern tick-associated rash illness (STARI), 136
- Sparganosis, 1516–1517
- Spasmodic torticollis, 1003
- Spasticity, **1012–1013**
- motor neuron lesions and, 977, 1012, 1019, 1020
 - spinal trauma causing, 1018
 - in tetanus, 1429, 1430
- Specimen collection, tubes for, 1736*t*
- SPECT. *See* Single photon emission computed tomography
- Spectazole. *See* Econazole
- Spectrin, in hereditary spherocytosis, 501
- Speech/language, in schizophrenia/psychotic disorders, 1054
- Speech discrimination
- in hearing loss, 199, 212
 - presbycusis and, 206
 - testing, 199
 - vestibular schwannoma affecting, 212
- Speech therapy, for stroke patient, 983
- SPEP. *See* Serum protein electrophoresis
- Sperm, deficiencies of, infertility and, 768, 954*f*, 955
- Sperm analysis, in infertility workup, 768, 954, 954*f*, 955
- Spermatogenesis
- hormone therapy for improvement of, 1097
 - in hypogonadism, 1173
- Spermicides
- in contraceptive products, 775
 - HIV infection/AIDS and, 775
- Sphenoid sinusitis, 215
- Spheroocytes
- in autoimmune hemolytic anemia, 506
 - in hereditary spherocytosis, 501
- Spherocytosis, hereditary, **500–501**
- Sphincter of Oddi dilation, for cholelithiasis/choledocholithiasis/choolangitis, 707
- Sphincter of Oddi dysfunction
- pancreatitis and, 706, 711, 713
 - in postcholecystectomy syndrome, 706
- Sphincterotomy
- for cholelithiasis/choolangitis, 707, 708
 - during pregnancy, 807
 - in pancreatitis, 714
 - for sphincter of Oddi dysfunction, 706
- Sphincters. *See specific type*
- Spingolipid, accumulation of in Gaucher disease, 1668
- Spider angiomas, in cirrhosis, 686
- Spider bites, 149, **1590**
- Spinal cord
- cavitation of (syringomyelia), **1018–1019**
 - compression of
 - spinal trauma causing, 1018
 - tumors causing, 993, **1644–1645**
 - dural arteriovenous fistulae of, 989
 - epidural/subdural hemorrhage and, 989
 - infarction of, 988–989
 - lesions/tumors of, **993**
 - back pain caused by, 819, 993, 1644, 1683, 1684
 - cord compression by, 993, **1644–1645**
 - in HIV infection/AIDS, 1328
 - sensory disturbances and, 976
 - syringomyelia and, 1019
 - subacute combined degeneration of, **1013**
 - transection of, 1018
 - traumatic injury of, **1018**
 - near drowning and, 1556
 - shock and, 485–486
 - syringomyelia and, 1019
 - vascular diseases of, **988–989**
 - vasculitis of (primary angiitis of central nervous system), **854**
- Spinal cord stimulation, for angina, 358
- Spinal dural arteriovenous fistulae, 989
- Spinal manipulation
- for back pain, 818, 1684
 - for neck pain, 1687
- Spinal motion, testing, 820
- Spinal muscular atrophy
- juvenile, 1020
 - progressive, 1019, 1020
- Spinal poliomyelitis, 1372
- Spinal (neurogenic) shock, 485–486, 486
- Spinal stenosis, **822, 1685**
- Spinal surgery
- for back pain, 821, 1684
 - for neck pain, 1029, 1687
 - for spinal stenosis, 822, 1685
 - for traumatic injury, 1018
 - for tumors/cord compression, 993, 1645
- Spinal tumors. *See* Spinal cord, lesions/tumors of
- Spine. *See also* Spinal cord
- bamboo, 855
 - disorders of, **1683–1687**, 1684*t*, 1687*t*
 - anogenital pruritus and, 146
 - back pain and, **818–821**, 820*t*, 821*t*, 1683–1685, 1684*t*. *See also* Back pain
 - fractures, 1018. *See also* Vertebral compression/fracture
 - infection. *See* Vertebral osteomyelitis
 - lumbar disk herniation, 820, 820*t*, **1685–1686**
 - neck pain and, 818, 1029, 1030–1031*f*, 1686–1687, 1687*t*. *See also* Neck pain
 - stenosis, **822, 1685**
 - tuberculosis (Pott disease), **863–864**
 - tumors. *See* Spinal cord, lesions/tumors of
- SPINK1 gene, in chronic pancreatitis, 715
- Spinocerebellar degeneration, in vitamin E deficiency, 1012
- Spiral (helical) CT. *See* Computed tomography; Helical (spiral) CT
- Spiramycin, for toxoplasmosis during pregnancy, 1502
- Spirillum minus*, 1476
- Spiritual challenges, for terminally ill/dying patient, 92, 92*t*
- Spirochetal infections, 1300*t*, **1464–1483**. *See also specific type*
- anaerobic, periodontal infection caused by, 1454
 - meningitis caused by, 1286*t*
 - myocarditis in, 409*t*
 - non-sexually transmitted, **1474–1475**
 - syphilis, **1464–1474**, 1465*t*
- Spirometra* tapeworms, 1516–1517
- Spirometry. *See also* Pulmonary function tests
- in asthma, 246
 - in COPD, 260–261
 - in cough evaluation, 22
 - in dyspnea evaluation, 25
 - incentive, prevention of postoperative pulmonary complications and, 51
 - in lung cancer, 1598–1599
- Spirolactone
- for adrenal hyperplasia/Conn syndrome, 1166
 - for cirrhotic ascites, 688
 - for heart failure, 401, 402
 - infarct-related, 371
 - for hirsutism/virilization, 1163
 - for hypertension, 445*t*, 449–453, 458*t* with hydrochlorothiazide, 445*t*
 - lithium interactions and, 1074, 1074*t*
- Spirulina, toxicity of, 1578*t*

- Spleen
 in hereditary spherocytosis, 501
 platelet sequestration in, 539t, 547, 547t
 in polycythemia, 512
 in sickle cell disease, 504
- Splenda. *See* Sucralose
- Splenectomy
 for autoimmune hemolytic anemia, 506
 babesiosis and, 1499, 1500
 for Felty syndrome, 510
 for Gaucher disease, 1668
 for hereditary spherocytosis, 501
 for immune thrombocytopenia, 541, 541f, 542
 immunization recommendations in, 1309t
 for neutropenia, 510
 for noncirrhotic portal hypertension, 700
 for platelet sequestration/
 thrombocytopenia, 547
 for primary myelofibrosis, 515
- Splenic rupture, in infectious mononucleosis, 1362
- Splenic vein thrombosis, noncirrhotic portal hypertension caused by, 699, 700
- Splenomegaly, 547t
 in chronic lymphocytic leukemia, 522
 in chronic myeloid leukemia, 516
 in cirrhosis, 686
 in essential thrombocytosis, 513
 in hairy cell leukemia, 523
 in mononucleosis, 1361, 1362
 in noncirrhotic portal hypertension, 699
 platelet sequestration and, 539t, 547, 547t
 in polycythemia, 512
 in primary myelofibrosis, 514
 thrombocytopenia and, 547, 547t
 in visceral leishmaniasis, 1487
- Splinter hemorrhages, in endocarditis, 1435, 1436f
- Spondylitic heart disease, 855
- Spondylitis
 in alkaptonuria, 1665
 ankylosing. *See* Ankylosing spondylitis
 in inflammatory bowel disease, 855, 858
 psoriatic, 856
- Spondyloarthropathies, seronegative, 854–858. *See also specific type*
 back pain in, 820
 rheumatoid arthritis differentiated from, 828
- Spondylolisthesis, back pain in, 820
- Spondylosis, cervical, 818, 1029
- Spongiform encephalopathies, 1381–1382
- Spongiosis, in prion diseases, 1381
- Spontaneous abortion, 788–789
 in antiphospholipid antibody syndrome, 789, 799, 836
 with IUD in place, 774
 in Q fever, 1416
- Spontaneous bacterial peritonitis, 589–590, 689
 in cirrhosis, 589, 689
- Spontaneous fractures. *See* Pathologic fractures
- Spontaneous pneumothorax, 316–317. *See also* Pneumothorax
- Spoon nails, 157
- Sporadic Creutzfeldt-Jakob disease, 1381, 1382
- Sporadic thyroiditis, painless, 1120, 1121
- Sporanox. *See* Itraconazole
- Sporothrix schenckii* (sporotrichosis), 1539
- Sports medicine, 1673–1705. *See also* Musculoskeletal disorders; Orthopedics
 ACL injury, 1693–1698
 ankle injuries/sprains, 1703–1705, 1703t, 1704t
 collateral ligament injury, 1695–1696t, 1698–1699
 dislocated shoulder, 1679–1680t, 1681–1682
 general approach to musculoskeletal injuries and, 1673–1674
 hip fractures, 1689–1690, 1690t
 lateral and medial epicondylitis, 1687–1688
 meniscus injuries, 1696–1697t, 1700
 patellofemoral pain, 1692, 1697t, 1700–1701
 PCL injury, 1696t, 1699–1700
 rotator cuff tears and, 1675–1681, 1677–1678t
- Spotted fever group rickettsia 364D, 1414
- Spotted fever rickettsiosis, 1414
- Spotted fevers, 1409t, 1412–1414, 1412f
- Spousal abuse (domestic violence), 17, 1078, 1079, 1711–1712
 prevention of, 17, 1712
- Sprains, ankle, 1703–1705, 1703t, 1704t
 eversion (high), 1704–1705, 1704t
 inversion, 1703–1704, 1703t, 1704t
- Sprue, celiac. *See* Celiac disease
- Sprycel. *See* Dasatinib
- Spurling test, 1686, 1687t
- Sputum/sputum examination
 in asthma, 248
 blood found on (hemoptysis), 26–27
 in bronchiectasis, 266
 in COPD, 260, 260t, 261
 in cough, 22
 in cystic fibrosis, 267, 268
 in lung cancer, 1597
 in nontuberculous mycobacterial infection, 288
 in paragonimiasis, 1513
 in pneumonia
 anaerobic/lung abscess, 278
 in community-acquired disease, 270, 271, 272t
 in immunocompromised host, 279
 nosocomial, 276–277
 pneumococcal, 271, 1423
Pneumocystis, 279, 1325, 1534
 in solitary pulmonary nodule, 291
 in strongyloidiasis, 1519
 in tuberculosis, 280, 281, 286
- Sputum eosinophilia, in asthma, 248
- Sputum induction
 in pneumonia, 272
 in immunocompromised host, 279
 in tuberculosis, 280
- Squamous cell carcinoma
 of anus, 1629–1630
 in HIV infection/AIDS, 1332, 1629
 of bladder, 1638
 cervical, 756
 of ear canal, 201
 of esophagus, 1613
 intraepidermal (Bowen disease), 117
 of larynx, 236–237
 laryngeal leukoplakia and, 236
 of lung, 1595
 nasopharyngeal, 223, 1363
 inverted/schneiderian papillomas and, 222
 oral, 224, 224–225, 225f
 of skin, 143, 143f
 actinic keratoses and, 117, 143
 of vulva, 760
- Squamous intraepithelial lesions (SIL), 754t, 755
- “Square root” sign, 422
- Squaric acid dibutylester, for wart removal, 141
- Squatting, heart murmurs affected by, 337t
- Squint, in sixth nerve paralysis, 190
- Squirrels, flying, in epidemic louse-borne typhus, 1408
- SRP antibody, in polymyositis/dermatomyositis, 841
- SRS. *See* Somatostatin receptor scintigraphy
- SRY gene, in testicular dysgenesis, 1175
- SS-A/Ro antibody, 833t
 in lupus/SLE, 114, 833t
 in Sjögren syndrome, 833t, 843
- SS-B/La antibody, 833t
 in lupus/SLE, 114, 833t
 in Sjögren syndrome, 833t, 843
- SSc. *See* Scleroderma
- SSI. *See* Surgical site infection
- SSNRIs. *See* Serotonin-selective norepinephrine reuptake inhibitors
- SSPE. *See* Subacute sclerosing panencephalitis
- SSRIs. *See* Serotonin-selective reuptake inhibitors
- SST (serum separator tubes), gold top, 1736t
- ST elevation acute coronary syndromes. *See* Myocardial infarction; ST-segment elevation myocardial infarction
- St. Louis encephalitis, 1378–1380
- ST segment changes. *See also* Electrocardiogram
 in acute coronary syndromes, 360, 361. *See also* Acute coronary syndromes; Myocardial infarction
 in angina, 352, 353
 Prinzmetal (variant), 360
 antipsychotic drugs causing, 1059
 in hypertension, 440
 in myocardial infarction, 366. *See also* Myocardial infarction
 reperfusion assessment and, 370
 in pericarditis, 420
 in Tako-Tsubo cardiomyopathy, 413

- ST-segment elevation myocardial infarction (STEMI), 360, 364t, **365–376**, 367t, 369t. *See also* Myocardial infarction
- Staggers, 1557
- Stalevo. *See* Entacapone, with levodopa and carbidopa
- Standard days method of contraception, 775–776
- Standing, heart murmurs affected by, 337t
- Stanford V regimen, for Hodgkin lymphoma, 527
- Stannosis, 309t
- Stapedectomy, 205
- Staphylococcus* (staphylococcal infections), 1299t
- abscesses, 1421t, 1425, 1425f
- arthritis, 858, 859, 1302t
- atopic dermatitis and, 103, 104
- aureus*, **1425–1428**
- abscesses, 1421t, 1425, 1425f
- arthritis, 858, 859, 1302t
- bacteremia, **1427**
- breast abscess/mastitis, 721, 797, 798
- cellulitis, 136–138, 1303t, 1421t
- community-associated methicillin-resistant (CA-MRSA), 5
- cellulitis, 137
- impetigo/ecthyma, 123
- pneumonia, 273, 273t
- diarrhea/food poisoning/gastroenteritis, 574t, 575, 1293, 1294t
- endocarditis, 1302t, 1435, 1437, 1438–1439
- furunculosis/carbuncles and, 151, 1303t, 1421t, 1425, 1425f
- impetigo, 123
- mastitis, 721, 797, 798
- methicillin-resistant (MRSA), 5, 1299t
- arthritis, 858, 859
- cellulitis, 137
- community-acquired pneumonia, 273, 273t
- endocarditis and, 1439
- furunculosis, 151
- in HIV infection/AIDS, 1331
- impetigo, 123
- in mastitis, 798
- skin/soft tissue infections, 1425, 1425f, 1426
- surgical site infection, 56
- nasal vestibulitis, 217
- osteomyelitis, 862, 1302t, **1426**
- of skin and soft tissues, 1421t, **1425–1426**, 1425f
- in HIV infection/AIDS, 1331
- toxic shock syndrome, **1427**, 1427f
- carrier state and, 1425
- impetigo and, 123
- nasal vestibulitis and, 217
- surgical site infection associated with, 55–56, 1284
- cellulitis, 136–138, 1303t, 1421t
- coagulase-negative, **1427–1428**
- endocarditis, 1428, 1435, 1439
- cohnii*, 1428
- drug resistance and, 1425. *See also Staphylococcus* (staphylococcal infections), *aureus*, methicillin-resistant
- epidermidis*, 1428
- folliculitis and, 129, 130, 1331, 1425
- furunculosis/carbuncles and, 151, 1303t, 1421t, 1425, 1425f
- haemolyticus*, 1428
- hominis*, 1428
- impetigo, 123
- keratitis, 172
- methicillin-resistant (MRSA). *See Staphylococcus* (staphylococcal infections), *aureus*, methicillin-resistant
- non-penicillinase-producing, 1299t
- osteomyelitis, 862, 1302t, **1426**
- penicillinase-producing, 1299t
- saccharolyticus*, 1428
- saprophyticus*, 1428
- warneri*, 1428
- STARI (Southern tick-associated rash illness), 136
- Starlix. *See* Nateglinide
- Starvation (protein–energy malnutrition), **1257–1258**
- Stasis dermatitis, 34, 478. *See also* Venous insufficiency/stasis
- leg ulcers and, 153
- Statin drugs (HMG-CoA reductase inhibitors), 1253–1254, 1255t
- adverse ophthalmic effects of, 196t
- for Hashimoto thyroiditis, 1122
- hepatotoxicity and, 683
- for lipid modification/cardiovascular/heart disease prevention, 8–10, 1246–1247, 1248, 1253–1254, 1255t. *See also* Lipid-lowering therapy
- acute coronary syndromes and, 364
- heart failure and, 405
- in HIV infection/AIDS, 1344
- hypertension and, 443–444
- in nephrotic syndrome/nephrotic spectrum disorders, 928
- in older patients, 1251–1252
- perioperative, 47–48
- rhabdomyolysis/myopathy/myositis caused by, 842, 844, 1254
- Statoconia, detached, vertigo associated with, 211
- Status epilepticus, 970, 970t, 974, 975
- alcohol withdrawal and, 974
- in antidepressant overdose, 1591
- drug noncompliance and, 974
- nonconvulsive, 975
- in theophylline overdose, 1591
- tonic-clonic, 970, 974
- Statutory rape, 777
- Stauffer syndrome, 1641
- Stavudine (d4T), 1341t, 1343, 1347, 1348f. *See also* Antiretroviral therapy/HAART
- neuropathy caused by, 1328, 1343
- resistance to, 1349
- STDs. *See* Sexually transmitted diseases
- Steatohepatitis, nonalcoholic (NASH), 684, 685
- Steatorrhea, 621t. *See also* Malabsorption
- in hyperoxaluric calcium nephrolithiasis, 949
- in pancreatitis, 716
- Steatosis, hepatic. *See* Fatty liver
- STEC. *See* Shiga-toxin producing *E coli*
- Stein-Leventhal syndrome. *See* Polycystic ovary syndrome
- Stelara. *See* Ustekinumab
- Stelazine. *See* Trifluoperazine
- Stellwag sign, 1112
- Stem cell disorders
- aplastic anemia, **508–509**, 508t
- leukemias/myeloproliferative neoplasms, **511–524**, 511t
- paroxysmal nocturnal hemoglobinuria, **501–502**
- Stem cell transplantation, **532–534**. *See also* Bone marrow/stem cell transplantation
- STEMI. *See also* Myocardial infarction
- Steno-2 study, 1203–1204
- Stenson duct
- calculus formation in, 232
- in mumps, 1370
- Stent thrombosis, 363
- Stents/stent grafts (“covered stents”). *See also* Endovascular surgery/prostheses
- for abdominal aortic aneurysm, 473
- for angina, 357–358
- aortic valve replacement and, 343–344
- for aortoiliac occlusive disease, 465
- for biliary stricture, 708–709
- carotid, 470
- for cholangiocarcinoma, 1607
- for choledocholithiasis/cholangitis, 707
- for coarctation of aorta, 327
- for esophageal cancer, 1614
- for femoral/popliteal occlusive disease, 466
- for hepatic vein obstruction (Budd-Chiari syndrome), 698
- intracoronary, 357–358, 367–368. *See also* Percutaneous coronary intervention
- subsequent perioperative risks/management and, 48–49
- for myocardial infarction, 367–368
- antithrombotic therapy and, 363, 371
- for pancreatic duct disease, 717
- for pancreatic/periampullary carcinoma, 1609
- for primary sclerosing cholangitis, 710
- for renal artery stenosis/renal vascular hypertension, 437, 917–918
- for superior vena caval obstruction, 482
- ureteral, after shock wave lithotripsy, 950
- for visceral artery insufficiency/intestinal angina, 471
- Stereotactic guided core needle biopsies, in breast cancer, 729
- Stereotactic radiosurgery. *See also* Cyberknife radiosurgery; Gamma knife radiation/gamma radiosurgery
- for intracranial arteriovenous malformations, 988
- for lung cancer, 1599
- for pituitary adenoma, 1102, 1104, 1160

- Stereotypy, stimulant abuse and, 1055
 Sterile pyuria, in tuberculosis, 936
 Sterility. *See* Infertility
 Sterilization, for birth control, 777
 Steroid acne/folliculitis, 126, 129
 Steroid rosacea, 100, 128
 Steroidogenic enzyme defects
 amenorrhea and, 1179
 hirsutism/virilization and, 1156, 1162
 Steroids. *See* Anabolic steroids;
 Corticosteroids
 Stevens-Johnson syndrome, 134, 135
 drugs causing, 134, 135, 159*t*, 161
 herpes simplex infection causing, 1351, 1355
 Stevens-Johnson syndrome/toxic
 epidermal necrolysis overlap,
 134, 135, 159*t*
 drugs causing, 134, 135, 159*t*, 161
 sTfR. *See* Transferrin receptor, soluble
 STI571. *See* Imatinib
 Stibogluconate (antimony), for
 leishmaniasis, 1488–1489
 Stiff knee gait, in ACL injury, 1693
 Stiff man syndrome, 1596*t*
 Stiffness
 in ankylosing spondylitis, 855
 in fibromyalgia, 823
 in myotonic dystrophy/myotonia
 congenita, 1034, 1036
 in osteoarthritis, 810
 in parkinsonism, 998
 in polymyalgia rheumatica, 845
 in rheumatoid arthritis, 826
 Still disease, **831**
 Stimson procedure, for dislocated
 shoulder, 1681–1682
 Stimulant laxatives, 571, 572*t*
 Stimulants
 abuse of, **1085–1086**
 aggressive/violent/psychotic
 behavior and, 1078
 kindling and, 1079, 1085
 OTC medications and, 1086
 for depression, 1066–1067
 for narcolepsy, 1077
 Stings. *See* Insect bites/stings
 Stippling (nail), 157
 in psoriasis, 106, 106*f*, 856
 in reactive arthritis, 857
STK11/LKB1 mutation, pancreatic/
 periampullary carcinoma
 and, 1608
 Stomach disorders, **607–621**. *See also*
under Gastric and
Gastrointestinal and Gastritis
 in syphilis, 1471
 tumors
 benign, **620–621**
 GI bleeding and, 581
 malignant, 1612*t*. *See also* Gastric
 cancer
 gastric adenocarcinoma,
1615–1618
 gastric carcinoids, **1619**, 1621
 gastric lymphoma, **1618–1619**
 mesenchymal, **1619–1620**
 Stomatitis
 herpetic, **227**
 ulcerative (aphthous ulcers), **227**, 227*f*
 in Behçet syndrome, 853
 in Crohn disease, 641
 in HIV infection/AIDS, 1329
 Stool. *See also* Stool analysis
 blood in. *See* Diarrhea, bloody;
 Dysentery; Fecal occult
 blood testing
 fat in. *See* Fecal fat
 impacted. *See* Fecal impaction
 incontinence of, **659–660**. *See also*
 Fecal incontinence
 leukocytes in. *See* Fecal leukocytes
 rice water, in cholera, 1448
 Stool analysis
 in amebiasis, 576, 1503–1504
 in antibiotic-associated colitis, 637
 in ascariasis, 1517
 in bacterial overgrowth, 625
 in clonorchiasis and opisthorchiasis,
 1513
 in colorectal cancer screening/polyp
 detection, 15*t*, 16, 1627
 in Crohn disease, 642
 in cryptosporidiosis, 576, 579, 1330,
 1507–1508
 in cyclosporiasis, 576, 579, 1508
 in diarrhea, 575, 576, 576*f*, 578, 579*f*,
 1293, 1296
 in fascioliasis, 1512
 in giardiasis, 576, 579, 1509
 in hookworm disease, 1518
 in intestinal flagellate infection, 1510
 in intestinal fluke infection, 1514
 in irritable bowel syndrome, 634
 in isosporiasis, 1508
 in microsporidiosis, 1508
 for ova and parasites, 576, 576*f*, 579.
See also specific disorder
 in paragonimiasis, 1513
 in protein-losing enteropathy, 632
 in sarcocystosis, 1508
 in schistosomiasis, 1511–1512
 in strongyloidiasis, 1519
 in tapeworm infections, 1514
 in trichuriasis/whipworm, 1518
 Stool antigen assay
 for *E histolytica*, 576, 579, 1504
 for *Giardia*, 576, 579, 1509
 Stool impaction. *See* Fecal impaction
 Stool softeners/surfactants, 86, 572*t*
 Stool weight, in diarrhea evaluation,
 579–580, 579*f*
 STOP questionnaire, 50
 Storage pool disease, 548
 albinism-associated, 548
 Straight leg raising test, 820, 1683, 1684*t*
 “Strain” pattern, in hypertension, 440
 Strains (musculotendinous), cervical,
 acute, 817–818
 Strawberry gallbladder, 705
 Strawberry tongue
 in Kawasaki disease, 1417
 in scarlet fever, 1419
 Strep throat. *See* Pharyngitis,
 streptococcal
 Streptobacillary fever, rat-bite fever
 differentiated from, 1476
Streptobacillus moniliformis, 1476
Streptococcus (streptococcal infections),
 1299*t*, **1419–1425**
bovis, endocarditis caused by, 1422,
 1438
 cellulitis, 136–138, 1303*t*, 1421*t*
 endocarditis, 1302*t*, 1421, 1422, 1423,
 1435, 1437–1438, 1438
 eruptive (guttate) psoriasis after, 106
 erysipelas, **136**, 137*f*, 1303*t*, 1420–1421,
 1421*t*
 glomerulonephritis after, 919*t*, 922,
 1419
 group A. *See* Group A β -hemolytic
 streptococcal infection
 group B. *See* Group B streptococcal
 infection
 impetigo, 123, 1303*t*, 1420
 non-group A, **1422**
 pharyngitis. *See* Pharyngitis,
 streptococcal
 pneumonia, 271, 272–273, 274, 276,
 1302*t*, 1303*t*, 1421,
1422–1424
pneumoniae (pneumococcal
 infections), 1299*t*, 1302*t*,
1422–1425. *See also*
Pneumococcal (Streptococcus
pneumoniae) infections
 drug resistance and, 228, 273,
 273–274, 1423, 1424
 in pregnancy, 784–785, 804
pyogenes. *See* Group A β -hemolytic
 streptococcal infection
 rheumatic fever and, 229, 417, 418
 of skin, **1420–1422**, 1421*t*
 toxic shock syndrome caused by,
 1421–1422
 viridans, 1299*t*, 1422
 endocarditis caused by, 1302*t*, 1422,
 1435, 1437–1438
Streptococcus thermophilus probiotic, for
 antibiotic-associated colitis,
 636
 Streptokinase, 369*t*. *See also*
 Thrombolytic therapy
 for myocardial infarction, 369, 369*t*
 for pulmonary embolism, 303
 Streptomycin, 284*t*, 289*t*. *See also*
 Aminoglycosides
 for actinomycetoma, 1540
 adverse ophthalmic effects of, 197*t*
 for endocarditis, 1438
 for tuberculosis, 284*t*, 285, 289*t*
 contraindications to in pregnancy,
 285, 805
 Streptozocin, for insulinoma, 1241
 Stress cardiomyopathy. *See* Tako-Tsubo
 (stress/catecholamine-
 induced) cardiomyopathy
 Stress disorders (psychiatric/psychologic),
1038–1039
 depression and, 1063
 irritable bowel syndrome and, 633
 posttraumatic, **1039–1040**
 abuse victims and, 1039
 rape and, 778
 suicide and, 1064
 Stress fractures. *See* Pathologic fractures
 Stress gastritis/ulcers, 321, 607, 608
 Stress incontinence, 68, 69
 Stress reduction techniques, 1038
 for chronic pain, 1048

- Stress testing. *See also* Exercise testing
in angina/chest pain evaluation, 29,
352–353
echocardiography, 46, 353, 400
electrocardiography, 12, 352–353
before exercise program initiation, 12
in heart failure, 400
in musculoskeletal evaluation, 1673
ankle sprains and, 1703, 1703*t*
perfusion scintigraphy, 353
postinfarction, 375
preoperative, 46–47, 48*f*
radionuclide angiography, 353
in syncope evaluation, 397
- Striae distensae, 1160
- Striant, 1176. *See also* Testosterone
replacement therapy
- Stridor, 233
recurrent respiratory papillomatosis
causing, 234
vocal fold paralysis causing, 238
- Stroke, 979–989, 980*t*
arteriovenous malformations causing,
980*t*, 987–988
atrial fibrillation and, 385, 385*t*, 469
anticoagulation in management/
prevention of, 385*t*, 386–387,
388
atrial flutter and, 389
carotid intervention causing, 469–470
carotid occlusion causing, 469–470,
980*t*
cerebral infarct causing, 980*t*, 981–983
cerebrovascular occlusive disease
causing, 469–470, 981–983
coma caused by, 981, 982, 1014
in diabetic patient, 1232*t*
coxibs (COX-2 inhibitors) associated
with, 612
in endocarditis, 1435
estrogen replacement therapy and, 780,
1182, 1183
hemorrhagic, 979, 980*t*, 983–988
hypertension/hypertension
management and, 10–11,
433, 439, 440, 442*t*, 457
in emergencies/urgencies, 460–461,
461*t*
in women, 1706
hypopituitarism associated with, 1093
intracerebral hemorrhage causing,
980*t*, 983–984
intracranial aneurysm causing, 980*t*, 986
intracranial venous thrombosis
causing, 988
ischemic (infarcts), 979, 979–983, 980*t*
lacunar infarct causing, 979–981, 980*t*
olanzapine use and, 1057
oral contraceptive use and, 770
patent foramen ovale and, 329
postoperative, 53–54
prevention of, 5–11, 7*t*
carotid intervention in, 469
chemoprevention/aspirin use and,
7*t*, 11
cholesterol screening and, 7*t*, 8–10
exercise/activity in, 7*t*, 12–13
hypertension prevention/
management and, 7*t*, 10–11,
442*t*, 457
in women, 1706
lipid disorder prevention/
management and, 7*t*, 8–10.
See also Lipid-lowering
therapy
smoking/smoking cessation and,
6–8, 7*t*, 9–10*t*, 10*t*
risk factors for, 5–6, 979
spinal cord vascular disease causing,
988–989
subarachnoid hemorrhage causing,
980*t*, 984–986
transient ischemic attacks and, 469,
470, 977, 977–978
varicella zoster virus infection and,
1359
vertebrobasilar occlusion causing, 980*t*,
981
- Stroke (heat), 1548–1549
- Stroke volume, in aortic regurgitation,
344–345
- Stroke work index, in myocardial
infarction, 367*t*
- Stromal tumors (gastrointestinal stromal
tumor/GIST), 1619–1620,
1622
- Strongyloides fulleborni/stercoralis*
(strongyloidiasis), 578,
1518–1519
- eosinophilic pulmonary syndromes
and, 296
- Strontium, for metastatic bone pain,
1658*t*
- Struma ovarii, 1111, 1114
- Struvite urinary stones, 946, 947, 949
- Strychnine poisoning, seizures caused by,
1565*t*
- Study to Understand Prognoses and
Preferences for Outcomes
and Risks of Treatment
(SUPPORT), prognosis at
end of life and, 87
- Stunning, myocardial, 351
- Stupor, 1013–1016. *See also* Coma
- Sturge-Weber syndrome, 997
- Sty (external hordeolum), 163, 163*f*
- Subacromial impingement syndrome,
1674–1675, 1678–1679*t*
- Subacute cerebellar degeneration/
syndrome. *See* Cerebellar
degeneration
- Subacute combined degeneration of
spinal cord, 1013
- Subacute cutaneous lupus erythematosus
(SCLE), 114–115
- Subacute mountain sickness, 1559
- Subacute sclerosing panencephalitis, 1368
myoclonus in, 1004
- Subacute (de Quervain) thyroiditis, 1111,
1113, 1114, 1117, 1120, 1121,
1122
hypothyroid phase in, 1106, 1111, 1121
- Subarachnoid hemorrhage, 980*t*, 984–
986. *See also* Stroke
arteriovenous malformations/fistulae
causing
intracranial, 984, 985, 987
spinal, 989
head injury and, 984, 1014
headache in, 41, 42, 962, 966, 984
- hypopituitarism associated with, 1093
intracranial aneurysms causing, 984,
985, 986
oral contraceptive use and, 770
- Subareolar abscess, 721, 721*f*
- Subclavian steal syndrome, 977
- Subclavian vessels, compression of in
thoracic outlet/cervical rib
syndromes, 818, 1031
- Subclinical hyperthyroidism, 1113, 1119
- Subclinical hypothyroidism, 800, 1107
- Subclinical thyroiditis, 1120
- Subcutaneous insulin infusion,
continuous, 1217, 1219. *See
also* Insulin infusion pumps
- Subcutaneous nodules
in cysticercosis, 1515
in erythema nodosum, 150
in gnathostomiasis, 1523
in loiasis, 1527
in nocardiosis, 1457
in onchocerciasis, 1526
in polyarteritis nodosa, 150, 847
in rheumatic fever, 418
in rheumatoid arthritis, 827, 827*f*
gouty tophi differentiated from, 814,
828
in sporotrichosis, 1539
- Subcutaneous sensor, for glucose
monitoring system, 1200
- Subdural hemorrhage/hematoma
cerebral
acute, 1017*t*
chronic, 1017
falls in elderly and, 66
spinal, 989
- Suberosis, 309*t*
- Subglottic stenosis, 242
- Sublingual glands. *See* Salivary glands
- Submandibular glands. *See also* Salivary
glands
sialadenitis affecting, 232
tumors of, 233
- Submersion injury (near drowning),
1555–1557
- Subscapularis tendon
management of injuries of, 1680
testing strength of, 1678*t*, 1680
- Substance use disorders, 18–20, 1079–
1086. *See also specific
substance used and Injection
drug use*
aggressive/violent behavior and, 1078
atypical psychoses and, 1054, 1055
cognitive disorders/delirium caused by
withdrawal and, 1087*t*
concerns about, pain management in
terminally ill/dying patient
and, 76
febrile patient and, 1292–1293
hallucinations/hallucinosis caused by,
1088
HIV infection/AIDS and, 1292, 1321
prevention/postexposure
prophylaxis and, 1333, 1335
infections and, 1292–1293. *See also
Injection drug use, infections
and*
overdoses. *See* Poisoning/drug overdose
pregnancy and, 783

- Substance use disorders (*Cont.*):
 preventable disease/deaths and, 3*t*
 prevention of injury related to, 17
 prevention of/screening tests for, 18–20, 19*t*, 20*t*
 PTSD and, 1039, 1040, 1079
 schizophrenic/psychotic disorder self-treatment and, 1054–1055
 seizures and, 969
 toxicology screen in, 1569–1570, 1569*f*
- Subtalar tilt test, 1703, 1704*t*
- Subtentorial lesions. *See also* Brainstem
 coma or stupor caused by, 1014, 1015
- Subungual capillary pulsations (Quincke pulses), 344
- Succimer (DMSA)
 for arsenic poisoning, 1575
 for lead poisoning, 1582
 for mercury poisoning, 1583
- Succinylcholine
 lithium interactions and, 1074*t*
 MAOI interactions and, 1071*t*
- Succussion splash, in gastric outlet obstruction, 619
- Sucralfate
 reduction of ventilator-associated pneumonia and, 276
 for stress gastritis, 321, 608
- Sucralose, for diabetics, 1205
- Sudden death, 365, 392–393
 aborted, driving recommendations and, 397–398
 of athlete, 431–432
 cardiomyopathy causing, 414, 431, 432
 cardiomyopathy and, 414, 415, 431, 432
 myocardial infarction and, 365, 392
 ventricular fibrillation causing, 392–393
 ventricular premature beats and, 390
 ventricular tachycardia and, 391, 392
- Sudeck atrophy, 825
- Sugar alcohols, for diabetics, 1205
- Suicide, 1064–1065
 acetaminophen overdose/liver failure and, 672
 alcohol use/abuse and, 1064, 1080
 antidepressant overdose in, 1065, 1067, 1591
 carbon monoxide poisoning and, 1576
 caustic esophageal injury and, 599
 depression associated with
 hospitalization/illness and, 1064, 1091
 dispensing medications and, 1065, 1067
 in elderly, 63
 hospitalization for patient threatening, 1064–1065
 panic disorder and, 1064
 personality disorders and, 1052
 poisoning/overdose and, 1562
 schizophrenia/psychotic disorders and, 1054, 1056, 1060, 1064
- Sular. *See* Nisoldipine
- Sulconazole, 97*t*
- Sulfacetamide, for ophthalmic disorders, 168*t*
- Sulfadiazine, for toxoplasmosis, 1338*t*, 1502
- Sulfadoxine, with pyrimethamine (Fansidar), 1492*t*, 1493, 1496
 with amodiaquine, 1496
 with artesunate, 1493*t*, 1496
 for isosporiasis, 1508
 for prophylaxis in pregnancy/infants, 1498
 resistance to, 1493, 1496
- Sulfamethoxazole-trimethoprim. *See* Trimethoprim-sulfamethoxazole
- Sulfasalazine
 for ankylosing spondylitis, 855
 for inflammatory bowel disease, 638, 639
 ulcerative colitis, 647–648, 649
 for rheumatoid arthritis, 829–830
- Sulfapyrazone, for gout, 815
- Sulfonamides, adverse ophthalmic effects of, 197*t*
- Sulfonylureas, 1205–1208, 1206*t*, 1220.
See also specific agent
 factitious hypoglycemia and, 1239, 1243
 hypoglycemia caused by, 1207, 1221–1222, 1580
 intensive therapy with, 1202, 1203
 MAOI interactions and, 1071*t*
 overdose/toxicity of, 1207, 1566*t*, 1580
- Sulfur-sodium sulfacetamide, for rosacea, 129
- Sulindac, 78*t*
 for familial adenomatous polyposis, 655
 in pain management, 78*t*
- Sumatriptan
 for cluster headache, 965
 for migraine headache, 42, 963
- Sumatriptan-naproxen, for migraine headache, 42
- Summer gripe, 1406
- Sun exposure. *See* Ultraviolet light/sunlight, exposure to
- Sunday neuroses, 1040
- “Sundowning,” 1088
- Sunitinib, 1655*t*
 for gastrointestinal mesenchymal tumors, 1620
 for thyroid carcinoma, 1130
 thyroid dysfunction caused by, 1106, 1111
- Sunscreens, 99. *See also* Ultraviolet light/sunlight
 in herpes simplex prophylaxis, 118, 1352
 for hyperpigmentation disorders, 156
 for lupus/SLE, 114, 834
 for photodermatitis/photosensitivity, 153
 for rosacea, 128
- Superficial femoral artery (SFA), atherosclerotic/occlusive disease of, 465–466
- Superficial reflux
 in chronic venous insufficiency, 480, 481
 in varicose veins, 478, 479
- Superficial spreading melanoma, 102
- Superficial venous thrombophlebitis, 479–480
- Superior semicircular canal dehiscence, vertigo and, 212
- Superior vena caval obstruction/syndrome, 482–483
 in lung cancer, 482, 1597
- Superwarfarins, poisoning caused by, 1573
- Supplements, dietary. *See* Dietary supplements
- SUPPORT, prognosis at end of life and, 87
- Support groups. *See also* Group therapy for alcohol use/abuse, 1082
 for Alzheimer’s disease/dementia, 61
 for anxiety disorders, 1044
 for chronic pain, 1049
 for depression, 1072
 grief, 93
 for inflammatory bowel disease, 641
 in obesity management, 14, 1260
 for paraphilias and gender identity disorders, 1051
 for personality disorders, 1052
 for schizophrenia/psychotic disorders, 1061
 for smoking cessation, 8
 for somatoform disorders, 1047
 for victim of violence, 1079
- Suppurative sialadenitis, 232
- Suppurative thyroiditis, 1120, 1121, 1122
- Supraclavicular lymph nodes, in breast cancer, 726, 727
 palpation for evaluation of, 726
- Supraglottic carcinoma, 236, 237
- Supraglottitis (epiglottitis), 235, 1420
Haemophilus causing, 235, 1442
- Supranuclear palsy, progressive, parkinsonism differentiated from, 998
- Supraspinatus tendon
 testing strength of, 1675–1680, 1677*t*
 torn, 1675
- Supratentorial arteriovenous malformations, 987
- Supratentorial mass lesion, coma or stupor caused by, 1014–1015
- Supraventricular beats
 aberrantly conducted, differentiation of from ventricular beats, 381, 391
 premature. *See* Atrial (supraventricular) premature beats
- Supraventricular tachycardia
 accessory atrioventricular pathways causing, 381, 383–384
 bradyarrhythmias and, 394
 in myocardial infarction, 372, 376
 palpitations in, 31
 paroxysmal, 381–383
 preoperative evaluation/perioperative management of, 49
 treatment/prevention of, 378–379*t*, 382–383, 383–384
- Suramin, for African trypanosomiasis, 1485, 1485*t*
- Surfer’s ear, 201
- Surgery. *See also specific disorder or procedure*
 antibiotic prophylaxis and, 55–56

- anxiety before/after, 1090
 cardiac complications of
 preoperative risk assessment/
 reduction and, **46–50**, 47t,
 48f, 48t, 429, 430f
 prosthetic heart valve patients and,
 349
 in cardiac patient, **429**, 430f
 corticosteroid replacement
 requirement and, 54
 in diabetic patient, 54, 54t, 1229, 1229t
 evaluation of patient before, **46–56**. *See also* Preoperative evaluation/
 perioperative management
 fever after, 1283
 hyponatremia after, 872
 ileus after, 627
 insulin needs and, 54, 1215, 1229,
 1229t
 liver function and, 51
 patient management and, **46–56**. *See also* Preoperative evaluation/
 perioperative management
 during pregnancy, **807–808**
 for refractive error correction, **162–163**
 thyroid function tests affected by, 1107
 for wart removal, 140
 Surgery proneness (polysurgery), 1090
 somatization disorder and, 1045
 Surgical menopause. *See* Menopause/
 menopausal syndrome,
 surgical
 Surgical site infection, 55, 1283, 1284
 antibiotic prophylaxis of, **55–56**
 in diabetic patients, 54
 Surmontil. *See* Trimipramine
 Surrogate, Durable Power of Attorney for
 Health Care, 89
 Surveillance. *See* Watchful waiting/
 surveillance
 Survival motor neuron (SMN) gene, in
 spinal muscular atrophies,
 1020
 Susceptibility testing. *See* Drug resistance;
 Drug susceptibility testing
 Succinate dehydrogenase (SDH)
 mutations, in
 pheochromocytoma/
 paraganglioma, 1167, 1168,
 1171
 Sushi. *See* Fish
 Sustained ventricular tachycardia, 391
 Sustiva. *See* Efavirenz
 Sutent. *See* Sunitinib
 Swallowing disorders. *See* Dysarthria;
 Dysphagia; Odynophagia
 Swan-neck deformity, 831, 833
 Sweat chloride test, in cystic fibrosis,
 267–268
 Sweating
 fluid loss in, replacement guidelines
 for, 897t
 in myocardial infarction, 365
 in pheochromocytoma, 1167
 Sweet 'N Low. *See* Saccharin
 Sweet One. *See* Acesulfame potassium
 Sweeteners, artificial, for diabetics, 1205
 SWI. *See* Stroke work index
 Swimmer's ear, 200
 Swimmer's itch, 1511
 Swimming pool granuloma, 1458
 Swimming pool safety, 1556
 Swine/swine-origin (H1N1) influenza,
 23, 214, 1395, 1396, **1399–**
1400. *See also* Influenza
 drug resistance and, 1396, 1399
 prevention of, 1400. *See also* H1N1
 influenza vaccine
 SWL. *See* Shock wave lithotripsy
 Sycosis, **129–130**
 Sydenham chorea, 418, 1002
 Symblepharon, 194
 Symlin. *See* Pramlintide
 Sympathectomy, for Raynaud
 phenomenon, 838
 Sympathetic nervous system, in
 hypertension, 435
 peripheral inhibitors in management
 of, 453–457, 456t
 Sympatho-adrenal response, impaired,
 hypoglycemia and, 1222
 Sympatholytic agents, 456t
 for alcohol detoxification/withdrawal,
 18
 for hypertension, 453, 456t
 in urgencies/emergencies, 462t
 overdose/toxicity of, 456t, **1577**
 Sympatholytic syndrome, 1568
 Sympathomimetic agents
 adverse ophthalmic effects of, 195t
 antidepressant drug interactions and,
 1071t
 for glaucoma/ocular hypertension,
 170–171t
 MAOI interactions and, 1071t, 1585
 Sympathomimetic effects/syndrome,
 1568
 MAOIs causing, 1069
 Symptom evaluation/management,
21–45. *See also specific*
symptom
 Symptothermal natural family planning,
 775
 Synaptobrevin, in tetanus, 1429
 Synchronized intermittent mandatory
 ventilation (SIMV), for
 respiratory failure, 321
 Syncope/near syncope, **396–397**
 in aortic stenosis, 342, 396
 cardiogenic, 396
 in cardiomyopathy, 414
 driving recommendations and, **397–**
398
 dysautonomia and, 975, 976
 heat, **1547**
 palpitations and, 31
 seizures differentiated from, 971
 stress-induced, anomalous coronary
 artery and, 432
 vasodepressor/vasovagal, 396
 Syndrome of apparent mineralocorticoid
 excess
 genetic mutation in, 437, 878t
 hypertension and, 437
 Syndrome of inappropriate ADH
 secretion (SIADH), 871f,
 873, 873t, 874, 875
 antipsychotic drug use and, 1059
 cancer-related, 873, 873t,
 1596t, 1597
 Syndrome X. *See* Metabolic syndrome
 Synechia, posterior, in uveitis, 178
 Synercid. *See* Quinupristin/dalfopristin
 Synergistic necrotizing cellulitis, 1456
 Syngeneic stem cell transplant, 533
 Synovial fluid examination, 809, 810t,
 811t, 1674
 in gonococcal arthritis, 860
 in gout/pseudogout, 814, 817, 1674
 in Lyme arthritis, 1479
 in nongonococcal acute bacterial
 (septic) arthritis, 859
 in rheumatoid arthritis, 827
 in sarcoid arthritis, 864
 in tuberculous arthritis, 864
 Synovitis
 remitting seronegative, with non-
 pitting edema, 864
 in rheumatoid arthritis, 826
 in SLE, 833
 Sympatholytic hematuria, 922
 Synthroid. *See* Levothyroxine
 Syphilis, 1300t, 1304t, **1464–1474**, 1465t
 anoctal involvement and, 658–659,
 1465, 1469, 1469f
 aortic aneurysms and, 474, 1471, 1471f
 cardiovascular involvement and, 1304t,
 1464, 1471, 1471f
 cerebrospinal fluid examination in,
 1469, 1472, 1472–1473, 1473
 in HIV infection/AIDS, 1335, 1468,
 1473
 indications for, 1472–1473
 treatment failures and, 1468, 1473
 congenital, 806, 1464, **1474**
 penicillin treatment in maternal
 disease and, 1474
 contact treatment and, 1468
 course/prognosis of, **1464**
 drug therapy for, 1304t, 1467–1468,
 1468t. *See also* Syphilis,
 penicillin for
 HIV infection/AIDS and, 1335,
 1468, 1473, 1473–1474
 Jarisch-Herxheimer reaction and,
 1467
 for neurosyphilis, 1304t, 1467, 1468t,
 1473
 serologic tests in evaluation of, 1466,
 1468
 early, 1304t, 1464, 1468t
 endemic, **1475**
 follow-up care in, 1468
 gummatous, 1464, 1471, 1471f
 HIV infection/AIDS and, 1334–1335,
 1465, 1467–1468, 1468,
 1473–1474
 late (tertiary), 1304t, 1464, 1465t,
 1468t, **1470–1472**, 1471f
 latent, 1304t, 1464, **1470**
 early, 1304t, 1464, 1468t, 1470
 late (hidden), 1304t, 1468t, 1470
 meningovascular/meningitis, 1286,
 1469, 1472. *See also*
 Neurosyphilis
 microscopic examination in,
 1465–1466
 mucous membrane involvement in,
 1467, 1469, 1469f
 natural history of, **1464**, 1465t

- Syphilis (*Cont.*):
 neurologic involvement in, 1304*t*, 1464, 1472–1473, 1472*f*. *See also* Neurosyphilis
 PCR testing in, 1467
 penicillin for, 1304*t*, 1467, 1468*t*
 HIV infection/AIDS and, 1335, 1473
 neurosyphilis and, 1304*t*, 1467, 1468*t*, 1473
 pregnancy and, 1467, 1474
 pregnancy and, 784, **806**, 1467, **1474**
 prevention of/screening for. *See also* Syphilis, serologic tests for
 in HIV infection/AIDS, 1334–1335, 1473
 in pregnancy, 784, 806, 1467, 1474
 primary, 1304*t*, **1464–1468**, 1465*f*, 1465*t*, 1466*t*, 1468*t*
 public health measures in management of, 1467–1468
 rape/sexual assault in transmission of, 778, 1291
 screening blood for, 536
 secondary, 1304*t*, 1465*t*, 1468*t*, **1469–1470**, 1469*f*, 1470*f*
 pityriasis rosea differentiated from, 108–109
 serologic tests for, 1466–1467, 1466*t*.
 See also specific test
 false-negative, 1466
 false-positive, 1466
 anticardiolipin/antiphospholipid antibody/lupus anticoagulant causing, 833, 836
 in SLE, 833, 834*t*
 follow-up, 1468
 HIV infection/AIDS and, 1334–1335, 1468, 1473
 in neurosyphilis, 1472–1473, 1473
 non-sexually transmitted
 treponematoses and, 1466
 pityriasis rosea differential diagnosis and, 108–109
 in pregnant patient, 784, 806, 1467, 1474
 in STD patients, 1291
 treatment failures and, 1468, 1473
 uveitis in, 178, 1469
 Syringobulbia, 1019
 Syringomyelia, **1018–1019**
 Syrup of ipecac, for poisoning/drug overdose, 1566
 Systemic fibrosing syndrome, Dupuytren contracture and, 824
 Systemic fibrosis, nephrogenic, **937**
 Systemic hypertension. *See* Hypertension
 Systemic inflammatory response syndrome (SIRS)
 pancreatitis and, 713, 715
 shock and, 485
 Systemic lupus erythematosus (SLE), **831–835**, 832*t*, 833*t*, 834*t*
 arthritis in, 833
 rheumatoid arthritis differentiated from, 828
 autoantibodies in, 832, 833–834, 833*t*
 cardiac/pericardial involvement in, 427, 833, 835
 criteria for, 832, 832*t*
 cutaneous lesions and, **114–115**, 832–833
 DHEA for, 834
 drugs associated with, 159*t*, 312*t*, 832, 832*t*
 lupus anticoagulant/antiphospholipid antibody syndrome and, 833–834, 834*t*
 mixed connective tissue disease/overlap syndrome and, 842
 renal involvement in, 833, 834, 835, 919*t*, 921*f*, **926–927**
 Systemic sclerosis, **838–840**. *See also* Scleroderma
 Systolic blood pressure, 434*t*. *See also* Blood pressure
 cardiovascular/heart disease risk and, 10, 433, 1249*t*
 in GI bleeding, 581
 in hypertension, 433, 434*t*, 435*f*
 treatment goals and, 443
 in hypertensive urgencies/emergencies, 460
 in hypotension/shock, 486
 in preeclampsia-eclampsia, 793, 793*t*, 795
 in prehypertension, 434, 434*t*, 441
 Systolic dysfunction. *See* Congestive heart (cardiac) failure
 Systolic murmurs. *See* Heart murmurs
 T₃. *See* Triiodothyronine
 T₄. *See* Thyroxine
 T315I mutation, in chronic myeloid leukemia, 516–517
 T cell lymphoma, 524, 524*t*, 525
 adult (ATL), 1383–1384. *See also* Human T cell lymphotropic/leukemia virus
 in celiac disease, 623
 cutaneous (mycosis fungoides), **115–116**
 exfoliative dermatitis/erythroderma and, 116
 Epstein-Barr virus and, 1363
 intestinal, 1620
 nose and paranasal sinus involvement and, 223
 tacrolimus/pimecrolimus associated with, 104
 T cell-mediated (delayed/type IV)
 hypersensitivity, 866
 T cell proliferative assay, in Lyme disease, 1480
 T cell tolerance genes, in type 1 diabetes, 1193
 T-DM1, for breast cancer, 741
 T helper cells. *See* CD4 T cells
 T lymphocytes
 in common variable
 immunodeficiency, 869
 in delayed hypersensitivity, 866
 in HIV infection/AIDS. *See* CD4 T cells
 t-PA. *See* Tissue plasminogen activator
 T pallidum hemagglutination (TPHA) test, 1466
 T pallidum particle agglutination (TPPA) test, 1466, 1466*t*
 T score, 1145–1146, 1710
 T tube, for choledocholithiasis/choolangitis, 707
 T waves. *See also* Electrocardiogram
 in acute coronary syndromes/STEMI, 366
 in angina, 352
 antipsychotic drugs affecting, 1059
 lithium affecting, 1073, 1582
 in pericardial effusion, 421
 in pericarditis, 420
 uremic, 912
 in Tako-Tsubo cardiomyopathy, 413
 Tabes dorsalis, 1472
 neurogenic arthropathy (Charcot joint) in, 865, 1472, 1472*f*
 Tabun (GA) poisoning, 1587
 TAC regimen, for breast cancer, 737
 TACE. *See* Transarterial chemoembolization
 Tâche noire, in tick typhus, 1414
 “Tachy-brady syndrome,” 394
 Tachycardia/tachyarrhythmia, 380–381
 antidromic reentrant, 383
 atrial, multifocal, **389**
 AV nodal reentrant (AVNRT), 381
 palpitations in, 31
 AV reentrant (AVRT), 381, 383
 cardiomyopathy and, 391, 411, 412
 in hyperthyroidism, 1112, 1118
 nonparoxysmal junctional, 390
 orthodromic reentrant, 383
 in pheochromocytoma, 1166, 1167, 1169
 in poisoning/drug overdose, 1564*t*
 sinus. *See* Sinus tachycardia
 in sleep apnea, 319
 supraventricular
 accessory atrioventricular pathways causing, 381, **383–384**
 in myocardial infarction, 372, 376
 palpitations in, 31
 paroxysmal, **381–383**
 preoperative evaluation/
 perioperative management of, 49
 treatment of, 378–379*t*, 382
 ventricular, 390–392. *See also* Ventricular tachycardia
 in myocardial infarction, 365, 373
 in poisoning/drug overdose, 1564, 1564*t*
 preoperative evaluation/perioperative management of, 49
 treatment of, 378–379*t*, 391–392
 Tachypnea, in pulmonary embolism, 298
 TACI. *See* Transarterial chemoembolization
 Tacrolimus, 1724*t*
 adverse ophthalmic effects of, 196*t*
 hyperkalemia caused by, 879–880
 topical, 97*t*
 for atopic dermatitis, 104
 for Crohn disease, 642
 for lichen planus, 144
 T cell lymphoma and, 104
 TACSTD1 mutation, in HNPCC, 656
 Tadalafil
 for benign prostatic hyperplasia, 959*t*, 960
 for erectile dysfunction, 952, 1051
 antidepressant-induced, 1051, 1067
 in diabetes, 1226
 nitrate/nitroglycerin contraindications and, 370, 952, 1051, 1226

- Taenia*
saginata (beef tapeworm), 1514
solium (pork tapeworm), 1514
 cysticercosis and, 1514, 1515
- Tafeluprost, for glaucoma/ocular hypertension, 171*t*, 176
- Takayasu disease, 428
- Tako-Tsubo (stress/catecholamine-induced) cardiomyopathy/LV apical ballooning, 411, 413
 myocardial infarction mimicked by, 365
 pheochromocytoma and, 1169, 1170
- Talc, for pleurodesis for malignant effusions, 1646
- Talcosis (talc exposure), 309*t*, 311
- Tall stature
 GH excess causing, 1100. *See also* Gigantism
 in Klinefelter syndrome, 1174, 1669
 in Marfan syndrome, 1670
- Talofibular ligament, ankle sprains involving, 1703, 1704
- Tamm-Horsfall urinary mucoprotein, 898
- Tamoxifen, 738, 740*t*, 1656*t*, 1708
 adverse effects of, 723, 740, 1656*t*, 1708
 ophthalmic, 196*t*
 for breast cancer, 738, 739, 739–740, 740, 740*t*
 hormone receptor status and, 738, 739
 in male, 746
 as preventive agent, 723, 1708
 endometrial carcinoma and, 723, 759, 1708
 for gynecomastia, 1179
 for mastalgia, 1717
 for osteoporosis, 1181, 1185
 for Riedel thyroiditis/struma, 1122
- Tamponade, 420–421
 cancer-related, 419, 1645
 in pericarditis, 419, 420, 420–421, 422, 912
 pneumococcal, 1423
 postinfarction/Dressler syndrome, 419–420
 in traumatic cardiac injury, 428
 in uremic pericarditis, 419, 420, 912
- TAMs (thymidine analog mutations), antiretroviral drug resistance and, 1349
- Tamsulosin
 adverse ophthalmic effects of, 179, 196*t*
 for benign prostatic hyperplasia, 959, 959*t*
 ureteral stone expulsion and, 950
 for urinary incontinence, 69
- Tap water enema, 572*t*
- Tapeworm infections, 1514–1517. *See also* Cysticercosis; *Echinococcus*
 invasive, 1515–1517
 noninvasive, 1514–1515
 vitamin B₁₂ deficiency in, 497
- TAR. *See* Thrombocytopenia-absent radius syndrome
- Tar preparations, for psoriasis, 107
- Tarceva. *See* Erlotinib
- Tardive dyskinesia, 1004, 1061
 metoclopramide causing, 566, 629
- Tardive dystonia, antipsychotics causing, 1060–1061
- TARE. *See* Transarterial radioembolization
- Target cells
 in hemoglobin C disorders, 505
 in sickle cell syndromes, 504
- Targeted therapy, in cancer treatment, 1653–1655*t*
 for breast cancer, 737–738, 739–741, 740*t*
 for lung cancer, 1600
 for renal cell carcinoma, 1641
- Tarka. *See* Trandolapril, with verapamil
- Tarsal tunnel syndrome, 1027
- Tasigna. *See* Nilotinib
- Tau protein, in dementia, 1007
- TAVI. *See* Transcatheter aortic valve implantation
- tax* gene, in adult T cell lymphoma/leukemia, 1384
- Taxanes, 1652*t*
 for breast cancer, 737
 neuropathy caused by, 1661
- Taxol. *See* Paclitaxel
- Taxotere. *See* Docetaxel
- Tay-Sachs disease, screening for, 783
- Tazarotene, for acne, 127
- Tazorac. *See* Tazarotene
- Taztia. *See* Diltiazem
- TBCE* gene, in hypoparathyroidism, 1136
- TBE (tick-borne encephalitis). *See* Ticks, encephalitis transmitted by
- TBG. *See* Thyroxine-binding globulin
- TBPs. *See* Thyroxine-binding proteins
- 3TC. *See* Lamivudine
- TC regimen, for breast cancer, 737
- TCAs. *See* Tricyclic antidepressants
- TCF7L2* gene, in type 2 diabetes, 1194
- TCH regimen, for breast cancer, 737
- TCu380A IUD, 773–774
 for emergency/postcoital contraception, 774, 776
- Td vaccine, 1308*t*, 1309*t*, 1310*t*, 1430, 1430*t*, 1440
 adverse effects/contraindications and, 1317*t*
 burn injury and, 1551
 in immunocompromised host/HIV infection/AIDS, 1309*t*, 1335
 pregnancy and, 787, 1307, 1309*t*
 Tdap replacing, 3, 1440
- Tdap vaccine, 3, 1308*t*, 1309*t*, 1310*t*, 1430, 1430*t*, 1440
 adverse effects/contraindications and, 1317*t*
 booster and, 1307, 1430, 1430*t*
 burn injury and, 1551
 in immunocompromised host/HIV infection/AIDS, 1309*t*, 1314, 1335
 pregnancy and, 787, 1307, 1309*t*, 1440
- TdT. *See* Terminal deoxynucleotidyl transferase
- Tear deficiency, 166
- Tears, artificial, for dry eye, 166
- Technetium-99m scintigraphy
 in angina, 353
 in myocardial infarction, 366
 for thyroid scanning, 1105*t*
- TEE (transesophageal echocardiography). *See* Echocardiography
- Teeth, disorders of. *See* Dental disorders
- Tegaserod, withdrawal of from market, 635, 1226
- Tekturna/Tekturna HCT. *See* Aliskiren
- Telangiectasia
 GI bleeding and, 581, 584
 hereditary hemorrhagic, 1671–1672
 epistaxis in, 220, 1671
 GI bleeding and, 581, 584, 1671
 in rosacea, 128, 129, 129*f*
- Telaprevir, for hepatitis C, 677, 1329, 1354*t*
- Telavancin, for staphylococcal skin infections, 1426
- Telbivudine, for hepatitis B, 675, 676, 1354*t*
- Telcagepant, for migraine headache, 964
- Telemicine
 burn care and, 1549, 1550, 1552
 cold injury and, 1546
- Telepaque. *See* Iopanoic acid
- Telmisartan, 451*t*
 with amlodipine, 452*t*
 with hydrochlorothiazide, 451*t*
- Telogen effluvium, 157
- C-Telopeptide
 beta-cross-linked, reference values for, 1728*t*
 in Paget disease of bone, 1152
- Temazepam, 1042*t*
- Temodar. *See* Temozolomide
- Temovate. *See* Clobetasol
- Temozolomide, 1650*t*
 for gliomas, 992
 for pituitary adenoma/prolactinoma, 1104–1105
- Temperature. *See* Body temperature; Fever
- Temporal artery biopsy, in giant cell arteritis, 183, 846–847
- Temporal (giant cell/cranial) arteritis. *See* Giant cell (temporal/cranial) arteritis
- Temporal lobe herniation, intracranial tumors causing, 989
- Temporal lobe lesions, 989–990
- Temporomandibular joint dysfunction
 earache and, 206
 facial pain caused by, 968
 headache and, 962
- Temsirolimus, 1654*t*
- TEN. *See* Toxic epidermal necrolysis
- Tendinopathy (tendinosis), upper extremity (lateral and medial epicondylitis), 1687–1688
- Tendinous xanthoma, 1247–1248
- Tendon friction rub, in scleroderma, 838
- Tenecteplase (TNK-t-PA), for myocardial infarction, 369, 369*t*
- Tenex. *See* Guanfacine
- Tennis elbow, 1688
- Tenofovir, 1341*t*, 1343, 1344, 1347, 1348*f*, 1354*t*. *See also* Antiretroviral therapy/HAART
 with emtricitabine, 1343, 1344, 1347, 1348*f*
 prophylactic, 1291, 1333
 with emtricitabine and efavirenz, 1344, 1346, 1347, 1348*f*
 with emtricitabine and rilpivirine, 1346, 1347

- Tenofovir (*Cont.*):
 for hepatitis B, 675, 676, 1329, 1343, 1344, 1354*t*
 herpes simplex acquisition and, 1352
 prophylactic, 1333
 resistance to, 675, 1349
- Tenormin. *See* Atenolol
- Tenosynovitis
 in gonococcal arthritis, 860, 1452
 in tuberculous arthritis, 864
- Tension pneumothorax, 316, 317
- Tension-type headache, 962, 965
- Teoptic. *See* Carteolol
- Teplizumab, in new-onset type 1 diabetes, 1202
- Tequin. *See* Gatifloxacin
- Teratogenic drugs, 782, 782*t*. *See also* specific agent
- Teratomas, testicular, 1642
- Terazosin, 456*t*
 adverse ophthalmic effects of, 195*t*, 196*t*
 for benign prostatic hyperplasia, 959, 959*t*, 960
 for hypertension, 453, 456*t*
 for urinary incontinence, 69
- Terbinafine, 98*t*, 110, 1542*t*
 for chromoblastomycosis, 1540
 for onychomycosis, 158
 for sporotrichosis, 1539
 for tinea infection, 111, 112, 113
- Terbutaline
 for asthma/bronchospasm, 255
 for preterm labor prevention, 796
- Terconazole, for vulvovaginal candidiasis, 752
- Teres minor, evaluation of, 1680
- Terfenadine, antidepressant drug interactions and, 1068, 1071*t*
- Teriparatide
 for bisphosphonate-related atypical fractures, 1147, 1148
 for hypoparathyroidism, 1138
 for hypophosphatasia, 1150, 1151
 for osteoporosis, 1147–1148
 corticosteroid use and, 1148, 1191
- Terlipressin, for GI bleeding/esophageal varices, 583, 602
- Terminal delirium, 86–87, 1088
- Terminal deoxynucleotidyl transferase, in acute leukemia, 520
- Terminal illness. *See* End of life
- Terminal restlessness, 86
- Terrorism. *See* Bioterrorism; Chemical warfare agents
- Testes
 diseases of, 1173–1179, 1173*t*
 examination of in hypogonadism/infertility, 954–955, 1175
 intra-abdominal
 cancer in, 1175, 1178, 1642
 in pseudohermaphroditism, 1179
 masses/tumors of, 1177, 1642–1644.
See also Testicular cancer
 gynecomastia and, 1178
 secondary/metastatic, 1644
 retractile, 1177
 undescended (cryptorchism), 1177–1178
 pseudohermaphroditism and, 1179
 testicular cancer and, 1175, 1178, 1642
- Testicular cancer, 1611*t*, 1642–1644
 bone marrow/stem cell transplantation for, 532
 cryptorchism and, 1175, 1178, 1642
 gynecomastia and, 1178, 1643
 screening for, 16
 secondary/metastatic, 1644
- Testicular dysgenesis, 1175
- Testicular failure, 955, 1174–1175. *See also* Hypogonadism
- Testicular feminization, 1179
- Testicular lymphoma, 1642
- Testicular masses. *See* Testes, masses/tumors of
- Testicular pain, cancer causing, 1643
- Testicular torsion, 945
- Testim, 1176. *See also* Testosterone replacement therapy
- Testis. *See* Testes
- Testoderm, 1176. *See also* Testosterone replacement therapy
- Testogel, 1176. *See also* Testosterone replacement therapy
- Testosterone. *See also* Androgens; Testosterone replacement therapy
 deficiency of, 1173–1177, 1173*t*. *See also* Hypogonadism
 pseudohermaphroditism/amenorrhea and, 1179
 in women, 1185
 excess of. *See* Hyperandrogenism
 insensitivity/resistance to, 1175
 prostate cancer and, 1176, 1177, 1636, 1637*t*
 serum levels of
 in gynecomastia, 1178
 in hirsutism/virilization, 1162, 1162–1163
 in hypogonadism, 1095, 1175
 in infertility workup, 955
 in polycystic ovary syndrome, 1162
 in postmenopausal women, 1185
 reference/normal values for, 1175, 1734*t*
- Testosterone cyponate/enanthate, 1176. *See also* Testosterone replacement therapy
- Testosterone replacement therapy, 1176–1177
 for AIDS wasting, 1325
 buccal, 1176
 for erectile dysfunction, 952
 for hypogonadism, 1176–1177
 in Klinefelter syndrome, 1670
 in men, 1176–1177
 oral, 1176, 1185
 parenteral, 1176
 topical, 1176
 transdermal, 1176, 1185, 1325
 in women, 780, 1181, 1185
- Testosterone undecanoate, 1176. *See also* Testosterone replacement therapy
- Tetanospasmin, 1429
- Tetanus, 1300*t*, 1429–1430
 prevention/immunization and, 1430, 1430*t*. *See also* Tetanus and diphtheria toxoids and pertussis vaccine
 bite wounds and, 1290
 burn injury and, 1551
 frostbite and, 1546
- Tetanus-diphtheria 5-component acellular pertussis (Tdap) vaccine, 3, 1308*t*, 1309*t*, 1310*t*, 1430, 1430*t*, 1434, 1440
 adverse effects/contraindications and, 1317*t*
 booster and, 1307, 1430, 1430*t*, 1434, 1440
 burn injury and, 1551
 in immunocompromised host/HIV infection/AIDS, 1309*t*, 1314, 1335
 pregnancy and, 787, 1307, 1309*t*, 1440
- Tetanus-diphtheria toxoid (Td vaccine), 1308*t*, 1309*t*, 1310*t*, 1430, 1430*t*, 1434, 1440
 adverse effects/contraindications and, 1317*t*
 burn injury and, 1551
 in immunocompromised host/HIV infection/AIDS, 1309*t*, 1314, 1335
 pregnancy and, 787, 1307, 1309*t*
 Tdap replacing, 3, 1440
- Tetanus and diphtheria toxoids and pertussis vaccine (DTaP/Tdap vaccines), 3, 1308*t*, 1309*t*, 1314, 1430, 1430*t*, 1434, 1440
 adverse effects/contraindications and, 1317*t*
 booster and, 1307, 1430, 1430*t*, 1434, 1440
 burn injury and, 1551
 in immunocompromised host/HIV infection/AIDS, 1309*t*, 1314, 1335
 pregnancy and, 787, 1307, 1309*t*, 1440
- Tetanus immune globulin, 1430, 1430*t*
 burn injury and, 1551
- Tetany
 in hyperthyroidism, 1113
 in hypocalcemia/hypoparathyroidism, 882, 1136, 1137, 1137*t*
 malabsorption and, 621*t*
 after parathyroidectomy, 1143
 in respiratory alkalosis, 896
- Tetrabenazine
 for Huntington disease, 1002
 for Tourette syndrome, 1005
- Tetracycline
 for acne, 127
 adverse ophthalmic effects of, 197*t*
 for amebiasis, 1504, 1505*t*
 in *H pylori* eradication therapy, 613, 614*t*
 for malaria, 1497
 for non-sexually transmitted treponematoses, 1474
 for rosacea, 129
 for syphilis, 1468*t*
- Tetrafosmin scintigraphy, in angina, 353
- Tetrahydrocannabinol, 1085. *See also* Dronabinol; Marijuana
- Tetrahydrozoline, overdose/toxicity of, 1577
- Tetralogy of Fallot, 331–332
 pulmonary valve regurgitation and, 332, 348

- Tetrodotoxin, puffer fish poisoning
caused by, 1589t
- Teveten/Teveten HCT. *See* Eprosartan
- TFR2* (transferrin receptor 2) gene
mutation, in
hemochromatosis, 695
- Tg. *See* Thyroglobulin
- Tg (thyroglobulin) antibodies. *See*
Antithyroid
(antithyroglobulin/
antithyroperoxidase)
antibodies
- TGF- β . *See* Transforming growth factor β
- Thalamic hemorrhage, stroke and, 983
- Thalamic stimulation
for benign essential (familial) tremor,
997
for idiopathic torsion dystonia, 1003
for parkinsonism, 1001
- Thalamic syndrome
intracranial tumors causing, 991
in vertebrobasilar obstruction, 981
- Thalamotomy
for idiopathic torsion dystonia, 1003
for parkinsonism, 1001
- Thalassemias, 492, 494–496, 494t, 495t
sickle, 505, 505t
- Thalidomide
for cancer chemotherapy, 1656t
for erythema nodosum leprosum,
1460–1461
for lupus, 115
for myeloma, 529
neuropathy caused by, 1661
teratogenicity of, 115
- Thalitone. *See* Chlorthalidone
- Thallium-201 scintigraphy
in angina, 353
in myocardial infarction, 366
in thyroid cancer surveillance, 1133
- Thalomid. *See* Thalidomide
- THC ($\Delta 9$ -tetrahydrocannabinol). *See*
Dronabinol; Marijuana
- Theophylline, 1724t
for asthma, 249f, 252, 252t, 255
for COPD, 263, 264
lithium interactions and, 1074t
monitoring levels of, 252, 255, 263,
264, 1724t
overdose/toxicity of, 252, 255, 263,
1569t, 1590–1591
hemodialysis for, 1568t
seizures and, 1565t, 1591
perioperative management of patient
taking, 51
- Therapeutic abortion. *See* Abortion,
elective/induced
- Therapeutic diets, 1268–1270. *See also*
Diet; Nutrition
- Therapeutic drug monitoring, 1722–
1724t. *See also specific agent*
in elderly, 72
- Thermal injury. *See* Burns
- Thermocoagulation, endoscopic, for
bleeding peptic ulcer, 618
- Thermoregulation, 1543
hyperthermia/heat exposure
syndromes and, 1547
hypothermia (systemic) and, 1543
- Thessaly test, 1697t, 1700
- Thiabendazole
for cutaneous larva migrans, 1523
for strongyloidiasis, 1519
- Thiamine (vitamin B₁)
for alcohol withdrawal, 1083
for coma, 1563
deficiency of, 1264
alcohol use/alcoholic ketoacidosis
and, 681, 891, 893, 1083,
1264
amnesic syndrome and, 1088
neuropathy associated with, 1023, 1264
Wernicke encephalopathy/Wernicke-
Korsakoff syndrome caused
by, 681, 893, 1013, 1081,
1264
for Wernicke encephalopathy/thiamine
deficiency, 681, 893, 1013,
1081, 1264
- Thiazide diuretics. *See also* Diuretics
for acute tubular necrosis, 906
adverse effects of, 445t, 446
ophthalmic, 196t
for diabetes insipidus, 1099
for heart failure, 401
chronic kidney disease and, 912
hypercalcemia and, 884, 1142
for hypercalciuria, 948
for hyperkalemia, 879
for hypertension, 434t, 444–446, 445t,
457–458, 457f, 458t
in chronic kidney disease, 459
in combination products, 445t, 450t,
451t, 452t
in combination regimens, 457–458,
457f, 458t
hyponatremia caused by, 871f, 872
lithium interactions and, 1074, 1074t
for nephrotic syndrome/nephrotic
spectrum disorders, 928
- Thiazolidinediones
for diabetes mellitus, 1206t, 1209–1210
overdose/toxicity of, 1209–1210, 1580
- Thick blood film, for malaria diagnosis,
1491
- Thienopyridines, platelet function
affected by, 549t
- Thimerosal-free vaccines, 669
- Thin blood film, for malaria diagnosis,
1491, 1491f
- Thioglitazones, lower extremity edema
caused by, 33
- Thioguanine, 639
- Thiopurine methyltransferase
azathioprine therapy and, 639
mercaptopurine therapy and, 639
testing for variants of, 1726t
- Thioridazine, 1056t, 1057t
overdose/toxicity of, 1057t, 1059, 1574
ophthalmic, 196t
- Thiosulfate, for cyanide poisoning, 1566t,
1577, 1578t
- Thiotepa, for bladder cancer, 1639
- Thiothixene, 1056t, 1057t
- Thioureas
for goiter, 1114
for hyperthyroidism/Graves disease,
1114–1115, 1115
during pregnancy/lactation, 800,
1115, 1117
- RAI therapy and, 1115
thyroid crisis/storm and, 1118
for toxic solitary thyroid nodule, 1116
- Thioxanthenes, 1055. *See also*
Antipsychotic drugs
- Third-degree burns, 1550
- Third-degree (complete) heart block, 394,
395
in atrial septal defect, 328
in myocardial infarction, 373
- Third heart sound (S₃/ventricular gallop).
See Heart sounds
- Third nerve paralysis/palsy, 190
in ophthalmoplegic migraine, 963
- Third-trimester bleeding, 797
- Thirst. *See* Polydipsia
- Thoracentesis, 313. *See also* Pleural fluid
analysis
diagnostic, 313
in lung cancer, 1597
for malignant effusions, 315,
1645–1646
in pleural effusion, 272, 313, 315,
1645–1646
in pneumonia, 272, 1423
- Thoracic actinomycosis, 1457
- Thoracic aortic aneurysms, 474–475
giant cell arteritis and, 846, 847
- Thoracic carcinoid, in MEN, 1188t
- Thoracic outlet syndrome, 818–819
chest pain/discomfort in, 355
neck pain and, 1686
Raynaud phenomenon and, 837
- Thoracic spine/disk disease
chest pain/discomfort in, 355
tuberculosis (Pott disease) and, 863
- Thoracoscopic surgery, video-assisted
(VATS)
for hepatic hydrothorax, 688
in lung cancer diagnosis, 1597
in mesothelioma diagnosis, 1602
for pulmonary effusion/tamponade,
421
for pulmonary infiltrates in
immunocompromised host,
279
for solitary pulmonary nodule, 291
- Thoracoscopy
for hemothorax, 316
in lung cancer, 1597
in pleural effusion, 315
for pneumothorax, 317
- Thoracostomy, tube. *See* Tube
thoracostomy
- Thoracotomy
for hemothorax, 316
for pneumothorax, 317
- Thorazine. *See* Chlorpromazine
- Thorotrast exposure, ureteral/renal pelvic
cancer and, 1640
- Thought content, in schizophrenia/
psychotic disorders, 1054
- Threatened abortion, 788
- Three-dimensional conformal radiation
therapy, for prostate cancer,
1635
- Three-item word recall, in dementia
screening, 60, 1007
- 3P tumor suppressor gene, in thyroid
cancer, 1127

- “3” sign, in coarctation of aorta, 327
- “Thrifty” (*LITH*) gene, in cholelithiasis/gallstones, 702
- Throat culture, in pharyngitis, 228, 1419
- Thrombasthenia, Glanzmann, 548
- Thrombin inhibitors
for heparin-induced thrombocytopenia, 544, 544t
for venous thromboembolism, 558
- Thrombin time, heparin affecting, 554
- Thromboangiitis obliterans (Buerger disease), 471–472
Raynaud disease/phenomenon and, 472, 837
- Thrombocytopenia, 538–548, 539t, 541f, 543t, 544t, 546t, 547t
amegakaryocytic, 538, 539
in antiphospholipid antibody syndrome, 835
aplastic anemia and, 508, 538, 539–540
with autoimmune hemolytic anemia (Evans syndrome), 506
in bone marrow failure, 538–540
in bone marrow infiltration, 540
in cancer chemotherapy/irradiation, 540, 547t, 1649–1659
in cirrhosis, 686
cyclic, 540
decreased platelet production causing, 539–540, 539t
DIC and, 545–546, 546t
drug-induced, 546, 547t
gestational, 547
in gram-negative bacteremia/sepsis, 1444
in hairy cell leukemia, 523
heparin-induced, 544–545, 544t, 554
reference values in, 1731t
immune, 540–542, 541f
increased platelet destruction causing, 539t, 540–546, 541f, 543t, 544t, 546t
infection/sepsis-related, 547
nutritional deficiencies and, 540
platelet sequestration and, 539t, 547, 547t
platelet transfusion for, 536, 540
in posttransfusion purpura (PTP), 546
in preeclampsia-eclampsia, 793, 793t
pregnancy and, 542, 547
retinal disease associated with, 186–187
with severe fever, 1385
in SLE, 834, 834t
in thrombotic microangiopathy, 542, 543, 543t
diarrhea and, 543
in von Willebrand disease type 2B, 547, 551
- Thrombocytopenia-absent radius syndrome, 538
- Thrombocytosis
essential, 511t, 513–514
reactive, 513
- Thromboembolism. *See also* Embolism; Thrombosis; Venous thromboembolic disease
acute arterial limb occlusion caused by, 468
in antiphospholipid antibody syndrome, 799, 835, 836
in atrial fibrillation, 384–385, 385t
anticoagulation in prevention of, 385t, 386–387, 388
- in atrial flutter, 389
in Behçet syndrome, 853
estrogen replacement therapy and, 780, 1183
fever and, 1283
in granulomatosis with polyangiitis, 849
in heart failure, 297, 405
in myocardial infarction, 365, 375
in nephrotic syndrome/nephrotic spectrum disorders, 928
oral contraceptive use and, 770
perioperative anticoagulation management and, 52, 53t
during pregnancy, 431
prosthetic heart valves and, 338
pulmonary. *See* Pulmonary venous thromboembolism
pulmonary hypertension and, 304, 305, 423t, 424
- Thromboendarterectomy
carotid. *See* Carotid endarterectomy/thromboendarterectomy
for femoral/popliteal occlusive disease, 466
pulmonary, 305–306
visceral, for visceral ischemia, 471
- Thrombolytic therapy
for acute arterial limb occlusion, 468
for deep venous thrombosis, 563
for frostbite, 1546
for hepatic vein obstruction (Budd-Chiari syndrome), 698
for myocardial infarction, 364t, 368–370, 369t
contraindications to without ST elevation, 363, 367
PCI and, 357, 368
for pulmonary embolism, 303, 556, 562–563, 562t
for retinal artery occlusion, 183
for stroke, 982, 983
for venous thromboembolic disease, 303, 556, 562–563, 562t
- Thrombophilia
oral contraceptive use and, 770
work up for, 559–560
- Thrombophlebitis. *See also* Deep venous thrombosis; Thrombosis
cancer-related, 1596t
leg ulcers and, 153
oral contraceptive use and, 770
septic. *See* Septic thrombophlebitis
of superficial veins, 479–480
varicosities and, 478, 479
venous insufficiency/stasis and, 33, 33t, 34, 480
- Thrombopoietin, chemotherapy-induced thrombocytopenia and, 1649
- Thrombopoietin receptor agonists. *See also* Eltrombopag; Romiplostim
for immune thrombocytopenia, 541–542, 541f
- Thrombosis. *See also* Thromboembolism; Thrombophlebitis
acute arterial limb occlusion caused by, 468
- in antiphospholipid antibody syndrome, 799, 835, 836
in antiphospholipid antibody syndrome, 799, 835, 836
in aortic aneurysm, 473
cancer-associated, 301t, 1596t
cavernous sinus, bacterial rhinosinusitis and, 216
cerebrovascular occlusion and, 469–470
of deep veins. *See* Deep venous thrombosis
in DIC, 545, 546
in essential thrombocytosis, 513
in granulomatosis with polyangiitis, 849
hemorrhoidal, 658
in heparin-induced thrombocytopenia, 544–545
in homocystinuria, 1669
intracranial, 988. *See also* Stroke
mesenteric, 470, 471
in paroxysmal nocturnal hemoglobinuria, 502
peripheral arterial aneurysms and, 475–476
in polycythemia, 512
prosthetic heart valves and, 338
sigmoid sinus, otitis media and, 205
stent, 363
venous. *See* Venous thromboembolic disease
venous sinus, 994, 995
- Thrombotic microangiopathy, 542–544, 543t
diarrhea and, 543
- Thrombotic thrombocytopenic purpura, 542–544, 543t
diarrhea and, 543, 1447
microangiopathic hemolytic anemias and, 508, 542, 543, 543t
- Thrush (oral candidiasis), 131, 131f, 225–226, 226f
esophagitis and, 598, 1529
in HIV infection/AIDS, 131, 225–226, 226, 226f, 1325, 1328–1329, 1337
- Thumb sign, 235
- “Thunderclap headache,” 41
- Thymectomy
in MEN 1, 1188–1189
for myasthenia gravis, 1033
- Thymidine analog mutations (TAMs), antiretroviral drug resistance and, 1349
- Thymidylate synthase gene mutations, pancreatic/periampullary carcinoma and, 1608
- Thymoma
myasthenia gravis associated with, 1032
paraneoplastic syndromes associated with, 1596t
pure red cell aplasia caused by, 500, 1596t
- Thyrogen. *See* Thyrotropin- α
- Thyroglobulin
antibodies against. *See* Antithyroid (antithyroglobulin/antithyroperoxidase) antibodies
serum levels of

- reference values for, 1734*t*
in thyroid cancer diagnosis/
surveillance, 1128, 1131,
1132, 1133
- Thyroglossal duct cysts, **239**
- Thyroid acropachy, 1113
- Thyroid adenoma, toxic
in MEN, 1188*t*
multiple (toxic multinodular goiter),
1111, 1114, 1116
solitary (toxic solitary thyroid nodule),
1111, 1116
- Thyroid antibodies. *See* Antithyroid
(antithyroglobulin/
antithyroperoxidase)
antibodies
- Thyroid cancer, **1126–1134**, 1127*t*, 1130*t*,
1612*t*
anaplastic/undifferentiated, 1127*t*,
1128, 1131, 1134
differentiated, 1126–1127, 1129–1131,
1130*t*, 1132–1133, 1133
fine-needle aspiration biopsy in,
1124–1125, 1124*t*
follicular, 1124–1125, 1127, 1127*t*,
1129, 1133
functioning, 1127, 1128
incidence/mortality/risk of, 1594*t*
long-term followup/surveillance for,
1132–1133
lymphoma, 1128, 1131, 1134
medullary, 1127–1128, 1127*t*, 1128,
1131, 1133–1134
liraglutide use and, 1212
in MEN, 1123, 1127, 1131, 1133,
1188*t*, 1189, 1189–1190
metastatic, 1112, 1127, 1128, 1130,
1130–1131, 1130*t*
surveillance and, 1132–1133
micropapillary, 1127
papillary, 1124, 1126–1127, 1127*t*,
1129, 1130*t*, 1133
follicular variant of (mixed
papillary-follicular), 1126,
1133
pregnancy and, 1130
radiation exposure and, 1123, 1126, 1554
staging of, 1129, 1130*t*, 1131
thyroid nodules and, 1121, 1123, 1124,
1124*t*, 1125, 1128
thyroid surgery for, 1125, 1129–1130,
1130*t*
radioactive iodine therapy after,
1130–1131
thyroid testing in, 1124*t*, 1127*t*, 1128
- Thyroid crisis/storm, 1118–1119
during pregnancy, 800
propranolol for, 1116, 1118
- Thyroid cysts, 1125
- Thyroid gland
biopsy of, 1105*t*, 1124–1125, 1124*t*
in thyroid nodules/cancer, 1105*t*,
1124–1125, 1124*t*
in thyroiditis, 1121
disorders of, **1105–1135**. *See also*
Hyperthyroidism;
Hypothyroidism; Thyroid
cancer
eye disease associated with, **191**,
1110, 1112–1113, 1117–1118
- RAI treatment for
hyperthyroidism and,
1115–1116, 1117–1118
in HIV infection/AIDS, 1330
lipid abnormalities and, 1248*t*
lithium causing, 1073, 1111
neoplastic. *See* Thyroid cancer;
Thyroid nodules
pheochromocytoma/paraganglioma
and, 1168*t*
during pregnancy, **800**, 1106, 1108,
1109, 1111, 1111–1112, 1113,
1117, 1119, 1120, 1121
hyperemesis gravidarum and, 787,
1111
preoperative evaluation/
perioperative management
and, 55
thyroid testing in, **1105**, 1105*t*. *See also*
Thyroid testing
- enlarged. *See* Goiter
infection of (suppurative thyroiditis),
1120, 1121, 1122
nodular. *See* Multinodular (nodular)
goiter; Thyroid cancer;
Thyroid nodules
- Thyroid hormone. *See also* Thyroxine;
Triiodothyronine
antidepressant drug augmentation and,
1065, 1069
excess/deficiency of. *See*
Hyperthyroidism;
Hypothyroidism
exogenous, excess ingestion of
(thyrotoxicosis factitia),
1111, 1113
replacement therapy with. *See*
Levothyroxine
- Thyroid incidentalomas (incidentally
discovered thyroid nodules),
1121, 1123, 1124
- Thyroid nodules, 1105*t*, **1123–1126**,
1124*t*. *See also* Goiter;
Thyroid cancer
cystic, 1125
solitary, 1123
toxic (thyroid adenoma), 1111, 1116
in MEN, 1188*t*
thyroid testing in, 1105*t*, 1123, 1124*t*
- Thyroid radioactive iodine uptake and
scan. *See* Radioiodine thyroid
scans and uptake
- Thyroid remnant ablation, 1130
- Thyroid-stimulating hormone (TSH/
thyrotropin), 1105, 1105*t*
deficiency of, 1093, 1094, 1096
in euthyroid sick syndrome, 1107
fetal, 1117
in goiter, 1134
in hyperthyroidism, 1105*t*, 1110, 1113
amiodarone-induced, 1113
factors affecting, 1111*t*, 1114
pituitary adenoma/hyperplasia and,
1111
pregnancy and, 800, 1111, 1113,
1117
in hypopituitarism, 1093, 1094, 1095
in hypothyroidism, 1094, 1096, 1105*t*,
1106, 1107, 1109–1110
amiodarone-induced, 1106
- factors affecting, 1107–1108, 1107*t*
levothyroxine replacement and,
1096, 1107, 1108, 1109,
1109–1110
pregnancy and, 800, 1109
pregnancy and, 800, 1109, 1111, 1113
recombinant human (rhTSH), RAI
therapy/surveillance for
thyroid cancer and, 1131,
1132–1133
hyperthyroidism and, 1112
reference values for, 1734*t*
suppression of. *See* Levothyroxine
in thyroid cancer
postsurgical, 1130
surveillance and, 1132
in thyroid nodules, 1123
levothyroxine therapy and, 1125
in thyroiditis, 1121
- Thyroid-stimulating hormone receptor
antibody (TSAb/TSH-R
Ab[stim]). *See also*
Thyrotropin receptor
antibody
in hyperthyroidism/Graves disease,
1105*t*, 1110, 1113
during pregnancy, 1113
reference values for, 1735*t*
- Thyroid-stimulating immunoglobulins,
1105*t*
in hyperthyroidism, 1110, 1113
during pregnancy, 1113
reference values for, 1735*t*
- Thyroid-stimulating immunoglobulins,
1105*t*
in hyperthyroidism, 1110, 1113
during pregnancy, 1113
- Thyroid storm. *See* Thyroid crisis/storm
- Thyroid surgery/thyroidectomy
for goiter, 1116, 1135
for hyperthyroidism/Graves disease,
1116
multinodular goiter and, 1116, 1135
during pregnancy, 1116, 1117
toxic solitary thyroid nodule and,
1116
hypoparathyroidism after, 1116, 1119,
1129, 1135
hypothyroidism after, 1119, 1129
during pregnancy, 1116, 1117, 1130
prophylactic, in MEN, 1131, 1189, 1190
for thyroid cancer, 1125, 1129–1130,
1130*t*
radioactive iodine treatment after,
1130–1131
RAI surveillance and, 1132
for thyroid nodules, 1125
vocal fold paralysis/recurrent laryngeal
nerve damage and, 237, 238,
1116, 1119, 1129
- Thyroid testing, **1105**, 1105*t*
in heart failure, 399, 400
in HIV infection/AIDS, 1330
in hyperthyroidism, 1105*t*, 1113–1114
factors confounding, 1111*t*, 1114
in hypothyroidism, 1105*t*, 1107
factors confounding, 1107–1108,
1107*t*
in thyroid cancer, 1124*t*, 1127*t*, 1128
in thyroid nodules, 1105*t*, 1123, 1124*t*
in thyroiditis, 1121
- Thyroid transcription factor-1 (TTF-1),
in lung cancer, 1601
- Thyroidectomy. *See* Thyroid surgery/
thyroidectomy

- Thyroiditis, **1119–1122**
 Hashimoto. *See* Hashimoto (chronic lymphocytic/autoimmune) thyroiditis
 hepatitis C and, 1106
 hyperthyroidism and, 1111, 1113, 1121
 painless, 1120, 1121
 postpartum/pregnancy and, 800, 1111, 1119, 1120, 1121
 Riedel, 1120, 1121, 1122
 silent, 1111, 1121
 sporadic, 1120, 1121
 subacute. *See* Subacute (de Quervain) thyroiditis
 suppurative, 1120, 1121, 1122
 transient autoimmune, postpartum, 800
- Thyroperoxidase, antibodies against. *See* Antithyroid (antithyroglobulin/antithyropoxidase) antibodies
- Thyrotoxic hypokalemic periodic paralysis, 1036, 1113, 1119
- Thyrotoxicosis, 1105*t*, **1110–1119**, 1111*t*.
See also Hyperthyroidism factitia, 1111, 1113
- Thyrotrope pituitary adenoma, 1111, 1117
- Thyrotrope pituitary hyperplasia, 1106, 1107, 1111, 1117
- Thyrotropin. *See* Thyroid-stimulating hormone
- Thyrotropin receptor antibody (TRAb)
 Hashimoto thyroiditis and, 1112, 1120
 hyperthyroidism/Graves disease in pregnancy and, 1111
- Thyroxine (T_4)
 replacement therapy with. *See* Levothyroxine
 serum levels of
 in euthyroid sick syndrome, 1107
 free. *See* Free thyroxine assay
 in goiter, 1134
 in hyperthyroidism, 1110, 1113
 amiodarone-induced, 1113
 factors affecting, 1111*t*, 1114
 pregnancy and, 800, 1113, 1117
 thyroiditis and, 1121
 after treatment, 1115, 1116
 in hypothyroidism, 1107
 factors affecting, 1107–1108, 1107*t*
 pregnancy and, 800, 1109
 thyroid cancer surveillance and, 1132
 total, reference values for, 1735*t*
 suppression of. *See also* Levothyroxine in goiter, 1135
 in thyroid cancer management, 1125, 1129, 1130
 thyroid cancer secreting, 1127, 1128
 uptake of (resin). *See* Resin T_3/T_4 uptake
- Thyroxine-binding globulin (TBG), 1105
 hyperthyroidism during pregnancy and, 1113
 hypothyroidism during pregnancy and, 1109
- Thyroxine-binding proteins (TBPs), in euthyroid sick syndrome, 1107
- Thyroxine (T_4) index, free (FT₄I). *See* Free thyroxine index
- Thyroxine/triiodothyronine preparations, for hypothyroidism, 1108
- Thyroxine-withdrawal stimulated ¹³¹I therapy, for thyroid cancer, 1131
- TIA. *See* Transient ischemic attacks
- Tiagabine, 972, 973*t*
 overdose/toxicity of, 973*t*, 1574
- Tiazac. *See* Diltiazem
- TIBC. *See* Total iron-binding capacity
- Tibia, 1692
- Tibial artery, atherosclerotic/occlusive disease of, 467
- Tibial nerve, entrapment of (tarsal tunnel syndrome), **1027**
- Tibial osteotomy, for osteoarthritis of knee, 1702
- Tibiofibular ligament, in ankle sprains, 1704
- Tibolone, 1185
- Tic douloureux. *See* Trigeminal neuralgia
- Ticagrelor
 for acute coronary syndromes, 361, 362*t*, 363
 for myocardial infarction, 362*t*, 367, 376
 proton pump interaction/
 coadministration and, 616
- Ticar. *See* Ticarcillin
- Ticarcillin, platelet function affected by, 549*t*
- Tick typhus, 1409*t*, **1414**
- Ticks
 babesiosis transmitted by, 1499
 Colorado tick fever transmitted by, **1391–1392**
 ehrlichiosis/anaplasmosis transmitted by, 1409*t*, 1414, 1415
 encephalitis transmitted by, 1378, **1390–1391**
 hemorrhagic fevers transmitted by, 1385
 Lyme disease transmitted by, 135, 240, 1478, 1481
 relapsing fever transmitted by, 1475, 1476
 removal of, 1478
 Rocky Mountain spotted fever transmitted by, 1409*t*, 1412
 skin lesions caused by, 135, 149
 Southern tick-associated rash illness (STARI) transmitted by, 136
 spotted fevers transmitted by (tick typhus), 1409*t*
 tularemia transmitted by, 1450
- Ticlopidine. *See also* Antiplatelet therapy platelet function affected by, 549*t*
- Tics
 in OCD, 1041
 in Tourette syndrome, 1004–1005
- Tietze syndrome, 355
- TIG. *See* Tetanus immune globulin
- Tigecycline
 for anaerobic abdominal infections, 1455, 1455*t*
 for staphylococcal skin infections, 1426
- Tilt table testing
 in dysautonomia, 976
 in syncope, 397
- Tiludronate, for Paget disease of bone, 1153
- TIMI Risk Score, 364, 375
- Timolol
 for glaucoma/ocular hypertension, 171*t*, 176
 in combination agents, 171–172*t*, 176
 for migraine prophylaxis, 964*t*
 for systemic hypertension, 448*t*
- Timoptic/Timoptic-XE/Timoptic GFS.
See Timolol
- Tincture of opium, for diarrhea, 580
- Tinea
 acne caused by, 126
 circinata/corporis, **110–111**, 111*f*
 cruris, **111–112**
 manuum, **112–113**
 pedis, 111*f*, **112–113**, 113*f*
 cellulitis and, 112, 137
 pityriasis rosea differentiated from, 109
 profunda, furuncles differentiated from, 151
 unguium (onychomycosis), 157, **158**
 versicolor (pityriasis versicolor), **113–114**
- Tinel sign, in carpal tunnel syndrome, 824, 1688, 1689*t*
- Tinidazole
 for amebiasis, 1504, 1505*t*
 for bacterial vaginosis, 753
 for giardiasis, 1509
 in *H pylori* eradication therapy, 613, 614
 for trichomoniasis, 753, 1510
- Tinnitus, **208**
 glomus tumors causing, 206, 208
 in labyrinthitis, 211
 in Ménière syndrome, 210
 in pseudotumor cerebri, 995
 vertigo and, 209, 210
- Tinzaparin, 559*t*
- Tioconazole, for vulvovaginal candidiasis, 752
- Tiotropium
 for asthma, 252, 252*t*
 for COPD, 262, 263
- Tipranavir, 1344, 1345, 1348*f*. *See also* Antiretroviral therapy/HAART
 with ritonavir, 1342*t*, 1345, 1347
- TIPS. *See* Transvenous (transjugular) intrahepatic portosystemic shunts
- Tirofiban
 for acute coronary syndromes, 362*t*, 363
 for myocardial infarction, 362*t*
 platelet function affected by, 549*t*
- Tissue plasminogen activator (t-PA/alteplase), 369*t*. *See also* Thrombolytic therapy
 for acute arterial limb occlusion, 468
 for myocardial infarction, 368–369, 369*t*
 pleural instillation of, 316
 for pulmonary embolism, 303, 562*t*, 563
 for retinal vein occlusion, 182
 for stroke, 982

- Tissue transglutaminase. *See* Transglutaminase
- TIV influenza vaccine, 1396. *See also* Influenza virus vaccine
- Tizanidine
overdose/toxicity of, 1577
for spasticity, 1012
- TLC (total lung capacity). *See also* Pulmonary function tests
in COPD, 261
in cystic fibrosis, 267
- TLS. *See* Tumor lysis syndrome
- TMA. *See* Thrombotic microangiopathy
- TMP-SMZ. *See* Trimethoprim-sulfamethoxazole
- TNF. *See* Tumor necrosis factor
- TNK-t-PA. *See* Tenecteplase
- TNM staging classification, 1594. *See also* specific type of cancer
- Tobacco use. *See also* Smoking
cancer and, 6, 1593
esophageal cancer, 1613
laryngeal cancer, 236
lung cancer, 6, 1593, 1595
as co-carcinogen, 311
screening for, 289, 1599
in women, 1709
oral cancer, 224
pancreatic/periampullary cancer, 1607
health hazards of, 6, 1593
postoperative pulmonary complications and, 51
during pregnancy, 783
preventable disease/deaths and, 3*t*, 6–8, 7*t*
in thromboangiitis obliterans (Buerger disease), 472
- Tobramycin, 1724*t*. *See also* Aminoglycosides
for ophthalmic disorders, 168*t*
for pneumonia, 273*t*, 277*t*
- Tobrex. *See* Tobramycin
- Tocilizumab, for rheumatoid arthritis, 830–831
- Tocolytics, 796
adverse ophthalmic effects of, 196*t*
- Toe amputations, in lower leg/foot occlusive disease, 467
- Toe web (interdigital) tinea pedis, 112, 113*f*
cellulitis and, 112, 137
- Toenails, disorders of. *See* Nail disorders
- Toes
callosities and corns of, 141
in diabetes/vascular disorders, 141, 1224
in gout, 813
thromboangiitis obliterans (Buerger disease) involving, 472
- Tofranil. *See* Imipramine
- Togaviruses, encephalitis caused by, 1378–1380
- Tolazamide, 1206*t*, 1207
- Tolazoline, clonidine overdose and, 1577
- Tolbutamide, 1206*t*, 1207
in insulinoma diagnosis, 1240
- Tolcapone, for parkinsonism, 1000
- Tolectin. *See* Tolmetin
- Tolerance (drug), 1079. *See also* Substance use disorders
- in opioid therapy, 76, 79
in stimulant abuse, 1085
- Tolinase. *See* Tolazamide
- Toll-like receptors
in gout, 812
in tick-borne encephalitis, 1390
- Tolmetin, 78*t*
- Tolterodine, for urinary incontinence, 68
- Toluene toxicity/abuse, 1086, 1583
anion gap and, 891
- Tolvaptan, for hyponatremia/SIADH, 875
- Tomographic coronary calcium, in chest pain evaluation, 29
- Tonal tinnitus, 208
- Tongue disorders (glossitis/glossodynia), 226
- Tonic-clonic (grand mal) seizures, 970, 970*t*. *See also* Seizures
- Tonic-clonic status epilepticus, 970, 974
- Tonic seizures, 970. *See also* Seizures
- Tonicity, 870
- Tonsillectomy, 230
for peritonsillar abscess (quinsy), 229–230
- Tonsillitis, 227–229, 228*f*. *See also* Pharyngitis
- Tooth disorders. *See* Dental disorders
- Tophus (tophi)/tophaceous arthritis, 812, 813, 813*f*, 816
rheumatoid nodule differentiated from, 814
- Topical therapy, for skin disorders, 94–100, 95–99*t*
complications of, 99–100
- Topiramate, 972, 973*t*
for alcohol use/abuse, 18
for migraine prophylaxis, 964*t*
for obesity, 1261
overdose/toxicity of, 973*t*, 1574
ophthalmic effects and, 196*t*
for pseudotumor cerebri, 995
for seizures, 972, 973*t*
pregnancy and, 803
for Tourette syndrome, 1005
- Topoisomerase inhibitors, in cancer chemotherapy, 1653*t*
for breast cancer, 737
- Topotecan, 1653*t*
- Toprol XL. *See* Metoprolol
- Toradol. *See* Ketorolac
- Torcetrapib, 1252
- Toremifene, 740*t*, 1656*t*
- Torisel. *See* Temsirolimus
- Toroviruses, gastroenteritis caused by, 1404–1405
- Torsades de pointes, 391, 393
in hypomagnesemia, 888
in poisoning/drug toxicity, 393, 1564, 1564*t*
antiarrhythmics in, 393, 1588
antidepressants in, 1591
antipsychotics/phenothiazines in, 1058, 1059, 1574
droperidol in, 569
opioids in, 1586
- Torsemede
for heart failure, 401
for hypertension, 445*t*
- Torsion dystonia
focal, 1003
idiopathic, 1002–1003
- Torticollis, 1003
- Tositumomab, 1654*t*
for non-Hodgkin lymphoma, 525
- Total body iron, 492
- Total body water. *See* Body water
- Total iron-binding capacity (TIBC), 492, 1731*t*
in anemia of chronic disease, 492
- Total lung capacity (TLC). *See also* Pulmonary function tests
in COPD, 261
in cystic fibrosis, 267
- Total parenteral nutrition. *See* Central vein nutritional support
- Total protein. *See* Protein
- Tourette syndrome, 1004–1005
OCD and, 1005, 1041
- Toxic adenoma
multiple (toxic multinodular goiter), 1111, 1114, 1116
solitary (toxic solitary thyroid nodule), 1111, 1116
in MEN, 1188*t*
- Toxic epidermal necrolysis, 134, 135
drugs causing, 134, 135, 159*t*, 161
- Toxic erythema, drugs causing, 159*t*
- Toxic lung injury, 311
aspiration and, 308
smoke inhalation and, 307
- Toxic megacolon
acute colonic pseudo-obstruction (Ogilvie syndrome)
differentiated from, 628
in ulcerative colitis, 649
- Toxic multinodular goiter, 1111, 1114, 1116
- Toxic myocarditis, 409*t*, 410–411
- Toxic neuropathies, 1024
- Toxic psychosis, 1055
- Toxic shock syndrome
clostridial, 1429
diaphragm/cervical cap use and, 775
staphylococcal, 1427, 1427*f*
streptococcal, 1421–1422
- Toxic solitary thyroid nodule (toxic adenoma), 1111, 1116
in MEN, 1188*t*
- Toxicology screen, in poisoning/drug overdose, 1569–1570, 1569*t*
- Toxicosis, T₃, 1113
- Toxins. *See also* Poisoning/drug overdose
anion gap affected by, 877, 891
in *C difficile* colitis, 574*t*, 575, 576, 636, 637
in diarrhea/food poisoning/
gastroenteritis, 574*t*, 575, 1293, 1294*t*
liver disease caused by, 682–684. *See also* Hepatotoxicity
osmolar/osmol gap affected by, 877
screening for, 1569–1570, 1569*t*
- Toxocara canis/cati* (toxocariasis), 1523
- Toxoplasma/Toxoplasma gondii* (toxoplasmosis), 1500–1503
in HIV infection/AIDS, 993, 1327, 1338*t*, 1501, 1502
prevention/chemoprophylaxis and, 1335, 1337, 1502
during pregnancy/congenital, 1501, 1502
uveitis caused by, 178, 1501

- TP53* gene mutations. *See also* P53 gene mutations
in chronic lymphocytic leukemia, 522
gallbladder cancer and, 1606
hepatocellular carcinoma and, 1603
pancreatic/periampullary carcinoma and, 1607
- TPHA test, 1466
- TPMT. *See* Thiopurine methyltransferase
- TPN (total parenteral nutrition). *See*
Central vein nutritional support
- TPPA test, 1466, 1466t
- TRAb. *See* Thyrotropin receptor antibody
- Trabeculectomy, for glaucoma, 177
- Trabeculoplasty, laser, for glaucoma, 177
- Trace elements, in nutritional support, 1272
- Trachea
foreign body in, 238–239, 308
obstruction of, 242
stenosis of, 242
- Tracheal intubation. *See also* Intubation;
Mechanical ventilation
in ARDS, 323
for respiratory failure, 320, 321
- Tracheostomy/tracheotomy, 238. *See also*
specific disorder
for sleep apnea, 319
- Trachoma, 165–166
- Tractional retinal detachment, 179–180, 180
- Traditional serrated adenoma, 652, 653, 1622
- Tradjenta. *See* Linagliptin
- TRALI. *See* Transfusion-related acute lung injury
- TRAM (trans-rectus abdominis muscle) flap, for breast reconstruction, 745
- Tramadol
MAOI interactions and, 1585
for neuropathic pain, 84t, 85
overdose/toxicity of, 1586–1587
- Trandate. *See* Labetalol
- Trandolapril, 451t
with verapamil, 451t
- Tranquilizers. *See specific agent and*
Antipsychotic drugs
- Trans fatty acids, preventable disease/deaths caused by high intake of, 3t
- Transapical aortic valve replacement, 344
- Transarterial chemoembolization (TACE), for hepatocellular carcinoma, 1605
- Transarterial chemoinfusion (TACI), for hepatocellular carcinoma, 1605
- Transarterial radioembolization (TARE), for hepatocellular carcinoma, 1605
- Transbronchial lung biopsy. *See* Lung biopsy
- Transcobalamins, in polycythemia, 512
- Transcranial magnetic stimulation
for depression, 1065, 1071
for tinnitus, 208
- Transcatheter aortic valve implantation, 343–344
- Transdermal contraceptive patch, 773
- Transdermal testosterone, 1176. *See also*
Testosterone replacement therapy
- Transesophageal echocardiography. *See*
Echocardiography
- Transesophageal echocardiography-guided cardioversion, for atrial fibrillation, 386
- Transferrin
in anemia of chronic disease, 492, 493
carbohydrate deficient, alcohol use/abuse and, 1081
in hemochromatosis, 695
in iron deficiency anemia, 492
reference values for, 1735t
in sideroblastic anemia, 497
- Transferrin receptor, soluble, 493, 1735t
- Transferrin receptor 2 (*TFR2*) gene mutation, in hemochromatosis, 695
- Transforming growth factor β (*TGF- β*)
Marfan syndrome and, 1670
mutations in receptor for, pulmonary hypertension and, 423
- Transfusion (blood/blood products), 534–537. *See also specific type*
acute lung injury caused by, 536
for anticoagulant overdose, 1573
for aplastic anemia, 509
in autoimmune hemolytic anemia, 506
for bleeding disorders, 534, 536
for chemotherapy-associated anemia, 1649
contaminated blood and, 535
for DIC, 545, 546t
disease transmission and, 535–536
arbovirus encephalitides, 1378, 1379, 1380
Chagas disease, 1486
donor screening programs and, 535–536
erythrovirus (parvovirus), 1402
hepatitis, 535–536, 667, 669
HIV, 536, 1321, 1334
HTLV, 536, 1384
variant Creutzfeldt-Jakob disease, 1382
for fluid management/volume replacement
in GI bleeding/variceal hemorrhage, 582, 602
in shock, 487
graft-versus-host disease caused by, 536
for myelodysplastic syndromes, 518
preoperative, 52
for primary myelofibrosis, 515
purpura associated with, 546
for sickle cell anemia, 504
pregnancy and, 799
for sideroblastic anemia, 497
for thalassemia, 495, 495t, 496
for thrombotic microangiopathies, 543
- Transfusion graft-versus-host disease, 536
- Transfusion reactions
compatibility testing in prevention of, 534
contaminated blood causing, 535
hemolytic, 534–535
hypersensitivity reactions, 535
leukoagglutinin, 535
leukocyte-poor blood in prevention of, 534, 535
- Transfusion-related acute lung injury (TRALI), 536
- Transglutaminase/tissue transglutaminase (tTG), in celiac disease/dermatitis herpetiformis, 123, 622
- Transient autoimmune thyroiditis, postpartum, 800
- Transient elastography, in liver disease/cirrhosis, 687
- Transient ischemic attacks, 469, 470, 977–979
atrial fibrillation and, 385t, 469, 977, 978–979
carotid, 469, 977, 978
cerebrovascular occlusion/
embolization and, 469, 470, 977, 978–979
patent foramen ovale and, 329, 977
seizures differentiated from, 971, 978
strokes/stroke risk and, 469, 470, 977, 977–978
vertebrobasilar, 469, 978
- Transient monocular blindness, 184, 469
- Transjugular intrahepatic portosystemic shunts. *See* Transvenous (transjugular) intrahepatic portosystemic shunts
- Transketolase activity coefficient, in thiamine deficiency, 1264
- Translocational hyponatremia, 872, 874
- Transmetatarsal amputation, in lower leg/foot occlusive disease, 467
- Transmissible spongiform encephalopathies, 1381–1382
- Transnasal ventilation, for COPD, 264
- Transplantation. *See also specific type or organ and*
Immunocompromised host
fever/FUO and, 1276, 1277
hyperkalemia and, 879–880
hyperuricemia/gout and, 816
immunization in recipients and, 1314
infections following, 1279, 1279–1280, 1280–1281. *See also*
Opportunistic infections
adenoviruses causing, 1401, 1402
arbovirus encephalitides, 1378, 1379
CMV causing, 1280–1281, 1364, 1366
Creutzfeldt-Jakob, 1381
erythrovirus (parvovirus), 1402
fungal, 1281
hepatitis, 1402
herpes simplex, 1280
Pneumocystis, 1280, 1535
pneumonia, 279, 1402
prevention of, 1280–1281
toxoplasmosis, 1501, 1502
lymphoproliferative disorder after, 1277, 1362, 1363
organ donation for, 93
rabies transmitted by, 1376
squamous cell carcinoma after, 143
- Transrectal ultrasound. *See*
Ultrasonography

- Trans-rectus abdominis muscle (TRAM) flap, for breast reconstruction, 745
- Transsexualism, 1050
- Transthoracic needle aspiration/biopsy (TTNA/TTNB)
in lung cancer, 1597
in solitary pulmonary nodule, 290
- Transthyretin (TTR) hereditary amyloidosis, 531
- Transtacheal oxygen, for COPD, 262
- Transtubular potassium concentration gradient (TTKG), 878
- Transudates, pleural fluid, 313, 313*t*, 314, 315
- Transurethral electrovaporization of prostate, for benign prostatic hyperplasia, 961
- Transurethral incision of prostate (TUIP), for benign prostatic hyperplasia, 958*t*, 960
- Transurethral laser-induced prostatectomy (TULIP), for benign prostatic hyperplasia, 961
- Transurethral needle ablation of prostate (TUNA), for benign prostatic hyperplasia, 961
- Transurethral resection of bladder, for bladder cancer, 1639
- Transurethral resection of prostate (TURP), for benign prostatic hyperplasia, 958*t*, 960
- Transurethral resection syndrome, 960
- Transvaginal sonography/ultrasound. *See* Ultrasonography
- Transvenous (transjugular) intrahepatic portosystemic shunts (TIPS), 583
for cirrhotic ascites, 688
for esophageal varices, 583, 603
in noncirrhotic portal hypertension, 700
rebleeding prevention and, 603
for GI bleeding, 583, 603
for hepatic hydrothorax, 688
for hepatic vein obstruction (Budd-Chiari syndrome), 698
for hepatorenal syndrome, 689
- Transvestism, 1049
- Tranxene. *See* Clorazepate
- Tranylcypromine, 1070*t*
- Trastuzumab, 736, 741, 1654*t*
for breast cancer, 734, 736, 737, 741
cardiac toxicity of, 411, 737
for gastric adenocarcinoma, 1617
- Trauma
auricular (traumatic auricular hematoma), 199
cardiac injury and, 428–429
sudden death of athlete and, 431
cognitive disorders/delirium caused by, 1087*t*
complex regional pain syndrome and, 824–825
corneal, 165*t*
fat necrosis of breast caused by, 721
head injury and, 1016–1018, 1017*t*. *See also* Head injury
headache associated with, 965
hearing loss associated with, 207
hypokalemia and, 878
middle ear, 205, 206*f*
nasal, 221–222
epistaxis and, 220, 221
ocular, 192–194, 193*f*
pneumothorax and, 316
prevention of, 17
psychologic/psychiatric disorders after (posttraumatic stress disorder), 1039–1040
abuse victims and, 1039
rape and, 778
rhabdomyolysis/renal failure and, 844
seizures caused by, 969
spinal, 1018
subarachnoid hemorrhage and, 984, 1014
syringomyelia associated with, 1019
vertigo caused by, 211
- Travatan. *See* Travoprost
- Travel. *See also* Air travel
immunizations recommended for, 4, 1314–1316
hepatitis A, 667, 1315
hepatitis B, 1315
infectious disease and, 1296–1297
during pregnancy, 786–787
retinal detachment and, 180
SARS transmission and, 1400, 1401
tick typhus and, 1414
- Traveler's diarrhea, 575, 576, 1297, 1297–1298, 1447
coccidial and microsporidial, 1506
during pregnancy, 787, 1298
- Travoprost, for glaucoma/ocular hypertension, 171*t*, 176
- Travoprost/timolol, for glaucoma/ocular hypertension, 171*t*, 176
- Trazodone, 1069, 1070*t*. *See also* Antidepressants
for depression, 1069, 1070*t*
for insomnia, 1076–1077
in dementia, 1009
MAOI-induced, 1069
overdose/toxicity of, 1069, 1070*t*, 1591–1592
priapism caused by, 1069, 1076–1077
- Treanda. *See* Bendamustine
- Treatment refusal/withdrawal, 91, 91*t*
advance directives and, 89
- Trelstar. *See* Triptorelin
- Trematode (flake) infections, 1511–1514. *See also specific type*
blood flukes (schistosomiasis), 1511–1512
liver/lung/intestinal flukes, 1512–1514
- Tremor
benign essential (familial), 997
parkinsonism differentiated from, 998
drug-induced, 1004
fragile-X tremor-ataxia syndrome and, 1667
in parkinsonism, 998
in pheochromocytoma, 1167
- Trench fever, 1454
- Trench (immersion) foot/hand, 1545–1546
- Trench mouth, 226
- Trendelenburg test, 1690, 1690*t*
- Treponema*
non-sexually transmitted diseases caused by, 1474–1475
pallidum, 1300*t*, 1304*t*, 1464. *See also* Syphilis
carateum, 1475
endemicum, 1475
pertenue, 1300*t*, 1475
- Treponemal antibody tests, for syphilis, 1466, 1466*t*
- Treponemal tests, rapid, 1467
- Treprostinil, for pulmonary hypertension, 305, 424, 425, 425*f*
- Tretinoin. *See also* Retinoic acid
for acne, 126–127, 127
adverse ophthalmic effects of, 197*t*
for cancer chemotherapy, 1656*t*
for hyperpigmentation, 156
teratogenicity of, 127
- Trexall. *See* Methotrexate
- Triad asthma, 222
- Triamcinolone, 96*t*, 1190*t*. *See also* Corticosteroids
for acne, 128
for alopecia, 157
for asthma, 253*t*
intra-articular injection of, 812
- Triamterene
for heart failure, 401
with hydrochlorothiazide, for hypertension, 445*t*
hyperkalemia caused by, 401, 879
lithium interactions and, 1074, 1074*t*
- Triatomine bugs, Chagas disease transmitted by, 1486
- Triazines, in cancer chemotherapy, 1650*t*
- Triazolam, 1042*t*, 1043, 1076, 1077
overdose/toxicity of, 1077, 1579–1580
- Tribenzor (olmesartan HCTZ and amlodipine). *See* Olmesartan/olmesartan HCTZ
- Trichiasis, in trachoma, 166
- Trichinella/Trichinella spiralis* (trichinosis/trichinellosis), 1521–1522
- Trichloroethylene, toxicity of, 1583, 1588
- Trichoderma longibrachiatum*, in opportunistic infection, 1540–1541
- Trichomonas vaginalis* (trichomoniasis), 751, 752*f*, 753, 1510–1511
rape/sexual assault in transmission of, 778, 1291
- Trichophyton/Trichophyton rubrum*
tinea corporis/circinata caused by, 110
tinea pedis caused by, 112
tinea unguium caused by, 158
- Trichosporon*, in opportunistic infection, 1540–1541
- Trichotillomania, 157, 1041
- Trichuris trichiura* (trichuriasis/whipworm), 1517–1518
- Triclabendazole, for fascioliasis, 1513
- Tricor. *See* Fenofibrate
- Tricuspid regurgitation, 333, 334–336*t*, 347–348, 349
- Tricuspid stenosis, 334–336*t*, 346–347, 349

- Tricuspid valve
 replacement of, 346, 347, 349. *See also*
 Valve replacement
 in rheumatic fever/heart disease, 337, 417
- Tricyclic antidepressants, 1068–1069, 1070*t*. *See also*
 Antidepressants
 drug interactions of, 1071*t*
 in elderly, 63, 1068
 for neuropathic pain/painful diabetic neuropathy, 84, 84*t*, 1021, 1049, 1225
 overdose/toxicity of, 1068–1069, 1070*t*, 1563, 1564, 1575, **1591–1592**
 arrhythmias and, 1068, 1564, 1588, 1591, 1591*f*
 hypotension and, 1068, 1563
 ophthalmic effects and, 196*t*
 seizures and, 1068–1069, 1565*t*, 1591
 suicidal, 1065, 1067, 1591
 in pain management, 84, 84*t*, 1021, 1049
- Trientine, for Wilson disease, 697
- Trifascicular block, 395
- Trifluoperazine, 1056, 1056*t*, 1057*t*
- Trifluridine, for ophthalmic disorders, 169*t*, 1354*t*
- Trigeminal nerve
 herpes zoster ophthalmicus and, 120, 173, 1358, 1359
 postherpetic neuralgia and, 120, 968
- Trigeminal neuralgia (tic douloureux), **967**
 chemotherapy-induced, 1661
 headache and, 962
- Trigeminy, 390
- Triglycerides, 1246
 antiretroviral therapy and, 1344
 elevated levels of. *See*
 Hypertriglyceridemia
 in insulin resistance syndrome/diabetes mellitus, 1197, 1228
 lowering levels of, 1253, 1254, 1255–1256, 1255*t*
 reference values for, 1735*t*
 thiazolidinedione use and, 1210
- Trihexyphenidyl, for parkinsonism, 999*t*.
See also Antiparkinsonism drugs
- Triiodothyronine (T₃), 1105, 1105*t*
 serum levels of
 in euthyroid sick syndrome, 1107
 free, 1105, 1105*t*
 in hyperthyroidism, 1105*t*, 1110, 1113
 amiodarone-induced, 1113
 factors affecting, 1111*t*, 1114
 pregnancy and, 1117
 thyroiditis and, 1121
 in hypothyroidism
 factors affecting, 1107–1108, 1107*t*
 levothyroxine therapy and, 1109
 reference values for, 1735*t*
 total, 1105, 1105*t*, 1735*t*
 TSH/T₄ levels affected by, 1096
 uptake of (resin). *See* Resin T₃/T₄ uptake
- Triiodothyronine (T₃) toxicosis, 1113
- Triiodothyronine/thyroxine preparations, for hypothyroidism, 1108
- Trilafon. *See* Perphenazine
- Trilasate. *See* Choline magnesium salicylate
- Trilpix. *See* Fenofibric acid
- Trimethobenzamide, 568*t*. *See also*
 Antiemetics
- Trimethoprim
 hyperkalemia caused by, 879
 for *P jiroveci* infection, 1338*t*, 1339, 1534, 1535
 Trimethoprim/polymyxin B, for ophthalmic disorders, 168*t*
- Trimethoprim-sulfamethoxazole
 for actinomycetoma, 1540
 for bacterial rhinosinusitis, 216*t*
 for cyclosporiasis, 1508
 for isosporiasis, 1508
 for malaria, 1496
 for *Pneumocystis* infection, 1280, 1337*t*, 1338*t*, 1534
 resistance to, 940, 1534
 for toxoplasma treatment/prophylaxis, 1337, 1502
 for urinary tract infection, 939, 940, 940*t*
- Trimetrexate, for *P jiroveci* infection, 1338*t*
- Trimipramine, 1070*t*
- Trinucleotide repeats
 in fragile X mental retardation, 1667
 in Friedreich ataxia, 1022
 in Huntington disease, 1001
 in X-linked bulbospinal neuronopathy, 1020
- Triple A (Allgrove) syndrome, 1156, 1157, 1157–1158
- Triple test, in breast mass evaluation, 1719
- Triptans, for migraine headache, 42, 963–964
- Triptorelin pamoate, 1657*t*
- Trisenox. *See* Arsenic trioxide
- Trismus
 in cervicofacial actinomycosis, 1457
 in mumps, 1370
 in tetanus, 1429
- Trisomy 21 (Down syndrome), **1666–1667**
 prenatal screening for, 783, 1666
- Trivalent inactivated (TIV) influenza vaccine, 1396. *See also*
 Influenza virus vaccine
- Trivalent live-inactivated (LAIV) influenza vaccine, 1396. *See also*
 Influenza virus vaccine
- Trizivir. *See* Abacavir, with zidovudine and lamivudine
- TRK gene mutation, in papillary thyroid carcinoma, 1126
- Trochanteric bursitis, 825
- Troglitazone, withdrawal of from market, 1209, 1210
- Trombiculid mite larvae
 scrub typhus transmitted by, 1411
 skin lesions caused by, 149
- Trondane. *See* Pramoxine
- Tronothane. *See* Pramoxine
- Tropheryma whippelii*, 623, 624. *See also*
 Whipple disease
- Trophoblastic disease. *See* Gestational trophoblastic disease
- Tropical anhidrosis and asthenia, 131
- Tropical pancreatitis, 715
- Tropical pulmonary eosinophilia, 296, 1525
- Tropical spastic paraparesis, 1383–1384
- Tropisetron, 1660. *See also* Antiemetics
- Troponins
 in acute coronary syndromes/STEMI, 361, 366
 in chest pain evaluation, 29
 in DVT/PE (venous thromboembolic disease), 299
 in infectious myocarditis, 410
 reference values for, 1735*t*
- Trospium, for urinary incontinence, 68
- Trousseau sign (carpal spasm)
 in hypocalcemia/hypoparathyroidism, 882, 1136
 malabsorption and, 621*t*
- Trousseau syndrome, 545, 546
- True vocal fold (glottic) cancer, 236, 237
- Trusopt. *See* Dorzolamide
- Truvada. *See* Tenofovir, with emtricitabine
- Truvia. *See* Rebiana
- Trypanosoma* (trypanosomiasis)
 African, **1484–1485**, 1485*t*
 American (Chagas disease), **1486–1487**
 achalasia and, 605
brucei gambiense, 1484
brucei rhodesiense, 1484
cruzi, 1486
- Trypsinogen
 in acute pancreatitis, 711
 in chronic pancreatitis, 715
- Tryptophan, MAOI interactions and, 1585
- TSC1/TSC2 genes, in tuberous sclerosis, 996
- TSE. *See* Transmissible spongiform encephalopathies
- Tsetse flies. *See* Flies
- TSH. *See* Thyroid-stimulating hormone
- TSH receptor antibody (TSH-R Ab [stim]). *See* Thyroid-stimulating hormone receptor antibody
- TSL. *See* Thyroid-stimulating immunoglobulin
- TSP. *See* Tropical spastic paraparesis
- Tsutsugamushi fever (scrub typhus), 1409*t*, **1411–1412**
- TT virus (TTV), 670
- TT677 mutation
 in hepatic vein obstruction (Budd-Chiari syndrome), 698
 in noncirrhotic portal hypertension, 700
- TTF-1. *See* Thyroid transcription factor-1
- tTG. *See* Transglutaminase/tissue transglutaminase
- TTKG. *See* Transtubular potassium concentration gradient
- TTNA/TTNB. *See* Transthoracic needle aspiration/biopsy
- TTP. *See* Thrombotic thrombocytopenic purpura
- TTV. *See* TT virus

- Tubal ligation/sterilization, 777
- Tubal pregnancy, 790, 791. *See also*
Ectopic pregnancy
- Tube cecostomy, for acute colonic pseudo-obstruction (Ogilvie syndrome), 629
- Tube enterostomies, 1271, 1271f. *See also*
Enteral nutritional support
- Tube feedings. *See* Enteral nutritional support
- Tube thoracostomy (chest tube drainage)
for empyema, 279
for hemothorax, 316
for malignant effusions, 1646
for parapneumonic effusion, 315–316
for pneumothorax, 317
- Tuberculin skin test, 4, 282, 283t, 286
BCG vaccine affecting, 282, 287
in HIV infection/AIDS, 283t, 1326, 1334, 1337
in intestinal tuberculosis, 631
latent disease treatment and, 286, 286–287
in pregnancy, 783, 805
in spinal tuberculosis, 863
in tuberculous meningitis, 1459
- Tubercloid leprosy, 1460. *See also*
Leprosy
- Tuberculosis, **279–287**, 281t, 282f, 283t, 284t, 289t, 1459
Addison disease caused by, 1155, 1158
blood tests/interferon gamma release assays in identification of, 4, 282–283, 286, 315, 1334
spinal disease and, 863
bone and joint infection in, 285, **863–864**
drug-resistant/multi-drug resistant/ extensively drug-resistant, 280, 281, 281t, 285, 286
directly observed therapy (DOT) and, 284, 285, 286
tests in identification of, 281, 281t, 285
treatment of contacts and, 286
in drug users, 1292
extrapulmonary, 285. *See also specific type or site*
fever/FUO in, 1277
in HIV infection/AIDS, 4, 280, 281, 1326
chemoprophylaxis/prevention and, 4, 1334, 1337
drug-resistant disease and, 280, 281, 281t, 1326
drug use and, 1292
intestinal involvement and, 631
treatment of, 4, 285, 1326
intestinal, **631**
latent, 280, 286–287
testing for, 282–283, 283t
meningitis and, **1459–1460**
miliary, 282
musculoskeletal involvement and, 285, **863–864**
pericarditis and, 419, 420
peritoneal involvement in, 588, 590
pleural effusion in, 282, 314–315, 314t
during pregnancy/lactation, 285–286, 287, **805**
prevention/control of, 4
HIV infection/AIDS and, 4, 1334, 1337
primary, 280
progressive primary, 280
pulmonary, **279–287**, 281t, 282f, 283t, 284t, 289t
reactivation, 4, 280, 282, 282f
anti-TNF agents and, 640, 830, 1281
renal manifestations of, **936**
as reportable disease, 283
salpingitis and, 763
silicosis and, 309
skin test for. *See* Tuberculin skin test
spinal (Pott disease), **863–864**
treatment of, 4, 283–287, 284t, 289t, 1300t. *See also*
Antituberculous drugs
- Tuberculous arthritis, **864**
- Tuberculous lymphadenitis, **240**, 1458
- Tuberculous meningitis, **1459–1460**
- Tuberculous pericarditis, 419, 420
- Tuberculous peritonitis, 588, 590
- Tuberculous salpingitis, 763
- Tuberin gene, in tuberous sclerosis, 996
- Tuberous sclerosis, **996**
angiomyolipoma of kidney in, 1642
- Tuberous sclerosis complex, neuroendocrine tumors in, 1172
- Tube-ovarian abscess, 763–764
anaerobic, 1456
appendicitis differentiated from, 631
- Tubular acidosis. *See* Renal tubular acidosis
- Tubular necrosis, acute, 902t, **904–906**
in pancreatitis, 713
rhabdomyolysis and, 844, 905
urinalysis in, 898, 902t, 905
- Tubular proteinuria, 899
- Tubulointerstitial diseases, 909t, **932–933**, 932t
in SLE, 926
- TUIP. *See* Transurethral incision of prostate
- Tularemia, **1450–1451**
- TULIP. *See* Transurethral laser-induced prostatectomy
- Tumefactive chronic pancreatitis, 716
- Tumor embolization, pulmonary metastases and, 1601
- Tumor lysis syndrome, **1647–1648**
allopurinol for, 1647, 1658t
rasburicase for, 1647, 1658t
- Tumor necrosis factor (TNF/cachectin) agents inhibiting. *See* Anti-TNF agents
in alcoholic liver disease, 680–681
in fever, 35
in inflammatory bowel disease, 640
insulin action in obesity and, 1194
- Tumor plop, 427
- Tumor suppressor gene mutations. *See also specific type*
in breast cancer, 722
in colorectal cancer, 1622
in pancreatic/periampullary carcinoma, 1607–1608
in thyroid cancer, 1127, 1128
- Tumoral calcinosis, 912
- Tums (calcium carbonate). *See* Calcium, dietary/supplementary
- TUNA. *See* Transurethral needle ablation of prostate
- Tungiasis (*Tunga penetrans*), 149
- Tuning fork tests, of hearing, 198–199
- Turcot syndrome, 655. *See also* Familial adenomatous polyposis
- Turner syndrome (gonadal dysgenesis), **1186–1188**, 1187t
amenorrhea caused by, 1179, 1180, 1186, 1187
thyroid dysfunction and, 1120
- TURP. *See* Transurethral resection of prostate
- TVS (transvaginal sonography/ultrasound). *See* Ultrasonography
- 12-lead ECG. *See* Electrocardiogram
- Twinrix (hepatitis A and B vaccine), 667
- TwoDay method of contraception, 776
- Twynsta. *See* Telmisartan, with amlodipine
- Ty21a vaccine. *See* Typhoid vaccine
- Tygalil. *See* Tigecycline
- Tykerb. *See* Lapatinib
- Tylenol. *See* Acetaminophen
- Tylox. *See* Oxycodone
- Tympanic membrane
in acute otitis media, 203
in chronic otitis media/cholesteatoma, 204
in eustachian tube dysfunction, 201, 202
in external otitis, 200
perforation of
in acute otitis media, 203
cerumen removal and, 200
in chronic otitis media, 203, 204
ototoxic ear drops contraindicated in, 207
traumatic, 205, 206f
underwater diving contraindicated in, 203
reconstruction of, 204
in serous otitis media, 202
- Tympanocentesis, in otitis media, 203
- Typhoid fever, 1445, **1445–1446**
prevention/immunization and, 1315, 1446
- Typhoid vaccine, 1315, 1446
- Typhus, 1357t. *See also specific type*
- Tyramine, MAOI interactions and, 1000, 1585
- Tyrosine kinase inhibitors, 1654–1655t
for acute lymphoblastic leukemia, 521
for chronic myeloid leukemia, 516–517
for gastrointestinal mesenchymal tumors, 1619–1620
hypothyroidism caused by, 1106
- Tyrosine phosphatases, antibodies to, in type 1 diabetes, 1193, 1193t
- Tyrosinemia, hepatocellular carcinoma and, 1604
- U-Lactin, 99t
- U waves, antipsychotic drugs causing, 1059
- UGFS. *See* Ultrasound-guided foam sclerotherapy
- “Ugly duckling sign,” 102

- UGT 1A1 (uridine diphosphoglucuronosyltransferase 1A1) variants, clinical relevance of testing for, 1726t
- Uhl disease, 411
- UIP. *See* Usual interstitial pneumonia
- UKPDS (United Kingdom Prospective Diabetes Study), 1202–1203
- Ulcer perforation, **618–619**
- Ulcerative colitis, 638, **646–650**, 646t. *See also* Inflammatory bowel disease
- arthritis in, 858
- colorectal cancer and, 649, 1623
- diarrhea in, 574t, 578, 646, 647
- drug therapy for, 647–649
- fulminant, 646, 649
- GI bleeding and, 584, 646
- primary sclerosing cholangitis and, 709, 710
- social support and, 641
- Ulcerative stomatitis. *See* Stomatitis, ulcerative
- Ulcers. *See also* Peptic ulcer disease
- amebic, 1504, 1504f
- anal fissures, 660–661
- aphthous. *See* Aphthous ulcer
- Buruli, 1458
- contact, of arytenoid cartilage, 235
- corneal, **167–174**. *See also* Keratitis
- contact lens wear and, 162, 172, 173, 174
- genital/genitourinary. *See* Genital ulcers
- intraoral, **226–227**, 227f
- in Behçet syndrome, 853
- chemotherapy-induced, 1660
- herpes simplex esophagitis and, 598
- in HIV infection/AIDS, 1329
- skin. *See* Skin disorders, ulcers
- Ulipristal, for emergency/postcoital contraception, 776
- Ulnar nerve lesions, **1026–1027**
- in leprosy, 1023, 1460
- Ultram. *See* Tramadol
- Ultrarapid detoxification, for heroin/opioid withdrawal, 1084
- Ultrasonography/Doppler
- ultrasonography/duplex ultrasonography. *See also* Echocardiography
- in abdominal aortic aneurysm screening/diagnosis, 6, 7t, 473
- in abnormal premenopausal bleeding, 747
- in acute arterial limb occlusion, 468
- in aortic regurgitation, 336t, 345
- in aortic stenosis, 336t, 342
- in aortoiliac occlusive disease, 464
- in appendicitis, 630
- in ascites, 588
- in atrial septal defect/patent foramen ovale, 328
- in breast lump evaluation, 718, 727, 728f, 729
- pregnancy and, 807, 1718
- in cardiomyopathy, 412, 414, 416
- in carotid occlusive disease, 469
- in cerebrovascular occlusive disease, 469
- for cholecystitis, 704–705
- in chronic kidney disease, 911
- in chronic venous insufficiency, 33t, 34, 481
- in cirrhosis, 687
- in coarctation of aorta, 327
- in DVT/PE (venous thromboembolic disease), 33t, 34, 300
- in ectopic pregnancy, 790
- fetal, 781, 783, 784
- maternal diabetes and, 801
- in gastric adenocarcinoma, 1616
- in gastric lymphoma, 1618
- in gastrointestinal mesenchymal tumors, 1619
- in gestational trophoblastic disease, 791, 792
- in heart disease. *See* Echocardiography
- in hepatic vein obstruction (Budd-Chiari syndrome), 698
- in infertility workup, 768, 955
- in insulinoma detection, 1172, 1240
- intravascular, in angina, 354
- in leiomyoma of uterus, 758
- in liver cancer, 1604
- in liver disease/jaundice, 664–665
- in lower extremity edema, 34
- in mesenteric ischemia, 471
- in mitral regurgitation, 336t, 339
- in mitral stenosis, 336t, 338
- musculoskeletal, 1674
- in myocardial infarction, 366
- for ovarian cancer screening/evaluation, 16, 764, 1710
- in pancreatic/periampullary carcinoma, 1608
- in pancreatitis, 712, 713, 716, 717
- in patent ductus arteriosus, 333
- pelvic, 1715
- in peripheral artery aneurysms, 476
- in polycystic kidney disease, 935
- in postmenopausal bleeding, 749
- during pregnancy, 781, 783, 784, 790
- in prostate cancer
- for biopsy guidance, 1631, 1633f
- for screening, 1631
- for staging, 1631
- in pulmonary hypertension, 305, 424
- in pulmonary stenosis, 325, 326
- in pulmonary valve regurgitation, 348
- in renal artery stenosis/renal vascular hypertension, 437, 917
- in renal cell carcinoma, 1641
- in simple renal cysts, 934
- in spontaneous abortion, 788
- in testicular cancer, 1643
- in tetralogy of Fallot, 331
- in thyroid disorders
- hyperthyroidism, 1114
- thyroid cancer, 1124t, 1128, 1129, 1132
- thyroid nodules, 1105t, 1123, 1123–1124, 1124, 1124t
- thyroiditis, 1121
- in tricuspid regurgitation, 336t
- tricuspid stenosis, 336t
- in urinary stone disease, 947
- in valvular heart disease, 336t
- in varicose veins, 478
- in ventricular septal defect, 330
- in Zollinger-Ellison syndrome/gastrinoma, 620
- Ultrasound-guided foam sclerotherapy, for varicose veins, 1720
- Ultravate. *See* Halobetasol
- Ultraviolet (actinic) keratitis, **194**
- Ultraviolet light/sunlight exposure to
- actinic keratoses and, 117
- basal cell carcinoma and, 142
- herpes simplex recurrence and, 118
- hyperpigmentation and, 156
- hypersensitivity to (photosensitivity/photodermatitis), 95t, **152–153**. *See also* Photodermatitis/photosensitivity
- in lupus/SLE, 114, 834
- for osteoporosis/osteomalacia, 1146, 1151
- in porphyria cutanea tarda, 122
- squamous cell carcinoma and, 143
- vitamin D and, 1146, 1149, 1151
- protection from
- in cancer prevention, 15, 99
- in lupus/SLE, 114, 834
- in photodermatitis, 153
- in porphyria cutanea tarda, 122
- in rosacea, 128
- sunscreens for, **99**
- vitamin D deficiency and, 1149
- with psoralen. *See* PUVA therapy
- Umbilical cord blood, stem cells in, for transplantation, 533
- Unasyn. *See* Ampicillin-sulbactam
- Uncinate (temporal lobe) lesions, 989–990
- Undernutrition. *See also* Malnutrition; Nutritional disorders
- in elderly, **69–70**
- Underwater diving. *See* Scuba/deep sea diving
- Undescended testes. *See* Cryptorchism
- Undifferentiated schizophrenia, 1053
- Unicuspid aortic valve, 341–342
- Unilateral fold paralysis, 237–238
- Unipolar disorder, endogenous, 1063. *See also* Depression
- Uniretic. *See* Moexipril, with hydrochlorothiazide
- United Kingdom Prospective Diabetes Study (UKPDS), 1202–1203
- Unithiol, for mercury poisoning, 1583
- Univasc. *See* Moexipril
- Universal precautions, 1284. *See also* Body substance isolation
- HIV infection/AIDS prevention and, 1334
- Unlawful sexual intercourse (statutory rape), 777
- Unoprostone, for glaucoma/ocular hypertension, 171t, 176
- Unstable angina. *See also* Acute coronary syndromes
- β-blockers for, 363
- calcium channel blockers for, 363
- chest pain/discomfort in, 28, 28t, 29
- clopidogrel for, 356, 361
- revascularization procedures/PCI for, 364, 364t

- Urinary tract infection (*Cont.*):
 dysuria and, 43–45, 44f
E coli causing, 1299t, 1302t, 1303t
 health care (hospital)-associated, 1282, 1284
 incontinence and, 67
 kidney injury and, 910t, 932
 in polycystic kidney disease, 934–935, 935
 during pregnancy, **803–804**
 in schistosomiasis, 1511
 struvite calculi and, 946, 947, 949
 vesicoureteral reflux and, 932
- Urinary tract obstruction
 kidney injury and, 903, 910t
 tubulointerstitial disease caused by, 932
- Urinary urgency. *See* Irritative voiding symptoms; Urge incontinence
- Urination. *See* Voiding
- Urine
 acidification of, in poisoning/drug overdose, 1567
 alkalization of
 for cystine calculi, 949
 for lithium overdose/toxicity, 1073
 in poisoning/drug overdose, 1567
 for salicylate toxicity, 1589
 for uric acid calculi, 949
 candida in, 1529, 1530
 ketones in. *See* Ketonuria
 osmolality of. *See* Osmolality, urine
 pH of
 calcium stones and, 947, 949
 cystine calculi and, 947, 949
 manipulation of in poisoning/drug overdose, 1567
 in normal anion gap/renal tubular acidosis, 892, 892t, 893
 stone disease and, 947
 struvite calculi and, 947, 949
 uric acid calculi and, 947, 949
 sodium in. *See* Sodium, urine
 for toxicology screening, 1569–1570
- Urine culture, in dysuria evaluation, 43
- Urine output
 in acute kidney injury, 901, 903
 in acute tubular necrosis, 905, 906
 in diabetes insipidus, 1098, 1099
 incontinence in elderly and, 67–68
 monitoring
 in burn care, 1551
 in heat stroke, 1548
 in oliguria, 903
 in preeclampsia-eclampsia, 793t, 794, 795
- Urine protein-to-creatinine ratio, 899. *See also* Proteinuria
 in glomerulonephritis, 908
- Urodynamic studies
 in benign prostatic hyperplasia, 957
 in interstitial cystitis, 945–946
 in prostatodynia, 944
- Urofollitropins, for male infertility, 1097
- Urokinase. *See also* Thrombolytic therapy
 for pulmonary embolism, 303, 562t
- Urolithiasis, **946–950**, 947t. *See also* Nephrolithiasis; Urinary stone disease
- Urologic disorders, **938–961**. *See also* Genitourinary system, disorders of
- Uropathy, obstructive
 postrenal, 903
 tubulointerstitial disease caused by, 932
- Uroporphyrins, in porphyria cutanea tarda, 122
- Urosepsis, 43. *See also* Urinary tract infection
- Urothelial cell carcinoma
 of bladder, 1638
 of ureter/renal pelvis, 1641
- Ursodeoxycholic acid
 for biliary cirrhosis, 693–694
 for cholelithiasis/gallstones, 704
 for intrahepatic cholestasis of pregnancy, 807
 for primary sclerosing cholangitis, 610
- Urticaria, **132–134**, 133f, 866
 ACE inhibitor/angiotensin II receptor antagonist therapy and, 132
 antihistamines for, 99, 133
 cholinergic, 133
 cold, 133
 drugs causing, 133, 159t
 desensitization reaction and, 1307
 insect bites/stings causing, 133, 149
 transfusion causing, 535
- Urticating hairs, skin lesions caused by, 149
- Ustekinumab, for psoriasis, 108
- Usual interstitial pneumonia (UIP), 293, 294t, 295
- Uterine bleeding. *See* Menstruation; Vaginal bleeding
- Uterine suspension, for pelvic organ prolapse, 762
- Uterine tubes, ligation of, 777
- Uterus
 cancer of. *See* Endometrial carcinoma
 disorders of, amenorrhea in, 1179, 1180–1181
 gravid. *See* Pregnancy
 leiomyoma (fibroid tumor) of, **757–759**
 perforation of by IUD, 774
 peripartum infection of, **798**
- UVA therapy, with psoralen. *See* PUVA therapy
- UVB therapy. *See also* Phototherapy
 for atopic dermatitis, 104
 for lichen planus, 144
 for psoriasis, 107
- Uveitis, 165t, **177–178**
 in ankylosing spondylitis, 855
 anterior (iritis), 165t, 173, 177, 177–178, 178
 in Behçet syndrome, 178, 853
 immune recovery, 187
 in leptospirosis, 1477
 posterior, 177, 178
 in syphilis, 178, 1469
 in toxoplasmosis, 178, 1501
- Uvulopalatopharyngoplasty, for sleep apnea, 319
- V1/V2 vasopressin receptors, in diabetes insipidus, 1098
- V2 vasopressin receptor antagonists, for hyponatremia/SIADH, 875
- V617F mutation, 1732t
 in hepatic vein obstruction (Budd-Chiari syndrome), 698
 in noncirrhotic portal hypertension, 700
- V/Q scans. *See* Ventilation-perfusion scans
- v wave
 in constrictive pericarditis, 422
 in heart failure, 399
- VA. *See* Visual acuity
- vacA* gene, in *H pylori* gastritis, 609
- Vaccine bacillus Calmette-Guérin. *See* BCG vaccine
- Vaccine-derived polio virus (VDPV), 1372, 1374
- Vaccine-preventable infections, 3, **1367–1375**. *See also* specific type
- Vaccines. *See* specific type and Immunization
- Vaccinia, 1403–1404
 in atopic dermatitis/eczema patients, 104, 1403, 1404
 monkeypox prevention and, 1404
 smallpox vaccination and, 1403, 1404
- Vaccinia immune globulin, 1404
- Vaccinia syndrome, acute, 1403
- Vacuum erection device, for erectile dysfunction, 953, 1227
- VADT (Veteran Administration Diabetes Trial), 1204
- Vagal nerve. *See* Vagus nerve
- Vagal nerve stimulation
 for depression, 1071
 for seizures, 974
- Vagifem, 1184
- Vagina. *See also* under Vaginal anaerobic flora/infection of, 1455–1456
 inflammation/infection of. *See* Vaginitis/vulvovaginitis
 pH of, 751
- Vaginal atrophy. *See* Atrophic vaginitis
- Vaginal bleeding
 abnormal premenopausal, **747–749**
 in polycystic ovary syndrome, 765, 1162
 in cervical cancer, 757
 in endometrial carcinoma, 749, 759
 leiomyomas causing, 758
 normal menstrual, 747. *See also* Menstruation
 postmenopausal, **749**
 during pregnancy
 ectopic pregnancy and, 790
 gestational trophoblastic disease and, 791
 third-trimester, **797**
 in spontaneous abortion, 788, 789
- Vaginal cancer, Pap smear in screening for, 16
- Vaginal cones, for urinary incontinence, 69
- Vaginal discharge, 1290. *See also* Vaginitis/vulvovaginitis
 STDs causing, 1290
- Vaginal dryness. *See* Atrophic vaginitis
- Vaginal estrogen, 780, 1184
- Vaginal hernias (pelvic organ prolapse), **762**
- Vaginal pessary. *See* Pessary

- Vaginal ring
 contraceptive, 773
 for estrogen replacement therapy, 780, 1184
- Vaginal ultrasound. *See* Ultrasonography
- Vaginal vault suspension, for pelvic organ prolapse, 762
- Vaginal warts, 752, 753. *See also* Venereal (genital) warts
- Vaginismus, 767, 1050, 1051
- Vaginitis/vulvovaginitis, 751–753, 751f, 1290. *See also* Vulvovaginal candidiasis
 atrophic. *See* Atrophic vaginitis
 dysuria and, 43
 gonococcal, 1452
 sexual pain caused by, 767
 STDs causing, 1290
Trichomonas vaginalis causing, 751, 752f, 753, 1510–1511
- Vaginosis, bacterial, 751–752, 752f, 753
 rape/sexual assault in transmission of, 1291
- Vagus nerve
 hiccups caused by irritation of, 569
 lesion/damage of, vocal fold paralysis and, 237–238
 stimulation of. *See* Vagal nerve stimulation
- Valacyclovir, 1354t
 for herpes simplex infections, 118–119, 173, 598, 1330, 1338t, 1352, 1354t, 1355
 for herpes zoster, 120, 173, 1331, 1339t, 1354t, 1359
 prophylactic/suppressive, 118, 119
- Valcyte. *See* Valganciclovir
- Valganciclovir, 1354t
 for CMV infection, 187, 598, 1280, 1281, 1338t, 1354t, 1365, 1366
- Valgus stress test, 1695t, 1698
- Valium. *See* Diazepam
- Valosin-containing protein gene mutation, in Paget disease, 1152
- Valproic acid/valproate, 972, 973t, 1074, 1724t
 for aggressive/violent patient, 1078
 for bipolar disease/mania, 1074
 lithium interactions and, 1074t
 for migraine prophylaxis, 964t, 1074
 overdose/toxicity of, 973t, 1074, 1569t, 1573
 hemodialysis for, 1568t, 1574
 for panic attacks, 1044, 1074
 pregnancy and, 803, 972, 1074
 for seizures, 972, 973t
 status epilepticus and, 974
 teratogenic effects of, 803, 972, 1074
- Valsalva maneuver
 heart murmurs affected by, 337t
 palpitations affected by, 31
 for paroxysmal supraventricular tachycardia, 382
 response to in syncope, 397
- Valsartan
 for heart failure, 402
 for hypertension, 452t
 with aliskiren, 452t
 with amlodipine, 452t
 with amlodipine and hydrochlorothiazide, 452t
 with hydrochlorothiazide, 452t
 for myocardial infarction, 371
- Valtrex. *See* Valacyclovir
- Valturna. *See* Aliskiren, with valsartan
- Valve replacement, 349–350
 anticoagulation after, 343, 349
 endocarditis and, 1439
 pregnancy and, 349
 for aortic regurgitation, 345
 for aortic stenosis, 343–344
 choice and management of prosthetic valves for, 349–350
 coagulase-negative staphylococcal infection and, 1428
 for endocarditis, 349, 1439
 for mitral regurgitation, 340, 349
 for mitral stenosis, 338
 before planned noncardiac surgery, 49
 for pulmonary stenosis, 326, 349
 for pulmonary valve regurgitation, 348, 349
 for tricuspid regurgitation, 347, 349
 for tricuspid stenosis, 346, 349
- Valves
 cardiac. *See also* Prosthetic heart valves; Valve replacement; Valvular heart disease
 endocarditis affecting, 338, 1435, 1437, 1439. *See also* Endocarditis
 venous, incompetence of
 chronic venous insufficiency and, 33, 480, 481
 varicose veins and, 478
- Valvular heart disease, 333–350, 334–336t, 337t. *See also specific type*
 in alkaptonuria, 1665
 endocarditis and, 1435. *See also* Endocarditis
 Q fever, 1415, 1416
 in Marfan syndrome, 345, 428, 1670, 1671
 pregnancy and, 338, 349, 431
 preoperative evaluation/perioperative management and, 49
 rheumatic fever/rheumatic heart disease and, 333, 337, 417, 418–419
 in Turner syndrome, 1186, 1187
- Valvular papillary fibroelastoma, 427
- Valvular rupture, 428
- Valvuloplasty, 349
 for aortic stenosis, 343, 349
 for mitral stenosis, 338, 349
 before planned noncardiac surgery, 49
 during pregnancy, 349
 for pulmonary stenosis, 326
- Vancocin. *See* Vancomycin
- Vancomycin, 1724t
 for anthrax, 1433t
 for antibiotic-associated colitis, 637, 638
 for endocarditis, 1421, 1437, 1438, 1439
 for meningitis, 1286t
 nephrotoxicity of, 904
 for pneumonia, 273, 273t, 277t
 red man syndrome caused by, 867
 resistance to, 273
- Vandetanib, 1655t
- Vanicream, 94, 103
- Vanillylmandelic acid, urinary, reference values for, 1735t
- Vaniqua. *See* Eflornithine
- Vantin. *See* Cefpodoxime
- VAP. *See* Ventilator-associated pneumonia
- Vaqtta. *See* Hepatitis A vaccine
- Vardenafil
 for erectile dysfunction, 952, 1051
 antidepressant-induced, 1051, 1067
 in diabetes, 1226
 nitrate/nitroglycerin contraindications and, 370, 952, 1051, 1226
- Varenicline, for smoking cessation, 8, 1593
- Variant (Prinzmetal) angina, 360
- Variant Creutzfeldt-Jakob disease, 1381–1382, 1382. *See also* Creutzfeldt-Jakob disease
- Varicella (chickenpox), 1356–1361, 1357t, 1358f
 during pregnancy/congenital, 804–805, 1359
 prevention/immunization and. *See* Varicella vaccine
 reactivation of, 119–120, 120f, 1357. *See also* Herpes zoster
- Varicella vaccine, 5, 120, 1308t, 1309t, 1310t, 1359
 adverse effects/contraindications and, 1317t
 immunocompromised host/HIV infection/AIDS and, 5, 1309t, 1314, 1360
 postexposure, 1360
 pregnancy and, 786, 1309t, 1360
- Varicella-zoster immune globulin, 1360
 for newborn, 805, 1360
 during pregnancy, 805, 1360
- Varicella zoster virus, 1356. *See also* Herpes zoster; Varicella
 Bell palsy caused by, 1028, 1359
 immunization against. *See* Herpes zoster vaccine; Varicella vaccine
 infection with during pregnancy, 804–805, 1359
 reactivation of, 119–120, 120f, 1357. *See also* Herpes zoster
- Varicocele, in infertility, 769, 954–955, 955
- Varicose veins (varicosities/varices), 478–479
 esophageal. *See* Esophageal varices
 GI bleeding from, 581, 601–604
 portal hypertension/portal hypertensive gastropathy causing, 581, 601
 leg ulcers and, 153, 479
 pelvic, pain and, 1715
 treatment of in women, 1720
 venous insufficiency/stasis and, 479, 481
- Variegate porphyria, 1022
- Varilrix. *See* Varicella vaccine
- Variola (smallpox), 1357t, 1403–1404

- Variola (smallpox) vaccination, 1403–1404
atopic dermatitis/eczema and, 104, 1403, 1404
- VARIVAX. *See* Varicella vaccine
- VariZIG. *See* Varicella-zoster immune globulin
- Varus stress test, 1696*t*, 1698
- Vas deferens
absence of, in cystic fibrosis/infertility, 267, 955
obstruction of, in male infertility, 955–956
- Vasa previa, third-trimester bleeding caused by, 797
- Vascular access. *See also* Arterial lines; Catheters/intravenous lines
in burn care, 1550
- Vascular dementia, 59, 1008*t*
hypertension and, 439
- Vascular disorders (vascular occlusion/anomalies), **464–483**. *See also specific type or vessel affected and* Vasculitis
- acute kidney injury and, 902
- arterial aneurysms, **472–478**
- atherosclerotic, **464–471**
homocysteine/
hyperhomocysteinemia and, 1668–1669
- chronic kidney disease and, 909*t*, 911, 912
- in diabetes mellitus, 356, 1197, 1227–1228
aspirin in prevention of, 1203, 1227
foot ulcers/gangrene and, 154, 467, 1227–1228
glycemic control and, 356, 1201, 1202, 1203, 1204
hypertension control and, 433, 442*t*, 443, 457, 458, 1202, 1203, 1227
- erectile dysfunction and, 464, 951, 952, 953
- GI bleeding and, 581, 584
- glomerulonephritis and, 306, 849, 851, 907
- headache and, 41, 966
- hepatic vein
Budd-Chiari syndrome, **697–699**
sinusoidal obstruction syndrome, 683, 698
- in hypertension, 439
- nonatherosclerotic, **471–472**
- osteomyelitis and, 154, 862
- in preeclampsia-eclampsia, 793*t*
- pregnancy and, **431**
- in Q fever, 1416
- seizures caused by, 969
- shock and, **485–489**, 485*t*
- in sickle cell syndromes, 503, 504
- spinal cord, **988–989**
- transient ischemic attacks and, 977
- venous, **478–483**
- Vascular endothelial growth factor (VEGF), inhibitors of. *See* Anti-VEGF therapy
- Vascular loops, 213
- Vascular reconstruction. *See* Bypass grafting
- Vasculitis, **844–854**, 845*t*. *See also specific disorder*
allergic, drugs causing, 159*t*
brain and spinal cord involvement and (primary angiitis of central nervous system), **854**
cancer and, 864
coronary artery involvement and, 428
glomerulonephritis in, 919*t*, 921*f*
pulmonary, **306**
asthma differentiated from, 248
retinal, 178. *See also* Uveitis
retinal artery occlusion and, 183
in rheumatoid arthritis, 827
in SLE, 833
urticarial, 133
- Vasectomy, 777
- Vaseretic. *See* Enalapril, for hypertension, with hydrochlorothiazide
- Vasoactive drug therapy
for dysautonomia, 976
in erectile dysfunction, 952, 952–953
in diabetes, 1226–1227
diagnosis and, 952
for esophageal varices, 602
for shock, 487–488
- Vasoactive intestinal polypeptide (VIP), tumors secreting (VIPoma), 1172, 1189
diarrhea and, 580, 1172, 1189
- Vasodepressor syncope, 396
- Vasodilator therapy
for heart failure, 404
left ventricular (infarct-related), 373
for hypertension, 453, 456*t*, 458*t*
in urgencies/emergencies, 462*t*
for pulmonary hypertension, 305, 424, 425*f*
- Vasodilatory (distributive) shock, 485, 485*t*, 488
- Vasography, in male infertility, 955
- Vasomotor disorders
in menopause (hot flashes), 779, 779–780, 1181, 1186
estrogen replacement therapy for, 779–780, 1182
topical progesterone for, 1185
in pheochromocytoma/paraganglioma, 1167, 1168*t*
rhinitis, 218, 219
syncope (vasovagal syncope), 396
- Vaso-occlusive episodes, in sickle cell syndromes, 503, 504
pregnancy and, 799
- Vasopressin. *See also* Antidiuretic hormone; Desmopressin
in diabetes insipidus, 1098
for shock, 488
in volume overload, 877
- Vasopressin challenge test, in diabetes insipidus, 1099
- Vasopressin-resistant diabetes insipidus, 1098
- Vasopressin V1/V2 receptors, in diabetes insipidus, 1098
- Vasopressin V2 receptor antagonists, for hyponatremia/SIADH, 875
- Vasopressinase, diabetes insipidus caused by, 1098
- Vasospasm. *See also* Vasomotor disorders
- coronary, **359–360**
in pheochromocytoma/paraganglioma, 1167, 1168*t*
in Raynaud phenomenon, 836, 837
subarachnoid hemorrhage and, 985
- Vasotec. *See* Enalapril; Enalaprilat
- Vasovagal syncope, 396
- Vater, ampulla of. *See* Ampulla of Vater
- VATS. *See* Video-assisted thoracoscopic surgery
- VC (vital capacity), forced. *See* FVC
- vCJD. *See* Variant Creutzfeldt-Jakob disease
- VDPV. *See* Vaccine-derived polio virus
- VDRL test, 659, 1466, 1466*t*
on cerebrospinal fluid (CSF-VDRL), 1473
in HIV infection/AIDS, 1335
in HIV infection/AIDS, 1334, 1335
for rape victim, 778
- Vectibix. *See* Panitumumab
- Vegetarians/vegans
diet in pregnancy/lactation and, 785, 786
dietary vitamin B₁₂ deficiency in, 497
- Vegetative state, persistent, **1016**
- Vegetectomy, for endocarditis, 1439
- Vein stripping, for varicose veins, 479, 1720
- Veins
deep, thrombosis of. *See* Deep venous thrombosis
disorders of, **478–483**. *See also under Venous and Veno-occlusive disease*
superficial, thrombophlebitis involving, **479–480**
varicose. *See* Varicose veins
- Velban. *See* Vinblastine
- Velcade. *See* Bortezomib
- VEMPs. *See* Vestibular-evoked myogenic potentials
- Vemurafenib, 1655*t*
- Vena cava, superior, obstruction of, **482–483**
in lung cancer, 482, 1597
- Vena cava filters/interruption, for pulmonary embolism, 303, 563
- Venereal Disease Research Laboratory test. *See* VDRL test
- Venereal infections. *See* Sexually transmitted diseases
- Venereal (genital) warts, 139, 140, 140*f*, 141, 752, 753
anorectal involvement and, 139, 140*f*, 659
cervical/vaginal/vulvar, 752, 753
HPV vaccination in prevention of, 4, 140, 659, 1709
imiquimod for removal of, 140, 753
podophyllum resin for removal of, 140, 753
- Venezuelan equine encephalitis, 1378–1380
- Venlafaxine, 1067, 1068, 1070*t*
for anxiety, 1043
in elderly, 63
MAOI interactions and, 1585
for neuropathic pain, 84*t*, 85, 1021, 1067

- overdose/toxicity of, 1068, 1070t, 1591–1592
 during pregnancy, 1067–1068
- Venography
 in DVT/PE (venous thromboembolic disease), 300
 in superior vena caval obstruction, 482
- Venomous insect bites/stings, 149
 anaphylaxis caused by, 866
 myocarditis caused by, 409t
- Venomous snake bites, 1566t, **1589–1590**
 myocarditis caused by, 409t
- Veno-occlusive disease
 hepatic
 Budd-Chiari syndrome, **697–699**
 sinusoidal obstruction syndrome, 683, 698
 pulmonary hypertension and, 304–305, 423t, 424
- Venous access. *See* Catheters/intravenous lines
- Venous blood gases, in acid-base disorders, 889
- Venous catheterization. *See* Catheters/intravenous lines
- Venous disease, **478–483**. *See also specific type and Veno-occlusive disease; Venous insufficiency/stasis*
- Venous insufficiency/stasis, 33, 34, **480–482**
 DVT/PE (venous thromboembolic disease), 33, 33t, 34, 297, 480, 481
 leg ulcers and, 33, 34, **153–155**, 154f, 481
 osteomyelitis and, 154, 862
 lower extremity edema and, 33, 34, 481
 varicose veins and, 479, 481
- Venous pressure
 central. *See* Central venous pressure
 elevated, in superior vena cava obstruction/syndrome, 482
 in lower extremity
 edema and, 33
 normal, 33
- Venous reflux
 in chronic venous insufficiency, 480, 481
 in varicose veins, 478, 479
- Venous sinus thrombosis
 cancer-related, 994
 in pseudotumor cerebri, 995
- Venous stasis. *See* Venous insufficiency/stasis
- Venous thromboembolic disease, 555
 air travel and, 34, 1560
 in antiphospholipid antibody syndrome, 799, 835, 836
 cancer-associated, 301t, 1596t
 chest pain/discomfort and, 28, 29, 29–30, 298, 298t, 355
 of deep veins. *See* Deep venous thrombosis
 detection of, 33, 33t, 300
 pulmonary embolism diagnosis and, 300, 301t
 in essential thrombocytosis, 513
 estrogen replacement therapy and, 780, 1183
- fever and, 1283
 in granulomatosis with polyangiitis, 849
 in homocystinuria, 1669
 hypercoagulability and, 297
 intracranial, **988**. *See also* Stroke
 in nephrotic syndrome/nephrotic spectrum disorders, 928
 oral contraceptive use and, 770
 prevention of, 301, 555–556, 556t, 557t, 558t
 pulmonary embolism and, 297, 300, 301, 301t, 555. *See also* Pulmonary venous thromboembolism
 risk/risk stratification and, 33, 33t, 297, 297–301, 298t, 301f, 301t, 302t, 555–556, 556–557, 556t, 560t
 treatment of, 301–303, 556–563
 anticoagulation in, 301–303, 556–562, 559t, 560t, 561t, 562t
 nonpharmacologic therapy in, 563
 thrombolytic therapy in, 303, 556, 562–563, 562t
- Venous thrombophlebitis, superficial, **479–480**
- Venous valves, incompetence of
 chronic venous insufficiency and, 33, 480, 481
 varicose veins and, 478
- Venovenous/continuous venovenous hemodiafiltration, for poisoning/drug overdose, 1567–1568
- Ventilation
 disorders of control of, **317–319**. *See also* Hyperventilation; Hypoventilation
 mechanical. *See* Mechanical ventilation
- Ventilation-perfusion scans, 299–300
 in COPD, 260t
 in cor pulmonale, 426
 in pulmonary embolism, 299–300, 300, 302t
 chest pain evaluation and, 29
 in pulmonary hypertension, 305, 424
- Ventilator-associated pneumonia, **275–278**, 277t, 321, 1283, 1284
- Ventricular aneurysm, myocardial infarction and, 375
- Ventricular arrhythmias. *See also specific type*
 in cardiomyopathy, 391, 411, 412, 414
 catheter ablation of, 380
 differentiation of from aberrantly conducted supraventricular beats, 381, 391
 in myocardial infarction, 365, 372–373
 antiarrhythmic prophylaxis/treatment and, 371, 372–373
 in poisoning/drug overdose, 1564, 1564t
- Ventricular assist devices, 406
 for cardiomyopathy, 413
 for infectious myocarditis, 410
- Ventricular cysts, in cysticercosis, 1515
- Ventricular dysfunction/failure. *See* Congestive heart (cardiac) failure
- Ventricular fibrillation, **392–393**
 catheter ablation of, 380
 in myocardial infarction, 365, 373, 392
 antiarrhythmic prophylaxis/treatment and, 371, 373
 sudden death caused by, **392–393**
 treatment of, 378–379t, 392
- Ventricular gallop. *See* Heart sounds
- Ventricular noncompaction, 411
- Ventricular premature beats (ventricular extrasystoles/premature ventricular contractions/PVCs), **390**
 in infectious myocarditis, 410
 in myocardial infarction, 372
 in poisoning/drug overdose, 1564t
 treatment of, 378t, 390
- Ventricular rate control. *See* Rate control
- Ventricular reduction surgery, for heart failure, 406
- Ventricular septal aneurysm, 330
- Ventricular septal defect, **329–330**
- Ventricular tachycardia, **390–392**. *See also* Torsades de pointes
 catheter ablation of, 380, 391
 driving recommendations and, **397–398**
 in myocardial infarction, 365, 373, 391
 antiarrhythmic prophylaxis/treatment and, 371, 373
 palpitations and, 31
 in poisoning/drug overdose, 1564, 1564t
 preoperative evaluation/perioperative management of, 49
 treatment of, 378–379t, 391–392
- Ventriculoencephalitis, CMV, 1364
- Vepesid. *See* Etoposide
- Verapamil, 454t. *See also* Calcium channel blocking drugs
 for acute coronary syndromes, 363
 for angina, 356
 for arrhythmias, 379t
 atrial fibrillation, 386
 supraventricular tachycardia, 379t, 382
 for hypertension, 453, 454t
 with trandolapril, 451t
 for islet cell tumors/insulinomas, 1241
 for migraine prophylaxis, 964t
 overdose/toxicity of, 379t, 454t, 1576
- Verbal utterances, in schizophrenia/psychotic disorders, 1054
- Verbigeration, in schizophrenia/psychotic disorders, 1054
- Verelan/Verelan PM. *See* Verapamil
- Vernal keratoconjunctivitis, 167
- Verner–Morrison syndrome, 1172, 1189
- Verocell rabies vaccine, 1377
- Verrucae. *See* Warts
- Versed. *See* Midazolam
- Vertebrae. *See* Spinal cord; Spine
- Vertebral artery occlusion, in stroke, 981
- Vertebral compression/fracture
 back pain caused by, 819, 1683
 in osteoporosis, 1144, 1710
 in Paget disease, 1152, 1153

- Vertebral osteomyelitis, 861–862, 862, 1426
 back pain and, 819, 820, 1426
 epidural abscess and, 861–862, 862, 1426
 injection drug use and, 861–862, 1292
- Vertebrobasilar insufficiency/obstruction stroke caused by, 980*t*, 981
 transient ischemic attacks caused by, 469, 978
 vertigo caused by, 210*t*, 213
- Vertigo, **209–212**, 209*t*, 210*t*
 in audiovestibular disorders, 208, 210*t*, 212–213
 barotrauma and, 202, 203
 benign paroxysmal positioning (BPPV), 210*t*, 211
 central causes of, 209*t*, 210, 210*t*, 212, 212–213
 cervical, 211–212
 in labyrinthitis, 210–211, 210*t*
 in Ménière syndrome, 210, 210*t*
 migrainous, 210*t*, 212
 mixed central and peripheral causes of, 209*t*
 in multiple sclerosis, 210*t*, 213
 in perilymphatic fistula, 210*t*, 211
 peripheral causes of, 209–210, 209*t*, 210–212
 in superior semicircular canal dehiscence, 212
 traumatic, 211
 vascular compromise causing, 213
 in vestibular neuronitis, 210*t*, 211
 vestibular schwannoma (acoustic neurinoma) causing, 210*t*, 212
- Very-low-calorie diets, in obesity management, 1260
- Very-low-density lipoproteins/cholesterol, 1246. *See also* Triglycerides
 in atherosclerosis/heart disease, 1245, 1246
 lowering levels of. *See* Lipid-lowering therapy
- Vesanioid. *See* Tretinoin
- Vesicoureteral reflux, tubulointerstitial disease caused by, 932
- Vesicular dermatoses, 95*t*, **118–123**. *See also specific type*
- Vesiculobullous hand eczema/
 vesiculobullous dermatitis of palms and soles (pompholyx), **121–122**, 121*f*
 tinea differentiated from, 113
- Vestibular disorders (vestibulopathy), 209*t*, 210, 210*t*, 212, **212–213**
 autoimmune hearing loss and, 208, 210*t*
 central, 209*t*, 210, 210*t*, 212, **212–213**
 nausea and vomiting caused by, 86, 567*t*
 neuronitis, 210*t*, 211
 peripheral, 209–210, 209*t*, 210–212
 schwannoma. *See* Schwannoma, vestibular
 vertigo in, 209–212, 209*t*, 210*t*, 212–213. *See also* Vertigo
- Vestibular-evoked myogenic potentials (VEMPs), in vertigo, 210
- Vestibulitis
 nasal, **217**
 vulvar, 767
- Veteran Administration Diabetes Trial (VADT), 1204
- Vexol. *See* Rimexolone
- VFend. *See* Voriconazole
- VHL. *See* von Hippel-Lindau syndrome
- VHL gene, in pheochromocytoma/paranglioma, 1168
- Vi capsular polysaccharide (Vi CPS) vaccine. *See* Typhoid vaccine
- Viagra. *See* Sildenafil
- Vibration sense, disorders of, in tabs dorsalis, 1472
- Vibrio, 1300*t*, **1448–1449**
alginolyticus, 1448, 1449
cholerae, 1293, 1295*t*, 1300*t*, 1448. *See also* Cholera
 immunization against, 1314–1315, 1448
 diarrhea/food poisoning caused by, 574*t*, 576, 1293, 1298, 1448
parahaemolyticus, 574*t*, 1293, 1294*t*, 1448, 1449
vulnificus, 1448, 1449
- Vicodin. *See* Hydrocodone
- Victoza. *See* Liraglutide
- Vidarabine, 1354*t*
- Vidaza. *See* Azacitidine
- Video-assisted thoracoscopic surgery (VATS)
 for hepatic hydrothorax, 688
 in lung cancer diagnosis, 1597
 in mesothelioma diagnosis, 1602
 for pulmonary effusion/tamponade, 421
 for pulmonary infiltrates in immunocompromised host, 279
 for solitary pulmonary nodule, 291
- Videosophagography, 592
- Videonystagmography (VNG), in vertigo, 210
- Videx. *See* Didanosine
- Vidian nerve, in vasomotor rhinitis, 218
- Vigabatrin, overdose/toxicity of, 1573
 ophthalmic effects and, 196*t*
- Vigamox. *See* Moxifloxacin
- Viibryd. *See* Vilazodone
- Vilazodone, 1067, 1070*t*
- Vildagliptin, 1207*t*, 1213
- VIN. *See* Vulvar intraepithelial neoplasia
- Vinblastine, 1652*t*
 for Kaposi sarcoma, 145, 1339*t*
 for renal cell carcinoma, 1641
- Vinca alkaloids, 1652*t*
 neuropathy caused by, 1661
- Vincent angina (necrotizing ulcerative/fusospirochetal gingivitis), **226**
- Vincristine, 1652*t*
 adverse ophthalmic effects of, 197*t*
 neuropathy caused by, 1661
 Raynaud phenomenon caused by, 837
- Vinorelbine, 1652*t*
- Vinyl chloride exposure, liver cancer and, 1604
- Vioform. *See* Iodoquinol
- Violence, **1078–1079**. *See also* Rape
- alcohol use/abuse and, 1078, 1079
 anabolic steroid use and, 1078, 1086
 domestic, 17, 1078, 1079
 elder abuse and, 17
 intimate partner, 17, 1078, 1079, **1711–1712**
 prevention of, 17, 1712
 phencyclidine use/abuse and, 1055, 1078, 1084
 prevention of, 17
- VIP. *See* Vasoactive intestinal polypeptide
- VIPomas, 1172, 1189
 diarrhea and, 580, 1172, 1189
- Vira-A. *See* Vidarabine
- Viracept. *See* Nelfinavir
- Viral diseases, **1350–1408**. *See also specific type*
 adenovirus, **1401–1402**
 arthritis and, **861**
 blood transfusion in transmission of, 535–536
 conjunctivitis, **164–165**
 diarrhea/gastroenteritis, 574*t*, 575, 1293, 1330, **1404–1405**
 drug therapy for, 1353–1354*t*
 enterovirus, 1356*t*, **1405–1408**
 exanthematous, 1356–1357*t*, **1402–1404**
 hepatitis. *See* Hepatitis
 herpesvirus, **1350–1367**
 meningitis. *See* Aseptic meningitis
 myocarditis in, 409, 409*t*
 neurotropic, **1376–1384**
 pericarditis, 419, 420
 respiratory, **1393–1401**
 rhinosinusitis (common cold), **213–214**, 1401
 bacterial rhinosinusitis and, 213, 214
 cough in, 21
 systemic, **1384–1393**
 vaccine-preventable, **1367–1375**
- Viral load tests (HIV). *See* HIV viral load tests
- Viramune/Viramune XR. *See* Nevirapine
- Virchow node, 1616
- Virchow triad, 297
- Viread. *See* Tenofovir
- Viridans streptococci, 1299*t*, 1422
 endocarditis caused by, 1302*t*, 1422, 1435, 1437–1438
- Virilization, **1161–1164**
 in polycystic ovary syndrome, 765, 1162
- Viroptic. *See* Trifluridine
- Virtual colonoscopy
 in colorectal cancer screening and evaluation/polyip identification, 16, 653, 1624, 1626*t*, 1628
 in diverticular disease, 651, 652
- Viruses. *See* Viral diseases
- Visceral artery endarterectomy, for visceral ischemia, 471
- Visceral artery insufficiency, **470–471**
- Visceral hypersensitivity (heightened visceral nociception)
 chest pain/discomfort and, 606–607
 irritable bowel syndrome and, 633
- Visceral ischemia, 470–471
- Visceral larva migrans, 1523

- Visceral leishmaniasis (kala azar), 1487, 1487–1488, 1488, 1488–1489
 dermal leishmaniasis after, 1487–1488
 in HIV infection/AIDS, 1488
- Viscerotropic disease
 leishmaniasis, 1488. *See also* Visceral leishmaniasis
 yellow fever vaccine-associated, 1316, 1390
- Viscocanalostomy, for glaucoma, 177
- Visicol. *See* Sodium phosphate
- Vision
 double. *See* Diplopia
 impaired/blurred. *See* Visual impairment/loss
- Visken. *See* Pindolol
- Vistaril. *See* Hydroxyzine
- Visual acuity
 assessment of in elderly, 72
 in optic neuritis, 188, 188–189
 reduced. *See* Visual impairment/loss
 in retinal artery occlusion, 183
 in retinal vein occlusion, 182
 in vitreous hemorrhage, 180
- Visual field defects/loss. *See also* Visual impairment/loss
 in dysthyroid eye disease, 1112
 in glaucoma, 176, 177
 in headache, 41–42, 963
 intracranial tumors causing, 990, 991
 in ischemic optic neuropathy, 188
 in optic neuritis, 188
 in retinal artery occlusion, 183
 in retinal detachment, 180
 in stroke, 981
 in Sturge-Weber syndrome, 997
 in transient monocular blindness, 184, 469
- Visual impairment/loss. *See also* Visual field defects/loss
 in acute angle-closure glaucoma, 174, 175
 in age-related macular degeneration, 181
 antipsychotics causing, 1059
 in blood dyscrasias, 186–187
 in botulism, 1034, 1431
 cataract causing, 179
 in diabetes, 185–186, 185f, 1197, 1197t, 1201, 1223
 in elderly, 72
 episodic, in transient monocular blindness, 184, 469
 in giant cell arteritis, 845, 845–846, 846
 in glaucoma, 174, 175, 176, 177
 in headache, 41–42, 963
 in ischemic optic neuropathy, 188
 onchocerciasis causing, 1526–1527
 in optic neuritis, 188
 in pseudotumor cerebri, 995
 refractive errors causing, 162–163
 in retinal artery occlusion, 183
 in retinal detachment, 180
 in retinal vein occlusion, 182
 in stroke, 981
 in Sturge-Weber syndrome, 997
 in thyroid disease. *See* Dysthyroid eye disease
 in trachoma, 165–166
 in transient monocular blindness, 184, 469, 981
 in uveitis, 178
 in vitamin A deficiency, 1266, 1267
 in vitreous hemorrhage, 180
- Visuospatial impairment, in dementia, 1006
- Vital capacity, forced. *See* FVC
- Vitamin A. *See also* Beta-carotene
 deficiency of, **1266–1267**
 toxicity of, **1267**
 ophthalmic effects and, 197t
- Vitamin B₁. *See* Thiamine
- Vitamin B₂. *See* Riboflavin
- Vitamin B₃. *See* Niacin
- Vitamin B₆ (pyridoxine)
 deficiency of, **1265–1266**
 homocystinuria/
 hyperhomocysteinemia and, 1668, 1669
 for isoniazid overdose/toxicity, 285, 285–286, 286, 805, 1566t, 1581
 toxicity of, **1266**
- Vitamin B₁₂ (cobalamin), 497
 deficiency of, **497–498**, 497t
 in bacterial overgrowth, 497, 624, 625
 dementia and, 60, 498, 1007
 fish tapeworm infection and, 497, 1514
 folic acid deficiency and, 498, 499
 neuropathy associated with, 498, 1023
 pernicious anemia and, 497, 498, 610
 short bowel syndrome/ileal resection and, 497, 625
 subacute combined degeneration of spinal cord caused by, 1013
 thrombocytopenia associated with, 540
- homocystinuria/
 hyperhomocysteinemia and, 1668, 1669
- serum levels of
 in polycythemia, 512
 reference values for, 1735t
 in vitamin B₁₂ deficiency, 497
- supplemental, 498
 during pregnancy/lactation, 785, 786, 787
 for short bowel syndrome, 625
 for subacute combined degeneration of spinal cord, 1013
- Vitamin B₁₂ absorption test (Schilling test), short bowel syndrome/ileal resection and, 625
- Vitamin C (ascorbic acid)
 in chemoprevention, 11, 23
 deficiency of, **1266**
 toxicity of, **1266**
- Vitamin D, 1149, 1267
 adverse ophthalmic effects of, 197t
 deficiency of/resistance to, 1149, 1150, 1151
 in chronic kidney disease/renal osteodystrophy, 912, 912f
 in cirrhosis, 687
 in HIV infection/AIDS, 1328
 in hyperparathyroidism, 1140, 1142, 1143
 in hypocalcemia, 882
 in osteomalacia, 912, 1149, 1150
 in osteoporosis, 1145, 1710
 dietary/supplementary, 1146, 1151, 1267
 hypercalcemia and, 107, 884, 1141–1142, 1151
 for hyperparathyroidism, 1140, 1143–1144
 for hypocalcemia/
 hypoparathyroidism/tetany, 882, 1137, 1137t, 1138
 for metabolic bone disorders/renal osteodystrophy, 913
 for osteomalacia, 1151
 for osteoporosis prevention/
 management, 11, 66, 67t, 780, 1146, 1710
 in hypercalcemia, 107, 883, 884, 1141–1142, 1151
 in hypercalciuria, 884, 947t, 948
 hypophosphatemia/hypophosphatemic rickets and, 878t, 1149, 1150, 1151
 in Paget disease of bone, 1152
 phosphate metabolism and, 884, 885
 receptors for, 1149
 reference values for, 1735t
 sun exposure and, 1146, 1149, 1151
- Vitamin D₂ (ergocalciferol/ergosterol), 1149. *See also* Vitamin D
 for hypoparathyroidism, 1137t, 1138
 for vitamin D deficiency/osteomalacia, 1151
- Vitamin D₃ (cholecalciferol), 1149. *See also* Vitamin D
 in hypercalcemia, 883, 884, 1141–1142
 for hypoparathyroidism, 1137t
 for vitamin D deficiency/osteomalacia, 1151
- Vitamin D analogs. *See also* Vitamin D
 for hyperparathyroidism, 1143–1144
 for psoriasis, 107
- Vitamin D-dependent rickets, 1149
- Vitamin D-resistant (hypophosphatemic) rickets, 878t, 1150, 1151
- Vitamin E
 in chemoprevention, 11
 deficiency of, **1012**, **1267**
 toxicity of, **1267**
- Vitamin K, 1268
 for anticoagulant overdose, 1573
 in coagulation, 553
 deficiency and, **553**
 for esophageal varices, 602
 for hypoprothrombinemia, in cirrhosis, 690
- Vitamin K antagonists, 555. *See also* Warfarin
- Vitamin K epoxide reductase complex (VKORC1), 553
 clinical relevance of testing for variants of, 1726t
- Vitamin supplements, in HIV infection/AIDS, 1335
- Vitamins. *See also specific vitamin*
 adverse ophthalmic effects of, 197t
 deficiency of, in alcoholic liver disease/cirrhosis, 680, 686

- Vitamins (*Cont.*):
 disorders of metabolism of, **1264–1268**
 prenatal, 783
 requirements for in nutritional support, 1272
- Vitiligo, 155, 156
 in Addison disease, 1156
 tinea versicolor differentiated from, 114
- Vitreotomy
 for diabetic retinopathy, 186
 for retinal detachment, 180
 for retinal vein occlusion, 182
- Vitreous hemorrhage, **180**
- Vivactil. *See* Protriptyline
- Vivelle/Vivelle-Dot, 1183
- VKORC1 (vitamin K epoxide reductase complex), 553
 clinical relevance of testing for variants of, 1726*t*
- VLDL. *See* Very-low-density lipoproteins/cholesterol
- VLP vaccine. *See* Human papillomavirus (HPV) virus-like particle (VLP) vaccine
- VMA. *See* Vanillylmandelic acid
- VNG. *See* Videonystagmography
- VO₂ (maximal oxygen uptake), lung cancer surgery and, 1599
- Vocal fold cysts, 235
- Vocal fold dysfunction, 242
 dyspnea and, 25, 242
- Vocal fold nodules, 235
- Vocal fold polyps, 235
- Vocal folds
 cancer of, 236
 in hoarseness, 233
 leukoplakia of, 236
 paralysis of, **237–238**
 thyroid surgery and, 237, 238, 1116, 1119, 1129
 traumatic lesions of, **235–236**
 laryngitis and, 233
- Voglibose, 1206*t*, 1210
- Vogt-Koyanagi-Harada syndrome, 178
- Voice, abnormal, 233
 in laryngeal cancer, 236
 in lung cancer, 233, 1597
 in peritonsillar abscess/cellulitis, 229
 in vocal fold paralysis, 237, 238
- Voice rehabilitation, after laryngeal surgery, 237
- Voiding. *See also* Irritative voiding symptoms; Obstructive voiding symptoms
 dysfunctional, in prostatodynia, 944
 increased. *See* Polyuria
 involuntary. *See also* Urinary incontinence
 during sleep. *See* Enuresis
 painful (dysuria), **43–45**, 44*f*
- Voltaren/Voltaren-XR. *See* Diclofenac
- Volume-control ventilation, for ARDS, 323
- Volume depletion. *See also* Dehydration
 kidney injury and, 902, 910*t*
 saline-responsive metabolic alkalosis and, 894–895
- Volume overload, **876–877**
- Volume reduction surgery, for COPD, 265
- Volume replacement. *See* Fluid management/hydration
- Volume status
 hyponatremia and, 875, 876
 hyperosmolality and, **877**
 hyponatremia and, 871*f*, 872–874
 kidney injury and, 902, 910*t*
 metabolic alkalosis and, 894–895
- Volutrauma. *See* Barotrauma
- Vomiting, **86**, **566–569**, 567*t*. *See also*
 Nausea and vomiting
 in cholecystitis, 703*t*, 704
 in chronic intestinal pseudo-obstruction/gastroparesis, 568, 629
 with diarrhea/food poisoning/gastroenteritis, 575, 1293, 1294–1295*t*
 in gastric outlet obstruction, 567*t*, 568, 619
 induced
 in bulimia nervosa, 1263
 for poisoning/drug overdose, 1566
 in intracerebral hemorrhage, 983, 984
 Mallory-Weiss syndrome/tears and, 568, 582, 599
 palliation of, **86**
 of pregnancy, 781, **787**
 gestational trophoblastic disease and, 791
 Wernicke encephalopathy and, 1013
 radiation exposure and, 567*t*
 in subarachnoid hemorrhage, 984
 underwater diving/barotrauma and, 202, 203
- Vomiting center, 86, 566
- von Graefe sign, 1112
- von Hippel-Lindau syndrome
 neuroendocrine tumors in, 1172
 pheochromocytoma/paraganglioma in, 1167, 1168
 renal cell carcinoma in, 1641
- von Recklinghausen disease, **996**, 996*f*
 pheochromocytoma/paraganglioma in, 1167
- von Willebrand disease, 550*t*, **551–552**, 552*t*
 type 2B, **547**, 551, 552*t*
- von Willebrand factor, 551
 reference values for, 1735*t*
- von Willebrand factor cleaving protease (vWF₁₃/ADAMTS-13), in thrombotic microangiopathies, 542
- von Willebrand factor concentrate, 550*t*, 552
- von Willebrand factor-containing factor VIII concentrate, 550*t*, 552
- von Willebrand factor receptor, in Bernard-Soulier syndrome, 548
- Voriconazole, 1542, 1542*t*
 for aspergillosis, 1538
 for candidiasis, 598, 1530
 for ophthalmic disorders, 168*t*
 for paracoccidioidomycosis, 1539
 prophylactic, 1281
 squamous cell carcinoma development and, 143
- Votrient. *See* Pazopanib
- Voyeurism, 1049
- VPBs. *See* Ventricular premature beats
- V/Q scans. *See* Ventilation-perfusion scans
- VSD. *See* Ventricular septal defect
- VSL#3 probiotic
 for irritable bowel syndrome, 635–636
 for ulcerative colitis/pouchitis, 648, 649–650
- VTE. *See* Venous thromboembolic disease
- Vulvar carcinoma, **759–760**
- Vulvar dystrophy, 760
- Vulvar intraepithelial neoplasia (VIN), 760
- Vulvar vestibulitis, 767
- Vulvar warts, 752, 753. *See also* Venereal (genital) warts
- Vulvectomy, 760
- Vulvodynia, 767, 1715
- Vulvovaginal candidiasis, 132, 751, 751*f*, 752–753, 1529, 1530
 in diabetes, 1197, 1197*t*, 1228
 in HIV infection/AIDS, 1332, 1337, 1338*t*
 rape/sexual assault and, 1291
- Vulvovaginitis. *See* Vaginitis
- vWD. *See* von Willebrand disease
- vWF. *See* von Willebrand factor
- vWF₁₃. *See* von Willebrand factor cleaving protease
- VX poisoning, 1587
- VZIG. *See* Varicella zoster immune globulin
- VZV. *See* Varicella zoster virus
- VZV vaccine. *See* Herpes zoster vaccine
- Waist-hip ratio, in obesity, 1259
- Waldenström macroglobulinemia, **529–530**, 1610*t*
 cold agglutinin disease and, 507, 530
- Walking program
 for COPD, 264
 for osteoarthritis, 811
- Warfarin, 555, 557*t*, 558, 560*t*, 561*t*
 for antiphospholipid antibody syndrome, 836
 in SLE, 834
 for atrial fibrillation, 386
 in hyperthyroidism, 1118
 in mitral stenosis, 338
 benzodiazepine interactions and, 1043*t*
 after cardiac valve replacement surgery, 343, 349
 drug interactions and, 560*t*
 for DVT/PE (venous thromboembolic disease) prevention/treatment, 301, 302, 303, 557*t*, 558, 560*t*, 561*t*
 for heparin-induced thrombocytopenia, 544–545, 544*t*
 in myocardial infarction, 371, 376
 overdose/toxicity of, 303, 1573
 perioperative, 52, 349
 pregnancy and, 349
 for pulmonary hypertension, 424
 SSRI interaction and, 1067
 for transient ischemic attacks, 979
- Warts (verrucae), **139–141**, 140*f*
 venereal. *See* Venereal (genital) warts

- Washout time, in antidepressant drug therapy, 1069
- WAST (Women Abuse Screening tool), 1712
- Wasting
in HIV infection/AIDS, 1325
in protein-energy malnutrition, 1258
- Watchful waiting/surveillance
for benign prostatic hyperplasia, 958*t*, 959, 1636
for prostate cancer, 1632, 1633, 1636
for testicular cancer, 1643
- Water
body. *See* Body water
contaminated
amebiasis and, 1503, 1504, 1505
cholera and, 1448
coccidial/microsporidial infection and, 1506, 1508
cyclosporiasis and, 1507
diarrhea and, 1293
dracunculiasis and, 1520, 1521
enteric (typhoid) fever and, 1445, 1446
fascioliasis and, 1512, 1513
fasciolopsiasis and, 1513
giardiasis and, 1509, 1510
gnathostomiasis and, 1522
Legionnaires disease and, 1443
leptospirosis and, 1477
paragonimiasis and, 1513
purification for pregnant patients and, 787
schistosomiasis and, 1511, 1512
- Water deficit. *See also* Dehydration
calculation of, 876
- Water drinking. *See* Psychogenic polydipsia; Water/fluid intake
- Water fleas, dracunculiasis transmitted by, 1520–1521
- Water/fluid intake. *See also* Fluid management/hydration
in diabetes insipidus, 1098, 1099
disorders of/inappropriate, 1055
genetic disorders and, 878*t*
hypernatremia caused by, 875, 876
hyponatremia caused by, 871, 1055
heat exposure prevention and, 1547
requirements for in nutritional support, 1271
restriction of
for chronic kidney disease, 915
for hyponatremia, 874
urinary stone formation and, 947, 948, 949
withholding, in terminally ill/dying patient, 90–91
- Water-hammer pulse, 344
- Water shifts, hyperosmolality with and without, 877
- Waterhouse-Friderichsen syndrome, 1154
- Waterston-Cooley shunt, for tetralogy of Fallot, 331
- WDHA, 1189
- Weakness/muscle weakness, 977. *See also* Myopathies; Myositis; Paralysis
in botulism, 1033–1034
in Cushing syndrome, 841, 1158
in diabetes, 1197, 1197*t*
differential diagnosis of, 841–842
drugs causing, 841–842
in Guillain-Barré syndrome, 1024
in HIV infection/antiretroviral therapy, 861, 1325, 1328
in inclusion body myositis, 841, 1036
in metabolic bone disorders/renal osteodystrophy, 912
in motor neuron diseases, 977, 1019, 1020
in multiple sclerosis, 1010
in muscular dystrophy, 1034
in myasthenia gravis, 1032
in myasthenic (Lambert-Eaton) syndrome, 1033
in polymyositis/dermatomyositis, 840, 841
spinal trauma causing, 1018
in stroke, 981
- Web space (interdigital) tinea pedis, 112, 113*f*
cellulitis and, 112, 137
- WEB (Women's Experience with Battering) scale, 1712
- Weber test, 199
- Webs, esophageal. *See* Esophageal webs
- Weeping/crusted skin lesions, 95*t*, 123–125. *See also specific type*
drying agents for, 94
- Wegener granulomatosis. *See* Granulomatosis, with polyangiitis
- Weight
changes in. *See also* Weight gain; Weight loss
water balance and, 870, 897
exercise/activity in maintenance of, 12–13, 13
normal, 37
- Weight gain. *See also* Obesity
binge eating disorder and, 1714
drugs causing
antipsychotic agents, 1059, 1060*t*
lithium, 1073
thiazolidinediones, 1210
in pregnancy, 783, 785
prevention of, exercise/activity and, 12–13, 13
smoking cessation and, 8
- Weight loss (involuntary/unintended), 37–38, 37*t*. *See also specific disorder and* Weight reduction
in anorexia, 1262
in diabetes, 1197, 1197*t*
diabetic neuropathic cachexia and, 1226
in elderly, 37, 37*t*, 69–70
in HIV infection/AIDS, 1325
malabsorption and, 621*t*
in protein-energy malnutrition, 1257, 1258
in Whipple disease, 623
- Weight reduction, 1260–1261
in arthritis prevention/management, 811
exercise/activity in, 12–13, 13
in GERD management, 596
in hypertension management/prevention, 436, 441, 441*t*
for obese patient, 14, 1260–1261
obesity-hypoventilation (Pickwickian) syndrome and, 318
with type 2 diabetes, 1205, 1220
for polycystic ovary syndrome, 766
in psoriasis management, 106
for sleep apnea, 319
for snoring, 231
- Weil-Felix test, in relapsing fever, 1475
- Weil syndrome, 1477
- WelChol. *See* Colesevelam
- Wellbutrin. *See* Bupropion
- “Wells rule,” 34
- Wenckebach (Mobitz type I)
atrioventricular block, 394, 394–395
in myocardial infarction, 373
- Werdnig-Hoffmann disease, 1020
- Wermer syndrome. *See* Multiple endocrine neoplasia (MEN), type 1
- Wernicke aphasia, stroke causing, 981
- Wernicke encephalopathy/syndrome, 893, 1013, 1081, 1264
- Wernicke-Korsakoff syndrome, 681, 1013, 1081, 1264
- West African trypanosomiasis, 1484, 1485, 1485*t*
- West Nile fever/encephalitis, 1378–1380
screening blood for virus causing, 536, 1379, 1380
- Westermarck sign, in pulmonary embolism, 299
- Western blot assay
in HIV infection/AIDS, 1323, 1324*t*
reference values for, 1731*t*
in Lyme disease, 1480
- Western (equine) encephalitis, 1378–1380
- Western subtype tick-borne encephalitis, 1391
- Wet drowning, 1556
- WFS1 gene mutation, in Wolfram syndrome, 1195
- Wharton duct, calculus formation in, 232
- Wheals. *See* Urticaria
- Wheat procedure, 343, 346
for aortic regurgitation, 346
for aortic stenosis, 343
- Wheezes
in asthma, 244, 246, 247*t*
dyspnea and, 25
emotional laryngeal, 248
in heart failure (cardiac asthma), 243
in pulmonary embolism, 298*t*
- Whiplash injuries, 1018
neck pain in, 817–818, 1686
- Whipple disease, 623–624
arthritis in, 623, 858
- Whipple resection, for pancreatic/periampullary carcinoma, 1609
- Whipple triad, 1239
- Whipworm infections (trichuriasis), 1517–1518
- Whispered voice test, 72, 198, 199*t*
- White blood cell count (leukocyte count), 1732*t*, 1735*t*
in acute leukemia, 520

- White blood cell count (leukocyte count)
(*Cont.*):
ascitic fluid, 588
in bacterial peritonitis, 588, 589, 689
in peritoneal carcinomatosis, 588, 590
in tuberculous peritonitis, 588
cerebrospinal fluid, 1286*t*
chemotherapy dosage modification
and, 1559*t*
in cholecystitis, 703*t*, 704
in chronic lymphocytic leukemia, 522
in chronic myeloid leukemia, 511*t*, 516
in essential thrombocytosis, 511*t*, 513
joint fluid, 809, 810*t*, 811*t*
in gonococcal arthritis, 860
in nongonococcal acute bacterial
(septic) arthritis, 859
in myeloproliferative neoplasms, 511*t*
pleural fluid, 314, 314*t*
in polycythemia, 511*t*, 512
in primary myelofibrosis, 511*t*, 514
reference values for, 1732*t*, 1735*t*
- White blood cells. *See* Leukocytes
- White cell aplasia, pure, 510
- White cell casts, 898, 899*t*
in interstitial nephritis, 898, 907
- White top PPT, 1736*t*
- Whitewater Arroyo virus, 1384
- Whitlow, herpetic, 1351, 1351*f*
- Whole blood. *See* Fresh whole blood
- Whole bowel irrigation, for poisoning/
drug overdose, 1567
- Whooping cough (pertussis). *See*
Pertussis
- Wickham striae, 144
- Wide QRS complex. *See* QRS complex,
wide
- Williams syndrome, hypercalcemia in,
1142
- Wilson disease (hepatolenticular
degeneration), 696–697,
697*f*
movement disorders in, 696, 1004
parkinsonism differentiated from, 998
- Winging, scapula, in impingement
syndrome, 1675
- WinRho. *See* Anti-D
- Winterbottom sign, 1484
- Wiskott-Aldrich syndrome, 538
- Withdrawal. *See also specific substance*
cognitive disorders/delirium caused by,
1087*t*
seizures caused by, 969
- Withdrawal response, in coma or stupor,
1014
- Withdrawal/withholding of curative
effort, in terminally ill/dying
patient, 91, 91*t*
advance directives and, 89
- Wolbachia* bacteria
filariasis and, 1526
onchocerciasis and, 1526, 1527
- Wolff-Parkinson-White syndrome, 383
palpitations in, 31
- Wolfram syndrome, 1098, 1195
- Women Abuse Screening tool (WAST),
1712
- Women's Experience with Battering
(WEB) scale, 1712
- Women's health issues, 1706–1721. *See*
also specific issue
age-related facial changes and,
1720–1721
breast mass and, 1717–1719. *See also*
Breast cancer; Lump (breast)
cancer prevention and, 1708–1710
cardiovascular disease/prevention and,
1706–1707
chronic pelvic pain and, 1714–1716
depression screening in, 1711
eating disorders and, 1712–1714
hair loss and, 1719–1720
health maintenance/preventive care
and, 1706–1711
intimate partner violence and,
1711–1712
mastalgia (breast pain) and,
1716–1717
nipple discharge and, 1719
osteoporosis prevention and,
1710–1711
sexuality/sexual health and, 1714
STD prevention and, 1711
varicose vein treatment and, 1720
- Wood alcohol. *See* Methanol
- Wood light
in erythrasma diagnosis, 112
in pigmentary disorder evaluation,
156
in rape victim examination, 778
- Woody (Riedel) thyroiditis, 1120, 1121,
1122
- Word-finding difficulty, in dementia,
1006
- Word recall, three-item, in dementia
screening, 60, 1007
- Wound botulism, 1431, 1586
- Wound care
for bite wounds, 1289
rabies and, 1377
in burn injuries, 1551
for frostbite, 1546
for leg ulcers, 154
for lymphangitis/lymphadenitis, 484
for pressure ulcers, 70–71, 71*t*
tetanus prophylaxis/treatment and,
1430, 1430*t*
- Wound infections
clostridial
botulism, 1431, 1586
myonecrosis/gas gangrene, 1300*t*,
1428–1429
tetanus, 1300*t*, 1429–1430. *See also*
Tetanus
surgical, 55, 1283, 1284
antibiotic prophylaxis of, 55–56
in diabetic patients, 54
- Wrestlers, epidemic herpes in (herpes
gladiatorum), 1351
- Wrist
in carpal tunnel syndrome, 823, 824,
1688–1689, 1689*t*
examination of, 1688, 1689, 1689*t*
in lateral and medial epicondylitis,
1687–1688
ulnar nerve lesions at, 1027
- Writer's cramp, 1003
- WT1, in mesothelioma, 1602
- Wuchereria bancrofti*, 1524
- eosinophilic pulmonary syndromes
and, 296, 1525
- Wyntensin. *See* Guanabenz
- X chromosome
in Charcot-Marie-Tooth disease, 1021
in Duchenne muscular dystrophy,
1034, 1035*t*
fragile site on, mental retardation and,
1667
in idiopathic torsion dystonia, 1002
in Klinefelter syndrome, 1174, 1669
in Turner syndrome, 1186, 1187
- X chromosome mosaicism, 1180, 1181
in Turner syndrome, 1186, 1187
- x descent, in tricuspid regurgitation, 347
- X-inactive-specific transcriptase (XIST),
in Klinefelter syndrome,
1174
- X-linked bulbospinal neuronopathy, 1020
- X-linked congenital adrenal hypoplasia,
1093, 1094, 1175
- X-linked hypophosphatemic rickets,
1150, 1151
- X-ray studies. *See also specific disorder*
and under Radiation
radiation exposure and, 1554, 1555
cancer risk and, 1555, 1594
- Xalacom. *See* Latanoprost/timolol
- Xalatan. *See* Latanoprost
- Xalkori. *See* Crizotinib
- Xanax. *See* Alprazolam
- Xanthine oxidase inhibitors, for gout,
815–816
- Xanthogranulomatous cholecystitis, 705
- Xanthomas
in biliary cirrhosis, 693
eruptive, 1247, 1248*f*
in diabetes, 1197, 1228, 1248*f*
tendinous, 1247–1248
- Xeloda. *See* Capecitabine
- Xerosis
in HIV infection/AIDS, 1331
in vitamin A deficiency, 1266
- Xerostomia, in Sjögren syndrome, 843
- Xgeva. *See* Denosumab
- Xibrom. *See* Bromfenac
- XIST. *See* X-inactive-specific transcriptase
- XO karyotype, in Turner syndrome, 1186,
1186–1187
- Xp-, in Turner syndrome, 1187
- Xp11.2 translocation, in renal cell
carcinoma, 1641
- Xq, in Turner syndrome, 1186
- XXY karyotype, 1174, 1669. *See also*
Klinefelter syndrome
- XY gonadal dysgenesis, 1174–1175
- XY karyotype, hirsutism/virilization and,
1162
- Xylitol, 1205
- Xyloprim. *See* Allopurinol
- d-(¹⁴C)Xylose breath test, in bacterial
overgrowth, 580
- Xyrem. *See* Gamma-hydroxybutyrate
- Y chromosome, in Klinefelter syndrome,
1174
- Y chromosome microdeletions, in male
infertility, 955
- Yaws (frambesia), 1300*t*, 1475

- Yellow fever, **1389–1390**
prevention/immunization and, 1315–1316, 1390
- Yellow fever virus vaccine, 1315–1316, 1390
- Yellow top tubes, 1736t
- Yersinia*
enterocolitica, diarrhea/gastroenteritis caused by, 574t, 575, 576, 1293, 1295t
pestis, 1300t, 1451
- Yervoy. *See* Ipilimumab
- Yoga, for back pain, 821
- Yohimbine, toxicity of, 1578t
- Yttrium-90 ibritumomab tiuxetan. *See* also Ibritumomab tiuxetan
for non-Hodgkin lymphoma, 525
- Z score, 1146
- Zaditor. *See* Ketotifen
- Zafirlukast, for asthma, 252t, 253
- Zalcitabine (ddC), 1341t, 1343, 1344, 1348f. *See also* Antiretroviral therapy/HAART
- Zaleplon, 1042t, 1076
overdose/toxicity of, 1579–1580
- Zanamivir, for influenza, 23, 1354t, 1395, 1396, 1398, 1399
prophylactic, 1397
resistance to, 1396
- ZAP-70, in chronic lymphocytic leukemia, 522
- Zaroxolyn. *See* Metolazone
- ZEBRA antibodies, in mononucleosis, 1362
- Zegerid, for stress gastritis, 608
- Zelboraf. *See* Vemurafenib
- Zelnorm. *See* Tegaserod
- Zemplar. *See* Paricalcitol
- Zenker diverticulum, **601**
- Zerit. *See* Stavudine
- Zestoretic. *See* Lisinopril, for
hypertension, with
hydrochlorothiazide
- Zestril. *See* Lisinopril
- Zeta-associated protein (ZAP-70), in chronic lymphocytic leukemia, 522
- Zetia. *See* Ezetimibe
- Zevalin. *See* Ibritumomab tiuxetan
- Ziac. *See* Bisoprolol, with
hydrochlorothiazide
- Ziagen. *See* Abacavir
- Zidovudine (AZT), 1341t, 1343, 1347, 1348f. *See also* Antiretroviral therapy/HAART
with lamivudine, 1343, 1347, 1348f
postexposure/after needle stick, 1335
with lamivudine and abacavir, 1344, 1348f
myopathy caused by, 1036, 1328
for prevention of HIV transmission to fetus/newborn, 805, 1336
postexposure/after needle stick, 1335–1336
resistance to, 1349
- ZIFT. *See* Zygote intrafallopian transfer
- Zileuton, for asthma, 249f, 252t, 253
- Zinacef. *See* Cefuroxime
- Zinc
parenteral nutritional support and, 1272, 1274t
toxicity of, 1578t
for viral rhinosinusitis (common cold), 23, 214
for Wilson disease, 697
- Zinc-finger protein-9 gene, in myotonic dystrophy, 1034, 1035t
- Zinc transporter 8 antibodies, in type 1 diabetes, 1193, 1193t
- Zinecard. *See* Dexamethasone
- Zioptan. *See* Tafluprost
- Ziprasidone, 1055, 1056t, 1057–1058, 1057t, 1060t
overdose/toxicity of, 1057–1058, 1057t, 1059, 1060t, 1574
- Zirgan. *See* Ganciclovir
- Zithromax. *See* Azithromycin
- ZnT8 antibodies, in type 1 diabetes, 1193, 1193t
- Zocor. *See* Simvastatin
- Zoladex. *See* Goserelin
- Zoledronate/zoledronic acid, 1146, 1147.
See also Bisphosphonates
in breast cancer management, 738, 739
for chemotherapy-induced toxicity/
bone pain, 1659t
for hypercalcemia/
hyperparathyroidism, 1143, 1647
for osteoporosis prevention/
management, 1146, 1147
corticosteroid use and, 1191
for Paget disease of bone, 1153
for thyroid cancer bone metastases, 1130
- Zollinger-Ellison syndrome (gastrinoma), **619–620**, 1172, 1189
carcinoid tumors and, 1619
GERD and, 597, 619
in MEN, 619, 620, 1172, 1189
peptic ulcer disease and, 617, 619–620, 1172, 1189
- Zolmitriptan
for cluster headache, 965
for migraine headache, 963–964
- Zolof. *See* Sertraline
- Zolpidem, 1042t, 1076
overdose/toxicity of, 1579–1580
- Zometa. *See* Zoledronate/zoledronic acid
- Zona-free hamster egg penetration tests, in infertility workup, 768
- Zonalon. *See* Doxepin
- Zonisamide, 972, 973t
for obesity, 1261
overdose/toxicity of, 973t, 1573
- Zostavax. *See* Herpes zoster vaccine;
Varicella vaccine
- Zoster. *See* Herpes zoster
- Zoster ophthalmicus, 120, **173**, 1331, 1358
- Zoster sine herpete, 1359
- Zoster vaccine. *See* Herpes zoster vaccine
- Zostrix. *See* Capsaicin
- Zosyn. *See* Piperacillin-tazobactam
- Zovirax. *See* Acyclovir
- Zygomycosis (mucormycosis), **1538**, 1542
rhinocerebral, 217
- Zygote intrafallopian transfer (ZIFT), 769
- Zymar. *See* Gatifloxacin
- Zyprexa. *See* Olanzapine
- Zytiga. *See* Abiraterone